FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/99ISR Number: 3285897-3Report Type:Direct Company Report #
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS			PO Q AM	
Initial or Prolonged	Diarrhoea	Professional						
	Diarrhoea Haemorrhagic							

Date:06/23/99ISR Number: 3289505-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx					
Hospitalization -	Gastrointestinal		-Merck	PS	Merck	ORAL	12.5MG PO QD	
Initial or Prolonged	Haemorrhage		Atenolol	C				
	Haematocrit Decreased		Elavil	C				

Date:06/24/99ISR Number: 3290610-XReport Type:Expedited (15-DaCompany Report #WAES 99061072
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization -	Cross Sensitivity	Professional	Bentyl	C				
Initial or Prolonged	Reaction		Lasix	C				
	Dysarthria		Lortab	C				
	Face Oedema		Oxycontin	C				
	Saliva Altered		Premarin	C				
	Tongue Oedema		Prevacid	C				
			Prozac	C				
			Trovan	C				

Date:06/24/99ISR Number: 3290615-9Report Type:Expedited (15-DaCompany Report #WAES 99060659
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/ PO	
	Confusional State	Company Representative						
	Dehydration							
	Faecal Occult Blood Positive							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Gastrointestinal Ulcer							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Nausea							
	Pain In Extremity							
	Renal Failure Chronic							
	Sedation							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/99ISR Number: 3290619-6Report Type:Expedited (15-DaCompany Report #WAES 99061160
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Hallucination	Professional Company Representative						

Date:06/28/99ISR Number: 3291668-4Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Prothrombin Time		Vioxx (12.5 Oz 25					
Initial or Prolonged	Prolonged		Oz?) Ms+D (Investigational)	PS		ORAL	ORAL QD	

Date:06/28/99ISR Number: 3292278-5Report Type:Expedited (15-DaCompany Report #WAES 99061160
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Condition Aggravated	Professional					MG/DAILY/PO	
	Confusional State	Company	Inderal	C				
	Hallucination	Representative						

Date:06/28/99ISR Number: 3292282-7Report Type:Expedited (15-DaCompany Report #WAES 99061394
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Feeling Abnormal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Professional	Famvir	C				

			(Therapy Unspecified)	C		

Date:06/29/99ISR Number: 3293138-6Report Type:Direct Company Report #
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Ammonia Increased		Vioxx 50mg Qd	PS		ORAL	50MG PO	4 DAY
Intervention to Prevent Permanent Impairment/Damage	Blood Bilirubin Increased		Asendin	C				
	Confusional State		Levsin	C				
			Spironolactone	C				
			Prilosec	C				
			Zomig	C				
			Lactulose	C				

Date:06/30/99ISR Number: 3294511-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health Professional	Rofecoxib - Vioxx - Merck	PS		ORAL	2 TAB + 2 TAB PO	
Required	Aphasia							
Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity							
	Localised Oedema							
	Salivary Hypersecretion							
	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/99ISR Number: 3294630-0Report Type:Expedited (15-DaCompany Report #WAES 99061395
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Congestive	Professional					MG/DAILY/PO	
Initial or Prolonged	Coronary Artery Surgery	Company	Calan Sr	C				
Other	Dyspnoea	Representative	Nitro-Bid	C				
	Myocardial Infarction		Aspirin	C				
	Pleural Effusion		Glyburide	C				
	Pulmonary Oedema							

Date:06/30/99ISR Number: 3294633-6Report Type:Expedited (15-DaCompany Report #WAES 99061669
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Professional					MG/BID/PO	
			Alphagan	C				
			Prilosec	C				
			Ultram	C				
			Folic Acid	C				
			Methotrexate	C				

Date:07/01/99ISR Number: 3295729-5Report Type:Expedited (15-DaCompany Report #WAES 99061160
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Condition Aggravated	Professional					MG/DAILY/PO	
	Confusional State	Company	Inderal	C				
	Hallucination	Representative	Therapy Unspecified	C				

Date:07/06/99ISR Number: 3296498-5Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema		Vioxx	PS				
	Pain		Humulin	C				
	Pulmonary Oedema		Darvocet	C				
	Weight Increased		Norflex	C				
			Zoloft	C				
			Premarin	C				
			Cycrin	C				
			Synthroid	C				
			Serevent	C				
			Albuterol	C				
			Azmacort	C				
			Vancerase	C				
			Methadone	C				
			Neurontin	C				

Date:07/06/99ISR Number: 3297316-1Report Type:Expedited (15-DaCompany Report #WAES 99061866
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Erosive Oesophagitis	Health Professional

Company
Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:07/06/99ISR Number: 3297319-7Report Type:Expedited (15-DaCompany Report #WAES 99061577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Count Decreased	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	7 DAY
			Cardizem	C				
			Diabinese	C				

Date:07/06/99ISR Number: 3298868-8Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome	Health Professional	Vioxx (Cox Ii Inhibitor) Merck	PS	Merck	ORAL	12.5 MG BID ORAL	18 DAY
	Renal Failure Acute							
			Vasotec (Enalapril)	C				
			Ecotrin	C				
			Hctz	C				
			Prevacid	C				
			Atenolol	C				

Date:07/08/99ISR Number: 3298991-8Report Type:Expedited (15-DaCompany Report #WAES 99061582
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Dyspnoea	Professional	Propranolol Unk	SS			UNK/UNK/UNK	
	Palpitations		Hyzaar	C				
	Ventricular Tachycardia							

Date:07/08/99ISR Number: 3298995-5Report Type:Expedited (15-DaCompany Report #WAES 99061948
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Glucose Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/DAILY/PO	
	Blood Triglycerides	Professional	Flexeril	C				
	Increased	Company	Rezulin	C				
	Cardiac Arrest	Representative	Orlistat	C				
	Cardio-Respiratory Arrest							
	Cough							
	Malaise							
	Pulmonary Oedema							
	Salivary Hypersecretion							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/99ISR Number: 3299000-7Report Type:Expedited (15-DaCompany Report #WAES 99062020
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	3 DAY
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company	Nonsteroidal Anti-Inflammatory	C				
	Haemoglobin Decreased	Representative						

Date:07/12/99ISR Number: 3300265-3Report Type:Direct Company Report #
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough		Vioxx Merck	PS	Merck	ORAL	ORAL	
Initial or Prolonged	Drug Hypersensitivity		Lipitor	C				
	Dyspnoea		Synthroid	C				
	Oedema Peripheral		Vaseretic	C				
	Pruritus		Xalatan Eye Drops	C				
			Coumadin	C				
			Atarax	C				

Date:07/12/99ISR Number: 3301016-9Report Type:Expedited (15-DaCompany Report #WAES 99061953
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	12.5 MG DAILY	
Hospitalization -	Bacterial Toxaemia	Professional					PO	
Initial or Prolonged	Blood Creatine Increased		Adalat	C				
	Blood Urea Increased		Bumex	C				
	Dyspnoea		Elavil	C				
	Haemodialysis		Glucophage	C				
	Paraesthesia Oral		Glucotrol	C				
	Renal Failure Acute		Lipitor	C				
	Sepsis		Prevacid	C				
	Tongue Oedema		Aspirin	C				
			Atenolol	C				

			Captopril	C		

Date:07/13/99ISR Number: 3302386-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Vioxx	PS		ORAL	12.5MG QD PO	
	Depressed Mood							
	Feeling Of Despair							
	Flashback							
	Nightmare							
	Social Avoidant Behaviour							

Date:07/14/99ISR Number: 3302385-6Report Type:Direct Company Report #
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx (Rofecoxib)	PS			25MG QD X 1	
Initial or Prolonged	Haemoptysis						WEEK; 50MG QD	
							X 1 WEEK +/-	
							2 WEEKS TOTAL	2 WK
			Warfarin	SS				
							FOR 5 YRS	

CONTROLLED 5 YR

Date:07/14/99ISR Number: 3303897-1Report Type:Expedited (15-DaCompany Report #WAES 99070319
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Oesophageal Ulcer	Company	Tab Vioxx Unk	SS		ORAL	25	
Disability		Representative					MG/DAILY/PO	
			Imuran	C				
			Prednisone	C				

Date:07/14/99ISR Number: 3303898-3Report Type:Expedited (15-DaCompany Report #WAES 99060659
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	50	
Initial or Prolonged	Increased	Professional					MG/DAILY/PO	
	Blood Urea Increased	Company	Coreg	C				
	Condition Aggravated	Representative	Darvocet-N	C				
	Confusional State		Lipitor	C				
	Dehydration		Macrodantin	C				
	Faecal Occult Blood		Neurontin	C				
	Fatigue		Aspirin	C				
	Gastritis		Calcium Supplement					
	Gastrointestinal Ulcer		(Composition	C				
	Haemoglobin Decreased		Digoxin	C				
	Hyperkalaemia		Insulin	C				
	Joint Effusion		Vitamins	C				
	Metabolic Acidosis							
	Oliguria							
	Pain In Extremity							
	Pallor							
	Renal Impairment							

Sedation
Tongue Disorder
Vomiting

Date:07/15/99ISR Number: 3304279-9Report Type:Expedited (15-DaCompany Report #WAES 99060756
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Cognitive Disorder	Professional	Estrace	C				
	Fatigue		Hydrodiuril	C				
	Hallucination, Visual		Limbitrol	C				
	Hypotension		Lipitor	C				
			Prozac	C				
			Soma	C				
			Synthroid	C				
			Zanaflex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/99ISR Number: 3304283-0Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Diarrhoea	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastric Ulcer		Celebrex	C				
Other	Gastritis		Dyazide	C				
	Gastrointestinal		Relafen	C				
	Haemorrhage		Voltaren	C				
	Haematemesis		Atenolol	C				
	Haemoglobin Decreased							
	Melaena							

Date:07/16/99ISR Number: 3305294-1Report Type:Expedited (15-DaCompany Report #WAES 99070470
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Groin Pain		Coreg	C				
	Injury		Flomax	C				
	Oedema Peripheral		Levbid	C				
	Pelvic Pain		Norvasc	C				
			Synthroid	C				
			Tylenol	C				
			Vasotec	C				

Date:07/19/99ISR Number: 3305229-1Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx 12.5mg	PS		ORAL	1T PO BID	

Date:07/19/99ISR Number: 3306041-XReport Type:Expedited (15-DaCompany Report #WAES 99078208
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG	7 DAY
			Moduretic	C				

Date:07/19/99ISR Number: 3306044-5Report Type:Expedited (15-DaCompany Report #WAES 99070721
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY	
	Confusional State	Professional	Tylenol With Codeine #3	C				
	Memory Impairment	Company	Verapamil	C				
	Suicidal Ideation	Representative	Vitamin B{12}	C				

Date:07/19/99ISR Number: 3306047-0Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY	
	Diarrhoea	Professional	Celebrex	C				
	Drug Ineffective		Dyazide	C				
	Gastric Ulcer		Miacalcin	C				
	Gastritis		Relafen	C				
	Haematemesis		Voltaren	C				
	Haemoglobin Decreased		Atenolol	C				
	Melaena							
	Upper Gastrointestinal Haemorrhage							

Date:07/19/99ISR Number: 3306049-4Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY	
Hospitalization -	Diarrhoea	Professional	Celebrex	C				
Initial or Prolonged	Drug Ineffective		Dyazide	C				
Other	Gastric Ulcer		Relafen	C				
	Gastritis		Voltaren	C				
	Haematemesis		Atenolol	C				
	Haemoglobin Decreased							
	Melaena							
	Upper Gastrointestinal Haemorrhage							

Date:07/19/99ISR Number: 3306052-4Report Type:Expedited (15-DaCompany Report #WAES 99075038
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	12.5 MG	
		Professional	Diclofenac	C				
			Diltiazem	C				

			Hydroxypropyl Methylcellulose Liquid	C		
			Petrolatum/White Petrolatum	C		

Date:07/21/99ISR Number: 3307929-6Report Type:Expedited (15-DaCompany Report #WAES 99070439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcohol Withdrawal Syndrome	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	10 DAY
	Gastrointestinal Haemorrhage Oesophageal Haemorrhage	Company Representative	Ethyl Alcohol Unk	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/99ISR Number: 3307933-8Report Type:Expedited (15-DaCompany Report #WAES 99070787
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemoglobin Decreased	Professional					MG/DAILY/PO	
			Hyzaar	C				
			Zantac	C				
			Diltiazem	C				

Date:07/21/99ISR Number: 3307936-3Report Type:Expedited (15-DaCompany Report #WAES 99061948
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx 25 Mg	PS		ORAL	DAILY, PO	
	Cardio-Respiratory Arrest	Professional	Flexeril	C				
	Cough	Company	Rezulin	C				
	Malaise	Representative	Orlistat	C				
	Pulmonary Embolism							
	Pulmonary Oedema							
	Salivary Hypersecretion							
	Syncope							

Date:07/21/99ISR Number: 3307939-9Report Type:Expedited (15-DaCompany Report #WAES 99070788
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	DAILY, PO	
Initial or Prolonged	Gastrointestinal	Professional	Aricept	C				
	Haemorrhage	Company						
	Gastrointestinal	Representative						
	Perforation							
	Haemoglobin Decreased							

Date:07/22/99ISR Number: 3307989-2Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colour Blindness	Consumer	Vioxx Tablets	PS			SEE ITEM B5	6 WK
	Visual Acuity Reduced		Verapamil Sr	C				
			Clonazepam	C				
			Furosemide	C				
			Slo-K	C				
			Lipitor	C				
			Zyloprim	C				
			Entrex La	C				
			Vitamins	C				

Date:07/22/99ISR Number: 3308523-3Report Type:Expedited (15-DaCompany Report #WAES 99070769
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholelithiasis	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/PO	
Initial or Prolonged	Nausea		Reglan	C				

Date:07/22/99ISR Number: 3308526-9Report Type:Expedited (15-DaCompany Report #WAES 99075018
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Lower Diarrhoea Faeces Discoloured Melaena	Foreign	Tab Vioxx (Rofecoxib) [Therapy Unspecified] Aspirin	PS C C		ORAL	PO	

Date:07/22/99ISR Number: 3308529-4Report Type:Expedited (15-DaCompany Report #WAES 99075038
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Bronchopneumonia Cerebrovascular Accident Pneumonia	Foreign	Tab Vioxx (Rofecoxib) Diclofenac Diltiazem Hydroxypropyl Methylcellulose Liquid Petrolatum/White Petrolatum	PS C C C C		ORAL	12.5 MG PO	

Date:07/26/99ISR Number: 3310309-0Report Type:Expedited (15-DaCompany Report #WAES 99071558
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional Company Representative	Tab Vioxx 25 Mg Lasix Lipitor Percocet Prevacid Prinivil Prozac	PS C C C C C C		ORAL	25 MG/DAILY/PO	

			Tegretol	C		
			Aspirin	C		

Date:07/26/99ISR Number: 3310311-9Report Type:Expedited (15-DaCompany Report #WAES 99061866
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Erosive Oesophagitis	Professional					MG/DAILY/PO	
Other	Gastrointestinal	Company	Synthroid	C				
	Haemorrhage	Representative	Digoxin	C				
	Oesophageal Ulcer							

Date:07/26/99ISR Number: 3310315-6Report Type:Expedited (15-DaCompany Report #WAES 99075086
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Foreign	Tab Vioxx					
	Haemorrhage	Health	(Rofecoxib)	PS				
							PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/99ISR Number: 3310318-1Report Type:Expedited (15-DaCompany Report #WAES 99078207
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG, PO	5 DAY
		Professional	Inj Glucocorticoids	SS		INTRAVENOUS	IV	61 DAY
			Acetaminophen	C				
			Enoxaparin	C				
			Liquid Petrolatum (+) Phenolphthalein	C				
			Tizanidine	C				

Date:07/27/99ISR Number: 3310230-8Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy		Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG QD	
	Haematochezia							
Required Intervention to Prevent Permanent Impairment/Damage	Haematocrit Decreased		Warfarin	SS		ORAL	QD OP	
	Haemoglobin Decreased		Atenolol	C				
	Melaena		Amlopidine	C				
	Oesophageal Ulcer		Atorvastatin	C				
	Haemorrhage		Lansoprazole	C				

Date:07/27/99ISR Number: 3310550-7Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Small Intestine Ulcer		Vioxx (Rocecoxib)	PS		ORAL	25 PO QD	
	Upper Gastrointestinal Haemorrhage		Coumadin	C				

Date:07/28/99ISR Number: 3312282-8Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ageusia		Vioxx	PS		
	Glossodynia		Prevacid	C		
	Oral Intake Reduced		Wellbutrin Sr	C		
	Parosmia					
	Stomatitis					

Date:07/28/99ISR Number: 3312284-1Report Type:Expedited (15-DaCompany Report #WAES 99070858
Age:59 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bronchitis
	Cough
	Drug Interaction
	Gastrointestinal Haemorrhage
	Haematemesis
	Haemoptysis
	Influenza Like Illness
	International Normalised Ratio Increased
	Lower Respiratory Tract

	Infection						
	Lung Neoplasm Malignant						
	Pneumonia						
	Pneumonitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Prothrombin Time	Health	Tab Vioxx Unk	PS		ORAL	25 MG DAILY
	Prolonged	Professional					PO
	Pulmonary Haemorrhage		Coumadin	SS			2 MG QOD
	X-Ray Abnormal		Coumadin	SS			3 MG QOD
			Coumadin	SS			5 MG DAILY
			Arava	C			
			Celebrex	C			
			Cyclobenzaprine	C			
			Diclofenac	C			
			Folic Acid	C			
			Prednisone	C			

Date:07/28/99ISR Number: 3312286-5Report Type:Expedited (15-DaCompany Report #WAES 99070631
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	AM PO
	Diarrhoea Haemorrhagic	Professional					
	Haematochezia	Other					

Date:07/28/99ISR Number: 3312288-9Report Type:Expedited (15-DaCompany Report #WAES 99071314
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG
Initial or Prolonged	Haemorrhage	Professional					DAILY PO
	Haematemesis		Coumadin	C			
			Plavix	C			
			Ticlid	C			

Date:07/28/99ISR Number: 3312290-7Report Type:Expedited (15-DaCompany Report #WAES 99061577
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Count Decreased	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG	DAILY
			Tab Vioxx	SS		ORAL	50 MG	DAILY
			Cardizem	C				
			Diabinese	C				

Date:07/29/99ISR Number: 3313164-8Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS		ORAL	25MG QD PO	
	Myalgia							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/99ISR Number: 3313465-3Report Type:Expedited (15-DaCompany Report #WAES 99060659
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	50	
Initial or Prolonged	Atrioventricular Block	Professional					MG/DAILY/PO	
	First Degree	Company	Coreg	C				
	Cardiac Murmur	Representative	Darvocet-N	C				
	Condition Aggravated		Lipitor	C				
	Confusional State		Macrodanitin	C				
	Dehydration		Neurontin	C				
	Faecal Occult Blood		Aspirin	C				
	Haemoglobin Decreased		Calcium Supplement	C				
	Hyperkalaemia		Digoxin	C				
	Metabolic Acidosis		Insulin	C				
	Oliguria		Vitamins	C				
	Pain In Extremity							
	Pallor							
	Renal Impairment							
	Sedation							
	Skin Disorder							
	Tenderness							
	Tongue Disorder							
	Ventricular Hypertrophy							
	Vomiting							

Date:07/29/99ISR Number: 3313471-9Report Type:Expedited (15-DaCompany Report #WAES 99070888
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional	Lanoxin	C				
	Condition Aggravated	Company	Lasix	C				
		Representative	Lotensin	C				

Date:07/29/99ISR Number: 3313475-6Report Type:Expedited (15-DaCompany Report #WAES 99070971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cyanosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Peripheral Ischaemia	Professional	Prozac	C				
	Vasoconstriction		Ritalin	C				

Date:07/29/99ISR Number: 3313481-1Report Type:Expedited (15-DaCompany Report #WAES 99071424
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged			Cap Eulexin 125 Mg	C		ORAL	125 MG/Q8H/PO	
			Coumadin	C				

Date:07/29/99ISR Number: 3313488-4Report Type:Expedited (15-DaCompany Report #WAES 99075137
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL	PO	8 DAY
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/99ISR Number: 3314621-0Report Type:Expedited (15-DaCompany Report #WAES 99075127
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	PO	1 DAY
			Albuterol	C				
			Beclomethasone Dipropionate	C				
			Cetirizine	C				
			Dothiepin	C				
			Fluticasone Propionate	C				
			Lansoprazole	C				

Date:08/02/99ISR Number: 3315667-9Report Type:Expedited (15-DaCompany Report #WAES 99070971
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cyanosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Peripheral Ischaemia	Professional	Prozac	C				
	Vasoconstriction		Ritalin	C				

Date:08/02/99ISR Number: 3315700-4Report Type:Expedited (15-DaCompany Report #WAES 99070971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cyanosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Peripheral Ischaemia	Professional	Prozac	C				
	Vasoconstriction		Ritalin	C				

Date:08/02/99ISR Number: 3315718-1Report Type:Expedited (15-DaCompany Report #WAES 99070319
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal Ulcer	Company	Tab Vioxx Unk	SS		ORAL	25	
Disability	Oesophageal Ulcer	Representative					MG/DAILY/PO	
	Upper Gastrointestinal		Fosamax	C				
	Haemorrhage		Imuran	C				
			Prednisone	C				

Date:08/02/99ISR Number: 3315728-4Report Type:Expedited (15-DaCompany Report #WAES 99061582
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Dyspnoea	Professional	Propranolol	SS				
Initial or Prolonged	Electrocardiogram		Hyzaar	C				
Disability	Abnormal							
	Palpitations							
	Supraventricular							
	Extrasystoles							
	Syncope							
	Ventricular Tachycardia							

Date:08/02/99ISR Number: 3315735-1Report Type:Expedited (15-DaCompany Report #WAES 99071561
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Immunoglobulin G	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Increased	Professional						
Initial or Prolonged	Gastroenteritis	Company	Metamucil	C				
Other	Helicobacter	Representative	Synthroid	C				
	Gastrointestinal		Aspirin	C				
	Haemorrhage		Garlic Extract	C				
			Glyburide	C				
			Indapamide	C				

Date:08/02/99ISR Number: 3315742-9Report Type:Expedited (15-DaCompany Report #WAES 99071781
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactoid Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	1 DAY
	Dyspnoea	Professional	Skelaxin	C				
	Face Oedema	Company						
	Nephritis Interstitial	Representative						
	Renal Failure Acute							
	Tongue Oedema							

Date:08/02/99ISR Number: 3315752-1Report Type:Expedited (15-DaCompany Report #WAES 99075132
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Tab Rofecoxib	PS		ORAL	12.5 MG PO	18 DAY
Initial or Prolonged	Haemorrhage	Other	Aspirin	SS		ORAL	150 MG PO	
			Prinivil	C				
			Allopurinol	C				
			Amoxicillin Trihydrate (+) Clavulanic Ac	C				

Citalopram	C
Glimepiride	C
Metronidazole	C

Date:08/03/99ISR Number: 3316237-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS		ORAL	12.5MG 1QD PO	
	Chorea							
	Dry Mouth							
	Feeling Abnormal							
	Heart Rate Increased							
	Sedation							
	Throat Tightness							

Date:08/03/99ISR Number: 3316240-9Report Type:Direct Company Report #
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx And Plavix					
	Haemorrhage		Together	PS			QD	1 WK
	Melaena		Plavix	SS			75MG	3 YR

Covera C

Date:08/04/99ISR Number: 3317225-9Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cholecystectomy	Health	Vioxx 50mg Po	PS		ORAL	50MG PO X 1	1 DAY
	Dyspepsia	Professional						

Date:08/05/99ISR Number: 3319004-5Report Type:Expedited (15-DaCompany Report #WAES 99061394
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	1X / PO	
	Coronary Artery Disease	Professional	Famvir	C				
	Feeling Abnormal		(Therapy Unspecified)	C				

Date:08/06/99ISR Number: 3319072-0Report Type:Direct Company Report #
Age:37 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx (Rofecoxib)	PS				
	Pruritus							

Date:08/06/99ISR Number: 3319943-5Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Anaemia	Professional						

Initial or Prolonged	Blood Creatinine	Company	Tab Vioxx 12.5 Mg	SS	ORAL
PO					
Other	Increased	Representative	Celebrex	C	
	Blood Urea Increased		Dyazide	C	
	Condition Aggravated		Elavil	C	
	Diarrhoea		Miacalcin	C	
	Dizziness		Relafen	C	
	Faecal Occult Blood		Tums	C	
	Positive		Voltaren	C	
	Fatigue		Atenolol	C	
	Gastric Ulcer		Calcium Supplement	C	
	Gastritis				
	Haematocrit Decreased				
	Haemoglobin Decreased				
	Melaena				
	Upper Gastrointestinal				
	Haemorrhage				

Date:08/06/99ISR Number: 3319946-0Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization -	Diarrhoea
Initial or Prolonged	Drug Ineffective
Other	Gastric Ulcer

	Gastritis						
	Haematemesis						
	Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Upper Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage		Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Celebrex	C				
			Dyazide	C				
			Miacalcin	C				
			Relafen	C				
			Voltaren	C				
			Atenolol	C				

Date:08/06/99ISR Number: 3319952-6Report Type:Expedited (15-DaCompany Report #WAES 99070213
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Diarrhoea	Professional					MG/DAILY/PO	
Initial or Prolonged	Drug Ineffective		Tab Vioxx 12.5 Mg	SS		ORAL	PO	
Other	Gastric Ulcer		Celebrex	C				
	Gastritis		Dyazide	C				
	Haematemesis		Relafen	C				
	Haemoglobin Decreased		Voltaren	C				
	Melaena		Atenolol	C				
	Upper Gastrointestinal							
	Haemorrhage							

Date:08/06/99ISR Number: 3319962-9Report Type:Expedited (15-DaCompany Report #WAES 99075133
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					

Initial or Prolonged	International Normalised	Other	(Rofecoxib)	PS			ORAL
12.5 MG PO							
	Ratio Increased		Warfarin	SS			ORAL
PO							
			Pravastatin Na	C			

Date:08/06/99ISR Number: 3319969-1Report Type:Expedited (15-DaCompany Report #WAES 99075137
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL		
PO							8	DAY
		Professional						

Date:08/06/99ISR Number: 3319973-3Report Type:Expedited (15-DaCompany Report #WAES 99075137
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL		
PO							8	DAY
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/99ISR Number: 3320301-8Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Zyvox (Linezolid)	PS	Pharmacia & Upjohn			
			Vioxx (Rofecoxib)	SS	Merck			

Date:08/09/99ISR Number: 3320913-1Report Type:Expedited (15-DaCompany Report #WAES 99071618
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Asthenia	Professional	Duragesic	C				
	Chest Pain		K-Dur	C				
	Fatigue		Lasix	C				
	Lethargy		Singulair	C				
	Pulmonary Embolism		Prednisone	C				
	Retinal Haemorrhage							
	Thrombotic							
	Thrombocytopenic Purpura							
	Visual Disturbance							

Date:08/09/99ISR Number: 3320936-2Report Type:Expedited (15-DaCompany Report #WAES 99071972
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Myocardial Infarction	Professional Company Representative						

Date:08/09/99ISR Number: 3320942-8Report Type:Expedited (15-DaCompany Report #WAES 99080002
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Asthenia	Health	Tab Vioxx Unk	PS		ORAL
12.5						
Initial or Prolonged	Dizziness	Professional				
MG/DAILY/PO						
	Fall		Cardizem Cd	C		
	Hyponatraemia		Depakote	C		
	Muscular Weakness		Hydrodiuril	C		
			Levsin	C		
			Tenormin	C		
			Clonazepam	C		
			Nifedipine	C		
			Potassium Chloride	C		

Date:08/09/99ISR Number: 3320949-0Report Type:Expedited (15-DaCompany Report #WAES 99072059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Hospitalization -	Condition Aggravated	Professional				
MG/DAILY/PO						
Initial or Prolonged	Embolism		Miacalcin	C		
Disability	Gastric Ulcer Haemorrhage		Zantac	C		
Other	Haemoglobin Decreased		Nitroglycerin	C		
	Haemoptysis					
	Nausea					

Date:08/09/99ISR Number: 3320956-8Report Type:Expedited (15-DaCompany Report #WAES 99071841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Knee Deformity	Professional	Coumadin	SS				
	Prothrombin Time Prolonged	Company Representative						

Date:08/09/99ISR Number: 3320960-XReport Type:Expedited (15-DaCompany Report #WAES 99070319
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Tab Vioxx	SS		ORAL	25	
Disability	Haemoglobin Decreased	Representative					MG/DAILY/PO	
	Oesophageal Ulcer		Ecotrin	C				
	Haemorrhage		Fosamax	C				
			Imuran	C				
			Prednisone	C				
			Sulfalene	C				

Date:08/09/99ISR Number: 3320963-5Report Type:Expedited (15-DaCompany Report #WAES 99075214
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx					
Initial or Prolonged	Renal Impairment	Health	(Rofecoxib)	PS				
12.5 MG								
		Professional						

Date:08/09/99ISR Number: 3320967-2Report Type:Expedited (15-DaCompany Report #WAES 99075149
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Timoptic	C				
			Acetaminophen	C				
			Bendroflumethiazide	C				
			Metoclopramide	C				

Date:08/10/99ISR Number: 3321796-6Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health Professional	Vioxx	PS	Merck And Company		1- 12.5MG HS	1 DAY
	Disorientation		Calcium	C				
	Drug Interaction		Zantac	C				
	Feeling Abnormal		Senokot	C				
	Sedation		Vitamin E	C				
			Ms Contin	C				
			Ambien	C				
			Darvocet-N	C				
			Prozac	C				
			B-Complex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/99ISR Number: 3323063-3Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke		Vioxx ?Str	PS				PTA
Hospitalization -			Aspirin ?Str	SS		ORAL	PO DAILY	
Initial or Prolonged			Zestoretic 12.5 Mg	C				
Disability			Sinemet	C				
Required Intervention to Prevent Permanent Impairment/Damage			Vitamin C	C				

Date:08/11/99ISR Number: 3323862-8Report Type:Expedited (15-DaCompany Report #WAES 99080155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	DAILY/PO	
Initial or Prolonged	Gastric Ulcer	Professional Company Representative	Aspirin	C				
			Coumadin	C				
			Glucophage	C				
			Ismo	C				
			K-Dur	C				
			Lasix	C				
			Monopril	C				
			Norvasc	C				
			Zaroxolyn	C				
			Insulin	C				

Date:08/11/99ISR Number: 3323866-5Report Type:Expedited (15-DaCompany Report #WAES 99070858
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest X-Ray Abnormal	Health	Tab Vioxx Unk	PS		ORAL	25	
Initial or Prolonged	Drug Interaction	Professional					MG/DAILY/PO	

	Haemoptysis	Tab Vioxx	SS	ORAL
25 MG/BID/PO				
	International Normalised	Coumadin	SS	
2 MG/QOD/UNK				
	Ratio Increased	Coumadin	SS	
5				
	Pneumonia			
MG/DAILY/UNK				
	Pneumonitis	Coumadin	SS	
3 MG/QOD/UNK				
	Prothrombin Time	Arava	C	
	Prolonged	Celebrex	C	
	Pulmonary Haemorrhage	Flexeril	C	
		Diclofenac	C	
		Folic Acid	C	
		Prednisone	C	

Date:08/11/99ISR Number: 3323869-0Report Type:Expedited (15-DaCompany Report #WAES 99071561
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Blood Urea Increased
	Cerebrovascular Accident
Other	Condition Aggravated
	Decreased Appetite
	Diabetes Mellitus
	Inadequate Control
	Flushing

		Gastric Ulcer Haemorrhage					
		Gastroenteritis					
		Helicobacter	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Hyperhidrosis	Professional				
MG/DAILY/PO							
		Hypoaesthesia	Company	Metamucil	C		
		Hypoglycaemia	Representative	Norvasc	C		
		Hyponatraemia		Prevacid	C		
		Leukocytosis		Synthroid	C		
		Oral Intake Reduced		Aspirin	C		
		Pulse Absent		Garlic Extract	C		
		Renal Impairment		Glyburide	C		
		Respiratory Rate		Indapamide	C		
		Increased		Vitamins	C		
		Vomiting					

Date:08/12/99ISR Number: 3324321-9Report Type:Expedited (15-DaCompany Report #WAES 99080431
Age:50 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angioneurotic Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Initial or Prolonged			Professional				
MG/DAILY/PO							
			Company	Tab Hyzaar 50/12.5			
			Representative	Mg	SS		ORAL
50/12.5							
MG/DAILY/PO							

Date:08/12/99ISR Number: 3324326-8Report Type:Expedited (15-DaCompany Report #WAES 99080139
Age:84 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL
25 MG / DAILY							
Initial or Prolonged		Hemiplegia	Professional				
/ PO							

Disability	Thrombotic Stroke	Company	Caltrate	C
Other		Representative	Paxil	C
			Prevacid	C
			Procardia Xl	C
			Atropine Sulfate (+)	
			Diphenoxyla	C
			Vitamin B(12)	C

Date:08/13/99ISR Number: 3325272-6Report Type:Expedited (15-DaCompany Report #WAES 99070971
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Thrombosis	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Hospitalization -	Cyanosis	Professional	Premarin	C				
Initial or Prolonged	Peripheral Ischaemia		Prozac	C				
Disability	Vasospasm		Ritalin	C				
Other								

Date:08/13/99ISR Number: 3325276-3Report Type:Expedited (15-DaCompany Report #WAES 99071936
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abdominal Tenderness
Initial or Prolonged	Cholelithiasis
	Dyspepsia

	Leukocytosis Pyrexia White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO
		Company Representative	Flexeril	C			

Date:08/13/99ISR Number: 3325283-0Report Type:Expedited (15-DaCompany Report #WAES 99080112
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaemia Confusional State	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
Other	Haemoglobin Decreased Mental Impairment Neutropenia		Herbal Remedies (Composition Unspecified) Unk	SS			UNK/UNK/UNK
	Neutrophil Count Decreased Platelet Count Decreased White Blood Cell Count Decreased		Elavil Lortab Soma Morphine Sulfate	C C C C			

Date:08/13/99ISR Number: 3325287-8Report Type:Expedited (15-DaCompany Report #WAES 99080343
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Lung Infiltration	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO

Date:08/13/99ISR Number: 3325292-1Report Type:Expedited (15-DaCompany Report #WAES 99085025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:08/13/99ISR Number: 3325299-4Report Type:Expedited (15-DaCompany Report #WAES 99080385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Pain Vomiting	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	

Date:08/16/99ISR Number: 3325564-0Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx 12.5mg	PS		ORAL	1T AMPLE PO DAILY	
Required Intervention to Prevent Permanent Impairment/Damage			Brycol	C				
			Deltasone	C				
			Meclizine	C				
			Antibotics	C				

			Prevaobol	C		

Date:08/16/99ISR Number: 3325569-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Paraesthesia		Vioxx 25mg -Merck	PS	Merck	
1T Q.D.						
Other	Paraesthesia Oral		Moduretic	C		
Required	Pruritus		Xanax	C		
Intervention to Prevent Permanent Impairment/Damage						

Date:08/16/99ISR Number: 3325573-1Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Skin Lesion		Vioxx 25mg	PS		ORAL
25MG PO DAILY 1 WK						
Initial or Prolonged	Skin Ulcer		Demedex	C		
			Ditiazem	C		
			Singulair	C		
			Neuruntin	C		
			Theophyllin	C		
			Viracept	C		
			Zerit	C		
			Epivir	C		
			Enterla	C		

Date:08/16/99ISR Number: 3326316-8Report Type:Expedited (15-DaCompany Report #WAES 99075214
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx			
Initial or Prolonged	Increased	Health	(Rofecoxib)	PS		ORAL
25 MG PO 31 DAY						
	Dehydration	Professional	(Therapy			

	Renal Impairment		Unspecified)	C		

Date:08/16/99ISR Number: 3326319-3Report Type:Expedited (15-DaCompany Report #WAES 99071896
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - PO	Cough	Health	Tab Vioxx Unk	PS		ORAL
Initial or Prolonged	Drug Hypersensitivity	Professional	Atarax	C		
	Dyspnoea	Other	Coumadin	C		
	International Normalised		Lipitor	C		
	Ratio Increased		Synthroid	C		
	Oedema Peripheral		Vaseretic	C		
	Prothrombin Time		Xalatan	C		
	Prolonged					
	Pruritus					
	Red Blood Cell					
	Sedimentation Rate					
	Increased					
	Rheumatoid Factor					
	Positive					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/99ISR Number: 3326321-1Report Type:Expedited (15-DaCompany Report #WAES 99080130
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Health	Tab Vioxx Unk	PS		ORAL	25 MG/PO	
Life-Threatening		Professional Company Representative	Tylenol	C				

Date:08/16/99ISR Number: 3326323-5Report Type:Expedited (15-DaCompany Report #WAES 99080354
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis	Company	Tab Vioxx Unk	PS			10 DAY	
Initial or Prolonged		Representative	Sulfasalazine	C				

Date:08/17/99ISR Number: 3326927-XReport Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blister	Health	Vioxx 25mg	PS			1 QD	1 MON
Intervention to Prevent Permanent Impairment/Damage	Dermatitis	Professional						

Date:08/18/99ISR Number: 3327949-5Report Type:Expedited (15-DaCompany Report #WAES 99070888
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / AM	
Initial or Prolonged		Professional					/ PO	
Other		Company	Lanoxin	C				

		Representative	Lasix	C
			Lotensin	C
			(Therapy Unspecified)	C

Date:08/18/99ISR Number: 3328569-9Report Type:Expedited (15-DaCompany Report #WAES 99080555
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Pain	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5MG DAILY	
Initial or Prolonged	Meningitis Aseptic	Professional					PO	
	Photophobia	Company Representative	Zoloft	C				
			Atenolol	C				

Date:08/19/99ISR Number: 3328748-0Report Type:Expedited (15-DaCompany Report #WAES 99080343
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive Lung Infiltration	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/99ISR Number: 3328752-2Report Type:Expedited (15-DaCompany Report #WAES 99080582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cerebrovascular Accident		Coumadin	C				
	Delusion		Synthroid	C				
			Tagamet	C				
			Voltaren	C				
			Diuretic Preparation	C				

Date:08/19/99ISR Number: 3328754-6Report Type:Expedited (15-DaCompany Report #WAES 99080745
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	5 DAY
	Haematemesis	Company						
	Haematocrit Decreased	Representative						
	Malaise							

Date:08/20/99ISR Number: 3330413-0Report Type:Expedited (15-DaCompany Report #WAES 99078207
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Fibrosis	Health	(Rofecoxib)	PS		ORAL	50 MG	5 DAY
	Gastritis	Professional	Inj Glucocorticoids	SS				
INTRAVENOUS							61 DAY	
	Surgical Procedure		Acetaminophen	C				
	Repeated		Enoxaparin	C				
			Liquid Petrolatum					
			(+) Phenolphthalein	C				
			Tizanidine	C				

Date:08/22/99ISR Number: 3389748-8Report Type:Periodic Company Report #WAES 99071774
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Oedema							
PO								
			Elocon	C				
			Iberet-Folic-500	C				
			K-Dur	C				
			Lasix	C				
			Prevacid	C				
			Proscar	C				
			Tenormin	C				
			Zyloprim	C				
			Alprazolam	C				

Date:08/23/99ISR Number: 3330965-0Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT
	Chromaturia
	Faeces Discoloured
	Jaundice
	Nausea

	Pruritus Sedation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx 25 Mg	PS		ORAL	2 PO QD
		Professional	Uniphyl	C			
			Prednisone	C			
			Premarin	C			
			Calcium	C			
			Vitamin D	C			

Date:08/23/99ISR Number: 3331149-2Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Blood Potassium Increased Electrocardiogram T Wave		Vioxx 12.5mg / Merck & Co	PS	Merck & Co	ORAL	12.5MG PO; X
	Peaked						1T DOSE

Date:08/23/99ISR Number: 3331757-9Report Type:Expedited (15-DaCompany Report #WAES 99071245
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Injury	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO
	Road Traffic Accident Sedation	Professional	Cardura	C			
			Celebrex	C			
			Ultram	C			
			Atenolol	C			
			Ibuprofen	C			

Date:08/23/99ISR Number: 3331761-0Report Type:Expedited (15-DaCompany Report #WAES 99081238
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
		Company	Zestril	C		
		Representative	Therapy Unspecified	C		

Date:08/23/99ISR Number: 3331763-4Report Type:Expedited (15-DaCompany Report #WAES 99080719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Congestive	Professional				
	Fluid Retention	Company				
		Representative				

Date:08/23/99ISR Number: 3331766-XReport Type:Expedited (15-DaCompany Report #WAES 99078207
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Duodenal Ulcer
Initial or Prolonged	Perforation
	Fibrosis
	Gastritis
	Surgical Procedure

Repeated

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL
50 MG; OP	5 DAY					
INTRAVENOUS	UNK;IV 61 DAY		Inj Glucocoricoids	SS		
			Acetaminophen	C		
			Enoxaparin	C		
			Liquid Petrolatum (+) Phenolphthalein	C		
			Tizanidine	C		

Date:08/23/99ISR Number: 3331769-5Report Type:Expedited (15-DaCompany Report #WAES 99071894
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Hospitalization -	Distress Syndrome	Professional					MG/BID/PO	
Initial or Prolonged	Blood Creatinine	Other	Celebrex Unk	SS				
	Increased		Atenolol Msd	C				
	Pulmonary Arterial Wedge		Ecotrin	C				
	Pressure Decreased		Hydrodiuril	C				
	Renal Failure Acute		Prevacid	C				
			Vasotec	C				

Date:08/23/99ISR Number: 3331773-7Report Type:Expedited (15-DaCompany Report #WAES 99080373
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	UNK/DAILY/PO	
Initial or Prolonged	Increased	Professional	Aerobid	C				
	Blood Urea Increased	Company	Combivent	C				
	Cardiac Arrest	Representative	Elavil	C				
	Cardiac Failure		Lanoxin	C				
	Congestive		Lasix	C				

Cardiac Murmur
Drug Level Above
Therapeutic
Dyspnoea Paroxysmal
Nocturnal
Fluid Retention
Hyperkalaemia
Oedema
Oedema Peripheral
Pulmonary Arterial Wedge
Pressure Increased
Renal Failure
Resuscitation
Therapeutic Agent
Toxicity
Vasodilatation
Weight Increased

Neurontin	C
Oxycontin	C
Serevent	C
Vicodin Tablets	C
Prednisone	C
Verapamil	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/99ISR Number: 3331778-6Report Type:Expedited (15-DaCompany Report #WAES 99080996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Pain						MG/DAILY/PO	1 DAY
	Vomiting							

Date:08/23/99ISR Number: 3331781-6Report Type:Expedited (15-DaCompany Report #WAES 99085076
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Foreign Company	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG	
		Representative	Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Bendroflumethiazide	C				
			Calcium Carbonate (+) Etidronic Acid Dis	C				
			Quinineso4	C				

Date:08/26/99ISR Number: 3333945-4Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx 25mg	PS		ORAL	2MG QD PO	
Initial or Prolonged	Haemorrhage		Anacin Tablets	SS		ORAL	2TABS BID-TID	
	Haematochezia						PO; LONG TERM	
	Medication Error							

Date:08/26/99ISR Number: 3334304-0Report Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Vioxx	PS		ORAL	25 MG 1 QD PO	46 DAY
	Dyspepsia	Professional	Zantac	C				
	Dyspnoea		Doxycycline	C				
	Fatigue		Singulair	C				
	Headache		Serevent	C				
	Lethargy		Flovent	C				
	Malaise		B12 Vitamin	C				
	Myalgia		Zinc	C				
			Echinacia	C				
			Vitamin B	C				

Date:08/26/99ISR Number: 3334612-3Report Type:Expedited (15-DaCompany Report #WAES 99080942
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/99ISR Number: 3334615-9Report Type:Expedited (15-DaCompany Report #WAES 99080952
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Health	Tab Vioxx	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Neoplasm	Professional	Lozol	C				
	Pharyngitis	Company	Pepcid	C				
	Pharyngolaryngeal Pain	Representative						

Date:08/26/99ISR Number: 3334619-6Report Type:Expedited (15-DaCompany Report #WAES 99075018
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Diarrhoea	Health	(Rofecoxib)	PS		ORAL	12.5 MG	
	Faeces Discoloured	Professional	Aspirin	SS		ORAL	150 MG	
	Gastrointestinal		Allopurinol	SS		ORAL	100 MG	
	Haemorrhage		Amoxicillin					
	Melaena		Trihydrate (+)					
			Clavulanate P	C				
			Citalopram	C				
			Glimpiride	C				
			Lisinopril	C				
			Metronidazole	C				

Date:08/27/99ISR Number: 3334948-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx 50mg Po Qd	PS		ORAL	50MG PO QD	
	Blood Pressure Decreased		Asa	C				
	Haematemesis		Tiazax	C				
	Nausea		Tenomin	C				
			Morphine Sulfate	C				

Date:08/27/99ISR Number: 3335668-4Report Type:Expedited (15-DaCompany Report #WAES 99081243
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Renal Failure Acute	Company Representative	Amaryl	C				
			Evista	C				
			Neurontin	C				
			Rezulin	C				
			Ziac	C				
			[Composition Unspecified]	C				
			Aspirin	C				

Date:08/27/99ISR Number: 3335672-6Report Type:Expedited (15-DaCompany Report #WAES 99081266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonitis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/99ISR Number: 3335675-1Report Type:Expedited (15-DaCompany Report #WAES 99081276
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:08/27/99ISR Number: 3335679-9Report Type:Expedited (15-DaCompany Report #WAES 99081303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
Life-Threatening	Haemorrhage							
Hospitalization - Initial or Prolonged								

Date:08/30/99ISR Number: 3336337-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angioneurotic Oedema Face Oedema Laryngeal Oedema Tongue Oedema		Vioxx 25 Mg	PS			ONCE DAILY	

Date:08/30/99ISR Number: 3337159-3Report Type:Expedited (15-DaCompany Report #WAES 99081108
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged MG/DAILY/PO	Atrioventricular Block First Degree Blood Creatinine Increased Blood Glucose Increased Blood Urea Increased Cardiac Failure Congestive Cardiac Murmur Cough Ejection Fraction Abnormal Electrocardiogram Abnormal Haematocrit Decreased Haemoglobin Decreased Lung Infiltration Mitral Valve Incompetence Pleural Effusion Pneumonia Rales Tricuspid Valve Incompetence Ventricular Extrasystoles Weight Increased	Professional

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/99ISR Number: 3337160-XReport Type:Expedited (15-DaCompany Report #WAES 99080963
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Disturbance	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Professional	Bumex	C				
			K-Dur	C				
			Peri-Colace	C				
			Synthroid	C				
			Tylenol	C	C			
			Zoloft	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Atenolol	C				
			Lactulose	C				
			Prednisone	C				

Date:08/30/99ISR Number: 3337161-1Report Type:Expedited (15-DaCompany Report #WAES 99081036
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/PO	
Hospitalization - Initial or Prolonged	Tachycardia		Estraderm Transdermal System	C				
			Norflex	C				
			Prevacid	C				
			Tylenol Arthritis Extended Relief	C				

Date:08/30/99ISR Number: 3337162-3Report Type:Expedited (15-DaCompany Report #WAES 99081608
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:08/30/99ISR Number: 3337163-5Report Type:Expedited (15-DaCompany Report #WAES 99081302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Suicide Attempt	Health Professional	Tab Vioxx 25 Mg Therapy Unspecified	PS SS		ORAL	PO	

Date:08/30/99ISR Number: 3337166-0Report Type:Expedited (15-DaCompany Report #WAES 99085114
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoptysis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/99ISR Number: 3337170-2Report Type:Expedited (15-DaCompany Report #WAES 99075214
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Tab Rofecoxib	PS		ORAL	25 MG PO	31 DAY
Initial or Prolonged	Increased	Health	Acetaminophen/Propox					
	Condition Aggravated	Professional	yphene Hydrochloride	C				
	Renal Impairment		Aspirin	C				
			Capsaicin	C				
			Cetostearyl Alcohol					
			(+) Phenoxyethanol (	C				
			Fluoxetine Hcl	C				
			Folic Acid	C				
			Furosemide	C				
			Hydroxocobalamin	C				
			Influenza Virus					
			Vaccine	C				
			Lansoprazole	C				
			Nicorandil	C				
			Pravastatin Na	C				
			Trimeprazine					
			Tartrate	C				

Date:08/31/99ISR Number: 3337703-6Report Type:Expedited (15-DaCompany Report #WAES 99081406
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Transient	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
Hospitalization -	Haemorrhagic Stroke		Ativan	C				
Initial or Prolonged			Claritin	C				
			Cozaar	C				
			Estraderm	C				
			Fml Liquifilm	C				
			Miacalcin	C				
			Naprosyn	C				
			Orasone	C				
			Prilosec	C				
			Septra Ds	C				
			Timoptic-Xe	C				
			Tylenol	C				
			Voltaren Ophthalmic					

Solution	C
B Vitamins	C
Lidocaine	C
Methotrexate	C
Pilocarpine	C

Date:09/01/99ISR Number: 3338463-5Report Type:Expedited (15-DaCompany Report #WAES 99081445
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Confusional State	Professional					MG/DAILY/PO	
	Dyspnoea	Company					25MG/DAILY/PO	
	Fatigue	Representative	Celebrex	C				
	Hyponatraemia		Coumadin	C				
	Red Blood Cell		Tylenol	C				
	Sedimentation Rate							
	Increased							
	Speech Disorder							

Date:09/01/99ISR Number: 3338467-2Report Type:Expedited (15-DaCompany Report #WAES 99081390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Health	Tab Vioxx Unk	PS		ORAL	50 MG/IX/PO	
	Jaundice	Professional						
	Pruritus							

Date:09/01/99ISR Number: 3338471-4Report Type:Expedited (15-DaCompany Report #WAES 99085124
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention	Foreign	Tab Vioxx					
Initial or Prolonged	Pulmonary Oedema	Company	(Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
		Representative	Prinivil	C				
			Acetaminophen	C				
			Aspirin	C				
			Betahistine	C				
			Digoxin	C				
			Furosemide	C				
			Prednisolone	C				

Date:09/01/99ISR Number: 3338475-1Report Type:Expedited (15-DaCompany Report #WAES 99071894
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Life-Threatening	Distress Syndrome	Professional					MG/BID/PO	
Hospitalization -	Blood Creatinine	Other	Celebrex 100 Mg	SS			100 MG/BID	
Initial or Prolonged	Increased		Atenolol Msd	C				
Disability	Blood Urea Increased		Ecotrin	C				
	Drug Hypersensitivity		Hydrodiuril	C				
	Dyspnoea		Prevacid	C				
	Lung Infiltration		Vasotec	C				
	Medication Error							

	Pulmonary Arterial Wedge					
	Pressure Decreased					
	Pulmonary Oedema					
	Renal Failure Acute					
	Renal Impairment					

Date:09/01/99ISR Number: 3338477-5Report Type:Expedited (15-DaCompany Report #WAES 99080952
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysphagia	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Neoplasm	Company	Lozol	C				
	Neoplasm Malignant	Representative	Pepcid	C				
	Pharyngitis		Diuretic Preparation	C				
	Pharyngolaryngeal Pain							

Date:09/01/99ISR Number: 3338478-7Report Type:Expedited (15-DaCompany Report #WAES 99081150
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Confusional State

	Headache Hypoaesthesia Meningitis Aseptic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ DAILY / PO
			[Therapy Unspecified]	C			
			B Vitamins	C			

Date:09/02/99ISR Number: 3338886-4Report Type:Direct Company Report #
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx 50mg - Merck	PS	Merck		50 MG QD X 1WK PRIOR TO ADM TO HOSP 8/22-8/29/99 7 DAY

Date:09/02/99ISR Number: 3339288-7Report Type:Expedited (15-DaCompany Report #WAES 99080718
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abscess	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/
Hospitalization - Initial or Prolonged	Alveolitis Aphasia	Company Representative					PO; 12.5 MG/DAILY/PO
	Chills Communication Disorder Convulsion Dehydration Depressed Level Of Consciousness		Limbitrol Tablets Plaquenil Prednisone	C C C			

Encephalopathy
Haemorrhagic Stroke
Headache
Hyperhidrosis
Lethargy
Meningitis Aseptic
Mental Impairment
Pyrexia
Respiratory Distress
Sepsis
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection

Date:09/02/99ISR Number: 3339291-7Report Type:Expedited (15-DaCompany Report #WAES 99085173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/99ISR Number: 3341421-8Report Type:Expedited (15-DaCompany Report #WAES 99080582
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Cerebrovascular Accident	Health	Coumadin	C				
	Delusion	Professional	Synthroid	C				
	Feeling Abnormal		Tagamet	C				
			Voltaren	C				
			[Composition Unspecified]	C				
			Diuretic Preparation (Composition	C				

Date:09/07/99ISR Number: 3341430-9Report Type:Expedited (15-DaCompany Report #WAES 99081608
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	Glucophage	C				
Disability	Gastrointestinal	Company	Lipitor	C				
Other	Haemorrhage	Representative	Plavix	C				
			Glyburide	C				

Date:09/07/99ISR Number: 3341440-1Report Type:Expedited (15-DaCompany Report #WAES 99088220
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	UNK PO	
			Methotrexate	C				

Date:09/07/99ISR Number: 3341459-0Report Type:Expedited (15-DaCompany Report #WAES 99081987
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG	DAILY
Hospitalization -	Haemorrhage	Professional						
PO								
Initial or Prolonged		Company						
Other		Representative						

Date:09/07/99ISR Number: 3341464-4Report Type:Expedited (15-DaCompany Report #WAES 99080162
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5/25 MG	
	Eating Disorder	Professional						
DAILY PO								
	Gingivitis		Prevacid	C				
	Glossitis		Wellbutrin Sr	C				
	Glossodynia							
	Lip Ulceration							
	Mouth Ulceration							
	Oral Pain							
	Stomatitis							

Date:09/07/99ISR Number: 3341470-XReport Type:Expedited (15-DaCompany Report #WAES 99081654
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG	DAILY
Other	Blood Immunoglobulin G Increased		Lipitor	C		PO		
	Blood Ketone Body		Mellaril	C				
	Cerebral Ischaemia		Paxil	C				
	Chromaturia		Synthroid	C				
	Condition Aggravated		Docusae Sodium	C				
	Ecchymosis		Iron (Unspecified)	C				
	Gliosis		Lithium Bromide	C				
	Haematocrit Decreased		Trazodone	C				
	Haemoglobin Decreased							
	Hepatitis A Antibody Positive							
	Hepatitis B Antibody Positive							
	Intentional Self-Injury							
	International Normalised Ratio Decreased							
	Laboratory Test Abnormal							
	Lethargy							
	Mental Impairment							
	Nuclear Magnetic Resonance Imaging Brain Abnormal							
	Prothrombin Time Prolonged							
	Red Blood Cell Sedimentation Rate Increased							

Date:09/08/99ISR Number: 3341862-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neuropathy Peripheral	Health Professional	Vioxx 12.5mg Merck & Co, Inc	PS	Merck & Co, Inc	ORAL	12.5MG	

/TID /ORAL 54 DAY

Date:09/08/99ISR Number: 3342370-1Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - SEE IMAGE PO	Anaemia		Warfarin 5 Mg	PS		ORAL
Initial or Prolonged 12.5 MG QD PO	International Normalised		Vioxx 12.5 Mg	SS		ORAL
	Ratio Increased		Zantac	C		
			Quiandine	C		
			Lasix	C		
			Nifedipine	C		
			Darvon Hcl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/99ISR Number: 3342974-6Report Type:Direct Company Report #
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Anaemia Gastrointestinal Haemorrhage		Vioxx	PS		ORAL	PO	1 WK

Date:09/09/99ISR Number: 3343176-XReport Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastrointestinal		Rofecoxib (Vioxx-Merck)	PS	Merck	ORAL	25-50MG PO QD	1 WK
	Haemorrhage		Warfarin	C				
	Haematocrit Decreased		Atorvastatin	C				
	International Normalised Ratio Increased		Asa	C				
	Melaena		Lisinopril	C				
			Amlodipine	C				
			Tylenol	C				
			Flonase	C				

Date:09/09/99ISR Number: 3343203-XReport Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional	Rofecoxib (Vioxx) / Merck	PS	Merck	ORAL	UNKN /QD	
			Aspirin / 80mg /	SS		ORAL	/ORAL	1 MON
			Premarin	C			80MG QD ORAL	3 YR

Digoxin	C
Imdur	C
Furosemide	C
K-Dur	C
Synthroid	C
Vioxx	C
Coumadin	C
Asa	C

Date:09/09/99ISR Number: 3343322-8Report Type:Expedited (15-DaCompany Report #WAES 99080431
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Dyspnoea	Professional						
Other		Company Representative	Tab Hyzaar 50/12.5 Mg	SS		ORAL	50/12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/99ISR Number: 3343326-5Report Type:Expedited (15-DaCompany Report #WAES 99081956
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Haemorrhage	Professional						
	Vomiting	Company						
		Representative						

Date:09/09/99ISR Number: 3343330-7Report Type:Expedited (15-DaCompany Report #WAES 99082050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Haematochezia	Professional	Aspirin	C				
		Company	Warfarin	C				
		Representative						

Date:09/09/99ISR Number: 3343334-4Report Type:Expedited (15-DaCompany Report #WAES 99082309
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Hypertension	Professional					MG/DAILY/PO	
	Hypoaesthesia	Company	Toprol Xl Tablets	C				
	Tongue Disorder	Representative						

Date:09/09/99ISR Number: 3343338-1Report Type:Expedited (15-DaCompany Report #WAES 99082316
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5	

Initial or Prolonged	Atrophy	Professional				
MG/DAILY/PO,						
	Computerised Tomogram					
12.5						
	Abnormal					
MG/BID/PO						
	Confusional State		Plaquenil	C		
	Hyponatraemia		Tylenol	C		
	Sleep Disorder		Methotrexate	C		
	Vomiting					

Date:09/09/99ISR Number: 3343341-1Report Type:Expedited (15-DaCompany Report #WAES 99085184
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Aortic Valve Stenosis	Foreign	Tab Vioxx			
	Coronary Artery Occlusion	Other	(Rofecoxib)	PS		ORAL
12.5 MG						
	Myocardial Infarction		Bendroflumethiazide	C		

Date:09/09/99ISR Number: 3343358-7Report Type:Expedited (15-DaCompany Report #WAES 99082310
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
Hospitalization -		Professional				
Initial or Prolonged		Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/99ISR Number: 3343649-XReport Type:Direct Company Report #CTU 109257E
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Bicarbonate		Vioxx 12.5mg	PS			12.5MG DAILY	16 DAY
Initial or Prolonged	Increased		Synthroid	C				
	Blood Creatinine		Hctz	C				
	Increased		Vasotec	C				
	Blood Urea Increased		Tamoxifen	C				
	Malaise							
	Periorbital Oedema							
	Renal Failure							

Date:09/10/99ISR Number: 3343706-8Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG PO BID	
Initial or Prolonged	Increased							
	Renal Failure Acute							
	Rhabdomyolysis							

Date:09/13/99ISR Number: 3345336-0Report Type:Expedited (15-DaCompany Report #WAES 99080002
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Initial or Prolonged	Fall	Professional					MG/DAILY/PO	
	Hyponatraemia		Cardizem Cd	C				
	Muscular Weakness		Depakote	C				
			Hydrodiuril	C				
			Levsin	C				
			Tenormin	C				
			Clonazepam	C				
			Nifedipine	C				
			Potassium Chloride	C				

Date:09/13/99ISR Number: 3345343-8Report Type:Expedited (15-DaCompany Report #WAES 99071561
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Blood Urea Increased
Other	Cerebral Ischaemia
	Decreased Appetite
	Diabetes Mellitus
	Inadequate Control
	Electrocardiogram
	Abnormal
	Embolism
	Gastric Ulcer Haemorrhage
	Gastroenteritis
	Helicobacter
	Haematemesis
	Haematocrit Decreased
	Haemoglobin Decreased
	Haemorrhagic Stroke
	Hyperhidrosis
	Hypoaesthesia

		Hyponatraemia Hyporeflexia Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Intake Reduced	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Renal Impairment	Professional				
MG/DAILY/PO							
		White Blood Cell Count Increased	Company Representative	Metamucil	C		
				Norvasc	C		
				Prevacid	C		
				Synthroid	C		
				Aspirin	C		
				Garlic Extract	C		
				Glyburide	C		
				Indapamide	C		
				Vitamins	C		

Date:09/15/99ISR Number: 3347492-7Report Type:Expedited (15-DaCompany Report #WAES 99090342
Age:28 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper	Health	Tab Vioxx Unk	PS		ORAL
1							
Initial or Prolonged		Faeces Discoloured	Professional				
TABLET/DAILY/							
Other		Gastrointestinal	Company				
PO							
		Haemorrhage	Representative				
		Gastrointestinal Injury					
		Haematochezia					

Date:09/15/99ISR Number: 3347494-0Report Type:Expedited (15-DaCompany Report #WAES 99090204
Age:59 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Biopsy Liver Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Blood Alkaline	Professional				
MG/DAILY/PO							
		Phosphatase Increased	Company	Levaquin Unk	SS		

	Blood Bilirubin Increased	Representative	(Therapy
	Dermatitis		Unspecified) C
	Gallbladder Disorder		Vitamins C
	Hepatic Function Abnormal		
	Hypersensitivity		
	Liver Function Test		
	Abnormal		
	Neoplasm		
	Polyp		
	Pruritus		
	Rash Generalised		
	Red Blood Cell		
	Sedimentation Rate		
	Increased		

Date:09/15/99ISR Number: 3347496-4Report Type:Expedited (15-DaCompany Report #WAES 99082157
Age:60 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Blood Amylase Increased
Initial or Prolonged	Faeces Discoloured
	Gallbladder Disorder
	Hepatic Steatosis
	Lipase Increased
	Pancreatitis

	Polyp Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO
			Biaxin	C			
			Skelaxin	C			

Date:09/15/99ISR Number: 3347497-6Report Type:Expedited (15-DaCompany Report #WAES 99095019
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Left Ventricular Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO 9 DAY

Date:09/15/99ISR Number: 3347501-5Report Type:Expedited (15-DaCompany Report #WAES 99081445
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Arthralgia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO
Hospitalization - Initial or Prolonged	Asthenia						
	Confusional State						
Other	Drug Hypersensitivity						
	Dyspnoea		Celebrex	C			
	Hyponatraemia		Coumadin	C			
	Red Blood Cell Sedimentation Rate Increased		Tylenol	C			
	Speech Disorder						

Date:09/15/99ISR Number: 3347503-9Report Type:Expedited (15-DaCompany Report #WAES 99081238
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Anaemia	Professional					MG/DAILY/PO	
Other	Colitis	Company	Bumex	C				
	Colitis Ischaemic	Representative	Depakote	C				
	Colitis Ulcerative		Felbatol	C				
	Gastritis		Tegretol	C				
	Gastrointestinal		Zestril	C				
	Haemorrhage		Chloroquine	C				
	Haematemesis		Folic Acid	C				
	Haematocrit Decreased							
	Hyponatraemia							
	Malaise							
	Rectal Haemorrhage							

Date:09/15/99ISR Number: 3347505-2Report Type:Expedited (15-DaCompany Report #WAES 99081276
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/99ISR Number: 3347507-6Report Type:Expedited (15-DaCompany Report #WAES 99080963
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Visual Disturbance	Professional	Bumex	C				
			K-Dur	C				
			Peri-Colace	C				
			Synthroid	C				
			Tylenol	C				
			Zantac	C				
			Zoloft	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Atenolol	C				
			Lactulose	C				
			Prednisone	C				

Date:09/15/99ISR Number: 3347509-XReport Type:Expedited (15-DaCompany Report #WAES 99080942
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:09/15/99ISR Number: 3347979-7Report Type:Expedited (15-DaCompany Report #9938252
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dizziness	Consumer	Diflucan Tablets	PS		ORAL	150.00 MG	
Intervention to	Drug Interaction							
TOTAL: DAILY:								
Prevent Permanent	Dyspnoea							
ORAL								
Impairment/Damage	Face Oedema		Dilantin	SS				
	Feeling Jittery		Vioxx	SS		ORAL	25.00 MG	

	Headache					
TOTAL: ORAL						
	Nausea		Pencillin	SS		
			Mysoline	C		
			Vicodin	C		

Date:09/16/99ISR Number: 3349031-3Report Type:Expedited (15-DaCompany Report #WAES 99090781
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia	Health	Vioxx	PS		ORAL	25 MG DAILY	
Initial or Prolonged		Professional					PO	
		Company Representative	Accupril	C				

Date:09/16/99ISR Number: 3349043-XReport Type:Expedited (15-DaCompany Report #WAES 99090479
Age:80 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Blood Glucose Increased
Hospitalization -	Blood Urea Increased
Initial or Prolonged	Creatine Phosphokinase
Other	Decreased
	Decreased Appetite
	Duodenal Ulcer

		Duodenitis Endoscopy Upper Gastrointestinal Tract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Health	Vioxx	PS		ORAL
12.5MG/DAILY/							
		Faecal Occult Blood	Professional				
PO							
		Positive	Company	Ativan	C		
		Faeces Discoloured	Representative	Axid	C		
		Gastric Ulcer		Cardizem Cd	C		
		Gastrointestinal		Celexa	C		
		Haemorrhage		Flovent	C		
		Haematemesis		Hytrin	C		
		Haematocrit Decreased		Pepcid	C		
		Melaena		Theragram-M	C		
		Mucosal Inflammation		Tylenol	C		
		Upper Gastrointestinal		Sodium Salicylate	C		
		Haemorrhage					
		Venous Stasis					

Date:09/16/99ISR Number: 3349053-2Report Type:Expedited (15-DaCompany Report #WAES 99090214
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Peptic Ulcer Perforation	Health	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO							
			Professional Company Representative	Therapy Unspecified	C		

Date:09/16/99ISR Number: 3349056-8Report Type:Expedited (15-DaCompany Report #WAES 99082150
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Petechiae	Health	Vioxx	PS		ORAL
UNK/UNK/PO							
		Platelet Count Decreased	Professional Company Representative				

Date:09/16/99ISR Number: 3349062-3Report Type:Expedited (15-DaCompany Report #WAES 99088220
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG	24 DAY
Initial or Prolonged	Drug Interaction	Health	Methotrexate	SS		ORAL	7.5 MG	
	Haemoglobin Decreased	Professional	Prednisone	C				
	Nausea	Other						

Date:09/16/99ISR Number: 3349068-4Report Type:Expedited (15-DaCompany Report #WAES 99080719
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	5 DAY
Initial or Prolonged	Congestive	Professional						
	Fluid Retention	Company	...	C				
	Palpitations	Representative	Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/99ISR Number: 3349071-4Report Type:Expedited (15-DaCompany Report #WAES 99080385
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS		ORAL	25 MG/1X/PO	
	Gastrointestinal Disorder	Health						
	Vomiting	Professional						

Date:09/16/99ISR Number: 3349078-7Report Type:Expedited (15-DaCompany Report #WAES 99070319
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulitis	Health	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Diverticulum	Professional						
Initial or Prolonged	Haemoglobin Decreased	Company	Fosamax	SS		ORAL	10 MG/DAILY/PO	
Disability	Oesophageal Ulcer	Representative						
	Haemorrhage		Ecotrin	C				
			Imuran	C				
			Prednisone	C				
			Sulfalene	C				

Date:09/17/99ISR Number: 3350602-9Report Type:Expedited (15-DaCompany Report #10101772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Methotrexate Tabs					
Initial or Prolonged	Drug Level Above	Health	(Methotrexate)	PS		ORAL	15 MILLIGRAM,	
Other	Therapeutic	Professional					1/1 WEEK ORAL	
	Nausea		Vioxx (Rofecoxib)	SS		ORAL	25 MILLIGRAM,	
	Overdose						1/1 DAY ORAL	
			Spirocort					

(Budesonide) SS ORAL
7.5

MILLLIGRAM,

1/1 DAY ORAL

Date:09/20/99ISR Number: 3351627-XReport Type:Expedited (15-DaCompany Report #WAES 99081243
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
	Haematuria	Company	Amaryl	C				
	Renal Failure Acute	Representative	Cozaar	C				
			Evista	C				
			Neurontin	C				
			Rezulin	C				
			Ziac	C				
			Amitriptyline	C				
			Aspirin	C				
			Chondroitin	C				
			Glucosamine	C				
			Glyburide	C				
			Hypericin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/99ISR Number: 3351628-1Report Type:Expedited (15-DaCompany Report #WAES 99080373
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anuria	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Atrial Fibrillation	Professional	Heparin	SS				
	Cardiac Arrest	Company	Cipro	C				
	Cardiac Failure	Representative	Combivent	C				
	Congestive		Elavil	C				
	Confusional State		Lanoxin	C				
	Dyspnoea		Lasix	C				
	Hyperkalaemia		Neurontin	C				
	Hypoxia		Oxycontin	C				
	Liver Function Test		Premarin	C				
	Abnormal		Serevent	C				
	Metabolic Acidosis		Vicodin	C				
	Neuralgia		Prednisone	C				
	Oedema Peripheral		Verapamil	C				
	Pleural Effusion		Aerobid	C				
	Polyuria							
	Productive Cough							
	Renal Failure Acute							
	Renal Tubular Necrosis							
	Sputum Discoloured							
	Therapeutic Agent							
	Toxicity							
	Thrombocytopenia							

Date:09/20/99ISR Number: 3351630-XReport Type:Expedited (15-DaCompany Report #WAES 99071841
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aspiration Joint Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Interaction	Professional					MG/DAILY/PO	
	International Normalised	Company	Coumadin 5 Mg	SS			5 MG/DAILY	
	Ratio Increased	Representative						
	Joint Swelling							
	Petechiae							
	Prothrombin Time							

Prolonged

Date:09/20/99ISR Number: 3351632-3Report Type:Expedited (15-DaCompany Report #WAES 99090595
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Cancer	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Life-Threatening	Gastric Ulcer	Professional	Percocet	C				
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Company Representative						
Disability	Haematocrit Decreased							
	Platelet Count Decreased							

Date:09/20/99ISR Number: 3351634-7Report Type:Expedited (15-DaCompany Report #WAES 99090743
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
	Blood Magnesium Decreased
	Hypokalaemia

	Muscular Weakness Oedema					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
25 MG/BID/PO	2 WK	Health	Tab Vioxx 25 Mg	PS		ORAL
		Professional	Celebrex	C		
			Therapy Unspecified	C		

Date:09/20/99ISR Number: 3351636-0Report Type:Expedited (15-DaCompany Report #WAES 99090647
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
			Dilantin	C		
			Fioricet Tablets	C		
			Lomotil	C		
			Soma	C		

Date:09/20/99ISR Number: 3351638-4Report Type:Expedited (15-DaCompany Report #WAES 99095065
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx			
Initial or Prolonged	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL
PO						
	Haemorrhage	Professional				
	Haematemesis					

Date:09/21/99ISR Number: 3351837-1Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Dyspnoea		Vioxx	PS		
25MGM Q DAY						
	Oedema					

Date:09/21/99ISR Number: 3352571-4Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Rofecoxib (Vioxx)	PS		ORAL	25 MG PO QD	DAY
Initial or Prolonged	Increased	Professional						
	Pyrexia							

Date:09/21/99ISR Number: 3352882-2Report Type:Expedited (15-DaCompany Report #WAES 99090014
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	
Hospitalization -	Haemorrhage	Professional	Ditropan	C				
Initial or Prolonged	Faeces Discoloured	Company	Lopid	C				
	Haematocrit Decreased	Representative	Macrodantin	C				
	Haemoglobin Decreased		Aspirin	C				
	Orthostatic Hypotension		Clonidine	C				
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/99ISR Number: 3352887-1Report Type:Expedited (15-DaCompany Report #WAES 99061577
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	7 DAY
	Platelet Count Decreased	Professional	Cardizem	C				
			Diabinese	C				

Date:09/21/99ISR Number: 3352892-5Report Type:Expedited (15-DaCompany Report #WAES 99081036
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG	
Hospitalization -	Haemorrhage						/UNK/PO	
Initial or Prolonged	Insomnia		Estraderm					
	Oral Intake Reduced		Transdermal System	C				
	Stress		Norflex	C				
	Tachycardia		Prevacid	C				
	Ulcer		Tylenol Arthritis Extended Realief	C				

Date:09/22/99ISR Number: 3353251-1Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS		ORAL	1T PO QD	
Initial or Prolonged	Haemorrhage							

Date:09/22/99ISR Number: 3354343-3Report Type:Expedited (15-DaCompany Report #WAES 99090783
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Bilirubin Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Disability	Cholestasis	Professional				
MG/QID/PO						
Other	Jaundice	Company	Diovan Hct	C		
	Liver Function Test	Representative	Elavil	C		
	Abnormal		Neurontin	C		
	Pleural Effusion		Synthroid	C		
	Pruritus		Nicotinic Acid	C		

Date:09/22/99ISR Number: 3354348-2Report Type:Expedited (15-DaCompany Report #WAES 99081608
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						
Initial or Prolonged	Haemorrhage	Professional	Glucophage	C		
Disability	Faecal Occult Blood	Company	Lipitor	C		
Other	Positive	Representative	Plavix	C		
	Gastric Ulcer		Glyburide	C		
	Gastrointestinal					
	Haemorrhage					
	Haematemesis					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Melaena					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3354355-XReport Type:Expedited (15-DaCompany Report #WAES 99080474
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bleeding Time Prolonged	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Chest Pain	Professional					MG/DAILY/PO	
	Haematocrit Decreased	Company						
	Haemoglobin Decreased	Representative						
	Pancytopenia							
	Platelet Count Decreased							
	White Blood Cell Count Decreased							

Date:09/22/99ISR Number: 3354359-7Report Type:Expedited (15-DaCompany Report #WAES 99071618
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Chest Pain	Professional	Duragesic	C				
	Lethargy		K-Dur	C				
	Platelet Count Decreased		Lasix	C				
	Proteinuria		Singulair	C				
	Pulmonary Embolism		(Therapy					
	Retinal Haemorrhage		Unspecified)	C				
	Thrombotic		Prednisone	C				
	Thrombocytopenic Purpura							
	Visual Disturbance							

Date:09/22/99ISR Number: 3354892-8Report Type:Expedited (15-DaCompany Report #WAES 99090928
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Study	Tab Rofecoxib 50 Mg	PS		ORAL	50 MG/ DAILY/	
Initial or Prolonged	Ejection Fraction	Health					PO	

	Abnormal	Professional	Tab Placebo	SS		ORAL
1 TABLET/						
	Hypokinesia					
BID/ PO						
			Tab Acetaminophen 325 Mg	SS		ORAL
PRN/ PO						
			Tab Placebo	SS		ORAL
1 TABLET/						
DAILY/ PO						
			Sulfasalazine	C		

Date:09/22/99ISR Number: 3363206-9Report Type:Periodic Company Report #WAES 99070884
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Health	Tab Vioxx Unk	PS		ORAL
UNK/ UNK/ PO						
		Professional				

Date:09/22/99ISR Number: 3363210-0Report Type:Periodic Company Report #WAES 99070931
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						
		Professional	Keflex	SS		
		Company Representative				

Date:09/22/99ISR Number: 3363212-4Report Type:Periodic Company Report #WAES 99070933
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/22/99ISR Number: 3363216-1Report Type:Periodic Company Report #WAES 99070950
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg; 12.5 Mg	PS		ORAL	UNK/UNK/PO	
			Coumadin	C				

Date:09/22/99ISR Number: 3363242-2Report Type:Periodic Company Report #WAES 99070952
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/DAILY/PO	
	Red Blood Cell Sedimentation Rate Increased		[Composition Unspecified]	C				

Date:09/22/99ISR Number: 3363243-4Report Type:Periodic Company Report #WAES 99070953
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3363244-6Report Type:Periodic Company Report #WAES 99070954
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Oedema Peripheral	Professional Company Representative						

Date:09/22/99ISR Number: 3363247-1Report Type:Periodic Company Report #WAES 99070957
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
			Altace	C				
			Maxzide	C				
			Prevacid	C				

Date:09/22/99ISR Number: 3363252-5Report Type:Periodic Company Report #WAES 99071022
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Headache	Health
	Influenza	Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk 12.5 Mg	PS		ORAL	50 MG/DAILY/PO; 12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3363264-1Report Type:Periodic Company Report #WAES 99071031
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/AM/PO	
	Pruritus		Miacalcin	C				
			Xanax	C				
			Aspirin	C				
			Chondroitin Sulfate	C				
			Glucosamine	C				

Date:09/22/99ISR Number: 3363267-7Report Type:Periodic Company Report #WAES 99071032
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/BID/PO	
	Dyspepsia		Verapamil	C				

Date:09/22/99ISR Number: 3363268-9Report Type:Periodic Company Report #WAES 99071036
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chills	Consumer	Tab Vioxx 50 Mg	PS		ORAL
UNK/UNK/PO						
	Headache		Claritin-D	C		
	Hyperhidrosis					
	Pallor					

Date:09/22/99ISR Number: 3363270-7Report Type:Periodic Company Report #WAES 99071037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL
UNK/UNK/PO						
	Asthma		[Therapy			
	Feeling Abnormal		Unspecified]	C		
	Insomnia		Prednisone	C		

Date:09/22/99ISR Number: 3363272-0Report Type:Periodic Company Report #WAES 99071126
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
UNK/UNK/PO						
	Fatigue		Estrogenic			
	Feeling Abnormal		Preparations			
	Gastrooesophageal Reflux		(Composi Unk - Unk)	C		
	Disease					
	Hyperhidrosis					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3363273-2Report Type:Periodic Company Report #WAES 99071156
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional						
		Company						
		Representative						

Date:09/22/99ISR Number: 3363275-6Report Type:Periodic Company Report #WAES 99071157
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional						

Date:09/22/99ISR Number: 3363277-XReport Type:Periodic Company Report #WAES 99071184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health	Tab Vioxx 12.5 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dizziness	Professional						
	Dyspnoea	Company						
	Muscular Weakness	Representative						

Date:09/22/99ISR Number: 3363278-1Report Type:Periodic Company Report #WAES 99071190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Company						
		Representative						

Date:09/22/99ISR Number: 3363280-XReport Type:Periodic Company Report #WAES 99071196
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Dyspepsia							
			Bentyl	C				
			Levoxyl	C				
			Mirapex	C				
			Sinemet Cr	C				

Date:09/22/99ISR Number: 3363281-1Report Type:Periodic Company Report #WAES 99071217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3363314-2Report Type:Periodic Company Report #WAES 99071218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Mental Impairment	Professional						
	Nervous System Disorder	Company						
		Representative						

Date:09/22/99ISR Number: 3363315-4Report Type:Periodic Company Report #WAES 99071220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Mental Impairment	Professional						
	Nervous System Disorder	Company						
		Representative						

Date:09/22/99ISR Number: 3363317-8Report Type:Periodic Company Report #WAES 99071227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Tab Vioxx Unk	PS		ORAL	PO	4 DAY
	Faecal Occult Blood	Professional	Celebrex	C				
	Faeces Discoloured	Company						
		Representative						

Date:09/22/99ISR Number: 3363318-XReport Type:Periodic Company Report #WAES 99071236
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:09/22/99ISR Number: 3363320-8Report Type:Periodic Company Report #WAES 99071249
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	DAILY, PO	
	Oedema Peripheral	Professional Company Representative						

Date:09/22/99ISR Number: 3363321-XReport Type:Periodic Company Report #WAES 99071263
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO	
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3363323-3Report Type:Periodic Company Report #WAES 99071264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colour Vision Tests	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/PO	4 WK
	Abnormal Photosensitivity Reaction							
	Vision Blurred							

Date:09/22/99ISR Number: 3363324-5Report Type:Periodic Company Report #WAES 99071271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Tab Vioxx 12.5 Mg	PS				

Date:09/22/99ISR Number: 3363325-7Report Type:Periodic Company Report #WAES 99071273
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Vitamins	C				

Date:09/22/99ISR Number: 3363326-9Report Type:Periodic Company Report #WAES 99071282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Increased	Professional	Glucophage	C				
			Humibid L.A.	C				
			Lasix	C				
			Pepcid	C				
			Amiodarone	C				
			Cefadroxil	C				
			Potassium Supplement	C				

Date:09/22/99ISR Number: 3363327-0Report Type:Periodic Company Report #WAES 99071283
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Ery-Tab	C				
			Loestrin	C				
			Prilosec	C				
			Proventil	C				
			Vanceril	C				
			Zoloft	C				
			Lactulose	C				
			Metoclopramide	C				

Date:09/22/99ISR Number: 3363329-4Report Type:Periodic Company Report #WAES 99071321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3363330-0Report Type:Periodic Company Report #WAES 99071341
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Malaise							

Date:09/22/99ISR Number: 3363331-2Report Type:Periodic Company Report #WAES 99071347
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Toprol Xl Tablets	C				

Date:09/22/99ISR Number: 3363332-4Report Type:Periodic Company Report #WAES 99071355
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Health Professional	Cardizem	C				
			Prilosec	C				
			Zestoretic	C				
			Zestril	C				
			Ascorbic Acid	C				
			Insulin Injection (+) Isophane	C				

Date:09/22/99ISR Number: 3363333-6Report Type:Periodic Company Report #WAES 99071359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Vision Blurred	Professional Company Representative	Vicodin Tablets	C				

Date:09/22/99ISR Number: 3363334-8Report Type:Periodic Company Report #WAES 99071378
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Chronulac	C				
			Estraderm	C				
			Flonase	C				
			Premarin Vaginal Cream	C				
			Prevacid	C				

Date:09/22/99ISR Number: 3363335-XReport Type:Periodic Company Report #WAES 99071382
Age:36 YR Gender:Female I/FU:I

Outcome	PT
	Arthralgia
	Dyspnoea

		Ecchymosis					
		Gait Disturbance					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Tab Vioxx Mg	PS		ORAL
MG/PO							
			Professional Company Representative	Zomig	C		

Date:09/22/99ISR Number: 3363336-1Report Type:Periodic Company Report #WAES 99071399
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Pain	Health	Tab Vioxx Unk	PS		ORAL
PO							
			Professional				

Date:09/22/99ISR Number: 3363337-3Report Type:Periodic Company Report #WAES 99071403
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
BID, PO							
		Fatigue					
		Flushing					
		Sedation					

Date:09/22/99ISR Number: 3364261-2Report Type:Periodic Company Report #WAES 99070609
Age:82 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO							
		Feeling Abnormal		Zocor	C		
		Haemorrhage		Prednisone	C		
		Nausea					

Date:09/22/99ISR Number: 3364264-8Report Type:Periodic Company Report #WAES 99070614
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Premarin Vaginal Cream	C				
			Vaseretic	C				

Date:09/22/99ISR Number: 3364267-3Report Type:Periodic Company Report #WAES 99070664
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3364273-9Report Type:Periodic Company Report #WAES 99070696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3364276-4Report Type:Periodic Company Report #WAES 99070698
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Prednisone	C				

Date:09/22/99ISR Number: 3364277-6Report Type:Periodic Company Report #WAES 99070720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PM/PO	
	Weight Increased		Celebrex	C				

Date:09/22/99ISR Number: 3364279-XReport Type:Periodic Company Report #WAES 99070733
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3364280-6Report Type:Periodic Company Report #WAES 99070734
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammatory Bowel	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	5 DAY
	Disease	Health Professional	Allegra	C				
			Lanoxin	C				
			Taxol	C				
			Glycerol	C				

Date:09/22/99ISR Number: 3364281-8Report Type:Periodic Company Report #WAES 99070741
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3364282-XReport Type:Periodic Company Report #WAES 99070747
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Urticaria		Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3364284-3Report Type:Periodic Company Report #WAES 99070770
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Headache	Health	Citrucel Orange					
	Nausea	Professional	Flavor	C				
			Elavil	C				
			Excedrin					
			Extra-Strength	C				
			Premarin	C				
			Tenoretic	C				
			Docusate Sodium	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3364285-5Report Type:Periodic Company Report #WAES 99070771
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Urinary Tract Disorder	Professional						
		Company						
		Representative						

Date:09/22/99ISR Number: 3364286-7Report Type:Periodic Company Report #WAES 99070790
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspnoea	Professional					MG/DAILY/PO	
	Hypersensitivity	Company	Klonopin	C				
	Palpitations	Representative	Neurontin	C				
			Remeron	C				

Date:09/22/99ISR Number: 3364289-2Report Type:Periodic Company Report #WAES 99070797
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Syncope Vasovagal	Professional						
		Company Representative	Tylenol With Codeine #3 Unk	SS			PRN	
			Lodine	C				
			Maxzide	C				
			Premarin	C				
			Glucosamine	C				

Date:09/22/99ISR Number: 3364292-2Report Type:Periodic Company Report #WAES 99070800
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Ratio Increased	Professional	Coumadin	C				
		Company Representative	Feosol	C				
			Imdur	C				
			Lipitor	C				
			Lopressor	C				
			Macrobid	C				

Micronase	C
Nitroglycerin	C
Norvasc	C
Synthroid	C
Acetaminophen	C

Date:09/22/99ISR Number: 3364295-8Report Type:Periodic Company Report #WAES 99070801
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Photosensitivity Reaction	Professional	(Therapy Unspecified) Unk.	SS				

Date:09/22/99ISR Number: 3364296-XReport Type:Periodic Company Report #WAES 99070824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3364299-5Report Type:Periodic Company Report #WAES 99070829
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Headache	Professional						
	Oedema Peripheral							

Date:09/22/99ISR Number: 3364302-2Report Type:Periodic Company Report #WAES 99070831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Insomnia						MG/DAILY/PO	
	Nervousness		Lodine	C				
			Tylenol Pm	C				

Date:09/22/99ISR Number: 3364303-4Report Type:Periodic Company Report #WAES 99070832
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pruritus		Aspirin	C				
			Tylenol	C				
			Chondroitin Sulfate (+) Glucosam	C				

Date:09/22/99ISR Number: 3365038-4Report Type:Periodic Company Report #WAES 99061328
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG	
	Hypoaesthesia	Health					/DAILY/PO	
	Paraesthesia	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365079-7Report Type:Periodic Company Report #WAES 99061364
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/PO	
	Nausea							
	Tachycardia		Hydrodiuril	C				
			Kenalog	C				
			Premarin	C				
			Vicodin	C				
			Potassium Chloride	C				

Date:09/22/99ISR Number: 3365084-0Report Type:Periodic Company Report #WAES 99061365
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG /DAILY/PO	
			Donnatal	C				
			Hydrochlorothiazide	C				
			Prevacid	C				
			Synthroid	C				
			Ultram	C				

Date:09/22/99ISR Number: 3365089-XReport Type:Periodic Company Report #WAES 99061375
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG /DAILY/PO	
	Hyperglycaemia							
			Tarka	C				

Date:09/22/99ISR Number: 3365091-8Report Type:Periodic Company Report #WAES 99061376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365096-7Report Type:Periodic Company Report #WAES 99061388
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365101-8Report Type:Periodic Company Report #WAES 99061412
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG /DAILY/PO	
	Migraine							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365104-3Report Type:Periodic Company Report #WAES 99061438
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Diarrhoea							

Date:09/22/99ISR Number: 3365109-2Report Type:Periodic Company Report #WAES 99061450
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365113-4Report Type:Periodic Company Report #WAES 99061454
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Other	Tab Vioxx 25mg	PS		ORAL	25MG/AMPO	
	Back Pain		Darvocet-N	C				
	Fatigue		Imdur	C				
	Feeling Drunk		Premarin	C				
	Gait Disturbance		Prinivil	C				
	Hypokinesia		Zyrexa	C				
	Weight		Aspirin	C				

Date:09/22/99ISR Number: 3365116-XReport Type:Periodic Company Report #WAES 99061552
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG , 25MG	

	Blood Pressure Increased	Health					
/DAILY/PO							
	Dizziness Postural	Professional	Zantac	C			
	Tachycardia		Vitamins	C			

Date:09/22/99ISR Number: 3365121-3Report Type:Periodic Company Report #WAES 99061561
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG 12.5 MG	
	Drug Ineffective							
/DAILY/PO								
	Headache		Celebrex	C				
	Nausea		Micronase	C				
			Premarin	C				
			Prevacid	C				
			Zocor	C				
			Chondroitin	C				

Date:09/22/99ISR Number: 3365127-4Report Type:Periodic Company Report #WAES 99061563
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365129-8Report Type:Periodic Company Report #WAES 99061583
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx	PS		ORAL	12.5MG/DAILY/	
	International Normalised Ratio Increased	Professional	Coumadin	SS			PO	
	Nausea							

Date:09/22/99ISR Number: 3365132-8Report Type:Periodic Company Report #WAES 99061589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365145-6Report Type:Periodic Company Report #WAES 99061618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5MG	
	Dermatitis	Professional					/DAILY/PO	
	Pruritus	Company Representative						

Date:09/22/99ISR Number: 3365148-1Report Type:Periodic Company Report #WAES 99061624
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	
	Hypoaesthesia							

Date:09/22/99ISR Number: 3365154-7Report Type:Periodic Company Report #WAES 99061641
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG	/DAILY/PO
	Dizziness							
	Drug Ineffective		Plaquenil	C				

Date:09/22/99ISR Number: 3365158-4Report Type:Periodic Company Report #WAES 99061642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx	PS		ORAL	PO	
	Fatigue	Professional						
	Muscle Spasms							

Date:09/22/99ISR Number: 3365163-8Report Type:Periodic Company Report #WAES 99061653
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365236-XReport Type:Periodic Company Report #WAES 99081550
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ecotrin	C				
			Lanoxin	C				
			Lasix	C				
			Micro	C				
			Allopurinol	C				

Date:09/22/99ISR Number: 3365239-5Report Type:Periodic Company Report #WAES 99081564
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Celebrex	C				
			Prevacid	C				
			Timoptic	C				
			Xalatan	C				

Date:09/22/99ISR Number: 3365242-5Report Type:Periodic Company Report #WAES 99081565
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365244-9Report Type:Periodic Company Report #WAES 99081566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	24 HR
		Professional	Aldactazide	C				
			Elavil	C				
			Pravachol	C				
			Zoloft	C				
			Folic Acid	C				
			Methotrexate	C				

Date:09/22/99ISR Number: 3365248-6Report Type:Periodic Company Report #WAES 99081570
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Feeling Abnormal							
			Hydrodiuril	C				
			Oxazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365250-4Report Type:Periodic Company Report #WAES 99081580
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Drug Interaction	Professional	Velosef Unk	SS		ORAL	PO	
		Company Representative						

Date:09/22/99ISR Number: 3365252-8Report Type:Periodic Company Report #WAES 99081583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Paraesthesia	Professional	Lipitor	C				
			Requip	C				
			Quinine	C				

Date:09/22/99ISR Number: 3365256-5Report Type:Periodic Company Report #WAES 99081598
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:09/22/99ISR Number: 3365280-2Report Type:Periodic Company Report #WAES 99081599
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Professional

Date:09/22/99ISR Number: 3365283-8Report Type:Periodic Company Report #WAES 99081601
Age:2 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	75 MG / 1X/PO	
	Fatigue	Professional						

Date:09/22/99ISR Number: 3365285-1Report Type:Periodic Company Report #WAES 99081614
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:09/22/99ISR Number: 3365289-9Report Type:Periodic Company Report #WAES 99081617
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365290-5Report Type:Periodic Company Report #WAES 99081620
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /DAILY / PO	
		Company Representative	Celebrex Unk	SS				
			Premarin	C				

Date:09/22/99ISR Number: 3365293-0Report Type:Periodic Company Report #WAES 99081628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/ DAILY. PO	
	Dyspnoea							
	Rash Erythematous	Company Representative	Vaseretic	C				
	Tremor		Triamcinolone	C				

Date:09/22/99ISR Number: 3365294-2Report Type:Periodic Company Report #WAES 99081691
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILYU/ PO	
		Company Representative						

Date:09/22/99ISR Number: 3365295-4Report Type:Periodic Company Report #WAES 99081711
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG /						
	Oedema Peripheral	Professional				
DAILY/ PO						
		Company	Tab Vioxx 25 Mg	SS		ORAL
25 MG /						
		Representative				
DAILY/ PO						
			Ogen	C		
			Prozac	C		
			Zocor	C		
			Desonide	C		
			Vitamin E	C		

Date:09/22/99ISR Number: 3365296-6Report Type:Periodic Company Report #WAES 99081713
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG / DAILY						
	Dyspnoea	Professional				
/ PO						
	Weight Increased	Company	Coumadin	C		
		Representative	Hydrodiuril	C		
			Rythmol	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365298-XReport Type:Periodic Company Report #WAES 99081714
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:09/22/99ISR Number: 3365299-1Report Type:Periodic Company Report #WAES 99081727
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG / DAILY	
	Muscle Rigidity						/ PO	
			Catapres	C				
			Coreg	C				
			Diovan	C				
			Miacalcin	C				
			Synthroid	C				
			Glyburide	C				

Date:09/22/99ISR Number: 3365342-XReport Type:Periodic Company Report #WAES 99081810
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:09/22/99ISR Number: 3365352-2Report Type:Periodic Company Report #WAES 99070127
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Celebrex	C				

Date:09/22/99ISR Number: 3365356-XReport Type:Periodic Company Report #WAES 99070141
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Lanoxin	C				
			Tambocor	C				

Date:09/22/99ISR Number: 3365360-1Report Type:Periodic Company Report #WAES 99070142
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Daypro	C				
			Premarin	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365363-7Report Type:Periodic Company Report #WAES 99070217
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365364-9Report Type:Periodic Company Report #WAES 99070218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365365-0Report Type:Periodic Company Report #WAES 99070219
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365367-4Report Type:Periodic Company Report #WAES 99070220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	3 DAY
	Diarrhoea							
	Dysgeusia	Company Representative	Celebrex	C				
	Dyspepsia		Fioricet Tablets	C				
	Fatigue							

Nausea
Pain

Date:09/22/99ISR Number: 3365369-8Report Type:Periodic Company Report #WAES 99070229
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Glossitis	Health						
	Tongue Disorder	Professional	Synthroid	C				

Date:09/22/99ISR Number: 3365372-8Report Type:Periodic Company Report #WAES 99070231
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO - 25 MG/DAILY/PO	
			Dyazide	C				
			Elavil	C				
			Prempro	C				
			Synthroid	C				
			Zestril	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365375-3Report Type:Periodic Company Report #WAES 99070237
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspnoea		Celebrex	C				
	Oedema Peripheral		Lasix	C				

Date:09/22/99ISR Number: 3365376-5Report Type:Periodic Company Report #WAES 99071824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoarthritis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/AM/PO	
		Professional	Fosamax	C				
			Tiazac	C				

Date:09/22/99ISR Number: 3365378-9Report Type:Periodic Company Report #WAES 99070244
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Insomnia		Darvocet-N	C				
			Ultram	C				

Date:09/22/99ISR Number: 3365381-9Report Type:Periodic Company Report #WAES 99070249
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Nausea	Health					MG/DAILY/PO	
	Pruritus	Professional	Atenolol	C				

Date:09/22/99ISR Number: 3365382-0Report Type:Periodic Company Report #WAES 99071826
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Health	Tab Vioxx Unk	PS		ORAL	25	
	Melaena	Professional					MG/DAILY/PO	
			Atrovent	C				
			Cardura	C				
			Flovent	C				
			K-Dur	C				
			Naprosyn	C				
			Zantac	C				
			Piroxicam	C				

Date:09/22/99ISR Number: 3365384-4Report Type:Periodic Company Report #WAES 99070259
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne	Consumer	Tab Vioxx Unk	PS		ORAL	12.5	
	Change Of Bowel Habit						MG/DAILY/PO	
	Dizziness Postural		Prednisone	C				
	Headache							
	Keratoconjunctivitis							
	Sicca							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365387-XReport Type:Periodic Company Report #WAES 99070286
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Lorcet Plus	C				
			Piroxicam	C				

Date:09/22/99ISR Number: 3365390-XReport Type:Periodic Company Report #WAES 99070293
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:09/22/99ISR Number: 3365392-3Report Type:Periodic Company Report #WAES 99071839
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Blood Pressure Decreased		Proscar	C				

Date:09/22/99ISR Number: 3365393-5Report Type:Periodic Company Report #WAES 99070294
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	50 MG/UNK/PO	
		Professional						

Date:09/22/99ISR Number: 3365395-9Report Type:Periodic Company Report #WAES 99070306
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Constipation							
	Nausea		Sinemet	C				
			Sinemet Cr	C				
			Synthroid	C				
			Zantac	C				

Date:09/22/99ISR Number: 3365397-2Report Type:Periodic Company Report #WAES 99071845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365398-4Report Type:Periodic Company Report #WAES 99070311
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
	Dyspepsia		Clinoril	C				
	Dyspnoea		Mevacor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365401-1Report Type:Periodic Company Report #WAES 99070321
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Lanoxin	C				
			Restoril	C				

Date:09/22/99ISR Number: 3365406-0Report Type:Periodic Company Report #WAES 99071846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	C				
			Plavix	C				

Date:09/22/99ISR Number: 3365407-2Report Type:Periodic Company Report #WAES 99070333
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365410-2Report Type:Periodic Company Report #WAES 99071888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Claritin	C				
			Flexeril	C				
			Prilosec	C				

				Pulmicort	C	
				Albuterol	C	
				Verapamil	C	

Date:09/22/99ISR Number: 3365413-8Report Type:Periodic Company Report #WAES 99071914
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		
	Insomnia		Benadryl	C		
			Deconamine	C		
			Lasix	C		
			Levoxyl	C		
			Prozac	C		

Date:09/22/99ISR Number: 3365415-1Report Type:Periodic Company Report #WAES 99071429
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL
25 MG/AM/PO						
	Haemorrhoids					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365417-5Report Type:Periodic Company Report #WAES 99071924
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Armour Thyroid Tablets	C				
			Premarin	C				
			Prednisone	C				

Date:09/22/99ISR Number: 3365419-9Report Type:Periodic Company Report #WAES 99071431
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365421-7Report Type:Periodic Company Report #WAES 99071440
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Atenolol	C				
			Penicillin (Drug)	C				

Date:09/22/99ISR Number: 3365423-0Report Type:Periodic Company Report #WAES 99071447
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	4 DAY

Company
Representative

Date:09/22/99ISR Number: 3365425-4Report Type:Periodic Company Report #WAES 99071489
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365428-XReport Type:Periodic Company Report #WAES 99071497
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	
			Lortab	C				
			Mellaril	C				
			Sinemet Cr	C				
			Atenolol	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365429-1Report Type:Periodic Company Report #WAES 99071932
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Neurontin	C				
			Therapy Unspecified	C				

Date:09/22/99ISR Number: 3365430-8Report Type:Periodic Company Report #WAES 99071521
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO,	
	Hypoaesthesia						25MG/PO	
			Calan Sr	C				
			Lescol	C				
			Paxil	C				
			Premarin	C				

Date:09/22/99ISR Number: 3365431-XReport Type:Periodic Company Report #WAES 99071942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365434-5Report Type:Periodic Company Report #WAES 99071522
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/PO	

			Imitrex	C		

Date:09/22/99ISR Number: 3365435-7Report Type:Periodic Company Report #WAES 99071950
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Nausea							

Date:09/22/99ISR Number: 3365437-0Report Type:Periodic Company Report #WAES 99071538
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ecotrin	C				
			Tenormin	C				

Date:09/22/99ISR Number: 3365438-2Report Type:Periodic Company Report #WAES 99071957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365440-0Report Type:Periodic Company Report #WAES 99071541
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365442-4Report Type:Periodic Company Report #WAES 99071960
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365443-6Report Type:Periodic Company Report #WAES 99071545
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Celebrex	C				
			Lanoxin	C				

Date:09/22/99ISR Number: 3365447-3Report Type:Periodic Company Report #WAES 99071968
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	
	Flatulence		Climara	C				
			Atenolol	C				
			Hydrochlorothiazide	C				

Date:09/22/99ISR Number: 3365448-5Report Type:Periodic Company Report #WAES 99071546
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Amylase Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Therapy Unspecified	C				

Date:09/22/99ISR Number: 3365450-3Report Type:Periodic Company Report #WAES 99071556
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema Peripheral		Fosamax	C				
	Pain							

Date:09/22/99ISR Number: 3365451-5Report Type:Periodic Company Report #WAES 99071993
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Tab Vioxx Unk	PS		ORAL	1X/PO	1 DAY
	Ventricular Extrasystoles	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365452-7Report Type:Periodic Company Report #WAES 99071560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Attention Deficit/Hyperactivity Disorder	Professional Company Representative						
	Palpitations							

Date:09/22/99ISR Number: 3365453-9Report Type:Periodic Company Report #WAES 99071602
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Company	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Hypoaesthesia	Representative	Premarin	C				
	Mental Impairment	Other						
	Nausea							

Date:09/22/99ISR Number: 3365454-0Report Type:Periodic Company Report #WAES 99072035
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Rhinorrhoea		Aldactazide	C				
	Salivary Hypersecretion		Ativan	C				
			Inderal	C				
			Zyloprim	C				
			Hydrocodone	C				

Date:09/22/99ISR Number: 3365455-2Report Type:Periodic Company Report #WAES 99071607
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Mouth Ulceration	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL PO
			Premarin	C		
			Zocor	C		
			[Composition Unspecified]	C		

Date:09/22/99ISR Number: 3365459-XReport Type:Periodic Company Report #WAES 99072074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS			DAILY	
	Congestive Oedema	Professional	Bumex	C				
			Prinivil	C				
			Composition Unspecified	C				

Date:09/22/99ISR Number: 3365460-6Report Type:Periodic Company Report #WAES 99071610
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Mouth Ulceration	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365462-XReport Type:Periodic Company Report #WAES 99072075
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 12.5 Mg	PS				

Date:09/22/99ISR Number: 3365463-1Report Type:Periodic Company Report #WAES 99071676
Age:72 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Evista	C				
			Hydrodiuril	C				
			Synthroid	C				

Date:09/22/99ISR Number: 3365464-3Report Type:Periodic Company Report #WAES 99071693
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Fosamax	C				
			Synthroid	C				
			Aspirin	C				

Date:09/22/99ISR Number: 3365465-5Report Type:Periodic Company Report #WAES 99072076
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365466-7Report Type:Periodic Company Report #WAES 99072077
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365467-9Report Type:Periodic Company Report #WAES 99071697
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/PO	
	Drug Ineffective		Klonopin	C				
			Lozol	C				
			Mirapex	C				
			Voltaren	C				
			Voltaren	C				
			Zyloprim	C				
			B Vitamins	C				
			Nonsteroidal Anti-Inflammatory D	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3365469-2Report Type:Periodic Company Report #WAES 99081402
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Cozaar	C				
			Prevacid	C				

Date:09/22/99ISR Number: 3365470-9Report Type:Periodic Company Report #WAES 99081407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	

Date:09/22/99ISR Number: 3365472-2Report Type:Periodic Company Report #WAES 99081416
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Disorientation	Professional Company Representative						

Date:09/22/99ISR Number: 3365473-4Report Type:Periodic Company Report #WAES 99081419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional	Inderal	C				

Date:09/22/99ISR Number: 3365475-8Report Type:Periodic Company Report #WAES 99081421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/UNK/PO	4 DAY
			Plendil	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365478-3Report Type:Periodic Company Report #WAES 99081443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/UNK/PO	
	Influenza		Prevacid	C				
			Synthroid	C				
			Iron (Unspecified)	C				
			Methotrexate	C				

Date:09/22/99ISR Number: 3365481-3Report Type:Periodic Company Report #WAES 99081448
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO, 25 MG/DAILY/PO	
			Hytrin	C				
			Ziac	C				
			Zocor	C				
			Ascorbic Acid	C				
			Cortisone	C				
			Pyridoxine	C				
			Vitamin A	C				
			Vitamin E	C				
			Zinc Preparation (Composition Unspecified)	C				

Date:09/22/99ISR Number: 3365483-7Report Type:Periodic Company Report #WAES 99081449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
UNK/UNK/PO						

Date:09/22/99ISR Number: 3365486-2Report Type:Periodic Company Report #WAES 99081450
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Health	Tab Vioxx Unk	PS		ORAL
UNK/DAILY/PO						
		Professional				

Date:09/22/99ISR Number: 3365490-4Report Type:Periodic Company Report #WAES 99081453
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						
			Vitamins	C		

Date:09/22/99ISR Number: 3365492-8Report Type:Periodic Company Report #WAES 99081461
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Tab Vioxx Unk	PS		ORAL
25						
	Dyspnoea					
MG/DAILY/PO						
			Zantac	C		

Aspirin C

Date:09/22/99ISR Number: 3365496-5Report Type:Periodic Company Report #WAES 99081475
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx Unk	PS		ORAL	1	
	Feeling Abnormal	Professional						

TABLET/BID/PO

Date:09/22/99ISR Number: 3365501-6Report Type:Periodic Company Report #WAES 99081479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx Unk	PS		ORAL	25	
	Muscular Weakness	Professional						
	Myalgia							

MG/DAILY/PO 3 WK

Date:09/22/99ISR Number: 3365503-XReport Type:Periodic Company Report #WAES 99081483
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

MG/UNK/PO

Date:09/22/99ISR Number: 3365506-5Report Type:Periodic Company Report #WAES 99060316
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Feeling Abnormal		Prempro	C		
			Tenormin	C		
			Prednisone	C		

Date:09/22/99ISR Number: 3365508-9Report Type:Periodic Company Report #WAES 99081487
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Diarrhoea					
MG/DAILY/PO,						
	Drug Ineffective					
12.5						
	Pyrexia					
MG/QID/PO						
			Cardizem Cd	C		
			Cytomel	C		
			Hyzaar	C		
			Synthroid	C		
			Zocor	C		

Date:09/22/99ISR Number: 3365511-9Report Type:Periodic Company Report #WAES 99060575
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Tongue Discolouration	Health				
MG/DAILY/PO						
	Tongue Disorder	Professional	Norvasc	C		
			Hydrochlorothiazide			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(+) Triamter C

Date:09/22/99ISR Number: 3365513-2Report Type:Periodic Company Report #WAES 99081488
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Prednisone	C				

Date:09/22/99ISR Number: 3365515-6Report Type:Periodic Company Report #WAES 99060682
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO	
	Diarrhoea	Health Professional						
			Darvocet-N	C				
			Miacalin	C				
			Prilosec	C				
			Synthroid	C				

Date:09/22/99ISR Number: 3365518-1Report Type:Periodic Company Report #WAES 99060741
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Palsy	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365520-XReport Type:Periodic Company Report #WAES 99081505
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365521-1Report Type:Periodic Company Report #WAES 99081506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/DAILY/PO	
	Weight Increased							

Date:09/22/99ISR Number: 3365522-3Report Type:Periodic Company Report #WAES 99081518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Alopecia	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/22/99ISR Number: 3365524-7Report Type:Periodic Company Report #WAES 99081520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haemorrhage							
	Muscular Weakness							

Date:09/22/99ISR Number: 3365527-2Report Type:Periodic Company Report #WAES 99060752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Productive Cough	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Inhl [Therapy Unspecified]	SS		RESPIRATORY	(INHALATION)	INH
			Allegra	C				
			Elavil	C				
			L-Thyroxin	C				
			Estradiol	C				

Date:09/22/99ISR Number: 3365529-6Report Type:Periodic Company Report #WAES 99060754
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Pruritus	Professional					MG/DAILY/PO	
			Ambien	C				
			Celebrex	C				
			Estratest	C				
			Klonopin	C				
			Procrit	C				
			Serzone	C				
			Doxepin	C				

Date:09/22/99ISR Number: 3365536-3Report Type:Periodic Company Report #WAES 99080494
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:09/22/99ISR Number: 3365557-0Report Type:Periodic Company Report #WAES 99080501
Age: Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Feeling Abnormal

Increased Appetite
Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365573-9Report Type:Periodic Company Report #WAES 99080510
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Company Representative	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	
			Fosamax	C				
			Neurontin	C				
			Premarin	C				
			Zocor	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/22/99ISR Number: 3365575-2Report Type:Periodic Company Report #WAES 99080512
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	BID/PO	5 DAY
			Toprol Xl Tablets	C				

Date:09/22/99ISR Number: 3365576-4Report Type:Periodic Company Report #WAES 99080513
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Insomnia		Diovan	C				
			Norvasc	C				

			Premarin	C		
			Prevacid	C		
			Propulsid	C		
			Synthroid	C		
			Ultram	C		
			Alprazolam	C		
			Atenolol	C		
			Clonidine	C		
			Furosemide	C		

Date:09/22/99ISR Number: 3365582-XReport Type:Periodic Company Report #WAES 99080514
Age:78 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Weight Increased							
			Glucophage	C				
			Hydrodiuril	C				
			Prilosec	C				
			Rezulin	C				
			Synthroid	C				
			Zocor	C				
			Aspirin	C				
			Atenolol	C				
			Captopril	C				

			Chondroitin (+)	
			Glucosamine	C
			Vitamin E	C

Date:09/22/99ISR Number: 3365586-7Report Type:Periodic Company Report #WAES 99080516
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Nausea		Accupril	C				
			Elavil	C				
			Lipitor	C				
			Lortab	C				
			Xanax	C				

Date:09/22/99ISR Number: 3365588-0Report Type:Periodic Company Report #WAES 99080518
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	C				
			[Composition Unspecified]	C				
			Herbal Remedies (Composition Uns)	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3365591-0Report Type:Periodic Company Report #WAES 99080519
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Tab Vioxx Unk	PS				
			Celebrex	C				
			Hydrodiuril	C				

				Atenolol	C	
				Levothyroxine Sodium	C	
				Ranitidine	C	
				Terazosin	C	

Date:09/22/99ISR Number: 3365597-1Report Type:Periodic Company Report #WAES 99080520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Urticaria	Professional						

Date:09/22/99ISR Number: 3365600-9Report Type:Periodic Company Report #WAES 99080521
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Professional	Ambien	C				
			Cardizem Cd	C				
			Lopressor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365607-1Report Type:Periodic Company Report #WAES 99080525
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Oedema Peripheral	Professional					MG/DAILY/PO	

Date:09/22/99ISR Number: 3365609-5Report Type:Periodic Company Report #WAES 99080534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Professional					MG/DAILY/PO	3 DAY

Date:09/22/99ISR Number: 3365612-5Report Type:Periodic Company Report #WAES 99080537
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx Unk	PS		ORAL	12.5	
	Hypertension	Professional					MG/DAILY/PO	
		Company Representative	Claritin	C				
			Enbrel	C				
			Fosamax	C				
			Zantac	C				
			Prednisone	C				

Date:09/22/99ISR Number: 3365617-4Report Type:Periodic Company Report #WAES 99080540
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Weight Increased					
MG/BID/PO						
			Fosamax	C		

Date:09/22/99ISR Number: 3365618-6Report Type:Periodic Company Report #WAES 99080554
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

Date:09/22/99ISR Number: 3365620-4Report Type:Periodic Company Report #WAES 99080600
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction		Tab Vioxx 25 Mg	PS		ORAL
25						
	International Normalised					
MG/DAILY/PO						
	Ratio Increased		Coumadin 3 Mg	SS		
3 MG/						
DAILY/UNK						
			Claritin	C		
			Darvocet-N	C		
			Humibid L.A.	C		
			Imdur	C		
			Lopressor	C		
			Pepcid	C		
			Restoril	C		
			Tiazac	C		

			Zantac	C		
			Ibuprofen	C		
			Magnesium Oxide	C		

Date:09/22/99ISR Number: 3365623-XReport Type:Periodic Company Report #WAES 99080601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Synthroid	C				
			Xanax	C				
			Zantac	C				

Date:09/22/99ISR Number: 3365626-5Report Type:Periodic Company Report #WAES 99080605
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/UNK/PO	
	Oedema Peripheral							

Date:09/22/99ISR Number: 3365627-7Report Type:Periodic Company Report #WAES 99080606
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/UNK/PO	
	Fatigue							
	Insomnia		Coumadin	C				
			Diovan	C				
			Lanoxin	C				

Date:09/22/99ISR Number: 3365757-XReport Type:Periodic Company Report #WAES 99081255
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ PO	
	Paraesthesia		Calan Sr	C				
			Coumadin	C				
			Lipitor	C				

Date:09/22/99ISR Number: 3365761-1Report Type:Periodic Company Report #WAES 99081261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Ulceration	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365764-7Report Type:Periodic Company Report #WAES 99081263
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/ DAILY/ PO	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365765-9Report Type:Periodic Company Report #WAES 99081279
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
	Disorientation	Professional	Effexor	C				
	Dysphagia		Fiorinal With Codeine	C				
	Speech Disorder		Naprosyn	C				
	Tongue Disorder		Neurontin	C				
			Valium	C				
			Zanaflex	C				

Date:09/22/99ISR Number: 3365766-0Report Type:Periodic Company Report #WAES 99081281
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /DAILY/ PO	
			Tab Vioxx 25mg	SS		ORAL	25 MG/ DAILY/ PO	
			Serzone	C				
			Synthroid	C				
			Trazodone Hydrochloride	C				

Date:09/22/99ISR Number: 3365767-2Report Type:Periodic Company Report #WAES 99081284
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Pruritus		Lodine	C				
			Zantac	C				

Date:09/22/99ISR Number: 3365768-4Report Type:Periodic Company Report #WAES 99081286
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/ PO	
	Eye Irritation		Pepcid	C				
	Pain		Prilosec	C				
	Pharyngitis		Synthroid	C				
	Rhinorrhoea							

Date:09/22/99ISR Number: 3365769-6Report Type:Periodic Company Report #WAES 99081291
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	1 DAY
		Professional	Tab Vioxx 25 Mg	SS		ORAL	PO	
			Asacol	C				
			Zantac	C				
			Calcium Supplement	C				
			Chondroitin (+)					
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365770-2Report Type:Periodic Company Report #WAES 99081299
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Acetaminphen (+) Prpoxyphene	C				
			Aspirin	C				

Date:09/22/99ISR Number: 3365771-4Report Type:Periodic Company Report #WAES 99081323
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ DAILY/ PO	

Date:09/22/99ISR Number: 3365772-6Report Type:Periodic Company Report #WAES 99081338
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Chest Pain							
	Confusional State							
	Dry Mouth							
	Hypoaesthesia							
	Miosis							
	Vision Blurred							

Date:09/22/99ISR Number: 3365773-8Report Type:Periodic Company Report #WAES 99081341
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Dizziness	Professional Company Representative						

Date:09/22/99ISR Number: 3365774-XReport Type:Periodic Company Report #WAES 99081345
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ DAILY/ PO	
			Darvocet-N	C				
			Demadex	C				
			Lopid	C				
			Ultran	C				
			Zantac	C				

Date:09/22/99ISR Number: 3365775-1Report Type:Periodic Company Report #WAES 99081354
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	
	Pruritus		Fosamax	C				

			Lodine	C		
			Zantac	C		

Date:09/22/99ISR Number: 3365776-3Report Type:Periodic Company Report #WAES 99081368
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Aspirin	C				
		Company Representative	Theophylline	C				

Date:09/22/99ISR Number: 3365777-5Report Type:Periodic Company Report #WAES 99081376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Ridaura	C				

Date:09/22/99ISR Number: 3365778-7Report Type:Periodic Company Report #WAES 99081388
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx Unk	PS			PO	
	Dyspnoea	Professional						
	Fatigue							

Date:09/22/99ISR Number: 3365779-9Report Type:Periodic Company Report #WAES 99081396
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Dyspnoea					
MG/DAILY/PO						
	Headache		Bentyl	C		
	Nausea		Buspar	C		
			Buspar	C		
			Lortab	C		
			Wigraine	C		
			Kaolin	C		

Date:09/22/99ISR Number: 3365780-5Report Type:Periodic Company Report #WAES 99081398
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Oedema Peripheral		Lipitor	C		
			Plaquenil	C		
			Procardia	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365781-7Report Type:Periodic Company Report #WAES 99081399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365782-9Report Type:Periodic Company Report #WAES 99081159
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365783-0Report Type:Periodic Company Report #WAES 99081181
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Weight Increased		Plendil	C				

Date:09/22/99ISR Number: 3365784-2Report Type:Periodic Company Report #WAES 99081182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Nasonex	C				

Date:09/22/99ISR Number: 3365785-4Report Type:Periodic Company Report #WAES 99081196
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/UNK/PO	
	Fatigue							
	Muscle Rigidity							

Date:09/22/99ISR Number: 3365786-6Report Type:Periodic Company Report #WAES 99081199
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Asthenia	Professional						
	Fatigue	Company Representative						

Date:09/22/99ISR Number: 3365787-8Report Type:Periodic Company Report #WAES 99081200
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365788-XReport Type:Periodic Company Report #WAES 99081201
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365789-1Report Type:Periodic Company Report #WAES 99081205
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365790-8Report Type:Periodic Company Report #WAES 99081206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Nervousness							
	Oedema							

Date:09/22/99ISR Number: 3365791-XReport Type:Periodic Company Report #WAES 99081215
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Dilantin Infatabs	C				
			Neurontin	C				
			Premarin	C				

			Prozac	C		

Date:09/22/99ISR Number: 3365792-1Report Type:Periodic Company Report #WAES 99081217
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Constipation							
	Fluid Retention		Anusol Suppositories/Ointment	C				
			Prepulsid	C				
			Prinzide	C				
			Synthroid	C				
			Ranitidine	C				

Date:09/22/99ISR Number: 3365793-3Report Type:Periodic Company Report #WAES 99081219
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365794-5Report Type:Periodic Company Report #WAES 99081224
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Synthroid	C				

Date:09/22/99ISR Number: 3365795-7Report Type:Periodic Company Report #WAES 99081227
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aerobid	C				
			Coreg	C				
			Lasix	C				
			Serevent	C				
			Clonidine	C				

Date:09/22/99ISR Number: 3365796-9Report Type:Periodic Company Report #WAES 99081234
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:09/22/99ISR Number: 3365797-0Report Type:Periodic Company Report #WAES 99081236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Tab Vioxx Unk	PS				

Date:09/22/99ISR Number: 3365798-2Report Type:Periodic Company Report #WAES 99081237
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematuria							
	Haemoglobin Decreased	Company Representative	Celexa	C				
	Haemorrhage		Lanoxin	C				
			Mexitil	C				
			Ogen	C				
			Progesterone	C				

Date:09/22/99ISR Number: 3365799-4Report Type:Periodic Company Report #WAES 99081239
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

			Elavil	C

Date:09/22/99ISR Number: 3365800-8Report Type:Periodic Company Report #WAES 99081241
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	3 DAY

Date:09/22/99ISR Number: 3365801-XReport Type:Periodic Company Report #WAES 99081242
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	MG/PO	
			Prevacid	C				
			Prilosec	C				
			Valium	C				
			Vicodin Tablets	C				
			Iron (Unspecified)	C				
			Vitamin B(12)	C				

Date:09/22/99ISR Number: 3365802-1Report Type:Periodic Company Report #WAES 99080935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Flatulence							
	Pain							

Date:09/22/99ISR Number: 3365803-3Report Type:Periodic Company Report #WAES 99080943
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365804-5Report Type:Periodic Company Report #WAES 99080944
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365805-7Report Type:Periodic Company Report #WAES 99080945
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365806-9Report Type:Periodic Company Report #WAES 99080964
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO // 25 MG/DAILY/PO	
			Hydrodiuril	C				
			Luvox	C				
			Seroquel	C				
			Xanax	C				
			Trazodone	C				

Date:09/22/99ISR Number: 3365807-0Report Type:Periodic Company Report #WAES 99080969
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Feeling Hot		Prilosec	C				
			Valium	C				
			Vicodin	C				

Date:09/22/99ISR Number: 3365808-2Report Type:Periodic Company Report #WAES 99080972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365809-4Report Type:Periodic Company Report #WAES 99080978
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Ineffective		Cipro	C				
			Darvocet-N	C				
			Halcion	C				
			Pepcid	C				
			Procardia	C				
			Roxicodone	C				
			Zocor	C				

Date:09/22/99ISR Number: 3365810-0Report Type:Periodic Company Report #WAES 99080979
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365811-2Report Type:Periodic Company Report #WAES 99080985
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advil	C				

Date:09/22/99ISR Number: 3365812-4Report Type:Periodic Company Report #WAES 99080986
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above	Health	Tab Vioxx 12.5 Mg	PS		ORAL	125 MG/BID/PO	
	Therapeutic	Professional Company Representative	[Composition Unspecified]	C				

Date:09/22/99ISR Number: 3365813-6Report Type:Periodic Company Report #WAES 99081013
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Evista	C				

Date:09/22/99ISR Number: 3365814-8Report Type:Periodic Company Report #WAES 99081031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365815-XReport Type:Periodic Company Report #WAES 99081041
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Ogen	C				
			Provera	C				
			Synthroid	C				
			Aluminum Chlorhydroxide	C				

Date:09/22/99ISR Number: 3365816-1Report Type:Periodic Company Report #WAES 99081043
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx Unk	PS		ORAL	50 MG	DAILY/PO
	International Normalised Ratio Increased	Professional Company	Coumadin Unk	SS			7.5 MG/DAILY	
	Prothrombin Time Prolonged	Representative	Tab Vioxx	SS		ORAL	25 MG/DAIL/PO	

Date:09/22/99ISR Number: 3365817-3Report Type:Periodic Company Report #WAES 99081045
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urethral Obstruction	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Urinary Retention		[Therapy Unspecified]	C				

Date:09/22/99ISR Number: 3365818-5Report Type:Periodic Company Report #WAES 99081048
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS				

Date:09/22/99ISR Number: 3365819-7Report Type:Periodic Company Report #WAES 99081061
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/22/99ISR Number: 3365820-3Report Type:Periodic Company Report #WAES 99081070
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
	Pruritus	Company Representative						

Date:09/22/99ISR Number: 3365821-5Report Type:Periodic Company Report #WAES 99081154
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dyspepsia							
			Fosamax	C				
			Premarin	C				

Date:09/22/99ISR Number: 3365822-7Report Type:Periodic Company Report #WAES 99080314
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ambien	C				
			Avapro	C				
			Isordil	C				
			K-Dur	C				
			Norvasc	C				
			Prevacid	C				
			Acetaminophen (+) Propoxyphene	C				
			Colchicine	C				
			Furosemide	C				
			Hyoscyamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365823-9Report Type:Periodic Company Report #WAES 99080323
Age:73 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastritis							
			Miacalcin	C				
			Pepcid	C				
			Skelaxin	C				
			Synthroid	C				
			Phenobarbital	C				

Date:09/22/99ISR Number: 3365824-0Report Type:Periodic Company Report #WAES 99080324
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/AM/PO	
	Rash Erythematous		Alphagan	C				
			Flomax (Tamsulosin (R)-Form Hydr	C				
			Glucotrol Xl	C				
			Lozol	C				
			Sectral	C				
			Zocor	C				

Date:09/22/99ISR Number: 3365825-2Report Type:Periodic Company Report #WAES 99080325
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
			Calan Sr	C				
			Prilosec	C				
			Synthroid	C				
			Folic Acid	C				

				Indapamide	C		
				Methotrexate	C		
				Prednisone	C		

Date:09/22/99ISR Number: 3365826-4Report Type:Periodic Company Report #WAES 99080328
Age:67 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Lanoxin	C				
			Librium	C				

Date:09/22/99ISR Number: 3365827-6Report Type:Periodic Company Report #WAES 99080335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO 1 MON
			Estrace	C				
			Prilosec	C				
			Propulsid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365828-8Report Type:Periodic Company Report #WAES 99080342
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			Neurontin	C				

Date:09/22/99ISR Number: 3365829-XReport Type:Periodic Company Report #WAES 99080355
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Cozaar	C				
			Insulin	C				

Date:09/22/99ISR Number: 3365830-6Report Type:Periodic Company Report #WAES 99080358
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Insomnia							
	Nausea							

Date:09/22/99ISR Number: 3365831-8Report Type:Periodic Company Report #WAES 99080374
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Health Professional Company	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3365832-XReport Type:Periodic Company Report #WAES 99080379
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Feeling Abnormal	Professional						
			Coumadin	C				
			Lanoxin	C				
			Prinivil	C				

Date:09/22/99ISR Number: 3365833-1Report Type:Periodic Company Report #WAES 99080405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Blood Alkaline Phosphatase Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365834-3Report Type:Periodic Company Report #WAES 99080409
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hyperhidrosis							
			Fosamax	C				
			Zocor	C				

Date:09/22/99ISR Number: 3365835-5Report Type:Periodic Company Report #WAES 99080410
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
	Urticaria		Hydrodiuril	C				
			Hytrin	C				
			Rythmol	C				

Date:09/22/99ISR Number: 3365836-7Report Type:Periodic Company Report #WAES 99080414
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
			Actonel	C				
			Proscar	C				

Date:09/22/99ISR Number: 3365837-9Report Type:Periodic Company Report #WAES 99080435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO.	
			Plaquenil	C				
			Prilosec	C				
			Salagen Tablets	C				
			Talacen	C				

(SEE IMAGE)

Date:09/22/99ISR Number: 3365838-0Report Type:Periodic Company Report #WAES 99080438
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Celebrex	C				
			Hyalgan	C				

Date:09/22/99ISR Number: 3365839-2Report Type:Periodic Company Report #WAES 99080467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Avapro	C				
			Tylenol	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3365840-9Report Type:Periodic Company Report #WAES 99080474
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neutrophil Count	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Decreased	Professional Company Representative						

Date:09/22/99ISR Number: 3365841-0Report Type:Periodic Company Report #WAES 99080493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:09/22/99ISR Number: 3366061-6Report Type:Periodic Company Report #WAES 99080109
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Muscular Weakness		Flexeril	C				
	Myalgia							

Date:09/22/99ISR Number: 3366062-8Report Type:Periodic Company Report #WAES 99080128
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Insomnia		Premarin	C				
			Synthroid	C				

Date:09/22/99ISR Number: 3366064-1Report Type:Periodic Company Report #WAES 99080137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fatigue							

Date:09/22/99ISR Number: 3366065-3Report Type:Periodic Company Report #WAES 99080157
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspnoea	Professional	Tab Vioxx 50 Mg	SS		ORAL	PO	
	Fatigue	Company	Combivent	C				
	Oedema Peripheral	Representative	K-Dur	C				
	Pallor		Lanoxin	C				
			Proventil Inhaler	C				
			Furosemide	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366067-7Report Type:Periodic Company Report #WAES 99080169
Age:50 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	3XW/PO	
	Urinary Incontinence							

Date:09/22/99ISR Number: 3366068-9Report Type:Periodic Company Report #WAES 99080206
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Fosamax	C				
			Miacalcin	C				
			Acetaminophen	C				
			Calcium Supplement (Composition	C				

Date:09/22/99ISR Number: 3366071-9Report Type:Periodic Company Report #WAES 99080209
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Phosphokinase Increased	Professional	A.S.A.	C				
	Electrocardiogram		Dilantin	C				
	Abnormal		Levoxyl	C				
			Neurontin	C				

Date:09/22/99ISR Number: 3366076-8Report Type:Periodic Company Report #WAES 99080221
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

				Covera-Hs	C	
				Zantac	C	
				Digoxin	C	

Date:09/22/99ISR Number: 3366079-3Report Type:Periodic Company Report #WAES 99080226
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nausea		Prilosec	C				

Date:09/22/99ISR Number: 3366085-9Report Type:Periodic Company Report #WAES 99080233
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx Unk	PS		ORAL	25	MG/DAILY/PO
			Ativan	C				
			Dilantin	C				
			Lasix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366090-2Report Type:Periodic Company Report #WAES 99080246
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	12.5	
	Oedema Peripheral	Professional					MG/DAILY/PO;	
	Urinary Retention	Company					25	
		Representative					MG/DAILY/PO	4 DAY

Date:09/22/99ISR Number: 3366093-8Report Type:Periodic Company Report #WAES 99080253
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx	PS		ORAL	12.5	
							MG/DAILY/PO	
			Trental	C				
			Temazepam	C				

Date:09/22/99ISR Number: 3366096-3Report Type:Periodic Company Report #WAES 99080278
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure	Health Professional	Tab Vioxx	PS				

Date:09/22/99ISR Number: 3366098-7Report Type:Periodic Company Report #WAES 99080289
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:09/22/99ISR Number: 3366122-1Report Type:Periodic Company Report #WAES 99080294
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3366124-5Report Type:Periodic Company Report #WAES 99080301
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Pruritus							
			Calan Sr	C				
			Premarin	C				
			Synthroid	C				
			Furosemide	C				
			Ibuprofen	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366150-6Report Type:Periodic Company Report #WAES 99080304
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Zocor	C				
			Lorazepam	C				
			Thyroxine	C				

Date:09/22/99ISR Number: 3366151-8Report Type:Periodic Company Report #WAES 99080305
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/ PO	
	Menopausal Symptoms							
			Prilosec	C				
			Zebeta	C				
			Zocor	C				
			Estradiol	C				

Date:09/22/99ISR Number: 3366152-XReport Type:Periodic Company Report #WAES 99080308
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Bradycardia							
	Fatigue		Miacalcin	C				
	Malaise		Prilosec	C				
	Muscular Weakness		Prinivil	C				
			Prozac	C				
			Chlordiazepoxide	C				

Date:09/22/99ISR Number: 3366153-1Report Type:Periodic Company Report #WAES 99080310
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Other	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased		Estraderm	C				
			Neurontin	C				
			Ranitidine	C				

Date:09/22/99ISR Number: 3366527-9Report Type:Periodic Company Report #WAES 99080617
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO	
	Infection	Company						
		Representative						

Date:09/22/99ISR Number: 3366529-2Report Type:Periodic Company Report #WAES 99080620
Age:42 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Fatigue

Nervous System Disorder

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Prozac	C				
			Serzone	C				
			Phenobarbital	C				

Date:09/22/99ISR Number: 3366530-9Report Type:Periodic Company Report #WAES 99080642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Toprol Xl Tablets	C				
			Hydrochloride	C				

Date:09/22/99ISR Number: 3366531-0Report Type:Periodic Company Report #WAES 99080687
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:09/22/99ISR Number: 3366533-4Report Type:Periodic Company Report #WAES 99080688
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	25	
	Vomiting	Professional					MG/DAILY/PO	
		Company	Ginko Biloba Forte	C				

		Representative	Ibuprofen	C

Date:09/22/99ISR Number: 3366535-8Report Type:Periodic Company Report #WAES 99080695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional	Tab Vioxx Unk	PS		ORAL	1X/PO	

Date:09/22/99ISR Number: 3366538-3Report Type:Periodic Company Report #WAES 99080696
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	DAILY/PO	
	Diarrhoea		Allegra	C				
			Premarin	C				
			Provera	C				
			Soma	C				
			Tylenol With Codeine #3	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366540-1Report Type:Periodic Company Report #WAES 99080697
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
	Dyspepsia		Climara	C				
			Elavil	C				

Date:09/22/99ISR Number: 3366543-7Report Type:Periodic Company Report #WAES 99080704
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Dizziness		Coumadin	C				
	Nausea		Fosamax	C				
	Oedema		Lanoxin	C				
			Premarin	C				
			Slow-K	C				
			Vasotec	C				
			Folic Acid	C				
			Furosemide	C				
			Prednisone	C				

Date:09/22/99ISR Number: 3366546-2Report Type:Periodic Company Report #WAES 99080705
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Lipitor	C				
			Norvasc	C				
			Prilosec	C				
			Aspirin	C				

Date:09/22/99ISR Number: 3366548-6Report Type:Periodic Company Report #WAES 99080720
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Tab Vioxx Unk	PS				

Date:09/22/99ISR Number: 3366550-4Report Type:Periodic Company Report #WAES 99080730
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Biaxin	C				
			Hydrodiuril	C				
			Toprol Xl Tablets	C				
			Cortisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366552-8Report Type:Periodic Company Report #WAES 99080750
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366555-3Report Type:Periodic Company Report #WAES 99080764
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
		Company Representative	Elavil	C				
			Ultram	C				

Date:09/22/99ISR Number: 3366557-7Report Type:Periodic Company Report #WAES 99080850
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Moduretic	C				
			Pepcid	C				

Date:09/22/99ISR Number: 3366558-9Report Type:Periodic Company Report #WAES 99080851
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		OROPHARINGEAL	DAILY/PO	
			Prilosec	C				

			Synthroid	C		
			Propranolol	C		

Date:09/22/99ISR Number: 3366561-9Report Type:Periodic Company Report #WAES 99080854
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Miacalcin	C				
			Synthroid	C				
			Aspirin	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3366563-2Report Type:Periodic Company Report #WAES 99080869
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366568-1Report Type:Periodic Company Report #WAES 99080892
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Cardizem	C				
			Lanoxin	C				
			Mexitil	C				
			Ms Contin	C				
			Synthroid	C				
			Furosemide	C				
			Potassium Supplement	C				

Date:09/22/99ISR Number: 3366570-XReport Type:Periodic Company Report #WAES 99080926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Weight Increased							

Date:09/22/99ISR Number: 3366575-9Report Type:Periodic Company Report #WAES 99072078
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Disease	Professional Company Representative						

Date:09/22/99ISR Number: 3366577-2Report Type:Periodic Company Report #WAES 99072079
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

Date:09/22/99ISR Number: 3366578-4Report Type:Periodic Company Report #WAES 99072080
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

Date:09/22/99ISR Number: 3366580-2Report Type:Periodic Company Report #WAES 99072081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366581-4Report Type:Periodic Company Report #WAES 99080007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx Unk	PS				

Date:09/22/99ISR Number: 3366582-6Report Type:Periodic Company Report #WAES 99080017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluid Retention		Lanoxen	C				
	Weight Increased		Ogen	C				
			Serzone	C				
			Vasotec	C				
			Hydrochlorothiazide	C				
			Lorazepam	C				
			Verapamil	C				

Date:09/22/99ISR Number: 3366583-8Report Type:Periodic Company Report #WAES 99080023
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
			Prozac	C				

Date:09/22/99ISR Number: 3366584-XReport Type:Periodic Company Report #WAES 99080024
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Pain							

	Pruritus		Brethine	C
			Ventolin	C
			Aspirin	C
			Chondroitin (+)	
			Glucosamne	C
			Vitamins	C

Date:09/22/99ISR Number: 3366585-1Report Type:Periodic Company Report #WAES 99080027
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Increased Appetite		Ditropan	C				
	Oliguria		Percocet	C				
			Tagamet	C				
			Xanax	C				
			Baclofen	C				
			Clonidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366586-3Report Type:Periodic Company Report #WAES 99080047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366589-9Report Type:Periodic Company Report #WAES 99080061
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/AM/PO	
	Hypersensitivity							
	Pruritus							

Date:09/22/99ISR Number: 3366590-5Report Type:Periodic Company Report #WAES 99080062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx Unk	PS				

Date:09/22/99ISR Number: 3366591-7Report Type:Periodic Company Report #WAES 99080063
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional	Tab Vioxx Unk	PS				
			Lisinopril	C				

Date:09/22/99ISR Number: 3366594-2Report Type:Periodic Company Report #WAES 99080064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Acne	Health	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
		Professional Company Representative				

Date:09/22/99ISR Number: 3366596-6Report Type:Periodic Company Report #WAES 99080065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
		Professional Company Representative				

Date:09/22/99ISR Number: 3366597-8Report Type:Periodic Company Report #WAES 99080068
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Pain In Extremity	Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366599-1Report Type:Periodic Company Report #WAES 99080072
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Tab Vioxx Unk	PS				
	Hypertension							

Date:09/22/99ISR Number: 3366601-7Report Type:Periodic Company Report #WAES 99080085
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Celebrex	C				
			Fosamax	C				
			Therapy Unspecified	C				

Date:09/22/99ISR Number: 3366602-9Report Type:Periodic Company Report #WAES 99080091
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Erythema							
	Pruritus		Allegra	C				
			Dilacor Xr	C				
			Pepcid	C				

Date:09/22/99ISR Number: 3366604-2Report Type:Periodic Company Report #WAES 99080100
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Professional
MG/DAILY/PO

	Cardizem	C
	Lanoxin	C
	Lasix	C
	Synthroid	C
	Lactulose	C
	Morphine	C

Date:09/22/99ISR Number: 3366675-3Report Type:Periodic Company Report #WAES 99061654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Nicotinic Acid	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3366676-5Report Type:Periodic Company Report #WAES 99061662
Age:42 YR Gender:Female I/FU:I

Outcome	PT
	Dysphagia
	Hypersensitivity
	Nausea
	Sedation

	Throat Tightness						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366677-7Report Type:Periodic Company Report #WAES 99061668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Dysgeusia							
	Fatigue							

Date:09/22/99ISR Number: 3366678-9Report Type:Periodic Company Report #WAES 99061696
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366679-0Report Type:Periodic Company Report #WAES 99061699
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Nausea		Cardizem	C				
	Sleep Disorder		Therapy Unspecified	C				

Date:09/22/99ISR Number: 3366680-7Report Type:Periodic Company Report #WAES 99061712
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Levothroid	C				
			Lodine	C				
			Chondroitin Sulfate	C				
			Glucosamine	C				
			Ibuprofen	C				

Date:09/22/99ISR Number: 3366681-9Report Type:Periodic Company Report #WAES 99061718
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Depression	Professional						
	Fatigue							
	Sedation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366682-0Report Type:Periodic Company Report #WAES 99061762
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Dyspnoea	Professional						

Date:09/22/99ISR Number: 3366683-2Report Type:Periodic Company Report #WAES 99061771
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Urinary Retention						MG/DAILY/PO	
			Detrol	C				
			Glucophage	C				
			Lipitor	C				
			Atenolol	C				
			Glyburide	C				

Date:09/22/99ISR Number: 3366684-4Report Type:Periodic Company Report #WAES 99061780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/1X/PO	
	Feeling Drunk							
	Sedation							

Date:09/22/99ISR Number: 3366685-6Report Type:Periodic Company Report #WAES 99061787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366686-8Report Type:Periodic Company Report #WAES 99061806
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Face Oedema	Health						
	Headache	Professional	Celebrex	C				
	Hyperventilation		Composition Unspecified	C				

Date:09/22/99ISR Number: 3366687-XReport Type:Periodic Company Report #WAES 99061825
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366688-1Report Type:Periodic Company Report #WAES 99061827
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3366689-3Report Type:Periodic Company Report #WAES 99061831
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Pain							
			Lipitor	C				
			Prilosec	C				

Date:09/22/99ISR Number: 3366690-XReport Type:Periodic Company Report #WAES 99061915
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Tab Vioxx 1 Tablet	PS		ORAL	1 TABLET/DAILY/ PO	
	Chest Pain	Professional						
	Dyspnoea							
			Calan Sr	C				
			Lanoxin	C				
			Zantac	C				
			...	C				

Date:09/22/99ISR Number: 3366691-1Report Type:Periodic Company Report #WAES 99061926
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS			ORAL
25							
	Drug Ineffective	Professional					
MG/DAILY/PO							
			Ibuprofen	C			

Date:09/22/99ISR Number: 3366692-3Report Type:Periodic Company Report #WAES 99061932
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx Unk	PS		ORAL		
PO								
	Paraesthesia	Professional	Therapy Unspecified	C				

Date:09/22/99ISR Number: 3366693-5Report Type:Periodic Company Report #WAES 99061938
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL		
12.5								
	Abdominal Pain	Professional						
MG/DAILY/PO;								
	Diarrhoea							
25								
	Influenza							
MG/DAILY/PO								
	Juvenile Arthritis		Centrum	C				
			Propulsid	C				
			Composition					
			Unspecified	C				
			Calcium Carbonate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366694-7Report Type:Periodic Company Report #WAES 99061942
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Abdominal Pain	Health Professional	Adalat Cc	C				
	Dysgeusia		Glucotrol	C				
	Dyspepsia		Tylenol With Codeine # 3	C				
			Lorazepam	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3366695-9Report Type:Periodic Company Report #WAES 99062002
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY	

Date:09/22/99ISR Number: 3366696-0Report Type:Periodic Company Report #WAES 99062011
Age:78 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY	
			Buspar	C				
			Hytrin	C				
			Lupron	C				
			Paxil	C				
			Phospholine Iodide	C				
			Prilosec	C				
			Timoptic	C				
			Nitroglycerin	C				
			Verapamil	C				

Date:09/22/99ISR Number: 3366697-2Report Type:Periodic Company Report #WAES 99062016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL		
	Oedema Peripheral		Celebrex	C				

Date:09/22/99ISR Number: 3366698-4Report Type:Periodic Company Report #WAES 99062017
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL		

Date:09/22/99ISR Number: 3366699-6Report Type:Periodic Company Report #WAES 99062026
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
		Professional	Medrol	C				
			Prilosec	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366700-XReport Type:Periodic Company Report #WAES 99062050
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY	
	Vision Blurred	Health Professional	Ativan	C				
			Mirapex	C				
			Sinmet	C				
			Amantadine	C				

Date:09/22/99ISR Number: 3366701-1Report Type:Periodic Company Report #WAES 99062054
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx	PS		ORAL	50 MG/DAILY	

Date:09/22/99ISR Number: 3366702-3Report Type:Periodic Company Report #WAES 99062069
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachypnoea	Consumer	Tab Vioxx	PS		ORAL		
			Coumadin	C				
			Rythmol	C				
			Atenolol	C				

Date:09/22/99ISR Number: 3366703-5Report Type:Periodic Company Report #WAES 99070010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional Company Representative	Tab Vioxx	PS		ORAL		

Date:09/22/99ISR Number: 3366704-7Report Type:Periodic Company Report #WAES 99070017
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
			Soln Calcitonin	SS				
RESPIRATORY								
(INHALATION)								
			Darvocet-N	C				

Date:09/22/99ISR Number: 3366705-9Report Type:Periodic Company Report #WAES 99070022
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY	
	Periodontal Disease	Professional Company Representative	Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366706-0Report Type:Periodic Company Report #WAES 99070025
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Health	Tab Vioxx	PS		ORAL		
	Drug Interaction	Professional	Zanaflex	SS				
	Hallucination	Company						
	Vomiting	Representative						

Date:09/22/99ISR Number: 3366707-2Report Type:Periodic Company Report #WAES 99070030
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM	
	Pruritus	Professional	Calan Sr	C				
			Glucophage	C				
			Tagamet	C				
			Composition					
			Unspecified	C				
			Potassium Chloride	C				
			Procainamide Hydrochloride	C				
			Tetracycline	C				

Date:09/22/99ISR Number: 3366708-4Report Type:Periodic Company Report #WAES 99070031
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Tab Vioxx	PS		ORAL		
	Sedation		Albuterol	C				

Date:09/22/99ISR Number: 3366709-6Report Type:Periodic Company Report #WAES 99070053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL		

Professional

Date:09/22/99ISR Number: 3366710-2Report Type:Periodic Company Report #WAES 99070089
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
			Glucophage	C				
			Mevacor	C				
			Glipizide	C				

Date:09/22/99ISR Number: 3366711-4Report Type:Periodic Company Report #WAES 99070106
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx	PS		ORAL		
	Flushing							
	Nasal Dryness							
	Pharyngitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366712-6Report Type:Periodic Company Report #WAES 99070123
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS			PO	
	Influenza		Levoxyl	C				

Date:09/22/99ISR Number: 3366713-8Report Type:Periodic Company Report #WAES 99070124
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	12.5MG DAILY, 25MG DAILY	

Date:09/22/99ISR Number: 3366714-XReport Type:Periodic Company Report #WAES 99070125
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Tab Vioxx	PS		ORAL	12.5 MG	
	Dyspepsia		Fosamax	C				
			Premarin	C				

Date:09/22/99ISR Number: 3366976-9Report Type:Periodic Company Report #WAES 99070337
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Armour Thyroid Tablets	C				
			Hygroton	C				

Date:09/22/99ISR Number: 3366978-2Report Type:Periodic Company Report #WAES 99070353
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/ DAILY/PO	
	Joint Stiffness		Ecotrin	C				
	Muscle Rigidity		Diltiazem	C				
			Docusate Sodium	C				
			Lansoprazole	C				

Date:09/22/99ISR Number: 3366981-2Report Type:Periodic Company Report #WAES 99070356
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS				
	Speech Disorder		Microzide	C				
	Vomiting		Methotrexate	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3366983-6Report Type:Periodic Company Report #WAES 99070373
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/ PO	
	Dysgeusia							
	Muscular Weakness		Claritin	C				
			Pravachol	C				
			Prozac	C				
			Xanax	C				

Date:09/22/99ISR Number: 3366987-3Report Type:Periodic Company Report #WAES 99070390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK / UNK/ PO	

Date:09/22/99ISR Number: 3366991-5Report Type:Periodic Company Report #WAES 99070407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/UNK/PO	

Date:09/22/99ISR Number: 3366993-9Report Type:Periodic Company Report #WAES 99070434
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/ PO	

	Pruritus		Ultram	C

Date:09/22/99ISR Number: 3366996-4Report Type:Periodic Company Report #WAES 99070444
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	1 WK
	Haemorrhage	Professional Company Representative	Nonsteroidal Anti-Inflammatory	C				

Date:09/22/99ISR Number: 3366999-XReport Type:Periodic Company Report #WAES 99070455
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	UNK / UNK / PO	
		Professional						

Date:09/22/99ISR Number: 3367001-6Report Type:Periodic Company Report #WAES 99070469
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Oedema Peripheral	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Humulin 70/30	C				
Lipitor	C				
Lopressor	C				
Prinivil	C				

Date:09/22/99ISR Number: 3367004-1Report Type:Periodic Company Report #WAES 99070476
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Vision Blurred							
			Darvocet-N	C				
			Ethmozine	C				
			Propulsid	C				
			Xalatin	C				
			Verapamil	C				

Date:09/22/99ISR Number: 3367007-7Report Type:Periodic Company Report #WAES 99070477
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Chest Pain	Health						
	Dizziness	Professional	Ambien	C				
	Hyperhidrosis		Claritin-D	C				
	Palpitations		Parafon Forte Dsc	C				
	Tachycardia		Pravachol	C				
			Synthroid	C				
			Zantac	C				

Date:09/22/99ISR Number: 3367010-7Report Type:Periodic Company Report #WAES 99070517
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Feeling Abnormal							
	Urine Abnormality		Toprol Xl Tablets	C				
			Calcium Supplement (Composition)	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3367013-2Report Type:Periodic Company Report #WAES 99070541
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
			Levoxyl	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3367016-8Report Type:Periodic Company Report #WAES 99070547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/22/99ISR Number: 3367019-3Report Type:Periodic Company Report #WAES 99070551
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK / UNK / PO	
			Prozac	C				

Date:09/22/99ISR Number: 3367023-5Report Type:Periodic Company Report #WAES 99070563
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY / PO	
		Company Representative	Ecotrin	C				
			Imdur	C				
			Lipitor	C				
			Lopressor	C				
			Pepcid	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:09/22/99ISR Number: 3367027-2Report Type:Periodic Company Report #WAES 99070590
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/22/99ISR Number: 3367029-6Report Type:Periodic Company Report #WAES 99070595
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	
	Tachycardia							
			Cardizem	C				
			Caumadin	C				
			Levoxyl	C				
			Rythmol	C				
			Trental	C				
			Furosemide	C				

Date:09/22/99ISR Number: 3367034-XReport Type:Periodic Company Report #WAES 99070602
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	MG/AM/PO	
			K-Lor	C				
			Maxzide	C				
			Rocaltrol	C				

				Synthroid	C		

Date:09/22/99ISR Number: 3370188-2Report Type:Periodic Company Report #WAES 99060897
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/1X/PO	
		Health Professional	Ms Contin	C				
			Toprol Xl Tablets	C				

Date:09/22/99ISR Number: 3370191-2Report Type:Periodic Company Report #WAES 99060907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder		Arthrotec	C				
			Celebrex	C				
			Daypro	C				
			Naprosyn	C				
			Relafen	C				

Date:09/22/99ISR Number: 3370192-4Report Type:Periodic Company Report #WAES 99060979
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Dyspepsia		Avapro	C				
			Darvocet-N	C				
			Methotrexate	C				

Date:09/22/99ISR Number: 3370194-8Report Type:Periodic Company Report #WAES 99061066
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	50 MG/DAILY/PO	
			Darvocet-N	C				
			Elavil	C				
			Lozol	C				
			Tenormin	C				
			Tylenol	C				
			Vitamins	C				

Date:09/22/99ISR Number: 3370197-3Report Type:Periodic Company Report #WAES 99061075
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3370199-7Report Type:Periodic Company Report #WAES 99061091
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PM/PO	
			Cardizem Cd	C				
			Questran	C				
			Theo-Dur	C				
			Zestril	C				
			Zocor	C				

Date:09/22/99ISR Number: 3370202-4Report Type:Periodic Company Report #WAES 99061125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Lasix	C				
			Lipitor	C				
			Procardia Xl	C				

Date:09/22/99ISR Number: 3370204-8Report Type:Periodic Company Report #WAES 99061154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional	Tab Vioxx Unk	PS				
			Darvocet-N	C				
			Maxzide	C				
			Procardia Xl	C				
			Zyloprim	C				

Date:09/22/99ISR Number: 3370206-1Report Type:Periodic Company Report #WAES 99061166
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Arava	C				
			Lorcet 10/650	C				
			Medrol	C				
			Plaquenil	C				
			Prilosec	C				
			Soma	C				
			Diazepam	C				
			Prednisone	C				

Date:09/22/99ISR Number: 3370208-5Report Type:Periodic Company Report #WAES 99061183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Diarrhoea		Cardura	C				
			Diazide	C				
			Pepcid	C				
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3370211-5Report Type:Periodic Company Report #WAES 99061201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO	3 DAY

Date:09/22/99ISR Number: 3370213-9Report Type:Periodic Company Report #WAES 99061222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/22/99ISR Number: 3370215-2Report Type:Periodic Company Report #WAES 99061253
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Field Defect	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/22/99ISR Number: 3370218-8Report Type:Periodic Company Report #WAES 99061283
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Visual Disturbance							

Date:09/22/99ISR Number: 3389660-4Report Type:Periodic Company Report #WAES 99081915
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/22/99ISR Number: 3389665-3Report Type:Periodic Company Report #WAES 99081985
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Nervousness Tachycardia	Health Professional Company Representative	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/PO	

Date:09/22/99ISR Number: 3389670-7Report Type:Periodic Company Report #WAES 99081986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Flushing Skin Warm Urticaria	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3389675-6Report Type:Periodic Company Report #WAES 99081994
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
	Syncope		Prempro	C				
			Synthroid	C				
			Hydrochlorothiazide	C				

Date:09/22/99ISR Number: 3389682-3Report Type:Periodic Company Report #WAES 99081995
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Rash Erythematous						PO	
	Skin Disorder		Prempro	C				
			Prinivil	C				
			Zoloft	C				
			Alprazolam	C				
			Hydrochlorothiazide	C				

Date:09/22/99ISR Number: 3389685-9Report Type:Periodic Company Report #WAES 99082025
Age:69 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Tenderness	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Diarrhoea						PO	
	Dizziness		Levoxyl	C				
	Flatulence		Prempro	C				
	Paraesthesia							

Date:09/22/99ISR Number: 3389688-4Report Type:Periodic Company Report #WAES 99082035
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Hypoaesthesia						PO	
	Pain		Flomax	C				
			Saw Palmetto (Papain)	C				
			Aspirin	C				
			Cod Liver Oil	C				

Date:09/22/99ISR Number: 3389691-4Report Type:Periodic Company Report #WAES 99082039
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/BID/PO	
	Urticaria		Avonex	C				
			Fosamax	C				
			Imurel	C				
			Lanoxin	C				
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3389697-5Report Type:Periodic Company Report #WAES 99082136
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Pruritus						PO	
			Ocupress	C				
			Premarin	C				
			Synthroid	C				

Date:09/22/99ISR Number: 3389719-1Report Type:Periodic Company Report #WAES 99082143
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/BID/PO	
			Allegra	C				
			Baycol	C				
			Paxil	C				

Date:09/22/99ISR Number: 3389726-9Report Type:Periodic Company Report #WAES 99071701
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	
	Diarrhoea		Carisoprodol	C				
	Dizziness							
	Dysgeusia							
	Dyspnoea							
	Nausea							
	Palpitations							

Date:09/22/99ISR Number: 3389732-4Report Type:Periodic Company Report #WAES 99071705
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx	PS		ORAL	PO	
	Tachycardia	Professional	Citracal	C				
			Hytrin	C				
			Prevacid	C				
			Ascorbic Acid	C				
			Fluoride	C				
			Vitamin E	C				

Date:09/22/99ISR Number: 3389734-8Report Type:Periodic Company Report #WAES 99071709
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:09/22/99ISR Number: 3389738-5Report Type:Periodic Company Report #WAES 99071716
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
		Professional					PO	
			Lasix	C				

			Neurontin	C		
			Serzone	C		

Date:09/22/99ISR Number: 3389741-5Report Type:Periodic Company Report #WAES 99071718
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
			Cortef	C				
			Ocuvite	C				
			Synthroid	C				
			Tums	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:09/22/99ISR Number: 3389745-2Report Type:Periodic Company Report #WAES 99071745
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia							
	Nausea							

Date:09/22/99ISR Number: 3389751-8Report Type:Periodic Company Report #WAES 99071780
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	50MG/1X/PO	1 DAY
	Weight Increased	Professional	Tab Vioxx	SS		ORAL	25MG/DAILY/PO	1 DAY
		Company Representative	Remeron	C				

Date:09/22/99ISR Number: 3389754-3Report Type:Periodic Company Report #WAES 99071804
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
			Amaryl	C				
			Coumadin	C				
			Sectral	C				
			Synthroid	C				
			Hydrochlorothiazide	C				

Date:09/22/99ISR Number: 3389760-9Report Type:Periodic Company Report #WAES 99071806
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Fatigue		Tab Vioxx 25mg	SS		ORAL	PO	
	Mental Impairment		Estrace	C				
	Sedation		Synthroid	C				
			Insulin	C				
			Verapamil	C				
			Zantac	C				
			Reglan	C				
			Imdur	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/99ISR Number: 3389765-8Report Type:Periodic Company Report #WAES 99071810
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Tab Vioxx	PS		ORAL	PO	
	Dizziness	Professional	Norpramin	C				
	Nausea							
	Personality Change							

Date:09/22/99ISR Number: 3389773-7Report Type:Periodic Company Report #WAES 99071815
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
							PO	

Date:09/22/99ISR Number: 3389776-2Report Type:Periodic Company Report #WAES 99071821
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Vioxx	PS		ORAL	PO	
		Professional	Methotrexate	C				
		Company Representative						

Date:09/23/99ISR Number: 3355703-7Report Type:Expedited (15-DaCompany Report #WAES 99091176
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Bilirubin Increased	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5	
Initial or Prolonged	Cholelithiasis	Professional					MG/BID/PO	

	Chromaturia	Company	Accolate	C
	Hepatitis Cholestatic	Representative	Atarax	C
	Jaundice		Claritin	C
	Liver Function Test		Premarin	C
	Abnormal		Sinequan	C
			Zantac	C

Date:09/23/99ISR Number: 3355704-9Report Type:Expedited (15-DaCompany Report #WAES 99090752
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Faeces	Consumer	Tab Vioxx 12.5mg	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Coumadin	C				

Date:09/23/99ISR Number: 3355707-4Report Type:Expedited (15-DaCompany Report #WAES 99081303
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Life-Threatening	Haemorrhage	Professional						
Hospitalization -		Company						
Initial or Prolonged		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/99ISR Number: 3355710-4Report Type:Expedited (15-DaCompany Report #WAES 99082050
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx Unk	PS		ORAL	12.5-25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Faeces Discoloured	Company	Betapace	C				
	Haematochezia	Representative	Cardizem	C				
			Coumadin	C				
			Lanoxin	C				
			Propulsid	C				
			Aspirin	C				

Date:09/23/99ISR Number: 3355713-XReport Type:Expedited (15-DaCompany Report #WAES 99090009
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faecal Occult Blood	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5 MG/AM/PO	
Hospitalization -	Positive	Professional	Caltrate	C				
Initial or Prolonged	Melaena	Company	Cardizem	C				
		Representative	Ecotrin	C				
			Elavil	C				
			Imdur	C				
			Lanoxin	C				
			Lasix	C				
			Tylenol Pm	C				

Date:09/23/99ISR Number: 3355716-5Report Type:Expedited (15-DaCompany Report #WAES 99090781
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Hyperkalaemia	Company	Accupril	C				
		Representative	Avapro	C				

Brethine	C
Combivent	C
Fosamax	C
Norvasc	C
Os-Cal-D	C
Theo-Dur	C

Date:09/24/99ISR Number: 3356899-3Report Type:Expedited (15-DaCompany Report #WAES 99090595
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Death	Adenocarcinoma
Life-Threatening	Atherosclerosis
Hospitalization - Initial or Prolonged	Dyspnoea
Disability	Gastric Cancer
	Gastric Ulcer
	Gastrointestinal Haemorrhage
	Haematocrit Decreased
	Metastases To Bone
	Metastases To Lung
	Metastases To Lymph Nodes
	Platelet Count Decreased
	Syncope

		Tachycardia					
		Uterine Leiomyoma					
		Ventricular Hypertrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Health	Tab Vioxx 25 Mg	PS		ORAL
PO							
			Professional Company Representative	Percocet	C		

Date:09/24/99ISR Number: 3356906-8Report Type:Expedited (15-DaCompany Report #WAES 99061953
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL
12.5 MG DAILY						
Hospitalization -	Blood Creatinine	Professional				
PO						
Initial or Prolonged	Increased		Adalat Cc	C		
Other	Blood Urea Increased		Avandia	C		
	Dyspnoea		Bumex	C		
	Haemodialysis		Elavil	C		
	Paraesthesia		Glucophage	C		
	Renal Failure Acute		Glucotrol	C		
	Sepsis		Lipitor	C		
	Tongue Oedema		Prevacid	C		
			Aspirin	C		
			Atenolol	C		
			Captopril	C		

Date:09/24/99ISR Number: 3356911-1Report Type:Expedited (15-DaCompany Report #WAES 99071424
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Back Pain	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Gastric Ulcer Haemorrhage		Cap Eulexin 125 Mg	SS		ORAL
125 MG Q8H PO						
	Groin Pain		Coumadin	C		
	Rash Erythematous		Glucotrol Xl	C		
	Swelling		Lopressor	C		

Date:09/24/99ISR Number: 3356917-2Report Type:Expedited (15-DaCompany Report #WAES 99090204
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Bilirubin Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gallbladder Cancer	Professional						
	Gallbladder Disorder	Company	Levaquin Unk	SS				
	Hypersensitivity	Representative	Vitamins	C				
	Inflammation							
	Insomnia							
	Liver Disorder							
	Liver Function Test Abnormal							
	Polyp							
	Pruritus							
	Rash Generalised							
	Red Blood Cell Sedimentation Rate Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/99ISR Number: 3356921-4Report Type:Expedited (15-DaCompany Report #WAES 99070858
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	25	
Initial or Prolonged	Chest Pain	Professional					MG/DAILY/PO	
	Crepitations		Coumadin Unk	SS			2 MG	
	Drug Interaction						/QOD/UNK,	
	Dyspnoea						3MG, 5MG/	
	Haemophilus Infection						DAILY	
	Haemoptysis		Arava Unk	SS			20 MG/DAILY/	
	Heart Rate Increased						UNK	
	Influenza Like Illness		Celebrex	C				
	International Normalised		Flexeril	C				
	Ratio Increased		Nicoderm Patch	C				
	Lung Infiltration		Diclofenac	C				
	Necrosis		Folic Acid	C				
	Nodular Vasculitis		Prednisone	C				
	Oxygen Saturation							
	Decreased							
	Pco2 Decreased							
	Pneumonitis							
	Prothrombin Time							
	Prolonged							
	Pulmonary Haemorrhage							
	Respiratory Disorder							
	Sinus Tachycardia							

Date:09/27/99ISR Number: 3358567-0Report Type:Expedited (15-DaCompany Report #WAES 99075127
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Tab Rofecoxib	PS		ORAL	1	DAY
	Condition Aggravated	Health	Albuterol	C				

	Coronary Artery Disease	Professional	Beclomethasone	
	Myocardial Infarction	Other	Dipropionate	C
			Cetirizine	C
			Dothiepin	C
			Fluticasone	
			Propionate	C
			Lansoprazole	C
			Ranitidine	C

Date:09/27/99ISR Number: 3358577-3Report Type:Periodic Company Report #WAES 99080750
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Vioxx	PS		ORAL	UNK/UNK/PO	
		Professional						

Date:09/27/99ISR Number: 3358583-9Report Type:Expedited (15-DaCompany Report #WAES 99090961
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased	Health	Vioxx	PS		ORAL	12.5	
	Faeces Discoloured	Professional					MG/DAILY/PO	
	Gastrointestinal		Brethine	C				
	Haemorrhage		Theo-Dur	C				
	Heart Rate Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/99ISR Number: 3358589-XReport Type:Expedited (15-DaCompany Report #WAES 99091006
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS		ORAL	UNK/UNK/PO	

Date:09/27/99ISR Number: 3358594-3Report Type:Expedited (15-DaCompany Report #WAES 99091179
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged			Glucophage	C				
			Humulin	C				
			Lasix	C				
			Synthroid	C				
			Vasotec	C				
			Allopurinol	C				
			Amitriptyline	C				
			Atenolol	C				

Date:09/27/99ISR Number: 3358603-1Report Type:Expedited (15-DaCompany Report #WAES 99091180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Creatinine Renal Clearance Decreased	Health Professional Company Representative	Vioxx	PS		ORAL	UNK/DAILY/PO	
Other	Dialysis							
	Hyperkalaemia							
	Renal Failure							

Date:09/27/99ISR Number: 3358612-2Report Type:Expedited (15-DaCompany Report #WAES 99098226
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo	Foreign	Vioxx (Rofecoxib)	PS		ORAL	UNK, PO	
		Health Professional						

Date:09/27/99ISR Number: 3358617-1Report Type:Expedited (15-DaCompany Report #WAES 99080112
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS		ORAL	12.5	
Initial or Prolonged	Confusional State	Professional					MG/DAILY/PO	
Other	Depressed Level Of Consciousness		Herbal Remedies (Composition Unspecified) Unk	SS				
	Neutropenia		Elavil	C				
	Platelet Count Decreased		Lortab	C				
	White Blood Cell Count Decreased		Soma	C				
			Morphine Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/99ISR Number: 3358622-5Report Type:Expedited (15-DaCompany Report #WAES 99090743
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Asthenia	Professional	Celebrex	C				
	Cachexia		Therapy Unspecified	C				
	Chest Pain							
	Condition Aggravated							
	Confusional State							
	Coordination Abnormal							
	Dehydration							
	Dysphagia							
	Emotional Distress							
	Gastritis							
	Heart Rate Increased							
	Hypotension							
	Iron Deficiency							
	Malaise							
	Oedema							
	Palpitations							
	Refusal Of Treatment By Patient							
	Renal Failure							
	Renal Tubular Disorder							

Date:09/27/99ISR Number: 3358634-1Report Type:Expedited (15-DaCompany Report #WAES 99091184
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Vioxx	PS		ORAL	PO	
	Nausea	Professional Company Representative						

Date:09/27/99ISR Number: 3358640-7Report Type:Expedited (15-DaCompany Report #WAES 99080155
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Vioxx	PS		ORAL	12.5	
Initial or Prolonged	Nausea	Professional					MG/DAILY/PO	
Other	Vomiting	Company Representative	Arthrotec	C				
			Aspirin	C				
			Coumadin	C				
			Glucophage	C				
			Ismo	C				
			K-Dur	C				
			Lasix	C				
			Monopril	C				
			Norvasc	C				
			Zaroxolyn	C				
			Insulin	C				

Date:09/27/99ISR Number: 3358645-6Report Type:Expedited (15-DaCompany Report #WAES 99090214
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Duodenal Ulcer

Perforation

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Vioxx	PS		ORAL	25 MG/BID/PO; 12.5 MG/BID/PO	
			Sinemet	C				
			Sinemet Cr	C				
			Propranolol	C				

Date:09/27/99ISR Number: 3358648-1Report Type:Expedited (15-DaCompany Report #WAES 99080002
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Blood Sodium Increased							
	Dizziness		Cardizem Cd	C				
	Fall		Depakote	C				
	Hypochloraemia		Hydrodiuril	C				
	Hypokalaemia		Levsin	C				
	Hyponatraemia		Tenormin	C				
	Muscular Weakness		Clonazepam	C				
			Nifedipine	C				
			Potassium Chloride	C				

Date:09/29/99ISR Number: 3359627-0Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Septal Defect	Health Professional	Celebrex 200mg Bid	PS		ORAL	200MG PO BID	4 WK
Hospitalization - Initial or Prolonged	Cerebral Artery Occlusion		Vioxx 25 Mg	SS		ORAL	25 MG PO QD	10 DAY
Disability	Deep Vein Thrombosis		Dyazide	C				
	Embolism		Miacalcin	C				

	Hemiparesis	Caltrate	C
	Rash Maculo-Papular	Es Tylenol	C
	Rash Pruritic		

Date:09/29/99ISR Number: 3360320-9Report Type:Expedited (15-DaCompany Report #WAES 99071561
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Blood Pressure Increased
Other	Cardiac Murmur
	Cerebrovascular Accident
	Condition Aggravated
	Decreased Appetite
	Diabetes Mellitus
	Inadequate Control
	Gastric Ulcer Haemorrhage
	Gastroenteritis
	Helicobacter
	Haematemesis
	Hyperhidrosis
	Hypoglycaemia
	Hyponatraemia
	Ischaemic Stroke
	Motor Dysfunction

		Neurological Examination Abnormal					
		Oral Intake Reduced	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Impairment	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Sensory Loss	Professional				
MG/DAILY/PO							
		Vomiting	Company	Lipitor	C		
			Representative	Metamucil	C		
				Norvasc	C		
				Prevacid	C		
				Synthroid	C		
				Aspirin	C		
				Garlic Extract	C		
				Glyburide	C		
				Indapamide	C		
				Vitamins	C		

Date:09/29/99ISR Number: 3360325-8Report Type:Expedited (15-DaCompany Report #WAES 99080601
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Rash Maculo-Papular	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Skin Lesion	Professional				
MG/DAILY/PO							
				Synthroid	C		
				Xanax	C		
				Zantac	C		

Date:09/29/99ISR Number: 3360328-3Report Type:Expedited (15-DaCompany Report #WAES 99098307
Age:42 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Distension	Foreign	Tab Vioxx			
			Health	(Rofecoxib)	PS		ORAL
25 MG PO	7 DAY						
			Professional				

Date:09/29/99ISR Number: 3360334-9Report Type:Expedited (15-DaCompany Report #WAES 99095157
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased Blood Urea Increased Renal Failure	Foreign Consumer	Tab Vioxx (Rofecoxib) Therapy Unspecified	PS C				

Date:09/29/99ISR Number: 3360337-4Report Type:Expedited (15-DaCompany Report #WAES 99090982
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/99ISR Number: 3360916-4Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS		ORAL	12.5 PO BID X	
Life-Threatening	Distress Syndrome						2WKS	
Hospitalization -	Renal Failure Acute		Celebrex	SS		ORAL	100 PO BID X	
Initial or Prolonged							2 DAYS	
			Prevacid	C				
			Asa	C				
			Atenolol	C				
			Hctz	C				
			Enalapril	C				

Date:09/30/99ISR Number: 3361081-XReport Type:Expedited (15-DaCompany Report #WAES 99080162
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Glossitis	Professional					MG/DAILY/PO	
	Inflammation		Tab Vioxx 25 Mg	C		ORAL	25	
	Oral Intake Reduced						MG/DAILY/PO	
	Pain		Wellbutrin Sr	C				
	Stomatitis							

Date:09/30/99ISR Number: 3361083-3Report Type:Expedited (15-DaCompany Report #WAES 99098307
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG PO	7 DAY

Date:09/30/99ISR Number: 3361089-4Report Type:Expedited (15-DaCompany Report #WAES 99096307
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	7 DAY

Date:09/30/99ISR Number: 3361091-2Report Type:Expedited (15-DaCompany Report #WAES 99091155
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/01/99ISR Number: 3362140-8Report Type:Expedited (15-DaCompany Report #WAES 99082150
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Petechiae	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Thrombocytopenia	Professional Company Representative	Lasix	C				
			Lipitor	C				
			Composition Unspecified	C				
			Insulin	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/99ISR Number: 3362143-3Report Type:Expedited (15-DaCompany Report #WAES 99098305
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG PO	8 DAY
	Haemorrhage	Professional	Bamifylline	C				
			Warfarin Sodium	C				

Date:10/01/99ISR Number: 3362146-9Report Type:Expedited (15-DaCompany Report #WAES 99091619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Dermatitis							
	Movement Disorder							
	Pain							
	Scab							
	Scar							

Date:10/01/99ISR Number: 3363175-1Report Type:Expedited (15-DaCompany Report #10115368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Methotrexate	PS		ORAL	15	
Life-Threatening	Drug Interaction	Health					MILLIGRAMS,	
Hospitalization -	Sepsis	Professional					1/1 WEEK ORAL	
Initial or Prolonged	Stomatitis	Other	Rofecoxib	SS		ORAL	200	
Other	Thrombocytopenia						MILLIGRAM,	
							2/1 DAY ORAL	
			Paracetamol + Codeine (Paracetamol					

			+ Codeine)	C
			Deflazacort (Deflazacort)	C
			Meclobemide (Meclobemide)	C

Date:10/04/99ISR Number: 3362284-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Epistaxis	Health	Vioxx (25mg)	PS		
ONE A DAY 2 DAY						
Initial or Prolonged	Gingival Bleeding	Professional				
	Petechiae					
	Thrombocytopenia					
	Vaginal Haemorrhage					

Date:10/04/99ISR Number: 3362654-0Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Health	Rofecoxib 12.5 Mg			
Hospitalization -	Perforation	Professional	(Bid) Vioxx	PS		ORAL
1 TABLET BID						
Initial or Prolonged						
PO 1 MON						
			Warfarin 2mg Qd	SS		
2MG QD						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/99ISR Number: 3362979-9Report Type:Expedited (15-DaCompany Report #WAES 99070319
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Abdominal Tenderness	Professional					MG/DAILY/PO/2	
Initial or Prolonged	Asthenia						5 MG/DAILY/PO	
Disability	Benign Prostatic		Tab Fosamax	SS			10 MG/DAILY	
	Hyperplasia		Azulfidine	C				
	Breath Sounds Decreased		Imuran	C				
	Colonic Polyp		Sulfalene	C				
	Diverticulum Intestinal		Biaxin	C				
	Haemorrhagic		Azulfidine	C				
	Dyspepsia		Prednisone	C				
	Gastrointestinal		Ecotrin	C				
	Haemorrhage		Biaxin	C				
	Haematochezia							
	Haemoglobin Decreased							
	Hypotension							
	Oesophageal Ulcer							
	Oesophageal Ulcer							
	Haemorrhage							
	Pallor							

Date:10/04/99ISR Number: 3362984-2Report Type:Expedited (15-DaCompany Report #WAES 99080719
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
Other	Dyspnoea	Company	Cardizem Cd	C				
	Fluid Overload	Representative	Lanoxin	C				
	Oedema Peripheral		Aspirin	C				
	Orthopnoea							
	Palpitations							
	Venous Pressure Jugular Increased							

Date:10/04/99ISR Number: 3362986-6Report Type:Expedited (15-DaCompany Report #WAES 99071972
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
	Myocardial Infarction	Professional						
	Sudden Death	Company						
		Representative						

Date:10/04/99ISR Number: 3362989-1Report Type:Expedited (15-DaCompany Report #WAES 99095198
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/99ISR Number: 3362995-7Report Type:Expedited (15-DaCompany Report #WAES 99095143
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gangrene Peripheral Ischaemia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	65 DAY
			Albuterol	C				
			Amlodipine Benzenesulfonate	C				
			Folic Acid	C				
			Furosemide	C				
			Methotrexate	C				
			Ranitidine	C				
			Thyroxine	C				

Date:10/04/99ISR Number: 3362999-4Report Type:Expedited (15-DaCompany Report #WAES 99091675
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Headache Oedema	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/PO	
			Inj Methylprednisolone	C			80 MG/1X/INJ	

Date:10/04/99ISR Number: 3363003-4Report Type:Expedited (15-DaCompany Report #WAES 99091774
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Activity Joint Stiffness Local Swelling Muscle Rigidity Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/BID/PO	

Date:10/04/99ISR Number: 3363006-XReport Type:Expedited (15-DaCompany Report #WAES 99098226
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:10/04/99ISR Number: 3363009-5Report Type:Expedited (15-DaCompany Report #WAES 99098226
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:10/04/99ISR Number: 3363012-5Report Type:Expedited (15-DaCompany Report #WAES 99091937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/99ISR Number: 3363750-4Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx 12.5mg /Merck	PS	Merck	ORAL	12.5MG PO QD	
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Cozaar	C				
			Nortriptyline	C				
			Digoxin	C				
			Colace	C				
			Coumadin	C				
			Lasix	C				
			Norvasc	C				

Date:10/06/99ISR Number: 3365266-8Report Type:Expedited (15-DaCompany Report #WAES 99092063
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY PO	
Disability		Company Representative	Lasix	C				
			Norval	C				
			Synthroid	C				
			Amiodarone	C				
			Losartan Potassium	C				

Date:10/06/99ISR Number: 3365270-XReport Type:Expedited (15-DaCompany Report #WAES 99091828
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/06/99ISR Number: 3365272-3Report Type:Expedited (15-DaCompany Report #WAES 99091680
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	25 MG PO	
Initial or Prolonged	Headache	Professional	Inj Methylprednisolone Unk	SS		INJ		
	Nausea							
	Oedema							
	Vertigo							

Date:10/06/99ISR Number: 3365275-9Report Type:Expedited (15-DaCompany Report #WAES 99095202
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depressed Mood	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
	Depression	Other						
	Suicidal Ideation		Acetaminophen/Codeine Phosphate	C				
			Albuterol	C				
			Beclomethasone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/99ISR Number: 3365277-2Report Type:Expedited (15-DaCompany Report #WAES 99095194
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	17 DAY
			Acetaminophen/Codeine Phosphate	C				

Date:10/07/99ISR Number: 3365546-6Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional	Vioxx	PS		ORAL	50MG QD PO	2 WK
			Coumadin	SS			10MG/9MG ALT	CONTINUOUS
			Amitriptyline	C				
			Lasix	C				
			Kcl	C				
			Cafergot	C				

Date:10/07/99ISR Number: 3366112-9Report Type:Expedited (15-DaCompany Report #WAES 99091487
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial Prolonged	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
Life-Threatening	Thromboplastin Time Blood Fibrinogen Increased	Professional	Lovenox 90 Mg	SS			SUBCUTANEOUS	90 MG BID SC
	Coagulopathy							
	Haematocrit Decreased							
	Haemorrhage							
	Metabolic Acidosis							

Prothrombin Time
Prolonged
Splenic Rupture

Date:10/07/99ISR Number: 3366115-4Report Type:Expedited (15-DaCompany Report #WAES 99080601
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropod Bite	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Rash Maculo-Papular	Professional					PO	
	Skin Disorder		Synthroid	C				
	Skin Lesion		Xanax	C				
			Zantac	C				

Date:10/07/99ISR Number: 3366118-XReport Type:Expedited (15-DaCompany Report #WAES 99081825
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Face Oedema	Professional					PO, 25 MG	
	Paraesthesia	Other					DAILY PO	
	Pruritus		Moduretic	C				
			Ultram	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/99ISR Number: 3366119-1Report Type:Expedited (15-DaCompany Report #WAES 99090961
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Blood Pressure Decreased	Professional					PO	
	Faeces Discoloured		Brethine	C				
	Gastritis		Theo-Dur	C				
	Gastrointestinal							
	Haemorrhage							
	Haemoglobin Decreased							
	Heart Rate Increased							
	Nausea							

Date:10/08/99ISR Number: 3366360-8Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Celebrex 100 Mg	PS		ORAL	100 MG PO BID	
Hospitalization -	Oedema Peripheral	Professional	Vioxx 25mg	SS		ORAL	25MG PO QD	
Initial or Prolonged	Pulmonary Oedema							
	Respiratory Failure							
	Weight Increased							

Date:10/08/99ISR Number: 3368026-7Report Type:Expedited (15-DaCompany Report #WAES 99090961
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Blood Pressure Decreased	Professional					MG/DAILY/PO	
	Dyspepsia		A.S.A.	C				
	Faeces Discoloured		Brethine	C				
	Gastritis		Darvon	C				
	Gastrointestinal		Theo-Dur	C				

Haemorrhage
Haemoglobin Decreased
Heart Rate Increased
Nausea

Date:10/08/99ISR Number: 3368039-5Report Type:Expedited (15-DaCompany Report #WAES 99081448
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Dreams	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Other	Abnormal Sensation In Eye	Health Professional						
	Hallucination		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Nightmare							
	Visual Acuity Reduced		Hytrin	C				
	Visual Disturbance		Ziac	C				
			Zocor	C				
			Ascorbic Acid	C				
			Cortisone	C				
			Pyridoxine	C				
			Vitamin A	C				
			Vitamin E	C				
			Zinc Preparation (Composition Unk)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/99ISR Number: 3368049-8Report Type:Expedited (15-DaCompany Report #WAES 99081036
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
Initial or Prolonged	Faeces Discoloured	Health	Estraderm					
Other	Gastric Ulcer	Professional	Transdermal System	C				
	Gastric Ulcer Haemorrhage		Norflex	C				
	Gastritis		Prevacid	C				
	Gastrointestinal		Tylenol Arthritis					
	Haemorrhage		Extended Relief	C				
	Insomnia							
	Oral Intake Reduced							
	Stress							
	Tachycardia							
	Upper Gastrointestinal							
	Haemorrhage							

Date:10/08/99ISR Number: 3368055-3Report Type:Expedited (15-DaCompany Report #WAES 99070721
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Confusional State	Professional					MG/DAILY/PO	
	Memory Impairment	Company	Tylenol With Codeine					
	Suicidal Ideation	Representative	#3	C				
	Tattoo		Prednisone	C				
			Verapamil	C				
			Vitamin B{12}	C				

Date:10/08/99ISR Number: 3368064-4Report Type:Expedited (15-DaCompany Report #WAES 99100159
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/PRN/PO	
Other	Chills	Professional	Isordil	C				

	Diarrhoea	Company	Lasix	C
	Gastrointestinal	Representative	Norvasc	C
	Haemorrhage		Prinivil	C
	Hyperhidrosis		Digoxin	C
	Melaena			
	Vomiting			

Date:10/08/99ISR Number: 3368072-3Report Type:Expedited (15-DaCompany Report #WAES 99092338
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Haemorrhage	Professional	Percocet	C				
	Haemoglobin Decreased	Company	Vicodin Tablets	C				
		Representative	Xanax	C				

Date:10/08/99ISR Number: 3368080-2Report Type:Expedited (15-DaCompany Report #WAES 99092254
Age: Gender:Unknown I/FU:I

Outcome	PT
Hospitalization -	Haemorrhage
Initial or Prolonged	Prothrombin Time

Prolonged

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional Company Representative	Coumadin	C				

Date:10/08/99ISR Number: 3368092-9Report Type:Expedited (15-DaCompany Report #WAES 99091898
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	
	Haemorrhage International Normalised Ratio Increased	Professional Company Representative	Coumadin	C				

Date:10/08/99ISR Number: 3368100-5Report Type:Expedited (15-DaCompany Report #WAES 99091293
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Tab Vioxx Unk	PS		ORAL	25-50	
Initial or Prolonged	Condition Aggravated	Professional					MG/DAILY/PO	
Other	Faeces Discoloured	Other	Flonase	C				
	Gastrointestinal		Prinivil	C				
	Haemorrhage		Tylenol	C				
	Haematocrit Decreased		Amlodipine	C				
	International Normalised Ratio Increased		Aspirin	C				
			Atorvastatin	C				
			Warfarin	C				

Date:10/08/99ISR Number: 3368110-8Report Type:Expedited (15-DaCompany Report #WAES 99091292
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Creatinine Decreased Blood Creatinine Increased Creatine Phosphokinase Decreased Renal Failure Renal Failure Acute Rhabdomyolysis	Health Professional Other	Tab Vioxx Unk	PS		ORAL	25 MG/BID/PO	

Date:10/12/99ISR Number: 3368501-5Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Increased Blood Urea Increased Oedema Peripheral		Vioxx 12.5mg Astra-Merck	PS	Astra-Merck	ORAL	12.5MG DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/99ISR Number: 3369641-7Report Type:Expedited (15-DaCompany Report #WAES 99095157
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	5 DAY
	Blood Urea Increased	Professional	Cisapride	C				
	Condition Aggravated		Dexamethasone	C				
	Renal Impairment		Digoxin	C				
			Fentanyl	C				
			Ferrousso4	C				
			Furosemide	C				
			Lansoprazole	C				
			Metoclopramide	C				
			Paroxetine	C				
			Penicillin V	C				
			Temazepam	C				

Date:10/12/99ISR Number: 3369644-2Report Type:Expedited (15-DaCompany Report #WAES 99091006
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
		Professional						
		Company Representative	Cardura	C				

Date:10/12/99ISR Number: 3369649-1Report Type:Expedited (15-DaCompany Report #WAES 99081823
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Oedema	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Hospitalization -	Cerebrovascular Accident	Professional	Tab Aspirin	SS		ORAL	PO	
Initial or Prolonged	Haematocrit Decreased	Other	Coumadin	C				
Disability	Haemorrhagic Stroke		Sinemet	C				

Other	Hypertension	Zestoretic	C
		Ascorbic Acid	C

Date:10/12/99ISR Number: 3369654-5Report Type:Expedited (15-DaCompany Report #WAES 99090343
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Urea Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Life-Threatening	Electrocardiogram	Professional					MG/DAILY/PO	
	Abnormal	Other	Lasix	C				
	Hyperkalaemia		Gentamicin	C				

Date:10/12/99ISR Number: 3369658-2Report Type:Expedited (15-DaCompany Report #WAES 99091192
Age:44 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Blood Bilirubin Increased
	Cholelithiasis
	Fatigue
	Jaundice
	Liver Function Test Abnormal

	Obstruction Pancreatic Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO

Date:10/12/99ISR Number: 3369660-0Report Type:Expedited (15-DaCompany Report #WAES 99092017
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/1X/PO
Initial or Prolonged	Back Pain		Cortisone	C			
	Diarrhoea						
	Headache						
	Oral Intake Reduced						

Date:10/12/99ISR Number: 3369664-8Report Type:Expedited (15-DaCompany Report #WAES 99098312
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx				
Initial or Prolonged	Asthenia	Study	(Rofecoxib)	PS		ORAL	50 MG PO 154 DAY
	Dehydration	Health	Tab Placebo For				
	Jaundice	Professional	Naproxen	SS		ORAL	2 TABLET PO
	Vomiting		Acetaminophen	C			
			Chloroquine	C			
			Methotrexate	C			
			Ranitidine	C			

Date:10/12/99ISR Number: 3369666-1Report Type:Expedited (15-DaCompany Report #WAES 99100352
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Drug Hypersensitivity	Professional						
	Oedema	Company						
		Representative						

Date:10/13/99ISR Number: 3374173-6Report Type:Expedited (15-DaCompany Report #WAES 99090772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Aleve	C				
		Company						
		Representative						

Date:10/13/99ISR Number: 3374174-8Report Type:Expedited (15-DaCompany Report #WAES 99100368
Age:64 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Chest X-Ray Abnormal
Initial or Prolonged	Cough
	Crepitations
	Dyspnoea
	Pneumonitis

	Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Tab Vioxx Unk	PS		ORAL	PO
		Professional	Hytrin	C			

Date:10/13/99ISR Number: 3374177-3Report Type:Expedited (15-DaCompany Report #WAES 99100768
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dysphagia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25
	Dyspnoea						MG/DAILY/PO
	Face Oedema		Azmacort	C			
			Claritin-D	C			
			Nasonex	C			
			Serevent	C			
			(Therapy Unspecified)	C			
			Albuterol	C			
			Ibuprofen	C			

Date:10/14/99ISR Number: 3370869-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Blood Pressure Increased	Health	Vioxx 25mg 1 Per Day	PS		ORAL	1/DAY PO
	Bronchospasm	Professional	Ditropan Xl 5mg 1 Or 2/Day	SS		ORAL	1-2 / DAY PO
	Cardiac Failure						
	Congestive		Baby Asa	C			
	Cardiomegaly		Donnatal	C			
	Oedema		Tenrectic 50	I			
	Ventricular Hypertrophy		Premarin	I			
	Weight Increased						

Date:10/14/99ISR Number: 3372060-0Report Type:Expedited (15-DaCompany Report #WAES 99095216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Rheumatoid Arthritis	Foreign Health Professional	Vioxx (Rofecoxib) Acetaminophen	PS C				

Date:10/14/99ISR Number: 3372062-4Report Type:Expedited (15-DaCompany Report #WAES 99100006
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Creatinine Renal Clearance Decreased Haemodialysis Renal Failure	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/99ISR Number: 3372063-6Report Type:Expedited (15-DaCompany Report #WAES 99100008
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Health	Vioxx	PS		ORAL	PO	
	Perforation	Professional Company Representative						

Date:10/14/99ISR Number: 3372065-XReport Type:Expedited (15-DaCompany Report #WAES 99100122
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Health	Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:10/14/99ISR Number: 3372066-1Report Type:Expedited (15-DaCompany Report #WAES 99100354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
Other	Gastrointestinal	Company	Axid	C				
	Haemorrhage	Representative	Lopressor	C				
			Lotensin	C				
			Minipress	C				
			Naldecon	C				
			Serax	C				
			Zocor	C				
			Aspirin	C				

Date:10/14/99ISR Number: 3372068-5Report Type:Expedited (15-DaCompany Report #WAES 99078508
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence	Foreign	Vioxx					
	Aortic Valve Sclerosis	Study	(Rofecoxib)	PS		ORAL	50 MG DAILY	
	Atrioventricular Block	Health	Placebo	SS		ORAL		
	First Degree	Professional	Diclofenac Na	C				
	Cardiac Disorder		Enalapril Maleate	C				
	Pulmonary Hypertension		Glyburide	C				
	Pulmonary Oedema		Hydroxychloroquine	C				
	Ventricular Hypertrophy		Metoprolol	C				
			Ranitidine	C				

Date:10/14/99ISR Number: 3372071-5Report Type:Expedited (15-DaCompany Report #WAES 99081617
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State	Health Professional	Vioxx	PS		ORAL	12.5MG/DAILY/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/99ISR Number: 3372899-1Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS		ORAL	25MG PO	
Initial or Prolonged	Gastric Ulcer Perforation		Ec Aspirin	SS		ORAL	325MG PO	
Required	Surgery							
(LONG								
Intervention to								
STANDING)								
Prevent Permanent								
Impairment/Damage								

Date:10/15/99ISR Number: 3373110-8Report Type:Expedited (15-DaCompany Report #WAES 99092254
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx / Tab					
Initial or Prolonged	Dizziness	Professional	Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Drug Interaction	Company	Coumadin	SS			SEE IMAGE	
	Epistaxis	Representative	Plendil	C				
	Haematocrit Decreased		Proscar	C				
	Post Procedural Pain		Zocor	C				
	Prothrombin Time							
	Prolonged							
	Retroperitoneal							
	Haemorrhage							

Date:10/15/99ISR Number: 3396715-7Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Idiopathic	Health	Vioxx (Rofecoxib),					
Initial or Prolonged	Thrombocytopenic Purpura	Professional	12.5 Mg Merck	PS	Merck	ORAL	12.5 MG,	

Petechiae
DAILY, ORAL 7 DAY
Enalapril C

Date:10/16/99ISR Number: 3398038-9Report Type:Expedited (15-DaCompany Report #WAES 99117911
Age:44 YR Gender:Male I/FU:I

Outcome	PT
Death	Brain Damage
Life-Threatening	Coma
Hospitalization -	Epistaxis
Initial or Prolonged	Gastrointestinal
	Haemorrhage
	Haematemesis
	Haematocrit Decreased
	Haemodialysis
	Haemoptysis
	Haemorrhage Intracranial
	Idiopathic
	Thrombocytopenic Purpura
	Malaise
	Melaena
	Platelet Count Decreased
	Polyarteritis Nodosa
	Pulmonary Congestion
	Pulmonary Haemorrhage
	Renal Failure
	Respiratory Failure

Vasculitis
Wegener'S Granulomatosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	10 DAY

Date:10/18/99ISR Number: 3373106-6Report Type:Expedited (15-DaCompany Report #WAES 99100122
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Company Representative	Aspirin	C				

Date:10/18/99ISR Number: 3373975-XReport Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx 12.5	PS			QD	
	Dyspnoea		Ceftin 250	SS			BID	
	Urticaria		Prinizide	C				
			Zyrtec	C				
			Venolin Rotocaps	C				
			Sulfa	C				
			Augmnentin	C				

Date:10/18/99ISR Number: 3375073-8Report Type:Expedited (15-DaCompany Report #9943252
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Arthropathy	Consumer	Viagra Tablets	PS		ORAL
50.00 MG						
Intervention to	Back Pain					
TOTAL: PRN:						
Prevent Permanent	Drug Effect Decreased					
ORAL						
Impairment/Damage	Drug Interaction		Amitriptyline	SS		
	Spinal Laminectomy		Rofecoxib	SS		ORAL
25.00 MG						
TOTAL: DAILY:						
ORAL						
			Procardia Xl	C		
			Zocor	C		
			Enteric Coated			
			Aspirin	C		

Date:10/18/99ISR Number: 3375156-2Report Type:Expedited (15-DaCompany Report #WAES 99100455
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL
Life-Threatening		Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/99ISR Number: 3374279-1Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Back Pain		Vioxx-12.5mg Merck	PS	Merck		12.5MG QD	
Intervention to	International Normalised		Warfarin Barr	SS	Barr		6 OR 8 MG QD	
Prevent Permanent	Ratio Increased							
(LONG TERM)								
Impairment/Damage	Medication Error							
	Prothrombin Time							
	Prolonged							

Date:10/19/99ISR Number: 3374907-0Report Type:Direct Company Report #
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Haemoptysis	Health	Vioxx 12.5mg	PS		ORAL	12.5MG PO QD	
Intervention to	Upper Gastrointestinal	Professional	Coumadin 1mg & 2 Mg					
Prevent Permanent	Haemorrhage		(Alternating)	SS		ORAL	1MG&2MG PO	
Impairment/Damage							QOD SEVERAL	
MONTHS								

Date:10/19/99ISR Number: 3375154-9Report Type:Expedited (15-DaCompany Report #WAES 99075127
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Foreign	Tab Vioxx					
	Circulatory Collapse	Health	(Rofecoxib)	PS		ORAL	12.5 MG	1 DAY
	Myocardial Infarction	Professional	Albuterol	C				
			Beclomethasone					
			Dipropinate	C				
			Cetirizine	C				
			Dothiepin	C				

			Fluticasone Propionate	C		
			Lansoprazole	C		
			Ranitidine	C		

Date:10/19/99ISR Number: 3375660-7Report Type:Expedited (15-DaCompany Report #WAES 99100681
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Thrombosis	Consumer	Tab Vioxx	PS		ORAL		

Date:10/19/99ISR Number: 3375661-9Report Type:Expedited (15-DaCompany Report #WAES 99105006
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Personality Change	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	2	DAY
	Psychiatric Symptom		Captopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/99ISR Number: 3375662-0Report Type:Expedited (15-DaCompany Report #WAES 99100159
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	PRN/ PO	
	Chills	Professional	Isordil	C				
	Diarrhoea Haemorrhagic	Company	Lasix	C				
	Gastrointestinal	Representative	Norvasc	C				
	Haemorrhage		Prinivil	C				
	Hyperhidrosis		Digoxin	C				
	Insomnia		Nitroglycerin	C				
	Vomiting							

Date:10/20/99ISR Number: 3376179-XReport Type:Expedited (15-DaCompany Report #WAES 99105009
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Foreign	Tab Vioxx					
	Rhinitis	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	11 DAY
	Vertigo		Diclofenac Sodium					
			(+) Misoprostol	C				

Date:10/20/99ISR Number: 3376183-1Report Type:Expedited (15-DaCompany Report #WAES 99090752
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Faeces	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Coumadin	C				

Date:10/20/99ISR Number: 3376186-7Report Type:Expedited (15-DaCompany Report #WAES 99090743
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Abdominal Tenderness	Health	Tab Vioxx 25 Mg	PS	ORAL 25
Hospitalization -	Anaemia	Professional			MG/DAILY/PO
Initial or Prolonged	Cachexia		Celebrex	C	
Other	Chest Pain		Climara	C	
	Condition Aggravated		Prilosec	C	
	Confusional State		Xanax	C	
	Dehydration		Amitriptyline	C	
	Depressed Level Of Consciousness		Nonsteroidal Anti-Inflammatory	C	
	Gastritis				
	Gastrointestinal Disorder				
	Hypotension				
	Laboratory Test Abnormal				
	Oedema Peripheral				
	Oral Intake Reduced				
	Palpitations				
	Peptic Ulcer				
	Pyrexia				
	Red Blood Cell Sedimentation Rate Increased				
	Renal Tubular Disorder				
	Tachycardia				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/99ISR Number: 3376188-0Report Type:Expedited (15-DaCompany Report #WAES 99081970
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
	Blister	Health					PO	
	Bronchospasm	Professional	Dyazide	C				
	Dermatitis		Entex La	C				
	Drug Hypersensitivity		Humulin 70/30	C				
	Fungal Infection		Neurotonin Capsules	C				
	Oedema		Rezulin	C				
	Oedema Genital		Vitamins	C				
	Vaginal Candidiasis							
	Vaginal Haemorrhage							

Date:10/20/99ISR Number: 3376193-4Report Type:Expedited (15-DaCompany Report #WAES 99100613
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Supraventricular		Zyrtec	C				
	Tachycardia		Verapamil	C				

Date:10/20/99ISR Number: 3376194-6Report Type:Expedited (15-DaCompany Report #WAES 99109301
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG PO	3 DAY
Disability		Professional						

Date:10/21/99ISR Number: 3376417-3Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx 25mg Qd-Merck	PS	Merck	ORAL	25MG PO QD	1 MON

Date:10/21/99ISR Number: 3376420-3Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine		Vioxx 25mg	PS		ORAL	1T QD PO X 5	
Initial or Prolonged	Phosphokinase Increased						DAYS	
	Blood Creatine		Ziac	C				
	Phosphokinase Mb		Zystrel	C				
	Increased		Prilosec	C				
	Electrocardiogram							
	Abnormal							
	Oedema							

Date:10/21/99ISR Number: 3376422-7Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx-Merck	PS	Merck	ORAL	25MG QD PO	1 MON
	Tongue Ulceration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/99ISR Number: 3377228-5Report Type:Expedited (15-DaCompany Report #WAES 99109256
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haemorrhagic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	3 DAY

Date:10/21/99ISR Number: 3377229-7Report Type:Expedited (15-DaCompany Report #WAES 99107904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	4 DAY

Date:10/21/99ISR Number: 3377230-3Report Type:Expedited (15-DaCompany Report #WAES 99105085
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Foreign	Tab Vioxx					
	Diabetes Mellitus	Other	(Rofecoxib)	PS		ORAL	25 MG PO	
	Diabetes Mellitus		Acetaminophen/Propoxyphene Hydrochloride	C				
	Inadequate Control		Aspirin	C				
			Atorvastatin	C				
			Diltiazem	C				
			Glipizide	C				
			Metformin	C				
			Nicorandil	C				

Date:10/21/99ISR Number: 3377231-5Report Type:Expedited (15-DaCompany Report #WAES 99095157
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Foreign	Tab Vioxx					

	Increased	Health	(Rofecoxib)	PS		ORAL
25 MG PO 5 DAY						
	Blood Urea Increased	Professional	Cisapride	C		
	Renal Impairment		Dexamethasone	C		
			Digoxin	C		
			Fentanyl	C		
			Ferrouss04	C		
			Furosemide	C		
			Lansoprazole	C		
			Metoclopramide	C		
			Paroxetine	C		
			Penicillin V	C		
			Temazepam	C		

Date:10/21/99ISR Number: 3377239-XReport Type:Expedited (15-DaCompany Report #WAES 99101104
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactoid Reaction	Health	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						
Hospitalization -	Condition Aggravated	Professional	Coumadin	C		
Initial or Prolonged	Dermatitis	Company				
	Drug Hypersensitivity	Representative				
	Pyrexia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/99ISR Number: 3377242-XReport Type:Expedited (15-DaCompany Report #WAES 99101035
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Liver Function Test	Professional					MG/DAILY/PO	
Other	Abnormal	Company	Cardizem	C				
	Myalgia	Representative	Quinamm	C				
	Pain In Extremity							

Date:10/21/99ISR Number: 3377246-7Report Type:Expedited (15-DaCompany Report #WAES 99101033
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Ratio Increased	Professional					MG/DAILY/PO	
	Prothrombin Time	Company	Aldactone	C				
	Prolonged	Representative	Coumadin	C				
			Darvocet-N	C				
			Lanoxin	C				
			Lasix	C				
			Lopressor	C				
			Vasotec	C				
			Zocor	C				
			Aspirin	C				
			B Vitamins	C				
			Folic Acid	C				

Date:10/21/99ISR Number: 3377251-0Report Type:Expedited (15-DaCompany Report #WAES 99100710
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Face Oedema	Professional					MG/DAILY/PO	

	Oedema Peripheral	Company	Colestid	C
	Respiratory Distress	Representative	Elavil	C
			Enbrel	C
			Glucophage	C
			Glynase Prestab Tablets	C
			Klor-Con	C
			Lipitor	C
			Plaquenil	C
			Prilosec	C
			Rezulin	C
			Zestril	C
			Atenolol	C
			Estrone Sulfate Piperazine Salt	C
			Methotrexate	C
			Prednisone	C

Date:10/21/99ISR Number: 3377258-3Report Type:Expedited (15-DaCompany Report #WAES 99091487
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial Thromboplastin Time Prolonged
Life-Threatening	

		Coagulopathy					
		Coma					
		Drug Interaction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fibrin Degradation	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/UNK/PO							
		Products Increased	Professional	Lovenox 90 Mg	SS		
SUBCUTANEOUS	90 MG/BID/SC						
		Haematocrit Decreased					
		Hypotension					
		Metabolic Acidosis					
		Prothrombin Level					
		Increased					
		Splenic Haemorrhage					
		Splenic Rupture					

Date:10/21/99ISR Number: 3377269-8Report Type:Expedited (15-DaCompany Report #WAES 99100074
Age:73 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Bile Duct Obstruction	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Chromaturia	Professional				
MG/DAILY\PO							
		Condition Aggravated	Other	Tab Vioxx 25 Mg	SS		ORAL
25 MG/WKY/PO							
		Difficulty In Walking		Neurontin	C		
		Dyspnoea		Vasotec	C		
		Hypertension		Metoprolol	C		
		Liver Function Test		Verapamil	C		
		Abnormal					
		Oedema Peripheral					
		Pruritus					

Date:10/21/99ISR Number: 3377272-8Report Type:Expedited (15-DaCompany Report #WAES 99100514
Age:37 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaphylactic Shock	Health	Tab Vioxx	PS		ORAL
PO							
		Dyspnoea	Professional				

		Company Representative				

Date:10/21/99ISR Number: 3377276-5Report Type:Expedited (15-DaCompany Report #WAES 99100583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Hepatitis	Professional Company Representative	Amiodarone	C				
			Verapamil	C				

Date:10/21/99ISR Number: 3377280-7Report Type:Expedited (15-DaCompany Report #WAES 99100815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
Initial or Prolonged	Urticaria	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/99ISR Number: 3377283-2Report Type:Expedited (15-DaCompany Report #WAES 99100977
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:10/21/99ISR Number: 3377287-XReport Type:Expedited (15-DaCompany Report #WAES 99101029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Anxiety						MG/DAILY/PO	15 DAY
	Blood Pressure Increased							
	Depressed Mood							
	Depression							
	Emotional Distress							
	Headache							
	Suicidal Ideation							

Date:10/21/99ISR Number: 3377290-XReport Type:Expedited (15-DaCompany Report #WAES 99101121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY\PO	
		Company Representative	Diabeta	C				
			Glucophage	C				
			Procardia	C				
			Proscar	C				

Date:10/21/99ISR Number: 3377293-5Report Type:Expedited (15-DaCompany Report #WAES 99109302
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Gastric Ulcer Haemorrhage Hypovolaemic Shock	Foreign Health Professional	Tab Vioxx (Rofecoxib) Unspecific Drug Therapy	PS C		ORAL	25 MG PO	5 DAY

Date:10/22/99ISR Number: 3377470-3Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Medication Error	Health Professional	Vioxx 12.5 Mg (Merck)	PS	Merck	ORAL	12.5 MG PO QD	6-8WEEKS AGO
			Vioxx 25mg	SS		ORAL	25MG PO QD	

Date:10/22/99ISR Number: 3377472-7Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health Professional	Vioxx 25 Mg	PS		ORAL	25MG PO Q DAY	RA 9 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/99ISR Number: 3378898-8Report Type:Expedited (15-DaCompany Report #WAES 99100122
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS		ORAL	50 MG/DAILY	
Hospitalization - Initial or Prolonged	Asthenia	Professional Company Representative	Atrovent	C				
	Dyspnoea		Lotensin	C				
	Embolism		Percocet	C				
	Gastric Ulcer Haemorrhage		Albuterol	C				
	Melaena		Aspirin	C				

Date:10/22/99ISR Number: 3378905-2Report Type:Expedited (15-DaCompany Report #WAES 99100368
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alveolitis Allergic	Health	Vioxx	PS		ORAL	50 MG/DAILY	
	Bronchoscopy Abnormal	Professional	Hytrin	C				
	Condition Aggravated							
	Cough							
	Crepitations							
	Dyspnoea							
	Hypoxia							
	Lung Infiltration							
	Pneumonitis							
	Tachycardia							

Date:10/22/99ISR Number: 3378910-6Report Type:Expedited (15-DaCompany Report #WAES 99101281
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS		ORAL	25 MG/DAILY	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative	Procardia	C				
			Vasotec	C				

Date:10/22/99ISR Number: 3378916-7Report Type:Expedited (15-DaCompany Report #WAES 99090911
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Vioxx	PS		ORAL	25 MG/DAILY	
	Duodenal Ulcer	Professional	Axid	C				
	Duodenitis	Company	Lipitor	C				
	Gastritis Erosive	Representative	Lupron	C				
	Gastrointestinal Disorder		Prevacid	C				
	Melaena		Atenolol	C				
	Oesophagitis		Colchicine	C				

Date:10/22/99ISR Number: 3378921-0Report Type:Expedited (15-DaCompany Report #WAES 99100077
Age:74 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
	Arthralgia
	Back Pain
	Blood Bilirubin Increased
	Blood Creatinine Increased

		Blood Glucose Increased					
		Blood Urea Increased					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Congestive	Health	Vioxx	PS		ORAL
UNK/UNK/PO;							
		Constipation	Professional				
25							
		Crepitations	Other				
MG/DAILY/PO							
		Diarrhoea		Lescol	SS		
UNK							
		Dyspnoea		Trental	SS		
		Eructation		Altace	C		
		Haematocrit Decreased		Cardizem Cd	C		
		Haemoglobin Decreased		Cardura	C		
		Platelet Count Decreased		Claritan	C		
		Pneumonia		Coumadin	C		
		Pyrexia		Glucophage	C		
		Tympanic Membrane		Glucotrol	C		
		Perforation		Imdur	C		
				Lasix	C		
				Lopid	C		
				Nitrostat	C		
				Prilosec	C		
				Timoptic	C		
				[Therapy			
				Unspecified]	C		
				Allopurinol	C		
				Hydroxychloroquine	C		
				Quinine	C		
				K-Dur	C		

Date:10/22/99ISR Number: 3378943-XReport Type:Expedited (15-DaCompany Report #WAES 99105143
Age:50 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Creatinine	Foreign	Vioxx	PS		ORAL
12.5 MG PO							
		Increased	Other	Mg Oh	C		
		Renal Impairment		Acetaminophen (+)			
				Dihdrocodeine			
				Bitartr	C		
				Amiloride			

Hydrochloride (+)	
Furosemide	C
Aspirin	C
Ferrous S04	C
Imipramine	C
Insulin Injection/Isophane Insulin Suspe	C
Isophane Insulin Suspension	C
Nitroglycerin	C
Pravastatin Na	C

Date:10/22/99ISR Number: 3378951-9Report Type:Expedited (15-DaCompany Report #WAES 99101080
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx Unk	PS		ORAL	PO	
	Loss Of Consciousness	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/99ISR Number: 3379620-1Report Type:Direct Company Report #
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health Professional	Vioxx 25 Mg Tabs	PS		ORAL	25 MG PO QDAY	(IN AM) 2 DAY
			Atenolol	C				

Date:10/25/99ISR Number: 3380632-2Report Type:Expedited (15-DaCompany Report #WAES 99105140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accommodation Disorder	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL		
	Agitation		Carbamazepine	SS				
	Akathisia		Omeprazole	C				
	Coordination Abnormal							
	Drug Interaction							
	Dyskinesia							
	Headache							
	Hypertension							
	Restlessness							
	Speech Disorder							
	Tremor							
	Visual Disturbance							

Date:10/25/99ISR Number: 3380633-4Report Type:Expedited (15-DaCompany Report #WAES 99105100
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	72 DAY	
	Drug Interaction							
	Mouth Ulceration		Prinivil	C				
	Neutropenia		Atenolol	C				
	Thrombocytopenia		Isosorbide-5-Mononitrate	C				
			Lansoprazole	C				
			Methotrexate	C				

			Nicorandil	C		
			Pravastatin Na	C		
			Temazepam	C		

Date:10/25/99ISR Number: 3380634-6Report Type:Expedited (15-DaCompany Report #WAES 99092136
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amenorrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Menstrual Disorder	Professional					MG/DAILY/PO	
			Zostrix	C				

Date:10/25/99ISR Number: 3380636-XReport Type:Expedited (15-DaCompany Report #WAES 99100830
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Brain Damage	Professional					MG/DAILY/PO	
	Subdural Haematoma		Coumadin	C				
			Plaquenil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/99ISR Number: 3380637-1Report Type:Expedited (15-DaCompany Report #WAES 99100740
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Muscular Weakness	Health					MG/DAILY/PO	
	Pain In Extremity	Professional	Hydrodiuril	C				
	Sciatica		Redisol	C				
	Urinary Incontinence		Donepezil Hydrochloride	C				
			Sertraline Hydrochloride	C				
			Vitamin E	C				

Date:10/25/99ISR Number: 3380639-5Report Type:Expedited (15-DaCompany Report #WAES 99100613
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Supraventricular Tachycardia		Zyrtec	C				
			Verapamil	C				

Date:10/25/99ISR Number: 3380641-3Report Type:Expedited (15-DaCompany Report #WAES 99091155
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:10/25/99ISR Number: 3380643-7Report Type:Expedited (15-DaCompany Report #WAES 99090743
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS	ORAL 25
Hospitalization -	Blood Urea Increased	Professional			MG/DAILY/PO
Initial or Prolonged	Confusional State		Celebrex	C	
Other	Dehydration		Climara	C	
	Depressed Level Of		Prilosec	C	
	Consciousness		Xanax	C	
	Dyspnoea		Amitriptyline	C	
	Dysuria		Nonsteroidal		
	Gastritis		Anti-Inflammatory	C	
	Haematuria				
	Hypokalaemia				
	Hypotension				
	Malaise				
	Oedema Peripheral				
	Oral Intake Reduced				
	Palpitations				
	Peripheral Coldness				
	Pollakiuria				
	Pyrexia				
	Red Blood Cell				
	Sedimentation Rate				
	Increased				
	Renal Tubular Disorder				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/99ISR Number: 3381104-1Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx 12.5 Mg Merck	PS	Merck	ORAL	12.5MG PO QD	19 DAY
Initial or Prolonged	Increased	Professional	Atenolol	C				
	Blood Urea Increased		Diovan	C				
	Condition Aggravated		Prilosec	C				
	Renal Failure		Cardizem Cd	C				
			Ativan	C				
			Zaroxolyn	C				
			Furosemide	C				
			Darvocet N	I				

Date:10/27/99ISR Number: 3381787-6Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Retention		Vioxx 12.5mg (Merck)	PS	Merck		1 TAB DAILY	
							WITH FOOD	
			Coumadin	C				

Date:10/27/99ISR Number: 3382553-8Report Type:Expedited (15-DaCompany Report #WAES 99091176
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Bilirubin Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Cholelithiasis	Professional					MG/BID/PO	
	Chromaturia	Company	Accolate	C				
	Hepatitis Cholestatic	Representative	Atarax	C				
	Jaundice		Claritin	C				
	Liver Function Test		Premarin	C				
	Abnormal		Sinequan	C				
			Zantac	C				

Date:10/27/99ISR Number: 3382558-7Report Type:Expedited (15-DaCompany Report #WAES 99090911
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Duodenal Ulcer	Professional						
	Duodenitis	Company	Axid	C				
	Gastritis Erosive	Representative	Lipitor	C				
	Gastrointestinal Disorder		Lupron	C				
	Melaena		Prevacid	C				
	Oesophagitis		Atenolol	C				
			Colchicine	C				

Date:10/28/99ISR Number: 3383686-2Report Type:Expedited (15-DaCompany Report #WAES 99101281
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Gastric Ulcer
Hospitalization - Initial or Prolonged	Gastritis
	Gastroenteritis
	Helicobacter
	Gastrointestinal Haemorrhage

Haemoglobin Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Procardia	C				
	Vasotec	C				

Date:10/28/99ISR Number: 3383689-8Report Type:Expedited (15-DaCompany Report #WAES 99101033
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised Ratio Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Prothrombin Time Prolonged	Company Representative	Aldactone	C				
			Coumadin	C				
			Darvocet-N	C				
			Lanoxin	C				
			Lasix	C				
			Lopressor	C				
			Lopressor	C				
			Vasotec	C				
			Zocor	C				
			Aspirin	C				
			Folic Acid	C				
			Pyridoxine	C				

Date:10/28/99ISR Number: 3383694-1Report Type:Expedited (15-DaCompany Report #WAES 99107904
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Drug Hypersensitivity	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG MG PO	2 DAY

Date:10/28/99ISR Number: 3383699-0Report Type:Expedited (15-DaCompany Report #WAES 99109305
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Foreign	Tab Vioxx					
	Diarrhoea	Health	(Rofecoxib)	PS		ORAL	25 - 50 MG PO	
	Dyspepsia	Professional						

Date:10/28/99ISR Number: 3383704-1Report Type:Expedited (15-DaCompany Report #WAES 99091795
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cross Sensitivity	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Reaction	Professional					MG/DAILY/PO	
	Dermatitis							

Date:10/28/99ISR Number: 3383711-9Report Type:Expedited (15-DaCompany Report #WAES 99092228
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Difficulty In Walking	Professional						
	Multiple Sclerosis		Betaseron	C				
			Estratest	C				
			Zanaflex	C				
			Clonazepam	C				

Date:10/28/99ISR Number: 3383715-6Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Health	Tab Vioxx	PS		ORAL	PO	
	Thrombocytopenia	Professional						

Date:10/28/99ISR Number: 3383720-XReport Type:Expedited (15-DaCompany Report #WAES 99101188
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Full Blood Count	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
Initial or Prolonged	Decreased	Professional						
	Gastrointestinal	Company						
	Haemorrhage	Representative						
	Haematemesis							

Date:10/28/99ISR Number: 3383722-3Report Type:Expedited (15-DaCompany Report #WAES 99101240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Balance Disorder	Consumer	Tab Vioxx	PS		ORAL
25 MG/PO						
Initial or Prolonged	Blood Pressure Decreased		Estratest	C		
	Difficulty In Walking		Klonopin	C		
	Fall		Prozac	C		
	Multiple Sclerosis		Zanaflex	C		
			Baclofen	C		
			Interferon-(Beta)	C		

Date:10/28/99ISR Number: 3383726-0Report Type:Expedited (15-DaCompany Report #WAES 99101592
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx	PS		ORAL
25						
Initial or Prolonged	Haematochezia	Professional				
MG/DAILY/PO						
	Haemoglobin Decreased	Company Representative	Aspirin	C		

Date:10/28/99ISR Number: 3383730-2Report Type:Expedited (15-DaCompany Report #WAES 99109305
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain	Foreign	Tab Vioxx			
	Diarrhoea	Health	(Rofecoxib)	PS		ORAL
25-50 MG PO 10 DAY						
	Dyspepsia	Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3385211-9Report Type:Expedited (15-DaCompany Report #WAES 99100971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephritis Interstitial	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:10/29/99ISR Number: 3385213-2Report Type:Expedited (15-DaCompany Report #WAES 99101870
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:10/29/99ISR Number: 3385217-XReport Type:Expedited (15-DaCompany Report #WAES 99105147
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Oedema Peripheral	Foreign Other	Tab Vioxx (Rofecoxib) 25 Mg	PS		ORAL	PO	
			Allopurinol	C				
			Captopril	C				
			Furosemide	C				
			Omeprazole	C				

Date:10/29/99ISR Number: 3385222-3Report Type:Expedited (15-DaCompany Report #WAES 99105203
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Osteoarthritis	Foreign	Tab Vioxx					

Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL
12.5 MG PO 5 DAY						
			Acetaminophen	C		
			Digoxin	C		
			Hydrocortisone	C		
			Ranitidine	C		
			Terbutaline	C		
			Warfarin	C		

Date:10/29/99ISR Number: 3385225-9Report Type:Expedited (15-DaCompany Report #WAES 99105215
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bronchospasm	Foreign	Tab Vioxx			
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL
12.5 MG PO 5 DAY						
			Albuterol	C		
			Calcium Supplement (Nos)	C		
			Fluoxetine	C		
			Ipratropium Bromide	C		
			Omeprazole	C		
			Prednisolone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/99ISR Number: 3385227-2Report Type:Expedited (15-DaCompany Report #WAES 99101321
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ascites	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Hepatic Failure	Professional Company Representative						

Date:11/01/99ISR Number: 3386431-XReport Type:Expedited (15-DaCompany Report #WAES 99101950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Level Changed		Lithium Carbonate	C				
	Suicidal Ideation							

Date:11/01/99ISR Number: 3386434-5Report Type:Expedited (15-DaCompany Report #WAES 99101792
Age:65 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised	Health	Tab Vioxx Unk	PS		ORAL	25	
	Ratio Increased	Professional					MG/DAILY/PO	
			Coumadin	C				
			Oxycontin	C				

Date:11/01/99ISR Number: 3386437-0Report Type:Expedited (15-DaCompany Report #WAES 99101117
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged Gastric Ulcer Haemorrhage Professional
MG/DAILY/PO 5 WK
Gastrointestinal Prilosec C
Haemorrhage Aspirin C

Date:11/01/99ISR Number: 3386440-0Report Type:Expedited (15-DaCompany Report #WAES 99102156
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Dermatitis	Professional						
Initial or Prolonged		Company Representative	Coumadin	C				
			Heparin	C				

Date:11/01/99ISR Number: 3386442-4Report Type:Expedited (15-DaCompany Report #WAES 99101575
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Initial or Prolonged	Gastric Ulcer Perforation	Professional						

MG/BID/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/99ISR Number: 3386444-8Report Type:Expedited (15-DaCompany Report #WAES 99108938
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:11/01/99ISR Number: 3386445-XReport Type:Expedited (15-DaCompany Report #WAES 99105179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Gastrointestinal Haemorrhage		[Therapy Unspecified	C				
	Haematemesis		Acetaminophen/Propoxyphene Hydrochloride	C				
	Overdose		Doxycycline	C				
			Erythromycin	C				
			Estradiol (+) Norethindrone	C				
			Folic Acid	C				
			Lacidipine	C				
			Lisinopril	C				

Date:11/01/99ISR Number: 3386453-9Report Type:Expedited (15-DaCompany Report #WAES 99095216
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Rheumatoid Arthritis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
Disability			Acetaminophen	C				
			Digoxin	C				
			Dihydrocodeine	C				
			Ranitidine	C				
			Terbutaline	C				
			Warfarin	C				

Date:11/01/99ISR Number: 3386456-4Report Type:Expedited (15-DaCompany Report #WAES 99105100
Age:66 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign Company	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	72 DAY
	Drug Interaction							
	Mouth Ulceration	Representative	Prinivil	C				
	Neutropenia		Atenolol	C				
	Thrombocytopenia		Isosorbide-5-Mononitrate	C				
			Lansoprazole	C				
			Methotrexate	C				
			Nicorandil	C				
			Pravastin Na	C				
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/99ISR Number: 3386458-8Report Type:Expedited (15-DaCompany Report #WAES 99100352
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Drug Hypersensitivity	Professional						
	Swelling	Company Representative						

Date:11/01/99ISR Number: 3386461-8Report Type:Expedited (15-DaCompany Report #WAES 99081448
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bronchitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Drug Ineffective	Health					MG/DAILY/PO	
	Eye Movement Disorder	Professional	Tab Vioxx 25 Mg	SS		ORAL	25	
	Hallucination						MG/DAILY/PO	
	Hallucination, Visual		Dyazide	C				
	Hyalosis Asteroid		Hytrin	C				
	Migraine		Ziac	C				
	Nervous System Disorder		Zocor	C				
	Nightmare		Ascorbic Acid	C				
	Scintillating Scotoma		Cortisone	C				
	Scotoma		Pyridoxine	C				
	Visual Acuity Reduced		Vitamin A	C				
	Visual Disturbance		Vitamin E	C				
	Vitreous Detachment		Zinc Preparation					
	Vitreous Floaters		(Composition Un	C				

Date:11/01/99ISR Number: 3386468-0Report Type:Expedited (15-DaCompany Report #WAES 99102094
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged	Haemorrhage	Professional		
MG/DAILY/PO				
		Company Representative	Accupril	C
			Axid Ar	C
			Cardizem	C
			Flexeril	C
			Humibid	C
			Lasix	C
			Micro K	C
			Reglan	C
			Sinemet Cr	C
			Synthroid	C
			Tylenol	C

Date:11/01/99ISR Number: 3386469-2Report Type:Expedited (15-DaCompany Report #WAES 99081827
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25	Rash Macular	Health	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged	Scab	Professional				
MG/DAILY/PO 1 WK						
Other	Skin Lesion	Other	Celexa	C		
	Skin Ulcer		Demadex	C		
	White Blood Cell Count Increased		Diovan	C		
			Entex La	C		
			Epivir	C		
			Neurontin	C		

Relafen	C
Singulair	C
Soma	C
Trovan	C
Viracept	C
Zerit	C
Diltiazem	C
Theophylline	C

Date:11/02/99ISR Number: 3386746-5Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx	PS		ORAL	PO	

Date:11/02/99ISR Number: 3386748-9Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS			12.5MG ONCE	
Hospitalization - Initial or Prolonged	Drug Interaction						DAILY	11 DAY
	Dysphonia		Kenalog Inj	SS				
	Headache		Sarapin Inj	SS				
	Hypoaesthesia		Lanoxin	C				
	Throat Tightness		Inderal La	C				
			Ismo	C				
			Vitamins	C				

Date:11/03/99ISR Number: 3387658-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health	Vioxx	PS		ORAL	25MG PO DAILY	2 DAY

	Scratch	Professional	Atenolol	C
	Skin Ulcer		Glucophage	C
	Urticaria		Premarin	C
			Progesterone	C
			Colestil	C
			Pulmocort	C
			Combivent	C
			Beconase	C
			Multivitamin	C
			Otc Healthy Woman	C
			B Complex	C

Date:11/03/99ISR Number: 3388380-XReport Type:Expedited (15-DaCompany Report #WAES 99107904
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Hypersensitivity	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/99ISR Number: 3388808-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Craniotomy Haemorrhage Intracranial		Coumadin Vioxx 12.5	PS SS			2.5 MG ALT WITH 5MG DAILY 12.5 MG	
Intervention to Prevent Permanent Impairment/Damage								

Date:11/04/99ISR Number: 3388858-9Report Type:Expedited (15-DaCompany Report #WAES 99105185
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Marrow Depression	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Malaise	Health Professional	(Rofecoxib) Acetaminophen / Codeine Phosphate Furosemide	PS C C		ORAL	12.5MG PO	

Date:11/04/99ISR Number: 3388863-2Report Type:Expedited (15-DaCompany Report #WAES 99101828
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:11/04/99ISR Number: 3388872-3Report Type:Expedited (15-DaCompany Report #WAES 99105212
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Hepatic Function Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG PO	
	Liver Function Test Abnormal		Aspirin	C				
			Atenolol	C				
			Morphine S04	C				
			Paroxetine	C				
			Ranitidine	C				

Date:11/04/99ISR Number: 3388877-2Report Type:Expedited (15-DaCompany Report #WAES 99102437
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Blood Potassium Increased Haemodialysis Renal Failure Acute	Professional Company Representative	Ciprofloxacin	C				

Date:11/04/99ISR Number: 3388880-2Report Type:Expedited (15-DaCompany Report #WAES 99102013
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Other	Convulsion	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx 12.5 Mg	PS		ORAL
PO							

Date:11/04/99ISR Number: 3388884-XReport Type:Expedited (15-DaCompany Report #WAES 99101722
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Duodenitis	Health	Tab Vioxx Unk	PS		ORAL
25						
Initial or Prolonged	Gastritis	Professional				
MG/DAILY/PO						
	Gastrointestinal Haemorrhage	Company Representative	Hydrocodone	C		

Date:11/04/99ISR Number: 3388886-3Report Type:Expedited (15-DaCompany Report #WAES 99100653
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Congestive	Professional				
MG/DAILY/PO						
Initial or Prolonged	Fluid Overload	Company Representative				
Other						

Date:11/04/99ISR Number: 3388964-9Report Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Muscle Twitching		Vioxx, Merck			
	Paraesthesia		(Strength Unknown)	PS	Merck	ORAL
PO QD	1 WK					

Date:11/05/99ISR Number: 3388845-0Report Type:Direct Company Report #
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Papular		Vioxx 25mg	PS			25MG QD	5 MON

Date:11/05/99ISR Number: 3389038-3Report Type:Expedited (15-DaCompany Report #WAES 99102439
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Insomnia	Health	Vioxx	PS		ORAL	12.5	
Initial or Prolonged	International Normalised	Professional					MG/DAILY/PO	
	Ratio Increased	Company	Levothyroid	C				
	Pain	Representative	Nitroglycerin	C				
	Prothrombin Time		Warfarin	C				
	Prolonged							

Date:11/05/99ISR Number: 3389044-9Report Type:Expedited (15-DaCompany Report #WAES 99102268
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertensive Crisis	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional	Medrol	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/99ISR Number: 3389050-4Report Type:Expedited (15-DaCompany Report #WAES 99102270
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Epilepsy	Professional						

Date:11/05/99ISR Number: 3389054-1Report Type:Expedited (15-DaCompany Report #WAES 99108250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
		Professional						

Date:11/05/99ISR Number: 3389059-0Report Type:Expedited (15-DaCompany Report #WAES 99091155
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS		ORAL	12.5 MG/	
Initial or Prolonged	Diarrhoea	Professional					DAILY/ PO	
Other	Pancreatitis		Lotensin	C				
	Vomiting		Ibuprofen	C				

Date:11/05/99ISR Number: 3389064-4Report Type:Expedited (15-DaCompany Report #WAES 99101723
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis	Health	Tab Vioxx	PS		ORAL	PO	
	Drug Effect Decreased	Professional	Celebrex	SS				
	Renal Failure	Company Representative						

Date:11/05/99ISR Number: 3389069-3Report Type:Expedited (15-DaCompany Report #WAES 99098312
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholecystitis	Foreign	Rofecoxib	PS		ORAL	50 MG PO	154 DAY
Initial or Prolonged	Jaundice	Study	Acetaminophen	C				
	Oesophagitis	Health	Chloroquine	C				
		Professional	Methotrexate	C				
			Ranitidine	C				

Date:11/05/99ISR Number: 3389072-3Report Type:Expedited (15-DaCompany Report #WAES 99100681
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Embolism	Consumer	Vioxx	PS		ORAL	PO	
Life-Threatening	Myocardial Infarction	Health						
Hospitalization -	Pulmonary Embolism	Professional						
Initial or Prolonged		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/99ISR Number: 3389076-0Report Type:Expedited (15-DaCompany Report #WAES 99101080
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Health	Vioxx	PS		ORAL	PO	
	Loss Of Consciousness	Professional						
	Syncope							

Date:11/08/99ISR Number: 3390362-9Report Type:Expedited (15-DaCompany Report #WAES 99102284
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Cardiac Arrest	Professional	Talwin	C				
	Drug Ineffective	Company						
	Pain	Representative						

Date:11/08/99ISR Number: 3390365-4Report Type:Expedited (15-DaCompany Report #WAES 99101395
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
Initial or Prolonged	Cardiac Failure	Professional	(Therapy					
	Congestive	Company	Unspecified)	C				
		Representative						

Date:11/08/99ISR Number: 3390366-6Report Type:Expedited (15-DaCompany Report #WAES 99102245
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Dyspepsia	Professional	Aspirin	C				
	Faecal Occult Blood		Ibuprofen	C				

Gastroenteritis
Helicobacter
Gastrointestinal
Haemorrhage
Haematocrit Decreased
Haemoglobin Decreased
Nausea

Date:11/08/99ISR Number: 3390368-XReport Type:Expedited (15-DaCompany Report #WAES 99101898
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Tab Vioxx	PS		ORAL	PO	14 DAY

Date:11/08/99ISR Number: 3390370-8Report Type:Expedited (15-DaCompany Report #WAES 99101840
Age:85 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastroenteritis Helicobacter Gastrointestinal Haemorrhage

	Haematemesis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Company Representative	Vitamin E	SS		ORAL	PO
			Amlodipine	C			
			Ascorbic Acid	C			
			Calcium Supplement (Composition)	C			
			Hydrochlorothiazide	C			
			Lisinopril	C			
			Metoprolol	C			
			Vitamin D	C			

Date:11/08/99ISR Number: 3390372-1Report Type:Expedited (15-DaCompany Report #WAES 99102022
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Convulsion	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
		Company Representative					

Date:11/08/99ISR Number: 3390375-7Report Type:Expedited (15-DaCompany Report #WAES 99101990
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO
Initial or Prolonged	Haemorrhage		Tab Vioxx 25 Mg	SS		ORAL	25 MG/ DAILY/
	Haematochezia	Company Representative					PO
	International Normalised		Calan	C			

	Ratio Increased		Coumadin	C
	Rectal Haemorrhage		Lanoxin	C
			Lasix	C
			Pravachol	C
			Vasotec	C

Date:11/08/99ISR Number: 3390378-2Report Type:Expedited (15-DaCompany Report #WAES 99091294
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Blood Creatinine	Professional					MG/DAILY/PO	
	Increased	Other	Warfarin 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Bradycardia		Adalat	C				
	Coagulopathy		Lasix	C				
	Drug Level Above		Trovan	C				
	Therapeutic		Zantac	C				
	International Normalised		[Therapy					
	Ratio Increased		Unspecified]	C				
	Renal Impairment		Digoxin	C				
	Therapeutic Agent		Nifedipine	C				
	Toxicity		Prednisone	C				
			Quinidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/99ISR Number: 3390382-4Report Type:Expedited (15-DaCompany Report #WAES 99010073
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Faeces Discoloured	Professional	Lortab	C				
Other	Gastrointestinal Haemorrhage	Other	Serzone	C				

Date:11/08/99ISR Number: 3390383-6Report Type:Expedited (15-DaCompany Report #WAES 99110065
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Peptic Ulcer Haemorrhage							
	Ulcer		Procardia Xl	C				
			Synthroid	C				
			Acetaminophen (+) Propoxyphene	C				
			Amitriptyline	C				
			Gemfibrozil	C				

Date:11/08/99ISR Number: 3390384-8Report Type:Expedited (15-DaCompany Report #WAES 99105179
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alcohol Problem	Foreign	Tab Vioxx					
Other	Circulatory Collapse	Health	(Rofecoxib)	PS		ORAL		
	Fall	Professional	Therapy Unspecified	C				
	Gastrointestinal Haemorrhage		Acetaminophen/Propoxyphene Hydrochloride	C				
	Haematemesis		Doxycycline	C				
			Erythromycin	C				
			Estradiol (+) Norethindrone	C				
			Folic Acid	C				

			Lacidipine	C		
			Lisinopril	C		

Date:11/08/99ISR Number: 3390386-1Report Type:Expedited (15-DaCompany Report #WAES 99091795
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:11/08/99ISR Number: 3390389-7Report Type:Expedited (15-DaCompany Report #WAES 99101575
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastric Ulcer Perforation	Health Professional	Tab Vioxx Unk	PS		ORAL	12.5 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/99ISR Number: 3390391-5Report Type:Expedited (15-DaCompany Report #WAES 99101035
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Aspartate Aminotransferase Increased	Company Representative	Cardizem	C				
			Quinamm	C				
	Blood Alkaline Phosphatase Increased							
	Condition Aggravated							
	Liver Function Test Abnormal							
	Myalgia							
	Pain In Extremity							

Date:11/09/99ISR Number: 3390621-XReport Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS			UNKNOWN	25 MG DAILY
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional						
Required Intervention to Prevent Permanent Impairment/Damage	Haemoglobin Decreased							

Date:11/09/99ISR Number: 3391268-1Report Type:Direct Company Report #
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspepsia	Health	Vioxx (Rofecoxib)	PS		ORAL	25MG QD PO	
Hospitalization - Initial or Prolonged	Faeces Discoloured	Professional	Asa	C				
	Gastroenteritis		No Steroids	C				

Helicobacter
Gastrointestinal
Haemorrhage
Haematocrit Decreased
Haemoglobin Decreased
Malaise
Nausea

Date:11/09/99ISR Number: 3391288-7Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Asa 81mg	PS		ORAL	81MG DAILY PO	
Initial or Prolonged	Haemorrhage		Vioxx 25mg	SS				
	Rectal Haemorrhage							

Date:11/09/99ISR Number: 3391362-5Report Type:Expedited (15-DaCompany Report #WAES 99105280
Age:74 YR Gender:Male I/FU:I

Outcome	PT
Other	Anaphylactic Shock
	Tongue Oedema

	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO 8 DAY
		User Facility	Diclofenac	SS		ORAL	150 MG, PO 1 DAY
		Company Representative	Acetaminophen (+) Dihydrocodeine				
		Other	Bitartrate	SS		ORAL	PO

Date:11/09/99ISR Number: 3391368-6Report Type:Expedited (15-DaCompany Report #WAES 99107922
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal	Foreign	Vioxx (Rofecoxib)	PS		ORAL	50 MG MG, PO 1 DAY
Initial or Prolonged	Haemorrhage	Health	Tab Vioxx				
	Haemoglobin Decreased	Professional	(Rofecoxib)	SS		ORAL	25 MG MG, PO 5 DAY
	Melaena	Other	Moduretic	C			

Date:11/09/99ISR Number: 3391370-4Report Type:Expedited (15-DaCompany Report #WAES 99105278
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Oedema Peripheral	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG, PO 9 DAY
Initial or Prolonged		User Facility	Acetaminophen /				
		Other	Propoxyphene				
			Hydrochloride	C			
			Dothiepin Hcl	C			

Date:11/09/99ISR Number: 3391626-5Report Type:Expedited (15-DaCompany Report #9943252
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Drug Effect Decreased	Consumer	Viagra Tablets	PS		ORAL	50.00 MG	
Intervention to	Drug Ineffective	Health					TOTAL:PRN;ORA	
Prevent Permanent	Drug Interaction	Professional						
L								
Impairment/Damage			Amitriptyline	SS				
			Rofecoxib	SS		ORAL	25.00 MG	
							TOTAL:DAILY:O	
							RAL	
			Procardia Xl	C				
			Zocor	C				
			Enteric Coated					
			Aspirin	C				

Date:11/10/99ISR Number: 3391265-6Report Type:Direct Company Report #
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx (Rofecoxib)					
Initial or Prolonged	Haemorrhage	Professional	Merck	PS	Merck	ORAL		
PO								

Date:11/10/99ISR Number: 3393718-3Report Type:Expedited (15-DaCompany Report #WAES 99090982
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Distributor	Tab Vioxx Unk	PS		ORAL		

Date:11/10/99ISR Number: 3393722-5Report Type:Expedited (15-DaCompany Report #WAES 99100830
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Drug Interaction	Professional						
	Hyperaesthesia		Coumadin	SS			7.5 MG/DAILY/UNK	
	Subdural Haematoma							
			Plaquenil	C				

Date:11/10/99ISR Number: 3393730-4Report Type:Expedited (15-DaCompany Report #WAES 99108938
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	
		Professional	Aspirin	C				
			Cimetidine	C				

Date:11/10/99ISR Number: 3393955-8Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Activated Partial	Study	Cap Crixivan	PS	ORAL
800 MG/Q8H/PO					
Initial or Prolonged	Thromboplastin Time	Health	Cap Lodenosine	SS	ORAL
300 MG/BID/PO					
	Prolonged	Professional	Cap Stavudine	SS	ORAL
40 MG/BID/PO					
	Ammonia Increased		Tab Lorcet Plus	SS	ORAL
10 MG/BID/PO					
	Bacteriuria		Tab Vioxx	SS	ORAL
12.5					
	Cholecystitis				
MG/BID/PO					
	Cholelithiasis		Prevacid	C	
	Coma		Prilosec	C	
	Hepatic Function Abnormal		Soma	C	
	Hyperbilirubinaemia				
	Ketonuria				
	Lethargy				
	Liver Function Test				
	Abnormal				
	Prothrombin Time				
	Prolonged				
	Urinary Casts				
	White Blood Cells Urine				
	Positive				

Date:11/12/99ISR Number: 3394043-7Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Condition Aggravated
Initial or Prolonged	Gastrointestinal
	Haemorrhage

Gastrointestinal Ulcer

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Vioxx	PS		ORAL	25MG PO Q PM	
		Professional					WITH FOOD	6 MON
			Nitroglycerin Sl	C				
			Isosorbide	C				
			Toprol	C				

Date:11/12/99ISR Number: 3395714-9Report Type:Expedited (15-DaCompany Report #WAES 99107921
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Tab Vioxx					
	Congestive	Health	(Rofecoxib)	PS		ORAL	44 DAY	
	Oedema	Professional	Levothyroxine Na	C				
	Pleural Effusion							

Date:11/12/99ISR Number: 3395717-4Report Type:Expedited (15-DaCompany Report #WAES 99105262
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Tab Vioxx					
	Facial Pain	Health	(Rofecoxib)	PS		ORAL	2 WK	
	Oral Pain	Professional						
	Pain In Jaw							

Date:11/12/99ISR Number: 3395719-8Report Type:Expedited (15-DaCompany Report #WAES 99081159
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged	Nausea	Professional					
MG/DAILY/PO							
	Vomiting	Company Representative	Prednisone	C			

Date:11/15/99ISR Number: 3396935-1Report Type:Expedited (15-DaCompany Report #WAES 99110379
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
Life-Threatening		Professional						
Hospitalization -		Company						
Initial or Prolonged		Representative						
Disability								

Date:11/15/99ISR Number: 3396938-7Report Type:Expedited (15-DaCompany Report #WAES 99102152
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/99ISR Number: 3396940-5Report Type:Expedited (15-DaCompany Report #WAES 99101756
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Gingival Bleeding	Professional						
Initial or Prolonged	Petechiae	Other	Cap Quinine 1					
	Thrombocytopenia		Capsule	SS			1 CAPSULE/Q2W	2 MON
	Vaginal Haemorrhage		Axid	C				
			Azmacort	C				
			Flexeril	C				
			Klonopin	C				
			Naprosyn	C				
			Prozac	C				
			Zyrtec	C				
			Desipramine	C				

Date:11/15/99ISR Number: 3396944-2Report Type:Expedited (15-DaCompany Report #WAES 99101748
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Septal Defect	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Cerebral Artery Occlusion	Professional						
Initial or Prolonged	Cerebrovascular Accident	Other	Celebrex	SS		ORAL	200 MG/BID/PO	
Disability	Deep Vein Thrombosis		Caltrate	C				
	Embolism		Dyazide	C				
	Haemorrhagic Stroke		Miacalcin	C				
	Hemiparesis		Tylenol Extra					
	Rash Maculo-Papular		Strength	C				

Date:11/15/99ISR Number: 3396948-XReport Type:Expedited (15-DaCompany Report #WAES 99101749
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PO						
Initial or Prolonged	Gastric Ulcer Perforation	Professional	Aspirin	SS		ORAL
325 MG/PO						
Other		Other				

Date:11/15/99ISR Number: 3396951-XReport Type:Expedited (15-DaCompany Report #WAES 99110222
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Bleeding Time Prolonged	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Disseminated Intravascular Coagulation	Professional				

Date:11/15/99ISR Number: 3396954-5Report Type:Expedited (15-DaCompany Report #WAES 99110140
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/PO						
Initial or Prolonged	Blood Amylase Increased	Professional	Tab Vioxx 25 Mg	SS		ORAL
25 MG/BID/PO						
Other	Duodenal Ulcer Perforation	Company Representative	Lasix	C		
			Atenolol	C		
	Lipase Increased		Spironolactone	C		
	Pancreatitis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/99ISR Number: 3396958-2Report Type:Expedited (15-DaCompany Report #WAES 99102336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	7 DAY
	Increased Condition Aggravated Creatinine Renal Clearance Decreased Hyperkalaemia	Professional						

Date:11/15/99ISR Number: 3396964-8Report Type:Expedited (15-DaCompany Report #WAES 99102062
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest	Health	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Conduction Disorder	Professional					MG/DAILY/PO	
			Flomax (Tamsulosin (R)	C				

Date:11/15/99ISR Number: 3396968-5Report Type:Expedited (15-DaCompany Report #WAES 99102156
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Dermatitis	Professional					MG/DAILY/PO	
Initial or Prolonged	Oedema Peripheral	Company	Coumadin	C				
	Pain In Extremity	Representative	Heparin	C				
	Petechiae							

Date:11/15/99ISR Number: 3396972-7Report Type:Expedited (15-DaCompany Report #WAES 99090204
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Biliary Neoplasm	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Bilirubin Increased	Professional						
	Drug Hypersensitivity	Company	Levaquin	SS				
	Gallbladder Disorder	Representative	[Therapy					
	Hepatic Function Abnormal		Unspecified]	C				
	Hepatitis		Vitamins	C				
	Insomnia							
	Liver Function Test Abnormal							
	Polyp							
	Pruritus							
	Rash Erythematous							
	Rash Generalised							
	Red Blood Cell Sedimentation Rate Increased							

Date:11/15/99ISR Number: 3396979-XReport Type:Expedited (15-DaCompany Report #WAES 99100681
Age:58 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Myocardial Infarction Pulmonary Embolism Respiratory Distress	Health Professional Company Representative						

Date:11/15/99ISR Number: 3396981-8Report Type:Expedited (15-DaCompany Report #WAES 99102062
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest	Health	Tab Vioxx Unk	PS		ORAL	25	
Initial or Prolonged	Malaise	Professional					MG/DAILY/PO	
			Flomax (Tamsulosin (R)-Form Hydr	C				

Date:11/15/99ISR Number: 3396982-XReport Type:Expedited (15-DaCompany Report #WAES 99110177
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:11/15/99ISR Number: 3396984-3Report Type:Expedited (15-DaCompany Report #WAES 99105262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Foreign	Tab Vioxx					

	Facial Pain	Health	(Rofecoxib)	PS			ORAL
PO 2 WK							
	Oral Pain	Professional					

Date:11/15/99ISR Number: 3396985-5Report Type:Expedited (15-DaCompany Report #WAES 99110175
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dementia	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

Date:11/15/99ISR Number: 3396988-0Report Type:Expedited (15-DaCompany Report #WAES 99110178
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Blood Creatinine	Professional				
MG/DAILY/PO						
Initial or Prolonged	Increased	Company	Accupril	C		
	Blood Urea Increased	Representative	Celebrex	C		
	Bradycardia		Nonsteroidal			
	Diabetes Mellitus		Anti-Inflammatory	C		
	Renal Failure					
	Sepsis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/99ISR Number: 3396990-9Report Type:Expedited (15-DaCompany Report #WAES 99107921
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Tab Vioxx					
	Congestive	Health	(Rofecoxib)	PS		ORAL	PO	43 DAY
	Oedema	Professional	Levothyroxine	C				
	Pleural Effusion							

Date:11/15/99ISR Number: 3396992-2Report Type:Expedited (15-DaCompany Report #WAES 99101756
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Gingival Bleeding	Professional					MG/DAILY/PO	
Initial or Prolonged	Petechiae	Other	Cap Quinine 1					
	Thrombocytopenia		Capsule	SS			1 CAPSULE/Q2W	2 MON
	Vaginal Haemorrhage		Axid	C				
			Azmacort	C				
			Flexeril	C				
			Klonopin	C				
			Naprosyn	C				
			Prozac	C				
			Zyrtec	C				
			Desipramine	C				

Date:11/15/99ISR Number: 3396993-4Report Type:Expedited (15-DaCompany Report #WAES 99101898
Age:65 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx Unk	PS		ORAL	PO	2 WK
	Grand Mal Convulsion	Professional						

Date:11/15/99ISR Number: 3396995-8Report Type:Expedited (15-DaCompany Report #WAES 99102022
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:11/15/99ISR Number: 3396997-1Report Type:Expedited (15-DaCompany Report #WAES 99110180
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematocrit Decreased							
	Haemoglobin Decreased		Atrovent	C				
	Pancytopenia		Azmacort	C				
	Platelet Count Decreased		Proventil	C				
	Purpura		Zocor	C				
	White Blood Cell Count Decreased		Vitamin B (12)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/99ISR Number: 3396999-5Report Type:Expedited (15-DaCompany Report #WAES 99110294
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Coordination Abnormal	Professional					MG/DAILY/PO	
	Disorientation		Betapace	C				
	Dyspnoea		Cipro	C				
	Fatigue		Cytotec	C				
	Haemodialysis		Fosamax	C				
	Hyperkalaemia		Premarin	C				
	Renal Failure Acute		Prevacid	C				
			Ultram	C				
			Clcium Supplement (Composition)	C				
			Ginkgo Biloba Extract	C				
			Magnesium Preparation (Composition)	C				
			Sodium Folate	C				
			Vitamins	C				
			Zinc Preparartion (Composition)	C				

Date:11/15/99ISR Number: 3397000-XReport Type:Expedited (15-DaCompany Report #WAES 99110329
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Dermatitis Exfoliative	Professional	Celebrex	C				

Date:11/15/99ISR Number: 3397001-1Report Type:Expedited (15-DaCompany Report #WAES 99110344
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Hallucination	Consumer	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Myocardial Infarction				
MG/DAILY/PO					
	Speech Disorder		[Therapy Unspecified]	C	

Date:11/15/99ISR Number: 3398426-0Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Anorexia
Hospitalization -	Back Pain
Initial or Prolonged	Carpal Tunnel Syndrome
	Chest Pain
	Cholecystitis
	Cholelithiasis
	Diarrhoea
	Dysgeusia
	Dyspepsia
	Dysuria
	Headache
	Hepatic Function Abnormal
	Herpes Virus Infection
	Hyperbilirubinaemia

		Hypoaesthesia Jaundice Liver Function Test	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Study	Cap Crixivan Unk	PS		ORAL
800 MG/Q8H/PO							
		Neuropathy Peripheral	Health	Cap Crixivan Unk	SS		ORAL
800 MG/QH8/PO							
		Paraesthesia	Professional	Cap Crixivan Unk	SS		ORAL
800 MG/Q8H/PO							
		Weight Decreased		Cap Lodenosine Unk	SS		ORAL
300 MG/BID/PO							
				Cap Stavudine Unk	SS		ORAL
40 MG/BID/PO							
				Tab Lorcet 10/650 Unk	SS		ORAL
10 MG/BID/PO							
				Tab Vioxx Unk	SS		ORAL
12.5							
MG/BID/PO							
				Prevacid	C		
				Prilosec	C		
				Soma	C		

Date:11/16/99ISR Number: 3398027-4Report Type:Expedited (15-DaCompany Report #WAES 99110416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiomyopathy	Health	Tab Vioxx Unk	PS		
DAILY 2 MON						
		Professional Company Representative				

Date:11/16/99ISR Number: 3398031-6Report Type:Expedited (15-DaCompany Report #WAES 99101753
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL
25						

Hospitalization - MG/DAILY/PO	Increased	Professional				
Initial or Prolonged	Blood Urea Increased Dyspnoea Oedema Peripheral Pulmonary Oedema Rectal Haemorrhage Renal Failure Acute Weight Increased	Other	Celebrex	C		

Date:11/16/99ISR Number: 3398042-0Report Type:Expedited (15-DaCompany Report #WAES 99110512
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:11/16/99ISR Number: 3398046-8Report Type:Expedited (15-DaCompany Report #WAES 99115050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional	(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/99ISR Number: 3398053-5Report Type:Expedited (15-DaCompany Report #WAES 99110339
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Bilirubin Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Hepatitis	Professional					MG/DAILY/PO	
	Jaundice		A.S.A.	C				
	Liver Function Test		Capoten	C				
	Abnormal		Allopurinol	C				
	Vomiting		Digoxin	C				

Date:11/16/99ISR Number: 3398054-7Report Type:Expedited (15-DaCompany Report #WAES 99110345
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Drug Toxicity	Professional	Aspirin Unk	SS				
	Encephalopathy		Tagamet	C				
	Metabolic Acidosis		Tylenol With Codeine					
	Overdose		#3	C				
	Speech Disorder		(Therapy					
	Therapeutic Agent		Unspecified)	C				
	Toxicity							

Date:11/16/99ISR Number: 3398059-6Report Type:Expedited (15-DaCompany Report #WAES 99092313
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Triglycerides	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Increased	Professional					MG/DAILY/PO	
	Condition Aggravated	Company	Tab Premarin Unk	SS		ORAL	10 MG/AM/PO	
	Cushingoid	Representative	Lescol	C				
	Deep Vein Thrombosis		(Therapy					
	Joint Stiffness		Unspecified)	C				

	Leukocytosis	Atenolol	C
	Myalgia	Prednisone	C
	Oedema Peripheral		

Date:11/17/99ISR Number: 3399210-4Report Type:Expedited (15-DaCompany Report #WAES 99100740
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Atelectasis
	Atrophy
	Balance Disorder
	Body Temperature Decreased
	Breath Sounds Decreased
	Confusional State
	Difficulty In Walking
	Dyspnoea
	Faecal Incontinence
	Hyperreflexia
	Kyphoscoliosis
	Kyphosis
	Liver Function Test Abnormal
	Pain In Extremity

		Renal Impairment					
		Respiratory Rate Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sciatica	Study	Tab Vioxx 25 Mg	PS		ORAL
25							
		Urinary Incontinence	Health				
MG/DAILY/PO							
		Urine Analysis Abnormal	Professional	Hydrodiuril	C		
				Redisol	C		
				Donepezil Hydrochloride	C		
				Nifedipine	C		
				Sertraline Hydrochloride	C		
				Vitamin E	C		

Date:11/17/99ISR Number: 3399213-XReport Type:Expedited (15-DaCompany Report #WAES 99102094
Age:90 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
Initial or Prolonged		Blood Creatinine	Professional				
MG/DAILY/PO							
		Increased	Company	Accupril	C		
		Blood Glucose Increased	Representative	Axid Ar	C		
		Blood Urea Increased		Cardizem	C		
		Gastrointestinal		Flexeril	C		
		Haemorrhage		Humibid	C		
		Haematemesis		Lasix	C		
		Haematocrit Decreased		Micro K	C		
		Haemoglobin Decreased		Reglan	C		
		Hyperkalaemia		Sinemet Cr	C		
		Melaena		Synthroid	C		
		Red Blood Cell Count Decreased		Tylenol	C		
		White Blood Cell Count Increased					

Date:11/17/99ISR Number: 3399221-9Report Type:Expedited (15-DaCompany Report #WAES 99102270
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Eye Disorder	Professional	Celebrex	SS			200MG/BID	
Other	Grand Mal Convulsion Periorbital Haematoma	Other						

Date:11/17/99ISR Number: 3399225-6Report Type:Expedited (15-DaCompany Report #WAES 99100653
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Congestive	Professional					MG/DAILY/PO	
Initial or Prolonged	Condition Aggravated	Company	Composition					
Other	Fluid Overload	Representative	Unspecified	C				

Date:11/17/99ISR Number: 3399229-3Report Type:Expedited (15-DaCompany Report #WAES 99091180
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Tab Vioxx	PS		ORAL	DAILY/PO	
Initial or Prolonged	Arthritis Bacterial	Professional	Cipro [Composition					
Other	Blood Bicarbonate	Company	Unspecified]	C				
	Decreased	Representative	Antimicrobial					
	Blood Creatinine		Therapy	C				
	Increased		Cephalexin	C				
	Blood Ph Increased							
	Blood Urea Increased							
	Condition Aggravated							
	Dialysis							
	Difficulty In Walking							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Joint Swelling							
	Leukopenia							
	Memory Impairment							
	Pco2 Decreased							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Renal Failure							

Date:11/18/99ISR Number: 3401128-5Report Type:Expedited (15-DaCompany Report #WAES 99110652
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Binocular Eye Movement	Professional					MG/DAILY/PO	
	Disorder		Imdur	C				
	Blood Creatine		Lipitor	C				
	Phosphokinase Increased		Lopressor	C				
	Blood Pressure Diastolic		Norvasc	C				
	Decreased		Aspirin	C				
	Blood Urea Increased		Captopril	C				
	Convulsion		Insulin	C				

Coronary Artery Occlusion
Diabetes Mellitus
Dizziness Postural
Dyspnoea
Electrocardiogram
Abnormal
Hyperhidrosis
Myocardial Infarction
Nausea
Oedema Peripheral
Pallor
Vasodilatation
Vertigo

Date:11/19/99ISR Number: 3402788-5Report Type:Expedited (15-DaCompany Report #WAES 99111128
Age:65 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged	Atelectasis	Health	Vioxx	PS		ORAL	PO	
Other	Atrial Fibrillation	Professional	Coumadin	C				
	Cardiac Failure		Dyazide	C				
	Congestive		Premarin	C				
	Congestive Cardiomyopathy		Digoxin	C				
	Cough		Folic Acid	C				
	Drug Ineffective							
	Dyspnoea							
	Electrocardiogram St							
	Segment Abnormal							
	Hypertension							
	Orthopnoea							
	Palpitations							
	Productive Cough							
	Pulmonary Embolism							
	Rales							
	Sputum Abnormal							

Date:11/19/99ISR Number: 3402789-7Report Type:Expedited (15-DaCompany Report #WAES 99108250
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial	Foreign	Vioxx					
Initial or Prolonged	Haemorrhagic Stroke	Health	(Rofecoxib)	PS		ORAL	12.5 MG; PO	21 DAY
Disability		Professional						

Date:11/19/99ISR Number: 3402791-5Report Type:Expedited (15-DaCompany Report #WAES 99100455
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Haemorrhage	Health					MG/DAILY/PO	
Hospitalization -	Nervous System Disorder	Professional						

Initial or Prolonged	Pneumonia Respiratory Failure Sepsis

Date:11/19/99ISR Number: 3402793-9Report Type:Expedited (15-DaCompany Report #WAES 99101990
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Haemorrhage Haematochezia Haemoptysis Haemorrhage International Normalised Ratio Increased Rectal Haemorrhage	Professional Company Representative	Calan Coumadin Lanoxin Lasix Pravachol Vasotec	C C C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/99ISR Number: 3405220-0Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea Exertional	Health	Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG PO Q	
Initial or Prolonged	Fluid Overload	Professional					PM	
	Oedema Peripheral		Prempro	C				
			Prilosec	C				
			Verapamil Sr	I				

Date:11/23/99ISR Number: 3405898-1Report Type:Expedited (15-DaCompany Report #WAES 99111023
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:11/23/99ISR Number: 3405903-2Report Type:Expedited (15-DaCompany Report #WAES 99110919
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	2 DAY
			Prevacid	C				
			Aspirin	C				

Date:11/23/99ISR Number: 3405905-6Report Type:Expedited (15-DaCompany Report #WAES 99110818
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	

Initial or Prolonged Congestive Professional

Date:11/23/99ISR Number: 3405908-1Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Laboratory Test Abnormal	Professional					MG/DAILY/PO	
	Protein Total Increased	Company	Celebrex	C				
	Renal Failure Acute	Representative	Tylenol	C				

Date:11/23/99ISR Number: 3405910-XReport Type:Expedited (15-DaCompany Report #WAES 99102092
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Intal	C				
		Company	Singulair	C				
		Representative	Albuterol	C				
			Prednisone	C				

Date:11/23/99ISR Number: 3405915-9Report Type:Expedited (15-DaCompany Report #WAES 99111129
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Dyspnoea	Professional					MG/DAILY/PO	
	Dyspnoea Exertional	Company	Cardizem Cd	C				
	Nasopharyngitis	Representative	K-Dur	C				
	Oedema		Lanoxin	C				
	Oedema Peripheral		Lasix	C				
	Pulmonary Congestion		Restoril	C				
	Rales		Synthroid	C				
	Weight Increased							

Date:11/23/99ISR Number: 3405919-6Report Type:Expedited (15-DaCompany Report #WAES 99082249
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Increased	Professional	Ambien	C				
	Hypersensitivity		Zantac	C				
	Liver Function Test							
	Abnormal							
	Lung Infiltration							
	Nausea							
	Vomiting							

Date:11/23/99ISR Number: 3405923-8Report Type:Expedited (15-DaCompany Report #WAES 99101520
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema Multiforme	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Nausea	Professional					MG/DAILY/PO	
	Pharyngolaryngeal Pain	Company						
	Pyrexia	Representative						

Rash Erythematous
Vomiting

Date:11/23/99ISR Number: 3405930-5Report Type:Expedited (15-DaCompany Report #WAES 99110776
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	1 WK
	Condition Aggravated	Company Representative						

Date:11/23/99ISR Number: 3405933-0Report Type:Expedited (15-DaCompany Report #WAES 99110840
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Overload	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Covera-Hs	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/99ISR Number: 3405940-8Report Type:Expedited (15-DaCompany Report #WAES 99115071
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills	Foreign	Tab Vioxx					
	Hypertension	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	7 DAY
	Malaise		Bisoprolol	C				
			Candesartan	C				
			Heparinoid (+)					
			Salicylic Acid	C				
			Lansoprazole	C				

Date:11/23/99ISR Number: 3405942-1Report Type:Expedited (15-DaCompany Report #WAES 99119303
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Foreign	Tab Vioxx					
	Increased	Health	(Rofecoxib)	PS		ORAL	25 MG PO	3 DAY
	Oedema	Professional						
	Renal Impairment							

Date:11/23/99ISR Number: 3405943-3Report Type:Expedited (15-DaCompany Report #WAES 99111126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Affective Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Mania	Professional						
		Company						
		Representative						

Date:11/23/99ISR Number: 3405944-5Report Type:Expedited (15-DaCompany Report #WAES 99111124
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Creatinine	Health	Tab Vioxx 12.5mg	PS	ORAL 12.5MG DAILY PO
Hospitalization -	Increased	Professional			
Initial or Prolonged	Cellulitis	Company	Celebrex	C	
Disability	Dialysis	Representative	Hydrodiuril	C	
	Oedema Peripheral	Other	Norvasc	C	
	Renal Failure		Univasc	C	

Date:11/23/99ISR Number: 3405945-7Report Type:Expedited (15-DaCompany Report #WAES 99102245
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Asthenia
	Dyspnoea
	Early Morning Awakening
	Gastritis
	Gastroenteritis
	Helicobacter
	Gastrointestinal
	Haemorrhage
	Haematochezia
	Haematocrit Decreased
	Haemoglobin Decreased
	Hypertension

	Nausea						
	Rash Erythematous						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Aspirin	C				
			Ibuprofen	C				

Date:11/23/99ISR Number: 3405947-0Report Type:Expedited (15-DaCompany Report #WAES 99110468
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Study	Tab Vioxx Unk	PS		ORAL	5 MG DAILY	
Initial or Prolonged	Diplopia	Health					PO; 50 MG	
	Dizziness	Professional					DAILY PO	
	Herpes Zoster		Acetaminophen 325 Mg	SS			UNKNOWN	PRN UNK
			Tab Placebo Unk	SS		ORAL	2 TABLET	DAILY PO
			Tab Placebo Unk	SS		ORAL	3 TABLET	DAILY PO
			Lotensin	C				
			Panalgesic Gold Cream	C				
			Synthroid	C				
			Ventolin	C				
			[Composition Unspecified]	C				
			Acetaminophen	C				
			Glyburide	C				
			Leflunomide	C				
			Methotrexate	C				
			Theophylline	C				
			Elavil	C				
			Flexeril	C				

Date:11/23/99ISR Number: 3406031-2Report Type:Expedited (15-DaCompany Report #WAES 99110301
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Anaphylactic Shock		Voltaren	C				
	Chest Pain		Fosamax	C				
	Dizziness		Premarin	C				
	Dyspnoea							
	Hypotension							
	Pruritus							
	Rash Erythematous							
	Syncope							
	Tachycardia							
	Tachypnoea							
	Urticaria							

Date:11/23/99ISR Number: 3406043-9Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Lactic Acid Increased
Hospitalization - Initial or Prolonged	Cholecystitis

	Cholelithiasis						
	Coagulation Time Prolonged	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Coma	Study	Cap Crixivan Unk	PS		ORAL	800 MG Q8H PO
	Dyspepsia	Health	Cap Crixivan Unk	SS		ORAL	800 MG Q8H PO
	Hepatic Encephalopathy	Professional	Cap Crixivan Unk	SS		ORAL	800 MG Q8H PO
	Hepatic Function Abnormal		Cap Lodenosine Unk	SS		ORAL	300 MG BID PO
	Hepatorenal Failure		Cap Stavudine Unk	SS		ORAL	40 MG BID PO
	Hepatotoxicity		Tab Lorcet 10/650 Unk	SS		ORAL	1M MG BID PO
	Hyperbilirubinaemia						
	Hypoaesthesia		Tab Vioxx Unk	SS		ORAL	12.5 MG BID PO
	Jaundice						
	Lethargy		Prevacid	C			
	Liver Function Test Abnormal		Prilosec	C			
			Soma	C			
	Pancreatic Enzymes Increased						
	Paraesthesia						
	Respiratory Failure						
	Sepsis						
	Weight Decreased						

Date:11/23/99ISR Number: 3406077-4Report Type:Expedited (15-DaCompany Report #WAES 99091179
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Hospitalization -	Increased	Professional					
Initial or Prolonged	Renal Failure Acute	Company Representative	Glucophage	C			
			Humulin	C			
			Lasix	C			
			Synthroid	C			
			Vasotec	C			

Allopurinol	C
Amitriptyline	C
Atenolol	C

Date:11/23/99ISR Number: 3406082-8Report Type:Expedited (15-DaCompany Report #WAES 99110222
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged Bleeding Time Prolonged Blood Fibrinogen Decreased Prothrombin Time Prolonged Pyrexia	Professional						

Date:11/23/99ISR Number: 3406084-1Report Type:Expedited (15-DaCompany Report #WAES 99110344
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Cardiac Enzymes Increased

		Delusion					
		Electrocardiogram Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hallucination	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Myocardial Infarction	Health				
MG/DAILY/PO							
		Neurological Symptom	Professional				
		Psychotic Disorder					
		Restlessness					
		Speech Disorder					

Date:11/23/99ISR Number: 3406086-5Report Type:Expedited (15-DaCompany Report #WAES 99102268
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cyanosis	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Hypertensive Crisis	Professional	Medrol	C		
	Loss Of Consciousness		Xanax	C		
	Syncope					

Date:11/23/99ISR Number: 3406087-7Report Type:Expedited (15-DaCompany Report #WAES 99110294
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Blood Creatinine	Professional				
MG/DAILY/PO						
Initial or Prolonged	Increased	Company	Betapace	C		
	Blood Urea Increased	Representative	Cipro	C		
	Coordination Abnormal		Cytotec	C		
	Disorientation		Fosamax	C		
	Dyspnoea		Premarin	C		
	Fatigue		Prevacid	C		
	Haemodialysis		Ultram	C		
	Hyperkalaemia		Calcium Supplement	C		
	Renal Failure Acute		Ginkgo Biloba Extract	C		

			Magnesium Preparation	C		
			Sodium Folate	C		
			Vitamins	C		
			Zinc Preparation	C		

Date:11/23/99ISR Number: 3406089-0Report Type:Expedited (15-DaCompany Report #WAES 99115065
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	2-4 TABLET; PO	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Diclofenac Sodium (+) Misoprostol	C				
			Dothiepin	C				
			Lidocaine (+) Methylprednisolone	C				
			Trimethoprim	C				

Date:11/23/99ISR Number: 3406091-9Report Type:Expedited (15-DaCompany Report #WAES 99110797
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:11/24/99ISR Number: 3405937-8Report Type:Expedited (15-DaCompany Report #WAES 99115567
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Tab Vioxx					
	Congestive	Health	(Rofecoxib)	PS		ORAL	PO	2 WK
	Pleural Effusion	Professional						

Date:11/24/99ISR Number: 3406059-2Report Type:Expedited (15-DaCompany Report #WAES 99101794
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY	
	Oliguria	Professional					PO; TAB VIOXX	
	Refusal Of Treatment By	Company					25 MG	
	Patient	Representative	Prilosec	C				
	Renal Impairment		Estrogenic					
	Urine Abnormality		Preparations	C				
	Weight Increased		Saline	C				

Date:11/24/99ISR Number: 3406079-8Report Type:Expedited (15-DaCompany Report #WAES 99080474
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Bleeding Time Prolonged	Professional					MG/DAILY/PO	
	Chest Discomfort	Company						
	Chest Pain	Representative						
	Fatigue							
	Pancytopenia							
	Suffocation Feeling							

Date:11/24/99ISR Number: 3408476-3Report Type:Expedited (15-DaCompany Report #WAES 99100740
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Atelectasis
	Balance Disorder
	Blood Bilirubin Increased
	Blood Creatinine Increased
	Blood Potassium Decreased
	Blood Urea Increased
	Bronchospasm
	Condition Aggravated
	Confusional State
	Difficulty In Walking
	Dyspnoea

		Faecal Incontinence					
		Hyperreflexia					
		Liver Function Test	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Study	Tab Vioxx 25 Mg	PS		ORAL
25							
		Pain In Extremity	Health				
MG/DAILY/PO							
		Proteinuria	Professional	Hydrodiuril	C		
		Renal Impairment		Redisol	C		
		Sciatica		Donepezil			
		Urinary Incontinence		Hydrochloride	C		
				Nifedipine	C		
				Sertraline			
				Hydrochloride	C		
				Vitamin E	C		

Date:11/24/99ISR Number: 3408483-0Report Type:Expedited (15-DaCompany Report #WAES 99101029
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Aggression	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Anxiety	Health				
MG/DAILY/PO	15 DAY						
		Blood Pressure Increased	Professional				
		Depression					
		Emotional Distress					
		Fear					
		Headache					
		Suicidal Ideation					

Date:11/24/99ISR Number: 3408490-8Report Type:Expedited (15-DaCompany Report #WAES 99101592
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Hospitalization -		Gastritis	Professional				
MG/DAILY/PO							
Initial or Prolonged		Haemoglobin Decreased	Company	Feosol	C		

Other	Melaena	Representative	Ascorbic Acid	C
	Oesophagitis		Aspirin	C
			Lactulose	C

Date:11/24/99ISR Number: 3408496-9Report Type:Expedited (15-DaCompany Report #WAES 99101749
Age:87 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Other	Atrioventricular Block
	First Degree
	Cardiomegaly
	Crepitations
	Dry Skin
	Dysphagia
	Gastric Ulcer Perforation
	Gram Stain Positive
	Hyponatraemia
	Ileus Paralytic
	Malnutrition
	Mitral Valve Incompetence
	Pain
	Peritonitis

	Pneumonia						
	Pulmonary Congestion						
	Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pyrexia	Health	Tab Vioxx 25 Mg	PS		ORAL	25
	White Blood Cell Count	Professional					MG/DAILY/PO
	Increased	Other	Aspirin Unk	SS		ORAL	325 MG/UNK/PO
			Colace	C			
			Haldol	C			
			Xanax	C			
			Oxybutynin Chloride	C			

Date:11/24/99ISR Number: 3408517-3Report Type:Expedited (15-DaCompany Report #WAES 99110797
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Hospitalization -	Gastric Ulcer Haemorrhage	Professional					MG/DAILY/PO
Initial or Prolonged	Gastrointestinal	Company	Cardizem Cd	C			
	Haemorrhage	Representative	Coumadin	C			
			Lasix	C			
			Potassium Chloride	C			

Date:11/29/99ISR Number: 3409013-XReport Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia		Vioxx 25mg	PS			1 QD
Initial or Prolonged	Ascites						
Required	Blood Creatinine						
Intervention to	Increased						
Prevent Permanent	Condition Aggravated						
Impairment/Damage	Oliguria						
	Renal Impairment						

Date:11/29/99ISR Number: 3409015-3Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Fatigue		Vioxx 25mg Qd Merck	PS	Merck	ORAL	25MG PO QD	
Intervention to	Haematocrit Decreased		Rezulin 200mg Qd P-D	SS	P-D	ORAL	200MG PO QD	
Prevent Permanent Impairment/Damage	Haemoglobin Decreased							
	Insomnia							
	Platelet Count Decreased							

Date:11/30/99ISR Number: 3409984-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx 25mg	PS		ORAL	25MG QD PO	
Initial or Prolonged	Melaena		Hydrochlorothiazide	C				
	Upper Gastrointestinal		Plaquenil	C				
	Haemorrhage		Zoloft	C				
			Kcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/99ISR Number: 3409985-3Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Toxicity		Rofecoxib (Vioxx) 25 Mg	PS			25MG DAILY	2 WK
Hospitalization -	Renal Impairment							
Initial or Prolonged	Sedation		Atenolol	C				
			Estrogen	C				
			L-Thyaxine	C				

Date:11/30/99ISR Number: 3410862-2Report Type:Expedited (15-DaCompany Report #WAES 99110994
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiogram Abnormal	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Asthenia	Health Professional						
	Blood Creatinine Increased		Tab Placebo Unk	SS		ORAL	1 TABLET/BID/PO	
	Blood Thyroid Stimulating Hormone Increased		Tab Acetaminophen 325 Mg	SS		ORAL	UNK	PRN
	Cerebral Infarction						PO	
	Cerebrovascular Accident		Caltrate 600 Plus					
	Cerebrovascular Disorder		Vitamin D	C				
	Clumsiness		Synthroid	C				
	Computerised Tomogram Abnormal		Folic Acid	C				
			Methotrexate	C				
	Condition Aggravated							
	Dizziness							
	Electroencephalogram Abnormal							
	Goitre							
	Hypertension							
	Precerebral Artery Occlusion							
	Sedation							
	Thyroxine Decreased							

Transient Ischaemic
Attack
Ventricular Extrasystoles
Vision Blurred

Date:11/30/99ISR Number: 3410865-8Report Type:Expedited (15-DaCompany Report #WAES 99102009
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Neuropathy Peripheral	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Paraesthesia	Professional						
		Company Representative	Levothroid	C				

Date:11/30/99ISR Number: 3410869-5Report Type:Expedited (15-DaCompany Report #WAES 99110747
Age:81 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Blood Creatinine Increased
	Blood Urea Increased
	Fluid Retention

	Respiratory Distress Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Company Representative	Ativan	C			
			Coumadin	C			
			Darvocet-N	C			
			Nasocort	C			
			Prinivil	C			
			Ventolin	C			

Date:11/30/99ISR Number: 3410871-3Report Type:Expedited (15-DaCompany Report #WAES 99111131
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Upper Gastrointestinal Haemorrhage	Company Representative	Prednisone	C			

Date:11/30/99ISR Number: 3410874-9Report Type:Expedited (15-DaCompany Report #WAES 99111289
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Condition Aggravated	Health Professional	Tab Vioxx Unk	PS		ORAL	PO
	Gastrointestinal Perforation Ruptured Diverticulum Of Colon						

Date:11/30/99ISR Number: 3410876-2Report Type:Expedited (15-DaCompany Report #WAES 99111309
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Perforation	Health	Tab Vioxx Unk	PS		ORAL	PO	5 DAY
		Professional Company Representative	Toradol	C				

Date:11/30/99ISR Number: 3410879-8Report Type:Expedited (15-DaCompany Report #WAES 99111403
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemoglobin Decreased	Professional						

Date:11/30/99ISR Number: 3410882-8Report Type:Expedited (15-DaCompany Report #WAES 99115172
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Dreams	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	12.5 MG PO	5 DAY
Initial or Prolonged	Chest Pain	Other						
	Nightmare							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/99ISR Number: 3410884-1Report Type:Expedited (15-DaCompany Report #WAES 99117932
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cutaneous Vasculitis	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	25 MG PO	
	Dermatitis	Health	Mevacor	C				
	Stevens-Johnson Syndrome	Professional	Allopurinol	C				
			Nicergoline	C				
			Ramipril	C				

Date:11/30/99ISR Number: 3410888-9Report Type:Expedited (15-DaCompany Report #WAES 99118225
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	15 DAY
		Health						
		Professional	Vasotec	C				
		Other	Allopurinol	C				
			Lasix	C				

Date:12/01/99ISR Number: 3411749-1Report Type:Expedited (15-DaCompany Report #WAES 99111531
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/01/99ISR Number: 3411753-3Report Type:Expedited (15-DaCompany Report #WAES 99111537
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Peptic Ulcer Perforation	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative	Hyzaar	C		

Date:12/01/99ISR Number: 3411763-6Report Type:Expedited (15-DaCompany Report #WAES 99091373
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE						
Initial or Prolonged	Pain	Health				
Other	Rash Pruritic	Professional				
	Rash Pustular					

Date:12/01/99ISR Number: 3411767-3Report Type:Expedited (15-DaCompany Report #WAES 99111424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Cardiac Failure	Professional Company Representative				
	Congestive					
	Oedema					

Date:12/01/99ISR Number: 3411769-7Report Type:Expedited (15-DaCompany Report #WAES 99117937
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematuria	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Platelet Count Decreased	Health Professional	(Rofecoxib)	PS				

Date:12/01/99ISR Number: 3411772-7Report Type:Expedited (15-DaCompany Report #WAES 99117934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign	Tab Vioxx					
	Hypertension	Health	(Rofecoxib)	PS				
		Professional	Allopurinol	C				
			Enalapril Maleate	C				

OPHTHALMIC 25 MG OPHT 1 DAY

Date:12/01/99ISR Number: 3411775-2Report Type:Expedited (15-DaCompany Report #WAES 99115210
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Tab Vioxx					
	Condition Aggravated	Company	(Rofecoxib)	PS		ORAL	12.5 MG PO	27 DAY
	Constipation	Representative	Acetaminophen (+)					
	Diarrhoea		Carbinoxamine					
	Duodenitis		Maleate	C				
	Haematochezia		Lansoprazole	C				
	Rectal Haemorrhage							
	Weight Decreased							

Date:12/01/99ISR Number: 3411779-XReport Type:Expedited (15-DaCompany Report #WAES 99115168
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse	Foreign	Tab Vioxx					

	Syncope	Company	(Rofecoxib)	PS		ORAL
12.5 MG PO 2 DAY						
		Representative	Acetaminophen/Propoxyphene Hydrochloride	C		
			Dihydrocodeine	C		

Date:12/01/99ISR Number: 3411781-8Report Type:Expedited (15-DaCompany Report #WAES 99111539
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
	Haematocrit Decreased		Hydrodiuril	C		
	Haemoglobin Decreased		Plaquenil	C		
			Zoloft	C		
			Potassium Chloride	C		

Date:12/01/99ISR Number: 3411784-3Report Type:Expedited (15-DaCompany Report #WAES 99091433
Age:71 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Haemorrhage	Professional					MG/DAILY/PO	
Haemorrhage	Company Representative	Pravachol	C				
		Prilosec	C				

Date:12/01/99ISR Number: 3411786-7Report Type:Expedited (15-DaCompany Report #WAES 99105185
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	No Adverse Drug Effect	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	
Initial or Prolonged			Acetaminophen/Codein e Phosphate	C				
			Furosemide	C				

Date:12/01/99ISR Number: 3411820-4Report Type:Expedited (15-DaCompany Report #WAES 99101321
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ascites	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Hepatic Failure	Professional Company Representative						

Date:12/01/99ISR Number: 3411823-XReport Type:Expedited (15-DaCompany Report #WAES 99100514
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Other		Asthma	Professional				
MG/DAILY/PO							
		Dyspnoea	Company Representative				

Date:12/01/99ISR Number: 3411827-7Report Type:Expedited (15-DaCompany Report #WAES 99091261
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Tenderness Anisocytosis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL
50 MG; PO 29 DAY						
	Biopsy Liver Abnormal	Health	Nisoldipine	SS		
10 MG						
	Blood Amylase Increased	Professional	Placebo	SS		ORAL
1 TABLET; PO 29 DAY						
	Blood Bilirubin Increased Glycosuria Hepatic Fibrosis Hepatic Steatosis Hepatitis Lipase Increased Liver Function Test Abnormal Pancreatitis Acute Urobilinuria		Brotizolam	C		

Date:12/01/99ISR Number: 3411830-7Report Type:Expedited (15-DaCompany Report #WAES 99111288
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Flutter	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cardiac Failure	Professional					MG/DAILY/PO	
	Pulmonary Oedema	Company Representative	Plaquenil	C				
			[Composition Unspecified]	C				
			Influenza Virus Vaccine	C				

Date:12/01/99ISR Number: 3411831-9Report Type:Expedited (15-DaCompany Report #WAES 99101575
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Life-Threatening	Abdominal Pain Lower	Professional					MG/BID/PO	
Hospitalization -	Abdominal Tenderness		Gastrointestinal					
Initial or Prolonged	Asthenia		Preparation Unk	SS				
Disability	Condition Aggravated		Imdur	C				
Other	Constipation		Senokot (Senna)	C				
	Coordination Abnormal							
	Dyspnoea Exertional							
	Emotional Distress							
	Fall							
	Gastric Ulcer Perforation							
	Head Injury							
	Hypertension							
	Hyponatraemia							

Date:12/01/99ISR Number: 3411833-2Report Type:Expedited (15-DaCompany Report #WAES 99101240
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 25 MG/UNK/PO	Balance Disorder	Consumer	Tab Vioxx Unk	PS		ORAL
Initial or Prolonged	Blood Pressure Decreased	Health	Estratest	C		
	Difficulty In Walking	Professional	Klonopin	C		
	Fall		Prozac	C		
	Multiple Sclerosis		Zanaflex	C		
			Baclofen	C		
			Interferon - (Beta)	C		

Date:12/01/99ISR Number: 3411835-6Report Type:Expedited (15-DaCompany Report #WAES 99111288
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - PO	Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged		Professional	Plaquenil	C		
		Company	Influenza Virus			
		Representative	Vaccine	C		

Date:12/01/99ISR Number: 3411838-1Report Type:Expedited (15-DaCompany Report #WAES 99111497
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Other	Pulmonary Embolism	Health
		Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/01/99ISR Number: 3412694-8Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Study	Cap Crixivan Unk	PS		ORAL	SEE IMAGE	
Hospitalization -	Cholecystitis	Health	Cap Lodenosine Unk	SS		ORAL	300 MG/BID/PO	
Initial or Prolonged	Cholelithiasis	Professional	Cap Stavudine Unk	SS		ORAL	40 MG/BID/PO	
Other	Coagulation Time Prolonged		Tab Lorcet 10/650 Unk	SS		ORAL	10 MG/BID/PO	
	Coma		Tab Vioxx Unk	SS		ORAL	12.5 MG/BID/PO	
	Encephalopathy							
	Hepatic Enzyme Increased		Prevacid	C				
	Hepatic Function Abnormal		Prilosec	C				
	Hepatocellular Damage		Soma	C				
	Hepatorenal Failure							
	Hepatotoxicity							
	Hyperbilirubinaemia							
	Hypoproteinaemia							
	Jaundice							
	Lactic Acidosis							
	Nausea							
	Pancreatic Enzymes Increased							
	Prothrombin Time Prolonged							
	Respiratory Failure							
	Sepsis							

Date:12/01/99ISR Number: 3424714-5Report Type:Direct Company Report #
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematochezia		Vioxx 25mg Qd	PS		ORAL	25MG PO QD	
	Mouth Haemorrhage							

Date:12/02/99ISR Number: 3412632-8Report Type:Expedited (15-DaCompany Report #WAES 99111023
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
Initial or Prolonged	Csf Protein Abnormal	Professional					MG/DAILY/PO	
	Csf White Blood Cell Count Positive							
	Headache							
	Meningitis Aseptic							
	Musculoskeletal Stiffness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/99ISR Number: 3412637-7Report Type:Expedited (15-DaCompany Report #WAES 99117911
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Foreign	Tab Vioxx					
Life-Threatening	Epistaxis	Health	(Rofecoxib)	PS		ORAL	25 MG PO	10 DAY
Hospitalization -	Gastrointestinal	Professional						
Initial or Prolonged	Haemorrhage							
	Haematemesis							
	Haematocrit Decreased							
	Haemodialysis							
	Haemoptysis							
	Haemorrhage Intracranial							
	Idiopathic							
	Thrombocytopenic Purpura							
	Malaise							
	Melaena							
	Nervous System Disorder							
	Platelet Count Decreased							
	Pulmonary Congestion							
	Pulmonary Haemorrhage							
	Renal Failure							
	Respiratory Failure							
	Thrombocytopenia							
	Vasculitis							

Date:12/02/99ISR Number: 3412640-7Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / PO	
Initial or Prolonged	Increased	Professional	Celebrex	C				
	Blood Glucose Increased	Company	Hydrodiuril	C				
	Blood Thyroid Stimulating	Representative	Tylenol	C				
	Hormone Increased							
	Blood Urea Increased							
	Dehydration							
	Dyspnoea							
	Hypertension							
	Hypothyroidism							
	Nephritis Interstitial							

Oedema
Pleural Effusion
Proteinuria
Renal Failure Acute
Weight Increased

Date:12/02/99ISR Number: 3412776-0Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Cholecystitis
Hospitalization - Initial or Prolonged	Cholelithiasis
	Clostridium Colitis
Other	Coma
	Flatulence
	Gastrointestinal Haemorrhage
	Hepatic Encephalopathy
	Hepatic Failure

	Hepatic Function Abnormal						
	Hepatitis						
	Hepatotoxicity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hyperbilirubinaemia	Study	Cap Crixivan Unk	PS		ORAL	800 MG/Q8H/PO
	Impaired Gastric Emptying	Health	Cap Crixivan Unk	SS			
	Lactic Acidosis	Professional	Cap Crixivan Unk	SS			
	Leukocytosis		Cap Lodenosine Unk	SS		ORAL	300 MG/BID/PO
	Pancreatitis		Cap Stavudine Unk	SS		ORAL	40 MG/BID/PO
	Pulmonary Oedema		Tab Lorcet 10/650				
	Renal Failure Acute		Unk	SS		ORAL	10 MG/BID/PO
	Respiratory Failure		Tab Vioxx Unk	SS		ORAL	12.5
	Sepsis						MG/BID/PO
	Thrombocytopenia		Prevacid	C			
			Prilosec	C			
			Cholelithiasis	C			
			Colitis	C			
			Encephalopathy	C			
			Gastrointestinal Bleeding	C			

Date:12/02/99ISR Number: 3416476-2Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 5 DAY	Csf Neutrophil Count		Vioxx (Rofecoxib)	PS			
Initial or Prolonged	Positive						
Other	Csf Protein Increased						
	Csf White Blood Cell Count Positive						
	Headache						
	Meningism						
	Meningitis Aseptic						
	Neurological Examination Abnormal						

Date:12/02/99ISR Number: 3416481-6Report Type:Direct Company Report #
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hyperkalaemia		Rofecoxib (Vioxx)	PS		ORAL	12.5MG PO QD	
Intervention to	Renal Impairment		Rofecoxib	SS		ORAL	20MG PO BID	
Prevent Permanent								
LONG TERM							2	MON
Impairment/Damage								
			Alprazolam	C				
			Metoprolol	C				
			Digoxin	C				
			Hydralazine	C				
			Transdermal Nitroglycerine	C				
			Iron Supplement	C				
			Omeprazole	C				
			Warfarin	C				
			K-Dur	C				
			Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/99ISR Number: 3416484-1Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG QD	
ORAL								

Date:12/02/99ISR Number: 3423450-9Report Type:Periodic Company Report #99090716
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stomatitis	Consumer	Enbrel 25 Mg	PS				
SUBCUTANEOUS							25 MG, BIW,	
SUBCUTANEOUS								
			Etidronate	SS				
			Rofecoxib	SS				
			Prednisone	C				
			Conjugated Estrogens/Medroxyprogesterone	C				

Date:12/03/99ISR Number: 3413351-4Report Type:Expedited (15-DaCompany Report #WAES 99111309
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation	Health	Tab Vioxx Unk	PS		ORAL	PO	5 DAY
Hospitalization - Initial or Prolonged		Professional Company Representative	Toradol	C				

Date:12/03/99ISR Number: 3413355-1Report Type:Expedited (15-DaCompany Report #WAES 99111129
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cardiac Failure	Professional						
	Congestive	Company	Cardizem Cd	C				
	Condition Aggravated	Representative	K-Dur	C				
	Dyspnoea Exertional		Lanoxin	C				
	Joint Swelling		Lasix	C				
	Medication Error		Restoril	C				
	Nasopharyngitis		Synthroid	C				
	Oedema							
	Oedema Peripheral							
	Rales							
	Weight Increased							

Date:12/03/99ISR Number: 3413360-5Report Type:Expedited (15-DaCompany Report #WAES 99110818
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional	Imdur	C				
Other		Company	Lipitor	C				
		Representative	Prevacid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/99ISR Number: 3413364-2Report Type:Expedited (15-DaCompany Report #WAES 99111667
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Pulmonary Oedema	Professional	Lopressor	C				
		Company	Zoloft	C				
		Representative	Captopril	C				

Date:12/03/99ISR Number: 3413366-6Report Type:Expedited (15-DaCompany Report #WAES 99111666
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Coumadin	C				
		Company	Lasix	C				
		Representative	Toprol Xl Tablets	C				
			Zantac	C				
			Digoxin	C				

Date:12/03/99ISR Number: 3413367-8Report Type:Expedited (15-DaCompany Report #WAES 99111571
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bowel Sounds Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Condition Aggravated	Professional					MG/DAILY/PO	
	Faecal Occult Blood	Company	Actigall	C				
	Positive	Representative	Hydrodiuril	C				
	Faeces Discoloured		Premarin	C				
	Fatigue		Doxepin	C				
	Gastrointestinal		Potassium Chloride	C				
	Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypertension							
	Nausea							

Platelet Count Decreased

Date:12/06/99ISR Number: 3413908-0Report Type:Expedited (15-DaCompany Report #WAES 99110994
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angiogram Abnormal
	Asthenia
	Blood Thyroid Stimulating Hormone Increased
	Cerebral Infarction
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Clumsiness
	Dizziness
	Goitre
	Hypertension
	Thyroxine Decreased
	Transient Ischaemic Attack
	Tri-Iodothyronine Decreased
	Ventricular Extrasystoles

Vision Blurred

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Study	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Tab Placebo Unk	SS		ORAL	1	
							TABLET/BID/PO	
			Tab Acetaminophen 325 Mg	SS		ORAL	PRN/PO	
			Caltrate 600 Plus					
			Vitamin D	C				
			Synthroid	C				
			Folic Acid	C				
			Methotrexate	C				

Date:12/06/99ISR Number: 3413909-2Report Type:Expedited (15-DaCompany Report #WAES 99101749
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Abdominal Pain Lower	Professional					MG/DAILY/PO	
Initial or Prolonged	Abdominal Pain Upper	Other	Aspirin Unk	SS		ORAL	325 MG/UNK/PO	
Other	Abdominal Tenderness		Colace	C				
	Ascites		Haldol	C				
	Atrioventricular Block		Xanax	C				
	First Degree		Oxybutynin Chloride	C				
	Candidiasis							
	Cardiomegaly							
	Cholecystitis Acute							
	Crepitations							
	Dry Skin							
	Gastric Ulcer Perforation							
	Hyponatraemia							
	Peritonitis							
	Pneumonia							

Post Procedural
Complication
Pulmonary Congestion
Sputum Abnormal
Sputum Discoloured
White Blood Cell Count
Increased

Date:12/06/99ISR Number: 3413912-2Report Type:Expedited (15-DaCompany Report #WAES 99102092
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional	Intal	C				
		Company	Singulair	C				
		Representative	Albuterol	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/99ISR Number: 3413914-6Report Type:Expedited (15-DaCompany Report #WAES 99102284
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris	Health	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/UNK/PO	
Other	Cardiac Arrest Drug Ineffective	Professional Company Representative	Talwin	C				

Date:12/06/99ISR Number: 3413916-XReport Type:Expedited (15-DaCompany Report #WAES 99110919
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO; 37.5 MG/DAILY/PO	2 DAY
			Prevacid	C				
			Aspirin	C				

Date:12/06/99ISR Number: 3414180-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Anaphylactic Reaction Bronchospasm Intubation		Vioxx	PS				

Date:12/07/99ISR Number: 3414996-8Report Type:Expedited (15-DaCompany Report #WAES 99118276
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	25 MG PO	11 DAY
	Haemorrhage		Aspirin	C				
	Haematemesis							
	Melaena							

Date:12/07/99ISR Number: 3414997-XReport Type:Expedited (15-DaCompany Report #WAES 99115212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Foreign	Tab Vioxx					
	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	11.5 MG PO	13 DAY
	Melaena		Allopurinol	C				
			Metformin	C				

Date:12/07/99ISR Number: 3414998-1Report Type:Expedited (15-DaCompany Report #WAES 99115239
Age:77 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage

Haematemesis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
	Amiloride Hydrochloride/Hctz	C				
	Folic Acid	C				
	Lofepramine	C				
	Naproxen	C				
	Ranitidine	C				

Date:12/07/99ISR Number: 3414999-3Report Type:Expedited (15-DaCompany Report #WAES 99111520
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome Dyspnoea Hypertensive Crisis Pneumonia Swelling	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/07/99ISR Number: 3415000-8Report Type:Expedited (15-DaCompany Report #WAES 99111611
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx Unk	C		ORAL	50 MG/DAILY/PO	
			[Composition Unspecified]	C				

Date:12/07/99ISR Number: 3415001-XReport Type:Expedited (15-DaCompany Report #WAES 99111704
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Asthenia	Professional						
	Gait Disturbance	Company						
	Muscle Spasms	Representative						
	Muscular Weakness							
	Myalgia							
	Pain In Extremity							

Date:12/08/99ISR Number: 3415252-4Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health	Vioxx 12.5	PS			1 DAILY	
	Urticaria	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/99ISR Number: 3415253-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Rofecoxib (Vioxx)	PS		ORAL	25MG PO QD	1 MON
Initial or Prolonged	Gastrointestinal	Professional	Digoxin	C				
Required	Haemorrhage		Quinapril	C				
Intervention to	Renal Impairment		Nizatidine	C				
Prevent Permanent			Metolazone	C				
Impairment/Damage			Furosemide	C				
			Terazosin	C				
			Feso4	C				
			Warfarin	C				

Date:12/08/99ISR Number: 3415507-3Report Type:Direct Company Report #USP 52690
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Zyvox (Linezolid)	PS	Upjohn			
			Vioxx (Rofecoxib)	SS	Merck			

Date:12/08/99ISR Number: 3416493-2Report Type:Expedited (15-DaCompany Report #WAES 99110829
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Atrial Fibrillation	Professional	Coumadin	C				
	Colon Cancer	Company	Plavix	C				
	Dyspnoea	Representative	Aspirin	C				
	Ecchymosis							
	Faeces Discoloured							
	Fatigue							
	Gastric Ulcer Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Haemorrhage							
	International Normalised							
	Ratio Increased							

Jaundice
Ovarian Cancer

Date:12/08/99ISR Number: 3416494-4Report Type:Expedited (15-DaCompany Report #WAES 99111717
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/PO	12 DAY

Date:12/08/99ISR Number: 3416497-XReport Type:Expedited (15-DaCompany Report #WAES 99111771
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive		Amaryl	C				
			Coumadin	C				
			Ditropan	C				

Lasix	C
Neurontin	C
Prandin	C
Prevacid	C
Propulsid	C
Prozac	C
Allopurinol	C
Colchicine	C
Estrogenic Preparations (Composi	C
Metoprolol	C

Date:12/08/99ISR Number: 3416501-9Report Type:Expedited (15-DaCompany Report #WAES 99125006
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:12/08/99ISR Number: 3416507-XReport Type:Expedited (15-DaCompany Report #WAES 99111890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Rhabdomyolysis							

Date:12/08/99ISR Number: 3416510-XReport Type:Expedited (15-DaCompany Report #WAES 99111889
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
Other	Duodenal Ulcer	Company	Aspirin	C				

	Haemorrhage	Representative
	Faeces Discoloured	
	Gastric Ulcer Haemorrhage	
	Haemoglobin Decreased	

Date:12/08/99ISR Number: 3416513-5Report Type:Expedited (15-DaCompany Report #WAES 99111294
Age:76 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Anxiety
Initial or Prolonged	Blood Urea Increased
Disability	Diverticulitis
Other	Dizziness
	Duodenal Ulcer
	Gastric Ulcer Haemorrhage
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haematochezia
	Haematocrit Decreased
	Haemoglobin Decreased

	Infection						
	Mean Cell Volume Abnormal						
	Pallor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rectal Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	50
	Rectal Polyp	Professional					MG/DAILY/PO
	Tachycardia	Company	Tab Vioxx 25 Mg	SS		ORAL	25
	White Blood Cell Count	Representative					MG/DAILY/PO
	Increased		Darvocet-N 100 Mg	SS			100 MG/PRN
			Berocca Tablets	C			
			Prinivil	C			
			Aspirin	C			
			Verapamil Hydrochloride	C			

Date:12/09/99ISR Number: 3416490-7Report Type:Expedited (15-DaCompany Report #WAES 99115318
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia	Foreign	Tab Vioxx				
Initial or Prolonged	Mouth Ulceration	Health	(Rofecoxib)	PS			25 MG
	Pyrexia	Professional	Tab Vioxx				
	Rash Vesicular		(Rofecoxib)	SS			12.5 MG
	Stevens-Johnson Syndrome		Prednisolone	C			

Date:12/09/99ISR Number: 3417532-5Report Type:Expedited (15-DaCompany Report #WAES 99100710
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Bronchospasm	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Other	Cardiac Failure	Professional					MG/DAILY/PO
	Congestive	Company	Colestid	C			

	Face Oedema	Representative	Elavil	C
	Oedema Peripheral		Enbrel	C
	Respiratory Distress		Glucophage	C
			Glynase Prestab Tablets	C
			Klor-Con	C
			Lipitor	C
			Plaquenil	C
			Prilosec	C
			Rezulin	C
			Zestril	C
			Atenolol	C
			Estrone Sulfate Piperazine Salt	C
			Methotrexate	C
			Prednisone	C

Date:12/10/99ISR Number: 3417796-8Report Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Confusional State		Rofecoxib 25mg Merck & Co	PS	Merck & Co	ORAL
25MG QD ORAL						
	Haematemesis		Fosamax	C		
	Loss Of Consciousness		Synthroid	C		
	Melaena		Citracal	C		
			Multivitamin	C		

			Lasix	C			

Date:12/10/99ISR Number: 3418330-9Report Type:Expedited (15-DaCompany Report #WAES 99100830
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/ PO	
Disability	Drug Interaction	Professional						
Other	Hypoaesthesia		Coumadin Unk	SS		ORAL	7.5 MG/ DAILY/ PO	
	International Normalised Ratio Decreased		Avapro	C				
	Nervous System Disorder		Plaquenil	C				
	Subdural Haematoma							

Date:12/10/99ISR Number: 3418333-4Report Type:Expedited (15-DaCompany Report #WAES 99061948
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Asthenia	Professional						
	Atrioventricular Block Complete	Company Representative	Flexeril	C				
			Rezulin	C				
	Blood Glucose Increased							
	Cardiac Arrest							
	Cardiomegaly							
	Cholelithiasis							
	Cough							
	Dyspnoea							
	Hepatic Steatosis							
	Hyperlipidaemia							
	Malaise							
	Myocardial Infarction							
	Pericardial Effusion							
	Pleural Effusion							
	Productive Cough							

Pulmonary Embolism
Pulmonary Oedema
Renal Disorder
Respiratory Distress

Date:12/10/99ISR Number: 3418335-8Report Type:Expedited (15-DaCompany Report #WAES 99101188
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Full Blood Count	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/ PO	
Hospitalization - Initial or Prolonged	Decreased	Professional						
Other	Gastrointestinal Haemorrhage Haematemesis	Company Representative	Effexor	C				
			Elavil	C				
			Estrace	C				
			Ritalin	C				
			Skelaxin	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/99ISR Number: 3418337-1Report Type:Expedited (15-DaCompany Report #WAES 99105185
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Marrow Depression	Foreign	Tab Vioxx					
Hospitalization -	Malaise	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
Initial or Prolonged		Professional	Acetaminophen/Codein					
			e Phosphate	C				
			Furosemide	C				

Date:12/10/99ISR Number: 3418338-3Report Type:Expedited (15-DaCompany Report #WAES 99111666
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Coumadin	C				
		Company	Lasix	C				
		Representative						

Date:12/13/99ISR Number: 3420215-9Report Type:Expedited (15-DaCompany Report #WAES 99110175
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dementia	Professional						
MG/DAILY/PO								
	Disorientation	Company	Therapy Unspecified	SS				
	Drug Interaction	Representative	Lotensin	C				
			Maxzide	C				
			Pravachol	C				
			Zantac	C				
			Metoprolol	C				

Date:12/13/99ISR Number: 3420225-1Report Type:Expedited (15-DaCompany Report #WAES 99110416
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG / UNK/ PO	
	Condition Aggravated							
	Ejection Fraction Abnormal	Company Representative	Coumadin	C				
	Fluid Retention							
	Oedema							
	Weight Increased							

Date:12/13/99ISR Number: 3420226-3Report Type:Expedited (15-DaCompany Report #WAES 99110797
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage							
	Haematemesis	Company Representative	Cardizem Cd	C				
	Haematocrit Decreased		Coumadin	C				
			Lasix	C				
			Tylenol	C				
			Potassim Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/99ISR Number: 3420227-5Report Type:Expedited (15-DaCompany Report #WAES 99111023
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/ DAILY/	
	Csf Test Abnormal	Professional					PO	
	Dizziness							
	Headache							
	Hypotension							
	Lymphocyte Count Decreased							
	Medication Error							
	Meningism							
	Meningitis Aseptic							
	Musculoskeletal Stiffness							
	Nausea							
	Night Sweats							
	Pain							
	Subarachnoid Haemorrhage							
	Viral Infection							

Date:12/13/99ISR Number: 3420231-7Report Type:Expedited (15-DaCompany Report #WAES 99120135
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	
	Caustic Injury	Professional					DAILY/PO	
	Chest Pain							
	Dysphagia							
	Oesophageal Ulcer							
	Thermal Burn							

Date:12/13/99ISR Number: 3420233-0Report Type:Expedited (15-DaCompany Report #WAES 99102062
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cardiac Arrest	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/						
Initial or Prolonged	Conduction Disorder	Professional				
DAILY/PO						
	Malaise		Flomax	C		

Date:12/14/99ISR Number: 3420622-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Vioxx 12.5mg Tablets			
Required	Back Pain	Professional	(Rofecoxib) Dist By			
Intervention to	Chest Discomfort		Merck&Co,Inc (Merck)	PS	Merck&Co,Inc (Merck)	ORAL
1 TAB DAILY						
Prevent Permanent	Chest Pain					
BY MOUTH						
Impairment/Damage	Dysuria					
	Fatigue					
	Headache					
	Oedema					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/99ISR Number: 3420625-XReport Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased Blood Urea Increased	Health Professional	Vioxx 12.5mg Po Qd	PS		ORAL	12.5MG PO QD	

Date:12/14/99ISR Number: 3421022-3Report Type:Expedited (15-DaCompany Report #WAES 99120328
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	

Date:12/14/99ISR Number: 3421026-0Report Type:Expedited (15-DaCompany Report #WAES 99115283
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/14/99ISR Number: 3421029-6Report Type:Expedited (15-DaCompany Report #WAES 99120068
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis Neutropenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

			Company Representative	Skelaxin	SS		
800 MG/TID							

Date:12/14/99ISR Number: 3421032-6Report Type:Expedited (15-DaCompany Report #WAES 99100648
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nephrolithiasis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Weight Increased	Professional Company Representative					MG/DAILY/PO	

Date:12/14/99ISR Number: 3421035-1Report Type:Expedited (15-DaCompany Report #WAES 99115284
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion	Foreign	Tab Vioxx					
	Haemoglobin Decreased	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	19 DAY
			Haloperidol	C				
			Paroxetine Hcl Hemihydrate	C				

Date:12/14/99ISR Number: 3421037-5Report Type:Expedited (15-DaCompany Report #WAES 99117949
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cor Pulmonale	Foreign	Tab Rofecoxib	PS		ORAL	PO	
Initial or Prolonged		Study	Tab Placebo	SS		ORAL	PO	180 DAY
		Health Professional	Chloroquine	C				
			Prednisone	C				

Date:12/14/99ISR Number: 3421039-9Report Type:Expedited (15-DaCompany Report #WAES 99120135
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caustic Injury	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Dysphagia							
	Oesophageal Ulcer							
	Pain							
	Tendonitis							
	Thermal Burn							

Date:12/14/99ISR Number: 3421041-7Report Type:Expedited (15-DaCompany Report #WAES 99111736
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Sodium Decreased	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Hypertension		Prinivil	C				
	Tremor							
	Urine Sodium Decreased							

Date:12/14/99ISR Number: 3421046-6Report Type:Expedited (15-DaCompany Report #WAES 99111907
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Acidosis	Health					MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Blood Ph Decreased	Professional						
	Chest X-Ray Abnormal							
	Duodenal Ulcer Perforation							
	Gastrointestinal Perforation							
	Hypoxia							
	Large Intestine Perforation							
	Peritoneal Disorder							
	White Blood Cell Count Increased							

Date:12/14/99ISR Number: 3421047-8Report Type:Expedited (15-DaCompany Report #WAES 99111839
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50MG/DAILY/PO	
	Dyspnoea							
	Malaise							
	Muscular Weakness							
	Panic Reaction							

Date:12/14/99ISR Number: 3421049-1Report Type:Expedited (15-DaCompany Report #WAES 99111829
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Other	Nonsteroidal					
	Gastrointestinal Ulcer		Anti-Inflammatory					
			Drug Therapy					
			(Composition					
			Unspecified)	SS				
			Isordil	C				
			Toprol Xl Tablets	C				
			Nitroglycerin	C				

Date:12/14/99ISR Number: 3421053-3Report Type:Expedited (15-DaCompany Report #WAES 99110342
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
	Congestive	Professional					MG/DAILY/PO.2	
	Condition Aggravated	Company					5 MG/DAILY/PO	
	Dyspnoea Exacerbated	Representative	Coumadin	C				
	Oedema Peripheral		Ditropan	C				
	Weight Increased		Zocor	C				
			Atenolol	C				
			Estradiol	C				
			Medroxyprogesterone	C				

Date:12/14/99ISR Number: 3421056-9Report Type:Expedited (15-DaCompany Report #WAES 99125023
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Foreign	Tab Vioxx					

	Haemorrhage	Company	(Rofecoxib)	PS		ORAL
12.5 MG PO 36 DAY						
	Haematemesis	Representative	Beclomethasone Dipropionate	C		
			Benzydamine Hc1	C		
			Budesonide	C		
			Electrolytes (+) Sodium			
			Carboxymethylcel	C		
			Gabapentin	C		
			Lactulose	C		
			Lansoprazole	C		
			Methotrimeprazine	C		
			Metoclopramide	C		
			Morphineso4	C		
			Prednisolone	C		
			Terbutaline	C		

Date:12/14/99ISR Number: 3421058-2Report Type:Expedited (15-DaCompany Report #WAES 99120489
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company	Pravachol	C		
		Representative	Prilosec	C		

Therapy Unspecified C

Date:12/14/99ISR Number: 3421060-0Report Type:Expedited (15-DaCompany Report #WAES 99100957
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blister	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dermatitis	Professional						
	Excoriation							
	Infection							
	Pain							
	Skin Ulcer							

Date:12/14/99ISR Number: 3421211-8Report Type:Direct Company Report #USP 52717
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx (Rofecoxib)	PS	Merck		VARIOUS	
			Zyvox (Linezolid)	SS	Pharmacia & Upjohn		VARIOUS	

Date:12/15/99ISR Number: 3421189-7Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyponatraemia	Health	Rofecoxib (Vioxx)					
	Inappropriate	Professional	Merck	PS	Merck	ORAL	UNKNOWN, PO	
	Antidiuretic Hormone							
	Secretion						UNKNOWN ~1WK	1 WK
			Sertraline	C				
			Megestrol	C				
			Lisinopril	C				
			Warfarin	C				
			Acetaminophen	C				

Propoxyphene	C
Nitroglycerin	C
Clorazepate	C
Multivamin	C
Methylcellulose	C
Magnesium Hydromide	C

Date:12/15/99ISR Number: 3422198-4Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Other	Vioxx Tablet 25mg					
	Bradycardia		Rofecoxib	PS				
	Fatigue							
	Fluid Retention							
	Weight Increased							

Date:12/15/99ISR Number: 3422303-XReport Type:Expedited (15-DaCompany Report #WAES 99120146
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Swelling	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	50 MG /PO	

Date:12/15/99ISR Number: 3422305-3Report Type:Expedited (15-DaCompany Report #WAES 99091930
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Other	First Degree	Professional						
	Blood Chloride Decreased	Company	Luvox	C				
	Chest Pain	Representative	Prevacid	C				
	Discomfort		Prilosec	C				
	Hyponatraemia		Proscar	C				
	Malaise		Risperdal	C				
	Sinus Tachycardia		Tylenol Extra Strength	C				

Date:12/15/99ISR Number: 3422310-7Report Type:Expedited (15-DaCompany Report #WAES 99125099
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	113 DAY
	Flatulence							
			Cisapride	C				
			Dothiepin	C				
			Lansoprazole	C				
			Temazepam	C				
			Tramadol	C				

Date:12/15/99ISR Number: 3422313-2Report Type:Expedited (15-DaCompany Report #WAES 99120416
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Bradycardia	Professional	Prinivil	C				
	Dizziness		Estrogen	C				
	Fatigue							
	Heart Rate Irregular							

Date:12/15/99ISR Number: 3422317-XReport Type:Expedited (15-DaCompany Report #WAES 99120493
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	
		Professional					DAILY/PO,	
		Company	Tab Vioxx 25 Mg	SS		ORAL	50 MG/	
		Representative					DAILY/PO	

Date:12/15/99ISR Number: 3422321-1Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Blood Thyroid Stimulating	Professional					PO	
	Hormone Increased	Company	Celebrex	C				
	Blood Urea Increased	Representative	Ecotrin	C				
	Condition Aggravated		Hydrodiuril	C				
	Dehydration		Macrobid	C				
	Dyspnoea		Tylenol	C				
	Hyperglycaemia							
	Hypertension							
	Hypothyroidism							
	Nephritis Interstitial							
	Nephrotic Syndrome							
	Oedema							
	Oedema Peripheral							
	Pleural Effusion							
	Proteinuria							
	Weight Decreased							
	Weight Increased							

Date:12/15/99ISR Number: 3422326-0Report Type:Expedited (15-DaCompany Report #WAES 99100977
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -		Professional						
Initial or Prolonged		Company						
		Representative						

Date:12/15/99ISR Number: 3422329-6Report Type:Expedited (15-DaCompany Report #WAES 99115212
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Foreign	Tab Vioxx					

	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
11.5 MG PO 13 DAY						
	Melaena		Allopurinol	C		
			Metformin	C		

Date:12/15/99ISR Number: 3422331-4Report Type:Expedited (15-DaCompany Report #WAES 99111424
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/ BID/						
Initial or Prolonged	Congestive	Professional				
PO 4 WK						
	Fluid Overload	Company				
	Renal Failure Acute	Representative				

Date:12/16/99ISR Number: 3422672-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome
Life-Threatening
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Vioxx	PS		ORAL	25MG QD ORAL	5 DAY
	Increased Condition Aggravated Renal Impairment	Professional	Lasix	C				

Date:12/16/99ISR Number: 3422673-2Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG DAILY	
	Face Oedema	Professional					ORAL	3 DAY

Date:12/16/99ISR Number: 3422788-9Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine	Health	Digoxin 0.125mg	PS		ORAL	0.125 MG DAILY PO	
	Increased Bradycardia Hyperkalaemia Hypothyroidism Lethargy Renal Impairment Therapeutic Agent Toxicity	Professional	Vioxx (Rofecoxib) Dose Unknown	SS			UNKNOWN	UNKNOWN 1 MON
			Glucotrol Xl	C				
			Premarin	C				
			Lopressor	C				
			Asa	C				
			Prozac	C				
			Detrol	C				
			Prilosec	C				
			Halcion	C				
			Ativan	C				

Date:12/16/99ISR Number: 3423315-2Report Type:Expedited (15-DaCompany Report #WAES 99111771
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Condition Aggravated	Company	Amaryl	C				
	Fluid Retention	Representative	Coumadin	C				
			Ditropan	C				
			Lasix	C				
			Neurontin	C				
			Prandin	C				
			Prevacid	C				
			Propulsid	C				
			Prozac	C				
			Allopurinol	C				
			Colchicine	C				
			Estrogenic Preparations Composi	C				
			Metoprolol	C				

Date:12/16/99ISR Number: 3423320-6Report Type:Expedited (15-DaCompany Report #WAES 99120328
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Congestive	Professional					MG/UNK/PO	
		Company Representative						

Date:12/16/99ISR Number: 3423323-1Report Type:Expedited (15-DaCompany Report #WAES 99102152
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company Representative						

Date:12/17/99ISR Number: 3424572-9Report Type:Expedited (15-DaCompany Report #WAES 99091707
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Abdominal Pain Upper	Professional					MG/DAILY/PO	
Initial or Prolonged	Asthenia	Company	Advil	C				
Other	Condition Aggravated	Representative	Lanoxin	C				
	Gastrointestinal		Nitrostat	C				
	Haemorrhage		Trental	C				
	Haematemesis		Zocor	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased		Benzonatate	C				
	Heart Rate Increased		Captopril	C				
	Hypokalaemia		Sucralfate	C				
	Melaena		Triamterene	C				
	Pallor							

Red Blood Cell Count
Decreased

Date:12/17/99ISR Number: 3424575-4Report Type:Expedited (15-DaCompany Report #WAES 99120015
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Vioxx	PS		ORAL	PO	3 DAY
Initial or Prolonged		Professional	Ascriptin	C				
			Avapro	C				
			Hydrodiuril	C				
			Hytrin	C				
			Nasonex	C				
			Zocor	C				

Date:12/17/99ISR Number: 3424583-3Report Type:Expedited (15-DaCompany Report #WAES 99111940
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Blood Bilirubin Increased
Initial or Prolonged	Cholelithiasis
	Jaundice
	Liver Function Test

	Abnormal						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Vioxx	PS		ORAL	PO	
		Professional Company Representative	Avandia	C				
			Coumadin	C				
			Hydrodiuril	C				
			Neurontin	C				
			Novolin	C				
			Prozac	C				
			Synthroid	C				
			Therapy Unspecified	C				
			Albuterol	C				
			Quinine	C				

Date:12/17/99ISR Number: 3424586-9Report Type:Expedited (15-DaCompany Report #WAES 99110445
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive Oedema	Professional Company Representative						

Date:12/17/99ISR Number: 3424588-2Report Type:Expedited (15-DaCompany Report #WAES 99101966
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Health	Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Faeces Discoloured	Professional Company Representative						
	Gastric Ulcer Haemorrhage							
	Haemoglobin Decreased							

Date:12/17/99ISR Number: 3424593-6Report Type:Expedited (15-DaCompany Report #WAES 99120772
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Dyspepsia Gastric Ulcer Haemorrhage Nausea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:12/17/99ISR Number: 3424595-XReport Type:Expedited (15-DaCompany Report #WAES 99120607
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/17/99ISR Number: 3424599-7Report Type:Expedited (15-DaCompany Report #WAES 99111025
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Chest Pain	Professional	Aspirin	C				
	Condition Aggravated	Company						
	Dyspnoea	Representative						
	Faeces Discoloured							
	Gastric Ulcer							
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Gastritis Erosive							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							
	Intestinal Ischaemia							
	Mucosal Ulceration							
	Nausea							
	Oesophagitis							

Date:12/17/99ISR Number: 3424601-2Report Type:Expedited (15-DaCompany Report #WAES 99120824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
Initial or Prolonged	Haemorrhage	Professional	A.S.A.	C				
		Company	Avapro	C				
		Representative	Betapace	C				
			Isordil	C				
			Lasix	C				
			Iron (Unspecified)	C				
			Potassium Supplement (Composition)	C				

Date:12/17/99ISR Number: 3424605-XReport Type:Expedited (15-DaCompany Report #WAES 99120693
Age:98 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Confusional State	Professional						

Date:12/17/99ISR Number: 3424612-7Report Type:Expedited (15-DaCompany Report #WAES 99090186
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Foreign	Tab Vioxx					
Initial or Prolonged	Bradycardia	Study	(Rofecoxib)	PS		ORAL	50 MG PO	9 DAY
Disability	Cardiac Failure	Health	Lasix	C				
	Congestive	Professional	Placebo	C				
	Condition Aggravated		Theophylline	C				

Date:12/17/99ISR Number: 3424617-6Report Type:Expedited (15-DaCompany Report #WAES 99117932
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Other	Dermatitis
	Stevens-Johnson Syndrome

Vasculitis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	33 DAY
			Mevacor	C				
			Allopurinol	C				
			Nicergoline	C				
			Ramipril	C				

Date:12/17/99ISR Number: 3424621-8Report Type:Expedited (15-DaCompany Report #WAES 99111611
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG-50 MG/DAILY/PO	
	Congestive Dyspnoea	Company Representative	Detrol	C				
	Fluid Retention		Fosamax	C				
	Injury		Glucotrol Xl	C				
	Oedema Peripheral		Lipitor	C				
	Pulmonary Oedema		Aspirin	C				
			Atenolol	C				

Date:12/20/99ISR Number: 3424712-1Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx (Taken Outpatient)	PS				

Date:12/20/99ISR Number: 3424716-9Report Type:Direct Company Report #
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastrointestinal		Vioxx	PS	ORAL
25MG PO QD					
Initial or Prolonged	Haemorrhage		Tagamet	C	
	Haematochezia		Ticlid	C	
	Mouth Haemorrhage				

Date:12/20/99ISR Number: 3424719-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Faecal Occult Blood		Vioxx 25mg	PS		ORAL
1T PO QD						
Hospitalization -	Positive					
Initial or Prolonged	Gastrointestinal					
Required	Haemorrhage					
Intervention to	Haematocrit Decreased					
Prevent Permanent	Haemoglobin Decreased					
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/99ISR Number: 3425390-8Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx 12.5 Mg	PS		ORAL	12.5MG PO QD	
Hospitalization - RECENTLY?	Faeces Discoloured							
Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage Oesophageal Ulcer Syncope Vomiting		Asa	C				
			Claritin	C				
			Hctz	C				
			Atrovent	C				
			Terazosin	C				
			Serevent	C				

Date:12/20/99ISR Number: 3425951-6Report Type:Expedited (15-DaCompany Report #WAES 99121100
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	50	
Initial or Prolonged	Increased	Professional					MG/DAILY/PO	2 DAY
	Renal Impairment	Company Representative						

Date:12/20/99ISR Number: 3425952-8Report Type:Expedited (15-DaCompany Report #WAES 99091238
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG;	
	Ecchymosis	Health					DAILY; PO	
	Haemorrhage Subcutaneous	Professional	Levsin	C				
			Lopressor	C				
			Lotensin	C				
			Prozac	C				
			Aspirin	C				
			Folic Acid	C				

Omeprazole	C
Vitamin B(12)	C
Vitamins	C

Date:12/20/99ISR Number: 3425953-XReport Type:Expedited (15-DaCompany Report #WAES 99121188
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	3 DAY
Other	Renal Failure	Company Representative	Lotensin	C				

Date:12/20/99ISR Number: 3425954-1Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age:88 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Bleeding Time Prolonged
	Blood Fibrinogen Decreased
	Fibrin Degradation Products Increased
	Prothrombin Time

		Prolonged Thrombocytopenia Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO	3 DAY						
				Calan Sr	C		
				Colace	C		
				Lasix	C		
				Zoloft	C		
				Potassium Chloride	C		
				Tamoxifen	C		
				Vitamins	C		

Date:12/20/99ISR Number: 3425955-3Report Type:Expedited (15-DaCompany Report #WAES 99102013
Age:82 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Grand Mal Convulsion	Health Professional Company Representative	Vioxx 12.5 Mg	PS		ORAL
PO						

Date:12/20/99ISR Number: 3425956-5Report Type:Expedited (15-DaCompany Report #WAES 99075214
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG; PO	31 DAY					
Initial or Prolonged	Increased Condition Aggravated Renal Impairment	Health Professional Other	Acetaminophen/Propoxyphene Hydrochloride	C		
			Aspirin	C		
			Benzalkonium Chloride (+)			
			Chlorhexidine	C		
			Capsaicin	C		
			Cetirizine Dihc1	C		
			Cetostearyl Alcohol			

(+) Phenoxyethanol	C
Epoetin Alfa	C
Fluoxetine Hc1	C
Folic Acid	C
Furosemide	C
Hydroxocobalamin	C
Influenza Virus Vaccine	C
Lansoprazole	C
Nicorandil	C
Nitroglycerin	C
Nutritional Supplements	C
Pravastatin Na	C
Trimeprazine Tartrate	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/99ISR Number: 3425958-9Report Type:Expedited (15-DaCompany Report #WAES 99101302
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bone Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
	Condition Aggravated	Professional						
	Muscle Spasms		Buspar	C				
	Myalgia		Slow-Mag	C				
	Pain In Extremity		Calcium Supplement	C				
	Tendon Disorder		Influenza Virus Vaccine	C				
			Vitamins	C				

Date:12/21/99ISR Number: 3425944-9Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine		Vioxx	PS			UNKNOWN	UNKNOWN
	Increased Condition Aggravated		Ibuprofen	C				
	Dialysis							
	Renal Failure Chronic							

Date:12/21/99ISR Number: 3426935-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx 12.5 Mg	PS				

Date:12/22/99ISR Number: 3427928-3Report Type:Direct Company Report #
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Lipid Metabolism Disorder	Health	Rofecoxib (Vioxx)	PS		ORAL
12.5 MG PO QD						
Hospitalization -	Nephritis Interstitial	Professional				
Initial or Prolonged	Nephrotic Syndrome					
Required	Oedema					
Intervention to	Proteinuria					
Prevent Permanent	Renal Failure Acute					
Impairment/Damage	Weight Increased					

Date:12/23/99ISR Number: 3429687-7Report Type:Expedited (15-DaCompany Report #WAES 99120015
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Vioxx Unk	PS		ORAL	PO	3 DAY
Initial or Prolonged		Professional	Advil	SS		ORAL	PO	3 DAY
			Ascriptin	C				
			Avapro	C				
			Hydrodiuril	C				
			Hytrin	C				
			Nasonex	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3429694-4Report Type:Expedited (15-DaCompany Report #WAES 99121142
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration	Health	Vioxx	PS		ORAL	12.5	MG/DAILY/PO
	Renal Failure Acute	Professional						
		Company	Cozaar	SS		ORAL	PO	
		Representative	Bumex	C				
			Imdur	C				
			Aspirin	C				
			Digoxin	C				
			Rifampin	C				

Date:12/23/99ISR Number: 3429697-XReport Type:Expedited (15-DaCompany Report #WAES 99121109
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
Initial or Prolonged	Renal Failure Acute	Professional						
		Company	Cozaar Unk	SS				
		Representative	Pepcid	C				
			Amlodipine	C				
			Digoxin	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:12/23/99ISR Number: 3429701-9Report Type:Expedited (15-DaCompany Report #WAES 99121135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
	Congestive	Professional						
	Condition Aggravated	Company						

	Pulmonary Oedema	Representative					
	Weight Increased						

Date:12/23/99ISR Number: 3429705-6Report Type:Expedited (15-DaCompany Report #WAES 99120729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Confusional State	Health	Vioxx 0	PS		ORAL	25
Initial or Prolonged	Fall	Professional					MG/DAILY/PO
	Gait Disturbance	Company					
	Pelvic Fracture	Representative					

Date:12/23/99ISR Number: 3429708-1Report Type:Expedited (15-DaCompany Report #WAES 99120135
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Caustic Injury	Health	Vioxx	PS		ORAL	25 MG/1X/PO
Other	Chest Pain	Professional					
	Dysphagia						
	Oesophageal Ulcer						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3429718-4Report Type:Expedited (15-DaCompany Report #WAES 99129761
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Tab Vioxx					
	Dizziness	Health	(Rofecoxib)	PS		ORAL	25 MG; PO	
	Hypertension	Professional	Thyroxine	C				
	Palpitations	Other						
	Stress							

Date:12/23/99ISR Number: 3429721-4Report Type:Expedited (15-DaCompany Report #WAES 99120933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Sulfasalazine	C				

Date:12/23/99ISR Number: 3429724-XReport Type:Expedited (15-DaCompany Report #WAES 99129761
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Tab Vioxx					
	Dizziness	Health	(Rofecoxib)	PS		ORAL	25 MG; PO	
	Hypertension	Professional	Thyroxine	C				
	Palpitations	Other						
	Stress							

Date:12/23/99ISR Number: 3429736-6Report Type:Expedited (15-DaCompany Report #WAES 99121113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Amylase Increased	Health	Vioxx	PS		ORAL	PO	5 DAY
Initial or Prolonged	Cardiac Failure	Professional	Lanoxin	C				

	Congestive	Company	Lasix	C
	Hepatitis	Representative		
	Lipase Increased			
	Liver Function Test			
	Abnormal			
	Pancreatitis			

Date:12/23/99ISR Number: 3429741-XReport Type:Expedited (15-DaCompany Report #WAES 99120216
Age:44 YR Gender:Male I/FU:I

Outcome	PT
Death	Abnormal Behaviour
Life-Threatening	Blood Pressure Increased
Hospitalization -	Brain Herniation
Initial or Prolonged	Coma
	Computerised Tomogram
	Abnormal
	Haemorrhage Intracranial
	International Normalised
	Ratio Increased
	Medication Error
	Miosis
	Nervous System Disorder
	Pseudomonas Infection
	Pupillary Disorder

	Urinary Retention Urinary Tract Infection						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx 25 Mg	PS		ORAL	50 MG/ DAILY/ PO	
			Lovenox	C				
			Warfarin	C				

Date:12/23/99ISR Number: 3429747-0Report Type:Expedited (15-DaCompany Report #WAES 99100681
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Consumer	Vioxx	PS		ORAL	PO	
Life-Threatening	Distress Syndrome	Health						
Hospitalization - Initial or Prolonged	Anaphylactic Shock	Professional						
	Anaphylactoid Reaction	Company						
	Condition Aggravated	Representative						
	Dermatitis							
	Dyspnoea							
	Embolism							
	Myocardial Infarction							
	Pulmonary Embolism							
	Syncope							

Date:12/23/99ISR Number: 3429751-2Report Type:Expedited (15-DaCompany Report #WAES 99080474
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
Other	Bleeding Time Prolonged	Professional						
	Chest Pain	Company						
	Fatigue	Representative						
	Haemorrhage							
	Pancytopenia							

Date:12/23/99ISR Number: 3429754-8Report Type:Expedited (15-DaCompany Report #WAES 99101561
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Health	Vioxx	PS		ORAL	12.5 MG/ DAILY/ PO	
	Urticaria	Professional						
			Ceftin	SS			250 MG/BID/UNK	
			Nasarel	C				
			Prinzide	C				
			Ventolin	C				
			Zyrtec	C				

Date:12/23/99ISR Number: 3429756-1Report Type:Expedited (15-DaCompany Report #WAES 99101434
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Asthenia
	Blood Pressure Decreased
	Bradycardia
	Chest Pain
	Fatigue

	Fluid Retention Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	10 DAY
			Premarin	C				

Date:12/23/99ISR Number: 3429759-7Report Type:Expedited (15-DaCompany Report #WAES 99100971
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health Professional	Vioxx	PS		ORAL	PO	
	Laboratory Test Interference	Company Representative						
	Nephritis Interstitial							

Date:12/23/99ISR Number: 3429763-9Report Type:Expedited (15-DaCompany Report #WAES 99105179
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Tab Vioxx					
Other	Condition Aggravated	Health Professional	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
	Gastrointestinal Haemorrhage	Other	Acetaminophen/Propoxyphene Hydrochloride	C				
	Haematemesis		Doxycycline	C				
	Infectious Mononucleosis		Erythromycin	C				
	Lower Respiratory Tract Infection		Estradiol (+) Norethindrone	C				
	Overdose		Folic Acid	C				
	Pharyngitis		Lacidipine	C				
			Lisinopril	C				

Date:12/23/99ISR Number: 3429772-XReport Type:Expedited (15-DaCompany Report #WAES 99120824
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY / PO	
	Gastric Ulcer Haemorrhage	Company Representative	A.S.A	C				
			Avapro	C				
			Betapace	C				
			Isordil	C				
			Lasix	C				
			Iron (Unspecified)	C				
			Potassium Supplement	C				

Date:12/23/99ISR Number: 3429775-5Report Type:Expedited (15-DaCompany Report #WAES 99111666
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative	Coumadin	C				
Other			Lasix	C				
			Toprol Xl Tablets	C				
			Zantac	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3429778-0Report Type:Expedited (15-DaCompany Report #WAES 99111537
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Hospitalization -	Anaemia	Professional					/PO	
Initial or Prolonged	Cardiac Failure	Company	Humulin N	C				
Other	Congestive	Representative	Hyzaar	C				
	Condition Aggravated		Lasix	C				
	Gastric Ulcer Perforation		Norvasc	C				
	Urinary Tract Infection		Tenormin	C				

Date:12/23/99ISR Number: 3429785-8Report Type:Expedited (15-DaCompany Report #WAES 99111492
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
	Hypertension	Professional					DAILY/ PO	
	Oedema	Company						
	Syncope	Representative						

Date:12/23/99ISR Number: 3429786-XReport Type:Expedited (15-DaCompany Report #WAES 99120475
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Propulsid	C				
		Company						
		Representative						

Date:12/23/99ISR Number: 3429789-5Report Type:Expedited (15-DaCompany Report #WAES 99110818
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Professional Company Representative	Imdur	C				
Other			Lipitor	C				
			Prevacid	C				
			Atenolol	C				

Date:12/23/99ISR Number: 3429790-1Report Type:Expedited (15-DaCompany Report #WAES 99111289
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY / PO	
	Diverticulum Intestinal	Professional						
	Gastrointestinal Haemorrhage							

Date:12/23/99ISR Number: 3429791-3Report Type:Expedited (15-DaCompany Report #WAES 99111704
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Movement Disorder
	Muscle Spasms
	Muscular Weakness

		Musculoskeletal Disorder					
		Myalgia					
		Myopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myositis	Health	Tab Vioxx 12.5 Mg	PS		ORAL
PO							
		Neuropathy Peripheral	Professional	Influenza Virus			
		Pain In Extremity	Company	Vaccine Unk	SS		
		White Blood Cell Count	Representative	Vitamins	C		
		Decreased					

Date:12/23/99ISR Number: 3430256-3Report Type:Periodic Company Report #WAES 99110404
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
Initial or Prolonged	Diarrhoea	Professional	Dolobid	C		
	Dyspepsia		Premarin	C		
			Methotrexate	C		

Date:12/23/99ISR Number: 3430257-5Report Type:Periodic Company Report #WAES 99110234
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	International Normalised	Health	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY/PO						
	Ratio Increased	Professional	Cardizem Cd	C		
	Prothrombin Time	Company	Coumadin	C		
	Prolonged	Representative	Coumadin	C		
			Digoxin	C		
			Prednisone	C		

Date:12/23/99ISR Number: 3430259-9Report Type:Periodic Company Report #WAES 99110231
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	International Normalised	Health	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE						
	Ratio Increased	Professional	Coumadin	C		
	Prothrombin Time	Company	Coumadin	C		
	Prolonged	Representative	Darvocet-N	C		
			Fosamax	C		
			Nasonex	C		
			Premarin	C		
			Tenormin	C		
			Vitamins	C		

Date:12/23/99ISR Number: 3430262-9Report Type:Periodic Company Report #WAES 99101562
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
PRN/PO						
	Vomiting	Professional	Tab Flexeril Unk	SS		ORAL
PO						

Date:12/23/99ISR Number: 3430264-2Report Type:Periodic Company Report #WAES 99101510
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY/PO						
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/99ISR Number: 3430265-4Report Type:Periodic Company Report #WAES 99101335
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Other		Professional	Carafate	C				
		Company	Imdur	C				
		Representative	Premarin	C				

Date:12/23/99ISR Number: 3430267-8Report Type:Periodic Company Report #WAES 99100103
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Platelet Count Decreased	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:12/23/99ISR Number: 3430268-XReport Type:Periodic Company Report #WAES 99092137
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Oedema Peripheral	Professional	Prilosec	C				
			Tenormin	C				
			Zantac	C				

Date:12/23/99ISR Number: 3430272-1Report Type:Periodic Company Report #WAES 99091859
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
		Professional	[Therapy					
		Other	Unspecified]	C				
			Morphine	C				

Date:12/23/99ISR Number: 3430274-5Report Type:Periodic Company Report #WAES 99082308
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Professional	T1b Vioxx 12.5 Mg	SS		ORAL	12.5 MG/ PO	
			A.S.A.	C				
			Celebrex	C				
			Ocuvite	C				
			Tylenol Pm	C				
			Potassium Chloride	C				
			Verapamil	C				

Date:12/27/99ISR Number: 3430545-2Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Vioxx / 25mg /Merck	PS	Merck		25MG QD X 5	
	Asthenia						BID	
	Back Pain		Warfarin 2mg Dupont	SS	Dupont		2MG QD	
	Faeces Discoloured		Verapamil	C				
	Fatigue		Lozol	C				
	Gastric Ulcer							
	Gastritis							
	Haematocrit Decreased							

Date:12/27/99ISR Number: 3430907-3Report Type:Expedited (15-DaCompany Report #WAES 99120947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged		Professional						

Date:12/27/99ISR Number: 3430911-5Report Type:Expedited (15-DaCompany Report #WAES 99121138
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastroenteritis	Company	Celebrex	C				
Disability	Helicobacter	Representative	Glucophage	C				
Other	Gastrointestinal		Lipitor	C				
	Haemorrhage		Norvasc	C				
			Zoloft	C				
			Aspirin	C				

Date:12/27/99ISR Number: 3430917-6Report Type:Expedited (15-DaCompany Report #WAES 99121463
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:12/27/99ISR Number: 3430920-6Report Type:Expedited (15-DaCompany Report #WAES 99121225
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Muscle Disorder	Professional						
			Prilosec	C				
			Hyoscyamine	C				

Date:12/27/99ISR Number: 3430923-1Report Type:Expedited (15-DaCompany Report #WAES 99121255
Age:60 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Haematochezia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Haemoglobin Decreased	Professional						
Rectal Haemorrhage	Company Representative						

Date:12/27/99ISR Number: 3430927-9Report Type:Expedited (15-DaCompany Report #WAES 99127288
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
	Haematochezia	Other						
	Haemoglobin Decreased		Acetaminophen	C				
	Melaena		Citalopram Hydrobromide	C				
	Oesophageal Stenosis		Pindolol	C				
			Zolpidem Tartrate	C				

Date:12/27/99ISR Number: 3430930-9Report Type:Expedited (15-DaCompany Report #WAES 99128278
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholecystectomy	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	13 DAY
	Cholecystitis	Other						
	Gallbladder Disorder							
	Intervertebral Disc Protrusion							

Date:12/27/99ISR Number: 3430934-6Report Type:Expedited (15-DaCompany Report #WAES 99115239
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism	Foreign	Tab Vioxx					
Hospitalization -	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
Initial or Prolonged	Haemorrhage	Professional	Naproxen	SS			500 MG	2 DAY
Other	Haematemesis		Amiloride					
	Haemoglobin Decreased		Hydrochloride/Hctz	C				
	Melaena		Folic Acid	C				
			Lofepramine	C				
			Ranitidine	C				

Date:12/27/99ISR Number: 3430939-5Report Type:Expedited (15-DaCompany Report #WAES 99125078
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Foreign	Tab Vioxx					
Initial or Prolonged			(Rofecoxib)	PS		ORAL	PO	28 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/99ISR Number: 3430940-1Report Type:Expedited (15-DaCompany Report #WAES 99125141
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness Syncope	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional	Timoptol	C				
			Temazepam	C				

Date:12/27/99ISR Number: 3430942-5Report Type:Expedited (15-DaCompany Report #WAES 99115239
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG	8 DAY
Hospitalization - Initial or Prolonged	Haematemesis	Professional	Naproxen	SS			500 MG	2 DAY
Other	Haemoglobin Decreased Melaena		Amiloride Hydrochloride/Hctz	C				
			Folic Acid	C				
			Lofepramine	C				
			Ranitidine	C				

Date:12/27/99ISR Number: 3430946-2Report Type:Expedited (15-DaCompany Report #WAES 99111667
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchospasm	Health	Tab Vioxx Unk	PS		ORAL	PO	
Other	Dyspnoea Lung Infiltration Pulmonary Oedema	Professional Company Representative	Flomax (Tamsulosin (R) - Form Hydr	C				
			Lopressor	C				
			Zoloft	C				
			Captopril	C				

Date:12/27/99ISR Number: 3430949-8Report Type:Expedited (15-DaCompany Report #WAES 99120406
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Chest Pain		Tab Vioxx 12.5 Mg	SS		ORAL	12.5	
	Hypertension						MG/DAILY/PO	
	Unevaluable Event		Cardizem	C				
			Hydrodiuril	C				
			Oxycontin	C				
			Oxyir	C				
			Prinivil	C				

Date:12/27/99ISR Number: 3430952-8Report Type:Expedited (15-DaCompany Report #WAES 99120815
Age:98 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Cardiac Failure	Professional					MG/DAILY/PO	
Initial or Prolonged	Congestive	Company						
Other	Dyspnoea	Representative						
	Pulmonary Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/99ISR Number: 3430954-1Report Type:Expedited (15-DaCompany Report #WAES 99120816
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Feeling Drunk		Hydrodiuril	C				
	Hallucination		Lortab	C				
	Nausea		Lotensin	C				
			Prozac	C				
			Aspirin	C				

Date:12/27/99ISR Number: 3430955-3Report Type:Expedited (15-DaCompany Report #WAES 99120922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
			Fosamax	C				
			Hyzaar	C				
			Synthroid	C				

Date:12/27/99ISR Number: 3430960-7Report Type:Expedited (15-DaCompany Report #WAES 99091934
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Medical Device	Professional					MG/DAILY/PO	
	Complication	Company	Miacalcin	C				
	Renal Failure	Representative	Alprazolam	C				
	Thrombocythaemia		Glucosamine	C				
			Thiamine	C				

Date:12/27/99ISR Number: 3430963-2Report Type:Expedited (15-DaCompany Report #WAES 99111667
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Dyspnoea	Professional	Flomax (Tamsulosin					
Other	Lung Infiltration	Company	(R)-Form Hydr	C				
	Pulmonary Oedema	Representative	Zoloft	C				
			Captopril	C				

Date:12/27/99ISR Number: 3430967-XReport Type:Expedited (15-DaCompany Report #WAES 99125077
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Foreign	Tab Vioxx					
Initial or Prolonged	Gastrointestinal		(Rofecoxib)	PS		ORAL		
	Haemorrhage		Diclofenac Na	C				
	Oesophagitis							

Date:12/27/99ISR Number: 3442609-8Report Type:Expedited (15-DaCompany Report #99120466
Age: Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Dermatitis	Health	Enbrel 25 Mg	PS			SUBCUTANEOUS	25 MG, BIW,
Pyrexia	Professional					SUBCUTANEOUS	
Shock		Leflunomide	SS			UNKNOWN,	
						UNKNOWN,	
						UNKNOWN	
		Rofecoxib	SS			UNKNOWN,	
						UNKNOWN,	
						UNKNOWN	
		Prednisone	SS			UNKNOWN,	
						UNKNOWN,	
						UNKNOWN	

Date:12/28/99ISR Number: 3432348-1Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Celecoxib (Celebrex, Searle)	PS	Searle		16 WK	
	Genital Pruritus Female							
	Mouth Ulceration		Rofecoxib (Vioxx, Merck)	SS	Merck		2 WK	
	Oedema Genital							
	Rash Erythematous							
	Stomatitis							
	Vaginal Disorder							
	Vaginal Infection							
	Vaginal Pain							
	Vaginal Ulceration							
	Vulvovaginal Discomfort							

Date:12/28/99ISR Number: 3432497-8Report Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis	Health	Vioxx	PS		ORAL	25MG PO	
Initial or Prolonged		Professional	Benemid	C				
			Colchicine	C				
			Kcl	C				
			Atenolol	C				
			Lasix	C				
			Glucophage	C				
			Zaroxolyn	C				
			Neurintin	C				
			Onormovas	C				
			Tylenol	C				

Date:12/30/99ISR Number: 3434302-2Report Type:Expedited (15-DaCompany Report #WAES 99101950
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Level Changed	Health					MG/DAILY/PO	
	Suicidal Ideation	Professional	Ativan	C				
			Lithium Carbonate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/99ISR Number: 3434303-4Report Type:Expedited (15-DaCompany Report #WAES 99111520
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Distress Syndrome	Professional						
	Dyspnoea							
	Hypertensive Crisis							
	Pneumonia							
	Swelling							

Date:12/30/99ISR Number: 3434304-6Report Type:Expedited (15-DaCompany Report #WAES 99100613
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Palpitations	Health					MG/DAILY/PO	
Initial or Prolonged	Supraventricular	Professional	Zyrtec	C				
Disability	Tachycardia		Verapamil	C				
Other								

Date:12/30/99ISR Number: 3434308-3Report Type:Expedited (15-DaCompany Report #WAES 99060659
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Atrioventricular Block	Professional					MG/DAILY/PO	
	First Degree	Company	Coreg	C				
	Bursitis	Representative	Darvocet-N	C				
	Cardiac Murmur		Humulin	C				
	Confusional State		Lipitor	C				
	Dehydration		Macrodantin	C				
	Faecal Occult Blood		Neurontin	C				
	Gastric Ulcer Haemorrhage		Aspirin	C				
	Gastritis		Calcium Supplement	C				

	Hyperkalaemia	Digoxin	C
	Joint Effusion	Vitamins	C
	Metabolic Acidosis		
	Oliguria		
	Oxygen Saturation Decreased		
	Pco2 Decreased		
	Renal Failure		
	Renal Failure Chronic		
	Sedation		
	Ventricular Hypertrophy		
	Vomiting		

Date:12/30/99ISR Number: 3434309-5Report Type:Expedited (15-DaCompany Report #WAES 99111839
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Chest Pain							
	Dyspnoea							
	Muscular Weakness							
	Panic Attack							
	Thinking Abnormal							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/99ISR Number: 3434337-XReport Type:Expedited (15-DaCompany Report #WAES 99100961
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Diarrhoea	Professional					MG/DAILY/PO	
Initial or Prolonged	Diverticulum		Celebrex	C				
Other	Diverticulum Intestinal							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Melaena							
	Rectal Haemorrhage							
	Stomach Discomfort							

Date:12/30/99ISR Number: 3434339-3Report Type:Expedited (15-DaCompany Report #WAES 99110956
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Weight Increased	Professional					MG/DAILY/PO	
		Company Representative	Cozaar	C				
			Synthroid	C				
			Toprol Xl Tablets (Composition Unspecified)	C				
			Oxybutynin Chloride	C				

Date:12/30/99ISR Number: 3434341-1Report Type:Expedited (15-DaCompany Report #WAES 99101840
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastroenteritis	Professional					MG/DAILY/PO	

	Helicobacter	Company	Vitamin E Unk	SS		ORAL PO
	Gastrooesophageal Reflux	Representative	Aspirin 81 Mg	SS		ORAL DAILY/PO
	Disease		Ibuprofen 600 Mg	SS		ORAL 600 MG/TID/PO
	Haematemesis		Hydrodiuril	C		
	Haemoglobin Decreased		Lopressor	C		
	Nausea		Norvasc	C		
	Peptic Ulcer Reactivated		Zestril	C		
	Respiratory Rate Increased		Ascorbic Acid	C		
			Calcium Carbonate (+) Vitamin D	C		
			Vitamin D	C		

Date:12/30/99ISR Number: 3434344-7Report Type:Expedited (15-DaCompany Report #WAES 99121972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haemorrhage	Professional						
	Pancreatitis	Company Representative	Klonopin	C				
			Miacalcin	C				
			Os-Cal	C				
			Pancrease (Pancreatin)	C				
			Pepcid	C				
			Plaquenil	C				

			Zyprexa	C		
			Prednisone	C		

Date:12/30/99ISR Number: 3434345-9Report Type:Expedited (15-DaCompany Report #WAES 99128913
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Decreased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	4 DAY
	Nephritis Interstitial	Professional	Acetaminophen	C				
	Pyuria		Augmentin	C				
	Renal Failure Acute		Ceftriaxone	C				
	Urinary Retention		Cloxacillin	C				
			Cloxacillin	C				
			Penicillin Cryst	C				
			Tenormin	C				

Date:12/30/99ISR Number: 3434347-2Report Type:Expedited (15-DaCompany Report #WAES 99121796
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage		Covera-Hs	C				
			Hytrin	C				
			Mevacor	C				

Date:12/30/99ISR Number: 3434348-4Report Type:Expedited (15-DaCompany Report #WAES 99121859
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal	Professional						
	Haemorrhage	Company	Fosamax	C				
	Haematemesis	Representative	Lasix	C				

			Synthroid	C		

Date:12/30/99ISR Number: 3434350-2Report Type:Expedited (15-DaCompany Report #WAES 99121532
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal	Professional						
	Haemorrhage							
	Haematochezia							
	Haematocrit Decreased							
	Thrombocytopenia							

Date:12/30/99ISR Number: 3434351-4Report Type:Expedited (15-DaCompany Report #WAES 99100613
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Atrial Fibrillation
Hospitalization -	Electrocardiogram
Initial or Prolonged	Abnormal
Disability	Palpitations
Other	Sinus Bradycardia

		Supraventricular Extrasystoles					
		Supraventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO							
		Ventricular Extrasystoles	Health Professional	Zyrtec	C		
				Verapamil	C		

Date:12/30/99ISR Number: 3434352-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Oedema Peripheral		Vioxx 25mg Tablet			
		Weight Increased		(Msd)	PS	Msd	ORAL
25MG ONCE DAILY ORALLY							

Date:01/03/00ISR Number: 3435075-XReport Type:Expedited (15-DaCompany Report #WAES 99128913
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Creatinine Increased	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG PO	4 DAY						
		Nephritis Interstitial		Acetaminophen	C		
		Pyuria		Augmentin	C		
		Renal Failure Acute		Ceftriaxone	C		
		Urinary Casts		Cloxacillin	C		
		Urinary Retention		Penicillin Cryst	C		
				Tenormin	C		

Date:01/03/00ISR Number: 3435077-3Report Type:Expedited (15-DaCompany Report #WAES 99125075
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Faeces Discoloured	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
	Gastrointestinal Haemorrhage Haematemesis Melaena Vomiting		Acetaminophen (+) Dihydrocodeine Bitartrate Amiloride Hydrochloride (+)	C				
			Furosemide	C				
			Aspirin	C				

Date:01/03/00ISR Number: 3435081-5Report Type:Expedited (15-DaCompany Report #WAES 99121590
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Mass Hyperkalaemia Renal Impairment	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/00ISR Number: 3435087-6Report Type:Expedited (15-DaCompany Report #WAES 99125246
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Tab Vioxx					
	Duodenitis	Other	(Rofecoxib)	PS		ORAL	25 MG PO	
	Melaena		Acetaminophen	C				
	Oesophagitis		Atorvastatin	C				
	Pain		Lactulose	C				

Date:01/03/00ISR Number: 3435092-XReport Type:Expedited (15-DaCompany Report #WAES 99125245
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Foreign	Tab Vioxx					
	Malaise		(Rofecoxib)	PS		ORAL	12.5 MG PO	9 DAY
	Paralysis		Acetaminophen/Propoxyphene Hydrochloride	C				
			Albuterol	C				
			Danthron (+)					
			Poloxamer 188	C				
			Nitroglycerin	C				
			Perindopril	C				

Date:01/03/00ISR Number: 3435096-7Report Type:Expedited (15-DaCompany Report #WAES 99125650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Foreign	Tab Vioxx					
	Deep Vein Thrombosis		(Rofecoxib)	PS		ORAL	PO	
	Dizziness		Heparin	C				
	Loss Of Consciousness							
	Syncope							
	Vomiting							

Date:01/03/00ISR Number: 3435104-3Report Type:Expedited (15-DaCompany Report #WAES 99110339
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ DAILY/ PO	
	Cholecystitis							
	Cholelithiasis		Capoten	C				
	Chromaturia		Ecotrin	C				
	Hepatitis		Allopurinol	C				
	Jaundice		Digoxin	C				
	Liver Function Test Abnormal		Digoxin	C				
	Splenomegaly							
	Vomiting							

Date:01/03/00ISR Number: 3435108-0Report Type:Expedited (15-DaCompany Report #WAES 99125240
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG	2 DAY
			Carbamazepine	C				
			Diclofenac Sodium					

(+) Misoprostol C

Date:01/03/00ISR Number: 3435114-6Report Type:Expedited (15-DaCompany Report #WAES 99111830
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	International Normalised	Professional					MG/DAILY/PO	
Other	Ratio Increased	Other	Coumadin 2.5 Mg	SS				
			Coumadin 5 Mg	SS				

Date:01/03/00ISR Number: 3435117-1Report Type:Expedited (15-DaCompany Report #WAES 99111828
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Confusional State	Other					MG/DAILY/PO	
Initial or Prolonged	Convulsion		Inderal La	C				
	Drug Interaction		Ismo	C				
	Drug Withdrawal Syndrome		Kenalog	C				
	Headache		Lanoxin	C				
	Hypoaesthesia		Marcaine	C				
	Muscle Rigidity		Mirapex	C				
	Neuroleptic Malignant Syndrome		Valium [Therapy Unspecified]	C				
	Throat Tightness			C				
	Transient Ischaemic Attack		Vitamins	C				

Date:01/03/00ISR Number: 3435123-7Report Type:Expedited (15-DaCompany Report #WAES 99128248
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					

Initial or Prolonged	Haematoma	Health	(Rofecoxib)	PS		ORAL
25 MG 15 DAY						
		Professional	Tab Clopidogrel Bisulfate	SS		ORAL
75 MG						
			Amiloride Hydrochloride/Hctz	C		
			Eltroxin	C		
			Tramadol Hc1	C		

Date:01/03/00ISR Number: 3435128-6Report Type:Expedited (15-DaCompany Report #WAES 99125166
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx			
Initial or Prolonged	Congestive	Company	(Rofecoxib)	PS		ORAL
12.5 MG PO 139 DAY						
	Condition Aggravated	Representative	Albuterol Sulfate			
	Fluid Retention		(+) Ipratropium Bromid	C		
			Aluminum Hydroxide/Magnesium Carbonate	C		
			Becolmethasone Dipropionate	C		
			Calcium Carbonate	C		
			Dihydrocodeine	C		

				Furosemide	C		

Date:01/03/00ISR Number: 3435129-8Report Type:Expedited (15-DaCompany Report #WAES 99111717
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional						
MG/DAILY/PO	12	DAY						
		Company	Prilosec	C				
		Representative	Hyoscyamine	C				

Date:01/03/00ISR Number: 3435131-6Report Type:Expedited (15-DaCompany Report #WAES 99121108
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	25	
Initial or Prolonged	Duodenitis	Professional						
MG/DAILY/PO								
	Faecal Occult Blood	Company	Tab Vioxx 12.5 Mg	SS		ORAL	12.5	
	Positive	Representative						
MG/DAILY/PO								
	Faeces Discoloured		Lanoxin	C				
	Fatigue		Prinzide	C				
	Gastritis		Aspirin	C				
	Gastroenteritis		Atenolol	C				
	Helicobacter							
	Gastrointestinal							
	Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:01/03/00ISR Number: 3435133-XReport Type:Expedited (15-DaCompany Report #WAES 99120607
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	1 WK
Initial or Prolonged	Condition Aggravated Gastritis	Professional Company Representative	[Therapy Unspecified]	C				

Date:01/03/00ISR Number: 3435134-1Report Type:Expedited (15-DaCompany Report #WAES 99120922
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Congestive	Professional						
	Pulmonary Oedema		Fosamax	C				
			Hyzaar	C				
			Synthroid	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:01/03/00ISR Number: 3435140-7Report Type:Expedited (15-DaCompany Report #WAES 99122019
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Pain Upper Burning Sensation

		Diarrhoea					
		Dry Throat					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PO							
		Gastrointestinal Disorder		Imuran	C		
		Headache		Methotrexate	C		
		Oral Pain		Prednisone	C		
		Upper Respiratory Tract Infection					

Date:01/03/00ISR Number: 3435142-0Report Type:Expedited (15-DaCompany Report #WAES 99129773
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Pain	Foreign	Tab Vioxx			
Initial or Prolonged	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL
PO						
	Haemorrhage	Professional	Fosamax	C		
			Clonazepam	C		

Date:01/03/00ISR Number: 3435143-2Report Type:Expedited (15-DaCompany Report #WAES 99125020
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Arthralgia	Foreign	Tab Vioxx			
	Benign Prostatic	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO;						
	Hyperplasia	Professional				
25 MG						
	Blood Pressure Increased		Bisoprolol Fumarate	C		
	Condition Aggravated		Budesonide	C		
	Spinal Cord Compression		D-Pseudoephedrine			
	Urinary Tract Disorder		Hcl	C		
			Tamsulosin	C		

Date:01/03/00ISR Number: 3435145-6Report Type:Expedited (15-DaCompany Report #WAES 99125212
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign	Tab Vioxx					
	Fluid Retention	Company	(Rofecoxib)	PS		ORAL	25 MG	
	Left Ventricular Failure	Representative	Aspirin	C				
			Irbesartan	C				

Date:01/03/00ISR Number: 3435146-8Report Type:Expedited (15-DaCompany Report #WAES 99125210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Foreign	Tab Vioxx					
	Left Ventricular Failure	Company	(Rofecoxib)	PS		ORAL	25 MG	
	Myocardial Infarction	Representative	Acetaminophen/Propoxyphene Hydrochloride	C				

Date:01/03/00ISR Number: 3435147-XReport Type:Expedited (15-DaCompany Report #WAES 99125209
Age:61 YR Gender:Male I/FU:I

Outcome	PT
Death	Coronary Artery Disease
	Left Ventricular Failure

Myocardial Ischaemia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG PO	
			Erythromycin	C				
			Iodine	C				
			Nizatidine	C				

Date:01/03/00ISR Number: 3435148-1Report Type:Expedited (15-DaCompany Report #WAES 99125241
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Ulceration	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO; 25 MG	54 DAY
	Oral Candidiasis							
	Polyarthritis							
	Stevens-Johnson Syndrome		Progesterone	C				
	Stomatitis							

Date:01/03/00ISR Number: 3435150-XReport Type:Expedited (15-DaCompany Report #WAES 99128572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				
	Stevens-Johnson Syndrome		Allopurinol	C				
			Furosemide	C				

Date:01/03/00ISR Number: 3435154-7Report Type:Expedited (15-DaCompany Report #WAES 99110342
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

	Congestive	Professional	Coumadin	C
	Condition Aggravated	Company	Zocor	C
	Dyspnoea	Representative	Atenolol	C
	Oedema Peripheral		Estradiol	C
	Weight Increased		Medroxyprogesterone	C
			Ditropan	C

Date:01/03/00ISR Number: 3435157-2Report Type:Expedited (15-DaCompany Report #WAES 99111403
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemoglobin Decreased	Professional						

Date:01/03/00ISR Number: 3435161-4Report Type:Expedited (15-DaCompany Report #WAES 99120933
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agranulocytosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
Initial or Prolonged	Differential White Blood	Professional	Azulfidine 500mg	SS		ORAL	500MG BID PO;	
	Cell Count Abnormal						1000	
	Haematocrit Decreased						MG/BID/PO	
	Nasopharyngitis		Cardizem Cd	C				

Hydrodiuril	C
Micro K	C

Date:01/03/00ISR Number: 3435166-3Report Type:Expedited (15-DaCompany Report #WAES 99121135
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY	
	Congestive	Professional					PO	
	Condition Aggravated	Company						
	Pulmonary Oedema	Representative						
	Weight Increased							

Date:01/03/00ISR Number: 3435170-5Report Type:Expedited (15-DaCompany Report #WAES 99120889
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Increased	Professional						
Initial or Prolonged	Blood Potassium Increased	Company						
Other	Blood Urea Increased	Representative						
	Haemodialysis							
	Nephrolithiasis							
	Renal Failure Acute							

Date:01/03/00ISR Number: 3435173-0Report Type:Expedited (15-DaCompany Report #WAES 99121808
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY	
Initial or Prolonged	Gastroenteritis	Professional					PO; 25	
	Helicobacter						MG/BID/PO	

	Gastrointestinal Haemorrhage International Normalised Ratio Increased	Coumadin	C
		Lozol	C
		Verapamil	C

Date:01/03/00ISR Number: 3435176-6Report Type:Expedited (15-DaCompany Report #WAES 99121828
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY	
Hospitalization -	Haemorrhage	Professional				PO		
Initial or Prolonged	Pneumonia		Therpay Unspecified	C				
Other								

Date:01/03/00ISR Number: 3435179-1Report Type:Expedited (15-DaCompany Report #WAES 99121933
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pruritus	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Renal Impairment	Professional	Therapy Unspecified	C				
Initial or Prolonged		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/00ISR Number: 3435181-XReport Type:Expedited (15-DaCompany Report #WAES 99121992
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Congestive	Professional						
Initial or Prolonged	Hypoxia							
	Muscle Contractions Involuntary							
	Oedema							

Date:01/03/00ISR Number: 3435183-3Report Type:Expedited (15-DaCompany Report #WAES 99121676
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vasculitis	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:01/03/00ISR Number: 3435186-9Report Type:Expedited (15-DaCompany Report #WAES 99121450
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Attention	Professional						
	Deficit/Hyperactivity		Tab Vioxx 25 Mg	SS		ORAL	500 MG/1X/PO	
	Disorder		Tab Parnate	SS		ORAL	10 TABLET/1X/PO	
	Confusional State							
	Hepatic Function Abnormal		Tab Seroquel 200 Mg	SS		ORAL	4000 MG/1X/PO	

	Intentional Misuse		Tab Propecia 1 Mg	SS		ORAL
20 MG/1X/PO						
	Pneumonia		Tab Propecia 1 Mg	SS		ORAL
1 MG/DAILY/PO						
	Suicide Attempt					
	Thrombocythaemia					

Date:01/03/00ISR Number: 3435189-4Report Type:Expedited (15-DaCompany Report #WAES 99129761
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Thyroid Stimulating	Foreign	Tab Vioxx			
	Hormone Increased	Health	(Rofecoxib)	PS		ORAL
25 MG, PO						
	Convulsion	Professional	Thyroxine	C		
	Dizziness					
	Hypertension					
	Palpitations					

Date:01/03/00ISR Number: 3435194-8Report Type:Expedited (15-DaCompany Report #WAES 99105179
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Other	Alcohol Poisoning
	Analgesic Drug Level
	Above Therapeutic
	Blood Alcohol Increased
	Circulatory Collapse
	Condition Aggravated
	Drug Level Above
	Therapeutic

		Drug Toxicity Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis Infectious Mononucleosis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG, PO							
		Lower Respiratory Tract Infection Overdose Pharyngitis	Professional	Acetaminophen/Propox yphene Hydrochloride Doxycycline Erythromycin Estradiol (+) Norethindrone Folic Acid Lacidipine Lisinopril	 C C C C C C C		

Date:01/03/00ISR Number: 3435197-3Report Type:Expedited (15-DaCompany Report #WAES 99121576
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Increased	Professional				
MG/DAILY/PO						
Other	Dyspnoea Myocardial Infarction Pulmonary Oedema Renal Impairment	Company Representative	Cozaar	C		

Date:01/03/00ISR Number: 3435198-5Report Type:Expedited (15-DaCompany Report #WAES 99121450
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Agitation	Health	Tab Vioxx 25 Mg	PS		ORAL
500 MG/1X/PO						
Initial or Prolonged	Attention	Professional	Tab Parnate	SS		ORAL
10						
	Deficit/Hyperactivity					
TABLET/1X/PO						

	Disorder		Tab Seroquel 200 Mg	SS		ORAL
4000 MG/1X/PO						
	Confusional State					
	Intentional Misuse					

Date:01/03/00ISR Number: 3435199-7Report Type:Expedited (15-DaCompany Report #WAES 99101240
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Bradycardia	Health				
MG/DAILY/PO						
	Condition Aggravated	Professional	Estratest	C		
	Coordination Abnormal		Klonopin	C		
	Dizziness		Prozac	C		
	Fall		Zanaflex	C		
	Heart Rate Decreased		Baclofen	C		
	Multiple Sclerosis		Interferon-(Beta)	C		

Date:01/03/00ISR Number: 3435200-0Report Type:Expedited (15-DaCompany Report #WAES 99100681
Age:58 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Respiratory	Consumer	Vioxx 1	PS		ORAL	UNK/UNK/PO	
	Distress Syndrome	Health	[Therapy					
	Anaphylactic Shock	Professional	Unspecified]	C				
	Coagulopathy	Company						
	Condition Aggravated	Representative						
	Dermatitis							
	Dyspnoea							
	Myocardial Infarction							
	Pulmonary Embolism							
	Syncope							

Date:01/03/00ISR Number: 3435202-4Report Type:Expedited (15-DaCompany Report #WAES 99120489
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Blood Creatine Increased	Professional					MG/DAILY/PO	
	Blood Potassium Decreased	Company	Pravachol	C				
	Blood Urea Increased	Representative	Prilosec	C				
	Dialysis		[Therapy					
	Haemoglobin Decreased		Unspecified]	C				
	Hypertension							
	Malaise							
	Pco2 Decreased							
	Renal Failure Acute							

Date:01/03/00ISR Number: 3435204-8Report Type:Expedited (15-DaCompany Report #WAES 99120824
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	

Initial or Prolonged	Gastric Ulcer Haemorrhage	Company	A.S.A.	C
Other	Gastrointestinal	Representative	Avapro	C
	Haemorrhage		Betapace	C
			Imdur	C
			Lasix	C
			Iron (Unspecified)	C
			Potassium Supplement	
			(Compositio	C

Date:01/03/00ISR Number: 3435206-1Report Type:Expedited (15-DaCompany Report #WAES 99125743
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx (Rofecoxib)	PS		ORAL	UNK	PO
Initial or Prolonged	Tachycardia	Health Professional Other	...	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/00ISR Number: 3435208-5Report Type:Expedited (15-DaCompany Report #WAES 99125731
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	4 DAY
	Fall	Health						
	Haematemesis	Professional						
	Haematochezia	Other						
	Vomiting							

Date:01/03/00ISR Number: 3435210-3Report Type:Expedited (15-DaCompany Report #WAES 99125217
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	11 DAY
	Haemorrhage	Other						
	Haemoglobin Decreased		Bumetanide	C				
			Digoxin	C				
			Perindopril	C				
			Sertraline	C				
			Tramadol	C				

Date:01/04/00ISR Number: 3435293-0Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension	Health	Vioxx 12.5mg	PS		ORAL	1 QD ORAL	
		Professional	Atenol	C				
			Maxzide	C				

Date:01/05/00ISR Number: 3438027-9Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Vioxx-12.5mg	PS		ORAL	PO -BID	

Date:01/06/00ISR Number: 3439199-2Report Type:Expedited (15-DaCompany Report #WAES 99122034
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Cytotec	C				
			Voltaren	C				

Date:01/07/00ISR Number: 3439385-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Rofecoxib (Vioxx)	PS		ORAL	25MG DAILY PO	
	Diarrhoea							
	Dyspepsia							
	Flatulence							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/00ISR Number: 3440237-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Health Professional	Warfarin 6mg Qd 6mg Po Qd Aortic Valve Repl	PS				
	Arthropathy		Vioxx 25mg Qd 25 Mg Po Qd Arthritis/Gout					
	Difficulty In Walking		Pain In Foot	SS				
	Ecchymosis		Hctz Vasotec					
	Gout		Cardizem Tylenol	C				
	Haemorrhage							
	Joint Swelling							
	Oedema Peripheral							
	Pain							
	Pulse Pressure Decreased							

Date:01/10/00ISR Number: 3441620-0Report Type:Expedited (15-DaCompany Report #WAES 99129773
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Duodenal Ulcer		Fosamax	C				
	Haemorrhage		Clonazepam	C				

Date:01/10/00ISR Number: 3441621-2Report Type:Expedited (15-DaCompany Report #WAES 99120475
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
			Propulsid	C				

Date:01/10/00ISR Number: 3441634-0Report Type:Expedited (15-DaCompany Report #WAES 99125217
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	11 DAY
	Haemoglobin Decreased		Bumetanide	C				
			Digoxin	C				
			Perindopril	C				
			Sertraline	C				
			Tramadol	C				

Date:01/10/00ISR Number: 3441822-3Report Type:Expedited (15-DaCompany Report #WAES 99122268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, PO	
	Haematochezia		Percocet	C				
	Nausea		Therapy Unspecified	C				
	Rectal Haemorrhage							
	Vomiting							

Date:01/10/00ISR Number: 3441827-2Report Type:Expedited (15-DaCompany Report #WAES 99122118
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Methotrexate	C				

Date:01/10/00ISR Number: 3441847-8Report Type:Expedited (15-DaCompany Report #WAES 00010094
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bowel Sounds Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Culture Positive	Professional					MG/DAILY/PO	
	Faecal Occult Blood	Company	Celebrex	C				
	Positive	Representative	Darvocet-N	C				
	Faeces Discoloured		Tylenol	C				
	Gastric Ulcer Haemorrhage		Ultram	C				
	Gastritis		Glucosamine	C				
	Gastroenteritis		Lorazepam	C				
	Helicobacter							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							
	Supraventricular							
	Extrasystoles							
	Upper Gastrointestinal							
	Haemorrhage							

Date:01/10/00ISR Number: 3441964-2Report Type:Expedited (15-DaCompany Report #WAES 99125228
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign	Tab Vioxx					
	Duodenitis	Other	(Rofecoxib)	PS		ORAL	12.5 MG, PO	26 DAY
	Gastrointestinal		Prinivil	C				
	Haemorrhage		Zocor	C				

	Haematemesis	Acetaminphen/Propoxy	
	Haemoglobin Decreased	phene Hydrochloride	C
	Melaena	Aspirin	C
		Bumetamide	C
		Diclofenac	C
		Diltiazem D-Cis Form	
		Hcl	C
		Spironolactone	C
		Tramadol	C

Date:01/10/00ISR Number: 3441970-8Report Type:Expedited (15-DaCompany Report #WAES 99111598
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY,PO	
Initial or Prolonged	Haemorrhage	Company	Imdur	C				
	Haematocrit Decreased	Representative	Norvasc	C				
	Haemoglobin Decreased		Tylenol	C				
	Melaena		Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/00ISR Number: 3441972-1Report Type:Expedited (15-DaCompany Report #WAES 00010028
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
Initial or Prolonged	Haematoma	Professional					DAILY, PO	
	International Normalised	Company	Coumadin	C				
	Ratio Increased	Representative	Therapy Unspecified	C				
	Prothrombin Time							
	Prolonged							

Date:01/10/00ISR Number: 3442237-4Report Type:Expedited (15-DaCompany Report #WAES 99121972
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Anaemia	Professional					MG/DAILY/PO	
Initial or Prolonged	Barrett'S Oesophagus	Company	Klonopin	C				
	Gastric Haemorrhage	Representative	Miacalcin	C				
	Gastric Ulcer		Os-Cal	C				
	Gastrointestinal		Pancrease					
	Haemorrhage		(Pancreatin)	C				
	Gastrooesophageal Reflux		Pepcid	C				
	Disease		Plaquenil	C				
	Haematemesis		Zyprexa	C				
	Lipase Increased		Prednisone	C				
	Malaise							
	Mallory-Weiss Syndrome							
	Melaena							
	Nausea							
	Oesophageal Haemorrhage							
	Oesophageal Ulcer							
	Oesophagitis							
	Pancreatitis							
	Rash Erythematous							

Date:01/10/00ISR Number: 3442266-0Report Type:Expedited (15-DaCompany Report #WAES 99129761
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Blood Thyroid Stimulating Hormone Increased Convulsion Dizziness Palpitations	Foreign Health Professional	Tab Vioxx (Rofecoxib) Thyroxine	PS C		ORAL	25 MG	

Date:01/10/00ISR Number: 3442268-4Report Type:Expedited (15-DaCompany Report #WAES 99125210
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Left Ventricular Failure Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib) Acetaminophen / Propoxyphene Hydrochloride	PS C		ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/00ISR Number: 3442270-2Report Type:Expedited (15-DaCompany Report #WAES 99125650
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Deep Vein Thrombosis Dizziness Fall Loss Of Consciousness Syncope Vomiting	Foreign Health Professional	Tab Vioxx (Rofecoxib) Heparin	PS C		ORAL		

Date:01/10/00ISR Number: 3442275-1Report Type:Expedited (15-DaCompany Report #WAES 99125245
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Malaise Paralysis	Foreign Health Professional	Tab Vioxx (Rofecoxib) Acetaminophen/Propoxyphene Hydrochloride Albuterol Danthron (+) Poloxamer 188 Nitroglycerin Perindopril	PS C C C C C		ORAL	12.5 MG	9 DAY

Date:01/10/00ISR Number: 3446203-4Report Type:Expedited (15-DaCompany Report #WAES 00010945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health Professional	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Company Representative	Ambien Cardizem Cd Coumadin Lasix Mavik	C C C C C				

			Plavix	C		
			Ultram	C		

Date:01/11/00ISR Number: 3442554-8Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged	Haemorrhage							

Date:01/12/00ISR Number: 3443338-7Report Type:Expedited (15-DaCompany Report #WAES 00010043
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Pruritus	Professional					MG/DAILY/PO	
	Urticaria	Company	Lortab	C				
		Representative	Aspirin	C				

Date:01/12/00ISR Number: 3443339-9Report Type:Expedited (15-DaCompany Report #WAES 99110797
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haematocrit Decreased	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Cardizem Cd	C				
Other		Representative	Coumadin	C				
			Lasix	C				
			Tylenol	C				
			Potassium Chloride	C				

Date:01/12/00ISR Number: 3443367-3Report Type:Expedited (15-DaCompany Report #WAES 00010114
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Abdominal Pain						MG/DAILY/PO	
	Colitis		Antimicrobial					
	Diverticulitis		Therapy	C				
	Influenza Like Illness							
	Malaise							
	Oral Intake Reduced							

Date:01/12/00ISR Number: 3443620-3Report Type:Expedited (15-DaCompany Report #WAES 00010371
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Dyspnoea	Professional					MG/DAILY/PO	
Initial or Prolonged	Muscular Weakness	Company						
Disability		Representative						
Other								

Date:01/12/00ISR Number: 3443622-7Report Type:Expedited (15-DaCompany Report #WAES 00018501
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Diarrhoea	Consumer	(Rofecoxib)	PS		ORAL	PO	
	Suicidal Ideation							

Date:01/13/00ISR Number: 3443961-XReport Type:Periodic Company Report #990929-SK594
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Celebrex	PS				
Hospitalization -	Haemorrhage	Professional	Vioxx	SS		ORAL	12.500 MG QD	
Initial or Prolonged							PO	
Other			Hypotensives	C				

Date:01/13/00ISR Number: 3444116-5Report Type:Periodic Company Report #991029-SK187
Age:83 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Celebrex	PS		ORAL	UNKNOWN PO	
	Gastric Ulcer Haemorrhage		Rofecoxib	SS		ORAL	25.000 MG QD	
							PO	
			Anti-Parkinson Drugs	C				
			Selegiline	C				
			Paroxetine	C				
			Muscle Relaxants	C				

Date:01/14/00ISR Number: 3444330-9Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	3 DAY
	Condition Aggravated	Professional	Prinivil	C				
	Hepatic Failure		Pepcid	C				
	Oesophageal Varices		Imipram	C				
	Haemorrhage							

Date:01/14/00ISR Number: 3444497-2Report Type:Expedited (15-DaCompany Report #WAES 99081227
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lip Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Mouth Ulceration	Health	Aerobid	C				
	Stomatitis	Professional	Coreg	C				
			Lasix	C				
			Serevent	C				
			Clonidine	C				

Date:01/14/00ISR Number: 3444499-6Report Type:Expedited (15-DaCompany Report #WAES 99101748
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Septal Defect	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
Hospitalization -	Cerebral Artery Embolism	Professional	Celebrex Unk	SS		ORAL	200MG BID PO	
Initial or Prolonged	Cerebrovascular Accident	Other	Caltrate	C				
Disability	Deep Vein Thrombosis		Dyazide	C				
Other	Hemiparesis		Miacalcin	C				
	Rash Maculo-Papular		Tylenol Extra Strength	C				

Date:01/14/00ISR Number: 3444539-4Report Type:Expedited (15-DaCompany Report #WAES 00010168
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Oedema	Professional					MG/DAILY/PO	
		Company Representative	Atenolol Msd	C				
			Isordil	C				
			Norvasc	C				
			Zestril	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/00ISR Number: 3444540-0Report Type:Expedited (15-DaCompany Report #WAES 00010300
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Faecal Occult Blood	Professional					MG/DAILY/PO	
	Positive	Company	Ms Contin	C				
	Gastritis	Representative	Prilosec	C				
	Vomiting		Vicodin Tablets	C				

Date:01/14/00ISR Number: 3444544-8Report Type:Expedited (15-DaCompany Report #WAES 00010306
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage						MG/DAILY/PO	
	Rectal Haemorrhage							

Date:01/14/00ISR Number: 3444547-3Report Type:Expedited (15-DaCompany Report #WAES 00010332
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Congestive		[Therapy					
	Hepatic Function Abnormal		Unspecified]	C				
	Liver Function Test		[Therapy					
	Abnormal		Unspecified]	C				

Date:01/14/00ISR Number: 3444634-XReport Type:Expedited (15-DaCompany Report #WAES 99122121
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Conjunctival Haemorrhage	Health	Tab Vioxx 25 Mg	PS			ORAL
25							
	Diarrhoea	Professional					
MG/DAILY/PO							
	Dizziness	Company	Coumadin	C			
	International Normalised Ratio Increased	Representative					
	Prothrombin Time Ratio Increased						

Date:01/14/00ISR Number: 3444636-3Report Type:Expedited (15-DaCompany Report #WAES 99120293
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Headache	Health	Tab Vioxx 25 Mg	PS		ORAL
50						
	Hypertension	Professional				
MG/DAILY/PO						
			Toprol Xl Tablets	C		

Date:01/14/00ISR Number: 3444638-7Report Type:Expedited (15-DaCompany Report #WAES 00018250
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG PO 4 DAY						
	Dyspnoea		Vasotec	C		
	Hypotension		Hygroton	C		
	Urticaria					

Date:01/14/00ISR Number: 3444848-9Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
Hospitalization -	Increased	Professional					DAILY/PO	
Initial or Prolonged	Blood Glucose Increased	Company	Celebrex	C				
Disability	Blood Thyroid Stimulating	Representative	Ecotrin	C				
	Hormone Increased		Hydrodiuril	C				
	Blood Urea Increased		Macrobid	C				
	Dehydration		Tylenol	C				
	Dyspnoea							
	Hypertension							
	Hypothyroidism							
	Nephritis Interstitial							
	Nephrotic Syndrome							
	Oedema							
	Oedema Peripheral							
	Pleural Effusion							
	Protein Total Increased							
	Proteinuria							
	Renal Failure Acute							
	Weight Increased							

Date:01/14/00ISR Number: 3445523-7Report Type:Expedited (15-DaCompany Report #99090266
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Consumer	Enbrel 25 Mg	PS				
SUBCUTANEOUS	25 MG, BIW,							
Hospitalization -	Joint Stiffness	Health						
SUBCUTANEOUS								
Initial or Prolonged		Professional	Rofecoxib	SS		ORAL	25 MG, QD,	
PER ORAL								
			Gold	C				

Date:01/18/00ISR Number: 3444757-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage		Vioxx 12.5mg Bid	PS		ORAL	12.5MG PO BID	
Initial or Prolonged	Gastric Ulcer							

Date:01/18/00ISR Number: 3444864-7Report Type:Expedited (15-DaCompany Report #WAES 00010168
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Oedema	Professional					PO	
		Company	Atenolol Msd	C				
		Representative	Isordil	C				
			Norvasc	C				
			Zestril	C				
			Diazepam	C				

Date:01/18/00ISR Number: 3444881-7Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG PO DAILY	
Initial or Prolonged	Oral Mucosal Petechiae							
	Petechiae							

Date:01/18/00ISR Number: 3445109-4Report Type:Expedited (15-DaCompany Report #00GB-10015
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Voltarol Unknown					
	Duodenal Ulcer	Health	(Diclofenac Sodium)	PS		ORAL	DAILY, ORAL	
	Haemorrhage	Professional	Vioxx (Rofecoxib)	SS		ORAL	12.5 MG,	
		Other					DAILY, ORAL	14 DAY
			Digoxin	C				
			Atenolol	C				
			Warfarin	C				
			Frusemide	C				

Date:01/18/00ISR Number: 3445115-XReport Type:Expedited (15-DaCompany Report #WAES 99102009
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Neuropathy Peripheral	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Paraesthesia	Professional					MG/DAILY/PO	
		Company Representative	Levothroid	C				

Date:01/18/00ISR Number: 3445116-1Report Type:Expedited (15-DaCompany Report #WAES 99120416
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
Initial or Prolonged	Dizziness	Professional	Prinivil	C				
Other	Fatigue		Estrogenic					
	Headache		Preparations	C				
	Heart Rate Decreased							
	Heart Rate Irregular							
	Palpitations							
	Ventricular Extrasystoles							

Date:01/18/00ISR Number: 3445117-3Report Type:Expedited (15-DaCompany Report #WAES 99121138
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Hospitalization -	Confusional State	Professional						
Initial or Prolonged	Drug Ineffective	Company	Celebrex	C				
Disability	Duodenal Ulcer	Representative	Glucophage	C				
	Haemorrhage		Lipitor	C				
	Gastroenteritis		Norvasc	C				
	Helicobacter		Zoloft	C				
	Haemoglobin Decreased		Aspirin	C				
	Lethargy							
	Renal Impairment							

Date:01/18/00ISR Number: 3445118-5Report Type:Expedited (15-DaCompany Report #WAES 99111940
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL
	Cholelithiasis		Avandia	C		
	Jaundice		Coumadin	C		
	Liver Function Test Abnormal		Hydrodiuril	C		
	Pruritus		Neurontin	C		
			Novolin	C		
			Prozac	C		
			Synthroid	C		
			Albuterol	C		
			Quinine	C		
			[Therapy Unspecified]	C		

Date:01/18/00ISR Number: 3445120-3Report Type:Expedited (15-DaCompany Report #WAES 99111771
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
	Congestive Condition Aggravated		Amaryl	C		
	Fluid Retention		Coumadin	C		
			Ditropan	C		
			Lasix	C		
			Neurontin	C		
			Prandin	C		
			Prevacid	C		
			Propulsid	C		
			Prozac	C		
			Allopurinol	C		
			Colchicine	C		
			Estrogenic Preparations	C		
			Metoprolol	C		

Date:01/19/00ISR Number: 3444960-4Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nausea		Vioxx	PS		ORAL	2.5MG QD PO	
Initial or Prolonged	Pruritus							

Date:01/19/00ISR Number: 3445182-3Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx 25 Mg Qd	PS			25MG QD	
Initial or Prolonged	Haemoglobin Decreased							

Date:01/19/00ISR Number: 3445612-7Report Type:Expedited (15-DaCompany Report #WAES 00010651
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Hospitalization -	Renal Impairment	Health
Initial or Prolonged		Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	

Date:01/19/00ISR Number: 3445613-9Report Type:Expedited (15-DaCompany Report #WAES 00010659
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
	Migraine						PO	
	Thinking Abnormal		Tegretol	C				
			Vicodin Tablets	C				

Date:01/19/00ISR Number: 3445614-0Report Type:Expedited (15-DaCompany Report #WAES 00010398
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Amylase Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Lipase Increased	Professional					PO	
	Pancreatitis		Accolate	C				
			Ativan	C				
			Hydrodiuril	C				
			Miacalcin	C				
			Premarin	C				
			Rocephin	C				
			Serevent	C				
			Solu-Medrol	C				
			Univasc	C				
			Guaifenesin	C				

Date:01/19/00ISR Number: 3445615-2Report Type:Expedited (15-DaCompany Report #WAES 00010676
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Rupture	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged	Gastrointestinal						PO	
	Haemorrhage		Allegra	C				
	Haematochezia		Alphagan	C				
			Inflamase	C				
			Trusopt	C				
			Vasotec	C				
			Xalatan	C				
			Vitamins	C				

Date:01/20/00ISR Number: 3445437-2Report Type:Expedited (15-DaCompany Report #WAES 00010827
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
Hospitalization -							DAILY/ PO	
Initial or Prolonged			Trusopt	C				
			Vasotec	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/00ISR Number: 3445448-7Report Type:Expedited (15-DaCompany Report #WAES 00010816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	108 DAY

Date:01/20/00ISR Number: 3445450-5Report Type:Expedited (15-DaCompany Report #WAES 00010789
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/ PO	

Date:01/20/00ISR Number: 3445452-9Report Type:Expedited (15-DaCompany Report #WAES 00010635
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis Gastrointestinal Haemorrhage Haematemesis Influenza Like Illness	Consumer	Tab Vioxx 12.5 Mg Lipitor Vicodin Clonidine Theophylline	PS C C C C		ORAL	12.5 - 25 MG / DAILY/ PO	

Date:01/20/00ISR Number: 3445458-XReport Type:Expedited (15-DaCompany Report #WAES 00015005
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	108 DAY

	Haemorrhage		Aspirin	SS		ORAL 75 MG PO
	Haematemesis		Acetaminophen	C		
	Melaena		Amiloride Hydrochloride (+)			
			Furosemide	C		
			Digoxin	C		
			Lithium Co3	C		
			Phenelzine	C		
			Trimethoprim	C		

Date:01/20/00ISR Number: 3445581-XReport Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged (RECENTLY TAKEN!)	Abdominal Pain Upper Vomiting		Vioxx 12.5 Mg (Merck)	PS	Merck	ORAL	1 QD PO	
			Hctz	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/00ISR Number: 3445687-5Report Type:Expedited (15-DaCompany Report #WAES 00018518
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	1 WK

Date:01/20/00ISR Number: 3445689-9Report Type:Expedited (15-DaCompany Report #WAES 00010120
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Duodenal Ulcer		Lipitor	C				
	Haemorrhage		Miacalcin	C				
	Hyperhidrosis		Norvasc	C				
	Melaena		Tylenol	C				
			Vanceril	C				

Date:01/20/00ISR Number: 3445691-7Report Type:Expedited (15-DaCompany Report #WAES 99111828
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG DAILY	
Hospitalization - Initial or Prolonged	Confusional State	Other					PO	
	Convulsion		Inj Kenalog 10mg	SS		INTRAVENOUS	10MG DAILY	
	Drug Interaction					INJ		
	Drug Withdrawal Syndrome		Inj [Therapy Unspecified] Unk	SS		INTRAVENOUS	INJ	
	Headache							
	Hypoaesthesia		Inj Marcaine Unk	SS		INTRAVENOUS	INJ	
	Neuroleptic Malignant		Inj [Composition					

	Syndrome		Unspecifed] Unk	SS		
INTRAVENOUS INJ						
	Transient Ischaemic		Mirapex Unk	SS		ORAL
0.25MG TID PO						
	Attack		Inderal La	C		
			Lanoxin	C		
			Valium	C		
			Vitamins	C		
			Ismo	C		

Date:01/20/00ISR Number: 3446224-1Report Type:Expedited (15-DaCompany Report #WAES 00010028
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coma	Health	Vioxx	PS		ORAL
12.5 MG						
Initial or Prolonged	Drug Interaction	Professional				
/DAILY/PO						
	Empyema	Company	Coumadin	SS		
4 MG/DAILY/						
	International Normalised	Representative	Synthroid [Therapy			
	Ratio Increased		Unspecified]	C		
	Pleuritic Pain					
	Pneumonia					
	Prothrombin Time					
	Prolonged					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/00ISR Number: 3446237-XReport Type:Expedited (15-DaCompany Report #WAES 00010300
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Faecal Occult Blood	Professional					MG/DAILY/PO	
Disability	Positive	Company	Ativan	C				
Other	Flatulence	Representative	Cardizem	C				
	Gastritis		Fioricet Tablets	C				
	Vomiting		Lanoxin	C				
			Ms Contin	C				
			Prilosec	C				
			Vicodin Tablets	C				

Date:01/20/00ISR Number: 3446242-3Report Type:Expedited (15-DaCompany Report #WAES 99120216
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Health	Vioxx 25 Mg	PS		ORAL	50	
Life-Threatening	Blood Pressure Increased	Professional					MG/DAILY/PO	
Hospitalization -	Cerebrovascular Accident		Elavil	C				
Initial or Prolonged	Coma		Lioresal	C				
Disability	Haemorrhage Intracranial		Lovenox	C				
	Haemorrhagic Stroke		Lovenox	C				
	International Normalised		Pepcid	C				
	Ratio Increased		Peri-Colace	C				
	Mydriasis		Toradol	C				
	Pseudomonas Infection		Toradol	C				
			Zoloft	C				
			Ceftazidime	C				
			Gentamicin	C				
			Warfarin	C				
			Warfarin	C				

Date:01/21/00ISR Number: 3445172-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx 12.5 Mg Tabs	PS				

Date:01/21/00ISR Number: 3445238-5Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis	Health	Lopid 600mg	PS		ORAL	600MG, BID,PO	2 MON
Hospitalization -	Drug Interaction	Professional	Vioxx 25mg	SS		ORAL	25MG, QD,PO	2 WK
Initial or Prolonged	Renal Failure		Halcion	C				
Required	Rhabdomyolysis		Percocet	C				
Intervention to			Nitrobid	C				
Prevent Permanent			Ecotrin	C				
Impairment/Damage			Combivent	C				
			Theo-Dur	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/00ISR Number: 3445241-5Report Type:Direct Company Report #
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Fluid Retention	Health Professional	Vioxx Prednisone	PS C		ORAL	PO	7 DAY

Date:01/21/00ISR Number: 3445254-3Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cough Epistaxis Haematemesis Hypertension		Vioxx 12.5mg (Merck)	PS	Merck	ORAL	12.5MG PO QD	

Date:01/24/00ISR Number: 3446141-7Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health Professional	Vioxx 25 Mg	PS		ORAL	25MG QAM, PO	

Date:01/24/00ISR Number: 3446880-8Report Type:Expedited (15-DaCompany Report #WAES 99127511
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Skin Necrosis Vasculitis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	
		Health Professional	Tab Placebo	SS		ORAL	2 TABLET PO	

		Professional	Tab Placebo	SS		ORAL
1 TABLET PO						
			Captopril	C		
			Digoxin	C		
			Folic Acid	C		
			Molsidomine	C		
			Prednisolone	C		

Date:01/24/00ISR Number: 3446997-8Report Type:Expedited (15-DaCompany Report #WAES 00011108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL
BID/PO 4 DAY						
Initial or Prolonged	Ulcer Haemorrhage					

Date:01/24/00ISR Number: 3447025-0Report Type:Expedited (15-DaCompany Report #WAES 99101434
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL
12.5						
	Bradycardia	Professional				
MG/DAILY/PO 10 DAY						
	Chest Pain		Premarin	C		
	Fatigue					
	Fluid Retention					
	Hypotension					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/00ISR Number: 3447027-4Report Type:Expedited (15-DaCompany Report #WAES 00010660
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Crohn'S Disease		Estrace	C				
	Inflammatory Bowel Disease							
	Intestinal Ischaemia							
	Mesenteric Occlusion							
	Pain							
	Vomiting							

Date:01/24/00ISR Number: 3447222-4Report Type:Expedited (15-DaCompany Report #WAES 99110747
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Initial or Prolonged	Atrial Fibrillation	Professional					/ PO	
	Blood Creatinine Increased	Company Representative	Ativan	C				
	Blood Urea Increased		Atrovent	C				
	Bronchitis		Coumadin	C				
	Cardiac Failure		Darvocet-N	C				
	Congestive		Lasix	C				
	Condition Aggravated		Nasocort	C				
	Diarrhoea		Prinivil	C				
	Dyspnoea Exertional		Ventolin	C				
	Dysuria							
	Fluid Retention							
	Influenza Like Illness							
	Palpitations							
	Pulmonary Embolism							
	Renal Failure Acute							
	Respiratory Distress							
	Sinusitis							
	Tachypnoea							
	Ventricular Extrasystoles							
	Weight Increased							

Date:01/24/00ISR Number: 3447223-6Report Type:Expedited (15-DaCompany Report #WAES 99121828
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
Hospitalization -	Haemorrhage	Professional					DAILY / PO	
Initial or Prolonged	Pneumonia		[Therapy					
Other			Unspecified]	C				

Date:01/24/00ISR Number: 3447309-6Report Type:Expedited (15-DaCompany Report #WAES 00015539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal	Foreign	Tab Vioxx					
Initial or Prolonged	Haemorrhagic	Health	(Rofecoxib)	PS		ORAL	PO	10 DAY
	Gastrointestinal	Professional						
	Haemorrhage							
	Haematochezia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/00ISR Number: 3447310-2Report Type:Expedited (15-DaCompany Report #WAES 00018254
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	
			Acetaminophen	C				
			Tramadol Hcl	C				
			Zantic	C				

Date:01/24/00ISR Number: 3447311-4Report Type:Expedited (15-DaCompany Report #WAES 00019775
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	4 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Nsaid	C				

Date:01/24/00ISR Number: 3447312-6Report Type:Expedited (15-DaCompany Report #WAES 00010837
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Dysphonia							
	Eyelid Oedema							
	Face Oedema							
	Oxygen Saturation Decreased							
	Pneumonia							
	Pulmonary Oedema							

Date:01/24/00ISR Number: 3447313-8Report Type:Expedited (15-DaCompany Report #WAES 00011246
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis	Health	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged	Petechiae	Professional	Xanax	C				
	Platelet Count Decreased	Company Representative						

Date:01/24/00ISR Number: 3447348-5Report Type:Expedited (15-DaCompany Report #991227-SK832
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Celebrex	PS		ORAL	100.000 MG	
Initial or Prolonged	Embolic Stroke	Health					BID PO	
Other	Haemorrhage Intracranial	Professional	Vioxx	SS		ORAL	PO	
	Haemorrhagic Stroke		Atenolol	C				
			Amlodipine Besylate	C				
			Warfarin	C				
			Enalapril	C				
			Glyburide	C				
			Simvastatin	C				
			Troglitazone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/00ISR Number: 3447495-8Report Type:Expedited (15-DaCompany Report #WAES 00019779
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Abdominal Pain Upper	Other	(Rofecoxib)	PS		ORAL	25MG PO	1 DAY
	Back Pain		Unknown Drug	SS				
	Chest Discomfort		Dypirone	C				
	Chest Pain		Propoxyphene Hcl	C				
	Drug Interaction							
	Electrocardiogram St							
	Segment Depression							
	Electrocardiogram T Wave							
	Inversion							
	Musculoskeletal Pain							

Date:01/24/00ISR Number: 3447499-5Report Type:Expedited (15-DaCompany Report #WAES 00015574
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastritis Erosive	Foreign	Tab Vioxx					
Hospitalization -	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	12 DAY
Initial or Prolonged	Haemorrhage		Diclofenac	SS			75-100 MG	
	Haematemesis		Elavil	C				
	Hiatus Hernia		Diazepam	C				
	Metastasis		Dipyrone	C				
	Oesophagitis		Rabeprazole Sodium	C				
	Prothrombin Time							
	Shortened							
	Renal Failure							
	Renal Failure Chronic							

Date:01/24/00ISR Number: 3447751-3Report Type:Expedited (15-DaCompany Report #WAES 00011236
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Renal Impairment	Health Professional Company Representative	Vioxx 25 Mg	PS	ORAL 25 MG/DAILY/ORAL

Date:01/26/00ISR Number: 3643777-5Report Type:Periodic Company Report #WAES 00092149
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	

Date:01/26/00ISR Number: 3644960-5Report Type:Periodic Company Report #WAES 00111255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/00ISR Number: 3646346-6Report Type:Periodic Company Report #WAES 00081956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/27/00ISR Number: 3447367-9Report Type:Expedited (15-DaCompany Report #WAES 00011062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephritis Interstitial	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Impairment	Professional Company Representative	[Therapy Unspecified]	C				

Date:01/27/00ISR Number: 3447369-2Report Type:Expedited (15-DaCompany Report #WAES 00010657
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alcoholism	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Asthenia						MG/DAILY/PO	
	Concussion		Skelaxin	C				
	Fall		Vicodin Tablets	C				
	Feeling Abnormal							
	Laceration							
	Liver Function Test Abnormal							
	Syncope							

Date:01/27/00ISR Number: 3447370-9Report Type:Expedited (15-DaCompany Report #WAES 00010586
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Faecal Occult Blood	Professional	Celebrex	SS		ORAL	200	
Initial or Prolonged	Positive						MG/DAILY/PO	
Other	Fall		Prinivil	C				
	Gastric Ulcer Haemorrhage		Amlodipine					
	Haemoglobin Decreased		Benzenesulfonate	C				

Date:01/27/00ISR Number: 3447656-8Report Type:Expedited (15-DaCompany Report #WAES 99111828
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Aphasia
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Cognitive Disorder
	Confusional State
	Drug Interaction
	Drug Withdrawal Syndrome
	Headache
	Hypoaesthesia
	Neuroleptic Malignant
	Syndrome
	Throat Tightness
	Transient Ischaemic

Attack

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Health Professional	Inj Kenalog 10 Mg	SS			10 MG/DAILY/INJ	
Other	Inj (Therapy Unspecified) Unk	SS			INJ	
	Inj Marcaine Unk	SS			INJ	
	Mirapex Unk	SS		ORAL	0.25 MG/TID/PO	
	Inj [Composition Unspecified] Unk	SS			INJ	
	Lanoxin	C				
	Valium	C				
	Vitamins	C				

Date:01/27/00ISR Number: 3447659-3Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Increased Blood Glucose Increased	Company Representative	Celebrex	C				
Disability	Blood Thyroid Stimulating Hormone Increased	Other	Ecotrin	C				
Other	Blood Urea Increased		Hydrodiuril	C				
	Dehydration		L-Thyroxine	C				
	Dyspnoea		Macrobid	C				
	Hypertension		Tylenol	C				
	Hypothyroidism							

Lipid Metabolism Disorder
Nephritis Interstitial
Nephrotic Syndrome
Oedema
Pleural Effusion
Protein Total Increased
Proteinuria
Renal Failure Acute
Urine Osmolarity
Increased
Weight Increased

Date:01/27/00ISR Number: 3447663-5Report Type:Expedited (15-DaCompany Report #WAES 99078508
Age:60 YR Gender:Female I/FU:F

Outcome PT
Other Aortic Valve Sclerosis
Atrioventricular Block
First Degree
Blood Ph Increased
Blood Pressure Systolic
Increased
Cardiac Disorder
Cardiomegaly
Dizziness
Dyspnoea
Fatigue

	Hyperhidrosis						
	Metabolic Alkalosis						
	Muscular Weakness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pleural Effusion	Foreign	Tab Vioxx				
	Po2 Increased	Study	(Rofecoxib)	PS		ORAL	50 MG PO
	Pulmonary Hypertension	Health	Tab Placebo	SS		ORAL	PO
	Pulmonary Oedema	Professional	Vasotec	C			
			Diclofenac Na	C			
			Glyburide	C			
			Hydroxychloroquine	C			
			Metoprolol	C			
			Ranitidine	C			

Date:01/27/00ISR Number: 3447682-9Report Type:Expedited (15-DaCompany Report #WAES 00011821
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO
Hospitalization -	Gastric Ulcer		Coumadin	C			
Initial or Prolonged	Haemorrhage		Digoxin	C			

Date:01/28/00ISR Number: 3448602-3Report Type:Expedited (15-DaCompany Report #WAES 00011200
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	50
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO;
Initial or Prolonged		Company					25
		Representative					MG/DAILY/PO
			Flomax (Tamsulosin				
			(R) -Form Hydro	C			
			Levaquin	C			
			Lopressor	C			

				Aspirin	C		

Date:01/28/00ISR Number: 3448606-0Report Type:Expedited (15-DaCompany Report #WAES 00010306
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Hospitalization -	Haemorrhage	Health					PO	
Initial or Prolonged	Rectal Haemorrhage	Professional Company Representative						

Date:01/28/00ISR Number: 3448613-8Report Type:Expedited (15-DaCompany Report #WAES 99078508
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Other	Cardiomegaly
	Dizziness
	Dyspnoea
	Fatigue
	Hyperhidrosis
	Metabolic Alkalosis
	Muscular Weakness
	Pleural Effusion

	Pulmonary Hypertension Pulmonary Oedema						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG	
		Health Professional	Tab Placebo	SS		ORAL		
			Vasotec	C				
			Vasotec	C				
			Vasotec	C				
			Diclofenac Na	C				
			Glyburide	C				
			Hydroxychloroquine	C				
			Metoprolol	C				
			Ranitidine	C				

Date:01/28/00ISR Number: 3448674-6Report Type:Expedited (15-DaCompany Report #WAES 99115318
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Malaise	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG ; 12.5 MG PO	
Other	Mouth Ulceration	Professional						
	Pyrexia		Prednisolone	C				
	Rash Vesicular							
	Stevens-Johnson Syndrome							

Date:01/31/00ISR Number: 3447875-0Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx 25 Mg	PS		ORAL	25MG QAM PO	

Date:01/31/00ISR Number: 3448666-7Report Type:Expedited (15-DaCompany Report #WAES 99121255
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Duodenal Ulcer	Professional					PO	
Initial or Prolonged	Haematochezia	Company	Hydrodiuril	C				
	Haemoglobin Decreased	Representative	Procardia	C				
	Rectal Haemorrhage		Theo-Dur	C				
			Iron (Unspecified)	C				

Date:01/31/00ISR Number: 3448667-9Report Type:Expedited (15-DaCompany Report #WAES 99122132
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Oedema Peripheral	Professional						

Date:01/31/00ISR Number: 3448713-2Report Type:Expedited (15-DaCompany Report #WAES 00015642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Leukopenia	Foreign	Tab Vioxx					
Initial or Prolonged	Sepsis	Other	(Rofecoxib)	PS		ORAL	PO	

			Cortisone	C		
			Methotrexate	C		
			Oral Gold Preparations (Composition Unsp	C		

Date:01/31/00ISR Number: 3448717-XReport Type:Expedited (15-DaCompany Report #WAES 00015137
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
			Fluphenazine	C				
			Ibuprofen	C				
			Nortriptyline	C				

Date:01/31/00ISR Number: 3448720-XReport Type:Expedited (15-DaCompany Report #WAES 00018296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Immobile Vertigo	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:01/31/00ISR Number: 3448723-5Report Type:Expedited (15-DaCompany Report #WAES 00010992
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / BID / PO	

Date:01/31/00ISR Number: 3448726-0Report Type:Expedited (15-DaCompany Report #WAES 00010884
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Condition Aggravated		Celexa	C				
	Retinal Haemorrhage		Osteo-Bi-Flex	C				
	Visual Disturbance		Prilosec	C				
			Alprazolam	C				
			Aspirin	C				
			Chromium Picolinate	C				
			Furosemide	C				
			Lysine	C				
			Melatonin	C				
			Potassium Chloride	C				
			Vitamins	C				

Date:01/31/00ISR Number: 3448728-4Report Type:Expedited (15-DaCompany Report #WAES 00011253
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/00ISR Number: 3448738-7Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Triavil 2-10 1 Po	PS		ORAL	2-10 1 PO	
	Pruritus	Professional						0740
			Vioxx 12.5mg Po	SS		ORAL	12.5MG PO	
								0740

Date:01/31/00ISR Number: 3448757-0Report Type:Expedited (15-DaCompany Report #WAES 00011988
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Condition Aggravated	Professional					MG/DAILY/PO	
	Haemorrhoids							
	Muscle Spasms							

Date:01/31/00ISR Number: 3448759-4Report Type:Expedited (15-DaCompany Report #WAES 00012250
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Mental Impairment	Professional	Enduron	C				
	Muscular Weakness		Glynase Prestab					
	Speech Disorder		Tablets	C				
	Urinary Incontinence		Norvasc	C				
			Plavix	C				
			Pravachol	C				
			Proscar	C				
			Trental	C				
			Zantac	C				
			Insulin	C				

			Magnesium Oxide	C		

Date:01/31/00ISR Number: 3448761-2Report Type:Expedited (15-DaCompany Report #WAES 00012248
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Blood Pressure Increased	Professional	Vasotec	C				
	Hyperhidrosis							

Date:01/31/00ISR Number: 3448764-8Report Type:Expedited (15-DaCompany Report #WAES 00012267
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
Life-Threatening	Malaise							
Disability	Pain							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/00ISR Number: 3448767-3Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Bronchospasm Dizziness Heart Rate Increased Hypertension Insomnia Syncope	Health Professional	Vioxx 12.5 Mg Merck & Co,Inc	PS	Merck & Co,Inc			

Date:01/31/00ISR Number: 3449070-8Report Type:Expedited (15-DaCompany Report #WAES 00010114
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Colitis Diverticulitis Influenza Like Illness Malaise Oral Intake Reduced Viral Infection	Consumer	Tab Vioxx 12.5 Mg Antimicrobial Therapy	PS C		ORAL	12.5 MG/DAILY/PO	

Date:01/31/00ISR Number: 3449074-5Report Type:Expedited (15-DaCompany Report #WAES 00011887
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Asthma Chest Discomfort Chest Pain Dermatitis Fatigue Influenza Like Illness Insomnia Pruritus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Supraventricular
Extrasystoles
Ventricular Extrasystoles

Date:01/31/00ISR Number: 3449075-7Report Type:Expedited (15-DaCompany Report #WAES 00011898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Renal Failure	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Elavil	C				
Disability		Representative	Valium	C				
			Vasotec	C				
			Vicodin Tablets	C				
			Xanax	C				
			Allopurinol	C				
			Labetalol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/00ISR Number: 3449077-0Report Type:Expedited (15-DaCompany Report #WAES 00011909
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Fosamax	C				

Date:01/31/00ISR Number: 3449079-4Report Type:Expedited (15-DaCompany Report #WAES 00011911
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inappropriate	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Antidiuretic Hormone Secretion	Professional	Fosamax	C				
			Lasix	C				
			Levoxyl	C				
			Medrol	C				
			Nitrofortin	C				
			Propulsid	C				
			Timoptic	C				
			Trusopt	C				
			Xalatan	C				
			Atenolol	C				
			Pilocarpine	C				

Date:01/31/00ISR Number: 3449080-0Report Type:Expedited (15-DaCompany Report #WAES 00011983
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:01/31/00ISR Number: 3449082-4Report Type:Expedited (15-DaCompany Report #WAES 99111131
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other		Company Representative	Prednisone	C				

Date:01/31/00ISR Number: 3449083-6Report Type:Expedited (15-DaCompany Report #WAES 99120816
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Interaction	Health Professional						
	Feeling Drunk		Copaxone	C				
	Hallucination		Hydrodiuril	C				
	Nausea		Lortab	C				
			Lotensin	C				
			Neurontin	C				
			Prozac	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/00ISR Number: 3449095-2Report Type:Expedited (15-DaCompany Report #WAES 00015539
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	9 DAY
	Diverticulum Intestinal							
	Haemorrhagic		Tab Aspirin	SS		ORAL	100 MG PO	
	Rectal Haemorrhage		Diltiazem D-Cis Form Hcl	C				
			Glyburide	C				
			Molsidomine	C				
			Simvastatin	C				

Date:01/31/00ISR Number: 3449102-7Report Type:Expedited (15-DaCompany Report #WAES 99082150
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Petechiae	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Thrombocytopenia	Professional						
		Company Representative	Lasix	C				
			Lipitor	C				
			Insulin	C				
			Metoprolol	C				
			Vitamin B {12}	C				

Date:01/31/00ISR Number: 3449103-9Report Type:Expedited (15-DaCompany Report #WAES 00011246
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Petechiae	Professional						
	Platelet Count Decreased	Company Representative	Xanax	C				

Date:01/31/00ISR Number: 3449176-3Report Type:Expedited (15-DaCompany Report #WAES 99125228
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign	Tab Vioxx					
	Duodenitis	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	26 DAY
	Gastrointestinal		Acetaminophen/Propox					
	Haemorrhage		yphene Hydrochloride	C				
	Haematemesis		Aspirin	C				
	Haemoglobin Decreased		Bumetanide	C				
	Melaena		Diclofenac	C				
			Diltiazem D-Cis Form					
			Hcl	C				
			Lisinopril	C				
			Simvastatin	C				
			Spironolactone	C				
			Tramadol	C				

Date:01/31/00ISR Number: 3449178-7Report Type:Expedited (15-DaCompany Report #WAES 00019779
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper

	Back Pain Chest Discomfort Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Interaction Electrocardiogram St	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO 1 DAY
	Segment Depression Electrocardiogram T Wave Inversion Musculoskeletal Pain	Professional	Unknown Drug Dypirone Propoxyphene Hcl	SS C C			

Date:01/31/00ISR Number: 3449181-7Report Type:Expedited (15-DaCompany Report #WAES 99121859
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Hospitalization -	Dizziness	Professional					
Initial or Prolonged	Gastrointestinal	Company	Fosamax	C			
Other	Haemorrhage	Representative	Lasix	C			
	Haematemesis		Synthroid	C			
	Muscular Weakness						
	Vomiting						

Date:01/31/00ISR Number: 3449184-2Report Type:Expedited (15-DaCompany Report #WAES 99122034
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastric Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO
Initial or Prolonged	Ulcer Haemorrhage		Cytotec	C			
			Voltaren	C			

Date:01/31/00ISR Number: 3449189-1Report Type:Expedited (15-DaCompany Report #WAES 99121796
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum Intestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Haemorrhagic	Health					PO	
Initial or Prolonged		Professional	Covera-Hs	C				
Disability			Hytrin	C				
Other			Mevacor	C				

Date:01/31/00ISR Number: 3449273-2Report Type:Expedited (15-DaCompany Report #WAES 00012014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oesophageal Ulcer	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:01/31/00ISR Number: 3449295-1Report Type:Expedited (15-DaCompany Report #WAES 00011666
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Anorexia
Initial or Prolonged	Anxiety
Disability	Asthenia
Other	Fatigue

Gastric Ulcer Haemorrhage
Haemoglobin Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Dilacor Xr	C				
	Humulin	C				
	Lanoxin	C				
	Lasix	C				
	Oxycontin	C				
	Plaquenil	C				
	Synthroid	C				
	Xanax	C				
	Zaroxolyn	C				
	Zestril	C				
	Atenolol	C				
	Potassium Supplement (Composition	C				
	Prednisone	C				

Date:01/31/00ISR Number: 3449296-3Report Type:Expedited (15-DaCompany Report #WAES 00011788
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Renal Failure Acute	Professional	Therapy Unspecified	C				

Date:01/31/00ISR Number: 3449455-XReport Type:Expedited (15-DaCompany Report #WAES 00015101
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS		ORAL	25 MG; PO	33 DAY

	Blood Urea Increased		Sulfasalazine	SS			ORAL
1.5 GM; ORAL 33 DAY							
	Renal Failure Acute						

Date:01/31/00ISR Number: 3449459-7Report Type:Expedited (15-DaCompany Report #WAES 00011884
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Confusional State	Professional				
MG/DAILY/PO						
	Convulsion	Company				
	Disorientation	Representative				
	Fatigue					
	Lethargy					

Date:01/31/00ISR Number: 3449462-7Report Type:Expedited (15-DaCompany Report #WAES 00012020
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Life-Threatening	Haemorrhage	Professional				
MG/DAILY/PO						
Hospitalization -		Company				
Initial or Prolonged		Representative				
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/00ISR Number: 3448780-6Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased		Rofecoxib	PS			25MG QD X 7D	
Initial or Prolonged			Celecoxib	SS			200MG BID	X14D
			Diclofenac	SS				

Date:02/02/00ISR Number: 3450482-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Asa	PS		ORAL	81MG PO QD	
Initial or Prolonged	Faeces Discoloured		Vioxx	SS			2 WITH SUPPER	
Other								

Date:02/02/00ISR Number: 3450521-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS		ORAL	25MG PO BID	
Hospitalization -	Haemorrhage		Ibuprofen	SS		ORAL	600MG PO BID	
Initial or Prolonged								

Date:02/02/00ISR Number: 3450587-0Report Type:Expedited (15-DaCompany Report #WAES 00011994
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Bronchospasm	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG /						
Initial or Prolonged	Gastrointestinal					
DAILY/ PO 2 WK						
	Haemorrhage		Colace	C		
			Cordarone	C		
			Coumadin	C		
			Metamucil	C		
			Synthroid	C		
			Vasotec	C		
			Zocor	C		
			Allopurinol	C		
			Atenolol	C		

Date:02/02/00ISR Number: 3450591-2Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Activated Partial	Professional				
MG/DAILY/PO 3 DAY						
	Thromboplastin Time		Calan Sr	C		
	Prolonged		Colace	C		
	Bleeding Time Prolonged		Lasix	C		
	Blood Fibrinogen		Zoloft	C		
	Decreased		Potassium Chloride	C		
	Nausea		Tamoxifen	C		
	Prothrombin Time		Vitamins	C		
	Prolonged					
	Pyrexia					
	Thrombocytopenia					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/00ISR Number: 3450596-1Report Type:Expedited (15-DaCompany Report #WAES 00010992
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /BID/ PO	
	Blood Urea Increased		Lasix	C				
	Coma		Prinivil	C				
	Dehydration		Transderm - Nitro	C				
	Depressed Level Of Consciousness		Tylenol	C				
			Tylenol With Codeine	C				
	Hyperkalaemia		Zoloft	C				
	Hypotension		Calcium Supplement (Composition Metoprolol)	C				
	Lethargy							
	Oral Intake Reduced							
	Renal Disorder							
	Renal Failure							
	Renal Failure Acute							

Date:02/02/00ISR Number: 3450598-5Report Type:Expedited (15-DaCompany Report #WAES 00010371
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Professional						
	Dyspnoea	Company Representative	Testosterone	C				
Disability								
Other								

Date:02/02/00ISR Number: 3450607-3Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Thrombocytopenia	Professional						

Date:02/02/00ISR Number: 3450618-8Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Disseminated Intravascular Coagulation	Professional						

Date:02/02/00ISR Number: 3450621-8Report Type:Expedited (15-DaCompany Report #WAES 99100951
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Activated Partial Thromboplastin Time Prolonged	Professional						
	Bleeding Time Prolonged							
	Blood Fibrinogen Decreased							
	Prothrombin Time Prolonged							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/00ISR Number: 3450626-7Report Type:Expedited (15-DaCompany Report #WAES 99091934
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Atrial Fibrillation	Professional					MG/DAILY/PO	
	Haematocrit Decreased	Company	Miacalcin	C				
	Haemoglobin Decreased	Representative	Alprazolam	C				
	Mean Cell Volume		Glucosamine	C				
	Decreased		Thiamine	C				
	Medical Device							
	Complication							
	Oedema							
	Renal Failure Chronic							

Date:02/02/00ISR Number: 3450628-0Report Type:Expedited (15-DaCompany Report #WAES 00010884
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Hypertension	Health	Celebrex	C				
	Retinal Haemorrhage	Professional	Celexa	C				
	Visual Acuity Reduced		Lasix	C				
			Osteo-Bi-Flex	C				
			Prilosec	C				
			Alprazolam	C				
			Aspirin	C				
			Chromium Picolinate	C				
			Lysine	C				
			Melatonin	C				
			Potassium Chloride	C				
			Vitamins	C				

Date:02/02/00ISR Number: 3450629-2Report Type:Expedited (15-DaCompany Report #WAES 00010837
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Cardiac Failure					
	Congestive					
	Condition Aggravated					
	Dysphonia					
	Face Oedema					
	Oxygen Saturation					
	Decreased					
	Pneumonia					
	Pulmonary Oedema					

Date:02/02/00ISR Number: 3450701-7Report Type:Expedited (15-DaCompany Report #WAES 00015637
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL
12.5 MG; PO 9 DAY						
Initial or Prolonged		Health	Ibuprofen	C		
		Professional	Piroxicam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/00ISR Number: 3450704-2Report Type:Expedited (15-DaCompany Report #WAES 99121658
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bone Pain	Health	Vioxx	PS		ORAL	25	
Initial or Prolonged	Brain Scan Abnormal	Professional					MG/DAILY/PO	
Other	Confusional State		Lasix	C				
	Delirium		Synthroid	C				
	Depressed Level Of		Tylenol	C				
	Consciousness		Vasotec	C				
	Disorientation		Technetium	C				
	Drug Toxicity							
	Encephalopathy							
	Mental Disorder							
	Sedation							
	Sinus Tachycardia							
	Speech Disorder							
	Tachycardia							
	Ventricular Hypertrophy							

Date:02/02/00ISR Number: 3450706-6Report Type:Expedited (15-DaCompany Report #WAES 00012361
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Gastric Ulcer Haemorrhage						MG/DAILY/PO	
			Aricept	C				
			Iron (Unspecified)	C				

Date:02/02/00ISR Number: 3450707-8Report Type:Expedited (15-DaCompany Report #WAES 00012481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS		ORAL	PO	
Hospitalization -	Haemorrhage	Professional						

Initial or Prolonged			Company Representative				

Date:02/02/00ISR Number: 3450708-XReport Type:Expedited (15-DaCompany Report #WAES 00012295
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Vioxx Unk	PS		ORAL	PO	

Date:02/02/00ISR Number: 3451150-8Report Type:Direct Company Report #
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx Merck	PS	Merck	ORAL	PO	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Aspirin	C				
Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Ulcer							
	Hypotension							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/00ISR Number: 3450654-1Report Type:Direct Company Report #
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mouth Ulceration		Vioxx 12.5 Mg	PS		ORAL	12.5MG PO QD	2 WK
Initial or Prolonged	Neutropenia							
	Pyrexia							

Date:02/03/00ISR Number: 3451193-4Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Insomnia		Rofecoxib (Vioxx)	PS				
	Pain In Extremity							

Date:02/03/00ISR Number: 3451569-5Report Type:Expedited (15-DaCompany Report #A002541
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Cancer Female	Consumer	Procardia Xl					
Initial or Prolonged	Drug Ineffective		Extended Release					
Required	Insomnia		Tablets	PS		ORAL	30.00 MG	
Intervention to	Pruritus						TOTAL:DAILY:O	
Prevent Permanent	Weight Increased						RAL	
Impairment/Damage			Tamoxifen	SS				
			Vioxx	SS		ORAL	ORAL	
			Celebrex	SS		ORAL	400.00 MG	
							TOTAL:BID:ORA	
							L	
			Fosamax	C				

Date:02/04/00ISR Number: 3452383-7Report Type:Expedited (15-DaCompany Report #WAES 00015613
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder	Foreign	Tab Vioxx					
	Dyspnoea Exertional	Health	(Rofecoxib)	PS		ORAL	25 MG PO	37 DAY
	Fluid Retention	Professional	Hctz/Triamterene	C				
	Hypotension		Digitoxin	C				
	Right Ventricular Failure		Doxazosin Monomethanesulfonate	C				
			Indapamide	C				

Date:02/04/00ISR Number: 3452384-9Report Type:Expedited (15-DaCompany Report #WAES 99121933
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Abdomen	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Colonic Obstruction	Professional						
Initial or Prolonged	Diverticulitis	Company	Tab Vasotec	SS			5 MG/BID	
Other	Intestinal Obstruction	Representative	Covera-Hs	C				
	Multi-Organ Failure		Hygroton	C				
	Pruritus							
	Renal Failure							
	Sick Sinus Syndrome							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/00ISR Number: 3452395-3Report Type:Expedited (15-DaCompany Report #WAES 00011253
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dehydration	Health	Tab Vioxx	PS		ORAL	QOD/PO	
	Renal Failure Acute	Professional						

Date:02/04/00ISR Number: 3452397-7Report Type:Expedited (15-DaCompany Report #WAES 00010660
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
Initial or Prolonged	Crohn'S Disease		Estrace	C				
	Inflammatory Bowel Disease							
	Intestinal Ischaemia							
	Mesenteric Vascular Insufficiency							
	Pain							
	Vomiting							

Date:02/04/00ISR Number: 3452406-5Report Type:Expedited (15-DaCompany Report #WAES 00012335
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Erosive Oesophagitis	Professional					MG/DAILY/PO	
	Haematemesis	Company						
	Haemoglobin Decreased	Representative						
	Haemoptysis							

Date:02/04/00ISR Number: 3452467-3Report Type:Expedited (15-DaCompany Report #WAES 00012523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:02/04/00ISR Number: 3452469-7Report Type:Expedited (15-DaCompany Report #WAES 00012355
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Abdominal Pain Upper						MG/DAILY/PO	
	Irritable Bowel Syndrome							

Date:02/04/00ISR Number: 3452542-3Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx 12.5mg Merck	PS	Merck		12.5MG QD	
Initial or Prolonged	Gastric Ulcer		Hctz	C				
Required	Gastrointestinal		Prilosec	C				
Intervention to	Haemorrhage		Glucotrol	C				
Prevent Permanent			Plendil	C				
Impairment/Damage			Vitamin C	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/00ISR Number: 3452774-4Report Type:Expedited (15-DaCompany Report #WAES 00012246
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
			Ultram	C				

Date:02/04/00ISR Number: 3452775-6Report Type:Expedited (15-DaCompany Report #WAES 00012182
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Albumin Decreased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 - 25	
Hospitalization -	Blood Glucose Increased	Professional					MG/DAILY/PO	
Initial or Prolonged	Dermatitis	Company	Celebrex	C				
Disability	Erosive Oesophagitis	Representative	Daypro	C				
Other	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Haematuria							
	Henoch-Schonlein Purpura							
	Iron Deficiency							
	Leukocytosis							
	Microcytic Anaemia							
	Pallor							
	Proteinuria							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Renal Impairment							
	Thrombocythaemia							
	Trichomoniasis							
	Urinary Tract Infection							
	Vasculitis							
	White Blood Cells Urine							
	Positive							

Date:02/04/00ISR Number: 3453094-4Report Type:Expedited (15-DaCompany Report #WAES 99122135
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Cardiac Failure Congestive	Professional Company Representative	Cardura	C				
			Estrace	C				
			Lopid	C				
			Prevacid	C				
			Synthroid	C				

Date:02/04/00ISR Number: 3453096-8Report Type:Expedited (15-DaCompany Report #WAES 00012525
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematemesis		Zestril	C				
	Mouth Haemorrhage		Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/00ISR Number: 3453097-XReport Type:Expedited (15-DaCompany Report #WAES 00012330
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastric Ulcer Haemorrhage							
	Gastrointestinal Haemorrhage	Company Representative	Miacalcin	C				
	Melaena		Premarin	C				
			Synthroid	C				
			Vicodin Tablets	C				
			Zantac	C				
			Aspirin	C				
			Verapamil	C				

Date:02/04/00ISR Number: 3453208-6Report Type:Direct Company Report #
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS				

Date:02/07/00ISR Number: 3453349-3Report Type:Expedited (15-DaCompany Report #WAES 99120487
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/PO	
	Condition Aggravated							
	Gastritis	Company Representative	Axid	C				
	Gastrooesophageal Reflux Disease		Cozaar	C				
	Oesophagitis		Diovan	C				
			Ortho-Est	C				
			Prevacid	C				
			Vitamin B(12)	C				
			Vitamins	C				

Date:02/07/00ISR Number: 3453356-0Report Type:Expedited (15-DaCompany Report #WAES 00016523
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
	Hypokalaemia		Aspirin	C				
	Pneumonia		Diclofenac Sodium (+) Misoprostol	C				
			Potassium Chloride	C				

Date:02/07/00ISR Number: 3453385-7Report Type:Expedited (15-DaCompany Report #WAES 99102245
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anaemia
	Blood Urea Increased
	Dyspepsia
	Embolism
	Endoscopy Abnormal
	Faecal Occult Blood Positive

		Gastric Ulcer					
		Gastritis					
		Gastroenteritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Helicobacter	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO							
		Gastrointestinal	Professional	Aspirin	C		
		Haemorrhage		Ibuprofen	C		
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Haemorrhage					
		Hyperaemia					
		Hyperglycaemia					
		Hypotension					
		Lipoma					
		Nausea					
		Oedema					
		Shock					
		Varicose Vein					

Date:02/07/00ISR Number: 3453484-XReport Type:Expedited (15-DaCompany Report #WAES 00015657
Age:61 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Condition Aggravated	Foreign	Tab Vioxx			
Hospitalization -		Endocarditis	Health	(Rofecoxib)	PS		ORAL
Initial or Prolonged		Hepatic Failure	Professional				
		Jaundice					
		Pyrexia					
		Renal Failure					
		Sepsis					

Date:02/07/00ISR Number: 3453485-1Report Type:Expedited (15-DaCompany Report #WAES 00020099
Age:70 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastric Ulcer Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Initial or Prolonged			Professional				
MG/DAILY/PO							
			Company	Prednisone	C		

Date:02/07/00ISR Number: 3453916-7Report Type:Expedited (15-DaCompany Report #WAES 00012690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Embolism	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhagic Stroke	Professional	Tab Celebrex	SS		ORAL	100 MG/BID/PO	
Other	Hypertension		Coumadin	C				
			Coumadin	C				
			Vasotec	C				
			Zocor	C				
			Amlodipine Benzenesulfonate	C				
			Atenolol	C				
			Glyburide	C				
			Troglitazone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/00ISR Number: 3453917-9Report Type:Expedited (15-DaCompany Report #WAES 00012613
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PRN/PO	
Hospitalization - Initial or Prolonged	Myocardial Infarction		Accolate	C				
			Atacand	C				
			Azmacort	C				
			Buspar	C				
			Cozaar	C				
			Glucophage	C				
			Lasix	C				
			Norvasc	C				
			Nph Insulin	C				
			Prempo	C				
			Regular Insulin	C				
			Ventolin	C				
			Zoloft	C				

Date:02/07/00ISR Number: 3453918-0Report Type:Expedited (15-DaCompany Report #WAES 00012248
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hyperhidrosis							
	Hypertension		Vasotec	C				

Date:02/07/00ISR Number: 3453930-1Report Type:Expedited (15-DaCompany Report #WAES 00011062
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Renal Impairment							
		Company Representative	Therapy Unspecified	C				

Date:02/07/00ISR Number: 3453933-7Report Type:Expedited (15-DaCompany Report #WAES 99110829
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Asthenia
	Basophil Count Decreased
	Blood Thyroid Stimulating
	Hormone Increased
	Colon Cancer
	Condition Aggravated
	Eosinophil Count
	Decreased
	Faeces Discoloured
	Fatigue
	Gastric Ulcer Haemorrhage
	Haematocrit Decreased
	Haemoglobin Decreased
	International Normalised
	Ratio Increased
	Jaundice

		Monocyte Count Decreased					
		Ovarian Cancer					
		Prothrombin Time	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prolonged	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Thrombocythaemia	Professional				
MG/DAILY/PO							
			Company	Coumadin	C		
			Representative	Plavix	C		
				Aspirin	C		

Date:02/07/00ISR Number: 3453937-4Report Type:Expedited (15-DaCompany Report #WAES 99122121
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Conjunctival Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Diarrhoea	Professional				
MG/DAILY/PO							
		Dizziness	Company	Coumadin	C		
		Haemorrhagic Stroke	Representative				
		International Normalised					
		Ratio Increased					
		Prothrombin Time					
		Prolonged					

Date:02/07/00ISR Number: 3453940-4Report Type:Expedited (15-DaCompany Report #WAES 99100977
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Respiratory	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/HS/PO							
Life-Threatening		Distress Syndrome	Professional	Prilosec	C		
Hospitalization -		Blood Amylase Increased	Company	Skelaxin	C		
Initial or Prolonged		Lipase Increased	Representative	Therapy Unspecified	C		
Other		Pancreatitis		Vitamins	C		
		Renal Failure					

Date:02/07/00ISR Number: 3453942-8Report Type:Expedited (15-DaCompany Report #WAES 00010751
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaesthetic Complication	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Neurological	Professional					MG/DAILY/PO	
	Benign Intracranial		Elavil	C				
	Hypertension		Inderal	C				
	Headache		Therapy Unspecified	C				
	Papilloedema							
	Visual Disturbance							

Date:02/07/00ISR Number: 3453943-XReport Type:Expedited (15-DaCompany Report #WAES 00020022
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Bronchospasm							
	Dizziness							
	Dyspnoea							
	Headache							
	Insomnia							
	Nausea							
	Tachycardia							

Date:02/07/00ISR Number: 3453959-3Report Type:Expedited (15-DaCompany Report #WAES 00020017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:02/07/00ISR Number: 3453961-1Report Type:Expedited (15-DaCompany Report #WAES 00010815
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Coordination Abnormal						MG/DAILY/PO	
	Dysarthria		Tab Vioxx 25 Mg	SS		ORAL	25	
	Fluid Retention						MG/DAILY/PO	
	Transient Ischaemic Attack		(Therapy Unspecified) Unk	SS				
			Celebrex	C				
			Diovan	C				
			Lasix	C				
			Pravachol	C				
			Ascorbic Acid	C				
			Labetalol	C				
			Potassium Supplment (Composition	C				

Date:02/07/00ISR Number: 3454142-8Report Type:Expedited (15-DaCompany Report #WAES 00020060
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Urea Increased	Health	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Dehydration	Professional	Glucophage	C				

	Hyperaldosteronism	Company	Lotensin	C
	Hyperkalaemia	Representative		
	Hyponatraemia			

Date:02/07/00ISR Number: 3454143-XReport Type:Expedited (15-DaCompany Report #WAES 00020059
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Dermatitis	Professional					MG/DAILY/PO;	
	Flushing	Company					12.5	
		Representative					MG/QOD/PO	
			..	SS				
			Synthroid	C				
			Tagamet	C				
			Tenormin	C				
			Vicodin Tablets	C				
			Estrogenic Preparations (Composi	C				
			Triamterene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/00ISR Number: 3454145-3Report Type:Expedited (15-DaCompany Report #WAES 00012691
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Anorexia						MG/DAILY/PO	
Other	Drug Ineffective		Tab Celebrex Unk	SS		ORAL	PO	
	Gastric Ulcer Haemorrhage		Paroxetine	C				
	Haematemesis		Ropinirole					
	Melaena		Hyhdrochloride	C				
	Nausea		Selegiline	C				
	Rectal Haemorrhage							

Date:02/07/00ISR Number: 3454208-2Report Type:Expedited (15-DaCompany Report #WAES 00020099
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Prednisone	C				

Date:02/08/00ISR Number: 3454399-3Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension		Vioxx 12.5mg 1qd	PS				

Date:02/08/00ISR Number: 3470830-1Report Type:Direct Company Report #
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS			25MG QAM	
Initial or Prolonged	Increased	Professional					12.5MG QPM	
	Blood Potassium Increased		Enteric Coated Asa	C				
	Blood Urea Increased		Metolazone	C				
	Gastric Ulcer		Torsemide	C				
	Gastric Ulcer Haemorrhage		Spironolactone	C				
	Renal Failure		Pepcid	C				
			Doxepin	C				
			Vicon Forte	C				
			Simethicone	C				
			Maalox	C				
			Tylenol #3	C				
			Nitropaste	C				
			Colace	C				
			Senokot	C				
			Oscal	C				
			Diltiazem	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/00ISR Number: 3455037-6Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic	Health Professional	Triavil 2-10 1 Po	PS		ORAL	2-10 1 PO	0740
			Vioxx 12.5 Mg Po	SS		ORAL	12.5 MG PO	0740

Date:02/09/00ISR Number: 3455552-5Report Type:Expedited (15-DaCompany Report #WAES 00020096
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx 12.56 Mg	PS		ORAL	12.5 MG/AM/PO	
	Hypertension		Fosamax	C				
			Synthroid	C				

Date:02/09/00ISR Number: 3455568-9Report Type:Expedited (15-DaCompany Report #WAES 99120255
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	[Therapy Unspecified]	C				

Date:02/09/00ISR Number: 3455569-0Report Type:Expedited (15-DaCompany Report #WAES 00011039
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Nail Avulsion	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Nail Discolouration		Celebrex	C		
	Nail Disorder		Famvir	C		
			Prosom	C		
			Prozac	C		
			Synthroid	C		

Date:02/09/00ISR Number: 3455571-9Report Type:Expedited (15-DaCompany Report #WAES 00012665
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Lower	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG /						
Hospitalization -	Abdominal Tenderness	Professional				
PRN/ PO						
Initial or Prolonged	Blood Chloride Decreased		Ditropan	C		
Other	Bowel Sounds Abnormal		Slow Fe	C		
	Diarrhoea		[Therapy			
	Diverticular Perforation		Unspecified]	C		
	Diverticulitis		Calcium Supplement			
	Haematocrit Decreased		(Composition	C		
	Hyponatraemia		Propranolol	C		
	Ileus Paralytic					
	Peptic Ulcer Perforation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/00ISR Number: 3455573-2Report Type:Expedited (15-DaCompany Report #WAES 00015179
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Paranoia							
	Psychotic Disorder		Acamprosate Calcium	C				

Date:02/09/00ISR Number: 3455575-6Report Type:Expedited (15-DaCompany Report #WAES 00015196
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	111 DAY
Hospitalization - Initial or Prolonged	Influenza Like Illness							
	Pulmonary Embolism		Timoptic	C				
			Vasotec	C				
			Allopurinol	C				
			Dipyridamole	C				
			Furosemide	C				
			Omeprazole	C				

Date:02/10/00ISR Number: 3455153-9Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased	Health Professional	Vioxx 25 Mg Merck & Co.	PS	Merck & Co.	ORAL	50 MG QHS PO	
	Blood Urea Increased		Ventolin	C				
	Hyperkalaemia		Atrovent	C				
			Atenolol	C				
			Miacalcin	C				
			Neurontin	C				
			Lipitor	C				
			Duragesic	C				
			Bactim Ds	C				
			Trazodone	C				
			Remeron	C				

Oscal W/ Uhd C

Date:02/10/00ISR Number: 3456255-3Report Type:Expedited (15-DaCompany Report #WAES 00020306
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister	Health	Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Dermatitis	Professional						
Initial or Prolonged	Dermatitis Exfoliative	Company						
	Skin Disorder	Representative						
	Skin Exfoliation							
	Skin Graft							
	Skin Necrosis							

Date:02/10/00ISR Number: 3456257-7Report Type:Expedited (15-DaCompany Report #WAES 00010866
Age:75 YR Gender:Female I/FU:I

Outcome	PT
Death	Haemodialysis
Hospitalization -	Haemoptysis
Initial or Prolonged	Hypotension

		Interstitial Lung Disease Renal Failure Acute Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Vioxx Unk	PS		ORAL
PO							
			Professional Other	Ibuprofen	C		

Date:02/10/00ISR Number: 3456272-3Report Type:Expedited (15-DaCompany Report #WAES 99127511
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation	Foreign	Tab Vioxx			
Initial or Prolonged	Cardiac Failure	Study	(Rofecoxib)	PS		ORAL
50 MG 131 DAY						
	Congestive	Health	Tab Placebo	SS		ORAL
2 TABLET 131 DAY						
	Skin Necrosis	Professional	Captopril	C		
	Vasculitis		Digoxin	C		
			Folic Acid	C		
			Molsidomine	C		
			Prednisolone	C		

Date:02/10/00ISR Number: 3456330-3Report Type:Expedited (15-DaCompany Report #WAES 00015675
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Leukopenia	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
25 MG. PO 8 DAY						
			Captooril	C		
			Ceftriaxone Dina			
			Hemiheptahydrate	C		
			Digoxin			
			B-Acetyldigoxin	C		
			Dipyrone	C		
			Electrolytes (+)			
			Glucose	C		
			Furosemide	C		
			Glucose	C		

Melperone Hc1	C
Nadroparin	C
Omeprazole	C
Potassium Chloride	C
Tramadol Hc1	C

Date:02/10/00ISR Number: 3456332-7Report Type:Expedited (15-DaCompany Report #WAES 00020314
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	2 DAY
	Haematochezia	Company						
	Malaise	Representative						

Date:02/10/00ISR Number: 3456369-8Report Type:Expedited (15-DaCompany Report #WAES 00012612
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oliguria	Health	Tab Vioxx Unk	PS		ORAL	50	
Initial or Prolonged	Renal Failure Acute	Professional					MG/DAILY/PO	

				[Therapy Unspecified]	C		
				Allopurinol	C		

Date:02/11/00ISR Number: 3456729-5Report Type:Direct Company Report #
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Aspirin	PS		ORAL	162MG DAILY	
Initial or Prolonged	Gastritis Erosive					ORAL		
	Melaena		Vioxx	SS		ORAL	25MG DAILY	
	Oesophagitis					ORAL		

Date:02/14/00ISR Number: 3457422-5Report Type:Expedited (15-DaCompany Report #WAES 00010871
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Increased	Professional	Lanoxin 0.125 Mg	SS			0.125 MG	
Initial or Prolonged	Blood Potassium Increased	Other	Ativan	C				
	Blood Thyroid Stimulating		Detrol	C				
	Hormone Increased		Glucotrol Xl	C				
	Bradycardia		Halcion	C				
	Cardiac Murmur		Lopressor	C				
	Diabetes Mellitus		Premarin	C				
	Dizziness		Prilosec	C				
	Drug Level Above		Prozac	C				
	Therapeutic		Aspirin	C				
	Hypotension							
	Lethargy							
	Multi-Organ Failure							
	Renal Impairment							
	Sick Sinus Syndrome							
	Supraventricular							
	Tachycardia							

Therapeutic Agent
Toxicity

Date:02/14/00ISR Number: 3457438-9Report Type:Expedited (15-DaCompany Report #WAES 00020351
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Increased	Professional	Ginkor	C				
	Blood Urea Increased		Thyroxine	C				
	Renal Disorder							

Date:02/14/00ISR Number: 3457440-7Report Type:Expedited (15-DaCompany Report #WAES 00020444
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	50	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	1 DAY
Initial or Prolonged			Tab Vioxx	SS		ORAL	25	
							MG/DAILY/PO	4 DAY
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/00ISR Number: 3457441-9Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Health	Vioxx	PS		ORAL	12.5 MG PO QD	1 WK
Initial or Prolonged	Haematemesis	Professional	Didiban	C				
Required	Haemoglobin Decreased		Tiazac	C				
Intervention to	Melaena		Claritin	C				
Prevent Permanent			Nasonex	C				
Impairment/Damage								

Date:02/14/00ISR Number: 3457449-3Report Type:Expedited (15-DaCompany Report #WAES 00025523
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall	Foreign	Tab Vioxx					
Hospitalization -	Gastric Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG PO	
Initial or Prolonged	Gastric Perforation							
	Joint Dislocation							
	Medical Device							
	Complication							
	Post Procedural							
	Complication							

Date:02/14/00ISR Number: 3457458-4Report Type:Expedited (15-DaCompany Report #WAES 00029757
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Syncope	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG PO	

Date:02/14/00ISR Number: 3457488-2Report Type:Expedited (15-DaCompany Report #WAES 99120947
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Hospitalization - Initial or Prolonged		Professional						

Date:02/14/00ISR Number: 3457489-4Report Type:Expedited (15-DaCompany Report #WAES 99111289
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea	Professional						
	Diverticulum Intestinal		Claritin	C				
	Flatulence		Darvocet-N	C				
	Gastrointestinal		Klonopin	C				
	Haemorrhage		Lipitor	C				
	Rectal Haemorrhage		Maxzide	C				
	Syncope		Tylenol	C				
	Vomiting		Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/00ISR Number: 3457490-0Report Type:Expedited (15-DaCompany Report #WAES 99100830
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Disability	Brain Damage	Professional						
Other	Drug Interaction		Coumadin Unk	SS			7.5 MG/DAILY/UNK	
	Hypoaesthesia							
	Nervous System Disorder		Avapro	C				
	Subdural Haematoma		Celebrex	C				
			Plaquenil	C				
			Ziac	C				
			Acetaminophen	C				

Date:02/14/00ISR Number: 3457491-2Report Type:Expedited (15-DaCompany Report #WAES 00025501
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	7 DAY
	Renal Failure	Professional	Ciprofloxacin Monhcl Monohydrate	C				

Date:02/14/00ISR Number: 3457493-6Report Type:Expedited (15-DaCompany Report #WAES 00017751
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bilirubinuria	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	2 DAY
	Cardiac Failure							
	Congestive Dyspnoea Paroxysmal Nocturnal	Professional						
	Ejection Fraction Abnormal							

Hallucination
Jaundice
Lung Infiltration
Oedema Peripheral
Pleural Effusion
Pneumonia

Date:02/14/00ISR Number: 3457888-0Report Type:Expedited (15-DaCompany Report #WAES 00010586
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Hospitalization -	Drug Ineffective	Professional	Celebrex Unk	SS		ORAL	200	
Initial or Prolonged	Faecal Occult Blood						MG/DAILY/PO	
Other	Positive		Darvocet-N	C				
	Fall		Monistat	C				
	Gastric Ulcer Haemorrhage		Prinivil	C				
	Gastritis		Relafen	C				
	Haemoglobin Decreased		Amlodipine					
	Medication Error		Benzenesulfonate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/00ISR Number: 3458544-5Report Type:Expedited (15-DaCompany Report #WAES 00012020
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colonic Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Gastrointestinal	Professional					MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Company Representative	Claritin	C				
	Haematochezia		Gaviscon Liquid Antacid	C				
Other	Haemoglobin Decreased		Glucophage	C				
	Platelet Count Decreased		Glucotrol	C				
			Humibid L.A.	C				
			Metamucil	C				
			Prilosec	C				
			Proventil	C				
			Proventil Repetabs And Tablets	C				
			Theo-Dur	C				
			Tylenol Pm	C				
			Vasotec (Therapy Unspecified)	C				
			Albuterol	C				
			Corticosteroids (Composition Uns	C				
			Minerals (+) Vitamins	C				

Date:02/14/00ISR Number: 3458546-9Report Type:Expedited (15-DaCompany Report #WAES 00020064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Tubular Necrosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:02/14/00ISR Number: 3458548-2Report Type:Expedited (15-DaCompany Report #WAES 00020324
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Creatinine Renal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Clearance Decreased Renal Impairment	Professional	Prinivil	C				

Date:02/15/00ISR Number: 3457472-9Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx 12.5 Mg Po					
Initial or Prolonged	Increased	Professional	Daily (Rofecoxib)	PS		ORAL	12.5 MG PO Q	
Required	Electrocardiogram Qrs						DAY	
Intervention to	Complex Prolonged		Vioxx 25 Mg Po Daily	SS		ORAL	25 MG PO Q	
Prevent Permanent	Hyperkalaemia						DAY	
Impairment/Damage	Renal Failure Acute		Actos	C				
			70/30 Insulin	C				
			Cordarone	C				
			Macrobid	C				
			Prozac	C				
			Norpace	C				

Phenergan With Codeine	C
Humibid La	C
Capoten	C
Trental	C
Vicodin	C
Albuterol	C
Insulin 70/30	C

Date:02/15/00ISR Number: 3458563-9Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Blood Thyroid Stimulating	Professional						
Initial or Prolonged	Hormone Increased	Company	Celebrex	C				
Disability	Blood Urea Increased	Representative	Ecotrin	C				
Other	Dyspnoea	Other	Hydrodiuril	C				
	Hyperglycaemia		L-Thyroxine	C				
	Hypertension		Macrobid	C				
	Hypothyroidism		Tylenol	C				
	Lipid Metabolism Disorder							
	Nephritis Interstitial							
	Nephrotic Syndrome							
	Oedema							
	Oedema Peripheral							
	Pleural Effusion							
	Proteinuria							
	Renal Failure Acute							
	Urine Osmolarity Decreased							
	Weight Increased							

Date:02/15/00ISR Number: 3458580-9Report Type:Expedited (15-DaCompany Report #WAES 00020022
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Initial or Prolonged	Chest Pain	Health
	Dizziness	Professional
	Dyspnoea	
	Headache	
	Hypertension	
	Insomnia	
	Nausea	
	Panic Disorder Without	
	Agoraphobia	
	Tachycardia	

Date:02/15/00ISR Number: 3458584-6Report Type:Expedited (15-DaCompany Report #WAES 00010306
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization -	Fatigue
Initial or Prolonged	Gastrointestinal
Disability	Haemorrhage
	Haematochezia

Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
Health Professional	[Therapy Unspecified]	C				
Company Representative						

Date:02/15/00ISR Number: 3458592-5Report Type:Expedited (15-DaCompany Report #WAES 00012250
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Blood Creatinine Increased	Professional	Trental Unk	SS				
			Pravachol Unk	SS				
	Blood Urea Increased		Enduron	C				
	Haemoglobin Decreased		Glynase Prestab	C				
	Hyperglycaemia		Humulin L	C				
	Hypertension		Humulin R	C				
	Mental Disorder		Norvasc	C				
	Muscular Weakness		Plavix	C				
	Pollakiuria		Proscar	C				
	Speech Disorder		Zantac	C				
	Supraventricular Extrasystoles		[Therapy Unspecified]	C				
	Urinary Incontinence		Magnesium Oxide	C				

Date:02/15/00ISR Number: 3458598-6Report Type:Expedited (15-DaCompany Report #WAES 00017751
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bilirubinuria	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	2 DAY
Initial or Prolonged	Cardiac Failure							
	Congestive		Ranitidine Hcl	C				
	Hallucination							

Jaundice
Oedema Peripheral

Date:02/16/00ISR Number: 3458792-4Report Type:Expedited (15-DaCompany Report #WAES 00020638
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Initial or Prolonged	Duodenal Ulcer	Professional					PO;	
Other	Fatigue	Company					UNK/3XW/PO	
	Gastritis	Representative	Aspirin	C				
	Haematochezia							
	Hiatus Hernia							
	Medication Error							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/00ISR Number: 3458794-8Report Type:Expedited (15-DaCompany Report #WAES 00028521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Delirium	Foreign	Tab Vioxx					
	Paranoia	Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	Haloperidol	C				

Date:02/16/00ISR Number: 3458859-0Report Type:Expedited (15-DaCompany Report #WAES 00012014
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faecal Occult Blood	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Positive	Professional					MG/DAILY/PO	
Initial or Prolonged	Haematemesis	Company						
Other	Haematocrit Decreased	Representative						
	Haemoglobin Decreased							
	Melaena							
	Oesophageal Ulcer							
	Upper Gastrointestinal							
	Haemorrhage							

Date:02/16/00ISR Number: 3458860-7Report Type:Expedited (15-DaCompany Report #WAES 00020351
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Increased	Professional	Ginkor	C				
	Blood Urea Increased		Thyroxine	C				
	Renal Impairment							

Date:02/16/00ISR Number: 3459251-5Report Type:Expedited (15-DaCompany Report #WAES 99111828
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Aggression
Hospitalization - Initial or Prolonged	Arterial Disorder
	Arthralgia
	Asthenia
	Balance Disorder
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Confusional State
	Convulsion
	Dementia
	Drug Interaction
	Drug Withdrawal Syndrome
	Dysarthria
	Dysphagia
	Fall
	Hallucination, Visual
	Headache
	Hypoaesthesia
	Insomnia
	Neuroleptic Malignant Syndrome
	Parkinson'S Disease
	Pharyngeal Oedema

	Pyrexia Sedation Speech Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Syncope	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY
	Thrombocytopenia	Health					PO
	Transient Ischaemic	Professional	Inj Kenalog 10 Mg	SS			10 MG DAILY
	Attack	Other					INJ
			Inj [Therapy Unspecified] Unk	SS			INJ
			Inj Marcaine Unk	SS			INJ
			Mirapex Unk	SS		ORAL	0.25 MG TID PO
			Mirapex Unk	SS		ORAL	0.25 MG TID PO
			Inj [Composition Unspecified] Unk	SS			INJ
			Inderal La	C			
			Ismo	C			
			Lanoxin	C			
			Valium	C			
			Vitamins	C			

Date:02/16/00ISR Number: 3459252-7Report Type:Expedited (15-DaCompany Report #WAES 99110178
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY
Hospitalization -	Blood Creatinine	Professional					PO
Initial or Prolonged	Increased	Company	Accupril	C			
	Blood Urea Increased	Representative	Celebrex	C			

	Diabetes Mellitus		Nonsteroidal			
	Renal Failure		Anti-Inflammatory	C		
	Sepsis					

Date:02/16/00ISR Number: 3459253-9Report Type:Expedited (15-DaCompany Report #WAES 00010676
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angiopathy	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG DAILY						
Initial or Prolonged	Gastrointestinal	Health				
PO						
	Haemorrhage	Professional	Allegra	C		
	Haematochezia		Alphagan	C		
			Inflamase	C		
			Trusopt	C		
			Vasotec	C		
			Xalatan	C		
			Vitamins	C		

Date:02/16/00ISR Number: 3459254-0Report Type:Expedited (15-DaCompany Report #WAES 99121188
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatine Increased	Health	Tab Vioxx 25 Mg	PS		ORAL
50 MG DAILY						
Initial or Prolonged	Renal Failure	Professional				
PO						
Disability		Company	Lotensin	C		
Other		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/00ISR Number: 3459148-0Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS		ORAL	12.5 MG	ORAL
Initial or Prolonged	Gastrointestinal		Aspirin	SS		ORAL	325 QD	ORAL
	Haemorrhage							
	Haematemesis							
	Nausea							

Date:02/17/00ISR Number: 3459149-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS				
Initial or Prolonged	Haemorrhage							

Date:02/17/00ISR Number: 3459345-4Report Type:Expedited (15-DaCompany Report #WAES 00010398
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Amylase Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Lipase Increased	Professional					MG/DAILY/PO	
Initial or Prolonged	Pancreatic Pseudocyst		Accolate	C				
Other	Pancreatitis		Ativan	C				
			Hydrodiuril	C				
			Miacalcin	C				
			Premarin	C				
			Rocephin	C				
			Serevent	C				
			Solu-Medrol	C				
			Univasc	C				
			Guaifenesin	C				

Date:02/17/00ISR Number: 3459423-XReport Type:Expedited (15-DaCompany Report #WAES 00020804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Hearing Impaired		Vaseretic	C				
			Vitamins	C				

Date:02/17/00ISR Number: 3459427-7Report Type:Expedited (15-DaCompany Report #WAES 00020985
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:02/17/00ISR Number: 3459445-9Report Type:Expedited (15-DaCompany Report #WAES 00010945
Age:85 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
	Cerebrovascular Accident	Professional					DAILY, PO	
	Gastric Ulcer Haemorrhage	Company	Ambien	C				
	Haemoglobin Decreased	Representative	Cardizem Cd	C				
			Coumadin	C				
			Lasix	C				
			Ultram	C				
			Mavik	C				
			Plavix	C				

Date:02/17/00ISR Number: 3459448-4Report Type:Expedited (15-DaCompany Report #WAES 00020314
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY	
Hospitalization -	Gastrointestinal	Professional					PO	
Initial or Prolonged	Haemorrhage	Company	Fosamax	C				
Other	Haematochezia	Representative	Maxzide	C				
	Haemoglobin Decreased		Procardia	C				
	Malaise		Synthroid	C				
	Melaena		Zocor	C				
			Aspirin	C				

Date:02/17/00ISR Number: 3459449-6Report Type:Expedited (15-DaCompany Report #WAES 99108250
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	21 DAY
Disability		Professional						

Date:02/18/00ISR Number: 3459212-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm		Vioxx	PS		ORAL	25 MG PO X1	
Initial or Prolonged	Confusional State							
	Dyspnoea							
	Erythema							
	Hypertension							
	Swelling							

Date:02/18/00ISR Number: 3459220-5Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Vioxx 12.5 Mg	PS		ORAL	12.5 MG QD PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/00ISR Number: 3459221-7Report Type:Direct Company Report #
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx 12.5 Mg	PS		ORAL	12.5 QD PO	
Initial or Prolonged	Congestive		Lasix	C				
	Oedema Peripheral		Digoxin	C				
			Vasotec	C				
			Coreg	C				
			Asa	C				

Date:02/18/00ISR Number: 3459226-6Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea Exertional		Vioxx 25 Mg	PS			25 MG QD	
Initial or Prolonged	Faeces Discoloured		Buffered Asa Prn	SS			PRN	
	Nausea		Glucophage	C				
			Labetalol	C				
			Hytrin	C				
			Lipitor	C				
			Glyburide	C				
			Prinivil	C				
			Cytomel	C				

Date:02/18/00ISR Number: 3459239-4Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage	Health	Rofecoxib	PS			25MG QD	
Initial or Prolonged	Tachypnoea	Professional	Warfarin	SS			3 MG QD	
			Ditropan Xl	C				
			Ferrous Sulfate	C				
			Oxycontin Sa	C				
			Pepcid	C				

				Verapamil Sa	C		
				Clindamycin	C		
				Zoloft	C		

Date:02/18/00ISR Number: 3460052-2Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Rofecoxib (Vioxx)	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Increased							
Required	Renal Impairment							
Intervention to	Therapeutic Agent							
Prevent Permanent	Toxicity							
Impairment/Damage								

Date:02/22/00ISR Number: 3460000-5Report Type:Direct Company Report #
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypoaesthesia		Vioxx 12.5 Mgm Merck	PS	Merck	ORAL	12.5 MGM QD	
Intervention to	Myalgia							
Prevent Permanent	Neuropathy Peripheral		Vitamins	C				
Impairment/Damage	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3460042-XReport Type:Direct Company Report #
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Pulmonary Oedema		Rofecoxib (Strength Not Available)	PS		ORAL	PO (DOSE AND FREQUENCY NOT AVAILABLE)	
			K-Dur	C				
			Lasix	C				
			Zoloft	C				
			Norvasc	C				
			Prilosec	C				
			Aricept	C				
			Synthroid	C				

Date:02/22/00ISR Number: 3460782-2Report Type:Expedited (15-DaCompany Report #WAES 00025623
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured Gastric Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:02/22/00ISR Number: 3460784-6Report Type:Expedited (15-DaCompany Report #WAES 00021209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal Renal Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:02/22/00ISR Number: 3460819-0Report Type:Expedited (15-DaCompany Report #WAES 00020872
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/22/00ISR Number: 3460821-9Report Type:Expedited (15-DaCompany Report #WAES 00011982
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
Disability	Gastrointestinal Haemorrhage Haematochezia Haematocrit Decreased Haemoglobin Decreased	Company Representative	Gastrointestinal Preparations Nonsteroidal Anti-Inflammatory D	C C				

Date:02/22/00ISR Number: 3460835-9Report Type:Expedited (15-DaCompany Report #WAES 00020526
Age:78 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive

	Condition Aggravated Haemodialysis Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	3 DAY

Date:02/22/00ISR Number: 3460838-4Report Type:Expedited (15-DaCompany Report #WAES 00021046
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/22/00ISR Number: 3460840-2Report Type:Expedited (15-DaCompany Report #WAES 00020714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Congestive Gastrointestinal Haemorrhage	Company Representative	Capoten	C				
			Lasix	C				
			Insulin	C				

Date:02/22/00ISR Number: 3460843-8Report Type:Expedited (15-DaCompany Report #WAES 00025579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:02/22/00ISR Number: 3460844-XReport Type:Expedited (15-DaCompany Report #WAES 00020738
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/22/00ISR Number: 3461092-XReport Type:Expedited (15-DaCompany Report #WAES 00021101
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Biopsy Liver Abnormal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased	Professional	Neurontin	SS				
	Hepatic Cirrhosis		Celebrex	SS				
	Hepatic Failure		Ambien	C				
	Hepatitis Cholestatic		Cozaar	C				
	Jaundice		Norvasc	C				
	Liver Function Test Abnormal		Reglan	C				
	Prothrombin Time Prolonged							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3461094-3Report Type:Expedited (15-DaCompany Report #WAES 00021250
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Diverticulitis						MG/DAILY/PO	14 DAY
Initial or Prolonged	Hypertension		Cardura	C				
	Oedema Peripheral		Tambocor	C				

Date:02/22/00ISR Number: 3461096-7Report Type:Expedited (15-DaCompany Report #WAES 00010874
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Bronchospasm	Professional	Eskalith	C				
Initial or Prolonged		Other						
Other								

Date:02/22/00ISR Number: 3461103-1Report Type:Expedited (15-DaCompany Report #WAES 00011234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health	Tab Vioxx Unk	PS				
Hospitalization -		Professional						
Initial or Prolonged		Company Representative						

Date:02/22/00ISR Number: 3461106-7Report Type:Expedited (15-DaCompany Report #WAES 00012188
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Hospitalization -	Urticaria	Professional					
MG/DAILY/PO							
Initial or Prolonged							
Other							

Date:02/22/00ISR Number: 3461109-2Report Type:Expedited (15-DaCompany Report #WAES 99122310
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Chest Discomfort	Professional						
MG/DAILY/PO								
Initial or Prolonged	Pharyngeal Oedema	Company						
Disability		Representative						
Other								

Date:02/22/00ISR Number: 3461113-4Report Type:Expedited (15-DaCompany Report #WAES 00010789
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS				
OPHTHALMIC							25	
		Health						
MG/DAILY/PO								
		Professional	Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3461117-1Report Type:Expedited (15-DaCompany Report #WAES 00010676
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhagic	Health					MG/DAILY/PO	
	Gastrointestinal	Professional	Tab Vioxx 25 Mg	SS		ORAL	25	
	Haemorrhage						MG/DAILY/PO	
	Haematochezia		Allegra	C				
	Haematocrit Decreased		Alphagan	C				
			Ditropan	C				
			Inflamase	C				
			Trusopt	C				
			Vasotec	C				
			Xalatan	C				
			Vitamins	C				

Date:02/22/00ISR Number: 3461119-5Report Type:Expedited (15-DaCompany Report #WAES 99120255
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Heart Rate Increased	Professional					MG/DAILY/PO	
		Company Representative	Tylenol	C				

Date:02/22/00ISR Number: 3461121-3Report Type:Expedited (15-DaCompany Report #WAES 00020324
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Prinivil	C				
			Amiodarone	C				

Date:02/22/00ISR Number: 3461147-XReport Type:Expedited (15-DaCompany Report #WAES 00025579
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:02/22/00ISR Number: 3461162-6Report Type:Expedited (15-DaCompany Report #WAES 00025164
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	6 DAY
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation		Cisapride	C				
			Danthron (+)					
			Poloxamer 188	C				
			Morphine So4	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3461169-9Report Type:Expedited (15-DaCompany Report #WAES 00025558
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Tab Vioxx					
	Blood Bilirubin Increased	Health	(Rofecoxib)	PS		ORAL	25 MG PO	25 DAY
	Hepatitis	Professional	Aspirin	C				
	Hepatomegaly		Dipyrone	C				
	Liver Function Test Abnormal		Fenoterol Hydrobromide (+)					
			Ipratropium B	C				
			Trihexyphenidyl Hcl	C				

Date:02/22/00ISR Number: 3461173-0Report Type:Expedited (15-DaCompany Report #WAES 00020417
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Constipation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Life-Threatening	Dehydration	Professional						
Hospitalization - Initial or Prolonged	Faecaloma		Cytotec	C				
	Intestinal Obstruction		Prevacid	C				
	Intestinal Perforation		(Therapy Unspecified)	C				
	Pneumonia		Aspirin	C				
	Weight Decreased		Hyoscyamine	C				

Date:02/22/00ISR Number: 3461519-3Report Type:Expedited (15-DaCompany Report #WAES 00020714
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Congestive Gastrointestinal Haemorrhage	Professional Company Representative	Capoten	C				
			Lasix	C				
			Insulin	C				

Date:02/22/00ISR Number: 3461521-1Report Type:Expedited (15-DaCompany Report #WAES 00020444
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Health	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastritis Erosive	Professional					25 MG/DAILY/PO	4 DAY
	Gastrointestinal Haemorrhage							
			Aspirin 325 Mg	SS			325 MG/DAILY	2 YR

Date:02/22/00ISR Number: 3461523-5Report Type:Expedited (15-DaCompany Report #WAES 00020017
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anorexia
	Asthenia
	Atrial Fibrillation
	Blood Albumin Decreased
	Blood Pressure Systolic Increased
	Bronchospasm
	Cardiac Failure

		Congestive					
		Cardiac Murmur					
		Cardiomegaly					
		Coronary Artery Embolism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cough	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Crepitations	Professional				
MG/DAILY/PO							
		Culture Urine Positive	Company	Combivent	C		
		Dehydration	Representative	Coumadin	C		
		Drug Toxicity		Keflex	C		
		Dyspnoea		Lanoxin	C		
		Ecchymosis		Lasix	C		
		Electrocardiogram		Metamucil	C		
		Abnormal		Norvasc	C		
		Escherichia Infection		Paxil	C		
		Faeces Discoloured		Prevacid	C		
		Gastric Ulcer Haemorrhage		Serevent	C		
		Haematemesis		Synthroid	C		
		Haematochezia		Tegretol	C		
		Heart Rate Increased		Ultram	C		
		Hypertension		Vanceril	C		
		Inflammation		Ziac	C		
		Intestinal Infarction		Ampicillin	C		
		Intestinal Ischaemia		Aspirin	C		
		Lung Infiltration		Potassium Chloride	C		
		Myocardial Ischaemia		Spironolactone	C		
		Oedema					
		Oesophagitis					
		Pallor					
		Platelet Count Decreased					
		Pneumonia					
		Pulmonary Congestion					
		Pulmonary Oedema					
		Pyelonephritis					
		Pyrexia					
		Respiratory Distress					
		Respiratory Rate					
		Increased					
		Sepsis					
		Speech Disorder					
		Sputum Discoloured					
		Syncope					
		Tachypnoea					
		Urinary Tract Infection					
		Wheelchair User					
		White Blood Cell Count					

Increased

Date:02/22/00ISR Number: 3462207-XReport Type:Expedited (15-DaCompany Report #WAES 00010651
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Creatinine	Professional					MG/DAILY/PO	
Disability	Increased	Company	Accupril	C				
	Cardiac Failure	Representative	Aldactazide	C				
	Congestive		Coumadin	C				
	Chest Pain		Darvocet-N	C				
	Dyspnoea		Synthroid	C				
	Renal Impairment		Atenolol	C				

Date:02/22/00ISR Number: 3462210-XReport Type:Expedited (15-DaCompany Report #WAES 00010120
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastroenteritis	Company	Combivent	C				
Other	Helicobacter	Representative	Lipitor	C				
	Haematocrit Decreased		Miacalcin	C				
	Haemoglobin Decreased		Norvasc	C				
	Iron Binding Capacity		Prevacid	C				
	Total Increased		Tylenol	C				
	Red Blood Cell Count		Vanceril	C				
	Decreased							
	Serum Ferritin Decreased							

Date:02/22/00ISR Number: 3462215-9Report Type:Expedited (15-DaCompany Report #WAES 00011236
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gait Disturbance	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Medication Error	Professional					MG/DAILY/PO	
	Muscular Weakness	Company	Motrin 600 Mg	SS		ORAL	600 MGBID/PO	
	Renal Impairment	Representative	Accupril	C				
			Dyazide	C				
			Paxil	C				

Date:02/22/00ISR Number: 3462218-4Report Type:Expedited (15-DaCompany Report #WAES 00011666
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization -	Anorexia	Professional	Dilacor Xr	C				
Initial or Prolonged	Anxiety		Humulin	C				

Other	Asthenia	Lanoxin	C
	Fatigue	Lasix	C
	Feeling Abnormal	Oxycontin	C
	Gastric Ulcer Haemorrhage	Plaquentil	C
	Haemoglobin Decreased	Synthroid	C
		Xanax	C
		Zaroxolyn	C
		Zestril	C
		Atenolol	C
		Potassium Supplement (Composition	C
		Prednisone	C

Date:02/22/00ISR Number: 3462222-6Report Type:Expedited (15-DaCompany Report #WAES 00011788
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Electrocardiogram Qrs	Health	Tab Vioxx Unk	PS		ORAL	25	
Initial or Prolonged	Complex Prolonged	Professional					MG/DAILY/PO	
	Hyperkalaemia		Therapy Unspecified	C				
	Renal Failure Acute							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/00ISR Number: 3462233-0Report Type:Expedited (15-DaCompany Report #WAES 99101361
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cholecystitis	Study	Cap Crixivan	PS		ORAL	800 MG/Q8H/PO	
Hospitalization -	Cholelithiasis	Health	Cap Crixivan	SS		ORAL	800 MG/Q8H/PO	
Initial or Prolonged	Coagulation Time	Professional	Cap Crixivan	SS		ORAL	800 MG/Q8H/PO	
Other	Prolonged		Cap Lodenosine	SS		ORAL	300 MG/BID/PO	
	Colitis		Cap Stavudine	SS		ORAL	40 MG/BID/PO	
	Coma		Tab Lorcet 10/560	SS		ORAL	10 MG/BID/PO	
	Gastrointestinal		Tab Vioxx	SS		ORAL	12.5 MG/BID/PO	
	Haemorrhage							
	Hepatic Encephalopathy		Prevacid	C				
	Hepatic Failure		Prilosec	C				
	Hepatic Function Abnormal		Soma	C				
	Hepatitis							
	Hiv Infection Cdc Group Iv Subgroup C1							
	Hyperbilirubinaemia							
	Hypokalaemia							
	Hypoproteinaemia							
	Lactic Acidosis							
	Pancreatitis							
	Respiratory Failure							
	Sepsis							
	Thrombocytopenia							

Date:02/22/00ISR Number: 3462288-3Report Type:Expedited (15-DaCompany Report #WAES 00020017
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anorexia
	Asthenia
	Atrial Fibrillation
	Blood Albumin Decreased

Blood Pressure Systolic
Increased
Bronchospasm
Cardiac Failure
Congestive
Cardiac Murmur
Cardiomegaly
Coronary Artery Embolism
Cough
Crepitations
Culture Urine Positive
Dehydration
Drug Toxicity
Dyspnoea
Ecchymosis
Electrocardiogram
Abnormal
Escherichia Infection
Faeces Discoloured
Gastric Ulcer Haemorrhage
Haematemesis
Haematochezia
Heart Rate Increased
Hypertension
Inflammation

		Intestinal Infarction					
		Intestinal Ischaemia					
		Lung Infiltration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia	Health	Tab Vioxx Unk	PS		ORAL
UNKNOWN PO							
		Oedema	Professional	Combivent	C		
		Oesophagitis	Company	Coumadin	C		
		Pallor	Representative	Keflex	C		
		Platelet Count Decreased		Lanoxin	C		
		Pneumonia		Lasix	C		
		Pulmonary Congestion		Metamucil	C		
		Pulmonary Oedema		Norvasc	C		
		Pyelonephritis		Paxil	C		
		Pyrexia		Prevacid	C		
		Respiratory Distress		Serevent	C		
		Respiratory Rate		Synthroid	C		
		Increased		Tegretol	C		
		Sepsis		Ultram	C		
		Speech Disorder		Vanceril	C		
		Sputum Discoloured		Ziac	C		
		Syncope		Ampicillin	C		
		Tachypnoea		Aspirin	C		
		Urinary Tract Infection		Potassium Chloride	C		
		Wheelchair User		Spironolactone	C		
		White Blood Cell Count Increased					

Date:02/22/00ISR Number: 3462383-9Report Type:Expedited (15-DaCompany Report #WAES 00012335
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Tenderness	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
Initial or Prolonged		Chest Pain	Professional				
MG/DAILY/PO							
		Dyspnoea	Company	Prilosec	C		
		Faeces Discoloured	Representative	Reglan	C		
		Gastritis		Synthroid	C		
		Gastritis Erosive					
		Gastrointestinal Haemorrhage					
		Haematemesis					
		Haemoglobin Decreased					

Heart Rate Increased
Hiatus Hernia

Date:02/22/00ISR Number: 3462389-XReport Type:Expedited (15-DaCompany Report #WAES 99122118
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Methotrexate	C				

Date:02/22/00ISR Number: 3462392-XReport Type:Expedited (15-DaCompany Report #WAES 00020306
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blister
Hospitalization -	Burns Second Degree
Initial or Prolonged	Drug Eruption
	Nodular Vasculitis

	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Company Representative	Lipitor	C			
			Serevent	C			

Date:02/23/00ISR Number: 3461280-2Report Type:Expedited (15-DaCompany Report #000214-SK614
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Bilirubin Increased	Health	Celebrex	PS		ORAL	PO
Initial or Prolonged	Hepatic Cirrhosis	Professional	Vioxx	SS		ORAL	PO
Other	Hepatitis Cholestatic		Metoclopramide	C			
	Jaundice		Zolipidem	C			
	Liver Function Test Abnormal		Losartan Potassium	C			
			Amlodipine Besylate	C			
	Prothrombin Time Prolonged		Gabapentin	C			

Date:02/24/00ISR Number: 3462123-3Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS		ORAL	12.5 MG PO QD
			Estrogen	C			
			Vasotec	C			
			Zoloft	C			
			Tylenol	C			
			Neurontin	C			
			Fioricet	C			

Date:02/24/00ISR Number: 3463513-5Report Type:Direct Company Report #
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Clopidogrel (Plavix)	PS		ORAL	75MG QAM PO	
Initial or Prolonged	Faeces Discoloured		Rofexcoxib (Vioxx)	SS		ORAL	1T PO BID	
	Haematochezia		Naproxen	SS		ORAL	500MG PO BID	30 YR
	Vomiting		Tylenol	C				
			Lasix	C				
			Attace	C				
			Norvasc	C				
			Atenolol	C				

Date:02/25/00ISR Number: 3463278-7Report Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional	Vioxx 25 Mg (M 5 X D)	PS			25MG QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/00ISR Number: 3463441-5Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Vioxx 25 Mg	PS			2 INITIALLY,	
Life-Threatening	Increased						THEN 1 BID	
Hospitalization -	Blood Urea Increased		Insulin	C				
Initial or Prolonged	Condition Aggravated		Procainamide Sr	C				
	Oliguria		Digoxin	C				
			Nitropatch	C				
			Captopril	C				
			Isordil	C				
			Duragesic Patch	C				
			Lasix	C				
			Coumadin	C				
			Tylenol #3	C				
			Lortab	C				
			Oxycontin	C				
			Diflucan	C				
			...	C				

Date:02/25/00ISR Number: 3464122-4Report Type:Expedited (15-DaCompany Report #WAES 00025192
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Tab Vioxx					
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG PO	53 DAY
	Haematemesis		Tolbutamide	C				
	Oesophageal Ulcer		Tramadol	C				

Date:02/25/00ISR Number: 3464124-8Report Type:Expedited (15-DaCompany Report #WAES 00021415
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	

Hospitalization - DAILY/ PO	Asthenia	Professional		
Initial or Prolonged	Dyspepsia	Company	Indocin	
	Oesophagitis	Representative	(Indomethacin) Unk	SS
	Upper Gastrointestinal		Diovan	C
	Haemorrhage		Viagra	C

Date:02/25/00ISR Number: 3464125-XReport Type:Expedited (15-DaCompany Report #WAES 00020892
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Failure Acute	Professional Company Representative						

Date:02/25/00ISR Number: 3464206-0Report Type:Expedited (15-DaCompany Report #WAES 00021611
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Composition Unspecified	C				

Date:02/25/00ISR Number: 3464208-4Report Type:Expedited (15-DaCompany Report #WAES 00021542
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypersensitivity	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Failure							

Date:02/25/00ISR Number: 3464231-XReport Type:Expedited (15-DaCompany Report #WAES 99125141
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness	Foreign	Tab Vioxx					
	Syncope	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
		Professional	Timoptic	C				
			Temazepam	C				

Date:02/25/00ISR Number: 3464234-5Report Type:Expedited (15-DaCompany Report #WAES 00015642
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess	Foreign	Tab Vioxx					
	Leukopenia	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	13 DAY
		Professional	Inj Gold Sodium					
		Other	Thiomalate	SS			7 MON	
			Diclofenac	C				
			Ferroglycine So4	C				
			Hydrochlorothiazide	C				
			Methotrexate	C				
			Prednisone	C				
			Temazepam	C				
			Tramadol Hcl	C				

Date:02/25/00ISR Number: 3464238-2Report Type:Expedited (15-DaCompany Report #WAES 00020064
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Tubular Necrosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:02/25/00ISR Number: 3464242-4Report Type:Expedited (15-DaCompany Report #WAES 00021046
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:02/25/00ISR Number: 3464255-2Report Type:Expedited (15-DaCompany Report #WAES 00011976
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Influenza Like Illness	Health	Ambien	C				
	Oedema Peripheral	Professional	Diovan	C				
	Weight Increased		Paxil	C				
			Rezulin	C				

			Aspirin	C
			Doxycycline	C
			Glipizide	C
			Vitamin E	C

Date:02/25/00ISR Number: 3464259-XReport Type:Expedited (15-DaCompany Report #WAES 00028557
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphagia	Foreign	Tab Vioxx					
	Eyelid Oedema	Consumer	(Rofecoxib)	PS		ORAL	PO	
	Face Oedema							
	Pruritus							

Date:02/25/00ISR Number: 3464269-2Report Type:Expedited (15-DaCompany Report #WAES 00025637
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Tab Vioxx					
	Condition Aggravated	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	3 DAY
	Sudden Death	Professional	Budesonide	C				
			Fenoterol Hydrobromide (+)					
			Ipratropium B Magnseium Preparation	C				
			Piretadine (+)					
			Ramipril	C				
			Theophylline	C				
			Verapamil	C				
			Xipamide	C				

Date:02/25/00ISR Number: 3464273-4Report Type:Expedited (15-DaCompany Report #WAES 00025634
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Bundle Branch Block Right	Foreign	Tab Vioxx			
Initial or Prolonged	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL
SEE IMAGE 2 DAY						
		Professional	Phenprocoumon	C		

Date:02/25/00ISR Number: 3464278-3Report Type:Expedited (15-DaCompany Report #WAES 00025610
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Epistaxis	Foreign	Tab Vioxx			
Hospitalization -	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO 8 DAY						
Initial or Prolonged	Haemorrhage	Professional	Allopurinol	C		
	Thrombocytopenia		Aspirin	C		
			Candesartan			
			Cilexetil	C		
			Isosorbide-5-Mononit			
			rate	C		
			Levothyroxine Na	C		
			Theophylline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/00ISR Number: 3464282-5Report Type:Expedited (15-DaCompany Report #WAES 00021324
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Fall		Humulin N	C				
	Lower Limb Fracture		K-Dur	C				
	Oedema Peripheral		Lasix	C				
	Pulmonary Oedema		Lipitor	C				
			Norvasc	C				
			Zestril	C				
			Allopurinol	C				
			Folic Acid	C				
			Isosorbide	C				

Date:02/25/00ISR Number: 3464287-4Report Type:Expedited (15-DaCompany Report #WAES 00021261
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional						

Date:02/25/00ISR Number: 3464290-4Report Type:Expedited (15-DaCompany Report #WAES 00021414
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ AM/ PO	
Initial or Prolonged	Influenza	Professional	Rolaids	C				
	Pancreatitis		Zantac	C				
	Vomiting		Vitamins	C				

Date:02/25/00ISR Number: 3464295-3Report Type:Expedited (15-DaCompany Report #WAES 00021619
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Convulsion						PO	
	Fatigue		Buspar Unk	SS			15 MG	
	Sedation		Cardura	C				
			Prevacid	I				

Date:02/25/00ISR Number: 3464299-0Report Type:Expedited (15-DaCompany Report #WAES 00021540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Convulsion		Dilantin	C				

Date:02/28/00ISR Number: 3463902-9Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased		Captopril	PS		ORAL	6.25 - 12.5 MG TID PO	
	Cardiac Disorder							
	Cerebral Artery Embolism		Rofecoxib Vioxx	SS		ORAL	25MG QDAY PO	
	Cerebrovascular Accident		Paroxetine	C				
	Confusional State		Morphine	C				
	Dermatitis		Metoprolol	C				
	Dyspnoea		Digoxin	C				
	Pulmonary Oedema		Levofloxacin	C				
	Renal Failure Acute		Percocet	C				
	Respiratory Distress		Propranolol	C				
			Fluconazole	C				
			Cytarabine	C				
			Estropipate	C				
			Levothyroxine	C				
			Omeprazole	C				

Date:02/28/00ISR Number: 3464115-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anuria		Vioxx Merck & Co	PS	Merck & Co	ORAL	12.5 MG QD PO	
Initial or Prolonged	Confusional State		Warfarin	C				
Required	Depressed Level Of		Heparin	C				
Intervention to	Consciousness		Morphine	C				
Prevent Permanent	Metabolic Encephalopathy		Tylenol	C				
Impairment/Damage	Renal Failure Acute		Trazadone	C				
			Famotidine	C				
			Allopurinol	C				
			Trandolapril	C				
			Hydrochlorothiazide	C				

Date:02/28/00ISR Number: 3464368-5Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Vioxx 25 Mg Tablet	PS		ORAL	25MG QD PO	
Initial or Prolonged	Haematemesis		Baby Asa 81mg Tablet	SS		ORAL	81 MG QD PO	

Date:02/28/00ISR Number: 3465422-4Report Type:Expedited (15-DaCompany Report #WAES 00027293
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS		ORAL	12,5 MG	
	Haemoglobin Decreased		Tab Methotrexate					
	Leukopenia		Dina	SS		ORAL	8 YR	
	Oedema		Acetaminophen/Codein					
	Pancytopenia		e Phosphate	C				
	Thrombocytopenia		B Vitamins (+)					
			Caffeine	C				
			Enoxaparin	C				
			Estradiol/Northindro					
			ne Acetate	C				
			Propoxyphene					
			Napsylate					

			Monohydrate	C
			Sotaolol Hydrochloride	C

Date:02/28/00ISR Number: 3465428-5Report Type:Expedited (15-DaCompany Report #WAES 00027291
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Flutter	Foreign	Tab Vioxx					
	Chest Discomfort	Other	(Rofecoxib)	PS		ORAL	12,5 MG	31 DAY
	Diarrhoea		Acetaminophen/Propoxyphene Napsylate Mon	C				
	Supraventricular Tachycardia		Citalopram Hydrobromide	C				
	Tachyarrhythmia		Estriol	C				
			Mirtazapine	C				
			Omeprazole	C				
			Sertraline Hcl	C				
			Vitamin B{12}	C				

Date:02/28/00ISR Number: 3465432-7Report Type:Expedited (15-DaCompany Report #WAES 00021699
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Ulcer	Company Representative	Celebrex	C				
	Haematemesis		Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:02/28/00ISR Number: 3465436-4Report Type:Expedited (15-DaCompany Report #WAES 00021660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Congestive	Professional Company Representative				

Date:02/28/00ISR Number: 3465438-8Report Type:Expedited (15-DaCompany Report #WAES 00021041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Breast Engorgement	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Choking Sensation	Professional				
MG/DAILY/PO						
	Dyspnoea	Company	Effexor Xr	C		
	Laryngeal Oedema	Representative	Maxzide	C		
			Xanax	C		

Date:02/28/00ISR Number: 3465465-0Report Type:Expedited (15-DaCompany Report #WAES 00020099
Age:71 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company	Axid	C				
	Pneumonia	Representative	Elavil	C				
			Neurontin	C				
			Prilosec	C				
			Verelan	C				
			Xanax	C				
			Prednisone	C				

Date:02/28/00ISR Number: 3465467-4Report Type:Expedited (15-DaCompany Report #WAES 99117949
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cor Pulmonale	Foreign	Tab Vioxx					
Initial or Prolonged		Study	(Rofecoxib)	PS		ORAL	PO	183 DAY
		Health	Tab Placebo	SS		ORAL	PO	183 DAY
		Professional	Chloroquine	C				
			Ferrous So4	C				
			Folic Acid	C				
			Nifedipine	C				
			Prednisone	C				

Date:02/28/00ISR Number: 3465469-8Report Type:Expedited (15-DaCompany Report #WAES 99115318
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Tab Vioxx					
Initial or Prolonged	Arthritis	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	14 DAY
Other	Malaise	Professional	Progesterone	C				
	Mouth Ulceration							
	Oral Candidiasis							

Polyarthritis
Pyrexia
Rash Vesicular
Stevens-Johnson Syndrome
Stomatitis

Date:02/28/00ISR Number: 3465473-XReport Type:Expedited (15-DaCompany Report #WAES 99071894
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	12.5	
Life-Threatening	Distress Syndrome	Professional					MG/BID/PO	
Hospitalization -	Blood Creatinine	Other	Celebrex 100 Mg	SS			100 MG/BID	
Initial or Prolonged	Increased		Atenolol	C				
Disability	Blood Urea Increased		Ecotrin	C				
	Dyspnoea		Hydrodiuril	C				
	Medication Error		Prevacid	C				
	Pneumonia		Vasotec	C				
	Pulmonary Arterial Wedge							
	Pressure Decreased							
	Pulmonary Oedema							
	Renal Failure Acute							
	Renal Impairment							

Date:02/28/00ISR Number: 3465516-3Report Type:Expedited (15-DaCompany Report #WAES 00020426
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking	Health	Tab Vioxx (See					
	Ecchymosis	Professional	Image)	PS		ORAL	25; 12.5	
Disability	Haemarthrosis	Other					MG/DAILY/PO	
Other	International Normalised		Warfarin Sodium 6 Mg	SS		ORAL	6 MG/DAILY/PO	
	Ratio Increased		Cardizem	C				
	Oedema Peripheral		Hydrodiuril	C				
	Poor Peripheral		Tylenol	C				
	Circulation		Vasotec	C				

Date:02/28/00ISR Number: 3465520-5Report Type:Expedited (15-DaCompany Report #WAES 00029147
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Foreign	Tab Vioxx					
	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
	Cardiac Failure	Professional	Vasotec	C				
	Congestive		Acetaminophen	C				
	Cardiomegaly		Humulin	C				
	Dyspnoea		Torsemide	C				
	Po2 Decreased							
	Pulmonary Fibrosis							

Date:02/28/00ISR Number: 3465555-2Report Type:Expedited (15-DaCompany Report #WAES 00020314
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
Hospitalization -	Duodenal Ulcer	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Tab Fosamax 10 Mg	SS		ORAL	10	

Other	Gastric Ulcer	Representative			
MG/DAILY/PO					
	Gastrointestinal		Maxzide	C	
	Haemorrhage		Procardia	C	
	Haematochezia		Synthroid	C	
	Haemoglobin Decreased		Zocor	C	
	Malaise		Aspirin	C	

Date:02/28/00ISR Number: 3465557-6Report Type:Expedited (15-DaCompany Report #WAES 99122019
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Diarrhoea	Health	Imuran	C				
	Dry Throat	Professional	Methotrexate	C				
	Dyspnoea		Prednisone	C				
	Face Oedema							
	Gastrointestinal Disorder							
	Headache							
	Oesophageal Pain							
	Oral Pain							
	Pharyngeal Oedema							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/00ISR Number: 3465610-7Report Type:Expedited (15-DaCompany Report #WAES 00025610
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Autoimmune Disorder	Foreign	Tab Vioxx					
Hospitalization -	Epistaxis	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
Initial or Prolonged	Gastrointestinal	Professional	Allopurinol	C				
	Haemorrhage		Aspirin	C				
	Thrombocytopenia		Candesartan					
			Cilexetil	C				
			Isosorbide-5-Mononit					
			rate	C				
			Levothyroxine Na	C				
			Theophylline	C				

Date:02/28/00ISR Number: 3465612-0Report Type:Expedited (15-DaCompany Report #WAES 00020714
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Congestive	Professional					MG/DAILY/PO	
Hospitalization -	Duodenal Ulcer	Company	Capoten	C				
Initial or Prolonged	Gastrointestinal	Representative	Elavil	C				
Other	Haemorrhage		Lasix	C				
	Haemoglobin Decreased		Naprosyn	C				
			Norvasc	C				
			Reglan	C				
			Soma	C				
			Synthroid	C				
			Tranxene	C				
			Tylenol	C				
			Aspirin	C				
			Calcium Supplement	C				
			Codeine	C				
			Insulin	C				
			Vitamin D	C				

Date:02/28/00ISR Number: 3466001-5Report Type:Expedited (15-DaCompany Report #WAES 00020638
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Asthenia	Professional						
	Duodenal Ulcer	Company	Aspirin	C				
	Faecal Occult Blood Positive	Representative						
	Faeces Discoloured							
	Fatigue							
	Gastritis							
	Haematochezia							
	Haemoglobin Decreased							
	Hiatus Hernia							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/00ISR Number: 3537112-0Report Type:Periodic Company Report #JRFUSA2000000168
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Propulsid	PS	Janssen Research Fdn			
	Cataract	Health			Div Johnson And			
	Diplopia	Professional			Johnson	ORAL	20 MG, 10 MG,	
	Dyskinesia						3 IN 1	
	Fall						DAY(S),ORAL	
	Hallucination		Tylenol Extra					
	Injury		Strength					
	Nausea		(Paracetamol)	SS			PRN	
	Paraesthesia		Vioxx (Rofecoxib)	SS		ORAL	25MG, ORAL	
	Personality Disorder		Temazepam	SS				
	Pruritus		Monistat (Miconazole					
	Visual Disturbance		Nitrate)	SS				
			Colchicine	C				
			Sorbitol	C				
			Tamoxifen	C				
			Multivitamins	C				
			Calcium	C				
			Antioxidant	C				
			Vitamin B Complex	C				

Date:02/29/00ISR Number: 3464535-0Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Coumadin	PS		ORAL	5MG PO QD	
Initial or Prolonged	Melaena		Vioxx	SS		ORAL	25MG PO QD	
Other			Asa	SS		ORAL	81MG PO QD	

Date:02/29/00ISR Number: 3464536-2Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx 25 Mg	PS		ORAL	1 TABLET	
Initial or Prolonged							DAILY , PO	5 DAY
			Lipitor	C				
			Ativan	C				
			Darvocet N-100	C				
			Lopressor	C				
			Cardura	C				
			Isordil	C				
			Coumadin	C				
			K-Dur	C				
			...	C				
			Niferex	C				

Date:02/29/00ISR Number: 3465592-8Report Type:Expedited (15-DaCompany Report #WAES 00027275
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis	Foreign	Tab Vioxx					
Initial or Prolonged	Pancreatitis	Health	(Rofecoxib)	PS		ORAL	12,5 MG, PO	
		Professional	Azathioprine	SS		ORAL	50 MG, 100MG,	
							PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/29/00ISR Number: 3466011-8Report Type:Expedited (15-DaCompany Report #WAES 00021565
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
	Hypertension							
	Keratoconjunctivitis							
	Sicca							
	Lacrimation Decreased							
	Oedema Peripheral							
	Ophthalmoplegia							
	Thermal Burn							

Date:02/29/00ISR Number: 3466134-3Report Type:Expedited (15-DaCompany Report #200010711HMRI
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Consumer	Leflunomide (Arava) Tablets	PS		ORAL	100 MG/DAY PO	DAY
	Diarrhoea							
	Dyspepsia		Leflunomide (Arava) Tablets	SS		ORAL	10 MG/DAY PO	1 WK
	Eructation							
	Vertigo		Rofecoxib (Vioxx)	SS			5	DAY
	Vision Blurred		Acetylsalicylic Acid (Aspirine)	C				
			Metoprolol	C				
			Propafenone Hydrochloride (Rythmol)	C				
			Vitamin C	C				
			Vitamin E	C				
			Lisinopril (Zestril)	C				

Date:02/29/00ISR Number: 3466412-8Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastric Ulcer Haematemesis Photosensitivity Reaction Rash Erythematous		Vioxx (Rofecoxib), 25mg, Merck Fragmin	PS C	Merck	ORAL

25MG PO QD

Date:02/29/00ISR Number: 3466524-9Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Asthenia Blood Creatinine Increased Creatinine Renal Clearance Decreased Drug Level Above Therapeutic Dyspnoea Hallucination Hypothyroidism Pneumonia	Health Professional	Ibu 800 Mg Qid (Ibuprofen) Vioxx 25mg 2 Qd	PS SS		ORAL ORAL

Dose Duration

800 MG QID PO

25MG 2 QD PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/29/00ISR Number: 3466526-2Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Health	Vioxx 12.5mg	PS			TABLET ONE	
	Migraine With Aura	Professional					PER DAY	
	Visual Disturbance							

Date:03/01/00ISR Number: 3465545-XReport Type:Expedited (15-DaCompany Report #A005956
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Drug Ineffective	Health	Norvasc Tablets	PS		ORAL	5.00 MG	
Intervention to	Hypertension	Professional					TOTAL:DAILY:O	
Prevent Permanent							RAL	
Impairment/Damage			Rofecoxib	SS				
			Insulin	C				
			Hydrochlorothiazide	C				

Date:03/01/00ISR Number: 3465968-9Report Type:Direct Company Report #
Age:62 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx Po 12.5 Mg	PS		ORAL	12.5MG PO ?	
Initial or Prolonged	Hypokalaemia	Professional					Q?	
	Vomiting							

Date:03/01/00ISR Number: 3466068-4Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Vioxx 25mg	PS		ORAL	1 PO Q AM	
	Pruritus							

Date:03/01/00ISR Number: 3466667-XReport Type:Expedited (15-DaCompany Report #WAES 00011851
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Other	Congestive	Professional						
	Condition Aggravated		Lasix	C				
	Dyspnoea		Lipitor	C				
			Lopressor	C				
			Premarin	C				
			Zestril	C				
			[Therapy Unspecified]	C				
			Prednisone	C				
			Vitamins	C				

Date:03/01/00ISR Number: 3466672-3Report Type:Expedited (15-DaCompany Report #WAES 00020427
Age:61 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Renal Failure	Professional	Lopid 600 Mg	SS		ORAL	600 MG/BID/PO	
	Rhabdomyolysis	Other	Combivent	C				
	White Blood Cell Count Increased		Ecotrin	C				
			Halcion	C				
			Nitro-Bid	C				
			Percocet	C				
			Theo-Dur	C				

Date:03/01/00ISR Number: 3466676-0Report Type:Expedited (15-DaCompany Report #WAES 00020439
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional						
		Other	Celebrex Unk	SS			200 MG/BID	
			Diclofenac Unk	SS				

Date:03/01/00ISR Number: 3466681-4Report Type:Expedited (15-DaCompany Report #WAES 00021342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Melaena	Professional	Coumadin	C				
		Company Representative						

Date:03/01/00ISR Number: 3466684-XReport Type:Expedited (15-DaCompany Report #WAES 00021752
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
			Prilosec	C			PO	

Date:03/01/00ISR Number: 3466689-9Report Type:Expedited (15-DaCompany Report #WAES 00021413
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/ DAILY/	
Hospitalization -	Duodenal Ulcer	Professional					PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Avapro	C				
	Haematocrit Decreased		Cardizem Cd	C				
	Haemoglobin Decreased		K-Dur	C				
			Lasix	C				
			Levbid	C				
			Prilosec	C				
			Procanbid	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3466693-0Report Type:Expedited (15-DaCompany Report #WAES 99102270
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ BID/	
Initial or Prolonged	Periorbital Haematoma	Professional					PO	
Other			Celebrex	C				
			Neurontin	C				

Date:03/01/00ISR Number: 3466849-7Report Type:Expedited (15-DaCompany Report #WAES 00011976
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Influenza Like Illness	Health					PO	
	Oedema Peripheral	Professional	Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG DAILY	
	Weight Increased						PO	
			Ambien	C				
			Diovan	C				
			Paxil	C				
			Rezulin	C				
			Aspirin	C				
			Doxycycline	C				
			Glipizide	C				
			Vitamin E	C				

Date:03/01/00ISR Number: 3466853-9Report Type:Expedited (15-DaCompany Report #WAES 99120489
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Hospitalization -	Asthenia	Professional					PO	

Initial or Prolonged Disability	Blood Creatine Increased Blood Urea Increased Dialysis Fatigue Haematocrit Decreased Haemoglobin Decreased Hypercholesterolaemia Hyperglycaemia Hypertriglyceridaemia Hypokalaemia Neutropenia Pco2 Decreased Red Blood Cell Count Decreased Renal Failure Acute	Company Representative	Microzide Pravachol Prilosec Zyrtec [Therapy Unspecified]	C C C C C

Date:03/01/00ISR Number: 3466855-2Report Type:Expedited (15-DaCompany Report #WAES 00010168
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Oedema	Professional					PO	
		Company Representative	Atenolol Msd	C				
			Isordil	C				
			Norvasc	C				
			Zestril	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/00ISR Number: 3466909-0Report Type:Expedited (15-DaCompany Report #WAES 00020985
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:03/01/00ISR Number: 3466917-XReport Type:Expedited (15-DaCompany Report #WAES 00020306
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
Hospitalization - Initial or Prolonged	Burns Second Degree						PO	
Other	Dermatitis		Flovent	C				
	Drug Eruption		Lipitor	C				
	Nodular Vasculitis		Proscar	C				
	Skin Exfoliation		Serevent	C				
	Skin Necrosis		Symmetrel	C				
	Stevens-Johnson Syndrome		Prednisone	C				
	Toxic Epidermal Necrolysis							

Date:03/01/00ISR Number: 3467061-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Rofecoxib (Vioxx) Merck	PS	Merck		12.5 - 25MG	
	Anaemia							
	Asthenia						DAILY	1 MON
	Gastrointestinal		Tagamet	C				
	Haemorrhage		Reglan	C				
	Hypovolaemia		Premarin	C				
	Melaena		Accupril	C				

	Renal Failure Chronic		Elavil	C		
			Labetalol	C		

Date:03/01/00ISR Number: 3467505-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Rofecoxib 12.5 Mg	PS		
12.5MG ONCE						
	Congestive					
DAILY						
	Dyspnoea		Synthroid	C		
			Sinemet	C		
			Triamterene	C		
			Premarin	C		

Date:03/01/00ISR Number: 3467554-3Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured		Vioxx	PS		ORAL
PO 1 WK						
Initial or Prolonged	Gastric Ulcer		Synthroid	C		
	Haematemesis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/00ISR Number: 3467148-XReport Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx (Rofecoxib)	PS		ORAL	25MG PO QD	
			Zosyn	C				
			Morphine Sulfate	C				

Date:03/02/00ISR Number: 3467200-9Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS				
Initial or Prolonged	Chest Pain	Professional						
	Ventricular Tachycardia		Nyquil	C				
			Delsym	C				
			Vasotec	C				
			Gluctrol Xl	C				
			Glucotro Xkl	C				
			Aspirin	C				

Date:03/02/00ISR Number: 3467577-4Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antinuclear Antibody	Health	Vioxx (Rofecoxib)	PS				
Hospitalization -	Positive	Professional						
Initial or Prolonged	Asthenia							
	Autoimmune Hepatitis							
	Confusional State							
	Fatigue							
	Jaundice							
	Nausea							
	Vomiting							

Date:03/02/00ISR Number: 3467668-8Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Vioxx	PS				
	Congestive	Professional						
	Condition Aggravated							
	Fluid Retention							
	Oedema							
	Renal Impairment							

Date:03/02/00ISR Number: 3468386-2Report Type:Expedited (15-DaCompany Report #WAES 00025694
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Abdominal Pain Upper	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
	Faeces Discoloured	Professional	Cortisone	C				
	Gastric Haemorrhage							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/00ISR Number: 3468389-8Report Type:Expedited (15-DaCompany Report #WAES 00025666
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Cardiovascular Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	

Date:03/02/00ISR Number: 3468391-6Report Type:Expedited (15-DaCompany Report #WAES 00018574
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort Chest Pain	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	2 DAY
	Dyspnoea Nausea	Professional	Singulair	C				
			Acetaminophen/Codeine Phosphate	C				
			Atorvastatin Calcium	C				
			Calcium Carbonate (+) Etidronic Acid Dis	C				
			Flunisolide	C				
			Fluticasone Propionate	C				
			Ipratropium Bromide	C				
			Levothyroxine Na	C				
			Paroxetine Hcl Hemihydrate	C				
			Quinapril Hcl	C				
			Salmeterol 1-Hydroxy-2-Naphthoate	C				

Date:03/02/00ISR Number: 3468393-XReport Type:Expedited (15-DaCompany Report #WAES 00021853
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Colitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Colitis Ischaemic		Hydrodiuril	C		
	Face Oedema		Tiazac	C		
	Fluid Retention					
	Mesenteric Vascular Insufficiency					
	Oedema Peripheral					

Date:03/02/00ISR Number: 3468604-0Report Type:Expedited (15-DaCompany Report #001-0981-M000052
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Consumer Health	Lipitor Tablets 20 Mg (Atorvastatin)	PS		ORAL
20 MG						
	Petechiae	Professional				
(DAILY), PER						
		Company				
ORAL						
		Representative	Vioxx	SS		
			Synthroid (Levothyroxine Sodium)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/00ISR Number: 3469836-8Report Type:Expedited (15-DaCompany Report #WAES 00021726
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tachycardia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization -			Cartrol	C				
Initial or Prolonged			Lipitor	C				
			Norvasc	C				

Date:03/02/00ISR Number: 3469839-3Report Type:Expedited (15-DaCompany Report #WAES 99121840
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactoid Reaction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Asthma	Professional	Ogen	C				
Other	Condition Aggravated	Company	Xalatan	C				
	Dyspnoea	Representative	Nonsteroidal					
	Throat Tightness		Anti-Inflammatory	C				
			Vitamins	C				

Date:03/03/00ISR Number: 3469450-4Report Type:Expedited (15-DaCompany Report #WAES 00011994
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY	
Initial or Prolonged	Bronchospasm							
/ PO							2	WK
	Gastrointestinal		Colace	C				
	Haemorrhage		Cordarone	C				
			Coumadin	C				
			Metamucil	C				
			Synthroid	C				
			Vasotec	C				
			Zocor	C				
			Allopurinol	C				
			Atenolol	C				

Date:03/03/00ISR Number: 3469453-XReport Type:Expedited (15-DaCompany Report #WAES 99101346
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO / 12.5 MG/ DAILY/ PO	
Disability	Dizziness	Health Professional						
	Dyskinesia Oesophageal							
	Eye Pain							
	Flushing		Lanoxin	C				
	Headache		Lexxel	C				
	Nausea		Lodine	C				
	Vision Blurred		Tambocor	C				
			Lithium Carbonate	C				

Date:03/03/00ISR Number: 3469515-7Report Type:Expedited (15-DaCompany Report #WAES 00025616
Age:30 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Discomfort
	Chest Pain
	Convulsion
	Dizziness

	Hyperhidrosis						
	Hypertension						
	Hypokalaemia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			[Composition Unspecified]	C				

Date:03/03/00ISR Number: 3469520-0Report Type:Expedited (15-DaCompany Report #WAES 00022155
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Hypersensitivity							
Initial or Prolonged			Allegra	C				
			Avapro	C				
			Prozac	C				
			Cyproheptadine	C				

Date:03/03/00ISR Number: 3469522-4Report Type:Expedited (15-DaCompany Report #WAES 00029168
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Foreign	Tab Vioxx					
Hospitalization -	Hypertensive Crisis		(Rofecoxib)	PS		ORAL	25 MG PO	
Initial or Prolonged			Nifedipine	C				

Date:03/03/00ISR Number: 3469819-8Report Type:Expedited (15-DaCompany Report #WAES 99125743
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx					
Initial or Prolonged	Tachycardia	Health	(Rofecoxib)	PS		ORAL		

Professional

Date:03/03/00ISR Number: 3469827-7Report Type:Expedited (15-DaCompany Report #WAES 00025610
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Autoimmune Disorder	Foreign	Tab Vioxx					
Hospitalization -	Bone Marrow Depression	Health	(Rofecoxib)	PS		ORAL	12.5 MG	
Initial or Prolonged	Cardiac Disorder	Professional	Allopurinol	C				
	Epistaxis		Aspirin	C				
	Haematocrit Decreased		Candesartan					
	Haemoglobin Decreased		Cilexetil	C				
	Leukocytosis		Isosorbide-5					
	Red Blood Cell Count		Mononitrate	C				
	Decreased		Levothyroxine Na	C				
	Thrombocytopenia		Theophylline	C				

Date:03/03/00ISR Number: 3469830-7Report Type:Expedited (15-DaCompany Report #WAES 00010398
Age:52 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blood Amylase Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Infection	Professional						
Lipase Increased		Accolate	C				
Pancreatic Disorder		Ativan	C				
Pancreatic Pseudocyst		Atrovent	C				
Pancreatitis		Flovent	C				
		Hydrodiuril	C				
		Miacalcin	C				
		Premarin	C				
		Rocephin	C				
		Serevent	C				
		Solu-Medrol	C				
		Tums	C				
		Univasc	C				
		Zantac	C				
		Albuterol	C				
		Guaifenesin	C				
		Prednisone	C				

Date:03/03/00ISR Number: 3469858-7Report Type:Expedited (15-DaCompany Report #WAES 00025558
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					
Initial or Prolonged	Blood Bilirubin Increased	Health	(Rofecoxib)	PS		ORAL	25 MG PO	25 DAY
	Hepatitis	Professional	Aspirin	C				
	Liver Function Test		Dipyrone	C				
	Abnormal		Fenoterol					
			Hydrobromide (+)					
			Ipratropium B	C				
			Trihexyphenidyl Hcl	C				

Date:03/06/00ISR Number: 3469154-8Report Type:Direct Company Report #
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event		Vioxx	PS		ORAL	25MG PO DAILY	
			Lasix	C				
			K Dur	C				
			Lanoxin	C				
			Synthroid	C				
			Plendil	C				
			Zestril	C				

Date:03/06/00ISR Number: 3469987-8Report Type:Expedited (15-DaCompany Report #WAES 00022442
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Haemorrhage	Professional Company Representative	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3469998-2Report Type:Expedited (15-DaCompany Report #WAES 00010586
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/UNK/ PO	
Hospitalization -	Confusional State	Professional	Celebrex Unk	SS		ORAL	200	
Initial or Prolonged	Fall						MG/DAILY/PO	
Other	Gastric Ulcer		Darvocet-N	C				
	Gastric Ulcer Haemorrhage		Monistat	C				
	Gastritis		Prinivil	C				
	Gastritis Erosive		Relafen	C				
	Gastrointestinal		Zantac	C				
	Haemorrhage		Amlodipine					
	Haematochezia		Benzenesulfonate	C				
	Haemoglobin Decreased							

Date:03/06/00ISR Number: 3469999-4Report Type:Expedited (15-DaCompany Report #WAES 00010869
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Condition Aggravated	Professional					MG/DAILY/PO	
Initial or Prolonged	Faecal Occult Blood	Other	Prilosec	C				
Other	Positive							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Laboratory Test Abnormal							
	Upper Gastrointestinal							
	Haemorrhage							
	Urine Abnormality							
	Vomiting							

Date:03/06/00ISR Number: 3470000-7Report Type:Expedited (15-DaCompany Report #WAES 00022221
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Hallucination	Professional					MG/DAILY/PO	
		Company Representative	Darvocet-N	C				
			Elavil	C				
			Fosamax	C				
			Lanoxin	C				
			Prilosec	C				
			Proventil	C				
			Potassium Chloride	C				

Date:03/06/00ISR Number: 3470001-9Report Type:Expedited (15-DaCompany Report #WAES 00025701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:03/06/00ISR Number: 3470002-0Report Type:Expedited (15-DaCompany Report #WAES 00022270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Testicular Disorder							

Date:03/06/00ISR Number: 3470003-2Report Type:Expedited (15-DaCompany Report #WAES 00022223
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	1 WK
Hospitalization - Initial or Prolonged	Haemorrhage	Professional						
	Hyperbilirubinaemia	Other						
	Jaundice							

Date:03/06/00ISR Number: 3470005-6Report Type:Expedited (15-DaCompany Report #WAES 00022450
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	8 DAY
	Rectal Haemorrhage	Professional						
		Company Representative						

Date:03/06/00ISR Number: 3470006-8Report Type:Expedited (15-DaCompany Report #WAES 00010676
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Polyp	Consumer	Tab Vioxx 12.5 Mg/25					
Hospitalization -	Diverticulum Intestinal	Health	Mg	PS		ORAL	12.5	

Initial or Prolonged	Dizziness Postural	Professional		
MG/DAILY/PO				
Other	Electrocardiogram			
(SEE IMAGE)				
	Abnormal		Allegra	C
	Gastrointestinal		Alphagan	C
	Haemorrhage		Ditropan	C
	Haematochezia		Inflamase	C
	Haematocrit Decreased		Maalox	C
	Hypertension		Trusopt	C
	Oedema Peripheral		Tums	C
	Pupillary Disorder		Vasotec	C
	Pyrexia		Xalatan	C
			Ascorbic Acid	C
			Echinacea	C
			Vitamins	C

Date:03/06/00ISR Number: 3470007-XReport Type:Expedited (15-DaCompany Report #WAES 00021611
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Sinus Bradycardia	Professional	(Composition			
			Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3470008-1Report Type:Expedited (15-DaCompany Report #WAES 99120386
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urea Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Professional Company Representative	Aspirin	C				
Other	Gastrointestinal Haemorrhage	Other						
	Gastrointestinal Ulcer							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypotension							
	Vomiting							

Date:03/06/00ISR Number: 3470009-3Report Type:Expedited (15-DaCompany Report #WAES 00020872
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	(Therapy Unspecified)	C				

Date:03/06/00ISR Number: 3470010-XReport Type:Expedited (15-DaCompany Report #WAES 00020738
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:03/06/00ISR Number: 3470011-1Report Type:Expedited (15-DaCompany Report #WAES 00020417
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Cardiac Failure	Professional					MG/DAILY/PO	
Hospitalization - Initial or Prolonged Disability Other	Congestive		Cytotec	C				
	Cholecystitis		Lasix	C				
	Condition Aggravated		Paxil	C				
	Constipation		Prevacid	C				
	Dehydration		Zestril	C				
	Faecaloma		(Therapy Unspecified)	C				
	Gastrointestinal Perforation		Aspirin	C				
	Intestinal Obstruction		Clonidine	C				
	Intestinal Perforation		Hyoscyamine	C				
	Mental Impairment		Potassium Chloride	C				
	Osteoarthritis							
	Pneumonia							
	Surgery							
	Ulcer							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3470012-3Report Type:Expedited (15-DaCompany Report #WAES 00012188
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Urticaria	Professional						
Initial or Prolonged		Company						
Other		Representative						

Date:03/06/00ISR Number: 3470013-5Report Type:Expedited (15-DaCompany Report #WAES 00021250
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	14 DAY
Hospitalization -	Blood Pressure Increased	Health						
Initial or Prolonged	Diverticulitis	Professional	Cardura	C				
	Oedema		Tambocor	C				

Date:03/06/00ISR Number: 3470458-3Report Type:Expedited (15-DaCompany Report #WAES 00030022
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional						
		Company	Cardura	C				
		Representative	Prevacid	C				
			Vicoprofen	C				

Date:03/06/00ISR Number: 3470459-5Report Type:Expedited (15-DaCompany Report #WAES 00022446
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	100-200 MG/DAILY/PO	
	Overdose	Professional						
	Thrombocytopenia							

Date:03/06/00ISR Number: 3470464-9Report Type:Expedited (15-DaCompany Report #WAES 00022379
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:03/06/00ISR Number: 3470467-4Report Type:Expedited (15-DaCompany Report #WAES 00022322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Respiratory Disorder Respiratory Failure	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3470471-6Report Type:Expedited (15-DaCompany Report #WAES 00022287
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypoglycaemia	Professional						
	Periorbital Oedema		Humulin R	C				
	Shock Hypoglycaemic		Nph Insulin	C				
			Synthroid	C				
			Vasotec	C				

Date:03/06/00ISR Number: 3470474-1Report Type:Expedited (15-DaCompany Report #WAES 00022074
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:03/06/00ISR Number: 3470479-0Report Type:Expedited (15-DaCompany Report #WAES 00020129
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Cough	Health	Tab Vioxx	SS		ORAL	PO	
	Dyspnoea	Professional	Tab Vioxx	SS		ORAL	PO	
			Glucophage	C				
			Lipitor	C				
			Premarin	C				
			Prilosec	C				
			Slow-Mag	C				
			Tiazac	C				
			Vasotec	C				

				[Therapy Unspecified]	C		
				Allopurinol	C		
				Atenolol	C		
				Doxepin	C		

Date:03/06/00ISR Number: 3470495-9Report Type:Expedited (15-DaCompany Report #WAES 00022580
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Face Oedema	Professional						
	Headache	Company	Glucotrol	C				
	Oedema Peripheral	Representative	Prempro	C				
	Palpitations							
	Panic Attack							

Date:03/06/00ISR Number: 3470497-2Report Type:Expedited (15-DaCompany Report #WAES 00022509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oesophageal Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
Initial or Prolonged		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3470499-6Report Type:Expedited (15-DaCompany Report #WAES 00022372
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatocellular Damage	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Liver Disorder	Professional						
	Pancreatitis	Company Representative						

Date:03/06/00ISR Number: 3470618-1Report Type:Expedited (15-DaCompany Report #WAES 00025368
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	41 DAY
	Melaena							

Date:03/06/00ISR Number: 3470620-XReport Type:Expedited (15-DaCompany Report #WAES 00025674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign	Tab Vioxx					
	Gastrointestinal Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO	
	Gastrointestinal Ulcer	Professional						

Date:03/06/00ISR Number: 3470622-3Report Type:Expedited (15-DaCompany Report #WAES 00028582
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Foreign	Tab Vioxx					
	Dysarthria	Health	(Rofecoxib)	PS		ORAL	25 MG PO	
	Face Oedema	Professional	Acetaminophen/Codein					

	Tongue Oedema		e Phosphate	C

Date:03/06/00ISR Number: 3470624-7Report Type:Expedited (15-DaCompany Report #WAES 00025371
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
			Aspirin	C				
			Digoxin	C				

Date:03/06/00ISR Number: 3470631-4Report Type:Expedited (15-DaCompany Report #WAES 00022581
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Acarodermatitis
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
Disability	Blood Pressure Increased
Other	Calculus Urinary
	Dermatitis
	Dialysis
	Dry Skin
	Eczema

		Haematuria					
		Influenza Like Illness					
		Pulmonary Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
50 MG DAILY							
			Professional				
PO							
			Company	Tab Vioxx 12.5 Mg	SS		ORAL
12.5 MG							
			Representative				
/DAILY/PO							
				Aristocort	C		
				Atarax	C		
				Ceclor Cd	C		
				Eucerin Lotion	C		
				Kwell Cream And Lotion	C		
				Librax Capsules	C		
				Medrol	C		
				Premarin	C		
				Prilosec	C		
				Prinivil	C		
				Provera	C		
				Tylenol	C		
				Aspirin	C		

Date:03/06/00ISR Number: 3470645-4Report Type:Expedited (15-DaCompany Report #WAES 00011983
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthenia	Health	Tab Vioxx Unk	PS		ORAL
PO							
		Dizziness	Professional	Aspirin	C		
		Duodenitis	Company				
		Gastric Ulcer	Representative				
		Gastritis Erosive					
		Gastroenteritis					
		Helicobacter					
		Hiatus Hernia					
		Melaena					

Date:03/06/00ISR Number: 3470648-XReport Type:Expedited (15-DaCompany Report #WAES 00020022
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Other	Fluctuation	Health Professional						
	Bronchospasm	Other						
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Headache							
	Hypertension							
	Injury Asphyxiation							
	Insomnia							
	Myocardial Infarction							
	Nausea							
	Panic Disorder							
	Syncope							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/00ISR Number: 3471324-XReport Type:Expedited (15-DaCompany Report #WAES 00010043
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysphagia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Feeling Abnormal	Professional					MG/DAILY/PO	
Initial or Prolonged	Pruritus	Company	Lortab	C				
Other	Respiratory Disorder	Representative	Aspirin	C				
	Urticaria		Vitamins	C				

Date:03/06/00ISR Number: 3471330-5Report Type:Expedited (15-DaCompany Report #WAES 00012481
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atelectasis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Creatinine	Professional					MG/DAILY/PO	
	Increased	Company	Actos	C				
	Blood Urea Increased	Representative	Elavil	C				
	Condition Aggravated		Hytrin	C				
	Diarrhoea		Trental	C				
	Dizziness		Aspirin	C				
	Duodenal Ulcer							
	Emphysema							
	Endoscopy Abnormal							
	Haematemesis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Lung Disorder							
	Mallory-Weiss Syndrome							
	Oesophagitis							
	Pallor							
	Renal Impairment							
	Retching							
	Tachycardia							
	Upper Gastrointestinal							
	Haemorrhage							

Date:03/06/00ISR Number: 3471960-0Report Type:Expedited (15-DaCompany Report #HQ9652223DEC1999
Age:35 YR Gender:Female I/FU:I

Outcome	PT
Death	Blood Creatine
	Phosphokinase Increased
	Brain Oedema
	Cardiac Arrest
	Cerebral Ischaemia
	Dermatitis
	Electroencephalogram
	Abnormal
	Gaze Palsy
	Hypotension
	Influenza Like Illness
	Muscle Necrosis
	Pulmonary Embolism
	Pyrexia
	Sepsis
	Shock
	Toxic Shock Syndrome
	Vaginal Odour

Ventricular Fibrillation
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Enbrel (Etanercept)	PS		SUBCUTANEOUS	25 MG 2X PER 1 WK SC	
	Leflunomide	SS				
	Prednisone (Prednisone)	SS			10 MG 1X PER DAY	
	Rofecoxib (Rofecoxib)	SS				

Date:03/07/00ISR Number: 3470382-6Report Type:Direct Company Report #
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Coagulopathy		Coumadin	PS			4.5MG QD	
	Epistaxis		Vioxx	SS			50MG QD (PTA)	
	International Normalised Ratio Increased							

Date:03/07/00ISR Number: 3470696-XReport Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS			25 MG PO QD	
	Dizziness		Pepcid	C				
	Duodenal Ulcer							
	Haemoglobin Decreased							

Date:03/08/00ISR Number: 3471249-XReport Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ascites Oliguria Renal Failure Acute		Rofecoxib Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG / QD / ORAL	Required
Intervention to Prevent Permanent Impairment/Damage			Warfarin	C				
			Quinine	C				
			Potassium	C				
			Cyclobenzaprine	C				
			Conjugated Estrogen	C				
			Furosemide	C				
			Digoxin	C				
			Alprazolam	C				
			Famotidine	C				

Date:03/08/00ISR Number: 3471291-9Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT
Other	Blood Albumin Decreased
	Blood Chloride Decreased
	Blood Creatine Increased
	Blood Glucose Increased

	Blood Urea Increased						
	Decreased Appetite						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS		ORAL	12.5 MG PO QD

Date:03/08/00ISR Number: 3472512-9Report Type:Expedited (15-DaCompany Report #WAES 00020060
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG DAILY
Initial or Prolonged	Blood Albumin Decreased						PO
	Blood Alkaline	Company Representative	Lotensin Unk	SS		ORAL	10 MG/DAILY/PO
	Phosphatase Increased						
	Blood Chloride Decreased		Prilosec	C			
	Blood Magnesium Decreased		Glyburide	C			
	Cough						
	Croup Infectious						
	Decreased Appetite						
	Dehydration						
	Diabetes Mellitus Inadequate Control						
	Diabetic Nephropathy						
	Dizziness						
	Dyspnoea						
	Electrolyte Imbalance						
	Fatigue						
	Hepatic Cirrhosis						
	Hepatic Steatosis						
	Hepatosplenomegaly						
	Hyperglycaemia						
	Hyperkalaemia						
	Hypokalaemia						
	Hyponatraemia						
	Laryngotracheo Bronchitis						
	Lung Infiltration						
	Muscle Atrophy						
	Pco2 Decreased						

Portal Hypertension
Renal Failure
Respiratory Tract
Neoplasm
Rhonchi
Splenomegaly
Weight Decreased
White Blood Cell Count
Increased

Date:03/09/00ISR Number: 3472494-XReport Type:Expedited (15-DaCompany Report #WAES 00029304
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eyelid Oedema	Foreign	Tab Vioxx					
	Oliguria	Health	(Rofecoxib)	PS				
		Professional	Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/00ISR Number: 3472495-1Report Type:Expedited (15-DaCompany Report #WAES 00030079
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Lung Disorder		Indocin	C				

Date:03/09/00ISR Number: 3472496-3Report Type:Expedited (15-DaCompany Report #WAES 00022177
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Other	Cardiac Failure	Professional					PO	
	Congestive	Company	Buspar	C				
	Dyspnoea	Representative	Cardizem	C				
	Eyelid Oedema		Demadex	C				
	Oedema		Lanoxin	C				
	Orthopnoea		Micro K	C				
	Weight Increased		Zaroxolyn	C				
			Zestril	C				

Date:03/09/00ISR Number: 3472572-5Report Type:Expedited (15-DaCompany Report #WAES 00025701
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
	Gastrointestinal	Health						
	Haemorrhage	Professional						
	Haemoglobin Decreased	Other						

Date:03/09/00ISR Number: 3473222-4Report Type:Expedited (15-DaCompany Report #WAES 00021342
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastritis	Professional					MG/DAILY/PO	
	Haemoglobin Decreased	Company	Coumadin Unk	SS			(SEE IMAGE)	
	Haemorrhage	Representative	Avandia	C				
	International Normalised		Prilosec	C				
	Ratio Increased		(Composition					
	Melaena		Unspecified)	C				
	Retroperitoneal		Insulin	C				
	Haemorrhage		Prednisone	C				

Date:03/10/00ISR Number: 3473739-2Report Type:Expedited (15-DaCompany Report #WAES 00015587
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coagulopathy	Foreign	Tab Vioxx					
Hospitalization -	Dizziness	Health	(Rofecoxib)	PS		ORAL	6	DAY
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	Diclofenac	C				
	Gastritis Erosive							
	Haematemesis							
	Haemoglobin Decreased							
	Hypertrophy							
	Oesophagitis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/00ISR Number: 3473744-6Report Type:Expedited (15-DaCompany Report #WAES 00022372
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatocellular Damage	Health	Tab Vioxx	PS		ORAL	PO	
	Liver Disorder	Professional						
	Pancreatitis	Company Representative						

Date:03/10/00ISR Number: 3473746-XReport Type:Expedited (15-DaCompany Report #WAES 00010992
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Confusional State	Professional						
	Dehydration		Lasix	C				
	Depressed Level Of Consciousness		Prinivil	C				
			Transderm-Nitro	C				
	Lethargy		Tylenol	C				
	Oral Intake Reduced		Tylenol With Codeine	C				
	Renal Failure Acute		Zoloft	C				
	Renal Vessel Disorder		Calcium Supplement	C				
	Sedation		Metoprolol	C				

Date:03/10/00ISR Number: 3473779-3Report Type:Expedited (15-DaCompany Report #WAES 00029305
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscular Weakness	Foreign	Tab Rofecoxib	PS		ORAL	25 MG PO	1 DAY
	Nausea	Health						
	Vertigo	Professional						

Date:03/10/00ISR Number: 3473781-1Report Type:Expedited (15-DaCompany Report #WAES 00022489
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Hernia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Abdominal Pain	Professional						
	Swelling							
	Urinary Tract Infection							

Date:03/10/00ISR Number: 3473782-3Report Type:Expedited (15-DaCompany Report #WAES 00030254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Increased	Professional	Tab Cozaar	SS		ORAL	PO	
	Fluid Retention	Company	Lasix	C				
	Renal Failure Acute	Representative						

Date:03/10/00ISR Number: 3473865-8Report Type:Expedited (15-DaCompany Report #WAES 00030241
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Professional						
			Epogen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/00ISR Number: 3473868-3Report Type:Expedited (15-DaCompany Report #WAES 00030503
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25/MG/DAILY/P	
O								
			Alora	C				
			Klonopin	C				
			Levaquin	C				
			Nardil	C				
			Nasonex	C				

Date:03/10/00ISR Number: 3473871-3Report Type:Expedited (15-DaCompany Report #WAES 00030396
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Congestive						MG/DAILY/PO	
	Oedema Peripheral		Norvasc	C				
			Premarin	C				
			Prilosec	C				
			Synthroid	C				
			Calcium Supplement (Composition	C				

Date:03/10/00ISR Number: 3473877-4Report Type:Expedited (15-DaCompany Report #WAES 00030393
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Diarrhoea	Professional					MG/DAILY/PO	
Initial or Prolonged	Malaise	Company						
	Nausea	Representative						
	Pancreatitis							

Small Intestinal
Obstruction

Date:03/10/00ISR Number: 3473880-4Report Type:Expedited (15-DaCompany Report #WAES 00030370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/10/00ISR Number: 3473885-3Report Type:Expedited (15-DaCompany Report #WAES 00030050
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/PO	

Date:03/10/00ISR Number: 3474430-9Report Type:Expedited (15-DaCompany Report #WAES 00029162
Age:68 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Dizziness
	Headache

	Hypertensive Crisis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	2 DAY
		Professional	Nifedipine	C				

Date:03/10/00ISR Number: 3474433-4Report Type:Expedited (15-DaCompany Report #WAES 00035023
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG;PO	
	Blood Creatinine Increased		Allopurinol	C				
	Blood Urea Increased		Chlordiazepoxide	C				
	Erosive Duodenitis		Digoxin	C				
	Haemoptysis		Dothiepin Hcl	C				
	Melaena		Ferrouss04	C				
	Peptic Ulcer		Furosemide	C				
			Piroxicam	C				
			Vitamin B (12)	C				

Date:03/10/00ISR Number: 3474434-6Report Type:Expedited (15-DaCompany Report #WAES 00030052
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Congestive Fluid Overload	Professional						

Date:03/10/00ISR Number: 3474435-8Report Type:Expedited (15-DaCompany Report #WAES 00030234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Orthostatic Hypotension Syncope	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/10/00ISR Number: 3474441-3Report Type:Expedited (15-DaCompany Report #WAES 00025699
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis Immune System Disorder Pruritus Pyrexia Skin Irritation Vasculitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	5 DAY

Date:03/10/00ISR Number: 3474443-7Report Type:Expedited (15-DaCompany Report #WAES 00029167
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Vertigo	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	2 DAY

			Piroxicam	C		

Date:03/10/00ISR Number: 3474444-9Report Type:Expedited (15-DaCompany Report #WAES 00030033
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/DAILY/PO	3 WK
Initial or Prolonged	Congestive		Lasix	C				
	Oedema Peripheral		Thyroid	C				

Date:03/13/00ISR Number: 3474636-9Report Type:Expedited (15-DaCompany Report #WAES 00030399
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Haematemesis		Insulin	C				

Date:03/13/00ISR Number: 3474637-0Report Type:Expedited (15-DaCompany Report #WAES 00035532
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenia	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL		
		Professional	Cephalexin	SS				
			Heparin	C				

Date:03/13/00ISR Number: 3474640-0Report Type:Expedited (15-DaCompany Report #WAES 00028609
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgeusia	Foreign	Tab Vioxx					
	Myalgia	Health	(Rofecoxib)	PS		ORAL	3 DAY	

	Oedema Peripheral	Professional	Morphine	C
	Tongue Oedema		Omeprazole	C

Date:03/13/00ISR Number: 3474642-4Report Type:Expedited (15-DaCompany Report #WAES 00035004
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 - 25 MG	5 DAY
			Amiloride Hydrochloride (+) Furosemide	SS		ORAL	5/40 MG	15 DAY
			Acetaminophen/Codeine Phosphate	C				
			Albuterol	C				
			Lansoprazole	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/00ISR Number: 3474645-XReport Type:Expedited (15-DaCompany Report #WAES 00035004
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5-25 MG	5 DAY
			Amiloride Hydrochloride (+) Furosemide	SS		ORAL	5/40 MG	15 DAY
			Amiloride Hydrochloride (+) Furosemide	SS				
			Acetaminophen/Codeine Phosphate	C				
			Albuterol	C				
			Lansoprazole	C				
			Prednisolone	C				

Date:03/14/00ISR Number: 3474697-7Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Perforation	Health Professional	Celebrex 200mg Searle/Pfizer	PS	Searle/Pfizer	ORAL	200 MG BID ORAL	
			Vioxx 25 Mg Merck	SS	Merck	ORAL	25MG DAILY ORAL	

Date:03/14/00ISR Number: 3475243-4Report Type:Expedited (15-DaCompany Report #WAES 00022074
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	

Initial or Prolonged	Haemorrhage	Professional					
PO							
		Company Representative					

Date:03/14/00ISR Number: 3475660-2Report Type:Expedited (15-DaCompany Report #WAES 00020306
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Back Pain	Professional					MG/DAILY/PO	
Initial or Prolonged	Blister	Company	Flovent	C				
Other	Burns Second Degree	Representative	Lipitor	C				
	Dermatitis		Proscar	C				
	Drug Eruption		Serevent	C				
	Mucous Membrane Disorder		Symmetrel	C				
	Musculoskeletal Pain		Prednisone	C				
	Nodular Vasculitis							
	Skin Exfoliation							
	Skin Graft							
	Skin Necrosis							
	Stevens-Johnson Syndrome							
	Toxic Epidermal Necrolysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/00ISR Number: 3475256-2Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Rofecoxib	PS			UNKNOWN	UNKNOWN
Initial or Prolonged	Congestive	Professional	Atenolol	C				
	Condition Aggravated		Amitriptyline	C				
	Dyspnoea Exacerbated		Digoxin	C				
	Renal Impairment		Lasix	C				
			Coumadin	C				
			Flonase	C				
			Combivent	C				
			Ranitidine	C				
			Ntg	C				
			Darvocet	C				

Date:03/15/00ISR Number: 3475850-9Report Type:Expedited (15-DaCompany Report #WAES 00030289
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/15/00ISR Number: 3475901-1Report Type:Expedited (15-DaCompany Report #WAES 00020351
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Initial or Prolonged	Increased	Professional						
	Blood Urea Increased		Ginkor	C				
	Multiple Myeloma		L-Thyroxine	C				
	Nausea							
	Renal Impairment							
	Vomiting							

Date:03/15/00ISR Number: 3475903-5Report Type:Expedited (15-DaCompany Report #WAES 00030393
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Anorexia	Professional						
	Blood Amylase Increased	Company	Aricept	C				
	Diarrhoea	Representative	Ascorbic Acid	C				
	Gastric Ulcer Perforation							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							
	Haematocrit Decreased							
	Intestinal Obstruction							
	Malaise							
	Nausea							
	Pancreatitis							
	Renal Failure							
	Shock							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/00ISR Number: 3475906-0Report Type:Expedited (15-DaCompany Report #WAES 00035544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Tab Vioxx					
Hospitalization -	Gastric Ulcer	Health	(Rofecoxib)	PS		ORAL	50 MG PO	15 DAY
Initial or Prolonged	Medication Error	Professional						

Date:03/15/00ISR Number: 3476236-3Report Type:Expedited (15-DaCompany Report #WAES 00027939
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					
Initial or Prolonged	Renal Impairment	Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	Vasotec	C				

Date:03/15/00ISR Number: 3476311-3Report Type:Expedited (15-DaCompany Report #WAES 00025623
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL		
		Professional	Iron (Unspecified)	SS				

Date:03/15/00ISR Number: 3476312-5Report Type:Expedited (15-DaCompany Report #WAES 00010114
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Abdominal Pain	Health					MG/DAILY/PO	
Initial or Prolonged	Colitis	Professional	Prinivil	C				
Disability	Diarrhoea		Synthroid	C				
	Diverticulitis		Imipramine	C				

Gastritis
Influenza Like Illness
Urticaria

Date:03/15/00ISR Number: 3476335-6Report Type:Expedited (15-DaCompany Report #WAES 00030107
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Coronary Artery Disease	Health						
Initial or Prolonged	Coronary Artery Occlusion	Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
Disability	Electrocardiogram							
Other	Abnormal		Vitamins	C				
	Haematuria							
	Haemorrhage							
	Renal Failure							

Date:03/15/00ISR Number: 3476336-8Report Type:Expedited (15-DaCompany Report #WAES 00030292
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Death	Renal Failure	Health Professional Company

Representative

			Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx Unk	PS		ORAL	PO	

Date:03/15/00ISR Number: 3476337-XReport Type:Expedited (15-DaCompany Report #WAES 00030436
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Disorder	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Epistaxis	Professional	Coumadin	C				
	Prothrombin Time Prolonged		Tenormin	C				

Date:03/15/00ISR Number: 3476413-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Tolerance Decreased	Health	Piroxicam	PS		ORAL	20MG PO BID	3 YR
	Gastrointestinal Disorder	Professional	Ibuprofen	SS		ORAL	375MG PO BID	
			Vioxx 25mg Qd	SS			25 MG QD	
			Naproxen 800 Mg Tid Po	SS		ORAL	800 MG TID PO	

Date:03/16/00ISR Number: 3476240-5Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Face Oedema	Health	Vioxx 12.5	PS		ORAL	QD - PO	
Intervention to	Pharyngeal Oedema	Professional	Premarin	C				

Prevent Permanent Impairment/Damage	Urticaria

Date:03/16/00ISR Number: 3476265-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Rofecoxib (Vioxx) 12.5 Mg Tablet	PS		ORAL	12.5 MG PO Q DAY	
	Condition Aggravated							
	Dialysis		Allopurinol	C				
	Hyperkalaemia		Digoxin	C				
	Renal Failure Acute		Lasix	C				
	Renal Impairment		Prilosec	C				
			Micro-K	C				
			Lotensin	C				
			Flovent	C				
			Albuterol Nebs	C				
			Coumadin	C				
			Combivent Mdi	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/00ISR Number: 3476271-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Health	Vioxx	PS				
Required	Glomerulonephritis	Professional						
Intervention to Prevent Permanent Impairment/Damage	Leukocytoclastic Vasculitis							

Date:03/16/00ISR Number: 3476622-1Report Type:Expedited (15-DaCompany Report #WAES 00022481
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Hypersensitivity	Company						
	Erythema Multiforme	Representative	Prednisone	C				
	Eye Irritation							
	Hypersensitivity							
	Insomnia							
	Pain							
	Pruritus							

Date:03/16/00ISR Number: 3476626-9Report Type:Expedited (15-DaCompany Report #WAES 00025367
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Increased	Foreign	Tab Vioxx					
	Blood Urea Increased	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	33 DAY
	Hyperkalaemia		Trimethoprim	SS		ORAL	400 MG	9 DAY
	Hypokalaemia		Diazepam	C				
	Renal Impairment		Lansoprazole	C				
			Mirtazapine	C				

Date:03/16/00ISR Number: 3476950-XReport Type:Expedited (15-DaCompany Report #WAES 00025370
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	14 DAY
	Oedema Peripheral	Other						
			Trusopt	C				
			Allopurinol	C				
			Amiloride Hydrochlorie (+)					
			Furosemide	C				
			Captopril	C				
			Furosemide	C				
			Quinine	C				

Date:03/16/00ISR Number: 3476952-3Report Type:Expedited (15-DaCompany Report #WAES 00030563
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/00ISR Number: 3476953-5Report Type:Expedited (15-DaCompany Report #WAES 00030725
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/16/00ISR Number: 3476954-7Report Type:Expedited (15-DaCompany Report #WAES 00030879
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged	Duodenal Ulcer		Ascriptan	C				
	Haemorrhage		Synthroid	C				
	Faeces Discoloured							

Date:03/16/00ISR Number: 3476957-2Report Type:Expedited (15-DaCompany Report #WAES 00030912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Diarrhoea		Arava	SS				
	Dyspepsia							
	Eructation							
	Gastrointestinal Motility Disorder							
	Vertigo							
	Vision Blurred							

Date:03/16/00ISR Number: 3476958-4Report Type:Expedited (15-DaCompany Report #WAES 00037906
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Foreign	Tab Vioxx					

Consumer (Rofecoxib) PS ORAL
2 MON

Date:03/17/00ISR Number: 3477831-8Report Type:Expedited (15-DaCompany Report #WAES 00020983
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	6 WK
		Professional						
		Company						
		Representative						

Date:03/17/00ISR Number: 3477832-XReport Type:Expedited (15-DaCompany Report #WAES 00020430
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ BID/	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional					PO	
	Ulcer	Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/00ISR Number: 3477836-7Report Type:Expedited (15-DaCompany Report #WAES 00039105
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Tab Vioxx					
Hospitalization -	Abdominal Pain Upper	Health	(Rofecoxib)	PS		ORAL	25 MG PO	8 DAY
Initial or Prolonged	Anaemia	Professional	Inj Cosyntropin	SS			INJ	39 DAY
	Gastric Ulcer		Amiloride					
	Gastritis		Hydrochloride/Hctz	C				
	Gastrointestinal		Lorazepam	C				
	Haemorrhage							
	Melaena							
	Oesophageal Disorder							
	Oesophagitis							

Date:03/17/00ISR Number: 3477875-6Report Type:Expedited (15-DaCompany Report #200010191RGB
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia	Foreign	Frusemide/Amiloride	PS		ORAL	PO	15 DAY
Initial or Prolonged		Other	Rofecoxib (Vioxx)	SS		ORAL	12.5 - 25 MG	
							PO	5 DAY
			Prednisolone	C				
			Lansoprazole	C				
			Co-Codamol	C				
			Salbutamol	C				

Date:03/17/00ISR Number: 3478066-5Report Type:Expedited (15-DaCompany Report #WAES 00035512
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					
Initial or Prolonged	Liver Function Test	Health	(Rofecoxib)	PS		ORAL	25 MG PO	4 WK
	Abnormal	Professional						

Date:03/17/00ISR Number: 3478068-9Report Type:Expedited (15-DaCompany Report #WAES 00030863
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Ecchymosis	Professional						
Initial or Prolonged	Obstructive Airways	Company	Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	
	Disorder	Representative						
	Respiratory Distress							
	Skin Disorder							
	Throat Tightness							

Date:03/17/00ISR Number: 3478070-7Report Type:Expedited (15-DaCompany Report #WAES 00031063
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Initial or Prolonged	Grand Mal Convulsion	Professional						
		Company	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/00ISR Number: 3476741-XReport Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension		Vioxx 25mg Merck	PS	Merck	ORAL	25MG ONE A DAY ORAL	
			Prevacid	C				

Date:03/20/00ISR Number: 3477699-XReport Type:Expedited (15-DaCompany Report #WAES 00022580
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health	Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Dyspnoea	Professional						
	Face Oedema	Company	Glucotrol	C				
	Headache	Representative	Prempro	C				
	Oedema Peripheral							
	Palpitations							
	Panic Disorder Without Agoraphobia							

Date:03/20/00ISR Number: 3477702-7Report Type:Expedited (15-DaCompany Report #WAES 00020427
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Increased	Professional						
	Dialysis	Other	Lopid 600 Mg	SS		ORAL	600 MG/BID/PO	
Other	Drug Interaction		Combivent	C				
	Renal Failure		Ecotrin	C				
	Rhabdomyolysis		Halcion	C				
			Nitro-Bid	C				

			Percocet	C		
			Theo-Dur	C		

Date:03/20/00ISR Number: 3477707-6Report Type:Expedited (15-DaCompany Report #WAES 00035094
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation		Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG						
			Acetaminophen	C		
			Amiloride Hydrochloride (+) Furosemide	C		

Date:03/20/00ISR Number: 3477708-8Report Type:Expedited (15-DaCompany Report #WAES 00035071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/00ISR Number: 3477711-8Report Type:Expedited (15-DaCompany Report #WAES 00035580
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	11	DAY
			Cozaar	C				
			Alfuzosin	C				
			Aspirin	C				
			Bisoprolol	C				

Date:03/20/00ISR Number: 3477713-1Report Type:Expedited (15-DaCompany Report #WAES 00039110
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Aspirin	C				
			Cerivastatin Sodium	C				
			Chlorthalidone	C				

Date:03/20/00ISR Number: 3477716-7Report Type:Expedited (15-DaCompany Report #WAES 00037278
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS			1	WK
			Celecoxib	SS			1	WK
			Therapy Unspecified	C				

Date:03/20/00ISR Number: 3477816-1Report Type:Expedited (15-DaCompany Report #WAES 00030918
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Lung Infiltration	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Pyrexia	Professional Company Representative				

Date:03/20/00ISR Number: 3477820-3Report Type:Expedited (15-DaCompany Report #WAES 00030991
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional Company Representative				

Date:03/20/00ISR Number: 3477821-5Report Type:Expedited (15-DaCompany Report #WAES 00021593
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Cardiac Failure	Professional				
MG/DAILY/PO 2 WK						
	Congestive	Company	Vasotec	C		
	Dyspnoea	Representative				
	Hypertension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/00ISR Number: 3477833-1Report Type:Expedited (15-DaCompany Report #WAES 00030893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dialysis							
	Disorientation	Company Representative	Lithium 450 Mg	SS			450 MG/BID/UNK	
	Drug Level Above Therapeutic							

Date:03/20/00ISR Number: 3477835-5Report Type:Expedited (15-DaCompany Report #WAES 00030763
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							
	Dyspnoea		Coumadin	C				
	Fluid Retention		Cozaar	C				
	Pneumonia		Lanoxin	C				
	Pulmonary Oedema		Lasix	C				
			Verapamil	C				

Date:03/20/00ISR Number: 3477837-9Report Type:Expedited (15-DaCompany Report #WAES 00035133
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bone Marrow Depression	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	5 DAY
	Multiple Myeloma							
	Renal Failure		Acetaminophen/Codeine Phosphate	C				
			Diclofenac Sodium (+) Misoprostol	C				

Date:03/20/00ISR Number: 3478348-7Report Type:Expedited (15-DaCompany Report #WAES 99125006
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Amylase Increased Pancreatitis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	

Date:03/20/00ISR Number: 3478349-9Report Type:Expedited (15-DaCompany Report #WAES 00022223
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Death	Bradycardia
Life-Threatening	Cholestasis
Hospitalization - Initial or Prolonged	Embolism
Disability	Faecal Occult Blood Positive
	Gastric Ulcer Haemorrhage
	Gastrointestinal Haemorrhage
	Haematemesis
	Haemoglobin Decreased
	Hyperbilirubinaemia
	Hypovolaemia
	Jaundice

	Melaena Myocardial Infarction Syncope Vasovagal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
25 MG/DAILY/PO		Health Professional	Tab Vioxx 25 Mg	PS		ORAL
		Company Representative Other	Therapy Unspecified	C		

Date:03/21/00ISR Number: 3477237-1Report Type:Direct Company Report #
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening 25 MG	Angina Pectoris		Vioxx 25 Mg	PS		
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia Ecchymosis Faecal Occult Blood Positive Faeces Discoloured Fall		Pravachol Atrovent Inhaler	C C		

Date:03/21/00ISR Number: 3477731-3Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - PRIOR TO Initial or Prolonged 8-23-99	Gastric Ulcer		Vioxx 12.5 Mg Bid Po	PS		

Date:03/21/00ISR Number: 3477747-7Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	International Normalised		Coumadin	PS		
2.5MG 5MG						
	Ratio Increased					
(ALTERNATING)						
			Vioxx	SS		ORAL
25MG PO QD						

Date:03/21/00ISR Number: 3478298-6Report Type:Expedited (15-DaCompany Report #WAES 00031301
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Rocky Mountain Spotted	Professional				
	Fever	Company				
	Sepsis	Representative				

Date:03/21/00ISR Number: 3478299-8Report Type:Expedited (15-DaCompany Report #WAES 00031010
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Congestive	Professional				
MG/BID/PO;12.						
	Cellulitis	Company				
5						
	Oedema Peripheral	Representative				
MG/DAILY/PO;						
25						
			Cardura	C		
			Univasc	C		

Date:03/21/00ISR Number: 3478301-3Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anuria	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Renal Failure	Professional					MG/DAILY/PO	
		Company Representative	Lasix	C				

Date:03/21/00ISR Number: 3478303-7Report Type:Expedited (15-DaCompany Report #WAES 00039118
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Crepitations	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG DAILY	2 DAY
	Oedema Peripheral	Professional	Acetaminophen	C				
	Pulmonary Oedema							

Date:03/21/00ISR Number: 3478305-0Report Type:Expedited (15-DaCompany Report #WAES 00039109
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Tab Vioxx					
	Hypertension	Health	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Malaise	Professional	Ace Inhibitor, Nos	C				
			Calcium Antagonist, Nos	C				
			Diuretic, Nos	C				
			Halazepam	C				

Date:03/21/00ISR Number: 3478307-4Report Type:Expedited (15-DaCompany Report #WAES 00035086
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ulcerative	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	55 DAY
			Sulfasalazine	C				

Date:03/21/00ISR Number: 3478574-7Report Type:Expedited (15-DaCompany Report #WAES 00035548
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Tab Vioxx					
	Haemoglobin Decreased	Health	(Rofecoxib)	PS		ORAL	12.5 MG	35 DAY
	Malaise	Professional						

Date:03/21/00ISR Number: 3478580-2Report Type:Expedited (15-DaCompany Report #WAES 00030789
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization -	Loss Of Consciousness	Health	(Rofecoxib)	PS		ORAL	50 MG	1 DAY
Initial or Prolonged	Oedema	Professional	Controloc	C				
	Pruritus							
	Pulse Pressure Decreased							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/00ISR Number: 3478584-XReport Type:Expedited (15-DaCompany Report #WAES 00035065
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Pain	Foreign	Tab Vioxx			
Hospitalization -	Abdominal Rigidity	Health	(Rofecoxib)	PS		
12.5 MG						
Initial or Prolonged	Abdominal Tenderness	Professional	Acetaminophen	C		
	Bronchospasm		Calcium Supplement			
	Chest Pain		(Nos)	C		
	Chest X-Ray Abnormal		Cimetidine	C		
	Crepitations		Prednisolone	C		
	Duodenal Ulcer					
	Perforation					
	Dyspnoea					
	Hypoxia					
	Ileus Paralytic					
	Lower Respiratory Tract					
	Infection					
	Nausea					
	Oedema Peripheral					
	Oliguria					
	Oxygen Saturation					
	Decreased					
	Pneumonia					
	Post Procedural					
	Complication					
	Productive Cough					
	Pyrexia					
	Renal Impairment					
	Sepsis					

Date:03/21/00ISR Number: 3574223-8Report Type:Periodic Company Report #WAES 00032141
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vision Blurred	Consumer	Vioxx	PS	Merck Research	
	Visual Disturbance	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Coumadin	C		

			Digoxin	C		

Date:03/22/00ISR Number: 3478687-XReport Type:Expedited (15-DaCompany Report #WAES 00028521
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Confusional State	Health						
	Delirium	Professional	Allopurinol	SS				
	Delusion		Tab Prednisone 5 Mg	SS		ORAL	PO	
	Hypersomnia		Tab Metoprolol 50 Mg	SS		ORAL	PO	
	Memory Impairment		Zocor	C				
	Paranoia		Acetaminophan/Codeine Phosphate	C				
			Amitriptyline	C				
			Aspirin	C				
			Levothyroxine Na	C				
			Lisinopril	C				
			Ranitidine	C				
			Sertraline Hcl	C				

				Terazosin	C		

Date:03/22/00ISR Number: 3478713-8Report Type:Expedited (15-DaCompany Report #WAES 00038555
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/22/00ISR Number: 3478715-1Report Type:Expedited (15-DaCompany Report #WAES 00035602
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	10 DAY

Date:03/22/00ISR Number: 3478717-5Report Type:Expedited (15-DaCompany Report #WAES 00031291
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Other	Convulsion		Atrovent	C				
	Dysphagia		Cardizem Cd	C				
	Dysphonia							
	Fungal Infection							
	Haemoptysis							
	Haemorrhoids							
	Influenza Like Illness							
	Insomnia							
	Pyrexia							
	Tremor							

Date:03/22/00ISR Number: 3478967-8Report Type:Expedited (15-DaCompany Report #WAES 00031487
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional						
Other		Company Representative	Celebrex	C				
			Humulin	C				
			Prilosec	C				

Date:03/22/00ISR Number: 3478970-8Report Type:Expedited (15-DaCompany Report #WAES 00031305
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional Company Representative						

Date:03/22/00ISR Number: 3478974-5Report Type:Expedited (15-DaCompany Report #WAES 00035544
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Tab Vioxx					
Hospitalization -	Gastric Ulcer Haemorrhage		(Rofecoxib)	PS		ORAL	50 MG PO	15 DAY
Initial or Prolonged	Gastroenteritis		Aceclofenac	C				
	Helicobacter		Inbuprofen	C				
	Medication Error							

Date:03/22/00ISR Number: 3478975-7Report Type:Expedited (15-DaCompany Report #WAES 00030695
Age:101 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
Life-Threatening		Professional	Lasix	C				
Hospitalization -		Company	Pepcid	C				
Initial or Prolonged		Representative	Synthroid	C				
			Potassium Chloride	C				

Date:03/22/00ISR Number: 3478977-0Report Type:Expedited (15-DaCompany Report #WAES 00031226
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dysphagia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Mouth Ulceration						MG/TID/PO	
Initial or Prolonged	Pharyngitis							
Other	Pharyngolaryngeal Pain							
	Renal Failure							

Date:03/22/00ISR Number: 3479196-4Report Type:Expedited (15-DaCompany Report #WAES 00035004
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.50 MG	3 DAY
			Acetaminophen/Codein					
			e Phosphate	C				
			Albuterol	C				
			Lansoprazole	C				
			Prednisolone	C				

Date:03/22/00ISR Number: 3479233-7Report Type:Expedited (15-DaCompany Report #WAES 00030662
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Blood Bilirubin Increased
Hospitalization -	C-Reactive Protein
Initial or Prolonged	Increased
Other	Chills
	Chromaturia
	Face Oedema
	Haemolytic Anaemia
	Hepatic Enzyme Increased
	Jaundice
	Leukopenia
	Myalgia
	Nausea

		Pallor Pruritus Red Blood Cell Sedimentation Rate Increased Tachycardia Thrombocythaemia	Report Source Foreign Other	Product Tab Vioxx (Rofecoxib) Doliprane	Role PS C	Manufacturer	Route ORAL
Dose	Duration						
25 MG PO	1 DAY						

Date:03/22/00ISR Number: 3482420-5Report Type:Expedited (15-DaCompany Report #WAES 00031459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Disorientation	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Drug Interaction		Lithium Co3 Unknown	SS		ORAL
PO						

Date:03/22/00ISR Number: 3575830-9Report Type:Periodic Company Report #WAES 00042292
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ear Infection Hypertension Nausea Pharyngitis Sialoadenitis Sinusitis Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

Date:03/22/00ISR Number: 3575831-0Report Type:Periodic Company Report #WAES 00042295
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Consumer	Vioxx	PS	Merck Research	

Laboratories Div
Merck Co Inc ORAL
UNK/UNK/PO

Date:03/22/00ISR Number: 3575847-4Report Type:Periodic Company Report #WAES 00042328
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Detrol	C				
			Hyzaar	C				

Date:03/23/00ISR Number: 3478969-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS		ORAL	12.5MG PO QD	
Initial or Prolonged			Asa	SS		ORAL	650MG PO QD	

Date:03/23/00ISR Number: 3479126-5Report Type:Expedited (15-DaCompany Report #WAES 00031722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Circulatory Collapse							
	Gastric Ulcer Haemorrhage							

Date:03/23/00ISR Number: 3479127-7Report Type:Expedited (15-DaCompany Report #WAES 00031670
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Renal Disorder		Tenormin	C				
	Respiratory Disorder		Zestoretic	C				

Date:03/23/00ISR Number: 3479128-9Report Type:Expedited (15-DaCompany Report #WAES 00031624
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Company	Tab Vioxx Unk	PS		ORAL	PO	
		Representative						

Date:03/23/00ISR Number: 3479129-0Report Type:Expedited (15-DaCompany Report #WAES 00031623
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:03/23/00ISR Number: 3479130-7Report Type:Expedited (15-DaCompany Report #WAES 00031561
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY, PO	1 WK
	Syncope		Ismo	C				
			Procardia	C				
			Atenolol	C				

Date:03/23/00ISR Number: 3479131-9Report Type:Expedited (15-DaCompany Report #WAES 00031446
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Stevens-Johnson Syndrome	Professional Company Representative						

Date:03/23/00ISR Number: 3479133-2Report Type:Expedited (15-DaCompany Report #WAES 00031440
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomyopathy	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
			Coumadin	C				
			Lanoxin	C				
			Vasotec	C				

Date:03/23/00ISR Number: 3479135-6Report Type:Expedited (15-DaCompany Report #WAES 00030725
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional	Tabb Vioxx Unk	PS		ORAL	PO	

Date:03/23/00ISR Number: 3479235-0Report Type:Expedited (15-DaCompany Report #WAES 00035617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/23/00ISR Number: 3479238-6Report Type:Expedited (15-DaCompany Report #WAES 00035130
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
	Gastritis Erosive							
	Haematemesis		Tab Aluminum					

	Hydroxide/Mg Trisilicate	SS	
500 MG			
	Cap Lansoprazole	SS	ORAL
30 MG PO			
	Tab Thioridazine	SS	
50 MG			
	Morphine	SS	ORAL
SEE IMAGE 47 DAY			
	Tab Acetaminophen/Propoxyphene Hydrochloride	SS	
1-4 TABLET			
	Tab Estradiol Valerate	SS	ORAL
2 MG PO			
	Soln Lactulose	SS	
3.35 MG/5 ML			
GM			
	Tab Metoclopramide	SS	
30 PRN MG			
	Tab Prednisolone	SS	
2.5 MG			
	Diazepam	C	
	Nefazodone	C	

Date:03/23/00ISR Number: 3479267-2Report Type:Expedited (15-DaCompany Report #WAES 00022450
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Diverticulum
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage
Other	Gastrointestinal Perforation

	Rectal Haemorrhage Ruptured Diverticulum Of Colon	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
		Company Representative	Tab Vioxx Unk	SS		ORAL	25 MG/DAILY/PO

Date:03/23/00ISR Number: 3479270-2Report Type:Expedited (15-DaCompany Report #WAES 00020526
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Urea Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
	Cardiac Failure						
	Congestive Condition Aggravated		Combivent	C			
			Coumadin	C			
	Haemodialysis		Flovent	C			
	Hyperkalaemia		Lasix	C			
	Renal Failure Chronic		Lotensin	C			
			Micro K	C			
			Prilosec	C			
			Albuterol	C			
			Allopurinol	C			
			Digoxin	C			

Date:03/23/00ISR Number: 3479271-4Report Type:Expedited (15-DaCompany Report #WAES 00020022
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Bronchospasm	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO
Other	Chest Pain	Health Professional Other					
	Dizziness						
	Dyspnoea						

Headache
Hypertension
Insomnia
Lung Disorder
Nausea
Panic Attack
Syncope
Tachycardia

Date:03/23/00ISR Number: 3479338-0Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Abdomen		Vioxx	PS				
Life-Threatening	Gastric Ulcer Perforation							
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/00ISR Number: 3479373-2Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS			25MG Q DAY	
	Perforation							
	Pain							

Date:03/23/00ISR Number: 3479433-6Report Type:Expedited (15-DaCompany Report #000310-SK812
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Celebrex	PS		ORAL	200,000 MG QD	
Other	Haemorrhage	Professional					PO	
	Haemoptysis	Company	Vioxx	SS		ORAL	25.000 MG QD	
	Prothrombin Time	Representative					PO	
	Prolonged		Warfarin	C				
			Tramadol	C				
			Lisinopril	C				
			Diltiazem	C				
			Systemic Antibiotics	C				

Date:03/24/00ISR Number: 3479835-8Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx 12.5 Mg Merck	PS	Merck	ORAL	12.5 MG DAILY	
Initial or Prolonged	Blood Creatinine						PO	
	Increased		Nitropatch	C				
	Blood Urea Increased		Robitussin	C				
	International Normalised		Tambocor	C				
	Ratio Increased		Lanoxin	C				
			Xanax	C				

			Lasix	C		
			Coumadin	C		
			Combivent	C		
			Ntg Sl	C		

Date:03/24/00ISR Number: 3480314-2Report Type:Expedited (15-DaCompany Report #JRFUSA2000001964
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Duragesic (25 Mcg/Hr Patch) (Fentanyl)	PS		
TRANSDERMAL 25 MCG/H, 1						
Required IN 72	Memory Impairment					
Intervention to HOUR(S),	Nausea					
Prevent Permanent TRANSD	Palpitations					
Impairment/Damage ORAL	Sedation		Vioxx (Rofecoxib)	SS		ORAL
			Coumadin (Warfarin Sodium)	C		
			Hytrin (Terazosin Hydrochloride)	C		
			Coreg (Carvedilol)	C		
			Avapro (Irbesartan)	C		
			Klonopin (Clonazepam)	C		
			Prevacid (Lansoprazole)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3481646-4Report Type:Periodic Company Report #WAES 99101248
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:03/24/00ISR Number: 3481648-8Report Type:Periodic Company Report #WAES 99100615
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Tab Vioxx 12.5 Mg	SS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	50MG/DAILY/PO	
			Ambien	C				
			Albuterol	C				

Date:03/24/00ISR Number: 3481655-5Report Type:Periodic Company Report #WAES 99091859
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Level Above	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/PO	
	Therapeutic	Professional	Morphine	C				
	Opiates Positive	Other						
	Vomiting							

Date:03/24/00ISR Number: 3481656-7Report Type:Periodic Company Report #WAES 99121973
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other		Professional					MG/DAILY/PO	
		Company Representative						

Date:03/24/00ISR Number: 3481657-9Report Type:Periodic Company Report #WAES 99121363
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Initial or Prolonged							PO	
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Toprol Xl Tablets	C				

Date:03/24/00ISR Number: 3481658-0Report Type:Periodic Company Report #WAES 99120231
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dermatitis	Health					MG/DAILY/PO	
	Sputum Abnormal	Professional	Ambien	C				
	Urticaria		Estrace	C				
			Neurontin	C				

			Paxil	C		
			Synthroid	C		

Date:03/24/00ISR Number: 3481659-2Report Type:Periodic Company Report #WAES 00020102
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/PO	

Date:03/24/00ISR Number: 3481660-9Report Type:Periodic Company Report #WAES 00012264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Albuterol	C				
			Carvedilol	C				
			Cisapride	C				
			Digoxin	C				
			Isosorbide	C				
			Potassium Chloride	C				
			Temazepam	C				
			Torsemide	C				
			Warfarin	C				

Date:03/24/00ISR Number: 3481662-2Report Type:Periodic Company Report #WAES 00010838
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL PO
			Aleve	C		
			Chondroitin	C		

Date:03/24/00ISR Number: 3543143-7Report Type:Periodic Company Report #WAES 00021521
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO

Date:03/24/00ISR Number: 3543144-9Report Type:Periodic Company Report #WAES 00021532
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543145-0Report Type:Periodic Company Report #WAES 00021543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pustular	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3543146-2Report Type:Periodic Company Report #WAES 00021559
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aricept	C				
			Cartia	C				
			Darvocet-N	C				
			Glucotrol	C				
			K-Dur	C				
			Miacalcic	C				
			Os-Cal + D	C				
			Plavix	C				
			Remeron	C				
			Rezulin	C				
			Ferrous Sulfate	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3543147-4Report Type:Periodic Company Report #WAES 00021560
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Representative
MG/DAILY/PO

Date:03/24/00ISR Number: 3543148-6Report Type:Periodic Company Report #WAES 00021563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
		Representative	Vioxx	SS		ORAL	50MG/DAILY/PO	
			Advil	C				

Date:03/24/00ISR Number: 3543149-8Report Type:Periodic Company Report #WAES 00021572
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO ;25MG/DAILY/PO	
			Vasotec	C				

			Vicodin Tablets	C
			Bumetanide	C
			Dipyridamole	C
			Therapy Unspecified	C

Date:03/24/00ISR Number: 3543150-4Report Type:Periodic Company Report #WAES 00021587
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
	Dyspnoea							
			Prozac	C				
			Serevent	C				
			Theophylline	C				

Date:03/24/00ISR Number: 3543151-6Report Type:Periodic Company Report #WAES 00021592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3543152-8Report Type:Periodic Company Report #WAES 00021595
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
	Paranoid Personality							
	Disorder		Cardizem	C				
			Plendil	C				
			Trental	C				
			Vasotec	C				

			Zantac	C		
			Heparin	C		
			Therapy Unspecified	C		

Date:03/24/00ISR Number: 3543153-XReport Type:Periodic Company Report #WAES 00021598
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blister	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral				Laboratories Div	
	Rash Erythematous				Merck Co Inc	ORAL
12.5 MG DAILY						
PO						
			Covera-Hs	C		
			Estrace	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543154-1Report Type:Periodic Company Report #WAES 00021601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Premarin	C				
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3543155-3Report Type:Periodic Company Report #WAES 00021602
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Gait Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Mental Impairment		Mag-Ox	C				
			Plavix	C				
			Vasotec	C				
			Furosemide	C				
			Hydrochlorothiazide (+) Triamter	C				
			Labetalol Hydrochloride	C				

Date:03/24/00ISR Number: 3543156-5Report Type:Periodic Company Report #WAES 00021605
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Monopril	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3543157-7Report Type:Periodic Company Report #WAES 00021615
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO;25 MG/DAILY/PO	
			Zanaflex Unk	SS				

Date:03/24/00ISR Number: 3543158-9Report Type:Periodic Company Report #WAES 00021622
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Gait Disturbance Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543159-0Report Type:Periodic Company Report #WAES 00021623
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Vioxx	PS	Merck Research			
	Disorientation	Professional			Laboratories Div			
	Dyspnoea	Company			Merck Co Inc	ORAL	12.5 MG DAILY	
	Headache	Representative					PO/ 25 MG	
	Hypertension		Premarin	C				
	Tachycardia							

Date:03/24/00ISR Number: 3543160-7Report Type:Periodic Company Report #WAES 00021625
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research			
	Joint Swelling				Laboratories Div			
	Pain				Merck Co Inc	ORAL	25MG BID PO	
	Swelling							

Date:03/24/00ISR Number: 3543161-9Report Type:Periodic Company Report #WAES 00021630
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Accupril	C				
			Demadex	C				
			Normodyne	C				
			Prempro	C				
			Prozac	C				
			Cimetidine	C				
			Hydrochlorothiazide (+) Triamter	C				
			Iron	C				

Potassium Chloride	C	
Therapy Unspecified	C	

Date:03/24/00ISR Number: 3543162-0Report Type:Periodic Company Report #WAES 00021632
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:03/24/00ISR Number: 3543163-2Report Type:Periodic Company Report #WAES 00020716
Age:66 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Back Pain
	Blood Pressure Increased
	Cough
	Hyperhidrosis
	Liver Disorder
	Nocturia

		Oedema Peripheral Palpitations Respiratory Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO							
				Calan	C		
				Premarin	C		
				Slow-K	C		
				Insulin	C		
				Vitamins	C		

Date:03/24/00ISR Number: 3543164-4Report Type:Periodic Company Report #WAES 00020720
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO							
				Avapro	C		

Date:03/24/00ISR Number: 3543165-6Report Type:Periodic Company Report #WAES 00020729
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
MG/DAILY/PO							
				Prevacid	C		
				Albuterol	C		
				Prednisone	C		

Date:03/24/00ISR Number: 3543166-8Report Type:Periodic Company Report #WAES 00020737
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3543167-XReport Type:Periodic Company Report #WAES 00020739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543168-1Report Type:Periodic Company Report #WAES 00020741
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543169-3Report Type:Periodic Company Report #WAES 00020742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543170-XReport Type:Periodic Company Report #WAES 00020743
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543171-1Report Type:Periodic Company Report #WAES 00020746
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative				

Date:03/24/00ISR Number: 3543172-3Report Type:Periodic Company Report #WAES 00020747
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						

Date:03/24/00ISR Number: 3543173-5Report Type:Periodic Company Report #WAES 00020748
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	International Normalised Ratio Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative	Warfarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543174-7Report Type:Periodic Company Report #WAES 00020753
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Nodule	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Allegra	C				
			Lipitor	C				

Date:03/24/00ISR Number: 3543175-9Report Type:Periodic Company Report #WAES 00020754
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Allegra D	C				
			Celexa	C				
			Diprolene Af Cream	C				
			Lac-Hydrin 12%	C				
			Neurontin	C				
			Premarin	C				
			Prilosec	C				
			Procardia Xl	C				
			Acetaminophen (+) Propoxyphene	C				

Date:03/24/00ISR Number: 3543176-0Report Type:Periodic Company Report #WAES 00020767
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Memory Impairment Merck Co Inc ORAL
25 MG/

DAILY/PO

L-Thyroxine	C	
Allopurinol	C	
Propranolol	C	

Date:03/24/00ISR Number: 3543177-2Report Type:Periodic Company Report #WAES 00020771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543178-4Report Type:Periodic Company Report #WAES 00020774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543179-6Report Type:Periodic Company Report #WAES 00020775
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543180-2Report Type:Periodic Company Report #WAES 00020776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543181-4Report Type:Periodic Company Report #WAES 00020782
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3543182-6Report Type:Periodic Company Report #WAES 00020784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
			Therapy Unspecified Herbal Remedies	C				

				(Composition Unspecified)	C		
				Vitamins	C		

Date:03/24/00ISR Number: 3543183-8Report Type:Periodic Company Report #WAES 00020788
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543184-XReport Type:Periodic Company Report #WAES 00020791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543185-1Report Type:Periodic Company Report #WAES 00020793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543186-3Report Type:Periodic Company Report #WAES 00020799
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	10 DAY
			Imodium	C				
			Pepto-Bismol	C				
			Prednisona Sod. Pos	C				
			Synthroid	C				
			Glucosamie	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3543187-5Report Type:Periodic Company Report #WAES 00020800
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543188-7Report Type:Periodic Company Report #WAES 00020801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Urinary Incontinence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543189-9Report Type:Periodic Company Report #WAES 00020803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543190-5Report Type:Periodic Company Report #WAES 00020809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Malaise Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543191-7Report Type:Periodic Company Report #WAES 00020814
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(Therapy Unspecified)	C				
			Verapamil	C				

Date:03/24/00ISR Number: 3543192-9Report Type:Periodic Company Report #WAES 00020815
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Dysuria Oedema Peripheral Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			(Therapy Unspecified)	C				
			Hormones	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3543193-0Report Type:Periodic Company Report #WAES 00020816
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Gastrointestinal Motility Disorder Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				

			Ultram	C		
			Verelan	C		

Date:03/24/00ISR Number: 3543194-2Report Type:Periodic Company Report #WAES 00020818
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:03/24/00ISR Number: 3543195-4Report Type:Periodic Company Report #WAES 00020820
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased Hyperkalaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/50 MG /HS/PO	1 WK
			(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543196-6Report Type:Periodic Company Report #WAES 00020822
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Wellbutrin	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3543197-8Report Type:Periodic Company Report #WAES 00020823
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:03/24/00ISR Number: 3543198-XReport Type:Periodic Company Report #WAES 00020832
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alveolitis Allergic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			(Therapy Unspecified0	C				

Date:03/24/00ISR Number: 3543199-1Report Type:Periodic Company Report #WAES 00020839
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dermatitis Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Oral Soft Tissue Disorder		Hytrin	C				
	Paraesthesia		Vitamins	C				

Date:03/24/00ISR Number: 3543200-5Report Type:Periodic Company Report #WAES 00020840
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/[PO	

Date:03/24/00ISR Number: 3543201-7Report Type:Periodic Company Report #WAES 00020848
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543202-9Report Type:Periodic Company Report #WAES 00020849
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Nausea							
			Skelaxin	C				
			Synthroid	C				
			Tylenol	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3543203-0Report Type:Periodic Company Report #WAES 00020850
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Vomiting							
			Levothroid	C				
			Midrin	C				
			Paxil	C				
			Premarin	C				
			Prilosec	C				
			Vasotec	C				
			Baclofen	C				
			Morphine	C				

Date:03/24/00ISR Number: 3543204-2Report Type:Periodic Company Report #WAES 00020851
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:03/24/00ISR Number: 3543205-4Report Type:Periodic Company Report #WAES 00020864
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:03/24/00ISR Number: 3543206-6Report Type:Periodic Company Report #WAES 00020866
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Face Oedema Pharyngeal Oedema	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543207-8Report Type:Periodic Company Report #WAES 00020867
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diplopia							
	Dizziness							
	Vision Blurred							

Date:03/24/00ISR Number: 3543208-XReport Type:Periodic Company Report #WAES 00020869
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Fosamax	C				
			Tenormin	C				

Date:03/24/00ISR Number: 3543209-1Report Type:Periodic Company Report #WAES 00020871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Composition Unspecified	C				

Date:03/24/00ISR Number: 3543210-8Report Type:Periodic Company Report #WAES 00020878
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3543211-XReport Type:Periodic Company Report #WAES 00020891
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/24/00ISR Number: 3543212-1Report Type:Periodic Company Report #WAES 00020895
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543213-3Report Type:Periodic Company Report #WAES 00020905
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/HS/PO	
			Skelaxin	SS		ORAL	Q4H/PO	
			Percocet	SS		ORAL	Q4H/PO	
			Provigil	C				
			Synthorid	C				

Date:03/24/00ISR Number: 3543214-5Report Type:Periodic Company Report #WAES 00020912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3543215-7Report Type:Periodic Company Report #WAES 00020925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Coenzyme Q10	C				
			Calcium Supplement	C				
			Magnesium Preparation	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3543216-9Report Type:Periodic Company Report #WAES 00020929
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3543217-0Report Type:Periodic Company Report #WAES 00020937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia							
		Representative	Tab Vioxx 25 Mg	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543218-2Report Type:Periodic Company Report #WAES 00020939
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
	Oedema Peripheral	Company			Merck Co Inc	ORAL	25	
	Weight Increased	Representative					MG/DAILY/PO	
			Celebrex	C				

Date:03/24/00ISR Number: 3543219-4Report Type:Periodic Company Report #WAES 00020941
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Vioxx	PS	Merck Research			
	Pain				Laboratories Div			
	Psoriasis				Merck Co Inc	ORAL	DAILY, PO	
			Zantac	C				
			Doxepin	C				

Date:03/24/00ISR Number: 3543220-0Report Type:Periodic Company Report #WAES 00020955
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Asthenia				Laboratories Div			
	Faeces Discoloured				Merck Co Inc	ORAL	PO	
	Fatigue		Synthroid	C				
	Headache							

Date:03/24/00ISR Number: 3543221-2Report Type:Periodic Company Report #WAES 00020959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Lotrel	C				
			Valium	C				
			Estrogenic Preparation	C				

Date:03/24/00ISR Number: 3543222-4Report Type:Periodic Company Report #WAES 00020963
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543223-6Report Type:Periodic Company Report #WAES 99120267
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:03/24/00ISR Number: 3543224-8Report Type:Periodic Company Report #WAES 99120268
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Prilosec	C				
			Tiazac	C				

Date:03/24/00ISR Number: 3543225-XReport Type:Periodic Company Report #WAES 99120271
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543226-1Report Type:Periodic Company Report #WAES 99120276
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543227-3Report Type:Periodic Company Report #WAES 99120292
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Psychomotor Hyperactivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILYPO	
			Buspar	C				
			Synthroid	C				
			Corticosteroids	C				

Date:03/24/00ISR Number: 3543228-5Report Type:Periodic Company Report #WAES 99120312
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543229-7Report Type:Periodic Company Report #WAES 99120335
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			K-Dur	C				
			Mavik	C				
			Premarin	C				
			Tenormin	C				
			Ultram	C				

Date:03/24/00ISR Number: 3543230-3Report Type:Periodic Company Report #WAES 99120337
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Covera-Hs	C				
			Lipitor	C				
			Nonsteroidal Anti-Inflammatory)	C				

Date:03/24/00ISR Number: 3543231-5Report Type:Periodic Company Report #WAES 99120372
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543232-7Report Type:Periodic Company Report #WAES 99120374
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased	Health						
	Diarrhoea	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Ambien	C				
			Bentyl	C				
			Bumex	C				
			Lipitor	C				
			Norpace	C				
			Slow-K	C				
			Ultram	C				
			Voltaren	C				

Date:03/24/00ISR Number: 3543233-9Report Type:Periodic Company Report #WAES 99120383
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:03/24/00ISR Number: 3543234-0Report Type:Periodic Company Report #WAES 99120387
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Vioxx	PS	Merck Research			
	Back Pain	Professional			Laboratories Div			
	Gait Disturbance	Company			Merck Co Inc	ORAL	12.5	
	Pain In Extremity	Representative					MG/DAILY/PO	
			Claritin	C				
			Medrol	C				
			Slo-Bid	C				
			Theragran-M	C				
			Ascorbic Acid	C				

Date:03/24/00ISR Number: 3543235-2Report Type:Periodic Company Report #WAES 99120398
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			
	Transient Ischaemic	Professional			Laboratories Div			
	Attack				Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	

Date:03/24/00ISR Number: 3543236-4Report Type:Periodic Company Report #WAES 99120399
Age:90 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			

Merck Co Inc ORAL
UNK/PO

Date:03/24/00ISR Number: 3543237-6Report Type:Periodic Company Report #WAES 99120400
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3543238-8Report Type:Periodic Company Report #WAES 99120402
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3543239-XReport Type:Periodic Company Report #WAES 99120412
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 , 25 MG/BID/PO	30 DAY
			Avalide	C				
			Plendil	C				
			Meclizine	C				

Date:03/24/00ISR Number: 3543240-6Report Type:Periodic Company Report #WAES 99120417
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
	Pruritus							
	Sedation							
	Urine Abnormality		Centrum Silver	C				
			Lanoxin	C				
			Nitroglycerin	C				

Date:03/24/00ISR Number: 3543243-1Report Type:Periodic Company Report #WAES 99120419
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
	Fatigue							
	Muscular Weakness							
	Sedation		Pepcid	C				
			Prilosec	C				
			Imipramine	C				
			Quinine Sulfate	C				

Date:03/24/00ISR Number: 3543244-3Report Type:Periodic Company Report #WAES99120422
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Seborrhoeic Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/AM/PO						
			Lanoxin	C		
			Zocor	C		
			Estrogenic Preparations	C		
			Progesterone	C		

Date:03/24/00ISR Number: 3544105-6Report Type:Periodic Company Report #WAES 99111412
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNKNOWN PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544107-XReport Type:Periodic Company Report #WAES 99111442
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	

Date:03/24/00ISR Number: 3544110-XReport Type:Periodic Company Report #WAES 99111444
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Oedema Peripheral Syncope	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3544111-1Report Type:Periodic Company Report #WAES 99111549
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration Hyponatraemia International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Coumadin	C				
			Voltaren	C				

Date:03/24/00ISR Number: 3544112-3Report Type:Periodic Company Report #WAES 99111663
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Aerobid	C				
			Dyazide	C				
			Elavil	C				
			Paxil	C				
			Plavix	C				
			Serevent	C				
			Zantac	C				
			Theophylline	C				

Date:03/24/00ISR Number: 3544113-5Report Type:Periodic Company Report #WAES 99111665
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Speech Disorder Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Ambien	C				
			Norvasc	C				
			Ticlid	C				

			Zocor	C		
			[Composition Unspecified]	C		
			Imipramine	C		

Date:03/24/00ISR Number: 3544114-7Report Type:Periodic Company Report #WAES 99120152
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:03/24/00ISR Number: 3544536-4Report Type:Periodic Company Report #WAES 99101403
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
			Premarin	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3544537-6Report Type:Periodic Company Report #WAES 99101535
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Arthralgia Depression Face Oedema Flatulence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/IX/PO	

Flushing
Influenza Like Illness
Paraesthesia

Date:03/24/00ISR Number: 3544538-8Report Type:Periodic Company Report #WAES 99101717
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Vioxx	PS	Merck Research			
	Fluid Retention	Professional			Laboratories Div			
	Weight Increased				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Claritin	C				
			Demadex	C				
			Kay Ciel	C				
			Nasonex	C				
			Prilosec	C				
			Lorazepam	C				
			Meclizine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544539-XReport Type:Periodic Company Report #WAES 99101759
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
	Congestive	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	12.5	
	Weight Increased						MG/DAILY/PO	
			Celebrex	C				
			Lanoxin	C				
			Zestril	C				
			Aspirin	C				
			Furosemide	C				
			Losartan Potassium	C				

Date:03/24/00ISR Number: 3544540-6Report Type:Periodic Company Report #WAES 99101795
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/PO	
			Allegra	C				
			Diovan	C				
			Tiazac	C				

Date:03/24/00ISR Number: 3544541-8Report Type:Periodic Company Report #WAES 99101831
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Dizziness	Company			Merck Co Inc	ORAL	SEE IMAGE	
	Ecchymosis	Representative	Tenormin	C				
	Fatigue							
	Fluid Retention							

Headache
Hypertension
Nervousness
Weight Increased

Date:03/24/00ISR Number: 3544542-XReport Type:Periodic Company Report #WAES 99101911
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research			
	Insomnia	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG/PO	
			Norpace	C				
			Synthroid	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3544543-1Report Type:Periodic Company Report #WAES 99101982
Age:60 YR Gender:Male I/FU:F

Outcome	PT
	Abdominal Distension
	Abdominal Pain

	Impaired Gastric Emptying Weight Decreased					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
		Representative	Prilosec Unk [Composition Unspecified]	SS C		

Date:03/24/00ISR Number: 3544544-3Report Type:Periodic Company Report #WAES 99102031
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Plavix	C		
			[Therapy Unspecified]	C		

Date:03/24/00ISR Number: 3544545-5Report Type:Periodic Company Report #WAES 99102037
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3544546-7Report Type:Periodic Company Report #WAES 99102085
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Depression	Health	Vioxx	PS	Merck Research	

		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

25 MG/DAILY/PO

Date:03/24/00ISR Number: 3544547-9Report Type:Periodic Company Report #WAES 99102107
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Avapro	C				
			Lasix	C				
			Synthroid	C				
			Albuterol	C				
			Colchicine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544548-0Report Type:Periodic Company Report #WAES 99102151
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544549-2Report Type:Periodic Company Report #WAES 99102158
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:03/24/00ISR Number: 3544550-9Report Type:Periodic Company Report #WAES 99102229
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Arthrotec	C				
			Darvocet-N	C				
			Lamisil	C				
			Tylenol	C				

Date:03/24/00ISR Number: 3544551-0Report Type:Periodic Company Report #WAES 99102325
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Ecchymosis Petechiae Platelet Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

		Quinidine Unk	SS	

Date:03/24/00ISR Number: 3544552-2Report Type:Periodic Company Report #WAES 99110017
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

SEE IMAGE

Date:03/24/00ISR Number: 3544553-4Report Type:Periodic Company Report #WAES 99110274
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Pharyngitis Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

12.5 MG /

DAILY/PO

		Flexeril	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544554-6Report Type:Periodic Company Report #WAES 99110311
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Oral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Herbal Remedies (Composition Uns	C				
			Vitamins	C				
			Zinc Preparation (Composition	C				

Date:03/24/00ISR Number: 3544555-8Report Type:Periodic Company Report #WAES 99110341
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:03/24/00ISR Number: 3544664-3Report Type:Periodic Company Report #WAES 99110412
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3544667-9Report Type:Periodic Company Report #WAES 99110444
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bentyl	C				
			Dyazide	C				
			Prilosec	C				
			Soma	C				
			Tagamet	C				
			Ultram	C				

Date:03/24/00ISR Number: 3544669-2Report Type:Periodic Company Report #WAES 99110537
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression Agitation Paranoia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Demadex	C				
			Lanoxin	C				
			Prinivil	C				
			Remeron	C				
			Risperdal	C				
			Uniphyl	C				

				Aspirin	C		

Date:03/24/00ISR Number: 3544670-9Report Type:Periodic Company Report #WAES 99110625
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Methotrexate	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3544671-0Report Type:Periodic Company Report #WAES 99110629
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dermatitis Exfoliative Pruritus Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Caltrate 600 Plus Vitamin D	C				
			Tegretol	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3544675-8Report Type:Periodic Company Report #WAES 99110683
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 M/DAILY/PO	

Date:03/24/00ISR Number: 3544714-4Report Type:Periodic Company Report #WAES 99110692
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celexa	C				
			Norflex	C				
			Soma	C				
			Ultram	C				

Date:03/24/00ISR Number: 3544717-XReport Type:Periodic Company Report #WAES 99110700
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Neoral	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544719-3Report Type:Periodic Company Report #WAES 99110803
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Chest Pain	Health			Laboratories Div			
	Erythema	Professional			Merck Co Inc	ORAL	12.5	
	Flatulence						MG/DAILY/PO	
	Pruritus		Synthroid	C				
	Urticaria		Albuterol	C				

Date:03/24/00ISR Number: 3544722-3Report Type:Periodic Company Report #WAES 99110806
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Vioxx	PS	Merck Research			
	Rectal Haemorrhage	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5	
							MG/BID/PO	

Date:03/24/00ISR Number: 3544723-5Report Type:Periodic Company Report #WAES 99110822
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Compazine	C				
			Coumadin	C				
			Flonase	C				
			Glucotrol	C				
			Lasix	C				
			Roxicodone	C				

				Vasotec	C		
				Zyrtec	C		
				Digoxin	C		

Date:03/24/00ISR Number: 3544727-2Report Type:Periodic Company Report #WAES 99110892
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Abdominal Pain	Health			Laboratories Div			
	Diarrhoea	Professional			Merck Co Inc	ORAL	25	
	Dyspnoea						MG/DAILY/PO	
	Pharyngeal Oedema		Aatrovent	C				
	Urinary Tract Infection		Cardura	C				
			Lopressor	C				
			Prilosec	C				
			Proventil	C				
			Tylenol Extra Strength	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544742-9Report Type:Periodic Company Report #WAES 99110907
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Disorientation Dizziness Speech Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	7 DAY

Date:03/24/00ISR Number: 3544746-6Report Type:Periodic Company Report #WAES 99110987
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3544747-8Report Type:Periodic Company Report #WAES 99111022
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Soma	C				

Date:03/24/00ISR Number: 3544748-XReport Type:Periodic Company Report #WAES 99111205
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div	
					Merck Co Inc	ORAL
UNK/PO						
			Lasix	C		
			Potassium Supplement	C		
			Triamterene	C		

Date:03/24/00ISR Number: 3544749-1Report Type:Periodic Company Report #WAES 99111222
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Health	Vioxx	PS	Merck Research	
	Drug Toxicity	Professional			Laboratories Div	
	Nervousness	Company			Merck Co Inc	ORAL
UNK/PO						
		Representative				

Date:03/24/00ISR Number: 3544750-8Report Type:Periodic Company Report #WAES 99111287
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Non-Small Cell Lung	Health	Vioxx	PS	Merck Research	
	Cancer	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Os-Cal + D	C		
			Synthroid	C		

Atenolol	C
Iron (Unspecified)	C
Methotrexate	C
Emeprazole	C
Prednisone	C
Sodium Folate	C
Tamoxifen	C
Trazodone	C

Date:03/24/00ISR Number: 3544751-XReport Type:Periodic Company Report #WAES 99111318
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			
	Headache	Professional			Laboratories Div			
	Oedema				Merck Co Inc	ORAL	12.5	
	Weight Increased						MG/DAILY/PO	4 DAY

Date:03/24/00ISR Number: 3544752-1Report Type:Periodic Company Report #WAES 99111328
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	UNK/PO	
			Depo-Provera	C				
			Prozac	C				
			Synthroid	C				
			Zestril	C				
			Ziac	C				

Date:03/24/00ISR Number: 3544754-5Report Type:Periodic Company Report #WAES 99120713
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Visual Disturbance Visual Field Defect	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/DAILY;

PO

Advil	C	
Lipitor	C	
Vanceril	C	
Albuterol	C	

Date:03/24/00ISR Number: 3544755-7Report Type:Periodic Company Report #WAES 99120716
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Toxicologic Test Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:03/24/00ISR Number: 3544756-9Report Type:Periodic Company Report #WAES 991207720
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544757-0Report Type:Periodic Company Report #WAES 99120730
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	

Date:03/24/00ISR Number: 3544758-2Report Type:Periodic Company Report #WAES 99120734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Seborrhoeic Dermatitis Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544760-0Report Type:Periodic Company Report #WAES 99120739
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/DAILY;

PO

Date:03/24/00ISR Number: 3544761-2Report Type:Periodic Company Report #WAES 99120753
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG; PO	

Date:03/24/00ISR Number: 3544762-4Report Type:Periodic Company Report #WAES 99120758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544763-6Report Type:Periodic Company Report #WAES 99120763
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	

Date:03/24/00ISR Number: 3544765-XReport Type:Periodic Company Report #WAES 99120766
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Effect Decreased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY; PO	

Date:03/24/00ISR Number: 3544766-1Report Type:Periodic Company Report #WAES 99120768
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Hypotension Migraine Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/25 MG/DAILY; PO	
			Trazodone Imitrex	SS C				

Date:03/24/00ISR Number: 3544768-5Report Type:Periodic Company Report #WAES 99120770
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY; PO	

Date:03/24/00ISR Number: 3544770-3Report Type:Periodic Company Report #WAES 99120771
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
	Haemorrhage							

Date:03/24/00ISR Number: 3544772-7Report Type:Periodic Company Report #WAES 99120779
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Drug Ineffective Feeling Drunk	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	
			Chondroitin (+) Glucosamine	C				

Date:03/24/00ISR Number: 3544773-9Report Type:Periodic Company Report #WAES 99120781
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544775-2Report Type:Periodic Company Report #WAES 99120782
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM; PO	
			Lasix	C				
			Micro K	C				
			Zestril	C				
			Aspirin	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3544777-6Report Type:Periodic Company Report #WAES 99120785
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tenormin	C				
			[Composition Unspecified]	C				

Date:03/24/00ISR Number: 3544778-8Report Type:Periodic Company Report #WAES 99120786
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Visual Disturbance	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY; PO	
			Miacalcin	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3544780-6Report Type:Periodic Company Report #WAES 99120792
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emphysema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544781-8Report Type:Periodic Company Report #WAES 99120793
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/DAILY;

PO

Biaxin	C	
Coumadin	C	
Myambutol	C	

Date:03/24/00ISR Number: 3544785-5Report Type:Periodic Company Report #WAES 99120794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544791-0Report Type:Periodic Company Report #WAES 99120795
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hyperaesthesia Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Cordarone	C	
Lasix	C	
Mevacor	C	
Monopril	C	
Aspirin	C	
Digoxin	C	
Potassium Supplement	C	

Date:03/24/00ISR Number: 3544804-6Report Type:Periodic Company Report #WAES 99120800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO
			Lipitor	C			

Date:03/24/00ISR Number: 3544806-XReport Type:Periodic Company Report #WAES 99120803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544808-3Report Type:Periodic Company Report #WAES 99120805
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544809-5Report Type:Periodic Company Report #WAES 99120814
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukocytosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544811-3Report Type:Periodic Company Report #WAES 99120817
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Genital Pruritus Female Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Pain		Evista	C				

Date:03/24/00ISR Number: 3544813-7Report Type:Periodic Company Report #WAES 99120826
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody Positive Neuropathy Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544814-9Report Type:Periodic Company Report #WAES 99120837
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544815-0Report Type:Periodic Company Report #WAES 99120847
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544816-2Report Type:Periodic Company Report #WAES 99120875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Influenza Like Illness							
	Mouth Ulceration	Representative						
			Famvir	C				
			Paxil	C				
			Premarin	C				
			Prilosec	C				
			Folic Acid	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544817-4Report Type:Periodic Company Report #WAES 99120876
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health	Vioxx	PS	Merck Research			
	Pruritus	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PRN/PO	
		Representative	Ethyl Alcohol	SS				
			Claritin	C				
			Premarin	C				
			Prilosec	C				
			Ginger	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3544819-8Report Type:Periodic Company Report #WAES 99120885
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544821-6Report Type:Periodic Company Report #WAES 99120887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Vioxx	PS	Merck Research			
	Drug Toxicity	Professional			Laboratories Div			
	Mental Disorder	Company			Merck Co Inc	ORAL	PO	
	Nausea	Representative						

Date:03/24/00ISR Number: 3544822-8Report Type:Periodic Company Report #WAES 99120888
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544824-1Report Type:Periodic Company Report #WAES 99120890
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544826-5Report Type:Periodic Company Report #WAES 99120891
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx [Therapy	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Unspecified] SS

Date:03/24/00ISR Number: 3544828-9Report Type:Periodic Company Report #WAES 99120892
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Macular Degeneration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544829-0Report Type:Periodic Company Report #WAES 99120893
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544830-7Report Type:Periodic Company Report #WAES 99120894
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544835-6Report Type:Periodic Company Report #WAES 99070286
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lorcet Plus	C				
			Piroxicam	C				

Date:03/24/00ISR Number: 3544836-8Report Type:Periodic Company Report #WAES 99120916
Age:99 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Mental Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Alphagan	C				
			Prevacid	C				
			Allopurinol	C				
			Diltiazem	C				
			Prednisone Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544838-1Report Type:Periodic Company Report #WAES 99070353
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Muscle Rigidity	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Ecotrin	C				
			Diltiazem	C				
			Docusate Sodium	C				
			Lansoprazole	C				

Date:03/24/00ISR Number: 3544839-3Report Type:Periodic Company Report #WAES 99120921
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Health	Vioxx	PS	Merck Research			
	Phosphokinase Increased	Professional			Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/	
							PO	
			Lipitor	C				
			Prempro	C				
			Procardia Xl	C				

Date:03/24/00ISR Number: 3544841-1Report Type:Periodic Company Report #WAES 99070696
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck Research			
	Attention	Professional			Laboratories Div			
	Deficit/Hyperactivity	Company			Merck Co Inc			
							PO	
	Disorder	Representative	Aventyl	C				
	Dizziness		Premarin	C				
	Hypersensitivity							

Date:03/24/00ISR Number: 3544842-3Report Type:Periodic Company Report #WAES 99120926
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/ PO						
			Benadryl	C		
			Crixivan	C		
			Dapsone	C		
			Epivir	C		
			Neupogen	C		
			Neurontin	C		
			Prilosec	C		
			Sinemet	C		
			Zerit	C		
			Zithromax	C		
			Aspirin	C		
			Hydroxyzine	C		
			Valproic Acid	C		
			Vitamins	C		

Date:03/24/00ISR Number: 3544843-5Report Type:Periodic Company Report #WAES 99071271
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:03/24/00ISR Number: 3544845-9Report Type:Periodic Company Report #WAES 99120936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544846-0Report Type:Periodic Company Report #WAES 99080157
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Chest Sound Asthenia Dyspnoea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue	Representative						
	Oedema Peripheral		Combivent	C				
	Pallor		D-Dur	C				

Date:03/24/00ISR Number: 3544847-2Report Type:Periodic Company Report #WAES 99120938
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Inadequate Analgesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO,2

5 MG/BID/PO
Therapy Unspecified C

Date:03/24/00ISR Number: 3544852-6Report Type:Periodic Company Report #WAES 99120952
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:03/24/00ISR Number: 3544854-XReport Type:Periodic Company Report #WAES 99120955
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544857-5Report Type:Periodic Company Report #WAES 99080513
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Headache	Health			Laboratories Div			
	Insomnia	Professional			Merck Co Inc	ORAL	25 MG/AM/PO	
	Nausea		Diovan	C				
			Norvasc	C				
			Premarin	C				
			Prevacid	C				
			Propulsid	C				
			Synthroid	C				
			Ultram	C				
			Alprazolam	C				
			Atenolol	C				
			Clonidine	C				
			Furosemide	C				

Date:03/24/00ISR Number: 3544858-7Report Type:Periodic Company Report #WAES 99081538
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Hypertension	Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Muscular Weakness							
			Climara	C				
			Fosamax	C				
			Aspirin	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3544859-9Report Type:Periodic Company Report #WAES 99120998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div Merck Co Inc	ORAL

PO

Date:03/24/00ISR Number: 3544860-5Report Type:Periodic Company Report #WAES 99081690
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Headache					
	Muscular Weakness					
	Syncope		Estradiol	C		
	Tremor					
	Visual Disturbance					

PO

Date:03/24/00ISR Number: 3544861-7Report Type:Periodic Company Report #WAES 99120999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/ DAILY/

PO

	Celebrex	C	
	Diovan	C	
	Tylenol Pm	C	

Date:03/24/00ISR Number: 3544863-0Report Type:Periodic Company Report #WAES 99121000
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health	Vioxx	PS	Merck Research			
	Pharyngitis	Professional			Laboratories Div			
	Pulmonary Congestion				Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544864-2Report Type:Periodic Company Report #WAES 99081782
Age:98 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25 MG/PO	
			Dyazide	C				
			Premarin	C				

Date:03/24/00ISR Number: 3544866-6Report Type:Periodic Company Report #WAES 99121002
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Mouth Haemorrhage				Laboratories Div			
					Merck Co Inc	ORAL	25 MG / PO	
			Prilosec	C				
			Vicodin	C				
			Therapy Unspecified	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3544867-8Report Type:Periodic Company Report #WAES 99121006
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
	Cough							
	Fatigue							
	Pain							
	Pharyngitis		Synthroid	C				
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3544869-1Report Type:Periodic Company Report #WAES 99081858
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Fall							
	Gait Disturbance							
	Gastrointestinal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544871-XReport Type:Periodic Company Report #WAES 99121008
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Ptosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / PO	
			Lotensin	C				
			Allopurinol	C				
			Trazodone	C				

Date:03/24/00ISR Number: 3544874-5Report Type:Periodic Company Report #WAES 99121015
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Synthroid	C				

Date:03/24/00ISR Number: 3544876-9Report Type:Periodic Company Report #WAES 99121017
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO, 25 MG/QOD/PO	1 MON
			Lipitor	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3544878-2Report Type:Periodic Company Report #WAES 99121018
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY/ PO	4 DAY
	Constipation							
	Diarrhoea							
	Faeces Discoloured							
			Fosamax	C				
			Prempro	C				
			Synthroid	C				
			Lithium Carbonate	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3544880-0Report Type:Periodic Company Report #WAES 99121020
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Celebrex	C				
			Hydrodiuril	C				
			Synthroid	C				

			Tenormin	C		

Date:03/24/00ISR Number: 3544882-4Report Type:Periodic Company Report #WAES 99121024
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Elavil	C				
			Allopurinol	C				

Date:03/24/00ISR Number: 3544883-6Report Type:Periodic Company Report #WAES 99081985
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Dizziness Hypertension Nervousness Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5/DAILY/PO	

Date:03/24/00ISR Number: 3544884-8Report Type:Periodic Company Report #WAES 99121025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544886-1Report Type:Periodic Company Report #WAES 99090120
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Provera	C				

Date:03/24/00ISR Number: 3544887-3Report Type:Periodic Company Report #WAES 99121026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ascites Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/ PO	
			Rythmol Unk	SS				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544890-3Report Type:Periodic Company Report #WAES 99090435
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research			
	Erythema				Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Evista	C				
			Synthroid	C				
			Zantac	C				
			Atenolol	C				
			Chlordiazepoxide	C				

Date:03/24/00ISR Number: 3544892-7Report Type:Periodic Company Report #WAES 99091014
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Feeling Abnormal	Professional			Merck Co Inc	ORAL	12.5MG/DAILY/	
	Vision Blurred						PO	
			Tab Vioxx 25 Mg	SS		ORAL	25	
							MG/DAILY/PO	
			Antivert	C				
			Levobunolol	C				
			Zantac	C				
			Ultram	C				

Date:03/24/00ISR Number: 3544894-0Report Type:Periodic Company Report #WAES 99091109
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research			
	Ulcer	Health			Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3544896-4Report Type:Periodic Company Report #WAES 99091223
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Vioxx	PS	Merck Research	
	Oedema Peripheral	Professional			Laboratories Div	
	Urticaria	Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Celebrex	C		
			Fosamax	C		
			Plaquenil	C		
			Prevacid	C		
			Propulsid	C		
			Prednisone	C		

Date:03/24/00ISR Number: 3544898-8Report Type:Periodic Company Report #WAES 99091418
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25						

MG/DAILY/PO 7 DAY

Date:03/24/00ISR Number: 3544899-XReport Type:Periodic Company Report #WAES 99091807
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544900-3Report Type:Periodic Company Report #WAES 99122216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Monopril	C				

Date:03/24/00ISR Number: 3544901-5Report Type:Periodic Company Report #WAES 99091829
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544902-7Report Type:Periodic Company Report #WAES 99122227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dyazide	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3544904-0Report Type:Periodic Company Report #WAES 99091834
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544905-2Report Type:Periodic Company Report #WAES 99122228
Age:75 YR Gender:Female I/FU:I

Outcome	PT
	Diarrhoea Eye Pain

		Nausea Pruritus Sedation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	1 WK						
				Ativan	C		
				Lasix	C		
				Ludiomil	C		
				Medrol	C		
				Neurontin	C		
				Pamelor	C		
				Zantac	C		
				Methotrexate	C		

Date:03/24/00ISR Number: 3544907-6Report Type:Periodic Company Report #WAES 99122235
Age:82 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Zestril	C		
				Digoxin	C		

Date:03/24/00ISR Number: 3544920-9Report Type:Periodic Company Report #WAES 99122237
Age:68 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chills Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY;							
PO							
				Dyazide	C		
				Fosamax	C		
				Calcium Supplement	C		

Date:03/24/00ISR Number: 3544923-4Report Type:Periodic Company Report #WAES 99122239
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	

Date:03/24/00ISR Number: 3544924-6Report Type:Periodic Company Report #WAES 99122242
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544927-1Report Type:Periodic Company Report #WAES 99122243
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
			Monopril	C				
			Prilosec	C				

Date:03/24/00ISR Number: 3544928-3Report Type:Periodic Company Report #WAES 99122244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pruritus Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY;	
			Miacalcin	C			PO	
			Timoptic	C				
			Calcium Supplement	C				

Date:03/24/00ISR Number: 3544930-1Report Type:Periodic Company Report #WAES 99122255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Darvocet-N	C				
			Premarin	C				
			Folic Acid	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3544932-5Report Type:Periodic Company Report #WAES 99122262
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 / 25 MG/DAILY; PO	
			K-Dur	C				
			Lasix	C				
			Lopressor	C				
			Neurontin	C				

Date:03/24/00ISR Number: 3544934-9Report Type:Periodic Company Report #WAES 99122263
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY; PO	
			Cardizem	C				
			Prilosec	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544937-4Report Type:Periodic Company Report #WAES 99122267
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Dyazide	C				
			Inderal	C				
			Tamoxifen	C				

Date:03/24/00ISR Number: 3544940-4Report Type:Periodic Company Report #WAES 99122269
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544943-XReport Type:Periodic Company Report #WAES 99122271
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544944-1Report Type:Periodic Company Report #WAES 99122296
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Effusion	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Ms Contin	C	
Synvisc	C	
Chondroitin (+)		
Glucosamine	C	
Phenobarbital	C	
Vitamins	C	

Date:03/24/00ISR Number: 3544947-7Report Type:Periodic Company Report #WAES 99122298
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY; PO	
			Cozaar	C				
			Extendryl	C				
			Fosomax	C				
			Prempro	C				
			Singulair	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544950-7Report Type:Periodic Company Report #WAES 99122306
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID; PO	
			Gas-X	C				

Date:03/24/00ISR Number: 3544951-9Report Type:Periodic Company Report #WAES 99122307
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM; PO	
			Cardura	C				
			Cozaar	C				
			Premarin	C				
			Glyburide	C				

Date:03/24/00ISR Number: 3544953-2Report Type:Periodic Company Report #WAES 99060741
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Facial Palsy Hypoaesthesia Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY; PO	

Date:03/24/00ISR Number: 3544955-6Report Type:Periodic Company Report #WAES 00020042
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lescol	C				
			Calcium Supplemental (Compostion)	C				

Date:03/24/00ISR Number: 3544957-XReport Type:Periodic Company Report #WAES 00020044
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Lopressor	C				
			Norvasc	C				
			Premarin	C				
			Tylenol	C				
			Indapamide	C				
			Sucralfate	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544960-XReport Type:Periodic Company Report #WAES 00020047
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins	C				

Date:03/24/00ISR Number: 3544967-2Report Type:Periodic Company Report #WAES 00020056
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Oral Soft Tissue Disorder Pharyngeal Oedema Tongue Disorder Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/24/00ISR Number: 3544968-4Report Type:Periodic Company Report #WAES 00020063
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Rash Erythematous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544969-6Report Type:Periodic Company Report #WAES 00020065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
		Representative	Coumadin	C				

Date:03/24/00ISR Number: 3544971-4Report Type:Periodic Company Report #WAES 00020067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:03/24/00ISR Number: 3544974-XReport Type:Periodic Company Report #WAES 00020088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Allegra	C				
			Lopressor	C				

			Lotrel	C
			Prilosec	C
			Allopurinol	C

Date:03/24/00ISR Number: 3544976-3Report Type:Periodic Company Report #WAES 00020090
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				

Date:03/24/00ISR Number: 3544977-5Report Type:Periodic Company Report #WAES 00020098
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3544979-9Report Type:Periodic Company Report #WAES 00020122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Pravachol	C				
			Synthroid	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3544981-7Report Type:Periodic Company Report #WAES 00020123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:03/24/00ISR Number: 3544982-9Report Type:Periodic Company Report #WAES 00012429
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544984-2Report Type:Periodic Company Report #WAES 00020132
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
							12.5 MG/DAILY/PO	
			Bellergal-S Tablets	C				
			Fosamax	C				
			Neurotonin Capsules	C				
			Tamoxifen	C				

Date:03/24/00ISR Number: 3544986-6Report Type:Periodic Company Report #WAES 00012430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544987-8Report Type:Periodic Company Report #WAES 00020135
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544989-1Report Type:Periodic Company Report #WAES 00012431
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Normal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544990-8Report Type:Periodic Company Report #WAES 00020139
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Ecotrin	C				
			Lipitor	C				
			Prilosec	C				
			Trental	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544991-XReport Type:Periodic Company Report #WAES 00012432
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Fosamax	C				
			Prilosec	C				
			Procardia Xl	C				
			Synthroid	C				
			Hydrochlorothiazide + Triamter	C				

Date:03/24/00ISR Number: 3544992-1Report Type:Periodic Company Report #WAES 00020140
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Gastrointestinal Disorder Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Monopril	C				
			Procardia	C				
			Zaroxolyn	C				

Date:03/24/00ISR Number: 3544993-3Report Type:Periodic Company Report #WAES 00012457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Oxycontin	C				

Date:03/24/00ISR Number: 3544994-5Report Type:Periodic Company Report #WAES 00020145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 DAY

Date:03/24/00ISR Number: 3544995-7Report Type:Periodic Company Report #WAES 00020158
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Diovan Hct	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3544996-9Report Type:Periodic Company Report #WAES 00012460
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Flushing							
	Pulmonary Congestion							

Date:03/24/00ISR Number: 3544997-0Report Type:Periodic Company Report #WAES 00020161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544998-2Report Type:Periodic Company Report #WAES 00012461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3544999-4Report Type:Periodic Company Report #WAES 00012501
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition					

Unspecified	C	
Aspirin	C	
Diuretic Preparation	C	

Date:03/24/00ISR Number: 3545000-9Report Type:Periodic Company Report #WAES 00012511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/24/00ISR Number: 3545001-0Report Type:Periodic Company Report #WAES 00012513
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545002-2Report Type:Periodic Company Report #WAES 00012518
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research			
	Influenza Like Illness	Health			Laboratories Div			
	Neck Pain	Professional			Merck Co Inc	ORAL	12.5	
	Respiratory Disorder						MG/DAILY/PO;	
							25	
							MG/DAILY/PO	
			Propranolol	C				

Date:03/24/00ISR Number: 3545003-4Report Type:Periodic Company Report #WAES 00012521
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research			
	Medication Error				Laboratories Div			
	Weight Increased				Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Pravachol	C				
			Premarin	C				
			Calcium Supplement	C				
			Verapamil Hydrochloride	C				
			Vitamin D	C				

Date:03/24/00ISR Number: 3545004-6Report Type:Periodic Company Report #WAES 00012540
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Headache				Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Therapy Unspecified C
Estrogenic
Preparations C

Date:03/24/00ISR Number: 3545006-XReport Type:Periodic Company Report #WAES 00012572
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545007-1Report Type:Periodic Company Report #WAES 00012574
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545008-3Report Type:Periodic Company Report #WAES 00012579
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Influenza	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545009-5Report Type:Periodic Company Report #WAES 00012595
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Skin Nodule	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Advil	C				
			Tylenol	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3545010-1Report Type:Periodic Company Report #WAES 00012601
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Delusion Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO; 25MG/PO	
			Co-Gesic	C				
			Ditropan	C				
			Levsin	C				
			Paxil	C				
			Tagamet	C				
			Meclizine	C				

Date:03/24/00ISR Number: 3545011-3Report Type:Periodic Company Report #WAES 00012607
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Glucophage	C				
			Hydrodiuril	C				
			Premarin	C				
			Zocor	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Chondroitin	C				
			Glucosamine	C				

Date:03/24/00ISR Number: 3545012-5Report Type:Periodic Company Report #WAES 00012610
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50MG/DAILY/PO

Date:03/24/00ISR Number: 3545013-7Report Type:Periodic Company Report #WAES 00011397
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Prempro	C				

Date:03/24/00ISR Number: 3545014-9Report Type:Periodic Company Report #WAES 00012616
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545015-0Report Type:Periodic Company Report #WAES 00011398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Gastritis Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545016-2Report Type:Periodic Company Report #WAES 00012620
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3545017-4Report Type:Periodic Company Report #WAES 00011399
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prinivil	C				
			Estradiol	C				

Date:03/24/00ISR Number: 3545018-6Report Type:Periodic Company Report #WAES 00012626
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/AM/PO	
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545019-8Report Type:Periodic Company Report #WAES 00011406
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Dilantin	C				
			Prinivil	C				
			Propax	C				
			Diltiazem	C				
			Glyburide	C				

Date:03/24/00ISR Number: 3545020-4Report Type:Periodic Company Report #WAES 00012632
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage Melaena	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			K-Dur	C				
			Zestoretic	C				
			Calcium Supplement	C				
			Ginseng	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545022-8Report Type:Periodic Company Report #WAES 00011434
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545023-XReport Type:Periodic Company Report #WAES 00012634
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	2 DAY

Date:03/24/00ISR Number: 3545024-1Report Type:Periodic Company Report #WAES 00011436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545025-3Report Type:Periodic Company Report #WAES 00012652
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
			Azulfidine	C				
			Estratest	C				
			Norco	C				
			Xanax	C				
			Zanaflex	C				

Date:03/24/00ISR Number: 3545027-7Report Type:Periodic Company Report #WAES 00011437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperthyroidism Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545028-9Report Type:Periodic Company Report #WAES 00012660
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Akathisia Anxiety Restless Legs Syndrome	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	HS/PO	

Date:03/24/00ISR Number: 3545030-7Report Type:Periodic Company Report #WAES 00011642
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Joint Swelling Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545031-9Report Type:Periodic Company Report #WAES 00012662
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Tenormin	C				
			Xanax	C				

Date:03/24/00ISR Number: 3545033-2Report Type:Periodic Company Report #WAES 00011657
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5
MG/PRN/PO

Cipro	C
Ditropan	C
Propulsid	C
Synthroid	C
Ranitidine Hydrochloride	C

Date:03/24/00ISR Number: 3545034-4Report Type:Periodic Company Report #WAES 00012672
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Hypersensitivity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
		Representative	Vioxx	SS		ORAL	PO	
			Prinivil	SS				
			Lipitor	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3545035-6Report Type:Periodic Company Report #WAES 00011660
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:03/24/00ISR Number: 3545036-8Report Type:Periodic Company Report #WAES 00012674
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Mydriasis	Other	Vioxx	PS	Merck Research	
	Vision Blurred				Laboratories Div	
					Merck Co Inc	
PO						

Date:03/24/00ISR Number: 3545037-XReport Type:Periodic Company Report #WAES 00011662
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research	
	Oedema Peripheral	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:03/24/00ISR Number: 3545038-1Report Type:Periodic Company Report #WAES 00012676
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
	Eye Disorder				Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL
25MG/DAILY/PO						
			Prevacid	C		
			Zocor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545039-3Report Type:Periodic Company Report #WAES 00011664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545040-XReport Type:Periodic Company Report #WAES 00012683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545041-1Report Type:Periodic Company Report #WAES 00011665
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545042-3Report Type:Periodic Company Report #WAES 00012692
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Flatulence Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545043-5Report Type:Periodic Company Report #WAES 00011670
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspnoea Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545044-7Report Type:Periodic Company Report #WAES 00020006
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/PO, 25MG/PO	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545045-9Report Type:Periodic Company Report #WAES 00011672
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Activity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Sedation							
			Claritin-D 12 Hour	C				
			Nasacort Aq	C				

Date:03/24/00ISR Number: 3545046-0Report Type:Periodic Company Report #WAES 00020012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5MG/DAILY/ PO	

Date:03/24/00ISR Number: 3545047-2Report Type:Periodic Company Report #WAES 00011742
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Asthenia	Health						
	Fatigue	Professional						
	Pelvic Pain		Hyzaar	C				
	Sensation Of Heaviness		Imdur	C				
			Tenormin	C				

Date:03/24/00ISR Number: 3545048-4Report Type:Periodic Company Report #WAES 00020015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545049-6Report Type:Periodic Company Report #WAES 00011744
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Myalgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prednisone	C				

Date:03/24/00ISR Number: 3545050-2Report Type:Periodic Company Report #WAES 00020030
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Oedema Peripheral		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545051-4Report Type:Periodic Company Report #WAES 00011745
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Depression							
	Dizziness							
	Fatigue							
	Movement Disorder		Tylenol	C				

Date:03/24/00ISR Number: 3545052-6Report Type:Periodic Company Report #WAES 00020038
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Dizziness							
	Paraesthesia							
			Evista	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3545053-8Report Type:Periodic Company Report #WAES 00011753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545054-XReport Type:Periodic Company Report #WAES 00020039
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Lip Dry	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Aspirin	C				
			Ranitidine	C				

Date:03/24/00ISR Number: 3545055-1Report Type:Periodic Company Report #WAES 00011755
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prevacid	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545056-3Report Type:Periodic Company Report #WAES 99120120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Headache	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/							
DAILY/PO							

Date:03/24/00ISR Number: 3545057-5Report Type:Periodic Company Report #WAES 99120123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Toxicologic Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Zoloft	C		

Date:03/24/00ISR Number: 3545058-7Report Type:Periodic Company Report #WAES 99120130
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						

Date:03/24/00ISR Number: 3545059-9Report Type:Periodic Company Report #WAES 99120132
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Abdominal Pain Upper Feeling Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

	Flushing	Company Representative			Merck Co Inc	ORAL 25 MG/ DAILY/PO

Date:03/24/00ISR Number: 3545060-5Report Type:Periodic Company Report #WAES 99120136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO	

Date:03/24/00ISR Number: 3545061-7Report Type:Periodic Company Report #WAES 99120140
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545062-9Report Type:Periodic Company Report #WAES 99120157
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545063-0Report Type:Periodic Company Report #WAES 99120168
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	

Date:03/24/00ISR Number: 3545064-2Report Type:Periodic Company Report #WAES 99120172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545065-4Report Type:Periodic Company Report #WAES 99120192
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / 25 MG/PO	

Celebrex	C
Fosamax	C
Ascorbic Acid	C
Vitamin E	C

Date:03/24/00ISR Number: 3545066-6Report Type:Periodic Company Report #WAES 99121160
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545067-8Report Type:Periodic Company Report #WAES 99120196
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545068-XReport Type:Periodic Company Report #WAES 99120206
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3545069-1Report Type:Periodic Company Report #WAES 99120207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	/DAILY/PO
			Claritin	C				

Date:03/24/00ISR Number: 3545071-XReport Type:Periodic Company Report #WAES 99120212
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celexa	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3545072-1Report Type:Periodic Company Report #WAES 99120220
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prozac	C				

Date:03/24/00ISR Number: 3545073-3Report Type:Periodic Company Report #WAES 99120228
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Proscar	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545074-5Report Type:Periodic Company Report #WAES 99120232
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Lip Dry Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Arava	C
Darvocet-N	C
Imuran	C
Prilosec	C

Date:03/24/00ISR Number: 3545076-9Report Type:Periodic Company Report #WAES 99120237
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545077-0Report Type:Periodic Company Report #WAES 99120238
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545079-4Report Type:Periodic Company Report #WAES 99120257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /PO	

Date:03/24/00ISR Number: 3545081-2Report Type:Periodic Company Report #WAES 99092019
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Minocin Unk	SS			UNK/UNK/UNK	

Date:03/24/00ISR Number: 3545082-4Report Type:Periodic Company Report #WAES 99092187
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Flovent	C				
			Miacalcin	C				
			Singulair	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545084-8Report Type:Periodic Company Report #WAES 99100273
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eating Disorder	Consumer	Vioxx	PS	Merck Research			
	Mouth Ulceration	Health			Laboratories Div			
	Tongue Disorder	Professional			Merck Co Inc	ORAL	12.5 MG/UNK/PO; 25 MG/UNK/PO	
			Aspirin	C				
			Celebrex	C				
			Timoptic	C				

Date:03/24/00ISR Number: 3545086-1Report Type:Periodic Company Report #WAES 99100504
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colour Blindness	Health	Vioxx	PS	Merck Research			
	Vision Blurred	Professional			Laboratories Div			
	Visual Disturbance				Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			Loestrin	C				
			Zantac	C				

Date:03/24/00ISR Number: 3545088-5Report Type:Periodic Company Report #WAES 99100581
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Lip Dry	Health			Laboratories Div			

	Mouth Haemorrhage	Professional			Merck Co Inc	ORAL
12.5						
	Oral Pain					
MG/DAILY/PO						
			Cipro	C		
			Miacalcin	C		
			Pepcid	C		
			Tylenol	C		
			Calcium Supplement (Composition)	C		
			Folic Acid	C		
			Methotrexate	C		
			Phenobarbital	C		
			Prednisone	C		
			Vitamins	C		

Date:03/24/00ISR Number: 3545089-7Report Type:Periodic Company Report #WAES 99100597
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Chest Pain					
	Pruritus				Merck Co Inc	ORAL
UNK/UNK/PO						
			Fosamax	SS		
			Accupril	C		
			Pravachol	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545091-5Report Type:Periodic Company Report #WAES 99100624
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3545093-9Report Type:Periodic Company Report #WAES 99100628
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Flushing	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Darvocet-N	C				
			Serzone	C				

Date:03/24/00ISR Number: 3545094-0Report Type:Periodic Company Report #WAES 99100652
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Radiation Skin Injury	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545096-4Report Type:Periodic Company Report #WAES 99100744
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS	Merck Research			

	Headache	Professional			Laboratories Div	
	Sedation	Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative	Plaquenit	C		
			Synthroid	C		
			Zoloft	C		

Date:03/24/00ISR Number: 3545097-6Report Type:Periodic Company Report #WAES 99100801
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5						
MG/BID/PO						
			Coumadin	C		
			Fosamax	C		
			Lanoxin	C		
			Toprol Xl Tablets	C		
			Pednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545099-XReport Type:Periodic Company Report #WAES 99101034
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			
	Face Oedema	Professional			Laboratories Div			
	Muscular Weakness	Company			Merck Co Inc	ORAL	25	
	Nausea	Representative					MG/DAILY/PO;	
	Pruritus						12.5	
							MG/DAILY/PO	
			Norflex	C				
			Norvasc	C				
			Os-Cal	C				
			Therapy Unspecified	C				
			Aspirin	C				
			Propranolol	C				

Date:03/24/00ISR Number: 3545100-3Report Type:Periodic Company Report #WAES 99101054
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Humulin	C				
			Valium	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545101-5Report Type:Periodic Company Report #WAES 99120427
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
25-50

MG/DAILY/PO

Date:03/24/00ISR Number: 3545102-7Report Type:Periodic Company Report #WAES 99101180
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3545103-9Report Type:Periodic Company Report #WAES 99101214
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545104-0Report Type:Periodic Company Report #WAES 99101250
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545105-2Report Type:Periodic Company Report #WAES 99120432
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Zestril	C				
			Glyburide	C				

Date:03/24/00ISR Number: 3545106-4Report Type:Periodic Company Report #WAES 99101291
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Betapace	C				
			Coumadin	C				
			Lanoxin	C				
			Maxzide	C				
			Zocor	C				

Date:03/24/00ISR Number: 3545107-6Report Type:Periodic Company Report #WAES 99120433
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	(SEE IMAGE)
			Hyzaar	C				
			Neoral	C				
			Pepcid	C				
			Zyrtec	C				
			Methotrexate	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3545108-8Report Type:Periodic Company Report #WAES 99121167
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Tricor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545109-XReport Type:Periodic Company Report #WAES 99101299
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Mysoline	C				
			Oxybutynin Chloride	C				

Date:03/24/00ISR Number: 3545111-8Report Type:Periodic Company Report #WAES 99121168
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545112-XReport Type:Periodic Company Report #WAES 99101303
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Adalat	C				
			Donnatal	C				
			Premarin	C				
			Albuterol	C				

Date:03/24/00ISR Number: 3545114-3Report Type:Periodic Company Report #WAES 99121177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545115-5Report Type:Periodic Company Report #WAES 99101396
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3545117-9Report Type:Periodic Company Report #WAES 99121178
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Conduction Disorder	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545118-0Report Type:Periodic Company Report #WAES 99121179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:03/24/00ISR Number: 3545120-9Report Type:Periodic Company Report #WAES 99121181
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545122-2Report Type:Periodic Company Report #WAES 99121182
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	
							PO	

Date:03/24/00ISR Number: 3545124-6Report Type:Periodic Company Report #WAES 99121187
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Hyperhidrosis							
			Paxil	C				
			Tylenol	C				

Date:03/24/00ISR Number: 3545127-1Report Type:Periodic Company Report #WAES 99121194
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545129-5Report Type:Periodic Company Report #WAES 99121204
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545131-3Report Type:Periodic Company Report #WAES 99121228
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Chest Pain Cough	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Colace	C				
			Flonase	C				
			Hydrodiuril	C				
			Lipitor	C				
			Lotrel	C				
			Neurontin	C				
			Prevacid	C				
			(Therapy Unspecified)	C				
			Atenolol	C				
			Clonazepam	C				
			Prednisone	C				
			Trazodone	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545132-5Report Type:Periodic Company Report #WAES 99120442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Nervousness							
	Tremor							

Date:03/24/00ISR Number: 3545134-9Report Type:Periodic Company Report #WAES 99121257
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Joint Stiffness							
	Oedema Peripheral							
			Depakote	C				
			Estrace	C				
			Imitrex	C				
			Prevacid	C				
			Aspirin	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545135-0Report Type:Periodic Company Report #WAES 99120453
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Slow-K	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3545137-4Report Type:Periodic Company Report #WAES 99120459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/HS/PO	
			Synthroid	C				

Date:03/24/00ISR Number: 3545139-8Report Type:Periodic Company Report #WAES 99121258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/24/00ISR Number: 3545140-4Report Type:Periodic Company Report #WAES 99120461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3545141-6Report Type:Periodic Company Report #WAES 99121261
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor (Therapy Inspecified)	C C				

Date:03/24/00ISR Number: 3545143-XReport Type:Periodic Company Report #WAES 99120463
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				

		Prilosec	C
		Prozac	C
		Sonate	C
		Synthroid	C

Date:03/24/00ISR Number: 3545144-1Report Type:Periodic Company Report #WAES 99121262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lithium Carbonate	C				

Date:03/24/00ISR Number: 3545146-5Report Type:Periodic Company Report #WAES 99121265
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis International Normalised Ratio Decreased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	4 MON
	Uterine Haemorrhage	Representative	Influenza Virus Vaccine	C				
			Prednisone	C				
			Vitamin B (12)	C				

Date:03/24/00ISR Number: 3545148-9Report Type:Periodic Company Report #WAES 99121266
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	

			Insulin	C		

Date:03/24/00ISR Number: 3545149-0Report Type:Periodic Company Report #WAES 99121273
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545150-7Report Type:Periodic Company Report #WAES 99121359
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Claritin-D	C				
			Colestid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545204-5Report Type:Periodic Company Report #WAES 99120470
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545206-9Report Type:Periodic Company Report #WAES 99120472
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545208-2Report Type:Periodic Company Report #WAES 99120488
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Dyspepsia Flatulence	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545211-2Report Type:Periodic Company Report #WAES 99120490
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Pruritus Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3545212-4Report Type:Periodic Company Report #WAES 99120511
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545214-8Report Type:Periodic Company Report #WAES 99120532
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Accupril	C				
			Flovent	C				
			Uniphyl	C				
			Allopurinol	C				

Date:03/24/00ISR Number: 3545216-1Report Type:Periodic Company Report #WAES 99120543
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Sensation Of Heaviness Tachycardia Tremor	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545217-3Report Type:Periodic Company Report #WAES 99120559
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545220-3Report Type:Periodic Company Report #WAES 99120562
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

(SEE IMAGE)

Date:03/24/00ISR Number: 3545221-5Report Type:Periodic Company Report #WAES 99120567
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545224-0Report Type:Periodic Company Report #WAES 99120568
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Baycol	C				
			Plavix	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545236-7Report Type:Periodic Company Report #WAES 99120583
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Inderal	C
Naprosyn	C
Prilosec	C
Synthroid	C
Morphine	C

Date:03/24/00ISR Number: 3545253-7Report Type:Periodic Company Report #WAES 99120587
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Serum Sickness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545255-0Report Type:Periodic Company Report #WAES 99120591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545257-4Report Type:Periodic Company Report #WAES 99120592
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Accupril	C		
			Flomax (Tamsulosin (R)-Form Hydr	C		
			Atenolol	C		

Date:03/24/00ISR Number: 3545259-8Report Type:Periodic Company Report #WAES 99120596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Nausea				Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3545260-4Report Type:Periodic Company Report #WAES 99120600
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Fluid Retention					
	Nausea				Merck Co Inc	ORAL
PO						
	Paraesthesia		Levsin	C		
	Weight Increased		Neurontin	C		
			Rhinocort	C		

Date:03/24/00ISR Number: 3545262-8Report Type:Periodic Company Report #WAES 99120602
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545264-1Report Type:Periodic Company Report #WAES 99120605
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:03/24/00ISR Number: 3545265-3Report Type:Periodic Company Report #WAES 99120608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PRN/PO	

Date:03/24/00ISR Number: 3545269-0Report Type:Periodic Company Report #WAES 99120614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545271-9Report Type:Periodic Company Report #WAES 99120628
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY	/ PO
			Mevacor	C				
			Pepcid	C				
			Premarin	C				
			Trental	C				
			Vasotec	C				
			Zyloprim	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545274-4Report Type:Periodic Company Report #WAES 99120638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545278-1Report Type:Periodic Company Report #WAES 99120642
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Fosamax	C				

Date:03/24/00ISR Number: 3545284-7Report Type:Periodic Company Report #WAES 99120646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545287-2Report Type:Periodic Company Report #WAES 99120655
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Constipation Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545291-4Report Type:Periodic Company Report #WAES 99120670
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Lipitor	C
Prilosec	C
[Therapy Unspecified]	C
Aspirin	C
Atenolol	C
Estrogenic Preparations (Composi	C

Date:03/24/00ISR Number: 3545298-7Report Type:Periodic Company Report #WAES 99120676
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG /DAILY/

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545319-1Report Type:Periodic Company Report #WAES 99120680
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Nasal Congestion							
	Nocturia							
	Pain In Extremity		Flonase	C				
			Norvasc	C				
			Aspirin	C				
			Indapamide	C				

Date:03/24/00ISR Number: 3545320-8Report Type:Periodic Company Report #WAES 99120682
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545322-1Report Type:Periodic Company Report #WAES 99120703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Urinary Tract Infection							

Date:03/24/00ISR Number: 3545324-5Report Type:Periodic Company Report #WAES 99120709
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:03/24/00ISR Number: 3545328-2Report Type:Periodic Company Report #WAES 00010882
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Premarin	C				

Date:03/24/00ISR Number: 3545330-0Report Type:Periodic Company Report #WAES 00010885
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Pycnogenol	C				

Chondroitin Sulfate	C	
Glucosamine	C	
Vitamin E	C	

Date:03/24/00ISR Number: 3545334-8Report Type:Periodic Company Report #WAES 00010886
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:03/24/00ISR Number: 3545337-3Report Type:Periodic Company Report #WAES 00010890
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Evista	C				
			Prempro	C				
			Calcium Supplement	C				
			Ibuprofen	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545340-3Report Type:Periodic Company Report #WAES 00010895
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Tab Vioxx SS ORAL

25 MG DAILY

PO

Tab Vioxx SS ORAL

50 MG DAILY

PO

Tab Vioxx SS ORAL

75 MG DAILY

PO

Date:03/24/00ISR Number: 3545343-9Report Type:Periodic Company Report #WAES 00010896
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

12.5 MG DAILY

PO

Azulfidine C
Hytrin C
Maxzide C
Nasonex C
Synthroid C

Date:03/24/00ISR Number: 3545346-4Report Type:Periodic Company Report #WAES 00010899
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 3 MON
			Hydrodiuril	C				
			Lasix	C				
			Vasotec	C				
			Potassium Supplement	C				

Date:03/24/00ISR Number: 3545347-6Report Type:Periodic Company Report #WAES 00010904
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				

Date:03/24/00ISR Number: 3545348-8Report Type:Periodic Company Report #WAES 00010910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Filariasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545350-6Report Type:Periodic Company Report #WAES 00010924
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				

Date:03/24/00ISR Number: 3545353-1Report Type:Periodic Company Report #WAES 00010926
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Nasacort	C				
			Neurontin	C				
			Nyazin	C				
			Tylenol	C				
			Xanax	C				
			Zestril	C				
			Zyban	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545356-7Report Type:Periodic Company Report #WAES 00010944
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Monopril	C				
			Zantac	C				
			Zocor	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3545358-0Report Type:Periodic Company Report #WAES 00010948
Age:63 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Buspar	C				
			Cytomel	C				
			Pancreased (Pancrelipase)	C				
			Prilosec	C				
			Lorazepam	C				

Date:03/24/00ISR Number: 3545362-2Report Type:Periodic Company Report #WAES 00010996
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545364-6Report Type:Periodic Company Report #WAES 00010993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545368-3Report Type:Periodic Company Report #WAES 00010997
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545371-3Report Type:Periodic Company Report #WAES 00010998
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545374-9Report Type:Periodic Company Report #WAES 00011009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545377-4Report Type:Periodic Company Report #WAES 00011024
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Balance Disorder							
	Fatigue		Amaryl	C				
	Sedation		Lanoxin	C				
			Lasix	C				

Date:03/24/00ISR Number: 3545379-8Report Type:Periodic Company Report #WAES 00011025
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Dysuria							

Pelvic Pain Merck Co Inc ORAL
PO
Urinary Retention
Weight Increased

Date:03/24/00ISR Number: 3545381-6Report Type:Periodic Company Report #WAES 00012214
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545382-8Report Type:Periodic Company Report #WAES 00012217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545383-XReport Type:Periodic Company Report #WAES 00012223
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Norvasc	C				
			Pacerone	C				
			[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3545384-1Report Type:Periodic Company Report #WAES 00012227
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Muscle Spasms Nasal Dryness Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:03/24/00ISR Number: 3545385-3Report Type:Periodic Company Report #WAES 00012228
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	60 DAY
			Allegra	C				
			Zantac	C				

Date:03/24/00ISR Number: 3545386-5Report Type:Periodic Company Report #WAES 00012230
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Evista	C				

Date:03/24/00ISR Number: 3545387-7Report Type:Periodic Company Report #WAES 00012232
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			[Therapy Unspecified]	C				
			Chlordiazepoxide	C				
			Chlordiazepoxide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545389-0Report Type:Periodic Company Report #WAES 00012242
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Valium	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3545391-9Report Type:Periodic Company Report #WAES 00012257
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 MON
			Coumadin	C				
			Diazide	C				
			Diuretic Preparation	C				
			Iron (Unspecified)	C				
			Vitamin E	C				
			Zinc Preparation	C				

Date:03/24/00ISR Number: 3545396-8Report Type:Periodic Company Report #WAES 00012266
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545398-1Report Type:Periodic Company Report #WAES 00012268
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	3 DAY

Date:03/24/00ISR Number: 3545400-7Report Type:Periodic Company Report #WAES 00012269
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Insomnia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545403-2Report Type:Periodic Company Report #WAES 00012270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Premarin	C				
			Prevacid	C				
			Provera	C				

Date:03/24/00ISR Number: 3545409-3Report Type:Periodic Company Report #WAES 00012271
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dyazide	C				
			Norvasc	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545411-1Report Type:Periodic Company Report #WAES 00012289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545412-3Report Type:Periodic Company Report #WAES 00012292
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545415-9Report Type:Periodic Company Report #WAES 00012293
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545420-2Report Type:Periodic Company Report #WAES 00012294
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Renal Disorder	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545423-8Report Type:Periodic Company Report #WAES 00012300
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545426-3Report Type:Periodic Company Report #WAES 00012302
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	

Date:03/24/00ISR Number: 3545433-0Report Type:Periodic Company Report #WAES 00020326
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545434-2Report Type:Periodic Company Report #WAES 00020328
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545443-3Report Type:Periodic Company Report #WAES 00020330
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				
			Prinivil	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545445-7Report Type:Periodic Company Report #WAES 00020334
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545447-0Report Type:Periodic Company Report #WAES 00020337
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Atenolol	C				

Date:03/24/00ISR Number: 3545448-2Report Type:Periodic Company Report #WAES 00020339
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zantac	C				
			Atenolol	C				
			Tamoxifen	C				

Date:03/24/00ISR Number: 3545449-4Report Type:Periodic Company Report #WAES 00020342
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG

12.5MG/DAILY/

PO

	Norvasc	SS	
	Avapro	C	

Date:03/24/00ISR Number: 3545452-4Report Type:Periodic Company Report #WAES 00020350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:03/24/00ISR Number: 3545457-3Report Type:Periodic Company Report #WAES 00020353
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Alopecia Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

12.5MG/DAILY/

PO

Hydrodiuril	C
Pravachol	C
Premarin	C
Provera	C
Calcium Supplement (Composition Unk)	C
Glucosamine	C

Date:03/24/00ISR Number: 3545458-5Report Type:Periodic Company Report #WAES 00020359
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/24/00ISR Number: 3545459-7Report Type:Periodic Company Report #WAES 00020363
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG 12.5 MG/DAILY/PO	

Cardura	C
Elavil	C
Prevacid	C
Prinzide	C
Synthroid	C

Date:03/24/00ISR Number: 3545484-6Report Type:Periodic Company Report #WAES 00020366
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Naproxen	C		

Date:03/24/00ISR Number: 3545486-XReport Type:Periodic Company Report #WAES 00020368
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain Hypertrophy Breast	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO 2 WK						
			Motrin	C		
			Naprosyn	C		
			Ultram	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545490-1Report Type:Periodic Company Report #WAES 00020369
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Klonopin	C				
			Lipitor	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545491-3Report Type:Periodic Company Report #WAES 00020398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, 25MG/PO	

Date:03/24/00ISR Number: 3545493-7Report Type:Periodic Company Report #WAES 00020399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545497-4Report Type:Periodic Company Report #WAES 00020408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Dyspnoea Fluid Retention Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545498-6Report Type:Periodic Company Report #WAES 00020411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545499-8Report Type:Periodic Company Report #WAES 00020419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545500-1Report Type:Periodic Company Report #WAES 00020424
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Ventricular Extrasystoles	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	SS				
			Cardura	SS				
			Lipitor	SS				

Date:03/24/00ISR Number: 3545501-3Report Type:Periodic Company Report #WAES 00020425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Muscular Weakness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545503-7Report Type:Periodic Company Report #WAES 00020447
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545504-9Report Type:Periodic Company Report #WAES 00020448
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
SEE IMAGE

Coumadin	C	
Darvocet-N	C	
Mevacor	C	
Triamcinolone Acetonide	C	

Date:03/24/00ISR Number: 3545505-0Report Type:Periodic Company Report #WAES 00020449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545507-4Report Type:Periodic Company Report #WAES 00020458
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

			Buspar	C
			Hytrin	C
			K-Tab	C
			Norvasc	C
			Zocor	C
			Aspirin	C
			Glucosamine	C
			Hydrochlorothiazide	C
			Temazepam	C

Date:03/24/00ISR Number: 3545509-8Report Type:Periodic Company Report #WAES 00020463
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Emotional Disorder							
	Fatigue							
	Malaise							
			Coumadin	C				
			Ec Naprosyn	C				
			Klor-Con	C				
			Alprazolam	C				
			Atenolol	C				
			Hydrochlorothiazide	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545512-8Report Type:Periodic Company Report #WAES 00020464
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Pulmonary Oedema							
			Biaxin	C				
			Duragesic	C				
			Klonopin	C				
			Zestril	C				

Date:03/24/00ISR Number: 3545516-5Report Type:Periodic Company Report #WAES 00020480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545520-7Report Type:Periodic Company Report #WAES 00020484
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem Cd	C				
			Claritin	C				

Microzide C

Date:03/24/00ISR Number: 3545523-2Report Type:Periodic Company Report #WAES 00020499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545526-8Report Type:Periodic Company Report #WAES 00020504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545531-1Report Type:Periodic Company Report #WAES 00020521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Weight Increased	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545533-5Report Type:Periodic Company Report #WAES 00020523
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Urinary Incontinence Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3545535-9Report Type:Periodic Company Report #WAES 00020530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545537-2Report Type:Periodic Company Report #WAES 00020545
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545539-6Report Type:Periodic Company Report #WAES 00020546
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary Haematuria Hyperhidrosis Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545541-4Report Type:Periodic Company Report #WAES 00020552
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545543-8Report Type:Periodic Company Report #WAES 00020553
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545546-3Report Type:Periodic Company Report #WAES 00020568
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Dermatitis Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Face Oedema		Ms Contin	C				

	Localised Oedema		Msir	C			
	Sinusitis		Neurontin	C			
	Vomiting						

Date:03/24/00ISR Number: 3545549-9Report Type:Periodic Company Report #WAES 00020570
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Baycol	C				
			Lipitor	C				

Date:03/24/00ISR Number: 3545552-9Report Type:Periodic Company Report #WAES 00020573
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

[Therapy
Unspecified] C

Date:03/24/00ISR Number: 3545556-6Report Type:Periodic Company Report #WAES 00020574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545559-1Report Type:Periodic Company Report #WAES 00020598
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Tolerance Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO 25 MG/DAILY/PO	50
			Prinivil	C				
			Tylenol	C				
			Furosemide	C				

Date:03/24/00ISR Number: 3545566-9Report Type:Periodic Company Report #WAES 00020609
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO 4 DAY
[Therapy
Unspecified] C

Date:03/24/00ISR Number: 3545585-2Report Type:Periodic Company Report #WAES 00020632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anorexia	Company	Vioxx	PS	Merck Research	
	Insomnia	Representative			Laboratories Div	
					Merck Co Inc	ORAL

PO

Date:03/24/00ISR Number: 3545590-6Report Type:Periodic Company Report #WAES 00020634
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Vioxx	PS	Merck Research	
	Dyspepsia	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL

PO 25MG
Representative

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545617-1Report Type:Periodic Company Report #WAES 00020635
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Deserol	C				
			Dyazide	C				
			Normodyne	C				
			Tagamet	C				

Date:03/24/00ISR Number: 3545624-9Report Type:Periodic Company Report #WAES 00020641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3545625-0Report Type:Periodic Company Report #WAES 00020654
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545626-2Report Type:Periodic Company Report #WAES 00020656
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO			Warfarin	SS		

Date:03/24/00ISR Number: 3545627-4Report Type:Periodic Company Report #WAES 00020661
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Diarrhoea Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Creon	C		
			Flovent	C		
			Fosamax	C		
			Singulair	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545628-6Report Type:Periodic Company Report #WAES 00020663
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Weight Increased	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545629-8Report Type:Periodic Company Report #WAES 00020664
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545630-4Report Type:Periodic Company Report #WAES 00020666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545631-6Report Type:Periodic Company Report #WAES 00020670
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Back Pain Constipation Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Celexa C

Date:03/24/00ISR Number: 3545632-8Report Type:Periodic Company Report #WAES 00020678
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
							25 MG/DAILY/PO	
			Vicodin Tablets	C				
			Xanax	C				

Date:03/24/00ISR Number: 3545633-XReport Type:Periodic Company Report #WAES 00020687
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Pneumonia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545634-1Report Type:Periodic Company Report #WAES 00020690
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Blood Pressure Increased							
	Malaise							
	Tachycardia							
			Fosamax	C				
			Hydrodiuril	C				
			Synthroid	C				
			Potassium Chloride	C				
			Reserpine	C				

Date:03/24/00ISR Number: 3545635-3Report Type:Periodic Company Report #WAES 00020702
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
							25 MG/DAILY/PO	
							12.5	
			Tylenol	C				
			Vicodin Tablets	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545636-5Report Type:Periodic Company Report #WAES 00020711
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective Joint Stiffness Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Cozaar	C		
			Glucophage	C		
			Plavix	C		
			Trantan	C		
			Zocor	C		

Date:03/24/00ISR Number: 3545685-7Report Type:Periodic Company Report #WAES99121028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				

Date:03/24/00ISR Number: 3545686-9Report Type:Periodic Company Report #WAES 99121031
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pruritus Female Vaginal Discharge	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Cleocin	C	
Hormones (Composition Unspecified)	C	

Date:03/24/00ISR Number: 3545687-0Report Type:Periodic Company Report #WAES 99121036
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Atrovent	C				
			Flovent	C				
			Premarin	C				
			Proventil	C				
			Serevent	C				
			Synthroid	C				
			Tegretol	C				
			Tums	C				
			Xalatan	C				
			Calcium Supplement (Composition	C				
			Hydrocodone	C				

Date:03/24/00ISR Number: 3545688-2Report Type:Periodic Company Report #WAES 99121039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Glucosamine	C				

Date:03/24/00ISR Number: 3545689-4Report Type:Periodic Company Report #WAES 99121040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Constipation							
	Fatigue							

Date:03/24/00ISR Number: 3545690-0Report Type:Periodic Company Report #WAES 99121041
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Atenolol Msd	C				
			Verelan	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545691-2Report Type:Periodic Company Report #WAES 99121043
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Claritin	C				
			Evista	C				
			Nasonex	C				

Date:03/24/00ISR Number: 3545692-4Report Type:Periodic Company Report #WAES 99121050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545693-6Report Type:Periodic Company Report #WAES 99121085
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D 12 Hour	C				
			Evista	C				

Date:03/24/00ISR Number: 3545694-8Report Type:Periodic Company Report #WAES 99121087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545695-XReport Type:Periodic Company Report #WAES 99121110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545696-1Report Type:Periodic Company Report #WAES 99121112
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545697-3Report Type:Periodic Company Report #WAES 99121114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545698-5Report Type:Periodic Company Report #WAES 99121123
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Imdur	C				
			Norvasc	C				
			Pravachol	C				

Date:03/24/00ISR Number: 3545699-7Report Type:Periodic Company Report #WAES 99121124
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	

Date:03/24/00ISR Number: 3545700-0Report Type:Periodic Company Report #WAES99121137
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	

Date:03/24/00ISR Number: 3545701-2Report Type:Periodic Company Report #WAES 99121141
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Ortho Tri-Cyclen	C				

Date:03/24/00ISR Number: 3545702-4Report Type:Periodic Company Report #WAES 99121147
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/50 MG / DAILY/PO	
			Medrol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545703-6Report Type:Periodic Company Report #WAES 99121151
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypertension Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545704-8Report Type:Periodic Company Report #WAES 99121153
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545792-9Report Type:Periodic Company Report #WAES 00011125
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lopressor Hct	C				

Date:03/24/00ISR Number: 3545793-0Report Type:Periodic Company Report #WAES 00011127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Food Allergy	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/PO

Date:03/24/00ISR Number: 3545794-2Report Type:Periodic Company Report #WAES 00011162
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Hyperaesthesia					
	Sedation				Merck Co Inc	ORAL
12.5 MG/BID/PO						
			Alimix	C		
			Bilimix	C		
			Detrol	C		
			Didronel	C		
			Lipitor	C		
			Miacalcin	C		
			Paxil	C		
			Premarin	C		
			Prilosec	C		
			Proventil	C		
			Salagen Tablets	C		
			Singulair	C		
			Tylenol	C		
			Amitriptyline	C		
			Calcium Supplement	C		

			Codeine	C		
			Naproxen	C		
			Nitroglycerin	C		
			Trazodone	C		
			Vitamins	C		

Date:03/24/00ISR Number: 3545798-XReport Type:Periodic Company Report #WAES 00011164
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Accupril	C				
			Lipitor	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3545800-5Report Type:Periodic Company Report #WAES 00011171
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Arthropathy Crepitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Myalgia							
	Pain		Elavil	C				
			Eldepryl	C				
			Prevacid	C				
			Requip	C				
			Furosemide	C				
			Lorazepam	C				
			Potasssium Supplement	C				

Date:03/24/00ISR Number: 3545803-0Report Type:Periodic Company Report #WAES 00011177
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Diarrhoea							
	Gastrointestinal							
	Infection		Cosopt	C				
			Transderm-Nitro	C				
			Verelan	C				

Date:03/24/00ISR Number: 3545805-4Report Type:Periodic Company Report #WAES 00011178
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dyspnoea							
	Eye Irritation							
	Eye Pain							
	Headache		Ventolin	C				
	Increased Appetite		Potassium Supplement	C				
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545809-1Report Type:Periodic Company Report #WAES 00011180
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Propoxyphene Hydrochloride	C				

Date:03/24/00ISR Number: 3545810-8Report Type:Periodic Company Report #WAES 00011202
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Depakote	C				
			Prozac	C				
			Seroquel	C				
			Phenobarbital	C				

Date:03/24/00ISR Number: 3545812-1Report Type:Periodic Company Report #WAES 00011205
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Insomnia							
	Oedema							
	Pain		Celebrex	C				

Date:03/24/00ISR Number: 3545814-5Report Type:Periodic Company Report #WAES 00011208
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
OPHTHALMIC 12.5 MG/DAILY/PO						
			Hytrin	C		
			Lioresal	C		

Date:03/24/00ISR Number: 3545816-9Report Type:Periodic Company Report #WAES 00011217
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Inflammation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545817-0Report Type:Periodic Company Report #WAES 00011245
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545818-2Report Type:Periodic Company Report #WAES 00011249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545819-4Report Type:Periodic Company Report #WAES 00012109
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	; QOD/PO
			Glucosamine	C				

Date:03/24/00ISR Number: 3545821-2Report Type:Periodic Company Report #WAES 00012111
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Weight Decreased Merck Co Inc ORAL
12.5MG/DAILY/

PO;

25MG/DAILY/PO

Atrovent	C
Cipro	C
Plavix	C
Prilosec	C
Hydrocodone	C
Meclizine	C
Propoxyphene	C

Date:03/24/00ISR Number: 3545823-6Report Type:Periodic Company Report #WAES 00012117
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5MG/PO;

25MG/PO

Iimdur	C
Prilosec	C
Toprol Xl	C
Ultram	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545826-1Report Type:Periodic Company Report #WAES 00012122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Fatigue							
	Oedema Peripheral							
	Pulmonary Congestion							
	Vision Blurred		Cozaar	C				
			Pepcid	C				
			Aspirin	C				
			Hydrochlorothiazide	C				

Date:03/24/00ISR Number: 3545828-5Report Type:Periodic Company Report #WAES 00012125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
	Dizziness							
	Feeling Cold							
	Muscular Weakness		Ultram	C				
			Influenza Virus Vaccine	C				

Date:03/24/00ISR Number: 3545831-5Report Type:Periodic Company Report #WAES 00012146
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5MG/DAILY/ PO	
			Claritin	C				
			Voltaren-Xr	C				
			Atenolol	C				

			Ranitidine	C		

Date:03/24/00ISR Number: 3545832-7Report Type:Periodic Company Report #WAES 00012147
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cardura	C				
			Proscar	C				
			Vasotec	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3545834-0Report Type:Periodic Company Report #WAES 00012170
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545837-6Report Type:Periodic Company Report #WAES 00012172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545840-6Report Type:Periodic Company Report #WAES 00012173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545843-1Report Type:Periodic Company Report #WAES 00012174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545847-9Report Type:Periodic Company Report #WAES 00012177
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/AM/PO	
			Celexa	C				
			Flexeril	C				

Ultram C

Date:03/24/00ISR Number: 3545850-9Report Type:Periodic Company Report #WAES 00012180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3545853-4Report Type:Periodic Company Report #WAES 00012184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545854-6Report Type:Periodic Company Report #WAES 00012185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Analgesic Or Anesthetic Preparations (Composition Unspecified)	C				

Date:03/24/00ISR Number: 3545857-1Report Type:Periodic Company Report #WAES 00012186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/QOD/PO	

Date:03/24/00ISR Number: 3545860-1Report Type:Periodic Company Report #WAES 00012192
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dizziness		Smz-Tmp	C				
	Feeling Drunk							
	Insomnia							
	Tachycardia							
	Tremor							

Date:03/24/00ISR Number: 3545864-9Report Type:Periodic Company Report #WAES 00012193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545868-6Report Type:Periodic Company Report #WAES 00012208
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
	Weight Increased		Premarin	C				
			Ascorbic Acid	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545870-4Report Type:Periodic Company Report #WAES 00012213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545873-XReport Type:Periodic Company Report #WAES 00021459
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	/PO
			Premarin	C				

Date:03/24/00ISR Number: 3545875-3Report Type:Periodic Company Report #WAES 99121696
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Centrum Silver	C				

Date:03/24/00ISR Number: 3545876-5Report Type:Periodic Company Report #WAES 00021461
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:03/24/00ISR Number: 3545877-7Report Type:Periodic Company Report #WAES 99121700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:03/24/00ISR Number: 3545878-9Report Type:Periodic Company Report #WAES 99121701
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545879-0Report Type:Periodic Company Report #WAES 99121704
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspnoea Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/24/00ISR Number: 3545881-9Report Type:Periodic Company Report #WAES 99121719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545882-0Report Type:Periodic Company Report #WAES 99121721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	75 MG/DAILY/PO	10 DAY

Date:03/24/00ISR Number: 3545885-6Report Type:Periodic Company Report #WAES 99121736
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3545886-8Report Type:Periodic Company Report #WAES 00021470
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Advil	C				
			Ambien	C				
			Proventil	C				

Date:03/24/00ISR Number: 3545887-XReport Type:Periodic Company Report #WAES 99121753
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:03/24/00ISR Number: 3545889-3Report Type:Periodic Company Report #WAES 00021474
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545890-XReport Type:Periodic Company Report #WAES 99121759
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545891-1Report Type:Periodic Company Report #WAES 00021477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545893-5Report Type:Periodic Company Report #WAES 00021482
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:03/24/00ISR Number: 3545894-7Report Type:Periodic Company Report #WAES 00021485
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	2 WK
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545896-0Report Type:Periodic Company Report #WAES 99121765
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Oedema Peripheral Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545897-2Report Type:Periodic Company Report #WAES 00021486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545898-4Report Type:Periodic Company Report #WAES 99121766
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Provera	C				
			Tagamet	C				

Date:03/24/00ISR Number: 3545900-XReport Type:Periodic Company Report #WAES 00021487
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Asthenia Face Oedema Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral		Atrovent	C				
			Claritin	C				
			Corgard	C				
			Flovent	C				
			Humibid	C				
			Prempro	C				
			Prevacid	C				

			Singulair	C		
			Synthroid	C		

Date:03/24/00ISR Number: 3545901-1Report Type:Periodic Company Report #WAES 99121767
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Tylenol	C		
			Valsartan	C		

Date:03/24/00ISR Number: 3545903-5Report Type:Periodic Company Report #WAES 00021488
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Accupril	C		
			Fosamax	C		

				(Therapy Unspecified)	C		
				Vitamin E	C		

Date:03/24/00ISR Number: 3545904-7Report Type:Periodic Company Report #WAES 99121768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lopid	C				
			Synthroid	C				
			Zestril	C				

Date:03/24/00ISR Number: 3545905-9Report Type:Periodic Company Report #WAES 99121769
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545906-0Report Type:Periodic Company Report #WAES 00021491
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:03/24/00ISR Number: 3545909-6Report Type:Periodic Company Report #WAES 99121771
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO 2 WK
			Tab Vioxx 25 Mg	SS		ORAL	25	MG/DAILY/PO 1 WK
			Lotrel	C				
			Lotrel	C				
			Zestoretic	C				
			Hydrocodone	C				
			Ibuprofen	C				

Date:03/24/00ISR Number: 3545910-2Report Type:Periodic Company Report #WAES 00021492
Age:64 YR Gender:Male I/FU:I

Outcome	PT
	Cough
	Dry Throat

Glossodynia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Cardizem Cd	C				
	Imdur	C				
	Lipitor	C				
	Prevacid	C				
	Propulsid	C				
	Aspirin	C				
	Atenolol	C				
	Ubiquinones	C				

Date:03/24/00ISR Number: 3545911-4Report Type:Periodic Company Report #WAES 99121775
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			L-Thyroxine (+)					
			Liothyronine	C				
			Aspirin	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545913-8Report Type:Periodic Company Report #WAES 00021498
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Hydrodiuril	C				

			Premarin	C		
			Synthroid	C		

Date:03/24/00ISR Number: 3545915-1Report Type:Periodic Company Report #WAES 99121776
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Clinoril	C				
			Folic Acid	C				
			Methotrexate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545916-3Report Type:Periodic Company Report #WAES 00021499
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Lipitor (Therapy Unspecified)	C C				

Date:03/24/00ISR Number: 3545919-9Report Type:Periodic Company Report #WAES 99121779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	DAILY/PO
			Tab Vioxx	SS		ORAL	25	MG/DAILY/PO

Date:03/24/00ISR Number: 3545920-5Report Type:Periodic Company Report #WAES 00021512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3545922-9Report Type:Periodic Company Report #WAES 00021514
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY/UNK	

Date:03/24/00ISR Number: 3545924-2Report Type:Periodic Company Report #WAES 00021515
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aspirin	C				
			Ismo	C				
			Norvasc	C				
			Synthroid	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545927-8Report Type:Periodic Company Report #WAES 00021518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545929-1Report Type:Periodic Company Report #WAES 99121783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fall	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO; 12.5 MG/DAILY/PO;	25 MG/BID/PO 2 DAY

Date:03/24/00ISR Number: 3545930-8Report Type:Periodic Company Report #WAES 00021519
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545931-XReport Type:Periodic Company Report #WAES 99121787
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				
			Zantac	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545933-3Report Type:Periodic Company Report #WAES 00021057
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Akathisia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Feldene	C				
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545934-5Report Type:Periodic Company Report #WAES 00021520
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Nervousness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3545937-0Report Type:Periodic Company Report #WAES 00021067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545939-4Report Type:Periodic Company Report #WAES 00011360
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Buspar	C				
			Cardura	C				
			Darvocet-N	C				

Date:03/24/00ISR Number: 3545940-0Report Type:Periodic Company Report #WAES 00011363
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Hytrin	C		
			Isoptine	C		
			Maxide	C		
			Zocor	C		
			Aspirin	C		

Date:03/24/00ISR Number: 3545942-4Report Type:Periodic Company Report #WAES 00021068
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Hot Flushing Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Norvasc	C		
			Prevacid	C		
			Zocor	C		
			Aspirin	C		
			Metoprolol	C		
			Therapy Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545943-6Report Type:Periodic Company Report #WAES 00011366
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	SEE IMAGE
			Premarin	C				
			Provera	C				
			Xanax	C				
			Atenelol	C				
			Hydrocodone	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3545944-8Report Type:Periodic Company Report #WAES 00011373
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration Nervousness Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545945-XReport Type:Periodic Company Report #WAES00011377
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Fosamax	C		
			Premarin	C		
			Zestril	C		
			Zocor	C		
			Albuterol	C		
			Cough, Cold And Flu Therapies	C		

Date:03/24/00ISR Number: 3545946-1Report Type:Periodic Company Report #WAES 00011387
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Joint Swelling Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxicaps	C				
			Librax Capsules	C				
			Xanax	C				
			Clonidine	C				
			Nortriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545947-3Report Type:Periodic Company Report #WAES 99121404
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK BID PO	

Date:03/24/00ISR Number: 3545948-5Report Type:Periodic Company Report #WAES 00010669
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vasotec	C				
			Composition Unspecified	C				
			Insulin	C				

Date:03/24/00ISR Number: 3545949-7Report Type:Periodic Company Report #WAES 00021069
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Fosamax	C				
			Lipitor	C				
			Myoflex External Analgesic Creme	C				

Date:03/24/00ISR Number: 3545950-3Report Type:Periodic Company Report #WAES 00010672
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Renagel	C				
			Therapy Unspecified	C				
			Calcium Supplement	C				
			Digoxin	C				
			Folic Acid	C				

Date:03/24/00ISR Number: 3545951-5Report Type:Periodic Company Report #WAES 00010673
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				
			Zantac	C				
			Amitriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545952-7Report Type:Periodic Company Report #WAES 99121788
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Drug Ineffective							
	Dry Mouth							
	Urticaria							

PO

Date:03/24/00ISR Number: 3545953-9Report Type:Periodic Company Report #WAES 00012333
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Inadequate Control							
	Hypoglycaemia							
			Claritin	C				
			Genuine Bayer Aspirin	C				
			Glucophage	C				
			Isopto Carpine	C				
			Prandin	C				
			Trental	C				
			Ascorbic Acid	C				
			Calcium Supplement (Composition	C				
			Metoprolol	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3545954-0Report Type:Periodic Company Report #WAES 00010674
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective							

	Dyspnoea				Merck Co Inc	ORAL
SEE IMAGE						
	Oedema Peripheral		Diazide	C		
			Premarin	C		

Date:03/24/00ISR Number: 3545955-2Report Type:Periodic Company Report #WAES 00021076
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Renal Impairment	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO		Representative				

Date:03/24/00ISR Number: 3545956-4Report Type:Periodic Company Report #WAES 99121790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Diarrhoea Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Hormones	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545957-6Report Type:Periodic Company Report #WAES 00010680
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Face Oedema Tongue Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:03/24/00ISR Number: 3545958-8Report Type:Periodic Company Report #WAES 00021079
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545959-XReport Type:Periodic Company Report #WAES 00012339
Age:89 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Eye Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ecotrin	C				
			Proscar	C				

Date:03/24/00ISR Number: 3545961-8Report Type:Periodic Company Report #WAES 99121405
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea	Consumer	Vioxx	PS	Merck Research	
	Face Oedema				Laboratories Div	
					Merck Co Inc	ORAL

PO

Date:03/24/00ISR Number: 3545962-XReport Type:Periodic Company Report #WAES 00010695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Influenza Like Illness				Laboratories Div	
					Merck Co Inc	ORAL

PO

	Elavil	C
	Premarin	C
	Synthroid	C
	Calcium Supplement	C
	Hydrocodone	C
	Meclizine	C
	Vitamins	C

Date:03/24/00ISR Number: 3545963-1Report Type:Periodic Company Report #WAES 00012350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Skin Disorder	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	

Merck Co Inc ORAL
50

MG/DAILY/PO
Plaquenil SS

Date:03/24/00ISR Number: 3545964-3Report Type:Periodic Company Report #WAES 00021080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545965-5Report Type:Periodic Company Report #WAES 00010702
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
			Ativan	C				
			Evista	C				
			Imdur	C				
			Inderal	C				
			Lanoxin	C				
			Prevacid	C				
			Meclizine	C				

Date:03/24/00ISR Number: 3545966-7Report Type:Periodic Company Report #WAES 00012359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain Oesophageal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

50

MG/DAILY/PO 4 WK

Date:03/24/00ISR Number: 3545967-9Report Type:Periodic Company Report #WAES 00010708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:03/24/00ISR Number: 3545968-0Report Type:Periodic Company Report #WAES 00011758
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Prevacid	C		
			Propulsid	C		
			Tylenol	C		

Dose Duration

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545969-2Report Type:Periodic Company Report #WAES 99121409
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG BID PO	
	Cough							
	Fatigue							
	Polyuria		Zantac	C				

Date:03/24/00ISR Number: 3545970-9Report Type:Periodic Company Report #WAES 00021087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
	Insomnia							
			Ambien	SS			HS	

Date:03/24/00ISR Number: 3545971-0Report Type:Periodic Company Report #WAES 00012360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545972-2Report Type:Periodic Company Report #WAES 00010731
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545973-4Report Type:Periodic Company Report #WAES 00010735
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545974-6Report Type:Periodic Company Report #WAES 00012363
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545975-8Report Type:Periodic Company Report #WAES 00011765
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Date:03/24/00ISR Number: 3545976-XReport Type:Periodic Company Report #WAES 00010737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/ PO	
			Aspirin	C				
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545977-1Report Type:Periodic Company Report #WAES 00010749
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	

Date:03/24/00ISR Number: 3545978-3Report Type:Periodic Company Report #WAES 99121411
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Hypoaesthesia	Health			Laboratories Div			
	Tachycardia	Professional			Merck Co Inc	ORAL	25 MG DAILY	
						PO		
			Klor-Con	C				
			Premarin	C				
			Clidinium Bromide	C				

Date:03/24/00ISR Number: 3545979-5Report Type:Periodic Company Report #WAES 00012371
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Flatulence				Laboratories Div			
	Gastrooesophageal Reflux				Merck Co Inc	ORAL	25	
	Disease						MG/DAILY/PO	
			Accupril	C				

Date:03/24/00ISR Number: 3545980-1Report Type:Periodic Company Report #WAES 00010750
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral				Laboratories Div			

Merck Co Inc ORAL
12.5 MG/

DAILY/PO

Norvasc Unk	SS
Toprol Xl Tablets Unk	SS
Accupril	C
Diovan	C
Atenolol	C

Date:03/24/00ISR Number: 3545981-3Report Type:Periodic Company Report #WAES 00012384
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aspartate Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Lipase Increased							
			Serax	C				
			Therapy Unspecified	C				
			Risperidone	C				
			Trazodone	C				

Date:03/24/00ISR Number: 3545982-5Report Type:Periodic Company Report #WAES 99121412
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3545983-7Report Type:Periodic Company Report #WAES 00010761
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Unevaluable Event	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Meridia	C				
			Monopril	C				

Date:03/24/00ISR Number: 3545984-9Report Type:Periodic Company Report #WAES 00021089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545985-0Report Type:Periodic Company Report #WAES 00012389
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:03/24/00ISR Number: 3545986-2Report Type:Periodic Company Report #WAES 00010763
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Darvon	C				

Date:03/24/00ISR Number: 3545987-4Report Type:Periodic Company Report #WAES 00011781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge Eye Pain Lacrimation Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:03/24/00ISR Number: 3545988-6Report Type:Periodic Company Report #WAES 00012392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Composition Unspecified	C				

Date:03/24/00ISR Number: 3545989-8Report Type:Periodic Company Report #WAES 00010764
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pelvic Pain Sinusitis Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3545990-4Report Type:Periodic Company Report #WAES 00021095
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Advil	C				

Date:03/24/00ISR Number: 3545991-6Report Type:Periodic Company Report #WAES 00010765
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/ DAILY/

PO

Date:03/24/00ISR Number: 3545992-8Report Type:Periodic Company Report #WAES 00012400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3545993-XReport Type:Periodic Company Report #WAES 00011787
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/24/00ISR Number: 3545994-1Report Type:Periodic Company Report #WAES 00010767
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO

Date:03/24/00ISR Number: 3545995-3Report Type:Periodic Company Report #WAES 99121416
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Vitamins	C				

Date:03/24/00ISR Number: 3545996-5Report Type:Periodic Company Report #WAES 00010768
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG	/PO 8 DAY
			Antrimicrobial Therapy	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3545997-7Report Type:Periodic Company Report #WAES 00011801
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET, DAILY, PO	
			Digoxin	C				
			Verapamil	C				

Date:03/24/00ISR Number: 3545998-9Report Type:Periodic Company Report #WAES 00021104
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3545999-0Report Type:Periodic Company Report #WAES 00012401
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546000-5Report Type:Periodic Company Report #WAES 00021108
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIY/PO	

Date:03/24/00ISR Number: 3546001-7Report Type:Periodic Company Report #WAES 00012402
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	1 MON
			Adalat	C				
			Tenormin	C				
			Nitroglycerin	C				

Date:03/24/00ISR Number: 3546002-9Report Type:Periodic Company Report #WAES 00011808
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546004-2Report Type:Periodic Company Report #WAES 00010769
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Periodontal Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO 3 WK
			Cozaar	C				
			Premarin	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546005-4Report Type:Periodic Company Report #WAES 00021126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546006-6Report Type:Periodic Company Report #WAES 00012411
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Drug Ineffective		Darvocet-N	SS				
	Insomnia		Ultram	C				

Date:03/24/00ISR Number: 3546007-8Report Type:Periodic Company Report #WAES 99121422
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	
			Diabeta	C				
			Dynacirc	C				
			Prinivil	C				

Date:03/24/00ISR Number: 3546008-XReport Type:Periodic Company Report #WAES 00012416
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Medrol	C				

Date:03/24/00ISR Number: 3546009-1Report Type:Periodic Company Report #WAES 00021132
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Hypertension	Health
	Oedema	Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	(Composition Unspecified)	C				
	Composition Unspecified)	C				

Date:03/24/00ISR Number: 3546010-8Report Type:Periodic Company Report #WAES 99121429
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Migraine	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3546011-XReport Type:Periodic Company Report #WAES 00012419
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
			Celexa	C				
			Prozac	C				

Date:03/24/00ISR Number: 3546012-1Report Type:Periodic Company Report #WAES 00012421
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546013-3Report Type:Periodic Company Report #WAES 00021134
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546014-5Report Type:Periodic Company Report #WAES 00012423
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Haematuria	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546015-7Report Type:Periodic Company Report #WAES 99121448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Bentyl	C				
			Evista	C				
			Zantac	C				

Date:03/24/00ISR Number: 3546016-9Report Type:Periodic Company Report #WAES 00012424
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative						

Date:03/24/00ISR Number: 3546017-0Report Type:Periodic Company Report #WAES 00011814
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO						
			Fiorinal	C		
			Fosamax	C		
			Prempro	C		

Date:03/24/00ISR Number: 3546018-2Report Type:Periodic Company Report #WAES 99121451
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Leukocytosis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY						
PO						
			Motrin	C		
			Tylenol	C		
			Vicks Dayquil	C		
			Vicks Formula 44 Cold & Cough	C		
			Erythromycin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546019-4Report Type:Periodic Company Report #WAES 00012427
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546020-0Report Type:Periodic Company Report #WAES 99121793
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	
			Hydrodiuril	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3546021-2Report Type:Periodic Company Report #WAES 00011820
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Zithromax	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546022-4Report Type:Periodic Company Report #WAES 99121456
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Neurontin	C		
			Prilosec	C		

Date:03/24/00ISR Number: 3546023-6Report Type:Periodic Company Report #WAES 99121798
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						

Date:03/24/00ISR Number: 3546024-8Report Type:Periodic Company Report #WAES 00011822
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG, PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546025-XReport Type:Periodic Company Report #WAES 00011973
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546026-1Report Type:Periodic Company Report #WAES 99121462
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546027-3Report Type:Periodic Company Report #WAES 99121799
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Cough Sneezing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection		Ocuvite Zovirax Calcium Supplement	C C C				

Date:03/24/00ISR Number: 3546028-5Report Type:Periodic Company Report #WAES 00011824
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Buspar	C	
Lamisil	C	
Metrolotion	C	
Prempro	C	

Date:03/24/00ISR Number: 3546029-7Report Type:Periodic Company Report #WAES 00011978
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Lasix	C				

Date:03/24/00ISR Number: 3546030-3Report Type:Periodic Company Report #WAES 99121464
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546031-5Report Type:Periodic Company Report #WAES 99121800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	
	Drug Interaction							
	Erection Increased							
	Flushing		Inj Cortisone	SS			INJ	
	Insomnia		Allegra	C				
			Astelin	C				
			Atrovent Inhalation Solution	C				

Date:03/24/00ISR Number: 3546032-7Report Type:Periodic Company Report #WAES 00011984
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	

Date:03/24/00ISR Number: 3546033-9Report Type:Periodic Company Report #WAES 00011826
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, BID, PO	
	Weight Increased							

Date:03/24/00ISR Number: 3546034-0Report Type:Periodic Company Report #WAES 99121465
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546035-2Report Type:Periodic Company Report #WAES 99121807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Increased Appetite Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG AM PO	
			Halcion	C				
			Tylenol	C				
			Tums	C				

Date:03/24/00ISR Number: 3546036-4Report Type:Periodic Company Report #WAES 00011987
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

			Larabid	C		

Date:03/24/00ISR Number: 3546037-6Report Type:Periodic Company Report #WAES 00011828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546038-8Report Type:Periodic Company Report #WAES 99121466
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Motrin	C				

Date:03/24/00ISR Number: 3546039-XReport Type:Periodic Company Report #WAES 00011989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546040-6Report Type:Periodic Company Report #WAES 99121809
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25 MG DAILY

PO
Cardura C

Date:03/24/00ISR Number: 3546041-8Report Type:Periodic Company Report #WAES 00011834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Diarrhoea							

Date:03/24/00ISR Number: 3546042-XReport Type:Periodic Company Report #WAES 00021135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
		Representative	(Therapy Sunspecified) (Therapy	C				

				Unspecified)	C		
				(Therapy Unspecified)	C		

Date:03/24/00ISR Number: 3546043-1Report Type:Periodic Company Report #WAES 00011995
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avandia	C				
			Prevacid	C				
			Sulfium	C				
			Zestril	C				
			Insulin	C				

Date:03/24/00ISR Number: 3546044-3Report Type:Periodic Company Report #WAES 99121841
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546045-5Report Type:Periodic Company Report #WAES 99121483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546046-7Report Type:Periodic Company Report #WAES 00011840
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, DAILY, PO	
			Premarin	C				
			Prilosec	C				

Date:03/24/00ISR Number: 3546047-9Report Type:Periodic Company Report #WAES 00012002
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ambien	C				
			Inderal	C				
			Premarin	C				

			Synthroid	C		

Date:03/24/00ISR Number: 3546048-0Report Type:Periodic Company Report #WAES 00011857
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, DAILY, PO	
	Flushing							
	Headache							
	Muscular Weakness							
	Pain		Vioxx 25 Mg	SS		ORAL	25 MG /DAILY/PO	
			Zocor	SS				
			Zantac	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546049-2Report Type:Periodic Company Report #WAES 99121489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:03/24/00ISR Number: 3546050-9Report Type:Periodic Company Report #WAES 00021136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Company Representative		Merck Co Inc		ORAL

UNK/PO

Date:03/24/00ISR Number: 3546051-0Report Type:Periodic Company Report #WAES 99121843
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Oedema Peripheral					
	Rheumatoid Arthritis				Merck Co Inc	ORAL
25MG DAILY PO						
			Allegra	C		
			Elavil	C		
			Ester-C	C		
			Flovent	C		
			Klonopin	C		
			Slo-Bid	C		
			Sudafed	C		
			Linseed Oil	C		
			Vitamins	C		
			Nature Rx Msm Plus C	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546052-2Report Type:Periodic Company Report #WAES 00012006
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546053-4Report Type:Periodic Company Report #WAES 00011869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactoid Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Covera-Hs	C				
			Intal	C				
			Tricor	C				
			Amitriptyline	C				

Date:03/24/00ISR Number: 3546054-6Report Type:Periodic Company Report #WAES 00012013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea Supraventricular Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY

Date:03/24/00ISR Number: 3546055-8Report Type:Periodic Company Report #WAES 99121880
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Irritability	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546056-XReport Type:Periodic Company Report #WAES 00012015
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546057-1Report Type:Periodic Company Report #WAES 99121494
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546058-3Report Type:Periodic Company Report #WAES 99121888
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Ear Disorder							
	Influenza Like Illness							
	Mouth Ulceration							
PO								1 WK
			Lipitor	C				
			Premarin	C				
			Synthroid	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546059-5Report Type:Periodic Company Report #WAES 00012016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Congestive							

Date:03/24/00ISR Number: 3546060-1Report Type:Periodic Company Report #WAES 99121889
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Insomnia							
			Darvocet-N	C			PO	
			Lipitor	C				
			Remeron	C				
			Synthroid	C				

			Valium	C		

Date:03/24/00ISR Number: 3546061-3Report Type:Periodic Company Report #WAES 99121504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546062-5Report Type:Periodic Company Report #WAES 99121514
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/1X/PO	
	Sneezing		Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546063-7Report Type:Periodic Company Report #WAES 00012017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546064-9Report Type:Periodic Company Report #WAES 99121890
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	SEE IMAGE
			Ascorbic Acid	C				
			Linseed Oil	C				
			Vitamins	C				
			Composition Unspecified	C				

Date:03/24/00ISR Number: 3546065-0Report Type:Periodic Company Report #WAES 00011870
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546066-2Report Type:Periodic Company Report #WAES 00021142
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	14 DAY

Date:03/24/00ISR Number: 3546067-4Report Type:Periodic Company Report #WAES 00012057
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urinary Tract Infection Urticaria	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546068-6Report Type:Periodic Company Report #WAES 00011875
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, DAILY, PO	
			Demadex	C				
			Lanoxin	C				

		Prilosec	C
		Zyrtec	C
		Potassium Chloride	C

Date:03/24/00ISR Number: 3546069-8Report Type:Periodic Company Report #WAES 00021143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DALIY/PO // 12.5MG DAILY PO	

Date:03/24/00ISR Number: 3546070-4Report Type:Periodic Company Report #WAES 00012067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Muscular Weakness Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Celebrex	C				
			Crixivan	C				
			Lamivudine	C				
			Zidovudine	C				

Date:03/24/00ISR Number: 3546071-6Report Type:Periodic Company Report #WAES 00011877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Skin Warm	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG,,

DAILY, PO

Date:03/24/00ISR Number: 3546072-8Report Type:Periodic Company Report #WAES 00012072
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546073-XReport Type:Periodic Company Report #WAES 00011878
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Bowel Sounds Abnormal Faecal Occult Blood Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG,,/DAILY/PO	
			Vioxx 25 Mg	SS		ORAL	50MG/25MG/DAILY/PO	7 DAY
			Ultram	C				

			Therapy Unspecified	C
			Acetaminophen	C
			Glucosamine	C
			Herbal Remedies	C
			Hydrocodone	C

Date:03/24/00ISR Number: 3546074-1Report Type:Periodic Company Report #WAES 00021157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Motrin	C				

Date:03/24/00ISR Number: 3546075-3Report Type:Periodic Company Report #WAES 99121894
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Anxiety Crying	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Depression						PO SEE IMAGE	
			Claritin	C				
			Cozaar	C				
			Fareston	C				
			Plavix	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3546076-5Report Type:Periodic Company Report #WAES 00012075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546077-7Report Type:Periodic Company Report #WAES 00012079
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Hypersensitivity Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				

Date:03/24/00ISR Number: 3546078-9Report Type:Periodic Company Report #WAES 99121897
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Prilosec	C				

Zoloft	C
Aspirin	C
Folic Acid	C
Hydrochlorothiazide (+) Lisinopril	C
Iron	C

Date:03/24/00ISR Number: 3546079-0Report Type:Periodic Company Report #WAES 00012090
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Novolin	C				
			Proscar	C				
			Vasotec	C				

Date:03/24/00ISR Number: 3546080-7Report Type:Periodic Company Report #WAES 99111979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Incontinence Gastrointestinal Disorder Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546081-9Report Type:Periodic Company Report #WAES 00012093
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

Sedation

MG/DAILY/PO

Tab Vioxx 25 Mg	SS	ORAL

25

MG/DAILY/PO

Azmacort	C
Calan Sr	C
Copeten	C
Centrum Silver	C
Coumdin	C
Demedex	C
Glucophage	C
K-Lyte	C
Lanoxin	C
Serevent	C
Synthroid	C
Zaroxoly In	C
Calcium, Supplement (Composition	C
Magnesium Preparation (Composition)	C
Nitric Oxide	C
Oxygen	C
Vitamin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546082-0Report Type:Periodic Company Report #WAES 00012106
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Diarrhoea							
	Dizziness							
	Dyspepsia							
	Gastrointestinal Disorder							
	Headache							
	Nausea							
	Oedema Peripheral							
	Pain							

Date:03/24/00ISR Number: 3546083-2Report Type:Periodic Company Report #WAES 99112006
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546084-4Report Type:Periodic Company Report #WAES 99112017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elmiron	C				
			Hydrodiuril	C				
			Prevacid	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3546085-6Report Type:Periodic Company Report #WAES 99112028
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Vioxx	PS	Merck Research			
	Chest Pain	Professional			Laboratories Div			
	Cognitive Disorder	Company			Merck Co Inc	ORAL	DAILY/PO	
	Hypertension	Representative	Metamucil	C				
	Oedema Peripheral		Synthroid	C				
	Weight Increased		Fluoxetine Hydrochloride	C				
			Nitroglycerin	C				
			Omeprazole	C				

Date:03/24/00ISR Number: 3546086-8Report Type:Periodic Company Report #WAES 99120087
Age:65 YR Gender:Female I/FU:I

Outcome	PT
	Arthralgia
	Cheilitis
	Dyspepsia
	Face Oedema

		Oral Pain Paraesthesia Tongue Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO							
				Claritin-D	C		
				Fosamax	C		
				Premarin	C		
				Timoptic	C		
				Hydrochlorothizide (+) Triamter	C		
				Vitamins	C		

Date:03/24/00ISR Number: 3546087-XReport Type:Periodic Company Report #WAES 00010491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Faeces Discoloured Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/AM/PO						

Date:03/24/00ISR Number: 3546088-1Report Type:Periodic Company Report #WAES 99120051
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthma	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Antivert	C		
			Darvocet-N	C		
			Flonase	C		
			Pulmicort	C		
			Synthroid	C		

			Albuterol	C		

Date:03/24/00ISR Number: 3546089-3Report Type:Periodic Company Report #WAES 99121899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Oedema Peripheral					
	Weight Increased					
25 MG DAILY PO						
			Therapy Unspecified	C		

Date:03/24/00ISR Number: 3546090-XReport Type:Periodic Company Report #WAES 99121900
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						
			Neurontin	C		
			Ultram	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546091-1Report Type:Periodic Company Report #WAES 00020048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546092-3Report Type:Periodic Company Report #WAES 99121901
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Cardizem	C				
			K-Dur	C				
			Nitro-Dur	C				
			Vasotec	C				

Date:03/24/00ISR Number: 3546093-5Report Type:Periodic Company Report #WAES 99121903
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea		Ambien	C				
			Diovan	C				
			Neurontin	C				
			Premarin	C				
			Synthroid	C				
			Sucralfate	C				

Date:03/24/00ISR Number: 3546094-7Report Type:Periodic Company Report #WAES 99120021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Flatulence							
	Nausea							
			Diabeta	C				
			Synthroid	C				
			Vasotec	C				

Date:03/24/00ISR Number: 3546095-9Report Type:Periodic Company Report #WAES 99121905
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK / PO	
			Lanoxin	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3546096-0Report Type:Periodic Company Report #WAES 99120023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546097-2Report Type:Periodic Company Report #WAES 99121910
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY /PO	
			Fosamax	C				

Date:03/24/00ISR Number: 3546098-4Report Type:Periodic Company Report #WAES 99112025
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546099-6Report Type:Periodic Company Report #WAES 99121912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Tab Vioxx 25mg C ORAL
UNK UNK PO

Calan C

Date:03/24/00ISR Number: 3546100-XReport Type:Periodic Company Report #WAES 99121917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
	Urinary Incontinence							
	Vocal Cord Disorder							
			Normodyne	C				
			Prilosec	C				

Date:03/24/00ISR Number: 3546101-1Report Type:Periodic Company Report #WAES 99121920
Age: Gender:Female I/FU:I

Outcome	PT
	Deafness
	Dizziness
	Drug Ineffective
	Dry Mouth
	Headache

	Nausea Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK /PO
			[Therapy Unspecified]	C			

Date:03/24/00ISR Number: 3546102-3Report Type:Periodic Company Report #WAES 99121925
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO
			Accupril	C			
			Adalat	C			
			Hytrin	C			

Date:03/24/00ISR Number: 3546103-5Report Type:Periodic Company Report #WAES 99121927
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UN UNK/PO
			Rocaltrol	C			
			Synthroid	C			
			Calcitonin	C			
			Calcium Supplement	C			

Date:03/24/00ISR Number: 3546104-7Report Type:Periodic Company Report #WAES 99121930
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck And Co	ORAL	12.5 MG	
	Nausea						/UNK/PO	
	Pain In Extremity		Lasix	C				
	Tremor		Librax Capsules	C				
			Ultram	C				

Date:03/24/00ISR Number: 3546105-9Report Type:Periodic Company Report #WAES 99121931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG / DAILY/	
							PO	
			Toprol Xl Tablets	C				
			[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3546106-0Report Type:Periodic Company Report #WAES 99121951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrooesophageal Reflux Disease	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/ PO

Date:03/24/00ISR Number: 3546108-4Report Type:Periodic Company Report #WAES 99121952
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/ PO

Date:03/24/00ISR Number: 3546109-6Report Type:Periodic Company Report #WAES 99121953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/ PO

Date:03/24/00ISR Number: 3546110-2Report Type:Periodic Company Report #WAES 99121955
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	UNK/ PO

Date:03/24/00ISR Number: 3546112-6Report Type:Periodic Company Report #WAES 99121956
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ UNK/ PO						

Date:03/24/00ISR Number: 3546113-8Report Type:Periodic Company Report #WAES 99121957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Orgasm Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK UNK / PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546114-XReport Type:Periodic Company Report #WAES 99121963
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3546116-3Report Type:Periodic Company Report #WAES 99121970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	DAILY/
		Company Representative	Elavil	C				
			Norvasc	C				
			Relafen	C				
			Tambocor	C				
			[Therapy Unspecified]	C				
			Calcium Supplement (Composition	C				
			Glyburide	C				
			Ranitidine	C				

Date:03/24/00ISR Number: 3546122-9Report Type:Periodic Company Report #WAES 99121979
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/	DAILY/
		Company Representative	Synthroid	C				

				Propranolol Hydrochloride	C		

Date:03/24/00ISR Number: 3546124-2Report Type:Periodic Company Report #WAES 99121981
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY /PO	
			Glucotrol	C				
			Lipitor	C				
			Prilosec	C				
			Zestril	C				

Date:03/24/00ISR Number: 3546125-4Report Type:Periodic Company Report #WAES 00010494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546127-8Report Type:Periodic Company Report #WAES 00010495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3546128-XReport Type:Periodic Company Report #WAES 99112029
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546130-8Report Type:Periodic Company Report #WAES 00010504
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Prednisone	C				

Date:03/24/00ISR Number: 3546131-XReport Type:Periodic Company Report #WAES 99120009
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546133-3Report Type:Periodic Company Report #WAES 00010505
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tamoxifen	C				

Date:03/24/00ISR Number: 3546134-5Report Type:Periodic Company Report #WAES 99120018
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cholelithiasis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546136-9Report Type:Periodic Company Report #WAES 99120038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Bronchitis Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:03/24/00ISR Number: 3546137-0Report Type:Periodic Company Report #WAES 00010507
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Rhinorrhoea Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Detrol	C				
			Dulcolax	C				
			Lanoxin	C				
			Lipitor	C				
			Os-Cal	C				
			Premarin	C				
			Zestril	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546139-4Report Type:Periodic Company Report #WAES 00010517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Laryngitis Vocal Cord Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:03/24/00ISR Number: 3546141-2Report Type:Periodic Company Report #WAES 00010518
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546142-4Report Type:Periodic Company Report #WAES 00010525
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Skin Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	12 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546144-8Report Type:Periodic Company Report #WAES 00010526
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Aspirin	C				
			Ibuprofen	C				
			Ranitidine	C				

Date:03/24/00ISR Number: 3546145-XReport Type:Periodic Company Report #WAES 00010527
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Paxil	C				

Date:03/24/00ISR Number: 3546146-1Report Type:Periodic Company Report #WAES 00010528
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Upper Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Tinnitus		Nitroglycerin	C				

Date:03/24/00ISR Number: 3546148-5Report Type:Periodic Company Report #WAES 00010534
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546150-3Report Type:Periodic Company Report #WAES 00010538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	10 DAY
			Fosamax	C				

Date:03/24/00ISR Number: 3546152-7Report Type:Periodic Company Report #WAES 00010540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546154-0Report Type:Periodic Company Report #WAES 99120046
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. MG/PO	
			Synthroid	C				
			Zyloprim	C				

Date:03/24/00ISR Number: 3546155-2Report Type:Periodic Company Report #WAES 00010543
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546156-4Report Type:Periodic Company Report #WAES 99120047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546157-6Report Type:Periodic Company Report #WAES 00010550
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546158-8Report Type:Periodic Company Report #WAES 00010583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Drug Ineffective Gastrointestinal Disorder Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY

Date:03/24/00ISR Number: 3546159-XReport Type:Periodic Company Report #WAES 00010596
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Betoptic	C	
Zocor	C	
Verapamil	C	

Date:03/24/00ISR Number: 3546160-6Report Type:Periodic Company Report #WAES 00010611
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546161-8Report Type:Periodic Company Report #WAES 99121996
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/PO	

Date:03/24/00ISR Number: 3546162-XReport Type:Periodic Company Report #WAES 00010620
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Dizziness Feeling Cold	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Night Sweats		Glucophage	C				
			Paxil	C				
			Prinivil	C				
			Zestril	C				

Date:03/24/00ISR Number: 3546163-1Report Type:Periodic Company Report #WAES 00010623
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Migraine							
	Oedema Peripheral							

Date:03/24/00ISR Number: 3546164-3Report Type:Periodic Company Report #WAES 00010624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Influenza							
	Oedema Peripheral							
	Pyrexia		Tylenol	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546165-5Report Type:Periodic Company Report #WAES 00010625
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				

Date:03/24/00ISR Number: 3546166-7Report Type:Periodic Company Report #WAES 00010626
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Breast Engorgement	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Premarin	C				
			Zocor	C				

Date:03/24/00ISR Number: 3546167-9Report Type:Periodic Company Report #WAES 00010629
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Hyperthyroidism Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Oedema Peripheral Tremor		Coumadin	C				
			Depakote	C				
			Lasix	C				

Date:03/24/00ISR Number: 3546168-0Report Type:Periodic Company Report #WAES 99122003
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	
			Antivert	C				
			Claritin	C				
			Inderal	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3546169-2Report Type:Periodic Company Report #WAES 00010631
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain Gait Disturbance Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bufferin	C				
			Lescol	C				
			Percocet	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546170-9Report Type:Periodic Company Report #WAES 00010632
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:03/24/00ISR Number: 3546171-0Report Type:Periodic Company Report #WAES 99122004
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Diarrhoea	Health Professional						
	Dizziness							
	Fatigue						MG/DAILY/PO	
	Nausea		Hyrdocodone	C				

Date:03/24/00ISR Number: 3546172-2Report Type:Periodic Company Report #WAES 00010637
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Muscle Spasms							
	Muscular Weakness							
	Pruritus		Neurontin	C				
	Renal Disorder		Plavix	C				
	Transient Ischaemic Attack		Sinemet	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3546173-4Report Type:Periodic Company Report #WAES 99122007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
		Representative						

Date:03/24/00ISR Number: 3546174-6Report Type:Periodic Company Report #WAES 99122008
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Buspar	C				
			Plendil	C				
			Synthroid	C				
			Chondroitin (+) Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546175-8Report Type:Periodic Company Report #WAES 99122011
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Robaxin	C				

Date:03/24/00ISR Number: 3546176-XReport Type:Periodic Company Report #WAES 00021323
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Dilantin	C				
			Inderal	C				

Date:03/24/00ISR Number: 3546177-1Report Type:Periodic Company Report #WAES 99122014
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tamoxifen	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546178-3Report Type:Periodic Company Report #WAES 00010638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546179-5Report Type:Periodic Company Report #WAES 00021333
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Buspar	C				
			Fosamax	C				

Date:03/24/00ISR Number: 3546180-1Report Type:Periodic Company Report #WAES 99120069
Age:80 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Advil	C		

Date:03/24/00ISR Number: 3546181-3Report Type:Periodic Company Report #WAES 00010645
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DILY/PO	
			Lipitor	C				
			Acyclovir	C				

Date:03/24/00ISR Number: 3546182-5Report Type:Periodic Company Report #WAES 99122018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orthostatic Hypotension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Prozac	C				
			Zoloft	C				

Date:03/24/00ISR Number: 3546183-7Report Type:Periodic Company Report #WAES 00021349
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Eye Pain Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Vision Blurred		Estrogenic Preparations (Compostion)	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3546184-9Report Type:Periodic Company Report #WAES 00010646
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Atrovent	C				
			Azmacort	C				
			Flovent	C				
			Zoloft	C				
			Albuterol	C				

Date:03/24/00ISR Number: 3546185-0Report Type:Periodic Company Report #WAES 99122022
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Calcium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546186-2Report Type:Periodic Company Report #WAES 00021351
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546187-4Report Type:Periodic Company Report #WAES 00010647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546188-6Report Type:Periodic Company Report #WAES 00021358
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis Skin Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546189-8Report Type:Periodic Company Report #WAES 99122023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Date:03/24/00ISR Number: 3546190-4Report Type:Periodic Company Report #WAES 00010648
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/24/00ISR Number: 3546191-6Report Type:Periodic Company Report #WAES 00021365
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Normodyne	C				
			[Composition Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546192-8Report Type:Periodic Company Report #WAES 99120070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated Drug Ineffective Muscle Spasms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546193-XReport Type:Periodic Company Report #WAES 99122024
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	; 12.5 MG/DAILY/PO
			Dulcolax	C				
			Glucotrol Xl	C				
			Klor-Con	C				
			Mevacor	C				
			Norvasc	C				
			Tylenol	C				
			Vasotec	C				
			Bumetanide	C				
			Isosorbide	C				

Date:03/24/00ISR Number: 3546194-1Report Type:Periodic Company Report #WAES 00010652
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Paraesthesia				Merck Co Inc	ORAL
PO						
	Tongue Disorder		Naprosyn	C		
			Singulair	C		
			Zyrtec	C		

Date:03/24/00ISR Number: 3546195-3Report Type:Periodic Company Report #WAES 99120088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3546196-5Report Type:Periodic Company Report #WAES 00021367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Balance Disorder	Consumer	Vioxx	PS	Merck Research	
	Dizziness				Laboratories Div	
	Tremor				Merck Co Inc	ORAL
PO						
			Cardura	C		
			Monopril	C		
			Zocor	C		
			Clonidine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546197-7Report Type:Periodic Company Report #WAES 99120108
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546198-9Report Type:Periodic Company Report #WAES 00010653
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol	C				
			Vicodin Tablets	C				

Date:03/24/00ISR Number: 3546199-0Report Type:Periodic Company Report #WAES 99122025
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain Sleep Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:03/24/00ISR Number: 3546200-4Report Type:Periodic Company Report #WAES 00021368
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Date:03/24/00ISR Number: 3546201-6Report Type:Periodic Company Report #WAES 99122029
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tinnitus							
			Claritin	C				

Date:03/24/00ISR Number: 3546202-8Report Type:Periodic Company Report #WAES 00010654
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Muscular Weakness							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546203-XReport Type:Periodic Company Report #WAES 99120111
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546204-1Report Type:Periodic Company Report #WAES 00021372
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO 50 MG/DAILY/PO	1 DAY

Date:03/24/00ISR Number: 3546205-3Report Type:Periodic Company Report #WAES 00010661
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Flushing Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/24/00ISR Number: 3546206-5Report Type:Periodic Company Report #WAES 00021376
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546207-7Report Type:Periodic Company Report #WAES 00010663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinitis Allergic Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546208-9Report Type:Periodic Company Report #WAES 00021160
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea Post Procedural	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Complication Tooth Injury Vomiting		Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546209-0Report Type:Periodic Company Report #WAES 00021168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546210-7Report Type:Periodic Company Report #WAES 00010667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546211-9Report Type:Periodic Company Report #WAES 00021379
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Dyspnoea Flushing	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Wellbutrin	C				
			Zocor	C				

Date:03/24/00ISR Number: 3546212-0Report Type:Periodic Company Report #WAES 00021405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546213-2Report Type:Periodic Company Report #WAES 00021419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546214-4Report Type:Periodic Company Report #WAES 00021237
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Influenza Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Traumatic Arthropathy							
			Librium	C				
			Persantine	C				
			Vicodin Tablets	C				
			Wellbutrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546215-6Report Type:Periodic Company Report #WAES 00021421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546216-8Report Type:Periodic Company Report #WAES 00021223
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3546217-XReport Type:Periodic Company Report #WAES 00021426
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546218-1Report Type:Periodic Company Report #WAES 00021230
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research			

					Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						
			Prempro	C		
			Relafen	C		
			Synthroid	C		

Date:03/24/00ISR Number: 3546219-3Report Type:Periodic Company Report #WAES 00021428
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Coordination Abnormal	Consumer	Vioxx	PS	Merck Research	
	Dizziness				Laboratories Div	
					Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Cardizem Cd	C		
			Ditropan	C		
			Hydrodiuril	C		
			Nizoral 2% Shampoo	C		
			Potassium Chloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546220-XReport Type:Periodic Company Report #WAES 00021232
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Excoriation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				
			Ultran	C				
			Terazosin	C				

Date:03/24/00ISR Number: 3546221-1Report Type:Periodic Company Report #WAES 00021435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Thirst	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3546222-3Report Type:Periodic Company Report #WAES 00021440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546223-5Report Type:Periodic Company Report #WAES 99122049
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546224-7Report Type:Periodic Company Report #WAES 00021442
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophagitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546225-9Report Type:Periodic Company Report #WAES 99122050
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Aspirin	C
K-Dur	C
Norvasc	C
Plavix	C
Hydrochlorothiazide (+) Triamter	C
Metoprolol Tartrate	C

Date:03/24/00ISR Number: 3546226-0Report Type:Periodic Company Report #WAES 99122051
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3546227-2Report Type:Periodic Company Report #WAES 99122061
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Avapro	C				
			Cordarone	C				
			Lanoxin	C				
			Premarin	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3546228-4Report Type:Periodic Company Report #WAES 99122088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546229-6Report Type:Periodic Company Report #WAES 00021214
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Flatulence							
	Haemorrhoids							
			Cozaar	C				
			Lipitor	C				

Date:03/24/00ISR Number: 3546230-2Report Type:Periodic Company Report #WAES 99122099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO
Prilosec C

Date:03/24/00ISR Number: 3546231-4Report Type:Periodic Company Report #WAES 99122101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25 MG/BID/PO	

Date:03/24/00ISR Number: 3546232-6Report Type:Periodic Company Report #WAES 00021447
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coma Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546233-8Report Type:Periodic Company Report #WAES 00021203
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Flomax (Tamsulosin (R) - Form Hydr	C				
			Zocor	C				
			Cyclobenzaprine	C				

Date:03/24/00ISR Number: 3546234-XReport Type:Periodic Company Report #WAES 99122105
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546235-1Report Type:Periodic Company Report #WAES 99122129
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;	
			Estrogenic Preparations	C			12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546236-3Report Type:Periodic Company Report #WAES 00011032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Vioxx	SS		ORAL	25MG DAILY PO	

Date:03/24/00ISR Number: 3546237-5Report Type:Periodic Company Report #WAES 00021194
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Diovan	C				
			Humulin N	C				
			Humulin R	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3546238-7Report Type:Periodic Company Report #WAES 99122130
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Centrum	C				
			Tylenol	C				
			[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3546239-9Report Type:Periodic Company Report #WAES 99122133
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							
	Headache							
	Weight Increased		Tarka	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Herbal Remedies	C				

Date:03/24/00ISR Number: 3546240-5Report Type:Periodic Company Report #WAES 00021197
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Hair Disorder							
			Glucotrol Xl	C				
			Norvasc	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546241-7Report Type:Periodic Company Report #WAES 99122134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				
			Ultram	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546242-9Report Type:Periodic Company Report #WAES 00011033
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Prevacid	C				
			Zocor	C				

Date:03/24/00ISR Number: 3546243-0Report Type:Periodic Company Report #WAES 00021191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Micronase	C				
			Nitro-Dur	C				

			Norvasc	C		
			Questran	C		
			...	C		

Date:03/24/00ISR Number: 3546244-2Report Type:Periodic Company Report #WAES 99122136
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Alactazide	C		
			Flomax	C		
			Keflex	C		

Date:03/24/00ISR Number: 3546245-4Report Type:Periodic Company Report #WAES 00011038
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG DAILY PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546246-6Report Type:Periodic Company Report #WAES 00021193
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscular Weakness Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lozol	C				
			Norvasc	C				
			Prednisona Sod. Fos	C				
			...	C				
			Glucosamine	C				

Date:03/24/00ISR Number: 3546247-8Report Type:Periodic Company Report #WAES 99122137
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	HS/PO	
			Fosamax	C				
			Dimethyl Sulfone	C				

Date:03/24/00ISR Number: 3546248-XReport Type:Periodic Company Report #WAES 00011041
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:03/24/00ISR Number: 3546249-1Report Type:Periodic Company Report #WAES 99122138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Urticaria							
			[Therapy Unspecified]	SS				
			Advil	C				
			Premarin	C				
			Zantac	C				
			Ziac	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3546250-8Report Type:Periodic Company Report #WAES 00021184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546251-XReport Type:Periodic Company Report #WAES 00011046
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/24/00ISR Number: 3546252-1Report Type:Periodic Company Report #WAES 00021198
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546253-3Report Type:Periodic Company Report #WAES 99122142
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Constipation							
	Drug Ineffective							
	Rectal Haemorrhage		Claritin	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3546254-5Report Type:Periodic Company Report #WAES 00011052
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Insomnia							

Merck Co Inc ORAL
25MG DAILY PO

Date:03/24/00ISR Number: 3546255-7Report Type:Periodic Company Report #WAES 99122152
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Flatulence							
	Gastrointestinal Disorder				Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Upper Respiratory Tract Infection		Fosamax	C				

Date:03/24/00ISR Number: 3546256-9Report Type:Periodic Company Report #WAES 00011058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Face Oedema							
	Pruritus				Merck Co Inc	ORAL	PO	
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546257-0Report Type:Periodic Company Report #WAES 00011065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/24/00ISR Number: 3546258-2Report Type:Periodic Company Report #WAES 00011068
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Xanax	C				

Date:03/24/00ISR Number: 3546259-4Report Type:Periodic Company Report #WAES 99122153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Celebrex	C				
			Imitrex	C				
			Lozol	C				

Date:03/24/00ISR Number: 3546260-0Report Type:Periodic Company Report #WAES 00011077
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5 MG DAILY

PO

Date:03/24/00ISR Number: 3546261-2Report Type:Periodic Company Report #WAES 99122154
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Methotrexate	C		

Dose Duration

12.5 MG DAILY

PO

Date:03/24/00ISR Number: 3546262-4Report Type:Periodic Company Report #WAES 00011080
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Eyelid Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546263-6Report Type:Periodic Company Report #WAES 99122157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3546264-8Report Type:Periodic Company Report #WAES 00011081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546265-XReport Type:Periodic Company Report #WAES 99122159
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria Urine Abnormality		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				

Date:03/24/00ISR Number: 3546266-1Report Type:Periodic Company Report #WAES 00011082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL
PO	10 DAY					

Date:03/24/00ISR Number: 3546267-3Report Type:Periodic Company Report #WAES 00011084
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Disorder Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3546268-5Report Type:Periodic Company Report #WAES 99122163
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546269-7Report Type:Periodic Company Report #WAES 00011085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546270-3Report Type:Periodic Company Report #WAES 99122170
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Atenolol	C				
			Trazodone	C				

Date:03/24/00ISR Number: 3546271-5Report Type:Periodic Company Report #WAES 00011086
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546272-7Report Type:Periodic Company Report #WAES 99122174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prinzide	C				
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3546273-9Report Type:Periodic Company Report #WAES 00011087
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:03/24/00ISR Number: 3546274-0Report Type:Periodic Company Report #WAES 99122175
Age:61 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Pain In Extremity
	Rash Erythematous

	Swelling						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Accupril	C			
			Estrol	C			
			[Composition Unspecified]	C			
			Allergenic Extract	C			

Date:03/24/00ISR Number: 3546275-2Report Type:Periodic Company Report #WAES 99122182
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	OPHT
			Celexa	C			
			Cytomel	C			
			Tamoxifen	C			

Date:03/24/00ISR Number: 3546276-4Report Type:Periodic Company Report #WAES 00011088
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:03/24/00ISR Number: 3546277-6Report Type:Periodic Company Report #WAES 00011089
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546278-8Report Type:Periodic Company Report #WAES 99122186
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546279-XReport Type:Periodic Company Report #WAES 00011090
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546280-6Report Type:Periodic Company Report #WAES 99122193
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Sensation Of Heaviness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546281-8Report Type:Periodic Company Report #WAES 00021199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546289-2Report Type:Periodic Company Report #WAES 00021205
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO

Date:03/24/00ISR Number: 3546290-9Report Type:Periodic Company Report #WAES 00021207
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dimetapp	C				
			Motrin	C				

Date:03/24/00ISR Number: 3546291-0Report Type:Periodic Company Report #WAES 00021210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Flatulence Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546292-2Report Type:Periodic Company Report #WAES 00021221
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3546293-4Report Type:Periodic Company Report #WAES 00021234
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Digoxin	C				

Date:03/24/00ISR Number: 3546294-6Report Type:Periodic Company Report #WAES 00021808
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema Face Oedema Oedema Peripheral Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546297-1Report Type:Periodic Company Report #WAES 00021892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Eye Haemorrhage Influenza Like Illness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:03/24/00ISR Number: 3546302-2Report Type:Periodic Company Report #WAES 00022065
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis Necrosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546308-3Report Type:Periodic Company Report #WAES 00022142
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
			Catapres	C				
			Glucophage	C				

Glucotrol	C
Lotensin	C
Norvasc	C
Minoxidil	C

Date:03/24/00ISR Number: 3546310-1Report Type:Periodic Company Report #WAES 00022291
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546311-3Report Type:Periodic Company Report #WAES 00030192
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Tenosynovitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Darvocet-N	C				
			Paxil	C				
			Pravachol	C				

Date:03/24/00ISR Number: 3546314-9Report Type:Periodic Company Report #WAES 99110814
Age:20 MON Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activated Partial Thromboplastin Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Albuterol	C		

Date:03/24/00ISR Number: 3546315-0Report Type:Periodic Company Report #WAES 00021240
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:03/24/00ISR Number: 3546317-4Report Type:Periodic Company Report #WAES 00021249
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucotrol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546319-8Report Type:Periodic Company Report #WAES 99111644
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				
			Zantac	C				
			Aspirin	C				

Date:03/24/00ISR Number: 3546322-8Report Type:Periodic Company Report #WAES 99111691
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Lorazepam	C				
			Trazodone	C				

Date:03/24/00ISR Number: 3546324-1Report Type:Periodic Company Report #WAES 99111696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Cozaar	C				
			Lasix	C				
			Lescol	C				

Date:03/24/00ISR Number: 3546325-3Report Type:Periodic Company Report #WAES 00021891
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Haematuria Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546327-7Report Type:Periodic Company Report #WAES 00021893
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546328-9Report Type:Periodic Company Report #WAES 00021251
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Dilantin C
Neurontin C
Premarin C

Date:03/24/00ISR Number: 3546330-7Report Type:Periodic Company Report #WAES 00021253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Abdominal Pain Upper							
	Diarrhoea							
	Red Blood Cell Count Decreased		Aspirin	C				

Date:03/24/00ISR Number: 3546331-9Report Type:Periodic Company Report #WAES 00021894
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546332-0Report Type:Periodic Company Report #WAES 00021255
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 1 DAY

Daypro	C
Ortho Cyclen	C
Pepcid	C
Prilosec	C
Propulsid	C
Folic Acid	C
Methotrexate	C

Date:03/24/00ISR Number: 3546333-2Report Type:Periodic Company Report #WAES 00021906
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orthostatic Hypotension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546335-6Report Type:Periodic Company Report #WAES 00022060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Rectal Haemorrhage	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546336-8Report Type:Periodic Company Report #WAES 00021256
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Axid	C				
			Calan	C				
			Detrol	C				
			Hydrocodone	C				

Date:03/24/00ISR Number: 3546338-1Report Type:Periodic Company Report #WAES 00022582
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546339-3Report Type:Periodic Company Report #WAES00021260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3546341-1Report Type:Periodic Company Report #WAES 00021262
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546342-3Report Type:Periodic Company Report #WAES 00030635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546344-7Report Type:Periodic Company Report #WAES 00021263
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546345-9Report Type:Periodic Company Report #WAES 99111635
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dry Mouth Tachypnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546346-0Report Type:Periodic Company Report #WAES 99111675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546347-2Report Type:Periodic Company Report #WAES 00021268
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance	Consumer	Vioxx	PS	Merck Research			

Oedema Peripheral

Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO

Avil	C
Flovent	C
Neurontin	C
Prempro	C
Synthroid	C
Therapy Unspecified	C
Indapamide	C

Date:03/24/00ISR Number: 3546349-6Report Type:Periodic Company Report #WAES 99111676
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO 5 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546350-2Report Type:Periodic Company Report #WAES 00021273
Age:64 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Cozaar	C				
			Maxzide	C				

Date:03/24/00ISR Number: 3546353-8Report Type:Periodic Company Report #WAES 00021274
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Plaquenil	C				
			Folic Acid	C				
			Levothyroxine Sodium	C				
			Methotrexate	C				
			Sulfamethazine	C				

Date:03/24/00ISR Number: 3546355-1Report Type:Periodic Company Report #WAES 00021289
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Diarrhoea Drug Ineffective Mouth Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Atenolol	C				

Date:03/24/00ISR Number: 3546357-5Report Type:Periodic Company Report #WAES 00021290
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Oesophageal Disorder							
	Vomiting							
			Darvocet-N	C				
			Lopressor	C				
			Premarin	C				
			Remeron	C				
			Tagamet	C				
			Diphenhydramine	C				

Date:03/24/00ISR Number: 3546359-9Report Type:Periodic Company Report #WAES 00021293
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	18 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546361-7Report Type:Periodic Company Report #WAES 00021296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546365-4Report Type:Periodic Company Report #WAES 00021306
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Donnatal	C				
			Evista	C				
			Prevacid	C				
			Calcium Supplement	C				

Date:03/24/00ISR Number: 3546367-8Report Type:Periodic Company Report #WAES 00021311
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Celebrex	C				
			Estraderm	C				
			Prevacid	C				
			Medroxyprogesterone	C				

Date:03/24/00ISR Number: 3546369-1Report Type:Periodic Company Report #WAES 00021319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Pyelonephritis Upper Respiratory Tract Infection Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546372-1Report Type:Periodic Company Report #WAES 00021322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dry Skin	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546376-9Report Type:Periodic Company Report #WAES 00020163
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy Blindness Blood Creatinine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	20 DAY
	Increased		Naproxen	SS			PO	
			Ibuprofen	SS		ORAL	PO	
			Aspirin	SS		ORAL	PO	
			Tramadol	C				

Date:03/24/00ISR Number: 3546378-2Report Type:Periodic Company Report #WAES 00020177
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546381-2Report Type:Periodic Company Report #WAES 00020178
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546383-6Report Type:Periodic Company Report #WAES 00020180
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546385-XReport Type:Periodic Company Report #WAES 00020181
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546387-3Report Type:Periodic Company Report #WAES 00020182
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546390-3Report Type:Periodic Company Report #WAES 00020200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/QID/PO	

Date:03/24/00ISR Number: 3546392-7Report Type:Periodic Company Report #WAES 00020209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pruritus Female	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546395-2Report Type:Periodic Company Report #WAES 00020215
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Ambien	C				
			Cozaar	C				
			Norvasc	C				
			Medroxyprogesterone	C				
			Propranolol	C				

Date:03/24/00ISR Number: 3546397-6Report Type:Periodic Company Report #WAES 00020216
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Diazide	C				
			Synthroid	C				
			Tylenol	C				
			Xanax	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3546398-8Report Type:Periodic Company Report #WAES 00020218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546402-7Report Type:Periodic Company Report #WAES 00020228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/24/00ISR Number: 3546404-0Report Type:Periodic Company Report #WAES 00020232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/24/00ISR Number: 3546407-6Report Type:Periodic Company Report #WAES 00020233
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546409-XReport Type:Periodic Company Report #WAES 00020244
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:03/24/00ISR Number: 3546412-XReport Type:Periodic Company Report #WAES 00020255
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hytrin	C				
			Paxil	C				
			Amoxicillin	C				
			Glyburide	C				
			Lorazepam	C				
			Lopressor	C				

Date:03/24/00ISR Number: 3546414-3Report Type:Periodic Company Report #WAES 00020283
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Face Oedema Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546417-9Report Type:Periodic Company Report #WAES 00020291
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546419-2Report Type:Periodic Company Report #WAES 00020301
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Synthroid	C				
			Trazodone	C				

Date:03/24/00ISR Number: 3546421-0Report Type:Periodic Company Report #WAES 20000313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546423-4Report Type:Periodic Company Report #WAES 00020964
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546425-8Report Type:Periodic Company Report #WAES 00020966
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aldactone	C				
			Cardene	C				
			Centrum Silver	C				
			Paxil	C				
			Premarin	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546427-1Report Type:Periodic Company Report #WAES 00020969
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Pain In Extremity							
			Monopril	C				
			Procardia Xl	C				
			Furosemide	C				

Date:03/24/00ISR Number: 3546430-1Report Type:Periodic Company Report #WAES 00020980
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	[Therapy Unspecified]	C				

Date:03/24/00ISR Number: 3546433-7Report Type:Periodic Company Report #WAES 00020981
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pericarditis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:03/24/00ISR Number: 3546436-2Report Type:Periodic Company Report #WAES 00020982
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:03/24/00ISR Number: 3546438-6Report Type:Periodic Company Report #WAES 00020984
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Myalgia Pyrexia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546442-8Report Type:Periodic Company Report #WAES 00020986
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546444-1Report Type:Periodic Company Report #WAES 00020987
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546446-5Report Type:Periodic Company Report #WAES 00020988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546449-0Report Type:Periodic Company Report #WAES 00020992
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546451-9Report Type:Periodic Company Report #WAES 00020995
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	Coumadin	C		

Date:03/24/00ISR Number: 3546454-4Report Type:Periodic Company Report #WAES 00020996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						

Date:03/24/00ISR Number: 3546456-8Report Type:Periodic Company Report #WAES 00021002
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haematoma	Health	Vioxx	PS	Merck Research	
	Vascular Injury	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Coumadin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546459-3Report Type:Periodic Company Report #WAES 00021005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fentanyl 25 Microgm 50 Microgm 75 Microgm	SS		TOPICAL	25 MICROGM/DAILY /TOP 50 MICROGM/DAILY /TOP 75	
			Atrovent	C				
			Flovent	C				
			Miacalcin	C				
			Propulsid	C				
			Serevent	C				
			Azithromycin	C				
			Calcium Supplement (Composition)	C				
			Meclizine	C				

Date:03/24/00ISR Number: 3546460-XReport Type:Periodic Company Report #WAES 00021019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abscess Dermatitis Drug Ineffective Fungal Infection Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546463-5Report Type:Periodic Company Report #WAES 00021047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest X-Ray Abnormal Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546465-9Report Type:Periodic Company Report #WAES 00021053
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ambien	C				
			Aspirin	C				
			Lipitor	C				
			Nephrocaps	C				
			Niferex	C				
			Phoslo	C				
			Prilosec	C				
			Propulsid	C				

			Vasotec	C		
			[Therapy Unspecified]	C		
			Ascorbic Acid	C		
			Nutritional Supplements	C		

Date:03/24/00ISR Number: 3546468-4Report Type:Periodic Company Report #WAES 00021054
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Imuran	C				
			Plaquenil	C				
			Synthroid	C				
			Trazodone Hydrochloride	C				

Date:03/24/00ISR Number: 3546471-4Report Type:Periodic Company Report #WAES 00021055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546766-4Report Type:Periodic Company Report #WAES 00021644
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO

Date:03/24/00ISR Number: 3546767-6Report Type:Periodic Company Report #WAES 00021653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MGM/DAILY/PO	
			Voltaren	C				
			...	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546768-8Report Type:Periodic Company Report #WAES 00021665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Seborrhoeic Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546769-XReport Type:Periodic Company Report #WAES 00021694
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			...	C				

Date:03/24/00ISR Number: 3546770-6Report Type:Periodic Company Report #WAES 00021700
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Dry Mouth Feeling Drunk	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Anaflex	C				

Date:03/24/00ISR Number: 3546771-8Report Type:Periodic Company Report #WAES 00021706
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/BID/PO;

12.5

MG/DAILY/PO

Prilosec	C	
Propulsid	C	

Date:03/24/00ISR Number: 3546772-XReport Type:Periodic Company Report #WAES 00021711
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5

MG/DAILY/PO

Pepcid	C	

Date:03/24/00ISR Number: 3546773-1Report Type:Periodic Company Report #WAES 00021714
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Haemorrhage	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546774-3Report Type:Periodic Company Report #WAES 00021715
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Hydrodiuril	C				
			Digoxin	C				

Date:03/24/00ISR Number: 3546775-5Report Type:Periodic Company Report #WAES 00021716
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546776-7Report Type:Periodic Company Report #WAES 00021718
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/BID/PO

Ecotrin C
Aspirin C

Date:03/24/00ISR Number: 3546778-0Report Type:Periodic Company Report #WAES 00021725
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546779-2Report Type:Periodic Company Report #WAES 00021728
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Dyazide	C				

Date:03/24/00ISR Number: 3546780-9Report Type:Periodic Company Report #WAES 00021734
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Cardizem	C				
			Lanoxin	C				

Date:03/24/00ISR Number: 3546782-2Report Type:Periodic Company Report #WAES 00021744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546784-6Report Type:Periodic Company Report #WAES 00021746
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546785-8Report Type:Periodic Company Report #WAES 00021748
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO 1 DAY

Date:03/24/00ISR Number: 3546787-1Report Type:Periodic Company Report #WAES 00021750
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrace	C				
			Hyzaar	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3546789-5Report Type:Periodic Company Report #WAES 00021756
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546790-1Report Type:Periodic Company Report #WAES 00021800
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3546890-6Report Type:Periodic Company Report #WAES 99121519
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/ PO	
			Pepcid	C				

Date:03/24/00ISR Number: 3546891-8Report Type:Periodic Company Report #WAES 99121523
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/PO	
			Glucophage	C				
			Synthroid	C				
			Vasotec	C				

Date:03/24/00ISR Number: 3546892-XReport Type:Periodic Company Report #WAES 99121524
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/ PM /PO
Nasacort C

Date:03/24/00ISR Number: 3546893-1Report Type:Periodic Company Report #WAES 99121526
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Feeling Abnormal				Laboratories Div	
					Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Norvasc	C		
			Xanax	C		
			Nortriptyline	C		

Date:03/24/00ISR Number: 3546894-3Report Type:Periodic Company Report #WAES 99121530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Condition Aggravated	Consumer	Vioxx	PS	Merck Research	
	Ulcer				Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG /						
DAILY/ PO; 25						

MG DAILY/PO 1 WK

Cardizem	C
Estratab	C
Fibercon	C
Prilosec	C
Calcium Supplement	C

Date:03/24/00ISR Number: 3546895-5Report Type:Periodic Company Report #WAES 99121533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UKN/PO	

Date:03/24/00ISR Number: 3546896-7Report Type:Periodic Company Report #WAES 99121534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/ PO;	

Date:03/24/00ISR Number: 3546897-9Report Type:Periodic Company Report #WAES 99121537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Diarrhoea Dizziness Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAY/PO	

Date:03/24/00ISR Number: 3546898-0Report Type:Periodic Company Report #WAES 99121539
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/PO
	Hypersensitivity							
	Swelling							

Date:03/24/00ISR Number: 3546899-2Report Type:Periodic Company Report #WAES 99121540
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/PO
	Chest Pain							
	Dyspnoea							
	Sweat Gland Disorder		Fosamax	C				
			Lipitor	C				
			Premarin	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546900-6Report Type:Periodic Company Report #WAES 99121546
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO;25MG /DAILY/PO	
	Fall							
	Injury							
	Oedema Peripheral							
			Avantyl	C				
			Micronase	C				
			Trandate	C				
			Tamoxifen	C				

Date:03/24/00ISR Number: 3546901-8Report Type:Periodic Company Report #WAES 99121547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
	Sensation Of Heaviness							
			Verapamil	C				

Date:03/24/00ISR Number: 3546902-XReport Type:Periodic Company Report #WAES 99121552
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			L-Thyroxine	C				

Date:03/24/00ISR Number: 3546903-1Report Type:Periodic Company Report #WAES 99121562
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/PO	

Date:03/24/00ISR Number: 3546904-3Report Type:Periodic Company Report #WAES 99121563
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546905-5Report Type:Periodic Company Report #WAES 99121591
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK/PO	

Date:03/24/00ISR Number: 3546906-7Report Type:Periodic Company Report #WAES 99121592
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK/PO	

Date:03/24/00ISR Number: 3546907-9Report Type:Periodic Company Report #WAES 99121604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK / PO	

Date:03/24/00ISR Number: 3546908-0Report Type:Periodic Company Report #WAES 99121620
Age:72 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY/	

PO

			Premarin	C
			Synthroid	C
			Zoloft	C

Date:03/24/00ISR Number: 3546909-2Report Type:Periodic Company Report #WAES 99121625
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research	
	Paraesthesia				Laboratories Div	
					Merck Co Inc	ORAL
25 MG/ DAILY/						
ORAL						
			Allegra	C		
			Zoloft	C		
			Acetaminophen	C		
			Carisoprodol	C		
			Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546954-7Report Type:Periodic Company Report #WAES 99111699
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Vitamin D	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3546956-0Report Type:Periodic Company Report #WAES 99111721
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria Urine Abnormality Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Syntroid	C				
			Pilocarpine	C				

Date:03/24/00ISR Number: 3546957-2Report Type:Periodic Company Report #WAES 99111766
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3546958-4Report Type:Periodic Company Report #WAES 99111797
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dry Skin Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				
			Premarin	C				

Date:03/24/00ISR Number: 3546959-6Report Type:Periodic Company Report #WAES 99111833
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546960-2Report Type:Periodic Company Report #WAES 99111834
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546961-4Report Type:Periodic Company Report #WAES 99111835
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546963-8Report Type:Periodic Company Report #WAES 99111837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546964-XReport Type:Periodic Company Report #WAES 99111856
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546965-1Report Type:Periodic Company Report #WAES 99111860
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Minerals	C				
			Vitamin E	C				

Date:03/24/00ISR Number: 3546966-3Report Type:Periodic Company Report #WAES 99111861
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546967-5Report Type:Periodic Company Report #WAES 99111887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546968-7Report Type:Periodic Company Report #WAES 99111902
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Chest Pain Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546970-5Report Type:Periodic Company Report #WAES 99111912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546971-7Report Type:Periodic Company Report #WAES 99111922
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

	Celebrex	SS	
	Prempo	C	
	Prilosec	C	

Date:03/24/00ISR Number: 3546972-9Report Type:Periodic Company Report #WAES 99111931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3546973-0Report Type:Periodic Company Report #WAES 99111935
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Azulfidine	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3546974-2Report Type:Periodic Company Report #WAES 99111939
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Gastrointestinal Disorder	Professional			Merck Co Inc	ORAL	25	
	Influenza Like Illness						MG/DAILY/PO;	
							PO	

Date:03/24/00ISR Number: 3546975-4Report Type:Periodic Company Report #WAES 99111955
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25 MG/QOD/PO	
			Ecotrin	C				

Date:03/24/00ISR Number: 3546977-8Report Type:Periodic Company Report #WAES 99111977
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25 MG/BID/PO;	
		Representative					12.5	
							MG/DAILY/PO	
			Maxair	C				
			Paxil	C				
			Valium	C				
			Zestoretic	C				

Date:03/24/00ISR Number: 3546996-1Report Type:Periodic Company Report #WAES 99121646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		OCCLUSIVE DRESSING	UNK/PPO

Date:03/24/00ISR Number: 3546997-3Report Type:Periodic Company Report #WAES 99121654
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Synthroid	C				

Date:03/24/00ISR Number: 3546998-5Report Type:Periodic Company Report #WAES 99121655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

(Therapy
Unspecified) C
Codeine C

Date:03/24/00ISR Number: 3546999-7Report Type:Periodic Company Report #WAES 99121656
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Mouth Ulceration							
			Celebrex	C				
			Zocor	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3547001-3Report Type:Periodic Company Report #WAES 99121660
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Insomnia		Lotrel	C				
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3547006-2Report Type:Periodic Company Report #WAES 99121663
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/PO						
			Prempro	C		

Date:03/24/00ISR Number: 3547008-6Report Type:Periodic Company Report #WAES 99121666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						

Date:03/24/00ISR Number: 3547010-4Report Type:Periodic Company Report #WAES 99121670
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus Scab	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/DAILY/PO						
			Voltaren	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547014-1Report Type:Periodic Company Report #WAES 99121672
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis Dizziness Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol	C				

Date:03/24/00ISR Number: 3547018-9Report Type:Periodic Company Report #WAES 99121674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Throat Tightness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3547024-4Report Type:Periodic Company Report #WAES 99121675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3547035-9Report Type:Periodic Company Report #WAES 99121677
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Irritability	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Sleep Disorder				Merck Co Inc	ORAL
UNK/PO						
			Catapres	C		
			Premarin	C		
			Prevacd	C		
			Wytensin	C		
			Zebeta	C		
			Zocor	C		

Date:03/24/00ISR Number: 3547042-6Report Type:Periodic Company Report #WAES 99121678
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/PO						
			Evista	C		
			Fosamax	C		

Date:03/24/00ISR Number: 3547044-XReport Type:Periodic Company Report #WAES 99121681
Age:61 YR Gender:Male I/FU:I

Outcome	PT
	Abdominal Pain
	Constipation
	Dermatitis

	Haemorrhoids Mouth Ulceration					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Plavix	C		
			Zocor	C		
			(Therapy Unspecified)	C		
			Digoxin	C		
			Iron (Unspecified) (+) Vitamins	C		
			Lansoprazole	C		
			Nitroglycerin	C		

Date:03/24/00ISR Number: 3547046-3Report Type:Periodic Company Report #WAES 99121685
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased Dyspnoea Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/PO						
	Tachycardia		Ultram	C		
			Aspirin	C		
			Vitamins	C		

Date:03/24/00ISR Number: 3547050-5Report Type:Periodic Company Report #WAES 99121689
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/PO						
			Cardizem	C		

			Cozaar	C		
			Lipitor	C		
			Diurectic Preparation	C		
			Glucosamine	C		

Date:03/24/00ISR Number: 3547053-0Report Type:Periodic Company Report #WAES 99121690
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol, Arthritis Extended Relieunk	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547056-6Report Type:Periodic Company Report #WAES 99121691
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			(Therapy Unspecified)	C				

Date:03/24/00ISR Number: 3547058-XReport Type:Periodic Company Report #WAES 99121694
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Rectal Haemorrhage							
	Tongue Oedema		Tab Methotrexate Unk	SS		ORAL	3 TABLETS/WKY/PO	
			Citracal	C				
			Fosamax	C				
			Ascorbic Acid	C				
			Prednisone	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3547061-XReport Type:Periodic Company Report #WAES 99121695
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Electrocardiogram	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Abnormal				Merck Co Inc	ORAL
UNK/PO						

Date:03/24/00ISR Number: 3547082-7Report Type:Periodic Company Report #WAES 00011885
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Tenderness	Consumer	Vioxx	PS	Merck Research	
	Pollakiuria				Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:03/24/00ISR Number: 3547087-6Report Type:Periodic Company Report #WAES 00011889
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research	
	Inflammation				Laboratories Div	
	Lower Respiratory Tract				Merck Co Inc	ORAL
PO						
	Infection		Vanceril	C		
	Upper Respiratory Tract		Albuterol	C		
	Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547089-XReport Type:Periodic Company Report #WAES 00011890
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Plaquenil	C				
			Tylenol	C				
			Methotrexate	C				

Date:03/24/00ISR Number: 3547091-8Report Type:Periodic Company Report #WAES 00011894
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3547094-3Report Type:Periodic Company Report #WAES 00011897
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Colace	C				
			Ecotrin	C				
			Flomax (Tamsulosin (R) - Form Hydr	C				
			Neurontin	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3547096-7Report Type:Periodic Company Report #WAES 00011901
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO;	
	Asthenia							
	Asthma							
	Chest Pain						25 MG/DAILY/PO	
	Fatigue							
	Myalgia		Vitamins	C				
	Supraventricular Extrasystoles							
	Supraventricular Tachycardia							

Date:03/24/00ISR Number: 3547097-9Report Type:Periodic Company Report #WAES 00011902
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547098-0Report Type:Periodic Company Report #WAES 00011905
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:03/24/00ISR Number: 3547099-2Report Type:Periodic Company Report #WAES 00011910
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Blood Pressure Increased Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Vicodin Tablets	C				
			Zestoretic	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3547100-6Report Type:Periodic Company Report #WAES 00011918
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
			Serzone	C				
			Diuretic Preparation					

[Composition C

Date:03/24/00ISR Number: 3547101-8Report Type:Periodic Company Report #WAES 00011919
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Procardia	C				

Date:03/24/00ISR Number: 3547103-1Report Type:Periodic Company Report #WAES 00011921
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Lipitor	C				
			Prempro	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547104-3Report Type:Periodic Company Report #WAES 00011923
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Dysgeusia Tremor	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Methotrexate 12.5 Mg	SS		ORAL	12.5	MG/WKY/PO
			Hydrodiuril	C				
			Vitamins	C				
			Prevacid	C				
			Premarin	C				

Date:03/24/00ISR Number: 3547105-5Report Type:Periodic Company Report #WAES 00011925
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Impaired Gastric Emptying	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Effexor	C				
			Prevacid	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3547107-9Report Type:Periodic Company Report #WAES 00011927
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypertension Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

Upper Respiratory Tract
MG/DAILY/PO;
Infection
25

MG/DAILY/PO;

50
Aspirin C
Vitamins C

Date:03/24/00ISR Number: 3547110-9Report Type:Periodic Company Report #WAES 00011934
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 MON

Date:03/24/00ISR Number: 3547111-0Report Type:Periodic Company Report #WAES 00011947
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Melaena Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Ambien	C				
			Avandia	C				

Casodex	C
Glucophage	C
Niaspan	C
Norvasc	C
Atenolol	C
Ferrous Sulfate	C
Furosemide	C
Glyburide	C

Date:03/24/00ISR Number: 3547113-4Report Type:Periodic Company Report #WAES 00011951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	

Date:03/24/00ISR Number: 3547116-XReport Type:Periodic Company Report #WAES 00011966
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Cardura	C
Flovent	C
Isordil	C
Lasix	C
Lotensin	C
Norvasc	C
Parafon Forte	C
Serevent	C
Slow-K	C
Ascorbic Acid	C
Aspirin	C
Insulin	C
Iron (Unspecified)	C

			Vitamin E	C
			Vitamins	C

Date:03/24/00ISR Number: 3547118-3Report Type:Periodic Company Report #WAES 00011969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/24/00ISR Number: 3547124-9Report Type:Periodic Company Report #WAES 00010002
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Corneal Erosion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Relafen	C		
			Ultram	C		

Date:03/24/00ISR Number: 3547127-4Report Type:Periodic Company Report #WAES 00010003
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	10 DAY
	Flushing							
			Kerlone	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3547128-6Report Type:Periodic Company Report #WAES 00010004
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Urinary Incontinence	Health						
	Vomiting	Professional						
			Catapres	C				
			Oxycontin	C				
			Atenolol	C				

Date:03/24/00ISR Number: 3547130-4Report Type:Periodic Company Report #WAES 00010009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bowel Sounds Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3547131-6Report Type:Periodic Company Report #WAES 00010018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	14 DAY
	Flatulence							
	Pain							
			Flovent	C				
			Intal	C				
			Konsyl Powder	C				
			Lomotil	C				
			Proventil	C				
			Albuterol	C				

Date:03/24/00ISR Number: 3547134-1Report Type:Periodic Company Report #WAES 00010022
Age:75 YR Gender:Female I/FU:I

Outcome	PT
	Dysphonia
	Dyspnoea
	Muscular Weakness

Tremor

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Darvocet-N	C				
			Diovan	C				
			Lipitor	C				
			Neurontin	C				
			Prevacid	C				
			Propulsid	C				
			Zaroxolyn	C				
			Prednisone	C				

Date:03/24/00ISR Number: 3547135-3Report Type:Periodic Company Report #WAES 00010023
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Purulent Discharge Sputum Abnormal Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 , 50 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	50 MG/DAILY/PO	

Date:03/24/00ISR Number: 3547138-9Report Type:Periodic Company Report #WAES 00010024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Celebrex C
Fosamax C

Date:03/24/00ISR Number: 3547140-7Report Type:Periodic Company Report #WAES 00010030
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazepam	C				

Date:03/24/00ISR Number: 3547141-9Report Type:Periodic Company Report #WAES 00010034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547144-4Report Type:Periodic Company Report #WAES 00010035
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3547145-6Report Type:Periodic Company Report #WAES 00010057
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3547147-XReport Type:Periodic Company Report #WAES 00010060
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				

Date:03/24/00ISR Number: 3547149-3Report Type:Periodic Company Report #WAES 00010061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Rash Pruritic	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Evista C

Date:03/24/00ISR Number: 3547150-XReport Type:Periodic Company Report #WAES 00010063
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Neuropathy Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3547153-5Report Type:Periodic Company Report #WAES 00010065
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Haemoptysis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Agrylin	C				
			Synthroid	C				
			Toprol Xl Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3547156-0Report Type:Periodic Company Report #WAES 00010069
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Crdizem Cd	C				
			Lipitor	C				
			Pentasa	C				
			Vancenase Aq Nasal Spray	C				
			Atenolol	C				
			Clorazepic Acid Dipotassium Salt	C				
			Potassium Chloride	C				
			Ranitidine	C				

Date:03/24/00ISR Number: 3547158-4Report Type:Periodic Company Report #WAES 00010087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Chills Hypersomnia Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:03/24/00ISR Number: 3547160-2Report Type:Periodic Company Report #WAES 00010099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Therapy					

Unspecified) SS

Date:03/24/00ISR Number: 3547162-6Report Type:Periodic Company Report #WAES 00010109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548329-3Report Type:Periodic Company Report #WAES 00010406
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			A.S.A.	C				
			Celebrex	C				
			Mevacor	C				
			Prinivil	C				

			Tenormin	C		
			[Therapy Unspecified]	C		
			Allopurinol	C		

Date:03/24/00ISR Number: 3548332-3Report Type:Periodic Company Report #WAES 00010412
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAY/PO	
			Hydrodiuril	C				
			Valium	C				

Date:03/24/00ISR Number: 3548335-9Report Type:Periodic Company Report #WAES 00010414
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoma Oedema Peripheral Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3548339-6Report Type:Periodic Company Report #WAES 00010416
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research			

Sedation Laboratories Div
Merck Co Inc ORAL
25 MG/BID/PO

Date:03/24/00ISR Number: 3548340-2Report Type:Periodic Company Report #WAES 00010417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Hypercholesterolaemia							
	Palpitations		Allegra	C				
			Aspirin	C				
			Atrovent	C				
			Chloraseptic Spray & Gargle	C				
			Detrol	C				
			Dilantin	C				
			Fosamax	C				
			Lipitor	C				
			Prempro	C				
			Prilosec	C				
			Reglan	C				
			Vocodin Tablets	C				
			Zocor	C				

		Albuterol	C
		Calcium Supplement	C
		Clonidine	C
		Folic Acid	C
		Nicotinic Acid	C
		Prednisone	C

Date:03/24/00ISR Number: 3548344-XReport Type:Periodic Company Report #WAES 00010420
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hytrin	C				
			Norvasc	C				

Date:03/24/00ISR Number: 3548348-7Report Type:Periodic Company Report #WAES 00010421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Mylanta & Mylanta Ds	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3548350-5Report Type:Periodic Company Report #WAES 00010426
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2	

TABLET/DAILY/

PO

Tylenol	C	
Voltaren	C	

Date:03/24/00ISR Number: 3548354-2Report Type:Periodic Company Report #WAES 00010427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548357-8Report Type:Periodic Company Report #WAES 00010431
Age:77 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Fatigue
	Headache
	Nausea

Oedema Peripheral

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Premarin	C				
	Vitamins	C				

Date:03/24/00ISR Number: 3548359-1Report Type:Periodic Company Report #WAES 00010434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25.0 MG	1 WK

Date:03/24/00ISR Number: 3548367-0Report Type:Periodic Company Report #WAES 00010438
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/24/00ISR Number: 3548369-4Report Type:Periodic Company Report #WAES 00010440
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO
Hytrin C

Date:03/24/00ISR Number: 3548370-0Report Type:Periodic Company Report #WAES 00010442
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:03/24/00ISR Number: 3548373-6Report Type:Periodic Company Report #WAES 00010446
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypervigilance Insomnia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X /PO	
			Flexeril	C				
			Klonopin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548377-3Report Type:Periodic Company Report #WAES 00010458
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548379-7Report Type:Periodic Company Report #WAES 00010459
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548380-3Report Type:Periodic Company Report #WAES 00010460
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548383-9Report Type:Periodic Company Report #WAES 00010461
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Date:03/24/00ISR Number: 3548386-4Report Type:Periodic Company Report #WAES 00010489
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukopenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548390-6Report Type:Periodic Company Report #WAES 00010770
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Glossodynia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548393-1Report Type:Periodic Company Report #WAES 00010771
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548394-3Report Type:Periodic Company Report #WAES 00010773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG BID PO	

Date:03/24/00ISR Number: 3548397-9Report Type:Periodic Company Report #WAES 00010777
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Aerobid	C				
			Lasix	C				
			Serevent	C				
			Ventolin	C				
			Albuterol	C				
			Potassium Supplement	C				

Date:03/24/00ISR Number: 3548624-8Report Type:Periodic Company Report #WAES 00010223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder Vaginal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/OP	

Date:03/24/00ISR Number: 3548626-1Report Type:Periodic Company Report #WAES 00010224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548628-5Report Type:Periodic Company Report #WAES 00010225
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548631-5Report Type:Periodic Company Report #WAES 00010226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Tylenol Extra Strength	C				

Date:03/24/00ISR Number: 3548634-0Report Type:Periodic Company Report #WAES 00010229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:03/24/00ISR Number: 3548637-6Report Type:Periodic Company Report #WAES 00010231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cipro	C				

Date:03/24/00ISR Number: 3548640-6Report Type:Periodic Company Report #WAES 00010238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3548643-1Report Type:Periodic Company Report #WAES 00010252
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/24/00ISR Number: 3548651-0Report Type:Periodic Company Report #WAES 00010258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Ultram	C				
			Cyclobenzaprine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548655-8Report Type:Periodic Company Report #WAES 00010259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/P	

Date:03/24/00ISR Number: 3548659-5Report Type:Periodic Company Report #WAES 00010260
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Moduretic	C				

Date:03/24/00ISR Number: 3548661-3Report Type:Periodic Company Report #WAES 00010266
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548662-5Report Type:Periodic Company Report #WAES 00010270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548665-0Report Type:Periodic Company Report #WAES 00010273
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548668-6Report Type:Periodic Company Report #WAES 00010279
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Amaryl	C				
			Coumadin	C				
			Glucophage	C				
			Lipitor	C				
			Prilosec	C				
			Zestril	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548672-8Report Type:Periodic Company Report #WAES 00010284
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
	Vomiting							
			Ultram	C				

Date:03/24/00ISR Number: 3548675-3Report Type:Periodic Company Report #WAES 00010286
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548677-7Report Type:Periodic Company Report #WAES 00010293
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metabolic Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Tenormin	C				

Date:03/24/00ISR Number: 3548680-7Report Type:Periodic Company Report #WAES 00010299
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:03/24/00ISR Number: 3548682-0Report Type:Periodic Company Report #WAES 00010305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK

Date:03/24/00ISR Number: 3548702-3Report Type:Periodic Company Report #WAES 00010112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Flexeril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548705-9Report Type:Periodic Company Report #WAES 00010113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3548706-0Report Type:Periodic Company Report #WAES 00010116
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	4 MON
			Norvasc	C				
			Indapamide	C				

Date:03/24/00ISR Number: 3548708-4Report Type:Periodic Company Report #WAES 00010123
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Miacalcin	C				
			Prempro	C				
			Verapamil Hydrochloride	C				
			Chonodroitis	C				
			Glucosamine	I	C			

Date:03/24/00ISR Number: 3548710-2Report Type:Periodic Company Report #WAES 00010125
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Prilosec	C				
			Timoptic	C				
			Toprol Xl	C				
			Thyroid	C				

Date:03/24/00ISR Number: 3548713-8Report Type:Periodic Company Report #WAES 00010132
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548719-9Report Type:Periodic Company Report #WAES 00010133
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3548720-5Report Type:Periodic Company Report #WAES 00010778
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Flushing Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Darvocet-N	C				
			Ultram	C				
			Zantac	C				
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3548723-0Report Type:Periodic Company Report #WAES 00010134
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Discolouration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Effexor	C				
			Premarin	C				

Date:03/24/00ISR Number: 3548724-2Report Type:Periodic Company Report #WAES 00010779
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:03/24/00ISR Number: 3548727-8Report Type:Periodic Company Report #WAES 00010791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:03/24/00ISR Number: 3548730-8Report Type:Periodic Company Report #WAES 00010796
Age:76 YR Gender:Female I/FU:I

Outcome	PT
	Abnormal Dreams Dizziness Headache Influenza Like Illness Memory Impairment

	Muscular Weakness Myalgia Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actos	C				
			Celebrex	C				
			Dilantin	C				
			Lanoxin	C				
			Lopressor	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3548731-XReport Type:Periodic Company Report #WAES 00010136
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cipro	C				
			Detrol	C				
			Diovan	C				
			Elavil	C				
			Fioricet Tablets	C				
			Fosamaxc	C				
			Luvox	C				
			Omega-3	C				
			Oruvail	C				
			Prilosec	C				
			Synthroid	C				

Date:03/24/00ISR Number: 3548735-7Report Type:Periodic Company Report #WAES 00010141
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cough	Consumer	Vioxx	PS	Merck Research	
	Laryngitis				Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						
			Ambien	C		
			Klonopin	C		
			Zocor	C		
			Zyrtec	C		

Date:03/24/00ISR Number: 3548736-9Report Type:Periodic Company Report #WAES 00010148
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Anorexia				Laboratories Div	
	Feeling Abnormal				Merck Co Inc	ORAL
UNK/PO						
	Gastroenteritis		Prilosec	C		
	Helicobacter		Trental	C		
	Vomiting					
	Weight Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548739-4Report Type:Periodic Company Report #WAES 00010152
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Palpitations	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flonase	C				
			Maxzide	C				
			Miacalcin	C				
			Norvasc	C				
			Premarin	C				
			Sinemet	C				
			Tums	C				
			Ascoric Acid	C				
			Nitroglycerin	C				
			Pindolol	C				
			Vitamin E	C				
			Vitamins	C				

Date:03/24/00ISR Number: 3548741-2Report Type:Periodic Company Report #WAES 00010158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3548742-4Report Type:Periodic Company Report #WAES 00010797
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Prednisone C

Date:03/24/00ISR Number: 3548745-XReport Type:Periodic Company Report #WAES 00010164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Estrogenic Preparations	C				

Date:03/24/00ISR Number: 3548747-3Report Type:Periodic Company Report #WAES 00010177
Age: Gender:Female I/FU:I

Outcome	PT
	Dizziness
	Gastrooesophageal Reflux Disease
	Nausea
	Pollakiuria

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	45 DAY

Date:03/24/00ISR Number: 3548749-7Report Type:Periodic Company Report #WAES 00010804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				

Date:03/24/00ISR Number: 3548751-5Report Type:Periodic Company Report #WAES 00010191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:03/24/00ISR Number: 3548753-9Report Type:Periodic Company Report #WAES 00010812
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Influenza Like Illness Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548754-0Report Type:Periodic Company Report #WAES 00010203
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/24/00ISR Number: 3548755-2Report Type:Periodic Company Report #WAES 00010814
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548756-4Report Type:Periodic Company Report #WAES 00010206
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:03/24/00ISR Number: 3548758-8Report Type:Periodic Company Report #WAES 00010817
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	
	Oedema Peripheral							
			Cardura	C				
			Demadex	C				
			K-Dur	C				

Date:03/24/00ISR Number: 3548759-XReport Type:Periodic Company Report #WAES 00010219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	POP	
	Oral Soft Tissue Disorder							

Date:03/24/00ISR Number: 3548761-8Report Type:Periodic Company Report #WAES 00010823
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Lipitor	C				

Date:03/24/00ISR Number: 3548762-XReport Type:Periodic Company Report #WAES 00010221
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548764-3Report Type:Periodic Company Report #WAES 00010825
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548767-9Report Type:Periodic Company Report #WAES 00010831
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3548768-0Report Type:Periodic Company Report #WAES 00010848
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	

Date:03/24/00ISR Number: 3548770-9Report Type:Periodic Company Report #WAES 00010858
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	

Date:03/24/00ISR Number: 3548772-2Report Type:Periodic Company Report #WAES 00010877
Age:48 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/24/00ISR Number: 3548774-6Report Type:Periodic Company Report #WAES 00010881
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

			Flexeril	C
			Neurontin	C
			Vicoprofen	C

Date:03/24/00ISR Number: 3549261-1Report Type:Periodic Company Report #WAES 00010309
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO 5 DAY						
			Atenolol	C		
			Norvasc	C		
			Aspirin	C		

Date:03/24/00ISR Number: 3549262-3Report Type:Periodic Company Report #WAES 00010312
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						

			Celebrex	C		
			Celebrex	C		
			Zocor	C		

Date:03/24/00ISR Number: 3549264-7Report Type:Periodic Company Report #WAES 00010321
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	
		Representative						

Date:03/24/00ISR Number: 3549266-0Report Type:Periodic Company Report #WAES 00010322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK / PO	
		Representative	Methotrexate	C				

Date:03/24/00ISR Number: 3549269-6Report Type:Periodic Company Report #WAES 00010323
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK / PO	
		Representative						

Date:03/24/00ISR Number: 3549272-6Report Type:Periodic Company Report #WAES 00010324
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Diarrhoea Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY/ PO	
			Estrace	C				
			Pepcid	C				
			Zestril	C				

Date:03/24/00ISR Number: 3549275-1Report Type:Periodic Company Report #WAES 00010328
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3549276-3Report Type:Periodic Company Report #WAES 00010341
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:03/24/00ISR Number: 3549279-9Report Type:Periodic Company Report #WAES 00010343
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous Palpitations Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:03/24/00ISR Number: 3549282-9Report Type:Periodic Company Report #WAES 00010361
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		0.625/ 2.5 MG/ DAILY/ UNK	
			Zantac Unk	SS			UNKNOWN	UNK UNK
			Celebrex	SS			UNKNOWN	UNK UNK
			Tab Fosamax	SS		ORAL	UNK / PO	

			Prempro	SS		
0.625/2.5 MG						
			Prevacid	C		
			Prozac	C		
			Xanax	C		

Date:03/24/00ISR Number: 3549283-0Report Type:Periodic Company Report #WAES 00010365
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Urea Increased	Health	Vioxx	PS	Merck Research	
	Hyperkalaemia	Professional			Laboratories Div	
	Renal Tubular Disorder				Merck Co Inc	ORAL
12.5 MG /						
DAILY/ PO						
			Acetaminophen	C		

Date:03/24/00ISR Number: 3549284-2Report Type:Periodic Company Report #WAES 00010367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
UNK UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3549285-4Report Type:Periodic Company Report #WAES 00010369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	DAILY/

PO

Date:03/24/00ISR Number: 3549287-8Report Type:Periodic Company Report #WAES 00010374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/	DAILY/

PO

			Zyrtec	C				

Date:03/24/00ISR Number: 3549288-XReport Type:Periodic Company Report #WAES 00010376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Chest Pain Dyspnoea Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	PO

Date:03/24/00ISR Number: 3549289-1Report Type:Periodic Company Report #WAES 00010388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Depression Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/ UNK/ PO						
			Tab Vioxx 25 Mg	SS		ORAL
UNK/ QOD/PO						
			Claritin	C		
			Cozaar	C		
			Fareston	C		
			Plavix	C		
			Synthroid	C		

Date:03/24/00ISR Number: 3549291-XReport Type:Periodic Company Report #WAES 00010390
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK /PO						
			Natures Rx Msm Plus C	C		
			Tenormin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/00ISR Number: 3549293-3Report Type:Periodic Company Report #WAES 00010391
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Lopressor	C				

Date:03/24/00ISR Number: 3549295-7Report Type:Periodic Company Report #WAES 00010393
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Tachycardia Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY /PO; 12.5 MG / DAILY/ PO	
			Diabeta	C				

Date:03/24/00ISR Number: 3549296-9Report Type:Periodic Company Report #WAES 00010396
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Micturition Urgency	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID /PO	
			Avapro	C				
			Detrol	C				
			Lipitor	C				
			Premarin	C				

Verapamil C

Date:03/27/00ISR Number: 3479844-9Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Vioxx 25mg Merck	PS	Merck	ORAL	25MG 1QD ORAL	
	Pruritus	Professional						
	Rash Papular							

Date:03/27/00ISR Number: 3479845-0Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Health	Vioxx 25mf	PS		ORAL	ONE TABLE QD	
		Professional					ORAL	

Date:03/27/00ISR Number: 3479972-8Report Type:Direct Company Report #
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Health	Vioxx 25mg Merck	PS	Merck	ORAL	25MG 1 DAILY	
		Professional					ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/00ISR Number: 3480014-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coordination Abnormal		Lithium Carbonate					
Hospitalization -	Dialysis		300 Mg	PS		ORAL	300 MG TID	
Initial or Prolonged	Difficulty In Walking						ORAL	
	Drug Toxicity		Rofecoxib 25 Mg	SS		ORAL	25MG QD ORAL	
	Nystagmus		Stelazine	C				
	Oral Intake Reduced		Ditropan	C				
	Tremor							
	Visual Disturbance							

Date:03/27/00ISR Number: 3480197-0Report Type:Expedited (15-DaCompany Report #WAES 00031627
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional						
	Renal Failure	Company						
		Representative						

Date:03/27/00ISR Number: 3480198-2Report Type:Expedited (15-DaCompany Report #WAES 00031864
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Vioxx 25 Mg	PS		ORAL	25	
Other	Melaena	Professional					MG/DAILY/PO	
		Company						
		Representative						

Date:03/27/00ISR Number: 3480200-8Report Type:Expedited (15-DaCompany Report #WAES 00031848
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional						
	Renal Failure	Company						
		Representative						

Date:03/27/00ISR Number: 3480201-XReport Type:Expedited (15-DaCompany Report #WAES 00031643
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depressed Level Of	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Consciousness	Professional						
	Sedation							

Date:03/27/00ISR Number: 3480204-5Report Type:Expedited (15-DaCompany Report #WAES 00031865
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder	Health	Vioxx	PS		ORAL	25 MG/AM/PO	
Hospitalization -	Duodenal Ulcer	Professional	Aricept	C				
Initial or Prolonged	Gastric Ulcer Haemorrhage	Company	Lopid	C				
Other		Representative	Miacalcin	C				
			Atenolol	C				

Minerals (+)
Vitamins C

Date:03/27/00ISR Number: 3480206-9Report Type:Expedited (15-DaCompany Report #WAES 00031879
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Gastrointestinal	Professional						
Initial or Prolonged	Haemorrhage	Company	Fosamax	C				
Other		Representative						

Date:03/27/00ISR Number: 3480211-2Report Type:Expedited (15-DaCompany Report #WAES 00031903
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Professional						
	Congestive	Company						
	Pulmonary Oedema	Representative						

Date:03/27/00ISR Number: 3480213-6Report Type:Expedited (15-DaCompany Report #WAES 00031907
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
Initial or Prolonged	Dermatitis	Professional					DAILY / PO	
	Pruritus							

Date:03/27/00ISR Number: 3480214-8Report Type:Expedited (15-DaCompany Report #WAES 00031912
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Initial or Prolonged	Renal Failure						/ PO	
			Cipro	C				

Date:03/27/00ISR Number: 3480218-5Report Type:Expedited (15-DaCompany Report #WAES 00032061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Initial or Prolonged	Haemorrhage	Professional					/ PO	
		Company Representative						

Date:03/27/00ISR Number: 3480225-2Report Type:Expedited (15-DaCompany Report #WAES 99101950
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
	Drug Level Changed	Health					/ PO	
	Suicidal Ideation	Professional	Ativan	C				
			Lithium Carbonate	C				

Date:03/27/00ISR Number: 3480259-8Report Type:Expedited (15-DaCompany Report #WAES 00012295
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/27/00ISR Number: 3480260-4Report Type:Expedited (15-DaCompany Report #WAES 00011909
Age:60 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ PO	

Date:03/27/00ISR Number: 3480262-8Report Type:Expedited (15-DaCompany Report #WAES 00030079
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Lung Disorder Respiratory Disorder		Indocin	C				

Date:03/27/00ISR Number: 3480263-XReport Type:Expedited (15-DaCompany Report #WAES 00031486
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Ecchymosis	Professional	Elavil	C				

Initial or Prolonged Disability	Obstructive Airways Disorder Respiratory Disorder Swelling	Company Representative	Neurontin	C

Date:03/27/00ISR Number: 3480265-3Report Type:Expedited (15-DaCompany Report #WAES 00031629
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Prothrombin Time	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Prolonged	Professional Company Representative						

Date:03/27/00ISR Number: 3480297-5Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache	Health	Vioxx	PS		ORAL	25 MG PO QAM	5 DAY
	Hypertension Hypertensive Crisis Nervousness	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/00ISR Number: 3480298-7Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Health	Vioxx	PS		ORAL	25 MG PO QD	4 DAY
Hospitalization - Initial or Prolonged	Gastritis Erosive Haematemesis Malaise	Professional	Aspirin	C				

Date:03/27/00ISR Number: 3480305-1Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Coumadin Vioxx	PS SS		ORAL	4 MG PO QD PRN	

Date:03/27/00ISR Number: 3480435-4Report Type:Expedited (15-DaCompany Report #WAES 00035047
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nail Discolouration Nail Disorder Nail Dystrophy Onychomycosis	Foreign Health Professional Other	Tab Vioxx (Rofecoxib) Acetaminophen/Codeine Phosphate Benserazide/Levodopa	PS C C		ORAL	12.5 MG PO	

Date:03/27/00ISR Number: 3480441-XReport Type:Expedited (15-DaCompany Report #WAES 00035647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke Hypertension	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

			Professional			
			Other			

Date:03/27/00ISR Number: 3480442-1Report Type:Expedited (15-DaCompany Report #WAES 00035611
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis	Foreign	Tab Vioxx					
	C-Reactive Protein	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	47 DAY
	Increased	Professional	Liq Dipyrone	SS		ORAL	20 DROPS PO	1 DAY
	Leukopenia	Other	Cortisone	C				
			Sulfasalazine	C				

Date:03/27/00ISR Number: 3480457-3Report Type:Expedited (15-DaCompany Report #WAES 00037906
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Foreign	Tab Vioxx					
		Consumer	(Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/00ISR Number: 3480487-1Report Type:Expedited (15-DaCompany Report #001-0981-M000052
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Health Professional	Lipitor (Atorvastatin)	PS		ORAL	10 MG (DAILY), PER ORAL	
	Petechiae	Company Representative						
	Thrombocytopenia							
			Vioxx	SS			20 MG (DAILY)	
			Synthroid (Levothy-Roxine Sodium)	C				
			.....	C				

Date:03/27/00ISR Number: 3480540-2Report Type:Expedited (15-DaCompany Report #WAES 00022299
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Visual	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Mental Impairment							
		Company Representative	Eldepryl	C				
			Permax	C				
			Sinemet Cr	C				
			Zaroxolyn	C				
			Amantadine	C				

Date:03/27/00ISR Number: 3480542-6Report Type:Expedited (15-DaCompany Report #WAES 00031226
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Neoplasm	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/TID/PO	
Hospitalization -	Condition Aggravated	Health						

Initial or Prolonged	Dysphagia Mouth Ulceration Pharyngitis Renal Failure	Professional				

Date:03/27/00ISR Number: 3480545-1Report Type:Expedited (15-DaCompany Report #WAES 00031063
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Grand Mal Convulsion	Professional				
MG/DAILY/PO						
Other	Tremor	Company Representative	Ambien	C		
			Klor-Con	C		
			Synthroid	C		
			Hydrochlorothiazide (+) Triamter	C		

Date:03/27/00ISR Number: 3480549-9Report Type:Expedited (15-DaCompany Report #WAES 00031649
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hallucination	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
			Ambien	C		
			Centrum	C		
			Os-Cal	C		

				[Therapy Unspecified]	C		

Date:03/27/00ISR Number: 3480551-7Report Type:Expedited (15-DaCompany Report #WAES 00031768
Age:30 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Thromboplastin Time Prolonged	Professional	Prinivil	C				
	Blood Creatinine Increased							
	Blood Urea Increased							
	Coombs Direct Test Positive							
	Dialysis							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Prothrombin Time Shortened							
	Thrombocytopenia							
	Vaginal Haemorrhage							
	White Blood Cell Count Increased							

Date:03/27/00ISR Number: 3480558-XReport Type:Expedited (15-DaCompany Report #WAES 00035574
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	9 DAY
	Blood Potassium Increased		[Compositon Unspecified]	C				
	Cardiac Failure		Enalapril Maleate	C				
	Congestive Creatinine Renal Clearance Decreased		Morhine So4 Pentahydrate	C				
	Fluid Retention							
	Oedema Peripheral							
	Weight Increased							

Date:03/27/00ISR Number: 3480559-1Report Type:Expedited (15-DaCompany Report #WAES 00035575
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	5 DAY
	Cardiac Failure Congestive Fluid Retention		Leflunomide	C				

Date:03/27/00ISR Number: 3480560-8Report Type:Expedited (15-DaCompany Report #WAES 00035622
Age:89 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Diverticulum Intestinal
Hospitalization - Initial or Prolonged	Gastrointestinal Angiodysplasia

	Gastrointestinal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	15 DAY

Date:03/27/00ISR Number: 3480574-8Report Type:Expedited (15-DaCompany Report #WAES 00031481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Idiopathic	Health	Tab Vioxx Unk	PS		ORAL	PO	2 MON
Initial or Prolonged	Thrombocytopenic Purpura	Professional						
	Petechiae	Company						
	Thrombocytopenia	Representative						

Date:03/27/00ISR Number: 3480578-5Report Type:Expedited (15-DaCompany Report #WAES 00031584
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 25mg	PS		ORAL	25	
	Congestive	Professional					MG/DAILY/PO	
	Dyspnoea Paroxysmal		Amaryl	C				
	Nocturnal		Avandia	C				
	Oedema Peripheral		Persantine	C				
			Plavix	C				

Date:03/27/00ISR Number: 3480581-5Report Type:Expedited (15-DaCompany Report #WAES 00030763
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged	Diarrhoea	Health		
MG/DAILY/PO				
	Dyspnoea Exertional	Professional	Coumadin	C
	Dyspnoea Paroxysmal		Cozaar	C
	Nocturnal			
	Fluid Retention			
	Insomnia			
	Pneumonia			
	Pulmonary Oedema			

Date:03/27/00ISR Number: 3480584-0Report Type:Expedited (15-DaCompany Report #WAES 00032012
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Peptic Ulcer Perforation	Health	Tab Vioxx 25mg	PS		ORAL
25						
Hospitalization -		Professional				
MG/DAILY/PO						
Initial or Prolonged		Company Representative	Oxycontin	C		

Date:03/27/00ISR Number: 3480585-2Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Creatinine
Initial or Prolonged	Increased
	Blood Urea Increased

	Oliguria Renal Failure Renal Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urine Flow Decreased	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO
		Company Representative	Lasix	C			

Date:03/27/00ISR Number: 3480780-2Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anuria Blood Creatinine Increased Blood Urea Increased Condition Aggravated Hyperkalaemia Medication Error Oliguria Renal Disorder Renal Failure Weight Decreased	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO
		Company Representative	Lasix	C			

Date:03/27/00ISR Number: 3480969-2Report Type:Expedited (15-DaCompany Report #WAES 00015179
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Delusion Drug Effect Decreased Fear Ideas Of Reference	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	UNK PO
			Acamprosate Calcium	SS			UNKNOWN UNKNOWN

Medication Error
Overdose
Paranoia
Psychotic Disorder

Date:03/27/00ISR Number: 3481242-9Report Type:Expedited (15-DaCompany Report #WAES 00035574
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	1	WK
	Cardiac Failure Congestive Fluid Retention	Professional						

Date:03/27/00ISR Number: 3481244-2Report Type:Expedited (15-DaCompany Report #WAES 00035575
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Other	Blood Creatinine Increased
	Cardiac Failure
	Cardiac Failure

	Congestive Fluid Retention						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	1	WK

Date:03/27/00ISR Number: 3481245-4Report Type:Expedited (15-DaCompany Report #WAES 00035587
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Pruritus	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	5 DAY
		Other	Clopidogrel Bisulfate	C				
			Dipyrone	C				
			Furosemide	C				
			Naloxone Hydrochloride (+)					
			Tilidine	C				

Date:03/27/00ISR Number: 3481249-1Report Type:Expedited (15-DaCompany Report #WAES 00039115
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Coma	Other	(Rofecoxib)	PS		ORAL	8 DAY	
	Encephalopathy		Acetaminophen	C				
	Lung Infiltration		Lorazepam	C				
	Thrombocytopenia		Pygeum African Extract	C				
			Tramadol Hcl	C				

Date:03/27/00ISR Number: 3481334-4Report Type:Expedited (15-DaCompany Report #WAES 00012330
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Clostridium Colitis	Professional					PO	
	Colitis	Company	Celebrex	C				
	Colitis Ischaemic	Representative	Miacalcin	C				
	Erythropenia		Premarin	C				
	Gastric Ulcer Haemorrhage		Synthroid	C				
	Gastrointestinal Disorder		Vicodin Tablets	C				
	Gastrointestinal Ulcer		Zantac	C				
	Inflammation		Aspirin	C				
	Leukocytosis		Verapamil	C				
	Lymphocyte Count Decreased							
	Melaena							
	Metastasis							
	Neutrophilia							
	Rectal Ulcer							
	Thrombocythaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/00ISR Number: 3481336-8Report Type:Expedited (15-DaCompany Report #WAES 00010660
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Consumer	Tab Vioxx Unk	PS		ORAL	UNK DAILY PO	
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Estrace	C				
Other	Arteriopathic Disease							
	Colitis							
	Crohn'S Disease							
	Enteritis							
	Gastrointestinal Haemorrhage							
	Haemorrhage							
	Inflammation							
	Intestinal Ischaemia							
	Intestinal Obstruction							
	Mesenteric Vascular Insufficiency							
	Pain							
	Vomiting							

Date:03/27/00ISR Number: 3481337-XReport Type:Expedited (15-DaCompany Report #WAES 00010629
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Hyperthyroidism	Health Professional						
	Malaise		Coumadin	C				
	Oedema Peripheral		Depakote	C				
	Renal Impairment		Lasix	C				
	Tremor		[Composition Unspecified]	C				

Date:03/27/00ISR Number: 3481338-1Report Type:Expedited (15-DaCompany Report #WAES 00020429
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Diarrhoea Haemorrhagic	Health	Tab Vioxx 25 Mg	PS	ORAL
25 MG DAILY					
Initial or Prolonged	Gastrointestinal	Professional			
PO					
	Haemorrhage	Other	Ambien	C	
	Haematocrit Decreased		Axid	C	
	Haemoglobin Decreased		Carafate	C	
	Haemorrhoids		Lortab	C	
			Prozac	C	
			Lithium Bromide	C	

Date:03/27/00ISR Number: 3481339-3Report Type:Expedited (15-DaCompany Report #WAES 00021415
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization -	Asthenia
Initial or Prolonged	Dyspepsia
	Faecal Occult Blood
	Positive
	Gastroenteritis
	Helicobacter
	Haematemesis
	Haematocrit Decreased

		Haemoglobin Decreased					
		Heart Rate Decreased					
		Melaena	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophagitis Haemorrhagic	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG DAILY							
		Orthostatic Hypotension	Professional				
PO							
		Upper Gastrointestinal	Company	Indocin			
		Haemorrhage	Representative	(Indomethacin) Unk	SS		
UNKNOWN	UNKNOWN						
				Diovan	C		
				Viagra	C		
				Gastrointestinal			
				Preparations	C		

Date:03/28/00ISR Number: 3480994-1Report Type:Expedited (15-DaCompany Report #ZANA030589 (0)
Age:52 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Decreased	Health	Zanaflex (Tizanidine			
		Drug Interaction	Professional	Hydrochloride)	PS		ORAL
TWO 4MG DOSES							
		Dysphagia					
DAILY, PER							
		Hallucination					
ORAL							
		Heart Rate Increased		Vioxx (Rofecoxib)	SS		
TWO 25MG							
		Psychotic Disorder					
DOSES DAILY							

Date:03/28/00ISR Number: 3480995-3Report Type:Expedited (15-DaCompany Report #ZANA030590 (0)
Age:40 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bradycardia	Health	Zanaflex (Tizanidine			
		Chest Discomfort	Professional	Hydrochloride)	PS		ORAL
4 MG DAILY,							
		Dizziness					
PER ORAL							

	Hypotension		Vioxx	SS		
25 MG						
			Maxalt	C		

Date:03/28/00ISR Number: 3481259-4Report Type:Expedited (15-DaCompany Report #000214-SK614
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Alcoholic Liver Disease	Health	Celebrex	PS		ORAL
PO						
Hospitalization -	Blood Bilirubin Increased	Professional	Vioxx	SS		ORAL
PO						
Initial or Prolonged	Cholestasis		Metoclopramide	C		
Other	Condition Aggravated		Zolpidem	C		
	Hepatic Cirrhosis		Losartan Potassium	C		
	Hepatic Neoplasm		Amlodipine Besylate	C		
	Malignant		Gabapentin	C		
	Hepatitis Cholestatic		Acetaminophen	C		
	Jaundice		Oxycodone			
	Liver Function Test		Hydrochloride	C		
	Abnormal		Clonazepam	C		
	Prothrombin Time					
	Prolonged					

Date:03/29/00ISR Number: 3481461-1Report Type:Direct Company Report #
Age:17 YR Gender:Male I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx 25 Mg	PS		ORAL	TWO TABLETS	
	Pruritus						EVERY MORNING	
	Urticaria						ORAL	
			Adderall	C				
			Paxil	C				

Date:03/29/00ISR Number: 3481463-5Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urea Increased		Vioxx 25 Mg Merck	PS	Merck		25 MG	1 MON
Hospitalization - Initial or Prolonged	Hyperkalaemia		Prilosec	C				
			Pravachol	C				
			Ntg Patch	C				
			Fe So4	C				
			Reglan	C				
			Oscal	C				
			Epogen	C				

Date:03/29/00ISR Number: 3481477-5Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS			25 MGM	
	Sedation		Aciphex	C				
			Klonopin	C				
			Remeron	C				

Date:03/29/00ISR Number: 3481532-XReport Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health Professional	Vioxx 25 Mg Merck	PS	Merck		2 QD X 4 DAYS; 1 QD X 7 DYS	

Date:03/29/00ISR Number: 3539136-6Report Type:Periodic Company Report #PERCOCET2000-00038
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Sedation	Consumer	Percocet	PS	Endo Pharmaceuticals Inc	ORAL	1 TAB Q4HR PO	
			Provigil	SS		ORAL	200 MG BID PO	
			Vioxx	SS		ORAL	25 MG QHS PO	
			Skelaxin	SS		ORAL	1 TAB Q4HR PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/00ISR Number: 3482279-6Report Type:Expedited (15-DaCompany Report #WAES 00031446
Age:60 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 WK
	Dermatitis Exfoliative	Professional						
	Erythema Multiforme	Company Representative						

Date:03/31/00ISR Number: 3482971-3Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis Exfoliative		Vioxx	PS		ORAL	PO QD	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Drug Hypersensitivity		Flovent	C				
	Mucous Membrane Disorder		Serevent	C				
	Rash Papular		Lipitor	C				
			Symmetrel	C				
			Proscar	C				

Date:04/03/00ISR Number: 3482937-3Report Type:Direct Company Report #
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Vioxx 25 Mg	PS		ORAL	25 MG PO QHS	
	Dyspnoea Exertional		Demulen	C				
	Pain		Excedrin	C				

Date:04/03/00ISR Number: 3483035-5Report Type:Direct Company Report #
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Confusional State		Vioxx 12.5 Mg Merck	PS	Merck	ORAL
12.5MG QD						
Initial or Prolonged	Csf Lymphocyte Count					
ORAL						
Disability	Increased		Ibuprofen	SS		ORAL
200-600						
	Csf Protein Increased					
MG/PRN/ORAL						
	Headache					
	Hypoaesthesia					
	Meningitis Aseptic					
	Mental Impairment					
	Migraine					

Date:04/03/00ISR Number: 3483271-8Report Type:Expedited (15-DaCompany Report #WAES 00022280
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Gastrointestinal	Professional	Aricept	C		
	Haemorrhage	Other	Combivent	C		
			Isordil	C		
			K-Dur	C		
			Lasix	C		
			Lopressor	C		
			Plavix	C		
			Amiodarone	C		
			Aspirin	C		
			Digoxin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/00ISR Number: 3483276-7Report Type:Expedited (15-DaCompany Report #WAES 00032015
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Tab Vioxx Unk	PS		ORAL	25 MG/	
Life-Threatening	Gastrointestinal	Professional					DAILY/PO	
Disability	Haemorrhage	Company	Cardizem	C				
Other	Knee Arthroplasty	Representative	Coumadin	C				
	Stress		Tylenol	C				
			Zestril	C				

Date:04/03/00ISR Number: 3483284-6Report Type:Expedited (15-DaCompany Report #WAES 00032421
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Duodenal Ulcer	Professional					MG/DAILY/PO	
	Haemorrhage	Company	Procardia Xl	C				
	Gastric Ulcer Haemorrhage	Representative	Atenolol	C				

Date:04/03/00ISR Number: 3483288-3Report Type:Expedited (15-DaCompany Report #WAES 00032244
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
Initial or Prolonged	Loss Of Consciousness		Prilosec	C				
	Syncope		Zestoretic	C				

Date:04/03/00ISR Number: 3483291-3Report Type:Expedited (15-DaCompany Report #WAES 00032408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Overdose	Health Professional Company Representative	Tab Vioxx Unk Tylenol	PS C			ORAL PO

Date:04/03/00ISR Number: 3483294-9Report Type:Expedited (15-DaCompany Report #WAES 00021714
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL PO		
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Professional Company Representative	Paxil Sinemet	C C				
Other	Flatulence							

Date:04/03/00ISR Number: 3483295-0Report Type:Expedited (15-DaCompany Report #WAES 00032570
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/00ISR Number: 3483297-4Report Type:Expedited (15-DaCompany Report #WAES 00032601
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	12.5 MG /DAILY/PO	
		Company Representative	Plavix	C				

Date:04/03/00ISR Number: 3483305-0Report Type:Expedited (15-DaCompany Report #WAES 99105147
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Tab Vioxx					
	Cardiac Failure	Other	(Rofecoxib)	PS		ORAL	PO 25 MG	9 DAY
	Oedema Peripheral		Allopurinol	C				
			Captopril	C				
			Furosemide	C				
			Omeprazole	C				
			Paroxetine	C				

Date:04/03/00ISR Number: 3483306-2Report Type:Expedited (15-DaCompany Report #WAES 00018254
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	25 MG PO	3 DAY
		Professional	Acetaminophen	C				
			Haldol	C				
			Marcoumar	C				
			Navelbine	C				
			Paspertin	C				
			Tramadol Hcl	C				
			Zantic	C				

Date:04/03/00ISR Number: 3483335-9Report Type:Expedited (15-DaCompany Report #WAES 00025674
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antibody Test Positive	Foreign	Tab Vioxx					
Hospitalization -	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	25.0 MG	2 WK
Initial or Prolonged	Gastroenteritis	Professional	Naloxone					
	Helicobacter		Hydrochloride (+)					
	Gastrointestinal		Tilidine	C				
	Haemorrhage		Ranitidine	C				
	Haemoglobin Decreased							
	Melaena							

Date:04/03/00ISR Number: 3483354-2Report Type:Expedited (15-DaCompany Report #WAES 00032730
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal	Professional						
	Haemorrhage	Company	Celebrex	C				
	Gastrointestinal Ulcer	Representative	Darvon	C				
			Niferex	C				
			Norvasc	C				

			Phenergan (Promethazine Hcl)	C		
			Restoril	C		
			Suprax	C		
			Tylenol	C		
			Aspirin	C		
			....	C		

Date:04/03/00ISR Number: 3483419-5Report Type:Expedited (15-DaCompany Report #WAES 99075018
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower Diarrhoea	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
	Faeces Discoloured	Professional	Aspirin	SS		ORAL	PO	
	Gastrointestinal	Company	Allopurinol	SS		ORAL	100 MG PO	
	Haemorrhage Melaena	Representative	Prinivil	C				
			Metronidazole	C				
			Amoxicillin Trihydrate (+) Clavulanate P	C				
			Citalopram	C				
			Glimepiride	C				

Date:04/03/00ISR Number: 3483422-5Report Type:Expedited (15-DaCompany Report #WAES 00032883
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Endocarditis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Life-Threatening Hospitalization - Initial or Prolonged Disability	Blood Thrombin Decreased Haemorrhage International Normalised Ratio Increased Pulmonary Embolism Sudden Death	Professional	Coumadin	C				
			Plaquenil	C				
			Folic Acid	C				
			Prednisone	C				

Date:04/03/00ISR Number: 3483441-9Report Type:Expedited (15-DaCompany Report #WAES 00035668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/03/00ISR Number: 3483442-0Report Type:Expedited (15-DaCompany Report #WAES 00032455
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Haemorrhage Intracranial Haemorrhagic Stroke	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/00ISR Number: 3483444-4Report Type:Expedited (15-DaCompany Report #WAES 00031768
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Thromboplastin Time Shortened	Professional	Prinivil	C				
	Blood Creatinine Increased							
	Blood Urea Increased							
	Coombs Indirect Test Positive							
	Dialysis							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Hypokalaemia							
	Leukocytosis							
	Neutropenia							
	Post Procedural Haemorrhage							
	Thrombocytopenia							
	Vaginal Haemorrhage							

Date:04/03/00ISR Number: 3483445-6Report Type:Expedited (15-DaCompany Report #WAES 00031903
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Professional Company Representative						

Date:04/03/00ISR Number: 3483449-3Report Type:Expedited (15-DaCompany Report #WAES 00031624
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Tab Vioxx Unk	PS		ORAL	PO	

		Professional Company Representative				

Date:04/03/00ISR Number: 3483452-3Report Type:Expedited (15-DaCompany Report #WAES 00031440
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/						
Initial or Prolonged	Congestive	Professional				
DAILY/PO						
Other	Cardiomyopathy		Coumadin	C		
	Ejection Fraction		Lanoxin	C		
	Abnormal		Vasotec	C		

Date:04/03/00ISR Number: 3483455-9Report Type:Expedited (15-DaCompany Report #WAES 00021660
Age: Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Cardiac Failure	Health
	Congestive	Professional
	Renal Failure	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/00ISR Number: 3483486-9Report Type:Expedited (15-DaCompany Report #WAES 99101575
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Life-Threatening	Abdominal Pain Lower	Professional					MG/BID/PO	
Hospitalization -	Abdominal Rigidity		Gastrointestinal					
Initial or Prolonged	Asthenia		Preparation Unk	SS				
Disability	Condition Aggravated		Imdur	C				
Other	Constipation		Senokot (Senna)	C				
	Coordination Abnormal							
	Dyspnoea Exertional							
	Emotional Distress							
	Fall							
	Gastric Ulcer Perforation							
	Head Injury							
	Hypertension							
	Hyponatraemia							
	Post Procedural							
	Complication							
	Weight Decreased							

Date:04/03/00ISR Number: 3483489-4Report Type:Expedited (15-DaCompany Report #WAES 99090752
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Faeces	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Coumadin	C				

Date:04/03/00ISR Number: 3483541-3Report Type:Expedited (15-DaCompany Report #WAES 00030241
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypoglycaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Life-Threatening	Myocardial Infarction	Professional						
			Epogen	C				

Date:04/03/00ISR Number: 3483548-6Report Type:Expedited (15-DaCompany Report #WAES 00032552
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Eye Haemorrhage							
	Visual Disturbance		Mestinon	C				
			Premarin	C				
			Procardia	C				
			Zestril	C				
			Insulin	C				

Date:04/03/00ISR Number: 3483549-8Report Type:Expedited (15-DaCompany Report #WAES 00035675
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Health Professional	Vioxx (Rofecoxib)	PS		ORAL		

Date:04/03/00ISR Number: 3483550-4Report Type:Expedited (15-DaCompany Report #WAES 00035663
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
	Sudden Death	Health Professional	Aluminum Hydroxide/Magnesiumhydroxide	C				
			Candesartan Cilexetil	C				
			Digoxin B-Acetyldigoxin	C				
			Molsidomine	C				
			Phenprocoumon	C				
			Verapamil Hcl	C				
			Xipamide	C				

Date:04/03/00ISR Number: 3483551-6Report Type:Expedited (15-DaCompany Report #WAES 00022509
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematemesis	Health Professional	Vioxx	PS		ORAL	50 MG/ DAILY/ PO	2 MON
	Oesophageal Haemorrhage							
	Oesophagitis							

Date:04/03/00ISR Number: 3483552-8Report Type:Expedited (15-DaCompany Report #WAES 00032344
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health Professional Company Representative	Vioxx Unk	PS		ORAL	PO	

Date:04/03/00ISR Number: 3483553-XReport Type:Expedited (15-DaCompany Report #WAES 00032325
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Consumer	Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Haematuria Hypertension Weight Increased		Lipitor	C				

Date:04/03/00ISR Number: 3483648-0Report Type:Expedited (15-DaCompany Report #WAES 00032298
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased

Rhabdomyolysis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Other	Tab Vioxx Unk	PS		ORAL	UNKNOWN PO	

Date:04/03/00ISR Number: 3483649-2Report Type:Expedited (15-DaCompany Report #WAES 99081654
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activated Partial	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Other	Thromboplastin Time	Professional					PO	
	Prolonged		Depakote	C				
	Blood Alkaline		Lipitor	C				
	Phosphatase Increased		Mellaril	C				
	Blood Fibrinogen		Paxil	C				
	Increased		Synthroid	C				
	Cerebral Ischaemia		Docusate Sodium	C				
	Chromaturia		Iron (Unspecified)	C				
	Condition Aggravated		Lithium Bromide	C				
	Ecchymosis		Trazodone	C				
	Gliosis							
	Glycosylated Haemoglobin							
	Increased							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hepatitis A Antibody							
	Positive							
	Hepatitis B Surface							
	Antigen Positive							
	Hypoproteinaemia							
	Intentional Self-Injury							
	Ketonuria							
	Lethargy							
	Mental Impairment							
	Nuclear Magnetic							
	Resonance Imaging Brain							
	Abnormal							
	Prothrombin Time							
	Prolonged							
	Red Blood Cell							

Sedimentation Rate
Increased
Temporal Arteritis
Thyroxine Increased

Date:04/03/00ISR Number: 3483650-9Report Type:Expedited (15-DaCompany Report #WAES 00021894
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	UNKNOWN PO	
	Congestive	Professional						
	Renal Failure Acute	Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/00ISR Number: 3483651-0Report Type:Expedited (15-DaCompany Report #WAES 00022273
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Gastrointestinal	Professional					PO	
	Haemorrhage	Other	Warfarin Unk	SS			UNKNOWN	3 MG DAILY
	Haematocrit Decreased						UNKNOWN	
	Haemoglobin Decreased		Ditropan	C				
	International Normalised		Oxycontin	C				
	Ratio Increased		Pepcid	C				
	Rectal Haemorrhage		Zoloft	C				
			Clindamycin	C				
			Ferrous Sulfate	C				
			Verapamil	C				

Date:04/03/00ISR Number: 3483655-8Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Blood Creatinine	Professional					PO	
Initial or Prolonged	Increased	Company	Lasix	C				
Other	Blood Urea Increased	Representative	Lisinopril	C				
	Cardiac Failure							
	Congestive							
	Condition Aggravated							
	Hyperkalaemia							
	Medication Error							
	Oliguria							
	Renal Failure Acute							
	Weight Decreased							

Date:04/03/00ISR Number: 3483660-1Report Type:Expedited (15-DaCompany Report #WAES 00039136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Tab Vioxx					
	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL	25 MG PO	
	Malaise	Professional	Nifedipine	C				

Date:04/03/00ISR Number: 3483667-4Report Type:Expedited (15-DaCompany Report #WAES 00039137
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Tab Vioxx					
	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL	25 MG PO	
	Malaise	Professional						

Date:04/03/00ISR Number: 3483672-8Report Type:Expedited (15-DaCompany Report #WAES 00035662
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/00ISR Number: 3483676-5Report Type:Expedited (15-DaCompany Report #WAES 00031937
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Dizziness						MG/DAILY/PO	
	Paresis		Aspirin	C				
	Vertigo		Vitamins	C				

Date:04/03/00ISR Number: 3483693-5Report Type:Expedited (15-DaCompany Report #WAES 00032136
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:04/03/00ISR Number: 3483696-0Report Type:Expedited (15-DaCompany Report #WAES 00022128
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	2 MON
	Abdominal Pain Upper		[Therapy					
	Cerebrovascular Accident		Unspecified]	C				
	Coagulopathy							
	Haemorrhage Subepidermal							

Date:04/03/00ISR Number: 3483698-4Report Type:Expedited (15-DaCompany Report #WAES 00032256
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO 10 DAY						
Initial or Prolonged	Pancreatitis		Hydrodiuril	C		
			Procardia	C		
			Aspirin	C		
			Orphenadrine	C		

Date:04/03/00ISR Number: 3483702-3Report Type:Expedited (15-DaCompany Report #WAES 00032303
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL
PO						
	Paresis					

Date:04/03/00ISR Number: 3487024-6Report Type:Expedited (15-DaCompany Report #WAES 00022489
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Hernia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Abdominal Mass	Professional				
MG/DAILY/PO						
	Abdominal Pain					
	Asthenia					
	Condition Aggravated					
	Incisional Hernia					
	Procedural Site Reaction					
	Urinary Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/00ISR Number: 3484093-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS		ORAL	2.5 MG PO QD	2 WK
	Drug Level Above		Lanoxin	SS		ORAL	0.25 MG PO QD	
	Therapeutic							
LONG TERM -								
	Heart Rate Decreased							
YEARS								
	Vision Blurred							

Date:04/05/00ISR Number: 3484106-XReport Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum	Health	Vioxx	PS		ORAL	PRN ORAL	
Initial or Prolonged	Haematochezia	Professional	Hypertensive					
	Haemorrhoids		Medications	C				
	Large Intestinal Ulcer							

Date:04/05/00ISR Number: 3484385-9Report Type:Expedited (15-DaCompany Report #WAES 00032771
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephritis Interstitial	Foreign	Tab Vioxx					
Hospitalization -	Renal Failure Acute	Health	(Rofecoxib)	PS		ORAL	125 MG, PO	8 DAY
Initial or Prolonged		Professional	Ciprofloxacin	C				
Disability			Digoxin	C				

Date:04/05/00ISR Number: 3484407-5Report Type:Expedited (15-DaCompany Report #WAES 00032936
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Disease	Professional					MG/DAILY/PO	
	Palpitations	Company Representative						

Date:04/05/00ISR Number: 3484410-5Report Type:Expedited (15-DaCompany Report #WAES00035321
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulopathy	Foreign	Tab Vioxx					
	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG, PO	
	Haemorrhage		Amlodipine					
	Hyperbilirubinaemia		Benzenesulfonate	C				
			Bicalutamide	C				
			Doxazosin	C				
			Metformin	C				
			Triptorelin Acetate	C				
			Warfarin	C				

Date:04/05/00ISR Number: 3484413-0Report Type:Expedited (15-DaCompany Report #WAES 00035665
Age:81 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Gastric Ulcer	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25.0 MG, PO	22 DAY
	Professional	Maprotiline Hcl	C				
		Oxybutycincl	C				

Date:04/05/00ISR Number: 3484415-4Report Type:Expedited (15-DaCompany Report #WAES 00038583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:04/05/00ISR Number: 3484417-8Report Type:Expedited (15-DaCompany Report #WAES 00036124
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Haemolytic Anaemia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	1 DAY
			Tab Acetaminophen	SS		ORAL	500 MG, PO	

Date:04/05/00ISR Number: 3484419-1Report Type:Expedited (15-DaCompany Report #WAES 00038598
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	12 DAY
	Confusional State Dehydration	Professional						

Gastritis
Hypotension
Renal Failure Acute
Viral Infection

Date:04/05/00ISR Number: 3484422-1Report Type:Expedited (15-DaCompany Report #WAES 00039155
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces	Foreign	Tab Vioxx					
	Colitis Ulcerative	Health	(Rofecoxib)	PS		ORAL	25 MG, PO	16 DAY
	Diarrhoea Haemorrhagic	Professional	Deflazacort	C				
			Methotrexate	C				
			Sulfasalazine	C				

Date:04/05/00ISR Number: 3484437-3Report Type:Expedited (15-DaCompany Report #WAES 99092054
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angiopathy
Other	Blood Albumin Decreased
	Blood Urea Increased
	Calcinosis
	Cardiomegaly

	Dehydration						
	Haematocrit Decreased						
	Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypotension	Study	Tab Rofecoxib Unk	PS		ORAL	25
	Lung Infiltration	Health					MG/DAILY/PO
	Mitral Valve Incompetence	Professional	Tab Placebo Unk	SS		ORAL	1
	Oedema						TABLET/BID/PO
	Proteinuria		Tab Acetaminophen				
	Pulmonary Fibrosis		Unk	SS		ORAL	PRN/PO
	Respiratory Distress		Avandia	C			
	Tricuspid Valve		Cardura	C			
	Incompetence		Cozaar	C			
			Glucophage	C			
			Lasix	C			
			Lipitor	C			
			Voltaren	C			
			Glipizide	C			

Date:04/05/00ISR Number: 3484442-7Report Type:Expedited (15-DaCompany Report #WAES 00030254
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Hospitalization -	Congestive	Professional					MG/DAILY/PO
Initial or Prolonged	Condition Aggravated	Company	Tab Cozaar Unk	SS		ORAL	50
Disability	Drug Interaction	Representative					MG/DAILY/PO
Other	Dyspnoea		Actos	C			
	Fluid Retention		Demadex	C			
	Muscle Spasms		Flovent	C			
	Nephropathy Toxic		K-Dur	C			
	Oedema		Lasix	C			
	Oliguria		Serevent	C			
	Renal Failure Acute		Zocor	C			
	Respiratory Rate		Glyburide	C			

	Increased		Metoprolol	C
	Weight Increased			

Date:04/05/00ISR Number: 3484482-8Report Type:Expedited (15-DaCompany Report #WAES 00020820
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Vioxx 25 Mg	PS		ORAL	25-50 MG	
	Increased	Professional					DAILY PO; 50	
	Blood Urea Increased						MG HS PO	
	Hyperkalaemia		Atrovent	C				
			Bactrim Ds Tablets	C				
			Duragesic	C				
			Lipitor	C				
			Neurontin	C				
			Remeron	C				
			Tylenol	C				
			Albuterol	C				
			Atenolol	C				
			Calcitonin	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/00ISR Number: 3484485-3Report Type:Expedited (15-DaCompany Report #WAES 00032379
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Health	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Hyperkalaemia	Professional					PO	
	Renal Failure		Betapace	C				
			Neurontin	C				
			Premarin	C				
			Prevacid	C				
			Septra	C				
			Vicodin Tablets	C				

Date:04/05/00ISR Number: 3484488-9Report Type:Expedited (15-DaCompany Report #WAES 00032405
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx 25 Mg	PS		ORAL	UNKNOWN PO	
Initial or Prolonged	Abdominal Pain Upper		Hytrin	C				
Other	Anaemia		Neurontin	C				
	Cardiac Failure		Plendil	C				
	Congestive		Robaxin	C				
	Gastric Outlet		Vicodin Es Tablets	C				
	Obstruction		Iron	C				
	Gastric Ulcer Haemorrhage		Vitamin E	C				
	Haematemesis		Zinc Preparation	C				
	Haemoglobin Decreased							
	Oedema Peripheral							
	Weight Decreased							

Date:04/05/00ISR Number: 3484492-0Report Type:Expedited (15-DaCompany Report #WAES 00032672
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx Unk	PS		ORAL	UNKNOWN PO	
Initial or Prolonged	Constipation		Baycol	C				

	Haemorrhage		Rythmol	C			
			Aspirin	C			
			Vitamins	C			

Date:04/05/00ISR Number: 3484494-4Report Type:Expedited (15-DaCompany Report #WAES 00032760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Bronchospasm						PO	
	Dyspnoea		Azmacort	C				
	Face Oedema		Proventil	C				
	Pulmonary Congestion							
	Tongue Disorder							

Date:04/05/00ISR Number: 3484497-XReport Type:Expedited (15-DaCompany Report #WAES 00032806
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Consumer	Vioxx Unk	PS		ORAL	UNKNOWN PO	
Initial or Prolonged			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/00ISR Number: 3484499-3Report Type:Expedited (15-DaCompany Report #WAES 00032859
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx Unk	PS		ORAL	UNKNOWN PO	
Initial or Prolonged	Congestive	Professional Company Representative						

Date:04/05/00ISR Number: 3484502-0Report Type:Expedited (15-DaCompany Report #WAES 00032864
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Haemorrhage	Professional					PO	
Initial or Prolonged		Company Representative	Actos	C				
			Imdur	C				
			Lopid	C				
			Minipress	C				
			Procardia	C				
			Relafen	C				
			Atenolol	C				

Date:04/05/00ISR Number: 3484617-7Report Type:Expedited (15-DaCompany Report #WAES 00039772
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	3 WK
Initial or Prolonged	Perforation	Health Professional Other	Diclofenac Na	C				
			Nimesulide	C				

Date:04/05/00ISR Number: 3484618-9Report Type:Expedited (15-DaCompany Report #WAES 00039818
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	1 DAY
		Health Professional Other	Carbamazepine	C				
			Estazolam	C				
			Fenoterol Hydrobromide	C				
			Theophylline	C				

Date:04/06/00ISR Number: 3484557-3Report Type:Expedited (15-DaCompany Report #WAES 99111289
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Arthralgia
	Asthenia
	Atelectasis
	Blood Creatinine Increased
	Blood Pressure Diastolic Decreased
	Blood Urea Increased
	Condition Aggravated
	Diaphragmatic Disorder

		Diarrhoea					
		Diverticulum Intestinal					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Duodenitis	Professional				
MG/DAILY/PO							
		Flatulence		Celebrex	C		
		Frequent Bowel Movements		Claritin	C		
		Gastrointestinal		Darvocet-N	C		
		Haemorrhage		Klonopin	C		
		Haematocrit Decreased		Lipitor	C		
		Haemoglobin Decreased		Maxzide	C		
		Haemorrhage		Prozac	C		
		Haemorrhoids		Tylenol	C		
		Hypovolaemia		Zantac	C		
		International Normalised		Ascorbic Acid	C		
		Ratio Decreased		Estrogenic			
		Leukocytosis		Preparations			
		Medication Error		(Composi	C		
		Melaena		Glucosamine	C		
		Nausea					
		Pain In Extremity					
		Pleural Effusion					
		Rectal Haemorrhage					
		Red Blood Cell Count					
		Decreased					
		Respiratory Rate					
		Increased					
		Restless Legs Syndrome					
		Sinus Bradycardia					
		Small Intestinal					
		Obstruction					
		Syncope					
		Tachycardia					

Date:04/06/00ISR Number: 3484668-2Report Type:Expedited (15-DaCompany Report #WAES 00039109
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Chest Pain	Foreign	Tab Vioxx			
Hospitalization -		Hypertension	Other	(Rofecoxib)	PS		ORAL
25 MG PO	3 DAY						

Initial or Prolonged	Hypertensive Crisis	Ace Inhibitor, Noc	C
	Malaise	Acetaminophen	C
		Amlodipine	C
		Halazepam	C
		Indapamide	C

Date:04/06/00ISR Number: 3484670-0Report Type:Expedited (15-DaCompany Report #WAES 00039460
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx			
	Haemorrhage	Other	(Rofecoxib)	PS		
	Gastrointestinal					
	Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/00ISR Number: 3484672-4Report Type:Expedited (15-DaCompany Report #WAES 99100977
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
Life-Threatening	Distress Syndrome	Professional					PRN/PO	
Hospitalization -	Blood Amylase Increased	Company	Lortab	C				
Initial or Prolonged	Lipase Increased	Representative	Motrin	C				
Disability	Pancreatitis		Prilosec	C				
Other	Renal Failure		Skelaxin	C				
			Xanax	C				
			Zantac	C				
			[Therapy Unspecified]	C				
			Vitamins	C				

Date:04/06/00ISR Number: 3484706-7Report Type:Direct Company Report #
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Diastolic	Health	Vioxx	PS				
Initial or Prolonged	Decreased	Professional						
Blood Pressure Systolic			Dyazide	C				
Increased			Calan Sr	C				
Diarrhoea			Digoxin	C				
Faeces Discoloured			B-12	C				
Haematemesis			Paxil	C				
Lethargy								
Pallor								

Date:04/06/00ISR Number: 3484943-1Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Disc Haemorrhage		Vioxx	PS		ORAL	25 MG PO	

Retinal Tear
DAILY 4 WK

	Coumadin	SS
SEE ITEM B5		
	Synthroid	C
	Lipitor	C

Date:04/06/00ISR Number: 3484944-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL
25 MG PO						
Hospitalization -	Congestive					
DAILY						
Initial or Prolonged	Oedema					

Date:04/06/00ISR Number: 3485003-6Report Type:Expedited (15-DaCompany Report #WAES 00035047
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Nail Dystrophy	Foreign	Tab Vioxx			
	Onychomycosis	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO						
		Professional	Acetaminophen/Codein			
			e Phosphate	C		
			Benserazide/Levodopa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/00ISR Number: 3485004-8Report Type:Expedited (15-DaCompany Report #WAES 00035611
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis	Foreign	Tab Vioxx					
	C-Reactive Protein	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	47 DAY
	Increased	Professional	Liq Dipyrone	SS		ORAL	20 DROPS; PO	1 DAY
	Neutrophil Count Decreased							
	White Blood Cell Count Decreased							

Date:04/06/00ISR Number: 3485012-7Report Type:Expedited (15-DaCompany Report #WAES 00020129
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea Exacerbated	Health Professional	Deepen	C				
			Ecotrin	C				
			Glucophage	C				
			Lipitor	C				
			Premarin	C				
			Prilosec	C				
			Slow-Mag	C				
			Tiazac	C				
			Vasotec	C				
			Allopurinol	C				
			Atenolol	C				
			Doxepin	C				

Date:04/06/00ISR Number: 3485013-9Report Type:Expedited (15-DaCompany Report #WAES 00020283
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Face Oedema	Professional				
MG/DAILY/PO						
	Oedema Peripheral	Company Representative				

Date:04/06/00ISR Number: 3485014-0Report Type:Expedited (15-DaCompany Report #WAES 00022481
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Emotional Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Erythema Multiforme	Health				
MG/DAILY/PO						
	Eye Irritation	Professional	Pravachol	C		
	Hypersensitivity	Company	Prilosec	C		
	Insomnia	Representative	Rhinocort	C		
	Pain		Vocodin Es Tablets	C		
	Pruritus		Levobunolol	C		
	Rash Erythematous		Prednisone	C		
	Rash Maculo-Papular		Vitamins	C		
	Skin Exfoliation					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/00ISR Number: 3485016-4Report Type:Expedited (15-DaCompany Report #WAES 00025699
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Tab Vioxx					
	Dermatitis	Health	(Rofecoxib)	PS		ORAL	26	DAY
	Phlebitis	Professional	Phenprocoumon	SS				
	Red Blood Cell		Prinivil	C				
	Sedimentation Rate		B-Methyldigoxin	C				
	Increased		Levofloxacin	C				
	Urinary Tract Infection		Metoprolol Succinate	C				
	Vasculitis		Torsemide	C				
			Urtica	C				

Date:04/06/00ISR Number: 3485018-8Report Type:Expedited (15-DaCompany Report #WAES 00032015
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	25	MG/DAILY/PO
Life-Threatening	Gastrointestinal	Professional						
Disability	Haemorrhage	Company	Ultram	SS				
Other	Haemoptysis	Representative	Cardizem	C				
	Lung Disorder		Celebrex	C				
	Post Procedural		Coumadin	C				
	Complication		Tylenol	C				
	Post Procedural Pain		Zestril	C				
	Stress		Aspirin	C				

Date:04/06/00ISR Number: 3485020-6Report Type:Expedited (15-DaCompany Report #WAES 00031291
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Convulsion		Atrovent	C				
Other	Dysphagia		Cardizem Cd	C				
	Dysphonia		Flovent	C				

Fungal Infection	Prilosec	C
Haemoptysis	Singular	C
Haemorrhoids	Nitroglycerin	C
Influenza Like Illness		
Insomnia		
Oral Candidiasis		
Pyrexia		
Tremor		

Date:04/06/00ISR Number: 3485022-XReport Type:Expedited (15-DaCompany Report #WAES 00032455
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Haemorrhage Intracranial	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/00ISR Number: 3485073-5Report Type:Expedited (15-DaCompany Report #WAES 00033224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma Haemorrhage	Health Professional	Tab Vioxx 25 Mg/ 50mg/25mg	PS		ORAL	SEE IMAGE	
	International Normalised Ratio Increased	Company Representative	Cardizem	C				
			Coumadin	C				
			Daypro	C				
			Daxil	C				
			Pravachol	C				

Date:04/06/00ISR Number: 3485074-7Report Type:Expedited (15-DaCompany Report #WAES 00039149
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Gastric Mucosal Lesion	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	
	Gastritis Gastrointestinal Haemorrhage	Professional	Timoptic	C				
			Acetaminophen	C				
			Lansoprazole	C				
			Lorazepam	C				

Date:04/06/00ISR Number: 3485179-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS		ORAL	25 MG PO	
Hospitalization -	Gastrointestinal						DAILY	
Initial or Prolonged	Haemorrhage		Synthroid	C				
Required			Tylenol #3	C				
Intervention to			Glyburide	C				
Prevent Permanent			Cozaar	C				
Impairment/Damage			Prozac	C				

Date:04/07/00ISR Number: 3484883-8Report Type:Expedited (15-DaCompany Report #WAES 00032441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Frequent Bowel Movements							
	Heart Rate Increased							
	Heart Rate Irregular							
	Tachycardia							

Date:04/07/00ISR Number: 3484886-3Report Type:Expedited (15-DaCompany Report #WAES 00032634
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/07/00ISR Number: 3484889-9Report Type:Expedited (15-DaCompany Report #WAES 00032665
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Dyspnoea
	Hypersensitivity

	Throat Tightness						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/07/00ISR Number: 3484893-0Report Type:Expedited (15-DaCompany Report #WAES 00032953
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Ear Disorder		Prilosec	C				
	Haemorrhage		Insulin	C				
	Hypertension							
	Upper Respiratory Tract Infection							

Date:04/07/00ISR Number: 3485175-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exertional		Rofecoxib 25 Mg -					
	Throat Tightness		Vioxx	PS		ORAL	25 MG QD ORAL	

Date:04/10/00ISR Number: 3485956-6Report Type:Expedited (15-DaCompany Report #WAES 00033129
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Professional						
	Congestive	Company						
	Oedema Peripheral	Representative						

Date:04/10/00ISR Number: 3485957-8Report Type:Expedited (15-DaCompany Report #WAES 00033094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Haemorrhagic	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Motrin	C				
			Tylenol	C				

Date:04/10/00ISR Number: 3485958-XReport Type:Expedited (15-DaCompany Report #WAES 00033001
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Aphasia		Risperdal	SS				
	Condition Aggravated		Celebrex	C				
	Decreased Activity		Zoloft	C				
	Dementia Alzheimer'S Type		Captopril	C				
	Haematochezia		Furosemide	C				
	Haemoglobin Decreased		Metoprolol Succinate	C				
	Hallucination		Omeprazole	C				
	Lethargy		Quinine Sulfate	C				
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/00ISR Number: 3485960-8Report Type:Expedited (15-DaCompany Report #WAES 00032291
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 DAY
		Company Representative	[Therapy Unspecified]	C				
			Aspirin	C				

Date:04/10/00ISR Number: 3485962-1Report Type:Expedited (15-DaCompany Report #WAES 00035360
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	9 DAY
			Elavil	C				
			Bendroflumethiazide	C				
			Citalopram	C				
			Irbesartan	C				

Date:04/10/00ISR Number: 3485996-7Report Type:Expedited (15-DaCompany Report #WAES 00010120
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Dizziness							
	Duodenal Ulcer	Company Representative	Combivent	C				
Disability	Duodenal Ulcer		Lipitor	C				
Other	Haemorrhage		Miacalcin	C				
	Duodenal Ulcer		Norvasc	C				
	Perforation		Prevacid	C				
	Gastroenteritis		Tylenol	C				
	Helicobacter		Vanceril	C				
	Haematocrit Decreased							

Haemoglobin Decreased
Hyperhidrosis
Iron Binding Capacity
Total Increased
Melaena
Neutrophil Count
Increased

Date:04/10/00ISR Number: 3486054-8Report Type:Expedited (15-DaCompany Report #WAES 00032170
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure Congestive	Professional Company Representative						

Date:04/10/00ISR Number: 3486057-3Report Type:Expedited (15-DaCompany Report #WAES 00039156
Age:69 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	22 DAY
			Tab Aspirin	SS		ORAL	PO	
			Citric Acid	C				
			Doxazosin	C				
			Potassium Citrate	C				

Date:04/10/00ISR Number: 3486058-5Report Type:Expedited (15-DaCompany Report #WAES 00033230
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Increased	Professional						
Initial or Prolonged	Blood Urea Increased	Company	Disalcid	C				
Disability	Cardiac Failure	Representative	Evista	C				
Other	Congestive		Lasix	C				
	Dialysis		Lotensin	C				
	Dyspepsia		Reglan	C				
	Renal Disorder		Trilisate					
	Renal Failure		Tablets/Liquid	C				

Date:04/10/00ISR Number: 3486061-5Report Type:Expedited (15-DaCompany Report #WAES 00040025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Psychotic Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	3 DAY
Initial or Prolonged		Professional	Depakote	C				
			Risperdal	C				
			Clonazepam	C				

Date:04/10/00ISR Number: 3486065-2Report Type:Expedited (15-DaCompany Report #WAES 00040045
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Colonic Haemorrhage	Professional					MG/DAILY/PO	
	Gastrointestinal Haemorrhage		Cozaar	C				
			Glucophage	C				
			Imitrex	C				
			Prozac	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				
			Estradiol	C				
			Glyburide	C				

Date:04/10/00ISR Number: 3486067-6Report Type:Expedited (15-DaCompany Report #WAES 00040049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Renal Failure	Professional Company Representative	Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/00ISR Number: 3486068-8Report Type:Expedited (15-DaCompany Report #WAES 00040122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Hepatitis							
	Pancreatitis							
	Pneumonia							

Date:04/10/00ISR Number: 3486070-6Report Type:Expedited (15-DaCompany Report #WAES 00045503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx					
Initial or Prolonged	Hallucination	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	
	Psychotic Disorder	Professional	Tab Vioxx					
			(Rofecoxib)	SS			25 MG PO	

Date:04/10/00ISR Number: 3486076-7Report Type:Expedited (15-DaCompany Report #WAES 00025579
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					
Initial or Prolonged	Asthenia	Health	(Rofecoxib)	PS		ORAL	25 MG PO	
	Diarrhoea	Professional	Aspirin (+) Lithium					
	Gastric Ulcer		Citrate (+) Quinine	C				
	Gastritis							
	Gastroenteritis							
	Helicobacter							
	Gastrointestinal							
	Haemorrhage							
	Haemoglobin Decreased							
	Melaena							
	Nausea							
	Prothrombin Time							
	Prolonged							

Date:04/10/00ISR Number: 3486079-2Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
Hospitalization -	Congestive	Professional					PO	
Initial or Prolonged	Condition Aggravated	Company	Lasix	C				
Other	Hyperkalaemia	Representative	Prinivil	C				
	Medication Error							
	Oliguria							
	Renal Failure Acute							

Date:04/10/00ISR Number: 3486083-4Report Type:Expedited (15-DaCompany Report #WAES 00032730
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY /	
Initial or Prolonged	Gastrointestinal	Professional					PO	
	Haemorrhage	Company	Celebrex	C				
	Gastrointestinal Ulcer	Representative	Darvon	C				
			Niferex	C				

Norvasc	C
Phenergan (Promethazine	
Hydrochl	C
Prilosec	C
Restoril	C
Suprax	C
Tylenol	C
Aspirin	C
Therapy Unspecified	C

Date:04/10/00ISR Number: 3486086-XReport Type:Expedited (15-DaCompany Report #WAES 00035532
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antibody Test Abnormal	Foreign	Tab Vioxx					
	Aortic Atherosclerosis	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	6 DAY
	Bronchopneumonia	Professional	Certoparin Sodium	SS			3000 IU	24 DAY
	Intestinal Infarction		Acetylcysteine	C				
	Mesenteric Occlusion		Cephalexin	C				
	Pneumonia		Fluticasone Propionate (+)					
	Rectal Haemorrhage							
	Thrombocytopenia		Salmeterol	C				
	Thrombosis		Theophylline	C				
			Torsemide	C				

Date:04/10/00ISR Number: 3486089-5Report Type:Expedited (15-DaCompany Report #WAES 00032022
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY / PO	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Professional						
	Confusional State	Other	Captopril	SS		ORAL	6.25-12.5 MG/TID/ PO	
Other	Dermatitis							
	Dyspnoea		L-Thyroxine	C				

	Pulmonary Oedema	Percocet	C
	Renal Failure Acute	Antineoplastic	
	Respiratory Distress	Agents	C
		Cytarabine	C
		Digoxin	C
		Estrone Sulfate	
		Piperazine Salt	C
		Fluconazole	C
		Metoprolol	C
		Morphine	C
		Ofloxacin S-(-)	
		Form	C
		Omeprazole	C
		Paroxetine	C
		Propranolol	C

Date:04/10/00ISR Number: 3486091-3Report Type:Expedited (15-DaCompany Report #WAES 00035357
Age:89 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
	Haemoglobin Decreased

	Hyperkalaemia						
	Oesophageal Ulcer						
	Platelet Count Decreased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Tab Vioxx				
		Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	
			Propecia	C				
			Amlodipine	C				
			Isosorbide-5-Mononitrate	C				
			Venlafaxine	C				

Date:04/10/00ISR Number: 3486121-9Report Type:Expedited (15-DaCompany Report #WAES 00045514
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Tab Vioxx					
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	10 DAY

Date:04/10/00ISR Number: 3486136-0Report Type:Expedited (15-DaCompany Report #WAES 00040260
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Cardiac Failure	Professional						
Other	Congestive	Company	Glucophage	C				
	Dyspnoea	Representative	Glucotrol Xl	C				
	Fluid Retention		Macrobid	C				
	Hypertension		Tenormin	C				
	Oedema		Vasotec	C				

Date:04/10/00ISR Number: 3486363-2Report Type:Expedited (15-DaCompany Report #WAES 99120947
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional						

Date:04/10/00ISR Number: 3486364-4Report Type:Expedited (15-DaCompany Report #WAES 00020351
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Vioxx	PS		ORAL	12.5	
Other	Increased	Professional					MG/DAILY/PO	
	Blood Urea Increased		Ginkor	C				
	Dialysis		L-Thyroxine	C				
	Multiple Myeloma							
	Renal Failure Acute							
	Renal Impairment							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/00ISR Number: 3486365-6Report Type:Expedited (15-DaCompany Report #WAES 00039150
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG PO	8 DAY
Initial or Prolonged		Professional						
		Other						

Date:04/10/00ISR Number: 3486366-8Report Type:Expedited (15-DaCompany Report #WAES 00040075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Haemorrhage	Consumer	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal							
	Haemorrhage							

Date:04/10/00ISR Number: 3486412-1Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx 12.5 Mg	PS		ORAL	PO QD (2-3 WEEKS PRIOR TO 3/13/00	
Hospitalization -	Asthenia							
Initial or Prolonged	Duodenal Ulcer							
Required Intervention to Prevent Permanent Impairment/Damage	Haemorrhage							
	Duodenal Ulcer							
	Perforation							
	Melaena							

Date:04/10/00ISR Number: 3486424-8Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS		ORAL	25MG PO	
	Abdominal Symptom		Lorazepam	C				
	Oedema Peripheral							
	Pruritus							

Date:04/10/00ISR Number: 3486475-3Report Type:Expedited (15-DaCompany Report #WAES 00033129
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Professional						
	Cardiac Failure	Company						
	Congestive	Representative						
	Oedema Peripheral							

Date:04/10/00ISR Number: 3486479-0Report Type:Expedited (15-DaCompany Report #WAES 00033001
Age:87 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Condition Aggravated
	Dementia Alzheimer'S Type
	Haematochezia
	Hallucination

	Lethargy Oral Intake Reduced Poverty Of Speech	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO
			Risperdal	SS			
			Celebrex	C			
			Zoloft	C			
			Captopril	C			
			Furosemide	C			
			Metoprolol Succinate	C			
			Omeprazole	C			
			Quinine Sulfate	C			

Date:04/10/00ISR Number: 3486618-1Report Type:Expedited (15-DaCompany Report #WAES 00032291
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO 2 DAY
		Professional	Therapy Unspecified	C			
		Company Representative	Aspirin	C			

Date:04/10/00ISR Number: 3486620-XReport Type:Expedited (15-DaCompany Report #WAES 00035360
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO 9 DAY
			Elavil	C			
			Bendroflumethiazide	C			
			Citalopram	C			
			Irbesartan	C			

Date:04/10/00ISR Number: 3486623-5Report Type:Expedited (15-DaCompany Report #WAES 00039148
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	
	Haemoglobin Decreased	Professional						
	Melaena							

Date:04/10/00ISR Number: 3486626-0Report Type:Expedited (15-DaCompany Report #WAES 00039152
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	5 DAY
	Haematemesis	Professional	Beclomethasone	C				
	Melaena		Lorazepam	C				
			Omeprazole	C				
			Risperidone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/00ISR Number: 3486638-7Report Type:Expedited (15-DaCompany Report #WAES 00033212
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive	Health						
	Dyspnoea	Professional	Tab Placebo	SS		ORAL	BID/PO	
	Lung Infiltration		Tab Acetaminophen 325 Mg	SS		ORAL	325 MG/PRN/PO	
			Inderal La	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Lotensin	C				
			Premarin	C				
			Relafen	C				
			Synthroid	C				
			Urecholine	C				
			Aspirin	C				
			Calcium Supplement (Composition	C				

Date:04/10/00ISR Number: 3486657-0Report Type:Expedited (15-DaCompany Report #WAES 00039148
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO / 5 DOSES	
	Haemoglobin Decreased							
	Melaena							

Date:04/10/00ISR Number: 3486659-4Report Type:Expedited (15-DaCompany Report #WAES 00039152
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Tab Vioxx					
	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG , PO	
	Haemorrhage		Beclomethasone	C				
	Haematemesis		Lorazepam	C				
	Melaena		Omeprazole	C				
			Risperidone	C				

Date:04/10/00ISR Number: 3486681-8Report Type:Expedited (15-DaCompany Report #WAES 00033212
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Initial or Prolonged	Congestive	Health					/ PO	
	Dyspnoea	Professional	Tab Placebo	SS		ORAL	BID / PO	
	Lung Infiltration		Tab Acetaminophen 325 Mg	SS		ORAL	325 MG / PRN	
							/ PO	
			Inderal La	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Lotensin	C				
			Premarin	C				
			Relafen	C				

			Synthroid	C		
			Urecholine	C		
			Aspirin	C		
			Calcium Supplement	C		

Date:04/10/00ISR Number: 3486841-6Report Type:Expedited (15-DaCompany Report #WAES 00010120
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Dizziness	Professional				
MG/DAILY/PO						
Initial or Prolonged	Duodenal Perforation	Company	Combivent	C		
Disability	Duodenal Ulcer	Representative	Lipitor	C		
Other	Haemorrhage		Miacalcin	C		
	Gastroenteritis		Norvasc	C		
	Helicobacter		Prevacid	C		
	Gastrointestinal Disorder		Tylenol	C		
	Gastrointestinal		Vanceril	C		
	Haemorrhage					
	Hyperhidrosis					
	Iron Binding Capacity					
	Total Increased					
	Lymphocyte Count					
	Decreased					
	Melaena					
	Neutrophil Count					
	Increased					
	Red Blood Cell Count					
	Decreased					

Date:04/10/00ISR Number: 3486845-3Report Type:Expedited (15-DaCompany Report #WAES 00025579
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx			
Initial or Prolonged	Asthenia	Health	(Rofecoxib)	PS		ORAL
25 MG						
	Diarrhoea	Professional	Aspirin	C		
	Gastric Ulcer		Lithium Citrate	C		

	Gastritis Erosive	Quinine	C
	Haemoglobin Decreased		
	Melaena		
	Nausea		
	Prothrombin Time		
	Shortened		
	Upper Gastrointestinal		
	Haemorrhage		

Date:04/10/00ISR Number: 3486847-7Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Creatinine
Hospitalization -	Increased
Initial or Prolonged	Blood Urea Increased
Other	Cardiac Failure
	Hyperkalaemia
	Medication Error
	Oliguria

	Renal Failure Acute Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Tab Vioxx 25 Mg	PS		ORAL	25
		Professional					MG/DAILY/PO
		Company	Lasix	C			
		Representative	Lasix	C			
			Prinivil	C			

Date:04/10/00ISR Number: 3486851-9Report Type:Expedited (15-DaCompany Report #WAES 00032730
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Diverticulum Intestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO
	Haemorrhage	Company	Celebrex	C			
	Gastrointestinal Ulcer	Representative	Darvon	C			
			Niferex	C			
			Norvasc	C			
			Phenergan (Promethazine				
			Hydrochl	C			
			Prilosec	C			
			Restoril	C			
			Suprax	C			
			Tylenol	C			
			Aspirin	C			

Date:04/12/00ISR Number: 3487382-2Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia	Health	Vioxx 12.5mg	PS		ORAL	12.5MG PO 2 DAY
	Chills	Professional	Metabolife	C			
	Costochondritis						

Dyspnoea
Pharyngolaryngeal Pain
Pruritus
Pyrexia
Rash Maculo-Papular

Date:04/12/00ISR Number: 3487444-XReport Type:Expedited (15-DaCompany Report #WAES 00040160
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Transient Ischaemic Attack		Cardura	C				
			Prilosec	C				
			Vasotec	C				
			Aspirin	C				

Date:04/12/00ISR Number: 3487447-5Report Type:Expedited (15-DaCompany Report #WAES 00040227
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Death	Cardiac Failure Congestive	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx Unk	PS		ORAL
PO						

Date:04/12/00ISR Number: 3487450-5Report Type:Expedited (15-DaCompany Report #WAES 00040251
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia	Health	Tab Vioxx 25mg	PS		ORAL
25MG/BID/PO						
Hospitalization -	Gastric Ulcer Haemorrhage	Professional	Zantac	C		
Initial or Prolonged		Company				
Other		Representative				

Date:04/12/00ISR Number: 3487451-7Report Type:Expedited (15-DaCompany Report #WAES 00040347
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 12.5mg	PS		ORAL
12.5						
Initial or Prolonged	Gastrointestinal	Professional				
MG/DAILY/PO						
	Haemorrhage	Company				
		Representative				

Date:04/12/00ISR Number: 3487453-0Report Type:Expedited (15-DaCompany Report #WAES 00045505
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Blood Creatinine	Foreign	Tab Vioxx			
	Increased	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO 2 MON						
	Condition Aggravated	Professional				
		Other				

Date:04/12/00ISR Number: 3487465-7Report Type:Expedited (15-DaCompany Report #WAES 00047251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				3 DAY
			Piroxicam	C				

Date:04/12/00ISR Number: 3487667-XReport Type:Expedited (15-DaCompany Report #WAES 00032552
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	35 MG/DAILY/PO	
	Eye Haemorrhage							
			Mestinon	C				
			Premarin	C				
			Procardia	C				
			Zestril	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/00ISR Number: 3487668-1Report Type:Expedited (15-DaCompany Report #WAES 00032672
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Constipation	Health	Baycol	C				
	Haemorrhage	Professional	Rythmol	C				
			Aspirin	C				
			Vitamins	C				

Date:04/12/00ISR Number: 3487669-3Report Type:Expedited (15-DaCompany Report #WAES 00035675
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Foreign	Tab Vioxx					
Initial or Prolonged	Pneumonia	Health	(Rofecoxib)	PS		ORAL	PO	
	Pubic Rami Fracture	Professional						
	Renal Failure Acute							

Date:04/12/00ISR Number: 3487682-6Report Type:Expedited (15-DaCompany Report #WAES 00031643
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
	Convulsion	Professional					MG/DAILY/PO	
	Depressed Level Of		Tab Vioxx 25 Mg	SS		ORAL	25	
	Consciousness						MG/DAILY/PO	
			Lortab	C				

Date:04/12/00ISR Number: 3487787-XReport Type:Expedited (15-DaCompany Report #WAES 00039149
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Gastritis Erosive	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	4 DAY
	Gastrointestinal Haemorrhage		Timoptic	C				
			Acetaminophen	C				
			Lansoprazole	C				
			Lorazepam	C				

Date:04/12/00ISR Number: 3487788-1Report Type:Expedited (15-DaCompany Report #WAES 00022110
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Extrasystoles	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/12/00ISR Number: 3487790-XReport Type:Expedited (15-DaCompany Report #WAES 00030809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Arava	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/00ISR Number: 3487792-3Report Type:Expedited (15-DaCompany Report #WAES 00038605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/12/00ISR Number: 3487794-7Report Type:Expedited (15-DaCompany Report #WAES 00033099
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/12/00ISR Number: 3487797-2Report Type:Expedited (15-DaCompany Report #WAES 00040048
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	

Date:04/12/00ISR Number: 3487799-6Report Type:Expedited (15-DaCompany Report #WAES 00040079
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	
Hospitalization -	Breath Sounds Decreased	Professional					DAILY/PO	
Initial or Prolonged	Cardiac Failure		Atrovent	C				
Other	Congestive		Isorbid	C				

	Cardiac Murmur	Lasix	C
	Cardiomegaly	Lopressor	C
	Condition Aggravated	Plavix	C
	Dyspnoea Exertional	Zocor	C
	Electrocardiogram T Wave	Albuterol	C
	Inversion	Folic Acid	C
	Hypertension	Influenza Virus	
	Hypoxia	Vaccine	C
	Mitral Valve Incompetence	Vitamin E	C
	Neuromyopathy		
	Oedema Peripheral		
	Oxygen Saturation		
	Abnormal		
	Paraparesis		
	Pulmonary Hypertension		
	Pyrexia		
	Rales		
	Sleep Apnoea Syndrome		
	Tachypnoea		
	Tricuspid Valve		
	Incompetence		
	Venous Pressure Jugular		
	Increased		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/00ISR Number: 3487807-2Report Type:Expedited (15-DaCompany Report #WAES 00040081
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Pruritus							
	Rash Generalised	Company Representative	Amaryl	C				
	Stevens-Johnson Syndrome		Cozaar	C				
			Lanoxin	C				
			Pavabid	C				
			Synthroid	C				
			Insulin	C				

Date:04/13/00ISR Number: 3487891-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Vioxx	PS				
	Gastrointestinal Haemorrhage							
	Medication Error							

Date:04/13/00ISR Number: 3488062-XReport Type:Expedited (15-DaCompany Report #62038
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Study	Naproxen	PS				
	Haemoptysis	Health Professional	Rofecoxib	SS				
	Lung Disorder		Aricept	C				
			Asa	C				
			Triamterene	C				
			Zocor	C				

Date:04/13/00ISR Number: 3555290-4Report Type:Periodic Company Report #000209-SK083
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Celebrex	PS	Gd Searle And Co	ORAL	100.000 MG, BID, PO	
			Vioxx	SS		ORAL	PO	

Date:04/13/00ISR Number: 3555328-4Report Type:Periodic Company Report #000214-SK300
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG, QD, PO	
	Dyspnoea							
	Weight Increased		Vioxx	SS		ORAL	PO	
			Hydrocodone	C				
			Acetaminophen	C				
			Hormonal Contraceptives; Non Topical	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/00ISR Number: 3556579-5Report Type:Periodic Company Report #000313-SK210
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	PO	
			Vioxx	SS		ORAL	PO	

Date:04/13/00ISR Number: 3556812-XReport Type:Periodic Company Report #000309-SK216
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Celebrex	PS	Gd Searle And Co	ORAL	PO	
		Professional	Vioxx	SS		ORAL	12.500 MG PO	
			Potassium	C				
			Insulin	C				
			Vitamins	C				

Date:04/14/00ISR Number: 3488452-5Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25mg	PS			25MG ONE BY	
Hospitalization -	Congestive						MOUTH DAILY	
Initial or Prolonged	Fluid Retention		Vicodin	C				
Required			Insulin	C				
Intervention to			Avandia	C				
Prevent Permanent			Lotensin	C				
Impairment/Damage			Paxil	C				

Date:04/14/00ISR Number: 3488513-0Report Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer Gastrointestinal Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib) Analgesic Or Anesthetic Preparations	PS C		ORAL	25 MG PO	3 DAY

Date:04/14/00ISR Number: 3488515-4Report Type:Expedited (15-DaCompany Report #WAES 00045534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis Prothrombin Time Prolonged	Foreign Health Professional	Tab Vioxx (Rofecoxib) Phenprocoumon	PS C		ORAL		

Date:04/14/00ISR Number: 3488516-6Report Type:Expedited (15-DaCompany Report #WAES 00045531
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Hallucination Psychotic Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib) [Composition Unspecified]	PS C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/00ISR Number: 3488518-XReport Type:Expedited (15-DaCompany Report #WAES 00048901
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ecchymosis	Foreign	Tab Vioxx					
Disability	Face Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG PO	4 DAY
	Periorbital Oedema	Professional	Hydrodiuril	C				
	Rash Generalised		Atenolol	C				
			Potassium Chloride	C				

Date:04/14/00ISR Number: 3488520-8Report Type:Expedited (15-DaCompany Report #WAES 00040583
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Increased	Professional						

Date:04/14/00ISR Number: 3488521-XReport Type:Expedited (15-DaCompany Report #WAES 00040519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Coma							
	Fatigue							
	Loss Of Consciousness							

Date:04/14/00ISR Number: 3488523-3Report Type:Expedited (15-DaCompany Report #WAES 00040392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fatigue							

Date:04/14/00ISR Number: 3488526-9Report Type:Expedited (15-DaCompany Report #WAES 00040254
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Hospitalization -	Duodenal Perforation	Professional					PO	
Initial or Prolonged	Duodenal Ulcer		Fosamax	C				
Other	Haemorrhage							
	Melaena							
	Vomiting							

Date:04/14/00ISR Number: 3488553-1Report Type:Expedited (15-DaCompany Report #WAES 00048518
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyponatraemia	Foreign	Tab Vioxx					
Initial or Prolonged	Oedema Peripheral	Health	(Rofecoxib)	PS				
		Professional	Digoxin	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/00ISR Number: 3488554-3Report Type:Expedited (15-DaCompany Report #WAES 00040257
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Increased	Professional					MG/DAILY/PO	
Hospitalization -	Blood Urea Increased		Catapres Tts	C				
Initial or Prolonged	Dysarthria		Colace	C				
Other	Dyspnoea		Darvocet-N	C				
	Haemodialysis		Lasix	C				
	Renal Failure		Synthroid	C				
	Respiratory Failure		Colchicine	C				
			Labetalol	C				
			Nitroglycerin	C				
			Prazosin	C				
			Vitamin E	C				

Date:04/14/00ISR Number: 3488557-9Report Type:Expedited (15-DaCompany Report #WAES 00040307
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:04/14/00ISR Number: 3488559-2Report Type:Expedited (15-DaCompany Report #WAES 00040120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Diverticulum Intestinal		Aspirin Unk	SS				
	Gastrointestinal							
	Haemorrhage							
	Haemorrhage							

Date:04/14/00ISR Number: 3488560-9Report Type:Expedited (15-DaCompany Report #WAES 00045536
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign	Tab Vioxx					
	Gastric Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO	15 DAY
	Melaena	Professional	Amiloride Hydrochloride	C				
			Levothyroxine Na	C				
			Verapamil	C				

Date:04/14/00ISR Number: 3488705-0Report Type:Expedited (15-DaCompany Report #WAES 00031937
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Hemiparesis		Aspirin	C				
	Malaise		Vitamins	C				
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/00ISR Number: 3488715-3Report Type:Expedited (15-DaCompany Report #WAES 00035703
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
Initial or Prolonged	Pleural Effusion	Health Professional Other	Captopril	C				
			Dimenhydrinate	C				
			Naloxone Hydrochloride (+)					
			Tilidine	C				

Date:04/14/00ISR Number: 3488717-7Report Type:Expedited (15-DaCompany Report #WAES 00039776
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Failure	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	2 DAY
Hospitalization -	Hepatitis Fulminant	Health Professional Other	Moduretic	C				
Initial or Prolonged	Renal Impairment		Amitriptyline	C				
			Atenolol	C				
			Fluoxetine Hcl	C				

Date:04/14/00ISR Number: 3488746-3Report Type:Expedited (15-DaCompany Report #WAES 00039115
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	8 DAY
Hospitalization -	Coma	Other						
Initial or Prolonged	Encephalopathy		Acetaminophen	C				
	Lung Infiltration		Lorazepam	C				
	Neutropenia		Pygeum African Extract	C				
			Tramadol Hcl	C				

Date:04/14/00ISR Number: 3488749-9Report Type:Expedited (15-DaCompany Report #WAES 00037906
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	2 MON

Date:04/14/00ISR Number: 3488753-0Report Type:Expedited (15-DaCompany Report #WAES 00025701
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis Gastrointestinal Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/17/00ISR Number: 3488903-6Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Asthma Bronchospasm Chest Pain Dizziness Hyperhidrosis

Malaise

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 25 Mg	PS			1	12 HOURS
	Doxycycline	C				
	Niacin	C				

Date:04/17/00ISR Number: 3489061-4Report Type:Expedited (15-DaCompany Report #WAES 00032408
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Coordination Abnormal	Professional	Tylenol	SS				
	Drug Level Above	Company	Tab Flexeril	SS				
	Therapeutic	Representative						
	Intentional Misuse							
	Posture Abnormal							
	Posturing							
	Suicide Attempt							

Date:04/17/00ISR Number: 3489067-5Report Type:Expedited (15-DaCompany Report #WAES 00040583
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Increased	Professional					MG/DAILY/PO	
	Cardiac Failure							
	Congestive							
	Condition Aggravated							
	Renal Impairment							

Date:04/17/00ISR Number: 3489068-7Report Type:Expedited (15-DaCompany Report #WAES 00033099
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:04/17/00ISR Number: 3489070-5Report Type:Expedited (15-DaCompany Report #WAES 00010815
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Coordination Abnormal Dysarthria Fluid Retention Transient Ischaemic Attack	Consumer Health Professional	Tab Vioxx 12.5 Mg, 25 Mg	PS		ORAL	12.5 MG /DAILY/PO, 25 MG	
			Celebrex	C				
			Diovan	C				
			Lasix	C				
			Pravachol	C				
			Ascorbic Acid	C				
			Labetalol	C				
			Potassium Suplement (Composition Unkn)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/17/00ISR Number: 3489072-9Report Type:Expedited (15-DaCompany Report #WAES 00030052
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Atelectasis	Professional					MG/DAILY/PO	
Hospitalization -	Blood Creatine	Company	Artificial Tears	C				
Initial or Prolonged	Phosphokinase Increased	Representative	Betapace	C				
	Blood Creatine		Celebrex	C				
	Phosphokinase Mb		Premarin	C				
	Increased		Prilosec	C				
	Breath Sounds Decreased		Tums	C				
	Cardiac Failure		Tylenol	C				
	Congestive		Aspirin	C				
	Cardiac Murmur		Hydroxyurea	C				
	Cardiomegaly		Lactulose	C				
	Chest X-Ray Abnormal		Prednisone	C				
	Cough							
	Drug Effect Decreased							
	Dyspepsia							
	Dyspnoea							
	Electrocardiogram							
	Abnormal							
	Electrocardiogram St							
	Segment Abnormal							
	Fatigue							
	Haematocrit Decreased							
	Hyperglycaemia							
	Hypochloraemia							
	Hyponatraemia							
	International Normalised							
	Ratio Decreased							
	Leukocytosis							
	Malaise							
	Oedema							
	Pco2 Decreased							
	Pleural Effusion							
	Pneumonia							
	Pulmonary Congestion							
	Pulmonary Hypertension							
	Pulmonary Oedema							
	Rales							
	Sinus Tachycardia							
	Sudden Death							

Date:04/17/00ISR Number: 3489075-4Report Type:Expedited (15-DaCompany Report #WAES 00049105
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Tab Acenocoumarol	SS		ORAL		

Date:04/17/00ISR Number: 3489182-6Report Type:Expedited (15-DaCompany Report #000403-SK981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Foreign Health Professional	Celebrex (Celecoxib)	PS		ORAL	PO	
			Vioxx (Rofecoxib)	SS		ORAL	PO	
Other								

Date:04/17/00ISR Number: 3489210-8Report Type:Expedited (15-DaCompany Report #WAES 00022279
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm	Health	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Confusional State	Professional					MG/DAILY/PO	
	Dyspnoea	Other						
	Erythema							
	Hypertension							
	Swelling							

Date:04/17/00ISR Number: 3489211-XReport Type:Expedited (15-DaCompany Report #WAES 00040429
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Vioxx	PS		ORAL	12.5	
Hospitalization -	Increased	Professional					MG/DAILY/PO	
Initial or Prolonged	Blood Urea Increased	Company	Coumadin	SS				
	Cardiac Failure	Representative	K-Dur	C				
	Congestive		Lanoxin	C				
	Condition Aggravated		Lasix	C				
	Drug Interaction		Prinivil	C				
	Drug Level Above		Synthroid	C				
	Therapeutic		Allopurinol	C				
	Fall							
	Haemodialysis							
	Hyperkalaemia							
	International Normalised							
	Ratio Increased							
	Lung Injury							
	Pneumothorax							
	Procedural Complication							
	Prothrombin Time							
	Prolonged							
	Renal Failure Acute							
	Respiratory Distress							
	Respiratory Failure							
	Therapeutic Agent							
	Toxicity							

Date:04/17/00ISR Number: 3489212-1Report Type:Expedited (15-DaCompany Report #WAES 00040748
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Difficulty In Walking	Consumer	Vioxx	PS		ORAL	PO	3 DAY
Hospitalization - Initial or Prolonged	Dyspnoea		Avandia	C				
	Face Oedema		Cardizem	C				
	Gait Disturbance		Lanoxin	C				
	Oedema Peripheral		Synthroid	C				
	Pharyngeal Oedema							
	Pneumonia							
	Pulmonary Oedema							
	Respiratory Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/17/00ISR Number: 3489213-3Report Type:Expedited (15-DaCompany Report #WAES 00040730
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Respiratory Disorder	Consumer	Vioxx	PS		ORAL	PO	

Date:04/17/00ISR Number: 3489214-5Report Type:Expedited (15-DaCompany Report #WAES 00048541
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/17/00ISR Number: 3489215-7Report Type:Expedited (15-DaCompany Report #WAES 00045527
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchitis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	
	Haematoma	Health	Diclofenac	C				
	Haemoglobin Decreased	Professional	Fluvastatin Na	C				
	Thrombocytopenia		Roxithomycin	C				

Date:04/17/00ISR Number: 3489216-9Report Type:Expedited (15-DaCompany Report #WAES 00045516
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	2 MON
	Haematemesis	Professional	Tab Aspirin	SS		ORAL	PO	

			Tab Ibuprofen	SS		ORAL
PO						
			Tab Diclofenac	SS		ORAL
PO						

Date:04/17/00ISR Number: 3489217-0Report Type:Expedited (15-DaCompany Report #WAES 00045064
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Distension	Foreign	Tab Vioxx			
Initial or Prolonged	Oliguria	Other	(Rofecoxib)	PS		ORAL
12.5 MG PO 10 DAY						
	Weight Increased		Aspirin	C		
			Conjugated			
			Estrogenic Hormones	C		
			Metoprolol	C		
			Propranolol	C		

Date:04/17/00ISR Number: 3489218-2Report Type:Expedited (15-DaCompany Report #WAES 00040662
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hepatitis	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/						
Initial or Prolonged		Professional				
DAILY/PO						
		Company	Celexa	C		
		Representative	Diflucan	C		
			Flagyl	C		
			Levaquin	C		
			Restoril	C		

				Tegretol	C		

Date:04/17/00ISR Number: 3489219-4Report Type:Expedited (15-DaCompany Report #WAES 00040789
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Congestive Condition Aggravated							
	Dyspnoea							
	Face Oedema							
	Pulmonary Oedema							

Date:04/17/00ISR Number: 3489220-0Report Type:Expedited (15-DaCompany Report #WAES 00039776
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Function Abnormal	Foreign	Tab Vioxx					
Hospitalization -	Hepatitis	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	2 DAY
Initial or Prolonged	Hepatitis Fulminant	Professional	Moduretic	C				
	Renal Impairment		Amitriptyline	C				
			Atenolol	C				
			Fluoxetine Hcl	C				

Date:04/17/00ISR Number: 3489221-2Report Type:Expedited (15-DaCompany Report #WAES 00039772
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective	Foreign	Tab Vioxx					
Initial or Prolonged	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	25 MG PO	5 DAY
	Perforation	Professional	Diclofenac Na	C				
			Nimesulide	C				

Date:04/17/00ISR Number: 3489222-4Report Type:Expedited (15-DaCompany Report #WAES 00039136
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache	Foreign	Tab Vioxx					
	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL	25 MG PO	3 DAY
	Malaise	Professional	Nifedipine	C				

Date:04/17/00ISR Number: 3489223-6Report Type:Expedited (15-DaCompany Report #WAES 00032343
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional						
	Renal Failure							

Date:04/17/00ISR Number: 3489246-7Report Type:Expedited (15-DaCompany Report #WAES 00045059
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Pallor	Other	Diclofenac Sodium					

(+) Misoprostol C

Date:04/17/00ISR Number: 3489247-9Report Type:Expedited (15-DaCompany Report #WAES 00037313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Foreign	Tab Vioxx					
Life-Threatening	Leukopenia	Other	(Rofecoxib)	PS		ORAL	PO	1 WK
	Neoplasm Malignant		Ketobemidone	C				
			Nitrofurantoin	C				

Date:04/17/00ISR Number: 3489248-0Report Type:Expedited (15-DaCompany Report #WAES 00040780
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Distress Syndrome	Professional						

Date:04/17/00ISR Number: 3489249-2Report Type:Expedited (15-DaCompany Report #WAES 00040820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Relapsing	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:04/17/00ISR Number: 3489250-9Report Type:Expedited (15-DaCompany Report #WAES 00040281
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Other	Cardiac Failure	Professional					
MG/DAILY/PO							
	Congestive	Company Representative	Synthroid	SS			
			Actos	C			
			Zyloprim	C			
			Zyprexa	C			

Date:04/17/00ISR Number: 3489251-0Report Type:Expedited (15-DaCompany Report #WAES 00022216
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
	Cyanosis	Professional						
MG/DAILY/PO								
	Dermatitis		Celestone	C				
	Flushing		Lidocaine	C				
	Respiratory Disorder							
	Urticaria							

Date:04/18/00ISR Number: 3489022-5Report Type:Expedited (15-DaCompany Report #WAES 00048544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aplastic Anaemia	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/00ISR Number: 3489144-9Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia	Health Professional	Vioxx (Rofecoxib) 25 Mg Qd	PS		ORAL	25MG PO QD	
			Norvasc (Amlodipine) 2.5mg Qd	SS		ORAL	2.5MG PO QD	
			Plavix (Clopidogrel)	C				

Date:04/18/00ISR Number: 3489383-7Report Type:Expedited (15-DaCompany Report #WAES 99107018
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein	Foreign	Tab Rofecoxib	PS		ORAL	50 MG ORAL	96 DAY
Initial or Prolonged	Increased	Study	Methotrexate	C				
	Chest Pain	Health Professional	Prednisolone	C				

Date:04/18/00ISR Number: 3489586-1Report Type:Expedited (15-DaCompany Report #WAES 00030662
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bilirubin Increased	Foreign	Tab Vioxx					
Hospitalization -	Chills	Health	(Rofecoxib)	PS		ORAL	25 MG PO	1 DAY
Initial or Prolonged	Chromaturia	Professional	Doliprane	C				
Other	Face Oedema							
	Fatigue							
	Haemolytic Anaemia							
	Jaundice							
	Leukopenia							
	Myalgia							
	Nausea							
	Pallor							
	Pruritus							
	Red Blood Cell							

Sedimentation Rate
Increased
Tachycardia

Date:04/18/00ISR Number: 3489589-7Report Type:Expedited (15-DaCompany Report #WAES 00031440
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bacterial Infection	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Cardiac Failure	Professional					MG/DAILY/PO	
Initial or Prolonged	Congestive		Coumadin	C				
Disability	Cardiomyopathy		Lanoxin	C				
	Condition Aggravated		Lasix	C				
	Ejection Fraction		Prilosec	C				
	Abnormal		Vasotec	C				

Date:04/18/00ISR Number: 3489908-1Report Type:Expedited (15-DaCompany Report #WAES 00040049
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Bacterial Infection
Initial or Prolonged	Blood Urea Increased

	Hepatic Encephalopathy Hepatic Failure Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pancytopenia	Health	Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO
	Renal Failure Acute Sepsis	Professional Company Representative	Antimicrobial Therapy (Composition Unspecified) Unk [Therapy Unspecified]	SS C			

Date:04/18/00ISR Number: 3558256-3Report Type:Periodic Company Report #US001812
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Provigil	PS	Cephalon Inc	ORAL	200 MG QAM
	Drug Interaction					ORAL	
			Provigil	SS		ORAL	200 MG QAM/MD
						ORAL	
			Vioxx	SS		ORAL	25 MG QHS
						ORAL	
			Skelaxin	SS		ORAL	1 DF Q4 HR
						ORAL	
			Percocet	SS		ORAL	1 DF Q4HR
						ORAL	
			Synthroid	C			

Date:04/19/00ISR Number: 3490183-2Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness		Vioxx	PS		ORAL	25MG QD PO	
	Headache							
	Hypertension							

Date:04/19/00ISR Number: 3490193-5Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces		Rofecoxib	PS		ORAL	12.5MG PO QD	
	Colitis							
	Diarrhoea Haemorrhagic							
	Faeces Discoloured							
	Nausea							

Date:04/19/00ISR Number: 3490196-0Report Type:Direct Company Report #
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema		Rofecoxib	PS				
	Dermatitis		Buprofion	C				
	Pharyngeal Oedema		Gabapentin	C				
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/00ISR Number: 3490339-9Report Type:Expedited (15-DaCompany Report #WAES 00041165
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Thrombocytopenia	Professional					MG/DAILY/PO	
Other		Company Representative	Antivert	C				
			Cipro	C				

Date:04/19/00ISR Number: 3490340-5Report Type:Expedited (15-DaCompany Report #WAES 00041028
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Papillary Necrosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Oruvail	SS				

Date:04/19/00ISR Number: 3490341-7Report Type:Expedited (15-DaCompany Report #WAES 00041001
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Increased	Professional					MG/DAILY/PO	
Initial or Prolonged	Condition Aggravated	Company Representative	Pletal	C				
	Decreased Appetite		Prevacid	C				
	Hypotension		Remeron	C				
	Renal Failure		Zestril	C				
	Sluggishness							

Date:04/19/00ISR Number: 3490873-1Report Type:Expedited (15-DaCompany Report #WAES 00021414
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization - Initial or Prolonged	Abdominal Pain	Professional	Nyquil	C				
	Abdominal Tenderness		Rolaids	C				
	Duodenitis		Tylenol	C				
	Gastrooesophageal Reflux Disease		Zantac	C				
	Influenza		[Therapy Unspecified]	C				
	Leukocytosis		Vitamins	C				
	Pancreatitis Acute							
	Peptic Ulcer							
	Pyrexia							
	Vomiting							

Date:04/19/00ISR Number: 3490905-0Report Type:Expedited (15-DaCompany Report #WAES 00030763
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Dyspnoea	Health						
	Fluid Retention	Professional	Coumadin	C				
	Pneumonia		Cozaar	C				
	Pulmonary Oedema		Lanoxin	C				
			Lasix	C				
			Zestril	C				

				Verapamil	C		

Date:04/19/00ISR Number: 3490907-4Report Type:Expedited (15-DaCompany Report #WAES 00032455
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Hospitalization -	Haemorrhage Intracranial	Professional	Tab Vioxx 25 Mg	SS		ORAL	PO	2 WK
Initial or Prolonged	Haemorrhagic Stroke	Company						
	Intracranial Aneurysm	Representative						

Date:04/19/00ISR Number: 3490909-8Report Type:Expedited (15-DaCompany Report #WAES 00040045
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage		Ibuprofen	SS			1800	MG/DAILY/
			Cozaar	C				
			Glucophage	C				
			Imitrex	C				
			Prozac	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				
			Estradiol	C				
			Glyburide	C				

Date:04/21/00ISR Number: 3490631-8Report Type:Direct Company Report #
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx 50 Mg Msd	PS	Msd	ORAL	50MG QD PO	
Hospitalization - Initial or Prolonged	Diarrhoea		Paxil	C				
	Duodenal Ulcer		Multivits	C				
	Dyspepsia		Baby Aspirin	C				
	Faeces Discoloured							
	Gastrointestinal Haemorrhage							
	Melaena							

Date:04/21/00ISR Number: 3490643-4Report Type:Direct Company Report #
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx 50 Mg Msd	PS		ORAL	50 MG /OD/PO	
Hospitalization - Initial or Prolonged	Diarrhoea		Paxil	C				
	Duodenal Ulcer		Multivits	C				
	Dyspepsia		Baby Aspirin	C				
	Faeces Discoloured							
	Gastrointestinal Haemorrhage							
	Haemoglobin Decreased							
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/00ISR Number: 3490858-5Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Rofecoxib	PS		ORAL	25 MG QD PO	
Initial or Prolonged	Acute Prerenal Failure		Aspirin	SS		ORAL	325 MG QD PO	
	Chest Pain		Prozac	C				
	Dizziness		Furosemide	C				
	Duodenal Ulcer		Lipitor	C				
	Gastric Mucosal Lesion							
	Gastrointestinal Haemorrhage							
	Haemoglobin Decreased							
	Hyperkalaemia							
	Melaena							
	Peptic Ulcer							
	Renal Failure Acute							

Date:04/21/00ISR Number: 3490859-7Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Rofecoxib	PS		ORAL	12.5 MG QD PO	
	Increased		Rofecoxib	SS		ORAL	25 MG QD PO	
	Blood Urea Increased		Glucosamine	C				
	Renal Failure Acute		Meclizine	C				
			Levothyroxine	C				

Date:04/21/00ISR Number: 3491043-3Report Type:Expedited (15-DaCompany Report #WAES 00045558
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/21/00ISR Number: 3491044-5Report Type:Expedited (15-DaCompany Report #WAES 00040859
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Blood Creatinine	Professional						
Initial or Prolonged	Increased		Accupril	C				
	Confusional State		Arava	C				
	Dehydration							
	Fatigue							
	Haemoglobin Decreased							
	Renal Failure Acute							
	Renal Impairment							

Date:04/21/00ISR Number: 3491045-7Report Type:Expedited (15-DaCompany Report #WAES 00041031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:04/21/00ISR Number: 3491046-9Report Type:Expedited (15-DaCompany Report #WAES 00041127
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/21/00ISR Number: 3491048-2Report Type:Expedited (15-DaCompany Report #WAES 00041198
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Hypoaesthesia Hypoaesthesia Oral Hypotension Joint Swelling Multiple Sclerosis Tinnitus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/21/00ISR Number: 3491050-0Report Type:Expedited (15-DaCompany Report #WAES 00041259
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/21/00ISR Number: 3491052-4Report Type:Expedited (15-DaCompany Report #WAES 00041201
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Malaise							
Other	Palpitations							
	Pancreatitis							
	Pharyngolaryngeal Pain							
	Pneumonia							
	Stress							

Date:04/21/00ISR Number: 3491053-6Report Type:Expedited (15-DaCompany Report #WAES 00041326
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
Other	International Normalised	Company	Capoten	C				
	Ratio Abnormal	Representative	Coumadin	C				
			K-Dur	C				
			Lasix	C				
			Nitro-Dur	C				

Date:04/21/00ISR Number: 3491106-2Report Type:Expedited (15-DaCompany Report #WAES 00045546
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haemolytic Autoimmune	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	

Date:04/21/00ISR Number: 3491107-4Report Type:Expedited (15-DaCompany Report #WAES 00041327
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastrointestinal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Disability	Haemorrhage Haemoglobin Decreased	Company Representative	Lotrel	C				

Date:04/21/00ISR Number: 3491108-6Report Type:Expedited (15-DaCompany Report #WAES 00041325
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Muscular Weakness	Professional						
Other		Company Representative	Claritin	C				
			Micardis	C				
			Prempro	C				
			Prozac	C				
			Aspirin	C				

Date:04/21/00ISR Number: 3491109-8Report Type:Expedited (15-DaCompany Report #WAES 00041323
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Alcohol Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Gastroenteritis	Professional	Norvasc	C				
	Helicobacter	Company	Zantac	C				
Other	Peptic Ulcer Haemorrhage	Representative	Aspirin	C				
	Upper Gastrointestinal Haemorrhage		Nitroglycerin	C				

Date:04/21/00ISR Number: 3491114-1Report Type:Expedited (15-DaCompany Report #WAES 00025164
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Ulcer	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Perforation	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	6 DAY
			Cisapride	C				
			Danthron (+)					
			Poloxamer 188	C				
			Morphineso4	C				
			Omeprazole	C				

Date:04/21/00ISR Number: 3491115-3Report Type:Expedited (15-DaCompany Report #WAES 00040025
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Condition Aggravated	Professional	Risperdal Ukn	SS			2 MG/HS	
	Drug Interaction		Depakote	C				
	Hallucination		Clonazepam	C				
	Imprisonment							
	Psychotic Disorder							

Date:04/21/00ISR Number: 3491116-5Report Type:Expedited (15-DaCompany Report #WAES 00040048
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	

Date:04/21/00ISR Number: 3491117-7Report Type:Expedited (15-DaCompany Report #WAES 00048901
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Foreign	Tab Vioxx					
Disability	Ecchymosis	Health	(Rofecoxib)	PS		ORAL	25 MG PO	
	Face Oedema	Professional	Hydrodiuril	C				
	Periorbital Oedema		Atenolol	C				
	Refusal Of Treatment By Patient		Potassium Chloride	C				
	Stevens-Johnson Syndrome							

Date:04/21/00ISR Number: 3491119-0Report Type:Expedited (15-DaCompany Report #WAES 00039156
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	22 DAY
Initial or Prolonged		Professional	Tab Aspirin	SS		ORAL	PO	
			Citric Acid	C				
			Doxazosin	C				
			Potassium Citrate	C				

Date:04/21/00ISR Number: 3491120-7Report Type:Expedited (15-DaCompany Report #WAES 00036124
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema	Foreign	Tab Vioxx					
Initial or Prolonged	Haemolytic Anaemia	Other	(Rofecoxib)	PS		ORAL	PO	1 DAY
			Tab Acetaminophen	SS		ORAL	500 MG PO	1 DAY

Date:04/21/00ISR Number: 3491121-9Report Type:Expedited (15-DaCompany Report #WAES 00048902
Age:69 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Anaemia
Hospitalization -	Asthenia
Initial or Prolonged	Erosive Duodenitis
	Faeces Discoloured

		Gastritis Erosive Gastroenteritis Helicobacter	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG PO	14 DAY						
		Haematochezia Nausea Upper Gastrointestinal Haemorrhage	Professional				

Date:04/21/00ISR Number: 3491129-3Report Type:Expedited (15-DaCompany Report #WAES 00041292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Consumer	Vioxx	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage					

Date:04/21/00ISR Number: 3491320-6Report Type:Expedited (15-DaCompany Report #WAES 00045553
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx			
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL
25 MG, PO	85 DAY					
Initial or Prolonged	Haematemesis Haemoglobin Decreased	Professional				

Date:04/24/00ISR Number: 3491118-9Report Type:Expedited (15-DaCompany Report #WAES 00049105
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx			
Initial or Prolonged	Increased	Health	(Rofecoxib)	PS		ORAL
25 MG PO						

	Blood Uric Acid Increased	Professional	Tab Acenocumarol	SS ORAL 2 MG PO
	Cardiac Disorder		Hyzaar	C
	Coronary Artery Occlusion		Indocin	C
	Duodenal Ulcer			
	Haemorrhage			
	Gastric Ulcer			
	Gastrointestinal Haemorrhage			
	Haematemesis			
	Haematocrit Decreased			
	Haemoglobin Decreased			
	Melaena			
	Necrosis			
	Prothrombin Level Decreased			
	Red Blood Cell Sedimentation Rate Increased			

Date:04/24/00ISR Number: 3491442-XReport Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased

	Menorrhagia Systemic Lupus Erythematosus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Coumadin 2.5 Mg (Dupont)	PS	Dupont	ORAL	2.5 MG DAILY
			Vioxx (Merck)	SS	Merck	ORAL	
			Peaquenil	C			
			Prednisone	C			
			Montelukast	C			

Date:04/24/00ISR Number: 3492013-1Report Type:Expedited (15-DaCompany Report #200011757DDC
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Pain Upper	Foreign	Leflunomide	PS			
	Dyspepsia	Study	Vioxx	SS		ORAL	25 G / DAY PO
	Gastric Haemorrhage	Health	Meticorten	SS		ORAL	5 MG / DAY PO
	Gastritis Erosive	Professional Other	Higroton	C			

Date:04/24/00ISR Number: 3492266-XReport Type:Expedited (15-DaCompany Report #WAES 00048556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG PO

Date:04/24/00ISR Number: 3492292-0Report Type:Expedited (15-DaCompany Report #WAES 00010761
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Drug Interaction	Professional					MG/DAILY/PO	
	Hypertension		Monopril	SS		ORAL	PO	
	Hypoaesthesia		Elavil	C				
	Migraine		Meclizine	C				
	Migraine With Aura							
	Paraesthesia							
	Visual Disturbance							

Date:04/24/00ISR Number: 3492294-4Report Type:Expedited (15-DaCompany Report #WAES 00029757
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Memory Impairment	Foreign	Tab Vioxx					
Initial or Prolonged	Syncope	Health	(Rofecoxib)	PS		ORAL	25 MG	4 DAY
		Professional						

Date:04/24/00ISR Number: 3492403-7Report Type:Expedited (15-DaCompany Report #WAES 00041094
Age:76 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Respiratory Disorder						MG/DAILY/PO	
			Lasix	C				
			Synthroid	C				
			Zoloft	C				
			Digoxin	C				
			Megestrol Acetate	C				

Date:04/26/00ISR Number: 3493127-2Report Type:Expedited (15-DaCompany Report #WAES 99115207
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Foreign	Tab Rofecoxib	PS		ORAL	SEE IMAGE	24 DAY
Hospitalization -	Abdominal Pain Upper	Study	Insulin Lispro Rdna					
Initial or Prolonged	Melaena	Health	Origin	C				
	Nausea	Professional	Isophane Insulin Suspension	C				
			Methotrexate	C				

Date:04/26/00ISR Number: 3493128-4Report Type:Expedited (15-DaCompany Report #WAES 00041165
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biopsy Bone Marrow	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Abnormal	Professional					MG/DAILY/PO	
Other	Ecchymosis	Company	Antivert	C				
	Thrombocytopenia	Representative	Cipro	C				
			Isordil	C				
			Mevacor	C				
			Nitrostat	C				
			Norvasc	C				
			Zyloprim	C				

			Aspirin	C		
			Beclomethasone	C		

Date:04/26/00ISR Number: 3493129-6Report Type:Expedited (15-DaCompany Report #WAES 00032953
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Chest Pain	Health	Prilosec	C				
	Coronary Artery Disease	Professional	Insulin	C				
	Ear Haemorrhage							
	Hypertension							
	Myocardial Ischaemia							
	Upper Respiratory Tract Infection							

Date:04/26/00ISR Number: 3493130-2Report Type:Expedited (15-DaCompany Report #WAES 00021699
Age:78 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fluctuation	Professional					MG/DAILY/PO	
	Faecal Occult Blood	Company	Celebrex	C				
	Positive	Representative	Synthroid	C				
	Gastric Ulcer Haemorrhage		(Therapy					
	Haematemesis		Unspecified)	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased		Nonsteroidal					
	Pulse Abnormal		Anti-Inflammatory	C				

Date:04/26/00ISR Number: 3493131-4Report Type:Expedited (15-DaCompany Report #WAES 00021853
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Colitis Ischaemic	Health	Hydrodiuril	C				
	Face Oedema	Professional	Tiazac	C				
	Fluid Retention							
	Mesenteric Occlusion							
	Oedema Peripheral							

Date:04/26/00ISR Number: 3493134-XReport Type:Expedited (15-DaCompany Report #WAES 99111126
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Affective Disorder	Professional					MG/DAILY/PO	
	Agitation	Company	Effexor Xr	C				
	Anxiety	Representative	Lipitor	C				
	Chills		Ultram	C				
	Crying		Aspirin	C				
	Disturbance In Attention		Atenolol	C				

Drug Ineffective
Flight Of Ideas
Flushing
Hallucination
Mania
Muscle Twitching
Nausea
Nervousness
Pain
Psychotic Disorder
Retching
Tension

Date:04/26/00ISR Number: 3493141-7Report Type:Expedited (15-DaCompany Report #WAES 00025634
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Right	Foreign	Tab Vioxx					
	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL	12.5 MG PO	2 DAY
	Cardiac Failure	Professional	Hydrodiuril	C				
	Congestive		[Composition					
			Unspecified]	C				
			Phenprocoumon	C				

			Torsemide	C		

Date:04/26/00ISR Number: 3493160-0Report Type:Expedited (15-DaCompany Report #WAES 00035617
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	
			Tab Diclofenac	SS		ORAL	100 MG PO	
			Maxalt	C				

Date:04/26/00ISR Number: 3493162-4Report Type:Expedited (15-DaCompany Report #WAES 00011062
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Blood Creatinine	Health Professional	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
Disability	Increased	Company	Arava Unk	SS				
Other	Haemoglobin Decreased	Representative	Tab Vioxx Unk	SS		ORAL	12.5 MG/DAILY/PO	
	Nephritis Interstitial							
	Pyuria		Enbrel	C				
	Renal Failure Acute		[Therapy					
	Urine Abnormality		Unspecified]	C				

Date:04/27/00ISR Number: 3493646-9Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Consumer	Vioxx	PS			1 PER DAY	2
Required	Pruritus							
DOSES ONLY	2	DAY						

Intervention to Prevent Permanent Impairment/Damage
Respiratory Disorder
Urticaria

Date:04/27/00ISR Number: 3493661-5Report Type:Expedited (15-DaCompany Report #WAES 00041739
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukaemia	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional Company Representative						

Date:04/27/00ISR Number: 3493663-9Report Type:Expedited (15-DaCompany Report #WAES 00041794
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/00ISR Number: 3493666-4Report Type:Expedited (15-DaCompany Report #WAES 00041804
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Other	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Premarin	C				
			Synthroid	C				
			Propranolol	C				
			Vitamins	C				

Date:04/27/00ISR Number: 3493697-4Report Type:Expedited (15-DaCompany Report #WAES 00045583
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	UNKNOWN PO	2 WK
	Haemoglobin Decreased	Other						
	Thrombocytopenia		Captopril	C				
			Sotalol Hydrochloride	C				

Date:04/27/00ISR Number: 3493719-0Report Type:Expedited (15-DaCompany Report #WAES 00041330
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cystitis Haemorrhagic	Health Professional	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO	
	Urinary Retention							
		Company Representative	Claritin-D	C				

Date:04/27/00ISR Number: 3493721-9Report Type:Expedited (15-DaCompany Report #WAES 00041558
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	1	
	Ulcer	Professional					TABLET/DAILY/	
		Company					PO	
		Representative	Aspirin	C				

Date:04/27/00ISR Number: 3493724-4Report Type:Expedited (15-DaCompany Report #WAES 00041571
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Renal Failure	Professional						
		Company						
		Representative						

Date:04/27/00ISR Number: 3493766-9Report Type:Expedited (15-DaCompany Report #WAES 00040953
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
	Cholecystitis
	Diarrhoea

Gallbladder Disorder
Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx Unk	PS		ORAL	PO	6 WK
Health Professional	Atenolol	C				

Date:04/27/00ISR Number: 3493770-0Report Type:Expedited (15-DaCompany Report #WAES 00041370
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 25	Abdominal Mass	Health Professional	Vioxx	PS		ORAL	Initial or Prolonged MG/DAILY/PO;	
	Blood Creatine Increased						25 MG/ BID/ PO	
	Blood Immunoglobulin G Decreased							
	Blood Immunoglobulin M Decreased		Cozaar	C				
			Zocor	C				
	Calcinosis							
	Electrophoresis Abnormal							
	Glomerulonephritis							
	Minimal Lesion							
	Hypoproteinaemia							
	Lipiduria							
	Nephritis							
	Nephrotic Syndrome							
	Periorbital Oedema							
	Proteinuria							
	Renal Disorder							
	Renal Failure Acute							
	Urinary Casts							

Date:04/27/00ISR Number: 3493783-9Report Type:Expedited (15-DaCompany Report #WAES 00041845
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Upper Gastrointestinal	Professional				
MG/DAILY/PO						
Initial or Prolonged	Haemorrhage	Company	Accupril	C		
Other		Representative	Calan Sr	C		
			Caltrate	C		
			Hydrodiuril	C		
			Lasix	C		
			Miacalcin	C		
			Paxil	C		
			Tagamet	C		
			Tylenol With Codeine #3	C		
			Ferrous Sulfate	C		
			Trazodone	C		

Date:04/27/00ISR Number: 3493785-2Report Type:Expedited (15-DaCompany Report #WAES 00041933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Pulmonary Hypertension	Professional				
MG/DAILY/PO						
		Company Representative	Daypro	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/00ISR Number: 3493787-6Report Type:Expedited (15-DaCompany Report #WAES 00041735
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Consumer	Tab Vioxx	PS		ORAL	DAILY/ PO	
Initial or Prolonged	Haemoglobin Decreased		Avandia	C				
	Melaena		Zocor	C				

Date:04/27/00ISR Number: 3493788-8Report Type:Expedited (15-DaCompany Report #WAES 00045123
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Foreign	Tab Vioxx					
Initial or Prolonged	Thromboplastin Time	Other	(Rofecoxib)	PS		ORAL	12.5 MG, PO	
	Prolonged		Acetaminophen/Codein					
	Dehydration		e Phosphate	C				
	Haemorrhage		Factor Viii	C				
	Haemorrhage Intracranial		Ipratropium Bromide	C				
	Headache							
	Hepatitis C Antibody							
	Positive							
	Nausea							
	Vomiting							

Date:04/27/00ISR Number: 3493789-XReport Type:Expedited (15-DaCompany Report #WAES 00048213
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Tab Vioxx					
Initial or Prolonged	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	12.5 MG, PO	5 DAY
	Oesophageal Ulcer	Professional	Diclofenac Na	C				
			Ranitidine Hcl	C				

Date:04/27/00ISR Number: 3493790-6Report Type:Expedited (15-DaCompany Report #WAES 00045145
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG, PO	
			Amiloride Hydrochloride (+) Furosemide	C				
			Ferrous S04	C				

Date:04/27/00ISR Number: 3493792-XReport Type:Expedited (15-DaCompany Report #WAES 00047520
Age:98 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Hallucination	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	14 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/00ISR Number: 3493852-3Report Type:Expedited (15-DaCompany Report #WAES 00021866
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Coronary Artery Disease	Professional	Naprosyn	SS				
	Leukopenia	Company						
	Neutropenia	Representative						

Date:04/28/00ISR Number: 3493728-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Zyvox	PS				
			Vioxx	SS				

Date:04/28/00ISR Number: 3493771-2Report Type:Direct Company Report #
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine	Health	Vioxx	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Increased Hyperkalaemia	Professional						

Date:04/28/00ISR Number: 3494011-0Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Rofecoxib (Vioxx)	PS		ORAL	50MG PO 2	
Initial or Prolonged	Anaemia						WEEKS PTA	
	Cardiac Failure		Metoprolol Xl	C				
	Congestive		Nifedipine Xl	C				

	Chest Pain	Isordil	C
	Condition Aggravated	Mevacor	C
	Gastrointestinal	Ticlid	C
	Haemorrhage	Vioxx	C
	Melaena	Cozaar	C
	Oedema Peripheral	Xanax	C
	Pain In Jaw		

Date:04/28/00ISR Number: 3494399-0Report Type:Expedited (15-DaCompany Report #WAES 00022128
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cerebrovascular Accident							
	Drug Ineffective		Therapy Unspecified	C				
	Haemorrhage							
	Haemorrhage Subcutaneous							

Date:04/28/00ISR Number: 3494400-4Report Type:Expedited (15-DaCompany Report #WAES 00030292
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source
Death	Renal Failure	Health Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:05/01/00ISR Number: 3494525-3Report Type:Expedited (15-DaCompany Report #WAES 99111907
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Abdominal Pain	Health					MG/DAILY/PO	
Hospitalization -	Abdominal Tenderness	Professional	Proctocort	C				
Initial or Prolonged	Acute Respiratory		Tylenol	C				
	Distress Syndrome							
	Asthenia							
	Atelectasis							
	Bacterial Infection							
	Blood Creatine							
	Phosphokinase Increased							
	Candidiasis							
	Cardiac Arrest							
	Coma							
	Cyanosis							
	Differential White Blood							
	Cell Count Abnormal							
	Duodenal Ulcer							
	Perforation							
	Electrocardiogram							
	Abnormal							
	Escherichia Infection							
	Hyperhidrosis							
	Hyperkalaemia							
	Hypotension							
	Lethargy							
	Leukocytosis							
	Livedo Reticularis							
	Metabolic Acidosis							
	Oxygen Saturation							
	Decreased							
	Peritoneal Disorder							

Rales
Renal Impairment
Sepsis
Sinus Tachycardia
Staphylococcal Infection
Staphylococcal Sepsis
Streptococcal Infection
Tachypnoea
Urine Analysis Abnormal

Date:05/01/00ISR Number: 3494596-4Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome PT
Arthropathy
Cerebrovascular Disorder
Feeling Abnormal
Flushing
Headache

Malaise

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx 12.5mg Merck & Co	PS	Merck & Co		TABS 1 OD	

Date:05/01/00ISR Number: 3494606-4Report Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Perforation		Vioxx 25 Merck	PS		ORAL	25MG TID ORAL	

Date:05/01/00ISR Number: 3494622-2Report Type:Expedited (15-DaCompany Report #WAES 00048901
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ecchymosis	Foreign	Tab Vioxx					
Disability	Periorbital Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG PO	4 DAY
	Rash Generalised	Professional	Hydrodiuril	C				
	Stevens-Johnson Syndrome		Atenolol	C				
			Potassium Chloride	C				

Date:05/01/00ISR Number: 3494625-8Report Type:Expedited (15-DaCompany Report #WAES 00027939
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					
Initial or Prolonged	Renal Impairment	Health	(Rofecoxib)	PS		ORAL	25 MG PO	10 DAY
		Professional	Tab Vasotec					
			(Enalapril Maleate)	SS		ORAL	PO	9 YR

Date:05/01/00ISR Number: 3494626-XReport Type:Expedited (15-DaCompany Report #WAES 00041816
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Cardiac Disorder	Professional	Cardizem	C				
Other	Cardiac Failure		Darvocet-N	C				
	Congestive		Ecotrin	C				
	Cardiac Valve Disease		Fosamax	C				
	Cardiomegaly		Imdur	C				
	Dyspnoea		K-Dur	C				
	Electrocardiogram		Lasix	C				
	Abnormal		Os-Cal + D	C				
	Haematocrit Decreased		Zantac	C				
	Haemoglobin Decreased		Zocor	C				
	Heart Rate Irregular		Acetaminosalol	C				
	Hyperglycaemia		Atenolol	C				
	Hypertension		Prednisone	C				
	Hypokinesia		Vitamins	C				
	Myocardial Infarction							
	Oedema Peripheral							
	Pulmonary Oedema							
	Tachypnoea							
	Thrombocytopenia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3494640-4Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Rofecoxib 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Ecchymosis							
Initial or Prolonged	Facial Bones Fracture							
Required	Fall							
Intervention to	Haemorrhage							
Prevent Permanent	Idiopathic							
Impairment/Damage	Thrombocytopenic Purpura							
	Injury							
	Swelling							
	Syncope							
	Thrombocytopenia							

Date:05/01/00ISR Number: 3494641-6Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Transient		Vioxx	PS				
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Difficulty In Walking							
Disability	Dizziness							
	Eye Movement Disorder							
	Hypertension							
	Motor Dysfunction							
	Muscle Disorder							
	Speech Disorder							
	Vomiting							

Date:05/01/00ISR Number: 3494786-0Report Type:Expedited (15-DaCompany Report #WAES 00038598
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Foreign	Tab Rofecoxib	PS		ORAL	25 MG PO	11 DAY
Hospitalization -	Increased	Health	Fosamax	C				

Initial or Prolonged	Confusional State	Professional	Ascorbic Acid /B-Carotene/Vitamin E	C
	Fluid Retention		Diclofenac	C
	Hyponatraemia		Mometasone Furoate	C
	Klebsiella Infection		Valproic Acid Sodium Salt	C
	Orthostatic Hypotension		Vitamin B(12)	C
	Renal Failure Acute			
	Urinary Tract Infection			

Date:05/01/00ISR Number: 3494787-2Report Type:Expedited (15-DaCompany Report #WAES 00048902
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Asthenia
	Erosive Duodenitis
	Gastric Mucosal Lesion
	Gastritis Erosive
	Gastroenteritis
	Helicobacter
	Haematochezia
	Melaena

	Nausea Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO 14 DAY

Date:05/01/00ISR Number: 3494788-4Report Type:Expedited (15-DaCompany Report #WAES 00047520
Age:97 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Hallucination	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO 13 DAY
		Professional	Etidronic Acid Dina	C			
			Lisinopril	C			
			Magnesium Preparation	C			
			Niflunic Acid	C			
			Nitroglycerin	C			
			Piracetam	C			

Date:05/01/00ISR Number: 3494790-2Report Type:Expedited (15-DaCompany Report #WAES 00048518
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Fluid Retention Hyponatraemia Oedema Peripheral	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO 62 DAY
			Pepcid	C			
			Acetaminophen	C			
			Methotrexate	C			
			Prednisolone	C			

Date:05/01/00ISR Number: 3494792-6Report Type:Expedited (15-DaCompany Report #WAES 00047251
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Tab Vioxx					
	Chest Pain	Health	(Rofecoxib)	PS		ORAL	12.5 - 25 MG	
	Electrocardiogram St	Professional						
	Segment Depression		Tab Piroxicam	SS		ORAL	PO	
	Flatulence		Acetaminophen/Codein					
	Fluid Retention		e Phosphate	C				
	Gastroenteritis		Amiloride					
	Helicobacter		Hydochloride/Hctz	C				
	Peptic Ulcer Perforation		Ipratropium Bromide	C				
	Peritonitis							

Date:05/01/00ISR Number: 3494794-XReport Type:Expedited (15-DaCompany Report #WAES 00027293
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Tab Vioxx					
	Infection	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	
	Oedema		Tab Methotrexate					
	Pancytopenia		Dina	SS		ORAL	PO	8 YR
	Renal Failure		Acetaminopphen/Codei					
			ne Phosphate	C				

B Vitamin (+)	
Caffeine	C
Enoxaparin	C
Estradiol/Norethindr one Acetate	C

Date:05/01/00ISR Number: 3494796-3Report Type:Expedited (15-DaCompany Report #WAES 00010629
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Hyperthyroidism	Health Professional	Coumadin	C				
	Malaise		Depakote	C				
	Oedema Peripheral		Lasix	C				
	Renal Impairment		Composition Unspecified	C				
	Tremor							

Date:05/01/00ISR Number: 3495023-3Report Type:Expedited (15-DaCompany Report #WAES 00041135
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/ PO	
	Bite		Coumadin	C				
	Convulsion		K-Dur	C				
	Drug Hypersensitivity		Lasix	C				
	Electroencephalogram Abnormal		Paxil	C				
	Haemorrhage							
	Tongue Disorder							

Date:05/01/00ISR Number: 3495028-2Report Type:Expedited (15-DaCompany Report #WAES 00049123
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx					

Initial or Prolonged	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL
25 MG PO						
	Haemorrhage		Tab Aspirin	SS		ORAL
300 MG PO						
	Haematocrit Decreased		Vitamin E	C		
	Haemoglobin Decreased					

Date:05/01/00ISR Number: 3495029-4Report Type:Expedited (15-DaCompany Report #WAES 00045574
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Haemorrhage	Foreign	Tab Vioxx			
Hospitalization -		Other	(Rofecoxib)	PS		ORAL
12.5 MG 27 DAY						
Initial or Prolonged						

Date:05/01/00ISR Number: 3495057-9Report Type:Expedited (15-DaCompany Report #WAES 00045573
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia	Foreign	Tab Vioxx			
	Gastric Haemorrhage	Other	(Rofecoxib)	PS		ORAL
PO						
	Haemoglobin Decreased		Inhl Fluticasone			
	Melaena		Propionate (+)			

				Salmeterol	SS		
RESPIRATORY							
(INHALATION)	INH						
				L-Thyroxine	C		
				Digitoxin	C		
				Irbesartan	C		
				Metformin	C		
				Xipamide	C		

Date:05/01/00ISR Number: 3495061-0Report Type:Expedited (15-DaCompany Report #WAES 00045078
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Thrombosis Limb	Foreign	Tab Vioxx					
Hospitalization -	Myocardial Infarction	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	6 WK
Initial or Prolonged	Peripheral Embolism							

Date:05/01/00ISR Number: 3495064-6Report Type:Expedited (15-DaCompany Report #WAES 00041786
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	UNK/ UNK/ PO	
Initial or Prolonged	Congestive	Professional	Celebrex 200 Mg	SS		ORAL	200 MG /BID/	
	Condition Aggravated						PO	
	Drug Interaction		Coumadin 2.5 Mg	SS		ORAL	2.5 MG /	
	International Normalised						DAILY / PO	
	Ratio Increased		Digoxin	C				

Date:05/01/00ISR Number: 3495066-XReport Type:Expedited (15-DaCompany Report #WAES 00041958
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Arrest	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Hospitalization -	Renal Disorder		Coumadin	C		
Initial or Prolonged			Cozaar	C		
Disability			Lipitor	C		
			Composition			
			Unspecified	C		
			Aspirin	C		

Date:05/01/00ISR Number: 3495069-5Report Type:Expedited (15-DaCompany Report #WAES 00041847
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/						
Initial or Prolonged	Gastrointestinal	Professional				
DAILY/PO						
	Haemorrhage					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Pallor					

Date:05/01/00ISR Number: 3495226-8Report Type:Expedited (15-DaCompany Report #WAES 00022110
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Extrasystoles	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/						
		Health				
PO						
		Professional	Tab Vioxx 12.5 Mg	SS		ORAL
12.5 MG/						

DAILY/PO

Date:05/01/00ISR Number: 3495228-1Report Type:Expedited (15-DaCompany Report #WAES 00035611
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agranulocytosis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25.0 MG DAILY	22 DAY
Initial or Prolonged	Biopsy Bone Marrow	Health	Dipyrone Liq	SS		ORAL	20 DROPS DAILY	1 DAY
	Abnormal	Professional						
	Bone Marrow Depression		Allopurinol	C				
	Bronchopneumonia		Captopril	C				
	Haematocrit Decreased		Furosemide	C				
	Haemoglobin Decreased		Glimepiride	C				
	Laboratory Test Abnormal		Omeprazole	C				
	Red Blood Cell Count Decreased		Prednisolone	C				
	Red Blood Cell Sedimentation Rate Increased		Sulfasalazine	C				
	White Blood Cell Count Decreased							

Date:05/01/00ISR Number: 3495230-XReport Type:Expedited (15-DaCompany Report #WAES 00030695
Age:101 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Life-Threatening	Renal Failure Acute	Professional	Lasix	C				
Hospitalization -		Company	Pepcid	C				
Initial or Prolonged		Representative	Synthroid	C				
			Potassium Chloride	C				

Date:05/01/00ISR Number: 3495233-5Report Type:Expedited (15-DaCompany Report #WAES 00031624
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx	PS		ORAL	UNK / UNK / PO	

Date:05/01/00ISR Number: 3495234-7Report Type:Expedited (15-DaCompany Report #WAES 00032298
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization -	Phosphokinase Increased	Professional	Lescol	SS			3	YR
Initial or Prolonged	Drug Interaction	Other						
Disability	Renal Failure Acute							
Other	Rhabdomyolysis							

Date:05/01/00ISR Number: 3495237-2Report Type:Expedited (15-DaCompany Report #WAES 00032570
Age: Gender: I/FU:F

Outcome	PT	Report Source
Other	Renal Failure	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx Unk	PS		ORAL
50						
MG/DAILY/PO						
			[Therapy Unspecified]	C		

Date:05/01/00ISR Number: 3495240-2Report Type:Expedited (15-DaCompany Report #WAES 00040260
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Cardiac Failure	Professional				
MG/DAILY/PO						
Disability	Congestive	Company	Glucophage	C		
Other	Dyspnoea	Representative	Glucotrol Xl	C		
	Fluid Retention		Macrobid	C		
	Hypertension		Tenormin	C		
	Oedema		Toprol Xl Tablets	C		
	Ventricular Tachycardia		Vasotec	C		

Date:05/01/00ISR Number: 3495243-8Report Type:Expedited (15-DaCompany Report #WAES 00041739
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myeloid Leukaemia	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Petechiae	Professional				
	Thrombocytopenia	Company Representative				

Date:05/01/00ISR Number: 3495247-5Report Type:Expedited (15-DaCompany Report #WAES 00030905
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Congestive	Professional					PO	
Initial or Prolonged	Condition Aggravated	Company	Lasix	C				
Other	Hyperkalaemia	Representative	Prinivil	C				
	Medication Error		Allopurinol	C				
	Oliguria		Aspirin	C				
	Renal Failure Acute		Glyburide	C				
			Heparin	C				

Date:05/01/00ISR Number: 3495248-7Report Type:Expedited (15-DaCompany Report #WAES 00022322
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased
Other	Breath Sounds Decreased
	Cardiac Failure
	Congestive
	Condition Aggravated
	Confusional State
	Crepitations
	Dyspnoea
	Fluid Overload

		Haematocrit Decreased					
		Haemoglobin Decreased					
		Hyperglycaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence	Health	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY/PO							
		Oedema Peripheral	Professional	Imdur	C		
		Orthopnoea	Company	Norvasc	C		
		Protein Total Decreased	Representative	Proventil	C		
		Pulmonary Valve		Serevent	C		
		Incompetence		Aspirin	C		
		Weight Decreased					

Date:05/01/00ISR Number: 3495251-7Report Type:Expedited (15-DaCompany Report #WAES 00030863
Age:22 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Blood Pressure Increased	Health	Vioxx 12.5 Mg	PS		ORAL
12.5 MG/							
Hospitalization -		Chest Pain	Professional				
DAILY/ PO;							
Initial or Prolonged		Dermatitis	Company				
50 MG/ DAILY/							
		Ecchymosis	Representative				
PO							
		Hypersensitivity					
		Periorbital Oedema					
		Tongue Oedema					

Date:05/01/00ISR Number: 3495253-0Report Type:Expedited (15-DaCompany Report #WAES 00045546
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia Haemolytic	Foreign	Tab Vioxx			
Initial or Prolonged		Autoimmune	Health	(Rofecoxib)	PS		ORAL
25 MG PO							
		Coombs Direct Test	Professional	Cozaar	C		
		Positive					
		Haemoglobin Decreased					
		Hyperbilirubinaemia					

Date:05/01/00ISR Number: 3495302-XReport Type:Expedited (15-DaCompany Report #WAES 00041742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY /	
Hospitalization -	Hypotension	Health					PO	
Initial or Prolonged	Influenza Like Illness	Professional	Lipitor	C				
	Jaundice							
	Joint Swelling							
	Sepsis							
	Tachycardia							

Date:05/01/00ISR Number: 3495305-5Report Type:Expedited (15-DaCompany Report #WAES 00030337
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG /	
		Professional					DAILY/ PO	
		Company Representative	Relafen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3495307-9Report Type:Expedited (15-DaCompany Report #WAES 00045570
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Foreign	Tab Vioxx	PS		ORAL	75-125 MG PO	2 WK
Initial or Prolonged	Confusional State	Health						
	Hallucination	Professional						
	Medication Error							
	Memory Impairment							
	Overdose							
	Psychomotor Retardation							

Date:05/01/00ISR Number: 3495309-2Report Type:Expedited (15-DaCompany Report #WAES 00045578
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Tab Vioxx					
Initial or Prolonged	Gastric Ulcer Perforation		(Rofecoxib)	PS		ORAL	12.5 MG PO	
	Peritonitis							

Date:05/01/00ISR Number: 3495310-9Report Type:Expedited (15-DaCompany Report #WAES 00048578
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Foreign	Tab Vioxx					
Initial or Prolonged	Gastric Ulcer	Health	(Rofecoxib)	PS		ORAL	25 MG PO	29 DAY
	Gastritis	Professional	Acebutolol	C				
	Gastrointestinal		Acetaminophen	C				
	Haemorrhage		Allopurinol	C				
	Vomiting		Amlodipine Benzenesulfonate	C				
			Diltiazem D-Cis Form Hcl	C				
			Docusate Ca	C				
			Ferrous Gluconate	C				
			Furesemide	C				
			Levothyroxine Na	C				

Lorazepam	C
Nefidipine	C
Nonsteroidal Anti-Inflammatory Drug Ther	C
Ranitidine	C

Date:05/01/00ISR Number: 3495525-XReport Type:Expedited (15-DaCompany Report #2000USA00526
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Disseminated	Health	Plavix	PS		ORAL	75 MG QD PO	
Initial or Prolonged	Intravascular Coagulation	Professional	Vioxx	SS				
Other	Gastrointestinal Haemorrhage							
	Haemorrhage							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3495573-XReport Type:Expedited (15-DaCompany Report #WAES 99091573
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Aggression	Professional						
	Anxiety		Ambien	C				
	Asthenia		Plaquenil	C				
	Chills		Trazodone	C				
	Cold Sweat							
	Gastritis							
	Gastroenteritis							
	Helicobacter							
	Hunger							
	Irritable Bowel Syndrome							
	Nausea							
	Nervousness							
	Oral Intake Reduced							
	Suicidal Ideation							
	Weight Decreased							

Date:05/01/00ISR Number: 3495574-1Report Type:Expedited (15-DaCompany Report #WAES 00025699
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Tab Vioxx					
	Autoimmune Disorder	Health	(Rofecoxib)	PS		ORAL	PO	26 DAY
	Benign Prostatic	Professional	Phenprocoumon	SS				
	Hyperplasia	Company	Prinvil	C				
	Cardiac Failure	Representative	B-Methyldigoxin	C				
	Congestive		Levofloxacin	C				
	Condition Aggravated		Metoprolol Succinate	C				
	Coronary Artery Disease		Torsemide	C				
	Dermatitis		Urtica	C				
	Hypertension							
	Phlebitis							
	Phlebothrombosis							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							

Urinary Tract Infection
Vasculitis

Date:05/01/00ISR Number: 3495576-5Report Type:Expedited (15-DaCompany Report #WAES 00041094
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Health					MG/DAILY/PO	
	Condition Aggravated	Professional	Lasix	C				
	Lung Disorder		Synthroid	C				
	Pulmonary Oedema		Zoloft	C				
			Digoxin	C				
			Megestrol Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3495577-7Report Type:Expedited (15-DaCompany Report #WAES 00040347
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract Operation	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Duodenal Ulcer	Professional						
	Gastritis	Company	Premarin	C				
	Gastroenteritis	Representative	Atenolol	C				
	Helicobacter		Hydrochlorothiazide					
	Melaena		(+) Spironol	C				
	Nausea		Ketorolac	C				
			Prednisone	C				

Date:05/02/00ISR Number: 3495146-9Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Vioxx	PS		ORAL	PO	5 DAY
	Dermatitis Exfoliative							
	Dyspnoea							
	Oedema Peripheral							

Date:05/02/00ISR Number: 3495296-7Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy	Health	Captopril 50 Mg					
Life-Threatening	Cardiac Failure	Professional	Tablets	PS		ORAL	50MG PO TID	
Hospitalization -	Congestive		Vioxx 12.5 Mg Tablet	SS			12.5 MG QD	
Initial or Prolonged	Condition Aggravated		Ns W/ K+ 20 Meg/L	SS			75 CC/ML X 24HR	
	Congestive Cardiomyopathy							
	Diabetes Mellitus		Fdur	SS		ORAL	20MCG TID PO	

	Non-Insulin-Dependent	Captopril	C
	Hyperkalaemia	Furosemide	C
	Lobar Pneumonia	Zaroxolyn	C
	Renal Failure Acute	Synthroid	C
	Retching	Ec Asa	C
		Coumadin	C
		K-Dur	C
		Ferrous Sulfate	C
		Vioxx	C

Date:05/03/00ISR Number: 3495751-XReport Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematochezia	Consumer	Vioxx 50 Mg Tablet Msd	PS	Msd		1 TABLET PER DAY BY MOUTH	2 DAY

Date:05/03/00ISR Number: 3495790-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vomiting		Vioxx 12.5mg Po Qd	PS		ORAL	12.5MG PO QD	
			En Coat Asa 5gm Po QD	SS		ORAL	5GM QD PO	
			Prbc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/00ISR Number: 3496567-0Report Type:Expedited (15-DaCompany Report #WAES 00042599
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Thromboplastin Time	Professional					MG/DAILY/PO	
Initial or Prolonged	Prolonged	Company	Bacicoline A L					
	Blood Creatinine	Representative	Bacitracine	C				
	Increased		Colace	C				
	Blood Urea Increased		Coumadin	C				
	Disseminated		Coumadin	C				
	Intravascular Coagulation		Fleet Enema	C				
	Haematocrit Decreased		Isordil	C				
	Haematuria		Lanoxin	C				
	Haemoglobin Decreased		Lopressor	C				
	International Normalised		Phillips' Milk Of					
	Ratio Increased		Magnesia	C				
	Sepsis		Ventolin	C				
	Urinary Tract Infection		Zantac	C				
	White Blood Cell Count							
	Increased							

Date:05/03/00ISR Number: 3496570-0Report Type:Expedited (15-DaCompany Report #WAES 00042582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Prozac	C				
			Tylenol	C				
			Analgesic Or					
			Anesthetic Preparat	C				

Date:05/03/00ISR Number: 3496584-0Report Type:Expedited (15-DaCompany Report #WAES 00021101
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cholestasis	Health	Tab Vioxx	PS		ORAL	PO	
Life-Threatening	Condition Aggravated	Professional	Neurontin	SS				
Hospitalization -	Hepatic Cirrhosis		Celebrex	SS		ORAL	PO	
Initial or Prolonged	Hepatic Failure		Ambien	C				
Other	Hepatic Neoplasm		Cozaar	C				
	Malignant		Klonopin	C				
	Hepatitis Cholestatic		Norvasc	C				
	Hyperbilirubinaemia		Percocet	C				
	Jaundice		Reglan	C				
	Liver Function Test Abnormal							
	Prothrombin Time Prolonged							

Date:05/03/00ISR Number: 3496654-7Report Type:Expedited (15-DaCompany Report #WAES 00042598
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/	
Other		Professional					PO	
		Company Representative						

Date:05/03/00ISR Number: 3496656-0Report Type:Expedited (15-DaCompany Report #WAES 00022278
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Other	Composition Unspecified	C				
	Gastrointestinal Ulcer							
	Melaena							

Date:05/03/00ISR Number: 3496657-2Report Type:Expedited (15-DaCompany Report #WAES 00042498
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Calculus Urinary	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged								

Date:05/03/00ISR Number: 3496659-6Report Type:Expedited (15-DaCompany Report #WAES 00030912
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization -	Diarrhoea	Health	Arava Unk	SS				
Initial or Prolonged	Dyspepsia	Professional	Medrol	C				
Other	Eructation		Premarin	C				
	Gastrointestinal Motility		Tylenol	C				
	Disorder		Calcium Supplement					
	Hypertension		(Composition)	C				
	Rheumatoid Arthritis							
	Vertigo							
	Vision Blurred							
	Vomiting							

Date:05/03/00ISR Number: 3496661-4Report Type:Expedited (15-DaCompany Report #WAES 00032015
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Abnormal	Health	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	
Life-Threatening	Cardiac Failure	Professional	Ultram Unk	SS				
Disability	Duodenal Ulcer	Company	Cardizem	C				
Other	Gastric Perforation	Representative	Celebrex	C				
	Gastritis Erosive		Coumadin	C				
	Haemoptysis		Tylenol	C				
	Knee Arthroplasty		Zestril	C				
	Pain		[Therapy Unspecified]	C				
	Post Procedural Complication		Aspirin	C				
	Prothrombin Time Prolonged							
	Pulse Abnormal							
	Respiratory Failure							
	Stress							
	Upper Gastrointestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/00ISR Number: 3496727-9Report Type:Expedited (15-DaCompany Report #WAES 00042381
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Lung Infiltration	Professional						
	Pneumonia		Sectral	C				
	Pulmonary Fibrosis		Zocor	C				
	Pulmonary Function Test Decreased		Influenza Virus Vaccine	C				

Date:05/04/00ISR Number: 3495961-1Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Consumer	Vioxx As Prescribed	PS				
	Coagulopathy							
	Liver Function Test Abnormal							
	Myocardial Infarction							
	Post Procedural Complication							

Date:05/04/00ISR Number: 3496535-9Report Type:Expedited (15-DaCompany Report #WAES 00042094
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY PO	
	Muscular Weakness							
	Tremor		Coumadin	C				
			Lanoxin	C				

Date:05/04/00ISR Number: 3496537-2Report Type:Expedited (15-DaCompany Report #WAES 00042136
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Face Oedema		Diabinese	C				
			Lanoxin	C				

Date:05/04/00ISR Number: 3496540-2Report Type:Expedited (15-DaCompany Report #WAES 00042319
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PRN	PO
	Haemorrhage	Professional Company Representative						

Date:05/04/00ISR Number: 3496546-3Report Type:Expedited (15-DaCompany Report #WAES 00042400
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/00ISR Number: 3496547-5Report Type:Expedited (15-DaCompany Report #WAES 00010815
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5MG/DAILY/						
Initial or Prolonged	Coordination Abnormal	Health				
PO SEE IMAGE						
	Dysarthria	Professional	Celebrex	C		
	Transient Ischaemic		Diovan	C		
	Attack		Lasix	C		
			Pravachol	C		
			Ascorbic Acid	C		
			Labetalol	C		
			Potassium Supplement			
			(Compositio	C		

Date:05/04/00ISR Number: 3496551-7Report Type:Expedited (15-DaCompany Report #WAES 00035668
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx			
Initial or Prolonged	Increased	Health	(Rofecoxib)	PS		ORAL
PO						
	Blood Urea Increased	Professional	Khco3/K Citrate	C		
	Haemoglobin Decreased		Amlodipine	C		
	Liver Function Test		Calcitriol	C		
	Abnormal		Cyclosporin A	C		
	Oedema Peripheral		Metoprolol	C		
	Renal Failure Acute		Omeprazole	C		
	Syncope		Prednisone	C		
			Torsemide	C		

Date:05/04/00ISR Number: 3496555-4Report Type:Expedited (15-DaCompany Report #WAES 00045186
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Colonic Haemorrhage	Foreign	Tab Vioxx			
Hospitalization -	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL
12.5 MG;PO 30 DAY						

Initial or Prolonged	Diverticulum Intestinal	Zocor	C
Disability	Haemorrhagic	Aspirin	C
		Omeprazole	C

Date:05/04/00ISR Number: 3496556-6Report Type:Expedited (15-DaCompany Report #WAES 00037313
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Leukopenia	Foreign	Tab Vioxx					
Life-Threatening	Neoplasm Malignant	Health	(Rofecoxib)	PS		ORAL	PO	1 WK
	Pain	Professional	Tab Nitrofurantoin	SS		ORAL	PO	2 WK
			Ketobemidone	C				

Date:05/04/00ISR Number: 3496565-7Report Type:Expedited (15-DaCompany Report #WAES 00045078
Age:88 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization -	Arterial Thrombosis Limb
Initial or Prolonged	Atherosclerosis
Disability	Bursitis
Other	Cardiac Murmur

		Chest Pain					
		Condition Aggravated					
		Echocardiogram Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis	Foreign	Tab Vioxx			
		Gastroenteritis	Health	(Rofecoxib)	PS		ORAL
25 MG, PO	124 DAY						
		Haemoglobin Decreased	Professional	Albuterol	C		
		Hypotension		Aspirin	C		
		Left Ventricular Failure		Beclomethasone			
		Livedo Reticularis		Dipropionate	C		
		Lower Respiratory Tract		Captopril/Hctz	C		
		Infection		Digoxin	C		
		Medication Error		Diltiazem	C		
		Myocardial Infarction		Tamoxifen	C		
		Nausea					
		Pain In Extremity					
		Pallor					
		Peripheral Coldness					
		Peripheral Vascular					
		Disorder					
		Renal Failure					
		Vomiting					

Date:05/04/00ISR Number: 3496609-2Report Type:Expedited (15-DaCompany Report #WAES 00045536
Age:85 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Haemorrhage	Foreign	Tab Vioxx			
Hospitalization -		Gastritis Erosive	Health	(Rofecoxib)	PS		ORAL
PO	15 DAY						
Initial or Prolonged		Melaena	Professional	Levothyroxine Na	C		
Disability				Verapamil	C		

Date:05/04/00ISR Number: 3496698-5Report Type:Expedited (15-DaCompany Report #WAES 00042066
Age:88 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Consumer	Vioxx 12.5 Mg	PS		ORAL
12.5							

Initial or Prolonged		Bradycardia					
MG/DAILY/PO							
		Dermatitis		Inderal	C		
		Haematuria					
		Pneumonia					

Date:05/04/00ISR Number: 3496701-2Report Type:Expedited (15-DaCompany Report #WAES 00042092
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dyspnoea	Consumer	Vioxx 12.5 Mg	PS		ORAL
12.5 MG/1X/PO							
		Heart Rate Increased					
		Respiratory Arrest					
		Respiratory Failure					
		Sedation					
		Sensation Of Heaviness					
		Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/00ISR Number: 3496891-1Report Type:Expedited (15-DaCompany Report #2000COU0532
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Coumadin	PS		ORAL	2.5 MG QD PO	
Initial or Prolonged	Cardiac Failure	Professional	Celebrex (Celecoxib)	SS		ORAL	0-200 MG BID	
	Congestive						PO	
	Condition Aggravated		Vioxx (Rofecoxib)	SS				
	Drug Interaction		Digoxin	C				
	International Normalised Ratio Increased							

Date:05/04/00ISR Number: 3496940-0Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neck Pain		Vioxx	PS				
FRI --> TUES								
Hospitalization -	Pulmonary Congestion							
Initial or Prolonged								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:05/04/00ISR Number: 3496963-1Report Type:Direct Company Report #
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ulcer	Health Professional	Vioxx	PS				

Date:05/04/00ISR Number: 3496964-3Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis	Health Professional	Vioxx	PS				

Date:05/04/00ISR Number: 3510775-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain		Vioxx	PS	Merck			
	Skin Lesion							

Date:05/05/00ISR Number: 3497048-0Report Type:Expedited (15-DaCompany Report #WAES 00042319
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Haemorrhage	Professional	Zoloft	C				
	Melaena	Company	Imipramine	C				
		Representative	Verapamil	C				

Date:05/05/00ISR Number: 3497066-2Report Type:Expedited (15-DaCompany Report #WAES 00030241
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypoglycaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Life-Threatening	Myocardial Infarction	Professional					MG/DAILY/PO	
			Epogen	C				

Date:05/05/00ISR Number: 3497068-6Report Type:Expedited (15-DaCompany Report #WAES 00040257
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Increased	Professional					MG/DAILY/PO	
Hospitalization -	Blood Urea Increased		Catapres Tts	C				
Initial or Prolonged	Dialysis		Colace	C				
Other	Dysarthria		Darvocet-N	C				
	Dyspnoea		Lasix	C				
	Renal Failure		Synthroid	C				
	Respiratory Failure		Colchicine	C				
			Labetalol	C				
			Nitroglycerin	C				
			Prazosin	C				
			Vitamin E	C				

Date:05/05/00ISR Number: 3497069-8Report Type:Expedited (15-DaCompany Report #WAES 00032864
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Dizziness	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Company	Actos	C				
	Melaena	Representative	Imdur	C				
	Myocardial Infarction		Lopid	C				

			Minipress	C		
			Procardia Xl	C		
			Relafen	C		
			Aspirin	C		
			Atenolol	C		

Date:05/05/00ISR Number: 3497071-6Report Type:Expedited (15-DaCompany Report #WAES 00049123
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haematocrit Decreased	Health	(Rofecoxib)	PS		ORAL	12.5 MG, PO	42 DAY
Initial or Prolonged	Haemoglobin Decreased	Professional	Tab Aspirin	SS		ORAL	300MG, PO	
	Upper Gastrointestinal Haemorrhage		Vitamin E	C				

Date:05/05/00ISR Number: 3497127-8Report Type:Expedited (15-DaCompany Report #000214-SK614
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prothrombin Time	Health	Celebrex	PS		ORAL	PO	
Hospitalization -	Prolonged	Professional	Vioxx	SS		ORAL	PO	
Initial or Prolonged			Metoclopramide	C				
Other			Zolpidem	C				

Losartan Potassium	C
Amlodipine Besylate	C
Gabapentin	C
Acetaminophen	C
Oxycodone Hydrochloride	C
Clonazepam	C

Date:05/05/00ISR Number: 3497143-6Report Type:Expedited (15-DaCompany Report #WAES 00032029
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Health	Tab Vioxx Unk	PS		ORAL	PO	1 WK
Initial or Prolonged	Gastric Ulcer	Professional	Synthroid	C				
	Gastrointestinal Haemorrhage	Other						
	Haematemesis							
	Haemoglobin Decreased							

Date:05/05/00ISR Number: 3497147-3Report Type:Expedited (15-DaCompany Report #WAES 00045183
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Foreign	Tab Vioxx					
	Arthralgia	Consumer	(Rofecoxib)	PS		ORAL	PO	
	Asthenia		Diclofenac Sodium					
	Back Pain		(+) Misoprostol	C				
	Depression		Warfarin	C				
	Dermatitis Exfoliative							
	Difficulty In Walking							
	Ecchymosis							
	Fatigue							
	Headache							
	Influenza							
	Insomnia							
	Listless							
	Mouth Ulceration							
	Muscle Haemorrhage							
	Pain In Extremity							

Rhinorrhoea
Skin Exfoliation
Sleep Disorder Due To
General Medical
Condition, Insomnia Type
Spinal Disorder
Stress

Date:05/05/00ISR Number: 3497156-4Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Coumadin	PS		ORAL	5 MG PO	
Hospitalization - Initial or Prolonged			Vioxx	SS		ORAL	12.5/25 PO	

Date:05/08/00ISR Number: 3497704-4Report Type:Expedited (15-DaCompany Report #WAES 00030399
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / BID /	
Hospitalization -	Duodenal Ulcer	Health					PO	
Initial or Prolonged	Haemorrhage	Professional	Insulin	C				
Disability	Haematemesis							
Other	Upper Gastrointestinal Haemorrhage							

Date:05/08/00ISR Number: 3497711-1Report Type:Expedited (15-DaCompany Report #WAES 00022223
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Bilirubin Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Life-Threatening	Bradycardia	Professional					/ PO	
Hospitalization -	Cardiogenic Shock	Company Representative	Therapy Unspecified	C				
Initial or Prolonged	Cholestasis	Other						
Disability	Embolism							
Other	Faecal Occult Blood Positive							
	Gastric Ulcer Haemorrhage							
	Gastritis Erosive							
	Haematemesis							
	Haemoglobin Decreased							
	Hypovolaemia							
	Jaundice							
	Melaena							
	Myocardial Infarction							
	Syncope Vasovagal							
	Upper Gastrointestinal Haemorrhage							

Date:05/08/00ISR Number: 3497717-2Report Type:Expedited (15-DaCompany Report #WAES 00032421
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
Initial or Prolonged	Duodenal Ulcer	Professional					DAILY / PO	
	Haemorrhage	Company	Isordil	C				
	Gastric Ulcer Haemorrhage	Representative	Procardia Xl	C				
			Atenolol	C				

Date:05/08/00ISR Number: 3497723-8Report Type:Expedited (15-DaCompany Report #WAES 00040122
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Hepatitis							
	Pancreatitis							
	Pneumonia							

Date:05/08/00ISR Number: 3497728-7Report Type:Expedited (15-DaCompany Report #WAES 00040251
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anaemia Endoscopy Abnormal Gastric Ulcer Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
Other	Haematemesis Haematocrit Decreased Haemoglobin Decreased Melaena Orthostatic Hypotension	Representative	Tab Vioxx 25 Mg Tylenol Zantac (Therapy Unspecified) Ibuprofen	SS C C C C		ORAL	25 MG/DAILY/PO	

Date:05/08/00ISR Number: 3497741-XReport Type:Expedited (15-DaCompany Report #WAES 00040662
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Hepatitis Fulminant Nausea	Professional Company	Celexa	C				
Other	Vomiting	Representative	Diflucan Don Quai Complex Flagyl Levaquin Restoril Tegretol	C C C C C C				

Date:05/08/00ISR Number: 3497745-7Report Type:Expedited (15-DaCompany Report #WAES 00025558
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					

Initial or Prolonged	Blood Bilirubin Increased	Health	(Rofecoxib)	PS		ORAL
25 MG PO 25 DAY						
	Hepatitis	Professional	Aspirin	C		
	Liver Function Test		Dipyrone	C		
	Abnormal		Fenoterol			
	Nausea		Hydrobromide (+)			
			Ipratropium B	C		
			Trihexyphnidyl Hcl	C		

Date:05/08/00ISR Number: 3497749-4Report Type:Expedited (15-DaCompany Report #WAES 00045214
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer Perforation	Foreign	Tab Vioxx			
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL
25 MG PO						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Methyldopa	C		
			Nifedipine	C		
			Nizatidine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/00ISR Number: 3497752-4Report Type:Expedited (15-DaCompany Report #WAES 00045619
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Professional	Aspirin	C				
			Verapamil	C				

Date:05/08/00ISR Number: 3497754-8Report Type:Expedited (15-DaCompany Report #WAES 00042000
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ventricular Fibrillation	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Azulfidine	C				

Date:05/08/00ISR Number: 3497755-XReport Type:Expedited (15-DaCompany Report #WAES 00050038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Syncope	Professional					MG/DAILY/PO	
			Estrogenic Preparations	C				

Date:05/08/00ISR Number: 3497757-3Report Type:Expedited (15-DaCompany Report #WAES 00050135
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aplastic Anaemia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	3 DAY
Initial or Prolonged	Capillary Disorder							
	Epistaxis							

Swelling

Date:05/08/00ISR Number: 3497759-7Report Type:Expedited (15-DaCompany Report #WAES 00050103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	10 DAY
	Haemorrhage	Professional						

Date:05/08/00ISR Number: 3497760-3Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Rofecoxib 25 Mg Qd	PS			25MG DAILY	
	Congestive Condition Aggravated	Professional						
	Oedema Peripheral							

Date:05/08/00ISR Number: 3497761-5Report Type:Expedited (15-DaCompany Report #WAES 00050115
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal	Health
	Haemorrhage	Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:05/08/00ISR Number: 3497762-7Report Type:Expedited (15-DaCompany Report #WAES 00047297
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Foreign	Tab Vioxx					
Hospitalization -	Increased		(Rofecoxib)	PS		ORAL	12.5 MG	6 DAY
Initial or Prolonged	C-Reactive Protein		Vasotec	C				
	Increased		Acetaminophen	C				
	Dehydration		Allopurinol	C				
	Myoglobin Blood Increased		Clopidogrel					
	Renal Failure		Bisulfate	C				
	Rhabdomyolysis		Dixyrazine	C				
			Furosemide	C				
			Ketobemidone Hcl	C				
			Metoprolol Tartrate	C				
			Nitroglycerin	C				
			Tramadol	C				
			Vitamin B{12}	C				

Date:05/08/00ISR Number: 3497764-0Report Type:Expedited (15-DaCompany Report #WAES 00047524
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Foreign	Tab Vioxx					
	Hypotension	Health	(Rofecoxib)	PS		ORAL	12.5 MG	
	Nausea	Professional	Bezafibrate	C				
	Syncope							
	Tachycardia							
	Weight Decreased							

Date:05/08/00ISR Number: 3497767-6Report Type:Expedited (15-DaCompany Report #WAES 00021855
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
Initial or Prolonged	Oedema Peripheral	Health					/ PO	
	Skin Ulcer	Professional	Potassium Supplement	C				
			Therapy Unspecified	C				

Date:05/08/00ISR Number: 3497771-8Report Type:Expedited (15-DaCompany Report #WAES 00032541
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dizziness	Health					MG/DAILY/PO	
	Dysphagia	Professional	Wellbutrin Sr 150 Mg	SS		ORAL	150 MG/BID/PO	
	Pharyngeal Oedema							
	Pharyngitis							
	Pyrexia							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/00ISR Number: 3497774-3Report Type:Expedited (15-DaCompany Report #WAES 00042556
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	2 MON
Initial or Prolonged	Haematuria		Augmentin	C				
	Pneumonia		Timoptic	C				
			Aspirin	C				

Date:05/08/00ISR Number: 3497776-7Report Type:Expedited (15-DaCompany Report #WAES 00042511
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ BID/PO	
Initial or Prolonged	Disorientation		Compositon					
	Feeling Abnormal		Unspecified	C				
	Grand Mal Convulsion							
	Oedema Peripheral							

Date:05/08/00ISR Number: 3497777-9Report Type:Expedited (15-DaCompany Report #WAES 00042507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gingival Recession	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oral Soft Tissue Disorder							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:05/08/00ISR Number: 3497780-9Report Type:Expedited (15-DaCompany Report #WAES 00042665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Gastrointestinal Disorder		Prevacid	C				
	Suicidal Ideation		Vicodin Tablets	C				

Date:05/08/00ISR Number: 3497783-4Report Type:Expedited (15-DaCompany Report #WAES 00050003
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiac Disorder							

Date:05/08/00ISR Number: 3497786-XReport Type:Expedited (15-DaCompany Report #WAES 00050154
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Epistaxis						MG/DAILY/PO	
	Paraesthesia		Cardizem Cd	C				
			Effexor	C				
			Elavil	C				
			Nph Insulin	C				
			Prinivil	C				
			Tagamet	C				
			Estradiol	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/00ISR Number: 3497799-8Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Rofecoxib 25mg	PS		ORAL	25MG PO QD	
Initial or Prolonged	Congestive Dyspnoea Orthopnoea							

Date:05/08/00ISR Number: 3497804-9Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Rofecoxib 25mg	PS			25MG QD	

Date:05/08/00ISR Number: 3497805-0Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Rofecoxib 25 Mg Qd	PS			25MG QD	
Initial or Prolonged	Congestive Condition Aggravated							

Date:05/08/00ISR Number: 3497870-0Report Type:Expedited (15-DaCompany Report #WAES 00048757
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Blood Amylase Increased	Health	(Rofecoxib)	PS		ORAL	25 MG PO	4 DAY
Other	Pancreatitis	Professional Other						

Date:05/08/00ISR Number: 3497872-4Report Type:Expedited (15-DaCompany Report #WAES 00048605
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:05/08/00ISR Number: 3497873-6Report Type:Expedited (15-DaCompany Report #WAES 00047309
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	13 DAY
			Albutetrol Sulfate	C				
			Budesonide	C				
			Dipyridamole	C				
			Estradiol/Norethrindrone Acetate	C				
			Papaverine	C				

Date:05/08/00ISR Number: 3497876-1Report Type:Expedited (15-DaCompany Report #WAES 00045616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	3 DAY

Date:05/08/00ISR Number: 3498077-3Report Type:Expedited (15-DaCompany Report #WAES 00045610
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paresis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG, PO	

Date:05/08/00ISR Number: 3498078-5Report Type:Expedited (15-DaCompany Report #WAES 00045216
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG, PO	
	Myocardial Infarction							

Date:05/08/00ISR Number: 3498080-3Report Type:Expedited (15-DaCompany Report #WAES 00042537
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive	Professional						
	Oedema		Ecotrin	C				
	Weight Increased		Zocor	C				

				Amiodarone	C		
				Atenolol	C		

Date:05/08/00ISR Number: 3498081-5Report Type:Expedited (15-DaCompany Report #WAES 00042786
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
Initial or Prolonged	Abdominal Pain		Phenergan			
	Diarrhoea		Tablets/Suppositorie			
	Hypertension		s	C		
	Urticaria		Premarin	C		
	Vomiting					

Date:05/08/00ISR Number: 3498086-4Report Type:Expedited (15-DaCompany Report #WAES 00042816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Fall	Health	Tab Vioxx Unk	PS		ORAL
PO						
Life-Threatening	Gastrointestinal	Professional	Prednisone	C		
Hospitalization -	Haemorrhage	Company				
Initial or Prolonged	Haemoglobin Decreased	Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/00ISR Number: 3498090-6Report Type:Expedited (15-DaCompany Report #WAES 00032098
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Premarin (Composition Unspecified)	C				
			Calcium Supplement (Composition	C				
			Cortisone	C				
			Vitamin D	C				

Date:05/08/00ISR Number: 3498094-3Report Type:Expedited (15-DaCompany Report #WAES 00021619
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Convulsion							
	Fatigue		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Headache							
	Sedation		Buspar Unk	SS			15 MG	
			Cardura	C				
			Prevacid	C				

Date:05/08/00ISR Number: 3498098-0Report Type:Expedited (15-DaCompany Report #WAES 00031912
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Glomerulonephritis	Professional		
MG/DAILY/PO				
	Gout		Cipro	C
	Haemodialysis		Indocin	
	Nephritis		(Indomethacin)	C
	Oedema		Medrol	C
	Renal Failure Acute			
	Renal Failure Chronic			
	Renal Impairment			

Date:05/09/00ISR Number: 3497751-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Skin Ulcer		Vioxx 25mg Qd	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Vasculitis		Asthma Inhalers	C				

Date:05/09/00ISR Number: 3498549-1Report Type:Expedited (15-DaCompany Report #200011419HMRI
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Other	Balance Disorder
	Drug Hypersensitivity
	Electrolyte Imbalance
	Faeces Discoloured

Feeling Hot

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lasix	PS	Aventis Pharmaceuticals Inc	ORAL	PO	
	Hyaluronate Sodium (Synvisc) Solution For Injection	SS			QW	
	Rofecoxib (Vioxx) Tablets	SS		ORAL	25MG/DAY PO	
	Calcium	C				
	Glucosamine	C				
	Fluoxetine Hydrochloride (Prozac)	C				
	Triamterene	C				
	Vitamins Nos (Vitamin Nos)	C				
	Alprazolam (Xanax)	C				

Date:05/10/00ISR Number: 3498207-3Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Vioxx	PS	Merck Sharp & Dohme			

Date:05/10/00ISR Number: 3498492-8Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG ORALLY	
Hospitalization -	Blood Urea Increased							DAILY
Initial or Prolonged	Condition Aggravated		Lasix	C				
Required	Drug Interaction		Zaroxolyn	C				
Intervention to	Gastric Ulcer		Potassium	C				

Prevent Permanent Impairment/Damage	Hyperkalaemia Oedema Renal Failure Acute Renal Impairment		Zestril	C

Date:05/10/00ISR Number: 3498497-7Report Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure Jaundice		Parafon Forte 500mg Bid	PS			500MG BID	
			Vioxx 25mg Qd	SS			25MG QD	

Date:05/10/00ISR Number: 3498804-5Report Type:Expedited (15-DaCompany Report #WAES 00040045
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Upper Gastrointestinal Haemorrhage		Ibuprofen Unk	SS			1800	

MG/DAILY/UNK

	Cozaar	C
	Glucophage	C
	Imitrex	C
	Prozac	C
	Synthroid	C
	Tylenol With Codeine #3	C
	Estradiol	C
	Glyburide	C

Date:05/10/00ISR Number: 3498806-9Report Type:Expedited (15-DaCompany Report #WAES 00041028
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis Condition Aggravated Haematuria Malaise	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
	Musculoskeletal Stiffness Pain		Oruvail Unk	SS		ORAL	200 MG/DAILY/PO	
	Renal Necrosis Renal Papillary Necrosis Urine Abnormality		Orudis Aspirin	C C				

Date:05/10/00ISR Number: 3498808-2Report Type:Expedited (15-DaCompany Report #WAES 00045574
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	27 DAY

Date:05/10/00ISR Number: 3498809-4Report Type:Expedited (15-DaCompany Report #WAES 00048757
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Pancreatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY

Date:05/10/00ISR Number: 3498811-2Report Type:Expedited (15-DaCompany Report #WAES 00048757
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Pancreatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY

Date:05/10/00ISR Number: 3498875-6Report Type:Expedited (15-DaCompany Report #WAES 00047253
Age:63 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris Angina Unstable Blood Amylase Decreased Chest Discomfort

		Chest Pain					
		Dyspnoea					
		Leukocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Disorder	Foreign	Tab Vioxx			
		Pleural Disorder	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO							
		Pneumothorax	Professional	Acetaminophen	C		
		Pulmonary Fibrosis		Fluticasone (+)			
		Respiratory Acidosis		Salmeterol	C		
		Sinus Tachycardia		Furosemide	C		
		Subcutaneous Emphysema		Prednisolone	C		
				Terbutaline Sulfate	C		
				Theophylline	C		
				Warfarin Sodium	C		

Date:05/10/00ISR Number: 3498876-8Report Type:Expedited (15-DaCompany Report #WAES 00048608
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Disorientation	Foreign	Tab Vioxx			
		Memory Impairment	Health	(Rofecoxib)	PS		ORAL
50 MG PO							
		Neurosis	Professional	Vasotec	C		
		Speech Disorder		Docusate Na	C		
				Lansoprazole	C		

Date:05/10/00ISR Number: 3498877-XReport Type:Expedited (15-DaCompany Report #WAES 00049823
Age:55 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Angioneurotic Oedema	Foreign	Tab Vioxx			
		Stridor	Health	(Rofecoxib)	PS		ORAL
12.5 MG PO	3 DAY						
		Urticaria	Professional	Tetrazepam	C		

Date:05/10/00ISR Number: 3498985-3Report Type:Expedited (15-DaCompany Report #WAES 00040041
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Health	Tab Vioxx 25 Mg	PS	Merck Research			
	Optic Disc Haemorrhage	Professional			Laboratories Div			
	Optic Nerve Sheath				Merck Co Inc	ORAL	25	
	Haemorrhage						MG/DAILY/PO	
	Retinal Tear		Coumadin	SS				
			Lipitor	C				
			Relafen	C				
			Synthroid	C				
			Triazolam	C				

Date:05/10/00ISR Number: 3499014-8Report Type:Expedited (15-DaCompany Report #WAES 00050150
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diverticular Perforation	Health	Vioxx	PS	Merck Research			
Life-Threatening	Diverticulitis	Professional			Laboratories Div			
Hospitalization -					Merck Co Inc	ORAL	25	
Initial or Prolonged							MG/DAILY/PO	
Disability			Celebrex	C				

Date:05/10/00ISR Number: 3499016-1Report Type:Expedited (15-DaCompany Report #WAES 00050209
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Prevacid	C				

Date:05/10/00ISR Number: 3499019-7Report Type:Expedited (15-DaCompany Report #WAES 00050212
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort Cold Sweat Myocardial Infarction Neck Pain Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:05/10/00ISR Number: 3499022-7Report Type:Expedited (15-DaCompany Report #WAES 00050235
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Aspirin	C				
			Vitamins	C				

Date:05/10/00ISR Number: 3499082-3Report Type:Expedited (15-DaCompany Report #WAES 00050299
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Bronchospasm Dry Skin	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea Face Oedema Hypersensitivity Pruritus Rash Erythematous Stevens-Johnson Syndrome		Lamisil Estrace Aspirin	SS C C				

Date:05/10/00ISR Number: 3499084-7Report Type:Expedited (15-DaCompany Report #WAES 00050313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/00ISR Number: 3499086-0Report Type:Expedited (15-DaCompany Report #WAES 00050339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:05/10/00ISR Number: 3499087-2Report Type:Expedited (15-DaCompany Report #WAES 00050665
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Detrol	C				

Date:05/10/00ISR Number: 3499088-4Report Type:Expedited (15-DaCompany Report #WAES 00055515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Valve Disease Purpura Skin Lesion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/10/00ISR Number: 3499090-2Report Type:Expedited (15-DaCompany Report #WAES 00010398
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Health	Vioxx	PS	Merck Research			

Life-Threatening	Bacterial Infection	Professional			Laboratories Div	
Hospitalization -	Blood Alkaline				Merck Co Inc	ORAL
25						
Initial or Prolonged	Phosphatase Increased					
MG/DAILY/PO						
Disability	Blood Amylase Increased		Inj Primaxin	SS		
INTRAVENOUS IV						
Other	Blood Bilirubin Increased		Accolate	C		
	Blood Creatinine		Ativan	C		
	Increased		Atrovent	C		
	Convulsion		Flovent	C		
	Hepatic Failure		Hydrodiuril	C		
	Leukocytosis		Miacalcin	C		
	Lipase Increased		Premarin	C		
	Multi-Organ Failure		Rocephin	C		
	Pancreatic Cyst		Serevent	C		
	Pancreatic Disorder		Solu-Medrol	C		
	Pancreatitis		Tums	C		
	Renal Failure Acute		Univasc	C		
	Sepsis		Zantac	C		
	White Blood Cell Count		Albuterol	C		
	Increased		Guaifenesin	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/00ISR Number: 3499091-4Report Type:Expedited (15-DaCompany Report #WAES 00012250
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Bicarbonate Increased							
	Blood Creatinine Increased		Tab Trental	SS		ORAL	400 MG/DAILY/PO	
	Blood Urea Increased		Pravachol	SS				
	Constipation		Enduron	C				
	Diabetes Mellitus		Glynase Prestab Tablets	C				
	Dysarthria		Humulin L	C				
	Haematocrit Decreased		Humulin R	C				
	Haemoglobin Decreased		Norvasc	C				
	Hyperglycaemia		Pepcid	C				
	Hypertension		Plavix	C				
	Mental Impairment		Proscar	C				
	Muscular Weakness		Zantac	C				
	Pollakiuria							
	Speech Disorder							
	Supraventricular Extrasystoles							
	Urinary Incontinence							

Date:05/10/00ISR Number: 3504254-5Report Type:Expedited (15-DaCompany Report #WAES 00050357
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dizziness							
	Myocardial Infarction							
			Claritin	C				
			Synthroid	C				

Date:05/11/00ISR Number: 3498677-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx (Rofecoxib)	PS	Merck			
			Zyvox (Linezolid)	SS	Pharmacia & Upjohn			

Date:05/11/00ISR Number: 3498716-7Report Type:Direct Company Report #
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tremor		Vioxx 25 Mg Merck	PS	Merck			
FIRST DOSE								

Date:05/11/00ISR Number: 3498722-2Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - RECENTLY	Melaena		Vioxx	PS				
Initial or Prolonged	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/00ISR Number: 3498910-5Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Health	Vioxx 25 Mg (Merck)	PS	Merck		1 QD	
		Professional	Cyclobenzaprine 10mg Watson	SS	Watson		1 TID PRN	

Date:05/11/00ISR Number: 3498911-7Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthenia	Health	Vioxx 25mg	PS			1 PER DIEM	2 MON
Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased	Professional	Coumadin	C				
	Difficulty In Walking		Atenolol	C				
	Lethargy		Furosemide	C				
			Proscar	C				
			Potassium	C				

Date:05/11/00ISR Number: 3498931-2Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer	Health	Vioxx / 25 Mg / Msd	PS				
		Professional	Procardia	C				
			Ultram	C				
			Asa	C				

Date:05/11/00ISR Number: 3498932-4Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS			25MG QD X 2	

Initial or Prolonged Haemorrhage Professional
WEEKS

Date:05/11/00ISR Number: 3499179-8Report Type:Expedited (15-DaCompany Report #WAES 00032027
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Blood Pressure Systolic Increased	Other						
	Dizziness							
	Duodenal Ulcer		Gaviscon Antacid Tablets	C				
	Haemorrhage		Pepcid	C				
	Haemoglobin Decreased							
	Red Blood Cell Count Decreased							
	Thrombocytopenia							

Date:05/11/00ISR Number: 3499214-7Report Type:Expedited (15-DaCompany Report #WAES 00055536
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage		Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/00ISR Number: 3499379-7Report Type:Expedited (15-DaCompany Report #WAES 00047310
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG PO	52 DAY
	Cardiac Failure Congestive							
	Deep Vein Thrombosis		Bambuterol Hcl	C				
			Calcium Supplement (Nos)	C				
			Citalopram Hydrobromide	C				
			Digoxin	C				
			Flunitrazepam	C				
			Furosemide	C				
			Lisinopril	C				

Date:05/11/00ISR Number: 3499380-3Report Type:Expedited (15-DaCompany Report #WAES 00047311
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG PO	13 DAY
	Condition Aggravated							
	Gastritis		La-Hydroxycholecalciferol	C				
			Acetylcysteine	C				
			Digitoxin	C				
			Dipyridamole	C				
			Furosemide	C				
			Insulin Injection/Isophane Insulin Suspe	C				
			Irbesartan	C				
			Isosorbide-5-Mononitrate	C				
			Potassium Chloride	C				

Date:05/11/00ISR Number: 3499381-5Report Type:Expedited (15-DaCompany Report #WAES 00050173
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Cardiac Failure Congestive Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	(SEE IMAGE)

Date:05/11/00ISR Number: 3499386-4Report Type:Expedited (15-DaCompany Report #WAES 00042761
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx Relafen	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/00ISR Number: 3499452-3Report Type:Expedited (15-DaCompany Report #WAES 00050317
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO;	
	Dizziness							
	Duodenitis							
	Gastritis							
	Haematocrit Decreased						25 MG/DAILY/PO	
	Headache							
	Melaena		Accolate	C				
	Migraine		Allegra	C				
	Rectal Haemorrhage		Flovent	C				
	Upper Gastrointestinal Haemorrhage		Imitrex	C				
			Serevent	C				

Date:05/11/00ISR Number: 3499458-4Report Type:Expedited (15-DaCompany Report #WAES 00050398
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eyelid Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	4 DAY
	Face Oedema							
	Oedema							
	Oedema Peripheral		Cardura	C				
			Renitec	C				

Date:05/11/00ISR Number: 3499503-6Report Type:Expedited (15-DaCompany Report #WAES 00031862
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Blood Creatinine Increased							

	Bradycardia	Representative		
MG/DAILY/PO				
	Cardiac Failure		K-Dur	C
	Congestive		Zestoretic	C
	Dyspnoea		Calcium Supplement	C
	Dyspnoea Exertional		Furosemide	C
	Echocardiogram Abnormal		Prednisone	C
	Hypertension			
	Hypokalaemia			
	Oedema Peripheral			
	Orthopnoea			
	Oxygen Saturation Decreased			
	Pain In Extremity			
	Tachypnoea			
	Urinary Tract Infection			
	Ventricular Hypertrophy			
	Weight Increased			

Date:05/11/00ISR Number: 3499514-0Report Type:Expedited (15-DaCompany Report #WAES 00050799
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diverticulum Intestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Haemorrhagic	Professional				
MG/DAILY/PO						
		Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/00ISR Number: 3499516-4Report Type:Expedited (15-DaCompany Report #WAES 00056508
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Acetaminophen	C				
			Aspirin	C				
			Metoprolol Tartrate	C				

Date:05/11/00ISR Number: 3499518-8Report Type:Expedited (15-DaCompany Report #WAES 00050188
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Malaise							
	Myocardial Infarction							
			Flomax (Niflumic Acid (Beta)-Mor	C				
			Proscar	C				

Date:05/11/00ISR Number: 3499559-0Report Type:Expedited (15-DaCompany Report #WAES 00055007
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1-2 TABLET PO	15 DAY
	Blood Pressure Increased							
	Dizziness							
	Erythema		Clonazepam	C				
	Fatigue		Diazepam	C				
	Flushing							
	Hypertension							
	Nausea							
	Oedema Peripheral							
	Paraesthesia							
	Pharyngeal Oedema							

Pharyngitis
Syncope
Transient Ischaemic
Attack

Date:05/11/00ISR Number: 3499561-9Report Type:Expedited (15-DaCompany Report #WAES 00055519
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Hypertensive Crisis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/11/00ISR Number: 3499587-5Report Type:Expedited (15-DaCompany Report #WAES 00047301
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/00ISR Number: 3499164-6Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haematemesis		Rofecoxib	PS		ORAL	12.5MG PO QD	

Date:05/12/00ISR Number: 3499705-9Report Type:Expedited (15-DaCompany Report #WAES 00032672
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain	Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Constipation							
	Decreased Appetite							
	Diarrhoea							
	Gastrointestinal		Baycol	C				
	Haemorrhage		Celebrex	C				
	Muscle Spasms		Rythmol	C				
	Nausea		Aspirin	C				
	Rectal Haemorrhage		Vitamins	C				
	Weight Decreased							

Date:05/12/00ISR Number: 3499727-8Report Type:Expedited (15-DaCompany Report #WAES 00050076
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/QOD/PO	
	Congestive Fluid Retention							
	Pneumonia							

Date:05/12/00ISR Number: 3499729-1Report Type:Expedited (15-DaCompany Report #WAES 00050193
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Convulsion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/12/00ISR Number: 3499734-5Report Type:Expedited (15-DaCompany Report #WAES 00050041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/00ISR Number: 3499736-9Report Type:Expedited (15-DaCompany Report #WAES 00042719
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Lopressor	C				
			Pepcid	C				
			Pravachol	C				
			Aspirin	C				

Date:05/12/00ISR Number: 3499740-0Report Type:Expedited (15-DaCompany Report #WAES 00047314
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Increased	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Cefuroxime	SS			2.2 GM	7 DAY
	Oliguria		Acetaminophen	C				
	Renal Failure		Calcium Carbonate (+) Vitamin D(3)	C				
	Synovitis		Omeprazole	C				
			Oxazepam	C				
			Propoxyphene Napsylate Monohydrate	C				
			Vitamin B(12)	C				

Date:05/12/00ISR Number: 3499804-1Report Type:Direct Company Report #
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Haemorrhage		Coumadin 7.5mg	PS		ORAL	7.5MG QD ORAL	
			Vioxx 25mg	SS				

Date:05/12/00ISR Number: 3499806-5Report Type:Expedited (15-DaCompany Report #WAES 00050405
Age:79 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Aphasia
Hospitalization - Initial or Prolonged	Aspiration
Disability	Asthenia
Other	Bronchitis
	Convulsion
	Dermatitis
	Diabetes Mellitus
	Dyspnoea
	Electroencephalogram Abnormal
	Gout
	Haemorrhage Intracranial
	Hemiplegia
	Inappropriate Antidiuretic Hormone Secretion
	Muscle Twitching
	Pneumonia Aspiration

		Pseudomonas Infection Pyrexia Respiratory Distress Salivary Hypersecretion Sepsis Speech Disorder Staphylococcal Infection Tracheitis	Report Source Health Professional Company Representative	Product Vioxx	Role PS	Manufacturer Merck Research Laboratories Div Merck Co Inc	Route ORAL
Dose	Duration						
25 MG/DAY/PO							

Date:05/12/00ISR Number: 3499811-9Report Type:Expedited (15-DaCompany Report #WAES 00047302
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Ascites Depressed Level Of Consciousness Foetor Hepaticus Hepatic Encephalopathy Jaundice	Foreign Other	Vioxx Vasotec Clomethiazole Ethanedisulfonate Doxazosin Monomethanesulfonate Ferrous Succinate Ferrousso4 Omeprazole	PS C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL
Dose	Duration					
PO	30 DAY					

Date:05/12/00ISR Number: 3499814-4Report Type:Expedited (15-DaCompany Report #WAES 00047306
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Death Hospitalization - Initial or Prolonged	Agranulocytosis Dyspnoea Sepsis	Foreign Other	Vioxx Tab Allopurinol Furosemide Levothyroxine Na Omeprazole	PS SS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL ORAL
Dose	Duration					
25 MG PO	50 DAY					
200 MG PO	44 DAY					

			Ramipril	C
			Vitamin B {12}	C

Date:05/12/00ISR Number: 3499816-8Report Type:Expedited (15-DaCompany Report #WAES 00050286
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health	Vioxx	PS	Merck Research			
	Faeces Discoloured	Professional			Laboratories Div			
	Gastrointestinal				Merck Co Inc	ORAL	25	
	Haemorrhage						MG/DAILY/PO	
	Oesophagitis							

Date:05/12/00ISR Number: 3499818-1Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Therapeutic Response		Vioxx 25mg Merck	PS	Merck	ORAL	25MG ONCE	
	Unexpected						DAILY ORAL	
	Weight Decreased		Insulin	C				
			Lipitor	C				

		Furosemide	C
		Amitriptyline	C
		Amitriptyline	C
		Monopril	C
		Celebrex	C

Date:05/12/00ISR Number: 3499820-XReport Type:Expedited (15-DaCompany Report #WAES 00042870
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Dyspnoea	Company			Merck Co Inc	ORAL	25	
	Fluid Retention	Representative					MG/DAILY/PO	
	Oedema		Coumadin	C				
	Weight Increased							

Date:05/12/00ISR Number: 3499826-0Report Type:Expedited (15-DaCompany Report #WAES 00047318
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			
	Headache				Merck Co Inc	ORAL	25 MG PO	11 DAY
	Hypertension		Azathioprine	C				
	Laboratory Test Abnormal		Hydroxychloroquineso 4	C				
	Myocardial Infarction							
	Nausea		Levothyroxine Na	C				
	Renal Disorder		Prednisolone	C				
	Vomiting							

Date:05/15/00ISR Number: 3499977-0Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Anuria		Vioxx	PS		ORAL
50MG 1 PO QD						
Initial or Prolonged	Oedema					
Required	Renal Failure Acute					
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:05/15/00ISR Number: 3499993-9Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Hallucination, Visual		Vioxx 12.5mg - Merck	PS	Merck	
12.5MG PO QD						

Date:05/16/00ISR Number: 3500778-5Report Type:Direct Company Report #
Age:82 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Coumadin Dose	PS		
VARIABLE 40 DAY						
Initial or Prolonged	Haemorrhage		Vioxx 25	SS		
DAILY						
	Haematochezia		Vioxx	C		
			Vanco	C		

			Refampin	C		
			Vemlim	C		

Date:05/17/00ISR Number: 3500886-9Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Rofecoxib 25mg Qd	PS			25MG DAILY	
	Congestive Oedema Peripheral							

Date:05/17/00ISR Number: 3500887-0Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Rofecoxib 25mg Qd	PS			25MG QD	
	Congestive Condition Aggravated							

Date:05/17/00ISR Number: 3500890-0Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Rofecoxib 25 Mg	PS		ORAL	25MG PO QD	
	Congestive Dyspnoea Orthopnoea							

Date:05/17/00ISR Number: 3500892-4Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Back Pain		Rofecoxib 25mg	PS		
25MG QD						

Date:05/17/00ISR Number: 3501109-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Cardiac Failure		Vioxx	PS		ORAL
25MG PO QD						
Intervention to Prevent Permanent Impairment/Damage	Congestive Oedema Peripheral					

Date:05/17/00ISR Number: 3501110-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Swelling		Vioxx	PS		ORAL
25MG PO QD						
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/00ISR Number: 3501130-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Cardiac Failure Congestive Weight Increased							

Date:05/17/00ISR Number: 3501324-2Report Type:Expedited (15-DaCompany Report #WAES 00055013
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	76 DAY
	Melaena		Acetaminophen	C				
			Citalopram	C				
			Donepezil Hydrochloride	C				

Date:05/17/00ISR Number: 3501325-4Report Type:Expedited (15-DaCompany Report #WAES 00050321
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Torsade De Pointes	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
		Representative	Flexeril	C				
			Toradol	C				
			Morphine	C				

Date:05/17/00ISR Number: 3501326-6Report Type:Expedited (15-DaCompany Report #WAES00050267
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Dermatitis Periorbital Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
		Representative	Claritin	C				

Date:05/17/00ISR Number: 3501369-2Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Duodenal Ulcer	Health Professional	Vioxx 12.5mg By Merck	PS	Merck	ORAL	12.5 MG PO	1 MON
	Haemorrhage		Coumadin	SS		ORAL	10MG/5MG PO	
	Dyspnoea							YEARS YR
	Dyspnoea Exertional		Zoloft	C				
	Fatigue		Synthroid	C				
	Haematocrit Decreased		Ferrous Sulfate	C				
	Haemoglobin Decreased		Disoxin	C				
	International Normalised Ratio Increased		Lasix	C				
	Pallor							
	Vomiting							

Date:05/17/00ISR Number: 3501376-XReport Type:Expedited (15-DaCompany Report #WAES 00050672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability Other	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	

Date:05/17/00ISR Number: 3501378-3Report Type:Expedited (15-DaCompany Report #WAES 00050744
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Neoplasm Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets [Therapy Unspecified	C C				

Date:05/17/00ISR Number: 3501379-5Report Type:Expedited (15-DaCompany Report #WAES 00055539
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Oesophageal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	13 DAY

Date:05/17/00ISR Number: 3501381-3Report Type:Expedited (15-DaCompany Report #WAES 00051163
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vasculitis Necrotising	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
4 DAY

Disulfiram SS ORAL
Orudis (Ketoprofen) SS
TOPICAL 4 DAY

Lamisil
(Terbinafine) SS
TOPICAL 4 DAY

Lederspan C

Date:05/17/00ISR Number: 3501384-9Report Type:Expedited (15-DaCompany Report #WAES 00050926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Body Temperature Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Disorientation				Merck Co Inc	ORAL
PO 5 DAY						
	Feeling Abnormal					
	Hallucination, Visual					
	Memory Impairment					
	Syncope					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/00ISR Number: 3501386-2Report Type:Expedited (15-DaCompany Report #WAES 00050978
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Calculus Urinary							
	Dehydration							
	Gallbladder Disorder							
	Malaise		Demerol	C				
	Nephrolithiasis		Ultram (Composition Unspecified)	C				
	Ovarian Cyst							
	Shock			C				
	Vomiting		Prednisone	C				

Date:05/17/00ISR Number: 3501389-8Report Type:Expedited (15-DaCompany Report #WAES 00051197
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO, 25MG/DAILY/PO	
	Dizziness							
	Dyspnoea							
	Hyperhidrosis							
	Nausea		Buspar	C				
	Renal Failure		Depakote	C				
			Imdur	C				
			Lanoxin	C				
			Lipitor	C				
			Neurontin	C				
			Niaspan	C				
			Remeron	C				
			Tricor	C				
			Zestril	C				
			Aspirin	C				
			Atenolol	C				
			Furosemide	C				
			Nitroglycerin	C				
			Vitamin E	C				
			Vitamins	C				

Date:05/17/00ISR Number: 3501391-6Report Type:Expedited (15-DaCompany Report #WAES 00055010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:05/17/00ISR Number: 3502436-XReport Type:Expedited (15-DaCompany Report #WAES 00027275
Age:13 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatosplenomegaly Pancreatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
		Other	Tab Azathioprine	SS		ORAL	50 MG, PO	
			Tab Azathioprine	SS		ORAL	100 MG, PO	14 DAY
			Tab Sulfasalazine	SS		ORAL	2000 MG, PO	
			Ursodiol	C				

Date:05/17/00ISR Number: 3502437-1Report Type:Expedited (15-DaCompany Report #WAES 00050173
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Cardiac Failure Congestive Chest Pain Condition Aggravated Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/17/00ISR Number: 3502438-3Report Type:Expedited (15-DaCompany Report #WAES 00050103
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

Date:05/17/00ISR Number: 3502439-5Report Type:Expedited (15-DaCompany Report #WAES 00042598
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ibuprofen	SS				

Date:05/17/00ISR Number: 3502441-3Report Type:Expedited (15-DaCompany Report #WAES 00020430
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			[Therapy Unspecified] Unk\	SS				
			Zantac	SS				
			[Therapy Unspecified]	C				

Date:05/17/00ISR Number: 3502496-6Report Type:Expedited (15-DaCompany Report #001-0981-M0002373
Age:41 YR Gender:Female I/FU:I

Outcome	PT
Required Intervention to Prevent Permanent Impairment/Damage	Arthralgia
	Burning Sensation
	Difficulty In Walking
	Fatigue
	Hypoaesthesia
	Insomnia
	Joint Stiffness
	Movement Disorder
	Muscular Weakness
	Oedema
	Oedema Peripheral

		Pain Paraesthesia Tendon Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Lipitor	PS	Warner Lambert Export Ltd	ORAL
10 MG (DAILY), PER ORAL							
				Vioxx (Rofecoxib)	SS		
12.5 MG							
				Prozac (Fluoxetine Hydrochloride)	C		
				Tylenol (Paracetamol)	C		
				Tylenol Pm (Diphenhydramine, Paracetamol)	C		
				Allegra (Fexofenadine Hydrochloride)	C		

Date:05/17/00ISR Number: 3502729-6Report Type:Expedited (15-DaCompany Report #WAES 00047300
Age:81 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Drug Interaction Dyspnoea Oedema Peripheral	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO							
		Prothrombin Level Decreased		Acetaminophen/Propoxyphene Hydrochloride	C		
				Allopurinol	C		
				Digitoxin	C		
				Ferrous So4	C		

Date:05/17/00ISR Number: 3503272-0Report Type:Expedited (15-DaCompany Report #WAES 00045553
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Faeces Discoloured Haemoglobin Decreased Malaise	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:05/18/00ISR Number: 3501487-9Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Mental Disorder Pain Speech Disorder Visual Disturbance Vomiting		Vioxx I Tab 25mg Po	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3501604-0Report Type:Expedited (15-DaCompany Report #WAES 00055519
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Hypertensive Crisis Nausea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Amlodipine Benzenesulfonate	C				
			Nitroglycerin	C				

Date:05/18/00ISR Number: 3501605-2Report Type:Expedited (15-DaCompany Report #WAES 00050150
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Life-Threatening	Bacterial Infection							
Hospitalization - Initial or Prolonged	Constipation							
	Diverticular Perforation							
Disability	Peritonitis		Celebrex	C				
	Sepsis		Lanoxin	C				
			Prilosec	C				
			Synthroid	C				
			Ultram	C				
			Atenolol	C				
			Verapamil	C				

Date:05/18/00ISR Number: 3501616-7Report Type:Expedited (15-DaCompany Report #WAES 00051193
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/18/00ISR Number: 3501617-9Report Type:Expedited (15-DaCompany Report #WAES 00051058
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Abdominal Tenderness							
	Arthralgia							
	Back Pain							
	Cholecystectomy		Claritin	C				
	Cholecystitis		Darvocet-N	C				
			Nasonex	C				
			Premarin	C				
			Prevacid	C				

Date:05/18/00ISR Number: 3501619-2Report Type:Expedited (15-DaCompany Report #WAES 00051031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolism	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Epistaxis							
			Benadryl	C				

			Centrum Silver	C		
			Glucosamine	C		

Date:05/18/00ISR Number: 3501620-9Report Type:Expedited (15-DaCompany Report #WAES 00051019
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:05/18/00ISR Number: 3501621-0Report Type:Expedited (15-DaCompany Report #WAES 00050990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	1 MON
			Cardizem	C				
			Lopressor	C				
			Percocet	C				
			Zestril	C				

Date:05/18/00ISR Number: 3501622-2Report Type:Expedited (15-DaCompany Report #WAES 00050966
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Haemorrhage				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Aspirin	C		

Date:05/18/00ISR Number: 3501662-3Report Type:Expedited (15-DaCompany Report #WAES 00055515
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Congestive	Health			Laboratories Div	
Initial or Prolonged	Condition Aggravated	Professional			Merck Co Inc	ORAL
12.5 MG PO						
	Leukocytoclastic		Amlodipine			
	Vasculitis		Benzenesulfonate	C		
	Purpura		Aspirin	C		
			Isosorbide-5-Mononit			
			rate	C		

Date:05/18/00ISR Number: 3501663-5Report Type:Expedited (15-DaCompany Report #WAES 00050299
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Blood Pressure Increased

	Bronchospasm						
	Drug Hypersensitivity						
	Dry Skin	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Vioxx	PS	Merck Research			
	Face Oedema	Professional			Laboratories Div			
	Pruritus				Merck Co Inc	ORAL	PO	
	Rash Erythematous		Lamisil	SS				
			Estrace	C				
			Aspirin	C				

Date:05/18/00ISR Number: 3501664-7Report Type:Expedited (15-DaCompany Report #WAES 00035622
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Diverticulum	Health			Laboratories Div			
	Gastrointestinal	Professional			Merck Co Inc	ORAL	12.5 MG PO	
	Angiodysplasia							
(SEE IMAGE)								
	Haemorrhagic		Aspirin	SS		ORAL	PO	
	Haematochezia		Fosamax	C				
			Digoxin					
			B-Acetyldigoxin	C				
			Isosorbide Dinitrate	C				
			Lorazepam	C				

Date:05/18/00ISR Number: 3501737-9Report Type:Expedited (15-DaCompany Report #WAES 00045606
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urea Increased	Foreign	Vioxx	PS	Merck Research			
Other	Cardiac Failure	Health			Laboratories Div			
	Congestive	Professional			Merck Co Inc	ORAL	12.5 MG PO	
	Condition Aggravated		Allopurinol	C				
	Dyspnoea		Aminophylline (+)					
	Fluid Retention		Quinine Sulfate	C				

	Liver Disorder	Captopril	C
	Pleural Effusion	Digitoxin	C
	Pulmonary Function Test Decreased	Magnesium Preparation	C
	Renal Impairment	Metoprolol	C

Date:05/18/00ISR Number: 3501740-9Report Type:Expedited (15-DaCompany Report #WAES 00055012
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Dizziness Fall	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
	Headache Staring Syncope		Aspirin Ethinyl Estradiol/Norethindrone Acetate	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3501743-4Report Type:Expedited (15-DaCompany Report #WAES 00057003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allopurinol	C				
			Digitoxin	C				
			Furosemide	C				
			Verapamil Hcl	C				

Date:05/18/00ISR Number: 3501745-8Report Type:Expedited (15-DaCompany Report #WAES 00050524
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis Bacterial Nausea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	
			Azulfidine	C				

Date:05/18/00ISR Number: 3501746-XReport Type:Expedited (15-DaCompany Report #WAES 00050521
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Heart Rate Irregular Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
	Myocardial Infarction Pain In Extremity Palpitations		Aleve	C				
			Tylenol	C				

Date:05/18/00ISR Number: 3501747-1Report Type:Expedited (15-DaCompany Report #WAES 00050620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Artane	C				
			Klonopin	C				
			Sinemet	C				

Date:05/18/00ISR Number: 3501748-3Report Type:Expedited (15-DaCompany Report #WAES 00050677
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Asthenia Blood Thyroid Stimulating Hormone Increased Chest Pain Coronary Artery Disease Hypothyroidism Lethargy Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PM/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3502028-2Report Type:Expedited (15-DaCompany Report #WAES 00048578
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrophy	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	29 DAY
	Faeces Discoloured	Health Professional						
	Gastric Ulcer							
	Gastritis		Acebutolol	C				
	Gastrointestinal Disorder		Acetaminophen	C				
	Gastrointestinal Haemorrhage		Allopurinol	C				
	Vomiting		Amlodipine Benzenesulfonate	C				
			Diltiazem D-Cis Form Hcl	C				
			Docusate Ca	C				
			Ferrous Fluconate	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Lorazepam	C				
			Nifedipine	C				
			Nonsteroidal Anti-Inflammatory Drug Ther	C				
			Ranitidine	C				

Date:05/18/00ISR Number: 3502199-8Report Type:Expedited (15-DaCompany Report #WAES 00022442
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Back Pain	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Fall							
	Gastrointestinal Haemorrhage							
	Haematemesis		Cardizem Cd	C				
			Coumadin	C				
			Detrol	C				
			Lanoxin	C				
			Metamucil	C				
			Miacalcin	C				
			Synthroid	C				

			Vitamins	C		

Date:05/18/00ISR Number: 3502238-4Report Type:Expedited (15-DaCompany Report #WAES 00050801
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Confusional State Coordination Abnormal Drug Toxicity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO	Fall	Representative				
			Prozac	C		
			Valium	C		
			Insulin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3502243-8Report Type:Expedited (15-DaCompany Report #WAES 99069309
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Foreign	Vioxx	PS	Merck Research			
	Abdominal Tenderness	Study			Laboratories Div			
	Duodenal Ulcer	Health			Merck Co Inc	ORAL	1000 MG, PO	96 DAY
	Gastritis Erosive	Professional	Tab					
	Gastroenteritis		Methylprednisolone	SS		ORAL	4 MG, PO	
	Helicobacter		Tab Placebo	SS		ORAL	PO	
	Oesophagitis		Tab Methotrexate	SS		ORAL	PO	
			Chloroquine	C				
			Methotrexate	C				
			Methylprednisolone	C				
			Metoprolol	C				

Date:05/18/00ISR Number: 3502245-1Report Type:Expedited (15-DaCompany Report #WAES 99069305
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
	Faeces Discoloured	Study			Laboratories Div			
	Gastritis	Health			Merck Co Inc	ORAL	1000 MG, PO	27 DAY
	Gastroenteritis	Professional	Tab Prednisone	SS		ORAL	10 MG, PO	1089 DAY
	Helicobacter		Tab Placebo	SS		ORAL	PO	
	Melaena		Chloroquine	C				
			Methotrexate	C				

Date:05/18/00ISR Number: 3502248-7Report Type:Expedited (15-DaCompany Report #WAES 99069315
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			

		Frequent Bowel Movements	Study			Laboratories Div	
		Gastric Ulcer Haemorrhage	Health			Merck Co Inc	ORAL
1000 MG, PO	15 DAY						
		Gastroenteritis	Professional	Tab Prednisone	SS		ORAL
10 MG, PO							
		Helicobacter		Tab Placebo	SS		ORAL
PO	15 DAY						
		Hiatus Hernia		Acetaminophen	C		
		Melaena		Methotrexate	C		
				Aluminum Hydroxide	C		
				Captopril	C		
				Gold Preparation (Composition Unspecified)	C		

Date:05/18/00ISR Number: 3502251-7Report Type:Expedited (15-DaCompany Report #WAES 00055582
Age:80 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Hypertensive Crisis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				.....	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3502255-4Report Type:Expedited (15-DaCompany Report #WAES 00055550
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Cold Sweat Drug Hypersensitivity Dyspnoea Erythema Fatigue Sweat Gland Disorder Tremor	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY

Date:05/18/00ISR Number: 3502265-7Report Type:Expedited (15-DaCompany Report #WAES 00055043
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Microcytic Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	85 DAY
			Fluvastatin	C				
			Primidone	C				

Date:05/18/00ISR Number: 3502266-9Report Type:Expedited (15-DaCompany Report #WAES 00055041
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/18/00ISR Number: 3502269-4Report Type:Expedited (15-DaCompany Report #WAES 00051302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Coma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:05/18/00ISR Number: 3502404-8Report Type:Expedited (15-DaCompany Report #WAES 00051259
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Colace	C				
			Imdur	C				
			Lasix	C				
			Prilosec	C				
			Aspirin	C				
			Ferrous Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3502407-3Report Type:Expedited (15-DaCompany Report #WAES 00051194
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenitis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Gastritis	Company			Merck Co Inc	ORAL	25 MG / DAILY	
Other	Upper Gastrointestinal	Representative					/ PO	
	Haemorrhage		Betapase	C				
			Cardura	C				
			Darvocet-N	C				
			Lescol	C				
			Lotensin	C				
			Zantac	C				
			Tolazamide	C				

Date:05/18/00ISR Number: 3502408-5Report Type:Expedited (15-DaCompany Report #WAES 00051136
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Level Above	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Therapeutic	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Phenytoin	SS				

Date:05/18/00ISR Number: 3502410-3Report Type:Expedited (15-DaCompany Report #WAES 00051120
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Infarction	Health	Vioxx	PS	Merck Research			
Life-Threatening		Professional			Laboratories Div			
Hospitalization -		Company			Merck Co Inc	ORAL	PO	
Initial or Prolonged		Representative	Atenolol	C				

Date:05/18/00ISR Number: 3502413-9Report Type:Expedited (15-DaCompany Report #WAES 00051011
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
Hospitalization - Initial or Prolonged			Fosamax	C				

Date:05/18/00ISR Number: 3502415-2Report Type:Expedited (15-DaCompany Report #WAES 00045503
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Hallucination Psychotic Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. 5 MG PO, 25 MG PO	2 DAY
			Moduretic	C				
			Amantadine	C				
			Benserazide/Levodopa	C				
			Melperone	C				
			Memantine Hcl	C				
			Sulfamethoxazole/Tri					

methoprim C

Date:05/18/00ISR Number: 3502416-4Report Type:Expedited (15-DaCompany Report #WAES 00041037
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Fluid Retention Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	

Date:05/18/00ISR Number: 3502419-XReport Type:Expedited (15-DaCompany Report #WAES 00022362
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fungal Infection Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Prempro	C				
			Prilosec	C				

Date:05/18/00ISR Number: 3502421-8Report Type:Expedited (15-DaCompany Report #WAES 00041558
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Multi-Organ Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 MON
			Aspirin	C				

Date:05/18/00ISR Number: 3502423-1Report Type:Expedited (15-DaCompany Report #WAES 00035622
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. 5 MG PO;	
	Diarrhoea							
	Diverticulitis Intestinal							
	Haemorrhagic						25 MG PO	
	Diverticulum		Aspirin	SS		ORAL		
	Gastrointestinal		Fosamax	C				
	Angiodysplasia		Digoxin					
	Gastrointestinal		B-Acetyldigoxin	C				
	Haemorrhage		Isosorbide Dinitrate	C				
	Haematochezia		Lorazepam	C				
	Haemoglobin Decreased							

Date:05/18/00ISR Number: 3502424-3Report Type:Expedited (15-DaCompany Report #WAES 00040300
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /	
	Haematochezia							
	Rectal Haemorrhage							
							DAILY / PO	

				Hytrin	C		
				Lasix	C		
				Macrodantin	C		
				Zoloft	C		

Date:05/18/00ISR Number: 3502426-7Report Type:Expedited (15-DaCompany Report #WAES 00035622
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Diverticulum Diverticulum Intestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO;	
	Haemorrhagic						25 MG	
	Gastrointestinal Angiodysplasia Gastrointestinal Haemorrhage Haematochezia Haemoglobin Decreased		Aspirin	SS		ORAL		

Date:05/18/00ISR Number: 3502428-0Report Type:Expedited (15-DaCompany Report #WAES 00035047
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nail Dystrophy Psoriasis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Acetaminophen/Codeine Phosphate	C				
			Benserazide/Levodopa	C				

Date:05/18/00ISR Number: 3502432-2Report Type:Expedited (15-DaCompany Report #WAES 00058539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Bronchospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc

Date:05/18/00ISR Number: 3502433-4Report Type:Expedited (15-DaCompany Report #WAES 00058201
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Headache							
	Hepatic Steatosis							
	Renal Disorder	Other	Pepcid	C				
			Magnesium Preparation (Composition Unspe	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/00ISR Number: 3502434-6Report Type:Expedited (15-DaCompany Report #WAES 00058202
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastroenteritis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Helicobacter	Health			Laboratories Div			
Initial or Prolonged	Peptic Ulcer Perforation	Professional			Merck Co Inc	ORAL	25-50 MG PO	110 DAY
	Peritonitis	Other	Prinivil	C				
			Atenolol	C				
			Nicorandil	C				
			Pramipexole	C				

Date:05/18/00ISR Number: 3502435-8Report Type:Expedited (15-DaCompany Report #WAES 00057908
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
	Congestive	Health			Laboratories Div			
	Drug Interaction	Professional			Merck Co Inc	ORAL	PO	1 DAY
	Respiratory Failure		Irbesartan	C				

Date:05/18/00ISR Number: 3502451-6Report Type:Expedited (15-DaCompany Report #WAES 00022279
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm	Health	Vioxx	PS	Merck Research			
Hospitalization -	Confusional State	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea	Other			Merck Co Inc	ORAL	25	
Other	Erythema						MG/DAILY/PO	
	Hypertension		[Composition					
	Swelling		Unspecified]	C				
			Fentanyl	C				

Date:05/18/00ISR Number: 3502536-4Report Type:Expedited (15-DaCompany Report #WAES 99114062
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Study	Vioxx	PS	Merck Research Laboratories Div			
	Duodenal Ulcer	Health						
	Haemorrhage	Professional			Merck Co Inc	ORAL	500 MG/BID/PO	
	Faecal Occult Blood		Tab Placebo	SS		ORAL	1 TABLET/DAILY/ PO	
	Positive							
	Faeces Discoloured							
	Haematocrit Decreased		Folic Acid	C				
	Haemoglobin Decreased		Methotrexate	C				
			Sildenafil Citrate	C				

Date:05/18/00ISR Number: 3502631-XReport Type:Expedited (15-DaCompany Report #WAES 99079211
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Barrett'S Oesophagus
	Bronchitis Acute
	Duodenal Ulcer
	Haemorrhage
	Gastric Ulcer
	Gastrointestinal

		Haemorrhage Haematemesis Hiatus Hernia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1000 MG, PO	26 DAY						
			Professional	Tab Fosamax (Alendronate Sodium)	SS		ORAL
5 MG, PO	131 DAY						
				Tab Placebo	SS		ORAL
PO	26 DAY						
				Tab Naproxen	SS		ORAL
PO	26 DAY						
				Meloxicam	C		
				Methotrexate	C		
				Prednisone	C		
				Ranitidine	C		

Date:05/18/00ISR Number: 3502641-2Report Type:Expedited (15-DaCompany Report #WAES 99099807
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Faecal Occult Blood Positive Gastritis Erosive	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1000 MG, PO	155 DAY						
		Gastritis Haemorrhagic	Professional	Tab Methotrexate	SS		ORAL
PO							
		Haemoglobin Decreased		Tab Placebo	SS		ORAL
PO	155 DAY						
		Vomiting Weight Decreased		Bisoprolol	C		
				Folic Acid	C		
				Methotrexate	C		
				Tramadol Hcl	C		

Date:05/18/00ISR Number: 3502650-3Report Type:Expedited (15-DaCompany Report #WAES 00047300
Age:81 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Drug Interaction Dyspnoea International Normalised Ratio Increased Laboratory Test Abnormal Oedema Peripheral Prothrombin Level Decreased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 12,5 MG PO 9 DAY
			Tab Warfarin Sodium	SS		ORAL PO
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Allopurinol	C		
			Digitoxin	C		
			Ferrous S04	C		
			Furosemide	C		
			Omeprazole	C		
			Prednisolone	C		
			Spironolactone	C		
			Vitamin B{12}	C		
			Zolpidem Tartrate	C		

Date:05/18/00ISR Number: 3502651-5Report Type:Expedited (15-DaCompany Report #WAES 00047300
Age:81 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Drug Interaction Dyspnoea International Normalised Ratio Increased Oedema Peripheral

		Prothrombin Level Decreased Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12,5 MG PO	9 DAY						
				Tab Warfarin Sodium	SS		ORAL
PO							
				Acetaminophen/Propoxyphene Hydrochloride	C		
				Allopurinol	C		
				Digitoxin	C		
				Ferrous S04	C		
				Furosemide	C		
				Omeprazole	C		
				Prednisolone	C		
				Spironolactone	C		
				Vitamin B {12}	C		
				Zolpidem Tartrate	C		

Date:05/18/00ISR Number: 3502654-0Report Type:Expedited (15-DaCompany Report #WAES 00049123
Age:90 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Duodenal Ulcer Haematocrit Decreased Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO	42 DAY						
		Upper Gastrointestinal		Tab Aspirin	SS		ORAL
300 MG PO							
		Haemorrhage		Vitamin E	C		

Date:05/18/00ISR Number: 3502663-1Report Type:Expedited (15-DaCompany Report #WAES 00050339
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cholelithiasis Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

					Merck Co Inc	ORAL
PO						
			Aspirin	C		

Date:05/19/00ISR Number: 3502902-7Report Type:Direct Company Report #
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx 25 Mg	PS		ORAL
1T PO D						
Initial or Prolonged	Haemorrhage					

Date:05/19/00ISR Number: 3503057-5Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cellulitis	Health	Vioxx 25mg/Tab Merck			
	Deep Vein Thrombosis	Professional	& Co	PS	Merck &Co	ORAL
25 MG QD PO						
	Feeling Abnormal		Tamsulosin	C		
	Hypertension		Amlodipine	C		
			Atenolol	C		
			Enalapril	C		
			Isosorbide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/00ISR Number: 3503237-9Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Impairment		Vioxx 12.5 Mg Tab	PS		ORAL	12.5MG PO QD	
Initial or Prolonged			Lasix 40mg Td	SS			40MG PO QD	

CHRONIC WITH

INCREASED

DOSE

Date:05/19/00ISR Number: 3503311-7Report Type:Direct Company Report #
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous		Vioxx	PS		ORAL	12.5MG PO QD	

Date:05/22/00ISR Number: 3502391-2Report Type:Expedited (15-DaCompany Report #WAES 00045619
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Oesophageal Ulcer	Health			Laboratories Div			
Initial or Prolonged	Oesophagitis	Professional			Merck Co Inc	ORAL	25 MG	4 DAY
	Upper Gastrointestinal		Aspirin	C				
	Haemorrhage		Metoprolol Succinate	C				
			Verapamil	C				

Date:05/22/00ISR Number: 3502401-2Report Type:Expedited (15-DaCompany Report #WAES 00040820
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension	Health	Vioxx	PS	Merck Research			
	Abdominal Pain	Professional			Laboratories Div			
	Asthenia	Company			Merck Co Inc	ORAL	25	
	Calcinosis	Representative					MG/DAILY/PO	
	Condition Aggravated		Sortis					
	Hyperhidrosis		(Atorvastatin)	C				
	Oral Intake Reduced		Aspirin	C				
	Pancreatitis		Metoprolol	C				

Date:05/22/00ISR Number: 3502851-4Report Type:Expedited (15-DaCompany Report #WAES 00041038
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage Intracranial	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhagic Stroke	Company			Merck Co Inc	ORAL	25	
Disability	Hemiparesis	Representative					MG/DAILY/PO	
	International Normalised		Coumadin	C				
	Ratio Increased		L-Thyroxine	C				
			Premarin	C				
			Furosemide	C				
			Metoprolol	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/00ISR Number: 3502852-6Report Type:Expedited (15-DaCompany Report #WAES 00051475
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Oesophageal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/22/00ISR Number: 3502855-1Report Type:Expedited (15-DaCompany Report #WAES 00051467
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/22/00ISR Number: 3502863-0Report Type:Expedited (15-DaCompany Report #WAES 00057276
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Shock	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:05/22/00ISR Number: 3502865-4Report Type:Expedited (15-DaCompany Report #WAES 00051472
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Asthenia Duodenal Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged Fatigue Company Merck Co Inc ORAL
25
Other Gastrointestinal Representative
MG/DAILY/PO
Haemorrhage
Haematocrit Decreased
Pallor

Date:05/22/00ISR Number: 3502912-XReport Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG PO 3 DAY						
		Other	Mepivacaine Hcl	C		

Date:05/22/00ISR Number: 3502962-3Report Type:Expedited (15-DaCompany Report #WAES 00051634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/00ISR Number: 3502964-7Report Type:Expedited (15-DaCompany Report #WAES 00051635
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal				Merck Co Inc	ORAL	25 MG/BID/PO	
Other	Haemorrhage							

Date:05/22/00ISR Number: 3502966-0Report Type:Expedited (15-DaCompany Report #WAES 00051636
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Embolism	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	25	
	Gastrointestinal Motility	Representative					MG/DAILY/PO	
	Disorder		Demadex	C				
			Fosamax	C				
			K-Dur	C				
			Os-Cal	C				
			Plaquenil	C				
			Pravachol	C				
			Aspirin	C				
			Atenolol	C				
			Vitamins	C				

Date:05/22/00ISR Number: 3502970-2Report Type:Expedited (15-DaCompany Report #WAES 00051637
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	

Date:05/22/00ISR Number: 3502971-4Report Type:Expedited (15-DaCompany Report #WAES 00051681
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	4 WK

Date:05/22/00ISR Number: 3502983-0Report Type:Expedited (15-DaCompany Report #WAES 00042498
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Calculus Urinary	Consumer Health Professional	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/00ISR Number: 3503164-7Report Type:Expedited (15-DaCompany Report #WAES 00051192
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/22/00ISR Number: 3503212-4Report Type:Expedited (15-DaCompany Report #WAES 00041958
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Disability	Atrioventricular Block First Degree		A.S.A.	C				
	Blood Creatinine Increased		Coumadin	C				
	Blood Urea Increased		Cozaar	C				
	Bundle Branch Block Left		Imdur	C				
	Cardiac Arrest		Lanoxin	C				
	Chest Pain		Lipitor	C				
	Condition Aggravated		Zantac	C				
	Fatigue		Atenolol	C				
	Hyperkalaemia							
	Hypotension							
	Lethargy							
	Renal Impairment							
	White Blood Cell Count Increased							

Date:05/22/00ISR Number: 3503221-5Report Type:Expedited (15-DaCompany Report #WAES 00045531
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Delusional Disorder, Persecutory Type	Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5-25 MG PO 15 DAY	Hallucination					

Date:05/22/00ISR Number: 3503267-7Report Type:Expedited (15-DaCompany Report #WAES 00058552
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:05/22/00ISR Number: 3503269-0Report Type:Expedited (15-DaCompany Report #WAES 00059110
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 25 DAY						
			Levobunolol	C		

Mineral Bone Complex C

Date:05/22/00ISR Number: 3503337-3Report Type:Expedited (15-DaCompany Report #WAES 00032859
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:05/22/00ISR Number: 3503338-5Report Type:Expedited (15-DaCompany Report #WAES 00041135
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Coma Convulsion Drug Hypersensitivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
	Laceration		Accupril	C				
	Laryngospasm		Coumadin	C				
	Mouth Haemorrhage		K-Dur	C				
	Tongue Disorder		Lasix	C				
			Paxil	C				
			Pravachol	C				

Date:05/22/00ISR Number: 3503343-9Report Type:Expedited (15-DaCompany Report #WAES 00059601
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Bisoprolol Fumarate	C				

			Kolantyl	C		

Date:05/22/00ISR Number: 3503350-6Report Type:Expedited (15-DaCompany Report #WAES 00029355
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastric Ulcer	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG PO 299 DAY						
		Professional	Tab Placebo	SS		ORAL
PO 299 DAY						
			Acetaminophen	C		
			Atenolol	C		
			Calcium Supplement	C		
			Diphenhydramine	C		
			Famotidine	C		
			Nifedipine	C		
			Psyllium Hydrophylic Mucilloid	C		

Date:05/22/00ISR Number: 3503351-8Report Type:Expedited (15-DaCompany Report #WAES 00040566
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation	Health	Vioxx	PS	Merck Research			
	Neuritis	Professional			Laboratories Div			
	Neuropathy Peripheral				Merck Co Inc	ORAL	25	
	Paraesthesia						MG/DAILY/PO	

Date:05/22/00ISR Number: 3503352-XReport Type:Expedited (15-DaCompany Report #WAES 00055121
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Congestive	Other			Laboratories Div			
	Condition Aggravated				Merck Co Inc	ORAL	25 MG PO	
	Difficulty In Walking		Prinivil	C				
	Dyspnoea		Bumetanide	C				
	Oedema Peripheral		Carvedilol	C				
			Isosorbide-5-Mononit rate	C				
			Nicorandil	C				
			Temazepam	C				
			Warfarin	C				

Date:05/22/00ISR Number: 3503353-1Report Type:Expedited (15-DaCompany Report #WAES 00050625
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Bladder Disorder	Professional			Laboratories Div			
Initial or Prolonged	Cerebrovascular Accident	Company			Merck Co Inc	ORAL	12.5	
Other	Confusional State	Representative					MG/DAILY/PO	
	Dysarthria		Cardizem	C				
	Hypertension		Darvocet-N	C				

	Transient Ischaemic Attack		Lanoxin	C			
			Lasix	C			
			Slow-K	C			
			Vasotec	C			
			Allopurinol	C			
			Atenolol	C			
			Magnesium Hydroxide	C			
			Nitroglycerin	C			

Date:05/22/00ISR Number: 3503354-3Report Type:Expedited (15-DaCompany Report #WAES 00051313
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Feeling Abnormal							
	Hypertension		Lasix	C				
	Lung Disorder		Synthroid	C				
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/00ISR Number: 3503355-5Report Type:Expedited (15-DaCompany Report #WAES 00051300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/22/00ISR Number: 3503365-8Report Type:Expedited (15-DaCompany Report #WAES 00042074
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Back Pain							
	Dizziness							
	Drug Hypersensitivity							
	Haemorrhage		Prozac	C				
	Influenza Like Illness		Vicoprofen	C				
	Joint Stiffness							
	Nausea							
	Orthostatic Hypotension							
	Retching							
	Vomiting							

Date:05/22/00ISR Number: 3503550-5Report Type:Expedited (15-DaCompany Report #WAES 00041794
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged								
Other								
			Adalat Cc	C				
			Atarax	C				
			Ecotrin	C				

			Xalatan	C		
			Hydrochlorothiazide	C		
			Ibuprofen	C		

Date:05/22/00ISR Number: 3503554-2Report Type:Expedited (15-DaCompany Report #WAES 00055120
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Cerebrovascular Accident Memory Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Acetaminophen/Codeine Phosphate	C				

Date:05/22/00ISR Number: 3503555-4Report Type:Expedited (15-DaCompany Report #WAES 00057506
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Hypertensive Crisis Medication Error	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 MON
			Bisoprolol Fumarate Codeine	C				

			Phosphate/Guaifenesin/Pseudoephe	C		
			Loratadine (+) Pseudoephedrine Sulfate	C		

Date:05/22/00ISR Number: 3503556-6Report Type:Expedited (15-DaCompany Report #WAES 00058905
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise Salivary Hypersecretion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY
			Aspilets	C				
			Centrum	C				
			Plendil	C				

Date:05/22/00ISR Number: 3503557-8Report Type:Expedited (15-DaCompany Report #WAES 00025582
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Circulatory Collapse Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
	Gastric Haemorrhage Gastroenteritis Helicobacter Gastrointestinal Disorder Haemoglobin Decreased Melaena		Diclofenac Oxycodone Hcl Ranitidine	C C C				

Date:05/22/00ISR Number: 3503558-XReport Type:Expedited (15-DaCompany Report #WAES 00051351
Age:88 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:05/22/00ISR Number: 3503711-5Report Type:Expedited (15-DaCompany Report #WAES 00051417
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:05/22/00ISR Number: 3503730-9Report Type:Expedited (15-DaCompany Report #WAES 00019759
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Duodenitis
	Dyspepsia
	Faecal Occult Blood

		Positive Haemoglobin Decreased Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG PO	202 DAY						
				Tab Placebo	SS		ORAL
PO	202 DAY						
				1(Alpha) - Hydroxycholecalcifer ol	C		
				Alendronate Sodium	C		
				Calcium Carbonate	C		
				Conjugated Estrogenic Hormones	C		
				Folic Acid	C		
				Prasterone	C		
				Vitamin B(12)	C		
				Vitamin E	C		

Date:05/22/00ISR Number: 3503743-7Report Type:Expedited (15-DaCompany Report #WAES 99129355
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Pain Upper Dyspepsia Faecal Occult Blood	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1000 MG PO	244 DAY						
		Positive	Professional	Tab Placebo	SS		ORAL
PO	244 DAY						
		Gastritis Erosive Gastritis Haemorrhagic Nausea		Atenolol	C		
				Enalapril	C		
				Imipramine	C		
				Isosorbide	C		
				Methotrexate	C		
				Prednisone	C		

Date:05/22/00ISR Number: 3503744-9Report Type:Expedited (15-DaCompany Report #WAES 99129352
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
	Abdominal Tenderness	Study			Laboratories Div			
	Faecal Occult Blood	Health			Merck Co Inc	ORAL	1000 MG PO	253 DAY
	Positive	Professional	Tab Placebo	SS		ORAL	PO	253 DAY
	Gastric Ulcer Haemorrhage		Acetaminophen	C				
	Gastritis		Brompheniramine	C				
	Gastroenteritis		Prednisone	C				
	Helicobacter							
	Gastrointestinal Disorder							

Date:05/23/00ISR Number: 3503732-2Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS				
25MG TABLET								
Initial or Prolonged	Haematemesis	Professional						
ONE DAILY								
	Melaena		Sular	C				
	Vomiting		Endocet	C				
			Glucotrol	C				
			Tylenol	C				

			Pepcid	C		

Date:05/23/00ISR Number: 3503823-6Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cognitive Disorder	Health	Vioxx 25 Mg (Merck)	PS	Merck	ORAL	25MG PO QD	
Initial or Prolonged	Depressed Level Of Consciousness	Professional	Asa	C				
	Disturbance In Attention		Calcium	C				
	Feeling Abnormal		Prednisone	C				
	Hypoaesthesia		Plaquinil					
	Memory Impairment		Hydroxychloroquine	C				
	Paraesthesia		Tylenol	C				
	Thinking Abnormal		Miacalcin Nasal Spray	C				
	Visual Acuity Reduced		Imdur	C				
	Visual Disturbance		Digoxin	C				
			Vasotec	C				
			Senokot	C				
			Multivitamin	C				
			Lasix	C				

Date:05/23/00ISR Number: 3503824-8Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Abdominal Distension	Health	Vioxx 25 Mg	PS		ORAL	1 QD PO	
Intervention to Prevent Permanent Impairment/Damage	Oedema	Professional						

Date:05/23/00ISR Number: 3503827-3Report Type:Direct Company Report #
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 25MG PO QD	Cognitive Disorder	Health	Vioxx 25 Mg (Merck)	PS	Merck	ORAL
Initial or Prolonged		Professional	Synthroid	C		
			Rhythmol	C		
			Colace	C		
			Oscal W/ Vit D	C		
			Fosamax	C		
			Multivitamin	C		
			Androderm Patch	C		
			Sinimet	C		
			Asa	C		
			Prilosec	C		

Date:05/24/00ISR Number: 3504019-4Report Type:Expedited (15-DaCompany Report #WAES 00040414
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blighted Ovum	Consumer	Vioxx	PS	Merck Research	
	Heart Disease Congenital	Health			Laboratories Div	
	Pregnancy	Professional			Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/00ISR Number: 3504020-0Report Type:Expedited (15-DaCompany Report #WAES 00051757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Chondrotin (+) Glucosamine	C				
			Estrogenic Preparations	C				

Date:05/24/00ISR Number: 3504022-4Report Type:Expedited (15-DaCompany Report #WAE00051931
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diaphragmatic Hernia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage							
	Gastrointestinal Perforation							
	Haematemesis		Prevacid	C				
	Haematochezia		Tylenol	C				
	Haemoglobin Decreased		Methotrexate	C				
	Hiatus Hernia		Vioxx	C	Merck Research Laboratories Div Merck Co Inc			

Date:05/24/00ISR Number: 3504024-8Report Type:Expedited (15-DaCompany Report #WAES 00051631
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Anaemia							
	Duodenal Ulcer Perforation							

Date:05/24/00ISR Number: 3504025-XReport Type:Expedited (15-DaCompany Report #WAES 00051657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Face Oedema							
	Influenza Like Illness							
	Oedema Peripheral							
	Pruritus		Liptor	C				
			Zestril	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:05/24/00ISR Number: 3504027-3Report Type:Expedited (15-DaCompany Report #WAES 00050046
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Other	Blood Parathyroid Hormone Increased
	Difficulty In Walking
	Hypercalcaemia

	Muscular Weakness Parathyroid Tumour Benign	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Avandia	C			
			Lanoxin	C			

Date:05/24/00ISR Number: 3504028-5Report Type:Expedited (15-DaCompany Report #WAES 00057283
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Dizziness Dysarthria Muscle Spasms Speech Disorder	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 15 DAY
			Aspirin	C			
			Estriol	C			
			Glyburide	C			
			Isosorbide	C			
			Sotalol	C			

Date:05/24/00ISR Number: 3504029-7Report Type:Expedited (15-DaCompany Report #WAES 00042094
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Fall Muscular Weakness Syncope	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
	Tremor		Tab Vioxx	SS		ORAL	PO
	Urinary Tract Infection		Coumadin	C			
			Lanoxin	C			

Date:05/24/00ISR Number: 3504031-5Report Type:Expedited (15-DaCompany Report #WAES 00041847
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Faecal Occult Blood Positive Faeces Discoloured Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased Pallor	Health Professional	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:05/24/00ISR Number: 3504044-3Report Type:Expedited (15-DaCompany Report #WAES 00041404
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Disability	Arthritis Back Pain Discomfort Drug Ineffective

Pain In Extremity

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	
			Hytrin	C				
			Norvasc	C				

Date:05/24/00ISR Number: 3504119-9Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS			25MG /D (1X)	

Date:05/24/00ISR Number: 3504146-1Report Type:Expedited (15-DaCompany Report #WAES 00051635
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Gastroenteritis	Company			Merck Co Inc	ORAL	25 MG/ BID/	
Other	Helicobacter	Representative					PO	
			Proscar	C				

Date:05/24/00ISR Number: 3504452-0Report Type:Expedited (15-DaCompany Report #WAES 00057285
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Increased	Health			Laboratories Div			
	Hyperkalaemia	Professional			Merck Co Inc	ORAL	PO	

International Normalised Ratio Increased	Elavil C
Leukocytosis	Acetaminophen C
Renal Failure	Acetylcysteine C
Thrombocythaemia	Diazepam C
	Doxazosin C
	Furosemide C
	Lactulose C
	Loratadine C
	Metoprolol Tartrate C
	Oxycodone Hcl C
	Picosulfate Na C
	Verapamil Hcl C
	Warfarin Sodium C

Date:05/24/00ISR Number: 3504453-2Report Type:Expedited (15-DaCompany Report #WAES 00051784
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/00ISR Number: 3504454-4Report Type:Expedited (15-DaCompany Report #WAES 00051805
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Allegra	C				
			Cardizem	C				
			Prevacid	C				
			Synthroid	C				
			Doxepin	C				

Date:05/24/00ISR Number: 3504496-9Report Type:Direct Company Report #
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx 25mg	PS		ORAL	1T P.O. D.	

Date:05/24/00ISR Number: 3504588-4Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Health	Vioxx	PS			PRN	
	Haemorrhage	Professional	Coumiden	SS			DAILY	
			Heparin	SS				

Date:05/24/00ISR Number: 3504591-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Zyvox	PS				
			Vioxx	SS				

Date:05/24/00ISR Number: 3504650-6Report Type:Expedited (15-DaCompany Report #WAES 00051633
Age:101 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage	Company			Merck Co Inc	ORAL	25	
Disability		Representative					MG/DAILY/PO	
Other			Lasix	C				
			Synthroid	C				

Date:05/24/00ISR Number: 3505042-6Report Type:Expedited (15-DaCompany Report #WAES 00055515
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Failure
Hospitalization -	Congestive
Initial or Prolonged	Condition Aggravated
	Leukocytoclastic
	Vasculitis
	Purpura

	Skin Ulcer						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 1 WK
			Amlodipine Benzenesulfonate	C			
			Aspirin	C			
			Isosorbide-5-Mononitrate	C			

Date:05/24/00ISR Number: 3505043-8Report Type:Expedited (15-DaCompany Report #WAES 00047318
Age:45 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Mb Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO
	Cardiac Enzymes Increased		Azathioprine	C			
	Headache		Hydroxychloroquineso4	C			
	Hypertension		Levothyroxine Na	C			
	Myocardial Infarction		Prednisolone	C			
	Nausea						
	Renal Disorder						
	Vomiting						

Date:05/24/00ISR Number: 3505045-1Report Type:Expedited (15-DaCompany Report #WAES 00045574
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Faeces Discoloured Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 27 DAY
	Gastroenteritis		Dipyrone	C			
	Helicobacter		Ibuprofen	C			
	Haematemesis		Theophylline	C			

Ketonuria

Date:05/25/00ISR Number: 3504708-1Report Type:Expedited (15-DaCompany Report #WAES 00055539
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	13 DAY
	Faeces Discoloured	Health						
	Hiatus Hernia	Professional						
	Oesophageal Ulcer	Other	Dipyrone	C				
	Haemorrhage		Furosemide	C				
	Oesophagitis		Ranitidine Hcl	C				
			Sulfamethoxazole/Trimethoprim	C				
			Tramadol Hcl	C				

Date:05/25/00ISR Number: 3504721-4Report Type:Expedited (15-DaCompany Report #WAES 00055140
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Haemolysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	52 DAY
			Hydrodiuril	C				
			Folic Acid	C				
			Lansoprazole	C				
			Penicillin V	C				
			Prednisolone	C				

Date:05/25/00ISR Number: 3504722-6Report Type:Expedited (15-DaCompany Report #WAES 00055131
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Metronidazole	C				

Date:05/25/00ISR Number: 3504723-8Report Type:Expedited (15-DaCompany Report #WAES 00055065
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Decreased Haemoglobin Decreased Mallory-Weiss Syndrome	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Melaena Proteinuria		Acetaminophen/Propoxyphene Hydrochloride	C				
			Lactulose	C				
			Raloxifene	C				

Date:05/25/00ISR Number: 3504726-3Report Type:Expedited (15-DaCompany Report #WAES 00055595
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Hepatitis Cholestatic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

Date:05/25/00ISR Number: 3504727-5Report Type:Expedited (15-DaCompany Report #WAES 00055600
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Blood Urea Increased Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	
	Tachycardia		Hctz/Quinapril	C				
			Chloroquine Diphosphate	C				

Date:05/25/00ISR Number: 3504728-7Report Type:Expedited (15-DaCompany Report #WAES 00055164
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspepsia Loss Of Consciousness Malaise	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Dexamethasone	C				
			Omeprazole	C				

Date:05/25/00ISR Number: 3504799-8Report Type:Expedited (15-DaCompany Report #WAES 00040048
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	DAILY

Date:05/25/00ISR Number: 3504800-1Report Type:Expedited (15-DaCompany Report #WAES 00032665
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Hypersensitivity Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/25/00ISR Number: 3504801-3Report Type:Expedited (15-DaCompany Report #WAES 00040041
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Optic Disc Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Optic Nerve Sheath				Merck Co Inc	ORAL
PRN/PO						
	Haemorrhage		Coumadin	SS		
	Photopsia		Levoxyl	C		
	Retinal Haemorrhage		Lipitor	C		
	Retinal Tear		Relafen	C		
	Vision Blurred		Triazolam	C		
	Visual Disturbance					
	Vitreous Detachment					
	Vitreous Floaters					

Date:05/25/00ISR Number: 3504948-1Report Type:Expedited (15-DaCompany Report #000403-SK981
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Meningitis	Foreign	Celebrex	PS	Gd Searle And Co	ORAL
PO						
Initial or Prolonged		Health	Vioxx (Rofecoxib)	SS		ORAL
PO						
Other		Professional				

Date:05/25/00ISR Number: 3505027-XReport Type:Expedited (15-DaCompany Report #WAES00051708
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged					Laboratories Div	

Merck Co Inc ORAL
12.5 MG/PO
Miacalcin C

Date:05/25/00ISR Number: 3505028-1Report Type:Expedited (15-DaCompany Report #WAES00050800
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukocytoclastic Vasculitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Provera	C				
			Tagamet	C				

Date:05/25/00ISR Number: 3505029-3Report Type:Expedited (15-DaCompany Report #WAES00052147
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accupril	C				
			Coumadin	C				
			Lipitor	C				
			Prevacid	C				

Date:05/25/00ISR Number: 3505030-XReport Type:Expedited (15-DaCompany Report #WAES00051945
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	6 DAY
Other	Dehydration							
	Diarrhoea							

	Fatigue	Representative
	Haematuria	
	Malaise	
	Pyrexia	
	Vomiting	

Date:05/25/00ISR Number: 3505044-XReport Type:Expedited (15-DaCompany Report #WAES 00047306
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	50 DAY
Hospitalization - Initial or Prolonged	Dyspnoea	Other						
	Sepsis							
			Tab Allopurinol	SS		ORAL	200 MG PO	44 DAY
			Furosemide	C				
			Levothyroxine Na	C				
			Omeprazole	C				
			Ramipril	C				
			Vitamin B{12}	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/00ISR Number: 3505200-0Report Type:Expedited (15-DaCompany Report #WAES 00027293
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Bone Marrow Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Blood Creatinine Increased		Tab Methotrexate Dina	SS		ORAL	PO	
	Drug Level Above Therapeutic		Acetaminophen/Codeine Phosphate	C				
	Haemoglobin Decreased		B Vitamins (+)					
	Oedema		Caffeine	C				
	Pancytopenia		Enoxaparin	C				
	Plasmacytosis		Estradiol/Norethindrone Acetate	C				
	Renal Failure		Propoxyphene Napsylate Monohydrate	C				
	Thrombocytopenia		Sotalol Hydrochloride	C				
	White Blood Cell Count Decreased							

Date:05/26/00ISR Number: 3505201-2Report Type:Expedited (15-DaCompany Report #WAES 00055600
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, PO	
	Blood Urea Increased							
	Hypertension							
	Tachycardia		Hctz/Quinapril	C				
			Chloroquine Diphosphate	C				

Date:05/26/00ISR Number: 3505202-4Report Type:Expedited (15-DaCompany Report #WAES 00053737
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Akathisia Disorientation Restlessness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO 6 DAY
	Vomiting		Pepcid	C			

Date:05/26/00ISR Number: 3505231-0Report Type:Expedited (15-DaCompany Report #WAES 00031010
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Cardiac Failure Congestive Cellulitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO;
	Oedema Peripheral	Representative					12.5 MG/DAILY/PO; 25 MG/DAILY/POO
			Cardura	C			
			Flonase	C			
			Univasc	C			
			Glucosamine	C			
			Vitamins	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/00ISR Number: 3505232-2Report Type:Expedited (15-DaCompany Report #WAES 00011253
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation	Health	Vioxx	PS	Merck Research			
Hospitalization -	Anxiety	Professional			Laboratories Div			
Initial or Prolonged	Blood Albumin Decreased				Merck Co Inc	ORAL	25	
	Blood Creatinine						MG/DAILY/PO;	
	Increased						12.5	
	Blood Urea Increased						MG/DAILY/PO	
	Crying		Bactrim	C				
	Dehydration		Coumadin	C				
	Flushing		Darvcet-N	C				
	Insomnia		Tylenol With Codeine	C				
	International Normalised		Ultram	C				
	Ratio Increased							
	Nervousness							
	Oedema Peripheral							
	Prothrombin Time							
	Prolonged							
	Renal Failure Acute							

Date:05/26/00ISR Number: 3505292-9Report Type:Direct Company Report #
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Rofecoxib	PS				
	Dizziness							
	Erythema							
	Hypotension							
	Syncope							

Date:05/26/00ISR Number: 3505348-0Report Type:Expedited (15-DaCompany Report #WAES 00010884
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blood Pressure Increased Drug Ineffective Retinal Haemorrhage	Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
	Visual Disturbance		Celexa	C		
			Lasix	C		
			Osteo-Bi-Flex	C		
			Prilosec	C		
			Alprazolam	C		
			Aspirin	C		
			Chromium Picolinate	C		
			Lysine	C		
			Melatonin	C		
			Potassium Chloride	C		
			Vitamins	C		

Date:05/26/00ISR Number: 3505361-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain		Rofecoxib 25mg Po Qd			
Hospitalization -	Anastomotic Ulcer		Or	PS		ORAL
25MG PO QD OR						
Initial or Prolonged	Perforation		Naproxen 200mg Po			
	Peritonitis		Bid Or	SS		

			Placebo	SS			

Date:05/26/00ISR Number: 3505523-5Report Type:Expedited (15-DaCompany Report #WAES 00052241
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Difficulty In Walking	Health	Vioxx	PS	Merck Research			
Other	Dysarthria	Professional			Laboratories Div			
	Gait Disturbance	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Hemiparesis	Representative					PO	
	Hypoaesthesia		Calcium Supplement	C				
	Muscular Weakness							
	Speech Disorder							

Date:05/26/00ISR Number: 3505530-2Report Type:Expedited (15-DaCompany Report #WAES 00052212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer Haemorrhage				Laboratories Div			
Initial or Prolonged	Peripheral Circulatory				Merck Co Inc	ORAL	PO	
	Failure		Coumadin	C				
			Heparin Sodium	C				

Date:05/26/00ISR Number: 3505531-4Report Type:Expedited (15-DaCompany Report #WAES 00051943
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
	Face Oedema	Company			Merck Co Inc	ORAL	25-50	
	Pharyngeal Oedema	Representative					MG/DAILY/ PO	
	Urticaria							

Date:05/26/00ISR Number: 3505533-8Report Type:Expedited (15-DaCompany Report #WAES 00051870
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Feeling Cold							
	Feeling Hot							
	Oedema Peripheral		Dilantin	C				
	Paraesthesia		Prilosec	C				
			Tylenol	C				
			Vanceril	C				
			Albuterol	C				
			Diazepam	C				
			Phenobarbital	C				
			Prednisone	C				
			Theophylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/00ISR Number: 3505534-XReport Type:Expedited (15-DaCompany Report #WAES 00051950
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Cerebrovascular Accident Hypertension Malaise Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/ PO	

Date:05/26/00ISR Number: 3505536-3Report Type:Expedited (15-DaCompany Report #WAES 00051895
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/26/00ISR Number: 3505537-5Report Type:Expedited (15-DaCompany Report #WAES 00051881
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/ PO	1 DAY
			Verapamil	C				

Date:05/26/00ISR Number: 3505538-7Report Type:Expedited (15-DaCompany Report #WAES 00051730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebral Infarction Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:05/26/00ISR Number: 3505539-9Report Type:Expedited (15-DaCompany Report #WAES 00051686
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased Feeling Drunk Haemorrhagic Stroke Stupor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Flexeril	C				
			Pravachol	C				
			Synthroid	C				
			Zestril	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/00ISR Number: 3505541-7Report Type:Expedited (15-DaCompany Report #WAES 00051632
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Condition Aggravated	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea	Company			Merck Co Inc	ORAL	25	
	Face Oedema	Representative					MG/DAILY/PO	
	Hypertension		Estratest	C				
	Hypoxia		Inderal La	C				
	Joint Stiffness		Stadol	C				
	Joint Swelling							
	Lung Infiltration							
	Obstructive Airways							
	Disorder							
	Oedema Peripheral							
	Orthopnoea							
	Oxygen Saturation							
	Decreased							
	Pulmonary Oedema							

Date:05/26/00ISR Number: 3505544-2Report Type:Expedited (15-DaCompany Report #WAES 00040805
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgraphia	Consumer	Vioxx	PS	Merck Research			
	Fall				Laboratories Div			
	Head Injury				Merck Co Inc	ORAL	PO; 12.5	
	Pain						MG/DAILY, PO	
	Weight Increased		Allegra	C				
			Darvocet-N	C				
			Oxycontin	C				
			Percocet	C				

Date:05/26/00ISR Number: 3505546-6Report Type:Expedited (15-DaCompany Report #WAES 00032030
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Dermatitis	Other			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastric Ulcer Haemorrhage							
	Haematemesis							
	Oesophageal Ulcer		Benadryl	C				
	Haemorrhage		Demerol	C				
	Photosensitivity Reaction		Elavil	C				
	Rash Erythematous		Fragmin	C				
	Rash Papular		Phenergan Injection	C				
	Vomiting		Prevacid	C				
			Propulsid	C				
			Septra	C				
			Phenytoin	C				

Date:05/26/00ISR Number: 3505548-XReport Type:Expedited (15-DaCompany Report #WAES 00051931
Age:63 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage Gastrointestinal Disorder Haematemesis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haematochezia	Representative						
	Haemoglobin Decreased Hiatus Hernia		Calcium Carbonate (+) Vitamin D Methotrexate Prednisone	 C C C				

Date:05/26/00ISR Number: 3505551-XReport Type:Expedited (15-DaCompany Report #WAES 00042537
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Ecotrin Zocor Amiodarone Atenolol	C C C C				

Date:05/26/00ISR Number: 3505552-1Report Type:Expedited (15-DaCompany Report #WAES 00051193
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Flatulence Gastric Ulcer Perforation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
Other		Representative	Miacalcin Os-Cal	C C				

Date:05/26/00ISR Number: 3505555-7Report Type:Expedited (15-DaCompany Report #WAES 00040045
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization -	Abdominal Pain
Initial or Prolonged	Cold Sweat
Other	Colitis
	Colitis Ischaemic
	Computerised Tomogram
	Abnormal
	Diarrhoea
	Diarrhoea Haemorrhagic
	Dizziness
	Gastrointestinal Disorder
	Postoperative
	Gastrointestinal
	Haemorrhage
	Granuloma
	Haematochezia
	Haematocrit Decreased
	Haemoglobin Decreased
	Intestinal Ulcer

		Mucous Membrane Disorder Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Stitch Abscess Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Ibuprofen Unk	SS		
1800 MG/DAILY							
				Cozaar	C		
				Glucophage	C		
				Imitrex	C		
				Levaquin	C		
				Prozac	C		
				Roxicet	C		
				Soma	C		
				Synthroid	C		
				Tylenol	C		
				Tylenol With Codeine #3	C		
				[Therapy Unspecified]	C		
				Amoxicillin	C		
				Estradiol	C		
				Glyburide	C		
				Promethazine	C		
				Trazodone	C		

Date:05/26/00ISR Number: 3506567-XReport Type:Periodic Company Report #7842
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Chest Pain Diarrhoea	Consumer	Niaspan	PS	Kos Pharmaceuticals Inc	ORAL
500 MG QHS PO							
		Flushing		Vioxx	SS		ORAL
50 MG QD PO	WK						

Date:05/26/00ISR Number: 3506910-1Report Type:Expedited (15-DaCompany Report #SP-200000767
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Remicade	PS		INTRAVENOUS	INTRAVENOUS 3 MG/KG	
			Voltaren	SS		ORAL	ORAL	
			Decortin	SS		ORAL	ORAL	
			Rofecoxib	SS		ORAL	ORAL	

Date:05/30/00ISR Number: 3505303-0Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx (Rofecoxib)	PS		ORAL	25MG PO Q D	2 MON
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Atrial Fibrillation Dizziness Palpitations Tachycardia		Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/00ISR Number: 3505304-2Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx (Rofecoxib)	PS		ORAL	PO	2 MON
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea Exertional Fatigue Myocardial Infarction							

Date:05/30/00ISR Number: 3505761-1Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Haemorrhage		Asa	SS		ORAL	ECASI 81MG PO QD	
	Haematemesis							

Date:05/30/00ISR Number: 3505801-XReport Type:Direct Company Report #
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25mg Merck &					
Initial or Prolonged	Migraine		Co	PS	Merck & Co		ONE TABLE AT NIGHT	

Date:05/30/00ISR Number: 3506304-9Report Type:Expedited (15-DaCompany Report #WAES 00040870
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Duodenal Ulcer	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Aspirin	SS		ORAL	650 MG/DAILY/PO	
			Aerobid	C				
			Atrovent	C				
			Premarin	C				
			Ultram	C				
			Zantac	C				
			Albuterol	C				
			Ascorbic Acid	C				
			Diltiazem	C				
			Prednisone	C				
			Temazepam	C				
			Vitamins	C				

Date:05/30/00ISR Number: 3506306-2Report Type:Expedited (15-DaCompany Report #WAES 00040877
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Diverticulitis Gastrointestinal Perforation
Other	

Inflammation

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex 200 Mg	SS		ORAL	200 MG/BID/PO	

Date:05/30/00ISR Number: 3506309-8Report Type:Expedited (15-DaCompany Report #WAES 00052151
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Blood Pressure Increased Thrombosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/30/00ISR Number: 3506321-9Report Type:Expedited (15-DaCompany Report #WAES 00050799
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:05/30/00ISR Number: 3506374-8Report Type:Expedited (15-DaCompany Report #WAES 00056136
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Congestive	Health			Laboratories Div	
	Drug Interaction	Professional			Merck Co Inc	ORAL
12.5 MG PO						
	International Normalised		Tab Acenocoumarol	SS		ORAL
PO						
	Ratio Increased		Therapy Unspecified	C		

Date:05/30/00ISR Number: 3506375-XReport Type:Expedited (15-DaCompany Report #WAES 00058914
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pruritus	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Rash Maculo-Papular	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
PO						
			Allopurinol	C		
			Ciprofloxacin	C		
			Coversyl	C		
			Glyburide	C		
			Metformin Hc1	C		

Date:05/30/00ISR Number: 3506377-3Report Type:Expedited (15-DaCompany Report #WAES 00059116
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5 MG PO						

			Cozaar	C		
			Zocor	C		
			Lercanidipine	C		

Date:05/30/00ISR Number: 3506378-5Report Type:Expedited (15-DaCompany Report #WAES 00059117
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen	C				
			Carbidopa/Levodopa	C				
			Vitamin	C				

Date:05/30/00ISR Number: 3506457-2Report Type:Expedited (15-DaCompany Report #WAES 00041326
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Mass	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Other	Asthenia							
	Benign Duodenal Neoplasm							
	Blood Pressure Diastolic Decreased	Representative	Capoten	C				
	Constipation		Coumadin	C				
	Decreased Appetite		Dulcolax	C				
	Diverticulum		K-Dur	C				
	Duodenal Polyp		Lanoxin	C				
	Duodenal Ulcer		Lasix	C				
	Haemorrhage		Lortab	C				
	Dyspepsia		Nitro-Dur	C				
	Faeces Discoloured		Aspirin	C				
	Gastritis							
	Gastritis Erosive							
	Gastrointestinal Haemorrhage							
	Hiatus Hernia							
	International Normalised							

	Ratio Increased					
	Iridectomy					
	Nausea					
	Syncope					
	Ulcer					
	Weight Decreased					

Date:05/30/00ISR Number: 3506483-3Report Type:Expedited (15-DaCompany Report #WAES 00010869
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faecal Occult Blood	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage	Other			Merck Co Inc	ORAL	25	
Other	Haematocrit Decreased						MG/DAILY/PO	
	Haemoglobin Decreased		Prilosec	C				
	Red Blood Cell Count Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/00ISR Number: 3506319-0Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx (Merck)	PS	Merck			
			Garamycin Cream	C				
			Bactroban	C				

Date:05/31/00ISR Number: 3506330-XReport Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Albumin Increased		Rofecoxib (Vioxx) 50					
Life-Threatening	Fall		Mg Qd	PS		ORAL	50MG PO QD	
Hospitalization -	Hepatic Failure		Tylenol	C				
Initial or Prolonged	Liver Function Test		Asa	C				
Required	Abnormal		Clonazepam	C				
Intervention to	Renal Failure Acute		Ntg	C				
Prevent Permanent	Upper Limb Fracture		Perphenazine	C				
Impairment/Damage			Propoxyphene	C				
			Sorbitol	C				
			Tramadol	C				
			Zolpidem	C				

Date:05/31/00ISR Number: 3507273-8Report Type:Periodic Company Report #9951462
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Feldene	PS	Pfizer Laboratories			
	Diarrhoea	Health			Div Pfizer Inc	ORAL	20.00 MG	
	Gastrointestinal Disorder	Professional					TOTAL; DAILY;	
	Malaise						ORAL	
	Nausea		Vioxx	SS		ORAL	ORAL	
	Neuropathy Peripheral		Lipitor	C				
	Pain		Aspirin	C				

Estrace	C
Dilacor Xr	C
Synthroid	C
Vasotec	C

Date:05/31/00ISR Number: 3507279-9Report Type:Periodic Company Report #A007263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Feldene	PS	Pfizer Laboratories Div Pfizer Inc	ORAL	20.00 MG	TOTAL; DAILY;
	Depression							
	Dyspepsia							
	Hypertension							
	Hypothyroidism		Vioxx	SS		ORAL	12.50 MG	TOTAL; DAILY;
	Rectal Haemorrhage							
	Weight Increased							

Date:05/31/00ISR Number: 3507365-3Report Type:Periodic Company Report #9940509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Feldene	PS	Pfizer Laboratories Div Pfizer Inc			
	Drug Interaction							

			Vioxx	SS		

Date:06/01/00ISR Number: 3507345-8Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia		Vioxx	PS		
25MG QD /						
Initial or Prolonged	Blood Creatinine					
PRIOR TO						
	Increased					
ADMISSION						
	Fatigue		Lopressor	C		
	Renal Failure Acute		Imdur	C		
			Coumadin	C		
			Lanoxin	C		
			Tiazac	C		
			Lasix	C		

Date:06/01/00ISR Number: 3507377-XReport Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured		Voltaren 50 Mg			
Initial or Prolonged	Haematemesis		Novartis	PS	Novartis	ORAL
50MG ORAL						
	Iron Deficiency Anaemia		Vioxx 25 Mg Merck	SS	Merck	ORAL
25MG QD ORAL						
	Upper Gastrointestinal		Indocin 25mg Merck	SS	Merck	ORAL
25MG BID ORAL						
	Haemorrhage		Dyazide	C		
			Amlodipine	C		
			Glyburide	C		
			Calcium Carbonate	C		
			Vioxx	C		
			Indomethacin	C		

Date:06/01/00ISR Number: 3507425-7Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal Disorder		Vioxx	PS		ORAL
25MG QD PO						
Initial or Prolonged	Intestinal Obstruction		Demodex	C		
	Intestinal Ulcer		Tiazac	C		
	Oedema		K Tab	C		
			Serevent Mdi/ Combivent Mdi	C		
			Fosamax	C		
			Evista	C		

Date:06/01/00ISR Number: 3507454-3Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Health	Vioxx 25 Mg-Pfizer	PS	Pfizer	
25MG QD PO						
Initial or Prolonged	Faeces Discoloured	Professional				
	Fatigue					
	Upper Gastrointestinal Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/00ISR Number: 3507478-6Report Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urine Odour Abnormal		Vioxx	PS			25 MG / ONCE	DAILY

Date:06/02/00ISR Number: 3507755-9Report Type:Expedited (15-DaCompany Report #WAES 00055164
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspepsia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Loss Of Consciousness							
	Malaise							
	Mitral Valve Stenosis		Prilosec	C				
			Dexamethasone	C				

Date:06/02/00ISR Number: 3507756-0Report Type:Expedited (15-DaCompany Report #WAES 00041933
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cough	Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Diabetes Mellitus	Professional						
	Dyspnoea	Company						
Disability	Hyperglycaemia	Representative						
	Hypertension		Daypro	C				
	Oedema Peripheral		Premarin	C				
	Pulmonary Oedema		Synthroid	C				
	Skin Ulcer		Aspirin	C				
			Methotrexate	C				
			Prednisone	C				

Date:06/02/00ISR Number: 3507832-2Report Type:Expedited (15-DaCompany Report #A017083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Antivert	PS	Pfizer Agricultural Div			
	Back Pain							
	Pain In Extremity		Rofecoxib	SS		ORAL	12.50 MG	
	Renal Failure Acute							
TOTAL: DAILY:								
						ORAL		
			Glucosamine	C				
			Levothyroxine	C				

Date:06/02/00ISR Number: 3507875-9Report Type:Expedited (15-DaCompany Report #WAES 00047311
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
	Cardiac Failure Congestive
	Chest X-Ray Abnormal
	Cholecystitis
	Cough
	Duodenitis
	Endoscopy Upper Gastrointestinal Tract

		Abnormal Gastritis Gastrointestinal Disorder Melaena	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mucous Membrane Disorder Nausea Oxygen Saturation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12, 5 MG PO	13 DAY						
		Abnormal Pleural Effusion Pyrexia Swelling Upper Respiratory Tract Infection Weight Decreased		1a-Hydroxycholecalciferol	C		
				Acetylcysteine	C		
				Digitoxin	C		
				Dipyrimadole	C		
				Furosemide	C		
				Insulin Injection / Isophane Insulin Suspe	C		
				Irbesartan	C		
				Isosorbide-5-Mononitrate	C		
				Potassium Chloride	C		

Date:06/02/00ISR Number: 3507876-0Report Type:Expedited (15-DaCompany Report #WAES 00047310
Age:83 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Atrial Fibrillation Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12, 5 MG PO	34 DAY						
		Deep Vein Thrombosis Dyspnoea Hypokalaemia Oedema Peripheral		Prinivil	C		
				Bambuterol Hcl	C		
				Digoxin	C		
				Flunitrazepam	C		
				Furosemide	C		
				Loracarbef	C		
				Calcium Supplement (Nos)	C		
				Citalopram Hydrobromide	C		

Date:06/02/00ISR Number: 3508229-1Report Type:Expedited (15-DaCompany Report #WAES 00047316
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vasculitis Necrotising	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	4	DAY
			Tab Disulfiram	SS		ORAL		
			Triamcinolone Hexacetonide	C				

Date:06/02/00ISR Number: 3508243-6Report Type:Expedited (15-DaCompany Report #WAES 00052149
Age:75 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
	Blood Urea Increased
	Bradycardia
	Dehydration

	Syncope Therapeutic Agent Toxicity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Digoxin	SS			

Date:06/02/00ISR Number: 3508246-1Report Type:Expedited (15-DaCompany Report #WAES 00052205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Decreased Activity Drug Ineffective Fluid Retention Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO

Date:06/02/00ISR Number: 3508247-3Report Type:Expedited (15-DaCompany Report #WAES 00052386
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort Gastritis Erosive Headache	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO

Date:06/02/00ISR Number: 3508250-3Report Type:Expedited (15-DaCompany Report #WAES 00052417
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25

MG/DAILY/PO

			Celebrex	C
			Aspirin	C

Date:06/02/00ISR Number: 3508251-5Report Type:Expedited (15-DaCompany Report #WAES 00052425
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea Oedema Peripheral Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			(Therapy Unspecified)	C

Date:06/02/00ISR Number: 3508253-9Report Type:Expedited (15-DaCompany Report #WAES 00052596
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Blood Urea Increased Fluid Retention Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO

			Therapy Unspecified	C

Date:06/02/00ISR Number: 3508254-0Report Type:Expedited (15-DaCompany Report #WAES 00057918
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Decreased Cerebrovascular Accident Respiratory Failure	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	1 DAY
	Syncope		Ascorbic Acid/Ferrous Sulfate/Vitamin B	C				
			Nifedipine	C				
			Phenprocoumon	C				

Date:06/02/00ISR Number: 3508255-2Report Type:Expedited (15-DaCompany Report #WAES 00058911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/02/00ISR Number: 3508256-4Report Type:Expedited (15-DaCompany Report #WAES 00030667
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Adenocarcinoma Carcinoembryonic Antigen	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Drug Interaction Drug Toxicity Hepatic Neoplasm Malignant	Representative						

International Normalised
Ratio Increased
Metastases To Liver
Nausea
Prothrombin Level
Increased
Weight Decreased

Date:06/02/00ISR Number: 3508262-XReport Type:Expedited (15-DaCompany Report #WAES 00052060
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Urea Increased							
	Renal Failure							

Date:06/02/00ISR Number: 3508266-7Report Type:Expedited (15-DaCompany Report #WAES 00052244
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorectal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Drug Ineffective	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastric Ulcer Haemorrhage	Representative						
	Hiatus Hernia							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/ BID/PO	
			Paxil	C				
			Premarin	C				

Date:06/02/00ISR Number: 3508270-9Report Type:Expedited (15-DaCompany Report #WAES 00052338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Gastrointestinal Haemorrhage	Company			Merck Co Inc	ORAL	PO	2 WK
		Representative						

Date:06/02/00ISR Number: 3508271-0Report Type:Expedited (15-DaCompany Report #WAES 00052353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hepatic Pain							
	Malaise				Merck Co Inc	ORAL	PO	
	Pain							
	Vomiting							

Date:06/02/00ISR Number: 3508273-4Report Type:Expedited (15-DaCompany Report #WAES 00052403
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Professional			Laboratories Div			
Initial or Prolonged	Chest Discomfort	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
Disability	Deep Vein Thrombosis	Representative					PO	
	Dyspnoea Exertional		Tab Vioxx	SS		ORAL	PO	
	Ejection Fraction		Tab Vioxx 25 Mg	SS		ORAL	25	
	Abnormal						MG/DAILY/PO	
	Embolism		Arava	C				
	Hypertension		Coumadin	C				
	Oedema Peripheral		Nitroglycerin	C				
	Pain		Prednisone	C				
	Palpitations							
	Pulmonary Embolism							
	Pulmonary Oedema							

Date:06/02/00ISR Number: 3508278-3Report Type:Expedited (15-DaCompany Report #WAES 00055207
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Thrombocytopenia	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG PO	110 DAY
			Acetaminophen/Propox					

			yphene Hydrochloride	C
			Bendroflumethiazide	C

Date:06/02/00ISR Number: 3508282-5Report Type:Expedited (15-DaCompany Report #WAES 00058226
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Injury	Foreign	Vioxx	PS	Merck Research			
	Road Traffic Accident	Health			Laboratories Div			
	Syncope	Professional			Merck Co Inc	ORAL	12.5 MG PO	69 DAY
		Other	B Vitamins	C				
			Magnesium					
			Preparation					
			(Composition Unspe	C				

Date:06/02/00ISR Number: 3508285-0Report Type:Expedited (15-DaCompany Report #WAES 00058598
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc			

Date:06/02/00ISR Number: 3508292-8Report Type:Expedited (15-DaCompany Report #WAES 00058907
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Exfoliative	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Dysphagia	Health			Laboratories Div			
	Face Oedema	Professional			Merck Co Inc	ORAL	25 MG DAILY	44 DAY
	Mucosal Ulceration		Allopurinol	C				
	Rash Erythematous		Calcium Pantothenate	C				
	Rash Maculo-Papular		Digoxin	C				
			Diumide-K	C				
			Felodipine	C				
			Pizotifen Maleaate	C				

Date:06/02/00ISR Number: 3508310-7Report Type:Expedited (15-DaCompany Report #WAES 00045546
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Haemolytic Autoimmune Biopsy Bone Marrow	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Abnormal Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Coombs Direct Test Positive Dizziness Dyspnoea Exertional Fatigue Haematocrit Decreased Haemoglobin Decreased Haemolysis		Cozaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/00ISR Number: 3508314-4Report Type:Expedited (15-DaCompany Report #WAES 00045573
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research			
	Gastric Ulcer Haemorrhage	Health			Laboratories Div			
	Haemoglobin Decreased	Professional			Merck Co Inc	ORAL	PO	
	Melaena		Inhl Fluticasone Propionate (+) Salmeterol	SS			INH	3 YR
			L-Thyroxine	C				
			Digitoxin	C				
			Irbesartan	C				
			Metformin	C				
			Nonsteroidal Anti-Inflammatory Drug Ther	C				
			Xipamide	C				

Date:06/02/00ISR Number: 3508316-8Report Type:Expedited (15-DaCompany Report #WAES 00047302
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ascites	Foreign	Vioxx	PS	Merck Research			
	Depressed Level Of Consciousness	Other			Laboratories Div			
					Merck Co Inc	ORAL	PO	30 DAY
	Foetor Hepaticus		Vasotec	C				
	Hepatic Encephalopathy		Clomethiazole Ethanedisulfonate	C				
	Hypokalaemia		Doxazosin Monomethanesulfonate	C				
	Jaundice		Ferrous Succinate	C				
	Liver Scan Normal		Ferrousso4	C				
	Serum Ferritin Abnormal		Omeprazole	C				
	Ultrasound Scan Abnormal							

Date:06/02/00ISR Number: 3508318-1Report Type:Expedited (15-DaCompany Report #WAES 00050150
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization -	Abdominal Distension Constipation Diverticulitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
Initial or Prolonged Disability	Intestinal Perforation Peritonitis Ruptured Diverticulum Of Colon Sepsis		Celebrex Lanoxin Prilosec Synthroid Ultram Aspirin Atenolol Conjugated Estrogenic Hormones Verapamil	C C C C C C C C C			MG/DAILY/PO	

Date:06/02/00ISR Number: 3508365-XReport Type:Expedited (15-DaCompany Report #WAES 00025666
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Right Essential Hypertension Exercise Electrocardiogram Abnormal Gallop Rhythm Present Heart Rate Increased Hypertension Supraventricular Extrasystoles Ventricular Extrasystoles	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	40 DAY

Date:06/02/00ISR Number: 3508369-7Report Type:Expedited (15-DaCompany Report #WAES 00025694
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Faeces Discoloured Gastric Haemorrhage Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
			Prednisone	SS		ORAL	5 MG	
			Cozaar	C				
			Albuterol Sulfate	C				
			Ipratropium Bromide	C				
			Isosorbide Dinitrate	C				
			Molsidomine	C				
			Theophylline	C				

Date:06/02/00ISR Number: 3508373-9Report Type:Expedited (15-DaCompany Report #WAES 00035004
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
12.50 MG; 25 MG	2	DAY				
			Amiloride Hydrochloride (+) Furosemide	SS		ORAL
5/40 MG	15	DAY				
			Acetaminophen/Codeine Phosphate	C		
			Albuterol	C		
			Lansoprazole	C		
			Prednisolone	C		

Date:06/02/00ISR Number: 3508375-2Report Type:Expedited (15-DaCompany Report #WAES 00045536
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Faeces Discoloured	Health						
	Gastric Haemorrhage	Professional			Merck Co Inc	ORAL	15	DAY
	Gastritis Erosive		Amiloride Hydrochloride	C				
	Melaena		Levothyroxine Na	C				
			Verapamil	C				

			...	C		
			...	C		
			...	C		

Date:06/02/00ISR Number: 3566322-1Report Type:Periodic Company Report #WAES 00012421
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS				

Date:06/02/00ISR Number: 3576001-2Report Type:Periodic Company Report #WAES 00011171
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Arthropathy Myalgia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Eldepryl	C				
			Prevacid	C				
			Requip	C				
			Furosemide	C				
			Lorazepam	C				
			Potassium Supplement	C				

Date:06/02/00ISR Number: 3576760-9Report Type:Periodic Company Report #WAES 00050335
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY

PO

Diovan C
Norvasc C

Date:06/05/00ISR Number: 3507463-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer	Vioxx	PS	Merck Sharp & Dohme Quimica			

SAMPLE PACK

OF 4 TABLETS-

2 TABLETS

Date:06/05/00ISR Number: 3508440-XReport Type:Expedited (15-DaCompany Report #WAES 00048608
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Confusional State
	Disorientation

	Gastrointestinal Disorder Oedema Peripheral						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	
			Vasotec	C				
			Docusate	C				
			Lansoprazole	C				

Date:06/05/00ISR Number: 3508442-3Report Type:Expedited (15-DaCompany Report #WAES 00048541
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	4 DAY
			Omeprazole	C				

Date:06/05/00ISR Number: 3508445-9Report Type:Expedited (15-DaCompany Report #WAES 00031459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disorientation Drug Interaction Drug Level Above Therapeutic	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dysarthria		Lithiumco3	SS		ORAL	PO	
	Therapeutic Agent Toxicity Urinary Incontinence		Oxybutynin Chloride	C				

Date:06/05/00ISR Number: 3508450-2Report Type:Expedited (15-DaCompany Report #WAES 00040829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nonsteeroidal Anti-Inflamatory	C				

Date:06/05/00ISR Number: 3508471-XReport Type:Expedited (15-DaCompany Report #WAES 00052441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anhedonia Confusional State Dehydration Disorientation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/00ISR Number: 3508473-3Report Type:Expedited (15-DaCompany Report #WAES 00056148
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	2 DAY
			Fludrocortisone	C				
			Hydrocortisone	C				

Date:06/05/00ISR Number: 3508491-5Report Type:Expedited (15-DaCompany Report #WAES 00055010
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG DAILY	30 DAY
Hospitalization - Initial or Prolonged	Congestive Condition Aggravated							
Other	Myocardial Infarction		Acetaminophen (+) Dihydrocodeine Bitartr	C				
	Oedema		Aspirin	C				
			Diclofenac	C				
			Diltiazem D-Cis Form Hcl	C				
			Omeprazole	C				

Date:06/05/00ISR Number: 3508506-4Report Type:Expedited (15-DaCompany Report #WAES 00052604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/05/00ISR Number: 3508511-8Report Type:Expedited (15-DaCompany Report #WAES 00052509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/05/00ISR Number: 3508514-3Report Type:Expedited (15-DaCompany Report #WAES 00052422
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/DAIL Y/PO	6 WK
	Blood Calcium Decreased							
	Blood Potassium Decreased							
	Cardiac Disorder							
	Fatigue		Prilosec	C				
	Gastrointestinal Disorder		Zocor	C				
	Haemoglobin Decreased							
	Hypocalcaemia							
	Hypokalaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/00ISR Number: 3508580-5Report Type:Expedited (15-DaCompany Report #WAES 00030254
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Vioxx	PS	Merck Research			
Hospitalization -	Anuria	Professional			Laboratories Div			
Initial or Prolonged	Blood Creatinine	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
Disability	Increased	Representative					PO	
Other	Blood Pressure Diastolic		Cozaar Unk	SS		ORAL	50 MG/DAILY/	
	Decreased						PO	
	Blood Urea Increased		Actos	C				
	Bradycardia		Demadex	C				
	Cardiac Failure		Flovent	C				
	Congestive		K-Dur	C				
	Condition Aggravated		Lasix	C				
	Drug Interaction		Serevent	C				
	Dyspnoea		Zocor	C				
	Fluid Retention		Glyburide	C				
	Gastrointestinal Disorder		Metoprolol	C				
	Hepatomegaly							
	Hypoaesthesia							
	Hypothermia							
	Muscle Spasms							
	Oedema							
	Oedema Peripheral							
	Oliguria							
	Rales							
	Renal Failure Acute							
	Respiratory Rate Increased							
	Weight Increased							

Date:06/05/00ISR Number: 3508581-7Report Type:Expedited (15-DaCompany Report #WAES 00031722
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Circulatory Collapse	Health			Laboratories Div			

	Gastric Ulcer Haemorrhage	Professional			Merck Co Inc	ORAL
PO						
	Gastrointestinal Haemorrhage					

Date:06/05/00ISR Number: 3508582-9Report Type:Expedited (15-DaCompany Report #WAES 00055600
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arrhythmia	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Blood Urea Increased	Health				
	Hypertension	Professional			Merck Co Inc	ORAL
50 MG PO						
	Tachycardia	Other	Hctz/Quinapril	C		
			Chloroquine Diphosphate	C		

Date:06/05/00ISR Number: 3508585-4Report Type:Expedited (15-DaCompany Report #WAES 00042799
Age:76 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anaemia

	Arrhythmia						
	Asthenia						
	Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Duodenal Ulcer	Consumer	Vioxx	PS	Merck Research		
	Haemorrhage	Health			Laboratories Div		
	Ejection Fraction	Professional			Merck Co Inc	ORAL	25 MG/ DAILY
	Abnormal						/ ORAL
	Gastroenteritis		Calan Sr	C			
	Helicobacter		Minipress	C			
	Hypokalaemia						
	Melaena						
	Mitral Valve Incompetence						
	Renal Failure						
	Syncope						
	Ventricular Extrasystoles						
	Ventricular Hypertrophy						
	Viral Infection						
	Weight Decreased						

Date:06/05/00ISR Number: 3508586-6Report Type:Expedited (15-DaCompany Report #WAES 00052663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Test Abnormal	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Haemorrhage				Laboratories Div		
	Ulcer				Merck Co Inc	ORAL	PO
			Ultram	C			

Date:06/05/00ISR Number: 3508587-8Report Type:Expedited (15-DaCompany Report #WAES 00052750
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Gastric Haemorrhage				Laboratories Div		
	Oral Intake Reduced				Merck Co Inc	ORAL	50 MG/ DAILY/

	Pain					
PO						
	Vomiting		Estratest	C		
			Aspirin	C		

Date:06/05/00ISR Number: 3508588-XReport Type:Expedited (15-DaCompany Report #WAES 00052864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Intestinal Obstruction	Professional			Laboratories Div	
	Small Intestinal				Merck Co Inc	ORAL
PO						
	Obstruction					

Date:06/05/00ISR Number: 3508589-1Report Type:Expedited (15-DaCompany Report #WAES 00055159
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Cardiac Failure	Other			Laboratories Div	
	Congestive				Merck Co Inc	ORAL
SEE IMAGE						
	Dyspnoea		Amlodipine	C		
	Oedema Peripheral		Furosemide	C		

				Metyhyldopa	C		
				Omeprazole	C		

Date:06/05/00ISR Number: 3508590-8Report Type:Expedited (15-DaCompany Report #WAES 00056531
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	29 DAY
			Metoprolol Tartrate	C				

Date:06/05/00ISR Number: 3508591-XReport Type:Expedited (15-DaCompany Report #WAES 00057550
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/06/00ISR Number: 3508694-XReport Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dizziness Gastrointestinal Haemorrhage		Vioxx 25mg	PS		ORAL	25 MG PO QD	

Date:06/06/00ISR Number: 3508927-XReport Type:Expedited (15-DaCompany Report #WAES 99111309
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Arthralgia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
Other	Ascites	Representative					MG/DAILY/PO	
	Back Pain		Atrovent	C				
	Duodenal Ulcer		Capoten	C				
	Perforation		Darvocet-N	C				
	Dyspnoea Exacerbated		Demerol	C				
	Gastric Perforation		Flovent	C				
	Peritonitis		Isordil	C				
			Prevacid	C				
			Regular Insulin	C				
			Serevent	C				
			Toradol	C				
			Vistaril	C				
			Albuterol	C				
			Furosemide	C				
			Methylprednisolone	C				
			Prednisone	C				
			Zolpidem	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/00ISR Number: 3508950-5Report Type:Expedited (15-DaCompany Report #WAES 00051881
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Health	Vioxx	PS	Merck Research			
	Bradycardia	Professional			Laboratories Div			
	Conduction Disorder				Merck Co Inc	ORAL	12.5 MG/1X/PO	1 DAY
			Verapamil	C				

Date:06/06/00ISR Number: 3508953-0Report Type:Expedited (15-DaCompany Report #WAES 00042074
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Dizziness Postural	Health			Laboratories Div			
	Influenza Like Illness	Professional			Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Joint Stiffness							
	Rectal Tenesmus		Prozac	C				
	Retching		Vicoprofen	C				
	Vomiting		Therapy Unspecified	C				

Date:06/06/00ISR Number: 3508975-XReport Type:Expedited (15-DaCompany Report #WAES 00045617
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
	Renal Impairment				Merck Co Inc	ORAL	25 MG PO	6 DAY
			Pepcid	C				
			Prinzide	C				
			Aspirin	C				
			Carvedilol	C				
			Cerivastatin Sodium	C				
			Clonidine	C				
			Isosorbide	C				
			Molsidomine	C				

			Naloxone			
			Hdorchloride	C		
			Torsemide	C		
			Valsartan	C		

Date:06/06/00ISR Number: 3508977-3Report Type:Expedited (15-DaCompany Report #WAES 00050656
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Flushing	Health	Vioxx	PS	Merck Research			
	Headache	Professional			Laboratories Div			
	Malaise				Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Humibid	C				
			Rhinocort	C				
			Xalatan	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/00ISR Number: 3508978-5Report Type:Expedited (15-DaCompany Report #WAES 00050150
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Health	Vioxx	PS	Merck Research			
Life-Threatening	Bacterial Infection	Professional			Laboratories Div			
Hospitalization -	Constipation				Merck Co Inc	ORAL	25	
Initial or Prolonged	Diverticular Perforation						MG/DAILY/PO	
Disability	Diverticulitis		Celebrex	C				
	Intestinal Functional		Lanoxin	C				
	Disorder		Prilosec	C				
	Peritonitis		Synthroid	C				
	Sepsis		Ultram	C				
			Aspirin	C				
			Atenolol	C				
			Conjugated Estrogenic Hormones	C				
			Verapamil	C				

Date:06/06/00ISR Number: 3508981-5Report Type:Expedited (15-DaCompany Report #WAES 00050858
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Diverticulitis	Health			Laboratories Div			
	Gastrointestinal	Professional			Merck Co Inc	ORAL	12.5	
	Haemorrhage						MG/BID/PO	
	Rectal Haemorrhage		Atacand	C				
			Coreg	C				
			Coumadin	C				
			Imdur	C				
			Inh-Burgthal	C				
			Lasix	C				
			Lipitor	C				
			Aspirin	C				
			Digoxin	C				

Date:06/06/00ISR Number: 3508983-9Report Type:Expedited (15-DaCompany Report #WAES 00052662
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Convulsion Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fall Wheelchair User		Paxil	SS				
			Amantadine Hydrochloride	SS				
			Betaseron	C			8 IU/QOD/SC	

Date:06/06/00ISR Number: 3508985-2Report Type:Expedited (15-DaCompany Report #WAES 00052696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Thrombosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/00ISR Number: 3508987-6Report Type:Expedited (15-DaCompany Report #WAES 00052830
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Disability		Company			Merck Co Inc	ORAL	25	
Other		Representative					MG/DAILY/PO	
			Hydrodiuril	C				
			Lo/Oral	C				
			Ziac	C				

Date:06/06/00ISR Number: 3508993-1Report Type:Expedited (15-DaCompany Report #WAES 00052885
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Rectal Haemorrhage				Merck Co Inc	ORAL	PO	
			Zestril	C				
			Clonidine	C				

Date:06/06/00ISR Number: 3508996-7Report Type:Expedited (15-DaCompany Report #WAES 00052887
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fall							
	Haematoma				Merck Co Inc	ORAL	PO	
	Haemorrhage Subcutaneous		Synthroid	C				
	Oedema Peripheral		Tenormin	C				

Date:06/06/00ISR Number: 3509068-8Report Type:Expedited (15-DaCompany Report #WAES 00037313
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Leukopenia	Foreign	Vioxx	PS	Merck Research	
	Loss Of Consciousness	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5 MG DAILY 7 DAY						
		Other	Aspirin	C		
			Cisapride			
			Monohydrate	C		
			Dipyridamole	C		
			Furosemide	C		
			Ketobemidone	C		
			Nitrofurantoin	C		
			Potassium Chloride	C		
			Ramipril	C		

Date:06/06/00ISR Number: 3509071-8Report Type:Expedited (15-DaCompany Report #WAES 00058226
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Injury	Foreign	Vioxx	PS	Merck Research	
	Road Traffic Accident	Health			Laboratories Div	
	Syncope	Professional			Merck Co Inc	ORAL
12.5 MG DAILY 69 DAY						
		Other	B Vitamins	C		
			Magnesium			

			Preparation (Compositon Unspe	C		

Date:06/06/00ISR Number: 3509075-5Report Type:Expedited (15-DaCompany Report #WAES 00055536
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Duodenal Ulcer	Health						
	Haemorrhage	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Melaena	Other	Aspirin	SS		ORAL	200 MG DAILY	
			Candesartan Cilexetil	C				
			Citalopram Hydrobromide	C				
			Ginkgo Biloba Extract	C				
			Hypericin	C				
			Tamsulosin Hydrochloride	C				

Date:06/06/00ISR Number: 3509078-0Report Type:Expedited (15-DaCompany Report #WAES 00012267
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
Life-Threatening	Malaise	Health						
Disability	Pain	Professional			Merck Co Inc	ORAL	PO	
	Vomiting							

Date:06/06/00ISR Number: 3509082-2Report Type:Expedited (15-DaCompany Report #WAES 00042319
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck Research Laboratories Div			
Life-Threatening	Gastrointestinal	Professional						

Hospitalization -	Haemorrhage	Company		Merck Co Inc	ORAL
25 MG/ DAILY/					
Initial or Prolonged	Intestinal Ischaemia	Representative			
PO					
Disability	Melaena		Darvocet-N	C	
Other			Elavil	C	
			Zoloft	C	
			Analgesic Or Anesthetic Preparation	C	
			Imipramine	C	
			Verapamil	C	

Date:06/06/00ISR Number: 3509093-7Report Type:Expedited (15-DaCompany Report #WAES 00059766
Age:63 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Alpha 1 Foetoprotein
	Increased
	Asthenia
	Autoimmune Hepatitis
	Bile Duct Obstruction
	Biliary Cirrhosis

		Biliary Cirrhosis Primary Biliary Tract Disorder Blood Glucose Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Immunoglobulin G Increased Blood Test Abnormal	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	2 DAY						
		Cholangitis Sclerosing Cholestasis Chronic Hepatitis Cytomegalovirus Infection Diabetes Mellitus Diverticulum Intestinal Dubin-Johnson Syndrome Fatigue Hepatic Cirrhosis Hepatic Fibrosis Hepatic Necrosis Hepatitis Hepatitis A Hepatitis Chronic Active Hepatitis Chronic Persistent Hepatitis Infectious Hepatitis Viral Hepatocellular Damage Hyperbilirubinaemia Infectious Mononucleosis Intestinal Obstruction Jaundice Light Chain Disease Liver Disorder Liver Function Test Abnormal Liver Scan Abnormal Nausea Polyuria Portal Hypertension Rotor'S Syndrome Sepsis					

Date:06/06/00ISR Number: 3509094-9Report Type:Expedited (15-DaCompany Report #WAES 00056532
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:06/06/00ISR Number: 3509096-2Report Type:Expedited (15-DaCompany Report #WAES 00055245
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena Peptic Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Aluminum Hydroxide	C				
			Aspirin	C				
			Pravastatin Na	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/00ISR Number: 3508888-3Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx (Unknown)	PS		ORAL	PO QD	
Initial or Prolonged	Haematocrit Decreased		Coumadin	SS		ORAL	5MG PO QD	
Required	Haemoglobin Decreased							
Intervention to	Nausea							
Prevent Permanent	Ulcer							
Impairment/Damage	Vomiting							

Date:06/07/00ISR Number: 3509381-4Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Abdominal Pain Upper	Consumer	Celebrex (Searle)	PS	Searle		1 TABLET A	
Required	Anxiety						DAY 100MG	4 MON
Intervention to	Bronchitis		Vioxx Merck	SS	Merck		1 TABLET 30MG	
Prevent Permanent	Haemorrhoids						A DAY	3 MON
Impairment/Damage	Hypertension							
	Nervousness							

Date:06/07/00ISR Number: 3509727-7Report Type:Expedited (15-DaCompany Report #WAES 00055637
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Macular Degeneration	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		

Date:06/07/00ISR Number: 3509730-7Report Type:Expedited (15-DaCompany Report #WAES 00052946
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/07/00ISR Number: 3509732-0Report Type:Expedited (15-DaCompany Report #WAES 00052822
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
	Blood Urea Increased	Company						
	Confusional State	Representative	Cipro	C				
	Dehydration		Dilantin	C				
	Hyperkalaemia		Lomotil	C				
	Renal Disorder		Norvasc	C				

Date:06/07/00ISR Number: 3509745-9Report Type:Expedited (15-DaCompany Report #WAES 00052338
Age: Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Coma	Health Professional Company
Other	Gastrointestinal Haemorrhage	

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:06/07/00ISR Number: 3509749-6Report Type:Expedited (15-DaCompany Report #WAES 00039776
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hepatitis Fulminant Liver Disorder Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	2 DAY
			Elavil	C				
			Moduretic	C				
			Atenolol	C				
			Fluoxetine Hcl	C				

Date:06/07/00ISR Number: 3509795-2Report Type:Expedited (15-DaCompany Report #WAES 00037313
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain Leukopenia Loss Of Consciousness	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	7 DAY
	Respiratory Depression		Tab Nitrofurantoin	SS		ORAL	10 MG PO	
			Aspirin	C				
			Cisapride Monohydrate	C				
			Dipyridamole	C				
			Furosemide	C				
			Ketobemidone	C				
			Potassium Chloride	C				
			Ramipril	C				

Date:06/07/00ISR Number: 3509862-3Report Type:Expedited (15-DaCompany Report #WAES 00059140
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Transient Ischaemic Attack	Other						
			Antihypertensive	C				

Date:06/07/00ISR Number: 3509881-7Report Type:Expedited (15-DaCompany Report #WAES 00042523
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Fluid Retention	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Oedema Peripheral							
			Celebrex	C				
			Dyazide	C				
			Lipitor	C				
			Prilosec	C				

			Aspirin	C
			Diazepam	C
			Quinapril	C

Date:06/07/00ISR Number: 3509885-4Report Type:Expedited (15-DaCompany Report #WAES 00040784
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Consumer	Vioxx	PS	Merck Research			
Other	Dyspepsia	Health			Laboratories Div			
	Eye Irritation	Professional			Merck Co Inc	ORAL	12.5 MG/	
	Gastrooesophageal Reflux						DAILY/ PO	
	Disease		Elavil	C				
	Headache		Prilosec	C				
	Keratoconjunctivitis		Verelan	C				
	Sicca		B Vitamins	C				
	Nausea		Calcium Supplement	C				
			Vitamin E	C				

Date:06/08/00ISR Number: 3510442-4Report Type:Expedited (15-DaCompany Report #1700368
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatosplenomegaly	Health	Azathioprine	PS	Genpharm Inc	ORAL	50 MG	
	Pancreatitis	Professional	Salazopyrin					
		Other	(Sulfasalazine)	SS		ORAL	2.00 GM	3 MON
			Rofecoxib	SS		ORAL	12.00 MG	1 MON
			Ursodeoxycholic Acid	C				

Date:06/08/00ISR Number: 3510721-0Report Type:Expedited (15-DaCompany Report #WAES 00035065
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain

Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Abdominal Rigidity Abdominal Tenderness Appetite Disorder Bacterial Infection Bronchospasm Chest X-Ray Abnormal Crepitations Duodenal Ulcer Haemorrhage Duodenal Ulcer Perforation Dyspnoea Hypoxia Ileus Paralytic Influenza Lower Respiratory Tract Infection Malaise Nausea Oedema Peripheral Oliguria Oxygen Saturation Decreased

	Pneumonia Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Productive Cough Pyrexia Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG
	Sepsis		Acetaminophen	C			
			Calcium Supplement (Nos)	C			
			Cimetidine	C			
			Prednisolone	C			

Date:06/08/00ISR Number: 3510724-6Report Type:Expedited (15-DaCompany Report #WAES 00039149
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Gastritis Erosive Gastrointestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO
	Haemorrhage		Timpoptic	C			
			Acetaminophen	C			
			Diclofenac Sodium Ophthalmic	C			
			Lansoprazole	C			
			Lorazepam	C			

Date:06/08/00ISR Number: 3510726-XReport Type:Expedited (15-DaCompany Report #WAES 00045578
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastric Ulcer Perforation Peritonitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO
	X-Ray Abnormal		Albuterol Sulfate	C			
			Beclomethasone Dipropionate	C			

Date:06/08/00ISR Number: 3510731-3Report Type:Expedited (15-DaCompany Report #WAES 00047306
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	50 DAY
Hospitalization - Initial or Prolonged	Dyspnoea	Other						
	Sepsis							
			Tab Allopurinol	SS		ORAL	200 MG DAILY	44 DAY
			Furosemide	C				
			Levothyroxine Na	C				
			Omeprazole	C				
			Ramipril	C				
			Vitamin B{12}	C				

Date:06/08/00ISR Number: 3510732-5Report Type:Expedited (15-DaCompany Report #WAES 00050299
Age:70 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			
	Bronchospasm	Professional			Laboratories Div			
	Dermatitis				Merck Co Inc	ORAL	PO	
	Dermatitis Exfoliative		Lamisil	SS				
	Dry Skin		Benadryl	C				
	Dyspnoea		Estrace	C				
	Face Oedema		Aspirin	C				
	Hypersensitivity							
	Pruritus							

Date:06/08/00ISR Number: 3510737-4Report Type:Expedited (15-DaCompany Report #WAES 00055595
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Dermatitis Exfoliative	Health			Laboratories Div			
	Hepatitis Cholestatic	Professional			Merck Co Inc	ORAL	12.5 MG DAILY	
			Etidronic Acid Dina	SS				
			Sulfasalazine	SS				

Date:06/09/00ISR Number: 3510932-4Report Type:Expedited (15-DaCompany Report #WAES 00052831
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Ziac	C				

Date:06/09/00ISR Number: 3510934-8Report Type:Expedited (15-DaCompany Report #WAES 00060222
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Confusional State Drug Interaction Speech Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lithiumco3	SS			600 MG/DAILY/UNK	
			Fosamax	C				
			Klonopin	C				
			Calcium Supplement	C				
			Nortriptyline	C				
			Thyroid	C				

Date:06/09/00ISR Number: 3510935-XReport Type:Expedited (15-DaCompany Report #WAES 00051691
Age:63 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage

Rectal Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazide	C				
			Excedrin Extra-Strength	C				
			Vasotec	C				

Date:06/09/00ISR Number: 3510939-7Report Type:Expedited (15-DaCompany Report #WAES 00052677
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arrhythmia Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO (SEE IMAGE)	
			Celebrex	C				
			Lipitor	C				
			Lomotil	C				
			Prinivil	C				
			Diazepam	C				
			Lorazepam	C				

Date:06/09/00ISR Number: 3510972-5Report Type:Expedited (15-DaCompany Report #WAES 00052991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				

			Lanoxin	C		

Date:06/09/00ISR Number: 3510975-0Report Type:Expedited (15-DaCompany Report #WAES 00053018
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolism Enterocolitis Haemorrhagic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemorrhage							
	Vomiting		Allerest Tablets	C				
	Weight Decreased		Asacol	C				
			Claritin	C				

Date:06/09/00ISR Number: 3510976-2Report Type:Expedited (15-DaCompany Report #WAES 00053021
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/09/00ISR Number: 3511004-5Report Type:Expedited (15-DaCompany Report #WAES 00053090
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			L-Thyroxine	C				
			Aspirin	C				
			Glucosamine	C				
			Ibuprofen	C				
			Meclizine	C				
			Propoxyphene Napsylate Monohyra	C				

Date:06/09/00ISR Number: 3511008-2Report Type:Expedited (15-DaCompany Report #WAES 00053091
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Acute Prerenal Failure							
	Blood Creatine Increased							
	Blood Urea Increased							
	Chest Pain		Aspirin	SS		ORAL	325 MG/DAILY/PO	
	Dizziness							
	Gastrointestinal Haemorrhage		Lipitor	C				
			Prozac	C				
	Haemoglobin Decreased		Furosemide	C				
	Hyperkalaemia							
	Melaena							
	Peptic Ulcer							
	Renal Failure Acute							

Date:06/09/00ISR Number: 3511012-4Report Type:Expedited (15-DaCompany Report #WAES 00060123
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Face Oedema Oedema Peripheral Pharyngeal Oedema Pruritus Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/09/00ISR Number: 3511015-XReport Type:Expedited (15-DaCompany Report #WAES 00060184
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Duodenal Perforation Gastroenteritis Helicobacter	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinzide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/00ISR Number: 3511154-3Report Type:Expedited (15-DaCompany Report #WAES 00055010
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Cardiac Failure	Health			Laboratories Div			
Initial or Prolonged	Congestive	Professional			Merck Co Inc	ORAL	25.0 MG, PO	30 DAY
Other	Fluid Retention		Acetaminophen (+)					
	Myocardial Infarction		Dihydrocodeine					
	Oedema		Bitartr	C				
			Aspirin	C				
			Diclofenac	C				
			Diltiazem D-Cis Form					
			Hcl	C				
			Omeprazole	C				

Date:06/09/00ISR Number: 3511471-7Report Type:Expedited (15-DaCompany Report #WAES 00060185
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Wound Secretion	Professional			Laboratories Div			
Other		Company			Merck Co Inc	ORAL	PO	
		Representative	Percocet	C				

Date:06/09/00ISR Number: 3511473-0Report Type:Expedited (15-DaCompany Report #WAES 00050481
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gingival Bleeding	Health	Vioxx	PS	Merck Research			
Other	Platelet Count Decreased	Professional			Laboratories Div			
	Post Procedural	Company			Merck Co Inc	ORAL	25 MG/DAILY/	
	Haemorrhage	Representative					PO	

Date:06/09/00ISR Number: 3511475-4Report Type:Expedited (15-DaCompany Report #WAES 00060309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apnoea Cardiac Failure Congestive Fluid Retention Oedema Oedema Peripheral Pulmonary Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:06/09/00ISR Number: 3511476-6Report Type:Expedited (15-DaCompany Report #WAES 00040012
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faeces Discoloured Gastritis Erosive Gastrointestinal Haemorrhage Melaena	Consumer Health Professional	Vioxx Humulin N Monopril Valium	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/00ISR Number: 3511478-XReport Type:Expedited (15-DaCompany Report #WAES 00052935
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Embolism	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eye Disorder							
	Tachycardia							
	Thrombocythaemia		Fosamax	C				
	Visual Acuity Reduced Transiently		Lanoxin	C				
			Levoxyl	C				
			Lopressor	C				
			Relafen	C				
			Zocor	C				
			Aspirin	C				

Date:06/09/00ISR Number: 3511507-3Report Type:Expedited (15-DaCompany Report #WAES 00055626
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY
		Other	Aspirin	C				
			Omeprazole	C				

Date:06/09/00ISR Number: 3511512-7Report Type:Expedited (15-DaCompany Report #WAES 00065024
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	144 DAY
			Aspirin	C				
			Atenolol	C				
			Diltiazem	C				
			Pravastatin Na	C				
			Ranitidine	C				

Date:06/09/00ISR Number: 3511521-8Report Type:Expedited (15-DaCompany Report #WAES 00055654
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Hepatitis Hyperbilirubinaemia Jaundice Laboratory Test Abnormal	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG	

Date:06/09/00ISR Number: 3511526-7Report Type:Expedited (15-DaCompany Report #WAES 00055185
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Photosensitivity Reaction	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/00ISR Number: 3511527-9Report Type:Expedited (15-DaCompany Report #WAES 00057324
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	43 DAY
			Zopiclone	C				

Date:06/09/00ISR Number: 3511528-0Report Type:Expedited (15-DaCompany Report #WAES 00057326
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Conjunctival Haemorrhage Ecchymosis Haematoma	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG	23 DAY
	Pain Skin Disorder		Inj Tedelparin Sodium	SS		SUBCUTANEOUS	14000IU	16 DAY
			Tab Clopidogrel Bisulfate	SS		ORAL	75 MG	28 DAY
			Acetaminophen	C				
			Allopurinol	C				
			Atenolol	C				
			Benserazide/Levodopa	C				
			Calcium Carbonate (+) Vitamin D{3}	C				
			Cloramphenicol	C				
			Citalopram Hydrobromide	C				
			Dimethicone	C				
			Felodipine	C				
			Furosemide	C				
			Hydroxypropyl Methylcellulose	C				
			Isosorbide-5-Mononitrate	C				
			Morhpine	C				
			Prednisolone	C				

Date:06/09/00ISR Number: 3511530-9Report Type:Expedited (15-DaCompany Report #WAES 00035665
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG, PO	22 DAY
			Maprotiline Hcl	C				
			Oxybutynincl	C				

Date:06/09/00ISR Number: 3511531-0Report Type:Expedited (15-DaCompany Report #WAES 00045610
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Other	Agitation
	Depression
	Dystonia
	Electroencephalogram Abnormal
	Facial Palsy

	Masked Facies Paresis Spinal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO

Date:06/09/00ISR Number: 3511768-0Report Type:Expedited (15-DaCompany Report #WAES 00057544
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Chest X-Ray Abnormal	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO
Other	Oedema		Tab Nifedipine	SS		ORAL	PO
	Right Ventricular Failure		Acetaminophen	C			
			Chloroquineso4	C			
			Fosinopril Na	C			
			Guanfacine	C			
			Levothyroxine Na	C			

Date:06/09/00ISR Number: 3511771-0Report Type:Expedited (15-DaCompany Report #WAES 00042092
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea Respiratory Arrest Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
	Sensation Of Heaviness						
	Tachycardia		Glucosamine	C			

Date:06/09/00ISR Number: 3511773-4Report Type:Expedited (15-DaCompany Report #WAES 00030396
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Congestive Fluid Overload	Health Professional						
	Oedema Peripheral							
	Pleural Effusion		Hyzaar	C				
			Macrodantin	C				
			Norvasc	C				
			Premarin	C				
			Prilosec	C				
			Synthroid	C				
			Calcium Supplement	C				

Date:06/09/00ISR Number: 3511776-XReport Type:Expedited (15-DaCompany Report #WAES 00030393
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
Life-Threatening	Anorexia
Hospitalization - Initial or Prolonged	Blood Amylase Increased
	Circulatory Collapse
Disability	Diarrhoea
Other	Gastric Ulcer Perforation

	Gastrointestinal Haemorrhage Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Intestinal Obstruction Malaise Nausea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
	Pancreatitis	Representative					
	Renal Failure		Aricept	C			
	Shock		Ascorbic Acid	C			
	Small Intestinal Obstruction White Blood Cell Count Increased						

Date:06/12/00ISR Number: 3511407-9Report Type:Direct Company Report #
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Circulatory Collapse		Vioxx 12.5mg (Merck)	PS	Merck	ORAL	12.5MG X1 PO
	Confusional State Cyanosis Dizziness						

Date:06/12/00ISR Number: 3511767-9Report Type:Expedited (15-DaCompany Report #WAES 00060222
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Coordination Abnormal Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO 5 DAY
	Drug Toxicity						
	Dysarthria		Lithiumco 3	SS			600 MG, DAILY
	Speech Disorder		Allegra	C			
	Tremor		Fosamax	C			

			Klonopin	C		
			Levoxyl	C		
			Calcium Supplement	C		
			Nortriptyline	C		
			Thyroid	C		

Date:06/12/00ISR Number: 3511783-7Report Type:Expedited (15-DaCompany Report #WAES 00056228
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Corneal Ulcer	Foreign	Vioxx	PS	Merck Research	
	Eye Pain	Study			Laboratories Div	
		Other			Merck Co Inc	ORAL
12.5 MG PO 15 DAY						
			Calcium Carbonate/Vitamin D	C		
			Cicletanine	C		
			Diacerein	C		
			Diclofenac	C		
			Pravastatin Na	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/00ISR Number: 3511799-0Report Type:Expedited (15-DaCompany Report #WAES 00052205
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/12/00ISR Number: 3511800-4Report Type:Expedited (15-DaCompany Report #WAES 00031291
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Chills Convulsion Dysphagia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
Other	Dysphonia Haemoptysis Haemorrhoids Influenza Like Illness Insomnia Oesophagitis Oral Candidiasis Pyrexia Tremor		Amaryl Atrovent Carafate Cardizem Cd Depakote Flovent Lasix Levaquin Micro K Prilosec Reglan Singulair [Therapy Unspecified] Nitroglycerin	C C C C C C C C C C C C C C				

Date:06/12/00ISR Number: 3511801-6Report Type:Expedited (15-DaCompany Report #WAES 00050978
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Calculus Urinary	Consumer	Vioxx	PS	Merck Research			

	Dehydration				Laboratories Div	
	Gallbladder Disorder				Merck Co Inc	ORAL
25MG						
	Malaise					
/DAILY/PO						
	Nausea		Demerol	C		
	Pain		Prednisone	C		
	Shock					
	Tremor					
	Vomiting					

Date:06/12/00ISR Number: 3511821-1Report Type:Expedited (15-DaCompany Report #WAES 00060463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anuria	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Dialysis	Professional			Laboratories Div	
	Oliguria	Company			Merck Co Inc	ORAL
PO						
	Urinary Retention	Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/00ISR Number: 3511823-5Report Type:Expedited (15-DaCompany Report #WAES 00052931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:06/12/00ISR Number: 3511824-7Report Type:Expedited (15-DaCompany Report #WAES 00060620
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Celebrex	C				
			Esgic-Plus Tablets	C				
			Monopril	C				
			Plaquentil	C				
			Tegretol	C				
			Ultram	C				
			Ventax	C				
			Doxepin	C				

Date:06/12/00ISR Number: 3511825-9Report Type:Expedited (15-DaCompany Report #WAES 00060718
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Zocor	C				
			Isosorbide	C				
			Metoprolol	C				

Date:06/12/00ISR Number: 3511826-0Report Type:Expedited (15-DaCompany Report #WAES 00060588
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cognitive Disorder Confusional State Disorientation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/12/00ISR Number: 3512015-6Report Type:Expedited (15-DaCompany Report #WAES 00035703
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 MON
	Lung Disorder Pleural Effusion Urinary Tract Infection		Captopril Dimenhydrinate Leuprolide Naloxone Hydrochloride (+) Tilidine	C C C C				

			Sulfamethoxazole/Trimethoprim	C		

Date:06/12/00ISR Number: 3512016-8Report Type:Expedited (15-DaCompany Report #WAES 00047311
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	13 DAY
	Congestive Cholecystitis	Other						
	Condition Aggravated		La-Hydroxycholecalciferol	C				
	Cough		Acetylcysteine	C				
	Duodenal Ulcer		Digitoxin	C				
	Duodenitis		Dipyridamole	C				
	Gastritis							
	Melaena							
	Mucosal Haemorrhage							
	Nausea							
	Oedema							
	Oxygen Saturation Decreased							
	Pleural Effusion							
	Pyrexia							
	Renal Failure							
	Upper Respiratory Tract Infection							

Date:06/12/00ISR Number: 3512208-8Report Type:Expedited (15-DaCompany Report #WAES 00068508
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Intracranial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/12/00ISR Number: 3512221-0Report Type:Expedited (15-DaCompany Report #WAES 00069751
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Erosive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/12/00ISR Number: 3512229-5Report Type:Expedited (15-DaCompany Report #WAES 00057335
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Supraventricular Tachycardia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	2 DAY
			Estrogenic Preparations (Composition Uns	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/00ISR Number: 3512231-3Report Type:Expedited (15-DaCompany Report #WAES 00057506
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 MON
			Codeine Phosphate / Guaifenesin / Pseudoephe	C				
			Loratadine (+) Pseudoephedrine Sulfate	C				

Date:06/12/00ISR Number: 3512275-1Report Type:Expedited (15-DaCompany Report #WAES 00060598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia Gastrooesophageal Reflux Disease Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/12/00ISR Number: 3512277-5Report Type:Expedited (15-DaCompany Report #WAES 00060119
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Celebrex	C				
			Glucotrolc	C				

Date:06/12/00ISR Number: 3512280-5Report Type:Expedited (15-DaCompany Report #WAES 00050288
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Professional			Laboratories Div			
Initial or Prolonged	Diarrhoea	Other			Merck Co Inc	ORAL	50	
Disability	Duodenal Ulcer						MG/DAILY/PO	
Other	Dyspepsia		Paxil	C				
	Faeces Discoloured		Aspirin	C				
	Gastrointestinal		Vitamins	C				
	Haemorrhage							
	Haemoglobin Decreased							
	Haemorrhage							
	Melaena							

Date:06/12/00ISR Number: 3512286-6Report Type:Expedited (15-DaCompany Report #WAES 00060615
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization -	Gastrointestinal	Health
Initial or Prolonged	Haemorrhage	Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/12/00ISR Number: 3512289-1Report Type:Expedited (15-DaCompany Report #WAES 00060338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral Cerebrovascular Accident Headache Ivth Nerve Paralysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Relafen	C				

Date:06/12/00ISR Number: 3512292-1Report Type:Expedited (15-DaCompany Report #WAES 00060331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/12/00ISR Number: 3512308-2Report Type:Expedited (15-DaCompany Report #WAES 00060526
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Urticaria Merck Co Inc ORAL
PO 1 WK

Date:06/12/00ISR Number: 3512314-8Report Type:Expedited (15-DaCompany Report #WAES 00053112
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged								

Date:06/12/00ISR Number: 3512319-7Report Type:Expedited (15-DaCompany Report #WAES 00032672
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Colonoscopy
	Colonoscopy Abnormal
Disability	Condition Aggravated
	Constipation
	Decreased Appetite
	Diarrhoea
	Gastrointestinal Haemorrhage
	Inflammatory Bowel Disease

	Large Intestinal Ulcer Mucosal Inflammation Muscle Spasms	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Mucosal Rectal Haemorrhage Weight Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Baycol	C			
			Celebrex	C			
			Rythmol	C			
			Tylenol	C			
			[Therapy Unspecified]	C			
			Aspirin	C			
			Calcium Supplement (Composition	C			
			Vitamins	C			

Date:06/12/00ISR Number: 3512383-5Report Type:Expedited (15-DaCompany Report #WAES 00051259
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck Research		
Initial or Prolonged	Increased	Professional			Laboratories Div		
Other	Blood Urea Increased	Company			Merck Co Inc	ORAL	25
	Renal Failure Acute	Representative					MG/DAILY/PO
	Vomiting		Colace	C			
			Imdur	C			
			Lasix	C			
			Lopressor	C			
			Prilosec	C			
			Aspirin	C			
			Ferrous Sulfate	C			

Date:06/12/00ISR Number: 3512389-6Report Type:Expedited (15-DaCompany Report #WAES 00041804
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Clonic Convulsion Convulsion	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Premarin	C				
			Synthroid	C				
			Propranolol	C				
			Vitamins	C				

Date:06/12/00ISR Number: 3512400-2Report Type:Expedited (15-DaCompany Report #WAES 00040012
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis Erosive Gastrointestinal Haemorrhage Melaena	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Humulin N	C				
			Monopril	C				

			Valium	C		
			[Therapy Unspecified]	C		

Date:06/12/00ISR Number: 3512544-5Report Type:Expedited (15-DaCompany Report #WAES 00057334
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Congestive	Other				
	Chest Discomfort					
	Cyanosis					
	Dyspnoea					
	Hypertension					

Date:06/12/00ISR Number: 3512753-5Report Type:Expedited (15-DaCompany Report #WAES 00055650
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatinine	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged	Increased	Other				
	Liver Function Test					
25 MG, PO 4 MON						
	Abnormal		Mevacor	C		
	Renal Failure Acute		Magnesium Preparation (Composition Unspe	C		
			Methenolone 17-Enanthate	C		
			Nafronyl Acid Oxalate	C		
			Omeprazole	C		
			Oxazepam	C		
			Ramipril	C		

Date:06/12/00ISR Number: 3512755-9Report Type:Expedited (15-DaCompany Report #WAES 00055256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastritis Haemorrhagic	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/12/00ISR Number: 3524836-4Report Type:Expedited (15-DaCompany Report #7227950
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - ORAL O1X/D Initial or Prolonged	Aphasia Cerebrovascular Accident Paralysis	Study Health Professional	Aleve Rofecoxib Vitamin E Multivitamin Aricept Tylenol	PS SS C C C C	Bayer Corp Consumer Care Div	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/00ISR Number: 3524841-8Report Type:Expedited (15-DaCompany Report #7222920
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Hip Fracture	Study Health Professional	Aleve	PS	Bayer Corp Consumer Care Div	ORAL	ORAL O1X/D	
			Rofecoxib	SS				
			Premarin	C				
			Tenormin	C				
			Aspirin	C				
			Vitamin B12	C				

Date:06/13/00ISR Number: 3511822-3Report Type:Expedited (15-DaCompany Report #WAES 00060461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Tubular Acidosis Renal Tubular Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Taxol	C				

Date:06/13/00ISR Number: 3511988-5Report Type:Direct Company Report #
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema Peripheral Pruritus		Vioxx / 12.5 / Merck	PS	Merck			1 DAY

Date:06/13/00ISR Number: 3512051-XReport Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention	Health	Vioxx	PS		ORAL	25 MG PO QD	
Hospitalization - Initial or Prolonged	Hypertension	Professional	Arava	C				
	Pulmonary Oedema		Prednisone	C				

Date:06/13/00ISR Number: 3512601-3Report Type:Expedited (15-DaCompany Report #7222920
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Study	Aleve	PS	Bayer Corp Consumer Care Div	ORAL	ORAL 01X/D	
	Hip Fracture	Health						
		Professional	Rofecoxib	SS				
			Premarin	C				
			Tenormin	C				
			Aspirin	C				
			Vitamin B12	C				

Date:06/13/00ISR Number: 3512604-9Report Type:Expedited (15-DaCompany Report #7227950
Age:63 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia Cerebrovascular Accident	Study Health	Aleve	PS	Bayer Corp Consumer Care Div	ORAL	ORAL/01X/D	
	Paralysis	Professional	Rofecoxib	SS				
			Vitamin E	C				
			Multivitamin	C				
			Aricept	C				
			Tylenol	C				

Date:06/13/00ISR Number: 3512751-1Report Type:Expedited (15-DaCompany Report #WAES 00056537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
	Foetal Growth Retardation Oligohydramnios Ultrasound Antenatal Screen Abnormal							

Date:06/14/00ISR Number: 3513137-6Report Type:Direct Company Report #
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx 25mg	PS		ORAL	25MG PO QD	14 DAY
Initial or Prolonged	Congestive Condition Aggravated Renal Failure Renal Impairment		Celebrex	C				

Date:06/14/00ISR Number: 3513139-XReport Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx 50mg	PS			QD	
	Cold Sweat		Plavix	C				
	Faeces Discoloured		Lipitor	C				
	Haematemesis		Isordil	C				
			Lopressor	C				
			Sl Ntg	C				
			Glucotrol	C				
			Norvasc	C				

Date:06/14/00ISR Number: 3513437-XReport Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema		Vioxx	PS		ORAL	25 MG P.O.	
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/00ISR Number: 3513474-5Report Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx 2.5mg Merck	PS	Merck	ORAL	2.5MG BID PO	
			Axid	C				
			Tenormin	C				
			Zestrin	C				
			Lasix	C				
			Norvasc	C				
			Rengacin	C				

Date:06/14/00ISR Number: 3514953-7Report Type:Expedited (15-DaCompany Report #WAES 00069111
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
	Gastric Ulcer	Health			Laboratories Div			
	Gastrointestinal	Professional			Merck Co Inc	ORAL	25 MG PO	
	Haemorrhage	Other	Aspirin	SS		ORAL	300 MG PO	
	Haematemesis		Prinivil	C				
	Haemoglobin Decreased		Acarbose	C				
	Melaena		Amlodipine	C				

Date:06/14/00ISR Number: 3514954-9Report Type:Expedited (15-DaCompany Report #WAES 00069110
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
	Haemorrhage	Health			Laboratories Div			
	Melaena	Professional			Merck Co Inc	ORAL	PO	
			Nsaid	C				

Date:06/14/00ISR Number: 3514956-2Report Type:Expedited (15-DaCompany Report #WAES 00065057
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oesophageal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	36 DAY
	Haemorrhage	Other						
	Peripheral Embolism							
	Upper Gastrointestinal Haemorrhage		Aspirin	C				
			Atenolol	C				
			Digoxin	C				
			Isosorbide-5-Mononitrate	C				

Date:06/14/00ISR Number: 3514973-2Report Type:Expedited (15-DaCompany Report #WAES 00058921
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abscess	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Bile Duct Obstruction							
	Duodenal Ulcer							
	Gastric Cancer							
	Gastrointestinal Haemorrhage							
	Melaena							
	Pancreatic Carcinoma							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/00ISR Number: 3514974-4Report Type:Expedited (15-DaCompany Report #WAES 00065503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Hepatic Failure Jaundice	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Liver Function Test Abnormal		Metoprolol Phenprocoumon	C C				

Date:06/14/00ISR Number: 3514975-6Report Type:Expedited (15-DaCompany Report #WAES 00068539
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY

Date:06/14/00ISR Number: 3514977-XReport Type:Expedited (15-DaCompany Report #WAES 00069107
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	25 DAY

Date:06/14/00ISR Number: 3515131-8Report Type:Expedited (15-DaCompany Report #WAES 00057554
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Biopsy Colon Abnormal Colitis Ischaemic Colitis Ulcerative	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Iatrogenic Injury
Melaena
Mesenteric Vascular
Insufficiency
Petechiae

Date:06/15/00ISR Number: 3514563-1Report Type:Expedited (15-DaCompany Report #WAES 00041259
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Faecal Occult Blood				Merck Co Inc	ORAL	12.5	
Other	Positive						MG/DAILY/PO	
	Haemoglobin Decreased							
	Upper Gastrointestinal Haemorrhage							

Date:06/15/00ISR Number: 3514564-3Report Type:Expedited (15-DaCompany Report #WAES 00051351
Age:88 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colonic Polyp Gastritis Gastrointestinal Haemorrhage Haematochezia Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/15/00ISR Number: 3514572-2Report Type:Expedited (15-DaCompany Report #WAES 00040866
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Abdominal Abscess Abdominal Distension Abdominal Pain Abdominal Pain Upper Abdominal Rigidity Abdominal Tenderness Acute Abdomen Blood Albumin Increased Blood Alkaline Phosphatase Increased Blood Amylase Increased Blood Bilirubin Increased Confusional State Creatine Phosphokinase Decreased Duodenal Ulcer Perforation Electrocardiogram Abnormal Eosinophilia Faeces Hard Hyperglycaemia Hyperkalaemia Hyperpyrexia Lipase Increased Lymphopenia	Health Professional Other	Vioxx Biaxin Darvocet-N	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Neutropenia
Pancreatitis
Purulence
Pyrexia
Scan Abdomen Abnormal
Tachycardia
Tachypnoea

Date:06/15/00ISR Number: 3514661-2Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx 25mg	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Faecal Occult Blood Positive							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/00ISR Number: 3514739-3Report Type:Expedited (15-DaCompany Report #WAES 00057323
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis Hepatic Enzyme Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	41 DAY
			Tab Sulfasalazine	SS		ORAL	2000 MG PO	41 DAY
			Tab Prednisolone	SS				

Date:06/15/00ISR Number: 3514742-3Report Type:Expedited (15-DaCompany Report #WAES 00065030
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Pharyngeal Oedema Tongue Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 DAY
			Inositol Niacinate	C				

Date:06/15/00ISR Number: 3514753-8Report Type:Expedited (15-DaCompany Report #WAES 00056228
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Corneal Ulcer Eye Pain	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	15 DAY
		Professional Other	Calcium Carbonate/Vitamin D	C				
			Cicletanine	C				
			Diacerein	C				
			Diclofenac	C				
			Pravastatin Sodium	C				

Date:06/15/00ISR Number: 3515504-3Report Type:Expedited (15-DaCompany Report #WAES 00051638
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vertigo	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
		Representative	Celebrex	C				
			Lozol	C				
			Norvasc	C				
			Aspirin	C				

Date:06/15/00ISR Number: 3515508-0Report Type:Expedited (15-DaCompany Report #WAES 00060093
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	1 MON
		Representative						
			Premarin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/00ISR Number: 3515509-2Report Type:Expedited (15-DaCompany Report #WAES 00060758
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dyspnoea	Professional			Laboratories Div			
Initial or Prolonged	Gastric Ulcer Haemorrhage				Merck Co Inc	ORAL	25	
Other	Gastroenteritis						MG/DAILY/PO	
	Helicobacter		Coumadin	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							

Date:06/16/00ISR Number: 3514634-XReport Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer Female		Vioxx Merck	PS	Merck			

Date:06/16/00ISR Number: 3514700-9Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx 25 Mg	PS		ORAL	25MG PO BID	
Hospitalization -	Ascites							
Initial or Prolonged	Computerised Tomogram							
Required	Abnormal							
Intervention to	Duodenal Ulcer							
Prevent Permanent	Perforation							
Impairment/Damage	Peritoneal Disorder							

Date:06/16/00ISR Number: 3515216-6Report Type:Expedited (15-DaCompany Report #WAES 00060861
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Hepatic Function Abnormal Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Jaundice		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Monopril	C				

Date:06/16/00ISR Number: 3515254-3Report Type:Expedited (15-DaCompany Report #WAES 00052663
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Full Blood Count Decreased Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Ulcer		Ultram	C				

Date:06/16/00ISR Number: 3515409-8Report Type:Expedited (15-DaCompany Report #WAES 00060965
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris Feeling Abnormal

		Hypertension Oedema Peripheral Rash Maculo-Papular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash Morbilliform	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/1X/PO							
				Allegra	C		
				Atacand	C		
				Hydrodiuril	C		
				Mevacor	C		
				Norvasc	C		
				Premarin	C		
				Prilosec	C		
				Aspirin	C		
				Isosorbide	C		

Date:06/16/00ISR Number: 3515411-6Report Type:Expedited (15-DaCompany Report #WAES 00060969
Age:48 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain Upper Cholecystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div	
Other		Chromaturia				Merck Co Inc	ORAL
UNK/UNK/PO							
		Fatigue Hepatitis Malaise		[Therapy Unspecified]	C		

Date:06/16/00ISR Number: 3515413-XReport Type:Expedited (15-DaCompany Report #WAES 00061000
Age:42 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder Hypertension Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
						Merck Co Inc	ORAL
UNK/UNK/PO							
				[Composition Unspecified]	C		

Date:06/16/00ISR Number: 3515422-0Report Type:Expedited (15-DaCompany Report #WAES 00060674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaesthetic Complication	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Pulmonary Dyspnoea							
	Nausea							
	Pulmonary Oedema		Lasix	C				
	Respiratory Disorder		Prilosec	C				
	Respiratory Failure		Tenormin	C				
			Xanax	C				
			Prednisone	C				

Date:06/16/00ISR Number: 3515425-6Report Type:Expedited (15-DaCompany Report #WAES 00060848
Age:19 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anaphylactic Reaction
	Dyspnoea

		Lacrimation Increased Pharyngolaryngeal Pain Rhinorrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/DAILY/PO	3 DAY						

Date:06/19/00ISR Number: 3515823-0Report Type:Expedited (15-DaCompany Report #WAES 00059766
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain Alpha 1 Foetoprotein Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
2 DAY							
		Asthenia Bile Duct Obstruction Biliary Cirrhosis Cholangitis Sclerosing Cholestasis Diabetes Mellitus Diverticulum Fatigue Hepatic Cirrhosis Hepatic Fibrosis Hepatic Function Abnormal Hepatitis Chronic Active Hepatocellular Damage Hyperbilirubinaemia Hyperglycaemia Jaundice Liver Disorder Liver Function Test Abnormal Lymphadenopathy Malaise Nausea Necrosis Neoplasm Obstruction					

Pancreatitis
Polyuria
Portal Hypertension
Sepsis
Stress

Date:06/19/00ISR Number: 3515826-6Report Type:Expedited (15-DaCompany Report #WAES 00066504
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspnoea Urticaria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Moduretic	C		
			Diphenhydramine Hcl	C		
			Fexofenadine Hydrochloride	C		
			Methylprednisolone 21-Acetate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/00ISR Number: 3515855-2Report Type:Expedited (15-DaCompany Report #WAES 00058921
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Haemorrhage							
	Melaena							
	Rectal Haemorrhage							
	Stitch Abscess							

Date:06/19/00ISR Number: 3515857-6Report Type:Expedited (15-DaCompany Report #WAES 00045570
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	75-125 MG PO	2 WK
	Amnesia							
	Confusional State							
	Disorientation		Piroxicam	C				
	Drug Toxicity							
	Hallucination, Visual							
	Hypercholesterolaemia							
	Hypertriglyceridaemia							
	Memory Impairment							
	Sedation							

Date:06/19/00ISR Number: 3515862-XReport Type:Expedited (15-DaCompany Report #WAES 00058514
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	61 DAY
	Fall							
	Hip Fracture							
	Muscle Twitching		Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	38 DAY
	Nervousness							
	Tremor		Moduretic	C				

				Timoptic	C		
				Acetaminophen	C		
				Digoxin	C		

Date:06/19/00ISR Number: 3515893-XReport Type:Expedited (15-DaCompany Report #WAES 00061111
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Oesophageal Ulcer				Laboratories Div			
Initial or Prolonged	Syncope				Merck Co Inc	ORAL	PO	
			Diovan	C				
			Prevacid	C				

Date:06/19/00ISR Number: 3515902-8Report Type:Expedited (15-DaCompany Report #WAES 00051475
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastritis Erosive	Professional			Laboratories Div			
Initial or Prolonged	Oesophageal Ulcer	Company			Merck Co Inc	ORAL	25 MG/DAILY/	
Other	Haemorrhage	Representative					PO	

				Prednisone	C		
				Salsalate	C		

Date:06/19/00ISR Number: 3515984-3Report Type:Expedited (15-DaCompany Report #WAES 00067293
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	49 DAY
			Acetaminophen	C				
			Aspirin	C				
			Glyburide	C				
			Metformin Hcl	C				

Date:06/19/00ISR Number: 3516017-5Report Type:Expedited (15-DaCompany Report #WAES 00061279
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention Swelling		Coumadin	C				
			Inderal	C				
			Lanoxin	C				
			Novolin	C				
			Tylenol	C				

Date:06/19/00ISR Number: 3516021-7Report Type:Expedited (15-DaCompany Report #WAES 00061386
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemorrhage Shock	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Other Representative
MG/DAILY/PO

Celebrex	C	
Singulair	C	

Date:06/19/00ISR Number: 3516144-2Report Type:Expedited (15-DaCompany Report #WAES 00061225
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Diarrhoea							
	Dizziness		Imdur	C				
	Dyspepsia		Monopril	C				
	Fatigue		Norvasc	C				
	Headache		Pravachol	C				
	Hypertension		Aspirin	C				
	Nausea							
	Oedema Peripheral							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/00ISR Number: 3516145-4Report Type:Expedited (15-DaCompany Report #WAES 00061030
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
			Diovan	C				
			Hytrin	C				
			Lipitor	C				
			Atenolol	C				

Date:06/20/00ISR Number: 3515847-3Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx 25 Mg/Tab Merck & Co	PS	Merck & Co	ORAL	12.5 MG BID PO	
			Minocycline	C				
			Fentanyl	C				
			Labetalol	C				
			Lansoprazole	C				
			Multivitamin	C				
			Hydrocodone-Acetamin ophen	C				

Date:06/20/00ISR Number: 3515853-9Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema	Health Professional	Vioxx 12.5 Mg Merck	PS	Merck		1 TABLET TWICE DAILY	
	Oedema Peripheral							

			Furosemide	C		
			K-Dur	C		

Date:06/20/00ISR Number: 3515918-1Report Type:Direct Company Report #
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS			25MG QD	
Initial or Prolonged	Increased Cardiac Failure	Professional	Univasc 7.5mg Two Po Qd	SS		ORAL	7.5MG TWO PO QD	
	Congestive							
	Colitis		Glucophage 875 Mg Tid	SS			875 MG TID	
	Colon Polypectomy							
	Condition Aggravated		Bumex	SS				
	Drug Interaction							
	Haemodialysis							
	Hyperkalaemia							
	Hypotension							
	Oliguria							
	Rectal Haemorrhage							
	Renal Failure Acute							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/00ISR Number: 3574225-1Report Type:Periodic Company Report #WAES 00032148
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	50 MG/DAILY/PO	
			Chondroitin (+) Glucosamine	C				

Date:06/21/00ISR Number: 3516623-8Report Type:Direct Company Report #
Age:40 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS		ORAL	25 MG PO QD	2 MON
Initial or Prolonged	Haematemesis		Ranitidine	C				
	Oesophagitis		Premphase	C				
	Weight Decreased							

Date:06/21/00ISR Number: 3517062-6Report Type:Expedited (15-DaCompany Report #WAES 00055245
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	48 DAY
Initial or Prolonged	Peptic Ulcer Haemorrhage	Health Professional						
			Aluminum Hydroxide Gel/Magnesium Hydrox	C				
			Aspirin	C				
			Pravastatin Na	C				

Date:06/21/00ISR Number: 3517065-1Report Type:Expedited (15-DaCompany Report #WAES 00055519
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Foreign	Vioxx	PS	Merck Research			
	Hypertensive Crisis	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG	8 DAY
			Allopurinol	C				
			Atorvastatin	C				
			Brotizolam	C				
			Calcium Carbonate					
			(+) Vitamin D{3}	C				
			Clopidogrel	C				
			Isosorbide Dinitrate	C				
			Molsidomine	C				
			Prostaglandin E{1}	C				

Date:06/21/00ISR Number: 3517068-7Report Type:Expedited (15-DaCompany Report #WAES 00069110
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematocrit Decreased	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemoglobin Decreased	Health			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal	Professional			Merck Co Inc	ORAL	5	DAY
	Haemorrhage		Nsaid	C				

			Other Drugs	C		

Date:06/21/00ISR Number: 3517069-9Report Type:Expedited (15-DaCompany Report #WAES 00069751
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Upper Gastrointestinal	Health			Laboratories Div	
Initial or Prolonged	Haemorrhage	Professional			Merck Co Inc	ORAL

Date:06/21/00ISR Number: 3517186-3Report Type:Expedited (15-DaCompany Report #WAES 00032570
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Chloride Decreased	Health	Vioxx	PS	Merck Research	
	Blood Urea Increased	Professional			Laboratories Div	
	Cardiac Failure	Company			Merck Co Inc	ORAL
50						
	Congestive	Representative				
MG/DAILY/PO						
	Cardiomegaly		Coumadin	C		
	Chest X-Ray Abnormal		Elavil	C		
	Condition Aggravated		Lanoxin	C		
	Drug Level Above		Lasix	C		
	Therapeutic		Metamucil	C		
	Heart Rate Irregular		Prinivil	C		
	Hypotension		Tegretol	C		
	Pulmonary Oedema		B Vitamins	C		
	Renal Failure Acute		Nicotinic Acid	C		
	Renal Impairment					
	Syncope					
	Weight Decreased					

Date:06/21/00ISR Number: 3517200-5Report Type:Expedited (15-DaCompany Report #WAES 00061286
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anorexia	Health	Vioxx	PS	Merck Research	

	Blood Chloride Decreased	Professional			Laboratories Div	
	Blood Creatinine Abnormal	Company			Merck Co Inc	ORAL
50						
	Blood Urea Increased	Representative				
MG/DAILY/PO						
	Constipation		Keflex	C		
	Haemoglobin Decreased		Lasix	C		
	Hyponatraemia		Pepcid Ac	C		
	Hypotension		Voltaren-Xr	C		
	Pruritus		Zestoretic	C		
	Red Blood Cell		Calcium Carbonate			
	Sedimentation Rate		(+) Vitamin D	C		
	Increased		Vitamins	C		
	Renal Failure Acute					
	Urine Analysis Abnormal					

Date:06/21/00ISR Number: 3517208-XReport Type:Expedited (15-DaCompany Report #WAES 00061443
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged					Laboratories Div	
					Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/00ISR Number: 3517216-9Report Type:Expedited (15-DaCompany Report #WAES 00067809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	PO
			Diclofenac Na	C				

Date:06/21/00ISR Number: 3517218-2Report Type:Expedited (15-DaCompany Report #WAES 00065535
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	PO 92 DAY
			Deflazacort	C				
			Digitoxin	C				
			Furosemide	C				

Date:06/21/00ISR Number: 3517225-XReport Type:Expedited (15-DaCompany Report #WAES 00061619
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/21/00ISR Number: 3517227-3Report Type:Expedited (15-DaCompany Report #WAES 00061618
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/21/00ISR Number: 3517319-9Report Type:Expedited (15-DaCompany Report #WAES 00050193
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Celebrex	C		
			Tegretol	C		
			Tobradex	C		
			Belladonna (+)			
			Chloroform (+) Ka	C		
			Lorazepam	C		

Date:06/21/00ISR Number: 3517397-7Report Type:Expedited (15-DaCompany Report #WAES 00051302
Age:72 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness Transient Loss Of Consciousness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO;	
							UNK/UNK/PO	

Date:06/21/00ISR Number: 3517398-9Report Type:Expedited (15-DaCompany Report #WAES 00051659
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Endocarditis Staphylococcal Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/21/00ISR Number: 3571496-2Report Type:Periodic Company Report #WAES 00041550
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hyzaar	C				
			Vioxx	C				

Date:06/21/00ISR Number: 3571497-4Report Type:Periodic Company Report #WAES 00042119
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Glucophage C
Lopressor C
Norpace C
Pepcid C

Date:06/21/00ISR Number: 3571498-6Report Type:Periodic Company Report #WAES 00042335
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Humulin	C				
			Zantac	C				

Date:06/21/00ISR Number: 3576848-2Report Type:Expedited (15-DaCompany Report #WAES 00030242
Age:44 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Electrocardiogram Abnormal Electrocardiogram T Wave Inversion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Palpitations		Vitamins	C				

Date:06/22/00ISR Number: 3517734-3Report Type:Periodic Company Report #WAES00021002
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy Haematoma International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Prothrombin Time Prolonged		Coumadin	C				
			Lanoxin	C				
			Vasotec	C				
			Furosemide	C				
			Quinidine	C				
			Verapamil	C				

Date:06/22/00ISR Number: 3517737-9Report Type:Periodic Company Report #WAES00051987
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	14 DAY
			Cardizem	C				
			Glucophage	C				
			Glucotrol	C				

Date:06/22/00ISR Number: 3517740-9Report Type:Periodic Company Report #WAES 00051944
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Concussion	Health	Vioxx	PS	Merck Research	
	Ecchymosis	Professional			Laboratories Div	
	Epistaxis	Company			Merck Co Inc	ORAL
25 MG/PRN/PO						
	International Normalised	Representative	Cardura	C		
	Ratio Increased		Coumadin	C		
	Oedema		K-Dur	C		
	Prothrombin Time		Lanoxin	C		
	Prolonged		Lasix	C		
			Tylenol Extra			
			Strength	C		

Date:06/22/00ISR Number: 3517743-4Report Type:Periodic Company Report #WAES 00051446
Age: Gender: I/FU:I

Outcome	PT	Report Source
Death	Death	Health
		Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3517744-6Report Type:Periodic Company Report #WAES 00051338
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

Date:06/22/00ISR Number: 3517745-8Report Type:Periodic Company Report #WAES 00051219
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3517746-XReport Type:Periodic Company Report #WAES 00051189
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Avonex	C		
			Elavil	C		
			Klonopin	C		
			Neurontin	C		
			Vicodin Es Tablets	C		

Date:06/22/00ISR Number: 3517747-1Report Type:Periodic Company Report #WAES 00050543
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised Ratio Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Warfarin Sodium Salt	C				

Date:06/22/00ISR Number: 3517748-3Report Type:Periodic Company Report #WAES 00050513
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Altace	C				

Cytomel	C
Effexor	C
Elavil	C
Lipitor	C
Pepcid	C
Aspirin	C
Lorazepam	C
Trazodone	C
Warfarin	C

Date:06/22/00ISR Number: 3517749-5Report Type:Periodic Company Report #WAES 00050506
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:06/22/00ISR Number: 3517750-1Report Type:Periodic Company Report #WAES 00050382
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Prempro	C				
			Allopurinol	C				
			Propranolol	C				

Date:06/22/00ISR Number: 3517753-7Report Type:Periodic Company Report #WAES 00050251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health Professional Company Representative	Vioxx (Therapy Unspecified)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:06/22/00ISR Number: 3517755-0Report Type:Periodic Company Report #WAES 00042833
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:06/22/00ISR Number: 3517760-4Report Type:Periodic Company Report #WAES 00042679
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3517764-1Report Type:Periodic Company Report #WAES 00041791
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Rythmol	C				

Date:06/22/00ISR Number: 3517766-5Report Type:Periodic Company Report #WAES 00041380
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3517770-7Report Type:Periodic Company Report #WAES 00040945
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO
Hydrodiuril C
Prinivil C

Date:06/22/00ISR Number: 3517773-2Report Type:Periodic Company Report #WAES 00032484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hyzaar	C				

Date:06/22/00ISR Number: 3517776-8Report Type:Periodic Company Report #WAES 00032353
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3517779-3Report Type:Periodic Company Report #WAES 00031628
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3517782-3Report Type:Periodic Company Report #WAES 00031616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 DAY
			Celebrex	C				
			Lipitor	C				
			Vasotec	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3517784-7Report Type:Periodic Company Report #WAES 00030900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperglycaemia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avandia	C				
			Cardizem	C				
			Glucotrol	C				
			Insulin	C				

Date:06/22/00ISR Number: 3517787-2Report Type:Periodic Company Report #WAES 00030878
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3518135-4Report Type:Expedited (15-DaCompany Report #WAES 00067809
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Diclofenac Na	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3518136-6Report Type:Expedited (15-DaCompany Report #WAES 00035647
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hypertension Transient Ischaemic Attack	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY 5 DAY						
			Aspirin	C		
			Captopril/Hctz	C		
			Furosemide	C		
			Glyburide	C		
			Isosorbide Dinitrate	C		
			Nitrendipine	C		

Date:06/22/00ISR Number: 3518137-8Report Type:Expedited (15-DaCompany Report #WAES 00065048
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY 99 DAY						
			Acetaminophen (+) Dihydrocodeine Bitartr	C		

Date:06/22/00ISR Number: 3518138-XReport Type:Expedited (15-DaCompany Report #WAES 00065085
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Disorder Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Aluminum Hydroxide/Magnesium Carbonate	C		

			Amitriptyline	C
			Amlodipine	C
			Amoxicillin	C
			Aspirin	C
			Bendroflumethiazide	C
			Chlordiazepoxide	C
			Ferrous So4	C
			Ketoprofen	C
			Lansoprazole	C
			Nystatin	C
			Zopiclone	C

Date:06/22/00ISR Number: 3518169-XReport Type:Expedited (15-DaCompany Report #WAES 00051395
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Mass Gynaecomastia Weight Increased	Consumer Health Professional	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS				
			Prednisone	SS				
			Plaquenil	C				

				Rabeprazole Sodium	C		

Date:06/22/00ISR Number: 3518170-6Report Type:Expedited (15-DaCompany Report #WAES 00050978
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Vioxx 25 Mg	PS	Merck Research			
	Calculus Urinary	Health			Laboratories Div			
	Dehydration	Professional			Merck Co Inc	ORAL	25	
	Gallbladder Disorder						MG/DAILY/PO	
	Malaise		Demerol	C				
	Ovarian Cyst		Ultram	C				
	Shock		[Composition					
	Tremor		Unspecified]	C				
	Vomiting		Prednisone	C				

Date:06/22/00ISR Number: 3518172-XReport Type:Expedited (15-DaCompany Report #WAES 00050800
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukocytoclastic	Health	Vioxx 25 Mg	PS	Merck Research			
	Vasculitis	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Premarin	C				
			Provera	C				
			Tagamet	C				

Date:06/22/00ISR Number: 3518176-7Report Type:Expedited (15-DaCompany Report #WAES 00050339
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholelithiasis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Pancreatitis	Professional			Laboratories Div			

Merck Co Inc ORAL
PO
Aspirin C

Date:06/22/00ISR Number: 3518177-9Report Type:Expedited (15-DaCompany Report #WAES 00061772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3518178-0Report Type:Expedited (15-DaCompany Report #WAES 00060408
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia Blood Chloride Decreased Blood Creatinine Increased Blood Urea Increased Electrocardiogram Qrs Complex Prolonged

		Electrocardiogram T Wave Peaked					
		Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemodialysis	Literature	Vioxx	PS	Merck Research	
		Haemoglobin Decreased	Health			Laboratories Div	
		Hyperkalaemia	Professional			Merck Co Inc	ORAL
25							
		Hyponatraemia					
MG/DAILY/PO	14 DAY						
		Hypovolaemia		Glyburide	C		
		Oliguria		Oxybutynin Chloride	C		
		Pco2 Decreased		Ranitidine	C		
		Tachycardia		Sodium Bicarbonate	C		
				Vitamins	C		

Date:06/22/00ISR Number: 3518180-9Report Type:Expedited (15-DaCompany Report #WAES 00061612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blood Creatinine	Health	Vioxx 25 Mg	PS	Merck Research	
	Increased	Professional			Laboratories Div	
	Chest Pain	Company			Merck Co Inc	ORAL
PO						
	Renal Failure	Representative				

Date:06/22/00ISR Number: 3518242-6Report Type:Expedited (15-DaCompany Report #WAES 00060185
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Breast Discharge	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Gynaecomastia	Professional			Laboratories Div	
Other	Malaise	Company			Merck Co Inc	ORAL
PO						
	Post Procedural Haematoma	Representative	Percocet	C		
	Procedural Site Reaction					

Date:06/22/00ISR Number: 3566766-8Report Type:Periodic Company Report #WAES 00030892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diuretic Preparation (Composition Unk)	C				

Date:06/22/00ISR Number: 3566767-XReport Type:Periodic Company Report #WAES 00030897
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Aleve	C				
			Hytrin	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3566769-3Report Type:Periodic Company Report #WAES 00030899
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Diovan	C				

Date:06/22/00ISR Number: 3566770-XReport Type:Periodic Company Report #WAES 00030910
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON

Date:06/22/00ISR Number: 3566772-3Report Type:Periodic Company Report #WAES 00030911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ultram Unk [Therapy Unspecified]	SS C				

Date:06/22/00ISR Number: 3566773-5Report Type:Periodic Company Report #WAES 00030927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Inj Vitamin B{12} Unk	SS			INJ	

Date:06/22/00ISR Number: 3566775-9Report Type:Periodic Company Report #WAES 00030930
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Eyelid Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3566776-0Report Type:Periodic Company Report #WAES 00030931
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Asthma	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Ambien	C				
Klonopin	C				
Maxzide	C				
Premarin	C				
Pulmicort	C				
Serevent	C				
Zestril	C				

Date:06/22/00ISR Number: 3566778-4Report Type:Periodic Company Report #WAES 00030933
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3566779-6Report Type:Periodic Company Report #WAES 00030938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25 MG	
			Coumadin	C				
			Darvocet-N	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3566780-2Report Type:Periodic Company Report #WAES 00030948
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Relafen	C				

Date:06/22/00ISR Number: 3566782-6Report Type:Periodic Company Report #WAES 00030950
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Irritable Bowel Syndrome Muscular Weakness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Daypro	C	O			
			Lithium Bromide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3566783-8Report Type:Periodic Company Report #WAES 00030952
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bentyl	C				
			Pepcid	C				

Date:06/22/00ISR Number: 3566784-XReport Type:Periodic Company Report #WAES 00030959
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3566786-3Report Type:Periodic Company Report #WAES 00030963
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Prilosec	C				
			Zocor	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3566787-5Report Type:Periodic Company Report #WAES 00030964
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3566788-7Report Type:Periodic Company Report #WAES 00030966
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3566790-5Report Type:Periodic Company Report #WAES 00030969
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Betagen	C
Kaon-Cl	C
Lasix	C
Lortab	C
Nitrostat	C
Norvasc	C
Transderm-Nitro	C
Xanax	C
Zocor	C
Allopurinol	C

Date:06/22/00ISR Number: 3566791-7Report Type:Periodic Company Report #WAES 00030972
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 12.5 MG	
			Norvasc	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3566792-9Report Type:Periodic Company Report #WAES 00030977
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allopurinol	C				
			Aspirin	C				
			Furosemide	C				
			Verapamil	C				

Date:06/22/00ISR Number: 3567637-3Report Type:Periodic Company Report #WAES 00031115
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567638-5Report Type:Periodic Company Report #WAES 00031119
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN/PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567639-7Report Type:Periodic Company Report #WAES 00031122
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Celebrex	C				
			Coumadin	C				
			Dipentum	C				
			Lanoxin	C				
			Prempro	C				
			Slow-K	C				
			Synthroid	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3567640-3Report Type:Periodic Company Report #WAES 00031137
Age:69 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Prilosec	C				
			Morphine Sulfate	C				
			Spironolactone	C				

Date:06/22/00ISR Number: 3567641-5Report Type:Periodic Company Report #WAES 00031144
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Vioxx	PS	Merck Research			

	Proteinuria	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:06/22/00ISR Number: 3567642-7Report Type:Periodic Company Report #WAES 00031145
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

UNK/UNK/PO

Date:06/22/00ISR Number: 3567643-9Report Type:Periodic Company Report #WAES 00031147
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Conjunctivitis Dermatitis Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

50 MG/DAILY/PO 3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567644-0Report Type:Periodic Company Report #WAES 00031148
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567645-2Report Type:Periodic Company Report #WAES 00031149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Company Representative	Nonsteroidal Anti-Inflammatory	C				

Date:06/22/00ISR Number: 3567648-8Report Type:Periodic Company Report #WAES 00031150
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Company Representative						

Date:06/22/00ISR Number: 3567650-6Report Type:Periodic Company Report #WAES 00031151
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL

12.5

MG/UNK/PO

Date:06/22/00ISR Number: 3567651-8Report Type:Periodic Company Report #WAES 00031152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

UNK/UNK/PO

Date:06/22/00ISR Number: 3567653-1Report Type:Periodic Company Report #WAES 00031210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Intervertebral Disc Displacement	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567654-3Report Type:Periodic Company Report #WAES 00031219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Halitosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567656-7Report Type:Periodic Company Report #WAES 00031227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3567659-2Report Type:Periodic Company Report #WAES 00031237
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PRN/PO	
			Fosamax	C				

Date:06/22/00ISR Number: 3567661-0Report Type:Periodic Company Report #WAES 00031248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:06/22/00ISR Number: 3567662-2Report Type:Periodic Company Report #WAES 00031251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Weight Increased					

UNK/UNK/PO

Date:06/22/00ISR Number: 3567663-4Report Type:Periodic Company Report #WAES 00031252
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Blood Pressure Decreased					
	Blood Pressure Increased					

UNK/UNK/PO

	Muscle Rigidity	Accupril	C
	Sedation	Lipitor	C
	Weight Increased	Pain Free Aloe Vera Gel	C
		Verelan	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567664-6Report Type:Periodic Company Report #WAES 00031253
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

Date:06/22/00ISR Number: 3567665-8Report Type:Periodic Company Report #WAES 00030979
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1/2 TABLET	MG/DAILY/ PO
			Tylenol	C				

Date:06/22/00ISR Number: 3567666-XReport Type:Periodic Company Report #WAES 00030983
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3567667-1Report Type:Periodic Company Report #WAES 00030987
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/HS/PO	
			Tab Vioxx	SS		ORAL	50 MG/HS/PO	
			Celebrex	C				
			Ultram	C				
			Nasonex	C				
			Claritin	C				

Date:06/22/00ISR Number: 3567668-3Report Type:Periodic Company Report #WAES 00030993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Nodosum	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	
			Celebrex	SS				

Date:06/22/00ISR Number: 3567669-5Report Type:Periodic Company Report #WAES 00030997
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

PO 2 WK

Hygroton	C	
Synthroid	C	
Meclizine	C	

Date:06/22/00ISR Number: 3567670-1Report Type:Periodic Company Report #WAES 00030999
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	

PO

Diazepam	C	
Nitroglycerin	C	
Nitroglycerin	C	
Olanzapine	C	
Ranitidine	C	
Trazodone	C	

Date:06/22/00ISR Number: 3567671-3Report Type:Periodic Company Report #WAES 00031000
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	

Advil	C	
Atacand	C	
Cepacol	C	
Hydrodiuril	C	
Klor-Con	C	
Vasotec	C	
Allopurinol	C	

Date:06/22/00ISR Number: 3567672-5Report Type:Periodic Company Report #WAES 00031003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:06/22/00ISR Number: 3567673-7Report Type:Periodic Company Report #WAES 00031006
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dysphagia Feeling Abnormal Headache Hypertonia Myalgia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567674-9Report Type:Periodic Company Report #WAES 00031007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
		Representative						

Date:06/22/00ISR Number: 3567675-0Report Type:Periodic Company Report #WAES 00031008
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
		Representative						

Date:06/22/00ISR Number: 3567676-2Report Type:Periodic Company Report #WAES 00031042
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3567677-4Report Type:Periodic Company Report #WAES 00031057
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Chest Pain Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK / UNK /

PO

Norvasc	C		
Prempro	C		
Tenoretic	C		
Alprazolam	C		

Date:06/22/00ISR Number: 3567678-6Report Type:Periodic Company Report #WAES 00031062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK / UNK/ PO

Representative	Zocor	C	

Date:06/22/00ISR Number: 3567682-8Report Type:Periodic Company Report #WAES 00031096
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5

MG/DAILY/ PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567708-1Report Type:Periodic Company Report #WAES 00030160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Deafness Fatigue Gastric Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567709-3Report Type:Periodic Company Report #WAES 00030163
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dizziness Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567710-XReport Type:Periodic Company Report #WAES 00030177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 MON

Date:06/22/00ISR Number: 3567711-1Report Type:Periodic Company Report #WAES 00030178
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3567712-3Report Type:Periodic Company Report #WAES 00030191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research	
	Cardiac Murmur	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3567713-5Report Type:Periodic Company Report #WAES 00030195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567714-7Report Type:Periodic Company Report #WAES 00030207
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Overload	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567715-9Report Type:Periodic Company Report #WAES 00030231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567716-0Report Type:Periodic Company Report #WAES 00030233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567717-2Report Type:Periodic Company Report #WAES 00030235
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Cozaar C
Norvasc C
Atenolol C

Date:06/22/00ISR Number: 3567718-4Report Type:Periodic Company Report #WAES 00030239
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Sinemet	C				

Date:06/22/00ISR Number: 3567719-6Report Type:Periodic Company Report #WAES 00030242
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Electrocardiogram Abnormal Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567720-2Report Type:Periodic Company Report #WAES 00030243
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								3 DAY
			Hydrodiuril	C				
			Lipitor	C				
			Norvasc	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Zestril	C				

Date:06/22/00ISR Number: 3567721-4Report Type:Periodic Company Report #WAES 00030246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glaucoma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567722-6Report Type:Periodic Company Report #WAES 00030249
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Muscle Spasms Myalgia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Asacol	C				
			Robitussin-Cf	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3567723-8Report Type:Periodic Company Report #WAES 00030250
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Lopressor	C				
			Premarin	C				

Date:06/22/00ISR Number: 3567724-XReport Type:Periodic Company Report #WAES 00030253
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Arthralgia Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Nausea		Hydrochlorothiazide + Triamter	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567725-1Report Type:Periodic Company Report #WAES 00030258
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca Nasal Dryness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3567726-3Report Type:Periodic Company Report #WAES 00030262
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:06/22/00ISR Number: 3567727-5Report Type:Periodic Company Report #WAES 00030266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567733-0Report Type:Periodic Company Report #WAES 00030070
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Company Representative			Merck Co Inc	ORAL PO

Date:06/22/00ISR Number: 3567734-2Report Type:Periodic Company Report #WAES 00030087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Hallucination Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:06/22/00ISR Number: 3567735-4Report Type:Periodic Company Report #WAES 00030088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567736-6Report Type:Periodic Company Report #WAES 00030091
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567737-8Report Type:Periodic Company Report #WAES 00030114
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567738-XReport Type:Periodic Company Report #WAES 00030115
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Covera-Hs	C				
			Lopressor	C				
			Prevacid	C				
			Tegretol	C				

Date:06/22/00ISR Number: 3567739-1Report Type:Periodic Company Report #WAES 00030120
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain Eye Movement Disorder Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/00ISR Number: 3567740-8Report Type:Periodic Company Report #WAES 00030505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567741-XReport Type:Periodic Company Report #WAES 00030518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567742-1Report Type:Periodic Company Report #WAES 00030519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567743-3Report Type:Periodic Company Report #WAES 00030520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567744-5Report Type:Periodic Company Report #WAES 00030521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567745-7Report Type:Periodic Company Report #WAES 00030522
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eye Irritation							
	Headache							
	Insomnia		Adalat	C				
	Lacrimation Increased		Premarin	C				

	Pollakiuria		Synthroid	C
			Amitriptyline	C
			Folic Acid	C
			Lorazepam	C
			Vitamins	C

Date:06/22/00ISR Number: 3567746-9Report Type:Periodic Company Report #WAES 00030523
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Famvir	C		
			Miacalcin	C		
			Ortho Dienestrl Cream	C		
			Valium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567747-0Report Type:Periodic Company Report #WAES 00030123
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flexeril	C				

Date:06/22/00ISR Number: 3567748-2Report Type:Periodic Company Report #WAES 00030526
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567749-4Report Type:Periodic Company Report #WAES 00030527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Aspirin	C				

Date:06/22/00ISR Number: 3567750-0Report Type:Periodic Company Report #WAES 00030539
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Faecaloma Merck Co Inc ORAL
12.5MG/DAILY/
Nausea
PO
Pruritus
Weight Increased

Date:06/22/00ISR Number: 3567751-2Report Type:Periodic Company Report #WAES 00030124
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Meprobamate	C				

Date:06/22/00ISR Number: 3567752-4Report Type:Periodic Company Report #WAES 00030542
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567753-6Report Type:Periodic Company Report #WAES 00030127
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567754-8Report Type:Periodic Company Report #WAES 00030543
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Joint Swelling Oedema Peripheral Periorbital Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3567755-XReport Type:Periodic Company Report #WAES 00030547
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Headache Medication Error Oedema Peripheral ;	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Paraesthesia						50MG/DAILY/PO	
			Centrum Silver	C				
			Fosamax	C				
			Premarin	C				
			Surfak	C				
			Synthroid	C				
			Therapy Unspecified	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3567756-1Report Type:Periodic Company Report #WAES 00030130
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eye Pain							
	Flushing							
	Oral Mucosal		Zoloft	C				
	Discolouration		Vitamins	C				
	Urine Abnormality							

Date:06/22/00ISR Number: 3567757-3Report Type:Periodic Company Report #WAES 00030548
Age:78 YR Gender:Male I/FU:I

Outcome	PT
	Asthenia
	Blood Pressure Decreased
	Blood Pressure Increased
	Bowel Sounds Abnormal
	Fatigue
	Flatulence
	Gastrointestinal Disorder

Rectal Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Beclovent	C				
			Cortone	C				
			Lasix	C				
			Vasotec	C				
			Zantac	C				
			Therapy Unspecified	C				
			Albuterol Sulfate	C				
			Theophylline	C				

Date:06/22/00ISR Number: 3567758-5Report Type:Periodic Company Report #WAES 00030549
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Glipizide	C				

Date:06/22/00ISR Number: 3567759-7Report Type:Periodic Company Report #WAES 00030550
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Cozaar	C				
			Pravachol	C				

Prevacid C

Date:06/22/00ISR Number: 3567760-3Report Type:Periodic Company Report #WAES 00030138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

1) 12.5

MG/DAILY/PO;

2) 50

MG/DAILY/PO

Date:06/22/00ISR Number: 3567761-5Report Type:Periodic Company Report #WAES 00030555
Age:51 YR Gender:Female I/FU:I

Outcome PT
Diarrhoea
Drug Ineffective
Dyspepsia
Eye Disorder
Headache

	Nausea Vomiting	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO
			Bactrim	C			
			Botox	C			
			Zantac	C			
			Cortisone	C			
			Diazepam	C			
			Progesterone	C			

Date:06/22/00ISR Number: 3567762-7Report Type:Periodic Company Report #WAES 00030559
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Angiopathy Asthenia Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO
	Face Oedema		Paxil	C			
	Fatigue		Premarin	C			
	Oedema Peripheral		Prevacid	C			
			Serzone	C			
			Tenormin	C			
			Zestril	C			

Date:06/22/00ISR Number: 3567763-9Report Type:Periodic Company Report #WAES 00030139
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Breast Cancer Female Dyspnoea Nausea Respiratory Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Fosamax	C			

			Prevacid	C		
			Prozac	C		
			Hydrocodone	C		
			Trazodone	C		

Date:06/22/00ISR Number: 3567764-0Report Type:Periodic Company Report #WAES 00030570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Feeling Abnormal							
	Rash Erythematous							
			Miacalcin	C				
			Premarin	C				
			Calcium Supplement	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567765-2Report Type:Periodic Company Report #WAES 00030140
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3567766-4Report Type:Periodic Company Report #WAES 00030573
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:06/22/00ISR Number: 3567767-6Report Type:Periodic Company Report #WAES 00030144
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Norvasc	C				
			Prilosec	C				
			Synthroid	C				
			Ultram	C				
			Glucosamine	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3567768-8Report Type:Periodic Company Report #WAES 00030145
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:06/22/00ISR Number: 3567769-XReport Type:Periodic Company Report #WAES 00030149
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567770-6Report Type:Periodic Company Report #WAES 00030152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:06/22/00ISR Number: 3567771-8Report Type:Periodic Company Report #WAES 00030153
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Neurontin	C				

Date:06/22/00ISR Number: 3567772-XReport Type:Periodic Company Report #WAES 00030159
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Lorazepam	C				

Date:06/22/00ISR Number: 3567891-8Report Type:Periodic Company Report #WAES 00030582
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY/PO	
			Prempro	C				

Date:06/22/00ISR Number: 3567892-XReport Type:Periodic Company Report #WAES 00030588
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	NK/2XW/PO	
			Prilosec	C				
			Proscar	C				

Date:06/22/00ISR Number: 3567893-1Report Type:Periodic Company Report #WAES 00030593
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Claritin	C
Zocor	C

Date:06/22/00ISR Number: 3567894-3Report Type:Periodic Company Report #WAES 00030597
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:06/22/00ISR Number: 3567895-5Report Type:Periodic Company Report #WAES 00030599
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567896-7Report Type:Periodic Company Report #WAES 00030600
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567897-9Report Type:Periodic Company Report #WAES 00030601
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5 MG /

DAILY/PO

Date:06/22/00ISR Number: 3567898-0Report Type:Periodic Company Report #WAES 00030604
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
	Drug Ineffective							
			Celebrex	C				
			Vasotec	C				
			Vitamins	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3567899-2Report Type:Periodic Company Report #WAES 00030636
Age:46 YR Gender:Female I/FU:I

Outcome	PT
	Chest Pain
	Dermatitis

		Diarrhoea Nausea Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ DAILY/							
PO	2 DAY						
				Lorcet Plus	C		
				Norflex	C		
				Ultram	C		

Date:06/22/00ISR Number: 3567900-6Report Type:Periodic Company Report #WAES 00030654
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Dysgeusia Eating Disorder Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/DAILY/PO							

Date:06/22/00ISR Number: 3567901-8Report Type:Periodic Company Report #WAES 00030658
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO							

Date:06/22/00ISR Number: 3567902-XReport Type:Periodic Company Report #WAES 00030665
Age:57 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Arthralgia	Health	Vioxx	PS	Merck Research	

	Drug Ineffective	Professional			Laboratories Div	
	Joint Swelling				Merck Co Inc	ORAL
25 MG/						
	Muscle Rigidity					
DAILY/PO						
			Inj Synvisc	SS		
2 MG/WKY/INJ						
			Analgesic Or Anesthetic Preparation	C		

Date:06/22/00ISR Number: 3567903-1Report Type:Periodic Company Report #WAES 00030678
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Norvasc	C		
			Zocor	C		
			Indapamide	C		
			Temazepam	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567904-3Report Type:Periodic Company Report #WAES 00030688
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis							
	Dyspepsia							
	Urticaria							
			Plendil	C				
			Premarin	C				
			Prilosec	C				
			Xanax	C				
			Hydrochlorothiazide (+) Triamter	C				
			Vancenase	C				

Date:06/22/00ISR Number: 3567905-5Report Type:Periodic Company Report #WAES 00030703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Balance Disorder							
	Depression							
	Drug Ineffective							
	Face Oedema							
	Fatigue							
	Oedema Peripheral							
	Weight Increased							

Date:06/22/00ISR Number: 3567906-7Report Type:Periodic Company Report #WAES 00030713
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Blood Pressure Increased							
	Diarrhoea							

Fatigue
MG/DAILY/PO
Gastric Disorder Tenormin C
Nausea
Swelling

Date:06/22/00ISR Number: 3567907-9Report Type:Periodic Company Report #WAES 00030720
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567908-0Report Type:Periodic Company Report #WAES 00030721
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PRN/PO	
			Ortho Tri -Cyclen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567909-2Report Type:Periodic Company Report #WAES 00030722
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Hormones (Composition Unspeified)	C				
			Tums	C				

Date:06/22/00ISR Number: 3567910-9Report Type:Periodic Company Report #WAES 00030730
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Fosamax	C				
			Hormones (Composition Unspecified)	C				
			Ibuprofen	C				

Date:06/22/00ISR Number: 3567911-0Report Type:Periodic Company Report #WAES 00030736
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Lip Dry Mouth Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO;PO	
	Paraesthesia Oral		Prilosec	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3567912-2Report Type:Periodic Company Report #WAES 00030737
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Colan	C				
			Cozaar	C				

Date:06/22/00ISR Number: 3567913-4Report Type:Periodic Company Report #WAES 00030738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567914-6Report Type:Periodic Company Report #WAES 00030740
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythropenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dilatin	C				
			Evista	C				
			Mysoline	C				
			Zantac	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3567915-8Report Type:Periodic Company Report #WAES 00030741
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567916-XReport Type:Periodic Company Report #WAES 00030744
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Gozaar	C				
			Glucophage	C				
			Rezulin	C				
			Zocor	C				

Date:06/22/00ISR Number: 3567917-1Report Type:Periodic Company Report #WAES 00030748
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection Pollakiuria Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	4 DAY

Date:06/22/00ISR Number: 3567918-3Report Type:Periodic Company Report #WAES 00030753
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy Conjunctivitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAIL/PO	

Date:06/22/00ISR Number: 3567919-5Report Type:Periodic Company Report #WAES 00030754
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Antimicrobial
Therapy C

Date:06/22/00ISR Number: 3567920-1Report Type:Periodic Company Report #WAES 00030760
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hearing Impaired	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	SS				
			Sectral	C				
			Synthroid	C				
			Zocor	C				

Date:06/22/00ISR Number: 3567921-3Report Type:Periodic Company Report #WAES 00030766
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	6 MON
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3567922-5Report Type:Periodic Company Report #WAES 00030770
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

			Lithiumco 3 300mg;Lithiumco3	SS		
600 MG/TID;300 MG/BID						
			...	C		
300 MG/BID						

Date:06/22/00ISR Number: 3567923-7Report Type:Periodic Company Report #WAES 00030781
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
OPHTHALMIC 12.5 MG/DAILY/PO						
			Lipitor	C		
			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567924-9Report Type:Periodic Company Report #WAES 00030787
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

Date:06/22/00ISR Number: 3567925-0Report Type:Periodic Company Report #WAES 00030810
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567926-2Report Type:Periodic Company Report #WAES 00030812
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orgasm Abnormal Sexual Dysfunction	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567927-4Report Type:Periodic Company Report #WAES 00030813
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephritis Interstitial	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567928-6Report Type:Periodic Company Report #WAES 00030816
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Petechiae	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567929-8Report Type:Periodic Company Report #WAES 00030825
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Baycol	C				
			Coumadin	C				
			Lanoxin	C				
			Miacalcin	C				
			Tums	C				
			Hydrochlorothiazide					

(+) Spironol C

Date:06/22/00ISR Number: 3567930-4Report Type:Periodic Company Report #WAES 00030829
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/TID/PO	
			Allegra	C				
			Ditropan	C				
			Estrace	C				

Date:06/22/00ISR Number: 3567931-6Report Type:Periodic Company Report #WAES 00030830
Age:85 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO	
			Neurontin	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3567932-8Report Type:Periodic Company Report #WAES 00030831
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Lipitor	C
			Microzide	C
			Timoptic-Xe	C
			Zoloft	C

Date:06/22/00ISR Number: 3567933-XReport Type:Periodic Company Report #WAES 00030834
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	2 DAY
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3567934-1Report Type:Periodic Company Report #WAES 00030846
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567936-5Report Type:Periodic Company Report #WAES 00030849
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Dyspepsia							
	Gastrointestinal							
	Infection		Lamictal	C				
	Vomiting		Morphine	C				

Date:06/22/00ISR Number: 3567938-9Report Type:Periodic Company Report #WAES 00030850
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Depression							
	Dyspepsia							
	Fatigue							
			Coumadin	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3567939-0Report Type:Periodic Company Report #WAES 00030851
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Occult Blood	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567940-7Report Type:Periodic Company Report #WAES 00022035
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
	Headache							
	Hypoaesthesia							
	Oral Pain							
	Palpitations		Tab Vioxx 25 Mg	SS		ORAL	25 MG DAILY PO	
	Pollakiuria							
			Fosamax	C				
			Xalatan	C				
			Vitamin E	C				
			Calcium Supplement	C				
			Tylenol	C				
			Tums	C				

Date:06/22/00ISR Number: 3567941-9Report Type:Periodic Company Report #WAES 00022037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	17 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567942-0Report Type:Periodic Company Report #WAES 00030852
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Depression Fatigue	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567943-2Report Type:Periodic Company Report #WAES 00022072
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Palpitations Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Claritin D	SS				
			Z-Pak	SS				
			Ambien	C				
			Azmacort	C				
			Buspar	C				
			Vicodin Tablets	C				

Date:06/22/00ISR Number: 3567944-4Report Type:Periodic Company Report #WAES 00030853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3567945-6Report Type:Periodic Company Report #WAES 00022076
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Emphysema							
	Tinnitus		Hydrodiuril	C				
	Upper Respiratory Tract Infection		Lorcet 10/650	C				
			Robaxin	C				
			Reserpine	C				

Date:06/22/00ISR Number: 3567946-8Report Type:Periodic Company Report #WAES 00022080
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tagamet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567947-XReport Type:Periodic Company Report #WAES 00022081
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue Pain Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Neurontin	C				
			Oxycontin	C				
			Zocor	C				
			Nortriptyline	C				

Date:06/22/00ISR Number: 3567948-1Report Type:Periodic Company Report #WAES 00030854
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO; 25 MG/UNK/PO	

Date:06/22/00ISR Number: 3567949-3Report Type:Periodic Company Report #WAES 00022082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Epistaxis Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actifed	C				
			Allerfrim	C				
			Prilosec	C				
			Wellbutrin	C				
			Dicyclomine Hydrochloride	C				

Erythromycin	C
Guaifenesin	C
Metoprolol	C
Sulfasalazine	C

Date:06/22/00ISR Number: 3567950-XReport Type:Periodic Company Report #WAES 00030856
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567951-1Report Type:Periodic Company Report #WAES 00022087
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567952-3Report Type:Periodic Company Report #WAES 00022090
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Shock	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567953-5Report Type:Periodic Company Report #WAES 00022092
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abnormal Faeces Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Loperamide Hydrochloride	C				

Date:06/22/00ISR Number: 3567954-7Report Type:Periodic Company Report #WAES 00030857
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567955-9Report Type:Periodic Company Report #WAES 00022094
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperbilirubinaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			With Codeine #3	C				

Date:06/22/00ISR Number: 3567956-0Report Type:Periodic Company Report #WAES 00030860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Pharyngitis Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Coldrin	C				
			Flovent	C				
			Glucotrol	C				
			Serevent	C				
			Uni-Dur	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567957-2Report Type:Periodic Company Report #WAES 00030865
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3567958-4Report Type:Periodic Company Report #WAES 00022096
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Insulin	C				

Date:06/22/00ISR Number: 3567959-6Report Type:Periodic Company Report #WAES 00022103
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Toprol Xl Tablets	C				

Date:06/22/00ISR Number: 3567960-2Report Type:Periodic Company Report #WAES 00022107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG BID PO	
			Allopurinol Msd	C				
			Ultram	C				
			Lotensin	C				
			Flomax(Tamsulosin (R)-Form Hydr	C				

Date:06/22/00ISR Number: 3567961-4Report Type:Periodic Company Report #WAES 00030866
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Peri-Colace	C				
			Prilosec	C				
			Synthroid	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567962-6Report Type:Periodic Company Report #WAES 00022113
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

Date:06/22/00ISR Number: 3567963-8Report Type:Periodic Company Report #WAES 00022127
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dyspepsia Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Lotrel	C				

Date:06/22/00ISR Number: 3567964-XReport Type:Periodic Company Report #WAES 00030870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

Date:06/22/00ISR Number: 3567965-1Report Type:Periodic Company Report #WAES 00030873
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO

Hydrodiuril	C	
Prinivil	C	
Atenolol	C	
Thyroid	C	

Date:06/22/00ISR Number: 3567966-3Report Type:Periodic Company Report #WAES 00022129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567967-5Report Type:Periodic Company Report #WAES 00022130
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Arrhythmia	Health Professional Company
	Bradycardia	

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567968-7Report Type:Periodic Company Report #WAES 00022131
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567969-9Report Type:Periodic Company Report #WAES 00030882
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Lescol	C				
			Triam-A	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3567970-5Report Type:Periodic Company Report #WAES 00022144
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Constipation Diarrhoea Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
	Dysgeusia Mental Impairment Upper Respiratory Tract Infection		Fosamax Robitussin Dm Tamoxifen	SS C C		

Date:06/22/00ISR Number: 3567971-7Report Type:Periodic Company Report #WAES 00030885
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Fosamax Os-Cal+D	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567972-9Report Type:Periodic Company Report #WAES 00030886
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3567973-0Report Type:Periodic Company Report #WAES 00030267
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/BID/PO	
			Norvasc	C				
			Aspirin	C				
			Isosorbide	C				
			Metoprolol	C				
			Simvastatin	C				

Date:06/22/00ISR Number: 3567974-2Report Type:Periodic Company Report #WAES 00030268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Gastric Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/00ISR Number: 3567975-4Report Type:Periodic Company Report #WAES 00030272
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Fatigue							
	Headache		Lortab	C				
	Oedema Peripheral							
	Urinary Incontinence							

Date:06/22/00ISR Number: 3567976-6Report Type:Periodic Company Report #WAES 00030282
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG, PO	
			(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567977-8Report Type:Periodic Company Report #WAES 00030283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567978-XReport Type:Periodic Company Report #WAES 00030299
Age:48 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Neuropathy Peripheral Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567979-1Report Type:Periodic Company Report #WAES 00030300
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567980-8Report Type:Periodic Company Report #WAES 00021907
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Flomax	C
Librax	C
Pepcid	C
Allopurinol	C
Triazolam	C

Date:06/22/00ISR Number: 3567981-XReport Type:Periodic Company Report #WAES 00030301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567982-1Report Type:Periodic Company Report #WAES 00021908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Myalgia Rebound Effect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567983-3Report Type:Periodic Company Report #WAES 00030315
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pepcid	C				
			(Therapy Unspecified)	C				
			Captopril	C				
			Iron (Unspecified)	C				

Date:06/22/00ISR Number: 3567984-5Report Type:Periodic Company Report #WAES 00021912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/PO	

Date:06/22/00ISR Number: 3567985-7Report Type:Periodic Company Report #WAES 00030317
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lodine	C				

Date:06/22/00ISR Number: 3567986-9Report Type:Periodic Company Report #WAES 00030318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567987-0Report Type:Periodic Company Report #WAES 00030319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pelvic Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	9 DAY

Date:06/22/00ISR Number: 3567988-2Report Type:Periodic Company Report #WAES 00030340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567989-4Report Type:Periodic Company Report #WAES 00030355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depersonalisation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Drug Interaction							
	Feeling Abnormal							
	Headache							
	Tremor		Excedrin Extra-Strength Unk	SS				

Date:06/22/00ISR Number: 3567990-0Report Type:Periodic Company Report #WAES 00030358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567991-2Report Type:Periodic Company Report #WAES 00030383
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Urticaria							

Date:06/22/00ISR Number: 3567992-4Report Type:Periodic Company Report #WAES 00030398
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Erythema	Health						

	Insomnia	Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Tab Vioxx 12.5 Mg	SS		ORAL
12.5						
MG/BID/PO						
			Tab Vioxx 12.5 Mg	SS		ORAL
12.5						
MG/BID/PO						
			Adalat	C		
			Deltasone	C		
			Lipitor	C		
			Alprazolam	C		
			Terazosin	C		

Date:06/22/00ISR Number: 3567993-6Report Type:Periodic Company Report #WAES 00030400
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Lacrimation Increased	Consumer	Vioxx	PS	Merck Research	
	Vision Blurred				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Evista	C		
			Hydrodiuril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3567994-8Report Type:Periodic Company Report #WAES 00030409
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rheumatoid Arthritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Glucophage	C				
			Glucotrol	C				
			Hyzaar	C				
			Norvasc	C				
			Zestril	C				

Date:06/22/00ISR Number: 3567995-XReport Type:Periodic Company Report #WAES 00030416
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensation Of Heaviness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG	
			Zyrtec	C				

Date:06/22/00ISR Number: 3567996-1Report Type:Periodic Company Report #WAES 00030418
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Atrovent	C				
			Bentyl	C				
			Cartia	C				
			Combivent	C				
			Desyrel	C				
			Lorcet Plus	C				

Neurontin	C
Prilosec	C
Theo-Dur	C
Albuterol	C
Clonazepam	C
Nitroglycerin	C

Date:06/22/00ISR Number: 3567997-3Report Type:Periodic Company Report #WAES 00021914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3567998-5Report Type:Periodic Company Report #WAES 00021917
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	

PO

Acid-X	C		
Vitamins	C		

Date:06/22/00ISR Number: 3567999-7Report Type:Periodic Company Report #WAES 00030422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	4 WK

Date:06/22/00ISR Number: 3568000-1Report Type:Periodic Company Report #WAES 00021920
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rheumatoid Arthritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Synthroid	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3568001-3Report Type:Periodic Company Report #WAES 00021921
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Gastrointestinal Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Tylenol	C				
			Zebeta	C				

Date:06/22/00ISR Number: 3568002-5Report Type:Periodic Company Report #WAES 00021925
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Glossodynia	Consumer	Vioxx	PS	Merck Research	
	Mouth Ulceration	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25MG/DAILY/PO						
; 25MG/BID/PO						
			Diabeta	C		
			Elavil	C		

Date:06/22/00ISR Number: 3568003-7Report Type:Periodic Company Report #WAES 00021926
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Alopecia				Laboratories Div	
	Dyspepsia				Merck Co Inc	ORAL
25MG/DAILY/PO						
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568004-9Report Type:Periodic Company Report #WAES 00030425
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Prozac	C				

Date:06/22/00ISR Number: 3568005-0Report Type:Periodic Company Report #WAES 00030427
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Tenderness Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Avapro	C				
			Flovent	C				
			Lasix	C				
			Norvasc	C				
			Rezulin	C				
			Toprol Xl	C				
			Zocor	C				
			Albuterol	C				
			Insulin	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3568006-2Report Type:Periodic Company Report #WAES 00021931
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Drug Ineffective				Merck Co Inc	ORAL
25MG/DAILY/PO						
			Advil Cold And Sinus Caplets	C		
			Diovan	C		
			Plavix	C		
			Tylenol With Codeine	C		
			Vitamin E	C		

Date:06/22/00ISR Number: 3568007-4Report Type:Periodic Company Report #WAES 00021946
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/BID/PO						
			Claritin	C		
			Ultram	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568008-6Report Type:Periodic Company Report #WAES 00030429
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Aggression	Health	Vioxx	PS	Merck Research	
	Emotional Disorder	Professional			Laboratories Div	
					Merck Co Inc	ORAL
SEE IMAGE						
			Aricept	C		
			Pilocarpine	C		

Date:06/22/00ISR Number: 3568009-8Report Type:Periodic Company Report #WAES 00021948
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3568010-4Report Type:Periodic Company Report #WAES 00030431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25 MG/DAILY/						
PO						
			Zoloft	C		

Date:06/22/00ISR Number: 3568011-6Report Type:Periodic Company Report #WAES 00021952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	

Laboratories Div
Merck Co Inc ORAL
12.5MG/DAILY/

PO

Aleve	C	
Isoptin	C	
Xanax	C	

Date:06/22/00ISR Number: 3568012-8Report Type:Periodic Company Report #WAES 00030433
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/00ISR Number: 3568013-XReport Type:Periodic Company Report #WAES 00021962
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Feeling Hot And Cold							
	Hypoaesthesia							
	Rhinorrhoea		Miacalcin	C				
			Vicoprofen	C				

				Verapamil	C		
				Vitamin E	C		

Date:06/22/00ISR Number: 3568014-1Report Type:Periodic Company Report #WAES 00021967
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection		Vasotec	C				

Date:06/22/00ISR Number: 3568015-3Report Type:Periodic Company Report #WAES 00030434
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
	Constipation							
	Nausea							
			Diovan	C				
			Mevacor	C				
			Prozac	C				

Date:06/22/00ISR Number: 3568016-5Report Type:Periodic Company Report #WAES 00030446
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Lescol	C				
			Prempro	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3568017-7Report Type:Periodic Company Report #WAES 00021977
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Amaryl	C				
			Detrol	C				
			Lipitor	C				
			Nasonex	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3568018-9Report Type:Periodic Company Report #WAES 00021997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568019-0Report Type:Periodic Company Report #WAES 00021998
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568020-7Report Type:Periodic Company Report #WAES 00030450
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

Date:06/22/00ISR Number: 3568021-9Report Type:Periodic Company Report #WAES 00030451
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:06/22/00ISR Number: 3568022-0Report Type:Periodic Company Report #WAES 00030452
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	Therapy Unspecified	C		

Date:06/22/00ISR Number: 3568023-2Report Type:Periodic Company Report #WAES 00030458
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Vioxx	PS	Merck Research	
	Drug Interaction	Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Lasix Unk	SS		

Date:06/22/00ISR Number: 3568024-4Report Type:Periodic Company Report #WAES 00030467
Age:87 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Deafness	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG/						
DAILY/ PO						
			Cardizem	C		
			Prilosec	C		
			Hydrochlorothiazide			
			(+) Triamter	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568025-6Report Type:Periodic Company Report #WAES 00030470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568026-8Report Type:Periodic Company Report #WAES 00030474
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/00ISR Number: 3568027-XReport Type:Periodic Company Report #WAES 00030494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568028-1Report Type:Periodic Company Report #WAES 00030497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin Hydrochlorothiazide	C				

			(+) Triamter	C
			Nadolol	C

Date:06/22/00ISR Number: 3568029-3Report Type:Periodic Company Report #WAES 00022012
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50MG/DAILY	
	Dyspnoea							
	Erythema							
	Face Oedema							
			Benadryl	C				
			Diuretic Preparation	C				

Date:06/22/00ISR Number: 3568030-XReport Type:Periodic Company Report #WAES 00030500
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Muscular Weakness							
	Myalgia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568031-1Report Type:Periodic Company Report #WAES 00030502
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	
	Depression							
	Dizziness							
PO								
			Cardizem Sr	C				
			Ecotrin	C				
			Nitro-Dur	C				
			Percodan	C				
			Prilosec	C				
			Valium	C				

Date:06/22/00ISR Number: 3568032-3Report Type:Periodic Company Report #WAES 00022016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accolate	C				
			Flovent	C				
			Maxzide	C				
			Prilosec	C				
			Proventil	C				
			Serevent	C				
			Vancenase	C				

Date:06/22/00ISR Number: 3568033-5Report Type:Periodic Company Report #WAES 00021811
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hypoaesthesia							

Merck Co Inc ORAL
25 MG/QOD/PO

Date:06/22/00ISR Number: 3568034-7Report Type:Periodic Company Report #WAES 00021813
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/ DAILY/PO						
			Cozaar	C		
			Norvasc	C		

Date:06/22/00ISR Number: 3568035-9Report Type:Periodic Company Report #WAES 00021816
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/PO						
			Biotiren	C		

Lamictal	C
Neurontin	C
Prilosec	C
Prozac	C
Risperdal	C
[Composition Unspecified]	C
[Therapy Unspecified]	C

Date:06/22/00ISR Number: 3568036-0Report Type:Periodic Company Report #WAES 00031385
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568037-2Report Type:Periodic Company Report #WAES 00031386
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ibuprofen	C				
			Trazodone	C				

Date:06/22/00ISR Number: 3568038-4Report Type:Periodic Company Report #WAES 00021821
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

Pain Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/ORAL

Clonidine C
Morphine C

Date:06/22/00ISR Number: 3568039-6Report Type:Periodic Company Report #WAES 00031388
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Olfactory Nerve Disorder							

MG/DAILY/PO

Estrace C
Hydrodiuril C
Plaquenil C
Pravachol C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568040-2Report Type:Periodic Company Report #WAES 00021822
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Abnormal Faeces							
	Change Of Bowel Habit							
	Gastrointestinal Disorder							

Date:06/22/00ISR Number: 3568041-4Report Type:Periodic Company Report #WAES 00021824
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568042-6Report Type:Periodic Company Report #WAES 00021825
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Breast Pain							
	Dyspnoea		Ativan	C				
	Hypoaesthesia		Novolin	C				
	Musculoskeletal Disorder							
	Pain							
	Pain In Extremity							

Date:06/22/00ISR Number: 3568044-XReport Type:Periodic Company Report #WAES 00031390
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3568045-1Report Type:Periodic Company Report #WAES 00031391
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568046-3Report Type:Periodic Company Report #WAES 00031406
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Insomnia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG/PRN	
			Mylanta & Mylanta Ds	C				

Synthroid C

Date:06/22/00ISR Number: 3568047-5Report Type:Periodic Company Report #00031408
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Altace	C				

Date:06/22/00ISR Number: 3568049-9Report Type:Periodic Company Report #WAES 00031413
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorder Of Globe Maculopathy	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3568050-5Report Type:Periodic Company Report #WAES 00031415
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Disorder Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Isoxsuprine	C				

Date:06/22/00ISR Number: 3568051-7Report Type:Periodic Company Report #WAES 00021826
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Fatigue	Professional			Merck Co Inc	ORAL	12.5	
	Pruritus						MG/DAILY/PO	
	Urticaria		Lopressor	C				
			Norvasc	C				
			Synthroid	C				
			Zantac	C				

Date:06/22/00ISR Number: 3568052-9Report Type:Periodic Company Report #WAES 00021834
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Chest Pain				Laboratories Div			
	Choking				Merck Co Inc	ORAL	12.5 MG/ PO	
	Flatulence		Vasotec	C				
			Allopurinol	C				
			Imipenem	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568053-0Report Type:Periodic Company Report #WAES 00021835
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3568054-2Report Type:Periodic Company Report #WAES 00021841
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Dermatitis Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3568055-4Report Type:Periodic Company Report #WAES 00021845
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia Headache Influenza Like Illness Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Effexor	C				
			Prevacid	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3568056-6Report Type:Periodic Company Report #WAES 00021848
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:06/22/00ISR Number: 3568057-8Report Type:Periodic Company Report #WAES 00021849
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder Oedema Peripheral Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568058-XReport Type:Periodic Company Report #WAES 00021850
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lortab	C				
			Verelan	C				
			Zocor	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3568059-1Report Type:Periodic Company Report #WAES 00031426
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lupron	SS				
			Ascorbic Acid	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3568060-8Report Type:Periodic Company Report #WAES 00021858
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

25

MG/DAILY/PO 3 WK

Zestoretic	C	
Estrogens Preparations [Composi]	C	

Date:06/22/00ISR Number: 3568061-XReport Type:Periodic Company Report #WAES 00031434
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Zocor	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3568062-1Report Type:Periodic Company Report #WAES 00021864
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

			Zantac	C
			Zoloft	C

Date:06/22/00ISR Number: 3568063-3Report Type:Periodic Company Report #WAES 00021867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective	Company Representative			Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568064-5Report Type:Periodic Company Report #WAES 00021890
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synvisc	C				
			Acetaminophen	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Triamterene	C				
			Levothyroxine Sodium	C				
			Propoxyphene	C				
			Tamoxifen	C				

Date:06/22/00ISR Number: 3568065-7Report Type:Periodic Company Report #WAES 00021905
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Nausea Merck Co Inc ORAL
25
Rhinorrhoea
MG/DAILY/PO
Skin Disorder Miacalcin C
Verapamil C

Date:06/22/00ISR Number: 3568066-9Report Type:Periodic Company Report #WAES 00031435
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Eye Disorder							
	Eye Irritation				Merck Co Inc	ORAL	PO; 25	MG/DAILY/PO
			Os [Composition Unspecified] Unk	SS				

Date:06/22/00ISR Number: 3568067-0Report Type:Periodic Company Report #WAES 00031437
Age:73 YR Gender:Female I/FU:I

Outcome PT
Arthralgia
Facial Pain

Headache

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3568068-2Report Type:Periodic Company Report #WAES 00031445
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Mental Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3568069-4Report Type:Periodic Company Report #WAES 00031447
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspnoea Haemoglobin Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			K-Dur	C				
			Lanoxin	C				
			Norvasc	C				
			Ocupress	C				
			Xalatan	C				
			Doxepin	C				

			Gemfibrozil	C		
			Propoxyphene	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3568070-0Report Type:Periodic Company Report #WAES 00031448
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dyspepsia							
	Flatulence							
			Lipitor	C				
			Sular	C				
			Timolol Hydrogen Maleate Salt	C				

Date:06/22/00ISR Number: 3568073-6Report Type:Periodic Company Report #WAES 00031461
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Oedema	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568074-8Report Type:Periodic Company Report #WAES 00031482
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Prothrombin Time Prolonged		Coumadin Tylenol Voltaren	C C C				

Date:06/22/00ISR Number: 3568076-1Report Type:Periodic Company Report #WAES 00031483
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568078-5Report Type:Periodic Company Report #WAES 00031488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3568081-5Report Type:Periodic Company Report #WAES 00031500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568082-7Report Type:Periodic Company Report #WAES 00031503
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568083-9Report Type:Periodic Company Report #WAES 00031504
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, DAILY, PO	
			Lipitor	C				
			Prevacid	C				
			Zoloft	C				
			Triazolam	C				

Date:06/22/00ISR Number: 3568085-2Report Type:Periodic Company Report #WAES 00031507
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Cardizem Cd	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3568086-4Report Type:Periodic Company Report #WAES 00031517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568087-6Report Type:Periodic Company Report #WAES 00031518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gingival Bleeding Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568088-8Report Type:Periodic Company Report #WAES 00031526
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3568089-XReport Type:Periodic Company Report #WAES 00031527
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	

PO

			Claritin	C		
			Cough, Cold And Flu Therapies	C		

Date:06/22/00ISR Number: 3568090-6Report Type:Periodic Company Report #WAES 00031529
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, BID,	
PO								
			Zyrtec	C				

Date:06/22/00ISR Number: 3568091-8Report Type:Periodic Company Report #WAES 00031533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Axid	C				
			Lozol	C				
			Norvasc	C				
			Prinivil	C				
			Tenormin	C				
			Xanax	C				

Date:06/22/00ISR Number: 3568092-XReport Type:Periodic Company Report #WAES 00031547
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Lotrel	C		

Date:06/22/00ISR Number: 3568093-1Report Type:Periodic Company Report #WAES 00031552
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Prilosec	C		
			Xanax	C		
			Zoloft	C		
			Therapy Unspecified	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3568094-3Report Type:Periodic Company Report #WAES 00031555
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25 MG, DAILY,

PO
Cortisone C

Date:06/22/00ISR Number: 3568095-5Report Type:Periodic Company Report #WAES 00031556
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							

Date:06/22/00ISR Number: 3568096-7Report Type:Periodic Company Report #WAES 00031557
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	
			Celebrex	C			PO	
			Claritin	C				
			Estratab	C				
			Lotrel	C				
			Paxil	C				
			Plaquenil	C				
			Prilosec	C				
			Quinine	C				

Date:06/22/00ISR Number: 3568097-9Report Type:Periodic Company Report #WAES 00031562
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Vioxx	PS	Merck Research			

	Weight Increased	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3568098-0Report Type:Periodic Company Report #WAES 00031565
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3568099-2Report Type:Periodic Company Report #WAES 00031594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568100-6Report Type:Periodic Company Report #WAES 00031622
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568101-8Report Type:Periodic Company Report #WAES 00031630
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Claritin-D	C				
			Intal	C				
			Pulmicort	C				
			Rhinocort	C				
			Serevent	C				
			Venetlin	C				

Date:06/22/00ISR Number: 3568107-9Report Type:Periodic Company Report #WAES 00022476
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Natures Rx Msm Plus C	C				
			Zocor	C				
			Folic Acid	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3568108-0Report Type:Periodic Company Report #WAES 00022479
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
	Muscle Spasms							
			Coumadin	C				
			Empirin	C				
			K-Dur	C				
			Tylenol	C				
			Furosemide	C				

Date:06/22/00ISR Number: 3568109-2Report Type:Periodic Company Report #WAES 00022484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Keratoconjunctivitis							
	Sicca							
			Altace	C				

				Timoptic	C		

Date:06/22/00ISR Number: 3568110-9Report Type:Periodic Company Report #WAES 00022490
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Vioxx	PS	Merck Research			
	Visual Disturbance	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Calcium Supplement					
			(Composition	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3568111-0Report Type:Periodic Company Report #WAES 00022493
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Asthenia				Laboratories Div			
	Back Pain				Merck Co Inc	ORAL	12.5 MG/	
	Dyspepsia						DAILY/PO	
	Fatigue		Chlorazepate	C				
	Influenza		Darvocet-N	C				
			Butalbital	C				

Date:06/22/00ISR Number: 3568112-2Report Type:Periodic Company Report #WAES 00022504
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Chest Pain				Laboratories Div			
	Dyspnoea				Merck Co Inc	ORAL	PO	
	Vaginal Discharge		Claritin	C				
	Vaginal Haemorrhage		Darvocet-N	C				

Ortho Tri-Cyclen C

Date:06/22/00ISR Number: 3568113-4Report Type:Periodic Company Report #WAES 00022510
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568114-6Report Type:Periodic Company Report #WAES 00022511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568115-8Report Type:Periodic Company Report #WAES 00022520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3568116-XReport Type:Periodic Company Report #WAES 00022542
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568117-1Report Type:Periodic Company Report #WAES 00022562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

Date:06/22/00ISR Number: 3568118-3Report Type:Periodic Company Report #WAES 00022565
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Prilosec	C
			Aspirin	C

Date:06/22/00ISR Number: 3568119-5Report Type:Periodic Company Report #WAES 00022569
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Erythematous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

			Lipitor	C
			Premarin	C
			Tylenol With Codeine #3	C
			Zoloft	C
			Atenolol	C

Date:06/22/00ISR Number: 3568120-1Report Type:Periodic Company Report #WAES 00022575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bleeding Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3568121-3Report Type:Periodic Company Report #WAES 00022584
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
	Visual Disturbance							
			Estrace	C				
			Hydrodiuril	C				
			Progesterone	C				
			Thyroid	C				

Date:06/22/00ISR Number: 3568122-5Report Type:Periodic Company Report #WAES 00022588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568123-7Report Type:Periodic Company Report #WAES 00022592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568124-9Report Type:Periodic Company Report #WAES 00022594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568125-0Report Type:Periodic Company Report #WAES 00030002
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3568126-2Report Type:Periodic Company Report #WAES 00030003
Age:81 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Constipation

	Fatigue						
	Muscle Rigidity						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat	C				
			Aricept	C				
			Fosamax	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3568127-4Report Type:Periodic Company Report #WAES 00022161
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	AM/PO	
			Claritin	C				
			Neurontin	C				
			Premarin	C				
			Prevacid	C				
			Synthroid	C				
			Ultram	C				

Date:06/22/00ISR Number: 3568128-6Report Type:Periodic Company Report #WAES 00022163
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;	25
	Eyelid Oedema							
	Oedema Peripheral							

MG/DAILY/ORAL

Cardura	C
Glucotrol Xl	C
Lipitor	C
Nitro-Dur	C
Prevacid	C

Date:06/22/00ISR Number: 3568129-8Report Type:Periodic Company Report #WAES 00022181
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Irritability Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/ORAL

Date:06/22/00ISR Number: 3568130-4Report Type:Periodic Company Report #WAES 00022186
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia Hypertriglyceridaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:06/22/00ISR Number: 3568131-6Report Type:Periodic Company Report #WAES 00022189
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568132-8Report Type:Periodic Company Report #WAES 00022199
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Stiffness Muscle Rigidity Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3568133-XReport Type:Periodic Company Report #WAES 00022200
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568134-1Report Type:Periodic Company Report #WAES 00022204
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health	Vioxx	PS	Merck Research			

	Nasopharyngeal Disorder	Professional			Laboratories Div	
	Oedema				Merck Co Inc	ORAL
DAILY/PO						
			Combivent	C		
			Entex	C		
			Flonase	C		
			Proctofoam	C		
			Robitussin-Dm	C		
			Signulair	C		

Date:06/22/00ISR Number: 3568135-3Report Type:Periodic Company Report #WAES 00022207
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
12.5MG/DAILY/						
PO;25MG/DAILY						
/PO						
			Cardizem Cd	C		
			Diovan	C		
			Miacalcin	C		
			Prinivil	C		
			Methadone Hydrochloride	C		
			Potassium Supplement			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Composition) C

Date:06/22/00ISR Number: 3568136-5Report Type:Periodic Company Report #WAES 00022208
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Eye Discharge							
	Nausea							

Date:06/22/00ISR Number: 3568137-7Report Type:Periodic Company Report #WAES 00022209
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Detrol	C				
			Levothroid	C				
			Zocor	C				
			Atenolol	C				
			Furosemide	C				

Date:06/22/00ISR Number: 3568138-9Report Type:Periodic Company Report #WAES 00022215
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568139-0Report Type:Periodic Company Report #WAES 00022222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:06/22/00ISR Number: 3568140-7Report Type:Periodic Company Report #WAES 00022225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia Vascular Injury	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568141-9Report Type:Periodic Company Report #WAES 00022226
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Renal Impairment	Company			Merck Co Inc	ORAL	PO	
		Representative	Demadex	C				

Date:06/22/00ISR Number: 3568142-0Report Type:Periodic Company Report #WAES 00022227
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Vertigo							
	White Blood Cell Count Decreased				Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Valium	C				
			Therapy Unspecified	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3568143-2Report Type:Periodic Company Report #WAES 00022230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Palsy	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hypoaesthesia							
					Merck Co Inc	ORAL	12.5MG/BID/PO	
			Vancenase	C				
			Antimicrobial Therapy (Composition)	C				

Date:06/22/00ISR Number: 3568144-4Report Type:Periodic Company Report #WAES 00022235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
	Dizziness							
	Feeling Abnormal							
	Feeling Hot		Hydordiuril	C				
	Palpitations		Premarin	C				
	Weight Increased		Synthroid	C				
			Ascorbic Acid	C				
			Atenolol	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3568145-6Report Type:Periodic Company Report #WAES 00022236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine #3	C				

			Ultram	C		

Date:06/22/00ISR Number: 3568146-8Report Type:Periodic Company Report #WAES 00022238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Clorazepic Acid Dipotassium Salt	C				
			Dicyclomine Hydrochloride	C				

Date:06/22/00ISR Number: 3568148-1Report Type:Periodic Company Report #WAES 00030007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568150-XReport Type:Periodic Company Report #WAES 00030009
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3568152-3Report Type:Periodic Company Report #WAES 00030011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568153-5Report Type:Periodic Company Report #WAES 00030012
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	2 WK
			Diovan	C				
			Halcion	C				
			Norvasc	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568154-7Report Type:Periodic Company Report #WAES 00030018
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Vioxx	PS	Merck Research			
	Fluid Retention	Professional			Laboratories Div			
	Oedema Peripheral				Merck Co Inc	ORAL	25	
	Weight Increased						MG/DAILY/PO	
			Atenolol	C				

Date:06/22/00ISR Number: 3568155-9Report Type:Periodic Company Report #WAES 00030019
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Neurontin	C				
			Oxycontin	C				
			Ritalin	C				
			Selexid (Amdinocillin Pivoxil)	C				
			Xanax	C				
			Zanaflex	C				

Date:06/22/00ISR Number: 3568156-0Report Type:Periodic Company Report #WAES 00030026
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research			
	Pain				Laboratories Div			
					Merck Co Inc	ORAL	PO	

				Tab Vioxx 12.5 Mg	SS		ORAL
PO							
				Celebrex	C		
				Valium	C		
				Vicodin Tablets	C		

Date:06/22/00ISR Number: 3568157-2Report Type:Periodic Company Report #WAES 00030035
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3568158-4Report Type:Periodic Company Report #WAES 00030037
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Diarrhoea Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypertrophy Breast		Advil	C				

				Zantac	C		

Date:06/22/00ISR Number: 3568159-6Report Type:Periodic Company Report #WAES 00030039
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Alphagan	C				
			Betagan	C				
			Glyburide	C				

Date:06/22/00ISR Number: 3568160-2Report Type:Periodic Company Report #WAES 00030041
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryl	C				
			Lotensin	C				
			Norvasc	C				
			Prozac	C				
			Singulair	C				
			Ultram	C				
			Ventolin	C				
			Furosemide	C				
			Theophylline	C				

Date:06/22/00ISR Number: 3568161-4Report Type:Periodic Company Report #WAES 00030045
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Acepress	C				
			Avapro	C				
			Lasix	C				
			Levbid	C				
			Norvasc	C				
			Prozac	C				
			Trandate	C				
			(Therapy Inspecified)	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568162-6Report Type:Periodic Company Report #WAES 00030047
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache							
	Nausea							

Date:06/22/00ISR Number: 3568163-8Report Type:Periodic Company Report #WAES 00030054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Therapy Unspecified)	C				
			Codeine	C				

Date:06/22/00ISR Number: 3568164-XReport Type:Periodic Company Report #WAES 00030056
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Pepcid	C				
			Premarin	C				
			Xanax	C				
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3568165-1Report Type:Periodic Company Report #WAES 00030058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Eye Pain Eyelid Oedema Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Pruritus		Lasix	C				
			(Therapy Unspecified)	C				
			Calcium Cupplement (Composition	C				

Date:06/22/00ISR Number: 3568166-3Report Type:Periodic Company Report #WAES 00030060
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568167-5Report Type:Periodic Company Report #WAES 00030063
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Axid	C				
			Cholestin	C				
			Citrucel Orange Flavor	C				
			Compazine	C				
			Flexeril	C				
			Librax Capsules	C				
			Prilosec	C				
			Propulsid	C				
			Viokase	C				
			[Composition Unspecified]	C				

Date:06/22/00ISR Number: 3568168-7Report Type:Periodic Company Report #WAES 00030065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Corticosteroids (Composition	C				

Date:06/22/00ISR Number: 3568169-9Report Type:Periodic Company Report #WAES 00030069
Age:83 YR Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568284-XReport Type:Periodic Company Report #WAES 00031098
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3568285-1Report Type:Periodic Company Report #WAES 00031101
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Lanoxin	C				
			Pravachol	C				

Vasotec C

Date:06/22/00ISR Number: 3568286-3Report Type:Periodic Company Report #WAES 00031104
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Cardura	C				
			Diovan	C				
			Lasix	C				
			Zebeta	C				

Date:06/22/00ISR Number: 3568287-5Report Type:Periodic Company Report #WAES 00031108
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY / PO	
			Prevacid	C				
			Pulmicort	C				
			Serevent	C				
			Singulair	C				

Date:06/22/00ISR Number: 3568288-7Report Type:Periodic Company Report #WAES 00031111
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Coumadin C
Lenoxin C

Date:06/22/00ISR Number: 3568548-XReport Type:Periodic Company Report #WAES 00022240
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568560-0Report Type:Periodic Company Report #WAES 00022271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	ORAL	
			Nasacort	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3568565-XReport Type:Periodic Company Report #WAES 00022282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568568-5Report Type:Periodic Company Report #WAES 00022296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3568570-3Report Type:Periodic Company Report #WAES 00022298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tachycardia		Celebrex	C				

Date:06/22/00ISR Number: 3568575-2Report Type:Periodic Company Report #WAES 00022316
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dilantin	C				

			Premarin	C		
			Prilosec	C		

Date:06/22/00ISR Number: 3568578-8Report Type:Periodic Company Report #WAES 00022318
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3568595-8Report Type:Periodic Company Report #WAES 00022323
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Glucotrol Xl	C				
			Tylex (Acetaminophen					

(+) Codeine C

Date:06/22/00ISR Number: 3568599-5Report Type:Periodic Company Report #WAES 00022324
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prevacid	C				
			Furosemide	C				
			Potassium Supplement (Compositio	C				

Date:06/22/00ISR Number: 3568602-2Report Type:Periodic Company Report #WAES 00022325
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Flatulence							
	Gastrooesophageal Reflux Disease							
	Malaise							

Date:06/22/00ISR Number: 3568606-XReport Type:Periodic Company Report #WAES 00022326
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Fatigue							
	Musculoskeletal Pain							
	Nausea		Lipitor	C				

	Polymyalgia Rheumatica		Pepcid	C
			Vitamins	C

Date:06/22/00ISR Number: 3568610-1Report Type:Periodic Company Report #WAES 00022335
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Labetalol	C				
			Potassium Chloride	C				

Date:06/22/00ISR Number: 3568613-7Report Type:Periodic Company Report #WAES 00022336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy					

			Unspecified]	C		
			Potassium Supplement (Compositio	C		

Date:06/22/00ISR Number: 3568617-4Report Type:Periodic Company Report #WAES 00022344
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dyspnoea							
	Oedema Peripheral							
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3569360-8Report Type:Periodic Company Report #WAES 00022345
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Blood Pressure Decreased							
	Chest Pain							
	Diarrhoea		Allegra	C				
	Nausea		Azmacort	C				
			Flovent	C				
			Pepcid	C				
			Albuterol	C				
			Allergenic Extract	C				

Date:06/22/00ISR Number: 3569362-1Report Type:Periodic Company Report #WAES 00022346
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Health Professional | Laboratories Div Merck Co Inc | ORAL
25

MG/DAILY/PO

Soma | C

Date:06/22/00ISR Number: 3569367-0Report Type:Periodic Company Report #WAES 00022349
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:06/22/00ISR Number: 3569370-0Report Type:Periodic Company Report #WAES 00022350
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Paxil	C				

		Premarin	C
		Zestril	C
		[Therapy Unspecified]	C
		Clonidine	C

Date:06/22/00ISR Number: 3569373-6Report Type:Periodic Company Report #WAES 00022352
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Citrucel Orange Flavor	C				
			Fosamax	C				

Date:06/22/00ISR Number: 3569376-1Report Type:Periodic Company Report #WAES 00022366
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3569379-7Report Type:Periodic Company Report #WAES 00022378
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3569383-9Report Type:Periodic Company Report #WAES 00022380
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia Low Density Lipoprotein Increased	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3569388-8Report Type:Periodic Company Report #WAES 00022381
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3569391-8Report Type:Periodic Company Report #WAES 00022384
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3569394-3Report Type:Periodic Company Report #WAES 00022393
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Vosetec	C				
			Potassium Chloride	C				

Date:06/22/00ISR Number: 3569399-2Report Type:Periodic Company Report #WAES 00022401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3569403-1Report Type:Periodic Company Report #WAES 00022403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Eye Infection					

PO 5 DAY

Date:06/22/00ISR Number: 3569405-5Report Type:Periodic Company Report #WAES 00022428
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
UNK/UNK/PO

Date:06/22/00ISR Number: 3569406-7Report Type:Periodic Company Report #WAES 00022436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MD/UNKJ/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3569408-0Report Type:Periodic Company Report #WAES 00022438
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:06/22/00ISR Number: 3569410-9Report Type:Periodic Company Report #WAES 00022445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3569412-2Report Type:Periodic Company Report #WAES 00022447
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Vaginal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3569414-6Report Type:Periodic Company Report #WAES 00022451
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO
Therapy Unspecified C

Date:06/22/00ISR Number: 3569416-XReport Type:Periodic Company Report #WAES 00022458
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Erythema							
	Fatigue							
	Gastrointestinal Haemorrhage							
	Headache							
	Oedema Peripheral							

Date:06/22/00ISR Number: 3569418-3Report Type:Periodic Company Report #WAES 00022464
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Nervousness							
			Cardura	C				

K-Dur	C
Lasix	C
Norvasc	C
Oramorph	C
Pepcid	C
Tenormin	C
Xenical	C
Docor	C
Aspirin	C

Date:06/22/00ISR Number: 3569420-1Report Type:Periodic Company Report #WAES 00022465
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Vitamins	C				

Date:06/22/00ISR Number: 3569422-5Report Type:Periodic Company Report #WAES 00022468
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain Eating Disorder Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIL/PO	
	Feeling Abnormal Lymphadenopathy Muscular Weakness Oral Mucosal Discolouration Pharyngitis Tongue Oedema		Zocor	C				

Date:06/22/00ISR Number: 3569423-7Report Type:Periodic Company Report #WAES 00022470
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tagamet	C				
			Ascorbic Acid	C				

Date:06/22/00ISR Number: 3569425-0Report Type:Periodic Company Report #WAES 00022473
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Zantac	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Triamter	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3569427-4Report Type:Periodic Company Report #WAES 00022475
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Flatulence							
	Muscle Spasms							
	Pain		Cedur	C				
	Weight Decreased		Imdur	C				
			Zaroxolyn	C				

Date:06/22/00ISR Number: 3573943-9Report Type:Periodic Company Report #WAES00031254
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	
	Toothache							
			Lipitor	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3573946-4Report Type:Periodic Company Report #WAES00031258
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							

Date:06/22/00ISR Number: 3573948-8Report Type:Periodic Company Report #WAES00031260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3573951-8Report Type:Periodic Company Report #WAES00031263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3573953-1Report Type:Periodic Company Report #WAES00031264
Age:74 YR Gender:Female I/FU:I

Outcome	PT
	Chest Pain
	Flatulence
	Gastrooesophageal Reflux Disease

	Myalgia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pravachol	C				
			Prilosec	C				
			Tylenol	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3573956-7Report Type:Periodic Company Report #WAES00031265
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	
	Chest Pain							
	Swelling							
	Weight Increased							
			Prilosec	C				

Date:06/22/00ISR Number: 3573957-9Report Type:Periodic Company Report #WAES00031266
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dermatitis							
	Dizziness							
	Dysgeusia		Demerol	C				
	Nausea		Tylenol	C				
			Xanax	C				

Date:06/22/00ISR Number: 3573959-2Report Type:Periodic Company Report #WAES00031268
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dyspepsia Headache Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	
			[C0mposition Unspecified]	C				

Date:06/22/00ISR Number: 3573961-0Report Type:Periodic Company Report #WAES00031272
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3573963-4Report Type:Periodic Company Report #WAES00031273
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3573965-8Report Type:Periodic Company Report #WAES00031275
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	PO

Date:06/22/00ISR Number: 3573967-1Report Type:Periodic Company Report #WAES00031277
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	PO
			Lipitor	C				
			Lopid	C				
			Ternormin	C				

Date:06/22/00ISR Number: 3573969-5Report Type:Periodic Company Report #WAES00031279
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	
			Celebrex	C				
			Prempo	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3573971-3Report Type:Periodic Company Report #WAES00031280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3573973-7Report Type:Periodic Company Report #WAES00031286
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Lipitor C
Premarin C
Synthroid C

Date:06/22/00ISR Number: 3573974-9Report Type:Periodic Company Report #WAES00031293
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection							
			Synthroid	C				

Date:06/22/00ISR Number: 3573994-4Report Type:Periodic Company Report #WAES00031294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Feeling Abnormal							
	Hyperaesthesia							
	Muscle Spasms							
	Paraesthesia							

Date:06/22/00ISR Number: 3573996-8Report Type:Periodic Company Report #WAES00031295
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	
			Hydrodiuril	C			PO	

Date:06/22/00ISR Number: 3573997-XReport Type:Periodic Company Report #WAES00031297
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/ DAILY/ PO	
	Dizziness							
	Drug Ineffective							
	Fatigue							
	Malaise		Norvasc	C				
	Myocardial Infarction							

Date:06/22/00ISR Number: 3573999-3Report Type:Periodic Company Report #WAES 00031307
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
	Flushing							
	Lung Disorder							
			Soma	C				
			Estrogenic Preparation	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574001-XReport Type:Periodic Company Report #WAES 00031309
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Vicodin Tablets	C				
			Quinine	C				

Date:06/22/00ISR Number: 3574002-1Report Type:Periodic Company Report #WAES 00031310
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3574003-3Report Type:Periodic Company Report #WAES 00031311
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Temazepam	C				

Date:06/22/00ISR Number: 3574005-7Report Type:Periodic Company Report #WAES 00031313
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/DAILY/PO 1 WK

Date:06/22/00ISR Number: 3574006-9Report Type:Periodic Company Report #WAES 00031315
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Darvocet-N	C				
			Lanoxin	C				

Date:06/22/00ISR Number: 3574008-2Report Type:Periodic Company Report #WAES 00031317
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574009-4Report Type:Periodic Company Report #WAES 00031319
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				

Date:06/22/00ISR Number: 3574010-0Report Type:Periodic Company Report #WAES 00031320
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vasotec	C				

Date:06/22/00ISR Number: 3574012-4Report Type:Periodic Company Report #WAES 00031324
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nasal Congestion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574013-6Report Type:Periodic Company Report #WAES 00031326
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL 12.5MG/BID/PO

Date:06/22/00ISR Number: 3574015-XReport Type:Periodic Company Report #WAES 00031338
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cap Tylenol Extra Strength	SS		ORAL	1000MG/Q6H/PO	
			Lipitor	SS		ORAL	PO	
			Inderal	C				
			Lasix	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3574016-1Report Type:Periodic Company Report #WAES 00031340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3574017-3Report Type:Periodic Company Report #WAES 00031348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Lortab	C				

Date:06/22/00ISR Number: 3574019-7Report Type:Periodic Company Report #WAES 00031349
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation Dyspepsia Hyperchlorhydria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3574020-3Report Type:Periodic Company Report #WAES 00031367
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Prempro	C				
			Synthroid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3574021-5Report Type:Periodic Company Report #WAES 00031368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3574023-9Report Type:Periodic Company Report #WAES 00031369
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574024-0Report Type:Periodic Company Report #WAES 00031370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574025-2Report Type:Periodic Company Report #WAES 00031379
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Elavil	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3574027-6Report Type:Periodic Company Report #WAES 00031381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dysgeusia Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Respiratory Disorder		Biaxin	C				
			Erythromycin	C				

Date:06/22/00ISR Number: 3574030-6Report Type:Periodic Company Report #WAES 00031637
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Cardizem	C				
			Dilantin	C				

Date:06/22/00ISR Number: 3574032-XReport Type:Periodic Company Report #WAES 00031638
Age:58 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3574034-3Report Type:Periodic Company Report #WAES 00031645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Fatigue					
	Gait Disturbance					
	Muscular Weakness					
	Pruritus					
	Skin Warm					

Dose Duration

PO

Date:06/22/00ISR Number: 3574036-7Report Type:Periodic Company Report #WAES 00031650
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dyspnoea	Health Professional				

Dose Duration

12.5MG/DAILY/

PO

			Advil	C		
			Fosamax	C		
			Restoril	C		
			Therapy Unspecified	C		

Date:06/22/00ISR Number: 3574038-0Report Type:Periodic Company Report #WAES 00031651
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Oedema Peripheral					
12.5MG/BID/PO						
			Tenormin	C		
			Verapamil	C		
			Zestril	C		
			Lorazepam	C		

Date:06/22/00ISR Number: 3574041-0Report Type:Periodic Company Report #WAES 00031652
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Celexa	C		
			Effexor	C		
			Enbrel	C		
			Maxzide	C		
			Plaquenil	C		
			Prozac	C		
			Wellbutrin	C		
			Folic Acid	C		
			Methotrexate	C		
			Prednisone	C		

Date:06/22/00ISR Number: 3574042-2Report Type:Periodic Company Report #WAES 00031658
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG/BID/PO ; 12.5MG/TID/PO						
			Darvocet N	C		
			Sinemet	C		
			Somadril	C		
			Zoloft	C		

Date:06/22/00ISR Number: 3574044-6Report Type:Periodic Company Report #WAES 00031661
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased Inadequate Analgesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						

Celebrex	C
Evista	C
Lasix	C
Zocor	C
Aspirin	C
Medroxyprogesterone	C
Potassium Supplement	C

Date:06/22/00ISR Number: 3574047-1Report Type:Periodic Company Report #WAES 00031662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3574049-5Report Type:Periodic Company Report #WAES 00031666
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Face Oedema							
	Pharyngeal Oedema							
	Tongue Oedema		Zestril	C				

Date:06/22/00ISR Number: 3574052-5Report Type:Periodic Company Report #WAES 00031671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Abdominal Pain							
	Flatulence							
			Glucotrol	C				

Prevacid	C		
Diltiazem	C		

Date:06/22/00ISR Number: 3574053-7Report Type:Periodic Company Report #WAES 00031675
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574056-2Report Type:Periodic Company Report #WAES 00031681
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574058-6Report Type:Periodic Company Report #WAES 00031683
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574059-8Report Type:Periodic Company Report #WAES 00031685
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/	
	Dyspnoea							
	Fatigue							
	Feeling Abnormal							
	Hepatic Cyst		Axid	C			PO	
			Miacalcin	C				
			Valium	C				
			Zestril	C				
			Digoxin	C				
			Metoprolol	C				

Date:06/22/00ISR Number: 3574062-8Report Type:Periodic Company Report #WAES 00031688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Glucotrol	C				
			Microzide	C				

Date:06/22/00ISR Number: 3574063-XReport Type:Periodic Company Report #WAES 00031690
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Baycol	C				

Date:06/22/00ISR Number: 3574065-3Report Type:Periodic Company Report #WAES 00031694
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Miacalcin	C				
			Tenormin	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574068-9Report Type:Periodic Company Report #WAES 00031695
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Novadox	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3574069-0Report Type:Periodic Company Report #WAES 00031706
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Covera-Hs	C				

Date:06/22/00ISR Number: 3574073-2Report Type:Periodic Company Report #WAES 00032653
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Influenza Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Premarin	C				
			Questran	C				
			Ultram	C				
			Zantac	C				
			Hydrochlorothiazide (+) Triamter	C				
			Propranolol	C				
			Quinine Sulfate	C				

Date:06/22/00ISR Number: 3574076-8Report Type:Periodic Company Report #WAES 00032655
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Diovan	C				
			Glucotrol	C				
			Neurontin	C				
			Norvasc	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3574078-1Report Type:Periodic Company Report #WAES 00032656
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574080-XReport Type:Periodic Company Report #WAES 00032657
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574087-2Report Type:Periodic Company Report #WAES 00032660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574088-4Report Type:Periodic Company Report #WAES 00032661
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3574089-6Report Type:Periodic Company Report #WAES 00032668
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Coeliac Disease Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

			Vioxx	SS		ORAL

12.5

MG/BID/PO

			Allegra	C		
			(Therapy Unspecified)	C		

Date:06/22/00ISR Number: 3574091-4Report Type:Periodic Company Report #WAES 00032674
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis Drug Ineffective Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

Pharyngitis

MG/DAILY/PO

			Nyquil	SS		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574092-6Report Type:Periodic Company Report #WAES 00032681
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Celebrex	C				
			Tylenol	C				
			Therapy Unspecified	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3574093-8Report Type:Periodic Company Report #WAES 00032682
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 DAY
	Feeling Abnormal							
	Gastrointestinal Disorder							
	Headache							

Date:06/22/00ISR Number: 3574095-1Report Type:Periodic Company Report #WAES 00032684
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:06/22/00ISR Number: 3574096-3Report Type:Periodic Company Report #WAES 00032685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diabeta	C				
			Glucophage	C				
			Prilosec	C				
			Procardia	C				
			Vasotec	C				
			Aspirin	C				
			Furosemide	C				
			Hypericin	C				

Date:06/22/00ISR Number: 3574098-7Report Type:Periodic Company Report #WAES 00032687
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574099-9Report Type:Periodic Company Report #WAES 00032690
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574100-2Report Type:Periodic Company Report #WAES 00032691
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Plavix	C				
			Premarin	C				
			Tenormin	C				
			Univasc	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3574102-6Report Type:Periodic Company Report #WAES 00032692
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortef	C				
			Ogen	C				
			Nystatin	C				

Date:06/22/00ISR Number: 3574104-XReport Type:Periodic Company Report #WAES 00032693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Swelling							
	Weight Increased							
			Evista	C				

Date:06/22/00ISR Number: 3574105-1Report Type:Periodic Company Report #WAES 00032695
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
	Dyspnoea							
			Imdur	C				
			Toprol Xl Tablets	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574107-5Report Type:Periodic Company Report #WAES 00032696
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Pepcid	C				
			Robaxin	C				

Date:06/22/00ISR Number: 3574108-7Report Type:Periodic Company Report #WAES 00032697
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ecotrin	C				
			Tenormin	C				
			Valium	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3574110-5Report Type:Periodic Company Report #WAES 00031723
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574112-9Report Type:Periodic Company Report #WAES 00031724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574113-0Report Type:Periodic Company Report #WAES 00031725
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY

Date:06/22/00ISR Number: 3574114-2Report Type:Periodic Company Report #WAES 00031726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Verelan	C		

Date:06/22/00ISR Number: 3574116-6Report Type:Periodic Company Report #WAES 00031763
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
	Dermatitis							
	Headache							
			Composition Unspecified	SS				
			Chlor-Trimeton	C				
			Maalox	C				

Date:06/22/00ISR Number: 3574140-3Report Type:Periodic Company Report #WAES 00031772
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Joint Stiffness							
	Muscle Rigidity							
	Vision Blurred		Claritin	C				
			Dilacor Xr	C				
			Nasonex	C				
			Estrogenic Preparartions	C				

Date:06/22/00ISR Number: 3574142-7Report Type:Periodic Company Report #WAES 00031774
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Abdominal Pain							

Drug Ineffective Merck Co Inc ORAL
12.5 MG BID
Malaise
PO
Nausea Estrace C
Provera C

Date:06/22/00ISR Number: 3574143-9Report Type:Periodic Company Report #WAES 00031778
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY /PO, 25 MG DAILY/PO	
			Alesse	C				
			Provera	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574145-2Report Type:Periodic Company Report #WAES 00031779
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Headache Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Darvocet-N [Composition Unspecified]	C C				

Date:06/22/00ISR Number: 3574147-6Report Type:Periodic Company Report #WAES 00031788
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3574149-XReport Type:Periodic Company Report #WAES 00031790
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574151-8Report Type:Periodic Company Report #WAES 00031791
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Synthroid	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3574152-XReport Type:Periodic Company Report #WAES 00031792
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Consumer	Vioxx	PS	Merck Research	
	Headache				Laboratories Div	
	Hypertension				Merck Co Inc	ORAL
PO						
	Insomnia		Flovent	C		
	Nausea		Plaquenil	C		
	Oedema Peripheral		Premarin	C		
	Weight Increased		Aspirin	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3574153-1Report Type:Periodic Company Report #WAES 00031810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3574154-3Report Type:Periodic Company Report #WAES 00031818
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574155-5Report Type:Periodic Company Report #WAES 00031820
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3574156-7Report Type:Periodic Company Report #WAES 00031822
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Constipation Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574157-9Report Type:Periodic Company Report #WAES 00031824
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Prostatic Specific Antigen Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY / PO						
			Flomax	C		
			Sumycin	C		
			Vitamin A	C		
			Therapy Unspecified	C		

Date:06/22/00ISR Number: 3574158-0Report Type:Periodic Company Report #WAES 00031860
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG / DAILY / PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574159-2Report Type:Periodic Company Report #WAES 00031866
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG / DAILY / PO	

Date:06/22/00ISR Number: 3574162-2Report Type:Periodic Company Report #WAES 00031960
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mevacor	C				
			Premarin	C				
			Prinivil	C				

Date:06/22/00ISR Number: 3574163-4Report Type:Periodic Company Report #WAES 00031966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ecotrin	C				
			Ultram	C				
			Vasotec	C				
			Atenolol	C				
			Furosemide	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3574165-8Report Type:Periodic Company Report #WAES 00031968
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Vitamins	C				

Date:06/22/00ISR Number: 3574167-1Report Type:Periodic Company Report #WAES 00031982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574169-5Report Type:Periodic Company Report #WAES 00031983
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3574170-1Report Type:Periodic Company Report #WAES 00031984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3574172-5Report Type:Periodic Company Report #WAES 00031986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574173-7Report Type:Periodic Company Report #WAES 00031992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Celebrex C

Date:06/22/00ISR Number: 3574174-9Report Type:Periodic Company Report #WAES 00031997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3574176-2Report Type:Periodic Company Report #WAES 00032003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3574178-6Report Type:Periodic Company Report #WAES 00032008
Age:44 YR Gender:Female I/FU:I

Outcome PT
Blister
Cellulitis

		Necrosis Pain In Extremity Skin Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PRN/PO							

Date:06/22/00ISR Number: 3574180-4Report Type:Periodic Company Report #WAES 00032011
Age:77 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							
			Company Representative	Premarin	C		
				Synthroid	C		
				Vasotec	C		

Date:06/22/00ISR Number: 3574181-6Report Type:Periodic Company Report #WAES 00032013
Age:41 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Haemorrhage Haemoptysis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							
			Company Representative				

Date:06/22/00ISR Number: 3574183-XReport Type:Periodic Company Report #WAES 00032014
Age:42 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dermatitis Urticaria	Consumer Company	Vioxx	PS	Merck Research Laboratories Div	

Representative Merck Co Inc ORAL
25

MG/DAILY/PO

Prevacid C
Zyrtec C

Date:06/22/00ISR Number: 3574185-3Report Type:Periodic Company Report #WAES 00032026
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Sensation Of Heaviness							
			Vitamins	C				

Date:06/22/00ISR Number: 3574186-5Report Type:Periodic Company Report #WAES 00032031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574188-9Report Type:Periodic Company Report #WAES 00032045
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Limb Deformity							
	Oedema Peripheral							
			Atrovent	C				
			Flonase	C				
			Prilosec	C				
			Albuterol	C				

Date:06/22/00ISR Number: 3574190-7Report Type:Periodic Company Report #WAES 00032060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3574191-9Report Type:Periodic Company Report # WAES 00032062
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Paraesthesia							
			Toprol Xl Tablets Unk	SS				

Date:06/22/00ISR Number: 3574193-2Report Type:Periodic Company Report #WAES 00032063
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Tongue Oedema Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:06/22/00ISR Number: 3574194-4Report Type:Periodic Company Report #WAES 00032066
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Norvasc	C				
			Tylenol With Codeine	C				

Date:06/22/00ISR Number: 3574196-8Report Type:Periodic Company Report #WAES 00032069
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK / UNK /

PO

Date:06/22/00ISR Number: 3574197-XReport Type:Periodic Company Report #WAES 00032070
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Vioxx	PS	Merck Research			
	Jaw Disorder	Professional			Laboratories Div			
	Joint Swelling				Merck Co Inc	ORAL	UNK / UNK /	
							PO	
			Inj Synvisc	SS			2 ML/WKY/INJ	
			Allegra-D	C				
			Clinoril	C				
			Excedrin	C				
			L-Thyroxine	C				
			Ocuhist	C				
			Zocor	C				
			Aspirin	C				
			Butalbital	C				
			Carisoprodol	C				
			Clonazepam	C				
			Fluoxetine	C				
			Fluticasone	C				
			Gabapentin	C				
			Lansoprazole	C				
			Promethazine	C				
			Propranolol	C				
			Tramadol	C				
			Trazodone	C				

Date:06/22/00ISR Number: 3574199-3Report Type:Periodic Company Report #WAES 00032071
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrapyramidal Disorder	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			

Merck Co Inc ORAL
UNK / UNK /

PO

Date:06/22/00ISR Number: 3574200-7Report Type:Periodic Company Report #WAES 00032072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Prilosec	C			PO	

Date:06/22/00ISR Number: 3574201-9Report Type:Periodic Company Report #WAES 00032087
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	

			Hyzaar	C
			Synthroid	C
			Tylenol	C
			Tamoxifen	C

Date:06/22/00ISR Number: 3574203-2Report Type:Periodic Company Report #WAES 00032091
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
	Fluid Retention							
	Muscular Weakness							
			Aterax	C				
			Normodyne	C				
			Tagamet	C				
			Xanax	C				

Date:06/22/00ISR Number: 3574204-4Report Type:Periodic Company Report #WAES 00032099
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 DAY
			Norvasc	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3574206-8Report Type:Periodic Company Report #WAES 00032100
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	

Representative
PO

Date:06/22/00ISR Number: 3574207-XReport Type:Periodic Company Report #WAES 00032102
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/ DAILY/ PO						
			Prednisone	SS		ORAL
20 MG / DAILY / PO						
			Ceftin	C		
			Oxycontin	C		
			Percocet	C		
			Serevent	C		
			Albuterol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574209-3Report Type:Periodic Company Report #WAES 00032104
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Microzide	C				

Date:06/22/00ISR Number: 3574210-XReport Type:Periodic Company Report #WAES 00032105
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Corgard	C				
			Zantac	C				

Date:06/22/00ISR Number: 3574212-3Report Type:Periodic Company Report #WAES 00032106
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Glucamide	C				
			Lasix	C				
			Vasotec	C				
			Insulin	C				

Date:06/22/00ISR Number: 3574213-5Report Type:Periodic Company Report #WAES 00032107
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / UNK / PO	
	Diarrhoea							
	Fatigue							
			Inderal	C				
			Valium	C				

Date:06/22/00ISR Number: 3574214-7Report Type:Periodic Company Report #WAES 00032115
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	
	Drug Ineffective							
	Mydriasis							
			Folic Acid	C				
			Hydroxychloroquine	C				
			Methotrexate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574215-9Report Type:Periodic Company Report #WAES 00032121
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	

Date:06/22/00ISR Number: 3574216-0Report Type:Periodic Company Report #WAES 00032124
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	5 DAY
			Zantac	C				

Date:06/22/00ISR Number: 3574217-2Report Type:Periodic Company Report #WAES 00032127
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/ PO	
			Cozaar	C				
			Feldene	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3574218-4Report Type:Periodic Company Report #WAES 00032128
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
	Fluid Retention							
	Pain In Extremity							
	Pruritus							
	Weight Increased		Ortho-Novum	C				
			Skelaxin	C				
			Hydrochlorothiazide	C				

Date:06/22/00ISR Number: 3574219-6Report Type:Periodic Company Report #WAES 00032133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574220-2Report Type:Periodic Company Report #WAES 00032137
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Headache							
	Visual Disturbance							
			Naprosyn	C				
			Therapy Unspecified	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3574221-4Report Type:Periodic Company Report #WAES 00032139
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Darvocet-N	C				
			[Therapy Unspecified]	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3574222-6Report Type:Periodic Company Report #WAES 00032140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Oedema Peripheral							
	Palpitations							

			Celebrex	C		

Date:06/22/00ISR Number: 3574224-XReport Type:Periodic Company Report #WAES 00032147
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Enbrel	SS				

Date:06/22/00ISR Number: 3574226-3Report Type:Periodic Company Report #WAES 00032165
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574227-5Report Type:Periodic Company Report #WAES 00032166
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dysuria Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/MA/PO	
	Jaundice Pollakiuria Urine Abnormality		Neurontin	C				

Date:06/22/00ISR Number: 3574228-7Report Type:Periodic Company Report #WAES 00032190
Age:63 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:06/22/00ISR Number: 3574229-9Report Type:Periodic Company Report #WAES 00031875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574230-5Report Type:Periodic Company Report #WAES 00031885
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3574231-7Report Type:Periodic Company Report #WAES 00031886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574232-9Report Type:Periodic Company Report #WAES 00031904
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis Ecchymosis Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	

Zocor	C	
Allpurinol	C	

Date:06/22/00ISR Number: 3574233-0Report Type:Periodic Company Report #WAES 00031910
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY / PO	

Date:06/22/00ISR Number: 3574234-2Report Type:Periodic Company Report #WAES 00031911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	

Date:06/22/00ISR Number: 3574235-4Report Type:Periodic Company Report #WAES 00031913
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Urinary Retention	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	2 WK
			Tab Vioxx	SS		ORAL	25 MG / DAILY	

/ PO

				Skelaxin	C		

Date:06/22/00ISR Number: 3574236-6Report Type:Periodic Company Report #WAES 00051808
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synvisc	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3574237-8Report Type:Periodic Company Report #WAES 00031914
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
	Back Pain							
	Chest Pain							
	Diarrhoea						PO	
	Dizziness		Tab Vioxx	SS		ORAL	UNK / UNK /	
	Flatulence						PO	
	Muscular Weakness		Neurotonin Capsules	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574238-XReport Type:Periodic Company Report #WAES 00051827
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Hyperhidrosis							
			Premarin	C				
			Prilosec	C				
			Zoloft	C				

Date:06/22/00ISR Number: 3574239-1Report Type:Periodic Company Report #WAES 00031915
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	UNK / UNK /
	Headache							
	Hyperhidrosis							
			Estrace	C				
			Pravachol	C				
			Provera	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3574240-8Report Type:Periodic Company Report #WAES 00051838
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
	Weight Increased							

Date:06/22/00ISR Number: 3574241-XReport Type:Periodic Company Report #WAES 00051999
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Percocet	C				

Date:06/22/00ISR Number: 3574242-1Report Type:Periodic Company Report #WAES 00052000
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Zestoretic	C				
			Estrogenic Preparations	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574243-3Report Type:Periodic Company Report #WAES 00032195
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. 5 MG/DAILY/PO	
			Claritin-D	C				
			Ogen	C				
			Prilosec	C				
			Synthroid	C				
			Tylenol	C				
			Amitriptyline	C				
			Metoclopramide	C				

Date:06/22/00ISR Number: 3574244-5Report Type:Periodic Company Report #WAES 00051840
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestril	C				

Date:06/22/00ISR Number: 3574245-7Report Type:Periodic Company Report #WAES 00032216
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

Date:06/22/00ISR Number: 3574246-9Report Type:Periodic Company Report #WAES 00032217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	
	Drug Interaction							
	Vaginal Haemorrhage							
			Prempro Therapy Unspecified	SS C				

Date:06/22/00ISR Number: 3574247-0Report Type:Periodic Company Report #WAES 00051841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	3 WK
	Upper Respiratory Tract Infection							
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574248-2Report Type:Periodic Company Report #WAES 00032232
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia Dysphonia Malaise Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 2 DAY
			Albuterol	C				

Date:06/22/00ISR Number: 3574249-4Report Type:Periodic Company Report #WAES 00032237
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Coumadin	C				
			Dilacor Xr	C				
			Lanoxin	C				

Date:06/22/00ISR Number: 3574250-0Report Type:Periodic Company Report #WAES 00032238
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3574251-2Report Type:Periodic Company Report #WAES 00051842
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dermatitis Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus		Tab Vioxx	SS				
			Normodyne	C				
			Premarin	C				
			Synthroid	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3574252-4Report Type:Periodic Company Report #WAES 00031918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574253-6Report Type:Periodic Company Report #WAES 00051845
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				

Date:06/22/00ISR Number: 3574254-8Report Type:Periodic Company Report #WAES 00032240
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

Date:06/22/00ISR Number: 3574255-XReport Type:Periodic Company Report #WAES 00031919
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Ecotrin	C				
			Lasix	C				
			Allopurinol	C				

Date:06/22/00ISR Number: 3574256-1Report Type:Periodic Company Report #WAES 00051846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Dyspepsia					
	Oedema Peripheral				Merck Co Inc	ORAL

PO 30 DAY

Date:06/22/00ISR Number: 3574257-3Report Type:Periodic Company Report #WAES 00031921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL

25 MG/ BID/

PO

			Tab Vioxx 25 Mg	SS		ORAL

25 MG/ DAILY

/ PO

			Soma	C		
			Xanax	C		
			Tylenol	C		

Date:06/22/00ISR Number: 3574258-5Report Type:Periodic Company Report #WAES 00032247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
UNK PO
Evista C

Date:06/22/00ISR Number: 3574259-7Report Type:Periodic Company Report #WAES 00032249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	
	Headache							
			Pepcid	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3574260-3Report Type:Periodic Company Report #WAES 00051847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON

Date:06/22/00ISR Number: 3574261-5Report Type:Periodic Company Report #WAES 00032251
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG BID PO	
	Insomnia							
	Nausea							
			Valium	C				

Date:06/22/00ISR Number: 3574262-7Report Type:Periodic Company Report #WAES 00032255
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
PO								
			Celebrex	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3574263-9Report Type:Periodic Company Report #WAES 00051848
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Chest Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Dyspnoea Rectal Haemorrhage Upper Respiratory Tract Infection		Erythromycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574264-0Report Type:Periodic Company Report #WAES 00032257
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Cardura	SS				
			Lasix	C				
			Monopril	C				
			Prevacid	C				
			Sinemet	C				
			Ultram	C				

Date:06/22/00ISR Number: 3574265-2Report Type:Periodic Company Report #WAES 00032258
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			K-Dur	C				
			Tenoretic	C				
			Tyenol	C				
			Zephrex	C				

Date:06/22/00ISR Number: 3574266-4Report Type:Periodic Company Report #WAES 00051849
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Cardura C
Ceftin C
Guaifenex La C
Benzonatate C

Date:06/22/00ISR Number: 3574267-6Report Type:Periodic Company Report #WAES 00031923
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Chest Pain	Professional			Laboratories Div			
	Facial Pain				Merck Co Inc	ORAL	12.5 MG /	
	Palpitations						BID/ PO	
	Ventricular Extrasystoles		Tab Vioxx 25 Mg	SS		ORAL	25 MG / DAILY	
							/ PO	
			Celebrex	C				
			Lipitor	C				
			Pepcid	C				
			Prilosec	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574268-8Report Type:Periodic Company Report #WAES 00051853
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Depakote	C				
			Effexor	C				
			Neurontin	C				

Date:06/22/00ISR Number: 3574269-XReport Type:Periodic Company Report #WAES 00032259
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Skin Nodule	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fulvicin	C				
			Glucotrol	C				
			Premarin	C				

Date:06/22/00ISR Number: 3574270-6Report Type:Periodic Company Report #WAES 00032261
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO SEE IMAGE	
			Elmiron	C				
			Prilosec	C				

			Remeron	C		
			Topamax	C		
			Ultram	C		

Date:06/22/00ISR Number: 3574271-8Report Type:Periodic Company Report #WAES 00051856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	21 DAY
			Cardura	C				
			Hyzaar	C				
			Zantac	C				

Date:06/22/00ISR Number: 3574272-XReport Type:Periodic Company Report #WAES 00032266
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				

Hyzaar C

Date:06/22/00ISR Number: 3574273-1Report Type:Periodic Company Report #WAES 00031926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574274-3Report Type:Periodic Company Report #WAES 00032267
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Xanax	C				

Date:06/22/00ISR Number: 3574275-5Report Type:Periodic Company Report #WAES 00051857
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574276-7Report Type:Periodic Company Report #WAES 00031938
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Premarin	C				
			Synthroid	C				
			Tylenol With Codeine	C				
			Zocor	C				

Date:06/22/00ISR Number: 3574277-9Report Type:Periodic Company Report #WAES 00032268
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ascriptin	C				
			Premarin	C				
			Synthroid	C				
			Zocor	C				
			Therapy Unspecified	C				
			Aspirin	C				
			Iron	C				

				Metoprolol	C		

Date:06/22/00ISR Number: 3574278-0Report Type:Periodic Company Report #WAES 00032272
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hiccups							

Date:06/22/00ISR Number: 3574279-2Report Type:Periodic Company Report #WAES 00051859
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Urinary Retention							
			Plaquenil	C				
			Prempro	C				
			Thyroxine	C				

Date:06/22/00ISR Number: 3574280-9Report Type:Periodic Company Report #WAES 00031940
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Ativan	C				
			Duragesic	C				
			Elavil	C				
			Percocet	C				

Date:06/22/00ISR Number: 3574281-0Report Type:Periodic Company Report #WAES 00032273
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Tylenol	C				
			Zantac	C				
			Zestril	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3574282-2Report Type:Periodic Company Report #WAES 00032276
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

				Lipitor	C		
				Norvasc	C		

Date:06/22/00ISR Number: 3574283-4Report Type:Periodic Company Report #WAES 00032277
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Sweat Gland Disorder Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:06/22/00ISR Number: 3574284-6Report Type:Periodic Company Report #WAES 00031942
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / UNK / PO	
			Levoxyl	C				
			Lotrel	C				
			Prempro	C				

Date:06/22/00ISR Number: 3574285-8Report Type:Periodic Company Report #WAES 00051861
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				

			Ziac	C		
			[Therapy Unspecified]	C		

Date:06/22/00ISR Number: 3574286-XReport Type:Periodic Company Report #WAES 00032278
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dilantin	C				
			Dyazide	C				

Date:06/22/00ISR Number: 3574287-1Report Type:Periodic Company Report #WAES 00032281
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574288-3Report Type:Periodic Company Report #WAES 00031944
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Celebrex	C				
			Motrin	C				

Date:06/22/00ISR Number: 3574289-5Report Type:Periodic Company Report #WAES 00051862
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574290-1Report Type:Periodic Company Report #WAES 00032284
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Monopril	C				

Date:06/22/00ISR Number: 3574291-3Report Type:Periodic Company Report #WAES 00032285
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	SEE IMAGE
			Prilosec	C				
			Therapy Unspecified	C				
			Aspirin	C				
			Atenolol	C				
			Cortisone	C				
			Iron	C				

Date:06/22/00ISR Number: 3574292-5Report Type:Periodic Company Report #WAES 00031950
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Premarin	C				
			Zestoretic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574293-7Report Type:Periodic Company Report #WAES 00032294
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Prilosec	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3574294-9Report Type:Periodic Company Report #WAES 00051864
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				

Date:06/22/00ISR Number: 3574295-0Report Type:Periodic Company Report #WAES 00032295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dizziness Drug Ineffective Muscle Rigidity Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO; 25 MG/ DAILY/PO	3 WKN
			Lovacol	C				
			Plaquenil	C				
			Prevacid	C				

			Xanax	C
			Zantac	C
			Atenolol	C
			Prednisone	C

Date:06/22/00ISR Number: 3574296-2Report Type:Periodic Company Report #WAES 00031957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Field Defect	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574297-4Report Type:Periodic Company Report #WAES 00032300
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dilantin	C				
			Tylenol	C				

			Cortisone	C		

Date:06/22/00ISR Number: 3574298-6Report Type:Periodic Company Report #WAES 00032304
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO	
			Ambien	C				
			Allopurinol	C				
			Hydrocodone	C				

Date:06/22/00ISR Number: 3574299-8Report Type:Periodic Company Report #WAES 00032307
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Phenobarbital	C				

Date:06/22/00ISR Number: 3574300-1Report Type:Periodic Company Report #WAES 00051869
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574302-5Report Type:Periodic Company Report #WAES 00032309
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lozol	C				
			Norvasc	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3574303-7Report Type:Periodic Company Report #WAES 00051875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574304-9Report Type:Periodic Company Report #WAES 00032310
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Mevacor	C				

Date:06/22/00ISR Number: 3574306-2Report Type:Periodic Company Report #WAES 00032311
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite Flatulence	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prednisone	C				

Date:06/22/00ISR Number: 3574307-4Report Type:Periodic Company Report #WAES 00051877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Hydrodiuril	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3574309-8Report Type:Periodic Company Report #WAES 00032313
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574310-4Report Type:Periodic Company Report #WAES 00032328
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Antimicrobial Therapy (Compositiunk	C				

Date:06/22/00ISR Number: 3574311-6Report Type:Periodic Company Report #WAES 00032350
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Laceration	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Tab Vioxx 25 Mg SS ORAL
50

MG/DAILY/PO;

25

MG/DAILY/PO

Lopresor C
Premarin C
Doxepin C
Zantac C
Macrodantin C
Lortab C

Date:06/22/00ISR Number: 3574312-8Report Type:Periodic Company Report #WAES 00051878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY / PO						
			Plavix	C		
			Aspirin	C		

Date:06/22/00ISR Number: 3574313-XReport Type:Periodic Company Report #WAES 00032351
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Aldomet (Methyldopa)	C		
			Lopid	C		

			Norodine	C		
			Premarin	C		
			Prevacid	C		
			Diazepam	C		

Date:06/22/00ISR Number: 3574315-3Report Type:Periodic Company Report #WAES 00032352
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estratab	C				
			Histinex Hc	C				
			Syn-Rx Tablets	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/22/00ISR Number: 3574316-5Report Type:Periodic Company Report #WAES 00032354
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Climara	C	
Ziac	C	

Date:06/22/00ISR Number: 3574317-7Report Type:Periodic Company Report #WAES 00051879
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx25 Mg	SS		ORAL	UNK / UNK /	
			Maxzide	C				
			Monopril	C				
			Premarin	C				
			Vicodin Tablets	C				
			Hydrocortisone	C				

Date:06/22/00ISR Number: 3574318-9Report Type:Periodic Company Report #WAES 00032357
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
			Cozaar	C				
			Norvasc	C				
			Tylenol	C				
			Iron	C				

Date:06/22/00ISR Number: 3574320-7Report Type:Periodic Company Report #WAES 00032363
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Accolate	C				
			Uniphyl	C				
			Acetaminophen	C				
			Albuterol	C				
			Ventolin	C				
			Elavil	C				
			Azmacort	C				

Date:06/22/00ISR Number: 3574321-9Report Type:Periodic Company Report #WAES 00032367
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

			Hydrocortisone	C		

Date:06/22/00ISR Number: 3574322-0Report Type:Periodic Company Report #WAES 00051880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Coumadin	C				
			Lanoxin	C				
			Procainamide Hydrochloride	C				

Date:06/22/00ISR Number: 3574323-2Report Type:Periodic Company Report #WAES 00032368
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				

Date:06/22/00ISR Number: 3574325-6Report Type:Periodic Company Report #WAES 00032369
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Face Oedema Weight Increased		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Tenormin	C	
Insulin	C	
Thyroid	C	

Date:06/22/00ISR Number: 3574326-8Report Type:Periodic Company Report #WAES 00032371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574328-1Report Type:Periodic Company Report #WAES 00051886
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	0.5-1 TABLET/DAILY/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574329-3Report Type:Periodic Company Report #WAES 00032372
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAIL/PO	
			Lipitor	C				

Date:06/22/00ISR Number: 3574330-XReport Type:Periodic Company Report #WAES 00032376
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574331-1Report Type:Periodic Company Report #WAES 00032377
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Phosphokinase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574332-3Report Type:Periodic Company Report #WAES 00051887
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5 MG

/PRN/PO

Benadryl C
Estratest C

Date:06/22/00ISR Number: 3574333-5Report Type:Periodic Company Report #WAES 00032378
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Albuterol	C				

Date:06/22/00ISR Number: 3574334-7Report Type:Periodic Company Report #WAES 00032386
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574335-9Report Type:Periodic Company Report #WAES 00051893
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574336-0Report Type:Periodic Company Report #WAES 00032573
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PRN/PO	
			Lotrel	C				

Date:06/22/00ISR Number: 3574337-2Report Type:Periodic Company Report #WAES 00032579
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Valium	C				

Date:06/22/00ISR Number: 3574338-4Report Type:Periodic Company Report #WAES 00032580
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/3XW/PO

Pravachol	C	
Prilosec	C	
Zantac	C	
Estrogenic Preparations	C	

Date:06/22/00ISR Number: 3574339-6Report Type:Periodic Company Report #WAES 00051894
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Flatulence							
	Gastrointestinal Disorder				Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	SS				
			Hormones	C				

Date:06/22/00ISR Number: 3574340-2Report Type:Periodic Company Report #WAES 00032582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/DAILY/PO

Ativan	C	
Hydrodiuril	C	
Norvasc	C	
Pepcid	C	
Prinivil	C	

Date:06/22/00ISR Number: 3574342-6Report Type:Periodic Company Report #WAES 00032583
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acidosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Electrolyte Imbalance							
	Renal Tubular Disorder							

Date:06/22/00ISR Number: 3574343-8Report Type:Periodic Company Report #WAES 00032584
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574344-XReport Type:Periodic Company Report #WAES 00032585
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Joint Swelling							
			Sulfasalazine	C				

Date:06/22/00ISR Number: 3574345-1Report Type:Periodic Company Report #WAES 00032586
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health	Vioxx	PS	Merck Research			
	Respiratory Disorder	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3574347-5Report Type:Periodic Company Report #WAES 00032588
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			
	Gastrointestinal				Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574348-7Report Type:Periodic Company Report #WAES 00051896
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Lasix	C				

Date:06/22/00ISR Number: 3574350-5Report Type:Periodic Company Report #WAES 00032590
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Dipentum	C				
			Nasacort	C				
			Pepcid	C				
			Prempro	C				
			Reglan	C				

Date:06/22/00ISR Number: 3574351-7Report Type:Periodic Company Report #WAES 00032597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	2 DAY

Date:06/22/00ISR Number: 3574353-0Report Type:Periodic Company Report #WAES 00032602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3574354-2Report Type:Periodic Company Report #WAES 00051904
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline Phosphatase Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
	Cholelithiasis							
	Hyperbilirubinaemia	Representative						

Date:06/22/00ISR Number: 3574355-4Report Type:Periodic Company Report #WAES 00032620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574357-8Report Type:Periodic Company Report #WAES 00032635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Fatigue							
	Nervousness		Celebrex	C				

Date:06/22/00ISR Number: 3574358-XReport Type:Periodic Company Report #WAES 00032641
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cholecystitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	1 DAY

Date:06/22/00ISR Number: 3574359-1Report Type:Periodic Company Report #WAES 00051925
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Diazide	C				
			Didronel	C				
			Paxil	C				
			Valium	C				

Date:06/22/00ISR Number: 3574361-XReport Type:Periodic Company Report #WAES 00032644
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective	Other						
	Injection Site Pain							
	Joint Stiffness		Synvisc	SS			4ML/WKY/INJ	
			Propranolol	C				

Date:06/22/00ISR Number: 3574362-1Report Type:Periodic Company Report #WAES 00032645
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Oedema Peripheral							

Date:06/22/00ISR Number: 3574364-5Report Type:Periodic Company Report #WAES 00032647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/DAILY/PO

Date:06/22/00ISR Number: 3574365-7Report Type:Periodic Company Report #WAES 00051932
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID/ PO	
			Cardura	C				
			Aspirin	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3574366-9Report Type:Periodic Company Report #WAES 00032649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Allegra-D	C				
			Prilosec	C				
			Vitamin D	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3574368-2Report Type:Periodic Company Report #WAES 00032651
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
			Altace	C				

			Relafen	C		
			Tylenol	C		
			Xanax	C		

Date:06/22/00ISR Number: 3574369-4Report Type:Periodic Company Report #WAES 00051949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK/ PO						
			Fosamax	C		

Date:06/22/00ISR Number: 3574371-2Report Type:Periodic Company Report #WAES 00040055
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Accupril	C		
			Celebrex	C		

			Cozaar	C
			Lasix	C
			Premarin	C
			Tenormin	C

Date:06/22/00ISR Number: 3574372-4Report Type:Periodic Company Report #WAES 00051953
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:06/22/00ISR Number: 3574373-6Report Type:Periodic Company Report #WAES 00040057
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	
			Levoxyl	C			PO	
			Premarin	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3574374-8Report Type:Periodic Company Report #WAES 00040060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:06/22/00ISR Number: 3574375-XReport Type:Periodic Company Report #WAES 00040064
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3574376-1Report Type:Periodic Company Report #WAES 00051954
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ UNK / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574377-3Report Type:Periodic Company Report #WAES 00040065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/	UNK/ PO

Date:06/22/00ISR Number: 3574378-5Report Type:Periodic Company Report #WAES 00040066
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK /	UNK / PO

Date:06/22/00ISR Number: 3574379-7Report Type:Periodic Company Report #WAES 00051964
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Alopecia Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY /	PO
			Betimol	C				
			Diabeta	C				
			Glucophage	C				
			Lasix	C				
			Micro K	C				
			Salutensin	C				
			Trusopt	C				
			Xalatan	C				
			Zantac	C				

Pilocarpine C

Date:06/22/00ISR Number: 3574380-3Report Type:Periodic Company Report #WAES 00040070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK / PO						

Date:06/22/00ISR Number: 3574381-5Report Type:Periodic Company Report #WAES 00040083
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arrhythmia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY / PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574382-7Report Type:Periodic Company Report #WAES 00051971
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / DAILY / PO	
			Amaryl	C				
			Synthroid	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/22/00ISR Number: 3574383-9Report Type:Periodic Company Report #WAES 00040085
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Hypertension Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
			Tab Vioxx	SS		ORAL	25 MG / DAILY / PO	
			Cardura	C				
			Zyrtec	C				
			Estradiol	C				
			Zocor	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3574384-0Report Type:Periodic Company Report #WAES 00040093
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
UNK / UNK /

PO

Date:06/22/00ISR Number: 3574385-2Report Type:Periodic Company Report #WAES 00051972
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Vioxx	PS	Merck Research			
	Oral Pain	Professional			Laboratories Div			
	Stomatitis	Company			Merck Co Inc	ORAL	25 MG/ DAILY	
		Representative					/ PO; 50 MG	
							PO	
			Tab Vioxx 50 Mg	SS		ORAL	PO	

Date:06/22/00ISR Number: 3574386-4Report Type:Periodic Company Report #WAES 00040141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	50 MG/ BID/	
							PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574387-6Report Type:Periodic Company Report #WAES 00040142
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO 1 DAY

Date:06/22/00ISR Number: 3574388-8Report Type:Periodic Company Report #WAES 00040143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3574389-XReport Type:Periodic Company Report #WAES 00040155
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Oedema Peripheral Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ UNK /	PO 3 WK
			Cozaar	C				
			Fibercon	C				
			Glucotrol	C				
			Miacalcin	C				
			Pepcid	C				
			Prozac	C				
			Aspirin	C				
			Calcium	C				

		Fish Oil	C	
		Vitamins	C	

Date:06/22/00ISR Number: 3574390-6Report Type:Periodic Company Report #WAES 00051295
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carcinoembryonic Antigen Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Beta)-Carotene	C				
			Bellergal-S	C				
			Catapres	C				
			Detrol	C				
			Entex La	C				
			Femara	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Glucosamine Sulfate Salt	C				
			Selenium Preparation	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574391-8Report Type:Periodic Company Report #WAES 00040156
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Sweat Gland Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ UNK /	PO
			Hytrin	C				
			Prinivil	C				
			Proscar	C				
			Relafen	C				
			Ultram	C				

Date:06/22/00ISR Number: 3574392-XReport Type:Periodic Company Report #WAES 00040157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Aspirin	C				

Date:06/22/00ISR Number: 3574393-1Report Type:Periodic Company Report #WAES 00040158
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Arthritis Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /	DAILY / PO
	Drug Ineffective							
	Skin Nodule		Tab Vioxx	SS		ORAL	25 MG /	DAILY

/ PO

Pepcid	C
Vitamins	C
Tylenol	C
Synthroid	C

Date:06/22/00ISR Number: 3574394-3Report Type:Periodic Company Report #WAES 00051298
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574395-5Report Type:Periodic Company Report #WAES 00040159
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK /	DAILY

/ PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574396-7Report Type:Periodic Company Report #WAES 00040165
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG / Q3D/	UNK
			Synthroid	C				
			Verapamil Msd Lp	C				

Date:06/22/00ISR Number: 3574397-9Report Type:Periodic Company Report #WAES 00051319
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574398-0Report Type:Periodic Company Report #WAES 00040166
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
	Dry Mouth	Health Professional						
	Gastrooesophageal Reflux Disease						PO	
	Headache		Klonopin	C				
	Insomnia							

Date:06/22/00ISR Number: 3574399-2Report Type:Periodic Company Report #WAES 00051323
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Flomax (Tamsulosin (R) -Form Hydr	C				

Date:06/22/00ISR Number: 3574401-8Report Type:Periodic Company Report #WAES 00051333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574402-XReport Type:Periodic Company Report #WAES 00033217
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Pain	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK / PO	
Methotrexate	C				

Date:06/22/00ISR Number: 3574403-1Report Type:Periodic Company Report #WAES 00033225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depo-Provera	C				

Date:06/22/00ISR Number: 3574404-3Report Type:Periodic Company Report #WAES 00051342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574405-5Report Type:Periodic Company Report #WAES 00033228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 30 DAY

Date:06/22/00ISR Number: 3574406-7Report Type:Periodic Company Report #WAES 00033238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574407-9Report Type:Periodic Company Report #WAES 00040002
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lipitor	C				
			Chondroitin	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574408-0Report Type:Periodic Company Report #WAES 00051347
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574409-2Report Type:Periodic Company Report #WAES 00040004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Tylenol	C				

Date:06/22/00ISR Number: 3574410-9Report Type:Periodic Company Report #WAES 00040010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574411-0Report Type:Periodic Company Report #WAES 00051348
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574412-2Report Type:Periodic Company Report #WAES 00040013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:06/22/00ISR Number: 3574413-4Report Type:Periodic Company Report #WAES 00040017
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Ambien	C		
			Demerol	C		
			Sonata	C		
			Diazepam	C		
			Hydralazine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574414-6Report Type:Periodic Company Report #WAES 00051349
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dyspnoea Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY

Date:06/22/00ISR Number: 3574415-8Report Type:Periodic Company Report #WAES 00040020
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			A.S.A.	C				
			Ultram	C				
			Chondroitin	C				
			Ginkgo Biloba Extract	C				
			Prednisone	C				
			Pyridoxine	C				

Date:06/22/00ISR Number: 3574416-XReport Type:Periodic Company Report #WAES 00040021
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Adalat	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3574417-1Report Type:Periodic Company Report #WAES 00051352
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS	Merck Research			
	Mental Impairment	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:06/22/00ISR Number: 3574418-3Report Type:Periodic Company Report #WAES 00040023
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea	Health			Laboratories Div			
	Viral Infection	Professional			Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574419-5Report Type:Periodic Company Report #WAES 00040024
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	1 MON
			Vitamins	C				

Date:06/22/00ISR Number: 3574420-1Report Type:Periodic Company Report #WAES 00051354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:06/22/00ISR Number: 3574421-3Report Type:Periodic Company Report #WAES 00040026
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	

Date:06/22/00ISR Number: 3574422-5Report Type:Periodic Company Report #WAES 00040033
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		4 DAY	
			Glucophage	C				

			Glucotrol	C		
			Lipitor	C		
			Moduretic	C		
			Synthroid	C		

Date:06/22/00ISR Number: 3574423-7Report Type:Periodic Company Report #WAES 00051371
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Oedema Peripheral							
	Tinnitus							
			Cardizem Cd	C				
			Maxzide	C				
			Premarin	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3574424-9Report Type:Periodic Company Report #WAES 00040036
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Abdominal Pain Upper

Malaise

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
	Lipitor	C				

Date:06/22/00ISR Number: 3574425-0Report Type:Periodic Company Report #WAES 00040039
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Premarin	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3574426-2Report Type:Periodic Company Report #WAES 00051380
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574427-4Report Type:Periodic Company Report #WAES 00040042
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

50

MG/DAILY/PO

Date:06/22/00ISR Number: 3574428-6Report Type:Periodic Company Report #WAES 00040051
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Angioneurotic Oedema Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3574430-4Report Type:Periodic Company Report #WAES 00051390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Toxicologic Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

			Tab Maxalt (Rizatriptan Benzoate) Unk	SS		ORAL

PO

Prozac C

Date:06/22/00ISR Number: 3574431-6Report Type:Periodic Company Report #WAES 00040054
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Theo-Dur	C				

Date:06/22/00ISR Number: 3574432-8Report Type:Periodic Company Report #WAES 00051392
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	6 WK
			Aleve	C				
			Sular	C				
			Allopurinol	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3574433-XReport Type:Periodic Company Report #WAES 00032391
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	

			Cardizem	C		
			Miacalcin	C		
			Pepcid	C		

Date:06/22/00ISR Number: 3574435-3Report Type:Periodic Company Report #WAES 00032393
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	PO
			[Composition Unspecified]	C				

Date:06/22/00ISR Number: 3574436-5Report Type:Periodic Company Report #WAES 00051393
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				

			Lotrel	C		

Date:06/22/00ISR Number: 3574437-7Report Type:Periodic Company Report #WAES 00032395
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/ PRN/ PO	
			Cozaar	C				
			Hytrin	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3574439-0Report Type:Periodic Company Report #WAES 00032397
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	
			Dalmane	C				
			Dilaudid	C				
			Ms Contin	C				
			Soma	C				

Date:06/22/00ISR Number: 3574440-7Report Type:Periodic Company Report #WAES 00051394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excitability Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Zantac	C		
			Zocor	C		
			Zoloft	C		

Date:06/22/00ISR Number: 3574441-9Report Type:Periodic Company Report #WAES 00032400
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25MG/ DAILY/						
PO						
			Darvocet-N	C		
			Fosamax	C		
			Pravachol	C		
			Singulair	C		
			Aspirin	C		
			Calcium Supplement(Compositi on	C		
			Prednisone	C		
			Prilosec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574443-2Report Type:Periodic Company Report #WAES 00032401
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	PO
			Accupril	C				
			Atrovent	C				
			Glucotrol	C				
			Klor-Con	C				
			Premarin	C				
			Prevacid	C				
			Tiazac	C				
			Albuterol	C				
			Allopurinol	C				
			Alprazolam	C				
			Aspirin	C				
			Furosemide	C				
			Isosorbide	C				

Date:06/22/00ISR Number: 3574444-4Report Type:Periodic Company Report #WAES 00051395
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass Gynaecomastia Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Plaquenil	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3574445-6Report Type:Periodic Company Report #WAES 00032403
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	
							PO	
			Elavil	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3574446-8Report Type:Periodic Company Report #WAES 00032404
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Heat Exposure Injury Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	
							PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574448-1Report Type:Periodic Company Report #WAES 00051397
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Lipitor	C				
			Percocet	C				
			Zoloft	C				
			Aspirin	C				
			Digoxin	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3574449-3Report Type:Periodic Company Report #WAES 00032407
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5MG/ DAILY/ PO	6 MON

Date:06/22/00ISR Number: 3574450-XReport Type:Periodic Company Report #WAES 00032409
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Oedema Peripheral Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	
	Polyarteritis Nodosa	Representative						
			Diovan	C				
			Effexor	C				

Date:06/22/00ISR Number: 3574451-1Report Type:Periodic Company Report #WAES 00032410
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574452-3Report Type:Periodic Company Report #WAES 00051399
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574453-5Report Type:Periodic Company Report #WAES 00032411
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574454-7Report Type:Periodic Company Report #WAES 00032412
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3574455-9Report Type:Periodic Company Report #WAES 00032423
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dermatitis Exfoliative Erythema Pyrexia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	

Date:06/22/00ISR Number: 3574457-2Report Type:Periodic Company Report #WAES 00032424
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL PO

Date:06/22/00ISR Number: 3574458-4Report Type:Periodic Company Report #WAES 00032425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:06/22/00ISR Number: 3574459-6Report Type:Periodic Company Report #WAES 00032439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574460-2Report Type:Periodic Company Report #WAES 00032440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Depression Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

Date:06/22/00ISR Number: 3574461-4Report Type:Periodic Company Report #WAES 00032468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574463-8Report Type:Periodic Company Report #WAES 00032470
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574464-XReport Type:Periodic Company Report #WAES 00033110
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50	

MG/DAILY/PO

Date:06/22/00ISR Number: 3574465-1Report Type:Periodic Company Report #WAES 00033111
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				

Date:06/22/00ISR Number: 3574467-5Report Type:Periodic Company Report #WAES 00033113
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Below Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tegretol	SS			100 MG/Q6H/UNK	
			Acetaminophen	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574468-7Report Type:Periodic Company Report #WAES 00033124
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Toprol Xl Tablets	C				
			Digoxin	C				

Date:06/22/00ISR Number: 3574469-9Report Type:Periodic Company Report #WAES 00033128
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Diovan	C				
			Ziac	C				

Date:06/22/00ISR Number: 3574470-5Report Type:Periodic Company Report #WAES 00033131
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	25 MG/DAILY/ PO

			Arthrotec	C
			Celebrex	C
			Premarin	C
			Prilosec	C
			Tylenol	C
			Amoxicillin	C
			Aspirin	C

Date:06/22/00ISR Number: 3574472-9Report Type:Periodic Company Report #WAES 00033133
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574473-0Report Type:Periodic Company Report #WAES 00033134
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				

			Lanoxin	C		
			Atenolol	C		
			Furosemide	C		

Date:06/22/00ISR Number: 3574474-2Report Type:Periodic Company Report #WAES 00033137
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Hepatic Enzyme Increased				Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Zocor Unk	SS		ORAL	40 MG/DAILY/PO	
			Prevacid	C				
			Zoloft	C				
			Iron (Unspecified)	C				
			Metoprolol	C				

Date:06/22/00ISR Number: 3574475-4Report Type:Periodic Company Report #WAES 00033142
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/PO	
			Bumex	C				
			Cardizem	C				
			Lopressor	C				
			Synthroid	C				
			Insulin	C				
			Theophylline	C				

Date:06/22/00ISR Number: 3574476-6Report Type:Periodic Company Report #WAES 00033143
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3574477-8Report Type:Periodic Company Report #WAES 00033152
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Dyazide	C				
			Lopressor	C				
			Pepcid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574479-1Report Type:Periodic Company Report #WAES 00033154
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Vioxx	PS	Merck Research			
	Abdominal Pain Upper	Professional			Laboratories Div			
	Gastrooesophageal Reflux	Company			Merck Co Inc	ORAL	25MG/DAILY/PO	
	Disease	Representative	Ambien	C				
			Evista	C				
			Doxepin	C				

Date:06/22/00ISR Number: 3574481-XReport Type:Periodic Company Report #WAES 00033156
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research			
	Sweat Gland Disorder				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Hytrin	C				
			Naldecon	C				
			Phrenilin Forte	C				
			Prinivil	C				
			Proscar	C				
			Relafen	C				
			Ultram	C				

Date:06/22/00ISR Number: 3574482-1Report Type:Periodic Company Report #WAES 00033198
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:06/22/00ISR Number: 3574485-7Report Type:Periodic Company Report #WAES 00033201
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Skin Nodule	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Premarin	C				

Date:06/22/00ISR Number: 3574486-9Report Type:Periodic Company Report #WAES 00033202
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3574487-0Report Type:Periodic Company Report #WAES 00033214
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspnoea Fatigue	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3574489-4Report Type:Periodic Company Report #WAES 00033215
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3574490-0Report Type:Periodic Company Report #WAES 00033216
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575269-6Report Type:Periodic Company Report #WAES 00051463
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Adalat Cc	C	
Atrovent	C	
Combivent	C	
Theo-24	C	
Ultram	C	
Albuterol Sulfate	C	

Date:06/22/00ISR Number: 3575271-4Report Type:Periodic Company Report #WAES 00051476
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal	Health	Vioxx	PS	Merck Research	
	Mental Impairment	Professional			Laboratories Div	
	Sedation	Company			Merck Co Inc	ORAL
25						
		Representative				

MG/DAILY/PO

Date:06/22/00ISR Number: 3575273-8Report Type:Periodic Company Report #WAES 00051400
Age:56 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain Upper
	Diarrhoea

	Faeces Discoloured						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON

Date:06/22/00ISR Number: 3575274-XReport Type:Periodic Company Report #WAES 00051494
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575276-3Report Type:Periodic Company Report #WAES 00051402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Cardura	C				
			Lipitor	C				
			Imipramine	C				
			Quinine	C				

Date:06/22/00ISR Number: 3575277-5Report Type:Periodic Company Report #WAES 00051406
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Prevacid	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3575279-9Report Type:Periodic Company Report #WAES 00051495
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Faeces Discoloured	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3575281-7Report Type:Periodic Company Report #WAES 00051498
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						

Celebrex C

Date:06/22/00ISR Number: 3575282-9Report Type:Periodic Company Report #WAES 00051409
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575283-0Report Type:Periodic Company Report #WAES 00051411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575284-2Report Type:Periodic Company Report #WAES 00051412
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575285-4Report Type:Periodic Company Report #WAES 00051517
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative		Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3575286-6Report Type:Periodic Company Report #WAES 00051413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:06/22/00ISR Number: 3575287-8Report Type:Periodic Company Report #WAES 00051420
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Face Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Evista	C		
			Fosamax	C		
			Synthroid	C		

Dose Duration

PO 2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575288-XReport Type:Periodic Company Report #WAES 00051518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575289-1Report Type:Periodic Company Report #WAES 00051519
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammatory Bowel Disease	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575292-1Report Type:Periodic Company Report #WAES 00051520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cozaar	C				

Date:06/22/00ISR Number: 3575294-5Report Type:Periodic Company Report #WAES 00051521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Vioxx	PS	Merck Research			

	Feeling Abnormal	Professional			Laboratories Div	
	Skin Warm	Company			Merck Co Inc	ORAL
50						
		Representative				
MG/DAILY/PO						
			Depo-Medrol	SS		
INJ						

Date:06/22/00ISR Number: 3575295-7Report Type:Periodic Company Report #WAES 00051128
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Diarrhoea				Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Hydrodiuril	C		
			Prilosec	C		
			Prozac	C		
			Methotrexate	C		

Date:06/22/00ISR Number: 3575296-9Report Type:Periodic Company Report #WAES 00051425
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						

			Norpace	C		
			Premarin	C		

Date:06/22/00ISR Number: 3575297-0Report Type:Periodic Company Report #WAES 00051426
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Zantac	C				
			Zoloft	C				
			Glyburide	C				
			Lisinopril	C				

Date:06/22/00ISR Number: 3575299-4Report Type:Periodic Company Report #WAES 00051522
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575300-8Report Type:Periodic Company Report #WAES 00051427
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Cordarone	C				
			Coumadin	C				

Date:06/22/00ISR Number: 3575301-XReport Type:Periodic Company Report #WAES 00051428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Gastrointestinal Disorder							
	Nausea							
	Sinusitis							
	Weight Increased		Lipitor	C				
			Premarin	C				
			Prinivil	C				
			Quinine Sulfate	C				

Date:06/22/00ISR Number: 3575303-3Report Type:Periodic Company Report #WAES 00051433
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lopressor	C				

			Pepcid	C
			Tolectin	C
			Tylenol	C

Date:06/22/00ISR Number: 3575304-5Report Type:Periodic Company Report #WAES 00051524
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypoaesthesia							
	Insomnia							
	Paraesthesia							
			Altace	C				
			Amaryl	C				
			Avandia	C				
			Baycol	C				
			Prilosec	C				
			Tenormin	C				
			Miglitol	C				

Date:06/22/00ISR Number: 3575305-7Report Type:Periodic Company Report #WAES 00051435
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Accupril	C				

Date:06/22/00ISR Number: 3575307-0Report Type:Periodic Company Report #WAES 00051437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:06/22/00ISR Number: 3575308-2Report Type:Periodic Company Report #WAES 00051438
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Buspar	C				
			Paxil	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				
			Vancenase	C				
			Albuterol	C				
			Amitriptyline	C				
			Cyclobenzaprine Hydrochloride	C				
			Desipramine	C				

		Loratidine	C	
		Methocarbamol	C	

Date:06/22/00ISR Number: 3575309-4Report Type:Periodic Company Report #WAES 00051525
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575310-0Report Type:Periodic Company Report #WAES 00051448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				
			Voltaren	C				

Date:06/22/00ISR Number: 3575311-2Report Type:Periodic Company Report #WAES 00051454
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortisone	C				

Date:06/22/00ISR Number: 3575312-4Report Type:Periodic Company Report #WAES 00051459
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat Cc	C				
			Cozaar	C				

Date:06/22/00ISR Number: 3575313-6Report Type:Periodic Company Report #WAES 00051460
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Bumex	C				
			Lipitor	C				
			Norvasc	C				
			Prinivil	C				
			Timoptic	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575314-8Report Type:Periodic Company Report #WAES 00051530
Age:67 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG/BID	
			Darvocet-N	C				
			Miacalcin	C				
			Reglan	C				

Date:06/22/00ISR Number: 3575315-XReport Type:Periodic Company Report #WAES 00032805
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral Upper Respiratory Tract Infection		Trandate	C				

Date:06/22/00ISR Number: 3575316-1Report Type:Periodic Company Report #WAES 00032807
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Lip Dry Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Levothroid	C				
			Neurontin	C				
			Prozac	C				

Date:06/22/00ISR Number: 3575317-3Report Type:Periodic Company Report #WAES 00051536
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575318-5Report Type:Periodic Company Report #WAES 00032809
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				

Date:06/22/00ISR Number: 3575319-7Report Type:Periodic Company Report #WAES 00051547
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Celebrex C

Date:06/22/00ISR Number: 3575320-3Report Type:Periodic Company Report #WAES 00032810
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Capoten	C				
			Lipitor	C				
			Premarin	C				
			Synthroid	C				
			Zantac	C				
			Zoloft	C				
			Allopurinol	C				

Date:06/22/00ISR Number: 3575321-5Report Type:Periodic Company Report #WAES 00032812
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis Drug Ineffective Peripheral Vascular Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
			Fosamax	C				
			Chondroitin	C				
			Glucosamine	C				
			Vitamin A	C				
			Vitamin D	C				

Date:06/22/00ISR Number: 3575322-7Report Type:Periodic Company Report #WAES 00032816
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Cough Gastrointestinal Haemorrhage Pyrexia Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/00ISR Number: 3575323-9Report Type:Periodic Company Report #WAES 00051548
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575324-0Report Type:Periodic Company Report #WAES 00032817
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Diabeta	C				
			Maxzide	C				
			Paxil	C				
			Synthroid	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3575325-2Report Type:Periodic Company Report #WAES 00032818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575326-4Report Type:Periodic Company Report #WAES 00051549
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Zocor	C				

Date:06/22/00ISR Number: 3575327-6Report Type:Periodic Company Report #WAES 00032820
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / BID / PO	
	Cardiac Disorder							
	Dermatitis							
	Fatigue							
	Oedema Peripheral		Skelaxin	C				
	Polyuria		Ultram	C				
	Weight Increased							

Date:06/22/00ISR Number: 3575328-8Report Type:Periodic Company Report #WAES 00032822
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575329-XReport Type:Periodic Company Report #WAES 00051550
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Abdominal Pain Upper							
	Constipation							
			Microzide	C				
			Norvasc	C				
			Prinivil	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3575330-6Report Type:Periodic Company Report #WAES 00032824
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				
			Lanoxin	C				
			Lescol	C				
			Norvasc	C				
			Premarin	C				
			Theo-Dur	C				
			Aspirin	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3575331-8Report Type:Periodic Company Report #WAES 00032827
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orgasm Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/00ISR Number: 3575332-XReport Type:Periodic Company Report #WAES 00051557
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Vicodin Tablets	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3575333-1Report Type:Periodic Company Report #WAES 00032828
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575334-3Report Type:Periodic Company Report #WAES 00032830
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/12.5 MG/ DAILY/	PO
			Vicodin Tablets	C				
			Voltaren	C				
			[Therapy Unspecified]	C				
			Carisoprodol	C				

Date:06/22/00ISR Number: 3575335-5Report Type:Periodic Company Report #WAES 00051130
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Chest Pain Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dilantin	C				
			Lescol	C				
			Aspirin	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3575336-7Report Type:Periodic Company Report #WAES 00032832
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspepsia Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Levothroid	C				
			Neurontin	C				

Date:06/22/00ISR Number: 3575337-9Report Type:Periodic Company Report #WAES 00032838
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prilosec	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575338-0Report Type:Periodic Company Report #WAES 00051131
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575339-2Report Type:Periodic Company Report #WAES 00032842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Iron (Unspecified)	C				

Date:06/22/00ISR Number: 3575340-9Report Type:Periodic Company Report #WAES 00032845
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Paxil	C				
			Premarin	C				
			Prilosec	C				
			Tylenol With Codeine #3	C				
			Zocor	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:06/22/00ISR Number: 3575341-0Report Type:Periodic Company Report #WAES 00051558
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575342-2Report Type:Periodic Company Report #WAES 00051133
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575343-4Report Type:Periodic Company Report #WAES 00032846
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Headache Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Sular	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575344-6Report Type:Periodic Company Report #WAES 00051560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3575345-8Report Type:Periodic Company Report #WAES 00032853
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Confusional State	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Naprosyn	SS				
			Inderal	C				
			Lioresal	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3575346-XReport Type:Periodic Company Report #WAES 00051135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY
			Diazide	C				
			Diuril	C				
			Premaril	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3575347-1Report Type:Periodic Company Report #WAES 00051562
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575348-3Report Type:Periodic Company Report #WAES 00051137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Hytrin	C				
			Lasix	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575349-5Report Type:Periodic Company Report #WAES 00032854
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575350-1Report Type:Periodic Company Report #WAES 00032858
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575351-3Report Type:Periodic Company Report #WAES 00051564
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575352-5Report Type:Periodic Company Report #WAES 00032860
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia Renal Impairment	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/00ISR Number: 3575353-7Report Type:Periodic Company Report #WAES 00051138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Corgard	C				
			Lipitor	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3575354-9Report Type:Periodic Company Report #WAES 00032862
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Vioxx	PS	Merck Research			
	Hypertension	Professional			Laboratories Div			
	Oedema	Company			Merck Co Inc	ORAL	PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575355-0Report Type:Periodic Company Report #WAES 00051569
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Inderal	C				
			Mysoline	C				
			Prilosec	C				
			Robaxin	C				

Date:06/22/00ISR Number: 3575356-2Report Type:Periodic Company Report #WAES 00032863
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Micturition Disorder	Company Representative						

Date:06/22/00ISR Number: 3575357-4Report Type:Periodic Company Report #WAES 00051139
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dry Skin							
	Oedema Peripheral							
	Rash Pruritic		Plaquenil	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575358-6Report Type:Periodic Company Report #WAES 00032873
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Myalgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575359-8Report Type:Periodic Company Report #WAES 00051570
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID PO	
			Detrol	C				
			Diovan	C				
			Lescol	C				
			Prilosec	C				
			Propulsid	C				
			Aspirin	C				
			Atenolol	C				
			Hyoscyamine	C				
			Methotrexate	C				

	Prednisone	C	
	Vitamins	C	

Date:06/22/00ISR Number: 3575360-4Report Type:Periodic Company Report #WAES 00032884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral				Merck Co Inc	ORAL	PO	
	Renal Disorder							

Date:06/22/00ISR Number: 3575361-6Report Type:Periodic Company Report #WAES 00051140
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/AM/PO	

Date:06/22/00ISR Number: 3575363-XReport Type:Periodic Company Report #WAES 00051571
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

Date:06/22/00ISR Number: 3575364-1Report Type:Periodic Company Report #WAES 00032887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575366-5Report Type:Periodic Company Report #WAES 00032923
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575369-0Report Type:Periodic Company Report #WAES 00051573
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575370-7Report Type:Periodic Company Report #WAES 00051142
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:06/22/00ISR Number: 3575371-9Report Type:Periodic Company Report #WAES 00051146
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nervousness Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	
			Advil	C				
			Arthrotec	C				
			Elavil	C				
			Hydrodiuril	C				
			Hydrodiuril	C				
			Inderal	C				
			Lodine	C				
			Prevacid	C				
			Vasotec	C				
			Xanax	C				

Date:06/22/00ISR Number: 3575373-2Report Type:Periodic Company Report #WAES 00051575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Corgard	C				
			Synthroid	C				

Tylenol C

Date:06/22/00ISR Number: 3575374-4Report Type:Periodic Company Report #WAES 00051148
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575376-8Report Type:Periodic Company Report #WAES 00051166
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575377-XReport Type:Periodic Company Report #WAES 00051577
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Elavil	C				
			Glyburide	C				

Date:06/22/00ISR Number: 3575378-1Report Type:Periodic Company Report #WAES 00032926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575380-XReport Type:Periodic Company Report #WAES 00032927
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pleural Effusion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575381-1Report Type:Periodic Company Report #WAES 00032937
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:06/22/00ISR Number: 3575382-3Report Type:Periodic Company Report #WAES 00051582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:06/22/00ISR Number: 3575383-5Report Type:Periodic Company Report #WAES 00032938
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Lopressor	C				

		Norvasc	C
		Zocor	C
		Insulin	C

Date:06/22/00ISR Number: 3575385-9Report Type:Periodic Company Report #WAES 00051167
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575386-0Report Type:Periodic Company Report #WAES 00032939
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575387-2Report Type:Periodic Company Report #WAES 00051584
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Methotrexate	C				

Date:06/22/00ISR Number: 3575388-4Report Type:Periodic Company Report #WAES 00032940
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3575389-6Report Type:Periodic Company Report #WAES 00032947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575390-2Report Type:Periodic Company Report #WAES 00032948
Age: Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Bowel Sounds Abnormal

	Diarrhoea						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrocodone/Apap	C				
			Xanax	C				
			Antimicrobial Therapy	C				

Date:06/22/00ISR Number: 3575391-4Report Type:Periodic Company Report #WAES 00032949
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	(SEE IMAGE)
	Gastritis							
	Nausea							
	Oedema Peripheral							
	Sedation							
			Duragesic	C				
			Prilosec	C				
			Estrogenic Preparations	C				
			Lorazepam	C				
			Procainamide Hydrochloride	C				
			Temazepam	C				

Date:06/22/00ISR Number: 3575392-6Report Type:Periodic Company Report #WAES 00051586
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Weight Increased							

Merck Co Inc ORAL
PO

Claritin	C	
Humbid	C	
Paxil	C	
Ziac	C	
Temazepam	C	

Date:06/22/00ISR Number: 3575393-8Report Type:Periodic Company Report #WAES 00051169
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:06/22/00ISR Number: 3575394-XReport Type:Periodic Company Report #WAES 00032956
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Dilacor Xr C
Xanax C

Date:06/22/00ISR Number: 3575395-1Report Type:Periodic Company Report #WAES 00032958
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Midrin	C				

Date:06/22/00ISR Number: 3575397-5Report Type:Periodic Company Report #WAES 00051587
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Metamucil	C				

Date:06/22/00ISR Number: 3575398-7Report Type:Periodic Company Report #WAES 00051170
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575399-9Report Type:Periodic Company Report #WAES 00051172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575400-2Report Type:Periodic Company Report #WAES 00051173
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5-25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575401-4Report Type:Periodic Company Report #WAES 00051174
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575402-6Report Type:Periodic Company Report #WAES 00051181
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Oedema Peripheral Respiratory Disorder Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY/PO	
			Dilor-G Tablets	C				
			Dyazide	C				
			Estrace	C				
			K-Dur	C				
			Plendil	C				

Date:06/22/00ISR Number: 3575403-8Report Type:Periodic Company Report #WAES 00051593
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575405-1Report Type:Periodic Company Report #WAES 00051595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575407-5Report Type:Periodic Company Report #WAES 00051597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:06/22/00ISR Number: 3575408-7Report Type:Periodic Company Report #WAES 00010309
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Tab Vioxx 25 Mg SS ORAL
25 MG/
DAILY/PO 5 DAY
Norvasc C
Percocet C
Timoptic C
Aspirin C
Atenolol C

Date:06/22/00ISR Number: 3575409-9Report Type:Periodic Company Report #WAES 00010322
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Methotrexate	C				

Date:06/22/00ISR Number: 3575410-5Report Type:Periodic Company Report #WAES 00051598
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Rectal Haemorrhage		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	258 MG DAILY PO	

Date:06/22/00ISR Number: 3575412-9Report Type:Periodic Company Report #WAES 00051600
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3575414-2Report Type:Periodic Company Report #WAES 00051601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:06/22/00ISR Number: 3575415-4Report Type:Periodic Company Report #WAES 00010406
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				
			Mevacor	C				
			Norvasc	C				
			Prinivil	C				
			Tenormin	C				

			Allopurinol	C		
			Chondroitin (+) Glucosamine (Composition Unspecified) (Therapy Unspecified)	C		
			A.S.A.	C		

Date:06/22/00ISR Number: 3575417-8Report Type:Periodic Company Report #WAES 00010431
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Fatigue	Health Professional						
	Gastritis							
	Headache							
	Nausea		Axid	C				
	Oedema Peripheral		Lipitor	C				
			Maxzide	C				
			Plendil	C				
			Premarin	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575418-XReport Type:Periodic Company Report #WAES 00010442
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Weight Increased							
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3575419-1Report Type:Periodic Company Report #WAES 00010458
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575420-8Report Type:Periodic Company Report #WAES 00032698
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Combivent	C				
			Estratest	C				
			Hydrodiuril	C				
			Provera	C				
			Singulair	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575421-XReport Type:Periodic Company Report #WAES 00032702
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Fluid Retention Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575422-1Report Type:Periodic Company Report #WAES 00051604
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Minocin	C				

Date:06/22/00ISR Number: 3575423-3Report Type:Periodic Company Report #WAES 00010461
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				

Date:06/22/00ISR Number: 3575424-5Report Type:Periodic Company Report #WAES 00032703
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG DAILY PO 26 DAY

Glucophage C
Lortab C
Glyburide C

Date:06/22/00ISR Number: 3575425-7Report Type:Periodic Company Report #WAES 00032707
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	12 DAY

Date:06/22/00ISR Number: 3575426-9Report Type:Periodic Company Report #WAES 00032709
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Coreg C
Glucophage C
Glucotrol C
Imdur C

			Mysoline	C
			Ornade Spansule	C
			Prevacid	C
			Zoloft	C

Date:06/22/00ISR Number: 3575427-0Report Type:Periodic Company Report #WAES00051610
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Ziac	C				

Date:06/22/00ISR Number: 3575428-2Report Type:Periodic Company Report #WAES 00032710
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Slow-K	C				
			Ziac	C				

Date:06/22/00ISR Number: 3575429-4Report Type:Periodic Company Report #WAES 00032712
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Ambien	C				
			Claritin	C				

			Flonase	C		
			Zoloft	C		
			Ampicillin	C		

Date:06/22/00ISR Number: 3575430-0Report Type:Periodic Company Report #WAES 00051620
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colour Blindness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3575431-2Report Type:Periodic Company Report #WAES 00032717
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575432-4Report Type:Periodic Company Report #WAES 00032718
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575433-6Report Type:Periodic Company Report #WAES 00032720
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lotensin	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3575434-8Report Type:Periodic Company Report #WAES 00051629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575435-XReport Type:Periodic Company Report #WAES 00032725
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Therapy Unspecified C

Date:06/22/00ISR Number: 3575436-1Report Type:Periodic Company Report #WAES 00032743
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Melaena							
	Pain In Extremity							
			Actos	C				
			Effexor Xr	C				
			Elavil	C				
			Roxicet	C				
			Ultram	C				
			Diazepam	C				

Date:06/22/00ISR Number: 3575437-3Report Type:Periodic Company Report #WAES 00010517
Age: Gender:Female I/FU:F

Outcome	PT
	Cough
	Laryngitis

	Pulmonary Congestion Vocal Cord Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO

Date:06/22/00ISR Number: 3575438-5Report Type:Periodic Company Report #WAES 00032744
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO

Date:06/22/00ISR Number: 3575439-7Report Type:Periodic Company Report #WAES 00051638
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PM PO

Date:06/22/00ISR Number: 3575440-3Report Type:Periodic Company Report #WAES 00032748
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div		

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3575442-7Report Type:Periodic Company Report #WAES 00010623
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Migraine	Health						
	Oedema Peripheral	Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575443-9Report Type:Periodic Company Report #WAES 00032753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral				Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575444-0Report Type:Periodic Company Report #WAES 00032780
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breath Sounds Decreased Oedema Pleural Effusion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	

Date:06/22/00ISR Number: 3575445-2Report Type:Periodic Company Report #WAES 00051639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:06/22/00ISR Number: 3575446-4Report Type:Periodic Company Report #WAES 00010735
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3575447-6Report Type:Periodic Company Report #WAES 00032782
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estratab	C				

			Provera	C		
			Calcium Supplement	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3575449-XReport Type:Periodic Company Report #WAES 00032788
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
	Vaginal Haemorrhage				Laboratories Div	
	Weight Increased				Merck Co Inc	ORAL
25MG/DAILY/PO						
			Mirapex	C		
			Ziac	C		
			Acetaminophen + Propoxyphene	C		
			Chlordiazepoxide	C		
			Medroxyprogesterone	C		
			Verapamil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575450-6Report Type:Periodic Company Report #WAES 00010796
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Dizziness	Health Professional						
	Headache							
	Influenza Like Illness		Lanoxin	C				
	Memory Impairment		Lopressor	C				
	Muscular Weakness		Synthroid	C				
	Myalgia							
	Nausea							

Date:06/22/00ISR Number: 3575451-8Report Type:Periodic Company Report #WAES 00032799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	200MG/DAILY/PO	
	Fluid Retention							
			Fosamax	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3575452-XReport Type:Periodic Company Report #WAES 00051644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	

Date:06/22/00ISR Number: 3575453-1Report Type:Periodic Company Report #WAES 00032802
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO 8 DAY						
			Carafate	C		
			K-Dur	C		
			Lasix	C		
			Lopressor	C		
			Prilosec	C		

Date:06/22/00ISR Number: 3575454-3Report Type:Periodic Company Report #WAES 00051658
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Albumin Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575456-7Report Type:Periodic Company Report #WAES 00010797
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aspirin	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3575459-2Report Type:Periodic Company Report #WAES 00051659
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Endocarditis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575462-2Report Type:Periodic Company Report #WAES 00051660
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575464-6Report Type:Periodic Company Report #WAES 00010823
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Health Professional Company Representative	Vioxx (Therapy Unspecified) Lipitor	PS SS C	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:06/22/00ISR Number: 3575465-8Report Type:Periodic Company Report #WAES 00051661
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Composition Unspecified	C		

Dose Duration

PO

Date:06/22/00ISR Number: 3575466-XReport Type:Periodic Company Report #WAES 00010882
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Premarin C

Date:06/22/00ISR Number: 3575468-3Report Type:Periodic Company Report #WAES 00051665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Lichen Planus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575470-1Report Type:Periodic Company Report #WAES 00051679
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Bronchitis Hypertension Insomnia Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575471-3Report Type:Periodic Company Report #WAES 00010899
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Lasix	C				
			Vasotec	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3575473-7Report Type:Periodic Company Report #WAES 00051680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575475-0Report Type:Periodic Company Report #WAES 00010924
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575476-2Report Type:Periodic Company Report #WAES 00051682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

Date:06/22/00ISR Number: 3575477-4Report Type:Periodic Company Report #WAES 00010926
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nasacort	C				
			Neurontin	C				
			Nyazin	C				
			Tylenol	C				
			Xanax	C				
			Zestril	C				
			Zyban	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3575478-6Report Type:Periodic Company Report #WAES 00051683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:06/22/00ISR Number: 3575479-8Report Type:Periodic Company Report #WAES 00051685
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575480-4Report Type:Periodic Company Report #WAES 00010997
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575481-6Report Type:Periodic Company Report #WAES 00051689
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575482-8Report Type:Periodic Company Report #WAES 00051693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575483-XReport Type:Periodic Company Report #WAES 00051698
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Soma	C				
			Zestril	C				
			Diuretic Preparation	C				

Date:06/22/00ISR Number: 3575484-1Report Type:Periodic Company Report #WAES 00011009
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3575485-3Report Type:Periodic Company Report #WAES 00011068
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
UK/UNK/PO
Xanax C

Date:06/22/00ISR Number: 3575486-5Report Type:Periodic Company Report #WAES 00012192
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Attention Deficit/Hyperactivity Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness		Vioxx	SS		ORAL	25 MG/BID/PO	
	Drug Toxicity Insomnia Tachycardia Tremor		Smz-Tmp	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575487-7Report Type:Periodic Company Report #WAES 99120206
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Eye Haemorrhage Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	37.5 MG/DAILY/PO	
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3575488-9Report Type:Periodic Company Report #WAES 00012214
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Facial Pain Sinusitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	
			Vioxx	SS		ORAL	25 MG/ DAILY/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3575489-0Report Type:Periodic Company Report #WAES 99120562
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;1	

2.5

MG/BID/PO;25

MG/BID/PO

Date:06/22/00ISR Number: 3575490-7Report Type:Periodic Company Report #WAES 00012257
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG/DAILY PO	3 MON
			Coumadin	C				
			Diazide	C				
			Norvasc	C				
			Premarin	C				
			Slow Fe	C				
			Diuretic Preparation	C				
			Vitamin E	C				
			Zinc Preparation	C				

Date:06/22/00ISR Number: 3575491-9Report Type:Periodic Company Report #WAES 99120646
Age: Gender:Female I/FU:F

Outcome	PT
	Dermatitis
	Dry Skin

Oedema Peripheral
Pruritus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575492-0Report Type:Periodic Company Report #WAES 99120709
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575493-2Report Type:Periodic Company Report #WAES 00012266
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575494-4Report Type:Periodic Company Report #WAES 00012268
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	3 DAY

Date:06/22/00ISR Number: 3575495-6Report Type:Periodic Company Report #WAES 00012289
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575496-8Report Type:Periodic Company Report #WAES 99120713
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder Visual Disturbance	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Advil	C				
			Lipitor	C				
			Vanceril	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575497-XReport Type:Periodic Company Report #WAES 00012350
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Plaquenil	SS				

Date:06/22/00ISR Number: 3575498-1Report Type:Periodic Company Report #WAES 99120779
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident Dizziness Drug Ineffective Feeling Drunk	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Chondroitin (+) Glucosamine	C				

Date:06/22/00ISR Number: 3575499-3Report Type:Periodic Company Report #WAES 00012363
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vioxx	SS		ORAL	12.5 MG/DAILY PO	
			Ambien	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3575500-7Report Type:Periodic Company Report #WAES 99120800
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:06/22/00ISR Number: 3575501-9Report Type:Periodic Company Report #WAES 00012386
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazide	C				
			Diclomine	C				
			Estrace	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575502-0Report Type:Periodic Company Report #WAES 99121006
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Upper Respiratory Tract	Professional			Merck Co Inc	ORAL	12.5	
	Infection						MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	PO	
			Allegra D	C				
			Synthroid	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3575503-2Report Type:Periodic Company Report #WAES 00012401
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company			Merck Co Inc	ORAL	12.5	
		Representative					MG/DAILY/PO	

Date:06/22/00ISR Number: 3575504-4Report Type:Periodic Company Report #WAES 00012402
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG/AM/PO	1 MON
			Vioxx	SS		ORAL	12.5 MG/PM/PO	
			Adalat	C				
			Tenormin	C				

			Nitroglycerin	C		

Date:06/22/00ISR Number: 3575505-6Report Type:Periodic Company Report #WAES 00012411
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Drug Ineffective		Darvocet-N	SS		
	Insomnia		Ultram	C		

Date:06/22/00ISR Number: 3575506-8Report Type:Periodic Company Report #WAES 99121167
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erectile Dysfunction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Lipitor	C		
			Tricor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575507-XReport Type:Periodic Company Report #WAES 00012511
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vioxx	SS		ORAL	50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575508-1Report Type:Periodic Company Report #WAES 99121181
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575509-3Report Type:Periodic Company Report #WAES 00012546
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea	Health Professional						
	Fluid Retention							
	Oedema							
	Swelling		Lasix	SS				
			Diovan	C				
			Meridia	C				

Date:06/22/00ISR Number: 3575510-XReport Type:Periodic Company Report #WAES 99121514
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Rhinorrhoea	Professional			Merck Co Inc	ORAL	12.5 MG/1X/PO	
	Sneezing		Prempro	C				

Date:06/22/00ISR Number: 3575511-1Report Type:Periodic Company Report #WAES 99121654
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Dry Skin	Health			Laboratories Div			
	Laceration	Professional			Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Pruritus							
			Estrace	C				
			Flovent	C				
			Synthroid	C				
			Aspirin	C				
			Calcium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575512-3Report Type:Periodic Company Report #WAES 99121800
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Drug Interaction							
	Erection Increased							
	Flushing		Cortisone	SS		INJ		
	Insomnia		Allegra	C				
			Astelin	C				
			Atrovent Inhalation Solution	C				

Date:06/22/00ISR Number: 3575513-5Report Type:Periodic Company Report #WAES 00012595
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pruritus	Health Professional						
	Skin Nodule							
			Advil	C				
			Tylenol	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3575515-9Report Type:Periodic Company Report #WAES 00012610
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

Date:06/22/00ISR Number: 3575516-0Report Type:Periodic Company Report #WAES 99121897
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Darvocet-N	C				
			Naprosyn	C				
			Prevacid	C				
			Prilosec	C				
			Tylenol	C				
			Zestoretic	C				
			Zoloft	C				
			Therapy Unspecified	C				
			Aspirin	C				
			Folic Acid	C				
			Iron	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575519-6Report Type:Periodic Company Report #WAES 99121910
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				

Date:06/22/00ISR Number: 3575520-2Report Type:Periodic Company Report #WAES 00012616
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575523-8Report Type:Periodic Company Report #WAES 00012626
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Cosopt	C				
			Fosamax	C				
			Levothyroxine Sodium	C				

Date:06/22/00ISR Number: 3575524-XReport Type:Periodic Company Report #WAES 99121951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3575525-1Report Type:Periodic Company Report #WAES 00020030
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Epistaxis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Date:06/22/00ISR Number: 3575527-5Report Type:Periodic Company Report #WAES 99122008
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dizziness Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Buspar	C		
			Plendil	C		
			Prilosec	C		
			Synthroid	C		

Dose Duration

25 MG/AM/PO

			Tums	C		
			Chondroitin (+) Glucosamine	C		

Date:06/22/00ISR Number: 3575529-9Report Type:Periodic Company Report #WAES 00020042
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vioxx	SS		ORAL	25 MG/DAILY/PO	
			Lescol	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3575532-9Report Type:Periodic Company Report #WAES 99122017
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pain Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Regular Strength Doan'S	C				

Date:06/22/00ISR Number: 3575533-0Report Type:Periodic Company Report #WAES 00020044
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Arthrotec	C
Avapro	C
Levaquin	C
Lopressor	C
Norvasc	C
Premarin	C
Tylenol	C
Indapamide	C
Sucralfate	C
Vitamins	C

Date:06/22/00ISR Number: 3575535-4Report Type:Periodic Company Report #WAES 99122024
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspnoea Ecchymosis Fluid Retention	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5	

MG/DAILY/PO

Dulcolax	C	
Mevacor	C	
Tylenol	C	
Bumetanide	C	
Isosorbide	C	
Vasotec	C	
Norvasc	C	
Klor-Con	C	
Glucotrol Xl	C	

Date:06/22/00ISR Number: 3575536-6Report Type:Periodic Company Report #WAES 00020047
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research			
	Headache	Health			Laboratories Div			
	Skin Nodule	Professional			Merck Co Inc	ORAL	25	

MG/DAILY/PO

Ambien	C	
Estrace	C	
Vitamin B(12)	C	
Vitamins	C	

Date:06/22/00ISR Number: 3575540-8Report Type:Periodic Company Report #WAES 00020090
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Dysuria	Health			Laboratories Div			
	Urinary Retention	Professional			Merck Co Inc	ORAL	25	

MG/DAILY/PO

Hydrodiuril	C	

Date:06/22/00ISR Number: 3575543-3Report Type:Periodic Company Report #WAES 00020209
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pruritus Female	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575546-9Report Type:Periodic Company Report #WAES 99122028
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Didronel	C				
			Hydrodiuril	C				
			Maclicine	C				
			Prevacid	C				
			Tylenol	C				
			Xanax	C				

			Ascorbic Acid	C
			Glucosamine	C
			Vitamins	C

Date:06/22/00ISR Number: 3575548-2Report Type:Periodic Company Report #WAES 00020228
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575550-0Report Type:Periodic Company Report #WAES 99122174
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Prinivil	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3575551-2Report Type:Periodic Company Report #WAES 00020337
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dermatitis Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
	Nausea		Celebrex	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3575553-6Report Type:Periodic Company Report #WAES 00020339
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zantac	C				
			Atenolol	C				
			Tamoxifen	C				

Date:06/22/00ISR Number: 3575555-XReport Type:Periodic Company Report #WAES 00020342
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Interaction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;1 2.5 MG	

				Norvasc	SS		
				Avapro	C		ORAL
25							
MG/DAILY/PO							

Date:06/22/00ISR Number: 3575557-3Report Type:Periodic Company Report #WAES 00051755
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575559-7Report Type:Periodic Company Report #WAES 00020353
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Alopecia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Pravachol	C				
			Premarin	C				
			Provera	C				
			Calcium Supplement (Composition Chondroitin (+)	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3575560-3Report Type:Periodic Company Report #WAES 00051756
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575561-5Report Type:Periodic Company Report #WAES 00020359
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Lorazepam	C				
			Nortriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575563-9Report Type:Periodic Company Report #WAES 00051758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:06/22/00ISR Number: 3575565-2Report Type:Periodic Company Report #WAES 00020368
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Hypertrophy Breast	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
			Estrace	C				
			Motrin	C				
			Naprosyn	C				
			Norvasc	C				
			Prevacid	C				
			Ultram	C				

Date:06/22/00ISR Number: 3575567-6Report Type:Periodic Company Report #WAES 00051759
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:06/22/00ISR Number: 3575572-XReport Type:Periodic Company Report #WAES 00051760
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575573-1Report Type:Periodic Company Report #WAES 00020545
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendonitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575579-2Report Type:Periodic Company Report #WAES 00020552
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/00ISR Number: 3575580-9Report Type:Periodic Company Report #WAES 00051761
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575584-6Report Type:Periodic Company Report #WAES 00051762
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ocular Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575588-3Report Type:Periodic Company Report #WAES 00051763
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Insomnia Malaise Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Pain In Extremity Paraesthesia		Celebrex Vasotec Gemfibrozil Verapamil	C C C C				

Date:06/22/00ISR Number: 3575589-5Report Type:Periodic Company Report #WAES 00020568
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO;	
	Diarrhoea							
	Sinusitis							
	Vomiting						50 MG/DAILY/PO;2 5 MG/QOD/PO	
			Ms Contin	C				
			Msir	C				
			Neurontin	C				

Date:06/22/00ISR Number: 3575591-3Report Type:Periodic Company Report #WAES 00051769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575595-0Report Type:Periodic Company Report #WAES 00051770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:06/22/00ISR Number: 3575598-6Report Type:Periodic Company Report #WAES 00051773
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Tab Vicodin Tablets	SS		ORAL	PO	
			Tab Flexeril 10 Mg	SS		ORAL	5 MG DAILY PO	
			Naproxen	C				

Date:06/22/00ISR Number: 3575599-8Report Type:Periodic Company Report #WAES 00020570
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Cough	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Baycol	C				
			Evista	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3575601-3Report Type:Periodic Company Report #WAES 00051774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							
	Pain				Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575603-7Report Type:Periodic Company Report #WAES 00020702
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Hepatic Function Abnormal				Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO; 12.5	
			Tylenol	C				
			Vicodin Tablets	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575604-9Report Type:Periodic Company Report #WAES 00051776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Photosensitivity Reaction Rosacea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575606-2Report Type:Periodic Company Report #WAES 00020711
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Glucophage	C				
			Plavix	C				
			Trantan	C				
			Zocor	C				

Date:06/22/00ISR Number: 3575617-7Report Type:Periodic Company Report #WAES 00020737
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3575619-0Report Type:Periodic Company Report #WAES 00020799
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			

	Muscular Weakness	Health Professional			Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO	10 DAY					
			Donnatal	C		
			Imodium	C		
			Pepto-Bismol	C		
			Synthroid	C		
			Glucosamine	C		
			Prednisone	C		
			Vitamin E	C		

Date:06/22/00ISR Number: 3575625-6Report Type:Periodic Company Report #WAES 00020814
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Calan Sr	C		
			Caltrate	C		
			Centrum Silver	C		
			Dyazide	C		

			Premarin	C		
			Aspirin	C		
			Chondroitin (+)			
			Glucosamine	C		
			Vitamin E	C		

Date:06/22/00ISR Number: 3575628-1Report Type:Periodic Company Report #WAES 00020822
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UKN/UNK/PO	
			Wellbutrin	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3575631-1Report Type:Periodic Company Report #WAES 00020839
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dermatitis Stomatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Metamucil	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575634-7Report Type:Periodic Company Report #WAES 00020925
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/HS/PO 3 DAY

Coenzyme Q10	SS	
Calcium Supplement	C	
Magnesium Preparation	C	
Vitamin E	C	

Date:06/22/00ISR Number: 3575636-0Report Type:Periodic Company Report #WAES 00020939
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea Oedema Peripheral	Health Professional Distributor	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased		Celebrex	SS		ORAL	200 MG DAILY PO	
			Acetaminophen	C				
			Hormones	C				
			Hydrocodone	C				

Date:06/22/00ISR Number: 3575641-4Report Type:Periodic Company Report #WAES 00020959
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Dysgeusia	Professional			Merck Co Inc	ORAL	UNK/UNK/PO	
	Eyelid Oedema		Darvocet-N	C				
	Glossodynia		Flonase	C				
			Hydrodiuril	C				
			Lotrel	C				
			Maxzide	C				
			Ogen	C				
			Synthroid	C				
			Tessalon	C				
			Valium	C				
			(Therapy Unspecified)	C				
			Estrogenic Preparation	C				
			Thyroid	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3575643-8Report Type:Periodic Company Report #WAES 00020964
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3575649-9Report Type:Periodic Company Report #WAES 00020969
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Pain In Extremity	Professional			Merck Co Inc	ORAL	25	

MG/DAILY/PO

K-Dur	C
Lasix	C
Monopril	C
Procardia Xl	C
Allopurinol	C

Date:06/22/00ISR Number: 3575651-7Report Type:Periodic Company Report #WAES 00021047
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lung Disorder Neoplasm Malignant		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK.UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575657-8Report Type:Periodic Company Report #WAES 00021054
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
	Weight Increased	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Imuran	C				
			Plaquenil	C				
			Synthroid	C				
			Trazodone	C				

Date:06/22/00ISR Number: 3575658-XReport Type:Periodic Company Report #WAES 00021079
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	UNK	UNK/PO

Date:06/22/00ISR Number: 3575661-XReport Type:Periodic Company Report #WAES 00021080
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Vioxx	PS	Merck Research			
	Congestive	Professional			Laboratories Div			
	Oedema	Company			Merck Co Inc	ORAL	25	MG/DAILY/PO
		Representative						

Date:06/22/00ISR Number: 3575667-0Report Type:Periodic Company Report #WAES 00021089
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol With Codeine #3	C				
			Zantac	C				
			Doxepin	C				
			Propoxiphene	C				

Date:06/22/00ISR Number: 3575672-4Report Type:Periodic Company Report #WAES 00021108
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dry Skin Pain Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575677-3Report Type:Periodic Company Report #WAES 00021160
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fracture							
	Motion Sickness							
	Nausea							
	Pain		Azmacort	C				
	Tooth Disorder		Hydrodiuril	C				
	Toothache		Prevacid	C				
	Vomiting		Serevent	C				
			Valium	C				
			Zestril	C				

Date:06/22/00ISR Number: 3575679-7Report Type:Periodic Company Report #WAES 00021193
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypoaesthesia							
	Pain							
	Paraesthesia							
			Lozol	C				
			Norvasc	C				
			Glucosamine	C				
			Metoprolol	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3575681-5Report Type:Periodic Company Report #WAES 00021214
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea							

	Drug Ineffective				Merck Co Inc	ORAL
25 MG/DAILY/						
	Flatulence					
PO SEE IMAGE						
	Haemorrhoids		Cozaar	C		
			Lipitor	C		
			Ibuprofen	C		

Date:06/22/00ISR Number: 3575684-0Report Type:Periodic Company Report #WAES 00021234
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Lasix	C		
			Digoxin	C		

Date:06/22/00ISR Number: 3575687-6Report Type:Periodic Company Report #WAES 00021240
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25

MG/DAILY/PO

Prilosec C

Date:06/22/00ISR Number: 3575690-6Report Type:Periodic Company Report #WAES 00021255
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Daypro	C				
			Ortho Cyclen	C				
			Pepcid	C				
			Prilosec	C				
			Propulsid	C				
			Folic Acid	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3575692-XReport Type:Periodic Company Report #WAES 00021263
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575696-7Report Type:Periodic Company Report #WAES 00021270
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia Oedema Peripheral Tendon Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY / PO						
			Prinzide	C		
			Atenolol	C		
			Ibuprofen	C		

Date:06/22/00ISR Number: 3575697-9Report Type:Periodic Company Report #WAES 00021274
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY / PO						
			Plaquenil	C		
			Folic Acid	C		
			Levothyroxine Sodium	C		
			Sulfamethazine	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575699-2Report Type:Periodic Company Report #WAES 00021323
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
			Dilantin	C				
			Inderal	C				

Date:06/22/00ISR Number: 3575702-XReport Type:Periodic Company Report #WAES 00021351
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG	/DAILY / PO

Date:06/22/00ISR Number: 3575704-3Report Type:Periodic Company Report #WAES 00021367
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Dizziness Tremor	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Cardura	C				
			Monopril	C				
			Zocor	C				
			Clonidine	C				

Date:06/22/00ISR Number: 3575706-7Report Type:Periodic Company Report #WAES 00021372
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	
			Glucophage	C				
			Glynase Prestab Tablets	C				
			Zestril	C				

Date:06/22/00ISR Number: 3575708-0Report Type:Periodic Company Report #WAES 00021405
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575736-5Report Type:Periodic Company Report #WAES 00021435
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue				Laboratories Div			
	Thirst				Merck Co Inc	ORAL	UNK / UNK /	
							PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3575737-7Report Type:Periodic Company Report #WAES 00021470
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective	Health			Laboratories Div			
	Nausea	Professional			Merck Co Inc	ORAL	12.5	
	Weight Decreased						MG/DAILY/PO	
			Advil	C				
			Ambien	C				
			Flovent	C				
			Proventil	C				

Date:06/22/00ISR Number: 3575739-0Report Type:Periodic Company Report #WAES 00050745
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Gastritis				Laboratories Div			
	Rhinitis Allergic				Merck Co Inc	ORAL	25MG/PO	

Date:06/22/00ISR Number: 3575740-7Report Type:Periodic Company Report #WAES 00021474
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK / PO						
			Levaquin	SS		

Date:06/22/00ISR Number: 3575744-4Report Type:Periodic Company Report #WAES 00050749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Premarin	C		
			Synthroid	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575745-6Report Type:Periodic Company Report #WAES 00050750
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Pain							
	Saliva Altered							
	Tongue Disorder							

Date:06/22/00ISR Number: 3575746-8Report Type:Periodic Company Report #WAES 00050751
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Norvasc	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3575747-XReport Type:Periodic Company Report #WAES 00050754
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575748-1Report Type:Periodic Company Report #WAES 00050755
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lanoxin	C				
			Propulsid	C				

Date:06/22/00ISR Number: 3575750-XReport Type:Periodic Company Report #WAES 00050758
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Diarrhoea Disorientation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eating Disorder		Ambien	C				
	Faeces Discoloured		Darvocet-N	C				
	Feeling Abnormal		Elavil	C				
			Lasix	C				
			Potassium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575751-1Report Type:Periodic Company Report #WAES 00021482
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID / PO	

Date:06/22/00ISR Number: 3575753-5Report Type:Periodic Company Report #WAES 00021491
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:06/22/00ISR Number: 3575755-9Report Type:Periodic Company Report #WAES 00050766
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575758-4Report Type:Periodic Company Report #WAES 00050770
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Lopressor	C
Zocor	C
Nitroglycerin	C

Date:06/22/00ISR Number: 3575762-6Report Type:Periodic Company Report #WAES 00050786
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Lymphadenopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

12.5

MG/DAILY/PO

Fosamax	C
Lipitor	C
Synthroid	C

Date:06/22/00ISR Number: 3575763-8Report Type:Periodic Company Report #WAES 00021492
Age:64 YR Gender:Male I/FU:F

Outcome	PT
	Cough
	Dry Throat

Glossodynia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
	Tab Vioxx	SS		ORAL	UNK / UNK / PO	
	Altace	SS				
	Cardizem Cd	C				
	Imdur	C				
	Lipitor	C				
	Prevacid	C				
	Propulsid	C				
	Aspirin	C				
	Atenolol	C				
	Ubiquinones	C				

Date:06/22/00ISR Number: 3575766-3Report Type:Periodic Company Report #WAES 00021512
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:06/22/00ISR Number: 3575767-5Report Type:Periodic Company Report #WAES 00050790
Age:70 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Hytrin	C	
Prilosec	C	
Synthroid	C	
Zocor	C	
Atenolol (+) Chlorthalidone	C	

Date:06/22/00ISR Number: 3575769-9Report Type:Periodic Company Report #WAES 00021518
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Insomnia Malaise Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY / PO	

Date:06/22/00ISR Number: 3575771-7Report Type:Periodic Company Report #WAES 00021521
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source
	Hallucination	Health Professional

		Company Representative	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK /						
PO						

Date:06/22/00ISR Number: 3575772-9Report Type:Periodic Company Report #WAES 00021560
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/						
PO						

Date:06/22/00ISR Number: 3575773-0Report Type:Periodic Company Report #WAES 00050813
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3575775-4Report Type:Periodic Company Report #WAES 00021595
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oedema Peripheral Paranoia	Consumer Health	Vioxx	PS	Merck Research Laboratories Div	

	Urinary Tract Infection	Professional			Merck Co Inc	ORAL
12.5 MG/						
BID/PO	1 WK					
			Tab Vioxx	SS		ORAL
12.5 MG / D						
AILY / PO	2 WK					
			Cardizem	C		
			Vasotec	C		
			Therapy Unspecified	C		
			Heparin	C		
			Zantac	C		
			Trental	C		
			Plendil	C		

Date:06/22/00ISR Number: 3575778-XReport Type:Periodic Company Report #WAES00050814
Age:73 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Consumer	Vioxx	PS	Merck Research	
	Weight Increased				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Atacand	C		
			Dyazide	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575780-8Report Type:Periodic Company Report #WAES 00021602
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
	Dizziness							
	Gait Disturbance							
	Hypersomnia							
	Mental Impairment		Mag-Ox	C				
			Plavix	C				
			Vasotec	C				
			Furosemide	C				
			Hydrochlorothiazide (+) Triamter	C				
			Labetalol Hydrochloride	C				

Date:06/22/00ISR Number: 3575782-1Report Type:Periodic Company Report #WAES 00021605
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / DAILY/ PO	
	Oedema Peripheral							
			Tab Vioxx 12.5 Mg	SS		ORAL	UNK / DAILY / PO	
			Monopril	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3575784-5Report Type:Periodic Company Report #WAES 00050817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/00ISR Number: 3575788-2Report Type:Periodic Company Report #WAES 00050820
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575796-1Report Type:Periodic Company Report #WAES 00050827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575805-XReport Type:Periodic Company Report #WAES 00020828
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Premarin	C				
			Alprazolam	C				
			Progesterone	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575810-3Report Type:Periodic Company Report #WAES00050831
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Chest Pain Hiatus Hernia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Catapres	C				
			Glucotrol Xl	C				
			Prilosec	C				
			Ultram	C				

Date:06/22/00ISR Number: 3575814-0Report Type:Periodic Company Report #WAES 00050833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575818-8Report Type:Periodic Company Report #WAES 00050837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Lomotil	C				

Date:06/22/00ISR Number: 3575824-3Report Type:Periodic Company Report #WAES 00042240
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575825-5Report Type:Periodic Company Report #WAES 00042285
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:06/22/00ISR Number: 3575826-7Report Type:Periodic Company Report #WAES 00042287
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575828-0Report Type:Periodic Company Report #WAES 00042290
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	2 WK

Date:06/22/00ISR Number: 3575829-2Report Type:Periodic Company Report #WAES 00042291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575832-2Report Type:Periodic Company Report #WAES00042297
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis C	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
UNK/UNK/PO

Celebrex C
Therapy Unspecified C

Date:06/22/00ISR Number: 3575833-4Report Type:Periodic Company Report #WAES 00042298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575835-8Report Type:Periodic Company Report #WAES 00042300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575836-XReport Type:Periodic Company Report #WAES 00042303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Diarrhoea Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575837-1Report Type:Periodic Company Report #WAES 00042309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575838-3Report Type:Periodic Company Report #WAES 00042311
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575839-5Report Type:Periodic Company Report #WAES 00042312
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Haematuria Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

			Hydrocodin	C		
			Prilosec	C		
			Xanax	C		
			Amitriptyline	C		

Date:06/22/00ISR Number: 3575840-1Report Type:Periodic Company Report #WAES 00042320
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Synthroid	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3575844-9Report Type:Periodic Company Report #WAES 00042327
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO

	Inderal	C
	Lasix	C
	Lopressor	C
	Medroxyprogesterone 17-Acetate	C

Date:06/22/00ISR Number: 3575850-4Report Type:Periodic Company Report #WAES 00042329
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 1 MON
			Estratab	C				

Date:06/22/00ISR Number: 3575851-6Report Type:Periodic Company Report #WAES 00042336
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Depression Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575854-1Report Type:Periodic Company Report #WAES 00042338
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				

			Inderal	C		
			Zyrtec	C		

Date:06/22/00ISR Number: 3575857-7Report Type:Periodic Company Report #WAES 00042339
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aldactone	C				
			Lasix	C				
			Synthroid	C				
			Allopurinol	C				
			Diuretic Preparation (Compositio	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3575859-0Report Type:Periodic Company Report #WAES 00042342
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Glucotrol	C				
			Premarin	C				

Date:06/22/00ISR Number: 3575860-7Report Type:Periodic Company Report #WAES 00042343
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575863-2Report Type:Periodic Company Report #WAES 00042344
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				
			Robaxin	C				
			Ultram	C				

Date:06/22/00ISR Number: 3575864-4Report Type:Periodic Company Report #WAES 00042345
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fiebercon	C				
			Prinivil	C				
			Synthroid	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3575866-8Report Type:Periodic Company Report #WAES 00042346
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575869-3Report Type:Periodic Company Report #WAES 00042348
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Dyspepsia							
	Feeling Abnormal		Avapro	C				
	Nasopharyngeal Disorder		[Therapy Unspecified]	C				
	Nausea		Aspirin	C				

Date:06/22/00ISR Number: 3575872-3Report Type:Periodic Company Report #WAES 00042349
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pulmonary Congestion							
			Ibuprofen	C				

Date:06/22/00ISR Number: 3575875-9Report Type:Periodic Company Report #WAES 00042350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	12 WK
	Paraesthesia							
			Ziac	C				
			Calcium Supplement	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3575883-8Report Type:Periodic Company Report #WAES 00042352
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Buspar	C				
			Fosamax	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3575892-9Report Type:Periodic Company Report #WAES 00042357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Ecchymosis Hyperkeratosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Scar		Fosamax	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575894-2Report Type:Periodic Company Report #WAES 00042358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Headache Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575896-6Report Type:Periodic Company Report #WAES 00042359
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Plendil	C				
			Prinivil	C				

Date:06/22/00ISR Number: 3575899-1Report Type:Periodic Company Report #WAES 00042360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	No Adverse Drug Effect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO; 12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575906-6Report Type:Periodic Company Report #WAES 00042361
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3575907-8Report Type:Periodic Company Report #WAES 00042363
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prozac	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3575909-1Report Type:Periodic Company Report #WAES 00042365
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dysuria Oedema Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575911-XReport Type:Periodic Company Report #WAES 00042366
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3575912-1Report Type:Periodic Company Report #WAES 00042371
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrocodone	C				

Date:06/22/00ISR Number: 3575913-3Report Type:Periodic Company Report #WAES 00042373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575915-7Report Type:Periodic Company Report #WAES 00042376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Weight Increased				Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3575917-0Report Type:Periodic Company Report #WAES 00042378
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Synthroid	C		
			Zocor	C		
			Zoloft	C		
			Aspirin	C		
			Prednisone	C		

Date:06/22/00ISR Number: 3575918-2Report Type:Periodic Company Report #WAES 00042566
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575919-4Report Type:Periodic Company Report #WAES 00042380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Lipitor	C				
			Prempro	C				
			Glucosamine	C				
			Ticlopidine	C				

Date:06/22/00ISR Number: 3575920-0Report Type:Periodic Company Report #WAES 00042390
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Vancenase	C				
			Ziac	C				

Date:06/22/00ISR Number: 3575922-4Report Type:Periodic Company Report #WAES 00042397
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Clinoril	C				
			Maxzide	C				
			Prozac	C				

Date:06/22/00ISR Number: 3575924-8Report Type:Periodic Company Report #WAES 00042402
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Premarin	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3575925-XReport Type:Periodic Company Report #WAES 00042406
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575927-3Report Type:Periodic Company Report #WAES 00042417
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norco	C				

Date:06/22/00ISR Number: 3575928-5Report Type:Periodic Company Report #WAES 00042424
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575930-3Report Type:Periodic Company Report #WAES 00042435
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Propacet	C				
			Synthroid	C				
			Allopurinol	C				
			Lorazepam	C				

Date:06/22/00ISR Number: 3575932-7Report Type:Periodic Company Report #WAES 00042436
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Lipitor	C		
			Plendil	C		
			Synthroid	C		
			Atenolol	C		
			Chlordiazepoxide	C		
			Methotrexate	C		

Date:06/22/00ISR Number: 3575933-9Report Type:Periodic Company Report #WAES 00042437
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Panic Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO; 3) 50						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575935-2Report Type:Periodic Company Report #WAES 00042438
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575937-6Report Type:Periodic Company Report #WAES 00042439
Age:65 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575942-XReport Type:Periodic Company Report #WAES 00042441
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575945-5Report Type:Periodic Company Report #WAES 00042445
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Inflammatory Bowel Disease		Azulfidine	C				
			Celebrex	C				

Date:06/22/00ISR Number: 3575946-7Report Type:Periodic Company Report #WAES 00042458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Poisoning	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575947-9Report Type:Periodic Company Report #WAES 00032492
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Drug Ineffective Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	SS		ORAL	UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575948-0Report Type:Periodic Company Report #WAES 00042459
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Respiratory Disorder					
1) 25 MG/BID/PO; 2) 25 MG/DAILY/PO						
			Cozaar	C		
			Glucophage	C		
			Lasix	C		
			Ritalin	C		
			Tylenol With Codeine	C		
			Zocor	C		
			Aspirin	C		

Date:06/22/00ISR Number: 3575949-2Report Type:Periodic Company Report #WAES 00032495
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Coreg	C		
			Cozaar	C		
			Lipitor	C		
			Furosemide	C		

Date:06/22/00ISR Number: 3575950-9Report Type:Periodic Company Report #WAES 00032517
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Augmentin	C				
			Oruvail	C				
			(Therapy Unspecified)	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3575951-0Report Type:Periodic Company Report #WAES 00042464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				
			Norvasc	C				
			Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575952-2Report Type:Periodic Company Report #WAES 00032518
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/25 MG/DAILY/PO	
			Lipitor	C				
			Ocusert Pilo	C				
			Tenormin	C				
			Trusopt	C				
			Xalatan	C				
			Albuterol	C				
			Hydrochlorothiazide (+) Triamterine	C				

Date:06/22/00ISR Number: 3575953-4Report Type:Periodic Company Report #WAES 00042465
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fiorpap	C				
			Flonase	C				
			Premarin	C				
			Prilosec	C				
			Prozac	C				

Date:06/22/00ISR Number: 3575954-6Report Type:Periodic Company Report #WAES 00032519
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research			

	Diarrhoea	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO			Hydrocodone	C		

Date:06/22/00ISR Number: 3575955-8Report Type:Periodic Company Report #WAES 00052243
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575956-XReport Type:Periodic Company Report #WAES 00032520
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/12.5 MG/DAILY/PO	

			Zocor	C
			Glucosamine	C

Date:06/22/00ISR Number: 3575957-1Report Type:Periodic Company Report #WAES 00052326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Recombivax Hb	C				

Date:06/22/00ISR Number: 3575958-3Report Type:Periodic Company Report #WAES 00032524
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Buspar	C				
			Cytomel	C				
			Levoxyl	C				
			Paxil	C				
			Ritalin	C				

Date:06/22/00ISR Number: 3575959-5Report Type:Periodic Company Report #WAES 00052378
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

			Avapro	C		
			Celexa	C		
			Darvon	C		
			Depakote	C		
			Neurontin	C		
			Nortriptyline	C		

Date:06/22/00ISR Number: 3575961-3Report Type:Periodic Company Report #WAES 00052380
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Armour Thyroid	C				
			Calan Sr	C				
			Glucophage	C				
			K-Dur	C				
			Premarin	C				
			Glipizide	C				
			Hydrochlorothiazide	C				

Date:06/22/00ISR Number: 3575962-5Report Type:Periodic Company Report #WAES 00032526
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575963-7Report Type:Periodic Company Report #WAES 00052488
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575964-9Report Type:Periodic Company Report #WAES 00032527
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575965-0Report Type:Periodic Company Report #WAES 00052489
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Connective Tissue Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Lymphadenopathy	Company Representative			Merck Co Inc	ORAL PO

Date:06/22/00ISR Number: 3575966-2Report Type:Periodic Company Report #WAES 00032531
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Hydrocortone	C				
			Procardia	C				
			Zyrtec	C				
			Triamcinolone	C				
			Vitamins	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3575967-4Report Type:Periodic Company Report #WAES 00032533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575968-6Report Type:Periodic Company Report #WAES 00052642
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575969-8Report Type:Periodic Company Report #WAES 00032534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575970-4Report Type:Periodic Company Report #WAES 00052643
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575971-6Report Type:Periodic Company Report #WAES00052644
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia Upper Respiratory Tract Infection	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

		Representative	Vioxx	SS		ORAL

PRN/PO

Date:06/22/00ISR Number: 3575972-8Report Type:Periodic Company Report #WAES 00032535
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Celebrex	C		
			Diazide	C		
			Synthroid	C		
			(Therapy Unspecified)	C		

Date:06/22/00ISR Number: 3575973-XReport Type:Periodic Company Report #WAES 00052772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Laboratory Test Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575974-1Report Type:Periodic Company Report #WAES 00032539
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575975-3Report Type:Periodic Company Report #WAES 00052910
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575976-5Report Type:Periodic Company Report #WAES 00032545
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Laceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3575977-7Report Type:Periodic Company Report #WAES 00010002
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Corneal Erosion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Relafen	C				

			Ultram	C		

Date:06/22/00ISR Number: 3575978-9Report Type:Periodic Company Report #WAES 00032548
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diazide	C				

Date:06/22/00ISR Number: 3575979-0Report Type:Periodic Company Report #WAES 00032549
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575980-7Report Type:Periodic Company Report #WAES 00010023
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection Purulence Sputum Abnormal Urine Abnormality	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vioxx	SS		ORAL	50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575981-9Report Type:Periodic Company Report #WAES 00032555
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(Therapy Unspecified	C				

Date:06/22/00ISR Number: 3575982-0Report Type:Periodic Company Report #WAES 00010024
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vioxx	SS		ORAL	25 MG/AM/ PO	
			Celebrex	C				
			Fosamax	C				
			Os-Cal	C				

Date:06/22/00ISR Number: 3575983-2Report Type:Periodic Company Report #WAES 00032556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Pravachol	C				
			Procardia	C				
			Atenolol	C				
			Hydrochlorothizide (+) Triamterene	C				

Date:06/22/00ISR Number: 3575984-4Report Type:Periodic Company Report #WAES 00010035
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Feeling Abnormal Malaise	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Tylenol	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3575985-6Report Type:Periodic Company Report #WAES 00032564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Fosamax	C				

Date:06/22/00ISR Number: 3575986-8Report Type:Periodic Company Report #WAES 00010065
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Haemoptysis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Agrylin	C				
			Synthroid	C				
			Toprol Xl	C				

Date:06/22/00ISR Number: 3575987-XReport Type:Periodic Company Report #WAES 00040739
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Bladder Disorder Pain Toothache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575988-1Report Type:Periodic Company Report #WAES 00010136
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Disorder	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
	Pain				Merck Co Inc	ORAL	25	
	Paraesthesia						MG/DAILY/PO	
	Sleep Disorder		Cipro	C				
			Detrol	C				
			Diovan	C				
			Elavil	C				
			Fioricet Tablets	C				
			Fosamax	C				
			Luvox	C				
			Omega-3	C				
			Oruvail	C				
			Prilosec	C				
			Synthroid	C				
			Chondroitin (+) Glucosamine	C				

Date:06/22/00ISR Number: 3575989-3Report Type:Periodic Company Report #WAES 00040743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3575990-XReport Type:Periodic Company Report #WAES 00010221
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Tricor	C				
			Zocor	C				
			Zoloft	C				
			Lorazepam	C				

Date:06/22/00ISR Number: 3575991-1Report Type:Periodic Company Report #WAES 00040745
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Skin Lesion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:06/22/00ISR Number: 3575992-3Report Type:Periodic Company Report #WAES 00010226
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Ulcerative	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				

			Carafate	C
			Celebrex	C
			Synthroid	C
			Tylenol Extra Strength	C

Date:06/22/00ISR Number: 3575993-5Report Type:Periodic Company Report #WAES 00040745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575994-7Report Type:Periodic Company Report #WAES 00010260
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Moduretic	C				

Date:06/22/00ISR Number: 3575995-9Report Type:Periodic Company Report #WAES 00040760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575996-0Report Type:Periodic Company Report #WAES 00011077
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3575997-2Report Type:Periodic Company Report #WAES 00040763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3575998-4Report Type:Periodic Company Report #WAES00011158
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3575999-6Report Type:Periodic Company Report #WAES 00040764
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Percocet	C				

Date:06/22/00ISR Number: 3576000-0Report Type:Periodic Company Report #WAES 00040765
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Postural Dyspnoea Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576002-4Report Type:Periodic Company Report #WAES 00011217
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576003-6Report Type:Periodic Company Report #WAES 00040769
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Peri-Colace	C				
			Amiloride Hydrochloride	C				
			Diclofenac	C				

Date:06/22/00ISR Number: 3576004-8Report Type:Periodic Company Report #WAES 00011662
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/, 25 MG DAILY/PO	

Date:06/22/00ISR Number: 3576005-XReport Type:Periodic Company Report #WAES 00040770
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 10 DAY
			Aspirin	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576006-1Report Type:Periodic Company Report #WAES 00040772
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Prilosec	C				

Date:06/22/00ISR Number: 3576007-3Report Type:Periodic Company Report #WAES 00011665
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional
	Oedema Peripheral	

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/, 25 MG DAILY/PO	
	Cardura	C				
	Lopressor	C				
	Miacalcin	C				
	Prempro	C				

Date:06/22/00ISR Number: 3576008-5Report Type:Periodic Company Report #WAES 00040775
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Lipitor	C				
			Plendil	C				

Date:06/22/00ISR Number: 3576009-7Report Type:Periodic Company Report #WAES 00040776
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Dicloreum	C				
			Hydrodiuril	C				
			Calcium Supplement	C				
			Chondroitin (+) Glucosamine	C				

				Estrogenic Preparations	C		
				Vitamin E	C		

Date:06/22/00ISR Number: 3576010-3Report Type:Periodic Company Report #WAES 00040777
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							
	Urinary Tract Disorder							
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Vasotec	C				
			Colchicine	C				
			Potassium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576011-5Report Type:Periodic Company Report #WAES 00011670
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
	Oedema Peripheral	Company			Merck Co Inc	ORAL	12.5	
		Representative					MG/DAILY/PO	
			Diovan	C				
			Lasix	C				
			Lopid	C				
			Lopressor	C				
			Synthroid	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576012-7Report Type:Periodic Company Report #WAES 00040779
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	SEE IMAGE	
			Lipitor	C				
			Premarin	C				
			Prevacid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576013-9Report Type:Periodic Company Report #WAES 00011742
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Muscle Spasms	Professional			Merck Co Inc	ORAL	12.5	
	Nausea						MG/BID/PO	

	Sensation Of Heaviness	Hyzaar	C
		Imdur	C
		Pravachol	C
		Relafen	C
		Tenormin	C
		Aspirin	C

Date:06/22/00ISR Number: 3576014-0Report Type:Periodic Company Report #WAES 00040781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576015-2Report Type:Periodic Company Report #WAES 00011745
Age:74 YR Gender:Female I/FU:F

Outcome	PT
	Asthenia
	Depression
	Dizziness
	Fatigue

Movement Disorder

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Klonopin	C				
			Plaquenil	C				
			Premarin	C				
			Serecor	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576016-4Report Type:Periodic Company Report #WAES 00040782
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Prilosec	C				

Date:06/22/00ISR Number: 3576017-6Report Type:Periodic Company Report #WAES 00011753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dry Mouth Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS			6	WK

Date:06/22/00ISR Number: 3576018-8Report Type:Periodic Company Report #WAES 00040783
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Estrace	C				
			Provera	C				
			Ultram	C				
			Valium	C				
			Vasotec	C				
			Zantac	C				

Date:06/22/00ISR Number: 3576019-XReport Type:Periodic Company Report #WAES 00040785
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576020-6Report Type:Periodic Company Report #WAES 00011755
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Prevacid	C				
			Aspirin	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576021-8Report Type:Periodic Company Report #WAES 00040786
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 MON

Date:06/22/00ISR Number: 3576022-XReport Type:Periodic Company Report #WAES 00011808
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576023-1Report Type:Periodic Company Report #WAES 00011875
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral	Health			Laboratories Div	
	Pain	Professional			Merck Co Inc	ORAL
12.5 MG/PO						
			Accolate	C		
			Aerobid	C		
			Darvocet-N	C		
			Demadex	C		
			Flovent	C		
			Lanoxin	C		
			Prilosec	C		
			Zyrtec	C		
			Aspirin	C		
			Potassium Chloride	C		

Date:06/22/00ISR Number: 3576024-3Report Type:Periodic Company Report #WAES 00011902
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						
			[Therapy Unspecifed	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576025-5Report Type:Periodic Company Report #WAES 00012067
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Muscle Spasms Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Myalgia		Celebrex	C				
			Crixivan	C				
			Lamivudine	C				
			Zidovudine	C				

Date:06/22/00ISR Number: 3576026-7Report Type:Periodic Company Report #WAES 00012072
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Colace	C				
			Nasonex	C				
			Paxil	C				
			Premarin	C				
			Prinivil	C				
			Albuterol	C				
			Insulin Injection	C				
			Isophane Insulin Suspension	C				
			Metformin	C				
			Potassium Chloride	C				
			Vitamin B(12)	C				

Date:06/22/00ISR Number: 3576027-9Report Type:Periodic Company Report #WAES 00012087
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Prothrombin Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG, 25 MG /DAILY/PO						
			Coumadin	C		

Date:06/22/00ISR Number: 3576028-0Report Type:Periodic Company Report #WAES 00052155
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia Fatigue Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG DAILY PO						
			Prevacid	C		
			Valium	C		
			Estrogenic Prepartion	C		
			Progesterone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576029-2Report Type:Periodic Company Report #WAES 00012109
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Blood Pressure Increased Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5	MG/DAILY/PO

Date:06/22/00ISR Number: 3576030-9Report Type:Periodic Company Report #00012173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576031-0Report Type:Periodic Company Report #WAES 00012174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576032-2Report Type:Periodic Company Report #WAES 00052156
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Premarin	C		

Date:06/22/00ISR Number: 3576033-4Report Type:Periodic Company Report #WAES 00052158
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3576034-6Report Type:Periodic Company Report #WAES 00052159
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Compazine	C		
			Evista	C		
			Prilosec	C		
			Tenormin	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576035-8Report Type:Periodic Company Report #WAES 00051045
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576036-XReport Type:Periodic Company Report #WAES 00052160
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	
			Synthroid	C				
			Timpotic	C				

Date:06/22/00ISR Number: 3576037-1Report Type:Periodic Company Report #WAES 00051053
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Diazide	C				
			Fosamax	C				
			Premarin	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576038-3Report Type:Periodic Company Report #WAES 00052161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Claritin	C				
			Fosamax	C				
			Premarin	C				
			Zestril	C				
			Aspirin	C				
			Calcium Supplement	C				
			Folic Acid	C				
			Iron	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576039-5Report Type:Periodic Company Report #WAES 00051056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576040-1Report Type:Periodic Company Report #WAES 00052162
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Diabeta	C				
			Synthroid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576041-3Report Type:Periodic Company Report #WAES 00051057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3576042-5Report Type:Periodic Company Report #WAES 00052163
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Constipation							
	Faeces Discoloured							
	Nausea							
			Flomax (Tamsulosin (R)-Form Hydr	C				PO
			Nadolol	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576043-7Report Type:Periodic Company Report #WAES 00051061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576044-9Report Type:Periodic Company Report #WAES 00052165
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				

Date:06/22/00ISR Number: 3576045-0Report Type:Periodic Company Report #WAES 00051067
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Jaundice	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576046-2Report Type:Periodic Company Report #WAES 00051068
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50MG PO	

Representative

Date:06/22/00ISR Number: 3576047-4Report Type:Periodic Company Report #WAES 00052168
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allerest Tablets	C				

Date:06/22/00ISR Number: 3576048-6Report Type:Periodic Company Report #WAES 00052171
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Date:06/22/00ISR Number: 3576049-8Report Type:Periodic Company Report #WAES 00051081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tegretal	C				

Date:06/22/00ISR Number: 3576050-4Report Type:Periodic Company Report #WAES 00052177
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Glucosamine	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576051-6Report Type:Periodic Company Report #WAES 00051083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576052-8Report Type:Periodic Company Report #WAES 00051092
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Cozaar	C				
			Fioricet Tablets	C				
			Levaquin	C				
			Xanax	C				
			Zantac	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3576053-XReport Type:Periodic Company Report #WAES 00051094
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Oedema Peripheral Prostatic Disorder Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prilosec	C				
			Theo-Dur	C				
			Toprol Xl Tablets	C				
			Zestril	C				
			Zoloft	C				

Date:06/22/00ISR Number: 3576054-1Report Type:Periodic Company Report #WAES 00052178
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Cough							
	Pulmonary Congestion				Merck Co Inc	ORAL	PO	
			Allegra	C				

Date:06/22/00ISR Number: 3576055-3Report Type:Periodic Company Report #WAES 00051099
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Haematochezia							
					Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576056-5Report Type:Periodic Company Report #WAES 00052182
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Miacalcin	C				
			Paxil	C				
			Aspirin	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576057-7Report Type:Periodic Company Report #WAES 00051100
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO, 50 MG/DAILY/PO, 100	
			Lipitor	C				
			Paxil	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576058-9Report Type:Periodic Company Report #WAES 00052184
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY

PO

Prempro	C	
Prevacid	C	
Synthroid	C	

Date:06/22/00ISR Number: 3576059-0Report Type:Periodic Company Report #WAES 00051105
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576060-7Report Type:Periodic Company Report #WAES 00051107
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryl	C				
			Centrum Silver	C				
			Maxzide	C				

Os-Cal	C	
Prempro	C	
Prinivil	C	
Atenolol	C	

Date:06/22/00ISR Number: 3576061-9Report Type:Periodic Company Report #WAES 00052185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576062-0Report Type:Periodic Company Report #WAES 00052192
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Oliguria Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Vasotec	C			PO	
			Zyrtec	C				
			Calcium Supplement	C				
			Estradiol	C				

Date:06/22/00ISR Number: 3576063-2Report Type:Periodic Company Report #WAES 00051109
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Cardura	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3576064-4Report Type:Periodic Company Report #WAES 00052224
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Diarrhoea				Laboratories Div	
					Merck Co Inc	ORAL
25 MG DAILY						
PO						

Date:06/22/00ISR Number: 3576065-6Report Type:Periodic Company Report #WAES 00051110
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Celebrex	C		
			Plaquenil	C		

				Prempro	C		
				Methotrexate	C		

Date:06/22/00ISR Number: 3576066-8Report Type:Periodic Company Report #WAES 00052230
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
	Diarrhoea							
	Pruritus							
			Atacand	C				
			Norvasc	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3576067-XReport Type:Periodic Company Report #WAES 00051111
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576068-1Report Type:Periodic Company Report #WAES 00052232
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Postural	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Coumadin	C				
			Detrol	C				

Date:06/22/00ISR Number: 3576069-3Report Type:Periodic Company Report #WAES 00051122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576070-XReport Type:Periodic Company Report #WAES 00051123
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576072-3Report Type:Periodic Company Report #WAES 00040790
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576073-5Report Type:Periodic Company Report #WAES 00040791
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Miacalcin	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576074-7Report Type:Periodic Company Report #WAES 00051975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:06/22/00ISR Number: 3576076-0Report Type:Periodic Company Report #WAES 00040792
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO 15 DAY

Date:06/22/00ISR Number: 3576078-4Report Type:Periodic Company Report #WAES 00051978
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lanoxin	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576079-6Report Type:Periodic Company Report #WAES 00040797
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Premarin	C				

			Vasotec	C		

Date:06/22/00ISR Number: 3576081-4Report Type:Periodic Company Report #WAES 00040798
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral							
	Paraesthesia							
	Vaginal Discharge							
			Synthroid	C				
			Hydrochlorothiazide	C				

Date:06/22/00ISR Number: 3576082-6Report Type:Periodic Company Report #WAES 00051980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576084-XReport Type:Periodic Company Report #WAES 00040801
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
	Drug Ineffective							
	Vomiting							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/TID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

			Darvocet-N	C		
			Diazide	C		
			Premarin	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3576085-1Report Type:Periodic Company Report #WAES 00051981
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying Depression Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				

Date:06/22/00ISR Number: 3576087-5Report Type:Periodic Company Report #WAES 00040802
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actos	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576089-9Report Type:Periodic Company Report #WAES 00051982
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:06/22/00ISR Number: 3576090-5Report Type:Periodic Company Report #WAES 00040803
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3576091-7Report Type:Periodic Company Report #WAES 00051984
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Triamterene	C				

Date:06/22/00ISR Number: 3576092-9Report Type:Periodic Company Report #WAES 00040804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25 MG/PO						
			Excedrin Extra-Strength	C		
			Lasix	C		
			Zestril	C		
			Ascorbic Acid	C		

Date:06/22/00ISR Number: 3576093-0Report Type:Periodic Company Report #WAES 00040809
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Asthenia					
	Dry Mouth				Merck Co Inc	ORAL
25						
	Dyspepsia					
MG/DAILY/PO						
	Fatigue		Detrol	C		
	Rectal Haemorrhage		Effexor	C		
	Tremor		Miacalcin	C		
			Plavix	C		
			Zyprexa	C		
			Hydrochlorothiazide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576095-4Report Type:Periodic Company Report # WAES 00051989
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:06/22/00ISR Number: 3576096-6Report Type:Periodic Company Report #WAES 00040813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dermatitis							
	Diarrhoea							
	Dyspepsia		Prednisone	C				
	Oedema Peripheral							
	Pyrexia							

Date:06/22/00ISR Number: 3576097-8Report Type:Periodic Company Report #WAES 00051990
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vasotec	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576099-1Report Type:Periodic Company Report #WAES 00040815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/BID/PO						
			Lanoxin	C		
			Lipitor	C		
			Metoprolol	C		
			Ranitidine Hydrochloride	C		

Date:06/22/00ISR Number: 3576100-5Report Type:Periodic Company Report #WAES 00051991
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Benign Colonic Neoplasm Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Hydrodiuril	C		
			Levoxyl	C		
			Premarin	C		
			Prozac	C		
			Vasotec	C		
			Zocor	C		
			Methotrexate	C		

Prednisone C

Date:06/22/00ISR Number: 3576103-0Report Type:Periodic Company Report #WAES 00051992
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY/ PO	
			Norvasc	C				

Date:06/22/00ISR Number: 3576106-6Report Type:Periodic Company Report #WAES 00051995
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3576108-XReport Type:Periodic Company Report #WAES 00052001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:06/22/00ISR Number: 3576110-8Report Type:Periodic Company Report #WAES 00052006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	
							MG/DAILY/PO	
			Azulfidine	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Alprazolam	C				
			Isosorbide	C				

Date:06/22/00ISR Number: 3576111-XReport Type:Periodic Company Report #WAES 00040816
Age:67 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Alopecia
	Constipation
	Diarrhoea

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO
			Celexa	C			
			Clonopin	C			
			Donnatal	C			
			Lopressor	C			
			Prevacid	C			
			Synthroid	C			
			Zantac	C			

Date:06/22/00ISR Number: 3576113-3Report Type:Periodic Company Report #WAES 00052008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Headache						
	Hypoxia						
		Representative	Celebrex	C			

Date:06/22/00ISR Number: 3576117-0Report Type:Periodic Company Report #WAES 00052012
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO
	Eye Irritation						
	Flushing						
	Pruritus		Synthroid	C			

				Xanax	C		
				Zestril	C		
				Furosemide	C		

Date:06/22/00ISR Number: 3576118-2Report Type:Periodic Company Report #WAES 00040822
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Inderal	C				
			Lanoxin	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3576120-0Report Type:Periodic Company Report #WAES 00052013
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Pain Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

	Premarin	C	
	Prilosec	C	

Date:06/22/00ISR Number: 3576122-4Report Type:Periodic Company Report #WAES 00052014
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Hypertension							
	Nausea							
			Cozaar	C				

Date:06/22/00ISR Number: 3576123-6Report Type:Periodic Company Report #WAES 00052015
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY
	Eyelid Oedema							
	Oedema Peripheral							

Date:06/22/00ISR Number: 3576124-8Report Type:Periodic Company Report #WAES 00052016
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3576125-XReport Type:Periodic Company Report #WAES 00052017
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:06/22/00ISR Number: 3576126-1Report Type:Periodic Company Report #WAES 00052030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Cozaar	C				
			Hydrodiuril	C				

Date:06/22/00ISR Number: 3576127-3Report Type:Periodic Company Report #WAES 00052033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/ BID/PO
Dolobid C

Date:06/22/00ISR Number: 3576128-5Report Type:Periodic Company Report #WAES 00052059
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							
	Muscular Weakness				Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576130-3Report Type:Periodic Company Report #WAES 00052077
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Haemorrhage							
	Haemorrhoids				Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Vaginal Haemorrhage							
			Inderal	C				
			Lopid	C				
			Prilosec	C				
			Synthroid	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576131-5Report Type:Periodic Company Report #WAES 00052088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576132-7Report Type:Periodic Company Report #WAES 00052102
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Premarin	C				
			Synthroid	C				
			Zocor	C				

Date:06/22/00ISR Number: 3576134-0Report Type:Periodic Company Report #WAES 00052106
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576136-4Report Type:Periodic Company Report #WAES 00052115
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Vioxx	SS				
			Norvasc	C				
			Aspirin	C				
			Meclizine	C				
			Thyroxine	C				

Date:06/22/00ISR Number: 3576138-8Report Type:Periodic Company Report #WAES 00052117
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Corgard	C				
			Hygroton	C				

Date:06/22/00ISR Number: 3576140-6Report Type:Periodic Company Report #WAES 00052118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576142-XReport Type:Periodic Company Report #WAES 00052119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576144-3Report Type:Periodic Company Report #WAES 00052121
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Proscar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576145-5Report Type:Periodic Company Report #WAES 00052125
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Oliguria							
	Oral Pain							
	Sedation		Aspirin	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3576146-7Report Type:Periodic Company Report #WAES 00051699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	3 DAY
	Palpitations							
			Lipitor	C				

Date:06/22/00ISR Number: 3576147-9Report Type:Periodic Company Report #WAES 00051701
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 WK
	Fatigue							
	Urinary Tract Infection							

Date:06/22/00ISR Number: 3576148-0Report Type:Periodic Company Report #WAES 00051702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3576149-2Report Type:Periodic Company Report #WAES 00051703
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Prinivil	C				
			Hormones	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3576150-9Report Type:Periodic Company Report #WAES 00051705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576151-0Report Type:Periodic Company Report #WAES 00051707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576152-2Report Type:Periodic Company Report #WAES 00051709
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Depakote	C				
			Detrol	C				
			Monopril	C				
			Premarin	C				
			Sular	C				
			Benztropine Mesylate	C				
			Fluphenazine	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576153-4Report Type:Periodic Company Report #WAES 00051710
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Thyroid	C				

Date:06/22/00ISR Number: 3576154-6Report Type:Periodic Company Report #WAES 00051715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Niaspan	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576155-8Report Type:Periodic Company Report #WAES 00051725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Ear Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576156-XReport Type:Periodic Company Report #WAES 00051729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY
			Actigall	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3576157-1Report Type:Periodic Company Report #WAES 00051731
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Hypertension Pharyngitis Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576158-3Report Type:Periodic Company Report #WAES 00051735
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				

Date:06/22/00ISR Number: 3576159-5Report Type:Periodic Company Report #WAES 00051736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			Dyazide	C				
			Tenormin	C				
			Therapy Unspecified	C				
			Folic Acid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576160-1Report Type:Periodic Company Report #WAES 00051737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576161-3Report Type:Periodic Company Report #WAES 00051743
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/TID/PO	
			Neurontin	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576162-5Report Type:Periodic Company Report #WAES 00051745
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG;/DAILY/PO	
			Prilosec	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576163-7Report Type:Periodic Company Report #WAES 00051747
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Diazide	C				
			Ditropan	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3576164-9Report Type:Periodic Company Report #WAES 00051750
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Sinus Arrhythmia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Zyrtec	C				
			Quinine Sulfate	C				

Date:06/22/00ISR Number: 3576165-0Report Type:Periodic Company Report #WAES 00051754
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576166-2Report Type:Periodic Company Report #WAES 00040286
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	; 25MG/Q4D/PO
			Lipitor	C				
			Univasc	C				
			Zantac	C				

Date:06/22/00ISR Number: 3576167-4Report Type:Periodic Company Report #WAES 00040287
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Synthroid	C				
			Vasotec	C				
			Zantac	C				

Date:06/22/00ISR Number: 3576168-6Report Type:Periodic Company Report #WAES 00040303
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Pravachol	C				
			Hydrochlorothiazide	C				

Date:06/22/00ISR Number: 3576169-8Report Type:Periodic Company Report #WAES 00040309
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Fatigue	Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
	Headache		Premarin	C				
	Malaise							
	Nausea							

Date:06/22/00ISR Number: 3576170-4Report Type:Periodic Company Report #WAES 00040328
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25MG/DAILY/PO	
			Fosamax	C				
			Prempro	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576171-6Report Type:Periodic Company Report #WAES 00040336
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576172-8Report Type:Periodic Company Report #WAES 00040337
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
	Chest Pain	Health Professional						
	Dyspepsia							
	Pancreatitis		Lipitor	SS				
	Urinary Tract Infection		Celexa	C				
			Prilosec	C				
			Xanax	C				

Date:06/22/00ISR Number: 3576173-XReport Type:Periodic Company Report #WAES 00040339
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576174-1Report Type:Periodic Company Report #WAES 00040343
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 9 DAY

Cardisan	C
Cozaar	C
Mevacor	C
Os-Cal	C
Prilosec	C
Synthroid	C
Toprol Xl	C
Aspirin	C
Furosemide	C

Date:06/22/00ISR Number: 3576175-3Report Type:Periodic Company Report #WAES 00040344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576176-5Report Type:Periodic Company Report #WAES 00040351
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Ultram	C				
			Zoloft	C				

Date:06/22/00ISR Number: 3576177-7Report Type:Periodic Company Report #WAES 00040352
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3576178-9Report Type:Periodic Company Report #WAES 00040356
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3576179-0Report Type:Periodic Company Report #WAES 00040366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576180-7Report Type:Periodic Company Report #WAES 00040380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576181-9Report Type:Periodic Company Report #WAES 00040383
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG;DAILY;PO	
			Hydrodiuril	C				
			Premarin	C				
			Prilosec	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576182-0Report Type:Periodic Company Report #WAES 00040387
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	
PO								
			Prempro	C				
			Synthroid	C				
			Lorazepam	C				

Date:06/22/00ISR Number: 3576183-2Report Type:Periodic Company Report #WAES 00040400
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	
PO								
			Fosamax	C				
			Prinivil	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576184-4Report Type:Periodic Company Report #WAES 00040406
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG;DAILY;	
PO							2	DAY

Date:06/22/00ISR Number: 3576185-6Report Type:Periodic Company Report #WAES 00040412
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Vioxx	SS		ORAL	PO	

Date:06/22/00ISR Number: 3576186-8Report Type:Periodic Company Report #WAES 00040168
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	

Date:06/22/00ISR Number: 3576187-XReport Type:Periodic Company Report #WAES 00040169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG/DAILY	6 MON

			Altace	C
			Betapace	C
			Coumadin	C
			Lanoxin	C
			Tylenol	C

Date:06/22/00ISR Number: 3576188-1Report Type:Periodic Company Report #WAES 00040172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

Date:06/22/00ISR Number: 3576189-3Report Type:Periodic Company Report #WAES 00040182
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Xanax	C				
			Zantac	C				
			Therapy Unspecified	C				
			Calcium Supplement	C				
			Iron (Unspecified)	C				
			Prednisone	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576190-XReport Type:Periodic Company Report #WAES 00040183
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc
			Avandia	C	
			Pravachol	C	
			Proscar	C	
			Triam-A	C	
			Hydrochlorothiazide	C	

Date:06/22/00ISR Number: 3576191-1Report Type:Periodic Company Report #WAES 00040184
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Corgard	C				
			Prozac	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576192-3Report Type:Periodic Company Report #WAES 00040185
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prilosec	C				
			Synthroid	C				
			Tenormin	C				

Date:06/22/00ISR Number: 3576193-5Report Type:Periodic Company Report #WAES 00040188
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Haemorrhoids Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576194-7Report Type:Periodic Company Report #WAES 00040193
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Claritin	C				
			Paxil	C				
			Prevacid	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576195-9Report Type:Periodic Company Report #WAES 00040197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Movement Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576196-0Report Type:Periodic Company Report #WAES 00040201
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576197-2Report Type:Periodic Company Report #WAES 00040202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

			Therapy Unspecified	C

Date:06/22/00ISR Number: 3576198-4Report Type:Periodic Company Report #WAES 00040224
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Cardizem Cd	C				
			Celebrex	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3576200-XReport Type:Periodic Company Report #WAES 00040226
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akinesia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tranxene	C				
			Ziac	C				
			Diuretic Preparation (Composition Unk)	C				
			Potassium Supplement (Composition Unk)	C				

Date:06/22/00ISR Number: 3576201-1Report Type:Periodic Company Report #WAES 00040233
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/00ISR Number: 3576202-3Report Type:Periodic Company Report #WAES 00040244
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D	C				
			Premarin	C				

Date:06/22/00ISR Number: 3576203-5Report Type:Periodic Company Report #WAES 00040253
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576204-7Report Type:Periodic Company Report #WAES 00040255
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia Migraine Paraesthesia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO; 25 MG/DAILY/PO	
			Inderal	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3576205-9Report Type:Periodic Company Report #WAES 00040275
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Memory Impairment Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
	Transient Ischaemic Attack		Paxil	C				

Date:06/22/00ISR Number: 3576206-0Report Type:Periodic Company Report #WAES 00040279
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ortho Tri-Cyclen	C				

Date:06/22/00ISR Number: 3576207-2Report Type:Periodic Company Report #WAES 00032965
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3576208-4Report Type:Periodic Company Report #WAES 00032975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Defaecation Urgency Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness Feeling Abnormal Headache Tachycardia		Antivert Premarin Vitamin E	C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576209-6Report Type:Periodic Company Report #WAES 00032976
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Premarin	C				

Date:06/22/00ISR Number: 3576210-2Report Type:Periodic Company Report #WAES 00032985
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Nausea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3576211-4Report Type:Periodic Company Report #WAES 00032986
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY	/PO
			Accolate	C				
			Diovan	C				
			Norvasc	C				
			Theo-Dur	C				

Date:06/22/00ISR Number: 3576212-6Report Type:Periodic Company Report #WAES 00032988
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Prempro	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576213-8Report Type:Periodic Company Report #WAES 00032996
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	
			Lipitor	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576214-XReport Type:Periodic Company Report #WAES 00032999
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
PO							3	WK
			Synthroid	C				

Date:06/22/00ISR Number: 3576215-1Report Type:Periodic Company Report #WAES 00033018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576216-3Report Type:Periodic Company Report #WAES 00033019
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576217-5Report Type:Periodic Company Report #WAES 00033020
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Company Merck Co Inc ORAL
PO
Representative

Date:06/22/00ISR Number: 3576218-7Report Type:Periodic Company Report #WAES 00033021
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Vioxx	PS	Merck Research			
	Hypersensitivity	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	12.5 MG DAILY	
		Representative						
PO								
			Avapro	C				
			Celebrex	C				
			Prempro	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Wellbutrin	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576219-9Report Type:Periodic Company Report #WAES 00033022
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertensive Crisis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576220-5Report Type:Periodic Company Report #WAES 00033023
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576221-7Report Type:Periodic Company Report #WAES 00033093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576222-9Report Type:Periodic Company Report #WAES 00033101
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Company Merck Co Inc ORAL
PO
Representative

Date:06/22/00ISR Number: 3576223-0Report Type:Periodic Company Report #WAES 00033105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY	/PO

Date:06/22/00ISR Number: 3576224-2Report Type:Periodic Company Report #WAES 00033106
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576225-4Report Type:Periodic Company Report #WAES 00033107
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Blood Pressure Increased							
	Dizziness							
	Fatigue						PO	
	Nausea		Coumadin	C				
	Pain In Extremity		Fosamax	C				

Date:06/22/00ISR Number: 3576226-6Report Type:Periodic Company Report #WAES 00033108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/25	
							MG/DAILY/PO	
			Prilosec	C				
			Prozac	C				
			Tenormin	C				
			Cortisone	C				
			Estrogenic Preparation	C				

Date:06/22/00ISR Number: 3576227-8Report Type:Periodic Company Report #WAES 00042652
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			Estrogenic Preparations					

(Composi C

Date:06/22/00ISR Number: 3576228-XReport Type:Periodic Company Report #WAES 00042654
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576229-1Report Type:Periodic Company Report #WAES 00042655
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576230-8Report Type:Periodic Company Report #WAES 00042656
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Hydrodiuril	C				
			Premarin	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576231-XReport Type:Periodic Company Report #WAES 00042657
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576232-1Report Type:Periodic Company Report #WAES 00042659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/00ISR Number: 3576233-3Report Type:Periodic Company Report #WAES 00042660
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Diovan	C		
			Prempro	C		
			Prozac	C		
			Xenical	C		

Date:06/22/00ISR Number: 3576234-5Report Type:Periodic Company Report #WAES 00042661
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Ativan	C		
			Celebrex	C		
			Cozaar	C		
			Hydrodiuril	C		
			Neuroton	C		
			Prilosec	C		
			Zoloft	C		
			Aspirin	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576235-7Report Type:Periodic Company Report #WAES 00042667
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576236-9Report Type:Periodic Company Report #WAES 00042668
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Flatulence Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Buspar	C				
			Percocet	C				
			Phenergan Tablets/Suppositories	C				
			Tylenol With Codeine #3	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576237-0Report Type:Periodic Company Report #WAES 00042672
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				
			Chlorthalidone	C				

Date:06/22/00ISR Number: 3576238-2Report Type:Periodic Company Report #WAES 00042673
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Estrogenic Preparations (Composi	C				

Date:06/22/00ISR Number: 3576239-4Report Type:Periodic Company Report #WAES 00042675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Pepcid	C				

		Prinivil	C
		Toprol Xl Tablets	C
		Zyrtec	C

Date:06/22/00ISR Number: 3576240-0Report Type:Periodic Company Report #WAES 00042676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:06/22/00ISR Number: 3576241-2Report Type:Periodic Company Report #WAES 00042677
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Erectile Dysfunction							
	Feeling Abnormal							
	Urine Abnormality		Buspar	C				
			Lopressor	C				

Date:06/22/00ISR Number: 3576242-4Report Type:Periodic Company Report #WAES 00042680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576243-6Report Type:Periodic Company Report #WAES 00042682
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Flexeril	C				

Date:06/22/00ISR Number: 3576244-8Report Type:Periodic Company Report #WAES 00042686
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Celexa	C				
			Depakote	C				
			Dilantin	C				
			Synthroid	C				
			Zanaflex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576245-XReport Type:Periodic Company Report #WAES 00042689
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576246-1Report Type:Periodic Company Report #WAES 00042690
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				

Date:06/22/00ISR Number: 3576247-3Report Type:Periodic Company Report #WAES 00041146
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pruritus Retching	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Urticaria		Lipitor	C				
			Toprol, Xl	C				
			Glycerol	C				
			Insulin	C				

Date:06/22/00ISR Number: 3576248-5Report Type:Periodic Company Report #WAES 00041152
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oliguria Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Glucophage	C		
			Nitrol			
			(Nitoglycerin)	C		
			Therapy			
			Unspoecified)	C		

Date:06/22/00ISR Number: 3576249-7Report Type:Periodic Company Report #WAES 00041153
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576250-3Report Type:Periodic Company Report #WAES 00041154
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bellergal-S Tablets	C				
			Calan	C				
			Cipro	C				
			Hydrodiuril	C				
			Lotensin	C				
			Theo-Dur	C				
			Tamoxifen	C				

Date:06/22/00ISR Number: 3576251-5Report Type:Periodic Company Report #WAES 00041156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pharyngeal Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576252-7Report Type:Periodic Company Report #WAES 00041169
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	NK/UNK/PO	

Date:06/22/00ISR Number: 3576253-9Report Type:Periodic Company Report #WAES 00041174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lopressor	C				
			Tegretal	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3576254-0Report Type:Periodic Company Report #WAES 00041175
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576255-2Report Type:Periodic Company Report #WAES 00041182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	3 DAY

Date:06/22/00ISR Number: 3576256-4Report Type:Periodic Company Report #WAES 00041189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576257-6Report Type:Periodic Company Report #WAES 00041196
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lipitor	C				
			Prinivil	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576258-8Report Type:Periodic Company Report #WAES 00041203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcohol Poisoning Alcoholic Hangover	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Drug Interaction Merck Co Inc ORAL
UNK/UNK/PO

Ethyl Alcohol SS
UNK

Date:06/22/00ISR Number: 3576259-XReport Type:Periodic Company Report #WAES 00041204
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576260-6Report Type:Periodic Company Report #WAES 00041207
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576261-8Report Type:Periodic Company Report #WAES 00041212
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Flomax (Niflumic Acid (Beta)- Mor	C				
			Carafate	C				

Date:06/22/00ISR Number: 3576262-XReport Type:Periodic Company Report #WAES 00041216
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Baycol	C				
			Plavix	C				
			Aspirin	C				
			Calcium Supplement	C				
			Fish Oil	C				
			Methotrexate	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576263-1Report Type:Periodic Company Report #WAES 00041217
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Accolate	C				
			Claritin	C				
			Plavix	C				
			(Composition					

			Unspecified)	C		
			Aspirin	C		

Date:06/22/00ISR Number: 3576264-3Report Type:Periodic Company Report #WAES 00041218
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Nausea					
UNK/UNK/PO						
			Premarin	C		
			Thyroxine	C		
			Verapamil Hydrochloride	C		

Date:06/22/00ISR Number: 3576265-5Report Type:Periodic Company Report #WAES 00041222
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Chills
	Diarrhoea

Hyperhidrosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	2 DAY
	Lipitor	C				
	Prinzide	C				
	Atenolol	C				

Date:06/22/00ISR Number: 3576266-7Report Type:Periodic Company Report #WAES 00041225
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Stiffness Movement Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:06/22/00ISR Number: 3576267-9Report Type:Periodic Company Report #WAES 00040466
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Cozaar	C				
			Neurontin	C				
			Provest	C				
			Zocor	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576268-0Report Type:Periodic Company Report #WAES 00040473
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Drug Ineffective							
	Headache							
	Mental Impairment		Aspirin	C				

Date:06/22/00ISR Number: 3576269-2Report Type:Periodic Company Report #WAES 00040660
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
	Muscle Spasms							
			Synthroid	C				
			Cyclosporin A	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576270-9Report Type:Periodic Company Report #WAES 00040665
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cardura	C				
			K-Dur	C				
			Pepcid	C				
			Tricor	C				
			Vaseretic	C				

Date:06/22/00ISR Number: 3576271-0Report Type:Periodic Company Report #WAES 00040666
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Abdominal Pain							
	Diarrhoea							
	Gastritis							
	Malaise		Accupril	C				
			Glucophage	C				
			Synthroid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576272-2Report Type:Periodic Company Report #WAES 00040669
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Viral Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576273-4Report Type:Periodic Company Report #WAES 00040681
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nasal Discomfort							
	Sinusitis							
	Upper Respiratory Tract Infection		Tylenol	C				

Date:06/22/00ISR Number: 3576274-6Report Type:Periodic Company Report #WAES 00040310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Visual Disturbance							
	Vitreous Opacities							
			Timoptic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576275-8Report Type:Periodic Company Report #WAES 00040311
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Vioxx	SS		ORAL	25 MG/DAILY/PO	
			Acetaminophen	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576276-XReport Type:Periodic Company Report #WAES 00040312
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			K-Dur	C				
			Norvasc	C				
			Rythmol	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576277-1Report Type:Periodic Company Report #WAES 00040315
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3576278-3Report Type:Periodic Company Report #WAES 00040325
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Vasotec	C				

Date:06/22/00ISR Number: 3576279-5Report Type:Periodic Company Report #WAES 00040327
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Claritin	C				
			Cozaar	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576280-1Report Type:Periodic Company Report #WAES 00040682
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dysgeusia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576281-3Report Type:Periodic Company Report #WAES 00040686
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576282-5Report Type:Periodic Company Report #WAES 00040687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576283-7Report Type:Periodic Company Report #WAES 00040688
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/00ISR Number: 3576284-9Report Type:Periodic Company Report #WAES 00040689
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET DAILY;PO	

Date:06/22/00ISR Number: 3576285-0Report Type:Periodic Company Report #WAES 00040690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576286-2Report Type:Periodic Company Report #WAES 00040703
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/00ISR Number: 3576287-4Report Type:Periodic Company Report #WAES 00040704
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY;PO	
			Calan	C				
			Celebrex	C				
			Zocor	C				
			Furosemide	C				

Date:06/22/00ISR Number: 3576288-6Report Type:Periodic Company Report #WAES 00040732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576289-8Report Type:Periodic Company Report #WAES 00041226
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Fatigue Merck Co Inc ORAL
25 MG/DAILY/
Insomnia
PO

Allegra	C	
Evista	C	
Flovent	C	
Singulair	C	
Tagamet	C	
Vitamins	C	

Date:06/22/00ISR Number: 3576290-4Report Type:Periodic Company Report #WAES 00041228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck Research			
	Depression	Professional			Laboratories Div			
	Thyroxine Increased				Merck Co Inc	ORAL	UNK / UNK /	

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576291-6Report Type:Periodic Company Report #WAES 00041229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Condition Aggravated Drug Ineffective Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Norvasc	C				
			Zocor	C				

Date:06/22/00ISR Number: 3576292-8Report Type:Periodic Company Report #WAES 00041231
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Allegra D	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576293-XReport Type:Periodic Company Report #WAES 00041235
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / BID /	PO

Date:06/22/00ISR Number: 3576294-1Report Type:Periodic Company Report #WAES 00041238
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3576295-3Report Type:Periodic Company Report #WAES 00041239
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/	PO

Date:06/22/00ISR Number: 3576296-5Report Type:Periodic Company Report #WAES 00041246
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

			Catapres	C
			Ecotrin	C
			Isoptin	C
			Lasix	C

Date:06/22/00ISR Number: 3576297-7Report Type:Periodic Company Report #WAES 00041248
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	
	Dyspnoea							
			Flonase	C				
			Flovent	C				
			Proventil	C				
			Zyrtec	C				
			Vitamin E	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576298-9Report Type:Periodic Company Report #WAES 00041249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576299-0Report Type:Periodic Company Report #WAES 00041253
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research			

Paraesthesia
Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO

Date:06/22/00ISR Number: 3576300-4Report Type:Periodic Company Report #WAES 00041254
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
	Rectal Haemorrhage							
	Tongue Oedema							
			Accolate	C				
			Brethine	C				

Date:06/22/00ISR Number: 3576301-6Report Type:Periodic Company Report #WAES 00041264
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Abdominal Pain	Consumer
	Chest Pain	Health

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
Allegra	C				
Flonase	C				
Maxzide	C				
Plendil	C				
Prempro	C				
Prilosec	C				
Serevent	C				
Singulair	C				
Zocor	C				
Albuterol	C				

Date:06/22/00ISR Number: 3576302-8Report Type:Periodic Company Report #WAES 00041272
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
			Prilosec	C				
			Xalatan	C				
			Lorazepam	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3576303-XReport Type:Periodic Company Report #WAES 00041273
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/ DAILY

/ PO
Tylenol C

Date:06/22/00ISR Number: 3576304-1Report Type:Periodic Company Report #WAES 00041280
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	
			Advil	C				
			Darvocet-N	C				

PO

Date:06/22/00ISR Number: 3576305-3Report Type:Periodic Company Report #WAES 00041282
Age: Gender:Female I/FU:I

Outcome PT
Diarrhoea
Drug Interaction

Flatulence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
	Bumex	C				
	Lovoxil	C				
	Orasone	C				
	Prilosec	C				
	Tylenol With Codeine	C				
	Zoloft	C				
	Allopurinol	C				
	Naproxen	C				
	Prednisone	C				

Date:06/22/00ISR Number: 3576306-5Report Type:Periodic Company Report #WAES 00041287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Feeling Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3576307-7Report Type:Periodic Company Report #WAES 00041290
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3576308-9Report Type:Periodic Company Report #WAES 00041297
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/ PO	
			Aspirin	C				

Date:06/22/00ISR Number: 3576309-0Report Type:Periodic Company Report #WAES 00040837
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Corneal Deposits Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Naqua	C				
			Os-Cal	C				
			Rocaltrol	C				
			Synthroid	C				
			Urocit-K	C				

			Estrogenic Preparations (Composi	C		
			Vitamin D	C		

Date:06/22/00ISR Number: 3576310-7Report Type:Periodic Company Report #WAES 00040839
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Demadex	C				
			Synthroid	C				
			Allopurinol	C				
			Isosorbide	C				

Date:06/22/00ISR Number: 3576311-9Report Type:Periodic Company Report #WAES 00040843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:06/22/00ISR Number: 3576312-0Report Type:Periodic Company Report #WAES 00040846
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Effexor	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3576313-2Report Type:Periodic Company Report #WAES 00040856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576314-4Report Type:Periodic Company Report #WAES 00040880
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576315-6Report Type:Periodic Company Report #WAES 00040903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Insomnia							
			Ultram	C				

Date:06/22/00ISR Number: 3576316-8Report Type:Periodic Company Report #WAES 00040908
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576317-XReport Type:Periodic Company Report #WAES 00040909
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Gastric Ulcer							
			Cardizem Cd	C				
			Celexa	C				
			Mevacor	C				
			Gemfibrozil	C				
			Hydroxychloroquine	C				
			Ranitidine	C				

Date:06/22/00ISR Number: 3576318-1Report Type:Periodic Company Report #WAES 00040921
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Sleep Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576319-3Report Type:Periodic Company Report #WAES 00040926
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Faeces Discoloured Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				
			Synvisc	C				
			Xanax	C				
			Calcium Supplement (Composition	C				
			Glucosamine	C				
			Triamterene	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576320-XReport Type:Periodic Company Report #WAES 00040940
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Nausea							

Date:06/22/00ISR Number: 3576321-1Report Type:Periodic Company Report #WAES 00040941
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	05 MG/DAILY/PO	
			Paxil	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576322-3Report Type:Periodic Company Report #WAES 00040942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eye Irritation							
	Face Oedema							
	Pruritus							

Date:06/22/00ISR Number: 3576323-5Report Type:Periodic Company Report #WAES 00040946
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Vioxx	PS	Merck Research			

	Dermatitis Exfoliative	Professional			Laboratories Div	
	Oedema Peripheral	Company			Merck Co Inc	ORAL
25						
	Pruritus	Representative				
MG/DAILY/PO						

Date:06/22/00ISR Number: 3576324-7Report Type:Periodic Company Report #WAES 00040957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Sedation	Consumer	Vioxx	PS	Merck Research	
	Weight Increased				Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3576325-9Report Type:Periodic Company Report #WAES 00040959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Lotrex	C		
			Toprol Xl Tablets	C		
			Zoloft	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576326-0Report Type:Periodic Company Report #WAES 00040960
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIL/PO	21 DAY
	Retching							
	Upper Gastrointestinal							
	Haemorrhage		Prevacid	C				
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576327-2Report Type:Periodic Company Report #WAES 00040962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576328-4Report Type:Periodic Company Report #WAES 00040963
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Glossodynia	Health Professional						
			K-Dur	C				
			Mysoline	C				
			Premarin	C				
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576329-6Report Type:Periodic Company Report #WAES 00040969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576330-2Report Type:Periodic Company Report #WAES 00040974
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Blood Pressure Increased				Laboratories Div			
	Eating Disorder				Merck Co Inc	ORAL	25	
	Insomnia						MG/DAILY/PO	
	Weight Decreased		Atenolol	C				

Date:06/22/00ISR Number: 3576331-4Report Type:Periodic Company Report #WAES 00040976
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research			
	Pulmonary Congestion				Laboratories Div			

Merck Co Inc ORAL
12.5 MG/

DAILY/PO
Hormones C

Date:06/22/00ISR Number: 3576332-6Report Type:Periodic Company Report #WAES 00040977
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				

Date:06/22/00ISR Number: 3576333-8Report Type:Periodic Company Report #WAES 00040979
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576335-1Report Type:Periodic Company Report #WAES 00040980
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased Endometrial Neoplasm Headache Musculoskeletal Pain Uterine Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vaseretic	C				

Vision Blurred

Date:06/22/00ISR Number: 3576337-5Report Type:Periodic Company Report #WAES 00040981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Synthroid	C				
			Timoptic	C				

Date:06/22/00ISR Number: 3576340-5Report Type:Periodic Company Report #WAES 00040983
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Pain Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576342-9Report Type:Periodic Company Report #WAES 00040984
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Amaryl	C				
			Combipatch	C				
			Glucophage	C				
			K-Dur	C				
			Levoxyl	C				
			Lozol	C				
			Ultram	C				

Date:06/22/00ISR Number: 3576344-2Report Type:Periodic Company Report #WAES 00040985
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 WK

Date:06/22/00ISR Number: 3576348-XReport Type:Periodic Company Report #WAES 00040989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective Headache Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Altace	C				
			Darvocet-N	C				

Date:06/22/00ISR Number: 3576350-8Report Type:Periodic Company Report #WAES 00040993
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Dryness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pharyngitis							
	Rhinorrhoea							
			Covera-Hs	C				
			Lanoxin	C				
			Sudafed	C				
			Ibuprofen	C				

Date:06/22/00ISR Number: 3576353-3Report Type:Periodic Company Report #WAES 00040995
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3576356-9Report Type:Periodic Company Report #WAES 00040998
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576360-0Report Type:Periodic Company Report #WAES 00040999
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	

Date:06/22/00ISR Number: 3576363-6Report Type:Periodic Company Report #WAES 00041000
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Palmar Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Fioricet	C				
			Flexeril	C				
			Synthroid	C				
			Zestril	C				

Date:06/22/00ISR Number: 3576366-1Report Type:Periodic Company Report #WAES 00041004
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3576368-5Report Type:Periodic Company Report #WAES 00041007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dehydration Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dry Mouth		Actos	C				
			Glucophage	C				
			Zocor	C				
			Insulin Injection (+) Isophane	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576369-7Report Type:Periodic Company Report #WAES 00041009
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:06/22/00ISR Number: 3576370-3Report Type:Periodic Company Report #WAES 00041011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Zocor	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576371-5Report Type:Periodic Company Report #WAES 00041013
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lortab	C				
			Medrol	C				

Date:06/22/00ISR Number: 3576372-7Report Type:Periodic Company Report #WAES 00041017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
					Merck Co Inc	ORAL	25	MG/DAILY/PO 1 DAY

Date:06/22/00ISR Number: 3576373-9Report Type:Periodic Company Report #WAES 00041019
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	12.5	MG/DAILY.PO
			Lipitor	C				
			Norvasc	C				
			Tylenol Extra Strength	C				
			B Vitamins	C				
			Calcium Supplement	C				
			Glucosamine	C				

				Quinine Sulfate	C		

Date:06/22/00ISR Number: 3576374-0Report Type:Periodic Company Report #WAES 00041020
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins	SS				
			Lozol	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3576375-2Report Type:Periodic Company Report #WAES 00041022
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON

Date:06/22/00ISR Number: 3576376-4Report Type:Periodic Company Report #WAES 00041036
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activated Partial Thromboplastin Time Prolonged	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Labile Blood Pressure	Representative	Coumadin	C				
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576377-6Report Type:Periodic Company Report #WAES 00041039
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576378-8Report Type:Periodic Company Report #WAES 00041040
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Composition Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576379-XReport Type:Periodic Company Report #WAES 00041041
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576380-6Report Type:Periodic Company Report #WAES 00041042
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576381-8Report Type:Periodic Company Report #WAES 00041043
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx (Therapy Nspeciied)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576382-XReport Type:Periodic Company Report #WAES 00041044
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Carbamazepine	C		
			Ibuprofen	C		

Date:06/22/00ISR Number: 3576383-1Report Type:Periodic Company Report #WAES 00041055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3576384-3Report Type:Periodic Company Report #WAES 00041066
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Health	Vioxx	PS	Merck Research	
	Fatigue	Professional			Laboratories Div	
	Hypersomnia	Other			Merck Co Inc	ORAL
25 MG/DAILY/P						
			Tylenol Exrtra Strength	SS		
			Tab Effexor	SS		ORAL
1 TABLET /						
DAILY / PO						
			Prilosec	SS		ORAL
1 TABLET /						

DAILY / PO

	Infusion (Form)		
	Gamimune N, 10%	SS	
30 GM / 1X			
	Paxil	SS	ORAL
60 MG / DAILY			
/ PO			
	Premarin	C	
	Vitamins	C	

Date:06/22/00ISR Number: 3576385-5Report Type:Periodic Company Report #WAES 00041072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576386-7Report Type:Periodic Company Report #WAES 00041073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576387-9Report Type:Periodic Company Report #WAES 00041076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
1

TABLET/BID/PO

Date:06/22/00ISR Number: 3576388-0Report Type:Periodic Company Report #WAES 00041087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 12.5	MG/DAILY/PO 1 WK
	Insomnia							
	Nocturia							

Date:06/22/00ISR Number: 3576389-2Report Type:Periodic Company Report #WAES 00041088
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Therapy Unspecified)	C				
			Chondroitin (+) Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576390-9Report Type:Periodic Company Report #WAES 00041089
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Prevacid	C				
			Lorazepam	C				

Date:06/22/00ISR Number: 3576391-0Report Type:Periodic Company Report #WAES 00051777
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Vision Blurred	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576392-2Report Type:Periodic Company Report #WAES 00051780
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576393-4Report Type:Periodic Company Report #WAES 00051785
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3576394-6Report Type:Periodic Company Report #WAES 00051789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576395-8Report Type:Periodic Company Report #WAES 00051793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576396-XReport Type:Periodic Company Report #WAES 00051800
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576397-1Report Type:Periodic Company Report #WAES 00051804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576398-3Report Type:Periodic Company Report #WAES 00041300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576399-5Report Type:Periodic Company Report #WAES 00041301
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Apresazide Capsules	C		
			Xalatan	C		
			Glucosamine	C		

Date:06/22/00ISR Number: 3576400-9Report Type:Periodic Company Report #WAES 00041304
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative				

Date:06/22/00ISR Number: 3576401-0Report Type:Periodic Company Report #WAES 00041318
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Syncope	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576402-2Report Type:Periodic Company Report #WAES 00041321
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576403-4Report Type:Periodic Company Report #WAES 00041324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576404-6Report Type:Periodic Company Report #WAES 00041344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576405-8Report Type:Periodic Company Report #WAES 00041349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Hydrocodone	C				

Morphine C

Date:06/22/00ISR Number: 3576406-XReport Type:Periodic Company Report #WAES 00041360
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576407-1Report Type:Periodic Company Report #WAES 00041386
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Pharyngitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576408-3Report Type:Periodic Company Report #WAES 00041387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576409-5Report Type:Periodic Company Report #WAES 00041391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576410-1Report Type:Periodic Company Report #WAES 00041393
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3576412-5Report Type:Periodic Company Report #WAES 00041395
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Claritin	C				

Dolomite	C
Flonase	C
Nasalcrom	C
Proventil	C
Singulair	C
Theo-Dur	C
Bone Marrow Extract (As Drug)	C
Collagen	C
Glucosamine	C
Herbal Remedies	C
Pyridoxine	C
Vitamins	C

Date:06/22/00ISR Number: 3576413-7Report Type:Periodic Company Report #WAES 00041396
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	2 DAY
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576415-0Report Type:Periodic Company Report #WAES 00041398
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flonase	C				
			Lorazepam	C				

Date:06/22/00ISR Number: 3576417-4Report Type:Periodic Company Report #WAES 00041400
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Back Pain							
	Blood Pressure Increased							
	Fatigue		Ambien	C				
	Headache		Coumadin	C				
	Swelling		Demadex	C				
	Urinary Tract Infection		Nasonex	C				
			Ultram	C				
			Albuterol	C				
			Cortisone	C				

Date:06/22/00ISR Number: 3576419-8Report Type:Periodic Company Report #WAES 00041401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea							
	Sedation							

Date:06/22/00ISR Number: 3576420-4Report Type:Periodic Company Report #WAES 00041402
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3576421-6Report Type:Periodic Company Report #WAES 00041410
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576422-8Report Type:Periodic Company Report #WAES 00041093
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Lipitor	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576423-XReport Type:Periodic Company Report #WAES 00041100
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Monopril	C				

Date:06/22/00ISR Number: 3576424-1Report Type:Periodic Company Report #WAES 00041102
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

Date:06/22/00ISR Number: 3576425-3Report Type:Periodic Company Report #WAES 00041105
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG/DAILY						
PO						
			Lasix	C		
			Vicodin Tablets	C		

Date:06/22/00ISR Number: 3576426-5Report Type:Periodic Company Report #WAES 00041106
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
	Pruritus				Laboratories Div	
	Urticaria				Merck Co Inc	ORAL
SEE IMAGE						
			Prinivil	C		
			Synthroid	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3576429-0Report Type:Periodic Company Report #WAES 00041108
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Vaginal Infection	Consumer
		Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Elavil	C				

Date:06/22/00ISR Number: 3576430-7Report Type:Periodic Company Report #WAES 00041109
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Vioxx 12.5mg	SS		ORAL	PO	
			Tylenol	C				
			Ziac	C				

Date:06/22/00ISR Number: 3576432-0Report Type:Periodic Company Report #WAES 00041110
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:06/22/00ISR Number: 3576434-4Report Type:Periodic Company Report #WAES 00041111
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ear Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Lipitor	C		
			Synthroid	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3576436-8Report Type:Periodic Company Report #WAES 00041112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Cozaar	C		
			Glucophage	C		
			Aspirin	C		
			Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576437-XReport Type:Periodic Company Report #WAES 00041113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cosopt	C				
			Plendil	C				
			Polytrim	C				
			Xalatan	C				
			Zestril	C				
			Acyclovir	C				
			Fluorometholone	C				
			Oxybutynin Chloride	C				

Date:06/22/00ISR Number: 3576440-XReport Type:Periodic Company Report #WAES 00041116
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Fluid Retention Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Buspar	C				

Date:06/22/00ISR Number: 3576441-1Report Type:Periodic Company Report #WAES 00041117
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Retching	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO
			Prilosec	C				

Date:06/22/00ISR Number: 3576443-5Report Type:Periodic Company Report #WAES 00041125
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Micardis	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576444-7Report Type:Periodic Company Report #WAES 00041131
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576446-0Report Type:Periodic Company Report #WAES 00041134
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Pepcid	C				
			Zocor	C				
			Aspirin	C				
			Methyldopa	C				

Date:06/22/00ISR Number: 3576448-4Report Type:Periodic Company Report #WAES 00041136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:06/22/00ISR Number: 3576449-6Report Type:Periodic Company Report #WAES 00041138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:06/22/00ISR Number: 3576450-2Report Type:Periodic Company Report #WAES 00041139
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder Feeling Abnormal Muscular Weakness Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pain		Claritin-D	C				
			Pepcid	C				
			Synthroid	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576451-4Report Type:Periodic Company Report #WAES 00041141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Asacol	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Lopressor	C				
			Premarin	C				
			Serax	C				

			Vicodin Tablets	C		

Date:06/22/00ISR Number: 3576453-8Report Type:Periodic Company Report #WAES 00041560
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haemoptysis							
	Upper Respiratory Tract Infection							
			Desyrel	C				
			Evista	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576455-1Report Type:Periodic Company Report #WAES 00041884
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

PO

Date:06/22/00ISR Number: 3576456-3Report Type:Periodic Company Report #WAES 00041888
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID /	
	Oedema Peripheral							

PO

Date:06/22/00ISR Number: 3576458-7Report Type:Periodic Company Report #WAES 00041889
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	/ PO
			Accolate	C				
			Avapro	C				
			Claritin	C				
			Flonase	C				
			Flovent	C				
			Humibid	C				
			Norvasc	C				
			Albuterol	C				

Date:06/22/00ISR Number: 3576459-9Report Type:Periodic Company Report #WAES 00041562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576460-5Report Type:Periodic Company Report #WAES 00041893
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

Date:06/22/00ISR Number: 3576462-9Report Type:Periodic Company Report #WAES 00041564
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3576463-0Report Type:Periodic Company Report #WAES 00041567
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3576464-2Report Type:Periodic Company Report #WAES 00041894
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

Swelling
PO

Prilosec	C	
Synthroid	C	
Indapamide	C	

Date:06/22/00ISR Number: 3576465-4Report Type:Periodic Company Report #WAES 00041574
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Hepatic Function Abnormal							
	Hypoglycaemia							
	Nervousness		Pravachol	C				
	Tremor		Premarin	C				
	Vision Blurred		Provera	C				

Date:06/22/00ISR Number: 3576466-6Report Type:Periodic Company Report #WAES 00041897
Age:83 YR Gender:Male I/FU:I

Outcome	PT
	Drug Ineffective
	Dyspepsia
	Flatulence
	Oedema Peripheral

Pain In Extremity

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Celebrex	C				
	Hydrodiuril	C				
	Persantine	C				
	Trental	C				
	Vasotec	C				

Date:06/22/00ISR Number: 3576467-8Report Type:Periodic Company Report #WAES 00041575
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576468-XReport Type:Periodic Company Report #WAES 00041578
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lasix	C				
			Tagamet	C				
			Composition Unspecified	C				

Date:06/22/00ISR Number: 3576469-1Report Type:Periodic Company Report #WAES 00041579
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Estinyl	C				
			Levothyroxine Sodium	C				

Date:06/22/00ISR Number: 3576470-8Report Type:Periodic Company Report #WAES 00041899
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY / PO	
			Elavil	C				
			Neurontin	C				
			Provera	C				

		Synthroid	C	
		Ultram	C	

Date:06/22/00ISR Number: 3576471-XReport Type:Periodic Company Report #WAES 00041580
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
	Pruritus							
			Dilantin	C				
			Micardis	C				

Date:06/22/00ISR Number: 3576472-1Report Type:Periodic Company Report #WAES 00041902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
	Cough							
	Dyspepsia							
	Fatigue							
	Iron Deficiency		Prilosec	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576473-3Report Type:Periodic Company Report #WAES 00041582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Os-Cal	C				
			Folic Acid	C				

		Vitamins	C	

Date:06/22/00ISR Number: 3576474-5Report Type:Periodic Company Report #WAES 00041584
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fracture	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Tooth Disorder					
	Toothache				Merck Co Inc	ORAL
PO 8 WK						
			Ditropan	C		
			Fosamax	C		
			Calcium Supplement	C		
			Vitamin D	C		

Date:06/22/00ISR Number: 3576475-7Report Type:Periodic Company Report #WAES 00041904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG /						
DAILY / PO 3 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576476-9Report Type:Periodic Company Report #WAES 00041908
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY / PO	
			Provera	C				
			Zoloft	C				

Date:06/22/00ISR Number: 3576477-0Report Type:Periodic Company Report #WAES 00041909
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder Pain Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Keflex	C				

Date:06/22/00ISR Number: 3576478-2Report Type:Periodic Company Report #WAES 00041585
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Dyazide	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3576479-4Report Type:Periodic Company Report #WAES 00041910
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Malaise Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ UNK / PO	
			Flovent	C				
			Fosamax	C				
			Glucotrol	C				
			Lasix	C				
			Lipitor	C				
			Norflex	C				
			Serevent	C				
			Tronolane	C				
			Tylenol Extra Strength	C				
			Zestril	C				
			Glucosamine	C				
			Methotrexate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576480-0Report Type:Periodic Company Report #WAES 00041911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:06/22/00ISR Number: 3576481-2Report Type:Periodic Company Report #WAES 00041912
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
	Diarrhoea							
	Dizziness							
	Drug Ineffective							
	Mental Impairment		Chondroitin	C				
	Pain		Glucosamine	C				

Date:06/22/00ISR Number: 3576482-4Report Type:Periodic Company Report #WAES 00041913
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / BID/PO	
			Capoten	C				
			Klonopin	C				
			Lasix	C				
			Prozac	C				
			Synthroid	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576483-6Report Type:Periodic Company Report #WAES 00041915
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia Extrasystoles Hypotension Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
	Muscular Weakness		Tab Vioxx	SS		ORAL	25 MG / DAILY / PO	
			Tab Vioxx	SS		ORAL	25 MG / DAILY PO	
			Benadryl	C				
			Bumex	C				

Date:06/22/00ISR Number: 3576484-8Report Type:Periodic Company Report #WAES 00041916
Age: Gender:Female I/FU:I

Outcome	PT
	Asthenia Fatigue Hypersomnia Muscular Weakness

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO 1 DAY
	Detrol	C				
	Theragran-M	C				
	Zestril	C				
	Aspirin	C				
	Triamterene	C				

Date:06/22/00ISR Number: 3576485-XReport Type:Periodic Company Report #WAES 00041917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Feeling Drunk	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Tylenol	C				

Date:06/22/00ISR Number: 3576486-1Report Type:Periodic Company Report #WAES 00041918
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Prilosec	C				
			Prinivil	C				

Date:06/22/00ISR Number: 3576487-3Report Type:Periodic Company Report # WAES 00041586
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576488-5Report Type:Periodic Company Report #WAES 00041923
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Malaise Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY / PO	
			Tab Vioxx 50 Mg	SS		ORAL	UNK / UNK / PO	
			Glucosamine	C				
			Vitamin E	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576489-7Report Type:Periodic Company Report #WAES 00041587
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depakote	C				
			Neurontin	C				
			Valium	C				
			Oxycodone	C				

Date:06/22/00ISR Number: 3576490-3Report Type:Periodic Company Report #WAES 00041785
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3576491-5Report Type:Periodic Company Report #WAES 00041788
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Xanax	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3576492-7Report Type:Periodic Company Report #WAES 00041589
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576493-9Report Type:Periodic Company Report #WAES 00041795
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Zydone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576494-0Report Type:Periodic Company Report #WAES 00041796
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				
			Ventolin	C				

Date:06/22/00ISR Number: 3576495-2Report Type:Periodic Company Report #WAES 00041798
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Dyspepsia Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Gastrooesophageal Reflux Disease		Elavil	C				
			Xanax	C				

Date:06/22/00ISR Number: 3576497-6Report Type:Periodic Company Report #WAES 00041593
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pepcid	C				
			Toprol Xl Tablets	C				
			Estrogenic Preparations	C				
			Folic Acid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576498-8Report Type:Periodic Company Report #WAES 00041799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY

Date:06/22/00ISR Number: 3576499-XReport Type:Periodic Company Report #WAES 00041805
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	

Date:06/22/00ISR Number: 3576500-3Report Type:Periodic Company Report #WAES 00041594
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO
Premarin C

Date:06/22/00ISR Number: 3576501-5Report Type:Periodic Company Report #WAES 00041807
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Tylenol	C				

Date:06/22/00ISR Number: 3576503-9Report Type:Periodic Company Report #WAES 00041596
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 MON
			Maxalt	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576504-0Report Type:Periodic Company Report #WAES 00041808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576505-2Report Type:Periodic Company Report #WAES 00041811
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Lotensin	C				
			Proscar	C				

Date:06/22/00ISR Number: 3576506-4Report Type:Periodic Company Report #WAES 00041815
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Glucotrol	C				
			Isordil	C				
			Norvasc	C				
			Zestoretic	C				
			Zocor	C				
			Aspirin	C				
			Quinine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576507-6Report Type:Periodic Company Report #WAES 00041597
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	
			Cardura	C				
			Lasix	C				
			Lipitor	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Cardizem	C				

Date:06/22/00ISR Number: 3576508-8Report Type:Periodic Company Report #WAES 00041820
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Chest Pain Face Oedema Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Coumadin	C				
			Prilosec	C				
			Vasotec	C				
			Zocor	C				
			[Composition Unspecified]	C				

Date:06/22/00ISR Number: 3576509-XReport Type:Periodic Company Report #WAES 00041600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
	Dyspepsia						
	Erectile Dysfunction						
	Fatigue						
			Amitriptyline	C			

Date:06/22/00ISR Number: 3576510-6Report Type:Periodic Company Report #WAES 00041825
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/HS/PO	
			Cozaar	C				
			Lanoxin	C				

Date:06/22/00ISR Number: 3576511-8Report Type:Periodic Company Report #WAES 00041827
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							

			Darvocet-N	C
			[Therapy Unspecified]	C

Date:06/22/00ISR Number: 3576512-XReport Type:Periodic Company Report #WAES 00041828
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576513-1Report Type:Periodic Company Report #WAES 00041830
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Insulin	C				
			Potassium Supplement (Composition	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576514-3Report Type:Periodic Company Report #WAES 00041503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576515-5Report Type:Periodic Company Report #WAES 00041833
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3576516-7Report Type:Periodic Company Report #WAES 00041506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576517-9Report Type:Periodic Company Report #WAES 00041834
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder Confusional State Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
	Speech Disorder		Celebrex	C				
			Voltaren	C				

Date:06/22/00ISR Number: 3576519-2Report Type:Periodic Company Report #WAES 00041848
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3576520-9Report Type:Periodic Company Report #WAES 00041878
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Coreg	C				
			Coumadin	C				
			Glucophage	C				
			Lanoxin	C				
			Lasix	C				
			Synthroid	C				
			Vasotec	C				
			Colchicine	C				
			Glyburide	C				
			Nitroglycerin	C				

		Nortriptyline	C	
		Spironolactone	C	

Date:06/22/00ISR Number: 3576521-0Report Type:Periodic Company Report #WAES 00041507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576522-2Report Type:Periodic Company Report #WAES 00041724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576523-4Report Type:Periodic Company Report #WAES 00041728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576524-6Report Type:Periodic Company Report #WAES 00041733
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Pain Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	24 DAY
			Cardura	C				
			Prilosec	C				
			Diazepam	C				
			Quinine	C				

Date:06/22/00ISR Number: 3576526-XReport Type:Periodic Company Report #WAES 00041743
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ecotrin	C				
			Diuretic Preparation	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3576527-1Report Type:Periodic Company Report #WAES 00041744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
			Methotrexate	C				

Date:06/22/00ISR Number: 3576529-5Report Type:Periodic Company Report #WAES 00041746
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576530-1Report Type:Periodic Company Report #WAES 00041748
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Proventil	C				
			Tylenol	C				
			Corticosteroids	C				

Date:06/22/00ISR Number: 3576531-3Report Type:Periodic Company Report #WAES 00041751
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 12.5 MG/BID/PO	
			Sinement	C				
			Moveltipril	C				

Date:06/22/00ISR Number: 3576535-0Report Type:Periodic Company Report #WAES 00041518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/00ISR Number: 3576537-4Report Type:Periodic Company Report #WAES 00041753
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:06/22/00ISR Number: 3576538-6Report Type:Periodic Company Report #WAES 00041519
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576539-8Report Type:Periodic Company Report #WAES 00041754
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Myalgia		Tylenol	C				

Date:06/22/00ISR Number: 3576541-6Report Type:Periodic Company Report #WAES 00041523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576543-XReport Type:Periodic Company Report #WAES 00041755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576544-1Report Type:Periodic Company Report #WAES 00041533
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Insomnia Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3576545-3Report Type:Periodic Company Report #WAES 00041756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan	C				
			Lanoxin	C				
			Lipitor	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576547-7Report Type:Periodic Company Report #WAES 00041535
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Vision Blurred Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576549-0Report Type:Periodic Company Report #WAES 00041759
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Vitamins	C				

Date:06/22/00ISR Number: 3576550-7Report Type:Periodic Company Report #WAES 00041760
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aldactazide	C				
			Asacol	C				
			Paxil	C				
			Prilosec	C				
			Questran	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576551-9Report Type:Periodic Company Report #WAES 00041538
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Gastrointestinal Disorder Pharyngitis Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cosopt	C				

			Lipitor	C
			Codeine	C

Date:06/22/00ISR Number: 3576552-0Report Type:Periodic Company Report #WAES 00041770
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576554-4Report Type:Periodic Company Report #WAES 00041539
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576555-6Report Type:Periodic Company Report #WAES 00041772
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576556-8Report Type:Periodic Company Report #WAES 00041541
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia Gait Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576558-1Report Type:Periodic Company Report #WAES 00041773
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Hyperhidrosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576559-3Report Type:Periodic Company Report #WAES 00041542
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Tab Vioxx SS ORAL

50

MG/DAILY/PO

Therapy Unspecified C

Date:06/22/00ISR Number: 3576560-XReport Type:Periodic Company Report #WAES 00041779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO 14 DAY						
			Teflox	C		
			Aspirin	C		

Date:06/22/00ISR Number: 3576561-1Report Type:Periodic Company Report #WAES 00041782
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						

Celebrex	C
Inderal	C
Prempro	C
Synthroid	C
Zocor	C

Date:06/22/00ISR Number: 3576562-3Report Type:Periodic Company Report #WAES 00041784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Haemoptysis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	30 DAY

Date:06/22/00ISR Number: 3576564-7Report Type:Periodic Company Report #WAES 00041544
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576565-9Report Type:Periodic Company Report #WAES 00042171
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Biaxin	C				
			Ultram	C				

Date:06/22/00ISR Number: 3576567-2Report Type:Periodic Company Report #WAES 00041545
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				

Date:06/22/00ISR Number: 3576569-6Report Type:Periodic Company Report #WAES 00041546
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576571-4Report Type:Periodic Company Report #WAES 00042173
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3576572-6Report Type:Periodic Company Report #WAES 00041552
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Chloasma							
	Drug Ineffective							
	Fatigue							
	Headache		Tab Vioxx 25 Ml	SS		ORAL	25ML/DAILY/PO	
	Muscular Weakness		Lanoxin	C				
	Oedema Peripheral		Prevacid	C				
			Tenormin	C				
			Aspirin	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3576573-8Report Type:Periodic Company Report #WAES 00042176
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

			Metoprolol	C
			Terazosin	C

Date:06/22/00ISR Number: 3576575-1Report Type:Periodic Company Report #WAES 00041553
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DALY	
			Lopressor	C				
			Zocor	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576576-3Report Type:Periodic Company Report #WAES 00042177
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Pollakiuria Sedation Thirst	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25 MG; 12.5 MG;	/DAILY/PO

				Lipitor	C		
				Ziac	C		

Date:06/22/00ISR Number: 3576578-7Report Type:Periodic Company Report #WAES 00041554
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:06/22/00ISR Number: 3576579-9Report Type:Periodic Company Report #WAES 00042181
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Percocet	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576581-7Report Type:Periodic Company Report #WAES 00042183
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Lotrel	C				

Date:06/22/00ISR Number: 3576582-9Report Type:Periodic Company Report #WAES 00041555
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro Therapy Unspecified	C C				

Date:06/22/00ISR Number: 3576583-0Report Type:Periodic Company Report #WAES 00042184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576584-2Report Type:Periodic Company Report #WAES 00042190
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576585-4Report Type:Periodic Company Report #WAES 00041557
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Platelet Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol Extra Strength	C				

Date:06/22/00ISR Number: 3576587-8Report Type:Periodic Company Report #WAES 00042203
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576588-XReport Type:Periodic Company Report #WAES 00042212
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576589-1Report Type:Periodic Company Report #WAES 00042213
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576590-8Report Type:Periodic Company Report #WAES 00042214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576591-XReport Type:Periodic Company Report #WAES 00042217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/00ISR Number: 3576592-1Report Type:Periodic Company Report #WAES 00042218
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576593-3Report Type:Periodic Company Report #WAES 00042219
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576594-5Report Type:Periodic Company Report #WAES 00042221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3576595-7Report Type:Periodic Company Report #WAES 00042222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Disorder	Health	Vioxx	PS	Merck Research	
	Headache	Professional			Laboratories Div	
	Syncope	Company			Merck Co Inc	ORAL
PO						
	Transient Ischaemic	Representative				
	Attack					

Date:06/22/00ISR Number: 3576596-9Report Type:Periodic Company Report #WAES 00042223
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension		Vioxx	PS	Merck Research	
	Oedema				Laboratories Div	
					Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576597-0Report Type:Periodic Company Report #WAES 00041447
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				

Date:06/22/00ISR Number: 3576598-2Report Type:Periodic Company Report #WAES 00042235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estratab	C				
			Wellbutrin	C				

Date:06/22/00ISR Number: 3576599-4Report Type:Periodic Company Report #WAES 00042236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25 MG/PO	

Date:06/22/00ISR Number: 3576600-8Report Type:Periodic Company Report #WAES 00041450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Pulmonary Congestion Merck Co Inc ORAL
25

MG/DAILY/PO
Baycol C

Date:06/22/00ISR Number: 3576601-XReport Type:Periodic Company Report #WAES 00041925
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arava	C				
			Premarin	C				
			Progesterone	C				

Date:06/22/00ISR Number: 3576602-1Report Type:Periodic Company Report #WAES 00041451
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1X/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576603-3Report Type:Periodic Company Report #WAES 00041453
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zestril	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576604-5Report Type:Periodic Company Report #WAES 00041457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Arava	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3576605-7Report Type:Periodic Company Report #WAES 00041459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576606-9Report Type:Periodic Company Report #WAES 00041460
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3576607-0Report Type:Periodic Company Report #WAES 00041462
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3576608-2Report Type:Periodic Company Report #WAES 00041463
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576609-4Report Type:Periodic Company Report #WAES 00041928
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aldactone	C				
			Cozaar	C				
			Darvocet-N	C				
			Lasix	C				
			Plavix	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576610-0Report Type:Periodic Company Report #WAES 00041929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea Pallor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Ultram	C				

Date:06/22/00ISR Number: 3576611-2Report Type:Periodic Company Report #WAES 00041473
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem Cd	C				
			Claritin	C				
			Hydrodiuril	C				
			Prilosec	C				
			Pindolol	C				

Date:06/22/00ISR Number: 3576612-4Report Type:Periodic Company Report #WAES 00041930
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3576613-6Report Type:Periodic Company Report #WAES 00041477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ascites Hepatic Cirrhosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576614-8Report Type:Periodic Company Report #WAES 00041936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Anadrol	C				
			Coumadin	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3576615-XReport Type:Periodic Company Report #WAES 00041937
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3576616-1Report Type:Periodic Company Report #WAES 00041939
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imipenem	C				
			Insulin	C				

Date:06/22/00ISR Number: 3576617-3Report Type:Periodic Company Report #WAES 00041479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

Date:06/22/00ISR Number: 3576619-7Report Type:Periodic Company Report #WAES 00041942
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Dizziness Hyperventilation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Relafen	C				

Date:06/22/00ISR Number: 3576620-3Report Type:Periodic Company Report #WAES 00041946
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576621-5Report Type:Periodic Company Report #WAES 00041482
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Dizziness Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576622-7Report Type:Periodic Company Report #WAES 00041947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 6.25 MG/DAILY/PO; 6.25	
			Estrace	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3576623-9Report Type:Periodic Company Report #WAES 00041948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder Insomnia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Tylenol	C				
			Folic Acid	C				

Date:06/22/00ISR Number: 3576624-0Report Type:Periodic Company Report #WAES 00041486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Aspirin	C				

Date:06/22/00ISR Number: 3576625-2Report Type:Periodic Company Report #WAES 00041949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Azmacort	C				
			Cozaar	C				
			Intal Nebulizer Solution	C				
			Miacalcin	C				
			Neurontin	C				
			Prempro	C				
			Sinement	C				

Timoptic-Xe	C
Zocor	C
Calcium Supplement	C
Vitamin B (12)	C
Vitamins	C

Date:06/22/00ISR Number: 3576626-4Report Type:Periodic Company Report #WAES 00041950
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Flatulence							
	Pruritus				Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576627-6Report Type:Periodic Company Report #WAES 00041951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Glucotrol Xl	C				
			Premarin	C				
			Prinivil	C				
			Provera	C				

Date:06/22/00ISR Number: 3576628-8Report Type:Periodic Company Report #WAES 00041492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Weight Increased							

Merck Co Inc ORAL
25

MG/DAILY/PO;

50

MG/DAILY/PO 4 DAY

Date:06/22/00ISR Number: 3576629-XReport Type:Periodic Company Report #WAES 00041954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Toradol	C				

Date:06/22/00ISR Number: 3576630-6Report Type:Periodic Company Report #WAES 00041959
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dysentery	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576631-8Report Type:Periodic Company Report #WAES 00041493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576632-XReport Type:Periodic Company Report #WAES 00041962
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Haemorrhoids Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PM/PO	

Date:06/22/00ISR Number: 3576633-1Report Type:Periodic Company Report #WAES 00041971
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576634-3Report Type:Periodic Company Report #WAES 00041972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576635-5Report Type:Periodic Company Report #WAES 00041498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576636-7Report Type:Periodic Company Report #WAES 00041973
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Proteinuria	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Lasix	C				
			Nonsteroidal Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576637-9Report Type:Periodic Company Report #WAES 00041499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576638-0Report Type:Periodic Company Report #WAES 00041644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576639-2Report Type:Periodic Company Report #WAES 00041500
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	

Date:06/22/00ISR Number: 3576640-9Report Type:Periodic Company Report #WAES 00041646
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dysuria Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576641-0Report Type:Periodic Company Report #WAES 00041647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:06/22/00ISR Number: 3576642-2Report Type:Periodic Company Report #WAES 00041649
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Hypersensitivity Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				
			Lipitor	C				
			Toprol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576643-4Report Type:Periodic Company Report #WAES 00041502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Hypersensitivity							
	Paranoid Personality Disorder							
	Tongue Disorder							
	Tongue Oedema							

Date:06/22/00ISR Number: 3576644-6Report Type:Periodic Company Report #WAES 00041651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pneumonia							
			Betapace	C				
			Coumadin	C				
			Hyzaar	C				
			Synthroid	C				
			Antimicrobial Therapy	C				
			Calcium Supplement	C				
			Potassium Supplement	C				

Date:06/22/00ISR Number: 3576645-8Report Type:Periodic Company Report #WAES 00041653
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576647-1Report Type:Periodic Company Report #WAES 00041655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				
			Monopril	C				

Date:06/22/00ISR Number: 3576648-3Report Type:Periodic Company Report #WAES 00041656
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Azmacort	C				
			Serevent	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576649-5Report Type:Periodic Company Report #WAES 00041672
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Meridia	C				
			Premarin	C				
			Prometrium	C				
			Soma	C				
			Zovirax	C				

Date:06/22/00ISR Number: 3576650-1Report Type:Periodic Company Report #WAES 00041675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Maxair	C				
			Sinemet Cr	C				
			Selegiline Hydrochloride	C				

Date:06/22/00ISR Number: 3576651-3Report Type:Periodic Company Report #WAES 00041677
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Celebrex C

Date:06/22/00ISR Number: 3576652-5Report Type:Periodic Company Report #WAES 00041678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oliguria							
	Urine Abnormality							
	Weight Increased							

Date:06/22/00ISR Number: 3576653-7Report Type:Periodic Company Report #WAES 00041679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Sedation							

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576654-9Report Type:Periodic Company Report #WAES 00041681
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cytotec	C				
			Dilantin	C				
			Cimetidine	C				
			Indapamide	C				
			Oxybutynin Chloride	C				
			Trimethoprim	C				

Date:06/22/00ISR Number: 3576655-0Report Type:Periodic Company Report #WAES 00041685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Prednisone	C				

Date:06/22/00ISR Number: 3576656-2Report Type:Periodic Company Report #WAES 00041687
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576657-4Report Type:Periodic Company Report #WAES 00041690
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:06/22/00ISR Number: 3576658-6Report Type:Periodic Company Report #WAES 00041703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576659-8Report Type:Periodic Company Report #WAES 00041707
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Hytrin C

Date:06/22/00ISR Number: 3576660-4Report Type:Periodic Company Report #WAES 00041721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen	C				

Date:06/22/00ISR Number: 3576662-8Report Type:Periodic Company Report #WAES 00041411
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576663-XReport Type:Periodic Company Report #WAES 00041601
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Methylprednisolone	C				

Date:06/22/00ISR Number: 3576664-1Report Type:Periodic Company Report #WAES 00041602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain Tongue Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:06/22/00ISR Number: 3576665-3Report Type:Periodic Company Report #WAES 00041604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576666-5Report Type:Periodic Company Report #WAES 00041413
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:06/22/00ISR Number: 3576667-7Report Type:Periodic Company Report #WAES 00041607
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Upper Respiratory Tract Infection							
	Urticaria		Darvocet-N	C				

Date:06/22/00ISR Number: 3576668-9Report Type:Periodic Company Report #WAES 00041611
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Valium	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576669-0Report Type:Periodic Company Report #WAES 00041414
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576670-7Report Type:Periodic Company Report #WAES 00041615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576671-9Report Type:Periodic Company Report #WAES 00041617
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Estrace	C				
			Tylenol With Codeine #3	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576672-0Report Type:Periodic Company Report #WAES 00041415
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Tenormin	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3576673-2Report Type:Periodic Company Report #WAES 00041417
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576674-4Report Type:Periodic Company Report #WAES 00041619
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chronic Obstructive Pulmonary Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accupril	C				
			Proventil	C				
			Albuterol	C				

Date:06/22/00ISR Number: 3576675-6Report Type:Periodic Company Report #WAES 00041420
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Joint Stiffness							
	Pharyngeal Oedema							
	Sinusitis							
			Covera-Hs	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576676-8Report Type:Periodic Company Report #WAES 00041421
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/.UNK/PO	
	Weight Increased							
			Zocor	C				

Date:06/22/00ISR Number: 3576677-XReport Type:Periodic Company Report #WAES 00041428
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5	PS	Merck Research Laboratories Div Merck Co Inc			

	Glucotrol	C
	Mevacor	C
	Vasotec	C
	Procorum	C
	Insulin	C

Date:06/22/00ISR Number: 3576678-1Report Type:Periodic Company Report #WAES 00041621
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Hypokinesia Rash Morbilliform	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased		Imodium	C				
			Premarin	C				
			Zestril	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3576679-3Report Type:Periodic Company Report #WAES 00041624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:06/22/00ISR Number: 3576680-XReport Type:Periodic Company Report #WAES 00041429
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	3 WK

Date:06/22/00ISR Number: 3576681-1Report Type:Periodic Company Report #WAES 00041626
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Tenex	C				

Date:06/22/00ISR Number: 3576682-3Report Type:Periodic Company Report #WAES 00041628
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576683-5Report Type:Periodic Company Report #WAES 00041629
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dizziness							
	Fatigue							
	Sedation		Prozac	C				

Date:06/22/00ISR Number: 3576684-7Report Type:Periodic Company Report #WAES 00041430
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	25 MG/DAILY/PO	
	Dyspnoea							
	Oedema Peripheral							
	Pain In Extremity							
	Weight Increased		Evista	C				
			Norvasc	C				
			Vasotec	C				
			Furosemide	C				
			Thyroid	C				

Date:06/22/00ISR Number: 3576685-9Report Type:Periodic Company Report #WAES 00041431
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Sciatica							

Date:06/22/00ISR Number: 3576686-0Report Type:Periodic Company Report #WAES 00041432
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576687-2Report Type:Periodic Company Report #WAES 00041433
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Skin Warm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576688-4Report Type:Periodic Company Report #WAES 00041630
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Indocin C

Date:06/22/00ISR Number: 3576690-2Report Type:Periodic Company Report #WAES 00041631
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3576691-4Report Type:Periodic Company Report #WAES 00041635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Drug Ineffective							
	Fluid Retention		Diuretic Preparation	C				
	Pruritus							

Date:06/22/00ISR Number: 3576692-6Report Type:Periodic Company Report #WAES 00041637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Discomfort	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576693-8Report Type:Periodic Company Report #WAES 00041638
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576694-XReport Type:Periodic Company Report #WAES 00041639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Procardia	C				

Date:06/22/00ISR Number: 3576696-3Report Type:Periodic Company Report #WAES 00041437
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				

Hydrodiuril	C
Prempro	C
Cyclobenzaprine	C
Nadolol	C

Date:06/22/00ISR Number: 3576697-5Report Type:Periodic Company Report #WAES 00041642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576699-9Report Type:Periodic Company Report #WAES 00041438
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Blood Pressure Increased Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(Therapy Unspecified)	SS		ORAL	UNK/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3576700-2Report Type:Periodic Company Report #WAES 00041439
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pigmentation Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Premarin C

Date:06/22/00ISR Number: 3576702-6Report Type:Periodic Company Report #WAES 00041441
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576703-8Report Type:Periodic Company Report #WAES 00041442
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576704-XReport Type:Periodic Company Report #WAES 00041444
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Localised Oedema Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3576707-5Report Type:Periodic Company Report #WAES 00041445
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Premarin	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3576710-5Report Type:Periodic Company Report #WAES 00050220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Flovent	C				
			Maxzide	C				
			Prilosec	C				
			Zestril	C				

Date:06/22/00ISR Number: 3576715-4Report Type:Periodic Company Report #WAES 00050221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576716-6Report Type:Periodic Company Report #WAES 00050225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Stiffness Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576717-8Report Type:Periodic Company Report #WAES 00050227
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576719-1Report Type:Periodic Company Report #WAES 00050228
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prempro	C				
			Zocor	C				

Date:06/22/00ISR Number: 3576721-XReport Type:Periodic Company Report #WAES 00050238
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:06/22/00ISR Number: 3576723-3Report Type:Periodic Company Report #WAES 00050241
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Lipitor	C				
			Norvasc	C				
			Pepcid Ac	C				

			Aspirin	C
			Atenolol	C
			Vitamins	C

Date:06/22/00ISR Number: 3576726-9Report Type:Periodic Company Report #WAES 00050242
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Antivert	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3576728-2Report Type:Periodic Company Report #WAES 00050243
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576729-4Report Type:Periodic Company Report #WAES 00050244
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	

Date:06/22/00ISR Number: 3576731-2Report Type:Periodic Company Report #WAES 00050245
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILYPO	
			Ambien	C				
			Ulcyn	C				
			Aspirin	C				
			Cimetidine	C				

Date:06/22/00ISR Number: 3576733-6Report Type:Periodic Company Report #WAES 00050248
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576734-8Report Type:Periodic Company Report #WAES 00050249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/00ISR Number: 3576735-XReport Type:Periodic Company Report #WAES 00050256
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Face Oedema					
	Oedema Peripheral				Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Avapro	C		
			Levoxyl	C		
			Premarin	C		
			Atenolol	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576736-1Report Type:Periodic Company Report #WAES 00050257
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zoloft	C				
			Nadolol	C				
			Potassium Chloride	C				

Date:06/22/00ISR Number: 3576737-3Report Type:Periodic Company Report #WAES 00050258
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576738-5Report Type:Periodic Company Report #WAES 00050270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	1 MON

Date:06/22/00ISR Number: 3576739-7Report Type:Periodic Company Report #WAES 00050277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Drug Effect Decreased							
	Fatigue							
	Tongue Oedema							

Date:06/22/00ISR Number: 3576740-3Report Type:Periodic Company Report #WAES 00050297
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Fatigue							
	Sedation		Verelan	C				
			Zestril	C				

Date:06/22/00ISR Number: 3576741-5Report Type:Periodic Company Report #WAES 00050298
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1	

TABLET/DAILY/

PO

	Elmiron 100 Mg	SS	ORAL

100 MG/

TID/PO

Lescol	C
Miacalcin	C
Premarin	C
Prilosec	C
Calcium Supplement	C
Medroxyprogesterone	C

Date:06/22/00ISR Number: 3576742-7Report Type:Periodic Company Report #WAES 00050306
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Cardizem Cd	C
Glucotrol	C
Lipitor	C
Prilosec	C
Synthroid	C

Date:06/22/00ISR Number: 3576743-9Report Type:Periodic Company Report #WAES 00050310
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Aricept	C

Cardizem	C
Flovent	C
Levoxine	C
Prevacid	C
Singulair	C
Vasotec	C
Aspirin	C
Theophylline	C

Date:06/22/00ISR Number: 3576745-2Report Type:Periodic Company Report #WAES 00050314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576748-8Report Type:Periodic Company Report #WAES 00050316
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Palpitations	Health Professional Company

		Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3576749-XReport Type:Periodic Company Report #WAES 00050324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3576751-8Report Type:Periodic Company Report #WAES 00050325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Effect Decreased Ill-Defined Disorder Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Influenza Virus Vaccine	C		

Date:06/22/00ISR Number: 3576753-1Report Type:Periodic Company Report #WAES 00050327
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Increased Oedema Peripheral	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Genuine Bayer			

			Aspirin	C		

Date:06/22/00ISR Number: 3576755-5Report Type:Periodic Company Report #WAES 00050328
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nervousness	Consumer	Vioxx	PS	Merck Research	
	Palpitations				Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG DAILY						
PO 1 DAY						
			Celexa	C		
			Estratab	C		
			Lipitor	C		
			Niaspan	C		
			Norvasc	C		
			Xanax	C		

Date:06/22/00ISR Number: 3576756-7Report Type:Periodic Company Report #WAES 00050329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Full Blood Count Abnormal	Consumer	Vioxx	PS	Merck Research	
	Iron Deficiency				Laboratories Div	

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3576757-9Report Type:Periodic Company Report #WAES 00050331
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Pharyngeal Oedema							
			Prinivil	C				

Date:06/22/00ISR Number: 3576758-0Report Type:Periodic Company Report #WAES 00050332
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Estrogenic Preparation	C				
			Glyburide	C				

Date:06/22/00ISR Number: 3576759-2Report Type:Periodic Company Report #WAES 00050334
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3576761-0Report Type:Periodic Company Report #WAES 00050337
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Lipitor	C				
			Prilosec	C				
			Synthroid	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3576762-2Report Type:Periodic Company Report #WAES 00050340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576763-4Report Type:Periodic Company Report #WAES 00050347
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Vicodin Tablets	C				
			Testosterone	C				

Date:06/22/00ISR Number: 3576764-6Report Type:Periodic Company Report #WAES 00050350
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prozac	C				

Date:06/22/00ISR Number: 3576765-8Report Type:Periodic Company Report #WAES 00050353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Beclovent	C				
			Albuterol	C				

Date:06/22/00ISR Number: 3576766-XReport Type:Periodic Company Report #WAES 00050355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3576768-3Report Type:Periodic Company Report #WAES 00050358
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Headache Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Floxin	C				
			Quinoline	C				

Date:06/22/00ISR Number: 3576778-6Report Type:Periodic Company Report #WAES 00050361
Age:56 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis Face Oedema

	Pruritus Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576780-4Report Type:Periodic Company Report #WAES 00050365
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Lasix	C				
			Micronase	C				
			Norvasc	C				
			Tenormin	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3576781-6Report Type:Periodic Company Report #WAES 00050370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:06/22/00ISR Number: 3576783-XReport Type:Periodic Company Report #WAES 00050371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576785-3Report Type:Periodic Company Report #WAES 00050372
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3576787-7Report Type:Periodic Company Report #WAES 00050375
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis							
	Dry Skin							
	Fungal Skin Infection							
	Pruritus		Calcium Supplement	C				
	Rash Erythematous							

Date:06/22/00ISR Number: 3576789-0Report Type:Periodic Company Report #WAES 00050376
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576791-9Report Type:Periodic Company Report #WAES 00050378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased		Hyzaar	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3576792-0Report Type:Periodic Company Report #WAES 00050385
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576793-2Report Type:Periodic Company Report #WAES 00050389
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY/ PO	

Date:06/22/00ISR Number: 3576795-6Report Type:Periodic Company Report #WAES 00050390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576796-8Report Type:Periodic Company Report #WAES 00050393
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Disorder Platelet Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DIALY/PO	
			Sulfasalazine	C				

Date:06/22/00ISR Number: 3576797-XReport Type:Periodic Company Report #WAES 00050394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576798-1Report Type:Periodic Company Report #WAES 00050397
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET/DAILY/ PO	
			Duphalac	C				
			Fosamax	C				
			Lipitor	C				
			Abysa	C				
			Alprazolam	C				
			Stenolol	C				

Date:06/22/00ISR Number: 3576799-3Report Type:Periodic Company Report #WAES 00050404
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	100 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576800-7Report Type:Periodic Company Report #WAES 00050410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576801-9Report Type:Periodic Company Report #WAES 00050411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3576802-0Report Type:Periodic Company Report #WAES 00050416
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576803-2Report Type:Periodic Company Report #WAES 00050418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Infection Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tiazac	C				
			Zestril	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Dimethyl Sulfone	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3576804-4Report Type:Periodic Company Report #WAES 00050419
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3576805-6Report Type:Periodic Company Report #WAES 00042517
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mycilan	C				

Date:06/22/00ISR Number: 3576806-8Report Type:Periodic Company Report #WAES 00042518
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Zithromax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576807-XReport Type:Periodic Company Report #WAES 00042522
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	PO
			Premarin	C				

Date:06/22/00ISR Number: 3576808-1Report Type:Periodic Company Report #WAES 00042527
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Aspirin	C				

Date:06/22/00ISR Number: 3576809-3Report Type:Periodic Company Report #WAES 00042529
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3576810-XReport Type:Periodic Company Report #WAES 00042530
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5MG/BID/PO

Neurontin C
Pepcid C
Morphine C

Date:06/22/00ISR Number: 3576811-1Report Type:Periodic Company Report #WAES 00042531
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/BID/PO

SEE IMAGE

Celebrex C
Darvocet-N C
Chondroitin + Glucosamine C

Date:06/22/00ISR Number: 3576812-3Report Type:Periodic Company Report #WAES 00042535
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
12.5MG/DAILY/

PO

Toprol Xl C
Nitroglycerin C

Date:06/22/00ISR Number: 3576813-5Report Type:Periodic Company Report #WAES 00042538
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Premarin	C				

Date:06/22/00ISR Number: 3576814-7Report Type:Periodic Company Report #WAES 00042541
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve	C				
			Vicodin Tablets	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3576815-9Report Type:Periodic Company Report #WAES 00042542
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:06/22/00ISR Number: 3576816-0Report Type:Periodic Company Report #WAES 00042548
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576818-4Report Type:Periodic Company Report #WAES 00042549
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3576821-4Report Type:Periodic Company Report #WAES 00042550
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3576823-8Report Type:Periodic Company Report #WAES 00042551
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Tapazole	C				
			Zestril	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3576825-1Report Type:Periodic Company Report #WAES 00042552
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3576827-5Report Type:Periodic Company Report #WAES 00042554
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Elavil	C				

Date:06/22/00ISR Number: 3576829-9Report Type:Periodic Company Report #WAES 00042557
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Gait Disturbance Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain Weight Increased		Hydrodiuril	C				
			Lasix	C				
			Zocor	C				

Date:06/22/00ISR Number: 3576830-5Report Type:Periodic Company Report #WAES 00042558
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/00ISR Number: 3576832-9Report Type:Periodic Company Report #WAES 00042559
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3576998-0Report Type:Periodic Company Report #WAES 00052128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3577000-7Report Type:Periodic Company Report #WAES 00052132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ecotin	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577001-9Report Type:Periodic Company Report #WAES 00052136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Drug Effect Decreased							
	Fatigue							
			Darvocet-N	C				
			Dyazide	C				
			Lipitor	C				
			Hydrocodone	C				
			Imipramine	C				
			Lorazepam	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577003-2Report Type:Periodic Company Report #WAES 00052139
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Blood Pressure Increased							
	Dyspnoea							
	Pain In Extremity		Vasotec	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577004-4Report Type:Periodic Company Report #WAES 00052148
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Menest	C				
			Remeron	C				
			Ampicillin	C				
			Chlordiazepoxide Hydrochloride	C				
			Clonazepam	C				

Date:06/22/00ISR Number: 3577005-6Report Type:Periodic Company Report #WAES 00052150
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3577006-8Report Type:Periodic Company Report #WAES 00052153
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Darvocet-N	C				
			Lortab	C				
			Prilosec	C				

			Restoril	C		
			Synthroid	C		

Date:06/22/00ISR Number: 3577127-XReport Type:Periodic Company Report #WAES 00040475
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Nodule Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Fioricet Tablets	C				
			K-Tab	C				
			Klonopin	C				
			Plaquenil	C				
			Pravachol	C				
			Robaxin	C				
			Synthroid	C				
			Valium	C				
			Vicodin Tablets	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577130-XReport Type:Periodic Company Report #WAES 00040478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:06/22/00ISR Number: 3577131-1Report Type:Periodic Company Report #WAES 00040483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577133-5Report Type:Periodic Company Report #WAES 00040485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577134-7Report Type:Periodic Company Report #WAES 00040486
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Rezulin	C		
			Composition			
			Unspecified	C		
			Trazodone	C		

Date:06/22/00ISR Number: 3577135-9Report Type:Periodic Company Report #WAES 00040504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvon	C				
			Ecotrin	C				

Date:06/22/00ISR Number: 3577136-0Report Type:Periodic Company Report #WAES 00040513
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder Drug Ineffective Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Pepcid	C				

		Zoloft	C
		Prednisone	C

Date:06/22/00ISR Number: 3577139-6Report Type:Periodic Company Report #WAES 00040525
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577141-4Report Type:Periodic Company Report #WAES 00040526
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Ventricular Extrasystoles	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577145-1Report Type:Periodic Company Report #WAES 00040532
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Infection Oedema Skin Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Detrol	C				
			Levoxyl	C				
			Propulsid	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3577149-9Report Type:Periodic Company Report #WAES 00040536
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577151-7Report Type:Periodic Company Report #WAES 00040537
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577153-0Report Type:Periodic Company Report #WAES 00040528
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577156-6Report Type:Periodic Company Report #WAES 00040539
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577158-XReport Type:Periodic Company Report #WAES 00040540
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577161-XReport Type:Periodic Company Report #WAES 00040543
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Captopril Msd C
Cardizem C
Coumadin C
Vitamins C

Date:06/22/00ISR Number: 3577163-3Report Type:Periodic Company Report #WAES 00040544
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							
	Oedema Peripheral				Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atenolol	C				

Date:06/22/00ISR Number: 3577165-7Report Type:Periodic Company Report #WAES 00040546
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Nausea							
					Merck Co Inc	ORAL	PO	
			Buspar	C				

			Ultram	C		
			Amitriptyline	C		

Date:06/22/00ISR Number: 3577175-XReport Type:Periodic Company Report #WAES 00040552
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus Inadequate Control	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Glucophage	C				
			Lodine	C				
			Lotrel	C				
			Prevacid	C				
			Zoloft	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3577178-5Report Type:Periodic Company Report #WAES 00040556
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Colic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ativan	C				
			Pamelor	C				
			Wellbutrin	C				

Date:06/22/00ISR Number: 3577180-3Report Type:Periodic Company Report #WAES 00040558
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea	Health			Laboratories Div			
	Disorientation	Professional			Merck Co Inc	ORAL	12.5	
	Dizziness						MG/DAILY/PO	
	Fatigue		Coumadin	C				
	Movement Disorder		Elavil	C				
	Swelling		Lanoxin	C				
			Lasix	C				
			Synthroid	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577183-9Report Type:Periodic Company Report #WAES 00040559
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research			
	Dizziness				Laboratories Div			
	Dyspepsia				Merck Co Inc	ORAL	1) PO; 2) PO	
	Influenza		Coumadin	C				
	Sedation		Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577185-2Report Type:Periodic Company Report #WAES 00040562
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea	Other						
	Saliva Altered							

Date:06/22/00ISR Number: 3577187-6Report Type:Periodic Company Report #WAES 00040568
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Flatulence							
	Insomnia							
			Cogentin	C				
			Primaxin	C				

Date:06/22/00ISR Number: 3577191-8Report Type:Periodic Company Report #WAES 00040569
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Aspirin Unk	SS				
			Advil	SS				

Date:06/22/00ISR Number: 3577193-1Report Type:Periodic Company Report #WAES 00040572
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/DAILY/PO; 2) 25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577194-3Report Type:Periodic Company Report #WAES 00040584
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Nausea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3577196-7Report Type:Periodic Company Report #WAES 00040588
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Synthroid C

Date:06/22/00ISR Number: 3577198-0Report Type:Periodic Company Report #WAES 00040595
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotensin	C				
			Prempro	C				

Date:06/22/00ISR Number: 3577199-2Report Type:Periodic Company Report #WAES 00040598
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arthrotec	C				
			Aspirin	C				
			Diuretic Preparation (Composition Unk)	C				

Date:06/22/00ISR Number: 3577201-8Report Type:Periodic Company Report #WAES 00040600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577202-XReport Type:Periodic Company Report #WAES 00040645
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577203-1Report Type:Periodic Company Report #WAES 00040647
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Estratab	C				
			Neurontin	C				
			Synthroid	C				
			Zyrtec	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577205-5Report Type:Periodic Company Report #WAES 00040648
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				

Date:06/22/00ISR Number: 3577206-7Report Type:Periodic Company Report #WAES 00040650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Pyrexia Sensation Of Heaviness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/BID/PO; 2) 25 MG/BID/PO	
			Asacol	C				
			Synthroid	C				
			Ultram	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577208-0Report Type:Periodic Company Report #WAES 00040652
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577209-2Report Type:Periodic Company Report #WAES 00040657
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577210-9Report Type:Periodic Company Report #WAES 00040658
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577212-2Report Type:Periodic Company Report #WAES 00040418
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Fosamax	C
Lanoxin	C
Volmax	C
Therapy Unspecified	C
Ascorbic Acid	C
Calcium Supplement (Composition)	C
Vitamin E	C
Vitamins	C

Date:06/22/00ISR Number: 3577213-4Report Type:Periodic Company Report #WAES 00040419
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Diazide	C				

Date:06/22/00ISR Number: 3577214-6Report Type:Periodic Company Report #WAES 00040421
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Nocturia Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Acular	C				
			Allegra	C				
			Betoptic	C				
			Ecotrin	C				
			Fosamax	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3577215-8Report Type:Periodic Company Report #WAES 00040425
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
			Zocor	C				

Date:06/22/00ISR Number: 3577216-XReport Type:Periodic Company Report #WAES 00040428
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO; 12.5 MG/BID/PO	
			Inderal	C				
			Ditropan	C				
			Celebrex	C				
			Tofranil	C				

Aspirin C

Date:06/22/00ISR Number: 3577217-1Report Type:Periodic Company Report #WAES 00040430
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	/UNK/PO
			Coumadin	C				
			Fosamax	C				
			Lipitor	C				
			Vaseretic	C				

Date:06/22/00ISR Number: 3577218-3Report Type:Periodic Company Report #WAES 00040431
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Asacol	C				
			Premarin	C				

Date:06/22/00ISR Number: 3577219-5Report Type:Periodic Company Report #WAES 00040435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:06/22/00ISR Number: 3577220-1Report Type:Periodic Company Report #WAES 00040436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Arava	C				
			Climara	C				
			Dhea	C				
			Plaquenil	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577221-3Report Type:Periodic Company Report #WAES 00040438
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;	25

MG/DAILY/PO

	Centrum Silver	C	
	Darvocet-N	C	
	Vitamin E	C	

Date:06/22/00ISR Number: 3577222-5Report Type:Periodic Company Report #WAES 00040441
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577223-7Report Type:Periodic Company Report #WAES 00040442
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Depression							
	Fatigue							
	Hypertension		Prozac	C				
	Weight Increased		Nicardipine	C				

Date:06/22/00ISR Number: 3577224-9Report Type:Periodic Company Report #WAES 00040443
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Hytrin	C				

Date:06/22/00ISR Number: 3577225-0Report Type:Periodic Company Report #WAES 00040444
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Atenolol Msd	C				
			Zantac	C				
			Zocor	C				
			Zyban	C				

Date:06/22/00ISR Number: 3577226-2Report Type:Periodic Company Report #WAES 00040450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Wellbutrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577227-4Report Type:Periodic Company Report #WAES 00040451
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Malaise							
	Pain							
			Pravachol	C				
			Metoprolol	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577228-6Report Type:Periodic Company Report #WAES 00040455
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flonase	C				

Date:06/22/00ISR Number: 3577229-8Report Type:Periodic Company Report #WAES 00040460
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Lanoxin	C				
			Premarin	C				
			Xanax	C				
			Zoloft	C				

			Timolol	C		

Date:06/22/00ISR Number: 3577230-4Report Type:Periodic Company Report #WAES 00040462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Erythromycin	C				
			Ketoprofen	C				

Date:06/22/00ISR Number: 3577231-6Report Type:Periodic Company Report #WAES 00040465
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO; UNK/QOD/PO	

			Allegra	C		
			Ativan	C		
			Celexa	C		

Date:06/22/00ISR Number: 3577232-8Report Type:Periodic Company Report #WAES 00042110
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Spironolactone	C				

Date:06/22/00ISR Number: 3577233-XReport Type:Periodic Company Report #WAES 00042113
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Back Pain Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Coumadin	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577234-1Report Type:Periodic Company Report #WAES 00042115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Evista	C				
			Ascorbic Acid	C				
			Calcium Supplement (Composition	C				

			Vitamins	C		

Date:06/22/00ISR Number: 3577235-3Report Type:Periodic Company Report #WAES 00042120
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO 1 DAY						
			Lipitor	C		
			Norvasc	C		
			Paxil	C		
			Risperdal	C		
			Alprazolam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577236-5Report Type:Periodic Company Report #WAES 00042125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3577237-7Report Type:Periodic Company Report #WAES 00042132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Prevacid	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577238-9Report Type:Periodic Company Report #WAES 00042135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:06/22/00ISR Number: 3577239-0Report Type:Periodic Company Report #WAES 00042139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhagic Stroke	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:06/22/00ISR Number: 3577240-7Report Type:Periodic Company Report #WAES 00042143
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							
	Nausea				Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Rectal Haemorrhage							
			Diabeta	C				
			Isordil	C				
			Mevacor	C				
			Amiloride	C				
			Atenolol	C				
			Cimetidine	C				
			Diazepam	C				

Date:06/22/00ISR Number: 3577241-9Report Type:Periodic Company Report #WAES 00042145
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/00ISR Number: 3577242-0Report Type:Periodic Company Report #WAES 00042147
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Dilantin	C				

Date:06/22/00ISR Number: 3577243-2Report Type:Periodic Company Report #WAES 00042149
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577244-4Report Type:Periodic Company Report #WAES 00042156
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Eating Disorder Fatigue Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Headache		Prevacid	C				

Date:06/22/00ISR Number: 3577245-6Report Type:Periodic Company Report #WAES 00042158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Timoptic	C				

Date:06/22/00ISR Number: 3577246-8Report Type:Periodic Company Report #WAES 00042159
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Paxil	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577247-XReport Type:Periodic Company Report #WAES 00042161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lescol	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Thyroid	C				

Date:06/22/00ISR Number: 3577248-1Report Type:Periodic Company Report #WAES 00042165
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577249-3Report Type:Periodic Company Report #WAES 00042166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arterial Rupture Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/00ISR Number: 3577250-XReport Type:Periodic Company Report #WAES 00042168
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Allegra	C				
			Estratest	C				
			Lipitor	C				
			Premarin	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577251-1Report Type:Periodic Company Report #WAES 00042169
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577252-3Report Type:Periodic Company Report #WAES 00042069
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO;	25 MG/DAILY/PO
			Avapro	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3577253-5Report Type:Periodic Company Report #WAES 00042691
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Hydrodiuril	C				
			Questran	C				

Date:06/22/00ISR Number: 3577254-7Report Type:Periodic Company Report #WAES 00042695
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Incontinence Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/PO	
			Valium	C				

Date:06/22/00ISR Number: 3577255-9Report Type:Periodic Company Report #WAES 00042701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Clonidine	C				

Date:06/22/00ISR Number: 3577256-0Report Type:Periodic Company Report #WAES 00042704
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pain Rhinitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection		Diovan	C				
			Theragran Tablets Advanced Formu	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577257-2Report Type:Periodic Company Report #WAES 00042709
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxalt (Rizatriptan Benzoate)	C				
			Premarin	C				
			Synthroid	C				
			Atenolol	C				
			Nicotinic Acid	C				

Date:06/22/00ISR Number: 3577258-4Report Type:Periodic Company Report #WAES 00042712
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cytotec	C				
			Prevacid	C				
			Synthroid	C				
			Propranolol	C				

Date:06/22/00ISR Number: 3577259-6Report Type:Periodic Company Report #WAES 00042715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577260-2Report Type:Periodic Company Report #WAES 00042717
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Muscular Weakness							
	Nausea							
	Vomiting							
			Dyazide	C				
			Lipitor	C				
			Lopressor	C				
			Premarin	C				

Date:06/22/00ISR Number: 3577261-4Report Type:Periodic Company Report #WAES 00042720
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Mouth Ulceration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577262-6Report Type:Periodic Company Report #WAES 00042723
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Clinoril	C				
			Darvocet -N	C				
			Paxil	C				
			Diclofenac Sodium	C				

Date:06/22/00ISR Number: 3577263-8Report Type:Periodic Company Report #WAES 00042728
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3577264-XReport Type:Periodic Company Report #WAES 00042571
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:06/22/00ISR Number: 3577265-1Report Type:Periodic Company Report #WAES 00042573
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium Supplement	C				
			Hydrochlorothiazide (+) Triamter	C				
			Potassium Supplement	C				
			Warfarin Sodium Salt	C				

Date:06/22/00ISR Number: 3577266-3Report Type:Periodic Company Report #WAES 00042574
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577267-5Report Type:Periodic Company Report #WAES 00042589
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Atrovent	C				
			Flovent	C				
			Proventil	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577271-7Report Type:Periodic Company Report #WAES 00042600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577272-9Report Type:Periodic Company Report #WAES 00042601
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577273-0Report Type:Periodic Company Report #WAES 00042731
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypoglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 25 MG/PM/PO
			Coumadin	C		
			Toprol Xl Tablets	C		
			Aspirin	C		
			Glyburide	C		

Date:06/22/00ISR Number: 3577274-2Report Type:Periodic Company Report #WAES 00042733
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Oedema Peripheral	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
		Representative	Sular	C		

Date:06/22/00ISR Number: 3577276-6Report Type:Periodic Company Report #WAES 00042734
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Vertigo	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Celebrex	C				

Date:06/22/00ISR Number: 3577277-8Report Type:Periodic Company Report #WAES 00050008
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Hyperhidrosis Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
	Nausea		Accupril	C				
	Oedema Peripheral		Claritin-D	C				
	Vision Blurred		Glucophage	C				
			Nasonex	C				
			Prinivil	C				
			Timoptic-Xe	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3577278-XReport Type:Periodic Company Report #WAES 00050011
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577280-8Report Type:Periodic Company Report #WAES 00050012
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cardiac Failure	Health	Vioxx	PS	Merck Research	
	Congestive	Professional			Laboratories Div	
	Weight Increased	Company			Merck Co Inc	ORAL
SEE IMAGE						
		Representative	Aricept	C		
			Dyazide	C		
			Lanoxin	C		

Date:06/22/00ISR Number: 3577281-XReport Type:Periodic Company Report #WAES 00050014
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Health	Vioxx	PS	Merck Research	
	Nausea	Professional			Laboratories Div	
	Vomiting	Company			Merck Co Inc	ORAL
SEE IMAGE						
		Representative	Zestril	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577286-9Report Type:Periodic Company Report #WAES 00050020
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Headache							
	Nausea		Tylenol With Codeine	C				
	Urinary Tract Infection		Vistaril	C				
			Zantac	C				
			[Therapy Unspecified]	C				
			Iron (Unspecified)	C				

Date:06/22/00ISR Number: 3577287-0Report Type:Periodic Company Report #WAES 00042738
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577289-4Report Type:Periodic Company Report #WAES 00042741
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haematuria							
	Proteinuria							
	Urinary Tract Infection							
			Caltrate 600 Plus Vitamin D	C				
			Centrum Silver	C				
			Evista	C				
			Macrobid	C				
			Prilosec	C				

			Cephalexin	C		

Date:06/22/00ISR Number: 3577290-0Report Type:Periodic Company Report #WAES 00042755
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Headache							
	Nausea							
	Oedema Peripheral		Glucophage	C				
			Glucotrol	C				
			Humulin	C				
			Nadolol	C				

Date:06/22/00ISR Number: 3577292-4Report Type:Periodic Company Report #WAES 00042756
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Estratab	C		
			Norvasc	C		
			Zocor	C		

Date:06/22/00ISR Number: 3577294-8Report Type:Periodic Company Report #WAES 00042757
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Depression							
	Nausea							
			Premarin	C				

Date:06/22/00ISR Number: 3577295-XReport Type:Periodic Company Report #WAES 00042759
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache							
			Dyazide	C				
			Prozac	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577296-1Report Type:Periodic Company Report #WAES 00042762
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Feeling Hot							
	Tremor							
			Soma	C				
			Albuterol	C				
			Guaifenesin	C				

Date:06/22/00ISR Number: 3577298-5Report Type:Periodic Company Report #WAES 00042763
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3577302-4Report Type:Periodic Company Report #WAES 00042770
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 25 MG/BID/PO	
	Drug Ineffective							
	Thyroid Disorder							
			Cortaid	C				
			Ultram	C				

Therapy Unspecified C

Date:06/22/00ISR Number: 3577303-6Report Type:Periodic Company Report #WAES 00042771
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Azulfidine	C				
			Prempro	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577305-XReport Type:Periodic Company Report #WAES 00042772
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Pyrexia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 DAY

Date:06/22/00ISR Number: 3577306-1Report Type:Periodic Company Report #WAES 00042775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577307-3Report Type:Periodic Company Report #WAES 00042776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5; 25 MG/DAILY/PO	
			Benadryl	C				
			Sudafed	C				
			Calcium Supplement	C				
			Ferrous Sulfate Heptahydrate	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/22/00ISR Number: 3577308-5Report Type:Periodic Company Report #WAES 00042779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577309-7Report Type:Periodic Company Report #WAES 00042780
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Procardia	C				
			Toprol Xl Tablets	C				

Date:06/22/00ISR Number: 3577310-3Report Type:Periodic Company Report #WAES 00042781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577312-7Report Type:Periodic Company Report #WAES 00042782
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
	Rash Erythematous		Lipitor	C				

Date:06/22/00ISR Number: 3577313-9Report Type:Periodic Company Report #WAES 00042787
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Nausea				Merck Co Inc	ORAL
PO						
	Rhinorrhoea					
	Upper Respiratory Tract Infection					

Date:06/22/00ISR Number: 3577314-0Report Type:Periodic Company Report #WAES 00042791
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Pharyngitis					
	Sputum Abnormal				Merck Co Inc	ORAL
12.5						
	Throat Tightness					
MG/DAILY/PO						
			Oxygen	C		
			Prednisone	C		

Date:06/22/00ISR Number: 3577316-4Report Type:Periodic Company Report #WAES 00042796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
1X/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577317-6Report Type:Periodic Company Report #WAES 00050023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Muscle Spasms							
			Accupril	C				
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Prevacid	C				
			Atenolol	C				
			Potassium Chloride	C				

Date:06/22/00ISR Number: 3577318-8Report Type:Periodic Company Report #WAES 00050024
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Lozol	C				
			Prempro	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577319-XReport Type:Periodic Company Report #WAES 00042797
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Claritin	C
Detrol	C
Evista	C
Synthroid	C
Vasotec	C
Zoloft	C
Therapy Unspecified	C

Date:06/22/00ISR Number: 3577321-8Report Type:Periodic Company Report #WAES 00050027
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577322-XReport Type:Periodic Company Report #WAES 00050029
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/UNK/PO

Celebrex	C
Tylenol Arthritis Extended Relie	C
Calcium Supplement	C
Furosemide	C
Magnesium Preparation	C
Potassium Suplement	C

Date:06/22/00ISR Number: 3577323-1Report Type:Periodic Company Report #WAES 00042798
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Depression							
	Hyperhidrosis				Merck Co Inc	ORAL	PO	
	Pharyngitis		Xanax	C				
	Tachycardia		Diazepam	C				
	Thirst		Hydrocodone	C				
	Urticaria							

Date:06/22/00ISR Number: 3577324-3Report Type:Periodic Company Report #WAES 00050036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Influenza Like Illness							
					Merck Co Inc	ORAL	12.5	MG/DAILY/PO 1 DAY
			Premarin	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577325-5Report Type:Periodic Company Report #WAES 00050037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avalide	C				
			Estrogenic Preparations (Composi	C				

Date:06/22/00ISR Number: 3577326-7Report Type:Periodic Company Report #WAES 00042803
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Postural	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Cozaar	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577328-0Report Type:Periodic Company Report #WAES 00050039
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				
			[Composition Unspecified]	C				

Date:06/22/00ISR Number: 3577329-2Report Type:Periodic Company Report #WAES 00042807
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lopressor	C				

Date:06/22/00ISR Number: 3577330-9Report Type:Periodic Company Report #WAES 00050043
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577331-0Report Type:Periodic Company Report #WAES 00050045
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY
			Prempro	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3577332-2Report Type:Periodic Company Report #WAES 00042808
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cardizem	C				
			Flovent	C				
			Lescodil	C				
			Oxycontin	C				
			Pepcid	C				
			Percocet	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577333-4Report Type:Periodic Company Report #WAES 00050047
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Anorexia							
	Constipation							
			Allegra	C				
			Zantac	C				

Date:06/22/00ISR Number: 3577334-6Report Type:Periodic Company Report #WAES 00050048
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Effexor	C				
			Lipitor	C				

Date:06/22/00ISR Number: 3577335-8Report Type:Periodic Company Report #WAES 00042812
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Hyperglycaemia							
		Representative	Glynase Prestab Tablets	C				
			Procardia	C				

Date:06/22/00ISR Number: 3577337-1Report Type:Periodic Company Report #WAES 00050051
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamin B{12}	C				

Date:06/22/00ISR Number: 3577338-3Report Type:Periodic Company Report #WAES 00042813
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Claritin	C				
			Flovent	C				
			Prevacid	C				
			Serevent	C				
			Slo-Bid	C				
			Valium	C				
			Vicodin Tablets	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577339-5Report Type:Periodic Company Report #WAES 00050052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	3 DAY

Date:06/22/00ISR Number: 3577340-1Report Type:Periodic Company Report #WAES 00050055
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Disorder Pharyngitis Pulmonary Congestion Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577341-3Report Type:Periodic Company Report #WAES 00042814
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577342-5Report Type:Periodic Company Report #WAES 00050056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Glucophage	C
Humulin R	C
Micronase	C

Date:06/22/00ISR Number: 3577343-7Report Type:Periodic Company Report #WAES 00042815
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Oedema Peripheral					
	Urinary Tract Infection				Merck Co Inc	ORAL

25MG/DAILY/PO

Avalide	C
Cardura	C
Darvocet-N	C
Megace	C
Pravachol	C
Tylenol	C
Allopurinol	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577344-9Report Type:Periodic Company Report #WAES 00050681
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577345-0Report Type:Periodic Company Report #WAES 00050683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ UNK/PO	
	Flatulence							
	Pain							
	Tooth Disorder		Synthroid	C				

Date:06/22/00ISR Number: 3577347-4Report Type:Periodic Company Report #WAES 00042821
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	10 DAY

Date:06/22/00ISR Number: 3577348-6Report Type:Periodic Company Report #WAES 00050686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							

Merck Co Inc ORAL
25 MG/

DAILY/PO

Date:06/22/00ISR Number: 3577349-8Report Type:Periodic Company Report #WAES 00042825
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577350-4Report Type:Periodic Company Report #WAES 00050687
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Bradycardia Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Extrasystoles Nausea		Aspirin Estrone Sulfate Piperazine Salt	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577351-6Report Type:Periodic Company Report #WAES 00042847
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577352-8Report Type:Periodic Company Report #WAES 00050702
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577353-XReport Type:Periodic Company Report #WAES 00050717
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577354-1Report Type:Periodic Company Report #WAES 00042852
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577355-3Report Type:Periodic Company Report #WAES 00050718
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/PO; SEE IMAGE	
			Norco	C				

Date:06/22/00ISR Number: 3577356-5Report Type:Periodic Company Report #WAES 00042862
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577357-7Report Type:Periodic Company Report #WAES 00050719
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577358-9Report Type:Periodic Company Report #WAES 00042863
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577359-0Report Type:Periodic Company Report #WAES 00050724
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577360-7Report Type:Periodic Company Report #WAES 00050725
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Synthroid	C		

Date:06/22/00ISR Number: 3577361-9Report Type:Periodic Company Report #WAES 00042864
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/00ISR Number: 3577362-0Report Type:Periodic Company Report #WAES 00050838
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma Thrombosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				

Date:06/22/00ISR Number: 3577363-2Report Type:Periodic Company Report #WAES 00050726
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pain Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:06/22/00ISR Number: 3577364-4Report Type:Periodic Company Report #WAES 00042865
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577365-6Report Type:Periodic Company Report #WAES 00042868
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Gluophage	C				
			Synthroid	C				
			Synvisc	C				
			Composition Unspecified	C				

Date:06/22/00ISR Number: 3577366-8Report Type:Periodic Company Report #WAES 00050842
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Discomfort	Consumer	Vioxx	PS	Merck Research			

	Pruritus				Laboratories Div	
	Rhinorrhoea				Merck Co Inc	ORAL
PO						
			Norvasc	C		
			Prilosec	C		

Date:06/22/00ISR Number: 3577367-XReport Type:Periodic Company Report #WAES 00050005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mental Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/00ISR Number: 3577368-1Report Type:Periodic Company Report #WAES 00050007
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Evista	C		
			Lipitor	C		

			Vasotec	C		
			Temazepam	C		

Date:06/22/00ISR Number: 3577369-3Report Type:Periodic Company Report #WAES 00050844
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				

Date:06/22/00ISR Number: 3577370-XReport Type:Periodic Company Report #WAES 00050728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				

Date:06/22/00ISR Number: 3577371-1Report Type:Periodic Company Report #WAES 00050731
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				
			Miacalcin	C				

Date:06/22/00ISR Number: 3577372-3Report Type:Periodic Company Report #WAES 00050734
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3577373-5Report Type:Periodic Company Report #WAES 00050848
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577374-7Report Type:Periodic Company Report #WAES 00050736
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	PO; SEE IMAGE
			Cardizem	C				
			Zestoretic	C				

Date:06/22/00ISR Number: 3577375-9Report Type:Periodic Company Report #WAES 00050850
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Hydrochlorothiazide (+) Potassiu	C				
			S-Adenosylmethionine	C				

Date:06/22/00ISR Number: 3577376-0Report Type:Periodic Company Report #WAES 00050738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Premarin	C				

Date:06/22/00ISR Number: 3577377-2Report Type:Periodic Company Report #WAES 00050739
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Motrin	C				
			Theo-Dur	C				

Date:06/22/00ISR Number: 3577378-4Report Type:Periodic Company Report #WAES 00050740
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577379-6Report Type:Periodic Company Report #WAES 00050852
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Guaifed	C				
			Inderal	C				
			Monodox	C				
			Glucosamine	C				
			Spironolactone	C				
			Sucralfate	C				

Date:06/22/00ISR Number: 3577380-2Report Type:Periodic Company Report #WAES 00050741
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				

Date:06/22/00ISR Number: 3577381-4Report Type:Periodic Company Report #WAES 00050183
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Medication Error	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atacand	C				
			Glucotrol	C				
			Synthroid	C				
			Zocor	C				

Date:06/22/00ISR Number: 3577382-6Report Type:Periodic Company Report #WAES 00050742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Altace	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3577383-8Report Type:Periodic Company Report #WAES 00050184
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577384-XReport Type:Periodic Company Report #WAES 00050854
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations Sensation Of Heaviness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Cozaar	C				
			Prevacid	C				

Date:06/22/00ISR Number: 3577385-1Report Type:Periodic Company Report #WAES 00050194
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3577386-3Report Type:Periodic Company Report #WAES 00050855
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577387-5Report Type:Periodic Company Report #WAES 00050196
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Aspirin	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577388-7Report Type:Periodic Company Report #WAES 00050197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577389-9Report Type:Periodic Company Report #WAES 00050856
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:06/22/00ISR Number: 3577390-5Report Type:Periodic Company Report #WAES 00050198
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Neurontin	C				

Date:06/22/00ISR Number: 3577391-7Report Type:Periodic Company Report #WAES 00050199
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577392-9Report Type:Periodic Company Report #WAES 00050861
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Atrial Flutter Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Dyspepsia Fatigue		Aspirin Estrogenic	C				

	Headache		Preparations			
	Oedema		(Composi	C		
	Urinary Tract Infection					

Date:06/22/00ISR Number: 3577393-0Report Type:Periodic Company Report #WAES 00050200
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Pravachol	C		

Date:06/22/00ISR Number: 3577394-2Report Type:Periodic Company Report #WAES 00050201
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Celebrex	C		
			Fosamax	C		
			Lipitor	C		

			Premarin	C
			Procardia Xl	C
			Metoprolol	C

Date:06/22/00ISR Number: 3577395-4Report Type:Periodic Company Report #WAES 00050202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
	Dyspnoea							
			[Composition Unspecified]	C				
			Allergenic Extract	C				
			Estrogenic Preparations (Composunk - Unk	C				

Date:06/22/00ISR Number: 3577396-6Report Type:Periodic Company Report #WAES 00050872
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12	MG/DAILY/PO
	Feeling Hot							
	Haematuria							
			Ativan	C				
			Saridon	C				
			Tylenol	C				
			Aspirin	C				
			Estrogenic Preparations (Composi	C				

Date:06/22/00ISR Number: 3577397-8Report Type:Periodic Company Report #WAES 00050204
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Lipitor	C				
			Lozol	C				
			Vasotec	C				

Date:06/22/00ISR Number: 3577398-XReport Type:Periodic Company Report #WAES 00050205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577399-1Report Type:Periodic Company Report #WAES 00050877
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5 Mg	SS			PO	
			Axid	C				
			Claritin	C				
			Dyazide	C				
			Tenormin	C				
			Vasoretic	C				

Date:06/22/00ISR Number: 3577400-5Report Type:Periodic Company Report #WAES 00050207
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				
			[Therapy Unspecified]	C				
			Albuterol	C				
			Ipratropium Bromide	C				
			Methocarbamol	C				

Date:06/22/00ISR Number: 3577401-7Report Type:Periodic Company Report #WAES 00050208
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO 6 MON

Dyazide	C	
Estrace	C	
Prevacid	C	

Date:06/22/00ISR Number: 3577402-9Report Type:Periodic Company Report #WAES 00050879
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Synthroid	C				
			Tylenol	C				

Date:06/22/00ISR Number: 3577403-0Report Type:Periodic Company Report #WAES 00050210
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Fosamax	C	
Lipitor	C	
Lopressor	C	

Date:06/22/00ISR Number: 3577404-2Report Type:Periodic Company Report #WAES 00050211
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Glucotrol	C	
Atenolol	C	
Captopril	C	

Date:06/22/00ISR Number: 3577405-4Report Type:Periodic Company Report #WAES 00050882
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:06/22/00ISR Number: 3577406-6Report Type:Periodic Company Report #WAES 00050214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 4 DAY

Date:06/22/00ISR Number: 3577407-8Report Type:Periodic Company Report #WAES 00050216
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia Hypertriglyceridaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Elavil	C				
			Lasix	C				
			Lipitor	C				
			Lopressor	C				
			Premarin	C				
			Alprazolam	C				
			Temazepam	C				

Date:06/22/00ISR Number: 3577408-XReport Type:Periodic Company Report #WAES 00050883
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Dermatitis	Health Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577409-1Report Type:Periodic Company Report #WAES 00050217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577410-8Report Type:Periodic Company Report #WAES 00050218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577411-XReport Type:Periodic Company Report #WAES 00050885
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Prilosec	C		
				Atenolol	C		

Date:06/22/00ISR Number: 3577412-1Report Type:Periodic Company Report #WAES 00050890
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vasotec	C				
			Nitroglycerin	C				

Date:06/22/00ISR Number: 3577413-3Report Type:Periodic Company Report #WAES 00050902
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prilosec	C				
			Calcium Supplement (Composition	C				

			Folic Acid	C		

Date:06/22/00ISR Number: 3577414-5Report Type:Periodic Company Report #WAES 00050895
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				
			Prinivil	C				

Date:06/22/00ISR Number: 3577415-7Report Type:Periodic Company Report #WAES 00050905
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577416-9Report Type:Periodic Company Report #WAES 00050914
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577417-0Report Type:Periodic Company Report #WAES 00050931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577418-2Report Type:Periodic Company Report #WAES 00050900
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Lasix	C				
			Tenormin	C				
			Potassium Chloride	C				
			Prednisone	C				
			Ubiquinone 50	C				
			Vitamin E	C				
			Vitamins	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577419-4Report Type:Periodic Company Report #WAES 00050938
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Cardura	C				
			K-Dur	C				
			Prevacid	C				
			Proscar	C				
			Amiloride Hydrochloride (+) Hydr	C				
			Atenolol	C				

Date:06/22/00ISR Number: 3577420-0Report Type:Periodic Company Report #WAES 00050942
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Dermatitis							
	Fatigue							
	Micturition Disorder							
PO								
	Oedema Peripheral		Levoxyl	C				
	Pruritus		Lopressor	C				
			Nolvadex	C				
			Paxil	C				
			[Composition Unspecified]	C				
			Clonazepam	C				

Date:06/22/00ISR Number: 3577421-2Report Type:Periodic Company Report #WAES 00050901
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577422-4Report Type:Periodic Company Report #WAES 00050948
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Dizziness Visual Field Defect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cap Flomax (Tamsulosin (R)-Form Hydrochloride) 0.4mg	SS		ORAL	0.4 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577423-6Report Type:Periodic Company Report #WAES 00050961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577424-8Report Type:Periodic Company Report #WAES 00050967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577425-XReport Type:Periodic Company Report #WAES 00050058
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vascular Injury	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3577426-1Report Type:Periodic Company Report #WAES 00050968
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG	

Representative
DAILY PO

Date:06/22/00ISR Number: 3577427-3Report Type:Periodic Company Report #WAES 00050969
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Paxil	C			PO	

Date:06/22/00ISR Number: 3577428-5Report Type:Periodic Company Report #WAES 00050060
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577429-7Report Type:Periodic Company Report #WAES 00050970
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Corgard	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3577430-3Report Type:Periodic Company Report #WAES 00050973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY
			Acupril	C				
			Sular	C				

Date:06/22/00ISR Number: 3577431-5Report Type:Periodic Company Report #WAES 00050062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3577432-7Report Type:Periodic Company Report #WAES 00050974
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Microzide	C				
			Verapamil	C				

Date:06/22/00ISR Number: 3577433-9Report Type:Periodic Company Report #WAES 00050065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577434-0Report Type:Periodic Company Report #WAES 00050976
Age:50 YR Gender:Male I/FU:I

Outcome	PT
	Diarrhoea
	Nausea
	Oral Discomfort

Pyrexia
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Zantac	C				

Date:06/22/00ISR Number: 3577435-2Report Type:Periodic Company Report #WAES 00050979
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Diovan	C				
			Fosamax	C				

Date:06/22/00ISR Number: 3577436-4Report Type:Periodic Company Report #WAES 00050980
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG DAILY	PO : 25 MG DAILY PO

4 MON

Date:06/22/00ISR Number: 3577437-6Report Type:Periodic Company Report #WAES 00050067
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dyspepsia Oedema Peripheral	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3577438-8Report Type:Periodic Company Report #WAES 00050981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577439-XReport Type:Periodic Company Report #WAES 00050071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pericarditis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577440-6Report Type:Periodic Company Report #WAES 00050989
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577441-8Report Type:Periodic Company Report #WAES 00050992
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/00ISR Number: 3577442-XReport Type:Periodic Company Report #WAES 00050073
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Aldoril	C				
			Premarin	C				
			Prilosec	C				

Date:06/22/00ISR Number: 3577443-1Report Type:Periodic Company Report #WAES 00050074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577444-3Report Type:Periodic Company Report #WAES 00050077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3577445-5Report Type:Periodic Company Report #WAES 00050079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577446-7Report Type:Periodic Company Report #WAES 00050081
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pravachol	C				
			Estrogenic Preparations	C				
			Verapamil	C				

Date:06/22/00ISR Number: 3577447-9Report Type:Periodic Company Report #WAES 00050082
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577448-0Report Type:Periodic Company Report #WAES 00050084
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577449-2Report Type:Periodic Company Report #WAES 00050095
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Company Merck Co Inc ORAL
PO
Representative

Date:06/22/00ISR Number: 3577450-9Report Type:Periodic Company Report #WAES 00050096
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577451-0Report Type:Periodic Company Report #WAES 00050097
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577452-2Report Type:Periodic Company Report #WAES 00050098
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577453-4Report Type:Periodic Company Report #WAES 00050099
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577454-6Report Type:Periodic Company Report #WAES 00050100
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577455-8Report Type:Periodic Company Report #WAES 00050101
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	Celebrex	C		

Date:06/22/00ISR Number: 3577456-XReport Type:Periodic Company Report #WAES 00050102
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erythema	Health	Vioxx	PS	Merck Research	
	Skin Disorder	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/22/00ISR Number: 3577457-1Report Type:Periodic Company Report #WAES 00050104
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577458-3Report Type:Periodic Company Report #WAES 00050107
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577459-5Report Type:Periodic Company Report #WAES 00050113
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Lipitor	C				
			Novolin L	C				
			Peridex	C				
			Furosemide	C				
			Nitroglycerin	C				

Date:06/22/00ISR Number: 3577460-1Report Type:Periodic Company Report #WAES 00050129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577461-3Report Type:Periodic Company Report #WAES 00050146
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577462-5Report Type:Periodic Company Report #WAES 00050151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Micturition Urgency Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577463-7Report Type:Periodic Company Report #WAES 00050153
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577464-9Report Type:Periodic Company Report #WAES 00050993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	;25 MG/BID/PO

Date:06/22/00ISR Number: 3577465-0Report Type:Periodic Company Report #WAES 00050155
Age:82 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Demadex	C				
			Norvasc	C				
			Xalatan	C				

Date:06/22/00ISR Number: 3577466-2Report Type:Periodic Company Report #WAES 00050997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Diarrhoea Fatigue Gastritis Muscular Weakness Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577467-4Report Type:Periodic Company Report #WAES 00050156
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aspirin	C				
			Hydrochlorothiazide	C				

Date:06/22/00ISR Number: 3577468-6Report Type:Periodic Company Report #WAES 00050998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577469-8Report Type:Periodic Company Report #WAES 00050163
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577470-4Report Type:Periodic Company Report #WAES 00050167
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Chlorthalidone	C				

Date:06/22/00ISR Number: 3577471-6Report Type:Periodic Company Report #WAES 00050169
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Armour Thyroid Tablets	C				
			Hydrodiuril	C				

Date:06/22/00ISR Number: 3577472-8Report Type:Periodic Company Report #WAES 00050171
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/00ISR Number: 3577473-XReport Type:Periodic Company Report #WAES 00050172
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577474-1Report Type:Periodic Company Report #WAES 00050175
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alphagan	C				
			Lipitor	C				
			Nitroquick	C				
			Premarin	C				
			Provera	C				

			Aspirin	C		
			Atenolol	C		

Date:06/22/00ISR Number: 3577475-3Report Type:Periodic Company Report #WAES 00050177
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Maxzide	C				
			[Composition Unspecified]	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3577476-5Report Type:Periodic Company Report #WAES 00050178
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotensin	C				

Date:06/22/00ISR Number: 3577477-7Report Type:Periodic Company Report #WAES 00050180
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Chest Pain Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue		Miacalcin	C				
	Hyperbilirubinaemia		Myacine	C				

Oedema Peripheral		Vancenase	C
Tachycardia		Ranitidine	C

Date:06/22/00ISR Number: 3577478-9Report Type:Periodic Company Report #WAES 00050181
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Hormones (Composition Unspecified)	C				

Date:06/22/00ISR Number: 3577479-0Report Type:Periodic Company Report #WAES 00050999
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Avapro	C
Lasix	C
Paxil	C
Prempro	C
Prilosec	C
Tenormin	C
Vicodin Tablets	C
[Therapy Unspecified]	C
Insulin	C
Potassium Supplement	C

Date:06/22/00ISR Number: 3577480-7Report Type:Periodic Company Report #WAES 00051000
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							
	Pain				Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/00ISR Number: 3577481-9Report Type:Periodic Company Report #WAES 00051003
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Discomfort							
	Eyelid Disorder				Merck Co Inc	ORAL	25	
	Paraesthesia						MG/DAILY/PO	
	Pruritus		Ambien	C				
			Fioricet Tablets	C				

Date:06/22/00ISR Number: 3577482-0Report Type:Periodic Company Report #WAES 00051004
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased International Normalised Ratio Increased Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Coumadin	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577483-2Report Type:Periodic Company Report #WAES 00051006
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anxiety Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577484-4Report Type:Periodic Company Report #WAES 00051008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Lipitor	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3577485-6Report Type:Periodic Company Report #WAES 00051012
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pelvic Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/ DAILY/PO	
			Miacalcin	C				
			Paxil	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577486-8Report Type:Periodic Company Report #WAES 00050424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG PO	

Urinary Tract Infection
Weight Increased

Date:06/22/00ISR Number: 3577487-XReport Type:Periodic Company Report #WAES 00051015
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Lotensin	C				
			Miacalcin	C				
			Ocuvite	C				
			Os-Cal	C				
			Prilosec	C				
			Tylenol Arthritis Extended Relief	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577488-1Report Type:Periodic Company Report #WAES 00050470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toothache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577489-3Report Type:Periodic Company Report #WAES 00051017
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypoaesthesia							
	Insomnia							
	Tachycardia		Decadron (Dexamethasone)	C				
			Prilosec	C				
			Soma	C				

Date:06/22/00ISR Number: 3577490-XReport Type:Periodic Company Report #WAES 00050480
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Fosamax	C				
			Premarin	C				
			Synthroid	C				
			Tetanus Toxoid	C				

Date:06/22/00ISR Number: 3577491-1Report Type:Periodic Company Report #WAES 00051018
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Aldactazide	C				
			Avantyl	C				
			Inderal	C				
			Insulin	C				

Date:06/22/00ISR Number: 3577492-3Report Type:Periodic Company Report #WAES 00050482
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrogenic Preparations	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577493-5Report Type:Periodic Company Report #WAES 00051028
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577494-7Report Type:Periodic Company Report #WAES 00051030
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			[Therapy Unspecified]	C				
			Allergenic Extract	C				
			Estrogenic Preparations	C				

Date:06/22/00ISR Number: 3577495-9Report Type:Periodic Company Report #WAES 00050483
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Sexual Dysfunction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				
			Aspirin	C				
			Atenolol	C				

				Ranitidine Hydrochloride	C		
				Verapamil Hydrochloride	C		
				Vitamins	C		

Date:06/22/00ISR Number: 3577496-0Report Type:Periodic Company Report #WAES 00051032
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Buspar	C				
			Lanoxin	C				
			Lasix	C				
			Norvasc	C				
			[Therapy Unspecified]	C				
			Estrogenic Preparations	C				
			Potassium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577497-2Report Type:Periodic Company Report #WAES 00051038
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577498-4Report Type:Periodic Company Report #WAES 00050484
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO
			Pamelor	C				
			Premarin	C				

Date:06/22/00ISR Number: 3577499-6Report Type:Periodic Company Report #WAES 00051041
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rebound Effect	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577500-XReport Type:Periodic Company Report #WAES 00051042
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Prothrombin Time Prolonged	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							
		Representative	Warfarin	C			

Date:06/22/00ISR Number: 3577501-1Report Type:Periodic Company Report #WAES 00050489
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingivitis Glossitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAIL	
PO								
			Fosmax	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3577502-3Report Type:Periodic Company Report #WAES 00051043
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
		Representative	Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577503-5Report Type:Periodic Company Report #WAES 00050491
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Appetite Disorder Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 3 DAY
			Lipitor	C				

Date:06/22/00ISR Number: 3577504-7Report Type:Periodic Company Report #WAES 00050492
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Apresoline	C				
			Cephalexin	C				
			Levodopa	C				

Date:06/22/00ISR Number: 3577505-9Report Type:Periodic Company Report #WAES 00050493
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Depression Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Donnatal	C				
			Elavil	C				
			Prempro	C				

Date:06/22/00ISR Number: 3577506-0Report Type:Periodic Company Report #WAES 00050499
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Ear Infection							
			Ativan	C				
			Prozac	C				
			Robinul	C				
			Diazepam	C				

Date:06/22/00ISR Number: 3577507-2Report Type:Periodic Company Report #WAES 00050598
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Hydrocodone/Apap	C				

Date:06/22/00ISR Number: 3577508-4Report Type:Periodic Company Report #WAES 00050599
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3577509-6Report Type:Periodic Company Report #WAES 00050501
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Estrogenic Preparation	C				

Date:06/22/00ISR Number: 3577510-2Report Type:Periodic Company Report #WAES 00050502
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577511-4Report Type:Periodic Company Report #WAES 00050600
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 DAY
			Fosamax	C				
			Mysoline	C				
			Prempro	C				
			Zestril	C				

Date:06/22/00ISR Number: 3577512-6Report Type:Periodic Company Report #WAES 00050602
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577513-8Report Type:Periodic Company Report #WAES 00050504
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Daypro	C				
			Glucophage	C				
			Lipitor	C				
			Lotensin	C				

Date:06/22/00ISR Number: 3577514-XReport Type:Periodic Company Report #WAES 00050603
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:06/22/00ISR Number: 3577515-1Report Type:Periodic Company Report #WAES 00050608
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 DAY
			Flovent	C				

Date:06/22/00ISR Number: 3577516-3Report Type:Periodic Company Report #WAES 00050505
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Dysuria							
	Prostatic Disorder							
	Pruritus							
			Allegra	C				
			Flexeril	C				
			Lipitor	C				
			Lotrel	C				
			Plaquencil	C				
			Methotrexate	C				

Date:06/22/00ISR Number: 3577517-5Report Type:Periodic Company Report #WAES 00050609
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Lacrimation Increased							
	Rhinorrhoea							
	Skin Disorder						/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/BID/PO	

Aspirin	C
Prilosec	C
Zebeta	C
Aspirin	C
Glucosamine	C
Minerals	C
Vitamins	C

Date:06/22/00ISR Number: 3577518-7Report Type:Periodic Company Report #WAES 00050611
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Duragesic	C				

Date:06/22/00ISR Number: 3577519-9Report Type:Periodic Company Report #WAES 00050507
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3577520-5Report Type:Periodic Company Report #WAES 00050612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Tab Vioxx 25 Mg SS ORAL
25

MG/DAILY/PO

Lopressor C
Glucagon C

Date:06/22/00ISR Number: 3577521-7Report Type:Periodic Company Report #WAES 00050613
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Headache					

25 MG

/DAILY/PO

Premarin C
Prinzide C

Date:06/22/00ISR Number: 3577522-9Report Type:Periodic Company Report #WAES 00050510
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Drug Ineffective					

Merck Co Inc ORAL
PO

Hyzaar	C	
Synthroid	C	
Vicodin Tablets	C	
Vitamins	C	

Date:06/22/00ISR Number: 3577523-0Report Type:Periodic Company Report #WAES 00050616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/00ISR Number: 3577524-2Report Type:Periodic Company Report #WAES 00050631
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Combivent	C	
Monopril	C	
Hydrochlorothiazide	C	

Date:06/22/00ISR Number: 3577525-4Report Type:Periodic Company Report #WAES 00050643
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577526-6Report Type:Periodic Company Report #WAES 00050644
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:06/22/00ISR Number: 3577527-8Report Type:Periodic Company Report #WAES 00050645
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577528-XReport Type:Periodic Company Report #WAES 00050646
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/00ISR Number: 3577529-1Report Type:Periodic Company Report #WAES 00050647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577530-8Report Type:Periodic Company Report #WAES 00050511
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577531-XReport Type:Periodic Company Report #WAES 00050649
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577532-1Report Type:Periodic Company Report #WAES 00050515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	

Date:06/22/00ISR Number: 3577533-3Report Type:Periodic Company Report #WAES 00050678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PM/PO	
			Nizoral	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577534-5Report Type:Periodic Company Report #WAES 00050519
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryl	C				
			Betoptic	C				
			Celebrex	C				
			Darvocet-N	C				
			Lipitor	C				
			Trusopt	C				

Date:06/22/00ISR Number: 3577535-7Report Type:Periodic Company Report #WAES 00050520
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Arava	C				
			Lanoxin	C				
			Lopressor	C				
			Plaquenil	C				
			Pravachol	C				
			Prilosec	C				
			Captopril	C				
			Prednisone	C				

Date:06/22/00ISR Number: 3577536-9Report Type:Periodic Company Report #WAES 00050526
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
25 MG/BID/PO						
		Representative				
SEE IMAGE						

Date:06/22/00ISR Number: 3577537-0Report Type:Periodic Company Report #WAES 00050542
Age:81 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Cardizem Cd	C		
			Lipitor	C		
			Vitamins	C		

Date:06/22/00ISR Number: 3577538-2Report Type:Periodic Company Report #WAES 00050680
Age:66 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain
	Alanine Aminotransferase Increased

		Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Bilirubin Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Gamma-Glutamyltransferase Increased					
		Nausea		Tab Vioxx	SS		ORAL
PO							
		Vomiting					

Date:06/22/00ISR Number: 3577539-4Report Type:Periodic Company Report #WAES 00050544
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	Pain In Extremity					
			Betoptic S	C		
			Zocor	C		
			Furosemide	C		

Date:06/22/00ISR Number: 3577540-0Report Type:Periodic Company Report #WAES 00050545
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO	Pruritus					
			Covera-Hs	C		
			Diovan	C		
			Premarin	C		
			Allopurinol	C		

Date:06/22/00ISR Number: 3577541-2Report Type:Periodic Company Report #WAES 00021623
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck Research			
	Chest Pain	Professional			Laboratories Div			
	Disorientation	Company			Merck Co Inc	ORAL	12.5	
	Dyspnoea	Representative					MG/DAILY/PO;	
	Headache						SEE IMAGE	
	Hyperhidrosis		Premarin	C				
	Hypertension		Prinivil	C				
	Tachycardia		Alprazolam	C				

Date:06/22/00ISR Number: 3577542-4Report Type:Periodic Company Report #WAES 00021653
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Dry Skin	Health			Laboratories Div			
	Pruritus	Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	
							PO	
			Voltaren	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577543-6Report Type:Periodic Company Report #WAES 00050550
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Heart Rate Irregular							
	Nausea							
			Ambien	C				
			Paxil	C				
			Pepcid	C				
			Propulsid	C				
			Synthroid	C				
			Propoxyphene	C				

Date:06/22/00ISR Number: 3577544-8Report Type:Periodic Company Report #WAES 00021734
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Pruritus	Health						
	Skin Disorder	Professional						
			Celebrex	SS				

Date:06/22/00ISR Number: 3577545-XReport Type:Periodic Company Report #WAES 00021891
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haematuria	Professional						
	Hypertension	Company						
	Oedema	Representative						

Date:06/22/00ISR Number: 3577546-1Report Type:Periodic Company Report #WAES 00022065
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3577547-3Report Type:Periodic Company Report #WAES 00022142
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
			Catapres	C				
			Glucophage	C				
			Glucotrol	C				
			Lotensin	C				
			Norvasc	C				
			Minoxidil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577548-5Report Type:Periodic Company Report #WAES 00050567
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	3 DAY
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3577549-7Report Type:Periodic Company Report #WAES 00030192
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Tenosynovitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Darvocet-N	C				
			Paxil	C				
			Prvachol	C				

Date:06/22/00ISR Number: 3577550-3Report Type:Periodic Company Report #WAES 00050569
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Claritin-D	C				
			Synthroid	C				
			Zocor	C				

Date:06/22/00ISR Number: 3577551-5Report Type:Periodic Company Report #WAES 99071718
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortef	C				
			Ocuvite	C				
			Synthroid	C				
			Tums	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3577552-7Report Type:Periodic Company Report #WAES 00050572
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Confusional State Disorientation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Miacalcin	C				

			Pepcid	C		
			Synthroid	C		
			Warfarin	C		

Date:06/22/00ISR Number: 3577553-9Report Type:Periodic Company Report #WAES 99091114
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577554-0Report Type:Periodic Company Report #WAES 99091115
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577555-2Report Type:Periodic Company Report #WAES 00050574
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvon	C				

Date:06/22/00ISR Number: 3577556-4Report Type:Periodic Company Report #WAES 99100942
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Bentyl	C				
			Buspar	C				
			Cardizem	C				
			Lipitor	C				
			Prilosec	C				
			Synthroid	C				
			Xanax	C				

Date:06/22/00ISR Number: 3577557-6Report Type:Periodic Company Report #WAES 00050577
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia Flatulence	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Nausea		Ziac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577558-8Report Type:Periodic Company Report #WAES 99101535
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Abdominal Pain							
	Arthralgia							
	Depression							
	Face Oedema							
	Flatulence							
	Flushing							
	Influenza Like Illness							
	Paraesthesia							

Date:06/22/00ISR Number: 3577559-XReport Type:Periodic Company Report #WAES 00050578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577560-6Report Type:Periodic Company Report #WAES 99101578
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

Date:06/22/00ISR Number: 3577561-8Report Type:Periodic Company Report #WAES 00050581
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Flatulence Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

			Thearapy Unspecified	C		

Date:06/22/00ISR Number: 3577562-XReport Type:Periodic Company Report #WAES 99110349
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gingival Bleeding Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5

MG/BID/PO

Date:06/22/00ISR Number: 3577563-1Report Type:Periodic Company Report #WAES 99110625
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG /

DAILY/ PO

		Insulin	C	
		Methotrexate	C	
		Vioxx	C	Merck Research Laboratories Div Merck Co Inc

Date:06/22/00ISR Number: 3577564-3Report Type:Periodic Company Report #WAES 00050582
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Diovan	C				
			Endal-Hd	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3577565-5Report Type:Periodic Company Report #WAES 99110654
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased	Company						
	Cardiac Failure	Representative						
	Congestive Oedema		Cozaar	C				
			Glucotrol Xl	C				
			Lasix	C				
			Prilosec	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3577566-7Report Type:Periodic Company Report #WAES 99111696
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Insulin Increased Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Cozaar	C				
			Lasix	C				
			Lescol	C				

Date:06/22/00ISR Number: 3577567-9Report Type:Periodic Company Report #WAES 00050583
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577568-0Report Type:Periodic Company Report #WAES 00050584
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Insomnia							
	Urticaria		Cardizem	C				
			Lanoxin	C				
			Premarin	C				
			Calcium Supplement	C				

Date:06/22/00ISR Number: 3577569-2Report Type:Periodic Company Report #WAES 99111833
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrointestinal Disorder							

Date:06/22/00ISR Number: 3577570-9Report Type:Periodic Company Report #WAES 00050589
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Prempro	C				
			Singulair	C				
			Therapy Unspecified	C				

Date:06/22/00ISR Number: 3577571-0Report Type:Periodic Company Report #WAES 99120087
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research			
	Cheilitis	Health			Laboratories Div			
	Dyspepsia	Professional			Merck Co Inc	ORAL	12.4	
	Face Oedema						MG/DAILY/PO	
	Oral Pain		Claritin-D	C				
	Paraesthesia		Fosamax	C				
	Tongue Disorder		Premarin	C				
			Timoptic	C				
			Hydrochlorothiazide (+) Triamter	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577572-2Report Type:Periodic Company Report #WAES 00050591
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	6 WK
			Lipitor	C				

			Lopressor	C		
			Aspirin	C		

Date:06/22/00ISR Number: 3577573-4Report Type:Periodic Company Report #WAES 99120093
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Advil	C				
			Synvisc	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3577574-6Report Type:Periodic Company Report #WAES 00050592
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	3 DAY

Date:06/22/00ISR Number: 3577575-8Report Type:Periodic Company Report #WAES 00050595
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Hair Disorder Insomnia Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Restoril	C				
			Synthroid	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3577576-XReport Type:Periodic Company Report #WAES 00051238
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Atrovent	C				
			Caltrate 600 Plus Vitamin D	C				
			Darvocet-N	C				
			Dulcolax	C				
			Fleet (Liquid Petrolatum)	C				
			Fosamax	C				
			Peri-Colace	C				
			Phillips' Mild Of Magnesia	C				
			Prevacid	C				
			Riopan	C				
			Tylenol	C				
			Ventolin	C				
			Guaifenesin	C				

				Lorazepam	C		

Date:06/22/00ISR Number: 3577577-1Report Type:Periodic Company Report #WAES 00051239
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Coumadin	C				
			Cozaar	C				
			Demadex	C				
			Fleet (Sodium Phosphate)	C				
			Humalog	C				
			Humulin	C				
			Lortab	C				
			Micro K	C				
			Monopril	C				
			Novolin N	C				
			Pravachol	C				
			Prinivil	C				
			Riopan	C				
			Theo-24	C				
			Zocor	C				
			Acetaminophen	C				
			Aspirin	C				
			Bisacodyl	C				
			Casanthranol (+)					
			Docusate Sodium	C				
			Magnesium Hydroxide	C				
			Pentoxyfylline	C				

Date:06/22/00ISR Number: 3577578-3Report Type:Periodic Company Report #WAES 00051241
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Celebrex	C		
			Diflucan	C		
			Fleet (Liquid Petrolatum)	C		
			Nitro-Dur	C		
			Pepcid	C		
			Peri-Colace	C		
			Prevacid	C		
			Riopan	C		
			Tylenol	C		
			Valium	C		
			Vasotec	C		
			Chloral Hydrate	C		
			Ciprofloxacin	C		
			Magnesium Hydroxide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577579-5Report Type:Periodic Company Report #WAES 00051243
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Coumadin	C				
			Dulcolax	C				
			Estrace	C				
			Fleet Enema	C				
			Hyzaar	C				
			Oxycontin	C				
			Percocet	C				
			Peri-Colace	C				
			Prilosec	C				
			Tylenol	C				
			Vistaril	C				

Date:06/22/00ISR Number: 3577580-1Report Type:Periodic Company Report #WAES 00051252
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577581-3Report Type:Periodic Company Report #WAES 00051262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Oedema Peripheral Merck Co Inc ORAL
PO 2 WK
Prozac C

Date:06/22/00ISR Number: 3577582-5Report Type:Periodic Company Report #WAES 00051269
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / PO	

Date:06/22/00ISR Number: 3577583-7Report Type:Periodic Company Report #WAES 00051270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /D AILY / PO	
			Prevacid	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577584-9Report Type:Periodic Company Report #WAES 00051271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Flutter Facial Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Hydrodiuril	C				
			Pravachol	C				
			Prevacid	C				
			Rheumatrex	C				
			Tums	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Conjugated Estrogenic Hormones	C				
			Vitamin D	C				

Date:06/22/00ISR Number: 3577585-0Report Type:Periodic Company Report #WAES 00051274
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	16 DAY
			Claritin	C				
			Lanoxin	C				

Date:06/22/00ISR Number: 3577586-2Report Type:Periodic Company Report #WAES 00051275
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577587-4Report Type:Periodic Company Report #WAES 00051278
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/00ISR Number: 3577588-6Report Type:Periodic Company Report #WAES 00051282
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Serax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577589-8Report Type:Periodic Company Report #WAES 00051283
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
			Synthroid	C				

Date:06/22/00ISR Number: 3577590-4Report Type:Periodic Company Report #WAES 00051284
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prevalite	C				

Date:06/22/00ISR Number: 3577591-6Report Type:Periodic Company Report #WAES 00051285
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				
			Evista	C				
			Synthroid	C				
			Zocor	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3577592-8Report Type:Periodic Company Report #WAES 00051286
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Chondroitin	C				

Date:06/22/00ISR Number: 3577593-XReport Type:Periodic Company Report #WAES 00051288
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Glucophage	C				
			Glucotrol	C				
			Norvasc	C				
			Prevacid	C				
			Zestril	C				
			Calcium Supplement (Composition	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577594-1Report Type:Periodic Company Report #WAES 00051291
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Feeling Abnormal							
	Nausea							
			Diovan	C				
			Synthroid	C				
			Zocor	C				
			[Therapy Unspecified]	C				
			Calcium Supplement (Composition	C				
			Vitamin E	C				

Date:06/22/00ISR Number: 3577596-5Report Type:Periodic Company Report #WAES 00051292
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Chest Pain							
	Headache							
	Tachycardia							
			Celex	C				
			Synthroid	C				
			Tiazac	C				
			Atenolol	C				
			Estrogenic Preparations (Composi	C				

Date:06/22/00ISR Number: 3577598-9Report Type:Periodic Company Report #WAES 00051182
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO
Ditropan C
Prempro C

Date:06/22/00ISR Number: 3577601-6Report Type:Periodic Company Report #WAES 00051183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET/DAILY/	PO

Date:06/22/00ISR Number: 3577603-XReport Type:Periodic Company Report #WAES 00051190
Age:81 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis
	Oedema Peripheral

Pruritus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Centrum Silver	C				
	Pepcid	C				
	Prempro	C				
	Calcium Supplement	C				
	Lorazepam	C				

Date:06/22/00ISR Number: 3577605-3Report Type:Periodic Company Report #WAES 00051191
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hallucination Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Glucophage	C				
			Folic Acid	C				

Date:06/22/00ISR Number: 3577608-9Report Type:Periodic Company Report #WAES 00051198
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertriglyceridaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				

				Pepcid	C		
				Prinivil	C		
				Estradiol	C		
				Nortriptylne	C		

Date:06/22/00ISR Number: 3577610-7Report Type:Periodic Company Report #WAES 00051199
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Defaecation Urgency Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestoretic	C				

Date:06/22/00ISR Number: 3577612-0Report Type:Periodic Company Report #WAES 00051208
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Bactrim	C
Dantrium	C
Desitin	C
Fleet	C
Pepcid	C
Peri-Colace	C
Proventil	C
Reglan	C
Riopan	C
Tylenol	C
Ultram	C
Valium	C
Vicodin Es	C
[Therapy Unspecified]	C
Bisacodyl	C
Heparin	C
Magnesium Hydroxide	C
Nystatin	C
Potassium Iodide	C

Date:06/22/00ISR Number: 3577613-2Report Type:Periodic Company Report #WAES 00051210
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				
			Dulcolax	C				
			Fleet Enema	C				
			Glucophage	C				
			Isordil	C				
			Lanoxin	C				
			Lasix	C				
			Nitroglycerin	C				
			Peri-Colace	C				
			Prevacid	C				
			Riopan	C				
			Robitussin	C				
			Transderm-Nitro	C				
			Tylenol	C				
			Magnesium Hydroxide	C				

Phenobarbital	C
Pindolol	C
Verapamil	C

Date:06/22/00ISR Number: 3577614-4Report Type:Periodic Company Report #WAES 00051211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577615-6Report Type:Periodic Company Report #WAES 00051214
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3577616-8Report Type:Periodic Company Report #WAES 00051217
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Antivert	C				
			Celebrex	C				
			Claritin	C				
			Flagyl	C				
			Fleet	C				
			Levaquin	C				
			Lortab	C				
			Lovenox	C				
			Oxycontin	C				
			Peri-Colace	C				
			Riopan	C				
			Tylenol	C				
			Wygesic Tablets	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Bisacodyl	C				
			Diazepam	C				
			Ferrous Sulfate	C				
			Hydrocodone	C				
			Ibuprofen	C				
			Magnesium Hydroxide	C				

Date:06/22/00ISR Number: 3577617-XReport Type:Periodic Company Report #WAES 00051218
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alphagan	C				
			Ambien	C				
			Anusol Suppositories	C				
			Bactroban	C				
			Benadryl	C				
			Betasept	C				
			Celebrex	C				
			Claritin	C				
			Compazine	C				
			Fibercon	C				
			Fleet	C				
			Keflex	C				
			Lasix	C				
			Lopid	C				

Lortab	C
Micro K	C
Moduretic	C
Neosporin Plus Cream	C
Norvasc	C
Novolin	C
Oxycontin	C
Peri-Colace	C
Phenergan	C
Phillips' Milk Of Magnesia	C
Prevacid	C
Riopan	C
Synthroid	C
Trusopt	C
Tylenol	C
Ultram	C
Xalantan	C
Ascorbic Acid	C
Bisacodyl	C
Folic Acid	C
Magnesium Citrate	C
Nystatin	C
Vancomycin	C
Vitamins	C

Date:06/22/00ISR Number: 3577618-1Report Type:Periodic Company Report #WAES 00051225
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Ativan	C
Dulcolax	C
Duragesic	C
Evista	C
Lasix	C
Levoxyl	C
Lortab	C
Lovenox	C

Metamucil	C
Nitrostat	C
Ocean	C
Peri-Colace	C
Riopan	C
Tylenol	C
[Therapy Unspecified]	C
Calcium Carbonate + Vitamin D	C
Magnesium Hyrdoxide	C
Imdur	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577619-3Report Type:Periodic Company Report #WAES 00051227
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Dulcolax	C				
			Lasix	C				
			Lortab	C				
			Lovenox	C				
			Oxycontin	C				
			Peri-Colace	C				
			Prevacid	C				
			Riopan	C				
			Tylenol	C				
			Vasotec	C				
			Ferrous Sulfate	C				
			Temazepam	C				
			Vitamins	C				

Date:06/22/00ISR Number: 3577620-XReport Type:Periodic Company Report #WAES 00051229
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ambien	C				
			Avandia	C				
			Capoten	C				
			Cardizem Cd	C				
			Celexa	C				
			Ecotrin	C				
			Fleet	C				
			Humulin 70/30	C				

K-Dur	C
Lasix	C
Lipitor	C
Lortab	C
Micro K	C
Nitro-Bid	C
Nitro-Dur	C
Nitrostat	C
Phenergan Injection	C
Plavix	C
Prevacid	C
Reglan	C
Remeron	C
Theragran-M	C
Ascorbic Acid	C
Lactulose	C
Magnesium Hydroxide	C
Magnesium Oxide	C
Sodium Folate	C
Mylicon	C
Tigan	C
Tylenol	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3577621-1Report Type:Periodic Company Report #WAES 00051230
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Cardura	C				
			Compazine	C				
			Dulcolax	C				
			Duvoid	C				
			Lortab	C				
			Oxycontin	C				
			Peri-Colace	C				
			Phillips' Milk Of Magnesia	C				
			Riopan	C				
			Acetaminophen	C				
			Aspirin	C				
			Baclofen	C				

Date:06/22/00ISR Number: 3577622-3Report Type:Periodic Company Report #WAES 00051232
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Celebrex	C				
			Compazine	C				
			Fleet Enema	C				
			Lipitor	C				
			Lortab	C				
			Neosporin Plus Ointment	C				
			Peri-Colace	C				

Prevacid	C
Prinivil	C
Riopan	C
Tylenol	C
Zocor	C
[Therapy Unspecified]	C
Acetaminophen (+) Hydrocodone Bi	C
Bisacodyl	C
Indapamide	C
Magnesium Hydroxide	C

Date:06/22/00ISR Number: 3577623-5Report Type:Periodic Company Report #WAES 00051233
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Altace	C
Ambien	C
Ativan	C
Fleet Enema	C
Lubriderm Lotion	C
Oxycontin	C
Riopan	C
Tylenol	C
[Therapy Unspecified]	C
Bisacodyl	C
Calcium Carbonate (+) Vitamin D	C
Dimethicone (+) Silicon Dioxide	C
Lactulose	C
Magnesium Hydroxide	C
Lortab	C

Date:06/22/00ISR Number: 3577625-9Report Type:Periodic Company Report #WAES 00051234
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased Dehydration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				
			Darvocet-N	C				
			Equanil	C				
			Fleet (Sodium Phosphate)	C				
			Hydergine	C				
			Imdur	C				
			Lopressor	C				
			Lotensin	C				
			Niferex	C				
			Nitro-Dur	C				
			Nitroglycerin	C				
			Pepcid	C				
			Peri-Colace	C				
			Restoril	C				

Riopan	C
Seroquel	C
Synthroid	C
Tylenol	C
Ascorbic Acid	C
Bisacodyl	C
Magnesium Hydroxide	C
Vitamins	C

Date:06/22/00ISR Number: 3577627-2Report Type:Periodic Company Report #WAES 00051236
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Aricept	C
Dilantin	C
Dulcolax	C
Fleet (Liquid Petrolatum)	C
Keflex	C
Norvasc	C
Peri-Colace	C
Phillips' Milk Of Magnesia	C
Plavix	C
Riopan	C
Tylenol	C
Allopurinol	C
Aspirin	C
Atenolol	C

Date:06/22/00ISR Number: 3578351-2Report Type:Periodic Company Report #WAES 00040823
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY?	
PO								
			Hyzaar	C				
			Plendil	C				
			Nadolol	C				

Date:06/22/00ISR Number: 3578352-4Report Type:Periodic Company Report #WAES 00040824
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Paraesthesia	Study Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Lopressor	C				
			Hyzaar	C				

Date:06/22/00ISR Number: 3578353-6Report Type:Periodic Company Report #WAES 00040832
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Paxil	C				
			Premarin	C				
			Zestril	C				

Date:06/22/00ISR Number: 3578354-8Report Type:Periodic Company Report #WAES 00040834
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO 1 WK

Zocor	C	
Atenolol	C	

Date:06/22/00ISR Number: 3578356-1Report Type:Periodic Company Report #WAES 00040835
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Demadex	C	
Elavil	C	
K-Dur	C	
Maxzide	C	
Stadol	C	
Uroquid-Acid No. 2	C	
Valium	C	
Vicodin Tablets	C	
Zanaflex	C	
Trazodone	C	

Date:06/22/00ISR Number: 3578360-3Report Type:Periodic Company Report #WAES 00040836
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hallucination Vision Blurred Visual Disturbance	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Lasix	C	
Naprosyn	C	
Norvasc	C	
Prinivil	C	

Potassium Chloride C

Date:06/22/00ISR Number: 3578631-0Report Type:Periodic Company Report #WAES 00042070
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flomax (Niflumic Acid (Beta)-Mor	C				
			Lotrel	C				

Date:06/22/00ISR Number: 3578635-8Report Type:Periodic Company Report #WAES 00042071
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tylenol	C				

			Analgesic Or Anesthetic Preparat	C		
			Codeine	C		

Date:06/22/00ISR Number: 3578638-3Report Type:Periodic Company Report #WAES 00042073
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3578642-5Report Type:Periodic Company Report #WAES 00042075
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Prilosec	C				
			Glucosamine	C				

Date:06/22/00ISR Number: 3578646-2Report Type:Periodic Company Report #WAES 00042076
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578648-6Report Type:Periodic Company Report #WAES 00042077
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Petechiae	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578650-4Report Type:Periodic Company Report #WAES 00042079
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578654-1Report Type:Periodic Company Report #WAES 00042082
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				
			Premarin	C				
			Zoloft	C				

Date:06/22/00ISR Number: 3578657-7Report Type:Periodic Company Report #WAES 00042085
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothyroidism	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Red Blood Cell Count Decreased							
	White Blood Cell Count Decreased		Neurontin	C				
			Premphase	C				
			Synthroid	C				

Date:06/22/00ISR Number: 3578666-8Report Type:Periodic Company Report #WAES 00042095
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrointestinal Infection							
	Urinary Tract Infection		Prilosec	C				
			Aspriin	C				

Date:06/22/00ISR Number: 3578669-3Report Type:Periodic Company Report #WAES 00042096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrochlorothiazide (+) Triamter	C				

Date:06/22/00ISR Number: 3578670-XReport Type:Periodic Company Report #WAES 00042098
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Miacalcin	C				
			Synthroid	C				
			Sulfur	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578672-3Report Type:Periodic Company Report #WAES 00042099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578675-9Report Type:Periodic Company Report #WAES 00042101
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tessalon	C				

Date:06/22/00ISR Number: 3578677-2Report Type:Periodic Company Report #WAES 00042103
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Feeling Cold Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578679-6Report Type:Periodic Company Report #WAES 00042105
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Urinary Tract Infection				Merck Co Inc	ORAL
PO						
			Cipro	SS		
			Macrodantin	SS		
			Levaquin	C		
			Prilosec	C		

Date:06/22/00ISR Number: 3578682-6Report Type:Periodic Company Report #WAES 00042106
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Gastrointestinal Ulcer	Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						

Date:06/22/00ISR Number: 3578686-3Report Type:Periodic Company Report #WAES 00042107
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Diarrhoea					
	Influenza Like Illness				Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578690-5Report Type:Periodic Company Report #WAES 00042108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Klonopin	C				
			Stadol	C				

Date:06/22/00ISR Number: 3578695-4Report Type:Periodic Company Report #WAES 00041974
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Lacrimation Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578696-6Report Type:Periodic Company Report #WAES 00041975
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				

Date:06/22/00ISR Number: 3578697-8Report Type:Periodic Company Report #WAES 00041992
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/00ISR Number: 3578699-1Report Type:Periodic Company Report #WAES 00041994
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Verapamil Msd Lp	C				
			Zestril	C				

Date:06/22/00ISR Number: 3578700-5Report Type:Periodic Company Report #WAES 00042019
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Gait Disturbance Gastrointestinal Disorder Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578701-7Report Type:Periodic Company Report #WAES 00042038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578702-9Report Type:Periodic Company Report #WAES 00042041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578704-2Report Type:Periodic Company Report #WAES 00042044
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Chest Pain Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	
			Rabeprazole Sodium	C				

Date:06/22/00ISR Number: 3578708-XReport Type:Periodic Company Report #WAES 00042045
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				
			Estrogenic Preparations (Composi	C				
			Progesterone	C				

Date:06/22/00ISR Number: 3578711-XReport Type:Periodic Company Report #WAES 00042050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Musculoskeletal Disorder Musculoskeletal Pain Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578728-5Report Type:Periodic Company Report #WAES 00042056
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Adalat	C	
Dyazide	C	
Inderal	C	
Tylenol	C	
Vicodin Tablets	C	
Digoxin	C	

Date:06/22/00ISR Number: 3578730-3Report Type:Periodic Company Report #WAES 00042059
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578731-5Report Type:Periodic Company Report #WAES 00042060
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dysphagia Oral Soft Tissue Disorder Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Pravachol	C	
Meclizine	C	

Date:06/22/00ISR Number: 3578733-9Report Type:Periodic Company Report #WAES 00042061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Prednisone C

Date:06/22/00ISR Number: 3578735-2Report Type:Periodic Company Report #WAES 00042062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:06/22/00ISR Number: 3578737-6Report Type:Periodic Company Report #WAES 00042063
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			3 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578739-XReport Type:Periodic Company Report #WAES 00042064
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Hormones (Composition Unspecified)	C				

Date:06/22/00ISR Number: 3578741-8Report Type:Periodic Company Report #WAES 00042065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578743-1Report Type:Periodic Company Report #WAES 00042067
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				

Date:06/22/00ISR Number: 3578744-3Report Type:Periodic Company Report #WAES 00042068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Tab Vioxx 25 Mg	SS		ORAL
PO						
			Hydrodiuril	C		
			Diazepam	C		

Date:06/22/00ISR Number: 3578753-4Report Type:Periodic Company Report #WAES 00042469
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578754-6Report Type:Periodic Company Report #WAES 00042471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578757-1Report Type:Periodic Company Report #WAES 00042473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/00ISR Number: 3578760-1Report Type:Periodic Company Report #WAES 00042474
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578762-5Report Type:Periodic Company Report #WAES 00042476
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:06/22/00ISR Number: 3578766-2Report Type:Periodic Company Report #WAES 00042479
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO

Prempro	C		
Zoloft	C		
Vitamins	C		

Date:06/22/00ISR Number: 3578770-4Report Type:Periodic Company Report #WAES 00042483
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea							
	Drug Ineffective				Merck Co Inc	ORAL	PO	
	Rectal Haemorrhage		Alphagan	C				
			Bactrim	C				
			Cosopt	C				
			[Composition Unspecified]	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578773-XReport Type:Periodic Company Report #WAES 00042484
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Avapro	C				
			Catapres	C				
			Zantac	C				
			[Therapy Unspecified]	C				

Date:06/22/00ISR Number: 3578774-1Report Type:Periodic Company Report #WAES 00042488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:06/22/00ISR Number: 3578776-5Report Type:Periodic Company Report #WAES 00042489
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Diarrhoea Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia		Thyroid (As Drug)	C				

Date:06/22/00ISR Number: 3578777-7Report Type:Periodic Company Report #WAES 00042493
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucotrol	C				
			Zocor	C				

Date:06/22/00ISR Number: 3578778-9Report Type:Periodic Company Report #WAES 00042494
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Endometrial Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3578779-0Report Type:Periodic Company Report #WAES 00042496
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucosamine	C				

Date:06/22/00ISR Number: 3578780-7Report Type:Periodic Company Report #WAES 00042501
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				
			Zyrtec	C				

Date:06/22/00ISR Number: 3578782-0Report Type:Periodic Company Report #WAES 00042503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/00ISR Number: 3578783-2Report Type:Periodic Company Report #WAES 00042505
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucotrol Xl	C				
			Glustat	C				
			Hytrin	C				
			Microzide	C				
			Tambocor	C				
			Insulin	C				

Date:06/22/00ISR Number: 3578784-4Report Type:Periodic Company Report #WAES 00042512
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Percocet	C				
			Premarin	C				
			Prilosec	C				
			[Therapy Unspecified]	C				
			Folic Acid	C				
			Phenobarbital	C				

Date:06/22/00ISR Number: 3578786-8Report Type:Periodic Company Report #WAES 00042513
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3578788-1Report Type:Periodic Company Report #WAES 00042515
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	10 DAY
			Oxyir	C				

Date:06/22/00ISR Number: 3578789-3Report Type:Periodic Company Report #WAES 00042516
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Septum Disorder Nasopharyngeal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Maxzide	C				
			Synthroid	C				
			Captopril	C				
			Potassium Supplement (Composition	C				

Date:06/22/00ISR Number: 3588063-7Report Type:Periodic Company Report #WAES 00042567
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

Date:06/22/00ISR Number: 3588067-4Report Type:Periodic Company Report #WAES 00042568
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3588074-1Report Type:Periodic Company Report #WAES 00042569
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3588082-0Report Type:Periodic Company Report #WAES 00042570
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased International Normalised Ratio Increased Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/00ISR Number: 3588086-8Report Type:Periodic Company Report #WAES 00042610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3588088-1Report Type:Periodic Company Report #WAES 00042613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Field Defect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/00ISR Number: 3588090-XReport Type:Periodic Company Report #WAES 00042615
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Swelling	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Inj Cortisone	SS		
INJ							

Date:06/22/00ISR Number: 3588092-3Report Type:Periodic Company Report #WAES 00042631
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tenormin	C				

Date:06/22/00ISR Number: 3588095-9Report Type:Periodic Company Report #WAES 00042633
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Fosamax	C				
			Mevacor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3588101-1Report Type:Periodic Company Report #WAES 00042638
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Diazide	C				
			Lexxel	C				
			Aspirin	C				

Date:06/22/00ISR Number: 3588116-3Report Type:Periodic Company Report #WAES 00042640
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Climara	C				
			Miacalcin	C				
			Premarin	C				

Date:06/22/00ISR Number: 3588122-9Report Type:Periodic Company Report #WAES 00042641
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation Flatulence		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Swelling		Accolate	C				
			Avapro	C				
			Claritin	C				
			Evista	C				
			Flovent	C				
			Humibid	C				
			Norvasc	C				

Date:06/22/00ISR Number: 3588124-2Report Type:Periodic Company Report #WAES 00042643
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faeces Discoloured							
	Gait Disturbance							
			Maalox	C				
			Synthroid (Therapy Unspecified)	C				
			Calcium Supplement (Composition	C				
			Iron (Unspecified)	C				

Date:06/22/00ISR Number: 3588126-6Report Type:Periodic Company Report #WAES 00042645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/00ISR Number: 3588128-XReport Type:Periodic Company Report #WAES 00042647
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Lasix	C				
			Lopid	C				
			Paxil	C				
			Vicodin Tablets	C				
			Folic Acid	C				

Date:06/22/00ISR Number: 3588129-1Report Type:Periodic Company Report #WAES 00042648
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Buspar	C				
			Lopressor	C				

Date:06/22/00ISR Number: 3588131-XReport Type:Periodic Company Report #WAES 00042650
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Caltrate	C
Evista	C
Prilosec	C
Tagamet	C
Xanax	C
Propranolol	C

Date:06/22/00ISR Number: 3588133-3Report Type:Periodic Company Report #WAES 00042651
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dyspepsia							
	Muscular Weakness				Merck Co Inc	ORAL	12.5	

MG/BID/PO

Date:06/23/00ISR Number: 3518163-9Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Pepcid	PS	Merck			
			Vioxx (Rofecoxib)	SS	Merck			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/00ISR Number: 3518208-6Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx / 12.5mg /					
	Oedema Peripheral		Merck	PS	Merck	ORAL	1 TABLET	
	Palpitations						EVERY DAY	
ORAL								
			Labetolol	C				
			Procardia	C				

Date:06/23/00ISR Number: 3518214-1Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Effect Decreased		Vicodin 5mg/500mg					
Initial or Prolonged	Hallucination, Visual		Knoll	PS	Knoll	ORAL	ORAL	
			Vioxx 25mg Searle	SS	Searle	ORAL	ORAL	
			Sinemet	C				
			Coumadin	C				
			Lipitor	C				
			Levothyroxine	C				
			Glipizide	C				
			Losartan	C				
			Celexa	C				

Date:06/23/00ISR Number: 3518279-7Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Lower		Vioxx 12.5mg					
	Abnormal Faeces		Rofecoxib	PS			50MG X 1 "0"	
	Diarrhoea		Rofecoxib	SS			50MG X 2 "O"	

				Narvasc	C		
				Hctz	C		
				Cozaar	C		
				Prevacid	C		
				Zocor	C		
				Prempro	C		
				Flovex	C		
				Kcl	C		

Date:06/23/00ISR Number: 3518554-6Report Type:Expedited (15-DaCompany Report #WAES 00061957
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Celexa	C				
			Didronel	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/00ISR Number: 3518567-4Report Type:Expedited (15-DaCompany Report #WAES 00030033
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	3 WK
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive							
	Hypersensitivity		[Therapy Unspecified)	SS				
	Oedema Peripheral		Lasix	C				
	Pulmonary Oedema		Thyroid	C				
	Reaction To Medical Agent Preservatives							

Date:06/23/00ISR Number: 3518569-8Report Type:Expedited (15-DaCompany Report #WAES 00033094
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Haemorrhagic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				
			Tylenol	C				

Date:06/23/00ISR Number: 3518571-6Report Type:Expedited (15-DaCompany Report #WAES 00051686
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Feeling Abnormal	Health Professional						
	Hypertension							
	Stupor							
	Therapeutic Agent Toxicity		Cardura	C				
			Flexderil	C				
			Pravachol	C				
			Synthroid	C				
			Zestril	C				

Verapamil C

Date:06/23/00ISR Number: 3518572-8Report Type:Expedited (15-DaCompany Report #WAES 00050750
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking Insomnia Neuropathy Peripheral Oedema Peripheral Pain Saliva Altered Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/23/00ISR Number: 3518575-3Report Type:Expedited (15-DaCompany Report #WAES 00051736
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea Flatulence Gastrointestinal Motility Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

				Vioxx	SS		ORAL
12.5 MG/BID/PO							
				Dyazide	C		
				Tenormin	C		
				[Therapy Unspecified)	C		
				Folic Acid	C		
				Vitamins	C		

Date:06/23/00ISR Number: 3518582-0Report Type:Expedited (15-DaCompany Report #WAES 00060178
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Other						
Other	Dyspnoea							
	Dyspnoea Exertional		Coumadin	SS		ORAL	10.5 MG/DAILY/PO	
	Fatigue							
	Haematocrit Decreased		Lasix	C				
	Haemoglobin Decreased		Synthroid	C				
	International Normalised Ratio Decreased		Zoloft	C				
			Digoxin	C				
	International Normalised Ratio Increased		Ferrous Sulfate	C				
	Nausea							
	Pallor							
	Vomiting							

Date:06/23/00ISR Number: 3518585-6Report Type:Expedited (15-DaCompany Report #WAES 00061666
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative				

Date:06/23/00ISR Number: 3518587-XReport Type:Expedited (15-DaCompany Report #WAES 00061915
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research	
Hospitalization -	Blood Bilirubin Increased	Professional			Laboratories Div	
Initial or Prolonged	Dialysis				Merck Co Inc	ORAL
UNK/UNK/PO 2 MON						
	Hepatic Failure		Therapy Unspecified	C		
	Jaundice		Quinine	C		
	Renal Failure		Trazodone	C		
	Thrombocytopenia					

Date:06/23/00ISR Number: 3518592-3Report Type:Expedited (15-DaCompany Report #WAES 00061932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Pneumonia				Laboratories Div	
	Pruritus				Merck Co Inc	ORAL
UNK/UNK/PO						

				Therapy Unspecified	C		

Date:06/23/00ISR Number: 3518596-0Report Type:Expedited (15-DaCompany Report #WAES 00061282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Coronary Artery Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Lopressor	C				
			Monopril	C				
			Norvasc	C				
			Colchicine	C				
			Furosemide	C				
			Insulin	C				
			Isosorbide	C				
			Nitroglycerin	C				

Date:06/23/00ISR Number: 3518598-4Report Type:Expedited (15-DaCompany Report #WAES 00061688
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Ascites Cardiac Failure Congestive Dyspnoea Fluid Retention Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Allopurinol	C				
			Diltiazem	C				

Date:06/23/00ISR Number: 3518658-8Report Type:Expedited (15-DaCompany Report #WAES 00055041
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/23/00ISR Number: 3518660-6Report Type:Expedited (15-DaCompany Report #WAES 00055164
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspepsia Ill-Defined Disorder Loss Of Consciousness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Malaise Mitral Valve Stenosis		Dexamethasone Methotrexate Omeprazole	C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/00ISR Number: 3518743-0Report Type:Expedited (15-DaCompany Report #WAES 00065557
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Nephritis Interstitial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY

Date:06/23/00ISR Number: 3518746-6Report Type:Expedited (15-DaCompany Report #WAES 00066120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Phlebitis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/23/00ISR Number: 3518749-1Report Type:Expedited (15-DaCompany Report #WAES 00067514
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		50 MG	

Date:06/23/00ISR Number: 3518917-9Report Type:Expedited (15-DaCompany Report #WAES 00059116
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Gastroenteritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	7 DAY
			Cozaar	C				

			Zocor	C
			Lercanidipine	C
			Trimetazidine Dihcl	C

Date:06/23/00ISR Number: 3518920-9Report Type:Expedited (15-DaCompany Report #WAES 00065113
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Diarrhoea Haemorrhagic Rectal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Weight Decreased		Acetaminophen/Codeine Phosphate	C				
			Meloxicam	C				

Date:06/23/00ISR Number: 3518922-2Report Type:Expedited (15-DaCompany Report #WAES 00065107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Acetaminophen/Propox					

			phene Hydrochloride	C
			Amiloride Hydrochloride (+)	
			Furosemide	C
			Omeprazole	C

Date:06/23/00ISR Number: 3518924-6Report Type:Expedited (15-DaCompany Report #WAES 00065098
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hallucination, Visual	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Acetaminophen/Codeine Phosphate	C				
			Lansoprazole	C				

Date:06/23/00ISR Number: 3518926-XReport Type:Expedited (15-DaCompany Report #WAES 00069122
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	5 DAY
			Alprazolam	C				
			Betahistine	C				
			Imipramine	C				
			Sulpride	C				
			Tiroxin	C				
			Zolpidem	C				

Date:06/24/00ISR Number: 3588098-4Report Type:Periodic Company Report #WAES 00042634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/PO

Excedrin
Extra-Strength C

Date:06/26/00ISR Number: 3518557-1Report Type:Expedited (15-DaCompany Report #WAES 00061981
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Asthenia Faeces Discoloured Gastric Ulcer Haemorrhage Haematemesis	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 25 MG/DAILY/PO	
			Tab Aspirin	SS		ORAL	325 MG/DAILY/PO	
			Tab Advil	SS		ORAL	200 MG/DAILY/PO	
			Coreg	C				
			Blinded Therapy	C				
			Bumetanide	C				

Donepezil Hydrochloride	C
Enalapril	C
Vitamins	C

Date:06/26/00ISR Number: 3519046-0Report Type:Direct Company Report #
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm		Vioxx 25mg	PS		ORAL	25MG DAILY	
	Tachycardia							
	Urticaria							

Date:06/26/00ISR Number: 3519059-9Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased		Vioxx 25mg	PS			25MG BID X 6D, THEN 12.5MG BID	
	Cardiac Failure							
	Congestive Fluid Retention							

Date:06/26/00ISR Number: 3519761-9Report Type:Expedited (15-DaCompany Report #WAES 00056537
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
	Foetal Growth Retardation							
	Intra-Uterine Death							
	Oligohydramnios							

Date:06/26/00ISR Number: 3519869-8Report Type:Expedited (15-DaCompany Report #WAES 00047553
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ear Disorder Nausea Vertigo	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY

Date:06/26/00ISR Number: 3519872-8Report Type:Expedited (15-DaCompany Report #WAES 00069771
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 MON

Date:06/26/00ISR Number: 3519876-5Report Type:Expedited (15-DaCompany Report #WAES 00069767
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:06/26/00ISR Number: 3519878-9Report Type:Expedited (15-DaCompany Report #WAES 00066120
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Phlebitis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:06/26/00ISR Number: 3519881-9Report Type:Expedited (15-DaCompany Report #WAES 00059140
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
Hospitalization - Initial or Prolonged	Hypertensive Crisis							
	Transient Ischaemic Attack		Amlodipine	C				
			Arginine	C				
			Atorvastatin	C				
			Cyproheptadine	C				
			Omeprazole	C				

Date:06/26/00ISR Number: 3519882-0Report Type:Expedited (15-DaCompany Report #WAES 00056136
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Congestive	Health			Laboratories Div	
	Drug Interaction	Professional			Merck Co Inc	ORAL
12.5 MG PO						
	International Normalised		Tab Acenocoumarol	C		ORAL
PO						
	Ratio Increased					

Date:06/26/00ISR Number: 3519884-4Report Type:Expedited (15-DaCompany Report #WAES 00057283
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Clonic Convulsion	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Dizziness	Other			Laboratories Div	
	Dysarthria				Merck Co Inc	ORAL
12.5 MG PO 15 DAY						
	Muscle Spasms		Aspirin	C		
			Estriol	C		
			Glyburide	C		
			Isosorbide	C		
			Sotalol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/00ISR Number: 3519897-2Report Type:Expedited (15-DaCompany Report #WAES 00061990
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Plendil	C				
			Insulin	C				

Date:06/26/00ISR Number: 3519910-2Report Type:Expedited (15-DaCompany Report #WAES 00065556
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis Petechiae Thrombocytopenia	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:06/26/00ISR Number: 3519912-6Report Type:Expedited (15-DaCompany Report #WAES 00061767
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			[Therapy Unspecified]	C				

Date:06/26/00ISR Number: 3519913-8Report Type:Expedited (15-DaCompany Report #WAES 00068908
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY
			Aspilets	C				
			Ibuprofen	C				
			Neurobion	C				
			Renitec	C				
			Verapamil	C				

Date:06/26/00ISR Number: 3519915-1Report Type:Expedited (15-DaCompany Report #WAES 00061458
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Neoplasm		Coumadin	C				
	Prothrombin Time Prolonged							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/00ISR Number: 3519917-5Report Type:Expedited (15-DaCompany Report #WAES 00061647
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health	Vioxx	PS	Merck Research			
	Blood Chloride Decreased	Professional			Laboratories Div			
	Dementia				Merck Co Inc	ORAL	50 MG/25	
	Hyponatraemia						MG/DAILY/PO	
	Mental Impairment		Ginkogin	C				
	Paranoia		Glucophage	C				
			L-Thyroxine	C				
			Premarin	C				
			Zestoretic	C				
			Glyburide	C				
			Ranitidine	C				
			Riboflavine	C				

Date:06/26/00ISR Number: 3519922-9Report Type:Expedited (15-DaCompany Report #WAES 00065537
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Melaena	Health			Laboratories Div			
	Mucous Membrane Disorder	Professional			Merck Co Inc	ORAL	PO	
	Prothrombin Time		Phenprocoumon	C				
	Prolonged							

Date:06/26/00ISR Number: 3520025-8Report Type:Expedited (15-DaCompany Report #WAES 00030088
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Herpes Zoster	Health			Laboratories Div			
	Pruritus	Professional			Merck Co Inc	ORAL	PO	
	Urticaria		[Therapy Unspecified]	C				

			Ascorbic Acid	C		
			Aspirin	C		
			Conjugated Estrogenic Hormones	C		
			Folic Acid	C		
			Garlic Extract	C		
			Hydrochlorothiazide (+) Triamteril	C		
			Vitamin E	C		

Date:06/26/00ISR Number: 3520056-8Report Type:Expedited (15-DaCompany Report #WAES 00060718
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG BID						
PO						
			Zocor	C		
			Isosorbide	C		
			Metoprolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/00ISR Number: 3520060-XReport Type:Expedited (15-DaCompany Report #WAES 00060848
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction Dyspnoea Lacrimation Increased Pharyngolaryngeal Pain Rhinorrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO 3 DAY

Date:06/26/00ISR Number: 3520062-3Report Type:Expedited (15-DaCompany Report #WAES 00061211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	

Date:06/26/00ISR Number: 3520066-0Report Type:Expedited (15-DaCompany Report #WAES 00061412
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN PO	
			Aldactone	C				
			Cozaar	C				
			Lasix	C				
			Prilosec	C				
			Tegretol	C				
			Vasotec	C				
			Digoxin	C				

Date:06/26/00ISR Number: 3520069-6Report Type:Expedited (15-DaCompany Report #WAES 00032853
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Dreams	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN	PO
	Aphasia							
	Blindness							
	Cerebrovascular Accident		Naprosyn	SS			UNKNOWN	UNKNOWN
	Confusional State		Inderal	C				
	Epistaxis		Lioresal	C				
	Hemiparesis		Aspirin	C				
	Hypertension							
	Nightmare							
	Pain							
	Speech Disorder							

Date:06/26/00ISR Number: 3520073-8Report Type:Expedited (15-DaCompany Report #WAES 00041742
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Hepatic Failure
Hospitalization - Initial or Prolonged	Hepatitis
	Hypotension
	Influenza Like Illness

		Jaundice Joint Swelling Sepsis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY							
PO							
				Baycol	C		
				Lipitor	C		

Date:06/26/00ISR Number: 3520075-1Report Type:Expedited (15-DaCompany Report #WAES 00050193
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Convulsion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY							
PO							
				Celebrex	C		
				Tegretol	C		
				Tobradex	C		
				Belladonna (+)			
				Chloroform (+) Ka	C		
				Lorazepam	C		

Date:06/26/00ISR Number: 3520079-9Report Type:Expedited (15-DaCompany Report #WAES 00050339
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cholelithiasis Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNKNOWN PO							
				Aspirin	C		

Date:06/26/00ISR Number: 3520081-7Report Type:Expedited (15-DaCompany Report #WAES 00050459
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Menorrhagia	Other			Merck Co Inc	ORAL	UNKNOWN	PO
	Systemic Lupus Erythematosus		Coumadin	SS			UNKNOWN	2.5 MG DAILY
			Celebrex	C				
			Plaquenil	C				
			Wellbutrin Sr	C				
			Calcium Carbonate	C				
			Chlorguanide	C				
			Lansoprazole	C				
			Montelukast Sodium	C				
			Nonsteroidal Anti-Inflammatory D	C				
			Oxycodone	C				
			Prednisone	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/00ISR Number: 3520085-4Report Type:Expedited (15-DaCompany Report #WAES 00062033
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN PO	

Date:06/26/00ISR Number: 3520087-8Report Type:Expedited (15-DaCompany Report #WAES 00062132
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Blood Potassium Increased							
	Haemodialysis							
	Neck Pain							
	Renal Failure Acute		Synthroid	C				
			Zestril	C				
			Zocor	C				
			Insulin	C				

Date:06/26/00ISR Number: 3520802-3Report Type:Expedited (15-DaCompany Report #WAES 00065554
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial Thromboplastin Time Prolonged	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
Hospitalization - Initial or Prolonged								
Disability	Anaemia	Other	Elavil	C				
	Blood Creatinine Increased		Vasotec	C				
			Carbamazepine	C				
	Blood Urea Increased		Cefuroxime 1-Acetoxyethyl Ester	C				
	Dialysis							
	Gastritis Erosive		Furosemide	C				
	Gastroenteritis		Hydrotalcite	C				
	Helicobacter		Spironolactone	C				

	Haemoglobin Decreased		Tramadol Hcl	C			
	Hyperkalaemia						
	Oedema Peripheral						
	Renal Failure Acute						
	Thrombocytopenia						

Date:06/27/00ISR Number: 3519835-2Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Rofecoxib 2mg	PS			25MG QD	

Date:06/27/00ISR Number: 3520070-2Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia	Health	Vioxx (Rofecoxib)	PS		ORAL	25 MG PO X 1	
Initial or Prolonged	Bronchospasm	Professional						
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/00ISR Number: 3520154-9Report Type:Direct Company Report #
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Vicodin	PS		ORAL	UNK PO	
Life-Threatening	Increased		Vioxx	SS		ORAL	UNK PO	
Hospitalization - Initial or Prolonged	Blood Urea Increased		Calcitriol	C				
	Multi-Organ Failure		Dss	C				
	Skin Exfoliation		Omeprazole	C				
	Toxic Epidermal		Sertraline	C				
	Necrolysis		I-Thyroxine	C				
	Urinary Tract Infection		Atenolol	C				
	Enterococcal		Caco3	C				
			Furosemide	C				
			Captopril	C				
			Calcitonin	C				
			Trazodone	C				
			Mvi	C				
			Mom	C				
			Tylenol	C				

Date:06/27/00ISR Number: 3520221-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Coumadin	PS			5MG	
Hospitalization - Initial or Prolonged		Professional	Vioxx	SS		ORAL	12.5/25 PO	
Other								

Date:06/27/00ISR Number: 3520246-4Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Rofecoxib	PS			12.5 MG HS	

	Congestive	Professional
	Dyspnoea	
	Fluid Retention	

Date:06/27/00ISR Number: 3520257-9Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure		Rofecoxib 25mg	PS			25 MG QD	
	Congestive							
	Fluid Retention							

Date:06/27/00ISR Number: 3520456-6Report Type:Expedited (15-DaCompany Report #200011757DDC
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Barrett'S Oesophagus
	Burning Sensation
	Condition Aggravated
	Dyspepsia
	Gastritis Erosive
	Haemorrhage

	Hiatus Hernia Oesophagitis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Study	Arava	PS	Aventis Pharmaceuticals Inc		20 MG QD
		Health	Vioxx	SS		ORAL	25 MG/DAY PO
		Professional	Meticorten	SS		ORAL	5 MG/DAY PO
		Other	Higroton	C			
			Ranitidine	C			

Date:06/28/00ISR Number: 3521051-5Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Insomnia		Smz/Tmp	PS			DS TAB BID
Initial or Prolonged	Mental Impairment		Rofecoxib	SS			12.5MG QD
	Renal Failure Acute		Aspirin	SS			81 MG

Date:06/28/00ISR Number: 3521384-2Report Type:Expedited (15-DaCompany Report #WAES 00051058
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Abdominal Tenderness	Health			Laboratories Div		
	Arthralgia	Professional			Merck Co Inc	ORAL	25
	Cholecystitis						MG/DAILY/PO
	Condition Aggravated		Claritin	C			
	Emotional Distress		Darvocet-N	C			
			Nasonex	C			
			Premarin	C			
			Prevacid	C			

Date:06/28/00ISR Number: 3521387-8Report Type:Expedited (15-DaCompany Report #WAES 00060965
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Hypersensitivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
	Hypertension							
	Oedema							
	Rash Maculo-Papular		Allegra	C				
	Rash Morbilliform		Atacand	C				
			Hydrodiuril	C				
			Mevacor	C				
			Norvasc	C				
			Premarin	C				
			Prilosec	C				
			Aspirin	C				
			Isosorbide	C				

Date:06/28/00ISR Number: 3521465-3Report Type:Expedited (15-DaCompany Report #WAES 00020431
Age:51 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis
	Nausea
	Pruritus
	Rash Papular

Rash Pruritic

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Influenza Virus Vaccine	C				

Date:06/28/00ISR Number: 3521466-5Report Type:Expedited (15-DaCompany Report #WAES 00061667
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/28/00ISR Number: 3521467-7Report Type:Expedited (15-DaCompany Report #WAES 00061787
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Difficulty In Walking Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hemiplegia Inflammation Lacrimation Increased Nervous System Disorder Speech Disorder		Insulin	C				

Date:06/28/00ISR Number: 3521468-9Report Type:Expedited (15-DaCompany Report #WAES 00062122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Epistaxis Haemorrhage Headache Hypertension Mouth Haemorrhage Oedema Peripheral Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/28/00ISR Number: 3521469-0Report Type:Expedited (15-DaCompany Report #WAES 00062160
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Hyperkalaemia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Triamterene	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/00ISR Number: 3521470-7Report Type:Expedited (15-DaCompany Report #WAES 00062214
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Fall Gait Disturbance Gastric Disorder Laboratory Test Abnormal Liver Function Test Abnormal Movement Disorder Muscle Spasms Muscular Weakness Overdose Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/28/00ISR Number: 3521472-0Report Type:Expedited (15-DaCompany Report #WAES 00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Brain Scan Abnormal Brain Stem Infarction Cerebellar Infarction Cerebral Infarction Cerebrovascular Accident Coordination Abnormal Difficulty In Walking Dizziness Headache High Density Lipoprotein Decreased Hypercholesterolaemia Hyperglycaemia Hyperlipidaemia Hypertension Hypertriglyceridaemia Labyrinthitis Medication Error	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Nausea
Nystagmus
Osteoarthritis
Red Blood Cell
Sedimentation Rate
Increased
Vertigo

Date:06/28/00ISR Number: 3521475-6Report Type:Expedited (15-DaCompany Report #WAES 00061386
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Body Temperature
Hospitalization -	Decreased
Initial or Prolonged	Dyspepsia
Other	Embolism
	Gastric Ulcer
	Gastric Ulcer Haemorrhage
	Gastrointestinal
	Haemorrhage

	Haematemesis						
	Haematocrit Decreased						
	Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypotension	Health	Vioxx	PS	Merck Research		
	Lethargy	Professional			Laboratories Div		
	Respiratory Rate	Company			Merck Co Inc	ORAL	25 MG DAILY
	Increased	Representative					PO
	Shock		Aspirin 325 Mg	SS			325 MG/DAILY
			Catapres Tts	C			
			Celebrex	C			
			Diovan	C			
			Feldene	C			
			Glucophage	C			
			Relafen	C			
			Singulair	C			
			Insulin Injection	C			
			Isophane Insulin Suspension	C			
			Vitamin E	C			

Date:06/28/00ISR Number: 3521499-9Report Type:Expedited (15-DaCompany Report #WAES 00065098
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Hallucination, Visual	Foreign	Vioxx	PS	Merck Research		
Hospitalization -		Health			Laboratories Div		
Initial or Prolonged		Professional			Merck Co Inc		
			Acetaminophen/Codeine Phosphate	C			
			Lansoprazole	C			

Date:06/28/00ISR Number: 3521505-1Report Type:Expedited (15-DaCompany Report #WAES 00069762
Age:77 YR Gender:Female I/FU:I

Outcome	PT
Death	Arrhythmia
Life-Threatening	Asthenia
Hospitalization -	Blood Creatinine

Initial or Prolonged	Increased
	Blood Ph Decreased
	Bradycardia
	Cardiac Arrest
	Coma
	Decubitus Ulcer
	Depressed Level Of Consciousness
	Hemiparesis
	Hemiplegia
	Hyperkalaemia
	Inflammation
	Insomnia
	Loss Of Consciousness
	Medication Error
	Metabolic Acidosis
	Nervous System Disorder
	Oedema Peripheral
	Pyrexia
	Renal Failure Acute
	Respiratory Acidosis

		Rhonchi Sepsis Stasis Dermatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	5 DAY						
				Vasotec	C		
				Acetaminophen	C		
				Amoxicillin Trihydrate (+) Clavulanate P	C		
				Codeine	C		
				Levothyroxine Na	C		
				Oxybutynin Cl	C		

Date:06/28/00ISR Number: 3521508-7Report Type:Expedited (15-DaCompany Report #WAES 00069770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/28/00ISR Number: 3521628-7Report Type:Expedited (15-DaCompany Report #JRFUSA2000003194
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Discomfort Back Pain	Consumer Health Professional	Propulsid	PS	Janssen Research Fdn Div Johnson And Johnson	ORAL
Required	Burning Sensation					
10 MG, 4 IN 1						
Intervention to	Bursitis					
DAY (S), ORAL						
Prevent Permanent Impairment/Damage	Chest Pain Dry Mouth		Zoloft (Sertraline Hydrochloride)	SS		ORAL
1 TABLET, 1						
	Dyspnoea					
IN 1 DAY (S),						

	Electrocardiogram Qt		
ORAL			
	Corrected Interval	Vioxx (Rofecoxib)	SS
	Prolonged	Darvocet (Darvocet)	SS
	Electrocardiogram Qt	Cipro (Ciprofloxacin	
	Prolonged	Hydrochloride)	SS
	Feeling Cold	Evista (Raloxifene)	C
	Gait Disturbance	Claritin	
	Hypercholesterolaemia	(Loratadine)	C
	Hypersensitivity	Synthroid	
	Hypoaesthesia	(Levothyroxine	
	Insomnia	Sodium)	C
	Intervertebral Disc	Prevacid	
	Degeneration	(Lansoprazole)	C
	Joint Stiffness	Nasacort Aq	
	Lower Respiratory Tract	(Triamcinolone	
	Infection	Acetonide)	C
	Neck Pain	Vitamins (Vitamins)	C
	Pain In Extremity	Celebrex (Celecoxib)	C
	Palpitations	Daypro (Oxaprozin)	C
	Pyrexia	Ambien (Zolpidem	
	Rash Maculo-Papular	Tartrate)	C
	Scoliosis	Tylenol With Codeine	
	Tremor	(Unspecified)	
	Urinary Retention	(Acetaminophen/Codei	
		ne)	C

Trazodone (Trazodone)	C
Cefazolin (Cefazolin)	C
Ativan (Lorazepam)	C
Vicodin (Vicodin)	C
Lidogel (Unspecified)	C

Date:06/29/00ISR Number: 3521875-4Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS			25 MG 2X/DAY	
Initial or Prolonged	Abdominal Pain Lower		Percodan	C				
	Anaemia		Zanaflex	C				
	Back Pain		Soma	C				
	Condition Aggravated		Naproxen	C				
	Constipation							
	Haematochezia							
	Hyperpyrexia							
	Liver Function Test Abnormal							
	Red Blood Cell Sedimentation Rate Increased							

Date:06/30/00ISR Number: 3521898-5Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis		Vioxx 25 Merk	PS		ORAL	1 QD ORAL	

Date:06/30/00ISR Number: 3522815-4Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cough Dyspnoea		Coumadin 4mg Dupont/Pharm	PS	Dupont/Pharm	ORAL	4MG QD	
Required Intervention to Prevent Permanent Impairment/Damage	Pulmonary Haemorrhage		Vioxx 50mg Merck	SS	Merck	ORAL	50MG QD	OP
			Atenolol	C				
			Aspirin	C				

Date:06/30/00ISR Number: 3522908-1Report Type:Expedited (15-DaCompany Report #WAES 00063728
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/00ISR Number: 3522910-XReport Type:Expedited (15-DaCompany Report #WAES 00066149
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Oedema Peripheral Weight Increased	Foreign Study Health Professional	Vioxx Vasotec	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:06/30/00ISR Number: 3522913-5Report Type:Expedited (15-DaCompany Report #WAES 00058905
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise Salivary Hypersecretion	Foreign Health Professional	Vioxx Aspilets Centrum Plendil	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY

Date:06/30/00ISR Number: 3522940-8Report Type:Expedited (15-DaCompany Report #WAES 00060674
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Apnoea Cardiac Failure Congestive Medication Error Nausea Pulmonary Oedema Respiratory Disorder Respiratory Failure	Consumer Health Professional	Vioxx Lasix Prilosec Tenormin Xanax Prednisone	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/30/00ISR Number: 3522941-XReport Type:Expedited (15-DaCompany Report #WAES 00051895
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/30/00ISR Number: 3522951-2Report Type:Expedited (15-DaCompany Report #WAES 00051691
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Colon Abnormal Duodenal Ulcer Haemorrhage Gastrointestinal Haemorrhage Rectal Haemorrhage Rectal Polyp Sinus Bradycardia Supraventricular Extrasystoles	Consumer Health Professional	Vioxx Ambien Celebrex Diazide Excedrin Extra-Strength Pepcid Tiazac	PS C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Vasotec	C		

Date:06/30/00ISR Number: 3523038-5Report Type:Expedited (15-DaCompany Report #WAES 00056228
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Corneal Ulcer	Foreign	Vioxx	PS	Merck Research	
	Eye Pain	Study			Laboratories Div	
	Herpes Virus Infection	Health			Merck Co Inc	ORAL
		Professional	Calcium Carbonate/Vitamin D	C		
			Cicletanine	C		
			Diacerein	C		
			Diclofenac	C		

Dose: 12.5 MG PO Duration: 15 DAY

Date:06/30/00ISR Number: 3523172-XReport Type:Expedited (15-DaCompany Report #WAES 00068908
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Bronchospasm	Foreign	Vioxx	PS	Merck Research	
		Other			Laboratories Div	
					Merck Co Inc	ORAL
			Aspilets	C		
			Ibuprofen	C		
			Neurobion	C		
			Renitec	C		
			Verapamil	C		

Dose: 25 MG PO Duration: 2 DAY

Date:06/30/00ISR Number: 3523175-5Report Type:Expedited (15-DaCompany Report #WAES 00045527
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Agitation	Foreign	Vioxx	PS	Merck Research	
	Anxiety	Other			Laboratories Div	
	Haematoma				Merck Co Inc	ORAL

Dose: 12.5 MG PO

	Haemoglobin Decreased	Cerivastatin Sodium	C
	Idiopathic	Cimicifuga	C
	Thrombocytopenic Purpura	Diclofenac	C
	Infection	Dimethicone /Silicon	
	Myelodysplastic Syndrome	Dioxide	C
	Pernicious Anaemia	Flupentixol	
	Thrombocytopenia	Decanoate	C
	White Blood Cell Count	Levothyroxine Na	C
	Decreased	Roxithromycin	C
		Vitamin E	C

Date:06/30/00ISR Number: 3523177-9Report Type:Expedited (15-DaCompany Report #WAES 99127511
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Cardiac Failure
	Cardiac Failure
	Congestive
	Skin Lesion
	Skin Necrosis
	Vasculitis

Ventricular Arrhythmia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	
			Tab Placebo	SS		ORAL	2 TABLET PO	131 DAY
			Captopril	C				
			Digoxin	C				
			Folic Acid	C				
			Molsidomine	C				
			Prednisolone	C				

Date:06/30/00ISR Number: 3523179-2Report Type:Expedited (15-DaCompany Report #WAES 00065129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	

Date:06/30/00ISR Number: 3523207-4Report Type:Expedited (15-DaCompany Report #7268640
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Study Health	Aleve (Caplet)	PS	Bayer Corp Consumer Care Div	ORAL	ORAL 01X	
	Cerebrovascular Disorder							
	Haemorrhage	Professional	Rofecoxib	SS		ORAL	ORAL	
	Hypertension		Aricept	C				
	Perseveration		Aspirin	C				
	Speech Disorder		Lescol	C				
			Vitamin E	C				
			Vitamin B12	C				

Date:06/30/00ISR Number: 3523266-9Report Type:Expedited (15-DaCompany Report #WAES 00061211
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/30/00ISR Number: 3523268-2Report Type:Expedited (15-DaCompany Report #WAES 00050188
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Malaise Myocardial Infarction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flomax (Niflumic Acid (Beta) -Mor	C				
			Proscar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/00ISR Number: 3523269-4Report Type:Expedited (15-DaCompany Report #WAES 00033094
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis Haemorrhagic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged								
			Motrin	C				
			Tylenol	C				
			Vasotec	C				

Date:06/30/00ISR Number: 3523298-0Report Type:Expedited (15-DaCompany Report #WAES 00062970
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Bronchitis							
	Convulsion							
	Dyspnoea							
			[Therapy Unspecified]	C				

Date:06/30/00ISR Number: 3525096-0Report Type:Expedited (15-DaCompany Report #WAES 00062833
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Congestive							
	Chest Pain							
	Dyspnoea							
	Oedema		Flomax (Niflumic Acid (Beta)	C				
	Orthopnoea		Lipitor	C				

			Aspirin	C		

Date:07/03/00ISR Number: 3523532-7Report Type:Expedited (15-DaCompany Report #WAES 00053019
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pain Renal Cyst	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			K-Dur	C		
			Lasix	C		
			Lopressor	C		
			Plavix	C		
			Prilosec	C		
			Procardia	C		
			Ultram	C		
			Uni-Dur	C		
			[Therapy Unspecified]	C		
			Allopurinol	C		
			Meclizine	C		
			Nitroglycerin	C		

Date:07/03/00ISR Number: 3523536-4Report Type:Expedited (15-DaCompany Report #WAES 00060167
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Other	Perforation	Professional			Laboratories Div			
	Haematocrit Decreased	Other			Merck Co Inc	ORAL	25 MG/QID/PO	
	Haemoglobin Decreased		[Therapy Unspecified]	C				

Date:07/03/00ISR Number: 3523539-XReport Type:Expedited (15-DaCompany Report #WAES 00062722
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
	Abdominal Rigidity	Professional			Laboratories Div			
	Lipase Increased	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea	Representative						
	Pancreatitis Acute							

Date:07/03/00ISR Number: 3523542-XReport Type:Expedited (15-DaCompany Report #WAES 00062965
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health	Vioxx	PS	Merck Research			
	Coronary Artery Disease	Professional			Laboratories Div			
	Dyspnoea	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
		Representative						
			Celebrex	C				
			Coumadin	C				

Date:07/03/00ISR Number: 3523544-3Report Type:Expedited (15-DaCompany Report #WAES 00063069
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Acupril	C				
			Flomax (Niflumic Acid (Beta)-Mor	C				
			Atenolol	C				

Date:07/03/00ISR Number: 3523576-5Report Type:Expedited (15-DaCompany Report #WAES 00060856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Abdominal Distension Diarrhoea Irritable Bowel Syndrome Muscle Spasms Nausea Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/00ISR Number: 3523578-9Report Type:Expedited (15-DaCompany Report #WAES 00063099
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Drug Ineffective Hepatitis Cholestatic Jaundice	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/03/00ISR Number: 3523580-7Report Type:Expedited (15-DaCompany Report #WAES 00063039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haemorrhagic Haematochezia Hiatus Hernia Upper Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/03/00ISR Number: 3523582-0Report Type:Expedited (15-DaCompany Report #WAES 00064290
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/03/00ISR Number: 3523583-2Report Type:Expedited (15-DaCompany Report #WAES 00063108
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Lortab C

Date:07/03/00ISR Number: 3523585-6Report Type:Expedited (15-DaCompany Report #WAES 00064285
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Bronchospasm							
	Dyspnoea				Merck Co Inc	ORAL	PO	
	Fluid Retention							

Date:07/03/00ISR Number: 3523586-8Report Type:Expedited (15-DaCompany Report #WAES 00064287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Tremor							
Disability					Merck Co Inc	ORAL	PO	4 WK
			Lithiumco3	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/00ISR Number: 3523587-XReport Type:Expedited (15-DaCompany Report #WAES 00030543
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Fluid Retention Mediastinum Neoplasm Oedema Peripheral Superior Vena Caval Occlusion Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:07/03/00ISR Number: 3523588-1Report Type:Expedited (15-DaCompany Report #WAES 00041038
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aphasia Haemorrhage Intracranial Hemiparesis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
Disability	International Normalised Ratio Increased	Representative	Coumadin L-Thyroxine Premarin Furosemide Metoprolol Potassium Chloride	C C C C C C				

Date:07/03/00ISR Number: 3523589-3Report Type:Expedited (15-DaCompany Report #WAES 00050217
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination, Visual Oral Intake Reduced Screaming	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/03/00ISR Number: 3523590-XReport Type:Expedited (15-DaCompany Report #WAES 00050419
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage Prostatic Specific Antigen Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Inderal	C				
			L-Thyroxine	C				
			Tricor	C				
			Aspirin	C				

Date:07/03/00ISR Number: 3523591-1Report Type:Expedited (15-DaCompany Report #WAES 00051635
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Duodenal Ulcer
Hospitalization - Initial or Prolonged	Haemorrhage
	Gastroenteritis
Other	Helicobacter
	Haematocrit Decreased

		Haemoglobin Decreased Orthostatic Hypotension Upper Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							
			Representative	Proscar	C		
				Ibuprofen	C		

Date:07/03/00ISR Number: 3523794-6Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blood Pressure Diastolic		Vioxx 25 Mg Merck	PS	Merck	ORAL
1 DAILY ORAL						
	Increased		Zestril	C		

Date:07/03/00ISR Number: 3523843-5Report Type:Expedited (15-DaCompany Report #001-0981-M0002373
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Arthralgia	Health	Lipitor	PS	Warner Lambert	
Required	Asthenia	Professional			Export Ltd	ORAL
20 MG						
Intervention to	Burning Sensation					
(DAILY), PER						
Prevent Permanent	Difficulty In Walking					
ORAL						
Impairment/Damage	Hypoaesthesia		Vioxx (Rofecoxib)	SS		
12.5 MG						
	Insomnia		Prozac (Fluoxetine			
	Joint Contracture		Hydrochloride)	C		
	Joint Stiffness		Tylenol			
	Movement Disorder		(Paracetamol)	C		
	Muscular Weakness		Tylenol Pm			
	Oedema		(Diphenhydramine,			
	Pain In Extremity		Paracetamol)	C		
	Paraesthesia		Allegra			
	Swelling		(Fexofenadine			

	Tendon Disorder		Hydrochloride)	C		
	Tenosynovitis					

Date:07/03/00ISR Number: 3523867-8Report Type:Expedited (15-DaCompany Report #WAES 00064582
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aortic Valve Incompetence	Health	Vioxx	PS	Merck Research	
Disability	Cardiac Valve Disease	Professional			Laboratories Div	
	Dyspnoea	Company			Merck Co Inc	ORAL
25MG/DAILY/PO						
	Face Oedema	Representative				
	Fluid Retention					
	Oedema Peripheral					
	Pleural Effusion					
	Weight Increased					

Date:07/03/00ISR Number: 3523898-8Report Type:Expedited (15-DaCompany Report #WAES 00028592
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemoglobin Decreased	Other			Laboratories Div	
	Palpitations				Merck Co Inc	ORAL
25 MG PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/00ISR Number: 3523901-5Report Type:Expedited (15-DaCompany Report #WAES 00065604
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Decreased Appetite	Other						
	Dehydration							
	Dizziness		Hctz/Triamtere	C				
	Hyponatraemia							
	Vomiting							

Date:07/03/00ISR Number: 3523932-5Report Type:Expedited (15-DaCompany Report #WAES 00025192
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Haemorrhage	Other						
	Haematemesis							
	Oesophageal Ulcer		Ispaghula Husk	C				
			Pantoprazole	C				
			Primidone	C				
			Tolbutamide	C				
			Tramadol	C				

Date:07/03/00ISR Number: 3523973-8Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAY ORAL	
	Haemorrhage		Propranolol	C				
			Gemfibrozil	C				
			Clonazepam	C				
			Aspirin	C				
			Vitamins	C				

Date:07/03/00ISR Number: 3523991-XReport Type:Expedited (15-DaCompany Report #WAES 00068235
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	29 DAY
		Other	Alfuzosin Hydrochloride	C				
			Amiloride Hydrochloride/Hctz	C				
			Amiodarone Hydrochloride	C				
			Isosorbide Dinitrate	C				
			Lysine Acetylsalicylate	C				
			Phenprocoumon	C				
			Prednisone	C				
			Temazepam	C				
			Torsemide	C				
			Verapamil Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/00ISR Number: 3523993-3Report Type:Expedited (15-DaCompany Report #WAES 00065180
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG	
			Calcium Supplement	C				
			Fluoxetine	C				
			Gliclazide	C				
			Metformin	C				
			Prednisolone	C				
			Vaproic Acid Sodium Salt (1:1)	C				
			Vitamin D{2}	C				

Date:07/03/00ISR Number: 3523998-2Report Type:Expedited (15-DaCompany Report #WAES 00065147
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Haemorrhage Intracranial Haemorrhagic Stroke	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Acetaminophen (+) Dihydrocodeine Bitartr	C				
			Ibuprofen	C				
			Ranitidine	C				

Date:07/03/00ISR Number: 3524002-2Report Type:Expedited (15-DaCompany Report #WAES 00063718
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Anaemia Cardiac Arrest	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Coronary Artery Disease	Other	Aspirin	C				

Gastrointestinal
Haemorrhage
Haemoglobin Decreased
Myocardial Ischaemia

Date:07/03/00ISR Number: 3524530-XReport Type:Expedited (15-DaCompany Report #B0083343A
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Foreign	Zinacef	PS	Glaxo Wellcome Inc	INTRAVENOUS	750 MG/THREE TIMES PER DAY	
	Increased							
	C-Reactive Protein							
	Increased		Rofecoxib Tablet					
	Oliguria		(Rofecoxib)	SS		ORAL	PER DAY /	
	Renal Failure							
	Synovitis		Paracetamol	C				
	Thrombocytopenia		Behepan	C				
			Oxazepam	C				
			Dextropropoxyphene Nasylate	C				
			Calcium Carbonate	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/00ISR Number: 3523854-XReport Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure		Vioxx	PS			12.5MG QD;	
	Congestive						25MG QD	
	Diarrhoea		Digoxin	C				
	Dizziness		Kdur	C				
			Ativan	C				
			Meclizine	C				
			Elavil	C				
			Premarin	C				
			Glucotrol Xl	C				
			Lisinopril	C				

Date:07/05/00ISR Number: 3523983-0Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Vioxx (Rofecoxib)	PS			12.5MG BID	2 MON
Initial or Prolonged	Fatigue		Lescol	C				
	Upper Gastrointestinal		Aspirin	C				
	Haemorrhage		Fosamax	C				
			Timoptic Xe	C				
			Diazide	C				

Date:07/05/00ISR Number: 3524134-9Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia		Vioxx 25 G D	PS				
			Varotcox	C				
			Hctz	C				
			Ciain	C				

Date:07/06/00ISR Number: 3524720-6Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Rofecoxib	PS		ORAL	25 MG BID PO	1 MON
Initial or Prolonged	Increased	Professional	Bumetanide	SS		ORAL	2MG BID PO	
	Dyspnoea		Lisinopril	C				
	Oedema Peripheral		Premarin	C				
			Synthroid	C				
			Combivent	C				
			Lanoxin	C				
			Detrol	C				
			Aspirin	C				
			Elavil	C				
			Zantac	C				
			Coumadin	C				
			Zaroxolyn	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/00ISR Number: 3525181-3Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged		Professional	Contrast Dye	SS				

Date:07/06/00ISR Number: 3525332-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Oedema		Vioxx	PS		ORAL	50MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Weight Increased		Dapone	C				
			Decadron	C				
			Vp-16	C				
			Thalidomide	C				

Date:07/06/00ISR Number: 3582742-3Report Type:Periodic Company Report #2000022866US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Other	Detrol	PS	Pharmacia And Upjohn Co	ORAL	0, BID ORAL	
	Dyspepsia							
	Feeling Abnormal		Detrol, Regimen #2	SS		ORAL	DQ, ORAL	
			Detrol, Regimen #3	SS		ORAL	1 MG, BID, ORAL	
			Detrol, Regimen #4	SS		ORAL	2 MG, BID, ORAL	
			Vioxx	SS				
			Prozac (Fluoxetine Hydrochloride)	C				

Date:07/07/00ISR Number: 3526205-XReport Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Health	Vioxx	PS		ORAL	25 PO	
Hospitalization - Initial or Prolonged		Professional	Estrace	C				
			Synthroid	C				
			Pacerone	C				
			Lasix	C				
			Altace	C				
			K-Dur	C				
			Lanoxin	C				
			Aspirin	C				
			Calcium	C				
			Celebrex	C				

Date:07/07/00ISR Number: 3526334-0Report Type:Expedited (15-DaCompany Report #WAES 00063246
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/00ISR Number: 3526335-2Report Type:Expedited (15-DaCompany Report #WAES 00064426
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Eosinophilia Pleural Effusion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Betapace	C				
			Digoxin	C				
			Prednisone	C				

Date:07/07/00ISR Number: 3526359-5Report Type:Expedited (15-DaCompany Report #WAES 00068612
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Diarrhoea Face Oedema Granuloma Hypersensitivity Inflammation Leukocytosis Lung Disorder Nausea Pyrexia Scab Skin Lesion Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:07/07/00ISR Number: 3526360-1Report Type:Expedited (15-DaCompany Report #WAES 00069132
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	4 DAY
			Cap Clorazepic Acid					

				Dik	SS		ORAL
5 MG PO	4	DAY					
				Sertraline	SS		ORAL
50 MG PO	4	DAY					

Date:07/07/00ISR Number: 3526361-3Report Type:Expedited (15-DaCompany Report #WAES 00065288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema Bronchospasm Hypersensitivity	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO						
			Acetaminophen/Propoxyohene Hydrochloride	C		
			Dydrogesterone (+) Estradiol	C		

Date:07/07/00ISR Number: 3526446-1Report Type:Expedited (15-DaCompany Report #WAES 00052889
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthralgia

	Duodenal Ulcer Haemorrhage Faeces Discoloured	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haematocrit Decreased Haemoglobin Decreased Polymyalgia Rheumatica	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO
	Red Blood Cell Sedimentation Rate	Representative	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO
	Increased		Levaquin	C			
			Plavix	C			

Date:07/07/00ISR Number: 3526448-5Report Type:Expedited (15-DaCompany Report #WAES 00064581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO
		Representative	Advil	C			

Date:07/07/00ISR Number: 3526450-3Report Type:Expedited (15-DaCompany Report #WAES 00063233
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Meningitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
		Representative	Bactrim	C			

Date:07/07/00ISR Number: 3526451-5Report Type:Expedited (15-DaCompany Report #WAES 00063219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Heparin	SS				

Date:07/07/00ISR Number: 3526452-7Report Type:Expedited (15-DaCompany Report #WAES 00063232
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vasotec	C				

Date:07/07/00ISR Number: 3526461-8Report Type:Periodic Company Report #USA/00/00611/LAS
Age:70 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Dry Skin	Health Professional	Lamisil	PS	Novartis Pharmaceuticals Corp	ORAL	ORAL	
	Dyspnoea Hypersensitivity Hypertension Oedema Pruritus Rash Erythematous Stridor	Company Representative	Vioxx Estrace (Estradiol) Baby Aspirin	SS C C				

Date:07/07/00ISR Number: 3526524-7Report Type:Expedited (15-DaCompany Report #WAES 00060119
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated Gastric Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/PO	
	Haemoglobin Decreased		Cardizem Celebrex Glucotrol Therapy Unspecified	C C C C				

Date:07/07/00ISR Number: 3526526-0Report Type:Expedited (15-DaCompany Report #WAES 00060184
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Duodenal Perforation Gastroenteritis Helicobacter Perforated Duodenal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;	

Repair
25

MG/DAILY/PO

Darvocet-N	C
Prinzide	C

Date:07/07/00ISR Number: 3526529-6Report Type:Expedited (15-DaCompany Report #WAES 00062132
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Ascites
Hospitalization - Initial or Prolonged	Asthenia
	Blood Creatinine Increased
	Blood Urea Increased
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly
	Condition Aggravated
	Dialysis
	Dyspnoea
	Ejection Fraction Abnormal
	Haemoglobin Decreased

		Hyperkalaemia					
		Metastases To Bone					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral	Health	Vioxx	PS	Merck Research	
		Pericardial Disease	Professional			Laboratories Div	
		Pericarditis Uraemic	Company			Merck Co Inc	ORAL
25							
		Renal Failure	Representative				
MG/DAILY/PO							
		Renal Failure Acute		Zestril Unk	SS		
		Spinal Disorder		Benadryl	C		
		Swelling		Lasix	C		
		Ventricular Hypertrophy		Sandostatin	C		
		Weight Increased		Synthroid	C		
				Zantac	C		
				Zaroxolyn	C		
				Zocor	C		
				Digoxin	C		
				Insulin	C		

Date:07/07/00ISR Number: 3526553-3Report Type:Expedited (15-DaCompany Report #WAES 00065598
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Apathy	Foreign	Vioxx	PS	Merck Research	
		Feeling Hot	Health			Laboratories Div	
		Overdose	Professional			Merck Co Inc	ORAL
900-1000 MG,							
		Suicide Attempt					
PO	1 DAY						
		Vomiting		Cyclosporin A	C		
				Prednisone	C		

Date:07/07/00ISR Number: 3526554-5Report Type:Expedited (15-DaCompany Report #WAES 00069131
Age:59 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Dizziness	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Gastric Ulcer	Other			Laboratories Div	

		Gastric Ulcer Haemorrhage						Merck Co Inc	ORAL
25 MG, PO	20	DAY							
		Gastroenteritis			Cap Acetaminophen	SS			ORAL
PO	14	DAY							
		Helicobacter			Tab Tetrazepam	SS			ORAL
50 MG, PO	19	DAY							
		Telangiectasia			Cap Tramadol Hcl	SS			ORAL
PO	15	DAY							
					Top Methyl Salicylate	SS			
TOPICAL	TOP		19	DAY					
					Top Isonixin	SS			
TOPICAL	TOP		19	DAY					

Date:07/07/00ISR Number: 3526555-7Report Type:Expedited (15-DaCompany Report #WAES 00068269
Age:65 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Haemorrhage Intracranial	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Hemiplegia	Health			Laboratories Div	
Initial or Prolonged		Intracranial Venous Sinus	Professional			Merck Co Inc	ORAL
PO	7 DAY						
		Thrombosis	Other	Chondroitinso4			
		Sedation		Chondroitin 4-Sulfate Din	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/00ISR Number: 3526643-5Report Type:Expedited (15-DaCompany Report #WAES 00065578
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	5 DAY
			Cap Valsartan	SS		ORAL	80 MG PO	
			Acetylcysteine	C				
			Carvedilol	C				
			Clopidrigel Bisulfate	C				
			Doxepin Hcl	C				
			Furosemide	C				
			Prednisolone	C				
	Renal Impairment							

Date:07/07/00ISR Number: 3526644-7Report Type:Expedited (15-DaCompany Report #WAES 00049105
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
Hospitalization - Initial or Prolonged	Blood Uric Acid Increased							
	Chest X-Ray Abnormal	Other	Tab Acenocoumarol	SS		ORAL	2 MG PO	
	Coronary Artery Occlusion		Indocin	C				
	Drug Interaction		Moduretic	C				
	Duodenal Ulcer		Furosemide	C				
	Haemorrhage		Losartan Potassium	C				
	Gastroenteritis							
	Helicobacter							
	Haematemesis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							
	Myocardial Infarction							
	Prothrombin Level Decreased							
	Red Blood Cell Sedimentation Rate							

Increased
Upper Gastrointestinal
Haemorrhage

Date:07/07/00ISR Number: 3526645-9Report Type:Expedited (15-DaCompany Report #WAES 00057334
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Tenderness
	Cardiac Failure
	Congestive
	Cardiomegaly
	Chest Discomfort
	Cyanosis
	Dyspnoea
	Ejection Fraction
	Abnormal
	Electrocardiogram
	Abnormal
	Hypertension
	Left Ventricular Failure

	Myocardial Infarction Oedema Peripheral						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:07/07/00ISR Number: 3526646-0Report Type:Expedited (15-DaCompany Report #WAES 00063728
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Acetaminophen	C			
			Furosemide	C			
			Lynestrenol / Mestranol	C			
			Nitrazepam	C			

Date:07/07/00ISR Number: 3526647-2Report Type:Expedited (15-DaCompany Report #WAES 00055637
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Macular Degeneration Visual Acuity Reduced	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO
			[Composition Unspecified]	C			
			Bromelain (+) Rutin (+) Trypsin	C			
			Insulin	C			
			Repaglinide	C			
			Serenoa Repens	C			
			Viatmin E	C			

Date:07/07/00ISR Number: 3526648-4Report Type:Expedited (15-DaCompany Report #WAES 00063718
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Anaemia	Health			Laboratories Div			
Initial or Prolonged	Cardiac Arrest	Professional			Merck Co Inc	ORAL	25 MG PO	
	Cardiac Disorder		Aspirin	C				
	Coronary Artery Disease							
	Gastrointestinal							
	Haemorrhage							
	Haemoglobin Decreased							
	Hypoxia							
	Myocardial Ischaemia							

Date:07/10/00ISR Number: 3526768-4Report Type:Expedited (15-DaCompany Report #A021992
Age:73 YR Gender:Female I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calcinosis	Consumer	Glucotrol Xl	PS	Pfizer Inc	ORAL	5.00 MG	
	Constipation						TOTAL:DAILY:O	
	Flatulence						RAL	
	Gastrointestinal Disorder		Vioxx	SS		ORAL	ORAL	
	Pancreatic Disorder		Cardiazem	C				
	Polyp		Zoloft	C				

Date:07/10/00ISR Number: 3526781-7Report Type:Expedited (15-DaCompany Report #WAES 00075010
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 DAY
			Diclofenac	C				
			Dihydrocodeine	C				

Date:07/10/00ISR Number: 3526788-XReport Type:Expedited (15-DaCompany Report #WAES 00063581
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Amyloidosis Deep Vein Thrombosis Nephritis Interstitial	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	38 DAY
	Renal Failure Acute	Professional	Celecoxib	C				
			Methotrexate	C				
			Omeprazole	C				

Date:07/10/00ISR Number: 3526790-8Report Type:Expedited (15-DaCompany Report #WAES 00050286
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Diverticulum Intestinal							
	Erosive Oesophagitis							
	Faecal Occult Blood						/PO	
	Positive		Aspirin	C				
	Faeces Discoloured							
	Gastroenteritis							
	Helicobacter							
	Gastrointestinal							
	Haemorrhage							
	Melaena							
	Oesophageal Haemorrhage							
	Oesophagitis							

Date:07/10/00ISR Number: 3526791-XReport Type:Expedited (15-DaCompany Report #WAES 00033094
Age:91 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Angina Pectoris
	Ascites
	Atelectasis

		Blood Amylase Increased Blood Magnesium Decreased Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Confusional State Convulsion Differential White Blood Cell Count Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO							
		Diverticulitis Dysphagia Haematuria Hypertension Hypotension Intra-Abdominal Haemorrhage Leukaemoid Reaction Leukocytosis Lipase Increased Lung Infiltration Nausea Pancreatitis Haemorrhagic Pleural Effusion Pulmonary Embolism White Blood Cells Urine Positive		Motrin Tylenol	C C		

Date:07/10/00ISR Number: 3526792-1Report Type:Expedited (15-DaCompany Report #WAES 00031627
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:07/10/00ISR Number: 3526793-3Report Type:Expedited (15-DaCompany Report #WAES 00065598
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apathy Feeling Hot Intentional Misuse	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	800-1000 MG	1 DAY
	Refusal Of Treatment By Patient Suicide Attempt Vomiting		Cyclosporin A Prednisone	C C				

Date:07/10/00ISR Number: 3526795-7Report Type:Expedited (15-DaCompany Report #WAES 00065129
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/00ISR Number: 3526796-9Report Type:Expedited (15-DaCompany Report #WAES 00051680
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/00ISR Number: 3526798-2Report Type:Expedited (15-DaCompany Report #WAES 00051120
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization -	Cardiac Arrest Chest Pain Dyspepsia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
Initial or Prolonged	Hypertension	Representative					/DAILY/PO	
	Infarction		Ogen	C				
	Myocardial Infarction		Provera	C				
	Ventricular Fibrillation		Aspirin	C				
			Atenolol	C				
			Hydrochlorothiazide	C				

Date:07/10/00ISR Number: 3526842-2Report Type:Expedited (15-DaCompany Report #A021140
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Foreign	Zoloft	PS	Pfizer			
Initial or Prolonged	Confusional State	Health			Pharmaceuticals Inc	ORAL	50 MG	
		Professional					TOTAL:DAILY:O	
		Other					RAL	
			Clorazepate Dipotassium	SS		ORAL	5.00 MG	

TOTAL:DAILY:O

RAL

Rofecoxib SS ORAL

12.00 MG

TOTAL:DAILY:O

RAL

Haloperidol SS

Date:07/10/00ISR Number: 3526938-5Report Type:Expedited (15-DaCompany Report #WAES 00055041
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Arterial Thrombosis Deep Vein Thrombosis Haemorrhage Hypertension Myocardial Infarction Post Procedural Complication	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/00ISR Number: 3526978-6Report Type:Expedited (15-DaCompany Report #WAES 00064470
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Thyroiditis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:07/10/00ISR Number: 3526981-6Report Type:Expedited (15-DaCompany Report #WAES 00060341
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck Research			
	Congestive	Professional			Laboratories Div			
	Condition Aggravated	Company			Merck Co Inc	ORAL	12.5	
	Dyspnoea	Representative					MG/DAILY/PO	
	Left Ventricular Failure							
	Oedema							
	Pulmonary Oedema							
	Weight Increased							

Date:07/10/00ISR Number: 3527255-XReport Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Vioxx 50mg Merck	PS	Merck	ORAL	50MG ONCE PER	
	Joint Stiffness						ORAL	
	Joint Swelling		Celebrex 100mg					
	Oedema Peripheral		Pharmacia	SS	Pharmacia	ORAL	100MG ONCE	
	Pain						PER ORAL	
			Estratest	C				

Date:07/10/00ISR Number: 3527312-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Celebrex 100 Mg Po					

Initial or Prolonged	Condition Aggravated		Bid	PS		ORAL
PO 100MG BID						
	Pancreatitis		Vioxx 25 Mg Po Bid	SS		ORAL
PO 25 BID						
	Vomiting					

Date:07/10/00ISR Number: 3527408-0Report Type:Expedited (15-DaCompany Report #WAES 00064581
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
Hospitalization -	Angina Pectoris	Professional			Laboratories Div	
Initial or Prolonged	Asthenia	Company			Merck Co Inc	ORAL
25 MG/BID/PO						
	Chest Pain	Representative	Advil	C		
	Faeces Discoloured		Tylenol With Codeine			
	Gastric Ulcer		#3	C		
	Gastric Ulcer Haemorrhage		Ultram	C		
	Gastrointestinal					
	Haemorrhage					
	Haemoglobin Decreased					
	Malaise					

Date:07/10/00ISR Number: 3527409-2Report Type:Expedited (15-DaCompany Report #WAES 00053019
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Adhesions
Initial or Prolonged	Abdominal Pain

	Kidney Infection Nephrolithiasis Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Peritoneal Adhesions Renal Cyst	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
			K-Dur	C			
			Lasix	C			
			Lopressor	C			
			Plavix	C			
			Prilosec	C			
			Procardia	C			
			Ultram	C			
			Uni-Dur	C			
			Allopurinol	C			
			Meclizine	C			
			Nitroglycerin	C			

Date:07/10/00ISR Number: 3527411-0Report Type:Expedited (15-DaCompany Report #WAES 00060718
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Gastric Ulcer Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO
	Haemorrhage		Zocor	C			
			Aspirin	C			
			Isosorbide	C			
			Metoprolol	C			

Date:07/10/00ISR Number: 3527412-2Report Type:Expedited (15-DaCompany Report #WAES 00061211
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Haemorrhage							
	Haemoglobinaemia							
	Hyperhidrosis							
	Rectal Haemorrhage							

Date:07/10/00ISR Number: 3579760-8Report Type:Periodic Company Report #USA013495
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Meridia	PS	Knoll Pharmaceutical Co Sub Basf Corp	ORAL	10 MG OD PO	
	Diarrhoea	Other						
	Insomnia		Vioxx	SS		ORAL	25 MG BID PO	
	Myalgia		Synthroid	C				
			Evista	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/00ISR Number: 3580989-3Report Type:Periodic Company Report #USA013334
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Meridia	PS	Knoll Pharmaceutical Co Sub Basf Corp			
	Decreased Appetite	Other						
	Dry Mouth		Generic Robitussin D	SS				
	Haemorrhoids		Pro-Image	SS				
	Headache		Allegra	SS				
	Increased Appetite		Sudafed	SS				
	Insomnia		Benadryl	SS				
	Nausea		Cardizem	SS				
	Pain In Extremity		Aspirin	SS		ORAL	TAB UNK PO	
			Motrin	SS				
			Aleve	SS				
			Vioxx	SS				
			Naproxen	SS		ORAL	TAB UNK PO	
			Darvocet-N	SS				
			Vicodin	SS				
			Baclofen	SS		ORAL	TAB UNK PO	
			Phernilin-Forte (50/650 Mg)	SS		ORAL	TAB UNK PO	

Date:07/11/00ISR Number: 3526785-4Report Type:Expedited (15-DaCompany Report #WAES 00065218
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Diarrhoea	Other						
	Gastrointestinal							
	Haemorrhage		Acetaminophen	C				
	Haemoglobin Decreased		Aspirin	C				
	Melaena		Atenolol	C				
	Polyp		Diltiazem	C				
	Rectal Haemorrhage		Lidocaine(+)Methlpre dnisolone -21 Acet	C				
			Misoprostol	C				
			Naproxen	C				

Date:07/12/00ISR Number: 3527516-4Report Type:Expedited (15-DaCompany Report #C2000-0796.02
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Furosemide	PS	Mylan Pharmaceuticals Inc			
Other	Drug Interaction	Other	Vioxx Merck	SS				

Date:07/12/00ISR Number: 3527518-8Report Type:Expedited (15-DaCompany Report #C2000-0796.01
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Furosemide	PS	Mylan Pharmaceuticals Inc			
Other	Drug Interaction	Other	Vioxx Merck	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/00ISR Number: 3527546-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated		Vioxx Tablets	PS	Merck			
	Dermatitis							
	Joint Swelling							
	Oedema Peripheral							

Date:07/12/00ISR Number: 3527564-4Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Polyneuropathy		Vioxx	PS	Merck			

Date:07/12/00ISR Number: 3527929-0Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Coumadin 5mg	PS		ORAL	5MG QD ORAL	
Initial or Prolonged	Gastrointestinal		Vioxx 25mg	SS		ORAL	25MG QD ORAL	
	Haemorrhage							

Date:07/12/00ISR Number: 3527957-5Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Haemorrhage		Coumadin 4mg Endo	PS	Endo	ORAL	4 MG ORAL	
Hospitalization -			Vioxx 50mg Merck	SS	Merck	ORAL	50 MG ORAL	
Initial or Prolonged			Aspirin	C				
Required			Atenolol	C				
Intervention to								
Prevent Permanent								

Impairment/Damage

Date:07/12/00ISR Number: 3528236-2Report Type:Expedited (15-DaCompany Report #WAES 00068614
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY
	Cardiac Arrest							
	Hyperkalaemia		Citalopram	C				
	Nausea		Digoxin	C				
	Sudden Death		Enalapril Maleate	C				
			Furosemide	C				
			Nitroglycerin	C				
			Omeprazole	C				
			Semi-Synthetic Human Insulin	C				
			Spironolactone	C				
			Sulfamethoxazole/Trimethoprim	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/00ISR Number: 3528237-4Report Type:Expedited (15-DaCompany Report #WAES 00065211
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Gastrointestinal Haemorrhage	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5- 25 MG PO	4 DAY
			Digoxin	C				
			Ibuprofen	C				
			Misoprostol	C				
			Warfarin	C				

Date:07/12/00ISR Number: 3528327-6Report Type:Expedited (15-DaCompany Report #WAES 00070647
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY; PO	
			Hydroxychloroquine	C				

Date:07/12/00ISR Number: 3578105-7Report Type:Periodic Company Report #WAES 00040278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/12/00ISR Number: 3578106-9Report Type:Periodic Company Report #WAES 00041932
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Drug Ineffective					
	Oedema Peripheral				Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Cardura	C		
			Atenolol	C		

Date:07/13/00ISR Number: 3528894-2Report Type:Expedited (15-DaCompany Report #WAES 00075005
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Myocardial Infarction	Other				
					Merck Co Inc	ORAL
12.5 MG PO 7 DAY						
			Amitriptyline	C		
			Aspirin	C		
			Captopril	C		
			Diazepam	C		
			Furosemide	C		
			Isosorbide-5-Mononitrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/00ISR Number: 3528896-6Report Type:Expedited (15-DaCompany Report #WAES 00075507
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Study Health Professional	Vioxx Aesculus Celiprolol Hcl Magnesium Preparation Nisoldipine	PS C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	15 DAY

Date:07/13/00ISR Number: 3528898-XReport Type:Expedited (15-DaCompany Report #WAES 00075026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Psychosis	Foreign Other	Vioxx Acetaminophen/Codein e Phosphate Amitriptyline Diazepam Etidronic Acid Dina Lansoprazole	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	30 DAY

Date:07/13/00ISR Number: 3528906-6Report Type:Expedited (15-DaCompany Report #WAES 00069777
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Vioxx Furosemide	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:07/13/00ISR Number: 3528912-1Report Type:Expedited (15-DaCompany Report #WAES 00063738
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
	Epilepsy	Health Professional						
	Subdural Haematoma							

Date:07/13/00ISR Number: 3528950-9Report Type:Expedited (15-DaCompany Report #WAES 00069111
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	47 DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer	Other						
	Gastrointestinal							
	Haemorrhage		Cap Aspirin	SS		ORAL	300 MG PO	130 DAY
	Haematemesis		Prinivil	C				
	Haematocrit Decreased		Acarbose	C				
	Haemoglobin Decreased		Pygeum African Extract	C				
	Melaena		Ranitidine	C				
			Terazosin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/00ISR Number: 3529054-1Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS				
Required	Faeces Discoloured		Prednisone	SS			10 MG	
Intervention to	Gastrointestinal		Asa	SS			325 MG	
Prevent Permanent	Haemorrhage							
Impairment/Damage	Haematemesis							

Date:07/13/00ISR Number: 3529445-9Report Type:Expedited (15-DaCompany Report #B0083343A
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Foreign	Zinacef	PS	Glaxo Wellcome Inc		INTRAVENOUS	750 MG /
	Increased						THREE TIMES	
	Crystal Arthropathy						PER DAY	
	Oliguria						INTREAVENOUS	
	Renal Failure		Rofecoxib Tablet					
	Synovitis		(Rofecoxib)	SS		ORAL	PER DAY /	
	Thrombocytopenia						ORAL	
			Paracetamol	C				
			Behepan	C				
			Oxazepam	C				
			Dextropropoxyphene Napsyl	C				
			Calcium Carbonate	C				
			Omeprazole	C				

Date:07/13/00ISR Number: 3529579-9Report Type:Expedited (15-DaCompany Report #WAES 00070076
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:07/13/00ISR Number: 3529584-2Report Type:Expedited (15-DaCompany Report #WAES 00070005
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Oxycontin	C				

Date:07/13/00ISR Number: 3529586-6Report Type:Expedited (15-DaCompany Report #WAES 00070047
Age:94 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Disability	Asthenia							
	Cystitis							
	Difficulty In Walking							
	Oesophageal Ulcer		Nitro-Dur	C				
	Haemorrhage		Norvasc	C				
	Pneumonia		Ticlid	C				

Aspirin	C	
Atenolol	C	
Docusate Calcium	C	

Date:07/13/00ISR Number: 3529588-XReport Type:Expedited (15-DaCompany Report #WAES 00064288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Restlessness Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:07/13/00ISR Number: 3529589-1Report Type:Expedited (15-DaCompany Report #WAES 00064505
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Discomfort Abdominal Pain Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Arthritis		Tab Propulsid 10 Mg	SS		ORAL	40 MG/DAILY/PO	
	Back Pain							
	Bone Disorder		Tab Zoloft	SS		ORAL	1 TABLET/DAILY/	
	Bronchitis							
	Burning Sensation						PO	
	Bursitis		Darvocet-N	SS				
	Chest Pain		Cipro	SS				
	Dry Mouth		Ambien	C				
	Dyspnoea		Ativan	C				
	Electrocardiogram		Celebrex	C				
	Abnormal		Claritin	C				
	Feeling Cold		Daypro	C				
	Gait Disturbance		Evista	C				
	Gastrointestinal Disorder		Nasacort Aq	C				
	Hypercholesterolaemia		Prevacid	C				

	Hypersensitivity	Synthroid	C
	Hypertonia	Tylenol With Codeine	C
	Hypoaesthesia	Vicodin Tablets	C
	Insomnia	Cefazolin	C
	Lung Disorder	Lidocaine	C
	Musculoskeletal Stiffness	Trazodone	C
	Nausea	Vitamins	C
	Pain In Extremity		
	Palpitations		
	Paraesthesia		
	Pyrexia		
	Rash Maculo-Papular		
	Scoliosis		
	Tenderness		
	Tremor		
	Urinary Retention		
	Urinary Tract Infection		

Date:07/13/00ISR Number: 3529590-8Report Type:Expedited (15-DaCompany Report #WAES 00064678
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Other	Renal Failure	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Flomax (Niflumic Acid (Beta)-Mor	C		
			Monopril	C		
			Percocet	C		

Date:07/14/00ISR Number: 3529940-2Report Type:Expedited (15-DaCompany Report #WAES 00077505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Haematemesis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
2 WK						
	Haemoglobin Decreased					
	Oesophageal Ulcer					
	Oesophagitis		Aspirin	C		
	Upper Gastrointestinal Haemorrhage					

Date:07/14/00ISR Number: 3529948-7Report Type:Expedited (15-DaCompany Report #WAES 00076031
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY	1 MON					
	Duodenal Ulcer					
	Haemorrhage					
	Faeces Discoloured					
	Haemoglobin Decreased					

Date:07/14/00ISR Number: 3529950-5Report Type:Expedited (15-DaCompany Report #WAES 00076024
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine Phosphokinase Increased Difficulty In Walking Muscle Spasms	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	3 DAY

Date:07/14/00ISR Number: 3529952-9Report Type:Expedited (15-DaCompany Report #WAES 00075007
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	15 DAY
			Zocor	C				
			Atenolol	C				
			Enalapril	C				
			Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/00ISR Number: 3529954-2Report Type:Expedited (15-DaCompany Report #WAES 00065286
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Subarachnoid Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	36 DAY
			Fluoxetine	C				
			Lansoprazole	C				

Date:07/14/00ISR Number: 3530012-1Report Type:Expedited (15-DaCompany Report #WAES 00032061
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	No Adverse Drug Effect	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/14/00ISR Number: 3530014-5Report Type:Expedited (15-DaCompany Report #WAES 00042066
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Atrial Fibrillation							
	Dermatitis							
	Haematuria							
	Haemorrhage		Inderal	C				
	Heart Rate Decreased							
	Pneumonia							
	Sick Sinus Syndrome							

Date:07/14/00ISR Number: 3530017-0Report Type:Expedited (15-DaCompany Report #WAES 00050750
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Decreased Activity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Difficulty In Walking							
	Dry Mouth							
	Insomnia							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain							
	Saliva Altered							
	Tongue Disorder							

Date:07/14/00ISR Number: 3530020-0Report Type:Expedited (15-DaCompany Report #WAES 00051011
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Full Blood Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
Hospitalization - Initial or Prolonged	Rectal Haemorrhage							
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/00ISR Number: 3530023-6Report Type:Expedited (15-DaCompany Report #WAES 00052353
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Abdominal Pain Upper							
	Liver Tenderness							
	Malaise							
	Pain							
	Vomiting							

Date:07/14/00ISR Number: 3530025-XReport Type:Expedited (15-DaCompany Report #WAES 00050833
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Asthenia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Cardiomegaly							
	Cerebrovascular Accident							
	Clumsiness		Vioxx 25 Mg	SS		ORAL	25 MG DAILY	PO
	Hemiparesis							
	Hypertension		Carduca	C				
	Hypoaesthesia		Proscar	C				
	Transient Ischaemic Attack							

Date:07/14/00ISR Number: 3530058-3Report Type:Expedited (15-DaCompany Report #WAES 00065098
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hallucination	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Acetaminophen/Codeine Phosphate	C				
			Lansoprazole	C				

Date:07/14/00ISR Number: 3530059-5Report Type:Expedited (15-DaCompany Report #WAES 00068508
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Unevaluable Event	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:07/14/00ISR Number: 3530060-1Report Type:Expedited (15-DaCompany Report #WAES 99110375
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram St Segment Abnormal	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			
Other	Palpitations	Health			Merck Co Inc	ORAL	25 MG PO	38 DAY
	Pyrexia	Professional	Bucillamine	C				
			Gefarnate	C				
			Prednisolone	C				
			Tiopronin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/00ISR Number: 3530072-8Report Type:Expedited (15-DaCompany Report #WAES 00069788
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Anaemia Gastritis Erosive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
	Melaena		Tab Aspirin	SS		ORAL	100 MG PO	9 DAY
			Composition Unspecified	C				

Date:07/14/00ISR Number: 3530073-XReport Type:Expedited (15-DaCompany Report #WAES 00067522
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Diclofenac Na	C				

Date:07/14/00ISR Number: 3530074-1Report Type:Expedited (15-DaCompany Report #WAES 00067831
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY
	Melaena		Tab Aspirin	SS		ORAL	PO	
			Aspirin/Dipyridamole	C				

Date:07/14/00ISR Number: 3530075-3Report Type:Expedited (15-DaCompany Report #WAES 00068568
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	15 DAY
Disability			Betaxolol Hcl	C				

Date:07/14/00ISR Number: 3530076-5Report Type:Expedited (15-DaCompany Report #WAES 00075536
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/14/00ISR Number: 3530077-7Report Type:Expedited (15-DaCompany Report #WAES 00075533
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	86 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/00ISR Number: 3530078-9Report Type:Expedited (15-DaCompany Report #WAES 00073708
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL		
25 MG, PO							2	DAY
			Ca Acetylsalicylate	C				
			Hyzaar	C				
			Diclofenac Sodium					
			(+) Misoprostol	C				

Date:07/14/00ISR Number: 3530079-0Report Type:Expedited (15-DaCompany Report #WAES 00073709
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Dizziness	Other			Laboratories Div			
					Merck Co Inc	ORAL		
25 MG, PO							1	DAY
			Amoxicillin	C				
			Calcium Carbonate	C				
			Venlafaxine Hcl	C				

Date:07/14/00ISR Number: 3530080-7Report Type:Expedited (15-DaCompany Report #WAES 00075039
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Atrophic	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Melaena	Other			Laboratories Div			
					Merck Co Inc	ORAL		
25 MG PO								
			Alprazolam	C				
			Carbidopa/Levodopa	C				
			Iron (Unspecified)	C				
			Lactulose	C				
			Ranitidne Hc1	C				
			Tramadol Hc1	C				
			Zaleplon	C				

Date:07/14/00ISR Number: 3530115-1Report Type:Expedited (15-DaCompany Report #WAES 00070473
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Pharyngeal Oedema				Laboratories Div			
Initial or Prolonged	Urticaria				Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Acular	C				
			Synthroid	C				
			Nortriptyline	C				

Date:07/14/00ISR Number: 3530116-3Report Type:Expedited (15-DaCompany Report #WAES 00070425
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dialysis	Professional			Laboratories Div			
Initial or Prolonged	Hyperkalaemia	Company			Merck Co Inc	ORAL	25	
	Renal Failure Acute	Representative					MG/DAILY/PO	

Avandia	C
Cardizem Cd	C
Demadex	C
K-Dur	C
Mysoline	C
Zaroxolyn	C
Allopurinol	C
Hydrocodone	C

Date:07/14/00ISR Number: 3530117-5Report Type:Expedited (15-DaCompany Report #WAES 00070448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia Faeces Pale Gastrointestinal Disorder Liver Disorder White Blood Cell Count Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/14/00ISR Number: 3530122-9Report Type:Expedited (15-DaCompany Report #WAES 00070216
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/14/00ISR Number: 3530123-0Report Type:Expedited (15-DaCompany Report #WAES 00070285
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Abnormal Cardiac Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Congestive Merck Co Inc ORAL
25
Drug Effect Decreased
MG/DAILY/PO
Renal Failure
(SEE IMAGE)

Hytrin	C
Atenolol	C

Date:07/14/00ISR Number: 3530124-2Report Type:Expedited (15-DaCompany Report #WAES 00060170
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Coma
Hospitalization - Initial or Prolonged	Decreased Activity
Other	Ecchymosis
	Eyelid Oedema
	Face Oedema
	Facial Bones Fracture
	Fall
	Haemorrhage
	Idiopathic Thrombocytopenic Purpura
	Injury
	Loss Of Consciousness

		Myocardial Infarction					
		Oral Intake Reduced					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pancytopenia	Health	Vioxx	PS	Merck Research	
		Red Blood Cell	Professional			Laboratories Div	
		Abnormality	Other			Merck Co Inc	ORAL
25							
		Swelling					
MG/DAILY/PO							
		Syncope		Accupril	C		
		Systemic Lupus		Coumadin	C		
		Erythematosus		Darvocet-N	C		
				Atenolol	C		

Date:07/14/00ISR Number: 3530125-4Report Type:Expedited (15-DaCompany Report #WAES 00061047
Age:66 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Activated Partial	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Thromboplastin Time	Professional			Laboratories Div	
		Prolonged	Other			Merck Co Inc	ORAL
25							
		Asthenia					
MG/DAILY/PO							
		Blood Fibrinogen		Aspirin	SS		ORAL
81							
		Increased					
MG/DAILY/PO							
		Condition Aggravated		Amaryl	C		
		Diabetes Mellitus		Humulin N	C		
		Inadequate Control		Lasix	C		
		Dyspnoea Exertional		Neurontin	C		
		Erythropenia		Prilosec	C		
		Gastrointestinal		Proventil	C		
		Haemorrhage		Vasotec	C		
		Haematemesis		Therapy Unspecified	C		
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Iron Deficiency Anaemia					
		Lethargy					
		Oedema Peripheral					
		Prothrombin Time					
		Prolonged					

Rectal Haemorrhage
Tachycardia
Thrombocythaemia

Date:07/14/00ISR Number: 3530128-XReport Type:Expedited (15-DaCompany Report #WAES 00061044
Age:33 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anaphylactic Reaction
	Anxiety
	Bronchospasm
	Dizziness
	Dysphagia
	Dyspnoea
	Emotional Distress
	Erythema
	Heart Rate Increased
	Hypoaesthesia
	Hypotension
	Loss Of Consciousness
	Pallor
	Paraesthesia

	Pruritus						
	Pyrexia						
	Stridor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Syncope	Health	Vioxx	PS	Merck Research		
	Tachypnoea	Professional			Laboratories Div		
		Other			Merck Co Inc	ORAL	PO
			Skelaxin	C			
			Vicodin	C			
			Zyrtec	C			
			Therapy Unspecified	C			

Date:07/14/00ISR Number: 3530202-8Report Type:Expedited (15-DaCompany Report #A021953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Discomfort	Health	Zoloft	PS	Pfizer		
Initial or Prolonged	Abdominal Pain Upper	Professional			Pharmaceuticals Inc	ORAL	DAILY:ORAL
Required	Back Pain		Propulsid	SS		ORAL	40.00 MG
Intervention to	Burning Sensation						TOTAL:DAILY:O
Prevent Permanent	Bursitis						RAL
Impairment/Damage	Chest Pain		Vioxx	SS			
	Chest X-Ray Abnormal		Darvocet	SS			
	Condition Aggravated		Evista	C			
	Dry Mouth		Claritin	C			
	Dyspnoea		Synthroid	C			
	Electrocardiogram Qrs		Prevacid	C			
	Complex Abnormal		Nasacort Aq	C			
	Electrocardiogram Qt		Vitamins	C			
	Prolonged		Celebrex	C			
	Feeling Cold		Daypro	C			
	Gait Disturbance		Ambien	C			
	Hypercholesterolaemia		Tylenol With Codeine	C			
	Hypersensitivity		Trazodone	C			
	Hypoaesthesia		Cefazolin	C			
	Infection		Ativan	C			
	Insomnia		Vicodin	C			
	Intervertebral Disc		Lidogel	C			
	Degeneration		Cipro	C			

Musculoskeletal Stiffness
Nausea
Osteoarthritis
Pain In Extremity
Palpitations
Paraesthesia
Pyrexia
Rash Maculo-Papular
Scoliosis
Tenderness
Tremor
Urinary Retention

Date:07/17/00ISR Number: 3529849-4Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health	Vioxx	PS		ORAL	12.5 MG PO QD	
	Gastric Ulcer	Professional	Aspirin	SS		ORAL	81 MG PO QD	
	Gastrointestinal Haemorrhage							

Date:07/17/00ISR Number: 3529878-0Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx 25mg	PS		ORAL	25MG DLY PO	
Required Intervention to Prevent Permanent Impairment/Damage	Decreased Appetite							
	Dermatitis							
	Dysphagia							
	Erythema Multiforme							
	Furuncle							
	Hypersensitivity							
	Influenza Like Illness							
	Joint Swelling							
	Optic Neuritis							
	Oral Pain							
	Pharyngolaryngeal Pain							
	Pyrexia							
	Scar							
	Tongue Oedema							
	Uveitis							
	Vision Blurred							
	Visual Disturbance							

Date:07/17/00ISR Number: 3530302-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Potassium Increased		Vioxx	PS			12.5 QD	

Renal Failure Acute	Isordil	C
	Ntg	C
	Digoxin	C
	Captopril	C
	Lasix	C
	Lipitor	C
	Prevacid	C
	Insulin	C
	Prednisone	C
	Cellcept	C
	...	C
	Tacrolimus	C
	Calcitonin	C
	Calcium/Vit D	C
	Magnesium	C
	Thiamine	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/00ISR Number: 3530917-1Report Type:Expedited (15-DaCompany Report #WAES 00040784
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burn Oesophageal	Consumer	Vioxx	PS	Merck Research			
	Dyspepsia	Health			Laboratories Div			
	Eye Irritation	Professional			Merck Co Inc	ORAL	12.5	
	Headache						MG/DAILY/PO	
	Keratoconjunctivitis		Elavil	C				
	Sicca		Prilosec	C				
	Nausea		Verelan	C				
			Xanax	C				
			B Vitamins	C				
			Calcium Supplement					
			(Composition	C				
			Vitamin E	C				

Date:07/17/00ISR Number: 3530919-5Report Type:Expedited (15-DaCompany Report #WAES 00032730
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Sclerosis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Aortic Valve Stenosis	Professional			Laboratories Div			
Initial or Prolonged	Arterial Disorder	Company			Merck Co Inc	ORAL	25	
Other	Blood Pressure Systolic	Representative					MG/DAILY/PO	
	Increased		Ditropan	C				
	Blood Urea Increased		Fibercon	C				
	Bronchitis		Hyzaar	C				
	Cardiac Murmur		Norvasc	C				
	Diarrhoea		Premarin	C				
	Diverticulum Intestinal		Tylenol Pm	C				
	Dyspnoea		Zocor	C				
	Enzyme Abnormality		Aspirin	C				
	Failure Of Implant							
	Frequent Bowel Movements							
	Gait Disturbance							
	Gastric Ulcer							
	Gastric Ulcer Haemorrhage							
	Gastritis Erosive							

Gastrointestinal Disorder
Gastrointestinal
Haemorrhage
Haematochezia
Haematocrit Decreased
Haematuria
Hypertension
Klebsiella Infection
Lung Infiltration
Oedema
Osteoarthritis
Pneumonitis
Prothrombin Time
Prolonged
Pyrexia
Rectal Haemorrhage
Respiratory Rate
Increased
Urinary Incontinence
Urinary Tract Infection
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/00ISR Number: 3530923-7Report Type:Expedited (15-DaCompany Report #WAES 00051197
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Cardiac Failure							
	Chest Pain							
	Dizziness	Representative	Tab Vioxx 25 Mg	C		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Hyperhidrosis		Buspar	C				
	Nausea		Depakote	C				
	Red Blood Cell Sedimentation Rate Increased		Imdur	C				
			Lanoxin	C				
			Lipitor	C				
	Renal Failure		Neurontin	C				
			Niaspan	C				
			Remeron	C				
			Tricor	C				
			Zestril	C				
			Aspirin	C				
			Atenolol	C				
			Furosemide	C				
			Nitroglycerin	C				
			Vitamin E	C				
			Vitamins	C				

Date:07/17/00ISR Number: 3530936-5Report Type:Expedited (15-DaCompany Report #WAES 99090928
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG / DAILY/ PO	
	Blood Thyroid Stimulating Hormone Increased							
	Cardiomyopathy							
	Dyspnoea		Tab Acetaminophen 325 Mg	C		ORAL	UNK, PRN/ PO	
	Dyspnoea Exertional							
	Echocardiogram Abnormal		Sulfasalazine	C				

Ejection Fraction
Abnormal
Fatigue
Sinus Tachycardia

Date:07/17/00ISR Number: 3530938-9Report Type:Expedited (15-DaCompany Report #WAES 00063235
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoimmune Hepatitis Dermatitis Epistaxis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
	Haematemesis Hepatitis Mouth Haemorrhage Rash Macular Sedation		Prevacid	C				

Date:07/17/00ISR Number: 3530939-0Report Type:Expedited (15-DaCompany Report #WAES 00070472
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Acular	C				
			Ecotrin	C				
			Synthroid	C				
			Nortriptyline	C				

Date:07/17/00ISR Number: 3530948-1Report Type:Expedited (15-DaCompany Report #WAES 00065611
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Haemorrhage Intracranial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	1 DAY
			Albuterol	C				
			Eucalyptus Oil	C				
			Menthol	C				
			Oil Of Juniper	C				

Date:07/17/00ISR Number: 3530974-2Report Type:Expedited (15-DaCompany Report #WAES 00075046
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Paroxetine	C				
			Quinineso4	C				
			Thyroxine	C				

Date:07/17/00ISR Number: 3530986-9Report Type:Expedited (15-DaCompany Report #WAES 00070547
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Cumadin	C				

Date:07/17/00ISR Number: 3530987-0Report Type:Expedited (15-DaCompany Report #WAES 00079113
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 DAY
	Gastroenteritis	Other						
	Hyperhidrosis							
	Sweat Gland Disorder							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/00ISR Number: 3584092-8Report Type:Periodic Company Report #000615-SK588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Company	Celebrex	PS	Gd Searle And Co	ORAL	PO	
		Representative	Vioxx	SS		ORAL	PO	

Date:07/17/00ISR Number: 3584278-2Report Type:Periodic Company Report #000522-SK523
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	100.000 MG	BID PO
			Vioxx	SS		ORAL	PO	

Date:07/17/00ISR Number: 3584416-1Report Type:Periodic Company Report #000630-SK714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Company	Celebrex	PS	Gd Searle And Co	ORAL	PO	
		Representative	Vioxx	SS		ORAL	PO	

Date:07/17/00ISR Number: 3584840-7Report Type:Periodic Company Report #000511-SK338
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG	BID PO
		Health						

			Professional	Vioxx	SS		ORAL
PO							

Date:07/17/00ISR Number: 3584926-7Report Type:Periodic Company Report #000509-SK921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	100.000 MG	
							BID PO	
			Vioxx	SS		ORAL		
PO								

Date:07/18/00ISR Number: 3531363-7Report Type:Expedited (15-DaCompany Report #WAES 00062970
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Drug Withdrawal Syndrome	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	25	
	Pneumonia Viral						MG/DAILY/PO	
	Tremor							

Date:07/18/00ISR Number: 3531365-0Report Type:Expedited (15-DaCompany Report #WAES 00063246
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
	Skin Discolouration	Company			Merck Co Inc	ORAL	25	
	Thrombocytopenia	Representative					MG/DAILY/PO	

			Digoxin	C		
			Lisinopril	C		
			Spironolactone	C		

Date:07/18/00ISR Number: 3531368-6Report Type:Expedited (15-DaCompany Report #WAES 00070005
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Amylase Increased Lipase Increased Pancreatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2MG/DAILY/PO	
		Representative	Oxycontin	SS			6	WK

Date:07/19/00ISR Number: 3531234-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg	PS		ORAL	1 TAB PO QD	5 MON

Date:07/19/00ISR Number: 3531725-8Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Tachycardia		Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG DAILY ORAL	
			Tylenol Arthritis	C				
			Ca Citrate	C				
			Vit D	C				

Date:07/19/00ISR Number: 3532194-4Report Type:Expedited (15-DaCompany Report #WAES 00070408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Surgery	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:07/19/00ISR Number: 3532195-6Report Type:Expedited (15-DaCompany Report #WAES 00070398
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolytic Anaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:07/19/00ISR Number: 3532196-8Report Type:Expedited (15-DaCompany Report #WAES 00070561
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/00ISR Number: 3532230-5Report Type:Expedited (15-DaCompany Report #WAES 00070717
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis Atopic							
	Dermatitis Contact							
	Hypoaesthesia							
	Motor Dysfunction							
	Muscular Weakness							
	Musculoskeletal Pain							
	Nervous System Disorder							
	Rash Vesicular							
	Red Blood Cell Sedimentation Rate Increased							
	Sensory Disturbance							

Date:07/19/00ISR Number: 3532231-7Report Type:Expedited (15-DaCompany Report #WAES 00060177
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
	Gastroenteritis							
	Helicobacter Gastrointestinal Haemorrhage	Other						
	Melaena		Synthroid	C				
	Vomiting		Tylenol	C				

Date:07/19/00ISR Number: 3532232-9Report Type:Expedited (15-DaCompany Report #WAES 00061916
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			
	Dyspnoea							

	Productive Cough	Professional			Merck Co Inc	ORAL
UNK / UNK /						
	Sputum Abnormal					
PO						
	Sputum Discoloured		Ecotrin	C		
			Glucophage	C		
			Hyzaar	C		
			Propulsid	C		
			Trental	C		
			Atenolol	C		
			Insulin Injection	C		
			Potassium Chloride	C		
			Vitamin E	C		
			Vitamins	C		

Date:07/19/00ISR Number: 3532372-4Report Type:Expedited (15-DaCompany Report #WAES 00079115
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Chest Pain	Foreign	Vioxx	PS	Merck Research	
	Hypertension	Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG PO 3 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/00ISR Number: 3532374-8Report Type:Expedited (15-DaCompany Report #WAES 00079116
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctivitis Constipation Oliguria Rhinitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY

Date:07/19/00ISR Number: 3532376-1Report Type:Expedited (15-DaCompany Report #WAES 00079117
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	10 DAY
			Omeprazole	C				

Date:07/19/00ISR Number: 3532383-9Report Type:Expedited (15-DaCompany Report #WAES 00075093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:07/19/00ISR Number: 3532388-8Report Type:Expedited (15-DaCompany Report #WAES 00059140
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Blood Pressure Fluctuation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Hypertensive Crisis				Merck Co Inc	ORAL
25 MG PO 7 DAY						
	Transient Ischaemic Attack		Arginine	C		
			Atorvastatin	C		
			Cyproheptadine	C		
			Omeprazole	C		

Date:07/19/00ISR Number: 3532412-2Report Type:Expedited (15-DaCompany Report #WAES 00075547
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO						

Date:07/19/00ISR Number: 3532413-4Report Type:Expedited (15-DaCompany Report #WAES 00068530
Age:61 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Diarrhoea
	Gastritis
	Gastrointestinal Disorder
	Gastrointestinal

	Haemorrhage Haemoglobin Decreased Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG, PO
			Vasotec	C			

Date:07/19/00ISR Number: 3532414-6Report Type:Expedited (15-DaCompany Report #WAES 00079114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Rash Maculo-Papular Rash Morbilliform	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO 1 DAY
			Amiloride Hydrochloride	C			
			Aspirin	C			
			Bromazepam	C			
			Captopril	C			
			Digoxin	C			

Date:07/19/00ISR Number: 3532415-8Report Type:Expedited (15-DaCompany Report #WAES 00075548
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:07/19/00ISR Number: 3532476-6Report Type:Expedited (15-DaCompany Report #WAES 00033224
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Disability	Arthralgia	Health	Vioxx	PS	Merck Research	
	Haemarthrosis	Professional			Laboratories Div	
	Haematoma	Company			Merck Co Inc	ORAL
25 MG/5XD/PO;						
	Haemorrhage	Representative				
50						
	International Normalised					
MG/DAILY/PO;						
	Ratio Increased					
25						
	Movement Disorder					
MG/DAILY/PO						
	Prothrombin Time		Cardizem	C		
	Prolonged		Coumadin	C		
			Daypro	C		
			Paxil	C		
			Pravachol	C		

Date:07/19/00ISR Number: 3532571-1Report Type:Expedited (15-DaCompany Report #WAES 00061688
Age:70 YR Gender:Male I/FU:I

Outcome	PT
Death	Ascites
Life-Threatening	Cardiac Failure
Hospitalization -	Congestive
Initial or Prolonged	Dyspnoea
Disability	Hepatic Failure
	Hepatitis

	Oedema Peripheral Pleural Effusion Respiratory Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MGDAILY/PO
			Combivent	C			
			Allopurinol	C			

Date:07/19/00ISR Number: 3532981-2Report Type:Expedited (15-DaCompany Report #WAES 00032291
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO
			[Therapy Unspecified]	C			
			Aspirin	C			

Date:07/19/00ISR Number: 3532982-4Report Type:Expedited (15-DaCompany Report #WAES 00060331
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			[Therapy Unspecified]	C			

Date:07/19/00ISR Number: 3532983-6Report Type:Expedited (15-DaCompany Report #WAES 00060170
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Health	Vioxx	PS	Merck Research			
Hospitalization -	Decreased Activity	Professional			Laboratories Div			
Initial or Prolonged	Facial Bones Fracture	Other			Merck Co Inc	ORAL	25	
Other	Fall						MG/DAILY/PO	
	Haemorrhage		Accupril	C				
	Idiopathic		Coumadin	C				
	Thrombocytopenic Purpura		Darvocet-N	C				
	Injury		Atenolol	C				
	Oral Intake Reduced							
	Pain							
	Pancytopenia							
	Swelling							
	Syncope							
	Systemic Lupus Erythematosus							

Date:07/19/00ISR Number: 3532984-8Report Type:Expedited (15-DaCompany Report #WAES 00051193
Age:82 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Gastric Ulcer Perforation Ileus Paralytic Post Procedural Complication X-Ray Gastrointestinal Tract Abnormal	Health Professional Company Representative	Vioxx Miacalcin Os-Cal	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:07/19/00ISR Number: 3532985-XReport Type:Expedited (15-DaCompany Report #WAES 00062197
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angiopathy Deep Vein Thrombosis Oedema Peripheral Tenderness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:07/19/00ISR Number: 3532986-1Report Type:Expedited (15-DaCompany Report #WAES 00061647
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Chloride Decreased Dementia Hyponatraemia Paranoia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, 25 MG/DAILY/PO	
			Ginkogin Glucophage L-Thyroxine Premarin Zestoretic Glyburide Ranitidine	C C C C C C C				

				Riboflavine	C		

Date:07/19/00ISR Number: 3532987-3Report Type:Expedited (15-DaCompany Report #WAES 00064750
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse Confusional State Cyanosis Dizziness	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ibuprofen	C				

Date:07/19/00ISR Number: 3532988-5Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Disorder Headache Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				

Deltasone	C
K-Dur	C
Lasix	C
Plavix	C
Alprazolam	C
Atenolol	C
Captopril	C
Carbidopa (+)	
Levodopa	C
Clonazepam	C
Ibuprofen	C

Date:07/20/00ISR Number: 3532273-1Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS		ORAL	25MG PO QD	
	Oliguria		Glucophage	C				
			Delavil	C				
			Lasix	C				
			Glyburide	C				
			Elavil	C				
			Adalat	C				

Date:07/20/00ISR Number: 3532283-4Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Magnesium Decreased		Celebrex Caps- 100					
Hospitalization -	Choking		Mg- 2 Capsules Daily					
Initial or Prolonged	Cough		Merck-Medco Rx	PS	Merck-Medco		1 CAPSULE 2 X	
Other	Discomfort						A DAY	
	Dry Throat		Vioxx Tablets-25mg					
	Dyspepsia		1tablet Daily	SS			1-TABLET WITH	
	Dysphagia						FOOD	
	Dyspnoea							

Face Oedema
Fear
Gastric Ulcer
Haemorrhage
Oesophageal Ulcer
Throat Tightness

Date:07/20/00ISR Number: 3532288-3Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anorexia		Vioxx 25mg (Samples					
	Fatigue		From Ofc)	PS		ORAL	1QD PO	
	Jaundice		Prednisone	C				
	Malaise		Zoloft	C				
	Vomiting		Tenormin	C				

Date:07/20/00ISR Number: 3532356-6Report Type:Direct Company Report #
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx 12.5mg Merck	PS	Merick	ORAL	12.5MG QD	
Initial or Prolonged	Abdominal Tenderness						ORAL	
	Haemoglobin Decreased		Aspirin 325mg	SS		ORAL	325MG QD ORAL	
	Listless		Reglan	C				
	Pallor		Glucotrol	C				
	Vomiting		Lopressor	C				
			Pepcid	C				

Date:07/20/00ISR Number: 3532428-6Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis		Vioxx (Rofecoxib) Tablets	PS	Merck & Co, Inc			

Date:07/20/00ISR Number: 3532429-8Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co, Inc			

Date:07/21/00ISR Number: 3533437-3Report Type:Expedited (15-DaCompany Report #WAES 00062970
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Convulsion	Health			Laboratories Div			
	Drug Withdrawal Syndrome	Professional			Merck Co Inc	ORAL	25	

Dyspnoea
MG/DAILY/PO
Pneumonia Viral Celebrex C

Date:07/21/00ISR Number: 3533439-7Report Type:Expedited (15-DaCompany Report #WAES 00063232
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vasotec	C				

Date:07/21/00ISR Number: 3533441-5Report Type:Expedited (15-DaCompany Report #WAES 00060341
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Condition Aggravated Dyspnoea Left Ventricular Failure Oedema Pulmonary Oedema Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/00ISR Number: 3533476-2Report Type:Expedited (15-DaCompany Report #WAES 00071072
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:07/21/00ISR Number: 3533478-6Report Type:Expedited (15-DaCompany Report #WAES 00062156
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Gastric Ulcer Perforation Peritonitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
Disability Other		Representative	Celebrex	C				
			Naprosyn	C				
			Aspirin	C				

Date:07/21/00ISR Number: 3533479-8Report Type:Expedited (15-DaCompany Report #WAES 00052243
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Abdominal Tenderness	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
Other	Asthenia	Representative					MG/DAILY/PO	
	Blood Pressure Systolic Increased		Buspar	C				
	Bundle Branch Block Left		Lanoxin	C				
	Cardiac Murmur		Lasix	C				
	Cardiomegaly		Tylenol With Codeine #3	C				
	Chest Pain		Zestril	C				
	Chest X-Ray Abnormal		Aspirin	C				

Decreased Appetite Discomfort Duodenal Ulcer Perforation Faecal Occult Blood Positive Gallop Rhythm Present Gastrointestinal Haemorrhage Gastrooesophageal Reflux Disease Hyperglycaemia Hypoproteinaemia Impaired Gastric Emptying Laboratory Test Abnormal Leukocytosis Pain Peritonitis Post Procedural Complication Rales Tachycardia Vomiting	Potassium Chloride	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/00ISR Number: 3533494-4Report Type:Expedited (15-DaCompany Report #WAES 00075102
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Epilepsy	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	93 DAY
			La-Hydroxycholecalciferol	C				
			Zocor	C				
			Albuterol Sulfate	C				
			Beclomethasone Dipropionate	C				
			Buprenorphine	C				
			Calcium Carbonate	C				
			Carbamazepine	C				
			Ethinyl Estradiol/Norgestrel	C				
			Lodoxamide Tromethamine	C				
			Omeprazole	C				
			Phenytoin Na	C				
			Pizotyline	C				
			Vitamin B Complex	C				

Date:07/21/00ISR Number: 3533496-8Report Type:Expedited (15-DaCompany Report #WAES 00079111
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
	Psoriasis Skin Lesion		Antihypertensive Nos	C				
			Other Drugs	C				

Date:07/21/00ISR Number: 3533498-1Report Type:Expedited (15-DaCompany Report #WAES 00078251
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Drug Interaction Duodenal Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	PO
	Fall Gastric Ulcer Gastrointestinal Haemorrhage Haemoglobin Decreased Injury Polyarthritis Skin Lesion Ulcer	Other	Prednisone	C				

Date:07/21/00ISR Number: 3533506-8Report Type:Expedited (15-DaCompany Report #WAES 00075541
Age:80 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Hepatic Function Abnormal Hyperammonaemia Liver Function Test

		Abnormal Prothrombin Time Shortened					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO							

Date:07/21/00ISR Number: 3533507-XReport Type:Expedited (15-DaCompany Report #WAES00077260
Age:87 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Circulatory Collapse Confusional State Haematoma	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	13 DAY						
		Orthostatic Hypotension Pharyngeal Oedema		Vasotec (Enalapril Maleate)	SS		ORAL
PO							
		Pharyngolaryngeal Pain Swelling Vomiting		Aspirin	C		
				Calcium Carbonate	C		
				Citalopram Hydrobromide	C		
				Dihydroergotamine Methanesulfonate	C		
				Furosemdie	C		
				Insulin Injection	C		
				Insulin Injection/Isophane Insulin Suspe	C		
				Lactulose	C		
				Prednisolone	C		

Date:07/21/00ISR Number: 3533603-7Report Type:Expedited (15-DaCompany Report #WAES 00056228
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Corneal Ulcer Eye Pain	Foreign Study	Vioxx	PS	Merck Research Laboratories Div	

	Keratitis Herpetic	Other			Merck Co Inc	ORAL
12.5 MG PO 15 DAY						
			Calcium Carbonate/Vitamin D	C		
			Cicletanine	C		
			Diacerein	C		
			Diclofenac	C		
			Pravastatin Na	C		

Date:07/21/00ISR Number: 3533639-6Report Type:Expedited (15-DaCompany Report #WAES 00078260
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG PO 30 DAY						
			Aspirin	C		
			Diclofenac Sodium (+) Misoprostol	C		

Date:07/21/00ISR Number: 3533644-XReport Type:Expedited (15-DaCompany Report #WAES 00078911
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea Henoch-Schonlein Purpura Pulmonary Haemorrhage Rash Maculo-Papular Respiratory Distress	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:07/21/00ISR Number: 3533648-7Report Type:Expedited (15-DaCompany Report #WAES 00075545
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Gastric Haemorrhage Haematemesis Prostate Cancer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Tramadol Hcl	C				

Date:07/21/00ISR Number: 3533655-4Report Type:Expedited (15-DaCompany Report #WAES 00071278
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Failure Congestive Condition Aggravated Dyspnoea Pulmonary Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/21/00ISR Number: 3533681-5Report Type:Expedited (15-DaCompany Report #WAES 00070914
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Diverticulitis Intestinal	Health	Vioxx	PS	Merck Research		
Hospitalization -	Haemorrhagic	Professional			Laboratories Div		
Initial or Prolonged	Diverticulum Intestinal				Merck Co Inc	ORAL	
PO							
	Gastrointestinal						
	Haemorrhage						
	Overdose						
	Rectal Haemorrhage						
	Shock						

Date:07/21/00ISR Number: 3533682-7Report Type:Expedited (15-DaCompany Report #WAES 00070813
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Other	Pancreatitis	Health	Vioxx	PS	Merck Research		
		Professional			Laboratories Div		
					Merck Co Inc	ORAL	
PO							

Date:07/21/00ISR Number: 3533724-9Report Type:Expedited (15-DaCompany Report #WAES 00052864
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Diarrhoea
	Medication Error

		Peritoneal Adhesions Small Intestinal Obstruction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE							

Date:07/21/00ISR Number: 3533728-6Report Type:Expedited (15-DaCompany Report #WAES 00061647
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abnormal Behaviour Cognitive Disorder Dementia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE							
		Diarrhoea		Ginkogin	C		
		Hypochloraemia		Glucophage	C		
		Hyponatraemia		L-Thyroxine	C		
		Mental Impairment		Premarin	C		
		Paranoia		Zestoretic	C		
				Glyburide	C		
				Ranitidine	C		
				Riboflavine	C		

Date:07/21/00ISR Number: 3533731-6Report Type:Expedited (15-DaCompany Report #WAES 99121808
Age:83 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Anorexia Asthenia Back Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
Other		Blood Urea Increased					
MG/DAILY/PO							
		Fatigue		Coumadin	SS		
2 MG/DAILY/							
		Gastric Ulcer		Lozol	C		
		Gastroenteritis		Verapamil	C		
		Helicobacter					

Gastrointestinal
Haemorrhage
Haematochezia
Haematocrit Decreased
International Normalised
Ratio Increased

Date:07/21/00ISR Number: 3533738-9Report Type:Expedited (15-DaCompany Report #WAES 00061688
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Death	Ascites
Life-Threatening	Cardiac Failure
Hospitalization - Initial or Prolonged	Congestive Dyspnoea
Disability	Fluid Retention
	Hepatic Failure
	Hepatic Steatosis
	Hepatitis
	Hepatomegaly
	Liver Function Test Abnormal
	Oedema Peripheral

	Pleural Effusion Respiratory Failure Right Ventricular Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO
			Combivent	C			
			Allopurinol	C			
			Diltiazem	C			

Date:07/21/00ISR Number: 3533741-9Report Type:Expedited (15-DaCompany Report #WAES 00063246
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Autoimmune Disorder Ecchymosis Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
	Megakaryocytes Abnormal	Representative					
	Plasmapheresis Splenectomy Thrombocytopenia		[Therapy Unspecified]	C			
			Digoxin	C			
			Furosemide	C			
			Lisinopril	C			
			Spironolactone	C			

Date:07/21/00ISR Number: 3533996-0Report Type:Expedited (15-DaCompany Report #WAES 00060677
Age:98 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Asthenia Condition Aggravated Decreased Activity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Fatigue		Colace	C			
	Gait Disturbance		Acetaminophen	C			
	Gastric Ulcer Haemorrhage		Ibuprofen	C			
	Lethargy		Levobunolol	C			

	Malaise Mental Impairment		Magnesium Hydroxide	C			

Date:07/21/00ISR Number: 3533998-4Report Type:Expedited (15-DaCompany Report #WAES 00011246
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Epistaxis Oral Mucosal Petechiae Petechiae Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Xanax	C				

Date:07/21/00ISR Number: 3534002-4Report Type:Expedited (15-DaCompany Report #WAES 00042400
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/00ISR Number: 3534036-XReport Type:Expedited (15-DaCompany Report #WAES 00042092
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dyspnoea							
	Fatigue							
	Mental Impairment							
	Respiratory Arrest		Celebrex	C				
	Sedation		Glucosamine	C				
	Sensation Of Heaviness							
	Tachycardia							

Date:07/21/00ISR Number: 3534038-3Report Type:Expedited (15-DaCompany Report #WAES 00064753
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Atrial Fibrillation							
	Drug Interaction							
	Gastric Ulcer		Coumadin 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Haematemesis		Bactrim	SS				
	Haematocrit Decreased		Buspar	C				
	Haemoglobin Decreased		Lasix	C				
	International Normalised		Lopressor	C				
	Ratio Increased		Propulsid	C				
	Pneumonia		Prozac	C				
	Upper Gastrointestinal		Vitamins					
	Haemorrhage		(Unspecified)	C				
	Vomiting		Zinc Preparation					
			(Composition)	C				

Date:07/21/00ISR Number: 3534042-5Report Type:Expedited (15-DaCompany Report #WAES 00070714
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Csf Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		
	Csf White Blood Cell Count Positive						
	Lethargy		Lipitor	C			
	Meningitis Aseptic		Parafon Forte	C			
	Mental Impairment		Paxil	C			
	Pyrexia		Chlorzoxazone	C			

Date:07/21/00ISR Number: 3534063-2Report Type:Expedited (15-DaCompany Report #WAES 00041198
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypoaesthesia							
	Hypoaesthesia Oral							
	Hypotension							
	Joint Swelling							
	Multiple Sclerosis							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/00ISR Number: 3534065-6Report Type:Expedited (15-DaCompany Report #WAES 00030543
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Fluid Retention Joint Swelling Mediastinum Neoplasm Non-Small Cell Lung Cancer Oedema Peripheral Periorbital Oedema Pneumatic Compression Therapy Superior Vena Caval Occlusion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/21/00ISR Number: 3590076-6Report Type:Periodic Company Report #WAES 00072571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/24/00ISR Number: 3533513-5Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage Portal Hypertension Varices Oesophageal		Vioxx Lasix Lanonin Theo Dur Paxil Eyhipin Prilosec	PS C C C C C C		ORAL	50 MG PO QD	

			Gemfamicin	C		
			K-Dur	C		
			Diabeta	C		
			Glucophage	C		

Date:07/24/00ISR Number: 3533514-7Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dermatitis		Vioxx	PS		ORAL	50MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Upper Gastrointestinal Haemorrhage		Asa	SS		ORAL	81MG PO QD	

Date:07/24/00ISR Number: 3533555-XReport Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS				
	Haematochezia		Aspirin	SS				
	Large Intestinal Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3533557-3Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx 12.5mg Po Qd	PS				
	Gastrointestinal Haemorrhage		Asa 81mg Po Qd	SS		ORAL		
	Gastrointestinal Ulcer							
	Haemoglobin Decreased							

Date:07/24/00ISR Number: 3533559-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine		Vioxx	PS		ORAL	25 MG PO QD	
	Phosphokinase Increased							
	Dialysis							
	Renal Failure Acute							

Date:07/24/00ISR Number: 3533986-8Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx 25 Mg	PS		ORAL	25MG QD PO	
	Increased		Ms Contin	C				
	Renal Failure Acute		Coumadin	C				
			Nafcillin	C				
			Docusate	C				

Date:07/24/00ISR Number: 3534051-6Report Type:Expedited (15-DaCompany Report #WAES 00073708
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
25 MG PO	2 DAY					
			Ca Acetylsalicylate	C		
			Hyzaar	C		
			Diclofenac Sodium			
			(+) Misoprostol	C		

Date:07/24/00ISR Number: 3534107-8Report Type:Expedited (15-DaCompany Report #WAES 00075574
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hepatic Failure	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Liver Function Test	Health			Laboratories Div	
Initial or Prolonged	Abnormal	Professional			Merck Co Inc	ORAL
7 DAY						
		Other	Diclofenac	SS		

Date:07/24/00ISR Number: 3534108-XReport Type:Expedited (15-DaCompany Report #WAES 00075575
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Life-Threatening	Anaemia	Foreign
Hospitalization -	Faeces Discoloured	Health
Initial or Prolonged	Melaena	Professional

Other

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
Diclofenac	C				

Date:07/24/00ISR Number: 3534116-9Report Type:Expedited (15-DaCompany Report #WAES 00051657
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
Other	Influenza Like Illness	Health			Laboratories Div			
	Oedema	Professional			Merck Co Inc	ORAL	25 MG /DAILY	
	Pruritus						/PO	
	Urticaria		Lipitor	C				
			Zestril	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Triamterene	C				

Date:07/24/00ISR Number: 3534155-8Report Type:Expedited (15-DaCompany Report #WAES 00052422
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Asthenia	Health			Laboratories Div			
	Cardiac Disorder	Professional			Merck Co Inc	ORAL	SEE IMAGE	4 WK
	Fatigue		Evista	C				
	Gastric Ulcer		Fiorinal	C				
	Gastrointestinal Disorder		Prilosec	C				
	Haemoglobin Decreased		Zocor	C				
	Hypocalcaemia		Chondroitin (+) Glucosamine	C				
	Hypokalaemia							

Date:07/24/00ISR Number: 3534187-XReport Type:Expedited (15-DaCompany Report #WAES 00061279
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Urea Increased
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive
Other	Drug Level Below Therapeutic
	Dyspnoea
	Fluid Retention
	Haematocrit Decreased
	Haemoglobin Decreased
	Heart Rate Irregular
	Hypertension
	International Normalised Ratio Decreased
	Oedema
	Prothrombin Time Prolonged
	Pulmonary Valve Incompetence

		Rales Respiratory Distress Tachypnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence Venous Pressure Jugular	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Increased		Bumex	C		
				Coumadin	C		
				Diovan Hct	C		
				Inderal	C		
				Lanoxin	C		
				Novolin	C		
				Tylenol	C		

Date:07/24/00ISR Number: 3534188-1Report Type:Expedited (15-DaCompany Report #WAES 00070794
Age:88 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death Hospitalization - Initial or Prolonged		Cardiac Arrest Coagulopathy Duodenal Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Haemorrhage Haematemesis Haemoglobin Decreased Hypotension Rectal Haemorrhage Small Intestinal Haemorrhage	Representative	Plavix	C		

Date:07/24/00ISR Number: 3534189-3Report Type:Expedited (15-DaCompany Report #WAES 00060172
Age:80 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dementia Alzheimer'S Type Hallucination	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5							

MG/DAILY/PO

Fosamax	C
Prempro	C
Synthroid	C
Ascorbic Acid	C
Aspirin	C
Calcium Supplement (Composition	C
Vitamin E	C

Date:07/24/00ISR Number: 3534190-XReport Type:Expedited (15-DaCompany Report #WAES 00060677
Age:98 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia Condition Aggravated Fatigue	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gait Disturbance Lethargy Malaise		Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534191-1Report Type:Expedited (15-DaCompany Report #WAES 00070426
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/24/00ISR Number: 3534192-3Report Type:Expedited (15-DaCompany Report #WAES 00070668
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/24/00ISR Number: 3534193-5Report Type:Expedited (15-DaCompany Report #WAES 00070887
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Face Oedema Lung Disorder Mass Neoplasm Oedema Peripheral Respiratory Disorder	Consumer	Vioxx Catapres Celebrex Ditropan Plaquenil Tagamet Titralac Antacid Wygesic Tablets Zoloft [Therapy Unspecified] Amitriptline	PS C C C C C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

			Ferrous Sulfate	C		
			Methotrexate	C		
			Prednisone	C		

Date:07/24/00ISR Number: 3534202-3Report Type:Expedited (15-DaCompany Report #WAES 00052750
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Gastritis							
	Gastrointestinal Haemorrhage							
	Melaena		Estratest	C				
	Oral Intake Reduced		Aspirin	C				
	Vomiting							

Date:07/24/00ISR Number: 3534203-5Report Type:Expedited (15-DaCompany Report #WAES 00061612
Age:64 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Anuria Blood Creatinine Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
Renal Failure	Representative	Estratest	C				
		Normodyne	C				
		Xanax	C				
		Zaroxolyn	C				
		Zoloft	C				
		Therapy Unspecified	C				
		Codeine Sulfate	C				

Date:07/24/00ISR Number: 3534204-7Report Type:Expedited (15-DaCompany Report #WAES 99111023
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills Condition Aggravated Csf Protein Increased Csf Test Abnormal Dizziness Dyssomnia Headache Hypotension Lymphocyte Count Decreased Meningism Meningitis Aseptic Meningitis Viral Musculoskeletal Stiffness Nausea Neutrophil Count Increased Night Sweats Pain Red Blood Cell Count Increased Tachypnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY /PO	

White Blood Cell Count
Increased

Date:07/24/00ISR Number: 3534205-9Report Type:Expedited (15-DaCompany Report #WAES 00071095
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Myocardial Infarction Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imdur	C				
			Lopressor	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534212-6Report Type:Expedited (15-DaCompany Report #WAES 00079111
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	9 DAY
	Psoriasis Skin Lesion	Other	Allopurinol	C				
			Amlodipine	C				
			Aspartic Acid Potassium Salt 1 Form	C				
			Atenolol	C				
			Budesonide	C				
			Chlorthalidone	C				
			Formoterol	C				
			Insulin	C				
			Irbesartan	C				

Date:07/24/00ISR Number: 3534213-8Report Type:Expedited (15-DaCompany Report #WAES 00067514
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal Grand Mal Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	
		Other	Candesartan Cilexetil	C				
			Cyproterone Acetate(+) Estradiol Valera	C				
			Levothyroxine Na	C				
			Valerian	C				

Date:07/24/00ISR Number: 3534214-XReport Type:Expedited (15-DaCompany Report #WAES 00059116
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Diarrhoea Gastroenteritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG 7 DAY
		Other	Lercanidipine	C			
			Losartan Potassium	C			
			Simavastatin	C			
			Trimetazidine Dihcl	C			

Date:07/24/00ISR Number: 3534215-1Report Type:Expedited (15-DaCompany Report #WAES 00071095
Age:62 YR Gender:Female I/FU:I

Hospitalization - Initial or Prolonged	Abdominal Distension Myocardial Infarction Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Imdur	C			
			Lopressor	C			
			Prevacid	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534216-3Report Type:Expedited (15-DaCompany Report #WAES 00075543
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Electrolyte Imbalance Gastrointestinal Disorder Hepatic Function Abnormal Liver Function Test Abnormal Renal Impairment Weight Increased	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/24/00ISR Number: 3534243-6Report Type:Expedited (15-DaCompany Report #WAES 00062965
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain Coronary Artery Disease	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
Disability	Coronary Artery Surgery	Representative					MG/DAILY/PO	
	Dyspnoea Myocardial Infarction		Celebrex Coumadin	C C				

Date:07/24/00ISR Number: 3534270-9Report Type:Expedited (15-DaCompany Report #WAES 00066149
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Oedema Peripheral Weight Increased	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
		Professional	Vasotec	C				

Date:07/24/00ISR Number: 3534271-0Report Type:Expedited (15-DaCompany Report #WAES 00045183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angiopathy	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Arthralgia							
	Asthenia							
	Back Pain		Warfarin	SS				
	Depression		Diclofenac Sodium (+) Misoprostol	C				
	Dermatitis Exfoliative		Propafenone Hcl	C				
	Difficulty In Walking							
	Ecchymosis							
	Fatigue							
	Headache							
	Influenza Like Illness							
	Listless							
	Mouth Ulceration							
	Muscle Haemorrhage							
	Oral Intake Reduced							
	Pain In Extremity							
	Rhinorrhoea							
	Sleep Disorder Due To General Medical Condition, Insomnia Type							
	Spinal Disorder							
	Stress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534272-2Report Type:Expedited (15-DaCompany Report #WAES 00065557
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antibody Test Positive	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Arthritis	Health			Laboratories Div			
Initial or Prolonged	Blood Creatinine	Professional			Merck Co Inc	ORAL	25 MG PO	5 DAY
Disability	Increased		Ibuprofen	SS		ORAL	PO	3 DAY
	Blood Urea Increased							
	Complement Factor C3 Increased							
	Creatinine Renal Clearance Normal							
	Glycosuria							
	Haematuria							
	Nephritis Interstitial							
	Ph Urine Increased							
	Proteinuria							
	Renal Disorder							
	Renal Interstitial Fibrosis							
	Renal Tubular Atrophy							
	Rheumatoid Factor							
	Rheumatoid Factor Positive							
	Urine Sodium Increased							
	White Blood Cells Urine Positive							

Date:07/24/00ISR Number: 3534273-4Report Type:Expedited (15-DaCompany Report #WAES 00075523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
	Gastric Ulcer Haemorrhage	Health			Laboratories Div			
		Professional			Merck Co Inc			
			Tab Fosamax (Alendronate Sodium)	SS				

Date:07/24/00ISR Number: 3534274-6Report Type:Expedited (15-DaCompany Report #WAES 00075537
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Tenderness Bowel Sounds Abnormal Flatulence Mesenteric Occlusion Pulmonary Embolism	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:07/24/00ISR Number: 3534283-7Report Type:Expedited (15-DaCompany Report #WAES 00078267
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrotic Syndrome Oedema Proteinuria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	14 DAY
			Aspartic Acid Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/00ISR Number: 3534284-9Report Type:Expedited (15-DaCompany Report #WAES 00076509
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
			Acetaminophen	C				
			Aspirin	C				

Date:07/24/00ISR Number: 3534328-4Report Type:Expedited (15-DaCompany Report #WAES 00071295
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastrointestinal Haemorrhage Haematochezia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/24/00ISR Number: 3534330-2Report Type:Expedited (15-DaCompany Report #WAES 00071016
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	
			Fosamax	C				
			Aspirin	C				

Date:07/24/00ISR Number: 3534331-4Report Type:Expedited (15-DaCompany Report #WAES 00070696
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blister	Health	Vioxx	PS	Merck Research		
Hospitalization -	Creatinine Renal	Professional			Laboratories Div		
Initial or Prolonged	Clearance Decreased	Company			Merck Co Inc	ORAL	
25							
Disability	Dermatitis Exfoliative	Representative					
MG/DAILY/PO							
Other	Face Oedema		Zyloprim	SS			
	Hypersensitivity		Lasix	C			
	Skin Lesion		Zestoretic	C			
	Thermal Burn						
	Tongue Oedema						

Date:07/24/00ISR Number: 3534341-7Report Type:Expedited (15-DaCompany Report #WAES 00071184
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gait Disturbance	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Muscular Weakness				Laboratories Div			
	Pruritus				Merck Co Inc	ORAL	PO	4 MON

Date:07/24/00ISR Number: 3534344-2Report Type:Expedited (15-DaCompany Report #WAES 00071266
Age:71 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actos	C				
			Amaryl	C				
			Glucophage	C				

Date:07/24/00ISR Number: 3534741-5Report Type:Expedited (15-DaCompany Report #WAES 00061030
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
		Representative	Diovan	C				
			Hytrin	C				
			Lipitor	C				
			Atenolol	C				

Date:07/25/00ISR Number: 3534154-6Report Type:Expedited (15-DaCompany Report #WAES 00061225
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Back Pain Blood Pressure Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea		Imdur	C				
	Dizziness		Monopril	C				
	Fluid Retention		Norvasc	C				
	Gastrointestinal Disorder		Pravachol	C				
	Headache		Aspirin	C				
	Nausea							

Oedema Peripheral
Syncope

Date:07/25/00ISR Number: 3534610-0Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Vioxx	PS		ORAL	25MG PO X1T	
Intervention to Prevent Permanent Impairment/Damage	Increased		Cozaar	C				
			Aldara	C				

Date:07/25/00ISR Number: 3534724-5Report Type:Expedited (15-DaCompany Report #WAES 00075120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Other								

Date:07/25/00ISR Number: 3534725-7Report Type:Expedited (15-DaCompany Report #WAES 00075583
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Oedema Pericardial Effusion Pleural Effusion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/25/00ISR Number: 3534727-0Report Type:Expedited (15-DaCompany Report #WAES 00075585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pericardial Effusion Pleural Effusion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/25/00ISR Number: 3534731-2Report Type:Expedited (15-DaCompany Report #WAES 00075593
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Diverticulum Diverticulum Intestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Haemorrhagic Gastrointestinal Haemorrhage	Other						

Date:07/25/00ISR Number: 3534734-8Report Type:Expedited (15-DaCompany Report #WAES 00078259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lichen Planus Mouth Ulceration	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Captopril/Hctz	C
Conjugated Estrogenic Hormones	C
Flurbiprofen	C
Opipramol Dihcil	C

Date:07/25/00ISR Number: 3534751-8Report Type:Expedited (15-DaCompany Report #WAES 00078520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Blood Creatine Phosphokinase Increased Oedema Weight Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/25/00ISR Number: 3534757-9Report Type:Expedited (15-DaCompany Report #WAES 00057547
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Vertigo	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:07/25/00ISR Number: 3534982-7Report Type:Expedited (15-DaCompany Report #WAES 00071474
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:07/25/00ISR Number: 3534983-9Report Type:Expedited (15-DaCompany Report #WAES 00071615
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Calculus Urinary Nephrolithiasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/25/00ISR Number: 3535102-5Report Type:Expedited (15-DaCompany Report #WAES 00061614
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Effect Decreased Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

	Tab Vioxx 25 Mg	SS	ORAL

25

MG/DAILY/PO

Cardizem	C
Diazide	C
Zocor	C
Aspirin	C
Vitamins	C

Date:07/25/00ISR Number: 3535108-6Report Type:Expedited (15-DaCompany Report #WAES 00070716
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Vein Thrombosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Evista	C
Lipitor	C
Maxzide	C
Synthroid	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/00ISR Number: 3535112-8Report Type:Expedited (15-DaCompany Report #WAES 00071209
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia Eye Disorder Eye Pain Thrombosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:07/25/00ISR Number: 3535114-1Report Type:Expedited (15-DaCompany Report #WAES 00071401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolytic Anaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN PO	

Date:07/26/00ISR Number: 3535607-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Epistaxis Headache Hypertension		Vioxx 25mg Tabs-Merck	PS	Merck	ORAL	25MG PO DAILY PRN	

Date:07/26/00ISR Number: 3535633-8Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS		ORAL	25MG PO QD	2 MON

Initial or Prolonged Congestive

Date:07/26/00ISR Number: 3535753-8Report Type:Expedited (15-DaCompany Report #WAES 00064426
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Condition Aggravated					
	Eosinophilic Pneumonia					
PO						
	Pleural Effusion		Betapace	C		
			Digoxin	C		
			Prednisone	C		

Date:07/26/00ISR Number: 3535754-XReport Type:Expedited (15-DaCompany Report #WAES 00070717
Age:16 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Central Nervous System Neoplasm
Other	Constipation
	Dermatitis Atopic
	Dermatitis Contact
	Gastritis
	Gastrointestinal Disorder
	Hypoaesthesia
	Muscular Weakness

		Musculoskeletal Pain Oedema Peripheral Rash Vesicular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Red Blood Cell Sedimentation Rate Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO		Sensory Disturbance					

Date:07/26/00ISR Number: 3535784-8Report Type:Expedited (15-DaCompany Report #WAES 00051784
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:07/26/00ISR Number: 3535837-4Report Type:Expedited (15-DaCompany Report #WAES 00052663
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Condition Aggravated Duodenal Ulcer Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Haemorrhage Laboratory Test Abnormal Ulcer		Ultram	C		

Date:07/26/00ISR Number: 3535838-6Report Type:Expedited (15-DaCompany Report #WAES 00052887
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ecchymosis Fall	Consumer Health	Vioxx	PS	Merck Research Laboratories Div	

	Haematoma	Professional			Merck Co Inc	ORAL
PO						
	Haemorrhage Subcutaneous		Synthroid	C		
	Oedema Peripheral		Tenormin	C		
	Skin Graft					

Date:07/26/00ISR Number: 3535841-6Report Type:Expedited (15-DaCompany Report #WAES 00033107
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Blood Pressure Increased				Laboratories Div	
	Dizziness				Merck Co Inc	ORAL
25						
	Fatigue					
MG/DAILY/PO						
	Gastrointestinal		Coumadin	C		
	Haemorrhage		Fosamax	C		
	Nausea					
	Pain In Extremity					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/00ISR Number: 3535843-XReport Type:Expedited (15-DaCompany Report #WAES 00063069
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
	Rectal Haemorrhage		Acupril	C				
			Flomax	C				
			Prevacid	C				
			Zocor	C				
			Aspirin	C				
			Atenolol	C				

Date:07/26/00ISR Number: 3535974-4Report Type:Expedited (15-DaCompany Report #WAES 00051636
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation Diverticulum Intestinal Faeces Hard	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Haemorrhage Haematemesis	Representative						
			Demadex	C				
			Fosamax	C				
			K-Dur	C				
			Os-Cal	C				
			Plaquenil	C				
			Pravachol	C				
			Aspirin	C				
			Atenolol	C				
			Vitamins	C				

Date:07/26/00ISR Number: 3535977-XReport Type:Expedited (15-DaCompany Report #WAES 00051730
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Health	Vioxx	PS	Merck Research			

Initial or Prolonged Disability	Cerebrovascular Accident Disturbance In Attention Headache Hemiparesis Memory Impairment Migraine Sedation	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL PO

Date:07/26/00ISR Number: 3536116-1Report Type:Expedited (15-DaCompany Report #WAES 00022074
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Peptic Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/00ISR Number: 3536119-7Report Type:Expedited (15-DaCompany Report #WAES 00050750
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Difficulty In Walking	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Insomnia	Health			Laboratories Div			
Initial or Prolonged	Neuropathy Peripheral	Professional			Merck Co Inc	ORAL	25	
Other	Oedema Peripheral						MG/DAILY/PO	
	Pain							
	Saliva Altered							
	Tongue Disorder							
	Vasculitis							

Date:07/26/00ISR Number: 3536302-0Report Type:Expedited (15-DaCompany Report #WAES 00055595
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Blood Bilirubin Increased	Health			Laboratories Div			
	Blood Iron Decreased	Professional			Merck Co Inc	ORAL	12.5 MG PO	
	C-Reactive Protein		Sulfasalazine	SS		ORAL	1000 MG PO	
	Increased		Etidronic Acid Dina	C				
	Chills		Flupirtine Maleate	C				
	Chromaturia							
	Dermatitis							
	Dermatitis Exfoliative							
	Diarrhoea							
	Eosinophilia							
	Faeces Discoloured							
	Fatigue							
	Hepatitis Cholestatic							
	Hepatosplenomegaly							
	Hyperpyrexia							
	Jaundice							
	Leukocytosis							
	Liver Function Test							
	Abnormal							
	Pruritus							
	Pyrexia							

Red Blood Cell
Sedimentation Rate
Increased
Serum Ferritin Decreased
Vomiting

Date:07/26/00ISR Number: 3536305-6Report Type:Expedited (15-DaCompany Report #WAES 00055654
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Hepatitis Jaundice Liver Function Test Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/00ISR Number: 3536306-8Report Type:Expedited (15-DaCompany Report #WAES 00075575
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Faecal Occult Blood	Study			Laboratories Div			
Initial or Prolonged	Positive	Other			Merck Co Inc	ORAL	25 MG PO	8 DAY
	Faeces Discoloured		Tab Aspirin	SS		ORAL	100 MG PO	100 DAY
	Gastric Ulcer Haemorrhage		Diclovenac	C				
			Magnesium Preparation	C				
			Nebivolol	C				
			Triamcinolone	C				

Date:07/27/00ISR Number: 3535526-6Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemodialysis		Celebrex / All	PS		ORAL	ALL 1-3+ ORAL	
Hospitalization -	Renal Failure Acute		Viox All	SS		ORAL	ALL 1-3+ ORAL	
Initial or Prolonged								
Other								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:07/27/00ISR Number: 3535615-6Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Myocardial Infarction		Rofecoxib 25mg	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Renal Failure		Fosamax	C				
			Calcium +D	C				
			Multivitamin	C				

Date:07/27/00ISR Number: 3536045-3Report Type:Direct Company Report #
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety Drug Interaction Hyperventilation		Vioxx (Rofecoxib-Generic Name) Merck 25mg	PS	Merck	
25MG QD A FEW DAYS->1WK						

Date:07/27/00ISR Number: 3536407-4Report Type:Expedited (15-DaCompany Report #WAES 00068611
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Stevens-Johnson Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 2 DAY						
			Acetaminophen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/00ISR Number: 3536408-6Report Type:Expedited (15-DaCompany Report #WAES 00078517
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Migraine	Foreign	Vioxx	PS	Merck Research			
	Ruptured Cerebral	Health			Laboratories Div			
	Aneurysm	Professional			Merck Co Inc	ORAL	25 MG PO	8 DAY
			Methotrexate	C				

Date:07/27/00ISR Number: 3536409-8Report Type:Expedited (15-DaCompany Report #WAES 00076046
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia	Foreign	Vioxx	PS	Merck Research			
	Neutropenia	Health			Laboratories Div			
	Retinal Vein Thrombosis	Professional			Merck Co Inc	ORAL	25 MG PO	41 DAY
	Visual Acuity Reduced		Ranitidine	C				
			Timolol	C				

Date:07/27/00ISR Number: 3536438-4Report Type:Expedited (15-DaCompany Report #WAES 00075555
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Facial Palsy	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hyperaesthesia	Health			Laboratories Div			
	Muscular Weakness	Professional			Merck Co Inc	ORAL	25-50 MG PO	43 DAY
		Other	Lisinopril	C				
			Repaglinide	C				

Date:07/27/00ISR Number: 3536439-6Report Type:Expedited (15-DaCompany Report #WAES 00077506
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal	Foreign	Vioxx	PS	Merck Research			

	Liver Function Test	Health			Laboratories Div	
	Abnormal	Professional			Merck Co Inc	ORAL
25 MG PO 18 DAY						
		Other				

Date:07/27/00ISR Number: 3536440-2Report Type:Expedited (15-DaCompany Report #WAES 00075600
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dizziness	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Faeces Discoloured	Health			Laboratories Div	
Initial or Prolonged	Gastrointestinal	Professional			Merck Co Inc	ORAL
25 MG PO 48 DAY						
	Haemorrhage	Other				
	Haemoglobin Decreased					

Date:07/27/00ISR Number: 3536442-6Report Type:Expedited (15-DaCompany Report #WAES 00077518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Lung Infiltration	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
PO						
		Other				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/00ISR Number: 3536443-8Report Type:Expedited (15-DaCompany Report #WAES 00076054
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Coronary Artery Disease Reocclusion	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/27/00ISR Number: 3536458-XReport Type:Expedited (15-DaCompany Report #WAES 00075598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Haemorrhage Intracranial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	12.5MG
							PO	21 DAY

Date:07/27/00ISR Number: 3536459-1Report Type:Expedited (15-DaCompany Report #WAES 00075154
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	178 DAY
	Perforation		Acetaminophen	C				
			Allopurinol	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Hydroxocobalamin	C				
			Isosorbide-5-Mononitrate	C				

Date:07/27/00ISR Number: 3536521-3Report Type:Expedited (15-DaCompany Report #WAES 00071365
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy Blindness Hypertension Thrombosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				

Date:07/27/00ISR Number: 3536522-5Report Type:Expedited (15-DaCompany Report #WAES 00071329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:07/27/00ISR Number: 3536527-4Report Type:Expedited (15-DaCompany Report #WAES 00060174
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Activated Partial Thromboplastin Time Prolonged	Other						
	Asthenia		Tab Coumadin Unk	SS		ORAL	7.5 MG/DAILY/PO	
	Back Pain							
	Haematoma		Acetaminophen (+) Codeine Phosh	C				
	Haematuria							
	Haemorrhage							
	Hypoaesthesia							
	International Normalised Ratio Increased							
	Muscular Weakness							
	Pain							
	Prothrombin Time Prolonged							

Date:07/27/00ISR Number: 3536528-6Report Type:Expedited (15-DaCompany Report #WAES 00071501
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Company Representative						

Date:07/27/00ISR Number: 3536529-8Report Type:Expedited (15-DaCompany Report #WAES 00073483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			

Life-Threatening Congestive Health Laboratories Div
Hospitalization - Professional Merck Co Inc ORAL
PO
Initial or Prolonged Digoxin C

Date:07/27/00ISR Number: 3536596-1Report Type:Expedited (15-DaCompany Report #WAES 00071400
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS	Merck Research			
	Hyponatraemia	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
PO								
		Representative						

Date:07/27/00ISR Number: 3536597-3Report Type:Expedited (15-DaCompany Report #WAES 00071372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research			
	Haemorrhage	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
PO								
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/00ISR Number: 3537046-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Vioxx	PS	Merck And Co Inc			
	Oral Soft Tissue Disorder							

Date:07/28/00ISR Number: 3537274-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Rofecoxib 25 Mg					
Hospitalization -	Gastrointestinal		Merck	PS	Merck	ORAL	25 MG QD ORAL	
Initial or Prolonged	Haemorrhage		Aspirin 325 Mg	SS		ORAL	325 MG QD ORAL	
	Gastrointestinal Ulcer							
			Docusate	C				
			Hydrocodone/Apap	C				
			Quinpril	C				
			Albuterol/Ipratropium	C				
			Potassium	C				
			Metoprolol	C				
			Flunisolide	C				
			Furosemide	C				
			Isosorbide Mono Nitrate	C				
			Glyburide	C				

Date:07/28/00ISR Number: 3537579-8Report Type:Expedited (15-DaCompany Report #WAES 99115207
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Abdominal Pain Upper	Study			Laboratories Div			
Initial or Prolonged	Eating Disorder	Health			Merck Co Inc	ORAL	25 MG	85 DAY
	International Normalised	Professional	Insulin Lispro Rdna					

	Ratio Decreased	Other	Origin	C
	Melaena		Ispohane Insulin	
	Nausea		Suspension	C
			Methotrexate	C

Date:07/28/00ISR Number: 3537583-XReport Type:Expedited (15-DaCompany Report #WAES 00076082
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	33 DAY
	Haemoglobin Decreased	Study						
	Hepatitis C Antibody	Health						
	Positive	Professional	Crataegus (+)					
	Oesophageal Varices		Valerian	C				
	Haemorrhage		Ginkgo Biloba Extract	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/00ISR Number: 3537586-5Report Type:Expedited (15-DaCompany Report #WAES 00076027
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Drug Eruption Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	7 DAY
	Pruritus Rash Generalised		Tab Hydroxychloroquine	SS		ORAL	400 MG	
	Rash Pustular		Methotrexate	C				

Date:07/28/00ISR Number: 3537594-4Report Type:Expedited (15-DaCompany Report #WAES 00075609
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Shock	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	95 DAY
		Professional	Captopril/Hctz	C				

Date:07/28/00ISR Number: 3537602-0Report Type:Expedited (15-DaCompany Report #WAES 00073743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	9 DAY
			Ca Acetylsalicylate	C				

Date:07/28/00ISR Number: 3537668-8Report Type:Expedited (15-DaCompany Report #WAES 00042291
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Angioneurotic Oedema	Consumer	Vioxx	PS	Merck Research	
	Dermatitis	Health			Laboratories Div	
	Face Oedema	Professional			Merck Co Inc	ORAL
UNK/UNK/PO						
	Urticaria		Zantac	C		
			Zirtek	C		
			Loratadine	C		
			Prednisone	C		

Date:07/28/00ISR Number: 3537671-8Report Type:Expedited (15-DaCompany Report #WAES 00041198
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dizziness	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Drug Hypersensitivity				Laboratories Div	
	Hypoaesthesia				Merck Co Inc	ORAL
UNK/UNK/PO						
	Hypoaesthesia Oral					
	Hypotension					
	Joint Swelling					
	Multiple Sclerosis					
	Tinnitus					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/00ISR Number: 3537742-6Report Type:Expedited (15-DaCompany Report #WAES 00071658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysuria Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY/PO	

Date:07/28/00ISR Number: 3537771-2Report Type:Expedited (15-DaCompany Report #WAES 00071474
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Digoxin	C				

Date:07/28/00ISR Number: 3537784-0Report Type:Expedited (15-DaCompany Report #WAES 00071639
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/28/00ISR Number: 3537785-2Report Type:Expedited (15-DaCompany Report #WAES 00071230
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Cardiac Failure	Health	Vioxx	PS	Merck Research	
Other	Congestive	Professional			Laboratories Div	
	Condition Aggravated	Company			Merck Co Inc	ORAL
25						
	Dyspnoea	Representative				
MG/DAILY/PO						
	Pulmonary Oedema					

Date:07/28/00ISR Number: 3537818-3Report Type:Expedited (15-DaCompany Report #WAES 00078251
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Drug Interaction	Other			Laboratories Div	
Initial or Prolonged	Duodenal Ulcer				Merck Co Inc	ORAL
25 MG, PO						
	Gastric Ulcer		Prednisone	SS		ORAL
5 MG, PO						
	Gastrointestinal					
	Haemorrhage					

Date:07/28/00ISR Number: 3537874-2Report Type:Expedited (15-DaCompany Report #WAES 00052889
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Abdominal Rigidity
	Arthralgia
	Arthritis

		Atrioventricular Block First Degree					
		Cellulitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Duodenal Ulcer Haemorrhage Electrocardiogram Delta Waves Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ DAILY/PO; 25 MG/DAILY/PO		Faecal Occult Blood Positive		Adalat	C		
		Fluid Retention		K-Dur	C		
		Haematocrit Decreased		Levaquin	C		
		Haemoglobin Decreased		Nitroglycerin	C		
		Heart Rate Decreased		Plavix	C		
		Hypochloraemia		Zocor	C		
		Hypokalaemia		Aspirin	C		
		Hyponatraemia		Hydrochlorothiazide			
		Hypothermia		(+) Triamter	C		
		International Normalised Ratio Decreased		Nadolol	C		
		Malaise					
		Melaena					
		Oesophagitis					
		Prothrombin Time Shortened					
		Red Blood Cell Sedimentation Rate Increased					
		Renal Cyst					
		Respiratory Rate Increased					
		Sinus Bradycardia					
		Supraventricular Extrasystoles					
		Ventricular Hypertrophy					

Date:07/28/00ISR Number: 3537877-8Report Type:Expedited (15-DaCompany Report #WAES 00061688
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Life-Threatening	Ascites

Hospitalization - Initial or Prolonged Disability	Asthenia Atrial Fibrillation Blood Pressure Diastolic Increased Cardiac Failure Congestive Cardio-Respiratory Arrest Decreased Appetite Dyspnoea Fluid Retention Hepatic Failure Hepatic Fibrosis Hepatic Steatosis Hepatomegaly Hyponatraemia Laboratory Test Abnormal Lethargy Multi-Organ Failure Oedema Peripheral

		Peritoneal Disorder Pleural Effusion Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia Tachypnoea White Blood Cell Count Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Combivent	C		
				Allopurinol	C		
				Diltiazem	C		

Date:07/28/00ISR Number: 3537880-8Report Type:Expedited (15-DaCompany Report #WAES 00071400
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Convulsion Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
Other	Hyponatraemia Neuromyopathy	Representative	Diuretic Preparation	SS		

Date:07/31/00ISR Number: 3538438-7Report Type:Expedited (15-DaCompany Report #WAES 00075574
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Hepatic Failure Liver Function Test Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Diclofenac	SS		

Date:07/31/00ISR Number: 3538440-5Report Type:Expedited (15-DaCompany Report #WAES 99115207
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Upper Discomfort	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Gastritis Gastroenteritis Helicobacter International Normalised Ratio Decreased Melaena Nausea	Professional	Ethinyl Estradiol/ Norgestrel Insulin Lispro Rdna Origin Isophane Insulin Suspension Methotrexate	C C C C				

Date:07/31/00ISR Number: 3538453-3Report Type:Expedited (15-DaCompany Report #WAES 00075212
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Dyspepsia Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	32 DAY
			Aspirin	SS		ORAL	75 MG, PO	
			Zocor	C				
			Acetaminophen (+) Dihydrocodeine Bitartr	C				

			Atenolol	C
			Fluoxetine	C
			Trimethoprim	C

Date:07/31/00ISR Number: 3538455-7Report Type:Expedited (15-DaCompany Report #WAES 00077282
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Other			Laboratories Div			
Initial or Prolonged	Pain In Extremity				Merck Co Inc	ORAL	25 MG, PO	
	Renal Failure		Clomethiazaole					
	Urinary Tract Infection		Ethanedisulfonate	C				
			Cyanocobalamin	C				
			Cyclizine	C				
			Lactulose	C				
			Leuprolide					
			Monoacetate (Salt)	C				
			Medroxyprogesterone					
			17-Acetate	C				
			Morphine	C				
			Picosulfate Na	C				
			Propiomazine Maleate	C				

Date:07/31/00ISR Number: 3538457-0Report Type:Expedited (15-DaCompany Report #WAES 00077522
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhagic	Health			Laboratories Div			
	Rectal Haemorrhage	Professional			Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538458-2Report Type:Expedited (15-DaCompany Report #WAES 00075207
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Skin Ulcer Vasculitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Acetaminophen/Propoxyphene Hydrochloride	C			
			Azathioprine	C			

Date:07/31/00ISR Number: 3538460-0Report Type:Expedited (15-DaCompany Report #WAES 00079804
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis Dysphagia Dystonia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 DAY
	Leukopenia Mouth Ulceration Neutrophil Count Decreased Pyrexia		Vasotec	C				
			Acarbose	C				
			Acebutolol Hydrochloride	C				
			Tamsulosin Hydrochloride	C				
			Vinpocetine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538461-2Report Type:Expedited (15-DaCompany Report #WAES 00035130
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arthralgia	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Back Pain	Health			Laboratories Div	
	C-Reactive Protein	Professional			Merck Co Inc	ORAL
25.0 MG, PO 99 DAY						
	Increased		Acetaminophen	C		
	Gastric Haemorrhage		Acetaminophen/Propox			
	Gastritis Erosive		yphene Hydrochloride	C		
	Haematemesis		Aluminum			
	Insomnia		Hydroxide/Mg			
	Weight Increased		Trisilicate	C		
			Diazepam	C		
			Estradiol Valerate	C		
			Lactulose	C		
			Lansoprazole	C		
			Metoclopramide	C		
			Morphineso4	C		
			Nefazodone	C		
			Prednisolone	C		
			Thioridazine	C		

Date:07/31/00ISR Number: 3538462-4Report Type:Expedited (15-DaCompany Report #WAES 00079139
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactic Shock	Foreign	Vioxx	PS	Merck Research	
		Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG, PO 3 DAY						
			Diclofenac Na	C		
			Piroxicam	C		

Date:07/31/00ISR Number: 3538464-8Report Type:Expedited (15-DaCompany Report #WAES 00079140
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Interaction	Foreign	Vioxx	PS	Merck Research	

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Other			Laboratories Div Merck Co Inc	ORAL
PO 17 DAY						
			Fluoxetine	SS		ORAL
PO						

Date:07/31/00ISR Number: 3538467-3Report Type:Expedited (15-DaCompany Report #WAES 00057285
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Blood Potassium Increased					
	International Normalised Ratio Increased		Elavil	C		
			Acetaminophen	C		
	Leukocytosis		Acetylcysteine	C		
	Renal Failure		Diazepam	C		
	Thrombocythaemia		Doxazosin Monomethanesulfonate	C		
			Furosemide	C		
			Lactulose	C		
			Loratadine	C		
			Metoprolol Tartrate	C		

			Oxycodone Hcl	C
			Picosulfate Na	C
			Verapamil Hcl	C
			Warfarin Sodium	C

Date:07/31/00ISR Number: 3538469-7Report Type:Expedited (15-DaCompany Report #WAES 00047314
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Increased	Other			Laboratories Div			
Initial or Prolonged	Oliguria				Merck Co Inc	ORAL	25 MG PO	6 DAY
	Renal Failure		Inj Cefuroxime Na	SS			2.2 GM	7 DAY
	Synovitis		Acetaminophen	C				
			Calcium Carbonate (+) Vitamin D{3}	C				
			Omeprazole	C				
			Oxazepam	C				
			Propoxyphene Napsylate Monohydrate	C				
			Vitamin B {12}	C				

Date:07/31/00ISR Number: 3538470-3Report Type:Expedited (15-DaCompany Report #WAES 00047311
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Cardiac Failure	Other			Laboratories Div			
	Congestive				Merck Co Inc	ORAL	12,5 MG PO	13 DAY
	Cholecystitis		La-Hydroxycholecalci ferol	C				
	Cough		Acetylcysteine	C				
	Duodenitis Haemorrhagic		Digitoxin	C				
	Gastritis		Dipyridamole	C				
	Gastrointestinal Disorder		Furosemide	C				
	Melaena		Insulin Injection/Isophane					
	Oxygen Saturation Decreased							

	Pleural Effusion		Insulin Suspension	C		
	Pyrexia		Irbesartan	C		
	Renal Failure		Isosorbide-5-Mononit			
	Swelling		rate	C		
	Upper Respiratory Tract		Potassium Chloride	C		
	Infection					
	Weight Decreased					

Date:07/31/00ISR Number: 3538472-7Report Type:Expedited (15-DaCompany Report #WAES 00047297
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Increased	Other			Laboratories Div			
Initial or Prolonged	C-Reactive Protein				Merck Co Inc	ORAL	12,5 MG PO	6 DAY
	Increased		Vasotec	C				
	Dehydration		Acetaminophen	C				
	Myoglobin Blood Increased		Allopurinol	C				
	Renal Failure		Clpidogrel Bisulfate	C				
	Rhabdomyolysis		Dixydrazine	C				

			Furosemide	C
			Ketobemidone Hcl	C
			Metoprolol Tartate	C
			Nitroglycerin	C
			Tramadol	C
			Vitamin B{12}	C

Date:07/31/00ISR Number: 3538474-0Report Type:Expedited (15-DaCompany Report #WAES 00027293
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Bone Marrow Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12, 5 MG PO	
	Blood Creatinine							
	Increased Oedema		Tab Methotrexate Dina	SS		ORAL	PO	8 YR
	Pancytopenia		Acetaminophen/Codeine Phosphate	C				
	Renal Failure		B Vitamins (+)					
			Caffeine	C				
			Enoxaparin	C				
			Estradiol/Norenthindrone Acetate	C				
			Propoxyphene Napsylate Monohydrate	C				
			Sotalol Hydrochloride	C				

Date:07/31/00ISR Number: 3538488-0Report Type:Expedited (15-DaCompany Report #WAES 00075210
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	33 DAY
			Prinivil	C				
			Acetaminophen	C				

Amlodipine	C
Clotrimazole	C
Digoxin	C
Furosemide	C

Date:07/31/00ISR Number: 3538504-6Report Type:Expedited (15-DaCompany Report #WAES 00075227
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538508-3Report Type:Expedited (15-DaCompany Report #WAES 00075177
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG PO
Naproxen C

Date:07/31/00ISR Number: 3538509-5Report Type:Expedited (15-DaCompany Report #WAES 00078278
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumonia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
	Drug Interaction							
	Heart Rate Increased							
	Pleuritic Pain	Other	Tab Levofloxacin	SS		ORAL	500 MG PO	5 DAY
	Pulmonary Embolism		Hexetidine	C				
	Ventricular Tachycardia		Methotrexate Dina	C				
			Nystatin	C				
			Prednisone	C				
			Vitamin E	C				

Date:07/31/00ISR Number: 3538515-0Report Type:Expedited (15-DaCompany Report #WAES 00077521
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538539-3Report Type:Expedited (15-DaCompany Report #WAES 00075120
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Other								
			Celecoxib	SS		ORAL	PO	

Date:07/31/00ISR Number: 3538603-9Report Type:Expedited (15-DaCompany Report #WAES 00071839
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cyanocobalamin	C				
			Pyridoxine	C				

Date:07/31/00ISR Number: 3538604-0Report Type:Expedited (15-DaCompany Report #WAES 00072033
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Heat Exhaustion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538612-XReport Type:Expedited (15-DaCompany Report #WAES 00061458
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematoma	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haematuria	Professional			Laboratories Div			
Initial or Prolonged	International Normalised				Merck Co Inc	ORAL	PO	
Other	Ratio Increased		Coumadin	C				
	Prothrombin Time		Ismo	C				
	Prolonged		Lanoxin	C				
			Pravachol	C				
			Toprol Xl Tablets	C				

Date:07/31/00ISR Number: 3538613-1Report Type:Expedited (15-DaCompany Report #WAES 00060222
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Coordination Abnormal	Professional			Laboratories Div			
Other	Drug Interaction				Merck Co Inc	ORAL	12.5	
	Dysarthria						MG/DAILY/PO	
	Speech Disorder		Lithium Carbonate	SS		ORAL	600	
	Tremor						MG/DAILY/PO	
			Allegra	C				
			Fosamax	C				
			Klonopin	C				
			Levoxyl	C				
			Calcium Supplement (Composition Nortriptyline)	C				
			Thyroid	C				
			Nortriptyline	C				

Date:07/31/00ISR Number: 3538614-3Report Type:Expedited (15-DaCompany Report #WAES 00051681
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 WK

Date:07/31/00ISR Number: 3538616-7Report Type:Expedited (15-DaCompany Report #WAES 00050858
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis Gastrointestinal Haemorrhage Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/PO	
			Atacand	C				
			Coreg	C				
			Coumadin	C				
			Imdur	C				
			Inh-Burgthal	C				
			Lasix	C				
			Lipitor	C				
			Aspirin	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538619-2Report Type:Expedited (15-DaCompany Report #WAES 00072015
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea Exertional	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Inderal	C				

Date:07/31/00ISR Number: 3538620-9Report Type:Expedited (15-DaCompany Report #WAES 00071919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vasotec	C				
			Allopurinol	C				

Date:07/31/00ISR Number: 3538621-0Report Type:Expedited (15-DaCompany Report #WAES 00064515
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia Asthenia Blood Creatinine Increased Blood Uric Acid Increased Fatigue Gout Malaise	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / DAILY/PO	

Nausea
Oedema

Date:07/31/00ISR Number: 3538622-2Report Type:Expedited (15-DaCompany Report #WAES 00072200
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aleve	C				

Date:07/31/00ISR Number: 3538624-6Report Type:Expedited (15-DaCompany Report #WAES 00071796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538625-8Report Type:Expedited (15-DaCompany Report #WAES 00072141
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia Lymphocytosis Monocytosis Sepsis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538626-XReport Type:Expedited (15-DaCompany Report #WAES 00061666
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538627-1Report Type:Expedited (15-DaCompany Report #WAES 00061667
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/31/00ISR Number: 3538628-3Report Type:Expedited (15-DaCompany Report #WAES 00070005
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company		Merck Co Inc	ORAL
25 MG/BID/PO					
		Representative	Oxycontin 20 Mg	SS	ORAL
20 MG/BID/PO					
			Ortho-Cept	C	

Date:07/31/00ISR Number: 3538629-5Report Type:Expedited (15-DaCompany Report #WAES 00040784
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Discomfort	Consumer	Vioxx	PS	Merck Research	
Other	Burn Oesophageal	Health			Laboratories Div	
	Dyspepsia	Professional			Merck Co Inc	ORAL
PO						
	Eye Irritation		Celebrex	C		
	Headache		Elavil	C		
	Keratoconjunctivitis		Prilosec	C		
	Sicca		Verelan	C		
	Nausea		Xanax	C		
	Sinus Congestion		B Vitamins	C		
	Sinusitis		Calcium Supplement(Composition	C		
			Vitamin E	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538631-3Report Type:Expedited (15-DaCompany Report #WAES 00041198
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Hypoaesthesia Hypotension Joint Swelling Multiple Sclerosis Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:07/31/00ISR Number: 3538632-5Report Type:Expedited (15-DaCompany Report #WAES 00050665
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Diarrhoea Gastric Ulcer Gastric Ulcer Haemorrhage Haemoglobin Decreased Oesophageal Obstruction Oesophageal Stenosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Detrol	C				
			Elavil	C				
			Lasix	C				
			Lodine	C				
			Naprosyn	C				
			Premarin	C				
			Aspirin	C				
			Meclizine	C				
			Potassium Supplement	C				

Date:07/31/00ISR Number: 3538636-2Report Type:Expedited (15-DaCompany Report #WAES 00051870
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Feeling Cold Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

	Oedema Peripheral		
MG/TID/PO			
	Paraesthesia	Dilantin	C
		Prilosec	C
		Tylenol	C
		Vanceril	C
		Zyrtec	C
		Albuterol	C
		Diazepam	C
		Phenobarbital	C
		Potassium Supplement	C
		Prednisone	C
		Theophylline	C

Date:07/31/00ISR Number: 3538637-4Report Type:Expedited (15-DaCompany Report #WAES 00061386
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure Decreased
Hospitalization - Initial or Prolonged	Dyspepsia
	Embolism
Other	Faecal Occult Blood Positive

	Gastric Ulcer Haemorrhage Haematemesis Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased Hypothermia Lethargy	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Shock	Representative					MG/DAILY/PO	
	Tachypnoea		Aspirin	SS			325	
							MG/DAILY/UNK	
			Catapres Tts	C				
			Celebrex	C				
			Diovan	C				
			Feldene	C				
			Glucophage	C				
			Relafen	C				
			Singulair	C				
			...	C				
			...	C				
			Insulin Injection	C				
			Isophane Insulin Suspension	C				
			Vitamin E	C				

Date:07/31/00ISR Number: 3538638-6Report Type:Expedited (15-DaCompany Report #WAES 00072209
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer Gastrointestinal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
	Haemorrhage	Representative					MG/DAILY/PO	
	Haemoglobin Decreased		Darvon	C				
			Ecotrin	C				
			Lopressor	C				
			Norvasc	C				
			Zocor	C				

Date:07/31/00ISR Number: 3538639-8Report Type:Expedited (15-DaCompany Report #WAES 00072160
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 25 MG, PRN, PO	
			Plavix	C				
			Aspirin	C				

Date:07/31/00ISR Number: 3538640-4Report Type:Expedited (15-DaCompany Report #WAES 00072175
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY

Azmacort	C
Flonase	C
Pulmicort	C
Vasotec	C
Viagra	C
Acetaminophen +Hydorocone	C
Carbamazepine	C
Trazodone	C
Triamcinolone	C

Date:07/31/00ISR Number: 3538641-6Report Type:Expedited (15-DaCompany Report #WAES 00061049
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Professional			Laboratories Div			
Initial or Prolonged	Blood Creatinine	Other			Merck Co Inc	ORAL	25	
Other	Increased						MG/DAILY/PO	
	Blood Urea Increased		Lanoxin	SS		ORAL	0.125	
	Dyspnoea						MG/3XW/PO	
	Fatigue		Coumadin	C				
	Hyperkalaemia		Imdur	C				
	Medical Device		Lasix	C				
	Complication		Lopressor	C				
	Renal Failure Acute		Tiazac	C				
	Therapeutic Agent		Insulin	C				
	Toxicity							
	Weight Increased							

Date:07/31/00ISR Number: 3538870-1Report Type:Expedited (15-DaCompany Report #WAES 99121031
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gardnerella Infection	Consumer	Vioxx	PS	Merck Research			
	Nocturia	Health			Laboratories Div			

	Oedema Peripheral	Professional			Merck Co Inc	ORAL
25 MG/PO						
	Pollakiuria		Cleocin	C		
	Pruritus Genital		Estrace	C		
	Smear Cervix Abnormal		Zantac	C		
	Vaginal Discharge		[Therapy Unspecified]	C		
			Triazolam	C		

Date:07/31/00ISR Number: 3538873-7Report Type:Expedited (15-DaCompany Report #WAES 00033107
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Diverticulitis Intestinal Haemorrhagic				Merck Co Inc	ORAL
25 MG/DAILY/PO						
	Dizziness					
	Fatigue		Coumadin	C		
	Hypertension		Fosamax	C		
	Nausea					
	Pain In Extremity					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/00ISR Number: 3538876-2Report Type:Expedited (15-DaCompany Report #WAES 00040829
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nausea	Health	Vioxx	PS	Merck Research			
Hospitalization -	Pulmonary Oedema	Professional			Laboratories Div			
Initial or Prolonged	Therapeutic Agent	Company			Merck Co Inc	ORAL	25	
	Toxicity	Representative					MG/DAILY/PO	
	Vomiting	Other	Pacerone	SS				
	Weight Decreased		Altace	C				
			Celebrex	C				
			Daypro	C				
			Estrace	C				
			D-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Synthroid	C				
			Aspirin	C				
			Calcium Supplement (Composition					
			Nonsteroidal Anti-Inflammatory	C				

Date:07/31/00ISR Number: 3539478-4Report Type:Expedited (15-DaCompany Report #WAES 00051691
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Benign Anorectal Neoplasm	Health			Laboratories Div			
	Cardiac Murmur	Professional			Merck Co Inc	ORAL	25	
	Chest Pain						MG/DAILY/PO	
	Condition Aggravated		Ambien	C				
	Diverticulitis		Celebrex	C				
	Diverticulum		Diazide	C				
	Diverticulum Intestinal		Excedrin					
	Duodenal Ulcer		Extra-Strength	C				
	Haemorrhage		Pepcid	C				
	Dyspnoea Exertional		Tiazac	C				
	Electrocardiogram		Vasotec	C				

	Ambulatory Abnormal Erythema Faeces Discoloured Gastritis Gastrointestinal Haemorrhage Haematochezia Haematocrit Decreased Haemoglobin Decreased Headache Melaena Oesophagitis Palpitations Rectal Haemorrhage Rectal Polyp Sinus Bradycardia Supraventricular Extrasystoles Ventricular Extrasystoles	Estrogenic Preparations (Composi C

Date:08/01/00ISR Number: 3538177-2Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx Qd	PS			1 QD PAST 6 WEEKS	6 WK

Date:08/01/00ISR Number: 3539709-0Report Type:Direct Company Report #
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Coumadin 2mg & 2.5mg	PS		ORAL	2 MG	ALT
	Haematocrit Decreased						QD	ORAL
	Haemoglobin Decreased							
	International Normalised Ratio Increased		Vioxx 25mg	SS		ORAL	25MG	BID
	Oral Intake Reduced						ORAL	
	Pneumonia							

Date:08/01/00ISR Number: 3539710-7Report Type:Direct Company Report #
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx 25mg	PS		ORAL	25MG	QD
	Diverticulum Intestinal Obstruction						ORAL	
	Gastric Outlet		Ticlid 250 Mg	SS		ORAL	250MG	QD
	Gastric Ulcer		Aspirin	C			ORAL	
	Gastroenteritis		Lipitor	C				
	Helicobacter		Lactulose	C				

	Gastrointestinal Haemorrhage	Verapamil Sr	C
		Pilocarpine	C
		Timolol Eye Drops	C

Date:08/02/00ISR Number: 3539724-7Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Faeces Discoloured		Rofecoxib 25mg	PS		ORAL	2TT TAB PO QD	
Intervention to Prevent Permanent Impairment/Damage	Melaena		Lisinopril	C				

Date:08/02/00ISR Number: 3539746-6Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS		ORAL	25 MG PO Q.O.D.	6 MON
	Congestive Chest Discomfort							
	Condition Aggravated							
	Dyspnoea Exertional							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/00ISR Number: 3539816-2Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Vioxx 25mg Merck	PS	Merck	ORAL	25 MG PO QD	2 DAY
Hospitalization - Initial or Prolonged	Increased Blood Urea Increased	Professional	Oramorph	C				
	Cardiac Enzymes Increased		Monopril	C				
	Hyperkalaemia		Theophylline	C				
	Hypotension		Prednisone	C				
	Lethargy							
	Leukocytosis							
	Mental Impairment							
	Nephritis Interstitial							
	Respiratory Failure							

Date:08/03/00ISR Number: 3541063-5Report Type:Expedited (15-DaCompany Report #WAES 00072410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Road Traffic Accident	Company Representative			Merck Co Inc	ORAL	25 MG DAILY PO	

Date:08/03/00ISR Number: 3541066-0Report Type:Expedited (15-DaCompany Report #WAES 00071537
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hiatus Hernia							
	Oesophageal Obstruction				Merck Co Inc	ORAL	25 MG DAILY PO	
	Ulcer							
			Celebrex	C				
			Claritin	C				

				Lipitor	C		
				Prevacid	C		
				Synthroid	C		

Date:08/03/00ISR Number: 3541454-2Report Type:Expedited (15-DaCompany Report #WAES 00080170
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Prinivil	C				

Date:08/03/00ISR Number: 3541629-2Report Type:Expedited (15-DaCompany Report #WAES 00079140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	17 DAY
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Other						
			Fluoxetine	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/00ISR Number: 3541630-9Report Type:Expedited (15-DaCompany Report #WAES 00063581
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amyloidosis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Blood Creatinine Abnormal	Study			Laboratories Div			
Initial or Prolonged	Cellulitis	Health			Merck Co Inc	ORAL	50 MG PO	38 DAY
	Nephritis Interstitial	Professional	Methotrexate	SS		ORAL	7.5 MG PO	112 DAY
	Nephrosclerosis		Omeprazole	SS		ORAL	20 MG PO	
	Proteinuria		Celecoxib	SS		ORAL	200 MG PO	
	Renal Failure Acute		Conjugated					
	Ultrasound Kidney		Estrogenic Hormones	C				
	Abnormal							

Date:08/03/00ISR Number: 3541647-4Report Type:Expedited (15-DaCompany Report #WAES 00089301
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Other			Laboratories Div			
Disability					Merck Co Inc	ORAL	25 MG PO	6 DAY

Date:08/03/00ISR Number: 3541671-1Report Type:Expedited (15-DaCompany Report #WAES 00077283
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Increased	Other			Laboratories Div			
	Hyperkalaemia				Merck Co Inc	ORAL	25 MG	
	Hypokalaemia		Acetaminophen	C				
	Renal Failure		Cyclizine	C				
	Renal Impairment		Furosemide	C				
			Lactulose	C				
			Lansoprazole	C				

			Morphine	C
			Picosulfate Na	C

Date:08/03/00ISR Number: 3541672-3Report Type:Expedited (15-DaCompany Report #WAES 00067515
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Foreign	Vioxx	PS	Merck Research			
Other	Joint Stiffness	Health			Laboratories Div			
	Joint Swelling	Professional			Merck Co Inc	ORAL	25 MG	
	Pruritus		Atenolol	C				
	Rash Generalised		Betahistine Dihcl	C				
	Red Blood Cell Sedimentation Rate Increased		Sumatriptan	C				

Date:08/03/00ISR Number: 3541674-7Report Type:Expedited (15-DaCompany Report #WAES 00073755
Age:25 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25 MG	1 DAY

			Cyclosporin A	C		
			Sulfamethoxaxole/Tri methoprim	C		

Date:08/04/00ISR Number: 3541031-3Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Warfarin	PS		ORAL	25MG PO	
Hospitalization -	Haemorrhage						QID-CHRONIC	
Initial or Prolonged			Vioxx 25mg Tabs					
Required			Merck	SS	Merck	ORAL	25MG PO BID	
Intervention to							CHRONIC	
Prevent Permanent			Vicodin	C				
Impairment/Damage			Monopril	C				
			Trazodone	C				
			Celexa	C				
			Digoxin	C				
			Dilantin	C				
			Coreg	C				
			Lasix	C				

Date:08/04/00ISR Number: 3541038-6Report Type:Direct Company Report #
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Ketoprofen 50mg Po					
	Dizziness		Bid	PS		ORAL	50MG PO BID	
	Gastrointestinal							
							(LONG TIME)	
	Haemorrhage		Vioxx	SS				
	Haematemesis							
	Melaena							

Date:08/04/00ISR Number: 3541046-5Report Type:Direct Company Report #
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Disorder		Vioxx 25mg Tabs					
Hospitalization -	Medication Error		(Merck)	PS	Merck	ORAL	25-50MG PO QD	
Initial or Prolonged	Melaena		Prednisone	C				
Required	Upper Gastrointestinal		Vicodin	C				
Intervention to	Haemorrhage		Atenolol	C				
Prevent Permanent								
Impairment/Damage								

Date:08/04/00ISR Number: 3541048-9Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25mg Tabs					
Initial or Prolonged	Increased		(Merck)	PS	Merck	ORAL	PO	
	Cardiac Failure							
	Congestive							
	Chronic Obstructive							
	Airways Disease							
	Exacerbated							
	Renal Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3541250-6Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - NOT NOTED	Renal Failure Acute	Health	Vioxx 25mg Merck	PS	Merck	ORAL		
Initial or Prolonged		Professional						
ORAL								
Required			Folic Acid	C				
Intervention to			Fluconazole	C				
Prevent Permanent			Mycophenolate					
Impairment/Damage			Mofetil	C				
			Tacrolimus	C				
			Prednisone	C				
			Temazepam	C				
			Elavil	C				
			Pen Vk	C				
			Bactrim Ds	C				
			Omeprazole	C				

Date:08/04/00ISR Number: 3541304-4Report Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Rofecoxib-Vioxx- 25					
Intervention to	Increased		Mg Merck	PS	Merck	ORAL		
50MG QD ORAL								
Prevent Permanent			Ibuprofen 200mg					
Impairment/Damage			Generic	SS		ORAL		
200MG PRN								
ORAL								
			Atenolol	C				
			Levothyroxine	C				
			Allopurinol	C				

Date:08/04/00ISR Number: 3542417-3Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Thrombocytopenia	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
PO						
			Cortisone	C		

Date:08/04/00ISR Number: 3542420-3Report Type:Expedited (15-DaCompany Report #WAES 00079863
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Face Oedema	Foreign	Vioxx	PS	Merck Research	
	Hypertension	Health			Laboratories Div	
	Oedema Peripheral	Professional			Merck Co Inc	ORAL
25 MG PO 5 DAY						
			Alginic Acid/ Sodium Bicarbonate	C		
			Liothyronine	C		

Date:08/04/00ISR Number: 3542425-2Report Type:Expedited (15-DaCompany Report #WAES 00079861
Age:74 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Hypertension
Disability	Hypertensive Crisis
	Oedema

	Oedema Peripheral						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 5 DAY
			Fosamax	C			
			Calciumcarbonate (+) Cholecalciferol	C			
			Losartan Potassium /Hctz	C			

Date:08/04/00ISR Number: 3542429-XReport Type:Expedited (15-DaCompany Report #WAES 00079132
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO 8 DAY
	Haematemesis		Tab Aspirin	SS		ORAL	100 MG PO
	Melaena		Vasotec	C			
			Amlodipine	C			
			Furosemide	C			

Date:08/04/00ISR Number: 3542452-5Report Type:Expedited (15-DaCompany Report #WAES 00075160
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Atrial Flutter Confusional State Drug Interaction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 13 DAY
	Liver Disorder Liver Function Test		Elavil (Amitriptyline)	SS		ORAL	50 MG PO
	Abnormal Supraventricular		Acetaminophen Etidronic Acid Dina	C C			

	Tachycardia		Floxacillin	C		
			Loperamide	C		
			Penicillin V	C		

Date:08/04/00ISR Number: 3542456-2Report Type:Expedited (15-DaCompany Report #WAES 00067508
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Face Oedema	Foreign	Vioxx	PS	Merck Research	
	Oedema Peripheral	Health			Laboratories Div	
	Weight Increased	Professional			Merck Co Inc	ORAL
25 MG PO						

Date:08/04/00ISR Number: 3542459-8Report Type:Expedited (15-DaCompany Report #WAES 00067509
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Chest Pain	Foreign	Vioxx	PS	Merck Research	
	Headache	Health			Laboratories Div	
	Vertigo	Professional			Merck Co Inc	ORAL
SEE IMAGE 2 DAY						
			Bisoprolol Fumarate	C		
			Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3542492-6Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS		ORAL	25MG BID PO	
Hospitalization -	Diarrhoea						THAN	
Initial or Prolonged	Gastrointestinal						DAILY-RECENT	
	Haemorrhage		Atenolol	C				
	Haematochezia		Accupril	C				
	Nausea		Zocor	C				
			Flomax	C				
			Etrafon 2-1	C				
			Synthroid	C				

Date:08/04/00ISR Number: 3542505-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS				
Hospitalization -	Gastritis						DAILY	2 WK
Initial or Prolonged								

Date:08/04/00ISR Number: 3542519-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS				
Hospitalization -	Dizziness	Professional						
Initial or Prolonged	Dyspnoea							
	Haemorrhage							
	Melaena							

Date:08/04/00ISR Number: 3542615-9Report Type:Expedited (15-DaCompany Report #WAES 00075609
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemorrhage Shock	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 PO	95 DAY
		Professional	Captopril/Hctz	C				

Date:08/04/00ISR Number: 3542621-4Report Type:Expedited (15-DaCompany Report #WAES 00073483
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Amiloride Hydrochloride	C				
			Digoxin	C				
			Furosemide	C				
			Psyllium Hydrophilic Mucilloid	C				
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3542622-6Report Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Erythema	Health			Laboratories Div			
Initial or Prolonged	Gastric Ulcer	Professional			Merck Co Inc	ORAL	25 MG PO	3 DAY
	Gastroenteritis		Mepivacaine Hci	C				
	Helicobacter							
	Gastrointestinal Disorder							
	Hyperchlorhydria							
	Vomiting							

Date:08/04/00ISR Number: 3542623-8Report Type:Expedited (15-DaCompany Report #WAES 00077752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Respiratory Tract	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Infection	Consumer			Laboratories Div			
		Other			Merck Co Inc			

Date:08/04/00ISR Number: 3542626-3Report Type:Expedited (15-DaCompany Report #WAES00078604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoglycaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hyponatraemia	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	3 WK
		Other						

Date:08/04/00ISR Number: 3542630-5Report Type:Expedited (15-DaCompany Report #WAES 00078121
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Urticaria	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged			Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG PO	4	DAY					
			Other	Prednisolone	C		

Date:08/04/00ISR Number: 3542707-4Report Type:Expedited (15-DaCompany Report #WAES 00056532
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Sudden Death	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	1 DAY					
		Other				

Date:08/04/00ISR Number: 3542711-6Report Type:Expedited (15-DaCompany Report #WAES 00075575
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia	Foreign Study	Vioxx	PS	Merck Research Laboratories Div	
Hospitalization - Initial or Prolonged	Faecal Occult Blood Positive	Health Professional			Merck Co Inc	ORAL
25 MG, PO	8 DAY					
	Faeces Discoloured		Tab Aspirin	SS		ORAL
100 MG PO	100 DAY					
	Gastric Ulcer Haemorrhage		Diclofenac	C		

			Magnesium Preparation (Composition Unspe	C		
			Nebivolol Hydrochloride	C		
			Triamcinolone	C		

Date:08/04/00ISR Number: 3542713-XReport Type:Expedited (15-DaCompany Report #WAES 00075609
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haematemesis	Study			Laboratories Div			
Initial or Prolonged	Shock	Health			Merck Co Inc	ORAL	12.5 PO	95 DAY
		Professional	Captopril/Hctz	C				

Date:08/04/00ISR Number: 3542715-3Report Type:Expedited (15-DaCompany Report #WAES 00076082
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hepatitis C Antibody	Study			Laboratories Div			
	Positive	Health			Merck Co Inc	ORAL	12.5 MG, PO	33 DAY
	Melaena	Professional	Calcium Supplement (Nos)	C				
	Oesophageal Varices		Crataegus (+) Valerian	C				
	Haemorrhage		Diacerein	C				
			Etidronic Acid Dina	C				
			Ginkgo Biloba Extract	C				

Date:08/04/00ISR Number: 3542718-9Report Type:Expedited (15-DaCompany Report #WAES 00077522
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic Rectal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Dipyridamole	C		
			Lansoprazole	C		
			Pantoprazole	C		

Date:08/04/00ISR Number: 3542727-XReport Type:Expedited (15-DaCompany Report #WAES 00075213
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, 25 MG, PO	31 DAY
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Myocardial Infarction	Other						
			Aspirin	C				
			Diclofenac	C				
			Diltiazem Hydrochloride	C				
			Docusate Ca	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3542747-5Report Type:Expedited (15-DaCompany Report #WAES 00072274
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/04/00ISR Number: 3542751-7Report Type:Expedited (15-DaCompany Report #WAES 00072278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ill-Defined Disorder Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/04/00ISR Number: 3542754-2Report Type:Expedited (15-DaCompany Report #WAES 00072304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:08/04/00ISR Number: 3542756-6Report Type:Expedited (15-DaCompany Report #WAES 00072307
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Dreams Hypoglycaemia Nightmare	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
	Parasomnia		Fosamax	C				

	Sleep Talking		Humulin N	C		
			Synthroid	C		
			Potassium Supplement	C		

Date:08/04/00ISR Number: 3542789-XReport Type:Expedited (15-DaCompany Report #WAES 00072200
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aleve	C				
			Paxil	C				
			Premarin	C				
			Ziac	C				

Date:08/04/00ISR Number: 3542794-3Report Type:Expedited (15-DaCompany Report #WAES 00071072
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Zantac	SS		
			Estrogenic Preparations	SS		

Date:08/04/00ISR Number: 3542896-1Report Type:Expedited (15-DaCompany Report #WAES 00072559
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/04/00ISR Number: 3542899-7Report Type:Expedited (15-DaCompany Report #WAES 00072353
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
	Rectal Haemorrhage	Representative						
			Coumadin	C				
			Neurontin	C				
			Insulin	C				

Date:08/04/00ISR Number: 3542901-2Report Type:Expedited (15-DaCompany Report #WAES 00072561
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
Hospitalization - Initial or Prolonged	Congestive Myocardial Infarction							
	Pneumonia							
	Post Procedural Complication							

Rectal Haemorrhage

Date:08/04/00ISR Number: 3542903-6Report Type:Expedited (15-DaCompany Report #WAES 00071836
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/04/00ISR Number: 3542906-1Report Type:Expedited (15-DaCompany Report #WAES 00072159
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Difficulty In Walking Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Inflammation		Synvisc	SS			INJ	
	Osteoarthritis Pain Swelling		Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3542932-2Report Type:Expedited (15-DaCompany Report #WAES 00072586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation Frequent Bowel Movements Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acupril	C				
			Pepcid	C				
			Urispas	C				
			Hydroxyurea	C				

Date:08/04/00ISR Number: 3542933-4Report Type:Expedited (15-DaCompany Report #WAES 00072568
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease Pulse Absent Syncope Throat Tightness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins (Unspecified)	C				

Date:08/04/00ISR Number: 3542960-7Report Type:Expedited (15-DaCompany Report #WAES 00075635
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/04/00ISR Number: 3542982-6Report Type:Expedited (15-DaCompany Report #WAES 00071209
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Haemorrhage Conjunctival Hyperaemia Conjunctival Vascular Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:08/04/00ISR Number: 3543000-6Report Type:Expedited (15-DaCompany Report #WAES 00072405
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Darvocet-N	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3543001-8Report Type:Expedited (15-DaCompany Report #WAES 00071999
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Faecal Occult Blood Positive	Other			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastric Ulcer		Aspirin	C				
	Gastric Ulcer Haemorrhage		Clonazepam	C				
	Gastritis		Gemfibrozil	C				
	Haemoglobin Decreased		Propranolol	C				
			Vitmans (Unspecified)	C				

Date:08/04/00ISR Number: 3543002-XReport Type:Expedited (15-DaCompany Report #WAES 00064751
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haematemesis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Oesophagitis Upper Gastrointestinal Haemorrhage	Other			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Decreased		Premphase	C				
			Rantidine	C				

Date:08/04/00ISR Number: 3543283-2Report Type:Expedited (15-DaCompany Report #WAES 00071474
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism	Health	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage	Professional Company			Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastroenteritis	Representative						

	Helicobacter Gastrointestinal Haemorrhage Haematocrit Decreased		Digoxin	C			

Date:08/04/00ISR Number: 3543288-1Report Type:Expedited (15-DaCompany Report #WAES 00061412
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Malaise		Aldactone	C				
			Cozaar	C				
			Lasix	C				
			Prilosec	C				
			Tegretol	C				
			Vasotec	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/00ISR Number: 3543292-3Report Type:Expedited (15-DaCompany Report #WAES 00052149
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased							
	Bradycardia							
	Dehydration		Digoxin 0.25 Mg	SS			0.25 MG/DAILY	
	Drug Level Above Therapeutic		Ecotrin	C				
			Hydrodiuril	C				
	Syncope		Premarin	C				
	Therapeutic Agent		Tambocor	C				
	Toxicity		Tenormin	C				

Date:08/04/00ISR Number: 3543297-2Report Type:Expedited (15-DaCompany Report #WAES 00050750
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Anorexia	Health Professional						
	Difficulty In Walking							
Other	Hypothyroidism							
	Hypoxia							
	Insomnia							
	Lung Infiltration							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain							
	Saliva Altered							
	Tongue Disorder							
	Vasculitis							
	Weight Decreased							

Date:08/07/00ISR Number: 3542664-0Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Health	Coumadin	PS		ORAL	5 MG DAILY	
Initial or Prolonged	Haematuria	Professional				ORAL		
	Renal Failure Chronic		Vioxx	SS		ORAL	25 MG DAILY	
	Sepsis					ORAL		
	Urinary Tract Infection		Mvi	C				
			Bactrim Ds	C				
			Prevacid	C				
			Zantac	C				
			Zestoretic 20/12.5	C				
			Colace	C				
			Fibercon	C				

Date:08/07/00ISR Number: 3542666-4Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Health	Vioxx	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged	Gastric Ulcer	Professional				ORAL		
	Gastritis		Aspirin	SS		ORAL	325 MG DAILY	
	Haematochezia					ORAL		
			Vasotec	C				

Furosemide	C
Zocor	C
Doxepin	C
Metoprolol	C
Ismo	C

Date:08/07/00ISR Number: 3542688-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Vioxx 25mg	PS			25MG 1 DAY	
	Drug Level Above Therapeutic							
	Headache							
	Melanodermia							
	Muscle Spasms							
	Nausea							
	Oedema Peripheral							
	Pollakiuria							
	Rhinorrhoea							

Date:08/07/00ISR Number: 3543541-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Vioxx Tablet (Rofecoxib)	PS	Merck And Co Inc			
	Appetite Disorder							
	Chills							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Heart Rate Increased							
	Nausea							
	Peripheral Vascular Disorder							
	Vertigo							

Date:08/07/00ISR Number: 3543951-2Report Type:Expedited (15-DaCompany Report #WAES 00072258
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Vitmans (Unspecified)	C				

Date:08/07/00ISR Number: 3544160-3Report Type:Expedited (15-DaCompany Report #WAES 00075601
Age:71 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Anorexia Decreased Appetite

		Hypoglycaemia Therapeutic Response Unexpected	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG	22 DAY						
				Aspirin	C		
				B-Sitosterol	C		
				Insulin	C		
				Pentoxifylline	C		
				Ramipril	C		
				Thioctic Acid	C		

Date:08/07/00ISR Number: 3544162-7Report Type:Expedited (15-DaCompany Report #WAES 00073756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:08/07/00ISR Number: 3544166-4Report Type:Expedited (15-DaCompany Report #WES 00079556
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Zantac	C		

Date:08/07/00ISR Number: 3544169-XReport Type:Expedited (15-DaCompany Report #WAES 00073757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction	Foreign	Vioxx	PS	Merck Research	

Hospitalization -	Health	Laboratories Div
Initial or Prolonged	Professional	Merck Co Inc

Date:08/07/00ISR Number: 3544201-3Report Type:Expedited (15-DaCompany Report #WAES 00065598
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Apathy	Foreign	Vioxx	PS	Merck Research	
	Feeling Hot	Health			Laboratories Div	
	Intentional Misuse	Professional			Merck Co Inc	ORAL
SEE IMAGE 1 DAY						
	Suicide Attempt		Cyclosporin A	C		
	Vomiting		Prednisone	C		

Date:08/07/00ISR Number: 3544207-4Report Type:Expedited (15-DaCompany Report #WAES 00053112
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Death	Aggression
Hospitalization -	Agitation
Initial or Prolonged	Blood Pressure Decreased
	Condition Aggravated

		Dementia Alzheimer'S Type					
		Duodenal Ulcer					
		Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research	
		Tachycardia	Health			Laboratories Div	
			Professional			Merck Co Inc	ORAL
PO							

Date:08/07/00ISR Number: 3544219-0Report Type:Expedited (15-DaCompany Report #WAES 00061111
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Haemoglobin Decreased				Laboratories Div	
Initial or Prolonged	Haemorrhage				Merck Co Inc	ORAL
PO						
	Laboratory Test Abnormal		Diovan	C		
	Oesophageal Ulcer		Prevacid	C		
	Syncope					

Date:08/07/00ISR Number: 3544224-4Report Type:Expedited (15-DaCompany Report #WAES 00052830
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Nephritis Interstitial	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Renal Failure Acute	Professional			Laboratories Div	
Disability		Company			Merck Co Inc	ORAL
25						
Other		Representative				
MG/DAILY/PO						
			Hydrodiuril	C		
			Lo/Ovral	C		
			Ziac	C		
			Prednisone	C		

Date:08/07/00ISR Number: 3544226-8Report Type:Expedited (15-DaCompany Report #WAES 00050750
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Anorexia	Health			Laboratories Div			
Initial or Prolonged	Asthenia	Professional			Merck Co Inc	ORAL	25	
Other	Difficulty In Walking						MG/DAILY/PO	
	Dry Mouth		Levaquin	C				
	Fatigue		Synthroid	C				
	Hypothyroidism		Furosemide	C				
	Hypoxia							
	Insomnia							
	Lung Infiltration							
	Malaise							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain							
	Pyrexia							
	Saliva Altered							
	Tongue Disorder							
	Vasculitis							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/00ISR Number: 3544228-1Report Type:Expedited (15-DaCompany Report #WAES 00040780
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/07/00ISR Number: 3544230-XReport Type:Expedited (15-DaCompany Report #WAES 00070813
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/07/00ISR Number: 3544231-1Report Type:Expedited (15-DaCompany Report #WAES 00072410
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Duodenal Ulcer Injury Upper Gastrointestinal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIL/PO	
Other	Haemorrhage	Representative						

Date:08/07/00ISR Number: 3544233-5Report Type:Expedited (15-DaCompany Report #WAES 00072274
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/07/00ISR Number: 3544235-9Report Type:Expedited (15-DaCompany Report #WAES 99122174
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO (SEE IMAGE)	
	Drug Ineffective	Health Professional						
	Feeling Hot And Cold							
	Increased Appetite							
	Muscle Spasms							
	Oedema Peripheral		Hydrodiuril	C				
			Premarin	C				
			Prinivil	C				

Date:08/07/00ISR Number: 3544243-8Report Type:Expedited (15-DaCompany Report #WAES 00085508
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Oedema Mouth	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	1 DAY
			Elavil	C				
			Hydrodiuril	C				
			Vasotec	C				

Zocor	C
[Therapy Unspecified]	C
Allopurinol	C
Amlodipine Benzenesulfonate	C
Aspirin	C
Metoprolol	C
Molsidomine	C

Date:08/07/00ISR Number: 3544260-8Report Type:Expedited (15-DaCompany Report #WAES 00061619
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/07/00ISR Number: 3544261-XReport Type:Expedited (15-DaCompany Report #WAES 00060615
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Faecal Occult Blood Positive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Disability	Faeces Discoloured	Representative						
Other	Gastric Ulcer Haemorrhage		Arthrotec	C				

Date:08/07/00ISR Number: 3544262-1Report Type:Expedited (15-DaCompany Report #WAES 00060170
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Anisocytosis Arthralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Hospitalization - 25	Biopsy Bone Marrow	Other			Merck Co Inc	ORAL
Initial or Prolonged	Abnormal					
MG/DAILY/PO						
Disability	Coma		Accupril	C		
Other	Decreased Activity		Coumadin	C		
	Ecchymosis		Darvocet-N	C		
	Eyelid Oedema		Lovenox	C		
	Facial Bones Fracture		Atenolol	C		
	Fall					
	Haematoma					
	Haemorrhage					
	Haemorrhagic Stroke					
	Hereditary Spherocytosis					
	Idiopathic					
	Thrombocytopenic Purpura					
	Injury					
	Myocardial Infarction					
	Pancytopenia					
	Swelling					
	Syncope					
	White Blood Cell Count					
	Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/00ISR Number: 3544343-2Report Type:Expedited (15-DaCompany Report #WAES 00075548
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastroduodenal Ulcer Scar Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Hyzaar	C				
			Alfuzosin	C				
			Allopurinol	C				
			Ampicillin Sodium/Sulbactam Sodium	C				
			Gentamicin	C				

Date:08/07/00ISR Number: 3544345-6Report Type:Expedited (15-DaCompany Report #WAES 00065537
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	19 DAY
			Clenbuterol Hcl	C				
			Fenoterol Hydrobromide (+)					
			Ipratropium B	C				
			Methylprednisolone	C				
			Phenprocoumon	C				

Date:08/07/00ISR Number: 3544348-1Report Type:Expedited (15-DaCompany Report #WAES 00086012
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	4 DAY
			Atenolol	C				

Date:08/08/00ISR Number: 3544696-5Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx Qd (Don'T Know Dose)	PS			1 QD PAST SIX WEEKS	

Date:08/08/00ISR Number: 3545476-7Report Type:Expedited (15-DaCompany Report #WAES 00085511
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	47 DAY
	Gastrointestinal Disorder							
	Haemorrhage							
	Platelet Count Decreased	Professional	Aspirin	C				
	Rectal Haemorrhage	Other	Fluorouracil	C				

Date:08/08/00ISR Number: 3545478-0Report Type:Expedited (15-DaCompany Report #WAES 00089751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia Rectal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Diclofenac Na	C				

Date:08/08/00ISR Number: 3545481-0Report Type:Expedited (15-DaCompany Report #WAES 00076517
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	5 WK
		Other	Acebutolol	C				
			Furosemide	C				
			Moxonidine	C				

Date:08/08/00ISR Number: 3545483-4Report Type:Expedited (15-DaCompany Report #WAES 00063514
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dyspnoea Left Ventricular Failure Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	15 DAY
			Methotrexate	C				

Date:08/08/00ISR Number: 3545515-3Report Type:Expedited (15-DaCompany Report #WAES 00080003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	
PO						

Date:08/08/00ISR Number: 3545522-0Report Type:Expedited (15-DaCompany Report #WAES 00080180
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Amylase Increased Chest Pain Lipase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:08/08/00ISR Number: 3545525-6Report Type:Expedited (15-DaCompany Report #WAES 00080258
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Acute Respiratory Distress Syndrome	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/00ISR Number: 3545528-1Report Type:Expedited (15-DaCompany Report #WAES 00072350
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Diverticulum Intestinal Erythema Faecal Occult Blood Positive Gastrointestinal Haemorrhage Gastrointestinal Tract Mucosal Discolouration Haemoglobin Decreased Haemorrhoids Vision Blurred	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:08/08/00ISR Number: 3545529-3Report Type:Expedited (15-DaCompany Report #WAES 00062942
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Genital Pruritus Female Vaginal Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Vaginal Pain		Tylenol	C				

Date:08/08/00ISR Number: 3545532-3Report Type:Expedited (15-DaCompany Report #WAES 00080165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Haemorrhage Intracranial	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

Date:08/08/00ISR Number: 3545534-7Report Type:Expedited (15-DaCompany Report #WAES 00080114
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Feeling Abnormal							
	Hypoaesthesia							
	Pain		Elavil	C				
			Premarin	C				
			Synthroid	C				

Date:08/08/00ISR Number: 3545536-0Report Type:Expedited (15-DaCompany Report #WAES 00080104
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cryptogenic Organizing Pneumonia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/00ISR Number: 3545518-9Report Type:Expedited (15-DaCompany Report #WAES 00080024
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma Pneumonia Respiratory Disorder Sputum Discoloured	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/ PO	

Date:08/09/00ISR Number: 3548488-2Report Type:Periodic Company Report #1320423A
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal Overdose	Consumer	Tylenol	PS	Mcneil Consumer Products Co Div Mcneilab Inc	ORAL	1000 MG, Q5-6H, PO	235 DAY
			Lipitor (R)	SS		ORAL	PO	
			Vioxx	SS				
			Lasix (R)	C				
			Norvasc (R)	C				
			Inderal (R)	C				

Date:08/10/00ISR Number: 3547700-3Report Type:Expedited (15-DaCompany Report #WAES 00085519
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Speech Disorder Transient Ischaemic Attack Tremor	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	20 DAY
			Calcium Citrate (+)					
			Calcium Gluconate (+)	C				
			Metformin Hcl	C				

				Tramadol Hcl	C		

Date:08/10/00ISR Number: 3547719-2Report Type:Expedited (15-DaCompany Report #WAES 00085055
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Abdominal Pain Upper Headache Hypertension Nausea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	PO

Date:08/10/00ISR Number: 3547740-4Report Type:Expedited (15-DaCompany Report #WAES 00075636
Age:34 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Coagulopathy Convulsion Diplopia Drug Interaction Drug Level Above Therapeutic Metabolic Acidosis Neurological Symptom

		Prothrombin Time Prolonged Renal Impairment	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Sedation Therapeutic Agent Toxicity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	16 DAY
				Mesalamine	SS		ORAL	1500 MG PO	54 DAY
				Diclofenac	C				
				Dipyrone	C				
				Methotrexate	C				
				Prednisone	C				
				Tramadol Hcl	C				

Date:08/10/00ISR Number: 3547743-XReport Type:Expedited (15-DaCompany Report #WAES 00085533
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/10/00ISR Number: 3547745-3Report Type:Expedited (15-DaCompany Report #WAES 00085522
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Left Ventricular Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Phenprocoumon	C				

Date:08/10/00ISR Number: 3547746-5Report Type:Expedited (15-DaCompany Report #WAES 00085513
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis	Foreign	Vioxx	PS	Merck Research			
	Haemoglobin Decreased	Health			Laboratories Div			
	Shock	Professional			Merck Co Inc	ORAL	25 MG	PO
	Speech Disorder		Captopril	C				
	Tremor		Homeopathic					
	Ulcer		Medications	C				
	Upper Gastrointestinal Haemorrhage							

Date:08/10/00ISR Number: 3547750-7Report Type:Expedited (15-DaCompany Report #WAES 00085039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Jaundice	Foreign	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc		3	WK
			Bendroflumethiazide	C				
			Bumetanide	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/00ISR Number: 3547752-0Report Type:Expedited (15-DaCompany Report #WAES 00089301
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY

Date:08/10/00ISR Number: 3547754-4Report Type:Expedited (15-DaCompany Report #WAES 00075230
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Fear Feeling Abnormal Hallucination	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:08/10/00ISR Number: 3547756-8Report Type:Expedited (15-DaCompany Report #WAES 00088505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:08/10/00ISR Number: 3547811-2Report Type:Expedited (15-DaCompany Report #WAES 00085021
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET PO	
			Zocor	C				
			Acetaminophen/Codein					

			e Phosphate	C
			Actaminophen/Propoxy phene Hydrchloride	C
			Atenolol	C
			Ferrous Sulfate	C
			Lactulose	C
			Mirtazapine	C
			Nitroglycerin	C
			Valproic Acid	C
			Zopiclone	C

Date:08/10/00ISR Number: 3547814-8Report Type:Expedited (15-DaCompany Report #WAES 00085004
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY
			Acetaminophen/Codein e Phosphate	C				
			Diazepam	C				
			Lansoprazole	C				
			Quinine Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/00ISR Number: 3547817-3Report Type:Expedited (15-DaCompany Report #WAES 00085534
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other						

Date:08/10/00ISR Number: 3547819-7Report Type:Expedited (15-DaCompany Report #WAES 00089103
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Haemorrhage Haematemesis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Venlafaxine Hcl	SS		ORAL	75 MG PO	60 DAY
			Alprazolam	C				
			Nicardipine Hcl	C				
			Zopiclone	C				

Date:08/10/00ISR Number: 3547825-2Report Type:Expedited (15-DaCompany Report #WAES 00073766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	
			Sulfasalazine	C				

Date:08/10/00ISR Number: 3547929-4Report Type:Expedited (15-DaCompany Report #20000800116
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Foreign	Prilosec	PS	Astrazeneca Lp	ORAL	PO	
	Nephritis Interstitial	Other	Methotrexate	SS				
	Renal Failure Acute		Celecoxib	SS				
			Rofecoxib	SS				

Date:08/10/00ISR Number: 3548256-1Report Type:Expedited (15-DaCompany Report #WAES 00072018
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
	Anaemia	Professional			Laboratories Div			
	Gastric Ulcer				Merck Co Inc	ORAL	50 MG DAILY	
	Gastrointestinal						PO	
	Haemorrhage		Soma	C				
	Haemorrhoids		Tylenol	C				
	Melaena							
	Oesophagitis							
	Peptic Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/00ISR Number: 3548269-XReport Type:Expedited (15-DaCompany Report #WAES 00080549
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Haemoglobin Decreased				Laboratories Div			
Initial or Prolonged	Syncope				Merck Co Inc	ORAL	12.5 MG BID	
	Upper Gastrointestinal							
	Haemorrhage		Norvasc	C				
			Soma	C				
			Tenormin	C				
			Prednisone	C				
			Ranitidine	C				

Date:08/10/00ISR Number: 3548272-XReport Type:Expedited (15-DaCompany Report #WAES 00072602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Aspirin	C				

Date:08/10/00ISR Number: 3548274-3Report Type:Expedited (15-DaCompany Report #WAES 00080382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Haematochezia	Company			Laboratories Div			
	Hypoaesthesia	Representative			Merck Co Inc	ORAL	25 MG DAILY	
	Rectal Haemorrhage							
							PO	

Date:08/10/00ISR Number: 3548275-5Report Type:Expedited (15-DaCompany Report #WAES 00080432
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Actos	C				
			Altace	C				
			Aspirin	C				
			Claritin	C				
			Estrace	C				
			Fiorinal	C				
			Humulin N	C				
			Lipitor	C				
			Ultram	C				

Date:08/10/00ISR Number: 3548336-0Report Type:Expedited (15-DaCompany Report #WAES 00071798
Age:78 YR Gender:Female I/FU:I

Outcome	PT
Other	Asthenia
	Decreased Activity
	Fatigue
	Headache

	Joint Swelling Nausea Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:08/10/00ISR Number: 3548341-4Report Type:Expedited (15-DaCompany Report #WAES 00080436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hepatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO

Date:08/10/00ISR Number: 3548346-3Report Type:Expedited (15-DaCompany Report #WAES 00071201
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Chest Pain Duodenal Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO
	Gastrointestinal Haemorrhage		Motrin	C			

Date:08/10/00ISR Number: 3548353-0Report Type:Expedited (15-DaCompany Report #WAES 00080315
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Agitation	Health	Flexeril	PS	Merck And Co Inc	ORAL	PO

Initial or Prolonged	Hallucination Mental Impairment Paranoia	Professional	Tab Vioxx Propranolol	SS C

Date:08/11/00ISR Number: 3548155-5Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ecchymosis		Vioxx 25mg Merck	PS	Merck	ORAL	1/DAY ORAL	

Date:08/11/00ISR Number: 3548921-6Report Type:Expedited (15-DaCompany Report #WAES 00070047
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anaemia Asthenia Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Difficulty In Walking							
	Gastric Ulcer Haemorrhage		Ticlid 250 Mg	SS			250 MG / BID / DAILY	
	Oesophageal Ulcer							
	Haemorrhage		Aspirin Unk	SS				
	Pneumonia Renal Failure		[Therapy Unspecified] Nitro-Dur Norvasc	SS C C				

			Prevacid	C		
			Tenormin	C		
			Tylenol	C		
			Docusate Calcium	C		
			Ferrous Sulfate	C		
			Vitamins (Unspecified)	C		

Date:08/11/00ISR Number: 3548932-0Report Type:Expedited (15-DaCompany Report #WAES 00061767
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:08/11/00ISR Number: 3548936-8Report Type:Expedited (15-DaCompany Report #WAES 00052935
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Embolism Essential Thrombocythaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Eye Disorder Myeloproliferative Disorder Tachycardia Visual Disturbance		Fosamax	C				
			Lanoxin	C				
			Levoxyl	C				
			Lopressor	C				
			Relafen	C				
			Zocor	C				
			Aspirin	C				

Date:08/11/00ISR Number: 3548947-2Report Type:Expedited (15-DaCompany Report #WAES 00063039
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Dizziness							
	Gastritis		Calan	C				
	Haematochezia		Celebrex	C				
	Haematocrit Decreased		Hyzaar	C				
	Haemorrhage		Prilosec	C				
	Inguinal Hernia		Atenolol	C				
	Melaena							
	Upper Gastrointestinal Haemorrhage							

Date:08/11/00ISR Number: 3548962-9Report Type:Expedited (15-DaCompany Report #WAES 99090438
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Other	Adenoma Benign
	Colonic Polyp
	Diverticulum Intestinal

	Duodenitis						
	Faecal Occult Blood						
	Gastric Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastritis	Study	Vioxx	PS	Merck Research		
	Gastrointestinal	Health			Laboratories Div		
	Haemorrhage	Professional			Merck Co Inc	ORAL	25
	Gastrointestinal Ulcer						MG/DAILY/PO
	Haematocrit Decreased		Tab Acetaminophen				
	Haemoglobin Decreased		325 Mg	SS		ORAL	PRN/PO
	Neoplasm Prostate		Cardura	C			
	Rectal Polyp		Zestoretic	C			
			Zocor	C			
			Aspirin	C			
			Vitamin D	C			

Date:08/11/00ISR Number: 3549093-4Report Type:Expedited (15-DaCompany Report #WAES 00081061
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Arrhythmia	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:08/11/00ISR Number: 3549450-6Report Type:Expedited (15-DaCompany Report #S00-SWE-01147-01
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Foreign	Celexa	PS	Forest Laboratories Inc	ORAL	20 MG QD PO
	Melaena	Health					
	Oesophageal Stenosis	Professional	Vioxx(Rofecoxib)	SS		ORAL	12 MG QD PO
		Other	Panodil (Paracetamol)	C			
			Visken (Pindolol)	C			
			Stilnoct (Zolpidem				

			Tartrate)	C		

Date:08/11/00ISR Number: 3549539-1Report Type:Expedited (15-DaCompany Report #WAES 00075583
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspnoea Oedema Peripheral Pericardial Effusion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO						
	Pleural Effusion Weight Decreased		Digoxin Furosemide Metoprolol Succinate Naloxone Hydrochloride (+) Tilidine	C C C C		

Date:08/11/00ISR Number: 3549542-1Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Haemorrhage Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3548520-6Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration		Vioxx	PS	Merck			

Date:08/14/00ISR Number: 3549035-1Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia	Consumer	Vioxx	PS	Merck	ORAL	25MG DAY ORAL	
	Transient Ischaemic Attack	Other	Lotrel	C				
			Asprin	C				
			Cardura	C				

Date:08/14/00ISR Number: 3549986-8Report Type:Expedited (15-DaCompany Report #WAES 00072660
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/14/00ISR Number: 3550194-5Report Type:Expedited (15-DaCompany Report #WAES 00075156
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Purpura Vasculitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Tab Vioxx (Rofecoxib) 25 Mg	SS		ORAL	25 MG	8 DAY
			Atenolol	C				

			Isosorbide-5-Mononitrate	C		
			Omeprazole	C		
			Prednisolone	C		
			Thyroxine	C		

Date:08/14/00ISR Number: 3550342-7Report Type:Expedited (15-DaCompany Report #WAES 00079151
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Haemorrhage	Health			Laboratories Div	
Initial or Prolonged	Gastroenteritis	Professional			Merck Co Inc	ORAL
25 MG 36 DAY						
	Helicobacter	Other	Calcium Carbonate	C		
	Gastrointestinal		Calcium Glubionate	C		
	Haemorrhage		Enalapril Maleate	C		
			Propranolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550343-9Report Type:Expedited (15-DaCompany Report #WAES 00078520
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Antinuclear Antibody Positive Blood Creatine Phosphokinase Increased Oedema Weight Increased	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:08/14/00ISR Number: 3550344-0Report Type:Expedited (15-DaCompany Report #WAES 00085513
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Haematemesis Haemoglobin Decreased Oesophageal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Shock	Other	Captopril Homeopathic Medications	C C				

Date:08/14/00ISR Number: 3550346-4Report Type:Expedited (15-DaCompany Report #WAES 00078917
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
	Gastrointestinal Haemorrhage Haemoglobin Decreased		Colchicine Injection	C				

Date:08/14/00ISR Number: 3550347-6Report Type:Expedited (15-DaCompany Report #WAES 00027293
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Bone Marrow Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Blood Creatinine							
	Increased Oedema		Tab Methotrexate Dina	SS		ORAL	PO	8 YR
	Pancytopenia		Acetaminophen/Codeine Phosphate	C				
	Renal Failure		B Vitamins (+) Caffeine	C				
			Enoxaparin	C				
			Estradiol/Norethindrone Acetate	C				
			Propoxyphene Napsylate Monohydrate	C				
			Sotalol Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550348-8Report Type:Expedited (15-DaCompany Report #WAES 00057285
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Leukocytosis	Other						
	Renal Failure							
	Spinal Compression		Elavil	C				
	Fracture		Acetaminophen	C				
	Thrombocythaemia		Acetylcysteine	C				
			Diazepam	C				
			Doxazosin Monomethanesulfonate	C				
			Furosemide	C				
			Lactulose	C				
			Loratadine	C				
			Metoprolol Tartrate	C				
			Oxycodone Hcl	C				
			Picosulfate Na	C				
			Verapamil Hcl	C				
			Warfarin Sodium	C				

Date:08/14/00ISR Number: 3550365-8Report Type:Expedited (15-DaCompany Report #WAES 00075600
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	48 DAY
Hospitalization - Initial or Prolonged	Blood Iron Decreased	Health Professional						
	Dizziness							
	Dyspnoea	Other						
	Endoscopy Abnormal							
	Faeces Discoloured							
	Gastritis							
	Gastritis Atrophic							
	Gastrointestinal Disorder							
	Gastrointestinal Haemorrhage							
	Haemoglobin Decreased							
	Serum Ferritin Decreased							
	Vitamin B12 Decreased							

Date:08/14/00ISR Number: 3550372-5Report Type:Expedited (15-DaCompany Report #WAES 00089752
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Malaise Medication Error	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:08/14/00ISR Number: 3550374-9Report Type:Expedited (15-DaCompany Report #WAES 00087515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550382-8Report Type:Expedited (15-DaCompany Report #WAES 00075648
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Ecchymosis Haematocrit Decreased Haemoglobin Decreased Leukopenia Red Blood Cell Count Decreased Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	9 DAY

Date:08/14/00ISR Number: 3550384-1Report Type:Expedited (15-DaCompany Report #WAES 00077525
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Pravastatin Na	C				
			Sotalol Hydrochloride	C				
			Tibolone	C				

Date:08/14/00ISR Number: 3550387-7Report Type:Expedited (15-DaCompany Report #WAES 00085065
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Anaphylactic Reaction Angioneurotic Oedema Dermatitis Face Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG	
			Acetaminophen	C				
			Furosemide	C				
			Insulin Injection					

/Isophane Insulin Suspe	C
Methotrexate	C
Paroxetine	C
Prednisolone	C
Senna	C

Date:08/14/00ISR Number: 3550388-9Report Type:Expedited (15-DaCompany Report #WAES 00085045
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550390-7Report Type:Expedited (15-DaCompany Report #WAES 00085551
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anuria Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		OPHTHALMIC	50 MG 9 DAY
		Other	Hydrochlorothiazide (+) Valsartan	SS		ORAL	12.5/80 MG	
			Hctz/Triamterene	C				
			Carbimazole	C				
			Clonidine Hcl	C				
			Flecainide Monoacetate	C				
			Moxifloxacin Hydrochloride	C				

Date:08/14/00ISR Number: 3550393-2Report Type:Expedited (15-DaCompany Report #WAES 00075233
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other UNKNOWN	Chest Pain Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
		Other	Tab Vioxx (Rofecoxib)	SS		ORAL	50 MG PO	
			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG	
			Vasotec	C				
			Aspirin	C				
			Atenolol	C				
			Bendroflumethiazide	C				

Date:08/14/00ISR Number: 3550395-6Report Type:Expedited (15-DaCompany Report #WAES 00075547
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	69 DAY
	Gastritis Gastroenteritis Helicobacter Haemoglobin Decreased Melaena Upper Gastrointestinal Haemorrhage Vomiting	Other	Hyzaar Budesonide Clopidogrel Bisulfate Dipyrone Formoterol Fumarate Dihydrate Furosemide Gliquidone Metoclopramide Tramadol Hcl	C C C C C C C C C				

Date:08/14/00ISR Number: 3550396-8Report Type:Expedited (15-DaCompany Report #WAES 00035675
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Creatinine
Other	Increased
	Cardiac Failure

		Cardiac Failure					
		Congestive					
		Chest X-Ray Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dialysis	Foreign	Vioxx	PS	Merck Research	
		Pleural Effusion	Health			Laboratories Div	
		Renal Failure Acute	Professional			Merck Co Inc	ORAL
		Ultrasound Scan Abnormal	Other	Allopurinol	C		
				Amoxicillin	C		
				Dipyrone	C		
				Fluoxetine Hcl	C		
				Furosemide	C		
				Omeprazole	C		
				Promazine Hcl	C		

Date:08/14/00ISR Number: 3550398-1Report Type:Expedited (15-DaCompany Report #WAES 00078919
Age:33 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Condition Aggravated	Health			Laboratories Div	
Initial or Prolonged		Myocardial Infarction	Professional			Merck Co Inc	ORAL
25 MG							
		Oedema	Other				

Date:08/14/00ISR Number: 3550402-0Report Type:Expedited (15-DaCompany Report #WAES 00047297
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Creatinine	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Increased	Other			Laboratories Div	
Initial or Prolonged		C-Reactive Protein				Merck Co Inc	ORAL
12.5MG PO	6 DAY						
		Increased		Vasotec	C		
		Dehydration		Acetaminophen	C		
		Myoglobin Blood Increased		Allopurinol	C		
		Renal Failure		Clopidogrel			
		Rhabdomyolysis		Bisulfate	C		
				Dixyrazine	C		
				Furosemide	C		
				Ketobemidone Hcl	C		

Metoprolol Tartrate	C
Nitroglycerin	C
Tramadol	C
Vitamin B (12)	C

Date:08/14/00ISR Number: 3550403-2Report Type:Expedited (15-DaCompany Report #WAES 00047311
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
	Cardiac Failure
	Cardiac Failure
	Congestive
	Cholecystitis
	Cough
	Duodenitis
	Gastritis
	Hypoxia
	Melaena

		Nausea Oedema Pleural Effusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pyrexia Renal Failure Upper Respiratory Tract	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG PO	13 DAY						
		Infection Weight Decreased		La-Hydroxycholecalciferol	C		
				Acetylcysteine	C		
				Digitoxin	C		
				Dipyridamole	C		
				Furosemide	C		
				Insulin Injection/Isophane Insulin Suspe	C		
				Irbesartan	C		
				Isosorbide-5-Mononitrate	C		
				Potassium Chloride	C		

Date:08/14/00ISR Number: 3550404-4Report Type:Expedited (15-DaCompany Report #WAES 00047314
Age:92 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death Hospitalization - Initial or Prolonged		Blood Creatinine Increased C-Reactive Protein	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	6 DAY						
		Increased		Cefuroxime Na	SS		
2.2 GM	7 DAY						
		Oliguria Renal Failure Synovitis		Acetaminophen	C		
				Calcium Carbonate (+) Vitamin D (3)	C		
				Omeprazole	C		
				Oxazepam	C		
				Propoxyphene Napsylate Monohydrate	C		
				Vitamin B (12)	C		

Date:08/14/00ISR Number: 3550420-2Report Type:Expedited (15-DaCompany Report #WAES 00035653
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG PO	5 DAY
			Vasotec	C				
			Acetaminophen	C				
			Acetylcysteine	C				
			Bisoprolol Fumarate	C				
			Clotiazepam	C				
			Digoxin					
			B-Acetyldigoxin	C				
			Phenprocoumon	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550421-4Report Type:Expedited (15-DaCompany Report #WAES 00075632
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY
			Vasotec	C				
			Insulin Injection/Isophane Insulin Suspe	C				

Date:08/14/00ISR Number: 3550423-8Report Type:Expedited (15-DaCompany Report #WAES 00071697
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia Blood Urea Increased Dehydration Gastritis Erosive Gastroenteritis Gastrointestinal Haemorrhage Melaena Nephropathy Pallor Proteinuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Celebrex	C				
			Zocor	C				

Date:08/14/00ISR Number: 3550429-9Report Type:Expedited (15-DaCompany Report #WAES 00060093
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	

Representative
PO 1 MON

Premarin Unk	SS	
Therapy Unspecified	C	

Date:08/14/00ISR Number: 3550476-7Report Type:Expedited (15-DaCompany Report #WAES 00080432
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
		Representative						
			Actos	C				
			Altace	C				
			Aspirin	C				
			Claritin	C				
			Estrace	C				
			Fiorinal	C				
			Humulin N	C				
			Lipitor	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550478-0Report Type:Expedited (15-DaCompany Report #WAES 00080518
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Lasix	C				
			Levoxyl	C				
			Paxil	C				
			Premarin	C				
			Risperdal	C				
			Nitroglycerin	C				
			Potassium (Unspecified)	C				
			Trazodone	C				

Date:08/14/00ISR Number: 3550480-9Report Type:Expedited (15-DaCompany Report #WAES 00080593
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urine Potassium Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Lipitor	C				
			Bumetanide	C				
			Insulin	C				

Date:08/14/00ISR Number: 3550486-XReport Type:Expedited (15-DaCompany Report #WAES 00080446
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Faeces Discoloured Haemoglobin Decreased Laboratory Test Abnormal Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 25 MG/DAILY/PO
			Fosamax	C		
			Norvasc	C		
			Serevent	C		
			Synthroid	C		
			Acetaminophen (+) Propoxyphene	C		

Date:08/14/00ISR Number: 3550487-1Report Type:Expedited (15-DaCompany Report #WAES 00080567
Age:76 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Asthenia
Hospitalization -	Dementia
Initial or Prolonged	Dizziness
Other	Duodenal Ulcer
	Haemorrhage
	Dyspnoea
	Extrasystoles
	Faeces Discoloured

		Gastrointestinal Haemorrhage Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lethargy Pallor Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Glucophage	C		
				Humulin	C		
				Imdur	C		
				Lasix	C		
				Prinivil	C		
				Sinemet	C		
				Toprol Xl Tablets	C		
				Xanax	C		
				Zaroxolyn	C		
				Aspirin	C		

Date:08/14/00ISR Number: 3550489-5Report Type:Expedited (15-DaCompany Report #WAES 00080518
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:08/14/00ISR Number: 3550490-1Report Type:Expedited (15-DaCompany Report #WAES 00080512
Age:46 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Deafness Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/BID/PO							

Date:08/14/00ISR Number: 3550491-3Report Type:Expedited (15-DaCompany Report #WAES 00070909
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination, Olfactory Hallucinations, Mixed	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Miacalcin	C				
			Norvasc	C				
			Tums	C				
			Atenolol	C				
			Cholecalciferol	C				
			Prednisone	C				

Date:08/14/00ISR Number: 3550499-8Report Type:Expedited (15-DaCompany Report #WAES 00080566
Age:85 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Duodenal Ulcer				Merck Co Inc	ORAL	25 MG/PO	
	Gastric Ulcer		Ascriptin	C				
	Haematocrit Decreased		Celebrex	C				
	Haemoglobin Decreased		Lanoxin	C				
	Pallor							

Date:08/14/00ISR Number: 3550501-3Report Type:Expedited (15-DaCompany Report #WAES 00080666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Abdominal Pain				Laboratories Div			
	Abdominal Pain Upper				Merck Co Inc	ORAL	12.5	
	Diarrhoea						MG/DAILY/PO	
	Dizziness							
	Eating Disorder							
	Fall							
	Hyperhidrosis							
	Muscular Weakness							
	Nausea							
	Oral Intake Reduced							
	Pyrexia							
	Syncope							
	Upper Gastrointestinal							
	Haemorrhage							
	Vomiting							

Date:08/14/00ISR Number: 3550503-7Report Type:Expedited (15-DaCompany Report #WAES 00080462
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Calculus Urinary	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Confusional State			Laboratories Div	
	Disorientation			Merck Co Inc	ORAL
PO					
	Dizziness	Diazide	C		
	Eye Pain	Flomax (Tamsulosin			
	Headache	(R)-Form Hydr	C		
	Vision Blurred	Lotensin	C		
		Nitroglycerin	C		
		Prozac	C		
		Toprol Xl Tablets	C		
		Zocor	C		
		Aspirin	C		
		Diruetic Preparation			
		(Compositio	C		

Date:08/14/00ISR Number: 3550505-0Report Type:Expedited (15-DaCompany Report #WAES 00080488
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Distension
	Cardiac Disorder
	Dyspepsia

	Dyspnoea						
	Eye Disorder						
	Fluid Retention	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research		
	Renal Disorder				Laboratories Div		
	Weight Increased				Merck Co Inc	ORAL	12.5 MG/DAILY/PO
			Azmacort	C			
			Calan Sr	C			
			Lasix	C			
			Prilosec	C			
			Propulsid	C			
			Serevent	C			
			Synthroid	C			
			Albuterol	C			

Date:08/14/00ISR Number: 3550507-4Report Type:Expedited (15-DaCompany Report #WAES 00071140
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Failure	Health	Vioxx	PS	Merck Research		
	Congestive	Professional			Laboratories Div		
	Condition Aggravated	Company			Merck Co Inc	ORAL	12.5 MG/DAILY/ORAL
	Confusional State	Representative					
	Hallucinations, Mixed		Ceftin	C			
			Colace	C			
			Synthroid	C			
			Digoxin	C			
			Folic Acid	C			
			Vitamins	C			

Date:08/14/00ISR Number: 3550508-6Report Type:Expedited (15-DaCompany Report #WAES 00080767
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research		

Initial or Prolonged	Haemorrhage	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Calan	C		
			Lipitor	C		
			Prozac	C		
			Antimicrobial Therapy (Compositi	C		
			Aspirin	C		

Date:08/14/00ISR Number: 3550510-4Report Type:Expedited (15-DaCompany Report #WAES 00080641
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Nitrostat	C		
			Prevacid	C		
			Amoxicillin	C		
			Timolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550528-1Report Type:Expedited (15-DaCompany Report #WAES 00064754
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Asthenia							
	Dizziness							
	Faecal Occult Blood						PO	
	Positive		Accupril	C				
	Feeling Abnormal		Quinidine Sulfate	C				
	Gastrointestinal Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:08/14/00ISR Number: 3550554-2Report Type:Expedited (15-DaCompany Report #WAES 00032455
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
Life-Threatening	Coma							
Hospitalization - Initial or Prolonged	Drug Ineffective							
Disability	Haemorrhage Intracranial	Representative	Fosamax	C				
	Haemorrhagic Stroke		Calcium Supplement	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:08/14/00ISR Number: 3550555-4Report Type:Expedited (15-DaCompany Report #WAES 00070398
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anisocytosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diverticulum							
	Dyspnoea							
	Gastrointestinal	Representative	Celebrex	C				

Haemorrhage
Haemoglobin Decreased
Haemolytic Anaemia
Haemorrhoids
Iron Deficiency Anaemia

Date:08/14/00ISR Number: 3550582-7Report Type:Expedited (15-DaCompany Report #WAES 00072018
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Abdominal Pain Upper	Professional			Laboratories Div			
	Anaemia	Company			Merck Co Inc	ORAL	50	
	Gastric Mucosal Lesion	Representative					MG/DAILY/PO	
	Gastric Ulcer		Soma	C				
	Gastrointestinal		Tylenol	C				
	Haemorrhage							
	Haemorrhoids							
	Inflammation							
	Melaena							
	Oesophageal Ulcer							
	Oesophagitis							
	Peptic Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/00ISR Number: 3550589-XReport Type:Expedited (15-DaCompany Report #WAES 00072209
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Haemoglobin Decreased	Company			Merck Co Inc	ORAL	12.5	
Disability	Small Intestinal	Representative					MG/DAILY/PO	
Other	Haemorrhage		Darvon	C				
	Upper Gastrointestinal		Ecotrin	C				
	Haemorrhage		Lopressor	C				
			Norvasc	C				
			Tenormin	C				
			Zocor	C				
			Aspirin	C				
			Nitroglycerin	C				
			Prednisone	C				

Date:08/14/00ISR Number: 3550609-2Report Type:Expedited (15-DaCompany Report #WAES 00071501
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health	Tab Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	UNK / UNK/ PO	
		Representative						

Date:08/14/00ISR Number: 3550611-0Report Type:Expedited (15-DaCompany Report #WAES 00052244
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional			Laboratories Div			
Other	Hepatitis	Company			Merck Co Inc	ORAL	25 MG/BID/PO	
	Hepatomegaly	Representative	Tab Vioxx	SS		ORAL	25	

Hiatus Hernia
MG/DAILY/PO
Rectal Haemorrhage Tab Vioxx SS ORAL
25 MG / BID/

PO
Paxil C
Premarin C

Date:08/14/00ISR Number: 3550691-2Report Type:Expedited (15-DaCompany Report #WAES 00080871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peyronie'S Disease	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/14/00ISR Number: 3550693-6Report Type:Expedited (15-DaCompany Report #WAES 00080833
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other		Company Representative	Accupril	C				

			Betapace	C
			Coumadin	C
			Lipitor	C
			Wellbutrin	C
			Aspirin	C

Date:08/14/00ISR Number: 3550696-1Report Type:Expedited (15-DaCompany Report #WAES 00060616
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Plavix	C				
			Pravachol	C				
			Tylenol	C				
			Zoloft	C				

Date:08/14/00ISR Number: 3550698-5Report Type:Expedited (15-DaCompany Report #WAES 00080934
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/14/00ISR Number: 3550699-7Report Type:Expedited (15-DaCompany Report #WAES 00080957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:08/14/00ISR Number: 3550716-4Report Type:Expedited (15-DaCompany Report #WAES 00080872
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Hytrin	C				
			Norvasc	C				
			Timoptic	C				

Date:08/14/00ISR Number: 3550718-8Report Type:Expedited (15-DaCompany Report #WAES 00080912
Age:36 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased

Pyelonephritis
Pyrexia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:08/14/00ISR Number: 3550720-6Report Type:Expedited (15-DaCompany Report #WAES 00080924
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Flovent	C				
			Lasix	C				
			Theophylline	C				

Date:08/14/00ISR Number: 3550721-8Report Type:Expedited (15-DaCompany Report #WAES 00080778
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Ultram	C				
			Aspirin	C				

Date:08/14/00ISR Number: 3550722-XReport Type:Expedited (15-DaCompany Report #WAES 00080775
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Asthma							
	Blood Pressure Increased							
	Diarrhoea							
	Dizziness		Ultram	C				
	Upper Respiratory Tract Infection							
	Vomiting							

Date:08/14/00ISR Number: 3571783-8Report Type:Expedited (15-DaCompany Report #WAES 00082983
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Fluid Retention							
	Hypertension		K-Dur	C				
			Prinivil	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/00ISR Number: 3550368-3Report Type:Expedited (15-DaCompany Report #WAES 00035321
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Cholelithiasis	Other			Laboratories Div			
Initial or Prolonged	Coagulopathy				Merck Co Inc	ORAL	12.5 MG, PO	
Other	Erosive Oesophagitis		Warfarin	SS				
	Gastritis		Amlodipine					
	Gastritis Atrophic		Benzenesulfonate	C				
	Gastrointestinal		Bicalutamide	C				
	Haemorrhage		Doxazosin	C				
	Haematemesis		Metformin	C				
	Hiatus Hernia		Triptorelin Acetate	C				
	Hyperbilirubinaemia							
	Upper Gastrointestinal Haemorrhage							

Date:08/15/00ISR Number: 3551239-9Report Type:Expedited (15-DaCompany Report #001-0981-M0002373
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Lipitor	PS	Warner Lambert			
Required	Arthritis	Professional			Export Ltd	ORAL	20 MG	
Intervention to	Asthenia						(DAILY), PER	
Prevent Permanent	Burning Sensation						ORAL	
Impairment/Damage	Decreased Activity		Vioxx (Rofecoxib)	SS			12.5 MG	
	Difficulty In Walking						(DAILY)	
	Discomfort		Prozac	C				
	Fatigue		Tylenol	C				
	Hypoaesthesia		Allegra	C				
	Insomnia		(Hyoscyamine)	C				
	Joint Contracture		Feldene	C				
	Joint Stiffness		(Ibuprofen)	C				
	Muscular Weakness							
	Oedema							
	Pain							

Pain In Extremity
Paraesthesia
Sensation Of Pressure
Sensory Disturbance
Swelling
Tendon Disorder
Tenosynovitis
Weight Decreased

Date:08/17/00ISR Number: 3551935-3Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Ibuprofen	PS			600-800MG Q 6H	
	Dyspnoea							
	Dyspnoea Exertional		Vioxx 25mg Qd	SS			25MG QD	
	Gastrointestinal		Naproxen	SS			500MG BID	
	Haemorrhage							
	Haematochezia							
	Haematocrit Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/00ISR Number: 3552241-3Report Type:Expedited (15-DaCompany Report #000808-SK067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Foreign	Celebrex	PS	Gd Searle And Co	ORAL	UNKNOWN	PO
		Other	Rofecoxib (Rofecoxib)	SS		ORAL	UNKNOWN	PO

Date:08/17/00ISR Number: 3552350-9Report Type:Expedited (15-DaCompany Report #WAES 00080782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/17/00ISR Number: 3552358-3Report Type:Expedited (15-DaCompany Report #WAES 00035047
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nail Discolouration	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	PO
	Nail Disorder	Health						
	Nail Dystrophy	Professional						
	Psoriasis		Acetminophen/Codeine Phosphate	C				
			Benserazide/Levodopa	C				

Date:08/17/00ISR Number: 3552361-3Report Type:Expedited (15-DaCompany Report #WAES 00078911
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Henoch-Schonlein Purpura	Health						

		Pulmonary Haemorrhage	Professional			Merck Co Inc	ORAL
PO	3 DAY						
		Rash Maculo-Papular					
		Respiratory Distress					

Date:08/17/00ISR Number: 3552395-9Report Type:Expedited (15-DaCompany Report #WAES 00078911
Age:15 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Appendicitis	Foreign	Vioxx	PS	Merck Research	
Other		Dyspnoea	Health			Laboratories Div	
		Henoch-Schonlein Purpura	Professional			Merck Co Inc	ORAL
PO	3 DAY						
		Pulmonary Haemorrhage					
		Rash Maculo-Papular					
		Respiratory Distress					

Date:08/17/00ISR Number: 3552400-XReport Type:Expedited (15-DaCompany Report #WAES 00080838
Age: Gender:Female I/FU:I

Outcome	PT
Other	Aneurysm
	Blood Pressure Increased
	Dyspepsia
	Embolism
	Headache

		Hypertension Musculoskeletal Stiffness Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO							

Date:08/17/00ISR Number: 3552401-1Report Type:Expedited (15-DaCompany Report #WAES 00081076
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blister Cardiac Murmur Chest Pain Face Oedema Gastric Disorder Pharyngeal Oedema Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:08/17/00ISR Number: 3552403-5Report Type:Expedited (15-DaCompany Report #WAES 00061041
Age:80 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Asthenia Blood Creatinine Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY							
PO		Blood Urea Increased					
		Gastric Ulcer Haemorrhage		Calan Sr	C		
		Haematemesis		Sinequan	C		
		Haemoglobin Decreased		Zoloft	C		
		Malaise		Captopril	C		
		Renal Failure		Furosemide	C		
				Potassium Chloride	C		

Date:08/17/00ISR Number: 3552404-7Report Type:Expedited (15-DaCompany Report #WAES 00071378
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faecal Occult Blood Positive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Gastric Ulcer Haemorrhage							
	Haematemesis							
	Haematocrit Decreased		Synthroid	C				
	Haemoglobin Decreased		Tylenol With Codeine #3	C				
	Melaena							
	Orthostatic Hypotension		Atenolol	C				
	Pulse Abnormal		Methotrexate	C				
	Ulcer							

Date:08/17/00ISR Number: 3552617-4Report Type:Expedited (15-DaCompany Report #WAES 00071372
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
Life-Threatening								
Hospitalization - Initial or Prolonged	Haematemesis							

Allegra	C	
Zyprexa	C	
Glyburide	C	

Date:08/17/00ISR Number: 3552652-6Report Type:Expedited (15-DaCompany Report #WAES 00081061
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:08/17/00ISR Number: 3552653-8Report Type:Expedited (15-DaCompany Report #WAES 00080180
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Amylase Increased Chest Pain Lipase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:08/17/00ISR Number: 3552654-XReport Type:Expedited (15-DaCompany Report #WAES 00088505
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Convulsion Hypertension Hypertensive Crisis Hypertensive Encephalopathy Oedema Peripheral	Health Professional	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc			

Date:08/18/00ISR Number: 3553534-6Report Type:Expedited (15-DaCompany Report #WAES 00087509
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 DAY
			Acetaminophen (+) Caffeine (+) Codeine P	C				
			Tetrazepam	C				

Date:08/18/00ISR Number: 3553535-8Report Type:Expedited (15-DaCompany Report #WAES 00085568
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	111 DAY
		Other	B-Sitosterol	C				
			Gingko Biloba Extract	C				

			Glyburide	C		
			Herbal Remedies (Composition Unspecified	C		
			Metformin Hcl	C		

Date:08/18/00ISR Number: 3553540-1Report Type:Expedited (15-DaCompany Report #WAES 00087511
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Atenolol	C				
			Candesartan	C				
			Fenofibrate	C				
			Furosemide	C				
			Omeprazole	C				
			Prednisolone	C				

Date:08/18/00ISR Number: 3553558-9Report Type:Expedited (15-DaCompany Report #WAES 00076046
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Acute Myeloid Leukaemia Leukopenia Neutropenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	41 DAY
	Retinal Vascular Occlusion Retinal Vein Thrombosis Visual Acuity Reduced		Ranitidine Timolol	C C				

Date:08/18/00ISR Number: 3553572-3Report Type:Expedited (15-DaCompany Report #WAES 00089760
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO	2 WK						

Date:08/18/00ISR Number: 3553626-1Report Type:Expedited (15-DaCompany Report #WAES 00035321
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Cholelithiasis	Other			Laboratories Div			
	Coagulopathy				Merck Co Inc	ORAL	12.5 MG	
	Erosive Oesophagitis		Warfarin	SS			5 MG	
	Gastritis Atrophic		Amlodipine Benzenesulfonate	C				
	Haematemesis		Bicalutamide	C				
	Hiatus Hernia		Doxazosin	C				
	Hyperbilirubinaemia		Metformin	C				
	Oesophageal Haemorrhage		Triptorelin Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/00ISR Number: 3553656-XReport Type:Expedited (15-DaCompany Report #WAES 00089752
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Malaise	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:08/18/00ISR Number: 3553661-3Report Type:Expedited (15-DaCompany Report #WAES 00035321
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Back Pain Cholelithiasis Coagulopathy	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
Other	Erosive Oesophagitis		Warfarin	SS			5 MG	
	Gastritis Atrophic		Amlodipine	C				
	Gastrointestinal Haemorrhage		Bicalutamide	C				
	Haematemesis		Doxazosin	C				
	Hiatus Hernia		Metformin	C				
	Hyperbilirubinaemia							
	Upper Gastrointestinal Haemorrhage							

Date:08/18/00ISR Number: 3553711-4Report Type:Expedited (15-DaCompany Report #WAES 00080976
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Bilirubin Increased Cholecystitis Condition Aggravated	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hepatitis		Allegra	C				
	Liver Function Test Abnormal		Norflex	C				
	Malaise		Doxycycline	C				

Neck Pain
Pain
Pyrexia

Date:08/18/00ISR Number: 3553713-8Report Type:Expedited (15-DaCompany Report #WAES 00081005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Dizziness Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Avandia	C				
			Glucophage	C				
			Lipitor	C				
			Vasotec	C				
			Atenolol	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/00ISR Number: 3553729-1Report Type:Expedited (15-DaCompany Report #WAES 00081223
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage	Company			Merck Co Inc	ORAL	50	
	International Normalised	Representative					MG/DAILY/PO	
	Ratio Increased		Coumadin	C				

Date:08/18/00ISR Number: 3553787-4Report Type:Expedited (15-DaCompany Report #WAES 00076024
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine	Foreign	Vioxx	PS	Merck Research			
	Phosphokinase Increased	Health			Laboratories Div			
	Difficulty In Walking	Professional			Merck Co Inc	ORAL	12.5 MG	3 DAY
	Muscle Spasms							

Date:08/18/00ISR Number: 3553789-8Report Type:Expedited (15-DaCompany Report #WAES 00076054
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Coronary Artery Disease	Health			Laboratories Div			
Initial or Prolonged	Pulmonary Oedema	Professional			Merck Co Inc			
PO								
			Atorvastatin	C				
			Nitroglycerin	C				
			Omeprzole	C				
			Prednisone	C				
			Trandolapril	C				

Date:08/18/00ISR Number: 3553791-6Report Type:Expedited (15-DaCompany Report #WAES 99127251
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1000MG	53 DAY
			Tab Placebo	SS		ORAL	53 DAY	
			Tab Aspirin	SS		ORAL	75 MG	53 DAY
			Zocor	C				
			Nitroglycerin	C				

Date:08/18/00ISR Number: 3553838-7Report Type:Expedited (15-DaCompany Report #WAES 00060861
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Hepatic Function Abnormal Influenza Like Illness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Jaundice		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Monopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/00ISR Number: 3553839-9Report Type:Expedited (15-DaCompany Report #WAES 00071836
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bleeding Time Prolonged	Health	Vioxx	PS	Merck Research			
	Thrombocytopenia	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Dilantin	C				
			[Compression					
			Unspecified]	C				

Date:08/18/00ISR Number: 3553846-6Report Type:Expedited (15-DaCompany Report #WAES 00051870
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma	Consumer	Vioxx	PS	Merck Research			
	Convulsion				Laboratories Div			
	Difficulty In Walking				Merck Co Inc	ORAL	12.5	
	Drug Effect Decreased						MG/TID/PO	
	Feeling Cold		Dilantin	C				
	Oedema Peripheral		Prilosec	C				
	Paraesthesia		Tylenol	C				
	Sensory Loss		Vanceril	C				
			Zyrtec	C				
			Albuterol	C				
			Diazepam	C				
			Phenobarbital	C				
			Potassium Supplement					
			(Compositio	C				
			Prednisone	C				
			Theophylline	C				

Date:08/21/00ISR Number: 3554464-6Report Type:Expedited (15-DaCompany Report #2000COU0989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Coumadin	PS	Dupont Merck			

Initial or Prolonged Pharmaceutical Co ORAL
2.5 MG QD PO

Vioxx (Rofecoxib) SS ORAL
1 TAB DLY PO 4 DAY

Date:08/22/00ISR Number: 3554763-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx 25	PS		ORAL	1 QD ORAL	
	Gastrointestinal		Glyburide	C				
	Haemorrhage		Allegra	C				
	Haematemesis		Calcium	C				
			Multivitamin	C				
			Zyprexa	C				

Date:08/22/00ISR Number: 3554802-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vomiting		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	Initial or Prolonged
			Prempro	C				

		Alprazolam	C	
		Zoloft	C	

Date:08/22/00ISR Number: 3555332-6Report Type:Expedited (15-DaCompany Report #WAES 00087270
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholangitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	153 DAY
	Condition Aggravated	Other						
	Fatigue							
	Hepatic Cirrhosis		Tab Methotrexate	SS		ORAL	PO	
	Hepatic Fibrosis		Tab Sertraline Hcl	SS		ORAL	PO	
	Hepatic Steatosis		Tab Omeprazole Magnesium	SS		ORAL	153 DAY	
	Inflammation							
	Jaundice		Infusion (Form) Infliximab	SS		INTRAVENOUS	122 DAY	
	Liver Disorder							
	Liver Function Test Abnormal							
	Nausea							
	Pruritus							

Date:08/22/00ISR Number: 3555334-XReport Type:Expedited (15-DaCompany Report #WAES 00085525
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Faecal Occult Blood Positive	Health Professional						
	Faeces Discoloured	Other	Aspirin	SS		ORAL	100 MG PO	5 DAY
	Gastrointestinal Haemorrhage		Acetaminophen/Codeine Phosphate	C				
	Haematocrit Decreased		Herbal Remedies (Composition Unspecified)	C				
	Haemoglobin Decreased							
	Refusal Of Treatment By							

	Patient		Isosorbide Dinitrate	C		
			Lactulose	C		
			Metoprolol Succinate	C		

Date:08/22/00ISR Number: 3555335-1Report Type:Expedited (15-DaCompany Report #WAES 00085093
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Pruritus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				

Date:08/22/00ISR Number: 3555336-3Report Type:Expedited (15-DaCompany Report #WAES 00088903
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/00ISR Number: 3555341-7Report Type:Expedited (15-DaCompany Report #WAES 00075636
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acidosis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Coagulopathy	Health			Laboratories Div			
Initial or Prolonged	Convulsion	Professional			Merck Co Inc	ORAL	25 MG PO	16 DAY
	Diplopia		Mesalamine	SS		ORAL	1500 MG PO	67 DAY
	Drug Interaction		Diclofenac	C				
	Drug Toxicity		Dipyrone	C				
	Metabolic Acidosis		Methotrexate	C				
	Nervous System Disorder		Prednisone	C				
	Renal Impairment		Prednisone	C				
	Sedation		Tramadol Hcl	C				
	Therapeutic Agent							
	Toxicity							

Date:08/22/00ISR Number: 3555342-9Report Type:Expedited (15-DaCompany Report #WAES 00078919
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Myocardial Infarction	Health			Laboratories Div			
Initial or Prolonged	Oedema	Professional			Merck Co Inc	ORAL	25 MG PO	

Date:08/22/00ISR Number: 3555348-XReport Type:Expedited (15-DaCompany Report #WAES 00089763
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hypertensive Crisis	Health			Laboratories Div			
	Malignant Hypertension	Professional			Merck Co Inc	ORAL	50 MG PO	3 DAY
	Oedema Peripheral		Amlodipine					
	Renal Impairment		Benzenesulfonate	C				
			Aspirin	C				
			Atenolol	C				

			Famotidine	C		
			Isosorbide Dinitrate	C		
			Pravastatin Na	C		

Date:08/22/00ISR Number: 3555362-4Report Type:Expedited (15-DaCompany Report #WAES 00079151
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Haemorrhage	Health			Laboratories Div	
Initial or Prolonged	Gastroenteritis	Professional			Merck Co Inc	ORAL
25 MG 36 DAY						
	Helicobacter		Calcium Carbonate	C		
	Gastrointestinal		Calcium Glubionate	C		
	Haemorrhage		Enalapril Maleate	C		
			Propranolol	C		

Date:08/22/00ISR Number: 3555364-8Report Type:Expedited (15-DaCompany Report #WAES 00085101
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Gastritis Erosive
Initial or Prolonged	Gastrointestinal

Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	65 DAY
			Atenolol	C				
			Glucosamine	C				
			Perindopril	C				

Date:08/22/00ISR Number: 3555368-5Report Type:Expedited (15-DaCompany Report #WAES 00063514
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	15 DAY
	Chest Pain							
	Dyspnoea							
	Pulmonary Oedema		Methotrexate	C				

Date:08/22/00ISR Number: 3555370-3Report Type:Expedited (15-DaCompany Report #WAES 00073757
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	7 DAY
	Myocardial Infarction							
	Vomiting							
			Ca Acetylsalicylate	C				
			Diazepam	C				
			Oxazepam	C				
			Tolterodine Tartrate	C				

Date:08/22/00ISR Number: 3555382-XReport Type:Expedited (15-DaCompany Report #WAES 00086035
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG, PO 1 DAY						
			Allopurinol	C		
			Atorvastatin	C		
			Cetirizine	C		
			Indapamide	C		
			Verapamil	C		

Date:08/22/00ISR Number: 3555448-4Report Type:Expedited (15-DaCompany Report #WAES 00080871
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Peyronie'S Disease	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Prozac	C		

Date:08/22/00ISR Number: 3555466-6Report Type:Expedited (15-DaCompany Report #WAES 99110777
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine Increased	Health	Vioxx	PS	Merck Research			
Hospitalization -	Blood Thyroid Stimulating	Professional			Laboratories Div			
Initial or Prolonged	Hormone Increased	Company			Merck Co Inc	ORAL	12.5	
Disability	Blood Urea Increased	Representative					MG/DAILY/PO	
Other	Dehydration	Other	Celebrex	C				
	Dyspnoea		Ecotrin	C				
	Fluid Retention		Hydrodiuril	C				
	Hyperglycaemia		L-Thyroxine	C				
	Hypertension		Macrobid	C				
	Hypothyroidism		Tylenol	C				
	Lipid Metabolism Disorder							
	Nephritis Interstitial							
	Nephrotic Syndrome							
	Oedema							
	Oedema Peripheral							
	Pleural Effusion							
	Proteinuria							
	Renal Failure Acute							
	Weight Increased							

Date:08/22/00ISR Number: 3555487-3Report Type:Expedited (15-DaCompany Report #WAES 00020820
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Vioxx	PS	Merck Research			
	Increased	Professional			Laboratories Div			
	Blood Urea Increased				Merck Co Inc	ORAL	25-50	
	Hyperkalaemia						MG/DAILY/PO;	
							50 MG/HS/PO	
			Atrovent	C				
			Bactrim Ds	C				
			Duragesic	C				
			Lipitor	C				
			Neurontin	C				

Remeron	C
Tylenol	C
Albuterol	C
Atenolol	C
Calcitonin	C
Trazodone	C

Date:08/22/00ISR Number: 3555489-7Report Type:Expedited (15-DaCompany Report #WAES 00064288
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Drug Hypersensitivity Drug Ineffective Dyspnoea Swelling	Consumer Health Professional	Vioxx Celebrex	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/00ISR Number: 3555493-9Report Type:Expedited (15-DaCompany Report #WAES 00080767
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Lipitor	C				
			Prozac	C				
			Sumycin	C				
			Aspirin	C				

Date:08/22/00ISR Number: 3555495-2Report Type:Expedited (15-DaCompany Report #WAES 00080778
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haematemesis Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ultram	C				
			Aspirin	C				

Date:08/22/00ISR Number: 3555525-8Report Type:Expedited (15-DaCompany Report #WAES 00085570
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Atrial Fibrillation Tachycardia	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	29 DAY
			Trapidil	C				

Date:08/22/00ISR Number: 3555531-3Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction Pulmonary Haemorrhage Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			[Therapy Unspecified]	C				
			Methotrexate	C				

Date:08/22/00ISR Number: 3555532-5Report Type:Expedited (15-DaCompany Report #WAES 00072084
Age:69 YR Gender:Male I/FU:I

Outcome	PT
Other	Bleeding Time Prolonged Chorioretinal Disorder Choroidal Haemorrhage Detached Retina Repair Drug Interaction Eye Haemorrhage Oedema Post Procedural Pain Visual Acuity Reduced

Visual Disturbance

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Methotrexate	SS				
			Prednisone 10 Mg	SS			10 MG/DAILY	
			Prednisone 4 Mg	SS			4 MG/DAILY	
			Ecotrin	C				
			Mevacor	C				
			Nitroglycerin	C				

Date:08/22/00ISR Number: 3555536-2Report Type:Expedited (15-DaCompany Report #WAES 00085152
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Endoscopy Upper Gastrointestinal Tract Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	301 DAY
	Gastric Ulcer		Acetaminophen	C				
	Haematemesis		Amiloride Hydrochloride (+)					
	Upper Gastrointestinal Haemorrhage		Furosemide	C				
			Aspirin	C				
			Quinines04	C				

Date:08/22/00ISR Number: 3555571-4Report Type:Expedited (15-DaCompany Report #WAES 00080348
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Albumin Increased Blood Alkaline Phosphatase Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Blood Creatinine		Prilosec	C				

Increased
Chest Pain
Dyspnoea
Hyperglycaemia
Weight Increased

Date:08/22/00ISR Number: 3555572-6Report Type:Expedited (15-DaCompany Report #WAES 00081179
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Choking Dry Mouth Extrasystoles Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO; 50 MG/DAILY/PO	

Date:08/22/00ISR Number: 3555576-3Report Type:Expedited (15-DaCompany Report #WAES 00081103
Age:76 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Lower	Health	Vioxx	PS	Merck Research			
	Diarrhoea	Professional			Laboratories Div			
	Faeces Discoloured	Other			Merck Co Inc	ORAL	25 MG/BID/PO;	
	Gastrointestinal						25	
	Haemorrhage						MG/DAILY/PO	
	Haematochezia		Accupril	C				
	Haematocrit Decreased		Etrafon	C				
	Haemoglobin Decreased		Flomax	C				
	Nausea		Synthroid	C				
			Zocor	C				
			Atenolol	C				

Date:08/22/00ISR Number: 3555577-5Report Type:Expedited (15-DaCompany Report #WAES 00081102
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dizziness	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea	Other			Merck Co Inc	ORAL	PO	
	Faeces Discoloured		Celebrex	C				
	Gastrointestinal							
	Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:08/22/00ISR Number: 3555579-9Report Type:Expedited (15-DaCompany Report #WAES 00080818
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract	Health	Vioxx	PS	Merck Research			
	Cataract Operation	Professional			Laboratories Div			
	Drug Ineffective				Merck Co Inc	ORAL	75	

MG/DAILY/PO 30 DAY

Celebrex 200 Mg	SS	ORAL

200

MG/DAILY/PO

Aspirin	C
Atenolol	C
Chondroitin	C
Glucosamine	C
Isosorbide Dinitrate	C
Nitroglycerin	C
Pravastatin Sodium	C
Vitamins (Unspecified)	C

Date:08/22/00ISR Number: 3555582-9Report Type:Expedited (15-DaCompany Report #WAES 00081283
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
	Chromaturia
	Dermatitis
	Dyspnoea
	Gastric Disorder
	Hepatitis

	Influenza Like Illness Jaundice Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Aerobid	C			
			Atrovent	C			
			Humibid	C			
			Medrol	C			
			Premarin	C			
			[Therapy Unspecified]	C			
			Albuterol	C			

Date:08/22/00ISR Number: 3555584-2Report Type:Expedited (15-DaCompany Report #WAES 00081294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Imdur	C			
			Norvasc	C			
			[Therapy Unspecified]	C			
			Aspirin	C			
			Captopril	C			

Date:08/22/00ISR Number: 3555683-5Report Type:Expedited (15-DaCompany Report #WAES 00050299
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck Research		

Initial or Prolonged	Blood Pressure Increased	Professional		Laboratories Div	
Other	Bronchospasm			Merck Co Inc	ORAL
PO					
	Dermatitis Exfoliative		Lamisil	SS	
	Dry Skin		Benadryl	C	
	Dyspnoea		Estrace	C	
	Face Oedema		Aspirin	C	
	Hypersensitivity				
	Pruritus				
	Rash Erythematous				

Date:08/22/00ISR Number: 3555684-7Report Type:Expedited (15-DaCompany Report #WAES 00080775
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Asthma
	Blood Pressure Increased
	Diarrhoea
	Dizziness
	Eating Disorder
	Upper Respiratory Tract
	Infection

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				

Date:08/22/00ISR Number: 3555685-9Report Type:Expedited (15-DaCompany Report #WAES 00088505
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Convulsion Hypertension Hypertensive Crisis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypertensive Encephalopathy Oedema Peripheral		Therapy Unspecified	C				

Date:08/22/00ISR Number: 3555692-6Report Type:Expedited (15-DaCompany Report #WAES 00080841
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
Other			Tab Vioxx	SS		ORAL	PO	
			Celebrex	C				
			Fioricet Tablets	C				
			Guaifenex Dm	C				
			Nasacort Aq	C				
			Paxil	C				

			Zyrtec	C		

Date:08/22/00ISR Number: 3555695-1Report Type:Expedited (15-DaCompany Report #WAES 00081098
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other		Other			Merck Co Inc	ORAL	25 MG/BID/PO	
			Advil 200 Mg	SS		ORAL	PRN/PO	
			Hydrodiuril	C				
			L-Thyroxine	C				
			Premarin	C				
			Prinivil	C				
			Allopurinol	C				
			Atenolol	C				
			Omeprazole	C				

Date:08/22/00ISR Number: 3555696-3Report Type:Expedited (15-DaCompany Report #WAES 00081062
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dementia Mental Impairment Senile Dementia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 DAY

Date:08/22/00ISR Number: 3555799-3Report Type:Expedited (15-DaCompany Report #WAES 00081434
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Hypersomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/22/00ISR Number: 3555810-XReport Type:Expedited (15-DaCompany Report #WAES 00081166
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Perforation Intestinal Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:08/22/00ISR Number: 3555811-1Report Type:Expedited (15-DaCompany Report #WAES 00064752
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence	Health	Vioxx	PS	Merck Research			

Initial or Prolonged Disability	Blood Creatine Increased	Professional			Laboratories Div	
	Blood Urea Increased	Other			Merck Co Inc	ORAL
25						
Other	Calcinosis					
MG/DAILY/PO						
	Cardiac Failure		Celebrex	C		
	Congestive		Diovan	C		
	Cardiomegaly		Lasix	C		
	Condition Aggravated		Procrit	C		
	Dyspnoea		Allopurinol	C		
	Ejection Fraction		Aspirin	C		
	Abnormal		Glyburide	C		
	Hepatic Congestion		Trazodone	C		
	Hepatic Function Abnormal					
	Hyperglycaemia					
	Hypoaesthesia					
	Laboratory Test Abnormal					
	Liver Function Test Abnormal					
	Lung Infiltration					
	Mitral Valve Incompetence					
	Oedema Peripheral					
	Pleural Effusion					
	Pneumonitis					
	Pulmonary Hypertension					
	Pulmonary Oedema					
	Renal Failure Chronic					
	Renal Impairment					
	Stress					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/00ISR Number: 3555824-XReport Type:Expedited (15-DaCompany Report #WAES 00080462
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	
	Calculus Urinary							
	Confusional State							
	Disorientation							
	Dizziness		Diazide	C				
	Eye Pain		Flomax (Tamsulosin (R)-Form Hydr	C				
	Headache		Lotensin	C				
	Vision Blurred		Nitroglycerin	C				
			Prozac	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Aspirin	C				
			Diuretic Preparation (Compositio	C				

Date:08/22/00ISR Number: 3555833-0Report Type:Expedited (15-DaCompany Report #WAES 00050286
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antibody Test Positive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diverticulum Intestinal							
	Faecal Occult Blood							
	Positive							
	Faeces Discoloured		Aspirin	C				
	Gastroenteritis							
	Helicobacter							
	Gastrointestinal							
	Haemorrhage							
	Melaena							
	Oesophagitis							

Date:08/22/00ISR Number: 3555890-1Report Type:Expedited (15-DaCompany Report #WAES 00077282
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Gastric Ulcer Pain In Extremity Renal Failure Urinary Tract Infection	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG DAILY; 2) ORAL	
			Clomethiazole Ethanedisulfonate	C				
			Cyanocobalamin	C				
			Cyclizine	C				
			Lactulose	C				
			Leuprolide Monoacetate (Salt)	C				
			Medroxyprogesterone 17-Acetate	C				
			Morphine	C				
			Picosulfate Na	C				
			Prednisolone	C				
			Propiomazine Maleate	C				
			Trimethoprim	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/00ISR Number: 3555891-3Report Type:Expedited (15-DaCompany Report #WAES 00077283
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	31 DAY
	Hyperkalaemia							
			Acetaminophen	C				
			Cyclizine	C				
			Furosemide	C				
			Lactulose	C				
			Lansoprazole	C				
			Morphine	C				
			Picosulfate Na	C				

Date:08/23/00ISR Number: 3555632-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx 12.5 Mg	PS		ORAL	PO QD	
			Zoloft	C				
			Vit B & C	C				

Date:08/23/00ISR Number: 3556371-1Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS				
	Faeces Discoloured		Trilisate	SS				
	Melaena		Prednisone	SS				
	Syncope		Synthroid	C				
	Upper Gastrointestinal Haemorrhage		Xanax	C				
			Lanoxin	C				
			Darvocet	C				
			Premarin	C				
			Tagamet	C				
			Lasix	C				
			Celexa	C				

Date:08/24/00ISR Number: 3557561-4Report Type:Expedited (15-DaCompany Report #WAES 00089761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Dyspepsia Haemoglobin Decreased Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:08/24/00ISR Number: 3557564-XReport Type:Expedited (15-DaCompany Report #WAES 00085581
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Haemoglobin Decreased Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Composition Unspecified]	C				
			Aspirin	C				

Captopril	C	
Piracetam	C	

Date:08/24/00ISR Number: 3557785-6Report Type:Expedited (15-DaCompany Report #WAES 00080912
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Hepatitis Liver Function Test Abnormal Pyelonephritis Pyrexia	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	

Date:08/24/00ISR Number: 3557788-1Report Type:Expedited (15-DaCompany Report #WAES 00081179
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking Dry Mouth Extrasystoles Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ 1X/ PO	

Date:08/24/00ISR Number: 3557792-3Report Type:Expedited (15-DaCompany Report #WAES 00080104
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cryptogenic Organizing Pneumonia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/24/00ISR Number: 3557795-9Report Type:Expedited (15-DaCompany Report #WAES 00080518
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dehydration Oral Intake Reduced Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Lasix	SS			40 MG/ DAILY/ UNK	
			Adalat	C				
			Levoxyl	C				
			Paxil	C				
			Premarin	C				
			Risperdal	C				
			Antimicrobial (Unspecified)	C				
			Nitroglycerin	C				
			Potassium (Unspecified)	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/00ISR Number: 3557798-4Report Type:Expedited (15-DaCompany Report #WAES 00080872
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ UNK/ PO	
			Hytrin	C				
			Norvasc	C				
			Timoptic	C				

Date:08/24/00ISR Number: 3557808-4Report Type:Expedited (15-DaCompany Report #WAES 00081223
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coagulopathy	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	
Life-Threatening	Disseminated Intravascular Coagulation							
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Coumadin	SS			UNKNOWN	UNKNOWN
	International Normalised Ratio Increased							

Date:08/24/00ISR Number: 3557812-6Report Type:Expedited (15-DaCompany Report #WAES 00051259
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Blood Urea Increased							
Other	Nausea							
	Renal Failure Acute							
	Vomiting		Colace	C				

			Imdur	C		
			Lasix	C		
			Lopressor	C		
			Prilosec	C		
			Aspirin	C		
			Ferrous Sulfate	C		

Date:08/24/00ISR Number: 3557820-5Report Type:Expedited (15-DaCompany Report #WAES 00068539
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Sepsis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY

Date:08/24/00ISR Number: 3557823-0Report Type:Expedited (15-DaCompany Report #WAES 00057908
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive Respiratory Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
			Irbesartan	C				

Date:08/24/00ISR Number: 3557920-XReport Type:Expedited (15-DaCompany Report #WAES 00081326
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolism Haematemesis Oesophageal Haemorrhage Upper Gastrointestinal Haemorrhage Vomiting	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Centrum Silver	C				
			Fleet Enema	C				
			Ocuvite	C				
			Pepcid	C				
			Tylenol	C				
			Therapy Unspecified	C				

Date:08/24/00ISR Number: 3557928-4Report Type:Expedited (15-DaCompany Report #S00-SWE-01260-01
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased	Foreign Health	Celexa	PS	Forest Laboratories Inc	ORAL	20 MG QD PO	
		Professional	Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
		Other	Vioxx (Rofecoxib)	SS		ORAL	25 MG QD PO	
			Imovane (Zopiclone)	C				

Date:08/24/00ISR Number: 3557980-6Report Type:Expedited (15-DaCompany Report #WAES 00064604
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Retinal Haemorrhage Retinal Vascular Occlusion	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Retinal Vein Thrombosis	Fosamax	C
Vision Blurred	Premarin	C
	Prevacid	C

Date:08/24/00ISR Number: 3557981-8Report Type:Expedited (15-DaCompany Report #WAES 00081282
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastroenteritis Helicobacter	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1 X PO	

Date:08/24/00ISR Number: 3557982-XReport Type:Expedited (15-DaCompany Report #WAES 00081473
Age:67 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Chest Pain
	Duodenal Ulcer
	Faeces Discoloured
	Haematemesis
	Haematocrit Decreased
	Haemoglobin Decreased
	Upper Gastrointestinal

Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Lipitor	C				
	Premarin	C				
	Tylenol Extra Strength	C				

Date:08/24/00ISR Number: 3557983-1Report Type:Expedited (15-DaCompany Report #WAES 00081518
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
	Vomiting							

Date:08/24/00ISR Number: 3557984-3Report Type:Expedited (15-DaCompany Report #WAES 00052792
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
	Back Pain							
	Burning Sensation							
	Condition Aggravated							
	Diverticulitis		Ambien	SS				
	Drug Ineffective		Prednisone	C				
	Gastric Ulcer							
	Gastritis							
	Gastrointestinal Ulcer							

Date:08/24/00ISR Number: 3557985-5Report Type:Expedited (15-DaCompany Report #WAES 00062230
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Dermatitis Photosensitivity Reaction Thermal Burn	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Calcium Supplement	C				
			Vitamin B (12)	C				

Date:08/24/00ISR Number: 3565629-1Report Type:Expedited (15-DaCompany Report #SP-200001507
Age:63 YR Gender:Male I/FU:I

Outcome	PT
Other	Abdominal Pain Upper
	Arthralgia
	Fatigue
	Pain
	Penile Haemorrhage

Rectal Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Remicade	PS			INTRAVENOUS INFUSION	INTRAVENOUS
	Remicade	SS			INTRAVENOUS INFUSION	INTRAVENOUS
	Remicade	SS			INTRAVENOUS INFUSION	INTRAVENOUS
	Vioxx	SS				
	Vasotec	C				

Date:08/25/00ISR Number: 3557664-4Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Rofecoxib 50mg Merck	PS	Merck	ORAL	50MG QD ORAL	
Hospitalization - Initial or Prolonged	Haemorrhage		Atenolol	C				
	Gastritis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hyperchlorhydria							
	Melaena							
	Mucous Membrane Disorder							
	Rectal Haemorrhage							

Date:08/28/00ISR Number: 3558774-8Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Oedema Peripheral		Vioxx 25mg	PS		ORAL	25MG	

Intervention to	Sepsis		
DAILY-ORALLY			
Prevent Permanent	Urinary Retention	Dilantin	C
Impairment/Damage	Urinary Tract Infection	Premarin	C
		Miacalcin	C
		Vitamin C	C
		Zinc	C
		Lactulose	C
		Synthroid	C
		Glyburide	C
		Phenobarbital	C
		Calcium With Vit D	C
		Provera	C
		Neurontin	C

Date:08/28/00ISR Number: 3560275-8Report Type:Expedited (15-DaCompany Report #WAES 00081469
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Condition Aggravated	Health	Vioxx	PS	Merck Research	
Hospitalization -	Dehydration	Professional			Laboratories Div	
Initial or Prolonged	Diarrhoea	Company			Merck Co Inc	ORAL
25						
Other	Renal Failure Acute	Representative				
MG/DAILY/PO						
	Urinary Tract Infection		Fibercon	C		
			Levbid	C		
			Lomotil	C		
			Xanax	C		
			Atenolol	C		

				Trazodone	C		

Date:08/28/00ISR Number: 3560277-1Report Type:Expedited (15-DaCompany Report #WAES 00081697
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Relafen	C				

Date:08/28/00ISR Number: 3560279-5Report Type:Expedited (15-DaCompany Report #WAES 00071919
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amyloidosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Creatinine Increased	Company						
	Influenza	Representative						
	Nephritis Interstitial		Vasotec	C				
	Renal Failure Acute		Allopurinol	C				

Date:08/28/00ISR Number: 3560282-5Report Type:Expedited (15-DaCompany Report #WAES 00080024
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pneumonia							
	Respiratory Disorder							
	Sputum Discoloured							

Date:08/28/00ISR Number: 3560284-9Report Type:Expedited (15-DaCompany Report #WAES 00081591
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Pain	Health	Vioxx	PS	Merck Research			
	Headache	Professional			Laboratories Div			
	Hypertension				Merck Co Inc	ORAL	25	
	Vitreous Detachment						MG/DAILY/PO	
			Darvocet-N	C				
			Neuraxin	C				
			Wellbutrin Sr	C				

Date:08/28/00ISR Number: 3560285-0Report Type:Expedited (15-DaCompany Report #WAES 00081583
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea	Company			Merck Co Inc	ORAL	25	
Disability	Hypertension	Representative					MG/DAILY/PO	
Other			Prinivil	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/00ISR Number: 3560498-8Report Type:Expedited (15-DaCompany Report #WAES 00085609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/28/00ISR Number: 3560505-2Report Type:Expedited (15-DaCompany Report #WAES 00085622
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Study Health Professional	Vioxx Clopidogrel Bisulfate	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	15 DAY

Date:08/28/00ISR Number: 3560508-8Report Type:Expedited (15-DaCompany Report #WAES 00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Fatigue Hepatic Cirrhosis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	153 DAY
	Hepatic Enzyme Increased		Tab Methotrexate	SS		ORAL	PO	1 YR
	Hepatic Fibrosis		Tab Sertraline Hcl	SS		ORAL	PO	
	Hepatic Steatosis Jaundice		Tab Omeprazole Magnesium	SS		ORAL	20 MG PO	153 DAY
	Liver Disorder Nausea		Infusion (Form) Infliximab	SS			INTRAVENOUS IV	122 DAY
	Pruritus		Folic Acid Glyburide	C C				

Date:08/28/00ISR Number: 3560511-8Report Type:Expedited (15-DaCompany Report #WAES 00085164
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Aspirin	SS		ORAL	75 MG PO	
			Allopurinol	C				
			Beclomethasone Dipropionate	C				
			Ibuprofen	C				
			Isosorbide Dinitrate	C				
			Nitroglycerin	C				

Date:08/28/00ISR Number: 3560593-3Report Type:Expedited (15-DaCompany Report #WAES 00089801
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain
Other	Colitis Ulcerative
	Condition Aggravated
	Facial Palsy
	Faeces Discoloured

		Gastrointestinal Ulcer Perforation					
		Haematemesis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematochezia	Foreign	Vioxx	PS	Merck Research	
		Ileus Paralytic	Other			Laboratories Div	
		Peptic Ulcer Haemorrhage				Merck Co Inc	ORAL
25 MG PO	10 DAY						
		Sensory Disturbance		Hydrodiuril	C		
				Vasotec	C		
				Diclofenac Na	C		
				Digoxin	C		
				Furosemide	C		
				Potassium Supplement	C		

Date:08/28/00ISR Number: 3560594-5Report Type:Expedited (15-DaCompany Report #WAES 00085103
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG PO						
			Aspirin	C		
			Beclomethasone Dipropionate	C		
			Candesartan	C		

Date:08/28/00ISR Number: 3560598-2Report Type:Expedited (15-DaCompany Report #WAES 00073756
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Chest Discomfort	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Chest Pain	Other			Laboratories Div	
Initial or Prolonged	Myocardial Infarction				Merck Co Inc	ORAL
25 MG PO	5 DAY					
			Digoxin	C		
			Furosemide	C		
			Ipratropium Bromide	C		
			Verapamil Hcl	C		

Date:08/28/00ISR Number: 3560638-0Report Type:Expedited (15-DaCompany Report #WAES 00087515
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Amylase Increased	Other						
	Diarrhoea							
	Leukocytosis		Allopurinol	C				
	Lipase Increased		Prednisolone	C				
	Pancreatitis		Terazosin	C				
	Vomiting							

Date:08/28/00ISR Number: 3560640-9Report Type:Expedited (15-DaCompany Report #WAES 00087514
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
		Other						
			Levothyroxine Na	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/00ISR Number: 3560641-0Report Type:Expedited (15-DaCompany Report #WAES 00083711
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Blood Alkaline Phosphatase Increased	Other						
	Haematocrit Decreased		Bisacodyl	C				
	Haemoglobin Decreased		Diltiazem Hydrochloride	C				
	Hypoproteinaemia		Isosoride Dinitrate	C				
	Red Blood Cell Sedimentation Rate Increased		Nadroparin	C				
	Sudden Death							

Date:08/28/00ISR Number: 3560642-2Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	96 DAY
			Cap Celecoxib	SS		ORAL	PO	4 DAY
			Acetaminophen/Codeine Phosphate	C				
			Aspirin	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Furosemide	C				
			Isosorbide Dinitrate	C				
			Levothyroxine Na	C				
			Midazolam Maleate	C				
			Pantoprazole Na	C				

Date:08/28/00ISR Number: 3560643-4Report Type:Expedited (15-DaCompany Report #WAES 00063447
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive Condition Aggravated Coronary Artery Disease	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	

Date:08/28/00ISR Number: 3560645-8Report Type:Expedited (15-DaCompany Report #WAES 00085189
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	4 MON

Date:08/28/00ISR Number: 3560652-5Report Type:Expedited (15-DaCompany Report #WAES 00089802
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Hallucination Visual Disturbance	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	17 DAY

Date:08/28/00ISR Number: 3560653-7Report Type:Expedited (15-DaCompany Report #WAES 00085102
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Aspirin	C				
			Atenolol	C				
			Prednisolone	C				

Date:08/28/00ISR Number: 3560703-8Report Type:Expedited (15-DaCompany Report #WAES 00068269
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Intracranial	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke Hemiplegia	Other						
	Intracranial Venous Sinus Thrombosis Sedation		Chondroitinso4 Chondroitin 4-Sulfate	C				

Date:08/28/00ISR Number: 3560708-7Report Type:Expedited (15-DaCompany Report #WAES 00088566
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged Heart Transplant Health Laboratories Div
Low Cardiac Output Professional Merck Co Inc ORAL
PO 5 DAY
Syndrome [Therapy
Unspecified] C

Date:08/28/00ISR Number: 3560723-3Report Type:Expedited (15-DaCompany Report #WAES 00081651
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Consumer	Vioxx	PS	Merck Research			
Hospitalization -					Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL		
PO								
			Glucophage	C				
			(Therapy					
			Unspecified)	C				

Date:08/28/00ISR Number: 3560736-1Report Type:Expedited (15-DaCompany Report #WAES 00081434
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Depressed Level Of
Initial or Prolonged	Consciousness

		Hypersomnia Mental Disorder Sedation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				...	C		
				Neurontin	C		

Date:08/28/00ISR Number: 3560737-3Report Type:Expedited (15-DaCompany Report #WAES 00070398
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Anisocytosis Dyspnoea Gastrointestinal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
Other	Haemorrhage	Representative				
MG/DAILY/PO						
	Haemoglobin Decreased Haemolytic Anaemia Iron Deficiency Anaemia		Celebrex	C		

Date:08/28/00ISR Number: 3560743-9Report Type:Expedited (15-DaCompany Report #WAES 00064678
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Renal Failure Acute	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
Disability		Representative	Flomax (Niflumic			
Other			Acid(Beta))	C		
			Monopril	C		
			Percocet	C		

Date:08/28/00ISR Number: 3560744-0Report Type:Expedited (15-DaCompany Report #WAES 00062197
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Oedema Peripheral Tenderness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:08/28/00ISR Number: 3560761-0Report Type:Expedited (15-DaCompany Report #WAES 00081178
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Dyspnoea Gastritis Ventricular Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/00ISR Number: 3560762-2Report Type:Expedited (15-DaCompany Report #WAES 00062074
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Erectile Dysfunction	Health Professional						
Other	Infection				Merck Co Inc	ORAL	PO	
	Vasculitis							

Date:08/28/00ISR Number: 3560764-6Report Type:Expedited (15-DaCompany Report #WAES 00081329
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erosive Duodenitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Gastritis							
	Gastrointestinal Disorder				Merck Co Inc	ORAL	PO	
	Polyp		Centrum	C				
			Humibid	C				
			Protonix	C				
			Propranolol Hydrochloride	C				
			Therapy Unspecified	C				

Date:08/28/00ISR Number: 3560766-XReport Type:Expedited (15-DaCompany Report #WAES 00081826
Age:86 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anorexia
Hospitalization - Initial or Prolonged	Arterial Disorder
	Atelectasis
Disability	Blood Chloride Increased
Other	Blood Urea Increased
	Cardiac Failure
	Congestive
	Cardiomegaly
	Clostridium Colitis
	Confusional State
	Depression
	Diarrhoea

Dry Skin
Duodenal Ulcer
Haemorrhage
Fistula
Hiatus Hernia
Hyperglycaemia
Hypocalcaemia
Hypokalaemia
Hypophosphataemia
Hypoproteinaemia
Liver Function Test
Abnormal
Melaena
Nausea
Post Procedural
Complication
Prothrombin Time
Prolonged
Rectal Haemorrhage
Skin Atrophy
Skin Warm

		Thrombocythaemia Thrombocytopenia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO			Representative				
				Cardizem	C		
				Hydrodiuril	C		
				Vicodin Tablets	C		
				Xalatan	C		
				Zocor	C		
				Aspirin	C		
				Metoprolol	C		
				Potassium Chloride	C		

Date:08/28/00ISR Number: 3560770-1Report Type:Expedited (15-DaCompany Report #WAES 00081466
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Faecal Occult Blood Positive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO	Faeces Discoloured					
	Gastric Ulcer		Celebrex	C		
	Gastrointestinal Haemorrhage		Ditropan	C		
	Nausea		Elavil	C		
			Norvasc	C		
			Pepto-Bismol	C		
			Slow-K	C		
			Toprol Xl Tablets	C		
			Aspirin	C		
			Calcium Supplement	C		
			Quinine	C		
			Vitamins	C		

Date:08/28/00ISR Number: 3560784-1Report Type:Expedited (15-DaCompany Report #WAES 00081733
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Headache Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Lanoxin	C				
			Paxil	C				
			Procardia Xl	C				
			Synthroid	C				

Date:08/29/00ISR Number: 3560663-XReport Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Celebrex	PS			200MG DAILY	
Life-Threatening	Perforation							
			Vioxx	SS			25 MG DAILY	13 DAY
			Warfarin	C				

			Zestril	C		
			Tylenol	C		
			Ultram	C		

Date:08/29/00ISR Number: 3561388-7Report Type:Expedited (15-DaCompany Report #WAES 00072525
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	Haematocrit Decreased					
	Haemoglobin Decreased		Coumadin	C		
	Melaena		Lanoxin	C		
	Prothrombin Time Prolonged		Tiazac	C		
			Tylenol	C		
			Zestril	C		
			Ascorbic Acid	C		
			Vitamin E	C		

Date:08/29/00ISR Number: 3561389-9Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety Asthenia Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25	Fatigue					
MG/DAILY/PO	Gastrointestinal Disorder		Fosamax	C		
	Muscle Spasms		Glucosamine	C		
	Nausea					
	Palpitations					
	Peripheral Vascular Disorder					
	Tremor					
	Weight Decreased					

Date:08/29/00ISR Number: 3561390-5Report Type:Expedited (15-DaCompany Report #WAES 00060536
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Oral Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Motrin	C				
			Zestril	C				

Date:08/29/00ISR Number: 3561396-6Report Type:Expedited (15-DaCompany Report #WAES 00040122
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Disease Arterial Stenosis Atherosclerosis Cardiac Failure Congestive

	Carotid Artery Stenosis Gastrointestinal Disorder Hepatitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pancreatitis Pneumonia Respiratory Failure Subclavian Steal Syndrome	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:08/29/00ISR Number: 3561397-8Report Type:Expedited (15-DaCompany Report #WAES 00081950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:08/29/00ISR Number: 3561398-XReport Type:Expedited (15-DaCompany Report #WAES 00081790
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemoptysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Prilosec	C			

Date:08/29/00ISR Number: 3561399-1Report Type:Expedited (15-DaCompany Report #WAES 00081635
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Dizziness Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

	Gastrointestinal Haemorrhage		Aspirin	C		

Date:08/29/00ISR Number: 3561413-3Report Type:Expedited (15-DaCompany Report #WAES 00050801
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Coordination Abnormal Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Level Above Therapeutic Drug Toxicity	Representative	[Composition Unspecified] Unk	SS		ORAL	PO	
	Fall		Prozac	C				
			Valium	C				
			Zyprexa	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/00ISR Number: 3561415-7Report Type:Expedited (15-DaCompany Report #WAES 00040926
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Balance Disorder	Other						
Other	Drug Hypersensitivity				Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Electrolyte Imbalance							
	Faeces Discoloured		Inj Synvisc Unk	SS			WKY/INJ	
	Feeling Hot		Lasix	SS		ORAL	PO	
			Prozac	C				
			Xanax	C				
			Calcium Supplement (Composition	C				
			Glucosamine	C				
			Triamterene	C				
			Vitamins	C				

Date:08/29/00ISR Number: 3561423-6Report Type:Expedited (15-DaCompany Report #WAES 00061666
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/29/00ISR Number: 3561425-XReport Type:Expedited (15-DaCompany Report #WAES 00060463
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
Hospitalization - Initial or Prolonged	Dialysis							
	Renal Failure Acute							

Other	Urinary Retention	Representative

Date:08/29/00ISR Number: 3561428-5Report Type:Expedited (15-DaCompany Report #WAES 00080566
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Professional			Laboratories Div			
Initial or Prolonged	Duodenal Ulcer				Merck Co Inc	ORAL	25	
Other	Gastric Ulcer						MG/DAILY/PO	
	Haematocrit Decreased		Ascriptin	C				
	Haemoglobin Decreased		Celebrex	C				
	Pallor		Lanoxin	C				

Date:08/29/00ISR Number: 3561433-9Report Type:Expedited (15-DaCompany Report #WAES 00064750
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Health	Vioxx	PS	Merck Research			
	Confusional State	Professional			Laboratories Div			
	Cyanosis	Other			Merck Co Inc	ORAL	12.5 MG /	
	Dizziness						DAILY / PO	
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/00ISR Number: 3561438-8Report Type:Expedited (15-DaCompany Report #WAES 00071995
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BIG/PO	

Date:08/29/00ISR Number: 3561492-3Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Vertigo		Vioxx 50 Mg One Daily	PS				

Date:08/29/00ISR Number: 3561623-5Report Type:Expedited (15-DaCompany Report #WAES 00081921
Age:101 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Fosamax	C				
			Norvasc	C				
			Prilosec	C				
			Serevent	C				
			Synthroid	C				

Date:08/29/00ISR Number: 3561624-7Report Type:Expedited (15-DaCompany Report #WAES 00081785
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyskinesia Oesophageal Oesophageal Spasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				

Date:08/29/00ISR Number: 3561625-9Report Type:Expedited (15-DaCompany Report #WAES 00081811
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/29/00ISR Number: 3561626-0Report Type:Expedited (15-DaCompany Report #WAES 00081822
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/29/00ISR Number: 3561627-2Report Type:Expedited (15-DaCompany Report #WAES 00064215
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Antinuclear Antibody Positive							
	Arthralgia	Representative						
	Blood Creatine Phosphokinase Increased		Celebrex	C				
			Pepcid Ac	C				
	Bone Disorder							
	Cyst							
	Dermatitis							
	Dermatomyositis							
	Drug Hypersensitivity							
	Dysphagia							
	Erythema							
	Eyelid Oedema							
	Face Oedema							
	Hypersensitivity							
	Joint Swelling							
	Leukocytosis							
	Lip Disorder							
	Liver Function Test Abnormal							
	Localised Infection							
	Muscular Weakness							
	Neck Pain							
	Nodal Osteoarthritis							
	Pharyngeal Oedema							
	Polymyositis							
	Pruritus							
	Red Blood Cell Sedimentation Rate Increased							
	Scab							
	Sunburn							
	Tongue Oedema							

Date:08/29/00ISR Number: 3561628-4Report Type:Expedited (15-DaCompany Report #WAES 00081106
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Ulcer							
	Haematocrit Decreased		Aspirin	SS		ORAL	325 MG/DAILY/PO	
	Haemoglobin Decreased							
			Acetaminophen (+) Hydrocodone	C				
			Albuterol Sulfate (+) Ipratropiu	C				
			Docusate Sodium	C				
			Flunisolide	C				
			Furosemide	C				
			Glyburide	C				
			Isosorbide Mononitrate	C				
			Metoprolol	C				
			Potassium	C				

			Quinapril	C		

Date:08/29/00ISR Number: 3561632-6Report Type:Expedited (15-DaCompany Report #WAES 00050456
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Shortened	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Other PO						
	Blood Pressure Diastolic Decreased		Calan Sr	C		
			Dyazide	C		
	Blood Urea Increased		Meterazine	C		
	Confusional State		Paxil	C		
	Diabetes Mellitus		Digoxin	C		
	Diarrhoea		Vitamin B (12)	C		
	Faeces Discoloured					
	Gastric Ulcer Haemorrhage					
	Haematemesis					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Lethargy					
	Pallor					
	Prothrombin Time Prolonged					

Date:08/29/00ISR Number: 3561633-8Report Type:Expedited (15-DaCompany Report #WAES 00081867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Diabetes Mellitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged	Hyperglycaemia					
25	Pain					
MG/DAILY/PO	Ulcer Haemorrhage					
			Cardura	C		
			Glucophage	C		
			Lasix	C		
			Lotrial	C		
			Tylenol With Codeine			

			#3	C
			Insulin	C

Date:08/29/00ISR Number: 3561635-1Report Type:Expedited (15-DaCompany Report #WAES 00082216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Psoriasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/29/00ISR Number: 3561638-7Report Type:Expedited (15-DaCompany Report #WAES 00062722
Age:22 YR Gender:Male I/FU:F

Outcome	PT
	Abdominal Pain Lower
	Abdominal Pain Upper
	Abdominal Tenderness
	Back Pain

	Bradycardia Calculus Bladder Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Condition Aggravated Cystitis Interstitial Drug Ineffective	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
	Gastritis Haematuria Lipase Increased Nausea Nephritis Interstitial Oesophagitis Pain Pancreatic Disorder Pancreatic Enzymes Increased Pancreatitis	Representative				

Date:08/29/00ISR Number: 3561662-4Report Type:Expedited (15-DaCompany Report #WAES 00085615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			[Composition Unspecified]	C		

Date:08/29/00ISR Number: 3561664-8Report Type:Expedited (15-DaCompany Report #WAES 00082049
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	11 DAY					
			Idarac	C		
			Lanoxin	C		

			Reparil	C		
			Sinemet	C		
			Ticlid	C		
			[Therapy Unspecified]	C		
			Cloxacillin	C		

Date:08/29/00ISR Number: 3561667-3Report Type:Expedited (15-DaCompany Report #WAES 00085185
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Ecchymosis Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 6 DAY						
			Zocor	C		
			Acetaminophen/Codeine Phosphate	C		
			Aluminum Hydroxide/Magnesium Carbonate	C		
			Amlodipine	C		

Atenolol	C
Etidronate Disodium	C
Furosemide	C
Lansoprazole	C
Prednisolone	C
Thyroxine	C

Date:08/29/00ISR Number: 3561708-3Report Type:Expedited (15-DaCompany Report #WAES 00089311
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:08/29/00ISR Number: 3561721-6Report Type:Expedited (15-DaCompany Report #WAES 00088570
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abscess	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Arrhythmia	Other			Laboratories Div			
Hospitalization -	Duodenal Ulcer				Merck Co Inc	ORAL	PO	
Initial or Prolonged	Haemorrhage		Acetaminophen /					
	Duodenal Ulcer		Codeine Phosphate	C				
	Perforation		Paroxetine Hcl					
	Myocardial Infarction		Hemihydrate	C				
	Pleural Disorder							

Date:08/29/00ISR Number: 3561722-8Report Type:Expedited (15-DaCompany Report #WAES 00079132
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal Ulcer	Other			Laboratories Div			
	Haematemesis				Merck Co Inc	ORAL	25 MG PO	8 DAY

	Melaena		Tab Aspirin	SS		ORAL
100 MG PO						
			Vasotec	C		
			Amlodipine	C		
			Furosemide	C		

Date:08/29/00ISR Number: 3561727-7Report Type:Expedited (15-DaCompany Report #WAES 00076054
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Condition Aggravated	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Coronary Artery Disease	Other			Laboratories Div	
Initial or Prolonged	Pulmonary Oedema				Merck Co Inc	ORAL
25 MG PO						
			Atorvastatin	C		
			Nitroglycerin	C		
			Omeprazole	C		
			Prednisolone	C		
			Trandolapril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/00ISR Number: 3561739-3Report Type:Expedited (15-DaCompany Report #WAES 00085551
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Blood Creatinine	Other			Laboratories Div			
Initial or Prolonged	Increased				Merck Co Inc	ORAL	50 MG PO	10 DAY
	Blood Urea Increased		Tab					
	Cardiac Failure		Hydrochlorothiazide					
	Cardiac Failure		(+) Valsartan	SS		ORAL	12.5 / 80 MG	
	Congestive						PO	
	Condition Aggravated		Hctz / Triamterene	C				
	Creatinine Renal		Carbimazole	C				
	Clearance Decreased		Clonidine Hcl	C				
	Cyanosis		...	C				
	Dialysis		Flecainide					
	Dyspnoea		Monoacetate	C				
	Dyspnoea Exacerbated		Moxifloxacin					
	Oedema Peripheral		Hydrochloride	C				
	Pleural Effusion							
	Renal Failure							

Date:08/29/00ISR Number: 3561998-7Report Type:Expedited (15-DaCompany Report #WAES 00080436
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health	Vioxx	PS	Merck Research			
	Liver Function Test	Professional			Laboratories Div			
	Abnormal	Company			Merck Co Inc	ORAL	50 MG DAILY	
		Representative					PO	
			Donnatal	C				
			Keflex	C				
			Lortab	C				
			Phrenilin Forte	C				
			Prevacid	C				

Date:08/29/00ISR Number: 3562001-5Report Type:Expedited (15-DaCompany Report #WAES 00050672
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism	Health	Vioxx	PS	Merck Research			
Hospitalization -	Faecal Occult Blood	Professional			Laboratories Div			
Initial or Prolonged	Positive	Company			Merck Co Inc	ORAL	25 MG DAILY	
Disability	Gastric Ulcer	Representative					PO	
Other	Gastritis Erosive		Guai-Vent	C				
	Gastrointestinal		Levaquin	C				
	Haemorrhage		Propulsid	C				
	Haematemesis		Ultram	C				
	Haematocrit Decreased		Vicodin Tablets	C				
	Haemoglobin Decreased							
	Hypovolaemia							
	Melaena							
	Nausea							
	Orthostatic Hypotension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/00ISR Number: 3562003-9Report Type:Expedited (15-DaCompany Report #WAES 00080841
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck Research	
Hospitalization -		Professional			Laboratories Div	
Initial or Prolonged					Merck Co Inc	ORAL
25 MG BID PO						
Other			Vioxx	SS	Merck & Co., Inc.	ORAL
UNK PO						
			Celebrex	C		
			Fioricet Tablets	C		

Date:08/29/00ISR Number: 3562006-4Report Type:Expedited (15-DaCompany Report #WAES 00081591
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased	Health	Vioxx	PS	Merck Research	
	Eye Pain	Professional			Laboratories Div	
	Headache				Merck Co Inc	ORAL
25 MG DAILY						
	Hypertension					
PO						
	Vitreous Detachment		Darvocet-N	C		
			Neuraxin	C		
			Wellbutrin Sr	C		

Date:08/29/00ISR Number: 3562103-3Report Type:Expedited (15-DaCompany Report #WAES 00079117
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Condition Aggravated	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Gastrointestinal	Health			Laboratories Div	
Initial or Prolonged	Haemorrhage	Professional			Merck Co Inc	ORAL
7.5 MG, PO 14 DAY						
			Omeprazole	C		

Date:08/29/00ISR Number: 3562104-5Report Type:Expedited (15-DaCompany Report #WAES 00085189
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	4 MON

Date:08/29/00ISR Number: 3562112-4Report Type:Expedited (15-DaCompany Report #WAES 00085624
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Disorder	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, PO	4 DAY

Date:08/29/00ISR Number: 3562115-XReport Type:Expedited (15-DaCompany Report #WAES 00085637
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Gastritis Erosive Gastrointestinal Haemorrhage Haemoglobin Decreased

Melaena

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG, PO	69 DAY					
			Hctz/;Metoprolol Tartrate	C		
			Benserazine/Levodopa	C		
			Bromocriptine Mesylate	C		
			Digitoxin	C		
			Levothyroxine Na	C		
			Metformin Hcl	C		
			Methixene Hydrochloride	C		
			Tramadol Hcl	C		

Date:08/29/00ISR Number: 3562143-4Report Type:Expedited (15-DaCompany Report #WAES 00056537
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	25 DAY
	Foetal Growth Retardation Intra-Uterine Death Oligohydramnios		Acetaminophen Ibuprofen	C C				

Date:08/29/00ISR Number: 3562244-0Report Type:Expedited (15-DaCompany Report #WAES 00085625
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Tachycardia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 DAY

Date:08/29/00ISR Number: 3562245-2Report Type:Expedited (15-DaCompany Report #WAES 00086029
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Gastrooesophageal Reflux	Other			Merck Co Inc	ORAL	12.5 MG, PO	1 MON
	Disease		Omeprazole Sodium	C				
	Haemoptysis							
	Pulmonary Haemorrhage							

Date:08/29/00ISR Number: 3562248-8Report Type:Expedited (15-DaCompany Report #WAES 00085049
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Foreign	Vioxx	PS	Merck Research			
	Depression	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG PO	
			Aspirin	C				
			Atenolol	C				

			Nifedipine	C		
			Thioridazine	C		

Date:08/30/00ISR Number: 3561467-4Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx 25mg Merck	PS	Merck	ORAL
25MG DAY ORAL						
Initial or Prolonged	Nausea		Cardura	C		
			Prevacid	C		
			Lipitor	C		

Date:08/30/00ISR Number: 3561869-6Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pancreatitis Acute		Vioxx	PS		
CHECK WITH						
Initial or Prolonged						
M.D.						

Date:08/30/00ISR Number: 3561887-8Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx Tablets	PS		
12.5 MG ONCE						
Initial or Prolonged	Colitis					
DAILY 7 DAY						
	Large Intestinal Ulcer		Cyclobenzaprine	C		
	Rectal Haemorrhage		Multiple Vitamins	C		

Date:08/30/00ISR Number: 3561908-2Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Vioxx 25mg	PS		ORAL	25MG PO QD	
		Professional	Maxzide	C				
			Cardizem Cd	C				
			Imdur	C				
			Ranitidine	C				

Date:08/30/00ISR Number: 3562178-1Report Type:Expedited (15-DaCompany Report #000801-SK706
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG QD	
	Gastrointestinal Disorder	Health					PO	
	Gastrooesophageal Reflux	Professional	Vioxx	SS		ORAL	12.500 MG PO	
	Disease		Conjugated					
	Influenza Like Illness		Estrogrens	C				
	Medication Error		Medroxyprogesterone	C				
	Nausea							
	Uterine Cancer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/00ISR Number: 3562199-9Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	

Date:08/31/00ISR Number: 3562958-2Report Type:Expedited (15-DaCompany Report #WAES 00085613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/31/00ISR Number: 3562959-4Report Type:Expedited (15-DaCompany Report #WAES 00082310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Methotrexate	C				

Date:08/31/00ISR Number: 3562979-XReport Type:Expedited (15-DaCompany Report #WAES 00072304
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute Wegener'S Granulomatosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:08/31/00ISR Number: 3562981-8Report Type:Expedited (15-DaCompany Report #WAES 00052151
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Cardiovascular Disorder	Professional			Laboratories Div			
Initial or Prolonged	Colitis Ischaemic				Merck Co Inc	ORAL	25	
Other	Discomfort						MG/DAILY/PO	
	Embolism		Lasix	C				
	Haemorrhage		Lotensin	C				
	Hypertension		Atenolol	C				
	Mesenteric Artery Embolism							
	Mesenteric Vascular Insufficiency							
	Mitral Valve Prolapse							
	Palpitations							

Date:08/31/00ISR Number: 3562984-3Report Type:Expedited (15-DaCompany Report #WAES 00081434
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersomnia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Mental Impairment	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	

			Neurontin	C			

Date:08/31/00ISR Number: 3562987-9Report Type:Expedited (15-DaCompany Report #WAES 00081466
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
Hospitalization -	Faeces Discoloured	Professional			Laboratories Div			
Initial or Prolonged	Gastric Ulcer				Merck Co Inc	ORAL	25	
	Gastrointestinal							
	Haemorrhage		Celebrex	C			MG/DAILY/PO	
			Ditropan	C				
			Elavil	C				
			Norvasc	C				
			Pepto-Bismol	C				
			Slow-K	C				
			Toprol Xl	C				
			Aspirin	C				
			Calcium Supplement	C				
			Quinine	C				
			Vitamins	C				

Date:08/31/00ISR Number: 3563052-7Report Type:Expedited (15-DaCompany Report #WAES 00075545
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Gastric Haemorrhage	Health			Laboratories Div			
	Haematemesis	Professional			Merck Co Inc	ORAL	25.0 MG PO	
			[Composition Unspecified]	C				
			Digitoxin	C				
			Furosemide Sodium Salt	C				
			Tramadol Hcl	C				

Date:08/31/00ISR Number: 3563053-9Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Autoimmune Disorder	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Epistaxis	Health			Laboratories Div			
Initial or Prolonged	Megakaryocytes Increased	Professional			Merck Co Inc	ORAL	25 MG PO	4 DAY
	Thrombocytopenia		Prednisolone	C				

Date:08/31/00ISR Number: 3563313-1Report Type:Expedited (15-DaCompany Report #WAES 00079556
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	UNK PO	
		Other	Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/00ISR Number: 3562868-0Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Vioxx	PS			25MGM BID	
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Palpitations							
	Tricuspid Valve Incompetence							

Date:09/05/00ISR Number: 3565278-5Report Type:Expedited (15-DaCompany Report #WAES 00082846
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Haemoglobin Decreased							
			Accupril	C			PO	
			Lanoxin	C				
			Lipitor	C				
			Lopid	C				
			Paxil	C				
			Synthroid	C				
			Aspirin	C				
			Calcium Supplement (Unspecified)	C				
			Vitamin E	C				
			Vitamins	C				
			Zinc	C				

Date:09/05/00ISR Number: 3565284-0Report Type:Expedited (15-DaCompany Report #WAES 00061494
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Vioxx	PS	Merck Research			

	Gingival Bleeding	Professional			Laboratories Div	
	Periodontal Disease				Merck Co Inc	ORAL
UNK PO						
	Pocket Erosion		[Therapy Unspecified]	C		
			Methotrexate	C		

Date:09/05/00ISR Number: 3565285-2Report Type:Expedited (15-DaCompany Report #WAES 00082504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage				Laboratories Div	
	Malaise				Merck Co Inc	ORAL
UNK PO						
			Adalat	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565286-4Report Type:Expedited (15-DaCompany Report #WAES 00081104
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Bacterial Infection							
	Haematemesis							
	Haematuria							
	Renal Failure Chronic		Coumadin	SS		ORAL	5 MG DAILY PO	
	Sepsis							
	Upper Gastrointestinal Haemorrhage							
	Urinary Tract Infection							

Date:09/05/00ISR Number: 3565288-8Report Type:Expedited (15-DaCompany Report #WAES 00082266
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Articular Disc Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	
	Dyspepsia							
	Malaise							
	Polyarthritis							
	Pruritus		Celebrex	C				

Date:09/05/00ISR Number: 3565289-XReport Type:Expedited (15-DaCompany Report #WAES 00082651
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability Other	Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Deep Vein Thrombosis							
	Dyspnoea							
	Oedema Peripheral							
	Pain In Extremity		Cardizem	C				

	Pulmonary Embolism		Estratab	C		
	Tenderness		Ms Contin	C		
			Prilosec	C		

Date:09/05/00ISR Number: 3565296-7Report Type:Expedited (15-DaCompany Report #WAES 00082673
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Albumin Globulin Ratio	Health	Vioxx	PS	Merck Research			
Hospitalization -	Decreased	Professional			Laboratories Div			
Initial or Prolonged	Chest Pain	Company			Merck Co Inc	ORAL	25	
Disability	Deep Vein Thrombosis	Representative					MG/DAILY/PO	
Other	Dyspnoea		Coumadin	C				
	Dyspnoea Exertional		Heparin Sodium	C				
	Hepatic Enzyme Increased							
	Hypergammaglobulinaemia							
	Hyperhidrosis							
	Hypoxia							
	Oxygen Saturation Decreased							
	Pco2 Decreased							
	Protein Total Increased							
	Prothrombin Time Prolonged							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565301-8Report Type:Expedited (15-DaCompany Report #WAES 00063216
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer Perforation	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
Other		Representative					MG/DAILY/PO	
			Apresazide Capsules	C				
			Lopid	C				
			Pepcid	C				
			Allopurinol	C				

Date:09/05/00ISR Number: 3565303-1Report Type:Expedited (15-DaCompany Report #WAES 00082763
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Cerebrovascular Accident	Professional			Laboratories Div			
	Dizziness	Company			Merck Co Inc	ORAL	PRN/PO	
	Feeling Abnormal	Representative	Hytrin	C				
	Haemorrhage Intracranial		Lipitor	C				
	Haemorrhagic Stroke		Prilosec	C				
	Headache							

Date:09/05/00ISR Number: 3565319-5Report Type:Expedited (15-DaCompany Report #WAES 00074037
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Study	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	PO	
			Tab Blinded Therapy	SS		ORAL	PO	
			Fosamax	C				
			Hydrodiuril	C				

			Chondroitin Sulfate	C		
			Darvocet N	C		
			Finasteride	C		
			Glucosamine	C		
			Prednisone	C		
			Terazosin	C		

Date:09/05/00ISR Number: 3565326-2Report Type:Expedited (15-DaCompany Report #WAES 00082783
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen	C				

Date:09/05/00ISR Number: 3565331-6Report Type:Expedited (15-DaCompany Report #WAES 00071697
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Other	Blood Creatinine Increased

	Blood Urea Increased						
	Dehydration						
	Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastroenteritis	Health	Vioxx	PS	Merck Research		
	Haemoglobin Decreased	Professional			Laboratories Div		
	Melaena	Company			Merck Co Inc	ORAL	25 MG DAILY
	Nephritis	Representative					PO
	Nephropathy		Ambien	C			
	Pallor		Celebrex	C			
	Proteinuria		Tylenol	C			
	Upper Gastrointestinal		Zocor	C			
	Haemorrhage						

Date:09/05/00ISR Number: 3565335-3Report Type:Expedited (15-DaCompany Report #WAES 00041370
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck Research		
Initial or Prolonged	Increased	Professional			Laboratories Div		
	Blood Immunoglobulin G				Merck Co Inc	ORAL	25 MG DAILY
	Decreased						PO
	Blood Immunoglobulin M		Zocor	C		ORAL	UNK PO
	Hypoproteinaemia		Vocor	C			
	Nephrotic Syndrome						
	Periorbital Oedema						
	Proteinuria						
	Renal Cell Carcinoma						
	Stage Unspecified						
	Renal Disorder						
	Renal Failure Acute						
	Renal Scan Abnormal						
	Urinary Casts						
	Urine Abnormality						

Date:09/05/00ISR Number: 3565338-9Report Type:Expedited (15-DaCompany Report #WAES 00071329
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Fluid Retention Pulmonary Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	

Date:09/05/00ISR Number: 3565341-9Report Type:Expedited (15-DaCompany Report #WAES 00082175
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged Circulatory Collapse Dyspnoea Pulmonary Embolism	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565347-XReport Type:Expedited (15-DaCompany Report #WAES 00082387
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Aceon	C				
			Ambien	C				
			Aspirin	C				
			Cholecalciferol	C				
			Terazosin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/05/00ISR Number: 3565363-8Report Type:Expedited (15-DaCompany Report #WAES 00063232
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Face Oedema Oedema Peripheral Throat Tightness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Tongue Oedema		Vasotec	C				

Date:09/05/00ISR Number: 3565365-1Report Type:Expedited (15-DaCompany Report #WAES 00082650
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Condition Aggravated Deep Vein Thrombosis Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Tenderness
MG/DAILY/PO

Axid	C
Celebrex	C
Soma	C
Synthroid	C
Acetaminophen (+) Propoxyphene	C

Date:09/05/00ISR Number: 3565366-3Report Type:Expedited (15-DaCompany Report #WAES 00050321
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Blood Pressure Diastolic Decreased Hypokalaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
	Sudden Death Torsade De Pointes	Representative	Buprenex Flexeril Toradol Atenolol Morphine	C C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565368-7Report Type:Expedited (15-DaCompany Report #WAES 00082863
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/05/00ISR Number: 3565370-5Report Type:Expedited (15-DaCompany Report #WAES 00082607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/05/00ISR Number: 3565371-7Report Type:Expedited (15-DaCompany Report #WAES 00082691
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				
			Therapy Unspecified	C				

Date:09/05/00ISR Number: 3565376-6Report Type:Expedited (15-DaCompany Report #WAES 00071838
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Abdominal Mass Abdominal Tenderness Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Motrin	C		
			Relafen	C		
			(Composition Unspecified)	C		
			Aspirin	C		
			Estrogens (Unspecified)	C		

Date:09/05/00ISR Number: 3565378-XReport Type:Expedited (15-DaCompany Report #WAES 00081105
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastric Ulcer	Professional			Laboratories Div	
	Gastritis	Other			Merck Co Inc	ORAL
12.5						
	Haematochezia					
MG/DAILY/PO						
	Haematocrit Decreased		Aspirin 325 Mg	SS		ORAL
325						
	Haemoglobin Decreased					
MG/DAILY/PO						
	Rectal Haemorrhage		Ismo	C		
			Vasotec	C		
			Zocor	C		

			Doxepin	C		
			Furosemide	C		
			Metoprolol	C		

Date:09/05/00ISR Number: 3565386-9Report Type:Expedited (15-DaCompany Report #WAES 00071372
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research	
Life-Threatening	Haemorrhage	Professional			Laboratories Div	
Hospitalization -	Haematemesis	Company			Merck Co Inc	ORAL
25 MG/DAILY/						
Initial or Prolonged		Representative				
PO						
			Allegra	C		
			Zyprexa	C		
			Glyburide	C		

Date:09/05/00ISR Number: 3565387-0Report Type:Expedited (15-DaCompany Report #WAES 00081329
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Benign Gastric Neoplasm	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Duodenitis	Health			Laboratories Div	
	Gastric Polyps	Professional			Merck Co Inc	ORAL
UNK/UNK/ PO						
	Gastric Ulcer		Centrum	C		
	Gastritis Erosive		Humibid	C		
	Gastrointestinal Disorder		Protonix	C		
			Propranolol Hydrochloride	C		

Date:09/05/00ISR Number: 3565396-1Report Type:Expedited (15-DaCompany Report #WAES 00081473
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Chest Pain	Professional			Laboratories Div	

Other	Duodenal Ulcer				Merck Co Inc	ORAL
25						
	Haematemesis					
MG/DAILY/PO						
	Haematocrit Decreased		Lipitor	C		
	Haemoglobin Decreased		Premarin	C		
	Melaena		Tylenol Extra			
	Upper Gastrointestinal		Strength	C		
	Haemorrhage					

Date:09/05/00ISR Number: 3565399-7Report Type:Expedited (15-DaCompany Report #WAES 00081106
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastritis	Health	Vioxx	PS	Merck Research	
Hospitalization -	Gastrointestinal	Professional			Laboratories Div	
Initial or Prolonged	Haemorrhage	Other			Merck Co Inc	ORAL
25						
	Gastrointestinal Ulcer					
MG/DAILY/PO						
	Haematocrit Decreased		Aspirin 325 Mg	SS		ORAL
325						
	Haemoglobin Decreased					
MG/DAILY/PO						
			Acetaminophen	C		
			Albuterol Sulfate	C		
			Docusate Sodium	C		
			Flunisolide	C		

			Furosemide	C		
			Glyburide	C		
			Isosorbide Mononitrate	C		
			Metoprolol	C		
			Potassium	C		
			Quinapril	C		

Date:09/05/00ISR Number: 3565428-0Report Type:Expedited (15-DaCompany Report #WAES 00086128
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Electroencephalogram Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
			Verapamil Hc1	C				

Date:09/05/00ISR Number: 3565429-2Report Type:Expedited (15-DaCompany Report #WAES 00089307
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Herpes Virus Infection Stevens-Johnson Syndrome	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:09/05/00ISR Number: 3565431-0Report Type:Expedited (15-DaCompany Report #WAES 00087534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:09/05/00ISR Number: 3565434-6Report Type:Expedited (15-DaCompany Report #WAES 00087531
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Phenprocoumon	C				
			Piroxicam	C				

Date:09/05/00ISR Number: 3565435-8Report Type:Expedited (15-DaCompany Report #WAES 00069767
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565437-1Report Type:Expedited (15-DaCompany Report #WAES 00078911
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Foreign	Vioxx	PS	Merck Research			
Other	Henoch-Schonlein Purpura	Other			Laboratories Div			
	Pulmonary Haemorrhage				Merck Co Inc	ORAL	PO	2 DAY
	Rash Maculo-Papular							
	Respiratory Distress							

Date:09/05/00ISR Number: 3565457-7Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Vioxx (Rofecoxib)	PS	Merck			
	Gastrointestinal							
	Haemorrhage							

Date:09/05/00ISR Number: 3565544-3Report Type:Expedited (15-DaCompany Report #WAES 00075230
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fear	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hallucination, Visual	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG PO	12 DAY
			Acetaminophen/Codein					
			e Phosphate	C				
			Amoxicillin					
			Trihydrate (+)					
			Clavulanate P	C				
			Aspirin	C				
			Ferrousso4	C				
			Quinineso4	C				
			Vitamin B Complex	C				

Date:09/05/00ISR Number: 3565546-7Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Autoimmune Disorder	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Epistaxis	Other			Laboratories Div			
Initial or Prolonged	Megakaryocytes Abnormal				Merck Co Inc	ORAL	25 MG PO	4 DAY
	Megakaryocytes Increased		Prednisolone	C				
	Thrombocytopenia							

Date:09/05/00ISR Number: 3565623-0Report Type:Expedited (15-DaCompany Report #WAES 00083728
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haematemesis	Health			Laboratories Div			
	Upper Gastrointestinal	Professional			Merck Co Inc	ORAL	25 MG PO	4 DAY
	Haemorrhage		Zocor	C				
			Benazepril Hcl	C				
			Insulin, Biphasic					
			Isophane (Injection)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/00ISR Number: 3565625-4Report Type:Expedited (15-DaCompany Report #WAES 00085186
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Prinivil	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Aspirin	C				
			Cinnarizine	C				

Date:09/05/00ISR Number: 3565627-8Report Type:Expedited (15-DaCompany Report #WAES 00085187
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Cozaar	C				
			Feurrousso4	C				
			Furosemide	C				
			Lansoprazole	C				
			Thyroxine	C				

Date:09/05/00ISR Number: 3566157-XReport Type:Expedited (15-DaCompany Report #WAES 00089770
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Eyelid Oedema Face Oedema	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Nimesulide	C				

Date:09/05/00ISR Number: 3566172-6Report Type:Expedited (15-DaCompany Report #WAES 00088231
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Other	Aspirin	C				

Date:09/05/00ISR Number: 3566184-2Report Type:Expedited (15-DaCompany Report #WAES 00077521
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Alveolitis Allergic C-Reactive Protein Increased Chest X-Ray Abnormal Dyspnoea Exacerbated Haemothorax Leukocytosis Lung Disorder Neutrophilia

	Oxygen Saturation Decreased						
	Pleural Adhesion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pleural Effusion	Foreign	Vioxx	PS	Merck Research		
	Po2 Decreased	Health			Laboratories Div		
		Professional			Merck Co Inc	ORAL	12.5 MG PO 21 DAY
			Indocin (Indomethacin)	C			
			Tramadol Hcl	C			

Date:09/05/00ISR Number: 3566211-2Report Type:Expedited (15-DaCompany Report #WAES 00083730
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Nephritis Interstitial	Foreign	Vioxx	PS	Merck Research		
Hospitalization -	Renal Impairment	Other			Laboratories Div		
Initial or Prolonged					Merck Co Inc	ORAL	12.5 MG PO

Date:09/07/00ISR Number: 3566462-7Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper		Celecoxib 100mg	PS		ORAL	100MG TID
Initial or Prolonged	Blood Creatinine						ORAL
	Increased		Rofecoxib	SS			
	Blood Urea Increased						

Date:09/07/00ISR Number: 3566506-2Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastric Ulcer		Vioxx Daily (Merck)				

Initial or Prolonged	Upper Gastrointestinal		0006-0110-68	PS	Merck	
25MG DAILY						
	Haemorrhage					

Date:09/07/00ISR Number: 3567045-5Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia		Vioxx	PS		
DAILY 1 MON						
	Asthenia		Lasix	C		
	Burning Sensation					
	Feeling Abnormal					
	Headache					
	Influenza Like Illness					
	Oedema Peripheral					

Date:09/07/00ISR Number: 3567356-3Report Type:Expedited (15-DaCompany Report #WAES 00063725
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Chest Pain	Foreign	Vioxx	PS	Merck Research	
	Myocardial Infarction	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5 MG						
			Ca Acetylsalicylate	C		
			Hyzaar	C		

				Barnidipine	C		
				Diclofenac Sodium (+) Misoprostol	C		

Date:09/07/00ISR Number: 3567363-0Report Type:Expedited (15-DaCompany Report #WAES 00075632
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	6 DAY
			Vasotec	C				
			Insulin Injection/Isophane Insulin Suspe	C				

Date:09/07/00ISR Number: 3567366-6Report Type:Expedited (15-DaCompany Report #WAES 00069762
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Arrhythmia Asthenia Bacterial Infection Blood Creatine Increased Blood Ph Decreased Bradycardia Cardiac Arrest Cardiac Disorder Cerebrovascular Disorder Electrocardiogram Qrs Complex Abnormal Hemiparesis Hepatic Congestion Hyperkalaemia Loss Of Consciousness Metabolic Acidosis Obstruction Paralysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY
			Tab Vasotec (Enalapril Maleate)	SS		ORAL	2.5 MG	
			Acetaminophen Amoxicillin Trihydrate(+)	C				
			Clavulanate P	C				
			Codeine	C				
			Levothyroxine Na	C				
			Oxybutynincl	C				

		Pyrexia					
		Renal Disorder					
		Renal Failure					
		Respiratory Acidosis					
		Rhonchi					
		Sepsis					
		Spleen Disorder					

Date:09/07/00ISR Number: 3567369-1Report Type:Expedited (15-DaCompany Report #WAES 00086140
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Asthenia Fatigue	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	19 DAY
	Hyponatraemia		Acenocoumarol	C				
			Diltiazem Hydrochloride	C				
			Hydroxychloroquine So4	C				

				Omeprazole	C		

Date:09/07/00ISR Number: 3567373-3Report Type:Expedited (15-DaCompany Report #WAES 00085695
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:09/07/00ISR Number: 3567374-5Report Type:Expedited (15-DaCompany Report #WAES 00055654
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Asthenia Blood Bilirubin Increased Gamma-Glutamyltransferase Increased Hepatitis Jaundice Nausea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	11 DAY

Date:09/07/00ISR Number: 3567377-0Report Type:Expedited (15-DaCompany Report #WAES 00067514
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal Grand Mal Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	
			Candesartan Cilexetil	C				
			Cyproterone Acetate					
			(+) Estradiol Valera	C				
			Levothyroxine Na	C				

				Valerian	C		

Date:09/07/00ISR Number: 3567382-4Report Type:Expedited (15-DaCompany Report #WAES 00088583
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertensive Crisis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25,0 MG	

Date:09/07/00ISR Number: 3567384-8Report Type:Expedited (15-DaCompany Report #WAES 00085628
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Fracture Gastric Perforation Sepsis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
			[Composition Unspecified]	C				
			Certoparin Sodium	C				

				Dipyrone	C		

Date:09/07/00ISR Number: 3567386-1Report Type:Expedited (15-DaCompany Report #WAES 00086149
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	9	DAY
	Gastric Ulcer							
	Gastritis Atrophic							

Date:09/07/00ISR Number: 3567387-3Report Type:Expedited (15-DaCompany Report #WAES 00085643
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Pamidronic Acid Dina	C				

Date:09/07/00ISR Number: 3567393-9Report Type:Expedited (15-DaCompany Report #WAES 00085615
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aphasia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Arrhythmia							
	Brain Damage							
	Cerebral Infarction		Albuterol	C				
	Cerebrovascular Accident		Lisinopril	C				
	Convulsion		Nitroglycerin	C				
	Cyanosis		Theophylline	C				
	Dysarthria		Valerian	C				
	Grand Mal Convulsion							
	Hyperventilation							
	Hypoxia							
	Paresis							

Pulmonary Embolism
Respiratory Failure
Thrombosis
Vomiting

Date:09/07/00ISR Number: 3567436-2Report Type:Expedited (15-DaCompany Report #WAES 00075636
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acidosis
Hospitalization - Initial or Prolonged	Blood Urea Increased
	Coagulopathy
	Collagen Disorder
	Connective Tissue Disorder
	Convulsion
	Diplopia
	Drug Toxicity
	Meningism
	Prothrombin Time Prolonged
	Renal Impairment

		Sedation Therapeutic Agent Toxicity	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	16 DAY
				Mesalamine	SS		ORAL	1500 MG PO	67 DAY
				Diclofenac	C				
				Dipyrone	C				
				Methotrexate	C				
				Prednisone	C				
				Tramadol Hcl	C				

Date:09/07/00ISR Number: 3567517-3Report Type:Expedited (15-DaCompany Report #WAES 00075632
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured Gastric Haemorrhage Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY
			Vasotec	C				
			Insulin Injection/ Isophane Insulin Suspe	C				

Date:09/07/00ISR Number: 3567524-0Report Type:Expedited (15-DaCompany Report #WAES 00063447
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:09/07/00ISR Number: 3567526-4Report Type:Expedited (15-DaCompany Report #WAES 00076046
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myeloid Leukaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Other	Leukopenia	Health						
	Neutropenia	Professional			Merck Co Inc	ORAL	25 MG PO	41 DAY
	Retinal Vein Thrombosis		Ranitidine	C				
	Visual Acuity Reduced		Timolol	C				

Date:09/07/00ISR Number: 3567538-0Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaphylactic Reaction
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Conjunctival Haemorrhage
	Dermatitis
	Drug Hypersensitivity
	Ecchymosis
	Eyelid Oedema
	Face Oedema
	Hypotension
	Laryngeal Oedema

		Mouth Haemorrhage Petechiae Pulmonary Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Oedema Spleen Disorder Stomatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25.0 MG PO	1 DAY						
		Vasoconstriction	Other	Acetaminophen	C		
				Cyclosporin A	C		
				Furosemide	C		
				Insulin, Biphasic Isophane [Injection]	C		
				Methotrexate	C		
				Paroxetine	C		
				Prednisolone	C		
				Senna	C		

Date:09/07/00ISR Number: 3567542-2Report Type:Expedited (15-DaCompany Report #WAES 00088903
Age:93 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
Other							

Date:09/07/00ISR Number: 3567547-1Report Type:Expedited (15-DaCompany Report #WAES 00082804
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:09/07/00ISR Number: 3567549-5Report Type:Expedited (15-DaCompany Report #WAES 00071397
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis Hyperchloraemic	Health	Vioxx	PS	Merck Research			
Life-Threatening	Blood Bicarbonate	Professional			Laboratories Div			
Other	Increased	Company			Merck Co Inc	ORAL	12.5	
	Cardiac Failure	Representative					MG/DAILY/PO	
	Congestive		Lasix	C				
	Condition Aggravated		Zyprexa	C				
	Hyperkalaemia		Insulin, Biphasic					
	Nephropathy Toxic		Isophane	C				
	Renal Failure Acute		Pottassium Chloride	C				

Date:09/07/00ISR Number: 3567551-3Report Type:Expedited (15-DaCompany Report #WAES 00082926
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral				Laboratories Div			
	Pain				Merck Co Inc	ORAL	PO	
			Relafen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/00ISR Number: 3567553-7Report Type:Expedited (15-DaCompany Report #WAES 00082900
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Benign Prostatic Hyperplasia							
	Blood Creatinine Increased	Representative	Cipro	C				
	Chills		Flomax	C				
	Dysuria		Levaquin	C				
	Headache		Pyridium	C				
	Leukocytosis							
	Neoplasm Prostate							
	Palpitations							
	Prostatic Specific Antigen Increased							
	Prostatitis							
	Renal Failure Acute							
	Renal Tubular Necrosis							
	Sepsis							
	Supraventricular Extrasystoles							
	Tenderness							
	Urinary Retention							
	Urinary Tract Infection							
	Urine Analysis Abnormal							
	White Blood Cells Urine Positive							

Date:09/07/00ISR Number: 3567555-0Report Type:Expedited (15-DaCompany Report #WAES 00082864
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Gastrointestinal Haemorrhage							
	Syncope		Levoxyl	SS				
			Elavil	C				
			Tenormin	C				

Zantac	C
Flexeril	C
Hydrodiuril	C

Date:09/07/00ISR Number: 3567557-4Report Type:Expedited (15-DaCompany Report #WAES 00082974
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Dialysis Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/00ISR Number: 3567560-4Report Type:Expedited (15-DaCompany Report #WAES 00090014
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/07/00ISR Number: 3567561-6Report Type:Expedited (15-DaCompany Report #WAES 00080666
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Upper Asthenia Diarrhoea Fall Haematemesis Haemoglobin Decreased Hyperhidrosis Nausea Pyrexia Syncope Upper Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DILY/PO	

Date:09/07/00ISR Number: 3567571-9Report Type:Expedited (15-DaCompany Report #WAES 00071350
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Oedema Oedema Peripheral Rales	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

	Weight Increased	Betoptic	C
		Flonase	C
		Lanoxin	C
		Lasix	C
		Micro K	C
		Ocuvite	C
		Xalatan	C
		Zestril	C
		Allopurinol	C
		Calcium Supplement (Unspecified)	C
		Chondroitin (+) Glucosamine	C

Date:09/07/00ISR Number: 3567574-4Report Type:Expedited (15-DaCompany Report #WAES 00064286
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Eczema Middle Insomnia Pain Pruritus Skin Lesion	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/00ISR Number: 3567576-8Report Type:Expedited (15-DaCompany Report #WAES 00083061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage				Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	25	
			Prilosec	C			MG/DAILY/PO	
			Iron (Unspecified)	C				

Date:09/07/00ISR Number: 3567583-5Report Type:Expedited (15-DaCompany Report #WAES 00052644
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Health	Vioxx	PS	Merck Research			
Other	Pleural Effusion	Professional			Laboratories Div			
	Pneumonia	Company			Merck Co Inc	ORAL	SEE IMAGE	
	Upper Respiratory Tract Infection	Representative						

Date:09/07/00ISR Number: 3567588-4Report Type:Expedited (15-DaCompany Report #WAES 00081518
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastroenteritis Viral	Health			Laboratories Div			
	Nausea	Professional			Merck Co Inc	ORAL	PO	
	Vomiting							

Date:09/07/00ISR Number: 3567606-3Report Type:Expedited (15-DaCompany Report #WAES 00081635
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Asthenia Dizziness Faeces Discoloured Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx Aspirin	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/07/00ISR Number: 3567614-2Report Type:Expedited (15-DaCompany Report #WAES 00081950
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Dysarthria Hallucination Meningitis Aseptic Pyrexia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/07/00ISR Number: 3567615-4Report Type:Expedited (15-DaCompany Report #WAES 00050625
Age:90 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aphasia Asthenia Bladder Disorder Cerebral Atrophy Cerebral Ischaemia Cerebrovascular Accident Confusional State Diplopia Disorientation Dysarthria Encephalopathy Fall Hypertension Muscular Weakness Transient Ischaemic Attack	Health Professional Company Representative	Vioxx Cardizem Darvocet-N Lanoxin Lasix Slow-K Vasotec Allopurinol Atenolol Magnesium Hydroxide Nitroglycerin	PS C C C C C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/08/00ISR Number: 3568229-2Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx 12.5mg Merck	PS	Merck	ORAL	1 QD ORAL	
			Hctz	C				
			Asa	C				
			Fosomax	C				
			Lipitor	C				

Date:09/11/00ISR Number: 3568829-XReport Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Rofecoxib 25 Merck	PS	Merck	ORAL	25MG QD ORAL	

Date:09/11/00ISR Number: 3568836-7Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypertension	Health	Vioxx 25mg Merck	PS	Merck	ORAL	25MG PO DAILY	
Intervention to Prevent Permanent Impairment/Damage	Oedema	Professional	Lexxel	C				
			Atenolol	C				
			Hctz	C				

Date:09/11/00ISR Number: 3568838-0Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypertension	Health	Vioxx 12.5 Merck	PS	Merck	ORAL	12.5 MG PO DAILY	
Intervention to Prevent Permanent Impairment/Damage		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/00ISR Number: 3569232-9Report Type:Expedited (15-DaCompany Report #WAES 00082313
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Anorexia	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chromaturia	Representative						
	Drug Ineffective		Advil 2 Tablet	SS		ORAL	2 TABLET/PRN/PO	
	Hepatitis							
	Malaise		Demerol	C				
	Nausea		Lorcet	C				

Date:09/11/00ISR Number: 3569260-3Report Type:Expedited (15-DaCompany Report #WAES 00085642
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/11/00ISR Number: 3569278-0Report Type:Expedited (15-DaCompany Report #WAES 00088916
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:09/11/00ISR Number: 3569280-9Report Type:Expedited (15-DaCompany Report #WAES 00065503
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Antinuclear Antibody		Phenprocoumon	SS		ORAL	1.5-3 MG, PO	
	Positive		Metoprolol Succinate	SS		ORAL	47.5 MG PO	
	Asthenia		Diclofenac Na	SS		ORAL	PO	
	Blood Bilirubin Increased Blood Copper Increased C-Reactive Protein		Equilin Sodium Sulfate (+) Estrone Sodium Sulfa	SS		ORAL	0.3 MG PO	
	Increased		Medrogestone	SS		ORAL	5 MG, PO	
	Cholestasis Dialysis		Isosorbide-5-Mononitrate	SS		ORAL	60 MG PO	
	Hepatic Failure		Hctz/Quinapril	SS		ORAL	12.5/10 MG PO	
	Hepatomegaly Hepatotoxicity Jaundice Liver Function Test Abnormal Nausea Prothrombin Time Prolonged Pruritus Red Blood Cell Sedimentation Rate Increased Urine Abnormality							

Date:09/11/00ISR Number: 3569293-7Report Type:Expedited (15-DaCompany Report #WAES 00087541
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Lower Respiratory Tract Infection	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/11/00ISR Number: 3569352-9Report Type:Expedited (15-DaCompany Report #WAES 00075233
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Chest Pain Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) UNK DOSE; 2) 50 MG; 3) 25 MG	
			Vasotec	C				
			Aspirin	C				
			Atenolol	C				
			Bendroflumethiazide	C				
			Doxazosin	C				

Date:09/11/00ISR Number: 3569355-4Report Type:Expedited (15-DaCompany Report #WAES 00088618
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/11/00ISR Number: 3569358-XReport Type:Expedited (15-DaCompany Report #WAES 00087548
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Dizziness Tinnitus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

Date:09/11/00ISR Number: 3569359-1Report Type:Expedited (15-DaCompany Report #WAES 00089761
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Dyspepsia Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Intra-Abdominal Haemorrhage		Diltiazem Prednisone	C C				

Date:09/11/00ISR Number: 3569366-9Report Type:Expedited (15-DaCompany Report #WAES 00088617
Age:77 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anuria Blood Creatinine Increased Cardiac Failure

		Congestive Condition Aggravated Lung Disorder Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				[Therapy Unspecified]	C		

Date:09/11/00ISR Number: 3569369-4Report Type:Expedited (15-DaCompany Report #WAES 00085625
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arrhythmia	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Cardiac Failure	Health			Laboratories Div	
Hospitalization -	Cardiac Failure	Professional			Merck Co Inc	ORAL
25 MG PO	1 DAY					
Initial or Prolonged	Congestive		Cinnarizine (+)			
	Tachycardia		Dimenhydrinate	C		
			Gallopamil Hcl	C		

Date:09/11/00ISR Number: 3569462-6Report Type:Expedited (15-DaCompany Report #WAES 00077260
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Confusional State		Vioxx	PS	Merck Research	
Initial or Prolonged	Haematoma				Laboratories Div	
	Pharyngeal Oedema				Merck Co Inc	ORAL
PO	13 DAY					
	Pharyngolaryngeal Pain		Vasotec	SS		ORAL
PO						
	Syncope		Aspirin	C		
	Vomiting		Calcium Carbonate	C		
			Citalopram Hydrobromide	C		
			Dihydroergotamine Methanesulfonate	C		
			Furosemide	C		
			Insulin Injection	C		

Insuline Injection/Isophane Insuline Suspe	C
Lactulose	C
Prednisone	C

Date:09/11/00ISR Number: 3569465-1Report Type:Expedited (15-DaCompany Report #WAES 00097252
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Cardiac Failure Difficulty In Walking Dizziness Fatigue Hypertension Nausea Weight Decreased	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	6 DAY

Date:09/11/00ISR Number: 3569630-3Report Type:Expedited (15-DaCompany Report #WAES 00090060
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Oesophageal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/11/00ISR Number: 3569958-7Report Type:Expedited (15-DaCompany Report #WAES 00095502
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	171 DAY

Date:09/11/00ISR Number: 3569961-7Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antinuclear Antibody Positive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY
Hospitalization - Initial or Prolonged	Autoimmune Disorder							
	Blood Immunoglobulin G Increased		Prednisolone	C				
	Epistaxis							
	Megakaryocytes Increased							
	Thrombocytopenia							

Date:09/11/00ISR Number: 3569967-8Report Type:Expedited (15-DaCompany Report #WAES 00095024
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	126 DAY
			Aspirin	C				
			Digoxin	C				

Date:09/11/00ISR Number: 3569971-XReport Type:Expedited (15-DaCompany Report #WAES 00085643
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Pamidronic Acid Dina	C				

Date:09/11/00ISR Number: 3569981-2Report Type:Expedited (15-DaCompany Report #WAES 00059601
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Melaena	Foreign Study Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	38 DAY
Bisoprolol Fumarate	C				

Date:09/11/00ISR Number: 3569982-4Report Type:Expedited (15-DaCompany Report #WAES 00069771
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 MON

Date:09/11/00ISR Number: 3569983-6Report Type:Expedited (15-DaCompany Report #WAES 00085628
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Multi-Organ Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	7 DAY
	Peritonitis		[Composition Unspecified]	C				
			Certoparin Sodium	C				
			Dipyrone	C				

Date:09/11/00ISR Number: 3569985-XReport Type:Expedited (15-DaCompany Report #WAES 00095022
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL

12.5 MG PO 2 DAY

Acetaminophen/Codeine Phosphate	C
Aluminum Hydroxide/Magnesium Carbonate	C
Aspirin	C
Ibuprofen	C
Isosorbide Dinitrate	C
Lacidipine	C
Misoprostol	C
Prochlorperazine	C
Ranitidine	C

Date:09/11/00ISR Number: 3570081-6Report Type:Expedited (15-DaCompany Report #WAES 00083092
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Other	Gastrointestinal Disorder
	Gastrointestinal Haemorrhage
	Gastrointestinal Perforation

Oral Intake Reduced

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	PO
			Albuterol	C				

Date:09/11/00ISR Number: 3570087-7Report Type:Expedited (15-DaCompany Report #WAES 00090013
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oesophageal Varices Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	PO

Date:09/11/00ISR Number: 3570089-0Report Type:Expedited (15-DaCompany Report #WAES 00083127
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO

Date:09/11/00ISR Number: 3570114-7Report Type:Expedited (15-DaCompany Report #WAES 00081097
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Other			Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Nafcillin Na	SS		ORAL
2 GM Q6H PO						
			Coumadin	C		
			Ms Contin	C		
			Docusate Calcium	C		

Date:09/11/00ISR Number: 3570124-XReport Type:Expedited (15-DaCompany Report #WAES 00081651
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Nephritis Interstitial	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Renal Failure Acute	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Glucophage	C		
			Ultram	C		
			Therapy Unspecified	C		
			Methadone Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/00ISR Number: 3571306-3Report Type:Direct Company Report #
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Rofecoxib	PS			12.5 MG QD, PRN	
	Congestive Delirium		Chlorpheniramine	C				
	Hallucination, Auditory		Warfarin	C				
	Hallucination, Visual		Digoxin	C				
	Mental Impairment		Furosemide	C				
	Neoplasm		Captopril	C				
	Pancreatic Disorder		Glipizide	C				
	Portal Hypertension		Rosaglitazone	C				
	Portal Vein Thrombosis		Lansoprazole	C				
	Restlessness		Vancenase	C				
	Sleep Apnoea Syndrome		Nitroglycerin	C				
	Urinary Tract Infection		Hydrocodone/Acetaminophen	C				
			Diphenhydramine	C				
			Ciprofloxacin	C				
			Cyclobenzaprine	C				

Date:09/12/00ISR Number: 3591272-4Report Type:Periodic Company Report #WAES 00071062
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Estrogenic Preparations	C				

Date:09/13/00ISR Number: 3570362-6Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia		Rofecoxib / 25 Mg	PS		ORAL	25MG QD ORAL	
Initial or Prolonged	Epistaxis		Ec Asa 325mg	SS		ORAL	325MG QD ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Faeces Discoloured							
	Gastric Ulcer							

Date:09/13/00ISR Number: 3570375-4Report Type:Direct Company Report #
Age:102 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS				
Initial or Prolonged	Hyponatraemia							

Date:09/13/00ISR Number: 3570867-8Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Decreased Appetite		Rofecoxib 50mg Qd	PS		ORAL	50MG PO QD	
Initial or Prolonged	Vomiting		Ciprofloxacin	C				
			Glucophage	C				

		Norvasc	C
		Lasix	C
		Potassium	C
		Prednisone	C
		Omeprazole	C

Date:09/13/00ISR Number: 3571129-5Report Type:Expedited (15-DaCompany Report #A030241
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Liver Abnormal	Foreign	Zoloft	PS	Pfizer Pharmaceuticals Inc	ORAL	ORAL	
	Cholangitis Acute	Other						
	Fatigue		Methotrexate	SS			7.50 MG	TOTAL:WEEKLY
	Hepatic Cirrhosis							
	Hepatic Enzyme Increased		Rofecoxib	SS			25.00 MG	TOTAL:DAILY
	Hepatic Failure							
	Hepatic Steatosis		Omeprazole	SS				
	Jaundice		Remicade	C				
	Nausea		Folacin	C				
	Pruritus		Daonil	C				

Date:09/13/00ISR Number: 3571259-8Report Type:Expedited (15-DaCompany Report #2000029107SE
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain	Foreign	Delta-Cortef	PS	Pharmacia And Upjohn Co	ORAL	ORAL	
Hospitalization - Initial or Prolonged	Eating Disorder	Health						
	Gastric Ulcer	Professional	Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, QD, ORAL	
	Nausea	Other						
	Pain In Extremity							
	Renal Failure		Trimethoprim (Trimethoprim)	SS		ORAL	320 MG, QD,	
	Vomiting							

ORAL

Propiomazine	C	
Cyclizine	C	
Medroxprogesterone	C	
Lactulose	C	
Morfin	C	
Behepan	C	
Leuprorelin Acetate	C	
Sodium Picosulfate	C	

Date:09/13/00ISR Number: 3571316-6Report Type:Expedited (15-DaCompany Report #WAES 00081166
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other		Company			Merck Co Inc	ORAL	25MG/ DAILY/	
		Representative						
PO								
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/00ISR Number: 3571317-8Report Type:Expedited (15-DaCompany Report #WAES 00090677
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Avalide	C				
			Premarin	C				

Date:09/13/00ISR Number: 3573149-3Report Type:Expedited (15-DaCompany Report #SP-200001649
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholangitis Acute	Foreign	Remicade	PS			INTRAVENOUS 300MG	INTRAVENOUS
	Fatigue	Health Professional						
Other	Hepatic Cirrhosis		Remicade	SS			INTRAVENOUS 300MG	INTRAVENOUS
	Hepatic Enzyme Increased							
	Hepatic Fibrosis		(Rofecoxbib) Vioxx	SS		ORAL	ORAL 25MG/ DAY	
	Hepatic Steatosis							
	Hepatitis		(Omeprazole) Losec	SS		ORAL	ORAL 20MG/DAY	
	Jaundice		(Sertraline) Zoloft	SS		ORAL	ORAL	
	Nausea		Methotrexate	SS		ORAL	ORAL 7.5MG / WEEK	
	Pruritus							
			Glibenclamide	C				
			Folacin	C				
			Daonil	C				

Date:09/14/00ISR Number: 3571542-6Report Type:Expedited (15-DaCompany Report #WAES 00075537
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Life-Threatening	Abdominal Tenderness
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Valve Incompetence
	Blood Creatinine Increased
	Blood Ph Decreased
	Blood Urea Increased
	Cardiac Failure
	Cardiac Failure Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Condition Aggravated
	Disorientation
	Dyspnoea
	Echocardiogram Abnormal
	Electrocardiogram St Segment Abnormal
	Flatulence
	Haemorrhagic Stroke
	Hyperkalaemia
	Hyperventilation
	Mesenteric Occlusion
	Mesenteric Vein Thrombosis
	Metabolic Acidosis

		Mitral Valve Incompetence					
		Monoparesis					
		Orthopnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion	Foreign	Vioxx	PS	Merck Research	
		Po2 Decreased	Health			Laboratories Div	
		Pulmonary Congestion	Professional			Merck Co Inc	ORAL
PO	13 DAY						
		Rales		..	C		
		Renal Impairment					
		Respiratory Arrest					
		Respiratory Failure					
		Sinus Tachycardia					

Date:09/14/00ISR Number: 3571545-1Report Type:Expedited (15-DaCompany Report #WAES 00077522
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Diverticulum Intestinal	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Dizziness	Health			Laboratories Div	
		Gastrointestinal	Professional			Merck Co Inc	ORAL
25 MG PO							
		Angiodysplasia		B Vitamins	C		
		Haematocrit Decreased		Dipyridamole	C		
		Haemoglobin Decreased		Lansoprazole	C		
		Rectal Haemorrhage		Pantoprazole	C		
				Piracetam	C		

Date:09/14/00ISR Number: 3571546-3Report Type:Expedited (15-DaCompany Report #WAES 00069770
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Gastrointestinal	Foreign	Vioxx	PS	Merck Research	
		Haemorrhage	Health			Laboratories Div	
			Professional			Merck Co Inc	ORAL
25 MG PO							
				Amlodipine Besylate	C		
				Aspirin	C		
				Doxazosin	C		
				Furosemide	C		
				Propafenone	C		

Date:09/14/00ISR Number: 3571552-9Report Type:Expedited (15-DaCompany Report #WAES 00085609
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Chest Pain Flatulence Gastritis Gastritis Erosive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/14/00ISR Number: 3571553-0Report Type:Expedited (15-DaCompany Report #WAES 00055539
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Barrett'S Oesophagus Candidiasis Haemoglobin Decreased Hiatus Hernia

	Melaena Oesophageal Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oesophagitis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 13 DAY
			Dipyrone	C			
			Furosemide	C			
			Perazine	C			
			Ranitidine Hcl	C			
			Sulfamethoxazole/Trimethoprim	C			
			Tramadol Hcl	C			

Date:09/14/00ISR Number: 3571556-6Report Type:Expedited (15-DaCompany Report #WAES 00097503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Condition Aggravated Macular Degeneration Visual Field Defect	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/14/00ISR Number: 3571557-8Report Type:Expedited (15-DaCompany Report #WAES 00096020
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Hallucination Hyponatraemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 1 DAY
			Althiazide/Spironolactone	C			
			Lactitol	C			
			Nitroglycerin	C			
			Trimetazidine	C			
			Zopiclone	C			

Date:09/14/00ISR Number: 3571558-XReport Type:Expedited (15-DaCompany Report #WAES 00096019
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rhinitis Allergic	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	17 DAY
			Budesonide	C				
			Cetirizine	C				
			Trimetazidine	C				
			Troxerutin	C				

Date:09/14/00ISR Number: 3571559-1Report Type:Expedited (15-DaCompany Report #WAES 00096004
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Asthenia							
	Haemoglobin Decreased							
			Sulfasalazine	SS				
			Hydroxychloroquineso					

4 SS

Date:09/14/00ISR Number: 3571560-8Report Type:Expedited (15-DaCompany Report #WAES 00088620
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	10 DAY
	Leukocytoclastic Vasculitis Nephrotic Syndrome Pulmonary Oedema Renal Impairment		Cyclobenzaprine	C				

Date:09/14/00ISR Number: 3571561-XReport Type:Expedited (15-DaCompany Report #WAES 00029772
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Atenolol	C				
			Nifedipine	C				

Date:09/14/00ISR Number: 3571562-1Report Type:Expedited (15-DaCompany Report #WAES 00099100
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY
	Rectal Haemorrhage		Acetaminophen	C				
			Tetrazepam	C				

Date:09/14/00ISR Number: 3571710-3Report Type:Direct Company Report #
Age:90 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx 25mg	PS		
25MG QD						
Initial or Prolonged	Haemorrhage		Senokot	C		
			Nitro	C		
			Betapace	C		
			Imdur	C		
			Prinivil	C		
			Miacalcin	C		
			Allbecon	C		
			Prevacid	C		

Date:09/14/00ISR Number: 3571711-5Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Peptic Ulcer		Vioxx 25 Mg	PS		ORAL
2.5MG PO QD						
Initial or Prolonged			Asa	C		
			Levoxyl	C		
			Norvasc	C		

				Hytrin	C		

Date:09/14/00ISR Number: 3571813-3Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Condition Aggravated				Merck Co Inc	ORAL	25 MG DAILY	
	Dizziness							
PO								
	Feeling Jittery		Fosamax	C				
	Gastrointestinal Disorder		Glucosamine	C				
	Muscle Spasms							
	Nausea							
	Palpitations							
	Peripheral Vascular Disorder							
	Tremor							
	Weight Decreased							

Date:09/14/00ISR Number: 3571816-9Report Type:Expedited (15-DaCompany Report #WAES 00082974
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis	Health	Vioxx	PS	Merck Research			
	Renal Failure	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25 MG DAILY	
		Representative						
PO							10	DAY
			Anaprox	C				
			[Therapy Unspecifed]	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:09/14/00ISR Number: 3571817-0Report Type:Expedited (15-DaCompany Report #WAES 00050115
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Constipation Haemorrhoids	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

Date:09/14/00ISR Number: 3571858-3Report Type:Expedited (15-DaCompany Report #WAES 00081553
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Anaemia Gastric Ulcer Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Kerlone	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/00ISR Number: 3571859-5Report Type:Expedited (15-DaCompany Report #WAES 00090426
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Herpes Zoster	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Tylenol	C				
			Vitamins (Unspecified)	C				

Date:09/14/00ISR Number: 3571865-0Report Type:Expedited (15-DaCompany Report #WAES 00090201
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:09/14/00ISR Number: 3571878-9Report Type:Expedited (15-DaCompany Report #WAES 00051681
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorectal Disorder Haemorrhage Hypovolaemia Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 WK
			Aspirin	C				

Date:09/15/00ISR Number: 3571650-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthropathy		Estrostep Fe Tabs	PS			1 TAB DAILY	
	Limb Injury		Vioxx 25mg Tabs	SS			1 TAB DAILY	
	Pulmonary Embolism							

Date:09/15/00ISR Number: 3571997-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Decreased	Health Professional	Vioxx 25 Mg Merck	PS	Merck	ORAL	12.5 MG QD PO	
			Coumadin 5 Mg Dupont	SS	Dupont		VARIES	
	International Normalised Ratio Increased		Apap	C				
			Allopurinol	C				
			Digoxin	C				
			Docusate	C				
			Dorzolamide	C				
			Furosemide	C				
			Latanoprost	C				
			Primidone	C				
			Tolterodine	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/00ISR Number: 3572029-7Report Type:Direct Company Report #
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx 50 Mg Merck	PS	Merck	ORAL	ONCE ORAL	
	Diarrhoea						DAILY	

Date:09/15/00ISR Number: 3572036-4Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Fosamax 50mg Merck	PS	Merck	ORAL	50MG QD ORAL	
Initial or Prolonged	Gastrointestinal		Vioxx 25mg Merck	SS	Merck	ORAL	25MG QD ORAL	
Required	Haemorrhage		Labetolol	C				
Intervention to	Haemoglobin Decreased		Restoril	C				
Prevent Permanent								
Impairment/Damage								

Date:09/15/00ISR Number: 3572578-1Report Type:Expedited (15-DaCompany Report #WAES 00081293
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatinine	Consumer	Vioxx	PS	Merck Research			
	Increased	Health			Laboratories Div			
	Blood Urea Increased	Professional			Merck Co Inc	ORAL	25 NG	
	Dyspepsia						/DAILY/PO	
	Nausea		Allegra	C				
	Renal Disorder		Avalide	C				
	Systemic Lupus		Niferex Forte	C				
	Erythematosus		Ornade Spansule	C				
			Synthroid	C				
			Tricor	C				
			Ultram	C				
			Iron (Unspecified)	C				

			Tamoxifen	C		

Date:09/15/00ISR Number: 3572603-8Report Type:Expedited (15-DaCompany Report #WAES 00090259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haemorrhage	Consumer	Vioxx	PS	Merck Research	
	Liver Disorder				Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:09/15/00ISR Number: 3572605-1Report Type:Expedited (15-DaCompany Report #WAES 00090360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional			Laboratories Div	
Other	Gastrointestinal	Company			Merck Co Inc	ORAL
25 MG DAILY						
	Haemorrhage	Representative				
PO						
	Melaena		K-Dur	C		
			Levoxyl	C		
			Maxzide	C		
			Wellbutrin Sr	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/00ISR Number: 3572747-0Report Type:Expedited (15-DaCompany Report #WAES 00095010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Hypersensitivity	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Face Oedema	Other						
	Oedema Genital							
	Oedema Mouth		Inositol Niacinate	C				
	Vulval Disorder							

Date:09/15/00ISR Number: 3572750-0Report Type:Expedited (15-DaCompany Report #WAES 00085276
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
	Depressed Mood	Other						
	Schizophrenia, Paranoid							
	Type		Aspirin	C				
			Atenolol	C				
			Nifedipine	C				
			Thioridazine	C				

Date:09/15/00ISR Number: 3572751-2Report Type:Expedited (15-DaCompany Report #WAES 00079771
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG, PO	5 DAY
	Faeces Discoloured	Health						
	Haemorrhage	Professional						
			Pepcid	C				

Date:09/18/00ISR Number: 3573016-5Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased		Vioxx	PS	Merck & Company			

Date:09/18/00ISR Number: 3574804-1Report Type:Expedited (15-DaCompany Report #WAES 00096030
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	10 DAY
	Dyspnoea							
	Fatigue							
	Gastrointestinal Haemorrhage	Other	Acetaminophen	C				
	Haematemesis		Paroxetine	C				
	Haemoglobin Decreased		Rivastigimine	C				
	Melaena							

Date:09/18/00ISR Number: 3574805-3Report Type:Expedited (15-DaCompany Report #WAES 00085609
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Chest Discomfort

		Flatulence					
		Gastritis					
		Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
			Other				

Date:09/18/00ISR Number: 3574809-0Report Type:Expedited (15-DaCompany Report #WAES 00075574
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Ammonia Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged		Antinuclear Antibody Positive					
12.5 MG PO	6 DAY						
		Arthritis	Other	Diclofenac	SS		ORAL
SEE IMAGE	14 DAY						
		Ascites					
		Blood Albumin Increased					
		Blood Bilirubin Increased					
		Blood Urea Increased					
		Chromaturia					
		Condition Aggravated					
		Gastrointestinal Disorder					
		Hepatic Failure					
		Hepatitis					
		Hepatocellular Damage					
		Hypergammaglobulinaemia					
		Hyperglycaemia					
		Hypocalcaemia					
		Jaundice					
		Leukocytosis					
		Lipase Increased					
		Liver Disorder					
		Liver Function Test Abnormal					
		Nausea					
		Oedema Peripheral					
		Oesophageal Candidiasis					
		Protein Total Decreased					
		Prothrombin Time					

Prolonged
Thrombocytopenia

Date:09/18/00ISR Number: 3574893-4Report Type:Expedited (15-DaCompany Report #WAES 00087548
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Dizziness Tinnitus	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	45 DAY

Date:09/18/00ISR Number: 3574895-8Report Type:Expedited (15-DaCompany Report #WAES 00095540
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health

		Professional Other				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/18/00ISR Number: 3574896-XReport Type:Expedited (15-DaCompany Report #WAES 00095539
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Bone Marrow Depression	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Other				

Date:09/18/00ISR Number: 3574898-3Report Type:Expedited (15-DaCompany Report #WAES 00095090
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO	7 DAY					
			Aspirin	C		
			Dipyridamole	C		

Date:09/18/00ISR Number: 3574899-5Report Type:Expedited (15-DaCompany Report #WAES 00067529
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspnoea Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						

		Other	Naloxone Hydrochloride(+) Tilidine	C		

Date:09/18/00ISR Number: 3574901-0Report Type:Expedited (15-DaCompany Report #WAES 00086149
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastric Ulcer Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 9 DAY						
			Amlodipine	C		
			Aspirin Lysine	C		
			Furosemide	C		
			Omeprazole	C		
			Ramipril	C		

Date:09/18/00ISR Number: 3574902-2Report Type:Expedited (15-DaCompany Report #WAES 00085187
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
12.5 MG PO

Cozaar	C	
Ferrouss04	C	
Furosemide	C	
Lansoprazole	C	
Thyroxine	C	

Date:09/18/00ISR Number: 3574903-4Report Type:Expedited (15-DaCompany Report #WAES 00095045
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Flushing	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	43 DAY
			Bisoprolol	C				
			Carbamazepine	C				
			Naproxen	C				

Date:09/18/00ISR Number: 3574905-8Report Type:Expedited (15-DaCompany Report #WAES 00095526
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Surgery	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	166 DAY	
			Omeprazole	C				

Date:09/18/00ISR Number: 3574909-5Report Type:Expedited (15-DaCompany Report #WAES 00095513
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Circulatory Collapse Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Haemoglobin Decreased		Amiodarone					

Hydrochloride	C	
Levothyroxine Na	C	
Nifedipine	C	

Date:09/18/00ISR Number: 3574912-5Report Type:Expedited (15-DaCompany Report #WAES 00095508
Age:61 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

Date:09/18/00ISR Number: 3575035-1Report Type:Expedited (15-DaCompany Report #WAES 00083730
Age:83 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Nephritis Interstitial Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/00ISR Number: 3575046-6Report Type:Expedited (15-DaCompany Report #WAES 00088916
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Diclofenac Na	C				

Date:09/18/00ISR Number: 3575076-4Report Type:Expedited (15-DaCompany Report #WAES 00085525
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
	Faecal Occult Blood Positive							
	Faeces Discoloured	Other	Aspirin	SS		ORAL	100 MG PO	
	Gastrointestinal Haemorrhage		Acetaminophen/Codeine Phosphate	C				
	Haematocrit Decreased		Herbal Remedies	C				
	Haemoglobin Decreased		Isosorbide Dinitrate	C				
			Lactulose	C				
			Metoprolol Succinate	C				

Date:09/18/00ISR Number: 3575090-9Report Type:Expedited (15-DaCompany Report #WAES 00095520
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	6 DAY
	Oedema							

Date:09/18/00ISR Number: 3575094-6Report Type:Expedited (15-DaCompany Report #WAES 00085186
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Prinivil	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Aspirin	C				
			Cinnarizine	C				

Date:09/18/00ISR Number: 3575134-4Report Type:Expedited (15-DaCompany Report #WAES 00090813
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Glucotrol	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/00ISR Number: 3575135-6Report Type:Expedited (15-DaCompany Report #WAES 00071372
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Health	Vioxx	PS	Merck Research			
Life-Threatening	Haematemesis	Professional			Laboratories Div			
Hospitalization -	Upper Gastrointestinal	Company			Merck Co Inc	ORAL	25	
Initial or Prolonged	Haemorrhage	Representative					MG/DAILY/PO	
		Other	Allegra	C				
			Zyprexa	C				
			Calcium Supplement (Unspecified)	C				
			Glyburide	C				
			Vitamins (Unspecified)	C				

Date:09/18/00ISR Number: 3575137-XReport Type:Expedited (15-DaCompany Report #WAES 00081062
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Condition Aggravated	Professional			Laboratories Div			
	Disorientation				Merck Co Inc	ORAL	25	
	Hallucination						MG/DAILY/PO	5 DAY
	Mental Impairment							
	Senile Dementia							

Date:09/18/00ISR Number: 3575138-1Report Type:Expedited (15-DaCompany Report #WAES 00090779
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Thrombosis				Laboratories Div			
					Merck Co Inc	ORAL	25	

MG/DAILY/PO

Coumadin	C
Paxil	C
Wellbutrin	C
Zyprexa	C
Phentermine	C

Date:09/18/00ISR Number: 3575151-4Report Type:Expedited (15-DaCompany Report #WAES 00090601
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia
	Budd-Chiari Syndrome
	Cardiac Failure
	Congestive
	Delirium
	Hallucinations, Mixed
	Mental Disorder
	Neoplasm
	Pancreatic Cyst
	Pancreatic Disorder
	Portal Hypertension
	Portal Vein Thrombosis
	Restlessness
	Sleep Apnoea Syndrome

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN/PO	
	Vancenase	C				
	Acetaminophen (+) Hydrocodone	C				
	Captopril	C				
	Chlorpheniramine	C				
	Ciprofloxacin	C				
	Cyclobenzaprine	C				
	Digoxin	C				
	Diphenhydramine	C				
	Furosemide	C				
	Glipizide	C				
	Lansoprazole	C				
	Nitroglycerin	C				
	Rosiglitazone Maleate	C				
	Warfarin	C				

Date:09/18/00ISR Number: 3575153-8Report Type:Expedited (15-DaCompany Report #WAES 00090605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Full Blood Count Decreased Platelet Count Decreased White Blood Cell Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/18/00ISR Number: 3575166-6Report Type:Expedited (15-DaCompany Report #WAES 00090624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Health	Vioxx	PS	Merck Research			
	Gastrointestinal Disorder	Professional			Laboratories Div			
	Pancreatitis				Merck Co Inc	ORAL	25 MG/PRN/PO	
	Weight Decreased							

Date:09/18/00ISR Number: 3575168-XReport Type:Expedited (15-DaCompany Report #WAES 00081293
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatinine	Consumer	Vioxx	PS	Merck Research			
Other	Increased	Health			Laboratories Div			
	Blood Urea Increased	Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Nausea		Allegra	C				
	Renal Disorder		Avalide	C				
	Systemic Lupus		Niferex Forte	C				
	Erythematosus		Ornade Spansule	C				
			Synthroid	C				
			Tricor	C				
			Ultram	C				

[Composition Unspecified]	C	
Iron (Unspecified)	C	
Tamoxifen	C	

Date:09/18/00ISR Number: 3575169-1Report Type:Expedited (15-DaCompany Report #WAES 00051637
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage	Company			Merck Co Inc	ORAL	25	
	Haematochezia	Representative					MG/DAILY/PO	
	Haematocrit Decreased		Ambien	C				
	Syncope		Ativan	C				
			Cardizem	C				
			Glucophage	C				
			Lopressor	C				
			Lorcet Plus	C				
			Lotrel	C				
			Neurontin	C				
			Oxycontin	C				
			Nitroglycerin	C				

Date:09/18/00ISR Number: 3575171-XReport Type:Expedited (15-DaCompany Report #WAES 00090176
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Exsanguination				Merck Co Inc	ORAL	25 MG/AM/PO	
	Post Procedural		Florinef	C				
	Haemorrhage		Lanoxin	C				
			Synthroid	C				
			Wellbutrin	C				
			Quinidine	C				

Date:09/18/00ISR Number: 3575172-1Report Type:Expedited (15-DaCompany Report #WAES 00090200
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Faecal Occult Blood Positive Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/18/00ISR Number: 3575173-3Report Type:Expedited (15-DaCompany Report #WAES 00090419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Paralysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/00ISR Number: 3575174-5Report Type:Expedited (15-DaCompany Report #WAES 00071397
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis Hyperchloraemic	Health	Vioxx	PS	Merck Research			
Life-Threatening	Blood Creatinine	Professional			Laboratories Div			
Other	Increased	Company			Merck Co Inc	ORAL	12.5	
	Blood Urea Increased	Representative					MG/DAILY/PO	
	Cardiac Failure		Lasix	C				
	Cardiac Failure		Zyprexa	C				
	Congestive		[Therapy					
	Hyperkalaemia		Unspecified]	C				
	Renal Failure Acute		Insulin, Biphasic					
			Isophane Inj	C				
			Potassium Chloride	C				

Date:09/18/00ISR Number: 3575175-7Report Type:Expedited (15-DaCompany Report #WAES 00090838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Malaise				Laboratories Div			
	Paranoia				Merck Co Inc	ORAL	PO	

Date:09/19/00ISR Number: 3573353-4Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Vioxx	PS				
							12.5 MG QD	
Hospitalization -	Faecal Occult Blood		Norvasc	C				
Initial or Prolonged	Positive		Asa	C				
	Gastrointestinal		Atenolol	C				
	Haemorrhage		Lanoxin	C				
	Gastrointestinal Ulcer		Zestoretic	C				
	Perforation		Halcion	C				
	Haemoglobin Decreased		Tylenol	C				

			Diabeta	C		

Date:09/19/00ISR Number: 3574751-5Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Rectal Haemorrhage		Vioxx	PS		
25 MG Q.D.						
Intervention to Prevent Permanent Impairment/Damage						

Date:09/19/00ISR Number: 3590178-4Report Type:Periodic Company Report #WAES 00081537
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Flexeril	C		
			Hydrocodone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/00ISR Number: 3594237-1Report Type:Periodic Company Report #WAES 00062218
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastroenteritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/19/00ISR Number: 3596234-9Report Type:Periodic Company Report #WAES 00060007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/19/00ISR Number: 3596937-6Report Type:Periodic Company Report #WAES 00063083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Creatinine Increased							
	Blood Urea Increased		Therapy Unspecified	C				
	Gait Disturbance							
	Muscular Weakness							
	Oedema Peripheral							
	Tendonitis							
	Weight Increased							

Date:09/20/00ISR Number: 3575873-5Report Type:Expedited (15-DaCompany Report #WAES 00081178
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Blood Pressure Increased Chest Pain Dyspnoea Gastritis Haemoglobin Decreased Ventricular Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:09/20/00ISR Number: 3576542-8Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia Dysgeusia		Vioxx	PS		ORAL	ORAL	5 DAY

Date:09/20/00ISR Number: 3576711-7Report Type:Direct Company Report #
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Other	Anorexia Anxiety

Chills
Gastrointestinal Disorder
Heart Rate Increased
Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 125mg (Rofecoxib Tablets) Merck & Co.	PS	Merck & Co		1-PER DAY FOR 3 DAYS; ER ON JULY 4, 00	

Date:09/21/00ISR Number: 3576435-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema	Health Professional	Vioxx 25mg Merck	PS	Merck	ORAL	ONE DAILY ORAL	

Date:09/21/00ISR Number: 3576457-5Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rectal Haemorrhage	Health Professional	Vioxx	PS			25 MG QD	

Date:09/21/00ISR Number: 3576461-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Upper Gastrointestinal	Health	Vioxx	PS
25 MG QD 1 WK				
Initial or Prolonged	Haemorrhage	Professional	Prednisone	C
			Lopressor	C
			Zestril	C
			Lasix	C
			Prevacid	C
			Benemid	C

Date:09/21/00ISR Number: 3576839-1Report Type:Expedited (15-DaCompany Report #WAES 00090494
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Face Oedema	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged					Laboratories Div	
					Merck Co Inc	ORAL
SEE IMAGE						
			Benemid	C		
			Prinivil	C		
			Zocor	C		
			Verapamil Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3576840-8Report Type:Expedited (15-DaCompany Report #WAES 00090546
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diabetes Mellitus							
	Inadequate Control							
	Difficulty In Walking		Lasix	C				
	Fall		Nitroglycerin	C				
	Oedema		Tylenol	C				
	Renal Failure							
	Weight Increased							

Date:09/21/00ISR Number: 3576841-XReport Type:Expedited (15-DaCompany Report #WAES 00090835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
	Embolism							
	Rectal Haemorrhage							
			Pravachol	C				
			Prempro	C				
			Synthroid	C				
			Diltiazem Hydrochloride	C				
			Isosorbide Mononitrate	C				
			Nitroglycerin	C				

Date:09/21/00ISR Number: 3576843-3Report Type:Expedited (15-DaCompany Report #WAES 00091014
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3576870-6Report Type:Expedited (15-DaCompany Report #WAES 00090601
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Akathisia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN	
	Budd-Chiari Syndrome							
	Cardiac Failure							
	Congestive							
	Delirium		Vancenase	C			PO	
	Hallucinations, Mixed		Acetaminophen	C				
	Mental Impairment		Captopril	C				
	Neoplasm		Chlorpheniramine	C				
	Pancreatic Disorder		Ciprofloxacin	C				
	Portal Hypertension		Cyclobenzaprine	C				
	Portal Vein Thrombosis		Digoxin	C				
	Restlessness		Diphenhydramine	C				
	Sleep Apnoea Syndrome		Furosemide	C				
	Urinary Tract Infection		Glipizide	C				
			Lansoprazole	C				
			Nitroglycerin	C				
			Rosiglitazone					

		Maleate	C	
		Warfarin	C	

Date:09/21/00ISR Number: 3576872-XReport Type:Expedited (15-DaCompany Report #WAES 00064290
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Atelectasis	Professional			Laboratories Div			
Initial or Prolonged	Blood Pressure Diastolic	Company			Merck Co Inc	ORAL	25	
Disability	Decreased	Representative					MG/DAILY/PO	
Other	Diarrhoea		Ecotrin 325 Mg	SS			325 MG/DAILY	
	Drug Ineffective		Carafate	C				
	Duodenal Ulcer		Cetacaine	C				
	Perforation		Feosol	C				
	Duodenal Ulcer,		Isordil	C				
	Obstructive		Lopressor	C				
	Erosive Oesophagitis		Mylanta & Mylanta Ds	C				
	Erythema		Nitro-Dur	C				
	Fistula		Pepcid	C				
	Gastritis		Phenergan	C				
	Haematemesis		Prevacid	C				
	Haematocrit Decreased		Synthroid	C				
	Haemoglobin Decreased		Toprol Xl	C				
	Hepatic Function Abnormal		Tylenol	C				
	Hypoproteinaemia		Versed	C				
	Hypotension		Fentanyl	C				
	Liver Function Test							
	Abnormal							
	Nausea							
	Oedema Peripheral							
	Oesophagitis							
	Oesophagoscopy Abnormal							
	Oliguria							
	Pancreatic Disorder							
	Pleural Effusion							
	Pneumothorax							
	Post Procedural							
	Complication							
	Procedural Site Reaction							
	Renal Cyst							
	Respiratory Rate							

	Increased Upper Gastrointestinal Haemorrhage Urticaria X-Ray Gastrointestinal Tract Abnormal

Date:09/21/00ISR Number: 3576879-2Report Type:Expedited (15-DaCompany Report #WAES 00081867
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acidosis Hyperchloraemic
Hospitalization - Initial or Prolonged	Asthenia Atelectasis Blood Creatinine Increased Decreased Activity Fatigue

	Gallbladder Disorder						
	Gastric Ulcer Haemorrhage						
	Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastrointestinal Ulcer	Consumer	Vioxx	PS	Merck Research		
	Haematemesis				Laboratories Div		
	Hyperglycaemia				Merck Co Inc	ORAL	25
	Hyperkalaemia						MG/DAILY/PO
	Hypotension		Cardura	C			
	Melaena		Glucophage	C			
	Pain		Lasix	C			
	Pulmonary Congestion		Lotrial	C			
	Pulmonary Oedema		Tylenol With Codeine # 3	C			
			(Therapy Unspecified)	C			
			Insulin	C			

Date:09/21/00ISR Number: 3576897-4Report Type:Expedited (15-DaCompany Report #WAES 00052212
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck Research		
Life-Threatening	Gastric Ulcer Haemorrhage				Laboratories Div		
Hospitalization -					Merck Co Inc	ORAL	PO
Initial or Prolonged			Coumadin	C			

Date:09/21/00ISR Number: 3576899-8Report Type:Expedited (15-DaCompany Report #WAES 00060309
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Tenderness	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Cardiac Failure				Laboratories Div		
	Congestive				Merck Co Inc	ORAL	PO 3 WK
	Oedema						
	Oral Pain						
	Tooth Disorder						

Date:09/21/00ISR Number: 3576900-1Report Type:Expedited (15-DaCompany Report #WAES 00080871
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mood Swings Peyronie'S Disease	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	SS			20 MG/DAILY	

Date:09/21/00ISR Number: 3576902-5Report Type:Expedited (15-DaCompany Report #WAES 00082864
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Syncope		Elavil	C				
			Flexeril	C				
			Hydrodiuril	C				

			Levoxyl	C		
			Tenormin	C		
			Zantac	C		

Date:09/21/00ISR Number: 3576982-7Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Condition Aggravated		Vioxx	PS		
	Gastrointestinal					
	Haemorrhage					
	Neck Pain					

Date:09/21/00ISR Number: 3577101-3Report Type:Expedited (15-DaCompany Report #WAES 00085276
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Delusion	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG						
			Aspirin	C		
			Atenolol	C		
			Nifedipine	C		
			Thioridazine	C		

Date:09/21/00ISR Number: 3577103-7Report Type:Expedited (15-DaCompany Report #WAES 00079771
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastrointestinal	Health			Laboratories Div	
	Haemorrhage	Professional			Merck Co Inc	ORAL
25.0 MG 5 DAY						
	Melaena		Pepcid	C		

Date:09/21/00ISR Number: 3577104-9Report Type:Expedited (15-DaCompany Report #WAES 00085049
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
		Other	Aspirin	C				
			Atenolol	C				
			Nifedipine	C				
			Thioridazine	C				

Date:09/21/00ISR Number: 3577106-2Report Type:Expedited (15-DaCompany Report #WAES 00087534
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	55 DAY
	Colonic Polyp							
	Gastric Ulcer							
	Haemoglobin Decreased	Other	Aspirin	C				
	Melaena							
	Pallor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3577107-4Report Type:Expedited (15-DaCompany Report #WAES 00085622
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Atrial Fibrillation Atrioventricular Block	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	15 DAY
	Blood Creatinine Increased Bundle Branch Block Left Cardiac Failure Cardiovascular Disorder Dyspnoea Left Ventricular Failure Oedema Peripheral Pleural Effusion Pulmonary Congestion Tachycardia	Professional	Clopidogrel Bisulfate	C				

Date:09/21/00ISR Number: 3577109-8Report Type:Expedited (15-DaCompany Report #WAES 00073755
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Oliguria Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/25 MG	PO 2 DAY
			Cyclosporin A	C				
			Sulfamethoxazole/Tri methoprim	C				

Date:09/21/00ISR Number: 3577189-XReport Type:Expedited (15-DaCompany Report #WAES 00095083
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

Professional Merck Co Inc ORAL
25 MG PO

Date:09/21/00ISR Number: 3577195-5Report Type:Expedited (15-DaCompany Report #WAES 00097254
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive
	Biopsy Kidney Abnormal
	C-Reactive Protein Increased
	Echocardiogram Abnormal
	Fatigue
	Haematuria
	Headache
	Inflammation
	Leukocytosis
	Myalgia
	Pyrexia
	Red Blood Cell Sedimentation Rate Increased

	Tenderness Trismus Urinary Casts	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vasculitis White Blood Cells Urine Positive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 63 DAY
			Prednisolone	C			

Date:09/21/00ISR Number: 3579172-7Report Type:Periodic Company Report #WAES 00053027
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
		Representative	Coumadin	C			
			Plavix	C			

Date:09/21/00ISR Number: 3579175-2Report Type:Periodic Company Report #WAES 00052943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3579177-6Report Type:Periodic Company Report #WAES 00052740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3579179-XReport Type:Periodic Company Report #WAES 99122028
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Darvocet-N	C				
			Didronel	C				
			Hydrodiuril	C				
			Maclicine	C				
			Prevacid	C				
			Tylenol	C				
			Xanax	C				
			[Composition Unspecified]	C				
			Ascorbic Acid	C				
			Glucosamine	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3579180-6Report Type:Periodic Company Report #WAES 99102358
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3579181-8Report Type:Periodic Company Report #WAES 00051987
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
			Cardizem	C				
			Glucophage	C				
			Glucotrol	C				

Date:09/21/00ISR Number: 3579182-XReport Type:Periodic Company Report #WAES 00051446
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579183-1Report Type:Periodic Company Report #WAES 00042661
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Ativan	C				
			Celebrex	C				
			Cozaar	C				
			Hydrodiuril	C				
			Neuroton	C				
			Prilosec	C				
			Zoloft	C				
			Aspirin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3579184-3Report Type:Periodic Company Report #WAES 00031480
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
			Aricept	C				
			Celebrex	C				

Detrol	C
Florinef	C
Paxil	C
Plavix	C
Premarin	C
Relafen	C
Sinemet	C
Tenormin	C
Triavil	C
Calcium Supplement (Composition	C

Date:09/21/00ISR Number: 3579186-7Report Type:Periodic Company Report #WAES 00081458
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579189-2Report Type:Periodic Company Report #WAES 00081384
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579191-0Report Type:Periodic Company Report #WAES 00080107
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative	Feldene	C
	Hydrodiuril	C
	Zantac	C

Date:09/21/00ISR Number: 3579193-4Report Type:Periodic Company Report #WAES 00072665
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579196-XReport Type:Periodic Company Report #WAES 00071997
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Life-Threatening	Blood Pressure Increased	Health Professional Company Representative
Other		

Other

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Zestril	C				
[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3579197-1Report Type:Periodic Company Report #WAES 00071502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579200-9Report Type:Periodic Company Report #WAES 00071469
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alanine Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Aspartate Aminotransferase Increased		Arthrotec	C				
	Asthenia		Corgard	C				
	Fatigue		Estratest	C				
	Hyperhidrosis		Ultram	C				

Date:09/21/00ISR Number: 3579203-4Report Type:Periodic Company Report #WAES 00070554
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Tab Coumadin 3 Mg	SS		ORAL	3 MG/DAILY/PO	
			Tab Coumadin	SS		ORAL	4 MG/DAILY/PO	
			Aldactone	C				
			K-Dur	C				
			Amiodarone	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3579205-8Report Type:Periodic Company Report #WAES 00070286
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3579207-1Report Type:Periodic Company Report #WAES 00070022
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ditropan	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3579209-5Report Type:Periodic Company Report #WAES 00064448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pharyngeal Oedema Vomiting	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3579210-1Report Type:Periodic Company Report #WAES 00064400
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
			Synvisc	SS			INJ	
			Synvisc	SS			INJ	
			Avandia	C				
			Celebrex	C				
			Corgard	C				
			Diovan	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Norvasc	C				

			Synthroid	C		
			Amitriptyline	C		
			Meclizine	C		
			Naproxen	C		
			Phenobarbital	C		
			Vitamin B [12]	C		

Date:09/21/00ISR Number: 3579213-7Report Type:Periodic Company Report #WAES 00072241
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Blood Pressure Increased					
	Renal Cyst					
PO						
	Vomiting		Klonopin	C		
			Premarin	C		
			Sinemet	C		
			Synthroid	C		
			Trental	C		
			Tylenol With Codeine	C		
			Zoloft	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3579216-2Report Type:Periodic Company Report #WAES 00061629
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Accupril	C				
			Aleve	C				
			Glucophage	C				
			Prinizide	C				
			Insulin	C				

Date:09/21/00ISR Number: 3590027-4Report Type:Periodic Company Report #WAES 00080005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590028-6Report Type:Periodic Company Report #WAES 00080016
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Diazide	C				

Date:09/21/00ISR Number: 3590029-8Report Type:Periodic Company Report #WAES 00080017
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	

Date:09/21/00ISR Number: 3590030-4Report Type:Periodic Company Report #WAES 00080018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590031-6Report Type:Periodic Company Report #WAES 00080025
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590032-8Report Type:Periodic Company Report #WAES 00080028
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Joint Swelling Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	PO	
			Celebrex 200 Mg	SS			200 MG/BID	
			Celebrex	SS				
			Lanoxin	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590033-XReport Type:Periodic Company Report #WAES 00080029
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Imuran (Azathioprine Sodium Salt	C				
			Synthroid	C				
			Tylenol Arthritis Extended Relift	C				
			Verapamil Msd Lp	C				
			Aspirin	C				
			Diuretic Preparation (Composition Unspecified)	C				

Date:09/21/00ISR Number: 3590034-1Report Type:Periodic Company Report #WAES 00080035
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Detrol	C				
			Xanax	C				
			Estrogenic Preparations (Composi	C				
			Sertraline	C				

Date:09/21/00ISR Number: 3590035-3Report Type:Periodic Company Report #WAES 00080038
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin Estrogenic	C				

Preparations C

Date:09/21/00ISR Number: 3590036-5Report Type:Periodic Company Report #WAES 00080039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Glipizide	C				

Date:09/21/00ISR Number: 3590037-7Report Type:Periodic Company Report #WAES 00080040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590038-9Report Type:Periodic Company Report #WAES 00080043
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Oxycontin	C				

Date:09/21/00ISR Number: 3590039-0Report Type:Periodic Company Report #WAES 00080046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
			Hyzaar	C				

Date:09/21/00ISR Number: 3590040-7Report Type:Periodic Company Report #WAES 00080050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

Date:09/21/00ISR Number: 3590041-9Report Type:Periodic Company Report #WAES 00080051
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Actonel	C	
Axid	C	
Elavil	C	
Lescol	C	
Clacium Supplement (Composition	C	
Vitamins (Unspecified)	C	

Date:09/21/00ISR Number: 3590042-0Report Type:Periodic Company Report #WAES 00080052
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Estrogenic Preparations (Composi	C				

Date:09/21/00ISR Number: 3590043-2Report Type:Periodic Company Report #WAES 00080053
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged Ecchymosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
		Representative	Tab Vioxx Unk	SS		ORAL	50 MG/DAILY/PO	
			Flexeril	C				
			Zanaflex	C				

Date:09/21/00ISR Number: 3590044-4Report Type:Periodic Company Report #WAES 00080054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590045-6Report Type:Periodic Company Report #WAES 00080057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hormones (Composition Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590046-8Report Type:Periodic Company Report #WAES 00080058
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Headache							
	Hypertension				Merck Co Inc	ORAL	12.5 MG/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/PO	4 MON
			Captopril Msd	C				
			Celebrex	C				
			Prilosec	C				
			Verapamil Msg Lp	C				
			Zocor	C				
			Zoloft	C				
			Hyoscyamine	C				

Date:09/21/00ISR Number: 3590047-XReport Type:Periodic Company Report #WAES 00072603
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG	
							/DAILY/PO	
			Elavil	C				
			Estratest	C				
			Mellaril	C				
			Provera	C				

Date:09/21/00ISR Number: 3590048-1Report Type:Periodic Company Report #WAES 00072604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							

	Pruritus				Merck Co Inc	ORAL
12.5 MG/PO						

Date:09/21/00ISR Number: 3590049-3Report Type:Periodic Company Report #WAES 00072605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Cough					
	Dyspnoea				Merck Co Inc	ORAL
25 MG						
	Infection					
/DAILY/PO						
	Pharyngeal Oedema		Paxil	C		
			Prilosec	C		
			Synthroid	C		
			Tenormin	C		
			[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3590050-XReport Type:Periodic Company Report #WAES 00072608
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25

MG/DAILY/PO

Sinemet	C	
Atenolol	C	

Date:09/21/00ISR Number: 3590051-1Report Type:Periodic Company Report #WAES 00072610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	ORAL	
			Darvocet-N	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590052-3Report Type:Periodic Company Report #WAES 00072613
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Brain Oedema							
	Dizziness							
	Hypoaesthesia							
	Hypoglycaemia		Celebrex	C				
	Nausea		Glucosamine	C				
	Pain							

Date:09/21/00ISR Number: 3590053-5Report Type:Periodic Company Report #WAES 00072619
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Faecal Incontinence							

Merck Co Inc ORAL
25

MG/DAILY/PO

Coumadin	C
Diovan	C
X-Dur	C
Lipitor	C
Remeron	C
Toprol Xl Tablets	C
[Therapy Unspecified]	C
Amiodarone	C
Furosemde	C

Date:09/21/00ISR Number: 3590054-7Report Type:Periodic Company Report #WAES 00072621
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG /DAILY/PO						
			Dalmane	C		
			Pravachol	C		
			Synthroid	C		
			Hydrochlorothiazide			

Date:09/21/00ISR Number: 3590055-9Report Type:Periodic Company Report #WAES 00072622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590056-0Report Type:Periodic Company Report #WAES 00072641
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG /DAILY/PO	

Date:09/21/00ISR Number: 3590057-2Report Type:Periodic Company Report #WAES 00072647
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Premarin	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3590058-4Report Type:Periodic Company Report #WAES 00072651
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Hydroxyzine	C				

Date:09/21/00ISR Number: 3590059-6Report Type:Periodic Company Report #WAES 00072656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lodine	C				

Date:09/21/00ISR Number: 3590060-2Report Type:Periodic Company Report #WAES 00072659
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Diarrhoea	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:09/21/00ISR Number: 3590061-4Report Type:Periodic Company Report #WAES 00072661
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3590062-6Report Type:Periodic Company Report #WAES 00072662
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3590063-8Report Type:Periodic Company Report #WAES 00072663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3590064-XReport Type:Periodic Company Report #WAES 00072667
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/PO	
		Representative	Neurontin	C				
			Ultram	C				

Date:09/21/00ISR Number: 3590065-1Report Type:Periodic Company Report #WAES 00072668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590066-3Report Type:Periodic Company Report #WAES 00072670
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	12 DAY
			Ceclor	C				
			Lasix	C				

Date:09/21/00ISR Number: 3590067-5Report Type:Periodic Company Report #WAES 00072509
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Sular	C				

Date:09/21/00ISR Number: 3590068-7Report Type:Periodic Company Report #WAES 00072510
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Tylenol	C				
			Acetaminophen (+) Hydrocodone Bi	C				
			Estrogenic Preparation	C				

Date:09/21/00ISR Number: 3590069-9Report Type:Periodic Company Report #WAES 00072511
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;5 0 MG/DAILY/PO	
	Blood Pressure Increased							
	Dizziness							
	Headache							
	Nausea							
	Vertigo		Prednisone	C				

Date:09/21/00ISR Number: 3590070-5Report Type:Periodic Company Report #WAES 00072528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Syncope							
			Tab Sinemet	SS		ORAL	PO	
			Atorvastatin Calcium	C				

Date:09/21/00ISR Number: 3590071-7Report Type:Periodic Company Report #WAES 00072533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Uterine Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590072-9Report Type:Periodic Company Report #WAES 00072560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590073-0Report Type:Periodic Company Report #WAES 00072563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

Date:09/21/00ISR Number: 3590074-2Report Type:Periodic Company Report #WAES 00072564
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590075-4Report Type:Periodic Company Report #WAES 00072570
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Cardizem Cd	C				
			Glucophage	C				
			Lozol	C				
			Riopan	C				
			Accupril	C				

Date:09/21/00ISR Number: 3590077-8Report Type:Periodic Company Report #WAES 00072573
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avandia	C				
			Cardura	C				

			Flonase	C		

Date:09/21/00ISR Number: 3590078-XReport Type:Periodic Company Report #WAES 00072576
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Hydrodiuril	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3590079-1Report Type:Periodic Company Report #WAES 00072577
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Serzone	C				
			Xanax	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3590080-8Report Type:Periodic Company Report #WAES 00072578
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590081-XReport Type:Periodic Company Report #WAES 00072579
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Irritability	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590082-1Report Type:Periodic Company Report #WAES 00072584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	14 DAY
			Skelaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590083-3Report Type:Periodic Company Report #WAES 00072591
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Hydrodiuril	C				
			Pravachol	C				
			Clonazepam	C				
			Glyburide	C				
			Potassium Chloride	C				
			Trazodone	C				

Date:09/21/00ISR Number: 3590084-5Report Type:Periodic Company Report #WAES 00072593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Neoplasm	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Cardizem Cd	C				
			Ditropan	C				
			Premarin	C				

Date:09/21/00ISR Number: 3590085-7Report Type:Periodic Company Report #WAES 00072596
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Urised Tablets	C		

Date:09/21/00ISR Number: 3590086-9Report Type:Periodic Company Report #WAES 00072600
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective							
	Pain				Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Cosopt	C		
				Verapamil Msd Lp	C		

Date:09/21/00ISR Number: 3590087-0Report Type:Periodic Company Report #WAES 00072453
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Swelling							
	Urticaria				Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Ocupress	C		
				Pindolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590088-2Report Type:Periodic Company Report #WAES 00072455
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bilirubin Excretion Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hepatic Function Abnormal				Merck Co Inc	ORAL	25	MG/DAILY/PO
			(Therapy Unspecified)	C				
			Penicillin (As Drug)	C				

Date:09/21/00ISR Number: 3590089-4Report Type:Periodic Company Report #WAES 00072456
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hypertension							
	Oedema Peripheral				Merck Co Inc	ORAL	25	MG/DAILY/PO
	Vision Blurred							
			Hydrodiuril	C				
			Lipitor	C				
			Prandin	C				
			Vasotec	C				
			Cyanocobalamin	C				

Date:09/21/00ISR Number: 3590090-0Report Type:Periodic Company Report #WAES 00072464
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Timoptic	C				

Date:09/21/00ISR Number: 3590091-2Report Type:Periodic Company Report #WAES 00072467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Appetite Disorder							
	Bradycardia							
	Chills							
	Feeling Abnormal							
	Gastric Disorder							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux Disease							
	Insomnia							
	Joint Sprain							
	Malaise							
	Muscle Spasms							
	Nausea							
	Nervousness							
	Palpitations							
	Peripheral Vascular Disorder							
	Tremor							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590092-4Report Type:Periodic Company Report #WAES 00072468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Appetite Disorder							
	Chills							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Palpitations							
	Peripheral Vascular Disorder							
	Vertigo							

Date:09/21/00ISR Number: 3590093-6Report Type:Periodic Company Report #WAES 00072470
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulation Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dynacirc	C				
			Os-Cal	C				
			Premarin	C				
			Aspirin	C				
			Vitaimns (Unspecified)	C				
			Warfarin	C				

Date:09/21/00ISR Number: 3590094-8Report Type:Periodic Company Report #WAES 00072474
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
[PO

Zocor C
Aspirin C
Vitamins
9unspecified) C

Date:09/21/00ISR Number: 3590095-XReport Type:Periodic Company Report #WAES 00072480
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590096-1Report Type:Periodic Company Report #WAES 00072481
Age:61 YR Gender:Female I/FU:I

Outcome	PT
	Balance Disorder
	Dizziness
	Drug Ineffective

Nausea

	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:09/21/00ISR Number: 3590097-3Report Type:Periodic Company Report #WAES 00072486
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prempro	C				
			Prednisone	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3590098-5Report Type:Periodic Company Report #WAES 00072488
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:09/21/00ISR Number: 3590099-7Report Type:Periodic Company Report #WAES 00072490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Tinnitus	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO
			Acetaminophen (+) Dextromethorph	C			

Date:09/21/00ISR Number: 3590100-0Report Type:Periodic Company Report #WAES 00072491
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mechanical Complication Of Implant	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Serzone	C				

Date:09/21/00ISR Number: 3590101-2Report Type:Periodic Company Report #WAES 00072492
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Fluid Retention Oedema Peripheral Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Synthroid	C	
Aspirin	C	
Vitamins (Unspecified)	C	

Date:09/21/00ISR Number: 3590102-4Report Type:Periodic Company Report #WAES 00072494
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness	Health Professional						
	Gastric Disorder							
	Headache							
	Weight Decreased		Armour Thyroid Tablets	C				
			Estrace	C				
			Ultram	C				
			Calcium Carbonate (+) Vitamin D	C				
			Folic Acid	C				
			Glucosamine	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590103-6Report Type:Periodic Company Report #WAES 00072498
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Fatigue							
			Prinivil	C				
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3590104-8Report Type:Periodic Company Report #WAES 00072499
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Demadex	C				
			Lanosin	C				
			Sectral	C				
			Isosorbide	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3590105-XReport Type:Periodic Company Report #WAES 00072504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			(Therapy Unspecified) Vitamins	C				

(Unspecified) C

Date:09/21/00ISR Number: 3590106-1Report Type:Periodic Company Report #WAES 00072505
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Detrol	C				
			Effexor	C				
			Hydrodiuril	C				
			Prilosec	C				
			Prinivil	C				
			Hydrocodone	C				
			Imipramine	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3590107-3Report Type:Periodic Company Report #WAES 00072014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Bradycardia							
	Oedema Peripheral							
	Pain							
	Palpitations							
	Tinnitus							

Date:09/21/00ISR Number: 3590108-5Report Type:Periodic Company Report #WAES 00072016
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health	Vioxx	PS	Merck Research			

	Sleep Apnoea Syndrome	Professional			Laboratories Div Merck Co Inc		ORAL
25							
MG/DAILY/PO							
			Provigil	C			

Date:09/21/00ISR Number: 3590109-7Report Type:Periodic Company Report #WAES 00072017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health	Vioxx	PS	Merck Research			
	Vomiting	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:09/21/00ISR Number: 3590110-3Report Type:Periodic Company Report #WAES 00072022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Pruritus				Laboratories Div			
	Tinnitus				Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590111-5Report Type:Periodic Company Report #WAES 00072023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12/5 MG/BID/PO	
			Tylenol,Arthritis Extended Relieve	C				

Date:09/21/00ISR Number: 3590112-7Report Type:Periodic Company Report #WAES 00072025
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590113-9Report Type:Periodic Company Report #WAES 00072028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucopohage	C				

Date:09/21/00ISR Number: 3590114-0Report Type:Periodic Company Report #WAES 00072030
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:09/21/00ISR Number: 3590115-2Report Type:Periodic Company Report #WAES 00072031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Supraventricular Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590116-4Report Type:Periodic Company Report #WAES 00072032
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590117-6Report Type:Periodic Company Report #WAES 00072034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590118-8Report Type:Periodic Company Report #WAES 00072037
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
			Darvocet-N	C				
			Fiorinal	C				

Date:09/21/00ISR Number: 3590119-XReport Type:Periodic Company Report #WAES 00072039
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MH/AM/PO	
			Cozaar	C				
			Diazide	C				
			Prempro	C				
			Synthroid	C				
			Calcium Supplement	C				
			Calcium	C				

Date:09/21/00ISR Number: 3590120-6Report Type:Periodic Company Report #WAES 00072042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/UNK/PO	
			Lipitor	C				
			Tenormin	C				

Date:09/21/00ISR Number: 3590121-8Report Type:Periodic Company Report #WAES 00072050
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea		Coumadin	C				
			Lanoxin	C				
			Ocuvite	C				
			Pepcid	C				
			Septra	C				
			Vasotec	C				
			Calcium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590122-XReport Type:Periodic Company Report #WAES 00072053
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	3 DAY
			Vasotec	C				

Date:09/21/00ISR Number: 3590123-1Report Type:Periodic Company Report #WAES 00072055
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				

Date:09/21/00ISR Number: 3590124-3Report Type:Periodic Company Report #WAES 00072056
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Discomfort	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Flovent	C				
			Serevent	C				
			Singulair	C				

Date:09/21/00ISR Number: 3590125-5Report Type:Periodic Company Report #WAES 00072057
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	

Date:09/21/00ISR Number: 3590126-7Report Type:Periodic Company Report #WAES 00072060
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Synthroid	C				
			Atenolol	C				
			Tamoxifen	C				

Date:09/21/00ISR Number: 3590127-9Report Type:Periodic Company Report #WAES 00081426
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Allegra	C	
Lomotil	C	
Premarin	C	
Tagamet	C	

Date:09/21/00ISR Number: 3590128-0Report Type:Periodic Company Report #WAES 00081430
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Robaxin	C				

Date:09/21/00ISR Number: 3590129-2Report Type:Periodic Company Report #WAES 00081432
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Diuretic	C				
			Ibuprofen	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590130-9Report Type:Periodic Company Report #WAES 00081435
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Zantac C

Date:09/21/00ISR Number: 3590131-0Report Type:Periodic Company Report #WAES 00081436
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Detrol	C				
			Nitro-Dur	C				

Date:09/21/00ISR Number: 3590132-2Report Type:Periodic Company Report #WAES 00081437
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diflucan	C				

				Levaquin	C		

Date:09/21/00ISR Number: 3590133-4Report Type:Periodic Company Report #WAES 00081438
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Naprosyn	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590134-6Report Type:Periodic Company Report #WAES 00081444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590135-8Report Type:Periodic Company Report #WAES 00081447
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590136-XReport Type:Periodic Company Report #WAES 00081453
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590137-1Report Type:Periodic Company Report #WAES 00081455
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Mental Impairment Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Azmacort	C				
			Hydrodiuril	C				
			Lanoxin	C				
			Ocupress	C				
			Synthroid	C				
			Theo-Dur	C				
			Xalatan	C				
			Ziac	C				
			Albuterol	C				

			Potassium Chloride	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3590138-3Report Type:Periodic Company Report #WAES 00081456
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prempro	C				

Date:09/21/00ISR Number: 3590139-5Report Type:Periodic Company Report #WAES 00081467
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Oedema Peripheral Paraesthesia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Claritin-D	C				
			Allopurinol	C				

Date:09/21/00ISR Number: 3590140-1Report Type:Periodic Company Report #WAES 00081470
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Glucophage	C
Glucotrol Xl	C
Hydrodiuril	C
Lotensin	C
Rhinocort	C
Tenormin	C
Valium	C

Date:09/21/00ISR Number: 3590141-3Report Type:Periodic Company Report #WAES 00081472
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590142-5Report Type:Periodic Company Report #WAES 00081478
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Hytrin	C	
Tenoretic	C	

Date:09/21/00ISR Number: 3590143-7Report Type:Periodic Company Report #WAES 00081496
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Periodontal Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Cardizem	C	
Remeron	C	
Isosorbide	C	
Meclizine	C	

Date:09/21/00ISR Number: 3590144-9Report Type:Periodic Company Report #WAES 00081497
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Lotensin	C	
Miacalcin	C	
Zocor	C	

Date:09/21/00ISR Number: 3590145-0Report Type:Periodic Company Report #WAES 00081500
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
12.5 MG/PO						
			Tab Fosamax	SS		

Date:09/21/00ISR Number: 3590146-2Report Type:Periodic Company Report #WAES 00081504
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Joint Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Prinivil	C		
			Therapy Unspecified	C		

Date:09/21/00ISR Number: 3590147-4Report Type:Periodic Company Report #WAES 00081371
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Erythema Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
	Oedema Peripheral		Estrace	C		
	Pain In Extremity		Provera	C		
	Tongue Oedema		Tylenol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590148-6Report Type:Periodic Company Report #WAES 00081375
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
			Vasoretic	C				
			Metoprolol	C				

Date:09/21/00ISR Number: 3590149-8Report Type:Periodic Company Report #WAES 00081377
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Excedrin Extra-Strength	C				
			Parafon Forte Dsc	C				
			Zestril	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590150-4Report Type:Periodic Company Report #WAES 00081378
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590151-6Report Type:Periodic Company Report #WAES 00081379
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Haemorrhage							
	Urinary Incontinence				Merck Co Inc	ORAL	DAILY/PO	

Date:09/21/00ISR Number: 3590152-8Report Type:Periodic Company Report #WAES 00081381
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590153-XReport Type:Periodic Company Report #WAES 00081386
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3590154-1Report Type:Periodic Company Report #WAES 00081387
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				
			Zantac	C				
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3590155-3Report Type:Periodic Company Report #WAES 00081388
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Tagamet	C				

Date:09/21/00ISR Number: 3590156-5Report Type:Periodic Company Report #WAES 00081392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		ORAL
25 MG/DAILY/PO							
			Paxil	C			
			Prevacid	C			

Date:09/21/00ISR Number: 3590157-7Report Type:Periodic Company Report #WAES 00081397
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590158-9Report Type:Periodic Company Report #WAES 00081403
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	31 DAY
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590159-0Report Type:Periodic Company Report #WAES 00081404
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zantac	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3590160-7Report Type:Periodic Company Report #WAES 00081408
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590161-9Report Type:Periodic Company Report #WAES 00081409
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypertrophy Breast	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3590162-0Report Type:Periodic Company Report #WAES 00081412
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
SEE IMAGE

Date:09/21/00ISR Number: 3590163-2Report Type:Periodic Company Report #WAES 00081416
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Zocor	C				

Date:09/21/00ISR Number: 3590164-4Report Type:Periodic Company Report #WAES 00081421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	3 DAY
			Zanaflex	C				
			Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590165-6Report Type:Periodic Company Report #WAES 00081423
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Constipation				Laboratories Div			
					Merck Co Inc	ORAL	50	MG/DAILY/PO
			Oxycontin	C				

Date:09/21/00ISR Number: 3590166-8Report Type:Periodic Company Report #WAES 00081424
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective				Laboratories Div			
	Feeling Hot And Cold				Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:09/21/00ISR Number: 3590167-XReport Type:Periodic Company Report #WAES 00081507
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Vioxx	PS	Merck Research			
	Olfactory Nerve Disorder				Laboratories Div			
	Upper Respiratory Tract				Merck Co Inc	ORAL	25	MG/DAILY/PO
	Infection							
			Synthroid	C				
			Toprol Xl Tablets	C				
			Indapamide	C				

Date:09/21/00ISR Number: 3590168-1Report Type:Periodic Company Report #WAES 00081510
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Musculoskeletal Stiffness							
	Nausea							
			Pravachol	C				

Date:09/21/00ISR Number: 3590169-3Report Type:Periodic Company Report #WAES 00081516
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Calcium Supplement (Unspecified)	C				

Date:09/21/00ISR Number: 3590170-XReport Type:Periodic Company Report #WAES 00081517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590171-1Report Type:Periodic Company Report #WAES 00081520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Personality Change	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590172-3Report Type:Periodic Company Report #WAES 00081521
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lortab	C				

Date:09/21/00ISR Number: 3590173-5Report Type:Periodic Company Report #WAES 00081526
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Tylenol With Codeine	C				

Date:09/21/00ISR Number: 3590174-7Report Type:Periodic Company Report #WAES 00081532
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Navane C
Prempro C
Wellbutrin C

Date:09/21/00ISR Number: 3590175-9Report Type:Periodic Company Report #WAES 00081533
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590176-0Report Type:Periodic Company Report #WAES 00081535
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590177-2Report Type:Periodic Company Report #WAES 00081536
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Levaquin	C				
			Nadolol	C				
			Phenazopyridine Hydrochloride	C				

Date:09/21/00ISR Number: 3590179-6Report Type:Periodic Company Report #WAES 00081538
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	/DAILY/PO
			Prilosec	C				
			Ziac	C				

Date:09/21/00ISR Number: 3590180-2Report Type:Periodic Company Report #WAES 00081539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590181-4Report Type:Periodic Company Report #WAES 00081540
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin Free Excedrin	C				
			Citrucel Orange Flavor	C				
			Pepcid	C				
			Synthroid	C				
			Tranxene	C				
			Zocor	C				
			Atenolol	C				
			Dicyclomine Hydrochloride	C				
			Gemfibrozil	C				

Date:09/21/00ISR Number: 3590182-6Report Type:Periodic Company Report #WAES 00081550
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/DAILY/PO

Aricept	C
Celexa	C
Levoxyl	C
Pancrease (Pancreatin)	C
Tums	C
Zantac	C

Date:09/21/00ISR Number: 3590183-8Report Type:Periodic Company Report #WAES 00081552
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Xanax	C				

Date:09/21/00ISR Number: 3590184-XReport Type:Periodic Company Report #WAES 00081555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prozac	C				

Date:09/21/00ISR Number: 3590185-1Report Type:Periodic Company Report #WAES 00081556
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			

	Dermatitis				Laboratories Div	
	Dizziness				Merck Co Inc	ORAL
SEE IMAGE						
	Epistaxis		Accupril	C		
	Headache		Humulin	C		
			Paxil	C		
			Pravachol	C		
			Premarin	C		
			Cyclobenzaprine	C		
			Furosemide	C		
			Medroxyprogesterone	C		
			Trazodone	C		

Date:09/21/00ISR Number: 3590186-3Report Type:Periodic Company Report #WAES 00081557
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590187-5Report Type:Periodic Company Report #WAES 00081265
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Face Oedema							
	Fatigue							
	Oedema Peripheral							
	Sedation							

Date:09/21/00ISR Number: 3590188-7Report Type:Periodic Company Report #WAES 00081268
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AMPO	
			(Therapy Unhspecified)	C				
			(Therapy Unspecified)	C				

Date:09/21/00ISR Number: 3590189-9Report Type:Periodic Company Report #WAES 00081269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			(Therapy Unspecified)	C				

Date:09/21/00ISR Number: 3590190-5Report Type:Periodic Company Report #WAES 00081270
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
			Prinivil	C				

Date:09/21/00ISR Number: 3590191-7Report Type:Periodic Company Report #WAES 00081272
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590192-9Report Type:Periodic Company Report #WAES 00081274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Aciphex C

Date:09/21/00ISR Number: 3590193-0Report Type:Periodic Company Report #WAES 00081275
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Headache							
	Oedema Peripheral							
			Klonopin	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3590194-2Report Type:Periodic Company Report #WAES 00081280
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Estratab	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3590195-4Report Type:Periodic Company Report #WAES 00081286
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3590196-6Report Type:Periodic Company Report #WAES 00081291
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred Visual Acuity Reduced	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Premarin	C				
			Prevacid	C				
			Tenex	C				

Date:09/21/00ISR Number: 3590197-8Report Type:Periodic Company Report #WAES 00081307
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Fosamax	C				
			Hydrodiuril	C				
			Tylenol	C				
			Chondroitin (+)					

Glucosamine	C
Doxycycline Hyclate	C

Date:09/21/00ISR Number: 3590198-XReport Type:Periodic Company Report #WAES 00081308
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flomax (Tamsulosin (R) -Form Hydr	C				
			Rythmol	C				
			Vasotec	C				
			Zocor	C				
			Allopurinol	C				

Date:09/21/00ISR Number: 3590199-1Report Type:Periodic Company Report #WAES 00081324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590200-5Report Type:Periodic Company Report #WAES 00081332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590201-7Report Type:Periodic Company Report #WAES 00081334
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cap Sporanox 100mg	SS		ORAL	100 MG/TID/PO	
			Tab Tylenol With Codeine	SS		ORAL	PO	
			Orphenadrine	SS		ORAL	PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3590202-9Report Type:Periodic Company Report #WAES 00081336
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Neurontin	C				

Synthroid	C
Hydrochlorothiazide (+) Triamter	C
Potassium Chloride	C
Ranitidine	C

Date:09/21/00ISR Number: 3590203-0Report Type:Periodic Company Report #WAES 00081345
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590204-2Report Type:Periodic Company Report #WAES 00081346
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Hydrodiuril	C
Norvasc	C
Prinivil	C
Synthroid	C
Ultram	C
Potassium Chloride	C

Date:09/21/00ISR Number: 3590205-4Report Type:Periodic Company Report #WAES 00081347
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

Erythema Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3590206-6Report Type:Periodic Company Report #WAES 00081368
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590207-8Report Type:Periodic Company Report #WAES 00080167
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590209-1Report Type:Periodic Company Report #WAES 00080171
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intraocular Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Timoptic-Xe	C				

Date:09/21/00ISR Number: 3590210-8Report Type:Periodic Company Report #WAES 00080172
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Desyrel	C				
			Wellbutrin	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590211-XReport Type:Periodic Company Report #WAES 00080178
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Chlorothiazide	C				

Date:09/21/00ISR Number: 3590212-1Report Type:Periodic Company Report #WAES 00080185
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hyzaar	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3590213-3Report Type:Periodic Company Report #WAES 00080186
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Norvasc	C				
			Synthroid	C				
			Tamoxfen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590214-5Report Type:Periodic Company Report #WAES 00080193
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				

Date:09/21/00ISR Number: 3590215-7Report Type:Periodic Company Report #WAES 00080196
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Imitrex	C				
			Neurontin	C				
			Synthroid	C				
			Valium	C				
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3590216-9Report Type:Periodic Company Report #WAES 00080197
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cardura	C				
			Coumadin	C				
			Lasix	C				
			Spironolactone	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590217-0Report Type:Periodic Company Report #WAES 00080200
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590218-2Report Type:Periodic Company Report #WAES 00080201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590219-4Report Type:Periodic Company Report #WAES 00080202
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Abdominal Pain							
	Asthma							
	Constipation							
	Cough		Vicodin Tablets	C				
			...	C				

Date:09/21/00ISR Number: 3590220-0Report Type:Periodic Company Report #WAES 00080207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Aldactone	C				
			Celebrex	C				
			Lasix	C				

Date:09/21/00ISR Number: 3590221-2Report Type:Periodic Company Report #WAES 00080209
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Tinnitus							

Date:09/21/00ISR Number: 3590222-4Report Type:Periodic Company Report #WAES 00080212
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Dry	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Altace	C				
			Timoptic	C				
			Aspirin	C				
			Glucosamine	C				
			Prednisolone	C				

Date:09/21/00ISR Number: 3590223-6Report Type:Periodic Company Report #WAES 00080213
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Lopressor	C				
			Aspirin	C				

			Niacin	C		

Date:09/21/00ISR Number: 3590224-8Report Type:Periodic Company Report #WAES 00080216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Muscle Spasms							
	Pruritus							
			Centrum	C				
			Ecotrin	C				
			Monopril	C				
			Os-Cal	C				
			...	C				

Date:09/21/00ISR Number: 3590225-XReport Type:Periodic Company Report #WAES 00080217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590226-1Report Type:Periodic Company Report #WAES 00080218
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590227-3Report Type:Periodic Company Report #WAES 00080059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590228-5Report Type:Periodic Company Report #WAES 00080069
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Feeling Cold		Vitamin (Unspecified)	C				
	Hyperaesthesia							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590229-7Report Type:Periodic Company Report #WAES 00080074
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Betapace	C				
			Cardura	C				
			Lipitor	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590230-3Report Type:Periodic Company Report #WAES 00080075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Rigidity Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Risperdal	C				
			Liithium Chloride	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3590231-5Report Type:Periodic Company Report #WAES 00080078
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590232-7Report Type:Periodic Company Report #WAES 00080080
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Albumin Decreased Hepatic Function Abnormal Lymphopenia Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590233-9Report Type:Periodic Company Report #WAES 00080085
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nasal Congestion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Couomadin	C				
			Fosamax	C				
			Plaquenil	C				
			Folic Acid	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590234-0Report Type:Periodic Company Report #WAES 00080092
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590235-2Report Type:Periodic Company Report #WAES 00080099
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590236-4Report Type:Periodic Company Report #WAES 00080101
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/DAILY/PO	
	Blood Urea Increased							
	Oedema							
			Ditropan	C				
			Pravachol	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3590237-6Report Type:Periodic Company Report #WAES 00080102
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	35-50 MG/DAILY/PO	
			Axid	C				
			Evista	C				
			Maxzide	C				

Date:09/21/00ISR Number: 3590238-8Report Type:Periodic Company Report #WAES 00080108
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Monopril	C				
			Premarin	C				
			Sular	C				
			Synthroid	C				
			Ultram	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590239-XReport Type:Periodic Company Report #WAES 00080112
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cartia	C				
			Dilatrate	C				
			Maxzide	C				
			Nasonex	C				
			Pravachol	C				
			Clonidine	C				

Date:09/21/00ISR Number: 3590240-6Report Type:Periodic Company Report #WAES 00080113
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Micro K	C				
			Paxil	C				

Date:09/21/00ISR Number: 3590241-8Report Type:Periodic Company Report #WAES 00080117
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Rectal Haemorrhage		Tab Fosamax 10 Mg	SS		ORAL	10MG/DAILY/PO	
			Procardia Xl	C				

Date:09/21/00ISR Number: 3590242-XReport Type:Periodic Company Report #WAES 00080118
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Prevacid	C				
			Digoxin	C				

Date:09/21/00ISR Number: 3590243-1Report Type:Periodic Company Report #WAES 00080120
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590244-3Report Type:Periodic Company Report #WAES 00080123
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cartia	C				
			Nitrostat	C				
			Toprol Xl Tablets	C				
			Zocor	C				

Date:09/21/00ISR Number: 3590245-5Report Type:Periodic Company Report #WAES 00080139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590246-7Report Type:Periodic Company Report #WAES 00080154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Eye Pain Headache Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590247-9Report Type:Periodic Company Report #WAES 00081824
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590248-0Report Type:Periodic Company Report #WAES 00081853
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Celebrex	C				
			Glucotrol	C				
			Maxzide	C				
			Composition Unspecified	C				
			Aspirin	C				
			Colchicine	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590249-2Report Type:Periodic Company Report #WAES 00081854
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Medrol	C				
			Hydrocodone	C				
			Sulfasalazine	C				

Date:09/21/00ISR Number: 3590251-0Report Type:Periodic Company Report #WAES 00081855
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Therapy Unspecified	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3590252-2Report Type:Periodic Company Report #WAES 00064605
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Serevent	C				
			Albuterol	C				
			Rhinocort	C				

Date:09/21/00ISR Number: 3590253-4Report Type:Periodic Company Report #WAES 00081856
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3590254-6Report Type:Periodic Company Report #WAES 00064606
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY;	
ORAL								6 WK
			Atacand	C				
			Celebrex	C				
			Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590255-8Report Type:Periodic Company Report #WAES 00081857
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 MON
			Estrace	C				
			Fosamax	C				
			Hydrodiuril	C				
			Premarin	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3590256-XReport Type:Periodic Company Report #WAES 00064607
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Advil	C				
			Diabetoral	C				
			Proventil	C				
			Theo-Dur	C				
			Mesalamine	C				

Date:09/21/00ISR Number: 3590257-1Report Type:Periodic Company Report #WAES 00081859
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	6.25 MG/DAILY/PO	

			Hydrodiuril	C		

Date:09/21/00ISR Number: 3590258-3Report Type:Periodic Company Report #WAES 00064608
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Laboratory Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY; PO						

Date:09/21/00ISR Number: 3590259-5Report Type:Periodic Company Report #WAES 00081862
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590260-1Report Type:Periodic Company Report #WAES 00064610
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	DAILY; PO
			Premarin	C				

Date:09/21/00ISR Number: 3590261-3Report Type:Periodic Company Report #WAES 00081873
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	DAILY/PO
			(SEE IMAGE)					
			Centrum Silver	C				
			Exelon	C				
			Flovent	C				
			Norvasc	C				
			Pravachol	C				
			Proventil	C				
			Wellbutrin	C				
			Albuterol	C				
			Atenolol	C				
			Calcium Supplement	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590262-5Report Type:Periodic Company Report #WAES 00081877
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fluid Retention Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Lasix	C		
			Motrin	C		
			Pravachol	C		
			Aspirin	C		
			Insulin	C		
			Ranitidine	C		

Date:09/21/00ISR Number: 3590263-7Report Type:Periodic Company Report #WAES 00064611
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Celebrex	C		
			Fosamax	C		
			Tylenol Pm	C		
			Univasc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590264-9Report Type:Periodic Company Report #WAES 00064613
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	PO		
			Aspirin	C				
			Cardizem	C				
			Lasix	C				
			Singular	C				

Date:09/21/00ISR Number: 3590265-0Report Type:Periodic Company Report #WAES 00081878
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Fosamax	C				
			Miacalcin	C				

Date:09/21/00ISR Number: 3590266-2Report Type:Periodic Company Report #WAES 00081881
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Detrol	C				
			Hytrin	C				
			Paxil	C				
			Pravachol	C				

			Prilosec	C		
			Aspirin	C		
			Atenolol	C		
			Diazepam	C		

Date:09/21/00ISR Number: 3590267-4Report Type:Periodic Company Report #WAES 00064618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	
PO								
			Celebrex	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3590268-6Report Type:Periodic Company Report #WAES 00064620
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

DAILY; PO

Hydrodiuril	C	
Premarin	C	
Prilosec	C	
Vitamin	C	

Date:09/21/00ISR Number: 3590269-8Report Type:Periodic Company Report #WAES 00081883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590270-4Report Type:Periodic Company Report #WAES 00064622
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY;ORAL	
			Vioxx	SS		ORAL	25 MG DAILY; ORAL	

Date:09/21/00ISR Number: 3590271-6Report Type:Periodic Company Report #WAES 00081887
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Fosamax	C	
Hydrodiuril	C	
Therapy Unspecified	C	
Potassium	C	

Date:09/21/00ISR Number: 3590272-8Report Type:Periodic Company Report #WAES 00064625
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Difficulty In Walking	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Drug Ineffective					

12.5 MG

DAILY; PO

[Compositin Unspecified]	C	

Date:09/21/00ISR Number: 3590273-XReport Type:Periodic Company Report #WAES 00081889
Age:57 YR Gender:Male I/FU:I

Outcome	PT
	Chest Pain
	Chills
	Headache

	Musculoskeletal Stiffness Oedema Peripheral						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Sudafed	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590274-1Report Type:Periodic Company Report #WAES 00064626
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia Proteinuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atacand	C				
			Demadex	C				
			Excedrin P.M.	C				
			Lipitor	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3590275-3Report Type:Periodic Company Report #WAES 00081891
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Haemorrhage Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Hydrodiuril	C				
			Monopril	C				

Date:09/21/00ISR Number: 3590276-5Report Type:Periodic Company Report #WAES 00064627
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3590277-7Report Type:Periodic Company Report #WAES 00081900
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3590278-9Report Type:Periodic Company Report #WAES 00081902
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 9 DAY
Therapy Unspecified C

Date:09/21/00ISR Number: 3590279-0Report Type:Periodic Company Report #WAES 00081762
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ecotrin	C				
			Imdur	C				
			Lipitor	C				
			Synthroid	C				
			Insulin	C				

Date:09/21/00ISR Number: 3590280-7Report Type:Periodic Company Report #WAES 00081764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Fosamax	C				

Date:09/21/00ISR Number: 3590281-9Report Type:Periodic Company Report #WAES 00081771
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Pain		Xanax	C				
	Pyrexia		Prednisone	C				

Date:09/21/00ISR Number: 3590282-0Report Type:Periodic Company Report #WAES 00081766
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3590283-2Report Type:Periodic Company Report #WAES 00081772
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590284-4Report Type:Periodic Company Report #WAES 00081773
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	

Date:09/21/00ISR Number: 3590285-6Report Type:Periodic Company Report #WAES 00081775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Hydrodiuril	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3590286-8Report Type:Periodic Company Report #WAES 00081776
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estratest	C				
			Flonase	C				

Date:09/21/00ISR Number: 3590287-XReport Type:Periodic Company Report #WAES 00081783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	1 MON

Date:09/21/00ISR Number: 3590288-1Report Type:Periodic Company Report #WAES 00081784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Nasal Congestion Rhinorrhoea Sneezing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Triacet	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590289-3Report Type:Periodic Company Report #WAES 00081786
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Sulindac	C				

Date:09/21/00ISR Number: 3590290-XReport Type:Periodic Company Report #WAES 00081796
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ascorbic Acid	C				
			Aspirin	C				
			Folic Acid	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590291-1Report Type:Periodic Company Report #WAES 00081798
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Glucophage	C				
			Premarin	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3590292-3Report Type:Periodic Company Report #WAES 00081799
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Rythmol	C				

Date:09/21/00ISR Number: 3590293-5Report Type:Periodic Company Report #WAES 00081800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lotensin	C				
			Mevacor	C				
			Theo-Dur	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590294-7Report Type:Periodic Company Report #WAES 00081801
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Evista	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3590295-9Report Type:Periodic Company Report #WAES 00081802
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depaxote	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590296-0Report Type:Periodic Company Report #WAES 00081805
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3590297-2Report Type:Periodic Company Report #WAES 00064631
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra-D	C				
			Ambien	C				
			Biaxin	C				
			Claritin	C				
			Vancenase	C				
			Guaifenesin	C				

Date:09/21/00ISR Number: 3590298-4Report Type:Periodic Company Report #WAES 00081810
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590299-6Report Type:Periodic Company Report #WAES 00064633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO

Date:09/21/00ISR Number: 3590300-XReport Type:Periodic Company Report #WAES 00081823
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Stomatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 + 25 MG/UNK/PO	

Date:09/21/00ISR Number: 3590301-1Report Type:Periodic Company Report #WAES 00064640
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO
			Lopressor	C				
			Proscar	C				

Date:09/21/00ISR Number: 3590302-3Report Type:Periodic Company Report #WAES 00064641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Azulfidine	C				
			Singulair	C				
			Corticosteroids	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3590303-5Report Type:Periodic Company Report #WAES 00064642
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY; PO	
			Neosporin Ophthalmic Solution	C				
			Neurontin	C				
			Prempro	C				
			Prinivil	C				
			Synthroid	C				
			Zocor	C				
			Amoxicillin	C				

				Labetalol	C		

Date:09/21/00ISR Number: 3590304-7Report Type:Periodic Company Report #WAES 00064644
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO
			Lipitor	C				
			Prevacid	C				
			Aspirin	C				
			Calcium Supplement	C				
			Metoprolol	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3590305-9Report Type:Periodic Company Report #WAES 00064649
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Fluid Retention Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO
	Pruritus							
	Urinary Retention		Bumex	C				
			Lasix	C				
			[Therapy Unspecified]	C				
			Morphine	C				

Date:09/21/00ISR Number: 3590306-0Report Type:Periodic Company Report #WAES 00061727
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Lipitor	C				
			Neurontin	C				
			Glipizide	C				
			Indapamide	C				

Date:09/21/00ISR Number: 3590307-2Report Type:Periodic Company Report #WAES 00081660
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Paxil	C				
			Premarin	C				
			Ultram	C				

Date:09/21/00ISR Number: 3590308-4Report Type:Periodic Company Report #WAES 00061728
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO

Date:09/21/00ISR Number: 3590309-6Report Type:Periodic Company Report #WAES 00061729
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590310-2Report Type:Periodic Company Report #WAES 00081667
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Faeces Discoloured Gingival Bleeding	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Headache							
	Skin Disorder		Zantac	C				

Date:09/21/00ISR Number: 3590311-4Report Type:Periodic Company Report #WAES 00061735
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			K-Dur	C				
			Lanoxin	C				
			Sotalol Hydrochloride	C				

Date:09/21/00ISR Number: 3590312-6Report Type:Periodic Company Report #WAES 00081668
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Pravachol	C				

Date:09/21/00ISR Number: 3590313-8Report Type:Periodic Company Report #WAES 00061736
Age:80 YR Gender:Female I/FU:I

Outcome	PT
	Constipation
	Diarrhoea
	Nausea

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Aldactazide	C				
			Combivent	C				
			Ecotrin	C				
			Vasotec	C				
			Allopurinol	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590314-XReport Type:Periodic Company Report #WAES 00061739
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Proscar	C				
			Zocor	C				
			Terazosin	C				

Date:09/21/00ISR Number: 3590315-1Report Type:Periodic Company Report #WAES 00081675
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Norvasc	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Traimter	C				

			Quinidine	C		

Date:09/21/00ISR Number: 3590316-3Report Type:Periodic Company Report #WAES 00061742
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sulfadiazine	C				

Date:09/21/00ISR Number: 3590317-5Report Type:Periodic Company Report #WAES 00061745
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pravachol	C				
			Aspirin	C				
			Diltiazem	C				

			Vitamin E	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3590318-7Report Type:Periodic Company Report #WAES 00081676
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590319-9Report Type:Periodic Company Report #WAES 00061746
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Diarrhoea							
	Drug Effect Decreased							
	Pruritus Ani						PO	
	Pruritus Genital		Celebrex	C				
	Rectal Haemorrhage		Darvocet-N	C				
			Nuprin	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590320-5Report Type:Periodic Company Report #WAES 00081677
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Potassium	C				

Date:09/21/00ISR Number: 3590321-7Report Type:Periodic Company Report #WAES 00061748
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Loestrin	C				

Date:09/21/00ISR Number: 3590322-9Report Type:Periodic Company Report #WAES 00081678
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Leukopenia Platelet Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590323-0Report Type:Periodic Company Report #WAES 00061749
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intervertebral Disc Displacement	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590324-2Report Type:Periodic Company Report #WAES 00081681
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Loss	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:09/21/00ISR Number: 3590325-4Report Type:Periodic Company Report #WAES 00061750
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590326-6Report Type:Periodic Company Report #WAES 00081682
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL

25

MG/DAILY/PO

Alphagan	C
Amaryl	C
Ecotrin	C
Hydrodiuril	C
Hytrin	C
Lipitor	C
Trusopt	C
(Therapy Unspecified)	C
Docusate Sodium	C
Fosinopril	C
Isosoribide Dinitrate	C
Nitroglycerin	C
Pilocarpine	C
Rantidine	C
Vitamin E	C
Vitamin (Unspecified)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590327-8Report Type:Periodic Company Report #WAES 00061752
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590328-XReport Type:Periodic Company Report #WAES 00081687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590329-1Report Type:Periodic Company Report #WAES 00061754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Sinemet	SS		ORAL	PO	
			Lipitor	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590330-8Report Type:Periodic Company Report #WAES 00070362
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/DAILY

PO

Avandia	C
Baycol	C
Cartia	C
Lipitor	C
Furosemide	C
Insulin	C
Primidone	C

Date:09/21/00ISR Number: 3590331-XReport Type:Periodic Company Report #WAES 00061755
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Enbrel	C
Procardia Xl	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590332-1Report Type:Periodic Company Report #WAES 00081741
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Morbilliform	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
		Representative	Composition Unspecified	C				

Date:09/21/00ISR Number: 3590333-3Report Type:Periodic Company Report #WAES 00061763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:09/21/00ISR Number: 3590334-5Report Type:Periodic Company Report #WAES 00081742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Anaprel	C				
			Fosamax	C				
			Lipitor	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590335-7Report Type:Periodic Company Report #WAES 00061769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer User Facility	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590336-9Report Type:Periodic Company Report #WAES 00070363
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pravachol	C				

Date:09/21/00ISR Number: 3590337-0Report Type:Periodic Company Report #WAES 00081746
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

			Claritin	C
			Prevacid	C
			Serzone	C
			Toprol Xl Tablets	C
			Tussi-12	C
			Valium	C
			Amoxicillin	C
			Iron (Unspecified)	C

Date:09/21/00ISR Number: 3590338-2Report Type:Periodic Company Report #WAES 00061775
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Accupril	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3590339-4Report Type:Periodic Company Report #WAES 00070364
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Viox 25 Mg	SS		ORAL	PO	
			Aspirin	C				
			Carisoprodol	C				
			Hydrocodone	C				

Date:09/21/00ISR Number: 3590340-0Report Type:Periodic Company Report #WAES 00081749
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590341-2Report Type:Periodic Company Report #WAES 00061776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590342-4Report Type:Periodic Company Report #WAES 00081756
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Constipation							
	Dizziness							
	Fatigue							

Date:09/21/00ISR Number: 3590343-6Report Type:Periodic Company Report #WAES 00061777
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Cozaar	C				
			Lopressore	C				
			Plaquenil	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590344-8Report Type:Periodic Company Report #WAES 00081757
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Aldactone	C				
			K-Dur	C				
			Micardis	C				

Date:09/21/00ISR Number: 3590345-XReport Type:Periodic Company Report #WAES 00070365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Oedema Peripheral							
			Actos	C				
			Cozaar	C				
			Lipitor	C				
			Plavix	C				
			Zyrtec	C				
			Gemfibrozil	C				
			Hydrocodone	C				
			Metoclopramide	C				

Date:09/21/00ISR Number: 3590346-1Report Type:Periodic Company Report #WAES 00081758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590347-3Report Type:Periodic Company Report #WAES 00070371
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3590348-5Report Type:Periodic Company Report #WAES 00061641
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazide	C				
			Premarin	C				
			Synthroid	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3590349-7Report Type:Periodic Company Report #WAES 00081759
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ogen	C				

Date:09/21/00ISR Number: 3590350-3Report Type:Periodic Company Report #WAES 00070373
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	6.75 MG/DAILY/PO	
	Feeling Abnormal							
	Hyperaesthesia							
			Baycol	C				
			Levoxyl	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3590351-5Report Type:Periodic Company Report #WAES 00061642
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
	Dyspepsia							
	Dysphonia							
	Retching							
	Sedation		Skelaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590352-7Report Type:Periodic Company Report #WAES 00081760
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Oral Soft Tissue Disorder							
	Periodontal Disease							
			Prilosec	C				
			Iron (Unspecified)	C				

Date:09/21/00ISR Number: 3590353-9Report Type:Periodic Company Report #WAES 00070375
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Joint Stiffness							
			Celebrex	C				
			Fosamax	C				

Date:09/21/00ISR Number: 3590354-0Report Type:Periodic Company Report #WAES 00070377
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Feeling Abnormal							
			Premarin	C				

Date:09/21/00ISR Number: 3590355-2Report Type:Periodic Company Report #WAES 00081761
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25MG/DAILY/PO

Inderal	C	
Maxzide	C	
Synthroid	C	
Zocor	C	
Aspirin	C	

Date:09/21/00ISR Number: 3590356-4Report Type:Periodic Company Report #WAES 00070378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diazide	C				
			Diovan	C				
			Estrace	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590357-6Report Type:Periodic Company Report #WAES 00081570
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590358-8Report Type:Periodic Company Report #WAES 00081580
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea	Other						
	Malaise							
	Oedema Peripheral		Inj Synvisc 2 Ml	SS			INJ	
			Inj Synvisc 2 Ml	SS			INJ	

Date:09/21/00ISR Number: 3590359-XReport Type:Periodic Company Report #WAES 00081582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3590360-6Report Type:Periodic Company Report #WAES 00081592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590361-8Report Type:Periodic Company Report #WAES 00081602
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal Blood Pressure Increased Syncope Vasovagal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imodium	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3590362-XReport Type:Periodic Company Report #WAES 00070380
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malabsorption	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590363-1Report Type:Periodic Company Report #WAES 00081607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590364-3Report Type:Periodic Company Report #WAES 00081620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590365-5Report Type:Periodic Company Report #WAES 00070381
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Duragesic	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590366-7Report Type:Periodic Company Report #WAES 00081622
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:09/21/00ISR Number: 3590367-9Report Type:Periodic Company Report #WAES 00081625
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Coumadin	C				
			Lanoxin	C				

Date:09/21/00ISR Number: 3590368-0Report Type:Periodic Company Report #WAES 00070383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590369-2Report Type:Periodic Company Report #WAES 00081626
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				
			Aspirin	C				
			Docusate Sodium	C				
			Lorazepam	C				
			Nortriptyline	C				
			Vitamin A	C				

Date:09/21/00ISR Number: 3590370-9Report Type:Periodic Company Report #WAES 00081627
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Prempro	C				

Date:09/21/00ISR Number: 3590371-0Report Type:Periodic Company Report #WAES 00070388
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590372-2Report Type:Periodic Company Report #WAES 00070390
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/PO 12 DAY						
			Tab Vioxx 25 Mg	SS		ORAL
25 MG/PO 2 DAY						
			Tab Vioxx 50 Mg	SS		ORAL
50 MG/PO 6 DAY						
			Insulin	C		

Date:09/21/00ISR Number: 3590373-4Report Type:Periodic Company Report #WAES 00070394
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Aldactone	C		
			Cardura	C		
			Vivactil	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590374-6Report Type:Periodic Company Report #WAES 00070405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	4 DAY
			Lanoxin	C				
			Prevacid	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3590375-8Report Type:Periodic Company Report #WAES 00070407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590376-XReport Type:Periodic Company Report #WAES 00070409
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coreg	C				
			Prilosec	C				
			Synthroid	C				

			Insulin	C		

Date:09/21/00ISR Number: 3590377-1Report Type:Periodic Company Report #WAES 00070421
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Celebrex	C				
			Aspirin	C				
			Diuretic Preparation (Composition)	C				

Date:09/21/00ISR Number: 3590378-3Report Type:Periodic Company Report #WAES 00070422
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Meridia 10 Mg	SS		ORAL	10 MG/DAILY./PO	
			Tab Plendil	C				
			Micronor	C				

		Nasacort	C
		Tylenol With Codeine	C
		Zoladex	C
		Zyrtec	C

Date:09/21/00ISR Number: 3590379-5Report Type:Periodic Company Report #WAES 00061643
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Folliculitis							
	Pain							
			Ascorbic Acid	C				
			Aspirin	C				
			Naproxen	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590381-3Report Type:Periodic Company Report #WAES 00070270
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Respiratory Disorder							
			Prinivil	C				
			Synthroid	C				
			Zyrtec	C				
			Ranitidine	C				

Date:09/21/00ISR Number: 3590383-7Report Type:Periodic Company Report #WAES 00070277
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cranial Nerve Disorder	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL

1) PO; 2)

PRN/PO

Lopressor	C	
Minoxidil 2%	C	
Zantac	C	
Calcium Supplement	C	
Chondroitin	C	
Glucosamine	C	

Date:09/21/00ISR Number: 3590384-9Report Type:Periodic Company Report #WAES 00061655
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dry Mouth					

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590386-2Report Type:Periodic Company Report #WAES 00070278
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Cold Sweat							
	Confusional State							
	Face Oedema	Representative						
	Memory Impairment		Ultram	C				
	Nausea		Amitriptyline	C				
	Pain In Extremity		Fluoxetine	C				

Date:09/21/00ISR Number: 3590387-4Report Type:Periodic Company Report #WAES 00061662
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:09/21/00ISR Number: 3590388-6Report Type:Periodic Company Report #WAES 00070280
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
		Representative	Maxzide	C				

Date:09/21/00ISR Number: 3590390-4Report Type:Periodic Company Report #WAES 00081631
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Deafness Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Ear Disorder Fungal Infection Insomnia Laryngitis Migraine Nausea Upper Respiratory Tract Infection		Adderall Tablets Klonopin	C C				

Date:09/21/00ISR Number: 3590391-6Report Type:Periodic Company Report #WAES 00061663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590393-XReport Type:Periodic Company Report #WAES 00081636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590394-1Report Type:Periodic Company Report #WAES 00061664
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590396-5Report Type:Periodic Company Report #WAES 00070281
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Estratest	C				
			Levoxyl	C				
			Tiazac	C				

Date:09/21/00ISR Number: 3590397-7Report Type:Periodic Company Report #WAES 00081638
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pain Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO 5 DAY

Advil	C
Celebrex	C
Aspirin	C
Atenolol	C
Calcium Supplement (Unspecified)	C
Gemfibrozil	C
Temazepam	C
Triamterene	C

Date:09/21/00ISR Number: 3590399-0Report Type:Periodic Company Report #WAES 00061665
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Calculus Urinary	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590400-4Report Type:Periodic Company Report #WAES 00081645
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590401-6Report Type:Periodic Company Report #WAES 00070292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Face Oedema Oedema Oedema Peripheral Pharyngeal Oedema Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:09/21/00ISR Number: 3590403-XReport Type:Periodic Company Report #WAES 00081648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590405-3Report Type:Periodic Company Report #WAES 00061668
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL PO

Date:09/21/00ISR Number: 3590406-5Report Type:Periodic Company Report #WAES 00070318
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea							
	Hypoaesthesia				Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Paraesthesia							
	Tremor		Etrafon Tablets	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3590408-9Report Type:Periodic Company Report #WAES 00081654
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oral Soft Tissue Disorder							
					Merck Co Inc	ORAL	25 MG/BID/PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590409-0Report Type:Periodic Company Report #WAES 00061669
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590410-7Report Type:Periodic Company Report #WAES 00070324
Age:66 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Facial Pain Flatulence Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1)25 MG/PRN/PO; 2) 25MG/BID/P0; 3) 25MG/DAILY/PO	
			Lipitor	C				
			Aspirin	C				
			Minerals (Unspecified) (+)					
			Vitam	C				

Date:09/21/00ISR Number: 3590412-0Report Type:Periodic Company Report #WAES 00081656
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO

			Accupril	C		

Date:09/21/00ISR Number: 3590414-4Report Type:Periodic Company Report #WAES 00070328
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypersensitivity Sneezing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						

MG/DAILY/PO

			Lipitor	C		
			Allopurinol	C		

Date:09/21/00ISR Number: 3590415-6Report Type:Periodic Company Report #WAES 00061690
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/1X/PO 1 DAY						
			Phenobarbital (Lilly)	C		
			Serzone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590416-8Report Type:Periodic Company Report #WAES 00081657
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Tambocor	C				
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3590417-XReport Type:Periodic Company Report #WAES 00070329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590418-1Report Type:Periodic Company Report #WAES 00061698
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Haematuria International Normalised Ratio Increased Prothrombin Time Ratio Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) PO; 2) 12.5 MG/DAILY/PO	
			Coumadin 2.5 Mg	SS		ORAL	PO	
			Cap Chondroitinso4 250 Mg	SS		ORAL	250 MG/BID/PO	

			Lasix	C		
			Pravacol	C		

Date:09/21/00ISR Number: 3590419-3Report Type:Periodic Company Report #WAES 00081659
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet	C				
			Neurontin	C				
			Desipramine	C				

Date:09/21/00ISR Number: 3590420-XReport Type:Periodic Company Report #WAES 00070333
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590422-3Report Type:Periodic Company Report #WAES 00070345
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Procardia	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3590424-7Report Type:Periodic Company Report #WAES 00061700
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Baycol	C				
			Fosamax	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590426-0Report Type:Periodic Company Report #WAES 00070346
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	

Date:09/21/00ISR Number: 3590428-4Report Type:Periodic Company Report #WAES 00070348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:09/21/00ISR Number: 3590429-6Report Type:Periodic Company Report #WAES 00061704
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Axid	C				
			Buspar	C				
			Diflucan	C				
			Lotrel	C				
			Miacalcin	C				
			Microzide	C				
			Chlordiazepoxide	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590431-4Report Type:Periodic Company Report #WAES 00070350
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Hormones (Composition Unspecified)	C				

Date:09/21/00ISR Number: 3590433-8Report Type:Periodic Company Report #WAES 00061716
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotensin	C				
			Pravachol	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3590435-1Report Type:Periodic Company Report #WAES 00061717
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590436-3Report Type:Periodic Company Report #WAES 00070352
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Hydrodiuril	C				
			Plaquenil	C				
			Premarin	C				
			Ascorbic Acid	C				
			Nortriptyline	C				
			Prednisolone	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				
			Zinc Preparation (Composition Un	C				

Date:09/21/00ISR Number: 3590437-5Report Type:Periodic Company Report #WAES 00061719
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3590438-7Report Type:Periodic Company Report #WAES 00070353
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			
	Gastritis	Health			Laboratories Div			
	Gastrointestinal Disorder	Professional			Merck Co Inc	ORAL	25	
	Haemorrhoids						MG/DAILY/PO	
			Prevacid	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3590439-9Report Type:Periodic Company Report #WAES 00061721
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research			
	Sunburn	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5	
							MG/BID/PO	
			Covera-Hs	C				
			Reglan	C				

Date:09/21/00ISR Number: 3590441-7Report Type:Periodic Company Report #WAES 00070354
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research			
	Tachycardia	Health			Laboratories Div			
	Throat Tightness	Professional			Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	

				Celebrex	C		
				Celestone	C		
				Claritin	C		
				Hydrodiuril	C		
				Pepcid	C		
				Atenolol	C		
				Dexamethasone Phosphate	C		
				Diuretic Preparation (Composition	C		
				Estradiol	C		
				Lidocaine	C		

Date:09/21/00ISR Number: 3590442-9Report Type:Periodic Company Report #WAES 00061723
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Prilosec	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590444-2Report Type:Periodic Company Report #WAES 00070359
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hormonal Contraceptives (Composi	C				

Date:09/21/00ISR Number: 3590445-4Report Type:Periodic Company Report #WAES 00061725
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Lopressor	C				
			Premarin	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3590446-6Report Type:Periodic Company Report #WAES 00070360
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Lanoxin	C				

Date:09/21/00ISR Number: 3590447-8Report Type:Periodic Company Report #WAES 00021150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dyspepsia							
	Flatulence							
	Nausea							

Date:09/21/00ISR Number: 3590448-XReport Type:Periodic Company Report #WAES 00061589
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590449-1Report Type:Periodic Company Report #WAES 00061591
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Aldactone	C				
			Atrovent	C				
			Beclovent	C				
			Caltrate 600 Plus Vitamin D	C				
			Centrum	C				
			Coumadin	C				
			Dura-Tap/Pd	C				
			Lanoxin	C				
			Micro K	C				
			Prilosec	C				
			Quinaglute	C				
			Tylenol	C				
			Albuterol	C				
			Aspirin	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590450-8Report Type:Periodic Company Report #WAES 00061593
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Hypertrophy Breast	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/BID/PO; 2) 50 MG/PO	

Date:09/21/00ISR Number: 3590451-XReport Type:Periodic Company Report #WAES 00052200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	14 DAY
	Feeling Hot	Other						
	Hyperhidrosis							
	Hypoaesthesia							
	Pain In Extremity							

Date:09/21/00ISR Number: 3590452-1Report Type:Periodic Company Report #WAES 00061597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590453-3Report Type:Periodic Company Report #WAES 00052207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3590454-5Report Type:Periodic Company Report #WAES 00052221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590455-7Report Type:Periodic Company Report #WAES 00061600
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia Joint Stiffness Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hormones (Composition Unspecified)	C				

Date:09/21/00ISR Number: 3590456-9Report Type:Periodic Company Report #WAES 00061602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590457-0Report Type:Periodic Company Report #WAES 00052233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590458-2Report Type:Periodic Company Report #WAES 00061603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590459-4Report Type:Periodic Company Report #WAES 00061610
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Oxycontin	C				
			Plendil	C				

	Prilosec	C	
	Valium	C	
	Codeine	C	

Date:09/21/00ISR Number: 3590460-0Report Type:Periodic Company Report #WAES 00061613
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mevacor	C				
			Prandin	C				
			Prempro	C				

Date:09/21/00ISR Number: 3590461-2Report Type:Periodic Company Report #WAES 00052234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3590462-4Report Type:Periodic Company Report #WAES 00052235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder Asthenia Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Depression		Enduronyl	SS				
	Fatigue		Celebrex	C				
	Headache							

Memory Impairment
Reaction To Medical Agent
Preservatives

Date:09/21/00ISR Number: 3590463-6Report Type:Periodic Company Report #WAES 00061615
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Librium	C				
			Maxzide	C				
			Synthroid	C				
			Potassium Supplement (Composition	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590464-8Report Type:Periodic Company Report #WAES 00052248
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Capoten	C				
			Norvasc	C				
			Tenex	C				
			Clonidine	C				

Date:09/21/00ISR Number: 3590465-XReport Type:Periodic Company Report #WAES 00061617
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590466-1Report Type:Periodic Company Report #WAES 00052252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:09/21/00ISR Number: 3590467-3Report Type:Periodic Company Report #WAES 00052259
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:09/21/00ISR Number: 3590469-7Report Type:Periodic Company Report #WAES 00052260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Lopressor	C				
			Maxzide	C				

Date:09/21/00ISR Number: 3590470-3Report Type:Periodic Company Report #WAES 00052261
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
	Pain Weight Increased		Hydrodiuril	C				
			Miacalcin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590471-5Report Type:Periodic Company Report #WAES 00061622
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 DAY

Date:09/21/00ISR Number: 3590472-7Report Type:Periodic Company Report #WAES 00052262
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				
			Oxycodone	C				

Date:09/21/00ISR Number: 3590473-9Report Type:Periodic Company Report #WAES 00052270
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspnoea Feeling Abnormal Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590474-0Report Type:Periodic Company Report #WAES 00061623
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/DAILY/PO; 2) 25 MG/BID/PO	
			Insulin	C				

Date:09/21/00ISR Number: 3590475-2Report Type:Periodic Company Report #WAES 00061624
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Ziac	C				
			Amitriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590476-4Report Type:Periodic Company Report #WAES 00052272
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				

Date:09/21/00ISR Number: 3590477-6Report Type:Periodic Company Report #WAES 00061625
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Nausea Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Derma-Smoothe/Fs Topical Oil	C				
			Norvasc	C				
			Plavix	C				
			Premarin	C				
			Synthroid	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3590478-8Report Type:Periodic Company Report #WAES 00052274
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Depression Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590479-XReport Type:Periodic Company Report #WAES 00061626
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3590480-6Report Type:Periodic Company Report #WAES 00052275
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Post Procedural Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590481-8Report Type:Periodic Company Report #WAES 00061627
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590482-XReport Type:Periodic Company Report #WAES 00052276
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Tongue Discolouration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590483-1Report Type:Periodic Company Report #WAES 00061632
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590484-3Report Type:Periodic Company Report #WAES 00052277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Donnatal	C				
			Motrin	C				

			Robaxin	C		
			Tenormin	C		

Date:09/21/00ISR Number: 3590485-5Report Type:Periodic Company Report #WAES 00061635
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Fatigue							
	Headache							
			Allegra	C				
			Prilosec	C				
			Tenex	C				
			Xanax	C				

Date:09/21/00ISR Number: 3590486-7Report Type:Periodic Company Report #WAES 00052282
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea	Health						
	Oedema Peripheral	Professional						

			Benadryl	C		
			Lipitor	C		
			Ultram	C		

Date:09/21/00ISR Number: 3590487-9Report Type:Periodic Company Report #WAES 00061636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Lower Respiratory Tract Infection		Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590488-0Report Type:Periodic Company Report #WAES 00052333
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Estradiol	C				

Date:09/21/00ISR Number: 3590489-2Report Type:Periodic Company Report #WAES 00052335
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Feeling Drunk							
			Hyzaar	C				
			Zantac	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3590490-9Report Type:Periodic Company Report #WAES 00052336
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypermetropia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Increased Appetite					
PO						
			Premarin	C		
			Clozapine	C		

Date:09/21/00ISR Number: 3590491-0Report Type:Periodic Company Report #WAES 00052337
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Amaryl	C		
			Coumadin	C		
			Lanoxin	C		
			Tenormin	C		

			Insulin	C		

Date:09/21/00ISR Number: 3590492-2Report Type:Periodic Company Report #WAES 00052339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prothrombin Time Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Warfarin	C				

Date:09/21/00ISR Number: 3590493-4Report Type:Periodic Company Report #WAES 00052340
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Fosamax	C				
			Zoloft	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3590494-6Report Type:Periodic Company Report #WAES 00052343
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Prinivil	C
			Albuterol	C
			Vitamins	C

Date:09/21/00ISR Number: 3590495-8Report Type:Periodic Company Report #WAES 00052348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Effexor Xr	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3590496-XReport Type:Periodic Company Report #WAES 00052370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Migraine	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Thyroid	C

Date:09/21/00ISR Number: 3590497-1Report Type:Periodic Company Report #WAES 00052371
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590498-3Report Type:Periodic Company Report #WAES 00052392
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estratab	C				
			Evista	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590499-5Report Type:Periodic Company Report #WAES 00052398
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Prilosec	C				
			Toprol Xl Tablets	C				

			Aspirin	C		

Date:09/21/00ISR Number: 3590500-9Report Type:Periodic Company Report #WAES 00052399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Paraesthesia Tongue Discolouration Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	

Date:09/21/00ISR Number: 3590501-0Report Type:Periodic Company Report #WAES 00052405
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590502-2Report Type:Periodic Company Report #WAES 00052409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590503-4Report Type:Periodic Company Report #WAES 00052410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotensin	C				
			Aspirin	C				
			Glucosamine	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590504-6Report Type:Periodic Company Report #WAES 00052411
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Flomax (Niflumic Acid (Beta) - Mor	C				
			Zocor	C				

			Nicotinic Acid	C		

Date:09/21/00ISR Number: 3590505-8Report Type:Periodic Company Report #WAES 00052412
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Fatigue							
			Klonopin	C				
			Lescol	C				
			Paxil	C				
			Ziac	C				

Date:09/21/00ISR Number: 3590506-XReport Type:Periodic Company Report #WAES 00052413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Paxil	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590507-1Report Type:Periodic Company Report #WAES 00052415
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Florinef	C				
			Miacalcin	C				
			Prempro	C				
			Magnesium Preparation (Composition	C				
			Potassium Supplement (Compositon	C				

Date:09/21/00ISR Number: 3590508-3Report Type:Periodic Company Report #WAES 00064651
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Albuterol	C				
			Ibuprofen	C				
			Methotrexate	C				

Date:09/21/00ISR Number: 3590509-5Report Type:Periodic Company Report #WAES 00052283
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Ecchymosis Gait Disturbance Muscle Spasms	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Neuralgia
Neuropathy Peripheral
Vertigo

Date:09/21/00ISR Number: 3590510-1Report Type:Periodic Company Report #WAES 00064664
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Buspar	C				
			Lasix	C				
			(Therapy Unspecified)	C				
			Captopril	C				
			Insulin	C				
			Potassium Supplement (Compositio	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590511-3Report Type:Periodic Company Report #WAES 00052285
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Pain Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tegretol	C				
			Quinine	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590512-5Report Type:Periodic Company Report #WAES 00064665
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				
			Dilacor	C				
			Lanoxin	C				

Date:09/21/00ISR Number: 3590513-7Report Type:Periodic Company Report #WAES 00052286
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Hydrochlorothiazide	C				
			Insulin	C				
			Evista	C				
			Lescol	C				

Date:09/21/00ISR Number: 3590514-9Report Type:Periodic Company Report #WAES 00064679
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3590515-0Report Type:Periodic Company Report #WAES 00064680
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590516-2Report Type:Periodic Company Report #WAES 00052287
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Naprelan	C				

Date:09/21/00ISR Number: 3590517-4Report Type:Periodic Company Report #WAES 00064681
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Increased Appetite	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
							25MG	1 DAY

Date:09/21/00ISR Number: 3590518-6Report Type:Periodic Company Report #WAES 00070239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:09/21/00ISR Number: 3590519-8Report Type:Periodic Company Report #WAES 00070240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cozaar	C				
			Hydrodiuril	C				

Date:09/21/00ISR Number: 3590520-4Report Type:Periodic Company Report #WAES 00070243
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx	SS		ORAL	PO	
			Adalat	C				
			Celexa	C				
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Cough, Cold, And Flu Therapies	C				
			Hydroxyzine	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590521-6Report Type:Periodic Company Report #WAES 00064682
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590522-8Report Type:Periodic Company Report #WAES 00064725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prempro	C				

Date:09/21/00ISR Number: 3590523-XReport Type:Periodic Company Report #WAES 00064759
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590524-1Report Type:Periodic Company Report #WAES 00070003
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Oedema Peripheral Merck Co Inc ORAL
25

MG/DAILY/PO

Atenolol C
Diuretic Preparation
(Compositio C

Date:09/21/00ISR Number: 3590525-3Report Type:Periodic Company Report #WAES 00070246
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
	Headache							
	Oedema Peripheral							
OPHTHALMIC	OPHT							
			Ditropan	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3590526-5Report Type:Periodic Company Report #WAES 00070010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

PO

Vioxx SS ORAL
PO 5 DAY
Levoxine C

Date:09/21/00ISR Number: 3590527-7Report Type:Periodic Company Report #WAES 00070249
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Drug Effect Decreased							
	Headache							
	Nausea							

Date:09/21/00ISR Number: 3590528-9Report Type:Periodic Company Report #WAES 00070015
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3590529-0Report Type:Periodic Company Report #WAES 00070017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibrosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
	Pulmonary Oedema	Company Representative						

Date:09/21/00ISR Number: 3590530-7Report Type:Periodic Company Report #WAES 00070019
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Aspirin	C				
			Calcium Supplement (Composition	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590531-9Report Type:Periodic Company Report #WAES 00070027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590532-0Report Type:Periodic Company Report #WAES 00070032
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Panic Disorder Without Agoraphobia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:09/21/00ISR Number: 3590533-2Report Type:Periodic Company Report #WAES 00070033
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:09/21/00ISR Number: 3590534-4Report Type:Periodic Company Report #WAES 00070034
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	5 DAY
			Asacol	C				
			Lotensin	C				
			Premarin	C				

Date:09/21/00ISR Number: 3590535-6Report Type:Periodic Company Report #WAES 00070250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:09/21/00ISR Number: 3590536-8Report Type:Periodic Company Report #WAES 00070253
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3590537-XReport Type:Periodic Company Report #WAES 00070254
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Claritin	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590538-1Report Type:Periodic Company Report #WAES 00070255
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	1 DAY
			Darvocet-N	C				
			Vicodin Tablets	C				
			Insulin	C				

Date:09/21/00ISR Number: 3590539-3Report Type:Periodic Company Report #WAES 00070256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				
			Zantac	C				

Date:09/21/00ISR Number: 3590540-XReport Type:Periodic Company Report #WAES 00070257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590541-1Report Type:Periodic Company Report #WAES 00070035
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
	Constipation							

Date:09/21/00ISR Number: 3590542-3Report Type:Periodic Company Report #WAES 00070038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:09/21/00ISR Number: 3590543-5Report Type:Periodic Company Report #WAES 00070258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy					

		Unspecified]	C

Date:09/21/00ISR Number: 3590546-0Report Type:Periodic Company Report #WAES 00070259
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Drug Effect Decreased							
	Fatigue		Cardizem	C				
			Cytotec	C				
			Lipitor	C				
			Lodine	C				
			Prevacid	C				
			Aspirin	C				
			Folic Acid	C				
			Methotrexate	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590548-4Report Type:Periodic Company Report #WAES 00070261
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN/PO	

Date:09/21/00ISR Number: 3590549-6Report Type:Periodic Company Report #WAES 00070262
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO	4 DAY					
			Tab Vioxx Unk	SS		ORAL
CONT/PO						
			Axid	C		
			Celebrex	C		
			Estrace	C		
			Prozac	C		

Date:09/21/00ISR Number: 3590551-4Report Type:Periodic Company Report #WAES 00070263
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Prempro	C		
			Warfarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590553-8Report Type:Periodic Company Report #WAES 00070264
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulation Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3590554-XReport Type:Periodic Company Report #WAES 00070266
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Clonopin	C				

Date:09/21/00ISR Number: 3590555-1Report Type:Periodic Company Report #WAES 00070267
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590557-5Report Type:Periodic Company Report #WAES 00070268
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3590570-8Report Type:Periodic Company Report #WAES 00070110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Liver Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3590572-1Report Type:Periodic Company Report #WAES 00070112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Skin Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590575-7Report Type:Periodic Company Report #WAES 00070114
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3590577-0Report Type:Periodic Company Report #WAES 00070115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 MON
			Pulmicort	C				

Date:09/21/00ISR Number: 3590579-4Report Type:Periodic Company Report #WAES 00070120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:09/21/00ISR Number: 3590580-0Report Type:Periodic Company Report #WAES 00070122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590582-4Report Type:Periodic Company Report #WAES 00070125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3590584-8Report Type:Periodic Company Report #WAES 00070160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vancenase Aq Nasal Spray	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590585-XReport Type:Periodic Company Report #WAES 00070192
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				

Date:09/21/00ISR Number: 3590586-1Report Type:Periodic Company Report #WAES 00070193
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Feeling Abnormal Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Glucosamine	C				
			Hormones (Composition Unspecifie	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3590588-5Report Type:Periodic Company Report #WAES 00070199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Haemorrhage Menstrual Disorder Uterine Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG	

Date:09/21/00ISR Number: 3590590-3Report Type:Periodic Company Report #WAES 00070201
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Lotensin	C				
			Norvasc	C				
			Premarin	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3590592-7Report Type:Periodic Company Report #WAES 00070204
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				
			Maxzide	C				
			Premarin	C				
			Calcitriol	C				
			Estrogenic Preparations					

				(Composi	C	
				Magnesium Preparation		
				(Compositi	C	
				Potassium Chloride	C	

Date:09/21/00ISR Number: 3590593-9Report Type:Periodic Company Report #WAES 00070209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fluid Retention							
	Gastrointestinal Disorder				Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3590594-0Report Type:Periodic Company Report #WAES 00070212
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				
			Paxil	C				
			Tofranil	C				
			(Therapy Unspecified)	C				
			Metoprolol	C				

Date:09/21/00ISR Number: 3590595-2Report Type:Periodic Company Report #WAES 00070219
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO

Levoxyl	C
Lipitor	C
Premarin	C
Relafen	C
Vicodin Tablets	C
Medroxyprogesterone	C
Nortriptyline	C

Date:09/21/00ISR Number: 3590596-4Report Type:Periodic Company Report #WAES 00070231
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590597-6Report Type:Periodic Company Report #WAES 00070233
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardura	C				
			Monoket	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3590598-8Report Type:Periodic Company Report #WAES 00070235
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Antimicrobial Therapy (Compositi	C				

Date:09/21/00ISR Number: 3590599-XReport Type:Periodic Company Report #WAES 00070238
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3590600-3Report Type:Periodic Company Report #WAES 00052288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
			Os-Cal + D	C				
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3590601-5Report Type:Periodic Company Report #WAES 00052289
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Evista	C				
			K-Dur	C				
			Norvasc	C				
			Pravachol	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590603-9Report Type:Periodic Company Report #WAES 00052292
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Muscular Weakness							
			Allegra	C				
			Lotrel	C				
			Ogen	C				

Date:09/21/00ISR Number: 3590605-2Report Type:Periodic Company Report #WAES 00052293
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							

Date:09/21/00ISR Number: 3590608-8Report Type:Periodic Company Report #WAES 00052296
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							
			Darvocet-N	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3590610-6Report Type:Periodic Company Report #WAES 00052298
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer	Vioxx	PS	Merck Research			

Toothache
Vaginal Discharge
Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO
Synthroid C

Date:09/21/00ISR Number: 3590612-XReport Type:Periodic Company Report #WAES 00052300
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	20 DAY

Date:09/21/00ISR Number: 3590615-5Report Type:Periodic Company Report #WAES 00052301
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 50 MG PO	
			Allegra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590617-9Report Type:Periodic Company Report #WAES 00052303
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Arthrotec	C				
			Celebrex	C				
			Fosamax	C				
			Triamterene	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3590620-9Report Type:Periodic Company Report #WAES 00052304
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5/DAILY/PO	
			Fosamax	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3590653-2Report Type:Periodic Company Report #WAES 00052305
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	9 MON

Date:09/21/00ISR Number: 3590654-4Report Type:Periodic Company Report #WAES 00052308
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardura	C				
			Daraprim	C				
			Parafon Forte	C				
			Aspirin	C				
			Lithium Carbonate	C				
			Pentoxifylline	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3590656-8Report Type:Periodic Company Report #WAES 00052317
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3590658-1Report Type:Periodic Company Report #WAES 00052319
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nicoderm Patch	C				

Date:09/21/00ISR Number: 3590659-3Report Type:Periodic Company Report #WAES 00052324
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET/DAILY/ PO; 25 MG/DAILY/PO	
			Cardisan	C				
			Lipitor	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3590660-XReport Type:Periodic Company Report #WAES 00052332
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Premarin	C				
			Amitriptyline	C				

Hydroxyzine C

Date:09/21/00ISR Number: 3591106-8Report Type:Periodic Company Report #WAES 00070634
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591107-XReport Type:Periodic Company Report #WAES 00070636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591109-3Report Type:Periodic Company Report #WAES 00070639
Age: Gender: I/FU:I

Outcome	PT
	Hypoaesthesia
	Oedema Peripheral

	Pain In Extremity Paraesthesia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO 1 MON

Date:09/21/00ISR Number: 3591111-1Report Type:Periodic Company Report #WAES 00070644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO

Date:09/21/00ISR Number: 3591112-3Report Type:Periodic Company Report #WAES 00070652
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective Oedema Peripheral Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO
			Synthroid	C			

Date:09/21/00ISR Number: 3591113-5Report Type:Periodic Company Report #WAES 00070653
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

			Asacol	C		
			Hyzaar	C		
			Mevacor	C		
			Prilosec	C		
			Sulfasalazine	C		

Date:09/21/00ISR Number: 3591115-9Report Type:Periodic Company Report #WAES 00070635
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Diovan	C		
			Fosamax	C		
			Glucophage	C		
			Neurontin	C		
			Prempro	C		
			Glyburide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591118-4Report Type:Periodic Company Report #WAES 00070600
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Glyburide	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3591119-6Report Type:Periodic Company Report #WAES 00070662
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Migraine	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Lipitor	C				
			Tagamet	C				

Date:09/21/00ISR Number: 3591121-4Report Type:Periodic Company Report #WAES 00070664
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Enbrel	C				
			Miacalcin	C				
			Cyclobenzaprine	C				
			Folic Acid	C				

			Methotrexate	C		

Date:09/21/00ISR Number: 3591122-6Report Type:Periodic Company Report #WAES 00070666
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

Date:09/21/00ISR Number: 3591124-XReport Type:Periodic Company Report #WAES 00070667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia Muscle Spasms Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Synthoid Estrogenic Preparations (Composition Unspecified)	C		
			Prednisone	C		

			Vitamins (Unspecified)	C		

Date:09/21/00ISR Number: 3591126-3Report Type:Periodic Company Report #WAES 00070671
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591127-5Report Type:Periodic Company Report #WAES 00070676
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Cordarone	C				
			Imdur	C				
			Lipitor	C				
			Singulair	C				
			Atenolol	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3591129-9Report Type:Periodic Company Report #WAES 00070677
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	

Date:09/21/00ISR Number: 3591130-5Report Type:Periodic Company Report #WAES 00070681
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Baycol	C				
			Composition Unspecified	C				

Date:09/21/00ISR Number: 3591132-9Report Type:Periodic Company Report #WAES 00070684
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Proscar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591134-2Report Type:Periodic Company Report #WAES 00070687
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Prevacid	C				
			Aspirin	C				
			Atenolol	C				
			Calcium Supplement (Composition Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3591135-4Report Type:Periodic Company Report #WAES 00070688
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591137-8Report Type:Periodic Company Report #WAES 00070690
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tetracycline	C				

Date:09/21/00ISR Number: 3591149-4Report Type:Periodic Company Report #WAES 00062864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591151-2Report Type:Periodic Company Report #WAES 00062868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vasculitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591153-6Report Type:Periodic Company Report #WAES 00062931
Age:79 YR Gender:Male I/FU:I

Outcome	PT
	Deafness
	Dyspnoea

	Flushing Hypoaesthesia Malaise	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	11 DAY

Date:09/21/00ISR Number: 3591154-8Report Type:Periodic Company Report #WAES 00062934
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Myalgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5	
	Pain In Extremity						MG/PO; 2) 25	
	Urinary Tract Infection						MG/DAILY/PO	
			Avandia	C				
			Prandin	C				

Date:09/21/00ISR Number: 3591156-1Report Type:Periodic Company Report #WAES 00062935
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Miacalcin	C				
			Estrogenic Preparations (Composi	C				

Date:09/21/00ISR Number: 3591158-5Report Type:Periodic Company Report #WAES 00062937
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries Tooth Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Meridia	C				
			Micronor	C				
			Plendil	C				
			Tylenol With Codeine	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3591159-7Report Type:Periodic Company Report #WAES 00062938
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591161-5Report Type:Periodic Company Report #WAES 00062939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591163-9Report Type:Periodic Company Report #WAES 00062943
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prevacid	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591164-0Report Type:Periodic Company Report #WAES 00062944
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Feeling Abnormal Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	
	Headache		Advil	C				
	Joint Swelling		Aspirin	C				
	Oedema							
	Tinnitus							
	Tongue Discolouration							

Date:09/21/00ISR Number: 3591167-6Report Type:Periodic Company Report #WAES 00062946
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zantac	C				

Date:09/21/00ISR Number: 3591169-XReport Type:Periodic Company Report #WAES 00062947
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				
			Vitamin A	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591170-6Report Type:Periodic Company Report #WAES 00062949
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Hytrin	C				
			Premarin	C				
			Hydrochlorothiazide (+) Triamterene	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3591172-XReport Type:Periodic Company Report #WAES 00062951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norodin	C				

Date:09/21/00ISR Number: 3591174-3Report Type:Periodic Company Report #WAES 00062952
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cytoxan	C				
			Decadron (Dexamethasone)	C				

Date:09/21/00ISR Number: 3591176-7Report Type:Periodic Company Report #WAES 00062953
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Norvasc	C				
			Prilosec	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3591178-0Report Type:Periodic Company Report #WAES 00062954
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Headache Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Deseril	C				
			Progesterone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591179-2Report Type:Periodic Company Report #WAES 00062957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591182-2Report Type:Periodic Company Report #WAES 00062959
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Amitriptyline	C				
			Atenolol	C				
			Calcium Supplement (Composition	C				
			Methotrexate	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591184-6Report Type:Periodic Company Report #WAES 00062966
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591195-0Report Type:Periodic Company Report #WAES 00070509
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Sinemet	C				

Date:09/21/00ISR Number: 3591197-4Report Type:Periodic Company Report #WAES 00070511
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
			Coumadin	C				
			Toprol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591199-8Report Type:Periodic Company Report #WAES 00070512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

Date:09/21/00ISR Number: 3591200-1Report Type:Periodic Company Report #WAES 00070513
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Feeling Abnormal Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium Supplement	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591201-3Report Type:Periodic Company Report #WAES 00070514
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591203-7Report Type:Periodic Company Report #WAES 00070518
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Decreased Activity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Dyspnoea				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Lipitor	C		
			Proscar	C		
			Ascorbic Acid	C		
			B Vitamins	C		
			Calcium Supplement	C		
			Estradiol	C		
			Folic Acid	C		
			Ubidecarenone	C		
			Vitamin E	C		

Date:09/21/00ISR Number: 3591205-0Report Type:Periodic Company Report #WAES 00070521
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Evista	C		
			Premarin	C		
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591207-4Report Type:Periodic Company Report #WAES 00070523
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Cardizem Cd	C				
			Clinoril	C				
			Cozaar	C				
			Dilatrate	C				
			Lasix	C				
			Prilosec	C				
			Insulin	C				

Date:09/21/00ISR Number: 3591209-8Report Type:Periodic Company Report #WAES 00070524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Claritin-D	C				
			Synthroid	C				
			Ziac	C				

Date:09/21/00ISR Number: 3591211-6Report Type:Periodic Company Report #WAES 00070528
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO

Therapy Unspecified C

Date:09/21/00ISR Number: 3591212-8Report Type:Periodic Company Report #WAES 00070532
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Isoptin	C				
			Premarin	C				
			Timoptic	C				

Date:09/21/00ISR Number: 3591215-3Report Type:Periodic Company Report #WAES 00070534
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591217-7Report Type:Periodic Company Report #WAES 00070535
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tenormin	C				
			Timoptic	C				

Date:09/21/00ISR Number: 3591230-XReport Type:Periodic Company Report #WAES 00070536
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Hyzaar	C				

Date:09/21/00ISR Number: 3591233-5Report Type:Periodic Company Report #WAES 00070538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3591235-9Report Type:Periodic Company Report #WAES 00070548
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591239-6Report Type:Periodic Company Report #WAES 00070551
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591242-6Report Type:Periodic Company Report #WAES 00070553
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591245-1Report Type:Periodic Company Report #WAES 00070555
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased	Health						
	Dyspnoea	Professional			Merck Co Inc	ORAL	12.5 MG/	
	Pruritus						BID/PO	
	Pulse Abnormal		Sular	C				
	Tinnitus							

Date:09/21/00ISR Number: 3591248-7Report Type:Periodic Company Report #WAES 00070556
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Lodosin	C				
			Tiazac	C				

Date:09/21/00ISR Number: 3591258-XReport Type:Periodic Company Report #WAES 00071038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591262-1Report Type:Periodic Company Report #WAES 00071055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591266-9Report Type:Periodic Company Report #WAES 00071058
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngeal Disorder Pyrexia Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG QID PO	
			Aygestin	C				
			Lupron	C				

Date:09/21/00ISR Number: 3591268-2Report Type:Periodic Company Report #WAES 00071060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591271-2Report Type:Periodic Company Report #WAES 00071061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO

Date:09/21/00ISR Number: 3591274-8Report Type:Periodic Company Report #WAES 00071063
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

Date:09/21/00ISR Number: 3591275-XReport Type:Periodic Company Report #WAES 00071065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO
			Tylenol	C				

Date:09/21/00ISR Number: 3591276-1Report Type:Periodic Company Report #WAES 00071070
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Dyspepsia				Merck Co Inc	ORAL
25						
	Flatulence					
MG/DAILY/PO						
			Cleocin	C		
			Corgard	C		
			Coumadin	C		
			Lanoxin	C		
			Lipitor	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3591278-5Report Type:Periodic Company Report #WAES 00071071
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anorectal Disorder	Consumer	Vioxx	PS	Merck Research	
	Blister				Laboratories Div	
	Mouth Ulceration				Merck Co Inc	ORAL
25						
	Upper Respiratory Tract					
MG/DAILY/PO						
	Infection		L-Thyroxine	C		
			Skelaxin	C		
			Vicodin Tablets	C		
			Zyrtec	C		
			[Therapy			
			Unspecified]	C		
			Desogestrel (+)			
			Ethinyl Estradio	C		
			Vitamins			

(Unspecified) C

Date:09/21/00ISR Number: 3591279-7Report Type:Periodic Company Report #WAES 00071074
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Lipitor	C				
			Tenormin	C				

Date:09/21/00ISR Number: 3591280-3Report Type:Periodic Company Report #WAES 00071077
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mucous Membrane Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Acolate	C				
			Neurontin	C				
			Prempro	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3591281-5Report Type:Periodic Company Report #WAES 00071080
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	6 WK
			Norvasc	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3591282-7Report Type:Periodic Company Report #WAES 00071081
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Paxil	C				

Date:09/21/00ISR Number: 3591283-9Report Type:Periodic Company Report #WAES 00071083
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591284-0Report Type:Periodic Company Report #WAES 00071085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591285-2Report Type:Periodic Company Report #WAES 00071086
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:09/21/00ISR Number: 3591286-4Report Type:Periodic Company Report #WAES 00071087
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN PO	
	Dizziness							
	Fall							
	Gastrointestinal Disorder		Allegra	C				
	Nasal Congestion		Tiazac	C				
	Sputum Abnormal							
	Vomiting							

Date:09/21/00ISR Number: 3591287-6Report Type:Periodic Company Report #WAES 00071088
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema Nausea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Lopressor	C		
			Prilosec	C		
			Calcium Supplement (Composition	C		
			Vitamins (Unspecified)	C		

Date:09/21/00ISR Number: 3591476-0Report Type:Periodic Company Report #WAES 00062732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591477-2Report Type:Periodic Company Report #WAES 00062733
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Detrol	C				
			Pepcid	C				
			Plavix	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3591478-4Report Type:Periodic Company Report #WAES 00062734
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia Pulmonary Congestion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Darvocet-N	C				
			Diflucan	C				
			Fosamax	C				
			Maxzide	C				
			Zoloft	C				
			Estrogenic Preparations	C				
			Guaifenesin	C				

Date:09/21/00ISR Number: 3591479-6Report Type:Periodic Company Report #WAES 00062740
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Attention	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Deficit/Hyperactivity				Merck Co Inc	ORAL
12.5 MG /PO						
	Disorder		Tab Vioxx 25mg	SS		ORAL
25 MG/PO						
	Dehydration					
	Fatigue					
	Feeling Drunk					
	Pain					

Date:09/21/00ISR Number: 3591480-2Report Type:Periodic Company Report #WAES 00062741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO						
			Lopressor	C		
			Pravachol	C		
			Aspirin	C		
			Iron	C		
			Zinc Preparation	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591481-4Report Type:Periodic Company Report #WAES 00062742
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Premarin	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3591482-6Report Type:Periodic Company Report #WAES 00062745
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogenic Preparations	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591483-8Report Type:Periodic Company Report #WAES 00062761
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Dyspnoea Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3591484-XReport Type:Periodic Company Report #WAES 00062762
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspnoea Feeling Abnormal Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591485-1Report Type:Periodic Company Report #WAES 00062763
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Hyperhidrosis Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
	Visual Disturbance		Norvasc	C				
			Proscar	C				
			Vicodin Tablets	C				
			Zocor	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591486-3Report Type:Periodic Company Report #WAES 00062771
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Prinivil	C				
			Insulin Injection + Isophane	C				

Date:09/21/00ISR Number: 3591487-5Report Type:Periodic Company Report #WAES 00062772
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Effect Decreased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Vicodin Tablets	C				
			Zocor	C				

Date:09/21/00ISR Number: 3591488-7Report Type:Periodic Company Report #WAES 00062773
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Feeling Abnormal Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591489-9Report Type:Periodic Company Report #WAES 00062776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Pravachol	C		
			Toprol Xl Tablets	C		
			Aspirin	C		

Date:09/21/00ISR Number: 3591490-5Report Type:Periodic Company Report #WAES 00062777
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia Asthenia Fatigue	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Musculoskeletal Disorder		Ethinyl Estradiol + Norgestima	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591491-7Report Type:Periodic Company Report #WAES 00062779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							
	Flushing							
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3591492-9Report Type:Periodic Company Report #WAES 00062781
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Influenza Like Illness							

Date:09/21/00ISR Number: 3591493-0Report Type:Periodic Company Report #WAES 00062783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Desyrel	C				
			Estrace	C				
			Glucophage	C				
			Lasix	C				
			Synthroid	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3591494-2Report Type:Periodic Company Report #WAES 00062788
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591495-4Report Type:Periodic Company Report #WAES 00062809
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperammonaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Mental Impairment	Company Representative	Celebrex	C				

Date:09/21/00ISR Number: 3591496-6Report Type:Periodic Company Report #WAES 00062832
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Claritin	C	
Elavil	C	
Fosamax	C	
Nasocort	C	
Synthroid	C	
Estradiol	C	

Date:09/21/00ISR Number: 3591497-8Report Type:Periodic Company Report #WAES 00070557
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hypertension							
	Malaise				Merck Co Inc	ORAL	UNK/UNK/PO	
	Oedema		Diazide	C				
	Palpitations		Atenolol	C				
	Weight Increased							

Date:09/21/00ISR Number: 3591498-XReport Type:Periodic Company Report #WAES 00070558
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
	Tachycardia				Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Allegra	C				

Date:09/21/00ISR Number: 3591499-1Report Type:Periodic Company Report #WAES 00070564
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:09/21/00ISR Number: 3591500-5Report Type:Periodic Company Report #WAES 00070566
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

12.5 MG DAILY

PO 1 MON

Date:09/21/00ISR Number: 3591501-7Report Type:Periodic Company Report #WAES 00070568
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Hypoaesthesia Pain In Extremity	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591502-9Report Type:Periodic Company Report #WAES 00070569
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain Vaginal Discharge	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Ecotrin	C				
			Fosamax	C				
			Miacalcin	C				
			Os-Cal-D	C				
			Premarin	C				
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3591503-0Report Type:Periodic Company Report #WAES 00070573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591504-2Report Type:Periodic Company Report #WAES 00070577
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			(Therapy Unspecified)	C				

Date:09/21/00ISR Number: 3591505-4Report Type:Periodic Company Report #WAES 00070578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591506-6Report Type:Periodic Company Report #WAES 00070579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591507-8Report Type:Periodic Company Report #WAES 00070584
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591508-XReport Type:Periodic Company Report #WAES 00070591
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Darvocet-N	C				
			Aspirin	C				
			Ibuprofen	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3591509-1Report Type:Periodic Company Report #WAES 00070593
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591510-8Report Type:Periodic Company Report #WAES 00070596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Oedema Peripheral Consumer Vioxx PS Merck Research Laboratories Div Merck Co Inc ORAL 12.5 MG/UNK/PO

Beconase C

Date:09/21/00ISR Number: 3591511-XReport Type:Periodic Company Report #WAES 00070600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Nasonex	C				

Date:09/21/00ISR Number: 3591512-1Report Type:Periodic Company Report #WAES 00070606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacrimation Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591513-3Report Type:Periodic Company Report #WAES 00070607
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3591514-5Report Type:Periodic Company Report #WAES 00070614
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5/DAILY/PO	
			Dyazide	C				
			Fosamax	C				
			Elavix	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3591515-7Report Type:Periodic Company Report #WAES 00070619
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accolate	C				
			Claritin	C				
			Ditropan	C				
			Lipitor	C				
			Lozol	C				
			Miacalcin	C				
			Premarin	C				
			Medroxyprogesterone	C				

Date:09/21/00ISR Number: 3591516-9Report Type:Periodic Company Report #WAES 00070620
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Asthenia							
	Blood Pressure Increased							
	Dyspnoea							
	Fatigue		Lotrel	C				
	Menopausal Symptoms		Minocycline	C				

Date:09/21/00ISR Number: 3591529-7Report Type:Periodic Company Report #WAES 00070040
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Antineoplastic Agents	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591530-3Report Type:Periodic Company Report #WAES 00070046
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1XPO	
			Lanoxin	C				
			Tenormin	C				

Date:09/21/00ISR Number: 3591531-5Report Type:Periodic Company Report #WAES 00070048
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Amerge	C				
			Imitrex	C				
			Necon	C				

Date:09/21/00ISR Number: 3591532-7Report Type:Periodic Company Report #WAES 00070049
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3591533-9Report Type:Periodic Company Report #WAES 00070050
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Premarin	C				
			Zoloft	C				
			Medroxyprogesterone	C				

Date:09/21/00ISR Number: 3591534-0Report Type:Periodic Company Report #WAES 00070051
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 MON
			Detrol	C				
			Endur-Acin	C				
			Lipitor	C				
			Lopressor	C				
			Norvasc	C				

			Prevacid	C		

Date:09/21/00ISR Number: 3591535-2Report Type:Periodic Company Report #WAES 00070052
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cefalex	C				
			Glucophage	C				

Date:09/21/00ISR Number: 3591536-4Report Type:Periodic Company Report #WAES 00070053
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Movement Disorder							
	Muscle Spasms							
	Nausea		Cogentin	C				
	Oedema Peripheral		Lipitor	C				
	Pollakiuria		Premarin	C				
	Rhinorrhoea		Risperdal	C				
			Serzone	C				
			Lithium Chloride	C				
			Ranitidine	C				

Date:09/21/00ISR Number: 3591537-6Report Type:Periodic Company Report #WAES 00070057
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Glucophage	C		
			Synthroid	C		
			Folic Acid	C		

Date:09/21/00ISR Number: 3591538-8Report Type:Periodic Company Report #WAES 00070060
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea	Health			Laboratories Div			
	Faecal Incontinence	Professional			Merck Co Inc	ORAL	25	
	Hemianopia							
	Mental Impairment		Aleve	C				
	Migraine		Lozol	C				
	Oedema		Mevacor	C				
			Paxil	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				
			Trimethoprim	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591539-XReport Type:Periodic Company Report #WAES 00070064
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gout	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain In Extremity							
			Avapro	C				
			Pepcid	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591540-6Report Type:Periodic Company Report #WAES 00070065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				
			Prilosec	C				
			Singulair	C				
			Synthroid	C				
			Zantac	C				

Date:09/21/00ISR Number: 3591541-8Report Type:Periodic Company Report #WAES 00070067
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Ativan	C				
			Evista	C				
			Levothroid	C				
			Tylenol With Codeine	C				

Date:09/21/00ISR Number: 3591542-XReport Type:Periodic Company Report #WAES 00070070
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3591543-1Report Type:Periodic Company Report #WAES 00070073
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Cardiac Murmur Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Arthrotec	C				
			Lanoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591544-3Report Type:Periodic Company Report #WAES 00070077
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Oedema Peripheral							
	Rectal Haemorrhage							
			Darvocet-N	C				
			Elavil	C				
			Flexeril	C				
			Lasix	C				
			Macrodantin	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3591545-5Report Type:Periodic Company Report #WAES 00070080
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
			Cartia	C				

Date:09/21/00ISR Number: 3591546-7Report Type:Periodic Company Report #WAES 00070083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591547-9Report Type:Periodic Company Report #WAES 00070084
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Dilantin	C				
			Hyzaar	C				
			Atenolol	C				
			Herbal Remedies	C				
			Primidone	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591548-0Report Type:Periodic Company Report #WAES 00070087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Coumadin	C				
			Premarin	C				
			Tenormin	C				

Hydrochlorothiazide C

Date:09/21/00ISR Number: 3591549-2Report Type:Periodic Company Report #WAES 00062967
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3591550-9Report Type:Periodic Company Report #WAES 00062972
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Norvasc	C				
			Premarin	C				
			Provera	C				
			Aspirin	C				
			Calcium Supplement (Composition)	C				

Date:09/21/00ISR Number: 3591551-0Report Type:Periodic Company Report #WAES 00072091
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

			Arava	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3591552-2Report Type:Periodic Company Report #WAES 00072096
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						

Date:09/21/00ISR Number: 3591553-4Report Type:Periodic Company Report #WAES 00072100
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Estrace	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591554-6Report Type:Periodic Company Report #WAES 00072101
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Premarin	C				
			Procardia	C				

Date:09/21/00ISR Number: 3591555-8Report Type:Periodic Company Report #WAES 00072105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:09/21/00ISR Number: 3591556-XReport Type:Periodic Company Report #WAES 00072106
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tagamet	C				

Date:09/21/00ISR Number: 3591557-1Report Type:Periodic Company Report #WAES 00072129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Herpes Simplex Sciatica	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO 4 WK						
			Tab Vioxx 25 Mg	SS		ORAL
25 MG/DAILY/PO						

Date:09/21/00ISR Number: 3591558-3Report Type:Periodic Company Report #WAES 00072134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension Pain Rheumatoid Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3591559-5Report Type:Periodic Company Report #WAES 00072143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatic Function Abnormal Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591560-1Report Type:Periodic Company Report #WAES 00072150
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Bumex	C				
			Lipitor	C				
			Prempro	C				
			Tarka	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3591561-3Report Type:Periodic Company Report #WAES 00072162
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthma Diarrhoea Headache Oedema Peripheral Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:09/21/00ISR Number: 3591562-5Report Type:Periodic Company Report #WAES 00072173
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Evista C
Lipitor C
Prevacid C

Date:09/21/00ISR Number: 3591563-7Report Type:Periodic Company Report #WAES 00072190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dyspepsia							
	Oedema Peripheral				Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591564-9Report Type:Periodic Company Report #WAES 00072196
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	6 MON

K-Dur C
Ascorbic Acid C
Folic Acid C

			Glucosamine	C
			Vitamin E	C
			Vitamins (Unspecified)	C

Date:09/21/00ISR Number: 3591565-0Report Type:Periodic Company Report #WAES 00072201
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Arimidex	C				
			Claritin	C				
			Cozaar	C				
			Lozol	C				
			Vicodin Es Tablets	C				

Date:09/21/00ISR Number: 3591566-2Report Type:Periodic Company Report #WAES 00072202
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3591567-4Report Type:Periodic Company Report #WAES 00072206
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Balance Disorder				Merck Co Inc	ORAL
25						
	Fatigue					
MG/DAILY/PO						
	Feeling Abnormal		Claritin	C		
	Haemorrhage		Lescol	C		
	Intraocular Pressure		Seldane	C		
	Increased		Toprol Xl Tablets	C		
	Pruritus					
	Visual Disturbance					

Date:09/21/00ISR Number: 3591568-6Report Type:Periodic Company Report #WAES 00072207
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Feeling Abnormal				Laboratories Div	
	Insomnia				Merck Co Inc	
12.5 MG/TID						
	Pain In Extremity		Tab Vioxx 12.5 Mg	SS		
12.5 MG						
			Cozaar	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591630-8Report Type:Periodic Company Report #WAES 00071632
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dyspepsia							
	Headache							
			Celebrex	C				
			Cozaar	C				
			Lipitor	C				
			Maxzide	C				
			Prilosec	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591631-XReport Type:Periodic Company Report #WAES 00071635
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	

Date:09/21/00ISR Number: 3591632-1Report Type:Periodic Company Report #WAES 00071636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Hydroxychloroquine Sulfate	C				

Date:09/21/00ISR Number: 3591634-5Report Type:Periodic Company Report #WAES 00071641
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3591635-7Report Type:Periodic Company Report #WAES 00071642
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591638-2Report Type:Periodic Company Report #WAES 00071644
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Flushing							
	Hallucination		Synthroid	C				
	Night Sweats		Tagamet	C				
			Ultram	C				

Date:09/21/00ISR Number: 3591640-0Report Type:Periodic Company Report #WAES 00071647
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			Methotrexate	C				

Date:09/21/00ISR Number: 3591644-8Report Type:Periodic Company Report #WAES 00071651
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Ocupress 1%	C				
			Synthroid	C				
			Trusopt	C				
			Xalatan	C				
			Cyanocobalamin	C				
			Meclizine	C				

Date:09/21/00ISR Number: 3591645-XReport Type:Periodic Company Report #WAES 00071653
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
			Pepcid	C				
			Estrogenic Preprarations (Composi	C				

Date:09/21/00ISR Number: 3591646-1Report Type:Periodic Company Report #WAES 00071655
Age:77 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Cough
	Face Oedema
	Fatigue
	Oral Pain

		Pharyngitis Tongue Oedema Toothache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Ditropan	C		
				Nitro Mack	C		
				Premarin	C		
				Zoloft	C		
				[Composition Unspecified]	C		
				[Therapy Unspecified]	C		
				Aspirin	C		

Date:09/21/00ISR Number: 3591647-3Report Type:Periodic Company Report #WAES 00071656
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Parosmia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3591648-5Report Type:Periodic Company Report #WAES 00071659
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Celebrex	C		

Date:09/21/00ISR Number: 3591649-7Report Type:Periodic Company Report #WAES 00071661
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Nausea							
	Pharyngitis		Evista	C				

Date:09/21/00ISR Number: 3591670-9Report Type:Periodic Company Report #WAES 00071663
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Constipation							
	Urinary Tract Disorder							
			Asendin	C				
			Cardizem	C				
			Lopressor	C				
			Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591671-0Report Type:Periodic Company Report #WAES 00071666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excoriation Skin Lesion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Prozac	C				

Date:09/21/00ISR Number: 3591672-2Report Type:Periodic Company Report #WAES 00071667
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				

Date:09/21/00ISR Number: 3591673-4Report Type:Periodic Company Report #WAES 00071669
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Pericardial Effusion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591674-6Report Type:Periodic Company Report #WAES 00071671
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Allegra	C				
			Diazide	C				
			Prozac	C				

Date:09/21/00ISR Number: 3591675-8Report Type:Periodic Company Report #WAES 00071686
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591676-XReport Type:Periodic Company Report #WAES 00071693
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Rectal Haemorrhage	Health Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591679-5Report Type:Periodic Company Report #WAES 00071356
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tenoretic	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Garlic Extract	C				
			Vitamin E	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591680-1Report Type:Periodic Company Report #WAES 00071362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness Fluid Retention Oedema Oedema Peripheral		Diazide	C				

Date:09/21/00ISR Number: 3591681-3Report Type:Periodic Company Report #WAES 00071364
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Macular	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591682-5Report Type:Periodic Company Report #WAES 00071366
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Lasix	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3591683-7Report Type:Periodic Company Report #WAES 00071369
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Prothrombin Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591684-9Report Type:Periodic Company Report #WAES 00071376
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3591685-0Report Type:Periodic Company Report #WAES 00071377
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591686-2Report Type:Periodic Company Report #WAES 00071383
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

			Asacol	C		

Date:09/21/00ISR Number: 3591687-4Report Type:Periodic Company Report #WAES 00071384
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591688-6Report Type:Periodic Company Report #WAES 00071386
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591689-8Report Type:Periodic Company Report #WAES 00071389
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Merocet	C				
			Paxil	C				

Date:09/21/00ISR Number: 3591690-4Report Type:Periodic Company Report #WAES 00071390
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591700-4Report Type:Periodic Company Report #WAES 00071391
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:09/21/00ISR Number: 3591701-6Report Type:Periodic Company Report #WAES 00071393
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

Pruritus
Laboratories Div
Merck Co Inc ORAL
25 MG/PO

Cardura	C	
Detrol	C	
Diovan	C	
Hydrodiuril	C	
Prilosec	C	
Proscar	C	

Date:09/21/00ISR Number: 3591703-XReport Type:Periodic Company Report #WAES 00071398
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline Phosphatase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Hepatic Function Abnormal	Company Representative			Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591705-3Report Type:Periodic Company Report #WAES 00071399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Visual Disturbance	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:09/21/00ISR Number: 3591706-5Report Type:Periodic Company Report #WAES 00071402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3591707-7Report Type:Periodic Company Report #WAES 00071405
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3591709-0Report Type:Periodic Company Report #WAES 00071434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Toothache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3591711-9Report Type:Periodic Company Report #WAES 00071450
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591714-4Report Type:Periodic Company Report #WAES 00072260
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	4 DAY
			Bumex	C				
			Hytrin	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591716-8Report Type:Periodic Company Report #WAES 00072270
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hormone Level Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591718-1Report Type:Periodic Company Report #WAES 00072271
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3591720-XReport Type:Periodic Company Report #WAES 00072272
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Cardiac Failure Congestive Low Cardiac Output Syndrome	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591721-1Report Type:Periodic Company Report #WAES 00072273
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:09/21/00ISR Number: 3591726-0Report Type:Periodic Company Report #WAES 00072283
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Face Oedema							
	Headache							
	Oedema Peripheral		Citrucel Orange Flavor	C				
	Pain		Remeron	C				
			Ultram	C				
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591728-4Report Type:Periodic Company Report #WAES 00072294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3591730-2Report Type:Periodic Company Report #WAES 00072303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	3 DAY
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/PO	6 DAY

Date:09/21/00ISR Number: 3591732-6Report Type:Periodic Company Report #WAES 00072309
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Nausea		Hydrodiuril	C				
			Premarin	C				
			Prinivil	C				
			Zantac	C				

Date:09/21/00ISR Number: 3591734-XReport Type:Periodic Company Report #WAES 00072310
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fluid Retention Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Allegra	C	
Dyazide	C	
Effexor	C	
Evista	C	
Neurontin	C	
Calcium Ferrous Citrate	C	

Date:09/21/00ISR Number: 3591735-1Report Type:Periodic Company Report #WAES 00072333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dysphonia Throat Tightness Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Prinivil	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591736-3Report Type:Periodic Company Report #WAES 00072335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							
			Celebrex	C				

Date:09/21/00ISR Number: 3591737-5Report Type:Periodic Company Report #WAES 00072337
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591738-7Report Type:Periodic Company Report #WAES 00072340
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dyspnoea							
			Neurontin	C				
			Progesterone	C				

Date:09/21/00ISR Number: 3591740-5Report Type:Periodic Company Report #WAES 00072356
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591742-9Report Type:Periodic Company Report #WAES 00072357
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Fosamax	C				
			Neurontin	C				
			Ogen	C				
			Medroxyprogesterone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591743-0Report Type:Periodic Company Report #WAES 00072358
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	75	MG/DAILY/PO
			Synthroid	C				
			Estrogenic Peparations	C				

Date:09/21/00ISR Number: 3591745-4Report Type:Periodic Company Report #WAES 00072359
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/BID/PO
			Tab Vioxx 12.5 Mg	SS		ORAL	25	MMG/DAILY/PO;
			Paxil	C			25	MG/DAILY/PO
			Xanax	C				

Date:09/21/00ISR Number: 3591747-8Report Type:Periodic Company Report #WAES 00072362
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Vioxx	PS	Merck Research			

Personality Change Laboratories Div
Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3591749-1Report Type:Periodic Company Report #WAES 00072365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Tenderness Blood Pressure Increased Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Tylenol	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3591750-8Report Type:Periodic Company Report #WAES 00071927
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591751-XReport Type:Periodic Company Report #WAES 00050872
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Feeling Hot Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ativan	C				
			Saridon	C				
			Tylenol	C				
			Aspirin	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3591752-1Report Type:Periodic Company Report #WAES 00071928
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	
			Hydrocodone/Apap	C				
			Lipitor	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591753-3Report Type:Periodic Company Report #WAES 00071929
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3591754-5Report Type:Periodic Company Report #WAES 00071931
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5, 25 MG/DAILY/PO	
			Fosamax	C				
			Synthroid	C				
			Ultram	C				
			Xanax	C				

Date:09/21/00ISR Number: 3591755-7Report Type:Periodic Company Report #WAES 00071932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591756-9Report Type:Periodic Company Report #WAES 00071933
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591757-0Report Type:Periodic Company Report #WAES 00071936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PM/PO	

Date:09/21/00ISR Number: 3591758-2Report Type:Periodic Company Report #WAES 00071939
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:09/21/00ISR Number: 3591759-4Report Type:Periodic Company Report #WAES 00071941
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research			

	Pruritus	Health Professional			Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Allegra	C		
			Centrum Silver	C		
			Detrol	C		
			Diovan Hct	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3591760-0Report Type:Periodic Company Report #WAES 00071947
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Hyzaar	C		
			Neurontin	C		
			Zocor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591761-2Report Type:Periodic Company Report #WAES 00071954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Lasix	C				
			Insulin	C				
			Potassium Supplement	C				
			Pyridoxine	C				
			Thiamine	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3591762-4Report Type:Periodic Company Report #WAES 00071961
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25; 37.5; 50 MG/DAILY/PO	
			Flexeril	C				
			Paxil	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3591763-6Report Type:Periodic Company Report #WAES 00071963
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Lanoxin	C		
Neurontin	C		
Captopril	C		
Vitamins	C		

Date:09/21/00ISR Number: 3591764-8Report Type:Periodic Company Report #WAES 00071968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591765-XReport Type:Periodic Company Report #WAES 00071970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591766-1Report Type:Periodic Company Report #WAES 00071975
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Minocin	C				
			Premarin	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3591767-3Report Type:Periodic Company Report #WAES 00071983
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspepsia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591768-5Report Type:Periodic Company Report #WAES 00071994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591769-7Report Type:Periodic Company Report #WAES 00072008
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Prilosec	C				
			Propulsid	C				
			Rexan (Acyclovir)	C				

Date:09/21/00ISR Number: 3591770-3Report Type:Periodic Company Report #WAES 00072012
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591771-5Report Type:Periodic Company Report #WAES 99061075
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Medication Error	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3591772-7Report Type:Periodic Company Report #WAES 99070434
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Photosensitivity Reaction Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				

Date:09/21/00ISR Number: 3591773-9Report Type:Periodic Company Report #WAES 00050900
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Tenormin	C				
			Postassium Chloride	C				
			Prednisone	C				
			Ubiquinone 50	C				
			Vitamin E	C				
			Vitamins	C				
			Warfarin	C				

Date:09/21/00ISR Number: 3591774-0Report Type:Periodic Company Report #WAES 99071429
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Haemorrhoids	Health			Laboratories Div			
	Mouth Haemorrhage	Professional			Merck Co Inc	ORAL	12.5	MG/AMP/PO
			Lipitor	C				
			Norpace	C				
			Xanax	C				
			Aspirin	C				
			Atenolol	C				
			Warfarin	C				

Date:09/21/00ISR Number: 3591775-2Report Type:Periodic Company Report #WAES 00050970
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Corgard	C				

Norvasc C

Date:09/21/00ISR Number: 3591776-4Report Type:Periodic Company Report #WAES 99091114
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	SS				

Date:09/21/00ISR Number: 3591777-6Report Type:Periodic Company Report #WAES 00051000
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591778-8Report Type:Periodic Company Report #WAES 00051004
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Haematoma International Normalised Ratio Increased Prothrombin Time Ratio Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3591779-XReport Type:Periodic Company Report #WAES 00051006
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anxiety Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	
			Voltaren	C				

Date:09/21/00ISR Number: 3591780-6Report Type:Periodic Company Report #WAES 00051028
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591781-8Report Type:Periodic Company Report #WAES 00051030
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			[Therapy Unspecified]	C				
			Allergenic Extract	C				
			Estrogenic Preparations (Composi	C				

Date:09/21/00ISR Number: 3591782-XReport Type:Periodic Company Report #WAES 00051032
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Blood Pressure Increased Flatulence	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	12 .5 MG/DAILY/PO
			Asacol	C				
			Avapro	C				
			Baycol	C				
			Buspar	C				
			Fiorinal	C				
			Lanoxin	C				
			Lasix	C				
			Nitrostat	C				
			Norvasc	C				
			Premarin	C				
			Slow-K	C				
			Synthroid	C				
			Tylenol	C				

			Xanax	C		

Date:09/21/00ISR Number: 3591783-1Report Type:Periodic Company Report #WAES 00051092
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness Headache Insomnia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Allegra-D	C		
			Cozaar	C		
			Fioricet Tablets	C		
			Levaquin	C		
			Miralax	C		
			Xanax	C		
			Zantac	C		
			[Therapy Unpsecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591784-3Report Type:Periodic Company Report #WAES 00051100
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO; 100	
			Lipitor	C				
			Paxil	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3591785-5Report Type:Periodic Company Report #WAES 00051111
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591786-7Report Type:Periodic Company Report #WAES 00051130
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Chest Pain Pain In Extremity Supraventricular	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO;	

Tachycardia
25

MG/DAILY/PO

Dilantin	C	
Lescol	C	
Aspirin	C	
Atenolol	C	

Date:09/21/00ISR Number: 3591787-9Report Type:Periodic Company Report #WAES 00051138
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Corgard	C				
			Lipitor	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3591788-0Report Type:Periodic Company Report #WAES 00051172
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591789-2Report Type:Periodic Company Report #WAES 00051270
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Thermal Burn				Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Prevacid	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3591790-9Report Type:Periodic Company Report #WAES 00051271
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Palpitations	Health Professional			Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Hydrodiuril	C				
			Miacalcin	C				
			Pravachol	C				
			Prevacid	C				
			Rheumatrex	C				
			Tums	C				
			Aspirin	C				
			Atenolol	C				
			Conjugated Estrogenic Hormones	C				
			Folic Acid	C				
			Vitamin D	C				

Date:09/21/00ISR Number: 3591791-0Report Type:Periodic Company Report #WAES 00051282
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness Drug Ineffective Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

			Serax	C

Date:09/21/00ISR Number: 3591792-2Report Type:Periodic Company Report #WAES 00051284
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Colitis Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO; 12.5 MG;

25 MG

			Allegra	C
			Darvocet-N	C
			Prevalite	C
			Atenolol	C
			Hydrochlorothiazide	C
			Hypercin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591793-4Report Type:Periodic Company Report #WAES 00051323
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Flomax (Tamsulosin (R) -Form Hydr	C				

Date:09/21/00ISR Number: 3591795-8Report Type:Periodic Company Report #WAES 99110133
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk Hallucination Mental Impairment Sedation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3591796-XReport Type:Periodic Company Report #WAES 99120238
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO, 12.5 MG/BID/PO	
			Chondroitin	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3591798-3Report Type:Periodic Company Report #WAES 99122017
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Pain							
	Skin Disorder							
			Regular Strength Doan'S	C				
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3591800-9Report Type:Periodic Company Report #WAES 00072367
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591802-2Report Type:Periodic Company Report #WAES 00072371
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO;	
	Drug Effect Decreased						12.5 MG/DAILY/PO	
	Nausea							
			Coumadin	C				
			Imdur	C				
			Lopressor	C				
			Vasotec	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3591803-4Report Type:Periodic Company Report #WAES 00072372
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Fatigue							
	Oedema Peripheral							
			Lasix	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3591805-8Report Type:Periodic Company Report #WAES 00072375
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Neoplasm							

			Accolate	C
			Atrovent	C
			Flovent	C
			Maxair	C
			Prednisone	C

Date:09/21/00ISR Number: 3591807-1Report Type:Periodic Company Report #WAES 00072378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
			Topamax	C				

Date:09/21/00ISR Number: 3591809-5Report Type:Periodic Company Report #WAES 00072380
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Mevacor	C		
			Verapamil	C		

Date:09/21/00ISR Number: 3591811-3Report Type:Periodic Company Report #WAES 00072381
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591812-5Report Type:Periodic Company Report #WAES 00072383
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazide	C				
			Pravachol	C				
			Prevacid	C				
			Synthroid	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3591813-7Report Type:Periodic Company Report #WAES 00072385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hearing Impaired Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Fosamax	C				
			Antineoplastic Agents (Composition	C				

Date:09/21/00ISR Number: 3591814-9Report Type:Periodic Company Report #WAES 00072387
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/BID/PO; 2) 12.5 MG/DAILY/PO; 3) 25	1 WK
			Prednisolone	C				

Date:09/21/00ISR Number: 3591815-0Report Type:Periodic Company Report #WAES 00072388
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591816-2Report Type:Periodic Company Report #WAES 00072389
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ecotrin	C				
			Flonase	C				
			Prempro	C				
			Prevacid	C				
			Calcium Supplement (Composition	C				
			Cholecalciferol	C				
			Vitamin B Complex	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				
			Zinc Preparation (Composition Un	C				

Date:09/21/00ISR Number: 3591817-4Report Type:Periodic Company Report #WAES 00072392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3591818-6Report Type:Periodic Company Report #WAES 00072394
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO 7 WK

			Demadex	C
			Lopid	C

Date:09/21/00ISR Number: 3591819-8Report Type:Periodic Company Report #WAES 00072395
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Mental Impairment					
25 MG/BID/PO						
			Cortisone	C		

Date:09/21/00ISR Number: 3591820-4Report Type:Periodic Company Report #WAES 00072397
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3591821-6Report Type:Periodic Company Report #WAES 00072398
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Weight Increased	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Aleve	C				
			Compazine	C				
			Novocain	C				

Date:09/21/00ISR Number: 3591822-8Report Type:Periodic Company Report #WAES 00072400
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	

Date:09/21/00ISR Number: 3591823-XReport Type:Periodic Company Report #WAES 00072407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract	Health	Vioxx	PS	Merck Research			
	Infection	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:09/21/00ISR Number: 3591824-1Report Type:Periodic Company Report #WAES 00072431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3592307-5Report Type:Periodic Company Report #WAES 00071585
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592308-7Report Type:Periodic Company Report #WAES 00071586
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592309-9Report Type:Periodic Company Report #WAES 00071589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592310-5Report Type:Periodic Company Report #WAES 00071595
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Flovent	C				
			Plavix	C				
			Zyrtec	C				
			Albuterol	C				

Date:09/21/00ISR Number: 3592311-7Report Type:Periodic Company Report #WAES 00071602
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Nausea Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Claritin	C				
			Norvasc	C				
			Metoprolol Tartrate	C				
			Nitroglycerin	C				

Date:09/21/00ISR Number: 3592312-9Report Type:Periodic Company Report #WAES 00071609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592313-0Report Type:Periodic Company Report #WAES 00071612
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Drug Ineffective							
	Insomnia							
			Hydrodiuril	C				
			Ogen	C				
			Potassium Supplement	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592314-2Report Type:Periodic Company Report #WAES 00071613
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Premarin	C				
			Restoril	C				
			Therapy Unspecified	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3592315-4Report Type:Periodic Company Report #WAES 00071614
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
	Dizziness	Health Professional						
	Erythema							
	Fatigue							
	Sedation		Evista	C				
	Urticaria		Hydrodiuril	C				
			K-Dur	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3592316-6Report Type:Periodic Company Report #WAES 00071618
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gout	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Xanax	C				

Date:09/21/00ISR Number: 3592317-8Report Type:Periodic Company Report #WAES 00071619
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592318-XReport Type:Periodic Company Report #WAES 00071621
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592319-1Report Type:Periodic Company Report #WAES 00071622
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ PO	
			Atenolol Msd	C				
			Synthroid	C				
			Univasc	C				
			Folic Acid	C				

Date:09/21/00ISR Number: 3592320-8Report Type:Periodic Company Report #WAES 00071623
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Prozac	C				
			Cimetidine	C				

Date:09/21/00ISR Number: 3592321-XReport Type:Periodic Company Report #WAES 00071624
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
			Arcet	C				
			Lasix	C				
			Trental	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3592322-1Report Type:Periodic Company Report #WAES 00071625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research			
	Oral Pain				Laboratories Div			
					Merck Co Inc	ORAL		
SEE IMAGE								
			Elisor	C				

Date:09/21/00ISR Number: 3592323-3Report Type:Periodic Company Report #WAES 00071626
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Back Pain	Health			Laboratories Div			
	Blood Pressure Increased	Professional			Merck Co Inc	ORAL		
SEE IMAGE								
	Dermatitis		Pepcid	C				
	Dizziness		Premarin	C				
	Fatigue		Therapy Unsppecified	C				
	Headache							
	Influenza Like Illness							
	Nausea							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592324-5Report Type:Periodic Company Report #WAES 00071627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Dizziness							
	Gastrooesophageal Reflux Disease		Prilosec	C				

Date:09/21/00ISR Number: 3592325-7Report Type:Periodic Company Report #WAES 00071630
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/	DAILY/ PO
			Librax	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3592326-9Report Type:Periodic Company Report #WAES 00071631
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO

Date:09/21/00ISR Number: 3592650-XReport Type:Periodic Company Report #WAES 00071832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Evista	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3592651-1Report Type:Periodic Company Report #WAES 00071835
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Erythema Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Photosensitivity Reaction		Flomax (Niflumic Acid (Beta) -Mor	C				
			Hytrin	C				

Date:09/21/00ISR Number: 3592652-3Report Type:Periodic Company Report #WAES 00071841
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

	Lanoxin	C
	Lasix	C
	Premarin	C
	Prilosec	C
	Dicyclomine Hydrochloride	C
	Verapamil	C

Date:09/21/00ISR Number: 3592656-0Report Type:Periodic Company Report #WAES 00071842
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Elavil	C				
			Fioricet Tablets	C				
			Flexeril	C				
			Premarin	C				
			Tagamet	C				
			Vancenase	C				
			Zestril	C				
			Chlorpheniramine	C				
			Trazodone	C				

Date:09/21/00ISR Number: 3592658-4Report Type:Periodic Company Report #WAES 00071844
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Inderal	C				
			Periactin	C				

Date:09/21/00ISR Number: 3592667-5Report Type:Periodic Company Report #WAES 00071847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3592669-9Report Type:Periodic Company Report #WAES 00071850
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Proscar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592670-5Report Type:Periodic Company Report #WAES 00071851
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592676-6Report Type:Periodic Company Report #WAES 00071852
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Influenza	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Zoloft	C				

Date:09/21/00ISR Number: 3592677-8Report Type:Periodic Company Report #WAES 00071854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592678-XReport Type:Periodic Company Report #WAES 00071855
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			

	Headache				Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Aciphex	C		
			Claritin	C		
			Miacalcin	C		
			Rhinocort	C		
			Serzone	C		
			Xanax	C		
			Propranolol	C		

Date:09/21/00ISR Number: 3592679-1Report Type:Periodic Company Report #WAES 00071856
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Sunburn	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Synthroid	C		
			Estrogenic Preparations (Composi	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592680-8Report Type:Periodic Company Report #WAES 00071872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592681-XReport Type:Periodic Company Report #WAES 00071874
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592682-1Report Type:Periodic Company Report #WAES 00071910
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration Diarrhoea Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Cardizem Cd	C				
			Mevacor	C				
			Nitrostat	C				
			Albuterol	C				
			Theophylline	C				

Date:09/21/00ISR Number: 3592683-3Report Type:Periodic Company Report #WAES 00071917
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1) 25 MG/BID/PO; 2) 25 MG/DAILY/PO						
			Aspirin	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3592684-5Report Type:Periodic Company Report #WAES 00071920
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Mobic	C		
			Synthroid	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592685-7Report Type:Periodic Company Report #WAES 00071923
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nasal Congestion							
			Hydrodiuril	C				
			Lodosyn	C				
			Norvasc	C				
			Aspirin	C				
			Potassium Supplement (Composition	C				

Date:09/21/00ISR Number: 3592686-9Report Type:Periodic Company Report #WAES 00071924
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pruritus							
	Urticaria							
			Celebrex	C				
			Lipitor	C				
			Neurontin	C				
			Plaquenil	C				
			Premarin	C				
			Prilosec	C				
			Prinivil	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3592687-0Report Type:Periodic Company Report #WAES 00071925
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25 MG/BID/PO						
			Vitamins (Unspecified)	C		

Date:09/21/00ISR Number: 3592775-9Report Type:Periodic Company Report #WAES 00071091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Cough					
	Fatigue				Merck Co Inc	ORAL
PO						
	Respiratory Disorder		Baycol	C		
	Vocal Cord Disorder		Plavix	C		
			Premarin	C		
			Prevacid	C		
			Glucosamine	C		
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592794-2Report Type:Periodic Company Report #WAES 00071159
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Interaction							
	Oedema Peripheral							
	Pain		Tab Coumadin	SS		ORAL	2 TO 3 MG/DAILY/PO	
	Prothrombin Time							
	Prolonged		Tab Prinivil 10 Mg	SS			10 MG/DAILY/UNK	
			Metamucil	C				
			Stresstabs Advanced Formula	C				
			Voltaren	C				
			Zocor	C				
			Cortisone	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3592803-0Report Type:Periodic Company Report #WAES 00071165
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoarthritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAIL/PO	
			Cardizem	C				
			Megestrol Acetate	C				

Date:09/21/00ISR Number: 3592806-6Report Type:Periodic Company Report #WAES 00071176
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	18 DAY
			Hydrodiuril	C				
			Hytrin	C				
			Isorbid	C				
			Nitrostat	C				
			Pepcid	C				
			Synthroid	C				
			Aspirin	C				
			B Vitamins	C				
			Glipizide	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3592808-XReport Type:Periodic Company Report #WAES 00071177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592811-XReport Type:Periodic Company Report #WAES 00071180
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Celebrex	C				
			Dyazide	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3592819-4Report Type:Periodic Company Report #WAES 00071181
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	

Date:09/21/00ISR Number: 3592821-2Report Type:Periodic Company Report #WAES 00071187
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Lasix	C				

Date:09/21/00ISR Number: 3592823-6Report Type:Periodic Company Report #WAES 00071188
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Amoxicillin	C				

Date:09/21/00ISR Number: 3592824-8Report Type:Periodic Company Report #WAES 00071191
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	

Date:09/21/00ISR Number: 3592826-1Report Type:Periodic Company Report #WAES 00071192
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ PO	18 MON
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592827-3Report Type:Periodic Company Report #WAES 00071194
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		50 MG/DAILY/	
			Vicodin	C				

Date:09/21/00ISR Number: 3592829-7Report Type:Periodic Company Report #WAES 00071195
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Levaquin	C				
			Prilosec	C				
			Zyrtec	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3592831-5Report Type:Periodic Company Report #WAES 00071198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592833-9Report Type:Periodic Company Report #WAES 00071199
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3592835-2Report Type:Periodic Company Report #WAES 00071200
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Crying Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
			Lorcet 10/650	C				
			Neurontin	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592837-6Report Type:Periodic Company Report #WAES 00071202
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592838-8Report Type:Periodic Company Report #WAES 00071203
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Fatigue							
	Muscle Spasms							
	Night Sweats							
	Sleep Disorder		Ultram	C				

Date:09/21/00ISR Number: 3592840-6Report Type:Periodic Company Report #WAES 00071205
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Avandia	C				
			Cardene	C				
			Glucotrol Xl	C				
			Zantac	C				

			Zestril	C
			Lipitor	C

Date:09/21/00ISR Number: 3592842-XReport Type:Periodic Company Report #WAES 00071212
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research	
	Periodontal Disease				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO 3 WK						
			Estrogenic			
			Preparations	C		

Date:09/21/00ISR Number: 3592844-3Report Type:Periodic Company Report #WAES 00071213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypothyroidism	Consumer	Vioxx	PS	Merck Research	
	Pruritus				Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG/ PO						
			Estrace	C		
			Lanoxin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592847-9Report Type:Periodic Company Report #WAES 00071094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Zyrtec	C				

Date:09/21/00ISR Number: 3592850-9Report Type:Periodic Company Report #WAES 00071097
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Oedema Pain In Extremity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592851-0Report Type:Periodic Company Report #WAES 00071098
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PRN/PO	

Date:09/21/00ISR Number: 3592854-6Report Type:Periodic Company Report #WAES 00071100
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Fatigue				Merck Co Inc	ORAL
UNK/UNK/PO						
	Influenza Like Illness		Levaquin	C		
	Mouth Ulceration		Premarin	C		
	Tongue Disorder		Synthroid	C		
			Imipramine	C		
			Oxybutynin Chloride	C		

Date:09/21/00ISR Number: 3592859-5Report Type:Periodic Company Report #WAES 00071102
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO 30 DAY						
			Cyclobenzaprine	C		
			Hydrocodone	C		

Date:09/21/00ISR Number: 3592861-3Report Type:Periodic Company Report #WAES 00071106
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25 MG/BID/PO

Hydrodiuril	C	
Lipitor	C	
Toprol Xl Tablets	C	
Tylenol	C	

Date:09/21/00ISR Number: 3592864-9Report Type:Periodic Company Report #WAES 00071107
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				

Date:09/21/00ISR Number: 3592866-2Report Type:Periodic Company Report #WAES 00071108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592867-4Report Type:Periodic Company Report #WAES 00071112
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

			Estrogenic Preparations	C		

Date:09/21/00ISR Number: 3592870-4Report Type:Periodic Company Report #WAES 00071113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3592871-6Report Type:Periodic Company Report #WAES 00071115
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592872-8Report Type:Periodic Company Report #WAES 00071117
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Upper Respiratory Tract Infection							
			Maxzide	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3592873-XReport Type:Periodic Company Report #WAES 00071122
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Hytrin	C				
			Amitriptyline	C				
			Antimicrobial Therapy	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3592878-9Report Type:Periodic Company Report #WAES 00071125
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Asthenia							
	Confusional State							
	Fatigue							
	Irritability							
	Sedation							

Date:09/21/00ISR Number: 3592880-7Report Type:Periodic Company Report #WAES 00071126
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema Face Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Osteo-Bi-Flex	C				

Date:09/21/00ISR Number: 3592882-0Report Type:Periodic Company Report #WAES 00071127
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592883-2Report Type:Periodic Company Report #WAES 00071139
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592884-4Report Type:Periodic Company Report #WAES 00071155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592885-6Report Type:Periodic Company Report #WAES 00071156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592887-XReport Type:Periodic Company Report #WAES 00071158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Respiratory Disorder Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3592889-3Report Type:Periodic Company Report #WAES 00071215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Diarrhoea							
	Dry Mouth							
	Fatigue		Dioxanin	C				
			Monopril	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3592891-1Report Type:Periodic Company Report #WAES 00071219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hepatic Function Abnormal							
	Hepatitis C Antibody Positive							
	Jaundice							
	Paraesthesia							
	Pigmentation Disorder							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592892-3Report Type:Periodic Company Report #WAES 00071223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3592895-9Report Type:Periodic Company Report #WAES 00071225
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Verapamil Hydrochloride	C				

Date:09/21/00ISR Number: 3592896-0Report Type:Periodic Company Report #WAES 00071227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	1 WK

Date:09/21/00ISR Number: 3592899-6Report Type:Periodic Company Report #WAES 00071228
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Lasix	C		
			Norvasc	C		
			Vancenase	C		

Date:09/21/00ISR Number: 3592901-1Report Type:Periodic Company Report #WAES 00071238
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Flatulence Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Effexor Xr	C		
			Fosamax	C		
			Ogen	C		
			Prilosec	C		
			Ultram	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592903-5Report Type:Periodic Company Report #WAES 00071240
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Ambien	C				
			Evista	C				

Date:09/21/00ISR Number: 3592904-7Report Type:Periodic Company Report #WAES 00071241
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
			Micronor	C				
			Ultram	C				
			Nortriptyline	C				

Date:09/21/00ISR Number: 3592905-9Report Type:Periodic Company Report #WAES 00071254
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adrenal Insufficiency Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cap Prilosec	SS				
			Celebrex	C				

Date:09/21/00ISR Number: 3592909-6Report Type:Periodic Company Report #WAES 00071259
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592911-4Report Type:Periodic Company Report #WAES 00071265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3592914-XReport Type:Periodic Company Report #WAES 00071267
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colour Blindness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Celebrex	C
Acetaminophen	C
Allopurinol	C
Calcium Supplement	C
Clonidine	C
Estrone Sulfate	
Piperazine Salt	C
Metformin	C
Potassium Supplement	C
Propoxyphene	C
Timolol	C
Vitamin E	C

Date:09/21/00ISR Number: 3592915-1Report Type:Periodic Company Report #WAES 00071269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3592919-9Report Type:Periodic Company Report #WAES 00071270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS		ORAL	PO	

Date:09/21/00ISR Number: 3592922-9Report Type:Periodic Company Report #WAES 00071271
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Peptic Ulcer	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:09/21/00ISR Number: 3592923-0Report Type:Periodic Company Report #WAES 00071277
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prematin	C				
			Provera	C				

Date:09/21/00ISR Number: 3592925-4Report Type:Periodic Company Report #WAES 00071282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 4 DAY

Tylenol Extra
Strength C

Date:09/21/00ISR Number: 3592926-6Report Type:Periodic Company Report #WAES 00071283
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592928-XReport Type:Periodic Company Report #WAES 00071292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	3 DAY

Date:09/21/00ISR Number: 3592929-1Report Type:Periodic Company Report #WAES 00071304
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema Peripheral Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Paxil	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3592930-8Report Type:Periodic Company Report #WAES 00071306
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D	C				
			Zithromax	C				
			Estradiol	C				

Date:09/21/00ISR Number: 3592931-XReport Type:Periodic Company Report #WAES 00071309
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Balance Disorder Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Hydrodiuril	C				
			K-Dur	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592932-1Report Type:Periodic Company Report #WAES 00071320
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	30 DAY

Date:09/21/00ISR Number: 3592933-3Report Type:Periodic Company Report #WAES 00071321
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Feeling Hot Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Maxzide	C				
			Micro K	C				
			Proventil	C				
			Atenolol	C				
			Colchicine	C				

Date:09/21/00ISR Number: 3592934-5Report Type:Periodic Company Report #WAES 00071323
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lexxel	C				
			Synthroid	C				
			Folic Acid	C				
			Methotrexate	C				

Date:09/21/00ISR Number: 3592935-7Report Type:Periodic Company Report #WAES 00071327
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3592936-9Report Type:Periodic Company Report #WAES 00071328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592937-0Report Type:Periodic Company Report #WAES 00071332
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:09/21/00ISR Number: 3592938-2Report Type:Periodic Company Report #WAES 00071333
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation Bradycardia Tachycardia Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Digoxin	C				

Date:09/21/00ISR Number: 3592939-4Report Type:Periodic Company Report #WAES 00071334
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Premarin	C				

Date:09/21/00ISR Number: 3592940-0Report Type:Periodic Company Report #WAES 00071338
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Other	Vioxx	PS	Merck Research			

	Weight Increased				Laboratories Div Merck Co Inc	ORAL
PO						
			Actos	C		
			Amaryl	C		
			Glucophage	C		
			Lipitor	C		
			Lozol	C		

Date:09/21/00ISR Number: 3592941-2Report Type:Periodic Company Report #WAES 00071339
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Gastrointestinal Motility Disorder					
PO						
			Claritin	C		
			Cozaar	C		
			Prilosec	C		
			Zocor	C		
			Chondroitin (+) Glucosamine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592942-4Report Type:Periodic Company Report #WAES 00071340
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				
			Plaquenil	C				
			Rocaltrol	C				

Date:09/21/00ISR Number: 3592943-6Report Type:Periodic Company Report #WAES 00071343
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON
			Imdur	C				
			Lasix	C				
			Verelan	C				
			Atenolol	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3592945-XReport Type:Periodic Company Report #WAES 00071346
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Inderal	C				

Date:09/21/00ISR Number: 3592946-1Report Type:Periodic Company Report #WAES 00071348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592948-5Report Type:Periodic Company Report #WAES 00071349
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;	25 MG/DAILY/PO
			K-Dur	C				
			Lipitor	C				
			Monopril	C				
			Synthroid	C				

			Tiazac	C		
			Furosemide	C		

Date:09/21/00ISR Number: 3592950-3Report Type:Periodic Company Report #WAES 00071351
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Prilosec	C				
			Verelan	C				

Date:09/21/00ISR Number: 3592951-5Report Type:Periodic Company Report #WAES 00071354
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulation Time Prolonged Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/2XW/PO; 25 MG/DAILY/PO	(DURATION: 1
			Ativan	C				
			Coumadin	C				
			Plendil	C				
			Prevacid	C				
			Tenormin	C				
			Gemfibrozil	C				

Date:09/21/00ISR Number: 3592953-9Report Type:Periodic Company Report #WAES 00071760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Tremor							
	Vision Blurred							
			Cozaar	C				
			Fosamax	C				
			Lipitor	C				

Date:09/21/00ISR Number: 3592955-2Report Type:Periodic Company Report #WAES 00071787
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Feeling Abnormal							
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592956-4Report Type:Periodic Company Report #WAES 00071791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Ecchymosis							
	Increased Appetite							
	Weight Increased		Celebrex	C				

Date:09/21/00ISR Number: 3592957-6Report Type:Periodic Company Report #WAES 00071794
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
	Vaginal Haemorrhage							
			Neurontin	C				
			Aspirin	C				
			Calcium Supplement (Composition Chondroitin (+) Glucosamine	C				

Date:09/21/00ISR Number: 3592959-XReport Type:Periodic Company Report #WAES 00071799
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	4 MON
			Synthroid	C				
			Hydralazine	C				

Date:09/21/00ISR Number: 3592961-8Report Type:Periodic Company Report #WAES 00071800
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tenormin	C				

Date:09/21/00ISR Number: 3592962-XReport Type:Periodic Company Report #WAES 00071801
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3592964-3Report Type:Periodic Company Report #WAES 00071803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3592965-5Report Type:Periodic Company Report #00071804
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3592967-9Report Type:Periodic Company Report #WAES 00071807
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Hyperhidrosis Malaise Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aldactazide	C				
			Potassium Supplement (Composition	C				

Date:09/21/00ISR Number: 3592968-0Report Type:Periodic Company Report #WAES 00071809
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			

Weight Increased

Laboratories Div
Merck Co Inc ORAL
PO

Estrogenic
Preparations
(Composi C
Herbal Remedies
(Composition Uns C
Minerals
(Unspecified) (+)
Vitam C
Progesterone C

Date:09/21/00ISR Number: 3592969-2Report Type:Periodic Company Report #WAES 00071810
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3592970-9Report Type:Periodic Company Report #WAES 00071811
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				

Date:09/21/00ISR Number: 3592971-0Report Type:Periodic Company Report #WAES 00071812
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Skelaxin	C				

Date:09/21/00ISR Number: 3592972-2Report Type:Periodic Company Report #WAES 00071816
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Hypoaesthesia Muscular Weakness Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3592973-4Report Type:Periodic Company Report #WAES 00071819
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Coumadin	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3592974-6Report Type:Periodic Company Report #WAES 00071821
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity Varicose Vein	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Premarin	C				

Date:09/21/00ISR Number: 3592976-XReport Type:Periodic Company Report #WAES 00071825
Age: Gender:Female I/FU:I

Outcome	PT
	Ecchymosis Leukopenia

	Neutrophil Count Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3592978-3Report Type:Periodic Company Report #WAES 00071826
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral Varicose Vein	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO

Date:09/21/00ISR Number: 3592979-5Report Type:Periodic Company Report #WAES 00071827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Flat Affect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:09/21/00ISR Number: 3593211-9Report Type:Periodic Company Report #WAES 00071457
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG

DAILY;ORAL

			Ativan	C		

Date:09/21/00ISR Number: 3593212-0Report Type:Periodic Company Report #WAES 00071458
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY;						
ORAL						
			Accupril	C		
			Atrovent	C		
			Indapamide	C		

Date:09/21/00ISR Number: 3593214-4Report Type:Periodic Company Report #WAES 00071471
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG DAILY;						
		Representative				
25 MG; PO						
			Prevacid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593216-8Report Type:Periodic Company Report #WAES 00071475
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Pneumonia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593217-XReport Type:Periodic Company Report #WAES 00071477
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	
			Lipitor	C				
			Chlorporpamide	C				
			Metoprolol Tartrate	C				

Date:09/21/00ISR Number: 3593218-1Report Type:Periodic Company Report #WAES 00071479
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593221-1Report Type:Periodic Company Report #WAES 00071480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593222-3Report Type:Periodic Company Report #WAES 00071487
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:09/21/00ISR Number: 3593224-7Report Type:Periodic Company Report #WAES 00071488
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Urticaria		Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593225-9Report Type:Periodic Company Report #WAES 00071489
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593226-0Report Type:Periodic Company Report #WAES 00071492
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acupril	C				
			Lipitor	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593228-4Report Type:Periodic Company Report #WAES 00071493
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	
			Entex	C				
			Zantac	C				

Date:09/21/00ISR Number: 3593229-6Report Type:Periodic Company Report #WAES 00071496
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vitreous Opacities	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO ; 25 MG DAILY; PO	
			Estraderm	C				
			Xanax	C				
			Zantac	C				

Date:09/21/00ISR Number: 3593231-4Report Type:Periodic Company Report #WAES 00071498
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593232-6Report Type:Periodic Company Report #WAES 00071499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Dyazide C
Estrogenic
Preparations C

Date:09/21/00ISR Number: 3593234-XReport Type:Periodic Company Report #WAES 00071500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593235-1Report Type:Periodic Company Report #WAES 00071508
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	
			Ultram	C				

Date:09/21/00ISR Number: 3593237-5Report Type:Periodic Company Report #WAES 00071511
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	
			Mevacor	C				
			Mirapex	C				

			Sinemet	C		
			Furosemide	C		
			Isosorbide	C		

Date:09/21/00ISR Number: 3593238-7Report Type:Periodic Company Report #WAES 00071512
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID; PO	
			Accupril	C				
			Vicodin Tablets	C				
			Aspirin	C				
			Calcium Supplement	C				
			Cimicifuga	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593240-5Report Type:Periodic Company Report #WAES 00071513
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Dyspnoea Tachypnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593242-9Report Type:Periodic Company Report #WAES 00071516
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3593243-0Report Type:Periodic Company Report #WAES 00071519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593245-4Report Type:Periodic Company Report #WAES 00071522
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO
Lotrel C

Date:09/21/00ISR Number: 3593246-6Report Type:Periodic Company Report #WAES 00071523
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	3 MON

Date:09/21/00ISR Number: 3593247-8Report Type:Periodic Company Report #WAES 00071524
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction Sunburn	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
		Representative	Atenolol	C				

Date:09/21/00ISR Number: 3593249-1Report Type:Periodic Company Report #WAES 00071527
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				
			Xanax	C				
			Zantac	C				

Date:09/21/00ISR Number: 3593250-8Report Type:Periodic Company Report #WAES 00071534
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				
			Synthroid	C				
			Zebeta	C				

Date:09/21/00ISR Number: 3593252-1Report Type:Periodic Company Report #WAES 00071535
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Lipitor	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593253-3Report Type:Periodic Company Report #WAES 00071536
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593255-7Report Type:Periodic Company Report #WAES 00071538
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3593256-9Report Type:Periodic Company Report #WAES 00071539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neoplasm	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Advil	C
Axid	C
Calcijex	C
Epogen	C
Colchicine	C
Metoprolol	C
Prednisone	C

Date:09/21/00ISR Number: 3593257-0Report Type:Periodic Company Report #WAES 00071540
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Face Oedema							
	Rhinorrhoea							
			Fosamax	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593259-4Report Type:Periodic Company Report #WAES 00071541
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							

Date:09/21/00ISR Number: 3593261-2Report Type:Periodic Company Report #WAES 00071544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			

Drug Ineffective
Fatigue
Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Premarin C

Date:09/21/00ISR Number: 3593262-4Report Type:Periodic Company Report #WAES 00071546
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faecal Incontinence							
			Coumadin	C				
			Hytrin	C				
			Lasix	C				
			Prilosec	C				
			Remeron	C				
			Wellbutrin	C				
			Digoxin	C				
			Iron	C				
			Losartan Potassium	C				
			Potassium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593263-6Report Type:Periodic Company Report #WAES 00071548
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Fatigue							
	Oedema Peripheral							
	Weight Increased		Centrum Silver	C				
			Evista	C				
			Hydrocodone/Apap	C				
			Prevacid	C				
			Ascrobic Acid	C				
			Calcium Carbonate	C				
			Chondroitin	C				
			Glucosamine	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3593265-XReport Type:Periodic Company Report #WAES 00071562
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593266-1Report Type:Periodic Company Report #WAES 00071580
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593267-3Report Type:Periodic Company Report #WAES 00071583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Hypersensitivity Oedema Peripheral	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tongue Oedema	Representative	Prilosec	C				

Date:09/21/00ISR Number: 3593269-7Report Type:Periodic Company Report #WAES 00071584
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Fluid Retention Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea		Tab Methotrexate 7.5 Mg	SS		ORAL	7.5 MG/WKY/PO	
			Nabumetone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593270-3Report Type:Periodic Company Report #WAES 00061784
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593271-5Report Type:Periodic Company Report #WAES 00061789
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Triamterene	C				

Date:09/21/00ISR Number: 3593273-9Report Type:Periodic Company Report #WAES 00061790
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tenormin	C				
			Zocor	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593274-0Report Type:Periodic Company Report #WAES 00061791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Diarrhoea Toothache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO	2 WK						
			Vitamins	C			

Date:09/21/00ISR Number: 3593276-4Report Type:Periodic Company Report #WAES 00061793
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3593278-8Report Type:Periodic Company Report #WAES 00061799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593279-XReport Type:Periodic Company Report #WAES 00061821
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593280-6Report Type:Periodic Company Report #WAES 00061822
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Aspartate Aminotransferase Increased		Coumadin	C				
	Gamma-Glutamyltransferase Increased							
	Liver Function Test Abnormal							

Date:09/21/00ISR Number: 3593282-XReport Type:Periodic Company Report #WAES 00061833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593283-1Report Type:Periodic Company Report #WAES 00062976
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593285-5Report Type:Periodic Company Report #WAES 00062977
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
	Faeces Discoloured							
	Headache							
	Oedema Peripheral		Hytrin	C				
			K-Dur	C				
			Lasix	C				
			Neurontin	C				
			Nitro-Bid	C				
			Plavix	C				
			Prevacid	C				
			Requip	C				
			Vicodin Tablets	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593286-7Report Type:Periodic Company Report #WAES 00062985
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Hytrin	C				
			Norvasc	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3593287-9Report Type:Periodic Company Report #WAES 00062988
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Synthroid	C				
			Zestoretic	C				

Date:09/21/00ISR Number: 3593289-2Report Type:Periodic Company Report #WAES 00062991
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Xalatan	C				

Date:09/21/00ISR Number: 3593290-9Report Type:Periodic Company Report #WAES 00062996
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY, PO	
			Vaseretic	C				

Date:09/21/00ISR Number: 3593292-2Report Type:Periodic Company Report #WAES 00062997
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour Dizziness Insomnia Muscular Weakness Nausea Pain Psychomotor Hyperactivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Effexor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593293-4Report Type:Periodic Company Report #WAES 00062999
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3593294-6Report Type:Periodic Company Report #WAES 00063000
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Aldoril	C				
			Levoxyl	C				
			Ascorbic Acid	C				
			Methyldopa	C				

Date:09/21/00ISR Number: 3593296-XReport Type:Periodic Company Report #WAES 00063001
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, BID, PO; 25 MG/DAILY/PO	
			Cozaar	C				
			Premarin	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				
			Furosemide	C				

			Potassium Supplement	C		

Date:09/21/00ISR Number: 3593298-3Report Type:Periodic Company Report #WAES 00063002
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia				Laboratories Div	
					Merck Co Inc	ORAL
25 MG, DAILY,						
PO, 12.5						
MG/DAILY/PO						
			Effexor	C		
			Premarin	C		
			Metoprolol	C		

Date:09/21/00ISR Number: 3593300-9Report Type:Periodic Company Report #WAES 00070969
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593301-0Report Type:Periodic Company Report #WAES 00070980
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / AM/	PO
			Lipitor	C				
			Zantac	C				
			Calcium Supplement	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3593303-4Report Type:Periodic Company Report #WAES 00070982
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PM /	PO
			Elavil	C				
			Provera	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593305-8Report Type:Periodic Company Report #WAES 00070983
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO

			Tab Vioxx	SS		ORAL
25 MG / 1 X / PO						
			Arava	C		
			Calcium Supplement	C		
			Triamterene	C		
			Vitamins	C		
			Prednisone	C		
			Synthroid	C		
			Pepcid	C		

Date:09/21/00ISR Number: 3593306-XReport Type:Periodic Company Report #WAES 00070986
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Petechiae	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY / PO						
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593307-1Report Type:Periodic Company Report #WAES 00070987
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
	Drug Ineffective							
	Dyspepsia							
	Nausea							
			Ultram	C				

Date:09/21/00ISR Number: 3593309-5Report Type:Periodic Company Report #WAES 00070988
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
			Miacalcin	C				
			Prempro	C				
			Prilosec	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				

Date:09/21/00ISR Number: 3593310-1Report Type:Periodic Company Report #WAES 00070989
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
	Pain In Extremity							
			Tab Vioxx	SS		ORAL	25 MG / 1X/	

PO

		Cozaar	C	
		Zoloft	C	

Date:09/21/00ISR Number: 3593312-5Report Type:Periodic Company Report #WAES 00070994
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG / DAILY / PO 1 MON						

Date:09/21/00ISR Number: 3593313-7Report Type:Periodic Company Report #WAES 00070996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / UNK / PO 1 MON						
			Naprosyn	C		
			Zocor	C		
			Digoxin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593315-0Report Type:Periodic Company Report #WAES 00070999
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Lopid	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593316-2Report Type:Periodic Company Report #WAES 00071000
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO

Date:09/21/00ISR Number: 3593318-6Report Type:Periodic Company Report #WAES 00071005
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO

Date:09/21/00ISR Number: 3593319-8Report Type:Periodic Company Report #WAES 00071006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Gemzar	C				

Date:09/21/00ISR Number: 3593321-6Report Type:Periodic Company Report #WAES 00071007
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Lipitor	C				

Date:09/21/00ISR Number: 3593322-8Report Type:Periodic Company Report #WAES 00071011
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO

			Tylenol	C
			Cortisone	C

Date:09/21/00ISR Number: 3593324-1Report Type:Periodic Company Report #WAES 00071019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO 2 WK

Date:09/21/00ISR Number: 3593325-3Report Type:Periodic Company Report #WAES 00071020
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Celebrex	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Chondroitin Sulfate	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3593327-7Report Type:Periodic Company Report #WAES 00071029
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Petechiae	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /	

DAILY / PO

Date:09/21/00ISR Number: 3593329-0Report Type:Periodic Company Report #WAES 00071031
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Health	Vioxx	PS	Merck Research	
	Fatigue	Professional			Laboratories Div	
					Merck Co Inc	ORAL

UNK / UNK /

PO

Date:09/21/00ISR Number: 3593331-9Report Type:Periodic Company Report #WAES 00062693
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL

25 MG/ DAILY/

PO

Advil	C
Covera-Hs	C
Tylenol	C
Vicodin Tablets	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593333-2Report Type:Periodic Company Report #WAES 00062694
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Azmacort	C				
			Cozaar	C				
			Dhea	C				
			Evista	C				
			Serevent	C				
			Testosterone	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3593334-4Report Type:Periodic Company Report #WAES 00062695
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Paxil	C				
			Calcium Supplement	C				
			Estrogenic Preparations	C				
			Methotrexate	C				

Date:09/21/00ISR Number: 3593336-8Report Type:Periodic Company Report #WAES 00062696
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Celebrex 200 Mg	SS		ORAL
200 MG/BID/PO						

Date:09/21/00ISR Number: 3593337-XReport Type:Periodic Company Report #WAES 00062700
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Prevacid	C		
			Prednisolone	C		

Date:09/21/00ISR Number: 3593338-1Report Type:Periodic Company Report #WAES 00062701
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593339-3Report Type:Periodic Company Report #WAES 00062702
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Arthralgia							
	Dizziness							
	Weight Increased							
			Celexa	C			PO	
			Evista	C				
			Fosamax	C				

Date:09/21/00ISR Number: 3593341-1Report Type:Periodic Company Report #WAES 00062704
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593342-3Report Type:Periodic Company Report #WAES 00062707
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia Oesophageal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Hepatic Function Abnormal							
			Tab Vioxx 25 Mg	SS		ORAL	PO 25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593344-7Report Type:Periodic Company Report #WAES 00062708
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia							
	Nasal Congestion							
	Rhinorrhoea		Tab Vioxx 25 Mg	SS		ORAL	PO	
			Diovan	C				
			Hydrodiuril	C				
			Zocor	C				
			Synthroid	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593345-9Report Type:Periodic Company Report #WAES 00062710
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593347-2Report Type:Periodic Company Report #WAES 00062714
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:09/21/00ISR Number: 3593348-4Report Type:Periodic Company Report #WAES 00062716
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	5 MON
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Calcium Supplement	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593350-2Report Type:Periodic Company Report #WAES 00062718
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:09/21/00ISR Number: 3593351-4Report Type:Periodic Company Report #WAES 00062723
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pigmentation Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Lopressor	C				
			Estradiol	C				

Date:09/21/00ISR Number: 3593353-8Report Type:Periodic Company Report #WAES 00062725
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Evista	C				
			Paxil	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593354-XReport Type:Periodic Company Report #WAES 00062726
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Condrotec	C				
			Aspirin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593356-3Report Type:Periodic Company Report #WAES 00062728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593358-7Report Type:Periodic Company Report #WAES 00062729
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Drug Effect Decreased Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Oedema		Ativan	C				
			Buspar	C				

Date:09/21/00ISR Number: 3593360-5Report Type:Periodic Company Report #WAES 00062730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			

	Colonic Atony	Professional			Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL
DAILY/PO						
			Premarin	C		
			Prilosec	C		

Date:09/21/00ISR Number: 3593474-XReport Type:Periodic Company Report #WAES 00052805
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Warfarin	C				

Date:09/21/00ISR Number: 3593475-1Report Type:Periodic Company Report #WAES 00052812
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Lipitor	C
			Premarin	C

Date:09/21/00ISR Number: 3593476-3Report Type:Periodic Company Report #WAES 00052835
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593477-5Report Type:Periodic Company Report #WAES 00052842
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Furosemide	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593478-7Report Type:Periodic Company Report #WAES 00052843
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:09/21/00ISR Number: 3593481-7Report Type:Periodic Company Report #WAES 00052844
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Calan	C				
			Premarin	C				
			Provera	C				
			Levothyroxine Sodium	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593486-6Report Type:Periodic Company Report #WAES 00052850
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neutropenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

				[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3593489-1Report Type:Periodic Company Report #WAES 00052852
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	2 MON
			Norvasc	C				
			Pancrease (Pancreatin)	C				
			Prilosec	C				
			Prinvil	C				

Date:09/21/00ISR Number: 3593491-XReport Type:Periodic Company Report #WAES 00052853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Ambien	C				
			Maxzide	C				
			Ritalin	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3593493-3Report Type:Periodic Company Report #WAES 00052854
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Darvocet-N	SS		
			Ativan	C		
			Ecotrin	C		
			Effexor	C		
			Estraderm	C		
			Imdur	C		
			Lipitor	C		
			Lopressor	C		
			Macrobid	C		
			Norvasc	C		
			Remeron	C		
			Sonata	C		
			Ibuprofen	C		
			Nitroglycerin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593495-7Report Type:Periodic Company Report #WAES 00052855
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Aspirin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593496-9Report Type:Periodic Company Report #WAES 00052858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Bactrim	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3593497-0Report Type:Periodic Company Report #WAES 00052860
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prempro	C				
			Diphenhydramine Hydrochloride	C				

Date:09/21/00ISR Number: 3593498-2Report Type:Periodic Company Report #WAES 00052862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593499-4Report Type:Periodic Company Report #WAES 00052865
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Tab Vioxx	SS		ORAL	PO	
			Insulin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593500-8Report Type:Periodic Company Report #WAES 00052866
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	12.5 MG/BID/ PO	
			Atenolol Msd	C				
			Lasix	C				
			Composition Unspecified	C				
			Phenylpropanolamine Hydrochloride	C				

Date:09/21/00ISR Number: 3593502-1Report Type:Periodic Company Report #WAES 00052867
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Dyspepsia Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				
			Prempro	C				

Date:09/21/00ISR Number: 3593503-3Report Type:Periodic Company Report #WAES 00052868
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Nausea

MG/DAILY/PO

Tab Vioxx 25 Mg	SS		ORAL

25 MG/QID/PO

Neurontin	C		
[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3593505-7Report Type:Periodic Company Report #WAES 00052878
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hypersensitivity Vasculitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25 MG/

DAILY/PO

Tab Vioxx	SS		ORAL

PO

Methadone Hcl	C		
Synthroid	C		
Furosemide	C		
Glucosamine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593507-0Report Type:Periodic Company Report #WAES 00052879
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY

Date:09/21/00ISR Number: 3593510-0Report Type:Periodic Company Report #WAES 00080422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593512-4Report Type:Periodic Company Report #WAES 00080425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593514-8Report Type:Periodic Company Report #WAES 00080431
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:09/21/00ISR Number: 3593515-XReport Type:Periodic Company Report #WAES 00080434
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593517-3Report Type:Periodic Company Report #WAES 00080435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593518-5Report Type:Periodic Company Report #WAES 00080439
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Post Procedural Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593519-7Report Type:Periodic Company Report #WAES 00080440
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
			Motrin	C				

Date:09/21/00ISR Number: 3593521-5Report Type:Periodic Company Report #WAES 00080445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Avapro	C				
			Hydrodiuril	C				
			Prempro	C				
			[Therapy Unspecified]	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3593522-7Report Type:Periodic Company Report #WAES 00080449
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	
			Celebrex	C				
			Xanax	C				
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3593524-0Report Type:Periodic Company Report #WAES 00080453
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dysphonia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Norvasc	C				
			Premarin	C				
			Glucosamine	C				

			Hyoscyamine	C
			Trazodone	C
			Vitamins (Unspecified)	C

Date:09/21/00ISR Number: 3593526-4Report Type:Periodic Company Report #WAES 00080456
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	100-150 MG/DAILY/PO	
			Glucotrol	C				
			Metformin	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3593528-8Report Type:Periodic Company Report #WAES 00080457
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Procardia	C				
			Zocor	C				

Date:09/21/00ISR Number: 3593529-XReport Type:Periodic Company Report #WAES 00080458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Zocor	SS		

Date:09/21/00ISR Number: 3593530-6Report Type:Periodic Company Report #WAES 00080461
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO 4 DAY						
			Norvasc	C		
			Prilosec	C		
			Prinivil	C		
			Synthroid	C		
			Tenormin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593531-8Report Type:Periodic Company Report #WAES 00080465
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3593532-XReport Type:Periodic Company Report #WAES 00080466
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Hyperglycaemia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pravachol	C				
			Univasc	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593533-1Report Type:Periodic Company Report #WAES 00080470
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allopurinol	C				

Date:09/21/00ISR Number: 3593535-5Report Type:Periodic Company Report #WAES 00080473
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593536-7Report Type:Periodic Company Report #WAES 00080475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Diovan	C				

Date:09/21/00ISR Number: 3593537-9Report Type:Periodic Company Report #WAES 00080476
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

				Glucosamine	C		

Date:09/21/00ISR Number: 3593539-2Report Type:Periodic Company Report #WAES 00080478
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	
	Micturition Disorder							
	Tachycardia							
			Accupril	C				
			Levoxyl	C				
			Librium	C				
			Restoril	C				
			Nortriptyline	C				

Date:09/21/00ISR Number: 3593540-9Report Type:Periodic Company Report #WAES 00080480
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /BID/PO	5 DAY
	Micturition Disorder							
	Oedema Peripheral							
	Weight Increased		Estrace	C				

Date:09/21/00ISR Number: 3593542-2Report Type:Periodic Company Report #WAES 00080485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Irritability							
	Personality Change							

			Flomax (Niflumic Acid (Beta)	C
			Hytrin	C

Date:09/21/00ISR Number: 3593543-4Report Type:Periodic Company Report #WAES 00080486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	

Date:09/21/00ISR Number: 3593544-6Report Type:Periodic Company Report #WAES 00080494
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Hypoaesthesia Influenza Like Illness Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acyclovir	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593545-8Report Type:Periodic Company Report #WAES 00080496
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Glucophage	C				
			Lotensin	C				
			Glipizide	C				

Date:09/21/00ISR Number: 3593546-XReport Type:Periodic Company Report #WAES 00080498
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flovent	C				
			Percocet	C				
			Serevent	C				

Date:09/21/00ISR Number: 3593547-1Report Type:Periodic Company Report #WAES 00080499
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cipro	C				
			Duricef	C				
			Fosamax	C				
			Klonopin	C				
			Rocephin	C				
			Tylenol Pm	C				

	Calcium Supplement (Unspecified)	C	
	Vitamins (Unspecified)	C	

Date:09/21/00ISR Number: 3593548-3Report Type:Periodic Company Report #WAES 00080500
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspepsia Oesophageal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593549-5Report Type:Periodic Company Report #WAES 00080502
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593550-1Report Type:Periodic Company Report #WAES 00080506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Glucophage	C				

Date:09/21/00ISR Number: 3593551-3Report Type:Periodic Company Report #WAES 00080507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593552-5Report Type:Periodic Company Report #WAES 00080508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aleve	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3593553-7Report Type:Periodic Company Report #WAES 00080509
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Change Of Bowel Habit Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Haemorrhage		Cardizem Cd	C				
			Imdur	C				
			Lasix	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3593554-9Report Type:Periodic Company Report #WAES 00080510
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Digoxin	C				

Date:09/21/00ISR Number: 3593555-0Report Type:Periodic Company Report #WAES 00080514
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25
MG/DAILY/PO

Detrol	C
Estinyl	C
Tiazac	C
[Therapy Unspecified	C
Allopurinol	C
Aspirin	C
Hydrochlorothiazide (+) Triameter	C
Insulin	C

Date:09/21/00ISR Number: 3593556-2Report Type:Periodic Company Report #WAES 00080515
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholic Hangover	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Fatigue				Merck Co Inc	ORAL	25	
	Headache							

MG/DAILY/PO

Date:09/21/00ISR Number: 3593557-4Report Type:Periodic Company Report #WAES 00080519
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase	Health	Vioxx	PS	Merck Research			
	Increased	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Tiazac	C				

Date:09/21/00ISR Number: 3593558-6Report Type:Periodic Company Report #WAES 00080568
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:09/21/00ISR Number: 3593559-8Report Type:Periodic Company Report #WAES 00080572
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593560-4Report Type:Periodic Company Report #WAES 00041760
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY; PO SEE IMAGE	
			Aldactazide	C				

Asacol	C
Fosamax	C
Paxil	C
Prilosec	C
Questran	C
Synthroid	C

Date:09/21/00ISR Number: 3593561-6Report Type:Periodic Company Report #WAES 00041770
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593562-8Report Type:Periodic Company Report #WAES 00041807
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAIL, 50 MG DAILY;	PO
			Tylenol	C				

Date:09/21/00ISR Number: 3593563-XReport Type:Periodic Company Report #WAES 00041827
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Darvocet-N	C		

Date:09/21/00ISR Number: 3593564-1Report Type:Periodic Company Report #WAES 00041908
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Flatulence	Health			Laboratories Div	
	Hiccups	Professional			Merck Co Inc	ORAL
25 MG DAILY;						
	Vision Blurred					
PO						
			Fosamax	C		
			Provera	C		
			Zoloft	C		

Date:09/21/00ISR Number: 3593565-3Report Type:Periodic Company Report #WAES 00041909
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysuria	Consumer	Vioxx	PS	Merck Research	
	Micturition Disorder	Health			Laboratories Div	
	Pain	Professional			Merck Co Inc	
OPHTHALMIC 25 MG DAILY;						
	Pyrexia					
PO						
			Keflex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593566-5Report Type:Periodic Company Report #WAES 00041930
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperphagia Visual Disturbance	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO
			Synthroid	C				

Date:09/21/00ISR Number: 3593567-7Report Type:Periodic Company Report #WAES 00041942
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Dizziness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;	PO
	Dyspnoea							
	Gastritis Nausea Vomiting		Advil	C				
			Centrum	C				
			Relafen	C				
			Tums	C				
			Glucosamine	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/21/00ISR Number: 3593568-9Report Type:Periodic Company Report #WAES 00041959
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dysentery	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	25 MG DAILY;	PO

Date:09/21/00ISR Number: 3593569-0Report Type:Periodic Company Report #WAES 00042038
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593570-7Report Type:Periodic Company Report #WAES 00042041
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Gastrooesophageal Reflux Disease	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY; PO	
			Vioxx 12.5 Mg	SS		ORAL	12.5 MG DAILY; PO	
			Vioxx 12.5 Mg	SS		ORAL	12.5 MG DAILY; PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593571-9Report Type:Periodic Company Report #WAES 00042095
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research			
	Gastrointestinal	Health			Laboratories Div			
	Infection	Professional			Merck Co Inc	ORAL	PO	
	Urinary Tract Infection							

Date:09/21/00ISR Number: 3593572-0Report Type:Periodic Company Report #WAES 00042101
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Cough	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG DAILY;	
							PO	
			Tessalon	C				

Date:09/21/00ISR Number: 3593573-2Report Type:Periodic Company Report #WAES 00042108
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective				Laboratories Div			
	Nausea				Merck Co Inc	ORAL	25 MG DAILY;	
							PO	
			Klonopin	C				
			Stadol	C				

Date:09/21/00ISR Number: 3593574-4Report Type:Periodic Company Report #WAES 00042111
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	
			Prilosec [Therapy Unspecified]	SS C				

Date:09/21/00ISR Number: 3593575-6Report Type:Periodic Company Report #WAES 00042135
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593576-8Report Type:Periodic Company Report #WAES 00042235
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY;

PO

Estratab C
Wellbutrin C

Date:09/21/00ISR Number: 3593577-XReport Type:Periodic Company Report #WAES 00042236
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Vioxx	PS	Merck Research			
	Tinnitus	Professional			Laboratories Div			
					Merck Co Inc	ORAL		
12.5 MG								
DAILY; PO								
			Vioxx 25 Mg	SS		ORAL		
25 MG DAILY;								
PO								
			Accolate	C				
			Aerobid	C				
			Intal	C				
			Levothroid	C				
			Theo-Dur	C				

Date:09/21/00ISR Number: 3593578-1Report Type:Periodic Company Report #WAES 00042344
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research			
	Mental Impairment				Laboratories Div			
					Merck Co Inc	ORAL		
PO								
			Neurontin	C				
			Robaxin	C				
			Ultram	C				

Date:09/21/00ISR Number: 3593579-3Report Type:Periodic Company Report #WAES 00042348
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Chest Pain	Health			Laboratories Div			
	Dyspepsia	Professional			Merck Co Inc	ORAL	PO	
	Feeling Abnormal		Avapro	C				
	Nausea		[Therapy					
	Pharyngeal Oedema		Unspecified]	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593580-XReport Type:Periodic Company Report #WAES 00062468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593581-1Report Type:Periodic Company Report #WAES 00062469
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3593582-3Report Type:Periodic Company Report #WAES 00062470
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Appetite Disorder Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Bradycardia		Lanoxin	C				
	Chills		Aspirin	C				
	Drug Hypersensitivity Fatigue Gastric Disorder Gastrooesophageal Reflux Disease Malaise Muscular Weakness Nausea Palpitations Peripheral Vascular Disorder Tremor Vertigo							

Date:09/21/00ISR Number: 3593583-5Report Type:Periodic Company Report #WAES 00062471
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50 MG/PO
Zoloft C

Date:09/21/00ISR Number: 3593584-7Report Type:Periodic Company Report #WAES 00062472
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593585-9Report Type:Periodic Company Report #WAES 00062474
Age:76 YR Gender:Male I/FU:I

Outcome	PT
	Headache Vision Blurred

Visual Disturbance

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593586-0Report Type:Periodic Company Report #WAES 00062477
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593587-2Report Type:Periodic Company Report #WAES 00062478
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3593588-4Report Type:Periodic Company Report #WAES 00062480
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Amlodipine	C				
			Clonidine	C				
			Potassium Supplement	C				
			Spironolactone	C				

Date:09/21/00ISR Number: 3593589-6Report Type:Periodic Company Report #WAES 00062481
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aldactone	C				
			Coreg	C				
			Lanoxin	C				
			Lasix	C				
			Lotensin	C				
			Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593590-2Report Type:Periodic Company Report #WAES 00062486
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593591-4Report Type:Periodic Company Report #WAES 00062487
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			K-Dur	C				
			Lasix	C				
			Normodyne	C				
			Paxil	C				

Date:09/21/00ISR Number: 3593592-6Report Type:Periodic Company Report #WAES 00062488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lasix	C				
			Premarin	C				
			Prilosec	C				
			Calcium Supplement	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3593593-8Report Type:Periodic Company Report #WAES 00062490
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Plavix	C				
			Aspirin	C				
			Calcium Citrate	C				

Date:09/21/00ISR Number: 3593594-XReport Type:Periodic Company Report #WAES 00062496
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Didronel	C				
			Hydrodiuril	C				
			Lipitor	C				

			Vasotec	C		

Date:09/21/00ISR Number: 3593595-1Report Type:Periodic Company Report #WAES 00062543
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593596-3Report Type:Periodic Company Report #WAES 00062600
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Advil	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3593597-5Report Type:Periodic Company Report #WAES 00062603
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593598-7Report Type:Periodic Company Report #WAES 00062615
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Prevacid	C				
			Soma	C				
			Synvisc	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593599-9Report Type:Periodic Company Report #WAES 00062628
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Procardia Xl	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593600-2Report Type:Periodic Company Report #WAES 00070427
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593601-4Report Type:Periodic Company Report #WAES 00070443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593602-6Report Type:Periodic Company Report #WAES 00070444
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593603-8Report Type:Periodic Company Report #WAES 00070456
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3593604-XReport Type:Periodic Company Report #WAES 00070461
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Headache							
	Nausea				Merck Co Inc	ORAL	PO	6 WK
	Pollakiuria							
	Urine Abnormality							

Date:09/21/00ISR Number: 3593605-1Report Type:Periodic Company Report #WAES 00070462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593606-3Report Type:Periodic Company Report #WAES 00070463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593607-5Report Type:Periodic Company Report #WAES 00070464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593608-7Report Type:Periodic Company Report #WAES 00070480
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alloprinol	C				
			Darvocet-N	C				
			Mevacor	C				
			Norvasc	C				
			Prilosec	C				
			Clonidine	C				
			Potassium Chloride	C				
			Ranitidine Hydrochloride	C				

Date:09/21/00ISR Number: 3593609-9Report Type:Periodic Company Report #WAES 00070481
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ditropan	C				
			Zoloft	C				
			Amitriptyline Hydrochloride	C				
			Cimetidine	C				
			Clonidine	C				
			Folic Acid	C				
			Hydroxychloroquine Sulfate	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3593610-5Report Type:Periodic Company Report #WAES 00070485
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	
			Tiazac	C				

Date:09/21/00ISR Number: 3593611-7Report Type:Periodic Company Report #WAES 00070489
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Amitriptyline Hydrochloride	C				

Date:09/21/00ISR Number: 3593612-9Report Type:Periodic Company Report #WAES 00070496
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3593613-0Report Type:Periodic Company Report #WAES 00070497
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research			

	Oedema				Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL
25 MG/PO						
			Estinyl	C		
			Toprol Xl Tablets	C		

Date:09/21/00ISR Number: 3593614-2Report Type:Periodic Company Report #WAES 00070499
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25 MG/PO						
			Premarin	C		
			Cortisone	C		

Date:09/21/00ISR Number: 3593615-4Report Type:Periodic Company Report #WAES 00070502
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Muscle Rigidity				Laboratories Div	
	Muscle Spasms				Merck Co Inc	ORAL
1) 12.5						
	Muscular Weakness					
MG/DAILY/PO;						

2) 25

MG/DAILY/PO

Celebrex	C
Dixiben	C
Lipitor	C
Valium	C
Vicodin Tablets	C
Zantac	C
Iron (Unspecified)	C
Metoprolol	C
Vitamins (Unspecified)	C

Date:09/21/00ISR Number: 3593616-6Report Type:Periodic Company Report #WAES 00070503
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Lip Dry Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/PO; 2) 25 MG/PO	
			Lescol	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3593617-8Report Type:Periodic Company Report #WAES 00070505
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Gastritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arava	SS			20 MG	

			Potassium Supplement			
			Unk	SS		
			Prednisone	C		

Date:09/21/00ISR Number: 3593618-XReport Type:Periodic Company Report #WAES 00070506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
			Tylenol With Codeine #3	C				
			Xanax	C				

Date:09/21/00ISR Number: 3593619-1Report Type:Periodic Company Report #WAES 00070508
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Effexor	C				
			Estrogenic					

			Preparations (Composi	C		

Date:09/21/00ISR Number: 3593620-8Report Type:Periodic Company Report #WAES 00070880
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition Unspecified	C				

Date:09/21/00ISR Number: 3593621-XReport Type:Periodic Company Report #WAES 00070885
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Imdur	C				
			Atenolol	C				
			Calcium Supplement	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3593622-1Report Type:Periodic Company Report #WAES 00070902
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593623-3Report Type:Periodic Company Report #WAES 00070927
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Headache							
			Premarin	C				
			Synthroid	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3593624-5Report Type:Periodic Company Report #WAES 00070929
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Faecal Incontinence							
	Oedema Peripheral							
			Lasix	C				
			Potachlor	C				
			Premarin	C				
			Tiazac	C				

			Ultram	C		
			Zocor	C		

Date:09/21/00ISR Number: 3593625-7Report Type:Periodic Company Report #WAES 00070930
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan Hct	C				
			Humibid L.A.	C				

Date:09/21/00ISR Number: 3593627-0Report Type:Periodic Company Report #WAES 00070931
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Celexa	C				
			Protonix	C				
			Clonazepam	C				
			Methotrexate	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3593628-2Report Type:Periodic Company Report #WAES 00070934
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593629-4Report Type:Periodic Company Report #WAES 00070935
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593630-0Report Type:Periodic Company Report #WAES 00070936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593631-2Report Type:Periodic Company Report #WAES 00070937
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593632-4Report Type:Periodic Company Report #WAES 00070938
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Tab Vioxx 12.5	SS		ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:09/21/00ISR Number: 3593633-6Report Type:Periodic Company Report #WAES 00070943
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prothrombin Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Zestril	C				
			Warfarin	C				

Date:09/21/00ISR Number: 3593634-8Report Type:Periodic Company Report #WAES 00070944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593635-XReport Type:Periodic Company Report #WAES 00070954
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3593636-1Report Type:Periodic Company Report #WAES 00070955
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Elavil	C				

			Neurontin	C		
			Plaquenil	C		
			Zocor	C		
			Zoloft	C		
			Atenolol	C		
			Methadone Hydrochloride	C		

Date:09/21/00ISR Number: 3593637-3Report Type:Periodic Company Report #WAES 00070957
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:09/21/00ISR Number: 3593638-5Report Type:Periodic Company Report #WAES 00070962
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3593639-7Report Type:Periodic Company Report #WAES 00070963
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO
Tab Vioxx 25 Mg SS ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3593640-3Report Type:Periodic Company Report #WAES 00070964
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Periodontal Disease							
			Estradiol	C				
			Progesterone	C				

Date:09/21/00ISR Number: 3593641-5Report Type:Periodic Company Report #WAES 00072210
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Diarrhoea	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Glynase Prestab Tablets	C				
Hytrin	C				
Synthroid	C				

Date:09/21/00ISR Number: 3593642-7Report Type:Periodic Company Report #WAES 00072216
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atacand	C				
			Miacalcin	C				
			Premarin	C				
			Zestril	C				

Date:09/21/00ISR Number: 3593643-9Report Type:Periodic Company Report #WAES 00072218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	No Adverse Drug Effect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO;12. 5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593644-0Report Type:Periodic Company Report #WAES 00072219
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593645-2Report Type:Periodic Company Report #WAES 00072220
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	8 DAY
	Anorexia							
	Diarrhoea							
	Flatulence		Advil	C				
			Synthroid	C				
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593646-4Report Type:Periodic Company Report #WAES 00072222
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hytrin	C				
			Indurin	C				
			Prempro	C				

Date:09/21/00ISR Number: 3593648-8Report Type:Periodic Company Report #WAES 00072225
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alcohol Unk	SS				

Date:09/21/00ISR Number: 3593649-XReport Type:Periodic Company Report #WAES 00072228
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Fosamax	C				
			Premarin	C				

Date:09/21/00ISR Number: 3593650-6Report Type:Periodic Company Report #WAES 00080574
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Caltrate	C				
			Monopril	C				
			Norvasc	C				
			Aspirin	C				
			Potassium Supplement	C				
			Vitamins (Unspecifed)	C				

Date:09/21/00ISR Number: 3593651-8Report Type:Periodic Company Report #WAES 00080576
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593652-XReport Type:Periodic Company Report #WAES 00080578
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
			Corgard	C				
			Lasix	C				
			Norvasc	C				
			Aspirin	C				
			Potassium Supplement	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593653-1Report Type:Periodic Company Report #WAES 00080579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
	Back Pain							
	Diarrhoea							
	Dyspepsia		Premarin	C				
	Movement Disorder		Tenormin	C				
	Oedema Peripheral		Acidphilus	C				
	Weight Increased							

Date:09/21/00ISR Number: 3593654-3Report Type:Periodic Company Report #WAES 00080585
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3593655-5Report Type:Periodic Company Report #WAES 00080594
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY; PO	

Date:09/21/00ISR Number: 3593656-7Report Type:Periodic Company Report #WAES 00080595
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cartia	C				
			Lipitor	C				
			Prevacid	C				
			Xanax	C				
			Zantac	C				

	Aspirin	C
	C0lchicine	C
	Hydrochlorothiazide (+) Triamter	C

Date:09/21/00ISR Number: 3593657-9Report Type:Periodic Company Report #WAES 00080596
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Asthenia Diarrhoea Fatigue Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	2 WK

Date:09/21/00ISR Number: 3593658-0Report Type:Periodic Company Report #WAES 00080599
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593660-9Report Type:Periodic Company Report #WAES 00080600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593661-0Report Type:Periodic Company Report #WAES 00080602
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Teveten (Eprosartan)	C				

Date:09/21/00ISR Number: 3593662-2Report Type:Periodic Company Report #WAES 00080603
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593663-4Report Type:Periodic Company Report #WAES 00080607
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
	Balance Disorder							
	Drug Toxicity							
	Gait Disturbance		Astelin	C				
	Hypersomnia		Axid	C				
	Insomnia		Cytomel	C				
	Movement Disorder		Keflex	C				
	Pyrexia		Levoxyl	C				
	Tremor		Lithium Carbonate (Roxane)	C				
	Visual Disturbance		Nasacort	C				
	Vomiting		Ritalin	C				
			Tegretol	C				
			Amoxicillin	C				
			Hormonal Contraceptives (Unspecified)	C				

Date:09/21/00ISR Number: 3593664-6Report Type:Periodic Company Report #WAES 00080609
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Estrogenic Preparations	C				
			Fluoxetine Hydrochloride	C				

Date:09/21/00ISR Number: 3593665-8Report Type:Periodic Company Report #WAES 00080612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia Dyspnoea Fatigue Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 50 MG DAILY; 25 MG/DAILY/PO
			Acupril	C		
			Ativan	C		
			Coumadin	C		
			Elavil	C		
			Estrace	C		
			Micro K	C		
			Zantac	C		
			Ziac	C		
			(Therapy Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593666-XReport Type:Periodic Company Report #WAES 00080613
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Composition Unspecified)	C				
			Aspirin	C				
			Digoxin	C				

Date:09/21/00ISR Number: 3593667-1Report Type:Periodic Company Report #WAES 00080615
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Zestril	C				

Date:09/21/00ISR Number: 3593668-3Report Type:Periodic Company Report #WAES 00080619
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Effexor	C				
			Neurontin	C				
			Clindamycin	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593669-5Report Type:Periodic Company Report #WAES 00080621
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593670-1Report Type:Periodic Company Report #WAES 00080623
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593671-3Report Type:Periodic Company Report #WAES 00070827
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
			Captopril Msd	C				
			Lanoxin	C				
			Lipitor	C				
			(Therapy Unspecified)	C				
			Aspirin	C				
			Cortisone	C				
			Ibuprofen	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3593672-5Report Type:Periodic Company Report #WAES 00070828
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Centrum Silver	C				
			Dolobid	C				
			Lanoxin	C				
			Lopressor	C				
			Tagamet	C				
			Transderm-Nitro	C				
			Valium	C				
			Zocor	C				
			(Therapy Unspecified)	C				
			Aspirin	C				
			Folic Acid	C				
			Pyridoxine	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3593673-7Report Type:Periodic Company Report #WAES 00070829
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3593674-9Report Type:Periodic Company Report #WAES 00070830
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 DAY
			Celebrex	C				
			Hydrodiuril	C				
			(Therapy Unspecified)	C				

			Potassium Supplement (Compositio	C		
			Tamoxifen	C		

Date:09/21/00ISR Number: 3593675-0Report Type:Periodic Company Report #WAES 00070831
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastritis							
	Hyperhidrosis							
	Tremor							
			Lopressor	C				

Date:09/21/00ISR Number: 3593676-2Report Type:Periodic Company Report #WAES 00070832
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:09/21/00ISR Number: 3593677-4Report Type:Periodic Company Report #WAES 00070834
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	2 DAY
			Glucophage	C				
			Glucotrol	C				

			Tenormin	C		
			Aspirin	C		

Date:09/21/00ISR Number: 3593678-6Report Type:Periodic Company Report #WAES 00070839
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lescol	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593679-8Report Type:Periodic Company Report #WAES 00070847
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Buspar	C		
				Premarin	C		
				Synthroid	C		

Date:09/21/00ISR Number: 3593680-4Report Type:Periodic Company Report #WAES 00070848
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Motrin	C				
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593681-6Report Type:Periodic Company Report #WAES 00070849
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 50 MG/PO	

Date:09/21/00ISR Number: 3593682-8Report Type:Periodic Company Report #WAES 00070859
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			(Therapy Unspecified)	C

Date:09/21/00ISR Number: 3593683-XReport Type:Periodic Company Report #WAES 00070863
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Oedema Peripheral					
	Weight Increased				Merck Co Inc	ORAL
PO						
			Cardura	C		
			Spironolactone	C		

Date:09/21/00ISR Number: 3593684-1Report Type:Periodic Company Report #WAES 00070867
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Neoplasm	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Papilloedema					
					Merck Co Inc	ORAL
PO						
			Lipitor	C		
			Norvasc	C		
			(Therapy			

Unspecified) C

Date:09/21/00ISR Number: 3593685-3Report Type:Periodic Company Report #WAES 00070868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593686-5Report Type:Periodic Company Report #WAES 00070870
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Vocal Cord Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Zantac	C				
			Codeine	C				

Date:09/21/00ISR Number: 3593687-7Report Type:Periodic Company Report #WAES 00070873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593688-9Report Type:Periodic Company Report #WAES 00070876
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hyzaar	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3593689-0Report Type:Periodic Company Report #WAES 00070877
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestril	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593690-7Report Type:Periodic Company Report #WAES 00070879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:09/21/00ISR Number: 3593691-9Report Type:Periodic Company Report #WAES 00070754
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593692-0Report Type:Periodic Company Report #WAES 00070755
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593693-2Report Type:Periodic Company Report #WAES 00070756
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG/PO;						
25MG/PO						
			Diovan	C		

Date:09/21/00ISR Number: 3593694-4Report Type:Periodic Company Report #WAES 00070762
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hyaluronic Acid	C				

Date:09/21/00ISR Number: 3593695-6Report Type:Periodic Company Report #WAES 00070764
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593696-8Report Type:Periodic Company Report #WAES 00070778
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:09/21/00ISR Number: 3593697-XReport Type:Periodic Company Report #WAES 00070789
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593698-1Report Type:Periodic Company Report #WAES 00070800
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Astelin	C				
			Ativan	C				
			Carafate	C				
			Hydrodiuril	C				
			Norvasc	C				
			Prilosec	C				
			Toprol Xl Tablets	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3593699-3Report Type:Periodic Company Report #WAES 00070801
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
25 MG/DAILY						
			K-Dur	C		
			Norvasc	C		
			Prinivil	C		
			Lorazepam	C		
			Metoprolol	C		

Date:09/21/00ISR Number: 3593700-7Report Type:Periodic Company Report #WAES 00070809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593701-9Report Type:Periodic Company Report #WAES 00070811
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Metamucil	C				
			Prilosec	C				
			Ultram	C				
			Aspirin	C				
			Insulin Injection (+) Isophane	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3593702-0Report Type:Periodic Company Report #WAES 00070812
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lithium Carbonate (Roxane)	C				
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593703-2Report Type:Periodic Company Report #WAES 00070816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

					Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Evista	C		
			[Therapy			
			Unspecified]	C		

Date:09/21/00ISR Number: 3593704-4Report Type:Periodic Company Report #WAES 00070819
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research	
	Mental Impairment				Laboratories Div	
	Muscular Weakness				Merck Co Inc	ORAL
25 MG/1X/PO						
			Dolobid	C		
			Levoxyl	C		
			Norvasc	C		
			(Therapy			
			Unspecified)	C		
			Chlordiazepoxide			
			Hydrochloride	C		
			Estradiol	C		
			Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593705-6Report Type:Periodic Company Report #WAES 00070820
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593706-8Report Type:Periodic Company Report #WAES 00070821
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593707-XReport Type:Periodic Company Report #WAES 00070822
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593708-1Report Type:Periodic Company Report #WAES 00070823
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3593709-3Report Type:Periodic Company Report #WAES 00070824
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

Date:09/21/00ISR Number: 3593710-XReport Type:Periodic Company Report #WAES 00070825
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593711-1Report Type:Periodic Company Report #WAES 00081021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY
			Celebrex	C				

Date:09/21/00ISR Number: 3593712-3Report Type:Periodic Company Report #WAES 00081024
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timoptic-Xe	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3593713-5Report Type:Periodic Company Report #WAES 00081037
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Olfactory Nerve Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Luvox	C				

Date:09/21/00ISR Number: 3593714-7Report Type:Periodic Company Report #WAES 00081038
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

Vocal Cord Disorder Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3593715-9Report Type:Periodic Company Report #WAES 00081039
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3593716-0Report Type:Periodic Company Report #WAES 00081042
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Elavil	C				

Flexeril	C	
Tylenol With Codeine #3	C	

Date:09/21/00ISR Number: 3593717-2Report Type:Periodic Company Report #WAES 00081043
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Asthenia							
	Fatigue							
	Malaise		Vicodin Tablets	C				

Date:09/21/00ISR Number: 3593718-4Report Type:Periodic Company Report #WAES 00060968
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593719-6Report Type:Periodic Company Report #WAES 00081044
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
	Flushing							
	Headache							
	Influenza Like Illness							
	Muscular Weakness							
	Nausea							
	Sedation							

Date:09/21/00ISR Number: 3593720-2Report Type:Periodic Company Report #WAES 00060972
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:09/21/00ISR Number: 3593721-4Report Type:Periodic Company Report #WAES 00060973
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Fluid Retention Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synvisc	C				
			Glucosamine	C				
			Vitamin E	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593722-6Report Type:Periodic Company Report #WAES 00060974
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Advil	C				
			Zantac	C				

Date:09/21/00ISR Number: 3593723-8Report Type:Periodic Company Report #WAES 00060976
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Vasotec	C				

Date:09/21/00ISR Number: 3593724-XReport Type:Periodic Company Report #WAES 00081047
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tenormin	C				

Date:09/21/00ISR Number: 3593725-1Report Type:Periodic Company Report #WAES 00060978
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Interstitial Lung Disease Pulmonary Fibrosis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Glucotrol	C		
			Prevacid	C		
			Tricloryl	C		

Date:09/21/00ISR Number: 3593726-3Report Type:Periodic Company Report #WAES 00081050
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tongue Discolouration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Centrum Silver 1 Tablet	SS		ORAL
1 TABLET/DAILY/ PO						
			Acetylsalicylsalicylic Acid	C		
			Calcium Carbonate (+) Cholecalci	C		
			Metoprolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593727-5Report Type:Periodic Company Report #WAES 00060979
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Gastric Ulcer							
	Nausea							
			Cardioiquin	C				
			Hydrodiuril	C				
			Ticlid	C				

Date:09/21/00ISR Number: 3593728-7Report Type:Periodic Company Report #WAES 00060983
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593729-9Report Type:Periodic Company Report #WAES 00081055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral	Other						
	Renal Disorder							
			Advil	SS		ORAL	PO	
			Celocoxib	SS		ORAL	PO	

Date:09/21/00ISR Number: 3593730-5Report Type:Periodic Company Report #WAES 00060986
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pneumonia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO 5 MON						
			Neoral	C		
			Prevacid	C		
			Methotrexate	C		

Date:09/21/00ISR Number: 3593731-7Report Type:Periodic Company Report #WAES 00081082
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Imitrex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593732-9Report Type:Periodic Company Report #WAES 00060990
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593733-0Report Type:Periodic Company Report #WAES 00060991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593734-2Report Type:Periodic Company Report #WAES 00060992
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593735-4Report Type:Periodic Company Report #WAES 00061006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:09/21/00ISR Number: 3593736-6Report Type:Periodic Company Report #WAES 00081088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Premarin	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3593737-8Report Type:Periodic Company Report #WAES 00061014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Genital Oral Soft Tissue Disorder Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593738-XReport Type:Periodic Company Report #WAES 00081089
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593739-1Report Type:Periodic Company Report #WAES 00061018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		DAILY	

Date:09/21/00ISR Number: 3593740-8Report Type:Periodic Company Report #WAES 00061020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lactaid Caplets	C				

Date:09/21/00ISR Number: 3593741-XReport Type:Periodic Company Report #WAES 00081107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593742-1Report Type:Periodic Company Report #WAES 00061027
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Liver Function Test Abnormal							
			Adalat	C				
			Beclovent	C				
			Claritin	C				
			Evista	C				
			Fiorinal	C				
			Albuterol	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3593743-3Report Type:Periodic Company Report #WAES 00061029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593744-5Report Type:Periodic Company Report #WAES 00061036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:09/21/00ISR Number: 3593745-7Report Type:Periodic Company Report #WAES 00081109
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593746-9Report Type:Periodic Company Report #WAES 00061043
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synvisc	C				
			Atenolol	C				
			Fosinopril Sodium Salt	C				
			Ibuprofen	C				

Date:09/21/00ISR Number: 3593747-0Report Type:Periodic Company Report #WAES 00081113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593748-2Report Type:Periodic Company Report #WAES 00081117
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspnoea Influenza Like Illness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Zocor	C				

Date:09/21/00ISR Number: 3593750-0Report Type:Periodic Company Report #WAES 00081118
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Sleep Disorder Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593752-4Report Type:Periodic Company Report #WAES 00081119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593754-8Report Type:Periodic Company Report #WAES 00080962
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Lipitor	C				
			Pepcid	C				
			Prinivil	C				
			Alprazolam	C				

Date:09/21/00ISR Number: 3593755-XReport Type:Periodic Company Report #WAES 00080971
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Neurontin	C				
			Pepcid	C				

			Premarin	C		
			Calcium Supplement	C		
			Potassium Chloride	C		

Date:09/21/00ISR Number: 3593756-1Report Type:Periodic Company Report #WAES 00080974
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Celebrex	C		
			Cozaar	C		
			Hydrodiuril	C		
			Macrodantin	C		
			Prevacid	C		
			Zocor	C		

Date:09/21/00ISR Number: 3593757-3Report Type:Periodic Company Report #WAES 00080979
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3593758-5Report Type:Periodic Company Report #WAES 00080980
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
	Diarrhoea							
			Trimpex	C				
			Digitalis	C				

Date:09/21/00ISR Number: 3593759-7Report Type:Periodic Company Report #WAES 00080982
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chills							
	Confusional State							
	Dry Mouth		Imitrex	C				
	Face Oedema		Premarin	C				
	Fatigue		[Therapy Unspecified]	C				
	Headache		Oxycodone	C				
	Hypoaesthesia							
	Oedema Peripheral							
	Pain							
	Pyrexia							
	Respiratory Disorder							
	Tachycardia							
	Tremor							
	Urinary Tract Disorder							

Date:09/21/00ISR Number: 3593760-3Report Type:Periodic Company Report #WAES 00032691
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				
			Plavix	C				
			Premarin	C				
			Tenormin	C				
			Univasc	C				
			Potassium Supplement (Compositio	C				
			Sertraline Hydrochloride	C				

Date:09/21/00ISR Number: 3593761-5Report Type:Periodic Company Report #WAES 00080985
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Tenormin	C	
Isosorbide	C	

Date:09/21/00ISR Number: 3593762-7Report Type:Periodic Company Report #WAES 00080986
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593763-9Report Type:Periodic Company Report #WAES 00032753
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				
			Claritin	C				
			Flonase	C				
			Singulair	C				
			Albuterol	C				

Date:09/21/00ISR Number: 3593764-0Report Type:Periodic Company Report #WAES 00080991
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Fosamax	C				
			Motrin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593765-2Report Type:Periodic Company Report #WAES 00080995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593766-4Report Type:Periodic Company Report #WAES 00032940
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3593767-6Report Type:Periodic Company Report #WAES 00080997
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593768-8Report Type:Periodic Company Report #WAES 00033018
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Pravachol	C				
			Zestril	C				

Date:09/21/00ISR Number: 3593769-XReport Type:Periodic Company Report #WAES 00033019
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593770-6Report Type:Periodic Company Report #WAES 00080998
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Ogen	C				

Date:09/21/00ISR Number: 3593771-8Report Type:Periodic Company Report #WAES 00040002
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Chondroitin	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593772-XReport Type:Periodic Company Report #WAES 00040055
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Celebrex	C				
			Cozaar	C				
			Lasix	C				
			Premarin	C				
			Tenormin	C				

Date:09/21/00ISR Number: 3593773-1Report Type:Periodic Company Report #WAES 00040155
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Oedema Peripheral Pulmonary Congestion	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Fibercon	C				
			Glucotrol	C				
			Miacalcin	C				
			Pepcid	C				
			Prozac	C				
			Aspirin	C				
			Calcium Supplement (Composition	C				
			Fish Oil (Composition Unspecifie	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593774-3Report Type:Periodic Company Report #WAES 00040159
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:09/21/00ISR Number: 3593775-5Report Type:Periodic Company Report #WAES 00040180
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593776-7Report Type:Periodic Company Report #WAES 00040224
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem Cd	C				
			Celebrex	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3593777-9Report Type:Periodic Company Report #WAES 00040311
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Acetaminophen	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593778-0Report Type:Periodic Company Report #WAES 00040325
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vasotec	C				

Date:09/21/00ISR Number: 3593779-2Report Type:Periodic Company Report #WAES 00040328
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25; 12.5 MG/DAILY/PO	
			Fosamax	C				
			Prempro	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593780-9Report Type:Periodic Company Report #WAES 00040337
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Chest Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia		Lipitor	SS				
	Ecchymosis		Celexa	C				
	Fatigue		Prilosec	C				
	Pancreatitis		Xanax	C				
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593781-0Report Type:Periodic Company Report #WAES 00040339
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593782-2Report Type:Periodic Company Report #WAES 00040412
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593783-4Report Type:Periodic Company Report #WAES 00040466
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Change Of Bowel Habit	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Cozaar	C				
			Neurontin	C				
			Provest	C				
			Zocor	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593784-6Report Type:Periodic Company Report #WAES 00040539
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Pain Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593785-8Report Type:Periodic Company Report #WAES 00040540
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3593786-XReport Type:Periodic Company Report #WAES 00080999
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3593787-1Report Type:Periodic Company Report #WAES 00030253
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Arthralgia	Health			Laboratories Div			
	Drug Ineffective	Professional			Merck Co Inc	ORAL	12.5	
	Hepatic Function Abnormal						MG/DAILY/PO	
	Nausea		Dyazide	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3593788-3Report Type:Periodic Company Report #WAES 00030422
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	4 WK

Date:09/21/00ISR Number: 3593789-5Report Type:Periodic Company Report #WAES 00030665
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Vioxx	PS	Merck Research			
	Drug Ineffective	Professional			Laboratories Div			
	Joint Stiffness				Merck Co Inc	ORAL	25	
	Joint Swelling						MG/DAILY/PO	
	Muscle Rigidity		Inj Synvisc	SS		ORAL	2 ML/WKY/INJ	

			Analgesic Or Anesthetic Preparat	C		

Date:09/21/00ISR Number: 3593790-1Report Type:Periodic Company Report #WAES 00030720
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Compazine	C				
			Flexeril	C				
			Imitrex	C				
			Klonopin	C				
			Luvox	C				
			Midrin	C				
			Ms Contin	C				
			Serzone	C				
			Synthroid	C				
			Ultram	C				
			Baclofen	C				
			Nadolol	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593791-3Report Type:Periodic Company Report #WAES 00030744
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Cough							
	Dyspnoea							
	Oedema Peripheral		Cozaar	C				
			Diabeta	C				
			Glucophage	C				
			Lopid	C				
			Rezulin	C				
			Zocor	C				

Date:09/21/00ISR Number: 3593792-5Report Type:Periodic Company Report #WAES 00081000
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Carisoprodol	C				

Date:09/21/00ISR Number: 3593793-7Report Type:Periodic Company Report #WAES 00030760
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hearing Impaired	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	SS				
			Sectral	C				

			Synthroid	C
			Zocor	C

Date:09/21/00ISR Number: 3593794-9Report Type:Periodic Company Report #WAES 00081001
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO; 75 MG/DAILY/PO						
			Neurontin	C		
			Zanaflex	C		

Date:09/21/00ISR Number: 3593795-0Report Type:Periodic Company Report #WAES 00030938
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO; 25						

MG/BID/PO; 50

MG/AM/PO

Therapy Unspecified	C	
Coumadin	C	
Darvocet-N	C	

Date:09/21/00ISR Number: 3593796-2Report Type:Periodic Company Report #WAES 00031000
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Fungal Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Advil	C	
Atacand	C	
Ccepacol	C	
Hydrodiuril	C	
Klor-Con	C	
Vasotec	C	
Composition Unspecified	C	
Allopurinol	C	

Date:09/21/00ISR Number: 3593797-4Report Type:Periodic Company Report #WAES 00031483
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593798-6Report Type:Periodic Company Report #WAES 00081002
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO; 12.5 MG/BID/PO						
			Prempro	C		

Date:09/21/00ISR Number: 3593799-8Report Type:Periodic Company Report #WAES 00081010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/PO						
			Cardura	C		
			Corgard	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593800-1Report Type:Periodic Company Report #WAES 00081014
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Bronchitis							
	Cardiac Disorder							
			Avapro	C				
			Claritin	C				
			Hydrodiuril	C				
			Prilosec	C				
			Zocor	C				
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3593801-3Report Type:Periodic Company Report #WAES 00081016
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Fosamax	C				
			Synthroid	C				
			Zocor	C				
			Doxepin	C				

Date:09/21/00ISR Number: 3593802-5Report Type:Periodic Company Report #WAES 00081017
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:09/21/00ISR Number: 3593803-7Report Type:Periodic Company Report #WAES 00052881
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Coumadin	C				
			Lanoxin	C				
			Lipitor	C				
			Premarin	C				

Date:09/21/00ISR Number: 3593804-9Report Type:Periodic Company Report #WAES 00052882
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593805-0Report Type:Periodic Company Report #WAES 00052888
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Buspar	C				
			Dalmane	C				
			Dilantin	C				
			Lamictal	C				
			Soma	C				
			Zanaflex	C				

Date:09/21/00ISR Number: 3593806-2Report Type:Periodic Company Report #WAES 00052890
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY

Date:09/21/00ISR Number: 3593807-4Report Type:Periodic Company Report #WAES 00052891
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Claritin	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593808-6Report Type:Periodic Company Report #WAES 00052902
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593809-8Report Type:Periodic Company Report #WAES 00052903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
		Representative	Amaryl	C				
			Demadex	C				
			Flomax (Tamsulosin (R)-Form Hydr	C				
			Verelan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593810-4Report Type:Periodic Company Report #WAES 00052904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593811-6Report Type:Periodic Company Report #WAES 00052905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593812-8Report Type:Periodic Company Report #WAES 00031622
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Fluid Retention Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			L-Thyroxine	C				
			Paxil	C				

Date:09/21/00ISR Number: 3593813-XReport Type:Periodic Company Report #WAES 00031651
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5

MG/BID/PO

Tenormin	C	
Verappamil Msd Lp	C	
Zestril	C	
Lorazepam	C	

Date:09/21/00ISR Number: 3593814-1Report Type:Periodic Company Report #WAES 00031681
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:09/21/00ISR Number: 3593815-3Report Type:Periodic Company Report #WAES 00052906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased Hepatic Function Abnormal	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Methotrexate	C		

Date:09/21/00ISR Number: 3593816-5Report Type:Periodic Company Report #WAES 00052914
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3593817-7Report Type:Periodic Company Report #WAES 00032217
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Breast Pain Drug Interaction Vaginal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Prempro	SS		
			Therapy Unspecified	C		

Date:09/21/00ISR Number: 3593818-9Report Type:Periodic Company Report #WAES 00032272
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective Hiccups	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3593819-0Report Type:Periodic Company Report #WAES 00032307
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Phenobarbital	SS				

Date:09/21/00ISR Number: 3593820-7Report Type:Periodic Company Report #WAES 00052918
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593821-9Report Type:Periodic Company Report #WAES 00032309
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Lozol	C				
			Norvasc	C				
			Prevacid	C				
			Tenormin	C				
			Potassium Chloride	C				

Date:09/21/00ISR Number: 3593822-0Report Type:Periodic Company Report #WAES 00052933
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Ogen	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3593823-2Report Type:Periodic Company Report #WAES 00032468
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Accupril	C				

			Flexeril	C		
			Lasix	C		
			Slow-K	C		
			Insulin	C		

Date:09/21/00ISR Number: 3593824-4Report Type:Periodic Company Report #WAES 00032519
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Hydrocodone	C				

Date:09/21/00ISR Number: 3593825-6Report Type:Periodic Company Report #WAES 00032661
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593826-8Report Type:Periodic Company Report #WAES 00052937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593827-XReport Type:Periodic Company Report #WAES 00032684
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:09/21/00ISR Number: 3593828-1Report Type:Periodic Company Report #WAES 00052939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593829-3Report Type:Periodic Company Report #WAES 00052940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3593830-XReport Type:Periodic Company Report #WAES 00052941
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593831-1Report Type:Periodic Company Report #WAES 00052942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593832-3Report Type:Periodic Company Report #WAES 00052948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3593833-5Report Type:Periodic Company Report #WAES 00052950
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dyspnoea							
	Gastrooesophageal Reflux				Merck Co Inc	ORAL	PO	
	Disease							
	Oedema							

Date:09/21/00ISR Number: 3593834-7Report Type:Periodic Company Report #WAES 00052962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593835-9Report Type:Periodic Company Report #WAES 00052964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Joint Stiffness							
					Merck Co Inc	ORAL	PO	
			Advil	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3593836-0Report Type:Periodic Company Report #WAES 00052966
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593837-2Report Type:Periodic Company Report #WAES 00061992
Age:74 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Alphagan	C				
			Climara	C				
			Flonase	C				
			Prilosec	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593838-4Report Type:Periodic Company Report #WAES 00061994
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Hytrin	C				
			Prilosec	C				
			Synthroid	C				
			Zocor	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Tiramter	C				
			Metochlopramide	C				
			Triazolam	C				

Date:09/21/00ISR Number: 3593839-6Report Type:Periodic Company Report #WAES 00081908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593840-2Report Type:Periodic Company Report #WAES 00081909
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Antineoplastic	C				

Date:09/21/00ISR Number: 3593841-4Report Type:Periodic Company Report #WAES 00081910
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593842-6Report Type:Periodic Company Report #WAES 00081911
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593843-8Report Type:Periodic Company Report #WAES 00081917
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Minitran	C				
			Norvasc	C				
			Allopurinol	C				
			Ranitidine	C				

Date:09/21/00ISR Number: 3593844-XReport Type:Periodic Company Report #WAES 00062009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593845-1Report Type:Periodic Company Report #WAES 00082005
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593846-3Report Type:Periodic Company Report #WAES 00062014
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						
			Celebrex	C		
			Spironolactone	C		

Date:09/21/00ISR Number: 3593847-5Report Type:Periodic Company Report #WAES 00082050
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3593848-7Report Type:Periodic Company Report #WAES 00062016
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY						
PO						
			Fosamax	C		

Tegretol C

Date:09/21/00ISR Number: 3593849-9Report Type:Periodic Company Report #WAES 00082136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Tinea Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593850-5Report Type:Periodic Company Report #WAES 00082141
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593851-7Report Type:Periodic Company Report #WAES 00062017
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3593852-9Report Type:Periodic Company Report #WAES 00082292
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Company Merck Co Inc ORAL
25
Representative
MG/DAILY/PO
Prinzide C
Soma C

Date:09/21/00ISR Number: 3593853-0Report Type:Periodic Company Report #WAES 00090298
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593854-2Report Type:Periodic Company Report #WAES 00021486
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593855-4Report Type:Periodic Company Report #WAES 00021718
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinitis Sinusitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Tab Vioxx 25 Mg	SS		ORAL	25	MG/DAILY/PO
			Ecotrin	C				
			Rhinocort	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3593856-6Report Type:Periodic Company Report #WAES 00062021
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Cholecystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Neurontin	C				
			Prevacid	C				
			Seroquel	C				
			Nadolol	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593857-8Report Type:Periodic Company Report #WAES 00022035
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Hypoaesthesia	Professional			Merck Co Inc	ORAL
12.5						
	Oral Pain					
MG/DAILY/PO						
	Palpitations		Tab Vioxx 25 Mg	SS		ORAL
25/MG/DAILY/P						
	Pollakiuria					
O						
			Betoptic	C		
			Fosamax	C		
			Premarin	C		
			Tums	C		
			Tylenol	C		
			Xalatan	C		
			(Therapy Unspecified)	C		
			Calcium Supplement	C		
			Vitamin E	C		

Date:09/21/00ISR Number: 3593858-XReport Type:Periodic Company Report #WAES 00062024
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Fatigue				Laboratories Div	
	Influenza Like Illness				Merck Co Inc	ORAL
PO 1 MON						
	Upper Respiratory Tract Infection		Tenormin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593859-1Report Type:Periodic Company Report #WAES 00022082
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Epistaxis	Health						
	Oedema Peripheral	Professional			Merck Co Inc	ORAL	25	
	Swelling						MG/DAILY/PO	
			Actifed	C				
			Allerfrim	C				
			Prilosec	C				
			Wellbutrin	C				
			[Therapy Unspecified]	C				
			Chlorpheniramine	C				
			Dicyclomine Hydrochloride	C				
			Erythromycin	C				
			Guaifenesin	C				
			Metoprolol	C				
			Sulfasalazine	C				

Date:09/21/00ISR Number: 3593860-8Report Type:Periodic Company Report #WAES 00022209
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Detrol	C				
			Levothroid	C				
			Zocor	C				
			Atenolol	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3593861-XReport Type:Periodic Company Report #WAES 00062025
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
			Atenolol (+) Chlorthalidone	C				

Date:09/21/00ISR Number: 3593862-1Report Type:Periodic Company Report #WAES 00030009
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional						
	Pain In Extremity							
			Hytrin	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593863-3Report Type:Periodic Company Report #WAES 00062027
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593864-5Report Type:Periodic Company Report #WAES 00030037
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Gastrointestinal Disorder							
	Hypertrophy Breast		Advil	C				
			Zantac	C				

Date:09/21/00ISR Number: 3593865-7Report Type:Periodic Company Report #WAES 00062028
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dermatitis							
	Erythema							
	Gingival Bleeding							
	Joint Swelling							
	Swelling							

Date:09/21/00ISR Number: 3593866-9Report Type:Periodic Company Report #WAES 00030120
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research			

	Eye Movement Disorder				Laboratories Div	
	Myalgia				Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3593867-0Report Type:Periodic Company Report #WAES 00062030
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Glucose	C		

Date:09/21/00ISR Number: 3593868-2Report Type:Periodic Company Report #WAES 00030244
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Oedema Peripheral	Health Professional				
	Weight Increased					
25						
MG/DAILY/PO						
			Darvocet-N	C		
			Evista	C		
			Lasix	C		

			Prevacid	C		
			Xanax	C		
			Aspirin	C		
			Chlordiazepoxide Hydrochloride	C		
			Prilosec	C		

Date:09/21/00ISR Number: 3593869-4Report Type:Periodic Company Report #WAES 00062032
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593870-0Report Type:Periodic Company Report #WAES 00080365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Monopril	C				
			Norvasc	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3593871-2Report Type:Periodic Company Report #WAES 00062034
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG BID

PO 1 MON
Quinine Sulfate C

Date:09/21/00ISR Number: 3593872-4Report Type:Periodic Company Report #WAES 00080366
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypervigilance Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diazide	C				

Date:09/21/00ISR Number: 3593873-6Report Type:Periodic Company Report #WAES 00080367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593874-8Report Type:Periodic Company Report #WAES 00062036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Haemoptysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593875-XReport Type:Periodic Company Report #WAES 00080369
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
			Claritin	C				
			Diovan	C				
			Glucotrol	C				
			Prempro	C				

Date:09/21/00ISR Number: 3593876-1Report Type:Periodic Company Report #WAES 00080370
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM /PO	
			Glucophage	C				
			Lipitor	C				
			Plendil	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3593877-3Report Type:Periodic Company Report #WAES 00080372
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	21 DAY
			Hyzaar	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3593878-5Report Type:Periodic Company Report #WAES 00062038
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephrotic Syndrome	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593879-7Report Type:Periodic Company Report #WAES 00080375
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

			Synthroid	C
			Diuretic Preparation	C

Date:09/21/00ISR Number: 3593880-3Report Type:Periodic Company Report #WAES 00080376
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Hytrin	C				
			Pravachol	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3593881-5Report Type:Periodic Company Report #WAES 00062040
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoaesthesia Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Azulfidine	C				
			Premarin	C				

Date:09/21/00ISR Number: 3593882-7Report Type:Periodic Company Report #WAES 00011745
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Depression Dizziness Dyskinesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

	Fatigue		Klonopin	C
	Joint Stiffness		Plaquenil	C
			Premarin	C
			Serecor	C
			Tylenol	C

Date:09/21/00ISR Number: 3593883-9Report Type:Periodic Company Report #WAES 00011787
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/	PO
			Valium	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3593884-0Report Type:Periodic Company Report #WAES 00012079
Age:83 YR Gender:Female I/FU:F

Outcome	PT
	Breast Pain
	Erythema

		Hypersensitivity Paraesthesia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Avapro	C		

Date:09/21/00ISR Number: 3593885-2Report Type:Periodic Company Report #WAES 00012540
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Estrogenic Preparations	C		

Date:09/21/00ISR Number: 3593886-4Report Type:Periodic Company Report #WAES 00062043
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY PO						
			Aciphex	C		
			Depo-Medrol	C		
			Synvisc	C		

Date:09/21/00ISR Number: 3593887-6Report Type:Periodic Company Report #WAES 00020359
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG DAILY PO	
			Synthroid	C				
			Lorazepam	C				
			Nortriptyline	C				

Date:09/21/00ISR Number: 3593888-8Report Type:Periodic Company Report #WAES 00020666
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3593889-XReport Type:Periodic Company Report #WAES 00062044
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Pruritus							
	Rash Erythematous							
	Vomiting		Levoxyl	C				
			Xalatan	C				

Date:09/21/00ISR Number: 3593890-6Report Type:Periodic Company Report #WAES 00020767
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Hallucination	Health						
	Memory Impairment	Professional						
	Nervousness						PO	
	Vision Blurred		L-Thyroxine	C				
			L-Thyroxine	C				
			Allopurinol	C				
			Allopurinol	C				
			Propanolol	C				
			Propanolol	C				

Date:09/21/00ISR Number: 3593891-8Report Type:Periodic Company Report #WAES 00021054
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Oedema Peripheral	Health						
	Weight Increased	Professional						
							PO	
			Tab Vioxx 12.5	SS		ORAL	QOD PO	

Claritin	C
Synthroid	C
Trazodone	C
Tylenol Pm	C
Plaquenil	C
Imuran	C

Date:09/21/00ISR Number: 3593892-XReport Type:Periodic Company Report #WAES 00062053
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3593893-1Report Type:Periodic Company Report #WAES 00021237
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Influenza Like Illness Sinusitis Traumatic Arthropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

		Librium	C
		Presantine	C
		Vicodin Tablets	C
		Wellbutrin	C

Date:09/21/00ISR Number: 3593894-3Report Type:Periodic Company Report #WAES 00021249
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Glucotrol	C				

Date:09/21/00ISR Number: 3593895-5Report Type:Periodic Company Report #WAES 00021296
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

Date:09/21/00ISR Number: 3593896-7Report Type:Periodic Company Report #WAES 00021470
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Drug Effect Decreased Dyspepsia Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

	Weight Decreased		Tab Vioxx 12.5 Mg	SS		ORAL
12.5 MG PO						
			Advil	C		
			Ambien	C		
			Flovent	C		
			Proventil	C		

Date:09/21/00ISR Number: 3593897-9Report Type:Periodic Company Report #WAES 00061924
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Premarin Composition	C		
			Unspecofied	C		

Date:09/21/00ISR Number: 3593898-0Report Type:Periodic Company Report #WAES 00061926
Age: Gender:Female I/FU:I

Outcome	PT
	Eczema
	Infection

Pruritus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:09/21/00ISR Number: 3593899-2Report Type:Periodic Company Report #WAES 00061930
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Augmentin	C				
			Skelexin	C				
			Tussafed	C				

Date:09/21/00ISR Number: 3593900-6Report Type:Periodic Company Report #WAES 00061931
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem	C				
			Hyzaar	C				
			Levoxyl	C				

Date:09/21/00ISR Number: 3593901-8Report Type:Periodic Company Report #WAES 00061934
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Premarin	C				
			Synthroid	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593902-XReport Type:Periodic Company Report #WAES 00061935
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Depression Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
	Nail Disorder		Naprosyn	C				
			Verapamil Hydrochloride	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3593905-5Report Type:Periodic Company Report #WAES 00061936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Methylprednisolone	C				

Date:09/21/00ISR Number: 3593908-0Report Type:Periodic Company Report #WAES 00061937
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Ultram	C				

Date:09/21/00ISR Number: 3593913-4Report Type:Periodic Company Report #WAES 00061939
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Neck Pain Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/UNK/PO	
			Celebrex	C				
			Synthroid	C				
			Zocor	C				

Date:09/21/00ISR Number: 3593919-5Report Type:Periodic Company Report #WAES 00061940
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNK	
		Representative						

Date:09/21/00ISR Number: 3593927-4Report Type:Periodic Company Report #WAES 00061944
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	
			Vasotec	C				

Date:09/21/00ISR Number: 3593928-6Report Type:Periodic Company Report #WAES 00061949
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ecotrin	C				

Toprol Xl Tablets C

Date:09/21/00ISR Number: 3593929-8Report Type:Periodic Company Report #WAES 00061952
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3593930-4Report Type:Periodic Company Report #WAES 00061958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3593931-6Report Type:Periodic Company Report #WAES 00061965
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Chest Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Eye Discharge Face Oedema Fatigue Malaise		Levothroid	C				

Date:09/21/00ISR Number: 3593932-8Report Type:Periodic Company Report #WAES 00061966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3593934-1Report Type:Periodic Company Report #WAES 00061977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	40 DAY
			Motrin	C				

Date:09/21/00ISR Number: 3593935-3Report Type:Periodic Company Report #WAES 00061984
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Caltrate	C
Flomax (Tamsulosis (R) -Form Hydr	C
Fosamax	C
Lozol	C
Melatonin	C
Triazolan	C

Date:09/21/00ISR Number: 3593939-0Report Type:Periodic Company Report #WAES 00061985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3593944-4Report Type:Periodic Company Report #WAES 00061986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3593945-6Report Type:Periodic Company Report #WAES 00061989
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Viagra	C				

Date:09/21/00ISR Number: 3594090-6Report Type:Periodic Company Report #WAES 00062222
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Enzyme Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594092-XReport Type:Periodic Company Report #WAES 00062223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594093-1Report Type:Periodic Company Report #WAES 00062225
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Levoxyl	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3594095-5Report Type:Periodic Company Report #WAES 00062228
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Ibuprofen Unk	SS		ORAL	800 MG/ TID/	PO 1 WK

Date:09/21/00ISR Number: 3594098-0Report Type:Periodic Company Report #WAES 00062229
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
			B Vitamins	C				
			Calcium Supplement	C				
			Vitamin E	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594099-2Report Type:Periodic Company Report #WAES 00062232
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Arthralgia							
	Arthritis Infective							
	Back Pain		Tab Fosamax Unk	SS			10 MG	
	Pain		Serevent	C				

Date:09/21/00ISR Number: 3594100-6Report Type:Periodic Company Report #WAES 00062233
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594101-8Report Type:Periodic Company Report #WAES 00062234
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Chlorodin	C				
			Hyzaar	C				

Date:09/21/00ISR Number: 3594103-1Report Type:Periodic Company Report #WAES 00062240
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Normodyne	C				

Date:09/21/00ISR Number: 3594104-3Report Type:Periodic Company Report #WAES 00062249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /PM/ PO	

Date:09/21/00ISR Number: 3594105-5Report Type:Periodic Company Report #WAES 00062261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON

Date:09/21/00ISR Number: 3594106-7Report Type:Periodic Company Report #WAES 00062290
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dyspnoea Face Oedema Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/	PO
			Calan	C				
			Aspirin	C				
			Atenolol	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594108-0Report Type:Periodic Company Report #WAES 00062293
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Avandia	C
			Lopid	C
			Neurontin	C
			Allopurinol	C

Date:09/21/00ISR Number: 3594109-2Report Type:Periodic Company Report #WAES 00062301
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	20 MG/DAILY/	PO
			Hydrodiuril	C				
			Premarin	C				
			Cimetidine	C				
			Mebutamate	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3594110-9Report Type:Periodic Company Report #WAES 00062342
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/	PO
			Zestoretic	C				
			Hydroxyzine	C				
			Nifedipine	C				

Date:09/21/00ISR Number: 3594111-0Report Type:Periodic Company Report #WAES 00062346
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Roxicet	C				
			Atenolol	C				
			Fosinopril	C				

Date:09/21/00ISR Number: 3594112-2Report Type:Periodic Company Report #WAES 00062347
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Dimetapp	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594114-6Report Type:Periodic Company Report #WAES 00062349
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Myalgia Sensation Of Heaviness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prednisone	C				

Date:09/21/00ISR Number: 3594115-8Report Type:Periodic Company Report #WAES 00062350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594116-XReport Type:Periodic Company Report #WAES 00062351
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Imdur	C				
			Lipitor	C				
			Therapy Unspecified	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3594120-1Report Type:Periodic Company Report #WAES 00062388
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Pruritus					
PO						
			Prempro	C		

Date:09/21/00ISR Number: 3594121-3Report Type:Periodic Company Report #WAES 00062389
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Headache					
	Oedema Peripheral					
25						
	Tinnitus					
MG/DAILY/PO						

Date:09/21/00ISR Number: 3594123-7Report Type:Periodic Company Report #WAES 00062395
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO 2 YR						
			Allegra	C		

Date:09/21/00ISR Number: 3594124-9Report Type:Periodic Company Report #WAES 00062399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:09/21/00ISR Number: 3594125-0Report Type:Periodic Company Report #WAES 00062402
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Insomnia Nervousness Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	PRN/PO	
			Premarin	C				
			Synthroid	C				
			Amitriptyline	C				

Date:09/21/00ISR Number: 3594126-2Report Type:Periodic Company Report #WAES 00062403
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper Faeces Discoloured	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594127-4Report Type:Periodic Company Report #WAES 00062422
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem	C				
			Hydrochlorothiazide + Triamter	C				
	Blood Urea Increased							

Date:09/21/00ISR Number: 3594128-6Report Type:Periodic Company Report #WAES 00062424
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Eczema	Health Professional						
	Paraesthesia							
	Pruritus							
			Diazide	C				
			Estratab	C				
			Inderal	C				
			Synthroid	C				
			Zyrtec	C				
			Amitriptyline	C				

Fish Oil	C	
Glucosamine	C	
Vitamin E	C	
Vitamins	C	

Date:09/21/00ISR Number: 3594129-8Report Type:Periodic Company Report #WAES 00062425
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594131-6Report Type:Periodic Company Report #WAES 00062426
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				

Date:09/21/00ISR Number: 3594132-8Report Type:Periodic Company Report #WAES 00062430
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY,PO

Antivert C
Darvocet-N C

Date:09/21/00ISR Number: 3594135-3Report Type:Periodic Company Report #WAES 00062433
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Relafen	C				

Date:09/21/00ISR Number: 3594137-7Report Type:Periodic Company Report #WAES 00062434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594140-7Report Type:Periodic Company Report #WAES 00072229
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Insulin	C				

Date:09/21/00ISR Number: 3594142-0Report Type:Periodic Company Report #WAES 00062443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594143-2Report Type:Periodic Company Report #WAES 00072232
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594144-4Report Type:Periodic Company Report #WAES 00062444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3594145-6Report Type:Periodic Company Report #WAES 00072233
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephritis Interstitial	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594147-XReport Type:Periodic Company Report #WAES 00072237
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Lactaid Caplets	C				
			Neurontin	C				
			Synthroid	C				
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594148-1Report Type:Periodic Company Report #WAES 00062451
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Lanoxin	C				
			Norvasc	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3594151-1Report Type:Periodic Company Report #WAES 00062453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594152-3Report Type:Periodic Company Report #WAES 00072244
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Vomiting		Prevacid	C				
			Trental	C				
			Zocor	C				

Date:09/21/00ISR Number: 3594153-5Report Type:Periodic Company Report #WAES 00062457
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hytrin	C				
			Lozol	C				
			Prinivil	C				
			Proscar	C				
			Theo-Dur	C				
			Verapamil	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594154-7Report Type:Periodic Company Report #WAES 00072245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Misoprostol Unk	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594156-0Report Type:Periodic Company Report #WAES 00062459
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594157-2Report Type:Periodic Company Report #WAES 00072249
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 MON
			Diovan	C				
			Norco	C				
			Calcium Supplement (Composition	C				
			Diazepam	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3594159-6Report Type:Periodic Company Report #WAES 00062464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Allopurinol	C				
			B Vitamins	C				

Date:09/21/00ISR Number: 3594161-4Report Type:Periodic Company Report #WAES 00072250
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3594162-6Report Type:Periodic Company Report #WAES 00060736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Synthroid	C				
			Antineoplastic Agents (Compositi)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594163-8Report Type:Periodic Company Report #WAES 00072252
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	8 DAY
			Lescol	C				
			Lotensin	C				

Date:09/21/00ISR Number: 3594166-3Report Type:Periodic Company Report #WAES 00060750
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Feldene	C				

Date:09/21/00ISR Number: 3594167-5Report Type:Periodic Company Report #WAES 00072255
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Daypro	C				
			Premarin	C				
			[Therapy Unspecified]	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3594168-7Report Type:Periodic Company Report #WAES 00060751
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594171-7Report Type:Periodic Company Report #WAES 00072256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrogenic Preparations (Composi	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594172-9Report Type:Periodic Company Report #WAES 00060796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594175-4Report Type:Periodic Company Report #WAES 00067099
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Prempro	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3594176-6Report Type:Periodic Company Report #WAES 00072257
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Klor-Con	C				
			Prilosec	C				
			Synthroid	C				
			Furosemide	C				
			Metoprolol	C				

Date:09/21/00ISR Number: 3594177-8Report Type:Periodic Company Report #WAES 00060809
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fall							
	Feeling Cold							
	Feeling Hot		Vitamins	C				
	Head Injury							
	Headache							
	Hyperhidrosis							
	Nausea							
	Syncope							
	Tremor							

Date:09/21/00ISR Number: 3594179-1Report Type:Periodic Company Report #WAES 00060812
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Prilosec	C				

			Toprol Xl Tablets	C		

Date:09/21/00ISR Number: 3594180-8Report Type:Periodic Company Report #WAES 00062186
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3594184-5Report Type:Periodic Company Report #WAES 00062187
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cordarone	C				
			Coumadin	C				
			Glucophage	C				
			Lanoxin	C				
			Monopril	C				
			Nitrol (Nitroglycerin)	C				
			Norvasc	C				
			Atenolol	C				
			Potassium Supplemnt (Compositio	C				

Date:09/21/00ISR Number: 3594185-7Report Type:Periodic Company Report #WAES 00060814
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Limbitrol Tablets	C		
			Plaquenil	C		
			Prevacid	C		
			Rhinocort	C		

Date:09/21/00ISR Number: 3594186-9Report Type:Periodic Company Report #WAES 00062188
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG;50MG/DAILY						
/PO						
			Estrogenic Preparations	C		

Date:09/21/00ISR Number: 3594188-2Report Type:Periodic Company Report #WAES 00060815
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594190-0Report Type:Periodic Company Report #WAES 00062192
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Monocillin	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3594191-2Report Type:Periodic Company Report #WAES 00062193
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Evista	C				
			Prevacid	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3594192-4Report Type:Periodic Company Report #WAES 00062194
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Demadex	C				
			Zestril	C				
			Aminophylline	C				
			Glucosamine	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3594193-6Report Type:Periodic Company Report #WAES 00060819
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Insomnia Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Lotensin Hct	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594194-8Report Type:Periodic Company Report #WAES 00062196
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594195-XReport Type:Periodic Company Report #WAES 00060820
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				
			Xanax	C				

Date:09/21/00ISR Number: 3594197-3Report Type:Periodic Company Report #WAES 00060821
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Avonex	C				
			Baclofen	C				

Date:09/21/00ISR Number: 3594198-5Report Type:Periodic Company Report #WAES 00062199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actonel	C				
			Axid	C				
			Celebrex	C				
			Lodosin	C				
			Mevacor	C				
			Prilosec	C				
			Verelan	C				
			Trimethoprim	C				

Date:09/21/00ISR Number: 3594199-7Report Type:Periodic Company Report #WAES 00060822
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594201-2Report Type:Periodic Company Report #WAES 00060823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594202-4Report Type:Periodic Company Report #WAES 00062204
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Feeling Abnormal Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
			Levo-T	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3594204-8Report Type:Periodic Company Report #WAES 00060824
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Effect Decreased Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	3 WK
			Caltrate	C				
			Klonopin	C				

				Phazyme	C		
				Tylenol Arthritis Extended Relief	C		
				Zantac	C		
				Zestril	C		
				Chondroitin (+) Glucosamine	C		
				Estradiol	C		
				Vitamin E	C		
				Vitamins (Unspecified)	C		

Date:09/21/00ISR Number: 3594206-1Report Type:Periodic Company Report #WAES 00062205
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective Fatigue Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5/PO;25 MG/ /PO	
			Allegra	C				
			Cardizem	C				
			Climara	C				
			Effexor Xr	C				
			Pravachol	C				
			Synthroid	C				
			Aspirin	C				

			Nitroglycerin	C		

Date:09/21/00ISR Number: 3594207-3Report Type:Periodic Company Report #WAES 00060830
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research			
	Rash Pruritic	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	DAILY/PO	
			Claritin	C				
			Glucophage	C				
			Pravachol	C				
			Zestril	C				
			Cortisone	C				
			Propylthiouracil	C				

Date:09/21/00ISR Number: 3594209-7Report Type:Periodic Company Report #WAES 00060833
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Constipation				Laboratories Div			
	Fluid Retention				Merck Co Inc	ORAL	PO	
	Oedema Peripheral		Avapro	C				
	Oliguria		Zocor	C				
	Retching		Aspirin	C				
	Vomiting		Furosemide	C				
			Glyburide	C				
			Pentoxifylline	C				
			Potassium Supplement					
			(Compositio	C				
			Ranitidine	C				

Date:09/21/00ISR Number: 3594211-5Report Type:Periodic Company Report #WAES 00062208
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Phosphokinase Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
	Cardiac Enzymes Increased							
	Myalgia							
			Glucotrol	C				
			Vasotec	C				
			Zestril	C				

Date:09/21/00ISR Number: 3594214-0Report Type:Periodic Company Report #WAES 00060835
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Daypro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594215-2Report Type:Periodic Company Report #WAES 00062209
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	1 YR

Date:09/21/00ISR Number: 3594216-4Report Type:Periodic Company Report #WAES 00060836
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594221-8Report Type:Periodic Company Report #WAES 00062210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Muscular Weakness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Lanoxin	C				
			Ultram	C				
			Vasotec	C				
			Lithium Carbonate	C				

Date:09/21/00ISR Number: 3594223-1Report Type:Periodic Company Report #WAES 00060837
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Eye Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins	C				

Date:09/21/00ISR Number: 3594224-3Report Type:Periodic Company Report #WAES 00062211
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;2 5 MG//DAILY/PO	
			Lopressor	C				
			Calcium Supplement (Composition)	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594225-5Report Type:Periodic Company Report #WAES 00062213
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cough							
	Dyspnoea							
			Darvon	C				
			Lanoxin	C				
			Marax	C				
			Micronase	C				
			Aminophylline	C				

Date:09/21/00ISR Number: 3594228-0Report Type:Periodic Company Report #WAES 00062216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastric Disorder							
			[Therapy Unspecified]	C				
			Clomiphene	C				
			Doxepin	C				
			Lithium Acetate	C				

Date:09/21/00ISR Number: 3594230-9Report Type:Periodic Company Report #WAES 00060839
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Insomnia							
			Provera	C				

Date:09/21/00ISR Number: 3594231-0Report Type:Periodic Company Report #WAES 00062217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	

Date:09/21/00ISR Number: 3594232-2Report Type:Periodic Company Report #WAES 00060840
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594235-8Report Type:Periodic Company Report #WAES 00060841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematospermia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3594241-3Report Type:Periodic Company Report #WAES 00060842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594242-5Report Type:Periodic Company Report #WAES 00062220
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Guanfacine	C				

Date:09/21/00ISR Number: 3594244-9Report Type:Periodic Company Report #WAES 00060847
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO

Cardura	C
Celebrex	C
Prevacid	C
Zocor	C
Estrogenic Preparations (Composi	C

Date:09/21/00ISR Number: 3594245-0Report Type:Periodic Company Report #WAES 00062221
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594246-2Report Type:Periodic Company Report #WAES 00060850
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594248-6Report Type:Periodic Company Report #WAES 00060851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594249-8Report Type:Periodic Company Report #WAES 00062121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:09/21/00ISR Number: 3594250-4Report Type:Periodic Company Report #WAES 00060853
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Headache Musculoskeletal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Rectal Haemorrhage
MG/DAILY/PO
Ecotrin C

Date:09/21/00ISR Number: 3594251-6Report Type:Periodic Company Report #WAES 00062125
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperkalaemia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:09/21/00ISR Number: 3594252-8Report Type:Periodic Company Report #WAES 00062136
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25
MG/DAILY/PO
Azmacort C
Proventil C
Theo-Dur C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594253-XReport Type:Periodic Company Report #WAES 00060855
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
	Pain In Extremity							
			Accolate	C				
			Avapro	C				
			Cardura	C				
			Coumadin	C				
			Lasix	C				
			Lipitor	C				
			Premarin	C				
			Prevacid	C				
			Robitussin	C				
			Rythmol	C				
			Volmax	C				
			Aminophylline	C				

Date:09/21/00ISR Number: 3594254-1Report Type:Periodic Company Report #WAES 00062137
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	25 MG/DAILY/OPTH	10 DAY

Date:09/21/00ISR Number: 3594256-5Report Type:Periodic Company Report #WAES 00062139
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
	Asthenia							
	Drug Interaction							

Fatigue
MG/DAILY/PO
Mental Impairment Effexor SS
75
Sleep Disorder
MG/DAILY/UNK
Altace C
Synthroid C
Insulin C

Date:09/21/00ISR Number: 3594257-7Report Type:Periodic Company Report #WAES 00060857
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Floxin	C				
			Lipitor	C				
			Plavix	C				
			Transderm-Nitro	C				
			Valium	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594258-9Report Type:Periodic Company Report #WAES 00060858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594259-0Report Type:Periodic Company Report #WAES 00062152
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Monopril	C				
			Synthroid	C				
			Aspirin	C				
			Pentoxifylline	C				

Date:09/21/00ISR Number: 3594260-7Report Type:Periodic Company Report #WAES 00062155
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Malaise	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Inderal	C				
			Premarin	C				
			Soma	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3594261-9Report Type:Periodic Company Report #WAES 00060860
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Atenolol	C				
			Clonidine	C				

Date:09/21/00ISR Number: 3594262-0Report Type:Periodic Company Report #WAES 00062157
Age:50 YR Gender:Female I/FU:I

Outcome	PT
	Bronchospasm
	Cervix Disorder
	Dyspnoea
	Headache
	Oedema Peripheral
	Rash Erythematous
	Swelling

	Throat Tightness						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO
			Zoloft	C			

Date:09/21/00ISR Number: 3594263-2Report Type:Periodic Company Report #WAES 00062161
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO
			Clonopin	C			
			Prilosec	C			
			Serevent	C			
			Albuterol	C			

Date:09/21/00ISR Number: 3594264-4Report Type:Periodic Company Report #WAES 00060869
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3594265-6Report Type:Periodic Company Report #WAES 00060904
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Anaprox	C				
			Cenestin	C				
			Flonase	C				
			Flovent	C				
			Monopril	C				
			Patanol	C				
			Prilosec	C				
			Proventil	C				
			Prozac	C				
			Serevent	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3594266-8Report Type:Periodic Company Report #WAES 00061840
Age:82 YR Gender:Male I/FU:I

Outcome	PT
	Abdominal Distension
	Abdominal Pain
	Constipation

	Face Oedema Flatulence Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myalgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Proscar	C			

Date:09/21/00ISR Number: 3594267-XReport Type:Periodic Company Report #WAES 00061870
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypersensitivity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
		Representative	Celebrex	C			

Date:09/21/00ISR Number: 3594268-1Report Type:Periodic Company Report #WAES 00061876
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Constipation Dermatitis Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO
	Mouth Ulceration Oedema Peripheral		Prempro	C			
	Oral Pain		Vitamins	C			
	Pruritus						

Date:09/21/00ISR Number: 3594269-3Report Type:Periodic Company Report #WAES 00061878
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Depression							
	Fatigue							
	Pruritus		Hydrodiuril	C				
			Lipitor	C				
			Prilosec	C				
			Ultram	C				

Date:09/21/00ISR Number: 3594270-XReport Type:Periodic Company Report #WAES 00061881
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	100 DAY
			Lipitor	C				
			Maxzide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594271-1Report Type:Periodic Company Report #WAES 00061883
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3594273-5Report Type:Periodic Company Report #WAES 00061889
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timoptic	C				

Date:09/21/00ISR Number: 3594274-7Report Type:Periodic Company Report #WAES 00062162
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norco	C				
			Paxil	C				
			Percocet	C				
			Xanax	C				

Date:09/21/00ISR Number: 3594275-9Report Type:Periodic Company Report #WAES 00062165
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594276-0Report Type:Periodic Company Report #WAES 00061890
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Conjugated Estrogenic Hormones	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594277-2Report Type:Periodic Company Report #WAES 00062168
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				
			Inderal	C				
			Tylenol Extra Strength	C				
			Xanax	C				
			Zocor	C				
			Composition Unspecified	C				

Date:09/21/00ISR Number: 3594279-6Report Type:Periodic Company Report #WAES 00061894
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / PRN/ PO	
			Librax	C				
			Lotrel	C				

Date:09/21/00ISR Number: 3594280-2Report Type:Periodic Company Report #WAES 00061896
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Face Oedema Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

	Hypersomnia		Zocor	C
			Zoloft	C
			Therapy Unspecified	C
			Potassium Supplement	C
			Verapamil	C

Date:09/21/00ISR Number: 3594281-4Report Type:Periodic Company Report #WAES 00061897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
	Gastrointestinal Disorder							
	Oedema Peripheral							
			Diazide	C				
			Therapy Unspecified	C				
			Loratadine	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594283-8Report Type:Periodic Company Report #WAES 00061899
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Vicodin	C		

Date:09/21/00ISR Number: 3594284-XReport Type:Periodic Company Report #WAES 00061900
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea Haemoptysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO 2 MON						
			Elavil	C		
			Premarin	C		
			Tylenol With Codeine #3	C		
			Therapy Unspecified	C		
			Folic Acid	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3594286-3Report Type:Periodic Company Report #WAES 00062172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral Vaginal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Hormones (Composition Unspecified)	C		

Date:09/21/00ISR Number: 3594287-5Report Type:Periodic Company Report #WAES 00061901
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/ PO	
			Lomotil	C				
			Zoroxin	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594289-9Report Type:Periodic Company Report #WAES 00061902
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594291-7Report Type:Periodic Company Report #WAES 00062173
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Fatigue							
			Ambien	C				
			Capoten	C				
			Celebrex	C				
			Fosamax	C				
			Geritol Complete Tablets	C				
			Ocuvite	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594292-9Report Type:Periodic Company Report #WAES 00061904
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
			Avandia	C				
			Darvocet-N	C				
			Glucotrol	C				
			Norvasc	C				
			Premarin	C				
			Zocor	C				
			Amitriptyline	C				
			Furosemide	C				
			Insulin	C				
			Thiamine	C				

Date:09/21/00ISR Number: 3594294-2Report Type:Periodic Company Report #WAES 00062174
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	3 DAY
	Dry Mouth							
	Dry Throat							
	Pain		Composition					
	Pruritus		Unspecified	C				
			Aspirin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594296-6Report Type:Periodic Company Report #WAES 00062176
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Norvasc	C				
			Percocet	C				
			Prinivil	C				

			Tylenol	C		
			Indapamide	C		

Date:09/21/00ISR Number: 3594300-5Report Type:Periodic Company Report #WAES 00061907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594302-9Report Type:Periodic Company Report #WAES 00062180
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
	Chest Pain							
	Headache							
	Nausea		Allegra	C				
			Estrace	C				
			Prometrium	C				
			Tylenol	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3594303-0Report Type:Periodic Company Report #WAES 00061908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/	
	Cardiomegaly							
	Mitral Valve Disease							
			Accupril	C				
			Cozaar	C				
			Norvasc	C				

			Synthroid	C
			Furosemide	C

Date:09/21/00ISR Number: 3594306-6Report Type:Periodic Company Report #WAES 00062181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemoptysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Coumadin	C		
			Lipitor	C		
			Norvasc	C		

Date:09/21/00ISR Number: 3594307-8Report Type:Periodic Company Report #WAES 00061910
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

			Diazide	C		
			Minipress	C		

Date:09/21/00ISR Number: 3594308-XReport Type:Periodic Company Report #WAES 00061911
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Vioxx	PS	Merck Research			
	Dizziness	Professional			Laboratories Div			
	Drug Interaction				Merck Co Inc	ORAL	PO	
			Flexeril Unk	SS				
			Darvocet-N Unk	SS				
			Atarax Unk	SS				
			Pamelor	C				
			Procardia	C				
			Tranxene	C				
			Zantac	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594310-8Report Type:Periodic Company Report #WAES 00061912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall	Consumer	Vioxx	PS	Merck Research			
	Pain				Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594312-1Report Type:Periodic Company Report #WAES 00061917
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/DAILY/	

PO

Date:09/21/00ISR Number: 3594313-3Report Type:Periodic Company Report #WAES 00062184
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research	
	Headache				Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						
			Celebrex	C		

Date:09/21/00ISR Number: 3594314-5Report Type:Periodic Company Report #WAES 00061920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Fatigue				Laboratories Div	
	Feeling Abnormal				Merck Co Inc	ORAL
PO						
	Feeling Cold		Timoptic	C		
	Sedation		Zocor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594315-7Report Type:Periodic Company Report #WAES 00062185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Pain							
	Pruritus							

Date:09/21/00ISR Number: 3594318-2Report Type:Periodic Company Report #WAES 00062054
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Liptitor	C				
			Lotrel	C				
			Thyroxine	C				

Date:09/21/00ISR Number: 3594319-4Report Type:Periodic Company Report #WAES 00062056
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Oedema							
	Oedema Peripheral							
			Celexa	C				
			Glucosamine	C				
			Potassium Chloride	C				
			Triamterene	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594321-2Report Type:Periodic Company Report #WAES 00062062
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Baycol	C				
			Hydrodiuril	C				
			Prinivil	C				

Date:09/21/00ISR Number: 3594323-6Report Type:Periodic Company Report #WAES 00062064
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Constipation							
	Drug Ineffective							
	Insomnia		Soma	C				
			Hydrocortisone	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594326-1Report Type:Periodic Company Report #WAES 00062066
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594329-7Report Type:Periodic Company Report #WAES 00062068
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3594331-5Report Type:Periodic Company Report #WAES 00062069
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prinivil	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3594332-7Report Type:Periodic Company Report #WAES 00062071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased White Blood Cell Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			L-Thyroxine	C				
			Bupropion	C				
			Docusate Sodium	C				
			Folic Acid	C				
			Trazodone	C				
			Vitamin B	C				

Date:09/21/00ISR Number: 3594334-0Report Type:Periodic Company Report #WAES 00062076
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Humulin 70/30	C				
			Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594336-4Report Type:Periodic Company Report #WAES 00062077
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea							
	Tinnitus				Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Ambien	C				
			Premarin	C				

Date:09/21/00ISR Number: 3594337-6Report Type:Periodic Company Report #WAES 00062078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	2 WK

Date:09/21/00ISR Number: 3594338-8Report Type:Periodic Company Report #WAES 00062079
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594340-6Report Type:Periodic Company Report #WAES 00062080
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Prilosec C

Date:09/21/00ISR Number: 3594341-8Report Type:Periodic Company Report #WAES 00062081
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3594343-1Report Type:Periodic Company Report #WAES 00062085
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Scab	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ambien	C				
			Cozaar	C				
			Evista	C				

Lipitor	C
Plavix	C
Prevacid	C
Synthroid	C
Zyrtec	C
Folic Acid	C

Date:09/21/00ISR Number: 3594344-3Report Type:Periodic Company Report #WAES 00062094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody Positive Hypoaesthesia Hyporeflexia Neck Pain Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:09/21/00ISR Number: 3594347-9Report Type:Periodic Company Report #WAES 00062096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594350-9Report Type:Periodic Company Report #WAES 00062099
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594352-2Report Type:Periodic Company Report #WAES 00062115
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS			100 MG/BID	

Date:09/21/00ISR Number: 3594355-8Report Type:Periodic Company Report #WAES 00062116
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594381-9Report Type:Periodic Company Report #WAES 00070691
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Mavik	C				
			Toprol Xl Tablets	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3594384-4Report Type:Periodic Company Report #WAES 00070692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Digoxin	C				
			Isosorbide	C				
			Metoprolol	C				

Date:09/21/00ISR Number: 3594386-8Report Type:Periodic Company Report #WAES 00070694
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydroxychloroquine	C				

Date:09/21/00ISR Number: 3594388-1Report Type:Periodic Company Report #WAES 00070706
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594391-1Report Type:Periodic Company Report #WAES 00070708
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Aspirin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3594397-2Report Type:Periodic Company Report #WAES 00070709
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Hyperplasia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3594400-XReport Type:Periodic Company Report #WAES 00070712
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Disorder Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG / PO	
			Premarin	C				

Date:09/21/00ISR Number: 3594403-5Report Type:Periodic Company Report #WAES 00070713
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Calci-Mix	C				
			Celebrex	C				
			Iberet	C				
			Monopril	C				
			Niferex	C				

Norvasc	C
Pravachol	C
Tylenol	C
Allopurinol	C
Aspirin	C
Gastrointestinal Preparations	C

Date:09/21/00ISR Number: 3594405-9Report Type:Periodic Company Report #WAES 00070719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 WK
	Dermatitis							
	Eosinophil Count Increased							
	Pyrexia							

Date:09/21/00ISR Number: 3594411-4Report Type:Periodic Company Report #WAES 00070721
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Pollakiuria							

Merck Co Inc ORAL
25

MG/DAILY/PO

Hytrin	C	
Proscar	C	
Zocor	C	

Date:09/21/00ISR Number: 3594413-8Report Type:Periodic Company Report #WAES 00070722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Tenormin	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3594416-3Report Type:Periodic Company Report #WAES 00070723
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3594418-7Report Type:Periodic Company Report #WAES 00070724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Verelan C
Atenolol C

Date:09/21/00ISR Number: 3594419-9Report Type:Periodic Company Report #WAES 00070728
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Enbol	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3594421-7Report Type:Periodic Company Report #WAES 00070729
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actonel	C				

			Premarin	C
			Cyanocobalamin	C
			Insulin	C
			Isosorbide	C

Date:09/21/00ISR Number: 3594422-9Report Type:Periodic Company Report #WAES 00070730
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Erythema Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Allopurinol	C				
			Calcium Supplement (Composition	C				
			Cephalexin	C				
			Cholecalciferol	C				
			Furosemide	C				
			Hydrocodone	C				
			Omeprazole	C				
			Verapamil Hydrochloride	C				

Date:09/21/00ISR Number: 3594424-2Report Type:Periodic Company Report #WAES 00070731
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	1 WK
			Tab Vioxx 25 Mg	SS		ORAL	25	

MG/DAILY/PO 2 MON

Coumadin	C
Glucophage	C
Lanoxin	C
Pepcid	C
Premarin	C
Vaseretic	C
Atenolol	C
Glyburide	C
Nortriptyline	C

Date:09/21/00ISR Number: 3594427-8Report Type:Periodic Company Report #WAES 00070736
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Constipation							
	Fatigue							
			Promatine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594428-XReport Type:Periodic Company Report #WAES 00070738
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
	Drug Ineffective							
	Dyspepsia							
			Proscar	C				

Date:09/21/00ISR Number: 3594429-1Report Type:Periodic Company Report #WAES 00070751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Aspartate Aminotransferase Increased							
	Back Pain		Celebrex	C				
	Dyspepsia		Timoptic-Xe	C				
	Nausea							
	Oedema Peripheral							

Date:09/21/00ISR Number: 3594430-8Report Type:Periodic Company Report #WAES 00061054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594431-XReport Type:Periodic Company Report #WAES 00061056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594432-1Report Type:Periodic Company Report #WAES 00061057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594433-3Report Type:Periodic Company Report #WAES 00061061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594434-5Report Type:Periodic Company Report #WAES 00061065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	1 DAY

Date:09/21/00ISR Number: 3594443-6Report Type:Periodic Company Report #WAES 00061073
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glaucoma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO; DAILY	
			Evista	C				

Date:09/21/00ISR Number: 3594446-1Report Type:Periodic Company Report #WAES 00061078
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Elavil	C				
			Fosamax	C				
			Premarin	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3594447-3Report Type:Periodic Company Report #WAES 00061079
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Alphagan	C				
			Tambocor	C				

Date:09/21/00ISR Number: 3594450-3Report Type:Periodic Company Report #WAES 00061081
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Claritin	C				
			Cozaar	C				
			Hydrodiuril	C				
			Norvasc	C				
			Allergenic Extract	C				
			Aspirin	C				

Potassium Chloride C

Date:09/21/00ISR Number: 3594456-4Report Type:Periodic Company Report #WAES 00061082
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Headache Nervousness Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:09/21/00ISR Number: 3594460-6Report Type:Periodic Company Report #WAES 00061083
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3594465-5Report Type:Periodic Company Report #WAES 00061084
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Prilosec	C				

Date:09/21/00ISR Number: 3594467-9Report Type:Periodic Company Report #WAES 00061089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594469-2Report Type:Periodic Company Report #WAES 00061092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
	Rhinorrhoea		(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3594472-2Report Type:Periodic Company Report #WAES 00061093
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Oxycontin	C				

Date:09/21/00ISR Number: 3594474-6Report Type:Periodic Company Report #WAES 00061097
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				

Date:09/21/00ISR Number: 3594477-1Report Type:Periodic Company Report #WAES 00061101
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
			Evista	C				
			Urised Tablets	C				
			Garlic Extract	C				
			Vitamin E	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3594480-1Report Type:Periodic Company Report #WAES 00061102
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthma	Consumer	Vioxx	PS	Merck Research	
	Atrial Fibrillation	Health			Laboratories Div	
	Bronchitis	Professional			Merck Co Inc	
OPHTHALMIC 25						
	Dyspnoea					
MG/DAILY/PO						
			Azmacort	C		
			Combivent	C		
			Flovent	C		
			Serevent	C		
			Zantac	C		
			Antimicrobial Therapy	C		
			Spironolactone	C		

Date:09/21/00ISR Number: 3594485-0Report Type:Periodic Company Report #WAES 00061103
Age:57 YR Gender:Male I/FU:I

Outcome	PT
	Anxiety
	Dermatitis
	Dry Mouth

	Dysphagia Dyspnoea						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			K-Dur	C				
			Lasix	C				
			Norvasc	C				
			Serzone	C				
			Zyprexa	C				
			Baclofen	C				
			Glyburide	C				
			Iron (Unspecified)	C				

Date:09/21/00ISR Number: 3594489-8Report Type:Periodic Company Report #WAES 00061104
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO

Date:09/21/00ISR Number: 3594493-XReport Type:Periodic Company Report #WAES 00060905
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Altace	C				

Coumadin	C
K-Dur	C
Zocor	C
Therapy Unspecified	C
Furosemide	C

Date:09/21/00ISR Number: 3594497-7Report Type:Periodic Company Report #WAES 00060909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594500-4Report Type:Periodic Company Report #WAES 00060914
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Fatigue							
	Respiratory Disorder							
	Vomiting		Cipro	C				

Lipitor	C
Miacalcin	C
Prempro	C
Prilosec	C
Zoloft	C
Trazodone	C

Date:09/21/00ISR Number: 3594501-6Report Type:Periodic Company Report #WAES 00060925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3594503-XReport Type:Periodic Company Report #WAES 00060930
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				

Date:09/21/00ISR Number: 3594505-3Report Type:Periodic Company Report #WAES 00060931
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3594536-3Report Type:Periodic Company Report #WAES 00062921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Back Pain							
	Blood Pressure Increased							
	Dizziness							
	Fatigue		Therapy Unspecified	C				
	Headache		Aspirin	C				
	Oedema Peripheral							

Date:09/21/00ISR Number: 3594537-5Report Type:Periodic Company Report #WAES 00061922
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Neurontin	C				
			Reglan	C				
			Toprol Xl	C				

			Phenobarbital	C		

Date:09/21/00ISR Number: 3595015-XReport Type:Periodic Company Report #WAES 00064367
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595018-5Report Type:Periodic Company Report #WAES 00064388
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Ativan	C				
			Lasix	C				
			Mevacor	C				
			Norvasc	C				
			Prempro	C				
			Prinivil	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3595021-5Report Type:Periodic Company Report #WAES 00064423
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Demadex	C		
			Diabeta	C		
			Lipitor	C		
			Lopid	C		
			Premarin	C		
			Prinivil	C		
			Toprol Xl Tablets	C		
			[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3595026-4Report Type:Periodic Company Report #WAES 00064430
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Imdur	C				
			Lanoxin	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595031-8Report Type:Periodic Company Report #WAES 00064433
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Raynaud'S Phenomenon	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595034-3Report Type:Periodic Company Report #WAES 00064435
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 WK
			Flonase	C				
			Allopurinol	C				

Date:09/21/00ISR Number: 3595035-5Report Type:Periodic Company Report #WAES 00064438
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3595038-0Report Type:Periodic Company Report #WAES 00064440
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Tab Vioxx 25 Mg SS ORAL
25

MG/DAILY/PO

Lipitor C
Lopressor C
Lotensin C

Date:09/21/00ISR Number: 3595040-9Report Type:Periodic Company Report #WAES 00064441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Neuropathy Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:09/21/00ISR Number: 3595041-0Report Type:Periodic Company Report #WAES 00064443
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Disorder Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

			[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3595042-2Report Type:Periodic Company Report #WAES 00064445
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Dizziness		[Therapy Unspecified]	C				
	Sinus Tachycardia							

Date:09/21/00ISR Number: 3595044-6Report Type:Periodic Company Report #WAES 00064451
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lopid	C				
			Norvasc	C				
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595047-1Report Type:Periodic Company Report #WAES 00064453
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Swelling							

Date:09/21/00ISR Number: 3595050-1Report Type:Periodic Company Report #WAES 00064455
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoaesthesia Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3595052-5Report Type:Periodic Company Report #WAES 00064458
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Azulfidine	C				
			Prozac	C				

			Tetracycline	C		

Date:09/21/00ISR Number: 3595056-2Report Type:Periodic Company Report #WAES 00064460
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine #3	C				
			Chondroitin (+) Glucosamine	C				

Date:09/21/00ISR Number: 3595058-6Report Type:Periodic Company Report #WAES 00064462
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Diovan	C				
			Fosamax	C				
			Lasix	C				
			Synthroid	C				
			Zovirax	C				

Date:09/21/00ISR Number: 3595064-1Report Type:Periodic Company Report #WAES 00064464
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Aleve C

Date:09/21/00ISR Number: 3595066-5Report Type:Periodic Company Report #WAES 00064468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lanoxin	C				
			Synthroid	C				
			Tenormin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595067-7Report Type:Periodic Company Report #WAES 00080744
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3595068-9Report Type:Periodic Company Report #WAES 00080745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/DAILY/ PO	
			Accolate	C				
			Astelin	C				
			Atacand	C				
			Atrovent	C				
			Detrol	C				
			Flovent	C				
			Norvasc	C				
			Premarin	C				
			Xanax	C				
			Zoloft	C				
			Zyrtec	C				
			Docusate Sodium	C				
			Furosemide	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3595069-0Report Type:Periodic Company Report #WAES 00080751
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595070-7Report Type:Periodic Company Report #WAES 00080752
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	ORAL	
			Paxil	C				
			Premarin	C				
			Prevacid	C				
			Synthroid	C				
			Zyrtec	C				
			[Composition Unspecified]	C				
			Alprazolam	C				
			Aspirin	C				
			Naproxen	C				

Date:09/21/00ISR Number: 3595071-9Report Type:Periodic Company Report #WAES 00080754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595072-0Report Type:Periodic Company Report #WAES 00080755
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595073-2Report Type:Periodic Company Report #WAES 00080756
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Fluctuation							
	Blood Pressure Increased		Axid	C				
	Dyspnoea		Thyrolar	C				
	Fatigue		[Therapy Unspecified]	C				
	Malaise		Estrone Sulfate Piperazine Salt	C				

Date:09/21/00ISR Number: 3595074-4Report Type:Periodic Company Report #WAES 00080762
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryl	C				

Date:09/21/00ISR Number: 3595075-6Report Type:Periodic Company Report #WAES 00080764
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Prozac	C				
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3595076-8Report Type:Periodic Company Report #WAES 00080765
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Ambien SS
Darvocet-N SS
BID

Flomax (Tamsulosin
(R) - Form Hydr C

Date:09/21/00ISR Number: 3595077-XReport Type:Periodic Company Report #WAES 00080766
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Cardizem C
Fosamax C
Tenormin C

Date:09/21/00ISR Number: 3595078-1Report Type:Periodic Company Report #WAES 00080768
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:09/21/00ISR Number: 3595079-3Report Type:Periodic Company Report #WAES 00080771
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div	

	Myokymia				Merck Co Inc	ORAL
25 MG/BID/PO						
	Sedation		[Therapy Unspeficied]	C		

Date:09/21/00ISR Number: 3595080-XReport Type:Periodic Company Report #WAES 00080772
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Zithromax	C		
			[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3595082-3Report Type:Periodic Company Report #WAES 00080774
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PRN/PO						
			Atrovent	C		
			Synthroid	C		

			Tenormin	C		
			Xanax	C		

Date:09/21/00ISR Number: 3595085-9Report Type:Periodic Company Report #WAES 00080777
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Edecrin	C				
			Prinivil	C				

Date:09/21/00ISR Number: 3595086-0Report Type:Periodic Company Report #WAES 00080787
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3595089-6Report Type:Periodic Company Report #WAES 00080801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595091-4Report Type:Periodic Company Report #WAES 00080807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595100-2Report Type:Periodic Company Report #WAES 00080708
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
			Fosamax	C				
			Hydrodiuril	C				
			Toprol Xl Tablets	C				
			Insulin	C				
			Tamoxifen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595102-6Report Type:Periodic Company Report #WAES 00080709
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MGPM/PO	
			Allerest Tablets	C				
			Genuine Bayer Aspirin	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3595104-XReport Type:Periodic Company Report #WAES 00080711
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	3 WK

Date:09/21/00ISR Number: 3595105-1Report Type:Periodic Company Report #WAES 00080712
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Literature	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Elavil	C				
			Lopid	C				
			Moduretic	C				
			Premarin	C				
			Reglan	C				

Zantac	C
Ascorbic Acid	C
Vitamin E	C

Date:09/21/00ISR Number: 3595106-3Report Type:Periodic Company Report #WAES 00080713
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595107-5Report Type:Periodic Company Report #WAES 00080714
Age:74 YR Gender:Female I/FU:I

Outcome	PT
	Intraocular Pressure Increased
	Oedema Peripheral
	Pain In Extremity
	Photopsia

Vision Blurred

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:09/21/00ISR Number: 3595108-7Report Type:Periodic Company Report #WAES 00080715
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Lortab	C				
			Zantac	C				

Date:09/21/00ISR Number: 3595109-9Report Type:Periodic Company Report #WAES 00080719
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:09/21/00ISR Number: 3595111-7Report Type:Periodic Company Report #WAES 00080722
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			

	Diarrhoea				Laboratories Div	
	Drug Ineffective				Merck Co Inc	ORAL

25 MG/

DAILY/.PO

Compazine	C
Coumadin	C
Glucophage	C
Glucotrol	C
Lipitor	C
Maxizide	C
Procardia	C
Ynthroid	C
Tenormin	C
Viagra	C
Zoloft	C
Vitamins (Unspecified)	C

Date:09/21/00ISR Number: 3595113-0Report Type:Periodic Company Report #WAES 00080723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Mouth Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595115-4Report Type:Periodic Company Report #WAES 00080727
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Premarin	C				
			Synthroid	C				
			Hydrochlorothiazide	C				

Date:09/21/00ISR Number: 3595118-XReport Type:Periodic Company Report #WAES 00080728
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Gastritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prinivil	C				

Date:09/21/00ISR Number: 3595120-8Report Type:Periodic Company Report #WAES 00080730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595122-1Report Type:Periodic Company Report #WAES 00080732
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			

	Blood Pressure Increased				Laboratories Div	
	Dizziness				Merck Co Inc	ORAL
25 MG/UNK/PO						
	Drug Effect Decreased					
	Fatigue					
	Headache					
	Neck Pain					

Date:09/21/00ISR Number: 3595124-5Report Type:Periodic Company Report #WAES 00080733
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Coumadin	C		
			Glucamide	C		
			Neurontin	C		

Date:09/21/00ISR Number: 3595125-7Report Type:Periodic Company Report #WAES 00080734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595126-9Report Type:Periodic Company Report #WAES 00080735
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Donnatal	C				
			Evista	C				
			Lasix	C				
			Xanax	C				
			Potassium (Unspepcified)	C				

Date:09/21/00ISR Number: 3595127-0Report Type:Periodic Company Report #WAES 00080736
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Pravachol	C				

Date:09/21/00ISR Number: 3595128-2Report Type:Periodic Company Report #WAES 00080740
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:09/21/00ISR Number: 3595129-4Report Type:Periodic Company Report #WAES 00080741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	30 DAY
			Vitamins (Unspepcified)	C				

Date:09/21/00ISR Number: 3595142-7Report Type:Periodic Company Report #WAES 00061105
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Armour Thyroid					

	Tablets	C
	Glucotrol	C
	Verapamil Hydrochloride	C

Date:09/21/00ISR Number: 3595144-0Report Type:Periodic Company Report #WAES 00061108
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Polyuria							
	Weight Increased							

Date:09/21/00ISR Number: 3595147-6Report Type:Periodic Company Report #WAES 00061109
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Bronchitis	Health Professional						
	Cough							
			Claritin	C				
			Flovent	C				
			Lipitor	C				
			Medrol	C				
			Proventil	C				
			Prozac	C				
			Quinaglute	C				
			Soma	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595149-XReport Type:Periodic Company Report #WAES 00061113
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:09/21/00ISR Number: 3595151-8Report Type:Periodic Company Report #WAES 00061116
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Bone Pain					
	Nausea					
	Vomiting					

Dose Duration

25

MG/DAILY/PO

Date:09/21/00ISR Number: 3595153-1Report Type:Periodic Company Report #WAES 00061120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Mental Disorder					

Dose Duration

12.5

MG/DAIL/PO

Cardura	C
Coumadin	C
Cozaar	C
Lanoxin	C
Norvasc	C
Toprol Xl Tabets	C

Date:09/21/00ISR Number: 3595154-3Report Type:Periodic Company Report #WAES 00061122
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	2 DAY
			Vioxx	SS		ORAL	25 MG DAILY PO	2 WK

Date:09/21/00ISR Number: 3595156-7Report Type:Periodic Company Report #WAES 00061123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Tamoxifen	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595158-0Report Type:Periodic Company Report #WAES 00061125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
	Musculoskeletal Stiffness						
	Pruritus						
PO							

Date:09/21/00ISR Number: 3595161-0Report Type:Periodic Company Report #WAES 00061140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								

Date:09/21/00ISR Number: 3595164-6Report Type:Periodic Company Report #WAES 00061147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595165-8Report Type:Periodic Company Report #WAES 00061148
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Systolic Increased Hypertension	Health Professional Company Representative	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595166-XReport Type:Periodic Company Report #WAES 00061154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3595167-1Report Type:Periodic Company Report #WAES 00061160
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595168-3Report Type:Periodic Company Report #WAES 00061177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595169-5Report Type:Periodic Company Report #WAES 00061184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Discomfort	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Baycol	C				
			Procardia Xl	C				

Date:09/21/00ISR Number: 3595170-1Report Type:Periodic Company Report #WAES 00061192
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Altace	C				
			Coumadin	C				
			K-Dur	C				

Lanoxin	C
Lasix	C
Zocor	C
Hydroxyzine	C

Date:09/21/00ISR Number: 3595171-3Report Type:Periodic Company Report #WAES 00061202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595172-5Report Type:Periodic Company Report #WAES 00061212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3595174-9Report Type:Periodic Company Report #WAES 00061220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Flatulence							
	Oedema Peripheral							
	Respiratory Disorder							

Date:09/21/00ISR Number: 3595182-8Report Type:Periodic Company Report #WAES 00080624
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595183-XReport Type:Periodic Company Report #WAES 00080627
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Insulin	C				
			Lisinopril	C				

Date:09/21/00ISR Number: 3595184-1Report Type:Periodic Company Report #WAES 00080629
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Oedema Peripheral	Health Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:09/21/00ISR Number: 3595185-3Report Type:Periodic Company Report #WAES 00080632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hyperchlorhydria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595186-5Report Type:Periodic Company Report #WAES 00080634
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	30 DAY

Date:09/21/00ISR Number: 3595187-7Report Type:Periodic Company Report #WAES 00080638
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

				Captopril Msd	C		
				Prilosec	C		

Date:09/21/00ISR Number: 3595188-9Report Type:Periodic Company Report #WAES 00080660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3595189-0Report Type:Periodic Company Report #WAES 00080662
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595190-7Report Type:Periodic Company Report #WAES 00080663
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Change Of Bowel Habit							
	Dysuria							
	Flatulence		Tylenol	C				
	Pruritus							

Date:09/21/00ISR Number: 3595191-9Report Type:Periodic Company Report #WAES 00080675
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Vision Blurred							

Date:09/21/00ISR Number: 3595192-0Report Type:Periodic Company Report #WAES 00080679
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Insomnia							
			Altace	C				
			Cytotec	C				
			K-Dur	C				
			Lescol	C				
			Tenormin	C				

(SEE IMAGE)

Date:09/21/00ISR Number: 3595193-2Report Type:Periodic Company Report #WAES 00080680
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
	Weight Increased							
			Celebrex	C				

Date:09/21/00ISR Number: 3595194-4Report Type:Periodic Company Report #WAES 00080684
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595195-6Report Type:Periodic Company Report #WAES 00080686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Weight Increased							

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3595196-8Report Type:Periodic Company Report #WAES 00080695
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Chromagen	C				
			Prilosec	C				

Date:09/21/00ISR Number: 3595197-XReport Type:Periodic Company Report #WAES 00080699
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Fosamax	C				
			Prilosec	C				
			Reglan	C				

Date:09/21/00ISR Number: 3595198-1Report Type:Periodic Company Report #WAES 00080700
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			(SEE IMAGE)					
			Antimicrobial					

			Therapy	C

Date:09/21/00ISR Number: 3595199-3Report Type:Periodic Company Report #WAES 00080701
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Malnutrition	Consumer	Vioxx	PS	Merck Research	
	Metabolic Disorder				Laboratories Div	
					Merck Co Inc	ORAL
25 MG/PO						

Date:09/21/00ISR Number: 3595200-7Report Type:Periodic Company Report #WAES 00080703
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective				Laboratories Div	
	Nausea				Merck Co Inc	ORAL
PO						
			Calan Sr	C		
			Ziac	C		
			Zocor	C		
			Therapy Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595201-9Report Type:Periodic Company Report #WAES 00080706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotensin	C				
			Zocor	C				

Date:09/21/00ISR Number: 3595202-0Report Type:Periodic Company Report #WAES 00060936
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Premarin	C				

Date:09/21/00ISR Number: 3595203-2Report Type:Periodic Company Report #WAES 00060941
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	48 HR
			Avandia	C				
			Avapro	C				
			Diazide	C				
			Humulin	C				

Date:09/21/00ISR Number: 3595204-4Report Type:Periodic Company Report #WAES 00060942
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
	Mental Impairment							
	Sedation							
			Climara	C				

Date:09/21/00ISR Number: 3595205-6Report Type:Periodic Company Report #WAES 00060943
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:09/21/00ISR Number: 3595206-8Report Type:Periodic Company Report #WAES 00060944
Age:83 YR Gender:Female I/FU:I

Outcome	PT
	Drug Ineffective
	Flushing

Gait Disturbance

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595207-XReport Type:Periodic Company Report #WAES 00060948
Age:74 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrasystoles	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	SS		ORAL	20 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595208-1Report Type:Periodic Company Report #WAES 00060950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Zyloprim	C				

(SEE IMAGE)

Date:09/21/00ISR Number: 3595209-3Report Type:Periodic Company Report #WAES 00060952
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Headache							
	Nausea							
			Diovan	C				
			Ultram	C				

Date:09/21/00ISR Number: 3595210-XReport Type:Periodic Company Report #WAES 00060953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/HS/PO	
			Lipitor	C				
			Phazyme	C				
			Synthroid	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595211-1Report Type:Periodic Company Report #WAES 00060954
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Eminase	C				
			Fosamax	C				

Date:09/21/00ISR Number: 3595212-3Report Type:Periodic Company Report #WAES 00060956
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595213-5Report Type:Periodic Company Report #WAES 00060957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem	C				
			Cardura	C				
			Celebrex	C				
			Lasix	C				
			Prilosec	C				
			Vasotec	C				
			Potassium Supplement	C				
			Thyroxine	C				

Date:09/21/00ISR Number: 3595214-7Report Type:Periodic Company Report #WAES 00060959
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595215-9Report Type:Periodic Company Report #WAES 00060963
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	3 DAY
			Accupril	C				
			Premarin	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595273-1Report Type:Periodic Company Report #WAES 00063225
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haemorrhage							
	Myocardial Infarction							
	Ulcer							

Date:09/21/00ISR Number: 3595274-3Report Type:Periodic Company Report #WAES 00063226
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3595275-5Report Type:Periodic Company Report #WAES 00063228
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Malaise							
	Ulcer							
			Prilosec	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3595279-2Report Type:Periodic Company Report #WAES 00063230
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			L-Thyroxin	C		
			Aspirin	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3595282-2Report Type:Periodic Company Report #WAES 00063234
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Headache	Health			Laboratories Div	
	Oedema Peripheral	Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Estrace	C		
			Plaquenil	C		
			Synthroid	C		
			Tagamet	C		
			Atenolol	C		
			Chlorthalidone	C		
			Folic Acid	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595283-4Report Type:Periodic Company Report #WAES 00063236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/DAILY/PO; 2) 25 MG/DAILY/PO	(THERAPY 5 DAY
			Xanax	C				

Date:09/21/00ISR Number: 3595284-6Report Type:Periodic Company Report #WAES 00063241
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595285-8Report Type:Periodic Company Report #WAES 00063242
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595286-XReport Type:Periodic Company Report #WAES 00063245
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tenormin	C				
			Zocor	C				

Date:09/21/00ISR Number: 3595287-1Report Type:Periodic Company Report #WAES 00063247
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3595288-3Report Type:Periodic Company Report #WAES 00063249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dermatitis Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595289-5Report Type:Periodic Company Report #WAES 00063324
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595290-1Report Type:Periodic Company Report #WAES 00064141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3595291-3Report Type:Periodic Company Report #WAES 00064222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595292-5Report Type:Periodic Company Report #WAES 00064281
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595293-7Report Type:Periodic Company Report #WAES 00064289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	
	Chest Pain							
	Cough							
	Dyspnoea							
	Faeces Discoloured							
	Fatigue							
	Flatulence							
	Pharyngitis							
	Sinusitis							

Date:09/21/00ISR Number: 3595294-9Report Type:Periodic Company Report #WAES 00064291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595295-0Report Type:Periodic Company Report #WAES 00064297
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3595296-2Report Type:Periodic Company Report #WAES 00064301
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estraderm	C				
			Kerlone	C				
			Lipitor	C				
			Provera	C				
			Relafen	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3595297-4Report Type:Periodic Company Report #WAES 00064304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595298-6Report Type:Periodic Company Report #WAES 00063157
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Urethral Obstruction							
	Urinary Tract Infection							
			Levaquin	C				

Date:09/21/00ISR Number: 3595299-8Report Type:Periodic Company Report #WAES 00063158
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Univasc	C				
			Potassium Chloride	C				
			Pravastatin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595300-1Report Type:Periodic Company Report #WAES 00063166
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Effect Decreased							
	Fatigue							
			Vioxx	SS		ORAL	PO	
			Cardizem	C				
			Synthroid	C				
			Zestoretic	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595301-3Report Type:Periodic Company Report #WAES 00063167
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3595302-5Report Type:Periodic Company Report #WAES 00063168
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Dyazide	C				
			Allopurinol	C				

Date:09/21/00ISR Number: 3595303-7Report Type:Periodic Company Report #WAES 00063174
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flovent	C				
			Serevent	C				
			Synthroid	C				
			Wellbutrin	C				

Date:09/21/00ISR Number: 3595304-9Report Type:Periodic Company Report #WAES 00063178
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Urinary Retention Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595305-0Report Type:Periodic Company Report #WAES 00063179
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Metabolic Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Paxil	C				
			Prilosec	C				
			Synthroid	C				
			Clonazepam	C				
			Tamoxifen	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595306-2Report Type:Periodic Company Report #WAES 00063182
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Back Pain Bone Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3595307-4Report Type:Periodic Company Report #WAES 00063185
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Prevacid	C				
			Rocaltrol	C				
			Synthroid	C				
			Triaminic Syrup	C				
			Albuterol	C				

			Methyldopa	C		

Date:09/21/00ISR Number: 3595308-6Report Type:Periodic Company Report #WAES 00063187
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Dyspnoea					
	Neuralgia				Merck Co Inc	ORAL
12.5						
	Paraesthesia					
MG/DAILY/PO						
	Swelling		Lipitor	C		
			Premarin	C		
			Prilosec	C		
			Soma	C		
			Zoloft	C		
			Acetaminophen (+)			
			Hydrocodone	C		
			Atenolol	C		
			Magnesium Sulfate	C		
			Verapamil Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595309-8Report Type:Periodic Company Report #WAES 00063189
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3595310-4Report Type:Periodic Company Report #WAES 00063190
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Norvasc	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595311-6Report Type:Periodic Company Report #WAES 00063191
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
	Insomnia Malaise Nausea Paraesthesia Tachycardia Vomiting		Prevacid	C				

Date:09/21/00ISR Number: 3595312-8Report Type:Periodic Company Report #WAES 00063193
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595313-XReport Type:Periodic Company Report #WAES 00063203
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3595314-1Report Type:Periodic Company Report #WAES 00063204
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:09/21/00ISR Number: 3595315-3Report Type:Periodic Company Report #WAES 00063209
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO 5 DAY
			Laridal	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595316-5Report Type:Periodic Company Report #WAES 00063213
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595317-7Report Type:Periodic Company Report #WAES 00063221
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	10 DAY
			Darvocet-N	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3595318-9Report Type:Periodic Company Report #WAES 00051842
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Nausea	Professional			Merck Co Inc	ORAL	25	
	Pruritus						MG/DAILY/PO	
			Tab Vioxx	SS				
			Indocin (Indomethacin Sodium)	C				
			Normodyne	C				
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595319-0Report Type:Periodic Company Report #WAES 00051853
Age:36 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain Upper
	Drug Effect Decreased
	Jaundice
	Nausea
	Paraesthesia

		Scleral Disorder Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25-50 MG/DAILY/PO							
				Depakote	C		
				Effexor Xr	C		
				Neurontin	C		

Date:09/21/00ISR Number: 3595320-7Report Type:Periodic Company Report #WAES 00051856
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased Flushing Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO		Weight Increased					
				Ambien	C		
				Cardura	C		
				Hyzaar	C		
				Zantac	C		
				Zyrtec	C		

Date:09/21/00ISR Number: 3595321-9Report Type:Periodic Company Report #WAES 00051880
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea Flatulence Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MJG/DAILY/PO							
				Coumadin	C		

			Lanoxin	C
			Procainamide Hydrochloride	C

Date:09/21/00ISR Number: 3595322-0Report Type:Periodic Company Report #WAES 00051887
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Telangiectasia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12/5 MG/PRN/PO	
			Benadryl	C				
			Estratest	C				

Date:09/21/00ISR Number: 3595323-2Report Type:Periodic Company Report #WAES 00051894
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Flatulence	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

		Tylenol	SS
		Claritin	C
		Fosamax	C
		Hormones	C

Date:09/21/00ISR Number: 3595324-4Report Type:Periodic Company Report #WAES 00052000
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Zestoretic	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3595326-8Report Type:Periodic Company Report #WAES 00052059
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595327-XReport Type:Periodic Company Report #WAES 00052117
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Blood Pressure Increased Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Dyspepsia
MG/DAILY/PO
Malaise Corgard C
Oedema Hygroton C
Pain

Date:09/21/00ISR Number: 3595328-1Report Type:Periodic Company Report #WAES 00052132
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3595329-3Report Type:Periodic Company Report #WAES 00052156
Age:65 YR Gender:Female I/FU:I

Outcome PT
Arthralgia
Disorientation
Face Oedema
Headache

	Lymphoedema Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Premarin	C			

Date:09/21/00ISR Number: 3595330-XReport Type:Periodic Company Report #WAES 00052159
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Tab Vioxx 25 Mg	SS		ORAL	PO
			Compazine	C			
			Evista	C			
			Prilosec	C			
			Tenormin	C			
			Calcium Supplement (Unspecified Vitamins)	C			

Date:09/21/00ISR Number: 3595331-1Report Type:Periodic Company Report #WAES 00052168
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Insomnia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Allerest Tablets	C			

Date:09/21/00ISR Number: 3595332-3Report Type:Periodic Company Report #WAES 00052910
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595333-5Report Type:Periodic Company Report #WAES 00061356
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Klonopin	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595334-7Report Type:Periodic Company Report #WAES 00061391
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Intestinal Obstruction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DALY/PO	
			Antimicrobial Therapy	C				

Date:09/21/00ISR Number: 3595335-9Report Type:Periodic Company Report #WAES 00081293
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Allegra	C				
			Avalilde	C				
			Ornade Spansule	C				
			Synthropid	C				
			Tricor	C				
			Ultram	C				
			Composition Unspecified	C				
			Irin (Unspecified)	C				
			Tamoxifen	C				

Date:09/21/00ISR Number: 3595336-0Report Type:Periodic Company Report #WAES 00081553
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Kerlone	C		
			Premarin	C		

Date:09/21/00ISR Number: 3595337-2Report Type:Periodic Company Report #WAES 99060316
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dizziness					
	Feeling Abnormal					
25 MG/BID/PO						
			Plaquenil	C		
			Prempro	C		
			Tenormin	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3595338-4Report Type:Periodic Company Report #WAES 99060682
Age:88 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Asthenia

		Diarrhoea Fatigue Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscular Weakness Nervousness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO							
				Tab Vioxx 50 Mg	SS		ORAL
DAILY/PO							
				Darvocet-N	C		
				Miacalcin	C		
				Prilosec	C		
				Synthroid	C		
				...	C		

Date:09/21/00ISR Number: 3595339-6Report Type:Periodic Company Report #WAES 00051393
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY							
PO ; 25 MG							
QOD PO							
				Hydrodiuril	C		
				Lotrel	C		

Date:09/21/00ISR Number: 3595340-2Report Type:Periodic Company Report #WAES 00051428
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Back Pain Cough	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY							

Dyspepsia

PO

Nausea
Sinusitis
Weight Increased

Atacand	C
Celebrex	C
Darvocet-N	C
Lipitor	C
Miacalcin	C
Premarin	C
Prilosec	C
Prinivil	C
Valium	C
Zyrtec	C
Carisoprodol	C
Quinine Sulfate	C

Date:09/21/00ISR Number: 3595341-4Report Type:Periodic Company Report #WAES 00051437
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG /DAILY						
/PO						
			Celebrex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595342-6Report Type:Periodic Company Report #WAES 00051438
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY	/PO
			Buspar	C				
			Paxil	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				
			Vancenase	C				
			Albuterol	C				
			Amitriptyline	C				
			Cyclobenzaprine Hydrochloride	C				
			Desipramine	C				
			Loratadine	C				
			Methocarbamol	C				

Date:09/21/00ISR Number: 3595343-8Report Type:Periodic Company Report #WAES 00051546
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Hiatus Hernia Oesophageal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/	PO
			Cytotec	C				
			Norvasc	C				
			Prevacid	C				
			Toprol Xl Tablets	C				
			Ultram	C				
			Zocor	C				

Date:09/21/00ISR Number: 3595344-XReport Type:Periodic Company Report #WAES 00051549
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/	PO
			Synthroid	C				
			Zocor	C				

Date:09/21/00ISR Number: 3595345-1Report Type:Periodic Company Report #WAES 00051560
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO
			Celebrex	C				
			Isordil	C				
			Tenormin	C				
			Aspirin	C				

	Chondroitin + Glucosamine	C	
	Vitamins (Unspecified)	C	

Date:09/21/00ISR Number: 3595346-3Report Type:Periodic Company Report #WAES 00051564
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595347-5Report Type:Periodic Company Report #WAES 00051584
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psychomotor Hyperactivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	
			Cap Prednisone Unk	SS		ORAL	15 MG/ DAILY/ PO	
			Methotrexate	C				

Date:09/21/00ISR Number: 3595348-7Report Type:Periodic Company Report #WAES 00051586
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/	

DAILY /PO

Claritin	C
Humibid	C
Inderal	C
Paxil	C
Ziac	C
Temazepam	C

Date:09/21/00ISR Number: 3595349-9Report Type:Periodic Company Report #WAES 00051689
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595350-5Report Type:Periodic Company Report #WAES 00051699
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID	

/PO 3 DAY

				Lipitor	C		

Date:09/21/00ISR Number: 3595351-7Report Type:Periodic Company Report #WAES 00051707
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595352-9Report Type:Periodic Company Report #WAES 00051709
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
			Depakote	C				
			Detrol	C				
			Monopril	C				
			Premarin	C				
			Sular	C				
			Benztropine Mesylate	C				
			Fluphenazine	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595353-0Report Type:Periodic Company Report #WAES 00051743
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Loss Of Consciousness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /TID	

/PO

		Neurontin	C
		Proventil	C
		Tylenol	C

Date:09/21/00ISR Number: 3595354-2Report Type:Periodic Company Report #WAES 00051756
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595355-4Report Type:Periodic Company Report #WAES 00051758
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595356-6Report Type:Periodic Company Report #WAES 00051762
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glaucoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595357-8Report Type:Periodic Company Report #WAES 00051780
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595358-XReport Type:Periodic Company Report #WAES 00051827
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea Hyperhidrosis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
			Premarin	C				
			Prilosec	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3595359-1Report Type:Periodic Company Report #WAES 00080832
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/DAILY/PO;

50 MG/DAILY/PO

Date:09/21/00ISR Number: 3595360-8Report Type:Periodic Company Report #WAES 00080836
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595361-XReport Type:Periodic Company Report #WAES 00080840
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sulfonethylmethane	SS		ORAL	1500 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595362-1Report Type:Periodic Company Report #WAES 00080849
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
	Drug Ineffective							
	Pruritus							
	Urticaria		Estratab	C				
			Lamisil	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595363-3Report Type:Periodic Company Report #WAES 00080851
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Aspartate Aminotransferase Increased							

Date:09/21/00ISR Number: 3595364-5Report Type:Periodic Company Report #WAES 00080853
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Influenza Like Illness							
	Tongue Disorder		Celebrex	C				
			Darvocet-N	C				
			Soma	C				
			Ibuprofen	C				

Date:09/21/00ISR Number: 3595365-7Report Type:Periodic Company Report #WAES 00080856
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Hypoaesthesia							
			Celebrex	C				
			Fosamax	C				
			Prometrium	C				
			Estradiol	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3595366-9Report Type:Periodic Company Report #WAES 00080858
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Muscle Spasms							
	Musculoskeletal Disorder							
	Oedema Peripheral		Coumadin	C				
			Pravachol	C				
			Premarin	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595367-0Report Type:Periodic Company Report #WAES 00080859
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/BID/PO	
			Glucophage	C				
			Hytrin	C				

Date:09/21/00ISR Number: 3595368-2Report Type:Periodic Company Report #WAES 00080860
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3595369-4Report Type:Periodic Company Report #WAES 00080862
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3595370-0Report Type:Periodic Company Report #WAES 00080864
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dermatitis							
	Pruritus							
			Evista	C				
			Lipitor	C				
			Plavix	C				
			Prilosec	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3595371-2Report Type:Periodic Company Report #WAES 00080868
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595372-4Report Type:Periodic Company Report #WAES 00080869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Erythema							
	Fatigue							
	Hyperhidrosis							
	Mouth Ulceration							
	Paraesthesia							

Date:09/21/00ISR Number: 3595373-6Report Type:Periodic Company Report #WAES 00080870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
	Oedema Peripheral							
			Motrin	C				
			Relafen	C				

Date:09/21/00ISR Number: 3595374-8Report Type:Periodic Company Report #WAES 00080873
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Tachycardia							
			Unisom	C				

Date:09/21/00ISR Number: 3595375-XReport Type:Periodic Company Report #WAES 00080877
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILT/PO	
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3595376-1Report Type:Periodic Company Report #WAES 00080881
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595377-3Report Type:Periodic Company Report #WAES 00080885
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Headache							
	Vaginal Haemorrhage							

Date:09/21/00ISR Number: 3595378-5Report Type:Periodic Company Report #WAES 00080886
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Face Oedema							
	Influenza							
	Muscular Weakness		Levoxyl	C				
	Nausea		Paxil	C				
	Oedema Peripheral		Tricor	C				
	Pharyngitis		Morphine	C				
	Tongue Oedema							
	Ulcer							

Date:09/21/00ISR Number: 3595379-7Report Type:Periodic Company Report #WAES 00053014
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Baycol	C				
			Benadryl	C				
			Dynacirc	C				
			Moexipril Hydrochloride	C				

Date:09/21/00ISR Number: 3595380-3Report Type:Periodic Company Report #WAES 00053016
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Asthenia							
	Asthma							
	Bronchospasm							
	Dermatitis		Cozaar	C				
	Eye Pain		Glucotrol	C				
	Eyelid Oedema		Levothyroxine Sodium	C				
	Fatigue							
	Hypoaesthesia							
	Joint Effusion							
	Lacrimation Increased							
	Loose Body In Joint							
	Muscular Weakness							
	Oedema Peripheral							
	Pain							
	Pharyngitis							
	Pruritus							

Date:09/21/00ISR Number: 3595381-5Report Type:Periodic Company Report #WAES 00053017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595382-7Report Type:Periodic Company Report #WAES 00053020
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat	C				
			Pravachol	C				
			Synthroid	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3595383-9Report Type:Periodic Company Report #WAES 00053022
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Prednisone	C				
			Vitamin B(12)	C				

Date:09/21/00ISR Number: 3595384-0Report Type:Periodic Company Report #WAES 00053026
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Paraesthesia Vascular Injury	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flexeril	C				

Date:09/21/00ISR Number: 3595385-2Report Type:Periodic Company Report #WAES 00053029
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595386-4Report Type:Periodic Company Report #WAES 00053030
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Risperdal	C
Xanax	C
Zoloft	C
Amoxicillin	C
Clonazepam	C
Gastrointestinal Preparations	C

Date:09/21/00ISR Number: 3595387-6Report Type:Periodic Company Report #WAES 00053036
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Levoxyl	C				
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3595388-8Report Type:Periodic Company Report #WAES 00053037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Cozaar	C				

Date:09/21/00ISR Number: 3595389-XReport Type:Periodic Company Report #WAES 00053040
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1205 MG	

/DAILY/ORAL

			Mylanta & Mylanta Ds	C		
			Pepcid	C		
			Zantac	C		
			Aspirin	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3595390-6Report Type:Periodic Company Report #WAES 00053041
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 PO	
			Hyzaar	C				
			Estrogenic Preparation (Composition Unk)	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595391-8Report Type:Periodic Company Report #WAES 00053042
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO	
	Gastrointestinal Disorder							
	Malaise							
	Oedema Peripheral							
			[Therapy Unspecified	C				
			Aspirin	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3595392-XReport Type:Expedited (15-DaCompany Report #WAES 00053047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Muscular Weakness							
			Tylenol	C				
			Vitamin B (12)	C				

Date:09/21/00ISR Number: 3595393-1Report Type:Periodic Company Report #WAES 00053048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1X/PO	
			Vicodin Tablets	C				

Date:09/21/00ISR Number: 3595394-3Report Type:Periodic Company Report #WAES 00053050
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lipitor	C				
			Atenolol	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595395-5Report Type:Periodic Company Report #WAES 00053051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PRN/PO	
			Tab Vioxx 25 Mg	SS		ORAL	PRN/PO	
			Ibuprofen	C				

Date:09/21/00ISR Number: 3595396-7Report Type:Periodic Company Report #WAES 00053059
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595397-9Report Type:Periodic Company Report #WAES 00053064
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Zestoretic	C				

Date:09/21/00ISR Number: 3595398-0Report Type:Periodic Company Report #WAES 00053066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Diarrhoea Dizziness Eye Irritation Face Oedema Headache Nausea Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3595399-2Report Type:Periodic Company Report #WAES 00052969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595400-6Report Type:Periodic Company Report #WAES 00052980
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25/MG/DAILY/PO; 12.5 MG/DAILY/PO	
	Gastrointestinal Disorder	Health Professional						
	Gastrooesophageal Reflux Disease							
	Vomiting							
			Prilosec	C				
			Phenobarbital	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595401-8Report Type:Periodic Company Report #WAES 00052981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:09/21/00ISR Number: 3595402-XReport Type:Periodic Company Report #WAES 00052990
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Allegra	C				
			Ibuprofen	C				

Date:09/21/00ISR Number: 3595403-1Report Type:Periodic Company Report #WAES 00052992
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595405-5Report Type:Periodic Company Report #WAES 00052993
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG DAILY

PO
Tenormin C

Date:09/21/00ISR Number: 3595406-7Report Type:Periodic Company Report #WAES 00052995
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Diazide	C				
			Pravachol	C				

Date:09/21/00ISR Number: 3595407-9Report Type:Periodic Company Report #WAES 00052996
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595408-0Report Type:Periodic Company Report #WAES 00052997
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				

Date:09/21/00ISR Number: 3595409-2Report Type:Periodic Company Report #WAES 00053000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595410-9Report Type:Periodic Company Report #WAES 00053002
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Lotensin	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3595411-0Report Type:Periodic Company Report #WAES 00053003
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Gastrointestinal Haemorrhage		Vicodin Tablets	C				

Date:09/21/00ISR Number: 3595412-2Report Type:Periodic Company Report #WAES 00053004
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Memory Impairment Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pneumonia Renal Disorder		Spironolactone	C				

Date:09/21/00ISR Number: 3595413-4Report Type:Periodic Company Report #WAES 00053005
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	45 DAY

			Paxil	C		
			Tenormin	C		

Date:09/21/00ISR Number: 3595414-6Report Type:Periodic Company Report #WAES 00053007
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO; 50 MG	
							DAILY PO	5 DAY
			Prilosec	C				

Date:09/21/00ISR Number: 3595415-8Report Type:Periodic Company Report #WAES 00053008
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Dyspnoea							
	Fatigue		Pepcid	C				
	Feeling Abnormal		Premarin	C				
	Pain		Vasotec	C				
			Xanax	C				

Date:09/21/00ISR Number: 3595416-XReport Type:Periodic Company Report #WAES 00053010
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Sedation							

PO

			Aspirin	C
			Prozac	C
			Valium	C
			Zocor	C
			Glyburide	C
			Spironolactone	C

Date:09/21/00ISR Number: 3595417-1Report Type:Periodic Company Report #WAES 00053011
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Face Oedema	Health			Laboratories Div	
	Oedema	Professional			Merck Co Inc	ORAL

25

MG/DAILY/PO

			Dyazide	SS
			Celebrex	C
			Fosamax	C
			Calcium Supplement	
			(Composition	C
			Trazodone	C
			Vitamins	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595418-3Report Type:Periodic Company Report #WAES 00053012
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595419-5Report Type:Periodic Company Report #WAES 00060063
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595420-1Report Type:Periodic Company Report #WAES 00060068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG; 50 MG	/DAILY/PO

Date:09/21/00ISR Number: 3595421-3Report Type:Periodic Company Report #WAES 00060069
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Flatulence Merck Co Inc ORAL
12.5
Hypertrophy Breast
MG/DAILY/PO
Weight Increased

Date:09/21/00ISR Number: 3595422-5Report Type:Periodic Company Report #WAES 00060070
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595423-7Report Type:Periodic Company Report #WAES 00060072
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Coumadin	C				
			Fosamax	C				
			K-Dur	C				

Lasix	C
Lenoxin	C
Norvasc	C
Synthroid	C
Xanax	C
Zantac	C
Zocor	C

Date:09/21/00ISR Number: 3595424-9Report Type:Periodic Company Report #WAES 00060076
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	10 WK

Date:09/21/00ISR Number: 3595425-0Report Type:Periodic Company Report #WAES 00060077
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actos	C				

Date:09/21/00ISR Number: 3595426-2Report Type:Periodic Company Report #WAES 00060079
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Cozaar C
Lasix C

Date:09/21/00ISR Number: 3595427-4Report Type:Periodic Company Report #WAES 00060083
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595428-6Report Type:Periodic Company Report #WAES 00060084
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Azmacort	C				
			Serevent	C				
			Theo-Dur	C				

			Prednisone	C		

Date:09/21/00ISR Number: 3595429-8Report Type:Periodic Company Report #WAES 00060086
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parkinsonism	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Cogentin	C				
			Mirapex	C				
			Sinemet	C				
			Sinemet Cr	C				
			Amantadine	C				
			Lorazepam	C				
			Selegiline Hydrochloride	C				

Date:09/21/00ISR Number: 3595430-4Report Type:Periodic Company Report #WAES 00060087
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Maxzide	C				
			Premarin	C				

Date:09/21/00ISR Number: 3595431-6Report Type:Periodic Company Report #WAES 00060089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Indocin (Indomethacin)	C				

Date:09/21/00ISR Number: 3595432-8Report Type:Periodic Company Report #WAES 00060091
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595433-XReport Type:Periodic Company Report #WAES 00060096
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595434-1Report Type:Periodic Company Report #WAES 00060097
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Lithium Carbonate	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3595435-3Report Type:Periodic Company Report #WAES 00060101
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Coumadin	C				
			K-Dur	C				
			Neurontin	C				
			Pravachol	C				
			Synthroid	C				
			Tylenol	C				
			Aspirin	C				

Captopril	C
Furosemide	C
Vitamins	C

Date:09/21/00ISR Number: 3595436-5Report Type:Periodic Company Report #WAES 00060109
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pancreatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3595437-7Report Type:Periodic Company Report #WAES 00060114
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis Hypertension Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3595438-9Report Type:Periodic Company Report #WAES 00060117
Age:98 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Drug Ineffective	Company			Merck Co Inc	ORAL	25	
	Fatigue	Representative					MG/DAILY/PO	
	Muscular Weakness							

Date:09/21/00ISR Number: 3595439-0Report Type:Periodic Company Report #WAES 00064309
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Allegra D	C				
			Demadex	C				
			Lopressor	C				
			Synthroid	C				
			Valium	C				
			Amitriptyline Hydrochloride	C				
			Isosorbide	C				

Date:09/21/00ISR Number: 3595440-7Report Type:Periodic Company Report #WAES 00064312
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	2 WK
			Ditropan	C				

			Zestril	C
			Albuterol	C

Date:09/21/00ISR Number: 3595441-9Report Type:Periodic Company Report #WAES 00064314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3595442-0Report Type:Periodic Company Report #WAES 00064321
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Tylenol	C		
			[Therapy Unspecified]	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3595443-2Report Type:Periodic Company Report #WAES 00064323
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3595444-4Report Type:Periodic Company Report #WAES 00064324
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Diovan	C				

Date:09/21/00ISR Number: 3595445-6Report Type:Periodic Company Report #WAES 00064325
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Oedema Peripheral Pain In Extremity		[Therapy Unspecified]	C				
			Estrogenic Preparations (Composi	C				
			Thyroid	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3595446-8Report Type:Periodic Company Report #WAES 00064330
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pigmentation Disorder							
			Calan Sr	C				
			Lopressor	C				

Date:09/21/00ISR Number: 3595447-XReport Type:Periodic Company Report #WAES 00064331
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Bumex	C				
			Diovan	C				
			Hydrodiuril	C				
			Premarin	C				

Ziac C

Date:09/21/00ISR Number: 3595448-1Report Type:Periodic Company Report #WAES 00064332
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3595648-0Report Type:Periodic Company Report #WAES 00080747
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Emotional Disorder Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596048-XReport Type:Periodic Company Report #WAES 00072062
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 1 YR
			Neurontin	C				

Date:09/21/00ISR Number: 3596049-1Report Type:Periodic Company Report #WAES 00072063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID PO	
			Hydrodiuril	C				
			Inderal	C				

Date:09/21/00ISR Number: 3596051-XReport Type:Periodic Company Report #WAES 00072067
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	
			Avandia	C				
			Cardizem Cd	C				
			Coumadin	C				
			Diovan	C				
			Glucophage	C				
			Hydrodiuril	C				

			Lanoxin	C
			Lipitor	C
			Nitrostat	C
			Glyburide	C

Date:09/21/00ISR Number: 3596052-1Report Type:Periodic Company Report #WAES 00072070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596053-3Report Type:Periodic Company Report #WAES 00072072
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Malaise							
	Nausea							
			Fosamax	C				
			Norvasc	C				
			Prinivil	C				

Date:09/21/00ISR Number: 3596054-5Report Type:Periodic Company Report #WAES 00072075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596056-9Report Type:Periodic Company Report #WAES 00072076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596057-0Report Type:Periodic Company Report #WAES 00072082
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Dry Mouth Lip Dry	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Melatonin	C				

Date:09/21/00ISR Number: 3596069-7Report Type:Periodic Company Report #WAES 00072083
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG DAILY

PO
Glucosamine C

Date:09/21/00ISR Number: 3596070-3Report Type:Periodic Company Report #WAES 00072085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	
			Prozac	SS			PO	

Date:09/21/00ISR Number: 3596071-5Report Type:Periodic Company Report #WAES 00072086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Centrum	C				
			Prilosec	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3596073-9Report Type:Periodic Company Report #WAES 00080377
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Aldomet (Methyldopa)	C				

				Diuril	C		
				Chondroitin (+) Glucosamine	C		

Date:09/21/00ISR Number: 3596076-4Report Type:Periodic Company Report #WAES 00080378
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596079-XReport Type:Periodic Company Report #WAES 00080380
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO
			Asacol	C				
			Plavix	C				
			Vasotec	C				
			Folic Acid	C				

			Furosemide	C		
			Prednisone	C		

Date:09/21/00ISR Number: 3596081-8Report Type:Periodic Company Report #WAES 00080383
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Cardura	C		
			Lipitor	C		
			Insulin	C		

Date:09/21/00ISR Number: 3596083-1Report Type:Periodic Company Report #WAES 00080384
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3596086-7Report Type:Periodic Company Report #WAES 00080386
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain Blood Pressure Increased Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Anucort	C		
			Pamelor	C		
			Prozac	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3596089-2Report Type:Periodic Company Report #WAES 00080387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	

Date:09/21/00ISR Number: 3596090-9Report Type:Periodic Company Report #WAES 00080388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596094-6Report Type:Periodic Company Report #WAES 00080389
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596097-1Report Type:Periodic Company Report #WAES 00080887
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596098-3Report Type:Periodic Company Report #WAES 00080889
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3596100-9Report Type:Periodic Company Report #WAES 00080892
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Calcium Supplement	C		
			Hormones(Unspecified)	C		

Date:09/21/00ISR Number: 3596101-0Report Type:Periodic Company Report #WAES 00080895
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3596103-4Report Type:Periodic Company Report #WAES 00080896
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	
			Premarin	C				
			Rhinocort	C				
			Tiazac	C				

			Zyrtec	C		
			Calcium Supplement (Unspecified)	C		

Date:09/21/00ISR Number: 3596104-6Report Type:Periodic Company Report #WAES 00080898
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	PO
			Buspar	C				

Date:09/21/00ISR Number: 3596106-XReport Type:Periodic Company Report #WAES 00080900
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	PO
			Celebrex	C				

Date:09/21/00ISR Number: 3596107-1Report Type:Periodic Company Report #WAES 00080904
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Pharyngeal Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	TID PO
	Tongue Oedema		Premarin	C				

Date:09/21/00ISR Number: 3596108-3Report Type:Periodic Company Report #WAES 00080905
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	
			Estrogens (Unspecified)	C				

Date:09/21/00ISR Number: 3596109-5Report Type:Periodic Company Report #WAES 00080907
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	
			Prilosec	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596111-3Report Type:Periodic Company Report #WAES 00080908
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	PO

Date:09/21/00ISR Number: 3596112-5Report Type:Periodic Company Report #WAES 00080909
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
			Cardizem	C				
			Levoxil	C				
			Lotensin	C				
			Lyseen	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3596114-9Report Type:Periodic Company Report #WAES 00080915
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	UNK PO

Date:09/21/00ISR Number: 3596117-4Report Type:Periodic Company Report #WAES 00080918
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3596119-8Report Type:Periodic Company Report #WAES 00080919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	3 MON
			Vasotec	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3596120-4Report Type:Periodic Company Report #WAES 00080925
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

Date:09/21/00ISR Number: 3596123-XReport Type:Periodic Company Report #WAES 00080933
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	

Date:09/21/00ISR Number: 3596125-3Report Type:Periodic Company Report #WAES 00080935
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:09/21/00ISR Number: 3596127-7Report Type:Periodic Company Report #WAES 00080954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephritis Interstitial	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Date:09/21/00ISR Number: 3596129-0Report Type:Periodic Company Report #WAES 00080958
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health	Vioxx	PS	Merck Research			

Oedema Peripheral Professional Company Representative Laboratories Div Merck Co Inc ORAL
UNK / UNK /
PO

Date:09/21/00ISR Number: 3596143-5Report Type:Periodic Company Report #WAES 00080220
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;1	2.5 MG/DAILY/PO
			Bactrim	C				

Date:09/21/00ISR Number: 3596147-2Report Type:Periodic Company Report #WAES 00080222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dry Skin Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596149-6Report Type:Periodic Company Report #WAES 00080223
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO;25 MG/BID/PO;50 MG/DAILY/PO	1 WK
			Fosamax	C				
			Premarin	C				

Date:09/21/00ISR Number: 3596150-2Report Type:Periodic Company Report #WAES 00080228
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrogenic Preparations (Composi	C				
			Iron (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3596152-6Report Type:Periodic Company Report #WAES 00080229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Fosamax	C		

Date:09/21/00ISR Number: 3596153-8Report Type:Periodic Company Report #WAES 00080230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research	
	Flatulence				Laboratories Div	
	Nausea				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Aspirin	C		
			Calcium Supplement			
			(Composition	C		
			Doxepin	C		
			Estrogenic			
			Preparations			
			(Composi	C		
			Progesterone	C		
			Verapamil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596154-XReport Type:Periodic Company Report #WAES 00080234
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Rythmol	C				
			Skelaxin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3596157-5Report Type:Periodic Company Report #WAES 00080236
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596158-7Report Type:Periodic Company Report #WAES 00080237
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596160-5Report Type:Periodic Company Report #WAES 00080238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Swelling
Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Neurontin	C	
Zestril	C	
Zyloprim	C	
Quinine	C	

Date:09/21/00ISR Number: 3596161-7Report Type:Periodic Company Report #WAES 00080240
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596162-9Report Type:Periodic Company Report #WAES 00080247
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596164-2Report Type:Periodic Company Report #WAES 00080267
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596165-4Report Type:Periodic Company Report #WAES 00080274
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Prozac	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3596166-6Report Type:Periodic Company Report #WAES 00080293
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ultram	C				

Date:09/21/00ISR Number: 3596168-XReport Type:Periodic Company Report #WAES 00080297
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596169-1Report Type:Periodic Company Report #WAES 00080305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596170-8Report Type:Periodic Company Report #WAES 00080310
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			[Composition Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596173-3Report Type:Periodic Company Report #WAES 00080311
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Levaquin	C				

Date:09/21/00ISR Number: 3596174-5Report Type:Periodic Company Report #WAES 00080316
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Candidiasis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596176-9Report Type:Periodic Company Report #WAES 00080318
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:09/21/00ISR Number: 3596177-0Report Type:Periodic Company Report #WAES 00080319
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO
Synthroid C

Date:09/21/00ISR Number: 3596179-4Report Type:Periodic Company Report #WAES 00080320
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			Aspirin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596180-0Report Type:Periodic Company Report #WAES 00080323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596181-2Report Type:Periodic Company Report #WAES 00080324
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Triamterene	C				

Date:09/21/00ISR Number: 3596183-6Report Type:Periodic Company Report #WAES 00080328
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Back Pain Faeces Discoloured Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:09/21/00ISR Number: 3596185-XReport Type:Periodic Company Report #WAES 00053077
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Ocupress	C				
			Trusopt	C				
			Glyburide	C				

Date:09/21/00ISR Number: 3596186-1Report Type:Periodic Company Report #WAES 00080333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596188-5Report Type:Periodic Company Report #WAES 00080336
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596189-7Report Type:Periodic Company Report #WAES 00080337
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Acetaminophen +
Codeine Phosph C

Date:09/21/00ISR Number: 3596191-5Report Type:Periodic Company Report #WAES 00080341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Asthenia							
	Back Pain							
	Chest Pain							
	Fatigue		Lenoxin	C				
	Headache		Synthroid	C				
	Nocturia		Tenormin	C				

Date:09/21/00ISR Number: 3596192-7Report Type:Periodic Company Report #WAES 00053078
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
	Flatulence							
	Nausea							
			Fosamax	C				
			Prilosec	C				
			Vancenase Aq Nasal Spray	C				

Date:09/21/00ISR Number: 3596194-0Report Type:Periodic Company Report #WAES 00080342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Dry Mouth
Laboratories Div
Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3596196-4Report Type:Periodic Company Report #WAES 00080344
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596198-8Report Type:Periodic Company Report #WAES 00080345
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Lipitor	C				

Date:09/21/00ISR Number: 3596199-XReport Type:Periodic Company Report #WAES 00080346
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596201-5Report Type:Periodic Company Report #WAES 00080350
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Chills Diarrhoea Pyrexia Rhinorrhoea Sneezing Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Motrin	C				

Date:09/21/00ISR Number: 3596203-9Report Type:Periodic Company Report #WAES 00053085
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:09/21/00ISR Number: 3596204-0Report Type:Periodic Company Report #WAES 00080352
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Cellulitis							
			Trental	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3596206-4Report Type:Periodic Company Report #WAES 00080353
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cortizone-5	C				
			Ketorolac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596208-8Report Type:Periodic Company Report #WAES 00080354
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Buspar	C				
			Lasix	C				
			Zantac	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3596209-XReport Type:Periodic Company Report #WAES 00053087
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Interstitial Lung Disease	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596211-8Report Type:Periodic Company Report #WAES 00080358
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Anorexia							
	Blood Pressure Increased							
	Diarrhoea							
	Dysgeusia		Lodine	C				
	Faeces Discoloured		Thyroid	C				
	Headache							
	Olfactory Nerve Disorder							
	Weight Decreased							

Date:09/21/00ISR Number: 3596213-1Report Type:Periodic Company Report #WAES 00080361
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596214-3Report Type:Periodic Company Report #WAES 00053088
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596216-7Report Type:Periodic Company Report #WAES 00080362
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				

Date:09/21/00ISR Number: 3596217-9Report Type:Periodic Company Report #WAES 00053095
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Norvasc	C				
			Premarin	C				
			Prevacid	C				
			Thyroid	C				

Date:09/21/00ISR Number: 3596220-9Report Type:Periodic Company Report #WAES 00053104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596224-6Report Type:Periodic Company Report #WAES 00053114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspnoea Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596227-1Report Type:Periodic Company Report #WAES 00060002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596229-5Report Type:Periodic Company Report #WAES 00060003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596230-1Report Type:Periodic Company Report #WAES 00060004
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596231-3Report Type:Periodic Company Report #WAES 00060005
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596232-5Report Type:Periodic Company Report #WAES 00060006
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596233-7Report Type:Periodic Company Report #WAES 00050484
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/BID/PO

Pamelor C
Premarin C

Date:09/21/00ISR Number: 3596235-0Report Type:Periodic Company Report #WAES 00050493
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.54	
	Depression							
	Insomnia							

MG/DAILY/PO

Hypericin SS
BID

Donnatal C
Elavil C
Prempro C

Date:09/21/00ISR Number: 3596236-2Report Type:Periodic Company Report #WAES 00050499
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Dizziness	Consumer
	Ear Infection	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Ativan	C				
Prozac	C				
Robinul	C				
Diazepam	C				

Date:09/21/00ISR Number: 3596237-4Report Type:Periodic Company Report #WAES 00050504
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Daypro	C				
			Glucophage	C				
			Lipitor	C				
			Lotensin	C				

Date:09/21/00ISR Number: 3596238-6Report Type:Periodic Company Report #WAES 00050505
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dysuria Prostatic Disorder Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				

Flexeril	C
Lotrel	C
Plaquenil	C
Methotrexate	C
Lipitor	C

Date:09/21/00ISR Number: 3596239-8Report Type:Periodic Company Report #WAES 00060008
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3596240-4Report Type:Periodic Company Report #WAES 00050572
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Confusional State Disorientation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	, PRN

			Fosamax	C		
			Miacalcin	C		
			Pepcid	C		
			Synthroid	C		
			Warfarin	C		

Date:09/21/00ISR Number: 3596241-6Report Type:Periodic Company Report #WAES 00050591
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 WK
			Lipitor	C				
			Lopressor	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3596242-8Report Type:Periodic Company Report #WAES 00060009
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596248-9Report Type:Periodic Company Report #WAES 00060010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:09/21/00ISR Number: 3596252-0Report Type:Periodic Company Report #WAES 00060011
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596253-2Report Type:Periodic Company Report #WAES 00060012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Biaxin	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596254-4Report Type:Periodic Company Report #WAES 00060014
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596255-6Report Type:Periodic Company Report #WAES 00050598
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Hydrocodone/Apap	C				

Date:09/21/00ISR Number: 3596256-8Report Type:Periodic Company Report #WAES 00050599
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Fioricet Tablets	C				
			Prevacid	C				
			Glucosamine	C				
			Metoprolol	C				

Date:09/21/00ISR Number: 3596257-XReport Type:Periodic Company Report #WAES 00060015
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596258-1Report Type:Periodic Company Report #WAES 00050645
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PPO	
			Levoxyl	C				
			Oxycontin	C				
			Pepcid	C				
			Prozac	C				

Date:09/21/00ISR Number: 3596259-3Report Type:Periodic Company Report #WAES 00050681
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596260-XReport Type:Periodic Company Report #WAES 00050687
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Bradycardia	Health Professional						
	Dizziness							
	Extrasystoles							
	Muscular Weakness		Aspirin	C				
	Nausea		Estrone Sulfate Piperazine Salt	C				

Date:09/21/00ISR Number: 3596261-1Report Type:Periodic Company Report #WAES 00050736
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Neuralgia	Health Professional						
			Cardizem	C				
			Zestoretic	C				

Date:09/21/00ISR Number: 3596262-3Report Type:Periodic Company Report #WAES 00050745
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastritis Rhinitis Allergic	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/UNK/PO	

Date:09/21/00ISR Number: 3596263-5Report Type:Periodic Company Report #WAES 00050751
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO SEE IMAGE	
			Allegra	C				
			Buprenex	C				
			Decadron (Dexamethasone)	C				
			Flonase	C				
			Lipitor	C				
			Maxalt (Rizatriptan Benzoate)	C				
			Norvasc	C				
			Norvasc	C				
			Phenergan					

			(Promethazine Hydrochloride)	C		
			Phenergan Tablets/Suppositories	C		
			Prevacid	C		
			Symmetrel	C		
			Toprol Xl Tablets	C		
			Diazepam	C		

Date:09/21/00ISR Number: 3596264-7Report Type:Periodic Company Report #WAES 00050770
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Lopressor	C				
			Zocor	C				
			Nitroglycerin	C				

Date:09/21/00ISR Number: 3596265-9Report Type:Periodic Company Report #WAES 00050844
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				

Date:09/21/00ISR Number: 3596266-0Report Type:Periodic Company Report #WAES 00050854
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Insomnia Palpitations Sensation Of Heaviness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3596267-2Report Type:Periodic Company Report #WAES 00050855
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Herpetiformis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596272-6Report Type:Periodic Company Report #WAES 00064333
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accupril	C				
			Premarin	C				

Date:09/21/00ISR Number: 3596273-8Report Type:Periodic Company Report #WAES 00064335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Zestril	C				

Date:09/21/00ISR Number: 3596274-XReport Type:Periodic Company Report #WAES 00064339
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Cozaar	C				
			Lopressor	C				
			Cimetidine	C				

Date:09/21/00ISR Number: 3596276-3Report Type:Periodic Company Report #WAES 00064340
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Prevacid	C				
			Synthroid	C				
			Vasotec	C				
			Zoloft	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3596277-5Report Type:Periodic Company Report #WAES 00064341
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Evista	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596278-7Report Type:Periodic Company Report #WAES 00064342
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gait Disturbance							
			Procardia	C				

Date:09/21/00ISR Number: 3596280-5Report Type:Periodic Company Report #WAES 00064343
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:09/21/00ISR Number: 3596281-7Report Type:Periodic Company Report #WAES 00064346
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Centrum	C				
			Norvasc	C				
			Synthroid	C				
			Zocor	C				

Date:09/21/00ISR Number: 3596282-9Report Type:Periodic Company Report #WAES 00064357
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder Anxiety Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:09/21/00ISR Number: 3596283-0Report Type:Periodic Company Report #WAES 00064358
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO ; 25 MG PO	
			Benadryl	C				
			Premarin	C				
			Voltaren	C				
			Quinine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596284-2Report Type:Periodic Company Report #WAES 00064477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gout	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596285-4Report Type:Periodic Company Report #WAES 00064480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			Naprosyn	C				
			Premarin	C				
			Potassium Chloride	C				

Date:09/21/00ISR Number: 3596287-8Report Type:Periodic Company Report #WAES 00064484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Pepcid	C				

			Doxepin	C		

Date:09/21/00ISR Number: 3596288-XReport Type:Periodic Company Report #WAES 00064486
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lithium Carbonate (Roxane)	C				
			Miacalcin	C				
			Paxil	C				
			Soma	C				

Date:09/21/00ISR Number: 3596289-1Report Type:Periodic Company Report #WAES 00064487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Novocain	C				

	Antimicrobial Therapy	C
	Caffeine	C
	Codeine	C
	Morphine	C
	Penicillin (Drug)	C
	Tetanus Toxoid	C

Date:09/21/00ISR Number: 3596290-8Report Type:Periodic Company Report #WAES 00064489
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Hypertension Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				

Date:09/21/00ISR Number: 3596291-XReport Type:Periodic Company Report #WAES 00064492
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3596292-1Report Type:Periodic Company Report #WAES 00064493
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				

				Premarin	C		
				Prilosec	C		
				Relafen	C		

Date:09/21/00ISR Number: 3596293-3Report Type:Periodic Company Report #WAES 00064496
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Prinivil Unk	SS		ORAL	PO	

Date:09/21/00ISR Number: 3596294-5Report Type:Periodic Company Report #WAES 00064497
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				

				Zestril	C		
				Aspirin	C		

Date:09/21/00ISR Number: 3596295-7Report Type:Periodic Company Report #WAES 00064498
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				
			Valium	C				

Date:09/21/00ISR Number: 3596296-9Report Type:Periodic Company Report #WAES 00064499
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Eating Disorder							
	Nausea							
	Weight Increased		Prilosec	C				

Date:09/21/00ISR Number: 3596297-0Report Type:Periodic Company Report #WAES 00064518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596298-2Report Type:Periodic Company Report #WAES 00064519
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596300-8Report Type:Periodic Company Report #WAES 00064520
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596301-XReport Type:Periodic Company Report #WAES 00064521
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596306-9Report Type:Periodic Company Report #WAES 00064522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Anorexia Constipation Dermatitis Dry Mouth Dry Throat Fluid Retention Hyperhidrosis Insomnia Laceration Nail Disorder Nasal Congestion Oedema Pyrexia Upper Respiratory Tract Infection Urinary Tract Infection Vision Blurred Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596307-0Report Type:Periodic Company Report #WAES 00064534
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
50 MG/

DAILY/PO

Date:09/21/00ISR Number: 3596308-2Report Type:Periodic Company Report #WAES 00064600
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dermatitis							
	Diarrhoea							
	Dizziness		Norvasc	C				
	Dyspnoea							
	Urticaria							

Date:09/21/00ISR Number: 3596309-4Report Type:Periodic Company Report #WAES 00064602
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO

Combivent	C
Cozaar	C
Flovent	C
Clucotrol	C
Metrogel	C
Singulair	C
Zebeta	C
Aspirin	C
Furosemide	C

Date:09/21/00ISR Number: 3596315-XReport Type:Periodic Company Report #WAES 00060532
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596316-1Report Type:Periodic Company Report #WAES 00060533
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Amaryl	C
Celebrex	C
Lortab	C
Zoloft	C
Insulin	C

Date:09/21/00ISR Number: 3596317-3Report Type:Periodic Company Report #WAES 00060540
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dynacirc	C				
			Trandate	C				

Date:09/21/00ISR Number: 3596318-5Report Type:Periodic Company Report #WAES 00060541
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tylenol	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596319-7Report Type:Periodic Company Report #WAES 00060544
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Thyroid Therapy Unspecified	C C				

Date:09/21/00ISR Number: 3596320-3Report Type:Periodic Company Report #WAES 00060545
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Sedation		Altace Coumadin Lanoxin Quinidex Extentabs	C C C C				

Date:09/21/00ISR Number: 3596321-5Report Type:Periodic Company Report #WAES 00060547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596322-7Report Type:Periodic Company Report #WAES 00060548
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Asthma							
	Drug Ineffective				Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596323-9Report Type:Periodic Company Report #WAES 00060556
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Nausea							
					Merck Co Inc	ORAL	25 MG/DAILY/PO	2 MON
			Celebrex	C				
			Darvocet-N	C				
			Neurontin	C				
			Premarin	C				
			Tylenol	C				
			Vicodin Tablets	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596324-0Report Type:Periodic Company Report #WAES 00060577
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3596325-2Report Type:Periodic Company Report #WAES 00060578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596326-4Report Type:Periodic Company Report #WAES 00060583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596327-6Report Type:Periodic Company Report #WAES 00060586
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3596328-8Report Type:Periodic Company Report #WAES 00060593
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea							

Date:09/21/00ISR Number: 3596329-XReport Type:Periodic Company Report #WAES 00060596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Malaise							
	Swelling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596331-8Report Type:Periodic Company Report #WAES 00060597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596332-XReport Type:Periodic Company Report #WAES 00060614
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea Weight Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Bumex	C				
			Lanoxin	C				
			Premarin	C				
			Procardia	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3596333-1Report Type:Periodic Company Report #WAES 00060626
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596334-3Report Type:Periodic Company Report #WAES 00060629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage Upper Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3596335-5Report Type:Periodic Company Report #WAES 00060631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ascites	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ibuprofen	C				

Date:09/21/00ISR Number: 3596336-7Report Type:Periodic Company Report #WAES 00060458
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK / UNK /

PO

Lozol	C	
Metamucil	C	
Pravachol	C	
Prilosec	C	
Verelan	C	
Vitamins	C	

Date:09/21/00ISR Number: 3596337-9Report Type:Periodic Company Report #WAES 00060467
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/ DAILY/ PO						
			Os-Cal D	C		
			Premarin	C		
			Vicon-C	C		
			Zestril	C		
			Verapamil	C		

Date:09/21/00ISR Number: 3596338-0Report Type:Periodic Company Report #WAES 00060470
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY/ PO						
			Tab Vioxx 25 Mg	SS		ORAL
25 MG / DAILY / PO						
			Cardura	C		

			Claritin	C
			Neurontin	C
			Zestril	C

Date:09/21/00ISR Number: 3596340-9Report Type:Periodic Company Report #WAES 00060483
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / UNK /	PO 2 MON

Date:09/21/00ISR Number: 3596341-0Report Type:Periodic Company Report #WAES 00060485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Biaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596342-2Report Type:Periodic Company Report #WAES 00060493
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ UNK /						
PO 3 MON						
			Aricept	C		
			Prempro	C		
			Calcium Suplement	C		
			Cortisone	C		
			Sulfasalazine	C		
			Vitamin E	C		

Date:09/21/00ISR Number: 3596343-4Report Type:Periodic Company Report #WAES 00060496
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						

Date:09/21/00ISR Number: 3596344-6Report Type:Periodic Company Report #WAES 00060498
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK /						
PO						
			Pravachol	C		
			Vasotec	C		

Date:09/21/00ISR Number: 3596345-8Report Type:Periodic Company Report #WAES 00060507
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK UNK/ PO	
	Diarrhoea							
	Dyspepsia							
	Nausea		Prilosec	C				

Date:09/21/00ISR Number: 3596346-XReport Type:Periodic Company Report #WAES 00060509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MTG / DAILY/ PO	
	Drug Ineffective							
			Premarin	C				
			Prilosec	C				
			Provera	C				
			Atenolol	C				
			Hydrochlorothiazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596347-1Report Type:Periodic Company Report #WAES 00060511
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:09/21/00ISR Number: 3596349-5Report Type:Periodic Company Report #WAES 00060513
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder Oral Pain Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG / DAILY/ PO	
			Atacand	C				
			Hydrodiuril	C				
			Aspirin	C				
			Calcium Supplement	C				

Date:09/21/00ISR Number: 3596350-1Report Type:Periodic Company Report #WAES 00060516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder Photopsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

Tab Vioxx SS ORAL
UNK / UNK /

PO 3 DAY
Hormones C

Date:09/21/00ISR Number: 3596351-3Report Type:Periodic Company Report #WAES 00060518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / UNK	/ PO
			Azmacort	C				

Date:09/21/00ISR Number: 3596352-5Report Type:Periodic Company Report #WAES 00060519
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Cardura	C				
			Centrum	C				
			Colace	C				
			Premarin	C				

			Vitamin E	C

Date:09/21/00ISR Number: 3596353-7Report Type:Periodic Company Report #WAES 00060520
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	

Date:09/21/00ISR Number: 3596354-9Report Type:Periodic Company Report #WAES 00060521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / DAILY/ PO	9 DAY
			Avandia	C				
			Lanoxin	C				
			Ziac	C				
			Allopurinol	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3596355-0Report Type:Periodic Company Report #WAES 00060525
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

PO

Tab Vioxx 25 Mg SS ORAL

UNK / UNK /

PO

Prednisone C

Date:09/21/00ISR Number: 3596356-2Report Type:Periodic Company Report #WAES 00060528
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY/ PO	
			Prilosec	C				

Date:09/21/00ISR Number: 3596365-3Report Type:Periodic Company Report #WAES 00060530
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596366-5Report Type:Periodic Company Report #WAES 00060120
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596367-7Report Type:Periodic Company Report #WAES 00060121
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
		Company Representative	Amaryl	C				

Date:09/21/00ISR Number: 3596368-9Report Type:Periodic Company Report #WAES 00060171
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 12.5 MG/DAILY/PO	
		Company Representative	Premarin	C				

Date:09/21/00ISR Number: 3596369-0Report Type:Periodic Company Report #WAES 00060182
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
			Celexa	C				
			Claritin	C				
			Dynacirc	C				
			Flexeril	C				
			Nasacort (Therapy Unsepcified	C				
			Clonazepam	C				
			Estradiol	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3596370-7Report Type:Periodic Company Report #WAES 00060186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596371-9Report Type:Periodic Company Report #WAES 00060187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flat Affect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596372-0Report Type:Periodic Company Report #WAES 00060198
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Buspar	C				
			Catapres	C				
			Darvocet-N	C				

Date:09/21/00ISR Number: 3596373-2Report Type:Periodic Company Report #WAES 00060205
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Eye Haemorrhage Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased		Lortab	C				
			Herbal Remedies	C				

Date:09/21/00ISR Number: 3596375-6Report Type:Periodic Company Report #WAES 00060206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Celebrex	C		

Date:09/21/00ISR Number: 3596378-1Report Type:Periodic Company Report #WAES 00060207
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
	Pruritus	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
50 MG /DAILY/						
PO						
			Celebrex	C		
			Elavil	C		
			Premarin	C		
			Prozac	C		
			Tenormin	C		
			Zantac	C		
			Doxycycline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596379-3Report Type:Periodic Company Report #WAES 00060209
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Paxil	C				
			Premarin	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3596380-XReport Type:Periodic Company Report #WAES 00060212
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO
			K-Dur	C				
			Vicodin	C				
			Xanax	C				
			Diazepam	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3596381-1Report Type:Periodic Company Report #WAES 00060219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/	PO

Date:09/21/00ISR Number: 3596382-3Report Type:Periodic Company Report #WAES 00060220
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3596383-5Report Type:Periodic Company Report #WAES 00060225
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain Ecchymosis Muscular Weakness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO;P O						
			Centrum	C		
			Coumadin	C		
			Elavil	C		
			Premarin	C		
			Prevacid	C		
			Ascorbic Acid	C		

			B Vitamins	C
			Vitamin B Complex	C
			Vitamin E	C

Date:09/21/00ISR Number: 3596384-7Report Type:Periodic Company Report #WAES 00060228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			
	Pruritus	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596385-9Report Type:Periodic Company Report #WAES 00060229
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Hepatic Function Abnormal	Health			Laboratories Div			
	Pain	Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Swelling						PO	
			Tylenol Extra Strength	C				

Date:09/21/00ISR Number: 3596386-0Report Type:Periodic Company Report #WAES 00060234
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue				Laboratories Div			
					Merck Co Inc	ORAL	PO	5 WK
			Darvocet	C				
			Elavil	C				
			Xanax	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596387-2Report Type:Periodic Company Report #WAES 00060236
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596388-4Report Type:Periodic Company Report #WAES 00060240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596389-6Report Type:Periodic Company Report #WAES 00060020
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Allopurinol	C				
			Temazepam	C				

Date:09/21/00ISR Number: 3596390-2Report Type:Periodic Company Report #WAES 00060026
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Mavik	C				

Date:09/21/00ISR Number: 3596391-4Report Type:Periodic Company Report #WAES 00060027
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspepsia Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:09/21/00ISR Number: 3596392-6Report Type:Periodic Company Report #WAES 00060029
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Amaryl	C				
			Calan Sr	C				
			Daypro	C				
			Demadex	C				
			Glucophage	C				
			Ogen	C				
			Prilosec	C				
			Ziac	C				
			Sucralfate	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596393-8Report Type:Periodic Company Report #WAES 00060030
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benadryl	C				
			Celebex	C				
			Prempro	C				

Date:09/21/00ISR Number: 3596394-XReport Type:Periodic Company Report #WAES 00060031
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Methyldopa	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596395-1Report Type:Periodic Company Report #WAES 00060032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:09/21/00ISR Number: 3596396-3Report Type:Periodic Company Report #WAES 00060035
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Asthenia Blood Pressure Decreased Fatigue Gastrointestinal Infection Haematuria Influenza Like Illness Movement Disorder Nausea Swelling Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3596397-5Report Type:Periodic Company Report #WAES 00060039
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Flushing Lacrimation Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596398-7Report Type:Periodic Company Report #WAES 00060041
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Discharge	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Dyazide	C				
			Lopressor	C				
			Norvasc	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3596399-9Report Type:Periodic Company Report #WAES 00060042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fusamax	C				
			Zestril	C				

Date:09/21/00ISR Number: 3596400-2Report Type:Periodic Company Report #WAES 00060047
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:09/21/00ISR Number: 3596401-4Report Type:Periodic Company Report #WAES 00060049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Capoten	C				
			Fosamax	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Tylenol Pm	C				
			Zocor	C				
			Aspirin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596402-6Report Type:Periodic Company Report #WAES 00060050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIL;Y/PO	
			Hyzaar	C				

				Norvasc	C		

Date:09/21/00ISR Number: 3596403-8Report Type:Periodic Company Report #WAES 00060051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596404-XReport Type:Periodic Company Report #WAES 00060052
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596405-1Report Type:Periodic Company Report #WAES 00060053
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Tylenol Pm	C				
			Glucosaine	C				

Date:09/21/00ISR Number: 3596406-3Report Type:Periodic Company Report #WAES 00060057
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Caltrate	C				
			Coumadin	C				
			Dyazide	C				
			Synthroid	C				
			Zantac	C				
			Prednisone	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596407-5Report Type:Periodic Company Report #WAES 00060059
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY//PO	
			Tylenol	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596408-7Report Type:Periodic Company Report #WAES 00060062
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Dyazide	C				
			Flonase	C				
			Flovent	C				
			Fosamax	C				
			Nabumetone	C				

Date:09/21/00ISR Number: 3596847-4Report Type:Periodic Company Report #WAES 00061472
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:09/21/00ISR Number: 3596848-6Report Type:Periodic Company Report #WAES 00061475
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596849-8Report Type:Periodic Company Report #WAES 00061479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Asthenia							
	Fatigue							
	Pharyngitis		Plendil	C				
	Swelling		Atenolol	C				

Date:09/21/00ISR Number: 3596850-4Report Type:Periodic Company Report #WAES 00061482
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecifed	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596851-6Report Type:Periodic Company Report #WAES 00061488
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dysgraphia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
	Movement Disorder Reading Disorder		Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596852-8Report Type:Periodic Company Report #WAES 00061489
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/QOD/PO	
			Celebrex	C				
			Lipitor	C				
			Premarin	C				
			Calcium Supplement	C				
			Glucosamine	C				
			Phenobarbital	C				
			Progesterone	C				

Date:09/21/00ISR Number: 3596853-XReport Type:Periodic Company Report #WAES 00061495
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Centrum	C				

Ecotrin	C
Synthroid	C
Tenormin	C

Date:09/21/00ISR Number: 3596854-1Report Type:Periodic Company Report #WAES 00061497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596855-3Report Type:Periodic Company Report #WAES 00061498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall Pigmentation Disorder Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596856-5Report Type:Periodic Company Report #WAES 00061501
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Ascites	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596857-7Report Type:Periodic Company Report #WAES 00061511
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Hyperhidrosis Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem Cd	C				
			Humulin N	C				
			Humulin R	C				
			L-Thyroxin	C				
			Premarin	C				
			Zestril	C				
			Diazepam	C				
			Furosemide	C				
			Glyburide	C				
			Nortriptyline	C				

Date:09/21/00ISR Number: 3596859-0Report Type:Periodic Company Report #WAES 00061512
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Clartin-D	C
Tagamet	C
Atenolol	C
Clonidine	C

Date:09/21/00ISR Number: 3596860-7Report Type:Periodic Company Report #WAES 00061519
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596861-9Report Type:Periodic Company Report #WAES 00061521
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596862-0Report Type:Periodic Company Report #WAES 00061522
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sneezing	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596864-4Report Type:Periodic Company Report #WAES 00061546
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dermatitis Joint Swelling Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596865-6Report Type:Periodic Company Report #WAES 00061556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596867-XReport Type:Periodic Company Report #WAES 00061561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596868-1Report Type:Periodic Company Report #WAES 00061567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596869-3Report Type:Periodic Company Report #WAES 00061573
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596870-XReport Type:Periodic Company Report #WAES 00052566
Age: Gender:Male I/FU:I

Outcome	PT
	Anorectal Disorder Constipation

	Rectal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cardura	C				
			Coumadin	C				
			Dilacor Xr	C				
			K-Dur	C				
			Lanoxin	C				
			Lozol	C				
			Tenormin	C				

Date:09/21/00ISR Number: 3596871-1Report Type:Periodic Company Report #WAES 00052568
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Flatulence Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) PO; 2) 25 MG/DAILY/PO (THERAPY DATES UNK)	
			Elavil	C				
			Premarin	C				
			Verapamil	C				

Date:09/21/00ISR Number: 3596873-5Report Type:Periodic Company Report #WAES 00052569
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Hyperhidrosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Palpitations	Company Representative			Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Rythmol	C		
			Tapazole	C		

Date:09/21/00ISR Number: 3596874-7Report Type:Periodic Company Report #WAES 00052574
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Fluid Retention					
	Weight Increased				Merck Co Inc	ORAL
PO						
			Diovan	C		
			Norvasc	C		
			One-A-Day Essential Vitamins	C		
			Aspirin	C		
			Calcium Supplement	C		
			Vitamin E	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596875-9Report Type:Periodic Company Report #WAES 00052578
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Miacalcin	C				

Date:09/21/00ISR Number: 3596876-0Report Type:Periodic Company Report #WAES 00052580
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Glucotrol	C				

Date:09/21/00ISR Number: 3596877-2Report Type:Periodic Company Report #WAES 00052581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596879-6Report Type:Periodic Company Report #WAES 00052583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			

	Abdominal Tenderness					Laboratories Div	
	Chest Pain					Merck Co Inc	ORAL
25							
	Dyspnoea						
MG/DAILY/PO							
	Haemorrhoids						
	Nausea						

Date:09/21/00ISR Number: 3596880-2Report Type:Periodic Company Report #WAES 00052584
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research	
	Dizziness				Laboratories Div	
	Sensation Of Heaviness				Merck Co Inc	ORAL
PO						
			Lipitor	C		
			Toprol Xl Tablets	C		
			Zestril	C		

Date:09/21/00ISR Number: 3596881-4Report Type:Periodic Company Report #WAES 00052585
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
1) 12.5						

MG/BID/PO;

2) 25

MG/DAILY/PO

Celebrex	C	
Hydrodiuril	C	
Lipitor	C	
Tylenol	C	
Atenolol	C	
Vitamins	C	

Date:09/21/00ISR Number: 3596883-8Report Type:Periodic Company Report #WAES 00052587
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Epistaxis	Health			Laboratories Div			
	Mouth Haemorrhage	Professional			Merck Co Inc	ORAL	25	

MG/DAILY/PO

Hytrin	C	
Lasix	C	
Proscar	C	
Zestril	C	
Aspirin	C	
Atenolol	C	

Date:09/21/00ISR Number: 3596884-XReport Type:Periodic Company Report #WAES 00052589
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Pruritus				Laboratories Div			
	Urticaria				Merck Co Inc	ORAL	PO	

Levsin	C	
Proventil	C	
Vancenase Aq Nasal Spray	C	

			Vanceril	C		

Date:09/21/00ISR Number: 3596885-1Report Type:Periodic Company Report #WAES 00052591
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Bowel Sounds Abnormal					
	Face Oedema				Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Cephazolin	C		
			Claritin	C		
			Glucophage	C		
			Lasix	C		
			Prilosec	C		
			Propulsid	C		
			Insulin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596886-3Report Type:Periodic Company Report #WAES 00052595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat Cc	C				
			K-Dur	C				
			Lasix	C				
			Mirapex	C				
			Paxil	C				
			Transidione	C				
			Zyrtec	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3596888-7Report Type:Periodic Company Report #WAES 00052597
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Xanax	C				

Date:09/21/00ISR Number: 3596889-9Report Type:Periodic Company Report #WAES 00052602
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Sular	C				
			Zestril	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3596890-5Report Type:Periodic Company Report #WAES 00052606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596891-7Report Type:Periodic Company Report #WAES 00052607
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Theo-Dur	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596892-9Report Type:Periodic Company Report #WAES 00052610
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596894-2Report Type:Periodic Company Report #WAES 00052612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596902-9Report Type:Periodic Company Report #WAES 00052420
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Depression	Health Professional						
	Dizziness							
	Memory Impairment							
	Nausea		Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/BID/PO	
			Estrogenic Preparations	C				

Date:09/21/00ISR Number: 3596903-0Report Type:Periodic Company Report #WAES 00052421
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	PO	
			Tab Zocor	SS				
			Synthroid	C				

Date:09/21/00ISR Number: 3596905-4Report Type:Periodic Company Report #WAES 00052426
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat	C				
			Maxzide	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596906-6Report Type:Periodic Company Report #WAES 00052427
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Stomatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596908-XReport Type:Periodic Company Report #WAES 00052429
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Caltrate	C				
			Premarin	C				

Date:09/21/00ISR Number: 3596909-1Report Type:Periodic Company Report #WAES 00052433
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO

Date:09/21/00ISR Number: 3596910-8Report Type:Periodic Company Report #WAES 00052434
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve	C				
			Motrin	C				
			Tylenol	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3596911-XReport Type:Periodic Company Report #WAES 00052435
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596912-1Report Type:Periodic Company Report #WAES 00052436
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596913-3Report Type:Periodic Company Report #WAES 00052437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596914-5Report Type:Periodic Company Report #WAES 00052438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596915-7Report Type:Periodic Company Report #WAES 00052445
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain Eye Pain Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Ambien	C	
Asacol	C	
Fioricet Tablets	C	
Mirapex	C	
Paxil	C	
Trazodone	C	

Date:09/21/00ISR Number: 3596916-9Report Type:Periodic Company Report #WAES 00052448
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Nasacort	C	

Date:09/21/00ISR Number: 3596917-0Report Type:Periodic Company Report #WAES 00052452
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Pravachol	C		

Date:09/21/00ISR Number: 3596919-4Report Type:Periodic Company Report #WAES 00052456
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flomax (Niflumic Acid (Beta)-Mor	C				
			Lipitor	C				
			Verapamil	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596920-0Report Type:Periodic Company Report #WAES 00052457
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3596921-2Report Type:Periodic Company Report #WAES 00052458
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Ultram C

Date:09/21/00ISR Number: 3596923-6Report Type:Periodic Company Report #WAES 00052459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Therapy Unspecified)	C				

Date:09/21/00ISR Number: 3596924-8Report Type:Periodic Company Report #WAES 00052465
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596925-XReport Type:Periodic Company Report #WAES 00052466
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia	Health Professional						
	Flushing							
	Muscular Weakness							
			Hytrin	C				
			Lipitor	C				
			Norvasc	C				

Date:09/21/00ISR Number: 3596926-1Report Type:Periodic Company Report #WAES 00063003
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Estrogenic Preparations	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596927-3Report Type:Periodic Company Report #WAES 00063007
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
	Oedema Peripheral							
			Avandia	C				
			Diabeta	C				

Date:09/21/00ISR Number: 3596928-5Report Type:Periodic Company Report #WAES 00063009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3596929-7Report Type:Periodic Company Report #WAES 00063012
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596930-3Report Type:Periodic Company Report #WAES 00063013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596931-5Report Type:Periodic Company Report #WAES 00063018
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PRN, PO	
			Evista	C				
			Calcium Supplement	C				
			Carbidopa	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596932-7Report Type:Periodic Company Report #WAES 00063020
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, BID, PO	
			Baycol	C				
			K-Tab	C				
			Maxair Autohaler	C				
			Plavix	C				
			Timoptic-Xe	C				

Date:09/21/00ISR Number: 3596933-9Report Type:Periodic Company Report #WAES 00063043
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Synvisc	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596934-0Report Type:Periodic Company Report #WAES 00063071
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596935-2Report Type:Periodic Company Report #WAES 00063076
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	
			Famvir	C				
			Ogen	C				
			Synthroid	C				
			Nitrofurantoin	C				

Date:09/21/00ISR Number: 3596936-4Report Type:Periodic Company Report #WAES 00063081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3596938-8Report Type:Periodic Company Report #WAES 00052614
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				
			Vancenase	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3596939-XReport Type:Periodic Company Report #WAES 00063084
Age:64 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
	Dry Mouth							
	Nasal Congestion							
	Rhinorrhoea							
			Prinivil	C				
			Conjugated Estrogenic Hormones	C				

Date:09/21/00ISR Number: 3596940-6Report Type:Periodic Company Report #WAES 00052615
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amoxicillin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596941-8Report Type:Periodic Company Report #WAES 00063087
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	
	Dizziness							
	Faeces Discoloured							
	Fatigue							
			Lipitor	C				
			Timoptic	C				

Date:09/21/00ISR Number: 3596942-XReport Type:Periodic Company Report #WAES 00052616
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Diarrhoea	Health						
	Dry Mouth	Professional						
	Dyspepsia							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Bentyl	C				
			Plavix	C				
			Zestril	C				
			Atenolol	C				
			Thyroid	C				
			Insulin	C				
			Amitriptyline	C				
			Prinivil	C				
			Lasix	C				
			Humulin N	C				

Date:09/21/00ISR Number: 3596943-1Report Type:Periodic Company Report #WAES 00063089
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Evista	C				
			Lipitor	C				
			Prinzide	C				
			Zoloft	C				

Date:09/21/00ISR Number: 3596944-3Report Type:Periodic Company Report #WAES 00052620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596945-5Report Type:Periodic Company Report #WAES 00052637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1X/PO	
			Celebrex	C				
			Glyburide	C				
			Verapamil	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3596946-7Report Type:Periodic Company Report #WAES 00063101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Pravachol	C				

Date:09/21/00ISR Number: 3596947-9Report Type:Periodic Company Report #WAES 00052648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 MON

Date:09/21/00ISR Number: 3596948-0Report Type:Periodic Company Report #WAES 00063146
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3596949-2Report Type:Periodic Company Report #WAES 00052649
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596950-9Report Type:Periodic Company Report #WAES 00052650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen(+) Oxycodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596951-0Report Type:Periodic Company Report #WAES 00063149
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Baycol	C				
			Lanoxin	C				
			Pacerone	C				
			Synthroid	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3596952-2Report Type:Periodic Company Report #WAES 00052657
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596953-4Report Type:Periodic Company Report #WAES 00063151
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596954-6Report Type:Periodic Company Report #WAES 00052659
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		
			Celebrex	C			

Date:09/21/00ISR Number: 3596955-8Report Type:Periodic Company Report #WAES 00052660
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596956-XReport Type:Periodic Company Report #WAES 00052661
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Pepcid	C				

				Synvisc	C		
				Zoloft	C		

Date:09/21/00ISR Number: 3596957-1Report Type:Periodic Company Report #WAES 00052670
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Prinivil	C				

Date:09/21/00ISR Number: 3596958-3Report Type:Periodic Company Report #WAES 00052680
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596959-5Report Type:Periodic Company Report #WAES 00052687
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Mental Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

				Tab Vioxx 12.5 Mg	SS		ORAL
12.5 MG DAILY							
PO							
				Zantac	C		

Date:09/21/00ISR Number: 3596960-1Report Type:Periodic Company Report #WAES 00052688
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG /AM/PO						
			Aspirin	C		
			Atenolol	C		
			Glipizide	C		

Date:09/21/00ISR Number: 3596961-3Report Type:Periodic Company Report #WAES 00052689
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Norvasc	C		
			Ascorbic Acid	C		
			Vitamin E	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596962-5Report Type:Periodic Company Report #WAES 00052690
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Nausea	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Atenolol Msd	C				
			Xanax	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3596963-7Report Type:Periodic Company Report #WAES 00052691
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	
			Atenolol	C				

Date:09/21/00ISR Number: 3596964-9Report Type:Periodic Company Report #WAES 00052693
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration	Consumer	Vioxx	PS	Merck Research			
	Malaise				Laboratories Div			
	Vertigo				Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Tiazac	C				

Date:09/21/00ISR Number: 3596965-0Report Type:Periodic Company Report #WAES 00052698
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Prevacid	C				
			Synthroid	C				
			Tylenol	C				
			Amitriptyline	C				
			Folic Acid	C				
			Methotrexate	C				
			Tamoxifen	C				

Date:09/21/00ISR Number: 3596966-2Report Type:Periodic Company Report #WAES 00052707
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596967-4Report Type:Periodic Company Report #WAES 00052708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596968-6Report Type:Periodic Company Report #WAES 00052711
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrooesophageal Reflux Disease Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO	1 DAY
			Coumadin	C				

Date:09/21/00ISR Number: 3596969-8Report Type:Periodic Company Report #WAES 00052712
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:09/21/00ISR Number: 3596970-4Report Type:Periodic Company Report #WAES 00052713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596971-6Report Type:Periodic Company Report #WAES 00052715
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY/PO;	
	Fluid Retention							
	Insomnia							
	Weight Increased							
			Avandia	C			2) 25 MG/DAILY/PO	
			Demadex	C				
			Glucophage	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596972-8Report Type:Periodic Company Report #WAES 00052717
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intraocular Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timoptic-Xe	C				

Date:09/21/00ISR Number: 3596973-XReport Type:Periodic Company Report #WAES 00052719
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/BID/PO; 2) 25 MG/DAILY/PO	
			Premarin	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3596974-1Report Type:Periodic Company Report #WAES 00052720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3596975-3Report Type:Periodic Company Report #WAES 00052724
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596976-5Report Type:Periodic Company Report #WAES 00052725
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3596977-7Report Type:Periodic Company Report #WAES 00052726
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

		Lotensin	C
		Tylenol Extra Strength	C
		Zocor	C
		Vitamins	C

Date:09/21/00ISR Number: 3596978-9Report Type:Periodic Company Report #WAES 00052728
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Capoten	C				

Date:09/21/00ISR Number: 3596979-0Report Type:Periodic Company Report #WAES 00052729
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan	C				
			Maxzide	C				
			Premarin	C				
			Prozac	C				

Date:09/21/00ISR Number: 3596980-7Report Type:Periodic Company Report #WAES 00052735
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

			Lasix	C
			Norvasc	C
			Tylenol	C

Date:09/21/00ISR Number: 3596981-9Report Type:Periodic Company Report #WAES 00052468
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Cardura	C
			Glucotrol Xl	C
			Neurontin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596982-0Report Type:Periodic Company Report #WAES 00052738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596983-2Report Type:Periodic Company Report #WAES 00052739
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Drug Ineffective Fatigue Hyperhidrosis Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596984-4Report Type:Periodic Company Report #WAES 00052472
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem Cd	C				
			Lipitor	C				
			Tiazac	C				

Date:09/21/00ISR Number: 3596985-6Report Type:Periodic Company Report #WAES 00052474
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Micro K	C				
			Synthroid	C				
			Tenex	C				
			Vasotec	C				
			Atenolol	C				
			Furosemide	C				

Date:09/21/00ISR Number: 3596986-8Report Type:Periodic Company Report #WAES 00052741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596987-XReport Type:Periodic Company Report #WAES 00052742
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/DAILY/PO; 2) 37.5 MG/DAILY/PO	
	Cough							
	Drug Effect Decreased							
			Azmacort	C				
			Albuterol	C				

Date:09/21/00ISR Number: 3596988-1Report Type:Periodic Company Report #WAES 00052496
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596989-3Report Type:Periodic Company Report #WAES 00052497
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596990-XReport Type:Periodic Company Report #WAES 00052507
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
	Dermatitis							
	Dry Mouth							
	Dyspnoea							
	Fatigue							
	Vocal Cord Disorder							

Date:09/21/00ISR Number: 3596991-1Report Type:Periodic Company Report #WAES 00052508
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	30 DAY

Date:09/21/00ISR Number: 3596992-3Report Type:Periodic Company Report #WAES 00052512
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3596993-5Report Type:Periodic Company Report #WAES 00052743
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Constipation							
	Drug Ineffective				Merck Co Inc	ORAL	12.5, 25 MG , DAILY, PO	

Date:09/21/00ISR Number: 3596994-7Report Type:Periodic Company Report #WAES 00052531
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596995-9Report Type:Periodic Company Report #WAES 00052533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3596996-0Report Type:Periodic Company Report #WAES 00052744
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chronic Leukaemia	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective				Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL

25 MG AND 75

MG, DAILY, PO

Corgard	C	
Mysoline	C	
Vitamins	C	

Date:09/21/00ISR Number: 3596997-2Report Type:Periodic Company Report #WAES 00052746
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia				Laboratories Div	
	Hypoaesthesia				Merck Co Inc	ORAL

Dose Duration

12.5 MG, BID,

PO

Dimethyl Sulfone	C	
Glucosamine	C	
Vitamins	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3596998-4Report Type:Periodic Company Report #WAES 00052747
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY, PO	6 WK

Date:09/21/00ISR Number: 3596999-6Report Type:Periodic Company Report #WAES 00052540
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Terazosin	C				

Date:09/21/00ISR Number: 3597000-0Report Type:Periodic Company Report #WAES 00052749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Sleep Disorder		Lanoxin	C				
			Premarin	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597001-2Report Type:Periodic Company Report #WAES 00052542
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Flushing Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

50

MG/DAILY/PO

Fosamax	C	
Zocor	C	
Atenolol	C	

Date:09/21/00ISR Number: 3597002-4Report Type:Periodic Company Report #WAES 00052544
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Myalgia Nausea Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Ambien	C	
Percocet	C	
Estrogenic Preparations (Composi	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597003-6Report Type:Periodic Company Report #WAES 00052571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597004-8Report Type:Periodic Company Report #WAES 00052549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597005-XReport Type:Periodic Company Report #WAES 00052556
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO; 25 MG/PM/PO	
			..	C				
			Prilosec	C				
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3597007-3Report Type:Periodic Company Report #WAES 00052557
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597008-5Report Type:Periodic Company Report #WAES 00052558
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	10 DAY
			Levatol	C				
			Plavix	C				
			Pravachol	C				
			Prilosec	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597009-7Report Type:Periodic Company Report #WAES 00052752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Prilosec	C				
			Zestril	C				
			Verapamil	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597011-5Report Type:Periodic Company Report #WAES 00052753
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597012-7Report Type:Periodic Company Report #WAES 00052754
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Warfarin	C				

Date:09/21/00ISR Number: 3597013-9Report Type:Periodic Company Report #WAES 00052755
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	3 WK
			Tenormin	C				

Date:09/21/00ISR Number: 3597014-0Report Type:Periodic Company Report #WAES 00052756
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597015-2Report Type:Periodic Company Report #WAES 00052757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				
			Norvasc	C				
			Zocor	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3597016-4Report Type:Periodic Company Report #WAES 00052771
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597017-6Report Type:Periodic Company Report #WAES 00052780
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Cognitive Disorder Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gait Disturbance		K-Dur	C				
			Lasix	C				
			Lipitor	C				
			Synthroid	C				
			Aspirin	C				
			Nortriptyline	C				

Date:09/21/00ISR Number: 3597018-8Report Type:Periodic Company Report #WAES 00052789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Relafen	C				

Date:09/21/00ISR Number: 3597019-XReport Type:Periodic Company Report #WAES 00052790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Movement Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597020-6Report Type:Periodic Company Report #WAES 00052791
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597021-8Report Type:Periodic Company Report #WAES 00052794
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	25 MG/DAILY/PO	
			Arava	C				
			Celebrex	C				
			Plaquenil	C				
			Methotrexate	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3597022-XReport Type:Periodic Company Report #WAES 00052795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Cardura	C				
			Lescol	C				

Date:09/21/00ISR Number: 3597023-1Report Type:Periodic Company Report #WAES 00052803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597044-9Report Type:Periodic Company Report #WAES 00052560
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accupril	C				
			Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597047-4Report Type:Periodic Company Report #WAES 00052562
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Calcium Supplement (Composition	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597050-4Report Type:Periodic Company Report #WAES 00052563
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Anadrol	C				
			Antivert	C				
			Ativan	C				
			Celebrex	C				
			Inderal	C				
			Parafon Forte	C				
			Diuretic Preparation (Compositio	C				

Date:09/21/00ISR Number: 3597054-1Report Type:Periodic Company Report #WAES 00060241
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Avapro	C	
Lipitor	C	
Zocor	C	
Nitroglycerin	C	

Date:09/21/00ISR Number: 3597055-3Report Type:Periodic Company Report #WAES 00060243
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Memory Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO; 25 MG/PO	

Date:09/21/00ISR Number: 3597057-7Report Type:Periodic Company Report #WAES 00060245
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597058-9Report Type:Periodic Company Report #WAES 00060247
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Headache Jaundice	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Atenolol	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3597059-0Report Type:Periodic Company Report #WAES 00060254
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597060-7Report Type:Periodic Company Report #WAES 00060256
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597061-9Report Type:Periodic Company Report #WAES 00060263
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:09/21/00ISR Number: 3597063-2Report Type:Periodic Company Report #WAES 00060282
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspnoea Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Respiratory Disorder		Inj Leuprolide Monoacetate (Salt)	SS			3.75 MG/DAILY/INJ	
			Celebrex	C				

Date:09/21/00ISR Number: 3597065-6Report Type:Periodic Company Report #WAES 00060287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597066-8Report Type:Periodic Company Report #WAES 00060292
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Florinef	C				
			Synthroid	C				
			Allopurinol	C				
			Potassium Supplement (Compositio	C				

Date:09/21/00ISR Number: 3597068-1Report Type:Periodic Company Report #WAES 00060293
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celexa	C				
			Fosamax	C				
			Pravachol	C				
			Atenolol	C				
			Lorazepam	C				
			Spironolactone	C				

Date:09/21/00ISR Number: 3597069-3Report Type:Periodic Company Report #WAES 00060299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597071-1Report Type:Periodic Company Report #WAES 00060303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Captopril	C				

Date:09/21/00ISR Number: 3597074-7Report Type:Periodic Company Report #WAES 00060304
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597075-9Report Type:Periodic Company Report #WAES 00060306
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597079-6Report Type:Periodic Company Report #WAES 00060312
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			[Therapy Unspecified]	SS				
			Azmacort	C				
			Lanoxin	C				
			Proventil	C				
			Tenormin	C				
			Theo-Dur	C				
			Albuterol	C				
			Erythromycin	C				
			Potassium Supplement (Compositio	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597080-2Report Type:Periodic Company Report #WAES 00060313
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Occult Blood Haemorrhoids	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Rectal Haemorrhage	Professional			Merck Co Inc	ORAL
PO						
			Arimidex	C		
			Mevacor	C		
			[Therapy Unspecified]	C		

Date:09/21/00ISR Number: 3597082-6Report Type:Periodic Company Report #WAES 00060315
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Aspirin	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597084-XReport Type:Periodic Company Report #WAES 00060318
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Zestril	C				

Date:09/21/00ISR Number: 3597086-3Report Type:Periodic Company Report #WAES 00060326
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrace	C				
			Fioricet Tablets	C				

Date:09/21/00ISR Number: 3597088-7Report Type:Periodic Company Report #WAES 00060686
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Prilosec	C				
			Proventil Inhaler	C				
			Synthroid	C				
			Zyrtec	C				
			Sodium Bicarbonate	C				

Date:09/21/00ISR Number: 3597090-5Report Type:Periodic Company Report #WAES 00060688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Doxepin	C				
			Ibuprofen	C				

Date:09/21/00ISR Number: 3597091-7Report Type:Periodic Company Report #WAES 00060689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597092-9Report Type:Periodic Company Report #WAES 00060692
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Estrogenic Preparations (Composi	C				

Date:09/21/00ISR Number: 3597094-2Report Type:Periodic Company Report #WAES 00060695
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597096-6Report Type:Periodic Company Report #WAES 00060696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrace	C				
			Xanax	C				
			Zantac	C				

Date:09/21/00ISR Number: 3597097-8Report Type:Periodic Company Report #WAES 00060700
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Fosamax	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3597099-1Report Type:Periodic Company Report #WAES 00060703
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastroenteritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Estrogenic					

			Preparations (Composi	C		

Date:09/21/00ISR Number: 3597100-5Report Type:Periodic Company Report #WAES 00060704
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pamelor	C				
			Synthroid	C				
			Tylenol	C				

Date:09/21/00ISR Number: 3597102-9Report Type:Periodic Company Report #WAES 00060705
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiccups	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:09/21/00ISR Number: 3597104-2Report Type:Periodic Company Report #WAES 00060708
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Pepcid Ac	C				

Date:09/21/00ISR Number: 3597105-4Report Type:Periodic Company Report #WAES 00060709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Dyazide	C				
			Prempro	C				
			Prozac	C				

Date:09/21/00ISR Number: 3597107-8Report Type:Periodic Company Report #WAES 00060710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avandia	C				
			Glucophage	C				
			Lasix	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597110-8Report Type:Periodic Company Report #WAES 00060717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vancomycin	SS			9	WK
			Percocet	C				

Date:09/21/00ISR Number: 3597112-1Report Type:Periodic Company Report #WAES 00060721
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597114-5Report Type:Periodic Company Report #WAES 00060722
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
			Celebrex	C				
			Lipitor	C				
			Zyban	C				

Date:09/21/00ISR Number: 3597115-7Report Type:Periodic Company Report #WAES 00060725
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Betapace	C				
			Coumadin	C				
			Lanoxin	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3597117-0Report Type:Periodic Company Report #WAES 00060727
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597120-0Report Type:Periodic Company Report #WAES 00060728
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Indocin (Indomethacin Sodium Sal	C				
			Relafen	C				

Date:09/21/00ISR Number: 3597121-2Report Type:Periodic Company Report #WAES 00060729
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Keratoconjunctivitis Sicca	Health Professional						
	Mucous Membrane Disorder							
	Muscular Weakness							

Date:09/21/00ISR Number: 3597125-XReport Type:Periodic Company Report #WAES 00060641
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypoaesthesia							
	Muscular Weakness							
			Corgard	C				
			Zantac	C				

Date:09/21/00ISR Number: 3597127-3Report Type:Periodic Company Report #WAES 00060642
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctivitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:09/21/00ISR Number: 3597128-5Report Type:Periodic Company Report #WAES 00060643
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Viral Rash	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tamoxifen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597130-3Report Type:Periodic Company Report #WAES 00060645
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:09/21/00ISR Number: 3597131-5Report Type:Periodic Company Report #WAES 00060646
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/PO	
			Premarin	C				
			Prilosec	C				
			Provera	C				

Date:09/21/00ISR Number: 3597133-9Report Type:Periodic Company Report #WAES 00060648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:09/21/00ISR Number: 3597138-8Report Type:Periodic Company Report #WAES 00081163
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Drug Ineffective Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diazide	C				
			Premarin	C				

Date:09/21/00ISR Number: 3597142-XReport Type:Periodic Company Report #WAES 00060649
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carcinoembryonic Antigen Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3597144-3Report Type:Periodic Company Report #WAES 00060650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

			Duragesic	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3597147-9Report Type:Periodic Company Report #WAES 00060655
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/3XW/PO	
			Flovent	C				
			Prilosec	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3597149-2Report Type:Periodic Company Report #WAES 00081164
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lopressor	C				
			Tylenol	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3597151-0Report Type:Periodic Company Report #WAES 00060657
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 2 WK

			Premarin	C
			Synthroid	C

Date:09/21/00ISR Number: 3597152-2Report Type:Periodic Company Report #WAES 00081165
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Follicle Stimulating Hormone Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estradiol	C				

Date:09/21/00ISR Number: 3597153-4Report Type:Periodic Company Report #WAES 00060659
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG	
	Pruritus		Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597154-6Report Type:Periodic Company Report #WAES 00081168
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Zyrtec	C				

Date:09/21/00ISR Number: 3597155-8Report Type:Periodic Company Report #WAES 00060660
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN PO	

Date:09/21/00ISR Number: 3597156-XReport Type:Periodic Company Report #WAES 00081173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Zoloft	C				

Date:09/21/00ISR Number: 3597158-3Report Type:Periodic Company Report #WAES 00081176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:09/21/00ISR Number: 3597159-5Report Type:Periodic Company Report #WAES 00060663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Thirst	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597160-1Report Type:Periodic Company Report #WAES 00060666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597161-3Report Type:Periodic Company Report #WAES 00081182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prozac	C				
			[Therapy Unspecified]	C				

Date:09/21/00ISR Number: 3597162-5Report Type:Periodic Company Report #WAES 00060670
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prednisone	C				

Date:09/21/00ISR Number: 3597164-9Report Type:Periodic Company Report #WAES 00081185
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:09/21/00ISR Number: 3597166-2Report Type:Periodic Company Report #WAES 00060671
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukocytoclastic Vasculitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597167-4Report Type:Periodic Company Report #WAES 00081186
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3597169-8Report Type:Periodic Company Report #WAES 00060673
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
		Company Representative	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597170-4Report Type:Periodic Company Report #WAES 00081198
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597171-6Report Type:Periodic Company Report #WAES 00060675
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO	

Date:09/21/00ISR Number: 3597172-8Report Type:Periodic Company Report #WAES 00081222
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dermatitis							
	Fatigue							
	Hypersensitivity							
	Pruritus		Diflucan	C				
			Drixoral	C				
			Albuterol	C				
			Bupropion Hydrochloride	C				
			Clindamycin	C				

Date:09/21/00ISR Number: 3597173-XReport Type:Periodic Company Report #WAES 00060678
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	
			Diovan	C				

Date:09/21/00ISR Number: 3597174-1Report Type:Periodic Company Report #WAES 00081229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	[Therapeutic Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597176-5Report Type:Periodic Company Report #WAES 00060680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597178-9Report Type:Periodic Company Report #WAES 00081232
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspepsia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597180-7Report Type:Periodic Company Report #WAES 00081236
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3597181-9Report Type:Periodic Company Report #WAES 00060327
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Diovan Hct	C		
				Prevacid	C		
				Synthroid	C		

Date:09/21/00ISR Number: 3597183-2Report Type:Periodic Company Report #WAES 00060336
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
	Pruritus	Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	

Date:09/21/00ISR Number: 3597184-4Report Type:Periodic Company Report #WAES 00081243
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Allegra	C				
			Elavil	C				
			Estrace	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597185-6Report Type:Periodic Company Report #WAES 00060342
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Discharge	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				

Date:09/21/00ISR Number: 3597187-XReport Type:Periodic Company Report #WAES 00060347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ascriptin	C				

Date:09/21/00ISR Number: 3597188-1Report Type:Periodic Company Report #WAES 00060350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597191-1Report Type:Periodic Company Report #WAES 00060359
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Mucosal	Consumer	Vioxx	PS	Merck Research			

	Discolouration				Laboratories Div	
	Oral Pain				Merck Co Inc	ORAL

12.5

MG/BID/PO 1 MON

Prilosec	C
Trental	C
Therapy Unspecified	C
Theophylline	C

Date:09/21/00ISR Number: 3597192-3Report Type:Periodic Company Report #WAES 00081247
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia				Laboratories Div	
					Merck Co Inc	ORAL

25

MG/DAILY/PO

Maxzide	C
Methotrexate	C
Prednisone	C

Date:09/21/00ISR Number: 3597193-5Report Type:Periodic Company Report #WAES 00060361
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dermatitis Joint Swelling Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:09/21/00ISR Number: 3597195-9Report Type:Periodic Company Report #WAES 00081251
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:09/21/00ISR Number: 3597196-0Report Type:Periodic Company Report #WAES 00060367
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597197-2Report Type:Periodic Company Report #WAES 00060370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Cozaar	C		
			Norvasc	C		
			Prinivil	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3597199-6Report Type:Periodic Company Report #WAES 00081252
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Joint Stiffness	Consumer	Vioxx	PS	Merck Research	
	Pain				Laboratories Div	
	Pain In Extremity				Merck Co Inc	ORAL
25						
	Pollakiuria					
MG/DAILY/PO						
			Evista	C		
			Flonase	C		
			Norvasc	C		
			Terbinafine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597200-XReport Type:Periodic Company Report #WAES 00060372
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597201-1Report Type:Periodic Company Report #WAES 00060373
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597202-3Report Type:Periodic Company Report #WAES 00081262
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597203-5Report Type:Periodic Company Report #WAES 00081264
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Laryngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Lymphadenopathy				Merck Co Inc	ORAL
PO						
			Hydrodiuril	C		
			Norvasc	C		
			Prinivil	C		

Date:09/21/00ISR Number: 3597204-7Report Type:Periodic Company Report #WAES 00060407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Pain				Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3597205-9Report Type:Periodic Company Report #WAES 00060412
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
	Pruritus	Health			Laboratories Div	
	Urticaria	Professional			Merck Co Inc	ORAL
25						

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597206-0Report Type:Periodic Company Report #WAES 00060420
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Chlor-Trimeton	C				
			Evista	C				
			Imdur	C				
			Prilosec	C				
			Procardia Xl	C				
			Synthroid	C				
			Xalatan	C				

Date:09/21/00ISR Number: 3597208-4Report Type:Periodic Company Report #WAES 00060421
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Headache Oedema Peripheral Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597210-2Report Type:Periodic Company Report #WAES 00060429
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597211-4Report Type:Periodic Company Report #WAES 00060437
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection							
			Moduretic	C				
			Tenormin	C				
			Composition Unspecified	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597213-8Report Type:Periodic Company Report #WAES 00060438
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Ear Pain							
			Flovent	C				

Serevent	C	
Tenormin	C	
Therapy Unspecified	C	

Date:09/21/00ISR Number: 3597214-XReport Type:Periodic Company Report #WAES 00060446
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597215-1Report Type:Periodic Company Report #WAES 00060452
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597217-5Report Type:Periodic Company Report #WAES 00061226
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lamisil	C				
			Lasix	C				

			Moduretic	C		
			Premarin	C		
			Synthroid	C		

Date:09/21/00ISR Number: 3597219-9Report Type:Periodic Company Report #WAES 00061230
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oedema Peripheral Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	SS				
			Premarin	C				

Date:09/21/00ISR Number: 3597220-5Report Type:Periodic Company Report #WAES 00061231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597221-7Report Type:Periodic Company Report #WAES 00061233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:09/21/00ISR Number: 3597224-2Report Type:Periodic Company Report #WAES 00061236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597225-4Report Type:Periodic Company Report #WAES 00061237
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Composition Unspecified]	C				

Date:09/21/00ISR Number: 3597227-8Report Type:Periodic Company Report #WAES 00061238
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchiectasis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25	

MG/DAILY/PO

Aldactone	C
Cardizem Cd	C
Combivent	C
Coumadin	C
Prempro	C
Synthroid	C

Date:09/21/00ISR Number: 3597229-1Report Type:Periodic Company Report #WAES 00061239
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO;	

PO

Plendil	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597231-XReport Type:Periodic Company Report #WAES 00061240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							
	Influenza Like Illness				Merck Co Inc	ORAL	PO	3 WK
	Joint Swelling							
	Swelling							

Date:09/21/00ISR Number: 3597233-3Report Type:Periodic Company Report #WAES 00061242
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Effect Decreased							
					Merck Co Inc	ORAL	PO	
			L-Thyroxine	C				
			Lipitor	C				
			Folic Acid	C				
			Garlic Extract	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597235-7Report Type:Periodic Company Report #WAES 00061244
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea							
					Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Accolate	C				
			Tenormin	C				
			Zocor	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3597237-0Report Type:Periodic Company Report #WAES 00061245
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Eyelid Oedema Oedema Peripheral Pigmentation Disorder Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	6 WK

Date:09/21/00ISR Number: 3597239-4Report Type:Periodic Company Report #WAES 00061249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:09/21/00ISR Number: 3597241-2Report Type:Periodic Company Report #WAES 00061250
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia Muscle Spasms Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG	
	Oedema Peripheral Pain		Imitrex Zoloft [Therapy Unspecified]	C C C				

Date:09/21/00ISR Number: 3597243-6Report Type:Periodic Company Report #WAES 00061255
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Fatigue		Atacand Prilosec	C C				

Date:09/21/00ISR Number: 3597246-1Report Type:Periodic Company Report #WAES 00061256
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1X/PO	
	Vomiting							

Date:09/21/00ISR Number: 3597249-7Report Type:Periodic Company Report #WAES 00061257
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Imodium	C				
			Inderal	C				
			Prevacid	C				
			Synthroid	C				
			Tigan	C				
			Tylenol	C				
			[Therapy Unspecified]	C				
			Calcium Carbonate	C				
			Folic Acid	C				
			Methortexate	C				
			Methylprednisolone	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597250-3Report Type:Periodic Company Report #WAES 00061258
Age:57 YR Gender:Male I/FU:I

Outcome	PT
	Dyspepsia Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Atelin	C				
		Flonase	C				
		Nasalcrom	C				
		Tiazac	C				

Date:09/21/00ISR Number: 3597251-5Report Type:Periodic Company Report #WAES 00061259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Aspirin	C				
			Insulin	C				

Date:09/21/00ISR Number: 3597252-7Report Type:Periodic Company Report #WAES 00061260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597253-9Report Type:Periodic Company Report #WAES 00061261
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Pollakiuria Tachycardia Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
			Perdiem Fiber	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597254-0Report Type:Periodic Company Report #WAES 00061263
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogenic Preparation	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597255-2Report Type:Periodic Company Report #WAES 00061265
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	12 DAY
			Flonase	C				
			Flovent	C				
			Premarin	C				
			Theo-Dur	C				
			Ventolin	C				
			Diazepam	C				

Date:09/21/00ISR Number: 3597256-4Report Type:Periodic Company Report #WAES 00061267
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tylenol	C				

Date:09/21/00ISR Number: 3597257-6Report Type:Periodic Company Report #WAES 00061268
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				

Date:09/21/00ISR Number: 3597258-8Report Type:Periodic Company Report #WAES 00061270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
			Coumadin	C				
			Lipitor	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3597259-XReport Type:Periodic Company Report #WAES 00061271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597260-6Report Type:Periodic Company Report #WAES 00061272
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Composition Unspecified	C				

Date:09/21/00ISR Number: 3597261-8Report Type:Periodic Company Report #WAES 00061273
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia Crying	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Amoxicillin	C				

Date:09/21/00ISR Number: 3597262-XReport Type:Periodic Company Report #WAES 00061274
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pigmentation Disorder Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Avandia	C				
			Baycol	C				
			Carafate	C				
			Darvon	C				
			Esgic-Plus Tablet	C				
			Glucotrol	C				
			Losetin	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3597263-1Report Type:Periodic Company Report #WAES 00061276
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Face Oedema							
	Oedema Peripheral							
	Weight Increased		Premarin	C				

Date:09/21/00ISR Number: 3597264-3Report Type:Periodic Company Report #WAES 00061278
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
	Face Oedema							
	Glossodynia							
	Oedema Peripheral		Lortab	C				
	Tongue Disorder		[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597265-5Report Type:Periodic Company Report #WAES 00061285
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cholestin	C				
			Fosamax	C				
			Premarin	C				
			Procardia	C				
			Propine	C				
			Prozar	C				
			Synthroid	C				
			Toprol	C				
			Synthroid	C				
			Toprol Xl Tablet	C				

Date:09/21/00ISR Number: 3597266-7Report Type:Periodic Company Report #WAES 00061289
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Flatulence Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/PO	
			Allegra	C				
			Axid	C				
			Claritin	C				
			Darvocet-N	C				
			Elavil	C				
			Lipitor	C				
			Zestril	C				
			Atenolol	C				
			Glucosamine	C				

Date:09/21/00ISR Number: 3597267-9Report Type:Periodic Company Report #WAES 00061290
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Joint Swelling Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	
PO								
			Aralen	C				
			Estrace	C				
			Prinivil	C				
			Tranxene	C				
			Zantac	C				
			Furosemide	C				
			Metoprolol	C				
			Trazodone	C				

Date:09/21/00ISR Number: 3597268-0Report Type:Periodic Company Report #WAES 00061292
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								

Cozaar C

Date:09/21/00ISR Number: 3597269-2Report Type:Periodic Company Report #WAES 00061293
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597270-9Report Type:Periodic Company Report #WAES 00061295
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Papilloedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 WK

Date:09/21/00ISR Number: 3597271-0Report Type:Periodic Company Report #WAES 00061299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597272-2Report Type:Periodic Company Report #WAES 00061300
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO 3 MON
			Flexeril	C			

Date:09/21/00ISR Number: 3597273-4Report Type:Periodic Company Report #WAES 00061301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597274-6Report Type:Periodic Company Report #WAES 00061302
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nasal Congestion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Inderal	C				

			Lasix	C		
			Lipitor	C		

Date:09/21/00ISR Number: 3597275-8Report Type:Periodic Company Report #WAES 00061304
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Dyazide	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597276-XReport Type:Periodic Company Report #WAES 00061308
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Imdur	C				
			Norvasc	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/21/00ISR Number: 3597277-1Report Type:Periodic Company Report #WAES 00061309
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Inflammation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Darvocet-N	C		
			Synthroid	C		
			Vitamins	C		

Date:09/21/00ISR Number: 3597278-3Report Type:Periodic Company Report #WAES 00061310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				
			Prilosec	C				
			Proscar	C				

Date:09/21/00ISR Number: 3597279-5Report Type:Periodic Company Report #WAES 00061315
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Dysuria	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						

Date:09/21/00ISR Number: 3597280-1Report Type:Periodic Company Report #WAES 00061316
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:09/21/00ISR Number: 3597281-3Report Type:Periodic Company Report #WAES 00061330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Angiopathy Ecchymosis Fluid Retention	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Oedema	Representative	Celebrex	C		

Date:09/21/00ISR Number: 3597282-5Report Type:Periodic Company Report #WAES 00061331
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Depression	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

		Company			Merck Co Inc	ORAL
PO	6 MON					
		Representative				

Date:09/21/00ISR Number: 3597283-7Report Type:Periodic Company Report #WAES 00061335
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:09/21/00ISR Number: 3597284-9Report Type:Periodic Company Report #WAES 00061367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gout	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597285-0Report Type:Periodic Company Report #WAES 00061371
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms Premenstrual Syndrome Uterine Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597286-2Report Type:Periodic Company Report #WAES 00061374
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Toprol Xl Tablets	C				
			Lorazepam	C				

Date:09/21/00ISR Number: 3597287-4Report Type:Periodic Company Report #WAES 00061380
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulum Intestinal Gastritis Gastrointestinal Haemorrhage Pyelonephritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Inderal	C				
			Lescol	C				
			Lodine	C				
			Doxycycline	C				

				Methadone Hydrochloride	C		

Date:09/21/00ISR Number: 3597288-6Report Type:Periodic Company Report #WAES 00061400
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Dermatitis					
	Drug Interaction				Merck Co Inc	ORAL
SEE IMAGE						
	Oedema Peripheral		Evista	SS		
	Weight Increased		Celebrex	C		
			Citrucel Orange Flavor	C		
			Halcion	C		
			Prilosec	C		
			Tums	C		
			Chondroitin (+) Glucosamine	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597289-8Report Type:Periodic Company Report #WAES 00061401
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Celestone	C				
			Bupivacaine Hydrochloride Monohy	C				
			Estradiol	C				

Date:09/21/00ISR Number: 3597290-4Report Type:Periodic Company Report #WAES 00061402
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Miacalcin	C				
			Motrin	C				
			Zocor	C				
			Guaifenesin	C				

Date:09/21/00ISR Number: 3597291-6Report Type:Periodic Company Report #WAES 00061403
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597292-8Report Type:Periodic Company Report #WAES 00061407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597293-XReport Type:Periodic Company Report #WAES 00061408
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	(SEE IMAGE)
			Zithromax	C				
			Calcium Supplement	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597294-1Report Type:Periodic Company Report #WAES 00061416
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Postural	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Cardura	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3597295-3Report Type:Periodic Company Report #WAES 00061417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Klonopin	C				
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597296-5Report Type:Periodic Company Report #WAES 00061419
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat	C				
			Lasix	C				
			Zocor	C				
			Calcium Supplement	C				
			Chondroitin	C				
			Glucosamine	C				
			Potassium Supplement	C				

Date:09/21/00ISR Number: 3597297-7Report Type:Periodic Company Report #WAES 00061420
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Viral Infection	Professional			Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Dyazide	C				
			Evista	C				
			Tenormin	C				
			Xanax	C				
			Trazodone	C				

Date:09/21/00ISR Number: 3597298-9Report Type:Periodic Company Report #WAES 00061422
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

			Lortab	C
			Neurontin	C
			Soma	C

Date:09/21/00ISR Number: 3597299-0Report Type:Periodic Company Report #WAES 00061423
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	(SEE IMAGE)
			Allegra	C				
			Diovan Hct	C				
			Aspirin	C				

Date:09/21/00ISR Number: 3597300-4Report Type:Periodic Company Report #WAES 00061429
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Alupent	C				
			Medrol	C				
			Pepcid	C				
			Singulair	C				
			Volmax	C				

Date:09/21/00ISR Number: 3597301-6Report Type:Periodic Company Report #WAES 00061430
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Coumadin	C
Tylenol	C
Therapy Unspecified	C

Date:09/21/00ISR Number: 3597302-8Report Type:Periodic Company Report #WAES 00061432
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO 30 DAY

Proscar	C
Furosemide	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597303-XReport Type:Periodic Company Report #WAES 00061434
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597304-1Report Type:Periodic Company Report #WAES 00061435
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Zocor	C				

Date:09/21/00ISR Number: 3597305-3Report Type:Periodic Company Report #WAES 00061441
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				
			Prilosec	C				
			Salac	C				
			Acetaminophen (+)					
			Propoxyphene	C				
			Furosemide	C				
			Phenytoin	C				

Date:09/21/00ISR Number: 3597306-5Report Type:Periodic Company Report #WAES 00061444
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	1 DAY
			Monopril	C				
			Prevpac	C				

Date:09/21/00ISR Number: 3597307-7Report Type:Periodic Company Report #WAES 00061449
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve	C				
			Darvocet-N	C				
			Napralen	C				
			Tiger Balm Liquid	C				

Tylenol Pm C

Date:09/21/00ISR Number: 3597308-9Report Type:Periodic Company Report #WAES 00061456
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	(SEE IMAGE)
			Cardizem Cd	C				
			Proventil	C				
			Serevent	C				
			Synthroid	C				

Date:09/21/00ISR Number: 3597309-0Report Type:Periodic Company Report #WAES 00061457
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Zestril	C				

Date:09/21/00ISR Number: 3597310-7Report Type:Periodic Company Report #WAES 00061459
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Colace	C	
				Isordil	C	
				Lasix	C	
				Synthroid	C	
				Vasotec	C	
				Therapy Unspecified	C	
				Digoxin	C	
				Folic Acid	C	
				Potassium Chloride	C	
				Vitamins	C	

Date:09/21/00ISR Number: 3597311-9Report Type:Periodic Company Report #WAES 00061461
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Discolouration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Procardia	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597312-0Report Type:Periodic Company Report #WAES 00061470
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
			Coumadin	C				
			Trilisate	C				
			Ziac	C				
			Diltiazem	C				

Date:09/21/00ISR Number: 3597313-2Report Type:Periodic Company Report #WAES 00042349
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Headache Pharyngitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Pulmonary Congestion		Tab Vioxx 25 Mg	SS		ORAL	PO	
			Asacol	C				
			Evista	C				
			Lasix	C				
			Ibuprofen	C				

Date:09/21/00ISR Number: 3597314-4Report Type:Periodic Company Report #WAES 00042464
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	SS			5MG	
			Imdur	C				
			Pravachol	C				

Date:09/21/00ISR Number: 3597315-6Report Type:Periodic Company Report #WAES 00042474
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Kerlone	C				

Date:09/21/00ISR Number: 3597316-8Report Type:Periodic Company Report #WAES 00042493
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucotrol	C				
			Lipitor	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597317-XReport Type:Periodic Company Report #WAES 00042494
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Endometrial Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3597318-1Report Type:Periodic Company Report #WAES 00042501
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				
			Zyrtec	C				

Date:09/21/00ISR Number: 3597319-3Report Type:Periodic Company Report #WAES 00042517
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Dyspepsia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Mycilan	C				

Date:09/21/00ISR Number: 3597320-XReport Type:Periodic Company Report #WAES 00042535
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Muscle Rigidity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Proventil	C				
			Toprol Xl Tablets	C				
			Nitroglycerin	C				

Date:09/21/00ISR Number: 3597321-1Report Type:Periodic Company Report #WAES 00042551
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tapazole	C				
			Zestril	C				
			Calcium Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597322-3Report Type:Periodic Company Report #WAES 00042557
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance	Consumer	Vioxx	PS	Merck Research			
	Gastrointestinal Disorder	Health			Laboratories Div			
	Oedema Peripheral	Professional			Merck Co Inc	ORAL	12.5	
	Pain						MG/DAILY/PO	
	Rash Erythematous		Hydrodiuril	C				
	Weight Increased		Lasix	C				
			Zocor	C				

Date:09/21/00ISR Number: 3597323-5Report Type:Periodic Company Report #WAES 00042558
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:09/21/00ISR Number: 3597505-2Report Type:Periodic Company Report #WAES 00040543
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Captopril Msd	C				
			Cardizem	C				
			Coumadin	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3597509-XReport Type:Periodic Company Report #WAES 00040559
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Dyspepsia	Professional			Merck Co Inc	ORAL	12.5	
	Influenza						MG/DAILY/PO	
	Oedema Peripheral		Coumadin	C				
	Sedation		Nitroglycerin	C				
	Vertigo		Therapy Unspecified	C				

Date:09/21/00ISR Number: 3597571-4Report Type:Periodic Company Report #WAES 00040568
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research			
	Flatulence				Laboratories Div			
	Insomnia				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Cogentin	C				
			Primaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597572-6Report Type:Periodic Company Report #WAES 00040652
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3597573-8Report Type:Periodic Company Report #WAES 00040658
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition Unspecified	C				

Date:09/21/00ISR Number: 3597574-XReport Type:Periodic Company Report #WAES 00040769
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DILY/PO	SEE IMAGE
	Drug Ineffective							
	Dysuria							
	Memory Impairment							
	Sexual Dysfunction							
	Weight Increased		Glucophage	C				
			Hyzaar	C				
			Motrin	C				
			Peri-Colace	C				
			Tylenol	C				
			Amiloride Hydrochloride	C				
			Diclofenac	C				

			Ibuprofen	C

Date:09/21/00ISR Number: 3597576-3Report Type:Periodic Company Report #WAES 00040776
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PRN/ PO SEE IMAGE	
			Dicloreum	C				
			Diclacor Xr	C				
			Dyazide	C				
			Hydrodiuril	C				
			Calcium Supplement	C				
			Chondroitin (+) Glucosamine	C				
			Estrogenic Preparations	C				
			Vitamin B (12)	C				
			Vitamin A	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597578-7Report Type:Periodic Company Report #WAES 00040777
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Fluid Retention	Health			Laboratories Div			
	Urinary Retention	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Coumadin	C				
			K-Dur	C				
			Prozac	C				
			Tylenol With Codeine #3	C				
			Vasotec	C				
			Ventolin	C				
			Colchicine	C				

Date:09/21/00ISR Number: 3597580-5Report Type:Periodic Company Report #WAES 00040823
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Hyzaar	C				
			Plendil	C				
			Nadolol	C				

Date:09/21/00ISR Number: 3597582-9Report Type:Periodic Company Report #WAES 00040835
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
25 MG/DAILY						
			Demadex	C		
			Elavil	C		
			K=Dur	C		
			Maxzide	C		
			Prilosec	C		
			Stadol	C		
			Uroqid-Acid No. 2	C		
			Valium	C		
			Vicodin Tablets	C		
			Zanaflex	C		
			Trazodone	C		

Date:09/21/00ISR Number: 3597584-2Report Type:Periodic Company Report #WAES 00040993
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nasal Dryness	Consumer	Vioxx	PS	Merck Research	
	Pharyngitis				Laboratories Div	
	Rhinorrhoea				Merck Co Inc	ORAL
PO						
			Covera-Hs	C		
			Lanoxin	C		
			Sudafed	C		
			Ibuprofen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597586-6Report Type:Periodic Company Report #WAES 00041000
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity Palmar Erythema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Darvocet-N	C				
			Fioricet Tablets	C				
			Flexeril	C				
			Synthroid	C				
			Zestril	C				

Date:09/21/00ISR Number: 3597589-1Report Type:Periodic Company Report #WAES 00041020
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Vitamins	SS				
			Lozol	C				
			Vasotec	C				

Date:09/21/00ISR Number: 3597590-8Report Type:Periodic Company Report #WAES 00041028
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Necrosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25	MG/DAILY/UNK

Oruvail Unk SS
200

MG/DAILY/UNK

Orudis C
Aspirin C

Date:09/21/00ISR Number: 3597591-XReport Type:Periodic Company Report #WAES 00041106
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
	Pruritus							
	Urticaria							

MG/DAIULY/PO

Prinivil C
Sythroid C
Atenolol C

Date:09/21/00ISR Number: 3597593-3Report Type:Periodic Company Report #WAES 00041139
Age:45 YR Gender:Female I/FU:F

Outcome	PT
	Dizziness
	Emotional Disorder
	Feeling Abnormal

	Muscular Weakness						
	Nervousness						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D	C				
			Pepcid	C				
			Synthroid	C				
			Ascorbic Acid	C				
			Vitamin E	C				

Date:09/21/00ISR Number: 3597594-5Report Type:Periodic Company Report #WAES 00041154
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bellergal-S Tablets	C				
			Calan	C				
			Cipro	C				
			Hydrodiuril	C				
			Lotensin	C				
			Theo-Dur	C				
			Tamoxifen	C				

Date:09/21/00ISR Number: 3597595-7Report Type:Periodic Company Report #WAES 00041182
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research			
	Paraesthesia	Health			Laboratories Div			

	Pruritus	Professional			Merck Co Inc	ORAL
PO						
	Rash Erythematous		Allegra	C		
			Entex	C		
			Flonase	C		
			Pred Forte	C		
			Provera	C		

Date:09/21/00ISR Number: 3597596-9Report Type:Periodic Company Report #WAES 00041231
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research	
	Headache	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Allegra D	C		
			Tranxene	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3597597-0Report Type:Periodic Company Report #WAES 00041282
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Drug Interaction	Health			Laboratories Div			
	Flatulence	Professional			Merck Co Inc	ORAL	200	
	Insomnia						MG/DAILY/PO	
	Tremor		(Therapy Unspecified) Unk	SS				
			Bumex	C				
			Levoxyl	C				
			Orasone	C				
			Prilosec	C				
			Tylenol With Codeine	C				
			Zoloft	C				
			Allopurinol	C				
			Naproxen	C				
			Prednisone	C				

Date:09/21/00ISR Number: 3597989-XReport Type:Periodic Company Report #WAES 00042601
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			
	Dysgeusia	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

Date:09/21/00ISR Number: 3597990-6Report Type:Periodic Company Report #WAES 00042634
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Didronel	C
Dyazidel	C
Excedrin	
Extra-Strength	C
Levoxyl	C
Premarin	C

Date:09/21/00ISR Number: 3597992-XReport Type:Periodic Company Report #WAES 00042668
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Faecal Incontinence	Health			Laboratories Div	
	Migraine	Professional			Merck Co Inc	ORAL

25

MG/DAILY/PO

Buspar	C
Demerol	C
Percocet	C
Phenergan Tablets/Suppositories	C
Tylenol With Codeine	

			# 3	C		
			Aspirin	C		

Date:09/21/00ISR Number: 3597993-1Report Type:Periodic Company Report #WAES 00042695
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research			
	Faecal Incontinence	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5	MG/BID/PO
			Elavil	C				
			Hydrodiuril	C				
			Valium	C				

Date:09/21/00ISR Number: 3597994-3Report Type:Periodic Company Report #WAES 00042715
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
	Transient Ischaemic	Professional			Merck Co Inc	ORAL	PO	
	Attack							
	Visual Disturbance							

Date:09/21/00ISR Number: 3597995-5Report Type:Periodic Company Report #WAES 00042775
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	12.5	MG/BID/PO

Date:09/21/00ISR Number: 3597996-7Report Type:Periodic Company Report #WAES 00042776
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS				
			Benadryl	C				
			Sudafed	C				
			Calcium Supplement	C				
			Ferrous Sulfate Heptahydrate	C				
			Nonsteroidal Ant-Inflamatory	C				

Date:09/21/00ISR Number: 3597997-9Report Type:Periodic Company Report #WAES 00042797
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Abdominal Pain	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
Claritin	C				
Detrol	C				
Evista	C				
Synthroid	C				
Vasotec	C				
Zoloft	C				

Date:09/21/00ISR Number: 3597998-0Report Type:Periodic Company Report #WAES 00042807
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/ DAILY/ PO	
			Coumadin	C				
			Zoloft	C				
			Lopressor	C				

Date:09/21/00ISR Number: 3597999-2Report Type:Periodic Company Report #WAES 00042815
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Oedema Peripheral	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Urinary Tract Infection	Professional			Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Avalide	C		
			Cardura	C		
			Darvocet-N	C		
			Megace	C		
			Parvachol	C		
			Tylenol	C		
			Allopurinol	C		

Date:09/21/00ISR Number: 3598000-7Report Type:Periodic Company Report #WAES 00050011
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oral Pain	Health	Vioxx	PS	Merck Research	
	Stomatitis	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
25 MG/ DAILY						
		Representative				
/ PO 1 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598001-9Report Type:Periodic Company Report #WAES 00050024
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Fosamax	C				
			Lozol	C				
			Prempro	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3598002-0Report Type:Periodic Company Report #WAES 00050032
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
	Blood Glucose Abnormal							
	Blood Pressure							
	Fluctuation							
	Chest Pain							
	Muscle Spasms							
	Nausea							
	Oedema Peripheral							

Date:09/21/00ISR Number: 3598003-2Report Type:Periodic Company Report #WAES 00050047
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	PO
	Anorexia							
	Constipation							

			Allegra	C		
			Zantac	C		

Date:09/21/00ISR Number: 3598004-4Report Type:Periodic Company Report #WAES 00050067
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia	Company			Laboratories Div	
	Oedema Peripheral	Representative			Merck Co Inc	ORAL
25 MG/ BID /						
PO						
			Atrovent	C		
			Claritin	C		
			Flonase	C		
			Paxil	C		
			Prevacid	C		
			Toprol Xl Tablets	C		
			Valium	C		
			Ethinyl Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598005-6Report Type:Periodic Company Report #WAES 00050071
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Cardura	C				
			Ecotrin	C				
			Lipitor	C				
			Lopressor	C				
			Mevacor	C				
			Prevacid	C				

Date:09/21/00ISR Number: 3598006-8Report Type:Periodic Company Report #WAES 00050175
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Alphagan	C				
			Lipitor	C				
			Nitroquick	C				
			Premarin	C				
			Provera	C				
			Aspirin	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3598007-XReport Type:Periodic Company Report #WAES 00050184
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
25 MG /

DAILY/ PO

Date:09/21/00ISR Number: 3598008-1Report Type:Periodic Company Report #WAES 00050205
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

PO

Date:09/21/00ISR Number: 3598009-3Report Type:Periodic Company Report #WAES 00050211
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / BID /	
			Glucotrol	C				

PO

			Atenolol	C		
			Captopril	C		

Date:09/21/00ISR Number: 3598010-XReport Type:Periodic Company Report #WAES 00050225
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Stiffness Muscle Spasms	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Ultram	C				

Date:09/21/00ISR Number: 3598011-1Report Type:Periodic Company Report #WAES 00050228
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Irritable Bowel Syndrome	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Prempro	C				
			Zocor	C				

Date:09/21/00ISR Number: 3598012-3Report Type:Periodic Company Report #WAES 00050245
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO

			Ambien	C		
			Ulcyn	C		
			Aspirin	C		
			Cimetidine	C		

Date:09/21/00ISR Number: 3598013-5Report Type:Periodic Company Report #WAES 00050256
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	/ PO
			Avapro	C				
			Levoxyl	C				
			Premarin	C				
			Atenolol	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598014-7Report Type:Periodic Company Report #WAES 00050353
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Beclovent	C				
			Albuterol	C				

Date:09/21/00ISR Number: 3598015-9Report Type:Periodic Company Report #WAES 00050355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	

Date:09/21/00ISR Number: 3598016-0Report Type:Periodic Company Report #WAES 00050382
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Pepcid	C				
			Prempro	C				
			Albuterol	C				
			Allpurinol	C				
			Propranolol	C				

Date:09/21/00ISR Number: 3598069-XReport Type:Periodic Company Report #WAES 00041287
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Vioxx	PS	Merck Research			
	Feeling Abnormal	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3598070-6Report Type:Periodic Company Report #WAES 00041393
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Hypoaesthesia	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
	Malaise		Synthroid	C				
	Nausea							
	Oedema Peripheral							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598071-8Report Type:Periodic Company Report #WAES 00041402
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bentyl	C				
			Dyazide	C				
			Estrace	C				

Date:09/21/00ISR Number: 3598072-XReport Type:Periodic Company Report #WAES 00041441
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3598073-1Report Type:Periodic Company Report #WAES 00041450
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Chronic	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				

Date:09/21/00ISR Number: 3598074-3Report Type:Periodic Company Report #WAES 00041492
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral Weight Increased	Consumer Health Professional Company Representative	Vioxx Penicillin (Drug)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:09/21/00ISR Number: 3598075-5Report Type:Periodic Company Report #WAES 00041498
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/21/00ISR Number: 3598076-7Report Type:Periodic Company Report #WAES 00041506
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

				Naproxen	C		

Date:09/21/00ISR Number: 3598077-9Report Type:Periodic Company Report #WAES 00041538
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Gastrointestinal Disorder Pharyngitis Pyrexia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cosopt	C				
			Lipitor	C				
			Codeine	C				

Date:09/21/00ISR Number: 3598078-0Report Type:Periodic Company Report #WAES 00041585
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Lipitor	C				

Date:09/21/00ISR Number: 3598079-2Report Type:Periodic Company Report #WAES 00041630
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Elavil	C
Indocin (Indomethacin)	C
Klonopin	C
Lipitor	C
Relafen	C

Date:09/21/00ISR Number: 3598080-9Report Type:Periodic Company Report #WAES 00041631
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50	

MG/DAILY/PO

Date:09/21/00ISR Number: 3598081-0Report Type:Periodic Company Report #WAES 00041635
Age: Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain Upper
	Diarrhoea
	Drug Ineffective

	Fluid Retention						
	Pruritus						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diuretic Preparation	C				

Date:09/21/00ISR Number: 3598082-2Report Type:Periodic Company Report #WAES 00041639
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness	Health Professional						
	Nausea							
			Pepcid	C				
			Procardia	C				
			Atenolol	C				

Date:09/21/00ISR Number: 3598083-4Report Type:Periodic Company Report #WAES 00041655
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased	Health Professional						
			Atrovent	C				
			Azmacort	C				
			Lopressor	C				
			Monoprol	C				
			Premarin	C				
			Proventil	C				
			Provera	C				

Date:09/21/00ISR Number: 3598084-6Report Type:Periodic Company Report #WAES 00041678
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Oliguria							
	Tinnitus							
	Urine Abnormality							
	Weight Increased							

Date:09/21/00ISR Number: 3598085-8Report Type:Periodic Company Report #WAES 00041681
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Nausea							
			Cytotec	C				
			Dilantin	C				
			Cimetidine	C				
			Indapamide	C				
			Oxybutynin Chloride	C				

Trimethoprim C

Date:09/21/00ISR Number: 3598086-XReport Type:Periodic Company Report #WAES 00041685
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO;12.5 MG/DAILY/PO	
			Prednisone	C				

Date:09/21/00ISR Number: 3598087-1Report Type:Periodic Company Report #WAES 00041687
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/21/00ISR Number: 3598088-3Report Type:Periodic Company Report #WAES 00041753
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:09/21/00ISR Number: 3598089-5Report Type:Periodic Company Report #WAES 00081121
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	

Date:09/21/00ISR Number: 3598090-1Report Type:Periodic Company Report #WAES 00081122
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Premarin	C				
			Prinivil	C				
			Analgesic Or Anesthetic	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598091-3Report Type:Periodic Company Report #WAES 00081123
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	4 DAY
			Tylenol	C				
			Ultram	C				

Date:09/21/00ISR Number: 3598092-5Report Type:Periodic Company Report #WAES 00081124
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Cough							
	Feeling Hot							
	Productive Cough							
	Rash Erythematous		Fosamax	C				
	Swelling		Miacalcin	C				
			Phillips' Milk Of Magnesia	C				
			Magnesium (Unspecified)	C				
			Calcium Carbonate + Cholecalcium	C				

Date:09/21/00ISR Number: 3598093-7Report Type:Periodic Company Report #WAES 00081129
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Acupril	C
			Methotrexate	C

Date:09/21/00ISR Number: 3598094-9Report Type:Periodic Company Report #WAES 00081136
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Joint Stiffness	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral				Laboratories Div	
	Periodontal Disease				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Librax Capsules	C		
			Premarin	C		
			Vasotec	C		
			Aspirin	C		

Date:09/21/00ISR Number: 3598095-0Report Type:Periodic Company Report #WAES 00081138
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	
OPHTHALMIC 25 MG/UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598096-2Report Type:Periodic Company Report #WAES 00081139
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Lipitor	C				
			Aspirin	C				
			Atnolol	C				
			Niacin	C				
			Triamterene	C				

Date:09/21/00ISR Number: 3598097-4Report Type:Periodic Company Report #WAES 00081140
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Therapeutic Response Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Paxil	C				

Date:09/21/00ISR Number: 3598098-6Report Type:Periodic Company Report #WAES 00081141
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Gastrointestinal Disorder Haemorrhoids Renal Disorder		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Amaryl	C
			Celebrex	C
			Lasix	C
			Neurontin	C
			Zestril	C
			Zocor	C
			Atenolol	C
			Trazodone	C

Date:09/21/00ISR Number: 3598099-8Report Type:Periodic Company Report #WAES 00081143
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Feeling Drunk							
	Malaise							
	Nausea		Levothroid	C				
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598100-1Report Type:Periodic Company Report #WAES 00081145
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flexeril	C				
			Neurontin	C				
			Paxil	C				
			Plaquenil	C				
			Synthroid	C				
			Turloc	C				

Date:09/21/00ISR Number: 3598101-3Report Type:Periodic Company Report #WAES 00081147
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 G/DAILY/PO	
			Tums	C				
			Ultram	C				
			Minerals (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/21/00ISR Number: 3598102-5Report Type:Periodic Company Report #WAES 00081152
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hormones	C				
			Vitamins	C				

Date:09/21/00ISR Number: 3598103-7Report Type:Periodic Company Report #WAES 00081154
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Toprol Xl Tablets	C				

Date:09/21/00ISR Number: 3598104-9Report Type:Periodic Company Report #WAES 00081157
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/00ISR Number: 3598105-0Report Type:Periodic Company Report #WAES 00081158
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia							
	Nervousness							
			Deltasone	C				
			Placidyl	C				
			Teveten (Eprosartan)	C				

Date:09/21/00ISR Number: 3598106-2Report Type:Periodic Company Report #WAES 00081160
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Aredia	C				
			Betimol	C				
			Glucophage	C				

Date:09/21/00ISR Number: 3598107-4Report Type:Periodic Company Report #WAES 00081161
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Nausea							
	Vomiting							
			Aricept	C				
			Detrol	C				
			Feosol	C				
			Gaviscon Antacid Tablets	C				

			Ocuvite	C		
			Furosemide	C		

Date:09/21/00ISR Number: 3598108-6Report Type:Periodic Company Report #WAES 00081162
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Klonopin	C				
			Pravachol	C				
			Prilosec	C				
			Cortisone	C				

Date:09/21/00ISR Number: 3598193-1Report Type:Periodic Company Report #WAES 00063082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/21/00ISR Number: 3601993-2Report Type:Periodic Company Report #WAES 00081899
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fluid Retention							
			Sensidyn	C				
			Ziac	C				

Date:09/21/00ISR Number: 3601995-6Report Type:Periodic Company Report #WAES 00081879
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased							
			Pamelor	C				

Date:09/22/00ISR Number: 3577017-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx	PS				

Date:09/22/00ISR Number: 3578276-2Report Type:Expedited (15-DaCompany Report #WAES 00071295
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Elavil	C				
			Flexeril	C				
			Hydrodiuril	C				
			Levoxyl	C				
			Tenormin	C				
			Zantac	C				

Date:09/22/00ISR Number: 3578521-3Report Type:Expedited (15-DaCompany Report #WAES 00062126
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Headache Leukaemia Mental Impairment Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aleve (Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578527-4Report Type:Expedited (15-DaCompany Report #WAES 00091042
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Coumadin	C				

Date:09/22/00ISR Number: 3578532-8Report Type:Expedited (15-DaCompany Report #WAES 00091208
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer Haemorrhage Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Aspirin	C				

Date:09/22/00ISR Number: 3578564-XReport Type:Expedited (15-DaCompany Report #WAES 00090913
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Paralysis Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tenoretic	C				

Date:09/22/00ISR Number: 3578567-5Report Type:Expedited (15-DaCompany Report #WAES 00082296
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Haemorrhage				Laboratories Div	
	Nausea				Merck Co Inc	ORAL
25						
	Ulcer					
MG/DAILY/PO						
	Weight Decreased		Celebrex	SS		
			Tylenol	C		
			Chondroitin	C		

Date:09/22/00ISR Number: 3578573-0Report Type:Expedited (15-DaCompany Report #WAES 00091115
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Mouth Ulceration	Health	Vioxx	PS	Merck Research	
Other	Oedema Peripheral	Professional			Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						

Date:09/22/00ISR Number: 3578584-5Report Type:Expedited (15-DaCompany Report #WAES 00091113
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Blood Creatine	Health
Initial or Prolonged	Phosphokinase Increased	Professional
	Myositis	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	
Baycol	C				
Lipitor	C				

Date:09/22/00ISR Number: 3578587-0Report Type:Expedited (15-DaCompany Report #WAES 00091050
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Sulfasalazine	C				

Date:09/22/00ISR Number: 3578591-2Report Type:Expedited (15-DaCompany Report #WAES 00060170
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anisocytosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Life-Threatening	Decreased Activity							
Hospitalization - Initial or Prolonged	Difficulty In Walking	Other						
	Ecchymosis							
Disability	Eyelid Oedema		Coumadin	C				
Other	Facial Bones Fracture		Darvocet-N	C				
	Fall		Lovenox	C				
	Haemorrhagic Stroke		Atenolol	C				
	Hereditary Spherocytosis							
	Idiopathic Thrombocytopenic Purpura							
	Injury							
	Oral Intake Reduced							
	Pain							

Pancytopenia
Swelling
Syncope
Traumatic Haematoma
White Blood Cell Count
Decreased

Date:09/22/00ISR Number: 3578594-8Report Type:Expedited (15-DaCompany Report #WAES 00091179
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578598-5Report Type:Expedited (15-DaCompany Report #WAES 00052059
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue Muscular Weakness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Librax Capsules	C				
			Prempro	C				
			Sinequan	C				
			Synthroid	C				
			Cyanocobalamin	C				

Date:09/22/00ISR Number: 3578600-0Report Type:Expedited (15-DaCompany Report #WAES 00080247
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/22/00ISR Number: 3578601-2Report Type:Expedited (15-DaCompany Report #WAES 00091205
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			[Therapy Unspecified]	C				

			Vitamins (Unspecified)	C		

Date:09/22/00ISR Number: 3578602-4Report Type:Expedited (15-DaCompany Report #WAES 00081062
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;	
	Condition Aggravated							
	Disorientation							
	Hallucination							
	Medication Error						25 MG/DAILY/PO	
	Mental Impairment							
	Senile Dementia		Tab Tylenol With Codeine #3 1 Tablet	SS		ORAL	PRN/PO	

Date:09/22/00ISR Number: 3578603-6Report Type:Expedited (15-DaCompany Report #WAES 00091033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage							
	Ulcer							
Disability								

			Aspirin	C			

Date:09/22/00ISR Number: 3578605-XReport Type:Expedited (15-DaCompany Report #WAES 00070333
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Oedema Peripheral Phlebitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				

Date:09/22/00ISR Number: 3578606-1Report Type:Expedited (15-DaCompany Report #WAES 00081100
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Failure Congestive Chronic Obstructive Airways Disease Exacerbated Condition Aggravated Fluid Overload Haematocrit Decreased Haemoglobin Decreased Renal Impairment	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/22/00ISR Number: 3578608-5Report Type:Expedited (15-DaCompany Report #WAES 00080063
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Chest Pain Headache Muscular Weakness	Health Professional Company Representative	Vioxx Colestid	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

	Nausea		Neurontin	C		
			Prilosec	C		
			Proventil	C		
			Ticlid	C		
			Aspirin	C		

Date:09/22/00ISR Number: 3578610-3Report Type:Expedited (15-DaCompany Report #WAES 00071295
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Dizziness Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haematochezia Syncope		Elavil	C				
			Flexeril	C				
			Hydrodiuril	C				
			Levoxyl	C				
			Tenormin	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578613-9Report Type:Expedited (15-DaCompany Report #WAES 00071029
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dermatitis							
	Drug Toxicity							
	Ecchymosis							
	Fatigue		Enbrel	C				
	Haematocrit Decreased		Prednisone	C				
	Haemoglobin Decreased							
	Headache							
	Petechiae							
	Red Blood Cell Sedimentation Rate Increased							
	Thrombocytopenia							

Date:09/22/00ISR Number: 3578621-8Report Type:Expedited (15-DaCompany Report #WAES 00091274
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Joint Swelling							
	Muscular Weakness							
	Oedema Peripheral		Acupril	C				
			Flovent	C				
			Proventil	C				

Date:09/22/00ISR Number: 3578622-XReport Type:Expedited (15-DaCompany Report #WAES 00091227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Company Merck Co Inc ORAL
25 MG/
Representative
DAILY/PO

Date:09/22/00ISR Number: 3578623-1Report Type:Expedited (15-DaCompany Report #WAES 00082024
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemorrhoids							
	Hypertension							
	Rectal Haemorrhage							
			Hydrodiuril	C				
			Paxil	C				
			Zocor	C				
			Aspirin	C				

Date:09/22/00ISR Number: 3578630-9Report Type:Expedited (15-DaCompany Report #WAES 00081111
Age:89 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Faecal Occult Blood	Other			Merck Co Inc	ORAL	DAILY/PO	
	Positive		Vicodin Tablets	C				
	Gastric Ulcer		Atenolol	C				
	Gastric Ulcer Haemorrhage		Prednisone	C				
	Haematemesis							
	Haematocrit Decreased							
	Melaena							
	Upper Gastrointestinal Haemorrhage							

Date:09/22/00ISR Number: 3578636-XReport Type:Expedited (15-DaCompany Report #WAES 00091209
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Nephrotic Syndrome				Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:09/22/00ISR Number: 3578637-1Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional			Merck Co Inc	ORAL	25.0 MG	1 DAY
	Conjunctival Haemorrhage							
	Dermatitis	Other	Prinivil	C				
	Dermatitis Exfoliative		Acetaminophen	C				
	Drug Hypersensitivity		Cyclosporin A	C				
	Ecchymosis		Folic Acid	C				
	Erythema		Furosemide	C				
	Eyelid Oedema		Insulin, Biphasic					

	Face Oedema	Isophane [Injection]	C
	Hypotension	Methotrexate	C
	Inflammation	Paroxetine	C
	Laryngeal Oedema	Prednisolone	C
	Mouth Haemorrhage	Senna	C
	Mouth Ulceration		
	Necrosis		
	Petechiae		
	Pleural Disorder		
	Pulmonary Alveolar Haemorrhage		
	Pulmonary Haemorrhage		
	Pulmonary Oedema		
	Respiratory Disorder		
	Scar		
	Spleen Disorder		
	Stomatitis		
	Tracheal Oedema		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578639-5Report Type:Expedited (15-DaCompany Report #WAES 00096055
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	21 DAY
	Haematemesis Peptic Ulcer Perforation Peritonitis	Other	Furosemide	C				
			Ginkgo Biloba Extract	C				
			Ramipril	C				

Date:09/22/00ISR Number: 3578640-1Report Type:Expedited (15-DaCompany Report #WAES 00080895
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Scintillating Scotoma Transient Ischaemic Attack		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Vision Blurred							
			[Therapy Unspecified]	C				

Date:09/22/00ISR Number: 3578644-9Report Type:Expedited (15-DaCompany Report #WAES 00095084
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	8 DAY
			Diclofenac Sodium (+) Misoprostol	C				

Date:09/22/00ISR Number: 3578645-0Report Type:Expedited (15-DaCompany Report #WAES 00081518
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Congestive Diarrhoea							
	Gastroenteritis Viral		Lanoxin	C				
	Gastrointestinal Infection		Lasix	C				
			Lopressor	C				
	Nausea		Synthroid	C				
	Vomiting		Captopril	C				
			Ranitidine	C				

Date:09/22/00ISR Number: 3578647-4Report Type:Expedited (15-DaCompany Report #WAES 00085511
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	43 DAY
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Health						
	Gastritis	Professional						
	Melaena		Tab Aspirin	SS		ORAL	100 MG PO	
	Subcutaneous Haematoma		Eprosartan	C				
	Thrombocytopenia		Ranitidine	C				
			Sodium Fluoride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578681-4Report Type:Expedited (15-DaCompany Report #WAES 00085642
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/22/00ISR Number: 3578685-1Report Type:Expedited (15-DaCompany Report #WAES 00075598
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Haemorrhage Intracranial	Foreign Health Professional Other	Vioxx Atorvastatin Calcium	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	3 DAY

Date:09/22/00ISR Number: 3578691-7Report Type:Expedited (15-DaCompany Report #WAES 00098906
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia Cardiac Disorder Circulatory Collapse Pain	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	1 DAY

Date:09/22/00ISR Number: 3578692-9Report Type:Expedited (15-DaCompany Report #WAES 00099115
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Asthenia	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

	Cholelithiasis	Professional			Merck Co Inc	ORAL 25 MG
	Dyspnoea	Other	Fluoxetine	C		
	Gastric Ulcer Haemorrhage		Lovastatin	C		
	Hiatus Hernia					
	Iron Deficiency Anaemia					
	Palpitations					

Date:09/22/00ISR Number: 3578693-0Report Type:Expedited (15-DaCompany Report #WAES 00078104
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amyloidosis	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Blood Creatinine Increased	Study Health			Merck Co Inc	ORAL	25 MG	183 DAY
	Proteinuria	Professional	Vasotec (Enalapril Maleate)	SS		ORAL	20 MG	3454 DAY
	Renal Impairment	Other						
			Placebo For Naproxen	SS		ORAL	183 DAY	
			Placebo	SS			183 DAY	
			Allopurinol	C				
			Methotrexate	C				
			Methylprednisolone	C				
			Ranitidine	C				

Date:09/22/00ISR Number: 3578706-6Report Type:Expedited (15-DaCompany Report #WAES 00077283
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	31 DAY
	Blood Uric Acid Increased							
	Hyperkalaemia		Acetaminophen	C				
			Cyclizine	C				
			Furosemide	C				
			Lactulose	C				
			Lansoprazole	C				
			Morphine	C				
			Picosulfate Na	C				

Date:09/22/00ISR Number: 3578707-8Report Type:Expedited (15-DaCompany Report #WAES 00095560
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	64 DAY

Date:09/22/00ISR Number: 3578710-8Report Type:Expedited (15-DaCompany Report #WAES 00097503
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Macular Degeneration	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	68 DAY	
			Althiazide/Spironolactone	C				
			Atenolol	C				
			Ciprofibrate	C				
			Levothyroxine Na	C				

Date:09/22/00ISR Number: 3578713-3Report Type:Expedited (15-DaCompany Report #WAES 00097256
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Diarrhoea Gastrointestinal Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	5 DAY
			Acetaminophen	C				
			Aspirin/Caffeine/Codeine Phosphate	C				
			Diclofenac Na	C				
			Estrogens (Unspecified)	C				
			Propranolol Hcl	C				

Date:09/22/00ISR Number: 3578714-5Report Type:Expedited (15-DaCompany Report #WAES 00095568
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	38	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3578716-9Report Type:Expedited (15-DaCompany Report #WAES 00095562
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Abdominal Pain Upper	Health						
	Gastrointestinal	Professional						
	Perforation		Dipyrone	C				
			Fentanyl	C				
			Pamidronic Acid Dina	C				
			Tramadol Hcl	C				

Date:09/22/00ISR Number: 3578719-4Report Type:Expedited (15-DaCompany Report #WAES 00095123
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:09/22/00ISR Number: 3578798-4Report Type:Expedited (15-DaCompany Report #000801-SK706
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG QD	
	Dyspepsia	Health					PO	
	Endoscopy Abnormal	Professional	Vioxx	SS		ORAL	200.000 MG PO	
	Gastrooesophageal Reflux Disease		Conjugated Estrogens	C				
			Medroxyprogesterone	C				
	Influenza Like Illness		Nizatidine	C				
	Mucosal Inflammation							
	Nausea							
	Uterine Cancer							

Date:09/22/00ISR Number: 3578878-3Report Type:Expedited (15-DaCompany Report #WAES 00075537
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Life-Threatening	Angina Pectoris
Hospitalization -	Blood Creatinine
Initial or Prolonged	Increased
	Blood Ph Decreased
	Blood Urea Increased
	Cardiac Failure
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Disorientation
	Dyspnoea
	Electrocardiogram St
	Segment Depression
	Flatulence
	Haemorrhagic Stroke
	Hyperventilation
	Mesenteric Occlusion
	Mesenteric Vein
	Thrombosis

		Orthopnoea Paresis Pleural Effusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Po2 Decreased Pulmonary Congestion Rales	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Renal Impairment Respiratory Arrest Sensation Of Pressure Tachycardia Tenderness Thrombosis Ventricular Fibrillation					

Date:09/22/00ISR Number: 3578879-5Report Type:Expedited (15-DaCompany Report #WAES 00065503
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Activated Partial Thromboplastin Time Prolonged	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	21 DAY						
		Antinuclear Antibody		Phenprocoumon	SS		ORAL
1.5-3 MG PO							
		Positive		Metoprolol Succinate	SS		ORAL
47.5 MG PO							
		Asthenia		Diclofenac Na	SS		
PO							
		Blood Bilirubin Increased Blood Copper Increased C-Reactive Protein		Equilin Sodium Sulfate (+) Estrone Sodium Sulfa	SS		ORAL
PO							
		Increased		Medrogestone	SS		ORAL
5 MG PO							
		Cholestasis Chromaturia		Isosorbide-5-Mononitrate	SS		ORAL
60 MG PO							
		Dialysis		Hctz/Quinapril	SS		ORAL
12.5/10 MG PO							
		Faeces Pale Hepatic Failure Hepatitis					

Hepatocellular Damage
Hepatomegaly
Hepatotoxicity
Jaundice
Liver Function Test
Abnormal
Nausea
Prothrombin Time
Prolonged
Pruritus
Urine Analysis Abnormal

Date:09/22/00ISR Number: 3578880-1Report Type:Expedited (15-DaCompany Report #WAES 00085511
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastritis Haemorrhagic	Health			Laboratories Div			
Initial or Prolonged	Haematoma	Professional			Merck Co Inc	ORAL	25 MG PO	
	Thrombocytopenia		Tab Aspirin	SS				
			Eprosartan	C				
			Ranitidine	C				
			Sodium Fluoride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/00ISR Number: 3594278-4Report Type:Periodic Company Report #WAES 00061893
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/22/00ISR Number: 3595028-8Report Type:Periodic Company Report #WAES 00064432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				

Date:09/25/00ISR Number: 3578376-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematochezia	Health	Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY - ORAL	
Hospitalization -	Melaena	Professional						
Initial or Prolonged	Ulcer Haemorrhage							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:09/25/00ISR Number: 3578379-2Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Abdominal Pain	Health	Vioxx 25 Mgm Merck	PS	Merck	ORAL
1 TAB BID PO						
Hospitalization -	Duodenal Ulcer	Professional				
DAILY						
Initial or Prolonged	Haemorrhage		Aricept	C		
	Duodenal Ulcer		Lasix	C		
	Perforation		K-Dur	C		
			Cozaar	C		
			Ticlid	C		
			Zyprexa	C		
			Sinemet	C		

Date:09/25/00ISR Number: 3579441-0Report Type:Expedited (15-DaCompany Report #WAES 00096050
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Vascular Purpura	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG 8 DAY						

Date:09/25/00ISR Number: 3579443-4Report Type:Expedited (15-DaCompany Report #WAES 00096058
Age:71 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Drug Interaction
Initial or Prolonged	International Normalised

	Ratio Increased						
	Melaena						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
					Merck Co Inc	ORAL		
			Tab Fluindione	SS		ORAL		

Date:09/25/00ISR Number: 3579445-8Report Type:Expedited (15-DaCompany Report #WAES 00098540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholelithiasis	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Dyspnoea	Consumer			Laboratories Div			
	Myocardial Infarction				Merck Co Inc	ORAL	25 MG	
	Palpitations							

Date:09/25/00ISR Number: 3579447-1Report Type:Expedited (15-DaCompany Report #WAES 00098554
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Gastrointestinal	Other			Laboratories Div			
Hospitalization -	Haemorrhage				Merck Co Inc	ORAL	12.5 MG	
Initial or Prolonged	Myocardial Infarction		Allopurinol	C				
	Pneumonia		Aspirin	C				
	Urine Potassium Decreased		Atenolol	C				
			Diltiazem	C				

Date:09/25/00ISR Number: 3579448-3Report Type:Expedited (15-DaCompany Report #WAES 00098556
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haematemesis	Other			Laboratories Div			

	Upper Gastrointestinal Haemorrhage		Aspirin	C	Merck Co Inc

Date:09/25/00ISR Number: 3579450-1Report Type:Expedited (15-DaCompany Report #WAES 00098115
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 2 DAY						
			Canrenone Free Acid			
			K	C		
			Dipyrone	C		
			Furosemide	C		
			Sotalol	C		
			Trimetazidine	C		
			Warfarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/00ISR Number: 3579451-3Report Type:Expedited (15-DaCompany Report #WAES 00095136
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO;	
							25 MG PO	36 DAY
			Amitriptyline	C				
			Aspirin	C				
			Atorvastatin	C				
			Gliclazide	C				
			Ispaghula Husk (+)					
			Senna	C				
			Ramipril	C				

Date:09/25/00ISR Number: 3579599-3Report Type:Expedited (15-DaCompany Report #WAES 00091357
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
	Asthenia							
	Blood Pressure Increased							
	Dyspnoea		Armour Thyroid Tablets	C				
	Fatigue							
	Tachycardia		Skelaxin	C				

Date:09/25/00ISR Number: 3579602-0Report Type:Expedited (15-DaCompany Report #WAES 00091406
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pulmonary Oedema							
	Renal Failure							

			Celebrex	C		

Date:09/25/00ISR Number: 3579605-6Report Type:Expedited (15-DaCompany Report #WAES 00091036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Cardizem	C		
			Lescol	C		
			Proscar	C		
			Aspirin	C		
			Vitamin E	C		

Date:09/25/00ISR Number: 3581921-9Report Type:Periodic Company Report #A011309
Age: Gender:Female I/FU:I

Outcome	PT
Other	Abdominal Pain
	Arthritis
	Gastrointestinal Disorder

Myalgia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Norvasc	PS	Pfizer Agricultural Div		10.00 MG	TOTAL:DAILY
	Calcium	SS				
	Vioxx	SS			50.00 MG	TOTAL:BID

Date:09/25/00ISR Number: 3582054-8Report Type:Periodic Company Report #A009395
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Norvasc	PS	Pfizer Agricultural Div	ORAL	5.00 MG	TOTAL:DAILY:ORAL
	Diarrhoea	Health						
	Dizziness	Professional						
	Dyspepsia							
	Faecal Incontinence		Vioxx	SS		ORAL	12.50 MG	TOTAL:DAILY:ORAL
	Hypertonia							
	Sedation							
			Aspirin	C				
			Lopressor	C				
			Vicodin	C				

Date:09/26/00ISR Number: 3580157-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Abdominal Pain		Vioxx 50mg	PS		
50MG DAILY						
Intervention to Prevent Permanent Impairment/Damage	Liver Function Test Abnormal Malaise Nausea					

Date:09/26/00ISR Number: 3580416-6Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine	Health	Vioxx 50mg	PS		ORAL
50 MG QD PO X						
Initial or Prolonged	Increased	Professional				
3 D 3 DAY						
	Condition Aggravated Renal Impairment					

Date:09/26/00ISR Number: 3580471-3Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Prostatic Specific Antigen Increased	Consumer	Vioxx 25mg Rofecoxib Merck Inc	PS	Merck Inc	ORAL
ONE DAILY BY						
MOUTH						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/26/00ISR Number: 3580478-6Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Vioxx	PS		ORAL	50 MG (PO) QID	
			Toradol	SS			30 MG Q 6 HR X 24 HRS (4 DOSES)	

Date:09/26/00ISR Number: 3580481-6Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Cardiac Arrest Feeling Abnormal Hallucination, Visual Hyperglycaemia Hypoglycaemia Hypotension Loss Of Consciousness	Consumer	Diovan - 80 Mg. - Novartis Pharmaceuticals	PS	Novartis Pharmaceuticals	ORAL	1 A DAY ORALLY	
			Vioxx 25 Mg Merck & Co	SS	Merck & Co	ORAL	1 A DAY ORALLY	
			Fosamax	C				
			Allegra	C				
			Baycol	C				
			Levoxine	C				
			Allegra D	C				

Date:09/26/00ISR Number: 3580529-9Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx 10mg	PS			1 Q.D.	
	Haemorrhage							
	Necrosis Ischaemic							

Date:09/26/00ISR Number: 3580578-0Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Rofecoxib 25mg Po Qd	PS				
	Arthralgia		Naproxen 200 Mg Po Bid	SS				
	Blood Creatinine Increased		Placebo	SS				
	Duodenal Ulcer							
	Faecal Occult Blood Positive							

Date:09/27/00ISR Number: 3581414-9Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia		Vioxx 25 Mg 1 Po Daily	PS		ORAL	25 MG 1 PO	DAILY
	Decreased Appetite							
	Weight Decreased							
			Niacin	C				
			Lopressor	C				
			Aspirin	C				

Date:09/27/00ISR Number: 3581509-XReport Type:Expedited (15-DaCompany Report #WAES 00091529
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Subcutaneous International Normalised Ratio Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Petechiae							
	Thrombocytopenia		Coumadin	SS			5 MG/DAILY/	
			Diovan	C				
			Glucotrol	C				
			Imdur	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Aspirin	C				
			Nitroglycerin	C				

Date:09/27/00ISR Number: 3581510-6Report Type:Expedited (15-DaCompany Report #WAES 00091514
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peptic Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Company						
Other		Representative						
			Mysoline	C				
			Sinemet	C				

Date:09/27/00ISR Number: 3581511-8Report Type:Expedited (15-DaCompany Report #WAES 00091507
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Blood Pressure Increased				Merck Co Inc	ORAL
PO						
	Blood Urea Increased					
	Dizziness					
	Hypercalcaemia					
	Muscular Weakness					
	Rhabdomyolysis					

Date:09/27/00ISR Number: 3581544-1Report Type:Expedited (15-DaCompany Report #WAES 00091172
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Ulcer	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						

Date:09/27/00ISR Number: 3581567-2Report Type:Expedited (15-DaCompany Report #WAES 00091427
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:09/27/00ISR Number: 3581568-4Report Type:Expedited (15-DaCompany Report #WAES 00091463
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ativan	C				
			Colace	C				
			Coumadin	C				
			Fibercon	C				
			Flonase	C				
			Lanoxin	C				
			Mycilan	C				
			Prevacid	C				
			[Composition Unspecified]	C				
			Therapy Unspecified]	C				
			Metoprolol	C				

Date:09/27/00ISR Number: 3581569-6Report Type:Expedited (15-DaCompany Report #WAES 00081282
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	
Other	Gastric Ulcer Haemorrhage							
	Gastroenteritis							
	Helicobacter	Representative						
	Haematemesis							
	Haemoglobin Decreased							
	Hypovolaemia							
	Melaena							

Date:09/27/00ISR Number: 3581571-4Report Type:Expedited (15-DaCompany Report #WAES 00080267
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Vioxx	PS	Merck Research			

	Diarrhoea	Professional			Laboratories Div	
	Drug Tolerance Decreased	Company			Merck Co Inc	ORAL
PO						
	Dyspepsia	Representative	Effexor	C		
	Eructation		Lipitor	C		
	Faecal Occult Blood		Ultram	C		
	Flatulence		Aspirin	C		
	Nausea		Lithium Carbonate	C		

Date:09/27/00ISR Number: 3581573-8Report Type:Expedited (15-DaCompany Report #WAES 00062952
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Face Oedema	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral	Health			Laboratories Div	
	Rectal Haemorrhage	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Cytoxan	C		
			Decadron			
			(Dexamethasone)	C		

Date:09/27/00ISR Number: 3581578-7Report Type:Expedited (15-DaCompany Report #WAES 00061612
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Health	Vioxx	PS	Merck Research			
Hospitalization -	Blood Creatinine	Professional			Laboratories Div			
Initial or Prolonged	Increased	Company			Merck Co Inc	ORAL	25	
Disability	Cardiac Disorder	Representative					MG/DAILY/PO	
Other	Constipation		Estratest	C				
	Pericarditis		Normadyne	C				
	Renal Failure		Xanax	C				
			Zaroxolyn	C				
			Zoloft	C				
			[Therapy Unspecified]	C				
			Codeine Sulfate	C				

Date:09/27/00ISR Number: 3581581-7Report Type:Expedited (15-DaCompany Report #WAES 00072410
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haematemesis	Professional			Laboratories Div			
Disability	Haematocrit Decreased	Company			Merck Co Inc	ORAL	25	
Other	Haemoglobin Decreased	Representative					MG/DAILY/PO	
	Injury							
	Melaena							
	Road Traffic Accident							
	Upper Gastrointestinal Haemorrhage							

Date:09/27/00ISR Number: 3581583-0Report Type:Expedited (15-DaCompany Report #WAES 00091209
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck Research			

Initial or Prolonged	Increased	Professional		Laboratories Div	
	Condition Aggravated			Merck Co Inc	ORAL
PO					
	Hypertension		Zocor	C	
	Nephrotic Syndrome				
	Oedema				
	Proteinuria				

Date:09/27/00ISR Number: 3581592-1Report Type:Expedited (15-DaCompany Report #001-0981-M0002373
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
Required	Arthritis
Intervention to	Asthenia
Prevent Permanent	Burning Sensation
Impairment/Damage	Decreased Activity
	Difficulty In Walking
	Fatigue
	Hypoaesthesia
	Insomnia
	Joint Contracture
	Joint Stiffness
	Limb Discomfort

		Movement Disorder Muscular Weakness Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain Pain In Extremity	Health Professional	Lipitor	PS	Warner Lambert Export Ltd	ORAL
20 MG							
		Paraesthesia					
(DAILY), PER							
		Sensation Of Pressure					
ORAL							
		Swelling		Vioxx (Rofecoxib)	SS		
12.5 MG							
		Tendon Disorder					
(DAILY)							
		Tenosynovitis Weight Decreased		Prozac (Fluoxetine Hydrochloride)	C		
				Tylenol (Praracetamol)	C		
				Tylenol Pm(Diphenhydramine, Paracetamol)	C		
				Allegra (Fexofenadine Hydrochloride)	C		
				(Hyoscyamine)	C		
				Feldene (Piroxicam)	C		
				(Ibuprofen)	C		

Date:09/27/00ISR Number: 3581595-7Report Type:Expedited (15-DaCompany Report #WAES 00081591
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Eye Pain Hypertension Vision Blurred	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
		Vitreous Detachment	Representative				
MG/DAILY/PO							
				Darvocet-N	C		
				Neuraxin	C		
				Wellbutrin Sr	C		

Date:09/27/00ISR Number: 3581600-8Report Type:Expedited (15-DaCompany Report #WAES 00091661
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea				Merck Co Inc	ORAL	PO	
	Speech Disorder		Estrogens (Unspecified)	C				

Date:09/27/00ISR Number: 3581601-XReport Type:Expedited (15-DaCompany Report #WAES 00091693
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	[Composition Unspecified]	C				
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/00ISR Number: 3581703-8Report Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Erythema	Health			Laboratories Div			
Initial or Prolonged	Gastric Ulcer	Professional			Merck Co Inc	ORAL	25 MG PO	3 DAY
	Gastroenteritis		Mepivacaine Hcl	C				
	Helicobacter							
	Mucous Membrane Disorder							
	Vomiting							

Date:09/27/00ISR Number: 3581705-1Report Type:Expedited (15-DaCompany Report #WAES 00035668
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Increased	Health			Laboratories Div			
	Blood Urea Increased	Professional			Merck Co Inc	ORAL	PO; 50 MG PO	
	Haemoglobin Decreased		Khco3/K Citrate	C				
	Liver Function Test		Amlodipine	C				
	Abnormal		Calcitriol	C				
	Oedema Peripheral		Cyclosporin A	C				
	Orthostatic Hypotension		Metoprolol	C				
	Renal Failure Acute		Omeprazole	C				
	Syncope		Prednisone	C				
			Torsemide	C				

Date:09/27/00ISR Number: 3581707-5Report Type:Expedited (15-DaCompany Report #WAES 00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Bilirubin Increased	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Cholangitis Acute	Other			Laboratories Div			
	Condition Aggravated				Merck Co Inc	ORAL	25 MG PO	153 DAY
	Fatigue		Tab Methotrexate	SS		ORAL	PO	

		Hepatic Cirrhosis	Tab Sertraline Hcl	SS			ORAL PO
		Hepatic Fibrosis	Tab Omeprazole				
		Hepatic Steatosis	Magnesium	SS			ORAL 20 MG PO
153	DAY	Inflammation	Infusion (Form)				
		Jaundice	Infliximab	SS			INTRAVENOUS
IV	122	DAY					
		Liver Disorder	Folic Acid	C			
		Liver Function Test Abnormal	Glyburide	C			
		Nausea					
		Pruritus					
		Ultrasound Liver Abnormal					

Date:09/27/00ISR Number: 3581709-9Report Type:Expedited (15-DaCompany Report #WAES 00057334
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Tenderness
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cardiomegaly
	Chest Discomfort
	Cyanosis

	Dyspnoea Ejection Fraction Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension Left Ventricular Failure Myocardial Infarction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Oedema Peripheral						

Date:09/27/00ISR Number: 3581711-7Report Type:Expedited (15-DaCompany Report #WAES 00075635
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 64 DAY
			Acetyldigitoxins B-Form Nifedipine	 C C			

Date:09/27/00ISR Number: 3581713-0Report Type:Expedited (15-DaCompany Report #WAES 00095569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Cortiosteroids Methotrexate	C C			

Date:09/27/00ISR Number: 3581716-6Report Type:Expedited (15-DaCompany Report #WAES 00095574
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research		

Initial or Prolonged Health Laboratories Div
Professional Merck Co Inc ORAL
25 MG PO 5 DAY

Date:09/27/00ISR Number: 3581717-8Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaphylactic Reaction
Hospitalization -	Angioneurotic Oedema
Initial or Prolonged	Cardiac Disorder
	Conjunctival Haemorrhage
	Dermatitis
	Ecchymosis
	Face Oedema
	Hypersensitivity
	Laryngeal Oedema
	Mucosal Haemorrhage
	Mucosal Ulceration
	Necrosis
	Petechiae
	Pleural Adhesion
	Pleural Disorder
	Pulmonary Haemorrhage

		Pulmonary Oedema Scar Spleen Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vasoconstriction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25.0 MG PO	2 DAY						
			Other	Prinivil	C		
				Acetaminophen	C		
				Cyclosporin A	C		
				Folic Acid	C		
				Furosemide	C		
				Insulin, Biphasic Isophane [Injection]	C		
				Methotrexate	C		
				Paroxetine	C		
				Prednisolone	C		
				Senna	C		

Date:09/27/00ISR Number: 3581719-1Report Type:Expedited (15-DaCompany Report #WAES 00086029
Age:78 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Pressure Systolic Increased Flatulence	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO	33 DAY						
		Gastrooesophageal Reflux Disease Haemoptysis Mouth Ulceration Pulmonary Haemorrhage		Acetaminophen	C		
				Omeprazole Sodium	C		

Date:09/27/00ISR Number: 3581722-1Report Type:Expedited (15-DaCompany Report #WAES 00085522
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cardiac Valve Disease Cardiomegaly	Foreign Health	Vioxx	PS	Merck Research Laboratories Div	

	Cardiomyopathy	Professional			Merck Co Inc	ORAL
25 MG PO						
	Condition Aggravated		Vasoretic	C		
	Dyspnoea Exacerbated		Allopurinol	C		
	Dyspnoea Exertional		Phenprocoumon	C		
	Fluid Retention		Ticlopidine			
	Left Ventricular Failure		Hydrochloride	C		
	Pleural Effusion					

Date:09/27/00ISR Number: 3581723-3Report Type:Expedited (15-DaCompany Report #WAES 00096020
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Confusional State	Foreign	Vioxx	PS	Merck Research	
	Hallucination	Health			Laboratories Div	
	Hyponatraemia	Professional			Merck Co Inc	ORAL
12.5 MG PO 1 DAY						
			Tab Althiazide/Spironolactone	SS		ORAL
PO						
			Lactitol	C		
			Nitroglycerin	C		
			Trimetazidine	C		

				Zopiclone	C		

Date:09/27/00ISR Number: 3581725-7Report Type:Expedited (15-DaCompany Report #WAES 00095526
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	PO	
			Tab Vioxx (Rofecoxib)	SS		ORAL	PO	
			Omeprazole	C				

Date:09/27/00ISR Number: 3581738-5Report Type:Expedited (15-DaCompany Report #WAES 00085519
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Cardiovascular Disorder	Health			Laboratories Div			
	Cerebral Atrophy	Professional			Merck Co Inc	ORAL	25 MG PO	20 DAY
	Cerebral Ischaemia		Calcium Citrate (+)					
	Confusional State		Calcium Gluconate (+	C				
	Electroencephalogram		Diclofenac Na	C				
	Abnormal		Metformin Hcl	C				
	Encephalopathy		Tramadol Hcl	C				
	Hydrocephalus							
	Hyperglycaemia							
	Speech Disorder							
	Transient Ischaemic							
	Attack							
	Tremor							

Date:09/27/00ISR Number: 3581742-7Report Type:Expedited (15-DaCompany Report #WAES 00095572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	PO	
			Methotrexate	C				

Date:09/27/00ISR Number: 3581744-0Report Type:Expedited (15-DaCompany Report #WAES 00095112
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	International Normalised	Other			Laboratories Div			
	Ratio Increased				Merck Co Inc	ORAL	PO	5 DAY
	Platelet Count Decreased		Chlorpromazine	C				
	White Blood Cell Count		Lithiumco3	C				
	Decreased		Thyroxine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/00ISR Number: 3581746-4Report Type:Expedited (15-DaCompany Report #WAES 00095554
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/27/00ISR Number: 3581748-8Report Type:Expedited (15-DaCompany Report #WAES 00096095
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	11 DAY
			Tab Fluindione	SS		ORAL	PO	
			Tramadol	C				

Date:09/27/00ISR Number: 3581750-6Report Type:Expedited (15-DaCompany Report #WAES 00096097
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Dyspnoea Exertional	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
		Professional	Acebutolol	C				
			Fenofibrate	C				
			Furosemide/Spironolactone	C				
			Nitroglycerin	C				

Date:09/27/00ISR Number: 3581751-8Report Type:Expedited (15-DaCompany Report #WAES 00097278
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
			Acetaminophen	C				
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Amiloride Hydrochloride/Hctz	C				
			Dixyrazine	C				
			Omeprazole Magnesium	C				
			Prednisolone	C				
			Tramadol	C				
			Verapamil Hcl	C				
			Zolpidem Tartrate	C				

Date:09/27/00ISR Number: 3581753-1Report Type:Expedited (15-DaCompany Report #WAES 00096519
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 DAY
		Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/00ISR Number: 3581754-3Report Type:Expedited (15-DaCompany Report #WAES 00095142
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
			Albuterol Sulfate (+) Ipratropium Bromid	C				
			Beclomethasone	C				
			Theophylline	C				

Date:09/27/00ISR Number: 3581755-5Report Type:Expedited (15-DaCompany Report #WAES 00095146
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Urea Increased Haemoglobin Decreased Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	9 DAY
			Nabumetone	C				
			Nifedipine	C				

Date:09/27/00ISR Number: 3582171-2Report Type:Periodic Company Report #00USA10011
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Consumer	Voltaren	PS	Novartis Pharmaceuticals Corp	ORAL	DAILY, ORAL	16 MON
			Cytotec Tablet (Misoprostol)	SS		ORAL	ORAL	
			Vioxx Tablet (Rofecoxib)	SS		ORAL	ORAL	

Date:09/28/00ISR Number: 3583134-3Report Type:Expedited (15-DaCompany Report #A021992
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Calcinosis	Consumer	Glucotrol Xl	PS	Pfizer Inc	ORAL	5.00 MG	
Intervention to	Colonic Polyp	Health						
TOTAL: DAILY:								
Prevent Permanent	Constipation	Professional						
ORAL								
Impairment/Damage	Depression		Vioxx	SS		ORAL		
ORAL								
	Flatulence		Caridzem Cd	C				
	Gastrointestinal Disorder		Zoloft	C				

Date:09/28/00ISR Number: 3583234-8Report Type:Expedited (15-DaCompany Report #WAES 00095177
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer Haemorrhage	Other			Laboratories Div			
Initial or Prolonged	Haematemesis				Merck Co Inc	ORAL	12.5, PO	
	Melaena		Aspirin	SS		ORAL	75 MG, PO	
			Amlodipine	C				
			Atenolol	C				
			Citalopram Hydrobromide	C				
			Dipyridamole	C				

				Isosorbide Mononitrate	C		
				Senna	C		

Date:09/28/00ISR Number: 3583240-3Report Type:Expedited (15-DaCompany Report #WAES 00096104
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Hallucination	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
			Benserazide/ Levodopa	C				
			Bepridil Hydrochloride	C				
			Bromazepam	C				
			Citalopram Hydrobromide	C				
			Ropinirole Hydrochloride	C				

Date:09/28/00ISR Number: 3583510-9Report Type:Expedited (15-DaCompany Report #WAES 00091615
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/28/00ISR Number: 3583515-8Report Type:Expedited (15-DaCompany Report #WAES 00091623
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:09/28/00ISR Number: 3583519-5Report Type:Expedited (15-DaCompany Report #WAES 00091842
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ORAL	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							
	Haemoglobin Decreased							
	Peptic Ulcer Perforation							
	Refusal Of Treatment By Patient							

Date:09/28/00ISR Number: 3583530-4Report Type:Expedited (15-DaCompany Report #WAES 00091420
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Nonsteroidal Anti-Inflammatory D	C		

Date:09/28/00ISR Number: 3583534-1Report Type:Expedited (15-DaCompany Report #WAES 00091437
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Condition Aggravated Diplopia Facial Palsy Respiratory Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO	6 DAY					
			Aspirin	C		

Date:09/28/00ISR Number: 3583540-7Report Type:Expedited (15-DaCompany Report #WAES 00091473
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Asthenia Cardiac Failure Congestive Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Evista	C		
			Pravachol	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:09/28/00ISR Number: 3583545-6Report Type:Expedited (15-DaCompany Report #WAES 00091582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID PO	
			Lithium Carbonate	C				

Date:09/29/00ISR Number: 3583020-9Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS				3 WEEKS, NONE X 2 WEEKS
	Dyspnoea							
	Gastric Ulcer		Aspirin	SS				OCCASIONAL
	Melaena		Amitriptyline	C				
			Macrodantin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/00ISR Number: 3583076-3Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Pyrexia		Vioxx	PS	Merck & Company			

Date:09/29/00ISR Number: 3583087-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured		Vioxx 25 Mg	PS	Merck	ORAL	25MG	DAILY-ORAL
Hospitalization -	Haematochezia							
Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Ulcer Haemorrhage							

Date:09/29/00ISR Number: 3584446-XReport Type:Expedited (15-DaCompany Report #WAES 00098112
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	8 DAY
			Pat Flurbiprofen	SS			40 MG	8 DAY

Date:09/29/00ISR Number: 3584529-4Report Type:Expedited (15-DaCompany Report #WAES 00095560
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged Duodenal Ulcer Health Laboratories Div
Gastric Haemorrhage Professional Merck Co Inc ORAL
12.5 MG, PO 64 DAY
Vasotec C
Aspirin (+) Lithium
Citrate (+) Quinine C
Piretanide C
Thyroxine C

Date:09/29/00ISR Number: 3584533-6Report Type:Expedited (15-DaCompany Report #WAES 00045505
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Renal Impairment	Health			Laboratories Div	
Disability		Professional			Merck Co Inc	ORAL
12.5 MG, PO 2 MON						
		Other	Tab Amantadine			
			Sulfate	SS		ORAL
PO						

Date:09/29/00ISR Number: 3584611-1Report Type:Expedited (15-DaCompany Report #WAES 00095572
Age:70 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Pancytopenia	Health			Laboratories Div			
Sepsis	Professional			Merck Co Inc	ORAL	25 MG PO	
		Dipyrone	C				
		Methotrexate	C				

Date:09/29/00ISR Number: 3584613-5Report Type:Expedited (15-DaCompany Report #WAES 00078911
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Foreign	Vioxx	PS	Merck Research			
Other	Cardiac Arrest	Health			Laboratories Div			
	Condition Aggravated	Professional			Merck Co Inc	ORAL	25 MG PO	2 DAY
	Cyanosis		Pepcid	C				
	Dizziness		Ceftazidime	C				
	Dyspnoea		Diphenhydramine	C				
	Haemoptysis		Dobutamine	C				
	Headache		Dopamine	C				
	Henoch-Schonlein Purpura		Epinephrine	C				
	Hypersensitivity		Gentamicin	C				
	Hypotension		Glucose Preparation	C				
	Hypovolaemic Shock		Hydrocortisone	C				
	Pulmonary Haemorrhage		Ketorolac	C				
	Purpura		Kremil-S	C				
	Pyrexia		Metronidazole	C				
	Rash Macular		Netilmicin	C				
	Respiratory Rate		Nubain	C				
	Increased		Oxacillin	C				
	Tachycardia		Phenergan	C				
	Upper Gastrointestinal		Ringer'S Injection					
	Haemorrhage		(U.S.P. Xxii)	C				
	Vomiting		Sodium Bicarbonate	C				
			Spinal Anesthesia	C				

Date:09/29/00ISR Number: 3585119-XReport Type:Expedited (15-DaCompany Report #WAES 00082900
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Chills Condition Aggravated Dysuria Headache Leukocytosis Palpitations Prostatic Specific Antigen Increased Prostatitis Renal Failure Acute Renal Tubular Necrosis Supraventricular Extrasystoles Tenderness Urinary Tract Infection	Health Professional Company Representative	Vioxx Cipro Flomax (Morniflumate) Levaquin Pyridium	PS C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/00ISR Number: 3585120-6Report Type:Expedited (15-DaCompany Report #WAES 00080439
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Post Procedural Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:09/29/00ISR Number: 3585121-8Report Type:Expedited (15-DaCompany Report #WAES 00070717
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Benign Neoplasm Of Spinal Cord Constipation Dermatitis Atopic Dermatitis Contact Gastritis Gastrointestinal Disorder Hypoaesthesia Muscular Weakness Musculoskeletal Pain Oedema Peripheral Rash Vesicular Red Blood Cell Sedimentation Rate Increased Sensory Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:09/29/00ISR Number: 3585122-XReport Type:Expedited (15-DaCompany Report #WAES 00082024
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

	Haemorrhoids					
MG/DAILY/PO						
	Rectal Haemorrhage		Ativan	C		
			Hydrodiuril	C		
			Paxil	C		
			Zocor	C		
			Aspirin	C		

Date:09/29/00ISR Number: 3585123-1Report Type:Expedited (15-DaCompany Report #WAES 00064287
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div			
Disability	Injury							
	Pain				Merck Co Inc	ORAL	PO	4 WK
	Tremor		Lithiumco3	SS				

Date:09/29/00ISR Number: 3586333-XReport Type:Periodic Company Report #20000700454
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dental Caries	Health Professional	Plendil	PS	Astrazeneca Lp			
			Meridia	SS		ORAL	10 MG QD PO	

			Vioxx	SS		
			Fluoride	C		
			Zyrtec	C		
			Micronor	C		
			Nasacort	C		
			Zoladex	C		

Date:10/02/00ISR Number: 3585509-5Report Type:Expedited (15-DaCompany Report #WAES 00095611
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bronchospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG PO 26 DAY						
			Amlodipine Besylate	C		
			Atorvastatin	C		
			Clopidogrel Bisulfate	C		
			Hydrochlorothiazide (+) Irbesartan	C		
			Sotalol Hydrochloride	C		

Date:10/02/00ISR Number: 3585510-1Report Type:Expedited (15-DaCompany Report #WAES 00095614
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Interaction	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged	Gastric Haemorrhage					
25 MG PO 90 DAY						
			Digitoxin	C		
			Lisinopril	C		
			Ticlopidine Hydrochloride	C		
			Trazodone Hcl	C		
			Zolpidem Tartrate	C		

Date:10/02/00ISR Number: 3585511-3Report Type:Expedited (15-DaCompany Report #WAES 00099139
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faecal Occult Blood Positive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	36 DAY
	Iron Deficiency Anaemia							
	Melaena		Carvedilol	C				
			Gliclazide	C				
			Indapamide	C				
			Salmeterol	C				

Date:10/02/00ISR Number: 3585512-5Report Type:Expedited (15-DaCompany Report #WAES 00099140
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY
			Amlodipine					

		Benzenesulfonate	C
		Estradiol	C
		Fluoxetine Hcl	C
		Ketorolac	C

Date:10/02/00ISR Number: 3585513-7Report Type:Expedited (15-DaCompany Report #WAES 00099553
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Extradural Haematoma		Diuretic/Antihyperte nsive, Nos	C				
			Sintrom	C				

Date:10/02/00ISR Number: 3585515-0Report Type:Expedited (15-DaCompany Report #WAES 00095190
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper Anaemia Gastrointestinal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Haemoglobin Decreased Stomach Discomfort							

Date:10/02/00ISR Number: 3585516-2Report Type:Expedited (15-DaCompany Report #WAES 00089771
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Dizziness Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	13 DAY
			Ascorbic Acid	C				
			Chondroitin Sulfate (+) Glucosamine Hydr	C				

			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:10/02/00ISR Number: 3585518-6Report Type:Expedited (15-DaCompany Report #WAES 00085039
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Blood Bilirubin Increased	Foreign	Vioxx	PS	Merck Research	
	Hypoproteinaemia	Health			Laboratories Div	
	Jaundice	Professional			Merck Co Inc	ORAL
	Liver Function Test		Bumetanide	C		
	Abnormal		Digoxin	C		

Dose: 12.5 MG PO Duration: 15 WK

Date:10/02/00ISR Number: 3585521-6Report Type:Expedited (15-DaCompany Report #WAES 00095562
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
	Abdominal Pain Upper
	Gastrointestinal

Perforation

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Vaseretic	C				
			Acetylcysteine	C				
			Amiodarone Hydrochloride	C				
			Budesonide	C				
			Citalopram Hydrobromide	C				
			Dipyrone	C				
			Fentanyl	C				
			Formoterol Fumarate	C				
			Metoprolol Succinate	C				
			Pamidronic Acid Dina	C				
			Tramadol Hcl	C				

Date:10/02/00ISR Number: 3585540-XReport Type:Expedited (15-DaCompany Report #WAES 00096094
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	4 DAY
Life-Threatening	Haematoma							
Hospitalization - Initial or Prolonged	Multi-Organ Failure							
	Renal Impairment		Fluindione	SS		ORAL	PO	14 DAY
			Tramadol	C				

Date:10/02/00ISR Number: 3585541-1Report Type:Expedited (15-DaCompany Report #WAES 00096004
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aplastic Anaemia	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			
	Asthenia							

	Biopsy Bone Marrow	Professional			Merck Co Inc	ORAL
12.5 MG PO						
	Abnormal	Other	Sulfasalazine	SS		ORAL
2000 MG PO						
	Dyspnoea		Hydroxychloroquine			
	Haemoglobin Decreased		So4	SS		
200 MG						
	Tinnitus		Cetirizine			
			Hydrochloride	SS		
			Prednisone	C		

Date:10/02/00ISR Number: 3585543-5Report Type:Expedited (15-DaCompany Report #WAES 00085093
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis	Foreign	Vioxx	PS	Merck Research	
	Pruritus	Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG PO 31 DAY						
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3585544-7Report Type:Expedited (15-DaCompany Report #WAES 00095508
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Cholecystitis Chronic Cholestasis Cytomegalovirus Infection Faeces Pale Hepatitis Jaundice Laboratory Test Abnormal Liver Function Test Abnormal Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY

Date:10/02/00ISR Number: 3585545-9Report Type:Expedited (15-DaCompany Report #WAES 00097524
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/02/00ISR Number: 3585548-4Report Type:Expedited (15-DaCompany Report #WAES 00095609
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/02/00ISR Number: 3585549-6Report Type:Expedited (15-DaCompany Report #WAES 00098233
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG PO	

Date:10/02/00ISR Number: 3585551-4Report Type:Expedited (15-DaCompany Report #WAES 00095193
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	264 DAY
Hospitalization - Initial or Prolonged	Dyspepsia							
			Albuterol	C				
			Beclomethasone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3585560-5Report Type:Expedited (15-DaCompany Report #WAES 00096101
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Chest Pain Electrocardiogram	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	50 DAY
	Abnormal Myocardial Ischaemia	Professional	Acetaminophen	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Celiprolol	C				
			Estrogens (Unspecified)	C				
			Etidronate Disodium	C				
			Omeprazole	C				
			Progesterone	C				

Date:10/02/00ISR Number: 3585669-6Report Type:Expedited (15-DaCompany Report #WAES 00096130
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Haematemesis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
	Haemoglobin Decreased Melaena		Acetaminophen (+) Belladonna (+)					
			Caffien	C				
			Betahistine	C				
			Trimetazidine	C				

Date:10/02/00ISR Number: 3585681-7Report Type:Expedited (15-DaCompany Report #WAES 00075110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Dermatitis Bullous	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

			Other	Acetaminophen/Codein e Phosphate	C		
				Citalopram	C		
				Estrogens, Conjugated (+)			
				Medroxyprogest	C		

Date:10/02/00ISR Number: 3585683-0Report Type:Expedited (15-DaCompany Report #WAES 00095143
Age:85 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	31 DAY
	Gastritis	Other						
	Gastrointestinal Disorder							
	Melaena		Acetaminophen/Propox yphene Hydrochloride	C				
			Calcium Carbonate + Cholecalciferol	C				
			Nitrazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3585686-6Report Type:Expedited (15-DaCompany Report #WAES 00097504
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY

Date:10/02/00ISR Number: 3585689-1Report Type:Expedited (15-DaCompany Report #WAES 00096091
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	27 DAY
			Atenolol	C				
			Estrogens	C				
			Furosemide	C				
			Mianserin	C				
			Milnacipran	C				
			Progesterone	C				
			Zolpidem	C				

Date:10/02/00ISR Number: 3585691-XReport Type:Expedited (15-DaCompany Report #WAES 00096050
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukocytoclastic Vasculitis Purpura Skin Lesion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 DAY

Date:10/02/00ISR Number: 3585692-1Report Type:Expedited (15-DaCompany Report #WAES 00089752
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:10/02/00ISR Number: 3585840-3Report Type:Expedited (15-DaCompany Report #WAES 00080488
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Disorder Dyspepsia Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
	Eyelid Oedema							
	Fluid Retention		Azmacort	C				
	Gastrointestinal Disorder		Calan Sr	C				
	Lacrimation Increased		Claritin	C				
	Muscle Spasms		Hydrodiuril	C				
	Nausea		K-Dur	C				
	Oedema Peripheral		Lasix	C				
	Pulmonary Oedema		Premarin	C				
	Renal Disorder		Prilosec	C				
	Swelling		Propulsid	C				
	Weight Increased		Serevent	C				

			Synthroid	C		
			Vancenase	C		
			Albuterol	C		
			Allopurinol	C		
			Colchicine	C		

Date:10/02/00ISR Number: 3585841-5Report Type:Expedited (15-DaCompany Report #WAES 00092187
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research			
Hospitalization -		Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25 MG DAILY	
Disability		Representative					PO	
			Ecotrin	C				

Date:10/02/00ISR Number: 3585844-0Report Type:Expedited (15-DaCompany Report #WAES 00092150
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Infection	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Vasculitis	Professional			Laboratories Div			
Other					Merck Co Inc	ORAL	PO	

Date:10/02/00ISR Number: 3585849-XReport Type:Expedited (15-DaCompany Report #WAES 00080895
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Spasm	Health	Vioxx	PS	Merck Research			
	Eye Disorder	Professional			Laboratories Div			
	Nervous System Disorder	Other			Merck Co Inc	ORAL	25 MG DAILY	
	Transient Ischaemic						PO	
	Attack		Therapy Unspecified	C				

Vision Blurred

Date:10/02/00ISR Number: 3585860-9Report Type:Expedited (15-DaCompany Report #WAES 00052275
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Feeling Hot Haemarthrosis Haematoma	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Hypersensitivity	Representative						
	Joint Swelling		Imitrex	C				
	Pain In Extremity		Vicodin Tablets	C				
	Post Procedural Haemorrhage							
	Tenderness							

Date:10/02/00ISR Number: 3585861-0Report Type:Expedited (15-DaCompany Report #WAES 00099762
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion Diabetes Mellitus Diabetes Mellitus

		Inadequate Control Drug Interaction Hyperglycaemia Hypoglycaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Graft	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO							
				Metformin Hcl	SS		
				Glipizide	SS		
				Composition Unspecified	C		
				Levofloxacin	C		

Date:10/02/00ISR Number: 3585866-XReport Type:Expedited (15-DaCompany Report #WAES 00092015
Age:45 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Atrioventricular Block Second Degree Bradycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/1X/PO							
		Cardiac Arrest Fall Laceration Nausea Nodal Arrhythmia Syncope					

Date:10/02/00ISR Number: 3585868-3Report Type:Expedited (15-DaCompany Report #WAES 00062074
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erectile Dysfunction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO							

Date:10/02/00ISR Number: 3585870-1Report Type:Expedited (15-DaCompany Report #WAES 00080439
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Post Procedural Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:10/02/00ISR Number: 3585872-5Report Type:Expedited (15-DaCompany Report #WAES 00091420
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Haematemesis Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Proventil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/00ISR Number: 3586121-4Report Type:Expedited (15-DaCompany Report #WAES 00091600
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephritis Interstitial	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/02/00ISR Number: 3586122-6Report Type:Expedited (15-DaCompany Report #WAES 00091759
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Anaprox 550 Mg	SS			550 MG	
			Tetracycline	C				

Date:10/02/00ISR Number: 3586126-3Report Type:Expedited (15-DaCompany Report #WAES 00090813
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Glucotrol	C				
			[Therapy Unspecified]	C				

Date:10/02/00ISR Number: 3586144-5Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic		Vioxx	PS				

Date:10/02/00ISR Number: 3586149-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Abdominal Pain		Vioxx 50mg	PS			50MG DAILY	
Intervention to Prevent Permanent Impairment/Damage	Liver Function Test Abnormal Malaise Nausea							

Date:10/03/00ISR Number: 3585194-2Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Tasmar	PS	Roche		1194 DAY	
	Hallucination		Vioxx	SS			27 DAY	
	Liver Function Test		Aciphex	C				
	Abnormal		Sinemet	C				
	Pain In Extremity		Sinemet Cr	C				
			Mirapex	C				

			Unknown Medication Nos	C		

Date:10/03/00ISR Number: 3586536-4Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx 25mg	PS		ORAL	25MG PO QD	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haemorrhage Haematocrit Decreased Hypotension Pallor Tachycardia	Professional	Aspirin Zantac Sacralfate	C C C				

Date:10/03/00ISR Number: 3586548-0Report Type:Direct Company Report #
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute Vasculitis		Vioxx	PS		ORAL	ORAL	

Date:10/03/00ISR Number: 3586640-0Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis Gastritis Erosive		Rofecoxib (Vioxx)	PS		ORAL	PO	

Date:10/03/00ISR Number: 3586729-6Report Type:Expedited (15-DaCompany Report #WAES 00092253
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Plavix	C				
			Tylenol	C				
			Zantac	C				
			Zoloft	C				
			Calcium (Unspecified)	C				

Date:10/03/00ISR Number: 3586730-2Report Type:Expedited (15-DaCompany Report #WAES 00070253
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Disability	Agitation
Other	Atrophy
	Dizziness
	Headache
	Hypertension
	Respiratory Rate Increased

Vertigo

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Inj Droperidol	SS		INTRAMUSCULAR	2.5 MG/UNK/IM	

Date:10/03/00ISR Number: 3586732-6Report Type:Expedited (15-DaCompany Report #WAES 00092234
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Nitrofurantoin	C				

Date:10/03/00ISR Number: 3586740-5Report Type:Expedited (15-DaCompany Report #WAES 00092102
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Failure Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/03/00ISR Number: 3586742-9Report Type:Expedited (15-DaCompany Report #WAES 00090546
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Diabetes Mellitus	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Inadequate Control	Professional			Merck Co Inc	ORAL	25
	Difficulty In Walking						MG/DAILY/PO
	Fall		Lasix	C			
	Oedema		Nitroglycerin	C			
	Renal Failure						
	Weight Increased						

Date:10/03/00ISR Number: 3586745-4Report Type:Expedited (15-DaCompany Report #WAES 00091842
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Faecal Occult Blood	Professional			Laboratories Div			
Initial or Prolonged	Positive				Merck Co Inc	ORAL	12.5	
	Fatigue						MG/DAILY/PO	
	Gastrointestinal							
	Haemorrhage							
	Haemoglobin Decreased							
	Peptic Ulcer Perforation							
	Scan Abdomen Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/00ISR Number: 3586770-3Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased	Health Professional	Tasmar	PS	Hoffmann La Roche Inc	ORAL	100 MG 3 PER DAY ORAL	
	Anxiety							
	Aspartate Aminotransferase Increased		Vioxx (Rofecoxib) 25 Mg	SS		ORAL	25 MG DAILY ORAL	
	Hallucination		Aciphex (Rabeprazole Sodium)	C				
	Pain In Extremity		Sinemet (Carbidopa/Levodopa)	C				
			Sinemet Cr (Carbidopa/Levodopa)	C				
			Mirapex (Pramipexole)	C				
			Unknown Medicatin Nos (Generic Componet(S) Unknown	C				

Date:10/03/00ISR Number: 3586945-3Report Type:Expedited (15-DaCompany Report #WAES 00092121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/03/00ISR Number: 3586958-1Report Type:Expedited (15-DaCompany Report #WAES 00080114
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Dizziness				Laboratories Div	
	Feeling Abnormal				Merck Co Inc	ORAL
12.5						
	Pain					
MG/DAILY/PO						
	Paraesthesia		Elavil	C		
			Premarin	C		
			Synthroid	C		

Date:10/03/00ISR Number: 3587137-4Report Type:Expedited (15-DaCompany Report #WAES 00065556
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chronic Sinusitis	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Epistaxis	Other			Laboratories Div	
Initial or Prolonged	Haematuria				Merck Co Inc	ORAL
25 MG PO						
	Idiopathic		Diclofenac	SS		
	Thrombocytopenic Purpura		Acetaminophen	SS		
	Petechiae		Penicillin (As Drug)	SS		
	Radiculopathy					
	Splenomegaly					
	Thrombocytopenia					
	Tonsillitis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/00ISR Number: 3587138-6Report Type:Expedited (15-DaCompany Report #WAES 00099127
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Foreign	Vioxx	PS	Merck Research			
	Asthenia	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	25 MG, PO	1 DAY
	Fatigue							
	Hypersensitivity							
	Lethargy							
	Sensory Loss							

Date:10/03/00ISR Number: 3587148-9Report Type:Expedited (15-DaCompany Report #WAES 00095116
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
	Congestive	Other			Laboratories Div			
	Duodenal Ulcer				Merck Co Inc	ORAL	12.5 MG, PO	15 DAY
	Haemorrhage		Diclofenac Na	SS		ORAL	PO	
			Atenolol	C				
			Digoxin	C				
			Furosemide	C				
			Warfarin	C				

Date:10/03/00ISR Number: 3587153-2Report Type:Expedited (15-DaCompany Report #WAES 00095608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Foreign	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	

Date:10/03/00ISR Number: 3601674-5Report Type:Periodic Company Report #2000013115-1
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Avandia	PS	Smithkline Beecham Pharmaceuticals	ORAL	2 MILLIGRAMS	2.0 DAILY
	Dyspnoea							
	Insomnia							
	Oedema Peripheral							
	Orthopnoea		Vioxx (Rofecoxib)	SS				
	Weight Increased		Avandia	C		ORAL	4 MILLIGRAMS	2.0 DAILY
			Capoten (Captopril)	C				
			Lipitor (Atorvastatin)	C				
			Glucophage (Metformin Hcl)	C				
			Synthroid (Levothyroxine Sodium)	C				
			Calcium	C				
			Ginseng	C				
			Antioxidants	C				
			Vitamin C	C				
			Prilosec (Omeprazole Sa)	C				

			Humulog (Insulin Lispro)	C		
			Glynase (Glyburide)	C		
			Lente Insulin	C		
			Aspirin	C		

Date:10/04/00ISR Number: 3587686-9Report Type:Expedited (15-DaCompany Report #WAES 00082296
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemorrhage							
	Ill-Defined Disorder							
	Ulcer							
	Weight Decreased		Celebrex	SS				
			Tylenol	C				
			Chondroitin	C				

Date:10/04/00ISR Number: 3587687-0Report Type:Expedited (15-DaCompany Report #WAES 00082846
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemoglobin Decreased							
			Accupril	C				
			Coumadin	C				
			Lanoxin	C				
			Lipitor	C				
			Lopid	C				
			Paxil	C				
			Synthroid	C				
			Aspirin	C				
			Calcium Supplement (Unspecified)	C				
			Vitamin E	C				

			Vitamins (Unspecified)	C
			Zinc (Unspecified)	C

Date:10/04/00ISR Number: 3587688-2Report Type:Expedited (15-DaCompany Report #WAES 00071851
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Bullous	Health	Vioxx	PS	Merck Research			
	Dry Skin	Professional			Laboratories Div			
	Oedema Peripheral	Company			Merck Co Inc	ORAL	25	
	Pruritus	Representative					MG/DAILY/PO	
	Renal Failure Chronic		Elavil	C				
	Skin Exfoliation		Glucotrol Xl	C				
	Skin Ulcer		Lasix	C				
	Varicose Ulceration		Monopril	C				
			Nph Insulin	C				
			Tagamet	C				
			Hydrocodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/00ISR Number: 3587689-4Report Type:Expedited (15-DaCompany Report #WAES 00091529
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemorrhage Subcutaneous							
	International Normalised Ratio Increased							
	Petechiae		Coumadin	SS			5 MG/DAILY	
	Prothrombin Time Prolonged		Diovan	C				
			Glucotrol	C				
	Thrombocytopenia		Imdur	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Aspirin	C				
			Nitroglycerin	C				

Date:10/04/00ISR Number: 3587690-0Report Type:Expedited (15-DaCompany Report #WAES 00081293
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Antinuclear Antibody Positive Blood Creatinine Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased		Allegra	C				
	Dyspepsia		Avalide	C				
	Red Blood Cell Sedimentation Rate Increased		Niferex Forte	C				
			Ornade Spansule	C				
			Synthroid	C				
	Rheumatoid Factor Positive		Tricor	C				
			Ultram	C				
	Systemic Lupus Erythematosus		Iron (Unspecified)	C				
			Tamoxifen	C				

Date:10/04/00ISR Number: 3587722-XReport Type:Expedited (15-DaCompany Report #WAES 00086140
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Asthenia Fatigue	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	19 DAY
	Hyponatraemia		Acenocoumarol	C				
			Diltiazem Hydrochloride	C				
			Hydroxychloroquine So4	C				
			Omeprazole	C				

Date:10/04/00ISR Number: 3587723-1Report Type:Expedited (15-DaCompany Report #WAES 00089770
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Eyelid Oedema Face Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/00ISR Number: 3587724-3Report Type:Expedited (15-DaCompany Report #WAES 00095508
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Antibody Test Positive Blood Bilirubin Increased Blood Copper Increased Cholecystitis Chronic Cholestasis Condition Aggravated Faeces Pale Gallbladder Disorder Hepatitis Jaundice Laboratory Test Abnormal Liver Function Test Abnormal Pruritus Swelling	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 DAY

Date:10/04/00ISR Number: 3588354-XReport Type:Expedited (15-DaCompany Report #WAES 00080348
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Albumin Increased Blood Alkaline Phosphatase Increased Blood Creatinine Increased Chest Pain Dyspnoea Hyperglycaemia Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Prilosec	C				

Date:10/05/00ISR Number: 3588638-5Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Zyvox (Linezolid)	PS	Pharmacia & Upjohn			
			Vioxx (Rofecoxib)	SS	Merck			

Date:10/05/00ISR Number: 3588856-6Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx 50mg	PS				
			Vioxx 25mg	SS				

Date:10/05/00ISR Number: 3589181-XReport Type:Expedited (15-DaCompany Report #WAES 00092468
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/00ISR Number: 3589184-5Report Type:Expedited (15-DaCompany Report #WAES 00091050
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sulfasalazine	C				

Date:10/05/00ISR Number: 3589188-2Report Type:Expedited (15-DaCompany Report #WAES 00092337
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:10/05/00ISR Number: 3589192-4Report Type:Expedited (15-DaCompany Report #WAES 00092262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Fluid Retention							
	Haemoglobin Decreased							
	Hypoxia		Avandia	C				
	Oxygen Saturation Decreased		Lipitor	C				
			Plavix	C				
			Premarin	C				
			Zebeta	C				
			Aspirin	C				
			Glyburide	C				

Date:10/05/00ISR Number: 3589194-8Report Type:Expedited (15-DaCompany Report #WAES 00092265
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Other	Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:10/05/00ISR Number: 3589196-1Report Type:Expedited (15-DaCompany Report #WAES 00092303
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/05/00ISR Number: 3589200-0Report Type:Expedited (15-DaCompany Report #WAES 00092201
Age:57 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Unstable Cerebrovascular Accident	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
		Avapro	C				
		Hydrodiuril	C				
		Lipitor	C				
		Micronase	C				
		Prilosec	C				
		Toprol Xl Tablets	C				

Date:10/05/00ISR Number: 3589202-4Report Type:Expedited (15-DaCompany Report #WAES 00092214
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Haematocrit Decreased Haematoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lovenox	C				

Date:10/05/00ISR Number: 3589204-8Report Type:Expedited (15-DaCompany Report #WAES 00092202
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Gastrointestinal Haemorrhage Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Bactrim Ds Tablets	SS		ORAL	PO	

			Tab Accupril	SS		ORAL
20 MG/DAILY/PO						
			Coreg	C		
			Coumadin	C		
			Flagyl	C		
			Lasix	C		

Date:10/05/00ISR Number: 3589245-0Report Type:Expedited (15-DaCompany Report #WAES 00098917
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aplastic Anaemia Fatigue	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
25 MG PO 367 DAY						
			Sulfasalazine	C		

Date:10/05/00ISR Number: 3589246-2Report Type:Expedited (15-DaCompany Report #WAES 00099214
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Petit Mal Epilepsy	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						
			Clonazepam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/00ISR Number: 3589247-4Report Type:Expedited (15-DaCompany Report #WAES 00095652
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Pulmonary Congestion Ventricular Tachycardia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 WK

Date:10/05/00ISR Number: 3589249-8Report Type:Expedited (15-DaCompany Report #WAES 00095627
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Duodenal Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO ; 25 MG PO	 63 DAY

Date:10/05/00ISR Number: 3589252-8Report Type:Expedited (15-DaCompany Report #WAES 00096126
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Malaise Ventricular Tachycardia	Foreign Other	Vioxx Diuretic (Unspecified)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:10/05/00ISR Number: 3589254-1Report Type:Expedited (15-DaCompany Report #WAES 00096145
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea Malaise	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

	Pulmonary Oedema	Professional			Merck Co Inc	ORAL
12.5 MG PO ;						
25 MG 48 DAY						
			Anthocyanins (Unspecified) (+)			
			Beta Caro	C		
			Fluoxetine Hcl	C		

Date:10/05/00ISR Number: 3589259-0Report Type:Expedited (15-DaCompany Report #WAES 00095197
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Erythema Multiforme	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO						
			Budesonide	C		
			Estrogens, Conjugated	C		
			Formoterol Fumarate	C		
			Terbutaline Sulfate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/00ISR Number: 3589262-0Report Type:Expedited (15-DaCompany Report #WAES 00095212
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Other	Haemorrhage	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG	24 DAY
			Gliclazide	C				
			Indapamide	C				
			Nadolol	C				
			Ramipril	C				
			Tramodol	C				

Date:10/05/00ISR Number: 3589263-2Report Type:Expedited (15-DaCompany Report #WAES 00095621
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY

Date:10/05/00ISR Number: 3589274-7Report Type:Expedited (15-DaCompany Report #WAES 00096537
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged		Other			Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Aspirin	C				
			Estradiol Benzoate	C				
			Isosorbide Mononitrate	C				
			Triazolam	C				

Date:10/05/00ISR Number: 3589276-0Report Type:Expedited (15-DaCompany Report #WAES 00096539
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG	
			Acetaminophen	C				
			Chlorzoxazone	C				
			Codeine	C				
			Ketobemidone Hcl	C				

Date:10/05/00ISR Number: 3589282-6Report Type:Expedited (15-DaCompany Report #WAES 00095183
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
Hospitalization - Initial or Prolonged	Condition Aggravated	Other						
	Gastric Ulcer Haemorrhage							
	Haematemesis		Prinzide	C				
	Haemoglobin Decreased		Ciprofloxacin	C				
	Rectal Haemorrhage		Tramadol	C				

Date:10/05/00ISR Number: 3589288-7Report Type:Expedited (15-DaCompany Report #WAES 00096536
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG PO	54 DAY

Date:10/05/00ISR Number: 3604330-2Report Type:Periodic Company Report #WAES 00041479
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

Date:10/06/00ISR Number: 3589212-7Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured		Rofecoxib 25mg	PS		ORAL	25MG QD ORAL	
Hospitalization - Initial or Prolonged	Gastric Ulcer		Ec Asa 325mg	SS		ORAL	325MG QD ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Haematemesis Upper Gastrointestinal Haemorrhage							

Date:10/06/00ISR Number: 3590719-7Report Type:Expedited (15-DaCompany Report #WAES 00069762
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy	Foreign	Vioxx	PS	Merck Research			

Life-Threatening	Arrhythmia	Health			Laboratories Div	
Hospitalization -	Bradycardia	Professional			Merck Co Inc	ORAL
25 MG PO 5 DAY						
Initial or Prolonged	Cardiac Arrest		Vasotec	SS		ORAL
2.5 MG PO						
	Cardiomegaly		Acetaminophen	C		
	Coronary Artery Disease		Amoxicillin			
	Hemiplegia		Trihydrate (+)			
	Hepatic Congestion		Clavulanate P	C		
	Hyperkalaemia		Codeine	C		
	Loss Of Consciousness		Levothyroxine Na	C		
	Nervous System Disorder		Oxybutynincl	C		
	Pyrexia					
	Renal Failure					
	Rhonchi					
	Sepsis					
	Spleen Disorder					

Date:10/06/00ISR Number: 3598740-XReport Type:Periodic Company Report #USA014533
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dental Caries	Health	Meridia	PS	Knoll Pharmaceutical	
		Professional			Co Sub Basf Corp	ORAL
10 MG QD PO						
			Vioxx	SS		
			Plendil	SS		
			Zyrtec	SS		ORAL
10 MG QD PO						

			Zoladex	SS		
			Tylenol #2	SS		
			Micronor	SS		ORAL
1 DF QD PO						
			Nasacort	C		
			Fluoride	C		

Date:10/10/00ISR Number: 3591837-XReport Type:Expedited (15-DaCompany Report #WAES 00080169
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck Research	
Other	Oedema Peripheral	Professional			Laboratories Div	
	Pulmonary Oedema	Company			Merck Co Inc	ORAL
SEE IMAGE						
		Representative	Maxzide	C		
			Pravachol	C		
			Toprol Xl Tablets	C		
			Methotrexate	C		
			Prednisone	C		

Date:10/10/00ISR Number: 3591846-0Report Type:Expedited (15-DaCompany Report #WAES 00100086
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Professional			Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Antivert	C		
			Haldol	C		
			Klotrix	C		
			Lasix	C		
			Pepcid	C		
			Cassia Fistula	C		

Date:10/10/00ISR Number: 3591847-2Report Type:Expedited (15-DaCompany Report #WAES 00100085
Age:99 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Lipitor	C				
			Lopressor	C				
			Transderm-Nitro	C				
			Zantac	C				
			Aspirin	C				

Date:10/10/00ISR Number: 3591848-4Report Type:Expedited (15-DaCompany Report #WAES 00092550
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage Haematocrit Decreased Haemoglobin Decreased

	Syncope						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:10/10/00ISR Number: 3591855-1Report Type:Expedited (15-DaCompany Report #WAES 00091463
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO
			Ativan	C			
			Colace	C			
			Coumadin	C			
			Fibercon	C			
			Flonase	C			
			Lanoxin	C			
			Mycilan	C			
			Prevacid	C			
			Composition Unspecified	C			
			Therapy Unspecified	C			
			Metoprolol	C			

Date:10/10/00ISR Number: 3591902-7Report Type:Expedited (15-DaCompany Report #WAES 00090585
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Colitis Ulcerative Hyperbilirubinaemia Jaundice Liver Function Test	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Celexa	C			

	Abnormal		Prilosec	C
	Malaise		Synthroid	C
	Pyrexia		Composition Unspecified	C
			Hormonal Contraceptives	C

Date:10/10/00ISR Number: 3591955-6Report Type:Expedited (15-DaCompany Report #WAES 00100083
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/	PO
			Cordarone	C				
			Isordil	C				
			Klotrix	C				
			Lasix	C				
			Prevacid	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/00ISR Number: 3591957-XReport Type:Expedited (15-DaCompany Report #WAES 00092542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN PO	

Date:10/10/00ISR Number: 3591958-1Report Type:Expedited (15-DaCompany Report #WAES 00090487
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/ PO	
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							
	Oesophageal Ulcer		Prempro	C				
	Vomiting		Zoloft	C				
			Alprazolam	C				
			Calcium Carbonate (+) Cholecalci	C				

Date:10/10/00ISR Number: 3591969-6Report Type:Expedited (15-DaCompany Report #WAES 00100014
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO	

Date:10/10/00ISR Number: 3592113-1Report Type:Expedited (15-DaCompany Report #WAES 00095229
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	13 DAY
	Crepitations Dyspnoea		Amiloride Hydrochloride (+)					
			Furosemide	C				
			Amlodipine	C				
			Amoxicillin	C				

Date:10/10/00ISR Number: 3592114-3Report Type:Expedited (15-DaCompany Report #WAES 00095231
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Allopurinol	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Atenolol	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/00ISR Number: 3592119-2Report Type:Expedited (15-DaCompany Report #WAES 00095236
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Peritonitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Clonidine	C				
			Danazol	C				
			Dothiepin	C				
			Oil Of Peppermint	C				

Date:10/10/00ISR Number: 3592120-9Report Type:Expedited (15-DaCompany Report #WAES 00095233
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Left Ventricular Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Dihydrocodeine	C				
			Isosorbide Mononitrate	C				
			Nicorandil	C				

Date:10/10/00ISR Number: 3592121-0Report Type:Expedited (15-DaCompany Report #WAES 00105507
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET, PO	
			Soln Allergenic Extract	SS		SUBCUTANEOUS	SC	
			Barbexaclone	C				
			Ethosuximide	C				
			Prednisone	C				

Date:10/10/00ISR Number: 3592123-4Report Type:Expedited (15-DaCompany Report #WAES 00095554
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Anaemia Gastric Ulcer Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/10/00ISR Number: 3592191-XReport Type:Expedited (15-DaCompany Report #WAES 00055164
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspepsia Malaise Mitral Valve Stenosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Nausea Red Blood Cell Sedimentation Rate Increased	Other	Dexamethasone Methotrexate Omeprazole	C C C				

Date:10/10/00ISR Number: 3592192-1Report Type:Expedited (15-DaCompany Report #WAES 00096058
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Melaena		Tab Fluindione	SS		ORAL	20 MG, PO	2 YR
			Aspirin	C				

Date:10/10/00ISR Number: 3592193-3Report Type:Expedited (15-DaCompany Report #WAES 00095609
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Autoimmune Disorder Petechiae Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Homeopathic Medications (Unspecified)	C				
			Isosorbide Dinitrate	C				
			Levothyroxine Na	C				
			Theophylline	C				
			Verapamil Hcl	C				

Date:10/10/00ISR Number: 3592201-XReport Type:Expedited (15-DaCompany Report #WAES 00105502
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased Liver Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	17 DAY

Date:10/10/00ISR Number: 3592203-3Report Type:Expedited (15-DaCompany Report #WAES 00096155
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema	Foreign	Vioxx	PS	Merck Research			
	Pain	Health			Laboratories Div			
	Tendon Disorder	Professional			Merck Co Inc	ORAL	25 MG, PO	22 DAY
	Tendonitis		Thyroxine	C				

Date:10/10/00ISR Number: 3592240-9Report Type:Expedited (15-DaCompany Report #WAES 00088566
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bicarbonate	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Decreased	Health			Laboratories Div			
Initial or Prolonged	Blood Ph Decreased	Professional			Merck Co Inc	ORAL	25.0 PO	5 DAY
Disability	Condition Aggravated		Blinded Therapy	SS		ORAL	PO	37 DAY
	Heart Transplant		Carvedilol	C				
	Hepatitis		Furosemide	C				
	Liver Function Test		Potassium Chloride	C				
	Abnormal		Warfarin Sodium	C				
	Low Cardiac Output							
	Syndrome							
	Metabolic Acidosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/00ISR Number: 3592251-3Report Type:Expedited (15-DaCompany Report #WAES 00035602
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	10 DAY
		Other						

Date:10/10/00ISR Number: 3592254-9Report Type:Expedited (15-DaCompany Report #WAES 00035094
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Peritonitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Vomiting		Acetaminophen	C				
			Amiloride Hydrochloride (+) Furosemide	C				

Date:10/10/00ISR Number: 3592255-0Report Type:Expedited (15-DaCompany Report #WAES 00087531
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Prothrombin Time	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Prolonged		Tab Phenprcoumon	SS		ORAL	PO	
	Upper Gastrointestinal Haemorrhage							

Date:10/10/00ISR Number: 3592491-3Report Type:Expedited (15-DaCompany Report #WAES 00097538
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	22 DAY
			Benserazide/Levodopa	C				
			Captopril	C				
			Flunitrazepam	C				
			Insulin	C				
			Selegilline Hcl	C				

Date:10/10/00ISR Number: 3592730-9Report Type:Expedited (15-DaCompany Report #LBID00200005900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Above Therapeutic Renal Disorder	Health Professional Company Representative	Lithobid	PS	Solvay Pharmaceuticals	ORAL	300 MG BID PO, 300 MG QD PO	
			Vioxx	SS		ORAL	DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/00ISR Number: 3592830-3Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx 25mg	PS		ORAL	25MG PO QD	
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/11/00ISR Number: 3592995-3Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Conjunctivitis		Vioxx 12.5 Mg					
Intervention to	Haemoptysis		Merck	PS	Merck	ORAL	12.5MG, ONCE	
Prevent Permanent	Periorbital Oedema						PER, ORAL	
Impairment/Damage			Prednisone	C				
			Fosamax	C				

Date:10/11/00ISR Number: 3592998-9Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25mg Merck	PS	Merck	ORAL	25MG, QHS,	
Initial or Prolonged	Blood Urea						ORAL	
Required	Dyspnoea		Coumadin 2.5mg; 5mg;					
Intervention to	Erythema		7.5mg	SS	Dupont	ORAL	2.5/5/7.5 ,	
Prevent Permanent	International Normalised						QD, ORAL	
Impairment/Damage	Ratio Increased		Lasix	C				
			Coumadin	C				
			Diovan	C				
			Glucotrol	C				

Sodium Bicarbonate	C
Digoxin	C
Imdur	C
Nitro Patch	C
Vioxx	C
Tums	C

Date:10/11/00ISR Number: 3593984-5Report Type:Expedited (15-DaCompany Report #WAES 00099147
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Csf Test Abnormal Dizziness Headache Malaise Meningitis Nausea Pyrexia Syncope Vomiting	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/00ISR Number: 3597779-8Report Type:Periodic Company Report #000516-SK405
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG QD	
PO	Drug Effect Decreased	Health						
		Professional	Vioxx	SS		ORAL	75.000 MG QD	
PO								30 DAY
			Atenolol	C				
			Isosorbide Dinitrate	C				
			Nitroglycerin	C				
			Pravastatin	C				
			Aspirin	C				
			Glucosamine	C				
			Chondroitin Sulfate	C				
			Vitamins	C				

Date:10/11/00ISR Number: 3597985-2Report Type:Periodic Company Report #000906-SK253
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Company	Celebrex	PS	Gd Searle And Co	ORAL	PO	
		Representative	Vioxx	SS		ORAL	PO	

Date:10/11/00ISR Number: 3598585-0Report Type:Periodic Company Report #000726-SK528
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG QD	
	Hearing Impaired	Health					PO	
	Weight Increased	Professional	Rofecoxib	SS		ORAL	PO	

			Famotidine	C
			Furosemide	C
			Potassium	C
			Venlafaxine Hydrochloride	C
			Irbesartan	C

Date:10/11/00ISR Number: 3599596-1Report Type:Periodic Company Report #000714-SK968
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Company	Celebrex	PS	Gd Searle And Co	ORAL	PO	
		Representative	Vioxx	SS		ORAL	PO	

Date:10/11/00ISR Number: 3604537-4Report Type:Periodic Company Report #000221-SK719
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG	
	Leukopenia	Health					BID PO	
	Therapeutic Response Decreased	Professional	Fluoxetine	SS				
			Vioxx	SS		ORAL	PO	
	Thrombocytopenia		Terazosin	C				
	Weight Increased		Omeprazole	C				
			Simvastatin	C				
			Clopidogrel Bisulfate	C				

			Alprazolam	C		

Date:10/12/00ISR Number: 3594353-4Report Type:Expedited (15-DaCompany Report #A032987
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Zyrtec	PS	Pfizer Inc	ORAL		
Initial or Prolonged	Asthenia	Consumer	Plaquenil	SS		ORAL	200.00 MG	
	Blood Bilirubin Increased						TOTAL:DAILY:O	
	Dyspnoea						RAL	
	Haptoglobin Decreased		Rofecoxib	SS		ORAL	25.00 MG	
	Normochromic Normocytic						TOTAL:DAILY:O	
	Anaemia						RAL	
	Red Blood Cell Count		Salazopyrine	SS		ORAL	12.00 MG	
	Decreased						TOTAL:BID:ORA	
	Spinal Myelogram Abnormal						L	
	Tinnitus		Piroxicam	C				
			Omeprazole	C				
			Prednisone	C				

Date:10/12/00ISR Number: 3595490-0Report Type:Expedited (15-DaCompany Report #WAES 00095055
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Other			Laboratories Div			
Other	Oesophagitis				Merck Co Inc	ORAL		
PO							31	DAY
			Elavil	C				
			Timoptic	C				
			Amlodipine	C				

Isosorbide Mononitrate	C
Nizatidine	C
Thyroxine	C

Date:10/12/00ISR Number: 3595491-2Report Type:Expedited (15-DaCompany Report #WAES 00097539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:10/12/00ISR Number: 3595492-4Report Type:Expedited (15-DaCompany Report #WAES 00108521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Confusional State Drug Ineffective Fatigue	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/00ISR Number: 3595493-6Report Type:Expedited (15-DaCompany Report #WAES 00087545
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Malaise Nausea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:10/12/00ISR Number: 3595494-8Report Type:Expedited (15-DaCompany Report #WAES 00098587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Diarrhoea Drug Toxicity Myelodysplastic Syndrome Neutropenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO; 25 MG	79 DAY
Disability	Sepsis Thrombocytopenia		Infusion (Form)Fluorouracil Antineoplastic (Unspecified)	SS SS		INTRAVENOUS	IV	

Date:10/12/00ISR Number: 3595518-8Report Type:Expedited (15-DaCompany Report #WAES 00087544
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Alprazolam	C				
			Dipyridamole	C				
			Dothiepin	C				
			Levothyroxine Na	C				
			Pravastatin Na	C				
			Sotalol Hydrochloride	C				

Date:10/12/00ISR Number: 3595528-0Report Type:Expedited (15-DaCompany Report #WAES 00109301
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	6 DAY

Date:10/12/00ISR Number: 3595534-6Report Type:Expedited (15-DaCompany Report #WAES 00081101
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Gastritis	Other						
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/00ISR Number: 3595536-XReport Type:Expedited (15-DaCompany Report #WAES 00090889
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Gastrooesophageal Reflux Disease Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO; 25 MG/DAILY/PO	
			Cardura	C				
			Celebrex	C				
			Prilosec	C				

Date:10/12/00ISR Number: 3595538-3Report Type:Expedited (15-DaCompany Report #WAES 00092303
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Oxygen Saturation Decreased Pulmonary Embolism Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:10/12/00ISR Number: 3595540-1Report Type:Expedited (15-DaCompany Report #WAES 00100138
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea Oedema Peripheral Pulmonary Embolism Rectal Haemorrhage Thrombosis Urinary Incontinence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/12/00ISR Number: 3595541-3Report Type:Expedited (15-DaCompany Report #WAES 00100081
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cold Sweat	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Major Depression							
	Nausea							
	Pulmonary Embolism		Zyprexa	SS			10 MG/DAILY	
	Sweat Gland Disorder		Paxil	C				
			Wellbutrin Sr	C				

Date:10/12/00ISR Number: 3595557-7Report Type:Expedited (15-DaCompany Report #WAES 00091600
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
Other	Blood Creatinine Increased							
	Myocardial Infarction	Representative						
	Nephritis Interstitial		Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/00ISR Number: 3595558-9Report Type:Expedited (15-DaCompany Report #WAES 00080641
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Tongue Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nitrostat	C				
			Prevacid	C				
			Amoxicillin	C				
			Timolol	C				

Date:10/12/00ISR Number: 3595617-0Report Type:Expedited (15-DaCompany Report #WAES 00087532
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allopurinol	C				
			Celiprolol	C				
			Spironolactone	C				

Date:10/12/00ISR Number: 3595625-XReport Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer Gastroenteritis Helicobacter	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OCCLUSIVE DRESSING	25 MG	
	Gastrointestinal Disorder Hyperchlorhydria Vomiting		Mepivacaine Hcl	C				

Date:10/12/00ISR Number: 3595632-7Report Type:Expedited (15-DaCompany Report #WAES 00087541
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Difficulty In Walking	Health			Laboratories Div			
Initial or Prolonged	Disturbance In Attention	Professional			Merck Co Inc	ORAL	12.5 MG	
	Flushing		Bisoprolol Fumarate	C				
	Gait Disturbance		Candesartan	C				
	Lower Respiratory Tract		Furosemide	C				
	Infection		Lisinopril	C				
	Sedation		Molsidomine	C				
			Omeprazole	C				
			Spironolactone	C				

Date:10/12/00ISR Number: 3595633-9Report Type:Expedited (15-DaCompany Report #WAES 00088620
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cardiac Failure
Initial or Prolonged	Congestive
Disability	Hypertension

		Leukocytoclastic Vasculitis Lung Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nephrotic Syndrome Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG	10 DAY						
				Cyclobenzaprine	C		

Date:10/12/00ISR Number: 3595635-2Report Type:Expedited (15-DaCompany Report #WAES 00095526
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG						
			Dipyrone	C		
			Furosemide (+)			
			Triamterene	C		
			Omeprazole	C		

Date:10/12/00ISR Number: 3595637-6Report Type:Expedited (15-DaCompany Report #WAES 00098554
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death Life-Threatening Hospitalization -	Angina Unstable Cardiac Arrest Cardiac Enzymes Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG						
Initial or Prolonged	Electrocardiogram Change		Allopurinol	C		
	Gastric Ulcer		Aspirin	C		
	Gastrointestinal Haemorrhage		Atenolol	C		
	Hypokalaemia		Diltiazem	C		
	Hypotension					
	Melaena					
	Myocardial Infarction					
	Pneumonia					

Date:10/12/00ISR Number: 3595639-XReport Type:Expedited (15-DaCompany Report #WAES 00098556
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspepsia Haematemesis Melaena Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Aspirin	C		

Date:10/12/00ISR Number: 3595653-4Report Type:Expedited (15-DaCompany Report #WAES 00081076
Age: Gender:Female I/FU:F

Outcome	PT
Other	Blister Cardiac Murmur Chest Discomfort Chest Pain Choking Dyspnoea

	Face Oedema Gastrointestinal Disorder Pharyngeal Oedema	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:10/12/00ISR Number: 3595657-1Report Type:Expedited (15-DaCompany Report #WAES 00100205
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Norvasc	C				
			Premarin	C				
			Synthroid	C				
			Zyrtec	C				
			Folic Acid	C				

Date:10/12/00ISR Number: 3595659-5Report Type:Expedited (15-DaCompany Report #WAES 00092388
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Oedema Syncope Urticaria Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amoxil	C				
			Hydrodiuril	C				
			Premarin	C				
			Tums	C				
			Atenolol	C				
			Glucosamine	C				

			Vitamin E	C		

Date:10/12/00ISR Number: 3595661-3Report Type:Expedited (15-DaCompany Report #WAES 00091864
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research	
Hospitalization -	Perforation	Professional			Laboratories Div	
Initial or Prolonged		Company			Merck Co Inc	ORAL
25 MG/BID/PO						
		Representative	Aricept	C		
		Other	Cozaar	C		
			K-Dur	C		
			Lasix	C		
			Sinemet	C		
			Ticlid	C		
			Zyprexa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/00ISR Number: 3595662-5Report Type:Expedited (15-DaCompany Report #WAES 00080383
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Melaena	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Cardizem	C				
			Cardura	C				
			Humulin	C				
			Lipitor	C				
			Aspirin	C				
			Ibuprofen	C				
			Isosorbide Dinitrate	C				
			Vitamin E	C				

Date:10/12/00ISR Number: 3595666-2Report Type:Expedited (15-DaCompany Report #WAES 00092265
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:10/12/00ISR Number: 3595668-6Report Type:Expedited (15-DaCompany Report #WAES 00090802
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ecchymosis Hypoaesthesia International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

	Prothrombin Time Prolonged		Coumadin	C

Date:10/12/00ISR Number: 3595670-4Report Type:Expedited (15-DaCompany Report #WAES 00081283
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chromaturia							
	Dermatitis							
	Dyspnoea							
	Gastrointestinal Disorder		Aerobid	C				
	Hepatitis		Atrovent	C				
	Influenza Like Illness		Humibid	C				
	Jaundice		Medrol	C				
	Pruritus		Premarin	C				
	Sinusitis		[Therapy Unspecified]	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/00ISR Number: 3595673-XReport Type:Expedited (15-DaCompany Report #WAES 00081102
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dizziness	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea	Other			Merck Co Inc	ORAL	PO	
Other	Faecal Occult Blood		Celebrex	C				
	Positive		Lipitor	C				
	Gastric Ulcer		Paxil	C				
	Gastrointestinal							
	Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							
	Rectal Haemorrhage							

Date:10/12/00ISR Number: 3595675-3Report Type:Expedited (15-DaCompany Report #WAES 00091845
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research			
	Neuropathy Peripheral				Laboratories Div			
	Tenosynovitis				Merck Co Inc	ORAL	25 MG/PO	
			Cardizem	C				
			Lopid	C				
			Aspirin	C				

Date:10/13/00ISR Number: 3594991-9Report Type:Expedited (15-DaCompany Report #WAES 00100192
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Vioxx	PS	Merck Research			
	Haemorrhage	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:10/13/00ISR Number: 3594992-0Report Type:Expedited (15-DaCompany Report #WAES 00100225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/13/00ISR Number: 3594993-2Report Type:Expedited (15-DaCompany Report #WAES 00100504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
Hospitalization - Initial or Prolonged	Status Asthmaticus							
	Stevens-Johnson Syndrome							
		Representative	[Therapy Unspecified]	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/00ISR Number: 3595160-9Report Type:Expedited (15-DaCompany Report #WAES 00095574
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY

Date:10/13/00ISR Number: 3595162-2Report Type:Expedited (15-DaCompany Report #WAES 00085628
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
Hospitalization - Initial or Prolonged	Multi-Organ Failure							
	Peritonitis		Certoparin Sodium	C				
			Dipyrone	C				

Date:10/13/00ISR Number: 3595163-4Report Type:Expedited (15-DaCompany Report #WAES 00097524
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
		Other	Captopril	C				
			Diltiazem Hydrochloride	C				
			Fluoxetine Hcl	C				
			Molsidomine	C				
			Nitroglycerin	C				

Date:10/13/00ISR Number: 3595620-0Report Type:Expedited (15-DaCompany Report #WAES 00095190
Age:60 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper Anaemia Gastric Ulcer Haemoglobin Decreased Stomach Discomfort	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:10/13/00ISR Number: 3595623-6Report Type:Expedited (15-DaCompany Report #WAES 00095614
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Interaction Gastric Haemorrhage	Foreign Study Health Professional	Vioxx Cinnarizine (+) Dimenhydrinate Digitoxin Lisinopril / Hctz Ticlodipine Hydrochloride Trazodone Hcl Zolpidem Tartrate	PS C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	90 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/00ISR Number: 3595624-8Report Type:Expedited (15-DaCompany Report #WAES 00108206
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	31 DAY
	Hepatocellular Damage	Other						
	Liver Disorder							
	Liver Function Test		Omeprazole Magnesium	SS		ORAL	40 MG PO	28 DAY
	Abnormal		Inj Ceftriaxone Sodium	SS		INTRAVENOUS	2000 MG IV	3 DAY
			Aspirin	C				
			Calcium Carbonate	C				
			Cefuroxime Axetil	C				
			Cholecalciferol	C				
			Citalopram Hydrobromide	C				
			Dalteparin Sodium	C				
			Donepezil Hydrochloride	C				
			Haloperidol	C				
			Metronidazole	C				
			Morphineso4	C				
			Oxazepam	C				
			Prednisone	C				
			Trimipramine Maleate	C				

Date:10/13/00ISR Number: 3595628-5Report Type:Expedited (15-DaCompany Report #WAES 00085176
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Gastric Ulcer	Health Professional						
	Haemoglobin Decreased							
	Impetigo	Other	Tab Methotrexate	SS		ORAL	25 WEEKLY MG	
	Rhinitis Allergic						PO	
	Scab							
	Stomach Discomfort							

Urticaria

Date:10/13/00ISR Number: 3595636-4Report Type:Expedited (15-DaCompany Report #WAES 00086029
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased Flatulence	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	33 DAY
	Gastrooesophageal Reflux Disease Haemoptysis Mouth Ulceration Pulmonary Haemorrhage	Professional	Acetaminophen Omeprazole Sodium	C C				

Date:10/16/00ISR Number: 3594530-2Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety Hallucination Liver Function Test

		Abnormal Visual Disturbance					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Tasmar	PS	Roche	
				Vioxx	SS		
27	DAY						
				Aciphex	C		
				Sinemet	C		
				Sinemet Cr	C		
				Mirapex	C		
				Unknown Medication Nos	C		
				Vitamin E	C		
				Coenzyme Q10	C		
				Vitamin C	C		
				Nadh	C		

Date:10/16/00ISR Number: 3595770-9Report Type:Expedited (15-DaCompany Report #WAES 00072033
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Heat Exhaustion	Health	Vioxx	PS	Merck Research	
	Hyperhidrosis	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:10/16/00ISR Number: 3595775-8Report Type:Expedited (15-DaCompany Report #WAES 00051120
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Arrest	Health	Vioxx	PS	Merck Research	
Life-Threatening	Chest Pain	Professional			Laboratories Div	
Hospitalization -	Dyspepsia	Company			Merck Co Inc	ORAL
25						
Initial or Prolonged	Myocardial Infarction	Representative				
MG/DAILY/PO						
	Ventricular Fibrillation		Ogen	C		
			Provera	C		
			Aspirin	C		

			Atenolol	C		
			Hydrochlorothiazide	C		

Date:10/16/00ISR Number: 3595776-XReport Type:Expedited (15-DaCompany Report #WAES 00090779
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspnoea Embolism Pulmonary Embolism	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Paxil	C		
			Wellbutrin	C		
			Zyprexa	C		
			Phentermne	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3595777-1Report Type:Expedited (15-DaCompany Report #WAES 00062126
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Feeling Abnormal							
	Headache				Merck Co Inc	ORAL	12/5 MG/DAILY/PO	
	Leukaemia							
	Mental Impairment		Aleve	C				
	Visual Disturbance		[Therapy Unspecified]	C				

Date:10/16/00ISR Number: 3595793-XReport Type:Expedited (15-DaCompany Report #WAES 00081876
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Iron Decreased	Health Professional	Fosamax	PS	Merck And Co Inc	ORAL	10 MG/AM/PO	
Hospitalization - Initial or Prolonged	Decreased Activity		Vioxx	SS		ORAL	12.5 MG/DAILY/PO	
	Erythropenia							
	Faecal Occult Blood						(SEE IMAGE)	
	Positive		Aspirin	C				
	Faeces Discoloured		Calcium Supplement	C				
	Fatigue		Garlic Extract	C				
	Gastrointestinal Ulcer		Ginkgo Biloba Extract	C				
	Haematocrit Decreased		Herbal Remedies	C				
	Haemoglobin Decreased		Vitamin E	C				
	Headache		Vitamins	C				
	Insomnia							
	Pallor							

Date:10/16/00ISR Number: 3595800-4Report Type:Expedited (15-DaCompany Report #WAES 00082897
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Erosive Oesophagitis Faecal Occult Blood Positive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 Other MG/DAILY/PO	Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage Haematemesis Haematocrit Decreased Haemoglobin Decreased Melaena Oesophagitis Peptic Ulcer Haemorrhage	Representative				

Date:10/16/00ISR Number: 3595809-0Report Type:Expedited (15-DaCompany Report #WAES 00052792
Age:84 YR Gender:Female I/FU:F

Outcome Dose Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Diverticulitis Drug Ineffective Gastric Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE	Gastritis Ulcer		Ambien Unk [Therapy Unspecified] Prednisone	SS C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3595810-7Report Type:Expedited (15-DaCompany Report #WAES 00108902
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Obstruction	Foreign	Vioxx	PS	Merck Research			
	Pain	Health			Laboratories Div			
	Prostatic Disorder	Professional			Merck Co Inc	ORAL	25 MG	
	Renal Failure Acute		Antibiotics	C				
	Urinary Tract Infection		Muscle Relaxants	C				

Date:10/16/00ISR Number: 3595813-2Report Type:Expedited (15-DaCompany Report #WAES 00100319
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Health	Vioxx	PS	Merck Research			
	Difficulty In Walking	Professional			Laboratories Div			
	Oedema Peripheral				Merck Co Inc	ORAL	25 MG/AM/PO	
	Pain In Extremity							

Date:10/16/00ISR Number: 3595816-8Report Type:Expedited (15-DaCompany Report #WAES 00092102
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Failure	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Renal Failure				Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:10/16/00ISR Number: 3595817-XReport Type:Expedited (15-DaCompany Report #WAES 00090013
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure	Health	Vioxx	PS	Merck Research			
Hospitalization -	Fluctuation	Professional			Laboratories Div			

Initial or Prolonged	Circulatory Collapse	Company		Merck Co Inc	ORAL
25					
Other	Faeces Discoloured	Representative			
MG/DAILY/PO					
	Haematemesis		Celexa	C	
	Haematocrit Decreased		Darvocet-N	C	
	Haemoglobin Decreased		Pamelor	C	
	Hypoaesthesia		Plavix	C	
	Hypovolaemia				
	Melaena				
	Oesophageal Varices				
	Haemorrhage				
	Orthostatic Hypotension				
	Pulse Abnormal				
	Syncope				
	Visual Disturbance				

Date:10/16/00ISR Number: 3595826-0Report Type:Expedited (15-DaCompany Report #WAES 00099762
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Convulsion
Hospitalization -	Diabetes Mellitus
Initial or Prolonged	Inadequate Control
Other	Drug Interaction
	Haematocrit Decreased
	Hyponatraemia

		International Normalised Ratio Decreased Laboratory Test Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphopenia Mean Cell Volume Abnormal Prothrombin Time	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Prolonged Red Blood Cell Count Decreased Thrombocythaemia		Metformin Hcl Unk	SS		
				Glipizide Unk	SS		
				[Composition Unspecified]	C		
				Digoxin	C		
				Dipyridamole	C		
				Levofloxacin	C		
				Nitroglycerin	C		
				Vitamins (Unspecified)	C		

Date:10/16/00ISR Number: 3595895-8Report Type:Expedited (15-DaCompany Report #WAES 00091463
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO							
				Ativan	C		
				Celebrex	C		
				Colace	C		
				Coumadin	C		
				Fibercon	C		
				Flonase	C		
				Lanoxin	C		
				Mycilan	C		
				Prevacid	C		
				Zocor	C		
				[Composition Unspecified]	C		
				[Therapy Unspecified]	C		
				Metoprolol	C		

Date:10/16/00ISR Number: 3596065-XReport Type:Expedited (15-DaCompany Report #WAES 00108106
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Movement Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY

Date:10/16/00ISR Number: 3596068-5Report Type:Expedited (15-DaCompany Report #WAES 00109601
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Cardiac Arrest	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3596102-2Report Type:Expedited (15-DaCompany Report #WAES 00087542
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
	Congestive	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	25 MG, PO	13 DAY
	Hepatomegaly		Zocor	C				
	Hypertension		Acebutolol	C				
	Oedema Peripheral		Acenocoumarol	C				
	Weight Increased		Acetaminophen	C				
			Aspirin	C				
			Lormetazepam	C				

Date:10/16/00ISR Number: 3596115-0Report Type:Expedited (15-DaCompany Report #WAES 00095235
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Menopausal Symptoms	Foreign	Vioxx	PS	Merck Research			
	Postmenopausal	Other			Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	12.5 MG, PO	3 DAY
	Vaginal Haemorrhage		Dothiepin	C				
			Ramipril	C				

Date:10/16/00ISR Number: 3596121-6Report Type:Expedited (15-DaCompany Report #WAES 00097516
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
	Haemorrhoids	Health			Laboratories Div			
	Rectal Haemorrhage	Professional			Merck Co Inc	ORAL	25 MG, PO	
			Tab Aspirin	SS		ORAL	80 MG, PO	
			Vasotec	C				
			Paroxetine	C				

Date:10/16/00ISR Number: 3596243-XReport Type:Expedited (15-DaCompany Report #WAES 00095653
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Pulmonary Congestion Ventricular Tachycardia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1	WK
			Digitalis	C				
			Morphine	C				

Date:10/16/00ISR Number: 3596244-1Report Type:Expedited (15-DaCompany Report #WAES 00095213
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	109 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Dihydrocodeine	C				
			Ranitidine Hcl	C				
			Zopiclone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/00ISR Number: 3596245-3Report Type:Expedited (15-DaCompany Report #WAES 00096160
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
			Timoptic	C				
			Trusopt	C				
			Chymotrypsin (+) Rutin (+) Vitamins	C				
			Dipivefrin	C				
			Ginkgo Biloba Extract	C				

Date:10/16/00ISR Number: 3596249-0Report Type:Expedited (15-DaCompany Report #WAES 00095083
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Glyburide	C				
			Metformin	C				
			Ranitidine	C				

Date:10/16/00ISR Number: 3596250-7Report Type:Expedited (15-DaCompany Report #WAES 00105017
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Infection Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG	
			Chondroitin	C				
			Glucosamine	C				

Date:10/16/00ISR Number: 3596251-9Report Type:Expedited (15-DaCompany Report #WAES 00108205
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Chondroitin Sulfate Sodium	C				
			Estradiol/Norethindrone Acetate	C				
			Trimipramine Maleate	C				

Date:10/16/00ISR Number: 3596441-5Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health Professional	Tasmar	PS	Hoffmann La Roche Inc	ORAL	100 MG 3 PER DAY ORAL	
	Hallucination							
	Hallucination, Visual							
	Hepatic Enzyme Increased		Vioxx (Rofecoxib)	SS		ORAL	25 MG DAILY ORAL	
	Pain In Extremity							

Aciphex (Rabeprazole Sodium)	C
Sinemet (Carbidopa/Levodopa)	C
Mirapex (Pramipexole)	C
Vitamin E	C
Coenzyme Q10 (Ubidecarenone)	C
Vitamin C	C
Nadh (Nadide)	C

Date:10/17/00ISR Number: 3596838-3Report Type:Expedited (15-DaCompany Report #WAES 00108209
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
	Dermatitis							
		Other	Soln Dipyrone	SS		ORAL	120 DROPS PO	7 DAY
			Soln Nadroparin Calcium	SS		ORAL	0.6 ML PO	8 DAY
			Acetaminophen	C				
			Prednisone	C				

Date:10/17/00ISR Number: 3596839-5Report Type:Expedited (15-DaCompany Report #WAES 00105034
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Electrolytes Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Cardiac Failure							
	Congestive Condition Aggravated		Digoxin	C				
			Furosemide	C				
	Electrolyte Imbalance		Warfarin	C				
	Hepatic Function Abnormal							
	Liver Function Test							

Abnormal
Pulmonary Oedema

Date:10/17/00ISR Number: 3596841-3Report Type:Expedited (15-DaCompany Report #WAES 00105031
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
	Drug Interaction							
	Haematemesis		Prinivil (Lisinopril)	SS		ORAL	5 MG PO	
	Upper Gastrointestinal Haemorrhage		Zocor	C				
			Acetaminophen (+) Codeine	C				
			Aspirin	C				
			Danthron (+) Poloxamer 188	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/00ISR Number: 3596844-9Report Type:Expedited (15-DaCompany Report #WAES 00097326
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	5 DAY
	Diarrhoea	Other						
	Nausea							
			Acetaminophen	C				
			Aspirin/Caffeine/Codeine Phosphate	C				
			Estradiol/Norethindrone Acetate	C				
			Propranolol Hcl	C				
			Zolpidem Tartrate	C				

Date:10/17/00ISR Number: 3596845-0Report Type:Expedited (15-DaCompany Report #WAES 00105547
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25.0 MG PO	33 DAY
	Gastric Ulcer	Health						
	Gastritis Erosive	Professional						
	Melaena	Other	Digitoxin	C				
			Theophylline	C				

Date:10/17/00ISR Number: 3597385-5Report Type:Expedited (15-DaCompany Report #WAES 00091014
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anaemia	Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Arthralgia	Professional						
	Blood Bicarbonate Decreased	Company						
		Representative						
	Blood Chloride Decreased		Cisplatin	SS				
	Blood Glucose Increased		Duragesic	C				
	Blood Pressure Diastolic		Inapsine	C				

	Increased	Lasix	C
	Cachexia	Taxol	C
	Condition Aggravated	Tylox	C
	Metabolic Acidosis	Vasoretic	C
	Nephropathy Toxic	Dexamethasone	C
	Oedema Peripheral		
	Renal Failure Acute		
	Weight Increased		

Date:10/17/00ISR Number: 3597391-0Report Type:Expedited (15-DaCompany Report #WAES 00100716
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite Convulsion Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/00ISR Number: 3597393-4Report Type:Expedited (15-DaCompany Report #WAES 00100483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Pulmonary Embolism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN	PO

Date:10/17/00ISR Number: 3597395-8Report Type:Expedited (15-DaCompany Report #WAES 00100353
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN	PO
			[Therapy Unspecified]	C				

Date:10/17/00ISR Number: 3597397-1Report Type:Expedited (15-DaCompany Report #WAES 00100488
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNKNOWN	PO

Date:10/17/00ISR Number: 3597398-3Report Type:Expedited (15-DaCompany Report #WAES 00062864
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chills Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Hepatic Steatosis	Company			Merck Co Inc	ORAL
25 MG /DAILY/						
	Liver Function Test	Representative				
PO						
	Abnormal					
	Malaise					
	Pancreatic Cyst					
	Pyrexia					
	Tremor					
	Urine Analysis Abnormal					

Date:10/17/00ISR Number: 3597414-9Report Type:Expedited (15-DaCompany Report #WAES 00071295
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dizziness	Health	Vioxx	PS	Merck Research	
Hospitalization -	Gastric Ulcer Haemorrhage	Professional			Laboratories Div	
Initial or Prolonged	Gastrointestinal	Company			Merck Co Inc	ORAL
25 MG/ DAILY/						
Other	Haemorrhage	Representative				
PO						
	Haematochezia		Elavil	C		
	Surgery		Flexeril	C		
	Syncope		Hydrodiuril	C		
			Levoxyl	C		
			Tenormin	C		
			Zantac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/00ISR Number: 3597415-0Report Type:Expedited (15-DaCompany Report #WAES 00081282
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Gastric Ulcer	Company			Merck Co Inc	ORAL	SEE IMAGE /	
	Gastric Ulcer Haemorrhage	Representative					PO	
	Gastroenteritis							
	Helicobacter Gastrointestinal Haemorrhage							
	Haematemesis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							
	Red Blood Cell Count Decreased							
	Vomiting							

Date:10/17/00ISR Number: 3597416-2Report Type:Expedited (15-DaCompany Report #WAES 00081326
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy	Study	Vioxx	PS	Merck Research Laboratories Div			
	Haematemesis	Health Professional			Merck Co Inc	ORAL	12.5 MG/	
	Oesophageal Disorder							
	Oesophageal Haemorrhage						DAILY/ PO	
	Vomiting		Centrum Silver	C				
			Fleet Enema	C				
			Ocuvite	C				
			Pepcid	C				
			Tylenol	C				

Date:10/17/00ISR Number: 3597417-4Report Type:Expedited (15-DaCompany Report #WAES 00090360
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Abdominal Tenderness	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Asthenia	Representative						
	Diarrhoea							
	Dizziness		K-Dur	C				
	Faeces Discoloured		Levoxyl	C				
	Gastric Ulcer		Maxzide	C				
	Gastric Ulcer Haemorrhage		Tylenol	C				
	Gastrointestinal		Wellbutrin Sr	C				
	Haemorrhage		Aspirin	C				
	Haematocrit Decreased		Hydroxyzine	C				
	Haemoglobin Decreased		Iron (Unspecified)	C				
	Melaena		Lorazepam	C				
	Red Blood Cell Count Decreased							

Date:10/17/00ISR Number: 3597423-XReport Type:Expedited (15-DaCompany Report #WAES 00100432
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Vision Blurred							

Merck Co Inc ORAL
PO

Iron (Unspecified)
(+) Vitamins C

Date:10/18/00ISR Number: 3597494-0Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx 25 Mg	PS	Merck	ORAL	1/DAY/ORAL	
Initial or Prolonged	Embolism		Motrin	C				
Disability	Fatigue		Percocet	C				
Other	Haemorrhagic Stroke							
Required	Medication Error							
Intervention to	Speech Disorder							
Prevent Permanent								
Impairment/Damage								

Date:10/18/00ISR Number: 3603350-1Report Type:Periodic Company Report #200001967BWH (1)
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pallor	Health	Avelox	PS	Bayer Corp			
	Tremor	Professional			Pharmaceutical Div	ORAL	400 MG QD PO	
			Vioxx (Rofecoxib)					
			Tablet	SS		ORAL	25MG QD PO	

Date:10/19/00ISR Number: 3598435-2Report Type:Expedited (15-DaCompany Report #WAES 00100901
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research			
	Haemorrhage	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:10/19/00ISR Number: 3598437-6Report Type:Expedited (15-DaCompany Report #WAES 00100929
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Abdominal Pain Malignant Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other			Baycol	C				
			Fosamax	C				
			Lasix	C				
			Vasotec	C				

Date:10/19/00ISR Number: 3598458-3Report Type:Expedited (15-DaCompany Report #WAES 00105095
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apathy Malaise	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 DAY
			Acetaminophen (+) Dextropropoxyphene	C				

				Apazone	C		

Date:10/19/00ISR Number: 3598463-7Report Type:Expedited (15-DaCompany Report #WAES 00088231
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Diclofenac Na	SS		ORAL	PO	
			Aspirin	C				

Date:10/19/00ISR Number: 3598467-4Report Type:Expedited (15-DaCompany Report #WAES 00105091
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Upper Gastrointestinal Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY
			Aloin	C				
			Aspirin	C				
			Lactulose	C				
			Nitrazepam	C				
			Nitroglycerin	C				

Date:10/19/00ISR Number: 3598468-6Report Type:Expedited (15-DaCompany Report #WAES 00109751
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Creatinine Renal Clearance Decreased Dialysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 WK
	Renal Failure Acute Renal Impairment							

Date:10/19/00ISR Number: 3598482-0Report Type:Expedited (15-DaCompany Report #WAES 00095236
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Peritonitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Clonidine	C				
			Danazol	C				
			Dothiepin	C				
			Oil Of Peppermint	C				

Date:10/19/00ISR Number: 3598487-XReport Type:Expedited (15-DaCompany Report #WAES 00098587
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Bone Marrow Depression
Life-Threatening	Confusional State
Hospitalization - Initial or Prolonged	Dehydration
	Diarrhoea
	Hypotension

	Mucosal Inflammation						
	Mucous Membrane Disorder						
	Muscular Weakness	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neutropenia	Foreign	Vioxx	PS	Merck Research			
	Sepsis	Health			Laboratories Div			
	Tachycardia	Professional			Merck Co Inc	ORAL	12.5 MG PO	79 DAY
	Thrombocytopenia	Other	Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	
			Infusion (Form) Fluorouracil	SS		INTRAVENOUS	IV	
			Leucovorin Calcium	SS				
			Allopurinol	C				
			Amiodarone	C				
			Aspirin	C				
			Clonazepam	C				
			Furosemide	C				
			Indapamide	C				
			Irbesartan	C				
			Iron (Unspecified)	C				
			Metolazone	C				
			Omeprazole	C				

Date:10/19/00ISR Number: 3598497-2Report Type:Expedited (15-DaCompany Report #WAES 00105089
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Duodenal Ulcer	Other			Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	12.5 MG	20 DAY
	Oesophagitis		Aspirin	SS		ORAL	75 MG	
			Doxazosin	C				
			Glimepiride	C				

Date:10/19/00ISR Number: 3604611-2Report Type:Periodic Company Report #WAES 00100916
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Photophobia Vomiting	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:10/20/00ISR Number: 3598899-4Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Disability	Cerebrovascular Accident		Vioxx	PS			25 MG BID	

Date:10/20/00ISR Number: 3598908-2Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aplastic Anaemia Haemoglobin Decreased Leukopenia Thrombocytopenia		Rofecoxib 25 Mg Merck Sulfasalazine 500mg	PS SS	Merck	ORAL ORAL	25 MG QD ORAL 500MG QID ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/00ISR Number: 3598917-3Report Type:Direct Company Report #
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx (25mg Merck)	PS	Merck	ORAL	25MG QD PO	
Initial or Prolonged	Anaemia		Prednisone (5mg					
Required	Bone Marrow Depression		Mfr=Unknown)	SS		ORAL	5MG QD PO	
Intervention to	Erosive Oesophagitis		Vasotec	C				
Prevent Permanent	Gastric Ulcer		Dhea	C				
Impairment/Damage	Haematemesis		Maxide	C				
	Oesophageal Disorder		Verapamil	C				
	Oesophagitis		Singulair	C				
	Serum Ferritin Decreased		Plaquenil	C				
	Systemic Lupus		Neurontin	C				
	Erythematosus		Ambien	C				
	Vomiting		Asa	C				

Date:10/20/00ISR Number: 3598938-0Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25 Mg	PS		ORAL	25 MG, QD, PO	
Initial or Prolonged	Increased							
CHRONIC								
	Oedema Peripheral		Methadone	C				
			Fioricet	C				
			Valium W/Baclofen	C				
			Clomidin	C				
			Maxzide	C				
			Synthroid	C				
			Tylenol	C				
			Atenolol	C				
			Lasix	C				
			Effexor	C				
			Bactrim Bs	C				
			Ambien	C				
			Trazodone	C				

Date:10/20/00ISR Number: 3599158-6Report Type:Expedited (15-DaCompany Report #WAES 00100624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:10/20/00ISR Number: 3599242-7Report Type:Expedited (15-DaCompany Report #WAES 00095513
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Colonic Haemorrhage Diverticulum Gastric Haemorrhage Gastritis Gastrointestinal Angiodysplasia Gastrointestinal Haemorrhage Haematochezia

		Haemoglobin Decreased Hiatus Hernia Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Red Blood Cell Count Decreased Varices Oesophageal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG	135 DAY						
				Amiodarone Hydrochloride	C		
				Furosemide	C		
				Levothyroxine Sodium (+) Potassium Iodid	C		

Date:10/20/00ISR Number: 3599292-0Report Type:Expedited (15-DaCompany Report #WAES 00100376
Age:74 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Distension Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	2 MON						
		Feeling Abnormal Fluid Retention Tachycardia		Lasix Lopressor Mevacor	C C C		

Date:10/20/00ISR Number: 3599293-2Report Type:Expedited (15-DaCompany Report #WAES 00100716
Age:39 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Convulsion Epistaxis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO							

Date:10/20/00ISR Number: 3599294-4Report Type:Expedited (15-DaCompany Report #WAES 00100687
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/AM/PO	
	Face Oedema							
	Pharyngeal Oedema							
	Tongue Oedema		Prempro	C				
	Urticaria		Synthroid	C				
			Vicodin Tablets	C				
			Orphenadrine	C				

Date:10/20/00ISR Number: 3599319-6Report Type:Expedited (15-DaCompany Report #WAES 00045535
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	3 DAY
Hospitalization - Initial or Prolonged	Gastroenteritis	Health Professional						
	Helicobacter							
	Vomiting		Mepivacaine Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/00ISR Number: 3599322-6Report Type:Expedited (15-DaCompany Report #WAES 00109553
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Gastroenteritis Helicobacter	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	3 DAY

Date:10/20/00ISR Number: 3599323-8Report Type:Expedited (15-DaCompany Report #WAES 00106071
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
			Tab Nonsteroidal Anti-Inflammatory Drug (Unspecified)	SS		ORAL		
			Moxonidine	C				

Date:10/20/00ISR Number: 3599325-1Report Type:Expedited (15-DaCompany Report #WAES 00108109
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
			Methotrexate	C				

Date:10/20/00ISR Number: 3599329-9Report Type:Expedited (15-DaCompany Report #WAES 00105104
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Health Professional				Laboratories Div Merck Co Inc	ORAL
PO							

Date:10/20/00ISR Number: 3599331-7Report Type:Expedited (15-DaCompany Report #WAES 00105088
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 19 DAY						
			Nizatidine	C		

Date:10/20/00ISR Number: 3599364-0Report Type:Expedited (15-DaCompany Report #WAES 00100504
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthma	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged	Dermatitis Status Asthmaticus					
PO 5 DAY						
	Stevens-Johnson Syndrome	Representative	[Therapy Unspecified]	C		
			Albuterol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/00ISR Number: 3599385-8Report Type:Expedited (15-DaCompany Report #WAES 00092201
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Unstable Haemorrhagic Stroke Myocardial Ischaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other		Representative						
			Atrovent	C				
			Avapro	C				
			Cardura	C				
			Combivent	C				
			Hydrodiuril	C				
			Lipitor	C				
			Micronase	C				
			Prilosec	C				
			Toprol Xl Tablets	C				
			Albuterol	C				
			Ibuprofen	C				
			Insulin	C				
			Nitroglycerin	C				

Date:10/20/00ISR Number: 3599388-3Report Type:Expedited (15-DaCompany Report #WAES 00092187
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Gastrointestinal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Haemorrhage	Representative						
			Ecotrin	C				

Date:10/20/00ISR Number: 3599393-7Report Type:Expedited (15-DaCompany Report #WAES 00095112
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Haemoglobin Decreased International Normalised Ratio Increased	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 5 DAY
	Platelet Count Decreased White Blood Cell Count Decreased		Chlorpromazine Lithiumco3 Thyroxine	C C C			

Date:10/20/00ISR Number: 3599395-0Report Type:Expedited (15-DaCompany Report #WAES 00075536
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:10/20/00ISR Number: 3599396-2Report Type:Expedited (15-DaCompany Report #WAES 00085189
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Constipation
Hospitalization - Initial or Prolonged	Dyspepsia Gastric Ulcer Haemorrhage

Haematemesis

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO	45 DAY					
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Budesonide	C		
			Dipyridamole	C		
			Ipratropium Bromide	C		

Date:10/20/00ISR Number: 3599397-4Report Type:Expedited (15-DaCompany Report #WAES 00087543
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Flushing	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
	Hyperhidrosis							
	Hypertension							
	Oedema Peripheral		Lormetazepam	C				
	Rales		Sulpiride	C				
	Tremor							
	Weight Increased							

Date:10/20/00ISR Number: 3599398-6Report Type:Expedited (15-DaCompany Report #WAES 00108902
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostatic Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
Other	Renal Failure Acute							
	Urinary Tract Infection							
			Antibiotics	C				
			Muscle Relaxants	C				

Date:10/20/00ISR Number: 3599399-8Report Type:Expedited (15-DaCompany Report #WAES 00098233
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Chest Pain Pulmonary Embolism	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:10/23/00ISR Number: 3599799-6Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Gastric Ulcer Upper Gastrointestinal Haemorrhage		Vioxx Tablet 25mg	PS	Merck			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3599856-4Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Vioxx 50mg	PS		ORAL	50 MG ONCE	
Hospitalization -	Bradycardia	Professional					DAILY ORAL	
Initial or Prolonged	Chest Discomfort		Glucotrol Xl	C				
Disability	Feeling Abnormal		Glucophage	C				
Required	Heart Rate Irregular		Betapace	C				
Intervention to	Tachycardia		Cardizem	C				
Prevent Permanent								
Impairment/Damage								

Date:10/23/00ISR Number: 3599979-XReport Type:Expedited (15-DaCompany Report #WAES 00060309
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Abdominal Tenderness				Laboratories Div			
	Apnoea				Merck Co Inc	ORAL	PO	3 WK
	Cardiac Failure							
	Congestive							
	Difficulty In Walking							
	Haemoptysis							
	Oedema							
	Oedema Peripheral							
	Oral Intake Reduced							
	Oral Pain							
	Productive Cough							
	Pulmonary Oedema							
	Sensitivity Of Teeth							
	Tenderness							
	Toothache							

Date:10/23/00ISR Number: 3600004-2Report Type:Expedited (15-DaCompany Report #WAES 00070398
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anisocytosis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Condition Aggravated	Professional			Laboratories Div			
Initial or Prolonged	Diverticulum	Company			Merck Co Inc	ORAL	25	
Other	Dyspnoea	Representative					MG/DAILY/PO	
	Gastrointestinal		Celebrex	C				
	Haemorrhage							
	Haemoglobin Decreased							
	Haemolytic Anaemia							
	Haemorrhoids							
	Iron Deficiency Anaemia							

Date:10/23/00ISR Number: 3600005-4Report Type:Expedited (15-DaCompany Report #WAES 00051259
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Increased	Professional			Laboratories Div			
Other	Blood Urea Increased	Company			Merck Co Inc	ORAL	25	
	Renal Failure Acute	Representative					MG/DAILY/PO	
	Vomiting		Colace	C				
			Imdur	C				

			Lasix	C		
			Lopressor	C		
			Prilosec	C		
			Aspirin	C		
			Ferrous Sulfate	C		

Date:10/23/00ISR Number: 3600006-6Report Type:Expedited (15-DaCompany Report #WAES 00072160
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
Hospitalization -	Abdominal Tenderness	Professional			Laboratories Div	
Initial or Prolonged	Burning Sensation	Company			Merck Co Inc	ORAL
50 MG/PRN/PO						
Other	Endoscopy Upper	Representative	Aleve	C		
	Gastrointestinal Tract		Levaquin	C		
	Abnormal		Plavix	C		
	Gastric Ulcer Haemorrhage		Prevacid	C		
	Gastrointestinal		Restoril	C		
	Haemorrhage		Tums	C		
	Haematocrit Decreased		Tylenol	C		
	Haemoglobin Decreased		Aspirin	C		
	Leukocytosis		Heparin	C		
	Melaena		Magnesium Oxide	C		
	Thrombocythaemia		Quinine	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:10/23/00ISR Number: 3600026-1Report Type:Expedited (15-DaCompany Report #WAES 00101104
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/ PO						
			Aspirin	C		
			Niacin	C		

Date:10/23/00ISR Number: 3600027-3Report Type:Expedited (15-DaCompany Report #WAES 00071796
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Murmur Fluid Retention Headache Oedema Peripheral Renal Failure Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:10/23/00ISR Number: 3600028-5Report Type:Expedited (15-DaCompany Report #WAES 99101990
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Coagulopathy Gastrointestinal Haemorrhage Haematemesis

		Haematochezia Haemoptysis Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		International Normalised Ratio Increased Pulmonary Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							
		Rectal Haemorrhage	Representative	Calan	C		
				Coumadin	C		
				Lanoxin	C		
				Lasix	C		
				Pravachol	C		
				Vasotec	C		

Date:10/23/00ISR Number: 3600029-7Report Type:Expedited (15-DaCompany Report #WAES 00100991
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Renal Disorder Renal Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK / UNK /						
PO						
			Coumadin	C		
			Estratest	C		
			Verapamil	C		

Date:10/23/00ISR Number: 3600030-3Report Type:Expedited (15-DaCompany Report #WAES 00070887
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Decreased Activity Face Oedema Lung Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
	Mass					
MG/DAILY/PO						
	Myocardial Infarction		Catapres	C		
	Neoplasm		Celebrex	C		

Oedema Peripheral	Ditropan	C
Pulmonary Oedema	Plaquenil	C
Respiratory Disorder	Tagamet	C
	Titralac Antacid	C
	Wygesic Tablets	C
	Zoloft	C
	Amitriptyline	C
	Ferrous Sulfate	C
	Metnotrexate	C
	Prednisone	C

Date:10/23/00ISR Number: 3600031-5Report Type:Expedited (15-DaCompany Report #WAES 00100753
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria Hepatic Failure Influenza Like Illness Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3600032-7Report Type:Expedited (15-DaCompany Report #WAES 00090761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oliguria Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	5 DAY
			Naprosyn	C				

Date:10/23/00ISR Number: 3600035-2Report Type:Expedited (15-DaCompany Report #WAES 00090200
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension Abdominal Tenderness Atrial Fibrillation Colon Cancer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Diarrhoea		Colace	C				
	Faecal Occult Blood		Coumadin	C				
	Positive		Mylanta & Mylanta Ds	C				
	Flatulence		Transderm-Nitro	C				
	Gastrointestinal		Vasotec	C				
	Haemorrhage		Zoloft	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased		Digoxin	C				
	International Normalised		Metoprolol	C				
	Ratio Increased		Vitamin E	C				
	Prothrombin Time Prolonged							
	Vomiting							

Date:10/23/00ISR Number: 3600037-6Report Type:Expedited (15-DaCompany Report #WAES 00080348
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Albumin Increased Blood Alkaline Phosphatase Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
	Blood Creatine Increased Chest Pain Dyspnoea Hyperglycaemia Weight Increased		Prilosec	C		

Date:10/23/00ISR Number: 3600047-9Report Type:Expedited (15-DaCompany Report #WAES 00085045
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal Disorder	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3600302-2Report Type:Expedited (15-DaCompany Report #WAES 00106093
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	8 DAY
			Aspirin Lysine	C				

Date:10/23/00ISR Number: 3600303-4Report Type:Expedited (15-DaCompany Report #WAES 00107017
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
		Other	Furosemide	C				
			Levothyroxine Na	C				
			Loratadine	C				
			Potassium Chloride	C				

Date:10/23/00ISR Number: 3600304-6Report Type:Expedited (15-DaCompany Report #WAES 00106070
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Haematemesis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	5 DAY
			Benfluorex	C				
			Citalopram	C				
			Fenofibrate	C				
			Omeprazole	C				
			Piroxicam	C				

Date:10/23/00ISR Number: 3600305-8Report Type:Expedited (15-DaCompany Report #WAES 00105569
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alveolitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Bronchitis	Other						
	Candidiasis							
	Dyspnoea		Levothyroxine Na	C				
	Lung Infiltration		Methimazole	C				
	Pneumonia		Propranolol	C				
	Pulmonary Function Test Abnormal							
	Pyrexia							
	Respiratory Disorder							
	Streptococcal Infection							

Date:10/23/00ISR Number: 3600335-6Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Back Pain
	Condition Aggravated
	Gastric Ulcer

		Pruritus Renal Function Test Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Renal Impairment Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	96 DAY
			Other	Cap Celecoxib	SS		ORAL	PO	4 DAY
				Acetaminophen/ Codeine Phosphate	C				
				Aspirin	C				
				Calcium Carbonate (+) Cholecalciferol	C				
				Furosemide	C				
				Isosorbide Dinitrate	C				
				Levothyroxine Na	C				
				Midozolam Maleate	C				
				Pantoprazole Na	C				

Date:10/23/00ISR Number: 3600578-1Report Type:Expedited (15-DaCompany Report #WAES 00109119
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	39 DAY
			Durapatite	C				
			Etidronic Acid Dina	C				
			Levobunolol	C				

Date:10/23/00ISR Number: 3600580-XReport Type:Expedited (15-DaCompany Report #WAES 00095654
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Herpes Zoster Hypoaesthesia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	5 DAY

Date:10/23/00ISR Number: 3600989-4Report Type:Expedited (15-DaCompany Report #WAES 00095568
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arterial Occlusive Disease Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	29 DAY
	Cardiac Failure		Renacor	C				
	Congestive		Atorvastatin	C				
	Condition Aggravated		Clopidogrel					
	Coronary Artery Disease		Bisulfate	C				
	Dyspnoea		Furosemide	C				
	Pulmonary Congestion		Isosorbide					
	Pulmonary Oedema		Mononitrate	C				
	Rales		Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3600993-6Report Type:Expedited (15-DaCompany Report #WAES 00105104
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/23/00ISR Number: 3600995-XReport Type:Expedited (15-DaCompany Report #WAES 00095508
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Antibody Test Positive Blood Bilirubin Increased Blood Copper Increased Blood Immunoglobulin G Increased Cholecystitis Chronic Cholestasis Cytomegalovirus Infection Faeces Pale Gallbladder Disorder Hepatitis Laboratory Test Abnormal Liver Function Test Abnormal Oedema Pruritus	Foreign Health Professional	Vioxx Butylscopolamine Bromide Ginkgo Biloba Extract Magnesium Aspartate (+) Potassium Aspart Metoprolol Tartrate Omeprazole Magnesium	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	PO 2 DAY

Date:10/23/00ISR Number: 3600996-1Report Type:Expedited (15-DaCompany Report #WAES 00095614
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Drug Interaction Gastric Haemorrhage	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged		Health			Merck Co Inc	ORAL
25 MG PO 60 DAY						
		Professional	Cinnarizine (+)			
			Dimenhydrinate	C		
			Clopidogrel Bisulfate	C		
			Digitoxin	C		
			Lisinopril	C		
			Ticlopidine Hydrochloride	C		
			Trazodone Hcl	C		
			Zolpidem Tartrate	C		

Date:10/23/00ISR Number: 3600997-3Report Type:Expedited (15-DaCompany Report #WAES 00098233
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Chest Pain	Health			Laboratories Div	
	Pulmonary Embolism	Professional			Merck Co Inc	ORAL
25 MG PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3600998-5Report Type:Expedited (15-DaCompany Report #WAES 00085609
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Chest Discomfort Flatulence Gastritis Gastritis Erosive	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	4 DAY

Date:10/23/00ISR Number: 3600999-7Report Type:Expedited (15-DaCompany Report #WAES 00095136
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	(SEE IMAGE) 36 DAY
			Elavil	C				
			Aspirin	C				
			Atorvastatin	C				
			Gliclazide	C				
			Ispaghula Husk (+)					
			Senna	C				
			Ramipril	C				

Date:10/23/00ISR Number: 3601000-1Report Type:Expedited (15-DaCompany Report #WAES 00095653
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis Oedema Peripheral Pulmonary Congestion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	39 DAY
	Ventricular Extrasystoles		Hctz/Triamterene	C				
			Aspirin	C				
			Candesartan					

Cilexetil	C
Digitoxin	C
Isosorbide Dinitrate	C
Morphineso4	C

Date:10/23/00ISR Number: 3601001-3Report Type:Expedited (15-DaCompany Report #WAES 00085624
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastritis Erosive Gastrointestinal Disorder	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	4 DAY

Date:10/23/00ISR Number: 3601003-7Report Type:Expedited (15-DaCompany Report #WAES 00109556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/00ISR Number: 3608568-XReport Type:Periodic Company Report #WAES 00060537
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Health Professional	Propecia	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 MG/DAILY/PO	
	Glossodynia							
	Halitosis		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Tongue Disorder							

Date:10/24/00ISR Number: 3600483-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Disorder		Vioxx 12.5 Mg	PS		ORAL	12.5 MG PO	

Date:10/24/00ISR Number: 3600492-1Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Rofecoxib	PS			25 MG	
	Faecal Occult Blood		Warfarin	SS			1.5 MG	
	Positive Gastrointestinal Haemorrhage		Avandia	C				
			Ampicillin	C				
			Toprol Xl	C				
	Haemoglobin Decreased							
	Pulmonary Embolism							

Date:10/24/00ISR Number: 3600568-9Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic Urticaria		Vioxx 12.5 Mg, Or 25 Mg Bid Prn	PS		ORAL	12.5 OR 25 MG PO	
			Vioxx 12.5 Mg, Or 25 Mg Bid Prn	SS				
			Prometrium	C				
			Benadryl	C				

Date:10/24/00ISR Number: 3600619-1Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration		Vioxx ?Mg Merck	PS	Merck	ORAL	1 PO QD	
Initial or Prolonged	Diabetes Mellitus		Prilosec	C				
Disability	Jaundice Cholestatic							
Other								
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/00ISR Number: 3600720-2Report Type:Expedited (15-DaCompany Report #WAES 00101354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biliary Tract Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Blood Pressure Increased							
	Difficulty In Walking							
	Gait Disturbance		Insulin	C				
	Hyperglycaemia							
	Hyperhidrosis							

Date:10/24/00ISR Number: 3600737-8Report Type:Expedited (15-DaCompany Report #WAES 00101105
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional						
	Haematemesis							
	Hypotension		Arthrotec	C				
	Tachycardia		Colace	C				
			Haldol	C				
			Lasix	C				
			Miacalcin	C				
			Zantac	C				
			Aspirin	C				
			Hydralazine	C				
			Nitroglycerin	C				

Date:10/24/00ISR Number: 3601211-5Report Type:Expedited (15-DaCompany Report #WAES 00109754
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardio-Respiratory Arrest	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 MON
Hospitalization - Initial or Prolonged	Hypertension	Health						
	Pulmonary Oedema	Professional						
Other	Renal Disorder							
	Respiratory Failure							

Date:10/24/00ISR Number: 3601242-5Report Type:Expedited (15-DaCompany Report #WAES 00105141
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Electrolytes Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	19 DAY
	Condition Aggravated							
	Renal Impairment		Vasotec	C				
			Acetaminophen (+)					
			Codeine	C				
			Thyroxine	C				

Date:10/24/00ISR Number: 3601466-7Report Type:Expedited (15-DaCompany Report #WAES 00101094
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Bladder Pain
	Chills
	Middle Insomnia

		Pyrexia					
		Renal Disorder					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Celebrex	C		
				Methotrexate	C		
				Prednisone	C		
				Therapy Unspecified	C		

Date:10/24/00ISR Number: 3601489-8Report Type:Expedited (15-DaCompany Report #WAES 00101106
Age:90 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Biliary Tract Disorder					
		Blood Urea Increased					
12.5 MG; 25							
		Condition Aggravated					
MG; 25 MG; 25							
		Confusional State					
MG /DAILY/PO							
		Faeces Discoloured		Ativan	C		
		Gastrointestinal		Celebrex	C		
		Haemorrhage		Duragesic	C		
		Hepatic Function Abnormal		Haldol	C		
		Hypotension		Klonopin	C		
		Liver Function Test		Motrin	C		
		Abnormal		Mylanta & Mylanta Ds	C		
		Melaena		Paxil	C		
		Nausea		Riopan	C		
		Pallor		Senokot (Senna)	C		
		Tachycardia		Sinemet	C		
		Vomiting		[Therapy Unspecified]	C		
				Calcium Lactate	C		
				Fentanyl	C		
				Nitroglycerin	C		
				Vitamin E	C		
				Vitamins (Unspecified)	C		

Date:10/24/00ISR Number: 3601792-1Report Type:Expedited (15-DaCompany Report #WAES 00108571
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Suicide Attempt	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:10/25/00ISR Number: 3601190-0Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS			12.5 MG BID	
Initial or Prolonged	Duodenal Ulcer Melaena Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/00ISR Number: 3601280-2Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Impairment		Vioxx 50mg	PS			1 12 HR	
			Neurontin	C				

Date:10/26/00ISR Number: 3602013-6Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx 50 Mg	PS		ORAL	1 PO BID X 5	
	Malaise							
	Myocardial Infarction		Amaryl	C			DAYS	5 DAY
	Nausea		Atenolol	C				
	Overdose		Glucophage	C				
			Percocet	C				

Date:10/26/00ISR Number: 3602119-1Report Type:Expedited (15-DaCompany Report #WAES 00072405
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
	Bacteriuria	Health			Laboratories Div			
	Blood Pressure Systolic	Professional			Merck Co Inc	ORAL	12.5 MG	
	Increased						/UNKNOWN	/PO
	Constipation							
	Duodenal Ulcer							
	Faeces Discoloured							
	Glycosuria							
	Haematocrit Decreased							
	Haematuria							
	Haemoglobin Decreased							
	Nausea							
	Upper Gastrointestinal							

Haemorrhage
Urine Abnormality
Ventricular Hypertrophy
White Blood Cells Urine
Positive

Date:10/26/00ISR Number: 3602124-5Report Type:Expedited (15-DaCompany Report #WAES 00063246
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Arterial Disorder
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
Disability	Blood Urea Increased
Other	Diabetes Mellitus
	Drug Hypersensitivity
	Ecchymosis
	Epistaxis
	Hyperkalaemia
	Idiopathic Thrombocytopenic Purpura
	Leukocytosis
	Nasal Congestion
	Petechiae

	Poor Peripheral Circulation Thrombocytopenia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tongue Coated	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/ PO
			K-Lyte	C			
			Lasix	C			
			Novolin 70/30	C			
			Pepcid	C			
			Synthroid	C			
			Zestril	C			
			[Therapy Unspecified]	C			
			Digoxin	C			
			Spironolactone	C			

Date:10/26/00ISR Number: 3602128-2Report Type:Expedited (15-DaCompany Report #WAES 00081950
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	No Adverse Drug Effect	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO

Date:10/26/00ISR Number: 3602130-0Report Type:Expedited (15-DaCompany Report #WAES 00100901
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK PO
			Aspirin	C			

Date:10/26/00ISR Number: 3602170-1Report Type:Expedited (15-DaCompany Report #WAES 00090201
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Agitation							
	Arthralgia							
	Back Pain							
	Blood Creatinine Increased		Hytrin	C				
			Lasix	C				
	Blood Urea Increased		Ms Contin	C				
	Fall		Oxycontin	C				
	Gastroenteritis		Oxyir	C				
	Helicobacter		Prinivil	C				
	Gastrointestinal Haemorrhage		Senorot (Senna)	C				
			Acetaminophen	C				
	Haematemesis		Aspirin	C				
	Haematocrit Decreased		Atenolol	C				
	Haemoglobin Decreased		Insulin	C				
	Irritability		Iron	C				
	Pain		Sodium Folate	C				
	Vomiting		Sulfasalazine	C				

			Vitamins	C		

Date:10/26/00ISR Number: 3602172-5Report Type:Expedited (15-DaCompany Report #WAES 00082221
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Haematuria							
	Pain							
	Urinary Retention		Effexor	C				
	Urinary Tract Infection		Klonopin	C				
			Synthroid	C				

Date:10/26/00ISR Number: 3602173-7Report Type:Expedited (15-DaCompany Report #WAES 00091205
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
			Vicodin Tablets	C				
			Vitamins	C				

Date:10/26/00ISR Number: 3602174-9Report Type:Expedited (15-DaCompany Report #WAES 00070033
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Musculoskeletal Pain							
			Insulin	C				

Date:10/26/00ISR Number: 3602176-2Report Type:Expedited (15-DaCompany Report #WAES 00064604
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Retinal Haemorrhage	Health			Laboratories Div			
	Retinal Vascular	Professional			Merck Co Inc	ORAL	PRN/PO	
	Occlusion		Fosamax	C				
	Retinal Vein Thrombosis		Premarin	C				
	Vision Blurred		Prevacid	C				
	Visual Disturbance							

Date:10/26/00ISR Number: 3602189-0Report Type:Expedited (15-DaCompany Report #WAES 00064287
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Drug Interaction	Other			Laboratories Div			
	Tremor				Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lithiniumco3 450 Mg	SS			450 MG/DAILY	
			Avapro	C				
			Deseril	C				

		Fosamax	C
		Lipitor	C
		Premarin	C
		Aspirin	C

Date:10/26/00ISR Number: 3602204-4Report Type:Expedited (15-DaCompany Report #WAES 00101615
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coordination Abnormal Dehydration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:10/26/00ISR Number: 3602291-3Report Type:Expedited (15-DaCompany Report #WAES 00095652
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Pulmonary Congestion Ventricular Tachycardia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	1 WK

Date:10/26/00ISR Number: 3602300-1Report Type:Expedited (15-DaCompany Report #WAES 00105135
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Lofepramine Hcl	C				

Date:10/26/00ISR Number: 3602301-3Report Type:Expedited (15-DaCompany Report #WAES 00103715
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Haemoglobin Decreased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Omeprazole Magnesium	C				
			Prednisone	C				

Date:10/26/00ISR Number: 3602302-5Report Type:Expedited (15-DaCompany Report #WAES 00085182
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Angioneurotic Oedema Dyspnoea Face Oedema	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET PO	
	Paraesthesia Oral		Cyclosporin A	C				
			Furosemide	C				
			Insulin	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/00ISR Number: 3602303-7Report Type:Expedited (15-DaCompany Report #WAES 00107018
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal Memory Impairment Speech Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY
		Company Representative	Vasotec	C				
			Zocor	C				
			Aspirin (+) Magnesium Oxide	C				
			Lithium Citrate	C				
			Zopiclone	C				

Date:10/26/00ISR Number: 3602304-9Report Type:Expedited (15-DaCompany Report #WAES 00106776
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Dyspepsia Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	90 DAY
			Aspirin	C				
			Atorvastatin Calcium	C				
			Metoprolol	C				

Date:10/26/00ISR Number: 3602305-0Report Type:Expedited (15-DaCompany Report #WAES 00107521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
Other			Alprazolam	C				

Date:10/26/00ISR Number: 3602310-4Report Type:Expedited (15-DaCompany Report #WAES 00105502
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Health			Laboratories Div			
Initial or Prolonged	Blood Bilirubin Increased	Professional			Merck Co Inc	ORAL	12.5 MG, PO	11 DAY
	C-Reactive Protein		Beclomethasone					
	Increased		Dipropionate	C				
	Cholestasis		Fenoterol					
	Chromaturia		Hydrobromide (+)					
	Faeces Discoloured		Ipratropium B	C				
	Hepatitis A		Prednisone	C				
	Inflammation							
	Jaundice							
	Liver Disorder							
	Liver Function Test							
	Abnormal							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/00ISR Number: 3602314-1Report Type:Expedited (15-DaCompany Report #WAES 00105546
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/27/00ISR Number: 3602978-2Report Type:Expedited (15-DaCompany Report #WAES 00101618
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:10/27/00ISR Number: 3603036-3Report Type:Expedited (15-DaCompany Report #WAES 00101507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Chest Pain Dizziness Dyspepsia Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:10/27/00ISR Number: 3603037-5Report Type:Expedited (15-DaCompany Report #WAES 00101562
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
UNK PO						
			Celebrex	C		
			Estrogens, Conjugated	C		

Date:10/27/00ISR Number: 3603041-7Report Type:Expedited (15-DaCompany Report #WAES 00080107
Age:97 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angioneurotic Oedema	Health	Vioxx	PS	Merck Research	
Hospitalization -	Respiratory Distress	Professional			Laboratories Div	
Initial or Prolonged	Tongue Oedema	Company			Merck Co Inc	ORAL
PO						
Other		Representative	Feldene	C		
			Hydrodiuril	C		
			Zantac	C		

Date:10/27/00ISR Number: 3603043-0Report Type:Expedited (15-DaCompany Report #WAES 00101507
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Chest Pain				Laboratories Div	
	Dizziness				Merck Co Inc	ORAL
25						
	Dyspepsia					
MG/DAILY/PO						
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/00ISR Number: 3603045-4Report Type:Expedited (15-DaCompany Report #WAES 00101657
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Study	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Health			Laboratories Div			
Initial or Prolonged	Dyspnoea	Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Echocardiogram Abnormal						PO	
	Ejection Fraction		Tab Acetaminophen					
	Abnormal		325 Mg	SS		ORAL	PRN, PO	
	Electrocardiogram		Maxzide	C				
	Abnormal		Benazepril	C				
	Fatigue		Estrogens,					
	Hypertension		Conjugated	C				
	Mitral Valve Incompetence		Hydroxychloroquine					
	Orthopnoea		Sulfate	C				
	Productive Cough		Potassium Bitartrate	C				
	Pulmonary Oedema		Prednisone	C				
	Sinus Tachycardia		Verapamil	C				
	Ventricular Hypertrophy							

Date:10/27/00ISR Number: 3603046-6Report Type:Expedited (15-DaCompany Report #WAES 00101626
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Cardiac Disorder				Laboratories Div			
	Hepatic Function Abnormal				Merck Co Inc	ORAL	25 MG/DAILY/	
	Liver Function Test						PO	
	Abnormal							

Date:10/27/00ISR Number: 3603501-9Report Type:Expedited (15-DaCompany Report #2000AP04616
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Drug Interaction	Foreign	Seroquel	PS	Astrazeneca Uk Ltd	ORAL
125 MG DAILY						
Initial or Prolonged	Hyperhidrosis	Health				
PO						
	Melaena	Professional	Prozac	SS		ORAL
20 MG DAILY						
	Pyrexia	Other				
PO						
			Rofecoxib	SS		
25 MG DAILY						
			Aspirin	SS		
			Regulan	C		
			Madopar	C		
			Zimovane	C		
			Zacin	C		
			Radioactive Iodine	C		

Date:10/27/00ISR Number: 3603536-6Report Type:Expedited (15-DaCompany Report #WAES 00095562
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Pain	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Back Pain	Other			Laboratories Div	
	Condition Aggravated				Merck Co Inc	ORAL
25 MG PO 9 WK						
	Intestinal Infarction		Fosamax	C		
	Leukocytosis		Renacor	C		
	Mesenteric Occlusion		Acetylcysteine	C		
	Shock		Amiodarone Hydrochloride	C		

Budesonide	C
Citalopram Hydrobromide	C
Dipyrone	C
Fentanyl	C
Formoterol Fumarate	C
Metoclopramide Hydrochloride	C
Metoprolol Succinate	C
Naloxone Hydrochloride (+)	
Tilidine	C
Pamidronic Acid Dina	C
Tramadol Hcl	C

Date:10/27/00ISR Number: 3603582-2Report Type:Expedited (15-DaCompany Report #WAES 00095621
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 DAY

Date:10/27/00ISR Number: 3603583-4Report Type:Expedited (15-DaCompany Report #WAES 00109751
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis Neoplasm Renal Failure Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 WK

Date:10/27/00ISR Number: 3603584-6Report Type:Expedited (15-DaCompany Report #WAES 00085643
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anuria	Foreign	Vioxx	PS	Merck Research			

Hospitalization - Initial or Prolonged	Bacterial Infection Blood Creatine Phosphokinase Increased Blood Creatinine Increased Blood Urea Increased Breast Cancer Female C-Reactive Protein Increased Dehydration Dialysis Leukocytosis Pneumonia Renal Failure Acute Renal Impairment Sepsis	Health Professional	Dipyrone C Morphine C Pamidronic Acid Dina C Tramadol Hcl C	Laboratories Div Merck Co Inc	ORAL

25 MG PO 5 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/00ISR Number: 3603638-4Report Type:Expedited (15-DaCompany Report #WAES 00105185
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET	
	Gastroenteritis	Other						
	Helicobacter							
	Haematemesis		Acetaminophen					
	Upper Gastrointestinal Haemorrhage		Propoxyphene	C				
			Albuterol	C				
			Beclomethasone	C				
			Ranitidine	C				

Date:10/27/00ISR Number: 3603639-6Report Type:Expedited (15-DaCompany Report #WAES 00105193
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	109 DAY
	Dyspepsia	Other						
	Fatigue							
	Malaise		Dothiepin	C				
	Memory Impairment		Fluoxetine	C				
	Mouth Ulceration		Thyroxine	C				

Date:10/27/00ISR Number: 3603640-2Report Type:Expedited (15-DaCompany Report #WAES 00105194
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Erythema Multiforme	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	159 DAY
	Urticaria	Other						
			[Therapy Unspecified	C				
			Acetaminophen	C				
			Amoxicillin Trihydrate (+) Clavulanate P	C				
			Budesonide	C				

			Estrone	C		
			Formoterol	C		
			Terbutaline	C		

Date:10/27/00ISR Number: 3603641-4Report Type:Expedited (15-DaCompany Report #WAES 00088565
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	34 DAY
	Fluid Retention		Acebutolol Hydrochloride	C				
			Furosemide	C				

Date:10/27/00ISR Number: 3603642-6Report Type:Expedited (15-DaCompany Report #WAES 00109001
Age:76 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research			
	Fall	Health			Laboratories Div			
	Loss Of Consciousness	Professional			Merck Co Inc	ORAL	25 MG	17 DAY
			Zocor	C				
			Herbesser	C				
			Imdur	C				
			Nitroglycerin	C				

Date:10/27/00ISR Number: 3604058-9Report Type:Expedited (15-DaCompany Report #WAES 00095627
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Cholelithiasis	Health			Laboratories Div			
	Duodenal Ulcer	Professional			Merck Co Inc	ORAL	25 MG	77 DAY
	Duodenitis		Dimethicone (+)					
	Eructation		Pancreatin	C				
	Fibroma		Glimepiride	C				
	Gastroenteritis		Metformin Hcl	C				
	Helicobacter		Ramipril	C				
	Haemoglobin Decreased							
	Nausea							
	Pancreatic Disorder							
	Renal Neoplasm							
	Ultrasound Scan Abnormal							

Date:10/27/00ISR Number: 3604066-8Report Type:Expedited (15-DaCompany Report #WAES 00095609
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematoma	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Petechiae	Health			Laboratories Div			
Initial or Prolonged	Thrombocytopenia	Professional			Merck Co Inc	ORAL	25 MG	2 DAY
			Arnica	C				

Calcium Carbonate	C
Clonidine Hcl	C
Dexpanthenol	C
Homeopathic Medications (Unspecified)	C
Isosorbide Dinitrate	C
Levothyroxine Na	C
Promethazine Hcl	C
Theophylline	C
Tramadol Hcl	C
Valerian	C
Verapamil Hcl	C
Vitamin E	C
Vitamins (Unspecified)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/00ISR Number: 3604082-6Report Type:Expedited (15-DaCompany Report #WAES 00106096
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haematoma	Health			Laboratories Div			
Initial or Prolonged	Headache	Professional			Merck Co Inc	ORAL	12.5 MG	4 DAY
	International Normalised Ratio Increased		Tab Fluindione	SS				
	Melaena							

Date:10/27/00ISR Number: 3604088-7Report Type:Expedited (15-DaCompany Report #WAES 00106078
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Colonic Neoplasm	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Colitis	Health			Laboratories Div			
	Colonic Polyp	Professional			Merck Co Inc	ORAL	25 MG	16 DAY
	Diverticulum Intestinal		Acetaminophen	C				
	Rectal Haemorrhage							

Date:10/27/00ISR Number: 3604089-9Report Type:Expedited (15-DaCompany Report #WAES 00105592
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	25 MG	142 DAY

Date:10/27/00ISR Number: 3604091-7Report Type:Expedited (15-DaCompany Report #WAES 00085119
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign	Vioxx	PS	Merck Research			

		Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG						
			Methotrexate	C		

Date:10/27/00ISR Number: 3604092-9Report Type:Expedited (15-DaCompany Report #WAES 00108214
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Pharyngeal Oedema Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG 12 DAY						
		Other	Gran Magnesium Citrate	SS		ORAL
300 MG 12 DAY						
			Benazepril Hcl	C		
			Tamoxifen	C		

Date:10/27/00ISR Number: 3604096-6Report Type:Expedited (15-DaCompany Report #WAES 00105113
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG 8 DAY						

			Vasotec	C		
			Aspirin	C		
			Doxazosin	C		
			Furosemide	C		

Date:10/27/00ISR Number: 3604097-8Report Type:Expedited (15-DaCompany Report #WAES 00103530
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1	WK
		Other	Sulfasalazine	SS		ORAL	1	WK

Date:10/27/00ISR Number: 3604100-5Report Type:Expedited (15-DaCompany Report #WAES 00105175
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	94 DAY
	Renal Impairment		Zocor	C				
			Aspirin	C				
			Chlorpheniramine	C				
			Furosemide	C				
			Omeprazole	C				
			Ramipril	C				

Date:10/30/00ISR Number: 3603486-5Report Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia Oral		Rofecoxib	PS		ORAL	25 MG PO QD	3 WK

Date:10/30/00ISR Number: 3603553-6Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis		Vioxx	PS			10	DAY

Date:10/30/00ISR Number: 3603648-7Report Type:Expedited (15-DaCompany Report #WAES 00106012
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	2 DAY
	Prothrombin Time	Other	Acenocoumarol	SS		ORAL	1 MG	206 DAY
	Shortened		Benazepril Hcl/Hctz	C				
			Bromazepam	C				
			Clonazepam	C				
			Fluoxetine Hcl	C				
			Morphine S04	C				
			Prednisone	C				
			Sotalol Hydrochloride	C				

			Tramadol Hcl	C		
			Urapidil	C		

Date:10/30/00ISR Number: 3603649-9Report Type:Expedited (15-DaCompany Report #WAES 00108580
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Gastrointestinal Haemorrhage	Consumer Other				

Date:10/30/00ISR Number: 3603750-XReport Type:Expedited (15-DaCompany Report #WAES 00105192
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
Other	Pain	Other				
	Vomiting					ORAL
PO 93 DAY						

Date:10/30/00ISR Number: 3603969-8Report Type:Expedited (15-DaCompany Report #WAES 00100928
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
Other	Dysuria					
	Face Oedema					ORAL
25						
	Pruritus	Representative				
MG/DAILY/PO						
	Tongue Oedema		Isordil	C		
	Urticaria		Lasix	C		
			Lopressor	C		
			Oruvail	C		
			Pepcid	C		
			Procardia Xl	C		
			Valtrex	C		
			Zocor	C		

Date:10/30/00ISR Number: 3603975-3Report Type:Expedited (15-DaCompany Report #WAES 00101141
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Prinivil	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	5 MG/DAILY/PO	
	Drug Interaction							
	Gastrointestinal Haemorrhage		Rofecoxib 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Haematemesis		Acetaminophen (+)					
			Codeine	C				
			Aspirin	C				
			Danthron (+)					
			Poloxamer	C				
			Simvastatin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/00ISR Number: 3603998-4Report Type:Expedited (15-DaCompany Report #WAES 00100492
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Celebrex	C				
			Relafen	C				

Date:10/30/00ISR Number: 3604000-0Report Type:Expedited (15-DaCompany Report #WAES 00091473
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Cardiac Failure Congestive Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, DAILY, PO	
			Evista	C				
			Pravachol	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:10/30/00ISR Number: 3604002-4Report Type:Expedited (15-DaCompany Report #WAES 00090624
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Abdominal Pain Abnormal Faeces Diarrhoea Flatulence Malabsorption	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Pancreatitis
Weight Decreased

Date:10/30/00ISR Number: 3604004-8Report Type:Expedited (15-DaCompany Report #WAES 00082504
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Intestinal Perforation Malaise	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Adalat	C				
			Zestril	C				

Date:10/30/00ISR Number: 3604011-5Report Type:Expedited (15-DaCompany Report #WAES 00108553
Age:37 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Agitation Arterial Disorder Chills Faecal Occult Blood Faeces Discoloured Gastrointestinal

	Haemorrhage						
	Haemoglobin Decreased						
	Haemorrhage						
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oesophagitis	Foreign	Vioxx	PS	Merck Research		
	Pallor	Health			Laboratories Div		
	Pyrexia	Professional			Merck Co Inc	ORAL	25 MG PO
	Syncope	Other	Aspirin	SS		ORAL	81 MG PO
			Proscar	C			
			Acetaminophen	C			
			Niacin	C			

Date:10/30/00ISR Number: 3604057-7Report Type:Expedited (15-DaCompany Report #WAES 00095539
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Aplastic Anaemia	Foreign	Vioxx	PS	Merck Research		
Hospitalization -	Bone Marrow Depression	Health			Laboratories Div		
Initial or Prolonged	Dyspnoea Exertional	Professional			Merck Co Inc	ORAL	25.0 MG PO
	Haematoma		Fosamax	C			
	Haemorrhagic Diathesis		Enalapril	C			
	Injury		Nifedipine	C			
	Palpitations		Tetrazepam	C			
	Pancytopenia						
	Sepsis						

Date:10/30/00ISR Number: 3604111-XReport Type:Expedited (15-DaCompany Report #WAES 00095508
Age:61 YR Gender:Not SpecifiI/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Antibody Test Positive	Other			Laboratories Div		
	Blood Bilirubin Increased				Merck Co Inc	ORAL	12.5 MG 2 DAY
	Cholecystitis		Atorvastatin	C			
	Cholestasis		Butylscopolamine				
	Faeces Pale		Bromide	C			
	Gallbladder Disorder		Ginkgo Biloba				

	Hepatitis	Extract	C
	Infectious Mononucleosis	Magnesium Aspartate	
	Jaundice	(+) Potassium Aspart	C
	Liver Function Test	Metoprolol Tartrate	C
	Abnormal	Omeprazole Magnesium	C
	Oedema	Vitamin E	C
	Pruritus		

Date:10/30/00ISR Number: 3604207-2Report Type:Expedited (15-DaCompany Report #WAES 00102002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
		Representative	Cozaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/00ISR Number: 3604209-6Report Type:Expedited (15-DaCompany Report #WAES 00101967
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dysarthria	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
	Speech Disorder				Merck Co Inc	ORAL	25	MG/DAILY/PO
			Armour Thyroid Tablets	C				
			Celebrex	C				
			Premarin	C				

Date:10/30/00ISR Number: 3604211-4Report Type:Expedited (15-DaCompany Report #WAES 00101917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health	Vioxx	PS	Merck Research			
	Drug Level Above Therapeutic	Professional			Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Drug Toxicity		Lithobid 300 Mg	SS		ORAL	300 MG/BID/PO	
	Renal Disorder							

Date:10/30/00ISR Number: 3604212-6Report Type:Expedited (15-DaCompany Report #WAES 00090761
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oliguria	Consumer	Vioxx	PS	Merck Research			
	Rash Erythematous				Laboratories Div Merck Co Inc	ORAL	PO	
			Naprosyn	C				

Date:10/30/00ISR Number: 3604214-XReport Type:Expedited (15-DaCompany Report #WAES 00090913
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident Hemiparesis Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tenoretic	C				

Date:10/30/00ISR Number: 3604219-9Report Type:Expedited (15-DaCompany Report #WAES 00101618
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Renal Failure Acute Sepsis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:10/30/00ISR Number: 3604224-2Report Type:Expedited (15-DaCompany Report #WAES 00101829
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25; 50 MG/PO						
			Toprol Xl Tablets	C		
			Amiodarone	C		
			Calcium	C		
			Potassium	C		
			Vitamins	C		

Date:10/30/00ISR Number: 3604226-6Report Type:Expedited (15-DaCompany Report #WAES 00102108
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative	(Therapy Unspecified)	C		

Date:10/30/00ISR Number: 3604228-XReport Type:Expedited (15-DaCompany Report #WAES 00102073
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Back Pain					
	Bone Disorder				Merck Co Inc	ORAL
25						
	Decreased Activity					
MG/DAILY/PO						
	Fatigue		Bumex	C		
	Lethargy		Valium	C		
	Muscular Weakness		Amitriptyline	C		
	Myalgia		Aspirin	C		
			Ibuprofen	C		
			Isosorbide	C		
			Propranolol	C		

Date:10/30/00ISR Number: 3604229-1Report Type:Expedited (15-DaCompany Report #WAES00101839
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Diovan	C				
			Lopressor	C				

Date:10/30/00ISR Number: 3604234-5Report Type:Expedited (15-DaCompany Report #WAES 00108116
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Haemorrhage Tongue Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	2 DAY
	Ulcer	Other	Corticosteroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/00ISR Number: 3604237-0Report Type:Expedited (15-DaCompany Report #WAES 00105603
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Health			Laboratories Div			
Initial or Prolonged	Haemoglobin Decreased	Professional			Merck Co Inc	ORAL	12.5 MG	5 DAY
	Hypotension	Other	Tramadol Hcl	C				
	Tachycardia							

Date:10/30/00ISR Number: 3604240-0Report Type:Expedited (15-DaCompany Report #WAES 00107015
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Chest Pain	Health			Laboratories Div			
	Condition Aggravated	Professional			Merck Co Inc	ORAL	12.5 MG	4 DAY
	Coronary Artery Disease	Other	Candesartan					
	Fatigue		Cilexetil	C				

Date:10/30/00ISR Number: 3604243-6Report Type:Expedited (15-DaCompany Report #WAES 00109001
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Fall	Health			Laboratories Div			
Initial or Prolonged	Loss Of Consciousness	Professional			Merck Co Inc	ORAL	25 MG	17 DAY
		Other	Zocor	C				
			Herbesser	C				
			Imdur	C				
			Nitroglycerin	C				
			Warfarin Sodium	C				

Date:10/30/00ISR Number: 3604254-0Report Type:Expedited (15-DaCompany Report #WAES 00095007
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
		Other	Omeprazole	C				

Date:10/30/00ISR Number: 3604257-6Report Type:Expedited (15-DaCompany Report #WAES 00109556
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	2 DAY
		Other						

Date:10/30/00ISR Number: 3604260-6Report Type:Expedited (15-DaCompany Report #WAES 00095055
Age:91 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Hiatus Hernia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	31 DAY
	Oesophageal Ulcer Oesophagitis	Other	Elavil	C				
			Timoptic	C				
			Amlodipine	C				
			Isosorbide Mononitrate	C				
			Nizatidine	C				
			Omeprazole	C				
			Thyroxine	C				

Date:10/30/00ISR Number: 3604263-1Report Type:Expedited (15-DaCompany Report #WAES 00100901
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort Abdominal Pain Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Faeces Pale							
	Gastrointestinal Haemorrhage Haematochezia Haemoglobin Decreased Vomiting		Celebrex	C				
			Tylenol	C				
			Aspirin	C				

Date:10/30/00ISR Number: 3604264-3Report Type:Expedited (15-DaCompany Report #WAES 00108109
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY

Other	Methotrexate	C

Date:10/30/00ISR Number: 3604266-7Report Type:Expedited (15-DaCompany Report #WAES 00080666
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain Upper
	Asthenia
	Decreased Activity
	Diarrhoea
	Fall
	Gastrointestinal Haemorrhage
	Haemoglobin Decreased
	Haemorrhage
	Middle Insomnia
	Nausea
	Oral Intake Reduced
	Syncope
	Upper Gastrointestinal Haemorrhage

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:10/30/00ISR Number: 3604274-6Report Type:Expedited (15-DaCompany Report #WAES 00100216
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Perforation Jejunal Perforation Mesenteric Occlusion Necrosis Ischaemic Sudden Death	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	

Date:10/30/00ISR Number: 3604276-XReport Type:Expedited (15-DaCompany Report #WAES 00100217
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Upper Gastrointestinal Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Benemid	C				
			Lasix	C				
			Lopressor	C				
			Prevacid	C				

			Zestril	C
			Prednisone	C

Date:10/30/00ISR Number: 3604283-7Report Type:Expedited (15-DaCompany Report #WAES 00107515
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erythropenia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Faecal Occult Blood Positive	Health Professional						
	Gastric Haemorrhage		Cap Acetylsalicylic Acid	SS		ORAL	160 MG PO	
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:10/30/00ISR Number: 3604286-2Report Type:Expedited (15-DaCompany Report #WAES 00105134
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY
	Chest Pain	Other						
	Cough							
	Dyspepsia		Acetaminophen (+) Dextropropoxyphene	C				
			Diclofenac	C				

Sulfasalazine C

Date:10/30/00ISR Number: 3604287-4Report Type:Expedited (15-DaCompany Report #WAES 00105173
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	73 DAY
			Cozaar	C				
			Acetaminophen/Dyhydrocodeine Hcl	C				

Date:10/30/00ISR Number: 3604451-4Report Type:Expedited (15-DaCompany Report #WAES 00107309
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased International Normalised Ratio Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	45 DAY
			Tab Warfarin Sodium	SS		ORAL	2.5 MG ORAL	
			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG, ORAL	20 DAY
			Tab Warfarin Sodium	C		ORAL	ORAL	

Date:10/30/00ISR Number: 3604453-8Report Type:Expedited (15-DaCompany Report #WAES 00107313
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acidosis Dehydration Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Cefuroxime Sodium	C				

			Floxacillin Sodium	C		

Date:10/30/00ISR Number: 3605255-9Report Type:Expedited (15-DaCompany Report #WAES 00101911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prednisone	C				

Date:10/30/00ISR Number: 3605258-4Report Type:Expedited (15-DaCompany Report #WAES 00081005
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Dizziness Early Morning Awakening Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	
			Avandia	C				
			Glucophage	C				
			Lipitor	C				
			Vasotec	C				

			Atenolol	C		
			Glyburide	C		

Date:10/31/00ISR Number: 3603590-1Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Output Decreased		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	
Initial or Prolonged	Fluid Retention						ORAL	
	Renal Failure Acute							
	Swelling							

Date:10/31/00ISR Number: 3604616-1Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema		Zestril / 10	PS		ORAL	1 DAY ORAL	
	Tongue Oedema		Vioxx 25	SS		ORAL	1 DAY ORAL	

Date:10/31/00ISR Number: 3604633-1Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Vioxx 12.5 Mg, On					
	Urticaria		25mg Bid Prn	PS		ORAL	12.5 OR 25MG	
							PO	
			Vioxx 12.5 Mg Or 25					
			Mg Bid Prn	SS		ORAL	12.5 MG OR 25	
							MG PO	
			Prometrium 200 Mg	C				

				Benadryl 25 Mg	C	

Date:10/31/00ISR Number: 3604681-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Renal Failure Acute		Vioxx	PS		ORAL
25 MG PO QD						
Intervention to	Tumour Lysis Syndrome		Rituximab	SS		
INTRAVENOUS 700 MG IV						
Prevent Permanent			Neumega	C		
Impairment/Damage			Dexamethasone	C		
			Prilosec	C		
			Gcsf	C		
			Procrit	C		
			Bactrim	C		
			Kcl	C		
			Zantac	C		
			Metronizadole	C		
			Thalidomide	C		
			Sporonox	C		
			Fentanyl Patch	C		
			Rocephin	C		
			Lasix	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/00ISR Number: 3604996-7Report Type:Expedited (15-DaCompany Report #LBID00200005900
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Above	Health Professional	Lithobid	PS	Solvay Pharmaceuticals	ORAL	300 MG BID PO	10 YR
	Therapeutic Dysarthria Hemiparesis Renal Disorder	Company Representative	Vioxx (Rofecoxib)	SS		ORAL	UNKNOWN DAILY PO	

Date:10/31/00ISR Number: 3605288-2Report Type:Expedited (15-DaCompany Report #WAES 00057276
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Shock	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:10/31/00ISR Number: 3606775-3Report Type:Periodic Company Report #AMANTADI2000-00217
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Fall Grand Mal Convulsion	Health Professional Company Representative	Symmetrel	PS	Endo Pharmaceuticals Inc			
			Betaseron (Interferon)	SS		SUBCUTANEOUS	8 MIU QOD SC	
			Paxil (Paroxetine Hcl)	SS	Smithkline Beecham			
			Vioxx (Rofecoxib)	SS	Merck			

Date:11/01/00ISR Number: 3604690-2Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Oedema Peripheral		Vioxx (25mg/Merck)	PS	Merck		25MG DAILY	
Intervention to Prevent Permanent Impairment/Damage	Oliguria							

Date:11/01/00ISR Number: 3605225-0Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx 25mg	PS			QD	

Date:11/01/00ISR Number: 3605419-4Report Type:Expedited (15-DaCompany Report #WAES 00100991
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Condition Aggravated	Health			Laboratories Div			
	Renal Disorder	Professional			Merck Co Inc	ORAL	PO	
	Renal Impairment		Coumadin	C				
	Urinary Tract Infection		Estratest	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/00ISR Number: 3605650-8Report Type:Expedited (15-DaCompany Report #WAES 00091115
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Mouth Ulceration	Health	Vioxx	PS	Merck Research			
Other	Oedema Peripheral	Professional			Laboratories Div			
	Oral Soft Tissue Disorder				Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:11/01/00ISR Number: 3605850-7Report Type:Expedited (15-DaCompany Report #WAES 00107309
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemoglobin Decreased	Other			Laboratories Div			
	International Normalised				Merck Co Inc	ORAL	12.5 MG PO;	
	Ratio Increased						25 MG PO	20 DAY
			Warfarin	SS		ORAL	PO	

Date:11/01/00ISR Number: 3606426-8Report Type:Periodic Company Report #A023164
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Procardia Xl	PS	Pfizer Laboratories			
	Headache	Health			Div Pfizer Inc	ORAL	30.00 MG	TOTAL:
	Hypersensitivity	Professional						
	Insomnia							SEMI-WEEKLY:
	Pain							ORAL
	Rhinitis		Zyrtec	SS		ORAL	5.00 MG	

Synovitis
TOTAL: DAILY:

ORAL
Celebrex SS ORAL
200.00 MG

TOTAL: DAILY:

ORAL
Vioxx SS ORAL
12.50 MG

TOTAL: DAILY:

ORAL
Vicodin C
Flonase C
Serzone C
Trimethobenzamide Hydrochloride C
Vitamin E C
Vitamin C C
Selenium C
Lorazapam C

Date:11/02/00ISR Number: 3605907-0Report Type:Expedited (15-DaCompany Report #WAES 00102066
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertrophy Breast Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Sensation Of Heaviness		Elavil	C				
			Lasix	C				
			Norvasc	C				
			Prevacid	C				
			Xanax	C				

				Folic Acid	C		

Date:11/02/00ISR Number: 3605912-4Report Type:Expedited (15-DaCompany Report #WAES 00102083
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Difficulty In Walking Impaired Healing Pain Post Procedural Complication	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/02/00ISR Number: 3606016-7Report Type:Expedited (15-DaCompany Report #WAES 00109129
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	42 DAY
			Tab Chloroquine	SS		ORAL	250 MG PO	38 DAY
			Acetaminophen	C				
			Bromazepam	C				
			Diclofenac Na	C				
			Fluoxetine Hcl	C				
			Insulin	C				

Date:11/02/00ISR Number: 3606018-0Report Type:Expedited (15-DaCompany Report #WAES 00105145
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	54 DAY

			Aspirin	SS	ORAL
75 MG PO					
			Amiloride/Furosemide	C	
			Digoxin	C	
			Fluoxetine	C	
			Nitrazepam	C	
			Senna	C	

Date:11/02/00ISR Number: 3606022-2Report Type:Expedited (15-DaCompany Report #WAES 00109142
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain	Foreign	Vioxx	PS	Merck Research	
	Hypertension	Other			Laboratories Div	
	Urinary Retention				Merck Co Inc	ORAL
25 MG PO 3 DAY						

Date:11/02/00ISR Number: 3606025-8Report Type:Expedited (15-DaCompany Report #WAES 00109127
Age:33 YR Gender:Female I/FU:I

Outcome	PT
Death	Abortion Missed
Congenital Anomaly	Complications Of Maternal
	Exposure To Therapeutic

Drugs
Exomphalos

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 1 DOSE	
			Tab Tetrazepam	SS		ORAL	PO	

Date:11/02/00ISR Number: 3606028-3Report Type:Expedited (15-DaCompany Report #WAES 00105601
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - 15 DAY Initial or Prolonged	Cardiac Failure Congestive Cerebrovascular Accident Condition Aggravated Pulmonary Oedema	Foreign Study Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/02/00ISR Number: 3606151-3Report Type:Expedited (15-DaCompany Report #WAES 00106138
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy Convulsion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	16 DAY
			Theophylline	SS		ORAL	200 MG, PO	793 DAY

Date:11/02/00ISR Number: 3606152-5Report Type:Expedited (15-DaCompany Report #WAES 00106551
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acidosis	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Confusional State	Health			Laboratories Div	
	Renal Failure Acute	Professional			Merck Co Inc	ORAL
25 MG, PO						
		Other	Acetaminophen	C		
			Citalopram Hydrobromide	C		
			Propoxyphene	C		

Date:11/02/00ISR Number: 3607028-XReport Type:Expedited (15-DaCompany Report #ZANA030589 (1)
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Decreased	Health	Zanaflex	PS	Elan Pharma	
	Drug Interaction	Professional			International Ltd	ORAL
8 MG DAILY,						
	Dysphagia					
PER ORAL						
	Hallucination		Vioxx (Rofecoxib)	SS		ORAL
50 MG DAILY,						
	Heart Rate Increased					
PER ORAL						
	Psychotic Disorder					
	Speech Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/00ISR Number: 3606653-XReport Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Rofecoxib	PS		ORAL	30 MG PO QD	
	Increased		Fosinopril	SS		ORAL	30 MG PO	
	Hyperkalaemia							

Date:11/03/00ISR Number: 3606687-5Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS				
Initial or Prolonged	Drug Toxicity		Coumadin	SS		ORAL	5MG Q DAY	
	Faecal Occult Blood						ORAL	
	Positive							
	Gastrointestinal							
	Haemorrhage							
	Haematochezia							
	International Normalised							
	Ratio Increased							

Date:11/03/00ISR Number: 3606997-1Report Type:Expedited (15-DaCompany Report #A032987
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Foreign	Zyrtec	PS	Pfizer Inc	ORAL	ORAL	
Initial or Prolonged	Dyspnoea	Consumer	Plaquenil	SS		ORAL	200.00 MG	
	Haemoglobin Decreased						TOTAL DAILY	
	Normochromic Normocytic						ORAL	
	Anaemia		Salazopyrine	SS		ORAL	BID; ORAL	

	Spinal Myelogram Abnormal		Rofecoxib	SS		ORAL
25.00 MG						
	Tinnitus					
TOTAL:DAILY:						
ORAL						
			Piroxicam	C		
			Omeprazole	C		
			Prednisone	C		

Date:11/03/00ISR Number: 3607069-2Report Type:Expedited (15-DaCompany Report #WAES 00092550
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Haematocrit Decreased				Laboratories Div	
Initial or Prolonged	Haemoglobin Decreased				Merck Co Inc	ORAL
PO						
	Syncope		Zestril	C		

Date:11/03/00ISR Number: 3607072-2Report Type:Expedited (15-DaCompany Report #WAES 00101927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain	Health	Vioxx	PS	Merck Research	
	Condition Aggravated	Professional			Laboratories Div	
	Faecal Occult Blood				Merck Co Inc	ORAL
25						
	Positive					
MG/DAILY/PO						
	Gastrointestinal		Celebrex	C		
	Haemorrhage		Tylenol	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/00ISR Number: 3607073-4Report Type:Expedited (15-DaCompany Report #WAES 00102355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:11/03/00ISR Number: 3607075-8Report Type:Expedited (15-DaCompany Report #WAES 00102340
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphonia Face Oedema Periorbital Oedema Throat Tightness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Urticaria Visual Disturbance		Coumadin Norvasc Synthroid Digoxin	C C C C				

Date:11/03/00ISR Number: 3607085-0Report Type:Expedited (15-DaCompany Report #WAES 00091033
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Anaemia Blindness Condition Aggravated Gastrointestinal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Haemorrhage Retinal Haemorrhage Ulcer Visual Acuity Reduced		Aspirin	C				

Date:11/03/00ISR Number: 3607087-4Report Type:Expedited (15-DaCompany Report #WAES 00092202
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Renal Failure Acute	Company			Merck Co Inc	ORAL	25	
Other		Representative					MG/DAILY/PO	
			Tab Bactrim Ds Tablets	SS		ORAL	PO	
			Tab Accupril	SS		ORAL	20	
							MG/DAILY/PO	
			Coreg	C				
			Coumadin	C				
			Flagyl	C				
			Lasix	C				

Date:11/03/00ISR Number: 3607089-8Report Type:Expedited (15-DaCompany Report #WAES 00072559
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			

Merck Co Inc ORAL
PO

Date:11/03/00ISR Number: 3607340-4Report Type:Expedited (15-DaCompany Report #WAES 00105623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Shock	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/03/00ISR Number: 3607342-8Report Type:Expedited (15-DaCompany Report #WAES 00107553
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Fall Gastric Ulcer Haemorrhage Head Injury Syncope	Foreign Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	22 DAY	

Date:11/03/00ISR Number: 3607346-5Report Type:Expedited (15-DaCompany Report #WAES 00108612
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:11/03/00ISR Number: 3607347-7Report Type:Expedited (15-DaCompany Report #WAES 00095612
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Faeces Discoloured Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG 8 DAY
		Other	Aspirin	C			

Date:11/03/00ISR Number: 3607355-6Report Type:Expedited (15-DaCompany Report #WAES 00105264
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Photopsia Urinary Incontinence	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO 1 DAY
			Spironolactone	C			
			Thioridazine	C			

Date:11/03/00ISR Number: 3607357-XReport Type:Expedited (15-DaCompany Report #WAES 00105244
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Pain Upper Migraine Palpitations	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/00ISR Number: 3607361-1Report Type:Expedited (15-DaCompany Report #WAES 00105236
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Other	Endoscopy Upper Gastrointestinal Tract	Other			Merck Co Inc	ORAL	12.5 MG, PO	
	Abnormal		Aspirin	SS		ORAL	75 MG, PO	
	Gastritis		Amlodipine	C				
	Hiatus Hernia							
	Melaena							
	Oesophagitis							
	Rectal Haemorrhage							

Date:11/03/00ISR Number: 3607365-9Report Type:Expedited (15-DaCompany Report #WAES 00108630
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:11/03/00ISR Number: 3607372-6Report Type:Expedited (15-DaCompany Report #WAES 00105626
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	12 DAY
			Acetyldigoxin	C				
			Clopidogrel Bisulfate	C				
			Furosemide	C				
			Metoprolol Succinate	C				
			Omeprazole	C				
			Ramipril	C				
			Spironolactone	C				

Date:11/03/00ISR Number: 3607373-8Report Type:Expedited (15-DaCompany Report #WAES 00107360
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Omeprazole	C				

Date:11/03/00ISR Number: 3607387-8Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Gastric Ulcer							
	Pruritus							
	Renal Impairment	Other	Cap Celecoxib	SS		ORAL	400 MG	52 DAY
	Vomiting		Inj Diclofenac	SS		INTRAMUSCULAR		
			Acetaminophen/Codeine Phosphate	C				

Aspirin	C
Calcium Carbonate (+) Cholecalciferol	C
Furosemide	C
Isosorbide Dinitrate	C
Levothyroxine Na	C
Midalozan Maleate	C
Oxazepam	C
Pantoprazole Na	C

Date:11/03/00ISR Number: 3607389-1Report Type:Expedited (15-DaCompany Report #WAES 00088617
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG	
	Pulmonary Oedema Renal Failure Acute		Vasotec	C				
			Aspirin	C				
			Furosemide	C				
			Glyburide	C				
			Metformin	C				
			Metoprolol Tartrate	C				

Date:11/03/00ISR Number: 3607398-2Report Type:Expedited (15-DaCompany Report #WAES 00105266
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Thyroxine	C				

Date:11/03/00ISR Number: 3620004-6Report Type:Expedited (15-DaCompany Report #WAES 00118647
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	15 DAY
		Other	Betaxolol Hcl	C				

Date:11/06/00ISR Number: 3607847-XReport Type:Expedited (15-DaCompany Report #WAES 00102347
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gallbladder Perforation Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Methadone Hydrochloride	C				

Date:11/06/00ISR Number: 3607848-1Report Type:Expedited (15-DaCompany Report #WAES 00102304
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/06/00ISR Number: 3607850-XReport Type:Expedited (15-DaCompany Report #WAES 00101925
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
	Gastrointestinal Haemorrhage							
	Haematemesis		Coumadin	C				
	Haemoglobin Decreased		Tylenol	C				
			Aspirin	C				

Date:11/06/00ISR Number: 3607851-1Report Type:Expedited (15-DaCompany Report #WAES 00101924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Faecal Occult Blood	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
Hospitalization - Initial or Prolonged	Positive Gastrointestinal Haemorrhage						PO	
	Haemoglobin Decreased		Tylenol	C				
	Myocardial Infarction							

Date:11/06/00ISR Number: 3607852-3Report Type:Expedited (15-DaCompany Report #WAES 00101923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cardiac Arrest							
	Cardio-Respiratory Arrest							
	Gastrointestinal		Celebrex	C				
	Haemorrhage		Coumadin	C				
	Haematemesis		Tylenol	C				
	International Normalised Ratio Increased							
	Nausea							
	Pallor							
	Respiratory Failure							
	Vomiting							

Date:11/06/00ISR Number: 3607853-5Report Type:Expedited (15-DaCompany Report #WAES 00092465
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Condition Aggravated
Other	Deep Vein Thrombosis
	Erythema
	International Normalised Ratio Increased
	Oedema

	Prothrombin Time Prolonged						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ PO
			Coumadin	C			
			Cozaar	C			
			Demerol	C			
			Elavil	C			
			Fioricet	C			
			Inderal	C			
			Prilosec	C			
			Robaxin	C			
			Vicodin	C			
			Vistaril	C			

Date:11/06/00ISR Number: 3607989-9Report Type:Expedited (15-DaCompany Report #WAES 00101928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematochezia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Shock		A.S.A.	C			
	Vomiting		Tylenol	C			

Date:11/06/00ISR Number: 3608008-0Report Type:Expedited (15-DaCompany Report #WAES 00102108
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Facial Palsy Grand Mal Convulsion	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO
		Representative	[Therapy				

			Unspecified]	C		

Date:11/06/00ISR Number: 3608103-6Report Type:Expedited (15-DaCompany Report #WAES 00108571
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcoholism Depression Suicide Attempt	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	17 WK

Date:11/06/00ISR Number: 3608104-8Report Type:Expedited (15-DaCompany Report #WAES 00108613
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Lamotrigine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/00ISR Number: 3608105-XReport Type:Expedited (15-DaCompany Report #WAES 00103779
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	3 DAY
		Other	Carbaspirin Calcium	C				

Date:11/06/00ISR Number: 3608106-1Report Type:Expedited (15-DaCompany Report #WAES 00105213
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus Diabetes Mellitus Inadequate Control	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	13 DAY
	Malaise		Amlodipine	C				
			Gliclazide	C				
			Loratadine	C				
			Metformin	C				
			Moxonidine	C				

Date:11/06/00ISR Number: 3608113-9Report Type:Expedited (15-DaCompany Report #PHEH2000US09965
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Diovan	PS	Novartis Pharmaceuticals Corp	ORAL	160 MG, BID, ORAL	UNKNOWN UNK
		Company Representative	Vioxx (Rofecoxib)	SS				

Date:11/06/00ISR Number: 3608132-2Report Type:Expedited (15-DaCompany Report #WAES 00081103
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Diarrhoea							
	Gastritis							
	Gastrointestinal Haemorrhage		Tab Vioxx 50 Mg	SS		ORAL	50 MG DAILY PO	
	Haematochezia							
	Haematocrit Decreased		Accupril	C				
	Haemoglobin Decreased		Ecotrin	C				
	Nausea		Etrafon	C				
	Peptic Ulcer		Flomax (Tamsulosin (R)-Form Hydr	C				
	Rectal Haemorrhage		Synthroid	C				
			Zocor	C				
			Atenolol	C				

Date:11/06/00ISR Number: 3608133-4Report Type:Expedited (15-DaCompany Report #WAES 00062126
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Feeling Abnormal
	Headache
	Leukaemia

	Mental Impairment Visual Disturbance						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO
			Aleve	C			
			Therapy Unspecified	C			

Date:11/06/00ISR Number: 3610178-5Report Type:Periodic Company Report #2000022946US
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective Drug Interaction Vision Blurred Weight Increased	Consumer Health Professional	Detrol	PS	Pharmacia And Upjohn Co	ORAL	2 MG, BID, ORAL
			Vioxx ()	SS			
			Premarin (Estrogens Conjugated)	C			
			Miacalcin Nasal Spray (Calcitonin, Salmon)	C			
			Claritin-D (Pseudoephedrine Sulfate, Loratadine)	C			
			"Pain-Free" Chondrotin/Glucosamine	C			
			Vitamin And Mineral Supplement	C			

Date:11/07/00ISR Number: 3607725-6Report Type:Direct Company Report #
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Hyperkalaemia		Vioxx Rofecoxib	PS			

Date:11/07/00ISR Number: 3608580-0Report Type:Expedited (15-DaCompany Report #WAES 00102456
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dialysis	Health	Vioxx	PS	Merck Research			
Life-Threatening	Eosinophilia	Professional			Laboratories Div			
Hospitalization -	Nephritis Interstitial	Company			Merck Co Inc	ORAL	12.5 MG DAILY	
Initial or Prolonged	Psoriasis	Representative						
PO								
Disability								

Date:11/07/00ISR Number: 3608581-2Report Type:Expedited (15-DaCompany Report #WAES 00102463
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eyelid Oedema	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Face Oedema				Laboratories Div			
	Swelling				Merck Co Inc	ORAL		
PO								
			Catapres	C				

Celebrex	C
Cozaar	C
Dyazide	C
Xanax	C
Ascorbic Acid	C
Folic Acid	C
Glyburide	C
Quinine	C
Vitamin E	C
Vitamins (Unspecified)	C

Date:11/07/00ISR Number: 3608582-4Report Type:Expedited (15-DaCompany Report #WAES 00102583
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/07/00ISR Number: 3608583-6Report Type:Expedited (15-DaCompany Report #WAES 00100117
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematocrit Decreased Laboratory Test Abnormal Lymphadenopathy Parotitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Tab Vioxx	SS		ORAL	PO	

Date:11/07/00ISR Number: 3608584-8Report Type:Expedited (15-DaCompany Report #WAES 00102360
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Anaemia	Study	Vioxx	PS	Merck Research Laboratories Div	
	Blood Creatinine Increased	Health Professional			Merck Co Inc	ORAL 25 MG DAILY PO
	Blood Urea Increased					
	Cataract		Tab Vioxx 25 Mg	SS		ORAL 25 MG DAILY PO
	Dermatitis					
	Haematocrit Decreased		Tab Acetaminophen	SS		ORAL PO
	Haemoglobin Decreased		Lovastatin	C		
	Renal Failure		Ascorbic Acid	C		
			Calcium Carbonate	C		
			Folic Acid	C		
			Methotrexate	C		

Date:11/07/00ISR Number: 3608666-0Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Back Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Blood Creatinine Increased	Health Professional			Merck Co Inc	ORAL 25 MG PO
	Gastric Ulcer	Other	Cap Celecoxib	SS		ORAL 400 MG PO
	Pruritus		Inj Diclofenac	SS		INTRAMUSCULAR IM
	Renal Impairment		Acetaminophen/Codein			

e Phosphate	C
Aspirin	C
Calcium Carbonate	
(+) Cholecalciferol	C
Furosemide	C
Isosorbide Dinitrate	C
Levothyroxine Na	C
Midazolam Maleate	C
Oxazepam	C
Pantoprazole Na	C

Date:11/07/00ISR Number: 3608674-XReport Type:Expedited (15-DaCompany Report #WAES 00105285
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia	Foreign	Vioxx	PS	Merck Research			
Other	Condition Aggravated	Other			Laboratories Div			
					Merck Co Inc	ORAL	25 MG, PO	6 DAY
			Diclofenac	C				

Date:11/07/00ISR Number: 3608676-3Report Type:Expedited (15-DaCompany Report #WAES 00115002
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomyopathy	Foreign	Vioxx	PS	Merck Research			
	Chest Pain	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG, PO	7 DAY
			Prinivil	C				
			Amiodarone	C				
			Atorvastatin	C				
			Carvedilol	C				
			Furosemide	C				
			Warfarin	C				

Date:11/07/00ISR Number: 3608679-9Report Type:Expedited (15-DaCompany Report #WAES 00103587
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	5 DAY
			Morphine Sulfate	C				

Date:11/07/00ISR Number: 3608680-5Report Type:Expedited (15-DaCompany Report #WAES 00096160
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	7 DAY
		Professional Other	Timoptic	C				
			Trusopt	C				
			Chymotrypsin (+) Rutin (+) Vitamins	C				
			Dipivefrin	C				
			Ginkgo Biloba Extract	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/00ISR Number: 3608681-7Report Type:Expedited (15-DaCompany Report #WAES 00096030
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Fatigue	Other			Laboratories Div			
Initial or Prolonged	Gastrointestinal				Merck Co Inc	ORAL	12.5 MG, PO	10 DAY
	Haemorrhage		Acetaminophen	C				
	Haematemesis		Paroxetine	C				
	Haemoglobin Decreased		Rivastigmine	C				
	Melaena							

Date:11/07/00ISR Number: 3608684-2Report Type:Expedited (15-DaCompany Report #WAES 00105267
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Dehydration	Other			Laboratories Div			
Initial or Prolonged	Duodenal Ulcer				Merck Co Inc	ORAL	25.0 MG	236 DAY
	Perforation		Clonidine	C				
	Malaise		Danazol	C				
	Peritonitis		Dothiepin	C				
	Renal Impairment		Vitamins					
	Sepsis		(Unspecified)	C				
	Vomiting							

Date:11/07/00ISR Number: 3608689-1Report Type:Expedited (15-DaCompany Report #WAES 99125158
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State	Foreign	Vioxx	PS	Merck Research			
	Haematemesis	Health			Laboratories Div			
	Hyperkalaemia	Professional			Merck Co Inc	ORAL	12.5 MG	
	Sedation		Acetaminophen	C				
			Amoxicillin					
			Trihydrate (+)					
			Clavulanate P	C				

Atorvastatin	C
Cetirizine	C
Crotamiton	C
Diazepam	C
Dihydrocodeine	C
Floxacillin	C
Folic Acid	C
Lactulose	C
Loperamide	C
Metronidazole	C
Nefopam	C
Nifedipine	C
Vancomycin	C

Date:11/07/00ISR Number: 3609172-XReport Type:Expedited (15-DaCompany Report #WAES 00092015
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Bradycardia
Hospitalization - Initial or Prolonged	Cardiac Arrest
	Conduction Disorder
Other	Fall

		Laceration					
		Nausea					
		Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/1X/PO							

Date:11/07/00ISR Number: 3610520-5Report Type:Expedited (15-DaCompany Report #SP-200001649
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Bilirubin Increased	Foreign	Remicade	PS		
INTRAVENOUS	INTRAVENOUS						
Initial or Prolonged		Cholangitis Acute	Health				
300MG							
Disability		Fatigue	Professional	Remicade	SS		
INTRAVENOUS	INTRAVENOUS						
Other		Hepatic Cirrhosis					
300MG							
		Hepatic Enzyme Increased		(Omeprazole) Losec	SS		ORAL
ORAL 20MG /							
		Hepatic Fibrosis					
DAY							
		Hepatic Steatosis		(Rofecoxbib) Vioxx	SS		ORAL
ORAL 25MG /							
		Hepatitis					
DAY							
		Jaundice		(Sertraline) Zoloft	SS		ORAL
ORAL							
		Liver Disorder		Methotrexate	SS		ORAL
ORAL 7.5MG /							
		Nausea					
WEEK							
		Pruritus		Glibenclamide	C		
				Folacin	C		
				Daonil	C		

Date:11/08/00ISR Number: 3608344-8Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	
Hospitalization -	Eosinophilia							
Initial or Prolonged	Idiopathic							
Required	Thrombocytopenic Purpura							
Intervention to	Injection Site							
Prevent Permanent	Haemorrhage							
Impairment/Damage	Marrow Hyperplasia							
	Petechiae							

Date:11/08/00ISR Number: 3608900-7Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Bilirubin Increased		Vioxx (50mg Qd X 4					
	Jaundice		Days-> 25mg Qd)	PS				
	Liver Function Test		Atenolol	C				
	Abnormal		Lipitor	C				

Date:11/08/00ISR Number: 3608901-9Report Type:Expedited (15-DaCompany Report #WAES 00110106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	25	
	Haematochezia	Representative					MG/DAILY/PO	
			Nonsteroidal					

Anti-Inflammatory C

Date:11/08/00ISR Number: 3608903-2Report Type:Expedited (15-DaCompany Report #WAES 00100456
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Gastrointestinal Disorder							
	Hypotension							
	Muscular Weakness		Vioxx	SS		ORAL	50MG DAILY PO	
	Nausea		Celebrex	SS				
	Neuropathy Peripheral		Cytomel	C				
	Orthostatic Hypotension		Fosamax	C				
	Porphyria Acute		Miacalcin	C				
	Porphyria Non-Acute		Synthroid	C				

Date:11/08/00ISR Number: 3608954-8Report Type:Expedited (15-DaCompany Report #WAES 00052850
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Neutropenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	White Blood Cell Count Decreased							
			Therapy Unspecified	C				

Date:11/08/00ISR Number: 3608959-7Report Type:Expedited (15-DaCompany Report #WAES 00102002
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Hyperkalaemia							

		Company			Merck Co Inc	ORAL
12.5 MG,						
		Representative				
DAILY, PO						
			Tab Cozaar 25 Mgcet-N	C		ORAL
25 MG, PO						
			Percocet	C		
			Digoxin	C		

Date:11/08/00ISR Number: 3608961-5Report Type:Expedited (15-DaCompany Report #WAES 00100901
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Pain	Health	Vioxx	PS	Merck Research	
	Diarrhoea	Professional			Laboratories Div	
	Faeces Pale				Merck Co Inc	ORAL
12.5 MG,						
	Frequent Bowel Movements					
DAILY, PO						
	Gastrointestinal Disorder		Celebrex	C		
	Gastrointestinal		Tylenol	C		
	Haemorrhage		Aspirin	C		
	Haematochezia					
	Haemoglobin Decreased					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/00ISR Number: 3608972-XReport Type:Expedited (15-DaCompany Report #WAES 00082926
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research			
	Blood Pressure Systolic	Health			Laboratories Div			
	Increased	Professional			Merck Co Inc	ORAL	25	
	Breath Sounds Decreased						MG/DAILY/PO	
	Cardiac Arrest		Claritin-D	C				
	Cough		Prometrium	C				
	Dyspnoea Exertional		Relafen	C				
	Muscle Injury		Zoloft	C				
	Oedema Peripheral							
	Pain							
	Stress							

Date:11/08/00ISR Number: 3608982-2Report Type:Expedited (15-DaCompany Report #WAES 00110538
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aspiration	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Blood Immunoglobulin G	Professional			Laboratories Div			
	Increased	Company			Merck Co Inc	ORAL	25	
	Condition Aggravated	Representative					MG/DAILY/PO	
	Cough		Plaquenil	C				
	Haemoptysis							
	Hypertension							
	Lung Infiltration							
	Nephrotic Syndrome							
	Oedema Peripheral							
	Pancytopenia							
	Pneumonitis							
	Pulmonary Embolism							
	Rash Papular							
	Renal Vein Thrombosis							
	Systemic Lupus							
	Erythematosus							
	Vasculitis							
	Weight Increased							

Date:11/08/00ISR Number: 3608994-9Report Type:Expedited (15-DaCompany Report #WAES 00110190
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease Diverticulum Intestinal Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
	Gastrointestinal Ulcer Inflammation		Danocrine	C				

Date:11/08/00ISR Number: 3609011-7Report Type:Expedited (15-DaCompany Report #WAES 00096097
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris Chest Pain Condition Aggravated Dyspnoea

Dyspnoea Exertional

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Acebutolol	C				
	Fenofibrate	C				
	Furosemide/Spironolactone	C				
	Nitroglycerin	C				
	Troxerutin	C				

Date:11/08/00ISR Number: 3609034-8Report Type:Expedited (15-DaCompany Report #WAES 00075039
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Atrophic Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Sinemet	C				
			Alprazolam	C				
			Iron	C				
			Lactulose	C				
			Ranitidine Hcl	C				
			Tramadol Hcl	C				
			Zaleplon	C				

Date:11/08/00ISR Number: 3609270-0Report Type:Expedited (15-DaCompany Report #WAES 00105634
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/08/00ISR Number: 3609272-4Report Type:Expedited (15-DaCompany Report #WAES 00105622
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulum Gastrointestinal Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/08/00ISR Number: 3609279-7Report Type:Expedited (15-DaCompany Report #WAES 00089751
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Benign Gastric Neoplasm Duodenal Ulcer Haemorrhage Gastritis Haematemesis Loss Of Consciousness Melaena Polyp

		Upper Gastrointestinal Haemorrhage					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO							

Date:11/08/00ISR Number: 3609281-5Report Type:Expedited (15-DaCompany Report #WAES 00109129
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Psoriasis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	42 DAY						
				Tab Chloroquine	SS		ORAL
250 MG PO	38 DAY						
				Acetaminophen	C		
				Bromazepam	C		
				Diclofenac Na	C		
				Fluoxetine Hcl	C		
				Insulin	C		

Date:11/09/00ISR Number: 3608941-XReport Type:Direct Company Report #
Age:22 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required Intervention to Prevent Permanent Impairment/Damage		Blood Potassium Increased Renal Failure Acute		Rofecoxib 25 Mg, Merck & Co. Inc	PS	Merck & Co. Inc	ORAL
50 MG PO QD							
				Ceftazidime	C		
				Levafloxacin	C		
				Metronidazole	C		
				Fluconozole	C		
				Ixondrolone	C		
				Cefazolin	C		
				Vancomycin	C		

Date:11/09/00ISR Number: 3609614-XReport Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vasotec	PS		ORAL	10MG PO BID	
Initial or Prolonged	Blood Creatinine		Vioxx	SS		ORAL	25MG 50X1	
	Increased						THEN 25MG PO	
	Blood Urea Increased						QD	
	Condition Aggravated							
	Renal Failure Acute							
	Renal Tubular Necrosis							

Date:11/13/00ISR Number: 3610786-1Report Type:Expedited (15-DaCompany Report #001-0906-M0000206
Age:48 YR Gender:Female I/FU:I

Outcome	PT
Other	Asthenia
	Blood Pressure Decreased
	Condition Aggravated
	Difficulty In Walking
	Drug Interaction
	Irritability

	Medication Error Sedation Visual Acuity Reduced	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Accupril	PS	Parke Davis Div Warner Lambert Co	ORAL	40 MG (DAILY), PER ORAL
			Vioxx	SS			
			Ditopan (Oxybutynin)	C			
			(Amoxicillin)	C			

Date:11/13/00ISR Number: 3612980-2Report Type:Expedited (15-DaCompany Report #WAES 00102304
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:11/14/00ISR Number: 3610893-3Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Vision Blurred		Vioxx 25mg Qd	PS		ORAL	25MG PO QD
			Mvi	C			
			Colace	C			
			Folic Acid	C			
			Ecotrin	C			
			Percocet	C			
			Ambien	C			
			Bacitracin	C			
			Vit E Cream	C			
			Vicodin	C			

Date:11/14/00ISR Number: 3611474-8Report Type:Expedited (15-DaCompany Report #WAES 00110537
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/14/00ISR Number: 3611476-1Report Type:Expedited (15-DaCompany Report #WAES 00110445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
			Lithium Carbonate (Roxane)	SS			900 MG/DAILY/UNK	

Date:11/14/00ISR Number: 3611477-3Report Type:Expedited (15-DaCompany Report #WAES 00110185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other		Company Representative			Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:11/14/00ISR Number: 3611523-7Report Type:Expedited (15-DaCompany Report #WAES 00105248
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	224 DAY

Date:11/14/00ISR Number: 3611526-2Report Type:Expedited (15-DaCompany Report #WAES 00106172
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anuria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	2 DAY
			Furosemide	C				

Date:11/14/00ISR Number: 3611527-4Report Type:Expedited (15-DaCompany Report #WAES 00109154
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Haematemesis Merck Co Inc ORAL
50 MG 4 DAY
Melilot Extract C
Troxerutin C

Date:11/14/00ISR Number: 3611529-8Report Type:Expedited (15-DaCompany Report #WAES 00105625
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Status Asthmaticus	Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	25 MG	9 DAY
			Albuterol Sulfate	C				
			Leuprolide Acetate	C				
			Theophylline	C				

Date:11/14/00ISR Number: 3611530-4Report Type:Expedited (15-DaCompany Report #WAES 00105634
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hepatic Enzyme Increased	Other			Laboratories Div			
	Hepatitis				Merck Co Inc	ORAL	10	DAY
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3611532-8Report Type:Expedited (15-DaCompany Report #WAES 00105546
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Asthenia	Other						
Other	Dermatitis				Merck Co Inc	ORAL	12.5 MG	
	Dyspnoea		Cap Ioperamide Hcl	SS		ORAL	6 MG	1 DAY
	Implant Site Infection		Clopidogrel Bisulfate	C				
	Lung Disorder		Digitoxin	C				
	Postoperative Infection		Insulin Human	C				
	Pyrexia		Insulin, Neutral	C				
	Sepsis		Omeprazole	C				
	Septic Embolus							

Date:11/14/00ISR Number: 3611557-2Report Type:Expedited (15-DaCompany Report #WAES 00110617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Chest Pain							
	Dyspnoea				Merck Co Inc	ORAL	PO	
	Nausea		Tylenol	C				

Date:11/14/00ISR Number: 3611568-7Report Type:Expedited (15-DaCompany Report #WAES 00100483
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
	Pulmonary Embolism				Merck Co Inc	ORAL	PO	

Date:11/14/00ISR Number: 3611581-XReport Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction Enzyme Abnormality	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/14/00ISR Number: 3611658-9Report Type:Expedited (15-DaCompany Report #WAES 99125158
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State Haematemesis Hyperkalaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO, 25 MG PO	5 DAY
	Sedation							
	Sepsis		Diazepam	SS		ORAL	2 PRN MG PO	
	Upper Gastrointestinal		Dihydrocodeine	SS		ORAL	120-180 MG PO	
	Haemorrhage		Nefopam	SS		ORAL	90 MG PO	
			Therapy Unspecified	C				
			Crotamiton	C				
			Folic Acid	C				
			Loperamide	C				
			Nifedipine	C				
			Vancomycin	C				

	Metronidazole	C
	Lactulose	C
	Floxacillin	C
	Cetirizine	C
	Acetaminophen	C
	Atorvastatin	C
	Amoxicillin Trihydrate (+) Clavulanate P	C

Date:11/14/00ISR Number: 3611673-5Report Type:Expedited (15-DaCompany Report #WAES 00109143
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Guillain-Barre Syndrome Neuritis Thyroiditis	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:11/14/00ISR Number: 3611693-0Report Type:Expedited (15-DaCompany Report #WAES 00118203
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Ulcer Upper Gastrointestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	6 DAY
	Haemorrhage	Other	Tab Aspirin	SS		ORAL	300 MG PO	
			Buthiazide	C				
			Spironolactone	C				

Date:11/14/00ISR Number: 3611694-2Report Type:Expedited (15-DaCompany Report #WAES 00109569
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Oedema	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
25 MG PO						
			Calcium	C		
			Diuretic/ Antihypertensive, Nos	C		
			Etidronic Acid Dina	C		

Date:11/14/00ISR Number: 3611744-3Report Type:Expedited (15-DaCompany Report #WAES 00116021
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Pancreatitis Acute Vomiting	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO 10 DAY						

Date:11/14/00ISR Number: 3611745-5Report Type:Expedited (15-DaCompany Report #WAES 00097537
Age:95 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Hiatus Hernia

	Melaena						
	Oesophageal Ulcer						
	Oesophageal Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Vasotec	C				
			Diclofenac	C				
			Furosemide	C				
			Piracetam	C				
			Spironolactone	C				

Date:11/14/00ISR Number: 3611747-9Report Type:Expedited (15-DaCompany Report #WAES 00118525
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/14/00ISR Number: 3611749-2Report Type:Expedited (15-DaCompany Report #WAES 00108611
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Other						
	Gastric Ulcer							
	Oesophagitis		Aspirin	C				
			Atorvastatin Calcium	C				
			Ranitidine	C				

Date:11/14/00ISR Number: 3611750-9Report Type:Expedited (15-DaCompany Report #WAES 00085119
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Vasotec	C				
			Allopurinol	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Methotrexate	C				
			Zopiclone	C				

Date:11/14/00ISR Number: 3611753-4Report Type:Expedited (15-DaCompany Report #WAES 00085189
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Constipation Dyspepsia Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	45 DAY
	Haematemesis		Acetaminophen / Propoxyphene Hydrochloride	C				
			Budesonide	C				

			Dipyridamole	C		
			Ipratropium Bromide	C		

Date:11/14/00ISR Number: 3611789-3Report Type:Expedited (15-DaCompany Report #WAES 00115062
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Acetaminophen/Codeine Phosphate	C				
			Diltiazem Hydrochloride	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Ranitidine	C				
			Spironolactone	C				

Date:11/14/00ISR Number: 3611790-XReport Type:Expedited (15-DaCompany Report #WAES 00085149
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; PO	
		Other	Lansoprazole	SS		ORAL	30 MG; PO	
			Disopyramide	C				
			Thyroxine	C				

Date:11/14/00ISR Number: 3611794-7Report Type:Expedited (15-DaCompany Report #WAES 00109567
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG; PO 6 DAY		Other				

Date:11/14/00ISR Number: 3611796-0Report Type:Expedited (15-DaCompany Report #WAES 00107546
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema Peripheral Pain In Extremity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG						
			L-Thyroxine	C		
			Citalopram Hydrobromide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3611797-2Report Type:Expedited (15-DaCompany Report #WAES 00106171
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anuria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; PO	2 DAY
		Other	Furosemide	C				

Date:11/14/00ISR Number: 3611798-4Report Type:Expedited (15-DaCompany Report #WAES 00117009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY

Date:11/14/00ISR Number: 3611799-6Report Type:Expedited (15-DaCompany Report #WAES 00118510
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme Pyrexia Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Allopurinol	C				

Date:11/14/00ISR Number: 3611800-XReport Type:Expedited (15-DaCompany Report #WAES 00115030
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:11/14/00ISR Number: 3611801-1Report Type:Expedited (15-DaCompany Report #WAES 00095608
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis Vertigo	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Cozaar	C				
			Dihydralazine Sulfate (+) Hydrochlorothi	C				

Date:11/14/00ISR Number: 3611803-5Report Type:Expedited (15-DaCompany Report #WAES 00099147
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Csf Test Abnormal Dizziness Headache Malaise Meningitis Viral Pyrexia

		Syncope Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
2	DAY						
				Acetaminophen	C		
				Metoclopramide	C		

Date:11/14/00ISR Number: 3611805-9Report Type:Expedited (15-DaCompany Report #WAES 00106093
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG 8 DAY						
			Amiodarone Hydrochloride	C		
			Aspirin Lysine	C		
			Carbimazole	C		
			Fosinopril	C		
			Furosemide	C		

Date:11/14/00ISR Number: 3611808-4Report Type:Expedited (15-DaCompany Report #WAES 00106070
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Haematemesis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG 11 DAY						
			Benfluorex	C		
			Citalopram	C		
			Fenofibrate	C		
			Omeprazole	C		
			Piroxicam	C		

Date:11/14/00ISR Number: 3611810-2Report Type:Expedited (15-DaCompany Report #WAES 00095213
Age:44 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	109 DAY
			Acetaminophen/ Propoxyphene Hydrochloride	C				
			Dihydrocodeine	C				
			Ranitidine Hcl	C				
			Zopiclone	C				

Date:11/14/00ISR Number: 3611811-4Report Type:Expedited (15-DaCompany Report #WAES 00095055
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Gastrointestinal Haemorrhage Oesophageal Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	31 DAY

			Elavil	C		
			Timoptic	C		
			Amlodipine	C		
			Isosorbide Mononitrate	C		
			Omeprazole	C		
			Thyroxine	C		

Date:11/14/00ISR Number: 3611812-6Report Type:Expedited (15-DaCompany Report #A036271
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Feldene	PS	Pfizer Laboratories Div Pfizer Inc	INTRAMUSCULAR	2.00 ML	
Hospitalization - Initial or Prolonged	Fall	Health						
	Hypotension	Professional						
	Pruritus	Company						
	Pulse Absent	Representative	Rofecoxib	SS		ORAL	25.00 MG	TOTAL:DAILY:ORAL
			Propanolol Hcl	C				

Date:11/14/00ISR Number: 3611815-1Report Type:Expedited (15-DaCompany Report #WAES 00095083
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	26 DAY
			Aspirin (+) Isosorbide Mononitrate	C				
			Glyburide	C				
			Metformin	C				
			Ranitidine	C				

Date:11/14/00ISR Number: 3612065-5Report Type:Expedited (15-DaCompany Report #WAES 00110188
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
Other	Back Pain						PO	
	Cardiac Failure							
	Congestive							
			Celebrex	C				
			Ditropan	C				
			Klonopin	C				
			Relafen	C				
			Tylenol Pm	C				
			Voltaren	C				

Date:11/14/00ISR Number: 3612086-2Report Type:Expedited (15-DaCompany Report #WAES 00115056
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oesophageal Disorder	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

				Acetaminophen/Propoxyphene Hydrochloride	C		

Date:11/14/00ISR Number: 3612095-3Report Type:Expedited (15-DaCompany Report #WAES 00115086
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Allopurinol	C				
			Aspirin	C				
			Rantidine	C				

Date:11/14/00ISR Number: 3612096-5Report Type:Expedited (15-DaCompany Report #WAES 00115059
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	13 DAY
			Aspirin	C				
			Glyburide	C				
			Inositol Niacinate	C				
			Lansoprazole	C				
			Verapamil Hcl	C				

Date:11/14/00ISR Number: 3612177-6Report Type:Expedited (15-DaCompany Report #WAES 00081876
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Iron Decreased	Health	Fosamax	PS	Merck And Co Inc	ORAL	10 MG/AM/PO	
Hospitalization -	Diarrhoea	Professional	Tab Vioxx 12.5 Mg	SS		ORAL	12.5	

Initial or Prolonged	Dizziness		
MG/DAILY/PO;			
	Dyspepsia		
25 MG/BID/PO;			
	Faecal Occult Blood		
PO			
	Positive	Garlic Extract	C
	Faeces Discoloured	Ginkgo Biloba Extract	C
	Fatigue	Herbal Remedies	C
	Flatulence	Vitamin E	C
	Gastrointestinal	Vitamins	C
	Haemorrhage		
	Haematocrit Decreased		
	Haemoglobin Decreased		
	Headache		
	Insomnia		
	Mean Cell Volume Abnormal		
	Nausea		
	Pain		
	Pallor		
	Ulcer		
	Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3612231-9Report Type:Expedited (15-DaCompany Report #WAES 00091763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Dehydration	Health			Laboratories Div			
Other	Diarrhoea	Professional			Merck Co Inc	ORAL	50 MG/	
	Dizziness						DAILY/PO	
	Dyspepsia		Acular	C				
	Headache		Pred Forte	C				
			Timoptic-Xe	C				
			Xalatan	C				

Date:11/14/00ISR Number: 3612298-8Report Type:Expedited (15-DaCompany Report #WAES 00110029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Embolism	Consumer	Vioxx	PS	Merck Research			
	Eye Disorder				Laboratories Div			
	Fluid Retention				Merck Co Inc	ORAL	PO	
	Hypertension							
	Thrombosis							

Date:11/14/00ISR Number: 3612345-3Report Type:Expedited (15-DaCompany Report #WAES 00110565
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Vioxx	PS	Merck Research			
	Back Pain	Professional			Laboratories Div			
	Balance Disorder	Company			Merck Co Inc	ORAL	25 MG DAILY	
	Clonic Convulsion	Representative					PO	
	Dyskinesia		Ambien	C				
	Extrapyramidal Disorder							
	Eye Disorder							
	Fatigue							

Lethargy
Movement Disorder
Pupils Unequal

Date:11/14/00ISR Number: 3612346-5Report Type:Expedited (15-DaCompany Report #WAES 00110522
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
Other		Representative						
PO								
			Adlactone	C				
			Coumadin	C				
			Lasix	C				
			Prozac	C				
			Zestril	C				
			Digoxin	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3612347-7Report Type:Expedited (15-DaCompany Report #WAES 00102347
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gallbladder Perforation Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
			Naprosyn	C				
			Soma	C				
			Therapy Unspecified	C				
			Methadone Hydrochloride	C				

Date:11/14/00ISR Number: 3612348-9Report Type:Expedited (15-DaCompany Report #WAES 00081826
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial Thromboplastin Time Prolonged
Hospitalization - Initial or Prolonged	Anaemia
Disability	Anorexia
Other	Atelectasis
	Blood Chloride Increased
	Blood Glucose Increased
	Blood Magnesium Decreased
	Blood Phosphorus Decreased
	Blood Urea Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Depression
	Diarrhoea
	Dry Skin
	Duodenal Ulcer Haemorrhage
	Enzyme Abnormality
	Faeces Discoloured
	Fistula
	Haemoglobin Decreased

Hypocalcaemia
Hypokalaemia
Hypoproteinaemia
Hypotension
Leukocytosis
Liver Function Test
Abnormal
Melaena
Nausea
Pancreatic Disorder
Peptic Ulcer
Post Procedural
Complication
Prothrombin Time
Prolonged
Pyrexia
Rectal Haemorrhage
Tachycardia
Thrombocytopenia

	Upper Gastrointestinal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardizem	C				
			Hydrodiuril	C				
			Vicodin	C				
			Xalatan	C				
			Zocor	C				
			Therapy Unspecified	C				
			Aspirin	C				
			Metoprolol	C				
			Potassium Chloride	C				

Date:11/14/00ISR Number: 3612370-2Report Type:Expedited (15-DaCompany Report #WAES 00110603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Cardizem	C				
			Cardura	C				
			Trental	C				
			Vicodin Tablets	C				
			Zocor	C				

Date:11/14/00ISR Number: 3612375-1Report Type:Expedited (15-DaCompany Report #WAES 00110536
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Abdominal Pain Duodenal Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Perforation	Company			Merck Co Inc	ORAL
SEE IMAGE						
Disability		Representative	Tylenol With Codeine			
Other			#3	C		
			Vicodin Tablets	C		
			[Therapy			
			Unspecified]	C		

Date:11/14/00ISR Number: 3612376-3Report Type:Expedited (15-DaCompany Report #WAES 00052792
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Back Pain	Health			Laboratories Div	
	Condition Aggravated	Professional			Merck Co Inc	ORAL
12.5						
	Diverticulitis					
MG/DAILY/PO						
	Drug Ineffective		Ambien Unk	SS		
	Gastric Ulcer		[Therapy			
	Gastritis		Unspecified]	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/00ISR Number: 3620257-4Report Type:Periodic Company Report #20000300369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Prilosec	PS	Astrazeneca Lp	ORAL	PO	
	Condition Aggravated	Professional	Vioxx	SS				
	Drug Ineffective							

Date:11/14/00ISR Number: 3621259-4Report Type:Periodic Company Report #20000400371
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Prilosec	PS	Astrazeneca Lp	ORAL	QD PO	
	Depressed Mood	Professional	Paxil	SS		ORAL	60 MG QD PO	
	Pain		Vioxx	SS		ORAL	25 MG QD PO	
	Sedation		Tylenol Extra-Strength	SS				
			Immunoglobulin Human Normal	SS		INTRAVENOUS	30 GM IV	
			Effexor	SS		ORAL	TAB QD PO	
			Multivitamins	C				
			Premarin	C				

Date:11/16/00ISR Number: 3612883-3Report Type:Expedited (15-DaCompany Report #WAES 00105603
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Duodenal Ulcer	Health			Laboratories Div			
Initial or Prolonged	Gastroenteritis	Professional			Merck Co Inc	ORAL	12.5 MG PO	5 DAY
	Helicobacter	Other	Therapy Unspecified	C				
	Haemoglobin Decreased		Tetrazepam	C				
	Rectal Haemorrhage		Tramadol Hcl	C				

Tachycardia
Upper Gastrointestinal
Haemorrhage

Date:11/16/00ISR Number: 3612898-5Report Type:Expedited (15-DaCompany Report #WAES 00095572
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Bacterial Infection
Life-Threatening	Blood Creatinine Increased
	Bradycardia
	C-Reactive Protein Increased
	Cardiac Arrest
	Cardiac Failure
	Condition Aggravated
	Drug Interaction
	Epistaxis
	Erosive Oesophagitis
	Haematochezia
	Haemoglobin Decreased
	Hiatus Hernia
	Hypotension
	Leukopenia
	Mucosal Inflammation

	Nausea						
	Oedema						
	Oesophagitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain	Foreign	Vioxx	PS	Merck Research		
	Pancytopenia	Health			Laboratories Div		
	Pharyngeal Haemorrhage	Professional			Merck Co Inc	ORAL	25 MG 21 DAY
	Pyrexia	Other	Miethotrexate	SS			INTRAMUSCULAR 1 DAY
	Rheumatoid Factor		Methotrexate	SS			INTRAMUSCULAR 1 DAY
	Positive		Hctz/Triamterene	C			
	Sepsis		Khco3/K Citrate	C			
	Shock		Pepcid	C			
	Tachycardia		Aspirin	C			
	Thrombocytopenia		Calcium Carbonate (+) Cholecalciferol (+	C			
			Calcium Supplement	C			
			Cholecalciferol	C			
			Dipyrone	C			
			Folic Acid	C			
			...	C			
			Ibuprofen Lysine	C			
			Metoclopramide Hydrochloride	C			
			Nadroparin Calcium	C			
			Omeprazole Magnesium	C			
			...	C			

Date:11/16/00ISR Number: 3612901-2Report Type:Expedited (15-DaCompany Report #WAES 00105282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Duodenal Ulcer	Other			Laboratories Div		
	Haemorrhage				Merck Co Inc	ORAL	12.5-25 MG
	Gastroenteritis		Zocor	C			
	Helicobacter		Atenolol	C			
	Haemoglobin Decreased		Citalopram	C			
	Melaena		Clopidogrel	C			
			Dihydrocodeine	C			

				Nitroglycerin	C		

Date:11/16/00ISR Number: 3612903-6Report Type:Expedited (15-DaCompany Report #WAES 00119501
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia Myocardial Infarction Respiratory Arrest	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	1 DAY
	Sudden Death		Vasotec	C				
			Bisoprolol Fumarate	C				
			Clopamide	C				
			Isosorbide Mononitrate	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/00ISR Number: 3612939-5Report Type:Expedited (15-DaCompany Report #WAES 00110538
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antibody Test Positive Antiphospholipid Syndrome Coagulopathy Cough Haematocrit Decreased Haemoglobin Decreased Haemoptysis Hypertension Infection Leukopenia Lung Infiltration Lupus Nephritis Nephritis Nephrotic Syndrome Oedema Peripheral Pancytopenia Periodontal Disease Pneumonia Pneumonitis Rash Papular Renal Vein Thrombosis Systemic Lupus Erythematosus Thrombocytopenia Vasculitis Weight Increased	Health Professional Company Representative	Vioxx Plaquenil	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:11/16/00ISR Number: 3612953-XReport Type:Expedited (15-DaCompany Report #WAES 00110485
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/16/00ISR Number: 3612954-1Report Type:Expedited (15-DaCompany Report #WAES 00110719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastroenteritis Helicobacter Peptic Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lipitor	C				
			Toprol Xl	C				
			Naproxen	C				

Date:11/16/00ISR Number: 3612955-3Report Type:Expedited (15-DaCompany Report #WAES 00110826
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Other	Faeces Discoloured
	Gastric Haemorrhage
	Gastroenteritis
	Helicobacter

	Haemoglobin Decreased Hyperhidrosis Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO
			Aspirin	C			

Date:11/16/00ISR Number: 3612957-7Report Type:Expedited (15-DaCompany Report #WAES 00102555
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:11/16/00ISR Number: 3612959-0Report Type:Expedited (15-DaCompany Report #WAES 00110745
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthenia Fatigue Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Medical Device Complication		Darvocet-N	C			

Date:11/16/00ISR Number: 3612972-3Report Type:Expedited (15-DaCompany Report #WAES 00063187
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Disability	Arthralgia	Consumer	Vioxx	PS	Merck Research		
Other	Bronchospasm	Health			Laboratories Div		
	Cough	Professional			Merck Co Inc	ORAL	
12.5							
	Dyspnoea						
MG/DAILY/PO							
	Myalgia		Lipitor	C			
	Neuralgia		Premarin	C			
	Oedema		Prilosec	C			
	Pain		Soma	C			
	Paraesthesia		Sonata	C			
	Swelling		Zoloft	C			
	Viral Infection		Atenolol	C			
			Hydrocodone	C			
			Magnesium Sulfate	C			
			Verapamil Hydrochloride	C			

Date:11/16/00ISR Number: 3612982-6Report Type:Expedited (15-DaCompany Report #WAES 00110537
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
UNK/UNK/PO								
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/00ISR Number: 3612983-8Report Type:Expedited (15-DaCompany Report #WAES 00091894
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholelithiasis Liver Function Test Abnormal	Health Professional Company Representative	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:11/16/00ISR Number: 3612985-1Report Type:Expedited (15-DaCompany Report #WAES 00110632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:11/16/00ISR Number: 3613214-5Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Marrow Depression		Methotrexate	PS		ORAL	17.5MG Q WEEK	
Hospitalization -	Coma					ORAL		
Initial or Prolonged	Dehydration		Rofecoxib	SS		ORAL	12.5MG QD	
	Malnutrition					ORAL		
	Mouth Ulceration							
	Mucosal Inflammation							
	Mucosal Ulceration							
	Oral Candidiasis							
	Pain							
	Pancytopenia							
	Pyrexia							
	Tenderness							
	Tongue Ulceration							

Date:11/16/00ISR Number: 3614635-7Report Type:Expedited (15-DaCompany Report #00110280
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholelithiasis	Consumer	Enbrel 25 Mg	PS		SUBCUTANEOUS	25 MG, BIW, SUBCUTANEOUS	
	Decreased Appetite							
	Jaundice		Azathioprine	SS				
			Rofecoxib	SS				
			Hydrochlorothiazide	C				
			Lisinopril	C				
			Folic Acid	C				
			Ferrous Sulfate	C				
			Conj. Estrogens/Medroxyprogesterone	C				
			Ascorbic Acid	C				
			Tocopherol	C				
			"Centrum Silver" Multivitamins	C				
			Potassium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/00ISR Number: 3613250-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension		Vioxx	PS		ORAL	50MG PO Q D	

Date:11/17/00ISR Number: 3613400-4Report Type:Expedited (15-DaCompany Report #WAES 00091293
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Anaemia Diverticulum Diverticulum Intestinal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Dyspnoea Ecchymosis Fatigue Gastrointestinal Haemorrhage Haematocrit Decreased Haemorrhoids Hypotension Iron Deficiency Anaemia Microcytic Anaemia Pallor		Aspirin 81 Mg Aerobid Allegra Altace Chromagen Capsules Combivent Serevent Thyrolar Tiazac Xanax Zocor Nitroglycerin	SS C C C C C C C C C C C		ORAL	81 MG/DAILY/ PER ORAL	

Date:11/17/00ISR Number: 3613401-6Report Type:Expedited (15-DaCompany Report #WAES 00102397
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Dyspnoea	Company			Merck Co Inc	ORAL
25 MG/ DAILY/						
	Pulmonary Oedema	Representative				
PO						

Date:11/17/00ISR Number: 3613402-8Report Type:Expedited (15-DaCompany Report #WAES 00111025
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Haematocrit Decreased	Professional			Laboratories Div	
Other	Haemoglobin Decreased				Merck Co Inc	ORAL
PO						
	Upper Gastrointestinal		Covera-Hs	C		
	Haemorrhage		Plavix	C		

Date:11/17/00ISR Number: 3613447-8Report Type:Expedited (15-DaCompany Report #WAES 00118545
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Health			Laboratories Div	
	Gastrointestinal Ulcer	Professional			Merck Co Inc	
		Other	Urecholine	C		
			Acetaminophen/Codein e Phosphate	C		

Aspirin	C
Cyanocobalamin	C
Digoxin	C
Furosemide	C
Sertraline Hcl	C
Vitamin E	C

Date:11/17/00ISR Number: 3613448-XReport Type:Expedited (15-DaCompany Report #WAES 00115530
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased Hepatic Necrosis Hepatocellular Damage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Liver Disorder	Other	Corticosteroids (Unspecified)	C				

Date:11/20/00ISR Number: 3613972-XReport Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis		Vioxx (25mg)	PS		ORAL	OD PO	
Initial or Prolonged			Lotensin (20mg)	SS		ORAL	OD PO	

Date:11/20/00ISR Number: 3614158-5Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS		ORAL	ONCE ORAL	
	Dysphagia Dyspnoea Pruritus							

Date:11/20/00ISR Number: 3614689-8Report Type:Expedited (15-DaCompany Report #WAES 00091293
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum Intestinal	Consumer	Vioxx	PS	Merck Research			
Other	Dyspnoea	Health			Laboratories Div			
	Ecchymosis	Professional			Merck Co Inc	ORAL	50	
	Fatigue						MG/DAILY/PO	
	Gastrointestinal		Aerobid	C				
	Haemorrhage		Allegra	C				
	Haematocrit Decreased		Altace	C				
	Haemorrhoids		Chromagen Capsules	C				
	Hypotension		Combivent	C				
	Iron Deficiency Anaemia		Serevent	C				
	Microcytic Anaemia		Thyrolar	C				
	Pallor		Tiazac	C				
			Xanax	C				
			Zocor	C				
			Nitroglycerin	C				

Date:11/20/00ISR Number: 3614690-4Report Type:Expedited (15-DaCompany Report #WAES 00111025
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematocrit Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Other	Haemoglobin Decreased							
	Melaena							
	Upper Gastrointestinal Haemorrhage		Covera-Hs	C				
			Plavix	C				

Date:11/20/00ISR Number: 3614852-6Report Type:Expedited (15-DaCompany Report #WAES 00100791
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Rectal Haemorrhage							

Date:11/20/00ISR Number: 3614853-8Report Type:Expedited (15-DaCompany Report #WAES 00110606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/20/00ISR Number: 3614854-XReport Type:Expedited (15-DaCompany Report #WAES 00101626
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			
	Liver Function Test							

	Abnormal	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						

Date:11/20/00ISR Number: 3614856-3Report Type:Expedited (15-DaCompany Report #WAES 00102340
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Discomfort	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Chronic Obstructive Pulmonary Disease				Merck Co Inc	ORAL
25						
	Drug Interaction					
MG/DAILY/PO						
	Dysphonia		Coumadin	C		
	Dyspnoea		Norvasc	C		
	Face Oedema		Synthroid	C		
	Hyperthyroidism		Digoxin	C		
	Periorbital Oedema					
	Pulmonary Function Test Abnormal					
	Tachycardia					
	Temperature Intolerance					
	Thyroxine Increased					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3614874-5Report Type:Expedited (15-DaCompany Report #WAES 00020955
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Abnormal Faeces							
	Asthenia							
	Colitis		Synthroid	C				
	Embolism		Xalatan	C				
	Fatigue		Therapy Unspecified	C				
	Gastrointestinal Disorder							
	Headache							
	Myocardial Infarction							
	Thrombosis							

Date:11/20/00ISR Number: 3614899-XReport Type:Expedited (15-DaCompany Report #WAES 00111260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Dyspnoea							
	Fatigue		Levoxyl	C				
	Obesity							
	Sinus Congestion							
	Sinusitis							
	Vision Blurred							

Date:11/20/00ISR Number: 3614900-3Report Type:Expedited (15-DaCompany Report #WAES 00111202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Congestive							
	Oedema							
	Weight Increased							

Date:11/20/00ISR Number: 3614948-9Report Type:Expedited (15-DaCompany Report #WAES 00110610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypertension							
	Laboratory Test Abnormal							
	Oedema Peripheral							
	Renal Disorder		Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	
	Renal Impairment		Elavil	C				
			Maxzide	C				
			Folic Acid	C				
			Hydrocodone	C				
			Methotrexate	C				
			Prednisone	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3614950-7Report Type:Expedited (15-DaCompany Report #WAES 00110716
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Drug Ineffective							
	Feeling Abnormal							
	Suicidal Ideation							
	Upper Respiratory Tract Infection		Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/QOD/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:11/20/00ISR Number: 3614951-9Report Type:Expedited (15-DaCompany Report #WAES 00110898
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cardiac Failure Congestive	Other						
	Drug Ineffective		...	C		ORAL	PO	
	Feeling Abnormal		Accupril	C				
	Gastrointestinal Disorder		Bumex	C				
	Pain In Extremity		Celebrex	C				
			Inderide Tablets	C				
			Lescol	C				
			Prilosec	C				
			Relafen	C				
			Atenolol	C				
			Levothyroxine	C				

Date:11/20/00ISR Number: 3614952-0Report Type:Expedited (15-DaCompany Report #WAES 00111075
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:11/20/00ISR Number: 3614954-4Report Type:Expedited (15-DaCompany Report #WAES 00110906
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Monopril	C				
			Prozac	C				
			Allopurinol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/00ISR Number: 3614988-XReport Type:Expedited (15-DaCompany Report #WAES 00111042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alveolitis Allergic	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/20/00ISR Number: 3614989-1Report Type:Expedited (15-DaCompany Report #WAES 00111005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Zocor	C				
			(Therapy Unspecified)	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:11/20/00ISR Number: 3615164-7Report Type:Expedited (15-DaCompany Report #WAES 00055164
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspepsia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Loss Of Consciousness	Other						
	Malaise							
	Mitral Valve Stenosis		Dexamethasone	C				
	Nausea		Methotrexate	C				
	Red Blood Cell Sedimentation Rate Increased		Omeprazole	C				

Date:11/20/00ISR Number: 3615166-0Report Type:Expedited (15-DaCompany Report #WAES 00095569
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Duodenal Ulcer Haemorrhage Gastric Outlet Obstruction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO; 25 MG PO;	100 DAY
	Gastrointestinal Disorder		Methylprednisolone	SS		ORAL	8 MG, PO	920 DAY
	Haematocrit Decreased		Fosamax	C				
	Haemoglobin Decreased		Methotrexate	C				
	Vomiting		Ranitidine Hc1	C				
			Tramadol Hc1	C				

Date:11/20/00ISR Number: 3615168-4Report Type:Expedited (15-DaCompany Report #WAES 00088583
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hemiparesis Hypertensive Crisis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Estrogens, Conjugated	C		

Date:11/20/00ISR Number: 3615253-7Report Type:Expedited (15-DaCompany Report #WAES 00081651
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Blood Creatinine	Health			Laboratories Div	
Initial or Prolonged	Increased	Professional			Merck Co Inc	ORAL
25MG/DAILY/PO						
	Blood Urea Increased		Buspar	C		
	Haemodialysis		Glucophage	C		
	Nephritis Interstitial		Neurontin	C		
	Renal Failure Acute		Paxil	C		
			Ultram	C		
			Methadone Hydrochloride	C		

Date:11/20/00ISR Number: 3615254-9Report Type:Expedited (15-DaCompany Report #WAES 00082763
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Dizziness	Professional			Laboratories Div	
	Feeling Abnormal	Company			Merck Co Inc	ORAL
PRN/PO						
	Haemorrhagic Stroke	Representative	Hytrin	C		
	Headache		Lipitor	C		
			Prilosec	C		

Date:11/20/00ISR Number: 3615255-0Report Type:Expedited (15-DaCompany Report #WAES 00100014
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine	Health	Vioxx	PS	Merck Research	
	Increased	Professional			Laboratories Div	

	Blood Urea Increased	Company			Merck Co Inc	ORAL
PO						
	Renal Impairment	Representative				

Date:11/20/00ISR Number: 3615256-2Report Type:Expedited (15-DaCompany Report #WAES 00091406
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Pulmonary Oedema				Laboratories Div	
	Renal Failure Acute				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Celebrex	C		

Date:11/20/00ISR Number: 3615257-4Report Type:Expedited (15-DaCompany Report #WAES 00110188
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Cardiac Failure
Other	Congestive
	Dyspnoea

Fluid Retention

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Celebrex	C				
	Ditropan	C				
	Klonopin	C				
	Relafen	C				
	Tylenol Pm	C				
	Voltaren	C				

Date:11/20/00ISR Number: 3615362-2Report Type:Expedited (15-DaCompany Report #WAES 00116050
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25 MG	20 DAY
	Diarrhoea							
	Diverticulitis							
	Gastrointestinal Angiodysplasia							
	Pelvic Pain							

Date:11/20/00ISR Number: 3615363-4Report Type:Expedited (15-DaCompany Report #WAES 00116054
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Althiazide/Spironolactone	C				
			Cetirizine					

			Hydrochloride	C		

Date:11/20/00ISR Number: 3615364-6Report Type:Expedited (15-DaCompany Report #WAES 00115121
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Haemoglobin Decreased Melaena	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Amiloride Hydrochloride(+)			
			Furosemide	C		
			Digoxin	C		
			Glyburide	C		
			Metformin	C		

Dose	Duration
25.0 MG	82 DAY

Date:11/20/00ISR Number: 3615365-8Report Type:Expedited (15-DaCompany Report #WAES 00115113
Age:82 YR Gender:Female I/FU:I

Outcome	PT
Other	Confusional State Delirium

Hallucination

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	5 DAY

Date:11/20/00ISR Number: 3615367-1Report Type:Expedited (15-DaCompany Report #WAES 00106191
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			[Therapy Unspecified]	C				

Date:11/20/00ISR Number: 3615369-5Report Type:Expedited (15-DaCompany Report #WAES 00115089
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress Erythema Multiforme Rash Generalised	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 WKY MG	
			Clindamycin Hydrochloride	SS		INTRAVENOUS	2.7 GM	13 DAY
			Captopril	C				
			Estradiol	C				
			Floxacillin	C				
			Suriclone	C				

Date:11/20/00ISR Number: 3615396-8Report Type:Expedited (15-DaCompany Report #WAES 00085534
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/20/00ISR Number: 3615398-1Report Type:Expedited (15-DaCompany Report #WAES 00085533
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/20/00ISR Number: 3615401-9Report Type:Expedited (15-DaCompany Report #WAES 00115558
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Study Health

Professional
Other

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	78 DAY
Nifedipine	C				
Torsemide	C				

Date:11/20/00ISR Number: 3615402-0Report Type:Expedited (15-DaCompany Report #WAES 00119111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional Other	Anticoagulant, Nos	SS		ORAL		

Date:11/20/00ISR Number: 3615403-2Report Type:Expedited (15-DaCompany Report #WAES 00117275
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	4 DAY
			Acetaminophen	C				
			Allopurinol	C				
			Anastrozole	C				
			Calcium Carbonate (+) Etidronate Sodium	C				
			Cyancobalamin	C				
			Cyclizine	C				
			Doxazosin Mesylate	C				
			Furosemide	C				
			Ketobemidone Hcl	C				
			Morphine	C				
			Picosulfate Na	C				

			Warfarin Sodium	C		

Date:11/20/00ISR Number: 3615404-4Report Type:Expedited (15-DaCompany Report #WAES 00115541
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adenoma Benign Anorexia Cystocele Endometrial Hyperplasia Gastric Haemorrhage Gastritis Erosive Haemoglobin Decreased Pancreatic Pseudocyst Pyrexia Sepsis Urinary Tract Infection Vaginal Prolapse Weight Decreased	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Date:11/20/00ISR Number: 3616706-8Report Type:Expedited (15-DaCompany Report #WAES 00106191
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign Study Health Professional Other	Vioxx (Therapy Unspecified)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

Date:11/20/00ISR Number: 3616721-4Report Type:Expedited (15-DaCompany Report #WAES 00116054
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Althiazide / Spironolactone	C				
			Cetirizine Hydrochloride	C				

Date:11/21/00ISR Number: 3615501-3Report Type:Expedited (15-DaCompany Report #WAES 00041370
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Mass	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Blood Creatinine Increased							
	Blood Immunoglobulin G Decreased		Tab Cozaar Unk	SS		ORAL	PO	
	Blood Immunoglobulin M Decreased		Zocor	C				
	Calcinosis							
	Electrophoresis Abnormal							

Hypoproteinaemia
Nephrectomy
Nephrotic Syndrome
Periorbital Oedema
Proteinuria
Renal Cell Carcinoma
Stage Unspecified
Renal Failure Acute
Renal Scan Abnormal
Urinary Casts
Urine Analysis Abnormal

Date:11/21/00ISR Number: 3615503-7Report Type:Expedited (15-DaCompany Report #WAES 00080069
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Attention
Disability	Deficit/Hyperactivity
	Disorder
	Feeling Abnormal
	Feeling Cold
	Hypoaesthesia
	Nervousness
	Panic Disorder Without

Agoraphobia
Paraesthesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Vitamins (Unspecified)	C				

Date:11/21/00ISR Number: 3615505-0Report Type:Expedited (15-DaCompany Report #WAES 00102555
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:11/21/00ISR Number: 3615538-4Report Type:Expedited (15-DaCompany Report #WAES 00111178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:11/21/00ISR Number: 3615550-5Report Type:Expedited (15-DaCompany Report #WAES 00111186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Phosphokinase Increased				Laboratories Div	
	Rhabdomyolysis				Merck Co Inc	ORAL
25 MG BID PO						

Date:11/21/00ISR Number: 3615553-0Report Type:Expedited (15-DaCompany Report #WAES 00111014
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dialysis	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Disorientation	Professional			Laboratories Div	
	Renal Failure				Merck Co Inc	ORAL
PO						

Date:11/21/00ISR Number: 3615582-7Report Type:Expedited (15-DaCompany Report #WAES 00061981
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Study	Vioxx	PS	Merck Research	
Initial or Prolonged	Asthenia	Health			Laboratories Div	
	Faeces Discoloured	Professional			Merck Co Inc	ORAL
25						
	Gastric Ulcer Haemorrhage					
MG/DAILY/PO						
	Gastrointestinal		Tab Aspirin	SS		ORAL
325						
	Haemorrhage					
MG/DAILY/PO						
	Haemoglobin Decreased		Tab Advil	SS		ORAL
200						
	Vomiting					
MG/DAILY/PO						
			Coreg	C		

		Blinded Therapy	C
		Bumetanide	C
		Donepezil Hydrochloride	C
		Enalapril	C
		Vitamins	C

Date:11/21/00ISR Number: 3615722-XReport Type:Expedited (15-DaCompany Report #WAES 00113730
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haemorrhagic Peptic Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	24 DAY
		Other	Atenolol	C				
			Betahistine	C				
			Carbaspirin Calcium	C				
			Furosemide	C				
			Glicazide	C				
			Mirtazapine	C				

Date:11/21/00ISR Number: 3615723-1Report Type:Expedited (15-DaCompany Report #WAES 00115126
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	5 DAY
			Aspirin	C				
			Etidronate Disodium	C				

Date:11/21/00ISR Number: 3616657-9Report Type:Expedited (15-DaCompany Report #WAES 00109569
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Oedema Peripheral	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG PO						
			Calcium	C		
			Diuretic/Antihypertensive, Nos	C		
			Etidronic Acid Dina	C		

Date:11/21/00ISR Number: 3616716-0Report Type:Expedited (15-DaCompany Report #WAES 00086140
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anorexia	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Asthenia	Health			Laboratories Div	
	Fatigue	Professional			Merck Co Inc	ORAL
12.5 MG PO 19 DAY						
	Hyponatraemia		Acenocoumarol	C		
			Diltiazem Hydrochloride	C		
			Hydroxychloroquineso 4	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/00ISR Number: 3617557-0Report Type:Expedited (15-DaCompany Report #WAES 00111005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Zocor	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:11/21/00ISR Number: 3624972-8Report Type:Periodic Company Report #S00-USA-01422-01
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional	Celexa	PS	Forest Laboratories Inc			
	Dizziness	Company Representative	Vioxx	SS				

Date:11/22/00ISR Number: 3615368-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred		Vioxx 25mg Qd	PS		ORAL	25MG PO QD	
			Mvi	C				
			Colace	C				
			Folic Acid	C				
			Ecotrin	C				
			Percocet	C				
			Ambien	C				
			Bactrim	C				
			Vit E	C				
			Vicodin	C				

Date:11/22/00ISR Number: 3615385-3Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alveolitis Allergic		Vioxx (Msd) Tablet	PS	Msd	ORAL	12-15 MG PO	
Initial or Prolonged	Dermatitis						DAILY	30 DAY
	Dyspnoea							
	Eosinophil Count Increased							
	Hypoxia							
	Lung Infiltration							
	Pain							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/00ISR Number: 3615386-5Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum		Vioxx Tablets Msd	PS	Msd		DOSE ? DAILY	
Initial or Prolonged	Gastrointestinal Haemorrhage							

Date:11/22/00ISR Number: 3615387-7Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum		Vioxx Tablets Msd	PS	Msd	ORAL	25 MG PO	
Initial or Prolonged	Gastrointestinal Haemorrhage						DAILY	

Date:11/22/00ISR Number: 3615389-0Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS				
Initial or Prolonged	Haematemesis		Folic Acid	C				
	Melaena		Aldactone	C				
			Detrol	C				
			Premarin	C				
			Inderal	C				

Date:11/22/00ISR Number: 3615476-7Report Type:Direct Company Report #
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Increased		Vioxx	PS		ORAL	PO	
Initial or Prolonged	Blood Urea Increased		Carbamazapine	SS				

Confusional State
Dermatitis
Haemodialysis
Mental Impairment
Nephritis Interstitial

Date:11/22/00ISR Number: 3615500-1Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Fatigue							
	Oliguria							
	Renal Failure Acute							

Date:11/22/00ISR Number: 3616437-4Report Type:Expedited (15-DaCompany Report #WAES 00105089
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Duodenal Ulcer	Other			Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	12.5 MG	20 DAY
	Oesophagitis		Aspirin	SS		ORAL	75 MG	
			Doxazosin	C				

Glimepiride C

Date:11/24/00ISR Number: 3616364-2Report Type:Expedited (15-DaCompany Report #WAES 00111229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Zocor	C				

Date:11/24/00ISR Number: 3616366-6Report Type:Expedited (15-DaCompany Report #WAES 00111446
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Xenical	SS			120 MG/DAILY/UNK	

Date:11/24/00ISR Number: 3616371-XReport Type:Expedited (15-DaCompany Report #WAES 00111578
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Haemorrhagic Stroke	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:11/24/00ISR Number: 3616373-3Report Type:Expedited (15-DaCompany Report #WAES 00111470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:11/24/00ISR Number: 3616375-7Report Type:Expedited (15-DaCompany Report #WAES 00111588
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration Dialysis Hypovolaemic Shock Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:11/24/00ISR Number: 3616471-4Report Type:Expedited (15-DaCompany Report #WAES 00111608
Age:85 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Other	Abdominal Tenderness Anaemia Asthenia Blood Urea Increased Cardiac Murmur

		Emotional Distress Faeces Discoloured Gastric Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis Haemoglobin Decreased Nausea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY;							
		Pallor	Representative				
PO							
		Pyrexia		Cardura	C		
				K-Dur	C		
				Lasix	C		
				Plavix	C		
				Prevacid	C		
				Synthroid	C		
				Tiazac	C		
				Zestril	C		

Date:11/24/00ISR Number: 3616480-5Report Type:Expedited (15-DaCompany Report #WAES 00111498
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Advil	C		

Date:11/24/00ISR Number: 3616481-7Report Type:Expedited (15-DaCompany Report #WAES 00111479
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Rectal Haemorrhage Weight Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						

Date:11/24/00ISR Number: 3616482-9Report Type:Expedited (15-DaCompany Report #WAES 00111327
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				
			Pravachol	C				
			Trilisate Tablets/Liquid	C				

Date:11/24/00ISR Number: 3616483-0Report Type:Expedited (15-DaCompany Report #WAES 00111199
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/00ISR Number: 3616484-2Report Type:Expedited (15-DaCompany Report #WAES 00111037
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO; 50 MG/PO	
			Avapro	C				
			Lasix	C				
			Tambocor	C				

Date:11/24/00ISR Number: 3616485-4Report Type:Expedited (15-DaCompany Report #WAES 00110185
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Creatinine Increased Haemodialysis Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Flomax	C				

Date:11/24/00ISR Number: 3616487-8Report Type:Expedited (15-DaCompany Report #WAES 00102525
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated Renal Failure Acute Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coreg	C				
			Diuril	C				
			Amlodipine	C				
			Aspirin	C				

			Dobutamine	C		
			Furosemide	C		
			Glipizide	C		
			Isosorbide Mononitrate	C		
			Nitroglycerin	C		

Date:11/24/00ISR Number: 3616520-3Report Type:Expedited (15-DaCompany Report #1459391A
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Mb Increased	Study Health Professional	Rofecoxib	PS	Mcneil Consumer Healthcare	ORAL	12.5 MG/OD, PO	26 DAY
Other	Cardiac Enzymes Increased		Aspirin	C				
	Cardiomegaly		Multi-Vitamin	C				
	Chest Pain		Felodipine	C				
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Dyspnoea							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/00ISR Number: 3616530-6Report Type:Expedited (15-DaCompany Report #WAES 00102535
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Miacalcin	C				
			Mylanta & Mylanta Ds	C				
			Os-Cal	C				
			Premarin	C				
			Prilosec	C				
			Tylenol	C				

Date:11/24/00ISR Number: 3616754-8Report Type:Expedited (15-DaCompany Report #WAES 00111619
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Anaemia Asthenia Difficulty In Walking Emotional Distress Haematemesis Haemoglobin Decreased Mallory-Weiss Syndrome Oesophageal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Maxzide	C				
			Plavix	C				
			Tylenol	C				
			Visken	C				
			Zyloprim	C				
			Aspirin	C				

Date:11/24/00ISR Number: 3616755-XReport Type:Expedited (15-DaCompany Report #WAES 00111190
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Accolate	C		
			Bactrim	C		
			Betagen	C		
			Prilosec	C		
			Serevent	C		

Date:11/24/00ISR Number: 3616756-1Report Type:Expedited (15-DaCompany Report #WAES 00111024
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blister	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
	Constipation					
	Disorientation					
	Hypertension		Relafen	C		
	Iiird Nerve Paralysis		Zestril	C		
	Muscular Weakness		Atenolol	C		
			Pilocarpine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/00ISR Number: 3616758-5Report Type:Expedited (15-DaCompany Report #WAES 00110994
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute Vasculitis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/24/00ISR Number: 3616760-3Report Type:Expedited (15-DaCompany Report #1459893A
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenocarcinoma Benign Neoplasm Of Adrenal Gland	Study Health Professional	Rofecoxib	PS	Mcneil Consumer Healthcare	ORAL	12.5 MG, OD, PO	29 DAY
	Crepitations Dyspnoea Mass Non-Small Cell Lung Cancer Pleural Effusion Pneumothorax Throat Cancer		Furosemide Zestril Kcl Hytrin Catapres Asa Nicotine Transdermal Patch Albuterol Inhaler Ipratropium Inhaler	C C C C C C C C C				

Date:11/24/00ISR Number: 3616764-0Report Type:Expedited (15-DaCompany Report #1459717A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Disorder Cardiac Enzymes Increased Chest Pain	Study Health Professional	Rofecoxib	PS	Mcneil Consumer Healthcare	ORAL	12.5 MG, OD, PO	25 DAY
	Coronary Artery Occlusion Dyspnoea		Levothyroxine	C				

Dyspnoea Exertional
Ejection Fraction
Abnormal
Electrocardiogram
Abnormal
Hypokinesia
Myocardial Infarction
Palpitations

Date:11/24/00ISR Number: 3616766-4Report Type:Expedited (15-DaCompany Report #WAES 00091692
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Disability	Cerebrovascular Accident	Health Professional Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/00ISR Number: 3616767-6Report Type:Expedited (15-DaCompany Report #WAES 00100718
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Face Oedema	Health			Laboratories Div			
	Headache	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
	Oedema Peripheral		Dyazide	C				
			Lotronex	C				
			Zoloft	C				
			Trazodone	C				

Date:11/24/00ISR Number: 3616923-7Report Type:Expedited (15-DaCompany Report #WAES 00118113
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Foreign	Vioxx	PS	Merck Research			
	Melaena	Health			Laboratories Div			
	Upper Gastrointestinal	Professional			Merck Co Inc	ORAL	25 MG	2 DAY
	Haemorrhage	Other						

Date:11/24/00ISR Number: 3616925-0Report Type:Expedited (15-DaCompany Report #WAES 00116064
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG	3 DAY
		Other	Ibuprofen	SS		ORAL	1200 MG	
			Irbesartan	C				
			Metformin	C				
			Trimetazidine	C				

Date:11/24/00ISR Number: 3616928-6Report Type:Expedited (15-DaCompany Report #WAES 00115153
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Fatigue	Health						
	Lethargy	Professional						
	Sensation Of Heaviness	Other						

Date:11/24/00ISR Number: 3616930-4Report Type:Expedited (15-DaCompany Report #WAES 00115168
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyperhidrosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	183 DAY
	Pallor	Other						
	Tremor							
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Diazepam	C				
			Erythromycin	C				
			Estrogens, Conjugated (+)					
			Medroxyprogest	C				

Date:11/24/00ISR Number: 3616932-8Report Type:Expedited (15-DaCompany Report #WAES 00113740
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:11/24/00ISR Number: 3616934-1Report Type:Expedited (15-DaCompany Report #WAES 00115185
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ulcerative	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Amiloride Hydrochloride (+)					
			Bumetanide	C				
			Aspirin	C				
			Fluoxetine	C				
			Propranolol	C				
			Temazepam	C				

Date:11/24/00ISR Number: 3616935-3Report Type:Expedited (15-DaCompany Report #WAES 00115089
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress Erythema Multiforme Rash Generalised	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
		Other	Clindamycin Hydrochloride	SS			INTRAVENOUS	2.7 GM 13 DAY
			Captopril	C				
			Estradiol	C				
			Floxacillin	C				
			Suriclone	C				

			Tramadol Hcl	C		

Date:11/24/00ISR Number: 3616936-5Report Type:Expedited (15-DaCompany Report #WAES 00115195
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Perforation	Other			Laboratories Div	
Initial or Prolonged	Peritonitis				Merck Co Inc	ORAL
12.5 MG; 25						
MG 63 DAY						
			Acetaminophen	C		
			Bendroflumethiazide	C		
			Captopril	C		
			Nitrazepam	C		
			Tamoxifen	C		
			Trimethoprim	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/00ISR Number: 3616947-XReport Type:Expedited (15-DaCompany Report #WAES 00096155
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema	Foreign	Vioxx	PS	Merck Research			
	Pain	Health			Laboratories Div			
	Tendon Disorder	Professional			Merck Co Inc	ORAL	25 MG PO	22 DAY
	Tendonitis		Thyroxine	C				

Date:11/24/00ISR Number: 3616953-5Report Type:Expedited (15-DaCompany Report #WAES 00108613
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG PO	
			Lamotrigine	C				

Date:11/24/00ISR Number: 3617015-3Report Type:Expedited (15-DaCompany Report #WAES 00116101
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Anaemia	Study			Laboratories Div			
	Gastric Ulcer Haemorrhage	Health			Merck Co Inc	ORAL	12.5 MG PO	
		Professional						
(SEE IMAGE)							125 DAY	
			Benazepril Hcl/Hctz	C				
			Fluoxetine	C				
			Thyroxine	C				

Date:11/24/00ISR Number: 3617152-3Report Type:Expedited (15-DaCompany Report #WAES 00118109
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	28 DAY

Date:11/24/00ISR Number: 3617155-9Report Type:Expedited (15-DaCompany Report #WAES 00119508
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY

Date:11/24/00ISR Number: 3617160-2Report Type:Expedited (15-DaCompany Report #WAES 00113739
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY
			Insulin Human, Isophane	C				
			Insulin, Neutral	C				

Date:11/24/00ISR Number: 3617162-6Report Type:Expedited (15-DaCompany Report #WAES 00115054
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure Congestive Crepitations	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	10 DAY
	Dyspnoea		Acetaminophen / Prophoxyphene Hydrochloride	C				
			Amiloride Hydrochloride (+) Furosemide	C				
			Amlodipine Besylate	C				
			Aspirin	C				
			Warfarin	C				

Date:11/24/00ISR Number: 3617165-1Report Type:Expedited (15-DaCompany Report #WAES 00116065
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Erythropenia Faeces Discoloured	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	2 DAY
	Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased							

Date:11/24/00ISR Number: 3617168-7Report Type:Expedited (15-DaCompany Report #WAES 00115099
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Petechiae Platelet Count Decreased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	19 DAY
			Acetaminophen /					

Codeine Phosphate	C
Aspirin	C
Furosemide	C
Ranitidine	C

Date:11/24/00ISR Number: 3617170-5Report Type:Expedited (15-DaCompany Report #WAES 00118114
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Dysuria Myalgia Oedema Peripheral Pollakiuria Polyuria Pyrexia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3616276-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx 25mg Msd	PS	Msd	ORAL	25MG DAILY	
Hospitalization -								
ORAL								
Initial or Prolonged			Metoprolol	C				
Disability			Smz-Tmp	C				
Required			Zoloft	C				
Intervention to			Cozaar	C				
Prevent Permanent			Lorazepam	C				
Impairment/Damage								

Date:11/27/00ISR Number: 3616314-9Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx Mfr By Merck					
Disability	Dermatitis		25mg (30 Tablets)	PS	Merck			
ONE A DAY								
	Hypoaesthesia							
FROM 7-6-00								
	Oedema Peripheral							
TO JULY								
21,2000								
			Cyclobenzaprine	C				

Date:11/27/00ISR Number: 3617037-2Report Type:Expedited (15-DaCompany Report #WAES 00072175
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research			
	Face Oedema	Health			Laboratories Div			
	Pharyngeal Oedema	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Throat Tightness							
PO								

			Azmacort	C		
			Flonase	C		
			Pulmicort	C		
			Tegretol	C		
			Tylenol	C		
			Vasotec	C		
			Viagra	C		
			Acetaminophen (+)			
			Hydrocodone Bi	C		
			Aspirin	C		
			Trazodone	C		
			Triamcinolone	C		

Date:11/27/00ISR Number: 3617040-2Report Type:Expedited (15-DaCompany Report #WAES 00080473
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Chest Pain	Professional			Laboratories Div			
Initial or Prolonged	Condition Aggravated	Company			Merck Co Inc	ORAL	50 MG DAILY	
Other	Costochondritis	Representative					PO	
	Hypertension		Celebrex	C				
	Rash Erythematous		Lasix	C				
	Transient Ischaemic		Micro K	C				
	Attack		Norvasc	C				
	Visual Disturbance		Zocor	C				
			Clonidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3617049-9Report Type:Expedited (15-DaCompany Report #WAES 00082926
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research			
	Breath Sounds Decreased	Health			Laboratories Div			
	Cough	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Dyspnoea Exertional						PO	
	Muscle Injury		Claritin-D	C				
	Oedema Peripheral		Prometrium	C				
	Pain		Relafen	C				
	Stress		Zoloft	C				

Date:11/27/00ISR Number: 3617052-9Report Type:Expedited (15-DaCompany Report #WAES 00092337
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Acute Respiratory	Professional			Laboratories Div			
Initial or Prolonged	Distress Syndrome	Company			Merck Co Inc	ORAL	25 MG DAILY	
Disability	Duodenal Ulcer	Representative					PO	
Other	Perforation							
	Hypotension							
	Sepsis							

Date:11/27/00ISR Number: 3617072-4Report Type:Expedited (15-DaCompany Report #WAES 00111416
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Vioxx	PS	Merck Research			
Other	Cardiac Pacemaker	Professional			Laboratories Div			
	Insertion	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Dialysis	Representative					PO	
	Hyperkalaemia		Glucophage	C				

	Renal Failure		Maxzide	C
			Norvasc	C
			Tenormin	C
			Zocor	C

Date:11/27/00ISR Number: 3617074-8Report Type:Expedited (15-DaCompany Report #WAES 00110106
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriovenous Malformation	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Condition Aggravated	Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Diverticulum Intestinal	Representative					PO	
	Haemorrhagic		Nonsteroidal					
	Faecal Occult Blood		Anti-Inflammatory	C				
	Gastrointestinal Haemorrhage							

Date:11/27/00ISR Number: 3617075-XReport Type:Expedited (15-DaCompany Report #WAES 00082266
Age:32 YR Gender:Female I/FU:F

Outcome	PT
	Condition Aggravated
	Dyspepsia

	Malaise Pain Polyarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY / PO
			Celebrex	C			

Date:11/27/00ISR Number: 3617077-3Report Type:Expedited (15-DaCompany Report #WAES 00091692
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Haemorrhagic Stroke	Health Professional Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / BID / PO

Date:11/27/00ISR Number: 3617078-5Report Type:Expedited (15-DaCompany Report #WAES 00100791
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspepsia Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO

Date:11/27/00ISR Number: 3617080-3Report Type:Expedited (15-DaCompany Report #WAES 00102555
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	

Date:11/27/00ISR Number: 3617090-6Report Type:Expedited (15-DaCompany Report #WAES 00080472
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Failure Congestive Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Oedema							
	Orthopnoea		Tab Vioxx	SS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Prevacid	C				
			Serzone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3617195-XReport Type:Expedited (15-DaCompany Report #WAES 00119754
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal Stevens-Johnson Syndrome	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:11/27/00ISR Number: 3617197-3Report Type:Expedited (15-DaCompany Report #WAES 00115148
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena Rectal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	11 DAY

Date:11/27/00ISR Number: 3617199-7Report Type:Expedited (15-DaCompany Report #WAES 00115568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemolysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	46 DAY
			Prednisolone	C				

Date:11/27/00ISR Number: 3617215-2Report Type:Expedited (15-DaCompany Report #WAES 00075636
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Acidosis Blood Urea Increased Coagulopathy	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	16 DAY

	Collagen Disorder	Mesalamine	SS	ORAL 1500 MG PO
	Connective Tissue Disorder	Diclofenac	C	
		Dipyrone	C	
	Convulsion	Methotrexate	C	
	Diplopia	Prednisone	C	
	Drug Interaction	Tramadol Hcl	C	
	Drug Toxicity			
	Hypokalaemia			
	Hypothyroidism			
	Meningism			
	Metabolic Acidosis			
	Nervous System Disorder			
	Prothrombin Time Prolonged			
	Renal Impairment			
	Sedation			
	Systemic Lupus Erythematosus			
	Therapeutic Agent Toxicity			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/00ISR Number: 3617216-4Report Type:Expedited (15-DaCompany Report #WAES 00115124
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Rash Erythematous	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	15 DAY
			Oxybutynin Cl	C				

Date:11/27/00ISR Number: 3617218-8Report Type:Expedited (15-DaCompany Report #WAES 00116046
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulitis Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Haemoglobin Decreased Haemorrhage Haemorrhoids Rectal Haemorrhage		Acetaminophen (+) Dextropropoxyphene Serenoa Repens Trimetazidine Hydrochloride Zopiclone	C C C C				

Date:11/27/00ISR Number: 3617231-0Report Type:Expedited (15-DaCompany Report #WAES 00111432
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal Disorder Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/27/00ISR Number: 3617233-4Report Type:Expedited (15-DaCompany Report #WAES 00101943
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Test Abnormal Pain Rheumatoid Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Vision Blurred		Hydrochlorothiazide (+) Triamter	C				

Date:11/27/00ISR Number: 3617242-5Report Type:Expedited (15-DaCompany Report #WAES 00101559
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Blood Creatinine Increased Blood Urea Increased Dizziness Dyspnoea Faecal Occult Blood Positive Gastrointestinal Haemorrhage Haematemesis Haematocrit Decreased

	Haemoglobin Decreased						
	Hypotension						
	International Normalised	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ratio Increased	Consumer	Vioxx	PS	Merck Research			
	Melaena	Health			Laboratories Div			
	Myocardial Infarction	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Nausea						PO	
	Prothrombin Time		Tab Celebrex	SS			100 MG BID	
	Prolonged		Coumadin	SS				
	Thrombocytopenia		Ultram	SS			PRN	
			Accupril	C				
			Ecotrin	C				
			Lasix	C				
			Lipitor	C				
			Lopressor	C				
			Norvasc	C				
			Prilosec	C				
			Allopurinol	C				
			Dimenhydrinate	C				
			Quinidine	C				

Date:11/27/00ISR Number: 3617250-4Report Type:Expedited (15-DaCompany Report #A030241
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis	Foreign	Zoloft	PS	Pfizer			
Initial or Prolonged	Fatigue	Other			Pharmaceuticals Inc	ORAL	ORAL	
	Hepatic Cirrhosis		Remicade	SS			INTRAVENOUS	INTRAVENOUS
	Hepatic Fibrosis		Omeprazole	SS				
	Hepatic Function Abnormal		Rofecoxib	SS			25.00 MG	
	Hepatic Steatosis						TOTAL: DAILY	
	Inflammation		Methotrexate	C				
	Jaundice		Folacin	C				
	Nausea		Daonil	C				
	Pruritus							

Date:11/27/00ISR Number: 3617302-9Report Type:Expedited (15-DaCompany Report #WAES 00096104
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Hallucination, Visual	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO (SEE IMAGE)	1 DAY
			Benserazide/Levodopa	C				
			Bepridil Hydrochloride	C				
			Bromazepam	C				
			Citalopram Hydrobromide	C				
			Ropinirole Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/00ISR Number: 3616690-7Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alanine Aminotransferase	Health	Tasmar	PS	Roche	
	Increased	Professional	Vioxx	SS		
27 DAY						
	Anxiety		Aciphex	C		
	Aspartate		Sinemet	C		
	Aminotransferase		Sinemet Cr	C		
	Increased		Mirapex	C		
	Hallucination		Unknown Medication			
	Pain In Extremity		Nos	C		
REPORTED AS						
	Refusal Of Treatment By					
PUDITINE.						
	Patient		Vitamin E	C		
			Coenzyme Q10	C		
			Vitamin C	C		
			Nadh	C		

Date:11/28/00ISR Number: 3616703-2Report Type:Expedited (15-DaCompany Report #249457
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Confusional State	Consumer	Diazepam	PS	Roche	
	Haematemesis		Vioxx	SS		
90 DAY						
	Hyperkalaemia		Dihydrocodeine	SS		
	Sedation		Nefopam			
	Sepsis		Hydrochloride	SS		
			Acetaminophen	C		
			Atorvastatin	C		
			Cetirizine	C		
			Crotamiton	C		
			Floxacillin	C		
			Folic Acid	C		
			Lactulose	C		
			Metronidazole	C		
			Loperamide	C		
			Nifedipine	C		
			Vancomycin	C		
			Amoxicillin			

				Trihydrate	C		

Date:11/28/00ISR Number: 3617693-9Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Alanine Aminotransferase		Tasmar	PS	Roche	
	Increased		Vioxx	SS		
27 DAY						
	Anxiety		Aciphex	C		
	Aspartate		Sinemet	C		
	Aminotransferase		Sinemet Cr	C		
	Increased		Mirapex	C		
	Hallucination		Unknown Medication			
	Pain In Extremity		Nos	C		
REPORTED AS						
PUDITINE.						
			Vitamin E	C		
			Coenzyme Q10	C		
			Vitamin C	C		
			Nadh	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/00ISR Number: 3617711-8Report Type:Expedited (15-DaCompany Report #249457
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Confusional State		Diazepam	PS	Roche	
	Haematemesis		Vioxx	SS		
90 DAY						
	Hyperkalaemia		Dihydrocodeine	SS		
	Hypertension		Nefopam			
	Sedation		Hydrochloride	SS		
	Sepsis		Acetaminophen	C		
			Atorvastatin	C		
			Cetirizine	C		
			Crotamiton	C		
			Floxacillin	C		
			Folic Acid	C		
			Lactulose	C		
			Metronidazole	C		
			Loperamide	C		
			Nifedipine	C		
			Vancomycin	C		
			Amoxicillin Trihydrate	C		

Date:11/28/00ISR Number: 3618026-4Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx Merck & Co	PS	Merck & Co	
1 A DAY 50 MG 3 WK						
Initial or Prolonged						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:11/28/00ISR Number: 3618115-4Report Type:Expedited (15-DaCompany Report #245702
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Anxiety Condition Aggravated Hallucination Liver Function Test Abnormal Pain In Extremity	Health Professional	Tasmar	PS	Hoffmann La Roche Inc	ORAL 100 MG 3 PER DAY ORAL
			Vioxx (Rofecoxib) 25 Mg	SS		ORAL 25 MG DAILY ORAL
			Aciphex (Rabeprazole Sodium)	C		
			Sinemet (Carbidopa / Levodopa)	C		
			Mirapex (Pramipexole)	C		
			Unknown Medication Nos (Generic Component(S)	C		
			Vitamin E (Vitamin E)	C		
			Coenzyme Q 10 (Ubidecarenone)	C		
			Vitamin C (Ascorbic Acid)	C		
			Nadh (Nadide)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/00ISR Number: 3618183-XReport Type:Expedited (15-DaCompany Report #WAES 00118619
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Dizziness Feeling Jittery	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	27 DAY
	Hyperglycaemia Tremor	Company Representative	Albuterol Sulfate Clarithromycin Prednisone Zafirlukast	C C C C				

Date:11/28/00ISR Number: 3618184-1Report Type:Expedited (15-DaCompany Report #WAES 00118623
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Company Representative	Therapy Unspecified Diltiazem Hydrochloride Isosorbide Dinitrate Nitroglycerin	C C C C				

Date:11/28/00ISR Number: 3618248-2Report Type:Expedited (15-DaCompany Report #249457
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Confusional State Haematemesis Hyperkalaemia Hypertension Sedation Sepsis	Foreign Other	Valium Vioxx (Rofecoxib) Dihydrocodeine (Dihydrocodeine	PS SS	Hoffmann La Roche Inc	ORAL ORAL	2 MG 1 PER PRN ORAL 25 MG ORAL	

	Bitartrate)	SS	ORAL
120 MG ORAL			
	Nefopam Hydrochloride (Nefopam Hydrochloride)	SS	ORAL
90 MG DAILY			
ORAL			
	Acetaminophen	C	
	Atorvastatin	C	
	Cetirizine	C	
	Crotamiton	C	
	Floxacillin	C	
	Folic Acid	C	
	Lactulose	C	
	Metronidazole	C	
	Loperamide	C	
	Nifedipine	C	
	Vancomycin	C	
	Amoxicillin Trihydrate	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/00ISR Number: 3618708-4Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Level Above		Vioxx 25mg - Merck	PS	Merck	ORAL	25MG, PO, QD	
Initial or Prolonged	Therapeutic		Chf	C				

Date:11/29/00ISR Number: 3618728-XReport Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS			1 PER	
Hospitalization -	Haemorrhage							
Initial or Prolonged								

Date:11/29/00ISR Number: 3618734-5Report Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Faeces Discoloured		Vioxx (Rofecoxib)					
Intervention to	Gastrointestinal		25mg Merck	PS	Merck	ORAL	25MG PO QD	
Prevent Permanent	Haemorrhage							
Impairment/Damage	Haematemesis							
	Myocardial Infarction							

Date:11/29/00ISR Number: 3618740-0Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx (Rofecoxib)					
Initial or Prolonged	Blood Creatinine		25mg Merck	PS	Merck	ORAL	25MG QD PO	
	Increased							
	Blood Urea Increased							

Renal Failure Acute

Date:11/29/00ISR Number: 3618744-8Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis		Vioxx 25 Mg	PS		ORAL	25MG PO	
Initial or Prolonged	Glomerular Filtration		Cipro	SS		ORAL	PO BID 10	
Other	Rate Decreased						DAYS PRIOR TO	
	Nephritis Interstitial						HOSP	
	Renal Failure Acute		Premarin	C				
			Betaprea	C				
			Neurdom	C				
			Ultran	C				
			Prevacid	C				
			Ntg	C				
			Calcium	C				
			Zinc	C				
			Magnesium Folate	C				
			Vicodin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/00ISR Number: 3618923-XReport Type:Expedited (15-DaCompany Report #WAES 00111649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/29/00ISR Number: 3618935-6Report Type:Expedited (15-DaCompany Report #WAES 00117520
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia Deafness Palpitations	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	60 DAY
	Paralysis Porphyria Non-Acute Tinnitus Vertigo Vestibular Disorder		Tab Dydrogesterone (+) Estradiol	SS		ORAL	1 TABLET PO	

Date:11/29/00ISR Number: 3618937-XReport Type:Expedited (15-DaCompany Report #WAES 00118581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:11/29/00ISR Number: 3618940-XReport Type:Expedited (15-DaCompany Report #WAES 00118594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc

25 MG 3 WK

Date:11/29/00ISR Number: 3618951-4Report Type:Expedited (15-DaCompany Report #WAES 00119803
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Haemoglobin Decreased	Foreign	Vioxx	PS	Merck Research	
	Joint Stiffness	Other			Laboratories Div	
	Leukocytosis				Merck Co Inc	ORAL
	Oedema					
	Red Blood Cell Count		Calcium	C		
	Decreased		Prednisone	C		
	Red Blood Cell		Pyritinol			
	Sedimentation Rate		Hydrochloride	C		
	Increased		Ranitidine Hcl	C		
	Rheumatoid Arthritis					

Dose Duration

50 MG PO; 25 MG PO 4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/00ISR Number: 3619031-4Report Type:Expedited (15-DaCompany Report #WAES 00117521
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Iron Deficiency Anaemia	Foreign	Vioxx	PS	Merck Research			
	Microcytic Anaemia	Health			Laboratories Div			
	Serum Ferritin Decreased	Professional			Merck Co Inc	ORAL	12.5 MG, PO	52 DAY
			Diosmin Flavonoid Extract	C				
			Fenofibrate	C				
			Furosemide	C				
			Naloxone Hydrochloride (+)					
			Tilidine	C				
			Perindopril Erbumine	C				

Date:11/29/00ISR Number: 3619032-6Report Type:Expedited (15-DaCompany Report #WAES 00106037
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cystitis	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Escherichia Infection	Study			Laboratories Div			
	Haematuria	Health			Merck Co Inc	ORAL	12.5 MG, PO	84 DAY
		Professional	Timoptic	C				
			Trimebutine	C				

Date:11/29/00ISR Number: 3622596-XReport Type:Expedited (15-DaCompany Report #00110280
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholelithiasis	Consumer	Enbrel 25 Mg	PS				
SUBCUTANEOUS	25 MG, BIW,							
Initial or Prolonged	Decreased Appetite	Health						
SUBCUTANEOUS								
	Diarrhoea	Professional	Azathioprine	SS				
	Jaundice		Rofecoxib	SS				
	Liver Function Test		Hydrochlorothiazide	C				
	Abnormal		Lisinopril	C				

	Vomiting		Folic Acid	C		
			Ferrous Sulfate	C		
			Conj. Estrogens/Medroxyprogesterone	C		
			Ascorbic Acid	C		
			Tocopherol	C		
			Centrum Silver Multivitamins	C		
			Potassium	C		

Date:11/30/00ISR Number: 3619808-5Report Type:Direct Company Report #
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Rofecoxib 12.5mg	PS		ORAL	12.5MG QD X 5	
Initial or Prolonged	Dizziness						DAYS ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Faeces Discoloured							
	Gastrointestinal Haemorrhage							
	Gastrointestinal Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3619839-5Report Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria		Vioxx	PS		ORAL	50MG QD PO	
			Prozac	C				
			Synthroid	C				
			Ritalin	C				

Date:11/30/00ISR Number: 3620005-8Report Type:Expedited (15-DaCompany Report #WAES 00118663
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Pustular	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
		Other						

Date:11/30/00ISR Number: 3620006-XReport Type:Expedited (15-DaCompany Report #WAES 00118655
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Other	Furosemide	C				
			Nitroglycerin	C				
			Terbutaline Sulfate	C				
			Ticlopidine Hydrochloride	C				
			Valsartan	C				

Date:11/30/00ISR Number: 3620007-1Report Type:Expedited (15-DaCompany Report #WAES 00118648
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY
		Other	Acetaminophen	C				
			Clopidrogel Bisulfate	C				
			Docusate Na	C				
			Enalapril	C				
			Furosemide	C				
			Heparin	C				
			Ranitidine	C				

Date:11/30/00ISR Number: 3620008-3Report Type:Expedited (15-DaCompany Report #WAES 00118649
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	
		Other	Aspirin/Butalbital/ Caffeine	C				
			Carbamazepine	C				

				Dimenhydrinate	C		
				Venlafaxine Hcl	C		

Date:11/30/00ISR Number: 3620009-5Report Type:Expedited (15-DaCompany Report #WAES 00119762
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Ulceration Stomatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:11/30/00ISR Number: 3620010-1Report Type:Expedited (15-DaCompany Report #WAES 00118115
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Henoch-Schonlein Purpura	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	11 DAY
			Inj Heparin Sodium Injection Lilly	SS	Lilly		5000 UNITS	11 DAY
			Vasotec	C				
			Furosemide	C				

Date:11/30/00ISR Number: 3620011-3Report Type:Expedited (15-DaCompany Report #WAES 00115172
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	103 DAY
	Melaena		Sildenafil Citrate	C				

Date:11/30/00ISR Number: 3620013-7Report Type:Expedited (15-DaCompany Report #WAES 00111760
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Haemorrhage Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Syncope Ulcer Vomiting		Lopressor	C				

Date:11/30/00ISR Number: 3620014-9Report Type:Expedited (15-DaCompany Report #WAES 00111745
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3620015-0Report Type:Expedited (15-DaCompany Report #WAES 00111636
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:11/30/00ISR Number: 3620021-6Report Type:Expedited (15-DaCompany Report #WAES 00115186
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Enterocolitis Haemorrhagic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25 MG PO	
			Antineoplastic	SS				

Date:11/30/00ISR Number: 3620038-1Report Type:Expedited (15-DaCompany Report #WAES 00118643
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	43 DAY
		Other	Beclomethasone Dipropionate	C				
			Calcitonin	C				
			Loxapine	C				
			Prednisone	C				
			Quinine So4	C				
			Salmeterol	C				
			Verapamil	C				

Date:11/30/00ISR Number: 3620039-3Report Type:Expedited (15-DaCompany Report #WAES 00118646
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	91 DAY
		Other	Acetaminophen	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:11/30/00ISR Number: 3620040-XReport Type:Expedited (15-DaCompany Report #WAES 00118666
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
		Other	Prinivil	C				
			Acetaminophen	C				
			Aspirin	C				
			Chlorthalidone	C				
			Colestipol	C				

			Furosemide	C		
			Levothyroxine	C		
			Naproxen Sodium	C		
			Omeprazole	C		
			Potassium Chloride	C		
			Zoplicone	C		

Date:11/30/00ISR Number: 3620041-1Report Type:Expedited (15-DaCompany Report #WAES 00118642
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematemesis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Haematocrit Decreased					
	Haemoglobin Decreased					
12.5 MG PO 130 DAY						
	Melaena	Other	Aspirin	SS		
80 MG 178 DAY						
	Platelet Count Decreased		Acetminophen	C		
	Upper Gastrointestinal Haemorrhage		Acetaminophen/Codeine Phosphate	C		
			Beclomethasone Dipropionate	C		
			Diclofenac	C		
			Minerals (Unspecififed)	C		

Date:11/30/00ISR Number: 3620042-3Report Type:Expedited (15-DaCompany Report #WAES 00118661
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dyspnoea					
	Oedema					
25 MG PO						
		Other	Vasotec	C		
			Zocor	C		
			Amlodipine	C		
			Metformin	C		
			Ranitidine	C		
			Tolbutamide	C		

Date:11/30/00ISR Number: 3620043-5Report Type:Expedited (15-DaCompany Report #WAES 00118670
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
25 MG 2 MON	Blood Creatinine Increased					
	Blood Urea Increased	Other	Sinemet	C		
	Faeces Discoloured		Calcium Carbonate			
	Haematocrit Decreased		(+) Etidronate			
	Haemoglobin Decreased		Sodium	C		
	Platelet Count Decreased		Cisapride	C		
	Red Blood Cell Count Decreased		Furosemide	C		
			Quinapril Hcl	C		
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/00ISR Number: 3620044-7Report Type:Expedited (15-DaCompany Report #WAES 00118658
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Levothyroxine Na	C				
			Paroxetine Hcl	C				

Date:11/30/00ISR Number: 3620045-9Report Type:Expedited (15-DaCompany Report #WAES 00118669
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	4 DAY
	Coagulopathy							
	Gastric Haemorrhage							
	Haemoglobin Decreased	Other	Warfarin Sodium	C				
	International Normalised Ratio Increased							
	Melaena							
	Polyp							

Date:11/30/00ISR Number: 3620414-7Report Type:Expedited (15-DaCompany Report #WAES00118662
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	8 DAY
	Congestive							
	Dyspnoea							
	Vomiting	Other	Furosemide	C				
			Levothyroxine	C				
			Lithiumco3	C				
			Meperidine Hcl	C				
			Omeprazole Magnesium	C				
			Sertraline	C				

Date:11/30/00ISR Number: 3620415-9Report Type:Expedited (15-DaCompany Report #WAES 00118667
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	16 DAY
			Acetaminophen	C				
			Aspirin	C				
			Furosemide	C				
			Salcatonin	C				
			Sulfamethoxazole/Trimethoprim	C				

Date:11/30/00ISR Number: 3620417-2Report Type:Expedited (15-DaCompany Report #WAES 00118653
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Liver Disorder Melaena	Foreign Health Professional

Other

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	2 DAY

Date:11/30/00ISR Number: 3620418-4Report Type:Expedited (15-DaCompany Report #WAES 00118650
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 DAY
		Other	Carbamazepine	C				

Date:11/30/00ISR Number: 3620419-6Report Type:Expedited (15-DaCompany Report #WAES 00118651
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	10 DAY
			Hydrodiuril	C				
			Atorvastatin Calcium	C				
			Cilazapril	C				

Date:11/30/00ISR Number: 3620429-9Report Type:Expedited (15-DaCompany Report #WAES 00118667
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Haemorrhage Merck Co Inc ORAL
25 MG PO 16 DAY

Acetaminophen	C
Aspirin	C
Furosemide	C
Salcatonin	C
Sulfamethoxazole/Trimethoprim	C

Date:11/30/00ISR Number: 3620430-5Report Type:Expedited (15-DaCompany Report #WAES 00118653
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Disorder Melaena	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY

Date:11/30/00ISR Number: 3620431-7Report Type:Expedited (15-DaCompany Report #WAES 00118650
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal

	Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY
		Other	Carbamazepine	C				

Date:11/30/00ISR Number: 3620432-9Report Type:Expedited (15-DaCompany Report #WAES 00118651
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	10 DAY
			Hydrodiuril	C				
			Atorvastatin Calcium	C				
			Cilazapril	C				

Date:11/30/00ISR Number: 3620441-XReport Type:Expedited (15-DaCompany Report #WAES 00118665
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
	Dyspnoea							
	Malaise							
	Pulmonary Oedema	Other	Amiodarone	C				
			Aspirin	C				
			Atenolol	C				
			Enalapril	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Ranitidine	C				

Date:11/30/00ISR Number: 3620498-6Report Type:Expedited (15-DaCompany Report #WAES 00118665
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased Dyspnoea Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY
	Pulmonary Oedema	Other	Amiodarone	C				
			Aspirin	C				
			Atenolol	C				
			Enalapril	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Ranitidine	C				

Date:11/30/00ISR Number: 3620500-1Report Type:Expedited (15-DaCompany Report #WAES 00118654
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematochezia Haemoglobin Decreased

Rectal Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	50 DAY
Other	Ranitidine	C				

Date:11/30/00ISR Number: 3620503-7Report Type:Expedited (15-DaCompany Report #WAES 00118645
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	8 DAY
	Faeces Discoloured							
	Gastric Polyps							
	Melaena	Other	Midamor	C				
			Acetaminophen/Codeine Phosphate	C				
			Acyclovir	C				
			Captopril	C				
			Digoxin	C				
			Estrogens, Conjugated	C				
			Furosemide	C				
			Hydrochlorothiazide	C				
			Levothyroxine Na	C				
			Oxazepam	C				
			Sertraline	C				
			Ticlopidine	C				

Date:11/30/00ISR Number: 3620507-4Report Type:Expedited (15-DaCompany Report #WAES 00118664
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	10 DAY
	Melaena							

		Other	Diltiazem Hydrochloride	C		
			Furosemide	C		
			Nitroglycerin	C		
			Potassium Chloride	C		

Date:11/30/00ISR Number: 3620510-4Report Type:Expedited (15-DaCompany Report #WAES 00118668
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia Headache Ophthalmoplegia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
		Other	Naproxen	C				

Date:12/01/00ISR Number: 3620715-2Report Type:Expedited (15-DaCompany Report #WAES 00092303
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dyspnoea Exertional	Professional			Laboratories Div			
Initial or Prolonged	Hyperhidrosis	Company			Merck Co Inc	ORAL	12.5/DAILY/PO	
Other	Neoplasm	Representative	Prempro	C				
	Oxygen Saturation Decreased		Tenormin	C				
	Pulmonary Embolism							
	Syncope							
	Tachycardia							
	Varicose Vein							
	Ventilation/Perfusion Scan Abnormal							

Date:12/01/00ISR Number: 3620716-4Report Type:Expedited (15-DaCompany Report #WAES 00110745
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Asthenia				Laboratories Div			
	Diarrhoea				Merck Co Inc	ORAL	PO	
	Difficulty In Walking		Darvocet-N	C				
	Failure Of Implant							
	Fatigue							
	Gastrointestinal Haemorrhage							
	Haematochezia							
	Pain In Extremity							

Date:12/01/00ISR Number: 3620717-6Report Type:Expedited (15-DaCompany Report #WAES 00111042
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alveolitis Allergic	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:12/01/00ISR Number: 3620856-XReport Type:Expedited (15-DaCompany Report #WAES 00091093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure	Health	Vioxx	PS	Merck Research	
Hospitalization -	Congestive	Professional			Laboratories Div	
Initial or Prolonged		Company			Merck Co Inc	ORAL
PO 1 DAY						
		Representative				

Date:12/01/00ISR Number: 3620932-1Report Type:Expedited (15-DaCompany Report #WAES 00118619
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Other	Dizziness
	Feeling Jittery
	Hyperglycaemia
	Hypertension

Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	27 DAY
Other	Albuterol Sulfate	C				
	Clarithromycin	C				
	Prednisone	C				
	Zafirlukast	C				

Date:12/01/00ISR Number: 3620934-5Report Type:Expedited (15-DaCompany Report #WAES 00118623
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	[Therapy Unspecified]	C				
			Diltiazem Hydrochloride	C				
			Isosorbide Dinitrate	C				
			Nitroglycerin	C				

Date:12/01/00ISR Number: 3621313-7Report Type:Expedited (15-DaCompany Report #WAES 00102525
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased							
	Cardiac Failure							
	Cardiac Output Decreased	Other	Coreg	C				
	Fluid Retention		Diuril	C				
	Renal Failure Acute		Amlodipine	C				

	Swelling		Aspirin	C
			Dobutamine	C
			Furosemide	C
			Glipizide	C
			Isosorbide Mononitrate	C
			Nitroglycerin	C

Date:12/01/00ISR Number: 3621336-8Report Type:Expedited (15-DaCompany Report #WAES 00106172
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anuria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	2 DAY
		Other	Amiodarone	C				
			Ciprofibrate	C				
			Furosemide	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3621339-3Report Type:Expedited (15-DaCompany Report #WAES 00108580
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Faeces Discoloured	Consumer				
	Gastrointestinal Haemorrhage	Other				
	Gastrointestinal Ulcer		Aspirin	C		
	Haemoglobin Decreased		Atenolol	C		
	Hypotension		Atorvastatin Calcium	C		
			Digoxin	C		
			Furosemide	C		
			Potassium Chloride	C		
			Ramipril	C		
			Warfarin Sodium	C		

Date:12/01/00ISR Number: 3621340-XReport Type:Expedited (15-DaCompany Report #WAES 00025164
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
Hospitalization - Initial or Prolonged	Abdominal Rigidity	Other				
	Abdominal Tenderness					ORAL
12.5 MG PO 6 DAY						
	Bowel Sounds Abnormal		Cisapride	C		
	Intestinal Ulcer		Danthron (+)			
	Perforation		Poloxamer 188	C		
	Tachycardia		Morphine So4	C		
			Omeprazole	C		

Date:12/01/00ISR Number: 3621371-XReport Type:Expedited (15-DaCompany Report #WAES 00108630
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acidosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Anorexia	Health				
	Asthenia	Professional				ORAL
25 MG						
	Blood Creatinine Increased		Prednisone	C		

Confusional State
Fatigue
Hyperkalaemia
Nausea

Date:12/01/00ISR Number: 3621373-3Report Type:Expedited (15-DaCompany Report #WAES 00076031
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Haemorrhage Faeces Discoloured Haemangioma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	1 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3621375-7Report Type:Expedited (15-DaCompany Report #WAES 00105634
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Blood Bilirubin Increased Hepatitis		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	4 DAY
	Liver Function Test Abnormal		Zocor Aspirin	C C				

Date:12/01/00ISR Number: 3621376-9Report Type:Expedited (15-DaCompany Report #WAES 00115059
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	13 DAY
			Aspirin Glyburide Inositol Niacinate Lansoprazole Verapamil Hcl	C C C C C				

Date:12/01/00ISR Number: 3621383-6Report Type:Expedited (15-DaCompany Report #WAES 00069762
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Arrhythmia Blood Creatinine Abnormal Blood Culture Positive Blood Ph Decreased Bradycardia	Foreign Health Professional	Vioxx Tab Vasotec (Enalapril Maleate)	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO 2.5 MG, PO	5 DAY
	Brain Oedema Cardiomegaly Coronary Artery Disease Decubitus Ulcer		Acetaminophen Amoxicillin Trihydrate (+) Clavulanate P	C C				

Dermatitis
Fibrosis
Goitre
Hepatic Congestion
Hyperkalaemia
Marrow Hyperplasia
Obstruction
Oesophagitis
Pleural Adhesion
Pulmonary Congestion
Renal Artery
Atherosclerosis
Scar
Skin Inflammation
Skin Necrosis
Skin Ulcer
Spleen Disorder
Stasis Syndrome
Umbilical Hernia
Vascular Skin Disorder
Ventricular Hypertrophy

Codeine	C
Levothyroxine Na	C
Oxybutyninc1	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/00ISR Number: 3621384-8Report Type:Expedited (15-DaCompany Report #WAES 00075154
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Other			Laboratories Div			
Initial or Prolonged	Duodenal Ulcer				Merck Co Inc	ORAL	PO	178 DAY
	Perforation		Acetaminophen	C				
	Weight Decreased		Allopurinol	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Hydroxocobalamin	C				
			Isosorbide-5-Mononitrate	C				

Date:12/04/00ISR Number: 3620734-6Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Coumadin 2.5mg Tabs	PS		ORAL	2.5MG QD PO	
Hospitalization -	Asthenia		Vioxx 25mg	SS		ORAL	25MG QD PO	
Initial or Prolonged	Drug Tolerance Decreased						PRN	
Required	Dyspnoea		Meclizine	C				
Intervention to	Faecal Occult Blood		Hydroxyzine	C				
Prevent Permanent	Fatigue		Prilosec	C				
Impairment/Damage	Haemorrhage		Ambien	C				
	Hepatic Failure		Fosamax	C				
	Laboratory Test Abnormal		Trazodone	C				
	Renal Failure Acute		Synthroid	C				
			Butabarbital	C				
			Prevacid	C				
			Carisoprodol	C				
			Keflex	C				
			Lasix	C				
			K+-Dur	C				
			Ativan	C				

Phenergan	C
Percocet	C
Periolace	C
Flomax	C

Date:12/04/00ISR Number: 3621744-5Report Type:Expedited (15-DaCompany Report #WAES 00111891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Convulsion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/04/00ISR Number: 3621751-2Report Type:Expedited (15-DaCompany Report #WAES 00111853
Age:61 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alveolitis Allergic Dermatitis

	Dyspnoea Eosinophil Count Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoxia Lung Infiltration Pain Pyrexia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.4 MG/ DAILY/PO

Date:12/04/00ISR Number: 3622233-4Report Type:Expedited (15-DaCompany Report #WAES 00102079
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, DAILY, PO

Date:12/04/00ISR Number: 3622380-7Report Type:Expedited (15-DaCompany Report #WAES 00119761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	

Date:12/04/00ISR Number: 3622399-6Report Type:Expedited (15-DaCompany Report #WAES 00116515
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Drug Interaction Dyskinesia	Foreign Health	Vioxx	PS	Merck Research Laboratories Div		

			Professional			Merck Co Inc	ORAL
12,5 MG	2	DAY					
			Other	Vioxx (Rofecoxib)	SS		ORAL
25 MG	1	DAY					
				Sinemet Cr (Carbidopa/Levodopa)	SS		ORAL
75/300 MG	53	YR					
				Pergolide	C		
				Selegiline	C		

Date:12/04/00ISR Number: 3622408-4Report Type:Expedited (15-DaCompany Report #WAES 00119553
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Vomiting	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL

Date:12/04/00ISR Number: 3622446-1Report Type:Expedited (15-DaCompany Report #WAES 00115247
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastrointestinal	Health			Laboratories Div	
	Haemorrhage	Professional			Merck Co Inc	ORAL
25 MG PO 55 DAY						
	Melaena		Acetaminophen	C		
			Acyclovir	C		

Aluminum Hydroxide/Magnesium Carbonate	C
Amiloride Hydrochloride (+)	
Furosemide	C
Clodronate Disodium	C
Digoxin	C
Domperidone	C
Fluconazole	C
Morphineso4	C
Propranolol	C
Thyroxine	C
Valproate Sodium	C

Date:12/04/00ISR Number: 3622447-3Report Type:Expedited (15-DaCompany Report #WAES 00115241
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Acetaminophen	C				
			Aspirin/Dipyridamole	C				

Date:12/05/00ISR Number: 3621787-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Duodenal Ulcer Hiatus Hernia Upper Gastrointestinal Haemorrhage		Vioxx	PS			12.5 MG DAILY	8 MON

Date:12/05/00ISR Number: 3622833-1Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal		Baby Asa	PS		
	Haemorrhage		Vioxx	SS		
	Melaena		Prednisone	C		
			Ultram	C		
			Calan-Sr	C		
			Benadryl	C		
			Plaquenil	C		

Date:12/05/00ISR Number: 3622854-9Report Type:Expedited (15-DaCompany Report #WAES 00115242
Age:63 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Circulatory Collapse
Hospitalization - Initial or Prolonged	Gastric Ulcer
	Haematemesis
	Melaena
	Upper Gastrointestinal

Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Acetaminophen /Codeine Phosphate	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Bupivacaine Hcl	C				
			Triamcinolone Acetanide	C				

Date:12/05/00ISR Number: 3622878-1Report Type:Expedited (15-DaCompany Report #WAES 00117932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	3 DAY
			Enalapril	C				

Date:12/05/00ISR Number: 3622881-1Report Type:Expedited (15-DaCompany Report #WAES 00118209
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Necrosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/05/00ISR Number: 3622883-5Report Type:Expedited (15-DaCompany Report #WAES 00118610
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/05/00ISR Number: 3622886-0Report Type:Expedited (15-DaCompany Report #WAES 00116153
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Injury Memory Impairment Road Traffic Accident Sedation Speech Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

Date:12/05/00ISR Number: 3622891-4Report Type:Expedited (15-DaCompany Report #WAES 00117311
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	3 DAY
	Haemoglobin Decreased							
	Hyperkalaemia		Acetaminophen	C				
			Calcium Carbonate	C				
			Cyclizine	C				
			Lactulose	C				
			Lansoprazole	C				
			Metoprolol Tartrate	C				
			Tinzaparin Sodium	C				

Date:12/05/00ISR Number: 3622897-5Report Type:Expedited (15-DaCompany Report #WAES 00116144
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Above Therapeutic	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	24 DAY
	Renal Impairment							
			Tab Vaseretic (Enalapril Maleate/Hctz)	SS		ORAL	20/12.5 MG	
			Tab Morphine	SS		ORAL	25 MG	5 DAY
			Acetaminophen	C				
			Amitriptyline	C				
			Bromazepam	C				
			Phloroglucinol	C				
			Zolpidem	C				

Date:12/05/00ISR Number: 3622899-9Report Type:Expedited (15-DaCompany Report #WAES 00118644
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG 11 DAY
		Other	Aspirin	C			
			Cefuroxime Sodium	C			
			Diclofenac Sodium (+) Misoprostol	C			
			Flavoxate Hcl	C			
			Loperamide Hcl	C			
			Lorazepam	C			
			Omeprazole Magnesium	C			

Date:12/05/00ISR Number: 3622905-1Report Type:Expedited (15-DaCompany Report #WAES 00115253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Ventricular Arrhythmia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/00ISR Number: 3622908-7Report Type:Expedited (15-DaCompany Report #WAES 00115265
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Foreign	Vioxx	PS	Merck Research			
	Chest Discomfort	Other			Laboratories Div			
	Chest Pain				Merck Co Inc	ORAL	12.5 MG, PO	2 DAY
	Dyspnoea		Acetaminophen/Propoxyphene Hydrochloride	C				
			Furosemide	C				
			Metformin	C				
			Rabeprazole Sodium	C				
			Thyroxine	C				

Date:12/05/00ISR Number: 3623753-9Report Type:Expedited (15-DaCompany Report #WAES 00115295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pruritus	Foreign	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG, PO	3 DAY

Date:12/05/00ISR Number: 3623755-2Report Type:Expedited (15-DaCompany Report #WAES 00115629
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
					Merck Co Inc	ORAL	25 MG, PO	113 DAY

Date:12/05/00ISR Number: 3623756-4Report Type:Expedited (15-DaCompany Report #WAES 00119556
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO 5 DAY						
			Calcium Carbonate	C		
			One-Alpha	C		

Date:12/06/00ISR Number: 3623370-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Blood Creatinine		Vioxx	PS		ORAL
12.5 MG DAILY						
Intervention to	Increased					
PO						
Prevent Permanent Impairment/Damage			Catapres Tts	C		
			Zaroxolyn	C		
			Lanoxin	C		
			Zestril	C		
			Heparin	C		
			Pepcid	C		
			Colace	C		
			Norvasc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3623474-2Report Type:Expedited (15-DaCompany Report #WAES 00112211
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/06/00ISR Number: 3623525-5Report Type:Expedited (15-DaCompany Report #WAES 00112070
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction Dysphagia Dyspnoea Eyelid Oedema Face Oedema Pruritus Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:12/06/00ISR Number: 3623527-9Report Type:Expedited (15-DaCompany Report #WAES 00110995
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Oedema Peripheral	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified] Unk	SS				
			Ambien	C				
			Bactrim Ds Tablets	C				
			Effexor	C				
			Fiorcet Tablets	C				
			Lasix	C				

Maxzide	C
Synthroid	C
Tylenol	C
Valium	C
Atenolol	C
Baclofen	C
Clonidine	C
Methadone Hydrochloride	C
Trazodone	C

Date:12/06/00ISR Number: 3623529-2Report Type:Expedited (15-DaCompany Report #WAES 00100716
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bite Convulsion Epistaxis Tongue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3623679-0Report Type:Expedited (15-DaCompany Report #WAES 00088505
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Health	Vioxx	PS	Merck Research			
Hospitalization -	Convulsion	Professional			Laboratories Div			
Initial or Prolonged	Hypertensive Crisis				Merck Co Inc	ORAL	25 MG /DAILY/	
	Hypertensive							
	Encephalopathy		(Therapy					
	Oedema Peripheral		Unspecified)	C				

Date:12/06/00ISR Number: 3623683-2Report Type:Expedited (15-DaCompany Report #WAES 00111799
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Hepatic Failure	Professional			Laboratories Div			
	Hypotension	Company			Merck Co Inc	ORAL	25 MG DAILY	
	Pyrexia	Representative						

PO 2 WK

Date:12/06/00ISR Number: 3623697-2Report Type:Expedited (15-DaCompany Report #WAES 00091789
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Diverticulum Intestinal	Professional			Laboratories Div			
Other	Drug Interaction				Merck Co Inc	ORAL	PO	
	Gastrointestinal		Coumadin	SS				
	Angiodysplasia		Accupril	C				
	Gastrointestinal		Fosamax	C				
	Haemorrhage		Lasix	C				
	Haemorrhoids		Aspirin	C				
	Hiatus Hernia		Atenolol	C				
	International Normalised		Cyancobalamin	C				
	Ratio Increased		Potassium Chloride	C				

Date:12/06/00ISR Number: 3623729-1Report Type:Expedited (15-DaCompany Report #WAES 00116133
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	25 DAY
	Subcutaneous Haematoma		Fluindione	SS		ORAL	10 MG, PO	

Date:12/06/00ISR Number: 3623731-XReport Type:Expedited (15-DaCompany Report #WAES 00115656
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3623733-3Report Type:Expedited (15-DaCompany Report #WAES 00115308
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Digoxin	C				
			Warfarin	C				

Date:12/06/00ISR Number: 3623738-2Report Type:Expedited (15-DaCompany Report #WAES 00115642
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erosive Oesophagitis Oesophagitis	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	26 DAY
			Enalapril	C				
			Nortriptyline Hcl	C				

Date:12/06/00ISR Number: 3623806-5Report Type:Expedited (15-DaCompany Report #WAES 00115309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicidal Ideation	Foreign Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				

Date:12/06/00ISR Number: 3623807-7Report Type:Expedited (15-DaCompany Report #WAES 00115313
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Melaena Rectal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO 53 DAY
			Acetaminophen	C			
			Ranitidine	C			

Date:12/06/00ISR Number: 3623910-1Report Type:Expedited (15-DaCompany Report #WAES 00110190
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Abdominal Tenderness Crohn'S Disease Diverticulum Intestinal Faeces Discoloured	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO
Other	Gastrointestinal Haemorrhage Gastrointestinal Ulcer Haematochezia Haematocrit Decreased Haemoglobin Decreased Pyrexia Tachycardia		Danocrine Pravachol	C C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3624030-2Report Type:Expedited (15-DaCompany Report #WAES 00115655
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/06/00ISR Number: 3624031-4Report Type:Expedited (15-DaCompany Report #WAES 00116105
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Anorexia Gastroenteritis	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	116 DAY
	Helicobacter Renal Impairment Vomiting	Professional	Acetaminophen (+) Dextropropoxyphene Avocado Oil (+) Soybean Oil Carteolol Hcl Diosmin Dorzolamide Hcl Fenofibrate Ginkgo Biloba Extract Latanoprost Levothyroxine Na	 C C C C C C C C				

Date:12/06/00ISR Number: 3624034-XReport Type:Expedited (15-DaCompany Report #WAES 00115635
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	5 DAY
		Professional	Composition Unspecified	 C				

			Digitoxin	C		
			Ramipril	C		

Date:12/06/00ISR Number: 3624036-3Report Type:Expedited (15-DaCompany Report #WAES 00119856
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Conjunctivitis	Foreign	Vioxx	PS	Merck Research			
	Eyelid Oedema	Health			Laboratories Div			
	Herpes Virus Infection	Professional			Merck Co Inc	ORAL	25 MG PO	5 DAY
	Hypersensitivity		Fosamax	C				
	Pruritus		Calcium	C				
	Purulence							
	Pyrexia							
	Skin Lesion							
	Skin Necrosis							
	Stevens-Johnson Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/00ISR Number: 3624037-5Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea	Health						
	Face Oedema	Professional			Merck Co Inc	ORAL	50 MG PO	2 DAY
	Gastrointestinal Disorder		Clobazam	C				
	Hypertension		Metoclopramide	C				
	Hyponatraemia		Ranitidine	C				
	Insomnia		Tizanidine	C				
	Tremor							
	Vomiting							

Date:12/07/00ISR Number: 3624587-1Report Type:Expedited (15-DaCompany Report #WAES 00101849
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Vioxx	PS	Merck Research Laboratories Div			
	Chills	Professional						
	Gallbladder Disorder	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Headache	Representative						
	Liver Function Test		Esgic Plus Tablets	C				
	Abnormal							
	Nausea							
	Pyrexia							
	Vomiting							

Date:12/07/00ISR Number: 3624588-3Report Type:Expedited (15-DaCompany Report #WAES 00112082
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills	Study	Vioxx	PS	Merck Research Laboratories Div			
	Dyspnoea	Health						
	Face Oedema	Professional			Merck Co Inc	ORAL	UNK/UNK/PO	
	Oedema		Tab {Composition					

	Oedema Peripheral		Unspecified} 2.5 Mg	SS		ORAL
2.5						
	Pyrexia					
MG/DAILY/PO						
			Metformin	SS		
			Placebo			
			(Unspecified)	C		

Date:12/07/00ISR Number: 3624589-5Report Type:Expedited (15-DaCompany Report #WAES 00111860
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angiopathy	Health	Vioxx	PS	Merck Research	
	Ecchymosis	Professional			Laboratories Div	
	Haemorrhage				Merck Co Inc	ORAL
25						
	Pain In Extremity					
MG/DAILY/PO						
	Thrombocytopenia		Azmacort	C		
			Dyazide	C		
			Plendil	C		
			Premarin	C		
			Serevent	C		
			Allopurinol	C		
			Aspirin	C		
			Vitamins			
			(Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/00ISR Number: 3624590-1Report Type:Expedited (15-DaCompany Report #WAES 00111775
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Headache Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:12/07/00ISR Number: 3624591-3Report Type:Expedited (15-DaCompany Report #WAES 00110632
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/07/00ISR Number: 3624592-5Report Type:Expedited (15-DaCompany Report #WAES 00082504
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Intestinal Perforation Malaise	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Zestril	C				

Date:12/07/00ISR Number: 3624593-7Report Type:Expedited (15-DaCompany Report #WAES 00102535
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Abdominal Discomfort Blood Alkaline	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Phosphatase Increased	Professional			Merck Co Inc	ORAL
25 MG/ DAILY/						
	Drug Tolerance Decreased					
PO						
	Gastric Ulcer Haemorrhage		Celebrex	SS		ORAL
DAILY/ PO						
	Haematocrit Decreased		Dyazide	C		
	Haemoglobin Decreased		Miacalcin	C		
	Nausea		Mylanta & Mylanta Ds	C		
	Thrombocythaemia		Os-Cal	C		
	Vomiting		Premarin	C		
			Prilosec	C		
			Tylenol	C		

Date:12/07/00ISR Number: 3624641-4Report Type:Expedited (15-DaCompany Report #WAES 00112206
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research	
Hospitalization -	Electrolyte Imbalance	Professional			Laboratories Div	
Initial or Prolonged	Gastric Ulcer	Company			Merck Co Inc	ORAL
25						
Other	Rectal Haemorrhage	Representative				
MG/DAILY/PO						
			Hydrodiuril	C		
			K-Dur	C		
			Lescol	C		
			[Therapy			
			Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/00ISR Number: 3624642-6Report Type:Expedited (15-DaCompany Report #WAES 00060072
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck Research			
Other	Diarrhoea	Health			Laboratories Div			
	Fatigue	Professional			Merck Co Inc	ORAL	25	
	Feeling Abnormal						MG/DAILY/PO	
	Hypertension		Caltrate 600 Plus					
	Oedema Peripheral		Vitamin D	C				
			Celebrex	C				
			Coumadin	C				
			Fosamax	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Norvasc	C				
			Synthroid	C				
			Tylenol	C				
			Xanax	C				
			Zantac	C				
			Zocor	C				
			Calcium (Unspecified)	C				
			Magnesium (Unspecified)	C				

Date:12/07/00ISR Number: 3624643-8Report Type:Expedited (15-DaCompany Report #WAES 00040122
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence	Consumer	Vioxx	PS	Merck Research			
	Arterial Stenosis	Health			Laboratories Div			
	Cardiac Failure	Professional			Merck Co Inc	ORAL	PO	
	Congestive Gastrointestinal Disorder							
	Hepatitis							
	Pancreatitis							
	Pneumonia							
	Respiratory Failure							

Subclavian Steal Syndrome

Date:12/07/00ISR Number: 3624644-XReport Type:Expedited (15-DaCompany Report #WAES 00112265
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Perforation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aspirin	C				

Date:12/07/00ISR Number: 3624645-1Report Type:Expedited (15-DaCompany Report #WAES 00112455
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aspirin	C				

Date:12/07/00ISR Number: 3624646-3Report Type:Expedited (15-DaCompany Report #WAES 00120106
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eosinophilic Pneumonia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Pneumonia	Professional			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	PO	

Date:12/07/00ISR Number: 3624651-7Report Type:Expedited (15-DaCompany Report #WAES 00111799
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bilirubin Increased	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dermatitis	Professional			Laboratories Div			
Initial or Prolonged	Hepatic Failure	Company			Merck Co Inc	ORAL	25	
Disability	Hypotension	Representative					MG/DAILY/PO	
Other	Jaundice		Centrum	C				
	Liver Function Test Abnormal							
	Pyrexia							
	Vomiting							

Date:12/07/00ISR Number: 3624655-4Report Type:Expedited (15-DaCompany Report #WAES 00092253
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck Research			
Hospitalization -	Coma	Professional			Laboratories Div			
Initial or Prolonged	Crepitations				Merck Co Inc	ORAL	25	
	Hyperreflexia						MG/DAILY/PO	
	Hypertension		Darvocet-N	C				
	Mental Impairment		Fosamax	C				
	Miosis		Plavix	C				
	Speech Disorder		Tylenol	C				
			Zantac	C				

			Zoloft	C		
			[Therapy Unspecified]	C		
			Calcium (Unspecified) (+)			
			Vitamin	C		

Date:12/07/00ISR Number: 3624786-9Report Type:Expedited (15-DaCompany Report #WAES 00105282
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Duodenal Ulcer Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG PO	
	Haemoglobin Decreased Melaena		Zocor	C				
			Atenolol	C				
			Citalopram	C				
			Clopidogrel	C				
			Dihydrocodeine	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/00ISR Number: 3624790-0Report Type:Expedited (15-DaCompany Report #WAES 00119856
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Conjunctivitis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Dermatitis	Health			Laboratories Div			
Initial or Prolonged	Diabetes Mellitus	Professional			Merck Co Inc	ORAL	25 MG PO	5 DAY
	Eyelid Oedema		Fosamax	C				
	Herpes Simplex		Calcium	C				
	Hypersensitivity							
	Pruritus							
	Pseudomonal Sepsis							
	Pyrexia							
	Sepsis							
	Skin Lesion							
	Staphylococcal Sepsis							
	Stevens-Johnson Syndrome							
	Toxic Epidermal							
	Necrolysis							

Date:12/07/00ISR Number: 3624792-4Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Change Of Bowel Habit	Health			Laboratories Div			
	Diarrhoea	Professional			Merck Co Inc	ORAL	50 MG PO	2 DAY
	Face Oedema		Clobazam	C				
	Hypertension		Sertraline	C				
	Hyponatraemia		Tizanidine	C				
	Insomnia							
	Tremor							
	Vomiting							

Date:12/07/00ISR Number: 3624793-6Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
	Face Oedema						
	Hypertension						
50 MG PO	2 DAY						
	Hyponatraemia		Clobazam	C			
	Insomnia		Metoclopramide	C			
	Tremor		Ranitidine	C			
	Vomiting		Tizanidine	C			

Date:12/07/00ISR Number: 3625088-7Report Type:Expedited (15-DaCompany Report #WAES 00115648
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/00ISR Number: 3625092-9Report Type:Expedited (15-DaCompany Report #WAES 00118212
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	25 MG PO	23 DAY
			Vaseretic	C				
			Aspirin	C				

Date:12/07/00ISR Number: 3625094-2Report Type:Expedited (15-DaCompany Report #WAES 00116105
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal Disorder	Study			Laboratories Div			
	Renal Impairment	Health			Merck Co Inc	ORAL	12.5 MG PO	
	Urinary Tract Infection	Professional	Acetaminophen (+)					
			Dextropropoxyphene	C				
			Avocado Oil (+)					
			Soybean Oil	C				
			Carteolol Hcl	C				
			Diosmin	C				
			Dorzolamide Hcl	C				
			Fenofibrate	C				
			Ginkgo Biloba Extract	C				
			Latanoprost	C				
			Levothyroxine Na	C				

Date:12/07/00ISR Number: 3625095-4Report Type:Expedited (15-DaCompany Report #WAES 00116054
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG PO	

(SEE IMAGE)

			Althiazide/Spironolactone	C		
			Cetirizine Hydrochloride	C		

Date:12/07/00ISR Number: 3625098-XReport Type:Expedited (15-DaCompany Report #WAES 00118510
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphagia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Erythema Multiforme							
	Face Oedema							
	Pharyngolaryngeal Pain		Allopurinol	C				
	Pyrexia		Aspirin	C				
	Tongue Oedema		Atenolol	C				
			Atorvastatin Calcium	C				

Date:12/07/00ISR Number: 3625102-9Report Type:Expedited (15-DaCompany Report #WAES 00115153
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue Lethargy Sensation Of Heaviness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	6 DAY

Date:12/07/00ISR Number: 3625104-2Report Type:Expedited (15-DaCompany Report #WAES 00115613
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Iron Deficiency Anaemia Microcytic Anaemia Pericardial Effusion Pleural Effusion Pyrexia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON

Date:12/07/00ISR Number: 3625105-4Report Type:Expedited (15-DaCompany Report #WAES 00115670
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Small Intestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	2 WK
		Other	Vioxx	SS		ORAL	25 MG PO	12 DAY
			Phenprocoumon	C				

Date:12/07/00ISR Number: 3625106-6Report Type:Expedited (15-DaCompany Report #WAES 00115671
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Small Intestinal	Foreign	Vioxx	PS	Merck Research			

Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional				Laboratories Div Merck Co Inc	ORAL
25.0 MG PO 8 DAY							
		Other	Phenprocoumon	C			
			Ranitidine	C			
			Theophylline	C			
			Tramadol Hcl	C			

Date:12/07/00ISR Number: 3625108-XReport Type:Expedited (15-DaCompany Report #WAES 00115657
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Hospitalization - Initial or Prolonged		Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG PO 11 DAY						
		Other				

Date:12/07/00ISR Number: 3625110-8Report Type:Expedited (15-DaCompany Report #WAES 00115629
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 113 DAY						
		Other	Hctz/Triamterene	C		

				Allopurinol	C		
				Spirapril Hydrochloride	C		

Date:12/07/00ISR Number: 3625112-1Report Type:Expedited (15-DaCompany Report #WAES 00115655
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Oedema	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	10 DAY

Date:12/07/00ISR Number: 3625133-9Report Type:Expedited (15-DaCompany Report #WAES 00117822
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Iron Deficiency Anaemia Pericardial Effusion Pleural Effusion Pyrexia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	18 DAY

Date:12/07/00ISR Number: 3625134-0Report Type:Expedited (15-DaCompany Report #WAES 00119814
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO; 25 MG PO	12 DAY
			Aspirin	C				
			Isosorbide Mononitrate	C				

				Metoprolol Tartrate	C		
				Promazine	C		

Date:12/07/00ISR Number: 3625180-7Report Type:Expedited (15-DaCompany Report #WAES 00117815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Methotrexate	SS				
			Nonspecific Drug Therapy	C				

Date:12/07/00ISR Number: 3625184-4Report Type:Expedited (15-DaCompany Report #WAES 00119557
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	1 DAY
		Other	Fucidin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/00ISR Number: 3624648-7Report Type:Expedited (15-DaCompany Report #WAES 00111025
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Oesophageal	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Faeces Discoloured							
Other	Gastric Ulcer				Merck Co Inc	ORAL	PO	
	Gastritis		Tab Plavix	SS		ORAL	DAILY/PO	
	Haematocrit Decreased		Covera-Hs	C				
	Haemoglobin Decreased							
	Upper Gastrointestinal Haemorrhage							

Date:12/08/00ISR Number: 3625375-2Report Type:Expedited (15-DaCompany Report #WAES 00120147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
	Tongue Oedema							
					Merck Co Inc	ORAL	PO	

Date:12/08/00ISR Number: 3625377-6Report Type:Expedited (15-DaCompany Report #WAES 00112001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Gastrointestinal Disorder							
	Haemoptysis				Merck Co Inc	ORAL	PO	
	Upper Gastrointestinal Haemorrhage							

Date:12/08/00ISR Number: 3625381-8Report Type:Expedited (15-DaCompany Report #WAES 00088505
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Convulsion Hypertensive Crisis Hypertensive Encephalopathy Oedema Peripheral	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Date:12/08/00ISR Number: 3625383-1Report Type:Expedited (15-DaCompany Report #WAES 00070253
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Agitation Dizziness Headache Hypertension Malaise Vertigo	Consumer Health Professional	Vioxx Inj Droperidol	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, DAILY, PO INTRAMUSCULAR	2.5 MG, IM

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/00ISR Number: 3625384-3Report Type:Expedited (15-DaCompany Report #WAES 00120215
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Disability	Blood Pressure Increased	Company			Merck Co Inc	ORAL	25 MG, DAILY, PO	
Other	Blood Urea Increased	Representative						
	Cellulitis							
	Drug Ineffective							
	Oedema							

Date:12/08/00ISR Number: 3625465-4Report Type:Expedited (15-DaCompany Report #WAES 00118218
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Gastroenteritis	Other						
	Helicobacter				Merck Co Inc	ORAL	PO	3 WK

Date:12/08/00ISR Number: 3625478-2Report Type:Expedited (15-DaCompany Report #WAES 00117313
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea	Other						
	Fatigue				Merck Co Inc	ORAL	25 MG PO	36 DAY
	Pruritus		Estradiol	C				
			Lactulose	C				
			Loratadine	C				
			Zolpidem Tartrate	C				

Date:12/08/00ISR Number: 3625483-6Report Type:Expedited (15-DaCompany Report #WAES 00117315
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Necrosis Vasculitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 8 DAY						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Citalopram Hydrobromide	C		
			Cyanocobalamin	C		
			Flunitrazepam	C		
			Furosemide	C		
			Omeprazole Magnesium	C		
			Oxazepam	C		

Date:12/08/00ISR Number: 3625485-XReport Type:Expedited (15-DaCompany Report #WAES 00115638
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25.0 MG PO 5 DAY						
			Phenprocoumon	SS		
			Hctz/Triamterene	C		

		Acetyldigoxin	C
		Dimethindene Maleate	C
		Furosemide	C
		Furosemide/Spironolactone	C
		Molsidomine	C
		Verapamil Hcl	C

Date:12/08/00ISR Number: 3625490-3Report Type:Expedited (15-DaCompany Report #WAES 00125517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization -	Gastrointestinal Haemorrhage Pyrexia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 MON
Initial or Prolonged			Therapy Unspecified	C				

Date:12/08/00ISR Number: 3625491-5Report Type:Expedited (15-DaCompany Report #WAES 00125509
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Gastrointestinal Haemorrhage	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	PO	
			Phenprocoumon	C				

Date:12/08/00ISR Number: 3625502-7Report Type:Expedited (15-DaCompany Report #WAES 00105628
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia Hypoaesthesia Hypoaesthesia Oral	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	10 DAY
	Oral Mucosal Blistering	Other	Levothyroxine Sodium (+) Potassium Iodid	C				

Date:12/08/00ISR Number: 3625504-0Report Type:Expedited (15-DaCompany Report #WAES 00115637
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Eczema Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 WK
		Other	Alfacalcidol	C				
			Calcium Citrate (+)					
			Calcium Gluconate (+	C				
			Celiprolol Hc1	C				
			Metformin Hcl	C				
			Nitrendipine	C				
			Perindopril Erbumine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/00ISR Number: 3625508-8Report Type:Expedited (15-DaCompany Report #WAES 00117524
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Vioxx	PS	Merck Research			
	Fluid Retention	Health			Laboratories Div			
	Weight Increased	Professional			Merck Co Inc	ORAL	25.0 MG, PO	13 DAY
		Other	Aspirin	C				
			Atenolol	C				
			Molsidomine	C				
			Valsartan	C				

Date:12/08/00ISR Number: 3625510-6Report Type:Expedited (15-DaCompany Report #WAES 00118672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Vioxx	PS	Merck Research			
	Haemorrhage	Health			Laboratories Div			
	Ulcer	Professional			Merck Co Inc	ORAL	PO	
		Other	Warfarin Sodium	SS		ORAL	PO	

Date:12/08/00ISR Number: 3625680-XReport Type:Expedited (15-DaCompany Report #WAES 00117520
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia	Foreign	Vioxx	PS	Merck Research			
	Deafness	Health			Laboratories Div			
	Hearing Impaired	Professional			Merck Co Inc	ORAL	25 MG PO	60 DAY
	Palpitations		Dydrogesterone (+)					
	Paralysis		Estradiol	SS		ORAL	1 TABLET PO	
	Porphyria Non-Acute							
	Tinnitus							
	Vertigo							
	Vestibular Disorder							

Date:12/08/00ISR Number: 3625682-3Report Type:Expedited (15-DaCompany Report #WAES 00119508
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY

Date:12/08/00ISR Number: 3625686-0Report Type:Expedited (15-DaCompany Report #WAES 00119134
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Drug Interaction							
	Haemodialysis		Vasotec	SS		ORAL	5 MG PO	
	Nephritis Interstitial		Nsaid	C				
	Nephrosclerosis							
	Renal Tubular Atrophy							
	Renal Tubular Necrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/00ISR Number: 3625688-4Report Type:Expedited (15-DaCompany Report #WAES 00125508
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO (SEE IMAGE)	382 DAY
			Fosamax	C				
			Dipyrone	C				
			Magnesium	C				

Date:12/08/00ISR Number: 3625689-6Report Type:Expedited (15-DaCompany Report #WAES 00118649
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastric Ulcer Haematemesis Upper Gastrointestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	50 DAY
	Haemorrhage	Company Representative	Aspirin/Butalbital/C affeine	C				
			Carbamazepine	C				
			Dimenhydrinate	C				
			Venlafaxine Hcl	C				

Date:12/08/00ISR Number: 3625692-6Report Type:Expedited (15-DaCompany Report #WAES 00115666
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastroenteritis Helicobacter	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	140 DAY
			Hydrodiuril	C				
			Calcium Carbonate (+) Etidronate Sodium	C				

				Captopril	C		
				Gastrointestinal Preparations	C		
				Levothyroxine Na	C		

Date:12/11/00ISR Number: 3626237-7Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Ketorolac 10mg Tab	PS		ORAL	1 PO QD	
Required	Toxic Epidermal		Vioxx 12.5mg Tab	SS		ORAL	1 PO QD	
Intervention to Prevent Permanent Impairment/Damage	Necrolysis		Atenolol	C				
			Premarin	C				
			Multivitamin	C				
			Beconase Nasal Spray	C				
			Adalat Cc	C				
			Effexor Xr	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/00ISR Number: 3626276-6Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised		Vioxx / Merck	PS	Merck	ORAL	QD/ORAL	
Required	Ratio Increased		Coumadin	SS	Dupont	ORAL	23.75 MG/	
Intervention to							WEEK/ ORAL	
Prevent Permanent			Sotalol	C				
Impairment/Damage			Centrum	C				
			Vitamin C	C				
			Cozaar	C				
			Serevent	C				

Date:12/11/00ISR Number: 3626284-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	International Normalised		Vioxx 25mg Merck	PS	Merck	ORAL	25 MG QD ORAL	
Intervention to	Ratio Increased		Celebrex 200mg					
Prevent Permanent			Searle	SS	Searle	ORAL	200MG QD ORAL	
Impairment/Damage			Warfarin -Coumadin-	C				

Date:12/11/00ISR Number: 3626666-1Report Type:Expedited (15-DaCompany Report #WAES 00118653
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Disorder	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Melaena	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG PO	2 DAY
		Other						

Date:12/11/00ISR Number: 3626668-5Report Type:Expedited (15-DaCompany Report #WAES 00118510
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Aspartate Aminotransferase Increased		Allopurinol	C				
			Aspirin	C				
	Blood Alkaline Phosphatase Increased		Atenolol	C				
	Blood Bilirubin Increased		Atorvastatin Calcium	C				
	Blood Creatinine Increased							
	Drug Hypersensitivity							
	Erythema Multiforme							

Date:12/11/00ISR Number: 3626669-7Report Type:Expedited (15-DaCompany Report #WAES 00118647
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG PO	15 DAY
		Other	Betaxolol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/00ISR Number: 3626672-7Report Type:Expedited (15-DaCompany Report #WAES 00118661
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Other	Vasotec	C				
			Zocor	C				
			Amlodipine	C				
			Metformin	C				
			Ranitidine	C				
			Tolbutamide	C				

Date:12/11/00ISR Number: 3626675-2Report Type:Expedited (15-DaCompany Report #WAES 00076509
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	25 MG PO	4 DAY
			Tab Aspirin	SS		ORAL	PO	
			Tab Cr Diclofenac Na	SS		ORAL	150 MG PO	
			Acetaminophen	C				

Date:12/11/00ISR Number: 3626697-1Report Type:Expedited (15-DaCompany Report #WAES 00112206
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Asthenia Balance Disorder Gastric Ulcer Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				

			K-Dur	C		
			Lescol	C		

Date:12/11/00ISR Number: 3626758-7Report Type:Expedited (15-DaCompany Report #WAES 00111327
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hyperkalaemia Myocardial Infarction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Lopressor	C		
			Pravachol	C		
			Trilisate Tablets/Liquid	C		
			Vasotec	C		

Date:12/11/00ISR Number: 3627078-7Report Type:Expedited (15-DaCompany Report #WAES 00119553
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Breast Neoplasm Diarrhoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/00ISR Number: 3627079-9Report Type:Expedited (15-DaCompany Report #WAES 00129001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hypertensive Crisis Transient Ischaemic Attack	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
			Bromazepam	C				
			Cilazapril	C				
			Diosmin	C				
			Ticlopidine	C				
			Trazodone	C				

Date:12/12/00ISR Number: 3627222-1Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Aspirin (Ecotrin)	PS		ORAL	325MG PO QD	
	Gastritis Erosive						CHRONIC YEARS	
	Hyperhidrosis		Rofecoxib	SS			7 DAY	
	Melaena		Zestril	C				
			Metoprol	C				
			Folase	C				
			Vit B	C				
			Thiamine	C				

Date:12/12/00ISR Number: 3628748-7Report Type:Expedited (15-DaCompany Report #WAES 00119006
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	13 DAY
		Other	Amiloride Hydrochloride/Hctz	C				

			Gemfibrozil	C		

Date:12/12/00ISR Number: 3628775-XReport Type:Expedited (15-DaCompany Report #WAES 00101917
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Renal Disorder		Lithobid 300 Mg	SS		ORAL	300 MG/BID/PO	
			Lithobid 300 Mg	SS		ORAL	300 MG/DAILY/PO	

Date:12/12/00ISR Number: 3628778-5Report Type:Expedited (15-DaCompany Report #WAES 00115289
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hiatus Hernia Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	128 DAY
			Acetaminophen	C				
			Alprostadil	C				
			Aluminium					

Hydroxide/Magnesium Carbonate	C
Beclomethasone Dipropionate	C
Benorylate	C
Bumetanide	C
Nitroglycerin	C
Quinine	C
Rabeprazole Sodium	C
Ramipril	C
Salmeterol	C

Date:12/12/00ISR Number: 3628785-2Report Type:Expedited (15-DaCompany Report #WAES 00115186
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Colitis Ischaemic	Health						
Other	Cyst	Professional			Merck Co Inc	ORAL	25 MG PO	
	Enterocolitis	Other	Docetaxel	SS				15 DAY
	Haemorrhagic		Diacetylmorphine	C				
	Haemoglobin Abnormal		Haloperidol	C				
	Platelet Count Abnormal		Metoclopramide	C				
	Sigmoidoscopy Abnormal		Senna	C				
	White Blood Cell Count Abnormal							

Date:12/12/00ISR Number: 3628787-6Report Type:Expedited (15-DaCompany Report #WAES 00120395
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Level Changed							
					Merck Co Inc	ORAL	25 MG/PO	5 DAY
			Dilantin	SS				
			Glucophage	C				
			Hydrodiuril	C				

Date:12/12/00ISR Number: 3628790-6Report Type:Expedited (15-DaCompany Report #WAES 00116054
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
		Other	Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	
			Althiazide/Spironolactone	C				
			Cetirizine Hydrochloride	C				

Date:12/12/00ISR Number: 3628791-8Report Type:Expedited (15-DaCompany Report #WAES 00120364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
Celebrex	C				
K-Dur	C				
Lanoxin	C				
Lasix	C				
Tambocor	C				
Verapamil	C				

Date:12/12/00ISR Number: 3628792-XReport Type:Expedited (15-DaCompany Report #WAES 00116180
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 PO	33 DAY
			Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	
		Other	Levothyroxine Na	C				

Date:12/12/00ISR Number: 3628793-1Report Type:Expedited (15-DaCompany Report #WAES 00120107
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Propranolol	C				

Date:12/12/00ISR Number: 3628797-9Report Type:Expedited (15-DaCompany Report #WAES 00105601
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Congestive	Health			Laboratories Div			
Hospitalization -	Cerebrovascular Accident	Professional			Merck Co Inc	ORAL	25 MG PO	9 DAY
Initial or Prolonged	Condition Aggravated	Other	Captopril/Hctz	C				
	Malignant Hypertension		Carbamazepine	C				
			Digitoxin	C				
			Insulin	C				

Date:12/12/00ISR Number: 3628806-7Report Type:Expedited (15-DaCompany Report #WAES 00125022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ventricular Fibrillation	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	25 MG PO	
			Albuterol	C				
			Albuterol Sulfate (+) Ipratropium Bromid	C				
			Aspirin	C				

Diltiazem	C
Furosemide	C
Ipratropium Bromide	C
Meloxicam	C
Prednisolone	C

Date:12/12/00ISR Number: 3628807-9Report Type:Expedited (15-DaCompany Report #WAES 00125541
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:12/12/00ISR Number: 3628808-0Report Type:Expedited (15-DaCompany Report #WAES 00120145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:12/12/00ISR Number: 3628810-9Report Type:Expedited (15-DaCompany Report #WAES 00118618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:12/12/00ISR Number: 3628811-0Report Type:Expedited (15-DaCompany Report #WAES 00115573
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	7	DAY
			Chlorthalidone	C				
			Furosemide	C				
			Metoprolol Tartrate	C				
			Nifedipine	C				
			Reserpine	C				

Date:12/12/00ISR Number: 3628817-1Report Type:Expedited (15-DaCompany Report #WAES 00127906
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Pigmented Naevus Stevens-Johnson Syndrome	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 DAY
			Enalapril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/00ISR Number: 3628822-5Report Type:Expedited (15-DaCompany Report #WAES 00113740
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Fosamax	C				
			Aspirin	C				

Date:12/12/00ISR Number: 3628828-6Report Type:Expedited (15-DaCompany Report #WAES 00120017
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aspirin	C				

Date:12/12/00ISR Number: 3628829-8Report Type:Expedited (15-DaCompany Report #WAES 00112459
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Vomiting	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				
			Timoptic	C				
			Trusopt	C				
			Xalatan	C				
			Estradiol	C				
			Furosemide	C				
			Ranitidine	C				

Date:12/12/00ISR Number: 3628830-4Report Type:Expedited (15-DaCompany Report #WAES 00112460
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Asthenia
	Balance Disorder
	Blood Pressure Increased
	Bronchitis
	Condition Aggravated
	Dizziness
	Fall
	Fatigue
	Gastrooesophageal Reflux Disease
	Haematochezia
	Headache
	Hyponatraemia
	Laceration
	Nausea
	Oedema Peripheral
	Pleural Infection
	Pruritus
	Rectal Haemorrhage

	Tinnitus Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Reglan	SS			
			Dyazide	C			
			Evista	C			
			Lomotil	C			
			Pepcid Ac	C			
			Prevacid	C			
			Tigan	C			
			Ventolin	C			

Date:12/12/00ISR Number: 3628831-6Report Type:Expedited (15-DaCompany Report #WAES 00111199
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO
			Vitamins	C			

Date:12/12/00ISR Number: 3628832-8Report Type:Expedited (15-DaCompany Report #WAES 00110906
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Blindness Vitreous Haemorrhage	Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Monopril	C			
			Neurontin	C			
			Prozac	C			
			Allopurinol	C			

Date:12/12/00ISR Number: 3628833-XReport Type:Expedited (15-DaCompany Report #WAES 00101539
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Fluid Retention Migraine Oedema Peripheral Pulmonary Arterial Wedge Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	
			Effexor	C				
			Maxalt (Rizatriptan Benzoate)	C				
			Premarin	C				
			Prilosec	C				
			Tenormin	C				
			Zomig	C				
			Ascorbic Acid	C				
			Chondroitin (+) Glucosamine	C				
			Vitamin E	C				

			Vitamins	C		

Date:12/12/00ISR Number: 3628834-1Report Type:Expedited (15-DaCompany Report #WAES 00119553
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Diarrhoea Vomiting	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:12/12/00ISR Number: 3628835-3Report Type:Expedited (15-DaCompany Report #WAES 00116065
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Gastrointestinal Haemorrhage	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO; 12.5 MG, PO	3 DAY

Date:12/12/00ISR Number: 3628837-7Report Type:Expedited (15-DaCompany Report #WAES 00116173
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO; 25 MG, PO	29 DAY
			Fenofibrate	C				
			Fosinopril	C				
			Lorazepam	C				
			Melilot	C				

Date:12/12/00ISR Number: 3628839-0Report Type:Expedited (15-DaCompany Report #WAES 00126010
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Furosemide	C				

Date:12/12/00ISR Number: 3628843-2Report Type:Expedited (15-DaCompany Report #WAES 00125020
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Left Ventricular Failure Ventricular Fibrillation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	4 DAY
			Cozaar	C				
			Aspirin	C				
			Atenolol	C				
			Diclofenac	C				
			Diltiazem Hydrochloride	C				
			Isosorbide Mononitrate	C				

				Lolfepramine	C		
				Nitroglycerin	C		

Date:12/13/00ISR Number: 3627207-5Report Type:Direct Company Report #
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea		Vioxx 25mg	PS			1 X DAILY	
	Serum Ferritin Decreased							

Date:12/13/00ISR Number: 3627213-0Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Increased		Vioxx	PS		ORAL	50MG PO Q DAY	
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Peritoneal Haemorrhage							

Date:12/13/00ISR Number: 3627795-9Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Liver Function Test		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	
	Abnormal							

Date:12/13/00ISR Number: 3628580-4Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Abdominal Discomfort Rofecoxib 25mg PS
QD

Date:12/13/00ISR Number: 3628585-3Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Rofecoxib 25 Mg	PS				

Date:12/13/00ISR Number: 3628847-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Erosive Upper Gastrointestinal Haemorrhage		Vioxx	PS				

Date:12/13/00ISR Number: 3628964-4Report Type:Expedited (15-DaCompany Report #WAES 99110294
Age:79 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Asthenia Coordination Abnormal Disorientation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Dyspnoea	Representative						
Fatigue		Tab Cipro 500 Mg	SS		ORAL	500 MG/DAILY/PO	
Haemodialysis							
Nephritis Interstitial Renal Failure Acute		Betapace	C				
		Cytotec	C				
		Fosamax	C				
		Premarin	C				
		Prevacid	C				
		Ultram	C				
		Calcium Supplement	C				
		Ginkgo Biloba Extract	C				
		Magnesium Preparation	C				
		Sodium Folate	C				
		Vitamins	C				
		Zinc Preparation	C				

Date:12/13/00ISR Number: 3628967-XReport Type:Expedited (15-DaCompany Report #WAES 00120578
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Hypertension Urinary Tract Obstruction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Prinivil Unk	SS		ORAL	PO	
			Aspirin	C				
			Baclofen	C				

Date:12/13/00ISR Number: 3628968-1Report Type:Expedited (15-DaCompany Report #WAES 00120106
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Eosinophilic Pneumonia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/13/00ISR Number: 3628972-3Report Type:Expedited (15-DaCompany Report #WAES 00120504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pneumonitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Cartia	C				
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Pima Syrup	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/00ISR Number: 3628973-5Report Type:Expedited (15-DaCompany Report #WAES 00120270
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/13/00ISR Number: 3629003-1Report Type:Expedited (15-DaCompany Report #WAES 00091713
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Vioxx	PS	Merck Research			
Other		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	11 DAY
			Procrit	C				
			Prednisone	C				
			Vitamins	C				

Date:12/13/00ISR Number: 3629006-7Report Type:Expedited (15-DaCompany Report #WAES 00101953
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	
							PO	
			Celebrex	C				
			Hydrodiuril	C				
			Hormones (Unspecified)	C				

Date:12/13/00ISR Number: 3629008-0Report Type:Expedited (15-DaCompany Report #WAES 00111650
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Cardiac Failure	Other						
	Congestive							
	Condition Aggravated		Celebrex	C				
			K-Dur	C				
			Lanoxicaps	C				
			Lasix	C				
			Lopressor	C				
			Zantac	C				
			Therapy Unspecified	C				

Date:12/13/00ISR Number: 3629194-2Report Type:Expedited (15-DaCompany Report #WAES 00110990
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Diverticulitis Intestinal
Other	Haemorrhagic
	Dry Skin
	Hypokalaemia
	Hypotension

		Pallor Sinus Tachycardia Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Carafate	C		
				Dulcolax	C		
				K-Dur	C		
				Lasix	C		
				Motrin	C		
				Paxil	C		
				Peri-Colace	C		
				Surfak	C		
				Tylenol	C		
				Zantac	C		
				Aspirin	C		
				Famotidine	C		
				Globulin, Immune	C		
				Magnesium Hydroxide	C		
				Magnesium Oxide	C		
				Nitroglycerin	C		
				Senna	C		

Date:12/13/00ISR Number: 3629229-7Report Type:Expedited (15-DaCompany Report #WAES 00106191
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Exercise Test Abnormal Extrasystoles	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO							
				Pravastatin Na	C		

Date:12/13/00ISR Number: 3629245-5Report Type:Expedited (15-DaCompany Report #WAES 00115656
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	9 DAY
	Medication Error		Fosamax	C				
			Fosinopril Sodium	C				
			Gingko Biloba Extract	C				
			Methixene Hydrochloride	C				
			Mirtazapine	C				
			Piretanide	C				

Date:12/13/00ISR Number: 3629246-7Report Type:Expedited (15-DaCompany Report #WAES 00115661
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Interaction Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	93 DAY
			Tab Aspirin	SS		ORAL	PO	

			Diclofenac Sodium (+) Misoprostol	C		
			Digitoxin	C		
			Doxazosin Mesylate	C		
			Felodipine	C		
			Hydrochlorthiazide (+) Ramipril	C		
			Isosorbide Mononitrate	C		

Date:12/13/00ISR Number: 3629247-9Report Type:Expedited (15-DaCompany Report #WAES 00116177
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Acetaminophen	C				
			Fluoxetine	C				
			Lorazepam	C				
			Tramadol	C				

Date:12/13/00ISR Number: 3629248-0Report Type:Expedited (15-DaCompany Report #WAES 00128517
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia Renal Failure Chronic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY
			Therapy Unspecified	C				
			Furosemide	C				
			Insulin Human	C				
			Lansoprazole	C				
			Ramipril	C				

Date:12/13/00ISR Number: 3629288-1Report Type:Expedited (15-DaCompany Report #WAES 00126002
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Flutter	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
		Professional Other	Bromazepam	C		
			Chondroitin Sulfate Sodium	C		
			Etidronate Disodium	C		

Date:12/13/00ISR Number: 3629289-3Report Type:Expedited (15-DaCompany Report #WAES 00116021
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 10 DAY						
			Calcium Citrate (+) Cholecaliferol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/00ISR Number: 3632221-XReport Type:Expedited (15-DaCompany Report #WAES 00123725
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Other	Fluoxetine Hcl	C				

Date:12/15/00ISR Number: 3631560-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG PO	
	Hypoaesthesia						DAILY	2 MON
	Tongue Oedema		Folic Acid	C				
			Premarin	C				
			Lipitor	C				
			Gemfibrozil	C				
			Vasotec	C				
			Quinine	C				
			Hydrochorothiazide	C				
			Asa	C				
			Coumadin	C				
			Flovent	C				
			Atrovent	C				

Date:12/15/00ISR Number: 3631587-4Report Type:Expedited (15-DaCompany Report #WAES 00100487
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/15/00ISR Number: 3631667-3Report Type:Expedited (15-DaCompany Report #WAES 00111042
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alveolitis Allergic Respiratory Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Tolectin	C				
			Prednisone	C				

Date:12/15/00ISR Number: 3631668-5Report Type:Expedited (15-DaCompany Report #WAES 00120603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/00ISR Number: 3631673-9Report Type:Expedited (15-DaCompany Report #WAES 00120509
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardio-Respiratory Arrest Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:12/15/00ISR Number: 3631675-2Report Type:Expedited (15-DaCompany Report #WAES 00091033
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Anaemia Condition Aggravated Dyspepsia Gastrointestinal Haemorrhage Gastrointestinal Ulcer Retinal Haemorrhage Visual Acuity Reduced	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin 325 Mg	SS				

Date:12/15/00ISR Number: 3631680-6Report Type:Expedited (15-DaCompany Report #WAES 00120649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Swelling Tongue Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/15/00ISR Number: 3631681-8Report Type:Expedited (15-DaCompany Report #WAES 00120417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia Dyspnoea Face Oedema Influenza Like Illness Menorrhagia Nasopharyngeal Disorder Swelling Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/15/00ISR Number: 3631682-XReport Type:Expedited (15-DaCompany Report #WAES 00120776
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Mental Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/00ISR Number: 3631684-3Report Type:Expedited (15-DaCompany Report #WAES 00111637
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Gastrointestinal Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	SS		ORAL	5 MG/DAILY/PO	

Date:12/15/00ISR Number: 3631781-2Report Type:Expedited (15-DaCompany Report #WAES 00125501
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective	Foreign Study Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET	

Date:12/15/00ISR Number: 3631784-8Report Type:Expedited (15-DaCompany Report #WAES 00125043
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	127 DAY
			Acetaminophen/Codeine Phosphate	C				
			Fluoxetine	C				
			Meperidine	C				
			Temazepam	C				

Date:12/15/00ISR Number: 3632188-4Report Type:Expedited (15-DaCompany Report #WAES 00117932
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Neoplasm Of Skin Face Oedema Pigmented Naevus	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY
	Stevens-Johnson Syndrome		Enalapril	C				

Date:12/15/00ISR Number: 3632189-6Report Type:Expedited (15-DaCompany Report #WAES 00116133
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	25 DAY
	Subcutaneous Haematoma		Fluindione	SS		ORAL	10 MG PO	
			Fluindione	SS		ORAL	10 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/00ISR Number: 3632190-2Report Type:Expedited (15-DaCompany Report #WAES 00115289
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Hiatus Hernia Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	128 DAY
			Acetaminophen	C				
			Alprostadil	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Aspirin	C				
			Beclomethasone Dipropionate	C				
			Benorylate	C				
			Bumetanide	C				
			Nitroglycerin	C				
			Quinine	C				
			Rabeprazole Sodium	C				
			Ramipril	C				
			Salmeterol	C				

Date:12/15/00ISR Number: 3632191-4Report Type:Expedited (15-DaCompany Report #WAES 00113740
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Fosamax	C				
			Aspirin	C				

Date:12/15/00ISR Number: 3632192-6Report Type:Expedited (15-DaCompany Report #WAES 00105175
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			

	Congestive Condition Aggravated	Other			Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 94 DAY						
	Renal Impairment		Zocor	C		
			Aspirin	C		
			Chlorpheniramine Maleate	C		
			Furosemdie	C		
			Omeprazole	C		
			Ramipril	C		

Date:12/15/00ISR Number: 3632193-8Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anaphylactic Reaction	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Pulmonary Haemorrhage	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25.0 MG PO 2 DAY						
		Other	Prinivil	C		
			Acetaminophen	C		
			Cyclosporin A	C		
			Docusate Na	C		

Folic Acid	C
Furosemide	C
Insulin, Biphasic Isophane [Injection]	C
Methotrexate	C
Prednisolone	C
Senna	C
Thioridazine	C
Paroxetine	C

Date:12/15/00ISR Number: 3632201-4Report Type:Expedited (15-DaCompany Report #WAES 00125556
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 -25 MG PO	
			Acetyldigoxin	C				
			Aspirin	C				
			Cerivastatin Sodium	C				
			Lisinopril/Hctz	C				
			Sotalol Hydrochloride	C				

Date:12/15/00ISR Number: 3632206-3Report Type:Expedited (15-DaCompany Report #WAES 00127906
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Neoplasm Of Skin Face Oedema Pigmented Naevus	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY
	Stevens-Johnson Syndrome		Enalapril	C				

Date:12/15/00ISR Number: 3632208-7Report Type:Expedited (15-DaCompany Report #WAES 00127273
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY
			Allopurinol	C				
			Amiloride Hydrochloride	C				
			Aspirin	C				
			Digoxin	C				
			Furosemide	C				
			Omeprazole Sodium	C				

Date:12/15/00ISR Number: 3632218-XReport Type:Expedited (15-DaCompany Report #WAES 00085182
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angioneurotic Oedema	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 TABLET PO	
Hospitalization - Initial or Prolonged	Paraesthesia Oral	Other						
			Cyclosporin A	C				

			Furosemide	C		
			Insulin	C		
			Prednisolone	C		

Date:12/15/00ISR Number: 3632224-5Report Type:Expedited (15-DaCompany Report #WAES 00125522
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Ineffective Hypertensive Crisis	Foreign Study	Vioxx	PS	Merck Research Laboratories Div	
Other		Health			Merck Co Inc	ORAL
12.5 MG PO 51 DAY						
		Professional Other	...	C		

Date:12/18/00ISR Number: 3633852-3Report Type:Expedited (15-DaCompany Report #WAES 00125584
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25 MG PO						
			Calcium Carbonate (+) Cholecalciferol (+) Nizatidine	C		

Date:12/18/00ISR Number: 3633853-5Report Type:Expedited (15-DaCompany Report #WAES 00126002
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Flutter	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG PO;						
25 MG PO 58 DAY						
			Bromazepam	C		

			Chondroitin Sulfate Sodium	C		
			Etidronate Disodium	C		

Date:12/18/00ISR Number: 3633855-9Report Type:Expedited (15-DaCompany Report #WAES 00127271
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY
			Digoxin	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Prednisolone	C				
			Ranitidine Hcl	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3633644-5Report Type:Direct Company Report #
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Ecotrin (325mg Po Qd)	PS	Drurl	ORAL	35MG QD PO	SEVERAL MONTHS-PRESENT
			Vioxx (12.5mg Qd (Merck)	SS	Merck	ORAL	12.5MG QD PO	

Date:12/19/00ISR Number: 3633656-1Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Toxic Epidermal		Ketorolac (10mg Tab)	PS		ORAL	1T PO QD	
Required	Necrolysis		Vioxx (12.5mg Tab)	SS		ORAL	1T PO QD	
Intervention to Prevent Permanent Impairment/Damage			Atenolol	C				
			Premarin	C				
			Multivitamin	C				
			Beconase Nasal Spray	C				
			Adalat Cc	C				
			Effexor	C				

Date:12/19/00ISR Number: 3633730-XReport Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Abdominal Pain		Vioxx 12.5 Mg	PS			OCCLUSIVE	
Intervention to	Depression						DRESSING	12.5 MG QD

Prevent Permanent
OCCLUSIVE
Impairment/Damage
DRESSING

			Estroderm Patch	C
			Allegra	C

Date:12/19/00ISR Number: 3633810-9Report Type:Expedited (15-DaCompany Report #WAES 00125092
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Abdominal Tenderness Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
12.5 MG PO 7 DAY

Acetaminophen/Codeine Phosphate	C
Aspirin	C
Atenolol	C
Isosorbide Mononitrate	C
Nicorandil	C
Nitroglycerin	C
Omeprazole	C
Oxytetracycline	C
Venlafaxine	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3633814-6Report Type:Expedited (15-DaCompany Report #WAES 00125561
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Perforation Gastric Ulcer	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	22 DAY
			Doxepin Hcl	C				
			Furosemide	C				
			Lactulose	C				

Date:12/19/00ISR Number: 3633934-6Report Type:Expedited (15-DaCompany Report #WAES 00091845
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia Nerve Compression Tenosynovitis	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cardizem	C				
			Lopid	C				
			Aspirin	C				

Date:12/19/00ISR Number: 3633935-8Report Type:Expedited (15-DaCompany Report #WAES 00111202
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	4 DAY
		Representative	Avapro	C				
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Toprol Xl Tablets	C				
			Zyloprim	C				

Date:12/19/00ISR Number: 3633939-5Report Type:Expedited (15-DaCompany Report #WAES 00121101
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Bradycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/19/00ISR Number: 3633965-6Report Type:Expedited (15-DaCompany Report #WAES 00020955
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Asthenia Back Pain Colitis Ulcerative Faeces Discoloured Fatigue Gastrointestinal Disorder Headache Myocardial Infarction

Thrombosis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				
			Xalatan	C				

Date:12/19/00ISR Number: 3633967-XReport Type:Expedited (15-DaCompany Report #WAES 00112265
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Tolerance Decreased Gastric Ulcer Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Lasix	C				
			Lipitor	C				
			Metamucil	C				
			Osteo-Bi-Flex	C				
			Tylenol	C				
			Zestril	C				
			Aspirin	C				
			Atenolol	C				

Date:12/19/00ISR Number: 3633971-1Report Type:Expedited (15-DaCompany Report #WAES 00112455
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Glucophage	C				
			Glucotrol	C				
			Aspirin	C				

Date:12/19/00ISR Number: 3633982-6Report Type:Expedited (15-DaCompany Report #WAES 00120899
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	90 DAY

Date:12/19/00ISR Number: 3633986-3Report Type:Expedited (15-DaCompany Report #WAES 00120898
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3633989-9Report Type:Expedited (15-DaCompany Report #WAES 00120860
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Paralysis Paresis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
			Celebrex	C				
			Prevacid	C				

Date:12/19/00ISR Number: 3634362-XReport Type:Expedited (15-DaCompany Report #WAES 00100991
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Kidney Small Renal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
	Renal Impairment							
	Urinary Tract Infection		Coumadin	C				
	Vesicoureteral Reflux		Estratest	C				
	Surgery		Verapamil	C				

Date:12/19/00ISR Number: 3634363-1Report Type:Expedited (15-DaCompany Report #WAES 00100681
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	Other
			Hytrin	C				
			Proscar	C				
			Prozac	C				

				Zocor	C		
				Alprazolam	C		
				Aspirin	C		

Date:12/19/00ISR Number: 3634364-3Report Type:Expedited (15-DaCompany Report #WAES 00092388
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research			
	Syncope	Health			Laboratories Div			
	Urticaria	Professional			Merck Co Inc	ORAL	25	
	Vomiting						MG/DAILY/PO	
			Amoxil	C				
			Hydrodiuril	C				
			Premarin	C				
			Tums	C				
			Atenolol	C				
			Glucosamine	C				
			Vitamin E	C				

Date:12/19/00ISR Number: 3634365-5Report Type:Expedited (15-DaCompany Report #WAES 00120601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/19/00ISR Number: 3634368-0Report Type:Expedited (15-DaCompany Report #WAES 00110603
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cadizem	C				
			Cardura	C				
			Trental	C				
			Vicodin Tablets	C				
			Zocor	C				

Date:12/19/00ISR Number: 3634369-2Report Type:Expedited (15-DaCompany Report #WAES 00120504
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pneumonitis Spinal Fracture Sputum Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Cartia	C				
			Coumadin	C				
			Lanoxin	C				
			Lasix	C				
			Naprosyn	C				
			Pima Syrup	C				

			Vicodin Tablets	C		

Date:12/19/00ISR Number: 3634430-2Report Type:Expedited (15-DaCompany Report #WAES 99125650
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chills	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Circulatory Collapse	Health				
	Deep Vein Thrombosis	Professional			Merck Co Inc	ORAL
25 MG PO						
	Dizziness	Other	Hctz/Quinapril	C		
	Erysipelas		Amoxicillin			
	Oedema Peripheral		Trihydrate (+)			
	Pyrexia		Clavulanate P	C		
	Syncope		Calcium Gluconate			
	Vomiting		(+) Calcium			
			Phosphate	C		
			Nadroparin Calcium	C		
			Salcatonin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3634449-1Report Type:Expedited (15-DaCompany Report #WAES 00118212
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	25 MG PO	22 DAY
			Vaseretic	C				
			Aspirin	C				

Date:12/19/00ISR Number: 3634462-4Report Type:Expedited (15-DaCompany Report #WAES 00125042
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis	Foreign	Vioxx	PS	Merck Research			
	Pruritus	Other			Laboratories Div			
	Vomiting				Merck Co Inc	ORAL	12.5 MG PO	2 DAY
			Acetaminophen	C				
			Chlorpheniramine	C				
			Cyclizine	C				
			Granisetron	C				
			Morphine So4	C				

Date:12/19/00ISR Number: 3634464-8Report Type:Expedited (15-DaCompany Report #WAES 00125064
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faeces Discoloured	Foreign	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG PO	22 DAY
			Atorvastatin	C				
			Bezafibrate	C				

Date:12/19/00ISR Number: 3634465-XReport Type:Expedited (15-DaCompany Report #WAES 00125561
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Study			Laboratories Div			
Initial or Prolonged		Health			Merck Co Inc	ORAL	25 MG PO	22 DAY
		Professional	Doxepin Hcl	C				
			Furosemide	C				
			Lactulose	C				

Date:12/19/00ISR Number: 3634466-1Report Type:Expedited (15-DaCompany Report #WAES 00125567
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastric Haemorrhage	Study			Laboratories Div			
	Overdose	Health			Merck Co Inc	ORAL	75 MG PO	10 DAY
		Professional	Pantoprazole Sodium	C				
			Tramadol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/00ISR Number: 3634470-3Report Type:Expedited (15-DaCompany Report #WAES 00109001
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	25 MG PO	1 DAY
		Other	Zocor	C				
			Aspirin	C				
			Herbesser	C				
			Imdur	C				
			Isosorbide Mononitrate	C				
			Lorazepam	C				
			Nicorandil	C				
			Nifedipine	C				
			Nitroglycerin	C				
			Warfarin Sodium	C				

Date:12/19/00ISR Number: 3634478-8Report Type:Expedited (15-DaCompany Report #WAES 00119762
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Infection	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Heart Rate Increased	Health			Laboratories Div			
	Stomatitis	Professional			Merck Co Inc	ORAL	PO	1 MON
		Other						

Date:12/19/00ISR Number: 3634479-XReport Type:Expedited (15-DaCompany Report #WAES 00125517
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Haemorrhage	Health			Laboratories Div			
Hospitalization -	Shock	Professional			Merck Co Inc	ORAL	PO	6 MON
Initial or Prolonged		Other	Diclofenac Na	C				
			Ranitidine Hcl	C				

Date:12/19/00ISR Number: 3643340-6Report Type:Periodic Company Report #WAES 00083056
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Cardizem	C				
			Lipitor	C				
			Calcium Supplement	C				

Date:12/20/00ISR Number: 3633854-7Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Vioxx	PS				
	Tongue Oedema		Lotensin	C				
			Levoxyl	C				
			Ntg	C				

			Lipitor	C		
			Paxil	C		

Date:12/20/00ISR Number: 3633856-0Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia		Vioxx (Rofecoxib)	PS				
	International Normalised Ratio Increased		Pravachol	C				
			Meclizine	C				
			Valium	C				
			Asa	C				
			Coumadin	C				

Date:12/20/00ISR Number: 3633886-9Report Type:Direct Company Report #
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx 50mg	PS			ONE DAILY	4 DAY
	Palpitations		Orthotricyclens	C				

Date:12/20/00ISR Number: 3635474-7Report Type:Expedited (15-DaCompany Report #WAES 00116173
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
	Fall	Study			Laboratories Div			
	Osteoarthritis	Health			Merck Co Inc	ORAL	SEE IMAGE /	
		Professional					PO	29 DAY
			Fenofibrate	C				
			Fosinopril	C				
			Lorazepam	C				
			Melilot	C				

Date:12/20/00ISR Number: 3635565-0Report Type:Expedited (15-DaCompany Report #WAES 00120106
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Eosinophilic Pneumonia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25; 12.5 MG/DAILY/PO	
Life-Threatening	Interstitial Lung Disease							
Hospitalization - Initial or Prolonged	Pneumonia							
	Respiratory Failure							
			Motrin	C				
			Acetaminophen	C				
			Influenza Virus Vaccine	C				
			Therapy Unspecified	C				

Date:12/20/00ISR Number: 3635736-3Report Type:Expedited (15-DaCompany Report #001-0073-M0000484
Age:46 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Confusional State
	Convulsion
	Drug Level Below Therapeutic

Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Dilantin	PS	Parke Davis Div Warner Lambert Co	ORAL	PER ORAL	
			Vioxx	SS		ORAL	25 MG (DAILY), PER ORAL	
			Phenobarbital	C				
			Tenormin	C				
			Hydrochlorothiazide	C				

Date:12/20/00ISR Number: 3644141-5Report Type:Periodic Company Report #WAES 00111237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:12/21/00ISR Number: 3634620-9Report Type:Expedited (15-DaCompany Report #B0094379A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation		Ranitidine Hydrochloride	PS	Glaxo Wellcome	ORAL		
			Rofecoxib	SS		ORAL	4 DAY	
			Aspirin	SS		ORAL	75MG per day	4 YR

Date:12/22/00ISR Number: 3635316-XReport Type:Expedited (15-DaCompany Report #B0083343A
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	C-Reactive Protein	Consumer	Zinacef	PS	Glaxo Wellcome	INTRAVENOUS	750MG Three times per day	7 DAY
	Increased Platelet Count Decreased		Vioxx	SS		ORAL	25MG per day	6 DAY
	Renal Failure		Panodil	C				
	Synovitis		Behepan	C				
			Sobril	C				
			Dexofen	C				
			Calcichew	C				
			Losec	C				

Date:12/22/00ISR Number: 3635502-9Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx 12.5	PS			ONCE DAILY	
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3635930-1Report Type:Expedited (15-DaCompany Report #WAES 00120923
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Activity Dialysis Difficulty In Walking Dysgraphia Hepatic Failure Mental Impairment Pulmonary Congestion Renal Failure Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON

Date:12/22/00ISR Number: 3636337-3Report Type:Expedited (15-DaCompany Report #B0094379A
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign	Zantac 150	PS	Glaxo Wellcome Inc	ORAL	ORAL	
			Rofecoxib (Formulation Unknown) (Rofecoxib)	SS		ORAL	ORAL	
			Aspirin (Formulation Unknown) (Aspirin)	SS		ORAL	ORAL	

Date:12/22/00ISR Number: 3636444-5Report Type:Expedited (15-DaCompany Report #WAES 00129554
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Lonarid	C				
			Ranitidine	C				

Date:12/22/00ISR Number: 3636448-2Report Type:Expedited (15-DaCompany Report #WAES 00125023
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY
	Diarrhoea	Other						
	Gastrointestinal							
	Haemorrhage		Cozaar	C				
			Doxazosin	C				

Date:12/22/00ISR Number: 3636450-0Report Type:Expedited (15-DaCompany Report #WAES 00127277
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Dysarthria							
	Dysphagia							
	Personality Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3636474-3Report Type:Expedited (15-DaCompany Report #WAES 00126105
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Hypertension	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	145 DAY
		Professional	Indapamide	C				
			Irbesartan	C				
			Potassium Chloride	C				
			Tamsulosin Hydrochloride	C				

Date:12/22/00ISR Number: 3636476-7Report Type:Expedited (15-DaCompany Report #WAES 00126062
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haemorrhage		Inj Enoxaparin	SS			INTRAVENOUS IV	3 DAY
	Post Procedural Haemorrhage Renal Impairment Uterine Prolapse		Ketoprofen	C				

Date:12/22/00ISR Number: 3636479-2Report Type:Expedited (15-DaCompany Report #WAES 00115668
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis Ulcerative	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 MON
			Aesculus	C				
			Tramadol Hcl	C				
			Xipamide	C				

Date:12/22/00ISR Number: 3636515-3Report Type:Expedited (15-DaCompany Report #WAES 00125073
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	5 DAY
	Chest Discomfort	Other						
	Dyspnoea							
	Sleep Disorder		Prinivil	C				
			Acetaminophen/Codeine Phosphate	C				

Date:12/22/00ISR Number: 3636518-9Report Type:Expedited (15-DaCompany Report #WAES 00125583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/00ISR Number: 3644002-1Report Type:Periodic Company Report #WAES 00111471
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3636752-8Report Type:Periodic Company Report #WAES 00072453
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 Other MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Occupress	C				
			Visken	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3636755-3Report Type:Periodic Company Report #WAES 00072241
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Blood Pressure Increased Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Klonopin	C				
			Premarin	C				
			Sinemet	C				
			Synthroid	C				
			Trental	C				

			Tylenol With Codeine	C		
			Zoloft	C		

Date:12/26/00ISR Number: 3636758-9Report Type:Periodic Company Report #WAES 00071087
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Dizziness	Health			Laboratories Div	
	Fall	Professional			Merck Co Inc	ORAL
PRN/PO						
	Flatulence	User Facility	Allegra	C		
	Nasal Congestion		Neurontin	C		
	Nausea		Premarin	C		
	Productive Cough		Tiazec	C		
	Vomiting		Tylenol Arthritis			
			Extended Relief	C		
			Lorazepam	C		

Date:12/26/00ISR Number: 3636761-9Report Type:Periodic Company Report #WAES 00064302
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Asthenia	Health	Vioxx	PS	Merck Research	
	Fatigue	Professional			Laboratories Div	

Merck Co Inc ORAL
12.5/25 MG/

TID/PO

Avandia	C
Capoten	C
Glucophage	C
Lipitor	C
Novolin	C

Date:12/26/00ISR Number: 3636766-8Report Type:Periodic Company Report #WAES 00111547
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Dry Mouth Dyspepsia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Atenolol	C				
			Indapamide	C				

Date:12/26/00ISR Number: 3636767-XReport Type:Periodic Company Report #WAES 00110189
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Pravachol	C				

Date:12/26/00ISR Number: 3636769-3Report Type:Periodic Company Report #WAES 00100926
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vomiting	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3636770-XReport Type:Periodic Company Report #WAES 00100745
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Drug Ineffective Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Ditropan	C				
			Imdur	C				
			Proscar	C				
			Ticlid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3636771-1Report Type:Periodic Company Report #WAES 00100573
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Daypro	C				
			Lodine	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3636772-3Report Type:Periodic Company Report #WAES 00092092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactoid Reaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 WK

Date:12/26/00ISR Number: 3636773-5Report Type:Periodic Company Report #WAES 00091753
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	3 DAY
			Coumadin	C				

Date:12/26/00ISR Number: 3636774-7Report Type:Periodic Company Report #WAES 00090887
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
	Pain	Health			Laboratories Div	
	Rash Erythematous	Professional			Merck Co Inc	ORAL
25-50 MG/						
DAILY/ PO						
			Accupril	C		
			Baycol	C		
			Imdur	C		
			Nitrol (Isosorbide Dinitrate)	C		
			Prevacid	C		
			Alprazolam	C		
			Atenolol	C		

Date:12/26/00ISR Number: 3636775-9Report Type:Periodic Company Report #WAES 00090738
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/ PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3636776-0Report Type:Periodic Company Report #WAES 00090347
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Claritin	C				
			Demadex	C				
			Estratab	C				
			Monopril	C				
			Nitrofortin	C				
			Tibirox	C				

Date:12/26/00ISR Number: 3636777-2Report Type:Periodic Company Report #WAES 00090221
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3636778-4Report Type:Periodic Company Report #WAES 00082920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3636779-6Report Type:Periodic Company Report #WAES 00082654
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3636780-2Report Type:Periodic Company Report #WAES 00082656
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral Skin Lesion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Cardura	C				
			Mestinon	C				
			Prilosec	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3636781-4Report Type:Periodic Company Report #WAES 00082312
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Prevacid	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3637933-XReport Type:Expedited (15-DaCompany Report #WAES 00116177
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	78 DAY
			Acetaminophen	C				
			Fluoxetine	C				
			Lorazepam	C				
			Tramadol	C				

Date:12/26/00ISR Number: 3637936-5Report Type:Expedited (15-DaCompany Report #WAES 00116101
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Haemorrhage	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, 25 MG	118 DAY
			Benazepril Hcl/Hctz	C				

			Fluoxetine	C		
			Thyroxine	C		

Date:12/26/00ISR Number: 3637939-0Report Type:Expedited (15-DaCompany Report #WAES 00115648
Age:57 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG						
			Inj Dexamethasone	SS		
INTRAMUSCULAR 1 DOSE 1 DAY						
			Inj Diclofenac	SS		
INTRAMUSCULAR 1 DOSE 1 DAY						

Date:12/26/00ISR Number: 3637958-4Report Type:Expedited (15-DaCompany Report #WAES 00126117
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dehydration Renal Impairment	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE 30 DAY						
			Acetaminophen	C		
			Tramadol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3637961-4Report Type:Expedited (15-DaCompany Report #WAES 00125617
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Pyrexia Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	14 DAY

Date:12/26/00ISR Number: 3637962-6Report Type:Expedited (15-DaCompany Report #WAES 00125614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3637965-1Report Type:Expedited (15-DaCompany Report #WAES 00125070
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Blood Bilirubin Increased Hepatic Function Abnormal Jaundice	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	5 DAY
	Liver Function Test Abnormal		Acetaminophen Ibuprofen	C C				

Date:12/26/00ISR Number: 3637966-3Report Type:Expedited (15-DaCompany Report #WAES 00117009
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:12/26/00ISR Number: 3637967-5Report Type:Expedited (15-DaCompany Report #WAES 00115629
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Haemorrhage	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG PO 113 DAY						
			Hctz/Triamterene	C		
			Allopurinol	C		
			Spirapril Hydrochloride	C		

Date:12/26/00ISR Number: 3637971-7Report Type:Expedited (15-DaCompany Report #WAES 00129006
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Enterocolitis	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhagic	Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG 6 DAY						
			Alprazolam	C		
			Amlodipine	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3637984-5Report Type:Expedited (15-DaCompany Report #WAES 00117815
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Stomatitis Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Methotrexate	SS				
			Nonspecific Drug Therapy	C				

Date:12/26/00ISR Number: 3637989-4Report Type:Expedited (15-DaCompany Report #WAES 00129123
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Pulmonary Hypertension	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	12 DAY

Date:12/26/00ISR Number: 3637990-0Report Type:Expedited (15-DaCompany Report #WAES 00125115
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Petechiae	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	2 WK

Date:12/26/00ISR Number: 3637992-4Report Type:Expedited (15-DaCompany Report #WAES 00125124
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	65 DAY

			Acetaminophen	C		
			Prednisolone	C		
			Theophylline	C		

Date:12/26/00ISR Number: 3638031-1Report Type:Expedited (15-DaCompany Report #WAES 00105592
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG 89 DAY						
			Molsidomine	C		
			Nifedipine	C		
			Pentaerythritol			
			Tetranitrate	C		

Date:12/26/00ISR Number: 3638036-0Report Type:Expedited (15-DaCompany Report #WAES 00125053
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
	Congestive	Other			Laboratories Div	
	Condition Aggravated				Merck Co Inc	ORAL
25 MG 8 DAY						

				Amiloride Hydrochloride (+)			
				Furosemide	C		
				Digoxin	C		

Date:12/26/00ISR Number: 3638037-2Report Type:Expedited (15-DaCompany Report #WAES 00125517
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mallory-Weiss Syndrome	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Sepsis	Health			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal	Professional			Merck Co Inc	ORAL	12.5 MG	
	Haemorrhage		[Therapy Unspecified]	C				
			Diclofenac Na	C				
			Ranitidine Hcl	C				

Date:12/26/00ISR Number: 3638038-4Report Type:Expedited (15-DaCompany Report #WAES 00126050
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG	22 DAY
			Acetaminophen	C				
			Captopril/Hctz	C				
			Pravastatin Na	C				

Date:12/26/00ISR Number: 3638039-6Report Type:Expedited (15-DaCompany Report #WAES 00126115
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Appendicectomy	Study			Laboratories Div			
		Health			Merck Co Inc	ORAL	12.5 MG	28 DAY

		Professional	Bisoprolol Fumarate	C		

Date:12/26/00ISR Number: 3638040-2Report Type:Expedited (15-DaCompany Report #WAES 00126118
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	18 DAY
			Powd Aspirin	SS		ORAL		

Date:12/26/00ISR Number: 3638045-1Report Type:Expedited (15-DaCompany Report #WAES 00075643
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Immunoglobulin G Increased Epistaxis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY
	Megakaryocytes Increased Thrombocytopenia		Aspirin Hormonal Contraceptive	C C				

			Prednisolone	C		

Date:12/26/00ISR Number: 3638054-2Report Type:Expedited (15-DaCompany Report #WAES 00117815
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Stomatitis Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Methotrexate	SS				
			Unspecified Drug Therapy	SS				

Date:12/26/00ISR Number: 3638635-6Report Type:Expedited (15-DaCompany Report #WAES 00111446
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Xenical	SS			120 MG/DAILY	

Date:12/26/00ISR Number: 3638636-8Report Type:Expedited (15-DaCompany Report #WAES 00100456
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Abdominal Pain Drug Ineffective Gastrointestinal Disorder Nausea Neuropathy Peripheral Orthostatic Hypotension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex 200 Mg	SS				
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/ DAILY/	

Porphyria Acute
PO
Tab Fosamax 10 Mg SS ORAL
10

MG/DAILY/PO
Cytomel C
Miacalcin C
Synthroid C

Date:12/26/00ISR Number: 3638805-7Report Type:Expedited (15-DaCompany Report #WAES 00111190
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
Hospitalization -	Asthenia	Professional			Laboratories Div	
Initial or Prolonged	Duodenal Ulcer	Other			Merck Co Inc	ORAL
25						
Other	Gastrointestinal					
MG/DAILY/PO						
	Haemorrhage		Accolate	C		
	Haematocrit Decreased		Betagan	C		
	Haemoglobin Decreased		Prilosec	C		
	Melaena		Septra Ds	C		
	Pallor		Serevent	C		
			Nonsteroidal Anti-Inflammatory	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3638806-9Report Type:Expedited (15-DaCompany Report #200012-0896 (0)
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Haemoglobin Decreased Ulcer Haemorrhage	Consumer	Zantac 75	PS	Warner Lambert Co Consumer Products Div	ORAL	1 TABLET DAILY, PER ORAL	
			Celebrex	SS		ORAL	PER ORAL	
			Vioxx	SS		ORAL	PER ORAL	

Date:12/26/00ISR Number: 3638808-2Report Type:Expedited (15-DaCompany Report #WAES 00112305
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO (SEE IMAGE)	
			Avandia	C				
			Coumadin	C				
			Glucotrol Xl	C				
			Lanoxin	C				
			Lasix	C				
			Lescol	C				
			Lotensin	C				
			Aspirin	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3638812-4Report Type:Expedited (15-DaCompany Report #WAES 00121415
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased							
	Bradycardia							
	Breath Sounds Decreased	Representative						
	Dehydration		Bumex	C				
	Dyspnoea		Catapres Tts	C				
	Gastritis Haemorrhagic		Cozaar	C				
	Gastrointestinal		Aspirin	C				
	Haemorrhage		Estrogens	C				
	Haematemesis							
	Haematochezia							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Headache							
	Hiatus Hernia							
	Oedema Peripheral							
	Oesophagitis							
	Pco2 Increased							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3638815-XReport Type:Expedited (15-DaCompany Report #WAES 00120364
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Angiodysplasia							
	Haemorrhagic Gastrointestinal Haemorrhage							
			Celebrex	C				
			K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Tambocor	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3638816-1Report Type:Expedited (15-DaCompany Report #WAES 00121407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain Pruritus Rash Generalised	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3638959-2Report Type:Expedited (15-DaCompany Report #WAES 00126094
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angina Unstable Atrial Fibrillation Coronary Artery Disease	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	6 DAY
			Althiazide/Spironolactone	C				
			Ginkgo Biloba Extract	C				
			Pantoprazole	C				
			Rilmenidene	C				

			Verapamil Hcl	C		

Date:12/26/00ISR Number: 3638960-9Report Type:Expedited (15-DaCompany Report #WAES 00125096
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Diarrhoea	Foreign	Vioxx	PS	Merck Research	
Other	Gastrointestinal	Other			Laboratories Div	
	Haemorrhage				Merck Co Inc	ORAL
25 MG 56 DAY						
	Myocardial Ischaemia		Bendroflumethiazide	C		
			Cerivastatin	C		
			Ferrousso4	C		
			Irbesartan	C		
			Isosorbide Mononitrate	C		
			Meptazinol Hcl	C		
			Methotrexate	C		
			Prednisolone	C		
			Rabeprazole Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3638962-2Report Type:Expedited (15-DaCompany Report #WAES 00115642
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	32 DAY
	Oesophageal Candidiasis	Study						
	Oesophageal Ulcer	Other						
	Oesophagitis		Vasotec	C				
			Nortriptyline Hcl	C				

Date:12/26/00ISR Number: 3638964-6Report Type:Expedited (15-DaCompany Report #WAES 00115635
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OPHTHALMIC	12.5 MG	5 DAY
	Congestive	Study						
	Condition Aggravated	Other						
	Gastrointestinal Disorder		Aspirin	C				
	Pain		Digitoxin	C				
			Ramipril	C				
			Ranitidine	C				

Date:12/26/00ISR Number: 3638967-1Report Type:Expedited (15-DaCompany Report #WAES 00129512
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	8 DAY
Hospitalization - Initial or Prolonged	Congestive	Other						
	Hypertension							
Other								

Date:12/26/00ISR Number: 3638971-3Report Type:Expedited (15-DaCompany Report #WAES 00127282
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Other			Laboratories Div			
Initial or Prolonged	Melaena				Merck Co Inc	ORAL	12.5 MG	47 DAY
			Tab Aspirin	SS		ORAL	PO	55 DAY
			Acetaminophen	C				
			Citalopram Hydrobromide	C				
			Digoxin	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Risperidone	C				

Date:12/26/00ISR Number: 3638989-0Report Type:Expedited (15-DaCompany Report #WAES 00125093
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
	Ecchymosis	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG PO	18 DAY
			Aspirin	SS			75 MG	
			Acetaminophen/Codeine Phosphate	C				

			Amiloride Hydrochloride (+)			
			Furosemide	C		
			Digoxin	C		
			Omeprazole	C		
			Temazepam	C		

Date:12/26/00ISR Number: 3638993-2Report Type:Expedited (15-DaCompany Report #WAES 00129760
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Face Oedema Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Cozaar	C				
			Fosamax	C				
			Aspirin	C				
			Calcium Carbonate	C				
			Furosemide	C				
			Metoprolol Tartrate	C				
			Nifedipine	C				
			Pravastatin Na	C				
			Ramipril	C				

Date:12/26/00ISR Number: 3639004-5Report Type:Expedited (15-DaCompany Report #WAES 00125053
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Digoxin	C				

Date:12/26/00ISR Number: 3639140-3Report Type:Expedited (15-DaCompany Report #A036271
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Feldene	PS	Pfizer Laboratories			
Hospitalization -	Hypotension	Health			Div Pfizer Inc			
Initial or Prolonged	Pulse Absent	Professional						

INTRAMUSCULAR 2.00 ML
TOTAL: DAILY:

INTRAMUSCULAR

			Rofecoxib	SS		ORAL	25.00 MG

TOTAL: DAILY:

ORAL

			Propranolol Hcl	C			

Date:12/26/00ISR Number: 3639922-8Report Type:Expedited (15-DaCompany Report #WAES 00121455
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	25 MG/	
		Representative						

DAILY/PO

Date:12/26/00ISR Number: 3639926-5Report Type:Expedited (15-DaCompany Report #WAES 00112372
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acne Dysgeusia Face Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Furuncle							
	Hypersensitivity Oral Pain Purulent Discharge Salivary Gland Enlargement Skin Odour Abnormal Tooth Abscess Weight Increased		Prevacid Vitamins	C C				

Date:12/26/00ISR Number: 3639930-7Report Type:Expedited (15-DaCompany Report #WAES 00121286
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:12/26/00ISR Number: 3639932-0Report Type:Expedited (15-DaCompany Report #WAES 00121451
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3639938-1Report Type:Expedited (15-DaCompany Report #WAES 00121381
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3639944-7Report Type:Expedited (15-DaCompany Report #WAES 00100085
Age:99 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Urea Increased							
	Gastrointestinal Haemorrhage							
			Lasix	C				
			Lipitor	C				
			Lopressor	C				
			Transderm-Nitro	C				
			Zantac	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3639946-0Report Type:Expedited (15-DaCompany Report #WAES 00100086
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Ulcer Haemorrhage Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Antivert	C				
			Haldol	C				
			Klotrix	C				
			Lasix	C				
			Pepcid	C				
			Cassia Fistula	C				

Date:12/26/00ISR Number: 3640062-2Report Type:Expedited (15-DaCompany Report #WAES 00070422
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dental Caries	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Meridia	SS		ORAL	10 MG, DAILY, PO	
			Micronor	C				
			Nasacort	C				
			Tylenol With Codeine	C				
			Zoladex	C				
			Zyrtec	C				
			Sodium Fluoride	C				

Date:12/26/00ISR Number: 3640063-4Report Type:Expedited (15-DaCompany Report #WAES 00120364
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Angiodysplasia Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, DAILY, PO						
			Celebrex	C		
			K-Dur	C		
			Lanoxin	C		
			Lasix	C		
			Tambocor	C		
			Verapamil	C		

Date:12/26/00ISR Number: 3640066-XReport Type:Expedited (15-DaCompany Report #WAES 00111775
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Convulsion Headache Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25 MG, PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3640067-1Report Type:Expedited (15-DaCompany Report #WAES 00091789
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Diarrhoea							
	Diverticulum Intestinal				Merck Co Inc	ORAL	PO	
	Drug Interaction		Accupril	C				
	Gastrointestinal		Fosamax	C				
	Angiodysplasia		Lasix	C				
	Haemorrhagic		[Therapy					
	Haemorrhoids		Unspecified]	C				
	Hiatus Hernia		Aspirin	C				
	International Normalised		Atenolol	C				
	Ratio Increased		Cyanocobalamin	C				
			Potassium Chloride	C				

Date:12/26/00ISR Number: 3640068-3Report Type:Expedited (15-DaCompany Report #WAES 00112206
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization - Initial or Prolonged	Balance Disorder							
	Blood Urea Increased	Company			Merck Co Inc	ORAL	25 MG, DAILY,	
Other	Gastric Ulcer Haemorrhage	Representative						
	Hiatus Hernia		Hydrodiuril	C				
	Nausea		K-Dur	C				
	Rectal Haemorrhage		Lescol	C				
			[Therpay					
			Unspecified]	C				

Date:12/26/00ISR Number: 3640069-5Report Type:Expedited (15-DaCompany Report #WAES 00121370
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Cerebrovascular Accident							

	Skin Disorder					Merck Co Inc	ORAL
25 MG, DAILY,							
	Swelling						
PO							
	Vision Blurred						

Date:12/26/00ISR Number: 3640071-3Report Type:Expedited (15-DaCompany Report #WAES 00121415
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Gastrointestinal Ulcer	Company			Merck Co Inc	ORAL
25 MG, DAILY,						
	Thrombosis	Representative				
PO						
			[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3642982-1Report Type:Periodic Company Report #WAES 00090550
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Weight Increased					

Merck Co Inc ORAL
25

MG/DAILY/PO

Lanoxin	C	
Lopressor	C	
Furosemide	C	

Date:12/26/00ISR Number: 3642984-5Report Type:Periodic Company Report #WAES 00090552
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3642985-7Report Type:Periodic Company Report #WAES 00090553
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3642987-0Report Type:Periodic Company Report #WAES 00090568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3642988-2Report Type:Periodic Company Report #WAES 00090593
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Ditropan	C				
			Pulmicort	C				

Date:12/26/00ISR Number: 3642990-0Report Type:Periodic Company Report #WAES 00090594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3642992-4Report Type:Periodic Company Report #WAES 00090596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3642993-6Report Type:Periodic Company Report #WAES 00090603
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3642994-8Report Type:Periodic Company Report #WAES 00090611
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:12/26/00ISR Number: 3642996-1Report Type:Periodic Company Report #WAES 00090612
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Darvocet-N	C				
			Atenolol	C				

Spironolactone C

Date:12/26/00ISR Number: 3642998-5Report Type:Periodic Company Report #WAES 00090635
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	(SEE IMAGE)
			Hytrin	C				

Date:12/26/00ISR Number: 3643000-1Report Type:Periodic Company Report #WAES 00090637
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Prinivil	C				
			Hydrochlorothiazide (+) Triamter	C				

			Lansoprazole	C
			Sulfamethoxazole (+) Trimethoprim	C

Date:12/26/00ISR Number: 3643001-3Report Type:Periodic Company Report #WAES 00090638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Motrin	C				

Date:12/26/00ISR Number: 3643002-5Report Type:Periodic Company Report #WAES 00090641
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk Memory Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	

Date:12/26/00ISR Number: 3643004-9Report Type:Periodic Company Report #WAES 00090646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Oxycontin	C				
			Percocet	C				

Date:12/26/00ISR Number: 3643005-0Report Type:Periodic Company Report #WAES 00090647
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643006-2Report Type:Periodic Company Report #WAES 00090650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643008-6Report Type:Periodic Company Report #WAES 00090652
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Inderal	C				
			Lanoxin	C				
			Metamucil	C				
			Premarin	C				
			Aspirin	C				
			Chondroitin	C				

Date:12/26/00ISR Number: 3643009-8Report Type:Periodic Company Report #WAES 00090654
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estradiol	C				
			Progesterone	C				

Date:12/26/00ISR Number: 3643010-4Report Type:Periodic Company Report #WAES 00090656
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Gastrointestinal Haemorrhage							
	Haematocrit Decreased							

	Oedema Peripheral		Celebrex	C
			Keflex	C
			Lipitor	C
			Maxzide	C
			Neurontin	C
			Prilosec	C
			Vicodin Tablets	C
			Allopurinol	C
			Aspirin	C
			Iron	C

Date:12/26/00ISR Number: 3643014-1Report Type:Periodic Company Report #WAES 00090659
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643015-3Report Type:Periodic Company Report #WAES 00090661
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Prozac	C				
			Aspirin	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643016-5Report Type:Periodic Company Report #WAES 00090662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Congenital Melanosis Tongue Discolouration Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643017-7Report Type:Periodic Company Report #WAES 00090664
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643019-0Report Type:Periodic Company Report #WAES 00090665
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643020-7Report Type:Periodic Company Report #WAES 00090666
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prilosec	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643021-9Report Type:Periodic Company Report #WAES 00090668
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3643023-2Report Type:Periodic Company Report #WAES 00090671
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Chest Pain Cough Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Evista	C				

Date:12/26/00ISR Number: 3643024-4Report Type:Periodic Company Report #WAES 00090673
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Neoplasm	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Ceftin	C				

Date:12/26/00ISR Number: 3643026-8Report Type:Periodic Company Report #WAES 00090680
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643028-1Report Type:Periodic Company Report #WAES 00090684
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ PRN/ PO	
			Prinivil	C				
			Therapy Unspecified	C				
			Glipizide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643030-XReport Type:Periodic Company Report #WAES 00090693
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased White Blood Cell Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643031-1Report Type:Periodic Company Report #WAES 00090700
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
			Effexor	C				
			Premarin	C				
			Provera	C				
			Nortriptyline	C				
			Nystatin	C				

Date:12/26/00ISR Number: 3643032-3Report Type:Periodic Company Report #WAES 00090701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	

Date:12/26/00ISR Number: 3643033-5Report Type:Periodic Company Report #WAES 00090704
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Renal Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643035-9Report Type:Periodic Company Report #WAES 00090706
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
			Cartia	C				
			Diovan	C				
			Flovent	C				
			Prempro	C				
			Prilosec	C				
			Zocor	C				
			Furosemide	C				
			Potassium Chloride	C				
			Theophylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643036-0Report Type:Periodic Company Report #WAES 00090708
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO

Date:12/26/00ISR Number: 3643038-4Report Type:Periodic Company Report #WAES 00090709
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Dyspepsia Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Quinine Sulfate	C				

Date:12/26/00ISR Number: 3643039-6Report Type:Periodic Company Report #WAES 00090711
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/	PO
			Detrol	C				
			Prilosec	C				
			Zanaflex	C				
			Metoclopramide	C				
			Metoprolol Tartrate	C				
			Phenytoin	C				

Date:12/26/00ISR Number: 3643040-2Report Type:Periodic Company Report #WAES 00090715
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
	Dizziness							
	Fatigue							
	Palpitations							
	Tremor		Dilantin	C				
			Ecotrin	C				
			Lanoxin	C				
			Pacerone	C				
			Tylenol	C				
			Vasotec	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3643043-8Report Type:Periodic Company Report #WAES 00090717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643045-1Report Type:Periodic Company Report #WAES 00090718
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	1 DAY
			Atenolol	C				

Date:12/26/00ISR Number: 3643046-3Report Type:Periodic Company Report #WAES 00090724
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Breast Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix	C				
			Lipitor	C				
			Synthroid	C				
			Xanax	C				

Date:12/26/00ISR Number: 3643047-5Report Type:Periodic Company Report #WAES 00090725
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Hydrociuril	C				
			Vicodin Tablets	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643048-7Report Type:Periodic Company Report #WAES 00090726
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Influenza							
	Pain							
	Vomiting		Calan	C				
			Dyazide	C				
			Zocor	C				

Date:12/26/00ISR Number: 3643049-9Report Type:Periodic Company Report #WAES 00090727
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Face Oedema							
			Allegra	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643050-5Report Type:Periodic Company Report #WAES 00090729
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Flushing							
	Gastrooesophageal Reflux							
	Disease		Librax Capsules	C				
	Hyperhidrosis		Niferex Forte	C				
	Pruritus		Prempro	C				
	Tongue Disorder		Prilosec	C				
	Weight Increased		Zoloft	C				
			Lopressor	C				

Date:12/26/00ISR Number: 3643051-7Report Type:Periodic Company Report #WAES 00090731
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Accupril	C				
			Celebrex	C				
			Diabeta	C				
			Lipitor	C				
			Tenormin	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643052-9Report Type:Periodic Company Report #WAES 00090732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia							
	Weight Increased							
			Norvasc	C				
			Hormones					

			(Unspecified)	C		

Date:12/26/00ISR Number: 3643053-0Report Type:Periodic Company Report #WAES 00090734
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
12.5MG/DAILY /PO						
12.5MG/DAILY/						
			Premarin	C		
			Synthroid	C		
			Tenormin	C		
			[Therapy Unspecified]	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643055-4Report Type:Periodic Company Report #WAES 00090931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Limb Discomfort Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
			Lipitor	C				
			Tenormin	C				

Date:12/26/00ISR Number: 3643056-6Report Type:Periodic Company Report #WAES 00090932
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
			Prempro	C				
			Synthroid	C				
			Trental	C				

Date:12/26/00ISR Number: 3643057-8Report Type:Periodic Company Report #WAES 00090933
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ritalin	C				
			Septra	C				

Date:12/26/00ISR Number: 3643058-XReport Type:Periodic Company Report #WAES 00090934
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Carisoprodol	C				

Date:12/26/00ISR Number: 3643059-1Report Type:Periodic Company Report #WAES 00090936
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643060-8Report Type:Periodic Company Report #WAES 00090941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Cholestin C
Humibid C

Date:12/26/00ISR Number: 3643061-XReport Type:Periodic Company Report #WAES 00090943
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Haematuria	Health Professional						
			Axid	C				
			Hydrocodone/Apap	C				
			Norvasc	C				
			Ultram	C				

Date:12/26/00ISR Number: 3643062-1Report Type:Periodic Company Report #WAES 00090945
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO 5 DAY
			Allopurinol	C				

Date:12/26/00ISR Number: 3643063-3Report Type:Periodic Company Report #WAES 00090946
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO
Proscar C

Date:12/26/00ISR Number: 3643064-5Report Type:Periodic Company Report #WAES 00090948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Balance Disorder							
	Renal Disorder				Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643065-7Report Type:Periodic Company Report #WAES 00090950
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Balance Disorder							
	Renal Disorder				Merck Co Inc	ORAL	UNK/UNK/PO	
			Premarin	C				
			Synthroid	C				
			Verapamil Msd Lp	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643066-9Report Type:Periodic Company Report #WAES 00090952
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Drug Ineffective							
	Fatigue							
	Oedema Peripheral							
			Vitamin A	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3643067-0Report Type:Periodic Company Report #WAES 00090953
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
	Inadequate Control							
	Hyperglycaemia							
			Atacand	C				
			Insulin Human	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3643068-2Report Type:Periodic Company Report #WAES 00090958
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3643069-4Report Type:Periodic Company Report #WAES 00090961
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3643071-2Report Type:Periodic Company Report #WAES 00090962
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delirium Insomnia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Lanoxin	C				
			Pepcid	C				
			Tylenol	C				
			Valium	C				
			Calcium (Unspecified)	C				
			Vitamin A	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643072-4Report Type:Periodic Company Report #WAES 00090963
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3643074-8Report Type:Periodic Company Report #WAES 00090965
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Crying	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dizziness							
	Fatigue		Centrum	C				
	Feeling Abnormal		Premarin	C				
	Insomnia		Calcium Ferrous Sulfate	C				
	Nausea							
	Thyroid Disorder							
	Tremor							

Date:12/26/00ISR Number: 3643076-1Report Type:Periodic Company Report #WAES 00090966
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
			Naprosyn	SS			500 MG/BID/UNK	

Date:12/26/00ISR Number: 3643078-5Report Type:Periodic Company Report #WAES 00090970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643081-5Report Type:Periodic Company Report #WAES 00090982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Headache Sleep Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643083-9Report Type:Periodic Company Report #WAES 00090986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643084-0Report Type:Periodic Company Report #WAES 00090988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Paranoid Personality Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643086-4Report Type:Periodic Company Report #WAES 00091001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Musculoskeletal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643087-6Report Type:Periodic Company Report #WAES 00091004
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Rales	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3643088-8Report Type:Periodic Company Report #WAES 00091010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643090-6Report Type:Periodic Company Report #WAES 00091012
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643092-XReport Type:Periodic Company Report #WAES 00091019
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Ecchymosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643094-3Report Type:Periodic Company Report #WAES 00091026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643095-5Report Type:Periodic Company Report #WAES 00091027
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
			Nasonex	C				
			Prilosec	C				
			Prinivil	C				
			Slow-K	C				

Date:12/26/00ISR Number: 3643103-1Report Type:Periodic Company Report #WAES 00091031
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Eye Irritation Sneezing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PO	
			Miacalcin	C				
			Ogen	C				
			Calcium	C				

Date:12/26/00ISR Number: 3643106-7Report Type:Periodic Company Report #WAES 00091037
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Fosamax	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3643108-0Report Type:Periodic Company Report #WAES 00091039
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				
			Lopressor	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643109-2Report Type:Periodic Company Report #WAES 00091041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Lipitor	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3643111-0Report Type:Periodic Company Report #WAES 00091046
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
			Tab Vioxx 50 Mg	SS		ORAL	PO	2 WK
			Ativan	C				
			Premarin	C				

Date:12/26/00ISR Number: 3643113-4Report Type:Periodic Company Report #WAES 00091047
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Tenormin	C			PO	
			Vasotec	C				
			Megestrol Acetate	C				

Date:12/26/00ISR Number: 3643115-8Report Type:Periodic Company Report #WAES 00091048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3643116-XReport Type:Periodic Company Report #WAES 00091049
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Lacrimation Increased Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Cardizem	C				
			Diazide	C				
			Monopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643119-5Report Type:Periodic Company Report #WAES 00091051
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO

Date:12/26/00ISR Number: 3643120-1Report Type:Periodic Company Report #WAES 00091054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643123-7Report Type:Periodic Company Report #WAES 00083110
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Decreased		[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643124-9Report Type:Periodic Company Report #WAES 00101208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Synthroid	C	
Thorazine	C	
Xanax	C	

Date:12/26/00ISR Number: 3643125-0Report Type:Periodic Company Report #WAES 00083111
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Endometrial Cancer	Health			Laboratories Div			
	Insomnia	Professional			Merck Co Inc	ORAL	12.5	
	Pain							
	Sleep Apnoea Syndrome		Aflexa	C				
			Avalide	C				
			Cardura	C				
			Celebrex	C				
			Covera-Hs	C				
			Cozaar	C				
			Endocet	C				
			Flovent	C				
			K-Dur	C				
			Rhinocort Aqua	C				
			Theo-24	C				

MG/BID/PO

Tylenol Arthritis Extended Relief	C
Ultram	C
[Composition Unspecified]	C
Acetaminophen (+) Codeine	C
Allopurinol	C
Colchicine	C
Cyclobenzaprine	C
Fursosemide	C
Lorazepam	C
Prednisone	C

Date:12/26/00ISR Number: 3643126-2Report Type:Periodic Company Report #WAES 00083126
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Prilosec	C				

Date:12/26/00ISR Number: 3643127-4Report Type:Periodic Company Report #WAES 00101212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:12/26/00ISR Number: 3643128-6Report Type:Periodic Company Report #WAES 00083163
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Pruritus		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Coumadin	C				
			Fosamax	C				
			Oxycontin	C				
			Vaseretic	C				
			Vasotec	C				
			Aspirin	C				
			Furosemide	C				

Date:12/26/00ISR Number: 3643129-8Report Type:Periodic Company Report #WAES 00101215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Vicodin	C		

Date:12/26/00ISR Number: 3643130-4Report Type:Periodic Company Report #WAES 00083189
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	
			Citracal	C			PO	
			Claritin	C				
			Ditropan	C				
			Hydrodiuril	C				
			Miacalcin	C				
			Synvisc	C				
			[Therapy Unspecified]	C				
			Cholecalciferol (+) Vitamin A	C				
			Naproxen Sodium	C				
			Potassium (Unspecified)	C				
			Vitamin B Complex	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3643131-6Report Type:Periodic Company Report #WAES 00101216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643132-8Report Type:Periodic Company Report #WAES 00090002
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Feeling Abnormal Muscle Spasms	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY, PO	
			Paxil	C				
			Synthroid	C				
			Cyclobenzaprine	C				

Date:12/26/00ISR Number: 3643133-XReport Type:Periodic Company Report #WAES 00101217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	HS/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643134-1Report Type:Periodic Company Report #WAES 00101219
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	

Date:12/26/00ISR Number: 3643135-3Report Type:Periodic Company Report #WAES 00101221
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Tylenol	C				
			Furosemide	C				

Date:12/26/00ISR Number: 3643136-5Report Type:Periodic Company Report #WAES 00090006
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO SEE IMAGE	
			Fosamax	C				

Date:12/26/00ISR Number: 3643137-7Report Type:Periodic Company Report #WAES 00090010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Ditropan	C				
			Glucotrol	C				

Date:12/26/00ISR Number: 3643138-9Report Type:Periodic Company Report #WAES 00090015
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Olfactory Nerve Disorder Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Chondroitin	C				
			Cough, Cold, And Flu Therapies	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643139-0Report Type:Periodic Company Report #WAES 00101223
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				

Date:12/26/00ISR Number: 3643140-7Report Type:Periodic Company Report #WAES 00101230
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Coumadin	C				
			Premarin	C				
			Vicodin	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Digoxin	C				
			Magnesium (Unspecified)	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643141-9Report Type:Periodic Company Report #WAES 00101234
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Donnatal	C	
Lomotil	C	
Percocet	C	
Roxanol	C	
Estrogens (Unspecified)	C	

Date:12/26/00ISR Number: 3643142-0Report Type:Periodic Company Report #WAES 00090017
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG, DAILY,						
PO						
			Motrin	C		
			Naproxen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643145-6Report Type:Periodic Company Report #WAES 00091058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643147-XReport Type:Periodic Company Report #WAES 00091059
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Procardia	C				
			Trental	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3643148-1Report Type:Periodic Company Report #WAES 00091063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dizziness Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:12/26/00ISR Number: 3643149-3Report Type:Periodic Company Report #WAES 00091064
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643151-1Report Type:Periodic Company Report #WAES 00091065
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Musculoskeletal Disorder Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Calcium (Unspecified)	C				

Date:12/26/00ISR Number: 3643152-3Report Type:Periodic Company Report #WAES 00091070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gout	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Cozaar C
Aspirin C

Date:12/26/00ISR Number: 3643153-5Report Type:Periodic Company Report #WAES 00091071
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO						
			Tylenol	C		
			Ultram	C		

Date:12/26/00ISR Number: 3643155-9Report Type:Periodic Company Report #WAES 00091074
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Dyspepsia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Paxil	C		
			Prevacid	C		
			Prilosec	C		
			Synthroid	C		
			Xanax	C		

Date:12/26/00ISR Number: 3643156-0Report Type:Periodic Company Report #WAES 00091076
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine	Health	Vioxx	PS	Merck Research	

	Increased Blood Urea Increased	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

PO

Date:12/26/00ISR Number: 3643158-4Report Type:Periodic Company Report #WAES 00091077
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia Pain Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PRN/PO

Cosopt	C
Levoxyl	C
Micronase	C
Prinivil	C
Procardia Xl	C
Thyroxine	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643163-8Report Type:Periodic Company Report #WAES 00101727
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643164-XReport Type:Periodic Company Report #WAES 00101732
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Proteinuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3643165-1Report Type:Periodic Company Report #WAES 00091079
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maalox	C				
			Premarin	C				

Date:12/26/00ISR Number: 3643166-3Report Type:Periodic Company Report #WAES 00091080
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3643167-5Report Type:Periodic Company Report #WAES 00091082
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actonel	C				
			Anacin	C				
			Tylenol	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643168-7Report Type:Periodic Company Report #WAES 00101737
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lipitor	C				
			[Composition Unspecified]	C				
			Hydrocodone	C				

Date:12/26/00ISR Number: 3643169-9Report Type:Periodic Company Report #WAES 00101745
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ticlid	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643170-5Report Type:Periodic Company Report #WAES 00101749
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fall Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain		Premarin	C				

Date:12/26/00ISR Number: 3643171-7Report Type:Periodic Company Report #WAES 00101752
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643172-9Report Type:Periodic Company Report #WAES 00101770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643173-0Report Type:Periodic Company Report #WAES 00101771
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643174-2Report Type:Periodic Company Report #WAES 00101773
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flonase	C				
			Prozac	C				
			Synthroid	C				
			Tiazac	C				
			Meclizine	C				

Date:12/26/00ISR Number: 3643175-4Report Type:Periodic Company Report #WAES 00101777
Age:4 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Bronchospasm	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Singulair	C				

Date:12/26/00ISR Number: 3643176-6Report Type:Periodic Company Report #WAES 00100585
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Asthenia Fatigue	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Granuloma Annulare		Humibid	C				
	Panniculitis		Lorabid	C				

			Zyrtec	C		

Date:12/26/00ISR Number: 3643177-8Report Type:Periodic Company Report #WAES 00100589
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Estrace	C		
			Synthroid	C		

Date:12/26/00ISR Number: 3643178-XReport Type:Periodic Company Report #WAES 00100593
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Xanax	C		

Date:12/26/00ISR Number: 3643179-1Report Type:Periodic Company Report #WAES 00100594
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Nasarel	C				
			Pyridium	C				
			Zocor	C				
			Aspirin	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3643180-8Report Type:Periodic Company Report #WAES 00100597
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Ecotrin	C				
			K-Dur	C				
			Lasix	C				
			Norvasc	C				
			Premarin	C				
			Synthroid	C				
			Univasc	C				
			Valium	C				

Date:12/26/00ISR Number: 3643181-XReport Type:Periodic Company Report #WAES 00100598
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:12/26/00ISR Number: 3643182-1Report Type:Periodic Company Report #WAES 00100604
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
							MG/BID/PO	
			Ambien	C				
			Flovent	C				
			Lipitor	C				
			Serevent	C				
			Singulair	C				
			Pilocarpine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643183-3Report Type:Periodic Company Report #WAES 00100606
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Halcion	C				
			Phoslo	C				
			Procardia Xl	C				
			Atenolol	C				
			Quinine Sulfate	C				
			Sodium Polystyrene Sulfonate	C				

Date:12/26/00ISR Number: 3643184-5Report Type:Periodic Company Report #WAES 00100623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prinivil	C				

Date:12/26/00ISR Number: 3643185-7Report Type:Periodic Company Report #WAES 00100628
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				

			Roxicet	C
			Valium	C
			Zestril	C
			Temazepam	C
			Trimethobenzamide	C

Date:12/26/00ISR Number: 3643186-9Report Type:Periodic Company Report #WAES 00100629
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Bilirubin Increased Haematuria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Cordarone	C				
			Darvocet-N	C				
			K-Dur	C				
			Lasix	C				
			Synthroid	C				
			Zantac	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643187-0Report Type:Periodic Company Report #WAES 00100630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Headache Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	
			Atrovent	C				
			Dilantin	C				
			Librium	C				
			Prozac	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3643188-2Report Type:Periodic Company Report #WAES 00100631
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Albuterol	C				

Date:12/26/00ISR Number: 3643189-4Report Type:Periodic Company Report #WAES 00100632
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuralgia Sacroiliitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Triamterene	C				

Date:12/26/00ISR Number: 3643190-0Report Type:Periodic Company Report #WAES 00100633
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Lipitor	C				

Date:12/26/00ISR Number: 3643191-2Report Type:Periodic Company Report #WAES 00100642
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643192-4Report Type:Periodic Company Report #WAES 00100647
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Diarrhoea	Health Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643193-6Report Type:Periodic Company Report #WAES 00100654
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643194-8Report Type:Periodic Company Report #WAES 00100665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643195-XReport Type:Periodic Company Report #WAES 00100681
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Hytrin	C	
Proscar	C	
Prozac	C	
Zocor	C	
Alaprazolam	C	
Aspirin	C	

Date:12/26/00ISR Number: 3643196-1Report Type:Periodic Company Report #WAES 00100705
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

Date:12/26/00ISR Number: 3643197-3Report Type:Periodic Company Report #WAES 00100711
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Atenolol	C	

			Estrogens	C
			Triamterene	C
			Vitamins	C

Date:12/26/00ISR Number: 3643198-5Report Type:Periodic Company Report #WAES 00100713
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY

Date:12/26/00ISR Number: 3643199-7Report Type:Periodic Company Report #WAES 00100717
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				
			Butalbital	C				

Date:12/26/00ISR Number: 3643200-0Report Type:Periodic Company Report #WAES 00100719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Tylenol	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643201-2Report Type:Periodic Company Report #WAES 00100720
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Drug Ineffective	Professional			Laboratories Div			
	Eustachian Tube Disorder				Merck Co Inc	ORAL	25 MG/ PO	
	Vertigo		Tab Vioxx 50 Mg	SS		ORAL	5O MG/PO	1 WK
			Lipitor	C				
			Plavix	C				
			Prilosec	C				
			Zestril	C				

Date:12/26/00ISR Number: 3643202-4Report Type:Periodic Company Report #WAES 00100735
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctivitis	Health	Vioxx	PS	Merck Research			
	Haemoptysis	Professional			Laboratories Div			
	Upper Gastrointestinal				Merck Co Inc	ORAL	12.5MG/DAILY/	
	Haemorrhage						PO	
			Tab Fosamax	SS				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643203-6Report Type:Periodic Company Report #WAES 00100738
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY PO	

Date:12/26/00ISR Number: 3643204-8Report Type:Periodic Company Report #WAES 00100740
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hormones	C				

Date:12/26/00ISR Number: 3643205-XReport Type:Periodic Company Report #WAES 00100750
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Mental Impairment	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50	

MG/DAILY/PO

Tab Vioxx 50 Mg SS ORAL
50 MG/PRN/PO

Chondroitin C
Glucosamide C

Date:12/26/00ISR Number: 3643206-1Report Type:Periodic Company Report #WAES 00100755
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3643207-3Report Type:Periodic Company Report #WAES 00100756
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Faeces Discoloured Headache Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Glucotrol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643208-5Report Type:Periodic Company Report #WAES 00100777
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Urinary Tract Infection							
	Vomiting							
			Covera-Hs	C				
			Diovan	C				
			Miacalcin	C				
			Prilosec	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643209-7Report Type:Periodic Company Report #WAES 00100790
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Drug Ineffective							
	Headache							
	Hypertension							
	Nausea		Hyzaar	C				
	Nocturia		Lescol	C				
	Pain		Norvasc	C				
	Salivary Hypersecretion		Premarin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3643210-3Report Type:Periodic Company Report #WAES 00100808
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased							

Merck Co Inc ORAL
12.5

MG/BID/PO
Sinemet Cr C

Date:12/26/00ISR Number: 3643211-5Report Type:Periodic Company Report #WAES 00100814
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Coumadin	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3643212-7Report Type:Periodic Company Report #WAES 00100823
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643213-9Report Type:Periodic Company Report #WAES 00100824
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Health	Vioxx	PS	Merck Research			
	Arthralgia	Professional			Laboratories Div			
	Breast Pain				Merck Co Inc	ORAL	25 MG DAILY	
	Joint Swelling					PO		
	Neoplasm							
	Oedema Peripheral							

Date:12/26/00ISR Number: 3643214-0Report Type:Periodic Company Report #WAES 00100827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research			
	Nasal Congestion				Laboratories Div			
	Rhinorrhoea				Merck Co Inc	ORAL	UNK/UNK/PO	
			Hyzaar	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3643215-2Report Type:Periodic Company Report #WAES 00100828
Age:13 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS	Merck Research			
	Ear Disorder	Professional			Laboratories Div			
					Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3643216-4Report Type:Periodic Company Report #WAES 00100830
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Acupril	C
Coreg	C
Darvocet - N	C
Diuretic	C

Date:12/26/00ISR Number: 3643217-6Report Type:Periodic Company Report #WAES 00100842
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Hytrin	C
Intal	C
Singulair	C
Albuterol	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643218-8Report Type:Periodic Company Report #WAES 00100843
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 50 Mg	SS		ORAL	PO	
			Aldactazide	C				

Date:12/26/00ISR Number: 3643219-XReport Type:Periodic Company Report #WAES 00100849
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prilosec	C				
			Prozac	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643220-6Report Type:Periodic Company Report #WAES 00100858
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Clozapine	SS				

Date:12/26/00ISR Number: 3643221-8Report Type:Periodic Company Report #WAES 00100861
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643222-XReport Type:Periodic Company Report #WAES 00100868
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Cardura	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643223-1Report Type:Periodic Company Report #WAES 00100875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643224-3Report Type:Periodic Company Report #WAES 00100881
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Accupril	C				
			Norvasc	C				
			Plavix	C				
			Premarin	C				
			Aspirin	C				
			Quinine Sulfate	C				

Date:12/26/00ISR Number: 3643225-5Report Type:Periodic Company Report #WAES 00100887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Accupril	C				
			Avandia	C				
			Baycol	C				
			Glucotrol Xl	C				
			Synthroid	C				
			Aspirin	C				
			Miglitol	C				

Date:12/26/00ISR Number: 3643226-7Report Type:Periodic Company Report #WAES 00100895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643227-9Report Type:Periodic Company Report #WAES 00100917
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Elavil	C				
			Estratest	C				
			Flonase	C				
			K-Dur	C				
			Premarin	C				
			Prilosec	C				
			Synthroid	C				
			Tenormin	C				
			Zomig	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643228-0Report Type:Periodic Company Report #WAES 00100921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3643229-2Report Type:Periodic Company Report #WAES 00100922
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Tremor	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Inderal	C				
			Lasix	C				
			Mevacor	C				
			Miacalcin	C				
			Minipress	C				
			Persantine	C				
			Rhinocort	C				
			Aspirin	C				
			Digoxin	C				

Date:12/26/00ISR Number: 3643230-9Report Type:Periodic Company Report #WAES 00100923
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actonel	C				

Catapres	C
Hyzaar	C
Miacalcin	C
Nasonex	C
Surfak	C
Zoladex	C

Date:12/26/00ISR Number: 3643231-0Report Type:Periodic Company Report #WAES 00100927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643232-2Report Type:Periodic Company Report #WAES 00100936
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Flonase	C	
Pravachol	C	
Diltiazem	C	
Isosorbide Mononitrate	C	

Date:12/26/00ISR Number: 3643233-4Report Type:Periodic Company Report #WAES 00100940
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Premarin	C				
			Tagamet	C				
			Calcium	C				
			Doxepin	C				

Date:12/26/00ISR Number: 3643234-6Report Type:Periodic Company Report #WAES 00100941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643235-8Report Type:Periodic Company Report #WAES 00100947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643236-XReport Type:Periodic Company Report #WAES 00100960
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Fatigue							
	Hallucination							
	Oedema Peripheral		Catapres	C				
			Lortab	C				
			Premarin	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3643237-1Report Type:Periodic Company Report #WAES 00100965
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Dyspepsia							
	Oedema Peripheral							

		Hydrodiuril	C	
		Norvasc	C	

Date:12/26/00ISR Number: 3643238-3Report Type:Periodic Company Report #WAES 00100967
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Dyspepsia							
	Fatigue							
	Pruritus							

Date:12/26/00ISR Number: 3643240-1Report Type:Periodic Company Report #WAES 00100968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643241-3Report Type:Periodic Company Report #WAES 00100974
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3643242-5Report Type:Periodic Company Report #WAES 00100976
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Periodontal Disease Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643243-7Report Type:Periodic Company Report #WAES 00100985
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643244-9Report Type:Periodic Company Report #WAES 00100986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643245-0Report Type:Periodic Company Report #WAES 00100989
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643246-2Report Type:Periodic Company Report #WAES 00100992
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643247-4Report Type:Periodic Company Report #WAES 00100994
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accupril	C				
			Actase	C				
			Bel-Phen-Ergot S Tabs	C				
			Glucophage	C				
			Neurontin	C				
			Prempro	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643248-6Report Type:Periodic Company Report #WAES 00100996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				
			Estrogens (Unspecified)	C				

Date:12/26/00ISR Number: 3643249-8Report Type:Periodic Company Report #WAES 00100997
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643250-4Report Type:Periodic Company Report #WAES 00101000
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643251-6Report Type:Periodic Company Report #WAES 00101002
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Effexor	C				
			Pravachol	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643252-8Report Type:Periodic Company Report #WAES 00101009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643253-XReport Type:Periodic Company Report #WAES 00101015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643254-1Report Type:Periodic Company Report #WAES 00101019
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643255-3Report Type:Periodic Company Report #WAES 00101026
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Prilosec	C				
			Indapamide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643256-5Report Type:Periodic Company Report #WAES 00101033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotensin	C				

Date:12/26/00ISR Number: 3643328-5Report Type:Periodic Company Report #WAES 00083038
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3643329-7Report Type:Periodic Company Report #WAES 00083039
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Drug Ineffective	Health Professional						
	Fatigue							
	Pain In Extremity							
	Pruritus		Tab Vioxx 25 Mg	SS		ORAL	25 MG DAILY	PO
			Centrum Silver	C				
			Norvasc	C				
			Synthroid	C				
			Urex (Furosemide)	C				
			Chondroitin (+)					

			Glucosamine	C		

Date:12/26/00ISR Number: 3643330-3Report Type:Periodic Company Report #WAES 00083040
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Aspartate Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG DAILY						
	Blood Urea Increased					
PO 5 DAY						
			Vioxx	SS		ORAL
25MG DAILY PO						

Date:12/26/00ISR Number: 3643333-9Report Type:Periodic Company Report #WAES 00083041
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643334-0Report Type:Periodic Company Report #WAES 00083044
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643336-4Report Type:Periodic Company Report #WAES 00083047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643337-6Report Type:Periodic Company Report #WAES 00083053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643339-XReport Type:Periodic Company Report #WAES 00083055
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO

			Levoxyl	C
			Osteo-Bi-Flex	C
			Atenolol	C
			Triamterene	C

Date:12/26/00ISR Number: 3643342-XReport Type:Periodic Company Report #WAES 00083057
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3643344-3Report Type:Periodic Company Report #WAES 00091139
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643345-5Report Type:Periodic Company Report #WAES 00091142
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643346-7Report Type:Periodic Company Report #WAES 00091144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Toxicity Furuncle Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643348-0Report Type:Periodic Company Report #WAES 00091145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastroenteritis Helicobacter	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643350-9Report Type:Periodic Company Report #WAES 00091153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Palsy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643351-0Report Type:Periodic Company Report #WAES 00091154
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Disorder Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY PO						
			Vitamins	C		

Date:12/26/00ISR Number: 3643352-2Report Type:Periodic Company Report #WAES 00091156
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS		ORAL
25 MG PO 13 DAY						
			Composition Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643353-4Report Type:Periodic Company Report #WAES 00091157
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Cosopt	C				
			Tamoxifen	C				

Date:12/26/00ISR Number: 3643354-6Report Type:Periodic Company Report #WAES 00091158
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	
PO								2 MON
			Premarin	C				

Date:12/26/00ISR Number: 3643355-8Report Type:Periodic Company Report #WAES 00091159
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Lotrisone	C				
			Mescolor	C				
			Cephalexin	C				
			Oxybutynin Chloride	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3643356-XReport Type:Periodic Company Report #WAES 00090775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Feeling Abnormal							
			Ultram	C				
			Voltaren	C				

Date:12/26/00ISR Number: 3643357-1Report Type:Periodic Company Report #WAES 00090784
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Weight Increased							
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643358-3Report Type:Periodic Company Report #WAES 00090789
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diazide	C				
			Xanax	C				

Date:12/26/00ISR Number: 3643359-5Report Type:Periodic Company Report #WAES 00090790
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Drug Ineffective Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia		Atacand	C				
			Claritin	C				

Date:12/26/00ISR Number: 3643360-1Report Type:Periodic Company Report #WAES 00090792
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Muscular Weakness Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imdur	C				
			Prilosec	C				
			Ibuprofen	C				

Date:12/26/00ISR Number: 3643361-3Report Type:Periodic Company Report #WAES 00090797
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 DAY
			Estrogens	C				

Date:12/26/00ISR Number: 3643362-5Report Type:Periodic Company Report #WAES 00090801
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Bayer Enteric Aspirin	C				
			Niaspan	C				
			Paxil	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643363-7Report Type:Periodic Company Report #WAES 00090804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643364-9Report Type:Periodic Company Report #WAES 00090809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix	C				

Date:12/26/00ISR Number: 3643365-0Report Type:Periodic Company Report #WAES 00090810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643366-2Report Type:Periodic Company Report #WAES 00090902
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Flomax
(Morniflumate) C
Tylenol C

Date:12/26/00ISR Number: 3643367-4Report Type:Periodic Company Report #WAES 00090910
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lipitor	C				
			Potassium (Unspecified)	C				

Date:12/26/00ISR Number: 3643368-6Report Type:Periodic Company Report #WAES 00090914
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Zocor	C				

			Quinidine	C		

Date:12/26/00ISR Number: 3643369-8Report Type:Periodic Company Report #WAES 00090916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Miacalcin	C				

Date:12/26/00ISR Number: 3643370-4Report Type:Periodic Company Report #WAES 00090918
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. 5 MG/DAILY/PO	
			Bumex	C				
			Dilantin	C				
			Lanoxin	C				
			Mebaral	C				
			Slow-K	C				
			Albuterol	C				
			Calcium Supplement (Unspecifi	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643371-6Report Type:Periodic Company Report #WAES 00090919
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Proscar	C				
			Terazosin	C				

Date:12/26/00ISR Number: 3643372-8Report Type:Periodic Company Report #WAES 00090920
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643373-XReport Type:Periodic Company Report #WAES 00090921
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ibuprofen	C				

Date:12/26/00ISR Number: 3643374-1Report Type:Periodic Company Report #WAES 00090928
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643375-3Report Type:Periodic Company Report #WAES 00090929
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643376-5Report Type:Periodic Company Report #WAES 00101236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643377-7Report Type:Periodic Company Report #WAES 00101257
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			Effexor	C				
			Premarin	C				
			Diazepam	C				
			Medroxyprogesterone	C				

Date:12/26/00ISR Number: 3643378-9Report Type:Periodic Company Report #WAES 00101282
Age: Gender:Male I/FU:I

Outcome	PT
	Chills
	Dizziness

	Nausea						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3643379-0Report Type:Periodic Company Report #WAES 00101290
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3643380-7Report Type:Periodic Company Report #WAES 00101292
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3643381-9Report Type:Periodic Company Report #WAES 00101295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Conjunctivitis Dry Skin Dyspnoea Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3643382-0Report Type:Periodic Company Report #WAES 00101304
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Feeling Abnormal Fluid Retention Pain Urine Abnormality	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643383-2Report Type:Periodic Company Report #WAES 00101305
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643384-4Report Type:Periodic Company Report #WAES 00101306
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health	Vioxx	PS	Merck Research			
	Dyskinesia	Professional			Laboratories Div			
	Insomnia				Merck Co Inc	ORAL	12.5	
	Muscular Weakness						MG/DAILY/PO	
	Speech Disorder		Norvasc	C				
	Tremor		Requip	C				
			Sinemet	C				

Date:12/26/00ISR Number: 3643385-6Report Type:Periodic Company Report #WAES 00101307
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25 MG/UNK/PO	
			Coumadin	C				
			Covera-Ks	C				
			Lipitor	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3643386-8Report Type:Periodic Company Report #WAES 00101309
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Abnormal Faeces				Laboratories Div			
	Asthenia				Merck Co Inc	ORAL	PO	
	Diarrhoea		Flomax					
	Fatigue		(Morniflumate)	C				
	Flatulence		Prevacid	C				
	Urine Abnormality		Viagra	C				

Date:12/26/00ISR Number: 3643387-XReport Type:Periodic Company Report #WAES 00101315
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Synthroid	C				
			[Therapy Unspecified]	C				
			Folic Acid	C				
			Glucosamine	C				
			Melatonin	C				

Date:12/26/00ISR Number: 3643388-1Report Type:Periodic Company Report #WAES 00101318
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643389-3Report Type:Periodic Company Report #WAES 00101320
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Dyazide	C				
			Ogen	C				
			Synthroid	C				
			Ultram	C				
			Zantac	C				
			Clonidine	C				
			Ferrous Sulfate	C				

Date:12/26/00ISR Number: 3643390-XReport Type:Periodic Company Report #WAES 00101321
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643391-1Report Type:Periodic Company Report #WAES 00101325
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Lipitor	C		
			Sudafed	C		
			Ventolin	C		

Date:12/26/00ISR Number: 3643392-3Report Type:Periodic Company Report #WAES 00101332
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Zestril	C				
			Alprazolam	C				
			Aspirin	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3643393-5Report Type:Periodic Company Report #WAES 00101334
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Urgency Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

			Aspirin	C		

Date:12/26/00ISR Number: 3643394-7Report Type:Periodic Company Report #WAES 00101339
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prozac	C				

Date:12/26/00ISR Number: 3643395-9Report Type:Periodic Company Report #WAES 00101344
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643396-0Report Type:Periodic Company Report #WAES 00101349
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Fosamax	C				
			Lipitor	C				
			Premarin	C				
			Synthroid	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643397-2Report Type:Periodic Company Report #WAES 00101351
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Dyspepsia					
	Vomiting				Merck Co Inc	ORAL
PO						
			Dyazide	C		
			Premarin	C		
			Vasotec	C		
			Vicodin Tablets	C		
			Amitriptyline Hydrochloride	C		

Date:12/26/00ISR Number: 3643398-4Report Type:Periodic Company Report #WAES 00101361
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Actonel	C		
			Acupril	C		

Synthroid C

Date:12/26/00ISR Number: 3643399-6Report Type:Periodic Company Report #WAES 00101385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643400-XReport Type:Periodic Company Report #WAES 00101393
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643401-1Report Type:Periodic Company Report #WAES 00101407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643402-3Report Type:Periodic Company Report #WAES 00101409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Flexeril	C				

Date:12/26/00ISR Number: 3643403-5Report Type:Periodic Company Report #WAES 00101410
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643404-7Report Type:Periodic Company Report #WAES 00101411
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643405-9Report Type:Periodic Company Report #WAES 00101445
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:12/26/00ISR Number: 3643406-0Report Type:Periodic Company Report #WAES 00101452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643407-2Report Type:Periodic Company Report #WAES 00101492
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytone	C				
			Prilosec	C				
			Synalar	C				
			Temovate	C				

Date:12/26/00ISR Number: 3643408-4Report Type:Periodic Company Report #WAES 00101496
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
			Hydrodiuril	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3643411-4Report Type:Periodic Company Report #WAES 00101500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Verapamil	C				

Date:12/26/00ISR Number: 3643412-6Report Type:Periodic Company Report #WAES 00101505
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO
Synthroid C

Date:12/26/00ISR Number: 3643413-8Report Type:Periodic Company Report #WAES 00101508
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643414-XReport Type:Periodic Company Report #WAES 00101509
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643415-1Report Type:Periodic Company Report #WAES 00101511
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Pollakiuria Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Baycol	C				
			Dilantin	C				
			Zestril	C				
			Glipizide	C				

Date:12/26/00ISR Number: 3643416-3Report Type:Periodic Company Report #WAES 00101516
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			[Therapy Unspecified]	C				
			Zocor	C				
			Lotensin	C				

Date:12/26/00ISR Number: 3643417-5Report Type:Periodic Company Report #WAES 00101522
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Composition Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643418-7Report Type:Periodic Company Report #WAES 00101524
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Coumadin	C				
			Remeron	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3643419-9Report Type:Periodic Company Report #WAES 00101534
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3643420-5Report Type:Periodic Company Report #WAES 00101536
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Fibercon	C				
			Premarin	C				
			Aspirin	C				
			Magnesium Hydroxide	C				
			Niacin	C				
			Royal Jelly	C				

			Vitamins (Unspecified)	C		

Date:12/26/00ISR Number: 3643421-7Report Type:Periodic Company Report #WAES 00101538
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

Date:12/26/00ISR Number: 3643422-9Report Type:Periodic Company Report #WAES 00101539
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	
			Maxalt (Rizatriptan Benzoate)	C				

Premarin	C
Prilosec	C
Zomig	C
Ascorbic Acid	C
Chondroitin (+) Glucosamine	C
Vatamin E	C
Vitamins (Unspecified)	C

Date:12/26/00ISR Number: 3643423-0Report Type:Periodic Company Report #WAES 00101540
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Corgard	C				
			Lodine	C				
			Prozac	C				
			Alprazolam	C				
			Clonidine	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643424-2Report Type:Periodic Company Report #WAES 00101542
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Antimicrobial (Unspecified)	C				

Date:12/26/00ISR Number: 3643425-4Report Type:Periodic Company Report #WAES 00101543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	

Date:12/26/00ISR Number: 3643426-6Report Type:Periodic Company Report #WAES 00101563
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY / PO	
			Vicodin Es Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643427-8Report Type:Periodic Company Report #WAES 00101565
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retching Rib Fracture Vomiting	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Ultram	C				

Date:12/26/00ISR Number: 3643428-XReport Type:Periodic Company Report #WAES 00101570
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG TID PO	

Date:12/26/00ISR Number: 3643429-1Report Type:Periodic Company Report #WAES 00101571
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643430-8Report Type:Periodic Company Report #WAES 00101605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG DAILY

PO; 25 MG

DAILY PO

Date:12/26/00ISR Number: 3643431-XReport Type:Periodic Company Report #WAES 00101607
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased							
	Dizziness				Merck Co Inc	ORAL	25 MG DAILY	
	Feeling Abnormal							
PO							1	DAY

Date:12/26/00ISR Number: 3643432-1Report Type:Periodic Company Report #WAES 00101612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Bradycardia							
	Chills				Merck Co Inc	ORAL	PO	
	Diarrhoea		Ativan	C				
	Fatigue		Atenolol	C				
	Gait Disturbance							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643433-3Report Type:Periodic Company Report #WAES 00101613
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Vasotec	C				
			Furosemide	C				
			Potassium (Unspecified)	C				
			Vitamin A	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3643434-5Report Type:Periodic Company Report #WAES 00101617
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Ativan	C				
			Betoptic	C				
			Fosamax	C				
			Tylenol Extra Strength	C				
			Xalatan	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643435-7Report Type:Periodic Company Report #WAES 00101619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Therapy Unspeicified C

Date:12/26/00ISR Number: 3643436-9Report Type:Periodic Company Report #WAES 00101620
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Vioxx	PS	Merck Research			
	Facial Pain	Health			Laboratories Div			
	Headache	Professional			Merck Co Inc	ORAL	12.5 MG DAILY	
	Musculoskeletal Stiffness					PO		
			Estratest	C				
			Fosamax	C				
			Levoxyl	C				

Date:12/26/00ISR Number: 3643437-0Report Type:Periodic Company Report #WAES 00101624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643438-2Report Type:Periodic Company Report #WAES 00101632
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Celebrex	C				
			Vitamins (Unspecified) Composition Unspecified	C				

Date:12/26/00ISR Number: 3643439-4Report Type:Periodic Company Report #WAES 00101637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Avapro	C				
			Pepcid	C				

Date:12/26/00ISR Number: 3643440-0Report Type:Periodic Company Report #WAES 00101638
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Slow-Mag	C				
			Vitamin D (Unspecified)	C				

Date:12/26/00ISR Number: 3643447-3Report Type:Periodic Company Report #WAES 00101646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643451-5Report Type:Periodic Company Report #WAES 00101651
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643456-4Report Type:Expedited (15-DaCompany Report #WAES 00101652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Irritable Bowel Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fioricet Tablets	C				

Date:12/26/00ISR Number: 3643460-6Report Type:Periodic Company Report #WAES 00101664
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Limb Discomfort Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643461-8Report Type:Periodic Company Report #WAES 00101684
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:12/26/00ISR Number: 3643462-XReport Type:Periodic Company Report #WAES 00101688
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research		
	Fatigue				Laboratories Div		
	Memory Impairment				Merck Co Inc	ORAL	25
	Mental Impairment						MG/DAILY/PO
			Premarin	C			
			Synthroid	C			
			Zocor	C			

Date:12/26/00ISR Number: 3643463-1Report Type:Periodic Company Report #WAES 00101691
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643464-3Report Type:Periodic Company Report #WAES 00101695
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia Synovitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643465-5Report Type:Periodic Company Report #WAES 00101708
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Levoxyl	C				
			Lipitor	C				
			Lotrel	C				
			Prempro	C				

Date:12/26/00ISR Number: 3643466-7Report Type:Periodic Company Report #WAES 00101709
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Flushing Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
	Hyperhidrosis		Elavil	C				
	Rectal Haemorrhage		Cyclobenzaprine Hydrochloride	C				
	Upper Gastrointestinal Haemorrhage		Gabapentin	C				
	Weight Increased		Tramadol Hydrochloride	C				

Date:12/26/00ISR Number: 3643467-9Report Type:Periodic Company Report #WAES 00101710
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	7 DAY

			Actonel	C		
			Cardizem	C		
			Plavix	C		
			Prevacid	C		
			Zocor	C		
			Nitroglycerin	C		

Date:12/26/00ISR Number: 3643468-0Report Type:Periodic Company Report #WAES 00101713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO						
			Mevacor	C		
			Aspirin	C		
			Metoprolol	C		

Date:12/26/00ISR Number: 3643474-6Report Type:Periodic Company Report #WAES 00101714
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	
	Nausea							
	Pruritus							
			Fer-Sul	C				
			Levaquin	C				
			Ultram	C				

Date:12/26/00ISR Number: 3643476-XReport Type:Periodic Company Report #WAES 00101720
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY, PO	
	Congestive							
	Dyspnoea							
	Muscular Weakness		Midamor	C				
	Swelling		Synthroid	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3643477-1Report Type:Periodic Company Report #WAES 00101721
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	
	Weight Increased							
			Soma	C				
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3643478-3Report Type:Periodic Company Report #WAES 00101722
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petechiae	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643479-5Report Type:Periodic Company Report #WAES 00101724
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
			Evista	C				
			Pravachol	C				
			Ascorbic Acid	C				
			Calcium	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643696-4Report Type:Periodic Company Report #WAES 00090039
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Aerobid	C				
			Celebrex	C				
			Loestrin	C				
			Singulair	C				

Date:12/26/00ISR Number: 3643697-6Report Type:Periodic Company Report #WAES 00090046
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:12/26/00ISR Number: 3643698-8Report Type:Periodic Company Report #WAES 00090047
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Provera	C				

Date:12/26/00ISR Number: 3643699-XReport Type:Periodic Company Report #WAES 00090048
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Claritin-D	C		
			Premarin	C		
			Vitamins (Unspecified)	C		

Date:12/26/00ISR Number: 3643700-3Report Type:Periodic Company Report #WAES 00090050
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		
			Lescol	C				
			Zovirax	C				
			Aspirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643701-5Report Type:Periodic Company Report #WAES 00090052
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cozaar	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643702-7Report Type:Periodic Company Report #WAES 00090526
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Baycol	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643703-9Report Type:Periodic Company Report #WAES 00091284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Diarrhoea Nausea	Literature Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Imdur	C				
			Lopressor	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3643704-0Report Type:Periodic Company Report #WAES 00090527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				

Date:12/26/00ISR Number: 3643705-2Report Type:Periodic Company Report #WAES 00091285
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				
			Fosamax	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643706-4Report Type:Periodic Company Report #WAES 00090528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643707-6Report Type:Periodic Company Report #WAES 00091288
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	
			Excedrin Extra-Strength	C				
			Vancenase	C				
			Zyrtec	C				
			Lisinopril	C				

Date:12/26/00ISR Number: 3643708-8Report Type:Periodic Company Report #WAES 00090529
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Muscle Spasms	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;	
	Nausea						12.5 MG/DAILY/PO	
			Celebrex	C				
			Elavil	C				
			Fioricet	C				

			Flonase	C		
			Diazepam	C		
			Perphenazine	C		
			Verapamil	C		

Date:12/26/00ISR Number: 3643709-XReport Type:Periodic Company Report #WAES 00091289
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3643710-6Report Type:Periodic Company Report #WAES 00090533
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/BID/PO; 2) PRN/PO	

Avandia	C
Cardizem	C
Glucophage	C
Prandin	C
Vasotec	C
Zocor	C
Ascorbic Acid	C
Aspirin	C
Fish Oil (Unspecified)	C

Date:12/26/00ISR Number: 3643711-8Report Type:Periodic Company Report #WAES 00091291
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643712-XReport Type:Periodic Company Report #WAES 00090534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643713-1Report Type:Periodic Company Report #WAES 00091292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643714-3Report Type:Periodic Company Report #WAES 00090535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Hytrin	C				

Date:12/26/00ISR Number: 3643715-5Report Type:Periodic Company Report #WAES 00091294
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG AM PO	
			Celebrex	C				
			Coumadin	C				
			Effexor	C				

Imdur	C
Sinemet	C
Synthroid	C
Zocor	C
Amitriptyline Hydrochloride	C
Atenolol	C
Temazepam	C

Date:12/26/00ISR Number: 3643716-7Report Type:Periodic Company Report #WAES 00090536
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:12/26/00ISR Number: 3643717-9Report Type:Periodic Company Report #WAES 00091295
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643718-0Report Type:Periodic Company Report #WAES 00090537
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:12/26/00ISR Number: 3643719-2Report Type:Periodic Company Report #WAES 00091297
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperkalaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Hyzaar	C		
			Lescol	C		
			Synthroid	C		

Date:12/26/00ISR Number: 3643720-9Report Type:Periodic Company Report #WAES 00091303
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Vertigo	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Dilantin	C		
			Phenobarbital			

			(Lilly)	C
			Synthroid	C
			Zantac	C

Date:12/26/00ISR Number: 3643721-0Report Type:Periodic Company Report #WAES 00090548
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lasix	C				
			Lopressor	C				
			Minoximen	C				
			Pepcid	C				
			Restoril	C				
			Zocor	C				

Date:12/26/00ISR Number: 3643726-XReport Type:Periodic Company Report #WAES 00090616
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Premarin	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Quinine Sulfate	C				

Date:12/26/00ISR Number: 3643728-3Report Type:Periodic Company Report #WAES 00090618
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Feeling Cold Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				
			Calcium Supplement (Unspecified)	C				

Date:12/26/00ISR Number: 3643730-1Report Type:Periodic Company Report #WAES 00090620
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643732-5Report Type:Periodic Company Report #WAES 00090621
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Feeling Abnormal							
	Sleep Disorder							
			Imdur	C				
			Lasix	C				
			Lipitor	C				
			Prevacid	C				

Date:12/26/00ISR Number: 3643733-7Report Type:Periodic Company Report #WAES 00090625
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dry Mouth							
	Nasal Dryness							
			Astelin	C				
			Bentyl	C				
			Premarin	C				
			Reglan	C				
			Ultram	C				

Date:12/26/00ISR Number: 3643735-0Report Type:Periodic Company Report #WAES 00090627
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Irritability							
	Nervousness							
			Prozac	C				

Date:12/26/00ISR Number: 3643736-2Report Type:Periodic Company Report #WAES 00090628
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Pain	Health Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Dilantin	C				
			Tylenol	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643738-6Report Type:Periodic Company Report #WAES 00090053
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	SEE IMAGE	
			Hyzaar	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643739-8Report Type:Periodic Company Report #WAES 00090630
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Hydrodiuril	C				
			Synthroid	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3643741-6Report Type:Periodic Company Report #WAES 00090631
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actos	C				
			Detrol	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Hyzaar	C				
			Neurontin	C				
			Norvasc	C				
			Premarin	C				
			Synthroid	C				
			Tricor	C				
			Zocor	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643742-8Report Type:Periodic Company Report #WAES 00090054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		ORAL
PO							

Date:12/26/00ISR Number: 3643743-XReport Type:Periodic Company Report #WAES 00090632
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNKNOWN	25
MG/DAILY/UNK								
			Advil	C				

Date:12/26/00ISR Number: 3643745-3Report Type:Periodic Company Report #WAES 00090058
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
SEE IMAGE								

				Allopurinol	C		

Date:12/26/00ISR Number: 3643749-0Report Type:Periodic Company Report #WAES 00090061
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrace	C				
			Synthroid	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643754-4Report Type:Periodic Company Report #WAES 00090063
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Sinusitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cogentin	C				
			Zestril	C				
			Aspirin	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643756-8Report Type:Periodic Company Report #WAES 00090064
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:12/26/00ISR Number: 3643760-XReport Type:Periodic Company Report #WAES 00090065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Prevacid	C				

Date:12/26/00ISR Number: 3643761-1Report Type:Periodic Company Report #WAES 00090067
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
			Estrogens (Unspecified)	C				
			Morphine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643762-3Report Type:Periodic Company Report #WAES 00090071
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Flexeril	C				
			Pepcid Ac	C				
			Prozac	C				
			Vicodin Tablets	C				
			Xanax	C				

Date:12/26/00ISR Number: 3643763-5Report Type:Periodic Company Report #WAES 00090083
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Premarin	C				
			Prinivil	C				

Date:12/26/00ISR Number: 3643767-2Report Type:Periodic Company Report #WAES 00092129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lipitor	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643768-4Report Type:Periodic Company Report #WAES 00092132
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643770-2Report Type:Periodic Company Report #WAES 00092124
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lanoxin	C				
			Prempro	C				
			Singulair	C				
			Therapyunspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643771-4Report Type:Periodic Company Report #WAES 00092128
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Synthroid	C				
			Toprol Xl Tablets	C				
			Vicodin Tablets	C				
			Aspirin	C				
			Cardizem	C				
			Lasix	C				

Date:12/26/00ISR Number: 3643773-8Report Type:Periodic Company Report #WAES 00092133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	

Date:12/26/00ISR Number: 3643774-XReport Type:Periodic Company Report #WAES 00092138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/AM/PO	

Date:12/26/00ISR Number: 3643776-3Report Type:Periodic Company Report #WAES 00092148
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Swelling Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Urticaria Vomiting		Amoxil Hydrodiuril Premarin Prilosec Atenolol	SS C C C C				

Date:12/26/00ISR Number: 3643778-7Report Type:Periodic Company Report #WAES 00092122
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643779-9Report Type:Periodic Company Report #WAES 00092127
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dyspepsia							
	Influenza							
	Vomiting		Premarin	C				
			Reglan	C				
			Soma	C				
			Xanax	C				
			Elavil	C				
			Ms Contin	C				

Date:12/26/00ISR Number: 3643783-0Report Type:Periodic Company Report #WAES 00091086
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accolate	C				
			Asacol	C				
			Lipitor	C				
			Paxil	C				
			Prempro	C				
			Prilosec	C				
			Serevent	C				
			Vancenase	C				
			Hyoscyamine	C				

Date:12/26/00ISR Number: 3643785-4Report Type:Periodic Company Report #WAES 00091106
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Glucotrol C
Hytrin C
Pepcid C
Synthroid C

Date:12/26/00ISR Number: 3643786-6Report Type:Periodic Company Report #WAES 00091108
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tds Testoderm 5 Mg	SS			5 MG/DAILY	
			Baycol	C				
			Hytrin	C				
			Maxzide	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643788-XReport Type:Periodic Company Report #WAES 00091112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643790-8Report Type:Periodic Company Report #WAES 00091127
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643794-5Report Type:Periodic Company Report #WAES 00091134
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Arthralgia							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease		Ambien	C				
			Cardura	C				
	Constipation		Coumadin	C				
	Gastrointestinal Disorder		Hydrocodone	C				
	Pain In Extremity		Verapamil	C				
	Pollakiuria							
	Renal Impairment							

Date:12/26/00ISR Number: 3643795-7Report Type:Periodic Company Report #WAES 00090087
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	

Date:12/26/00ISR Number: 3643797-0Report Type:Periodic Company Report #WAES 00091136
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; PRN/PO	

Date:12/26/00ISR Number: 3643798-2Report Type:Periodic Company Report #WAES 00090094
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Aspirin	C	
Calcium Supplement (Unspecified)	C	
Vitamins (Unspecified)	C	

Date:12/26/00ISR Number: 3643801-XReport Type:Periodic Company Report #WAES 00091304
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643803-3Report Type:Periodic Company Report #WAES 00091305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643804-5Report Type:Periodic Company Report #WAES 00091307
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia Back Pain Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia		Calan	C				
	Irritability		Prozac	C				

Xanax C

Date:12/26/00ISR Number: 3643806-9Report Type:Periodic Company Report #WAES 00091309
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643808-2Report Type:Periodic Company Report #WAES 00091311
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arrhythmia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643809-4Report Type:Periodic Company Report #WAES 00091313
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

Date:12/26/00ISR Number: 3643811-2Report Type:Periodic Company Report #WAES 00091314
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 12.5 MG/PO	

Date:12/26/00ISR Number: 3643813-6Report Type:Periodic Company Report #WAES 00091315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643815-XReport Type:Periodic Company Report #WAES 00091316
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Company Merck Co Inc ORAL
PO
Representative

Date:12/26/00ISR Number: 3643817-3Report Type:Periodic Company Report #WAES 00090114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:12/26/00ISR Number: 3643818-5Report Type:Periodic Company Report #WAES 00091319
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Haematuria Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	6 DAY
			Adalat	C				
			Hyzaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643820-3Report Type:Periodic Company Report #WAES 00080480
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Micturition Disorder Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG BID PO	5 DAY
	Weight Increased		Estrace	C				

Date:12/26/00ISR Number: 3643821-5Report Type:Periodic Company Report #WAES 00090121
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643824-0Report Type:Periodic Company Report #WAES 00082439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:12/26/00ISR Number: 3643825-2Report Type:Periodic Company Report #WAES 00080486
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	

PO

			Vasotec	C

Date:12/26/00ISR Number: 3643826-4Report Type:Periodic Company Report #WAES 00091320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Tinnitus				Merck Co Inc	ORAL

25 MG DAILY

PO

			Insulin	C

Date:12/26/00ISR Number: 3643829-XReport Type:Periodic Company Report #WAES 00091322
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL

SEE IMAGE

	Fosamax	C
	Levoxyl	C
	Trental	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643830-6Report Type:Periodic Company Report #WAES 00091323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Headache Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Insulin	C				

Date:12/26/00ISR Number: 3643831-8Report Type:Periodic Company Report #WAES 00080495
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG PO	
			Miacalcin	C				

Date:12/26/00ISR Number: 3643832-XReport Type:Periodic Company Report #WAES 00082448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643833-1Report Type:Periodic Company Report #WAES 00091325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY

PO

Date:12/26/00ISR Number: 3643836-7Report Type:Periodic Company Report #WAES 00091326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Coumadin	C				
			Glucophage	C				
			Imdur	C				
			Lanoxin	C				
			Tranxene	C				
			Univasc	C				

Date:12/26/00ISR Number: 3643837-9Report Type:Periodic Company Report #WAES 00091330
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	

PO

			Premarin	C		

Date:12/26/00ISR Number: 3643838-0Report Type:Periodic Company Report #WAES 00080509
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
	Gastrointestinal Disorder	Health Professional						
	Rectal Haemorrhage							
			Cardizem Cd	C				
			Flomax(Tamsulosin (R)-Form Hydru)	C				
			Imdur	C				
			Lasix	C				
			Lopressor	C				
			Oruvail	C				
			Pravachol	C				
			Prilosec	C				
			Potassium Supplement (Compositio)	C				

Date:12/26/00ISR Number: 3643839-2Report Type:Periodic Company Report #WAES 00082450
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	
			Tab Elavil 50 Mg	SS		ORAL	50 MG/DAILY/PO	

PIO

Date:12/26/00ISR Number: 3643842-2Report Type:Periodic Company Report #WAES 00091361
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643843-4Report Type:Periodic Company Report #WAES 00082468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643844-6Report Type:Periodic Company Report #WAES 00091362
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Visual Disturbance	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Alcohol	C				

Date:12/26/00ISR Number: 3643847-1Report Type:Periodic Company Report #WAES 00091363
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DIALY	
			Coumadin	C			PO	
			Lonox	C				
			Zyrtec	C				
			Digitec	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3643848-3Report Type:Periodic Company Report #WAES 00091367
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PRN PO	
			Accolate	C				
			Diovan Hct	C				
			Patanol	C				
			Pravachol	C				
			Premarin	C				
			Prilosec	C				
			Proventil	C				

Synthroid	C
Ultram	C
Xenical	C
Zyrtec	C
Alprazolam	C
Clonidine	C
Methocarbamol	C

Date:12/26/00ISR Number: 3643849-5Report Type:Periodic Company Report #WAES 00080519
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Tiazac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643851-3Report Type:Periodic Company Report #WAES 00082475
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643853-7Report Type:Periodic Company Report #WAES 00082479
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cardizem Cd	C				
			Lasix	C				
			Premarin	C				
			Restoril	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3643854-9Report Type:Periodic Company Report #WAES 00080595
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthma Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Feeling Abnormal Vision Blurred		Cartia	C				
			Lipitor	C				
			Prevacid	C				
			Xanax	C				
			Zantac	C				
			Aspirin	C				
			Colochicine	C				
			Diltiazem Hydrochloride	C				

			Hydrochlorothiazide (+) Triamter	C		

Date:12/26/00ISR Number: 3643856-2Report Type:Periodic Company Report #WAES 00091382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643857-4Report Type:Periodic Company Report #WAES 00082498
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Bumex	C				
			Darvocet-N	C				

			Lanoxin	C		
			Prednisone	C		
			Warfarin	C		

Date:12/26/00ISR Number: 3643858-6Report Type:Periodic Company Report #WAES 00091384
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
			Hytrin	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643859-8Report Type:Periodic Company Report #WAES 00080599
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643861-6Report Type:Periodic Company Report #WAES 00082567
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Ibuprofen	C				

Date:12/26/00ISR Number: 3643863-XReport Type:Periodic Company Report #WAES 00082572
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Accupril	C		
			Ambien	C		
			Caltrate	C		
			Celebrex	C		
			Detrol	C		
			Hytrin	C		
			Imdur	C		
			K-Dur	C		
			Lanoxin	C		
			Lasix	C		
			Pravachol	C		
			Allopurinol	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643865-3Report Type:Periodic Company Report #WAES 00080607
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY PO	
	Asthenia							
	Balance Disorder							
	Drug Toxicity		Astelin	C				
	Fatigue		Axid	C				
	Gait Disturbance		Cytomel	C				
	Hypersomnia		Keflex	C				
	Insomnia		Levoxyl	C				
	Movement Disorder		Lithium Carbonate (Roxane)	C				
	Pyrexia		Nasacort	C				
	Tremor		Prevacid	C				
	Vertigo		Rhinocort	C				
	Vision Blurred		Ritalin	C				
	Visual Disturbance		Tegretol	C				
	Vomiting		Amoxicillin	C				
			Jormonal Contraceptives	C				

Date:12/26/00ISR Number: 3643866-5Report Type:Periodic Company Report #WAES 00082573
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Tylenol	C				
			Vicodin Tablets	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3643870-7Report Type:Periodic Company Report #WAES 00111323
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis Contact Herpes Virus Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO;

PO

Synthroid	C
Tresaderm	C
Estrogens	C
Progesterone	C

Date:12/26/00ISR Number: 3643871-9Report Type:Periodic Company Report #WAES 00091385
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25 MG/ DAILY/

PO

Darvocet-N	C
Diovan Hct	C
Lanoxin	C

			Norvasc	C		
			Metoprolol Tartrate	C		

Date:12/26/00ISR Number: 3643872-0Report Type:Periodic Company Report #WAES 00091386
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Halcion	C				
			Lasix	C				
			Ultram	C				
			Vasotec	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643873-2Report Type:Periodic Company Report #WAES 00080632
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643875-6Report Type:Periodic Company Report #WAES 00091396
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PM/PO	

Date:12/26/00ISR Number: 3643877-XReport Type:Periodic Company Report #WAES 00111329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				

Date:12/26/00ISR Number: 3643878-1Report Type:Periodic Company Report #WAES 00080662
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactoid Reaction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643879-3Report Type:Periodic Company Report #WAES 00091397
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	

Date:12/26/00ISR Number: 3643881-1Report Type:Periodic Company Report #WAES 00091400
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:12/26/00ISR Number: 3643883-5Report Type:Periodic Company Report #WAES 00091403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abnormal Faeces Asthenia Constipation Fatigue Headache Hypoaesthesia Oedema Peripheral Pain Pain In Extremity Paraesthesia Swelling Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643884-7Report Type:Periodic Company Report #WAES 00111337
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 50 MG/PO	

Date:12/26/00ISR Number: 3643885-9Report Type:Periodic Company Report #WAES 00091412
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Incontinence Gait Disturbance Micturition Disorder Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG / DAILY/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643886-0Report Type:Periodic Company Report #WAES 00091414
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Vioxx	PS	Merck Research			
	Depression	Professional			Laboratories Div			
	Diplopia				Merck Co Inc	ORAL	PO	
	Drug Interaction		Toprol Xl Tablets					
	Fatigue		50mg And 25mg	SS				
	Migraine							
	Muscular Weakness							
	Sedation							

Date:12/26/00ISR Number: 3643887-2Report Type:Periodic Company Report #WAES 00080680
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
	Weight Increased	Professional			Merck Co Inc	ORAL	PO	
			Avapro	C				
			Celebrex	C				
			Premarin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3643889-6Report Type:Periodic Company Report #WAES 00080708
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
	Skin Disorder	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	3 MON
			Fosamax	C				
			Hydrodiuril	C				
			Toprol Xl	C				
			Insulin	C				
			Tamoxifen	C				

Date:12/26/00ISR Number: 3643890-2Report Type:Periodic Company Report #WAES 00111344
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Furuncle	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Lopid	C				
			Lopressor	C				
			Aspirin	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3643893-8Report Type:Periodic Company Report #WAES 00091418
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643894-XReport Type:Periodic Company Report #WAES 00111349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643895-1Report Type:Periodic Company Report #WAES 00080713
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	

Date:12/26/00ISR Number: 3643896-3Report Type:Periodic Company Report #WAES 00111351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643897-5Report Type:Periodic Company Report #WAES 00091419
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Tenormin	C				

Date:12/26/00ISR Number: 3643898-7Report Type:Periodic Company Report #WAES 00080715
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	
	Drug Ineffective							
	Dyspepsia							
	Vomiting		Lortab	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643900-2Report Type:Periodic Company Report #WAES 00091422
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643902-6Report Type:Periodic Company Report #WAES 00111353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3643903-8Report Type:Periodic Company Report #WAES 00091424
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucotrol	C				
			Hydrodiuril	C				
			Lopressor	C				
			Procardia	C				
			Vasotec	C				
			Magnesium Chloride	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3643904-XReport Type:Periodic Company Report #WAES 00091425
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research			
	Pain	Health			Laboratories Div			

	Pharyngeal Oedema	Professional			Merck Co Inc	ORAL
25						
	Throat Tightness					
MG/DAILY/PO						

Date:12/26/00ISR Number: 3643905-1Report Type:Periodic Company Report #WAES 00080722
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Diarrhoea	Health			Laboratories Div	
	Drug Ineffective	Professional			Merck Co Inc	ORAL
25MG DAILY PO						
SEE IMAGE						
			Compazine	C		
			Coumadin	C		
			Glucophage	C		
			Lipitor	C		
			Maxide	C		
			Novolin	C		
			Procardia	C		
			Synthroid	C		
			Tenormin	C		
			Viagra	C		
			Zoloft	C		
			Therapy Unspecified	C		

			Vitamins	C		

Date:12/26/00ISR Number: 3643906-3Report Type:Periodic Company Report #WAES 00091426
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actonel	C				
			Azmacort	C				
			Azopt Drops	C				
			Cardizem	C				
			Pilopine Hs Gel	C				
			Proscar	C				
			Serevent	C				
			Singulair	C				
			Xalatan	C				
			Xopenex	C				
			Ipratropium Bromide	C				

Date:12/26/00ISR Number: 3643909-9Report Type:Periodic Company Report #WAES 00091428
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lopressor	C				
			Prinzide	C				
			Synthroid	C				
			Nitroglycerin	C				

Date:12/26/00ISR Number: 3643911-7Report Type:Periodic Company Report #WAES 00091432
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643912-9Report Type:Periodic Company Report #WAES 00091433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO0	
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643914-2Report Type:Periodic Company Report #WAES 00091436
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Bradycardia							
	Drug Ineffective							
	Drug Interaction							

Date:12/26/00ISR Number: 3643915-4Report Type:Periodic Company Report #WAES 00111365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Centrum	C				
			Synthroid	C				
			Atenolol	C				
			Calcium	C				

Date:12/26/00ISR Number: 3643916-6Report Type:Periodic Company Report #WAES 00080740
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG DAILY PO	

Date:12/26/00ISR Number: 3643919-1Report Type:Periodic Company Report #WAES 00080744
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Neck Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:12/26/00ISR Number: 3643920-8Report Type:Periodic Company Report #WAES 00080754
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Norvasc	C				
			Premarin	C				

Date:12/26/00ISR Number: 3643922-1Report Type:Periodic Company Report #WAES 00111371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Darvocet-N	C	
Dilantin	C	
Mebaral	C	
Salsalate	C	

Date:12/26/00ISR Number: 3643925-7Report Type:Periodic Company Report #WAES 00080762
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryl	C				

Date:12/26/00ISR Number: 3643927-0Report Type:Periodic Company Report #WAES 00111372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3643928-2Report Type:Periodic Company Report #WAES 00080771
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Myokymia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG BID PO	
	Sedation		Therapy Unspecified	C				

Date:12/26/00ISR Number: 3643935-XReport Type:Periodic Company Report #WAES 00111428
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Renal Impairment	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Tab Hyzaar	SS				

Date:12/26/00ISR Number: 3643936-1Report Type:Periodic Company Report #WAES 00091211
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3643938-5Report Type:Periodic Company Report #WAES 00091212
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
SEE IMAGE

Actonel	C
Synthroid	C
Thyroid	C
Vitamins	C

Date:12/26/00ISR Number: 3643941-5Report Type:Periodic Company Report #WAES 00091213
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Calcium	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3643943-9Report Type:Periodic Company Report #WAES 00091215
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Prilosec	C				
			Propulsid	C				
			Vicodin Tablets	C				

Date:12/26/00ISR Number: 3643945-2Report Type:Periodic Company Report #WAES 00091221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	
25 MG DAILY PO						ORAL

Date:12/26/00ISR Number: 3643946-4Report Type:Periodic Company Report #WAES 00091223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Pruritus					
PO						ORAL

Date:12/26/00ISR Number: 3643949-XReport Type:Periodic Company Report #WAES 00091228
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Acne	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
25 MG DAILY PO						ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643950-6Report Type:Periodic Company Report #WAES 00091246
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Disturbance In Social Behaviour Fatigue Libido Decreased Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643951-8Report Type:Periodic Company Report #WAES 00091263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3643952-XReport Type:Periodic Company Report #WAES 00091268
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643953-1Report Type:Periodic Company Report #WAES 00111429
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:12/26/00ISR Number: 3643954-3Report Type:Periodic Company Report #WAES 00091439
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Nonsteroidal Anti-Inflammatory	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3643955-5Report Type:Periodic Company Report #WAES 00092530
Age:14 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Influenza Like Illness	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643956-7Report Type:Periodic Company Report #WAES 00091442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643957-9Report Type:Periodic Company Report #WAES 00091443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643958-0Report Type:Periodic Company Report #WAES 00091445
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5 MG/PO;

25 MG/PO

Celebrex	C
Fosamax	C
[Therapy Unspecified]	C
Calcium (Unspecified)	C

Date:12/26/00ISR Number: 3643960-9Report Type:Periodic Company Report #WAES 00111430
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Toprol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643961-0Report Type:Periodic Company Report #WAES 00092541
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG / DAILY/PO	
			Astelin	C				
			Nasarel	C				
			Paxil	C				
			Prevacid	C				
			Trazodone	C				

Date:12/26/00ISR Number: 3643962-2Report Type:Periodic Company Report #WAES 00091452
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643963-4Report Type:Periodic Company Report #WAES 00091449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643964-6Report Type:Periodic Company Report #WAES 00092585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3643965-8Report Type:Periodic Company Report #WAES 00091450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	

Date:12/26/00ISR Number: 3643967-1Report Type:Periodic Company Report #WAES 00111454
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dilantin	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643968-3Report Type:Periodic Company Report #WAES 00092586
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident Disturbance In Attention Drug Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY

Date:12/26/00ISR Number: 3643969-5Report Type:Periodic Company Report #WAES 00091457
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chloasma Neoplasm Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			Atacand	C				
			Coumadin	C				
			Demadex	C				
			Ocuvite	C				
			[Therapy Unspecified]	C				
			Cyanocobalamin	C				
			Ranitidine	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3643970-1Report Type:Periodic Company Report #WAES 00091458
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25 MG/PO						
			Atenolol	C		

Date:12/26/00ISR Number: 3643971-3Report Type:Periodic Company Report #WAES 00092587
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research	
	Malaise				Laboratories Div	
	Nausea				Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3643972-5Report Type:Periodic Company Report #WAES 00091472
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG/TID/PO						
			Hyzaar	C		
			Lopressor	C		
			[Therapy			
			Unspecified]	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643973-7Report Type:Periodic Company Report #WAES 00100002
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	POP	

Date:12/26/00ISR Number: 3643974-9Report Type:Periodic Company Report #WAES 00100008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vasculitis		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	2 WK

Date:12/26/00ISR Number: 3643975-0Report Type:Periodic Company Report #WAES 00111455
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Muscle Spasms Vaginal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Effexor	C				
			Premarin	C				

Date:12/26/00ISR Number: 3643977-4Report Type:Periodic Company Report #WAES 00100009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3643979-8Report Type:Periodic Company Report #WAES 00100011
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

Date:12/26/00ISR Number: 3643980-4Report Type:Periodic Company Report #WAES 00100012
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Celebrex	C				
			Effexor	C				
			Premarin	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Cholecalciferol	C				

				Vitamin E	C		

Date:12/26/00ISR Number: 3643981-6Report Type:Periodic Company Report #WAES 00111456
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 25 MG/BID/PO	
			Glucophage	C				
			Lipitor	C				
			Prilosec	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3643982-8Report Type:Periodic Company Report #WAES 00091474
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3643984-1Report Type:Periodic Company Report #WAES 00091475
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Faecal Incontinence Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:12/26/00ISR Number: 3643985-3Report Type:Periodic Company Report #WAES 00092258
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Polyuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG/DAILY/						
PO						
			Cozaar	C		
			Fosamax	C		
			Moduretic	C		
			Prilosec	C		
			Synthroid	C		
			Aspirin	C		
			Calcium (Unspecified)	C		
			Estrogens (Unspecified)	C		
			Estrogens (Unspecified)	C		
			Glucosamine	C		
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643987-7Report Type:Periodic Company Report #WAES 00092266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Pravachol	C				
			Ranitidine	C				

Date:12/26/00ISR Number: 3643989-0Report Type:Periodic Company Report #WAES 00100016
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Prilosec	SS				
			Tylenol	C				

Date:12/26/00ISR Number: 3643990-7Report Type:Periodic Company Report #WAES 00100017
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Cyclobenzaprine Hcl 10 Mg	SS				

Date:12/26/00ISR Number: 3643991-9Report Type:Periodic Company Report #WAES 00091477
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoaesthesia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Hazaar	C				
			Tricor	C				
			Amitriptyline	C				

Date:12/26/00ISR Number: 3643992-0Report Type:Periodic Company Report #WAES 00092267
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643993-2Report Type:Periodic Company Report #WAES 00111461
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
	Irritable Bowel Syndrome							
			Ambien	C				
			Lipitor	C				
			Paxil	C				
			Prempro	C				
			Synthroid	C				
			Xanax	C				

Date:12/26/00ISR Number: 3643994-4Report Type:Periodic Company Report #WAES 00091485
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:12/26/00ISR Number: 3643995-6Report Type:Periodic Company Report #WAES 00100018
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Drug Ineffective							
	Dyspnoea							
	Muscular Weakness							
	Oliguria		Furosemide	C				
	Swelling							
	Weight Increased							

Date:12/26/00ISR Number: 3643996-8Report Type:Periodic Company Report #WAES 00091487
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium (Unspecified)	C				
			Potassium [Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3643997-XReport Type:Periodic Company Report #WAES 00092271
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3643998-1Report Type:Periodic Company Report #WAES 00100020
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Diarrhoea							
	Pruritus							
			Celebrex	C				
			Inderide Tablets	C				
			Klotrix	C				
			Premarin	C				
			Zantac	C				

Date:12/26/00ISR Number: 3643999-3Report Type:Periodic Company Report #WAES 00091490
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Coumadin	C				
			Hydrodiuril	C				
			Hytrin	C				
			Lasix	C				
			Serevent	C				
			Zestril	C				
			Aspirin	C				
			Potassium (Unspecified)	C				

Date:12/26/00ISR Number: 3644001-XReport Type:Periodic Company Report #WAES 00091500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Salivary Hypersecretion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644003-3Report Type:Periodic Company Report #WAES 00092274
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3644004-5Report Type:Periodic Company Report #WAES 00100022
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/UNK/PO

Tylenol Wth Codeine C

Date:12/26/00ISR Number: 3644005-7Report Type:Periodic Company Report #WAES 00091506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Baycol	C				
			Buspar	C				
			Centrum	C				
			Prozac	C				
			Synthroid	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3644006-9Report Type:Periodic Company Report #WAES 00091522
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644007-0Report Type:Periodic Company Report #WAES 00100029
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Iron Increased Gamma-Glutamyltransferase	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Increased	Company			Merck Co Inc	ORAL
12.5						
		Representative				
MG/DAILY/PO						

Date:12/26/00ISR Number: 3644008-2Report Type:Periodic Company Report #WAES 00092276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/UNK/PO						
			Zocor	C		

Date:12/26/00ISR Number: 3644009-4Report Type:Periodic Company Report #WAES 00111474
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644010-0Report Type:Periodic Company Report #WAES 00091524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644011-2Report Type:Periodic Company Report #WAES 00100031
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	7 DAY

Date:12/26/00ISR Number: 3644013-6Report Type:Periodic Company Report #WAES 00092277
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Morbilliform	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OCCLUSIVE DRESSING	25MG/DAILY/PO	
			Elavil	C				
			Oxycontin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3644014-8Report Type:Periodic Company Report #WAES 00111477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
50

MG/DAILY/PO

Date:12/26/00ISR Number: 3644015-XReport Type:Periodic Company Report #WAES 00091982
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Nausea							
			Isorbid	C				
			Premarin	C				
			Prozac	C				
			Zocor	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3644016-1Report Type:Periodic Company Report #WAES 00092281
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Rectal Haemorrhage							
	Weight Increased							

/DAILY/PO

Ambien	C	
Ativan	C	
Amoxicillin	C	

Date:12/26/00ISR Number: 3644017-3Report Type:Periodic Company Report #WAES 00091989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactose Intolerance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644018-5Report Type:Periodic Company Report #WAES 00100032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644019-7Report Type:Periodic Company Report #WAES 00092002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 DAY

Date:12/26/00ISR Number: 3644020-3Report Type:Periodic Company Report #WAES 00092007
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Evista	C				

Date:12/26/00ISR Number: 3644021-5Report Type:Periodic Company Report #WAES 00111486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644023-9Report Type:Periodic Company Report #WAES 00092262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

			Glucotrol	C		
			Pravachol	C		

Date:12/26/00ISR Number: 3644024-0Report Type:Periodic Company Report #WAES 00092008
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/UNK/PO	

Date:12/26/00ISR Number: 3644025-2Report Type:Periodic Company Report #WAES 00100038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Atenolol	C				

Date:12/26/00ISR Number: 3644026-4Report Type:Periodic Company Report #WAES 00092010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644027-6Report Type:Periodic Company Report #WAES 00092283
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Diasulfon	C				
			Carisoprodol	C				

Date:12/26/00ISR Number: 3644028-8Report Type:Periodic Company Report #WAES 00111497
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644030-6Report Type:Periodic Company Report #WAES 00100047
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3644031-8Report Type:Periodic Company Report #WAES 00092011
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	2 WK
			Ibuprofen	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644032-XReport Type:Periodic Company Report #WAES 00092284
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3644033-1Report Type:Periodic Company Report #WAES 00092018
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3644034-3Report Type:Periodic Company Report #WAES 00092019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:12/26/00ISR Number: 3644035-5Report Type:Periodic Company Report #WAES 00111504
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Dyazide	C				

			Estraderm	C
			Minipress	C
			Provera	C
			Quinine Sulfate	C

Date:12/26/00ISR Number: 3644036-7Report Type:Periodic Company Report #WAES 00092020
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Bicillin	C				
			Entex Pse	C				
			Flexeril	C				
			Inderal	C				
			Lithobid	C				
			Phenergan (Promethazine Hydrochl	C				
			Premarin	C				
			Prilosec	C				
			Prozac	C				
			Seroquel	C				
			Synthroid	C				
			Wygesic Tablets	C				
			Xanax	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3644037-9Report Type:Periodic Company Report #WAES 00092286
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Glucophage	C				
			Glucotrol Xl	C				
			Hytrin	C				

			Synthroid	C		

Date:12/26/00ISR Number: 3644039-2Report Type:Periodic Company Report #WAES 00092287
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ventricular Extrasystoles	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG/DAILY/						
PO						
			Lipitor	C		
			Prempro	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644040-9Report Type:Periodic Company Report #WAES 00092289
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Pravachol	C				
			Prilosec	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3644041-0Report Type:Periodic Company Report #WAES 00092022
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				
			Meclizine	C				

Date:12/26/00ISR Number: 3644042-2Report Type:Periodic Company Report #WAES 00092023
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Movement Disorder Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:12/26/00ISR Number: 3644043-4Report Type:Periodic Company Report #WAES 00092025
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Celebrex	C				
			Relafen	C				

Date:12/26/00ISR Number: 3644044-6Report Type:Periodic Company Report #WAES 00092294
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644045-8Report Type:Periodic Company Report #WAES 00100051
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Swelling Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/P	
			Catapres	C				
			Ditropan	C				
			Lanoxin	C				
			Nitro-Dur	C				
			Hydrochlorothiazide (+) Triamter	C				
			Potassium Chloride	C				

Date:12/26/00ISR Number: 3644046-XReport Type:Periodic Company Report #WAES 00092299
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Mephyton	C				
			Synthroid	C				
			Trinsicon (Ascorbic Acid (+) Cya)	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Cyanocobalamin	C				
			Folic Acid	C				
			Vitamin D (Unspecified)	C				

Date:12/26/00ISR Number: 3644047-1Report Type:Periodic Company Report #WAES 00111521
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644048-3Report Type:Periodic Company Report #WAES 00092026
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accuretic	C				
			Plendil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644049-5Report Type:Periodic Company Report #WAES 00092304
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644050-1Report Type:Periodic Company Report #WAES 00111524
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Aspartate Aminotransferase Increased		Flovent	C			PO	
			Norvasc	C				
			Serevent	C				

Date:12/26/00ISR Number: 3644051-3Report Type:Periodic Company Report #WAES 00092027
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644052-5Report Type:Periodic Company Report #WAES 00092028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:12/26/00ISR Number: 3644053-7Report Type:Periodic Company Report #WAES 00092306
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644054-9Report Type:Periodic Company Report #WAES 00092050
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Levoxyl	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644055-0Report Type:Periodic Company Report #WAES 00100054
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				
			Hydrodiuril	C				

Date:12/26/00ISR Number: 3644056-2Report Type:Periodic Company Report #WAES 00092052
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Preparation H Hemorrhoidal	C				

Date:12/26/00ISR Number: 3644057-4Report Type:Periodic Company Report #WAES 00111526
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Haemorrhage Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PRN PO	
			Dyazide	C				
			Premarin	C				
			Synthroid	C				
			Toprol Xl Tablets	C				

Date:12/26/00ISR Number: 3644059-8Report Type:Periodic Company Report #WAES 00092053
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Gingival Bleeding	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Ziac	C				

Date:12/26/00ISR Number: 3644060-4Report Type:Periodic Company Report #WAES 00100058
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PRN/PO	
			Claritin	C				
			Miralax	C				
			Paxil	C				
			Propade Extended Relief	C				
			Proventil	C				

Risperdal	C
Singulair	C
Synthroid	C
Theo-Dur	C
Wellbutrin	C
Alprazolam	C
Baclofen	C
Carbamazepine	C
Diphenhydramine	C
Hydrocodone /Apap	C
Ranitidine	C

Date:12/26/00ISR Number: 3644061-6Report Type:Periodic Company Report #WAES 00092060
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
			Hydrodiuril	C				
			Prempro	C				
			Prevacid	C				

Date:12/26/00ISR Number: 3644062-8Report Type:Periodic Company Report #WAES 00092307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644063-XReport Type:Periodic Company Report #WAES 00111529
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ditropan	C				
			Premarin	C				
			Synthroid	C				
			Furosemide	C				
			Meclizine	C				
			Potassium	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3644064-1Report Type:Periodic Company Report #WAES 00100060
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness Weight Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS		ORAL	200	

MG/DAILY/PO

Pepcid	C	
Furosemide	C	
Irbesartan	C	
Potassium (Unspecified)	C	
Venlafaxine Hydrochloride	C	

Date:12/26/00ISR Number: 3644065-3Report Type:Periodic Company Report #WAES 00092314
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Miacalcin	C				
			Prempro	C				
			Prevacid	C				
			Synthroid	C				
			Ultram	C				

Date:12/26/00ISR Number: 3644066-5Report Type:Periodic Company Report #WAES 00111531
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Oedema Peripheral Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Premarin	C				

Date:12/26/00ISR Number: 3644067-7Report Type:Periodic Company Report #WAES 00100061
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS		ORAL	PO	

Date:12/26/00ISR Number: 3644068-9Report Type:Periodic Company Report #WAES 00111532
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 WK

Date:12/26/00ISR Number: 3644069-0Report Type:Periodic Company Report #WAES 00111533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

				Lipitor	C		
				Pancrease (Pancrelipase)	C		
				Prilosec	C		
				Prinivil	C		
				Cyanocobalamin	C		
				Folic Acid	C		
				Glyburide	C		

Date:12/26/00ISR Number: 3644070-7Report Type:Periodic Company Report #WAES 00100088
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG OR 25MG/ Q12H/PO	
			Lipitor	C				
			Premarin	C				
			Prilosec	C				
			Prinivil	C				
			Acetaminbophen (+) Propoxyphene	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:12/26/00ISR Number: 3644071-9Report Type:Periodic Company Report #WAES 00092317
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coreg	C				
			Cozaar	C				
			Lipitor	C				

			Furosemide	C		

Date:12/26/00ISR Number: 3644072-0Report Type:Periodic Company Report #WAES 00091527
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation	Health	Vioxx	PS	Merck Research	
	Blood Pressure Increased	Professional			Laboratories Div	
	Chest Pain	Company			Merck Co Inc	ORAL
25 MG/PRN/PO						
	Chills	Representative	B Complex 100	C		
	Hypoaesthesia		Citracal	C		
	Nervousness		Estrace	C		
	Pain		Provera	C		
	Palpitations		Synthroid	C		
			Tilade	C		
			Vasotec	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644073-2Report Type:Periodic Company Report #WAES 00091530
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Chondroitin (+) Glucosamine	C				

Date:12/26/00ISR Number: 3644074-4Report Type:Periodic Company Report #WAES 00111374
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alprazolam	C				
			Doxepin Hydrochloride	C				

Date:12/26/00ISR Number: 3644075-6Report Type:Periodic Company Report #WAES 00100102
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Acyclovir	C				
			Estradiol	C				

			Prednisone	C		

Date:12/26/00ISR Number: 3644076-8Report Type:Periodic Company Report #WAES 00092325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hair Disorder							
	Mucosal Dryness							
	Skin Disorder							

Date:12/26/00ISR Number: 3644077-XReport Type:Periodic Company Report #WAES 00091531
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Actos	C				
			Premarin	C				
			Tiazac	C				
			Glipizide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644078-1Report Type:Periodic Company Report #WAES 00091539
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Actos	C				
			Lotensin	C				
			Pancrease Mt Capsules	C				
			Prilosec	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3644079-3Report Type:Periodic Company Report #WAES 00111375
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Priapism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3644080-XReport Type:Periodic Company Report #WAES 00092333
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:12/26/00ISR Number: 3644081-1Report Type:Periodic Company Report #WAES 00091540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Miacalcin	C				
			Perdiem Fiber	C				
			Indapamide	C				
			Xalatan	C				
			Cipro	I				

Date:12/26/00ISR Number: 3644082-3Report Type:Periodic Company Report #WAES 00091543
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	SEE IMAGE
			Fosamax	C				
			Penasa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644083-5Report Type:Periodic Company Report #WAES 00111376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Celebrex	C				

Date:12/26/00ISR Number: 3644084-7Report Type:Periodic Company Report #WAES 00091546
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644085-9Report Type:Periodic Company Report #WAES 00092334
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	

PO

Date:12/26/00ISR Number: 3644086-0Report Type:Periodic Company Report #WAES 00100112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Muscular Weakness	Professional			Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:12/26/00ISR Number: 3644087-2Report Type:Periodic Company Report #WAES 00091548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:12/26/00ISR Number: 3644088-4Report Type:Periodic Company Report #WAES 00111377
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Creatinine Renal Clearance Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644089-6Report Type:Periodic Company Report #WAES 00091552
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dyspepsia							
	Nausea							
	Vomiting		Estratest	C				
			Ms Contin	C				
			Paxil	C				
			Soma	C				
			Chloral Hydrate	C				

Date:12/26/00ISR Number: 3644090-2Report Type:Periodic Company Report #WAES 00100121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:12/26/00ISR Number: 3644091-4Report Type:Periodic Company Report #WAES 00092335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zyrtec	C				

Date:12/26/00ISR Number: 3644092-6Report Type:Periodic Company Report #WAES 00091564
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644093-8Report Type:Periodic Company Report #WAES 00111390
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO 25MG PRN	 PO

Date:12/26/00ISR Number: 3644094-XReport Type:Periodic Company Report #WAES 00100124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644095-1Report Type:Periodic Company Report #WAES 00092342
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/PO	

Date:12/26/00ISR Number: 3644097-5Report Type:Periodic Company Report #WAES 00092348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Parosmia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Pravachol	C				

Date:12/26/00ISR Number: 3644098-7Report Type:Periodic Company Report #WAES 00111408
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pleural Effusion	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Premarin	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3644099-9Report Type:Periodic Company Report #WAES 00091568
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research			

					Laboratories Div Merck Co Inc	ORAL
PO						
			Cardizem	C		
			Prinivil	C		
			Synthroid	C		
			Aspirin	C		
			Cyanocobalamin	C		
			Iron	C		

Date:12/26/00ISR Number: 3644100-2Report Type:Periodic Company Report #WAES 00091570
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/PM/PO						
			Estrogens	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644101-4Report Type:Periodic Company Report #WAES 00100126
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Os-Cal	C				
			Zestoretic	C				

Date:12/26/00ISR Number: 3644102-6Report Type:Periodic Company Report #WAES 00091572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Increased Appetite		Vicodin Tablets	C				

Date:12/26/00ISR Number: 3644103-8Report Type:Periodic Company Report #WAES 00111414
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Vicodin Es Tablets	C				

Date:12/26/00ISR Number: 3644104-XReport Type:Periodic Company Report #WAES 00091577
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Dilantin	C				
			Lipitor	C				

Date:12/26/00ISR Number: 3644105-1Report Type:Periodic Company Report #WAES 00092355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644106-3Report Type:Periodic Company Report #WAES 00091578
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Diovan	C
Allopurinol	C
Isosorbide	C
Sotalol	C
Warfarin	C

Date:12/26/00ISR Number: 3644107-5Report Type:Periodic Company Report #WAES 00100128
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Permarin	C				
			Provera	C				

Date:12/26/00ISR Number: 3644108-7Report Type:Periodic Company Report #WAES 00091585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644109-9Report Type:Periodic Company Report #WAES 00092359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:12/26/00ISR Number: 3644110-5Report Type:Periodic Company Report #WAES 00111418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Haematochezia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3644111-7Report Type:Periodic Company Report #WAES 00091586
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644112-9Report Type:Periodic Company Report #WAES 00100130
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prozac	C				

Date:12/26/00ISR Number: 3644113-0Report Type:Periodic Company Report #WAES 00092376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MGDAIL/PO	

Date:12/26/00ISR Number: 3644114-2Report Type:Periodic Company Report #WAES 00091594
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Systemic Lupus Erythematosus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Viagra	C				
			Zyban	C				

Date:12/26/00ISR Number: 3644115-4Report Type:Periodic Company Report #WAES 00111419
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Health	Vioxx	PS	Merck Research	
	Oedema	Professional			Laboratories Div	
	Oral Mucosal	Company			Merck Co Inc	ORAL
50 MG DAILY						
	Discolouration	Representative				
PO						
	Pruritus					

Date:12/26/00ISR Number: 3644116-6Report Type:Periodic Company Report #WAES 00091597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Coagulation Time	Consumer	Vioxx	PS	Merck Research	
	Prolonged				Laboratories Div	
					Merck Co Inc	ORAL
PO 3 WK						
			Coumadin	C		
			Lanoxin	C		
			Quinidex Extentabs	C		
			Syntroid	C		
			Iron	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644118-XReport Type:Periodic Company Report #WAES 00100131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lasix	C				
			Pravachol	C				
			Zestril	C				
			Folic Acid	C				
			Potassium	C				
			Trazodone Hydrochloride	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644119-1Report Type:Periodic Company Report #WAES 00091599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644120-8Report Type:Periodic Company Report #WAES 00092068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Mevacor	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3644121-XReport Type:Periodic Company Report #WAES 00100134
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Lanoxin	C				

Date:12/26/00ISR Number: 3644122-1Report Type:Periodic Company Report #WAES 00111427
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644123-3Report Type:Periodic Company Report #WAES 00092069
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ambien	C				
			Prilosec	C				
			Proscar	C				
			Zocor	C				

Date:12/26/00ISR Number: 3644124-5Report Type:Periodic Company Report #WAES 00100135
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ecotrin	C				
			K-Dur	C				
			Lasix	C				
			Lipitor	C				
			Synthroid	C				
			Zebeta	C				

Date:12/26/00ISR Number: 3644125-7Report Type:Periodic Company Report #WAES 00091601
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Prothrombin Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON

			Coumadin 2.5 Mg	SS		
2.5 MG/DAILY						

Date:12/26/00ISR Number: 3644126-9Report Type:Periodic Company Report #WAES 00092071
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Diarrhoea				Laboratories Div	
	Fatigue				Merck Co Inc	ORAL
50						
	Muscle Spasms					
MG/DAILY/PO						
			Asriptin	C		
			Miacalcin	C		
			Os-Cal + D	C		
			Prevacid	C		
			Amitriptyline Hydrochloride (+)	C		
			Indapamide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644127-0Report Type:Periodic Company Report #WAES 00111235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /PO	
			Tylenol	C				

Date:12/26/00ISR Number: 3644128-2Report Type:Periodic Company Report #WAES 00100137
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644129-4Report Type:Periodic Company Report #WAES 00091617
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3644130-0Report Type:Periodic Company Report #WAES 00091635
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrooesophageal Reflux	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Disease				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Protonix	C		
			Cyanocobalamin	C		
			Iron	C		

Date:12/26/00ISR Number: 3644131-2Report Type:Periodic Company Report #WAES 00092074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Vioxx	PS	Merck Research	
	Upper Respiratory Tract				Laboratories Div	
	Infection				Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3644132-4Report Type:Periodic Company Report #WAES 00091637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia				Laboratories Div	
					Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644133-6Report Type:Periodic Company Report #WAES 00100139
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:12/26/00ISR Number: 3644134-8Report Type:Periodic Company Report #WAES 00111236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 MON
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3644135-XReport Type:Periodic Company Report #WAES 00091666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644136-1Report Type:Periodic Company Report #WAES 00092077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25 MG/PM/PO						
			Celebrex	C		
			Zantac	C		
			Verapamil	C		

Date:12/26/00ISR Number: 3644137-3Report Type:Periodic Company Report #WAES 00100141
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Fatigue				Laboratories Div	
	Hypersensitivity				Merck Co Inc	ORAL
50 MG/PO						
	Respiratory Disorder		Claritin	C		
			Effexor	C		
			Lipitor	C		
			Neurontin	C		
			Prilosec	C		
			Soma	C		
			Synthroid	C		
			Xanax	C		
			Morphine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644138-5Report Type:Periodic Company Report #WAES 00091685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adjustment Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644139-7Report Type:Periodic Company Report #WAES 00091691
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

Date:12/26/00ISR Number: 3644140-3Report Type:Periodic Company Report #WAES 00100143
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				
			Ziac	C				
			Zocor	C				

Date:12/26/00ISR Number: 3644142-7Report Type:Periodic Company Report #WAES 00091694
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Creatinine Increased Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							

Date:12/26/00ISR Number: 3644143-9Report Type:Periodic Company Report #WAES 00092081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Pollakiuria Pruritus Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3644144-0Report Type:Periodic Company Report #WAES 00091695
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Lotrisone	C		

Date:12/26/00ISR Number: 3644145-2Report Type:Periodic Company Report #WAES 00100144
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Bactrim	C				
			Glucophage	C				
			K-Dur	C				
			Aspirin	C				
			Chondroitin (+) Glucosamine	C				
			Diuretic	C				
			Folic Acid	C				
			Glyburide	C				
			Methotrexate	C				
			Prednisone	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644146-4Report Type:Periodic Company Report #WAES 00091703
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Neck Pain		Neurontin	C				
	Upper Respiratory Tract Infection		Vicodin Tablets	C				
	Urticaria							

Date:12/26/00ISR Number: 3644147-6Report Type:Periodic Company Report #WAES 00092083
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anorexia Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ambien	C				
			Effexor	C				
			Lotrel	C				
			Premarin	C				
			Potassium (Unspecified)	C				

Date:12/26/00ISR Number: 3644148-8Report Type:Periodic Company Report #WAES 00100145
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Lopid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644150-6Report Type:Periodic Company Report #WAES 00092086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644151-8Report Type:Periodic Company Report #WAES 00100151
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Flexeril	C				
			Calcium	C				

Date:12/26/00ISR Number: 3644153-1Report Type:Periodic Company Report #WAES 00091708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Flatulence		Percocet	C				

Date:12/26/00ISR Number: 3644154-3Report Type:Periodic Company Report #WAES 00092088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocythaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3644155-5Report Type:Periodic Company Report #WAES 00100158
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO						
			Ensure	C		
			Natures Rx Msm Plus C	C		
			Dimethyl Sulfone	C		
			Glucosamine	C		
			Protein	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644156-7Report Type:Periodic Company Report #WAES 00091713
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Red Blood Cell Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PO 11 DAY						
			Procrit	C		
			Vitamins	C		

Date:12/26/00ISR Number: 3644157-9Report Type:Periodic Company Report #WAES 00091715
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO; 25 MG/DAILY/PO						
			Celebrex	C		
			Evista	C		
			Norvasc	C		
			Ocuvite	C		
			Osteo-Bi-Flex	C		
			Relafen	C		
			Tylenol	C		
			Xanax	C		
			Calcium	C		
			Vitamins	C		

Date:12/26/00ISR Number: 3644158-0Report Type:Periodic Company Report #WAES 00092093
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pharyngitis Sneezing		Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25 MG/PO
Altace C

Date:12/26/00ISR Number: 3644159-2Report Type:Periodic Company Report #WAES 00100159
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accolate	C				
			Fosamax	C				
			Lasix	C				
			Meusicort	C				
			Miacalcin	C				
			Prevacid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644160-9Report Type:Periodic Company Report #WAES 00091718
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Monopril	C				

Date:12/26/00ISR Number: 3644161-0Report Type:Periodic Company Report #WAES 00100170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644162-2Report Type:Periodic Company Report #WAES 00091720
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644163-4Report Type:Periodic Company Report #WAES 00091726
Age:100 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25 MG/PO

Date:12/26/00ISR Number: 3644164-6Report Type:Periodic Company Report #WAES 00111238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection							
			Napralen	C				

Date:12/26/00ISR Number: 3644165-8Report Type:Periodic Company Report #WAES 00100172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644166-XReport Type:Periodic Company Report #WAES 00091727
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Inderal	C				
			Premarin	C				
			Calcium	C				
			Folic Acid	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644167-1Report Type:Periodic Company Report #WAES 00100174
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Darvocet-N	C				
			Dilacor Xr	C				
			Zestril	C				

Date:12/26/00ISR Number: 3644168-3Report Type:Periodic Company Report #WAES 00091728
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644169-5Report Type:Periodic Company Report #WAES 00092097
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Glucosamine	C				

Date:12/26/00ISR Number: 3644170-1Report Type:Periodic Company Report #WAES 00091729
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644171-3Report Type:Periodic Company Report #WAES 00111239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644172-5Report Type:Periodic Company Report #WAES 00100178
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644174-9Report Type:Periodic Company Report #WAES 00091732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644175-0Report Type:Periodic Company Report #WAES 00092098
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal White Blood Cell Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:12/26/00ISR Number: 3644176-2Report Type:Periodic Company Report #WAES 00111240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Parafon Forte	C				
			Percodan	C				
			Voltaren	C				

Date:12/26/00ISR Number: 3644177-4Report Type:Periodic Company Report #WAES 00100180
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644178-6Report Type:Periodic Company Report #WAES 00092103
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644179-8Report Type:Periodic Company Report #WAES 00111241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lorcet 10/650	C				

Date:12/26/00ISR Number: 3644180-4Report Type:Periodic Company Report #WAES 00092105
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO; 25 MG/PM/PO	

Date:12/26/00ISR Number: 3644181-6Report Type:Periodic Company Report #WAES 00111242
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celecoxib	C				

Date:12/26/00ISR Number: 3644182-8Report Type:Periodic Company Report #WAES 00091898
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3644184-1Report Type:Periodic Company Report #WAES 00091967
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644185-3Report Type:Periodic Company Report #WAES 00092106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
	Post Procedural Haemorrhage		Coumadin	C				
			Toprol Xl	C				

Date:12/26/00ISR Number: 3644186-5Report Type:Periodic Company Report #WAES 00091968
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644187-7Report Type:Periodic Company Report #WAES 00111243
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644188-9Report Type:Periodic Company Report #WAES 00091186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Hydrodiuril C

Date:12/26/00ISR Number: 3644189-0Report Type:Periodic Company Report #WAES 00091970
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ortho Dienestrol Cream	C				
			Oxycontin	C				
			Synthroid	C				
			Calcium	C				
			Verapamil	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644190-7Report Type:Periodic Company Report #WAES 00091187
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:12/26/00ISR Number: 3644191-9Report Type:Periodic Company Report #WAES 00091971
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Actifed	C				
			Actos	C				
			Centrum	C				
			Diovan	C				
			Fosamax	C				
			Glucophage	C				
			Lipitor	C				
			Norvasc	C				
			Synthroid	C				
			Calcium (Unspecified)	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644192-0Report Type:Periodic Company Report #WAES 00092108
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644193-2Report Type:Periodic Company Report #WAES 00111244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	
	Renal Disorder							
			Celebrex Unk	SS				

Date:12/26/00ISR Number: 3644194-4Report Type:Periodic Company Report #WAES 00091188
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
	Fatigue							
	Feeling Drunk							
	Sedation		Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644195-6Report Type:Periodic Company Report #WAES 00091976
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3644196-8Report Type:Periodic Company Report #WAES 00092109
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia Diplopia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imiprin	C				

Date:12/26/00ISR Number: 3644197-XReport Type:Periodic Company Report #WAES 00091977
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3644198-1Report Type:Periodic Company Report #WAES 00091190
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
	Blood Pressure Increased						
	Nausea						
	Vomiting						
			Cozaar	C			
			Prandin	C			

Date:12/26/00ISR Number: 3644199-3Report Type:Periodic Company Report #WAES 00091978
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Pain							
			Tenormin	C				

Date:12/26/00ISR Number: 3644200-7Report Type:Periodic Company Report #WAES 00091195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Headache							
	Oedema Peripheral							

MG/DAILY/PO

Date:12/26/00ISR Number: 3644201-9Report Type:Periodic Company Report #WAES 00091979
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Emotional Disorder Hallucination Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644202-0Report Type:Periodic Company Report #WAES 00092111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644203-2Report Type:Periodic Company Report #WAES 00091197
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3644204-4Report Type:Periodic Company Report #WAES 00091980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sunburn	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lescol	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3644205-6Report Type:Periodic Company Report #WAES 00092113
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	External Ear Disorder Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Prilosec	C				
			Zyrtec	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644207-XReport Type:Periodic Company Report #WAES 00092120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644208-1Report Type:Periodic Company Report #WAES 00091198
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol Arthritis Extended	C				

Date:12/26/00ISR Number: 3644209-3Report Type:Periodic Company Report #WAES 00091201
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain Tooth Abscess	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hydrocodone	C				

Date:12/26/00ISR Number: 3644211-1Report Type:Periodic Company Report #WAES 00092212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644212-3Report Type:Periodic Company Report #WAES 00091203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Prednisone	C				

Date:12/26/00ISR Number: 3644213-5Report Type:Periodic Company Report #WAES 00091210
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644214-7Report Type:Periodic Company Report #WAES 00092236
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Sputum Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Glucophage	C				
			Hydrodiuril	C				
			Lipitor	C				
			Prinivil	C				
			Singulair	C				
			Albuterol	C				
			Glyburide	C				
			Lorazepam	C				
			Ranitidine	C				

Date:12/26/00ISR Number: 3644215-9Report Type:Periodic Company Report #WAES 00092237
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644217-2Report Type:Periodic Company Report #WAES 00092241
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	6 DAY
			Hyzaar	C				
			Toprol Xl Tablets	C				

Date:12/26/00ISR Number: 3644219-6Report Type:Periodic Company Report #WAES 00092244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644220-2Report Type:Periodic Company Report #WAES 00092245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644222-6Report Type:Periodic Company Report #WAES 00092246
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50; 25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644223-8Report Type:Periodic Company Report #WAES 00092249
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644225-1Report Type:Periodic Company Report #WAES 00092250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644226-3Report Type:Periodic Company Report #WAES 00092252
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Disorientation	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Memory Impairment	Company Representative			Merck Co Inc	ORAL

12.5
MG/DAILY/PO

Date:12/26/00ISR Number: 3644232-9Report Type:Periodic Company Report #WAES 00111224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Mobic	C				

Date:12/26/00ISR Number: 3644233-0Report Type:Periodic Company Report #WAES 00091161
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644234-2Report Type:Periodic Company Report #WAES 00111225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644235-4Report Type:Periodic Company Report #WAES 00091733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
			Ativan	C				
			Levatol	C				
			Microzide	C				

Date:12/26/00ISR Number: 3644237-8Report Type:Periodic Company Report #WAES 00091734
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	UNK/UNK/PO	
			Excedrin Extra-Strength	C				
			Lipitor	C				
			Tagamet	C				
			Tylenol Extra Strength	C				

Date:12/26/00ISR Number: 3644238-XReport Type:Periodic Company Report #WAES 00091162
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Nasal Congestion	Health Professional						
	Nausea							
	Retching		Hydrodiuril [Therapy Unspecified]	C C				

Date:12/26/00ISR Number: 3644239-1Report Type:Periodic Company Report #WAES 00111226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644240-8Report Type:Periodic Company Report #WAES00091736
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Ambien	C				
			K-Dur	C				
			Lasix	C				
			Lipitor	C				
			Prinivil	C				
			Vicodine Tablets	C				
			Zaroxolyn	C				
			Insulin	C				

Date:12/26/00ISR Number: 3644241-XReport Type:Periodic Company Report #WAES 00091744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis							
	Fatigue							
	Muscular Weakness							
	Pruritus		Therapy Unspecified	C				
			Furosemide	C				
			Potassaium Chloride	C				

Date:12/26/00ISR Number: 3644243-3Report Type:Periodic Company Report #WAES 00091163
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Salivary Hypersecretion							

Merck Co Inc ORAL
25

MG/DAILY/PO

Synthroid C
Metoprolol C

Date:12/26/00ISR Number: 3644244-5Report Type:Periodic Company Report #WAES 00111227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644245-7Report Type:Periodic Company Report #WAES 00091745
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Ativan	C				
			Levbid	C				

			Premarin	C
			Remeron	C
			Ultram	C
			Doxepin	C

Date:12/26/00ISR Number: 3644246-9Report Type:Periodic Company Report #WAES 00091164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Atacand	C				
			Hydrodiuril	C				

Date:12/26/00ISR Number: 3644247-0Report Type:Periodic Company Report #WAES 00091749
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition Unspecified	C				

Date:12/26/00ISR Number: 3644248-2Report Type:Periodic Company Report #WAES 00111228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Naproxen	C				

Date:12/26/00ISR Number: 3644249-4Report Type:Periodic Company Report #WAES 00091751
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research			
	Dyspnoea	Health			Laboratories Div			
	Eczema	Professional			Merck Co Inc	ORAL	25-50	
	Nausea						MG/BID/PO	
	Vomiting		Celebrex	C				
			Claritin	C				
			Flexeril	C				
			Oxycontin	C				
			Tagamet	C				
			Viagra	C				
			Vicodin Tablets (Therapy Unspecifed)	C				
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644250-0Report Type:Periodic Company Report #WAES 00091752
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644251-2Report Type:Periodic Company Report #WAES 00111230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644252-4Report Type:Periodic Company Report #WAES 00091755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Mevacor	C				
			Ascorbic Acid	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3644253-6Report Type:Periodic Company Report #WAES 00111231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644254-8Report Type:Periodic Company Report #WAES 00111232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3644255-XReport Type:Periodic Company Report #WAES 00111233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644256-1Report Type:Periodic Company Report #WAES 00111234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

Date:12/26/00ISR Number: 3644257-3Report Type:Periodic Company Report #WAES 00042371
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Caltrate	C				
			Tylenol	C				
			Hydrocodone	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644258-5Report Type:Periodic Company Report #WAES 00092155
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Lipitor	C				
			Tylenol	C				

Date:12/26/00ISR Number: 3644259-7Report Type:Periodic Company Report #WAES 00042763
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Mouth Ulceration Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrogenic Preparations	C				

Date:12/26/00ISR Number: 3644260-3Report Type:Periodic Company Report #WAES 00092160
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644261-5Report Type:Periodic Company Report #WAES 00092189
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Premarin	C	
Prinivil	C	
Nadolol	C	

Date:12/26/00ISR Number: 3644262-7Report Type:Periodic Company Report #WAES 00042847
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan Sr	C				
			Evista	C				
			Lipitor	C				
			Synthroid	C				
			Lorazepam	C				

Date:12/26/00ISR Number: 3644263-9Report Type:Periodic Company Report #WAES 00092195
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644264-0Report Type:Periodic Company Report #WAES 00092198
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Vioxx	PS	Merck Research			

	Dyspnoea	Professional			Laboratories Div	
	Hypertonia				Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Periostat	C		
			Singulair	C		
			Vanceril	C		
			Zestril	C		

Date:12/26/00ISR Number: 3644265-2Report Type:Periodic Company Report #WAES 00050113
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blindness	Consumer	Vioxx	PS	Merck Research	
	Dizziness	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Ambien	C		
			Lipitor	C		
			Novolin L	C		
			Peridex	C		
			Furosemide	C		
			Nitroglycerin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644266-4Report Type:Periodic Company Report #WAES 00092205
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644267-6Report Type:Periodic Company Report #WAES 00092206
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644268-8Report Type:Periodic Company Report #WAES 00050572
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Confusional State Disorientation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vioxx	SS		ORAL	PRN;PO	
			Fosamax	C				
			Miacalcin	C				
			Pepcid	C				
			Synthroid	C				
			Warfarin	C				

Date:12/26/00ISR Number: 3644269-XReport Type:Periodic Company Report #WAES 00092207
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3644270-6Report Type:Periodic Company Report #WAES 00051030
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			[Therapied Unspecified]	C				
			Allergenic Extract	C				
			Estrogenic Preparations	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644271-8Report Type:Periodic Company Report #WAES 00092208
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644272-XReport Type:Periodic Company Report #WAES 00092209
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644273-1Report Type:Periodic Company Report #WAES 00051139
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dry Skin Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus		Plaquenil [Therapy Unspecified] Vitamins	C C C				

Date:12/26/00ISR Number: 3644274-3Report Type:Periodic Company Report #WAES 00051181
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema	Consumer	Vioxx	PS	Merck Research		
	Oedema Peripheral	Health			Laboratories Div		
	Respiratory Disorder	Professional			Merck Co Inc	ORAL	
25							
	Weight Increased						
MG/DAILY/PO							
			Dilor-G Tablets	C			
			Dyazide	C			
			Estrace	C			
			K-Dur	C			
			Plendil	C			

Date:12/26/00ISR Number: 3644275-5Report Type:Periodic Company Report #WAES 00051352
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
	Mental Impairment	Company			Merck Co Inc	ORAL	25	
		Representative						
MG/DAILY/PO								
			Ortho Tri-Cylcen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644276-7Report Type:Periodic Company Report #WAES 00051463
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Nausea Nocturia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644277-9Report Type:Periodic Company Report #WAES 00100285
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acupril	C				
			Cardura	C				
			Lasix	C				
			Norvasc	C				
			Tenormin	C				

Date:12/26/00ISR Number: 3644278-0Report Type:Periodic Company Report #WAES 00100286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644279-2Report Type:Periodic Company Report #WAES 00100289
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644280-9Report Type:Periodic Company Report #WAES 00100290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644281-0Report Type:Periodic Company Report #WAES 00100301
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644282-2Report Type:Periodic Company Report #WAES 00100328
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				

Date:12/26/00ISR Number: 3644283-4Report Type:Periodic Company Report #WAES 00100347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Premarin	C				

Date:12/26/00ISR Number: 3644284-6Report Type:Periodic Company Report #WAES 00100351
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				
			Tenormin	C				

Date:12/26/00ISR Number: 3644285-8Report Type:Periodic Company Report #WAES 00100352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644286-XReport Type:Periodic Company Report #WAES 00100354
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	3 WK
			Mevacor	C				
			Zestoretic	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644291-3Report Type:Periodic Company Report #WAES 00091168
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Premarin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3644292-5Report Type:Periodic Company Report #WAES 00091169
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3644293-7Report Type:Periodic Company Report #WAES 00091173
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Flexeril	C				
			Flovent	C				
			Premarin	C				

Prevacid C

Date:12/26/00ISR Number: 3644294-9Report Type:Periodic Company Report #WAES 00091176
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	3 WK
			Betapace	C				
			Vasotec	C				

Date:12/26/00ISR Number: 3644295-0Report Type:Periodic Company Report #WAES 00091181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Swelling		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Cardizem [Composition Unspecified]	C
Potassium (Unspecified)	C

Date:12/26/00ISR Number: 3644296-2Report Type:Periodic Company Report #WAES 00091182
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Provera	C				
			Vitamin A	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3644297-4Report Type:Periodic Company Report #WAES 00092381
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644298-6Report Type:Periodic Company Report #WAES 00092382
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative		Merck Co Inc	ORAL PO

Date:12/26/00ISR Number: 3644299-8Report Type:Periodic Company Report #WAES 00092384
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company Representative			Merck Co Inc	ORAL PO		

Date:12/26/00ISR Number: 3644300-1Report Type:Periodic Company Report #WAES 00092385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company Representative			Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644301-3Report Type:Periodic Company Report #WAES 00092387
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644302-5Report Type:Periodic Company Report #WAES 00092416
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644303-7Report Type:Periodic Company Report #WAES 00092427
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3644304-9Report Type:Periodic Company Report #WAES 00092439
Age:26 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644305-0Report Type:Periodic Company Report #WAES 00092450
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Neurontin	C				
			Premarin	C				

Date:12/26/00ISR Number: 3644306-2Report Type:Periodic Company Report #WAES 00092460
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644307-4Report Type:Periodic Company Report #WAES 00092462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 1 MON

Date:12/26/00ISR Number: 3644308-6Report Type:Periodic Company Report #WAES 00092470
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Glucosamine	C				

Date:12/26/00ISR Number: 3644309-8Report Type:Periodic Company Report #WAES 00092473
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oral Pain Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Periodontal Disease		Accolate	C				
	Pruritus		Cardizem	C				
	Toothache		Cold-Eeze (Homeopathic Medication)	C				
			Estrogens (Unspecified)	C				
			Lysine	C				

Date:12/26/00ISR Number: 3644310-4Report Type:Periodic Company Report #WAES 00092475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 8 MON

Date:12/26/00ISR Number: 3644311-6Report Type:Periodic Company Report #WAES 00092476
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644312-8Report Type:Periodic Company Report #WAES 00092479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644313-XReport Type:Periodic Company Report #WAES 00092480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:12/26/00ISR Number: 3644314-1Report Type:Periodic Company Report #WAES 00092481
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
			Zocor [Composition Unspecified]	C C			PO	

Date:12/26/00ISR Number: 3644315-3Report Type:Periodic Company Report #WAES 00092482
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3644316-5Report Type:Periodic Company Report #WAES 00092483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Date:12/26/00ISR Number: 3644317-7Report Type:Periodic Company Report #WAES 00092484
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Norvasc	C				
			Prilosec	C				
			[Therapy Unspecified]	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644318-9Report Type:Periodic Company Report #WAES 00092490
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain							
	Red Blood Cell							
	Sedimentation Rate Increased		Synthroid	C				

Date:12/26/00ISR Number: 3644319-0Report Type:Periodic Company Report #WAES 00092495
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Captopril	C				

Date:12/26/00ISR Number: 3644320-7Report Type:Periodic Company Report #WAES 00092499
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				
			Atenolol	C				
			Ferrous Sulfate	C				
			Insulin	C				

Date:12/26/00ISR Number: 3644321-9Report Type:Periodic Company Report #WAES 00092501
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Hydrodiuril	C				
			Permax	C				

Date:12/26/00ISR Number: 3644322-0Report Type:Periodic Company Report #WAES 00092502
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	5 DAY
			Mavik	C				
			Micardis	C				
			Atenolol	C				
			Estrogens (Unspecified)	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644323-2Report Type:Periodic Company Report #WAES 00092505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atarax	C				
			Neurontin	C				
			Prevachol	C				
			Prevacid	C				
			Synthroid	C				
			Xanax	C				
			Zyrtec	C				
			Nitroglycerin	C				

Date:12/26/00ISR Number: 3644324-4Report Type:Periodic Company Report #WAES 00092526
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3644325-6Report Type:Periodic Company Report #WAES 00092527
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3644326-8Report Type:Periodic Company Report #WAES 00092528
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644341-4Report Type:Periodic Company Report #WAES 00111182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3644342-6Report Type:Periodic Company Report #WAES 00111183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:12/26/00ISR Number: 3644343-8Report Type:Periodic Company Report #WAES 00111185
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Monopril	C				

Date:12/26/00ISR Number: 3644344-XReport Type:Periodic Company Report #WAES 00111191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Oropharyngeal Swelling	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Zocor	C				

Date:12/26/00ISR Number: 3644345-1Report Type:Periodic Company Report #WAES 00111197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Dyspepsia Fatigue Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3644346-3Report Type:Periodic Company Report #WAES 00111204
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Therapy Unspecified	C				
			Diuretic (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644347-5Report Type:Periodic Company Report #WAES 00111207
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
			Synthroid	C				
			Vitamin E	C				
			Vitamins Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644348-7Report Type:Periodic Company Report #WAES 00111215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3644349-9Report Type:Periodic Company Report #WAES 00111221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3644350-5Report Type:Periodic Company Report #WAES 00111222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	3 WK
			Excedrin Extra-Strength	C				
			Tylenol	C				
			Acetaminophen (+) Propoxyphene	C				
			Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:12/26/00ISR Number: 3644351-7Report Type:Periodic Company Report #WAES 00091758
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Lasix	C				

Date:12/26/00ISR Number: 3644352-9Report Type:Periodic Company Report #WAES 00091762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG DAILY	INJ
			Darvocet-N	C				
			Imdur	C				
			Ticlid	C				
			Amitriptyline	C				
			Verapamil Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644353-0Report Type:Periodic Company Report #WAES 00091775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644354-2Report Type:Periodic Company Report #WAES 00091778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644355-4Report Type:Periodic Company Report #WAES 00091804
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Hormone Level Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
			Synthroid 0.025 Mg Prilosec	SS C			PO	

Date:12/26/00ISR Number: 3644356-6Report Type:Periodic Company Report #WAES 00091847
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research			

					Laboratories Div Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3644357-8Report Type:Periodic Company Report #WAES 00091850
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus Rhinorrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG AM PO						
			Colestid	C		
			Hydrodiuril	C		
			Tegretol	C		
			Zocor	C		
			Aspirin	C		
			Atenolol	C		
			Calcium (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644360-8Report Type:Periodic Company Report #WAES 00091853
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
	Erythema		Allegra	C				
	Pharyngitis		Lipitor	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3644361-XReport Type:Periodic Company Report #WAES 00091854
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Hypertension Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Pruritus		Lanoxin	C				
			Micro K	C				
			Therapy Unspecified	C				
			Warfarin	C				

Date:12/26/00ISR Number: 3644362-1Report Type:Periodic Company Report #WAES 00091860
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Estrogens (Unspecified)	C				

Date:12/26/00ISR Number: 3644363-3Report Type:Periodic Company Report #WAES 00091871
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Calcium (Unspecified)	C				

Date:12/26/00ISR Number: 3644364-5Report Type:Periodic Company Report #WAES 00091872
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lipitor	C				
			Toprol Xl Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644365-7Report Type:Periodic Company Report #WAES 00091875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Prilosec	C				
			Diazepam	C				
			Dicyclomine Hydrochloride	C				

Date:12/26/00ISR Number: 3644366-9Report Type:Periodic Company Report #WAES 00091877
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Candidiasis	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Prevacid	C				
			Sonata	C				

Date:12/26/00ISR Number: 3644367-0Report Type:Periodic Company Report #WAES 00091881
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25MG/DAILY/OR	
							AL	
			Zestril	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3644368-2Report Type:Periodic Company Report #WAES 00091885
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Weight Decreased					
25MG/DAILY/PO						
			Asacol	C		
			Diazide	C		
			Thyroid	C		
			Vitamin B (Unspecified)	C		
			Vitamin E	C		

Date:12/26/00ISR Number: 3644369-4Report Type:Periodic Company Report #WAES 00091887
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Drug Ineffective					
UNK/PO						
			Zestoretic	C		
			Zestril	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644370-0Report Type:Periodic Company Report #WAES 00091893
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644371-2Report Type:Periodic Company Report #WAES 00091896
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644372-4Report Type:Periodic Company Report #WAES 00091897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644827-2Report Type:Periodic Company Report #WAES 00111534
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG/

DAILY/PO

Date:12/26/00ISR Number: 3644828-4Report Type:Periodic Company Report #WAES 00111543
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644829-6Report Type:Periodic Company Report #WAES 00111535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice Nausea	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644830-2Report Type:Periodic Company Report #WAES 00111555
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Ambien	C				
			Diovan Hct	C				
			Flovent	C				
			Hydromet	C				
			Maxair	C				
			Paxil	C				
			Prilosec	C				
			Rhinocort	C				
			Serevent	C				
			Singulair	C				
			Synthroid	C				
			Zocor	C				
			Allopurinol	C				
			Colchicine	C				

Date:12/26/00ISR Number: 3644831-4Report Type:Periodic Company Report #WAES 00111558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder Malaise Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Ultram	C				
			Wellbutrin	C				
			Estrogens (Unspecified)	C				

Date:12/26/00ISR Number: 3644832-6Report Type:Periodic Company Report #WAES 00111560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/PO	

Date:12/26/00ISR Number: 3644833-8Report Type:Periodic Company Report #WAES 00111561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Limb Discomfort Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644834-XReport Type:Periodic Company Report #WAES 00111563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Methotrexate	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3644835-1Report Type:Periodic Company Report #WAES 00111617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644836-3Report Type:Periodic Company Report #WAES 00111621
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644837-5Report Type:Periodic Company Report #WAES 00090811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3644838-7Report Type:Periodic Company Report #WAES 00090828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644839-9Report Type:Periodic Company Report #WAES 00090832
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Throat Tightness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644840-5Report Type:Periodic Company Report #WAES 00090833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644841-7Report Type:Periodic Company Report #WAES 00090852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clonic Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	6 WK
			Paxil	C				

Date:12/26/00ISR Number: 3644842-9Report Type:Periodic Company Report #WAES 00090859
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Nolvadex	C				
			Doxepin Hydrochloride	C				
			Methadone Hydrochloride	C				

Date:12/26/00ISR Number: 3644843-0Report Type:Periodic Company Report #WAES 00090865
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644844-2Report Type:Periodic Company Report #WAES 00090874
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardisan	C				
			Combivent	C				
			K-Dur	C				
			Lasix	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644845-4Report Type:Periodic Company Report #WAES 00090876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3644846-6Report Type:Periodic Company Report #WAES 00090877
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/DAILY/PO; 2) 50 MG/DAILY/PO	
			Aspirin	C				

Date:12/26/00ISR Number: 3644847-8Report Type:Periodic Company Report #WAES 00111764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bowel Sounds Abnormal Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
	Nausea		Flomax (Tamsulosin Hydrochloride)	C				

Date:12/26/00ISR Number: 3644848-XReport Type:Periodic Company Report #WAES 00111782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Excedrin Extra-Strength	C				

Date:12/26/00ISR Number: 3644849-1Report Type:Periodic Company Report #WAES 00111786
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644850-8Report Type:Periodic Company Report #WAES 00111790
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Climara (Composition
Unspecified) C

Date:12/26/00ISR Number: 3644851-XReport Type:Periodic Company Report #WAES 00111795
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Evista	C				
			Prinivil	C				

Date:12/26/00ISR Number: 3644852-1Report Type:Periodic Company Report #WAES 00222796
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Synthroid	C				
			Amitriptyline	C				

Date:12/26/00ISR Number: 3644853-3Report Type:Periodic Company Report #WAES 00111801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoarthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				
			Tofranil	C				

			Zovirax	C
			Calcium	C

Date:12/26/00ISR Number: 3644854-5Report Type:Periodic Company Report #WAES 00111804
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Health	Vioxx	PS	Merck Research	
	Diarrhoea	Professional			Laboratories Div	
	Feeling Abnormal				Merck Co Inc	ORAL
SEE IMAGE						
	Flatulence		Micronor	C		
	Nausea		Monopril	C		
			Nasacort Aq	C		
			Premarin	C		
			Prilosec	C		
			Serzone	C		
			Synthroid	C		
			Spironolactone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644855-7Report Type:Periodic Company Report #WAES 00111811
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Candidiasis Glossodynia Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Pulmonary Congestion		Acular	C				

Date:12/26/00ISR Number: 3644856-9Report Type:Periodic Company Report #WAES 00111813
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	15 MG/PO	
			Aygestin	C				
			Calmipan	C				
			Halcion	C				
			Neurontin	C				
			Premarin	C				
			Robaxin	C				
			Valium	C				

Date:12/26/00ISR Number: 3644857-0Report Type:Periodic Company Report #WAES 00110836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Muscle Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644858-2Report Type:Periodic Company Report #WAES 00110848
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Azmacort	C				
			Singulair	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3644859-4Report Type:Periodic Company Report #WAES 00110853
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aspartate Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644860-0Report Type:Periodic Company Report #WAES 00110872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aleve	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3644861-2Report Type:Periodic Company Report #WAES 00110893
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/P0
	Eye Pain							
	Eyelid Oedema							
	Fatigue							
	Weight Increased		Maxzide	C				
			Wellbutrin	C				

Date:12/26/00ISR Number: 3644862-4Report Type:Periodic Company Report #WAES00053008
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS				
	Asthenia	Health	Vioxx	C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
	Dyspnoea	Professional						
	Fatigue							
	Feeling Abnormal						PO	
	Nervousness		Mevacor	C				
	Pain		Ogen	C				
			Pepcid	C				
			Premarin	C				
			Prilosec	C				

			Ultram	C
			Vasotec	C
			Xanax	C
			Zoloft	C
			Citracal Caplets + D	C
			Maalox	C

Date:12/26/00ISR Number: 3644863-6Report Type:Periodic Company Report #WAES 00053051
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Vioxx	SS		ORAL	PRN PO	
			Vioxx	SS		ORAL	PRN PO	
			Vioxx	SS		ORAL	50MG DAILY PO	
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644864-8Report Type:Periodic Company Report #WAES 00053095
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Nausea	Professional			Merck Co Inc	ORAL	25	
	Oedema						MG/DAILY/PO	
			Norvasc	C				
			Premarin	C				
			Prevacid	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3644865-XReport Type:Periodic Company Report #WAES 00110895
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644866-1Report Type:Periodic Company Report #WAES 00053104
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective	Health			Laboratories Div			
	Face Oedema	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
	Paraesthesia		Lipitor	C				
	Swelling		Prilosec	C				
			Q-Tuss	C				
			Aspirin	C				
			Calcium	C				

Date:12/26/00ISR Number: 3644867-3Report Type:Periodic Company Report #WAES 00060020
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Myalgia	Health			Laboratories Div			
	Paraesthesia	Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lanoxin	C				
			Restoril	C				
			Allopurinol	C				

Date:12/26/00ISR Number: 3644868-5Report Type:Periodic Company Report #WAES 00110930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	SEE IMAGE /	
							PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644869-7Report Type:Periodic Company Report #WAES 00060029
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Flatulence	Health			Laboratories Div			
	Pruritus	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Allegra	C				
			Amaryl	C				
			Calan Sr	C				
			Daypro	C				
			Demadex	C				
			Glucophage	C				
			Ogen	C				
			Prilosec	C				
			Ziac	C				
			Sucralfate	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3644870-3Report Type:Periodic Company Report #WAES 00060206
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Diarrhoea	Professional			Laboratories Div			
	Drug Ineffective				Merck Co Inc	ORAL	25MG	DAILY/PO
			Celebrex	C				
			Ecotrin	C				
			Maalox	C				
			Prilosec	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3644871-5Report Type:Periodic Company Report #WAES 00110934
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Aspirin	C			

Date:12/26/00ISR Number: 3644872-7Report Type:Periodic Company Report #WAES 00060234
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 WK
			Darvocet-N	C				
			Elavil	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644873-9Report Type:Periodic Company Report #WAES 00110937
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Claritin	C				
			Synthroid	C				
			Estrogens (Unspecified)	C				

Date:12/26/00ISR Number: 3644874-0Report Type:Periodic Company Report #WAES 00060303
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Captopril	C				

Date:12/26/00ISR Number: 3644875-2Report Type:Periodic Company Report #WAES 00110938
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Insulin	C				
			Methocarbamol	C				

Date:12/26/00ISR Number: 3644876-4Report Type:Periodic Company Report #WAES 00060835
Age:16 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Daypro	C				

Date:12/26/00ISR Number: 3644877-6Report Type:Periodic Company Report #WAES 00111816
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			[Therapy Unspecified]	C				
			Ascorbic Acid	C				
			Iron (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644878-8Report Type:Periodic Company Report #WAES 00111818
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Epistaxis							
	Upper Respiratory Tract Infection							
			Claritin	C				
			Hydrodiuril	C				
			Lotensin	C				
			Paxil	C				
			Hormones (Unspecified)	C				

Date:12/26/00ISR Number: 3644879-XReport Type:Periodic Company Report #WAES 00111819
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatomegaly	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Astaril	C				
			Flonase	C				
			Premarin	C				
			Provera	C				
			[Therapy Unspecified]	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3644880-6Report Type:Periodic Company Report #WAES 00061310
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Hydrodiuril	C
Hytrin	C
Imdur	C
Prilosec	C
Proscar	C
Tenormin	C
Nonsteroidal Anti-Inflammatory	C

Date:12/26/00ISR Number: 3644881-8Report Type:Periodic Company Report #WAES 00061374
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Fluid Retention	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Coumadin	C
Toprol Xl Tablets	C
Lorazepam	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644882-XReport Type:Periodic Company Report #WAES 00111822
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3644883-1Report Type:Periodic Company Report #WAES 00061381
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Hyperglycaemia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Elavil	C				
			Prandin	C				
			Prevacid	C				
			Prinivil	C				
			Acetaminophen (+)					
			Hydrocodone Bi	C				
			Allopurinol	C				
			Furosemide	C				

Date:12/26/00ISR Number: 3644884-3Report Type:Periodic Company Report #WAES 00111842
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Fluid Retention Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Enbrel	C	
Plaquenil	C	
Premarin	C	
Trazodone	C	

Date:12/26/00ISR Number: 3644885-5Report Type:Periodic Company Report #WAES 00061400
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Drug Interaction	Professional			Merck Co Inc	ORAL	PO SEE IMAGE	
	Dyspepsia		Citrucel Orange					
	Oedema		Flavor	C				
	Weight Increased		Halcion	C				
			Prilosec	C				
			Tums	C				
			Chondroitin (+)					
			Glucosamine	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644886-7Report Type:Periodic Company Report #WAES 00061459
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Cardiac Failure	Health			Laboratories Div			
	Congestive	Professional			Merck Co Inc	ORAL	PO	
	Oedema Peripheral		Colace	C				
	Weight Increased		Isordil	C				
			Lasix	C				
			Synthroid	C				
			Vasotec	C				
			Digoxin	C				
			Folic Acid	C				
			Potassium Chloride	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644887-9Report Type:Periodic Company Report #WAES 00111843
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Prempro	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3644888-0Report Type:Periodic Company Report #WAES 00061461
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Discolouration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Procardia	C				

Date:12/26/00ISR Number: 3644889-2Report Type:Periodic Company Report #WAES 00112006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Celebrex	C				

Date:12/26/00ISR Number: 3644890-9Report Type:Periodic Company Report #WAES 00061472
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644891-0Report Type:Periodic Company Report #WAES 00061488
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Dysgraphia							
	Headache							
	Movement Disorder							
	Reading Disorder							

Date:12/26/00ISR Number: 3644892-2Report Type:Periodic Company Report #WAES 00112118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644893-4Report Type:Periodic Company Report #WAES 00061511
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Hyperhidrosis	Health Professional						
	Nausea							
			Cardizem Cd	C				
			Humulin N	C				
			Humulin R	C				
			L-Thyroxin	C				
			Lipitor	C				
			Premarin	C				
			Zestril	C				
			Diazepam	C				
			Furosemide	C				

			Glyburide	C
			Nortriptyline	C

Date:12/26/00ISR Number: 3644894-6Report Type:Periodic Company Report #WAES 00112212
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644895-8Report Type:Periodic Company Report #WAES 00061512
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Pyrexia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Celebrex	C				
			Claritin-D	C				
			Tagamet	C				
			Atenolol	C				

			Clonidine	C		

Date:12/26/00ISR Number: 3644896-XReport Type:Periodic Company Report #WAES 00112213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ibuprofen	C				

Date:12/26/00ISR Number: 3644897-1Report Type:Periodic Company Report #WAES 00100234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:12/26/00ISR Number: 3644898-3Report Type:Periodic Company Report #WAES 00100237
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Darvocet-N	C				
			Calcium	C				
			Insulin	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644899-5Report Type:Periodic Company Report #WAES 00100240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:12/26/00ISR Number: 3644900-9Report Type:Periodic Company Report #WAES 00061561
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644901-0Report Type:Periodic Company Report #WAES 00100241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3644902-2Report Type:Periodic Company Report #WAES 00061641
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							
	Weight Increased				Merck Co Inc	ORAL	12.5 MG DAILY	
						PO		
			Diazide	C				
			Premarin	C				
			Synthroid	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3644903-4Report Type:Periodic Company Report #WAES 00100242
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Flatulence							
	Weight Increased				Merck Co Inc	ORAL	25 MG/ PO	
			Nutrajoint	C				
			Valium	C				

Date:12/26/00ISR Number: 3644904-6Report Type:Periodic Company Report #WAES 00061642
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dyspepsia	Health						
	Dysphonia	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Retching							
						PO		

	Sedation		Skelaxin	C		

Date:12/26/00ISR Number: 3644905-8Report Type:Periodic Company Report #WAES 00061725
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
	Urticaria	Professional			Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Lopressore	C				
			Lozol	C				
			Premarin	C				
			Provera	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3644906-XReport Type:Periodic Company Report #WAES 00100243
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective				Laboratories Div			
	Movement Disorder				Merck Co Inc	ORAL	25 MG/ DAILY/	
	Muscular Weakness						PO	

			Premarin	C		

Date:12/26/00ISR Number: 3644907-1Report Type:Periodic Company Report #WAES 00061901
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Skin Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Bumex	C				
			Lomotil	C				
			Slow-K	C				
			Tylenol With Codeine #3	C				
			Zoroxin	C				

Date:12/26/00ISR Number: 3644908-3Report Type:Periodic Company Report #WAES 00100244
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertensive Crisis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/	PO
			Coumadin	C				
			Lipitor	C				
			Lopressor	C				
			Niaspan	C				
			Prinivil	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3644909-5Report Type:Periodic Company Report #WAES 00061934
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Premarin	C			
			Synthroid	C			
			Vitamins	C			

Date:12/26/00ISR Number: 3644910-1Report Type:Periodic Company Report #WAES 00062077
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Ambien	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644911-3Report Type:Periodic Company Report #WAES 00100248
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Parazone	C				
			Valium	C				
			Therapy Unspecified	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3644912-5Report Type:Periodic Company Report #WAES 00062139
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
	Asthenia	Health Professional						
	Depression							
	Drug Interaction						PO	
	Fatigue		Effexor	SS			75 MG DAILY	
	Insomnia		Altace	C				
	Mental Impairment		Synthroid	C				
			Insulin	C				

Date:12/26/00ISR Number: 3644913-7Report Type:Periodic Company Report #WAES 00062174
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 DAY
	Dry Mouth							
	Dry Throat							
	Dyspepsia		Aspirin	C				
	Pain		Vitamins	C				
	Pruritus							

Date:12/26/00ISR Number: 3644914-9Report Type:Periodic Company Report #WAES 00100250
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	

PO

Date:12/26/00ISR Number: 3644915-0Report Type:Periodic Company Report #WAES 00062232
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Back Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Bursitis Cellulitis Immune System Disorder		Serevent	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644916-2Report Type:Periodic Company Report #WAES 00100256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	2 WK

Date:12/26/00ISR Number: 3644917-4Report Type:Periodic Company Report #WAES 00100186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Thyroid Disorder Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/PO	
			Arava	SS				
			Paxil	C				
			Sonata	C				
			Valium	C				
			Trazodone	C				

Date:12/26/00ISR Number: 3644918-6Report Type:Periodic Company Report #WAES 00100188
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644919-8Report Type:Periodic Company Report #WAES 00062234
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

	Pruritus	Health			Laboratories Div	
	Urticaria	Professional			Merck Co Inc	ORAL
25 MG/UNK/PO						
			Chloridin	C		
			Hyzaar	C		
			...	C		

Date:12/26/00ISR Number: 3644920-4Report Type:Periodic Company Report #WAES 00100189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3644921-6Report Type:Periodic Company Report #WAES 00062349
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Myalgia	Health Professional				
UNK/UNK/PO						
			Fosamax	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644922-8Report Type:Periodic Company Report #WAES 00100194
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Pruritus	Professional			Laboratories Div			
	Urticaria				Merck Co Inc	ORAL	25MG/DAILY/PO	
			Coenzyme Q10	C				
			Lopressor	C				
			Lozol	C				
			Premarin	C				
			Provera	C				

Date:12/26/00ISR Number: 3644923-XReport Type:Periodic Company Report #WAES 00062716
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
	Swelling	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			..	C				
			Calcium Supplement	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644924-1Report Type:Periodic Company Report #WAES 00062944
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Feeling Abnormal				Laboratories Div			
	Gait Disturbance				Merck Co Inc	ORAL	12.5 MG/1X/PO	
	Headache		Advil	C				
	Joint Swelling		Aspirin	C				
	Oedema Peripheral							
	Swelling							

Tinnitus
Tongue Discolouration

Date:12/26/00ISR Number: 3644925-3Report Type:Periodic Company Report #WAES 00100202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644926-5Report Type:Periodic Company Report #WAES 00062949
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				
			Hytrin	C				
			Premarin	C				

			Hydrochlorothiazide			
			(+) Triamter	C		
			Verapamil	C		

Date:12/26/00ISR Number: 3644927-7Report Type:Periodic Company Report #WAES 00100209
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Premarin	C				
			Provera	C				
			Sporanox	C				

Date:12/26/00ISR Number: 3644928-9Report Type:Periodic Company Report #WAES 00062954
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Headache Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Deseril	C				
			Progesterone	C				

Date:12/26/00ISR Number: 3644929-0Report Type:Periodic Company Report #WAES 00100224
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

;

50MG/DAILY/PO

				Celebrex	C		

Date:12/26/00ISR Number: 3644930-7Report Type:Periodic Company Report #WAES 00063009
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Premarin	C				
			Synthroid	C				
			Zoloft	C				

Date:12/26/00ISR Number: 3644931-9Report Type:Periodic Company Report #WAES 00063084
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dry Mouth Hypertension Nasal Congestion	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

			Cozaar	C		
			Prempro	C		
			Prinivil	C		

Date:12/26/00ISR Number: 3644932-0Report Type:Periodic Company Report #WAES 00100228
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dysuria							
	Oliguria							
			Allerga	C				

Date:12/26/00ISR Number: 3644933-2Report Type:Periodic Company Report #WAES 00064289
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/BID/PO	
	Chest Pain							
	Cough							
	Dyspnoea							
	Faeces Discoloured							
	Fatigue							
	Flatulence							
	Pharyngitis							
	Sinusitis							

Date:12/26/00ISR Number: 3644934-4Report Type:Periodic Company Report #WAES 00100232
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrooesophageal Reflux Disease							
			Verapamil	C				

Date:12/26/00ISR Number: 3644935-6Report Type:Periodic Company Report #WAES 00064291
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Memory Impairment Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	2 WK

Date:12/26/00ISR Number: 3644936-8Report Type:Periodic Company Report #WAES 00100233
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Zofran	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644937-XReport Type:Periodic Company Report #WAES 00070464
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644938-1Report Type:Periodic Company Report #WAES 00070511
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Oral Discomfort	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	
							PO	
			Coumadin	C				
			Darvocet-N	C				
			Premarin	C				
			Toprol Xl	C				

Date:12/26/00ISR Number: 3644939-3Report Type:Periodic Company Report #WAES 00070553
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644940-XReport Type:Periodic Company Report #WAES 00070606
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacrimation Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644941-1Report Type:Periodic Company Report #WAES 00070634
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:12/26/00ISR Number: 3644942-3Report Type:Periodic Company Report #WAES 00070652
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oliguria		Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644943-5Report Type:Periodic Company Report #WAES 00070660
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerumen Impaction	Consumer	Vioxx	PS	Merck Research			
	Deafness	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5	MG/DAILY/ PO
			Hydrodiuril	C				
			Glyburide	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3644944-7Report Type:Periodic Company Report #WAES 00110944
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inappropriate	Health	Vioxx	PS	Merck Research			
	Antidiuretic Hormone	Professional			Laboratories Div			
	Secretion				Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644945-9Report Type:Periodic Company Report #WAES 00070679
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			
	Insomnia	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Aldomet	C				
			Celebrex	C				
			Claritin	C				
			Demadex	C				
			Micro K	C				
			Novadox	C				
			Os-Cal	C				

Date:12/26/00ISR Number: 3644946-0Report Type:Periodic Company Report #WAES 00110967
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644947-2Report Type:Periodic Company Report #WAES 00110968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644948-4Report Type:Periodic Company Report #WAES 00111016
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
	Headache							
	Palpitations							
			Diovan	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3644949-6Report Type:Periodic Company Report #WAES 00070694
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral	Health Professional						
			Therapy Unspecified	C				
			Hydroxychloroquine	C				

Date:12/26/00ISR Number: 3644950-2Report Type:Periodic Company Report #WAES 00111019
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache							

Date:12/26/00ISR Number: 3644951-4Report Type:Periodic Company Report #WAES 00111021
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dizziness							

	Fatigue				Merck Co Inc	ORAL
25						
	Headache					
MG/DAILY/PO						
	Nausea		Alesse	C		
	Vomiting		Skelaxin	C		

Date:12/26/00ISR Number: 3644952-6Report Type:Periodic Company Report #WAES 00070728
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/						
PO						
			Enbol	C		
			Therapy Unspecified	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3644953-8Report Type:Periodic Company Report #WAES 00111022
Age: Gender:Female I/FU:I

Outcome	PT
	Dermatitis
	Dyspnoea

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Injury Pharyngeal Oedema Swelling							
	Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644954-XReport Type:Periodic Company Report #WAES 00111023
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644955-1Report Type:Periodic Company Report #WAES 00111027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	

Date:12/26/00ISR Number: 3644956-3Report Type:Periodic Company Report #WAES 00070736
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Constipation Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
			Proamatine	C				

Date:12/26/00ISR Number: 3644957-5Report Type:Periodic Company Report #WAES 00111031
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/ PO						
			Darvon	C		
			Effexor	C		

Date:12/26/00ISR Number: 3644958-7Report Type:Periodic Company Report #WAES 00070764
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Fioricet Tablets	C		
			Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644959-9Report Type:Periodic Company Report #WAES 00070823
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Eye Irritation Gastric Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644961-7Report Type:Periodic Company Report #WAES 00070876
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hyzaar	C				
			Tylenol	C				

Date:12/26/00ISR Number: 3644962-9Report Type:Periodic Company Report #WAES 00111256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON

Date:12/26/00ISR Number: 3644963-0Report Type:Periodic Company Report #WAES 00111270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			

	Headache				Laboratories Div	
	Pain				Merck Co Inc	ORAL
PO						
			Tylenol	C		

Date:12/26/00ISR Number: 3644964-2Report Type:Periodic Company Report #WAES 00070929
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Faecal Incontinence	Health			Laboratories Div	
	Oedema Peripheral	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Lasix	C		
			Potachlor 10%	C		
			Premarin	C		
			Tiazac	C		
			Ultram	C		
			Zocor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644965-4Report Type:Periodic Company Report #WAES 00111271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:12/26/00ISR Number: 3644966-6Report Type:Periodic Company Report #WAES 00111272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644967-8Report Type:Periodic Company Report #WAES 00111273
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Musculoskeletal Pain Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			..	C				

Date:12/26/00ISR Number: 3644968-XReport Type:Periodic Company Report #WAES 00070962
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral Petechiae	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/	DAILY/

PO

Fosamax	C	
Norvasc	C	

Date:12/26/00ISR Number: 3644969-1Report Type:Periodic Company Report #WAES 00111274
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	11 DAY

Date:12/26/00ISR Number: 3644970-8Report Type:Periodic Company Report #WAES 00111280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644971-XReport Type:Periodic Company Report #WAES 00071038
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bactrim	C				
			Ranitidine	C				

Date:12/26/00ISR Number: 3644972-1Report Type:Periodic Company Report #WAES 00111281
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644973-3Report Type:Periodic Company Report #WAES 00111321
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Spasms Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogens (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3644974-5Report Type:Periodic Company Report #WAES 00071058
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/QID/PO	
	Nasopharyngeal Disorder							
	Pyrexia							
	Vaginal Haemorrhage		Aygestin	C				
			Lupron	C				

Date:12/26/00ISR Number: 3644975-7Report Type:Periodic Company Report #WAES 00071107
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Flatulence							
	Gastric Disorder							
			Celebrex	C				
			Elavil	C				
			Ultram	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644976-9Report Type:Periodic Company Report #WAES 00071117
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3644977-0Report Type:Periodic Company Report #WAES 00071402
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644978-2Report Type:Periodic Company Report #WAES 00071496
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vitreous Opacities	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Estraderm	C				
			Xanax	C				
			Zantac	C				

Date:12/26/00ISR Number: 3644979-4Report Type:Periodic Company Report #WAES 00071498
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644980-0Report Type:Periodic Company Report #WAES 00071508
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Headache							
	Libido Decreased							
	Malaise							
			Ultram	C				

Date:12/26/00ISR Number: 3644981-2Report Type:Periodic Company Report #WAES 00071519
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:12/26/00ISR Number: 3644982-4Report Type:Periodic Company Report #WAES 00071522
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lotrel	C				

Date:12/26/00ISR Number: 3644983-6Report Type:Periodic Company Report #WAES 00071539
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Advil	C				
			Axid	C				
			Calcijex	C				
			Darvocent-N	C				
			Epogen	C				
			Colchicine	C				
			Metoprolol	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3644984-8Report Type:Periodic Company Report #WAES 00071540
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Eyelid Oedema Face Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

Rhinorrhoea
MG/DAILY/PO

Fosamax	C	
Aspirin	C	

Date:12/26/00ISR Number: 3644985-XReport Type:Periodic Company Report #WAES 00071644
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Flushing	Professional			Merck Co Inc	ORAL	PO	
	Hallucination		Indocin					
	Night Sweats		(Indomethacin)	C				
			Synthroid	C				
			Tagamet	C				
			Ultram	C				

Date:12/26/00ISR Number: 3644986-1Report Type:Periodic Company Report #WAES 00071663
Age:65 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Chest Pain

	Constipation Dysuria						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Asendin	C				
			Cardizem	C				
			Lopressor	C				
			Valium	C				

Date:12/26/00ISR Number: 3644987-3Report Type:Periodic Company Report #WAES 00032099
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Premarin	C				
			Prilosec	C				
			Synthorid	C				
			Nonsteroidal Anti-Inflammatory	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644988-5Report Type:Periodic Company Report #WAES 00040946
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis Exfoliative Erythema Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Pain
Pruritus

Date:12/26/00ISR Number: 3644989-7Report Type:Periodic Company Report #WAES 00040998
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644990-3Report Type:Periodic Company Report #WAES 00041318
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3644991-5Report Type:Periodic Company Report #WAES 00041395
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Eye Irritation	Health			Laboratories Div			
	Fluid Retention	Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
			Claritin	C				
			Dolomite	C				
			Flonase	C				
			Nasalcrom	C				
			Proventil	C				
			Singulair	C				
			Theo-Dur	C				
			Bone Marrow Extract (As Drug)	C				
			Collagen	C				
			Glucosamine	C				
			Herbal Remedies	C				
			Prednisone	C				
			Pyridoxine	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644992-7Report Type:Periodic Company Report #WAES 00041503
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3644993-9Report Type:Periodic Company Report #WAES 00041833
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			

		Professional Company			Laboratories Div Merck Co Inc	ORAL PO
		Representative	Celebrex	SS		ORAL 100 MG/BID/PO

Date:12/26/00ISR Number: 3644994-0Report Type:Periodic Company Report #WAES 00042050
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Muscle Rigidity							
	Musculoskeletal Pain							
	Oedema Peripheral							
	Tachycardia							

Date:12/26/00ISR Number: 3644995-2Report Type:Periodic Company Report #WAES 00042203
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	
	Oedema Peripheral							

MG/DAILY/PO

	Aldomet (Methyldopa)	C
	Antivert	C
	Betapace	C
	Coumadin	C
	Floxacin	C
	Lanoxin	C
	Maxzide	C
	Proxine	C
	Synthroid	C

Date:12/26/00ISR Number: 3644996-4Report Type:Periodic Company Report #WAES 00042287
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Pollakiuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3644997-6Report Type:Periodic Company Report #WAES 00090881
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO

	Prevacid	C
	Tums	C
	Vasotec	C

Date:12/26/00ISR Number: 3644998-8Report Type:Periodic Company Report #WAES 00090883
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mylanta & Ds	C				
			Prempro	C				
			Valium	C				
			Zantac	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3644999-XReport Type:Periodic Company Report #WAES 00090884
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Ceftin	C				
			Ziac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645000-4Report Type:Periodic Company Report #WAES 00090888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645001-6Report Type:Periodic Company Report #WAES 00090890
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	3 DAY
			Premarin	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3645002-8Report Type:Periodic Company Report #WAES 00090893
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ocupress	C				

Date:12/26/00ISR Number: 3645003-XReport Type:Periodic Company Report #WAES 00090895
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Ecotrin	C		
			Eldepryl	C		
			Permax	C		
			Sinemet	C		
			Vicodin Tablets	C		
			Zoloft	C		
			...	C		ORAL
25						
MG/DAILY/PO						

Date:12/26/00ISR Number: 3645004-1Report Type:Periodic Company Report #WAES 00090899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
	Urinary Tract Infection				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Sinemet	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645005-3Report Type:Periodic Company Report #WAES 00090900
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							
			Flovent	C				
			Prempro	C				
			Zoloft	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3645006-5Report Type:Periodic Company Report #WAES 00090901
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645007-7Report Type:Periodic Company Report #WAES 00111171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645008-9Report Type:Periodic Company Report #WAES 00081660
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chills	Consumer	Vioxx	PS	Merck Research	
	Hyperhidrosis	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL

25 MG/BID/PO

Paxil	C		
Premarin	C		
Ultram	C		

Date:12/26/00ISR Number: 3645009-0Report Type:Periodic Company Report #WAES 00111172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Date:12/26/00ISR Number: 3645010-7Report Type:Periodic Company Report #WAES 00111173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO 60 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645011-9Report Type:Periodic Company Report #WAES 00081678
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Leukopenia Platelet Count Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:12/26/00ISR Number: 3645013-2Report Type:Periodic Company Report #WAES 00111174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:12/26/00ISR Number: 3645014-4Report Type:Periodic Company Report #WAES 00111175
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prednisone	C				

Date:12/26/00ISR Number: 3645015-6Report Type:Periodic Company Report #WAES 00111176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 5 MON

Date:12/26/00ISR Number: 3645016-8Report Type:Periodic Company Report #WAES 00111177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645017-XReport Type:Periodic Company Report #WAES 00111180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Celebrex	C				
			Serevent	C				
			Theo-Dur	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645018-1Report Type:Periodic Company Report #WAES 00111181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chloasma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan Hct	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3645019-3Report Type:Periodic Company Report #WAES 00090287
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /BID	/ PO
			Ativan	C				

Date:12/26/00ISR Number: 3645020-XReport Type:Periodic Company Report #WAES 00081741
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Iberet-Folic-500	C				
			L-Thyroxin	C				
			Captopril	C				
			Furosemide	C				
			Nitroglycerin	C				

Date:12/26/00ISR Number: 3645021-1Report Type:Periodic Company Report #WAES 00090289
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	1 WK
	Headache							
	Hypoaesthesia							
	Pain		Neurontin	C				
			Meprednisone	C				

Date:12/26/00ISR Number: 3645022-3Report Type:Periodic Company Report #WAES 00090295
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645023-5Report Type:Periodic Company Report #WAES 00090312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3645024-7Report Type:Periodic Company Report #WAES 00081760
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Glossodynia Mouth Ulceration Periodontal Disease	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Prilosec	C				
			Iron (Unspecified)	C				

Date:12/26/00ISR Number: 3645025-9Report Type:Periodic Company Report #WAES 00090341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645026-0Report Type:Periodic Company Report #WAES 00090349
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Vioxx	PS	Merck Research			

	Panic Disorder	Professional			Laboratories Div	
					Merck Co Inc	ORAL

25

MG/DAILY/PO

	Arava	C
	Folic Acid	C
	Methotrexate	C
	Naproxen	C
	Prednisone	C

Date:12/26/00ISR Number: 3645027-2Report Type:Periodic Company Report #WAES 00081762
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research	
	Oedema	Health			Laboratories Div	
	Weight Increased	Professional			Merck Co Inc	ORAL

25

MG/DAILY/PO

	Ecotrin	C
	Imdur	C
	Lasix	C
	Levoxyl	C
	Lipitor	C
	Xanax	C
	Insulin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645028-4Report Type:Periodic Company Report #WAES 00090350
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiccups	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645029-6Report Type:Periodic Company Report #WAES 00090355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Elavil	C				
			Methotrexate	C				

Date:12/26/00ISR Number: 3645030-2Report Type:Periodic Company Report #WAES 00081764
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:12/26/00ISR Number: 3645031-4Report Type:Periodic Company Report #WAES 00090358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3645032-6Report Type:Periodic Company Report #WAES 00090359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645033-8Report Type:Periodic Company Report #WAES 00081771
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Fatigue							
	Pain		Xanax	C				
	Pyrexia		Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645034-XReport Type:Periodic Company Report #WAES 00081775
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Lorazepam	C				

Date:12/26/00ISR Number: 3645035-1Report Type:Periodic Company Report #WAES 00090270
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645036-3Report Type:Periodic Company Report #WAES 00081799
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Palpitations	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Rythmol	C				

Date:12/26/00ISR Number: 3645037-5Report Type:Periodic Company Report #WAES 00090272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645038-7Report Type:Periodic Company Report #WAES 00090273
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
	Diarrhoea							
	Dyspepsia							
	Sedation		Celebrex	C				
	Weight Increased		Dilantin	C				
			Phenobarbital	C				

Date:12/26/00ISR Number: 3645039-9Report Type:Periodic Company Report #WAES 00081802
Age:73 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Blood Pressure Increased

	Diarrhoea Nausea						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depakote	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3645040-5Report Type:Periodic Company Report #WAES 00090274
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dysphonia Fatigue Hyperhidrosis Malaise Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				

Date:12/26/00ISR Number: 3645041-7Report Type:Periodic Company Report #WAES 00090277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645042-9Report Type:Periodic Company Report #WAES 00090278
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Alopecia							
	Blood Pressure Increased							
			Tab Vioxx 50 Mg	SS		ORAL	PO	

Date:12/26/00ISR Number: 3645043-0Report Type:Periodic Company Report #WAES 00090279
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
	Swelling							
			Procardia	C				

Date:12/26/00ISR Number: 3645044-2Report Type:Periodic Company Report #WAES 00090282
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645045-4Report Type:Periodic Company Report #WAES 00090285
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dysphonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Tiazac	C				

Date:12/26/00ISR Number: 3645046-6Report Type:Periodic Company Report #WAES 00090286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645047-8Report Type:Periodic Company Report #WAES 00110751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645048-XReport Type:Periodic Company Report #WAES 00110756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Rectal Haemorrhage					

PO 5 DAY

Date:12/26/00ISR Number: 3645049-1Report Type:Periodic Company Report #WAES 00110758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	

Date:12/26/00ISR Number: 3645050-8Report Type:Periodic Company Report #WAES 00110768
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645051-XReport Type:Periodic Company Report #WAES 00110773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645052-1Report Type:Periodic Company Report #WAES 00110774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Dizziness Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tongue Disorder		Tab Vioxx	SS		ORAL	PO	

Date:12/26/00ISR Number: 3645053-3Report Type:Periodic Company Report #WAES 00110780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645054-5Report Type:Periodic Company Report #WAES 00110783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
50						
		Representative				
MG/DAILY/PO						

Date:12/26/00ISR Number: 3645055-7Report Type:Periodic Company Report #WAES 00110791
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Joint Stiffness	Consumer	Vioxx	PS	Merck Research	
	Oedema				Laboratories Div	
					Merck Co Inc	ORAL
25/MG/DAILY/P						
O						
			Acetiaminophen (+)			
			Codeine	C		

Date:12/26/00ISR Number: 3645056-9Report Type:Periodic Company Report #WAES 00110796
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Covera-Hs	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645057-0Report Type:Periodic Company Report #WAES 00064330
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/HS/PO	
	Nausea	Health Professional						
	Pigmentation Disorder							
			Calan	C				
			Lopressor	C				
			Vicodin Tablets	C				

Date:12/26/00ISR Number: 3645058-2Report Type:Periodic Company Report #WAES 00090019
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				

Date:12/26/00ISR Number: 3645059-4Report Type:Periodic Company Report #WAES 00090021
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645060-0Report Type:Periodic Company Report #WAES 00090025
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Drug Interaction					
	Fatigue				Merck Co Inc	ORAL

25

MG/DAILY/PO

Glucophage	C	
Mavik	C	
Ortho-Est	C	
Prandin	C	
Prilosec	C	
Atenolol (+) Chlorthalidone	C	

Date:12/26/00ISR Number: 3645061-2Report Type:Periodic Company Report #WAES 00064331
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Bumex	C	
Diovan	C	
Hydrodiuril	C	
Premarin	C	
Ziac	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645062-4Report Type:Periodic Company Report #WAES 00090027
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Dyazide	C				
			Normodyne	C				

Date:12/26/00ISR Number: 3645063-6Report Type:Periodic Company Report #WAES 00090028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645064-8Report Type:Periodic Company Report #WAES 00090034
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Diarrhoea	Health Professional						
	Flatulence							
	Haemorrhoids							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Caltrate 600 Plus Vitamin D	C				
			Celebrex	C				
			Centrum Silver	C				
			Coumadin	C				
			Norvasc	C				

			Prilosec	C		
			Prozac	C		
			Synthroid	C		
			Ascorbic Acid	C		
			Aspirin	C		
			Glyburide	C		
			Nitrofurantoin	C		

Date:12/26/00ISR Number: 3645065-XReport Type:Periodic Company Report #WAES 00090035
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Levaquin	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645066-1Report Type:Periodic Company Report #WAES 00090036
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:12/26/00ISR Number: 3645067-3Report Type:Periodic Company Report #WAES 00090037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645068-5Report Type:Periodic Company Report #WAES 00090038
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645069-7Report Type:Periodic Company Report #WAES 00064423
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

	Daypro	C
	Demadex	C
	Diabeta	C
	Elavil	C
	Glucophage	C
	Lipitor	C
	Lopid	C
	Prandin	C
	Premarin	C
	Prinivil	C
	Synthroid	C
	Toprol Xl Tablets	C
	Aspirin	C

Date:12/26/00ISR Number: 3645070-3Report Type:Periodic Company Report #WAES 00080853
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective	Health			Laboratories Div	
	Influenza Like Illness	Professional			Merck Co Inc	ORAL
25						
	Oral Soft Tissue Disorder					
MG/DAILY/PO						
	Tongue Disorder		Celebrex	C		
			Darvocet-N	C		

			Relafen	C
			Soma	C
			Ibuprofen	C

Date:12/26/00ISR Number: 3645071-5Report Type:Periodic Company Report #WAES 00064438
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3645072-7Report Type:Periodic Company Report #WAES 00064487
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645073-9Report Type:Periodic Company Report #WAES 00064631
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra-D	C				
			Ambien	C				
			Biaxin	C				
			Claritin	C				
			Vancenase	C				

			Guaifenesin	C		

Date:12/26/00ISR Number: 3645074-0Report Type:Periodic Company Report #WAES 00064641
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Health	Vioxx	PS	Merck Research	
	Dermatitis	Professional			Laboratories Div	
	Dyspepsia				Merck Co Inc	ORAL
PO						
			Azulfidine	C		
			Singulair	C		
			Corticosteroids	C		
			Estrogenic Preparations	C		

Date:12/26/00ISR Number: 3645075-2Report Type:Periodic Company Report #WAES 00064759
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645076-4Report Type:Periodic Company Report #WAES 00070027
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645077-6Report Type:Periodic Company Report #WAES 00080869
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Erythema Fatigue Hyperhidrosis Mouth Ulceration Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Erythromycin	SS				

Date:12/26/00ISR Number: 3645078-8Report Type:Periodic Company Report #WAES 00070057
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Synthroid	C				
			Folic Acid	C				

Date:12/26/00ISR Number: 3645079-XReport Type:Periodic Company Report #WAES 00060840
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research			
	Bronchospasm	Health			Laboratories Div			
	Respiratory Disorder	Professional			Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645080-6Report Type:Periodic Company Report #WAES 00090246
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research			
	Asthenia				Laboratories Div			
	Blood Pressure Increased				Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Tachycardia		Arthro-7	C				
			Cozaar	C				
			Calcium Supplement	C				
			Tamoxifen	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645081-8Report Type:Periodic Company Report #WAES 00060904
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			
	Abdominal Pain	Health			Laboratories Div			
	Chest Pain	Professional			Merck Co Inc	ORAL	25	
	Diarrhoea						MG/DAILY/PO	
	Dyspepsia		Anaprox	C				
			Cenestin	C				
			Flonase	C				
			Flovent	C				
			Monopril	C				
			Patanol	C				
			Prilosec	C				
			Proventil	C				
			Prozac	C				
			Serevent	C				
			Zyrtec	C				

Date:12/26/00ISR Number: 3645082-XReport Type:Periodic Company Report #WAES 00090251
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Dermatitis Exfoliative	Health			Laboratories Div			
	Lip Dry	Professional			Merck Co Inc	ORAL	25	
	Paraesthesia						MG/DAILY/PO	
	Pruritus							

Date:12/26/00ISR Number: 3645083-1Report Type:Periodic Company Report #WAES 00090255
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			

Professional Merck Co Inc ORAL
25

MG/DAILY/PO

Date:12/26/00ISR Number: 3645084-3Report Type:Periodic Company Report #WAES 00060914
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Change Of Bowel Habit							
	Fatigue							
	Nausea							
	Respiratory Disorder		Celebrex	C				
	Vomiting		Cipro	C				
			Lipitor	C				
			Miacalcin	C				
			Prempro	C				
			Prilosec	C				
			Zoloft	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645085-5Report Type:Periodic Company Report #WAES 00090256
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tenormin	C				

Date:12/26/00ISR Number: 3645087-9Report Type:Periodic Company Report #WAES 00090257
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Rhinocort	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3645088-0Report Type:Periodic Company Report #WAES 00090261
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Meridia	C				

Date:12/26/00ISR Number: 3645089-2Report Type:Periodic Company Report #WAES 00090262
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY
			Neurontin	C				
			Hydrocodone	C				
			Hyoscyamine	C				
			Promethazine	C				
			Temazepam	C				

Date:12/26/00ISR Number: 3645090-9Report Type:Periodic Company Report #WAES 00060976
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645091-0Report Type:Periodic Company Report #WAES 00090263
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645092-2Report Type:Periodic Company Report #WAES 00090265
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Lymphadenopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645093-4Report Type:Periodic Company Report #WAES 00061036
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645094-6Report Type:Periodic Company Report #WAES 00090266
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Glaucoma	Consumer	Vioxx	PS	Merck Research	
	Headache				Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Zyrtec	C		

Date:12/26/00ISR Number: 3645095-8Report Type:Periodic Company Report #WAES 00061120
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research	
	Confusional State	Health			Laboratories Div	
	Mental Disorder	Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Cardura	C		
			Coumadin	C		
			Cozaar	C		
			Lanoxin	C		
			Norvasc	C		
			Toprol Xl Tablets	C		

Date:12/26/00ISR Number: 3645096-XReport Type:Periodic Company Report #WAES 00061202
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Diarrhoea	Consumer
	Palpitations	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645097-1Report Type:Periodic Company Report #WAES 00090225
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Dyspepsia							
	Eye Pain							
	Haemorrhage		Gaviscon Antacid	C				
	Lymphadenopathy		Premarin	C				
	Mouth Ulceration							
	Pain							

Date:12/26/00ISR Number: 3645098-3Report Type:Periodic Company Report #WAES 00061212
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Hypertrophy Breast	Health						
	Weight Increased	Professional						
			Prempro	C				
			Prilosec	C				
			Ultram	C				
			Zyrtec	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3645099-5Report Type:Periodic Company Report #WAES 00090226
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645100-9Report Type:Periodic Company Report #WAES 00061299
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645101-0Report Type:Periodic Company Report #WAES 00090227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645102-2Report Type:Periodic Company Report #WAES 00061304
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Dyazide	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3645103-4Report Type:Periodic Company Report #WAES 00090229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder Ear Disorder Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645104-6Report Type:Periodic Company Report #WAES 00090232
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dinacrin	C				
			Epogen For Injection	C				
			Prednisone	C				
			Pronethalol	C				

Date:12/26/00ISR Number: 3645105-8Report Type:Periodic Company Report #WAES 00071941
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Centrum Silver	C				
			Detrol	C				
			Diovan Hct	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645106-XReport Type:Periodic Company Report #WAES 00090236
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645107-1Report Type:Periodic Company Report #WAES 00071954
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Aspartate Aminotransferase Increased		Hytrin	C				
	Drug Effect Decreased		Lasix	C				
			Tylenol	C				
			Insulin	C				
			Potassium Supplement	C				
			Pyridoxine	C				
			Thiamine	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645108-3Report Type:Periodic Company Report #WAES 00090237
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydrodiuril	C				

			Premarin	C		
			Atenolol	C		

Date:12/26/00ISR Number: 3645109-5Report Type:Periodic Company Report #WAES 00090238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Dizziness Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Furosemide	C				
			Warfarin	C				

Date:12/26/00ISR Number: 3645110-1Report Type:Periodic Company Report #WAES 00071963
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lanoxin	C				

			Neurontin	C
			Captopril	C
			Vitamins (Unspecified)	C

Date:12/26/00ISR Number: 3645111-3Report Type:Periodic Company Report #WAES 00090241
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lescol	C				
			Monopril	C				

Date:12/26/00ISR Number: 3645112-5Report Type:Periodic Company Report #WAES 00071994
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645113-7Report Type:Periodic Company Report #WAES 00090244
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 16 DAY

Date:12/26/00ISR Number: 3645114-9Report Type:Periodic Company Report #WAES 00072028
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Estrogens	C				

Date:12/26/00ISR Number: 3645115-0Report Type:Periodic Company Report #WAES 00072082
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Dry Mouth Lip Dry	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Melatonin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645116-2Report Type:Periodic Company Report #WAES 00090122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645117-4Report Type:Periodic Company Report #WAES 00090137
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Aspartate Aminotransferase	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Increased Creatinine Renal Clearance Normal		Celebrex	C				
			Hytrin	C				
			Aspirin	C				
	Haematuria		Cimetidine	C				
	Insomnia		Vitamins (Unspecified)	C				
	Oedema Genital							
	Pain							
	Penis Disorder							
	Proteinuria							
	Testicular Disorder							

Date:12/26/00ISR Number: 3645118-6Report Type:Periodic Company Report #WAES 00090149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645119-8Report Type:Periodic Company Report #WAES 00072201
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/PO	
			Arimidex	C				
			Claritin	C				
			Cozaar	C				
			Lozol	C				
			Vicodin Es Tablets	C				

Date:12/26/00ISR Number: 3645120-4Report Type:Periodic Company Report #WAES 00090190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research			
	Sensation Of Heaviness				Laboratories Div			
					Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645121-6Report Type:Periodic Company Report #WAES 00090192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645122-8Report Type:Periodic Company Report #WAES 00090211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645123-XReport Type:Periodic Company Report #WAES 00072219
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645124-1Report Type:Periodic Company Report #WAES 00090216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Proteinuria
MG/DAILY/PO

Date:12/26/00ISR Number: 3645125-3Report Type:Periodic Company Report #WAES 00090219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Glossodynia Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645126-5Report Type:Periodic Company Report #WAES 00072222
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Indurin	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645127-7Report Type:Periodic Company Report #WAES 00090220
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research			
	Flushing	Health			Laboratories Div			
	Headache	Professional			Merck Co Inc	ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
	Pain		Estrace	C				

Date:12/26/00ISR Number: 3645128-9Report Type:Periodic Company Report #WAES 00072228
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
	Vision Blurred	Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Timoptic	C				
			Calcium (Unspecified)	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3645129-0Report Type:Periodic Company Report #WAES 00090224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	

Date:12/26/00ISR Number: 3645130-7Report Type:Periodic Company Report #WAES 00082973
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	

Date:12/26/00ISR Number: 3645131-9Report Type:Periodic Company Report #WAES 00071669
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Pericardial Effusion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645132-0Report Type:Periodic Company Report #WAES 00082982
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Vioxx	PS	Merck Research			
	Oedema	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:12/26/00ISR Number: 3645133-2Report Type:Periodic Company Report #WAES 00082986
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25	MG/DAILY/PO
			Azulfidine	C				
			Premarin	C				
			Prilosec	C				
			Prozac	C				
			Methotrexate	C				

Date:12/26/00ISR Number: 3645134-4Report Type:Periodic Company Report #WAES 00082990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc			

Date:12/26/00ISR Number: 3645135-6Report Type:Periodic Company Report #WAES 00083001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645136-8Report Type:Periodic Company Report #WAES 00071787
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Dizziness Feeling Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO SEE IMAGE	
			Prilosec	C				

Date:12/26/00ISR Number: 3645137-XReport Type:Periodic Company Report #WAES 00083002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645138-1Report Type:Periodic Company Report #WAES 00083003
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Irritable Bowel Syndrome	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:12/26/00ISR Number: 3645139-3Report Type:Periodic Company Report #WAES 00083021
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Ativan	C				
			Fosamax	C				
			Lac-Hydrin 12%	C				
			Lipitor	C				
			Nolvadex	C				
			Norvasc	C				
			Percocet	C				
			Prilosec	C				
			Westcort-Cream	C				
			Amitriptyline	C				
			Clonidine	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:12/26/00ISR Number: 3645140-XReport Type:Periodic Company Report #WAES 00083032
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO

Hyzaar	C	
Monopril	C	
Norvasc	C	
Zocor	C	
Aspirin	C	
Codeine	C	
Insulin	C	
Terazosin	C	

Date:12/26/00ISR Number: 3645141-1Report Type:Periodic Company Report #WAES 00080881
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Augmentin	C	
Cafergot	C	
Fosamax	C	

			Microzide	C
			Premarin	C
			Potassium	C
			Vitamins	C

Date:12/26/00ISR Number: 3645142-3Report Type:Periodic Company Report #WAES 00071794
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			
	Menstrual Disorder	Health			Laboratories Div			
	Vaginal Haemorrhage	Professional			Merck Co Inc	ORAL	50 MG BID PO	
			Neurontin	C				
			Aspirin	C				
			Calcium Supplement	C				
			Chondroitin (+) Glucosamine	C				

Date:12/26/00ISR Number: 3645143-5Report Type:Periodic Company Report #WAES 00083037
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Vioxx	PS	Merck Research			
	Disorientation	Professional			Laboratories Div			
					Merck Co Inc	ORAL	37.5 MG/DAILYPO	
			Vioxx	SS		ORAL	50 MG DAILY/PO	
			Synthroid	C				
			Zantac	C				

Date:12/26/00ISR Number: 3645144-7Report Type:Periodic Company Report #WAES 00080885
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Headache	Professional			Merck Co Inc	ORAL	25	
	Vaginal Haemorrhage						MG/DAILY/PO	

Date:12/26/00ISR Number: 3645145-9Report Type:Periodic Company Report #WAES 00080904
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research			
	Pharyngeal Oedema				Laboratories Div			
	Pruritus				Merck Co Inc	ORAL	25	
	Tongue Oedema						MG/DAILY/PO	
			Premarin	C				

Date:12/26/00ISR Number: 3645146-0Report Type:Periodic Company Report #WAES 00080985
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Tenormin C
Isosorbide C

Date:12/26/00ISR Number: 3645147-2Report Type:Periodic Company Report #WAES 00082946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645148-4Report Type:Periodic Company Report #WAES 00071807
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Hyperhidrosis Malaise Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Aldactazide	C				
			Potassium Supplement	C				

Date:12/26/00ISR Number: 3645149-6Report Type:Periodic Company Report #WAES 00082949
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Claritin	C				

Date:12/26/00ISR Number: 3645150-2Report Type:Periodic Company Report #WAES 00080986
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645151-4Report Type:Periodic Company Report #WAES 00082952
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Tab Vioxx	SS		ORAL	PO	
			Azmacort	C				
			Lozol	C				
			Monopril	C				

			Serevent	C		
			Calcium Supplement (Unspecified)	C		
			Chondroitin (+) Glucosamine	C		
			Vitamins (Unspecified)	C		

Date:12/26/00ISR Number: 3645152-6Report Type:Periodic Company Report #WAES 00082957
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Celebrex	C				
			Hydrodiuril	C				
			Albuterol	C				

Date:12/26/00ISR Number: 3645153-8Report Type:Periodic Company Report #WAES 00071821
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain In Extremity Varicose Vein	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Premarin	C				

Date:12/26/00ISR Number: 3645154-XReport Type:Periodic Company Report #WAES 00082963
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

	Oedema Peripheral				Laboratories Div Merck Co Inc	ORAL
25 MG/PO 10 DAY						
			Cytotect	C		
			Tiazac	C		

Date:12/26/00ISR Number: 3645155-1Report Type:Periodic Company Report #WAES 00082964
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO; 50 MG/DAILY/PO						
			Oxycontin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645156-3Report Type:Periodic Company Report #WAES 00071842
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Malaise	Professional			Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Elavil	C				
			Fioricet Tablets	C				
			Flexeril	C				
			Premarin	C				
			Tagment	C				
			Vancenase	C				
			Zestril	C				
			Chlorpheniramine	C				
			Nonsteroidal Anti-Inflammatory	C				
			Trazodone	C				

Date:12/26/00ISR Number: 3645157-5Report Type:Periodic Company Report #WAES 00082969
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Vioxx	PS	Merck Research			
	Dizziness	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Celexa	C				
			Prilosec	C				
			Proscar	C				
			Trental	C				
			Tylenol	C				
			Atenolol	C				
			Cyproheptadine	C				
			Hydrocodone	C				

Date:12/26/00ISR Number: 3645158-7Report Type:Periodic Company Report #WAES 00082970
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645159-9Report Type:Periodic Company Report #WAES 00071847
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645160-5Report Type:Periodic Company Report #WAES 00082971
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3645161-7Report Type:Periodic Company Report #WAES 00082972
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645162-9Report Type:Periodic Company Report #WAES 00071910
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration Diarrhoea Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Atrovent	C				
			Cardizem Cd	C				
			Mevacor	C				
			Notrostat	C				
			Albuterol	C				
			Theophylline	C				

Date:12/26/00ISR Number: 3645163-0Report Type:Periodic Company Report #WAES 00071931
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Fosamax	C		
			Synthroid	C		
			Ultram	C		
			Xanax	C		

Date:12/26/00ISR Number: 3645164-2Report Type:Periodic Company Report #WAES 00071940
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Lotrel	C		
			Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645165-4Report Type:Periodic Company Report #WAES 00080998
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Azmacort	C				
			Beconase	C				
			Elavil	C				
			Hydrodiuril	C				
			Ogen	C				

Date:12/26/00ISR Number: 3645166-6Report Type:Periodic Company Report #WAES 00081014
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Bronchitis	Health			Laboratories Div			
	Cardiac Disorder	Professional			Merck Co Inc	ORAL	25 MG/UNK/PO	
			Avapro	C				
			Claritin	C				
			Hydrodiuril	C				
			Prilosec	C				
			Zocor	C				

Date:12/26/00ISR Number: 3645167-8Report Type:Periodic Company Report #WAES 00081016
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

Fosamax	C		
Synthroid	C		
Zocor	C		
Doxepin	C		

Date:12/26/00ISR Number: 3645168-XReport Type:Periodic Company Report #WAES 00081043
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Asthenia							
	Fatigue							
	Malaise		Vicodin	C				

Date:12/26/00ISR Number: 3645169-1Report Type:Periodic Company Report #WAES 00081107
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645170-8Report Type:Periodic Company Report #WAES 00081117
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Influenza							
	Upper Respiratory Tract Infection		Zocor	C				

Date:12/26/00ISR Number: 3645171-XReport Type:Periodic Company Report #WAES 00081129
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Neck Pain	Health Professional						
			Acupril	C				
			Methotrexate	C				

Date:12/26/00ISR Number: 3645172-1Report Type:Periodic Company Report #WAES 00081139
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendonitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
			Adalat	C				

			Lipitor	C		
			Lortab	C		
			Neurontin	C		
			Aspirin	C		
			Atenolol	C		
			Niacin	C		
			Triamterene	C		

Date:12/26/00ISR Number: 3645173-3Report Type:Periodic Company Report #WAES 00081140
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Dizziness	Health			Laboratories Div			
	Drug Effect Decreased	Professional			Merck Co Inc	ORAL	12.5	
	Nausea							
			Pamelor Unk	SS			MG/DAILY/PO	
			Lipitor	C				
			Paxil	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645174-5Report Type:Periodic Company Report #WAES 00081141
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Disorder							
	Haemorrhoids							
	Renal Disorder							
			Amaryl	C				
			Celebrex	C				
			Lasix	C				
			Neurontin	C				
			Zestril	C				
			Zocor	C				
			Atenolol	C				
			Trazodone	C				

Date:12/26/00ISR Number: 3645175-7Report Type:Periodic Company Report #WAES 00081145
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flexeril	C				
			Neurontin	C				
			Paxil	C				
			Plaquenil	C				
			Synthroid	C				
			Turloc	C				

Date:12/26/00ISR Number: 3645176-9Report Type:Periodic Company Report #WAES 00081158
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Insomnia	Health						

	Nervousness	Professional			Merck Co Inc	ORAL
DAILY/PO						
			Deltasone	C		
			Placidyl	C		
			Teveten	C		

Date:12/26/00ISR Number: 3645177-0Report Type:Periodic Company Report #WAES 00081160
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Vioxx	PS	Merck Research	
	Drug Effect Decreased				Laboratories Div	
	Migraine				Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Ambien	C		
			Aredia	C		
			Betimol	C		
			Glucophage	C		
			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645178-2Report Type:Periodic Company Report #WAES 00081161
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Nausea Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Aricept	C				
			Detrol	C				
			Feosol	C				
			Gaviscon Antacid Tablets	C				
			Neurontin	C				
			Ocuvite	C				
			[Therapy Unspecified]	C				
			Furosemide	C				

Date:12/26/00ISR Number: 3645179-4Report Type:Periodic Company Report #WAES 00082611
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3645180-0Report Type:Periodic Company Report #WAES 00082615
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Fatigue				Merck Co Inc	ORAL
UNK/UNK/PO						
	Insomnia		Bentyly	C		
	Weight Increased		Imdur	C		
			Lasix	C		
			Prinivil	C		
			Toprol Xl Tablets	C		
			Vasotec	C		
			Xanax	C		
			[Compostition Unspecified]	C		
			Aspirin	C		
			Clonidine	C		

Date:12/26/00ISR Number: 3645181-2Report Type:Periodic Company Report #WAES 00081251
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Urticaria				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Celebrex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645182-4Report Type:Periodic Company Report #WAES 00082618
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645183-6Report Type:Periodic Company Report #WAES 00082620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645184-8Report Type:Periodic Company Report #WAES 00081269
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3645185-XReport Type:Periodic Company Report #WAES 00082621
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645186-1Report Type:Periodic Company Report #WAES 00081272
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Drug Ineffective							
	Pollakiuria							

Date:12/26/00ISR Number: 3645187-3Report Type:Periodic Company Report #WAES 00082631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Dyspepsia							
	Flatulence							
	Nausea		Celebrex	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645188-5Report Type:Periodic Company Report #WAES 00082660
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lanoxin	C				

Date:12/26/00ISR Number: 3645189-7Report Type:Periodic Company Report #WAES 00082661
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lortab	C				

Date:12/26/00ISR Number: 3645190-3Report Type:Periodic Company Report #WAES 00081275
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
			Klonopin	C				
			Ultram	C				

Date:12/26/00ISR Number: 3645191-5Report Type:Periodic Company Report #WEAS 00082665
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Celebrex	C		

Date:12/26/00ISR Number: 3645192-7Report Type:Periodic Company Report #WAES 00082668
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/DAILY/PO 1 DAY						
			Coumadin	C		
			Zestril	C		

Date:12/26/00ISR Number: 3645193-9Report Type:Periodic Company Report #WAES 00081286
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645194-0Report Type:Periodic Company Report #WAES 00081347
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:12/26/00ISR Number: 3645195-2Report Type:Periodic Company Report #WAES 00081375
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Vasoretic	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3645196-4Report Type:Periodic Company Report #WAES 00081386
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Aspirin	C				

Date:12/26/00ISR Number: 3645197-6Report Type:Periodic Company Report #WAES 00081403
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/QOD/PO	11 DAY
			Tenormin	C				

Date:12/26/00ISR Number: 3645198-8Report Type:Periodic Company Report #WAES 00091742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				

Date:12/26/00ISR Number: 3645199-XReport Type:Periodic Company Report #WAES 00082577
Age:64 YR Gender:Female I/FU:I

Outcome	PT
	Alanine Aminotransferase Increased
	Anorexia

		Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gamma-Glutamyltransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div	
		Malaise				Merck Co Inc	ORAL
25 MG DAILY							
		Weight Decreased					
PO							
				Estrace	C		

Date:12/26/00ISR Number: 3645200-3Report Type:Periodic Company Report #WAES 00070077
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research	
		Face Oedema	Health			Laboratories Div	
		Oedema Peripheral	Professional			Merck Co Inc	ORAL
25							
		Rectal Haemorrhage					
MG/DAILY/PO;							
25 MG/BID/PO							
				Darvocet-N	C		
				Elavil	C		
				Flexeril	C		
				Lasix	C		
				Macrodantin	C		
				[Therapy Unspecified]	C		
				Prednisone	C		

Date:12/26/00ISR Number: 3645201-5Report Type:Periodic Company Report #WAES 00082579
Age:88 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia	Consumer	Vioxx	PS	Merck Research	
		Nervousness				Laboratories Div	
		Tremor				Merck Co Inc	ORAL
25 MG PO							

Date:12/26/00ISR Number: 3645202-7Report Type:Periodic Company Report #WAES 00082583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645203-9Report Type:Periodic Company Report #WAES 00082586
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Bioflex	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Calcium Supplement (Unspecified)	C				
			Vitamin E	C				

				Vitamins (Unspecified)	C		

Date:12/26/00ISR Number: 3645204-0Report Type:Periodic Company Report #WAES 00082595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645205-2Report Type:Periodic Company Report #WAES 00082596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Defaecation Urgency	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastritis							
			Toprol Xl Tablets	C				

Date:12/26/00ISR Number: 3645206-4Report Type:Periodic Company Report #WAES 00070201
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Dermatitis	Health						
	Erythema	Professional						
	Flushing		Lotensin	C				
	Oedema Peripheral		Norvasc	C				
			Premarin	C				
			Prevacid	C				

Date:12/26/00ISR Number: 3645207-6Report Type:Periodic Company Report #WAES 00082605
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Paraesthesia							
			Valium	C				

Date:12/26/00ISR Number: 3645208-8Report Type:Periodic Company Report #WAES 00082606
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Drug Ineffective	Health Professional						
	Nausea							
			Norvasc	C			PO	
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645209-XReport Type:Periodic Company Report #WAES 00070209
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Fluid Retention	Health Professional						
	Gastrointestinal Disorder							
	Oral Pain							
	Oral Soft Tissue Disorder							
	Periodontal Disease							

Date:12/26/00ISR Number: 3645210-6Report Type:Periodic Company Report #WAES 00082609
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
			Cardizem	C				
			Fosamax	C				

Date:12/26/00ISR Number: 3645211-8Report Type:Periodic Company Report #WAES 00070233
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Cardura	C				
			Monoket	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3645212-XReport Type:Periodic Company Report #WAES 00070263
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Flatulence							
	Tinnitus							
			Prempro	C				
			Warfarin	C				

Date:12/26/00ISR Number: 3645213-1Report Type:Periodic Company Report #WAES 00082610
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
	Oedema Peripheral							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645214-3Report Type:Periodic Company Report #WAES 00070280
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				

Date:12/26/00ISR Number: 3645215-5Report Type:Periodic Company Report #WAES 00070324
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective Facial Pain Flatulence Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 25 MG/BID/PO; 25 MG DAILY/PO	
			Lipitor	C				
			Aspirin	C				
			Minerals (Unspecified) (+)					
			Vitam	C				

Date:12/26/00ISR Number: 3645216-7Report Type:Periodic Company Report #WAES 00070380
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malabsorption	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						
			[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3645217-9Report Type:Periodic Company Report #WAES 00070461
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hair Disorder	Consumer	Vioxx	PS	Merck Research	
	Headache	Health			Laboratories Div	
	Nausea	Professional			Merck Co Inc	ORAL
12.5						
	Pollakiuria					
MG/DAILY/PO;						
	Pruritus					
25						
	Urine Abnormality					
MG/DAILY/PO						
			Synthroid	C		
			Tylenol Arthritis Extended Relie	C		
			Zestril	C		
			Zocor	C		
			Doxepin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645218-0Report Type:Periodic Company Report #WAES 00070463
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hair Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Hytrin	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3645219-2Report Type:Periodic Company Report #WAES 00082809
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645220-9Report Type:Periodic Company Report #WAES 00082811
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	(SEE IMAGE)
			Caltrate	C				
			Evista	C				
			Zantac	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3645221-0Report Type:Periodic Company Report #WAES 00082812
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopause	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645222-2Report Type:Periodic Company Report #WAES 00082814
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea Hyperhidrosis Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Ultram	C				

Date:12/26/00ISR Number: 3645223-4Report Type:Periodic Company Report #WAES 00082815
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG/PO

Baycol	C
Detrol	C
Fosamax	C
Humulin	C
Macrodantin	C
Synthroid	C
Aspirin	C
Hydrochlorothiazide (+) Triamter	C
Vitamins	C

Date:12/26/00ISR Number: 3645224-6Report Type:Periodic Company Report #WAES 00082818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogens	C				

Date:12/26/00ISR Number: 3645225-8Report Type:Periodic Company Report #WAES 00082822
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Prilosec	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3645226-XReport Type:Periodic Company Report #WAES 00082823
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Myalgia							
	Nausea							
	Oedema Peripheral							
			Hormones	SS				
			Synthroid	C				
			Atenolol	C				
			Diuretic	C				

Date:12/26/00ISR Number: 3645227-1Report Type:Periodic Company Report #WAES 00082824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			(SEE IMAGE)					
			Hydrodiuril	C				
			Lotrel	C				
			Pravachol	C				

		Synthroid	C
		Insulin	C
		Metoclopramide	C
		Nortriptyline	C

Date:12/26/00ISR Number: 3645228-3Report Type:Periodic Company Report #WAES 00082827
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Zestril	C				

Date:12/26/00ISR Number: 3645229-5Report Type:Periodic Company Report #WAES 00082831
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Composition Unsepcified]	C				

Date:12/26/00ISR Number: 3645230-1Report Type:Periodic Company Report #WAES 00082833
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO;	

25 MG/PRN/PO

Evista	C	
Plavix	C	
Aspirin	C	
Atenolol	C	

Date:12/26/00ISR Number: 3645231-3Report Type:Periodic Company Report #WAES 00082834
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Bones Fracture		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 WK
	Fall							
	Headache							
			Celebrex	C				
			Klor-Con	C				
			Synthroid	C				
			Aspirin	C				
			Indapamide	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645232-5Report Type:Periodic Company Report #WAES 00082837
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
			Lipitor	C				

Date:12/26/00ISR Number: 3645233-7Report Type:Periodic Company Report #WAES 00082842
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645234-9Report Type:Periodic Company Report #WAES 00082843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoglycaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 50 MG/PO	4 DAY
			Medrol	C				

Date:12/26/00ISR Number: 3645235-0Report Type:Periodic Company Report #WAES 00082844
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Darvocet-N C
Ethinyl Estradiol
(+) Norethindr C

Date:12/26/00ISR Number: 3645236-2Report Type:Periodic Company Report #WAES 00082848
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Relafen	C				

Date:12/26/00ISR Number: 3645237-4Report Type:Periodic Company Report #WAES 00082849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Detrol	C	
Estrace	C	
Zocor	C	
[Therapy Unspecified]	C	
Atenolol	C	

Date:12/26/00ISR Number: 3645238-6Report Type:Periodic Company Report #WAES 00082854
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Mental Impairment							
	Muscular Weakness		Hyzaar	C				
			Lasix	C				
			Lipitor	C				

Date:12/26/00ISR Number: 3645239-8Report Type:Periodic Company Report #WAES 00082716
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645240-4Report Type:Periodic Company Report #WAES 00082741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research			

	Urticaria				Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Tab Vioxx 25 Mg	SS		ORAL
PO						

Date:12/26/00ISR Number: 3645241-6Report Type:Periodic Company Report #WAES 00082742
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Health	Vioxx	PS	Merck Research	
	Pruritus	Professional			Laboratories Div	
	Urticaria				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Premarin	C		
			Minerals (+)			
			Vitamins	C		

Date:12/26/00ISR Number: 3645242-8Report Type:Periodic Company Report #WAES 00082753
Age: Gender:Female I/FU:I

Outcome	PT
	Back Pain
	Decreased Appetite
	Gastrointestinal Disorder

	Muscular Weakness						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645243-XReport Type:Periodic Company Report #WAES 00082754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Bc Powder	SS				

Date:12/26/00ISR Number: 3645244-1Report Type:Periodic Company Report #WAES 00082766
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Penis Disorder Urine Abnormality	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Entex	C				
			Voltaren	C				

Date:12/26/00ISR Number: 3645245-3Report Type:Periodic Company Report #WAES 00082769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3645246-5Report Type:Periodic Company Report #WAES 00082775
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Fatigue							
	Sedation							
			Cartia	C				
			Lipitor	C				
			Miacalcin	C				
			Synthroid	C				
			Diazepam	C				
			Estradiol	C				
			Hydrochlorothiazide (+) Spironol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645247-7Report Type:Periodic Company Report #WAES 00082798
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Zantac	C				

Date:12/26/00ISR Number: 3645248-9Report Type:Periodic Company Report #WAES 00082805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645249-0Report Type:Periodic Company Report #WAES 00100355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
	Constipation							
	Dyspnoea							
	Faeces Discoloured		Detrol	C				
	Feeling Abnormal							
	Nocturia							
	Sinusitis							

Date:12/26/00ISR Number: 3645250-7Report Type:Periodic Company Report #WAES 00100357
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/UNK/PO						
			(Composition Unspecified)	C		

Date:12/26/00ISR Number: 3645251-9Report Type:Periodic Company Report #WAES 00100364
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						

Date:12/26/00ISR Number: 3645252-0Report Type:Periodic Company Report #WAES 00100365
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention Muscular Weakness Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
	Weight Decreased		Darvocet-N	C		

				Klonopin	C		

Date:12/26/00ISR Number: 3645253-2Report Type:Periodic Company Report #WAES 00100366
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645254-4Report Type:Periodic Company Report #WAES 00100372
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea Rectal Haemorrhage Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3645255-6Report Type:Periodic Company Report #WAES 00100378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Erythema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Detrol	C				
			Oxycontin	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3645256-8Report Type:Periodic Company Report #WAES 00100379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3645257-XReport Type:Periodic Company Report #WAES 00100384
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645258-1Report Type:Periodic Company Report #WAES 00100422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3645259-3Report Type:Periodic Company Report #WAES 00111039
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645260-XReport Type:Periodic Company Report #WAES 00111044
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Fatigue Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Prometrium	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3645261-1Report Type:Periodic Company Report #WAES 00111067
Age:11 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645262-3Report Type:Periodic Company Report #WAES 00111068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Dyspepsia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645263-5Report Type:Periodic Company Report #WAES 00111070
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Synvisc	SS			2 ML/WKY/INJ	
			Synvisc 2 Ml	SS			2 ML/WKY/INJ	
			Celebrex	C				

Therapy Unspecified C

Date:12/26/00ISR Number: 3645264-7Report Type:Periodic Company Report #WAES 00111144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3645265-9Report Type:Periodic Company Report #WAES 00111158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Darvocet-N	C				

Date:12/26/00ISR Number: 3645266-0Report Type:Periodic Company Report #WAES 00111168
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Urinary Tract Infection	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coreg	C				
			Darvocet-N	C				
			Effexor Xr	C				
			Glucotrol Xl	C				
			Isordil	C				
			Lanoxin	C				
			Phenergan					

				(Promathazine Hydrochl)	C		
				Prilosec	C		
				Zocor	C		
				Aspirn	C		

Date:12/26/00ISR Number: 3645267-2Report Type:Periodic Company Report #WAES 00111169
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNK/DAILY/UNK	7 MON

Date:12/26/00ISR Number: 3645268-4Report Type:Periodic Company Report #WAES 00111170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Tylenol Arthritis					

Extended Relie C

Date:12/26/00ISR Number: 3645269-6Report Type:Periodic Company Report #WAES 00111245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/BID/PO; 2) 25 MG/BID/PO	

Date:12/26/00ISR Number: 3645270-2Report Type:Periodic Company Report #WAES 00111246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 MON
			Celebrex	C				

Date:12/26/00ISR Number: 3645271-4Report Type:Periodic Company Report #WAES 00111247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY

Date:12/26/00ISR Number: 3645272-6Report Type:Periodic Company Report #WAES 00111248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Arava	C				
			Norco	C				
			Oxycontin	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3645273-8Report Type:Periodic Company Report #WAES 00111249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Mobic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645274-XReport Type:Periodic Company Report #WAES 00111250
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Chondroitin (+) Glucosamine	C				

Date:12/26/00ISR Number: 3645275-1Report Type:Periodic Company Report #WAES 00111251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645276-3Report Type:Periodic Company Report #WAES 00111252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645277-5Report Type:Periodic Company Report #WAES 00111253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3645278-7Report Type:Periodic Company Report #WAES 00111254
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cytotec	C				

Date:12/26/00ISR Number: 3645279-9Report Type:Periodic Company Report #WAES 00090735
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased Platelet Count Decreased Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MGDAILY/PO	
			Coumadin	SS			7.5MG/DAILY/U NK	
			Ambien	C				
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645280-5Report Type:Periodic Company Report #WAES 00090736
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3645281-7Report Type:Periodic Company Report #WAES 00090737
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zoloft	C				

Date:12/26/00ISR Number: 3645282-9Report Type:Periodic Company Report #WAES 00090742
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Plaquenil	C				
			Premarin	C				
			Prometrium	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3645283-0Report Type:Periodic Company Report #WAES 00090745
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	

Date:12/26/00ISR Number: 3645284-2Report Type:Periodic Company Report #WAES 00090746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
		Representative	Rizatriptan Benzoate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645285-4Report Type:Periodic Company Report #WAES 00090748
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	11 DAY
			Arthrotec	C				
			Aspirin	C				
			Caltrate	C				
			Lopid	C				
			Prempro	C				
			Atenolol	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645286-6Report Type:Periodic Company Report #WAES 00090749
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Sudafed	C				
			(Therapy Unspecified)	C				

Date:12/26/00ISR Number: 3645287-8Report Type:Periodic Company Report #WAES 00090751
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50MG/DAILY/PO

Date:12/26/00ISR Number: 3645288-XReport Type:Periodic Company Report #WAES 00090754
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Eye Irritation							
	Face Oedema							
	Lacrimation Increased		Celebrex	C				
	Pruritus		Corticosteroids (Unspecified)	C				
	Vision Blurred							

Date:12/26/00ISR Number: 3645289-1Report Type:Periodic Company Report #WAES 00090755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645290-8Report Type:Periodic Company Report #WAES 00090757
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				
			Hydrochlorothiazide (+) Triamter	C				
			Potassium	C				

Date:12/26/00ISR Number: 3645291-XReport Type:Periodic Company Report #WAES 00090762
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Tums	C			PO	
			Tetracycline	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3645292-1Report Type:Periodic Company Report #WAES 00090765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anorexia Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	5 DAY
	Fatigue		Glucophage	C				
	Nausea		Glucotrol Xl	C				
			Lipitor	C				
			Toprol Xl Tablets	C				

Date:12/26/00ISR Number: 3645293-3Report Type:Periodic Company Report #WAES 00090766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3645294-5Report Type:Periodic Company Report #WAES 00090768
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Hypoglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645295-7Report Type:Periodic Company Report #WAES 00090769
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cyclobenzaprine`	C				

Date:12/26/00ISR Number: 3645296-9Report Type:Periodic Company Report #WAES 00090770
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Activity Flushing Hypertension Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Prevacid	C				
			Calcium	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3645297-0Report Type:Periodic Company Report #WAES 00090772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Aspirin	C				

Date:12/26/00ISR Number: 3645298-2Report Type:Periodic Company Report #WAES 00090773
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3645299-4Report Type:Periodic Company Report #WAES 00110799
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	AM/PO	
			Buspar	C				
			Maxzide	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645300-8Report Type:Periodic Company Report #WAES 00110801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Ambien	C				
			Cardizem	C				
			Effexor	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Prilosec	C				
			Voltaren	C				

Date:12/26/00ISR Number: 3645301-XReport Type:Periodic Company Report #WAES 00110802
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Zocor	C				
			Ginseng	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645302-1Report Type:Periodic Company Report #WAES 00110803
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3645303-3Report Type:Periodic Company Report #WAES 00110809
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Adalat	C				
			Aspirin	C				
			Isosorbide	C				

Date:12/26/00ISR Number: 3645304-5Report Type:Periodic Company Report #WAES 00110812
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645305-7Report Type:Periodic Company Report #WAES 00110814
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Musculoskeletal Disorder							
	Tongue Ulceration							
			Aleve	C				
			Diazide	C				
			Glucophage	C				
			Prinivil	C				
			Tricor	C				

Date:12/26/00ISR Number: 3645306-9Report Type:Periodic Company Report #WAES 00110819
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645307-0Report Type:Periodic Company Report #WAES 00110825
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3645308-2Report Type:Periodic Company Report #WAES 00110832
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645309-4Report Type:Periodic Company Report #WAES 00112219
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645310-0Report Type:Periodic Company Report #WAES 00112305
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Avandia	C
Coumadin	C
Glucotrol Xl	C
Lanoxin	C
Lescol	C
Lotensin	C
Aspirin	C
Furosemide	C
Metoprolol	C

Date:12/26/00ISR Number: 3645311-2Report Type:Periodic Company Report #WAES 00112340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Pepcid	C				
			Zocor	C				

Date:12/26/00ISR Number: 3645312-4Report Type:Periodic Company Report #WAES 00010226
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Ulcerative	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 25 MG/BID/PO; 25 MG/QOD/PO	
			Accupril	C				
			Carafate	C				
			Celebrex	C				
			Synthroid	C				
			Tylenol Extra Strength	C				

			Vicodin Es Tablets	C		
			Hydrocodone	C		

Date:12/26/00ISR Number: 3645313-6Report Type:Periodic Company Report #WAES 00011744
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Gait Disturbance					
	Myalgia					
25 MG/PO						
	Oedema Peripheral		Arthro-7	C		
			Chondroitin	C		
			Glucosamine	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3645314-8Report Type:Periodic Company Report #WAES 00012186
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Mydriasis	Health
	Vision Blurred	Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645315-XReport Type:Periodic Company Report #WAES 00012457
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Oxycontin	C				

Date:12/26/00ISR Number: 3645316-1Report Type:Periodic Company Report #WAES 00020905
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/HS/PO	
			Provogil	SS		ORAL	100 MG/AM/PO; 200 MG/AM/PO; 200 MG/BID/PO	
			Tab Skelaxin	SS		ORAL	1 TABLET Q4H/PO	

				Tab Percocet	SS		ORAL
1							
TABLET/Q4H/PO							
				Synthroid	C		

Date:12/26/00ISR Number: 3645317-3Report Type:Periodic Company Report #WAES 00030582
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Prempro	C		

Date:12/26/00ISR Number: 3645318-5Report Type:Periodic Company Report #WAES 00030593
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Arthrotec	C		
			Claritin	C		
			Elavil	C		
			Paxil	C		
			Prinivil	C		

			Protangix	C
			Zocor	C

Date:12/26/00ISR Number: 3645319-7Report Type:Periodic Company Report #WAES 00082855
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Bumex	C				
			Carditin-Same	C				
			Fulaid	C				
			Neutra-Phos	C				
			Pepcid	C				
			Synthroid	C				
			Atenolol	C				
			Cyanocobalamin	C				

Date:12/26/00ISR Number: 3645320-3Report Type:Periodic Company Report #WAES 00082859
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Hydrodiuril	C				
			Premarin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3645321-5Report Type:Periodic Company Report #WAES 00082860
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645322-7Report Type:Periodic Company Report #WAES 00082866
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645323-9Report Type:Periodic Company Report #WAES 00082868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Celebrex C
Clonopin C
Depakote C
Xanax C
Zoloft C
Trazodone C

Date:12/26/00ISR Number: 3645324-0Report Type:Periodic Company Report #WAES 00082869
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecifeid]	C				

Date:12/26/00ISR Number: 3645325-2Report Type:Periodic Company Report #WAES 00082891
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645326-4Report Type:Periodic Company Report #WAES 00082894
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Cardizem Cd	C		
			Celexa	C		
			Climara	C		
			Miacalcin	C		
			Zebeta	C		

Date:12/26/00ISR Number: 3645327-6Report Type:Periodic Company Report #WAES 00082899
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Coumadin	C		

Date:12/26/00ISR Number: 3645328-8Report Type:Periodic Company Report #WAES 00082902
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased Calculus Urinary	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3645783-3Report Type:Periodic Company Report #WAES 00090361
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645784-5Report Type:Periodic Company Report #WAES 00090365
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	

Date:12/26/00ISR Number: 3645786-9Report Type:Periodic Company Report #WAES 00090367
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	
			Altace	C				
			Amaryl	C				
			Diazide	C				
			Glucophage	C				

Date:12/26/00ISR Number: 3645790-0Report Type:Periodic Company Report #WAES 00090368
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ TID/.	
PO								

Date:12/26/00ISR Number: 3645792-4Report Type:Periodic Company Report #WAES 00090369
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petechiae	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
PO								
			Cytomel	C				
			Norvasc	C				
			Premarin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645794-8Report Type:Periodic Company Report #WAES 00090370
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Vioxx	PS	Merck Research			
	Faeces Discoloured	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Diazide	C				
			Excedrin Extra Strength	C				
			Hytrin	C				
			Neurontin	C				
			Vicodin Tablets	C				

Date:12/26/00ISR Number: 3645797-3Report Type:Periodic Company Report #WAES 00090373
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Gait Disturbance				Laboratories Div			
	Vomiting				Merck Co Inc	ORAL	25 MG/ DAILY/	
							PO	
			Amitriptyline	C				
			Aspirin	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3645800-0Report Type:Periodic Company Report #WAES 00090375
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research			
	Urticaria	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/DAILY/	
							PO	
			Composition					

			Unspecified	C		

Date:12/26/00ISR Number: 3645802-4Report Type:Periodic Company Report #WAES 00090384
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ DAILY/						
PO						
			Coumadin	C		
			Lasix	C		

Date:12/26/00ISR Number: 3645805-XReport Type:Periodic Company Report #WAES 00090386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Drug Ineffective	Health Professional				
	Influenza Like Illness					
25 MG/DAILY/						
	Vomiting					
PO						
			Adalat	C		
			Cardura	C		

			Diabinese	C		
			K-Dur	C		
			Lasix	C		
			Lotensin	C		

Date:12/26/00ISR Number: 3645807-3Report Type:Periodic Company Report #WAES 00082671
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Claritin	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3645809-7Report Type:Periodic Company Report #WAES 00082675
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Asthenia Blindness Dizziness Fatigue Headache Nausea Otitis Externa	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645812-7Report Type:Periodic Company Report #WAES 00082680
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research			

Periodontal Disease Laboratories Div
Merck Co Inc ORAL
12.5 MG DAILY

PO
Tylenol Extra
Strength C
Xanax C

Date:12/26/00ISR Number: 3645814-0Report Type:Periodic Company Report #WAES 00082681
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Accupril	C				
			Diovan	C				
			Hydrodiuril	C				
			Metamucil	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

			Atenolol	C		

Date:12/26/00ISR Number: 3645816-4Report Type:Periodic Company Report #WAES 00082688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645819-XReport Type:Periodic Company Report #WAES 00082689
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prilosec	C				
			Tylenol	C				
			Amitriptyline	C				

Date:12/26/00ISR Number: 3645821-8Report Type:Periodic Company Report #WAES 00082692
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645822-XReport Type:Periodic Company Report #WAES 00082693
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3645824-3Report Type:Periodic Company Report #WAES 00082695
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG UNK PO	
			Betaseron	C				
			Prempro	C				
			Tums	C				
			Antimicrobial (Unspecified)	C				
			Methadone Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645827-9Report Type:Periodic Company Report #WAES 00082712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645832-2Report Type:Periodic Company Report #WAES 00090387
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Influenza Like Illness Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		SEE IMAGE	
			Naprosyn	C				

Date:12/26/00ISR Number: 3645834-6Report Type:Periodic Company Report #WAES 00090388
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucosamine	C				

Date:12/26/00ISR Number: 3645835-8Report Type:Periodic Company Report #WAES 00080311
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

		Fosamax	C	
		Levaquin	C	

Date:12/26/00ISR Number: 3645836-XReport Type:Periodic Company Report #WAES 00090389
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysentery	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Corgard	C		
			Dyazide	C		
			Lipitor	C		

Date:12/26/00ISR Number: 3645837-1Report Type:Periodic Company Report #WAES 00090393
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						

			Buspar	C		
			Decadron (Dexamethasone 21-Acceta	C		
			Eulexin	C		
			Flexal	C		
			Proscar	C		
			Tylenol Extra Strength	C		
			Antineoplastic	C		
			Diazepam	C		
			Vitamins	C		

Date:12/26/00ISR Number: 3645838-3Report Type:Periodic Company Report #WAES 00090395
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Benadryl	C				
			Coumadin	C				
			Inderal	C				
			Premarin	C				
			Tylenol Extra Strength	C				
			Niacin	C				

Date:12/26/00ISR Number: 3645839-5Report Type:Periodic Company Report #WAES 00080319
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Synthroid [Therapy	C				

			Unspecified]	C		

Date:12/26/00ISR Number: 3645840-1Report Type:Periodic Company Report #WAES 00090396
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
SEE IMAGE 1 DAY						
			Cozaar	C		
			Detrol	C		
			Ecotrin	C		
			Inderal	C		
			Lipitor	C		
			Maclicine	C		
			Nitrol (Isosorbide)	C		
			Prilosec	C		
			Allopurinol	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645841-3Report Type:Periodic Company Report #WAES 00090399
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Insulin	C				

Date:12/26/00ISR Number: 3645842-5Report Type:Periodic Company Report #WAES 00090401
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Levoxyl	C				
			Prilosec	C				
			Zestril	C				
			Atenolol	C				
			Metoclopramide	C				
			Tamoxifen	C				

Date:12/26/00ISR Number: 3645843-7Report Type:Periodic Company Report #WAES 00080344
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			[Composition Unspecified] [Therapy	C				

			Unspecified]	C		

Date:12/26/00ISR Number: 3645844-9Report Type:Periodic Company Report #WAES 00090403
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PRN PO						

Date:12/26/00ISR Number: 3645845-0Report Type:Periodic Company Report #WAES 00090404
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY						
PO						
			Imdur	C		
			Aspirin	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645846-2Report Type:Periodic Company Report #WAES 00080350
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Chills	Health			Laboratories Div			
	Diarrhoea	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Pyrexia					PO		
	Rhinorrhoea		Motrin	C				
	Sneezing							
	Upper Respiratory Tract Infection							

Date:12/26/00ISR Number: 3645847-4Report Type:Periodic Company Report #WAES 00080358
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Dysgeusia	Health			Laboratories Div			
	Gastrointestinal	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Haemorrhage					PO		
	Gastrooesophageal Reflux		Lodine	C				
	Disease		[Therapy					
	Headache		Unspecified]	C				
	Olfactory Nerve Disorder		Thyroid	C				

Date:12/26/00ISR Number: 3645848-6Report Type:Periodic Company Report #WAES 00080362
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Vioxx	PS	Merck Research			
	Nervousness				Laboratories Div			
					Merck Co Inc	ORAL	UNK PO	
			Ambien	C				

Date:12/26/00ISR Number: 3645849-8Report Type:Periodic Company Report #WAES 00080370
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG AM PO	
			Glucophage	C				
			Lipitor	C				
			Plendil	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3645850-4Report Type:Periodic Company Report #WAES 00090405
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645851-6Report Type:Periodic Company Report #WAES 00080376
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Hytrin	C				
			Pravachol	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3645852-8Report Type:Periodic Company Report #WAES 00090406
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
	Oedema Peripheral	Health						
	Urinary Retention	Professional						
			Tab Vioxx	SS		ORAL	25 MG/UNK/PO	
			Flexeril	C				
			Meridia	C				

Date:12/26/00ISR Number: 3645853-XReport Type:Periodic Company Report #WAES 00090407
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Tab Vioxx	SS		ORAL
25 MG/PRN/PO						
			Enterozol	C		
			Lopid	C		
			Premarin	C		
			Therapy Unspecified	C		

Date:12/26/00ISR Number: 3645854-1Report Type:Periodic Company Report #WAES 00090409
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Tab Vioxx	SS		ORAL
25 MG/DAILY/PO						
			Armour Thyroid Tablets	C		
			Coreg	C		
			Lanoxin	C		
			Therapy Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645855-3Report Type:Periodic Company Report #WAES 00080475
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastric Ulcer Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Alphagan	C				
			Cosopt	C				
			Diazide	C				
			Diovan	C				
			Xalatan	C				
			Dipivefrin	C				
			Verapamil	C				

Date:12/26/00ISR Number: 3645856-5Report Type:Periodic Company Report #WAES 00090411
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Celebrex	C				
			Darvocet-N	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:12/26/00ISR Number: 3645857-7Report Type:Periodic Company Report #WAES 00090412
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
12.5 MG/UNK/PO						
			Tab Vioxx	SS		ORAL
25 MG/UNK/PO						
			Tab Vioxx	SS		ORAL
50 MG/UNK/PO						
			Composition Unspecified	C		

Date:12/26/00ISR Number: 3645858-9Report Type:Periodic Company Report #WAES 00080476
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG DAILY PO						
			Glucosamine	C		

Date:12/26/00ISR Number: 3645859-0Report Type:Periodic Company Report #WAES 00090416
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Evista	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3645860-7Report Type:Periodic Company Report #WAES 00090418
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Celebrex	C				
			Evista	C				
			Synthroid	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645861-9Report Type:Periodic Company Report #WAES 00090421
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	5 DAY

Date:12/26/00ISR Number: 3645862-0Report Type:Periodic Company Report #WAES 00080035
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Detrol	C				
			Xanax	C				
			Estrogenic Preparations (Composi	C				
			Sertraline	C				

Date:12/26/00ISR Number: 3645863-2Report Type:Periodic Company Report #WAES 00090427
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Hydrodiuril	C				
			Lipitor	C				
			Prevacid	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645864-4Report Type:Periodic Company Report #WAES 00080039
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance Hypoaesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Darvocet-N	C				
			Glucotrol Xl	C				
			Atenolol (+) Chlorthalidone	C				
			Potassium Chloride	C				

Date:12/26/00ISR Number: 3645865-6Report Type:Periodic Company Report #WAES 00080074
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Betapace	C				
			Cardura	C				
			Lipitor	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3645866-8Report Type:Periodic Company Report #WAES 00090428
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Hypertension					
PO						
			Diovan	C		
			Fenesin	C		
			Prevacid	C		

Date:12/26/00ISR Number: 3645867-XReport Type:Periodic Company Report #WAES 00090429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Valtrex	C		

Date:12/26/00ISR Number: 3645868-1Report Type:Periodic Company Report #WAES 00090430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645869-3Report Type:Periodic Company Report #WAES 00080139
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645870-XReport Type:Periodic Company Report #WAES 00090431
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645871-1Report Type:Periodic Company Report #WAES 00090432
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	SEE IMAGE 1 MON

Date:12/26/00ISR Number: 3645872-3Report Type:Periodic Company Report #WAES 00090433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 1 MON

Aspirin With Codeine C

Date:12/26/00ISR Number: 3645873-5Report Type:Periodic Company Report #WAES 00080172
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Desyrel	C				
			Wellbutrin	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645874-7Report Type:Periodic Company Report #WAES 00090440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Hyperkalaemia	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645875-9Report Type:Periodic Company Report #WAES 00090446
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3645876-0Report Type:Periodic Company Report #WAES 00080185
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flonase	C				
			Hydrodiuril	C				
			Hyzaar	C				
			Prempro	C				
			Remeron	C				
			Tylenol Pm	C				
			Captopril	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3645877-2Report Type:Periodic Company Report #WAES 00090447
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645878-4Report Type:Periodic Company Report #WAES 00090453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PRN/PO	

Date:12/26/00ISR Number: 3645879-6Report Type:Periodic Company Report #WAES 00080186
Age:80 YR Gender:Female I/FU:F

Outcome	PT
	Diarrhoea Headache

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Feldene	C				
	Norvasc	C				
	Synthroid	C				
	Tamoxifen	C				

Date:12/26/00ISR Number: 3645880-2Report Type:Periodic Company Report #WAES 00090491
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Fosamax	C				
			Levoxyl	C				
			Norvasc	C				

Date:12/26/00ISR Number: 3645881-4Report Type:Periodic Company Report #WAES 00090493
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact Diarrhoea Drug Ineffective Drug Interaction Vocal Cord Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/BID/PO
			Prednisone	SS				
			Avandia	C				
			Hytrin	C				
			Proscar	C				

			Zocor	C		

Date:12/26/00ISR Number: 3645882-6Report Type:Periodic Company Report #WAES 00090497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Residue	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3645883-8Report Type:Periodic Company Report #WAES 00090502
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY/PO						
			Accupril	C		
			Verelan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645884-XReport Type:Periodic Company Report #WAES 00090503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nervousness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ativan	C				

Date:12/26/00ISR Number: 3645885-1Report Type:Periodic Company Report #WAES 00090508
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Ditropan	C				
			Lotrel	C				
			Pepcid	C				
			Plavix	C				
			Synthroid	C				
			Clonidine	C				
			Metroprolol	C				

Date:12/26/00ISR Number: 3645886-3Report Type:Periodic Company Report #WAES 00090512
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3645887-5Report Type:Periodic Company Report #WAES 00090515
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Musculoskeletal Stiffness Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix	C				
			Prinivil	C				

Date:12/26/00ISR Number: 3645888-7Report Type:Periodic Company Report #WAES 00090519
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
			Acupril	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645889-9Report Type:Periodic Company Report #WAES 00090523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mobic	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3645890-5Report Type:Periodic Company Report #WAES 00082907
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645891-7Report Type:Periodic Company Report #WAES 00082909
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Amaryl	C				
			Prevacid	C				
			Zocor	C				

Date:12/26/00ISR Number: 3645892-9Report Type:Periodic Company Report #WAES 00082910
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensation Of Heaviness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Verapamil Msd Lp	C				

Date:12/26/00ISR Number: 3645893-0Report Type:Periodic Company Report #WAES 00082934
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645894-2Report Type:Periodic Company Report #WAES 00082935
Age:75 YR Gender:Female I/FU:I

Outcome	PT
	Fluid Retention
	Olfactory Nerve Disorder

Skin Disorder
Urine Abnormality

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Premarin	C				
	Synthroid	C				
	Azatadine Dimaleate	C				
	Calcium Supplement (Unspecified)	C				
	Chondroitin (+) Glucosamine	C				
	Vitamin E	C				
	Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3645895-4Report Type:Periodic Company Report #WAES 00082937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective Fluid Retention Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 50 MG/PO	
			Celebrex	C				
			Fosamax	C				
			Loestrin	C				
			Nasarel	C				
			Synthroid	C				
			Calcium Supplement (Unspecified)	C				

Date:12/26/00ISR Number: 3645896-6Report Type:Periodic Company Report #WAES 00082938
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Tongue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prempro	C				
			Zocor	C				

Date:12/26/00ISR Number: 3645897-8Report Type:Periodic Company Report #WAES 00082940
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645898-XReport Type:Periodic Company Report #WAES 00082941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645899-1Report Type:Periodic Company Report #WAES 00082945
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 12.5 MG	
			Premarin	C				
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3645900-5Report Type:Periodic Company Report #WAES 00071122
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				
			Amitriptyline	C				
			Antimicrobial Therapy (Compositi	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3645901-7Report Type:Periodic Company Report #WAES 00071158
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Dyspepsia Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Respiratory Disorder Weight Increased		Celebrex	C				

Date:12/26/00ISR Number: 3645902-9Report Type:Periodic Company Report #WAES 00080222
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Erythema Multiforme Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				

Date:12/26/00ISR Number: 3645903-0Report Type:Periodic Company Report #WAES 00071165
Age:76 YR Gender:Male I/FU:F

Outcome	PT
	Arthralgia Drug Ineffective

	Muscle Rigidity						
	Oedema Peripheral						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain In Extremity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO
			Cardizem	C			
			Megestrol Acetate	C			

Date:12/26/00ISR Number: 3645904-2Report Type:Periodic Company Report #WAES 00071200
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Crying	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO
	Depression						
			Lorcet	C			
			Neurontin	C			
			Premarin	C			

Date:12/26/00ISR Number: 3645905-4Report Type:Periodic Company Report #WAES 00080237
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Dizziness						
	Headache						
			Motrin	C			

Date:12/26/00ISR Number: 3645906-6Report Type:Periodic Company Report #WAES 00071212
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Periodontal Disease	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE /	
							PO	
			Celebrex	C				
			Premarin	C				
			Calcium Supplement (Unspecified)	C				
			Glucosamine	C				
			Progesterone	C				

Date:12/26/00ISR Number: 3645907-8Report Type:Periodic Company Report #WAES 00071219
Age:38 YR Gender:Male I/FU:F

Outcome	PT
	Abnormal Faeces
	Hepatic Function Abnormal
	Hepatitis C Antibody Positive
	Jaundice
	Paraesthesia
	Pigmentation Disorder

Pruritus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO

Date:12/26/00ISR Number: 3645908-XReport Type:Periodic Company Report #WAES 00071334
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Darvocet-N	C				
			Premarin	C				

Date:12/26/00ISR Number: 3645909-1Report Type:Periodic Company Report #WAES 00071338
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/	PO
			Actos	C				
			Amaryl	C				
			Glucophage	C				
			Lipitor	C				
			Lozol	C				

Date:12/26/00ISR Number: 3645910-8Report Type:Periodic Company Report #WAES 00071340
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Faeces Discoloured	Health			Laboratories Div			
	Visual Disturbance	Professional			Merck Co Inc	ORAL	25 MG/ DAILY/	
							PO	
			Evista	C				
			Plaquenil	C				
			Rocaltrol	C				

Date:12/26/00ISR Number: 3645911-XReport Type:Periodic Company Report #WAES 00071390
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
		Representative					PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645912-1Report Type:Periodic Company Report #WAES 00080238
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Prandin	C				
			Zestril	C				
			Zyloprim	C				
			Quinine Sulfate	C				

Date:12/26/00ISR Number: 3645913-3Report Type:Periodic Company Report #WAES 00072395
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Mental Disorder Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO	
			Cortisone	C				

Date:12/26/00ISR Number: 3645914-5Report Type:Periodic Company Report #WAES 00072455
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Liver Function Test Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			(Therapy Unspecified)	C				
			Penicillin (As Drug)	C				

Date:12/26/00ISR Number: 3645915-7Report Type:Periodic Company Report #WAES 00072470
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulation Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dynacirc	C				
			Os-Cal	C				
			Premarin	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				
			Warfarin	C				

Date:12/26/00ISR Number: 3645916-9Report Type:Periodic Company Report #WAES 00072480
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645917-0Report Type:Periodic Company Report #WAES 00072511
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, 50MG/DAILY/PO	
	Blood Pressure Increased							
	Connective Tissue Disorder							
	Depressed Level Of Consciousness		Prednisone	C				
	Dizziness							
	Eyelid Oedema							
	Headache							
	Nausea							
	Tongue Oedema							
	Vertigo							

Date:12/26/00ISR Number: 3645918-2Report Type:Periodic Company Report #WAES 00072560
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Drug Ineffective							
			Natures Rx Msm Plus C	SS				

Date:12/26/00ISR Number: 3645919-4Report Type:Periodic Company Report #WAES 00072570
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	

SEE IMAGE

				Accupril	C		
				Avandia	C		
				Cardizem Cd	C		
				Glucophage	C		
				Lozol	C		
				Riopan	C		
				[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3645920-0Report Type:Periodic Company Report #WAES 00072656
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lodine	C				

Date:12/26/00ISR Number: 3645921-2Report Type:Periodic Company Report #WAES 00080017
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Sprain Muscle Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645922-4Report Type:Periodic Company Report #WAES 00080018
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3645923-6Report Type:Periodic Company Report #WAES 00081823
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Stomatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 + 25 MG/PO	
		Company Representative	Celebrex	C				

Date:12/26/00ISR Number: 3645924-8Report Type:Periodic Company Report #WAES 00081854
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research			

		Health Professional			Laboratories Div Merck Co Inc	ORAL
DAILY/PO						
			Arava	C		
			Lortab	C		
			Medrol	C		
			Hydrocodone	C		
			Sulfasalazine	C		

Date:12/26/00ISR Number: 3645925-XReport Type:Periodic Company Report #WAES 00081857
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO 8 MON						
			Estrace	C		
			Fosamax	C		
			Hydrodiuril	C		
			Premarin	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645928-5Report Type:Periodic Company Report #WAES 00081873
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective	Health			Laboratories Div	
	Pain In Extremity	Professional			Merck Co Inc	ORAL
12.5 MG /						
DAILY / PO						
			Centrum Silver	C		
			Exelon	C		
			Flovent	C		
			Norvasc	C		
			Pravachol	C		
			Proventil	C		
			Wellbutrin	C		
			Albuterol	C		
			Atenolol	C		
			Calcium Supplement (Unspecified)	C		
			Vitamin E	C		

Date:12/26/00ISR Number: 3645931-5Report Type:Periodic Company Report #WAES 00081891
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Vioxx	PS	Merck Research	
	Haemorrhage	Health			Laboratories Div	
	Rectal Haemorrhage	Professional			Merck Co Inc	ORAL
25 MG/PRN/PO						
	Urinary Tract Infection		Colace	C		
			Hydrodiuril	C		
			Monopril	C		
			Tylenol	C		
			Zantac	C		
			Potassium (Unspecified)	C		

Date:12/26/00ISR Number: 3645933-9Report Type:Periodic Company Report #WAES 00081902
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	9 DAY
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3645936-4Report Type:Periodic Company Report #WAES 00081910
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645938-8Report Type:Periodic Company Report #WAES 00081911
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3645941-8Report Type:Periodic Company Report #WAES 00091463
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ativan	C				
			Celebrex	C				
			Colace	C				
			Coumadin	C				
			Fibercon	C				
			Flonase	C				
			Lanoxin	C				
			Mycilan	C				
			Prevacid	C				
			Zocor	C				
			[Compositon Unspecified]	C				
			[Therapy Unspecified]	C				
			Metoprolol	C				

Date:12/26/00ISR Number: 3645942-XReport Type:Periodic Company Report #WAES 99060316
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Feeling Abnormal	Professional			Merck Co Inc	ORAL
25 MG/BID/PO						
			Plaquenil	C		
			Prempro	C		
			Tenormin	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3645943-1Report Type:Periodic Company Report #WAES 00081421
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG BID PO						
			Zanaflex	C		
			Estrogens	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645944-3Report Type:Periodic Company Report #WAES 00081496
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research			
	Oral Pain	Health			Laboratories Div			
	Paraesthesia	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Periodontal Disease						PO	
			Cardizem	C				
			Isordil	C				
			Remeron	C				
			Meclizine	C				

Date:12/26/00ISR Number: 3645945-5Report Type:Periodic Company Report #WAES 00081498
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Vioxx	PS	Merck Research			
	Pharyngeal Oedema	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	SEE IMAGE	
			Aldactone	C				
			Prozac	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3645946-7Report Type:Periodic Company Report #WAES 00081507
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Vioxx	PS	Merck Research			
	Olfactory Nerve Disorder	Health			Laboratories Div			
	Upper Respiratory Tract	Professional			Merck Co Inc	ORAL	25 MG DAILY	
	Infection						PO	
			Synthroid	C				
			Toprol Xl Tablets	C				
			Indapamide	C				

Date:12/26/00ISR Number: 3645947-9Report Type:Periodic Company Report #WAES 00081510
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Headache	Health			Laboratories Div			
	Musculoskeletal Stiffness	Professional			Merck Co Inc	ORAL	PO	
	Nausea		Pravachol	C				

Date:12/26/00ISR Number: 3645948-0Report Type:Periodic Company Report #WAES 00081532
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG PO	
			Navane	C				
			Prempro	C				
			Wellbutrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3645949-2Report Type:Periodic Company Report #WAES 00081552
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Ambien	C				
			Xanax	C				

Date:12/26/00ISR Number: 3645950-9Report Type:Periodic Company Report #WAES 00081582
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Rash Morbilliform	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Celebrex	C				
			Cozaar	C				
			Maxzide	C				
			Aspirin	C				
			Digoxin	C				

Date:12/26/00ISR Number: 3645951-0Report Type:Periodic Company Report #WAES 00081656
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID PO	
			Accupril	C				

Date:12/26/00ISR Number: 3645952-2Report Type:Periodic Company Report #WAES 00081657
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY PO						
			Coumadin	C		
			Tambocor	C		
			Toprol Xl Tablets	C		

Date:12/26/00ISR Number: 3646102-9Report Type:Periodic Company Report #WAES 00072143
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG DAILY PO	Aspartate Aminotransferase Increased		Methotrexate	C		
	Hypertension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646104-2Report Type:Periodic Company Report #WAES 00072244
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Dizziness							
	Vomiting							
			Prevacid	C				
			Trental	C				
			Zocor	C				

Date:12/26/00ISR Number: 3646105-4Report Type:Periodic Company Report #WAES 00072252
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	4 DAY
			Lescol	C				
			Lotensin	C				

Date:12/26/00ISR Number: 3646106-6Report Type:Periodic Company Report #WAES 00072256
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective	Health						
	Fatigue	Professional						
	Pruritus		Estrogenic	C				

Date:12/26/00ISR Number: 3646107-8Report Type:Periodic Company Report #WAES 00072310
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Fatigue	Health			Laboratories Div	
	Fluid Retention	Professional			Merck Co Inc	ORAL
25MG DAILY PO						
	Urinary Retention		Allegra	C		
			Dyazide	C		
			Effexor	C		
			Evista	C		
			Neurontin	C		
			Calcium Ferrous Citrate	C		

Date:12/26/00ISR Number: 3646112-1Report Type:Periodic Company Report #WAES 00072359
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25MG DAILY PO						
			Paxil	C		
			Xanax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646114-5Report Type:Periodic Company Report #WAES 00072367
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG PO	
	Dyspnoea							
	Paraesthesia							
			Cozaar	C				
			Vasotec	C				

Date:12/26/00ISR Number: 3646115-7Report Type:Periodic Company Report #WAES 00072371
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Drug Ineffective	Health						
	Nausea	Professional						
			Coumadin	C				
			Imdur	C				
			Lopressor	C				
			Vasotec	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3646118-2Report Type:Periodic Company Report #WAES 00072372
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG BID PO	
	Fatigue	Health						
	Oedema Peripheral	Professional						
			Lasix	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3646119-4Report Type:Periodic Company Report #WAES 00072385
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Deafness	Consumer	Vioxx	PS	Merck Research	
	Hearing Impaired	Health			Laboratories Div	
	Tinnitus	Professional			Merck Co Inc	ORAL
SEE IMAGE						
			Celebrex	C		
			Fosamax	C		
			Antineoplastic			
			Agents9compositi)	C		

Date:12/26/00ISR Number: 3646268-0Report Type:Periodic Company Report #WAES 00111179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Mobic	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646335-1Report Type:Periodic Company Report #WAES 00101043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646337-5Report Type:Periodic Company Report #WAES 00101072
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ativan	C				
			Synthroid	C				
			Lithium Carbonate	C				

Date:12/26/00ISR Number: 3646338-7Report Type:Periodic Company Report #WAES 00101082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Respiratory Tract Infection Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	2 WK

Date:12/26/00ISR Number: 3646340-5Report Type:Periodic Company Report #WAES 00101084
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Conjunctivitis	Consumer	Vioxx	PS	Merck Research	
	Flushing				Laboratories Div	
	Swelling				Merck Co Inc	ORAL

25 MG/

DAILY/PO 17 DAY

Elavil	C	
Chondroitin	C	
Glucosamine	C	

Date:12/26/00ISR Number: 3646341-7Report Type:Periodic Company Report #WAES 00101085
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysgeusia	Consumer	Vioxx	PS	Merck Research	
	Olfactory Nerve Disorder	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL

25 MG/

DAILY/PO

Prempro	C	

Date:12/26/00ISR Number: 3646342-9Report Type:Periodic Company Report #WAES 00101088
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	

Merck Co Inc ORAL
25 MG/
DAILY/PO

Lipitor C
[Therapy
Unspecified] C

Date:12/26/00ISR Number: 3646343-0Report Type:Periodic Company Report #WAES 00081940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Tab Lasix Unk	SS		ORAL	160 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646344-2Report Type:Periodic Company Report #WAES 00101089
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Septum Disorder Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Corgard	C				
			Corgard	C				
			Nasacort	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646345-4Report Type:Periodic Company Report #WAES 00101092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3646347-8Report Type:Periodic Company Report #WAES 00101102
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646348-XReport Type:Periodic Company Report #WAES 00101103
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mean Cell Volume Increased White Blood Cell Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	3 MON
			Elavil	C				

Date:12/26/00ISR Number: 3646349-1Report Type:Periodic Company Report #WAES 00081974
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Demadex	C				
			Glucotrol Xl	C				
			Trental	C				
			[Therapy Unspecified]	C				
			Insulin	C				

Date:12/26/00ISR Number: 3646350-8Report Type:Periodic Company Report #WAES 00081975
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucotrol	C				
			Norvasc	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3646351-XReport Type:Periodic Company Report #WAES 00101125
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646352-1Report Type:Periodic Company Report #WAES 00081976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Flomax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646353-3Report Type:Periodic Company Report #WAES 00101126
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646354-5Report Type:Periodic Company Report #WAES 00101138
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Date:12/26/00ISR Number: 3646355-7Report Type:Periodic Company Report #WAES 00081977
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Lipitor	C				
			Norvasc	C				
			Zebeta	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3646356-9Report Type:Periodic Company Report #WAES 00101145
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:12/26/00ISR Number: 3646357-0Report Type:Periodic Company Report #WAES 00081979
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Ambien	C
Claritin	C
Desyrel	C
Fosamax	C
Neurontin	C
Norco	C
Premarin	C
Soma	C
Synthroid	C
Hydrocodone	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646358-2Report Type:Periodic Company Report #WAES 00101179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646359-4Report Type:Periodic Company Report #WAES 00081980
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Zantac	C				

Date:12/26/00ISR Number: 3646360-0Report Type:Periodic Company Report #WAES 00101193
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646361-2Report Type:Periodic Company Report #WAES 00081985
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

Professional Merck Co Inc ORAL
25

MG/DAILY/PO

Asacol	C	
Lotensin	C	
Zantac	C	
Leuprolide Acetate	C	

Date:12/26/00ISR Number: 3646362-4Report Type:Periodic Company Report #WAES 00101194
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Detrol	C				
			Tylenol	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3646363-6Report Type:Periodic Company Report #WAES 00101197
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thirst Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

		Coumadin	C	
		Maxzide	C	
		Tenormin	C	

Date:12/26/00ISR Number: 3646364-8Report Type:Periodic Company Report #WAES 00081986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Vasotec	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646365-XReport Type:Periodic Company Report #WAES 00101198
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Headache Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Date:12/26/00ISR Number: 3646366-1Report Type:Periodic Company Report #WAES 00081987
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mucous Membrane Disorder Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Claritin	C				

			Climara	C		
			Prevacid	C		
			Prinizide	C		
			Allopurinol	C		
			Glyburide	C		

Date:12/26/00ISR Number: 3646367-3Report Type:Periodic Company Report #WAES 00101202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aleve	C				

Date:12/26/00ISR Number: 3646368-5Report Type:Periodic Company Report #WAES 00081990
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646369-7Report Type:Periodic Company Report #WAES 00081995
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Oedema Peripheral Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:12/26/00ISR Number: 3646370-3Report Type:Periodic Company Report #WAES 00081996
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Cordarone	C				

Date:12/26/00ISR Number: 3646371-5Report Type:Periodic Company Report #WAES 00081997
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646372-7Report Type:Periodic Company Report #WAES 00082001
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastric Disorder	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Hydrochlorthiazide (+) Triamter	C		

Date:12/26/00ISR Number: 3646373-9Report Type:Periodic Company Report #WAES 00082006
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Tylenol Arthritis Extended Relief	C		

Date:12/26/00ISR Number: 3646374-0Report Type:Periodic Company Report #WAES 00082014
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Lescol	C		
			Paxil	C		

				Synthroid	C		
				Valium	C		

Date:12/26/00ISR Number: 3646375-2Report Type:Periodic Company Report #WAES 00082015
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG DAILY PO	
			Neurontin	C				
			Ranitidine	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3646376-4Report Type:Periodic Company Report #WAES 00082020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646377-6Report Type:Periodic Company Report #WAES 00110353
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Insomnia Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

		Lipitor	C	
		Plendil	C	

Date:12/26/00ISR Number: 3646378-8Report Type:Periodic Company Report #WAES 00082027
Age:60 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ PO	

Date:12/26/00ISR Number: 3646379-XReport Type:Periodic Company Report #WAES 00110357
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646380-6Report Type:Periodic Company Report #WAES 00082028
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cipro	C				
			Hydrodiuril	C				
			Lipitor	C				
			Metaprel	C				
			Norvasc	C				
			Proscar	C				
			Nitroglycerin	C				
			Ranitidine	C				

Date:12/26/00ISR Number: 3646381-8Report Type:Periodic Company Report #WAES 00110366
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation Cardiac Disorder Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646382-XReport Type:Periodic Company Report #WAES 00082031
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hyzaar	C				
			Miacalcin	C				
			Plaquenil	C				
			Prevacid	C				

Tenormin	C
Vicodin Tablets	C
Zocor	C
Folic Acid	C
Glucosamine	C
Thyroid	C
Vitamins (Unspecified)	C

Date:12/26/00ISR Number: 3646383-1Report Type:Periodic Company Report #WAES 00110367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646384-3Report Type:Periodic Company Report #WAES 00110371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646385-5Report Type:Periodic Company Report #WAES 00082035
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Face Oedema Pharyngitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Miacalcin	C				
			Norvasc	C				
			Vicodin Tablets	C				

Date:12/26/00ISR Number: 3646386-7Report Type:Periodic Company Report #WAES 00110378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646387-9Report Type:Periodic Company Report #WAES 00082041
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Synthroid	C				
			Zocor	C				

Date:12/26/00ISR Number: 3646388-0Report Type:Periodic Company Report #WAES 00110381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646389-2Report Type:Periodic Company Report #WAES 00110384
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

[Therapy
Unspecified] C
Folic Acid C
Methotrexate C
Prednisone C

Date:12/26/00ISR Number: 3646390-9Report Type:Periodic Company Report #WAES 00082044
Age:54 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Drug Effect Decreased Consumer Vioxx PS Merck Research
Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Iron (Unspecified) C

Date:12/26/00ISR Number: 3646391-0Report Type:Periodic Company Report #WAES 00082045
Age:68 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Hypoaesthesia Consumer Vioxx PS Merck Research
Oedema Peripheral
Laboratories Div
Weight Increased
Merck Co Inc ORAL
PO

Neurontin C
Glyburide C

Date:12/26/00ISR Number: 3646392-2Report Type:Periodic Company Report #WAES 00110390
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Hepatic Function Abnormal Health Vioxx PS Merck Research
Viral Infection Professional
Laboratories Div

Merck Co Inc ORAL
PO 5 DAY
[Therapy
Unspecified] C

Date:12/26/00ISR Number: 3646393-4Report Type:Periodic Company Report #WAES 00082046
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Dysphonia Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/PO	
	Pharyngitis		Monopril	C				

Date:12/26/00ISR Number: 3646394-6Report Type:Periodic Company Report #WAES 00110406
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646395-8Report Type:Periodic Company Report #WAES 00082047
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dental Caries	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				
			Aspirin	C				
			Metoprolol	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3646396-XReport Type:Periodic Company Report #WAES 00110424
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646397-1Report Type:Periodic Company Report #WAES 00110431
Age:59 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Flexeril	C				
			Hydergine	C				
			Prinivil	C				
			Ultram	C				
			Diazepam	C				

Date:12/26/00ISR Number: 3646398-3Report Type:Periodic Company Report #WAES 00110444
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Fatigue							
	Flatulence							
			Diazide	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3646399-5Report Type:Periodic Company Report #WAES 00110454
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Tylenol	C				
			Zantac	C				
			(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646400-9Report Type:Periodic Company Report #WAES 00110455
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Prempro	C				
			Prozac	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3646401-0Report Type:Periodic Company Report #WAES 00082048
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Skelaxin	C				
			Soma	C				
			Hydrocodone	C				
			Ibuprofen	C				

Date:12/26/00ISR Number: 3646402-2Report Type:Periodic Company Report #WAES 00110456
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Chest Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE / PO	5 MON
			Lescol	C				

			Xanax	C
			Potassum (Unspecified)	C

Date:12/26/00ISR Number: 3646403-4Report Type:Periodic Company Report #WAES 00110461
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Warfarin	C				

Date:12/26/00ISR Number: 3646404-6Report Type:Periodic Company Report #WAES 00110472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646405-8Report Type:Periodic Company Report #WAES 00110476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Pulmonary Congestion							
	Sputum Abnormal							

Date:12/26/00ISR Number: 3646406-XReport Type:Periodic Company Report #WAES 00110487
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zestril	C				

Date:12/26/00ISR Number: 3646407-1Report Type:Periodic Company Report #WAES 00110492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accolate	C				
			Fosamax	C				
			Lipitor	C				
			Lortab	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3646408-3Report Type:Periodic Company Report #WAES 00110495
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Glossodynia							
	Tongue Disorder							
	Vaginal Haemorrhage		Salagen Tablets	C				
	Vulval Disorder		Ultram	C				

Date:12/26/00ISR Number: 3646409-5Report Type:Periodic Company Report #WAES 00110496
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646410-1Report Type:Periodic Company Report #WAES 00110503
Age: Gender:Male I/FU:I

Outcome	PT
	Constipation
	Drug Ineffective

	Nausea						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3646411-3Report Type:Periodic Company Report #WAES 00110516
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Odour Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3646412-5Report Type:Periodic Company Report #WAES 00110519
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3646413-7Report Type:Periodic Company Report #WAES 00110520
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:12/26/00ISR Number: 3646414-9Report Type:Periodic Company Report #WAES 00110521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Methotrexate	C				

Date:12/26/00ISR Number: 3646415-0Report Type:Periodic Company Report #WAES 00110528
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646416-2Report Type:Periodic Company Report #WAES 00110547
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Flomax
(Mornifulmate) C
Sonata C
Vicoprofen C
Methotrexate C

Date:12/26/00ISR Number: 3646422-8Report Type:Periodic Company Report #WAES 00110552
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain							
	Diarrhoea							
	Dyspepsia							
	Rectal Haemorrhage							

Date:12/26/00ISR Number: 3646423-XReport Type:Periodic Company Report #WAES 00110558
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Actonel C
Lipitor C

Date:12/26/00ISR Number: 3646424-1Report Type:Periodic Company Report #WAES 00110566
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research			

	Bone Disorder				Laboratories Div	
	Hypotonia				Merck Co Inc	ORAL
PO						
	Peripheral Vascular		Ativan	C		
	Disorder		Diovan	C		
	Vein Disorder		Imdur	C		
			Lipitor	C		
			Lopressor	C		
			Maxzide	C		
			Norvasc	C		
			Premarin	C		
			Prilosec	C		
			Aspirin	C		

Date:12/26/00ISR Number: 3646425-3Report Type:Periodic Company Report #WAES 00110570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research	
	Weight Increased				Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG DAILY						
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646426-5Report Type:Periodic Company Report #WAES 00110573
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3646427-7Report Type:Periodic Company Report #WAES 00110575
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Pravachol	C				

Date:12/26/00ISR Number: 3646429-0Report Type:Periodic Company Report #WAES 00110576
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urethral Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				

Date:12/26/00ISR Number: 3646430-7Report Type:Periodic Company Report #WAES 00110578
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Diarrhoea				Merck Co Inc	ORAL
PO						
	Fatigue					

Date:12/26/00ISR Number: 3646432-0Report Type:Periodic Company Report #WAES 00110581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Estrace	C		
			Fosamax	C		
			Folic Acid	C		
			Methotrexate	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3646434-4Report Type:Periodic Company Report #WAES 00110582
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Pruritus		Hydrodiuril	C		

				Lipitor	C		
				Zestril	C		

Date:12/26/00ISR Number: 3646636-7Report Type:Periodic Company Report #WAES 00082051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646637-9Report Type:Periodic Company Report #WAES 00082057
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dizziness Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Tylox	C				

Date:12/26/00ISR Number: 3646638-0Report Type:Periodic Company Report #WAES 00082058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:12/26/00ISR Number: 3646639-2Report Type:Periodic Company Report #WAES 00082086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646640-9Report Type:Periodic Company Report #WAES 00082097
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
			Ortho Tri-Cyclen	C				

Date:12/26/00ISR Number: 3646641-0Report Type:Periodic Company Report #WAES 00082100
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Detrol	C	
Diovan	C	
Librium	C	
Lipitor	C	
Prempro	C	

Date:12/26/00ISR Number: 3646642-2Report Type:Periodic Company Report #WAES 00082110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	

Date:12/26/00ISR Number: 3646643-4Report Type:Periodic Company Report #WAES 00082122
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO 4 DAY						
			Tylenol	C		

Date:12/26/00ISR Number: 3646644-6Report Type:Periodic Company Report #WAES 00082123
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ear Pain Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Therapy Unspecified	C		

Date:12/26/00ISR Number: 3646645-8Report Type:Periodic Company Report #WAES 00082124
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 DAY
			Lipitor	C				
			Ziac	C				

Date:12/26/00ISR Number: 3646646-XReport Type:Periodic Company Report #WAES 00083058
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Demadex	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646647-1Report Type:Periodic Company Report #WAES 00083062
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
	Diarrhoea							
	Viral Infection							
			Cardura	C				
			Alprazolam	C				

Date:12/26/00ISR Number: 3646648-3Report Type:Periodic Company Report #WAES 00083064
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lung Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Vocal Cord Disorder							
			Hydrodiuril	C				
			Plavix	C				
			Prempro	C				

Date:12/26/00ISR Number: 3646649-5Report Type:Periodic Company Report #WAES 00083066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Lipitor	C				
			Norvasc	C				
			Vasotec	C				

Date:12/26/00ISR Number: 3646650-1Report Type:Periodic Company Report #WAES 00083067
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea							
	Sinusitis							
			Lipitor	C				
			Zestril	C				

Date:12/26/00ISR Number: 3646651-3Report Type:Periodic Company Report #WAES 00083070
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							
	Dyspepsia							
			Aciphex	C				
			Lipitor	C				
			Miacalcin	C				
			Aspirin	C				
			Calcium Supplement	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646652-5Report Type:Periodic Company Report #WAES 00083072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Cardizem	C				
			Atenolol	C				
			Glucosamine Sulfate	C				

Date:12/26/00ISR Number: 3646653-7Report Type:Periodic Company Report #WAES 00083074
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Dyazide	C				
			Pravachol	C				

Date:12/26/00ISR Number: 3646654-9Report Type:Periodic Company Report #WAES 00083077
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646655-0Report Type:Periodic Company Report #WAES 00083080
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diacid	C				
			Diovan	C				
			Synthroid	C				
			Allpurinol	C				
			Potassium	C				

Date:12/26/00ISR Number: 3646656-2Report Type:Periodic Company Report #WAES 00083086
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646657-4Report Type:Periodic Company Report #WAES 00083089
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Calcium Supplement	C				
			Thyroid	C				

Date:12/26/00ISR Number: 3646658-6Report Type:Periodic Company Report #WAES 00083090
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Premarin	C				

Date:12/26/00ISR Number: 3646659-8Report Type:Periodic Company Report #WAES 00083091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50MG /PO	

Date:12/26/00ISR Number: 3646660-4Report Type:Periodic Company Report #WAES 00083093
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ativan	C				
			Elavil	C				
			Imodium	C				
			Soma	C				

Date:12/26/00ISR Number: 3646661-6Report Type:Periodic Company Report #WAES 00083095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646662-8Report Type:Periodic Company Report #WAES 00083096
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Leukopenia							
	Thrombocytopenia		Celebrex 100 Mg	SS		ORAL	100 MG/BID/PO	
	Weight Increased		Celebrex 200 Mg	SS		ORAL	100 MG/BID/PO; 200 MG/BID/PO	
			Fluoxetine	SS		ORAL	PO	
			Zocor	C				
			Alprazolam	C				
			Clopidogrel Bisulfate	C				
			Omeprazole	C				
			Terazosin	C				

Date:12/26/00ISR Number: 3646663-XReport Type:Periodic Company Report #WAES 00083102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646664-1Report Type:Periodic Company Report #WAES 00083108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			

Blood Pressure Increased
Dizziness
Dyspepsia

Laboratories Div
Merck Co Inc

ORAL
PO

Date:12/26/00ISR Number: 3646665-3Report Type:Periodic Company Report #WAES 00083109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:12/26/00ISR Number: 3646666-5Report Type:Periodic Company Report #WAES 00111626
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			K-Dur	C				
			Levoxyl	C				
			Vasotec	C				
			Zaroxolyn	C				
			Aspirin	C				
			Diltiazem	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646667-7Report Type:Periodic Company Report #WAES 00111628
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1-2	MG/DAILY/PO
	Congenital Melanosis							
			Flovent	C				
			Prilosec	C				
			Serevent	C				
			Sinemet	C				
			Singulair	C				

Date:12/26/00ISR Number: 3646668-9Report Type:Periodic Company Report #WAES 00111630
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Baycol	C				
			Claritin	C				
			Alprazolam	C				
			Quinine Sulfate	C				

Date:12/26/00ISR Number: 3646669-0Report Type:Periodic Company Report #WAES 00111631
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/'DAILY/PO

			Luvox	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3646670-7Report Type:Periodic Company Report #WAES 00111652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Hytrin	C				
			Procardia	C				
			Tylenol	C				

Date:12/26/00ISR Number: 3646671-9Report Type:Periodic Company Report #WAES 00111654
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646672-0Report Type:Periodic Company Report #WAES 00111663
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retroperitoneal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646673-2Report Type:Periodic Company Report #WAES 00111667
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Face Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Levothyroxine	C				

Date:12/26/00ISR Number: 3646674-4Report Type:Periodic Company Report #WAES 00111673
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				

Date:12/26/00ISR Number: 3646675-6Report Type:Periodic Company Report #WAES 00111702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25 MG/ TID/PO
Ibuprofen 800 Mg SS
800 MG/QID

Date:12/26/00ISR Number: 3646676-8Report Type:Periodic Company Report #WAES 00111717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646677-XReport Type:Periodic Company Report #WAES 00111734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646678-1Report Type:Periodic Company Report #WAES 00111739
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646679-3Report Type:Periodic Company Report #WAES 00111740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646680-XReport Type:Periodic Company Report #WAES 00111741
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646681-1Report Type:Periodic Company Report #WAES 00111742
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:12/26/00ISR Number: 3646682-3Report Type:Periodic Company Report #WAES 00111744
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646683-5Report Type:Periodic Company Report #WAES 00111746
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646684-7Report Type:Periodic Company Report #WAES 00111749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646685-9Report Type:Periodic Company Report #WAES 00111750
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3646748-8Report Type:Periodic Company Report #WAES 00082388
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Lipitor	C				
			Plavix	C				

Date:12/26/00ISR Number: 3646749-XReport Type:Periodic Company Report #WAES 00082389
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research			

	Visual Disturbance				Laboratories Div Merck Co Inc	ORAL
PO						
			Adalat	C		

Date:12/26/00ISR Number: 3646750-6Report Type:Periodic Company Report #WAES 00082391
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY PO						
			Miacalcin	C		

Date:12/26/00ISR Number: 3646751-8Report Type:Periodic Company Report #WAES 00082394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Klonopin	C		
			Zantac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646752-XReport Type:Periodic Company Report #WAES 00082395
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3646753-1Report Type:Periodic Company Report #WAES 00082397
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3646754-3Report Type:Periodic Company Report #WAES 00082398
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646755-5Report Type:Periodic Company Report #WAES 00082399
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyst Diarrhoea	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

	Influenza Like Illness	Professional			Merck Co Inc	ORAL
25 MG BID PO						
	Nausea					
	Urinary Tract Infection					

Date:12/26/00ISR Number: 3646756-7Report Type:Periodic Company Report #WAES 00082405
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Blood Pressure Increased				Laboratories Div	
					Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Singulair	C		
			Tenormin	C		
			Estrogens	C		

Date:12/26/00ISR Number: 3646757-9Report Type:Periodic Company Report #WAES 00082406
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal	Health	Vioxx	PS	Merck Research	
	Haemorrhage	Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Coumadin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646758-0Report Type:Periodic Company Report #WAES 00082409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intervertebral Disc Displacement	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646759-2Report Type:Periodic Company Report #WAES 00082410
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3646760-9Report Type:Periodic Company Report #WAES 00082415
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646761-0Report Type:Periodic Company Report #WAES 00082427
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Blood Pressure Increased Headache	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				

Date:12/26/00ISR Number: 3646762-2Report Type:Periodic Company Report #WAES 00082428
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Mental Impairment Muscular Weakness Nausea Sensation Of Heaviness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646763-4Report Type:Periodic Company Report #WAES 00082429
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Estrogens	C				

Date:12/26/00ISR Number: 3646764-6Report Type:Periodic Company Report #WAES 00082431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	9 DAY
			Aspirin	C				

Date:12/26/00ISR Number: 3646765-8Report Type:Periodic Company Report #WAES 00082433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
			Celebrex	C				

Date:12/26/00ISR Number: 3646766-XReport Type:Periodic Company Report #WAES 00082434
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Coagulopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Levothroid	C		

Date:12/26/00ISR Number: 3646767-1Report Type:Periodic Company Report #WAES 00082438
Age:100 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3646768-3Report Type:Periodic Company Report #WAES 00051495
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Faeces Discoloured Gastritis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646769-5Report Type:Periodic Company Report #WAES 00051525
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:12/26/00ISR Number: 3646770-1Report Type:Periodic Company Report #WAES 00051665
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Lichen Planus Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Hydrodiuril	C				
			Premarin Vaginal Cream	C				
			Prinivil	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3646771-3Report Type:Periodic Company Report #WAES 00052102
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Goitre Influenza Like Illness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Tab Vioxx	SS		ORAL	PO	
			Premarin	C				
			Synthroid	C				
			Zocor	C				

Date:12/26/00ISR Number: 3646772-5Report Type:Periodic Company Report #WAES 00052132
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3646773-7Report Type:Periodic Company Report #WAES 00052230
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Diarrhoea Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Atacand	C				
			Celebrex	C				
			Norvasc	C				
			Prevacid	C				
			Prilosec	C				

Xanax C

Date:12/26/00ISR Number: 3646774-9Report Type:Periodic Company Report #WAES 00052232
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinusitis Vestibular Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Detrol	C				

Date:12/26/00ISR Number: 3646775-0Report Type:Periodic Company Report #WAES 00052378
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Avapro	C				
			Celexa	C				
			Darvon	C				
			Depakote	C				
			Neurontin	C				
			Nortriptyline	C				

Date:12/26/00ISR Number: 3646776-2Report Type:Periodic Company Report #WAES 00052465
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Synthroid	C		
			Zantac	C		

Date:12/26/00ISR Number: 3646777-4Report Type:Periodic Company Report #WAES 00052474
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Micro K	C		
			Synthroid	C		
			Tenex	C		
			Vasotec	C		
			Atenolol	C		
			Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646778-6Report Type:Periodic Company Report #WAES 00052477
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Gastrointestinal Disorder	Health			Laboratories Div			
	Oedema Peripheral	Professional			Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Celbrex 100 Mg	C			100 MG BID	
			Avapro	C				
			Diovan	C				
			Hydrodiuril	C				

Date:12/26/00ISR Number: 3646779-8Report Type:Periodic Company Report #WAES 00052543
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Dyspepsia	Health			Laboratories Div			
	Headache	Professional			Merck Co Inc	ORAL	SEE IMAGE	
			Fosamax	C				
			Atenolol	C				
			Hydrochlorothiazide (+)Triamter	C				

Date:12/26/00ISR Number: 3646780-4Report Type:Periodic Company Report #WAES 00052589
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
	Urticaria	Professional			Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Levsin	C				

				Proventil	C		
				Vancenase Aq Nasal Spray	C		
				Vanceril	C		

Date:12/26/00ISR Number: 3646781-6Report Type:Periodic Company Report #WAES 00052725
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Premarin	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3646782-8Report Type:Periodic Company Report #WAES 00052791
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646783-XReport Type:Periodic Company Report #WAES 00052812
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Liptior	C				
			Premarin	C				

Date:12/26/00ISR Number: 3646784-1Report Type:Periodic Company Report #WAES 00052878
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukocytoclastic Vasculitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Methadone Hcl	C				
			Synthroid	C				
			Furosemide	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3646785-3Report Type:Periodic Company Report #WAES 00052948
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646786-5Report Type:Periodic Company Report #WAES 00052992
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Delestrogen	C				
			Diazide	C				
			Prozac	C				
			Calcium	C				
			Potassium	C				

Date:12/26/00ISR Number: 3646787-7Report Type:Periodic Company Report #WAES 00053002
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Lotensin	C				
			Tylenol	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3646788-9Report Type:Periodic Company Report #WAES 00102332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coeliac Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646789-0Report Type:Periodic Company Report #WAES 00102335
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health Professional User Facility	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:12/26/00ISR Number: 3646790-7Report Type:Periodic Company Report #WAES 00102337
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646791-9Report Type:Periodic Company Report #WAES 00102346
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Lipitor	C	
Lotensine	C	
Ticlid	C	
Uniphyl	C	
Aspirin	C	
Atenolol	C	
Pentoxifylline	C	

Date:12/26/00ISR Number: 3646792-0Report Type:Periodic Company Report #WAES 00102349
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Prevacid	C				
			Reglan	C				

Date:12/26/00ISR Number: 3646793-2Report Type:Periodic Company Report #WAES 00102351
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG PO

Klonopin	C	
Neurontin	C	
Premarin	C	
Wellbutrin	C	
Calcium	C	
Vitamins	C	

Date:12/26/00ISR Number: 3646794-4Report Type:Periodic Company Report #WAES 00102353
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Nausea							
	Viral Infection				Merck Co Inc	ORAL	25 MG PO	
	Vomiting		Nitroglycerin	C				

Date:12/26/00ISR Number: 3646795-6Report Type:Periodic Company Report #WAES 00102381
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
	Feeling Abnormal				Merck Co Inc	ORAL	50 MG PO	

Date:12/26/00ISR Number: 3646796-8Report Type:Periodic Company Report #WAES 00102382
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Speech Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Ambien	C				

Date:12/26/00ISR Number: 3646797-XReport Type:Periodic Company Report #WAES 00102383
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646798-1Report Type:Periodic Company Report #WAES 00102384
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646799-3Report Type:Periodic Company Report #WAES 00102386
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646800-7Report Type:Periodic Company Report #WAES 00102388
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646801-9Report Type:Periodic Company Report #WAES 00102410
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Macrodantin	C				
			Premarin	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3646802-0Report Type:Periodic Company Report #WAES 00102419
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Health	Vioxx	PS	Merck Research	
	Influenza Like Illness	Professional			Laboratories Div	
	Palpitations				Merck Co Inc	ORAL

PO

Date:12/26/00ISR Number: 3646803-2Report Type:Periodic Company Report #WAES 00102426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nail Disorder	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
					Merck Co Inc	ORAL

PO

	Flonase	C	
	Ranitidine	C	

Date:12/26/00ISR Number: 3646804-4Report Type:Periodic Company Report #WAES 00102429
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Vioxx	PS	Merck Research	
	Dizziness				Laboratories Div	
	Dysphagia				Merck Co Inc	ORAL

UNK/PO

	Face Oedema	Pepcid	C
	Oedema Peripheral	Digoxin	C
		Thyroid	C

Therapy Unspecified C

Date:12/26/00ISR Number: 3646805-6Report Type:Periodic Company Report #WAES 00102432
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				

Date:12/26/00ISR Number: 3646806-8Report Type:Periodic Company Report #WAES 00102434
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Allegra	C				

Date:12/26/00ISR Number: 3646807-XReport Type:Periodic Company Report #WAES 00102436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Polyuria Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 MON
			Hydrodiuril	C				
			Lopid	C				
			Lotensin	C				
			Prinivil	C				

Date:12/26/00ISR Number: 3646808-1Report Type:Periodic Company Report #WAES 00102441
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ditrei	C				
			Premarin	C				
			Prilosec	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3646809-3Report Type:Periodic Company Report #WAES 00102442
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Humulin N	C				
			Lasix	C				
			Zocor	C				
			Albuterol	C				

		Enalapril	C
		Lithium Carbonate	C
		Potassium (Unspecified)	C

Date:12/26/00ISR Number: 3646810-XReport Type:Periodic Company Report #WAES 00102446
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Furosemide	C				

Date:12/26/00ISR Number: 3646811-1Report Type:Periodic Company Report #WAES 00102447
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Circulatory Collapse Fatigue Sensation Of Heaviness Tachycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	

Date:12/26/00ISR Number: 3646812-3Report Type:Periodic Company Report #WAES 00102461
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646813-5Report Type:Periodic Company Report #WAES 00102486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3646814-7Report Type:Periodic Company Report #WAES 00102487
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646815-9Report Type:Periodic Company Report #WAES 00102491
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:12/26/00ISR Number: 3646816-0Report Type:Periodic Company Report #WAES 00102492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:12/26/00ISR Number: 3646817-2Report Type:Periodic Company Report #WAES 00102509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646818-4Report Type:Periodic Company Report #WAES 00102514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646819-6Report Type:Periodic Company Report #WAES 00102515
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	

Date:12/26/00ISR Number: 3646820-2Report Type:Periodic Company Report #WAES 00102528
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Carafate	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646821-4Report Type:Periodic Company Report #WAES 00102549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646822-6Report Type:Periodic Company Report #WAES 00102550
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Accupril	C				
			Coumadin	C				
			Toprol Xl Tablets	C				
			Oxygen	C				

Date:12/26/00ISR Number: 3646823-8Report Type:Periodic Company Report #WAES 00102551
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646824-XReport Type:Periodic Company Report #WAES 00102552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Renal Disorder Merck Co Inc ORAL
25

MG/DAILY/PO

Date:12/26/00ISR Number: 3646825-1Report Type:Periodic Company Report #WAES 00101978
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Lorcet Plus	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3646826-3Report Type:Periodic Company Report #WAES 00102554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Aspirin	C				
			Hydrocodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646827-5Report Type:Periodic Company Report #WAES 00101981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	5 DAY
	Asthenia							
	Fatigue							
			Levoxyl	C				
			Norvasc	C				
			Pravachol	C				
			Prinivil	C				
			Aspirin	C				
			Insulin	C				

Date:12/26/00ISR Number: 3646828-7Report Type:Periodic Company Report #WAES 00102556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				
			Levoxyl	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3646829-9Report Type:Periodic Company Report #WAES 00101982
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Premarin	C				
			)Therapy Unspecified)	C				

Date:12/26/00ISR Number: 3646830-5Report Type:Periodic Company Report #WAES 00102559
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Myalgia							
	Weight Increased				Merck Co Inc	ORAL	PO	
			Composotion Unspecified	C				

Date:12/26/00ISR Number: 3646831-7Report Type:Periodic Company Report #WAES 00101983
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Pruritus	Health Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Klonopin	C				
			Synthroid	C				
			Ultram	C				

Vasotec C

Date:12/26/00ISR Number: 3646832-9Report Type:Periodic Company Report #WAES 00102560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				

Date:12/26/00ISR Number: 3646833-0Report Type:Periodic Company Report #WAES 00101991
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Motrin	C				

Date:12/26/00ISR Number: 3646834-2Report Type:Periodic Company Report #WAES 00101992
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lopid	C				

Date:12/26/00ISR Number: 3646835-4Report Type:Periodic Company Report #WAES 00101995
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Pyrexia Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646836-6Report Type:Periodic Company Report #WAES 00102561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Bentyl	C				
			Minocycline	C				

Date:12/26/00ISR Number: 3646837-8Report Type:Periodic Company Report #WAES 00102569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Oral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	

PO

Levaquin	C
Lopressor	C
Prilosec	C

Date:12/26/00ISR Number: 3646838-XReport Type:Periodic Company Report #WAES 00102570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO

Date:12/26/00ISR Number: 3646839-1Report Type:Periodic Company Report #WAES 00102577
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO

Date:12/26/00ISR Number: 3646840-8Report Type:Periodic Company Report #WAES 00102585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/	PO

Date:12/26/00ISR Number: 3646841-XReport Type:Periodic Company Report #WAES 00102586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646842-1Report Type:Periodic Company Report #WAES 00102595
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646843-3Report Type:Periodic Company Report #WAES 00101996
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Pyrexia Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646844-5Report Type:Periodic Company Report #WAES 00102596
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment Nervous System Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646845-7Report Type:Periodic Company Report #WAES 00101999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646846-9Report Type:Periodic Company Report #WAES 00102597
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646847-0Report Type:Periodic Company Report #WAES 00102000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646848-2Report Type:Periodic Company Report #WAES 00102607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disorder Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646849-4Report Type:Periodic Company Report #WAES 00102624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis Liver Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646850-0Report Type:Periodic Company Report #WAES 00102035
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Lipitor	C				

Date:12/26/00ISR Number: 3646851-2Report Type:Periodic Company Report #WAES 00102036
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Drug Ineffective							
	Dyspnoea							
	Fatigue		Ambien	C				
			Nolvadex	C				
			Paxil	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646852-4Report Type:Periodic Company Report #WAES 00102047
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Pain In Extremity							
			Fosamax	C				
			Lasix	C				
			Xanax	C				
			Digoxin	C				

			Spironolactone	C

Date:12/26/00ISR Number: 3646853-6Report Type:Periodic Company Report #WAES 00102049
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Face Oedema Herpes Simplex Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:12/26/00ISR Number: 3646854-8Report Type:Periodic Company Report #WAES 00102051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646855-XReport Type:Periodic Company Report #WAES 00102055
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nasal Congestion							
	Rhinorrhoea							

Date:12/26/00ISR Number: 3646856-1Report Type:Periodic Company Report #WAES 00102060
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Myalgia							
			Ecotrin	C				
			Tenoretic	C				
			Trental	C				
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3646857-3Report Type:Periodic Company Report #WAES 00102063
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faecal Occult Blood							
	Fatigue							
	Feeling Cold		Ambien	C				
			Premarin	C				
			Prilosec	C				
			Proventil	C				

Date:12/26/00ISR Number: 3646858-5Report Type:Periodic Company Report #WAES 00102655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacrimation Increased Pruritus Scratch	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646859-7Report Type:Periodic Company Report #WAES 00102069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:12/26/00ISR Number: 3646860-3Report Type:Periodic Company Report #WAES 00102660
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Synthrioid 25
Microgm SS ORAL
UNK/UNK/PO

[Therapy
Unspecified] SS
UNK/UNK/UNK

[Therapy
Unspecified] SS
UNK/UNK/UNK

Date:12/26/00ISR Number: 3646861-5Report Type:Periodic Company Report #WAES 00102078
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Joint Stiffness							
			Actigall	C				
			Celebrex	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3646862-7Report Type:Periodic Company Report #WAES 00110003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646863-9Report Type:Periodic Company Report #WAES 00110010
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Darvocet-N C
Premarin C
Provera C

Date:12/26/00ISR Number: 3646864-0Report Type:Periodic Company Report #WAES 00102080
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				

Date:12/26/00ISR Number: 3646865-2Report Type:Periodic Company Report #WAES 00110013
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Motrin	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646866-4Report Type:Periodic Company Report #WAES 00102091
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY
			Naproxen	C				

Date:12/26/00ISR Number: 3646867-6Report Type:Periodic Company Report #WAES 00110014
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/UNK/PO	
			Ativan	C				
			Elavil	C				
			Tylenol	C				
			Atenolol	C				
			Vitamins (Unspecificed)	C				

Date:12/26/00ISR Number: 3646868-8Report Type:Periodic Company Report #WAES 00110020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Lipitor	C				
			Lopressor	C				
			Synthroid	C				

			Zantac	C		

Date:12/26/00ISR Number: 3646869-XReport Type:Periodic Company Report #WAES 00102096
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Oedema Peripheral					
	Urinary Tract Infection					
38 DAY						
	Weight Increased		Ogen	C		
			[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3646870-6Report Type:Periodic Company Report #WAES 00102098
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Nausea					
	Nervousness					ORAL
PO						
			Hypericin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646871-8Report Type:Periodic Company Report #WAES 00110022
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Baycol	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3646873-1Report Type:Periodic Company Report #WAES 00102099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avelox	C				
			Singulair	C				
			Zyrtec	C				
			Prednisone	C				

Date:12/26/00ISR Number: 3646874-3Report Type:Periodic Company Report #WAES 00110587
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Propecia	C				
			Ritalin	C				

Date:12/26/00ISR Number: 3646875-5Report Type:Periodic Company Report #WAES 00102135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646877-9Report Type:Periodic Company Report #WAES 00110588
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Isoptin	C				

Date:12/26/00ISR Number: 3646878-0Report Type:Periodic Company Report #WAES 00102138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:12/26/00ISR Number: 3646879-2Report Type:Periodic Company Report #WAES 00110590
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Arthralgia							
	Dyspepsia				Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:12/26/00ISR Number: 3646881-0Report Type:Periodic Company Report #WAES 00102178
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Other	Vioxx	PS	Merck Research Laboratories Div			
	Hypoaesthesia							
	Pain In Extremity				Merck Co Inc	ORAL	25 MG/1X/PO	
			Imitrex	C				
			Zocor	C				

Date:12/26/00ISR Number: 3646882-2Report Type:Periodic Company Report #WAES 00110592
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/UNK/PO	
			Dyazide	C				
			Premarin	C				
			Provera	C				
			Calcium (Unspecified)	C				
			Glucosamine	C				
			Vitamin E	C				
			Vitamins					

			(Unspecified)	C		

Date:12/26/00ISR Number: 3646884-6Report Type:Periodic Company Report #WAES 00110596
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/QOD/PO						
			Aggrenox	C		
			Atrovent	C		
			Hyzaar	C		
			Luride Lozi-Tabs	C		
			Pravachol	C		
			Thyroxine	C		

Date:12/26/00ISR Number: 3646885-8Report Type:Periodic Company Report #WAES 00102179
Age:83 YR Gender:Male I/FU:I

Outcome	PT
	Abdominal Distension
	Abdominal Pain

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cutivate	C				
	Hyzaar	C				
	Zocor	C				
	Gemfibrozil	C				

Date:12/26/00ISR Number: 3646886-XReport Type:Periodic Company Report #WAES 00110597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3646887-1Report Type:Periodic Company Report #WAES 00102185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646889-5Report Type:Periodic Company Report #WAES 00110598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research			

	Pain				Laboratories Div	
	Pulmonary Congestion				Merck Co Inc	ORAL
UNK/UNK/PO						

Date:12/26/00ISR Number: 3646890-1Report Type:Periodic Company Report #WAES 00110600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Vioxx	PS	Merck Research	
	Blood Pressure Increased				Laboratories Div	
					Merck Co Inc	ORAL
25 MG/UNK/PO						
			Celebrex	C		

Date:12/26/00ISR Number: 3646892-5Report Type:Periodic Company Report #WAES 00102192
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatic Function Abnormal	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
12.5-25						
		Representative				
MG/DAILY/PO						
			Cardizem Cd	C		
			Moduretic	C		

			Prempro	C
			Glyburide	C

Date:12/26/00ISR Number: 3646893-7Report Type:Periodic Company Report #WAES 00110601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
			Celebrex	SS			UNK/UNK/UNK	
			Naproxen	C				

Date:12/26/00ISR Number: 3646894-9Report Type:Periodic Company Report #WAES 00102194
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:12/26/00ISR Number: 3646895-0Report Type:Periodic Company Report #WAES 00110602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3646896-2Report Type:Periodic Company Report #WAES 00102199
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Belladonna	C				

Date:12/26/00ISR Number: 3646897-4Report Type:Periodic Company Report #WAES 00102200
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
	Dry Mouth							
	Face Oedema		Insulin	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646898-6Report Type:Periodic Company Report #WAES 00110604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3646899-8Report Type:Periodic Company Report #WAES 00110605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Indocin	C				
			Vicodin	C				

Date:12/26/00ISR Number: 3646900-1Report Type:Periodic Company Report #WAES 00102207
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan	C				
			Centrum Silver	C				
			Maxzide	C				
			Calcium	C				
			Glucosamine	C				
			Vitamin E	C				

Date:12/26/00ISR Number: 3646901-3Report Type:Periodic Company Report #WAES 00110607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Cozaar	C				
			Lipitor	C				
			Normodyne	C				

Date:12/26/00ISR Number: 3646902-5Report Type:Periodic Company Report #WAES 00102209
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Drug Ineffective							
	Gait Disturbance							
	Muscular Weakness		Cardizem	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646903-7Report Type:Periodic Company Report #WAES 00110608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	6 WK
			..	C				
			...	C				

Date:12/26/00ISR Number: 3646904-9Report Type:Periodic Company Report #WAES 00102218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance Visual Field Defect	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

(SEE IMAGE)

Date:12/26/00ISR Number: 3646905-0Report Type:Periodic Company Report #WAES 00110609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/3WX/PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646907-4Report Type:Periodic Company Report #WAES 00102222
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Indocin	C				

Date:12/26/00ISR Number: 3646908-6Report Type:Periodic Company Report #WAES 00110611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646909-8Report Type:Periodic Company Report #WAES 00102232
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

		Lansoprazole	C	
		Simethicone	C	

Date:12/26/00ISR Number: 3646910-4Report Type:Periodic Company Report #WAES 00110612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646911-6Report Type:Periodic Company Report #WAES 00102236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646912-8Report Type:Periodic Company Report #WAES 00110613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Endocet	C				

Date:12/26/00ISR Number: 3646913-XReport Type:Periodic Company Report #WAES 00110614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646914-1Report Type:Periodic Company Report #WAES 00110615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646916-5Report Type:Periodic Company Report #WAES 00110616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3646918-9Report Type:Periodic Company Report #WAES 00110618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646919-0Report Type:Periodic Company Report #WAES 00110619
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Palpitations		Acetaminophen (+) Codeine	C				

Date:12/26/00ISR Number: 3646920-7Report Type:Periodic Company Report #WAES 00110620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3646922-0Report Type:Periodic Company Report #WAES 00110621
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactose Intolerance	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:12/26/00ISR Number: 3646924-4Report Type:Periodic Company Report #WAES 00110622
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ecotrin	C				

Date:12/26/00ISR Number: 3646925-6Report Type:Periodic Company Report #WAES 00110623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Gastric Disorder		Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646927-XReport Type:Periodic Company Report #WAES 00110624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Voltaren	C				

Date:12/26/00ISR Number: 3646928-1Report Type:Periodic Company Report #WAES 00110625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/4X/PO	

Date:12/26/00ISR Number: 3646929-3Report Type:Periodic Company Report #WAES 00110626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	30 DAY
			Prednisone	C				

Date:12/26/00ISR Number: 3646931-1Report Type:Periodic Company Report #WAES 00110627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			[Therapy Unspecified]	C		

Date:12/26/00ISR Number: 3646932-3Report Type:Periodic Company Report #WAES 00110628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646933-5Report Type:Periodic Company Report #WAES 00110629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646934-7Report Type:Periodic Company Report #WAES 00110630
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646935-9Report Type:Periodic Company Report #WAES 00110159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646936-0Report Type:Periodic Company Report #WAES 00110631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrocodone	C				

Date:12/26/00ISR Number: 3646937-2Report Type:Periodic Company Report #WAES 00110160
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Skin Nodule	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

			Tab Vioxx 25mg	SS		ORAL
UNK/UNK/PO						
			Aspirin	SS		
UNK/UNK/UNK						
			Ibuprofen	SS		
UNK/UNK/UNK						

Date:12/26/00ISR Number: 3646938-4Report Type:Periodic Company Report #WAES 00110646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:12/26/00ISR Number: 3646939-6Report Type:Periodic Company Report #WAES 00110648
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tendon Rupture	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646940-2Report Type:Periodic Company Report #WAES 00110162
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Diarrhoea							
	Face Oedema							
	Oedema Peripheral		Lopressor	C				
	Weight Increased		Premair	C				
			Zantac	C				

Date:12/26/00ISR Number: 3646942-6Report Type:Periodic Company Report #WAES 00110654
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Diarrhoea							
	Nausea							
			Altace	C				
			Plendil	C				
			Zocor	C				

Date:12/26/00ISR Number: 3646943-8Report Type:Periodic Company Report #WAES 00110163
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Capoten	C				
			Synthroid	C				
			Ziac	C				
			Glipizide	C				

Date:12/26/00ISR Number: 3646944-XReport Type:Periodic Company Report #WAES 00110658
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flexeril	C				
			Fosamax	C				
			Pepcid	C				
			Zoloft	C				
			Alprazolam	C				

Date:12/26/00ISR Number: 3646946-3Report Type:Periodic Company Report #WAES 00110166
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Therapy					

Unspecified] C

Date:12/26/00ISR Number: 3646947-5Report Type:Periodic Company Report #WAES 00110694
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON
			[Therapy Unspecified]	C				
			Levothyroxine Sodium	C				
			Nadolol	C				

Date:12/26/00ISR Number: 3646948-7Report Type:Periodic Company Report #WAES 00110169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Eye Irritation Keratoconjunctivitis Sicca	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646949-9Report Type:Periodic Company Report #WAES 00110173
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3646950-5Report Type:Periodic Company Report #WAES 00100427
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Aspirin	C				

Date:12/26/00ISR Number: 3646952-9Report Type:Periodic Company Report #WAES 00110175
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendon Rupture	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646953-0Report Type:Periodic Company Report #WAES 00100430
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatomyositis Systemic Lupus Erythematosus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646955-4Report Type:Periodic Company Report #WAES 00110176
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Company Representative	[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646956-6Report Type:Periodic Company Report #WAES 00100433
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Calan Sr	C				
			Inderal	C				

Date:12/26/00ISR Number: 3646957-8Report Type:Periodic Company Report #WAES 00110182
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO
[Therapy
Unspecified] C

Date:12/26/00ISR Number: 3646959-1Report Type:Periodic Company Report #WAES 00100435
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ibuprofen	C				

Date:12/26/00ISR Number: 3646960-8Report Type:Periodic Company Report #WAES 00100457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Zydone	C				

Date:12/26/00ISR Number: 3646962-1Report Type:Periodic Company Report #WAES 00100464
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:12/26/00ISR Number: 3646964-5Report Type:Periodic Company Report #WAES 00100466
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 50 MG	4 MON
			Aleve	C				
			Hyzaar	C				

Date:12/26/00ISR Number: 3646965-7Report Type:Periodic Company Report #WAES 00100467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646967-0Report Type:Periodic Company Report #WAES 00100468
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:12/26/00ISR Number: 3646968-2Report Type:Periodic Company Report #WAES 00100472
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Upper Respiratory Tract Infection							
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3646971-2Report Type:Periodic Company Report #WAES 00100475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646976-1Report Type:Periodic Company Report #WAES 00100487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:12/26/00ISR Number: 3646977-3Report Type:Periodic Company Report #WAES 00100506
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Vancenase Aq Nasal Spray	C				
			Zocor	C				
			Atenolol	C				
			Cyclobenzaprine Hydrochloride	C				

Date:12/26/00ISR Number: 3646979-7Report Type:Periodic Company Report #WAES 00100523
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
			Elavil	C				
			Lotrel	C				
			Norvasc	C				
			Premarin	C				
			Zocor	C				
			Potassium (Unspecified)	C				

Date:12/26/00ISR Number: 3646981-5Report Type:Periodic Company Report #WAES 00100524
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Tylenol	C				

Date:12/26/00ISR Number: 3646983-9Report Type:Periodic Company Report #WAES 00100526
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Hydrodiuril	C				
			Diltiazem	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646985-2Report Type:Periodic Company Report #WAES 00100568
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	PO
			Aldactazide	C				
			Inderal	C				
			Vasotec	C				
			Aspirin	C				
			Chondroitin (+) Glucosamine	C				

Date:12/26/00ISR Number: 3646986-4Report Type:Periodic Company Report #WAES 00110184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Viral Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3646987-6Report Type:Periodic Company Report #WAES 00110191
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Procardia Xl	C				
			Reglan	C				
			Synthroid	C				

			Nitroglycerin	C
			Potassium Chloride	C

Date:12/26/00ISR Number: 3646988-8Report Type:Periodic Company Report #WAES 00110192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	
			Tab Vioxx	SS		ORAL	25 MG/UNK/PO	

Date:12/26/00ISR Number: 3646990-6Report Type:Periodic Company Report #WAES 00110193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3646992-XReport Type:Periodic Company Report #WAES 00110195
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Dyspnoea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Oedema	Representative						
			Avandia	C				
			Celebrex	C				
			Diovan	C				
			Lasix	C				
			Lopid	C				
			Allopurinol	C				
			Cimetidine	C				
			Digoxin	C				

Date:12/26/00ISR Number: 3646994-3Report Type:Periodic Company Report #WAES 00110339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Premarin	C				

Date:12/26/00ISR Number: 3646996-7Report Type:Periodic Company Report #WAES 00110344
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder Gastrointestinal Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
		Representative						

Date:12/26/00ISR Number: 3646997-9Report Type:Periodic Company Report #WAES 00110346
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Colace	C				
			Fibercon	C				
			Megace	C				
			Paxil	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3646999-2Report Type:Periodic Company Report #WAES 00110347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Actonel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647001-9Report Type:Periodic Company Report #WAES 00110350
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
		Representative	Vicodin	C				

Date:12/26/00ISR Number: 3647004-4Report Type:Periodic Company Report #WAES 00110038
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lescol [Therapy Unspecidied	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3647005-6Report Type:Periodic Company Report #WAES 00110041
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647006-8Report Type:Periodic Company Report #WAES 00110043
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Premarin C

Date:12/26/00ISR Number: 3647007-XReport Type:Periodic Company Report #WAES 00110045
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid [Therapy Unspecified]	C				
			Atenolol	C				

Date:12/26/00ISR Number: 3647008-1Report Type:Periodic Company Report #WAES 00110050
Age:71 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Feeling Abnormal
	Oedema Peripheral

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Glucophage	C				
			Glucotrol	C				
			Pravachol	C				
			Xanax	C				
			Zantac	C				

Date:12/26/00ISR Number: 3647009-3Report Type:Periodic Company Report #WAES 00110059
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Composition Unspecified]	C				

Date:12/26/00ISR Number: 3647010-XReport Type:Periodic Company Report #WAES 00100574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Synthroid	C				

Date:12/26/00ISR Number: 3647011-1Report Type:Periodic Company Report #WAES 00110079
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Pravachol	C				
			Zocor	C				

Date:12/26/00ISR Number: 3647012-3Report Type:Periodic Company Report #WAES 00100581
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	
			Glucophage	C				
			Clucotrol	C				
			Nifedipine	C				
			Triamterene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647013-5Report Type:Periodic Company Report #WAES 00110081
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	5 MON

Date:12/26/00ISR Number: 3647014-7Report Type:Periodic Company Report #WAES 00100582
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:12/26/00ISR Number: 3647018-4Report Type:Periodic Company Report #WAES 00110085
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prednisone	C				

Date:12/26/00ISR Number: 3647019-6Report Type:Periodic Company Report #WAES 00110086
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Malaise	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	

/DAILY/PO

Date:12/26/00ISR Number: 3647021-4Report Type:Periodic Company Report #WAES 00110093
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / DAILY/ PO	
	Gastrooesophageal Reflux Disease							
	Haematochezia							
			Darvocet-N	C				
			Neurontin	C				
			Prevacid	C				
			Serzone	C				
			Skelaxin	C				

Date:12/26/00ISR Number: 3647023-8Report Type:Periodic Company Report #WAES 00110104
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Drug Effect Decreased							
	Joint Effusion							
			Inj Synvisc 2 Ml	SS			WKY/INJ	

Advil	C
Tenex	C

Date:12/26/00ISR Number: 3647025-1Report Type:Periodic Company Report #WAES 00110119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PO	

Date:12/26/00ISR Number: 3647026-3Report Type:Periodic Company Report #WAES 00110124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNK	

Date:12/26/00ISR Number: 3647028-7Report Type:Periodic Company Report #WAES 00110126
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647030-5Report Type:Periodic Company Report #WAES 00110133
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk	Consumer	Vioxx	PS	Merck Research			

	Gait Disturbance				Laboratories Div	
	Headache				Merck Co Inc	ORAL
25 MG/PO						
	Nausea		Norvasc	C		
			Methotrexate	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3647033-0Report Type:Periodic Company Report #WAES 00110134
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25 MG/UNK/PO						
			Celbrex	C		
			Flonase	C		
			Prempro	C		
			Singulair	C		
			Zyrtec	C		
			Albuterol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647035-4Report Type:Periodic Company Report #WAES 00110137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Insomnia		Prempro	C				
			Tiazac	C				
			Calcium (Unspecified)	C				
			Levothyroxine	C				

Date:12/26/00ISR Number: 3647037-8Report Type:Periodic Company Report #WAES 00110149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647039-1Report Type:Periodic Company Report #WAES 00110153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Paxil	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3647044-5Report Type:Periodic Company Report #WAES 00101779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647046-9Report Type:Periodic Company Report #WAES 00101786
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647049-4Report Type:Periodic Company Report #WAES 00101791
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647051-2Report Type:Periodic Company Report #WAES 00101803
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647066-4Report Type:Periodic Company Report #WAES 00101810
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Paxil	C				

Date:12/26/00ISR Number: 3647068-8Report Type:Periodic Company Report #WAES 00101813
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Flutter	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				
			Diazepam	C				
			Digoxin	C				

Date:12/26/00ISR Number: 3647070-6Report Type:Periodic Company Report #WAES 00101816
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Lipitor	C	
Premarin	C	

Date:12/26/00ISR Number: 3647071-8Report Type:Periodic Company Report #WAES 00101819
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

/PO

Cardura	C
Darvocet-N	C
Lanoxin	C
Lasix	C
Normodyne	C
Norvasc	C
Zaroxolyn	C
[Therapy Unspecified]	C
Potassium	

(Unspecified) C

Date:12/26/00ISR Number: 3647073-1Report Type:Periodic Company Report #WAES 00101820
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY/PO	
			Celebrex	C				

Date:12/26/00ISR Number: 3647075-5Report Type:Periodic Company Report #WAES 00101822
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Rash Erythematous	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Climara	C				
			Nasonex	C				
			Zyrtec	C				

Date:12/26/00ISR Number: 3647078-0Report Type:Periodic Company Report #WAES 00101823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea Pharyngitis Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO,	

25

MG/DAILY/PO 5 WKY

Date:12/26/00ISR Number: 3647080-9Report Type:Periodic Company Report #WAES 00101830
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Back Pain					
	Diarrhoea				Merck Co Inc	ORAL
50 MG/UNK/PO						

Date:12/26/00ISR Number: 3647104-9Report Type:Periodic Company Report #WAES 00101834
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
UNK/UNK/PO						
			Synthroid	C		
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647106-2Report Type:Periodic Company Report #WAES 00101835
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Neurontin	C				

Date:12/26/00ISR Number: 3647107-4Report Type:Periodic Company Report #WAES 00101836
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Clonopin	C				
			Tenormin	C				

Date:12/26/00ISR Number: 3647109-8Report Type:Periodic Company Report #WAES 00101850
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avonex	C				
			Dietary Supplement (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/26/00ISR Number: 3647110-4Report Type:Periodic Company Report #WAES 00101879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:12/26/00ISR Number: 3647111-6Report Type:Periodic Company Report #WAES 00101883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3647112-8Report Type:Periodic Company Report #WAES 00101890
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:12/26/00ISR Number: 3647113-XReport Type:Periodic Company Report #WAES 00101897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
	Pain							
	Photosensitivity Reaction							
	Pruritus							

Date:12/26/00ISR Number: 3647114-1Report Type:Periodic Company Report #WAES 00101898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	AM/PO	
			Ascal	C				

Date:12/26/00ISR Number: 3647116-5Report Type:Periodic Company Report #WAES 00101902
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Pruritus							
			Effexor	C			PO	
			Maxzide	C				
			Procardia Xl	C				
			Xalatan	C				

Date:12/26/00ISR Number: 3647118-9Report Type:Periodic Company Report #WAES 00101907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Flatulence							

Date:12/26/00ISR Number: 3647119-0Report Type:Periodic Company Report #WAES 00101909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Pain							
	Paraesthesia							

Date:12/26/00ISR Number: 3647121-9Report Type:Periodic Company Report #WAES 00101919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

	Cardizem	C
	Lipitor	C
	Hydrochlorothiazide + Triamter	C

Date:12/26/00ISR Number: 3647123-2Report Type:Periodic Company Report #WAES 00101921
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Tylenol	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3647125-6Report Type:Periodic Company Report #WAES 00101922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Tylenol	C				

Date:12/26/00ISR Number: 3647126-8Report Type:Periodic Company Report #WAES 00101926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Tylenol Arthritis Extended Relie	C				

Aspirin C

Date:12/26/00ISR Number: 3647127-XReport Type:Periodic Company Report #WAES 00101930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Premarin	C				

Date:12/26/00ISR Number: 3647128-1Report Type:Periodic Company Report #WAES 00101936
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647129-3Report Type:Periodic Company Report #WAES 00101951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Lomotil	C				
			Premarin	C				
			Reglan	C				
			Synthroid	C				
			Iron (Unspecified)	C				

Date:12/26/00ISR Number: 3647130-XReport Type:Periodic Company Report #WAES 00101953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Diuretic (Unspecified)	C				
			Hormones (Unspecified)	C				

Date:12/26/00ISR Number: 3647131-1Report Type:Periodic Company Report #WAES 00101956
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothermia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Slow-Mag	C				
			Verapamil Hydrochloride	C				

Date:12/26/00ISR Number: 3647132-3Report Type:Periodic Company Report #WAES 00101957
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Pravachol	C				

Date:12/26/00ISR Number: 3647133-5Report Type:Periodic Company Report #WAES 00101960
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
			Antimicrobial (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647134-7Report Type:Periodic Company Report #WAES 00101961
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				

Date:12/26/00ISR Number: 3647135-9Report Type:Periodic Company Report #WAES 00101963
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lanoxin	C				

Date:12/26/00ISR Number: 3647136-0Report Type:Periodic Company Report #WAES 00101969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Betagan	C				
			Lipitor	C				
			Xalatan	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3647137-2Report Type:Periodic Company Report #WAES 00101975
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Verapamil Msd Lp	C				

Date:12/26/00ISR Number: 3647138-4Report Type:Periodic Company Report #WAES 00101977
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3647385-1Report Type:Periodic Company Report #WAES 00110697
Age:70 YR Gender:Female I/FU:I

Outcome	PT
	Diabetes Mellitus Inadequate Control Eye Irritation

	Face Oedema Keratoconjunctivitis Sicca	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/ PO

Date:12/26/00ISR Number: 3647388-7Report Type:Periodic Company Report #WAES 00110698
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Premarin	C			
			Prozac	C			
			Dextropropoxyphene	C			
			Diazepam	C			

Date:12/26/00ISR Number: 3647389-9Report Type:Periodic Company Report #WAES 00110707
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK / PO
			Tab Vioxx 12.5 Mg	SS		ORAL	UNK / UNK / PO
			Coumadin	C			
			Glucophage	C			
			Lasix	C			

			Levoxyl	C		
			Toprol Xl Tablets	C		
			Captopril	C		

Date:12/26/00ISR Number: 3647390-5Report Type:Periodic Company Report #WAES 00110709
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research	
	Abdominal Pain				Laboratories Div	
	Eating Disorder				Merck Co Inc	ORAL
UNK / UNK /						
	Haemorrhage					
PO 1 WK						
	Micturition Disorder		Valium	C		
	Oedema Peripheral					
	Urinary Tract Infection					
	Urine Abnormality					
	Urogenital Disorder					

Date:12/26/00ISR Number: 3647391-7Report Type:Periodic Company Report #WAES 00110714
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
UNK / UNK /

PO

Date:12/26/00ISR Number: 3647392-9Report Type:Periodic Company Report #WAES 00110715
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK /	

PO

Date:12/26/00ISR Number: 3647393-0Report Type:Periodic Company Report #WES 00110718
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Hyperhidrosis Muscular Weakness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PRN/	
			Antineoplastic	C				

PO

Date:12/26/00ISR Number: 3647398-XReport Type:Periodic Company Report #WAES 00110728
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/	
			Cardizem Cd	C				

PO

Lasix	C
Zestril	C
Zosyn	C
Heparin	C
Hydralazine	C
Insulin	C
Rifampin	C
Vancomycin	C

Date:12/26/00ISR Number: 3647402-9Report Type:Periodic Company Report #WAES 00110733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK/ PO	

Date:12/26/00ISR Number: 3647404-2Report Type:Periodic Company Report #WAES 00110744
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647529-1Report Type:Periodic Company Report #WAES 00082213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647530-8Report Type:Periodic Company Report #WAES 00082215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647532-1Report Type:Periodic Company Report #WAES 00082217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647533-3Report Type:Periodic Company Report #WAES 00082302
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Cipro	C		
			Prinivil	C		
			Uniphyl	C		
			Albuterol	C		
			Cromolyn Sodium	C		
			Prednisone	C		

Date:12/26/00ISR Number: 3647534-5Report Type:Periodic Company Report #WAES 00082304
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Prevacid	C				
			Captopril (+)					
			Hydrochlorothiazid	C				
			Metoprolol Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3647545-XReport Type:Periodic Company Report #WAES 00082307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:12/26/00ISR Number: 3647564-3Report Type:Periodic Company Report #WAES 00082314
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:12/26/00ISR Number: 3647566-7Report Type:Periodic Company Report #WAES 00082315
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline Phosphatase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647567-9Report Type:Periodic Company Report #WAES 00082316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:12/26/00ISR Number: 3647568-0Report Type:Periodic Company Report #WAES 00082342
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research	
	Oedema Peripheral	Health			Laboratories Div	
	Pain In Extremity	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Singulair	C		

Date:12/26/00ISR Number: 3647612-0Report Type:Periodic Company Report #WAES 00082162
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
PO						
			Prilosec	C		

Date:12/26/00ISR Number: 3647615-6Report Type:Periodic Company Report #WAES 00082166
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bruxism	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3647617-XReport Type:Periodic Company Report #WAES 00082170
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dermatitis Dyspnoea Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3647619-3Report Type:Periodic Company Report #WAES 00082173
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Insomnia Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Allegra	C				
			Lipitor	C				
			Minocycline	C				

Date:12/26/00ISR Number: 3647620-XReport Type:Periodic Company Report #WAES 00082177
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research			

Dry Mouth
Hyperhidrosis
Tremor

					Laboratories Div	
					Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Soma	C		

Date:12/26/00ISR Number: 3647621-1Report Type:Periodic Company Report #WAES 00082178
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Eye Disorder				Laboratories Div			
	Fatigue				Merck Co Inc	ORAL	25 MG/PO	
	Oedema		Desyrel	C				
			Neurontin	C				
			Prozac	C				
			Requip	C				

Date:12/26/00ISR Number: 3647622-3Report Type:Periodic Company Report #WAES 00082182
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research			
	Feeling Drunk	Health			Laboratories Div			
	Movement Disorder	Professional			Merck Co Inc	ORAL	PO	4 DAY

			Hydrodiuril	C
			Aspirin	C

Date:12/26/00ISR Number: 3647623-5Report Type:Periodic Company Report #WAES 00082184
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Normodyne	C				
			Norvasc	C				
			Premarin	C				

Date:12/26/00ISR Number: 3647624-7Report Type:Periodic Company Report #WAES 00082195
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	9 WK
			Maxzide	C				
			Premarin	C				

Date:12/26/00ISR Number: 3647625-9Report Type:Periodic Company Report #WAES 00082198
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

			Synthroid	C		
			Hormones			
			(Unspecified)	C		

Date:12/26/00ISR Number: 3647948-3Report Type:Periodic Company Report #WAES 99102339
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS				
			Iron (Unspecified)	C				
			Vitamins	C				

Date:12/26/00ISR Number: 3647950-1Report Type:Periodic Company Report #WAES 99120220
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Prozac	C		

Date:12/26/00ISR Number: 3647952-5Report Type:Periodic Company Report #WAES 99120562
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DIALY/PO; 12.5 MG/BID/PO; 25 MG/BID/PO	

Date:12/26/00ISR Number: 3647955-0Report Type:Periodic Company Report #WAES 99120753
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Promethazine W/Dm	C				
			Relafen	C				
			Talwin	C				
			Ultran	C				
			Zanaflex	C				
			[Therapy Unspecified]	C				

Date:12/26/00ISR Number: 3647973-2Report Type:Periodic Company Report #WAES 00102307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		SEE IMAGE	1 WK
			Lipitor	C				

Date:12/26/00ISR Number: 3647974-4Report Type:Periodic Company Report #WAES 00102310
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Loestrin	C				
			Synthroid	C				
			Wellbutrin	C				

Date:12/26/00ISR Number: 3647975-6Report Type:Periodic Company Report #WAES 00102315
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Ambien	C	
Elavil	C	
Vicodin Tablets	C	
Ibuprofen	C	

Date:12/26/00ISR Number: 3647976-8Report Type:Periodic Company Report #WAES 00102319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cardura	C				
			Mevacor	C				
			Proscar	C				

Date:12/26/00ISR Number: 3647978-1Report Type:Periodic Company Report #WAES 00102323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:12/26/00ISR Number: 3647979-3Report Type:Periodic Company Report #WAES 00102325
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID PO	
			Diovan	C				

			Prevacid	C		
			Zocor	C		
			Amiodarone	C		
			Aspirin	C		

Date:12/26/00ISR Number: 3647981-1Report Type:Periodic Company Report #WAES 00102327
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Endocet	C				
			Prilosec	C				

Date:12/26/00ISR Number: 3647984-7Report Type:Periodic Company Report #WAES 00102328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY

K-Dur	C
Lasix	C
Lipitor	C
Prozac	C
Xanax	C
Zantac	C
Zestril	C

Date:12/26/00ISR Number: 3647986-0Report Type:Periodic Company Report #WAES 00102329
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Lipitor	C				

Date:12/26/00ISR Number: 3647988-4Report Type:Periodic Company Report #WAES 00102331
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Ibuprofen	C				

Date:12/26/00ISR Number: 3648365-2Report Type:Periodic Company Report #WAES 00082127
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	

Cardura	C		
Hyzaar	C		
Tricloryl	C		
Zocor	C		

Date:12/26/00ISR Number: 3648368-8Report Type:Periodic Company Report #WAES 00082130
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Dyspepsia	Professional			Merck Co Inc	ORAL	12.5 MG/AM/PO	
	Fatigue		Allegra	C				
	Headache		Zyrtec	C				
	Oedema Peripheral		Therapy Unspecified	C				
	Pruritus							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3648370-6Report Type:Periodic Company Report #WAES 00082132
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3648372-XReport Type:Periodic Company Report #WAES 00082135
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acular	C				
			Synthroid	C				
			Timoptic	C				
			Glucosamine	C				

Date:12/26/00ISR Number: 3648375-5Report Type:Periodic Company Report #WAES 00082139
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Carafate	C				
			Famciclovir	C				
			Therapy Unspecified	C				

Date:12/26/00ISR Number: 3648376-7Report Type:Periodic Company Report #WAES 00082150
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Amaryl	C				
			Synthroid	C				
			Aspirin	C				

Date:12/26/00ISR Number: 3648379-2Report Type:Periodic Company Report #WAES 00082153
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Duragesic	C				
			Ecotrin	C				
			Fosamax	C				
			Humulin	C				
			Lasix	C				
			Lopressor	C				

Metamucil	C
Prilosec	C
Prinivil	C
Vicodin Tablets	C
Vicodin Forte	C
Zocor	C
Calcium Supplemet	C
Iron	C
Prednisone	C

Date:12/26/00ISR Number: 3648381-0Report Type:Periodic Company Report #WAES 00082159
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Librium	C				
			Pravachol	C				

Date:12/26/00ISR Number: 3648383-4Report Type:Periodic Company Report #WAES 00082160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Muscular Weakness Panic Disorder Without Agoraphobia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins	C				

Date:12/26/00ISR Number: 3648386-XReport Type:Periodic Company Report #WAES 00082161
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research			

Syncope
Laboratories Div
Merck Co Inc ORAL
PO
Tramadol
Hydrochloride C

Date:12/26/00ISR Number: 3648525-0Report Type:Periodic Company Report #WAES 00102237
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Estrace	C				
			Provera	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3648526-2Report Type:Periodic Company Report #WAES 00102247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS		ORAL	PO	

Date:12/26/00ISR Number: 3648528-6Report Type:Periodic Company Report #WAES 00102273
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lescol	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3648530-4Report Type:Periodic Company Report #WAES 00102282
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/26/00ISR Number: 3648533-XReport Type:Periodic Company Report #WAES 00102284
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Vioxx	PS	Merck Research			

	Haemorrhage	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL PO

Date:12/26/00ISR Number: 3648534-1Report Type:Periodic Company Report #WAES 00102295
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Vasotec	C				

Date:12/26/00ISR Number: 3648536-5Report Type:Periodic Company Report #WAES 00102297
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Normal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/00ISR Number: 3648537-7Report Type:Periodic Company Report #WAES 00102298
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:12/26/00ISR Number: 3648540-7Report Type:Periodic Company Report #WAES 00102302
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Pharyngeal Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix	C				

Date:12/26/00ISR Number: 3648541-9Report Type:Periodic Company Report #WAES 00102303
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Monopril	C				
			Prilosec	C				
			Synthroid	C				

Date:12/26/00ISR Number: 3649625-1Report Type:Periodic Company Report #WAES 00091492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			[Thearapy Unspecified]	C				
			Calcium (Unspecified)	C				

Date:12/27/00ISR Number: 3637669-5Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx 12.5mg	PS		ORAL	12.5M QD	
Initial or Prolonged	Congestive						ORAL	
	Oedema Peripheral		Hctz	C				
	Pleural Effusion		Vasotec	C				
			Glipizide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/00ISR Number: 3637737-8Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx 50mg Merck	PS	Merck	ORAL	50MG 1 PER	
	Faecal Incontinence						DAY ORAL	
	Motor Dysfunction							
	Urinary Incontinence							
	Vomiting							

Date:12/27/00ISR Number: 3637763-9Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx 12.5 Mgms					
Hospitalization -	Bronchospasm		Merck	PS	Merck	ORAL	1 QD PO	
Initial or Prolonged	Circulatory Collapse		Celebrex 100 Mgms					
Disability	Dyspnoea		Mfr Unk	SS		ORAL	1 QD PO	
	Myocardial Infarction		Aspirin	C				
	Sciatica							
	Speech Disorder							
	Tinnitus							

Date:12/28/00ISR Number: 3638069-4Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx 50 Mg & 25					
Initial or Prolonged	Perforation		Mg Merck	PS	Merck	ORAL	SEE IMAGE /	
	Lower Respiratory Tract						ORAL	
	Infection							

Date:12/28/00ISR Number: 3638081-5Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG QD PO	
	Blood Pressure Increased		Monopril	C				
			Synthroid	C				
			Coumadin	C				

Date:12/28/00ISR Number: 3639925-3Report Type:Expedited (15-DaCompany Report #WAES 00102583
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:12/29/00ISR Number: 3639670-4Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS			50 MG QD	
			Lasix	C				
			Mvi	C				
			K Supp	C				

Zantac	C
Hemocyte	C
Tylenol	C
Mom	C
Maalox	C
Percocet	C
Levaquin	C

Date:01/02/01ISR Number: 3640338-9Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS			12.5 MG DAILY	
Hospitalization - Initial or Prolonged	Dialysis Renal Failure							
Disability	Urinary Tract Infection							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/02/01ISR Number: 3640416-4Report Type:Expedited (15-DaCompany Report #WAES 00121820
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Optic Ischaemic Neuropathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/02/01ISR Number: 3640417-6Report Type:Expedited (15-DaCompany Report #WAES 00121762
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Hypotension Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged Renal Tubular Necrosis Company Merck Co Inc ORAL
50 MG/
Disability Representative
DAILY/PO
Other

Date:01/02/01ISR Number: 3640433-4Report Type:Expedited (15-DaCompany Report #WAES 00121805
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO		Representative				

Date:01/02/01ISR Number: 3640434-6Report Type:Expedited (15-DaCompany Report #WAES 00121837
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
	Hypotension				Merck Co Inc	
			Synthroid	C		

			Zanaflex	C
			Diazepam	C
			Diethylcarbamazine	C
			Metoclopramide	C
			Morphine	C

Date:01/02/01ISR Number: 3640435-8Report Type:Expedited (15-DaCompany Report #WAES 00121756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Bile Duct Obstruction							
	Blood Bilirubin Increased							
	Obstruction							
	Pancreatic Disorder							

Date:01/02/01ISR Number: 3640436-XReport Type:Expedited (15-DaCompany Report #WAES 00121742
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Congestive							
	Syncope							
			Fosamax	C				
			Xanax	C				
			Ziac	C				

Date:01/02/01ISR Number: 3640437-1Report Type:Expedited (15-DaCompany Report #WAES 00121790
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Arthotec	C
			Motrin	C

Date:01/02/01ISR Number: 3640438-3Report Type:Expedited (15-DaCompany Report #WAES 00121433
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/02/01ISR Number: 3640441-3Report Type:Expedited (15-DaCompany Report #WAES 00121715
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bone Pain Diarrhoea Dry Mouth Face Oedema Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO (SEE IMAGE)	

			Maxzide	C		
			Therapy Unspecified	C		
			Atenolol	C		

Date:01/02/01ISR Number: 3640803-4Report Type:Expedited (15-DaCompany Report #WAES 00117525
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Captopril	C				
			Furosemide	C				
			Omeprazole	C				
			Paroxetine	C				
			Propoxyphene Hcl	C				

Date:01/02/01ISR Number: 3640804-6Report Type:Expedited (15-DaCompany Report #WAES 00125620
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased Dizziness Urticaria	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY

Date:01/02/01ISR Number: 3640805-8Report Type:Expedited (15-DaCompany Report #WAES 00125120
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Dyspepsia Microcytic Anaemia	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	17 DAY
			Ranitidine	C				

Date:01/02/01ISR Number: 3640838-1Report Type:Expedited (15-DaCompany Report #WAES 00120145
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Disability	Congestive	Professional			Laboratories Div			
Other	Condition Aggravated	Company			Merck Co Inc	ORAL	25	
	Pulmonary Oedema	Representative					MG/DAILY//PO	
			Lanoxin	C				
			Lasix	C				
			Toprol Xl	C				
			Allopurinol	C				
			Ferrous Gluconate	C				

Date:01/02/01ISR Number: 3640851-4Report Type:Expedited (15-DaCompany Report #WAES 00112304
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Unevaluable Event	Consumer	Vioxx	PS	Merck Research			
Other		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/02/01ISR Number: 3640865-4Report Type:Expedited (15-DaCompany Report #WAES 00121762
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Hypotension Renal Failure Acute Renal Tubular Necrosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:01/02/01ISR Number: 3640867-8Report Type:Expedited (15-DaCompany Report #WAES 00121854
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin	C				

Date:01/02/01ISR Number: 3640955-6Report Type:Expedited (15-DaCompany Report #WAES 00125597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Blood Pressure Increased Weight Increased	Foreign Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:01/02/01ISR Number: 3640956-8Report Type:Expedited (15-DaCompany Report #WAES 00125627
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Condition Aggravated	Foreign	Vioxx	PS	Merck Research		
Hospitalization -	Fluid Retention	Other			Laboratories Div		
Initial or Prolonged	Renal Impairment				Merck Co Inc	ORAL	
4 DAY							

Date:01/02/01ISR Number: 3640957-XReport Type:Expedited (15-DaCompany Report #WAES 00128912
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Foreign	Vioxx	PS	Merck Research			
	Dyspnoea	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG	
		Other	Imidapril	C				
			Verapamil	C				

Date:01/02/01ISR Number: 3640973-8Report Type:Expedited (15-DaCompany Report #WAES 00107313
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Dyspnoea	Other			Laboratories Div			
	Metabolic Acidosis				Merck Co Inc	ORAL	PO	
			Cefuroxime Sodium	C				
			Floxacillin Sodium	C				

Date:01/02/01ISR Number: 3640974-XReport Type:Expedited (15-DaCompany Report #WAES 00129755
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:01/02/01ISR Number: 3640978-7Report Type:Expedited (15-DaCompany Report #WAES 00126115
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain	Foreign Study Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO; 25 MG, PO	11 DAY
			Bisoprolol Fumarate	C				

Date:01/02/01ISR Number: 3641112-XReport Type:Expedited (15-DaCompany Report #WAES 00129755
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:01/02/01ISR Number: 3641114-3Report Type:Expedited (15-DaCompany Report #WAES 00129755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged		Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG		Other				

Date:01/02/01ISR Number: 3641119-2Report Type:Expedited (15-DaCompany Report #WAES 00129016
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Haemorrhage	Foreign	Vioxx	PS	Merck Research	
	Proctitis	Health			Laboratories Div	
	Rectal Tenesmus	Professional			Merck Co Inc	ORAL
31 DAY						
		Other	Pantoprazole	C		

Date:01/02/01ISR Number: 3641120-9Report Type:Expedited (15-DaCompany Report #WAES 00129763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypersensitivity	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
2 DAY						
		Other				

Date:01/02/01ISR Number: 3641122-2Report Type:Expedited (15-DaCompany Report #WAES 00129823
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	7 DAY
		Other	Aspirin	C				
			Spironolactone	C				

Date:01/02/01ISR Number: 3641127-1Report Type:Expedited (15-DaCompany Report #WAES 00125633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	50 DAY
		Other	Mevacor	C				
			Aspirin	C				
			Corticosteroids (Unspecified)	C				
			Methotrexate	C				

Date:01/02/01ISR Number: 3641133-7Report Type:Expedited (15-DaCompany Report #WAES 00129763
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Stress	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Other	Loratadine	C				
			Prednisone	C				

Date:01/02/01ISR Number: 3641136-2Report Type:Expedited (15-DaCompany Report #WAES 00115616
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma Prothrombin Time Ratio Decreased	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO, 25 MG PO	61 DAY
			Phenprocoumon	C				
			Tramadol Hcl	C				

Date:01/02/01ISR Number: 3641138-6Report Type:Expedited (15-DaCompany Report #WAES 00125561
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Perforation Gastric Ulcer	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	22 DAY
			Doxepin Hcl	C				
			Furosemide	C				
			Lactulose	C				
			Nonsteroidal Anti-Inflammatory Drug (Uns	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/01ISR Number: 3654492-6Report Type:Periodic Company Report #200021101US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Leflunomide (Arava)					
	Thyroid Disorder	Professional	Tablets	PS		ORAL	20 MG QD PO	
	Weight Increased		Leflunomide(Arava)					
			Tablets	SS		ORAL	20 MG QD PO	
			Rofecoxib (Vioxx)	SS			50 MG	
			Paroxetine Hydrochloride (Paxil)	C				
			Zaleplon (Sonata)	C				
			Trazodone	C				
			Diazepam (Valium)	C				

Date:01/04/01ISR Number: 3640924-6Report Type:Expedited (15-DaCompany Report #251642
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Torasemid	PS	Roche			
Initial or Prolonged	Congestive	Professional	Carvedilol	SS	Roche			
	Condition Aggravated		Losartan	SS			34 DAY	
			Rofecoxib	SS				

Date:01/05/01ISR Number: 3641953-9Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Lotronex	PS			1 MG TWICE	
Hospitalization -	Diarrhoea Haemorrhagic						DAILY	
Initial or Prolonged			Vioxx	SS			25 MG	
Required								

Intervention to
Prevent Permanent
Impairment/Damage

Date:01/05/01ISR Number: 3641960-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx (25mg)	PS		ORAL	PO QD	

Date:01/05/01ISR Number: 3641962-XReport Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Mucosal Blistering		Vioxx (25mgm)	PS		ORAL	QD PO	14 DAY
	Pain		Synthroid	C				
			Estrogen Patch	C				

Date:01/05/01ISR Number: 3642560-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Purpura		Vioxx 25mg Merck	PS	Merck	ORAL	1 PO	QD

Date:01/05/01ISR Number: 3642651-8Report Type:Expedited (15-DaCompany Report #251642
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Pulmonary Congestion	Foreign Study Health Professional	Demadex	PS	Hoffmann La Roche Inc	ORAL	2.5 MG 1 PER DAY	ORAL
			Carvedilol (Carvedilol)	SS		ORAL	3.125 MG 2 PER DAY	ORAL
			Losartan (Losartan Potassium)	SS		ORAL	50 MG 1 PER DAY	ORAL
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG 1 PER DAY	ORAL

Date:01/05/01ISR Number: 3642661-0Report Type:Expedited (15-DaCompany Report #WAES 00128238
Age:86 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia	Foreign Literature Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	30	DAY

Other

Date:01/05/01ISR Number: 3642663-4Report Type:Expedited (15-DaCompany Report #WAES 00028205
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Antidiuretic Hormone Decreased Hyponatraemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	28 DAY
			Hydrodiuril (Hydrochlorothiazide) Indapamide	SS C		ORAL		

Date:01/05/01ISR Number: 3642664-6Report Type:Expedited (15-DaCompany Report #WAES 00125173
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Confusional State
	Cough
	Decreased Appetite
	Dehydration
	Dyspnoea
	Ecchymosis
	Fatigue
	Hepatic Failure

		Hyponatraemia Inappropriate Antidiuretic Hormone	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Secretion	Foreign	Vioxx	PS	Merck Research	
		Lung Infiltration	Other			Laboratories Div	
		Rash Pruritic				Merck Co Inc	ORAL
12.5 MG	4 DAY						
		Sedation		Acetaminophen/Propoxyphene Hydrochloride	C		
		Vasculitis		Omeprazole	C		
				Temazepam	C		

Date:01/05/01ISR Number: 3642667-1Report Type:Expedited (15-DaCompany Report #WAES 00105622
Age:79 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Condition Aggravated	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Diverticulum Intestinal	Health			Laboratories Div	
Initial or Prolonged		Haemorrhagic	Professional			Merck Co Inc	ORAL
		Oesophagitis	Other	Amantadine Sulfate	SS		
				Bisoprolol Fumarate	C		
				Calcium Supplement (Unspecified)	C		
				Lactulose	C		
				Melperone Hcl	C		
				Omeprazole	C		
				Piracetam	C		
				Valproate Sodium	C		

Date:01/05/01ISR Number: 3642674-9Report Type:Expedited (15-DaCompany Report #WAES 00123782
Age:87 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Sudden Death	Foreign	Vioxx	PS	Merck Research	
Hospitalization -			Health			Laboratories Div	
Initial or Prolonged			Professional			Merck Co Inc	ORAL
12.5 MG	8 DAY						
			Other	Acetaminophen	C		
				Aspirin	C		
				Calcium Carbonate	C		

			Chlorthalidone	C		
			Etidronate Disodium	C		
			Lactulose	C		
			Piracetam	C		
			Prednisolone	C		

Date:01/05/01ISR Number: 3642684-1Report Type:Expedited (15-DaCompany Report #WAES 00119006
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	13 DAY
			Amiloride Hydrochloride/Hctz	C				
			Gemfibrozil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/01ISR Number: 3642685-3Report Type:Expedited (15-DaCompany Report #WAES 00115558
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	78 DAY
			Nifedipine	C				
			Torsemide	C				

Date:01/05/01ISR Number: 3642697-XReport Type:Expedited (15-DaCompany Report #WAES 00122078
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Upper Faeces Discoloured	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Gastric Ulcer							
	Gastrointestinal Disorder		Cap Celebrex	SS		ORAL	200 MG/BID/PO	
	Gastrointestinal Haemorrhage Haematemesis Weight Decreased		Fosamax	C				
			Hydrodiuril	C				
			Zantac	C				
			Acetaminophen	C				
			Calcium	C				
			Codeine Phosphate	C				
			Dextropropoxyphene	C				
			Estrogens, Conjugated	C				
			Ranitidine Hydrochloride	C				
			Salcatonin	C				
			Tramadol Hydrochloride	C				
			Triamterene	C				

Date:01/05/01ISR Number: 3642702-0Report Type:Expedited (15-DaCompany Report #WAES 00122196
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dyspepsia	Professional			Laboratories Div			
Initial or Prolonged	Gastric Ulcer				Merck Co Inc	ORAL	25	
Other	Haematocrit Decreased						MG/DAILY/PO	
	Haemoglobin Decreased		Tab Vioxx 12.5 Mg	SS		ORAL	12.5	
	Hiatus Hernia						MG/DAILY/PO	
	Melaena		Haloperidol	C				
	Oesophagitis							

Date:01/05/01ISR Number: 3642707-XReport Type:Expedited (15-DaCompany Report #WAES 00111853
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alveolitis Allergic	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Chest X-Ray Abnormal	Professional			Laboratories Div			
	Dyspnoea	Other			Merck Co Inc	ORAL	12.5	
	Hypoxia						MG/DAILY/PO	
	Pain							
	Pyrexia							
	Rash Generalised							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/01ISR Number: 3642710-XReport Type:Expedited (15-DaCompany Report #WAES 00121521
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							
	Rash Generalised							

Date:01/05/01ISR Number: 3642877-3Report Type:Expedited (15-DaCompany Report #WAES 00052239
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Arthralgia							
	Colonic Polyp							
	Difficulty In Walking							
	Dyssomnia		Mk-0966 50 Mg	SS		ORAL	50 MG/DAILY/PO	
	Faecal Occult Blood							
	Positive		Acetaminophen	SS			325 MG/PRN	
	Gastrointestinal Ulcer		Glucotrol Xl	C				
	Limb Discomfort		Hydroiuril	C				
	Restless Legs Syndrome		Synthroid	C				
			Ferrous Gluconate	C				
			Hydroxychloroquine	C				
			Methotrexate	C				

Date:01/08/01ISR Number: 3642612-9Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis		Prinivil 10mg Qd	PS		ORAL	PO DAILY	
			Vioxx 25mg Qd	SS		ORAL	PO DAILY	

			Morphine	C		
			Dilaudid	C		
			Compazine	C		
			Ventolin	C		
			Heparin	C		

Date:01/08/01ISR Number: 3643630-7Report Type:Expedited (15-DaCompany Report #WAES 00102347
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Gallbladder Perforation	Health			Laboratories Div	
	Gastritis	Professional			Merck Co Inc	ORAL
50						
	Urinary Tract Infection					
MG/DAILY/PO						
			Celebrex	C		
			Darvocet-N	C		
			Elavil	C		
			Lortab	C		
			Motrin	C		
			Naprosyn	C		
			Soma	C		
			Ultram	C		
			Zantac	C		
			Methadone Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/08/01ISR Number: 3643659-9Report Type:Expedited (15-DaCompany Report #WAES 00111637
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Drug Interaction Drug Toxicity Gastrointestinal Haemorrhage International Normalised Ratio Increased Laboratory Test Abnormal Prothrombin Time Prolonged	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Coumadin	SS		ORAL	5 MG DAILY PO	

Date:01/08/01ISR Number: 3643662-9Report Type:Expedited (15-DaCompany Report #WAES 00110565
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Asthenia Binocular Eye Movement Disorder Clonic Convulsion Disorientation Extrapyramidal Disorder Fatigue Lethargy Movement Disorder Pupillary Disorder Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				

Date:01/08/01ISR Number: 3643663-0Report Type:Expedited (15-DaCompany Report #WAES 00122232
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Aspirin	C				

Date:01/08/01ISR Number: 3643667-8Report Type:Expedited (15-DaCompany Report #WAES 01010065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous Accidental Exposure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Indocin (Indomethacin)	C				

Date:01/08/01ISR Number: 3643852-5Report Type:Expedited (15-DaCompany Report #WAES 00126780
Age:70 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Thromboplastin Decreased

		Drug Interaction Haemarthrosis Haematoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	28 DAY						
			Other	Warfarin	SS		ORAL
PO							
				Vasotec	C		
				Furosemide	C		
				Temazepam	C		
				Verapamil	C		

Date:01/08/01ISR Number: 3643864-1Report Type:Expedited (15-DaCompany Report #WAES 00125584
Age:85 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain C-Reactive Protein Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO							
		Diverticulitis Gastric Ulcer Haemorrhage Haemoglobin Decreased Red Blood Cell Sedimentation Rate Increased Weight Decreased White Blood Cell Count Decreased	Other	Allopurinol	C		
				Calcium Carbonate (+) Cholecalciferol			
				(+	C		
				Captopril	C		
				Certoparin Sodium	C		
				Nizatidine	C		
				Oxycodone Hcl	C		
				Pentoxifylline	C		
				Tolperisone Hcl	C		

Date:01/08/01ISR Number: 3643867-7Report Type:Expedited (15-DaCompany Report #WAES 00125567
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Iron Decreased Embolism	Foreign Study	Vioxx	PS	Merck Research Laboratories Div	

	Gastric Ulcer Haemorrhage	Health			Merck Co Inc	ORAL	
75 MG PO	10 DAY						
	Haemoglobin Decreased	Professional	Pantoprazole Sodium	C			
	Medication Error	Other	Tramadol	C			
	Overdose						

Date:01/08/01ISR Number: 3643876-8Report Type:Expedited (15-DaCompany Report #WAES 00128912
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Foreign	Vioxx	PS	Merck Research			
	Dyspnoea	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG PO	
		Other	Imidapril	C				
			Verapamil	C				

Date:01/08/01ISR Number: 3643880-XReport Type:Expedited (15-DaCompany Report #WAES 00123782
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Death	Sudden Death	Foreign
		Health

Professional
Other

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY
Acetaminophen	C				
Aspirin	C				
Calcium Carbonate	C				
Chlorthalidone	C				
Etidronate Disodium	C				
Lactulose	C				
Piracetam	C				
Prednisolone	C				

Date:01/08/01ISR Number: 3643891-4Report Type:Expedited (15-DaCompany Report #WAES 00117529
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Blood Immunoglobulin E Increased							
	Hypotension	Other	Captopril	C				
	Peripheral Vascular Disorder		Triazolam	C				
	Tachycardia							

Date:01/08/01ISR Number: 3643899-9Report Type:Expedited (15-DaCompany Report #WAES 00126191
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 PO	45 DAY
		Other	Fenoprofen	SS		ORAL	PO	
			Acetaminophen	C				

			Allopurinol	C
			Digoxin	C
			Furosemide	C
			Potassium (Unspecified)	C

Date:01/08/01ISR Number: 3643907-5Report Type:Expedited (15-DaCompany Report #WAES 00125640
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	6	MON

Date:01/08/01ISR Number: 3643929-4Report Type:Expedited (15-DaCompany Report #WAES 00125509
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	No Adverse Drug Effect	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

				Phenprocoumon	C		

Date:01/08/01ISR Number: 3643932-4Report Type:Expedited (15-DaCompany Report #WAES 00127282
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Health			Laboratories Div			
Initial or Prolonged	Gastrointestinal	Professional			Merck Co Inc	ORAL	12.5 MG	47 DAY
	Haemorrhage	Other	Tab Aspirin	SS		ORAL	75 MG	55 DAY
	Melaena		Acetaminophen	C				
			Digoxin	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Risperidone	C				

Date:01/08/01ISR Number: 3643937-3Report Type:Expedited (15-DaCompany Report #WAES 00108612
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:01/08/01ISR Number: 3643947-6Report Type:Expedited (15-DaCompany Report #WAES 00125630
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
	Haemoglobin Decreased	Health			Laboratories Div			
	Reticulocyte Count	Professional			Merck Co Inc	ORAL	25 MG	6 DAY
	Increased	Other	Aspirin	C				
			Penicillin V Potassium	C				

			(Unspecified)	C		

Date:01/08/01ISR Number: 3643948-8Report Type:Expedited (15-DaCompany Report #WAES 01016502
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Tinnitus	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	32 DAY

Date:01/08/01ISR Number: 3643959-2Report Type:Expedited (15-DaCompany Report #WAES 01016503
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	15 DAY
		Other	Aspirin	SS		ORAL	150 MG	
			Acetaminophen	C				
			Ketobemidone Hcl	C				

Potassium Chloride C

Date:01/08/01ISR Number: 3644490-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage		Aspirin 325mg	PS		ORAL	325 MG	QD
			Rofecoxib 25 Mg Merck	SS	Merck	ORAL	25MG	QD

Date:01/08/01ISR Number: 3644559-0Report Type:Expedited (15-DaCompany Report #WAES 00102461
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Vision Blurred	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:01/08/01ISR Number: 3644560-7Report Type:Expedited (15-DaCompany Report #WAES 00111760
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer Syncope Upper Gastrointestinal Haemorrhage Vomiting	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopressor	C				

Date:01/08/01ISR Number: 3644561-9Report Type:Expedited (15-DaCompany Report #WAES 00120603
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Vasotec	C				

Date:01/08/01ISR Number: 3644565-6Report Type:Expedited (15-DaCompany Report #WAES 00100875
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/08/01ISR Number: 3644577-2Report Type:Expedited (15-DaCompany Report #WAES 01010053
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Gemfibrozil	C				
			Medroxprogesterone	C				

Date:01/08/01ISR Number: 3644580-2Report Type:Expedited (15-DaCompany Report #WAES 00112237
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Herpes Zoster	Consumer Health Professional	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin 10 Mg	SS		ORAL	10 MG/DAILY/PO	
			Flomax	C				

Date:01/08/01ISR Number: 3650480-4Report Type:Periodic Company Report #2000033032US
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer	Detrol	PS	Pharmacia And Upjohn Co	ORAL	1 DF BID ORAL	
			Vioxx	SS				
			Celebrex	C				
			Mobic (Meloxicam)	C				
			Mycelex					

			(Clotrimazole)	C

Date:01/08/01ISR Number: 3650740-7Report Type:Periodic Company Report #2000022946US
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Detrol	PS	Pharmacia And Upjohn			
	Drug Interaction	Health			Co	ORAL	2 MG, BID,	
	Vision Blurred	Professional					ORAL	
	Weight Increased		Vioxx ()	SS				
			Premarin (Estrogens Conjugated)	C				
			Miacalcin Nasal Spray (Calcitonin, Salmon)	C				
			Claritin-D (Pseudoephedrine Sulfate, Loratadine)	C				
			"Pain-Free" Chondrotin/Glucosamine	C				
			Vitamin And Mineral Supplement	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/01ISR Number: 3644753-9Report Type:Expedited (15-DaCompany Report #WAES 01010495
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma Renal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/10/01ISR Number: 3645462-2Report Type:Expedited (15-DaCompany Report #WAES 00092586
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	6 DAY

Date:01/10/01ISR Number: 3645464-6Report Type:Expedited (15-DaCompany Report #WAES 00122196
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dyspepsia Gastric Ulcer Haematocrit Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Haemoglobin Decreased Hiatus Hernia Melaena Oesophagitis		Haloperidol	C				

Date:01/10/01ISR Number: 3645495-6Report Type:Expedited (15-DaCompany Report #WAES 00127282
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research		
Hospitalization -	Gastric Ulcer	Health			Laboratories Div		
Initial or Prolonged	Melaena	Professional			Merck Co Inc	ORAL	
12.5 MG, PO	47	DAY					
		Other	Tab Aspirin	SS		ORAL	
75 MG, PO	55	DAY					
			Tab Citalopram Hydrobromide	SS		ORAL	
10 MG, PO							
			Acetaminophen	C			
			Digoxin	C			
			Furosemide	C			
			Isosorbide Mononitrate	C			
			Risperidone	C			

Date:01/10/01ISR Number: 3645500-7Report Type:Expedited (15-DaCompany Report #WAES 01015510
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Nicotinic Acid Deficiency	Health			Laboratories Div			
	Weight Decreased	Professional			Merck Co Inc	ORAL	25 MG, PO	2 WK
			(Therapy Unspecified)	C				
			Amitriptyline	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/01ISR Number: 3645503-2Report Type:Expedited (15-DaCompany Report #WAES 00085101
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	65 DAY
			Atenolol	C				
			Glucosamine	C				
			Perindopril	C				

Date:01/10/01ISR Number: 3645509-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis		Vioxx (25mg Merck)	PS	Merck	ORAL	25MG PO BID	4 MON
			Cardizem Cd	C				

Date:01/10/01ISR Number: 3645510-XReport Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cutaneous Vasculitis		Vioxx	PS		ORAL	PO 5-6 MONTHS PRIOR TO ADMIT	
	Eosinophilia							
	Necrosis							
	Skin Disorder							
	Skin Lesion							
	Ulcer							
	Weight Decreased							

Date:01/10/01ISR Number: 3645517-2Report Type:Expedited (15-DaCompany Report #WAES 00102347
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gallbladder Perforation Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Motrin	C				
			Naprosyn	C				
			Soma	C				
			[Therapy Unspecified]	C				
			Methadone Hydrochloride	C				

Date:01/10/01ISR Number: 3645519-6Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability
Other
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Vioxx (25mg)	PS		ORAL	QD & PO	
	Blood Pressure Increased							
	Deafness							
	Dizziness							
	Haematemesis							
	Loss Of Consciousness							

Date:01/10/01ISR Number: 3645521-4Report Type:Expedited (15-DaCompany Report #WAES 00110825
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Prilosec	C				
			Aspirin	C				

Date:01/10/01ISR Number: 3645535-4Report Type:Expedited (15-DaCompany Report #WAES 00119762
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Body Temperature Decreased							
	Dermatitis							
	Eye Infection							
	Heart Rate Increased							
	Mucosal Erosion							
	Stomatitis							
	Tongue Disorder							

Date:01/10/01ISR Number: 3645542-1Report Type:Expedited (15-DaCompany Report #WAES 00125173
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	4 DAY
Hospitalization - Initial or Prolonged	Bronchopneumonia	Other						
	Dehydration							
	Drug Eruption		Acetaminophen/Propoxyphene Hydrochloride	C				
	Ecchymosis							
	Hepatic Failure		Omeprazole	C				
	Hyponatraemia		Temazepam	C				
	Lung Infiltration							
	Pruritus							
	Sedation							
	Vasculitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/01ISR Number: 3645553-6Report Type:Expedited (15-DaCompany Report #WAES 00129512
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY
Other								

Date:01/10/01ISR Number: 3645556-1Report Type:Expedited (15-DaCompany Report #WAES 00115637
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	7 DAY
			Alfacalcidol	C				
			Calcium Citrate (+)					
			Calcium Gluconate (+	C				
			Celiprolol Hcl	C				
			Metformin Hcl	C				
			Nitrendipine	C				
			Perindopril Erbumine	C				

Date:01/10/01ISR Number: 3645557-3Report Type:Expedited (15-DaCompany Report #WAES 00127277
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Dysarthria Dysphasia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	11 DAY
	Personality Disorder Speech Disorder		Elavil	C				
			Acetaminophen	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Metoprolol Succinate	C				

				Morphine	C		

Date:01/10/01ISR Number: 3645558-5Report Type:Expedited (15-DaCompany Report #WAES 00126050
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	22 DAY
			Acetaminophen	C				
			Captopril/Hctz	C				
			Pravastatin Na	C				

Date:01/10/01ISR Number: 3645591-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria		Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5MG QD	
			Zoloft	C			ORAL	
			Diazepam	C				

				Vasotec	C		

Date:01/10/01ISR Number: 3645602-5Report Type:Expedited (15-DaCompany Report #WAES 00051904
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholelithiasis Gallbladder Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:01/10/01ISR Number: 3645995-9Report Type:Periodic Company Report #001030-SK952
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Consumer	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG BID PO	
Hospitalization -	Drug Effect Decreased	Health						
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	Vioxx	SS		ORAL	25.000 MG QD PO	
Other								
			Triamterene	C				
			Hydrochlorothiazide	C				
			Calcium	C				
			Acetaminophen	C				
			Codeine Phosphate	C				
			Propoxyphene	C				
			Tramadol Hydrochloride	C				
			Conjugated Estrogens	C				
			Calcitonin, Salmon	C				
			Alendronate	C				
			Ranitidine Hydrochloride	C				

Date:01/11/01ISR Number: 3646418-6Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention		Vioxx	PS			12.5 MG ONCE	
	Left Ventricular Failure						DAILY	16 DAY
	Weight Increased		Lisinopril	C				
			Lansoprazole	C				
			Guaifenesin	C				
			Mineral Liquid					
			Vitamins	C				
			Soybean Products	C				
			Wheat Germ	C				

Date:01/11/01ISR Number: 3646495-2Report Type:Expedited (15-DaCompany Report #WAES 00102304
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Caltrate	C				
			Premarin	C				

			Univasc	C		
			Vitamins (Unspecified)	C		

Date:01/12/01ISR Number: 3646876-7Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal Disorder		Rofecoxib	PS		
			Beclomethasone	C		
			Sulfamethoxazole	C		
			Lansoprazole	C		
			Atenolol	C		
			Lovastatin	C		

Date:01/12/01ISR Number: 3647102-5Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis		Vioxx (25)	PS		
1T QD WITH FOOD						
			Synthroid	C		
			Aciphex	C		
			Allopurinol	C		
			Cephalexin	C		
			Evista	C		
			Maxzide	C		
			Entex	C		

Date:01/12/01ISR Number: 3647237-7Report Type:Expedited (15-DaCompany Report #WAES 00110576
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haematuria	Consumer	Vioxx	PS	Merck Research	
	Haemorrhage	Health			Laboratories Div	

	Urethral Disorder	Professional			Merck Co Inc	ORAL
PO						
			Hytrin	C		
			Aspirin	C		

Date:01/12/01ISR Number: 3647239-0Report Type:Expedited (15-DaCompany Report #WAES 00110812
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dysmenorrhoea	Consumer	Vioxx	PS	Merck Research	
		Menorrhagia	Health			Laboratories Div	
		Metrorrhagia	Professional			Merck Co Inc	ORAL
PO							
		Postmenopausal					
		Haemorrhage					
		Stress					
		Vaginal Discharge					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/01ISR Number: 3647309-7Report Type:Expedited (15-DaCompany Report #WAES 00110898
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div			
Other	Cardiac Failure	Health Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Congestive Drug Ineffective							
	Dyspnoea		Accupril	C				
	Feeling Abnormal		Bumex	C				
	Gastrointestinal Disorder		Celebrex	C				
	Joint Stiffness		Inderide Tablets	C				
	Pain In Extremity		Lescol	C				
			Prilosec	C				
			Relafen	C				
			Atenolol	C				
			Levothyroxine	C				

Date:01/12/01ISR Number: 3647314-0Report Type:Expedited (15-DaCompany Report #WAES 99080718
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alveolitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization - Initial or Prolonged	Chronic Sinusitis				Merck Co Inc	ORAL	25 MG/DAILY/PO ; 12.5 MG/DAILY/PO	
	Convulsion							
	Depressed Level Of Consciousness							
	Drug Hypersensitivity							
	Encephalopathy		Limbitrol Tablets	C				
	Meningitis Aseptic		Plaquenil	C				
	Mental Impairment		Prednisone	C				
	Pyrexia		Naproxen	C				
	Respiratory Distress							

Date:01/12/01ISR Number: 3647315-2Report Type:Expedited (15-DaCompany Report #WAES 00110719
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Oral Intake Reduced Peptic Ulcer Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Hydrocodone/Apap	C				
			Lipitor	C				
			Toprol Xl Tablets	C				
			Naproxen	C				

Date:01/12/01ISR Number: 3647318-8Report Type:Expedited (15-DaCompany Report #WAES 00052239
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Arthralgia Colonic Polyp Faecal Occult Blood Positive Gastritis Erosive Iron Deficiency Anaemia Middle Insomnia

	Pain In Extremity Restless Legs Syndrome					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/DAILY/PO						
			Acetaminophen	SS		
325 MG/PRN						
			Glucotrol Xl	C		
			Hydrodiuril	C		
			Synthroid	C		
			Ferrous Gluconate	C		
			Hydroxychloroquine	C		
			Methotrexate	C		

Date:01/12/01ISR Number: 3647328-0Report Type:Expedited (15-DaCompany Report #WAES 00020955
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia Back Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/UNK/PO						
	Blood Potassium Decreased		Synthroid	C		
	Colitis Ulcerative		Xalatan	C		
	Deep Vein Thrombosis					
	Difficulty In Walking					
	Diverticulum Intestinal					
	Electrocardiogram T Wave Inversion					
	Fungaemia					
	Fungal Infection					
	Gastrointestinal Haemorrhage					
	Headache					
	Hypertension					
	Mesenteric Occlusion					
	Myocardial Infarction					
	Post Procedural Complication					

Pseudopolyposis
Pulmonary Embolism
Pulmonary Infarction
Rectal Haemorrhage
Thrombosis

Date:01/12/01ISR Number: 3647330-9Report Type:Expedited (15-DaCompany Report #WAES 00120603
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/01ISR Number: 3647332-2Report Type:Expedited (15-DaCompany Report #WAES 00110485
Age:52 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
Disability	Condition Aggravated							
Other	Dialysis							
	Haemoglobin Decreased							
	Renal Failure							

Date:01/12/01ISR Number: 3647334-6Report Type:Expedited (15-DaCompany Report #WAES 00051708
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Miacalcin	C				
			Prevacid	C				

Date:01/12/01ISR Number: 3647352-8Report Type:Expedited (15-DaCompany Report #WAES 00120364
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastrointestinal Angiodysplasia							
Disability	Gastrointestinal	Representative						
Other	Haemorrhage		Celebrex	C				
	Oedema Peripheral		K-Dur	C				
			Lanoxin	C				
			Lasix	C				
			Tambocor	C				

Verapamil C

Date:01/12/01ISR Number: 3647359-0Report Type:Expedited (15-DaCompany Report #WAES 00116065
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Faeces Discoloured Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased Red Blood Cell Count Decreased	Foreign Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / 12.5 MG	3 DAY

Date:01/12/01ISR Number: 3647361-9Report Type:Expedited (15-DaCompany Report #WAES 00125023
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Lower Abdominal Pain Upper Diarrhoea Gastrointestinal

Haemorrhage
Melaena

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	8 DAY
Other	Cozaar	C				
	Doxazosin	C				

Date:01/16/01ISR Number: 3647417-0Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperkalaemia		Vioxx	PS				
Hospitalization - Initial or Prolonged	Renal Impairment							

Date:01/16/01ISR Number: 3647465-0Report Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness		Xenical	PS	Roche			302 DAY
	Haematemesis		Rofecoxib	SS				
			Nitrazepam	C			QN.	
			Frusemide	C			QAM.	
			Bisoprolol Fumarate	C			QAM.	
			Citalopram	C				
			Lisinopril	C				
			Benoral	C				
			Gaviscon Advance	C				
			Carisoprodol	C				
			Chlorpheniramine Maleate	C				

ALSO REPORTED

AS RECEIVING

PIRITON

(CHLORPHRENIR

AMINE

	Nicardipine Hydrochloride	C
	Glyceroltrinitrat	C

REPORTED AS

GLYCEROL

TRINITRATE

SPRAY PRN.

	Simvastatin	C

QN.

Date:01/16/01ISR Number: 3648217-8Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx (25mg Qd)	PS			25MG QD	

Date:01/16/01ISR Number: 3648282-8Report Type:Expedited (15-DaCompany Report #WAES 00121218
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchospasm	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:01/16/01ISR Number: 3648284-1Report Type:Expedited (15-DaCompany Report #WAES 00121456
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/16/01ISR Number: 3648285-3Report Type:Expedited (15-DaCompany Report #WAES 01010329
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension Dyspnoea Fluid Retention Urticaria Weight Increased	Consumer	Vioxx Celebrex	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

Date:01/16/01ISR Number: 3648772-8Report Type:Expedited (15-DaCompany Report #WAES 01010367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased Dermatitis Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Disability	Night Sweats Oedema Oedema Peripheral Paraesthesia Urticaria Weight Increased		Natures Rx Msm Plus C Prempro Ascorbic Acid Vitamin E	C C C C				

Date:01/16/01ISR Number: 3648773-XReport Type:Expedited (15-DaCompany Report #WAES 01010253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Flexeril	C				

Date:01/16/01ISR Number: 3648859-XReport Type:Expedited (15-DaCompany Report #WAES 00118619
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Dizziness Feeling Jittery	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	27 DAY
	Hyperglycaemia Tremor	Other	Albuterol Sulfate Clarithromycin Prednisone Zafirlukast	C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/01ISR Number: 3648863-1Report Type:Expedited (15-DaCompany Report #WAES 01019102
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:01/16/01ISR Number: 3648873-4Report Type:Expedited (15-DaCompany Report #WAES 01010338
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Colestid	C				
			Darvocet-N	C				
			Paxil	C				
			Synthroid	C				
			Trilan	C				
			Tylenol	C				

Date:01/16/01ISR Number: 3648875-8Report Type:Expedited (15-DaCompany Report #WAES 01010341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	
			Tylenol	C				

Date:01/16/01ISR Number: 3648878-3Report Type:Expedited (15-DaCompany Report #WAES 00120509
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Motrin	SS				
			Celebrex	C				

Date:01/16/01ISR Number: 3649260-5Report Type:Expedited (15-DaCompany Report #WAES 01019104
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	58 DAY
			Prinivil	C				
			Folic Acid	C				
			Furosemide	C				
			Iron (Unspecified)	C				
			Piracetam	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/01ISR Number: 3649265-4Report Type:Expedited (15-DaCompany Report #WAES 01019002
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypertension Transient Ischaemic Attack	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
			Cilazapril	C				
			Diosmin	C				
			Ticlopidine	C				
			Trazodone	C				

Date:01/16/01ISR Number: 3649267-8Report Type:Expedited (15-DaCompany Report #WAES 01018508
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:01/16/01ISR Number: 3649270-8Report Type:Expedited (15-DaCompany Report #WAES 01015520
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/16/01ISR Number: 3649273-3Report Type:Expedited (15-DaCompany Report #WAES 00107522
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Arthralgia	Health			Laboratories Div
Other	Atrial Fibrillation	Professional			Merck Co Inc
	Calcinosis	Distributor	Aspirin	C	
	Cardiac Valve Disease	Other	Atenolol/Chlorthalid		
	Cardiomegaly		one	C	
	Condition Aggravated		Flunitrazepam	C	
	Crest Syndrome		Prazosin Hcl	C	
	Dizziness				
	Dyspnoea Exertional				
	Fall				
	Flushing				
	Haematoma				
	Hypoventilation				
	Normochromic Normocytic				
	Anaemia				
	Oedema Peripheral				
	Supraventricular				
	Tachycardia				
	Syncope				
	Thrombocytopenia				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/01ISR Number: 3649278-2Report Type:Expedited (15-DaCompany Report #WAES 01018101
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Scan Abnormal Disorientation	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	9 DAY

Date:01/17/01ISR Number: 3649383-0Report Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Foreign Consumer Health Professional	Xenical	PS	Hlr Technology	ORAL	120 MG 3 PER DAY ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG 1 PER DAY ORAL	
			Nitrazepam (Nitrazepam)	C				
			Frusemide (Furosemide)	C				
			Bisoprolol Fumarate (Bisoprolol Fumarate)	C				
			Citalopram (Citalopram)	C				
			Lisinopril (Lisinopril)	C				
			Benoral (Benorilate)	C				
			Gaviscon Advance (Potassium Bicarbonate/Sodium Alginate)	C				
			Carisoprodol (Carisoprodol)	C				
			Chlorpheniramine Maleate					

(Chlorpheniraminde Maleat)	C
Nicardipine Hydrochloride (Nicardipine Hydrochloride)	C
Glycerol Trinitrat (Nitroglycerin)	C
Simvastatin (Simvastatin)	C

Date:01/17/01ISR Number: 3649936-XReport Type:Expedited (15-DaCompany Report #001027-SK729
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nephrotic Syndrome	Health Professional	Celebrex	PS	Gd Searle And Co	ORAL	200.000 MG QD PO	
		Company Representative	Vioxx	SS		ORAL	25.000 MG QD PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/01ISR Number: 3650623-2Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis Helicobacter Haemoglobin Decreased Peptic Ulcer Haemorrhage		Rofecoxib (Vioxx)	PS		ORAL	12.5MG QD PO	-BEFORE ADMISSION

Date:01/19/01ISR Number: 3650572-XReport Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Vioxx	PS		ORAL	12.5MG QD ORAL	
			Furosemide	C				
			Lisinopril	C				

Date:01/19/01ISR Number: 3650580-9Report Type:Direct Company Report #
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Increased		Vioxx	PS		ORAL	DAILY ORAL	

Date:01/19/01ISR Number: 3650597-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx / 25 Mg / Merck	PS	Merck	ORAL	25 MG ONCE A	

DAY ORAL

			Actonel	C		
			Chewable Baby Aspirin	C		

Date:01/19/01ISR Number: 3651311-9Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx 12.5 Mg Merc	PS	Merck		1 DAILY	
	Flushing							
	Gastrooesophageal Reflux Disease							
	Nausea							
	Palpitations							
	Paraesthesia							

Date:01/19/01ISR Number: 3651388-0Report Type:Expedited (15-DaCompany Report #WAES 01010829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aleve	C				
			Anacin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3651394-6Report Type:Expedited (15-DaCompany Report #WAES 00121371
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Health	Vioxx	PS	Merck Research			
	Blood Creatinine	Professional			Laboratories Div			
	Increased	Company			Merck Co Inc	ORAL	SEE IMAGE /	
		Representative					PO	
			Betapace	C				
			Coumadin	C				
			Prevacid	C				
			Zocor	C				
			Prednisone	C				

Date:01/19/01ISR Number: 3651400-9Report Type:Expedited (15-DaCompany Report #WAES 00111024
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Confusional State	Health			Laboratories Div			
	Constipation	Professional			Merck Co Inc	ORAL	25 MG/DAILY/	
	Disorientation						PO	
	Hypertension		Adalat	C				
	Iiird Nerve Paralysis		Relafen	C				
	Muscular Weakness		Zestril	C				
			Atenolol	C				
			Pilocarpine	C				

Date:01/19/01ISR Number: 3651404-6Report Type:Expedited (15-DaCompany Report #WAES 01010844
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
	Gastroenteritis				Merck Co Inc	ORAL	PO	

	Helicobacter	Aspirin	C

Date:01/19/01ISR Number: 3651405-8Report Type:Expedited (15-DaCompany Report #WAES 01010808
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Retention	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Flexeril	SS				

Date:01/19/01ISR Number: 3651406-XReport Type:Expedited (15-DaCompany Report #WAES 01010451
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis Vaginal Ulceration	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	6 WKY
		Representative	Coumadin	SS			1 MON	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3651500-3Report Type:Expedited (15-DaCompany Report #WAES 00121348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Retention	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
		Representative	Flexeril	SS				

Date:01/19/01ISR Number: 3651521-0Report Type:Expedited (15-DaCompany Report #WAES 00111637
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Toxicity							
	Gastrointestinal Haemorrhage							
			Coumadin	SS		ORAL	5 MG/DAILY/PO	

Date:01/19/01ISR Number: 3651523-4Report Type:Expedited (15-DaCompany Report #WAES 00101829
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrophy	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Carcinoembryonic Antigen Increased							
	Cerebral Infarction							
	Drug Ineffective		Tab Vioxx 50 Mg	SS		ORAL	50 MG/PO	
	Hypokalaemia		Bumex	C				
	International Normalised Ratio Increased		Cordarone	C				
			Coumadin	C				
	Memory Impairment		Toprol Xl	C				
	Nervous System Disorder		Calcium	C				

	Prostatic Specific		Potassium	C		
	Antigen Increased		Vitamins	C		
	Rectal Haemorrhage					
	Renal Failure Acute					

Date:01/19/01ISR Number: 3651524-6Report Type:Expedited (15-DaCompany Report #WAES 00121742
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Congestive				Laboratories Div			
Initial or Prolonged	Dyspnoea				Merck Co Inc	ORAL	12.5	
	Oedema Peripheral						MG/DAILY/PO	
	Syncope		Tab Ziac	SS		ORAL	1	
							TABLET/DAILY/	
							PO	
			Fosamax	C				
			Glucophage	C				
			Xanax	C				
			Aspirin	C				
			Calcium	C				
			Cyanocobalamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3651525-8Report Type:Expedited (15-DaCompany Report #WAES 01010927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/19/01ISR Number: 3651530-1Report Type:Expedited (15-DaCompany Report #WAES 01010859
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased Renal Disorder Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Chromagen Capsules	C				
			Coreg	C				
			Genebs Extra Strength	C				
			Lasix	C				
			Lotensin	C				
			Pravachol	C				
			Aspirin	C				
			Digoxin	C				
			Docusate Sodium	C				
			Hydralazine	C				

Date:01/19/01ISR Number: 3651571-4Report Type:Expedited (15-DaCompany Report #WAES 00128901
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, PO	2 DAY
	Blood Urea Increased		Anethetic, Nos	C				

	Gastrointestinal	Cefepime	C
	Haemorrhage	Imipenem (+)	
	Glycosuria	Cilastatin Sodium ->	
	Haemangioma	Cilast	C
	Haematuria	Metronidazole	C
	Hypotension	Netromycin	C
	Sepsis		

Date:01/19/01ISR Number: 3651573-8Report Type:Expedited (15-DaCompany Report #WAES 00128902
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Death	Coma
Hospitalization -	Convulsion
Initial or Prolonged	Electrolyte Imbalance
	Eye Haemorrhage
	Gastrointestinal
	Haemorrhage
	Haemodialysis
	Haemorrhage Intracranial
	Loss Of Consciousness
	Nausea
	Periorbital Haematoma

		Renal Failure					
		Renal Failure Acute					
		Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG, PO	5 DAY						
				Cefepime	C		
				Ceftazidime	C		
				Cefuroxime 1-Acetoxyethl Ester	C		
				Furosemide	C		
				Metronidazole	C		
				Omeprazole	C		
				Vitamins	C		

Date:01/19/01ISR Number: 3651574-XReport Type:Expedited (15-DaCompany Report #WAES 00125620
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dizziness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Tachycardia					
	Urticaria					
25 MG, PO	1 DAY					

Date:01/19/01ISR Number: 3651576-3Report Type:Expedited (15-DaCompany Report #WAES 01015097
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Familial Periodic Paralysis					
PO						
			Acetazolamide	C		
			Diclofenac Na	C		

Date:01/19/01ISR Number: 3651578-7Report Type:Expedited (15-DaCompany Report #WAES 01019752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/19/01ISR Number: 3651985-2Report Type:Expedited (15-DaCompany Report #WAES 01015079
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	40 DAY
			Ferrous S04	C				
			Isosorbide Mononitrate	C				
			Rabeprazole Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3651986-4Report Type:Expedited (15-DaCompany Report #WAES 01015105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	360 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Amlodipine	C				
			Aspirin	C				
			Calcium Carbonate (+)Cholecalciferol	C				
			Doxazosin	C				
			Furosemide	C				
			Prednisolone	C				
			Senna	C				

Date:01/19/01ISR Number: 3651987-6Report Type:Expedited (15-DaCompany Report #WAES 01015111
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Gastric Ulcer Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Ascorbic Acid	C				
			Minerals (Unspecified)	C				
			Tramadol Hcl	C				
			Zopiclone	C				

Date:01/19/01ISR Number: 3651990-6Report Type:Expedited (15-DaCompany Report #WAES 01017802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						
		Other				

Date:01/19/01ISR Number: 3651992-XReport Type:Expedited (15-DaCompany Report #WAES 01019751
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Congestive	Health			Laboratories Div	
	Fluid Retention	Professional			Merck Co Inc	ORAL
25 MG PO						
		Other	Zocor	C		
			Albuterol Sulfate	C		
			Aspirin	C		
			Atenolol	C		
			Ipratropium Bromide	C		
			Isosorbide Mononitrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3652002-0Report Type:Expedited (15-DaCompany Report #WAES 00127282
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Other			Laboratories Div			
Initial or Prolonged	International Normalised				Merck Co Inc	ORAL	12.5 MG PO	47 DAY
	Ratio Abnormal		Tab Aspirin	SS		ORAL	75 MG PO	55 DAY
	Melaena		Tab Citalopram					
	X-Ray Gastrointestinal		Hydrobromide	SS		ORAL	10 MG PO	155 DAY
	Tract Abnormal		Acetaminophen	C				
			Digoxin	C				
			Furosemide	C				
			Isosorbide					
			Mononitrate	C				
			Risperidone	C				

Date:01/19/01ISR Number: 3652004-4Report Type:Expedited (15-DaCompany Report #WAES 00096091
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastric Ulcer	Study			Laboratories Div			
		Other			Merck Co Inc	ORAL	12.5 MG PO	27 DAY
			Atenolol	C				
			Estrogens					
			(Unspecified)	C				
			Furosemide	C				
			Mianserin	C				
			Milnacipran	C				
			Progesterone	C				
			Zolpidem	C				

Date:01/19/01ISR Number: 3652005-6Report Type:Expedited (15-DaCompany Report #WAES 99127511
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Cardiac Failure	Study						
	Congestive	Other			Merck Co Inc	ORAL	50 MG PO	130 DAY
	Skin Necrosis		Captopril	C				
	Vasculitis		Digoxin	C				
			Folic Acid	C				
			Molsidomine	C				
			Prednisolone	C				

Date:01/19/01ISR Number: 3652496-0Report Type:Expedited (15-DaCompany Report #WAES 00121381
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/01ISR Number: 3652499-6Report Type:Expedited (15-DaCompany Report #WAES 01010844
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Duodenal Ulcer Haemorrhage Gastroenteritis Helicobacter Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:01/19/01ISR Number: 3652502-3Report Type:Expedited (15-DaCompany Report #WAES 00111775
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Headache Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:01/19/01ISR Number: 3652504-7Report Type:Expedited (15-DaCompany Report #WAES 00121884
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Bacterial Infection Gastric Ulcer Perforation Gastrointestinal Perforation Peritonitis Sepsis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		50 MG	

Date:01/22/01ISR Number: 3652127-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Naprosyn	PS			2-3X/DAY	15 YR
Initial or Prolonged	Palpitations		Daypro	SS			1 DAY	
			Vioxx	SS			1 DAY	
			Atenolol	C				
			Premarin	C				
			Lopid	C				
			Vitamin E	C				
			Multivitamin	C				
			Calcium	C				
			Selenium	C				
			Chromium Picolinate	C				
			Baby Aspirin	C				

Date:01/22/01ISR Number: 3652766-6Report Type:Expedited (15-DaCompany Report #WAES 01017501
Age:79 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cardiomegaly
	Chest X-Ray Abnormal
	Dyspnoea

	Oedema						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO

(SEE IMAGE)

Date:01/22/01ISR Number: 3652767-8Report Type:Expedited (15-DaCompany Report #WAES 01015130
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aplastic Anaemia Hypothyroidism Medication Error	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO
	Renal Failure		Allopurinol	SS		ORAL	900 MG PO 171 DAY
	Ventricular Tachycardia		Acetaminophen	C			
			Aspirin	C			
			Atenolol	C			
			Betahistine	C			
			Bumetanide	C			
			Isosorbide Mononirate	C			
			Omeprazole	C			
			Perindopril	C			
			Thyroxine	C			

Date:01/22/01ISR Number: 3652768-XReport Type:Expedited (15-DaCompany Report #WAES 01015140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Diclofenac Sodium				

			(+) Misoprostol	C		

Date:01/22/01ISR Number: 3652769-1Report Type:Expedited (15-DaCompany Report #WAES 00125517
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Decreased	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Burns Second Degree	Health			Laboratories Div	
Initial or Prolonged	Diarrhoea	Professional			Merck Co Inc	ORAL
12.5 MG PO						
	Haematemesis		Therapy Unspecified	C		
	Hypoproteinaemia		Diclofenac Na	C		
	Mallory-Weiss Syndrome		Ranitidine Hcl	C		
	Nausea					
	Prothrombin Time					
	Shortened					
	Renal Failure					
	Sepsis					
	Shock					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3652770-8Report Type:Expedited (15-DaCompany Report #WAES 00126164
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO (SEE IMAGE)	25 DAY
			Therapy Unspecified	C				
			Amlodipine	C				
			Spironolactone	C				

Date:01/22/01ISR Number: 3652775-7Report Type:Expedited (15-DaCompany Report #WAES 01018549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Other	Cardiac Failure							
	Congestive Condition Aggravated		Furosemide	SS		ORAL		
	Drug Effect Decreased							
	Drug Interaction							

Date:01/22/01ISR Number: 3652776-9Report Type:Expedited (15-DaCompany Report #WAES 01016031
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	1 DAY
	Drug Interaction							
	Drug Level Below							
	Therapeutic		Tab Phenobarbital	SS		ORAL	50 MG	
			Leuprolide Acetate	C				

Date:01/22/01ISR Number: 3652777-0Report Type:Expedited (15-DaCompany Report #WAES 01015147
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
	Diarrhoea Haemorrhagic	Other			Laboratories Div			
	Rectal Haemorrhage				Merck Co Inc	ORAL	25 MG	16 DAY
			Dihydrocodeine	C				

Date:01/22/01ISR Number: 3652905-7Report Type:Expedited (15-DaCompany Report #WAES 01010889
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Health	Vioxx	PS	Merck Research			
Congenital Anomaly	Complications Of Maternal	Professional			Laboratories Div			
	Exposure To Therapeutic				Merck Co Inc	ORAL	UNK/UNK/PO	
	Drugs		Tab Placebo					
	Pregnancy		(Unspecified) Unk	SS		ORAL	"SEE IMAGE"	
	Ultrasound Antenatal		Correctol Laxative					
	Screen Abnormal		Tablets & Cap	C				
			Acetaminophen	C				
			Calcium (Unspecifed)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/01ISR Number: 3653013-1Report Type:Expedited (15-DaCompany Report #001-0991-M0100020
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block	Health	Rezulin	PS	Parke Davis			
Life-Threatening	Complete	Professional			Pharmaceuticals Ltd		200 MG	
	Blood Glucose Increased						(DAILY)	
	Cardiac Arrest		Vioxx(Rofecoxib)	SS			25 MG (DAILY)	
	Cardiomegaly		Flexeril(Cyclobenzap					
	Embolism		rine Hydrochloride)	C				
	Hepatic Steatosis		Xenical (Orlistat)	C				
	Hyperlipidaemia							
	Myocardial Infarction							
	Pericardial Drainage Test							
	Abnormal							
	Pneumatic Compression							
	Therapy							
	Pulmonary Embolism							
	Pulmonary Oedema							

Date:01/23/01ISR Number: 3652328-0Report Type:Direct Company Report #
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Coumadin 2.5mg					
Initial or Prolonged	Haemoptysis		Dupont	PS	Dupont	ORAL	2.5 MG	
	International Normalised						MON-FRI ORAL	
	Ratio Increased		Vioxx 12.5 Mg Merck	SS	Merck	ORAL	12.5 MG DAILY	
							ORAL	
			Prinivil	C				
			Lanoxin	C				
			Cordarone	C				
			Lasix	C				
			Kcl	C				

Date:01/23/01ISR Number: 3652377-2Report Type:Expedited (15-DaCompany Report #WAES 01011101
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Faeces Discoloured							
	Haemorrhage							
	Nausea							
	Oedema Peripheral		Celebrex	C				
	Rectal Haemorrhage		[Therapy Unspecified]	C				

Date:01/23/01ISR Number: 3652378-4Report Type:Expedited (15-DaCompany Report #WAES 01010997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Erythema							
	Mouth Haemorrhage							
	Prothrombin Time Abnormal							
	Swelling		Phytonadione Unk	SS				
			Allegra	C				
			Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/01ISR Number: 3653026-XReport Type:Expedited (15-DaCompany Report #WAES 01010864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Aspartate Aminotransferase Increased		Arava	C				
			Remicade	C				
	Blood Alkaline Phosphatase Increased		Zestril	C				
			Methotrexate	C				
	Blood Bilirubin Increased							

Date:01/23/01ISR Number: 3653036-2Report Type:Expedited (15-DaCompany Report #WAES 01011003
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/	PO
	Pancreatitis							
			Celebrex	C				
			Clonopin	C				
			Wellbutrin	C				
			Zanaflex	C				
			Zoloft	C				
			Cyanocobalamin	C				

Date:01/23/01ISR Number: 3653037-4Report Type:Expedited (15-DaCompany Report #WAES 01011113
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/ PO	

Date:01/23/01ISR Number: 3653043-XReport Type:Expedited (15-DaCompany Report #WAES 01011093
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Hydrodiuril	C				
			Premarin	C				
			Tylenol With Codeine	C				

Date:01/23/01ISR Number: 3653047-7Report Type:Expedited (15-DaCompany Report #WAES 01011284
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Blood Pressure Abnormal Duodenal Ulcer Gastritis Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/01ISR Number: 3653049-0Report Type:Expedited (15-DaCompany Report #WAES 00121935
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Vioxx	PS	Merck Research			
	Faeces Discoloured	Professional			Laboratories Div			
	Upper Gastrointestinal	Other			Merck Co Inc	ORAL	PO	
	Haemorrhage		Aldactone	C				
			Detrol	C				
			Inderal	C				
			Premarin	C				
			Folic Acid	C				

Date:01/23/01ISR Number: 3653721-2Report Type:Expedited (15-DaCompany Report #WAES 01010341
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Urticaria				Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	BID/PO	
			Tylenol	C				

Date:01/23/01ISR Number: 3653722-4Report Type:Expedited (15-DaCompany Report #WAES 00112237
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research			
	Immune System Disorder	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Claritin 10 Mg	SS		ORAL	10	MG/DAILY/PO
			Flomax	C				

Date:01/23/01ISR Number: 3653723-6Report Type:Expedited (15-DaCompany Report #WAES 00111760
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 50 MG/PO	
	Gastroenteritis							
	Helicobacter							
	Hypotension							
	Mallory-Weiss Syndrome		Ecotrin	C				
	Syncope		Flomax	C				
	Upper Gastrointestinal Haemorrhage		Lopressor	C				
			Maalox	C				
			Proscar	C				
			Zantac	C				
			Zestril	C				

Date:01/23/01ISR Number: 3654138-7Report Type:Expedited (15-DaCompany Report #WAES 00073756
Age:86 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Potassium Decreased
Hospitalization - Initial or Prolonged	Blood Urea Increased
	Chest Discomfort
	Chest Pain
	International Normalised

Ratio Increased
Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY
	Acetylcysteine	C				
	Albuterol Sulfate	C				
	Captopril	C				
	Digoxin	C				
	Disopyramide	C				
	Fluticasone Propionate	C				
	Furosemide	C				
	Ipratropium Bromide	C				
	Temazepam	C				
	Verapamil Hcl	C				

Date:01/24/01ISR Number: 3653942-9Report Type:Direct Company Report #
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Asthenia Dehydration Diarrhoea Fluid Retention Hallucination Hyponatraemia Influenza Like Illness Nausea		Dyazide -Triamterene Hctz 37.5/25 Cap					
			Geneva Skbee	PS	Geneva Skbee	ORAL	1 QD THEN 1 BID PO	
			Vioxx 12.5 Mg Tab Merck	SS	Merck	ORAL	1 OR 2 QD PO	
			Tapazole	C				

Date:01/25/01ISR Number: 3655128-0Report Type:Expedited (15-DaCompany Report #WAES 00051708
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Asthenia Malaise Small Intestinal Haemorrhage Ulcer Haemorrhage	Consumer Health Professional	Vioxx Miacalcin Prevacid	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL 12.5 MG/PO

Date:01/25/01ISR Number: 3655129-2Report Type:Expedited (15-DaCompany Report #WAES 00121762
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Dehydration Hypotension Renal Failure Acute Renal Tubular Necrosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/01ISR Number: 3655131-0Report Type:Expedited (15-DaCompany Report #WAES 01011380
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test Abnormal Thrombocytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/25/01ISR Number: 3655132-2Report Type:Expedited (15-DaCompany Report #WAES 01011438
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung Post Procedural Complication	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Renal Failure		Ambien	C				
	Staphylococcal Infection		[Therapy Unspecified]	C				

Date:01/25/01ISR Number: 3655134-6Report Type:Expedited (15-DaCompany Report #WAES 01010850
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/25/01ISR Number: 3655135-8Report Type:Expedited (15-DaCompany Report #WAES 01011261
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:01/25/01ISR Number: 3655145-0Report Type:Expedited (15-DaCompany Report #WAES 00111533
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrophy	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Blood Sodium Decreased							
	Dementia							
	Nervous System Disorder		Prilosec	SS		ORAL	20 MG/DAILY/PO	
	Road Traffic Accident							
			Fosamax	C				
			Lipitor	C				
			Pancrease (Pancrelipase)	C				
			Prinivil	C				
			Vicodine Tablets	C				
			Cyanocobalamin	C				
			Folic Acid	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/01ISR Number: 3655153-XReport Type:Expedited (15-DaCompany Report #WAES 01011069
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:01/25/01ISR Number: 3655154-1Report Type:Expedited (15-DaCompany Report #WAES 01011002
Age:99 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:01/25/01ISR Number: 3655155-3Report Type:Expedited (15-DaCompany Report #WAES 01011070
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:01/25/01ISR Number: 3655160-7Report Type:Expedited (15-DaCompany Report #WAES 01011248
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/25/01ISR Number: 3655232-7Report Type:Expedited (15-DaCompany Report #WAES 01011076
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:01/25/01ISR Number: 3655765-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx (25mg Tab)	PS		ORAL	50MG PO BID	
Hospitalization -	Blood Pressure Decreased						X3 DAYS, 50MG	
Initial or Prolonged	Diarrhoea						PO Q AM	
	Duodenal Ulcer		Asa (325mg Tab)	SS		ORAL	325MG PO QD	
	Eating Disorder						W7 FOR	
	Faeces Discoloured							
	Gastric Ulcer							
	Haematemesis							
	Malaise							
	Pallor							

Date:01/25/01ISR Number: 3655766-5Report Type:Expedited (15-DaCompany Report #WAES 00118610
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction Ventricle Rupture	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	7 DAY

Date:01/25/01ISR Number: 3655768-9Report Type:Expedited (15-DaCompany Report #WAES 00129512
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension Viral Upper Respiratory Tract Infection	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	8 DAY

Date:01/25/01ISR Number: 3655769-0Report Type:Expedited (15-DaCompany Report #WAES 00125522
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Hypertension Hypertensive Crisis	Foreign Study Health Professional	Vioxx Composition Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5; 25; 25 MG PO	51 DAY

Date:01/25/01ISR Number: 3655797-5Report Type:Expedited (15-DaCompany Report #WAES 01019808
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Methylprednisolone Acetate	C				

Date:01/25/01ISR Number: 3655801-4Report Type:Expedited (15-DaCompany Report #WAES 01015169
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	296 DAY
			Bendroflumethiazide	C				
			Enalapril	C				

Date:01/25/01ISR Number: 3655803-8Report Type:Expedited (15-DaCompany Report #WAES 01015564
Age: Gender:Male I/FU:I

Outcome	PT
Disability	Dyspnoea
	Flatulence
	Fluid Retention

	Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	33 DAY

Date:01/25/01ISR Number: 3655806-3Report Type:Expedited (15-DaCompany Report #WAES 01015160
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	
		Other	Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Moxonidine	C				

Date:01/25/01ISR Number: 3656405-XReport Type:Expedited (15-DaCompany Report #WAES 00115638
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Blood Creatinine Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	11 DAY
	Blood Urea Increased		Tab Phenprocoumon	SS		ORAL	PO	25 DAY
	Colonic Stenosis		Hctz/Triamterene	C				
	Diverticulum		Acetyldigoxin	C				
	Duodenal Ulcer		Dimethindene Maleate	C				
	Haemorrhage		Furosemide	C				
	Erosive Duodenitis		Furosemide/Spironolactone	C				
	Hernia		Molsidomine	C				
	Oesophagitis		Verapamil Hc1	C				
	Petechiae							
	Thrombocytopenia							

Upper Gastrointestinal
Haemorrhage
Vomiting
White Blood Cell Count
Increased

Date:01/25/01ISR Number: 3656841-1Report Type:Expedited (15-DaCompany Report #041-0955-M0100001
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Accuretic	PS	Parke Davis	ORAL	10 MG/12.5 MG	
Initial or Prolonged	Renal Impairment	Health					(DAILY), PER	
		Professional					ORAL	
			Rofecoxib	SS		ORAL	25 MG	
							(DAILY), PER	
							ORAL	
			Isoket	C				
			Theolair	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/01ISR Number: 3701935-5Report Type:Periodic Company Report #WAES 00111253
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Bronchospasm							
	Fatigue							
	Headache		Astaril	C				
	Hepatic Function Abnormal		Flonase	C				
	Liver Disorder		Naprosyn	C				
	Nausea		Premarin	C				
	Pruritus		Provera	C				
	Sinusitis		(Therapy Unspecified)	C				
	Upper Respiratory Tract Infection		Albuterol	C				
	Vaginal Haemorrhage							

Date:01/26/01ISR Number: 3655679-9Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Vioxx / 12.5mg / Merck	PS	Merck	ORAL	12.5 MG QD	ORAL
	Oedema Peripheral							

Date:01/26/01ISR Number: 3655683-0Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx / 25mg / Merck	PS	Merck	ORAL	25MG DAILY	ORAL
	Oedema							

Date:01/26/01ISR Number: 3655789-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx (25mg)	PS			25QD	
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatine Increased		Aldonet	C				
	Duodenal Ulcer		Dyazide	C				
	Oedema		Propranolol	C				
			Aspirin	C				
			Exesta	C				
			Lipitor	C				
			Amben	C				

Date:01/26/01ISR Number: 3655971-8Report Type:Expedited (15-DaCompany Report #WAES 00120899
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrointestinal Haemorrhage							

Date:01/26/01ISR Number: 3655976-7Report Type:Expedited (15-DaCompany Report #WAES 01011368
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:01/26/01ISR Number: 3655978-0Report Type:Expedited (15-DaCompany Report #WAES 00121936
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ascites	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Atelectasis							
Other	Pancreatic Disorder	Other						
	Pancreatitis Acute		Lotensin 20 Mg	SS		ORAL	20 MG/DAILY/PO	
			Diazide	C				
			Levoxyl	C				
			Lotronex	C				
			Nasonex	C				
			Premarin	C				
			Prevacid	C				
			Rythmol	C				
			Tiazac	C				
			Digoxin	C				
			Isosorbide	C				
			Metoprolol	C				

Date:01/26/01ISR Number: 3655987-1Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chondropathy	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Condition Aggravated	Health			Laboratories Div	
	Fluid Retention	Professional			Merck Co Inc	ORAL
25 MG/BID/PO						
	Hypotonia		Vioxx	SS		ORAL
25 MG/PRN/PO						
	Muscular Weakness		Darvocet-N	C		
	Pain		Klonopin	C		
	Rhabdomyolysis					
	Spinal Fracture					

Date:01/26/01ISR Number: 3656010-5Report Type:Expedited (15-DaCompany Report #WAES 00126105
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Hypertension	Study			Laboratories Div	
		Health			Merck Co Inc	ORAL
12.5; 25 MG						
		Professional				
PO 51 DAY						
			Indapamide	C		
			Irbesartan	C		
			Potassium Chloride	C		
			Tamsulosin Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/01ISR Number: 3656013-0Report Type:Expedited (15-DaCompany Report #WAES 00125508
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Bone Neoplasm Malignant Gastric Ulcer Haemorrhage	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5; 25 MG PO	382 DAY
			Fosamax	C				
			Dipyrone	C				
			Magnesium	C				

Date:01/26/01ISR Number: 3656014-2Report Type:Expedited (15-DaCompany Report #WAES 00123514
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Delirium Feeding Disorder Nervous System Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Red Blood Cell Sedimentation Rate Increased Upper Respiratory Tract Infection		Calcitriol	C				
			Prednisolone	C				
			Propranolol Hcl	C				

Date:01/26/01ISR Number: 3656017-8Report Type:Expedited (15-DaCompany Report #WAES 00116064
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	3 DAY
			Tab Ibuprofen	SS		ORAL	1200 MG PO	
			Irbesartan	C				
			Metformin	C				

			Trimetazidine	C		

Date:01/26/01ISR Number: 3656030-0Report Type:Expedited (15-DaCompany Report #WAES 01016515
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 12 DAY						
		Other	Buspirone	C		
			Digitalis	C		
			Tramadol	C		

Date:01/26/01ISR Number: 3656044-0Report Type:Expedited (15-DaCompany Report #WAES 01016514
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Fatigue Myalgia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO						
		Other				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/01ISR Number: 3656056-7Report Type:Expedited (15-DaCompany Report #WAES 01016022
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer Haemorrhage	Study			Laboratories Div			
Initial or Prolonged	Haemoglobin Decreased	Health			Merck Co Inc	ORAL	SEE IMAGE	159 DAY
	Melaena	Professional	Aspirine Lysine	SS		ORAL	160 MG PO	
			Ascorbic Acid (+) Hesperidin Methyl Chal	C				
			Diltiazem Hydrochloride	C				
			Glimepiride	C				
			Metformin Hcl	C				
			Nitroglycerin	C				
			Omeprazole	C				

Date:01/26/01ISR Number: 3656058-0Report Type:Expedited (15-DaCompany Report #WAES 01015580
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastritis Haemorrhagic	Health			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal	Professional			Merck Co Inc	ORAL	PO	250 DAY
	Haemorrhage							

Date:01/29/01ISR Number: 3656431-0Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hallucination, Visual		Vioxx 25mg/D Merck	PS	Merck	ORAL	25 MG PO /	
Intervention to							DAY	
Prevent Permanent			Lanoxin	C				
Impairment/Damage			Levothroid	C				

Date:01/29/01ISR Number: 3656508-XReport Type:Expedited (15-DaCompany Report #WAES 00082055
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	
			Centrum Silver	C				
			Prinivil	C				
			Tylenol	C				
			Ascorbic Acid	C				
			Fexofenadine Hydrochloride	C				
			Megestrol Acetate	C				
			Naproxen	C				
			Tamoxifen Citrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/01ISR Number: 3658344-7Report Type:Expedited (15-DaCompany Report #WAES 00121942
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Blood Urea Increased	Other			Merck Co Inc	ORAL	25 MG/BID/PO	
	Drug Level Above		Digoxin	SS			0.25 MG/DAILY	
	Therapeutic		Accupril	C				
			Bumex	C				
			Coreg	C				
			K-Dur	C				
			Prevacid	C				
			Zoloft	C				
			Aspirin	C				
			Nitroglycerin	C				

Date:01/29/01ISR Number: 3659160-2Report Type:Expedited (15-DaCompany Report #WAES 01011868
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Syncope				Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Lozol	C				
			Prevacid	C				

Date:01/29/01ISR Number: 3659162-6Report Type:Expedited (15-DaCompany Report #WAES 01011775
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Grand Mal Convulsion	Company			Merck Co Inc	ORAL	PO	

Representative

Date:01/29/01ISR Number: 3659163-8Report Type:Expedited (15-DaCompany Report #WAES 01011751
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Benadryl	C		
			Buspar	C		
			Cipro	C		
			Coumadin	C		
			Lasix	C		
			Pepcid	C		
			Prinivil	C		
			Risperdal	C		
			Vicodin Tablets	C		
			Ferrous Sulfate	C		
			Trazodone	C		
			Vitamins	C		
			Zinc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/01ISR Number: 3659164-XReport Type:Expedited (15-DaCompany Report #WAES 01011492
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faeces Discoloured							
	Gastrointestinal							
	Haemorrhage		Celebrex	SS				
			Aspirin	C				

Date:01/29/01ISR Number: 3659165-1Report Type:Expedited (15-DaCompany Report #WAES 01011457
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Aspartate							
	Aminotransferase Increased							
	Blood Alkaline Phosphatase Increased							
	Blood Amylase Increased							
	Blood Lactate Dehydrogenase Increased							
	Pancreatitis							

Date:01/29/01ISR Number: 3659168-7Report Type:Expedited (15-DaCompany Report #WAES 01011419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PRN PO	
	Chest Pain							
	Duodenal Ulcer							
	Haemorrhage		Lipitor	C				
	Gastric Ulcer Haemorrhage		Prozac	C				
			Questran	C				
			Wellbutrin	C				

Date:01/29/01ISR Number: 3659277-2Report Type:Expedited (15-DaCompany Report #WAES 01018224
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	29 DAY
			Tab Hctz/Quinapril	SS		ORAL	12.5/10 MG	
			Celecoxib	C				
			Isosorbide Dinitrate	C				
			Theophylline	C				

Date:01/29/01ISR Number: 3659280-2Report Type:Expedited (15-DaCompany Report #WAES 01015580
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastritis Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	250 DAY	

Date:01/29/01ISR Number: 3659282-6Report Type:Expedited (15-DaCompany Report #WAES 01015223
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia	Foreign	Vioxx	PS	Merck Research			
	Gastric Ulcer Perforation	Other			Laboratories Div			
	Nausea				Merck Co Inc	ORAL	12.5 MG	241 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				

Date:01/29/01ISR Number: 3659283-8Report Type:Expedited (15-DaCompany Report #WAES 01015161
Age:95 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research			
	Gastrointestinal	Other			Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	25 MG	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Furosemide	C				
			Lactulose	C				
			Oxybutynincl	C				
			Quinine	C				
			Senna	C				

Date:01/29/01ISR Number: 3659285-1Report Type:Expedited (15-DaCompany Report #WAES 01015156
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dermatitis	Foreign	Vioxx	PS	Merck Research			
	Erythema Multiforme	Other			Laboratories Div			
	Haematemesis				Merck Co Inc	ORAL	25 MG	32 DAY
	Lower Respiratory Tract Infection		Acetaminophen/Codeine Phosphate	C				
	Upper Gastrointestinal Haemorrhage		Bumetanide	C				
			Fluoxetine	C				

			Lactulose	C		

Date:01/29/01ISR Number: 3659287-5Report Type:Expedited (15-DaCompany Report #WAES 01015106
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Blood Amylase Increased	Other				
	Gastritis				Merck Co Inc	ORAL
12.5 MG 7 DAY						
	Pancreatitis		Acetaminophen/Codeine Phosphate	C		
	Vomiting		Dihydrocodeine	C		
	White Blood Cell Count Increased		Etidronate Disodium	C		
			Lansoprazole	C		

Date:01/30/01ISR Number: 3657377-4Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Hospitalization - Initial or Prolonged	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health	Vioxx	PS	Merck	ORAL	ORAL	
	Gastric Ulcer Perforation	Professional	Asa	SS				
	Gastrointestinal		Prevacid	C				
	Haemorrhage		Klonopin	C				
			Lasix	C				
			Ativan	C				
			Verapamil	C				
			Albuterol	C				
			Rfemeron	C				
			Trazadone	C				
			Macrobid	C				
			Ambien	C				
			Lanoxin	C				
			Vasotec	C				
			Glucophage	C				
			Glucotrol	C				

Date:01/30/01ISR Number: 3657380-4Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation	Health	Vioxx	PS	Merck	ORAL	25 MG QD ORAL	
Life-Threatening	Post Procedural	Professional	Prednisone	SS		ORAL	10 MG QD ORAL	
	Complication		Asorbic Acid	C				
	Rectal Haemorrhage		Plavix	C				
			Arava	C				
			Allegra	C				
			Ca Carbonate	C				
			Laix	C				
			Kcl	C				
			Premarin	C				
			Ultram	C				

Date:01/30/01ISR Number: 3657763-2Report Type:Expedited (15-DaCompany Report #WAES 01015222
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Ferrous Sulfate	C				

Date:01/30/01ISR Number: 3657764-4Report Type:Expedited (15-DaCompany Report #WAES 01015224
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Disorientation Migraine	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	10 DAY
		Other	Amiloride Hydrochloride/Hctz	C				

				Diclofenac Sodium + Misoprostol	C	
				Estradiol Valerate/Norgestrel	C	

Date:01/30/01ISR Number: 3657765-6Report Type:Expedited (15-DaCompany Report #WAES 01015221
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Palpitations	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	10 DAY
			Allopurinol	C				
			Mesalamine	C				
			...	C				

Date:01/30/01ISR Number: 3657780-2Report Type:Expedited (15-DaCompany Report #WAES 01016122
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue Gastric Ulcer Haemorrhage Malaise	Foreign Study Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25 MG	140 MON

Date:01/30/01ISR Number: 3657782-6Report Type:Expedited (15-DaCompany Report #WAES 01016022
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Duodenal Ulcer Haemoglobin Decreased	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25	

	Melaena	Professional				
MG 159 DAY						
		Other	Aspirin Lysine	SS		ORAL
160 MG						
			Ascorbic Acid			
			(+)Hesperidin Methyl Chal	C		
			Diltiazem Hydrochloride	C		
			Glimepride	C		
			Metformin Hcl	C		
			Nitroglycerine	C		
			Omeprazole	C		

Date:01/30/01ISR Number: 3658316-2Report Type:Expedited (15-DaCompany Report #WAES 00120395
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Confusional State Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/UNK/PO 5 DAY						
			Dilantin	SS		
			Glucophage	C		
			Hydrodiuril	C		
			Phenobarbital	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3658317-4Report Type:Expedited (15-DaCompany Report #WAES 00112343
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Blood Pressure Increased Cerebrovascular Accident	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	3 MON

Date:01/30/01ISR Number: 3658320-4Report Type:Expedited (15-DaCompany Report #WAES 00081283
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Upper Anorexia Asthma Autoimmune Hepatitis Bile Duct Stone Blood Albumin Decreased Blood Calcium Decreased Blood Ph Decreased Blood Potassium Decreased Blood Sodium Decreased Bundle Branch Block Left Chills Chronic Obstructive Airways Disease Exacerbated Gastrointestinal Disorder Hepatitis Viral Hepatocellular Damage Hyperhidrosis Hypogammaglobulinaemia Inflammation Influenza Like Illness Jaundice Liver Disorder Muscle Atrophy Myoglobin Blood Increased Pco2 Decreased	Consumer Health Professional	Vioxx Aerobid Atrovent Dyazide Humibid Medrol Pepcid Premarin Vancenase Aq Nasal Spray Albuterol	PS C C C C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Platelet Count Decreased
Productive Cough
Pyrexia
Rash Pruritic
Respiratory Distress
Sinusitis

Date:01/30/01ISR Number: 3658321-6Report Type:Expedited (15-DaCompany Report #WAES 01011361
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Coma							
	Dizziness							
	Headache							
	Myocardial Infarction		Lopressor	C				
	Oedema Peripheral							
	Rash Pruritic							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3658323-XReport Type:Expedited (15-DaCompany Report #WAES 00120114
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Hepatic Steatosis							
	Hepatitis Viral							
	Jaundice Cholestatic		Indocin	C				
	Pyrexia		Visine	C				
	Red Blood Cell Sedimentation Rate Increased							

Date:01/30/01ISR Number: 3658330-7Report Type:Expedited (15-DaCompany Report #WAES 00112460
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Balance Disorder							
	Blood Pressure Increased							
	Bronchitis		Reglan	SS				
	Chest Pain		Beconase	C				
	Condition Aggravated		Dyazide	C				
	Diarrhoea		Evista	C				
	Dizziness		Lomotil	C				
	Fall		Pepcid Ac	C				
	Fatigue		Prevacid	C				
	Gastrooesophageal Reflux		Tigan	C				
	Disease		Ventolin	C				
	Haematochezia		[Therapy					
	Headache		Unspecified]	C				
	Nausea							
	Oedema Peripheral							
	Pleural Infection							
	Pruritus							
	Tinnitus							
	Vomiting							

Date:01/30/01ISR Number: 3658333-2Report Type:Expedited (15-DaCompany Report #WAES 01011783
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/30/01ISR Number: 3658338-1Report Type:Expedited (15-DaCompany Report #WAES 01011384
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Tylenol	C				
			Capsaicin	C				
			Ferrous Sulfate	C				
			Lansoprazole	C				

Simethicone C

Date:01/30/01ISR Number: 3658340-XReport Type:Expedited (15-DaCompany Report #WAES 01011369
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Bronchospasm Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	2 WK

Date:01/30/01ISR Number: 3658342-3Report Type:Expedited (15-DaCompany Report #WAES 01011248
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Sepsis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/30/01ISR Number: 3658346-0Report Type:Expedited (15-DaCompany Report #WAES 00111498
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Advil	SS				
			Aleve	SS				

Date:01/30/01ISR Number: 3658614-2Report Type:Expedited (15-DaCompany Report #WAES 01016139
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Therapy Unspecified	SS		ORAL	PO	

Date:01/30/01ISR Number: 3658625-7Report Type:Expedited (15-DaCompany Report #WAES 01016071
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	93 DAY
			Zocor	C				
			Estradiol (+) Medroxyprogesterone Acetat	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3658720-2Report Type:Expedited (15-DaCompany Report #WAES 01012017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:01/30/01ISR Number: 3658722-6Report Type:Expedited (15-DaCompany Report #WAES 01011902
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Ibuprofen	C				

Date:01/30/01ISR Number: 3658727-5Report Type:Expedited (15-DaCompany Report #WAES 00122232
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Eye Injury Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Syncope		Aspirin	C				

Date:01/30/01ISR Number: 3658731-7Report Type:Expedited (15-DaCompany Report #WAES 01010864
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Hepatitis C Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY/ PO						
			Arava	C		
			Remicade	C		
			Zestril	C		
			Methotrexate	C		
			Nonsteroidal Anti-Inflammatory D	C		

Date:01/30/01ISR Number: 3659159-6Report Type:Expedited (15-DaCompany Report #WAES 00120107
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Propranolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/01ISR Number: 3659366-2Report Type:Expedited (15-DaCompany Report #WAES 00126118
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemoglobin Decreased Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	12 DAY
			Powd Aspirin	SS		ORAL	300 MG, PO	1926 DAY
			Vasotec	C				
			Acetaminophen	C				
			Calcium Citrate (+)					
			Cholecalciferol	C				
			Diltiazem	C				

Date:01/30/01ISR Number: 3659367-4Report Type:Expedited (15-DaCompany Report #WAES 00126094
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angina Unstable Atrial Fibrillation Coronary Artery Disease	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	6 DAY
			Althiazide/Spironolactone	C				
			Ginkgo Biloba Extract	C				
			Pantoprazole	C				
			Rilmenidene	C				
			Verapamil Hcl	C				

Date:01/30/01ISR Number: 3659368-6Report Type:Expedited (15-DaCompany Report #WAES 00118218
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	3 WK

Aspirin Lysine	C
Diltiazem Hydrochloride	C
Lorazepam	C

Date:01/30/01ISR Number: 3659369-8Report Type:Expedited (15-DaCompany Report #WAES 01019765
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:01/30/01ISR Number: 3659934-8Report Type:Expedited (15-DaCompany Report #WAES 00119762
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Blood Urea Increased
	Dermatitis
	Diabetes Mellitus
	Eye Infection

		Mouth Ulceration Mucosal Erosion Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Stomatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO	1 MON						

Date:01/30/01ISR Number: 3659935-XReport Type:Expedited (15-DaCompany Report #WAES 01019610
Age:87 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	4 MON						
				Bisoprolol Fumarate	C		
				Isosorbide Mononitrate	C		

Date:01/30/01ISR Number: 3659943-9Report Type:Expedited (15-DaCompany Report #WAES 01018121
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Creatinine Increased Blood Urea Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO	5 DAY						
		Hyperkalaemia Pulmonary Oedema		Prinzide	C		
				Disopyramide	C		
				Nifedipine	C		

Date:01/31/01ISR Number: 3657804-2Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck	ORAL
25 1T QD PO						
Required			Premarin	C		
Intervention to			Allegra	C		
Prevent Permanent			Elavil	C		
Impairment/Damage			Zestoril	C		

Date:01/31/01ISR Number: 3657823-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dehydration	Health	Sulfasalazine			
	Faecaloma	Professional	(Azulfidine)	PS		ORAL
PO 1 G Q						
	Metabolic Disorder					
12-8H						
	Renal Failure		Allopurinol 100 Mg &			
	Stevens-Johnson Syndrome		300 Mg Tab/ 500 Mg			
	Toxic Epidermal		Tab Pharmacia &			
	Necrolysis		Upjohn	SS		ORAL
PO 200-300MG						
QD						
			Vioxx 25mg Or 50 Mg			
			Tablet	SS	Merck	ORAL
PO 25-50 MG						
QD						
			Asa	C		
			Andestyramine	C		
			Lansoprazole	C		

Metoprolol	C
Olanzapine	C
Prednisone	C
Zyprexa	C

Date:01/31/01ISR Number: 3657852-2Report Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Burning Sensation		Vioxx	PS		ORAL	25 MG PO O.D.	
Intervention to Prevent Permanent Impairment/Damage	Dyspnoea		Prempro	C				
	Fatigue		Vit E	C				
	Feeling Jittery		Folic Acid	C				
	Heart Rate Increased		Slow Fe	C				
	Hypoaesthesia							
	Insomnia							
	Laboratory Test Abnormal							
	Malaise							
	Paraesthesia							
	Pyrexia							
	Thyroiditis							

Date:01/31/01ISR Number: 3657857-1Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS				
	Oedema Peripheral							

Date:02/01/01ISR Number: 3658245-4Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx / 25mg	PS		ORAL	25-50 MG QDAY	ORAL

Amitriptyline	C
Atenolol	C
Lotrel	C
Glucophage	C
Maxzide	C

Date:02/01/01ISR Number: 3658284-3Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx 25mg	PS		ORAL	25 MG QD	
Initial or Prolonged	Gastritis Erosive					ORAL		
Required	Haematemesis		Plavix 75mg	SS		ORAL	75 MG QD	
Intervention to	Mallory-Weiss Syndrome					ORAL		
Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659451-5Report Type:Periodic Company Report #ZANA000592 (0)
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams	Health	Zanaflex	PS	Elan Pharma			
	Drug Interaction	Professional			International Ltd	ORAL	4 MG DAILY	
						ORAL		
			Vioxx	SS			50 MG DAILY	

Date:02/01/01ISR Number: 3659487-4Report Type:Periodic Company Report #ZANA000573(0)
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypotension	Company	Zanaflex	PS	Elan Pharma			
Initial or Prolonged		Representative			International Ltd	ORAL	60 MG DAILY	
						ORAL		
			Vioxx	SS				

Date:02/01/01ISR Number: 3659491-6Report Type:Periodic Company Report #ZANA000567(0)
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Health	Zanaflex	PS	Elan Pharma			
	Hallucination	Professional			International Ltd	ORAL	UNKNOWN ORAL	
	Insomnia		Vioxx	SS		ORAL	25 MG DAILY	
	Nausea						ORAL	
			Neurontin	C				

Date:02/01/01ISR Number: 3659976-2Report Type:Expedited (15-DaCompany Report #WAES 01011958
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Drug Interaction Haemorrhage Hepatic Failure Hepatotoxicity Intestinal Perforation Sepsis	Health Professional Company Representative	Vioxx [Therapy Unspecified]	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/01/01ISR Number: 3660229-7Report Type:Expedited (15-DaCompany Report #WAES 01011751
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Blood Potassium Decreased Renal Failure	Health Professional	Vioxx Benadryl Buspar	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:02/01/01ISR Number: 3660231-5Report Type:Expedited (15-DaCompany Report #WAES 01012170
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3660233-9Report Type:Expedited (15-DaCompany Report #WAES 01012114
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Prilosec	C				
			Therapy Unspecified	C				
			Chondroitin (+) Glucosamine	C				
			Potassium Gluconate	C				

Date:02/01/01ISR Number: 3660236-4Report Type:Expedited (15-DaCompany Report #WAES 01012080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/01/01ISR Number: 3660254-6Report Type:Expedited (15-DaCompany Report #WAES 00102304
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Caltrate	C				
			Premarin	C				
			Univasc	C				

Vitamins C

Date:02/01/01ISR Number: 3660259-5Report Type:Expedited (15-DaCompany Report #WAES 01012018
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Benign Intracranial Hypertension Headache	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:02/01/01ISR Number: 3660260-1Report Type:Expedited (15-DaCompany Report #WAES 01011944
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Influenza Like Illness Torticollis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3660262-5Report Type:Expedited (15-DaCompany Report #WAES 00072005
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombocytopenia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Hydrodiuril	C				
			Vasotec	C				

Date:02/01/01ISR Number: 3660263-7Report Type:Expedited (15-DaCompany Report #WAES 01011775
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Malaise Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:02/01/01ISR Number: 3660267-4Report Type:Expedited (15-DaCompany Report #WAES 01011438
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung Oliguria Post Procedural Complication Renal Failure Staphylococcal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien [Therapy Unspecified]	C C				

Date:02/01/01ISR Number: 3660271-6Report Type:Expedited (15-DaCompany Report #WAES 00120601
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema Dyspnoea Tongue Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 DAY

Date:02/01/01ISR Number: 3660273-XReport Type:Expedited (15-DaCompany Report #WAES 00110445
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Drug Level Above Therapeutic Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lithium Carbonate (Roxane) 300 Mg	SS		ORAL	200 MG/TID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3660807-5Report Type:Expedited (15-DaCompany Report #WAES 00063725
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Ca Acetylsalicylate	C				
			Hyzaar	C				
			Barnidipine	C				
			Diclofenac Sodium (+) Misoprostol	C				

Date:02/01/01ISR Number: 3660838-5Report Type:Expedited (15-DaCompany Report #WAES 01013718
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	13 DAY
			Atenolol	C				
			Carbaspirin Calcium	C				
			Cerivastatin	C				

Date:02/01/01ISR Number: 3660840-3Report Type:Expedited (15-DaCompany Report #WAES 01015241
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea Epistaxis Haemoptysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
	Rhinorrhoea		Acetaminophen/Codein e Phosphate	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Calcium Carbonate					

			(+) Sodium Alginate			
			(+) Nitrazepam	C		
			Zomepirac Sodium	C		

Date:02/01/01ISR Number: 3660841-5Report Type:Expedited (15-DaCompany Report #WAES 01015244
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Disseminated	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Intravascular Coagulation	Other			Laboratories Div	
Initial or Prolonged					Merck Co Inc	ORAL
25 MG, PO 67 DAY						
Disability			Acetaminophen/Codein			
			e Phosphate	C		
			Carbamazepine	C		
			Cyclizine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3660842-7Report Type:Expedited (15-DaCompany Report #WAES 01017517
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cytomegalovirus Infection	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Leukopenia	Health						
	Mouth Haemorrhage	Professional			Merck Co Inc	ORAL	PO	
	Nasal Congestion		Calcium Carbonate					
	Petechiae		(+) Sodium Alginate					
	Thrombocytopenia		(+)	C				
	Viral Infection		Tramadol Hcl	C				

Date:02/01/01ISR Number: 3660843-9Report Type:Expedited (15-DaCompany Report #WAES 01019152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Rhinitis	Other						
	Visual Disturbance				Merck Co Inc	ORAL	12.5 MG, PO	3 DAY
			Enalapril	C				

Date:02/01/01ISR Number: 3660845-2Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Condition Aggravated	Health						
Other	Decreased Activity	Professional			Merck Co Inc	ORAL	25 MG, PO	
	Gastric Ulcer	Other	Cap Celecoxib	SS		ORAL	400 MG, PO	
	Pruritus		Inj Diclofenac	SS			INTRAMUSCULAR	IM
	Renal Failure		Acetaminophen/Codein					
	Renal Impairment		e Phosphate	C				
			Aspirin	C				
			Calcium Carbonate					
			(+) Cholecalciferol	C				

			Furosemide	C		
			Isosorbide Dinitrate	C		
			Levothyroxine Na	C		
			Midazolam Maleate	C		
			Oxazepam	C		
			Pantoprazole Na	C		

Date:02/02/01ISR Number: 3659196-1Report Type:Expedited (15-DaCompany Report #00-12-0057
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Thalomid	PS	Celgene Corp	ORAL	3000 MG	
Initial or Prolonged	Congestive	Professional					DAILY ORAL	
	Fluid Retention		Vioxx	SS		ORAL	50 MG DAILY	
	Pulmonary Congestion						ORAL	
	Weight Increased		Dapsone	C				
			Decadron	C				
			Etoposide Oral	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3659681-2Report Type:Expedited (15-DaCompany Report #WAES 00121715
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bone Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Diarrhoea							
	Dry Mouth							
	Face Oedema		Maxzide	C				
	Gastritis		Therapy Unspecified	C				
	Hepatic Enzyme Increased		Atenolol	C				

Date:02/02/01ISR Number: 3659683-6Report Type:Expedited (15-DaCompany Report #WAES 00121870
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematocrit Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
			Premarin	C				
			Provera	C				

Date:02/02/01ISR Number: 3659685-XReport Type:Expedited (15-DaCompany Report #WAES 01011891
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arterial Stenosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cardiac Disorder							
	Cardiac Valve Disease							
	Disorientation		Atacand Unk	SS				
	Dysuria		Aciphex	C				
	Gout		Claritin	C				
	Ill-Defined Disorder		Coreg	C				
	Irritable Bowel Syndrome		Flomax	C				
	Oedema Peripheral		Flovent	C				
	Pneumonia		Norvasc	C				

	Pulmonary Hypertension		Gemfibrozil	C		
	Renal Failure Acute		Ibuprofen	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:02/02/01ISR Number: 3659687-3Report Type:Expedited (15-DaCompany Report #WAES 01012215
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Malaise Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ DAILY/						
PO						
			Therapy Unspecified	C		
			Nortriptyline	C		

Date:02/02/01ISR Number: 3659808-2Report Type:Expedited (15-DaCompany Report #WAES 00090176
Age:72 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer Haemorrhage Exsanguination	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	
		Representative	Florinef	C				
			Lanoxin	C				
			Synthroid	C				
			Wellbutrin	C				
			Quinidine	C				

Date:02/02/01ISR Number: 3659810-0Report Type:Expedited (15-DaCompany Report #WAES 00080934
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:02/02/01ISR Number: 3659811-2Report Type:Expedited (15-DaCompany Report #WAES 00111470
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Haemorrhoids	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/02/01ISR Number: 3659814-8Report Type:Expedited (15-DaCompany Report #WAES 00100215
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			

Hospitalization -	Back Pain	Professional			Laboratories Div	
Initial or Prolonged	Blood Urea Increased	Other			Merck Co Inc	ORAL
25						
	Gastric Ulcer					
MG/DAILY/PO						
	Gastrointestinal		Nonsteroidal			
	Haemorrhage		Anti-Inflammatory	C		
	Melaena					

Date:02/02/01ISR Number: 3659816-1Report Type:Expedited (15-DaCompany Report #WAES 00081294
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Duodenal Ulcer	Health			Laboratories Div	
Initial or Prolonged	Faeces Discoloured	Professional			Merck Co Inc	ORAL
25						
	Gastrooesophageal Reflux					
MG/DAILY/PO						
	Disease		Ecotrin	C		
	Haemoglobin Decreased		Imdur	C		
	Oesophagitis		Norvasc	C		
	Vomiting		Captopril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3659902-6Report Type:Expedited (15-DaCompany Report #200110168BWH
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Health	Cipro	PS	Bayer Corp	ORAL	1000 MG DAILY	
Hospitalization -	Hypotension	Professional						
Initial or Prolonged	Renal Failure Acute	Other	Vioxx	SS				
	Sepsis							

Date:02/02/01ISR Number: 3660141-3Report Type:Expedited (15-DaCompany Report #WAES 01015250
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Myocardial Infarction	Other			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal				Merck Co Inc	ORAL	12.5 MG	15 DAY
	Haemorrhage		Prinivil	C				
			Aspirin	C				
			Atenolol	C				

Date:02/02/01ISR Number: 3660144-9Report Type:Expedited (15-DaCompany Report #WAES 01016171
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Vioxx	PS	Merck Research			
	Dizziness	Study			Laboratories Div			
	Nausea	Health			Merck Co Inc	ORAL	12.5 MG	109 DAY
		Professional	Cetirizine	C				
			Ferrouss04	C				
			Omeprazole	C				

Date:02/02/01ISR Number: 3660150-4Report Type:Expedited (15-DaCompany Report #WAES 01019156
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema Flushing Oedema Peripheral	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	3 DAY
	Pruritus Rash Erythematous	Other	Citalopram Hydrobromide	C				

Date:02/02/01ISR Number: 3660156-5Report Type:Expedited (15-DaCompany Report #WAES 01019701
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Hepatic Function Abnormal Liver Function Test Abnormal Pyelonephritis	Foreign Study Health Professional	Vioxx Mevacor Vasotec	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	34 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/01ISR Number: 3660157-7Report Type:Expedited (15-DaCompany Report #WAES 00115530
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Necrosis Hepatic Steatosis Hepatocellular Damage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	5 MON
	Liver Disorder		Acetylcysteine	C				
			Albuterol	C				
			Budesonide	C				
			Calcium Carbonate	C				
			Magnesium (Unspecified)	C				
			Methyprednisolone	C				
			Ranitidine	C				
			Xylometazoline Hcl	C				

Date:02/02/01ISR Number: 3660158-9Report Type:Expedited (15-DaCompany Report #WAES 00115530
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 MON

Date:02/02/01ISR Number: 3660160-7Report Type:Expedited (15-DaCompany Report #WAES 00103530
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Steatosis Hepatitis Inflammation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	18 DAY
			Tab Sulfasalazine	SS		ORAL	2500 MG, PO	18 DAY

Date:02/02/01ISR Number: 3660164-4Report Type:Expedited (15-DaCompany Report #WAES 00125640
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 MON

Date:02/02/01ISR Number: 3660166-8Report Type:Expedited (15-DaCompany Report #WAES 01013490
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis Skin Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/02/01ISR Number: 3660185-1Report Type:Expedited (15-DaCompany Report #WAES 01019551
Age:65 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Shock	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3661237-2Report Type:Expedited (15-DaCompany Report #WAES 01010264
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aortic Valve Stenosis Atrial Fibrillation Blood Cholesterol	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
Other	Increased	Representative					PO	
	Cardiac Failure		Accupril	C				
	Congestive		Axid	C				
	Cardiac Murmur							
	Coronary Artery Disease							
	Crepitations							
	Diabetes Mellitus							
	Fluid Overload							
	Fluid Retention							
	Hyperglycaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypothyroidism							
	Leukocytosis							
	Myocardial Infarction							
	Paraesthesia							
	Protein Total Increased							
	Supraventricular							
	Extrasystoles							
	Supraventricular							
	Tachycardia							
	Ventricular Tachycardia							

Date:02/05/01ISR Number: 3661243-8Report Type:Expedited (15-DaCompany Report #WAES 01010065
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous Accidental Exposure Pregnancy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Indocin (Indomethacin)	C				

Date:02/05/01ISR Number: 3661244-XReport Type:Expedited (15-DaCompany Report #WAES 01010829
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Haematemesis Haematocrit Decreased Haemoglobin Decreased Melaena	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve	C				
			Anacin	C				
			Baycol	C				
			Hyzaar	C				
			Synthroid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3661245-1Report Type:Expedited (15-DaCompany Report #WAES 01012063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Arimidex	C				
			Baycol	C				
			Norflex	C				
			Paxil	C				
			Prevacid	C				
			Verapamil	C				

Date:02/05/01ISR Number: 3661248-7Report Type:Expedited (15-DaCompany Report #WAES 01012569
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/05/01ISR Number: 3661252-9Report Type:Expedited (15-DaCompany Report #WAES 01020002
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Chest Pain Eating Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Gastrointestinal Disorder		Prevacid	C				
			Prilosec	C				

Date:02/05/01ISR Number: 3661361-4Report Type:Expedited (15-DaCompany Report #WAES 00053090
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	"SEE IMAGE"	
			L-Thyroxine	C				
			Aspirin	C				
			Glucosamine	C				
			Ibuprofen	C				
			Meclizine	C				
			Propoxyphene Napsylate Monohydra	C				

Date:02/05/01ISR Number: 3661363-8Report Type:Expedited (15-DaCompany Report #WAES 00122078
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Arthralgia
	Asthenia
Other	Duodenal Ulcer
	Embolism
	Gait Disturbance
	Gastrointestinal

	Haemorrhage Haematemesis Haemoglobin Decreased Melaena	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Cap Celebrex 200 Mg	SS		ORAL	200 MG/BID/PO
			Fosamax	C			
			Hydrodiuril	C			
			Acetaminophen	C			
			Calcium (Unspecified)	C			
			Codeine Phosphate	C			
			Dextropropoxyphene	C			
			Estrogens, Conjugated	C			
			Ranitidine Hydrochloride	C			
			Salcatonin	C			
			Tramadol Hydrochloride	C			
			Triamterene	C			

Date:02/05/01ISR Number: 3661569-8Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cholestasis Haemolysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	

Date:02/05/01ISR Number: 3661570-4Report Type:Expedited (15-DaCompany Report #WAES 01015626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Left Ventricular Failure	Foreign	Vioxx	PS	Merck Research		

Initial or Prolonged	Health Professional		Laboratories Div Merck Co Inc
OPHTHALMIC			

Date:02/05/01ISR Number: 3661571-6Report Type:Expedited (15-DaCompany Report #WAES 01017524
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Aortic Aneurysm Cholelithiasis Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
OPHTHALMIC						
	Gastric Ulcer Haematemesis Rectal Haemorrhage Upper Gastrointestinal Haemorrhage					

Date:02/05/01ISR Number: 3661572-8Report Type:Expedited (15-DaCompany Report #WAES 01019775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Date:02/05/01ISR Number: 3661573-XReport Type:Expedited (15-DaCompany Report #WAES 01015140
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Hospitalization - Initial or Prolonged	Cholelithiasis							
	Circulatory Collapse							
	Gastric Ulcer Haemorrhage		Acetaminophen/Propoxyphene Hydrochloride	C				
			Diclofenac Sodium (+) Misoprostol	C				

Date:02/05/01ISR Number: 3661578-9Report Type:Expedited (15-DaCompany Report #WAES 01015617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Methotrexate	SS				

Date:02/05/01ISR Number: 3661579-0Report Type:Expedited (15-DaCompany Report #WAES 01016139
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Vioxx	PS	Merck Research			

	International Normalised Ratio Increased	Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 5 MON						
			Tab Fluindione	SS		ORAL
15 MG PO						

Date:02/05/01ISR Number: 3661580-7Report Type:Expedited (15-DaCompany Report #WAES 01016162
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactoid Reaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 7 DAY						
			Irbesartan	C		

Date:02/05/01ISR Number: 3661582-0Report Type:Expedited (15-DaCompany Report #WAES 01019148
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertension Retinal Vein Thrombosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG PO 59 DAY						
			Hctz/Quinapril	C		
			Allopurinol	C		
			Escin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3661584-4Report Type:Expedited (15-DaCompany Report #WAES 01019155
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia Chromatopsia Colour Blindness Acquired	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	14 DAY
	Drug Interaction Drug Level Above Therapeutic Nausea Renal Impairment		Tab Digoxin	SS		ORAL	PO	

Date:02/05/01ISR Number: 3661645-XReport Type:Expedited (15-DaCompany Report #WAES 00073757
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	2 DAY
			Ca Acetylsalicylate	C				
			Diazepam	C				
			Oxazepam	C				
			Tolterodine Tartrate	C				

Date:02/05/01ISR Number: 3661646-1Report Type:Expedited (15-DaCompany Report #WAES 00095136
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other (SEE IMAGE)	Gastrointestinal Haemorrhage Melaena	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	36 DAY
			Elavil	C				
			Aspirin	C				

				Atorvastatin	C		
				Gliclazide	C		
				Ispaghula Husk (+)			
				Senna	C		
				Ramipril	C		

Date:02/05/01ISR Number: 3661691-6Report Type:Expedited (15-DaCompany Report #WAES 00074037
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Hydrodiuril	C				
			Proscar	C				
			Chondroitin Sulfate	C				
			Darvocet N	C				
			Glucosamine	C				
			Prednisone	C				
			Terazosin	C				

Date:02/05/01ISR Number: 3661696-5Report Type:Expedited (15-DaCompany Report #WAES 01011944
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Influenza Like Illness Musculoskeletal Stiffness Pleural Infection Torticollis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:02/05/01ISR Number: 3661747-8Report Type:Expedited (15-DaCompany Report #WAES 01012477
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain Condition Aggravated Hypoaesthesia Motor Dysfunction	Consumer	Tab Vioxx 50 Mg Amoxicillin	PS C		ORAL	50 MG / DAILY / PO	

Date:02/05/01ISR Number: 3661748-XReport Type:Expedited (15-DaCompany Report #WAES 01012488
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Cardiomyopathy Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:02/05/01ISR Number: 3661749-1Report Type:Expedited (15-DaCompany Report #WAES 01012519
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nephrotic Syndrome	Health	Vioxx	PS	Merck Research			

	Proteinuria	Professional			Laboratories Div Merck Co Inc	ORAL
25 MG /DAILY/PO						
			Celebrex 200 Mg	SS		ORAL
200 MG/DAILY/PO						
			Feldene	C		

Date:02/05/01ISR Number: 3661751-XReport Type:Expedited (15-DaCompany Report #WAES 00080069
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Attention Deficit/Hyperactivity Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Disability						
25 MG/DAILY/PO	Feeling Abnormal					
	Feeling Cold		Vitamins	C		
	Hypoaesthesia					
	Paraesthesia					

Date:02/05/01ISR Number: 3661753-3Report Type:Expedited (15-DaCompany Report #WAES 00111037
Age:66 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure	Consumer	Tab Vioxx	PS		ORAL	25	
Congestive	Health					MG/DAILY/PO	
Dyspnoea	Professional	Avapro	C				
Oedema Peripheral		Coumadin	C				
Weight Increased		Lasix	C				
		Tambocor	C				

Date:02/05/01ISR Number: 3661754-5Report Type:Expedited (15-DaCompany Report #WAES 01012353
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				

Date:02/05/01ISR Number: 3661755-7Report Type:Expedited (15-DaCompany Report #WAES 01012300
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Celexa	C				
			Alprazolam	C				
			Aspirin	C				
			Verapamil	C				
			Niaspan	C				

Date:02/05/01ISR Number: 3661756-9Report Type:Expedited (15-DaCompany Report #WAES 01012335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dyspnoea Hypersensitivity Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/05/01ISR Number: 3661760-0Report Type:Expedited (15-DaCompany Report #WAES 01012449
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Claritin	C				
			Zanaflex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3662156-8Report Type:Periodic Company Report #A025844
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dental Caries	Health Professional	Zyrtec	PS		ORAL	10.00 MG	
			Sibutramine	SS		ORAL	10.00 MG	
			Rofecoxib	SS				
			Felodipine	SS				
			Micronor	C				
			Nasacort	C				
			Tylenol #2	C				
			Zoladex	C				

TOTAL:ORALL

TOTAL:ORAL

Date:02/05/01ISR Number: 3663239-9Report Type:Expedited (15-DaCompany Report #WAES 01015621
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	130 DAY
			Pentaerythritol Tetranitrate	C				
			Verapamil	C				

Date:02/05/01ISR Number: 3663240-5Report Type:Expedited (15-DaCompany Report #WAES 01016171
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Dizziness Hallucination	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	109 MON
	Nausea		Cetirizine	C				

		Other	Ferrous Sulfate	C
			Omeprazole	C

Date:02/05/01ISR Number: 3663241-7Report Type:Expedited (15-DaCompany Report #WAES 01016197
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 29 DAY						
		Professional Other	Melilot	C		

Date:02/05/01ISR Number: 3663243-0Report Type:Expedited (15-DaCompany Report #WAES 01016198
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulitis	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG PO 115 DAY						
		Professional Other	Acepromazine (+) Aceprometazine (+) Clor Althiazide/Spironola	C		

		ctone	C
		Metoprolol	C

Date:02/05/01ISR Number: 3663247-8Report Type:Expedited (15-DaCompany Report #WAES 01015618
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Haemorrhagic Rectal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	26 DAY
		Other	Diclofenac	SS				
			Aminophylline	C				
			Cholecalciferol	C				
			Dimenhydrinate	C				
			Eprosartan	C				
			Prednisolone	C				
			Tramadol Hc1	C				

Date:02/05/01ISR Number: 3663256-9Report Type:Expedited (15-DaCompany Report #WAES 00125614
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastritis Erosive Gastroenteritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	5 DAY
	Helicobacter Haematemesis Mallory-Weiss Syndrome	Other	Allopurinol	C				
			Diltiazem	C				
			Xipamide	C				

Date:02/05/01ISR Number: 3663257-0Report Type:Expedited (15-DaCompany Report #WAES 01015140
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Circulatory Collapse Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

		Other	Acetaminophen / Propoxyphene Hydrochloride	C		
			Diclofenac Sodium (+) Misoprostol	C		

Date:02/05/01ISR Number: 3663258-2Report Type:Expedited (15-DaCompany Report #WAES 01015185
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	40 DAY
			Sulfasalazine	SS		ORAL	2 GM PO	25 DAY
			Acetaminophen /Propoxyphene Hydrochloride	C				
			Diclofenac	C				

Date:02/05/01ISR Number: 3663259-4Report Type:Expedited (15-DaCompany Report #WAES 01016176
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Exertional	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	3 WK
		Other						

Date:02/05/01ISR Number: 3663260-0Report Type:Expedited (15-DaCompany Report #WAES 01015186
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Penicillamine	C				

Date:02/05/01ISR Number: 3663349-6Report Type:Expedited (15-DaCompany Report #WAES 00115661
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Haemorrhagic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	93 DAY
			Tab Aspirin	SS		ORAL	100 MG PO	
			Diclofenac Sodium (+) Misoprostol	C				
			Digitoxin	C				
			Doxasozin Mesylate	C				
			Glimepiride	C				
			Hydrochlorothiazide (+) Ramipril	C				
			Isosorbide Mononitrate	C				
			Piracetam	C				

Date:02/05/01ISR Number: 3663355-1Report Type:Expedited (15-DaCompany Report #WAES 01015520
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Gastritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:02/05/01ISR Number: 3663357-5Report Type:Expedited (15-DaCompany Report #WAES 00125517
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Death Hospitalization - Initial or Prolonged	Back Pain Blister Blood Pressure Systolic Decreased Burns Second Degree Diarrhoea Haematemesis Haemoglobin Decreased Hypoproteinaemia

	Mallory-Weiss Syndrome						
	Nausea						
	Prothrombin Level	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased	Foreign	Vioxx	PS	Merck Research		
	Renal Failure	Health			Laboratories Div		
	Sepsis	Professional			Merck Co Inc	ORAL	12.5 MG PO
	Shock	Other	(Therapy				
			Unspecified)	C			
			Diclofenac Na	C			
			Ranitidine Hcl	C			

Date:02/05/01ISR Number: 3663359-9Report Type:Expedited (15-DaCompany Report #WAES 00088227
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Back Pain	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Condition Aggravated	Health			Laboratories Div		
Other	Decreased Activity	Professional			Merck Co Inc	ORAL	25 MG PO
	Gastric Ulcer	Company	Cap Celecoxib	SS		ORAL	400 MG PO
	Haemoglobin Decreased	Representative	Inj Diclofenac	SS		INTRAMUSCULAR	IM
	Pruritus		Acetaminophen/Codein				
	Renal Impairment		e Phosphate	C			
			Aspirin	C			
			Calcium Carbonate				
			(+) Cholecalciferol	C			
			Furosemide	C			
			Isosorbide Dinitrate	C			
			Levothyroxine Na	C			
			Midazolam Maleate	C			
			Oxazepam	C			
			Pantoprazole Na	C			

Date:02/05/01ISR Number: 3663367-8Report Type:Expedited (15-DaCompany Report #WAES 01015185
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	40 DAY
			Sulfasalazine	SS		ORAL	2 GM PO	25 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Diclofenac	C				

Date:02/05/01ISR Number: 3663368-XReport Type:Expedited (15-DaCompany Report #WAES 01015186
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Upper Gastrointestinal Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Penicillamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/01ISR Number: 3663369-1Report Type:Expedited (15-DaCompany Report #WAES 00095004
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antibody Test Abnormal	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Other	Blood Thyroid Stimulating Hormone Increased	Health Professional			Merck Co Inc	ORAL	12.5 MG PO	
	Confusional State		Acetaminophen/Codeine Phosphate	C				
	Hallucination		Amitriptyline	C				
	Thyroid Disorder		Diazepam	C				
			Etidronate Disodium	C				
			Lansoprazole	C				
			Temazepam	C				

Date:02/06/01ISR Number: 3660887-7Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension		Vioxx (12.5mg)	PS		ORAL	12.5MG PO QD	

Date:02/06/01ISR Number: 3663206-5Report Type:Expedited (15-DaCompany Report #NSADSS2001000776
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Foreign	Remicade (5 Mg/Ml Lyophilized Powder)					
	Arthritis	Study						
	Back Pain	Health						
	Inflammation	Professional	(Infliximab, Recombinant)	PS		INTRAVENOUS	5 MG/KG, 1 IN 1 TIME(S),	
	Tachycardia							
			Vioxx (Rofecoxib)	SS		IV		

			Zithromax (Azithromycin)	C		
			Calcium-Sandoz (Calcium Glubionate)	C		
			Vitamin D (Ergocalcieferol)	C		
			Stilnox (Zolpidem)	C		

Date:02/06/01ISR Number: 3667065-6Report Type:Expedited (15-DaCompany Report #00110280
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Enbrel 25 Mg	PS		SUBCUTANEOUS	25 MG, BIW, SUBCUNTANEOUS	
	Cholelithiasis	Health Professional						
	Decreased Appetite		Azathioprine	SS				
	Diarrhoea		Rofecoxib	SS				
	Jaundice		Hydrochlorothiazide	C				
	Liver Function Test Abnormal		Lisinopril	C				
			Folic Acid	C				
	Vomiting		Ferrous Sulfate	C				
			Conj. Estrogens/Medroxyprogesterone	C				
			Ascorbic Acid	C				

		Tocopherol	C
		"Centrum Silver"	
		Multivitamins	C
		Potassium	C

Date:02/07/01ISR Number: 3661583-2Report Type:Expedited (15-DaCompany Report #WAES 01019154
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	33 DAY

Date:02/08/01ISR Number: 3662251-3Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Warfarin	PS		ORAL	VARIABLE AS DIRECT ORAL	
	Diarrhoea							
	Dizziness		Rofecoxib	SS		ORAL	25 MG QD ORAL	
	Faeces Discoloured		Phenzopyridine	C				
	Gastrointestinal Disorder		Terazosin	C				
	Haematemesis							
	Nausea							
	Vomiting							

Date:02/08/01ISR Number: 3662290-2Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain		Vioxx	PS				

Date:02/09/01ISR Number: 3663437-4Report Type:Expedited (15-DaCompany Report #WAES 01012768
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural Complication Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/09/01ISR Number: 3663438-6Report Type:Expedited (15-DaCompany Report #WAES 01012717
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia Dermatitis Haemoptysis Haemorrhage Hand Fracture Hepatocellular Damage Joint Swelling Tendon Disorder	Consumer	Vioxx Oxycontin Percocet	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/01ISR Number: 3663439-8Report Type:Expedited (15-DaCompany Report #WAES 01012771
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Gentamicin	C				

Date:02/09/01ISR Number: 3663448-9Report Type:Expedited (15-DaCompany Report #WAES 01012766
Age:40 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/09/01ISR Number: 3663449-0Report Type:Expedited (15-DaCompany Report #WAES 00052239
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Arthralgia Colonic Polyp	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
	Difficulty In Walking						PO	
	Discomfort		Acetaminophen	SS			325 MG PRN	
	Faecal Occult Blood		Glucotrol Xl	C				
	Positive		Hydrodiuril	C				
	Gastric Ulcer		Synthroid	C				
	Oesophageal Ulcer		Ferrous Gluconate	C				
	Pain In Extremity		Hydroxychloroquine	C				
	Restless Legs Syndrome		Methotrexate	C				

Date:02/09/01ISR Number: 3663450-7Report Type:Expedited (15-DaCompany Report #WAES 00121370
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Asthenia Circulatory Collapse Confusional State Difficulty In Walking Disorientation Hypoaesthesia Oedema Peripheral Speech Disorder Swelling Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:02/09/01ISR Number: 3663451-9Report Type:Expedited (15-DaCompany Report #WAES 00112070
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaphylactic Shock
Other	Dyspnoea
	Eyelid Oedema
	Oedema Mouth

	Pharyngeal Oedema Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Fosamax	C				
			Lipitor	C				
			Miacalcin	C				
			Synthroid	C				
			Aspirin	C				

Date:02/09/01ISR Number: 3663756-1Report Type:Expedited (15-DaCompany Report #WAES 00126780
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Shortened	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	28 DAY
	Arthralgia Drug Effect Decreased Drug Interaction Haemarthrosis Haematoma	Other	Warfarin	SS		ORAL		
			Vasotec	C				
			Furosemide	C				
			Temazepam	C				
			Verapamil	C				

Date:02/09/01ISR Number: 3663758-5Report Type:Expedited (15-DaCompany Report #WAES 00125617
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pneumonia Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	14 DAY	
		Other	Oxazepam	C				
			Prednisone	C				

Date:02/09/01ISR Number: 3663760-3Report Type:Expedited (15-DaCompany Report #WAES 01019551
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	2 DAY
		Other	Vioxx	C				

Date:02/09/01ISR Number: 3663770-6Report Type:Expedited (15-DaCompany Report #WAES 01016146
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Disorientation Hyponatraemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Althiazide/Spironolactone	SS		ORAL	PO	
			Calcium Carbonate (+) Cholecalciferol	C				
			Clopidogrel Bisulfate	C				

			Diacerein	C		
			Folic Acid	C		
			Isosorbide Dinitrate	C		
			Nicergoline	C		

Date:02/09/01ISR Number: 3663771-8Report Type:Expedited (15-DaCompany Report #WAES 00107531
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Drug Interaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Propafenone Hcl	SS		ORAL	PO	
			Cozaar	C				
			Fosamax	C				
			Tibolone	C				

Date:02/09/01ISR Number: 3663772-XReport Type:Expedited (15-DaCompany Report #WAES 01019701
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Hepatic Function Abnormal Pyelonephritis	Foreign Study Health Professional	Vioxx Mevacor Vasotec	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	34 DAY

Date:02/09/01ISR Number: 3663773-1Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholestasis Haemolysis	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						

Date:02/09/01ISR Number: 3663774-3Report Type:Expedited (15-DaCompany Report #WAES 00119006
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO						
			Amiloride Hydrochloride/Hctz	C		
			Gemfibrozil	C		

Date:02/09/01ISR Number: 3663775-5Report Type:Expedited (15-DaCompany Report #WAES 00125627
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Fluid Retention Renal Impairment	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Weight Increased		Insulin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/01ISR Number: 3663782-2Report Type:Expedited (15-DaCompany Report #WAES 01015246
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
			Cap Orlistat	SS		ORAL	360 MG	302 DAY
			Prinivil	C				
			Zocor	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Bisoprolol Fumarate	C				
			Carisoprodol	C				
			Chlorpheniramine Maleate	C				
			Citalopram	C				
			Furosemide	C				
			Nicardipine Hcl	C				
			Nitrazepam	C				
			Nitroglycerin	C				

Date:02/09/01ISR Number: 3663784-6Report Type:Expedited (15-DaCompany Report #WAES 01025006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Jaundice	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	3	WK

Date:02/09/01ISR Number: 3663795-0Report Type:Expedited (15-DaCompany Report #WAES 01012770
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Company Merck Co Inc ORAL
PO
Representative

Date:02/09/01ISR Number: 3663797-4Report Type:Expedited (15-DaCompany Report #WAES 01012769
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypotension Renal Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

Date:02/09/01ISR Number: 3663811-6Report Type:Expedited (15-DaCompany Report #WAES 01012767
Age:74 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration Renal Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/01ISR Number: 3663812-8Report Type:Expedited (15-DaCompany Report #WAES 01012604
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/12/01ISR Number: 3663711-1Report Type:Direct Company Report #
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg	PS		ORAL	ONE DAILY PO	
Required	Chest Pain		Remicade 20mg	SS			ONE DAILY PO	
Intervention to Prevent Permanent Impairment/Damage	Paraesthesia							

Date:02/12/01ISR Number: 3663827-XReport Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Liver Function Test	Health Professional	Rofecoxib	PS		ORAL	50 MG PO DAILY	
Intervention to Prevent Permanent Impairment/Damage	Abnormal		Rofecoxib	SS		ORAL	12.5 MG PO DAILY	
			Acetaminophen	C				
			Atorvastatin	C				

Date:02/12/01ISR Number: 3664164-XReport Type:Expedited (15-DaCompany Report #WAES 01020449
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cipro	C				
			Estrogens (Unspecified)	C				

Date:02/12/01ISR Number: 3664361-3Report Type:Expedited (15-DaCompany Report #WAES 01019164
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hepatitis Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
			Atenolol/Chlorthalid one	C				
			Halazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/01ISR Number: 3664470-9Report Type:Expedited (15-DaCompany Report #WAES 01026033
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ecchymosis	Foreign	Tab Vioxx					
	Haematoma	Study	(Rofecoxib)	PS		ORAL	12.5 MG, PO	98 DAY
	Thrombocytopenia	Other	Tab Vioxx					
			(Rofecoxib)	SS		ORAL	25 MG, PO	2 MON
			Albuterol	C				
			Bambuterol	C				
			Budesonide	C				
			Cetirizine	C				

Date:02/12/01ISR Number: 3664473-4Report Type:Expedited (15-DaCompany Report #WAES 01028103
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign	Tab Vioxx					
	Erythema	Other	(Rofecoxib)	PS		ORAL	25 MG, PO	7 DAY

Date:02/12/01ISR Number: 3664523-5Report Type:Expedited (15-DaCompany Report #WAES 01026021
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Oedema	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	12.5 MG, PO	12 DAY
			Zocor	C				
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				
			Furosemide	C				
			Metformin	C				
			Nitroglycerin	C				

Date:02/13/01ISR Number: 3664666-6Report Type:Expedited (15-DaCompany Report #WAES 01011457
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Lactate Dehydrogenase Increased Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/13/01ISR Number: 3664668-XReport Type:Expedited (15-DaCompany Report #WAES 00121381
Age:86 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Albumin Decreased
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic
Other	Dyspnoea

		Gastrointestinal Haemorrhage Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyponatraemia Rectal Haemorrhage Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Centrum Silver	C		
				Macrobid	C		
				Metamucil	C		
				Aspirin	C		
				Verapamil	C		

Date:02/13/01ISR Number: 3664673-3Report Type:Expedited (15-DaCompany Report #WAES 00111555
Age:75 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Oedema Peripheral Renal Impairment Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Ambien	C		
				Diovan Hct	C		
				Flovent	C		
				Hydromet	C		
				Lasix	C		
				Maxair	C		
				Paxil	C		
				Prilosec	C		
				Rhinocort	C		
				Serevent	C		
				Singulair	C		
				Synthroid	C		
				Zocor	C		
				Allopurinol	C		
				Colchicine	C		

Date:02/13/01ISR Number: 3664725-8Report Type:Expedited (15-DaCompany Report #WAES 01010114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Disturbance In Attention	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	5 DAY
	Drug Effect Decreased	Professional	Os-Cal	C				
	Major Depression		Vitamins (Unspecified)	C				

Date:02/13/01ISR Number: 3664737-4Report Type:Expedited (15-DaCompany Report #WAES 01020257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/01ISR Number: 3664786-6Report Type:Expedited (15-DaCompany Report #WAES 01020233
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/UNK/PO	

Date:02/13/01ISR Number: 3665047-1Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Rofecoxib	PS				

Date:02/13/01ISR Number: 3665325-6Report Type:Expedited (15-DaCompany Report #WAES 00125115
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Petechiae	Foreign Health Professional	Vioxx	PS		ORAL	25 MG PO	6 DAY

Date:02/13/01ISR Number: 3665331-1Report Type:Expedited (15-DaCompany Report #WAES 01025507
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:02/13/01ISR Number: 3665332-3Report Type:Expedited (15-DaCompany Report #WAES 01023403
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Orthostatic Hypotension	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:02/13/01ISR Number: 3665334-7Report Type:Expedited (15-DaCompany Report #WAES 01015140
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG, PO	3 DAY
Life-Threatening	Circulatory Collapse							
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Tab Vioxx (Rofecoxib)	SS		ORAL	PO	3 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/01ISR Number: 3665344-XReport Type:Expedited (15-DaCompany Report #WAES 00105625
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Hypersensitivity	Foreign	Vioxx	PS		ORAL	25 MG PO	9 DAY
Hospitalization -	Faeces Discoloured	Health	Albuterol Sulfate	C				
Initial or Prolonged	Gastritis Erosive	Professional	Leuprolide Acetate	C				
	Status Asthmaticus	Other	Theophylline	C				

Date:02/13/01ISR Number: 3665353-0Report Type:Expedited (15-DaCompany Report #WAES 00121742
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Congestive				Laboratories Div			
Initial or Prolonged	Memory Impairment				Merck Co Inc	ORAL	12.5	
	Syncope						MG/DAILY/PO	
			Tab Ziac	SS		ORAL	1	
							TABLET/DAILY/	
							PO	
			Fosamax	C				
			Glucophage	C				
			Xanax	C				
			Aspirin	C				
			Calcium (+) Vitamin	C				
			Cyanocobalamin	C				

Date:02/14/01ISR Number: 3665100-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx	PS		ORAL	25 MG PO QD	

Initial or Prolonged	Nausea		Coumadin	SS			ORAL
5 MG PO QOD							

Date:02/14/01ISR Number: 3665111-7Report Type:Direct Company Report #
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Rofecoxib	PS				

Date:02/14/01ISR Number: 3665116-6Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage		Rofecoxib	PS				

Date:02/14/01ISR Number: 3665129-4Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena		Vioxx	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/01ISR Number: 3665132-4Report Type:Direct Company Report #
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Blood Creatinine Increased							
	Blood Urea Increased							

Date:02/14/01ISR Number: 3665147-6Report Type:Direct Company Report #
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough		Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged	Malaise							
	Renal Failure Acute							

Date:02/14/01ISR Number: 3665383-9Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Vioxx 12.5 Mg	PS				
	Balance Disorder		Vioxx 25 Mg	SS				
	Oedema Peripheral							

Date:02/14/01ISR Number: 3665814-4Report Type:Expedited (15-DaCompany Report #WAES 00122144
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE /	
Hospitalization -	Congestive	Professional					DAILY/ PO	
Initial or Prolonged	Confusional State	Company	Lanoxin	C				
	Dialysis	Representative	Lopressor	C				

Drug Toxicity
Dyspnoea
Fluid Retention
Renal Failure
Renal Tubular Necrosis

Date:02/14/01ISR Number: 3665815-6Report Type:Expedited (15-DaCompany Report #WAES 01011775
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Amnesia	Professional					MG/DAILY/PO	
	Balance Disorder	Company	Premarin	C				
	Blood Potassium Decreased	Representative						
	Confusional State							
	Coordination Abnormal							
	Depressed Level Of Consciousness							
	Disturbance In Attention							
	Grand Mal Convulsion							
	Hyporeflexia							
	Malaise							
	Nausea							
	Sedation							
	Speech Disorder							

Date:02/14/01ISR Number: 3665818-1Report Type:Expedited (15-DaCompany Report #WAES 01012018
Age:13 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Benign Intracranial	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertension	Professional						

Date:02/14/01ISR Number: 3665819-3Report Type:Expedited (15-DaCompany Report #WAES 00121854
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -		Professional						
Initial or Prolonged		Company Representative	Vicodin Tablets	C				
Other								

Date:02/14/01ISR Number: 3666416-6Report Type:Expedited (15-DaCompany Report #WAES 01026035
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Iron Increased	Foreign	Vioxx	PS		ORAL	12	DAY
Initial or Prolonged	Gastric Ulcer	Other	Acebutolol Hydrochloride	C				
	Gastritis							
	Gastrointestinal Haemorrhage							
	Heart Rate Increased							
	Malaise							
	Petechiae							
	Serum Ferritin Increased							

Date:02/14/01ISR Number: 3666423-3Report Type:Expedited (15-DaCompany Report #WAES 01016176
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Exertional	Foreign Health Professional	Vioxx	PS		ORAL	25 MG	33 WK

Date:02/14/01ISR Number: 3667154-6Report Type:Expedited (15-DaCompany Report #WAES 01026059
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	48 DAY
		Health Professional	Chlordiazepoxide Hcl/Clidinium Bromide	C				
			Estradiol	C				
			Felodipine/Metoprolol Succinate	C				
			Ispaghula Husk	C				
			Phloroglucinol	C				
			Progesterone	C				
			Tolterodine Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/01ISR Number: 3665786-2Report Type:Expedited (15-DaCompany Report #WAES 01020400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
			Composition Unspecified	C				

Date:02/15/01ISR Number: 3665978-2Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic		Vioxx / 25 Mg / Merck	PS	Merck	ORAL	25 ONCE PER ORAL	

Date:02/15/01ISR Number: 3666011-9Report Type:Direct Company Report #
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx (25mg)	PS		ORAL	25MG PO Q DAY	
	Faeces Discoloured		Coumadin (6mg)	SS		ORAL	6MG PO Q DAY	
	Gastric Ulcer		Lasix	C				
	Gastroenteritis		Multivit	C				
	Helicobacter		Prozac	C				
	Haemorrhage		Vicodin	C				
	Rectal Haemorrhage		Tylenol	C				
			Lorazepam	C				

Date:02/15/01ISR Number: 3666560-3Report Type:Expedited (15-DaCompany Report #WAES 01025033
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Intolerance	Foreign	Tab Vioxx					
	Fat Intolerance	Company	(Rofecoxib)	PS		ORAL	25 MG PO	
	Hepatotoxicity	Representative	Carbamazepine	C				
	Nausea		Lansoprazole	C				
	Steatorrhoea		Thyroxine	C				

Date:02/15/01ISR Number: 3666561-5Report Type:Expedited (15-DaCompany Report #WAES 01025531
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	Corticosteroids					
			(Unspecified)	C				
			Phenprocoumon	C				

Date:02/15/01ISR Number: 3666562-7Report Type:Expedited (15-DaCompany Report #WAES 01025525
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	Digitalis	C				
			Diuretic					

(Unspecified) C

Date:02/15/01ISR Number: 3666563-9Report Type:Expedited (15-DaCompany Report #WAES 01025004
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia Face Oedema	Foreign Company	Tab Vioxx (Rofecoxib)	PS		ORAL	25-50 MG PO	6 DAY
	Oedema Peripheral Tongue Oedema	Representative	Acetaminophen (+) Dihydrocodeine Bitartr Benzydamine Hcl Hydroquinone	 C C C				

Date:02/15/01ISR Number: 3666949-2Report Type:Expedited (15-DaCompany Report #WAES 01020686
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:02/15/01ISR Number: 3667131-5Report Type:Expedited (15-DaCompany Report #WAES 01020645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/16/01ISR Number: 3666094-6Report Type:Direct Company Report #
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastrointestinal	Vioxx	PS
PTA			
Hospitalization -	Haemorrhage	Fosamax	SS
PTA			
Initial or Prolonged		Phenobarbital	C
Required		Tiazac	C
Intervention to		Potassium	C
Prevent Permanent		Zestril	C
Impairment/Damage		Zoloft	C

Date:02/16/01ISR Number: 3666109-5Report Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acidosis		Vioxx				25 Mg	
Initial or Prolonged	Fluid Retention		Merck	PS	Merck	ORAL	25 MG Q DAY	
	Hypoxia							
	Pulmonary Oedema		Zestril				20 Mg	
	Respiratory Distress		Merck	SS	Merck	ORAL	20 MG Q DAY	
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/01ISR Number: 3667509-XReport Type:Expedited (15-DaCompany Report #WAES 00082296
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	C		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	C		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Mobic	C				
			Tylenol	C				
			Chondroitin	C				

Date:02/16/01ISR Number: 3667512-XReport Type:Expedited (15-DaCompany Report #WAES 00112460
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Balance Disorder	Health Professional	Reglan	SS		ORAL	20 MG/DAILY/PO	
	Blood Sodium Decreased		Beconase	C				
	Bronchitis		Dyazide	C				
	Condition Aggravated		Elavil	C				
	Coordination Abnormal		Evista	C				
	Diarrhoea		Lomotil	C				
	Discomfort		Lortab	C				
	Dizziness		Pepcid Ac	C				
	Ecchymosis		Prevacid	C				
	Fall							
	Fatigue							

	Gastrooesophageal Reflux	Ventolin	C
	Disease	Therapy Unspecified	C
	Haematochezia		
	Headache		
	Hypertension		
	Medication Error		
	Nausea		
	Oedema Peripheral		
	Pruritus		
	Tinnitus		
	Vomiting		

Date:02/16/01ISR Number: 3667515-5Report Type:Expedited (15-DaCompany Report #WAES 00121870
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematocrit Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Health Professional	Premarin	C				
			Provera	C				

Date:02/16/01ISR Number: 3667516-7Report Type:Expedited (15-DaCompany Report #WAES 01010850
Age:87 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Diverticulitis
	Gastric Ulcer
	Gastrointestinal

Haemorrhage
Haematochezia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Health Professional	Ambien	C				
	Ultram	C				
	Aspirin	C				

Date:02/16/01ISR Number: 3667520-9Report Type:Expedited (15-DaCompany Report #WAES 00102461
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Transient Ischaemic Attack	Company Representative						
	Vision Blurred							

Date:02/16/01ISR Number: 3667528-3Report Type:Expedited (15-DaCompany Report #WAES 01016071
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	93 DAY
		Health Professional	Zocor	C				
			Estradiol (+) Medroxyprogesterone Acetat	C				
			Lorazepam	C				

Date:02/16/01ISR Number: 3667743-9Report Type:Expedited (15-DaCompany Report #WAES 01010665
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL
DAILY/ PO						
Hospitalization -	Dehydration	Professional	Carboplatin	SS		
Initial or Prolonged	Diarrhoea	Company	Taxol	SS		
	Haemodialysis	Representative	Therapy Unspecified	SS		
INTRAVENOUS 100 ML/1X/IV						
	Malaise		Therapy Unspecified	SS		
INTRAVENOUS 50 ML/1X/IV						
	Medication Error		Monopril	C		
	Renal Failure		Toprol Xl Tablets	C		
			Ibuprofen	C		

Date:02/16/01ISR Number: 3667744-0Report Type:Expedited (15-DaCompany Report #WAES 01011194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Potassium Increased	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Chest Pain	Company				
	Fatigue	Representative				
	Gastrooesophageal Reflux					
	Disease					
	Haemoglobin Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/01ISR Number: 3667745-2Report Type:Expedited (15-DaCompany Report #WAES 01012353
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other			Cardizem	C				

Date:02/16/01ISR Number: 3667747-6Report Type:Expedited (15-DaCompany Report #WAES 01020875
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cardiac Failure						MG/DAILY/PO	
	Congestive		Calan	C				
	Condition Aggravated		Fosamax	C				
	Cough		Lipitor	C				
	Dyspnoea		Albuterol	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Insulin	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				
			(Therapy Unspecified)	C				

Date:02/16/01ISR Number: 3667749-XReport Type:Expedited (15-DaCompany Report #WAES 01020857
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Health	Tab Vioxx Unk	PS		ORAL	PO	2 DAY
		Professional	Zestril	C				
			Hydrochlorothiazide	C				

Date:02/16/01ISR Number: 3667752-XReport Type:Expedited (15-DaCompany Report #WAES 01020646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Chronic	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/16/01ISR Number: 3667753-1Report Type:Expedited (15-DaCompany Report #WAES 01020909
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Gastric Ulcer	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/01ISR Number: 3667755-5Report Type:Expedited (15-DaCompany Report #WAES 01020935
Age:81 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/UNK/PO	

Date:02/16/01ISR Number: 3667757-9Report Type:Expedited (15-DaCompany Report #WAES 00102347
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Bile Duct Stone	Health Professional						
	Blood Glucose Increased		Celebrex	C				
	Cholecystitis Acute		Darvocet-N	C				
	Decreased Appetite		Elavil	C				
	Emotional Distress		Lortab	C				
	Gallbladder Disorder		Motrin	C				
	Injection Site		Naprosyn	C				
	Inflammation		Prilosec	C				
	Pain		Soma	C				
	Platelet Count Decreased		Ultram	C				
	Sedation		Zantac	C				
	Swelling		Therapy Unspecified	C				
	Thermal Burn		Methadone Hydrochloride	C				
	Urinary Tract Infection							
	Vomiting							

Date:02/16/01ISR Number: 3668321-8Report Type:Expedited (15-DaCompany Report #WAES 01027259
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div			

Difficulty In Walking Merck Co Inc ORAL
12.5 MG, PO 9 DAY
Dyspnoea
Gait Disturbance
Hypertension
Palpitations
Pulmonary Oedema

Date:02/16/01ISR Number: 3668328-0Report Type:Expedited (15-DaCompany Report #WAES 01029125
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Dyspepsia	Other						
	Face Oedema				Merck Co Inc	ORAL	PO	5 DAY
	Rash Erythematous							

Date:02/16/01ISR Number: 3668329-2Report Type:Expedited (15-DaCompany Report #WAES 01029126
Age:85 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Condition Aggravated Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY
			Fosinopril Sodium	C				
			Furosemide	C				
			Ibuprofen	C				
			Lorazepam	C				
			Nifedipine	C				
			Paroxetine Hcl	C				
			Thiethylperazine Maleate	C				

Date:02/16/01ISR Number: 3668331-0Report Type:Expedited (15-DaCompany Report #WAES 01020414
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Convulsion Hypertension Nephritis Interstitial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	5 DAY
Disability	Oedema		Tab Mobic (Meloxicam)	SS		ORAL	20 MG, PO	1 DAY
			Sectral	C				
			Isoniazid	C				
			Rifampin	C				

Date:02/16/01ISR Number: 3668334-6Report Type:Expedited (15-DaCompany Report #WAES 01029133
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
			Acetaminophen	C				

			Lormetazepam	C		

Date:02/16/01ISR Number: 3668336-XReport Type:Expedited (15-DaCompany Report #WAES 01025507
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Face Oedema	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Tongue Oedema	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG, PO 12 MON						
			[Therapy Unspecified]	C		

Date:02/16/01ISR Number: 3668339-5Report Type:Expedited (15-DaCompany Report #WAES 01025122
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Other			Laboratories Div	
					Merck Co Inc	ORAL
25 MG, PO						
			Aspirin	C		
			Atenolol	C		

Domperidone C

Date:02/20/01ISR Number: 3666724-9Report Type:Direct Company Report #
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous		Vioxx 25mg	PS		ORAL	VIOX ONCE PO	
	Rash Papular						QD	
	Rash Pustular		Flexeril	SS		ORAL	10MG ONE PO	
							QHS	

Date:02/20/01ISR Number: 3666857-7Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL	50 PO QD	
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive							
Required Intervention to Prevent Permanent Impairment/Damage	Fluid Retention							

Date:02/20/01ISR Number: 3666867-XReport Type:Direct Company Report #
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Tegretol (400 Mg Po Q Day (Purepac)	PS	Purepac	ORAL	400 MG PO QD	
Hospitalization - Initial or Prolonged	Jaundice							
	Liver Transplant		Vioxx (25 Mg Po Q Day (Msd)	SS	Msd	ORAL	25 MG PO QD	
	Nausea							

	Sedation			Estratab	C		

Date:02/20/01ISR Number: 3667147-9Report Type:Direct Company Report #
Age:92 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Cardiac Failure		Vioxx	PS		ORAL	12.5 MG DAILY	
Intervention to	Congestive					ORAL		
Prevent Permanent	Pulmonary Congestion		Vioxx	C				
Impairment/Damage			Lasix	C				

Date:02/20/01ISR Number: 3667331-4Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema		Vioxx (Merck)	PS	Merck		25MG QD	
	Urticaria		Covera	C				
			Prometrium	C				
			Estratest	C				
			Premarin	C				
			Hydroxyzine	C				
			Darvocet	C				
			Hydrocodone	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/01ISR Number: 3668127-XReport Type:Expedited (15-DaCompany Report #WAES 01012017
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastritis Erosive	Professional			Laboratories Div			
Initial or Prolonged	Gastrointestinal	Company			Merck Co Inc	ORAL	25 MG DAILY	
	Haemorrhage	Representative					PO	
			Monopril	C				
			Tiazac	C				
			Nitroglycerin	C				

Date:02/21/01ISR Number: 3667740-3Report Type:Direct Company Report #
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Rofecoxib Merck	PS	Merck	ORAL	MG DAILY	
Initial or Prolonged	Faeces Discoloured						ORAL	
	Haematemesis		Vicodin	C				
	Nausea							

Date:02/21/01ISR Number: 3667792-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Zoloft (Sertraline)	PS	Roerig			
	Medication Error		Vioxx (Rolecoxib)	SS	Bristol Myers			

Date:02/21/01ISR Number: 3667893-7Report Type:Direct Company Report #
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma		Vioxx 12.5 Po Qd					

	Condition Aggravated		(Ms&D)	PS		
12.5 MG QD						
	Confusional State		Kava-Kava 25 Mg Bid	SS		ORAL
25 MG PO BID						
	Depressed Level Of Consciousness					
	Renal Impairment					
	Tremor					

Date:02/21/01ISR Number: 3667948-7Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx 25mg Po Daily	PS		
25MG PO DAILY						
Initial or Prolonged	Gastric Ulcer					
	Melaena					
	Nausea					
	Oesophagitis					

Date:02/21/01ISR Number: 3668130-XReport Type:Expedited (15-DaCompany Report #WAES 00101539
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Dyspnoea
Initial or Prolonged	Oedema Peripheral
	Pulmonary Arterial Wedge

Pressure Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Celebrex	C				
	Effexor	C				
	Maxalt (Rizatriptab Benzoate)	C				
	Premarin	C				
	Prilosec	C				
	Tenormin	C				
	Zomig (Ascorbic Acid)	C				
	Chondroitin (+) Glucosamine	C				
	Vitamin E	C				
	Vitamins (Unspecified)	C				

Date:02/21/01ISR Number: 3668136-0Report Type:Expedited (15-DaCompany Report #WAES 01010621
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/21/01ISR Number: 3669206-3Report Type:Expedited (15-DaCompany Report #WAES 01011368
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

Date:02/21/01ISR Number: 3669209-9Report Type:Expedited (15-DaCompany Report #WAES 00122196
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure Diastolic
Hospitalization -	Decreased
Initial or Prolonged	Blood Urea Increased
Other	Cardiac Murmur
	Cataract
	Chest X-Ray Abnormal
	Constipation
	Delusion
	Dementia
	Diarrhoea
	Differential White Blood
	Cell Count Abnormal
	Dry Skin
	Dyspnoea Exertional
	Electrocardiogram

		Abnormal Electrocardiogram St Segment Abnormal					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Ulcer	Health	Vioxx	PS	Merck Research	
		Gastric Ulcer Haemorrhage	Professional			Laboratories Div	
		Gastritis				Merck Co Inc	ORAL
SEE IMAGE							
		Gastrooesophageal Reflux		Haldol	C		
		Disease					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Hiatus Hernia					
		Hypoproteinaemia					
		Miosis					
		Oesophagitis					
		Respiratory Rate					
		Increased					
		Sinus Tachycardia					
		Skin Warm					
		Spinal Compression					
		Fracture					
		Supraventricular					
		Extrasystoles					
		Thrombocythaemia					
		Ventricular Hypertrophy					
		White Blood Cell Count					
		Increased					

Date:02/21/01ISR Number: 3669211-7Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Transient Ischaemic	Other	Vioxx	PS	Merck Research	
Initial or Prolonged		Attack				Laboratories Div	
						Merck Co Inc	ORAL
PO							

Date:02/21/01ISR Number: 3669216-6Report Type:Expedited (15-DaCompany Report #WAES 00111199
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Gastrointestinal Haemorrhage				Merck Co Inc	ORAL		
SEE IMAGE								
	Haematocrit Decreased		Atrovent	C				
	Haemoglobin Decreased		Lortab	C				
			Mavix	C				
			Serevent	C				
			Singulair	C				
			Albuterol	C				
			Vitamins (Unspecified)	C				

Date:02/21/01ISR Number: 3669224-5Report Type:Expedited (15-DaCompany Report #WAES 00100718
Age:42 YR Gender:Female I/FU:F

Outcome	PT
	Dermatitis
	Eye Pain
	Face Oedema

Headache
Oedema Peripheral

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/ PO	
	Dyazide	C				
	Lotronex	C				
	Zoloft	C				
	Trazodone	C				

Date:02/21/01ISR Number: 3669227-0Report Type:Expedited (15-DaCompany Report #WAES 01010673
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/21/01ISR Number: 3669410-4Report Type:Expedited (15-DaCompany Report #HQ7328516FEB2001
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Pancreatitis	Health Professional	Premphase 14/14	PS	Wyeth Ayerst Laboratories	ORAL	ONE TABLET (STRENGTH NOT SPECIFIED) DAILY ORAL	
			Vioxx (Rofecoxib, Tablet)	SS				
			Insulin (Insulin)	C				

			Prilosec (Omeprazole)	C		
			Tylenol (Paracetamol)	C		
			Advil (Ibuprofen)	C		
			Topiramate (Topiramate)	C		
			Placebo (Placebo)	C		

Date:02/21/01ISR Number: 3669507-9Report Type:Expedited (15-DaCompany Report #WAES 01015156
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia Coronary Artery Disease Erythema Multiforme	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	32 DAY
	Lower Respiratory Tract Infection Petechiae Upper Gastrointestinal Haemorrhage		Acetaminophen / Codeine Phosphate Bumetanide Fluoxetine Lactulose	C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/01ISR Number: 3669537-7Report Type:Expedited (15-DaCompany Report #WAES 01025120
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Syncope Tooth Loss	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
			Estradiol (+) Norethindrone	C				
			Glucosamine	C				
			Meloxicam	C				

Date:02/21/01ISR Number: 3669540-7Report Type:Expedited (15-DaCompany Report #WAES 01029004
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	11 DAY
			Omeprazole	C				

Date:02/21/01ISR Number: 3669542-0Report Type:Expedited (15-DaCompany Report #WAES 01026075
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; S5 MG	31 DAY

Date:02/21/01ISR Number: 3669543-2Report Type:Expedited (15-DaCompany Report #WAES 01025121
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG; 25 MG 27 DAY						
			Danthron (+)			
			Poloxamer 188	C		
			Fentanyl	C		
			Haloperidol	C		
			Lansoprazole	C		
			Tamoxifen	C		

Date:02/21/01ISR Number: 3669980-6Report Type:Expedited (15-DaCompany Report #WAES 01015617
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Agranulocytosis	Foreign	Vioxx	PS	Merck Research	
Hospitalization - Initial or Prolonged	Cystitis Haemorrhagic	Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG PO						
			Tab Vioxx (Rofecoxib) 25 Mg	SS		ORAL
PO 2 DAY						
			Methotrexate 0.0 Mg	SS		
			Acetylcysteine	C		
			Amitriptyline Hydrochloride	C		

Beclomethasone Dipropionate	C
Captopril	C
Cefuroxime	C
Formoterol Fumarate	C

Date:02/22/01ISR Number: 3667990-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx (25 Mg) (Merck + Co)	PS	Merck+ Co	ORAL	25MG PO BID	
Required Intervention to Prevent Permanent Impairment/Damage	Renal Impairment		Imdur	C				
			Inderal La	C				
			Prednisone	C				

Date:02/22/01ISR Number: 3668873-8Report Type:Expedited (15-DaCompany Report #WAES 00119856
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bacterial Infection	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	5 DAY
Life-Threatening	Conjunctivitis	Health						
Hospitalization - Initial or Prolonged	Diabetes Mellitus	Professional						
	Hypersensitivity		Fosamax	C				
	Multi-Organ Failure		Calcium (Unspecified)	C				
	Pyrexia							
	Sepsis							
	Skin Lesion							
	Staphylococcal Infection							
	Stevens-Johnson Syndrome							
	Toxic Epidermal Necrolysis							

Date:02/23/01ISR Number: 3669796-0Report Type:Expedited (15-DaCompany Report #WAES 01011868
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Duodenal Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage				Merck Co Inc	ORAL	25	
Other	Haematochezia						MG/DAILY/PO	
	Haemoglobin Decreased		Detrol	C				
	Loss Of Consciousness		Lozol	C				
			Prevacid	C				

Date:02/23/01ISR Number: 3669797-2Report Type:Expedited (15-DaCompany Report #WAES 01011944
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Influenza Like Illness	Professional			Laboratories Div			
	Pleural Infection	Other			Merck Co Inc	ORAL	50	
	Torticollis						MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/01ISR Number: 3669917-XReport Type:Expedited (15-DaCompany Report #WAES 01015250
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Myocardial Infarction	Other			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal				Merck Co Inc	ORAL	12.5 MG PO	15 DAY
	Haemorrhage		Privinvil	C				
			Aspirin	C				
			Atenolol	C				

Date:02/23/01ISR Number: 3669919-3Report Type:Expedited (15-DaCompany Report #WAES 00126191
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Diverticulum Intestinal	Health			Laboratories Div			
	Melaena	Professional			Merck Co Inc	ORAL	25 MG PO	45 DAY
			Tab Fenoprofen	SS		ORAL	900 MG PO	2 YR
			Acetaminophen	C				
			Allopurinol	C				
			Digoxin	C				
			Furosemide	C				
			Potassium (Unspecified)	C				

Date:02/23/01ISR Number: 3669957-0Report Type:Expedited (15-DaCompany Report #WAES 01011457
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alanine Aminotransferase	Health	Vioxx	PS	Merck Research			
Hospitalization -	Increased	Professional			Laboratories Div			
Initial or Prolonged	Arrhythmia				Merck Co Inc	ORAL	25	
Other	Ascites						MG/DAILY/PO	
	Aspartate							

Aminotransferase
Increased
Blood Alkaline
Phosphatase Increased
Multi-Organ Failure
Pancreatitis Acute
Pleural Effusion
Renal Impairment
Respiratory Failure

Date:02/23/01ISR Number: 3669959-4Report Type:Expedited (15-DaCompany Report #WAES 01020746
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Dyspnoea Enzyme Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Renal Disorder		Coumadin	C				
			Cozaar	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/01ISR Number: 3669962-4Report Type:Expedited (15-DaCompany Report #WAES 01020835
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/23/01ISR Number: 3670284-6Report Type:Expedited (15-DaCompany Report #WAES 01025183
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/23/01ISR Number: 3670287-1Report Type:Expedited (15-DaCompany Report #WAES 01025195
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	183 DAY
Other	Hepatic Function Abnormal	Other						
	Vomiting							
			Acetaminophen	C				
			Lansoprazole	C				

Date:02/23/01ISR Number: 3670289-5Report Type:Expedited (15-DaCompany Report #WAES 01025208
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peak Expiratory Flow Rate	Foreign	Vioxx	PS	Merck Research			
Other	Decreased	Other			Laboratories Div			

Merck Co Inc ORAL
12.5 MG, PO 246 DAY

Albuterol	C
Bendroflumethiazide	C
Beclomethasone Dipropionate	C
Fluticasone Propionate	C
Perindopril	C

Date:02/23/01ISR Number: 3670291-3Report Type:Expedited (15-DaCompany Report #WAES 01025535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:02/23/01ISR Number: 3670293-7Report Type:Expedited (15-DaCompany Report #WAES 01027504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/23/01ISR Number: 3670294-9Report Type:Expedited (15-DaCompany Report #WAES 01027808
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Dermatitis Sepsis Toxic Epidermal Necrolysis	Foreign Other	Vioxx Diclofenac Na	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/23/01ISR Number: 3670296-2Report Type:Expedited (15-DaCompany Report #WAES 01029552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anuria Haemodialysis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	

Date:02/23/01ISR Number: 3670297-4Report Type:Expedited (15-DaCompany Report #WAES 01029702
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	3 DAY

Date:02/26/01ISR Number: 3670306-2Report Type:Expedited (15-DaCompany Report #WAES 00090060
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Haemorrhage Oesophagitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Disability Representative
MG/DAILY/PO

Date:02/26/01ISR Number: 3670308-6Report Type:Expedited (15-DaCompany Report #WAES 01020829
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Actonel	C		
			Aspirin	C		

Date:02/26/01ISR Number: 3670311-6Report Type:Expedited (15-DaCompany Report #WAES 01020666
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Balance Disorder Burning Sensation Dialysis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
	Diarrhoea		Lithiumco3 Unk	SS		
	Drug Level Above Therapeutic		Avandia	C		
			Celexa	C		
	Dyspnoea		Glucotrol	C		
	Photopsia		Lopid	C		

		Seroquel	C
		Zestril	C
		Metoprolol	C

Date:02/26/01ISR Number: 3670313-XReport Type:Expedited (15-DaCompany Report #WAES 01021439
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction Chest Discomfort Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:02/26/01ISR Number: 3670316-5Report Type:Expedited (15-DaCompany Report #WAES 01021249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Haematochezia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/26/01ISR Number: 3670317-7Report Type:Expedited (15-DaCompany Report #WAES 01021198
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Small Intestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Aspirin	C				

Date:02/26/01ISR Number: 3670319-0Report Type:Expedited (15-DaCompany Report #WAES 01020983
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactoid Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	10 DAY
			Aspirin	C				
			Atenolol	C				

Date:02/26/01ISR Number: 3670322-0Report Type:Expedited (15-DaCompany Report #WAES 00111446
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Xenical Unk	SS		ORAL	120 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3670334-7Report Type:Expedited (15-DaCompany Report #WAES 01011368
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis Pneumonia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:02/26/01ISR Number: 3670336-0Report Type:Expedited (15-DaCompany Report #WAES 01020449
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Hepatitis Jaundice Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex Unk	SS				
			Cipro	C				
			Estrogens (Unspecified)	C				

Date:02/26/01ISR Number: 3670338-4Report Type:Expedited (15-DaCompany Report #WAES 01020686
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lipase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:02/26/01ISR Number: 3670340-2Report Type:Expedited (15-DaCompany Report #WAES 01020983
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Anaphylactic Reaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Atenolol	C				

Date:02/26/01ISR Number: 3670341-4Report Type:Expedited (15-DaCompany Report #WAES 01021277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Embolic Stroke Pain Pallor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12. 5MG / DAILY / PO	2 WK
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3670351-7Report Type:Expedited (15-DaCompany Report #WAES 00121875
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Increased	Health	Vioxx	PS	Merck Research			
Hospitalization -	Condition Aggravated	Professional			Laboratories Div			
Initial or Prolonged	Renal Failure				Merck Co Inc	ORAL	12.5	
Other	Weight Increased						MG/DAILY/PO	
			Aldactone	C				
			K-Dur	C				
			Lasix	C				
			Oramorph Sr	C				
			Pravachol	C				
			Atenolol	C				
			Folic Acid	C				

Date:02/26/01ISR Number: 3670352-9Report Type:Expedited (15-DaCompany Report #WAES 00121939
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged		Other			Merck Co Inc	ORAL	PO	
			Pepcid Ac	C				

Date:02/26/01ISR Number: 3670353-0Report Type:Expedited (15-DaCompany Report #WAES 00121918
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged					Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:02/26/01ISR Number: 3670357-8Report Type:Expedited (15-DaCompany Report #WAES 01010650
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia Tendonitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	75-100 MG/DAILY/PO	
			Enbrel	C				

Date:02/26/01ISR Number: 3670362-1Report Type:Expedited (15-DaCompany Report #WAES 01012239
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erosive Oesophagitis Gastritis Erosive Haematemesis Oesophagitis Sinusitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3670365-7Report Type:Expedited (15-DaCompany Report #WAES 01021156
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myeloid Leukaemia Pharyngolaryngeal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:02/26/01ISR Number: 3670366-9Report Type:Expedited (15-DaCompany Report #WAES 01020830
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage Gastroenteritis Helicobacter	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:02/26/01ISR Number: 3670368-2Report Type:Expedited (15-DaCompany Report #WAES 01021331
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Renal Failure Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ambien	C				
			Aricept	C				
			Zoloft	C				
			Digoxin	C				

Date:02/26/01ISR Number: 3670386-4Report Type:Expedited (15-DaCompany Report #WAES 00121971
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Sodium Decreased Urine Sodium Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol	C				
			Capsaicin	C				
			...	C				
			...	C				
			...	C				

Date:02/26/01ISR Number: 3670719-9Report Type:Expedited (15-DaCompany Report #WAES 01029154
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3670956-3Report Type:Expedited (15-DaCompany Report #WAES 01026116
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
			Zocor	C				
			Furosemide	C				
			Metformin	C				
			Trimetazidine	C				
			Valsartan	C				

Date:02/26/01ISR Number: 3670959-9Report Type:Expedited (15-DaCompany Report #WAES 01026110
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Hallucination	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	10 DAY	
			Atorvastatin	C				
			Bisoprolol	C				
			Diclofenac	C				
			Methotrexate	C				
			Nitroglycerin	C				
			Prednisone	C				
			Ticlopidine	C				

Date:02/26/01ISR Number: 3670961-7Report Type:Expedited (15-DaCompany Report #WAES 01025577
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoantibody Positive Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	89 DAY

Date:02/26/01ISR Number: 3670967-8Report Type:Expedited (15-DaCompany Report #WAES 01025245
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Dizziness	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	15 DAY
			Prinivil	C				
			Aspirin	C				
			Atenolol	C				
			Diltiazem	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				

Date:02/26/01ISR Number: 3670968-XReport Type:Expedited (15-DaCompany Report #WAES 01025120
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accident Syncope Tooth Loss	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY

Estradiol (+)		
Norethindrone	C	
Glucosamine	C	
Meloxicam	C	

Date:02/26/01ISR Number: 3670969-1Report Type:Expedited (15-DaCompany Report #WAES 00127523
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Toxicity Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	5 DAY
		Other						

Date:02/26/01ISR Number: 3670971-XReport Type:Expedited (15-DaCompany Report #WAES 01023403
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Inappropriate Antidiuretic Hormone Secretion Orthostatic Hypotension	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:02/26/01ISR Number: 3670972-1Report Type:Expedited (15-DaCompany Report #WAES 00125115
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Petechiae	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	6 DAY
			Ibuprofen	C				

Date:02/26/01ISR Number: 3670999-XReport Type:Expedited (15-DaCompany Report #WAES 01026033
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Ecchymosis Haematoma Thrombocytopenia	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Albuterol	C				
			Bambuterol	C				
			Budesonide	C				
			Cetirizine	C				

Date:02/26/01ISR Number: 3671001-6Report Type:Expedited (15-DaCompany Report #WAES 01025572
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Aspirin	C				
			Isosorbide Dinitrate	C				
			Metoprolol Succinate	C				
			Molsidomine	C				

Date:02/26/01ISR Number: 3671003-XReport Type:Expedited (15-DaCompany Report #WAES 01025570
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	

Date:02/26/01ISR Number: 3671005-3Report Type:Expedited (15-DaCompany Report #WAES 01025567
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal Hepatocellular Damage Jaundice	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	5 DAY
	Liver Disorder		Composition Unspecified	C				

Date:02/26/01ISR Number: 3671017-XReport Type:Expedited (15-DaCompany Report #WAES 01026075
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly Chest Pain Dyspnoea Exertional	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	31 DAY
	Ventricular Hypertrophy	Other	Fenofibrate	C				

Date:02/26/01ISR Number: 3671021-1Report Type:Expedited (15-DaCompany Report #WAES 01029123
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

	Haemorrhage	Professional			Merck Co Inc		
11 DAY							
		Other	Cap Dipyrone	SS			
2300 MG	11 DAY						

Date:02/26/01ISR Number: 3671023-5Report Type:Expedited (15-DaCompany Report #WAES 01026520
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PO	
		Other	Inj Globulin, Immune	SS			SUBCUTANEOUS	6.6 GM,SC
			Chlorambucil	C				
			Prednisone	C				

Date:02/26/01ISR Number: 3671025-9Report Type:Expedited (15-DaCompany Report #WAES 01025507
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Dysphagia Face Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	12 MON
	Salivary Hypersecretion Tongue Oedema		Captopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3671026-0Report Type:Expedited (15-DaCompany Report #WAES 01025230
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Left Ventricular Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	8 DAY
			Acetaminophen/Codeine Phosphate	C				
			Ferrousso4	C				

Date:02/26/01ISR Number: 3671027-2Report Type:Expedited (15-DaCompany Report #WAES 01025080
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	7 DAY
			Acetaminophen	C				
			Albuterol	C				
			Citalopram	C				
			Etidronate Disodium	C				
			Fluconazole	C				
			Fluticasone	C				
			Ipratropium Bromide	C				
			Prednisolone	C				
			Rabeprazole Sodium	C				
			Salmeterol	C				

Date:02/26/01ISR Number: 3671037-5Report Type:Expedited (15-DaCompany Report #WAES 01028542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Chest Pain Muscle Spasms Pallor	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Hydrodiuril	C				
			Vasotec	C				

Date:02/26/01ISR Number: 3671047-8Report Type:Expedited (15-DaCompany Report #WAES 01028212
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		6 WK
		Other	Tab Aspirin	SS		ORAL	100 MG	
			Cozaar	C				
			Acetaminophen	C				
			Diclofenac Na	C				
			Diclofenac Sodium (+) Misoprostol	C				
			Digoxin	C				
			Furosemide	C				
			Glimepiride	C				
			Metformin Hcl	C				
			Molsidomine	C				
			Nicorandil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/01ISR Number: 3671058-2Report Type:Expedited (15-DaCompany Report #WAES 01027026
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated Conjunctivitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:02/26/01ISR Number: 3671060-0Report Type:Expedited (15-DaCompany Report #WAES 01025207
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenitis Epistaxis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	61 DAY
			Hctz/Triamterene	C				
			Citalopram	C				
			Lercanidipine Hydrochloride	C				
			Lorazepam	C				

Date:02/27/01ISR Number: 3670422-5Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral Sensory Disturbance	Health Professional	Vioxx 25 Mg Merck	PS	Merck	ORAL	50 MG QD ORAL	

Date:02/27/01ISR Number: 3670424-9Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Perforation	Health	Vioxx / 25mg / Merck	PS	Merck	ORAL	25MG QD ORAL	

Initial or Prolonged Professional

Date:02/28/01ISR Number: 3670991-5Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Warfarin	PS		ORAL	2 MG QD PO	
Initial or Prolonged	Haematuria		Rofecoxib (Vioxx)	SS		ORAL	25 MG PO BID	
Required	Haemorrhage		Digoxin	C				
Intervention to	Renal Cyst		Lasix	C				
Prevent Permanent			Thyroxine	C				
Impairment/Damage			Estradiol	C				
			Univasc	C				
			Optipranol	C				

Date:02/28/01ISR Number: 3671011-9Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Ecchymosis		Warfarin 12.5 Mg	PS		ORAL	12.5 MG PO QD	
Intervention to	International Normalised		Vioxx 25 Mg	SS		ORAL	25 MG PO QD	
Prevent Permanent	Ratio Decreased							
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/01ISR Number: 3671051-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased		Vioxx 25 Mg	PS		ORAL	50 MG PO DAILY	

Date:02/28/01ISR Number: 3671072-7Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL	50 PO QD	
Hospitalization - Initial or Prolonged	Congestive Fluid Retention							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:02/28/01ISR Number: 3671624-4Report Type:Expedited (15-DaCompany Report #WAES 00121801
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
Other	Congestive Dyspnoea							
	Hypertension							
	Oedema		Coumadin	C				
			Lopressor	C				
			Premarin	C				

Date:02/28/01ISR Number: 3671633-5Report Type:Expedited (15-DaCompany Report #WAES 01021280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Cardiac Failure Congestive Chest Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	1 WK
	Condition Aggravated Dyspnoea Pulmonary Oedema Respiratory Arrest		Darvocet - N Imdur Lasix Pravachol [Therapy Unspecified]	C C C C C				

Date:02/28/01ISR Number: 3671635-9Report Type:Expedited (15-DaCompany Report #WAES 01021438
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dizziness Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Azmacort Plaquenil	C C				

Prandin	C
Prilosec	C
Serevent	C
Synthroid	C
Zoloft	C
[Therapy Unspecified]	C
Iron (Unspecified)	C
Prednisone	C

Date:02/28/01ISR Number: 3671669-4Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx 25mg	PS		ORAL	50 MG DAILY	
			Various Herbal Products	SS				

SEE IMAGE

Date:02/28/01ISR Number: 3671900-5Report Type:Expedited (15-DaCompany Report #WAES 01029903
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Valve Disease	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 MG PO	6 MON

Date:02/28/01ISR Number: 3671902-9Report Type:Expedited (15-DaCompany Report #WAES 01025231
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

	Oesophageal Ulcer				Merck Co Inc	ORAL 25 MG PO
	Oesophagitis		Lansoprazole	C		
			Morphine S04	C		
			Prochlorperazine	C		

Date:02/28/01ISR Number: 3671911-XReport Type:Expedited (15-DaCompany Report #2001SE01262
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Life-Threatening	Atrial Fibrillation	Foreign	Toprol-Xl	PS	Astrazeneca Lp	
Hospitalization -	Bronchospasm	Study	Prednisolon	SS		
Initial or Prolonged	Oxygen Saturation	Health	Centyl	SS		
Required	Decreased	Professional	Vioxx	SS		ORAL 5 MG DAILY PO
Intervention to		Other	Seroxat "Ciba-Geigy"	SS		ORAL 2.5 MG DAILY PO
Prevent Permanent						
Impairment/Damage			Insulatard	SS		
			Mixtard	SS		
			Arava	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/01ISR Number: 3672033-4Report Type:Direct Company Report #
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx (Rofecoxib)					
	Chills		50mg Tabs -Merck	PS	Merck	ORAL	50MG PO X 2	
	Pancreatitis						TABLETS	
	Vomiting		Flexeril	C				
			Ativan	C				

Date:03/01/01ISR Number: 3683083-6Report Type:Periodic Company Report #2000AU03354
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dental Caries	Health Professional	Plendil	PS	Astrazeneca Pharmaceuticals Lp			
			Meridia	SS		ORAL	10 MG QD PO	
			Vioxx	SS				
			Fluoride	C				
			Micronor	C				
			Nasacort	C				
			Tylenol With Codeine	C				
			Zoladex	C				
			Zyrtec	C				

Date:03/02/01ISR Number: 3672785-3Report Type:Expedited (15-DaCompany Report #WAES 01021769
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Cardiomegaly	Company Representative			Merck Co Inc	ORAL	PO	

Date:03/02/01ISR Number: 3672790-7Report Type:Expedited (15-DaCompany Report #WAES 01011350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eczema Asteatotic Hypersensitivity Rash Pruritic	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Celebrex	C				
			Monopril	C				
			Motrin	C				
			Neurontin	C				
			Pravachol	C				
			Prevacid	C				
			Relafen	C				
			Voltaren	C				
			Desipramine	C				
			Propranolol	C				

Date:03/02/01ISR Number: 3672792-0Report Type:Expedited (15-DaCompany Report #WAES 01021840
Age:37 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Diarrhoea

	Drug Interaction Muscular Weakness	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/ORAL

Date:03/02/01ISR Number: 3672795-6Report Type:Expedited (15-DaCompany Report #WAES 01010495
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma Nephrolithiasis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/02/01ISR Number: 3672800-7Report Type:Expedited (15-DaCompany Report #WAES 01020190
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ecchymosis Excoriation Laceration Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:03/02/01ISR Number: 3672806-8Report Type:Expedited (15-DaCompany Report #WAES 01021433
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alkalosis Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/02/01ISR Number: 3672812-3Report Type:Expedited (15-DaCompany Report #WAES 01021775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:03/02/01ISR Number: 3672814-7Report Type:Expedited (15-DaCompany Report #WAES 01012519
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Albumin Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Cholesterol Increased							
	Hypertension							
	Nephrotic Syndrome		Celebrex 200 Mg	SS		ORAL	200 MG/DAILY/PO	
			Feldene	C				
			Prevacid	C				
			Estrogens					

(Unspecified) C

Date:03/02/01ISR Number: 3672816-0Report Type:Expedited (15-DaCompany Report #WAES 00120603
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DILY/PO	
	Abdominal Tenderness							
	Blood Pressure Decreased							
	Cardiac Failure		Tab Vasotec 20 Mg	SS			20 MG/BID	
	Congestive		Imdur	C				
	Hypertension		Lasix	C				
	Oliguria		Micronase	C				
	Pulse Pressure Decreased		Norvasc	C				
	Pyrexia		Metoprolol	C				
	Renal Failure							
	Sepsis							

Date:03/02/01ISR Number: 3672819-6Report Type:Expedited (15-DaCompany Report #WAES 00111228
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	500 MG /PO	
Other	Diarrhoea							
	Drug Effect Decreased							
	Gait Disturbance		Naprosyn	C				
	Pain							

Date:03/02/01ISR Number: 3673022-6Report Type:Expedited (15-DaCompany Report #WAES 01025263
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1205 MG	
Disability								

Other			Aspirin	C		
			Atenolol	C		
			Danthron/Docusate Na	C		
			Furosemide	C		
			Indoramin	C		
			Lactulose	C		
			Pravastatin Na	C		
			Quinine	C		
			Ramipril	C		
			Senna	C		

Date:03/02/01ISR Number: 3673031-7Report Type:Expedited (15-DaCompany Report #WAES 01027279
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Duodenal Ulcer Pulmonary Embolism	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG 115 DAY						
			Atenolol	C		
			Estriol	C		
			Spironolactone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/01ISR Number: 3673038-XReport Type:Direct Company Report #
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity		Vioxx	PS			25MG X 1	

Date:03/02/01ISR Number: 3673069-XReport Type:Expedited (15-DaCompany Report #WAES 00115311
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Monarthritis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:03/02/01ISR Number: 3673096-2Report Type:Expedited (15-DaCompany Report #WAES 01027514
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Discomfort	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	
	Dyspepsia	Other						
	Gastrointestinal Disorder							
	Nausea		Methotrexate	C				
	Oedema		Metoprolol Succinate	C				
			Nitroglycerin	C				
			Prednisolone	C				

Date:03/02/01ISR Number: 3673101-3Report Type:Expedited (15-DaCompany Report #WAES 01027515
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Duodenal Ulcer	Other						

	Pneumonia				Merck Co Inc	ORAL
12.5 MG						

Date:03/02/01ISR Number: 3673103-7Report Type:Expedited (15-DaCompany Report #WAES 01027808
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dermatitis	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Sepsis	Health			Laboratories Div	
Hospitalization -	Toxic Epidermal	Professional			Merck Co Inc	ORAL
12.5 MG 12 DAY						
Initial or Prolonged	Necrolysis		Diclofenac Na	SS		

Date:03/02/01ISR Number: 3673131-1Report Type:Expedited (15-DaCompany Report #WAES 01025183
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/01ISR Number: 3673135-9Report Type:Expedited (15-DaCompany Report #WAES 01029903
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Endocarditis Bacterial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 MON
			Sulfasalazine	C				

Date:03/02/01ISR Number: 3673146-3Report Type:Expedited (15-DaCompany Report #WAES 00086128
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Electroencephalogram Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	4	DAY
			Verapamil Hcl	C				

Date:03/02/01ISR Number: 3673186-4Report Type:Expedited (15-DaCompany Report #WAES 01015074
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Brain Neoplasm Grand Mal Convulsion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Estrogens	C				

Date:03/02/01ISR Number: 3673206-7Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia Faeces Discoloured Haemolysis Haemolytic Anaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Levothyroxine	C				

Hepatic Necrosis
Hepatic Steatosis
Hepatitis
Hepatitis Cholestatic
Jaundice
Spider Naevus

Date:03/02/01ISR Number: 3673233-XReport Type:Expedited (15-DaCompany Report #WAES 01029702
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastritis Erosive Proteinuria	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
	Pyelonephritis Pyelonephritis Acute Renal Disorder White Blood Cell Count Increased	Professional	Piroxicam Tramadol Hcl	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/01ISR Number: 3692234-9Report Type:Periodic Company Report #01010863
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis	Consumer	Enbrel 25 Mg	PS		
SUBCUTANEOUS 25 MG,	Q2D,					
	Oedema Peripheral					
SUBCUTANEOUS						
	Paraesthesia		Rofecoxib	SS		
	Skin Disorder		Cortisone Injections (Knee)	C		

Date:03/05/01ISR Number: 3672601-XReport Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 302 DAY	Coronary Artery Disease		Xenical	PS	Roche	
Initial or Prolonged	Haematemesis		Rofecoxib	SS		
			Nitrazepam	C		
QN.						
			Frusemide	C		
QAM.						
			Bisoprolol Fumarate	C		
QAM.						
			Citalopram	C		
			Lisinopril	C		
			Benoral	C		
			Gaviscon Advance	C		
			Carisoprodol	C		
			Chlorpheniramine Maleate	C		
ALSO REPORTED						
AS RECEIVING						
PIRITON						
(CHLORPHRENIR						
AMINE						
			Nicardipine Hydrochloride	C		

Glyceroltrinitrat C

REPORTED AS

GLYCEROL

TRINITRATE

SPRAY PRN.

Simvastatin C

QN.

Aspirin C

Date:03/05/01ISR Number: 3672613-6Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased
	Blood Bilirubin Increased
	Blood Lactate Dehydrogenase Increased
	Blood Potassium Increased
	Cardiomegaly
	Culture Urine Positive
	Depressed Level Of Consciousness
	Electroencephalogram Abnormal
	Fatigue
	Headache
	Infection
	Liver Disorder
	Pain

		Pharyngolaryngeal Pain Proteus Infection Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Ulcer		Vasotec	PS	Merck & Co., Inc	ORAL
7	DAY						
		Varicose Ulceration		Vioxx	SS		ORAL
				Gabapentin	SS		ORAL
				Floxacillin Sodium	SS		ORAL
9	DAY						
				Leflunomide	SS		ORAL
				Furosemide	SS		ORAL
7	DAY						
				Metronidazole	SS		ORAL
9	DAY						
				Morphine	C		
				Vitamin E	C		
				[Therapy Unspecified]	C		
				Albuterol Sulfate And Ipratropium Bromide	C		
				Calcium Carbonate And Cholecalciferol	C		
				Loperamide	C		
				Prednisolone	C		
				Acetaminophen	C		
				Cisapride	C		
				Cetirizine Hydrochloride	C		
				Morphine	C		
				Folic Acid	C		
				Lansoprazole	C		
				Zolpidem Tartrate	C		

Date:03/05/01ISR Number: 3673817-9Report Type:Expedited (15-DaCompany Report #WAES 00022227
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Potassium Increased Blood Pressure Increased Bradycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							

	Deep Vein Thrombosis		
MG/DAILY/PO			
	Dermatitis	Cardizem	C
	Dyspnoea	Premarin	C
	Feeling Abnormal	Tenormin	C
	Heart Rate Irregular	Valium	C
	Hyperkalaemia	Vitamins	C
	Oedema Peripheral		
	Pain In Extremity		
	Pruritus		
	Pulmonary Embolism		
	Tachycardia		
	Vertigo		
	Weight Increased		
	White Blood Cell Count Decreased		

Date:03/05/01ISR Number: 3673834-9Report Type:Expedited (15-DaCompany Report #WAES 01022014
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional

Company
Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Coumadin	C				
Darvocet-N	C				
Glucophage	C				
Norvasc	C				
Pravachol	C				
Aspirin	C				

Date:03/05/01ISR Number: 3674035-0Report Type:Expedited (15-DaCompany Report #WAES 01029155
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:03/05/01ISR Number: 3674037-4Report Type:Expedited (15-DaCompany Report #WAES 01027808
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dermatitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	12 DAY
Life-Threatening	Sepsis	Other						
Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis		Diclofenac Na	SS				

Date:03/05/01ISR Number: 3674039-8Report Type:Expedited (15-DaCompany Report #WAES 01026520
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Thrombocytopenia	Foreign	Vioxx	PS	Merck Research	
		Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG PO						
			Inj Globulin, Immune	SS		
SUBCUTANEOUS 6.6 GM SC 209 DAY						
			Chlorambucil	C		
			Prednisolone	C		

Date:03/05/01ISR Number: 3674041-6Report Type:Expedited (15-DaCompany Report #WAES 01025277
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Diarrhoea	Foreign	Vioxx	PS	Merck Research	
	Drug Ineffective	Consumer			Laboratories Div	
	Gait Disturbance				Merck Co Inc	ORAL
25 MG PO 5 WK						
	Pain		Aspirin	C		
			Indapamide	C		
			Omeprazole	C		
			Perindopril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/01ISR Number: 3674109-4Report Type:Expedited (15-DaCompany Report #WAES 01015621
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	130 DAY
			Pentaerythritol Tetranitrate	C				
			Verapamil	C				

Date:03/05/01ISR Number: 3674119-7Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG PO	2 DAY
	Change Of Bowel Habit							
	Diarrhoea							
	Face Oedema		Clobazam	C				
	Hypertension		Sertraline	C				
	Hyponatraemia		Tizanidine	C				
	Insomnia							
	Tremor							
	Vomiting							

Date:03/05/01ISR Number: 3674121-5Report Type:Expedited (15-DaCompany Report #WAES 00115568
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pernicious Anaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Felodipine	C				
			Furosemide	C				
			Prednisolone	C				

Date:03/05/01ISR Number: 3674125-2Report Type:Expedited (15-DaCompany Report #WAES 01025033
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alcohol Intolerance	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
	Fat Intolerance	Other						
	Hepatotoxicity							
	Nausea		Carbamazepine	C				
	Steatorrhoea		Lansoprazole	C				
			Thyroxine	C				

Date:03/05/01ISR Number: 3674132-XReport Type:Expedited (15-DaCompany Report #WAES 00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Glucose Increased
	Cerebellar Infarction
	Cerebrovascular Accident
	Coordination Abnormal
	Hyperlipidaemia
	Hypertension
	Nausea

Vertigo

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/05/01ISR Number: 3674133-1Report Type:Expedited (15-DaCompany Report #WAES 01021910
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erosive Oesophagitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Faecal Occult Blood Positive							
	Faeces Discoloured		Aspirin	C				
	Gastric Ulcer		Nonsteroidal Anti-Inflammatory	C				
	Oesophagitis							

Date:03/06/01ISR Number: 3674536-5Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG PO QD	
	Haemorrhage		Fosamax	C				
	Large Intestinal Ulcer		Pravachol	C				
			Caltrate	C				
			Miacalcin	C				
			Imipramine	C				
			Diltiazem	C				

Date:03/06/01ISR Number: 3674629-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx 50 Mg Eckerd					
	Abdominal Pain Upper		Rx#6272614	PS		ORAL	50 MG QD PO	
	Haematochezia							

Date:03/06/01ISR Number: 3674642-5Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Warfarin	PS			2 MG 5	
	Fall						DAYS/WEEK	
	International Normalised		Rofecoxib	SS			1 MG 2	
	Ratio Increased						DAYS/WEEK	
			Acetaminophen	SS			12.5 MG -> 25	
							MG	
			Furosemide	C				
			Digoxin	C				
			Acetaminophen	C				
			Vioxx	C				
			Warfarin	C				

Date:03/06/01ISR Number: 3674808-4Report Type:Expedited (15-DaCompany Report #WAES 01027517
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/06/01ISR Number: 3674811-4Report Type:Expedited (15-DaCompany Report #WAES 01029157
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Sudden Death	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	4 DAY

Date:03/06/01ISR Number: 3674812-6Report Type:Expedited (15-DaCompany Report #WAES 01029177
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:03/06/01ISR Number: 3674815-1Report Type:Expedited (15-DaCompany Report #WAES 01016171
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Vioxx	PS	Merck Research			

	Dizziness	Study			Laboratories Div		
	Hallucination	Health			Merck Co Inc	ORAL	
12.5 MG/DAILY							
	Nausea	Professional					
PO	109 DAY						
		Other	Cetirizine	C			
			Ferrous So4	C			
			Omeprazole	C			

Date:03/06/01ISR Number: 3674816-3Report Type:Expedited (15-DaCompany Report #WAES 01025262
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Mouth Ulceration	Foreign	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		
12.5 MG/DAILY								
		Other						
PO	15 DAY							

Date:03/06/01ISR Number: 3674817-5Report Type:Expedited (15-DaCompany Report #WAES 01028226
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		
25 MG/DAILY								
		Other						
PO	6 WK							
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3674818-7Report Type:Expedited (15-DaCompany Report #WAES 01028771
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Amnesia					
25 MG/DAILY 92 DAY						
	Blood Alkaline Phosphatase Increased	Other	Acetaminophen	C		
			Cilazapril	C		
	Chest Pain		Diclofenac Na	C		
	Confusional State		Lidocaine	C		
	Dyspepsia		Triamcinolone	C		
	Haemoglobin Decreased					
	Hepatic Function Abnormal					
	Transient Ischaemic Attack					

Date:03/06/01ISR Number: 3674822-9Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased	Foreign Other	Vasotec	PS	Merck Research Laboratories Div Merck Co Inc	
	Cardiomegaly					ORAL
20 MG, PO 7 DAY						
	Culture Urine Positive		Tab Vioxx (Rofecoxib)	SS		ORAL
	Depressed Level Of Consciousness		Tab Metronidazole	SS		ORAL
25 MG, PO						
800 MG, PO 9 DAY						
	Fatigue		Cap Gabapentin	SS		ORAL
2400 MEQ, PO						
	Headache		Tab Furosemide	SS		ORAL
40 MG, PO 7 DAY						
	Hepatic Enzyme Increased		Tab Leflunomide	SS		ORAL
20 MG, PO						
	Hypervolaemia		Tab Floxacillin Sodium	SS		ORAL
	Liver Disorder					
2200 MG, PO 9 DAY						
	Metabolic Disorder		[Therapy Unspecified]	C		
	Pharyngolaryngeal Pain					
	Proteus Infection		Acetaminophen	C		

	Renal Failure	Albuterol Sulfate	
	Urinary Tract Infection	(+) Ipratropium Bromid	C
		Calcium Carbonate (+) Cholecalciferol	C
		Cetirizine Hydrochloride	C
		Folic Acid	C
		Lansoprazole	C
		Loperamide Morphine	C
		Prednisolone	C
		Vitamin E	C
		Zolpidem Tartrate	C

Date:03/06/01ISR Number: 3674828-XReport Type:Expedited (15-DaCompany Report #WAES 01023468
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psychotic Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	14 DAY
			Folic Acid	C				
			Methotrexate Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3674861-8Report Type:Expedited (15-DaCompany Report #WAES 01025320
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	7.5 MG/DAILY, PO	100 DAY
	Haematemesis	Other						
	Upper Gastrointestinal Haemorrhage							
			Acetaminophen	C				
			Amlodipine Besylate	C				
			Bendroflumethiazide	C				
			Diclofenac Sodium (+) Misoprostol	C				

Date:03/06/01ISR Number: 3674938-7Report Type:Expedited (15-DaCompany Report #WAES 00121801
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Dyspnoea	Company			Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Hypertension	Representative						
	Pulmonary Oedema		Coumadin	C				
			Detrol	C				
			Diovan Hct	C				
			Glucophage	C				
			Lopressor	C				
			Premarin	C				

Date:03/06/01ISR Number: 3674939-9Report Type:Expedited (15-DaCompany Report #WAES 01021738
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vitreous Detachment Vitreous Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
PO						
			Fosamax	C		
			Levoxyl	C		
			Pravachol	C		
			Aspirin	C		
			Estradiol	C		

Date:03/06/01ISR Number: 3674941-7Report Type:Expedited (15-DaCompany Report #WAES 01021902
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Glucose Increased Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Celexa	C		
			K-Dur	C		
			Nasocort	C		
			Synthroid	C		
			Furosemide	C		
			Quinine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3674943-0Report Type:Expedited (15-DaCompany Report #WAES 01021944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/06/01ISR Number: 3674944-2Report Type:Expedited (15-DaCompany Report #WAES 01022020
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Vomiting							
			Evista	C				
			Norvasc	C				
			Prinivil	C				
			Synthroid	C				
			Zantac	C				
			Zoloft	C				
			Allopurinol	C				
			Megestrol Acetate	C				

Date:03/06/01ISR Number: 3674945-4Report Type:Expedited (15-DaCompany Report #WAES 01022033
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Haematochezia							
			Librium	C				
			Prilosec	C				

Date:03/06/01ISR Number: 3674946-6Report Type:Expedited (15-DaCompany Report #WAES 01022079
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mental Disorder Suicidal Ideation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Lasix	C				
			Lipitor	C				
			Vicodin Tablets	C				

Date:03/06/01ISR Number: 3675257-5Report Type:Expedited (15-DaCompany Report #WAES 01022097
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased Cardiac Disorder Lung Disorder Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/01ISR Number: 3675293-9Report Type:Expedited (15-DaCompany Report #WAES 01029552
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anuria Dyspnoea Fluid Retention Haemodialysis Hypotension Renal Failure	Foreign	Vioxx Antidiabetic Agent, Nos Insulin	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:03/06/01ISR Number: 3675333-7Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx / 50 Mg / Merck	PS	Merck	ORAL	50 1T QD PO	

Date:03/07/01ISR Number: 3675260-5Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx / 50 Mg / Merck	PS	Merck	ORAL	50, ONE TAB QD PO	

Date:03/07/01ISR Number: 3675262-9Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx (25 Mg Tab) -					

(Merck) PS Merck ORAL
25 MG PO QD 6 DAY

Date:03/07/01ISR Number: 3675634-2Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Alopecia		Vioxx			
	Dermatitis		(Rofecoxib)-(Merck			
	Erythema Multiforme		Med Co.)	PS	Merck Med Co	ORAL
25 MG PO ONE						
	Measles					
TAB QD						
	Oedema Peripheral		Ibuprofen	C		
			Vicodin	C		

Date:03/07/01ISR Number: 3675762-1Report Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis	Foreign	Xenical	PS	Hlr Technology	ORAL
120 MG 3 PER						
Initial or Prolonged	Haematemesis	Consumer				
DAY ORAL						
		Health	Rofecoxib			
		Professional	(Rofecoxib)	SS		ORAL
25 MG 1 PER						
DAY ORAL						
			Nitrazepam			
			(Nitrazepam)	C		
			Frusemide			

(Furosemide)	C
Bisoprolol Fumarate (Bisoprolol Fumarate)	C
Citalopram (Citalopram)	C
Lisinopril (Lisinopril)	C
Benoral (Benorilate)	C
Gaviscon Advance (Potassium Bicarbonate/Sodium Alginate)	C
Carisoprodol (Carisoprodol)	C
Chlorpheniramine Maleate (Chlorpheniramine Maleate)	C
Nicardipine Hydrochloride (Nicardipine Hydrochloride)	C
Glycerol Trinitrat (Nitroglycerin)	C
Simvastatin (Simvastatin)	C
Aspirin (Aspirin)	C

Date:03/08/01ISR Number: 3676330-8Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Rofecoxib/25 Mg/Merck	PS	Merck	ORAL	25 MG/DAILY/ORAL	
	Faeces Discoloured							
	Haemorrhage							
	Hypotension							

Date:03/08/01ISR Number: 3676584-8Report Type:Expedited (15-DaCompany Report #WAES 01029552
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Anuria Dyspnoea Fluid Retention Haemodialysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY
	Hypotension Renal Failure Renal Impairment Rheumatoid Arthritis		Acetaminophen Actrapid Cefuroxime Diltiazem D-Cis Form Hcl Furosemide Isosorbide Dinitrate Methylprednisolone Metronidazole N-Butylscopolammonium Bromide Nitroglycerin Nph Insulin	C C C C C C C C C C C				

			Piperacillin Sodium Salt (+) Tazobactam	C		
			Prednisolone	C		
			Serum Albumin	C		

Date:03/08/01ISR Number: 3676589-7Report Type:Expedited (15-DaCompany Report #WAES 01029454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Vasotec	C				
			Glyburide	C				

Date:03/08/01ISR Number: 3676600-3Report Type:Expedited (15-DaCompany Report #WAES 00125583
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID	
			Aspirin	SS		ORAL	100 MG/DAILY	
			Tramadol Hcl	C				

Date:03/08/01ISR Number: 3676612-XReport Type:Expedited (15-DaCompany Report #WAES 01028248
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	70 DAY
			Fosamax	C				
			Furosemide	C				

Date:03/08/01ISR Number: 3676616-7Report Type:Expedited (15-DaCompany Report #WAES 01025314
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Erythema Face Oedema Hypersensitivity		Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID, PO	
	Pruritus		Elavil	C				
			Indocin (Indomethacin)	C				
			Estradiol	C				
			Medroxyprogesterone Acetate	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/01ISR Number: 3676624-6Report Type:Expedited (15-DaCompany Report #WAES 00085093
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	31 DAY
			Atenolol	C				

Date:03/08/01ISR Number: 3676743-4Report Type:Expedited (15-DaCompany Report #WAES 01021420
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Drug Ineffective Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 MG/DAILY/PO	
	Pain In Extremity		Tab Vioxx 25 Mg	SS		ORAL	50 MG/DAILY/PO	
	Palpitations							
			Celebrex	C				
			Lipitor	C				
			Mobic	C				
			Prempro	C				
			Synthroid	C				

Date:03/08/01ISR Number: 3677506-6Report Type:Expedited (15-DaCompany Report #WAES 00052662
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Convulsion Drug Interaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fall		Paxil	SS				
	Influenza Like Illness		Symmetrel	SS				

	Multiple Sclerosis		Betaseron	SS		
SUBCUTANEOUS	8 IU/QOD/SC					

Date:03/08/01ISR Number: 3677507-8Report Type:Expedited (15-DaCompany Report #WAES 00121936
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ascites	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Atelectasis	Professional			Laboratories Div	
Other	Cholelithiasis	Other			Merck Co Inc	ORAL
25						
	Pancreatic Carcinoma					
MG/DAILY/PO						
	Pancreatitis Acute		Lotensin	SS		ORAL
20						
	Pleural Effusion					
MG/DAILY/PO						
	White Blood Cell Count		Diazide	C		
	Increased		Levoxyl	C		
			Lotronex	C		
			Nasonex	C		
			Premarin	C		
			Prevacid	C		
			Rythmol	C		
			Tiazac	C		
			Digoxin	C		
			Isosorbide	C		
			Metoprolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/01ISR Number: 3677511-XReport Type:Expedited (15-DaCompany Report #WAES 01022103
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Activity Sciatica	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Soma	C				

Date:03/08/01ISR Number: 3677512-1Report Type:Expedited (15-DaCompany Report #WAES 01022103
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sciatica	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Soma	C				

Date:03/09/01ISR Number: 3678052-6Report Type:Expedited (15-DaCompany Report #WAES 00110826
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastritis Gastroenteritis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Helicobacter	Representative						
	Gastrointestinal Haemorrhage Hyperhidrosis Orthostatic Hypotension Scar		Aspirin	C				

Date:03/09/01ISR Number: 3678054-XReport Type:Expedited (15-DaCompany Report #WAES 01021198
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
Hospitalization -	Duodenal Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage				Merck Co Inc	ORAL	25 MG/BID/PO	
	Faeces Discoloured		Avapro	C				
	Haematemesis		Aspirin	C				
	Haemoglobin Decreased		Calcium (Unspecified)	C				
			Folic Acid	C				

Date:03/09/01ISR Number: 3678056-3Report Type:Expedited (15-DaCompany Report #WAES 00022227
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Bradycardia
Initial or Prolonged	Deep Vein Thrombosis
	Dermatitis
	Dyspnoea
	Hyperkalaemia
	Hypertension
	Oedema Peripheral

	Pruritus						
	Pulmonary Embolism						
	Sensation Of Heaviness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG/DAILY/PO
	Weight Increased						
	White Blood Cell Count						
	Decreased						
			Cardizem	C			
			Premarin	C			
			Tenormin	C			
			Valium	C			
			Vitamins	C			

Date:03/09/01ISR Number: 3678218-5Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx 25mg	PS		ORAL	25MG QD ORAL
	Chest Pain		Flovent	C			
	Dyspepsia		Biaxin	C			
	Dyspnoea		Prednisone	C			
	Nausea		Kdur	C			
	Vomiting		Captopril	C			
			Pepcid	C			

Date:03/12/01ISR Number: 3678798-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	International Normalised		Vioxx	PS		ORAL	25 MG ORAL 13 DAY
	Ratio Increased		Coumadin	C			
	Prothrombin Time		Lanoxin	C			
	Prolonged		Furosemide	C			
			Mevacor	C			

Date:03/12/01ISR Number: 3680231-9Report Type:Periodic Company Report #WAES 00062722
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Vioxx	PS	Merck Research			
	Cystitis	Professional			Laboratories Div			
	Drug Effect Decreased	Company			Merck Co Inc	ORAL	25 MG/BID/PO	
	Gastritis	Representative	Tab Vioxx	SS		ORAL	25 MG/BID/PO	
	Oesophagitis							
	Pancreatic Disorder							
	Pancreatitis Acute							

Date:03/12/01ISR Number: 3680575-0Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Cerebrovascular Accident
	Dysarthria
	Gait Disturbance
	Hypertension
	Tachycardia

	Transient Ischaemic Attack Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO

Date:03/12/01ISR Number: 3680577-4Report Type:Expedited (15-DaCompany Report #WAES 01022262
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Diabetes Mellitus Inadequate Control	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
	Hypoglycaemia		Glucophage	SS			
	Myocardial Infarction		Lasix	C			
	Reocclusion		Aspirin	C			
			Atenolol	C			
			Glucosamine	C			

Date:03/12/01ISR Number: 3680578-6Report Type:Expedited (15-DaCompany Report #WAES 01022285
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Coronary Artery Surgery Deep Vein Thrombosis Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Avapro	C			
			Evista	C			
			Lipitor	C			
			Prilosec	C			
			Synthroid	C			
			Albuterol	C			

			Metoclopramide	C		

Date:03/12/01ISR Number: 3680585-3Report Type:Expedited (15-DaCompany Report #WAES 01030364
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aricept	C				

Date:03/12/01ISR Number: 3680592-0Report Type:Expedited (15-DaCompany Report #WAES 00101917
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Toxicity Renal Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Lithobid 300 Mg	SS		ORAL	300 MG /BID/PO; 300MG/DAILY/P	

O

Date:03/12/01ISR Number: 3680596-8Report Type:Expedited (15-DaCompany Report #WAES 00091010
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Valtrex	C				
			Estradiol Benzoate	C				

Date:03/12/01ISR Number: 3680598-1Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Blood Creatine Phosphokinase Increased Chondropathy Compression Fracture	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /BID/PO;25M/PRN/PO	
	Condition Aggravated Fluid Retention Muscular Weakness Rhabdomyolysis Weight Decreased		Darvocet-N Klonopin	C C				

Date:03/12/01ISR Number: 3680751-7Report Type:Expedited (15-DaCompany Report #WAES 01028248
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Dyspnoea	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY 70 DAY						
		Other	Fosamax	C		
			Furosemide	C		

Date:03/12/01ISR Number: 3680779-7Report Type:Expedited (15-DaCompany Report #WAES 01038101
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastric Ulcer	Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY 50 DAY						
		Other				

Date:03/12/01ISR Number: 3680780-3Report Type:Expedited (15-DaCompany Report #WAES 01028922
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Decreased	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Haematemesis	Health Professional			Laboratories Div Merck Co Inc	ORAL
Hospitalization -	Haematochezia					
25 MG/DAILY						
Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Other				
Disability						
Other						

Date:03/12/01ISR Number: 3680782-7Report Type:Expedited (15-DaCompany Report #WAES 00116101
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Haemorrhage Melaena	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	29 DAY
		Professional Other	Vioxx (Rofecoxib) 25 Mg	SS		ORAL	118	DAY
			Benazepril Hcl/Hctz	C				
			Fluoxetine	C				
			Thyroxine	C				

Date:03/12/01ISR Number: 3680803-1Report Type:Expedited (15-DaCompany Report #WAES 01028125
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	1 DAY
			Technescan Mdp Kit	C				

Date:03/12/01ISR Number: 3680806-7Report Type:Expedited (15-DaCompany Report #WAES 00116021
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Aneurysm Pancreatitis Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	

Date:03/12/01ISR Number: 3680813-4Report Type:Expedited (15-DaCompany Report #WAES 01027518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Petechiae Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/12/01ISR Number: 3680816-XReport Type:Expedited (15-DaCompany Report #WAES 01029178
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	

Date:03/12/01ISR Number: 3680831-6Report Type:Expedited (15-DaCompany Report #WAES 01026196
Age:85 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Blood Pressure Decreased Gastric Ulcer Gastroenteritis Helicobacter

		Haematocrit Decreased					
		Haemoglobin Decreased					
		Melaena	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pallor	Foreign	Vioxx	PS	Merck Research	
		Platelet Count Decreased	Health			Laboratories Div	
		Red Blood Cell Count	Professional			Merck Co Inc	ORAL
25 MG/DAILY							
		Decreased	Other	Captopril	C		
				Clorazepate			
				Dipotassium	C		
				Ranitidine	C		

Date:03/12/01ISR Number: 3680833-XReport Type:Expedited (15-DaCompany Report #WAES 01025308
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Melaena	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
		Other	Amiloride			
			Hydrochloride (+)			
			Furosemide	C		
			Clopidogrel	C		
			Fluvastatin	C		

Date:03/12/01ISR Number: 3680840-7Report Type:Expedited (15-DaCompany Report #WAES 00127523
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaphylactic Shock	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Epistaxis	Health			Laboratories Div	
	Gastrooesophageal Reflux	Professional			Merck Co Inc	ORAL
12.5 MG/DAILY	5 DAY					
	Disease	Other				
	Haematuria					
	Haemorrhage					
	Hypersensitivity					
	Idiopathic					
	Thrombocytopenic Purpura					
	Melaena					

Oesophagitis
Prothrombin Time
Prolonged

Date:03/12/01ISR Number: 3682698-9Report Type:Expedited (15-DaCompany Report #WAES 00101626
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Blood Alkaline Phosphatase Increased
	Blood Bilirubin Increased
	Hepatic Function Abnormal
	Limb Injury
	Muscle Injury

		Pain					
		Road Traffic Accident					
		Tendonitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased	Consumer	Vioxx	PS	Merck Research	
			Health			Laboratories Div	
			Professional			Merck Co Inc	ORAL
25							
MG/DAILY/PO							
				Prevacid	C		
				Robinul	C		

Date:03/12/01ISR Number: 3682704-1Report Type:Expedited (15-DaCompany Report #WAES 01022014
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Abdominal Tenderness	Health	Vioxx	PS	Merck Research	
Hospitalization -		Blood Chloride Increased	Professional			Laboratories Div	
Initial or Prolonged		Blood Creatinine	Company			Merck Co Inc	ORAL
25							
Other		Increased	Representative				
MG/DAILY/PO							
		Blood Glucose Increased		Coumadin	SS		ORAL
7.5							
		Blood Urea Increased					
MG/DAILY/PO							
		Bronchospasm		Tab Aspirin	SS		ORAL
81							
		Cardiac Failure					
MG/DAILY/PO							
		Congestive		Darvocet-N	C		
		Cardiomegaly		Glucophage	C		
		Condition Aggravated		Lasix	C		
		Cough		Norvasc	C		
		Duodenal Ulcer		Pravachol	C		
		Duodenal Ulcer					
		Haemorrhage					
		Dyspnoea					
		Gastritis					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Lipase Increased					
		Monocytosis					

Mucosal Dryness
Pallor
Tachycardia

Date:03/13/01ISR Number: 3679573-2Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx 25mg	PS			6:30AM	6:30PM
			Atenolol	C				
			Ativan	C				

Date:03/13/01ISR Number: 3679878-5Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deafness		Vioxx (12.5 Mg) (Merk)	PS	Merk		ONE TABLET A	
Disability	Diarrhoea						DAY	
	Dizziness							
	Nausea		Doxycycline	C				
	Vertigo							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/01ISR Number: 3681196-6Report Type:Expedited (15-DaCompany Report #2000COU1071
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Coumadin	PS	Dupont Merck			
Hospitalization -	Chest Wall Pain	Professional			Pharmaceutical Co	ORAL	5 MG DLY PO	
Initial or Prolonged	Coagulopathy		Vioxx (Rofecoxib)	SS		ORAL	25 MG DLY PO	
	Gastric Ulcer		Propoxyphene/Apap	C				
	Haematemesis		Betapace (Sotalol Hcl)	C				
	Haemoglobin Decreased		Hytrin (Terazosin Hydrochloride)	C				
	International Normalised Ratio Increased		Amitriptyline	C				
	Melaena		Slow-Mag (Magnesium Chloride, Sustained Release)	C				
	Mucous Membrane Disorder		Nsaid(S)	C				
	Upper Gastrointestinal Haemorrhage							

Date:03/14/01ISR Number: 3681030-4Report Type:Expedited (15-DaCompany Report #WAES 01020935
Age:81 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25 MG/PO	
		Representative						

Date:03/14/01ISR Number: 3681031-6Report Type:Expedited (15-DaCompany Report #WAES 01021775
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Chest Pain	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:03/14/01ISR Number: 3681046-8Report Type:Expedited (15-DaCompany Report #WAES 01030175
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Fosamax	C				
			Prevacid	C				
			Remeron	C				
			Soma	C				
			Tylenol	C				
			Valium	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Chlorophyll	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3681047-XReport Type:Expedited (15-DaCompany Report #WAES 01030024
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Atrovent	C				
			Bactrim Ds Tablets	C				
			Cytoxan	C				
			Flovent	C				
			Prevacid	C				
			Serevent	C				
			Valtran	C				
			Doxorubicin	C				
			Prednisone	C				
			Vincristine	C				

Date:03/14/01ISR Number: 3681048-1Report Type:Expedited (15-DaCompany Report #WAES 01030609
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Syncope	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Iron	C				

Date:03/14/01ISR Number: 3681050-XReport Type:Expedited (15-DaCompany Report #WAES 01012239
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erosive Oesophagitis Gastric Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Gastritis Erosive				Merck Co Inc	ORAL
25 MG DAILY						
	Haematemesis					
PO						
	Influenza Like Illness					
	Mallory-Weiss Syndrome					
	Oesophagitis					
	Sinusitis					
	Vomiting					

Date:03/14/01ISR Number: 3681051-1Report Type:Expedited (15-DaCompany Report #WAES 01030366
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematemesis	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Rectal Haemorrhage	Professional			Laboratories Div	
Other					Merck Co Inc	ORAL
50 MG DAILY						
PO						
			Motrin	C		
			Prolixin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3681054-7Report Type:Expedited (15-DaCompany Report #WAES 00121551
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastritis	Consumer	Vioxx	PS	Merck Research			
Other	Mouth Ulceration	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	50 MG QID PO	
			Vicodin Tablets	C				

Date:03/14/01ISR Number: 3681056-0Report Type:Expedited (15-DaCompany Report #WAES 01020909
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health	Vioxx	PS	Merck Research			
	Gastric Ulcer	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	50 MG DAILY	
		Representative						
							PO	

Date:03/14/01ISR Number: 3681057-2Report Type:Expedited (15-DaCompany Report #WAES 00110617
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Chest Discomfort	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	25	
	Nausea						MG/DAILY/PO	
			Lopressor	SS			100 MG/DAILY	
			Prinivil	C				
			Tylenol	C				
			Zocor	C				

Date:03/14/01ISR Number: 3681066-3Report Type:Expedited (15-DaCompany Report #WAES 99121540
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Pancreatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/1X/PO	
			Celebrex	C				
			Fosamax	C				
			Lipitor	C				
			Premarin	C				
			Zantac	C				

Date:03/14/01ISR Number: 3681070-5Report Type:Expedited (15-DaCompany Report #WAES 99080718
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Alveolitis
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Convulsion
	Dehydration
	Depression
	Drug Hypersensitivity
	Encephalopathy
	Headache
	Lethargy
	Meningitis Aseptic

	Pneumonia Pyrexia Respiratory Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sepsis Transient Ischaemic Attack	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Tab Vioxx	SS		ORAL	25 MG/DAILY/PO
			Tab Vioxx	SS		ORAL	12.5 MG/DAILY PO
			Flovent	C			
			Limbitrol Tablets	C			
			Plaquenil	C			
			Prilosec	C			
			Xanax	C			
			Albuterol	C			
			Prednisone	C			

Date:03/14/01ISR Number: 3681077-8Report Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cellulitis Melaena Pancreatic Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO
Disability	Pancreatitis		Flexeril	C			
Other	Weight Decreased		Valium	C			

Date:03/14/01ISR Number: 3681079-1Report Type:Expedited (15-DaCompany Report #WAES 01011902
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Aspirin	C			
			Ibuprofen	C			

Date:03/14/01ISR Number: 3681081-XReport Type:Expedited (15-DaCompany Report #WAES 01012080
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Gastroenteritis							
	Helicobacter	Representative						
	Gastrointestinal Haemorrhage		Centrum Silver	C				
	Gastrointestinal Ulcer		Coreg	C				
	Haemoglobin Decreased		Diovan	C				
	Nausea		Glucotrol	C				
			Humulin 70/30	C				
			Lasix (Furosmide Sodium)	C				
			Nitrolingual Spray	C				
			Norvasc	C				
			Plavix	C				
			Prevacid	C				

			Therapy Unspecifeid	C
			Ascorbic Acid	C
			Atenolol	C
			Digoxin	C
			Glucosamine	C
			Magnesium Oxide	C
			Nonsteroidal Anti-Inflammatory	C
			Vitamin E	C

Date:03/14/01ISR Number: 3681083-3Report Type:Expedited (15-DaCompany Report #WAES 01022159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bursitis Difficulty In Walking Disorientation	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Feeling Abnormal Insomnia Muscle Spasms Muscular Weakness Oedema Peripheral Pain Pain In Extremity		Tylenol Naproxen	C C				

Date:03/14/01ISR Number: 3681099-7Report Type:Expedited (15-DaCompany Report #WAES 01020875
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma Cardiac Failure Congestive Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	
			Calan	C				
			Fosamax	C				
			Lipitor	C				
			[Therapy Unspecified]	C				

			Albuterol	C
			Ascorbic Acid	C
			Aspirin	C
			Insulin	C
			Potassium (Unspecified)	C
			Vitamins (Unspecified)	C

Date:03/14/01ISR Number: 3681103-6Report Type:Expedited (15-DaCompany Report #WAES 01030432
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Ear Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem Cd	C				
			Mevacor	C				
			Prilosec	C				
			[Therapy					

Unspecified] C

Date:03/14/01ISR Number: 3681107-3Report Type:Expedited (15-DaCompany Report #WAES 01030636
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/TID/PO	
	Nausea		Roxicet	C				
			Tylenol	C				
			Zyloprim	C				

Date:03/14/01ISR Number: 3681111-5Report Type:Expedited (15-DaCompany Report #WAES 01022097
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Lung Disorder Renal Impairment							

Date:03/14/01ISR Number: 3681122-XReport Type:Expedited (15-DaCompany Report #WAES 01020983
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Anaphylactic Reaction Dyspnoea Lacrimation Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pruritus	Representative						
	Swelling		Aspirin	C				
			Atenolol	C				

Date:03/14/01ISR Number: 3681124-3Report Type:Expedited (15-DaCompany Report #WAES 01030125
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/14/01ISR Number: 3681125-5Report Type:Expedited (15-DaCompany Report #WAES 01030192
Age: Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Bronchospasm
	Burning Sensation
	Drug Hypersensitivity
	Dysphagia
	Dyspnoea
	Face Oedema
	Mouth Ulceration
	Oral Intake Reduced
	Pain
	Speech Disorder
	Speech Disorder

Developmental
Swelling
Tongue Ulceration

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY

Date:03/14/01ISR Number: 3681127-9Report Type:Expedited (15-DaCompany Report #WAES 00121101
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Bradycardia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/14/01ISR Number: 3681136-XReport Type:Expedited (15-DaCompany Report #WAES 01030604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY

Date:03/14/01ISR Number: 3681138-3Report Type:Expedited (15-DaCompany Report #WAES 00121218
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchospasm	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div	
					Merck Co Inc	ORAL

PO

Date:03/14/01ISR Number: 3681145-0Report Type:Expedited (15-DaCompany Report #WAES 01022203
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Erythema	Health	Vioxx	PS	Merck Research	
	Photosensitivity Reaction	Professional			Laboratories Div	
	Pruritus				Merck Co Inc	ORAL

25

MG/DAILY/PO

			Tobradex	C		

Date:03/14/01ISR Number: 3681383-7Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Change Of Bowel Habit	Health			Laboratories Div	
	Face Oedema	Professional			Merck Co Inc	ORAL

25 MG/BID PO 2 DAY

	Hypertension	Other	Clobazam	C		
	Hyponatraemia		Sertraline	C		
	Insomnia		Tizanidine	C		
	Tremor					
	Vomiting					

Date:03/14/01ISR Number: 3681384-9Report Type:Expedited (15-DaCompany Report #WAES 01029454
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
		Other					PO	
			Enalapril	C				
			Glyburide	C				

Date:03/14/01ISR Number: 3681386-2Report Type:Expedited (15-DaCompany Report #WAES 01025567
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID	3 DAY
	Aminotransferase		Inj Etomidate	SS				1 DAY
	Increased		Inhl Desflurane	SS			RESPIRATORY (INHALATION)	
	Blood Bilirubin Increased							1 DAY
	Blood Lactate Dehydrogenase Increased		Succinylcholine Chloride	SS				1 DAY
	Hepatitis		Pancuronium Bromide	SS				1 DAY
			Bupivacaine Hcl	C				
			Piritramide	C				

Date:03/14/01ISR Number: 3681387-4Report Type:Expedited (15-DaCompany Report #WAES 01036501
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Gastric Ulcer	Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY 57 DAY						

Date:03/14/01ISR Number: 3681388-6Report Type:Expedited (15-DaCompany Report #WAES 00127523
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactic Shock	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Antinuclear Antibody	Health			Laboratories Div	
Initial or Prolonged	Positive	Professional			Merck Co Inc	ORAL
12.5 MG/DAILY 5 DAY						
Other	Drug Toxicity	Other	Infusion (Form)			
	Epistaxis		Platelet Concentrate	SS		
INTRAVENOUS						
	Haematuria					
	Haemorrhage					
	Idiopathic Thrombocytopenic Purpura					
	Melaena					
	Oesophagitis					
	Prothrombin Time Prolonged					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3681390-4Report Type:Expedited (15-DaCompany Report #WAES 01035510
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID	
			Acetaminophen (+) Codeine	C				
			Alfacalcidol	C				
			Aspirin	C				
			Bromazepam	C				
			Calcium (Unspecified)	C				
			Dipyrone	C				
			Doxepin Hcl	C				
			Furosemide	C				
			Isosorbide Dinitrate	C				
			Metoprolol Succinate	C				
			Tetrazepam	C				

Date:03/14/01ISR Number: 3681391-6Report Type:Expedited (15-DaCompany Report #WAES 01033460
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Diarrhoea							
	Syncope							
	Vomiting		Celecoxib	SS		ORAL		

Date:03/14/01ISR Number: 3681403-XReport Type:Expedited (15-DaCompany Report #WAES 01023793
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenomatous Polyposis Coli	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Blood Creatinine							

	Increased	Other	Aspirin	C
	Diverticulum			
	Haemoglobin Decreased			
	Rectal Haemorrhage			

Date:03/14/01ISR Number: 3681507-1Report Type:Expedited (15-DaCompany Report #WAES 00056537
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Foetal Growth Retardation	Foreign	Vioxx	PS	Merck Research			
Other	Intra-Uterine Death	Other			Laboratories Div			
	Oligohydramnios				Merck Co Inc	ORAL	12,5	MG/PRN;PO 25 DAY
			Acetaminophen	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3681633-7Report Type:Expedited (15-DaCompany Report #WAES 00095004
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Hallucination	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Acetaminophen/Codeine Phosphate	C				
			Amitriptyline	C				
			Diazepam	C				
			Etidronate Disodium	C				
			Lansoprazole	C				
			Temazepam	C				

Date:03/14/01ISR Number: 3681638-6Report Type:Expedited (15-DaCompany Report #WAES 01039754
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/14/01ISR Number: 3681641-6Report Type:Expedited (15-DaCompany Report #WAES 01037259
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Atrial Fibrillation Blood Sodium Decreased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Duodenal Ulcer Haemoglobin Decreased Vomiting		Aspirin/Caffeine	SS				
			Amiloride Hydrochloride/Hctz	C				
			Ferrouss04	C				
			Prednisolone	C				

			Verapamil	C		

Date:03/14/01ISR Number: 3681642-8Report Type:Expedited (15-DaCompany Report #WAES 01035520
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO 10 DAY						

Date:03/14/01ISR Number: 3681646-5Report Type:Expedited (15-DaCompany Report #WAES 01035007
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Iron Deficiency Anaemia Microcytic Anaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO 1 MON						
			Vioxx (Rofecoxib)	SS		ORAL
25 MG PO						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Atenolol/Chlorthalid			

one C

Date:03/14/01ISR Number: 3681658-1Report Type:Expedited (15-DaCompany Report #WAES 01028125
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Pruritus	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	1 DAY
			Technescan Mdp Kit	C				

Date:03/14/01ISR Number: 3681660-XReport Type:Expedited (15-DaCompany Report #WAES 01037256
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	235 DAY
			Acetaminophen	C				
			Propoxyphene Napsylate	C				
			Salmeterol Xinafoate	C				

Date:03/14/01ISR Number: 3681663-5Report Type:Expedited (15-DaCompany Report #WAES 01037258
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
25 MG PO	84 DAY					
			Allopurinol	C		
			Amiloride	C		
			Aspirin	C		
			Citalopram Hydrobromide	C		
			Digoxin	C		
			Furosemide	C		
			Metoprolol Tartrate	C		
			Mianserin Hcl	C		
			Omeprazole Magnesium	C		

Date:03/14/01ISR Number: 3682036-1Report Type:Expedited (15-DaCompany Report #WAES 01016197
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased Myocardial Infarction	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY 29 DAY						
		Professional	Vioxx (Rofecoxib)	SS		ORAL
25 MG 152 DAY						
		Other	Melilot	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3682639-4Report Type:Expedited (15-DaCompany Report #WAES 01027520
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Foreign	Vioxx	PS	Merck Research			
Other	Increased	Other			Laboratories Div			
	Blood Urea Increased				Merck Co Inc	ORAL	25 MG/DAILY	1 MON
	Hyperkalaemia		Tab Canrenoate Potassium	SS		ORAL	100 MG/DAILY	3 YR
			Cetirizine Hydrochloride	C				
			Citalopram Hydrobromide	C				
			Lormetazepam	C				

Date:03/15/01ISR Number: 3682279-7Report Type:Expedited (15-DaCompany Report #WAES 01033705
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research			
	Haemoglobin Abnormal	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		

Date:03/15/01ISR Number: 3682282-7Report Type:Expedited (15-DaCompany Report #WAES 01038206
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Coagulation Time Prolonged	Health Professional			Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
Other	Drug Interaction	Other	Tab Phenproxoumon	SS		ORAL		
	Electrocardiogram Abnormal		Chlorthalidone	C				
	Gastric Ulcer Haemorrhage		Digoxin	C				
			Glyburide	C				
			Isosorbide Dinitrate	C				
			Tamsulosin	C				

Date:03/15/01ISR Number: 3682361-4Report Type:Expedited (15-DaCompany Report #WAES 01020772
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			
Other	Diarrhoea	Health			Laboratories Div			
	Drug Ineffective	Professional			Merck Co Inc	ORAL	25 MG/TID/PO	
	Nausea		Motrin	C				
	Oedema Peripheral		Oxycontin	C				
	Pain In Extremity		Percocet	C				
	Skin Ulcer		Valium	C				
			Ibuprofen	C				

Date:03/15/01ISR Number: 3682364-XReport Type:Expedited (15-DaCompany Report #WAES 01020888
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/15/01ISR Number: 3682393-6Report Type:Expedited (15-DaCompany Report #WAES 01031431
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemoglobin Decreased Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depakote	C				
			Neurontin	C				

Date:03/15/01ISR Number: 3686294-9Report Type:Expedited (15-DaCompany Report #WAES 01039902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Hepatic Function Abnormal	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/16/01ISR Number: 3682949-0Report Type:Expedited (15-DaCompany Report #WAES 01025231
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction Oesophageal Ulcer Oesophagitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY;PO	
			Lansoprazole	C				
			Morphine So4	C				
			Prochlorperazine	C				

Date:03/16/01ISR Number: 3682979-9Report Type:Expedited (15-DaCompany Report #WAES 01025320
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastritis	Foreign	Tab Vioxx			
	Haematemesis	Other	(Rofecoxib)	PS	Merck Research	
	Upper Gastrointestinal				Laboratories Div	
	Haemorrhage				Merck Co Inc	ORAL
7.7 MG/DAILY,						
PO 100 DAY						
			Acetaminophen	C		
			Amlodipine Besylate	C		
			Bendroflumethiazide	C		
			Diclofenac Sodium			
			(+) Misoprostol	C		

Date:03/16/01ISR Number: 3682999-4Report Type:Expedited (15-DaCompany Report #WAES 01019148
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertension	Foreign	Tab Vioxx			
	Lung Disorder		(Rofecoxib)	PS	Merck Research	
	Phlebitis				Laboratories Div	
	Retinal Vein Thrombosis				Merck Co Inc	ORAL
25 MG, DAILY,						
PO						
			Hctz/Quinapril	C		
			Allopurinol	C		
			Escin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/01ISR Number: 3683001-0Report Type:Expedited (15-DaCompany Report #WAES 01030617
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal Hepatotoxicity Liver Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/16/01ISR Number: 3683002-2Report Type:Expedited (15-DaCompany Report #WAES 01030922
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis Drug Effect Decreased Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5	SS		ORAL	PO	
			Adalat	C				
			Chondroitin	C				
			Glucosamine	C				
			Vicodin Tablets	C				
			Celebrex	C				

Date:03/16/01ISR Number: 3683005-8Report Type:Expedited (15-DaCompany Report #WAES 01035062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Encephalopathy Hepatic Function Abnormal Liver Function Test Abnormal	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/16/01ISR Number: 3683007-1Report Type:Expedited (15-DaCompany Report #WAES 01037261
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	C-Reactive Protein Increased Cardiac Failure Difficulty In Walking Dyspnoea Oedema Peripheral Pain In Extremity Renal Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	
			Tab Furosemide	SS		ORAL	80 MG/DAILY, PO	
			Cyclizine	C				
			Dixyrazine	C				
			Lasoprazole	C				
			Leuprolide Acetate	C				
			Meprednisone	C				
			Metoprolol Tartrate	C				
			Morphine	C				
			Morphine Hcl	C				
			Nitroglycerin	C				
			Picosulfate Na	C				
			Prochlorperazine	C				

Date:03/16/01ISR Number: 3683008-3Report Type:Expedited (15-DaCompany Report #WAES 01037264
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Blood Potassium Decreased Blood Pressure Increased Bronchospasm	Foreign Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	14 DAY
	Cardiomegaly Cold Sweat Faecal Incontinence Fall Fluid Retention Heart Rate Irregular Hypertension Loss Of Consciousness Tachycardia Urinary Incontinence Weight Decreased		Vasotec [Therapy Unspecified] Allopurinol Furosemide Levothyroxine Na Sotalol Spironolactone Warfarin Sodium	C C C C C C C C				

Date:03/16/01ISR Number: 3683011-3Report Type:Expedited (15-DaCompany Report #WAES 01039126
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Face Oedema Pruritus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	75 DAY
			Gramicidin/Neomycins o4/Polymyxin Bso4	C				

Date:03/16/01ISR Number: 3683013-7Report Type:Expedited (15-DaCompany Report #WAES 01039129
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choreoathetosis Computerised Tomogram	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

	Abnormal				Merck Co Inc	ORAL
12.5 MG/DAILY						
			Cap Nicardipine Hcl	SS		ORAL
40 MG/DAILY						
			Cap Lansoprazole	SS		ORAL
30 MG						

Date:03/16/01ISR Number: 3683015-0Report Type:Expedited (15-DaCompany Report #WAES 00105628
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Ageusia	Foreign	Vioxx	PS	Merck Research	
	Hypoaesthesia	Health			Laboratories Div	
	Hypoaesthesia Oral	Professional			Merck Co Inc	ORAL
25 MG/DAILY 21 DAY						
	Oral Mucosal Blistering		Levothyroxine Sodium (+) Potassium Iodid	C		

Date:03/16/01ISR Number: 3684183-7Report Type:Expedited (15-DaCompany Report #WAES 01021910
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Gastric Ulcer
	Gastritis

		Melaena					
		Nausea					
		Oesophageal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophagitis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Hyzaar	C		
				Aspirin	C		

Date:03/16/01ISR Number: 3684187-4Report Type:Expedited (15-DaCompany Report #WAES 01022203
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Photosensitivity Reaction					
		Pruritus					
25 MG/DAILY/PO							
				Tobradex	C		

Date:03/16/01ISR Number: 3684192-8Report Type:Expedited (15-DaCompany Report #WAES 01021738
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Vitreous Detachment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Vitreous Haemorrhage					
PO							
				Fosamax	C		
				Levoxyl	C		
				Pravachol	C		
				Aspirin	C		
				Estradiol	C		

Date:03/16/01ISR Number: 3684195-3Report Type:Expedited (15-DaCompany Report #WAES 01021249
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Atelectasis							
	Blood Glucose Increased							
	Cardiac Murmur		Aspirin 81 Mg	SS				
	Cardiomegaly		Diovan	C				
	Dizziness		Imdur	C				
	Erosive Duodenitis		Maxzide	C				
	Gastritis Atrophic		Atenolol	C				
	Haematemesis		Vitamin E	C				
	Haematochezia							
	Hyperkalaemia							
	Oesophagitis							
	Renal Impairment							
	Ulcer							
	Upper Gastrointestinal Haemorrhage							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/01ISR Number: 3684219-3Report Type:Expedited (15-DaCompany Report #WAES 01030391
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Glucophage	C				
			Lotrel	C				
			Maxzide	C				
			Amitriptyline	C				
			Atenolol	C				

Date:03/19/01ISR Number: 3684177-1Report Type:Expedited (15-DaCompany Report #WAES 01010065
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous Accidental Exposure Pregnancy	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Indocin (Indomethacin)	C				

Date:03/19/01ISR Number: 3684351-4Report Type:Expedited (15-DaCompany Report #WAES 01029178
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY;PO	15 DAY
			Tab Vioxx (Rofecoxib)	SS			12.5 MG	

Date:03/19/01ISR Number: 3684369-1Report Type:Expedited (15-DaCompany Report #WAES 01019148
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypertension	Foreign	Vioxx	PS	Merck Research			
Other	Phlebitis	Health			Laboratories Div			
	Pulmonary Infarction	Professional			Merck Co Inc	ORAL	25 MG/DAILY	
	Retinal Vein Thrombosis							
							PO	59 DAY
			Hctz / Quinapril	C				
			Allopurinol	C				
			Escin	C				

Date:03/19/01ISR Number: 3684372-1Report Type:Expedited (15-DaCompany Report #WAES 01028771
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Confusional State	Health			Laboratories Div			
	Hepatic Function Abnormal	Professional			Merck Co Inc			
							25 MG/DAILY	92 DAY
	Transient Ischaemic		Acetaminophen	C				
	Attack		Cilazapril	C				
			Diclofenac Na	C				
			Lidocaine	C				
			Triamcinolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/01ISR Number: 3684377-0Report Type:Expedited (15-DaCompany Report #WAES 01015621
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Erythema	Other			Laboratories Div			
Initial or Prolonged	Pyrexia				Merck Co Inc	ORAL	12.5 MG	
	Toxic Epidermal							
	Necrolysis		Acetaminophen (+)				DAILY/PO	156 DAY
			Caffeine (+)					
			Propyphenazone	SS		ORAL	SEE IMAGE	10 DAY
			Cetirizine					
			Hydrochloride	C				
			Loratadine	C				
			Pentaerythritol					
			Tetranitrate	C				
			Verapamil	C				

Date:03/19/01ISR Number: 3684380-0Report Type:Expedited (15-DaCompany Report #WAES 00125120
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Iron Deficiency Anaemia	Other			Laboratories Div			
Other					Merck Co Inc	ORAL	25 MG / DAILY	
							/ PO	17 DAY
			Ranitidine	C				

Date:03/19/01ISR Number: 3684383-6Report Type:Expedited (15-DaCompany Report #WAES 01029702
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Pyelonephritis	Study			Laboratories Div			

Health Merck Co Inc ORAL
25 MG/DAILY
Professional
PO 8 DAY
[Therapy
Unspecified) SS
Piroxicam C
Tramadol Hcl C

Date:03/19/01ISR Number: 3684387-3Report Type:Expedited (15-DaCompany Report #WAES 01035520
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Oesophagitis	Other			Laboratories Div			
Hospitalization -	Upper Respiratory Tract				Merck Co Inc	ORAL	SEE IMAGE	96 DAY
Initial or Prolonged	Infection							

Date:03/19/01ISR Number: 3684388-5Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL	25 MG 1 PO QD	
Initial or Prolonged	Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/01ISR Number: 3684676-2Report Type:Expedited (15-DaCompany Report #WAES 00120417
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia Dyspnoea Face Oedema Feeling Abnormal Headache Hypersensitivity Influenza Like Illness Menorrhagia Swelling Tongue Disorder Urticaria	Consumer Health Professional	Vioxx (Therapy Unspecified)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/19/01ISR Number: 3684677-4Report Type:Expedited (15-DaCompany Report #WAES 01021944
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Health Professional	Vioxx (Therapy Unspecified)	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/19/01ISR Number: 3684679-8Report Type:Expedited (15-DaCompany Report #WAES 00111037
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Cardiac Failure Congestive Weight Increased	Consumer Health Professional	Vioxx Avapro Coumadin Lasix	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Tambocor	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:03/19/01ISR Number: 3684680-4Report Type:Expedited (15-DaCompany Report #WAES 99120406
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO, (SEE IMAGE)	
	Blood Pressure Increased							
	Chest Discomfort							
	Flatulence							
	Hypertension		Cardizem	SS				
	Nasal Congestion		Hydrodiuril	C				
	Nausea		Prinivil	C				
	Stomach Discomfort		Oxyir	C				
			Oxycontin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/01ISR Number: 3685104-3Report Type:Expedited (15-DaCompany Report #WAES 01028542
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	6 DAY
	Dizziness							
	Headache							
	Hypertension		Hydrodiuril	C				
	Muscle Spasms		Vasotec	C				
	Pallor							

Date:03/20/01ISR Number: 3685317-0Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS		ORAL	25 MG 1 PER DAY ORAL	

Date:03/20/01ISR Number: 3685573-9Report Type:Expedited (15-DaCompany Report #WAES 01030432
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	No Adverse Drug Effect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem Cd	C				
			Mevacor	C				
			Prilosec	C				

Date:03/20/01ISR Number: 3685578-8Report Type:Expedited (15-DaCompany Report #WAES 01031427
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Asthenia Haematochezia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/DAILY/PO	Haematuria	Representative				
	Hepatic Function Abnormal		Glucophage	C		
	Renal Failure Acute		Lasix (Furosemide)	C		
	Thrombocytopenia		Lopressor	C		
			Prcardia Xl	C		
			Vasotec	C		
			Volataren-Xr	C		
			Zocor	C		
			Aspirin	C		
			Dipyridamole	C		
			Glyburide	C		

Date:03/20/01ISR Number: 3685583-1Report Type:Expedited (15-DaCompany Report #WAES 01031080
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Major Depression	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25-50 MG/DAILY/PO						

Date:03/20/01ISR Number: 3685587-9Report Type:Expedited (15-DaCompany Report #WAES 01030998
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/20/01ISR Number: 3685600-9Report Type:Expedited (15-DaCompany Report #WAES 01020539
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia Metastases To Spine Paraesthesia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Depakote	C				
			Dilantin	C				

Date:03/20/01ISR Number: 3685645-9Report Type:Expedited (15-DaCompany Report #WAES 01020826
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Tongue Oedema	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				
			Lipitor	C				
			Lotensin	C				
			Paxil	C				
			Nitroglycerin	C				

Date:03/20/01ISR Number: 3685649-6Report Type:Expedited (15-DaCompany Report #WAES 01031467
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hair Disorder Headache Meningitis Aseptic Musculoskeletal Stiffness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyrenium	C				
			Keflex	C				
			Lescol	C				
			Prinivil	C				
			Sinequan	C				
			Synthroid	C				
			Estrogens (Unspecified)	C				
			Insulin	C				

Date:03/20/01ISR Number: 3685716-7Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Renal Impairment		Vioxx / 12.5 Mg / Merck	PS		ORAL	12.5 /QD /ORAL	

Date:03/20/01ISR Number: 3685819-7Report Type:Expedited (15-DaCompany Report #WAES 00109143
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Antibody Test Positive Guillain-Barre Syndrome Hypercholesterolaemia Hyperuricaemia Hyporeflexia Motor Dysfunction Paresis Polyneuropathy Thyroiditis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	3	DAY

Date:03/20/01ISR Number: 3685821-5Report Type:Expedited (15-DaCompany Report #WAES 01035030
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Urinary Incontinence	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	28 DAY
			Folic Acid	C				
			Levothyroxine Na	C				

Date:03/20/01ISR Number: 3685827-6Report Type:Expedited (15-DaCompany Report #WAES 01035541
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	WK

Date:03/20/01ISR Number: 3685829-XReport Type:Expedited (15-DaCompany Report #WAES 01029177
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:03/20/01ISR Number: 3685832-XReport Type:Expedited (15-DaCompany Report #WAES 01037004
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	62 DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Other						
	Haematemesis							
	Upper Gastrointestinal Haemorrhage		Vasotec	C				
			Zopiclone	C				

Date:03/20/01ISR Number: 3685840-9Report Type:Expedited (15-DaCompany Report #WAES 01039943
Age:89 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Amnesia
Hospitalization - Initial or Prolonged	Atrioventricular Block
	Blood Pressure Increased

		Bundle Branch Block					
		Condition Aggravated					
		Disorientation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Decreased	Foreign	Vioxx	PS	Merck Research	
		Hyperkalaemia	Health			Laboratories Div	
		Nodal Arrhythmia	Professional			Merck Co Inc	ORAL
25 MG/DAILY	3 DAY						
		Renal Impairment		Cozaar	C		
		Syncope		Metoprolol	C		
				Spironolactone	C		

Date:03/20/01ISR Number: 3685882-3Report Type:Expedited (15-DaCompany Report #WAES 01015627
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Bilirubin Increased	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Hepatic Function Abnormal	Other			Laboratories Div	
	Jaundice				Merck Co Inc	ORAL
25 MG/DAILY						
PO						
			Calcium Carbonate	C		
			Omeprazole Magnesium	C		
			Pamidronate Disodium	C		
			Ramipril	C		

Date:03/20/01ISR Number: 3685885-9Report Type:Expedited (15-DaCompany Report #WAES 01037260
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Agranulocytosis	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Dyspnoea	Other			Laboratories Div	
	Fatigue				Merck Co Inc	ORAL
12.5 MG/DAILY						
	Glomerulonephritis					
PO						
	Proliferative		Tab Furosemide	SS		ORAL
PO	64 DAY					
	Hypertension		Cap Lansoprazole	SS		ORAL
30 MG PO	64 DAY					

	Hypothyroidism		[Therapy	
	Microcytic Anaemia		Unspecified]	C
	Nephritis		Acetazolamide	C
	Renal Failure Acute		Calcium Carbonate	C
			Ibuprofen	C
			Levothyroxine Na	C
			Metoprolol	C
			Nystatin	C
			Potassium Chloride	C
			Prednisolone	C

Date:03/20/01ISR Number: 3686908-3Report Type:Expedited (15-DaCompany Report #WAES 01028562
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea	Health						
	Electrolyte Imbalance	Professional			Merck Co Inc	ORAL	25 MG/DAILY	
			Dextropropoxyphene	SS				UNKNOWN
			Morphine	SS				UNKNOWN
			Lithium Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/20/01ISR Number: 3686915-0Report Type:Expedited (15-DaCompany Report #WAES 01039127
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Vasotec	C				
			Acetaminophen	C				

Date:03/20/01ISR Number: 3686918-6Report Type:Expedited (15-DaCompany Report #WAES 01033723
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	266 DAY	
			Aspirin	C				
			Mirtazapine	C				

Date:03/21/01ISR Number: 3685465-5Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Mouth Ulceration Tongue Ulceration		Vioxx (25 Mg Per 1 Tablet)	PS				

Date:03/21/01ISR Number: 3685609-5Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx (12.5mg Q D) - (Merck Medco).	PS	Merck Med Co		12.5 MG QD	

Date:03/21/01ISR Number: 3686871-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth		Rofecoxib	PS				
ONCE DAILY							5	DAY
	Oedema Mouth							
	Pharyngeal Oedema							
	Salivary Gland Disorder							

Date:03/22/01ISR Number: 3687928-5Report Type:Expedited (15-DaCompany Report #WAES 01012680
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chills	Health	Vioxx	PS	Merck Research			
	Dizziness	Professional			Laboratories Div			
	Hyperhidrosis	Company			Merck Co Inc	ORAL	50	
	Nervousness	Representative						
MG/DAILY/PO								
	Paranoia		Darvocet-N	C				
			Doxycycline	C				

Date:03/22/01ISR Number: 3687930-3Report Type:Expedited (15-DaCompany Report #WAES 01021840
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Diarrhoea Drug Interaction Fatigue Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/22/01ISR Number: 3687933-9Report Type:Expedited (15-DaCompany Report #WAES 01031323
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Dermatitis Flushing Syncope Vasovagal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY / PO	
			Excedrin Extra-Strength	C				
			Tylenol Pm	C				

Date:03/22/01ISR Number: 3687938-8Report Type:Expedited (15-DaCompany Report #WAES 01030864
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/ UNK / PO	

Date:03/22/01ISR Number: 3687939-XReport Type:Expedited (15-DaCompany Report #WAES 01031095
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Toxicity Nephropathy Toxic	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG / DAILY / PO	
			Azulfidine	C				
			Methotrexate	C				

Date:03/22/01ISR Number: 3687940-6Report Type:Expedited (15-DaCompany Report #WAES 01032215
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Prempro	C				
			Tenormin	C				

Date:03/22/01ISR Number: 3687942-XReport Type:Expedited (15-DaCompany Report #WAES 01030851
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Bilirubin Increased Hepatic Enzyme Increased	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Zocor	C				

Date:03/22/01ISR Number: 3687944-3Report Type:Expedited (15-DaCompany Report #WAES 01030390
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Asthenia Gastritis Erosive Haematemesis Mallory-Weiss Syndrome	Health Professional Other	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Plavix 75 Mg	SS		ORAL	75 MG, DAILY, PO	
			Folic Acid	C				
			Omeprazole	C				
			Pravastatin Sodium	C				
			Simethicone	C				
			Trazodone	C				

Date:03/22/01ISR Number: 3687945-5Report Type:Expedited (15-DaCompany Report #WAES 01021498
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Anaemia Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG,	

DAILY, PO

Premarin	C	
Cimetidine	C	
Nonsteroidal Anti-Inflammatory	C	

Date:03/22/01ISR Number: 3687946-7Report Type:Expedited (15-DaCompany Report #WAES 01012215
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Malaise Nausea	Consumer	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, DAILY, PO	
			Therapy Unspecified	C				
			Nortriptyline	C				

Date:03/22/01ISR Number: 3687947-9Report Type:Expedited (15-DaCompany Report #WAES 01031327
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Disability	Arthralgia Blood Pressure Increased Difficulty In Walking Hypertonia

Joint Effusion
Paraesthesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, BID, PO	
	Celebrex	C				

Date:03/22/01ISR Number: 3687951-0Report Type:Expedited (15-DaCompany Report #WAES 01031465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Diovan	C				

Date:03/22/01ISR Number: 3687952-2Report Type:Expedited (15-DaCompany Report #WAES 01031627
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Toxicity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK / UNK / PO	
			Lithiumco3	SS				

Date:03/22/01ISR Number: 3688190-XReport Type:Expedited (15-DaCompany Report #WAES 01036513
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:03/22/01ISR Number: 3688191-1Report Type:Expedited (15-DaCompany Report #WAES 01036510
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Oesophagitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Fosinopril Sodium	C				
			Ketobemidone Hcl	C				
			Metoprolol Tartrate	C				
			Tramadol	C				

Date:03/22/01ISR Number: 3688193-5Report Type:Expedited (15-DaCompany Report #WAES 01035542
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/01ISR Number: 3688197-2Report Type:Expedited (15-DaCompany Report #WAES 01035007
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Iron Deficiency Anaemia Microcytic Anaemia Orthostatic Hypotension	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	1 MON
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Atenolol/Chlorthalidone	C				

Date:03/22/01ISR Number: 3688226-6Report Type:Expedited (15-DaCompany Report #WAES 01026110
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Hallucination Medication Error	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	9 DAY
			Atorvastatin	C				
			Bisoprolol	C				
			Diclofenac	C				
			Methotrexate	C				
			Nitroglycerin	C				
			Prednisone	C				
			Ticlopidine	C				

Date:03/22/01ISR Number: 3688240-0Report Type:Expedited (15-DaCompany Report #WAES 01039704
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative Pyrexia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
							PO	1 DAY
			Hyaluronic Acid	C				

Date:03/22/01ISR Number: 3688241-2Report Type:Expedited (15-DaCompany Report #WAES 01038549
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Acetaminophen (+) Methocarbamol	C				
			Acetaminophen/Codeine Phosphate	C				
			Carbamazepine	C				

Date:03/22/01ISR Number: 3688242-4Report Type:Expedited (15-DaCompany Report #WAES 01037517
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastric Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/01ISR Number: 3688260-6Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Glucose Increased Haemolytic Anaemia Haptoglobin Decreased Hepatic Necrosis Hepatic Steatosis Hepatitis A Antibody Positive Hepatitis Cholestatic Red Blood Cell Sedimentation Rate Increased Serum Ferritin Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Levothyroxine Na	C		

Date:03/22/01ISR Number: 3688265-5Report Type:Expedited (15-DaCompany Report #WAES 01025570
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Angioneurotic Oedema Urticaria	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY 1 DAY						
			Tab Vioxx (Rofecoxib)	SS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG 1 DAY						

Date:03/23/01ISR Number: 3688166-2Report Type:Expedited (15-DaCompany Report #256403
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 859 DAY	Calcinosis		Vasonase Retard	PS	Roche	
Initial or Prolonged 128 DAY	Choreoathetosis		Vioxx	SS		

Lansoprazole SS

DRUG NAME

REPORTED AS

"MONOLITUM" 128 DAY

Unknown Drug C

Date:03/23/01ISR Number: 3688640-9Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthenia		Vioxx (25mg)	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased Dehydration Diarrhoea							

Date:03/23/01ISR Number: 3688642-2Report Type:Direct Company Report #
Age:91 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Haemorrhagic		Vioxx (25mg)	PS		ORAL	25MG PO QD	
	Haematuria							
	Muscle Spasms							
	Nausea							
	Renal Impairment							

Date:03/23/01ISR Number: 3688646-XReport Type:Direct Company Report #
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Melaena		Vioxx	PS				
			Coumadin	SS				

Date:03/23/01ISR Number: 3688647-1Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Duodenal Ulcer		Vioxx	PS				
	Haematemesis							
	Melaena							

Date:03/23/01ISR Number: 3688648-3Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Pneumonia Vioxx PS ORAL
50MG PO QD 1 YR
Initial or Prolonged Renal Failure Acute
Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:03/23/01ISR Number: 3689618-1Report Type:Expedited (15-DaCompany Report #WAES 01033530
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:03/23/01ISR Number: 3689708-3Report Type:Expedited (15-DaCompany Report #WAES 00121218
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchospasm	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3689714-9Report Type:Expedited (15-DaCompany Report #WAES 01030604
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY

Date:03/23/01ISR Number: 3695286-5Report Type:Periodic Company Report #WAES 00102325
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
			Diovan	C				
			Prevacid	C				
			Zocor	C				
			Amiodarone	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3695288-9Report Type:Periodic Company Report #WAES 00091753
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased Prothrombin Time	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

	Prolonged	Representative	Coumadin 4 Mg	SS
4 MG				
			Lopressor	C
			Tylenol With Codeine #3	C
			Xanax	C
			Estrogens (Unspecified)	C

Date:03/23/01ISR Number: 3695291-9Report Type:Periodic Company Report #WAES 01012065
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3695293-2Report Type:Periodic Company Report #WAES 01010814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/PRN/PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3695296-8Report Type:Periodic Company Report #WAES 00121794
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3695297-XReport Type:Periodic Company Report #WAES 00120912
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vertigo	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cataflam	C				
			Lodine	C				
			Sonata	C				
			Estradiol	C				

Date:03/23/01ISR Number: 3705647-3Report Type:Periodic Company Report #WAES 01020196
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Fall Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/BID/PO; 2) 25	

MG/DAILY/PO

			Detrol	C
			Vitamins (Unspecified)	C

Date:03/23/01ISR Number: 3705649-7Report Type:Periodic Company Report #WAES 01020201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Sensation Of Heaviness Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Esgic-Plus Tablets	C				
			Estrogens (Unspecified)	C				

Date:03/23/01ISR Number: 3705650-3Report Type:Periodic Company Report #WAES 01020205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO 4 DAY

			Bentyl	C
			Persantine	C

			Valium	C		

Date:03/23/01ISR Number: 3705651-5Report Type:Periodic Company Report #WAES 01020210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Glucotrol	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3705652-7Report Type:Periodic Company Report #WAES 01020211
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dermatitis Feeling Hot	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache		Evista	C				
	Musculoskeletal Stiffness		Fosamax	C				
	Pruritus		Toprol Xl Tablets	C				
	Tinnitus		Aspirin	C				

Date:03/23/01ISR Number: 3705653-9Report Type:Periodic Company Report #WAES 01020213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pleural Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ortho-Cyclen	C				

Date:03/23/01ISR Number: 3705654-0Report Type:Periodic Company Report #WAES 01020219
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705655-2Report Type:Periodic Company Report #WAES 01020223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Agent Toxicity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705656-4Report Type:Periodic Company Report #WAES 01020234
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705657-6Report Type:Periodic Company Report #WAES 01020259
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705658-8Report Type:Periodic Company Report #WAES 01012247
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705659-XReport Type:Periodic Company Report #WAES 01012254
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Representative
MG/DAILY/PO

Date:03/23/01ISR Number: 3705660-6Report Type:Periodic Company Report #WAES 01012255
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705661-8Report Type:Periodic Company Report #WAES 01020153
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flexeril	C				
			Luvox	C				
			Pepcid Complete	C				
			Prempro	C				
			Semprex-D	C				
			Ultram	C				

			Xanax	C
			(Therapy Unspecified)	C
			Baclofen	C
			Imipramine	C
			Verapamil	C

Date:03/23/01ISR Number: 3705662-XReport Type:Periodic Company Report #WAES 01020172
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Depression							
	Fatigue							
	Gastrointestinal Disorder		Hydrodiuril	C				
			K-Dur	C				
			Premarin	C				
			Prinivil	C				

Date:03/23/01ISR Number: 3705663-1Report Type:Periodic Company Report #WAES 01020184
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lithiumco3	SS				

Date:03/23/01ISR Number: 3705664-3Report Type:Periodic Company Report #WAES 01020189
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:03/23/01ISR Number: 3705665-5Report Type:Periodic Company Report #WAES 01020191
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fall							
			Evista	C				
			Prozac	C				
			(Therapy Unspecified)	C				

Date:03/23/01ISR Number: 3705666-7Report Type:Periodic Company Report #WAES 01020193
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Varicose Vein	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Arthrotec C
Doxepin
Hydrochloride C

Date:03/23/01ISR Number: 3705667-9Report Type:Periodic Company Report #WAES 01020195
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Retin-A	C				
			Vancenase	C				

Date:03/23/01ISR Number: 3705668-0Report Type:Periodic Company Report #WAES 00120862
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Dyspepsia Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Hydroxyzine Hydrochloride	C				

(SEE IMAGE)

Date:03/23/01ISR Number: 3705669-2Report Type:Periodic Company Report #WAES 00120864
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Drug Ineffective				Laboratories Div	
	Headache				Merck Co Inc	ORAL
25						
	Pollakiuria					
MG/DAILY/PO						
			Zestril	C		
			Aspirin	C		
			Prednisone	C		

Date:03/23/01ISR Number: 3705670-9Report Type:Periodic Company Report #WAES 00120866
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research	
	Upper Gastrointestinal	Health			Laboratories Div	
	Haemorrhage	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Xalatan	C		
			Diltiazem	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705671-0Report Type:Periodic Company Report #WAES 00120920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Irritable Bowel Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Indocin (Indomethacin)	C				

Date:03/23/01ISR Number: 3705672-2Report Type:Periodic Company Report #WAES 00120940
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder Tenderness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Synthroid	C				
			Zocor	C				
			Atenolol	C				
			Indapamide	C				

Date:03/23/01ISR Number: 3705673-4Report Type:Periodic Company Report #WAES 00120944
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity Menstrual Disorder Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premsyn Pms	C				

Date:03/23/01ISR Number: 3705674-6Report Type:Periodic Company Report #WAES 00120968
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Muscular Weakness							
	Pain				Merck Co Inc	ORAL	PO	
			Lithium-Duriles	SS				
			Ambien	C				
			Singulair	C				
			(Therapy Unspecified)	C				
			Doxepin	C				

Date:03/23/01ISR Number: 3705675-8Report Type:Periodic Company Report #WAES 00120972
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective	Health						
	Dyspepsia	Professional			Merck Co Inc	ORAL	25	
	Fatigue						MG/DAILY/PO	
	Insomnia		(Therapy Unspecified)	C				
	Sedation							

			Promethazine	C		

Date:03/23/01ISR Number: 3705676-XReport Type:Periodic Company Report #WAES 00120973
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Oral Soft Tissue Disorder	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Avandia	C				
			Norvasc	C				
			Glyburide	C				

Date:03/23/01ISR Number: 3705677-1Report Type:Periodic Company Report #WAES 00120976
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Cozaar	C				
			Glucophage	C				
			Imdur	C				
			Lipitor	C				
			Lopid	C				
			Lopressor	C				
			(Therapy Unspecified)	C				
			Aspirin	C				

(SEE IMAGE)

Date:03/23/01ISR Number: 3705678-3Report Type:Periodic Company Report #WAES 00120834
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Haemoptysis Stomatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Prilosec	C				

Date:03/23/01ISR Number: 3705679-5Report Type:Periodic Company Report #WAES 00120837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Calcium	C				
			Hydrochlorothiazide	C				
			Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705680-1Report Type:Periodic Company Report #WAES 00120839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3705681-3Report Type:Periodic Company Report #WAES 00120840
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Cold Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hydroxyurea	C				

Date:03/23/01ISR Number: 3705682-5Report Type:Periodic Company Report #WAES 00120841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705683-7Report Type:Periodic Company Report #WAES 00120842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25 MG

/DAILY/PO

Date:03/23/01ISR Number: 3705684-9Report Type:Periodic Company Report #WAES 00120846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	
			Flonase	C				
			Lamisil	C				
			Lanoxin	C				
			Lasix	C				
			Premarin	C				
			Aspirin	C				
			Potassium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705685-0Report Type:Periodic Company Report #WAES 00120847
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Cardizem Sr	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3705686-2Report Type:Periodic Company Report #WAES 00120854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3705687-4Report Type:Periodic Company Report #WAES 00120857
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO

Date:03/23/01ISR Number: 3705688-6Report Type:Periodic Company Report #WAES 01011882
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Gastric Haemorrhage Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lescol	C				
			Primcort	C				
			Serevent	C				
			Vasotec	C				
			Zebeta	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3705689-8Report Type:Periodic Company Report #WAES 01011884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705690-4Report Type:Periodic Company Report #WAES 01011888
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705691-6Report Type:Periodic Company Report #WAES 01011889
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705692-8Report Type:Periodic Company Report #WAES 01011893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3705693-XReport Type:Periodic Company Report #WAES 01011894
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	[Therapy Unspecified]	C		

Date:03/23/01ISR Number: 3705694-1Report Type:Periodic Company Report #WAES 01011911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			...	C		

Date:03/23/01ISR Number: 3705695-3Report Type:Periodic Company Report #WAES 01011929
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Nizoral	C		
			Chondroitin (+)			

			Glucosamine	C		

Date:03/23/01ISR Number: 3705696-5Report Type:Periodic Company Report #WAES 01011935
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Corzide	C				
			Levbid	C				
			Nasacort Aq	C				
			Premarin	C				
			Synthroid	C				
			Zocor	C				
			Zoloft	C				

Date:03/23/01ISR Number: 3705697-7Report Type:Periodic Company Report #WAES 01011938
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dhea	C				
			Estrace	C				
			Levoxyl	C				
			Procardia Xl	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Chondroitin (+) Glucosamine	C				
			Vitamins					

(Unspecified) C

Date:03/23/01ISR Number: 3705698-9Report Type:Periodic Company Report #WAES 01011815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705699-0Report Type:Periodic Company Report #WAES 01011823
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Daypro	C				

			Detrol	C		
			Fosamax	C		
			Premarin	C		
			Estrogens (Unspecified)	C		
			Prednisone	C		
			Quinine Sulfate	C		

Date:03/23/01ISR Number: 3705700-4Report Type:Periodic Company Report #WAES 01011835
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Novex	C				

Date:03/23/01ISR Number: 3705701-6Report Type:Periodic Company Report #WAES 01011849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Shock	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		SEE IMAGE	
			Estraderm	C				
			Lasix	C				
			Miacalcin	C				
			Oxycontin	C				
			Prozac	C				
			Folic Acid	C				

Date:03/23/01ISR Number: 3705702-8Report Type:Periodic Company Report #WAES 01011851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Inderal	C				
			Proscar	C				

Date:03/23/01ISR Number: 3705703-XReport Type:Periodic Company Report #WAES 01011860
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Humibid	C				
			Hytrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705704-1Report Type:Periodic Company Report #WAES 01011864
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
	Nausea							
	Swelling							
	Weight Increased		Xanax	C				

Date:03/23/01ISR Number: 3705705-3Report Type:Periodic Company Report #WAES 01011867
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celebrex	C				
			Lorazepam	C				

Date:03/23/01ISR Number: 3705706-5Report Type:Periodic Company Report #WAES 01011876
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Toprol Xl Tablets	C				

Date:03/23/01ISR Number: 3705707-7Report Type:Periodic Company Report #WAES 01011877
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research			

	Blood Pressure Increased	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Ogen	C		
			Prinivil	C		

Date:03/23/01ISR Number: 3705708-9Report Type:Periodic Company Report #WAES 01011757
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Depression					
	Memory Impairment				Merck Co Inc	ORAL
25 MG/ PO						
			Celebrex	C		

Date:03/23/01ISR Number: 3705709-0Report Type:Periodic Company Report #WAES 01011762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705710-7Report Type:Periodic Company Report #WAES 01011764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium	C				

Date:03/23/01ISR Number: 3705711-9Report Type:Periodic Company Report #WAES 01011773
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705712-0Report Type:Periodic Company Report #WAES 01011776
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705713-2Report Type:Periodic Company Report #WAES 01011787
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/BID/PO

Glucophage C
Pravachol C
Glyburide C

Date:03/23/01ISR Number: 3705714-4Report Type:Periodic Company Report #WAES 01011792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Vioxx	PS	Merck Research			
	Weight Increased	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
		Representative						

Date:03/23/01ISR Number: 3705715-6Report Type:Periodic Company Report #WAES 01011793
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Disturbance In Attention				Laboratories Div			
	Fatigue				Merck Co Inc	ORAL		
	Feeling Abnormal							

12.5

MG/DAILY/PO

Ativan C

Fibercon	C
Hytrin	C
Lasix	C
Nitro-Dur	C
Prinivil	C
Aspirin	C
Vitamins	C

Date:03/23/01ISR Number: 3705716-8Report Type:Periodic Company Report #WAES 01011800
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705717-XReport Type:Periodic Company Report #WAES 01011801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705718-1Report Type:Periodic Company Report #WAES 01011723
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Semen Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

				Advil	C		
				Excedrin Extra-Strength	C		

Date:03/23/01ISR Number: 3705719-3Report Type:Periodic Company Report #WAES 01011725
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
			Premarin	C				

Date:03/23/01ISR Number: 3705720-XReport Type:Periodic Company Report #WAES 01011732
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pharyngitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				

			Indocin (Indomethacin)	C
			Zestril	C

Date:03/23/01ISR Number: 3705721-1Report Type:Periodic Company Report #WAES 01011742
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Joint Stiffness Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705722-3Report Type:Periodic Company Report #WAES 01011743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Pepto-Bismol	C				
			Ritalin	C				
			Wellbutrin	C				

Date:03/23/01ISR Number: 3705723-5Report Type:Periodic Company Report #WAES 01011747
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspnoea Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Dicetamin	C				
			Evista	C				
			Nucofed	C				

Date:03/23/01ISR Number: 3705724-7Report Type:Periodic Company Report #WAES 01011750
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Emotional Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Celebrex	C				
			Plaquenil	C				
			Protonix	C				
			Xanax	C				
			Hydrochlorothiazide	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3705725-9Report Type:Periodic Company Report #WAES 01011754
Age:50 YR Gender:Female I/FU:I

Outcome	PT
	Lip Dry
	Oedema Peripheral

	Sinusitis Skin Lesion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO
			Fastin	C			

Date:03/23/01ISR Number: 3705726-0Report Type:Periodic Company Report #WAES 01011755
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:03/23/01ISR Number: 3705727-2Report Type:Periodic Company Report #WAES 01011756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:03/23/01ISR Number: 3705728-4Report Type:Periodic Company Report #WAES 01011594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Inflammation Pain In Extremity	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:03/23/01ISR Number: 3705729-6Report Type:Periodic Company Report #WAES 01011612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705730-2Report Type:Periodic Company Report #WAES 01011707
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Hyperglycaemia Prostatic Specific Antigen Increased Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705731-4Report Type:Periodic Company Report #WAES 01011709
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Amaryl	C				
			Enbrel	C				
			Methotrexate (Methotrexate Sodium)	C				
			Tenormin	C				
			Calcium (Unspecified)	C				
			Nitrofurantoin	C				
			Prednisone	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3705732-6Report Type:Periodic Company Report #WAES 01011710
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3705733-8Report Type:Periodic Company Report #WAES 01011711
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Fosamax C
Plaquenil C

Date:03/23/01ISR Number: 3705734-XReport Type:Periodic Company Report #WAES 01011715
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuralgia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705735-1Report Type:Periodic Company Report #WAES 01011719
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Metoprolol	C				
			Terazosin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705736-3Report Type:Periodic Company Report #WAES 01011720
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Evista	C				

Date:03/23/01ISR Number: 3705737-5Report Type:Periodic Company Report #WAES 01011721
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY
			Prilosec	C				
			Valium	C				

Date:03/23/01ISR Number: 3705738-7Report Type:Periodic Company Report #WAES 01011445
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation Syncope	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Zanaflex Unk	SS				
			Acetaminophen (+) Hydrocodone	C				

Date:03/23/01ISR Number: 3705739-9Report Type:Periodic Company Report #WAES 01011447
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Cycrin	C		
			Ortho-Est	C		
			Synthroid	C		

Date:03/23/01ISR Number: 3705740-5Report Type:Periodic Company Report #WAES 01011452
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dyspnoea					
25 MG/BID/PO						
			Ibuprofen	C		

Date:03/23/01ISR Number: 3705741-7Report Type:Periodic Company Report #WAES 01011454
Age:52 YR Gender:Female I/FU:I

Outcome	PT
	Dermatitis
	Pharyngeal Oedema

Tinnitus
Urticaria

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Premarin	C				

Date:03/23/01ISR Number: 3705742-9Report Type:Periodic Company Report #WAES 01011456
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 DAY

Date:03/23/01ISR Number: 3705743-0Report Type:Periodic Company Report #WAES 01011461
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Paranoia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/23/01ISR Number: 3705744-2Report Type:Periodic Company Report #WAES 01011464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Insomnia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Weight Increased Merck Co Inc ORAL
25

MG/DAILY/PO 2 WK

Date:03/23/01ISR Number: 3705745-4Report Type:Periodic Company Report #WAES 01011481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Pain							
	Pharyngitis				Merck Co Inc	ORAL	25	
	Upper Respiratory Tract Infection						MG/DAILY/PO	

Date:03/23/01ISR Number: 3705746-6Report Type:Periodic Company Report #WAES 01011483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Rectal Haemorrhage				Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705747-8Report Type:Periodic Company Report #WAES 01011588
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Headache							
	Nausea							
			Cardizem	C				
			Prilosec	C				
			Prinivil	C				
			Zocor	C				

Date:03/23/01ISR Number: 3705775-2Report Type:Periodic Company Report #WAES 00100849
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health						
	Pruritus	Professional						
			Premarin	C				
			Prilosec	C				
			Prozac	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3705776-4Report Type:Periodic Company Report #WAES 00100868
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

				Cardura	C		
				Lodine	C		
				Aspirin	C		

Date:03/23/01ISR Number: 3705777-6Report Type:Periodic Company Report #WAES 00100922
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Vioxx	PS	Merck Research			
	Fatigue	Professional			Laboratories Div			
	Hypertension	Company			Merck Co Inc	ORAL	25	
	Tremor	Representative					MG/DAILY/PO	
			Inderal	C				
			Lasix	C				
			Mevacor	C				
			Miacalcin	C				
			Minipress	C				
			Persantine	C				
			Rhinocort	C				
			Aspirin	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705778-8Report Type:Periodic Company Report #WAES 00100940
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Premarin	C				
			Tagamet	C				
			Calcium (Unspecified)	C				
			Doxepin	C				

Date:03/23/01ISR Number: 3705779-XReport Type:Periodic Company Report #WAES 00100985
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705780-6Report Type:Periodic Company Report #WAES 00101208
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Constipation							
	Diarrhoea							
	Drug Ineffective							
	Laboratory Test Abnormal		Motrin Ib	C				
	Pain		Serzone	C				
			Synthroid	C				
			Thorazine	C				

			Xanax	C		

Date:03/23/01ISR Number: 3705781-8Report Type:Periodic Company Report #WAES 00101236
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Clinoril	SS				

Date:03/23/01ISR Number: 3705782-XReport Type:Periodic Company Report #WAES 00101309
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abnormal Faeces Asthenia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea Fatigue Flatulence		Flomax (Morniflumate) Prevacid Viagra	C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705783-1Report Type:Periodic Company Report #WAES 00101345
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3705784-3Report Type:Periodic Company Report #WAES 00101407
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol Arthritis Extended Release	C				
			Vicodin Tablets	C				
			Chondroitin (+) Glucosamine	C				

Date:03/23/01ISR Number: 3705785-5Report Type:Periodic Company Report #WAES 00120223
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3705786-7Report Type:Periodic Company Report #WAES 00120228
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:03/23/01ISR Number: 3705787-9Report Type:Periodic Company Report #WAES 00120229
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Accupril	C				
			Hydrodiuril	C				
			Premarin	C				

Date:03/23/01ISR Number: 3705788-0Report Type:Periodic Company Report #WAES 00120232
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Haemorrhoids	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				
			Cyanocobalamin	C				

Date:03/23/01ISR Number: 3705789-2Report Type:Periodic Company Report #WAES 00120233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705790-9Report Type:Periodic Company Report #WAES 00120235
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celexa	C				
			Estrace	C				
			Provera	C				

Date:03/23/01ISR Number: 3705791-0Report Type:Periodic Company Report #WAES 00120236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
12.5 MG /

DAILY/PO

Coreg	C
Flomax (Tamsulosin Hydrochloride)	C
Lanoxin	C
Testryl	C

Date:03/23/01ISR Number: 3705792-2Report Type:Periodic Company Report #WAES 00120240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Eyelid Oedema							
	Flushing							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705793-4Report Type:Periodic Company Report #WAES 00120242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amblyopia Diplopia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / PO	
			Flomax (Tamsulosin Hydrochloride)	C				
			Plavix	C				
			Clonazepam	C				

Date:03/23/01ISR Number: 3705794-6Report Type:Periodic Company Report #WAES 00120243
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Armour Thyroid Tablets	C				
			Avapro	C				
			Cardura	C				
			Flovent	C				
			Serevent	C				
			Tranxene	C				

Date:03/23/01ISR Number: 3705795-8Report Type:Periodic Company Report #WAES 01011947
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ogen	C				

Prinivil C

Date:03/23/01ISR Number: 3705796-XReport Type:Periodic Company Report #WAES 01011956
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705797-1Report Type:Periodic Company Report #WAES 01011964
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus Inadequate Control		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	
			Humalog	C				
			Humulin 70/30	C				

Prilosec	C
Zestril	C
Dimethyl Sulfone	C
Evening Primrose Oil	C
Glucosamine	C
Omega-3 Marine Triglycerides	C
Prednisone	C
Vitamin E	C

Date:03/23/01ISR Number: 3705798-3Report Type:Periodic Company Report #WAES 01011966
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypercholesterolaemia							
	Pain In Extremity							
	Paraesthesia		Plavix Unk	SS				
	Pruritus		Pravachol	C				
			Synthroid	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3705799-5Report Type:Periodic Company Report #WAES 01011969
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Postural	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atacand	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3705800-9Report Type:Periodic Company Report #WAES 01011978
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Throat Intentional Self-Injury Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				
			Verapamil Hydrochloride	C				

Date:03/23/01ISR Number: 3705801-0Report Type:Periodic Company Report #WAES 01011980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705802-2Report Type:Periodic Company Report #WAES 01011986
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705803-4Report Type:Periodic Company Report #WAES 01011990
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity Oedema Rash Erythematous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Derma-Smoothe/Fs Topical Oil	C				
			Dovonex	C				
			Temovate	C				
			Ultram	C				
			Zantac	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Hydrochlorothiazide (+) Methyldo	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3705804-6Report Type:Periodic Company Report #WAES 01012002
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3705805-8Report Type:Periodic Company Report #WAES 01021491
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	

Date:03/23/01ISR Number: 3705806-XReport Type:Periodic Company Report #WAES 01021493
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705807-1Report Type:Periodic Company Report #WAES 01021494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	

Date:03/23/01ISR Number: 3705808-3Report Type:Periodic Company Report #WAES 01021495
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				
			Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:03/23/01ISR Number: 3705809-5Report Type:Periodic Company Report #WAES 01021498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Faeces Discoloured	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Premarin	C				
			Cimetidine	C				

Date:03/23/01ISR Number: 3705811-3Report Type:Periodic Company Report #WAES 01021503
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatic Function Abnormal Hepatomegaly	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Premarin Vaginal Cream	C		
			Prempro	C		

Date:03/23/01ISR Number: 3705812-5Report Type:Periodic Company Report #WAES 01021542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						
			Tylenol	C		
			Verapamil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3705814-9Report Type:Periodic Company Report #WAES 01021543
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Thyroid	C				

Date:03/23/01ISR Number: 3705815-0Report Type:Periodic Company Report #WAES 01021545
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/ PO	

Date:03/23/01ISR Number: 3705817-4Report Type:Periodic Company Report #WAES 01021551
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Renal Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Avalide	C				

Date:03/23/01ISR Number: 3705820-4Report Type:Periodic Company Report #WAES 01012004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abscess	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3705821-6Report Type:Periodic Company Report #WAES 01012005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	
			Cardizem	C				
			Hydrodiuril	C				
			Levoxyl	C				
			Acetaminophen	C				

Date:03/23/01ISR Number: 3705823-XReport Type:Periodic Company Report #WAES 01012012
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Actonel	C
Darvocet-N	C
Plaquenil	C
Synthroid	C
Tylenol	C
Folic Acid	C
Methotrexate	C

Date:03/23/01ISR Number: 3705824-1Report Type:Periodic Company Report #WAES 01012025
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative						

Date:03/23/01ISR Number: 3705826-5Report Type:Periodic Company Report #WAES 01012046
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Flexeril	C
Premarin	C
Prinzide	C
Serzone	C
Ultram	C
Clonazepam	C

Date:03/23/01ISR Number: 3705827-7Report Type:Periodic Company Report #WAES 01012059
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Diarrhoea							
	Fatigue							
	Feeling Abnormal		Actos	C				
	Nausea		Glucophage	C				
	Palpitations		Lescol	C				
	Pigmentation Disorder		Robaxin	C				
	Renal Colic		Vicodin Tablets	C				
	Sensation Of Heaviness		[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3705828-9Report Type:Periodic Company Report #WAES 01012061
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY/PO	
	Blood Pressure Increased							
	Diarrhoea							
			Klor-Con	C				
			Synthroid	C				

Vasotec	C
[Therapy Unspecified]	C
Ascorbic Acid	C
Furosemide	C
Vitamin E	C
Vitamins (Unspecified)	I

Date:03/23/01ISR Number: 3705830-7Report Type:Periodic Company Report #WAES 01012062
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective	Health						
	Nocturia	Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pollakiuria							
	Sleep Disorder		Orudis	C				
			Voltaren	C				

Date:03/23/01ISR Number: 3705831-9Report Type:Periodic Company Report #WAES 01012064
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased	Professional						
	Dermatitis				Merck Co Inc	ORAL	UNK/UNK/PO	
	Drug Level Above Therapeutic							
	Eye Pain							
	Pruritus							
	Vocal Cord Disorder							

Date:03/23/01ISR Number: 3705833-2Report Type:Periodic Company Report #WAES 01012068
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3706625-0Report Type:Periodic Company Report #WAES 01020349
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706626-2Report Type:Periodic Company Report #WAES 01020352
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Glucophage	C	
Zocor	C	
Aspirin	C	
Glyburide	C	
Nitroglycerin	C	

Date:03/23/01ISR Number: 3706627-4Report Type:Periodic Company Report #WAES 01020356
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Myalgia							

Date:03/23/01ISR Number: 3706628-6Report Type:Periodic Company Report #WAES 01020358
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Influenza Like Illness							
	Lacrimation Increased							
	Muscular Weakness		Lipitor	C				
	Nervousness		Tylenol	C				
	Sneezing		Atenolol	C				
			Hydrochlorothiazide	C				

Date:03/23/01ISR Number: 3706629-8Report Type:Periodic Company Report #WAES 01020361
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Drunk	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706630-4Report Type:Periodic Company Report #WAES 01020374
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY
			Flexeril	C				
			Neurontin	C				

Date:03/23/01ISR Number: 3706631-6Report Type:Periodic Company Report #WAES 01020379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins					

			(Unspecified)	C

Date:03/23/01ISR Number: 3706632-8Report Type:Periodic Company Report #WAES 01020393
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							

Date:03/23/01ISR Number: 3706633-XReport Type:Periodic Company Report #WAES 01020399
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Nausea							
	Upper Respiratory Tract Infection		Ranitidine	C				

Date:03/23/01ISR Number: 3706634-1Report Type:Periodic Company Report #WAES 01020403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Flonase	C				
			Estrogens (Unspecified)	C				

Date:03/23/01ISR Number: 3706729-2Report Type:Periodic Company Report #WAES 01021423
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3706731-0Report Type:Periodic Company Report #WAES 01021428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3706733-4Report Type:Periodic Company Report #WAES 01021429
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ditropan Xl	C				
			Premarin	C				

Date:03/23/01ISR Number: 3706734-6Report Type:Periodic Company Report #WAES 01021442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Nasal Congestion Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Bactrim	C				

Date:03/23/01ISR Number: 3706737-1Report Type:Periodic Company Report #WAES 01021450
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3706738-3Report Type:Periodic Company Report #WAES 01021453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research			

	Hypercholesterolaemia				Laboratories Div	
	Hypertension				Merck Co Inc	ORAL
25 MG/BID/PO;						
			Vioxx	SS		
50 MG/ DAILY						
/ PO						
			Cipro	C		

Date:03/23/01ISR Number: 3706740-1Report Type:Periodic Company Report #WAES 01021476
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Pravachol	C		
			Prevacid	C		
			Procardia Xl	C		
			Xalatan	C		
			Carteolol Hydrochloride	C		
			Furosemide	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3706741-3Report Type:Periodic Company Report #WAES 01021481
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Celebrex	C				
			Inderal	C				
			Isordil	C				
			Terazosin	C				

Date:03/23/01ISR Number: 3706742-5Report Type:Periodic Company Report #WAES 01021484
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan Sr	C				
			Premarin	C				
			Prilosec	C				
			Alprazolam	C				

Date:03/23/01ISR Number: 3706743-7Report Type:Periodic Company Report #WAES 01021485
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706744-9Report Type:Periodic Company Report #WAES 01010771
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706745-0Report Type:Periodic Company Report #WAES 01010775
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3706746-2Report Type:Periodic Company Report #WAES 01010784
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Tendon Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706747-4Report Type:Periodic Company Report #WAES 01010809
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:03/23/01ISR Number: 3706748-6Report Type:Periodic Company Report #WAES 01010810
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:03/23/01ISR Number: 3706749-8Report Type:Periodic Company Report #WAES 01010811
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706750-4Report Type:Periodic Company Report #WAES 01010815
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3706751-6Report Type:Periodic Company Report #WAES 01010816
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Therapy					

	Unspecified)	C
	Ascorbic Acid	C
	Iron (Unspecified)	C
	Vitamin E	C

Date:03/23/01ISR Number: 3706752-8Report Type:Periodic Company Report #WAES 01010819
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Myalgia							
			Fosamax	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3706753-XReport Type:Periodic Company Report #WAES 01010820
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Sprain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3706762-0Report Type:Periodic Company Report #WAES 01021623
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Erythema							
	Headache							
	Photophobia							
	Vision Blurred		Corgard	C				
			Proscar	C				

Date:03/23/01ISR Number: 3706763-2Report Type:Periodic Company Report #WAES 01021682
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Oedema							
	Pollakiuria							
			Axid	C				
			Hyzaar	C				
			K-Tab	C				
			Pravachol	C				

Date:03/23/01ISR Number: 3706764-4Report Type:Periodic Company Report #WAES 01021683
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Labetalol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3706765-6Report Type:Periodic Company Report #WAES 01021777
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3706766-8Report Type:Periodic Company Report #WAES 01021874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neutropenia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3706767-XReport Type:Periodic Company Report #WAES 01021875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia Palpitations	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3706769-3Report Type:Periodic Company Report #WAES 01021980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative				

Date:03/23/01ISR Number: 3706771-1Report Type:Periodic Company Report #WAES 01021984
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative	Neurontin	C		

Date:03/23/01ISR Number: 3706773-5Report Type:Periodic Company Report #WAES 01022013
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3706775-9Report Type:Periodic Company Report #WAES 01022251
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	[Composition Unspecified]	C				

Date:03/23/01ISR Number: 3707377-0Report Type:Periodic Company Report #WAES 00122213
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Thyroid	C				

Date:03/23/01ISR Number: 3707381-2Report Type:Periodic Company Report #WAES 00122214
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Laryngitis Nasal Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Dyazide	C				
			K-Dur	C				

Date:03/23/01ISR Number: 3707387-3Report Type:Periodic Company Report #WAES 00122216
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Oliguria							
			Aldactazide	C				
			Cardizem Cd	C				
			Lopressor	C				

Date:03/23/01ISR Number: 3707395-2Report Type:Periodic Company Report #WAES 00122220
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tachycardia							

Date:03/23/01ISR Number: 3707401-5Report Type:Periodic Company Report #WAES 00122234
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Eye Discharge							

Merck Co Inc ORAL
PO
Midol C
Oxycontin C

Date:03/23/01ISR Number: 3707405-2Report Type:Periodic Company Report #WAES 00122235
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Allegra	C				
			Fosamax	C				
			Singulair	C				
			Synthroid	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3707409-XReport Type:Periodic Company Report #WAES 00122239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Intervertebral Disc Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema							

Date:03/23/01ISR Number: 3707412-XReport Type:Periodic Company Report #WAES 00122240
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

			Tenormin	C		

Date:03/23/01ISR Number: 3707414-3Report Type:Periodic Company Report #WAES 00122241
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Capoten	C				
			Coumadin	C				
			Lanoxin	C				
			Lipitor	C				
			Loppessor	C				

Date:03/23/01ISR Number: 3707416-7Report Type:Periodic Company Report #WAES 00122261
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertensive Crisis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Celebrex	C	
Prinzide	C	
Vicodin Tablets	C	

Date:03/23/01ISR Number: 3707422-2Report Type:Periodic Company Report #WAES 01010255
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/23/01ISR Number: 3707425-8Report Type:Periodic Company Report #WAES 01010265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vulvitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707428-3Report Type:Periodic Company Report #WAES 01010294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aleve	C				

Date:03/23/01ISR Number: 3707431-3Report Type:Periodic Company Report #WAES 01010308
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	
			Hytrin	SS			10 MG/DAILY	
			Aricept	C				

Date:03/23/01ISR Number: 3707433-7Report Type:Periodic Company Report #WAES 01010315
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Circulatory Collapse	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707435-0Report Type:Periodic Company Report #WAES 01010321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3707438-6Report Type:Periodic Company Report #WAES 01010330
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet	C				
			Flexeril	C				
			Norvasc	C				
			Premarin	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3707439-8Report Type:Periodic Company Report #WAES 01010331
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3707440-4Report Type:Periodic Company Report #WAES 01010345
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY PO	

Date:03/23/01ISR Number: 3707443-XReport Type:Periodic Company Report #WAES 01010348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/QOD/PO	

Date:03/23/01ISR Number: 3707486-6Report Type:Periodic Company Report #WAES 01010350
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
	Dizziness							
	Feeling Abnormal							
	Hypertrophy Breast							
	Muscular Weakness		Estrace	SS				
			Calcium	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707488-XReport Type:Periodic Company Report #WAES 01010353
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707489-1Report Type:Periodic Company Report #WAES 01010359
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /BID	
	Nausea							
	Oedema Peripheral							
	Pain							
			Avandia	C			/PO	
			Hydrodiuril	C				
			Ultram	C				
			Glyburide	C				
			(Therapy Unspecified)	C				

Date:03/23/01ISR Number: 3707491-XReport Type:Periodic Company Report #WAES 01010363
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707493-3Report Type:Periodic Company Report #WAES 01010365
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707495-7Report Type:Periodic Company Report #WAES 01010366
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vocal Cord Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Prednisone	C				
			Vitamin	C				

Date:03/23/01ISR Number: 3707496-9Report Type:Periodic Company Report #WAES 01010373
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

Acupril	C
Plaquenil	C
Premarin	C

Date:03/23/01ISR Number: 3707510-0Report Type:Periodic Company Report #WAES 01010377
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707513-6Report Type:Periodic Company Report #WAES 01010383
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707515-XReport Type:Periodic Company Report #WAES 01010388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Change Of Bowel Habit Conversion Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3707518-5Report Type:Periodic Company Report #WAES 01010390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3707521-5Report Type:Periodic Company Report #WAES 01010419
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Allegra	C				
			Lipitor	C				
			Sular	C				

Date:03/23/01ISR Number: 3707522-7Report Type:Periodic Company Report #WAES 01010421
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50	

MG/DAILY/PO

	Cardizem Cd	C
	Hydrodiuril	C
	Lovenox	C
	Ocupress 1%	C

Date:03/23/01ISR Number: 3707525-2Report Type:Periodic Company Report #WAES 01010429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:03/23/01ISR Number: 3707526-4Report Type:Periodic Company Report #WAES 01010439
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diplopia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

"SEE IMAGE"

	Evista	C
	Prilosec	C
	Vitamins (Unspecified)	C

Date:03/23/01ISR Number: 3707529-XReport Type:Periodic Company Report #WAES 01010447
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/HS/PO

	Flexeril	C

Date:03/23/01ISR Number: 3707530-6Report Type:Periodic Company Report #WAES 01010452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Asthenia Fatigue Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:03/23/01ISR Number: 3707533-1Report Type:Periodic Company Report #WAES 01010453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707534-3Report Type:Periodic Company Report #WAES 01010459
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	"SEE IMAGE"	
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3707540-9Report Type:Periodic Company Report #WAES 01010463
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Listrocol	C				
			Xanax	C				
			Zyprexa	C				
			Captopril	C				

Date:03/23/01ISR Number: 3707541-0Report Type:Periodic Company Report #WAES 01010466
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Aspirin	C				
			Atenolol	C				
			Isosorbide	C				

Date:03/23/01ISR Number: 3707544-6Report Type:Periodic Company Report #WAES 01010468
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypermagnesaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Amaryl	C				
			Pepcid	C				
			Allopurinol	C				
			Digoxin	C				
			Levofloxacin	C				

Date:03/23/01ISR Number: 3707546-XReport Type:Periodic Company Report #WAES 01010476
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Mouth Ulceration Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707548-3Report Type:Periodic Company Report #WAES 01010477
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Flexeril	C				
			Lactaid Caplets	C				
			Sucraid	C				
			Tofranil	C				
			Urised Tablets	C				
			Calcium Carbonate	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3707575-6Report Type:Periodic Company Report #WAES 01010505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Skelaxin	C				

Date:03/23/01ISR Number: 3707576-8Report Type:Periodic Company Report #WAES 01010547
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	
			Lipitor	C				

Date:03/23/01ISR Number: 3707577-XReport Type:Periodic Company Report #WAES 01010556
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Paxil	C				
			Procardia Xl	C				
			Xanax	C				
			Potassium Chloride	C				

Date:03/23/01ISR Number: 3707578-1Report Type:Periodic Company Report #WAES 01010558
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3707579-3Report Type:Periodic Company Report #WAES 01010586
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	37.5 MG DAILY PO	

Date:03/23/01ISR Number: 3707580-XReport Type:Periodic Company Report #WAES 01010590
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Asthenia Dizziness Fatigue Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	

Date:03/23/01ISR Number: 3707581-1Report Type:Periodic Company Report #WAES 01010592
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intraocular Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 25 MG DAILY PO	
			Xalatan	C				

Date:03/23/01ISR Number: 3707582-3Report Type:Periodic Company Report #WAES 01010595
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3707583-5Report Type:Periodic Company Report #WAES 01010597
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Prilosec	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3707584-7Report Type:Periodic Company Report #WAES 01010600
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

			Claritian	C		
			Vitamins (Unspecified)	C		

Date:03/23/01ISR Number: 3707585-9Report Type:Periodic Company Report #WAES 01010604
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Cough							
	Dyspepsia							
	Eye Irritation							
	Eye Pain							

Date:03/23/01ISR Number: 3707586-0Report Type:Periodic Company Report #WAES 01010605
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
	Oesophageal Pain							
			Synthroid	C				

Date:03/23/01ISR Number: 3707587-2Report Type:Periodic Company Report #WAES 01010612
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Cardizem	C				
			Lasix	C				
			Lorcet 10/650	C				
			Zyprexa	C				

			Insulin	C
			Nitroglycerin	C

Date:03/23/01ISR Number: 3707588-4Report Type:Periodic Company Report #WAES 01010613
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Palpitations					
25 MG/DAILY/PO						
			Lipitor	C		
			Prinivil	C		
			Aspirin	C		

Date:03/23/01ISR Number: 3707589-6Report Type:Periodic Company Report #WAES 01010614
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Constipation					

Merck Co Inc ORAL
25

MG/DAILY/PO
Vitamins C

Date:03/23/01ISR Number: 3707590-2Report Type:Periodic Company Report #WAES 01010619
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Vomiting	Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Tiazac	C				
			Zestril	C				

Date:03/23/01ISR Number: 3707591-4Report Type:Periodic Company Report #WAES 01010622
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG / DAILY	
							/ PO	
			Cedax	C				
			Levaquin	C				
			Tequin	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3707592-6Report Type:Periodic Company Report #WAES 01010626
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Corgard C
Hydrodiuril C
Imitrex C

Date:03/23/01ISR Number: 3707593-8Report Type:Periodic Company Report #WAES 01010628
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Lotrel	C				

Date:03/23/01ISR Number: 3707594-XReport Type:Periodic Company Report #WAES 01010629
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Plavix	C		
			Synthroid	C		
			Zebeta	C		
			Meclizine	C		

Date:03/23/01ISR Number: 3707595-1Report Type:Periodic Company Report #WAES 01010631
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Irritability Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				

Date:03/23/01ISR Number: 3707596-3Report Type:Periodic Company Report #WAES 01010632
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Insulin	C				

Date:03/23/01ISR Number: 3707597-5Report Type:Periodic Company Report #WAES 01010633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 DAY
			Celebrex	C				
			Effexor	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3707598-7Report Type:Periodic Company Report #WAES 01010634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Cardizem	C				

Date:03/23/01ISR Number: 3707599-9Report Type:Periodic Company Report #WAES 01010641
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO, 25 MG	14 DAY
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707600-2Report Type:Periodic Company Report #WAES 01010645
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3707601-4Report Type:Periodic Company Report #WAES 01010649
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707602-6Report Type:Periodic Company Report #WAES 01010653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707603-8Report Type:Periodic Company Report #WAES 01010679
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			

					Laboratories Div Merck Co Inc	ORAL
25 MG/DAILYPO						
			Claritin	C		
			Diovan	C		
			Prilosec	C		
			Amitriptyline	C		
			Furosemide	C		
			Potassium Chloride	C		
			Vitamins	C		

Date:03/23/01ISR Number: 3707604-XReport Type:Periodic Company Report #WAES 01010680
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Coumadin	C		
			Lanoxin	C		
			Lasix	C		
			Neurontin	C		
			Prinivil	C		
			Tenormin	C		
			Allopurinol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707605-1Report Type:Periodic Company Report #WAES 00111996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Fatigue							
	Headache		Tab Prinzide	SS				
	Myalgia		Glucophage	C				
	Nausea		Voltaren	C				
			Glyburide	C				

Date:03/23/01ISR Number: 3707606-3Report Type:Periodic Company Report #WAES 00111980
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		3	DAY

Date:03/23/01ISR Number: 3707607-5Report Type:Periodic Company Report #WAES 00111967
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

Date:03/23/01ISR Number: 3707608-7Report Type:Periodic Company Report #WAES 00111964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3707609-9Report Type:Periodic Company Report #WAES 00111963
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hyponatraemia							
			Actonel	C				

Date:03/23/01ISR Number: 3707610-5Report Type:Periodic Company Report #WAES 00111951
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Renal Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707611-7Report Type:Periodic Company Report #WAES 00111948
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyskinesia Oesophageal	Consumer	Vioxx	PS		ORAL	25 MG/ PO	
	Dyspepsia	Health Professional	Miacalcin	C				
			Neurontin	C				
			Prevacid	C				
			Tranxene	C				
			Chondroitin	C				
			Glucosamine	C				

Date:03/23/01ISR Number: 3707612-9Report Type:Periodic Company Report #WAES 00111946
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Furosemide	C				
			Hydroxyzine	C				
			Potassium Chloride	C				
			Ranitidine	C				
			Spironolactone	C				
			Thyroid	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3707613-0Report Type:Periodic Company Report #WAES 00111907
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Overload Joint Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Atacand	C		
			Coumadin	C		
			Lanoxin	C		
			Lasix	C		
			Lipitor	C		
			Mysoline	C		
			Slow-K	C		
			Insulin	C		

Date:03/23/01ISR Number: 3707614-2Report Type:Periodic Company Report #WAES 00111903
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatic Function Abnormal Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Toprol Xl Tablets	C		
			Zyrtec	C		
			Trazodone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707615-4Report Type:Periodic Company Report #WAES 01010158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707616-6Report Type:Periodic Company Report #WAES 01010164
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707617-8Report Type:Periodic Company Report #WAES 01010201
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Blood Pressure Increased Hypokalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Amitriptyline	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3707618-XReport Type:Periodic Company Report #WAES 01010203
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	Amoxicillin	C		
			Aspirin	C		
			Hormonal Contraceptives (Unspeci	C		

Date:03/23/01ISR Number: 3707619-1Report Type:Periodic Company Report #WAES 01010205
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anaphylactic Reaction	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3707620-8Report Type:Periodic Company Report #WAES 01010206
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						

			Aspirin	C		
			Norvasc	C		
			Zocor	C		

Date:03/23/01ISR Number: 3707621-XReport Type:Periodic Company Report #WAES 01010209
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Hypertrophy Breast	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO; 25 MG DAILY PO	
			Cardura	C				
			Coumadin	C				
			Lotensin	C				
			Lozol	C				
			Pravachol	C				
			Tylenol	C				
			Ultram	C				

Date:03/23/01ISR Number: 3707622-1Report Type:Periodic Company Report #WAES 01010212
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	

Date:03/23/01ISR Number: 3707623-3Report Type:Periodic Company Report #WAES 01010214
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG DAILY

PO; 50 MG

DAILY PO

Glucophage	C
Lasix	C
Maalox	C
Mylanta & Mylanta Ds	C
Tylenol With Codeine	C
Zantac	C
Zocor	C
Aspirin	C

Date:03/23/01ISR Number: 3707624-5Report Type:Periodic Company Report #WAES 01010223
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Abdominal Pain Alopecia Dyspepsia Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO; 25 MG

UNK PO

Atrovent	C

Lanoxin	C
Lasix	C
Serevent	C
Synthroid	C
Ventolin	C
Xalatan	C
Zantac	C
Chondroitin	C
Glucosamine	C
Potassium Chloride	C

Date:03/23/01ISR Number: 3707625-7Report Type:Periodic Company Report #WAES 00112003
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Fatigue							
	Muscle Spasms		Celebrex	C				

Date:03/23/01ISR Number: 3707626-9Report Type:Periodic Company Report #WAES 00112014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707627-0Report Type:Periodic Company Report #WAES 00112046
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707628-2Report Type:Periodic Company Report #WAES 00112052
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Dependence	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Drug Ineffective							
	Sexual Dysfunction				Merck Co Inc	ORAL	PO	
			Viagra	C				

Date:03/23/01ISR Number: 3707629-4Report Type:Periodic Company Report #WAES 00112055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707630-0Report Type:Periodic Company Report #WAES 00112056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:03/23/01ISR Number: 3707631-2Report Type:Periodic Company Report #WAES 00112066
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Prilosec	C				

Date:03/23/01ISR Number: 3707632-4Report Type:Periodic Company Report #WAES 00112072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707633-6Report Type:Periodic Company Report #WAES 00112083
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Vioxx	PS	Merck Research			

	Hypoaesthesia	Professional			Laboratories Div	
	Paraesthesia				Merck Co Inc	ORAL
PO						
			Paxil	SS		
			Sumatriptan	C		

Date:03/23/01ISR Number: 3707634-8Report Type:Periodic Company Report #WAES 00112102
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Consumer	Vioxx	PS	Merck Research	
	Swelling				Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3707635-XReport Type:Periodic Company Report #WAES 00121917
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Health	Vioxx	PS	Merck Research	
	Oedema	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707636-1Report Type:Periodic Company Report #WAES 00121931
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707637-3Report Type:Periodic Company Report #WAES 00121963
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Fluid Retention Palpitations Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707638-5Report Type:Periodic Company Report #WAES 00121965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707639-7Report Type:Periodic Company Report #WAES 00121968
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx Tylenol	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Aspirin	C		
				Sertraline	C		
				Tamsulosin	C		

Date:03/23/01ISR Number: 3707640-3Report Type:Periodic Company Report #WAES 00121984
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707641-5Report Type:Periodic Company Report #WAES 00121991
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aventyl	C				
			Plactidil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707642-7Report Type:Periodic Company Report #WAES 00121995
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Aspirin	C				
			Propranolol	C				

Date:03/23/01ISR Number: 3707643-9Report Type:Periodic Company Report #WAES 00121997
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Accupril	C				
			Norvasc	C				

Date:03/23/01ISR Number: 3707644-0Report Type:Periodic Company Report #WAES 00122003
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Valium	C				

Date:03/23/01ISR Number: 3707657-9Report Type:Periodic Company Report #WAES 01010225
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Oedema Peripheral Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707658-0Report Type:Periodic Company Report #WAES 01010227
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707661-0Report Type:Periodic Company Report #WAES 01010233
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:03/23/01ISR Number: 3707663-4Report Type:Periodic Company Report #WAES 01010235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Coumadin	C				
			Prinzide	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3707664-6Report Type:Periodic Company Report #WAES 01010236
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia							
	Dermatitis							
	Fatigue		Lortab	C				
	Influenza Like Illness		Synthroid	C				
	Nausea		[Composition					
	Upper Respiratory Tract Infection		Unspecified]	C				

Date:03/23/01ISR Number: 3707665-8Report Type:Periodic Company Report #WAES 01010242
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-37.5 MG/DAILY/PO;	
	Fatigue	Health						
	Liver Disorder	Professional						
	Nausea							

Oedema Peripheral
37.5 MG PO
Celebrex C

Date:03/23/01ISR Number: 3707667-1Report Type:Periodic Company Report #WAES 01010245
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ziac	C				

Date:03/23/01ISR Number: 3707668-3Report Type:Periodic Company Report #WAES 01010246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	1 MON
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707669-5Report Type:Periodic Company Report #WAES 01010251
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Vioxx	PS	Merck Research			
	Nausea	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3707670-1Report Type:Periodic Company Report #WAES 01010252
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Injury	Consumer	Vioxx	PS	Merck Research			
	Keratoconjunctivitis				Laboratories Div			
	Sicca				Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3707679-8Report Type:Periodic Company Report #WAES 01020749
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrateb	C				
			Liquibid	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3707680-4Report Type:Periodic Company Report #WAES 01020755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Sedation Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	

Date:03/23/01ISR Number: 3707681-6Report Type:Periodic Company Report #WAES 01020757
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Fosamax	C				
			Hydrodiuril	C				
			Lipitor	C				
			Micronase	C				
			Norvasc	C				
			Apirin	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707682-8Report Type:Periodic Company Report #WAES 01020759
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Axid	C				
			Flomax (Morniflumate)	C				
			Isoptin	C				
			Prevacid	C				
			Zocor	C				
			Herbal Remedies (Unspecified)	C				

Date:03/23/01ISR Number: 3707683-XReport Type:Periodic Company Report #WAES 01020761
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	18 DAY

Date:03/23/01ISR Number: 3707684-1Report Type:Periodic Company Report #WAES 01020762
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Methocarbamol	C				

Date:03/23/01ISR Number: 3707685-3Report Type:Periodic Company Report #WAES 01020764
Age:99 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				

Date:03/23/01ISR Number: 3707686-5Report Type:Periodic Company Report #WAES 01020766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707687-7Report Type:Periodic Company Report #WAES 01020775
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Hydrodiuril	C				
			Propranolol	C				

Date:03/23/01ISR Number: 3707688-9Report Type:Periodic Company Report #WAES 01020776
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Permarin	C				
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3707689-0Report Type:Periodic Company Report #WAES 00111902
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Altace	C				
			Plaquenil	C				
			Premarin	C				

Date:03/23/01ISR Number: 3707690-7Report Type:Periodic Company Report #WAES 00111896
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707691-9Report Type:Periodic Company Report #WAES 00111895
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/23/01ISR Number: 3707692-0Report Type:Periodic Company Report #WAES 00111894
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707693-2Report Type:Periodic Company Report #WAES 00111893
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		PM	
			Rythmol	C				
			Clonidine	C				
			Nifedipine	C				

Date:03/23/01ISR Number: 3707694-4Report Type:Periodic Company Report #WAES 00111888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:03/23/01ISR Number: 3707695-6Report Type:Periodic Company Report #WAES 00111886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:03/23/01ISR Number: 3707696-8Report Type:Periodic Company Report #WAES 00111873
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL PO

Date:03/23/01ISR Number: 3707697-XReport Type:Periodic Company Report #WAES 00111867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		
	Crying							
	Emotional Disorder							
	Hypokinesia							
	Weight Increased							

Date:03/23/01ISR Number: 3707698-1Report Type:Periodic Company Report #WAES 00111847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG AM PO	
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707699-3Report Type:Periodic Company Report #WAES 01010482
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707700-7Report Type:Periodic Company Report #WAES 01010485
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707701-9Report Type:Periodic Company Report #WAES 01010486
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707702-0Report Type:Periodic Company Report #WAES 01010489
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Humulin N	C	
Mevacor	C	
Synthroid	C	
Atenolol	C	
Furosemide	C	

Date:03/23/01ISR Number: 3707703-2Report Type:Periodic Company Report #WAES 01010503
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3707718-4Report Type:Periodic Company Report #WAES 01020778
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	37.5 MG DAILY PO	
	Influenza Like Illness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707720-2Report Type:Periodic Company Report #WAES 01020780
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
			Diazide	C				
			Prozac	C				
			Vicodin	C				

Date:03/23/01ISR Number: 3707721-4Report Type:Periodic Company Report #WAES 01020784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
			Celebrex	C				
			Lasix	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3707723-8Report Type:Expedited (15-DaCompany Report #WAES 01020785
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:03/23/01ISR Number: 3707724-XReport Type:Periodic Company Report #WAES 01020790
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Crying Depression	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Tab Flexeril	SS		
			Prempro	C		

Date:03/23/01ISR Number: 3707725-1Report Type:Periodic Company Report #WAES 01020840
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Blocadren	C		
			Celexa	C		
			Ecotrin	C		
			Norvasc	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707727-5Report Type:Periodic Company Report #WAES 01020853
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO
			Lipitor	C				
			Prempro	C				
			Glucosamine	C				

Date:03/23/01ISR Number: 3707728-7Report Type:Periodic Company Report #WAES 01020855
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dizziness Headache Muscular Weakness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Elavil	C				
			Neurontin	C				

Date:03/23/01ISR Number: 3707730-5Report Type:Periodic Company Report #WAES 01020863
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707731-7Report Type:Periodic Company Report #WAES 01020865
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Levoxyl	C				
			Naprosyn	C				
			Premarin	C				
			Trinsicon (Ascorbic Acid(+) Cya	C				
			Etodolac	C				
			Potassium	C				

Date:03/23/01ISR Number: 3707733-0Report Type:Periodic Company Report #WAES 01020869
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Axid	C				
			Klonopin	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707734-2Report Type:Periodic Company Report #WAES 01020870
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3707737-8Report Type:Periodic Company Report #WAES 01020873
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased		Norvasc	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3707738-XReport Type:Periodic Company Report #WAES 01020885
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms Oedema Peripheral Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Estrace	C				
			Synthroid	C				
			Ibuprofen	C				

Date:03/23/01ISR Number: 3707740-8Report Type:Periodic Company Report #WAES 01020893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Levothroid	C				

Date:03/23/01ISR Number: 3707741-XReport Type:Periodic Company Report #WAES 01020904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707742-1Report Type:Periodic Company Report #WAES 01020910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3707744-5Report Type:Periodic Company Report #WAES 01020925
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE / PO	
			Actos	C				
			Lotensin	C				
			Norvasc	C				
			Plendil	C				
			Premarin	C				
			Tylenol	C				
			Zocor	C				
			Calcium	C				
			Parsley Concentrate	C				
			Ubidecarenone	C				
			Vitamin E	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3707745-7Report Type:Periodic Company Report #WAES 01020933
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Attention	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Deficit/Hyperactivity				Merck Co Inc	ORAL
25						
	Disorder					
MG/DAILY/PO						
	Insomnia		Hydrodiuril	C		
			K-Tab	C		
			Synalgos-Dc	C		
			Prednisone	C		

Date:03/23/01ISR Number: 3707747-0Report Type:Periodic Company Report #WAES 01020934
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Vioxx	PS	Merck Research	
	Ecchymosis				Laboratories Div	
	Haemoptysis				Merck Co Inc	ORAL
25 MG/						
	Infection					
DAILY/PO						
	Pruritus		Avandia	C		
			Glucophage	C		
			Prinivil	C		
			Furosemide	C		
			Glyburide	C		
			Hydrochlorothiazide			
			(+) Triamter	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707753-6Report Type:Periodic Company Report #WAES 00092473
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS	Merck Research			
	Mouth Ulceration	Health			Laboratories Div			
	Oral Pain	Professional			Merck Co Inc	ORAL	25	
	Pain						MG/DAILY/PO	
	Paraesthesia		Accolate	C				
	Periodontal Disease		Cardizem	C				
	Pruritus		Estrogens	C				
	Tooth Disorder		Lysine	C				

Date:03/23/01ISR Number: 3707754-8Report Type:Periodic Company Report #WAES 00092495
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Depakote	C				
			Captopril	C				

Date:03/23/01ISR Number: 3707755-XReport Type:Periodic Company Report #WAES 00092530
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25MG/DAILY/PO	
		Representative						

Date:03/23/01ISR Number: 3707756-1Report Type:Periodic Company Report #WAES 01020668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urethral Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707757-3Report Type:Periodic Company Report #WAES 01020670
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Oxycodone	C				

Date:03/23/01ISR Number: 3707758-5Report Type:Periodic Company Report #WAES 00100134
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Drug Ineffective Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

			Lanoxin	C		

Date:03/23/01ISR Number: 3707759-7Report Type:Periodic Company Report #WAES 01020671
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Levothroid	C				
			Protonix	C				
			Zovia	C				

Date:03/23/01ISR Number: 3707760-3Report Type:Periodic Company Report #WAES 00100137
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILLY/PO	
			Flexeril	C				
			Prilosec	C				
			Propulsid	C				
			Vicodin Tablets	C				
			Zanaflex	C				

Date:03/23/01ISR Number: 3707761-5Report Type:Periodic Company Report #WAES 01020684
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:03/23/01ISR Number: 3707762-7Report Type:Periodic Company Report #WAES 01020685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:03/23/01ISR Number: 3707763-9Report Type:Periodic Company Report #WAES 00100209
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div	
					Merck Co Inc	ORAL
25MG/DAILY/PO						
			Premarin	C		
			Provera	C		
			Sporanox	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707764-0Report Type:Periodic Company Report #WAES 01020687
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Vision Blurred	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707765-2Report Type:Periodic Company Report #WAES 01020689
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Drug Tolerance	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3707766-4Report Type:Periodic Company Report #WAES 00100237
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastric Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	36MG/DAILY/PO	
			Darvocet-N	C				
			Calcium	C				
			Insulin	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3707767-6Report Type:Periodic Company Report #WAES 01020721
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Meclizine	C		

Date:03/23/01ISR Number: 3707768-8Report Type:Periodic Company Report #WAES 00100289
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY/ PO	

Date:03/23/01ISR Number: 3707769-XReport Type:Periodic Company Report #WAES 01020742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3707770-6Report Type:Periodic Company Report #WAES 01020743
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tenormin	C				

Date:03/23/01ISR Number: 3708190-0Report Type:Periodic Company Report #WAES 00100568
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Paraesthesia Psoriasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG	/DAILY / PO
			Aldactzide	C				
			Inderal	C				
			Vasotec	C				
			Aspirin	C				
			Chondroitin (+) Glucosamine	C				

Date:03/23/01ISR Number: 3708191-2Report Type:Periodic Company Report #WAES 00100705
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Celebrex	C				

Date:03/23/01ISR Number: 3708247-4Report Type:Periodic Company Report #WAES 01020956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Oxybutynin	C				

Date:03/23/01ISR Number: 3708248-6Report Type:Periodic Company Report #WAES 01020963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Below Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Prozac	C				

Date:03/23/01ISR Number: 3708249-8Report Type:Periodic Company Report #WAES 01020964
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Actonel	C	
Rentyl	C	
Lamictal	C	
Prilosec	C	
Tylenol'=	C	
Zoloft	C	
Vera...	C	

Date:03/23/01ISR Number: 3708250-4Report Type:Periodic Company Report #WAES 01020965
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	150 MG/DAILY/PO	
			Aspirin	C				
			Calcium	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3708251-6Report Type:Periodic Company Report #WAES 01020968
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D	C				
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3708252-8Report Type:Periodic Company Report #WAES 01020971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3708253-XReport Type:Periodic Company Report #WAES 01020972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:03/23/01ISR Number: 3708254-1Report Type:Periodic Company Report #WAES 01020973
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Armour Thyroid Tablets	C	
Premarin	C	

Date:03/23/01ISR Number: 3708255-3Report Type:Periodic Company Report #WAES 01020976
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/QODY	

/PO

Celebrex	C	
Loestrin	C	
Prozac	C	
Wellbutrin	C	

Date:03/23/01ISR Number: 3708256-5Report Type:Periodic Company Report #WAES 01020982
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:03/23/01ISR Number: 3708324-8Report Type:Periodic Company Report #WAES 01011213
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Capoten	C	

			Claritin	C		

Date:03/23/01ISR Number: 3708325-XReport Type:Periodic Company Report #WAES 01011214
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) PO; 2) 12.5 MG/DAILY/PO; 3) 12.5 MG/DAILY/PO	
	Dyspnoea							
	Fluid Retention							
	Oedema							
	Palpitations							
	Tachycardia							
	Tachypnoea							
			Capoten	C				
			Climara	C				
			Prevacid	C				
			Synthroid	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3708326-1Report Type:Periodic Company Report #WAES 01011228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3708327-3Report Type:Periodic Company Report #WAES 01011229
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
			Celebrex	C				

Date:03/23/01ISR Number: 3708328-5Report Type:Periodic Company Report #WAES 01011231
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dermatitis Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Mysoline	C				
			Propranolol	C				

Date:03/23/01ISR Number: 3708329-7Report Type:Periodic Company Report #WAES 01011233
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dry Mouth	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Pharyngitis				Merck Co Inc	ORAL
PO						
	Respiratory Disorder		Prempro	C		
			Atenolol	C		

Date:03/23/01ISR Number: 3708330-3Report Type:Periodic Company Report #WAES 01011234
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3708331-5Report Type:Periodic Company Report #WAES 01011236
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/ DAILY/						
PO						
			Actos	C		
			Demadex	C		
			Neurontin	C		
			Oxycontin	C		

			Ultram	C		
			Baclofen	C		

Date:03/23/01ISR Number: 3708332-7Report Type:Periodic Company Report #WAES 01011238
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Agitation Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Hytrin	C				
			Pepcid	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3708333-9Report Type:Periodic Company Report #WAES 01011240
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:03/23/01ISR Number: 3708371-6Report Type:Periodic Company Report #WAES 01010349
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709367-0Report Type:Periodic Company Report #WAES 01021562
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY.PO	
	Dysphonia							
	Dyspnoea							
	Pain							

Date:03/23/01ISR Number: 3709368-2Report Type:Periodic Company Report #WAES 01021565
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Blood Pressure Increased							
			Aricept	C				
			Lipitor	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709369-4Report Type:Periodic Company Report #WAES 01021570
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			
	Cardiac Murmur	Professional			Laboratories Div			
	Drug Ineffective				Merck Co Inc	ORAL	PO	
	Feeling Abnormal		Ambien	C				
	Headache		Celebrex	C				
	Vision Blurred		Klonopin	C				
			Prempro	C				
			Ultram	C				

Date:03/23/01ISR Number: 3709370-0Report Type:Periodic Company Report #WAES 01021571
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	50MG/BID/PO	
			Effexor	C				

Date:03/23/01ISR Number: 3709371-2Report Type:Periodic Company Report #WAES 01021572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709373-6Report Type:Periodic Company Report #WAES 01021573
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Intraocular Pressure Increased Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Allergy Drops	C		
			Synthroid	C		
			Atenolol	C		
			Vitamins(Unspecified)	C		

Date:03/23/01ISR Number: 3709374-8Report Type:Periodic Company Report #WAES 01021588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3709376-1Report Type:Periodic Company Report #WAES 01021592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3709377-3Report Type:Periodic Company Report #WAES 01021594
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
			Motrin	C				
			Premarin	C				
			Provera	C				

Date:03/23/01ISR Number: 3709378-5Report Type:Periodic Company Report #WAES 01021595
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Armour Thyroid Tablets	C				
			Premarin	C				

Date:03/23/01ISR Number: 3709391-8Report Type:Periodic Company Report #WAES 01011322
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Interaction							
			Vasotec	SS				
			Thyroxine	C				

Date:03/23/01ISR Number: 3709392-XReport Type:Periodic Company Report #WAES 01011327
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Dyspnoea							
			Hytrin	C				
			Vasotec	C				

Date:03/23/01ISR Number: 3709393-1Report Type:Periodic Company Report #WAES 01011331
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, BID, PO	
			Tiazac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709394-3Report Type:Periodic Company Report #WAES 01011332
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, DAILY,	
PO								
			Prevacid	C				
			Synthroid	C				
			Tambocor	C				
			Tylenol Arthritis Extended Relief	C				
			Amitriptyline	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3709395-5Report Type:Periodic Company Report #WAES 01011335
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dysphonia Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
	Nasal Congestion		Atacand	C				
	Nasopharyngeal Disorder		Celebrex	C				
	Oedema		Hydrodiuril	C				
	Palpitations		Mevacor	C				
	Pruritus		Sintrom	C				
			Synthroid	C				
			Amiodarone	C				

Date:03/23/01ISR Number: 3709396-7Report Type:Periodic Company Report #WAES 01011337
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Cardura	C				
			Lipitor	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709397-9Report Type:Periodic Company Report #WAES 01011346
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709398-0Report Type:Periodic Company Report #WAES 01011347
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, PRN,	PO
			Aspirin	C				
			Inderal	I	C			

Date:03/23/01ISR Number: 3709399-2Report Type:Periodic Company Report #WAES 01011366
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	PO

Date:03/23/01ISR Number: 3709400-6Report Type:Periodic Company Report #WAES 01011371
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY,	PO
			Lipitor	C				
			Paxil	C				
			Prempro	C				
			Prilosec	C				

Date:03/23/01ISR Number: 3709401-8Report Type:Periodic Company Report #WAES 01011378
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Faeces Discoloured Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Tab Vioxx 50 Mg	SS		ORAL	PO	

Date:03/23/01ISR Number: 3709402-XReport Type:Periodic Company Report #WAES 01011382
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 YR
		Representative	Mobic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709403-1Report Type:Periodic Company Report #WAES 01011385
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Vioxx	PS	Merck Research			
	Abdominal Pain Upper	Professional			Laboratories Div			
	Alanine Aminotransferase	Company			Merck Co Inc	ORAL	PO	
	Increased	Representative	Tab Vioxx 25 Mg	SS		ORAL	25 MG /BID/PO	
	Aspartate		Ms Contin	C				
	Aminotransferase							
	Increased							
	Blood Alkaline							
	Phosphatase Increased							
	Gamma-Glutamyltransferase							
	Increased							

Date:03/23/01ISR Number: 3709404-3Report Type:Periodic Company Report #WAES 01011415
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer	Vioxx	PS	Merck Research			
	Upper Respiratory Tract				Laboratories Div			
	Infection				Merck Co Inc	ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Oxycontin	C				
			Premarin	C				
			Prilosec	C				
			Zoloft	C				

Date:03/23/01ISR Number: 3709405-5Report Type:Periodic Company Report #WAES 01011420
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Joint Stiffness				Laboratories Div			

	Pain				Merck Co Inc	ORAL
25 MG/PM/PO						
			Armour Thyroid Tablets	C		
			Evista	C		
			Atenolol	C		
			Vitamins (Unspecified)	C		

Date:03/23/01ISR Number: 3709406-7Report Type:Periodic Company Report #WAES 01011423
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Flatulence				Merck Co Inc	ORAL
PO						
			Estrace	C		
			Fosamax	C		
			Maxzide	C		
			Restoril	C		
			Synthroid	C		
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709407-9Report Type:Periodic Company Report #WAES 01011426
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3709408-0Report Type:Periodic Company Report #WAES 01011429
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Asthenia Change Of Bowel Habit Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea		Zantac	C				

Date:03/23/01ISR Number: 3709409-2Report Type:Periodic Company Report #WAES 01011435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				

Date:03/23/01ISR Number: 3709410-9Report Type:Periodic Company Report #WAES 01011442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Salicylic Acid	C				

Date:03/23/01ISR Number: 3709411-0Report Type:Periodic Company Report #WAES 00102192
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG/DAILY/PO	
			Cardizem Cd	C				
			Moduretic	C				
			Prempro	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709412-2Report Type:Periodic Company Report #WAES 00102206
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Tenormin	C				

Date:03/23/01ISR Number: 3709413-4Report Type:Periodic Company Report # WAES 00102207
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan	C				
			Centrum Silver	C				
			Maxzide	C				
			Calcium	C				
			Glucosamine	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3709414-6Report Type:Periodic Company Report #WAES 00102241
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Persantine	C				

Date:03/23/01ISR Number: 3709415-8Report Type:Periodic Company Report #WAES 00102302
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nasopharyngeal Disorder							
	Oedema							
			Coumadin	C				
			Lasix	C				

Date:03/23/01ISR Number: 3709416-XReport Type:Periodic Company Report #WAES 00102346
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pain							
			Lipitor	C				
			Lotensin	C				
			Ticlid	C				
			Uniphyl	C				
			Aspirin	C				
			Atenolol	C				
			Pentoxifylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709417-1Report Type:Periodic Company Report #WAES 00102441
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ditrei	C				
			Premarin	C				
			Prilosec	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3709418-3Report Type:Periodic Company Report #WAES 00102487
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709419-5Report Type:Periodic Company Report #WAES 00102586
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Drug Interaction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709420-1Report Type:Periodic Company Report #WAES 00102596
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Memory Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:03/23/01ISR Number: 3709421-3Report Type:Periodic Company Report #WAES 00102607
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Insomnia Phobia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Prilosec	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709422-5Report Type:Periodic Company Report #WAES 00110038
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lescol	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709423-7Report Type:Periodic Company Report #WAES 00110043
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:03/23/01ISR Number: 3709424-9Report Type:Periodic Company Report #WAES 00110134
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Celebrex	C				
			Flonase	C				
			Prempro	C				
			Sigulair	C				
			Zyrtec	C				
			Albuterol	C				

Date:03/23/01ISR Number: 3709425-0Report Type:Periodic Company Report #WAES 00110163
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Capoten	C				
			Synthroid	C				
			Ziac	C				
			Glipizide	C				

Date:03/23/01ISR Number: 3709426-2Report Type:Periodic Company Report #WAES 00110175
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendon Rupture	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709427-4Report Type:Periodic Company Report #WAES 00110182
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Dizziness							
	Ear Pain		Baycol	C				
	Eye Pain		Veronal	C				
	Fatigue		Cortisone	C				
	Hypoaesthesia							
	Myocardial Infarction							
	Pain							
	Vomiting							

Date:03/23/01ISR Number: 3709428-6Report Type:Periodic Company Report #WAES 00110406
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709429-8Report Type:Periodic Company Report #WAES 00110431
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flexeril	C				
			Hydergine	C				
			Prinivil	C				

			Ultram	C		
			Diazepam	C		

Date:03/23/01ISR Number: 3709430-4Report Type:Periodic Company Report #WAES 00110472
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Dyspepsia							
	Pulmonary Congestion		Aciphex	C				
			Cozyme	C				
			Zocor	C				

Date:03/23/01ISR Number: 3709431-6Report Type:Periodic Company Report #WAES 00110476
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Drug Ineffective	Health Professional						
	Pulmonary Congestion							
	Sputum Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709432-8Report Type:Periodic Company Report #WAES 00110487
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	6.25MG/DAILY/ PO	
			Zestril	C				
			Zestril	C				

Date:03/23/01ISR Number: 3709433-XReport Type:Periodic Company Report #WAES 00110503
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709434-1Report Type:Periodic Company Report #WAES 00110547
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Insomnia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Daypro	C				
			Flomax (Moniflumate)	C				
			Sonata	C				
			Vicopropen	C				
			Methotrexate	C				

Date:03/23/01ISR Number: 3709435-3Report Type:Periodic Company Report #WAES 00110558
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Vitamins	SS		
			Actonel	C		
			Lipitor	C		
			Prilosec	C		

Date:03/23/01ISR Number: 3709436-5Report Type:Periodic Company Report #WAES 00110592
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erythema Multiforme	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Cycrin	C		
			Maxzide	C		
			Premarin	C		
			Provera	C		
			Calcium	C		
			Glucosamine	C		

	Vitamin E	C	
	Vatimins (Unspecified)	C	

Date:03/23/01ISR Number: 3709437-7Report Type:Periodic Company Report #WAES 00110597
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709438-9Report Type:Periodic Company Report #WAES 00110600
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Blood Pressure Increased Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3709439-0Report Type:Periodic Company Report #WAES 00110601
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Celebrex	SS				
			Naproxen	C				

Date:03/23/01ISR Number: 3709440-7Report Type:Periodic Company Report #WAES 00110605
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastric Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Indocin(Indomethacin Sodium)	C		
			Vicodin	C		

Date:03/23/01ISR Number: 3709441-9Report Type:Periodic Company Report #WAES 00110609
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG/DAILY/ PO						
			Actos	C		
			Estraderm Transdermal System	C		
			Glucophage	C		
			Prilosec	C		
			Ziac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709442-0Report Type:Periodic Company Report #WAES 00110611
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dizziness	Health						
	Drug Interaction	Professional						
	Headache		Tab Prinivil	SS				
	Hypertension		Hydrodiuril	C				
			Tenormin	C				
			Zestril	C				

Date:03/23/01ISR Number: 3709443-2Report Type:Periodic Company Report #WAES 00110613
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Endocet	C				
			Naproxen	C				

Date:03/23/01ISR Number: 3709444-4Report Type:Periodic Company Report #WAES 00110619
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia	Health						
	Insomnia	Professional						
	Palpitations		Acetaminophen (+) Codeine	C				

Date:03/23/01ISR Number: 3709445-6Report Type:Periodic Company Report #WAES 00110626
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY
			Prednisone	C				

Date:03/23/01ISR Number: 3709446-8Report Type:Periodic Company Report #WAES 00110627
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3709447-XReport Type:Periodic Company Report #WAES 00110648
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source
	Tendon Rupture	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709448-1Report Type:Periodic Company Report #WAES 00110727
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
			Fosamax	C				
			Lotenin	C				
			Methotrexate (Methotrexate Sodium)	C				
			Plaquenil	C				
			Premarin	C				
			Zocor	C				

Date:03/23/01ISR Number: 3709449-3Report Type:Periodic Company Report #WAES 00110728
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Cardizem	C				
			Humulin 70/30	C				
			Lasix	C				
			Zestril	C				
			Zosyn	C				

Heparin	C
Hydralazine	C
Rifampin	C
Vancomycin	C

Date:03/23/01ISR Number: 3709450-XReport Type:Periodic Company Report #WAES 00110758
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	

Date:03/23/01ISR Number: 3709451-1Report Type:Periodic Company Report #WAES 00110802
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

		Celebrex	C
		Zocor	C
		Ginseng	C
		Vitamins	C

Date:03/23/01ISR Number: 3709452-3Report Type:Periodic Company Report #WAES 00110819
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Vioxx	PS	Merck Research			
	Neoplasm	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

Date:03/23/01ISR Number: 3709453-5Report Type:Periodic Company Report #WAES 00110872
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research			
	Gastrointestinal Disorder				Laboratories Div			
	Headache				Merck Co Inc	ORAL	PO	
			Aleve	C				
			Aspirin	C				
			Naproxen	C				

Date:03/23/01ISR Number: 3709454-7Report Type:Periodic Company Report #WAES 00110930
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS	Merck Research			
	Medication Error	Professional			Laboratories Div			
					Merck Co Inc	ORAL	SEE IMAGE	

Date:03/23/01ISR Number: 3709455-9Report Type:Periodic Company Report #WAES 00111016
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache Palpitations	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	;PO
			Diovan	C				
			Hydrodiuril	C				
			Valium	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709456-0Report Type:Periodic Company Report #WAES 00111019
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	PO
			Accupril	C				
			Elavil	C				

Oxycontin	C
Aspirin	C
Digoxin	C

Date:03/23/01ISR Number: 3709457-2Report Type:Periodic Company Report #WAES 00111022
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Dermatitis	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	PO	
	Nausea		Therapy Unspecified	C				
	Oedema							
	Pharyngitis							
	Pruritus							
	Swelling							
	Vomiting							

Date:03/23/01ISR Number: 3709458-4Report Type:Periodic Company Report #WAES 00111039
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research			
	Pruritus				Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709459-6Report Type:Periodic Company Report #WAES 00111067
Age:11 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Disorder	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709460-2Report Type:Periodic Company Report #WAES 00111144
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709461-4Report Type:Periodic Company Report #WAES 00111158
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709462-6Report Type:Periodic Company Report #WAES 00111170
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol Arthritis	C				
			Nonsteroidal Anti-Inlfamatory	C				

Date:03/23/01ISR Number: 3709463-8Report Type:Periodic Company Report #WAES 00111174
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	No Adverse Drug Effect	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:03/23/01ISR Number: 3709464-XReport Type:Periodic Company Report #WAES 00111182
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709465-1Report Type:Periodic Company Report #WAES 00111233
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research			

		Health Professional			Laboratories Div Merck Co Inc	ORAL
12.5MG/DAILY/						
PO						
			Pravachol	C		
			Premarin	C		
			Prilosec	C		
			Synthroid	C		

Date:03/23/01ISR Number: 3709466-3Report Type:Periodic Company Report #WAES 00111270
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Headache					
	Pain					
PO						
			Tab Fosamax	SS		
			Tylenol	C		

Date:03/23/01ISR Number: 3709467-5Report Type:Periodic Company Report #WAES 00111271
Age: Gender:Female I/FU:F

Outcome	PT	Report Source
	Hypertension	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Coumadin	C				

Date:03/23/01ISR Number: 3709468-7Report Type:Periodic Company Report #WAES 00111273
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Laboratory Test Abnormal Musculoskeletal Pain Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/23/01ISR Number: 3709469-9Report Type:Periodic Company Report #WAES 00111337
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	

Date:03/23/01ISR Number: 3709470-5Report Type:Periodic Company Report #WAES 00111344
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

			Lopid	C		
			Lopressor	C		
			Aspirin	C		
			Vitamin C	C		

Date:03/23/01ISR Number: 3709471-7Report Type:Periodic Company Report #WAES 00111353
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Thyroid	C				

Date:03/23/01ISR Number: 3709472-9Report Type:Periodic Company Report #WAES 00111365
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Centrum	C	
Synthroid	C	
Therapy Unspecified	C	
Atenolol	C	
Calcium	C	

Date:03/23/01ISR Number: 3709473-0Report Type:Periodic Company Report #WAES 00111477
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

Date:03/23/01ISR Number: 3709474-2Report Type:Periodic Company Report #WAES 00111529
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective	Health Professional						
	Dyspnoea							
	Gastric Disorder		Ditropan	SS				
	Palpitations		Premarin	C				
			Relafen	C				
			Synthroid	C				
			Furosemide	C				
			Meclizine	C				
			Potassium	C				
			Verapamil	C				

Date:03/23/01ISR Number: 3709475-4Report Type:Periodic Company Report #WAES 00111543
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709476-6Report Type:Periodic Company Report #WAES 00111558
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Affective Disorder Malaise Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Ultram	C				
			Wellbutrin	C				
			Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709477-8Report Type:Periodic Company Report #WAES 00111740
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709478-XReport Type:Periodic Company Report #WAES 00111782
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Excedrin Extra-Strength	C				

Date:03/23/01ISR Number: 3709479-1Report Type:Periodic Company Report #WAES 00111790
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cipro	C				
			Climara	C				
			Glucophage	C				
			Glipizide	C				

Date:03/23/01ISR Number: 3709480-8Report Type:Periodic Company Report #WAES 00111796
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Premarin	C				
			Synthroid	C				
			Amitriptyline	C				

Date:03/23/01ISR Number: 3709481-XReport Type:Periodic Company Report #WAES 01010719
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/ DAILY/ PO; 2) 25 MG/ DAILY/ PO	
			Thyroid	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709482-1Report Type:Periodic Company Report #WAES 01010694
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/ DAILY/ PO; 25 MG/ DAILY/ PO	
			Talacen	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3709484-5Report Type:Periodic Company Report #WAES 01010695
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorder Of Globe Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709485-7Report Type:Periodic Company Report #WAES 01010699
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Menstrual Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	

Date:03/23/01ISR Number: 3709486-9Report Type:Periodic Company Report #WAES 01010700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
			Effexor	C				
			Tamoxifen	C				

Date:03/23/01ISR Number: 3709487-0Report Type:Periodic Company Report #WAES 01010709
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain							
			Actos	C				
			Glucotrol Xl	C				
			Lotensin	C				
			Paxil	C				
			Synthroid	C				
			Aspirin	C				
			Digoxin	C				
			Doxazosin	C				

		Ranitidine	C
		Verapamil	C
		Vitamins (Unspecified)	C

Date:03/23/01ISR Number: 3709488-2Report Type:Periodic Company Report #WAES 01010711
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Fatigue							
	Rhinitis Allergic							
			Effexor	C				
			Norvasc	C				
			Zebeta	C				

Date:03/23/01ISR Number: 3709490-0Report Type:Periodic Company Report #WAES 01010713
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Flatulence							
	Gastrooesophageal Reflux Disease							
	Glossodynia							
	Tongue Discolouration							
	Tongue Disorder							
	Vision Blurred							

Date:03/23/01ISR Number: 3709491-2Report Type:Periodic Company Report #WAES 01012070
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Headache							

Malaise Merck Co Inc ORAL
25

MG/DAILY/PO 2 DAY

Glyburide	C	
Guaifenesin	C	
Metformin	C	
Pioglitazone Hydrochloride	C	

Date:03/23/01ISR Number: 3709492-4Report Type:Periodic Company Report #WAES 01012074
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Chest Pain							
	Pollakiuria				Merck Co Inc	ORAL	12.5	

MG/BID/PO

Zantac	C	
Beta Carotene	C	
Morphine	C	
Prednisone	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709493-6Report Type:Periodic Company Report #WAES 01012092
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709494-8Report Type:Periodic Company Report #WAES 01012093
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				
			Prilosec	C				
			Ultram	C				
			Aspirin	C				
			Cimicifuga	C				
			Dimethyl Sulfone	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3709495-XReport Type:Periodic Company Report #WAES 01012094
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia Rib Fracture Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Ceclor Cd	C				
			Diflucan	C				
			Hydromet	C				
			Levaquin	C				

				Tussafed	C	
				Vicodin Es Tablets [Therapy Unspecified]	C	
				Acetaminophen (+) Hydrocodone Bi	C	
				Albuterol	C	
				Clonazepam	C	
				Fluconazole	C	
				Ibuprofen	C	
				Orphenadrine	C	

Date:03/23/01ISR Number: 3709496-1Report Type:Periodic Company Report #WAES 01012106
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				
			Diprolene	C				
			Captopril	C				

Hydrochlorothiazide C

Date:03/23/01ISR Number: 3709497-3Report Type:Periodic Company Report #WAES 01012113
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709498-5Report Type:Periodic Company Report #WAES 01012143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 DAY

Date:03/23/01ISR Number: 3709499-7Report Type:Periodic Company Report #WAES 01012160
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Nausea		Cozaar Fosamax Hydrodiuril	C C C				

Date:03/23/01ISR Number: 3709500-0Report Type:Periodic Company Report #WAES 01012163
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Prinivil	C				
			Verelan	C				
			Zyrtec	C				
			Potassium Chloride	C				

Date:03/23/01ISR Number: 3709501-2Report Type:Periodic Company Report #WAES 01012165
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Prinivil	C				
			Aspirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709502-4Report Type:Periodic Company Report #WAES 01012166
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
		Representative	Lithium Carbonate	C				

Date:03/23/01ISR Number: 3709503-6Report Type:Periodic Company Report #WAES 01012200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

Date:03/23/01ISR Number: 3709504-8Report Type:Periodic Company Report #WAES 01012208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Micturition Disorder Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Evista	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3709505-XReport Type:Periodic Company Report #WAES 01012216
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:03/23/01ISR Number: 3709506-1Report Type:Periodic Company Report #WAES 01012219
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:03/23/01ISR Number: 3709507-3Report Type:Periodic Company Report #WAES 01012228
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Depression Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

	Depakote	C
	Nardil	C
	Premarin	C
	Synthroid	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709508-5Report Type:Periodic Company Report #WAES 01012229
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/UNK/PO
	Drug Ineffective							
	Nausea							
			Glucophage	C				
			Oxycontin	C				
			Percodan	C				
			Vibra-Tabs	C				

Date:03/23/01ISR Number: 3709509-7Report Type:Periodic Company Report #WAES 01012235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK	UNK/PO
			Zestril	C				

Date:03/23/01ISR Number: 3709510-3Report Type:Periodic Company Report #WAES 01012237
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Tinnitus							
			Zithromax	C				
			Calcium (Unspecified)	C				

Date:03/23/01ISR Number: 3709511-5Report Type:Periodic Company Report #WAES 01010823
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				

Date:03/23/01ISR Number: 3709512-7Report Type:Periodic Company Report #WAES 01010824
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Pruritus							
	Upper Respiratory Tract Infection							
			Premarin	C				
	Vomiting		Ultram	C				
			Zoloft	C				
			Verapamil	C				

Date:03/23/01ISR Number: 3709513-9Report Type:Periodic Company Report #WAES 01010831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO/S	EE IMAGE 1 WK
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3709514-0Report Type:Periodic Company Report #WAES 01010832
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Claritin	C				
			Isoptin	C				
			Prozac	C				
			Zestoretic	C				

Date:03/23/01ISR Number: 3709515-2Report Type:Periodic Company Report #WAES 01010837
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3709516-4Report Type:Periodic Company Report #WAES 01010838
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Prilosec	C				
			Timoptic-Xe	C				
			[Therapy Unspecified]	C				
			Lorazepam	C				

Date:03/23/01ISR Number: 3709517-6Report Type:Periodic Company Report #WAES 01010841
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709518-8Report Type:Periodic Company Report #WAES 01010857
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acetexa	C				
			Neurontin	C				
			Oxycontin	C				
			Prempro	C				

Date:03/23/01ISR Number: 3709519-XReport Type:Periodic Company Report #WAES 01010862
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3709520-6Report Type:Periodic Company Report #WAES 01010865
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				

Date:03/23/01ISR Number: 3709521-8Report Type:Periodic Company Report #WAES 01010866
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709522-XReport Type:Periodic Company Report #WAES 01010870
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Oedema Peripheral							
			Claritin	C				
			Cyclobenzaprine Hydrochloride	C				

Date:03/23/01ISR Number: 3709523-1Report Type:Periodic Company Report #WAES 01010872
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY

PO

Neurontin C
Trazodone C

Date:03/23/01ISR Number: 3709524-3Report Type:Periodic Company Report #WAES 01010873
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Nausea							
			Dyazide	C				
			Glucophage	C				
			Zantac	C				
			Aspirin	C				
			Diltiazem	C				
			Glyburide	C				

Date:03/23/01ISR Number: 3709525-5Report Type:Periodic Company Report #WAES 01010874
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Lipitor	C				
			Norvasc	C				
			Furosemide	C				
			Pentoxifylline	C				
			Terazosin	C				

Date:03/23/01ISR Number: 3709526-7Report Type:Periodic Company Report #WAES 01010881
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709527-9Report Type:Periodic Company Report #WAES 01010882
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Thyroid Stimulating Hormone Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709528-0Report Type:Periodic Company Report #WAS 01010907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709529-2Report Type:Periodic Company Report #WAES 01010920
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709530-9Report Type:Periodic Company Report #WAES 01010923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709568-1Report Type:Periodic Company Report #WAES 01010730
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Avapro	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3709569-3Report Type:Periodic Company Report #WAES 01010731
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Deltison	C				
			Prinivil	C				
			Zantac	C				

Date:03/23/01ISR Number: 3709570-XReport Type:Periodic Company Report #WAES 01010732
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Inderide Tablets	C				

			Lipitor	C		

Date:03/23/01ISR Number: 3709571-1Report Type:Periodic Company Report #WAES 01021110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pain							
	Paraesthesia							
	Pruritus							
			Allegra	C				
			Diovan	C				

Date:03/23/01ISR Number: 3709572-3Report Type:Periodic Company Report #WAES 01010734
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrace	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Vasotec	C				
			Xanax	C				

Date:03/23/01ISR Number: 3709573-5Report Type:Periodic Company Report #WAES 01021111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/BID/PO
Plaquenil C
Prednisone C

Date:03/23/01ISR Number: 3709574-7Report Type:Periodic Company Report #WAES 01010742
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:03/23/01ISR Number: 3709575-9Report Type:Periodic Company Report #WAES 01021124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709576-0Report Type:Periodic Company Report #WAES 01010765
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	

Date:03/23/01ISR Number: 3709577-2Report Type:Periodic Company Report #WAES 01010770
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709578-4Report Type:Periodic Company Report #WAES 01010721
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Pravachol	C				
			Prevacid	C				
			Ultram	C				

Date:03/23/01ISR Number: 3709579-6Report Type:Periodic Company Report #WAES 01021128
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cough Hypersensitivity Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Fosamax	C		
			Prempro	C		

Date:03/23/01ISR Number: 3709580-2Report Type:Periodic Company Report #WAES 01010724
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Alphagan	C		
			Lotemax	C		
			Norvasc	C		
			Timolol Maleate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709581-4Report Type:Periodic Company Report #WAES 01021131
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Evista	C				
			Glucophage	C				
			Prilosec	C				
			Glipizide	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:03/23/01ISR Number: 3709582-6Report Type:Periodic Company Report #WAES 01010728
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO 5 DAY
			Lopressor	C				
			Pravachol	C				
			Tricor	C				

Date:03/23/01ISR Number: 3709583-8Report Type:Periodic Company Report #WAES 01021133
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/BID/PO

Hyzaar	C
Synthroid	C
Verelan	C

Date:03/23/01ISR Number: 3709584-XReport Type:Periodic Company Report #WAES 01030365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709585-1Report Type:Periodic Company Report #WAES 01030572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709586-3Report Type:Periodic Company Report #WAES 01021152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Vioxx	PS	Merck Research			
	Oedema	Professional			Laboratories Div			
	Visual Disturbance				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			[Therapy Unspecified]	C				
			Metoprolol	C				

Date:03/23/01ISR Number: 3709587-5Report Type:Periodic Company Report #WAES 01030603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	12.5MG/DAILY/	
		Representative					PO	

Date:03/23/01ISR Number: 3709588-7Report Type:Periodic Company Report #WAES 01021166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis	Consumer	Vioxx	PS	Merck Research			
	Rhinorrhoea				Laboratories Div			
	Upper Respiratory Tract				Merck Co Inc	ORAL	UNK/UNK/PO	
	Infection							

Date:03/23/01ISR Number: 3709589-9Report Type:Periodic Company Report #WAES 00010024
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Faeces Discoloured	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Fosamax	C				
			Os-Cal	C				

Date:03/23/01ISR Number: 3709590-5Report Type:Periodic Company Report #WAES 00030041
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	P[O	
			Benadryl	C				
			Lotensin	C				
			Norvasc	C				
			Prozac	C				
			Sigulair	C				
			Ultram	C				
			Ventolin	C				
			Furosemide	C				
			Theophylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709591-7Report Type:Periodic Company Report #WAES 01021168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3709592-9Report Type:Periodic Company Report #WAES 00051139
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dry Skin Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus		Plaquenil Vitamins	C C				

Date:03/23/01ISR Number: 3709593-0Report Type:Periodic Company Report #WAES 01021174
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3709594-2Report Type:Periodic Company Report #WAES 01021175
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

			Lovenox	C		

Date:03/23/01ISR Number: 3709595-4Report Type:Periodic Company Report #WAES 00051551
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Alopecia							
	Deafness							
	Dyspepsia							
			Didronel	C				
			Metamucil	C				
			Premarin	C				
			Ascorbic Acid	C				
			Calcium Supplement	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3709596-6Report Type:Periodic Company Report #WAES 01021072
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache							
	Nausea							

				Xanax	C		

Date:03/23/01ISR Number: 3709597-8Report Type:Periodic Company Report #WAES 00052371
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709598-XReport Type:Periodic Company Report #WAES 00052448
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Insomnia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	
	Sedation							/DAILY/PO
			Nasacort	C				

Date:03/23/01ISR Number: 3709599-1Report Type:Periodic Company Report #WAES 00052690
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol Msd	C				
			Xanax	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709600-5Report Type:Periodic Company Report #WAES 00072511
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Blood Pressure Increased							
	Connective Tissue Disorder		Prednisone	C				
	Depressed Level Of Consciousness							
	Dizziness							
	Eyelid Oedema							
	Headache							
	Nausea							
	Tongue Oedema							
	Vertigo							

Date:03/23/01ISR Number: 3709601-7Report Type:Periodic Company Report #WAES 00080017
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709602-9Report Type:Periodic Company Report #WAES 00080029
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imuran (Azathiophine Sodium Sal)	C				
			Synthroid	C				
			Tylenol, Arthritis Extended Relief	C				
			Aspirin	C				
			Diuretic (Preparation	C				
			Verapamil	C				

Date:03/23/01ISR Number: 3709603-0Report Type:Periodic Company Report #WAES 00080719
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709604-2Report Type:Periodic Company Report #WAES 00081173
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Chest Pain							
	Cough							
	Dyspnoea							
			Zoloft	C				

Date:03/23/01ISR Number: 3709605-4Report Type:Periodic Company Report #WAES 00081776
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Estratest	C				
			Flonase	C				

Date:03/23/01ISR Number: 3709606-6Report Type:Periodic Company Report #WAES 00082028
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Swelling Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cipro	C				
			Hydrodiuril	C				
			Lipitor	C				
			Metaprel	C				
			Norvasc	C				
			Proscar	C				

			Ranitidine	C		

Date:03/23/01ISR Number: 3709607-8Report Type:Periodic Company Report #WAES 00082307
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research			
	Hypersensitivity	Health			Laboratories Div			
	Upper Respiratory Tract	Professional			Merck Co Inc	ORAL	PO	1 WK
	Infection							

Date:03/23/01ISR Number: 3709608-XReport Type:Periodic Company Report #WAES 00082855
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research			
	Oedema Peripheral	Health			Laboratories Div			
	Pain	Professional			Merck Co Inc	ORAL	36MG/DAILY/PO	
			Bumex	C				
			Neutral Phos	C				
			Pepcid	C				
			Synthroid	C				
			Tylenol, Arthritis Extended Relief	C				
			Tylenol With Codeine	C				
			Ademetionine	C				
			Aspirin	C				
			Atenolol	C				
			Benzquercin	C				
			Brommelains	C				
			Cyanocobalamin	C				
			Digestive Enzymes	C				
			Estradiol	C				
			Sodium Folate	C				
			Ubidecarenone	C				

Date:03/23/01ISR Number: 3709609-1Report Type:Periodic Company Report #WAES 00082945
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Pruritus	Health			Laboratories Div			
	Rash Erythematous	Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
			Premarin	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709610-8Report Type:Periodic Company Report #WAES 00061655
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective				Laboratories Div			
	Dry Mouth				Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709611-XReport Type:Periodic Company Report #WAES 00061910
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Oedema Peripheral							
	Oliguria		Diazide	C				
	Pain		Minipress	C				
	Pollakiuria							

Date:03/23/01ISR Number: 3709612-1Report Type:Periodic Company Report #WAES 01021074
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	SS				
			Accupril	C				
			Claritin	C				
			K-Dur	C				
			Levoxyl	C				
			Zocor	C				
			Triamterene	C				

Date:03/23/01ISR Number: 3709613-3Report Type:Periodic Company Report #WAES 00062939
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Erythema	Health						
	Pruritus	Professional						

Date:03/23/01ISR Number: 3709614-5Report Type:Periodic Company Report #WAES 01021075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortisone	C				

Date:03/23/01ISR Number: 3709615-7Report Type:Periodic Company Report #WAES 00064358
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Benadryyl	C				
			Celebrex	C				
			Premarin	C				
			Valilum	C				
			Voltaren	C				
			Estrogens (Unspecified)	C				
			Quinine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709616-9Report Type:Periodic Company Report #WAES 00064372
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	36 MG/DAILY/PO	
	Dyspepsia	Health						
	Dysphoria	Professional						
	Nausea							
			Baycol	C				
			Cimetidine	C				
			Metoprolol	C				
			Prazosin	C				

Date:03/23/01ISR Number: 3709617-0Report Type:Periodic Company Report #WAES 01021086
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Prozac	C				
			Relafen	C				
			Acyclovir	C				
			Wellbutrin	C				
			Estrogens, Conjugaed	C				
			Medroxytprogesterone Acetate	C				

Date:03/23/01ISR Number: 3709618-2Report Type:Periodic Company Report #WAES 00070053
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	36MG/DAILY/PO	
	Gait Disturbance							
	Muscle Spasms							
	Nausea		Cogentin	C				

	Oedema Peripheral	Lipitor	C
	Pollakiuria	Premarin	C
	Rhinorrhoea	Risperdal	C
		Serzone	C
		Lithium Chloride	C
		Ranitidine	C

Date:03/23/01ISR Number: 3709619-4Report Type:Periodic Company Report #WAES 01021089
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Dyspepsia							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux		Vioxx	SS		ORAL	25MG/DAILY/PO	
	Disease		Celebrex	C				
	Nausea		Prevacid	C				
	Pain							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709620-0Report Type:Periodic Company Report #WAES 01021099
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							
			Valium	C				

Date:03/23/01ISR Number: 3709621-2Report Type:Periodic Company Report #WAES 00070740
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	2 WK
	Dizziness	Other						
	Nausea							
			Dyazide	C				
			Fosamax	C				
			Prilosec	C				
			Allopurinol	C				
			Hydrocodone	C				
			Quinine Sulfate	C				

Date:03/23/01ISR Number: 3709622-4Report Type:Periodic Company Report #WAES 01021100
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
	Genital Haemorrhage							
			Proscar	C				
			Prozac	C				
			Risperdal	C				

Date:03/23/01ISR Number: 3709623-6Report Type:Periodic Company Report #WAES 00070825
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis Urinary Tract Infection	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709624-8Report Type:Periodic Company Report #WAES 01021104
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Azulfedine	C				
			Elavil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709625-XReport Type:Periodic Company Report #WAES 00070987
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	
	Drug Ineffective	Health Professional						
	Dyspepsia							
	Nausea							
	Pain In Extremity		Ultrim	C				

Date:03/23/01ISR Number: 3709626-1Report Type:Periodic Company Report #WAES 01021105
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	\25/MG/DAILY/PO	
	Change Of Bowel Habit							
			Lipitor	C				
			Miacalcin	C				
			Prilosec	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3709627-3Report Type:Periodic Company Report #WAES 00071508
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Headache							
	Libido Decreased							
	Malaise		Ultram	C				

Date:03/23/01ISR Number: 3709628-5Report Type:Periodic Company Report #WAES 01021108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				
			Vicodin Tablets	C				

Date:03/23/01ISR Number: 3709629-7Report Type:Periodic Company Report #WAES 01021176
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dry Skin	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3709630-3Report Type:Periodic Company Report #WAES 01021177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
UNK/UNK/PO

Date:03/23/01ISR Number: 3709631-5Report Type:Periodic Company Report #WAES 01021178
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3709632-7Report Type:Periodic Company Report #WAES 01021181
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Hypoglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Calan	C				
			Glucophage	C				
			Vasotec	C				

Date:03/23/01ISR Number: 3709633-9Report Type:Periodic Company Report #WAES 01021182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO
			Evista	C				
			Prinzide	C				
			Thyroid	C				

Date:03/23/01ISR Number: 3709634-0Report Type:Periodic Company Report #WAES 01021183
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pain							
			Premarin	C				
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3709635-2Report Type:Periodic Company Report #WAES 01021185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709636-4Report Type:Periodic Company Report #WAES 01021187
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Vioxx	PS	Merck Research			
	Migraine	Professional			Laboratories Div			
	Photosensitivity Reaction				Merck Co Inc	ORAL	25	
	Visual Field Defect						MG/DAILY/PO	
			Prempro	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3709637-6Report Type:Periodic Company Report #WAES 01021190
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research			
	Urinary Tract Infection				Laboratories Div			
					Merck Co Inc	ORAL	12.5MG/DAILY/	
							PO	
			Antimicrobial (Unspecified)	C				

Date:03/23/01ISR Number: 3709638-8Report Type:Periodic Company Report #WAES 01021196
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Sprain	Consumer	Vioxx	PS	Merck Research			
	Joint Swelling				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Composition Unspecified	C				

Date:03/23/01ISR Number: 3709639-XReport Type:Periodic Company Report #WAES 01021197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrointestinal Haemorrhage							
	Vision Blurred		Claritin	C				
			Lotrel	C				

Date:03/23/01ISR Number: 3709640-6Report Type:Periodic Company Report #WAES 01021215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709641-8Report Type:Periodic Company Report #WAES 00090775
Age:58 YR Gender:Female I/FU:F

Outcome	PT
	Arthritis
	Drug Ineffective

Feeling Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				
			Voltaren	C				

Date:03/23/01ISR Number: 3709642-XReport Type:Periodic Company Report #WAES 01021231
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timoptic	C				
			Xalatan	C				

Date:03/23/01ISR Number: 3709643-1Report Type:Periodic Company Report #WAES 00090852
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clonic Convulsion Hyperkalaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Paxil	C				
			Relafen	C				

Date:03/23/01ISR Number: 3709644-3Report Type:Periodic Company Report #WAES 01021248
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Fosamax	C				
			Microzide	C				
			Verapamil	C				

Date:03/23/01ISR Number: 3709645-5Report Type:Periodic Company Report #WAES 00090963
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased	Health Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709646-7Report Type:Periodic Company Report #WAES 00091134
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Arthralgia							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease		Ambien	C				
			Cardura	C				
	Constipation		Coumadin	C				
	Gastrointestinal Disorder		Hydrocodone	C				
	Pain In Extremity		Verapamil	C				
	Pollakiuria							
	Renal Impairment							

Date:03/23/01ISR Number: 3709647-9Report Type:Periodic Company Report #WAES 01021265
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Fosamax	C				
			Pravachol	C				
			Teramine	C				
			Vasotec	C				

Date:03/23/01ISR Number: 3709648-0Report Type:Periodic Company Report #WAES 00091161
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

Date:03/23/01ISR Number: 3709649-2Report Type:Periodic Company Report #WAES 01021271
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS	Merck Research			
	Nausea	Professional			Laboratories Div			
	Palpitations	Company			Merck Co Inc	ORAL	25MG/DAILY/PO	
	Vomiting	Representative	Celexa	C				

Date:03/23/01ISR Number: 3709650-9Report Type:Periodic Company Report #WAES 00091173
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
		Other			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Atrovent	C				
			Flexeril	C				
			Flovent	C				
			Premarin	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709651-0Report Type:Periodic Company Report #WAES 00091323
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Headache Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Composition Unspecified)	C				
			Insulin	C				

Date:03/23/01ISR Number: 3709652-2Report Type:Periodic Company Report #WAES 01021278
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	

Date:03/23/01ISR Number: 3709653-4Report Type:Periodic Company Report #WAES 00091403
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abnormal Faeces Asthenia Constipation Fatigue Headache Hypoaesthesia Oedema Peripheral Pain Pain In Extremity Paraesthesia Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Weight Increased

Date:03/23/01ISR Number: 3709654-6Report Type:Periodic Company Report #WAES 00091749
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			(Composition Unspecified)	C				

Date:03/23/01ISR Number: 3709655-8Report Type:Periodic Company Report #WAES 00091762
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY/INJ	
			Darvocet-N	C				
			Imdur	C				

	Ticlid	C
	Amitriptyline	C
	Verapamil Hydrochloride	C

Date:03/23/01ISR Number: 3709656-XReport Type:Periodic Company Report #WAES 01021279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709657-1Report Type:Periodic Company Report #WAES 00090037
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709658-3Report Type:Periodic Company Report #WAES 01021281
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Premarin	C				
			Aspirin	C				
			Triamterene	C				

Date:03/23/01ISR Number: 3709659-5Report Type:Periodic Company Report #WAES 00090067
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Estrogen (Unspecified)	C				
			Morphine	C				

Date:03/23/01ISR Number: 3709660-1Report Type:Periodic Company Report #WAES 00090122
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709661-3Report Type:Periodic Company Report #WAES 01021284
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/PO	
	Rectal Haemorrhage							
			Veralan	C				
			Vitamin B (Unspecified)	C				
			Vitamin A	I				

Date:03/23/01ISR Number: 3709662-5Report Type:Periodic Company Report #WAES 00090137
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Aspartate Aminotransferase	Health Professional						
	Increased		Celebrex	C				
	Congenital Cystic Kidney Disease		Hytrin	C				
			Nasprosyn	C				
	Haematuria		Relafen	C				
	Insomnia		Aspirin	C				
	Oedema Genital		Cimetidine	C				
	Pain		Vitamins (Unspecified)	C				
	Penis Disorder							
	Proteinuria							
	Testicular Disorder							

Date:03/23/01ISR Number: 3709663-7Report Type:Periodic Company Report #WAES 00090274
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Dysphonia	Health Professional						
	Fatigue							

Hyperhidrosis
MG/DAILY/PO
Malaise Elavil C
Pharyngitis

Date:03/23/01ISR Number: 3709664-9Report Type:Periodic Company Report #WAES 01021288
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:03/23/01ISR Number: 3709665-0Report Type:Periodic Company Report #WAES 00090528
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709666-2Report Type:Periodic Company Report #WAES 00090662
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chloasma	Consumer	Vioxx	PS	Merck Research			
	Tongue Discolouration	Health			Laboratories Div			
	Tongue Oedema	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Alprazolam	C				
			Meclizine	C				

Date:03/23/01ISR Number: 3709668-6Report Type:Periodic Company Report #WAES 00090704
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Dysuria	Health			Laboratories Div			
	Renal Impairment	Professional			Merck Co Inc			

Date:03/23/01ISR Number: 3709669-8Report Type:Periodic Company Report #WAES 00090729
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research			
	Flushing	Health			Laboratories Div			
	Gastrooesophageal Reflux	Professional			Merck Co Inc	ORAL	PO	
	Disease		Librax Capsules	C				
	Hyperhidrosis		Lopressor	C				
	Menopausal Symptoms		Niferex Forte	C				
	Pruritus		Prilosec	C				
	Skin Disorder		Valium	C				
	Tongue Disorder		Zoloft	C				
	Weight Increased		Lyme Disease Vaccine	C				
			Vitamin B (Unspecified)	C				
			Vitamin E	C				
			Vitamins					

			(Uspecified)	C
			Prempro	C

Date:03/23/01ISR Number: 3709671-6Report Type:Periodic Company Report #WAES 00090735
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	International Normalised Ratio Increased							
	Platelet Count Decreased							
	Visual Disturbance		Coumadin	SS			7.5 MG/DAILY	
			Ambien	C				
			Tylenol	C				

Date:03/23/01ISR Number: 3709673-XReport Type:Periodic Company Report #WAES 01021294
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral							

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:03/23/01ISR Number: 3709674-1Report Type:Periodic Company Report #WAES 01021296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709675-3Report Type:Periodic Company Report #WAES 01021298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Clonopin	C				
			Plaquenil	C				
			Synthroid	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3709676-5Report Type:Periodic Company Report #WAES 01021318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Pain In Extremity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709677-7Report Type:Periodic Company Report #WAES 01021319
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/23/01ISR Number: 3709894-6Report Type:Periodic Company Report #WAES 00121013
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Ambien	C				
			Paxil	C				
			Percodan	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709896-XReport Type:Periodic Company Report #WAES 00121017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709897-1Report Type:Periodic Company Report #WAES 00121019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3709898-3Report Type:Periodic Company Report #WAES 00121020
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3709899-5Report Type:Periodic Company Report #WAES 00121022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709900-9Report Type:Periodic Company Report #WAES 00121024
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Headache Nasal Congestion Sedation Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709901-0Report Type:Periodic Company Report #WAES 00121034
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709902-2Report Type:Periodic Company Report #WAES 00121085
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chloasma Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Tylenol With Codeine #3	C				

Date:03/23/01ISR Number: 3709903-4Report Type:Periodic Company Report #WAES 00121103
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709904-6Report Type:Periodic Company Report #WAES 00121109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Systemic Lupus Erythematosus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/PO	

Date:03/23/01ISR Number: 3709905-8Report Type:Periodic Company Report #WAES 00121112
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timoptic	C				

Date:03/23/01ISR Number: 3709906-XReport Type:Periodic Company Report #WAES 00121113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:03/23/01ISR Number: 3709907-1Report Type:Periodic Company Report #WAES 00121117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Centrum	C				
			Hydrodiuril	C				
			Levoxyl	C				

			Xanax	C
			Calcium	C
			Glucosamine	C
			Ibuprofen	C

Date:03/23/01ISR Number: 3709909-5Report Type:Periodic Company Report #WAES 00121118
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge Eye Pain Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Mevacor	C				
			Trental	C				
			Tylenol	C				

Date:03/23/01ISR Number: 3709910-1Report Type:Periodic Company Report #WAES 00121124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Bilirubin Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709912-5Report Type:Periodic Company Report #WAES 00121126
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Flatulence Merck Co Inc ORAL
25 MG/BID/PO
Vitamins C

Date:03/23/01ISR Number: 3709914-9Report Type:Periodic Company Report #WAES 00121128
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:03/23/01ISR Number: 3709916-2Report Type:Periodic Company Report #WAES 00121138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	30 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709917-4Report Type:Periodic Company Report #WAES 00121139
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Eosinophil Count Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709919-8Report Type:Periodic Company Report #WAES 00121142
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709921-6Report Type:Periodic Company Report #WAES 00120614
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Creatinine Increased Blood Urea Increased	Consumer Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Dyazide	C				
			Trandate	C				
			Ultram	C				
			Valium	C				
			Zoloft	C				

Date:03/23/01ISR Number: 3709923-XReport Type:Periodic Company Report #WAES 00120618
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3709924-1Report Type:Periodic Company Report #WAES 00120622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Tongue Disorder Ulcer	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Nonsteroidal Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709927-7Report Type:Periodic Company Report #WAES 00120647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709930-7Report Type:Periodic Company Report #WAES 00120648
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709933-2Report Type:Periodic Company Report #WAES 00120650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709935-6Report Type:Periodic Company Report #WAES 00120651
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative	(Therapy Unspecified)	C		

Date:03/23/01ISR Number: 3709936-8Report Type:Periodic Company Report #WAES 00120677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3709938-1Report Type:Periodic Company Report #WAES 00120688
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysuria Haematuria Pollakiuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50						

MG/DAILY/PO

Date:03/23/01ISR Number: 3709939-3Report Type:Periodic Company Report #WAES 00120702
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709942-3Report Type:Periodic Company Report #WAES 00120710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diabeta	C				
			Furosemide	C				

Date:03/23/01ISR Number: 3709943-5Report Type:Periodic Company Report #WAES 00120714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Protonix	SS				

Date:03/23/01ISR Number: 3709944-7Report Type:Periodic Company Report #WAES 00120721
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research			

	Paraesthesia	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG / DAILY / PO						
			Toprol Xl	C		
			Zocor	C		
			Aspirin	C		

Date:03/23/01ISR Number: 3709945-9Report Type:Periodic Company Report #WAES 00120727
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/ PO						
			Lipitor	C		
			Atenolol	C		

Date:03/23/01ISR Number: 3709946-0Report Type:Periodic Company Report #WAES 00120732
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO
Zestril C

Date:03/23/01ISR Number: 3709947-2Report Type:Periodic Company Report #WAES 00120734
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/	
			Ortho-Novum	C				
			Antimicrobial	C				

Date:03/23/01ISR Number: 3709948-4Report Type:Periodic Company Report #WAES 00120738
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Norvasc	C				

Date:03/23/01ISR Number: 3709949-6Report Type:Periodic Company Report #WAES 00120743
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/	
			Valtrex	C				

			Zovirax	C		
			Doxycycline	C		

Date:03/23/01ISR Number: 3709950-2Report Type:Periodic Company Report #WAES 01011133
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Faeces Discoloured							
	Nausea							
			Alprazolam	C				

Date:03/23/01ISR Number: 3709951-4Report Type:Periodic Company Report #WAES 00120762
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrointestinal Disorder							
	Oedema							
			Fosamax	C				
			Methotrexate (Methotrexate Sodium)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709952-6Report Type:Periodic Company Report #WAES 01011142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709953-8Report Type:Periodic Company Report #WAES 00120765
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Hallucination Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

Date:03/23/01ISR Number: 3709954-XReport Type:Periodic Company Report #WAES 01011173
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan Hct	C				
			Paxil	C				
			Seroquel	C				
			Wellbutrin Sr	C				
			Diltiazem	C				

Date:03/23/01ISR Number: 3709955-1Report Type:Periodic Company Report #WAES 01011178
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Zantac	C				

Date:03/23/01ISR Number: 3709956-3Report Type:Periodic Company Report #WAES 01011196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709957-5Report Type:Periodic Company Report #WAES 01011199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness Postural Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Fosinopril 20 Mg	SS	
Tab Zocor 20 Mg	SS	
Hydrodiuril 12.5 Mg	SS	

Date:03/23/01ISR Number: 3709958-7Report Type:Periodic Company Report #WAES 01011207
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Proscar	C				
			Zocor	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709959-9Report Type:Periodic Company Report #WAES 01011208
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:03/23/01ISR Number: 3709960-5Report Type:Periodic Company Report #WAES 01011211
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Epakote	C
			Phenobarbital	C

Date:03/23/01ISR Number: 3709961-7Report Type:Periodic Company Report #WAES 01011212
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Equate	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3709965-4Report Type:Periodic Company Report #WAES 00120781
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Diarrhoea Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lescol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709967-8Report Type:Periodic Company Report #WAES 00120782
Age:51 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Climara	C				
			Levbid	C				
			[Therapy Unspecified]	C				
			Ranitidine Hydrochloride	C				

Date:03/23/01ISR Number: 3709970-8Report Type:Periodic Company Report #WAES 00120794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoarthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Celebrex	C				
			Naprosyn	C				

Date:03/23/01ISR Number: 3709974-5Report Type:Periodic Company Report #WAES 00120796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Diarrhoea Emotional Disorder Insomnia Mental Impairment Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Tinnitus

Date:03/23/01ISR Number: 3709975-7Report Type:Periodic Company Report #WAES 00120797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thyroid Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709976-9Report Type:Periodic Company Report #WAES 00120803
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol With Codeine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709977-0Report Type:Periodic Company Report #WAES 00120813
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
			Daypro	C				
			Macrodantin	C				
			Relafen	C				
			Amoxicillin	C				
			Nonsteroidal Anti Inflammatory	C				

Date:03/23/01ISR Number: 3709978-2Report Type:Periodic Company Report #WAES 00120821
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				
			Premarin	C				
			Tiazac	C				

Date:03/23/01ISR Number: 3709979-4Report Type:Periodic Company Report #WAES 00120826
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Muscular Weakness Nausea Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Composition					

Weight Increased Unspecified] C

Date:03/23/01ISR Number: 3709980-0Report Type:Periodic Company Report #WAES 00120828
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3709981-2Report Type:Periodic Company Report #WAES 01011242
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Enbrel	SS			25MG/2XW/INJ	
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3709982-4Report Type:Periodic Company Report #WAES 01011243
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3709983-6Report Type:Periodic Company Report #WAES 01011244
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Prevacid	C				
			...	C				
			Synthroid	C				
			Zantac	C				
			Lithium Carbonate	C				

Date:03/23/01ISR Number: 3709984-8Report Type:Periodic Company Report #WAES 01011279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3709987-3Report Type:Periodic Company Report #WAES 01011282
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710000-2Report Type:Periodic Company Report #WAES 01011288
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710002-6Report Type:Periodic Company Report #WAES 01011304
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	

PO

Date:03/23/01ISR Number: 3710003-8Report Type:Periodic Company Report #WAES 01011307
Age:84 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Ditropan	C				
			Fosamax	C				
			Macrodantin	C				
			[Therapy Unspecified]	C				
			Indapamide	C				

Date:03/23/01ISR Number: 3710004-XReport Type:Periodic Company Report #WAES 01011310
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
			Vioxx 25 Mg	SS		ORAL	25 MG DAILY	
			Enulose	C				
			Prilosec	C				
			Zoloft	C				
			Magnesia [Milk Of]	C				

Date:03/23/01ISR Number: 3710005-1Report Type:Periodic Company Report #WAES 01011321
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Timoptic	C				
			Xalatan	C				

Date:03/23/01ISR Number: 3710239-6Report Type:Periodic Company Report #WAES 00121468
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO							4	DAY
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710240-2Report Type:Periodic Company Report #WAES 00121469
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Blood Pressure Increased							
	Dyspnoea							
	Palpitations							
	Sensation Of Pressure		Betimol	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3710241-4Report Type:Periodic Company Report #WAES 00121470
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/PO	
	Dyspepsia							

Date:03/23/01ISR Number: 3710242-6Report Type:Periodic Company Report #WAES 00121471
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypertension							
			Cozaar	C				
			Pravachol	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3710243-8Report Type:Periodic Company Report #WAES 00121475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Synthroid	C				
			Tenormin	C				
			Zocor	C				

Date:03/23/01ISR Number: 3710244-XReport Type:Periodic Company Report #WAES 00121478
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Blood Pressure Increased							
	Dizziness							
	Oedema							
	Oedema Peripheral		Culpen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710245-1Report Type:Periodic Company Report #WAES 00121479
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Hypertension	Health						
	Weight Increased	Professional			Merck Co Inc	ORAL	SEE IMAGE /	
							PO	
			Vitamins	C				

Date:03/23/01ISR Number: 3710246-3Report Type:Periodic Company Report #WAES 00121481
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	50 MG/ DAILY/	
							PO	
			Celebrex	C				
			Naprosyn	C				

Date:03/23/01ISR Number: 3710247-5Report Type:Periodic Company Report #WAES 00121486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG/	
							DAILY/ PO	
			Buspar	C				
			Prinivil	C				
			Xanax	C				
			Aspirin	C				
			Glucosamine	C				

Date:03/23/01ISR Number: 3710248-7Report Type:Periodic Company Report #WAES 00121489
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3710249-9Report Type:Periodic Company Report #WAES 00122004
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Chills							
	Cough							
	Influenza Like Illness							
	Joint Swelling		Glucotrol	C				
	Nausea		Lipitor	C				
	Pain		Oxycontin	C				
	Rhinitis		Zestril	C				
	Sedation		[Therapy Unspecified]	C				

			Atenolol	C
			Chondroitin (+) Glucosamine	C

Date:03/23/01ISR Number: 3710250-5Report Type:Periodic Company Report #WAES 00122010
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium (Unspecified)	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3710251-7Report Type:Periodic Company Report #WAES 00122012
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hyzaar	C				

Date:03/23/01ISR Number: 3710252-9Report Type:Periodic Company Report #WAES 00122072
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Carafate	C				
			Digitek	C				

			Levsin	C		
			Norvasc	C		
			Folic Acid	C		

Date:03/23/01ISR Number: 3710253-0Report Type:Periodic Company Report #WAES 00122075
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Fosamax	C				
			Zocor	C				

Date:03/23/01ISR Number: 3710254-2Report Type:Periodic Company Report #WAES 00122076
Age:84 YR Gender:Male I/FU:I

Outcome	PT
	Abdominal Pain
	Dysgeusia

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY / PO	
	Sinemet	C				

Date:03/23/01ISR Number: 3710255-4Report Type:Periodic Company Report #WAES 00122088
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Diazide	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3710256-6Report Type:Periodic Company Report #WAES 00122090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Oedema Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3710257-8Report Type:Periodic Company Report #WAES 00122091
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norpace	C				
			Nadolol	C				

Date:03/23/01ISR Number: 3710258-XReport Type:Periodic Company Report #WAES 00122095
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Lasix	C				
			Penicillin (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710259-1Report Type:Periodic Company Report #WAES 00122097
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Hepatic Function Abnormal Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/23/01ISR Number: 3710260-8Report Type:Periodic Company Report #WAES 00122099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:03/23/01ISR Number: 3710261-XReport Type:Periodic Company Report #WAES 00122103
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3710262-1Report Type:Periodic Company Report #WAES 00122105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cozaar	C				
			Demadex	C				
			Levoxyl	C				
			Toprol Xl Tablets	C				
			Ultram	C				

Date:03/23/01ISR Number: 3710263-3Report Type:Periodic Company Report #WAES 00122115
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Bronchitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			[Therapy Unspecified]	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710264-5Report Type:Periodic Company Report #WAES 00122116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	

Date:03/23/01ISR Number: 3710265-7Report Type:Periodic Company Report #WAES 00122137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710266-9Report Type:Periodic Company Report #WAES 00122188
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucosamine 1 Dose	SS			1 DOSE/BID	
			Avandia	C				
			Synthroid	C				
			Zocor	C				
			Furosemide	C				

Date:03/23/01ISR Number: 3710267-0Report Type:Periodic Company Report #WAES 00122189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Plavix	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3710268-2Report Type:Periodic Company Report #WAES 01020984
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	

Date:03/23/01ISR Number: 3710269-4Report Type:Periodic Company Report #WAES 01020986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3710270-0Report Type:Periodic Company Report #WAES 01020998
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cellulitis							
			Cipro	C				
			Aspirin	C				
			Oxybutynin Chloride	C				

Date:03/23/01ISR Number: 3710271-2Report Type:Periodic Company Report #WAES 01021023
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710272-4Report Type:Periodic Company Report #WAES 01021036
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 WK
	Dermatitis							
	Tinea Pedis							
	Urticaria							
			Caltrate 600	C				
			Norvasc	C				
			Relafen	C				
			Toprol Xl Tablets	C				

			Tylenol	C		
			Vitamin E	C		

Date:03/23/01ISR Number: 3710273-6Report Type:Periodic Company Report #WAES 01021057
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Chest Pain							
	Influenza Like Illness							
	Laryngitis		Neuroton	C				

Date:03/23/01ISR Number: 3710274-8Report Type:Periodic Company Report #WAES 01021058
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Pruritus							
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710275-XReport Type:Periodic Company Report #WAES 01021066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix	C				
			Pravachol	C				
			Prilosec	C				
			Restoril	C				
			Tiazac	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Digoxin	C				
			Insulin	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3710276-1Report Type:Periodic Company Report #WAES 01021067
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Duodenal Ulcer Fatigue Haemoglobin Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO/SEE IMAGE	
			Hyzaar	C				
			Norvasc	C				
			Premarin	C				
			Prozac	C				
			Blinded Therapy	C				

Date:03/23/01ISR Number: 3710277-3Report Type:Periodic Company Report #WAES 01021070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710278-5Report Type:Periodic Company Report #WAES 01020277
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Synthroid	C				
			Zocor	C				
			Atenolol	C				
			Chlorthalidone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710279-7Report Type:Periodic Company Report #WAES 01020292
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx	SS		ORAL	PO	
			Tab Vioxx 50 Mg	SS		ORAL	PO	

Date:03/23/01ISR Number: 3710280-3Report Type:Periodic Company Report #WAES 01020297
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Blood Pressure Increased Epistaxis Fibromyalgia Oedema Peripheral Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710281-5Report Type:Periodic Company Report #WAES 01020305
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Triphasil	C				

Date:03/23/01ISR Number: 3710282-7Report Type:Periodic Company Report #WAES 01020314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710283-9Report Type:Periodic Company Report #WAES 01020315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
			Vitamins	C				

Date:03/23/01ISR Number: 3710284-0Report Type:Periodic Company Report #WAES 01020321
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIL/PO	
	Feeling Abnormal		Altace	C				

Ativan	C
Centrum	C
Lasix	C
Norvasc	C
Synthroid	C
Aspirin	C

Date:03/23/01ISR Number: 3710285-2Report Type:Periodic Company Report #WAES 01020329
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710286-4Report Type:Periodic Company Report #WAES 01020333
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Avalide	C				
			Hytrin	C				
			Phenergan	C				
			Valium	C				

Date:03/23/01ISR Number: 3710287-6Report Type:Periodic Company Report #WAES 01020345
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Dysphagia	Other	Vioxx	PS	Merck Research Laboratories Div			

	Gastrooesophageal Reflux				Merck Co Inc	ORAL
50						
	Disease					
MG/DAILY/PO						

Date:03/23/01ISR Number: 3710288-8Report Type:Periodic Company Report #WAES 01020451
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bronchospasm	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Diovan	C		
			Lipitor	C		

Date:03/23/01ISR Number: 3710289-XReport Type:Periodic Company Report #WAES 01020452
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710290-6Report Type:Periodic Company Report #WAES 01020454
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Weight Increased							
			Cozaar	C				
			Dyazide	C				

Date:03/23/01ISR Number: 3710291-8Report Type:Periodic Company Report #WAES 01020455
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
	Flushing							
			Cantan	C				
			Hydrodiuril	C				
			Paxil	C				
			Permax	C				
			Seroquel	C				
			Sinemet	C				
			Sinemet Cr	C				
			Ranitidine	C				

Date:03/23/01ISR Number: 3710292-XReport Type:Periodic Company Report #WAES 01020457
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emphysema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2	
	Oedema Peripheral							

5MG/DAILY/PO

Atrovent	C	
Albuterol	C	
Furosemide	C	
Potassium Chloride	C	

Date:03/23/01ISR Number: 3710293-1Report Type:Periodic Company Report #WAES 01020496
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	1 WK
			Cozaar	C				
			Floridin	C				
			Lanoxin	C				
			Miacalcin	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710294-3Report Type:Periodic Company Report #WAES 01020507
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Naproxen	C				

Date:03/23/01ISR Number: 3710295-5Report Type:Periodic Company Report #WAES 01020508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710296-7Report Type:Periodic Company Report #WAES 01020511
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Drug Ineffective Fatigue Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710297-9Report Type:Periodic Company Report #WAES 01020518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Pruritus Female Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Pruritus Ani				Merck Co Inc	ORAL
25 MG/PO						
	Rash Erythematous		Prevacid	C		
			Protegra	C		
			Synthroid	C		
			Tenormin	C		
			Therapy Unspecified	C		

Date:03/23/01ISR Number: 3710298-0Report Type:Periodic Company Report #WAES 01020522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3710299-2Report Type:Periodic Company Report #WAES 01020525
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral Pain In Extremity Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Darvocet-N	C		

			Lipitor	C		
			Codeine	C		

Date:03/23/01ISR Number: 3710300-6Report Type:Periodic Company Report #WAES 01020527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:03/23/01ISR Number: 3710301-8Report Type:Periodic Company Report #WAES 01020531
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Herbal Remedies (Unspecified)	C				

Date:03/23/01ISR Number: 3710302-XReport Type:Periodic Company Report #WAES 01020539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Depakote	C				
			Dilantin	C				

Date:03/23/01ISR Number: 3710303-1Report Type:Periodic Company Report #WAES 01020544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710304-3Report Type:Periodic Company Report #WAES 01020546
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Disorientation							
	Dyspepsia							
	Feeling Abnormal							
	Flatulence		Ativan	C				
	Movement Disorder		Wellbutrin	C				
	Nausea							
	Urine Abnormality							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710305-5Report Type:Periodic Company Report #WAES 01020551
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:03/23/01ISR Number: 3710306-7Report Type:Periodic Company Report #WAES 01020552
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Arthralgia Dyspepsia Joint Stiffness Joint Swelling Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710307-9Report Type:Periodic Company Report #WAES 01020557
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Soma	C				
			Vicodin Tablets	C				

Date:03/23/01ISR Number: 3710308-0Report Type:Periodic Company Report #WAES 01020561
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Premarin	C		
Zantac	C		

Date:03/23/01ISR Number: 3710309-2Report Type:Periodic Company Report #WAES 01020567
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Chest Pain Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

Tylenol With Codeine	C		

Date:03/23/01ISR Number: 3710310-9Report Type:Periodic Company Report #WAES 01020576
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3710311-0Report Type:Periodic Company Report #WAES 01020600
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dyspepsia Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Flovent	C		
			K-Dur	C		
			Nasonex	C		
			Plavix	C		
			Prilosec	C		
			Albuterol	C		
			Indapamide	C		

Date:03/23/01ISR Number: 3710312-2Report Type:Periodic Company Report #WAES 01020604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3710313-4Report Type:Periodic Company Report #WAES 01020616
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus		Coumadin	C				
			Flexeril	C				
			Paxil	C				

Date:03/23/01ISR Number: 3710314-6Report Type:Periodic Company Report #WAES 01020618
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Pletal	C				
			Aspirin	C				
			Metoprolol Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710315-8Report Type:Periodic Company Report #WAES 01020619
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Datril	C				
			Evista	C				

Date:03/23/01ISR Number: 3710316-XReport Type:Periodic Company Report #WAES 01020620
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710317-1Report Type:Periodic Company Report #WAES 01020625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3710318-3Report Type:Periodic Company Report #WAES 01020627
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3710319-5Report Type:Periodic Company Report #WAES 01020629
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Faeces Discoloured	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710320-1Report Type:Periodic Company Report #WAES 01020632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder Flatulence Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Dynacin	C				
			Levoxyl	C				
			Lipitor	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710321-3Report Type:Periodic Company Report #WAES 01020633
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Toprol Xl Tablets	C				
			Vasotec	C				

Date:03/23/01ISR Number: 3710322-5Report Type:Periodic Company Report #WAES 01020636
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal Dehydration Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Haemorrhage		Flonase	C				
	Headache		Flovent	C				
	Pollakiuria		Serevent	C				
	Pyrexia		Zanaflex	C				
			[Therapy Unspecified]	C				
			Albuterol	C				
			Amitriptyline	C				
			Diazepam	C				
			Methadone Hydrochloride	C				

Date:03/23/01ISR Number: 3710323-7Report Type:Periodic Company Report #WAES 01020637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Fluid Retention	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO
Atacand C

Date:03/23/01ISR Number: 3710324-9Report Type:Periodic Company Report #WAES 01020647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Pyrexia Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710325-0Report Type:Periodic Company Report #WAES 01020654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Duragesic	C				

				Prosom	C		

Date:03/23/01ISR Number: 3710326-2Report Type:Periodic Company Report #WAES 01020660
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Centrum Silver	C				
			Vasotec	C				
			Amidarone	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3710327-4Report Type:Periodic Company Report #WAES 01020667
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tegretol	C				
			Versene	C				
			Acetaminophen	C				

Date:03/23/01ISR Number: 3710358-4Report Type:Periodic Company Report #WAES 01010117
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / PO	
	Feeling Abnormal Influenza Like Illness		Prinivil	C				
			Prinzide	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3710359-6Report Type:Periodic Company Report #WAES 01010118
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/	PO
			Prilosec	C				
			Reglan	C				

Date:03/23/01ISR Number: 3710360-2Report Type:Periodic Company Report #WAES 01010121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Tenderness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Lanoxin	C				

		Lipitor	C
		Monopril	C
		Toprol Xl	C
		Glyburide	C

Date:03/23/01ISR Number: 3710361-4Report Type:Periodic Company Report #WAES 01010126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PRN/ PO	
			Evista	C				
			Maxzide	C				
			Toprol Xl	C				
			Vasotec	C				

Date:03/23/01ISR Number: 3710362-6Report Type:Periodic Company Report #WAES 01010127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Constipation Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO	
	Pigmentation Disorder Retching		Acetaminophen (+) Hydrocodone	C				
			Diazepam	C				

Date:03/23/01ISR Number: 3710363-8Report Type:Periodic Company Report #WAES 01010128
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Flushing				Merck Co Inc	ORAL
SEE IMAGE						
	Tinnitus					

Date:03/23/01ISR Number: 3710364-XReport Type:Periodic Company Report #WAES 01010130
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PRN/ PO						
			Accupril	C		
			Aspirin	C		

Date:03/23/01ISR Number: 3710365-1Report Type:Periodic Company Report #WAES 01010132
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Distension
	Diarrhoea
	Disturbance In Attention
	Dizziness

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ QID/ PO	3 DAY

Date:03/23/01ISR Number: 3710366-3Report Type:Periodic Company Report #WAES 01010135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dry Throat	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
			Zantac	C				
			Ziac	C				
			Hormones (Unspecified)	C				

Date:03/23/01ISR Number: 3710367-5Report Type:Periodic Company Report #WAES 01010145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/PO	2 DAY

Date:03/23/01ISR Number: 3710368-7Report Type:Periodic Company Report #WAES 00112107
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	75 MG DAILY	PO
			Evista	C				
			Glucophage	C				
			Ultram	C				
			Cephalexin	C				
			Glyburide	C				
			Pentoxifylline	C				
			Quinine Sulfate	C				

Date:03/23/01ISR Number: 3710369-9Report Type:Periodic Company Report #WAES 00112112
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Facial Pain Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vioxx	SS		ORAL	50 MG PO	
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710370-5Report Type:Periodic Company Report #WAES 00112114
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Ear Disorder							
			Corgard	C				
			Detrol	C				
			Lipitor	C				
			Permax	C				
			Doxepin	C				

Date:03/23/01ISR Number: 3710373-0Report Type:Periodic Company Report #WAES 00112115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN PO	
	Back Pain							
			Alprazolam	C				

Date:03/23/01ISR Number: 3710375-4Report Type:Periodic Company Report #WAES 00112117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Ulcerative	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PO	
	Malaise							
	Rectal Haemorrhage							
			Azulfidine	C				

Date:03/23/01ISR Number: 3710377-8Report Type:Periodic Company Report #WAES 00112120
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3710379-1Report Type:Periodic Company Report #WAES 00112125
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:03/23/01ISR Number: 3710382-1Report Type:Periodic Company Report #WAES 00112126
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Cozaar	C
			Norvasc	C
			Atenolol	C

Date:03/23/01ISR Number: 3710386-9Report Type:Periodic Company Report #WAES 00112128
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3710407-3Report Type:Periodic Company Report #WAES 00120977
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Musculoskeletal Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Glucophage	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3710408-5Report Type:Periodic Company Report #WAES 00120982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID,	10 MON
			Tab Vioxx 50 Mg	SS		ORAL	PO	2 MON

Diovan	C
Zoloft	C
Hormones	C

Date:03/23/01ISR Number: 3710409-7Report Type:Periodic Company Report #WAES 00121434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710410-3Report Type:Periodic Company Report #WAES 00120985
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710411-5Report Type:Periodic Company Report #WAES 00120986
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG PRN	PO
			Darvocet-N	C				

Date:03/23/01ISR Number: 3710412-7Report Type:Periodic Company Report #WAES 00120990
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Mouth Ulceration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3710413-9Report Type:Periodic Company Report #WAES 00121439
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Haematochezia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710414-0Report Type:Periodic Company Report #WAES 00120991
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	
			Desyrel	C				
			Dilaudid	C				
			Zoloft	C				
			Gastrointestinal Preparations	C				

Date:03/23/01ISR Number: 3710415-2Report Type:Periodic Company Report #WAES 00120993
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Flonase	C				
			Lipitor	C				
			Tenormin	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710416-4Report Type:Periodic Company Report #WAES 00121000
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Lipitor	C			PO, 25 MG 2XW	
			Propanolol	C			PO	
			Vitamins	C				

Date:03/23/01ISR Number: 3710417-6Report Type:Periodic Company Report #WAES 00121005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO,	
			Synthroid	C			25 MG DAILY	
							PO	

Date:03/23/01ISR Number: 3710418-8Report Type:Periodic Company Report #WAES 00121006
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
							PO	

Date:03/23/01ISR Number: 3710419-XReport Type:Periodic Company Report #WAES 00121440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710420-6Report Type:Periodic Company Report #WAES 01011088
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:03/23/01ISR Number: 3710421-8Report Type:Periodic Company Report #WAES 00121443
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Haematuria	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710422-XReport Type:Periodic Company Report #WAES 01011091
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pain Scar	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Skin Lesion						PO	

Date:03/23/01ISR Number: 3710423-1Report Type:Periodic Company Report #WAES 01011095
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspnoea Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Fatigue						PO	

Date:03/23/01ISR Number: 3710424-3Report Type:Periodic Company Report #WAES 01011100
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Accupril	C	
Humulin 70/30	C	
Toprol Xl Tablets	C	
Xalatan	C	
Aspirin	C	

Date:03/23/01ISR Number: 3710425-5Report Type:Periodic Company Report #WAES 01011102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Cholestin	C	
Estratest	C	
Medroxyprogesterone	C	

Date:03/23/01ISR Number: 3710426-7Report Type:Periodic Company Report #WAES 01011104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3710427-9Report Type:Periodic Company Report #WAES 01011109
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 4 WK

Date:03/23/01ISR Number: 3710428-0Report Type:Periodic Company Report #WAES 01011110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Chandroitin	C				
			Glucosamine	C				

Date:03/23/01ISR Number: 3710430-9Report Type:Periodic Company Report #WAES 01011119
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Cozaar	C				
			Norvasc	C				
			Zocor	C				

Date:03/23/01ISR Number: 3710431-0Report Type:Periodic Company Report #WAES 01011131
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG PO	
	Herpes Simplex							
			Premarin	C				
			Atenolol	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3710432-2Report Type:Periodic Company Report #WAES 00121445
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Sweat Gland Disorder							
			Cozaar	C				
			Hydrochloride (+)					
			Triameter	C				
			Oxybutynin Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710433-4Report Type:Periodic Company Report #WAES 00121446
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diltiazem	C				

Date:03/23/01ISR Number: 3710434-6Report Type:Periodic Company Report #WAES 00121448
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Dyspepsia Flatulence Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Climara	C				
			Valium	C				

Date:03/23/01ISR Number: 3710435-8Report Type:Periodic Company Report #WAES 00121453
Age:41 MON Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syphilis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710436-XReport Type:Periodic Company Report #WAES 00121457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage Vision Blurred	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710437-1Report Type:Periodic Company Report #WAES 00121465
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710438-3Report Type:Periodic Company Report #WAES 00111804
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Diarrhoea Feeling Abnormal Flatulence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO (SEE IMAGE)	
	Nausea		Celebrex	C				

Micronor	C
Monopril	C
Nasacort Aq	C
Premarin	C
Prilosec	C
Serzone	C
Synthroid	C
Spironolactone	C

Date:03/23/01ISR Number: 3710439-5Report Type:Periodic Company Report #WAES 00111811
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Candidiasis Glossodynia Pharyngitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
	Pulmonary Congestion		Acular	C				

Date:03/23/01ISR Number: 3710440-1Report Type:Periodic Company Report #WAES 00112006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Drug Ineffective Swelling	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Celebrex	SS			200 MG/BID	

Date:03/23/01ISR Number: 3710441-3Report Type:Periodic Company Report #WAES 01011001
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Date:03/23/01ISR Number: 3710442-5Report Type:Periodic Company Report #WAES 01011005
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Hallucination							
	Headache							
	Insomnia							
			Lescol	C			PO	
			Synthroid	C				
			Tylenol	C				
			Aspirin	C				
			Bumetanide	C				
			Metoprolol	C				
			Potassium	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710443-7Report Type:Periodic Company Report #WAES 00112340
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Zocor	C				

Date:03/23/01ISR Number: 3710444-9Report Type:Periodic Company Report #WAES 01011009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Neck Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710445-0Report Type:Periodic Company Report #WAES 01011012
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:03/23/01ISR Number: 3710446-2Report Type:Periodic Company Report #WAES 01011015
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Catapres	C		
			Cozaar	C		
			Atenolol	C		
			Furosemide	C		
			Potassium	C		

Date:03/23/01ISR Number: 3710447-4Report Type:Periodic Company Report #WAES 99070142
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia Angina Pectoris Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Daypro	C		
			Miacalcin	C		
			Premarin	C		
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710448-6Report Type:Periodic Company Report #WAES 01011022
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO
			Amoxi	C				

Date:03/23/01ISR Number: 3710449-8Report Type:Periodic Company Report #WAES 01011048
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Dry Skin Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							

Date:03/23/01ISR Number: 3710450-4Report Type:Periodic Company Report #WAES 99120583
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastrooesophageal Reflux Disease Oesophageal Pain		Inderal	C				
			Naprosyn	C				
			Prilosec	C				
			Synthroid	C				
			Morphine	C				

Date:03/23/01ISR Number: 3710451-6Report Type:Periodic Company Report #WAES 01011083
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Purpura	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710452-8Report Type:Periodic Company Report #WAES 99120753
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Promethazine W/Dm	C				
			Relafen	C				
			Talwin	C				
			Ultran	C				
			Zanaflex	C				
			(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710453-XReport Type:Periodic Company Report #WAES 01011086
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Synthroid	C				

Date:03/23/01ISR Number: 3710454-1Report Type:Periodic Company Report #WAES 01011087
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Oxycontin	C				
			Wellbutrin	C				

Date:03/23/01ISR Number: 3710455-3Report Type:Periodic Company Report #WAES 01010953
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Proteinuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710456-5Report Type:Periodic Company Report #WAES 01010955
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mesenteric Vascular Insufficiency	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710457-7Report Type:Periodic Company Report #WAES 99121526
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO (SEE IMAGE)	
	Asthenia							
	Diarrhoea							
	Dyspepsia							
	Fatigue							
	Feeling Abnormal		Norvasc	C				
			Tagamet	C				
			Xanax	C				
			Nortriptyline	C				

Date:03/23/01ISR Number: 3710458-9Report Type:Periodic Company Report #WAES 01010959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased Dyspnoea Gastrointestinal Disorder Headache Muscle Spasms Nausea Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710459-0Report Type:Periodic Company Report #WAES 01010971
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tenosynovitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO/SEE IMAGE	
			Nosteroidal Anti-Inflammatory	C				

Date:03/23/01ISR Number: 3710460-7Report Type:Periodic Company Report #WAES 01010977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Health Professional Company Representative	Vioxx	PS	Skyepharma Inc		50 MG DAILY PO	2 MON

Date:03/23/01ISR Number: 3710461-9Report Type:Periodic Company Report #WAES 01010978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710463-2Report Type:Periodic Company Report #WAES 01010979
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasal Congestion Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3710465-6Report Type:Periodic Company Report #WAES 01010980
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG/PO
Synthroid C

Date:03/23/01ISR Number: 3710466-8Report Type:Periodic Company Report #WAES 01010981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO/SEE IMAGE	
			Cozaar	C				

Date:03/23/01ISR Number: 3710467-XReport Type:Periodic Company Report #WAES 01010989
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3710470-XReport Type:Periodic Company Report #WAES 01021380
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Hydrea	C		
Synthroid	C		
Therapy Unspecified	C		
Cyanocobalamin	C		
Folic Acid	C		

Date:03/23/01ISR Number: 3710471-1Report Type:Periodic Company Report #WAES 01021383
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	1 WK

Date:03/23/01ISR Number: 3710472-3Report Type:Periodic Company Report #WAES 01021387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	3 DAY
			Premarin	C				
			Compositiopn Unspecified	C				

Date:03/23/01ISR Number: 3710473-5Report Type:Periodic Company Report #WAES 01021389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Cardura	C				
			Lescol	C				
			Vaseretic	C				
			Zoloft	C				
			Zyrtec	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3710474-7Report Type:Periodic Company Report #WAES 01021401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Cozaar	C				
			Clucophage	C				
			Prempro	C				

Date:03/23/01ISR Number: 3710475-9Report Type:Periodic Company Report #WAES 01021404
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Allegra	C				

			Ambien	C		
			Celebrex	C		
			Flexeril	C		
			Premarin	C		
			Provera	C		
			Tagamet	C		
			Talwin	C		
			Therapy Unspecified	C		
			Codeine (+)			
			Salicylic Acid	C		

Date:03/23/01ISR Number: 3710476-0Report Type:Periodic Company Report #WAES 01021405
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Allegra	C		
			Xanax	C		
			Calcium (Unspecified)	C		
			Estrogens (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710477-2Report Type:Periodic Company Report #WAES 01021406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710478-4Report Type:Periodic Company Report #WAES 01021412
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Prevacid	C				
			Univasc	C				
			Zocor	C				
			Metoprolol	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3710479-6Report Type:Periodic Company Report #WAES 01021419
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710480-2Report Type:Periodic Company Report #WAES 00122266
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3710481-4Report Type:Periodic Company Report #WAES 00122271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3710482-6Report Type:Periodic Company Report #WAES 00122282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710483-8Report Type:Periodic Company Report #WAES 00122285
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/	
PO								
			Ecotrin	C				
			Norvasc	C				
			Toprol Xl	C				
			Allopurinol	C				
			Ascorbic Acid	C				
			Vitamin B Complex	C				

Date:03/23/01ISR Number: 3710484-XReport Type:Periodic Company Report #WAES 01010002
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Dysphagia Rash Erythematous	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
PO								
			Atacand	C				
			Lopressor	C				

Date:03/23/01ISR Number: 3710485-1Report Type:Periodic Company Report #WAES 01010005
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis Sicca Lacrimation Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
PO								

			Labetalol	C		

Date:03/23/01ISR Number: 3710486-3Report Type:Periodic Company Report #WAES 01010006
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:03/23/01ISR Number: 3710487-5Report Type:Periodic Company Report #WAES 01010007
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Zocor	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3710489-9Report Type:Periodic Company Report #WAES 01010010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ BID/	PO
			Lasix	C				
			Prozac	C				
			Zoloft	C				
			Glucosamine	C				
			Lisinopril	C				
			Morphine Sulfate	C				

Date:03/23/01ISR Number: 3710490-5Report Type:Periodic Company Report #WAES 01010012
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Premarin	C				

Date:03/23/01ISR Number: 3711227-6Report Type:Periodic Company Report #WAES 00091853
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Dermatitis Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Erythema		Allegra	C				
	Pharyngitis		Lipitor	C				
			Prilosec	C				

Date:03/23/01ISR Number: 3711229-XReport Type:Periodic Company Report #WAES 00091881
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Osteoarthritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Zestril	C				
			Metoprolol	C				

Date:03/23/01ISR Number: 3711230-6Report Type:Periodic Company Report #WAES 00092020
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Bicillin	C				
			Entex Pse	C				
			Flexeril	C				
			Inderal	C				
			Lithobid	C				

			Phenergan (Promethazine Hydrochl	C		
			Premarin	C		
			Prilosec	C		
			Prozac	C		
			Seroquel	C		
			Synthroid	C		
			Wygesic Tablets	C		
			Xanax	C		
			Aspirin	C		

Date:03/23/01ISR Number: 3711232-XReport Type:Periodic Company Report #WAES 00092022
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Pravachol	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				
			Meclizine	C				

Date:03/23/01ISR Number: 3711233-1Report Type:Periodic Company Report #WAES 00092060
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/BID/PO/S	
EE IMAGE								
			Hydrodiuril	C				
			Prempro	C				
			Prevacid	C				

Date:03/23/01ISR Number: 3711239-2Report Type:Periodic Company Report #WAES 00092245
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711240-9Report Type:Periodic Company Report #WAES 00092267
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711241-0Report Type:Periodic Company Report #WAES 00092283
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Pharyngitis							
			Ambien	C				
			Diasulfon	C				
			Carisoprodol	C				

Date:03/23/01ISR Number: 3711243-4Report Type:Periodic Company Report #WAES 00092450
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Lipitor	C				
			Neuronitin	C				
			Premarin	C				

Date:03/23/01ISR Number: 3711245-8Report Type:Periodic Company Report #WAES 00092470
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Glucosamine	C				

Date:03/23/01ISR Number: 3711249-5Report Type:Periodic Company Report #WAES 01010013
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Prempro	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3711251-3Report Type:Periodic Company Report #WAES 01010014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	
			Dilantin	C				
			Enterfram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711252-5Report Type:Periodic Company Report #WAES 01010020
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3711256-2Report Type:Periodic Company Report #WAES 01010024
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lanoxin	C				
			Therapy Unspecified	C				
			Calcium (Unspecified)	C				
			Verapamil	C				
			Vitamin D (Unspecified)	C				

Date:03/23/01ISR Number: 3711258-6Report Type:Periodic Company Report #WAES 01010052
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711260-4Report Type:Periodic Company Report #WAES 01010060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711262-8Report Type:Periodic Company Report #WAES 01010062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711263-XReport Type:Periodic Company Report #WAES 01010064
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Hepatic Function Abnormal							
			Nonsteroidal Anti-Inflammatory	C				

Date:03/23/01ISR Number: 3711265-3Report Type:Periodic Company Report #WAES 01010066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	AM/PO	
			Tylenol Arthritis Extended Relie	C				

Date:03/23/01ISR Number: 3711266-5Report Type:Periodic Company Report #WAES 01010070
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Celexa	C				
			Depakote	C				
			Premarin	C				
			Seroquel	C				
			Alprazolam	C				

Date:03/23/01ISR Number: 3711271-9Report Type:Periodic Company Report #WAES 01010075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	PO		

Date:03/23/01ISR Number: 3711273-2Report Type:Periodic Company Report #WAES 01010077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711274-4Report Type:Periodic Company Report #WAES 01010081
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Mevacor	C		
			Prinivil	C		
			Synthroid	C		

Date:03/23/01ISR Number: 3711276-8Report Type:Periodic Company Report #WAES 01010086
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctivitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Eye Irritation							
	Skin Disorder							
	Vision Blurred		Buspar	C				

Date:03/23/01ISR Number: 3711277-XReport Type:Periodic Company Report #WAES 01010092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain In Extremity							
			Prevacid	C				
			Tenormin	C				

Date:03/23/01ISR Number: 3711279-3Report Type:Periodic Company Report #WAES 01010096
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711280-XReport Type:Periodic Company Report #WAES 01010097
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:03/23/01ISR Number: 3711282-3Report Type:Periodic Company Report #WAES 01010099
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Hydrodiuril	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711283-5Report Type:Periodic Company Report #WAES 01010104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Aspirin	C				
			Diltiazam	C				

Date:03/23/01ISR Number: 3711285-9Report Type:Periodic Company Report #WAES 01010115
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711289-6Report Type:Periodic Company Report #WAES 00101511
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Pollakiuria Sedation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Baycol	C				
			Dilantin	C				
			Zestril	C				
			Glipizide	C				

Date:03/23/01ISR Number: 3711293-8Report Type:Periodic Company Report #WAES 00101708
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Levoxyl	C				
			Lipitor	C				
			Lotrel	C				
			Nasocort	C				
			Prempro	C				
			Aspirin	C				
			Calcium	C				
			Pyridoxine	C				

Date:03/23/01ISR Number: 3711295-1Report Type:Periodic Company Report #WAES 00101709
Age:42 YR Gender:Male I/FU:F

Outcome	PT
	Chest Pain
	Flushing
	Gastrointestinal Disorder

		Hyperhidrosis					
		Nausea					
		Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Weight Increased					
25 MG/PO							
				Elavil	C		
				Cyclobenzaprine Hydrochloride	C		
				Gabapentin	C		
				Tramadol Hydrochloride	C		

Date:03/23/01ISR Number: 3711296-3Report Type:Periodic Company Report #WAES 00101714
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Nausea					
		Pruritus					
25 MG/DAILY/PO							
				Fer-Sul	C		
				Levaquin	C		
				Ultram	C		

Date:03/23/01ISR Number: 3711298-7Report Type:Periodic Company Report #WAES 00101752
Age:81 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ecchymosis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:03/23/01ISR Number: 3711299-9Report Type:Periodic Company Report #WAES 00101919
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Dyazide	C				
			Lipitor	C				

Date:03/23/01ISR Number: 3711301-4Report Type:Periodic Company Report #WAES 00101930
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Upper Respiratory Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711303-8Report Type:Periodic Company Report #WAES 00102049
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research			
	Face Oedema	Health			Laboratories Div			
	Herpes Simplex	Professional			Merck Co Inc	ORAL	25	
	Influenza Like Illness						MG/DAILY/PO	
	Oedema Peripheral		Ativan	C				
	Rhinorrhoea		Lozol	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3711304-XReport Type:Periodic Company Report #WAES 00102060
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
	Myalgia	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/DAILY/	
							PO	
			Ecotrin	C				
			Tenoretic	C				
			Trental	C				

Date:03/23/01ISR Number: 3711305-1Report Type:Periodic Company Report #WAES 00102063
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Faecal Occult Blood				Laboratories Div			
	Fatigue				Merck Co Inc	ORAL	PO	
	Feeling Cold		Ambien	C				
			Premarin	C				
			Prilosec	C				
			Proventil	C				

Date:03/23/01ISR Number: 3711306-3Report Type:Periodic Company Report #WAES 01021330
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3711307-5Report Type:Periodic Company Report #WAES 01021359
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Tricor	C				
			Atenolol	C				
			Calcium	C				
			Tamoxifen	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3711308-7Report Type:Periodic Company Report #WAES 01021360
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:03/23/01ISR Number: 3711309-9Report Type:Periodic Company Report #WAES 01021369
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tamoxifen	SS				
			Potassium (Unspecified)	SS				
			Hctz/Triamterene	SS				

Date:03/23/01ISR Number: 3711310-5Report Type:Periodic Company Report #WAES 01021377
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Potassium	C				

Date:03/23/01ISR Number: 3712002-9Report Type:Periodic Company Report #WAES 00120125
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arthrotec	C				
			Zestril	C				
			Therapy Unspecified	C				
			Diuretic	C				

Date:03/23/01ISR Number: 3712004-2Report Type:Periodic Company Report #WAES 00120131
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Flovent	C				
			Inotropin	C				
			Lasix	C				

Prilosec	C
Serevent	C
Synthroid	C
Therapy Unspecified	C
Albuterol	C

Date:03/23/01ISR Number: 3712005-4Report Type:Periodic Company Report #WAES 00120134
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712007-8Report Type:Periodic Company Report #WAES 00120144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK

Astelin	C
Detrol	C
Flovent	C
Nasonex	C
Prilosec	C
Prozac	C
Serevent	C

Date:03/23/01ISR Number: 3712008-XReport Type:Periodic Company Report #WAES 00120146
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research			

	Feeling Abnormal				Laboratories Div	
	Vomiting				Merck Co Inc	ORAL
PO						
			Prilosec	C		

Date:03/23/01ISR Number: 3712009-1Report Type:Periodic Company Report #WAES 00120157
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50						
MG/DAILY/PO						
			Hytrin	C		
			K-Dur	C		
			Xalatan	C		
			Indapamide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712011-XReport Type:Periodic Company Report #WAES 00120167
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3712012-1Report Type:Periodic Company Report #WAES 00120170
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712013-3Report Type:Periodic Company Report #WAES 00120168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712014-5Report Type:Periodic Company Report #WAES 00120171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712016-9Report Type:Periodic Company Report #WAES 00112318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712017-0Report Type:Periodic Company Report #WAES 00112319
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712018-2Report Type:Periodic Company Report #WAES 00112320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712019-4Report Type:Periodic Company Report #WAES 00112326
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Ecchymosis							
	Weight Increased							
			Cosoft	C				
			Hyerocodone/Apap	C				
			Skelaxin	C				
			Xanax	C				
			Nitrofurantoin	C				
			Nystatin	C				

Date:03/23/01ISR Number: 3712020-0Report Type:Periodic Company Report #WAES 00112328
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Noscapal	C				
			Prempro	C				
			Protonix	C				
			Serevent	C				
			Zocor	C				

Date:03/23/01ISR Number: 3712021-2Report Type:Periodic Company Report #WAES 00112335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3712022-4Report Type:Periodic Company Report #WAES 00112345
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Amaryl	C				
			Pravachol	C				
			Toprol Xl	C				
			Vaseretic	C				

Date:03/23/01ISR Number: 3712024-8Report Type:Periodic Company Report #WAES 00112357
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712026-1Report Type:Periodic Company Report #WAES 00112365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Maculopathy	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Corticosteroids	C				

Date:03/23/01ISR Number: 3712027-3Report Type:Periodic Company Report #WAES 00112368
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotensin	C				
			Atenolol	C				
			Diuretic	C				

Date:03/23/01ISR Number: 3712028-5Report Type:Periodic Company Report #WAES 00112369
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucophage	C				
			Inderal	C				
			K-Dur	C				
			Lasix	C				
			Lipitor	C				
			Prinivil	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3712029-7Report Type:Periodic Company Report #WAES 00112373
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	3 DAY

Date:03/23/01ISR Number: 3712031-5Report Type:Periodic Company Report #WAES 00112376
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712032-7Report Type:Periodic Company Report #WAES 00112381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3712033-9Report Type:Periodic Company Report #WAES 00112383
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Raloxifene	C				

Date:03/23/01ISR Number: 3712034-0Report Type:Periodic Company Report #WAES 00112393
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712035-2Report Type:Periodic Company Report #WAES 00112407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:03/23/01ISR Number: 3712036-4Report Type:Periodic Company Report #WAES 00112415
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Pressure Increased							
	Diarrhoea							
	Dizziness							
	Dyspepsia							
	Dyspnoea							
	Headache							
	Muscular Weakness							
	Tachycardia							

Date:03/23/01ISR Number: 3712037-6Report Type:Periodic Company Report #WAES 00112429
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Celebrex Unk	SS
Cozaar	C
K-Dur	C
Lasix	C
Lipitor	C
Lopressor	C
Nitroquick	C
Synthroid	C
Isosorbide Mononitrate	C
Lorazepam	C

Date:03/23/01ISR Number: 3712038-8Report Type:Periodic Company Report #WAES 00112431
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Asacol	C
Celebrex	C
Claritin	C
Fosamax	C
Neurontin	C
Premarin	C
Prilosec	C

Date:03/23/01ISR Number: 3712041-8Report Type:Periodic Company Report #WAES 00112435
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Indocin	C		

Date:03/23/01ISR Number: 3712042-XReport Type:Periodic Company Report #WAES 00112449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Endocet	C				

Date:03/23/01ISR Number: 3712043-1Report Type:Periodic Company Report #WAES 00120002
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Face Oedema Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712044-3Report Type:Periodic Company Report #WAES 00120003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712046-7Report Type:Periodic Company Report #WAES 00120007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	20 DAY

Date:03/23/01ISR Number: 3712048-0Report Type:Periodic Company Report #WAES 00120009
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atarax	C				
			Cardura	C				
			Elspar	C				

Date:03/23/01ISR Number: 3712049-2Report Type:Periodic Company Report #WAES 00120014
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Date:03/23/01ISR Number: 3712050-9Report Type:Periodic Company Report #WAES 00120016
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Vioxx	PS	Merck Research			
	Oedema	Professional			Laboratories Div			
					Merck Co Inc	ORAL		
PO								

Date:03/23/01ISR Number: 3712051-0Report Type:Periodic Company Report #WAES 00120018
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL		
25 MG/PO								
			Fosamax	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712052-2Report Type:Periodic Company Report #WAES 00120025
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712056-XReport Type:Periodic Company Report #WAES 00120030
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Flovent	C				
			Hydrodiuril	C				
			Serevent	C				
			Talacen	C				
			...	C				
			Benzonatate	C				
			Potassium (Unspecified)	C				

Date:03/23/01ISR Number: 3712057-1Report Type:Periodic Company Report #WAES 00120038
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Epistaxis Gastrointestinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Insomnia
MG/DAILY/PO

		Cardura	C	
		Lanoxin	C	

Date:03/23/01ISR Number: 3712059-5Report Type:Periodic Company Report #WAES 00120039
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3712060-1Report Type:Periodic Company Report #WAES 00120040
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712061-3Report Type:Periodic Company Report #WAES 00120041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bumex	C				
			Coumadin	C				
			Diovan	C				
			Glucophage	C				
			Zocor	C				
			Sotalol	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3712063-7Report Type:Periodic Company Report #WAES 00120045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712064-9Report Type:Periodic Company Report #WAES 00120053
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712066-2Report Type:Periodic Company Report #WAES 00120058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712067-4Report Type:Periodic Company Report #WAES 00120064
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Demerol	C				
			Ultram	C				
			Minocycline	C				
			Vancomycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712072-8Report Type:Periodic Company Report #WAES 00120068
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Alopecia							
	Gastritis							
	Nausea		Celebrex	C				
	Pain		Zantac	C				

Date:03/23/01ISR Number: 3712074-1Report Type:Periodic Company Report #WAES 00120070
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Flonase	C				
			Mevacor	C				
			Pepcid	C				
			Premarin	C				
			Zestril	C				

Date:03/23/01ISR Number: 3712075-3Report Type:Periodic Company Report #WAES 00120085
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Amitriptyline	C				

Date:03/23/01ISR Number: 3712076-5Report Type:Periodic Company Report #WAES 00120088
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Diovan Hct	C				
			Fosamax	C				
			Prilosec	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3712078-9Report Type:Periodic Company Report #WAES 00120102
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712080-7Report Type:Periodic Company Report #WAES 00120104
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				

Date:03/23/01ISR Number: 3712094-7Report Type:Periodic Company Report #WAES 00120105
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia Oesophageal Ulcer Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Glucophage	C				
			Lopid	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3712095-9Report Type:Periodic Company Report #WAES 00120109
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Keflex	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3712096-0Report Type:Periodic Company Report #WAES 00120111
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712097-2Report Type:Periodic Company Report #WAES 00120124
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills Insomnia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Paraesthesia Unevaluable Event		Immunotherapy (Unspecified)	C				

Date:03/23/01ISR Number: 3712102-3Report Type:Periodic Company Report #WAES 00112178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712103-5Report Type:Periodic Company Report #WAES 00112179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712105-9Report Type:Periodic Company Report #WAES 00112183
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Axid	C				
			Premarin	C				
			Serzone	C				
			Wellbutrin Sr	C				
			Calcium	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3712106-0Report Type:Periodic Company Report #WAES 00112192
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712109-6Report Type:Periodic Company Report #WAES 00112194
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712110-2Report Type:Periodic Company Report #WAES 00112208
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712111-4Report Type:Periodic Company Report #WAES 00112209
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712112-6Report Type:Periodic Company Report #WAES 00112214
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Petechiae	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712114-XReport Type:Periodic Company Report #WAES 00112233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Darvocet-N	C				
			Glucotrol	C				
			Levoxyl	C				
			Lotrel	C				
			Norvasc	C				
			Prandin	C				
			Premarin	C				

Date:03/23/01ISR Number: 3712115-1Report Type:Periodic Company Report #WAES 00112250
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Alphagan	C				

Date:03/23/01ISR Number: 3712485-4Report Type:Periodic Company Report #WAES 00121307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712486-6Report Type:Periodic Company Report #WAES 00121319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Soma	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712487-8Report Type:Periodic Company Report #WAES 00121323
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Joint Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 MG/DAILY/PO	
			Celebrex	C				
			Daypro	C				
			Fosamax	C				
			Plaquenil	C				
			Folic Acid	C				
			Methotrexate	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3712488-XReport Type:Periodic Company Report #WAES 00121330
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3712489-1Report Type:Periodic Company Report #WAES 00121341
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3712490-8Report Type:Periodic Company Report #WAES 00121357
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3712491-XReport Type:Periodic Company Report #WAES 00121358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Face Oedema							
	Oedema Peripheral							
			Glucophage	C				
			Humulin	C				
			Premarin	C				
			Verapamil Msd Lp	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3712492-1Report Type:Periodic Company Report #WAES 00121362
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	

Date:03/23/01ISR Number: 3712493-3Report Type:Periodic Company Report #WAES 00121363
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Protonix	C				

Date:03/23/01ISR Number: 3713390-XReport Type:Periodic Company Report #WAES 00120193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Myalgia Pyrexia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3713392-3Report Type:Periodic Company Report #WAES 00120194
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

		Representative	Warfarin	C		

Date:03/23/01ISR Number: 3713393-5Report Type:Periodic Company Report #WAES 00120195
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haematuria	Health	Vioxx	PS	Merck Research	
	Proteinuria	Professional			Laboratories Div	
	Urinary Incontinence	Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Celebrex	C		
			Effexor	C		
			Prevacid	C		
			Ritalin	C		
			Chondroitin (+)			
			Glucosamine	C		
			Ginseng	C		

Date:03/23/01ISR Number: 3713395-9Report Type:Periodic Company Report #WAES 00120200
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Consumer	Vioxx	PS	Merck Research	
	Swelling				Laboratories Div	

Merck Co Inc ORAL
25

MG/DAILY/PO

Ismo	C
Levsinex Timecaps	C
Premarin	C
Soma	C
Zocor	C
Folic Acid	C

Date:03/23/01ISR Number: 3713397-2Report Type:Periodic Company Report #WAES 00120204
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Ambien	C				
			Klonopin	C				
			Vasotec	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3713400-XReport Type:Periodic Company Report #WAES 00120208
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Ambien	C				
			Colace	C				
			Ecotrin	C				
			Percocet	C				
			Vicodin Tablets	C				
			Bacitracin	C				

Folic Acid	C	
Vitamin E	C	
Vitamins	C	

Date:03/23/01ISR Number: 3713403-5Report Type:Periodic Company Report #WAES 00120210
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY/ PO	

Date:03/23/01ISR Number: 3713405-9Report Type:Periodic Company Report #WAES 00120214
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3713407-2Report Type:Periodic Company Report #WAES 00120218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3713410-2Report Type:Periodic Company Report #WAES 00112131
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aciphex	C				
			Pravachol	C				
			Primperan	C				
			Prozac	C				
			Serevent	C				
			Ventilan (Albuterol)	C				
			Furosemide	C				
			Levothyroxine Sodium	C				
			Nifedipine	C				
			Prednisone	C				

Date:03/23/01ISR Number: 3713411-4Report Type:Periodic Company Report #WAES 00112134
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Palpitations	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Avapro	C
Capoten	C
Cardura	C
Humalog	C
Prilosec	C
Colchicine	C
Furosemide	C
Insulin Human, Isophane	C

Date:03/23/01ISR Number: 3713412-6Report Type:Periodic Company Report #WAES 00112135
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Celebrex	C		
			Darvocet-N	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3713413-8Report Type:Periodic Company Report #WAES 00112141
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Flutter	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Mevacor	C				

Date:03/23/01ISR Number: 3713414-XReport Type:Periodic Company Report #WAES 00112150
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3713415-1Report Type:Periodic Company Report #WAES 00112151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3713416-3Report Type:Periodic Company Report #WAES 00112154
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:03/23/01ISR Number: 3713417-5Report Type:Periodic Company Report #WAES 00112161
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ambien	C				

Date:03/23/01ISR Number: 3713419-9Report Type:Periodic Company Report #WAES 00112162
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces Liver Disorder Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Celebrex	C				
			Cortisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3713422-9Report Type:Periodic Company Report #WAES 00112172
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations Supraventricular Extrasystoles	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3713432-1Report Type:Periodic Company Report #WAES 00120246
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Darvocet-N	C				
			Paxil	C				

Date:03/23/01ISR Number: 3713435-7Report Type:Periodic Company Report #WAES 00120250
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hytrin	C				

Date:03/23/01ISR Number: 3713440-0Report Type:Periodic Company Report #WAES 00120252
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Lasix	C
Micro K	C
Prandin	C
Zocor	C
Cortisone	C

Date:03/23/01ISR Number: 3713444-8Report Type:Periodic Company Report #WAES 00120256
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia	Health			Laboratories Div	
	Flatulence	Professional			Merck Co Inc	ORAL
PO						
	Pain		Restoril	C		
			Synthroid	C		
			Zocor	C		
			Prednisone	C		
			...	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3713447-3Report Type:Periodic Company Report #WAES 00120258
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Covera-Hs	C				
			Zoloft	C				
			Prednisone	C				
			...	C				

Date:03/23/01ISR Number: 3713448-5Report Type:Periodic Company Report #WAES 00120259
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Plaquenil	C				
			Premarin	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3713449-7Report Type:Periodic Company Report #WAES 00120260
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY

Date:03/23/01ISR Number: 3713451-5Report Type:Periodic Company Report #WAES 00120261
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bile Duct Obstruction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Ibuprofen	C				

Date:03/23/01ISR Number: 3713453-9Report Type:Periodic Company Report #WAES 00120262
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3713455-2Report Type:Periodic Company Report #WAES 00120265
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3713458-8Report Type:Periodic Company Report #WAES 00121868
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3713459-XReport Type:Periodic Company Report #WAES 00121869
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:03/23/01ISR Number: 3713461-8Report Type:Periodic Company Report #WAES 00121877
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
SEE IMAGE

Glynase Prestab
Tablets C
Synthroid C

Date:03/23/01ISR Number: 3713462-XReport Type:Periodic Company Report #WAES 00121878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3713464-3Report Type:Periodic Company Report #WAES 00121883
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypervigilance Insomnia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Estrace	C				
			Lipitor	C				
			Prinivil	C				

Date:03/23/01ISR Number: 3713466-7Report Type:Periodic Company Report #WAES 00121885
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3713470-9Report Type:Periodic Company Report #WAES 00121886
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:03/23/01ISR Number: 3713475-8Report Type:Periodic Company Report #WAES 00121899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:03/23/01ISR Number: 3713478-3Report Type:Periodic Company Report #WAES 00121900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3713481-3Report Type:Periodic Company Report #WAES 00121916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
		Representative	Beconase	C				
			Darvocet-N	C				
			Flexeril	C				
			Flonase	C				
			Lipitor	C				
			Neurontin	C				
			Prempro	C				
			Prilosec	C				
			Prozac	C				
			Valium	C				
			Zyrtec	C				
			Doxepin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3714993-9Report Type:Periodic Company Report #WAES 00121366
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Therapy Unspecified]	C				

Date:03/23/01ISR Number: 3714994-0Report Type:Periodic Company Report #WAES 00121368
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lasix	C				
			Diazepam	C				

Date:03/23/01ISR Number: 3714995-2Report Type:Periodic Company Report #WAES 00121378
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3714996-4Report Type:Periodic Company Report #WAES 00121404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Pamprin	C				

Date:03/23/01ISR Number: 3714997-6Report Type:Periodic Company Report #WAES 00121410
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Folliculitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Cap Prevacid 30 Mg	SS		ORAL	30 MG/DAILY/ORAL	
			Glucotrol	C				
			Lasix	C				
			Lopid	C				
			Micro K	C				
			Plendil	C				
			Premarin	C				
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3714998-8Report Type:Periodic Company Report #WAES 00121414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain Oesophagitis Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3715001-6Report Type:Periodic Company Report #WAES 00121420
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Hydrochlorothiazide (+) Triamter	C				

Date:03/23/01ISR Number: 3715002-8Report Type:Periodic Company Report #WAES 00121421
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:03/23/01ISR Number: 3715004-1Report Type:Periodic Company Report #WAES 00121422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL

UNK/UNK/PO

Date:03/23/01ISR Number: 3715005-3Report Type:Periodic Company Report #WAES 00121430
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Muscle Rigidity Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Estrace	C		
			Humulin 70/30	C		
			Lamictal	C		
			Paxil	C		
			Prilosec	C		

Dose Duration

25

MG/DAILY/PO

Date:03/23/01ISR Number: 3715015-6Report Type:Periodic Company Report #WAES 00112251
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO 1 MON

			Procardia	C
			Xanax	C

Date:03/23/01ISR Number: 3715016-8Report Type:Periodic Company Report #WAES 00112252
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	50 DAY
	Dizziness							
	Drug Ineffective							
	Flushing		Neurontin	C				
	Headache		Thalwin Nx	C				
	Hyperhidrosis		Zocor	C				
	Nausea		Clonazepam	C				
			Trazodone	C				

Date:03/23/01ISR Number: 3715018-1Report Type:Periodic Company Report #WAES 00112253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Coreg	C				
			Zocor	C				

Date:03/23/01ISR Number: 3715019-3Report Type:Periodic Company Report #WAES 00112255
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.MG/DAILY/P O	6 DAY
	Haemorrhage							
	Haemorrhoids							

			Celebrex	C		
			Klonopin	C		
			Lipitor	C		
			Norvasc	C		
			Prozac	C		

Date:03/23/01ISR Number: 3715021-1Report Type:Periodic Company Report #WAES 00112256
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Calculus Urinary Cholelithiasis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
60MG/DAILY/PO						
			Estrogens Conjugated	C		
			Fluticasone	C		
			Progesterone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715022-3Report Type:Periodic Company Report #WAES 00112561
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fatigue							
	Irritability							
			Aceon	C				
			Lescol	C				
			Allopurinol	C				
			Aspirin	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:03/23/01ISR Number: 3715024-7Report Type:Periodic Company Report #WAES 00112269
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3715025-9Report Type:Periodic Company Report #WAES 00112294
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Musculoskeletal Disorder							
	Oedema Peripheral							
			Combivent	C				
			Estratest	C				
			Flonase	C				
			Flovent	C				
			Zyrtec	C				

Date:03/23/01ISR Number: 3715026-0Report Type:Periodic Company Report #WAES 00112297
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache							
	Musculoskeletal Stiffness							

Date:03/23/01ISR Number: 3715028-4Report Type:Periodic Company Report #WAES 00112301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715030-2Report Type:Periodic Company Report #WAES 00120266
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Chest Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/UNK/PO	
			Aspirin	C				
			Atenolol	C				

Date:03/23/01ISR Number: 3715031-4Report Type:Periodic Company Report #WAES 00120268
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:03/23/01ISR Number: 3715032-6Report Type:Periodic Company Report #WAES 00120269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/UNK/PO	

Date:03/23/01ISR Number: 3715033-8Report Type:Periodic Company Report #WAES 00120276
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams Hallucination	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
12.5MG/BID/PO						
			Avapro	C		
			Celebrex	C		
			Darvocet	C		
			Tylenlol With Codeine #3	C		

Date:03/23/01ISR Number: 3715034-XReport Type:Periodic Company Report #WAES 00120285
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3715035-1Report Type:Periodic Company Report #WAES 00120371
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness Nausea Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Benozil	C		
			Valium	C		

Potassium C

Date:03/23/01ISR Number: 3715036-3Report Type:Periodic Company Report #WAES 00120372
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fioricet Tablets	C				

Date:03/23/01ISR Number: 3715037-5Report Type:Periodic Company Report #WAES 00120378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	

Date:03/23/01ISR Number: 3715038-7Report Type:Periodic Company Report #WAES 00120380
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Herbal Remedies	C				

Date:03/23/01ISR Number: 3715039-9Report Type:Periodic Company Report #WAES 00120382
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research	
	Dyspepsia	Health			Laboratories Div	
	Emotional Disorder	Professional			Merck Co Inc	ORAL
25MG/DAILY/PO						
	Fatigue		Prevacid	C		
	Muscular Weakness					
	Palpitations					
	Vomiting					

Date:03/23/01ISR Number: 3715040-5Report Type:Periodic Company Report #WAES 00120386
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Cardizem Cd	C		
			C0zaar	C		
			Hydrodiuril	C		
			Mevacor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715041-7Report Type:Periodic Company Report #WAES 00120390
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715042-9Report Type:Periodic Company Report #WAES 00120397
Age:97 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Multiforme	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Effexor	C				
			Hytrin	C				
			Imodium	C				
			Mylanta & Mylanta Ds	C				
			Pepcid	C				
			Tylenol	C				
			Docusate Sodium	C				

Date:03/23/01ISR Number: 3715043-0Report Type:Periodic Company Report #WAES 00120400
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Imdur	C				
			Lasix	C				
			Tendormin	C				

Date:03/23/01ISR Number: 3715044-2Report Type:Periodic Company Report #WAES 00120401
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinusitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Tenormin	C				

Date:03/23/01ISR Number: 3715045-4Report Type:Periodic Company Report #WAES 00120404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715046-6Report Type:Periodic Company Report #WAES 00120405
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715047-8Report Type:Periodic Company Report #WAES 00120407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	2 MON
			Inderal	C				
			Prozac	C				
			Tylenol With Codeine	C				
			Hormones (Unspecified(	C				

Date:03/23/01ISR Number: 3715048-XReport Type:Periodic Company Report #WAES 00120408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715061-2Report Type:Periodic Company Report #WAES 00120414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3715066-1Report Type:Periodic Company Report #WAES 00120415
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3715067-3Report Type:Periodic Company Report #WAES 00120426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3715068-5Report Type:Periodic Company Report #WAES 00120427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO SEE IMAGE	3 MON

Date:03/23/01ISR Number: 3715069-7Report Type:Periodic Company Report #WAES 00120428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715075-2Report Type:Periodic Company Report #WAES 00120429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Indocin (Indomethacin Sodium)	C				

Date:03/23/01ISR Number: 3715076-4Report Type:Periodic Company Report #WAES 00120446
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Normal	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:03/23/01ISR Number: 3715078-8Report Type:Periodic Company Report #WAES 00120454
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3715079-XReport Type:Periodic Company Report #WAES 00120455
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715081-8Report Type:Periodic Company Report #WAES 00120456
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715082-XReport Type:Periodic Company Report #WAES 00120463
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Inflammation Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Sinusitis		Synvisc	SS			SEE IMAGE	
			Celebrex	C				
			Centrum	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3715088-0Report Type:Periodic Company Report #WAES 00121145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3715089-2Report Type:Periodic Company Report #WAES 00121147
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Daypro	C				
			Premarin	C				
			Synthroid	C				
			Tenoretic	C				
			Zyrtec	C				

Date:03/23/01ISR Number: 3715090-9Report Type:Periodic Company Report #WAES 00121158
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Fiorinal	C				
			Flonase	C				
			Imitrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715092-2Report Type:Periodic Company Report #WAES 00121183
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acne	Consumer	Vioxx	PS	Merck Research			
	Glossodynia	Health			Laboratories Div			
	Mouth Ulceration	Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
	Skin Lesion		Diovan	C				

Date:03/23/01ISR Number: 3715093-4Report Type:Periodic Company Report #WAES 00121237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Vioxx	PS	Merck Research			
	Malaise				Laboratories Div			
	Pain				Merck Co Inc	ORAL	SEE IMAGE	
	Urinary Tract Infection							

Date:03/23/01ISR Number: 3715094-6Report Type:Periodic Company Report #WAES 00121252
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue				Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Mevacor	C				
			Tenormin	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3715095-8Report Type:Periodic Company Report #WAES 00121255
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Vioxx	PS	Merck Research			

Health Laboratories Div
Professional Merck Co Inc ORAL
25

MG/DAILY/PO

Lipitor C
Zoloft C
Alprazolam C

Date:03/23/01ISR Number: 3715096-XReport Type:Periodic Company Report #WAES 00121257
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
			Therapy Unspecified	C				

Date:03/23/01ISR Number: 3715097-1Report Type:Periodic Company Report #WAES 00121258
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715098-3Report Type:Periodic Company Report #WAES 00121259
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Klonopin	C				
			Naprosyn	C				
			Ibuprofen	C				

Date:03/23/01ISR Number: 3715102-2Report Type:Periodic Company Report #WAES 00121260
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal Malaise Paraesthesia Oral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Advil	C				
			Lasix	C				
			Premarin	C				
			Prilosec	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3715103-4Report Type:Periodic Company Report #WAES 00121261
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Antivert	C		
			Celebrex	C		
			Centrum	C		
			Prevacid	C		
			Tylenol	C		
			Valium	C		
			Zoloft	C		

Date:03/23/01ISR Number: 3715104-6Report Type:Periodic Company Report #WAES 00121263
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Klonopin	C				
			Lasix	C				
			Lipitor	C				
			Nardil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715105-8Report Type:Periodic Company Report #WAES 00121265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Pravachol	C				
			Viagra	C				
			[Composition Unspecified]	C				

Date:03/23/01ISR Number: 3715106-XReport Type:Periodic Company Report #WAES 00121269
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Arava Unk	SS				
			Neurontin	C				

Date:03/23/01ISR Number: 3715107-1Report Type:Periodic Company Report #WAES 00121272
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Malaise Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Celebrex	C				
			Darvon	C				
			Xanax	C				

Date:03/23/01ISR Number: 3715108-3Report Type:Periodic Company Report #WAES 00121278
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Daypro	C				

Date:03/23/01ISR Number: 3715109-5Report Type:Periodic Company Report #WAES 00121282
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715110-1Report Type:Periodic Company Report #WAES 00121284
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	2 WK
	Localised Oedema							
	Oedema Peripheral							
			Allegra	C				

Date:03/23/01ISR Number: 3715881-4Report Type:Periodic Company Report #WAES 00120466
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Synthroid	C				
			Vasoretic	C				

Date:03/23/01ISR Number: 3715882-6Report Type:Periodic Company Report #WAES 00120479
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Norvasc	C				

Date:03/23/01ISR Number: 3715886-3Report Type:Periodic Company Report #WAES 00120499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cordarone	C				
			Lasix	C				
			Neurontin	C				
			Premarin	C				
			Potassium Chloride	C				

Date:03/23/01ISR Number: 3715888-7Report Type:Periodic Company Report #WAES 00120502
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715889-9Report Type:Periodic Company Report #WAES 00120505
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Colace	C				
			Cozaar	C				
			Flovent	C				
			Norvasc	C				
			Pepcid	C				
			Singulair	C				
			Synthroid	C				
			Zocor	C				
			Aspirin	C				
			Potassium	C				

Date:03/23/01ISR Number: 3715890-5Report Type:Periodic Company Report #WAES 00120517
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Valium	C				
			Zantac	C				
			Aspirin	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3715892-9Report Type:Periodic Company Report #WAES 00120519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thirst Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Weight Decreased				Merck Co Inc	ORAL
PO						
			K-Dur	C		
			Lasix	C		
			Mevacor	C		
			Synthroid	C		
			Tenormin	C		
			Vitamins	C		

Date:03/23/01ISR Number: 3715893-0Report Type:Periodic Company Report #WAES 00120520
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO						
			Amaryl	C		
			Prilosec	C		
			Ascorbic Acid	C		
			Vitamin E	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715897-8Report Type:Periodic Company Report #WAES 00120524
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Flonase	C				
			Pepcid	C				
			Synthroid	C				
			Alprazolam	C				
			Amitriptyline	C				
			Atenolol	C				
			Trimethoprim	C				

Date:03/23/01ISR Number: 3715899-1Report Type:Periodic Company Report #WAES 00120580
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Plendil	C				
			Lorazepam	C				

Date:03/23/01ISR Number: 3715900-5Report Type:Periodic Company Report #WAES 00120585
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/ PO	

Date:03/23/01ISR Number: 3715902-9Report Type:Periodic Company Report #WAES 00120589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) DAILY/ PO; 2) BID/ PO	

Date:03/23/01ISR Number: 3715903-0Report Type:Periodic Company Report #WAES 00120591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3715904-2Report Type:Periodic Company Report #WAES 00120592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3715906-6Report Type:Periodic Company Report #WAES 00120595
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Synthroid	C				
			Vasotec	C				
			Zantac	C				

Date:03/23/01ISR Number: 3715907-8Report Type:Periodic Company Report #WAES 00120598
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Fosamax 10 Mg	SS		ORAL	PO	
			Effexor	C				
			Klonopin	C				
			Lipitor	C				
			Prevacid	C				
			Tequin	C				

Ultram	C		
Zyprexa	C		
Prednisone	C		

Date:03/23/01ISR Number: 3715909-1Report Type:Periodic Company Report #WAES 00120604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Constipation							
	Diarrhoea							
	Fatigue		Antacid Tablets (Calcium Carbona	C				
	Gastrointestinal Disorder							
	Migraine		Relafen	C				
	Rectal Haemorrhage		Theo-Dur	C				

Date:03/23/01ISR Number: 3715910-8Report Type:Periodic Company Report #WAES 00120606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3717070-6Report Type:Periodic Company Report #WAES 00121490
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3717072-XReport Type:Periodic Company Report #WAES 00121502
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:03/23/01ISR Number: 3717073-1Report Type:Periodic Company Report #WAES 00121505
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

Date:03/23/01ISR Number: 3717074-3Report Type:Periodic Company Report #WAES 00121508
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

	Rhinorrhoea				Merck Co Inc	ORAL
PO						
			Prilosec	C		
			Synthroid	C		

Date:03/23/01ISR Number: 3717075-5Report Type:Periodic Company Report #WAES 00121510
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research	
	Oral Soft Tissue Disorder				Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Dyazide	C		
			Metamucil	C		
			Novadox	C		
			Synthroid	C		
			Ascorbic Acid	C		
			Aspirin	C		
			Calcium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3717076-7Report Type:Periodic Company Report #WAES 00121519
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3717077-9Report Type:Periodic Company Report #WAES 00121536
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:03/23/01ISR Number: 3717078-0Report Type:Periodic Company Report #WAES 00121539
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Tylenol Extra Strength	C				
			Zestril	C				
			Aspirin	C				

Date:03/23/01ISR Number: 3717872-6Report Type:Periodic Company Report #WAES 00121561
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Centrum Silver	C				
			Fosamax	C				
			Glucophage	C				
			Lipitor	C				
			Zestril	C				
			Ascorbic Acid	C				
			Calcium	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3717873-8Report Type:Periodic Company Report #WAES 00121574
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3717874-XReport Type:Periodic Company Report #WAES 00121577
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3717875-1Report Type:Periodic Company Report #WAES 00121578
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3717876-3Report Type:Periodic Company Report #WAES 00121580
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased		Ziac	C				

Date:03/23/01ISR Number: 3717877-5Report Type:Periodic Company Report #WAES 00121597
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research			

	Rectal Haemorrhage				Laboratories Div Merck Co Inc	ORAL
PO						
			Biaxin	C		

Date:03/23/01ISR Number: 3717878-7Report Type:Periodic Company Report #WAES 00121605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:03/23/01ISR Number: 3717879-9Report Type:Periodic Company Report #WAES 00121615
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Covera-Hs	C		
			Lipitor	C		
			Tylenol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3717880-5Report Type:Periodic Company Report #WAES 00121618
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3717881-7Report Type:Periodic Company Report #WAES 00121619
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Premarin	C				
			Synthroid	C				

Date:03/23/01ISR Number: 3717882-9Report Type:Periodic Company Report #WAES 00121622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/23/01ISR Number: 3717883-0Report Type:Periodic Company Report #WAES 00121624
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/23/01ISR Number: 3717884-2Report Type:Periodic Company Report #WAES 00121627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Carafate	C				
			Prilosec	C				

Date:03/23/01ISR Number: 3717885-4Report Type:Periodic Company Report #WAES 00121664
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3717886-6Report Type:Periodic Company Report #WAES 00121702
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dry Throat Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hydrodiuril	C				
			Lipitor	C				
			Prevacid	C				
			Prilosec	C				
			Vicodin	C				
			Therapy Unspecified	C				
			Atenolol	C				
			Baclofen	C				
			Potassium Chloride	C				

Date:03/23/01ISR Number: 3717887-8Report Type:Periodic Company Report #WAES 00121709
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Detrol	C				
			Micardis	C				
			Paxil	C				
			Therapy Unspecified	C				
			Flurazepam Hydrochloride	C				

Date:03/23/01ISR Number: 3717888-XReport Type:Periodic Company Report #WAES 00121716
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
SEE IMAGE
Baycol C
Vasotec C

Date:03/23/01ISR Number: 3717889-1Report Type:Periodic Company Report #WAES 00121720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Microzide	C				
			Zestril	C				

Date:03/23/01ISR Number: 3717890-8Report Type:Periodic Company Report #WAES 00121722
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50

MG/DAILY/PO 5 DAY

Prilosec C

Date:03/23/01ISR Number: 3718498-0Report Type:Periodic Company Report #WAES 00121723
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Celebrex	C				
			Glucotrol	C				
			Lasix	C				
			Prinivil	C				
			Tylenol	C				
			Aspirin	C				
			Folic Acid	C				
			Insulin, Hipasic Isophane Injection	C				
			Lansoprazole	C				

Date:03/23/01ISR Number: 3718499-2Report Type:Periodic Company Report #WAES 00121724
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Ditropan	C				
			Ortho-Novum	C				
			Prilosec	C				

			Xanix	C
			Zoloft	C
			Albuterol	C
			Atenolol	C

Date:03/23/01ISR Number: 3718500-6Report Type:Periodic Company Report #WAES 00121725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Cardura	C		
			Diazide	C		
			Diovan	C		
			Prilosec	C		
			Propulsid	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3718501-8Report Type:Periodic Company Report #WAES 00121727
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Nausea							
			Prozac	C				
			Lithium Citrate	C				

Date:03/23/01ISR Number: 3718502-XReport Type:Periodic Company Report #WAES 00121745
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Nausea							
	Sedation		Toprol Xl Tablets	C				

Date:03/23/01ISR Number: 3718503-1Report Type:Periodic Company Report #WAES 00121743
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Oedema Peripheral							
	Rhinorrhoea							

Date:03/23/01ISR Number: 3718504-3Report Type:Periodic Company Report #WAES 00121747
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Weight Increased							
			Tylenol	C				

Date:03/23/01ISR Number: 3718505-5Report Type:Periodic Company Report #WAES 00121749
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dry Skin							
	Erythema							
	Face Oedema							
	Pruritus		Flovent	C				
			Prilosec	C				
			Serevent	C				
			Albuterol	I				
			Phytonadione	I				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3718506-7Report Type:Periodic Company Report #WAES 00121752
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
	Gastrointestinal Haemorrhage							
			Cozaar	C				
			Synthroid	C				
			Zoloft	C				
			Acebutolol	C				

Date:03/23/01ISR Number: 3718507-9Report Type:Periodic Company Report #WAES 00121755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/PO	

Date:03/23/01ISR Number: 3718509-2Report Type:Periodic Company Report #WAES 00121787
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/23/01ISR Number: 3718510-9Report Type:Periodic Company Report #WAES 00121792
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			

	Dyspnoea				Laboratories Div	
	Face Oedema				Merck Co Inc	ORAL
12.5MG/BID/PO						
			K-Dur	C		
			Prempro	C		
			Zaroxolyn	C		

Date:03/23/01ISR Number: 3718511-0Report Type:Periodic Company Report #WAES 00121793
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypokinesia	Consumer	Vioxx	PS	Merck Research	
	Muscular Weakness				Laboratories Div	
					Merck Co Inc	ORAL
25MG/BID/PO						
			Hytrin	C		
			Miacalcin	C		
			Ultram	C		
			Zocor	C		
			Zoloft	C		
			Aspirin	C		
			Diazepam	C		
			Orphenadrine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3718512-2Report Type:Periodic Company Report #WAES 00121800
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/PO	

Date:03/23/01ISR Number: 3718513-4Report Type:Periodic Company Report #WAES 00121802
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3718514-6Report Type:Periodic Company Report #WAES 00121803
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3718515-8Report Type:Periodic Company Report #WAES 00121804
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL PO

Date:03/23/01ISR Number: 3718516-XReport Type:Periodic Company Report #WAES 00121806
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO		

Date:03/23/01ISR Number: 3718517-1Report Type:Periodic Company Report #WAES 00121809
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Disorientation Hallucination Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/UNK/PO	
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3718518-3Report Type:Periodic Company Report #WAES 00121833
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	11 DAY

Date:03/23/01ISR Number: 3718519-5Report Type:Periodic Company Report #WAES 00121834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/23/01ISR Number: 3718520-1Report Type:Periodic Company Report #WAES 00121842
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Musculoskeletal Pain Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Flovent	C				
			Levoxyl	C				
			Serevent	C				
			Singulair	C				
			Vitamins	C				

Date:03/23/01ISR Number: 3718521-3Report Type:Periodic Company Report #WAES 00121846
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
	Dysphagia					
	Lip Dry					
	Speech Disorder		Cozaar	C		
			Inderal	C		
			Lipitor	C		
			Synthroid	C		
			Xanax	C		
			Propranolol	C		

Date:03/23/01ISR Number: 3718522-5Report Type:Periodic Company Report #WAES 00121849
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Urinary Tract Infection					

25

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3718523-7Report Type:Periodic Company Report #WAES 00121852
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Neurontin	C				
			Vaseretic	C				

Date:03/23/01ISR Number: 3718524-9Report Type:Periodic Company Report #WAES 00121856
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Valium	C				

Date:03/23/01ISR Number: 3718525-0Report Type:Periodic Company Report #WAES 00121866
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				
			Gabapentin	C				
			Methocarbamol	C				

Date:03/23/01ISR Number: 3718526-2Report Type:Periodic Company Report #WAES 00121867
Age:84 YR Gender:Female I/FU:U

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Toprol Xl Tablets	C				

Date:03/23/01ISR Number: 3724471-9Report Type:Periodic Company Report #WAES 00121493
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/01ISR Number: 3726169-XReport Type:Periodic Company Report #WAES 01010704
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Avapro	C				
			Calcium	C				

Date:03/23/01ISR Number: 3726174-3Report Type:Periodic Company Report #WAES 01010715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Visual Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Calcium	C				
			Vitamin E	C				

Date:03/23/01ISR Number: 3728387-3Report Type:Periodic Company Report #WAES 00121732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				

Date:03/24/01ISR Number: 3712484-2Report Type:Periodic Company Report #WAES 00121306
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/26/01ISR Number: 3689565-5Report Type:Direct Company Report #
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS				
	Renal Failure Acute		Betapace	SS				

Date:03/26/01ISR Number: 3689590-4Report Type:Expedited (15-DaCompany Report #WAES 01032212
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DIALY	
Hospitalization - Initial or Prolonged	Pharyngeal Oedema							
	Pruritus							
Other	Purpura						PO	
	Rash Erythematous		Lipitor	C				
	Urticaria		Xenical	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3690197-3Report Type:Expedited (15-DaCompany Report #256403
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Calcinosis	Foreign	Cardene	PS	Syntex (Usa) Inc Llc		40 MG DAILY	
Initial or Prolonged	Choreoathetosis	Other	Vioxx (Rofecoxib)	SS		ORAL	12 MG DAILY	
			Lansoprazole (Lansoprazole)	SS		ORAL	30 MG DAILY	
			Unknown Drug (Generic Component(S) Unknown)	C				

Date:03/26/01ISR Number: 3690275-9Report Type:Expedited (15-DaCompany Report #PHBS2001CH02158
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis	Foreign Health Professional Other	Diovan	PS	Novartis Pharmaceuticals Corp	ORAL	80 MG/D, ORAL	
			Iscover (Clopidogrel Sulfate)	SS		ORAL	75 MG/D, ORAL	
			Dilatrend (Carvedilol)	SS		ORAL	12.5 MG/D, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	25 MG/D, ORAL	
			Zocor (Simvastatin)	SS		ORAL	20 MG/D, ORAL	
			Aurorix (Moclobemide)	C				
			Eltroxin	C				
			Seresta (Oxazepam)	C				

Date:03/26/01ISR Number: 3706651-1Report Type:Periodic Company Report #WAES 00112274
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sinemet	C				
			Theragran Liquid	C				
			Vioxx	C				
			Zoloft	C				
			Alprazolam	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:03/26/01ISR Number: 3706652-3Report Type:Periodic Company Report #WAES 00120503
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3706653-5Report Type:Periodic Company Report #WAES 01012654
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ BID/ PO	
			Sectral	C				
			Lorazepam	C				

Date:03/27/01ISR Number: 3690360-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Muscle Spasms		Rofecoxib 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	
	Tremor		Maxzide	C				
			Avapro	C				
			Glucosamine	C				
			Vitamin E	C				
			Calcium	C				
			Mvi	C				

Date:03/27/01ISR Number: 3690590-9Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx (25mg) (Merch And Co Qd)	PS	Merch And Co			

Date:03/27/01ISR Number: 3690933-6Report Type:Expedited (15-DaCompany Report #WAES 00076031
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Haemangioma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY 1 MON

Date:03/27/01ISR Number: 3690939-7Report Type:Expedited (15-DaCompany Report #WAES 01039943
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Arthralgia Atrioventricular Block	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Blood Creatinine Increased		Tab Spironolactone	SS		ORAL	25 MG/DAILY	
	Blood Pressure Systolic Increased		Tab Cozaar (Losartan Potassium)	SS		ORAL	50 MG PO	3 YR
	Bundle Branch Block							
	Conduction Disorder Difficulty In Walking Disorientation Heart Rate Decreased Hyperkalaemia Renal Impairment Syncope		Metoprolol	C			PO	3 DAY
							ORAL	3 YR

Date:03/27/01ISR Number: 3690960-9Report Type:Expedited (15-DaCompany Report #WAES 01033535
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bone Infection	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY; 2) 25 MG	
			Ciprofloxacin Hydrochloride	C				
			Morphines04	C				
			Rifampicin	C				

Date:03/27/01ISR Number: 3690961-0Report Type:Expedited (15-DaCompany Report #WAES 01035153
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	5 DAY
	Nausea	Other						
	Oral Pain							
	Vomiting		Ms Trisilicate	C				
			Acetaminophen/Codeine Phosphate	C				
			Azelastine Hydrochloride	C				
			Bendroflumethiazide	C				
			Benzydamine Hcl	C				
			Citalopram Hydrobromide	C				
			Lactulose	C				
			Mineral Oil (+) Petrolatum, White	C				
			Prochlorperazine Maleate	C				

Date:03/27/01ISR Number: 3690962-2Report Type:Expedited (15-DaCompany Report #WAES 01036514
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Peptic Ulcer Perforation	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Hospitalization - Initial or Prolonged		Other						
			Tab Ibuprofen	SS		ORAL	400 MG/TID	
			Lactulose	C				
			Picosulfate Na	C				

Date:03/27/01ISR Number: 3690983-XReport Type:Expedited (15-DaCompany Report #WAES 01028226
Age:92 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Blood Creatinine Increased
	Condition Aggravated
	Drug Interaction
	Gastric Haemorrhage
	Gastric Ulcer
	Melaena

		Upper Gastrointestinal Haemorrhage					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY							
			Other				
PO	1 YR						
				Tab Carbaspirin Calcium	SS		ORAL
250 MG DAILY							
PO							
				Moduretic	C		
				Herbal Remedies (Unspecified)	C		
				Nadolol	C		
				Nifedipine	C		

Date:03/27/01ISR Number: 3691122-1Report Type:Expedited (15-DaCompany Report #WAES 00111555
Age:75 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Oedema Peripheral Renal Impairment Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Ambien	C		
				Diovan Hct	C		
				Flovent	C		
				Hydromet	C		
				Lasix	C		
				Maxair	C		
				Paxil	C		
				Prilosec	C		
				Rhinocort	C		
				Serevent	C		
				Singulair	C		
				Synthroid	C		
				Zocor	C		
				Allopurinol	C		
				Colchicine	C		

			Nonsteroidal Anti-Inflammatory	C		

Date:03/27/01ISR Number: 3691123-3Report Type:Expedited (15-DaCompany Report #WAES 00111799
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dermatitis	Health	Vioxx	PS	Merck Research	
Life-Threatening	Diarrhoea	Professional			Laboratories Div	
Hospitalization -	Hepatic Failure	Company			Merck Co Inc	ORAL
25						
Initial or Prolonged	Hypertension	Representative				
MG/DAILY/PO						
Disability	Hypotension		Centrum	C		
Other	Jaundice					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/01ISR Number: 3691124-5Report Type:Expedited (15-DaCompany Report #WAES 01030024
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Vioxx	PS	Merck Research			
	Haemorrhage	Professional			Laboratories Div			
	Oedema				Merck Co Inc	ORAL	25	
	Platelet Count Decreased						MG/DAILY/PO	
	Synovitis		Tab Vioxx 25 Mg	SS		ORAL	25	
							MG/DAILY/PO	
			Atrovent	C				
			Bactrim Ds Tablets	C				
			Cytoxan	C				
			Flomax (Tamsulosin					
			Hydrochloride	C				
			Flovent	C				
			Medrol	C				
			Neupogen	C				
			Prevacid	C				
			Serevent	C				
			Valtrex	C				
			Doxorubicin	C				
			Globulin, Immune	C				
			Prednisone	C				
			Vincristine	C				

Date:03/27/01ISR Number: 3691126-9Report Type:Expedited (15-DaCompany Report #WAES 01030152
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Thromboplastin Time	Professional			Laboratories Div			
	Prolonged				Merck Co Inc	ORAL	25-50	
	Prothrombin Time						MG/DAILY/PO	
	Prolonged		Univasc	C				
			Vicodin Tablets	C				

Date:03/27/01ISR Number: 3691127-0Report Type:Expedited (15-DaCompany Report #WAES 01012353
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other			Cardizem	C				

Date:03/27/01ISR Number: 3691128-2Report Type:Expedited (15-DaCompany Report #WAES 01010453
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Ecchymosis Factor Viii Deficiency Haemarthrosis Oedema Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/01ISR Number: 3691129-4Report Type:Expedited (15-DaCompany Report #WAES 01010203
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis Haemorrhage Nausea Pallor Syncope Vomiting	Health Professional Company Representative	Vioxx Ambusol Amoxicillin Analgesic Or Anesthetic Aspirin Hormonal Contraceptives (Unspec	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:03/27/01ISR Number: 3691900-9Report Type:Expedited (15-DaCompany Report #WAES 01032216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Increased	Health Professional Company Representative	Tab Vioxx Motrin	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/27/01ISR Number: 3691903-4Report Type:Expedited (15-DaCompany Report #WAES 01031323
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Dermatitis Flushing Syncope Vasovagal	Health Professional	Tab Vioxx 25 Mg Excedrin	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	

Extra-Strength	C
Tylenol Pm	C

Date:03/28/01ISR Number: 3690370-4Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS		ORAL	25MG PO QD	

Date:03/28/01ISR Number: 3691207-XReport Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia		Vioxx	PS		ORAL	2 PILLS ORAL	
	Dyspnoea							
	Rash Erythematous							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/01ISR Number: 3691292-5Report Type:Expedited (15-DaCompany Report #WAES 01032303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/28/01ISR Number: 3691297-4Report Type:Expedited (15-DaCompany Report #WAES 01021330
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diverticulum Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY/PO	
	Hiatus Hernia							
	Oedema Peripheral		Aldomet (Methyldopa)	C				
	Peptic Ulcer		Dyazide	C				
	Renal Failure Chronic		Evista	C				
	Stress		Lipitor	C				
			Motrin	C				
			Naprosyn	C				
			Aspirin	C				
			Potassium Chloride	C				
			Propranolol Hydrochloride	C				

Date:03/28/01ISR Number: 3691302-5Report Type:Expedited (15-DaCompany Report #WAES 01020865
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bacteriuria Bilirubinuria Cells In Urine	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

		Chromaturia				
MG/DAILY/PO						
		Haematuria		Levoxyl	C	
		Ketonuria		Naprosyn	C	
		Proteinuria		Premarin	C	
		Urine Abnormality		Trinsicon (Ascorbic		
		White Blood Cells Urine		Acid (+) Cya	C	
		Positive		Tylenol	C	
				Etodolac	C	
				Potassium		
				(Unspecified)	C	

Date:03/28/01ISR Number: 3691307-4Report Type:Expedited (15-DaCompany Report #WAES 99101561
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthma	Health	Vioxx	PS	Merck Research	
	Urticaria	Professional			Laboratories Div	
					Merck Co Inc	ORAL
12.5						
MG/DAILY/PO						
			Ceftin	SS		
250						
MG/BID/UNK						
			Nasarel	C		
			Prinzide	C		
			Ventolin	C		

				Zyrtec	C		

Date:03/28/01ISR Number: 3691309-8Report Type:Expedited (15-DaCompany Report #WAES 01031593
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Flonase	C				
			Prozac	C				
			Tegretol-Xr	C				
			Zantac	C				
			[Therapy Unspecified]	C				
			Clonazepam	C				
			Terazosin	C				
			Vitamins (Unspecified)	C				

Date:03/28/01ISR Number: 3691310-4Report Type:Expedited (15-DaCompany Report #WAES 01031725
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Aspirin	C				

Date:03/28/01ISR Number: 3691314-1Report Type:Expedited (15-DaCompany Report #WAES 01032171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO

Date:03/28/01ISR Number: 3691315-3Report Type:Expedited (15-DaCompany Report #WAES 01032219
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	5 DAY

Date:03/28/01ISR Number: 3691316-5Report Type:Expedited (15-DaCompany Report #WAES 01032191
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma Emotional Disorder Gastritis

Pain
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/28/01ISR Number: 3691317-7Report Type:Expedited (15-DaCompany Report #WAES 01031727
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/28/01ISR Number: 3691318-9Report Type:Expedited (15-DaCompany Report #WAES 01032152
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/28/01ISR Number: 3691320-7Report Type:Expedited (15-DaCompany Report #WAES 01020604
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Failure Congestive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Representative
MG/DAILY/PO

Lotrel	C	
Tenormin	C	
Insulin, Isophane	C	

Date:03/28/01ISR Number: 3691321-9Report Type:Expedited (15-DaCompany Report #WAES 01021198
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
Hospitalization -	Duodenal Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Faeces Discoloured				Merck Co Inc	ORAL	25 MG/BID/PO	
	Gastrointestinal		Avapro	C				
	Haemorrhage		Aspirin	C				
	Haematemesis		Calcium	C				
			Folic Acid	C				

Date:03/28/01ISR Number: 3691322-0Report Type:Expedited (15-DaCompany Report #WAES 01022103
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research			
	Condition Aggravated	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Soma	C			

Date:03/28/01ISR Number: 3691328-1Report Type:Expedited (15-DaCompany Report #WAES 01031327
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Consumer	Vioxx	PS	Merck Research			
Other	Blood Pressure Increased	Health			Laboratories Div			
	Difficulty In Walking	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
	Oedema Peripheral		Celebrex	C				
	Paraesthesia		Flexeril	C				

Date:03/28/01ISR Number: 3691330-XReport Type:Expedited (15-DaCompany Report #WAES 01010367
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Dermatitis				Laboratories Div			
Initial or Prolonged	Diarrhoea				Merck Co Inc	ORAL	PO	
Disability	Face Oedema		Natures Rx Msm Plus					
	Night Sweats		C	C				
	Oedema Peripheral		Prempro	C				
	Paraesthesia							
	Tachycardia							
	Urticaria							
	Weight Increased							

Date:03/28/01ISR Number: 3692118-6Report Type:Expedited (15-DaCompany Report #WAES 01027504
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hyperhidrosis	Health			Laboratories Div			
Other	Hypotension	Professional			Merck Co Inc	ORAL	25 MG	

Amitriptyline	C
Estradiol Valerate /Norgestrel	C
Irbesartan	C
Levothyroxine Na	C
Lorazepam	C
Lormetazepam	C
Metoprolol Succinate	C
Oxybutynincl	C
Prazosin Hcl	C
Riboflavin	C

Date:03/28/01ISR Number: 3692119-8Report Type:Expedited (15-DaCompany Report #WAES 01039704
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Eruption Joint Swelling Oedema Peripheral	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	1 DAY
	Pyrexia Toxic Epidermal Necrolysis		Inj Hyaluronic Acid Na	SS			UNKNOWN	1 DAY

Date:03/28/01ISR Number: 3692120-4Report Type:Expedited (15-DaCompany Report #WAES 01039754
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Eosinophilia Hepatic Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY	

Date:03/28/01ISR Number: 3692122-8Report Type:Expedited (15-DaCompany Report #WAES 01039135
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Gastritis Erosive Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY	
			Aspirin Lysine	C				
			Omeprazole	C				
			Ranitidine	C				

Date:03/28/01ISR Number: 3692123-XReport Type:Expedited (15-DaCompany Report #WAES 01038757
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Oedema Genital Oedema Peripheral	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO 6 DAY

Date:03/28/01ISR Number: 3692124-1Report Type:Expedited (15-DaCompany Report #WAES 01036087
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Fluindione	SS		ORAL	PO	

Date:03/28/01ISR Number: 3692126-5Report Type:Expedited (15-DaCompany Report #WAES 01035085
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hepatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		1 TABLET/DAILY	8 DAY
			Acetaminophen	C				

Date:03/28/01ISR Number: 3692127-7Report Type:Expedited (15-DaCompany Report #WAES 01033502
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Injury	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Oedema Peripheral							
	Renal Failure							
	Wound Secretion		Fosamax	C				

			Vasotec	C		

Date:03/28/01ISR Number: 3692129-0Report Type:Expedited (15-DaCompany Report #WAES 01027508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fracture Malunion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ciprofibrate	C				
			Dipyridamole	C				

Date:03/28/01ISR Number: 3692130-7Report Type:Expedited (15-DaCompany Report #WAES 01027507
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Medical Device Complication	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen	C				
			Lorazepam	C				

Date:03/28/01ISR Number: 3692131-9Report Type:Expedited (15-DaCompany Report #WAES 01027506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Medical Device Complication	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Acetaminophen (+) Codeine	C				

Date:03/28/01ISR Number: 3716878-0Report Type:Periodic Company Report #01RUSWE0100038
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Thyroid Stimulating Hormone Increased	Consumer Health	Welchol	PS	Sankyo Pharma Inc	ORAL	1875 MG, QD, ORAL	
	Fatigue	Professional	Rofecoxib (Rofecoxib)	SS		ORAL	50 MG, QD, ORAL	
			Pioglitazone	C				
			Synthroid (Levothyroxine Sodium)	C				
			Aynthroid (Levothyroxine Sodium)	C				

Date:03/28/01ISR Number: 3717871-4Report Type:Periodic Company Report #WAES 00121555
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Allegra	C	
Synthroid	C	
Albuterol	C	

Date:03/29/01ISR Number: 3692280-5Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx 25mg	PS		ORAL	25MG TWICE	
Initial or Prolonged	Oedema Peripheral						DAILY ORAL	
			Glucophage	C				
			Dilantin	C				
			Glyburide	C				
			Ferrous Sulfate	C				
			Calcium Carbonate	C				
			Aspirin	C				
			Prempro	C				

Date:03/29/01ISR Number: 3692281-7Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx 12.5mg	PS		ORAL	12.5 MG ONCE	
Initial or Prolonged	Renal Failure Acute						DAILY ORAL	
Required			Warfarin 5mg	SS		ORAL	5MG ONCE	
Intervention to							DAILY ORAL	
Prevent Permanent			Digoxin	C				
Impairment/Damage			Foltrin	C				
			Nitroglycerin	C				
			Prevacid	C				
			Lasix	C				
			Urecholine	C				

			Remeron	C		
			Sucralfate	C		

Date:03/29/01ISR Number: 3692483-XReport Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Electrolyte Imbalance		Vioxx 25 Mg	PS		ORAL	25 MG ONCE	
Initial or Prolonged	Renal Failure Acute						DAILY ORAL	
Required			Zoloft	C				
Intervention to			Risperdal	C				
Prevent Permanent			Darvocet	C				
Impairment/Damage								

Date:03/29/01ISR Number: 3692497-XReport Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx 25mg	PS		ORAL	25 MG ONCE	
Initial or Prolonged	Melaena						DAILY ORAL	
	Upper Gastrointestinal		Vioxx 50mg	SS		ORAL	50 MG ONCE	
	Haemorrhage						DAILY ORAL	
	Vomiting		Cardura	C				
			Digoxin	C				

			Toprol	C		
			Ditropan	C		
			Synthroid	C		
			Methotrexate	C		
			Enteric-Coated Aspirin	C		
			Tylenol	C		

Date:03/29/01ISR Number: 3692499-3Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx 12.5 Mg	PS		ORAL	12.5MG ONCE	
Initial or Prolonged	Haemorrhage						DAILY ORAL	
	Melaena		Aspirin	C				
			Phoslo	C				
			Paxil	C				
			Vitamin E	C				
			Zinc	C				
			Vitamin C	C				
			Restoril	C				
			Pletal	C				
			Imodium	C				
			Vicodin	C				

Date:03/29/01ISR Number: 3692501-9Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nephritis Interstitial		Vioxx 12.5mg	PS		ORAL	VIOXX 12.5MG	
Initial or Prolonged							ORAL	
			Levaquin 500mg	SS		ORAL	500MGOD ORAL	
			Lisinopril	C				
			Ambien	C				
			Diltiazem	C				
			Iron	C				

			Digoxin	C		
			Pepcid	C		
			Paxil	C		

Date:03/29/01ISR Number: 3692506-8Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx 12.5 Mg	PS		ORAL	12.5 MG ONCE	
Initial or Prolonged	Cardiac Output Decreased						DAILY ORAL	
	Gastritis Erosive		Aspirin 325mg	SS		ORAL	325MG ONCE	
	Hypovolaemia						DAILY ORAL	
	Melaena		Lanoxin	C				
	Myocardial Ischaemia		Kcl	C				
	Renal Failure Acute		Plavix	C				
			Mvi	C				
			Isordil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/01ISR Number: 3692512-3Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx 25mg	PS		ORAL	25 MG ONCE	
Initial or Prolonged	Gastritis						DAILY ORAL	
	Vomiting		Nystatin Oral Susp	C				
			Premarin Vaginal Cream	C				
			Prednisone	C				
			Premarin 0.625mg	C				
			Kcl 10meq	C				
			Zoloft	C				
			Mvi	C				
			Lasix	C				
			Darvocet	C				
			Ultram	C				
			Tigan	C				

Date:03/29/01ISR Number: 3692522-6Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoptysis		Vioxx 12.5mg	PS			25MG BID PRN	
Initial or Prolonged			Lasix	C				
			Kcl	C				
			Prevacid	C				
			Oxycontin	C				
			Demerol	C				
			Neurontin	C				
			Capoten	C				

Date:03/29/01ISR Number: 3692639-6Report Type:Expedited (15-DaCompany Report #WAES 01010453
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Vioxx	PS	Merck Research			

Ecchymosis Professional Laboratories Div
Factor Viii Deficiency Merck Co Inc ORAL
25 MG DAILY
Haemarthrosis
PO 1 WK
Myalgia Antihemophilic
Oedema Factor C
Pain

Date:03/29/01ISR Number: 3692642-6Report Type:Expedited (15-DaCompany Report #WAES 01020829
Age:90 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Body Temperature Decreased
Disability	Cerebrovascular Accident
Other	Cough
	Dizziness
	Embolism
	Escherichia Infection
	Faecal Incontinence
	Gastrointestinal Haemorrhage

		Gastrointestinal Ulcer					
		Hypertension					
		Hypoproteinaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension	Health	Vioxx	PS	Merck Research	
		Hypothyroidism	Professional			Laboratories Div	
		Oxygen Saturation	Other			Merck Co Inc	ORAL
25 MG DAILY							
		Decreased					
PO							
		Respiratory Rate		Actonel 5 Mg	SS		
5 MG / DAILY							
		Increased					
/ UNK							
		Sinus Tachycardia		Celebrex	C		
		Thrombocytopenia		Miacalcin	C		
				Norvasc	C		
				Synthroid	C		
				Tylenol	C		
				Zithromax	C		
				Aspirin	C		
				Nonsteroidal			
				Anti-Inflammatory D	C		
				Vitamin D	C		

Date:03/29/01ISR Number: 3692645-1Report Type:Expedited (15-DaCompany Report #WAES 01030152
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Activated Partial	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Thromboplastin Time	Professional			Laboratories Div	
		Prolonged				Merck Co Inc	ORAL
25 - 50 MG							
		International Normalised					
DAILY PO							
		Ratio Increased		Univasc	C		
		Prothrombin Time		Vicodin	C		
		Prolonged					

Date:03/29/01ISR Number: 3692646-3Report Type:Expedited (15-DaCompany Report #WAES 00120601
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Vioxx	PS	Merck Research			
Other	Angioneurotic Oedema	Professional			Laboratories Div			
	Disorientation	Company			Merck Co Inc	ORAL	25 MG DAILY	
	Dyspnoea	Representative					PO	
	Fatigue		Cardizem	C				
	Headache		Plavix	C				
	Pruritus		Prevacid	C				
			Toprol Xl	C				
			Wellbutrin	C				
			Xanax	C				
			Nitroglycerin	C				

Date:03/29/01ISR Number: 3692808-5Report Type:Expedited (15-DaCompany Report #WAES 01025567
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Steatosis	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Hepatitis	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	50 MG/BID PO	
							(SEE IMAGE)	3 DAY
			Inj Etomidate	SS				
			Inhl Desflurane	SS			1 DAY	
							RESPIRATORY	

(INHALATION) INH 1 DAY

Succinylcholine Chloride	SS
Pancuronium Bromide	SS
Bupivacaine Hcl	C
Piritramide	C

1 DAY

1 DAY

Date:03/29/01ISR Number: 3692812-7Report Type:Expedited (15-DaCompany Report #WAES 01039754
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
		Other						

Date:03/30/01ISR Number: 3693311-9Report Type:Expedited (15-DaCompany Report #WAES 01036128
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO; 25MG PO	131 DAY

Timoptic	C
Amylase (+)	
Cellulase (+)	
Dimethicone (+)	C
Cisapride	C
Fenofibrate	C
Lansoprazole	C
Mianserin Hcl	C
Repaglinide	C

Date:03/30/01ISR Number: 3693336-3Report Type:Expedited (15-DaCompany Report #WAES 01035143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	539 DAY
	Gastroenteritis	Other						
	Helicobacter							
	Hiatus Hernia							
	Oesophageal Ulcer		Bendroflumethiazide	C				
	Vomiting		Ferrousso4	C				

Date:03/30/01ISR Number: 3693340-5Report Type:Expedited (15-DaCompany Report #WAES 01035572
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypercalcaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 DAY
Hospitalization - Initial or Prolonged	Neoplasm	Health Professional						
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/01ISR Number: 3693342-9Report Type:Expedited (15-DaCompany Report #WAES 01035575
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastritis Erosive Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	7 DAY

Date:03/30/01ISR Number: 3693347-8Report Type:Expedited (15-DaCompany Report #WAES 01038123
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	11 DAY

Date:03/30/01ISR Number: 3693348-XReport Type:Expedited (15-DaCompany Report #WAES 01038758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Hyponatraemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:03/30/01ISR Number: 3693349-1Report Type:Expedited (15-DaCompany Report #WAES 01020825
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faecal Occult Blood Positive	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	International Normalised	Other			Merck Co Inc	ORAL
PO						
	Ratio Increased		Coumadin	C		
			Pravachol	C		
			Valium	C		
			Aspirin	C		
			Meclizine	C		

Date:03/30/01ISR Number: 3693350-8Report Type:Expedited (15-DaCompany Report #WAES 01039139
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bacterial Infection	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Diverticulum Duodenal	Health			Laboratories Div	
	Duodenal Ulcer	Professional			Merck Co Inc	ORAL
25						
	Gastroenteritis					
MG/DAILY/PO 8 DAY						
	Helicobacter		Elcatonin	C		
	Gastrointestinal Disorder					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Hiatus Hernia					
	Melaena					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/01ISR Number: 3693352-1Report Type:Expedited (15-DaCompany Report #WAES 01035084
Age:85 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Perforation	Other			Laboratories Div			
Initial or Prolonged	Respiratory Failure				Merck Co Inc	ORAL	12.5 MG/DAILY	
	Sepsis							
PO								
			Prinivil	C				
			Bendroflumethiazide	C				
			Citalopram	C				
			Oxazepam	C				
			Oxybutynin Cl	C				
			Temazepam	C				
			Thyroxine	C				

Date:03/30/01ISR Number: 3693353-3Report Type:Expedited (15-DaCompany Report #WAES 01031675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research			
	Gastrooesophageal Reflux	Company			Laboratories Div			
	Disease	Representative			Merck Co Inc	ORAL		
PO								
	Pain		Nonsteroidal					
			Anti-Inflammatory					
			Drug (Unspecified)					
			Unk	SS				

Date:03/30/01ISR Number: 3693354-5Report Type:Expedited (15-DaCompany Report #WAES 01039758
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		
PO								

Date:03/30/01ISR Number: 3693356-9Report Type:Expedited (15-DaCompany Report #WAES 01039757
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:03/30/01ISR Number: 3693357-0Report Type:Expedited (15-DaCompany Report #WAES 01032444
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Morphine	C				

Date:03/30/01ISR Number: 3693359-4Report Type:Expedited (15-DaCompany Report #WAES 01032487
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Headache Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:03/30/01ISR Number: 3693360-0Report Type:Expedited (15-DaCompany Report #WAES 01032622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Glucophage	C				
			Lanoxin	C				
			Vicodin Es Tablets	C				

Date:03/30/01ISR Number: 3693378-8Report Type:Expedited (15-DaCompany Report #WAES 01033565
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

Date:03/30/01ISR Number: 3693380-6Report Type:Expedited (15-DaCompany Report #WAES 01028598
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrochlorthiazide	SS				

Date:03/30/01ISR Number: 3693646-XReport Type:Expedited (15-DaCompany Report #200110168BWH
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypotension	Health Professional	Cipro	PS	Bayer Corp	ORAL	1000 MG DAILY	
Hospitalization -	Oliguria						ORAL	
Initial or Prolonged	Renal Failure Acute	Other	Vioxx	SS		ORAL	50 MG DAILY	
	Sepsis						ORAL	

Date:03/30/01ISR Number: 3693901-3Report Type:Periodic Company Report #A031527
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erectile Dysfunction Libido Decreased	Consumer	Cardura	PS	Pfizer Laboratories Div Pfizer Inc	ORAL	ORAL	
			Rofecoxib	SS				
			Baycol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/01ISR Number: 3694396-6Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS		ORAL		
Initial or Prolonged	Abdominal Pain Lower		Fosamax	SS		ORAL		
Required	Abdominal Pain Upper		Aspirin	C				
Intervention to	Asthenia		Detrol	C				
Prevent Permanent	Cardiac Arrest		Evista	C				
Impairment/Damage	Chest Pain		Zocor	C				
	Haematemesis		Atenolol	C				
	Haematocrit Decreased		Tramadol	C				
	Hyperhidrosis							
	Hypotension							
	Nausea							
	Pharyngolaryngeal Pain							
	Rectal Haemorrhage							
	Restlessness							
	Vomiting							

Date:04/03/01ISR Number: 3695069-6Report Type:Expedited (15-DaCompany Report #WAES 01032444
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Rectal Haemorrhage	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		
12.5								
MG/BID/PO								
			Morphine	C				

Date:04/03/01ISR Number: 3695568-7Report Type:Expedited (15-DaCompany Report #WAES 01033064
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			

Merck Co Inc ORAL
PO
Prevacid C
Robitussin C

Date:04/03/01ISR Number: 3695570-5Report Type:Expedited (15-DaCompany Report #WAES 01032675
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			
Other	Pulmonary Oedema				Merck Co Inc	ORAL	25	MG/DAILY/PO
			Imbaral	C				
			Prednisone	C				

Date:04/03/01ISR Number: 3695578-XReport Type:Expedited (15-DaCompany Report #WAES 01032886
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disorientation Oedema Peripheral Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/01ISR Number: 3695584-5Report Type:Expedited (15-DaCompany Report #WAES 01011751
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Vioxx	PS	Merck Research			
Life-Threatening	Decreased	Professional			Laboratories Div			
Hospitalization -	Blood Potassium Decreased				Merck Co Inc	ORAL	25	
Initial or Prolonged	Blood Potassium Increased						MG/DAILY/PO	
Disability	Haemodialysis		Benadryl	C				
Other	Oedema Peripheral		Buspar	C				
	Pain In Extremity		Cipro	C				
	Renal Failure Acute		Coumadin	C				
			Lasix	C				
			Lortab	C				
			Pepcid	C				
			Prinivil	C				
			Vicodin Tablets	C				
			Ferrous Sulfate	C				
			Trazodone	C				
			Vitamins	C				
			Zinc	C				

Date:04/03/01ISR Number: 3695586-9Report Type:Expedited (15-DaCompany Report #WAES 01030367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck Research			
Hospitalization -	Fatigue	Professional			Laboratories Div			
Initial or Prolonged	Gastric Ulcer Haemorrhage	Company			Merck Co Inc	ORAL	50	
Other	Haemoglobin Decreased	Representative					MG/DAILY/PO	
			Pravachol	C				
			Zantac	C				
			Aspirin	C				

Date:04/03/01ISR Number: 3695588-2Report Type:Expedited (15-DaCompany Report #WAES 01021881
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous Pregnancy	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY /PO	
			Ultram	C				
			Prednisone	C				
			Vitamins	C				

Date:04/03/01ISR Number: 3695589-4Report Type:Expedited (15-DaCompany Report #WAES 01031080
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Major Depression Suicidal Ideation Thinking Abnormal	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/DAILY/PO	

Date:04/03/01ISR Number: 3695592-4Report Type:Expedited (15-DaCompany Report #WAES 01033074
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dextropropoxyphene	C				

Date:04/03/01ISR Number: 3696167-3Report Type:Expedited (15-DaCompany Report #WAES 01037260
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	
	Dyspnoea	Other						
	Hypertension							
	Hypothyroidism							
	Marrow Hyperplasia		Tab Furosemide	SS		ORAL	PO	64 DAY
	Microcytic Anaemia		Cap Lansoprazole	SS		ORAL	30 MG PO	64 DAY
	Nephritis		Acetazolamide	C				
	Renal Failure Acute		Calcium Carbonate	C				
			Ibuprofen	C				
			Levothyroxine Na	C				
			Metoprolol Tartrate	C				
			Nystatin	C				
			Potassium Chloride	C				
			Prednisolone	C				

Date:04/03/01ISR Number: 3696213-7Report Type:Expedited (15-DaCompany Report #WAES 01037258
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Sodium Decreased	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Dehydration	Other			Laboratories Div	
	Diarrhoea				Merck Co Inc	ORAL
25 MG PO 84 DAY						
	Renal Failure		Allopurinol	C		
			Amiloride	C		
			Aspirin	C		
			Citalopram Hydrobromide	C		
			Digoxin	C		
			Furosemide	C		
			Metoprolol Tartrate	C		
			Mianserin Hcl	C		
			Omeprazole Magnesium	C		

Date:04/03/01ISR Number: 3696217-4Report Type:Expedited (15-DaCompany Report #WAES 01037307
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG/DAILY						
PO						
			Cap Ketoprofen	SS		ORAL
PO						
			Tab Sulfasalazine	SS		ORAL
PO 30 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/01ISR Number: 3696329-5Report Type:Expedited (15-DaCompany Report #WAES 01039148
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Gastroenteritis Helicobacter Hypovolaemic Shock Melaena	Foreign Health Professional	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 9 MON

Date:04/03/01ISR Number: 3696334-9Report Type:Expedited (15-DaCompany Report #WAES 01035172
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations	Foreign Other	Vioxx Aspirin Bisoprolol Ciprofibrate Isosorbide Mononitrate Rabeprazole Sodium~	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 8 DAY

Date:04/03/01ISR Number: 3696341-6Report Type:Expedited (15-DaCompany Report #WAES 01035211
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Electrolytes Abnormal Blood Pressure Increased Laboratory Test Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/03/01ISR Number: 3696343-XReport Type:Expedited (15-DaCompany Report #WAES 01035573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Hypersensitivity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/03/01ISR Number: 3696386-6Report Type:Expedited (15-DaCompany Report #WAES 01039610
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Blood Pressure Increased Cardiac Failure Congestive	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	9 MON
Disability	Dyspnoea Fatigue Malaise Oedema Peripheral		Hyzaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/01ISR Number: 3696388-XReport Type:Expedited (15-DaCompany Report #WAES 01037320
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Visual Field Defect	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	38 DAY
			Metoprolol Tartrate	C				

Date:04/03/01ISR Number: 3696402-1Report Type:Expedited (15-DaCompany Report #WAES 01038227
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vasculitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Tab Clopidogrel Bisulfate	SS		ORAL	75 MG/DAILY	
			Cap Valsartan	SS		ORAL	80 MG	
			Tab Carvedilol	SS		ORAL	12.5 MG	
			Tab Zocor (Simvastatin)	SS		ORAL	20 MG	
			Flupentixol Hydrochloride (+) Melitracen	C				
			Levothyroxine Na	C				
			Loperamide Hcl	C				
			Moclobemide	C				
			Oxazepam	C				

Date:04/03/01ISR Number: 3696430-6Report Type:Expedited (15-DaCompany Report #WAES 01036087
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO						
			Tab Acenocoumarol	SS		ORAL
PO						
			Powd Aspirin	SS		ORAL
PO						
			Insulin	C		

Date:04/03/01ISR Number: 3696464-1Report Type:Expedited (15-DaCompany Report #WAES 01030364
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Health	Vioxx	PS	Merck Research	
Hospitalization -	Haemorrhage	Professional			Laboratories Div	
Initial or Prolonged		Company			Merck Co Inc	ORAL
25 MG DAILY						
		Representative				
PO						
			Aricept	C		

Date:04/03/01ISR Number: 3696472-0Report Type:Expedited (15-DaCompany Report #WAES 00119856
Age:57 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection Conjunctivitis Dermatitis Atopic Diabetes Mellitus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 5 DAY
	Multi-Organ Failure Pseudomonal Sepsis Staphylococcal Sepsis Stevens-Johnson Syndrome Toxic Epidermal Necrolysis		Fosamax Calcium (Unspecified)	C C				

Date:04/03/01ISR Number: 3696490-2Report Type:Expedited (15-DaCompany Report #WAES 01037259
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Blood Sodium Decreased Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haematemesis Haemoglobin Decreased		Aspirin/Caffeine Prednisolone Amiloride Hydrochloride/Hctz Ferrous So4 Verapamil	SS SS C C C				

Date:04/03/01ISR Number: 3696512-9Report Type:Expedited (15-DaCompany Report #01-04-001
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Study Health Professional	Vioxx 25 Mg Reserpine	PS C		ORAL	25 MG PO DAILY	

Hydrochlorothiazide	C
K-Dur	C
Cardizem	C
Lanoxin	C
Ultram	C
Neurontin	C
Coumadin	C

Date:04/03/01ISR Number: 3700614-8Report Type:Expedited (15-DaCompany Report #WAES 01026035
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Iron Increased
	Gastric Ulcer
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haematemesis
	Haemoglobin Decreased
	Malaise
	Melaena
	Petechiae
	Serum Ferritin Increased

		Varices Oesophageal					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12	DAY						
				Acebutolol Hydrochloride	C		

Date:04/06/01ISR Number: 3697715-XReport Type:Expedited (15-DaCompany Report #WAES 01032891
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Angina Pectoris	Health Professional	Maxalt (Rizatriptan Benzoate)	PS	Merck & Co., Inc	ORAL
	Coagulation Time Shortened		Vioxx	SS		
	Coronary Artery Occlusion		Zocor	C		
	Hypotension		Xanax	C		
	Myocardial Infarction					
	Post Procedural Complication					
	Post Procedural Pain					
	Vasospasm					

Date:04/06/01ISR Number: 3700153-4Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage		Vioxx	PS		
	Upper Gastrointestinal Haemorrhage					

Date:04/06/01ISR Number: 3700174-1Report Type:Expedited (15-DaCompany Report #WAES 01021369
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Pain Rash Erythematous Rash Scaly	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Skin Discolouration		Tamoxifen Unk Potassium (Unspecified) Unk Hctz/Triamterene Unk	SS SS SS				

Date:04/06/01ISR Number: 3700175-3Report Type:Expedited (15-DaCompany Report #WAES 01020646
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/06/01ISR Number: 3700176-5Report Type:Expedited (15-DaCompany Report #WAES 01034210
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatic Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/06/01ISR Number: 3700178-9Report Type:Expedited (15-DaCompany Report #WAES 01034213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Thrombosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Composition Unspecified	C				

Date:04/06/01ISR Number: 3700195-9Report Type:Expedited (15-DaCompany Report #WAES 01033155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Increased Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	

Date:04/06/01ISR Number: 3700214-XReport Type:Expedited (15-DaCompany Report #WAES 01011368
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis	Consumer	Vioxx	PS	Merck Research			
	Dry Mouth	Health			Laboratories Div			
	Dyspnoea	Professional			Merck Co Inc	ORAL	25	
	Hyperaemia						MG/DAILY/PO	
	Insomnia		Advil	C				
	Pain In Extremity		Celebrex	C				
	Pneumonia		Skelaxin	C				
	Pulmonary Congestion							
	Urinary Tract Infection							

Date:04/06/01ISR Number: 3700220-5Report Type:Expedited (15-DaCompany Report #WAES 01034317
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck Research			
	Dizziness	Professional			Laboratories Div			
	Haemorrhagic Stroke	Company			Merck Co Inc	ORAL	12.5	
	International Normalised	Representative					MG/DAILY/PO	
	Ratio Increased		Cardizem	C				
	Nausea		Coumadin	C				
	Prothrombin Time		Fosamax	C				
	Prolonged		Vitamin D (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700222-9Report Type:Expedited (15-DaCompany Report #WAES 01034316
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Non-Cardiogenic Pulmonary Oedema Oedema Pneumonia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO (SEE IMAGE)	
			Celexa	C				
			Sonata	C				
			Trazodone	C				

Date:04/06/01ISR Number: 3700223-0Report Type:Expedited (15-DaCompany Report #WAES 01032622
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Glucophage	C				
			Lanoxin	C				
			Vicodin Es Tablets	C				

Date:04/06/01ISR Number: 3700355-7Report Type:Expedited (15-DaCompany Report #WAES 01034115
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/06/01ISR Number: 3700372-7Report Type:Expedited (15-DaCompany Report #WAES 01032507
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Virus Culture Positive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Sustiva	C				

Date:04/06/01ISR Number: 3700382-XReport Type:Expedited (15-DaCompany Report #WAES 01034258
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700386-7Report Type:Expedited (15-DaCompany Report #WAES 01033208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Depakote	C				
			Topamax	C				
			Phenobarbital	C				

Date:04/06/01ISR Number: 3700387-9Report Type:Expedited (15-DaCompany Report #WAES 01022079
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Allerga	C				
			Lasix	C				
			Lipitor	C				
			Vicodin Tablets	C				
			Therapy Unspecified	C				

Date:04/06/01ISR Number: 3700389-2Report Type:Expedited (15-DaCompany Report #WAES 01030609
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased Syncope	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
Other		Representative						
			Hytrin	C				
			Motrin	C				
			Plendil	C				
			Atenolol	C				

			Naproxen	C		

Date:04/06/01ISR Number: 3700390-9Report Type:Expedited (15-DaCompany Report #WAES 01031675
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research	
	Back Pain	Company			Laboratories Div	
	Gastrointestinal Disorder	Representative			Merck Co Inc	ORAL
PO						
	Gastrooesophageal Reflux		Nonsteroidal			
	Disease		Anti-Infammatory			
			Drug (Unspecified)	SS		

Date:04/06/01ISR Number: 3700392-2Report Type:Expedited (15-DaCompany Report #WAES 01034341
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancreatic Disorder	Health	Vioxx	PS	Merck Research	
		Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700612-4Report Type:Expedited (15-DaCompany Report #WAES 00118662
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	8 DAY
	Vomiting	Professional Other	Furosemide	C				
			Levothyroxine	C				
			Lithiumco3	C				
			Meperidine Hcl	C				
			Omeprazole Magnesium	C				
			Perindopril	C				
			Sertraline	C				

Date:04/06/01ISR Number: 3700613-6Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased Chromaturia Coombs Direct Test Positive Faeces Pale Haemolytic Anaemia Hepatic Cirrhosis Hepatic Necrosis Hepatic Steatosis Hepatitis A Antibody Positive Hepatitis Cholestatic Hypergammaglobulinaemia Lipase Increased Red Blood Cell Sedimentation Rate Increased Serum Ferritin Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Levothyroxine Na	C				

Date:04/06/01ISR Number: 3700616-1Report Type:Expedited (15-DaCompany Report #WAES 00088565
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	34 DAY
		Professional	Acebutolol Hydrochloride	C				
			Furosemide	C				

Date:04/06/01ISR Number: 3700617-3Report Type:Expedited (15-DaCompany Report #WAES 00118647
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	15 DAY
		Professional Other	Betaxolol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700619-7Report Type:Expedited (15-DaCompany Report #WAES 00048518
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Literature			Laboratories Div			
Initial or Prolonged	Fluid Retention	Health			Merck Co Inc	ORAL	25 MG/DAILY	62 DAY
	Hyponatraemia	Professional	Pepcid	C				
	Oedema Peripheral		Acetaminophen	C				
			Methotrexate	C				
			Prednisolone	C				

Date:04/06/01ISR Number: 3700632-XReport Type:Expedited (15-DaCompany Report #WAES 01038630
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	

Date:04/06/01ISR Number: 3700633-1Report Type:Expedited (15-DaCompany Report #WAES 01039610
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Blood Pressure Increased	Consumer			Laboratories Div			
Initial or Prolonged	Cardiac Failure	Other			Merck Co Inc	ORAL	25 MG/DAILY	
Disability	Congestive							
PO								9 MON
	Dyspnoea		Hyzaar	C				
	Fatigue							
	Malaise							
	Oedema Peripheral							

Date:04/06/01ISR Number: 3700634-3Report Type:Expedited (15-DaCompany Report #WAES 00118911
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
	Change Of Bowel Habit							
	Face Oedema							
	Hypertension	Other	Sertraline	SS		ORAL	PO	1 DAY
	Hyponatraemia		Clobazam	C				
	Insomnia		Tizanidine	C				
	Tremor							
	Vomiting							

Date:04/06/01ISR Number: 3700664-1Report Type:Expedited (15-DaCompany Report #N128126
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Vasculitis	Health Professional	Plavix	PS	Sanofi Synthelabo Inc	ORAL	75 MG	
Hospitalization - Initial or Prolonged			Valsartan	SS			80 MG	
			Carvedilol	SS			12.5 MG	
			Rofecoxib	SS			25 MG	
			Simvastatin	SS			20 MG	
			Moclobemide	C				
			Oxazepam	C				

			Loperamide	C		
			Levothyroxin (Levothyroxine Sodium)	C		
			Melitracen	C		
			Flupentixol	C		

Date:04/06/01ISR Number: 3700675-6Report Type:Expedited (15-DaCompany Report #WAES 01035249
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/ORAL	3 DAY
			Cozaar	C				

Date:04/06/01ISR Number: 3700676-8Report Type:Expedited (15-DaCompany Report #WAES 01035572
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Hypercalcaemia Neoplasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	6 DAY
	Sedation		Methotrexate	C				

Date:04/06/01ISR Number: 3700678-1Report Type:Expedited (15-DaCompany Report #WAES 00126191
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Diverticulum	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

	Melaena	Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO 45 DAY						
			Tab Fenoprofen	SS		ORAL
300 MG/TID/PO 2 YR						
			Acetaminophen	C		
			Allopurinol	C		
			Digoxin	C		
			Furosemide	C		
			Potassium (Unspecified)	C		

Date:04/06/01ISR Number: 3700679-3Report Type:Expedited (15-DaCompany Report #WAES 01038601
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50 MG/25						
MG/DAILY/PO 3 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700681-1Report Type:Expedited (15-DaCompany Report #WAES 01035256
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hyponatraemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAY/PO	1 DAY
			Hydroflumethiazide (+) Spironolactone Propranolol	 C C				

Date:04/06/01ISR Number: 3700682-3Report Type:Expedited (15-DaCompany Report #WAES 01036781
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Circulatory Collapse Dizziness Loss Of Consciousness	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/06/01ISR Number: 3700683-5Report Type:Expedited (15-DaCompany Report #WAES 01037513
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	66 DAY
			Cozaar Allopurinol Citalopram Hydromide	C C C				

Date:04/06/01ISR Number: 3700684-7Report Type:Expedited (15-DaCompany Report #WAES 01038588
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 10 DAY

Date:04/06/01ISR Number: 3700686-0Report Type:Expedited (15-DaCompany Report #WAES 01037519
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO 121 DAY
Other	Gastric Ulcer Haemorrhage							
	Haematemesis							
			Terazosin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/01ISR Number: 3700687-2Report Type:Expedited (15-DaCompany Report #WAES 01035542
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO 11 MON
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				
			Atorvastatin	C				
			Estradiol	C				
			Insulin Human	C				
			Insulin Lispro	C				
			Morphines04	C				
			Piretanide	C				
			Timolol Maleate	C				

Date:04/06/01ISR Number: 3700689-6Report Type:Expedited (15-DaCompany Report #WAES 00075593
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic Gastrointestinal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Haemorrhage	Other						
			Aspirin	C				

Date:04/06/01ISR Number: 3700690-2Report Type:Expedited (15-DaCompany Report #WAES 01033778
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						

Date:04/06/01ISR Number: 3700692-6Report Type:Expedited (15-DaCompany Report #WAES 00118623
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Literature	Vioxx	PS	Merck Research Laboratories Div	
		Health			Merck Co Inc	ORAL
PO						
		Professional Other	[Therapy Unspecified]	C		
			Diltiazem Hydrochloride	C		
			Isosorbide Dinitrate	C		
			Nitroglycerin	C		

Date:04/06/01ISR Number: 3700694-XReport Type:Expedited (15-DaCompany Report #WAES 00088566
Age:42 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure Congestive Condition Aggravated	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	
Hepatitis	Professional					PO	5 DAY
Low Cardiac Output		Blinded Therapy	SS		ORAL	PO	37 DAY
Syndrome		Carvedilol	C				
		Furosemide	C				
		Potassium Chloride	C				
		Warfarin Sodium	C				

Date:04/06/01ISR Number: 3700696-3Report Type:Expedited (15-DaCompany Report #WAES 00088617
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	
	Renal Failure Acute	Professional					PO	
			Vasotec	C				
			Aspirin	C				
			Furosemide	C				
			Glyburide	C				
			Metformin	C				
			Metoprolol Tartrate	C				

Date:04/06/01ISR Number: 3715132-0Report Type:Periodic Company Report #2000034672US
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Oedema Peripheral	Consumer	Detrol	PS	Pharmacia And Upjohn Co	ORAL	2MG QD ORAL	

				Vioxx	SS		
UNKNOWN							
				Antibiotics	C		
				Estrace	C		

Date:04/06/01ISR Number: 3718531-6Report Type:Periodic Company Report #2000033032US
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer Health	Detrol	PS	Pharmacia And Upjohn Co	ORAL	1 DF, BID,	
		Professional						
ORAL								
			Vioxx	SS				
			Celebrex	C				
			Mobic (Meloxicam)	C				

Date:04/09/01ISR Number: 3699963-1Report Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Xenical	PS	Roche			
302 DAY								
Initial or Prolonged	Gastritis		Rofecoxib	SS				
	Haematemesis		Aspirin	SS	Roche			
			Nitrazepam	C				
QN.								

Frusemide C
QAM.

Bisoprolol Fumarate C
QAM.

Citalopram C
Lisinopril C
Benoral C
Gaviscon Advance C
Carisoprodol C
Chlorpheniramine
Maleate C
ALSO REPORTED

AS RECEIVING

PIRITON

(CHLORPHRENIR

AMINE

Nicardipine
Hydrochloride C
Glyceroltrinitrat C
REPORTED AS

GLYCEROL

TRINITRATE

SPRAY PRN.

Simvastatin C
QN.

Date:04/10/01ISR Number: 3701795-2Report Type:Direct Company Report #
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - ORALLY	Haemorrhage Intracranial		Vioxx (50mg Daily 12/15-20)	PS		ORAL		
Initial or Prolonged INTRAMUSCULAR IM			Toradol (60/21)	SS				
Disability Required			Percocet	C				
			Tylenol	C				

Intervention to
Prevent Permanent
Impairment/Damage

Date:04/10/01ISR Number: 3701814-3Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx (50mg)	PS				

Date:04/10/01ISR Number: 3702489-XReport Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination		Rofecoxib 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	ORAL
			Cimetidine	C				
			Potassium Chloride	C				
			Ferrous Gluconate	C				
			Bismuth Subgallate	C				
			Calcium Carbonate	C				
			Levofloxacin	C				
			Temazepam	C				
			Prochlorperazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/01ISR Number: 3702691-7Report Type:Expedited (15-DaCompany Report #250972
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Foreign	Xenical	PS	Hlr Technology	ORAL	120 MG 3 PER	
Initial or Prolonged	Haematemesis	Health					DAY ORAL	
		Professional	Rofecoxib	SS		ORAL	25 MG 1 PER	
							DAY ORAL	
			Aspirin	SS				
			Nitrazepam	C				
			Frusemide	C				
			Bisoprolol Fumarate	C				
			Citalopram	C				
			Lisinopril	C				
			Benoral	C				
			Gaviscon Advance	C				
			Carisoprodol	C				
			Chlorpheniramine Maleate	C				
			Nicardipine Hydrochloride	C				
			Glyceroltrinitrat	C				
			Simvastatin	C				

Date:04/10/01ISR Number: 3702991-0Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx (Rofecoxib)	PS				
PTA								
Initial or Prolonged	Gastrointestinal		Lasix	C				
Required	Haemorrhage		Tylenol	C				
Intervention to	Syncope		Fosamax	C				
Prevent Permanent			Atenolol	C				
Impairment/Damage			Hydralazine	C				
			Asa	C				
			Mvi	C				
			Norvasc	C				

Date:04/11/01ISR Number: 3702968-5Report Type:Direct Company Report #
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS			25 MG BID	
Initial or Prolonged	Dyspnoea		Adderall	C				
	Faecal Occult Blood							
	Positive							
	Melaena							
	Nausea							
	Pallor							
	Vomiting							

Date:04/11/01ISR Number: 3702969-7Report Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Back Pain
Initial or Prolonged	Constipation
	Nausea
	Tenderness

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS			12.5 MG QD	
			Asa	SS			? MG QD	
			Mevacor	C				
			Novolin	C				
			Clonidine	C				
			Lisinopril	C				
			Prempro	C				
			Nitrodur	C				
			Timolol	C				
			Aldactone	C				

Date:04/11/01ISR Number: 3703100-4Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS		ORAL	12.5 M QD	
Initial or Prolonged	Congestive						ORAL	
	Condition Aggravated							
	Dyspnoea Exacerbated							
	Oedema Peripheral							

Date:04/11/01ISR Number: 3703101-6Report Type:Expedited (15-DaCompany Report #WAES 01040575
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Vioxx	PS	Merck Research			
	Pruritus	Professional			Laboratories Div			
	Skin Warm				Merck Co Inc	ORAL	25 MG/AM/PO	
	Urticaria							

Date:04/11/01ISR Number: 3703107-7Report Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Duodenal Ulcer		Rofecoxib	PS		ORAL	DAILY ORAL	
Intervention to Prevent Permanent Impairment/Damage	Faecal Occult Blood Positive Haemoglobin Decreased							

Date:04/11/01ISR Number: 3703109-0Report Type:Expedited (15-DaCompany Report #WAES 01033155
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

SEE IMAGE

Date:04/11/01ISR Number: 3703111-9Report Type:Expedited (15-DaCompany Report #WAES 01030192
Age: Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Bronchospasm Dysphagia

	Dyspnoea Face Oedema Hypersensitivity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise Mouth Ulceration Oral Discomfort Pulmonary Congestion Speech Disorder Tongue Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; UNK/UNK/PO 5 DAY

Date:04/11/01ISR Number: 3703113-2Report Type:Expedited (15-DaCompany Report #WAES 01034317
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardio-Respiratory Arrest Dizziness Haemorrhagic Stroke International Normalised Ratio Increased Nausea Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO
			Cardizem	C			
			Coumadin	C			
			Fosamax	C			
			Vitamin D (Unspecified)	C			

Date:04/11/01ISR Number: 3703114-4Report Type:Expedited (15-DaCompany Report #WAES 01040184
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Abdominal Distension Chest Pain Dizziness Dyspnoea Headache Influenza Like Illness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE
			Estraderm	C			
			Maxzide	C			
			Nizoral 2% Shampoo	C			

	Vaginal Haemorrhage		Norpramin	C
			Proventil	C
			Serevent	C

Date:04/11/01ISR Number: 3703118-1Report Type:Expedited (15-DaCompany Report #WAES 01011384
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG / PO						
			Tylenol	C		
			Capsaicin	C		
			Ferrous Sulfate	C		
			Lansoprazole	C		
			Simethicone	C		

Date:04/11/01ISR Number: 3703119-3Report Type:Expedited (15-DaCompany Report #WAES 01022014
Age:77 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Lower Abdominal Pain Upper Blood Chloride Increased Blood Glucose Increased Blood Pressure Systolic Decreased Blood Sodium Increased Blood Urea Increased Bronchospasm Cardiac Failure Congestive Cardiomegaly Condition Aggravated Conjunctival Disorder Cough Crepitations Dizziness Duodenal Ulcer Dyspnoea Exacerbated Faecal Occult Blood Positive Faeces Discoloured Gallbladder Disorder Gastrointestinal Haemorrhage Haematemesis Haematocrit Decreased Haemoglobin Decreased Influenza Like Illness International Normalised Ratio Increased Lipase Increased Malaise Mallory-Weiss Syndrome Melaena	Health Professional Company Representative	Vioxx Coumadin Unk Tab Aspirin Actos Darvocet-N Glucophage Lasix Norvasc Pravachol Slow Fe	PS SS SS C C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL ORAL ORAL	50 MG/DAILY/ORAL ; 25 MG/DAILY/PO 7.5 MG/DAILY/PO 81 MG/DAILY/PO	

Monocytosis
Mucous Membrane Disorder
Orthopnoea
Oxygen Saturation
Decreased
Pallor
Prothrombin Time
Prolonged
Tachycardia
Tenderness
Venous Pressure Jugular
Increased
Vomiting

Date:04/11/01ISR Number: 3703137-5Report Type:Expedited (15-DaCompany Report #WAES 01032891
Age:59 YR Gender:Male I/FU:F

Outcome
Death

PT
Angina Pectoris
Arterial Occlusive
Disease
Disseminated

	Intravascular Coagulation Hypotension Infarction Medication Error	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain	Health	Maxalt	PS	Merck And Co Inc	ORAL	PO
	Vasospasm	Professional	Tab Vioxx Unk	SS			
			Xanax	C			
			Zocor	C			

Date:04/11/01ISR Number: 3703147-8Report Type:Expedited (15-DaCompany Report #WAES 01040273
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia Loss Of Consciousness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Ovcon	C			
			Ibuprofen	C			

Date:04/11/01ISR Number: 3703152-1Report Type:Expedited (15-DaCompany Report #WAES 01040026
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Eye Infection Fungal Nephropathy Toxic	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
		Representative	Imuran (Azathioprine Sodium)	C			
			Cyclosporine	C			

Date:04/11/01ISR Number: 3703155-7Report Type:Expedited (15-DaCompany Report #WAES 01034259
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				
			Aspirin	C				

Date:04/11/01ISR Number: 3703162-4Report Type:Expedited (15-DaCompany Report #WAES 00072467
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
Other	Arthritis
	Bradycardia
	Chills
	Decreased Appetite
	Feeling Abnormal
	Feeling Jittery
	Gastrointestinal Disorder
	Gastrooesophageal Reflux
	Disease
	Insomnia
	Joint Sprain
	Malaise

	Muscle Spasms						
	Nausea						
	Nervousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research		
	Peripheral Vascular	Health			Laboratories Div		
	Disorder	Professional			Merck Co Inc	ORAL	25
	Tremor						MG/DAILY/PO
	Vertigo		Fosamax	C			
	Visual Disturbance		Calcium (+) Vitami	C			
			Glucosamine	C			
			Vitamins (Unspecified)	C			

Date:04/11/01ISR Number: 3703167-3Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS			PRN
Initial or Prolonged	Dizziness		Macrodantin	C			
	Faeces Discoloured		Claritin	C			
	Headache		Glucotrol Xl	C			
			Provera	C			
			Premarin	C			
			Prilosec	C			
			Actonel	C			
			Iberet-Folic	C			
			Tylenol	C			

Date:04/11/01ISR Number: 3703169-7Report Type:Expedited (15-DaCompany Report #WAES 00122282
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Distension	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Abdominal Pain	Health			Laboratories Div		
	Abdominal Tenderness	Professional			Merck Co Inc	ORAL	PO
	Biopsy Stomach Abnormal		Claritin	C			

Blood Glucose Decreased	Imitrex	C
Diarrhoea	Intal	C
Eosinophil Count	Premarin	C
Increased	Singulair	C
Eructation	Vancenase	C
Frequent Bowel Movements	Vanceril	C
Gastritis	Ventolin	C
Haemorrhoids	...	C
Odynophagia		
Pharyngeal Ulceration		
Protein Total Decreased		

Date:04/11/01ISR Number: 3703209-5Report Type:Expedited (15-DaCompany Report #WAES 01033074
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dextropropoxyphene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3703212-5Report Type:Expedited (15-DaCompany Report #WAES 01040275
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	B-Cell Lymphoma T-Cell Lymphoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Flexeril	C				
			Premarin	C				
			Zantac	C				
			Calcium Carbonate (+) Vitamin D	C				

Date:04/11/01ISR Number: 3703214-9Report Type:Expedited (15-DaCompany Report #WAES 00061957
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Beclovent	C				
			Cardura	C				
			Celexa	C				
			Didronel	C				
			Therapy Unspecified	C				
			Albuterol	C				
			Glyburide	C				
			Verapamil	C				

Date:04/11/01ISR Number: 3703232-0Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck Research			

Other	Bradycardia	Professional		Laboratories Div	
	Chills			Merck Co Inc	ORAL
25					
	Dizziness				
MG/DAILY/PO					
	Fatigue		Fosamax	C	
	Feeling Jittery		Calcium Carbonate		
	Gastrointestinal Disorder		(+) Vitamin D	C	
	Insomnia		Glucosamine	C	
	Malaise		Vitamins		
	Muscle Spasms		(Unspecified)	C	
	Nausea				
	Palpitations				
	Peripheral Vascular				
	Disorder				
	Tremor				
	Visual Disturbance				
	Weight Decreased				

Date:04/11/01ISR Number: 3703235-6Report Type:Expedited (15-DaCompany Report #WAES 01030391
Age:70 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Chest Discomfort	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Dyspnoea		Amaryl	C				
	Heart Rate Increased		Elavil	C				
	Hypertension		Glucophage	C				
	Pulmonary Oedema		Lotrel	C				
	Respiratory Rate Increased		Maxzide	C				
			Atenolol	C				

Date:04/11/01ISR Number: 3703260-5Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Face Oedema		Vioxx	PS		ORAL	1 PO QD / ONE DOSE ONLY	
	Lymphadenopathy							
	Pharyngitis		Lasix	C				
			Imdur	C				
			Cardizem Cd	C				
			Kcl	C				
			Lactulose	C				
			Mvi	C				
			Zinc	C				
			Vit C	C				
			Minocycline	C				
			Prevacid	C				
			Coumadin	C				
			Cipro	C				

Date:04/11/01ISR Number: 3703379-9Report Type:Expedited (15-DaCompany Report #WAES 01035609
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research			

Hospitalization - Initial or Prolonged	Faeces Discoloured	Health Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
	Gastrointestinal					
PO 92 DAY						
	Haemorrhage					

Date:04/11/01ISR Number: 3703385-4Report Type:Expedited (15-DaCompany Report #WAES 01029177
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertension	Foreign	Vioxx	PS	Merck Research	
	Pulmonary Oedema	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG/DAILY						
PO 62 DAY						

Date:04/11/01ISR Number: 3703387-8Report Type:Expedited (15-DaCompany Report #WAES 01045504
Age:89 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Hospitalization -
Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure Gastric Perforation Post Procedural Complication	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 127 DAY
Respiratory Failure		Hctz/Triamterene Benserazide/Levodopa Cabergoline Furosemide	C C C C				

Date:04/11/01ISR Number: 3703388-XReport Type:Expedited (15-DaCompany Report #WAES 01045520
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	PO

Date:04/11/01ISR Number: 3703389-1Report Type:Expedited (15-DaCompany Report #WAES 01047501
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO

Date:04/11/01ISR Number: 3703391-XReport Type:Expedited (15-DaCompany Report #WAES 01040096
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Cardura	C				
			Prilosec	C				
			Zoloft	C				
			Alprazolam	C				
			Aspirin	C				

Date:04/11/01ISR Number: 3703393-3Report Type:Expedited (15-DaCompany Report #WAES 01022231
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Dyspnoea Palpitations Ventricular Extrasystoles	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Flexeril	C				

Date:04/11/01ISR Number: 3703396-9Report Type:Expedited (15-DaCompany Report #WAES 01034358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Chest Pain Dizziness Haemorrhage Subcutaneous Headache Hypoaesthesia Mouth Ulceration Pyrexia Rheumatoid Arthritis Systemic Lupus Erythematosus Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/11/01ISR Number: 3703457-4Report Type:Expedited (15-DaCompany Report #WAES 01045011
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	94 DAY
			Cozaar	C				
			Acetaminophen/Codeine Phosphate	C				
			Allopurinol	C				
			Aspirin	C				

Date:04/11/01ISR Number: 3703459-8Report Type:Expedited (15-DaCompany Report #WAES 01039757
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Other

Date:04/11/01ISR Number: 3703461-6Report Type:Expedited (15-DaCompany Report #WAES 01039758
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Date:04/11/01ISR Number: 3703463-XReport Type:Expedited (15-DaCompany Report #WAES 01029178
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspnoea	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY 15 DAY						
		Other	Tab Vioxx (Rofecoxib) 12.5 Mg	SS		ORAL
15 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3703469-0Report Type:Expedited (15-DaCompany Report #WAES 01045004
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Gastrointestinal Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Albuterol	C				
			Aspirin	C				
			Beclomethasone Dipropionate	C				
			Thyroxine	C				

Date:04/11/01ISR Number: 3703471-9Report Type:Expedited (15-DaCompany Report #WAES 01037537
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
			Sinemet	C				
			Amlodipine	C				
			Clonidine Hcl	C				
			Fenoterol Hydrobromide (+)					
			Ipratropium B	C				
			Pergolide Mesylate	C				

Date:04/11/01ISR Number: 3703560-9Report Type:Expedited (15-DaCompany Report #WAES 01038235
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Coagulation Time	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Prolonged	Other			Laboratories Div	
Initial or Prolonged	Drug Interaction				Merck Co Inc	ORAL
25 MG/DAILY 8 MON						
	Haemoglobin Decreased		Tab Mefenamic Acid	SS		ORAL
500 MG/TID 1 WK						
	Haemorrhoids		Tab Diclofenac	SS		ORAL
	Large Intestinal Ulcer		Tab Aspirin	SS		ORAL
	Rectal Haemorrhage					

Date:04/11/01ISR Number: 3703563-4Report Type:Expedited (15-DaCompany Report #WAES 01037520
Age:76 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Dehydration
Hospitalization -	Gastric Haemorrhage
Initial or Prolonged	Haematocrit Decreased
Other	Haemoglobin Decreased
	Hypotension
	Hypovolaemia
	Melaena
	Red Blood Cell Count
	Decreased
	Red Blood Cell
	Sedimentation Rate

Decreased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Diltiazem Hydrochloride	C				
			Spironolactone	C				
			Vitamin D	C				

Date:04/11/01ISR Number: 3703567-1Report Type:Expedited (15-DaCompany Report #WAES 01035259
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	86 DAY
			Carbamazepine	C				
			Codeine	C				
			Etidronate Disodium	C				
			Mianserin	C				

Date:04/11/01ISR Number: 3703569-5Report Type:Expedited (15-DaCompany Report #WAES 01035139
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Haemorrhoids Rectal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	

Date:04/11/01ISR Number: 3703580-4Report Type:Expedited (15-DaCompany Report #WAES 01038757
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Oedema Peripheral	Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	50 MG/DAILY	6 DAY

Date:04/11/01ISR Number: 3703581-6Report Type:Expedited (15-DaCompany Report #WAES 01037819
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Neoplasm	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Vertigo	Health			Laboratories Div			
	Vomiting	Professional			Merck Co Inc	ORAL	25 MG/1X	1 DAY
			Metoprolol Tartrate	C				

Date:04/11/01ISR Number: 3703609-3Report Type:Expedited (15-DaCompany Report #WAES 01038130
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
	Congestive	Health			Laboratories Div			
	Fluid Retention	Professional			Merck Co Inc	ORAL	25 MG/DAILY	8 DAY
	Pulmonary Oedema		Vasotec	C				

		Digoxin	C
		Furosemide Sodium	C
		Thyroxine	C

Date:04/11/01ISR Number: 3703617-2Report Type:Expedited (15-DaCompany Report #WAES 01038135
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Creatine Phosphokinase Increased Blood Creatinine Increased Blood Lactate Dehydrogenase Increased Blood Potassium Increased Haemolytic Uraemic Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	10 DAY

Date:04/11/01ISR Number: 3703620-2Report Type:Expedited (15-DaCompany Report #WAES 01035614
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY
		Other	Hctz/Triamterene	C				
			Allopurinol	C				
			Colchicine	C				
			Floxacillin Sodium	C				
			Isosorbide Dinitrate	C				
			Metoclopramide Hydrochloride	C				

			Oxazepam	C
			Pantoprazole Sodium	C
			Tramadol Hcl	C

Date:04/11/01ISR Number: 3703631-7Report Type:Expedited (15-DaCompany Report #WAES 01049942
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Bradycardia Cold Sweat Dizziness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	2 DAY
Disability	Hypotension Pulse Pressure Decreased Spinal Osteoarthritis Vomiting		Tizanidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3703650-0Report Type:Expedited (15-DaCompany Report #WAES 01037536
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	
		Other						
			Acetaminophen	C				
			Guanfacine	C				
			Quinapril	C				
			Tramadol Hc1	C				

Date:04/11/01ISR Number: 3703742-6Report Type:Expedited (15-DaCompany Report #200112306EU
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased	Foreign Other	Noritate	PS	Dermik Laboratories Inc	ORAL	800 MG/DAY PO	9 DAY
	Cardiomegaly		Leflunomide (Arava)	SS		ORAL	20 MG /D AY PO	
	Chest Pain							
	Depressed Level Of Consciousness		Gabapentin (Neurontin)	SS			2.4 G /D AY	
	Ear Pain		Furosemide (Furix)	SS		ORAL	40 MG/DAY PO	
	Electroencephalogram Abnormal		Enalapril Maleate (Renitec)	SS		ORAL	20 MG/ DAY PO	1 WK
	Fatigue		Flucloxacillin Sodium (Heracillin)	SS			2.2 G / DAY	9 DAY
	Gamma-Glutamyltransferase Increased		Rofecoxib (Vioxx)	SS		ORAL	25 G/DAY PO	
	Headache		Folic Acid, Calcium Phosphate (Folacin)	C				
	Hepatic Enzyme Increased		Vitamin E	C				
	Hypocalcaemia		Paracetamol					
	Infected Skin Ulcer							

Pharyngolaryngeal Pain	(Alvedon)	C	
Pleural Effusion	Prednisone	C	
Proteus Infection	Morfin	C	
Renal Failure	Cisapride		
Weight Decreased	(Prepulsid)	C	
	Cetirizine (Zyrlex)	C	
	Lansoprazole (Lanzo)	C	
	Zolpidem Tartrate (Stilnoct)	C	
	Loperamide	C	
	Colecalciferol, Calcium Carbonate (Calcichew D3)	C	
	Ipratropium Bromide, Salbutamol Sulfate (Combivent)	C	
	Spironolactone	C	

Date:04/11/01ISR Number: 3714139-7Report Type:Periodic Company Report #2000-BP-00649
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation Dizziness	Consumer	Flomax	PS	Boehringer Ingelheim Pharmaceuticals Inc	ORAL	0.4 MG/QD/PO	
	Visual Disturbance		Vioxx	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/01ISR Number: 3720898-XReport Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peptic Ulcer Perforation		Vioxx	PS			25 MG QD	
Hospitalization - Initial or Prolonged								

Date:04/12/01ISR Number: 3703904-8Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Vioxx	PS		ORAL	PO QD PRN	1 YR
			Wellbutrin	C				

Date:04/12/01ISR Number: 3703925-5Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS		ORAL	50MG PO QD	2 MON
	Duodenal Ulcer		Asa	SS		ORAL	325MG PO QD	
	Haematochezia							
	Oesophagitis							

Date:04/13/01ISR Number: 3704381-3Report Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petechiae		Vioxx (25mg)	PS		ORAL	1 PO QAM	
			Paxil	C				
			Trazodone	C				
			Prilosec	C				

Date:04/13/01ISR Number: 3704399-0Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Oedema		Rofecoxib (25 Mg)			
Initial or Prolonged	Pancreatitis		(Merck)	PS	Merck	
25MG DAILY						
Required			Divalproex Na	C		
Intervention to			Lisinopril	C		
Prevent Permanent			Furosemide	C		
Impairment/Damage						

Date:04/13/01ISR Number: 3704434-XReport Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx (25 Mg Tablet)	PS		
QD						
Initial or Prolonged	Pancreatitis		Norflex (100 Mg)	SS		
BID						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/01ISR Number: 3705908-8Report Type:Expedited (15-DaCompany Report #WAES 01038227
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Tab Clopidogrel Bisulfate	SS		ORAL	75 MG/DAILY	PO
			Cap Valsartan	SS		ORAL	80 MG PO	
			Tab Zocor (Simvastatin)	SS		ORAL	20 MG PO	
			Tab Carvedilol	SS		ORAL	12.5 MG PO	
			Flupentixol Hydrochloride (+) Melitracen	C				
			Levothyroxine Na	C				
			Loperamide Hcl	C				
			Moclobemide	C				
			Oxazepam	C				

Date:04/13/01ISR Number: 3705920-9Report Type:Expedited (15-DaCompany Report #WAES 01049452
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Overdose	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	100 MG/DAILY	PO 1 DAY

Date:04/13/01ISR Number: 3706870-4Report Type:Expedited (15-DaCompany Report #WAES 01034213
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease	Health Professional Company Representative	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hormonal Contraceptives	C				

Date:04/13/01ISR Number: 3706900-XReport Type:Expedited (15-DaCompany Report #WAES 01031327
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Arthralgia Blood Pressure Increased Difficulty In Walking	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Oedema Peripheral		Celebrex	C				
	Paraesthesia		Flexeril	C				

Date:04/16/01ISR Number: 3705644-8Report Type:Expedited (15-DaCompany Report #WAES 01047522
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Haemorrhage	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
Therapy Unspecified	C				

Date:04/16/01ISR Number: 3705907-6Report Type:Expedited (15-DaCompany Report #WAES 01035277
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephrotic Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diclofenac Sodium (+) Misoprostol	C				

Date:04/16/01ISR Number: 3705911-8Report Type:Expedited (15-DaCompany Report #WAES 00106012
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction International Normalised Ratio Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	2 DAY
		Company Representative	Acenocoumarol	SS		ORAL	1 MG/DAILY PO	206 DAY
			Benazepril Hcl/Hctz	C				
			Bromazepam	C				
			Clonazepam	C				
			Fluoxetine Hcl	C				
			Morphineso4	C				
			Prednisone	C				

			Sotalol Hydrochloride	C		
			Tramadol Hcl	C		
			Urapidil	C		

Date:04/16/01ISR Number: 3705914-3Report Type:Expedited (15-DaCompany Report #WAES 01035542
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haemodialysis Renal Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/BID PO (SEE IMAGE) 11 MON						
			Allopurinol	C		
			Aspirin	C		
			Atenolol	C		
			Atorvastatin	C		
			Estradiol	C		
			Insulin Human	C		
			Insulin Lispro	C		
			Morphineso4	C		
			Piretanide	C		
			Timolol Maleate	C		

Date:04/16/01ISR Number: 3705916-7Report Type:Expedited (15-DaCompany Report #WAES 01035510
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Health			Laboratories Div			
Initial or Prolonged		Professional			Merck Co Inc	ORAL	25 MG/BID PO	
			Acetaminophen (+)					
			Codeine	C				
			Alfacalcidol	C				
			Aspirin	C				
			Bromazepam	C				
			Calcium (Unspecified)	C				
			Dipyrone	C				
			Doxepin Hcl	C				
			Furosemide	C				
			Isosorbide Dinitrate	C				
			Metoprolol Succinate	C				
			Tetrazepam	C				

Date:04/16/01ISR Number: 3705928-3Report Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Anorexia	Professional			Laboratories Div			
Initial or Prolonged	Cellulitis	Other			Merck Co Inc	ORAL	50 MG/DAILY/PO	
Disability	Melaena							
Other	Nausea		Ativan	C				
	Pancreatic Disorder		Flexeril	C				
	Pancreatitis		Valium	C				
	Vomiting							
	Weight Decreased							

Date:04/16/01ISR Number: 3705930-1Report Type:Expedited (15-DaCompany Report #WAES 01031095
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Drug Toxicity	Company			Merck Co Inc	ORAL	50	
	Haematocrit Decreased	Representative					MG/DAILY/PO	
	Haemoglobin Decreased		Azulfidine	C				
			Methotrexate (Methotrexate Sodium)	C				

Date:04/16/01ISR Number: 3705932-5Report Type:Expedited (15-DaCompany Report #WAES 01030430
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Consumer	Vioxx	PS	Merck Research			
Other	Erythema Multiforme	Health			Laboratories Div			
	Pain	Professional			Merck Co Inc	ORAL	25	
	Pruritus						MG/DAILY/PO	
	Rash Maculo-Papular		Celebrex	C				
			Ditropan Xl	C				
			Hydrodiuril	C				

		Prevacid	C
		Calcium Carbonate (+) Cholecalci	C
		Vitamins (Unspecified)	C

Date:04/16/01ISR Number: 3705935-0Report Type:Expedited (15-DaCompany Report #WAES 01031427
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Asthenia	Professional			Laboratories Div			
Initial or Prolonged	Chest Pain	Company			Merck Co Inc	ORAL	50	
Other	Decreased Appetite	Representative					MG/DAILY/PO	
	Dyspnoea		Glucophage	C				
	Face Oedema		Lasix (Furosemide)	C				
	Faecal Occult Blood		Levaquin	C				
	Positive		Lopressor	C				
	Fatigue		Procardia Xl	C				
	Haematochezia		Vasotec	C				
	Haematuria		Voltaren-Xr	C				
	Hepatic Function Abnormal		Zocor	C				
	Malaise		Aspirin	C				
	Nausea		Dipyridamole	C				
	Oedema		Glyburide	C				
	Oedema Peripheral		Vitamin E	C				
	Pallor							
	Periorbital Oedema							
	Renal Failure Acute							
	Stasis Dermatitis							
	Thrombocytopenia							
	Urinary Tract Infection							
	Weight Decreased							

Date:04/16/01ISR Number: 3705937-4Report Type:Expedited (15-DaCompany Report #WAES 01031727
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research			

Hospitalization - Initial or Prolonged		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

Date:04/16/01ISR Number: 3705938-6Report Type:Expedited (15-DaCompany Report #WAES 01040830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO			Coumadin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/01ISR Number: 3705940-4Report Type:Expedited (15-DaCompany Report #WAES 01040520
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Post Procedural Complication	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:04/16/01ISR Number: 3705941-6Report Type:Expedited (15-DaCompany Report #WAES 01040555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Chondroitin	C				

Date:04/16/01ISR Number: 3705943-XReport Type:Expedited (15-DaCompany Report #WAES 01011093
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulopathy Mouth Haemorrhage Tooth Extraction	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Premarin	C				
			Tylenol With Codeine	C				

Date:04/16/01ISR Number: 3705944-1Report Type:Expedited (15-DaCompany Report #WAES 01020865
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bacteriuria	Health	Vioxx	PS	Merck Research			
Other	Bilirubinuria	Professional			Laboratories Div			
	Chromaturia				Merck Co Inc	ORAL	25 MG DAILY	
	Haematuria					PO		
	Hypercalciuria		Levoxyl	C				
	Urine Analysis Abnormal		Lodine	C				
	White Blood Cells Urine		Naprosyn	C				
	Positive		Premarin	C				
			Trinsicon (Ascorbic Acid (+) Cya	C				
			Tylenol	C				
			Potassium (Unspecified)	C				

Date:04/16/01ISR Number: 3705949-0Report Type:Expedited (15-DaCompany Report #WAES 01031431
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
	Upper Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	25 MG DAILY	
		Representative				PO		
			Depakote	C				

			Neurontin	C

Date:04/16/01ISR Number: 3705955-6Report Type:Expedited (15-DaCompany Report #WAES 01047751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Stevens-Johnson Syndrome	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/16/01ISR Number: 3705956-8Report Type:Expedited (15-DaCompany Report #WAES 01040245
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Burning Sensation Coma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dehydration		Benadryl	C				
	Diarrhoea		Effexor	C				
	Flushing		Zyrtec	C				
	Gallbladder Disorder		Cortisone	C				
	Nausea		Prednisone	C				
	Pruritus		Vitamins					
	Urticaria		(Unspecified)	C				
	Vomiting							

Date:04/16/01ISR Number: 3705958-1Report Type:Expedited (15-DaCompany Report #WAES 01011775
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Amnesia Balance Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

	Blood Potassium Decreased	Representative				
PO						
	Blood Pressure Increased		Diazide	C		
	Confusional State		Prempro	C		
	Coordination Abnormal					
	Disturbance In Attention					
	Grand Mal Convulsion					
	Loss Of Consciousness					
	Malaise					
	Nausea					
	Platelet Count Decreased					
	Sedation					

Date:04/16/01ISR Number: 3705964-7Report Type:Expedited (15-DaCompany Report #WAES 01040026
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dialysis	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Fungal Infection	Professional			Laboratories Div	
	Renal Failure	Company			Merck Co Inc	ORAL
PO						
		Representative	Imuran (Azathioprine			
			Sodium)	C		
			Cyclosporine	C		
			Nutritional			

Supplements C

Date:04/16/01ISR Number: 3705967-2Report Type:Expedited (15-DaCompany Report #WAES 01033064
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Acute Myeloid Leukaemia Pancytopenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 Other MG/DAILY/PO	
			Prevacid	C				
			Robitussin	C				

Date:04/16/01ISR Number: 3705970-2Report Type:Expedited (15-DaCompany Report #WAES 01031725
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Syncope Upper Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:04/16/01ISR Number: 3706012-5Report Type:Expedited (15-DaCompany Report #WAES 01040918
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/16/01ISR Number: 3706071-XReport Type:Expedited (15-DaCompany Report #WAES 01047254
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	13 DAY
	Dyspnoea	Other						
	Hyperkalaemia							
	Renal Failure		Zocor	C				
			Acetaminophen	C				
			Bezafibrate	C				
			Carvedilol	C				
			Digoxin	C				
			Furosemide	C				
			Insulin Human, Isophane	C				
			Insulin, Neutral	C				
			Isosorbide Mononitrate	C				
			Nitroglycerin	C				
			Ramipril	C				

Date:04/16/01ISR Number: 3706074-5Report Type:Expedited (15-DaCompany Report #WAES 01047253
Age:93 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Condition Aggravated
	Diarrhoea

		Dyspnoea Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage Nausea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY	41 DAY						
				Tab Aspirin	SS		ORAL
75 MG/DAILY	5454 DAY						
				Cyanocobalamin	C		
				Digoxin	C		
				Furosemide	C		
				Hydroxyzine Hydrochloride	C		
				Propoxyphene Napsylate	C		
				Sotalol Hydrochloride	C		
				Zolpidem Tartrate	C		

Date:04/16/01ISR Number: 3706346-4Report Type:Expedited (15-DaCompany Report #WAES 01038135
Age:14 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Alanine Aminotransferase Increased Aspartate	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY	10 DAY						
		Aminotransferase Increased	Other	Inj Corticosteroids (Unspecified)	SS		
INJ	1 DAY						
		Blood Alkaline Phosphatase Increased Blood Lactate Dehydrogenase Increased Haemolytic Uraemic Syndrome					

Date:04/16/01ISR Number: 3706350-6Report Type:Expedited (15-DaCompany Report #WAES 01048751
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	
		Other	Moduretic	C				
			Timoptic-Xe	C				
			Atenolol	C				
			Nutritional Supplements	C				

Date:04/16/01ISR Number: 3706368-3Report Type:Expedited (15-DaCompany Report #WAES 01049108
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Thrombosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
		Other	Hydrodiuril	C				
			Lacidipine	C				
			Omeprazole	C				

Date:04/16/01ISR Number: 3706540-2Report Type:Expedited (15-DaCompany Report #WAES 01045533
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis Purpura	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	97 YR

Date:04/16/01ISR Number: 3706542-6Report Type:Expedited (15-DaCompany Report #WAES 01047257
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	21 DAY

Date:04/16/01ISR Number: 3706547-5Report Type:Expedited (15-DaCompany Report #WAES 01039911
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ascites Blood Alkaline Phosphatase Increased Colitis	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	PO 29 DAY
	Dyspnoea Exertional Gamma-Glutamyltransferase Increased Hepatic Function Abnormal Pericardial Effusion Pyrexia Renal Cyst		Amoxicillin Trihydrate (+) Clavulanate P Atenolol Furosemide Metronidazole Nifedipine Potassium Chloride	C C C C C C				

Date:04/16/01ISR Number: 3706859-5Report Type:Expedited (15-DaCompany Report #WAES 01045528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis Renal Failure Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/16/01ISR Number: 3706863-7Report Type:Expedited (15-DaCompany Report #WAES 01048517
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen/Codeine Phosphate	C				

Date:04/16/01ISR Number: 3706901-1Report Type:Expedited (15-DaCompany Report #WAES 01031467
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Dyrenium	C	
Keflex	C	
Lescol	C	
Nph Insulin	C	
Ogen	C	
Percocet	C	
Prilosec	C	
Prinivil	C	
Regular Insulin	C	
Sinequan	C	
Synthroid	C	
Aspirin	C	

Date:04/16/01ISR Number: 3706926-6Report Type:Expedited (15-DaCompany Report #WAES 01040561
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Vioxx Diuretic	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/16/01ISR Number: 3706928-XReport Type:Expedited (15-DaCompany Report #WAES 01040654
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Condition Aggravated Vision Blurred	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:04/16/01ISR Number: 3706930-8Report Type:Expedited (15-DaCompany Report #WAES 01040697
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Diurectic	C				

Date:04/16/01ISR Number: 3706931-XReport Type:Expedited (15-DaCompany Report #WAES 01040372
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia Oedema Peripheral Stevens-Johnson Syndrome	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/01ISR Number: 3706936-9Report Type:Expedited (15-DaCompany Report #WAES 01040338
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Zocor	C				
			Calcium	C				
			Captopril	C				
			Iron	C				
			Vitamins	C				

Date:04/16/01ISR Number: 3706938-2Report Type:Expedited (15-DaCompany Report #WAES 01040164
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Convulsion							
	Drug Hypersensitivity							
	Drug Interaction							
	Loss Of Consciousness		Levaquin	SS			500 MG/1X	
	Urticaria		Hormonal Contraceptives	C				

Date:04/16/01ISR Number: 3706941-2Report Type:Expedited (15-DaCompany Report #WAES 01040028
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Haematocrit Decreased							

Haemoglobin Decreased
MG/DAILY/PO
Melaena Dyazide C
Tachycardia Vasotec C

Date:04/16/01ISR Number: 3706944-8Report Type:Expedited (15-DaCompany Report #WAES 01040371
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Health	Vioxx	PS	Merck Research			
	Neuropathy Peripheral	Professional			Laboratories Div			
	Oedema				Merck Co Inc	ORAL	25	
	Renal Failure Acute							
	Weight Increased		Celebrex	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:04/16/01ISR Number: 3709922-8Report Type:Expedited (15-DaCompany Report #WAES 01049110
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	172 DAY

Elavil	C
Diazepam	C
Gabapentin	C
Omeprazole	C
Raloxifene Hydrochloride	C

Date:04/17/01ISR Number: 3706008-3Report Type:Direct Company Report #USP 53901
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Vioxx 25mg Ud	PS	Msd			
			Pepcid 20mg Qd	SS	Msd			

Date:04/17/01ISR Number: 3706311-7Report Type:Direct Company Report #
Age:56 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Anxiety Atrial Fibrillation Disturbance In Attention Dizziness Heart Rate Increased Heart Rate Irregular Mania Vision Blurred		Vioxx / One Every 12 Hours	PS				
			Prednisone / Steroids Dose Pak/Epidural	SS				

Date:04/18/01ISR Number: 3706430-5Report Type:Direct Company Report #
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Gangrene Gastritis Sepsis		Vioxx	PS		ORAL	25 MG Q D PO	
			Ec Asa	SS		ORAL	325 MG Q AM PO	

Intervention to INTRAVENOUS TITRATE IV	Vomiting	Dopamine	SS
Prevent Permanent Impairment/Damage		Synthroid	C
		Humalog	C
		Rocephin	C
		Heparin	C
		Tums	C
		Niferex	C
		Halcion	C
		Nitrodur	C
		Humulin 70/30	C
		Epogen	C

Date:04/18/01ISR Number: 3707364-2Report Type:Direct Company Report #
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Renal Impairment		Vioxx	PS		
Intervention to Prevent Permanent Impairment/Damage			Aspirin	C		
			Atenolol	C		
			Furosemide	C		
			Lansoprazole	C		
			Terazosin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/01ISR Number: 3707372-1Report Type:Expedited (15-DaCompany Report #WAES 00120092
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Study	Vioxx	PS	Merck Research Laboratories Div			
	Haemoglobin Decreased	Health						
Other	Myocardial Infarction	Professional			Merck Co Inc	ORAL	DAILY/PO	
	Oesophageal Ulcer		Synthroid	C				
	Supraventricular Tachycardia		Acetaminophen	C				
			Vitamins (Unspecified)	C				

Date:04/18/01ISR Number: 3707374-5Report Type:Expedited (15-DaCompany Report #WAES 00120092
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Shortened	Study	Vioxx	PS	Merck Research Laboratories Div			
		Health						
Other		Professional			Merck Co Inc	ORAL	DAILY/PO	
	Anaemia		Synthroid	C				
	Aortic Valve Incompetence		Acetaminophen	C				
	Aortic Valve Sclerosis		Vitamins (Unspecified)	C				
	Atrioventricular Block First Degree							
	Blood Creatinine Increased							
	Blood Pressure Increased							
	Blood Urea Increased							
	Body Temperature Decreased							
	Cardiomegaly							
	Chest X-Ray Abnormal							
	Faecal Occult Blood Positive							
	Fatigue							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal Haemorrhage							
	High Density Lipoprotein Decreased							
	Ileus Paralytic							

Myocardial Infarction
Nausea
Platelet Count Decreased
Red Blood Cell Count
Decreased
Supraventricular
Tachycardia
Urinary Tract Infection
Vomiting
White Blood Cell Count
Increased

Date:04/18/01ISR Number: 3707375-7Report Type:Expedited (15-DaCompany Report #WAES 00120092
Age:88 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Activated Partial
Initial or Prolonged	Thromboplastin Time
Other	Shortened

		Anaemia					
		Aortic Valve Incompetence					
		Aortic Valve Sclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Arteriosclerosis	Study	Vioxx	PS	Merck Research	
		Blood Creatinine	Health			Laboratories Div	
		Increased	Professional			Merck Co Inc	ORAL
DAILY/PO							
		Blood Pressure Increased		Synthroid	C		
		Blood Urea Increased		Acetaminophen	C		
		Cardiomegaly		Vitamins			
		Faecal Occult Blood		(Unspecified)	C		
		Positive					
		Faeces Discoloured					
		Fatigue					
		Gastric Ulcer Haemorrhage					
		Gastrointestinal					
		Haemorrhage					
		Heart Rate Increased					
		Ileus Paralytic					
		Myocardial Infarction					
		Nausea					
		Osteoporosis					
		Platelet Count Decreased					
		Serum Ferritin Increased					
		Supraventricular					
		Tachycardia					
		White Blood Cell Count					
		Increased					

Date:04/18/01ISR Number: 3707379-4Report Type:Expedited (15-DaCompany Report #WAES 01040275
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Lymphoma	Health	Vioxx	PS	Merck Research	
		Metastases To Lymph Nodes	Professional			Laboratories Div	
			Company			Merck Co Inc	ORAL
12.5							
			Representative				
MG/DAILY/PO							
				Flexeril	C		
				Premarin	C		
				Zantac	C		
				Calcium Carbonate			

			(+) Vitamin D	C		

Date:04/18/01ISR Number: 3707411-8Report Type:Expedited (15-DaCompany Report #WAES 01040273
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Loss Of Consciousness Memory Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Ovcon	C		
			Ibuprofen	C		

Date:04/18/01ISR Number: 3707415-5Report Type:Expedited (15-DaCompany Report #WAES 01030604
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/18/01ISR Number: 3707418-0Report Type:Expedited (15-DaCompany Report #WAES 01034259
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumdain	C				
			Aspirin	C				

Date:04/18/01ISR Number: 3707507-0Report Type:Expedited (15-DaCompany Report #WAES 01037307
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG/DAILY PO	
			Cap Ketoprofen	SS		ORAL	PO	
			Tab Sulfasalazine	SS		ORAL	PO	30 DAY

Date:04/18/01ISR Number: 3707550-1Report Type:Expedited (15-DaCompany Report #001-0981-M0102484
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Decreased Appetite Dehydration	Consumer	Lipitor	PS	Pfizer Ireland Pharmaceuticals, Tablet Plant	ORAL	10 MG (DAILY) PER ORAL	
			Rofecoxib (Rofecoxib)	SS				
			Nabumetone (Nabumetone)	SS				
			Omeprazole (Omeprazole)	SS				
			Cyproheptadine	C				
			Furosemide	C				
			Enalapril Maleate	C				

Date:04/18/01ISR Number: 3707899-2Report Type:Expedited (15-DaCompany Report #THQ2001A00923
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agranulocytosis	Health Professional	Zoton (Lansoprazole)	PS		ORAL	30 MG	64 DAY
	Anaemia		Vioxx (Rofecoxib)	SS			12.5 MG	20 DAY
	Hypertension	Other	Furix (Furosemide)	SS			500 MG	64 DAY
	Nephritis		Diamox (Acetazolamide)	C				
			Brufen (Ibuprofen)	C				

Prednisolone	C
Mycostatin (Nystatin)	C
Levaxin (Levothyroxine Sodium)	C
Kalcium (Calcium)	C
Kalcitena (Calcium Carbonate)	C
Seloken (Metoprolol Tartrate)	C

Date:04/19/01ISR Number: 3708302-9Report Type:Expedited (15-DaCompany Report #WAES 01043469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Electrocardiogram Qt Prolonged	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization - Initial or Prolonged	Epilepsy	Other			Merck Co Inc	ORAL	12.5 MG/DAILY	
	Ventricular Tachycardia		Sotalol Hydrochloride	C				

Date:04/19/01ISR Number: 3709849-1Report Type:Periodic Company Report #HQ5234722DEC2000
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Consumer	Ziac	PS	Lederle Laboratories Div American			
Other	Syncope				Cyanamid Co	ORAL	1 TABLET 1X PER 1 DAY,	ORAL
			Vioxx	SS		ORAL	1 TABLET 1X PER 1 DAY,	ORAL

Glucophage (Metformin Hydrochloride)	C
Xanax (Alprazolam)	C
Asa (Acetylsaliicylic Acid)	C
Calcium With Vitamin D (Calicium Phosphate/Calcium Sodium Lactate/Ergocalcifer	C
Vitamin B12 (Cyanocobalamin)	C

Date:04/20/01ISR Number: 3708515-6Report Type:Expedited (15-DaCompany Report #WAES 01010328
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Bronchitis
	Condition Aggravated
	Drug Ineffective
	Injury

		Joint Swelling Knee Arthroplasty Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion Post Procedural Haemorrhage	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY/PO							
		Postnasal Drip Sinus Tachycardia Tricuspid Valve Incompetence		Catapres Cozaar Glucotrol Hyzaar Neurontin Premarin Procrit Toprol Xl Tablets	C C C C C C C C		

Date:04/20/01ISR Number: 3708602-2Report Type:Expedited (15-DaCompany Report #WAES 01049201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Angina Pectoris	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO	5 DAY					

Date:04/20/01ISR Number: 3708640-XReport Type:Expedited (15-DaCompany Report #WAES 01035277
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Nephrotic Syndrome	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Diclofenac Sodium (+) Misoprostol	C		

Date:04/20/01ISR Number: 3708641-1Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Health			Laboratories Div			
Initial or Prolonged	Haematemesis	Professional			Merck Co Inc	ORAL		

Date:04/20/01ISR Number: 3708642-3Report Type:Expedited (15-DaCompany Report #WAES 01045047
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Vioxx	PS	Merck Research			
	Dyspnoea	Consumer			Laboratories Div			
	Face Oedema				Merck Co Inc	ORAL	25 MG/DAILY	
	Muscle Spasms		Inj Corticosteroids	SS			1 DAY	
	Throat Tightness		Corticosteroids					
	Urticaria		(Unspecified)	SS		ORAL	1 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708646-0Report Type:Expedited (15-DaCompany Report #WAES 01045063
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	457 DAY
			Acetaminophen / Codeine Phosphate	C				
			Cimetidine	C				
			Folic Acid	C				
			Hydroxychloroquineso 4	C				
			Sulfasalazine	C				

Date:04/20/01ISR Number: 3708649-6Report Type:Expedited (15-DaCompany Report #WAES 01043741
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	6 DAY
		Other	Cholecalciferol	C				

Date:04/20/01ISR Number: 3708651-4Report Type:Expedited (15-DaCompany Report #WAES 01049109
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/KG/DAILY	170 DAY
			Hydrodiuril	C				
			Acetaminophen	C				
			Lacidipine	C				

Date:04/20/01ISR Number: 3708653-8Report Type:Expedited (15-DaCompany Report #WAES 01049902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anuria	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Neoplasm Malignant	Health			Laboratories Div			
Initial or Prolonged	Oedema Peripheral	Professional			Merck Co Inc			
	Renal Impairment		Furosemide	C				
	Swelling		Morphine	C				

Date:04/20/01ISR Number: 3708656-3Report Type:Expedited (15-DaCompany Report #WAES 01043754
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Other			Laboratories Div			
					Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708657-5Report Type:Expedited (15-DaCompany Report #WAES 01043743
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Duodenitis Gastritis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 1 MON
			Aspirin	C				
			Hydroxychloroquine So4	C				

Date:04/20/01ISR Number: 3708663-0Report Type:Expedited (15-DaCompany Report #WAES 01023401
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis Pyoderma Gangrenosum	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO 409 DAY
			Placebo (Unspecified)	SS			409 DAY	
			Hydroxychloroquine S04	C				

Date:04/20/01ISR Number: 3708664-2Report Type:Expedited (15-DaCompany Report #WAES 01019751
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
	Fluid Retention							

Date:04/20/01ISR Number: 3708671-XReport Type:Expedited (15-DaCompany Report #WAES 01038601
Age:15 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 6 DAY

Date:04/20/01ISR Number: 3708672-1Report Type:Expedited (15-DaCompany Report #WAES 01035270
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 155 DAY
			Acetaminophen/Codein e Phosphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708674-5Report Type:Expedited (15-DaCompany Report #WAES 01027513
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Iron Decreased	Other						
	Gastric Ulcer							
	Haematocrit Increased							
	Melaena		Tab Aspirin	SS		ORAL	100 MG/DAILY/PO	
	Red Blood Cell Count Increased		Betahistine	C				
			Citalopram Hydrobromide	C				
			Sotalol Hydrochloride	C				

Date:04/20/01ISR Number: 3708676-9Report Type:Expedited (15-DaCompany Report #WAES 01035270
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	155 DAY
		Other						
			Acetaminophen / Codeine Phosphate	C				

Date:04/20/01ISR Number: 3708678-2Report Type:Expedited (15-DaCompany Report #WAES 01045536
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Status Asthmaticus	Foreign	Vioxx	PS	Merck Research Laboratories Div			
		Other						

Merck Co Inc ORAL
25 MG/DAILY

PO 8 DAY

Date:04/20/01ISR Number: 3708682-4Report Type:Expedited (15-DaCompany Report #WAES 01049603
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Anaphylactoid Reaction	Other			Laboratories Div			
Initial or Prolonged	Arthralgia				Merck Co Inc	ORAL	25 MG/1X PO	1 DAY
	Delirium							
	Memory Impairment							

Date:04/20/01ISR Number: 3708684-8Report Type:Expedited (15-DaCompany Report #WAES 01048107
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mouth Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Petechiae	Other			Laboratories Div			
	Thrombocytopenia				Merck Co Inc	ORAL	SEE IMAGE	3 DAY
			Lomefloxacin Hydrochloride	C				

Date:04/20/01ISR Number: 3708687-3Report Type:Expedited (15-DaCompany Report #WAES 01046073
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	17 DAY
			Glimepiride	C				
			Trimetazidine Hydrochloride	C				

Date:04/20/01ISR Number: 3708706-4Report Type:Expedited (15-DaCompany Report #WAES 01040664
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
			Benadryl	C				
			Imodium	C				
			L-Thyroxin	C				
			Mylanta & Mylanta Ds	C				
			Paxil	C				
			Tylenol	C				
			Ferrous Glycine Sulfate	C				

Date:04/20/01ISR Number: 3708707-6Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Faeces	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Bilirubinuria							
	Jaundice							
	Liver Transplant							
	Rejection		Bactrim	C				

Calderol	C
Diflucan	C
Os-Cal	C
Procardia Xl	C
Zoloft	C
Cyclosporine	C
Ibuprofen	C
Prednisone	C

Date:04/20/01ISR Number: 3708709-XReport Type:Expedited (15-DaCompany Report #WAES 01040373
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708710-6Report Type:Expedited (15-DaCompany Report #WAES 01045047
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Face Oedema Muscle Spasms Throat Tightness Urticaria	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:04/20/01ISR Number: 3708711-8Report Type:Expedited (15-DaCompany Report #WAES 01041292
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Faeces Discoloured Gastrointestinal Disorder Haematocrit Decreased Haemoglobin Decreased Nausea Vomiting	Health Professional	Vioxx Coumadin Vasotec Vicodin Tablets Xanax Digoxin	PS C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/20/01ISR Number: 3708712-XReport Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/20/01ISR Number: 3708713-1Report Type:Expedited (15-DaCompany Report #WAES 01045534
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/20/01ISR Number: 3708714-3Report Type:Expedited (15-DaCompany Report #WAES 01040370
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:04/20/01ISR Number: 3708716-7Report Type:Expedited (15-DaCompany Report #WAES 01037335
Age:79 YR Gender:Female I/FU:I

Outcome	PT
Death	Acidosis
Hospitalization - Initial or Prolonged	Condition Aggravated
	Hyperkalaemia

	Renal Failure Sepsis Sudden Death	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO	2 DAY					
			Tab Spironolactone	SS		ORAL
50 MG/DAILY						
PO						
			Tab Calcium Carbonate (+) Cholecalciferol	SS		ORAL
PO						
			Powd Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	SS		ORAL
PO						
			Zocor	C		
			Aspirin	C		
			Dltiazem Hydrochloride	C		
			Etidronate Disodium	C		
			Flunitrazepam	C		
			Isosorbide	C		
			Nitroglycerin	C		
			Simethicone	C		
			Sotalol Hydrochloride	C		

Date:04/20/01ISR Number: 3708717-9Report Type:Expedited (15-DaCompany Report #WAES 01045535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:04/20/01ISR Number: 3708718-0Report Type:Expedited (15-DaCompany Report #WAES 01047006
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 6 DAY
			Acetaminophen/Codeine Phosphate	C				
			Carisoprodol	C				
			Oxazepam	C				

Date:04/20/01ISR Number: 3708719-2Report Type:Expedited (15-DaCompany Report #WAES 01031491
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/QOD/PO	
	Cough							
	Productive Cough							
	Sinus Congestion		Allergenic Extract	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708720-9Report Type:Expedited (15-DaCompany Report #WAES 01049903
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
	Constipation	Health Professional						
	Dermatitis							
	Hypokalaemia							
	Oedema		Amitriptyline	C				
	Oliguria		Chlorpheniramine Maleate	C				
	Renal Impairment		Ciprofloxacin Hydrochloride	C				
	Weight Increased		Furosemide	C				
			Lactulose	C				
			Morphine	C				
			Potassium (Unspecified)	C				
			Senna	C				

Date:04/20/01ISR Number: 3708722-2Report Type:Expedited (15-DaCompany Report #WAES 01041140
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/	PO
	Upper Gastrointestinal Haemorrhage							
			Betapace	C				
			Aspirin	C				
			Prednisone	C				

Date:04/20/01ISR Number: 3708723-4Report Type:Expedited (15-DaCompany Report #WAES 01041016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Non-Cardiogenic Pulmonary Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Date:04/20/01ISR Number: 3708724-6Report Type:Expedited (15-DaCompany Report #WAES 01040990
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research	
Hospitalization - Initial or Prolonged	Congestive Oedema				Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Accupril	C		
			Humulin	C		
			Hyzaar	C		
			Neurontin	C		
			Prozac	C		

Date:04/20/01ISR Number: 3708725-8Report Type:Expedited (15-DaCompany Report #WAES 01040983
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				
			Digitek	C				
			Neurontin	C				
			Atenolol	C				

Date:04/20/01ISR Number: 3708749-0Report Type:Expedited (15-DaCompany Report #WAES 01041053
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Visual	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Flovent	C				
			Prednisone	C				

Date:04/20/01ISR Number: 3708751-9Report Type:Expedited (15-DaCompany Report #WAES 01040843
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 MON
			Ibuprofen	C				

			Naproxen	C		

Date:04/20/01ISR Number: 3708754-4Report Type:Expedited (15-DaCompany Report #WAES 01040835
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogens (Unspecified)	C				
			Ibuprofen	C				
			Naproxen	C				

Date:04/20/01ISR Number: 3708755-6Report Type:Expedited (15-DaCompany Report #WAES 01040665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708756-8Report Type:Expedited (15-DaCompany Report #WAES 01040685
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx	PS	Merck Research			
Hospitalization -	Myocardial Infarction	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Ibuprofen	C				
			Naproxen	C				

Date:04/20/01ISR Number: 3708793-3Report Type:Expedited (15-DaCompany Report #WAES 01011891
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Anuria				Laboratories Div			
Initial or Prolonged	Cardiac Valve Disease				Merck Co Inc	ORAL	PO	
	Disorientation		Atacand	SS				
	Echocardiogram Abnormal		Aciphex	C				
	Gout		Claritin	C				
	Irritable Bowel Syndrome		Coreg	C				
	Oedema Peripheral		Flomax (Tamsulosin					
	Pneumonia		Hydrochloride)	C				
	Pulmonary Hypertension		Flovent	C				
	Renal Artery Stenosis		Norvasc	C				
	Renal Disorder		Gemfibrozil	C				
	Renal Failure Acute		Ibuprofen	C				
			Nonsteroidal					
			Anti-Inflammatory	C				

Date:04/20/01ISR Number: 3708794-5Report Type:Expedited (15-DaCompany Report #WAES 01010997
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research			
Hospitalization -	Aortic Valve Stenosis	Professional			Laboratories Div			

Initial or Prolonged	Blister	Company			Merck Co Inc	ORAL
25						
Other	Drug Toxicity	Representative				
MG/DAILY/PO						
	Ecchymosis		Allegra	SS		
	Flushing		Coumadin	C		
	Gingival Bleeding		Pravachol	C		
	International Normalised Ratio Increased					
	Prothrombin Time Prolonged					

Date:04/20/01ISR Number: 3708795-7Report Type:Expedited (15-DaCompany Report #WAES 01034316
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Blood Pressure Increased	Professional			Laboratories Div	
	Lung Infiltration	Company			Merck Co Inc	ORAL
50						
	Non-Cardiogenic Pulmonary	Representative				
MG/DAILY/PO						
	Oedema		Vioxx	SS		ORAL
25						
	Oedema					
MG/DAILY/PO						
			Celexa	C		
			Sonata	C		

			Trazodone	C		

Date:04/20/01ISR Number: 3708796-9Report Type:Expedited (15-DaCompany Report #WAES 01040371
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Neuropathy Peripheral							
	Oedema							
	Renal Failure Acute		Celebrex	C				
	Weight Increased		Neurontin	C				
			[Therapy Unspecified]	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:04/20/01ISR Number: 3708797-0Report Type:Expedited (15-DaCompany Report #WAES 01041284
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pneumonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged								
Disability								
			Evista	C				
			Levothroid	C				

Date:04/20/01ISR Number: 3708798-2Report Type:Expedited (15-DaCompany Report #WAES 01041230
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:04/20/01ISR Number: 3708799-4Report Type:Expedited (15-DaCompany Report #WAES 01041177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Colitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:04/20/01ISR Number: 3708800-8Report Type:Expedited (15-DaCompany Report #WAES 01040958
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiomyopathy	Health	Vioxx	PS	Merck Research	
	Dyspnoea	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708801-XReport Type:Expedited (15-DaCompany Report #WAES 01040957
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/20/01ISR Number: 3708802-1Report Type:Expedited (15-DaCompany Report #WAES 01040754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Hepatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
			Lipitor [Therapy Unspecified]	C C				

Date:04/20/01ISR Number: 3708803-3Report Type:Expedited (15-DaCompany Report #WAES 01041223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/20/01ISR Number: 3708804-5Report Type:Expedited (15-DaCompany Report #WAES 01031447
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

	Vioxx 12.5 Mg	SS	ORAL

PO

Aerobid	C
Celebrex	C
Hyzaar	C
Nasocort	C
Viagra	C

Date:04/20/01ISR Number: 3708805-7Report Type:Expedited (15-DaCompany Report #WAES 01040960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Blindness Cerebrovascular Accident	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708806-9Report Type:Expedited (15-DaCompany Report #WAES 01040819
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis	Health Professional Company Representative	Vioxx Nonsteroidal Anti-Inflammatory	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/20/01ISR Number: 3708807-0Report Type:Expedited (15-DaCompany Report #WAES 01040811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Jaundice Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/20/01ISR Number: 3708808-2Report Type:Expedited (15-DaCompany Report #WAES 01041142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Failure	Health Professional Company Representative	Vioxx [Theray Unspecified]	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/20/01ISR Number: 3708809-4Report Type:Expedited (15-DaCompany Report #WAES 01041222
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ruptured Cerebral	Health	Vioxx	PS	Merck Research			

	Aneurysm	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

Date:04/20/01ISR Number: 3708810-0Report Type:Expedited (15-DaCompany Report #WAES 01041133
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Hydrodiuril	C		
			Atenolol	C		
			Glyburide	C		

25

MG/DAILY/PO

Date:04/20/01ISR Number: 3708811-2Report Type:Expedited (15-DaCompany Report #WAES 01041073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Pulmonary Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged	Renal Failure					

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/01ISR Number: 3708839-2Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured Gastrointestinal Haemorrhage		Naproxen Vioxx	PS SS				

Date:04/20/01ISR Number: 3708977-4Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated		Vioxx	PS		ORAL	VIOXX 25MG PO QD	6 DAY

Date:04/23/01ISR Number: 3708862-8Report Type:Direct Company Report #
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased		Vioxx	PS		ORAL	25MG PO QD	

Date:04/23/01ISR Number: 3708863-XReport Type:Direct Company Report #
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena		Vioxx / Msd	PS	Msd			

Date:04/23/01ISR Number: 3708886-0Report Type:Direct Company Report #
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia		Rofecoxib	PS				4 WK

Date:04/23/01ISR Number: 3708987-7Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Wall Pain		Vioxx 12.5mg	PS		ORAL	25MG QD ORAL	
	Cough		Atenolol	C				
			Hctz/Triam	C				

Date:04/23/01ISR Number: 3709128-2Report Type:Expedited (15-DaCompany Report #WAES 01028922
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Decreased	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Haematemesis	Health			Laboratories Div			
Hospitalization -	Haematochezia	Professional			Merck Co Inc	ORAL	25 MG/DAILY	2 WK
Initial or Prolonged	Rectal Haemorrhage		Omeprazole	C				
Disability	Upper Gastrointestinal							
Other	Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/01ISR Number: 3709313-XReport Type:Expedited (15-DaCompany Report #200020382DE
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ascites	Foreign	Arava	PS	Aventis			
	Hepatic Cirrhosis	Health			Pharmaceuticals Inc	ORAL	60 MG/DAY;PO	3 DAY
	Hepatic Encephalopathy	Professional	Leflunomide (Arava)					
	Hepatic Failure	Other	Tablets	SS		ORAL	20 MG/DAY;PO	2 DAY
	Jaundice		Rofecoxib (Vioxx)	SS				
	Liver Disorder		Rofecoxib (Vioxx)	C				
	Pneumonia		Prednisolone (Decortin-H)	C				
	Pyrexia		Prednisolone	C				
			Metamizole Sodium (Novaminsulfon)	C				
			Cefuroxime	C				
			Metamizole Sodium (Novalgin)	C				
			Cefotiam Hydrochloride (Spizef)	C				
			Cefuroxime Axetil (Elobact)	C				
			Morphine Sulfate (Mst)	C				
			Sodium Aurothiomalate (Tauredon)	C				

Date:04/23/01ISR Number: 3715883-8Report Type:Periodic Company Report #WAES 00120480
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Insomnia							
	Oedema Peripheral				Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Ditropan Xl	C				
			Glucophage	C				

			Levothroid	C
			Pravachol	C
			Furosemide	C
			Glipizide	C

Date:04/23/01ISR Number: 3715885-1Report Type:Periodic Company Report #WAES 00120488
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Chills							
	Hyperhidrosis							
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/01ISR Number: 3718508-0Report Type:Periodic Company Report #WAES 00121766
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/24/01ISR Number: 3709240-8Report Type:Direct Company Report #
Age:39 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx 25mg Po Qd	PS		ORAL	25MG PO QD	
	Cholecystitis		Naprosyn	C				
	Urticaria		Flexeral	C				
	Vomiting		Effexor	C				

Date:04/24/01ISR Number: 3710108-1Report Type:Expedited (15-DaCompany Report #WAES 01041447
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactoid Reaction Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:04/24/01ISR Number: 3710110-XReport Type:Expedited (15-DaCompany Report #WAES 01041531
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
UNK/UNK/PO						
		Representative				

Date:04/24/01ISR Number: 3710113-5Report Type:Expedited (15-DaCompany Report #WAES 01041459
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Kidney Infection				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Avandia	C		
			Cardizem	C		
			Plavix	C		
			Prinivil	C		
			Zocor	C		
			Furosemide Sodium	C		

Date:04/24/01ISR Number: 3710114-7Report Type:Expedited (15-DaCompany Report #WAES 01031727
Age: Gender: I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	

Date:04/24/01ISR Number: 3710116-0Report Type:Expedited (15-DaCompany Report #WAES 01030851
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Bilirubin Increased Hepatic Enzyme Increased Hepatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:04/24/01ISR Number: 3710118-4Report Type:Expedited (15-DaCompany Report #WAES 00091036
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Embolism Haematuria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Lescol	C				
			Proscar	C				
			Aspirin	C				
			Vitamin E	C				

Date:04/24/01ISR Number: 3710123-8Report Type:Expedited (15-DaCompany Report #WAES 01031725
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Syncope	Professional			Laboratories Div			
Initial or Prolonged	Upper Gastrointestinal	Company			Merck Co Inc	ORAL	PO	
	Haemorrhage	Representative	Aspirin	C				

Date:04/24/01ISR Number: 3710124-XReport Type:Expedited (15-DaCompany Report #WAES 01031724
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:04/24/01ISR Number: 3710126-3Report Type:Expedited (15-DaCompany Report #WAES 01041053
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination, Visual	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Combivent	C	
Flovent	C	
Prednisone	C	

Date:04/24/01ISR Number: 3710128-7Report Type:Expedited (15-DaCompany Report #WAES 01040835
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Estrogens (Unspecified)	C				
			Ibuprofen	C				
			Naproxen	C				

Date:04/24/01ISR Number: 3710133-0Report Type:Expedited (15-DaCompany Report #WAES 01031722
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/24/01ISR Number: 3710134-2Report Type:Expedited (15-DaCompany Report #WAES 01030397
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Blood Creatinine	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Increased	Other			Merck Co Inc	ORAL
25 MG/ DAILY/						
	Blood Urea Increased					
PO						
	Decreased Activity		Lozol	C		
			Furosemide	C		
			Hydroxyzine	C		
			Levothyroxine	C		
			Lisinopril	C		

Date:04/24/01ISR Number: 3710139-1Report Type:Expedited (15-DaCompany Report #WAES 01041141
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypertension	Health	Vioxx	PS	Merck Research	
Disability	Hypoaesthesia	Professional			Laboratories Div	
	Transient Ischaemic				Merck Co Inc	ORAL
25						
	Attack					
MG/DAILY/PO						
			Celebrex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/01ISR Number: 3710509-1Report Type:Expedited (15-DaCompany Report #WAES 01047908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Insomnia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 7 DAY

Date:04/24/01ISR Number: 3710511-XReport Type:Expedited (15-DaCompany Report #WAES 01045525
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID PO	
	Dehydration							
	Depressed Level Of Consciousness		Doxylamine	SS				
	Disorientation		Piretanide	C				
	Transient Ischaemic Attack		Prednisolone	C				

Date:04/24/01ISR Number: 3710533-9Report Type:Expedited (15-DaCompany Report #WAES 01048751
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Atrial Fibrillation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	
	Coronary Artery Disease							
			Moduretic	C				
			Timoptic-Xe	C				
			Atenolol	C				
			Nutritional Supplements	C				

Date:04/24/01ISR Number: 3710541-8Report Type:Expedited (15-DaCompany Report #WAES 01025596
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	7 DAY
			Vasotec	C				
			Furosemide	C				
			Ranitidine	C				
			Tolperisone Hcl	C				

Date:04/24/01ISR Number: 3710544-3Report Type:Expedited (15-DaCompany Report #WAES 01038757
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Oedema Peripheral	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	6 DAY
			Acetaminophen	C				

Date:04/24/01ISR Number: 3710547-9Report Type:Expedited (15-DaCompany Report #WAES 01049603
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Anaphylactoid Reaction Arthralgia Delirium Memory Impairment	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	1 DAY

Date:04/24/01ISR Number: 3710892-7Report Type:Expedited (15-DaCompany Report #WAES 01041353
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased Blood Urea Increased Proteinuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/24/01ISR Number: 3710895-2Report Type:Expedited (15-DaCompany Report #WAES 01031727
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Ulcer Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/24/01ISR Number: 3710897-6Report Type:Expedited (15-DaCompany Report #WAES 01041150
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged	Haematemesis				Laboratories Div	
	Haematochezia				Merck Co Inc	ORAL
12.5						
	Haematuria					
MG/PRN/PO						
	Haemorrhage		Codeine	C		
	Ulcer					

Date:04/24/01ISR Number: 3710898-8Report Type:Expedited (15-DaCompany Report #WAES 01031724
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ulcer Haemorrhage	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:04/24/01ISR Number: 3710899-XReport Type:Expedited (15-DaCompany Report #WAES 01041306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Pulmonary Oedema				Laboratories Div	
					Merck Co Inc	
			Actos	C		
			Flomax	C		

Prinivil	C
Tolanase	C

Date:04/24/01ISR Number: 3710902-7Report Type:Expedited (15-DaCompany Report #WAES 01041353
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/24/01ISR Number: 3710911-8Report Type:Expedited (15-DaCompany Report #WAES 01040833
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Dizziness Drug Hypersensitivity Dysphonia Face Oedema Fatigue Headache Hypoaesthesia Malaise Myalgia Palpitations Panic Attack Throat Tightness Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY

Date:04/24/01ISR Number: 3711617-1Report Type:Expedited (15-DaCompany Report #WAES 01049120
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Confusional State	Health			Laboratories Div	
	Hallucination	Professional			Merck Co Inc	ORAL
12.5 MG DAILY 12 DAY						
	Insomnia		Vasotec	C		
	Nervousness		Lorazepam	C		

Date:04/24/01ISR Number: 3711618-3Report Type:Expedited (15-DaCompany Report #WAES 01045094
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Atrial Fibrillation	Foreign	Vioxx	PS	Merck Research	
		Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG DAILY						

Date:04/24/01ISR Number: 3711619-5Report Type:Expedited (15-DaCompany Report #WAES 01045086
Age:68 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Dizziness
Initial or Prolonged	Dysarthria
	Fall

		Pollakiuria Thirst					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY	10 DAY						
				Ibuprofen	C		
				Lansoprazole	C		
				Prochlorperazine Maleate	C		
				Thyroxine	C		

Date:04/24/01ISR Number: 3711620-1Report Type:Expedited (15-DaCompany Report #WAES 01045084
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Hypotension	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY	8 DAY					
	Melaena		Enalapril	C		
			Furosemide	C		

Date:04/24/01ISR Number: 3711621-3Report Type:Expedited (15-DaCompany Report #WAES 01045082
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG DAILY	15 DAY					
			Diclofenac Sodium (+) Misoprostol	C		
			Ibuprofen	C		

Date:04/24/01ISR Number: 3711622-5Report Type:Expedited (15-DaCompany Report #WAES 01035576
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Foreign	Vioxx	PS	Merck Research			
	Pleural Effusion	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25MG/DAILY	
			Cyclophosphamide	C				
			Furosemide	C				
			Pantoprazole Sodium	C				
			Pioglitazone Hcl	C				
			Prednisone	C				

Date:04/24/01ISR Number: 3711623-7Report Type:Expedited (15-DaCompany Report #WAES 01035188
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Dreams	Foreign	Vioxx	PS	Merck Research			
	Akathisia	Health			Laboratories Div			
	Pruritus	Professional			Merck Co Inc	ORAL	25MG/DAILY	
	Restless Legs Syndrome		Ascorbic Acid					
			(+)Dimethyl Sulfone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3710733-8Report Type:Direct Company Report #
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Duodenal Ulcer Gastric Ulcer Gastrointestinal Haemorrhage Melaena		Ibuprofen Rofecoxib	PS SS				

Date:04/25/01ISR Number: 3710894-0Report Type:Expedited (15-DaCompany Report #WAES 01041026
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/25/01ISR Number: 3710896-4Report Type:Expedited (15-DaCompany Report #WAES 01041804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:04/25/01ISR Number: 3710913-1Report Type:Expedited (15-DaCompany Report #WAES 00030223
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Dyspnoea	Study	Vioxx	PS	Merck Research		
Hospitalization -	Ventricular Tachycardia	Health			Laboratories Div		
Initial or Prolonged		Professional			Merck Co Inc	ORAL	
25							
Disability							
MG/DAILY/PO							
			Coumadin	C			
			Lopressor	C			
			Vasotec	C			
			Ascorbic Acid	C			
			Calcium Carbonate	C			
			Furosemide	C			
			Vitamin D	C			
			Vitamin E	C			
			Vitamins	C			

Date:04/25/01ISR Number: 3710916-7Report Type:Expedited (15-DaCompany Report #WAES 01040957
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose Duration							
Death	Cardiac Arrest	Health	Vioxx	PS	Merck Research		
	Cardiac Failure	Professional			Laboratories Div		
	Congestive	Company			Merck Co Inc	ORAL	
25							
		Representative					
MG/DAILY/PO							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3710919-2Report Type:Expedited (15-DaCompany Report #WAES 01031627
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Balance Disorder							
	Blood Pressure Increased							
	Confusional State	Representative	Lithiumco3 300 Mg	SS			DAILY	
	Drug Interaction		Fosamax	C				
	Drug Toxicity		Lortab	C				
	Gait Disturbance		Prempro	C				
	Haematocrit Decreased		Prevacid	C				
	Haemoglobin Decreased		Zestril	C				
	Hallucination							
	Headache							
	Memory Impairment							
	Mental Impairment							
	Oliguria							
	Peripheral Sensory Neuropathy							
	Pollakiuria							
	Sedation							
	Speech Disorder							
	Thirst							
	Tremor							
	Visual Acuity Reduced							
	Weight Decreased							

Date:04/25/01ISR Number: 3710920-9Report Type:Expedited (15-DaCompany Report #WAES 01040958
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomyopathy	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Celebrex	C				
			[Composition Unspecified]	C				

Date:04/25/01ISR Number: 3710923-4Report Type:Expedited (15-DaCompany Report #WAES 01040184
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Headache		Tab Vioxx 25 Mg	SS		ORAL	50 MG/DAILY/PO	
	Influenza Like Illness							
	Vaginal Haemorrhage		Estraderm	C				
			Maxzide	C				
			Nizoral 2% Shampoo	C				
			Norpramin	C				
			Proventil	C				
			Serevent	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3710928-3Report Type:Expedited (15-DaCompany Report #WAES 01041911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Level Below Therapeutic	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Dilantin 100 Mg	SS			100 MG/TID	

Date:04/25/01ISR Number: 3710967-2Report Type:Expedited (15-DaCompany Report #WAES 01043743
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Appetite Duodenal Ulcer Gastritis Gastrointestinal Disorder	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY	
							PO	1 MON
			Aspirin	C				
			Hydroxychloroquineso 4	C				

Date:04/25/01ISR Number: 3710968-4Report Type:Expedited (15-DaCompany Report #WAES 01019751
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
							PO	
	Fluid Retention		Vasotec	C				
			Zocor	C				
			Albuterol Sulfate	C				
			Aspirin	C				
			Atenolol	C				

			Ipratropium Bromide	C		
			Isosorbide Mononitrate	C		

Date:04/25/01ISR Number: 3710969-6Report Type:Expedited (15-DaCompany Report #WAES 00096050
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukocytoclastic Vasculitis Purpura Skin Lesion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY

Date:04/25/01ISR Number: 3710972-6Report Type:Expedited (15-DaCompany Report #WAES 01047501
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Prinivil	C				
			Acetaminophen	C				
			Carbamazepine	C				

Fenoterol Hydrobromide (+)	
Ipratropium B	C
Furosemide	C
Moxonidine	C
Nitroglycerin	C
Terazosin	C

Date:04/25/01ISR Number: 3710976-3Report Type:Expedited (15-DaCompany Report #WAES 01025584
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY PO	

Date:04/25/01ISR Number: 3711031-9Report Type:Expedited (15-DaCompany Report #WAES 01048540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/25/01ISR Number: 3711034-4Report Type:Expedited (15-DaCompany Report #WAES 01048557
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID PO	154 DAY

			Vasotec	C
			Atorvastatin Calcium	C
			Pantoprazole Sodium	C
			Prednisone	C
			Warfarin Sodium	C

Date:04/25/01ISR Number: 3711037-XReport Type:Expedited (15-DaCompany Report #WAES 01043745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/25/01ISR Number: 3711042-3Report Type:Expedited (15-DaCompany Report #WAES 01027518
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Petechiae Thrombocytopenia	Foreign Health Professional	Vioxx Sinemet	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Zocor	C
Amlodipine	C
Clonidine Hcl	C
Insulin	C
Pergolide	C
Sertraline	C

Date:04/25/01ISR Number: 3711047-2Report Type:Expedited (15-DaCompany Report #WAES 01043740
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Perforation	Foreign Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:04/25/01ISR Number: 3711048-4Report Type:Expedited (15-DaCompany Report #WAES 01043742
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemoglobin Decreased Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	8 DAY

Date:04/25/01ISR Number: 3711078-2Report Type:Expedited (15-DaCompany Report #WAES 01048211
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Aspartate	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	2 DAY

	Aminotransferase	Other	Tab Diclofenac Na	SS		ORAL
150 MG/DAILY 1 DAY						
	Increased		Arginine Aspartate	C		
	Blood Alkaline		Hypericin	C		
	Phosphatase Increased					
	Blood Bilirubin Increased					
	Diarrhoea					
	Gamma-Glutamyltransferase					
	Increased					
	Hepatocellular Damage					
	Liver Disorder					
	Nausea					

Date:04/25/01ISR Number: 3711089-7Report Type:Expedited (15-DaCompany Report #WAES 01049903
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Oedema Peripheral	Health			Laboratories Div	
	Renal Impairment	Professional			Merck Co Inc	ORAL
25 MG/DAILY						
	Weight Increased					
PO 7 DAY						
			Amitriptyline	C		
			Chlorpheniramine			
			Maleate	C		
			Ciprofloxacin			

			Hydrochloride	C		
			Furosemide	C		
			Lactulose	C		
			Morphine	C		
			Potassium (Unspecified)	C		
			Senna	C		

Date:04/25/01ISR Number: 3711095-2Report Type:Expedited (15-DaCompany Report #WAES 00048518
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Fluid Retention	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Hyponatraemia	Professional					PO	62 DAY
	Oedema Peripheral		Pepcid	C				
			Acetaminophen	C				
			Methotrexate	C				
			Prednisolone	C				

Date:04/25/01ISR Number: 3711098-8Report Type:Expedited (15-DaCompany Report #WAES 00088565
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Fluid Retention	Professional					PO	34 DAY
			Acebutolol Hydrochloride	C				
			Furosemide	C				

Date:04/25/01ISR Number: 3711106-4Report Type:Expedited (15-DaCompany Report #WAES 00088617
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anuria Blood Creatinine Increased Cardiac Failure Congestive Pulmonary Oedema Renal Failure Acute	Foreign Literature Health Professional	Vioxx Aspirin Enalapril Furosemide Glyburide Metformin Metoprolol Tartrate	PS C C C C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO

Date:04/25/01ISR Number: 3711118-0Report Type:Expedited (15-DaCompany Report #WAES 01043745
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Perforation	Foreign Health Professional	Vioxx Acetaminophen Glimepiride	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3711130-1Report Type:Expedited (15-DaCompany Report #WAES 01047522
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
	Duodenitis							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal Disorder							
	Microcytic Anaemia		Tab Aspirin	SS		ORAL	160 MG/DAILY	PO
	Vomiting							
			[Therapy Unspecified)	C				
			Piroxicam	C				
			Terazosin Hydrochloride	C				

Date:04/25/01ISR Number: 3711132-5Report Type:Expedited (15-DaCompany Report #WAES 01048751
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	PO
Other	Myocardial Ischaemia	Other						
			Moduretic	C				
			Timoptic-Xe	C				
			Atenolol	C				
			Nutritional Supplementals	C				

Date:04/25/01ISR Number: 3711137-4Report Type:Expedited (15-DaCompany Report #WAES 01047280
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Endoscopy Upper Gastrointestinal Tract Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY
	Gastric Ulcer Haemorrhage						
	Haemoglobin Decreased		Aspirin	SS		ORAL	75 MG/DAILY
	Melaena		Albuterol Sulfate	C			
			Amiloride Hydrochloride/Hctz	C			
			Ipratropium Bromide	C			
			Levothyroxine Na	C			
			Potassium (Unspecified)	C			
			Verapamil Hc1	C			

Date:04/25/01ISR Number: 3711139-8Report Type:Expedited (15-DaCompany Report #WAES 01047281
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Brain Oedema Haemorrhage Intracranial	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	18 DAY
	Haemorrhagic Stroke		Ketoprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3711143-XReport Type:Expedited (15-DaCompany Report #WAES 01046550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:04/25/01ISR Number: 3711145-3Report Type:Expedited (15-DaCompany Report #WAES 01043532
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Leflunomide	C				
			Methotrexate	C				
			Prednisolone	C				

Date:04/25/01ISR Number: 3711226-4Report Type:Expedited (15-DaCompany Report #WAES 01043753
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated Intravascular Coagulation Multi-Organ Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	
	Sepsis	Other					PO	
	Toxic Skin Eruption		Tab Allopurinol	SS		ORAL	300 MG/DAILY	
							PO	
			Acetaminophen	C				
			Alfacalcidol	C				
			Calcium Carbonate	C				
			Colchicine	C				
			Dextromethorphan Hydrobromide (+)					

			Promet	C		
			Diclofenac	C		
			Ferrousso4	C		
			Furosemide	C		
			Perindopril Erbumine	C		
			Propranolol Hcl	C		

Date:04/25/01ISR Number: 3711228-8Report Type:Expedited (15-DaCompany Report #WAES 00118623
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Professional Other	[Therapy Unspecified]	C		
			Diltiazem Hydrochloride	C		
			Isosorbide Dinitrate	C		
			Nitroglycerin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/01ISR Number: 3711231-8Report Type:Expedited (15-DaCompany Report #WAES 00118647
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive	Foreign Literature Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	15 DAY
		Other	Betaxolol Hcl	C				

Date:04/25/01ISR Number: 3711234-3Report Type:Expedited (15-DaCompany Report #WAES 00118662
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Foreign Literature Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	8 DAY
	Vomiting	Professional	Furosemide	C				
		Other	Levothyroxine	C				
			Lithiumco3	C				
			Meperidine Hcl	C				
			Omeprazole Magnesium	C				
			Perindopril	C				
			Sertraline	C				

Date:04/25/01ISR Number: 3711235-5Report Type:Expedited (15-DaCompany Report #WAES 00115637
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Hypersensitivity Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Alfacalcidol	C				
			Calcium Citrate (+) Calcium Gluconate (+)	C				

Celiprolol Hcl	C
Metformin Hcl	C
Nitrendipine	C
Perindopril Erbumine	C

Date:04/25/01ISR Number: 3711337-3Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Cerebrovascular Accident Tachycardia Transient Ischaemic Attack	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/AM/PO	

Date:04/25/01ISR Number: 3711468-8Report Type:Expedited (15-DaCompany Report #WAES 01012239
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain Chest Pain Diverticulum

		Erosive Oesophagitis					
		Gastritis					
		Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis	Consumer	Vioxx	PS	Merck Research	
		Haemorrhoids	Health			Laboratories Div	
		Hiatus Hernia	Professional			Merck Co Inc	ORAL
25							
		Influenza Like Illness					
MG/DAILY/PO							
		Lipoma		Chondroitin Sulfate			
		Mallory-Weiss Syndrome		Sodium	C		
		Neck Pain		Glucosamine	C		
		Oesophagitis		Influenza Virus			
		Sinusitis		Vaccine	C		
		Spinal Column Stenosis		Lorazepam	C		
		Vomiting					

Date:04/25/01ISR Number: 3711469-XReport Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
Hospitalization -	Anorexia	Health			Laboratories Div	
Initial or Prolonged	Cellulitis	Professional			Merck Co Inc	ORAL
50						
Disability	Melaena	Other				
MG/DAILY/PO						
Other	Pancreatic Disorder		Ativan	C		
	Pancreatitis		Flexeril	C		
	Weight Decreased		Valium	C		

Date:04/25/01ISR Number: 3711509-8Report Type:Expedited (15-DaCompany Report #WAES 01041808
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arrhythmia	Consumer	Vioxx	PS	Merck Research	
Initial or Prolonged	Blood Pressure Increased				Laboratories Div	
					Merck Co Inc	ORAL
PRN/PO						
			Lipitor	C		

				Allopurinol	C		

Date:04/25/01ISR Number: 3714081-1Report Type:Expedited (15-DaCompany Report #WAES 01041946
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:04/26/01ISR Number: 3711335-XReport Type:Expedited (15-DaCompany Report #WAES 01032216
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other		Company			Merck Co Inc	ORAL	50 MG/DAILY/PO	
		Representative						
			Levofloxacin 500 Mg	SS			500 MG/DAILY	
			Motrin	C				
			Diltiazem	C				
			Lisinopril	C				

			Theophylline	C		

Date:04/26/01ISR Number: 3711336-1Report Type:Expedited (15-DaCompany Report #WAES 01040665
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhage	Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			[Therapy Unspecified]	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:04/26/01ISR Number: 3711341-5Report Type:Expedited (15-DaCompany Report #WAES 00081876
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Health	Fosamax	PS	Merck And Co Inc	ORAL	10 MG/AM/PO	
Hospitalization -	Dizziness	Professional	Tab Vioxx	SS		ORAL	SEE IMAGE	
Initial or Prolonged	Dyspepsia		Aspirin	C				
	Faeces Discoloured		Calcium Supplement (Unspecified)	C				
	Fatigue		Garlic Extract	C				
	Feeling Abnormal		Ginkgo Biloba Extract	C				
	Flatulence		Herbal Remedies (Unspecified)	C				
	Gastrointestinal Haemorrhage		Vitamin E	C				
	Haemoglobin Decreased		Vitamins (Unspecified)	C				
	Headache							
	Insomnia							
	Nausea							
	Oedema Peripheral							
	Pain							
	Pallor							
	Red Blood Cell Count Decreased							

Ulcer
Vomiting

Date:04/26/01ISR Number: 3711674-2Report Type:Expedited (15-DaCompany Report #WAES 01041922
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:04/26/01ISR Number: 3711676-6Report Type:Expedited (15-DaCompany Report #WAES 01042028
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Back Pain Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide)	C				

				(Therapy Unspecified)	C		

Date:04/26/01ISR Number: 3711678-XReport Type:Expedited (15-DaCompany Report #WAES 01042077
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Vioxx	PS	Merck Research			
Hospitalization -	Dialysis	Professional			Laboratories Div			
Initial or Prolonged	Fluid Overload				Merck Co Inc	ORAL	UNK/DAILY/PO	
	Renal Failure		Calan Sr	C				
	Respiratory Failure		Fosamax	C				
			K-Dur	C				
			Lozol	C				
			Prevacid	C				
			Cephalosporin C	C				
			Ibuprofen	C				

Date:04/26/01ISR Number: 3712308-3Report Type:Expedited (15-DaCompany Report #WAES 01049905
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage				Laboratories Div			
					Merck Co Inc			

Date:04/26/01ISR Number: 3713667-8Report Type:Expedited (15-DaCompany Report #WAES 01048209
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Anaemia	Study			Laboratories Div			
Initial or Prolonged	Dyspepsia	Health			Merck Co Inc	ORAL	25 MG/DAILY	
Other	Gastric Ulcer Haemorrhage	Professional						
PO							44	DAY

	Gastrooesophageal Reflux	Company	Tab Blinded Therapy	SS			ORAL
400 MG/DAILY							
	Disease	Representative					
PO	44 DAY						
	Hernia		Tab Aspirin	SS			ORAL
2 GM PO (SEE							
	Influenza						
IMAGE)	1 DAY						

Date:04/26/01ISR Number: 3713669-1Report Type:Expedited (15-DaCompany Report #WAES 01043742
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY

Date:04/27/01ISR Number: 3713486-2Report Type:Periodic Company Report #SKEL000012 (0)
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Sedation	Health Professional Distributor	Skelaxin	PS	Carnrick Laboratories Inc Div Gw Carnrick Co	ORAL	ORAL	
			Vioxx	SS				

			Percocet	SS		
			Provigil	SS		
			Synthroid	C		

Date:04/27/01ISR Number: 3713491-6Report Type:Expedited (15-DaCompany Report #WAES 00102525
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Renal Failure Acute	Representative						
		Other	Coreg	C				
			Diuril	C				
			Amlodipine	C				
			Aspirin	C				
			Dobutamine	C				
			Furosemide	C				
			Glipizide	C				
			Isosorbide Mononitrate	C				
			Nitroglycerin	C				

Date:04/27/01ISR Number: 3713492-8Report Type:Expedited (15-DaCompany Report #WAES 01012063
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Arimidex	C				
			Baycol	C				
			Norflex	C				
			Paxil	C				
			Prevacid	C				
			Verapamil	C				

Date:04/27/01ISR Number: 3713493-XReport Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abnormal Faeces
Other	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Bilirubinuria
	Blood Albumin Abnormal
	Blood Alkaline Phosphatase Increased
	Hepatotoxicity
	International Normalised Ratio Decreased
	Jaundice
	Liver Disorder
	Liver Transplant Rejection

Protein Total Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bactrim	C				
			Calderol	C				
			Diflucan	C				
			Os-Cal	C				
			Procardia Xl	C				
			Zoloft	C				
			Cyclosporine	C				
			Ibuprofen	C				
			Prednisone	C				

Date:04/27/01ISR Number: 3713494-1Report Type:Expedited (15-DaCompany Report #WAES 01042141
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Gastric Ulcer Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:04/27/01ISR Number: 3713495-3Report Type:Expedited (15-DaCompany Report #WAES 01041838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy Bone Pain Cartilage Injury Furuncle	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Gait Disturbance
Insomnia
Joint Sprain
Joint Swelling
Muscle Spasms
Muscular Weakness
Oedema
Pain In Extremity
Paraesthesia
Peripheral Coldness
Tendonitis
Weight Increased

Date:04/27/01ISR Number: 3713496-5Report Type:Expedited (15-DaCompany Report #WAES 01021919
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG /DAILY	/PO
Other			Tab Vioxx 25mg	SS			25 MG DAILY/PO	
			Celebrex	C				

				Claritin-D	C		
				Aspirin	C		

Date:04/27/01ISR Number: 3713498-9Report Type:Expedited (15-DaCompany Report #WAES 01042169
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 MON
			Aspirin	C				

Date:04/27/01ISR Number: 3713714-3Report Type:Expedited (15-DaCompany Report #WAES 01049006
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, PO	5 DAY
			Acarbose	C				
			Captopril	C				
			Gliclazide	C				

Date:04/27/01ISR Number: 3713715-5Report Type:Expedited (15-DaCompany Report #WAES 01046096
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	17 DAY
			Insulin	C				

			Biphasic Isophane	C		

Date:04/27/01ISR Number: 3714939-3Report Type:Periodic Company Report #002403002
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cellulitis	Health Professional	Sublimaze Preservative Free	PS	Akorn Manufacturing Inc	
TRANSDERMAL 50 MG, 1 IN 72 HRS, TRANSD						
			Triazolam	SS		ORAL
ORAL						
			Sertraline Hydrochloride	SS		
50MG, 1 IN 1 DAY						
			Rofecoxib	SS		
1 TABLE, 1 IN 1 DAY						
			Tocopherol	SS		
400 IU, 1 IN 1 DAY						
			Celecoxib	SS		
400 MG, 1 IN 1 DAY						
			Triazolam 025mg	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/01ISR Number: 3713028-1Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm		Vioxx (25 Mg)	PS		ORAL	ONE PO DAILY	
	Choking						PRN	
	Cough							

Date:05/01/01ISR Number: 3714518-8Report Type:Expedited (15-DaCompany Report #WAES 01049312
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastrointestinal Haemorrhage Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	4 DAY
			Acetaminophen	C				
			Tizanidine	C				

Date:05/01/01ISR Number: 3714546-2Report Type:Expedited (15-DaCompany Report #WAES 01045124
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
		Other					PO	20 DAY
			Acetaminophen	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Quinine So4	C				

Date:05/01/01ISR Number: 3714548-6Report Type:Expedited (15-DaCompany Report #WAES 01028538
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypertension Renal Impairment	Foreign Health Professional Other	Vioxx Fosinopril Sodium Metoprolol	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY PO	

Date:05/01/01ISR Number: 3714555-3Report Type:Expedited (15-DaCompany Report #WAES 01045120
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		OPHTHALMIC 12.5 MG DAILY PO 25 MG	PO 41 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/01ISR Number: 3714556-5Report Type:Expedited (15-DaCompany Report #WAES 01045117
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
		Other					PO	8 DAY

Date:05/01/01ISR Number: 3714557-7Report Type:Expedited (15-DaCompany Report #WAES 01048107
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Haemorrhage Petechiae Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	6 DAY
			Lomefloxacin Hydrochloride	C				

Date:05/01/01ISR Number: 3714558-9Report Type:Expedited (15-DaCompany Report #WAES 01047281
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Haemorrhage Intracranial	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Ketoprofen	C				

Date:05/01/01ISR Number: 3714559-0Report Type:Expedited (15-DaCompany Report #WAES 00116021
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Aneurysm Pancreatitis Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	10 DAY
			Calcium Citrate (+) Cholecalciferol	C				

Date:05/01/01ISR Number: 3714560-7Report Type:Expedited (15-DaCompany Report #WAES 01035256
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Petechiae Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	71 DAY
			Sinemet	C				
			Zocor	C				
			Amlodipine	C				
			Aspirin	C				
			Clonidine Hcl	C				
			Insulin	C				
			Pergolide Mesylate	C				
			Sertraline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/01ISR Number: 3714561-9Report Type:Expedited (15-DaCompany Report #WAES 01043469
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Electrocardiogram Qt	Other			Laboratories Div			
Initial or Prolonged	Prolonged				Merck Co Inc	ORAL	12.5	
	Ventricular Tachycardia						MG/DAILY	
			Sotalol Hydrochloride	C				

Date:05/01/01ISR Number: 3714562-0Report Type:Expedited (15-DaCompany Report #WAES 01027518
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Petechiae	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Thrombocytopenia	Health			Laboratories Div			
Hospitalization -		Professional			Merck Co Inc	ORAL	25	
Initial or Prolonged							MG/DAILY/PO	71 DAY
Disability								
			Sinemet	C				
			Zocor	C				
			Amlodipine	C				
			Aspirin	C				
			Clonidine Hcl	C				
			Insulin	C				
			Pergolide Mesylate	C				
			Sertraline	C				

Date:05/01/01ISR Number: 3714575-9Report Type:Expedited (15-DaCompany Report #WAES 01037537
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thrombocytopenia	Foreign	Vioxx	PS	Merck Research			
Life-Threatening		Health			Laboratories Div			
Hospitalization -		Professional			Merck Co Inc	ORAL	25 MG/DAILY	

Initial or Prolonged
PO

Sinemet	C
Amlodipine	C
Clonidine Hcl	C
Fenoterol Hydrobromide (+)	
Ipratropium B	C
Pergolide Mesylate	C

Date:05/01/01ISR Number: 3714577-2Report Type:Expedited (15-DaCompany Report #WAES 01049905
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:05/01/01ISR Number: 3714578-4Report Type:Expedited (15-DaCompany Report #WAES 00045059
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Melaena

	Pallor						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	50 DAY

Date:05/01/01ISR Number: 3714748-5Report Type:Expedited (15-DaCompany Report #WAES 01042779
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/01/01ISR Number: 3714791-6Report Type:Expedited (15-DaCompany Report #WAES 00121218
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ascites	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Asthma							
	Atelectasis							
	Atherosclerosis		Alcohol	C				
	Blood Ethanol Increased							
	Brain Oedema							
	Bronchospasm							
	Coma							
	Ecchymosis							
	Emotional Distress							
	Excoriation							
	Gastrointestinal Haemorrhage							
	Gastrointestinal Necrosis							
	Haematochezia							
	Haemorrhage							

Hypoxic Encephalopathy
Injury
Laceration
Necrosis Ischaemic
Oedema Peripheral
Pericardial Effusion
Pleural Adhesion
Pleural Effusion
Pneumonia Aspiration
Pulmonary Haemorrhage
Pulmonary Oedema
Sternal Fracture

Date:05/01/01ISR Number: 3714798-9Report Type:Expedited (15-DaCompany Report #WAES 01034259
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Atrial Fibrillation	Professional			Laboratories Div			
Initial or Prolonged	Cardiac Failure	Company			Merck Co Inc	ORAL	12.5	
Other	Gastric Ulcer Haemorrhage	Representative					MG/DAILY/PO	
			Coumadin	C				

				Aspirin	C		

Date:05/01/01ISR Number: 3714799-0Report Type:Expedited (15-DaCompany Report #WAES 01040819
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage Haematemesis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Nonsteroidal Anti-Inflammatory D	C				

Date:05/01/01ISR Number: 3714803-XReport Type:Expedited (15-DaCompany Report #WAES 00111470
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased Burning Sensation Diverticulum Intestinal Haematochezia Haemorrhoids Platelet Count Decreased Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/01/01ISR Number: 3714804-1Report Type:Expedited (15-DaCompany Report #WAES 01041306
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Actos	C
Flomax (Tamsulosin Hydrochloride	C
Prinivil	C
Tolanase	C

Date:05/01/01ISR Number: 3714806-5Report Type:Expedited (15-DaCompany Report #WAES 01042353
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50; 25 MG/DAILY/PO	

Date:05/01/01ISR Number: 3714809-0Report Type:Expedited (15-DaCompany Report #WAES 01041531
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased Pancreatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Daypro	C		
			Flexeril	C		
			Relafen	C		
			Naproxen	C		

Date:05/02/01ISR Number: 3714773-4Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ejection Fraction		Vioxx	PS			12.5MG ONCE DAILY	16 DAY
	Abnormal Weight Increased		Lansoprazole	C				
			Synthroid	C				
			Lasix	C				
			Fish Oil	C				
			Guaifenesin	C				
			Mineral Liquid Vitamins	C				
			Soybean Products	C				
			Wheat Germ	C				

Date:05/02/01ISR Number: 3715344-6Report Type:Direct Company Report #
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage Hepatitis		Vioxx (12.5mg)	PS		ORAL	12.5MG PO QD	
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:05/02/01ISR Number: 3715626-8Report Type:Expedited (15-DaCompany Report #WAES 01049774
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/02/01ISR Number: 3715651-7Report Type:Expedited (15-DaCompany Report #WAES 01020772
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
Other	Abdominal Pain Upper	Health			Laboratories Div			
	Diarrhoea	Professional			Merck Co Inc	ORAL	25 MG/TID/PO	
	Nausea		Motrin	C				
	Oedema Peripheral		Oxycontin	C				
	Pain In Extremity		Percocet	C				
	Skin Ulcer		Valium	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/01ISR Number: 3715678-5Report Type:Expedited (15-DaCompany Report #WAES 01048517
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Acetaminophen/Codeine Phosphate	C				

Date:05/02/01ISR Number: 3715691-8Report Type:Expedited (15-DaCompany Report #WAES 01031095
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Toxicity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Haematocrit Decreased							
	Red Blood Cell							
	Sedimentation Rate							
	Increased Renal Impairment		Azulfidine	C				
			Methotrexate (Methotrexate Sodium)	C				

Date:05/02/01ISR Number: 3715692-XReport Type:Expedited (15-DaCompany Report #WAES 01010971
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tenosynovitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Niacin	C		
Nonsteroidal Anti-Inflammatory	C		

Date:05/02/01ISR Number: 3715697-9Report Type:Expedited (15-DaCompany Report #WAES 01042779
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/02/01ISR Number: 3715734-1Report Type:Expedited (15-DaCompany Report #WAES 01041846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Face Oedema Feeling Abnormal Oedema Peripheral Oral Pain Skin Exfoliation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WEEK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/01ISR Number: 3715736-5Report Type:Expedited (15-DaCompany Report #WAES 01042096
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/02/01ISR Number: 3715737-7Report Type:Expedited (15-DaCompany Report #WAES 01042522
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Hospitalization - Initial or Prolonged	Diarrhoea							
	Renal Failure Acute							
Disability	Vomiting							
			Coumadin	C				
			Lipitor	C				
			Pepcid	C				

Date:05/02/01ISR Number: 3715805-XReport Type:Expedited (15-DaCompany Report #WAES 00030107
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Study	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Coronary Artery Disease	Health Professional						
	Haematuria							
Disability	Haemorrhage							
Other	Renal Failure		Vitamins	C				

Date:05/02/01ISR Number: 3715809-7Report Type:Expedited (15-DaCompany Report #WAES 00030107
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Study	Vioxx	PS	Merck Research			
Hospitalization -	Coronary Artery Disease	Health			Laboratories Div			
Initial or Prolonged	Haematuria	Professional			Merck Co Inc	ORAL	25	
Disability	Renal Failure						MG/DAILY/PO	
Other			Vitamins	C				

Date:05/02/01ISR Number: 3715811-5Report Type:Expedited (15-DaCompany Report #WAES 01042497
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged					Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Flexeril	C				
			Zestril	C				

Date:05/02/01ISR Number: 3715812-7Report Type:Expedited (15-DaCompany Report #WAES 01042504
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Upper Gastrointestinal	Health
Initial or Prolonged	Haemorrhage	Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						

Date:05/02/01ISR Number: 3717276-6Report Type:Expedited (15-DaCompany Report #WAES 01049010
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Face Oedema Oedema Peripheral Periorbital Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, PO	4 DAY					

Date:05/02/01ISR Number: 3717302-4Report Type:Expedited (15-DaCompany Report #WAES 01046073
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Transient Ischaemic Attack	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO	17 DAY					
			Furosemide	C		
			Glimepirizide	C		
			Trimetazidine Hydrochloride	C		

Date:05/02/01ISR Number: 3717307-3Report Type:Expedited (15-DaCompany Report #WAES 01035575
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 9 DAY
			Aspirin	C				
			Metoprolol Succinate	C				
			Oxazepam	C				
			Pantoprazole Sodium	C				

Date:05/02/01ISR Number: 3717309-7Report Type:Expedited (15-DaCompany Report #WAES 01049942
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Glucose Increased
Hospitalization - Initial or Prolonged	Cold Sweat
Disability	Dizziness
	Hypotension
	Nausea
	Pulse Pressure Decreased
	Respiratory Rate Increased
	Sedation
	Sinus Bradycardia
	Spinal Osteoarthritis

Vomiting

			Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 2 DAY
				Tab Tizanidine	SS		ORAL		PO 1 DAY

Date:05/02/01ISR Number: 3717492-3Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Cardiomegaly							
	Circulatory Collapse							
	Coronary Artery Disease		Acetaminophen	C				
	Duodenal Ulcer		Atenolol	C				
	Faecal Incontinence							
	Haematemesis							
	Respiratory Tract Haemorrhage							
	Upper Gastrointestinal Haemorrhage							

Date:05/02/01ISR Number: 3717600-4Report Type:Expedited (15-DaCompany Report #WAES 01049604
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peptic Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN	PO 3 MON
Hospitalization - Initial or Prolonged			Acebutolol					

			Hydrochloride	C		
			Aspirin	C		
			Lisinopril	C		

Date:05/02/01ISR Number: 3717604-1Report Type:Expedited (15-DaCompany Report #WAES 01045180
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Bronchospasm	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO						
			Loratadine	C		
			Mebeverine	C		
			Omeprazole	C		
			Pizotyline Malate	C		

Date:05/02/01ISR Number: 3717792-7Report Type:Expedited (15-DaCompany Report #WAES 01045168
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Atrial Fibrillation	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/12.5MG	
Vasotec	C				
Aspirin	C				
Bendroflumethiazide	C				
Pravastatin Na	C				

Date:05/03/01ISR Number: 3715799-7Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS		ORAL	25MG / DAY PO	
Hospitalization - Initial or Prolonged	Congestive Renal Failure Acute							

Date:05/04/01ISR Number: 3717588-6Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm		Vioxx 25mg	PS		ORAL	ONE PO DAILY	
	Choking Sensation						PRN	
	Cough							
	Throat Tightness							

Date:05/04/01ISR Number: 3717648-XReport Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased Blood Urea Increased		Vioxx 12.5mg -Merck And Co	PS	Merck And C/O	ORAL	12.5MG PO QD	

Date:05/04/01ISR Number: 3717828-3Report Type:Expedited (15-DaCompany Report #WAES 01030514
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Blood Pressure Increased Dermatitis Diarrhoea Headache Pruritus	Consumer Health Professional	Vioxx Arthrotec Premarin Thyroid	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MGH/DAILY/PO	

Date:05/04/01ISR Number: 3717830-1Report Type:Expedited (15-DaCompany Report #WAES 01042313
Age:54 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Atelectasis Clostridium Colitis

	Condition Aggravated Dermatitis Dialysis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Diverticulitis Ileus Paralytic Renal Failure Acute	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	White Blood Cell Count Increased	Representative	Benadryl Cipro	C C			

Date:05/04/01ISR Number: 3717833-7Report Type:Expedited (15-DaCompany Report #WAES 01033074
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability Other	Cataract Joint Sprain Pain In Extremity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Dextropropoxyphene	C			

Date:05/04/01ISR Number: 3717835-0Report Type:Expedited (15-DaCompany Report #WAES 01042141
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO

Date:05/04/01ISR Number: 3717837-4Report Type:Expedited (15-DaCompany Report #WAES 00061981
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Anaemia Cardiomyopathy Gastric Ulcer Haemorrhage		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Tab Aspirin	SS		ORAL
325 MG/DAILY/PO						
			Tab Advil	SS		ORAL
200 MG/DAILY/PO						
			Coreg	C		
			Vasotec	C		
			Bumetanide	C		
			Donepezil Hydrochloride	C		
			Placebo (Unspecifed)	C		
			Vitamins	C		

Date:05/04/01ISR Number: 3717839-8Report Type:Expedited (15-DaCompany Report #WAES 01042624
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/01ISR Number: 3717841-6Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Health	Vioxx	PS	Merck Research			
Hospitalization -	Increased	Professional			Laboratories Div			
Initial or Prolonged	Aspartate	Company			Merck Co Inc	ORAL	25	
Other	Aminotransferase	Representative					MG/DAILY/PO	
	Increased		Bactrim	C				
	Bilirubinuria		Calderol	C				
	Blood Alkaline		Diflucan	C				
	Phosphatase Increased		Norvasc	C				
	Blood Bilirubin Increased		Os-Cal	C				
	Cholangitis		Procardia Xl	C				
	Cholestasis		Zoloft	C				
	Gamma-Glutamyltransferase		Cyclosporine	C				
	Increased		Ibuprofen	C				
	Jaundice		Prednisone	C				
	Liver Transplant							
	Rejection							

Date:05/04/01ISR Number: 3717918-5Report Type:Expedited (15-DaCompany Report #WAES 01043740
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Perforation	Health			Laboratories Div			
Initial or Prolonged	Nausea	Professional			Merck Co Inc	ORAL	25 MG/DAILY	
		Other						

Date:05/04/01ISR Number: 3718112-4Report Type:Expedited (15-DaCompany Report #WAES 01049774
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Other			Laboratories Div			

Merck Co Inc ORAL
PO
Paroxetine Hcl C

Date:05/04/01ISR Number: 3718114-8Report Type:Expedited (15-DaCompany Report #WAES 01046550
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MG / DAILY

PO 1 YR

Tab Aspirin / Codeine Phosphate	SS	

1 YR

Date:05/04/01ISR Number: 3718130-6Report Type:Expedited (15-DaCompany Report #WAES 01046557
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
12.5 MG DAILY

PO 9 MON

			Acetaminophen	C		
			Dipyridamole	C		
			Nitrazepam	C		
			Propoxyphene Napsylate	C		

Date:05/04/01ISR Number: 3718131-8Report Type:Expedited (15-DaCompany Report #WAES 01045163
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Dyspnoea	Other			Laboratories Div			
Initial or Prolonged	Left Ventricular Failure				Merck Co Inc	ORAL	12.5 MG DAILY	
	Pulmonary Oedema							
PO							4	DAY
			Aspirin	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Omeprazole	C				
			Ramipril	C				

Date:05/04/01ISR Number: 3718135-5Report Type:Expedited (15-DaCompany Report #WAES 01046557
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged		Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG DAILY	
PO							9	MON
			Acetaminophen	C				
			Dipyridamole	C				
			Nitrazepam	C				
			Propoxyphene Napsylate	C				

Date:05/04/01ISR Number: 3718136-7Report Type:Expedited (15-DaCompany Report #WAES 01045189
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Acetaminophen (+) Dihydrocodeine					
			Bitartr	C				
			Candesartan	C				
			Furosemide	C				
			Warfarin	C				

Date:05/04/01ISR Number: 3718139-2Report Type:Expedited (15-DaCompany Report #WAES 01045592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nervous System Disorder Pain	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/01ISR Number: 3718157-4Report Type:Expedited (15-DaCompany Report #WAES 01045162
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 78 DAY

Date:05/04/01ISR Number: 3718185-9Report Type:Expedited (15-DaCompany Report #WAES 99112038
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Bacteriuria Blood Glucose Increased Blood Urea Increased Cardiac Murmur Cellulitis Condition Aggravated Confusional State Dehydration Disorientation Electrocardiogram St Segment Abnormal Erythema Gallop Rhythm Present Gastritis Erosive Gastroenteritis Helicobacter Haematemesis Haematuria Haemoglobin Decreased Injection Site Reaction Lethargy Malaise Mallory-Weiss Syndrome Mental Impairment Rhabdomyolysis	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

	Sedation
	Sick Sinus Syndrome
	Sinus Bradycardia
	Upper Gastrointestinal
	Haemorrhage
	Urinary Tract Infection
	Vomiting

Date:05/04/01ISR Number: 3718186-0Report Type:Expedited (15-DaCompany Report #WAES 00022143
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Tenderness
Hospitalization -	Aneurysm
Initial or Prolonged	Aortic Aneurysm
	Asthenia
	Benign Gastrointestinal
	Neoplasm
	Blood Pressure
	Fluctuation
	Calcinosis

		Cholelithiasis					
		Electrocardiogram T Wave Amplitude Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram T Wave Inversion	Study	Vioxx	PS	Merck Research	
			Health			Laboratories Div	
		Extensor Plantar Response	Professional			Merck Co Inc	ORAL
25							
		Gastric Ulcer Haemorrhage					
MG/DAILY/PO							
		Gastritis		Allopurinol	C		
		Gastrointestinal		Levothyroxine Sodium	C		
		Haemorrhage		Nadolol	C		
		Haematemesis		Nitrofurantoin			
		Haematocrit Decreased		Monohydrate	C		
		Haemoglobin Decreased		Potassium Chloride	C		
		Leiomyoma		Vitamin E	C		
		Platelet Count Decreased					
		Portal Hypertension					
		Renal Cyst					
		Respiratory Disorder					
		Respiratory Rate Increased					
		Supraventricular Tachycardia					

Date:05/04/01ISR Number: 3718347-0Report Type:Expedited (15-DaCompany Report #WAES 01042624
Age:84 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
			Company			Merck Co Inc	ORAL
PO							
			Representative				

Date:05/07/01ISR Number: 3718068-4Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Oliguria		Rofecoxib Merck	PS	Merck	ORAL
DAILY ORAL						
Initial or Prolonged						

Date:05/07/01ISR Number: 3718069-6Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine		Losartan 50mg Merck	PS	Merck	ORAL
50MG BID ORAL						
Initial or Prolonged	Increased		Rofecoxib 25mg Merck	SS	Merck	ORAL
25MG QD ORAL						
	Hyperkalaemia					

Date:05/07/01ISR Number: 3718442-6Report Type:Expedited (15-DaCompany Report #WAES 01045141
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Haemorrhage	Other			Laboratories Div	
	Gastric Ulcer				Merck Co Inc	ORAL
12.5 MG/DAILY 879 DAY						
	Oesophagitis		Acetaminophen	C		
	Pain		Codeine Phosphate	C		
			Dothiepin Hcl	C		

			Ispagula Husk	C		

Date:05/07/01ISR Number: 3718451-7Report Type:Expedited (15-DaCompany Report #WAES 01045231
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Ulcer Gastrointestinal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	156 DAY
	Haemorrhage		Aspirin	SS		ORAL	75 MG/DAILY	2717 DAY
			Digoxin	C				
			Furosemide	C				
			Temazepam	C				

Date:05/07/01ISR Number: 3718750-9Report Type:Expedited (15-DaCompany Report #WAES 01042854
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:05/07/01ISR Number: 3718752-2Report Type:Expedited (15-DaCompany Report #WAES 01042417
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Transient Ischaemic Attack	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atenolol	C				

Date:05/07/01ISR Number: 3718753-4Report Type:Expedited (15-DaCompany Report #WAES 01042854
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:05/08/01ISR Number: 3718773-XReport Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faecal Occult Blood		Rofecoxib Merck	PS	Merck	ORAL	25-75MG	
Initial or Prolonged	Positive						DAILY ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Haemoglobin Decreased Hypotension Melaena Pallor		Aspirin Norvasc Flovent Servent Atrovent Inhalers Advil	C C C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/01ISR Number: 3718807-2Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Bronchospasm		Vioxx	PS			50 MG Q DAY X	
Intervention to	Dyspnoea						5 DAYS	
Prevent Permanent	Face Oedema		Vioxx	SS			25 MG Q DAY	
Impairment/Damage	Lip Disorder						THEREAFTER	
	Mouth Ulceration		Premarin	C				
	Oral Intake Reduced		Allegra	C				
	Oral Mucosal Blistering							
	Skin Exfoliation							
	Speech Disorder							
	Tongue Blistering							

Date:05/08/01ISR Number: 3718818-7Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Vioxx	PS	Merck And Co	ORAL	12.5MG PO QD	
Intervention to	Increased							
Prevent Permanent								
Impairment/Damage								

Date:05/08/01ISR Number: 3718956-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx (50 Mg)					
Initial or Prolonged	Increased		(Tablet)- (Merck +					
Required	Renal Impairment		Co)	PS	Merck & Co	ORAL	50 MG P.O.	
Intervention to							QD	
Prevent Permanent								

Impairment/Damage

Date:05/08/01ISR Number: 3719667-6Report Type:Expedited (15-DaCompany Report #WAES 00109555
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haematocrit Decreased	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	357 DAY
			Methylprednisolone	SS		ORAL	4 MG DAILY PO	
			Tab Blinded Therapy	SS		ORAL	PO	357 DAY
			Calcium Gluconate	C				
			Hydroxychloroquine	C				
			Lansoprazole	C				
			Lenothyroxine	C				
			Lisinopril	C				
			Methotrexate	C				
			Vitamin D (2)	C				

Date:05/08/01ISR Number: 3719672-XReport Type:Expedited (15-DaCompany Report #WAES 01045238
Age:76 YR Gender:Female I/FU:I

Outcome	PT
Other	Dizziness Dyspnoea

Nausea

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
PO	4 DAY							
			Albuterol Sulfate	C				
			Beclomethasone Dipropionate	C				
			Latanoprost	C				

Date:05/08/01ISR Number: 3719673-1Report Type:Expedited (15-DaCompany Report #WAES 01047304
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
PO	6 DAY							
			Therapy Unspecified	C				
			Acetaminophen	C				
			Allopurinol	C				
			Lactulose	C				
			Lansoprazole	C				
			Metoprolol Tartrate	C				
			Morphine	C				
			Picosulfate Na	C				
			Tinzaparin Sodium	C				

Date:05/08/01ISR Number: 3719674-3Report Type:Expedited (15-DaCompany Report #WAES 01049945
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Haemoglobin Decreased	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

Other	Upper Gastrointestinal Haemorrhage	Professional			Merck Co Inc

Date:05/08/01ISR Number: 3719992-9Report Type:Expedited (15-DaCompany Report #WAES 01045200
Age:86 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY 66 DAY						
			Therapy Unspecified	C		
			Carbimazole	C		
			Lactulose	C		
			Paroxetine	C		

Date:05/08/01ISR Number: 3719993-0Report Type:Expedited (15-DaCompany Report #WAES 01045235
Age:58 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dermatitis Atopic Face Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25 MG/DAILY 6 DAY

Calcium Carbonate	
(-) Etidronate Sodium	C
Tamoxifen	C

Date:05/08/01ISR Number: 3720007-7Report Type:Expedited (15-DaCompany Report #WAES 01049946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	2 DAY
			Aspirin	C				
			Metoprolol Succinate	C				

Date:05/08/01ISR Number: 3720010-7Report Type:Expedited (15-DaCompany Report #WAES 01045230
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Jaundice Cholestatic Myalgia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	380 DAY
			Floxacillin	SS		ORAL	250 MG/QID	35 DAY
			Hydroxyzine Hydrochloride	C				

Date:05/08/01ISR Number: 3720020-XReport Type:Expedited (15-DaCompany Report #WAES 01023401
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purulence Pyoderma Gangrenosum	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	409 DAY

			Professional	Naproxen	SS		
409 DAY							
			Other	Hydroxychloroquine So4	C		

Date:05/08/01ISR Number: 3720026-0Report Type:Expedited (15-DaCompany Report #WAES 01037536
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anuria Renal Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						

Date:05/08/01ISR Number: 3720027-2Report Type:Expedited (15-DaCompany Report #WAES 01035188
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abnormal Dreams Akathisia Pruritus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY 163 DAY						
	Restless Legs Syndrome		Ascorbic Acid (+)			
			Dimethyl Sulfone	C		
			Valerian	C		

Date:05/08/01ISR Number: 3720029-6Report Type:Expedited (15-DaCompany Report #WAES 01043587
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive Dyspnoea Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	11 DAY

Date:05/08/01ISR Number: 3720100-9Report Type:Expedited (15-DaCompany Report #WAES 01041922
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Dehydration Depressed Level Of Consciousness Encephalitis Hepatic Failure Herpes Virus Infection Liver Function Test Abnormal Mouth Ulceration Oral Intake Reduced Radiculopathy Renal Failure Acute	Health Professional	Vioxx Prednisone 4 Mg	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO 4 MG/DAILY	

Date:05/08/01ISR Number: 3720103-4Report Type:Expedited (15-DaCompany Report #WAES 01030024
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Bleeding Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 25 MG/DAILY/PO
	Condition Aggravated					
	Haemorrhage					
	Oedema					
	Platelet Count Decreased		Tab Vioxx 25 Mg	SS		ORAL 25 MG/DAILY/PO
	Skin Lesion					
	Synovitis		Atrovent	C		
			Bactrim Ds Tablets	C		
			Cytoxan	C		
			Flomax (Tamsulosin Hydrochloride)	C		
			Flovent	C		
			Medrol	C		
			Neupogen	C		
			Prevacid	C		
			Serevent	C		
			Valtrex	C		
			Doxorubicin	C		
			Globulin, Immune	C		
			Prednisone	C		
			Vincristine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/01ISR Number: 3720104-6Report Type:Expedited (15-DaCompany Report #WAES 00112082
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Cardiac Failure Congestive	Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PRN/PO	
	Chills Condition Aggravated		Tab [Composition Unspecified] 2.5 Mg	SS		ORAL	2.5 MG/DAILY/PO	
	Dyspnoea							
	Face Oedema Oedema Peripheral		Tab [Composition Unspecified] 7.5 Mg	SS		ORAL	7.5 MG/DAILY/PO	
	Pyrexia							
			Placebo (Unspecified)	SS		ORAL	DAILY/PO	
			Tab Metformin	SS		ORAL	2500 MG/DAILY/PO	
			Hydrodiuril	C				
			Captopril	C				
			Metoprolol Succinate	C				
			Warfarin Sodium	C				

Date:05/08/01ISR Number: 3720107-1Report Type:Expedited (15-DaCompany Report #WAES 01040833
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Burning Sensation Dizziness Drug Hypersensitivity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dysphonia Face Oedema Fatigue Headache Hypoaesthesia							

Malaise
Palpitations
Panic Attack
Pharyngeal Oedema
Tongue Oedema
Tremor

Date:05/08/01ISR Number: 3720207-6Report Type:Expedited (15-DaCompany Report #WAES 01042709
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/08/01ISR Number: 3720210-6Report Type:Expedited (15-DaCompany Report #WAES 01041140
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Melaena Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ PO	
			Betapace	C				

			Aspirin	C		
			Prednisone	C		

Date:05/08/01ISR Number: 3720212-XReport Type:Expedited (15-DaCompany Report #WAES 00101829
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Carcinoembryonic Antigen Increased	Health Professional						
	Cerebral Infarction		Bumex	C				
	Drug Ineffective		Cordarone	C				
	Faecal Occult Blood Positive		Coumadin	C				
			Toprol Xl Tablets	C				
	Hypokalaemia		Calcium	C				
	International Normalised Ratio Increased		Potassium	C				
			Vitamins	C				
	Memory Impairment							
	Oedema							
	Prostatic Specific Antigen Increased							
	Rectal Haemorrhage							
	Renal Failure Acute							
	Rib Fracture							
	Spinal Compression Fracture							

Date:05/08/01ISR Number: 3720218-0Report Type:Expedited (15-DaCompany Report #WAES 00080081
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Study	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Atrial Tachycardia	Health Professional						
	Extrasystoles							
	Tachyarrhythmia							
			Placebo	SS		ORAL	PO	

Acetaminophen	SS	ORAL
Diclofenac	C	

325 MG/PRN/PO

Date:05/08/01ISR Number: 3720221-0Report Type:Expedited (15-DaCompany Report #WAES 00022227
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Bradycardia
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis
	Dyspnoea
Other	Feeling Abnormal
	Hyperkalaemia
	Hypertension
	Oedema Peripheral
	Pain In Extremity
	Pleuritic Pain
	Pulmonary Embolism
	Rash Pruritic
	Tachycardia
	Vertigo
	Weight Increased
	White Blood Cell Count

Decreased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25 MG/DAILY/PO	
			Cardizem	C				
			Premarin	C				
			Tenormin	C				
			Valium	C				
			Vitamins	C				

Date:05/08/01ISR Number: 3720224-6Report Type:Expedited (15-DaCompany Report #WAES 01041946
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	SS				

Date:05/09/01ISR Number: 3719400-8Report Type:Direct Company Report #
Age:105 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haematocrit Decreased		Vioxx 25 Mg Daily	PS			DAILY	
	Haemoglobin Decreased		Asa 81mg Daily	SS			DAILY	

Date:05/09/01ISR Number: 3719881-XReport Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	International Normalised Ratio Increased		Vioxx / 25mg / Merck	PS	Merck	ORAL	25MG ORAL	
			Celebrex 100mg Pharmacia	SS	Pharmacia	ORAL	200MG ORAL	
			Cardizem Cd	C				
			Ferrous Sulfate	C				
			Pepcid	C				
			Digoxin	C				
			Nph And Regular Insulin	C				

Date:05/09/01ISR Number: 3720817-6Report Type:Expedited (15-DaCompany Report #WAES 01045084
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage
	Haemoglobin Decreased
	Hypotension
	Melaena
	Upper Gastrointestinal

Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY
			Vasotec	C				
			Furosemide	C				

Date:05/09/01ISR Number: 3720819-XReport Type:Expedited (15-DaCompany Report #WAES 01046572
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholelithiasis Jaundice	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 29 DAY
			Acetaminophen	C				
			Morphineso4	C				

Date:05/09/01ISR Number: 3720820-6Report Type:Expedited (15-DaCompany Report #WAES 01047305
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 21 DAY

Date:05/09/01ISR Number: 3720821-8Report Type:Expedited (15-DaCompany Report #WAES 01053712
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Prednisone	C		

Date:05/09/01ISR Number: 3720823-1Report Type:Expedited (15-DaCompany Report #WAES 01042723
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Suicide Attempt	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
325 MG/1X PO						
			Tab Motrin (Ibuprofen)	SS		
2 TABLET/1X						
			Tab Pepcid (Famotidine)	SS		

Date:05/09/01ISR Number: 3720827-9Report Type:Expedited (15-DaCompany Report #WAES 01047281
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Extensor Plantar Response Haemorrhage Intracranial	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 18 DAY
			Ketoprofen	C				

Date:05/09/01ISR Number: 3720829-2Report Type:Expedited (15-DaCompany Report #WAES 01045084
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Hypotension	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY
			Vasotec	C				
			Furosemide	C				

Date:05/09/01ISR Number: 3720900-5Report Type:Expedited (15-DaCompany Report #WAES 01050055
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction Rash Erythematous Rash Papular Throat Tightness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/09/01ISR Number: 3720902-9Report Type:Expedited (15-DaCompany Report #WAES 01050194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Advil	C		
			Pulmicort	C		
			Serevent	C		
			Creatine	C		
			Vitamins (Unspecified)	C		
			Naprosyn	C		

Date:05/09/01ISR Number: 3720903-0Report Type:Expedited (15-DaCompany Report #WAES 01050288
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arthralgia Blood Potassium Increased Electrolyte Imbalance	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO	Renal Failure Acute					
			Darvocet-N	C		
			Risperdal	C		
			Zoloft	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/01ISR Number: 3720936-4Report Type:Expedited (15-DaCompany Report #WAES 01042561
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Brain Neoplasm Gastrointestinal Motility Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/09/01ISR Number: 3720937-6Report Type:Expedited (15-DaCompany Report #WAES 01050048
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/09/01ISR Number: 3720938-8Report Type:Expedited (15-DaCompany Report #WAES 01042857
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Ear Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				
			Antioxidants (Unspecified)	C				

Date:05/09/01ISR Number: 3720945-5Report Type:Expedited (15-DaCompany Report #WAES 01040338
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Asthenia Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Gastric Ulcer				Merck Co Inc	ORAL
50						
Other	Haematocrit Decreased					
MG/DAILY/PO						
	Haemoglobin Decreased		Celebrex	C		
	Monocyte Count Decreased		Hydrodiuril	C		
	Mucosal Ulceration		Prevacid	C		
	Red Blood Cell Count		Zocor	C		
	Decreased		Aspirin	C		
	Thrombocythaemia		Captopril	C		
	Upper Gastrointestinal		Nonsteroidal			
	Haemorrhage		Anti-Inflammatory	C		

Date:05/09/01ISR Number: 3720946-7Report Type:Expedited (15-DaCompany Report #WAES 01022285
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deep Vein Thrombosis	Health	Vioxx	PS	Merck Research	
	Endometrial Cancer	Professional			Laboratories Div	
	Myocardial Infarction	Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Avapro	C		
			Evista	C		
			Lipitor	C		
			Prilosec	C		
			Synthroid	C		

				Albuterol	C		
				Metoclopramide	C		

Date:05/10/01ISR Number: 3720135-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Rofecoxib	PS		ORAL	25 MG QD PO	
Hospitalization - Initial or Prolonged	Diverticulum Intestinal		Tylenol	C				
	Haemorrhagic		Lasix	C				
	Hypotension		Glyburide	C				
	Oedema		Timolol Os	C				
	Rectal Haemorrhage		Vioxx	C				
	Renal Impairment		Senokot	C				
			Hctz	C				
			Insulin	C				
			B-Complex Vit	C				
			Multi-Vit	C				

Date:05/10/01ISR Number: 3720199-XReport Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Magnesium Decreased		Vioxx	PS				
	Blood Sodium Decreased							
	Hyperkalaemia							

Date:05/10/01ISR Number: 3721456-3Report Type:Expedited (15-DaCompany Report #2001055237SE
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Azulfidine	PS	Pharmacia And Upjohn Co		2 G	
	Gastrointestinal Disorder	Health						
	Haematochezia	Professional	Ketoprofen					
	Surgery	Other	(Ketoprofen)	SS			7 DAY	

Rofecoxib SS
7 DAY

Date:05/11/01ISR Number: 3720901-7Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx 25 Mg.	PS		ORAL	25 MG. 1 X A	
Initial or Prolonged	Blood Pressure Increased						DAY ORAL	
Other	Palpitations							
	Tremor							
	Visual Disturbance							

Date:05/11/01ISR Number: 3721988-8Report Type:Expedited (15-DaCompany Report #WAES 01010927
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Barrett'S Oesophagus
Hospitalization -	Duodenal Ulcer
Initial or Prolonged	Perforation
	Gastritis
	Gastrooesophageal Reflux

		Disease Migraine Oesophagitis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Imitrex	C		
				Premarin	C		

Date:05/11/01ISR Number: 3721989-XReport Type:Expedited (15-DaCompany Report #WAES 01041306
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Other	Congestive Dyspnoea					
25						
MG/DAILY/PO						
			Actos	C		
			Flomax	C		
			Prinivil	C		
			Tolanase	C		

Date:05/11/01ISR Number: 3722030-5Report Type:Expedited (15-DaCompany Report #WAES 01050455
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged						
PO						
Other			Tab Advil	SS		ORAL
PO						
			Tab Fosamax	SS		ORAL
PO						
			Tab Plavix	SS		ORAL
PO						
			Hydrodiuril	C		

			Tiazac	C
			Zestril	C
			Zoloft	C
			Calcium	C
			Potassium	C

Date:05/11/01ISR Number: 3722033-0Report Type:Expedited (15-DaCompany Report #WAES 01050097
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Gastric Ulcer Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nonsteroidal Anti-Inflammatory D	C				

Date:05/11/01ISR Number: 3722034-2Report Type:Expedited (15-DaCompany Report #WAES 01050044
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Actos	C				
Aldactone	C				
Cozaar	C				
Glucophage	C				
Lanoxin	C				
Lasix (Furosemide)	C				
Lopressor	C				
Pravachol	C				
Prilosec	C				
Aspirin	C				
Insulin	C				
Vitamins	C				

Date:05/11/01ISR Number: 3722036-6Report Type:Expedited (15-DaCompany Report #WAES 01050054
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/11/01ISR Number: 3722039-1Report Type:Expedited (15-DaCompany Report #WAES 01050279
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Extradural Abscess Hypoxia Medication Error	Health Professional Other	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/Q4H/PO	
	Pulmonary Oedema		Celexa	C				

			Hydrodiuril	C		
			Norvasc	C		
			Percocet	C		

Date:05/11/01ISR Number: 3722040-8Report Type:Expedited (15-DaCompany Report #WAES 01050287
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Other	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
	Haematemesis		Cardura	C		
	Melaena		Ditropan	C		
			Synthroid	C		
			Toprol Xl Tablets	C		
			Tylenol	C		
			Aspirin	C		
			Digoxin	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/01ISR Number: 3722041-XReport Type:Expedited (15-DaCompany Report #WAES 01050291
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div			
	Haematocrit Decreased	Other			Merck Co Inc	ORAL	12.5	
	Haemoglobin Decreased						MG/DAILY/PO	
	Melaena		Imodium	C				
			Paxil	C				
			Phoslo	C				
			Pletal	C				
			Restoril	C				
			Vicodin Tablets	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Vitamin E	C				
			Zinc	C				

Date:05/11/01ISR Number: 3722042-1Report Type:Expedited (15-DaCompany Report #WAES 01050482
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Eye Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	DAILY/PO	12 DAY
			Axid	C				
			Lasix (Furosemide)	C				
			Lopressor	C				
			Pred Forte	C				
			Timoptic	C				
			Oxycodone	C				
			Prednisone	C				

Date:05/11/01ISR Number: 3722043-3Report Type:Expedited (15-DaCompany Report #WAES 01050453
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive International Normalised Ratio Increased	Health Professional Company Representative	Vioxx Coumadin	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/11/01ISR Number: 3722053-6Report Type:Expedited (15-DaCompany Report #WAES 01042842
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	4 MON

Date:05/11/01ISR Number: 3722365-6Report Type:Expedited (15-DaCompany Report #WAES 01035573
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Dyspnoea Urticaria	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	1 MON
Levothyroxine (+) Potassium Iodide	C				

Date:05/11/01ISR Number: 3722367-XReport Type:Expedited (15-DaCompany Report #WAES 01042723
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicide Attempt Toxicologic Test Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	375 MG/1X	1 DAY
			Effexor	C				
			Klonopin	C				
			Prozac	C				
			Zyprexa	C				
			Naproxen	C				

Date:05/11/01ISR Number: 3722369-3Report Type:Expedited (15-DaCompany Report #WAES 01048751
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Atrial Fibrillation Myocardial Ischaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	
			Moduretic	C				
			Timoptic-Xe	C				
			Atenolol	C				
			Nutritional Supplements	C				

Date:05/11/01ISR Number: 3722371-1Report Type:Expedited (15-DaCompany Report #WAES 01037258
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Sodium Decreased	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	84 DAY
	Dehydration	Other						
	Diarrhoea							
	Renal Failure		Acetaminophen	C				
			Allopurinol	C				
			Amiloride	C				
			Aspirin	C				
			Citalopram Hydrobromide	C				
			Cyanocobalamin	C				
			Digoxin	C				
			Flunitrazepam	C				
			Furosemide	C				
			Metoprolol Tartrate	C				
			Mianserin Hcl	C				
			Omeprazole Magnesium	C				
			Oxazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/01ISR Number: 3722373-5Report Type:Expedited (15-DaCompany Report #WAES 01045141
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	879 DAY
	Haematemesis		Acetaminophen	C				
	Haemoglobin Decreased		Codeine Phosphate	C				
	Melaena		Dothiepin Hcl	C				
	Oesophagitis		Ispaghula Husk	C				
	Pain							
	Thrombocythaemia							

Date:05/11/01ISR Number: 3722502-3Report Type:Expedited (15-DaCompany Report #WAES 01055038
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache Rash Generalised	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	

PO; 25 MG 30 DAY

Date:05/11/01ISR Number: 3722504-7Report Type:Expedited (15-DaCompany Report #WAES 01015229
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Heart Rate Decreased Left Ventricular Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Other	Palpitations							
PO								
	Pulmonary Oedema		Atenolol	C				
			Doxazosin Mesylate	C				

Date:05/11/01ISR Number: 3722505-9Report Type:Expedited (15-DaCompany Report #WAES 01045596
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock Hypersensitivity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Vitamins (Unspecified)	C				

Date:05/11/01ISR Number: 3722508-4Report Type:Expedited (15-DaCompany Report #WAES 01045244
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Loss Of Consciousness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/01ISR Number: 3722510-2Report Type:Expedited (15-DaCompany Report #WAES 01058507
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Vascular Occlusion Vision Blurred	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Ramipril	C				

Date:05/11/01ISR Number: 3722515-1Report Type:Expedited (15-DaCompany Report #WAES 01049604
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	"SEE IMAGE"	ORAL 3 MON
			Acebutolol Hydrochloride	C				
			Aspirin	C				
			Lisinopril	C				

Date:05/11/01ISR Number: 3722516-3Report Type:Expedited (15-DaCompany Report #WAES 00075227
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:05/11/01ISR Number: 3722518-7Report Type:Expedited (15-DaCompany Report #WAES 01043754
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY	
			Morphineso4	C				

Date:05/11/01ISR Number: 3722530-8Report Type:Expedited (15-DaCompany Report #WAES 01055030
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bite Speech Disorder Tongue Disorder Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Tab Proscar (Finasteride)	SS		ORAL		

Date:05/14/01ISR Number: 3722475-3Report Type:Direct Company Report #
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage

	Upper Gastrointestinal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Rofecoxib	PS		ORAL	12.5 MG / DAILY / ORAL	
			Ziac	C				

Date:05/14/01ISR Number: 3723953-3Report Type:Expedited (15-DaCompany Report #WAES 01045238
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Dyspnoea Nausea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	4 DAY
			Albuterol Sulfate	C				
			Beclomethasone Dipropionate	C				
			Latanoprost	C				

Date:05/14/01ISR Number: 3726063-4Report Type:Periodic Company Report #RS001656-USA
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Aciphex	PS	Eisai Inc	ORAL	20 MG, 1 IN 1 D, PER ORAL	
			Ativan (Lorazepam)	SS		ORAL	2 MG, PER ORAL	
			Vioxx	SS		ORAL	PER ORAL	

Date:05/16/01ISR Number: 3724119-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough		Vioxx (25 Mg Qd)	PS			25 MG QD	
	Dyspnoea							
	Nausea							

Date:05/16/01ISR Number: 3724120-XReport Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Rofecoxib	PS				

Date:05/16/01ISR Number: 3724170-3Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx / 12.5mg /					
	Headache		Merck	PS	Merck	ORAL	12.5MG QD	
							ORAL	
			Tylenol	C				
			Doxycycline	C				
			Zoloft	C				
			Premarin	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3724186-7Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Vioxx (25 Mg Qd)	PS			25 MG QD	
	Oedema							

Date:05/16/01ISR Number: 3724187-9Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Vioxx (25 Mg Qd)	PS			25 MG QD	
	Vomiting							

Date:05/16/01ISR Number: 3724191-0Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS				

Date:05/16/01ISR Number: 3724230-7Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema		Vioxx 25 Mg Tabs	PS	Merck	ORAL	1 PO QD WITH FOOD	
Required Intervention to Prevent Permanent Impairment/Damage	Flushing							

Date:05/16/01ISR Number: 3724231-9Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx 25 Mg	PS	Merck	ORAL	25 MG QID X 1	
Intervention to	Crepitations							
WK PO								
Prevent Permanent	Dyspnoea		Zyrtec	C				
Impairment/Damage	Oedema Peripheral							
	Weight Increased							

Date:05/16/01ISR Number: 3724237-XReport Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS				
	Weight Increased							

Date:05/16/01ISR Number: 3724238-1Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Vioxx 25 Mg Qd	PS			25 MG QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3724240-XReport Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Rofecoxib	PS				

Date:05/16/01ISR Number: 3724292-7Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS			12.5MG QD	
Initial or Prolonged			Asa Ec	SS			325MG QD	

Date:05/16/01ISR Number: 3724807-9Report Type:Expedited (15-DaCompany Report #WAES 01050278
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
Other	International Normalised	Other			Merck Co Inc	ORAL	12.5	
	Ratio Increased						MG/DAILY/PO	
	Renal Failure Acute		Warfarin 5 Mg	SS		ORAL	5 MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Prevacid	C				
			Remeron	C				
			Urecholine	C				
			Digoxin	C				
			Nitroglycerin	C				
			Sucralfate	C				

Date:05/16/01ISR Number: 3724809-2Report Type:Expedited (15-DaCompany Report #WAES 01050839
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/16/01ISR Number: 3724813-4Report Type:Expedited (15-DaCompany Report #WAES 01041846
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Erythema Face Oedema Feeling Abnormal Oedema Peripheral Oral Discomfort Oral Pain Skin Exfoliation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DIALY PO	1 WK

Date:05/16/01ISR Number: 3724814-6Report Type:Expedited (15-DaCompany Report #WAES 01042141
Age:69 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Lipitor	C				
			Toprol Xl	C				
			Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:05/16/01ISR Number: 3724815-8Report Type:Expedited (15-DaCompany Report #WAES 01050048
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Upper Limb Fracture	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/16/01ISR Number: 3724816-XReport Type:Expedited (15-DaCompany Report #WAES 01050194
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Change Of Bowel Habit Pancreatitis Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Advil	C				
			Naprosyn	C				
			Pulmicort	C				
			Serevent	C				
			Creatine	C				
			Vitamins (Unspecified)	C				

Date:05/16/01ISR Number: 3724817-1Report Type:Expedited (15-DaCompany Report #WAES 01040833
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia Burning Sensation Dizziness Drug Hypersensitivity Dysphonia Face Oedema Fatigue Headache Hypoaesthesia Malaise Myalgia Palpitations Panic Attack Paraesthesia Pharyngeal Oedema Throat Tightness Tongue Oedema Tremor	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3724818-3Report Type:Expedited (15-DaCompany Report #WAES 01040958
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomyopathy	Health	Vioxx	PS	Merck Research			
	Dyspnoea	Professional			Laboratories Div			
	Ejection Fraction	Company			Merck Co Inc	ORAL	25 MG DAILY	
	Abnormal	Representative					PO	
			Celebrex	C				
			[Composition					
			Unspecified]	C				

Date:05/16/01ISR Number: 3724819-5Report Type:Expedited (15-DaCompany Report #WAES 99080718
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alveolitis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Anxiety	Professional			Laboratories Div			
Initial or Prolonged	Aphasia	Company			Merck Co Inc	ORAL	SEE IMAGE	
	Chills	Representative	Flovent	C				
	Computerised Tomogram		Limbitrol	C				
	Abnormal		Plaquenil	C				
	Convulsion		Prilosec	C				
	Csf Mycobacteria		Singulair	C				
	Identified		Xanax	C				
	Csf Neutrophil Count		Albuterol	C				
	Decreased Activity		Prednisone	C				
	Dehydration							
	Depressed Level Of							
	Consciousness							
	Depression							
	Encephalopathy							
	Fungus Csf Test Positive							
	Haemorrhagic Stroke							
	Hyperhidrosis							
	Lethargy							
	Meningitis							
	Meningitis Aseptic							
	Mental Disorder							
	Pneumonia							

	Pyrexia Respiratory Distress Sepsis Tearfulness Transient Ischaemic Attack Upper Respiratory Tract Infection

Date:05/16/01ISR Number: 3724821-3Report Type:Expedited (15-DaCompany Report #WAES 01050285
Age:82 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Cardiac Output Decreased Cardiomyopathy Gastritis Gastritis Erosive Hypovolaemia Melaena

Renal Failure Acute

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Aspirin 325 Mg	SS		ORAL	325 MG/DAILY/PO	
	Isordil	C				
	Lanoxin	C				
	Plavix	C				
	Potassium Chloride	C				
	Vitamins (Unspecified)	C				

Date:05/16/01ISR Number: 3724823-7Report Type:Expedited (15-DaCompany Report #WAES 01050310
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased Cardiac Arrest Cardiac Tamponade Cardiomyopathy Disseminated Intravascular Coagulation Electrocardiogram Abnormal Electrocardiogram St Segment Depression Eosinophilia Hepatosplenomegaly Left Ventricular Failure Leukocytosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Correctol Laxative Tablets & Caplet	SS				
			Vicodin Tablets	SS				
			Codeine	SS				

Mitral Valve Incompetence
Myocarditis
Nausea
Oedema
Oedema Peripheral
Pericardial Effusion
Respiratory Distress
Sinus Tachycardia
Tricuspid Valve
Incompetence
Venous Pressure Jugular
Abnormal

Date:05/16/01ISR Number: 3724824-9Report Type:Expedited (15-DaCompany Report #WAES 01050272
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Haemoptysis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Capoten	C				

			Demerol	C
			Lasix (Furosemide)	C
			Neurontin	C
			Oxycontin	C
			Prevacid	C
			Potassium Chloride	C

Date:05/16/01ISR Number: 3724825-0Report Type:Expedited (15-DaCompany Report #WAES 01050858
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine #3	C				
			Azathioprine	C				
			Dietary Supplement (Unspecified)	C				
			Hydroxychloroquine Sulfate	C				
			Prednisone	C				

Date:05/16/01ISR Number: 3724826-2Report Type:Expedited (15-DaCompany Report #WAES 01050144
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dizziness							
	Gastrointestinal Disorder							
	Hypoaesthesia							
	Paraesthesia		Oxycontin 80 Mg	SS		ORAL	80 MG/Q12H/PO	
	Respiratory Distress		Orsu Oxycodone Hcl	SS		ORAL	15-20	

MG/PRN/PO

Effexor	C
Elavil	C
Naprosyn	C
Prevacid	C
Zanaflex	C
Zocor	C
Baclofen	C

Date:05/16/01ISR Number: 3724828-6Report Type:Expedited (15-DaCompany Report #WAES 01050964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/16/01ISR Number: 3724830-4Report Type:Expedited (15-DaCompany Report #WAES 01040665
Age:63 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Abnormal Dyspnoea Faecal Occult Blood Positive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastric Ulcer Gastritis Erosive Haematocrit Decreased Haemoglobin Decreased Pallor Pulse Abnormal Upper Gastrointestinal Haemorrhage		Accupril Amaryl Darvocet-N Ditropan Effexor Fiorinal Glucophage Humulin Nph Maxzide Premarin Regular Insulin Nonsteroidal Anti-Inflammatory	C C C C C C C C C C C C				

Date:05/16/01ISR Number: 3724904-8Report Type:Expedited (15-DaCompany Report #WAES 01042141
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Composition Unspecified] Aspirin Nonsteroidal Anti-Inflammatory	C C C				

Date:05/16/01ISR Number: 3724906-1Report Type:Expedited (15-DaCompany Report #WAES 01040754
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Vioxx	PS	Merck Research			
Life-Threatening	Distress Syndrome	Professional			Laboratories Div			
Hospitalization -	Anorexia	Company			Merck Co Inc	ORAL	25	
Initial or Prolonged	Cardiac Arrest	Representative					MG/DAILY/PO	
	Disseminated		Lipitor	C				
	Intravascular Coagulation		Aspirin	C				
	Dyspepsia							
	Fatigue							
	Hepatic Failure							
	Hepatitis							
	Respiratory Arrest							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3724922-XReport Type:Expedited (15-DaCompany Report #WAES 01050886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 DAY
			Lopressor	C				
			Norvasc	C				
			Lopressor	C				
			Norvasc	C				

Date:05/16/01ISR Number: 3724929-2Report Type:Expedited (15-DaCompany Report #WAES 01050354
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve	C				

Date:05/16/01ISR Number: 3725021-3Report Type:Expedited (15-DaCompany Report #WAES 01030364
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Life-Threatening	Fatigue							
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							
Other	Haematemesis		Aricept	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							

Weight Decreased

Date:05/16/01ISR Number: 3725023-7Report Type:Expedited (15-DaCompany Report #WAES 01050571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Carafate	C				
			Celebrex	C				
			Prilosec	C				
			Tylenol	C				

Date:05/16/01ISR Number: 3725151-6Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Cardiomegaly
	Constipation
	Coronary Artery Atherosclerosis

		Duodenal Ulcer Haematemesis Haematochezia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Pulmonary Congestion Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	2 MON
				Acetaminophen	C				
				Atenolol	C				
				Dipiproverine Dihcl	C				
				Lactulose	C				

Date:05/16/01ISR Number: 3725152-8Report Type:Expedited (15-DaCompany Report #WAES 01053711
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Aspirin	C				

Date:05/16/01ISR Number: 3725156-5Report Type:Expedited (15-DaCompany Report #WAES 01056010
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	
							PO	18 DAY
			Cozaar	C				
			Zocor	C				
			Allopurinol	C				
			Carvedilol	C				
			Digoxin	C				
			Fluindione	C				
			Furosemide	C				
			Potassium Chloride	C				

				Spironolactone	C		

Date:05/16/01ISR Number: 3725161-9Report Type:Expedited (15-DaCompany Report #WAES 01055008
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/16/01ISR Number: 3725164-4Report Type:Expedited (15-DaCompany Report #WAES 01058548
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lithiumco3	C				

Date:05/16/01ISR Number: 3725165-6Report Type:Expedited (15-DaCompany Report #WAES 01055059
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Mouth Ulceration	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Bendroflumethiazide	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Prednisolone	C				
			Risedronate Sodium	C				

Date:05/16/01ISR Number: 3725166-8Report Type:Expedited (15-DaCompany Report #WAES 01059113
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Blood Urea Increased Dizziness Fatigue Gastrointestinal Disorder Haematocrit Decreased Haemoglobin Decreased Hyperhidrosis Melaena Neutrophil Count Abnormal Vomiting White Blood Cell Count Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 12 DAY

Date:05/16/01ISR Number: 3725167-XReport Type:Expedited (15-DaCompany Report #WAES 01058549
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Delirium	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Lithiumco3	C			

Date:05/16/01ISR Number: 3725168-1Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia Condition Aggravated Faeces Discoloured	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faeces Pale Haemolytic Anaemia Hepatic Cirrhosis Hepatic Fibrosis Hepatic Necrosis Hepatic Steatosis Hepatitis Hepatitis Cholestatic Hepatocellular Damage Hepatomegaly Spider Naevus		Levothyroxine Na	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3725169-3Report Type:Expedited (15-DaCompany Report #WAES 01015620
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoantibody Positive	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Glucose Increased	Other						
	Chromaturia							
	Coombs Direct Test Positive		Levothyroxine Na	C				
	Faeces Pale							
	Haemolytic Anaemia							
	Hepatic Cirrhosis							
	Hepatic Necrosis							
	Hepatic Steatosis							
	Hepatitis A Antibody Positive							
	Hepatitis Cholestatic							
	Hepatomegaly							
	Monocyte Count Abnormal							
	Red Blood Cell Sedimentation Rate Increased							
	Spider Naevus							
	Transferrin Abnormal							

Date:05/16/01ISR Number: 3725170-XReport Type:Expedited (15-DaCompany Report #WAES 01053711
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
		Other						
			Aspirin	C				

Date:05/16/01ISR Number: 3725172-3Report Type:Expedited (15-DaCompany Report #WAES 01049946
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Vomiting	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	2 DAY
			Metoclopramide Hydrochloride	SS			1 DAY	
			Aspirin	C				
			Lisinopril	C				
			Metoprolol Succinate	C				

Date:05/16/01ISR Number: 3725173-5Report Type:Expedited (15-DaCompany Report #WAES 00105104
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Circulatory Collapse Dyspepsia Gastritis Nausea	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3725174-7Report Type:Expedited (15-DaCompany Report #WAES 01045200
Age:86 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	66 DAY
			(Therapy Unspecified)	C				
			Carbimazole	C				
			Lactulose	C				
			Paroxetine	C				

Date:05/16/01ISR Number: 3725175-9Report Type:Expedited (15-DaCompany Report #WAES 01049312
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	4 DAY
			Acetaminophen	C				
			Tizanidine	C				

Date:05/16/01ISR Number: 3725176-0Report Type:Expedited (15-DaCompany Report #WAES 01023401
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Body Temperature Increased Chills	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	409 DAY
	Infection Pyoderma Gangrenosum		Hydroxychloroquineso 4	C				

Date:05/16/01ISR Number: 3725181-4Report Type:Expedited (15-DaCompany Report #WAES 01059109
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Gemfibrozil	C				

Date:05/16/01ISR Number: 3725182-6Report Type:Expedited (15-DaCompany Report #WAES 01043460
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Bile Duct Stone Cholelithiasis Decreased Appetite Dermatitis Hepatitis Liver Function Test Abnormal Pyrexia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/01ISR Number: 3725183-8Report Type:Expedited (15-DaCompany Report #WAES 01058537
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Ventricular Tachycardia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Herbs	C				

Date:05/16/01ISR Number: 3725184-XReport Type:Expedited (15-DaCompany Report #WAES 01058532
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia Hypoaesthesia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:05/16/01ISR Number: 3725186-3Report Type:Expedited (15-DaCompany Report #WAES 01025529
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated Immune System Disorder Keratitis Viral Visual Acuity Reduced	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY;PO	
			Tab Vioxx (Rofecoxib)	SS		ORAL	PO	
			Diclofenac	C				

Date:05/16/01ISR Number: 3725187-5Report Type:Expedited (15-DaCompany Report #WAES 01058101
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG MG/DAILY'PO	3 MON
			Lisinopril	SS				
			Tab Amlodipine Besylate	SS				
			Atenolol	C				

Date:05/17/01ISR Number: 3724412-4Report Type:Direct Company Report #
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Vioxx -25mg Merck Labs	PS	Merck Labs		ONE PER DAY	
	Erythema							
	Eyelid Oedema							
	Face Oedema							
	Fatigue							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/01ISR Number: 3724801-8Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx / 25 Mg / Merck	PS	Merck	ORAL	25MG QD ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Blood Urea Increased		Lasix	C				
	Dyspnoea		Ditropan Xlx	C				
	Hyperkalaemia		Lotensin	C				
			Diltiazem Cd	C				
			Micronase	C				
			Coumadin	C				

Date:05/18/01ISR Number: 3724549-XReport Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia		Rofecoxib	PS		ORAL	25 MG PO QD	
	Hepatitis							

Date:05/18/01ISR Number: 3725485-5Report Type:Expedited (15-DaCompany Report #WAES 01050012
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
	Headache							
	Myocardial Infarction							
	Nausea							
	Upper Respiratory Tract Infection		Prevacid	C				
			Zocor	C				

Date:05/18/01ISR Number: 3725774-4Report Type:Expedited (15-DaCompany Report #WAES 01058556
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 20 DAY

Date:05/18/01ISR Number: 3725816-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis		Vioxx (25mg Q D)	PS			25 MG QD	
	Dyspnoea		Keftab 500 Mg Q D	SS			500 MG Q D X	
	Lung Infiltration						10 DAYS	
	Renal Failure Acute		Amitriptyline	C				
			K Dur	C				
			Verapamil	C				
			Indapamide	C				
			Fosamax	C				
			Mvi	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/01ISR Number: 3725939-1Report Type:Expedited (15-DaCompany Report #WAES 01045244
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Loss Of Consciousness	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:05/18/01ISR Number: 3726612-6Report Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Accident Anaphylactic Reaction Back Pain	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO;	
	Blood Potassium Increased						25	
	Blood Urea Increased						MG/DAILY/PO	
	Cardiac Arrest Coma Dyspnoea Laboratory Test Abnormal Myocardial Fibrosis Neuralgia Pulmonary Congestion Renal Disorder Spleen Disorder		Pravachol	C				

Date:05/21/01ISR Number: 3725713-6Report Type:Expedited (15-DaCompany Report #258966
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis		Xenical	PS	Roche		1 DAY	
			Vioxx	SS			91 DAY	

Date:05/21/01ISR Number: 3726404-8Report Type:Expedited (15-DaCompany Report #WAES 01050285
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Blood Creatinine Increased							
	Blood Urea Increased							
	Cardiac Output Decreased		Aspirin 325 Mg	SS		ORAL	325 MG/DAILY/PO	
	Cardiomyopathy							
	Coronary Artery Disease		Isordil	C				
	Gastritis Erosive		Lanoxin	C				
	Hypovolaemia		Plavix	C				
	Melaena		Potassium Chloride	C				
	Renal Failure Acute		Vitamins (Unspecified)	C				

Date:05/21/01ISR Number: 3726410-3Report Type:Expedited (15-DaCompany Report #WAES 01041838
Age: Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Abscess
	Arthralgia
	Arthritis

		Back Pain					
		Bone Pain					
		Furuncle	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia	Consumer	Vioxx	PS	Merck Research	
		Insomnia				Laboratories Div	
		Joint Sprain				Merck Co Inc	ORAL
25							
		Joint Swelling					
MG/DAILY/PO							
		Muscle Spasms		Cortisone	C		
		Muscular Weakness					
		Oedema					
		Oedema Peripheral					
		Pain In Extremity					
		Paraesthesia					
		Peripheral Coldness					
		Tendonitis					
		Weight Increased					

Date:05/21/01ISR Number: 3726412-7Report Type:Expedited (15-DaCompany Report #WAES 01050279
Age:67 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Extradural Abscess	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Hypoxia	Professional			Laboratories Div	
		Medication Error	Other			Merck Co Inc	ORAL
25 MG/Q4H/PO							
		Pulmonary Oedema		Celexa	C		
				Hydrodiuril	C		
				Norvasc	C		
				Percocet	C		

Date:05/21/01ISR Number: 3726414-0Report Type:Expedited (15-DaCompany Report #WAES 01050291
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Duodenal Ulcer	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Haemorrhage	Professional			Laboratories Div	
		Faeces Discoloured	Other			Merck Co Inc	ORAL
12.5							

	Haematocrit Decreased			
MG/DAILY/PO				
	Haemoglobin Decreased		Imodium	C
			Paxil	C
			Phoslo	C
			Pletal	C
			Restoril	C
			Vicodin Tablets	C
			Ascorbic Acid	C
			Aspirin	C
			Vitamin E	C
			Zinc (Unspecified)	C

Date:05/21/01ISR Number: 3726416-4Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research	
	Hypertension	Health			Laboratories Div	
	Tachycardia	Professional			Merck Co Inc	ORAL
25 MG/AM/PO						
	Transient Ischaemic Attack		Xalatan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3726426-7Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck Research			
Other	Bradycardia	Professional			Laboratories Div			
	Dizziness				Merck Co Inc	ORAL	25	
	Feeling Jittery						MG/DAILY/PO	
	Gastrointestinal Disorder		Fosamax	C				
	Insomnia		Calcium Carbonate					
	Muscle Spasms		(+) Vitamin D	C				
	Nausea		Glucosamine	C				
	Nervous System Disorder		Vitamins					
	Palpitations		(Unspecified)	C				
	Peripheral Vascular							
	Disorder							
	Tremor							
	Visual Disturbance							
	Weight Decreased							

Date:05/21/01ISR Number: 3726429-2Report Type:Expedited (15-DaCompany Report #WAES 01050354
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
	Urinary Tract Infection	Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Aleve	C				
			Amaryl	C				
			Antivert	C				
			Bactrim	C				
			Coumadin	C				
			Cozaar	C				
			Humulin	C				
			Humulin N	C				
			Inderal	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				

			Lipitor	C		
			Micro K	C		
			[Therapy Unspecified]	C		
			Lorazepam	C		

Date:05/21/01ISR Number: 3726434-6Report Type:Expedited (15-DaCompany Report #WAES 01040372
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia Stevens-Johnson Syndrome		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3726578-9Report Type:Expedited (15-DaCompany Report #WAES 01051336
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Cardiac Valve Disease Chest Discomfort	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Circulatory Collapse		Tab Prednisone	SS		ORAL	PO	
	Gastritis Erosive Hyperhidrosis		Tab Presdnisone 10 Mg	SS		ORAL	10 MG/BID/PO	
	Myocardial Infarction Nausea Retching Syncope							

Date:05/21/01ISR Number: 3726579-0Report Type:Expedited (15-DaCompany Report #WAES 01050687
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolism Skin Discolouration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/21/01ISR Number: 3726580-7Report Type:Expedited (15-DaCompany Report #WAES 01051287
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Medication Error Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/21/01ISR Number: 3726581-9Report Type:Expedited (15-DaCompany Report #WAES 01051315
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:05/21/01ISR Number: 3726582-0Report Type:Expedited (15-DaCompany Report #WAES 01050820
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Discomfort Aortic Valve Replacement Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO (SEE IMAGE)	
	Haematochezia		Accupril	C				
	Intestinal Ulcer		Ecotrin	C				
	Myocardial Infarction		Estratest H.S.	C				
	Rectal Haemorrhage		Plavix	C				

			Pravachol	C		
			Synthroid	C		
			Metoprolol	C		

Date:05/21/01ISR Number: 3726583-2Report Type:Expedited (15-DaCompany Report #WAES 01050887
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:05/21/01ISR Number: 3726585-6Report Type:Expedited (15-DaCompany Report #WAES 01051120
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Nephritis Interstitial	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nonsteroidal Anti-Inflammatory	C				

Date:05/21/01ISR Number: 3727055-1Report Type:Expedited (15-DaCompany Report #WAES 01055117
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	

PO

	Cozaar	C	
	Digoxin	C	
	Furosemide	C	
	Spironolactone	C	
	Warfarin	C	

Date:05/21/01ISR Number: 3727056-3Report Type:Expedited (15-DaCompany Report #WAES 01059604
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Headache	Consumer			Laboratories Div			
Initial or Prolonged	Nausea				Merck Co Inc	ORAL	25 MG/DAILY	
Other	Oedema Peripheral							
PO							76	DAY
	Pulmonary Oedema		Estradiol	C				
	Right Ventricular Failure		Levothyroxine Na	C				

Date:05/21/01ISR Number: 3727059-9Report Type:Expedited (15-DaCompany Report #WAES 01055122
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia Tongue Ulceration	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	4 DAY

Date:05/21/01ISR Number: 3727076-9Report Type:Direct Company Report #
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Joint Swelling Pain Swelling Weight Increased		Vioxx 25mg Merck	PS	Merck		25MG 1 ADAY	

Date:05/21/01ISR Number: 3727155-6Report Type:Expedited (15-DaCompany Report #WAES 01059905
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis Erosive	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:05/21/01ISR Number: 3727157-XReport Type:Expedited (15-DaCompany Report #WAES 01051179
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

	Large Intestinal Ulcer	Professional			Merck Co Inc	ORAL
50 MG/DAILY						
	Large Intestine Perforation		[Therapy Unspecified	C		

Date:05/21/01ISR Number: 3727159-3Report Type:Expedited (15-DaCompany Report #WAES 01055098
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia	Foreign	Vioxx	PS	Merck Research	
	Confusional State	Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG/DAILY						
			Estrogens, Conjugated	C		
			Quinine	C		

Date:05/21/01ISR Number: 3727173-8Report Type:Expedited (15-DaCompany Report #WAES 01023793
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adenomatous Polyposis Coli	Foreign	Vioxx	PS	Merck Research	
		Other			Laboratories Div	
	Diverticulum				Merck Co Inc	ORAL
25/DAILY/PO 139 DAY						
	Haemoglobin Decreased		Aspirin	C		
	Rectal Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/01ISR Number: 3727177-5Report Type:Expedited (15-DaCompany Report #WAES 01045189
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research			
Other		Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5MG/DAILY/	
							PO	
			Acetaminophen (+)					
			Dihydrocodeine					
			Bitartr	C				
			Candesartan	C				
			Furosemide	C				
			Warfarin	C				

Date:05/21/01ISR Number: 3727178-7Report Type:Expedited (15-DaCompany Report #WAES 01039610
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Cardiac Failure	Health			Laboratories Div			
Initial or Prolonged	Congestive	Professional			Merck Co Inc	ORAL	25	
Disability	Dyspnoea						MG/DAILY/PO	9 MON
	Fatigue		Hyzaar	C				
	Hypertension							
	Malaise							
	Oedema Peripheral							

Date:05/22/01ISR Number: 3727490-1Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Haemorrhage		Vioxx (25 Mg)	PS		ORAL	25MG PO QD	
Initial or Prolonged			Coumadin (5mg)	SS		ORAL	5MG PO QD	

Date:05/22/01ISR Number: 3727598-0Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hyperkalaemia		Vasotec	PS		
5MG Q 12H						
Initial or Prolonged			Vioxx	SS		
25MG BID						

Date:05/22/01ISR Number: 3747636-9Report Type:Periodic Company Report #WAES 01021717
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research	
	Nausea				Laboratories Div	
					Merck Co Inc	ORAL
SEE IMAGE						
			Prilosec	C		
			Therapy Unspecified	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3727596-7Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial		Coumadin	PS			5MG DAILY	
Hospitalization -	Thromboplastin Time		Vioxx	SS			25MG ALT 50MG	
Initial or Prolonged	Prolonged						DAILY	2 DAY
	Gastrointestinal		Zoloft	C				
	Haemorrhage		Axid	C				
	International Normalised		Oxycodone	C				
	Ratio Increased		Atenolol	C				
	Prothrombin Time		Combivent	C				
	Prolonged		Amtriptyline	C				

Date:05/23/01ISR Number: 3727785-1Report Type:Expedited (15-DaCompany Report #WAES 01051104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
PO								
		Representative						

Date:05/23/01ISR Number: 3727786-3Report Type:Expedited (15-DaCompany Report #WAES 01051126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL		
PO								
		Representative						

Date:05/23/01ISR Number: 3727787-5Report Type:Expedited (15-DaCompany Report #WAES 01050284
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain	Other						
	Gastritis							
	Nausea							
	Vomiting		Darvocet-N	C				
			Lasix (Furosemide)	C				
			Premarin	C				
			Premarin Vaginal Cream	C				
			Tigan	C				
			Ultram	C				
			Zoloft	C				
			Nystatin	C				
			Potassium Chloride	C				
			Prednisone	C				
			Vitamins (Unspecified)	C				

Date:05/23/01ISR Number: 3727788-7Report Type:Expedited (15-DaCompany Report #WAES 01051655
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/23/01ISR Number: 3727789-9Report Type:Expedited (15-DaCompany Report #WAES 01030123
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Arthralgia Dermatitis Juvenile Arthritis Myalgia Pyrexia Rash Erythematous Rash Maculo-Papular Rash Pruritic Red Blood Cell Sedimentation Rate Increased Serum Ferritin Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/23/01ISR Number: 3727790-5Report Type:Expedited (15-DaCompany Report #WAES 01031799
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anaemia Blood Pressure Increased Colonic Polyp Diverticulum	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

	Drug Interaction		Coumadin 5 Mg	SS	ORAL
5 MG/QOD/PO					
	Faeces Discoloured		Coumadin 5 Mg	SS	ORAL
7.5 MG/QOD/PO					
	Gastritis		Coumadin 5 Mg	SS	
5 MG/DAILY					
	Gastrointestinal				
	Haemorrhage				
	Haematochezia				
	Hyperplasia				
	International Normalised				
	Ratio Increased				
	Oedema Peripheral				
	Rectal Haemorrhage				
	Rhonchi				

Date:05/23/01ISR Number: 3727792-9Report Type:Direct Company Report #
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Ecchymosis		Vioxx	PS		ORAL
25 MG PO QD						
INCREASE TO						
BID ON 4/16						
			Aspirin	C		
			Ascorbic Acid	C		
			Novalin	C		
			Miacalcin	C		

Combivent Inhaler	C
Lovenox	C
Flonase	C
Furosemide	C
Hydroxyzine	C
Lansoprazole	C
Mvi	C
Penicillin	C
Kcl	C
Zinc So4	C

Date:05/23/01ISR Number: 3727828-5Report Type:Expedited (15-DaCompany Report #WAES 01033074
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cataract	Health	Vioxx	PS	Merck Research			
Other		Professional			Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/	
							ORAL	
							PRN/PO	
			Dextropropoxyphene	C				

Date:05/23/01ISR Number: 3727830-3Report Type:Expedited (15-DaCompany Report #WAES 01031323
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphonia	Health	Vioxx	PS	Merck Research			
	Asthenia	Professional			Laboratories Div			
	Bronchospasm				Merck Co Inc	ORAL	25	
	Chest Discomfort						MG/DAILY/PO	
	Chest Pain		Excedrin					
	Dermatitis		Extra-Strength	C				
	Erythema		Tylenol Pm	C				
	Flushing							
	Pharyngolaryngeal Pain							

Syncope Vasovagal

Date:05/23/01ISR Number: 3727914-XReport Type:Expedited (15-DaCompany Report #WAES 01051662
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neutropenia	Health	Vioxx	PS	Merck Research			
Hospitalization -		Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	PO	
		Representative	Zithromax	C				

Date:05/23/01ISR Number: 3727916-3Report Type:Expedited (15-DaCompany Report #WAES 01051556
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Delirium	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Delusion	Professional			Laboratories Div			
	Disorientation				Merck Co Inc	ORAL	25	MG/DAILY/PO 2 MON
			Ditropan	C				
			Pravachol	C				

Zocor	C
Aspirin	C
Calcium (Unspecified)	C
Candesartan Cilexetil	C
Nonsteroidal Anti-Inflammatory	C

Date:05/23/01ISR Number: 3727920-5Report Type:Expedited (15-DaCompany Report #WAES 01051542
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/23/01ISR Number: 3727922-9Report Type:Expedited (15-DaCompany Report #WAES 01051534
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombotic Thrombocytopenic Purpura	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zyprexa	C				
			Desipramine Hydrochloride	C				

Date:05/23/01ISR Number: 3727925-4Report Type:Expedited (15-DaCompany Report #WAES 01051131
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia Constipation		Vioxx	PS	Merck Research Laboratories Div			

Eye Irritation Merck Co Inc ORAL
DAILY/ PO
Eye Pain
Pruritus
Suicidal Ideation

Date:05/23/01ISR Number: 3727927-8Report Type:Expedited (15-DaCompany Report #WAES 01051414
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Paxil	C				

Date:05/23/01ISR Number: 3727929-1Report Type:Expedited (15-DaCompany Report #WAES 01050394
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Chest Pain
Other	Dizziness
	Flushing

Headache
Hypertension

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Representative	Celebrex	C				
	Cozaar	C				
	Flonase	C				
	Microzide	C				
	Premarin	C				
	Oxybutynin Chloride	C				
	Vitamins (Unspecified)	C				

Date:05/23/01ISR Number: 3727932-1Report Type:Expedited (15-DaCompany Report #WAES 01050286
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Levaquin	SS		ORAL	500 MG/DAILY/PO	
			Ambien	C				
			Paxil	C				
			Pepcid	C				
			Prinivil	C				
			Digoxin	C				
			Diltiazem	C				
			Iron	C				

Date:05/23/01ISR Number: 3727935-7Report Type:Expedited (15-DaCompany Report #WAES 01050846
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/PRN/PO

Date:05/23/01ISR Number: 3727937-0Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Ascites	Health	Vioxx	PS	Merck Research	
Hospitalization -	Autoimmune Disorder	Professional			Laboratories Div	
Initial or Prolonged	Biliary Cirrhosis Primary	Company			Merck Co Inc	ORAL
25						
Other	Blood Creatinine	Representative				
MG/DAILY/PO						
	Increased		Bactrim	C		
	Cholangitis		Calderol	C		
	Chronic Hepatitis		Diflucan	C		
	Condition Aggravated		Norvasc	C		
	Hepatotoxicity		Os-Cal	C		
	Jaundice Cholestatic		Procardia Xl	C		
	Liver Abscess		Zoloft	C		
	Prothrombin Time		Cyclosporine	C		
	Prolonged		Ibuprofen	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3727961-8Report Type:Expedited (15-DaCompany Report #WAES 01042313
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenoma Benign	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
Other	Atelectasis							
	Clostridium Colitis							
	Colonic Polyp	Representative						
	Dialysis		Lotensin	SS		ORAL	20 MG/DAILY/PO	
	Diverticulitis							
	Diverticulum Intestinal		Norvasc	C				
	Drug Eruption		Atenolol	C				
	Haemorrhoids		Cefoxitin	C				
	Ileus Paralytic		Morphine	C				
	Renal Failure Acute							

Date:05/23/01ISR Number: 3727967-9Report Type:Expedited (15-DaCompany Report #WAES 01050310
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Tamponade	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest							
	Cardiomyopathy							
	Circulatory Collapse	Representative	Correctol Laxative Tablets & Caplet	SS				
	Conduction Disorder		Vicodin Tablets	SS				
	Dehydration		Codeine	SS				
	Dermatitis							
	Disseminated Intravascular Coagulation							
	Drug Effect Decreased							
	Eosinophilia							
	Hepatic Necrosis							
	Hepatitis							
	Hepatosplenomegaly							
	Leukocytosis							
	Myocardial Infarction							
	Myocarditis							
	Pericardial Effusion							

Date:05/23/01ISR Number: 3727968-0Report Type:Expedited (15-DaCompany Report #WAES 00052239
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Study	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Arthralgia	Health Professional						
	Colonic Polyp							
	Diabetes Mellitus							
	Faecal Occult Blood		Acetaminophen	SS			325 MG/PRN	
	Positive		Glucotrol Xl	C				
	Restless Legs Syndrome		Hydrodiuril	C				
			Synthroid	C				
			Ferrous Gluconate	C				
			Hydroxychlorquine	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3727969-2Report Type:Expedited (15-DaCompany Report #WAES 01050054
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Vioxx	PS	Merck Research			
Hospitalization -	Renal Failure Chronic	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
		Representative					MG/DAILY/PO	
			Aricept	C				
			Bentyl	C				
			Lopressor	C				
			Pepcid	C				
			Digoxin	C				

Date:05/23/01ISR Number: 3727970-9Report Type:Expedited (15-DaCompany Report #WAES 01021775
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Cardiac Disorder	Health			Laboratories Div			
Disability	Chest Pain	Professional			Merck Co Inc	ORAL	25	
	Dizziness	Company					MG/DAILY/PO	
	Hypoaesthesia	Representative	Celebrex	C				
	Nausea		Plavix	C				
	Sedation		Atenolol	C				
			Furosemide	C				

Date:05/23/01ISR Number: 3728022-4Report Type:Expedited (15-DaCompany Report #WAES 01053711
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG DAILY	
			Aspirin	C				

Date:05/23/01ISR Number: 3728026-1Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Oedema		Vioxx 25 Mg Msd	PS	Msd	ORAL	1 DAILY ORAL	
Intervention to Prevent Permanent Impairment/Damage	Ventricular Extrasystoles		Wellbutrin	C				
			Celexa	C				
			Trazadone	C				
			Multivit	C				
			Tetracycline	C				
			Allegra-D	C				
			Tylenol Es.	C				

Date:05/23/01ISR Number: 3728039-XReport Type:Expedited (15-DaCompany Report #WAES 01059113
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Asthenia
	Dizziness
	Fatigue
	Hyperhidrosis

		Melaena Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY	12 DAY						

Date:05/23/01ISR Number: 3728041-8Report Type:Expedited (15-DaCompany Report #WAES 00119134
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Other		Anorexia Asthenia Fibrosis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/BID							
		Haemodialysis Hyperkalaemia Malaise Metabolic Acidosis Nephritis Interstitial Normochromic Normocytic Anaemia Oedema Vomiting		Enalapril	C		

Date:05/23/01ISR Number: 3728044-3Report Type:Expedited (15-DaCompany Report #WAES 01045520
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Hepatic Necrosis Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY	70 DAY						
				Calcium Carbonate			
				(+) Cholecalciferol	C		
				Isosorbide Mononitrate	C		
				Propranolol Hcl	C		
				Xipamide	C		

Date:05/23/01ISR Number: 3728052-2Report Type:Expedited (15-DaCompany Report #WAES 01053460
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:05/23/01ISR Number: 3728054-6Report Type:Expedited (15-DaCompany Report #WAES 01053459
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Dermatitis Dermatitis Exfoliative Joint Swelling Pyrexia Staphylococcal Infection Ulcer	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		33	DAY

Date:05/23/01ISR Number: 3728097-2Report Type:Expedited (15-DaCompany Report #WAES 01035139
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Haemorrhoids Rectal Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

Date:05/23/01ISR Number: 3728122-9Report Type:Expedited (15-DaCompany Report #258966
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bile Duct Obstruction Cholelithiasis Hepatitis	Foreign Health Professional	Xenical Vioxx (Rofecoxib) 25 Mg	PS SS	Hlr Technology	ORAL ORAL	120 MG 3 PER DAY ORAL 25 MG 1 PER DAY ORAL	

Date:05/23/01ISR Number: 3728126-6Report Type:Expedited (15-DaCompany Report #WAES 01057037
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Compartment Syndrome Face Oedema Fatigue Hypothyroidism	Foreign Health Professional Other	Vioxx Carisoprodol	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 13 DAY

Date:05/23/01ISR Number: 3728129-1Report Type:Expedited (15-DaCompany Report #WAES 01053461
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:05/23/01ISR Number: 3728209-0Report Type:Expedited (15-DaCompany Report #WAES 01059758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	2 WK

Date:05/23/01ISR Number: 3728210-7Report Type:Expedited (15-DaCompany Report #WAES 01051612
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Erosive	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional			Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	17 DAY
Other	Haemoglobin Decreased Iron Binding Capacity Total Decreased		Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3728215-6Report Type:Expedited (15-DaCompany Report #WAES 01059109
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Duodenitis Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Gastrointestinal Haemorrhage	Other	Gemfibrozil	C				

Date:05/23/01ISR Number: 3728216-8Report Type:Expedited (15-DaCompany Report #WAES 01045168
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	29 DAY
		Other	Vasotec	C				
			Aspirin	C				
			Bendroflumethiazide	C				
			Pravastatin Na	C				

Date:05/23/01ISR Number: 3728223-5Report Type:Expedited (15-DaCompany Report #WAES 01047571
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Dyspnoea Exacerbated	Other	Cozaar	C				
			Calcium Carbonate	C				
			Carvedilol	C				
			Etidronate Disodium	C				
			Lorazepam	C				
			Trazodone	C				

Date:05/23/01ISR Number: 3728224-7Report Type:Expedited (15-DaCompany Report #WAES 01043556
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Hepatitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	5 DAY

Date:05/23/01ISR Number: 3728414-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx 25 Mg	PS		ORAL	25MG TWICE DAILY ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/01ISR Number: 3728417-9Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx / 25mg / Merck	PS		ORAL	1 TABLE DAILY	
Intervention to Prevent Permanent Impairment/Damage			Allegra	C				
			Accolate	C				

Date:05/23/01ISR Number: 3728812-8Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx 25 Mg	PS			QOD	
			Zoloft 50mg	SS			QD	

Date:05/24/01ISR Number: 3728469-6Report Type:Expedited (15-DaCompany Report #WAES 01052149
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Other	Congestive	Professional			Laboratories Div			
	Fluid Retention	Company			Merck Co Inc	ORAL	12.5	
		Representative					MG/DAILY/PO	
			Avapro	C				
			Catapres	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Ibuprofen	C				
			Spironolactone	C				
			Verapamil	C				

Date:05/24/01ISR Number: 3728500-8Report Type:Expedited (15-DaCompany Report #WAES 01050482
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Eye Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY PO	12 DAY
			Axid	C				
			Lasix (Furosemide)	C				
			Lopressor	C				
			Pred Forte	C				
			Timoptic	C				
			Oxycodone	C				
			Prednisone	C				

Date:05/24/01ISR Number: 3728501-XReport Type:Expedited (15-DaCompany Report #WAES 01021197
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Disability	Blood Cholesterol Increased Gastrointestinal Haemorrhage Haematuria Headache Hypergammaglobulinaemia

	Benign Monoclonal						
	Hypertension						
	Joint Swelling						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research		
	Proteinuria	Health			Laboratories Div		
	Vision Blurred	Professional			Merck Co Inc	ORAL	50MG/DAILY/PO
			Claritin	C			

Date:05/24/01ISR Number: 3728532-XReport Type:Expedited (15-DaCompany Report #WAES 01049774
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Decreased Appetite	Health			Laboratories Div		
	Dehydration	Professional			Merck Co Inc	ORAL	PO
	Glomerulonephritis		Celecoxib	C			
	Oedema Peripheral		Omeprazole	C			
	Renal Failure		Paroxetine Hcl	C			
	Renal Impairment						

Date:05/24/01ISR Number: 3728564-1Report Type:Expedited (15-DaCompany Report #WAES 01026075
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiomegaly	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Chest Pain	Other			Laboratories Div		
	Dyspnoea Exertional				Merck Co Inc	ORAL	SEE IMAGE 138 DAY
	Ventricular Hypertrophy		Fenofibrate	C			

Date:05/24/01ISR Number: 3728565-3Report Type:Expedited (15-DaCompany Report #WAES 01025531
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Drug Interaction	Foreign	Vioxx	PS	Merck Research		

Initial or Prolonged	Small Intestinal Haemorrhage	Other			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO	Upper Gastrointestinal Haemorrhage		Phenprocoumon	SS		ORAL
PO						
			Cozaar	C		
			Acetylcysteine	C		
			Budesonide	C		
			Fenoterol Hydrobromide + Ipratropium B	C		
			Prednisolone	C		
			Theophylline	C		

Date:05/24/01ISR Number: 3728573-2Report Type:Expedited (15-DaCompany Report #WAES 01055146
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Duodenal Ulcer	Company			Laboratories Div	
Initial or Prolonged	Haemorrhage	Representative			Merck Co Inc	ORAL
PO						
	Pancreatic Disorder		Acetaminophen	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/01ISR Number: 3728574-4Report Type:Expedited (15-DaCompany Report #WAES 01055145
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis Upper Gastrointestinal Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 168 DAY
			Beclomethasone Dipropionate	C				
			Bendroflumethiazide	C				

Date:05/24/01ISR Number: 3728575-6Report Type:Expedited (15-DaCompany Report #WAES 01058591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Delirium Electrolyte Imbalance Inappropriate Antidiuretic Hormone Secretion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/24/01ISR Number: 3728576-8Report Type:Expedited (15-DaCompany Report #WAES 01055120
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Atenolol	C				
			Bendroflumethiazide	C				
			Diazepam	C				
			Hydroxocobalamin	C				

Date:05/24/01ISR Number: 3728577-XReport Type:Expedited (15-DaCompany Report #WAES 01056508
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
			Diclofenac Na	C				

Date:05/24/01ISR Number: 3728789-5Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage THEREAFTER	Aphasia		Vioxx	PS			50 MG Q DAY X 5 DAYS	5 DAY
	Bronchospasm							
	Dyspnoea		Vioxx	SS			25 MG Q DAY	
	Eating Disorder							
	Face Oedema		Premarin 0.625	C				
	Mouth Ulceration		Allegra	C				
	Oral Mucosal Blistering							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/01ISR Number: 3728792-5Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenitis Gastrointestinal Haemorrhage Haematocrit Decreased		Rofecoxib	PS				

Date:05/28/01ISR Number: 3728923-7Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck	ORAL	25MG ONCE A DAY ORAL	
	Decreased Activity							
	Dyspnoea		Paxil	C				
	Oedema Peripheral		Mestinon	C				
	Pulmonary Embolism		Zantec	C				

Date:05/29/01ISR Number: 3728919-5Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx Merck	PS	Merck		ONCE DAILY BY MOUTH	
			Vasotec	C				
			Verelan	C				

Date:05/29/01ISR Number: 3729841-0Report Type:Expedited (15-DaCompany Report #WAES 01043587
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged Pulmonary Oedema Health Professional Laboratories Div Merck Co Inc ORAL
12.5 MG/DAILY

PO 11 DAY

Date:05/29/01ISR Number: 3729844-6Report Type:Expedited (15-DaCompany Report #WAES 01058101
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Hypertensive Crisis	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 3 MON
			Amlodipine Besylate	C				
			Atenolol	C				
			Lisinopril	C				

Date:05/29/01ISR Number: 3729848-3Report Type:Expedited (15-DaCompany Report #WAES 01059113
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Asthenia
	Blood Urea Increased
	Dizziness

		Fatigue					
		Gastrointestinal Disorder					
		Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Melaena	Foreign	Vioxx	PS	Merck Research	
		Vomiting	Health			Laboratories Div	
		White Blood Cell Count	Professional			Merck Co Inc	ORAL
25 MG/DAILY							
		Increased					
PO	12 DAY						

Date:05/29/01ISR Number: 3729851-3Report Type:Expedited (15-DaCompany Report #WAES 01051870
Age:55 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cough	Foreign	Vioxx	PS	Merck Research	
Hospitalization -		Dyspnoea	Health			Laboratories Div	
Initial or Prolonged		Pco2 Increased	Professional			Merck Co Inc	ORAL
25 MG/DAILY							
Other		Po2 Decreased					
PO	4 DAY						
		Pruritus					
		Pyrexia					
		Tachypnoea					
		Urticaria					

Date:05/29/01ISR Number: 3730010-9Report Type:Expedited (15-DaCompany Report #WAES 01051820
Age:76 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Asthenia	Consumer	Vioxx	PS	Merck Research	
		Blood Pressure Increased				Laboratories Div	
		Fatigue				Merck Co Inc	ORAL
25							
		Oedema Peripheral					
MG/DAILY/PO							
		Weight Increased		Lasix (Furosemide)	C		
				Premarin	C		
				Tylenol	C		
				Atenolol	C		

Date:05/29/01ISR Number: 3730012-2Report Type:Expedited (15-DaCompany Report #WAES 01051745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exacerbated Oedema Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/29/01ISR Number: 3730013-4Report Type:Expedited (15-DaCompany Report #WAES 01030774
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Hallucination	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Toprol Xl Tablets	C				
			Ultram	C				
			Vicodin Tablets	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/01ISR Number: 3730046-8Report Type:Expedited (15-DaCompany Report #WAES01051872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx Nonsteroidal Anti-Inflammatory	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:05/29/01ISR Number: 3730049-3Report Type:Expedited (15-DaCompany Report #WAES 01051852
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease Haematochezia	Health Professional Company Representative	Vioxx Celebrex Nonsteroidal Anti-Inflammatory Nonsteroidal Anti-Inflammatory	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK

Date:05/29/01ISR Number: 3730051-1Report Type:Expedited (15-DaCompany Report #WAES 01051287
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Condition Aggravated Hydronephrosis Medication Error Renal Failure	Health Professional Company Representative	Vioxx Anacin [Therapy Unspecified]	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:05/29/01ISR Number: 3730053-5Report Type:Expedited (15-DaCompany Report #WAES 01051754
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Electrocardiogram							
	Abnormal		Avandia Unk	SS			8 MG; 4 MG/DAILY/UNK	
	Irritable Bowel Syndrome							
	Oedema		Cenestin	C				
	Pulmonary Oedema		Lopid	C				
			Prilosec	C				
			Synthroid	C				
			Insulin	C				
			Accupril	C				
			Amaryl	C				

Date:05/29/01ISR Number: 3730054-7Report Type:Expedited (15-DaCompany Report #WAES 01042561
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source
	Abdominal Pain	Consumer
	Gastrointestinal Disorder	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Allegra	C				
Elavil	C				
Tegretol	C				
Zantac	C				
Insulin	C				

Date:05/29/01ISR Number: 3730079-1Report Type:Expedited (15-DaCompany Report #WAES 01051905
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemodialysis Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:05/29/01ISR Number: 3730141-3Report Type:Expedited (15-DaCompany Report #WAES 01055167
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Gastric Ulcer Perforation Peptic Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY; 25 MG	4 DAY
			Atenolol	C				
			Diclofenac	C				

		Furosemide	C
		Ramipril	C

Date:05/29/01ISR Number: 3730142-5Report Type:Expedited (15-DaCompany Report #WAES 01055158
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haematemesis	Foreign	Vioxx	PS	Merck Research	
	Oesophagitis	Other			Laboratories Div	
	Upper Gastrointestinal				Merck Co Inc	ORAL
25 MG/DAILY 76 DAY						
	Haemorrhage					

Date:05/30/01ISR Number: 3729592-2Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coma		Vioxx	PS		ORAL
25MG PO QD						
Initial or Prolonged	Dehydration					
	Mental Impairment					
	Renal Failure Acute					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/01ISR Number: 3729668-XReport Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx 25 Mg Merck &					
Other	Upper Respiratory Tract		Company	PS	Merck & Company1		1 PILL ONCE A	
	Infection						DAY	
			Cephalexin	C				

Date:05/30/01ISR Number: 3730871-3Report Type:Direct Company Report #
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx (25mg)	PS			25MG DAILY	2 WK
Initial or Prolonged	Congestive							
	Condition Aggravated							
	Hypertension							

Date:05/30/01ISR Number: 3731189-5Report Type:Expedited (15-DaCompany Report #HQ1137921MAY2001
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agranulocytosis	Health	Methotrexate Sodium	PS	Lederle Laboratories			
Initial or Prolonged	Leukopenia	Professional			Div American			
	Thrombocytopenia				Cyanamid Co	ORAL	10 MG 1X PER	
							1 WEEK; ORAL	
			Decortin-H (Prednisolone,)	SS		ORAL	7.5 MG 1X PER	
							1 DAY; ORAL	
			Penicillin G (Benzylpenicillin)	SS			8 DAY	
			Vioxx (Rofecoxib,					

Tablet) SS ORAL
25 MG 1X PER

1 DAY; ORAL

Date:06/01/01ISR Number: 3731216-5Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Blood Alkaline Phosphatase Increased
	Blood Bilirubin Increased
	Blood Lactate Dehydrogenase Increased
	Cardiomegaly
	Culture Urine Positive
	Depressed Level Of Consciousness
	Electroencephalogram Abnormal
	Fatigue
	Gamma-Glutamyltransferase Increased
	Headache

		Infected Skin Ulcer Pharyngolaryngeal Pain Pleural Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Proteus Infection		Vasotec	PS	Merck & Co., Inc	ORAL
7	DAY						
		Renal Failure		Vioxx	SS		ORAL
				Gabapentin	SS		ORAL
				Metronidazole	SS		ORAL
9	DAY						
				Furosemide	SS		ORAL
7	DAY						
				Floxacillin Sodium	SS		ORAL
9	DAY						
				Leflunomide	SS		ORAL
				Spironolactone	SS		ORAL
				Folic Acid	C		
				Cisapride	C		
				[Therapy Unspecified]	C		
				Albuterol Sulfate And Ipratropium Bromide	C		
				Calcium Carbonate And Cholecalciferol	C		
				Loperamide	C		
				Zolpidem Tartrate	C		
				Acetaminophen	C		
				Vitamin E	C		
				Cetirizine Hydrochloride	C		
				Lansoprazole	C		
				Morphine	C		
				Prednisolone	C		
				Morphine	C		

Date:06/01/01ISR Number: 3731278-5Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Coronary Artery Occlusion		Vioxx	PS		
Hospitalization - Initial or Prolonged Required		Myocardial Infarction		Vicoprophen	SS		

Intervention to
Prevent Permanent
Impairment/Damage

Date:06/01/01ISR Number: 3731988-XReport Type:Direct Company Report #
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL	TOOK ONCE	
Hospitalization -							DAILY PO	
Initial or Prolonged								
Other								

Date:06/01/01ISR Number: 3731999-4Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx 25mg	PS		ORAL	25MG PO QD	6 DAY
Initial or Prolonged								

Date:06/01/01ISR Number: 3732144-1Report Type:Expedited (15-DaCompany Report #WAES 01052040
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ PO/50MG	
	Dizziness							
	Malaise							
	Pain							
			Aspirin	C				
			Hormones (Unspecified)	C				

Date:06/01/01ISR Number: 3732146-5Report Type:Expedited (15-DaCompany Report #WAES 01051918
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Faeces Discoloured	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haematemesis							
	Haematocrit Decreased							
	Haemoglobin Decreased		Cozaar	C				
	Platelet Count Decreased		Enturen	C				
	Red Blood Cell Count Decreased		Lipitor	C				
			Sectral	C				

Date:06/01/01ISR Number: 3732147-7Report Type:Expedited (15-DaCompany Report #WAES 01051904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/01/01ISR Number: 3732150-7Report Type:Expedited (15-DaCompany Report #WAES 01051747
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Blood Potassium Increased							
	Blood Urea Increased							
	Crepitations							
	Dizziness							
	Joint Effusion							

Date:06/01/01ISR Number: 3732211-2Report Type:Expedited (15-DaCompany Report #PHEH2001US03195
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Study	Exelon	PS	Novartis Pharmaceuticals Corp	ORAL	4.5 MG, BID, ORAL	
Hospitalization -	Gastrointestinal							
Initial or Prolonged	Haemorrhage							
	Large Intestinal Ulcer		Vioxx(Rofecoxib)	SS			25 MG, QD,	135 DAY
	Lethargy		Aleve(Naproxen Sodium)	SS			135 DAY	
			Monopril (Fosinopril Sodium)	C				
			Ditropan					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Oxybutynin) C

Date:06/01/01ISR Number: 3732264-1Report Type:Expedited (15-DaCompany Report #WAES 01051404
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Oesophagitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

(SEE IMAGE)

Date:06/01/01ISR Number: 3732267-7Report Type:Expedited (15-DaCompany Report #WAES 01051741
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/01/01ISR Number: 3732269-0Report Type:Expedited (15-DaCompany Report #WAES 01051780
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/01/01ISR Number: 3732391-9Report Type:Expedited (15-DaCompany Report #WAES 01058118
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/01/01ISR Number: 3732392-0Report Type:Expedited (15-DaCompany Report #WAES 01026151
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	International Normalised Ratio Decreased	Health Professional			Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	3 MON
	International Normalised		Fluindione	SS		ORAL	5 MG/DAILY	
	Ratio Increased		Proscar	C				
	Pulmonary Haemorrhage		Fluvastatin	C				
	Pulmonary Oedema		Nicorandil	C				
			Trimetazidine Hydrochloride	C				

Date:06/01/01ISR Number: 3732393-2Report Type:Expedited (15-DaCompany Report #WAES 01055162
Age:89 YR Gender:Male I/FU:I

Outcome	PT
Other	Haematemesis
	Refusal Of Treatment By

	Patient Upper Gastrointestinal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Aspirin	C				
			Mirtazapine	C				
			Thyroxine	C				
			Zopiclone	C				

Date:06/01/01ISR Number: 3732394-4Report Type:Expedited (15-DaCompany Report #WAES 01059806
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	15 DAY
			Enalapril Maleate	C				
			Ginkgo Biloba Extract	C				
			Isosorbide Dinitrate	C				
			Nicergoline	C				
			Vitamin A/Vitamin E	C				

Date:06/01/01ISR Number: 3732407-XReport Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Malaise		Vioxx	PS				

Date:06/01/01ISR Number: 3732408-1Report Type:Expedited (15-DaCompany Report #WAES 01057513
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris Pulmonary Oedema Renal Artery Stenosis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/01/01ISR Number: 3732409-3Report Type:Expedited (15-DaCompany Report #WAES 01056041
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Malaise	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	2 WK

Date:06/01/01ISR Number: 3732410-XReport Type:Expedited (15-DaCompany Report #WAES 01055553
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Agranulocytosis Leukopenia Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
		Other	Tab Methotrexate	SS		ORAL	10 MG/WKY	

				Orso Penicillin (Unspecified)	SS		ORAL
30000 IU	8	DAY					
				Tab Prednisolone	SS		ORAL
7.5 MG							

Date:06/01/01ISR Number: 3745966-8Report Type:Periodic Company Report #99120199
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulation Time	Consumer	Enbrel 25 Mg	PS		SUBCUTANEOUS	25 MG, BIW,	
	Shortened							
SUBCUTANEOUS								
	Dyspnoea		Rofecoxib	SS		ORAL		
PER ORAL								
	Oedema		Warfarin	C				

Date:06/02/01ISR Number: 3773607-2Report Type:Periodic Company Report #WAES 01042316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
25 MG/ DAILY/								
PO								
			Depakote	C				
			Topamax	C				
			Insulin	C				

Date:06/04/01ISR Number: 3732640-7Report Type:Direct Company Report #
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Increased		Vioxx 25mg	PS		ORAL		
25MG ONCE								

	Palpitations						
DAILY ORAL							
			Diclofenac	C			
			Vivelle Patch	C			
			Provera	C			
			Quinine Sulfate	C			
			Carisoprodol	C			
			Allegra	C			

Date:06/04/01ISR Number: 3733054-6Report Type:Expedited (15-DaCompany Report #WAES 01041946
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Vioxx	PS	Merck Research			
Hospitalization -	Diarrhoea	Professional			Laboratories Div			
Initial or Prolonged	Drug Interaction				Merck Co Inc	ORAL	PO	
Other	Pancreatitis Acute		Prevacid	SS				
	Vomiting		Prilosec	SS				
			Prozac	C				

Date:06/04/01ISR Number: 3733055-8Report Type:Expedited (15-DaCompany Report #WAES 01022126
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Other	Hepatic Function Abnormal	Health
	Liver Function Test	Professional
	Abnormal	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/04/01ISR Number: 3733056-XReport Type:Expedited (15-DaCompany Report #WAES 01041846
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema Oedema Peripheral Oral Pain Skin Exfoliation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK

Date:06/04/01ISR Number: 3733058-3Report Type:Expedited (15-DaCompany Report #WAES 01050044
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Cardiac Failure Congestive Condition Aggravated Dyspnoea Weight Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
		Representative	Actos	C				
			Aldactone	C				
			Cozaar	C				
			Glucophage	C				
			Humulin N	C				
			Humulin R	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Lopressor	C				
			Pravachol	C				
			Prilosec	C				

Aspirin	C		
Vitamins (Unspecified)	C		

Date:06/04/01ISR Number: 3733060-1Report Type:Expedited (15-DaCompany Report #WAES 01040370
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/04/01ISR Number: 3733061-3Report Type:Expedited (15-DaCompany Report #WAES 01040960
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amaurosis Fugax Blindness Cerebrovascular Accident	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3733063-7Report Type:Expedited (15-DaCompany Report #WAES 01041946
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Health	Vioxx	PS	Merck Research			
Hospitalization -	Drug Interaction	Professional			Laboratories Div			
Initial or Prolonged	Pancreatitis Acute				Merck Co Inc	ORAL	PO	
Other	Sensation Of Pressure		Prevacid	SS				
	Vomiting		Prilosec	SS				
			Prozac	C				

Date:06/04/01ISR Number: 3733066-2Report Type:Expedited (15-DaCompany Report #WAES 01051532
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying	Consumer	Vioxx	PS	Merck Research			
	Dyskinesia	Health			Laboratories Div			
	Joint Stiffness	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
	Liver Function Test							
	Abnormal							
	Movement Disorder							
	Muscle Spasms							
	Tremor							

Date:06/04/01ISR Number: 3733070-4Report Type:Expedited (15-DaCompany Report #WAES 01051780
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
Other		Representative					MG/DAILY/PO	

Date:06/04/01ISR Number: 3733072-8Report Type:Expedited (15-DaCompany Report #WAES 01051104
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastritis Erosive Gastritis Haemorrhagic Melaena	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depo-Medrol	SS		INTRAMUSCULAR	IM	
			Celebrex	C				
			[Therapy Unspecified]	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/04/01ISR Number: 3733075-3Report Type:Expedited (15-DaCompany Report #WAES 01051748
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Exacerbated	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3733093-5Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Increased Cardiac Failure Congestive Cardiomegaly Depressed Level Of Consciousness Electroencephalogram Abnormal Fatigue Headache Hepatic Failure Infected Skin Ulcer Metabolic Disorder Pharyngolaryngeal Pain Proteus Infection Renal Failure Urinary Tract Infection	Foreign Company Representative	Vasotec	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	20 MG PO	7 DAY
			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG PO	
			Tab Metronidazole	SS		ORAL	800 MG PO	9 DAY
			Tab Furosemide	SS		ORAL	40 MG PO	7 DAY
			Cap Gabapentin	SS		ORAL	2400 MG PO	
			Tab Floxacillin Sodium	SS		ORAL	2200 MG PO	9 DAY
			Tab Spironolactone	SS		ORAL	50 MG PO	
			Tab Leflunomide	SS		ORAL	20 MG PO	
			(Therapy Unspecified)	C				
			Zolpidem Tartrate	C				
			Vitamin E	C				
			Prednisolone	C				
			Morphine	C				
			Loperamide	C				
			Acetaminophen	C				
			Cetirizine Hydrochloride	C				
			Cisapride	C				
			Lansoprazole	C				
			Folic Acid	C				
			Albuterol Sulfate (+) Ipratropium Bromide	C				
			Calcium Carbonate (+) Cholecalciferol	C				

Date:06/04/01ISR Number: 3733095-9Report Type:Expedited (15-DaCompany Report #WAES 01059132
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Gastrointestinal Haemorrhage	Other			Merck Co Inc	ORAL	25 MG/DAILY	116 DAY
	Oesophagitis		Tab Hydrocortisone	SS		ORAL		
			Calcifediol	C				
			Calcium Carbonate	C				
			Salcatonin	C				

Date:06/04/01ISR Number: 3733096-0Report Type:Expedited (15-DaCompany Report #WAES 01055550
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Nausea	Other						
	Pulmonary Oedema				Merck Co Inc	ORAL	25 MG/DAILY	3 DAY
	Shock							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3733097-2Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:06/04/01ISR Number: 3733099-6Report Type:Expedited (15-DaCompany Report #WAES 01055176
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypotension	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Other			Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Prednisolone	SS		ORAL	5 MG/DAILY	
			Acetaminophen	C				
			Bisoprolol	C				
			Digoxin	C				
			Dihydrocodeine	C				
			Etidronate Disodium	C				
			Ferrousso4	C				
			Furosemide	C				
			Omeprazole	C				
			Ramipril	C				
			Spironolactone	C				
			Warfarin	C				

Date:06/04/01ISR Number: 3733100-XReport Type:Expedited (15-DaCompany Report #WAES 01055008
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Perforation	Other			Laboratories Div			
	Pneumonia				Merck Co Inc	ORAL		
	Renal Failure		Prednisolone	C				
	Sepsis							

Date:06/04/01ISR Number: 3733112-6Report Type:Expedited (15-DaCompany Report #WAES 01053459
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Dermatitis Dermatitis Exfoliative Joint Swelling Pyrexia Staphylococcal Infection	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc			33 DAY

Date:06/04/01ISR Number: 3733116-3Report Type:Expedited (15-DaCompany Report #WAES 01059760
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Anaemia Duodenitis Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 3 DAY

Vasotec C

Date:06/04/01ISR Number: 3733119-9Report Type:Expedited (15-DaCompany Report #WAES 01035609
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Gastric Ulcer	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID PO	65 DAY

Date:06/04/01ISR Number: 3733122-9Report Type:Expedited (15-DaCompany Report #WAES 01057914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/04/01ISR Number: 3733124-2Report Type:Expedited (15-DaCompany Report #WAES 01058627
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
			Albuterol Sulfate (+) Ipratropium Bromid	C				
			Cetirizine Hydrochloride	C				
			Diltiazem					

Hydrochloride	C
Fluticasone Propionate	C
Fluticasone Propionate	C
Furosemide	C
Glyburide	C
Nefazodone Hcl	C
Nitroglycerin	C
Oxazepam	C
Oxygen	C
Pantoprazole Sodium	C
Raloxifene	C
Venlafaxine Hcl	C

Date:06/04/01ISR Number: 3733125-4Report Type:Expedited (15-DaCompany Report #WAES 01056530
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MG/DAILY 8 DAY

			Sulfamethizole	C		

Date:06/04/01ISR Number: 3733148-5Report Type:Expedited (15-DaCompany Report #WAES 01059005
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Oliguria	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	18 DAY
			Hyzaar	C				
			Amlodipine Besylate	C				

Date:06/04/01ISR Number: 3733151-5Report Type:Expedited (15-DaCompany Report #WAES 01059131
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY;PO	5 DAY

Date:06/04/01ISR Number: 3733159-XReport Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cardiomegaly Coronary Artery Disease Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	2 MON
	Pulmonary Congestion		Acetaminophen	C				
			Atenolol	C				
			Dipiproverine Dihcl	C				
			Lactulose	C				

Date:06/04/01ISR Number: 3733161-8Report Type:Expedited (15-DaCompany Report #WAES 01055190
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Peptic Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Hospitalization - Initial or Prolonged						
25 MG/DAILY;PO						
			Amlodipine Besylate	C		
			Aspirin	C		
			Digoxin	C		
			Lisinopril	C		

Date:06/04/01ISR Number: 3733277-6Report Type:Expedited (15-DaCompany Report #WAES 01059127
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Other	Anorexia
	Asthenia
	Blood Pressure Increased
	Dyspnoea
	Fatigue

	Oedema Peripheral Oliguria Orthopnoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO 12 DAY
			Vasotec	C			
			Therapy Unspecified	C			
			Acetaminophen (+) Codeine	C			

Date:06/04/01ISR Number: 3733334-4Report Type:Expedited (15-DaCompany Report #WAES 01051852
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Crohn'S Disease Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO
			Tab Vioxx 25 Mg	C		ORAL	25 MG/DAILY/PO
			Celebrex	C			
			Hydrodiuril	C			
			Zestril	C			
			Atenolol	C			

Date:06/04/01ISR Number: 3733335-6Report Type:Expedited (15-DaCompany Report #WAES 01052417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck Research Laboratories Div		

		Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/04/01ISR Number: 3733751-2Report Type:Expedited (15-DaCompany Report #WAES 01050687
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cyanosis	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Injury	Professional			Laboratories Div	
	Pain	Company			Merck Co Inc	ORAL
PO						
		Representative				

Date:06/04/01ISR Number: 3733753-6Report Type:Expedited (15-DaCompany Report #WAES 01051120
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Congestive	Professional			Laboratories Div	
	Condition Aggravated	Company			Merck Co Inc	ORAL
25						
	Nephritis Interstitial	Representative				
MG/DAILY/PO						
			Nonsteroidal Anti-Inflammatory	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3733756-1Report Type:Expedited (15-DaCompany Report #WAES 01056107
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Gingival Bleeding Thrombocytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Zocor	C			PO	
			Acetaminophen	C				
			Fosonopril Sodium	C				
			Ginkgo Biloba Extract	C				

Date:06/04/01ISR Number: 3733761-5Report Type:Expedited (15-DaCompany Report #WAES 01041284
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Chloride Decreased Blood Creatinine Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Disability	Blood Glucose Decreased							
Other	Blood Lactate Dehydrogenase Increased Blood Ph Decreased Empyema Lung Injury Multiple Myeloma Oesophageal Perforation Pneumococcal Infection Pneumonia Vomiting		Tab Fosamax	SS				
			Evista	C				
			Levothroid	C				
			Vanceril	C				
			Calcium	C				
			Vitamin D	C				

Date:06/04/01ISR Number: 3733763-9Report Type:Expedited (15-DaCompany Report #WAES 01011761
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/04/01ISR Number: 3733807-4Report Type:Expedited (15-DaCompany Report #WAES 01053520
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/04/01ISR Number: 3733870-0Report Type:Expedited (15-DaCompany Report #WAES 01015229
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Fluid Retention
Hospitalization - Initial or Prolonged	Heart Rate Decreased
	Left Ventricular Failure
Other	Oedema Peripheral

		Palpitations Pulmonary Oedema Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY							
				Atenolol	C		
				Doxazosin Mesylate	C		

Date:06/04/01ISR Number: 3733886-4Report Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Atherosclerosis Hypertension	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:06/04/01ISR Number: 3733887-6Report Type:Expedited (15-DaCompany Report #WAES 01051781
Age:50 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Cardiac Failure Congestive Chest Pain	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE							
		Dizziness Haematemesis					

Date:06/04/01ISR Number: 3733905-5Report Type:Expedited (15-DaCompany Report #WAES 01052158
Age:63 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization -		Angina Pectoris Blood Creatine	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

Initial or Prolonged	Phosphokinase Mb	Company	Merck Co Inc	ORAL
12.5				
Other	Increased	Representative		
MG/DAILY/PO				

Cardiac Failure	Glucophage	C
Congestive	Humulin	C
Fluid Retention	Imdur	C
Pulmonary Oedema	Lipitor	C
Weight Increased	Plavix	C
	Prandin	C
	Precose	C
	Synthroid	C
	Toprol Xl Tablets	C
	Zestril	C
	Zoloft	C
	Aspirin	C
	Cyanocobalamin	C
	Folic Acid	C

Date:06/04/01ISR Number: 3733907-9Report Type:Expedited (15-DaCompany Report #WAES 01051532
Age:30 YR Gender:Female I/FU:I

Outcome	PT
Other	Crying
	Joint Stiffness
	Liver Disorder

		Movement Disorder Muscle Spasms Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							

Date:06/04/01ISR Number: 3733908-0Report Type:Expedited (15-DaCompany Report #WAES 01051771
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
				Lasix	C		

Date:06/04/01ISR Number: 3733910-9Report Type:Expedited (15-DaCompany Report #WAES 01051748
Age: Gender:Unknown I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dyspnoea Exacerbated	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
MG/DAILY/PO							

Date:06/04/01ISR Number: 3733912-2Report Type:Expedited (15-DaCompany Report #WAES 01050431
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Coma Drug Interaction Ecchymosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID/PO							

	Haemoglobin Decreased		Tab Vioxx 25 Mg	SS		ORAL
25						
	International Normalised					
MG/DAILY/PO						
	Ratio Increased		Tab Noroxin	SS		
5 MG/DAILY						
			Coumadin 5 Mg	SS		ORAL
PO						

Date:06/04/01ISR Number: 3733914-6Report Type:Expedited (15-DaCompany Report #WAES 01050926
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured	Health	Tab Vioxx 25 Mg	PS	Merck Research	
Initial or Prolonged	Gastrointestinal	Professional			Laboratories Div	
Disability	Haemorrhage	Company			Merck Co Inc	ORAL
25						
Other	Haemoglobin Decreased	Representative				
MG/DAILY/PO						

Date:06/04/01ISR Number: 3733916-XReport Type:Expedited (15-DaCompany Report #WAES 01051852
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Crohn'S Disease	Health	Vioxx	PS	Merck Research	
Initial or Prolonged		Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative	Celebrex	C		
			Nonsteroidal			
			Anti-Inflammatory D	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/01ISR Number: 3733919-5Report Type:Expedited (15-DaCompany Report #WAES 01051414
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Vioxx	PS	Merck Research			
	Blood Albumin Increased	Professional			Laboratories Div			
	Cyst	Company			Merck Co Inc	ORAL	25	
	Depression	Representative					MG/DAILY/PO	
	Muscle Strain		Celestone	C				
	Pancreatitis Acute		Inderal	C				
	Pelvic Kidney		Kenalog	C				
	Performance Fear		Prevacid	C				
	Rotator Cuff Syndrome		Propecia	C				
	Viral Infection		Lidocaine	C				

Date:06/04/01ISR Number: 3733924-9Report Type:Expedited (15-DaCompany Report #WAES 01052922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Plaquenil	C				
			Pravachol	C				
			Premphase	C				
			Calcium (Unspecified)	C				
			Folic Acid	C				
			Methotrexate	C				
			Vitamins (Unspecified)	C				

Date:06/04/01ISR Number: 3733943-2Report Type:Expedited (15-DaCompany Report #WAES 01052205
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS	Merck Research			

		Professional			Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Dilantin	C		

Date:06/05/01ISR Number: 3733998-5Report Type:Expedited (15-DaCompany Report #WAES 01055177
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Faeces Discoloured	Foreign	Vioxx	PS	Merck Research	
	Gastrointestinal	Other			Laboratories Div	
	Haemorrhage				Merck Co Inc	ORAL
12.5 MG/DAILY PO 14 DAY						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Amiloride Hydrochloride (+)			
			Furosemide	C		
			Warfarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/01ISR Number: 3734002-5Report Type:Expedited (15-DaCompany Report #WAES 01059762
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/05/01ISR Number: 3734003-7Report Type:Expedited (15-DaCompany Report #WAES 01059135
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Other			Laboratories Div			
Initial or Prolonged	Fluid Overload				Merck Co Inc	ORAL	12.5 MG/DAILY	
	Oedema						PO	12 DAY
	Renal Impairment		Cyclosporine	SS		ORAL	175 MG/DAILY	
			Amlodipine Besylate	C			PO	
			Atorvastatin	C				
			Bisoprolol Fumarate	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Domperidone	C				
			Furosemide	C				
			Lisinopril	C				
			Nitroglycerin	C				
			Prednisone	C				
			Ranitidine	C				
			Sulfamethoxazole/Trimethoprim	C				

Date:06/05/01ISR Number: 3734006-2Report Type:Expedited (15-DaCompany Report #WAES 01059127
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Foreign	Vioxx	PS	Merck Research			
	Asthenia	Other			Laboratories Div			
	Blood Pressure Increased				Merck Co Inc	ORAL	25 MG/DAILY	
	Dyspnoea							
PO								12 DAY
	Fatigue		Vasotec	C				
	Oedema Peripheral		[Therapy					
	Oliguria		Unspecified]	C				
	Orthopnoea		Acetaminophen (+)					
			Codeine	C				

Date:06/05/01ISR Number: 3734009-8Report Type:Expedited (15-DaCompany Report #WAES 01058766
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Other			Laboratories Div			
	Gastrointestinal Ulcer				Merck Co Inc	ORAL	25 MG/DAILY	
PO								
			Aspirin	C				
			Bendroflumethiazide	C				
			Celecoxib	C				
			Diltiazem Hydrochloride	C				

	Isosorbide Mononitrate	C	
	Nitroglycerin	C	

Date:06/05/01ISR Number: 3734012-8Report Type:Expedited (15-DaCompany Report #WAES 01058223
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Other	Drug Interaction	Other						
	Fatigue				Merck Co Inc	ORAL	25 MG/DAILY	
	Oedema Peripheral							
	Sinus Bradycardia		Tab Tizanidine	SS		ORAL	4 MG/DAILY PO	5 DAY

Date:06/05/01ISR Number: 3734013-XReport Type:Expedited (15-DaCompany Report #WAES 01056536
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional			Merck Co Inc	ORAL	25 MG/DAILY	
			Methotrexate Sodium	SS				

Date:06/05/01ISR Number: 3734016-5Report Type:Expedited (15-DaCompany Report #WAES 01055208
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscular Weakness	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Other	Myalgia	Other						
					Merck Co Inc	ORAL	12.5 MG DAILY	
							PO	2 DAY

Date:06/05/01ISR Number: 3734018-9Report Type:Expedited (15-DaCompany Report #WAES 01056528
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			7 DAY

Date:06/05/01ISR Number: 3734021-9Report Type:Expedited (15-DaCompany Report #WAES 01055205
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 10 DAY
			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG/DAILY	PO
			Aspirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/01ISR Number: 3734022-0Report Type:Expedited (15-DaCompany Report #WAES 01059125
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Asthenia Drug Toxicity Face Oedema Fatigue Gastritis Erosive Urticaria	Foreign Health Professional	Vioxx Tab Vioxx (Rofecoxib)	PS SS	Merck Research Laboratories Div Merck Co Inc	ORAL ORAL	12.5 MG/DAILY 25 MG/DAILY	PO PO 1 MON

Date:06/05/01ISR Number: 3734026-8Report Type:Expedited (15-DaCompany Report #WAES 01056508
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx Diclofenac Na	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO

Date:06/05/01ISR Number: 3734029-3Report Type:Expedited (15-DaCompany Report #WAES 01058124
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Haemorrhage	Foreign Literature Health Professional	Vioxx Diclofenac Misoprostol Naproxen	PS C C C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:06/05/01ISR Number: 3734710-6Report Type:Expedited (15-DaCompany Report #WAES 01052397
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity Overdose	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Premarin	C				
			Colesevelam Hydrochloride	C				
			Vitamins (Unspecified)	C				

Date:06/05/01ISR Number: 3734712-XReport Type:Expedited (15-DaCompany Report #WAES 01052155
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased Dyspnoea Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Toprol Xl Tablets	C				
			Zestril	C				

			Thyroid	C		

Date:06/05/01ISR Number: 3734715-5Report Type:Expedited (15-DaCompany Report #WAES 01052149
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck Research			
Other	Congestive	Professional			Laboratories Div			
	Fluid Retention	Company			Merck Co Inc	ORAL	12.5	
	Ventricular Hypertrophy	Representative					MG/DAILY/PO	
			Avapro	C				
			Catapres	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Ibuprofen	C				
			Spironolactone	C				
			Verapamil	C				

Date:06/05/01ISR Number: 3734721-0Report Type:Expedited (15-DaCompany Report #WAES 01051872
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Ulcer	Health	Vioxx	PS	Merck Research			
	Perforation	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative	Nonsteroidal					
			Anti-Inflammatory	C				

Date:06/05/01ISR Number: 3734728-3Report Type:Expedited (15-DaCompany Report #WAES 01051747
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Vioxx	PS	Merck Research			
	Increased	Professional			Laboratories Div			

	Blood Potassium Increased				Merck Co Inc	ORAL
PO						
	Blood Urea Increased					
	Crepitations					
	Dizziness					
	Joint Contracture					

Date:06/05/01ISR Number: 3734729-5Report Type:Expedited (15-DaCompany Report #WAES 01050571
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
MG/BID/PO						
			Carafate	C		
			Celebrex	C		
			Elavil	C		
			Fosamax	C		
			Prilosec	C		
			Tylenol	C		
			Chondroitin (+) Glucosamine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/01ISR Number: 3734733-7Report Type:Expedited (15-DaCompany Report #WAES 01051534
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombotic Thrombocytopenic Purpura	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zyprexa	C				
			Desipramine Hydrochloride	C				

Date:06/05/01ISR Number: 3734735-0Report Type:Expedited (15-DaCompany Report #WAES 01040754
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Life-Threatening	Anorexia	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest	Representative						
	Disseminated		Lipitor 10 Mg	SS		ORAL	10 MG/HS/PO	
	Intravascular Coagulation		Aspirin	C				
	Dyspepsia							
	Fatigue							
	Hepatic Failure							
	Hepatitis							
	Platelet Count Decreased							
	White Blood Cell Count Increased							

Date:06/05/01ISR Number: 3734838-0Report Type:Expedited (15-DaCompany Report #WAES 01051741
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/06/01ISR Number: 3734828-8Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Vioxx	PS			25MG QD	

Date:06/07/01ISR Number: 3735628-5Report Type:Direct Company Report #
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Faecal Occult Blood		Vioxx 50 Mg	PS		ORAL	50 MG QD ORAL	
Intervention to Prevent Permanent Impairment/Damage	Positive Haemoglobin Decreased		Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/01ISR Number: 3735653-4Report Type:Direct Company Report #
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased		Rofecoxib 25 Mg Qd	PS			25 MG QD	3 WK
Initial or Prolonged	Blood Potassium Increased		Lisinopril 40 Mg Qd				40 MG QD	
	Gastrointestinal		(Gi & Renal Effects)	SS				
	Haemorrhage							

Date:06/07/01ISR Number: 3735655-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Asa 81 Mg Qd Po	PS		ORAL	81 MG QD PO	
Initial or Prolonged	Haemorrhage		Vioxx 50 Mg Po Qd	SS		ORAL	50 MG PO QD	
	Stress Ulcer		Nitric Oxide	C				
			Oxygen	C				
			Dobutamine	C				
			Milrinone	C				
			Digoxin	C				
			Lasix	C				
			Lansoprazole	C				
			Ranitidine	C				

Date:06/07/01ISR Number: 3735750-3Report Type:Expedited (15-DaCompany Report #200112306EU
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Alkaline	Foreign	Noritate	PS	Dermik Laboratories			
Initial or Prolonged	Phosphatase Increased	Other			Inc	ORAL	800 MG/DAY PO	9 DAY
	Blood Bilirubin Increased		Leflunomide (Arava)	SS		ORAL	20 MG/DAY PO	
	Cardiomegaly		Gabapentin					
	Chest Pain		(Neurontin)	SS			2.4 G/DAY	

		Depressed Level Of	Furosemide (Furix)	SS		ORAL
40 MG/DAY PO						
		Consciousness	Enalapril Maleate			
		Ear Pain	(Renitec)	SS		ORAL
20 MG/DAY PO	1	WK				
		Fatigue	Flucloxacillin			
		Gamma-Glutamyltransferase	Sodium (Heracillin)	SS		
2.2 G/DAY	9	DAY				
		Increased	Rofecoxib (Vioxx)	SS		ORAL
25 G/DAY PO						
		Headache	Folic Acid	C		
		Hypervolaemia	Calcium Phosphate			
		Hypocalcaemia	(Folacin)	C		
		Infected Skin Ulcer	Vitamin E	C		
		Liver Disorder	Paracetamol			
		Metabolic Disorder	(Alvedon)	C		
		Pharyngolaryngeal Pain	Prednisone	C		
		Pleural Effusion	Morfin	C		
		Proteus Infection	Cisapride			
		Renal Failure	(Prepulsid)	C		
		Weight Increased	Cetirizine (Zyrlex)	C		
			Morfin	C		
			Lansoprazole (Lanzo)	C		
			Zolpidem Tartrate			
			(Stilnoct)	C		
			Loperamide	C		
			Colecalciferol	C		
			Calcium Carbonate			
			(Calcichew D3)	C		
			Ipratropium Bromide	C		
			Salbutamol Sulfate			

		(Combivent)	C
		Spironolactone	C

Date:06/08/01ISR Number: 3736244-1Report Type:Expedited (15-DaCompany Report #WAES 01052822
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
Life-Threatening	Gastric Ulcer Perforation							
Hospitalization -								
25								
Initial or Prolonged								
MG/DAILY/PO								

Date:06/08/01ISR Number: 3736245-3Report Type:Expedited (15-DaCompany Report #WAES 01052701
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Initial or Prolonged	Haemorrhage							
PO								
			Prevacid	C				
			Toprol Xl Tablets	C				
			Tylenol	C				

Date:06/08/01ISR Number: 3736246-5Report Type:Expedited (15-DaCompany Report #WAES 01052494
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
	Diverticulitis	Health						
	Gastrointestinal	Professional						
25MG/DAILY/PO								
	Haemorrhage	Company Representative	Naprosyn	C				

Date:06/08/01ISR Number: 3736247-7Report Type:Expedited (15-DaCompany Report #WAES 01050280
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Bleeding Time Prolonged	Other			Merck Co Inc	ORAL	PO	
	Blood Creatinine Increased		Fosamax	C				
	Blood Urea Increased		Lasix (Furosemide)	C				
	Dizziness		Norvasc	C				
	Gastrointestinal Haemorrhage		Tylenol	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased		Atenolol	C				
	International Normalised Ratio Increased		Hydralazine	C				
	Platelet Count Decreased		Vitamins	C				

Date:06/08/01ISR Number: 3736276-3Report Type:Expedited (15-DaCompany Report #WAES 00062470
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Other	Appetite Disorder
	Asthenia

		Chills Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Decreased Nausea Nervous System Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Palpitations		Lanoxin	C		
		Peripheral Vascular Disorder		Aspirin	C		
		Tremor Vertigo					

Date:06/08/01ISR Number: 3736318-5Report Type:Expedited (15-DaCompany Report #WAES 01052155
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blood Pressure Increased Dyspnoea Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
			Toprol Xl Tablets	C		
			Zestril	C		
			Thyroid	C		

Date:06/08/01ISR Number: 3736339-2Report Type:Expedited (15-DaCompany Report #WAES 01052316
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Impaired Healing Upper Limb Fracture	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/08/01ISR Number: 3736346-XReport Type:Expedited (15-DaCompany Report #WAES 99121888
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Blister Influenza Like Illness Meniere'S Disease Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5
MG/DAILY/PO

Lipitor	C
Premarin	C
Synthroid	C
Zocor	C
(Composition Unspecified)	C
Calcium Supplement (Composition)	C
Vitamins	C

Date:06/08/01ISR Number: 3736358-6Report Type:Expedited (15-DaCompany Report #WAES 01050846
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Abdominal Pain Lipase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MG/ PRN/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3736364-1Report Type:Expedited (15-DaCompany Report #WAES 01051126
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/08/01ISR Number: 3736366-5Report Type:Expedited (15-DaCompany Report #WAES 01051820
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Blood Pressure Increased							
	Cardiac Failure							
	Fatigue							
	Oedema Peripheral		Lasix (Furosemide)	C				
	Weight Increased		Premarin	C				
			Tylenol	C				
			Atenolol	C				

Date:06/08/01ISR Number: 3736370-7Report Type:Expedited (15-DaCompany Report #WAES 01051542
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain	Health Professional						
	Hyperhidrosis							

Date:06/08/01ISR Number: 3736372-0Report Type:Expedited (15-DaCompany Report #WAES 01052453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						

Date:06/08/01ISR Number: 3736373-2Report Type:Expedited (15-DaCompany Report #WAES 01052647
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Other	Oedema					
	Weight Increased					
25 MG/ DAILY/						
PO						
			Avandia	C		
			Novolin	C		
			Vicodin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3736374-4Report Type:Expedited (15-DaCompany Report #WAES 01040358
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Haematocrit Decreased	Other			Merck Co Inc	ORAL	25 MG/ DAILY/	
	Haemoglobin Decreased						PO	
	Hypotension		Caltrate	C				
	Intestinal Ulcer		Fosamax	C				
	Tachycardia		Miacalcin	C				
			Pravachol	C				
			Diltiazem	C				
			Impipramine	C				

Date:06/08/01ISR Number: 3736379-3Report Type:Expedited (15-DaCompany Report #WAES 01052411
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased							
	Cerebral Infarction	Company			Merck Co Inc	ORAL	25	
	Cerebrovascular Accident	Representative					MG/DAILY/PO	
	Confusional State							
	Difficulty In Walking							
	Headache							

Date:06/08/01ISR Number: 3736383-5Report Type:Expedited (15-DaCompany Report #WAES 01060093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Congestive							
	Gastrointestinal	Company			Merck Co Inc	ORAL	PO	
	Haemorrhage	Representative	Coumadin	C				

Date:06/08/01ISR Number: 3736456-7Report Type:Expedited (15-DaCompany Report #WAES 01052780
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Activated Partial Thromboplastin Time Prolonged	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Bleeding Time Prolonged		Aspirin 325 Mg	SS		ORAL	325 MG/DAILY PO	
	Duodenal Ulcer							
	Faeces Discoloured Haematochezia Haemoglobin Decreased International Normalised Ratio Decreased Mean Cell Volume Abnormal Oesophagitis		Indocin (Indomethacin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3736457-9Report Type:Expedited (15-DaCompany Report #WAES 01052894
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Erosive Haemoglobin Decreased Small Intestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Prinivil	C				

Date:06/08/01ISR Number: 3736459-2Report Type:Expedited (15-DaCompany Report #WAES 01050049
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Fluctuation Colitis Ulcerative Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Asacol	C				
			Cortenema	C				
			Rowasa	C				
			Atenolol	C				

Date:06/08/01ISR Number: 3736556-1Report Type:Expedited (15-DaCompany Report #WAES 01031797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Gastrointestinal Disorder	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Excedrin Extra-Strength	SS				

Date:06/08/01ISR Number: 3736563-9Report Type:Expedited (15-DaCompany Report #WAES 01051745
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Condition Aggravated Dyspnoea Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/08/01ISR Number: 3736564-0Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
Other	Bradycardia
	Chills
	Decreased Activity
	Dizziness
	Fatigue
	Feeling Jittery
	Gastrointestinal Disorder
	Insomnia
	Muscle Spasms
	Nausea
	Palpitations

		Parkinson'S Disease Peripheral Vascular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tremor Visual Disturbance Weight Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Fosamax	C		
				Calcium Carbonate (+) Vitamin	C		
				Glucosamine	C		
				Vitamins (Unspecified)	C		

Date:06/08/01ISR Number: 3736565-2Report Type:Expedited (15-DaCompany Report #WAES 01032191
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Asthma Emotional Disorder Gastritis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO		Pain Weight Decreased					

Date:06/08/01ISR Number: 3736566-4Report Type:Expedited (15-DaCompany Report #WAES 01050048
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Convulsion Upper Limb Fracture	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO Disability Other							

Date:06/08/01ISR Number: 3736860-7Report Type:Expedited (15-DaCompany Report #WAES 01058537
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Arrest Ventricular Tachycardia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Cap Diltiazem	SS		ORAL	180 MG PO	
			Evening Primrose Oil	C				

Date:06/08/01ISR Number: 3736863-2Report Type:Expedited (15-DaCompany Report #WAES 01056530
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 8 DAY
			Sulfamethoxazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3736868-1Report Type:Expedited (15-DaCompany Report #WAES 01025006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK

Date:06/08/01ISR Number: 3736919-4Report Type:Expedited (15-DaCompany Report #WAES 01059923
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Erythema Pruritus Rash Generalised	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	
	Sleep Disorder Due To General Medical Condition, Insomnia Type		Acetaminophen (+) Orphenadrine Citrate	C				
			Chlorpheniramine Maleate	C				
			Cyanocobalamin (+) Pyridoxine (+) Thiami	C				
			Glucosamine Sulfate	C				

Date:06/08/01ISR Number: 3736921-2Report Type:Expedited (15-DaCompany Report #WAES 01058647
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	3 DAY
			Acetaminophen/Oxycodone Hydrochloride	C				

Date:06/08/01ISR Number: 3736924-8Report Type:Expedited (15-DaCompany Report #WAES 01053773
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Gastric Ulcer	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	ORAL
25 MG/DAILY 356 DAY						
			Amlodipine Besylate	C		
			Zolpidem Tartrate	C		

Date:06/08/01ISR Number: 3736925-XReport Type:Expedited (15-DaCompany Report #WAES 01055207
Age:53 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Migraine	Foreign	Vioxx	PS	Merck Research	
	Visual Field Defect	Other			Laboratories Div	
					Merck Co Inc	ORAL
12.5 MG/DAILY						
PO 4 DAY						
			Tramadol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3736927-3Report Type:Expedited (15-DaCompany Report #WAES 01055239
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	4 DAY
			Acetaminophen (+) Dihydrocodeine Bitartr	C				
			Ranitidine	C				

Date:06/08/01ISR Number: 3736928-5Report Type:Expedited (15-DaCompany Report #WAES 01053556
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celecoxib	C				

Date:06/08/01ISR Number: 3736941-8Report Type:Expedited (15-DaCompany Report #WAES 01053564
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/08/01ISR Number: 3736942-XReport Type:Expedited (15-DaCompany Report #WAES 01059708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			

		Other			Merck Co Inc	ORAL
25 MG/DAILY						
PO						

Date:06/08/01ISR Number: 3737583-0Report Type:Expedited (15-DaCompany Report #WAES 01052427
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Fall	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Neurontin	C		
			Lithium Carbonate	C		

Date:06/08/01ISR Number: 3737585-4Report Type:Expedited (15-DaCompany Report #WAES 01052786
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/01ISR Number: 3737598-2Report Type:Expedited (15-DaCompany Report #WAES 01052867
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				

Date:06/08/01ISR Number: 3737602-1Report Type:Expedited (15-DaCompany Report #WAES 01040275
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper B-Cell Lymphoma Lymphadenopathy	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Disability	Metastases To Lymph Nodes	Representative						
Other	Rash Erythematous		Feldene	C				
	Surgical Skin Tear		Flexeril	C				
	T-Cell Lymphoma		Os-Cal + D	C				
	Thermal Burn		Premarin	C				
	Vertigo Positional		Zantac	C				

Date:06/08/01ISR Number: 3738236-5Report Type:Expedited (15-DaCompany Report #WAES 01065004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/08/01ISR Number: 3738240-7Report Type:Expedited (15-DaCompany Report #WAES 01065015
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Respiratory Distress Syndrome Duodenal Ulcer Perforation Peritonitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Prinivil	C		
			Bendroflumethiazide	C		
			Citalopram	C		
			Levothyroxine Na	C		
			Oxazepam	C		
			Oxybutynincl	C		

Date:06/11/01ISR Number: 3736728-6Report Type:Direct Company Report #
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 50 MG ONCE	Retinal Haemorrhage		Vioxx	PS		ORAL
Initial or Prolonged DAILY ORAL	Retinitis Histoplasma					
Disability	Visual Disturbance					

Date:06/11/01ISR Number: 3737322-3Report Type:Expedited (15-DaCompany Report #WAES 01055207
Age:53 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Migraine Visual Field Defect	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 5 DAY
			Tramadol	C				

Date:06/11/01ISR Number: 3737324-7Report Type:Expedited (15-DaCompany Report #WAES 01025535
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Hctz/Triamterene	C				
			Amlodipine Besylate	C				
			Dipyrone	C				
			Metoprolol Succinate	C				
			Simethicone	C				

Date:06/11/01ISR Number: 3737445-9Report Type:Expedited (15-DaCompany Report #WAES 01058683
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia Cerebrovascular Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Clopidogrel Bisulfate	C				
			Diltiazem Hydrochloride	C				
			Glyburide	C				

			Metformin Hcl	C
			Omeprazole Magnesium	C

Date:06/11/01ISR Number: 3737758-0Report Type:Expedited (15-DaCompany Report #WAES 01045533
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Upper Agranulocytosis Cardiomegaly	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/ DAILY	
	Decreased Appetite							
	Dyspnoea		Clindamycin	SS			PO	98 DAY
	Emphysema		Flupirtine Maleate	C				
	Malaise		Spironolactone	C				
	Rash Generalised		Theophylline	C				
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/01ISR Number: 3737767-1Report Type:Expedited (15-DaCompany Report #WAES 01059125
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dyspnoea Exertional Face Oedema Gastritis Erosive Gastrointestinal Haemorrhage Hiatus Hernia Normochromic Normocytic Anaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO	25 MG/DAILY	

Date:06/11/01ISR Number: 3737870-6Report Type:Expedited (15-DaCompany Report #WAES 01058647
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity Nephritis Interstitial	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	3 DAY
			Acetaminophen/Oxycodone Hydrochloride	C				

Date:06/11/01ISR Number: 3737871-8Report Type:Expedited (15-DaCompany Report #WAES 01059708
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Endometrial Cancer	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	15 DAY

Date:06/11/01ISR Number: 3737873-1Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			
Other		Health Professional			Merck Co Inc	ORAL	25 MG DAILY	

Date:06/11/01ISR Number: 3737875-5Report Type:Expedited (15-DaCompany Report #WAES 01059762
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY	
			Antimicrobial (Unspecified)	C				

Date:06/11/01ISR Number: 3737952-9Report Type:Expedited (15-DaCompany Report #WAES 99121616
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Eosinophil Count Increased Gastrointestinal Haemorrhage Gastrointestinal Ulcer Haematemesis Melaena Red Blood Cell Count Decreased White Blood Cell Count Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/11/01ISR Number: 3737953-0Report Type:Expedited (15-DaCompany Report #WAES 01060090
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/11/01ISR Number: 3737954-2Report Type:Expedited (15-DaCompany Report #WAES 01060317
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anaemia Duodenal Ulcer Faecal Occult Blood Positive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue		Cardizem Cd Dyazide	C C				

			Lipitor	C
			Robaxin	C

Date:06/11/01ISR Number: 3737955-4Report Type:Expedited (15-DaCompany Report #WAES 01060064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/11/01ISR Number: 3737956-6Report Type:Expedited (15-DaCompany Report #WAES 01052893
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Paxil	C				

				Synthroid	C		

Date:06/11/01ISR Number: 3737957-8Report Type:Expedited (15-DaCompany Report #ENDOCET2001-00104
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Arrest	Consumer Other	Percocet	PS	Endo Pharmaceuticals Inc	ORAL	2 TABS Q4H PO	
			Oxycontin	SS	Purdue	ORAL	80 MG Q8H PO	
			Valium	SS		ORAL	5 MG QID PO	
			Duragesic	SS		TRANS	TRANSDERMAL 100 MCG/H Q3D	
			Klonopin	SS		ORAL	TID PO	
			Vioxx	SS		ORAL	25 MG DAILY PO	
			Pseudoephedrine	SS				

Date:06/11/01ISR Number: 3737980-3Report Type:Expedited (15-DaCompany Report #WAES 01022126
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/11/01ISR Number: 3737981-5Report Type:Expedited (15-DaCompany Report #WAES 01050048
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Convulsion Fracture	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Disability Other								

Date:06/11/01ISR Number: 3737982-7Report Type:Expedited (15-DaCompany Report #WAES 01052786
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis Helicobacter Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/12/01ISR Number: 3737326-0Report Type:Expedited (15-DaCompany Report #WAES 00045059
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	50 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/01ISR Number: 3737762-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety		Vioxx	PS				
	Drug Dependence							
	Gastrointestinal Disorder							
	Heart Rate Decreased							
	Malaise							
	Nausea							
	Nervous System Disorder							
	Tremor							

Date:06/12/01ISR Number: 3738557-6Report Type:Expedited (15-DaCompany Report #WAES 01051754
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Ascites							
	Dyspnoea							
	Exercise Test Abnormal							
	Face Oedema		Accupril	C				
	Irritable Bowel Syndrome		Amaryl	C				
	Oedema Peripheral		Cenestin	C				
	Pulmonary Oedema		Flexeril	C				
			Lopid	C				
			Prilosec	C				
			Synthroid	C				
			Ultram	C				
			Insulin	C				

Date:06/12/01ISR Number: 3738558-8Report Type:Expedited (15-DaCompany Report #WAES 01050012
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div			
	Cough							

Gastrooesophageal Reflux Merck Co Inc ORAL
25
Disease
MG/DAILY/PO
Headache Prevacid C
Hiatus Hernia Zocor C
Myocardial Infarction
Nausea
Upper Respiratory Tract
Infection

Date:06/12/01ISR Number: 3738559-XReport Type:Expedited (15-DaCompany Report #WAES 01041846
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK
	Erythema							
	Face Oedema							
	Feeling Abnormal							
	Lip Dry							
	Oedema Peripheral							
	Oral Pain							

Date:06/12/01ISR Number: 3738560-6Report Type:Expedited (15-DaCompany Report #WAES 01030851
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Bilirubin Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hepatitis	Professional						
			Zocor	C				

Date:06/12/01ISR Number: 3738804-0Report Type:Expedited (15-DaCompany Report #WAES 01059708
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	15 DAY
	Endometrial Cancer	Study						
		Other						

Date:06/12/01ISR Number: 3738806-4Report Type:Expedited (15-DaCompany Report #WAES 01058223
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	5 DAY
	Drug Interaction	Other						
Other	Fatigue							
	Oedema Peripheral		Tab Tizanidine	SS		ORAL	4 MG/DAILY	5 DAY
	Sinus Bradycardia							

Date:06/12/01ISR Number: 3738808-8Report Type:Expedited (15-DaCompany Report #WAES 01057513
Age:80 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris	Foreign	Vioxx	PS	Merck Research Laboratories Div			
Life-Threatening	Arterial Disorder	Other						

Hospitalization - Initial or Prolonged	Pulmonary Oedema				Merck Co Inc	ORAL
			Benserazide Hydrochloride (+)			
			Levodopa	C		
			Escin	C		

Date:06/12/01ISR Number: 3738810-6Report Type:Expedited (15-DaCompany Report #WAES 01059553
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Proteinuria	Foreign Study Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
			Tab Placebo	SS		ORAL
			Alfacalcidol	C		
			Calcitonin	C		
			Diltiazem	C		
			Leflunomide	C		
			Levothyroxin Na	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/01ISR Number: 3738921-5Report Type:Expedited (15-DaCompany Report #2001-DB-00022
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis	Foreign Other	Persantin	PS	Boehringer Ingelheim Pharmaceuticals Inc	ORAL	200/NR/PO	
			Hjertemagnyl	SS		ORAL	PO	
			Vioxx	SS		ORAL	PO	
			Prednisolon	C				

Date:06/12/01ISR Number: 3738949-5Report Type:Expedited (15-DaCompany Report #MPU-2001-00277(0)
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Pediapred	PS	Celltech Pharmaceuticals Inc		5 MG (ONCE DAILY)	
Hospitalization - Initial or Prolonged	Haematemesis							
	Hypotension							
	Melaena		Vioxx (Rofecoxib)	SS			5 MG (ONCE DAILY)	
	Upper Gastrointestinal Haemorrhage		Digoxin (Digoxin)	C				
			Ramipril (Ramipril)	C				
			Dihydrocodeine (Dihydrocodeine)	C				
			Paracetamol (Paracetamol)	C				
			Frusemide (Furosemide)	C				
			Spironolactone (Spironolactone)	C				
			Bisoprolol (Bisoprolol)	C				
			Omeprazole (Omeprazole)	C				
			Iron Sulphate (Ferrous Sulfate)	C				
			Warfarin (Warfarin)	C				

				Didronel Pmo (Didronel Pmo)	C	

Date:06/12/01ISR Number: 3742833-0Report Type:Expedited (15-DaCompany Report #01050505
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Consumer	Enbrel 25 Mg	PS			SUBCUTANEOUS	25 MG, BIW,
	Hypertension	Health Professional					SUBCUTANEOUS	
	Pneumonia		Rofecoxib	SS				
	Tachycardia		Amlodipine	C				
	Upper Respiratory Tract Infection		Cephalexin	C				
			Spironolactone	C				
			Oxycodone /Acetaminophen	C				
			Salmeterol	C				

Date:06/13/01ISR Number: 3738004-4Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia		Vioxx	PS		ORAL	50 MG Q DAY	
	Gastric Ulcer						PO	
	Gastritis		Vioxx	C				
	Weight Decreased		Lipitor	C				
			Darvocet	C				
			Monopril	C				
			Zoloft	C				
			Synthroid	C				

Date:06/13/01ISR Number: 3738029-9Report Type:Direct Company Report #
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS		ORAL	1 PO QD	
Initial or Prolonged	Upper Gastrointestinal						"SEVERAL	
	Haemorrhage						MONTHS"	
			Otc Nsaids	SS			PRN	

Date:06/13/01ISR Number: 3738061-5Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Rofecoxib	PS		ORAL	25MGM	
ONLY-ORAL	6	MON						

Date:06/13/01ISR Number: 3739009-XReport Type:Expedited (15-DaCompany Report #WAES 01063405
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG; DAILY;PO						
			Calcium (Unspecified)	C		
			Ferrouss04/Folic Acid	C		
			Methotrexate Sodium	C		

Date:06/13/01ISR Number: 3739010-6Report Type:Expedited (15-DaCompany Report #WAES 01058772
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG; DAILY;PO						

Date:06/13/01ISR Number: 3739012-XReport Type:Expedited (15-DaCompany Report #WAES 01055502
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Eosinophil Count Increased Face Oedema Hypergammaglobulinaemia Pharyngeal Oedema White Blood Cell Count Decreased White Blood Cell Count Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	6 DAY

Date:06/13/01ISR Number: 3739013-1Report Type:Expedited (15-DaCompany Report #WAES 01065012
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure Congestive		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	27 DAY
			Digoxin	C				
			Fluticasone Propionate (+) Salmeterol Xi	C				

Date:06/13/01ISR Number: 3739017-9Report Type:Expedited (15-DaCompany Report #WAES 01066015
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	

DAILY;PO 3 MON

Diosmin C

Date:06/13/01ISR Number: 3739027-1Report Type:Expedited (15-DaCompany Report #WAES 01065013
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Oropharyngeal Swelling	Foreign	Vioxx	PS	Merck Research	
	Stridor	Other			Laboratories Div	
	Tongue Oedema				Merck Co Inc	ORAL
12.5 MG/DAILY						

PO 2 DAY

Prinivil C
Amlodipine C

Date:06/13/01ISR Number: 3739029-5Report Type:Expedited (15-DaCompany Report #WAES 01025505
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Confusional State	Health			Laboratories Div	
Hospitalization -	Hallucination	Professional			Merck Co Inc	ORAL
12.5 MG/DAILY						
Initial or Prolonged	Left Ventricular Failure	Other				

PO 21 DAY

Tab Zolpidem

			Tartrate	SS		ORAL
5 MG/DAILY PO						
			Digitoxin	C		
			Enalapril Maleate	C		
			Pentaerythritol Tetranitrate	C		
			Torsemide	C		

Date:06/13/01ISR Number: 3739039-8Report Type:Expedited (15-DaCompany Report #WAES 01063421
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Full Blood Count Abnormal	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO (SEE IMAGE)	

Date:06/13/01ISR Number: 3739100-8Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Interstitial Lung Disease	Foreign Study Other	Arava	PS	Aventis Pharmaceuticals Inc	ORAL	10 VS 20 MG PO	106 DAY
		Health Professional Other	Vioxx	SS		ORAL	25 MG QD PO	59 DAY
			Marcumar	C				
			Zocor	C				

Date:06/13/01ISR Number: 3739276-2Report Type:Expedited (15-DaCompany Report #2001059670US
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper Cough Fatigue Lethargy	Study Health Professional	Fragmin (Dalteparrin Sodium) Solution, Sterile	PS	Pharmacia And Upjohn Co		
Other							
SUBCUTANEOUS	7500 IU, QD,						
	Thrombocytopenia						
SUBCUTANEOUS							
	Vomiting		Vioxx(Rofecoxib)	SS		ORAL	25 MG, QD,
ORAL							
			Coumadin(Warfarin Sodium)	SS		ORAL	2 MG, QD,
ORAL							
			Heparin Sodium(Heparin Sodium)	SS			
SUBCUTANEOUS	5000 U, BID,						
SUBCUTANEOUS							
			Prevacid (Lansoprazole)	C			
			Augmentin Oral (Amoxicillin Trihydrate)	C			
			Tylenol	C			
			Benadryl (Diphenhydramine Hydrochloride)	C			
			Dilaudid (Hydromorphone Hydrochloride)	C			

Date:06/13/01ISR Number: 3739524-9Report Type:Expedited (15-DaCompany Report #WAES 01060155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/13/01ISR Number: 3739534-1Report Type:Expedited (15-DaCompany Report #WAES 01060303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure Congestive	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Liver Function Test Abnormal							
	Weight Increased		Tab Arava 100 Mg	SS		ORAL	100 MG/DAILY/PO	

Date:06/13/01ISR Number: 3739536-5Report Type:Expedited (15-DaCompany Report #WAES 01060260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Hypotension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/13/01ISR Number: 3739539-0Report Type:Expedited (15-DaCompany Report #WAES 01060079
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Renal Disorder		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
Hospitalization - Initial or Prolonged						
			Acebutolol	C		
			Amantadine Hydrochloride	C		
			Chlorzoxazone	C		
			Hydr5ochlorothiazide (+) Triamterene	C		
			Nitroglycerin	C		

Date:06/14/01ISR Number: 3739763-7Report Type:Expedited (15-DaCompany Report #WAES 01060707
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/01ISR Number: 3739768-6Report Type:Expedited (15-DaCompany Report #WAES 01060481
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Amiodarone Msd	C				
			Captopril Msd	C				
			Coumadin	C				
			Dyazide	C				
			K-Dur	C				
			Lasix (Furosemide Sodium)	C				

Date:06/14/01ISR Number: 3739781-9Report Type:Expedited (15-DaCompany Report #WAES 01060440
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pulmonary Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Accupril	C				
			Coumadin	C				
			Digitek	C				
			Lipitor	C				
			Xalatan	C				
			Atenolol	C				

Date:06/14/01ISR Number: 3739782-0Report Type:Expedited (15-DaCompany Report #WAES 01060031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research			

	Hepatitis C	Company Representative			Laboratories Div Merck Co Inc	ORAL

50

MG/DAILY/PO

			Oxycontin	C		

Date:06/14/01ISR Number: 3739786-8Report Type:Expedited (15-DaCompany Report #WAES 01060256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Urinary Tract Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

UNK/UNK/PO

Date:06/14/01ISR Number: 3739787-XReport Type:Expedited (15-DaCompany Report #WAES 01060578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Bleeding Time Prolonged Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

UNK/UNK/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/01ISR Number: 3739788-1Report Type:Expedited (15-DaCompany Report #WAES 01052838
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/UNK/PO	

Date:06/14/01ISR Number: 3739984-3Report Type:Expedited (15-DaCompany Report #WAES 00119814
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Health			Laboratories Div			
Initial or Prolonged	Dyspnoea	Professional			Merck Co Inc	ORAL	12.5 MG/DAILY	4 DAY
	Oedema	Other	Vioxx	SS		ORAL	25 MG/DAILY	12 DAY
			Aspirin	C				
			Isosorbide Mononitrate	C				
			Metoprolol Tartrate	C				
			Promazine	C				

Date:06/14/01ISR Number: 3739985-5Report Type:Expedited (15-DaCompany Report #WAES 01057513
Age:80 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Oedema	Health			Laboratories Div			
Hospitalization -	Pulmonary Oedema	Professional			Merck Co Inc	ORAL		
Initial or Prolonged	Renal Vessel Disorder	Other	Benserazide Hydrochloride (+)					
			Levodopa	C				
			Escin	C				
			Papaverine Hcl	C				

Date:06/14/01ISR Number: 3739986-7Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Atrial Fibrillation Cardiac Failure Congestive	Foreign Study Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:06/14/01ISR Number: 3739987-9Report Type:Expedited (15-DaCompany Report #WAES 01058591
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain Confusional State Delirium Depression Disorientation Hyperkalaemia Hypochloraemia Hyponatraemia Musculoskeletal Pain

Pain In Extremity

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
		Other	Vioxx	SS		ORAL
25MG QOD						
			Vasotec	C		
			Acetaminophen	C		
			Calcium (Unspecified)	C		
			Docusate Na	C		
			Glyburide	C		
			Metoprolol	C		
			Quinine	C		

Date:06/14/01ISR Number: 3739990-9Report Type:Expedited (15-DaCompany Report #WAES 01068528
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/14/01ISR Number: 3739991-0Report Type:Expedited (15-DaCompany Report #WAES 01069302
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	1 DAY
	Haemoglobin Decreased							
	Melaena							
	Nausea							

Date:06/14/01ISR Number: 3739993-4Report Type:Expedited (15-DaCompany Report #WAES 01065021
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Foreign	Vioxx	PS	Merck Research			
	Balance Disorder	Other			Laboratories Div			
	Blindness Transient				Merck Co Inc	ORAL	25 MG DAILY	
	Depression							
PO							22	DAY
	Diarrhoea		Atenolol	C				
	Dizziness		Ibuprofen	C				
	Panic Disorder Without Agoraphobia							
	Psychiatric Symptom							

Date:06/14/01ISR Number: 3739997-1Report Type:Expedited (15-DaCompany Report #WAES 01059764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Vioxx	PS	Merck Research			
	Dehydration	Health			Laboratories Div			
	Malaise	Professional			Merck Co Inc	ORAL	25 MG/DAILY	
	Renal Failure							
PO								
			Cetrimide	C				

Date:06/14/01ISR Number: 3740024-0Report Type:Expedited (15-DaCompany Report #WAES 01065020
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	84 DAY
	Haematemesis	Other						
	Upper Gastrointestinal Haemorrhage		Acetaminophen	C				
			Dihydrocodeine	C				

Date:06/14/01ISR Number: 3740029-XReport Type:Expedited (15-DaCompany Report #WAES 01057037
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Compartment Syndrome	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	13 DAY
	Face Oedema	Other						
	Fatigue							
	Oedema		Carisoprodol	C				

Date:06/14/01ISR Number: 3740030-6Report Type:Expedited (15-DaCompany Report #WAES 01057037
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Compartment Syndrome	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	13 DAY
	Hypothyroidism	Other						
			Carisoprodol	C				

Date:06/14/01ISR Number: 3740031-8Report Type:Expedited (15-DaCompany Report #WAES 01068527
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Nodosum	Foreign	Vioxx	PS	Merck Research Laboratories Div			
		Health						

		Professional			Merck Co Inc	ORAL
			Zestril	C		

Date:06/14/01ISR Number: 3740032-XReport Type:Expedited (15-DaCompany Report #WAES 01065057
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Abdomen	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Duodenal Ulcer	Other			Laboratories Div	
Initial or Prolonged	Perforation				Merck Co Inc	ORAL
12.5 MG/BID 31 DAY						
			Acetaminophen	C		

Date:06/14/01ISR Number: 3740075-6Report Type:Expedited (15-DaCompany Report #WAES 01051781
Age:50 MON Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Arthralgia
Hospitalization -	Back Pain
Initial or Prolonged	Cardiac Failure
	Congestive
	Condition Aggravated
	Dizziness
	Haematemesis

Pulmonary Oedema

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Hyzaar	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				
			Zestril	C				
			[Composition Unspecified]	C				
			Acetaminophen (+) Hydrocodone Bi	C				
			Aspirin	C				
			Calcium Carbonate (=) Cholecalci	C				
			Estradiol	C				
			Folic Acid	C				
			Glucosamine Sulfate	C				
			Iron (Unspecified)	C				
			Medroxyprogesterone Acetate	C				
			Melatonin	C				
			Propranolol	C				
			Vitamin E	C				

Date:06/14/01ISR Number: 3740076-8Report Type:Expedited (15-DaCompany Report #WAES 01050431
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Drug Interaction							
	Ecchymosis							
	Haemoglobin Decreased		Coumadin	SS			UNKNOWN	5 MG DAILY
	Haemorrhage		Noroxin	SS		ORAL	PO	

International Normalised
Ratio Increased

Date:06/14/01ISR Number: 3740097-5Report Type:Expedited (15-DaCompany Report #WAES 01050887
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension	Health	Vioxx	PS	Merck Research			
Other		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25 MG/ DAILY/	
		Representative						
			Therapy Unspecified	C				

Date:06/15/01ISR Number: 3740608-XReport Type:Expedited (15-DaCompany Report #WAES 01042432
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Dysphagia
Initial or Prolonged	Dyspnoea
Other	Pharyngolaryngeal Pain

Throat Tightness

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Levoxyl	C				
			Prevacid	C				
			[Therapy Unspecified]	C				
			Calcium (Unspecified)	C				
			Phenobarbital	C				

Date:06/15/01ISR Number: 3740635-2Report Type:Expedited (15-DaCompany Report #WAES 01060582
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/15/01ISR Number: 3740638-8Report Type:Expedited (15-DaCompany Report #WAES 01060653
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis Relapsing	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/15/01ISR Number: 3740640-6Report Type:Expedited (15-DaCompany Report #WAES 01060705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prednisone	C				

Date:06/15/01ISR Number: 3740641-8Report Type:Expedited (15-DaCompany Report #WAES 01060575
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Disability	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Demadex	C				
			Detrol	C				
			K-Tab	C				
			Norvasc	C				
			Paxil	C				
			Prevacid	C				
			Tylenol Arthritis					

			Extended Relief	C
			Zestril	C

Date:06/15/01ISR Number: 3740676-5Report Type:Expedited (15-DaCompany Report #WAES 01050277
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Haemorrhage Intracranial Headache	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
Other			Toradol	SS			INTRAMUSCULAR	IM
			Demerol	C				
			Percocet	C				
			Tylenol	C				

Date:06/15/01ISR Number: 3740682-0Report Type:Expedited (15-DaCompany Report #WAES 01060381
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Valve Replacement	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Caltrate 600 Plus Vitamin D	C				
			Coumadin	C				
			Lanoxin	C				
			Miacalcin	C				
			Toprol Xl Tablets	C				
			Vitamins	C				

Date:06/15/01ISR Number: 3740697-2Report Type:Expedited (15-DaCompany Report #WAES 01060756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/PO	
			Prednisone	C				

Date:06/15/01ISR Number: 3740733-3Report Type:Expedited (15-DaCompany Report #WAES 01060317
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Cellulitis							
	Duodenal Ulcer							
	Faecal Occult Blood							
	Positive		Cardizem Cd	C				
	Fatigue		Dyazide	C				
			Lipitor	C				
			Prilosec	C				
			Robaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/01ISR Number: 3740736-9Report Type:Expedited (15-DaCompany Report #WAES 01063439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis Hepatic Function Abnormal Pulmonary Embolism	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 1 WK

Date:06/15/01ISR Number: 3740890-9Report Type:Expedited (15-DaCompany Report #WAES 01050310
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Disability	Alanine Aminotransferase Increased Anorectal Disorder Arthralgia Back Pain Cardiac Tamponade Cardio-Respiratory Arrest Cardiomyopathy Conduction Disorder Dehydration Dermatitis Drug Ineffective Electrocardiogram St Segment Depression Eosinophilia Gastrointestinal Disorder Haemorrhage Hepatic Necrosis Hepatitis Hepatosplenomegaly Infection Laboratory Test Abnormal Leukocytosis Liver Function Test	Representative	Correctol Laxative Tablets & Caplet Vicodin Tablets Codeine Excedrin Migraine Zoloft Atenolol	SS SS SS C C C					

Abnormal
Musculoskeletal Disorder
Musculoskeletal Stiffness
Myocardial Infarction
Myocarditis
Nausea
Necrosis
Pancreatic Disorder
Pericardial Effusion
Pyrexia
Renal Necrosis
Sinus Tachycardia
Spleen Disorder
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/01ISR Number: 3741092-2Report Type:Expedited (15-DaCompany Report #WAES 01017507
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tremor	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 203 DAY
			Omeprazole	C				

Date:06/15/01ISR Number: 3741094-6Report Type:Expedited (15-DaCompany Report #WAES 01053534
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 10 DAY
	Bronchospasm							
	Cardiac Failure							
	Congestive Condition Aggravated		Digoxin	C				
	Dyspnoea Exacerbated		Furosemide	C				
			Insulin Zinc	C				
			Insulin, Neutral	C				
			Temazepam	C				
			Warfarin	C				

Date:06/15/01ISR Number: 3741095-8Report Type:Expedited (15-DaCompany Report #WAES 01056123
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Scan Abnormal	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 4 DAY
	Headache							
	Hypertension							
			Dihydroergotamine					

			Mesylate	SS		ORAL
PO						
			Nicergoline	C		
			Piroxicam	C		

Date:06/15/01ISR Number: 3741143-5Report Type:Expedited (15-DaCompany Report #WAES 01067901
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Dizziness	Consumer			Laboratories Div	
	Drug Toxicity				Merck Co Inc	ORAL
50 MG/BID PO						
	Headache		Tab Vioxx			
	Nausea		(Rofecoxib)	SS		
25 MG/DAILY						

Date:06/15/01ISR Number: 3741145-9Report Type:Expedited (15-DaCompany Report #WAES 01066026
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Renal Impairment	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG/DAILY						
PO 1 DAY						
			Fluindione	C		
			Irbesartan	C		

Piretanide C

Date:06/15/01ISR Number: 3741147-2Report Type:Expedited (15-DaCompany Report #WAES 01065073
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
PO							27	DAY
			Amlodipine	C				
			Etidronate Disodium	C				
			Prednisolone	C				

Date:06/15/01ISR Number: 3741160-5Report Type:Expedited (15-DaCompany Report #WAES 01058118
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Face Oedema Periorbital Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO							2	DAY
	Pruritus Urticaria		Lisinopril	C				

Date:06/15/01ISR Number: 3741161-7Report Type:Expedited (15-DaCompany Report #WAES 01063421
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
PO								
			Tab Vioxx					

			(Rofecoxib)	SS		ORAL
25 MG/DAILY						
PO						

Date:06/15/01ISR Number: 3741162-9Report Type:Expedited (15-DaCompany Report #WAES 01058627
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO						
			Albuterol Sulfate (+) Ipratropium Bromid	C		
			Cetirizine Hydrochloride	C		
			Diltiazem Hydrochloride	C		
			Fluticasone Propionate	C		
			Furosemide	C		
			Glyburide	C		
			Nefazodone Hcl	C		
			Nitroglycerin	C		

			Oxazepam	C
			Oxygen	C
			Pantoprazole Sodium	C
			Raloxifene	C
			Venlafaxine Hcl	C

Date:06/18/01ISR Number: 3741455-5Report Type:Expedited (15-DaCompany Report #WAES 01069605
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Foreign	Vioxx	PS	Merck Research	
	Cardiac Failure	Health			Laboratories Div	
	Congestive	Professional			Merck Co Inc	ORAL
25 MG/DAILY 7 DAY						
	Condition Aggravated	Other	Carbaspirin Calcium	C		
			Digoxin	C		
			Furosemide	C		
			Isosorbide Dinitrate	C		
			Lorazepam	C		
			Ramipril	C		

Date:06/18/01ISR Number: 3741457-9Report Type:Expedited (15-DaCompany Report #WAES 01065071
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal	Foreign	Vioxx	PS	Merck Research	
	Haemorrhage	Other			Laboratories Div	
					Merck Co Inc	ORAL
1 DOSE/DAILY						
			Estrogens, Conjugated (+)			
			Norgestrel	C		

Date:06/18/01ISR Number: 3741458-0Report Type:Expedited (15-DaCompany Report #WAES 01065066
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bladder Cancer	Foreign	Vioxx	PS	Merck Research	

	Haematuria	Other			Laboratories Div	
	Urinary Tract Infection				Merck Co Inc	ORAL
12.5 MG/DAILY						
			Acetaminophen	C		
			Nonsteroidal Anti-Inflammatory Drug (Uns	C		

Date:06/18/01ISR Number: 3741717-1Report Type:Expedited (15-DaCompany Report #WAES 01051662
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myelofibrosis	Health	Tab Vioxx	PS	Merck Research	
Hospitalization -		Professional			Laboratories Div	
Initial or Prolonged		Company			Merck Co Inc	ORAL
PO						
		Representative	Zithromax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/01ISR Number: 3741721-3Report Type:Expedited (15-DaCompany Report #WAES 01060788
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/19/01ISR Number: 3742089-9Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Rofecoxib	PS				

Date:06/19/01ISR Number: 3742093-0Report Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anxiety Back Pain Condition Aggravated Influenza Like Illness		Vioxx 25mg Once Per Day Merck	PS	Merck	ORAL	25MG ONCE PER ORAL	

Date:06/19/01ISR Number: 3742267-9Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Rofecoxib 25 Mg	PS				

Date:06/19/01ISR Number: 3742269-2Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exacerbated		Rofecoxib	25mg Od	PS				

Date:06/19/01ISR Number: 3742278-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exacerbated		Rofecoxib	PS				
25 MG QD								
	Oedema Peripheral							

Date:06/19/01ISR Number: 3742279-5Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Rofecoxib	PS				
	Dizziness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/01ISR Number: 3742280-1Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Vioxx 25 Mg Qd	PS				

Date:06/19/01ISR Number: 3742383-1Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS			UNKNOWN DOSE	
	Dysphagia						& FREQUENCY;	
	Dyspnoea						PO	3 DAY
	Hyperventilation							
	Laryngospasm							
	Oedema							
	Throat Tightness							
	Tremor							

Date:06/20/01ISR Number: 3743668-5Report Type:Expedited (15-DaCompany Report #2001-NO-00020
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Persantin	PS	Boehringer Ingelheim			
Initial or Prolonged	Duodenal Ulcer	Other			Pharmaceuticals Inc			
	Haemoglobin Decreased						200/TWICE	
							DAILY/NR	4 MON
	Melaena		Vioxx	SS		ORAL	50 MG/PO	
			Albyl E	SS		ORAL	160 MG/PO	

Date:06/20/01ISR Number: 3743763-0Report Type:Expedited (15-DaCompany Report #WAES 01065094
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	10 DAY
			Ibuprofen	C				
			Prednisolone	C				

Date:06/20/01ISR Number: 3743786-1Report Type:Expedited (15-DaCompany Report #WAES01035062
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Encephalopathy Hepatic Failure	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/20/01ISR Number: 3743787-3Report Type:Expedited (15-DaCompany Report #WAES 01045504
Age:89 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	127 DAY
	Gastric Perforation Peritonitis Renal Failure	Other	Hctz/Triamterene	C				
			Benserazide/Levodopa	C				
			Cabergoline	C				
			Furosemide	C				

Date:06/20/01ISR Number: 3743836-2Report Type:Expedited (15-DaCompany Report #WAES 01058605
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN	
			Elavil	C				
			Estrogens, Conjugated	C				

Date:06/20/01ISR Number: 3743837-4Report Type:Expedited (15-DaCompany Report #WAES 01067272
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	
			Tab Aspirin	SS		ORAL	160 MG DAILY	
			Midamor	C				
			Acetaminophen	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				

Date:06/20/01ISR Number: 3743889-1Report Type:Expedited (15-DaCompany Report #WAES 01061114
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Fluid Retention Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lorcet Plus	C				
			Skelaxin	C				
			Synthroid	C				

Date:06/20/01ISR Number: 3743892-1Report Type:Expedited (15-DaCompany Report #WAES 01060862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity Medication Error Tongue Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/01ISR Number: 3743893-3Report Type:Expedited (15-DaCompany Report #WAES 01060852
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nitroglycerin	C				

Date:06/21/01ISR Number: 3743333-4Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Gastritis Erosive		Rofecoxib 25 Mg Po Qd	PS		ORAL	25MG PO QD	
	Haematochezia		Naproxen 200mg	SS		ORAL	200MG PO BID	
			Placebo	SS				

Date:06/21/01ISR Number: 3743428-5Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psychotic Disorder		Vioxx	PS		ORAL	50 MG PO	
			Mycin Antibiotics	SS				

Date:06/21/01ISR Number: 3743544-8Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Vioxx Merck	PS	Merck	ORAL	1 TAB QD ORAL	

Initial or Prolonged	Blister	Claritin	C
	Bronchospasm	Soma	C
	Diarrhoea	Xanax	C
	Headache		
	Nausea		
	Pruritus		
	Rash Generalised		
	Urticaria		
	Vomiting		

Date:06/21/01ISR Number: 3744011-8Report Type:Expedited (15-DaCompany Report #WAES 01041942
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Abnormal Faeces
Initial or Prolonged	Anaemia
Other	Blood Iron Decreased
	Diverticulum
	Erosive Oesophagitis
	Erythema
	Gastritis
	Haemangioma Of Liver
	Hiatus Hernia
	Iron Deficiency Anaemia
	Melaena
	Oesophagitis
	Peptic Ulcer

		Skin Discolouration					
		Small Intestinal Obstruction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Trigeminal Neuralgia	Health	Fosamax	PS	Merck And Co Inc	ORAL
10							
		Vomiting	Professional				
MG/DAILY/PO							
			Company	Tab Vioxx	SS		ORAL
PO							
			Representative				

Date:06/21/01ISR Number: 3744017-9Report Type:Expedited (15-DaCompany Report #WAES 01060773
Age:80 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
			Company			Merck Co Inc	ORAL
25							
			Representative				
MG/DAILY/PO							

Date:06/21/01ISR Number: 3744018-0Report Type:Expedited (15-DaCompany Report #WAES 01052417
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Anxiety	Health Professional	Vioxx	PS	Merck Research Laboratories Div	
			Company			Merck Co Inc	ORAL
25							
			Representative				
MG/DAILY/PO	3	DAY					
				Ibuprofen	C		

Date:06/21/01ISR Number: 3744020-9Report Type:Expedited (15-DaCompany Report #WAES 01060915
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Dizziness							
	Dyspepsia							
	Nausea							
			Cozaar	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Lopressor	C				
			Prilosec	C				
			Synthroid	C				

Date:06/21/01ISR Number: 3744021-0Report Type:Expedited (15-DaCompany Report #WAES 01061112
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Nausea							
	Pruritus							
	Urticaria							
	Vomiting							
			Covera-Hs	C				
			Glucophage	C				
			Hydrodiuril	C				
			Prilosec	C				
			Vasotec	C				
			Gemfibrozil	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/01ISR Number: 3744022-2Report Type:Expedited (15-DaCompany Report #WAES 01061051
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choking Speech Disorder Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Hydrodiuril	C				
			Synthroid	C				
			Glyburide	C				

Date:06/21/01ISR Number: 3744024-6Report Type:Expedited (15-DaCompany Report #WAES 01061126
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/21/01ISR Number: 3744025-8Report Type:Expedited (15-DaCompany Report #WAES 01051414
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Cyst Depression Joint Sprain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pancreatitis Performance Fear Rotator Cuff Syndrome		Celestone	C				
			Inderal	C				
			Kenalog	C				
			Prevacid	C				
			Propecia	C				
			Lidocaine	C				

Date:06/21/01ISR Number: 3744030-1Report Type:Expedited (15-DaCompany Report #WAES 01066508
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Bendroflumethiazide/ Kcl	C				
			Citalopram Hydrobromide	C				
			Hydroxyzine Hydrochloride	C				
			Zuclopenthixol Hydrochloride	C				

Date:06/21/01ISR Number: 3744034-9Report Type:Expedited (15-DaCompany Report #WAES 01066506
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/DAILY 8 DAY

Acetaminophen	C
Furosemide	C
Lorsartan Potassium	C
Potassium Chloride	C

Date:06/21/01ISR Number: 3744035-0Report Type:Expedited (15-DaCompany Report #WAES 01065562
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	Status Asthmaticus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MG/DAILY 6 DAY

Bemetizide (+) Triamterene	C
Ergoloid Mesylates	C
Iodine	C

Date:06/21/01ISR Number: 3744385-8Report Type:Expedited (15-DaCompany Report #WAES 01065101
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration
25 MG/DAILY

PO 2 DAY

Aspirin	C
Atorvastatin	C
Digoxin	C
Furosemide	C
Ramipril	C

Date:06/21/01ISR Number: 3744388-3Report Type:Expedited (15-DaCompany Report #WAES 01067266
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis Haemoglobin Decreased Syncope	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12, 5 MG/DAILY/PO	
			Tab. Citalopram Hydrobromide	SS		ORAL	20 MG DAILY PO	
			Acetaminophen	C				
			Calcium Carbonate					
			(+) Cholecalciferol	C				
			Candesartan Cliexetil	C				
			Cyanocobalamin	C				
			Digoxin	C				
			Ferrous Fumarate	C				
			Furosemide	C				
			Lactulose	C				
			Propiomazine	C				
			Rivastigmine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/01ISR Number: 3744401-3Report Type:Expedited (15-DaCompany Report #WAES 01068901
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	36 DAY
	Ear Pain	Study						
	Perineal Pain	Health						
	Rash Pruritic	Professional	Prinivil	C				
			Prazosin	C				
			Sennosides	C				
			Thymol	C				

Date:06/21/01ISR Number: 3744404-9Report Type:Expedited (15-DaCompany Report #WAES 01069552
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dermatitis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	2 DAY
Hospitalization - Initial or Prolonged	Dyspnoea	Health						
	Laryngeal Oedema	Professional						
	Laryngeal Pain		Acetaminophen (+) Orphenadrine Citrate	C				
	Pruritus		Cyanocobalamin (+) Pyridoxine (+) Thiami	C				

Date:06/21/01ISR Number: 3744407-4Report Type:Expedited (15-DaCompany Report #WAES 01066508
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
		Other						
			Bendroflumethiazide/ Kcl	C				
			Citalopram Hydrobromide	C				
			Hydroxyzine					

			Hydrochloride	C		
			Zuclopenthixol Hydrochloride	C		

Date:06/21/01ISR Number: 3744408-6Report Type:Expedited (15-DaCompany Report #WAES 01045535
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1 TABLET/DAILY						
			Allopurinol	C		
			Glyburide	C		
			Oxybutynincl	C		
			Ramipril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/01ISR Number: 3744411-6Report Type:Expedited (15-DaCompany Report #WAES 01045534
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/21/01ISR Number: 3744646-2Report Type:Expedited (15-DaCompany Report #WAES 01032152
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/21/01ISR Number: 3744649-8Report Type:Expedited (15-DaCompany Report #WAES 01021902
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased Diarrhoea Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY, PO	
			Celexa	C				
			K-Dur	C				
			Nasocort	C				
			Synthroid [Composition Unspecified]	C				
			Furosemide	C				
			Quinine	C				

Date:06/21/01ISR Number: 3744654-1Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension Tachycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, AM, PO	
	Transient Ischaemic Attack		Xalatan	C				

Date:06/21/01ISR Number: 3772675-1Report Type:Periodic Company Report #WAES 01031303
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Psychomotor Hyperactivity	Health Professional	Orsu Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	MG/UNK/PO	
			Dexedrine	C				
			Ornade Spansule	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/01ISR Number: 3772678-7Report Type:Periodic Company Report #WAES 01050355
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nonspecific Reaction	Health Professional Company	Orsu Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Vioxx	C				

Date:06/21/01ISR Number: 3772681-7Report Type:Periodic Company Report #WAES 01052794
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Haematuria							
	International Normalised Ratio Increased		Coumadin	C				
	Oedema Peripheral		Enbrel	C				
	Renal Colic		Foltx	C				
			Levoxyl	C				
			Medrol	C				
			Prevacid	C				
			Robaxin	C				
			Vicodin Tablets	C				
			Ziac	C				
			Potassium Chloride	C				

Date:06/22/01ISR Number: 3744949-1Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Tequin	PS		ORAL	ORAL	
Initial or Prolonged	Eye Rolling		Vioxx	SS		ORAL	ORAL	
	Grand Mal Convulsion							
	Mouth Haemorrhage							

Date:06/22/01ISR Number: 3745393-3Report Type:Periodic Company Report #WAES 01050264
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Oedema Peripheral	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Dilantin	C				
			Glucophage	C				
			Prempro	C				
			Aspirin	C				
			Calcium Carbonate	C				
			Ferrous Sulfate	C				
			Glyburide	C				

Date:06/22/01ISR Number: 3745394-5Report Type:Periodic Company Report #WAES 01050197
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Ambien	C
Plavix	C
Remeron	C
Alprazolam	C
Amiodarone	C
Amitriptyline	C
Furosemide	C

Date:06/22/01ISR Number: 3745395-7Report Type:Periodic Company Report #WAES 01042871
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3745396-9Report Type:Periodic Company Report #WAES 01034378
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Fluid Retention Respiratory Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; PO	

Tylenol	C
Dextropropoxyphene	C

Date:06/22/01ISR Number: 3745397-0Report Type:Periodic Company Report #WAES 01033100
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/01ISR Number: 3745398-2Report Type:Periodic Company Report #WAES 01032992
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3745399-4Report Type:Periodic Company Report #WAES 01032689
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3745400-8Report Type:Periodic Company Report #WAES 01031272
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	6 WK
			Lipitor	C				
			Prempro	C				

Date:06/22/01ISR Number: 3745401-XReport Type:Periodic Company Report #WAES 01030616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3745403-3Report Type:Periodic Company Report #WAES 01030565
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactoid Reaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3745406-9Report Type:Periodic Company Report #WAES 01030118
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Excedrin
Extra-Strength C

Date:06/22/01ISR Number: 3745408-2Report Type:Periodic Company Report #WAES 01021900
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotrel	C				
			Zocor	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3746438-7Report Type:Periodic Company Report #WAES 01040808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746440-5Report Type:Periodic Company Report #WAES 01040816
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Prilosec	C				
			Synthroid	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746442-9Report Type:Periodic Company Report #WAES 01040825
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3746443-0Report Type:Periodic Company Report #WAES 01040828
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atarax	C				
			Flonase	C				
			Miacalcin	C				
			Seconal Sodium	C				
			Ventolin	C				
			Wellbutrin	C				

			Therapy Unspecified	C
			Calcium Unspecified	C

Date:06/22/01ISR Number: 3746445-4Report Type:Periodic Company Report #WAES 01040831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alora	C				

Date:06/22/01ISR Number: 3746447-8Report Type:Periodic Company Report #WAES 01040832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746448-XReport Type:Periodic Company Report #WAES 01040842
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746450-8Report Type:Periodic Company Report #WAES 01040844
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746452-1Report Type:Periodic Company Report #WAES 01040886
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Prevacid	C				

Date:06/22/01ISR Number: 3746453-3Report Type:Periodic Company Report #WAES 01040889
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Vioxx	PS	Merck Research			

Dry Throat
Laboratories Div
Merck Co Inc ORAL
25

MG/DAILY/PO

Accupril C
Norvasc C
Zocor C

Date:06/22/01ISR Number: 3746456-9Report Type:Periodic Company Report #WAES 01040701
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS	Merck Research			
	Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	PO	
	Headache	Representative						
	Nausea							
	Vomiting							

Date:06/22/01ISR Number: 3746457-0Report Type:Periodic Company Report #WAES 01040708
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			

Merck Co Inc ORAL
12.5

MG/BID/PO

Alphagan	C
Cosopt	C
Lachydrin	C
Norvasc	C
Paxil	C
Tylenol	C
Xalatan	C
Iron	C

Date:06/22/01ISR Number: 3746459-4Report Type:Periodic Company Report #WAES 01040710
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Accupril	C				
			Allegra	C				

Date:06/22/01ISR Number: 3746461-2Report Type:Periodic Company Report # WAES 01040713
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardizem Cd	C				
			Effexor	C				
			Inderal	C				
			Klonopin	C				
			Luvox	C				
			Neurontin	C				
			Pepto-Bismol	C				
			Tricor	C				

Lithium Carbonate C

Date:06/22/01ISR Number: 3746462-4Report Type:Periodic Company Report #WAES 01040728
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746464-8Report Type:Periodic Company Report #WAES 01040736
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746465-XReport Type:Periodic Company Report #WAES 01040751
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Altace	C				
			Asorbic Acid	C				
			Garlic Extract	C				
			Silibinin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746466-1Report Type:Periodic Company Report #WAES 01040792
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Chondroitin	C				

Date:06/22/01ISR Number: 3746467-3Report Type:Periodic Company Report #WAES 01040798
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Nadolol	C				

			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3746468-5Report Type:Periodic Company Report #WAES 01040804
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746470-3Report Type:Periodic Company Report #WAES 01040579
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746472-7Report Type:Periodic Company Report #WAES 01040580
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746473-9Report Type:Periodic Company Report #WAES 01040587
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746475-2Report Type:Periodic Company Report #WAES 01040595
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Prinivil	C				
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3746476-4Report Type:Periodic Company Report #WAES 01040639
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective Oedema Peripheral	Consumer	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Coumadin	C		
			Lanoxin	C		
			Hydralazine	C		
			Spironolactone	C		

Date:06/22/01ISR Number: 3746478-8Report Type:Periodic Company Report #WAES 01040645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746479-XReport Type:Periodic Company Report #WAES 01040649
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 1 MON

Date:06/22/01ISR Number: 3746480-6Report Type:Periodic Company Report #WAES 01040657
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Stiffness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746482-XReport Type:Periodic Company Report #WAES 01040674
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Chest Pain Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
	Dyspnoea		Prevacid	C				
	Face Oedema		Vasotec	C				
	Sedation		Lithium Carbonate	C				
	Sleep Disorder							

Date:06/22/01ISR Number: 3746483-1Report Type:Periodic Company Report #WAES 01040677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /PO	
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3746486-7Report Type:Periodic Company Report #WAES01040388
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Dyspnoea	Health			Laboratories Div			
	Pruritus	Professional			Merck Co Inc	ORAL	25	
	Upper Respiratory Tract						MG/DAILY/PO	
	Infection		Keflex	C				
	Weight Increased		Levaquin	C				
			Ultram	C				
			Zoloft	C				

Date:06/22/01ISR Number: 3746488-0Report Type:Periodic Company Report #WAES 01040397
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PRN/PO	3 WK
			Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746489-2Report Type:Periodic Company Report #WAES 01040402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atarax	C				

Date:06/22/01ISR Number: 3746490-9Report Type:Periodic Company Report #WAES 01040406
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746491-0Report Type:Periodic Company Report #WAES 01040407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Dilantin	C				
			Tiazac	C				

Date:06/22/01ISR Number: 3746492-2Report Type:Periodic Company Report #WAES 01040410
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Advil	C				
			Lopressor	C				

Date:06/22/01ISR Number: 3746493-4Report Type:Periodic Company Report #WAES 01040414
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO	

Date:06/22/01ISR Number: 3746494-6Report Type:Periodic Company Report #WAES 01040415
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:06/22/01ISR Number: 3746495-8Report Type:Periodic Company Report #WAES 01040434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746496-XReport Type:Periodic Company Report #WAES 01040447
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746498-3Report Type:Periodic Company Report #WAES 01040312
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Levoxyl	C				
			Propranolol	C				
			Ranitidine	C				
			Spironolactone	C				

Date:06/22/01ISR Number: 3746501-0Report Type:Periodic Company Report #WAES 01040332
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ambien	C				
			Coumadin	C				
			Cozaar	C				
			Digitek	C				
			Lipitor	C				
			Tylenool Extra Strenght	C				
			Verelan	C				
			Estradiol	C				
			Folic Acid	C				
			Methotrexate	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746502-2Report Type:Periodic Company Report #WAES 01040345
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting Weight Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Buspar	C				
			Dermadex	C				
			Desyrel	C				
			Duragesic	C				
			Estraderm	C				
			Imdur	C				
			Prevacid	C				
			Synthroid	C				
			Vasotec	C				
			Xanax	C				
			Zoloft	C				
			Spironolactone	C				

Date:06/22/01ISR Number: 3746503-4Report Type:Periodic Company Report #WAES 01040347
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Ecchymosis Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Digitek	C				
			Flonase	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3746505-8Report Type:Periodic Company Report #WAES 01040348
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Centrum Silver	C				
			Ocuvite	C				
			Toprol Xl Tablets	C				
			Chondroitin (+) Glucosamine	C				
			Ginkgo Biloba Extract	C				
			Ranitidine	C				

Date:06/22/01ISR Number: 3746507-1Report Type:Periodic Company Report #WAES 01040352
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Pravachol	C		

Date:06/22/01ISR Number: 3746508-3Report Type:Periodic Company Report #WAES 01040359
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flomax	C				
			Ultram	C				

Date:06/22/01ISR Number: 3746510-1Report Type:Periodic Company Report #WAES 01040265
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Fluid Retention Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746511-3Report Type:Periodic Company Report #WAES 01040384
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Musculoskeletal Stiffness Neck Pain	Consumer Health Professional User Facility	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746512-5Report Type:Periodic Company Report #WAES 01040385
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:06/22/01ISR Number: 3746514-9Report Type:Periodic Company Report #WAES 01040262
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746515-0Report Type:Periodic Company Report #WAES 01040264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746516-2Report Type:Periodic Company Report #WAES 01040269
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3746519-8Report Type:Periodic Company Report #WAES 01040271
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:06/22/01ISR Number: 3746520-4Report Type:Periodic Company Report #WAES 01040274
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem Cd	C				
			Miacalcin	C				
			Paxil	C				
			Xanax	C				
			Zocor	C				

Date:06/22/01ISR Number: 3746521-6Report Type:Periodic Company Report #WAES 01040283
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY
			Pepcid	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3746522-8Report Type:Periodic Company Report #WAES 01040286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Keratoconjunctivitis Sicca							
	Pruritus							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746523-XReport Type:Periodic Company Report #WAES 01040294
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Depression Mental Impairment	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	SS				

Date:06/22/01ISR Number: 3746524-1Report Type:Periodic Company Report #WAES 01040305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Aspirin	C				

Date:06/22/01ISR Number: 3746525-3Report Type:Periodic Company Report #WAES 01040306
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Axid	C				
			Celebrex	C				
			Lipitor	C				

Date:06/22/01ISR Number: 3746526-5Report Type:Periodic Company Report #WAES 01040091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoporosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746527-7Report Type:Periodic Company Report #WAES 01040092
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746528-9Report Type:Periodic Company Report #WAES 01040182
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746529-0Report Type:Periodic Company Report #WAES 01040185
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Vioxx	PS	Merck Research			
	Rectal Haemorrhage	Professional			Laboratories Div			
	Vaginal Haemorrhage	Company			Merck Co Inc	ORAL	25	
	Weight Increased	Representative					MG/DAILY/PO	
			Flexeril	C				
			Premarin	C				
			Vicodin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3746530-7Report Type:Periodic Company Report #WAES 01040191
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research			
	Pruritus				Laboratories Div			
	Urticaria				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Evista	C				
			Fosamax	C				
			Zocor	C				
			Metoprolol Tartrate	C				

Date:06/22/01ISR Number: 3746531-9Report Type:Periodic Company Report #WAES 01040243
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Vomiting				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

			Pepcid Ac	C		

Date:06/22/01ISR Number: 3746532-0Report Type:Periodic Company Report #WAES 01040252
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oral Soft Tissue Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	
25 MG/DAILY/PO						
			Tab Vioxx 12.5 Mg	C		ORAL
12.5 MG/DAILY/PO						
			Lipitor	C		
			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3746533-2Report Type:Periodic Company Report #WAES 01040255
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
1) 25 MG/DAILY/PO;						

2) 25

MG/BID/PO

Celebrex	C	
Norvasc	C	
Xanax	C	

Date:06/22/01ISR Number: 3746534-4Report Type:Periodic Company Report #WAES 01040257
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Drug Effect Decreased							
	Pain							

MG/DAILY/PO

Fosamax	C	
Lipitor	C	
Premarin	C	
Prinivil	C	
Synthroid	C	
Toprol Xl Tablets	C	
Zoloft	C	
Potassium Chloride	C	

Date:06/22/01ISR Number: 3746535-6Report Type:Periodic Company Report #WAES 01040260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Upper Respiratory Tract							
	Infection							

Prilosec	C	
Theo-Dur	C	

Date:06/22/01ISR Number: 3746536-8Report Type:Periodic Company Report #WAES 01040044
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:06/22/01ISR Number: 3746537-XReport Type:Periodic Company Report #WAES 01040046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Bronchitis Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Headache Oedema Peripheral		Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746538-1Report Type:Periodic Company Report #WAES 01040050
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Isordil	C				
			Lotensin	C				
			Norpace	C				
			Sular	C				

Date:06/22/01ISR Number: 3746539-3Report Type:Periodic Company Report #WAES 01040051
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746540-XReport Type:Periodic Company Report #WAES 01040054
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Librax Capsules	C				
			Synthroid	C				
			Furosemide	C				
			Propranolol	C				

Date:06/22/01ISR Number: 3746541-1Report Type:Periodic Company Report #WAES 01040061
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746542-3Report Type:Periodic Company Report # WAES 01040085
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746543-5Report Type:Periodic Company Report #WAES 01040088
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746544-7Report Type:Periodic Company Report #WAES 01040089
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746545-9Report Type:Periodic Company Report #WAES 01040090
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Nausea Vomiting	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746546-0Report Type:Periodic Company Report #WAES 01034407
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3746547-2Report Type:Periodic Company Report #WAES 01034412
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actos	C				
			Glucophage	C				

Date:06/22/01ISR Number: 3746548-4Report Type:Periodic Company Report #WAES 01040007
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746549-6Report Type:Periodic Company Report #WAES 01040008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Verapamil	C				

Date:06/22/01ISR Number: 3746550-2Report Type:Periodic Company Report #WAES 01040011
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Norvasc	C				
			Toprol Xl Tablets	C				

Date:06/22/01ISR Number: 3746551-4Report Type:Periodic Company Report #WAES 01040013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder Oral Discomfort	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Miacalcin	C				

Date:06/22/01ISR Number: 3746552-6Report Type:Periodic Company Report #WAES 01040030
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Joint Stiffness Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Effexor Xr	C				
			Lipitor	C				
			Prilosec	C				
			Synthroid	C				
			Acetaminophen	C				

Date:06/22/01ISR Number: 3746553-8Report Type:Periodic Company Report #WAES 01040032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Codeine Phosphate (+) Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746554-XReport Type:Periodic Company Report #WAES 01040033
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Synthroid	C				
			Zantac	C				
			Allopurinol	C				

Date:06/22/01ISR Number: 3746555-1Report Type:Periodic Company Report #WAES 01040041
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arthro-7	C				

Date:06/22/01ISR Number: 3746556-3Report Type:Periodic Company Report #WAES 01034368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Flatulence Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:06/22/01ISR Number: 3746557-5Report Type:Periodic Company Report #WAES 01034376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746558-7Report Type:Periodic Company Report #WAES 01034380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			[Therapy Unspecified]	C				
			Cortisone	C				

Date:06/22/01ISR Number: 3746559-9Report Type:Periodic Company Report #WAES 01034386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	

Date:06/22/01ISR Number: 3746560-5Report Type:Periodic Company Report #WAES 01034388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
			[Composition Unspecified]	C			PO	

Date:06/22/01ISR Number: 3746561-7Report Type:Periodic Company Report #WAES 01034389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3746562-9Report Type:Periodic Company Report #WAES 01034393
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG DAILY

PO

Actonel	C	
Dilantin	C	

Date:06/22/01ISR Number: 3746563-0Report Type:Periodic Company Report #WAES 01034396
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Levoxyl	C	
Zocor	C	

Date:06/22/01ISR Number: 3746564-2Report Type:Periodic Company Report #WAES 01034399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

PO

Effexor	C
Elavil	C
Ultram	C
Verelan	C
Xanax	C

Date:06/22/01ISR Number: 3746565-4Report Type:Periodic Company Report #WAES 01034403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Pravachol	C				

Date:06/22/01ISR Number: 3746566-6Report Type:Periodic Company Report #WAES 01034265
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746567-8Report Type:Periodic Company Report #WAES 01034310
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diplopia Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Syncope
MG/DAILY/PO

Lipitor	C	
Norvasc	C	
Plavix	C	
Aspirin	C	

Date:06/22/01ISR Number: 3746568-XReport Type:Periodic Company Report #WAES 01034314
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Composition Unspecified	C				

Date:06/22/01ISR Number: 3746569-1Report Type:Periodic Company Report #WAES 01034318
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3746570-8Report Type:Periodic Company Report #WAES 01034326
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Urea Increased				Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Aldactazide	C				
			Isosorbide Mononitrate	C				
			Thyroid	C				

Date:06/22/01ISR Number: 3746571-XReport Type:Periodic Company Report #WAES 01034340
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746572-1Report Type:Periodic Company Report #WAES 01034342
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Naproxen	SS				

Date:06/22/01ISR Number: 3746573-3Report Type:Periodic Company Report #WAES 01034344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Synvisc	C				

Date:06/22/01ISR Number: 3746574-5Report Type:Periodic Company Report #WAES 01034359
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			K-Dur	C				
			Pravachol	C				
			Relafen	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746575-7Report Type:Periodic Company Report #WAES 01034364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746576-9Report Type:Periodic Company Report #WAES 01034237
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Epistaxis Nasal Congestion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Respiratory Disorder		Prometrium	C				

Date:06/22/01ISR Number: 3746577-0Report Type:Periodic Company Report #WAES 01034240
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Above Therapeutic Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

Date:06/22/01ISR Number: 3746578-2Report Type:Periodic Company Report #WAES 01034241
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/01ISR Number: 3746579-4Report Type:Periodic Company Report #WAES 01034243
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Flatulence				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Tab Fosamax	SS		ORAL
PO						
			Hydrodiuril	C		
			Lotrel	C		
			Synthroid	C		
			Trental	C		
			Aspirin	C		
			Glucosamine	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746580-0Report Type:Periodic Company Report #WAES 01034246
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/01ISR Number: 3746581-2Report Type:Periodic Company Report #WAES 01034252
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Menest	C				
			Provera	C				

Date:06/22/01ISR Number: 3746582-4Report Type:Periodic Company Report #WAES 01034253
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Avandia	C				
			Diovan	C				
			Lasix (Furosemide)	C				
			Norvasc	C				
			Timoptic	C				
			Aspirin	C				
			Insulin	C				

Date:06/22/01ISR Number: 3746583-6Report Type:Periodic Company Report #WAES 01034254
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Tenormin	C				
			Timoptic	C				

Date:06/22/01ISR Number: 3746584-8Report Type:Periodic Company Report #WAES 01034257
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746585-XReport Type:Periodic Company Report #WAES 01034263
Age:3 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		250 MG/1X/PO	

Date:06/22/01ISR Number: 3746586-1Report Type:Periodic Company Report #WAES 01034216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; SEE IMAGE	

Date:06/22/01ISR Number: 3746587-3Report Type:Periodic Company Report #WAES 01010064
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Hepatic Function Abnormal	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nonsteroidal Anti-Inflammatory Dunk	C				

Date:06/22/01ISR Number: 3746588-5Report Type:Periodic Company Report #WAES 01034220
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Fosamax	C				
			Plaquenil	C				
			Folic Acid	C				
			Methotrexate	C				

Date:06/22/01ISR Number: 3746589-7Report Type:Periodic Company Report #WAES 01034221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746590-3Report Type:Periodic Company Report #WAES 01034225
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL PO
			Premarin	C		
			Synthroid	C		

Date:06/22/01ISR Number: 3746591-5Report Type:Periodic Company Report #WAES 01034226
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746592-7Report Type:Periodic Company Report #WAES 01010117
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
	Dizziness							
	Fatigue							
	Feeling Abnormal		Prinvil	C				
	Influenza Like Illness		Prinzide	C				
			Synthroid	C				
			Ultram	C				

Date:06/22/01ISR Number: 3746593-9Report Type:Periodic Company Report #WAES 01034228
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO, SEE IMAGE	
	Pain In Extremity							
			Synthroid	C				

Date:06/22/01ISR Number: 3746594-0Report Type:Periodic Company Report #WAES 01034229
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
	Radiculopathy	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	PO	
			Baycol	C				
			Chondroitin	C				
			Glucosamine	C				

Date:06/22/01ISR Number: 3746595-2Report Type:Periodic Company Report #WAES 01010127
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Vioxx	PS	Merck Research			
	Constipation				Laboratories Div			
	Pain				Merck Co Inc	ORAL	25 MG/PO	
	Pigmentation Disorder		Acetaminophen (+)					
	Retching		Hydrocodone	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746596-4Report Type:Periodic Company Report #WAES 01034231
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Malaise Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Betagan	C				
			Hydtrin	C				

Date:06/22/01ISR Number: 3746597-6Report Type:Periodic Company Report #WAES 01034232
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Paxil	C				

Date:06/22/01ISR Number: 3746598-8Report Type:Periodic Company Report #WAES 01034233
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746599-XReport Type:Periodic Company Report #WAES 01010130
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Retinal Exudates							
			Accupril	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3746600-3Report Type:Periodic Company Report #WAES 01010132
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/QID/PO	
	Diarrhoea	Health						
	Dizziness	Professional						
	Mental Impairment		Celebrex	C				
	Vomiting							

Date:06/22/01ISR Number: 3746601-5Report Type:Periodic Company Report #WAES 01033397
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
	Asthma	Health						
	Diarrhoea	Professional						

MG/DAILY/PO

Date:06/22/01ISR Number: 3746602-7Report Type:Periodic Company Report #WAES 01034107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746603-9Report Type:Periodic Company Report #WAES 01034108
Age:62 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C	Humulin 70/30			

Date:06/22/01ISR Number: 3746604-0Report Type:Periodic Company Report #WAES 01010145
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	

Date:06/22/01ISR Number: 3746605-2Report Type:Periodic Company Report #WAES 01034109
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746606-4Report Type:Periodic Company Report #WAES 01034110
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:06/22/01ISR Number: 3746607-6Report Type:Periodic Company Report #WAES 01010206
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/4XWK/PO	
			Ascriptin	C				
			Norvasc	C				

			Zocor	C		

Date:06/22/01ISR Number: 3746608-8Report Type:Periodic Company Report #WAES 01034136
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Azopt Drops	C				
			Cardura	C				
			Ecotrin	C				
			Hydrodiuril	C				
			K-Dur	C				
			Pilocar Ophthalmic Solution	C				
			Tiloptic	C				
			Zocor	C				
			Propranolol	C				

Date:06/22/01ISR Number: 3746609-XReport Type:Periodic Company Report #WAES 01034140
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Lipitor	C				
			Pepcid	C				
			Saw Palmetto (Serenoa Repens)	C				
			Zestril	C				
			Vitamins (Unspecified)	C				

			Zinc (Unspecified	C		

Date:06/22/01ISR Number: 3746610-6Report Type:Periodic Company Report #WAES 01010236
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research	
	Asthenia	Health			Laboratories Div	
	Exanthem	Professional			Merck Co Inc	ORAL
PO						
	Fatigue		Duragesic	C		
	Influenza Like Illness		Lortab	C		
	Nausea		Oxycontin	C		
	Pruritus		Robaxin	C		
	Upper Respiratory Tract Infection		Synthroid	C		

Date:06/22/01ISR Number: 3746611-8Report Type:Periodic Company Report #WAES 01034183
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746612-XReport Type:Periodic Company Report #WAES 01034185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746613-1Report Type:Periodic Company Report #WAES 01034207
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zoloft	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746614-3Report Type:Periodic Company Report #WAES 01010251
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
			Celebrex	C				

Date:06/22/01ISR Number: 3746615-5Report Type:Periodic Company Report #WAES 01010350
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Feeling Abnormal							
	Hypertrophy Breast							
	Muscular Weakness		Estrace	SS				
			Calcium	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3746616-7Report Type:Periodic Company Report #WAES 01033359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Mavik C
[Therapy
Unspecified] C

Date:06/22/01ISR Number: 3746617-9Report Type:Periodic Company Report #WAES 01033360
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Prevacid	C				

Date:06/22/01ISR Number: 3746618-0Report Type:Periodic Company Report #WAES 01033362
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746619-2Report Type:Periodic Company Report #WAES 00121109
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
		Health Professional	Fosamax	C				
			Maxzide	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3746620-9Report Type:Periodic Company Report #WAES 01033369
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Monopril	C				
			Alprazolam	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3746621-0Report Type:Periodic Company Report #WAES 01033372
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dermatitis Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				
			Isosorbide	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746622-2Report Type:Periodic Company Report #WAES 01033373
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Pruritus							
	Rash Erythematous							
			Clonopin	C				
			Lortab	C				
			Soma	C				
			Vistaril	C				
			Xanax	C				
			Zoloft	C				
			Aspirin	C				
			Ranitidine	C				

Date:06/22/01ISR Number: 3746623-4Report Type:Periodic Company Report #WAES 01033376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Lipitor	C				
			Moduretic	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/22/01ISR Number: 3746624-6Report Type:Periodic Company Report #WAES 01033381
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Pulmonary Congestion							
			Fosamax	C				

Nonsteroidal
Anti-Inflammatory C

Date:06/22/01ISR Number: 3746625-8Report Type:Periodic Company Report #WAES 01033384
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Fosamax	C				

Date:06/22/01ISR Number: 3746626-XReport Type:Periodic Company Report #WAES 01033385
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746627-1Report Type:Periodic Company Report #WAES 00121284
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	2 WK
	Oedema Peripheral Pharyngeal Oedema	Health Professional	Allegra	C				

Date:06/22/01ISR Number: 3746628-3Report Type:Periodic Company Report #WAES 00121481
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	PO	
			Celebrex	C				
			Naprosyn	C				

Date:06/22/01ISR Number: 3746629-5Report Type:Periodic Company Report #WAES 00121505
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/BID/PO	
	Oedema Peripheral	Health Professional	Prilosec	C				

Date:06/22/01ISR Number: 3746630-1Report Type:Periodic Company Report #WAES 00121883
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypervigilance	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

	Insomnia	Health Professional	Estrace	C
			Lipitor	C
			Prinivil	C

Date:06/22/01ISR Number: 3746631-3Report Type:Periodic Company Report #WAES 00121997
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50MG/DAILY/PO	
	Dyspnoea	Health Professional	Accupril	C				
			Norvasc	C				

Date:06/22/01ISR Number: 3746632-5Report Type:Periodic Company Report #WAES 00122010
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence	Health Professional	Calcium (Unspecified)	C				
			Vitmain E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746633-7Report Type:Periodic Company Report #WAES 00122105
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Constipation	Professional						
	Drug Ineffective		Tab Vioxx 25 Mg	SS		ORAL	50 MG/DAILY/PO	
	Dyspnoea							
	Eyelid Oedema		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Fatigue							
			Cozaar	C				
			Demadex	C				
			Levoxyl	C				
			Toprol Xl Tablets	C				
			Ultram	C				

Date:06/22/01ISR Number: 3746634-9Report Type:Periodic Company Report #WAES 00122216
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Feeling Abnormal	Health	Aldactazide	C				
	Oliguria	Professional	Cardizem	C				
			Lopressor	C				

Date:06/22/01ISR Number: 3746635-0Report Type:Periodic Company Report #WAES 00122271
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746636-2Report Type:Periodic Company Report #WAES 00111144
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Syncope							
			Mecamylamine Hydrochloride	C				

Date:06/22/01ISR Number: 3746637-4Report Type:Periodic Company Report #WAES 00111197
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Asthenia	Health Professional						
	Dyspepsia							
	Fatigue							
	Musculoskeletal Stiffness							

Date:06/22/01ISR Number: 3746638-6Report Type:Periodic Company Report #WAES 00112114
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Disability	Dizziness	Consumer
Other	Ear Disorder	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Corgard	C				
Detrol	C				
Lipitor	C				
Permax	C				
Doxepin	C				

Date:06/22/01ISR Number: 3746639-8Report Type:Periodic Company Report #WAES 00112368
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
			Hydrodiuril	C				
			Lotensin	C				
			Voltaren	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3746640-4Report Type:Periodic Company Report #WAES 00120016
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Hypertension Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Visual Disturbance
MG/DAILY/PO

Date:06/22/01ISR Number: 3746641-6Report Type:Periodic Company Report #WAES 00120262
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Pravachol	C				

Date:06/22/01ISR Number: 3746642-8Report Type:Periodic Company Report #WAES 00120488
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Back Pain Chills Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746643-XReport Type:Periodic Company Report #WAES 00120595
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Weight Increased							
			Synthroid	C				
			Vasotec	C				
			Zantac	C				

Date:06/22/01ISR Number: 3746644-1Report Type:Periodic Company Report #WAES 00120690
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness	Health						
	Feeling Abnormal	Professional						
	Haemoglobin Decreased	Company						
	Nausea	Representative	Darvocet-N	C				
			Relapen	C				
			Tylenol	C				

Date:06/22/01ISR Number: 3746645-3Report Type:Periodic Company Report #WAES 00120710
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS		ORAL	PO	
	Pruritus		Diabeta	C				
			Furosemide	C				

Date:06/22/01ISR Number: 3746650-7Report Type:Periodic Company Report #WAES 01033224
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coordination Abnormal Pruritus Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:06/22/01ISR Number: 3746652-0Report Type:Periodic Company Report #WAES 01033232
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sudafed	C				

Date:06/22/01ISR Number: 3746653-2Report Type:Periodic Company Report #WAES 01033236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Back Pain Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Levothroid	C		

Date:06/22/01ISR Number: 3746654-4Report Type:Periodic Company Report #WAES 01033337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746655-6Report Type:Periodic Company Report #WAES 01033344
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Caltrate	C				
			Zantac	C				
			[Therapy Unspecified]	C				
			Cyanocobalamin	C				

Date:06/22/01ISR Number: 3746656-8Report Type:Periodic Company Report #WAES 01033346
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendonitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746657-XReport Type:Periodic Company Report #WAES 01033347
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Faeces Discoloured							
	Gastric Haemorrhage							
			Pepcid	C				
			Chondroitin (+) Glucosamine	C				

Date:06/22/01ISR Number: 3746669-6Report Type:Periodic Company Report #WAES 01033351
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Constipation	Health Professional						
	Ear Disorder							
	Epistaxis							
	Upper Respiratory Tract Infection		Aciphex	C				
			Ambien	C				
			Avapro	C				
			Elavil	C				

Prilosec C

Date:06/22/01ISR Number: 3746670-2Report Type:Periodic Company Report #WAES 01033353
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746671-4Report Type:Periodic Company Report #WAES 01033357
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/01ISR Number: 3746672-6Report Type:Periodic Company Report #WAES 01033056
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746673-8Report Type:Periodic Company Report #WAES 01033058
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		ORAL PO
			Evista	C			
			Synthroid	C			

Date:06/22/01ISR Number: 3746674-XReport Type:Periodic Company Report #WAES 01033079
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Skin Disorder		Zocor	C				

Date:06/22/01ISR Number: 3746675-1Report Type:Periodic Company Report #WAES 01033081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/TID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746676-3Report Type:Periodic Company Report #WAES 01033082
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Premarin	C				

Date:06/22/01ISR Number: 3746677-5Report Type:Periodic Company Report #WAES 01033087
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Coumadin	C				
			Lipitor	C				
			Amiodarone	C				
			Cloanazepam	C				

Date:06/22/01ISR Number: 3746678-7Report Type:Periodic Company Report #WAES 01033091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746679-9Report Type:Periodic Company Report #WAES 01033094
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746680-5Report Type:Periodic Company Report #WAES 01033107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746681-7Report Type:Periodic Company Report #WAES 01033112
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	10 DAY
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746682-9Report Type:Periodic Company Report #WAES 01051670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/01ISR Number: 3746683-0Report Type:Periodic Company Report #WAES 01032904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746684-2Report Type:Periodic Company Report #WAES 01032910
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain Toothache Trigeminal Neuralgia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Naproxen	C				

Date:06/22/01ISR Number: 3746685-4Report Type:Periodic Company Report #WAES 01051672
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company			Merck Co Inc	ORAL
25						
		Representative				
MG/DAILY/PO						
			Advil	C		
			Xanax	C		

Date:06/22/01ISR Number: 3746686-6Report Type:Periodic Company Report #WAES 01032913
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Vioxx	PS	Merck Research	
	Influenza				Laboratories Div	
	Tachycardia				Merck Co Inc	ORAL
50						
MG/DAILY/PO						
			Prevacid	C		

Date:06/22/01ISR Number: 3746687-8Report Type:Periodic Company Report #WAES 01051677
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscular Weakness	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Lasix (Furosemide)	C		

			Univasc	C		

Date:06/22/01ISR Number: 3746688-XReport Type:Periodic Company Report #WAES 01032921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746689-1Report Type:Periodic Company Report #WAES 01032922
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Detrol	C				
			Lipitor	C				
			Norvasc	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3746690-8Report Type:Periodic Company Report #WAES 01051678
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Anorexia Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Fatigue		Verapamil	C				

Date:06/22/01ISR Number: 3746691-XReport Type:Periodic Company Report #WAES 01032924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Zocor	SS		ORAL	PO	
			Thyroid	C				

Date:06/22/01ISR Number: 3746692-1Report Type:Periodic Company Report #WAES 01033048
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Baycol	C				
			Glucophage	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746693-3Report Type:Periodic Company Report #WAES 01051681
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain							
	Sunburn							
			Hydrea	C				

Date:06/22/01ISR Number: 3746694-5Report Type:Periodic Company Report #WAES 01033051
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY
	Vomiting							
			Glucotrol Xl	C				
			Pravachol	C				
			Tenormin	C				

Date:06/22/01ISR Number: 3746695-7Report Type:Periodic Company Report #WAES 01051688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Nonsteroidal Anti-Inflammatory D	C				

Date:06/22/01ISR Number: 3746696-9Report Type:Periodic Company Report #WAES 01033052
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	
PO							
			Zocor	C			

Date:06/22/01ISR Number: 3746697-0Report Type:Periodic Company Report #WAES 01051692
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	
MG/DAILY/PO								
			Nasonex	C				
			Prempro	C				
			Acetaminophen (+) Codeine Phosph	C				
			Potassium (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746698-2Report Type:Periodic Company Report #WAES 01033054
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Eye Irritation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Lasix (Furosemide)	C				
			Potassium	C				

Date:06/22/01ISR Number: 3746699-4Report Type:Periodic Company Report #WAES 01051696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746700-8Report Type:Periodic Company Report #WAES 01032881
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Left Ventricular Failure Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Lopressor	C				
			Norvasc	C				
			Prilosec	C				
			Insulin	C				

Date:06/22/01ISR Number: 3746701-XReport Type:Periodic Company Report #WAES 01051733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Amitriptyline	C				
			Hydroxychloroquine Sulfate	C				

Date:06/22/01ISR Number: 3746702-1Report Type:Periodic Company Report #WAES 01032882
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746703-3Report Type:Periodic Company Report #WAES 01051734
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Respiratory Disorder Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Motrin	C				

Date:06/22/01ISR Number: 3746704-5Report Type:Periodic Company Report #WAES 01032883
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucotrol	C				

Date:06/22/01ISR Number: 3746705-7Report Type:Periodic Company Report #WAES 01032884
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Crixivan	C				
			Retrovir	C				

Date:06/22/01ISR Number: 3746707-0Report Type:Periodic Company Report #WAES 01032885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Lipitor	C		
			[Therapy Unspecified]	C		

Date:06/22/01ISR Number: 3746708-2Report Type:Periodic Company Report #WAES 01032888
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Cardizem	C		
			Cardura	C		
			Lotensin	C		
			Percodan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746710-0Report Type:Periodic Company Report #WAES 01032889
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ibuprofen	C				

Date:06/22/01ISR Number: 3746711-2Report Type:Periodic Company Report #WAES 01032890
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Mysoline	C				
			Prevacid	C				
			Restoril	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3746713-6Report Type:Periodic Company Report #WAES 01032893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Drug Dependence	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO ; 25 MG DAILY PO	

Date:06/22/01ISR Number: 3746714-8Report Type:Periodic Company Report #WAES 01032895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Aleve	C				
			Synthroid	C				
			Ibuprofen	C				

Date:06/22/01ISR Number: 3746716-1Report Type:Periodic Company Report #WAES 01032681
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Macrodantin	C				

Date:06/22/01ISR Number: 3746718-5Report Type:Periodic Company Report #WAES 01032690
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746720-3Report Type:Periodic Company Report #WAES 01032693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746721-5Report Type:Periodic Company Report #WAES 01032696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746722-7Report Type:Periodic Company Report #WAES 01032702
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Date:06/22/01ISR Number: 3746723-9Report Type:Periodic Company Report #WAES 01032822
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG QOD						
PO						
			Prilosec	C		
			Acetaminophen	C		

Date:06/22/01ISR Number: 3746724-0Report Type:Periodic Company Report #WAES 01032673
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemoptysis Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746725-2Report Type:Periodic Company Report #WAES 01032876
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hyzaar	C				
			Lipitor	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3746726-4Report Type:Periodic Company Report #WAES 01032877
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia Migraine	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG BID	PO 2 WK
			Micardis	C				
			Prempro	C				
			Synthroid	C				
			Visken	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746727-6Report Type:Periodic Company Report #WAES 01032880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746728-8Report Type:Periodic Company Report #WAES 01032642
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Osteo-Bi-Flex	C				

Date:06/22/01ISR Number: 3746729-XReport Type:Periodic Company Report #WAES 01032644
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Alphagan	C				
			Tylenol	C				
			Vicodin Tablets	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746730-6Report Type:Periodic Company Report #WAES 01032647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Mental Impairment Speech Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746731-8Report Type:Periodic Company Report #WAES 01032651
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Estrace	C				
			Maxizide	C				
			Neurontin	C				
			Synthroid	C				
			Potassium (Unspecified)	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3746732-XReport Type:Periodic Company Report #WAES 01032662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:06/22/01ISR Number: 3746733-1Report Type:Periodic Company Report #WAES 01032664
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Methotrexate (Methotrexate Sodium)	C				
			Zestril	C				
			Potassium Chloride	C				

Date:06/22/01ISR Number: 3746736-7Report Type:Periodic Company Report #WAES 01032666
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 MON
			Effexor	C				
			Risperdal	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746737-9Report Type:Periodic Company Report #WAES 01051633
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Glucophage	C				
			Theo Dur	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3746738-0Report Type:Periodic Company Report #WAES 01032671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort	Consumer	Vioxx	PS		ORAL	PO	
	Drug Ineffective		Lorazepam	C				
	Eye Disorder							
	Face Oedema							

Date:06/22/01ISR Number: 3746739-2Report Type:Periodic Company Report #WAES 01032674
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Flatulence							
	Lip Disorder							
	Mouth Ulceration							

Date:06/22/01ISR Number: 3746740-9Report Type:Periodic Company Report #WAES 01051634
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Humulin	C				
			K-Dur	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Digoxin	C				

Date:06/22/01ISR Number: 3746741-0Report Type:Periodic Company Report #WAES 01032676
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746742-2Report Type:Periodic Company Report #WAES 01051635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
OPHTHALMIC							50	
MG/DAILY/PO								

Date:06/22/01ISR Number: 3746743-4Report Type:Periodic Company Report #WAES 01051636
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
25MG/UNK/PO								
			Synthroid	C				

Date:06/22/01ISR Number: 3746744-6Report Type:Periodic Company Report #WAES 01051639
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
25MG/DAILY/PO								
			Celexa	C				
			Desyrel	C				
			Premarin	C				
			Proventil	C				
			Semprex	C				
			Vancenase	C				
			Xanax	C				
			(Therapy Unspecified)	C				

Date:06/22/01ISR Number: 3746745-8Report Type:Periodic Company Report #WAES 01051644
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/DAILY/PO	
	Nausea							
	Rectal Haemorrhage							
			Maalox	C				
			Prinivil	C				
			Alloopurinol	C				
			Lithium Citrate	C				
			Propentofylline	C				

Date:06/22/01ISR Number: 3746746-XReport Type:Periodic Company Report #WAES 01051648
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Micronase	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746747-1Report Type:Periodic Company Report #WAES 01051653
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746748-3Report Type:Periodic Company Report #WAES 01051654
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746749-5Report Type:Periodic Company Report #WAES 01051661
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Dry Throat Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Keratoconjunctivitis							
	Sicca		Guaifenex	C				
	Pharyngitis		Trimox	C				

Date:06/22/01ISR Number: 3746766-5Report Type:Periodic Company Report #WAES 01051585
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO
Sudafed C

Date:06/22/01ISR Number: 3746767-7Report Type:Periodic Company Report #WAES 01051593
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746768-9Report Type:Periodic Company Report #WAES 01032504
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746769-0Report Type:Periodic Company Report #WAES 01051595
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746770-7Report Type:Periodic Company Report #WAES 01032505
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pigmentation Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746771-9Report Type:Periodic Company Report #WAES 01051603
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Miacalcin	C				
			Lorazepam	C				

Date:06/22/01ISR Number: 3746772-0Report Type:Periodic Company Report #WAES 01032508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Vioxx	PS	Merck Research			

	Dry Skin	Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

25MG/DAILY/PO

Date:06/22/01ISR Number: 3746773-2Report Type:Periodic Company Report #WAES 01032548
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Face Oedema					
	Oedema Peripheral					
	Rash Erythematous					
			Glucovance	C		
			Niaspan	C		
			Plendil	C		

25

MG/DAILY/PO

Date:06/22/01ISR Number: 3746774-4Report Type:Periodic Company Report #WAES 01032572
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

				Celebrex	C		
				Plaquenil	C		

Date:06/22/01ISR Number: 3746775-6Report Type:Periodic Company Report #WAES 01032593
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/	PO
			Prempro	C				

Date:06/22/01ISR Number: 3746776-8Report Type:Periodic Company Report #WAES 01032603
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Insulin	C				

Date:06/22/01ISR Number: 3746777-XReport Type:Periodic Company Report #WAES 01032635
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746778-1Report Type:Periodic Company Report #WAES 01032638
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Weight Increased	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	

Date:06/22/01ISR Number: 3746779-3Report Type:Periodic Company Report #WAES 01051604
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	BID/PO	
			Prilosec	C				

Date:06/22/01ISR Number: 3746780-XReport Type:Periodic Company Report #WAES 01032640
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Paraesthesia Tongue Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

				Pepcid	C		
				Tegretol	C		

Date:06/22/01ISR Number: 3746781-1Report Type:Periodic Company Report #WAES 01051614
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746782-3Report Type:Periodic Company Report #WAES 01051616
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Centrum Silver	C				

Date:06/22/01ISR Number: 3746783-5Report Type:Periodic Company Report #WAES 01051622
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3746784-7Report Type:Periodic Company Report #WAES 01051630
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	

Date:06/22/01ISR Number: 3746785-9Report Type:Periodic Company Report #WAES 01051631
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Interaction Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Acetaminophen With Codeine	SS			UNKNOWN	Unk
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746786-0Report Type:Periodic Company Report #WAES 01032360
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardura	C				
			Hydrodiuril	C				
			Isosorbide	C				
			Temazepam	C				
			Triamterene	C				

Date:06/22/01ISR Number: 3746787-2Report Type:Periodic Company Report #WAES 01032363
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral		Zocor	C				

Date:06/22/01ISR Number: 3746791-4Report Type:Periodic Company Report #WES 01032392
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/01ISR Number: 3746792-6Report Type:Periodic Company Report #WAES 01051552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 DAY
			Lipitor	C				

Date:06/22/01ISR Number: 3746793-8Report Type:Periodic Company Report #WAES 01051555
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746794-XReport Type:Periodic Company Report #WAES 01051561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

		Avapro	C
		Fosamax	C
		Prempro	C

Date:06/22/01ISR Number: 3746795-1Report Type:Periodic Company Report #WAES 01051568
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Alphagan	C				
			Aricept	C				
			Ditropan Xl	C				
			Effexor Xr	C				
			Klor-Con	C				
			Lipitor	C				
			Toprol Xl Tablets	C				
			Trusopt	C				
			Furosemide	C				
			Prednisone	C				
			Ranitidine	C				

Date:06/22/01ISR Number: 3746796-3Report Type:Periodic Company Report #WAES 01051569
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Effexor Xr	C				
			Norvasc	C				
			Prevacid	C				
			Acetaminophen (+) Hydrocodone Bi	C				

			Hydrocortisone	C		

Date:06/22/01ISR Number: 3746797-5Report Type:Periodic Company Report #WAES 01051574
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Health Professional	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/PO						
			Detrol	C		
			Duradrin	C		
			Luvox	C		
			Premarin	C		
			Sonata	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746798-7Report Type:Periodic Company Report #WAES 01051575
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Asthenia							
	Dyspepsia							
	Fatigue							
	Nausea		Premarin	C				
			Provera	C				
			Verapamil Msd Lp	C				

Date:06/22/01ISR Number: 3746799-9Report Type:Periodic Company Report #WAES 01051576
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Sedation							
			Altace	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Humulin N	C				
			Tiazac	C				

Date:06/22/01ISR Number: 3746800-2Report Type:Periodic Company Report #WAES 01051577
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746801-4Report Type:Periodic Company Report #WAES 01051580
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestril	C				

Date:06/22/01ISR Number: 3746802-6Report Type:Periodic Company Report #WAES 01040504
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain Change Of Bowel Habit Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Halitosis		Allegra	C				
			Pravachol	C				
			Premarin	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3746803-8Report Type:Periodic Company Report #WAES 01040518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746804-XReport Type:Periodic Company Report #WAES 01040519
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Hydrodiuril	C				
			Albuterol	C				
			Alendronate Sodium	C				
			Beclomethasone Dipropionate	C				
			Fluticasone Propionate	C				
			Folic Acid	C				
			Ipratropium Bromide	C				
			Lansoprazole	C				
			Lovastatin	C				
			Sertraline	C				

Date:06/22/01ISR Number: 3746805-1Report Type:Periodic Company Report #WAES 01040530
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Cozaar	C		
			Mevacor	C		

Date:06/22/01ISR Number: 3746806-3Report Type:Periodic Company Report #WAES 01040532
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Diarrhoea	Health			Laboratories Div			
	Hyperhidrosis	Professional			Merck Co Inc	ORAL	12.5	
	Oedema Peripheral						MG/DAILY/PO	
			Avapro	C				
			Cardizem	C				
			Darvocet-N	C				

Date:06/22/01ISR Number: 3746807-5Report Type:Periodic Company Report #WAES 01040535
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline	Health	Vioxx	PS	Merck Research			
	Phosphatase Increased	Professional			Laboratories Div			
	Jaundice				Merck Co Inc	ORAL	PO	

			Celebrex	C

Date:06/22/01ISR Number: 3746808-7Report Type:Periodic Company Report #WAES 01040558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/01ISR Number: 3746809-9Report Type:Periodic Company Report #WAES 01040562
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746810-5Report Type:Periodic Company Report #WAES 01040573
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/PRN/PO	
			Aciphex	C				
			Celebrex	C				
			Claritin	C				
			Lupron	C				
			Prozac	C				
			Skelaxin	C				
			Tenormin	C				
			Ultram	C				
			Calcium (Unspecified)	C				

Vitamin E C

Date:06/22/01ISR Number: 3746811-7Report Type:Periodic Company Report #WAES 01040578
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Zantac	C				

Date:06/22/01ISR Number: 3746812-9Report Type:Periodic Company Report #WAES 01033149
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

		Fibercon	C
		Klonopin	C
		Zantac	C
		Calcium (Unspecified)	C
		Doxepin	C
		Hypericin	C
		Vitamins (Unspecified)	C

Date:06/22/01ISR Number: 3746813-0Report Type:Periodic Company Report #WAES 01033190
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celebrex	C				
			Lipitor	C				
			Prilosec	C				
			Tylenol	C				

Date:06/22/01ISR Number: 3746814-2Report Type:Periodic Company Report #WAES 01033191
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aldactone	C				
			Diazide	C				
			Micro K	C				
			Tenormin	C				

Date:06/22/01ISR Number: 3746815-4Report Type:Periodic Company Report #WAES 01033199
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Meridia	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3746816-6Report Type:Periodic Company Report #WAES 01033204
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3746817-8Report Type:Periodic Company Report #WAES 01033205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3746818-XReport Type:Periodic Company Report #WAES 01033213
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Steatosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin Unk	SS				
			Accupril	C				
			Acetexa	C				
			Maxzide	C				
			Synthroid	C				
			Tiazac	C				

Date:06/22/01ISR Number: 3746819-1Report Type:Periodic Company Report #WAES 01033216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3746820-8Report Type:Periodic Company Report #WAES 01033221
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 12.5 MG/DAILY/PO	
			Aciphex	C				
			Pravachol	C				

Date:06/22/01ISR Number: 3746821-XReport Type:Periodic Company Report #WAES 01033222
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO; 25	
			Effexor	C				
			Oxycontin	C				
			Prevacid	C				

		Synthroid	C
		Zanaflex	C
		Captopril	C
		Vitamin E	C

Date:06/22/01ISR Number: 3747363-8Report Type:Periodic Company Report #WAES 01042691
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747373-0Report Type:Periodic Company Report #WAES 01042692
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Confusional State Dizziness Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Glucophage	C				
			Lopid	C				
			Synthroid	C				
			Liithium Carbonate	C				

Date:06/22/01ISR Number: 3747380-8Report Type:Periodic Company Report #WAES01042697
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Calan Sr	C	
Viagra	C	

Date:06/22/01ISR Number: 3747384-5Report Type:Periodic Company Report #WAES 01042700
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 MON

Date:06/22/01ISR Number: 3747391-2Report Type:Periodic Company Report #WAES 01042701
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747407-3Report Type:Periodic Company Report #WAES 01042707
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine	C				

Date:06/22/01ISR Number: 3747411-5Report Type:Periodic Company Report #WAES 01042708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747418-8Report Type:Periodic Company Report #WAES 01042714
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Altace	C				
			Desogen	C				
			Synthroid	C				
			Zyrtec	C				

Date:06/22/01ISR Number: 3747424-3Report Type:Periodic Company Report #WAES 01042715
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Prevacid	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3747428-0Report Type:Periodic Company Report #WAES 01042757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/22/01ISR Number: 3747462-0Report Type:Periodic Company Report #WAES 01051522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
50MF/DAILY/PO

Date:06/22/01ISR Number: 3747464-4Report Type:Periodic Company Report #WAES 01051524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Tinnitus							

Date:06/22/01ISR Number: 3747469-3Report Type:Periodic Company Report #WAES 01051526
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Estrace	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3747475-9Report Type:Periodic Company Report #WAES 01051527
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Urticaria							
		Representative	Zyban	C				

Date:06/22/01ISR Number: 3747478-4Report Type:Periodic Company Report #WAES 01051531
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747482-6Report Type:Periodic Company Report #WAES 01051535
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	PO	

Date:06/22/01ISR Number: 3747485-1Report Type:Periodic Company Report #WAES 01051536
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	OCCLUSIVE DRESSING	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747487-5Report Type:Periodic Company Report #WAES 01051538
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				

Date:06/22/01ISR Number: 3747488-7Report Type:Periodic Company Report #WAES 01051547
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Emotional Disorder Nausea Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lithium Carbonate	C				

Date:06/22/01ISR Number: 3747490-5Report Type:Periodic Company Report #WAES 01051550
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Amiloride	C				

Date:06/22/01ISR Number: 3747496-6Report Type:Periodic Company Report #WAES 01042154
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			

		Health Professional			Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Desyrel	C		
			Premarin	C		
			Synthroid	C		
			Voltaren	C		
			Nutritional Supplement	C		
			Vitamins	C		

Date:06/22/01ISR Number: 3747500-5Report Type:Periodic Company Report #WAES 01042158
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Hypoaesthesia Paraesthesia				Merck Co Inc	ORAL
25						
MG/DAILLY/PO						
			Hydrodiuril	C		
			Premarin	C		
			Clonidine	C		
			Hydrocodone	C		
			Labetalol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747504-2Report Type:Periodic Company Report #WAES 01042160
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Zestorectic	C				

Date:06/22/01ISR Number: 3747507-8Report Type:Periodic Company Report #WAES 01042161
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	

Date:06/22/01ISR Number: 3747510-8Report Type:Periodic Company Report #WAES 01042163
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG/DAILY/PO	
			Prozac	C				

Date:06/22/01ISR Number: 3747514-5Report Type:Periodic Company Report #WAES 01042165
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy Facial Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50, 25 MG/DAILY/PO	
			Ortho-Tri-Cyclen	C				
			Calcium	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3747521-2Report Type:Periodic Company Report #WAES 01042166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5MG/DAILY/ PO	
			Vitamins	C				

Date:06/22/01ISR Number: 3747525-XReport Type:Periodic Company Report #WAES 01042168
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Claritin C
Lipitor C

Date:06/22/01ISR Number: 3747527-3Report Type:Periodic Company Report #WAES 01042170
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus Non-Insulin-Dependent	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claratin	C				
			Coumadin	C				
			Glucovance	C				
			Lanoxin	C				
			Zestril	C				
			Zocor	C				
			Atenolol	C				
			Gemfibrozil	C				
			Nitroglycerin	C				

Date:06/22/01ISR Number: 3747533-9Report Type:Periodic Company Report #WAES 01042172
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Depression Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

Date:06/22/01ISR Number: 3747541-8Report Type:Periodic Company Report #WAES 01021844
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Rhinorrhoea Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/PO	
			Tylenol	C				

Date:06/22/01ISR Number: 3747546-7Report Type:Periodic Company Report #WAES 01021848
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3747551-0Report Type:Periodic Company Report #WAES 01021853
Age:76 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Decreased
	Chest Pain

	Dyspnoea Oedema Peripheral Palpitations	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Ativan	C			
			Avapro	C			
			Colace	C			
			Lalsix	C			
			Osteo-Bi-Flex	C			
			Synthroid	C			
			Ascrbic Acid	C			
			Aspirin	C			
			Calcium (Unspecified)	C			
			Glucosamine	C			
			Minerals	C			
			Potassium	C			
			Verapamil	C			
			Vitamin B Complex	C			
			Vitamin E	C			
			Vitamins	C			

Date:06/22/01ISR Number: 3747554-6Report Type:Periodic Company Report #WAES 01021854
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Appetite Disorder	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO
	Nausea						
			Hytrin	C			

Date:06/22/01ISR Number: 3747557-1Report Type:Periodic Company Report #WAES 01021867
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Red Blood Cell Count	Health	Vioxx	PS		ORAL	PO	
	Decreased	Professional	Loestrin	C				
			Sulfacet-R	C				

Date:06/22/01ISR Number: 3747562-5Report Type:Periodic Company Report #WAES 01021889
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS		ORAL	PO	
			Cap Prometrium	SS		ORAL	100 MG/DAILY/PO	
			Cap Prometrium	SS		ORAL	100MG/QOD/PO	
			Premarin	C				
			Calcium	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747567-4Report Type:Periodic Company Report #WAES 01021921
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS		ORAL	25 MG	DIALY/PO
	Diarrhoea		Detrol	C				
			Prevacid	C				
			Tiazac	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3747569-8Report Type:Periodic Company Report #WAES 01021922
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747571-6Report Type:Periodic Company Report #WAES 01021932
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS		ORAL	25	
	Hiccups						MG/DAILY/PO	
			Cortisone (Cortisone Acetate)	C				
			Lipitor	C				
			Motrin	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3747574-1Report Type:Periodic Company Report #WAES 01021937
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	6 WK
		Company Representative	Synthroid	C				
			Bucolome	C				

Date:06/22/01ISR Number: 3747583-2Report Type:Periodic Company Report #WAES 01021757
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Advil	C				

Date:06/22/01ISR Number: 3747585-6Report Type:Periodic Company Report #WAES 01021761
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inappropriate Antidiuretic Hormone Secretion	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

				Aciphex	C		
				Feosol	C		

Date:06/22/01ISR Number: 3747589-3Report Type:Periodic Company Report #WAES 01021764
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
	Dyspepsia							
	Insomnia		Flexeril	C				
			Synthroid	C				
			Tylenol	C				

Date:06/22/01ISR Number: 3747591-1Report Type:Periodic Company Report #WAES 01021767
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Vicodin Tablets	C				

Date:06/22/01ISR Number: 3747594-7Report Type:Periodic Company Report #WAES 01021770
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotrel	C				
			Aspirin	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3747597-2Report Type:Periodic Company Report #WAES 01021771
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Oedema Peripheral	Health Professional			Merck Co Inc	ORAL	PO	
			Acupril	C				
			Lipitor	C				
			Provera	C				
			Estradiol	C				
			Naproxen	C				

Date:06/22/01ISR Number: 3747598-4Report Type:Periodic Company Report #WAES 01021772
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/PO	

		Dimethyl Sulfone	C
		Vitamins Unspecified	C

Date:06/22/01ISR Number: 3747603-5Report Type:Periodic Company Report #WAES 01021774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747607-2Report Type:Periodic Company Report #WAES 01021831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematocrit Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747612-6Report Type:Periodic Company Report #WAES 01021836
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:06/22/01ISR Number: 3747631-XReport Type:Periodic Company Report #WAES 01021716
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dyspnoea							
	Fatigue							
	Insomnia							
	Swelling		Ativan	C				
			Levothroid	C				

Date:06/22/01ISR Number: 3747640-0Report Type:Periodic Company Report #WAES 01021718
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747643-6Report Type:Periodic Company Report #WAES 01021719
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lopid	C				
			Prizide	C				
			Vasotec	C				
			Glyburide	C				

Date:06/22/01ISR Number: 3747647-3Report Type:Periodic Company Report #WAES 01021727
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Vision Blurred	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Maxzide	C				
			Percocet	C				
			Plendil	C				
			Valium	C				

Date:06/22/01ISR Number: 3747651-5Report Type:Periodic Company Report #WAES 01021734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Centrum Silver	C				
			Lotensin	C				

		Premarin	C
		Zestoretic	C
		Aspirin	C
		Vitamin E	C

Date:06/22/01ISR Number: 3747656-4Report Type:Periodic Company Report #WAES 01021735
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3747663-1Report Type:Periodic Company Report #WAES 01021737
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Fatigue							
	Pruritus							
	Urine Abnormality		Synthroid	C				

			Calcium (Unspecified)	C		
			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3747666-7Report Type:Periodic Company Report #WAES 01021745
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria Vaginal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Celebrex	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3747669-2Report Type:Periodic Company Report #WAES 01021748
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glyburide	C				

Date:06/22/01ISR Number: 3747676-XReport Type:Periodic Company Report #WAES 01030340
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747680-1Report Type:Periodic Company Report #WAES 01030341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Paxil	C				
			Tylenol Pm	C				

Date:06/22/01ISR Number: 3747683-7Report Type:Periodic Company Report #WAES 01030342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Motrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747686-2Report Type:Periodic Company Report #WAES 01030343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747690-4Report Type:Periodic Company Report #WAES 01030344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747691-6Report Type:Periodic Company Report #WAES 01030345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747694-1Report Type:Periodic Company Report #WAES 01030346
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN PO	

Date:06/22/01ISR Number: 3747696-5Report Type:Periodic Company Report #WAES 01030347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:06/22/01ISR Number: 3747697-7Report Type:Periodic Company Report #WAES 01030348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747699-0Report Type:Periodic Company Report #WAES 01030350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Gastrointestinal Disorder Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
			Arthrotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747714-4Report Type:Periodic Company Report #WAES 01022050
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS		ORAL	25	
	Oral Pain	Health					MG/DAILY/PO	
		Professional	Arthrotec	C				
			Celebrex	C				

Date:06/22/01ISR Number: 3747716-8Report Type:Periodic Company Report #WAES 01022057
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Estrace	C				
			Flexeril	C				
			Flonase	C				
			Neurontin	C				
			Ultram	C				
			Zyrtec	C				

Date:06/22/01ISR Number: 3747718-1Report Type:Periodic Company Report #WAES 01022060
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS		ORAL	25	
	Bronchitis						MG/DAILY/PO	
	Diarrhoea		Avapro	C				
	Dyspepsia		Diazide	C				
	Nausea							
	Tenderness							
	Urinary Tract Infection							

Date:06/22/01ISR Number: 3747720-XReport Type:Periodic Company Report #WAES 01022064
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/22/01ISR Number: 3747722-3Report Type:Periodic Company Report #WAES 01022065
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3747724-7Report Type:Periodic Company Report #WAES 01022068
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/22/01ISR Number: 3747727-2Report Type:Periodic Company Report #WAES 01022069
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3747728-4Report Type:Periodic Company Report #WAES 01022070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Nasal Congestion		Diuretic (Unspecified)	C				
	Skin Disorder		Estradiol	C				

Date:06/22/01ISR Number: 3747733-8Report Type:Periodic Company Report #WAES 01022076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malnutrition	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Metabolic Disorder							

Date:06/22/01ISR Number: 3747737-5Report Type:Periodic Company Report #WAES 01022077
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
	Blood Pressure Increased	Health	Cozaar	C		
	Fatigue	Professional				
	Feeling Abnormal					
	Tachycardia					

Date:06/22/01ISR Number: 3747741-7Report Type:Periodic Company Report #WAES 01021943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Timoptic-Xe	C		

Date:06/22/01ISR Number: 3747744-2Report Type:Periodic Company Report #WAES 01021960
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Blood Urea Increased					
25 MG DAILY						
PO						
			Ultram	C		

Date:06/22/01ISR Number: 3747747-8Report Type:Periodic Company Report #WAES 01021965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Exfoliation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747750-8Report Type:Periodic Company Report #WAES 01021972
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747753-3Report Type:Periodic Company Report #WAES 01021982
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperbilirubinaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Xanax	C				

Date:06/22/01ISR Number: 3747756-9Report Type:Periodic Company Report #WAES 01022005
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:06/22/01ISR Number: 3747758-2Report Type:Periodic Company Report #WAES 01022017
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/01ISR Number: 3747763-6Report Type:Periodic Company Report #WAES 01022018
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Vancenase Aq	C				
			Captopril (+) Hydrochlorothiazid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747765-XReport Type:Periodic Company Report #WAES 01022021
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrooesophageal Reflux Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Flovent	C				
			K-Dur	C				
			Plavix	C				
			Prilosec	C				
			Singulair	C				
			Folic Acid	C				
			Indapamide	C				
			Temazepam	C				

Date:06/22/01ISR Number: 3747768-5Report Type:Periodic Company Report #WAES 01022049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747771-5Report Type:Periodic Company Report #WAES 01022082
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lozol	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3747773-9Report Type:Periodic Company Report #WAES 01022084
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO 4 DAY						

Date:06/22/01ISR Number: 3747774-0Report Type:Periodic Company Report #WAES 01022085
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscle Spasms	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Aldomet (Methyldopa)	C		
			Hydrodiuril	C		
			Pravachol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747775-2Report Type:Periodic Company Report #WAES 01022091
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperbilirubinaemia Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3747776-4Report Type:Periodic Company Report #WAES 01022099
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dizziness Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prozac	C				
			Trazodone	C				

Date:06/22/01ISR Number: 3747777-6Report Type:Periodic Company Report #WAES 01022100
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3747778-8Report Type:Periodic Company Report #WAES 01022104
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nasal Congestion							
	Respiratory Disorder							
			Aleve	C				
			Zocor	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Garlic Extract	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3747779-XReport Type:Periodic Company Report #WAES 01022106
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				

			[Therapy Unspecified]	C		
			Atenolol	C		

Date:06/22/01ISR Number: 3747780-6Report Type:Periodic Company Report #WAES 01022109
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3747781-8Report Type:Periodic Company Report #WAES 01022114
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 WK
			Atarax	C				
			Tenormin	C				
			Voltaren	C				
			Zyrtec	C				

Date:06/22/01ISR Number: 3747782-XReport Type:Periodic Company Report #WAES 01022116
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Cardiac Failure Congestive Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Lasix	C
Parafon Forte	C
Vasotec	C
Xanax	C
Potassium (Unspecified)	C

Date:06/22/01ISR Number: 3747783-1Report Type:Periodic Company Report #WAES 01022122
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	

Date:06/22/01ISR Number: 3747785-5Report Type:Periodic Company Report #WAES 01022149
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Colitis Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Claritin-D	C
Hyzaar	C
Patanol	C
Premarin	C

Date:06/22/01ISR Number: 3747786-7Report Type:Periodic Company Report #WAES 01022156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747787-9Report Type:Periodic Company Report #WAES 01022160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Asthenia Fatigue Headache Musculoskeletal Stiffness Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/01ISR Number: 3747789-2Report Type:Periodic Company Report #WAES 01022163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25MG/DAILY/PO	

Date:06/22/01ISR Number: 3747793-4Report Type:Periodic Company Report #WAES 01022165
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG; 50 MG/DAILY/PO	
			Aciphex	C				
			Carmol Hc	C				
			Glucotrol Xl	C				
			Macrodantin	C				
			Premarin	C				
			Acetaminophen	C				
			Albuterol Sulfate	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747796-XReport Type:Periodic Company Report #WAES 01022167
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estratest H.S.	C				
			Premarin	C				
			Prilosec	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3747802-2Report Type:Periodic Company Report #WAES 01022169
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Buspar	C				
			Fosamax	C				
			Premarin	C				

Date:06/22/01ISR Number: 3747809-5Report Type:Periodic Company Report #WAES 01022176
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/01ISR Number: 3747814-9Report Type:Periodic Company Report #WAES 01022177
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Throat Tightness							
	Urinary Retention				Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747818-6Report Type:Periodic Company Report #WAES 01022178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Vioxx	PS	Merck Research Laboratories Div			
	Fatigue							
	Retching				Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tums	C				

Date:06/22/01ISR Number: 3747822-8Report Type:Periodic Company Report #WAES 01022179
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Pain	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Claritin	C				
Detrol	C				
Zocor	C				
Estrogens, Conjugated (+)					
Proges	C				

Date:06/22/01ISR Number: 3747826-5Report Type:Periodic Company Report #WAES 01022181
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue	Health						
	Sedation	Professional						
	Urticaria							
			Claritin	C				
			Propranolol	C				

Date:06/22/01ISR Number: 3747827-7Report Type:Periodic Company Report #WAES 01022186
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG /DAILY / PO	2 WK
			Tenormin	C				

Date:06/22/01ISR Number: 3747829-0Report Type:Periodic Company Report #WAES 01022190
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Pain	Consumer	Vioxx	PS	Merck Research	
	Insomnia	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
SEE IMAGE						
			Atroven	C		
			Metrogel	C		
			Prempro	C		
			Provera	C		
			[Therapy Unspecified]	C		
			Estrogens [Unspecified]	C		

Date:06/22/01ISR Number: 3747831-9Report Type:Periodic Company Report #WAES 01022191
Age:50 YR Gender:Female I/FU:I

Outcome	PT
	Alanine Aminotransferase Increased
	Aspartate

	Aminotransferase Increased Gamma-Glutamyltransferase Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hepatic Steatosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/01ISR Number: 3747834-4Report Type:Periodic Company Report #WAES 01022195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
			Azulfidine [Therapy Unspecified]	C C			

Date:06/22/01ISR Number: 3747835-6Report Type:Periodic Company Report #WAES 01022197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO

Date:06/22/01ISR Number: 3747836-8Report Type:Periodic Company Report #WAES 01022201
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Accupril	C		
			Evista	C		
			Fosamax	C		
			Lipitor	C		
			Ziac	C		

Date:06/22/01ISR Number: 3747837-XReport Type:Periodic Company Report #WAES 01022209
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Norvasc	C		
			Toprol Xl Tablets	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3747838-1Report Type:Periodic Company Report #WAES 01022224
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cyclobenzaprine Hydrochloride	C				

Date:06/22/01ISR Number: 3747839-3Report Type:Periodic Company Report #WAES 01022226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3747841-1Report Type:Periodic Company Report #WAES 01022227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNK	
		Company Representative	Prilosec	SS			UNK	

Date:06/22/01ISR Number: 3747843-5Report Type:Periodic Company Report #WAES 01022229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747845-9Report Type:Periodic Company Report #WAES 01022230
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3747846-0Report Type:Periodic Company Report #WAES 01022258
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY/ PO	

			Tab Aleve	SS		ORAL
2						
TABLET/DAILY/						
PO						
			Saw Palmetto (Papain)	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3747848-4Report Type:Periodic Company Report #WAES 01022264
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscular Weakness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Cozaar	C		

Date:06/22/01ISR Number: 3747858-7Report Type:Periodic Company Report #WAES 01022277
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Hypertension					
25 MG/PRN/PO						
			Accupril	C		
			Hydrodiuril	C		
			Levoxyl	C		
			Premarin	C		
			Calcium (Unspecified)	C		
			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3747859-9Report Type:Periodic Company Report #WAES 01022287
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748155-6Report Type:Periodic Company Report #WAES 01022289
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Disorder Micturition Disorder Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748176-3Report Type:Periodic Company Report #WAES 01030008
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			[Therapy Unspecified]	C				
			Tamoxifen	C				

Date:06/22/01ISR Number: 3748178-7Report Type:Periodic Company Report #WAES 01030011
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Armour Thyroid Tablets	C				

Date:06/22/01ISR Number: 3748179-9Report Type:Periodic Company Report #WAES 01030012
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Radiation Skin Injury	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748182-9Report Type:Periodic Company Report #WAES 01030013
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748184-2Report Type:Periodic Company Report #WAES 01030019
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol	C				

Date:06/22/01ISR Number: 3748187-8Report Type:Periodic Company Report #WAES 01030028
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Altace	C
			Amaryl	C
			Avandia	C
			Darvocet-N	C
			Daypro	C
			Glucophage	C
			Prempro	C
			Procardia Xl	C
			Zyrtec	C
			Diclofenac	C

Date:06/22/01ISR Number: 3748189-1Report Type:Periodic Company Report #WAES 01030031
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Altace	C				
			Amaryl	C				
			Avandia	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Glucophage	C				
			Prempro	C				
			Zyrtec	C				
			Amitriptyline Hydrochloride	C				
			Aspirin	C				
			Niacin	C				

Date:06/22/01ISR Number: 3748190-8Report Type:Periodic Company Report #WAES 01030036
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Advil	C	
Coumadin	C	

Date:06/22/01ISR Number: 3748191-XReport Type:Periodic Company Report #WAES 01030040
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748192-1Report Type:Periodic Company Report #WAES 01030042
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Artacand	C
Cartia	C
Duradrin	C
Senokot (Senna)	C
Calcium (Unspecified)	C
Lorazepam	C
Methadone Hydrochloride	C
Oxygen	C

Date:06/22/01ISR Number: 3748195-7Report Type:Periodic Company Report #WAES 01030043
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748197-0Report Type:Periodic Company Report #WAES 01030046
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748198-2Report Type:Periodic Company Report #WAES 01030047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

				Potassium (Unspecified)	SS		

Date:06/22/01ISR Number: 3748201-XReport Type:Periodic Company Report #WAES 01030056
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Swelling Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

				Lorazepam	C		
				Methocarbamol	C		

Date:06/22/01ISR Number: 3748205-7Report Type:Periodic Company Report #WAES 01030064
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

	Pravachol	C	
	Prevacid	C	
	Atenolol	C	

Date:06/22/01ISR Number: 3748206-9Report Type:Periodic Company Report #WAES 01030077
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Zocor	C				

Date:06/22/01ISR Number: 3748209-4Report Type:Periodic Company Report #WAES 01030085
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	
			Atrovent	C				
			Premarin	C				
			Prevacid	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3748213-6Report Type:Periodic Company Report #WAES 01030091
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Atenolol	C
Levothyroxine	C
Nonsteroidal Anti-Inflammatory	C

Date:06/22/01ISR Number: 3748217-3Report Type:Periodic Company Report #WAES 01030113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY
	Arthralgia							
	Movement Disorder							
	Muscular Weakness		Tylenol	C				

Date:06/22/01ISR Number: 3748219-7Report Type:Periodic Company Report #WAES 01030130
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/01ISR Number: 3748221-5Report Type:Periodic Company Report #WAES 01030132
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1/2 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748224-0Report Type:Periodic Company Report #WAES 01030134
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myositis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	1 WK

Date:06/22/01ISR Number: 3748226-4Report Type:Periodic Company Report #WAES 01030135
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lozol	C				

Date:06/22/01ISR Number: 3748228-8Report Type:Periodic Company Report #WAES 01030142
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Influenza Like Illness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lanoxin	C				

Date:06/22/01ISR Number: 3748229-XReport Type:Periodic Company Report #WAES 01030144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:06/22/01ISR Number: 3748230-6Report Type:Periodic Company Report #WAES 01030155
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25	

MG/DAILY/PO 3 WK

Date:06/22/01ISR Number: 3748231-8Report Type:Periodic Company Report #WAES 01030157
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth Dyspnoea Insomnia Keratoconjunctivitis Sicca Thirst Vision Blurred Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	3 DAY

Date:06/22/01ISR Number: 3748233-1Report Type:Periodic Company Report #WAES 01030158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Anxiety	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Company Representative	(Therapy Unspecified)	C				

Date:06/22/01ISR Number: 3748236-7Report Type:Periodic Company Report #WAES 01030191
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3748238-0Report Type:Periodic Company Report #WAES 01030199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Vioxx	PS	Merck Research			
	Arthralgia	Professional			Laboratories Div			
	Depression	Company			Merck Co Inc	ORAL	PO	
	Emotional Disorder	Representative						

Date:06/22/01ISR Number: 3748239-2Report Type:Periodic Company Report #WAES 01030201
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Engorgement	Health	Vioxx	PS	Merck Research			
	Breast Pain	Professional			Laboratories Div			
					Merck Co Inc	ORAL	50	MG/DAILY/PO
			Estratest	C				
			Premarin	C				
			Provera	C				
			Timoptic	C				
			Trilisate Tablets/Liquid	C				

			Zantac	C		

Date:06/22/01ISR Number: 3748240-9Report Type:Periodic Company Report #WAES 01030240
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lortab	C				
			Oxycontin	C				
			Percocet	C				
			Relafen	C				

Date:06/22/01ISR Number: 3748257-4Report Type:Periodic Company Report #WAES 01030241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748260-4Report Type:Periodic Company Report #WAES 01030242
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Relafen	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3748262-8Report Type:Periodic Company Report #WAES 01030250
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Headache		Synthroid	C				

Date:06/22/01ISR Number: 3748264-1Report Type:Periodic Company Report #WAES 01030258
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Claritin	C				
			Prevacid	C				

Date:06/22/01ISR Number: 3748266-5Report Type:Periodic Company Report #WAES 01030260
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Evista	C		
			Calcium (Unspecified)	C		
			Vitamin E	C		

Date:06/22/01ISR Number: 3748267-7Report Type:Periodic Company Report #WAES 01030266
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calan Sr	C				
			Celebrex	C				
			[Therapy Unspecified]	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3748268-9Report Type:Periodic Company Report #WAES 01030269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748271-9Report Type:Periodic Company Report #WAES 01030271
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Estrace	C	
Lasix (Furosemide)	C	
Os-Cal	C	
Ascorbic Acid	C	
Potassium (Unspecified)	C	

Date:06/22/01ISR Number: 3748272-0Report Type:Periodic Company Report #WAES 01030276
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

UNK/UNK/PO

Abien	C	
Ecotrin	C	
Equate	C	
Glucophage	C	
Glucotrol Xl	C	
Lipitor	C	
Mavik	C	
Metoprolol	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748275-6Report Type:Periodic Company Report #WAES 01030281
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Dyspepsia	Health Professional						
	Insomnia							
			Ridaura	C				
			Xanax	C				

Date:06/22/01ISR Number: 3748276-8Report Type:Periodic Company Report #WAES 01030297
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
	Epistaxis							
	Pain In Extremity							
	Sinusitis		Claritin	C				
	Upper Respiratory Tract Infection		Insulatard Humana	C				
			K-Phos Neutral	C				
			Keflex	C				
			Relafen	C				

Date:06/22/01ISR Number: 3748279-3Report Type:Periodic Company Report #WAES 01030301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748280-XReport Type:Periodic Company Report #WAES 01030307
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748282-3Report Type:Periodic Company Report #WAES 01030335
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Lodine	C				

Date:06/22/01ISR Number: 3748283-5Report Type:Periodic Company Report #WAES 01030337
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		UNK/UNK/PO	

Date:06/22/01ISR Number: 3748285-9Report Type:Periodic Company Report #WAES 01030338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/BID/PO	

Date:06/22/01ISR Number: 3748286-0Report Type:Periodic Company Report #WAES 01030339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748287-2Report Type:Periodic Company Report #WAES 01030357
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiovascular Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748289-6Report Type:Periodic Company Report #WAES 01030359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748290-2Report Type:Periodic Company Report #WAES 01030413
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
	Fatigue							
	Muscular Weakness							
			Lipitor	C				
			Amiloride Hydrochloride	C				

Date:06/22/01ISR Number: 3748291-4Report Type:Periodic Company Report #WAES 01030425
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/BID/PO/SEE IMAGE
			Coumadin	C				5 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748293-8Report Type:Periodic Company Report #WAES 01030426
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:06/22/01ISR Number: 3748296-3Report Type:Periodic Company Report #WAES 01030433
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748298-7Report Type:Periodic Company Report #WAES 01030436
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Cardizem	C				
			Monopril	C				
			Synthroid	C				
			Zantac	C				
			Zocor	C				

Date:06/22/01ISR Number: 3748301-4Report Type:Periodic Company Report #WAES 01030438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Hypersensitivity Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO/S	EE IMAGE

Date:06/22/01ISR Number: 3748303-8Report Type:Periodic Company Report #WAES 01030440
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO/S	EE IMAGE

Date:06/22/01ISR Number: 3748306-3Report Type:Periodic Company Report #WAES 01030464
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Joint Stiffness	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/01ISR Number: 3748307-5Report Type:Periodic Company Report #WAES 01030466
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Calcium Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Therapy Unspecified	C		

Date:06/22/01ISR Number: 3748309-9Report Type:Periodic Company Report #WAES 01030467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Arrhythmia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO		Company Representative				

Date:06/22/01ISR Number: 3748310-5Report Type:Periodic Company Report #WAES 01030469
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/						

PO

		Dexedrine	C	
		Tylenol	C	

Date:06/22/01ISR Number: 3748311-7Report Type:Periodic Company Report #WAES 01030471
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Cardizem Cd	C		
			Colestid	C		
			Diovan	C		
			Glucophage	C		
			Glucotrol Xl	C		
			Imdur	C		
			Lipitor	C		
			Zantac	C		
			Aspirin	C		
			Hydrochlorothiazide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748312-9Report Type:Periodic Company Report #WAES 01030484
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Celebrex	C				
			Evista	C				
			Lipitor	C				

Date:06/22/01ISR Number: 3748316-6Report Type:Periodic Company Report #WAES 01030488
Age:72 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Prempro	C				
			Singulair	C				

Date:06/22/01ISR Number: 3748319-1Report Type:Periodic Company Report #WAES 01030507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Drug Interaction Fatigue	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hypoglycaemia		Humulin 30/70	SS				
			Glucotrol Xl	C				

			Toprol Xl	C		
			Zocor	C		

Date:06/22/01ISR Number: 3748322-1Report Type:Periodic Company Report #WAES 01030508
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zoloft	C				

Date:06/22/01ISR Number: 3748326-9Report Type:Periodic Company Report #WAES 01030522
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748329-4Report Type:Periodic Company Report #WAES 01030523
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Change Of Bowel Habit							
	Dizziness							
	Nausea							
			Buspar	C				
			Maxzide	C				
			Monopril	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3748333-6Report Type:Periodic Company Report #WAES 01030527
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748335-XReport Type:Periodic Company Report #WAES 01030529
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3748337-3Report Type:Periodic Company Report #WAES 01030533
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Ziac	C				

Date:06/22/01ISR Number: 3748340-3Report Type:Periodic Company Report #WAES 01030554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Flatulence Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Nonsteroidal Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748341-5Report Type:Periodic Company Report #WAES 01030559
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/UNK/PO	
			Imitrex	C				

Date:06/22/01ISR Number: 3748345-2Report Type:Periodic Company Report #WAES 01030562
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:06/22/01ISR Number: 3748348-8Report Type:Periodic Company Report #WAES 01030567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Toxicologic Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748350-6Report Type:Periodic Company Report #WAES 01030614
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/01ISR Number: 3748351-8Report Type:Periodic Company Report #WAES 01030615
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748353-1Report Type:Periodic Company Report #WAES 01030618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748361-0Report Type:Periodic Company Report #WAES 01030629
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			Celebrex	C				
			Zoloft	C				
			Atenolol	C				
			Fish Oil (Unspecified)	C				
			Omega-3 Marine Triglycerides	C				

Date:06/22/01ISR Number: 3748364-6Report Type:Periodic Company Report #WAES 01030635
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Constipation							
	Hypoglycaemia							
	Nervousness							
	Tremor		Humulin Nph	C				
			Hydrodiuril	C				
			Premarin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3748367-1Report Type:Periodic Company Report #WAES 01030767
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Claritin-D C
Paxil C
Wellbutrin C

Date:06/22/01ISR Number: 3748371-3Report Type:Periodic Company Report #WAES 01030779
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG; 25MG	
			Zantac	C			PO	

Date:06/22/01ISR Number: 3748375-0Report Type:Periodic Company Report #WAES 01030783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748379-8Report Type:Periodic Company Report #WAES 01030784
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Altace	C				
			Glucophage	C				

Date:06/22/01ISR Number: 3748381-6Report Type:Periodic Company Report #WAES 01030786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748382-8Report Type:Periodic Company Report #WAES 01030788
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Hytrin	C				
			Prevacid	C				

Date:06/22/01ISR Number: 3748384-1Report Type:Periodic Company Report #WAES 01030789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG, 50MG/DAILY/PO	
			[Composition Unspecified]	C				
			Ascorbic Acid	C				
			Glucosamine	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3748386-5Report Type:Periodic Company Report #WAES 01030792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748391-9Report Type:Periodic Company Report #WAES 01030803
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dizziness							
	Fatigue							
	Hepatic Function Abnormal							
	Memory Impairment		Minocycline	C				
	Skin Disorder							

Date:06/22/01ISR Number: 3748394-4Report Type:Periodic Company Report #WAES 01030814
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Mevacor	C				
			[Composition Unspecified]	C				

Date:06/22/01ISR Number: 3748395-6Report Type:Periodic Company Report #WAES 01030830
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nervousness							
			Advil	C				
			Celebrex	C				
			[Therapy Unspecified]	C				
			Nonsteroidal					

Anti-Inflammatory C

Date:06/22/01ISR Number: 3748397-XReport Type:Periodic Company Report #WAES 01030839
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748399-3Report Type:Periodic Company Report #WAES 01030840
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748401-9Report Type:Periodic Company Report #WAES 01030843
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Laboratory Test Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	SS				

Date:06/22/01ISR Number: 3748403-2Report Type:Periodic Company Report #WAES 01030844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748405-6Report Type:Periodic Company Report #WAES 01030859
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Interaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan Hct 12.5/80 Mg	SS		ORAL	12.5/80 MG/DAILY/PO	
			Fosamax	C				
			Tenormin	C				
			Zocor	C				

Date:06/22/01ISR Number: 3748409-3Report Type:Periodic Company Report #WAES 01030889
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Composition Unspecified]	C				

Date:06/22/01ISR Number: 3748411-1Report Type:Periodic Company Report #WAES 01030903
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Adalat	C				
			Hydrodiuril	C				
			Calcium	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748414-7Report Type:Periodic Company Report #WAES 01030905
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3748416-0Report Type:Periodic Company Report #WAES 01030906
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3748419-6Report Type:Periodic Company Report #WAES 01030916
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Celebrex	C				
			Miacalcin	C				
			Premarin	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3748422-6Report Type:Periodic Company Report #WAES 01030921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fiorinal	C				

Date:06/22/01ISR Number: 3748424-XReport Type:Periodic Company Report #WAES 01030961
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Brachial Plexus Lesion Headache Influenza Like Illness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Celexa	C				
			Centrum	C				
			Vitamin B50	C				
			Zithromax Z-Pak	C				
			Acetaminophen (+)					

Hydrocodone Bi	C
Amantadine	C
Ascorbic Acid	C
Bovine Colostrum	C
Cyanocobalamin	C
Cyanocobalamin	C
Folic Acid	C
Influenza Virus Vaccine	C
Minerals (Unspecified) (+)	
Vitamin	C
Pneumococcal Vaccine	C
Vitamin B Complex	C
Vitamin E	C

Date:06/22/01ISR Number: 3748426-3Report Type:Periodic Company Report #WAES 01030965
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748429-9Report Type:Periodic Company Report #WAES 01030966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3748431-7Report Type:Periodic Company Report #WAES 01030967
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence Urinary Retention	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748434-2Report Type:Periodic Company Report #WAES 01030969
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Baycol	C				
			Celebrex	C				
			Tegretol	C				
			Vasotec	C				
			Xanax	C				
			Zantac	C				
			Zoloft	C				

			Antineoplastic (Unspecified)	C		

Date:06/22/01ISR Number: 3748437-8Report Type:Periodic Company Report #WAES 01030970
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Amerge	C				
			Cafergot	C				
			Imitrex	C				
			Synthroid	C				
			Zomig	C				

Date:06/22/01ISR Number: 3748448-2Report Type:Periodic Company Report #WAES 01030972
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Allegra	C				
			Dilantin	C				
			Librax	C				
			Naproxen	C				

Date:06/22/01ISR Number: 3748449-4Report Type:Periodic Company Report #WAES 01030973
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 25 MG/DAILY/PO
			Zestril	C		

Date:06/22/01ISR Number: 3748451-2Report Type:Periodic Company Report #WAES 01030978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO
			Soma	C		

Date:06/22/01ISR Number: 3748453-6Report Type:Periodic Company Report #WAES 01031002
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 25

MG/DAILY/PO

Date:06/22/01ISR Number: 3748456-1Report Type:Periodic Company Report #WAES 01031014
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748457-3Report Type:Periodic Company Report #WAES 01031018
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748458-5Report Type:Periodic Company Report #WAES 01031030
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Advil	C				
			Celebrex	C				
			Norflex	C				
			Relafen	C				
			Tylenol	C				
			Cough, Cold, And Flu Therapies	C				

Date:06/22/01ISR Number: 3748462-7Report Type:Periodic Company Report #WAES 01031032
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research	
	Paraesthesia				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Prempro	C		
			Aspirin	C		
			Calcium	C		

Date:06/22/01ISR Number: 3748466-4Report Type:Periodic Company Report #WAES 01031046
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis	Health	Vioxx	PS	Merck Research	
	Heart Rate Irregular	Professional			Laboratories Div	
	Palpitations				Merck Co Inc	ORAL
25						
	Pruritus					
MG/DAILY/PO						
			Humalog	C		
			Ultralente Insulin	C		

Testosterone C

Date:06/22/01ISR Number: 3748469-XReport Type:Periodic Company Report #WAES 01031068
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/01ISR Number: 3748473-1Report Type:Periodic Company Report #WAES 01031069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748474-3Report Type:Periodic Company Report #WAES 01031070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748476-7Report Type:Periodic Company Report #WAES 01031072
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Therapy Unspecified	C				

Date:06/22/01ISR Number: 3748479-2Report Type:Periodic Company Report #WAES 01031078
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit Diarrhoea Flatulence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Duragesic	C				
			Doxazosin	C				

Date:06/22/01ISR Number: 3748482-2Report Type:Periodic Company Report #WAES 01031251
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Albuterol C

Date:06/22/01ISR Number: 3748486-XReport Type:Periodic Company Report #WAES 01031263
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748489-5Report Type:Periodic Company Report #WAES 01031274
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Hytrin	C				
			Lopid	C				
			Wytensin	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3748493-7Report Type:Periodic Company Report #WAES 01031281
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation Face Oedema Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5-25	

Rhinorrhoea
MG/DAILY/PO

Skin Lesion
Sneezing

Climara	C
Hydrodiuril	C
Thyrolar	C
Xanax	C
Zestril	C

Date:06/22/01ISR Number: 3748496-2Report Type:Periodic Company Report #WAES 01031291
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Humibid	C				
			Ms Contin	C				
			Vicodin Tablets	C				
			Amoxicillin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748498-6Report Type:Periodic Company Report #WAES 01031292
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Dilatrate	C				
			Hydrodiuril	C				
			Zestril	C				
			Atenolol	C				
			Diazepam	C				

Date:06/22/01ISR Number: 3748502-5Report Type:Periodic Company Report #WAES 01031293
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				
			Ultram	C				
			[Therapy Unspecified]	C				
			Aspirin	C				
			Chondroitin	C				
			Glucosamine	C				

Date:06/22/01ISR Number: 3748504-9Report Type:Periodic Company Report #WAES 01031298
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/	

PO

			[Therapy Unspecified]	C		

Date:06/22/01ISR Number: 3748507-4Report Type:Periodic Company Report #WAES 01031314
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	

Date:06/22/01ISR Number: 3748510-4Report Type:Periodic Company Report #WAES 01031317
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Toprol Xl Tablets [Therapy	C				

Unspecified] C

Date:06/22/01ISR Number: 3748513-XReport Type:Periodic Company Report #WAES 01031322
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Thyroid Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Armour Thyroid Tablets	C				
			Premarin	C				
			Tenormin	C				
			Ventolin	C				

Date:06/22/01ISR Number: 3748515-3Report Type:Periodic Company Report #WAES 01031325
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748518-9Report Type:Periodic Company Report #WAES 01031336
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748521-9Report Type:Periodic Company Report #WAES 01031342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix (Furosemide)	C				
			Toprol Xl Tablets	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3748536-0Report Type:Periodic Company Report #WAES 01031343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748551-7Report Type:Periodic Company Report #WAES 01031345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:06/22/01ISR Number: 3748553-0Report Type:Periodic Company Report #WAES 01031348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Celebrex	C				

Date:06/22/01ISR Number: 3748555-4Report Type:Periodic Company Report #WAES 01031351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
		Representative	Actos	C				
			Glucophage	C				
			Pravachol	C				

Date:06/22/01ISR Number: 3748558-XReport Type:Periodic Company Report #WAES 01031417
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Paxil	C				
			Slow-Pac	C				
			Nifedipine	C				
			Potassium Chloride	C				

Date:06/22/01ISR Number: 3748561-XReport Type:Periodic Company Report #WAES 01031425
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748563-3Report Type:Periodic Company Report #WAES 01031426
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Hormonal Contraceptives (Unspecified)	C				

Date:06/22/01ISR Number: 3748566-9Report Type:Periodic Company Report #WAES 01031445
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Pressure Increased Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Aldomet (Methyldopa)	C				
			Diazide	C				
			One-A-Day Essential Vitamins	C				
			Synthroid	C				
			Vasotec	C				
			Glucosamine	C				
			Vitamin C	C				

Date:06/22/01ISR Number: 3748568-2Report Type:Periodic Company Report #WAES 01031446
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Tenormin	C				

			Xanax	C		

Date:06/22/01ISR Number: 3748570-0Report Type:Periodic Company Report #WAES 01031453
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Composition Unspecified	C		

Date:06/22/01ISR Number: 3748572-4Report Type:Periodic Company Report #WAES 01031457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Therapy Unspecified	C		
			Methotrexate	C		

Date:06/22/01ISR Number: 3748573-6Report Type:Periodic Company Report #WAES 01031459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3748575-XReport Type:Periodic Company Report #WAES 01031460
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748578-5Report Type:Periodic Company Report #WAES 01031461
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ascorbic Acid	C				
			Garlic Extract	C				
			Potassium Chloride	C				
			Ubidecarenone	C				
			Vitamin E	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3748581-5Report Type:Periodic Company Report #WAES 01031462
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research			
	Nerve Compression	Health			Laboratories Div			
	Paraesthesia	Professional			Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Calcium	C				
			Potassium Chloride	C				

Date:06/22/01ISR Number: 3748584-0Report Type:Periodic Company Report #WAES 01031466
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	12.5	MG/DAILY/PO

Date:06/22/01ISR Number: 3748586-4Report Type:Periodic Company Report #WAES 01031468
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Arthralgia	Consumer
	Oedema Peripheral	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748588-8Report Type:Periodic Company Report #WAES 01031471
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748590-6Report Type:Periodic Company Report #WAES 01031481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:06/22/01ISR Number: 3748592-XReport Type:Periodic Company Report #WAES 01031487
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
Serevent C
Uniphyl C
Isosorbide C
Prednisone C

Date:06/22/01ISR Number: 3748593-1Report Type:Periodic Company Report #WAES 01031533
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan Sr	C				

Date:06/22/01ISR Number: 3748594-3Report Type:Periodic Company Report #WAES 01031551
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748595-5Report Type:Periodic Company Report #WAES 01031552
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Ambien	C				
			Estratab	C				
			Relafen	C				
			Thyroid Tablets Usp	C				
			Ziac	C				
			Acetaminophen (+) Dextropropoxyp	C				

Date:06/22/01ISR Number: 3748597-9Report Type:Periodic Company Report #WAES 01031555
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celexa	C				
			Lanoxicaps	C				
			Premarin	C				
			Synthroid	C				
			Prednisone	C				

Date:06/22/01ISR Number: 3748599-2Report Type:Periodic Company Report #WAES 01031557
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder	Health	Vioxx	PS	Merck Research			

	Vomiting	Professional			Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/01ISR Number: 3748601-8Report Type:Periodic Company Report #WAES 01031559
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Elavil	C		
			Hyzaar	C		
			Prempro	C		

Date:06/22/01ISR Number: 3748605-5Report Type:Periodic Company Report #WAES 01031596
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Ecchymosis Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
50						

MG/DAILY/PO

			Alphagan	C		
			Proscar	C		
			Acetaminophen (+)			
			Propoxyphene	C		
			Alprazolam	C		

Date:06/22/01ISR Number: 3748609-2Report Type:Periodic Company Report #WAES 01031624
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Celebrex	C				
			Ditropan Xl	C				
			Fosamax	C				
			Pravachol	C				

Date:06/22/01ISR Number: 3748612-2Report Type:Periodic Company Report #WAES 01031625
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				

Date:06/22/01ISR Number: 3748613-4Report Type:Periodic Company Report #WAES 01031629
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health	Vioxx	PS	Merck Research Laboratories Div			

		Professional			Merck Co Inc	ORAL
PO						
			Miacalcin	C		
			Prevacid	C		
			Calcium (Unspecified)	C		

Date:06/22/01ISR Number: 3748617-1Report Type:Periodic Company Report #WAES 01031635
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Headache				Merck Co Inc	ORAL
PO						
			Cardizem Cd	C		
			Celebrex	C		
			Pepcid	C		
			Pravachol	C		
			Synthroid	C		
			Calcium (Unspecified)	C		
			Pyridoxine	C		
			Vitamin E	C		

			Vitamins (Unspecified)	C		

Date:06/22/01ISR Number: 3748620-1Report Type:Periodic Company Report #WAES 01031641
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3748623-7Report Type:Periodic Company Report #WAES 01031643
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Haemorrhage Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Aciphex	C				
			Vasotec	C				
			Zoloft	C				
			Metoprolol	C				

Date:06/22/01ISR Number: 3748625-0Report Type:Periodic Company Report #WAES 01031653
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Zocor C

Date:06/22/01ISR Number: 3748629-8Report Type:Periodic Company Report #WAES 01031655
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Warfarin C

Date:06/22/01ISR Number: 3748630-4Report Type:Periodic Company Report #WAES 01031657
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

SEE IMAGE

Corgard C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748631-6Report Type:Periodic Company Report #WAES 01031665
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Norvasc	C				

Date:06/22/01ISR Number: 3748632-8Report Type:Periodic Company Report #WAES 01031669
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG	12.5MG
			Atenolol	C				

Date:06/22/01ISR Number: 3748633-XReport Type:Periodic Company Report #WAES 01031672
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3748634-1Report Type:Periodic Company Report #WAES 01031685
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL PO

Date:06/22/01ISR Number: 3748635-3Report Type:Periodic Company Report #WAES 01031687
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company			Merck Co Inc	ORAL	SEE IMAGE	
		Representative	Tab Vioxx 25 Mg	SS		ORAL	PO	

Date:06/22/01ISR Number: 3748637-7Report Type:Periodic Company Report #WAES 01031688
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:06/22/01ISR Number: 3748639-0Report Type:Periodic Company Report #WAES 01031703
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Erythema	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Date:06/22/01ISR Number: 3748640-7Report Type:Periodic Company Report #WAES 01031720
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Humulin 70/30	C				
			Lasix (Furosemide)	C				
			Persantine	C				
			Slow-K	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3748642-0Report Type:Periodic Company Report #WAES 01031734
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oral Soft Tissue Disorder Tongue Disorder	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Plavix 75 Mg	SS		ORAL	75 MG/DAILY/PO	
			Flexeril	C				

				Lipitor	C		
				Toprol Xl Tablets	C		
				Ibuprofen	C		
				Nonsteroidal Ant-Inflammatory	C		

Date:06/22/01ISR Number: 3748740-1Report Type:Periodic Company Report #WAES 01031736
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Blood Thyroid Stimulating Hormone Increased Fatigue	Health Professional	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Welchol 625 Mg	SS		ORAL	1875 MG/DAILY/PO	
			Synthroid	C				
			Synthroid	C				
			Pioglitazone Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748742-5Report Type:Periodic Company Report #WAES 01031745
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
			Motrin	C				

Date:06/22/01ISR Number: 3748746-2Report Type:Periodic Company Report #WAES 01031746
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Vision Blurred	Consumer	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aciphex	C				
			Evista	C				
			Levsin	C				
			Lomotil	C				
			Riopan	C				
			Docusate Sodium	C				

Date:06/22/01ISR Number: 3748751-6Report Type:Periodic Company Report #WAES 01031747
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Bactrim	C				
			Detrol	C				
			Levlite	C				

Date:06/22/01ISR Number: 3748752-8Report Type:Periodic Company Report #WAES 01031753
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				
			Folic Acid	C				

Date:06/22/01ISR Number: 3748754-1Report Type:Periodic Company Report #WAES 01031754
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Muscle Spasms Oedema Peripheral	Consumer Health Professional	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain In Extremity Paraesthesia		Cardura	C				
			Celebrex	C				
			Lasix (Furosemide)	C				
			Norvasc	C				
			Zestril	C				

		Diclofenac Sodium (+) Misoprosto	C
		Nonsteroidal Anti-Inflammatory	C

Date:06/22/01ISR Number: 3748758-9Report Type:Periodic Company Report #WAES 01031755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence Urinary Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ambien	C				
			Lipitor	C				
			Premarin	C				

Date:06/22/01ISR Number: 3748985-0Report Type:Periodic Company Report #WAES 01041231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748986-2Report Type:Periodic Company Report #WAES 01041232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3748988-6Report Type:Periodic Company Report #WAES 01041242
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748990-4Report Type:Periodic Company Report #WAES 01041249
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Diovan	C				
			Imdur	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3748993-XReport Type:Periodic Company Report #WAES 01041280
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO;5	
	Chills							
	Dizziness							
	Fatigue							
			Celebrex	C			0 MG/1X/PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3748996-5Report Type:Periodic Company Report #WAES 01041285
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3748998-9Report Type:Periodic Company Report #WAES 01041287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Metamucil	C				
			Prevacid	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3748999-0Report Type:Periodic Company Report #WAES 01041288
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Estrace	C				
			Lipitor	C				

Date:06/22/01ISR Number: 3749002-9Report Type:Periodic Company Report #WAES 01041289
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Nervousness Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestoretic	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749005-4Report Type:Periodic Company Report #WAES 01041290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY
			Celebrex	C				

Date:06/22/01ISR Number: 3749006-6Report Type:Periodic Company Report #WAES 01041293
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Feeling Drunk	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bisoprolol (+) Hydrochlorothiazi	C				

Date:06/22/01ISR Number: 3749009-1Report Type:Periodic Company Report #WAES 01041296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749012-1Report Type:Periodic Company Report #WAES 01041297
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 DAY
			Medrol Dosepak	C				

Date:06/22/01ISR Number: 3749014-5Report Type:Periodic Company Report #WAES 01041302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749016-9Report Type:Periodic Company Report #WAES 01041307
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Nail Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Declomycin	C				
			Evista	C				
			Ocuvite	C				

			Prilosec	C		
			Sodium Chloride	C		

Date:06/22/01ISR Number: 3749018-2Report Type:Periodic Company Report #WAES 01041309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO; 50 MG	

Date:06/22/01ISR Number: 3749021-2Report Type:Periodic Company Report #WAES 01041311
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Diarrhoea	Health Professional						
	Headache							
	Nausea		Nexium	C				
			Premarin	C				

Date:06/22/01ISR Number: 3749023-6Report Type:Periodic Company Report #WAES 01041315
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ditropan Xl	C				

Date:06/22/01ISR Number: 3749025-XReport Type:Periodic Company Report #WAES 01041319
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749026-1Report Type:Periodic Company Report #WAES 01041320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749029-7Report Type:Periodic Company Report #WAES 01041322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749030-3Report Type:Periodic Company Report #WAES 01041326
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO

Date:06/22/01ISR Number: 3749031-5Report Type:Periodic Company Report #WAES 01041341
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				

Date:06/22/01ISR Number: 3749032-7Report Type:Periodic Company Report #WAES 01041342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749035-2Report Type:Periodic Company Report #WAES 01041345
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Flatulence Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3749036-4Report Type:Periodic Company Report #WAES 01041351
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	
PO								
			Hydrodiuril	C				
			Metroprolol	C				

Date:06/22/01ISR Number: 3749038-8Report Type:Periodic Company Report #WAES 01041355
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Lopid	C				
			Questran	C				
			Verelan	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749040-6Report Type:Periodic Company Report #WAES 01041358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	6 DAY
			Accupril	C				
			Celebrex	C				
			Norvasc	C				
			Pravachol	C				
			Folic Acid	C				
			Prednisone	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3749042-XReport Type:Periodic Company Report #WAES 01041359
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Ditropan	C				
			Neurontin	C				
			Premarin	C				
			Prilosec	C				
			Thyroid	C				

Date:06/22/01ISR Number: 3749043-1Report Type:Periodic Company Report #WAES 01041362
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		
	Dyspepsia						
	Flatulence						
PO						ORAL	
	Nausea		Celebrex	C			
			Diovan	C			
			K-Dur	C			
			Labetalol	C			

Date:06/22/01ISR Number: 3749044-3Report Type:Periodic Company Report #WAES 01041363
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Paxil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749045-5Report Type:Periodic Company Report #WAES 01041375
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	

Date:06/22/01ISR Number: 3749046-7Report Type:Periodic Company Report #WAES 01041394
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotrel	C				
			Premarin	C				
			Synthroid	C				
			Tricor	C				
			Vaseline	C				
			Atenolol	C				
			Chlorthalidone	C				
			Insulin, Biphasic Isophane (Inje	C				

Date:06/22/01ISR Number: 3749048-0Report Type:Periodic Company Report #WAES 01041400
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749050-9Report Type:Periodic Company Report #WAES 01041403
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Flushing Sunburn	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Prilosec	C				
			Toprol Xl	C				

Date:06/22/01ISR Number: 3749052-2Report Type:Periodic Company Report #WAES 01041406
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Flomax (Tamsulosin Hydrochloride)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749053-4Report Type:Periodic Company Report #WAES 01041436
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Oedema Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749055-8Report Type:Periodic Company Report #WAES 01041437
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tylenol Pm Extra Strength Unk	SS		ORAL	2	CAPSULE/HS/PO
			Synthroid	C				
			Estrogen (Unspecified)	C				

Date:06/22/01ISR Number: 3749061-3Report Type:Periodic Company Report #WAES 01041439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749062-5Report Type:Periodic Company Report #WAES 01041452
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortisone	C				

Date:06/22/01ISR Number: 3749063-7Report Type:Periodic Company Report #WAES 01041453
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prevacid	C				
			Vicodin Tablets	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749065-0Report Type:Periodic Company Report #WAES 01041455
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
			Synthroid	C				
			Atenolol	C				
			Estrogens (Unspecified)	C				

Date:06/22/01ISR Number: 3749066-2Report Type:Periodic Company Report #WAES 01041456
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	29 DAY
			Synthroid	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3749067-4Report Type:Periodic Company Report #WAES 01041458
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Warfarin	C				

Date:06/22/01ISR Number: 3749069-8Report Type:Periodic Company Report #WAES 01041467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Estratest	C				
			Lamisil	C				
			Premarin	C				
			Prozac	C				

Date:06/22/01ISR Number: 3749116-3Report Type:Periodic Company Report #WAES 01041470
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749119-9Report Type:Periodic Company Report #WAES 01041471
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Colestid	C				
			Calcium (Unspecified)	C				
			Diflunisal	C				
			Folic Acid	C				
			Vitamin B Complex	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3749120-5Report Type:Periodic Company Report #WAES 01041475
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749123-0Report Type:Periodic Company Report #WAES 01041478
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK

Date:06/22/01ISR Number: 3749125-4Report Type:Periodic Company Report #WAES 01041479
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25/MG/DAILY/P	
O								
			Risperdal	C				

Date:06/22/01ISR Number: 3749126-6Report Type:Periodic Company Report #WAES 01041481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749127-8Report Type:Periodic Company Report #WAES 01041484
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749129-1Report Type:Periodic Company Report #WAES 01041493
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Azulfidine	C				
			Belladonna Alkaloids	C				

Date:06/22/01ISR Number: 3749131-XReport Type:Periodic Company Report #WAES 01041494
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Chlor-Trimeton	C				
			Neurontin	C				
			Robaxin	C				
			Methylprednisolone	C				

Date:06/22/01ISR Number: 3749133-3Report Type:Periodic Company Report #WAES 01041506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3749134-5Report Type:Periodic Company Report #WAES 01041507
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Monopril	C				

Date:06/22/01ISR Number: 3749136-9Report Type:Periodic Company Report #WAES 01041510
Age:66 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Fatigue

Influenza Like Illness

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Premarin	C				
	Synthroid	C				

Date:06/22/01ISR Number: 3749137-0Report Type:Periodic Company Report #WAES 01041532
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema							

Date:06/22/01ISR Number: 3749138-2Report Type:Periodic Company Report #WAES 01041720
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Fatigue							
	Nausea							
	Swelling							
			Actos	C				
			Cozaar	C				
			Lasix	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:06/22/01ISR Number: 3749139-4Report Type:Periodic Company Report #WAES 01041740
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:06/22/01ISR Number: 3749141-2Report Type:Periodic Company Report #WAES 01042109
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749142-4Report Type:Periodic Company Report #WAES 01042118
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Levoxyl	C				
			Miacalcin	C				
			Premarin	C				
			Prevacid	C				
			Alprazolam	C				
			Verapamil	C				

Date:06/22/01ISR Number: 3749143-6Report Type:Periodic Company Report #WAES 01042129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	

Date:06/22/01ISR Number: 3749145-XReport Type:Periodic Company Report #WAES 01042140
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749146-1Report Type:Periodic Company Report #WAES 01042143
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Deafness							
	Dizziness							
	Eye Movement Disorder							
	Gait Disturbance							
	Insomnia							
	Oedema Peripheral							
	Pyrexia							
	Tinnitus							

Date:06/22/01ISR Number: 3749147-3Report Type:Periodic Company Report #WAES 01042144
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Nausea							
			Valium	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749149-7Report Type:Periodic Company Report #WAES 01042147
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Dermatitis Exfoliative							
	Erythema							
	Face Oedema		Actonel	C				
	Fatigue		Codeine Phosphate					
	Hypersensitivity		(+) Promethazi	C				

Date:06/22/01ISR Number: 3749151-5Report Type:Periodic Company Report #WAES 01042150
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Detrol	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3749152-7Report Type:Periodic Company Report #WAES 01042151
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Paraesthesia							
	Rash Erythematous							
			Neurontin	C				

Date:06/22/01ISR Number: 3749154-0Report Type:Periodic Company Report #WAES 01042153
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749157-6Report Type:Periodic Company Report #WAES 01040892
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zocor	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749160-6Report Type:Periodic Company Report #WAES 01040893
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Respiratory Distress Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Pepcid	C				
			Restoril	C				

Date:06/22/01ISR Number: 3749161-8Report Type:Periodic Company Report #WAES 01040899
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intestinal Functional Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749163-1Report Type:Periodic Company Report #WAES 01040917
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO; 25/DAILY/PO	3 DAY
			Ativan	C				
			Celebrex	C				
			Fosamax	C				
			Menest	C				
			Xanax	C				

			Prednisone	C		

Date:06/22/01ISR Number: 3749165-5Report Type:Periodic Company Report #WAES 01040919
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research	
	Respiratory Disorder				Laboratories Div	
	Weight Increased				Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Avapro	C		
			Biaxin	C		
			Singulair	C		
			Synthroid	C		

Date:06/22/01ISR Number: 3749167-9Report Type:Periodic Company Report #WAES 01040921
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Gastrointestinal Disorder	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Premarin	C		

				Synthroid	C		
				Vasotec	C		

Date:06/22/01ISR Number: 3749169-2Report Type:Periodic Company Report #WAES 01040923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Prinivil	C				

Date:06/22/01ISR Number: 3749171-0Report Type:Periodic Company Report #WAES 01040925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cortisone	C				

Date:06/22/01ISR Number: 3749173-4Report Type:Periodic Company Report #WAES 01040926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				

Date:06/22/01ISR Number: 3749175-8Report Type:Periodic Company Report #WAES 01040935
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Altace	C				
			Aricept	C				
			Zocor	C				

Date:06/22/01ISR Number: 3749178-3Report Type:Periodic Company Report #WAES 01042651
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Thyroid Tablets Usp	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749179-5Report Type:Periodic Company Report #WAES 01042656
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Consumer	Vioxx	PS	Merck Research			
	Unevaluable Event	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	UNK/DAILY/PO	
			Glucophage	C				
			Humulin N	C				
			Synthroid	C				
			Zestril	C				
			Zocor	C				
			Iron (Unspecified)	C				
			Tamoxifen	C				

Date:06/22/01ISR Number: 3749180-1Report Type:Periodic Company Report #WAES 01042657
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	UNK/UNK/PO	
			Lipitor	C				
			Prempro	C				

Date:06/22/01ISR Number: 3749181-3Report Type:Periodic Company Report #WAES 01042658
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Vioxx	PS	Merck Research			
	Headache				Laboratories Div			
	Vision Blurred				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

Date:06/22/01ISR Number: 3749182-5Report Type:Periodic Company Report #WAES 01042675
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Mevacor	C				

Date:06/22/01ISR Number: 3749183-7Report Type:Periodic Company Report #WAES 01042689
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder Hepatic Function Abnormal Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749185-0Report Type:Periodic Company Report #WAES 01021565
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Blood Pressure Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aricept	C				
			Lipitor	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3749186-2Report Type:Periodic Company Report #WAES 01021595
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Armour Thyroid Tablets	C				
			Premarin	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749190-4Report Type:Periodic Company Report #WAES 99070142
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Angina Pectoris Chest Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY PO	
			Daypro	C				

			Miacalcin	C		
			Premarin	C		
			Synthroid	C		

Date:06/22/01ISR Number: 3749194-1Report Type:Periodic Company Report #WAES 99120232
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Vioxx	PS	Merck Research			
	Lip Dry	Professional			Laboratories Div			
	Oral Discomfort				Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Arava	C				
			Darvocet-N	C				
			Imuran	C				
			Prilosec	C				

Date:06/22/01ISR Number: 3749211-9Report Type:Periodic Company Report #WAES 01042569
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Ageusia	Health
	Parosmia	Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749213-2Report Type:Periodic Company Report #WAES 01042573
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain							
	Dizziness							
	Ecchymosis							
	Fall		Fosamax	C				
	Fatigue		Hydrodiuril	C				
	Feeling Cold		Estrogens (Unspecified)	C				
	Injury							
	Skin Disorder							

Date:06/22/01ISR Number: 3749214-4Report Type:Periodic Company Report #WAES 01042582
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3749216-8Report Type:Periodic Company Report #WAES 01042584
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3749217-XReport Type:Periodic Company Report #WAES 01042588
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pulmonary Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				

Date:06/22/01ISR Number: 3749219-3Report Type:Periodic Company Report #WAES 01042590
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

			Premarin	C			

Date:06/22/01ISR Number: 3749220-XReport Type:Periodic Company Report #WAES 01042600
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3749221-1Report Type:Periodic Company Report #WAES 01042629
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Detrol	C				
			Glucotrol Xl	C				
			Novolin N	C				
			Pletal	C				
			Prempro	C				
			Trusopt	C				
			Vasotec	C				
			Labetalol	C				

Date:06/22/01ISR Number: 3749222-3Report Type:Periodic Company Report #WAES 01042630
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Insomnia					
	Joint Stiffness					
UNK/UNK/PO						
	Muscle Rigidity		Claritin	C		
	Pruritus		Zyrtec	C		

Date:06/22/01ISR Number: 3749223-5Report Type:Periodic Company Report #WAES 01042647
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Syphilis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

Date:06/22/01ISR Number: 3749224-7Report Type:Periodic Company Report #WAES 01042542
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Oedema Peripheral					
UNK/UNK/PO						
			Imodium	SS		
			Lomotil	C		

		Micro K	C	
		Furosemide	C	

Date:06/22/01ISR Number: 3749225-9Report Type:Periodic Company Report #WAES 01042544
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749226-0Report Type:Periodic Company Report #WAES 01042547
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Avalide	C				
			Toprol Xl Tablets	C				
			Cimetidine	C				

Date:06/22/01ISR Number: 3749227-2Report Type:Periodic Company Report #WAES 01042549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3749228-4Report Type:Periodic Company Report #WAES 01042553
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO 90 DAY						
			Donnatal	C		
			Lipitor	C		
			Paxil	C		
			Singular	C		
			Toprol Xl Tablets	C		

Date:06/22/01ISR Number: 3749229-6Report Type:Periodic Company Report #WAES 01042555
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						
			Claritan-D	C		
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749230-2Report Type:Periodic Company Report #WAES 01042557
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Ativan	C				
			Synthroid	C				
			Xalatan	C				

Date:06/22/01ISR Number: 3749231-4Report Type:Periodic Company Report #WAES 01042563
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Ativan	C				
			Coumadin	C				
			Triavil	C				
			Zocor	C				

Date:06/22/01ISR Number: 3749232-6Report Type:Periodic Company Report #WAES 01042566
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Vision Blurred	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Procardia	C				
			Hormones (Unspecified)	C				

Date:06/22/01ISR Number: 3749233-8Report Type:Periodic Company Report #WAES 01042568
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	
			Flomax (Morniflumate)	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3749234-XReport Type:Periodic Company Report #WAES 01050515
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749235-1Report Type:Periodic Company Report #WAES 01050547
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Flagyl	C				
			Pensasa	C				
			Purinethol	C				
			Cyanocobalamin	C				

Date:06/22/01ISR Number: 3749236-3Report Type:Periodic Company Report #WAES 01050552
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Provera	C				
			Estrogens	C				

Date:06/22/01ISR Number: 3749237-5Report Type:Periodic Company Report #WAES 01050554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Retching	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749238-7Report Type:Periodic Company Report #WAES 01050562
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Headache Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			K-Dur	C				
			Premarin	C				
			Verapamil Msd Lp	C				

Date:06/22/01ISR Number: 3749239-9Report Type:Periodic Company Report #WAES 01050564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pelvic Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749240-5Report Type:Periodic Company Report #WAES 01050569
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3749241-7Report Type:Periodic Company Report #WAES 01050572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Diarrhoea Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia		Centrum	C				
	Fatigue		Detrol	C				
	Headache		Estroral	C				
	Oedema Peripheral		Lipitor	C				
	Vomiting		Synthroid	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3749242-9Report Type:Periodic Company Report #WAES 01050577
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lipitor	C				
			Norvasc	C				
			Alprazolam	C				

			Atenolol	C		
			Glucasamine	C		
			Glyburide	C		

Date:06/22/01ISR Number: 3749243-0Report Type:Periodic Company Report #WAES 01050583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Actos	C				
			Celebrex	C				
			Furosemide	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749244-2Report Type:Periodic Company Report #WAES 01050427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Elavil	C				
			Evista	C				

Date:06/22/01ISR Number: 3749245-4Report Type:Periodic Company Report #WAES 01050429
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression Emotional Disorder Irritability	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Depakote	C				

Date:06/22/01ISR Number: 3749246-6Report Type:Periodic Company Report #WAES 01050433
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749247-8Report Type:Periodic Company Report #WAES 01050446
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
"SEE IMAGE"						
			Celebrex	C		
			Norvasc	C		
			Paxil	C		
			Synthroid	C		
			Estrogens (Unspecified)	C		
			Furosemide	C		

Date:06/22/01ISR Number: 3749248-XReport Type:Periodic Company Report #WAES 01050459
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
UNK/UNK/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749249-1Report Type:Periodic Company Report #WAES 01050473
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Lip Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO

Date:06/22/01ISR Number: 3749250-8Report Type:Periodic Company Report #WAES 01050474
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	2 WK
			Coumadin	C				
			Neurontin	C				
			Antineoplastic (Unspecified)	C				

Date:06/22/01ISR Number: 3749251-XReport Type:Periodic Company Report #WAES 01050475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO

Date:06/22/01ISR Number: 3749252-1Report Type:Periodic Company Report #WAES 01050493
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3749253-3Report Type:Periodic Company Report #WAES 01050508
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	UNK/UNK/PO	

Date:06/22/01ISR Number: 3749254-5Report Type:Periodic Company Report #WAES 01050365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749255-7Report Type:Periodic Company Report #WAES 01050367
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:06/22/01ISR Number: 3749256-9Report Type:Periodic Company Report #WAES 01050374
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Imdur	C				
			Aspirin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3749257-0Report Type:Periodic Company Report #WAES 01050375
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Interaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Toprol Xl Tablets	SS				

Date:06/22/01ISR Number: 3749258-2Report Type:Periodic Company Report #WAES 01050378
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin-D 24 Hour	C				
			Estratest H.S.	C				
			Flexeril	C				
			Prilosec	C				
			Prozac	C				
			Synthroid	C				
			Wellbutrin	C				

Date:06/22/01ISR Number: 3749259-4Report Type:Periodic Company Report #WAES 01050398
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; PO; 12.5 MG/DAILY/PO	
			Avandia	C				

Glucotrol Xl C

Date:06/22/01ISR Number: 3749260-0Report Type:Periodic Company Report #WAES 01050399
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Mevacor	C				
			Zantac	C				
			...	C				
			...	C				
			...	C				
			...	C				
			...	C				

Date:06/22/01ISR Number: 3749262-4Report Type:Periodic Company Report #WAES 01050411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749264-8Report Type:Periodic Company Report #WAES 01050412
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO;

25

MG/DAILY/PO

Avandia	C
Coumadin	C
Glaucadrine	C
Lasix (Furosemide Sodium)	C
Lopressor	C
Prilosec	C
Potassium (Unspecified)	C

Date:06/22/01ISR Number: 3749267-3Report Type:Periodic Company Report #WAES 01050422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

Dose Duration

25

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749279-XReport Type:Periodic Company Report #WAES 01050338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Cough Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Diovan	C				
			Tiazac	C				
			Gemfibrozil	C				

Date:06/22/01ISR Number: 3749281-8Report Type:Periodic Company Report #WAES 01050339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis Rhinorrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zyrtec	C				

Date:06/22/01ISR Number: 3749283-1Report Type:Periodic Company Report #WAES 01050351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749286-7Report Type:Periodic Company Report #WAES 01050353
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749289-2Report Type:Periodic Company Report #WAES 01050356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Drug Ineffective	Health Professional Company Representative	Vioxx Therapy Unspecified	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:06/22/01ISR Number: 3749292-2Report Type:Periodic Company Report #WAES 01050358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749294-6Report Type:Periodic Company Report #WAES 01050360
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Claritin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3749296-XReport Type:Periodic Company Report #WAES 01050361
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prometrium	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749298-3Report Type:Periodic Company Report #WAES 01050362
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Darvocet-N	C				
			Lanoxin	C				
			Sinequan	C				

Date:06/22/01ISR Number: 3749301-0Report Type:Periodic Company Report #WAES 01050363
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Cough							
	Insomnia							
			Captopril	C				
			Herbs	C				

Date:06/22/01ISR Number: 3749303-4Report Type:Periodic Company Report #WAES 01041832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/01ISR Number: 3749305-8Report Type:Periodic Company Report #WAES 01041833
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Date:06/22/01ISR Number: 3749309-5Report Type:Periodic Company Report #WAES 01041837
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Erythema Photosensitivity Reaction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Prempro	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3749312-5Report Type:Periodic Company Report #WAES 01041842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Joint Swelling	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	8 DAY

Date:06/22/01ISR Number: 3749315-0Report Type:Periodic Company Report #WAES 01041845
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Exfoliative Erythema Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Betoptic	C				
			Nolvadex	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3749320-4Report Type:Periodic Company Report #WAES 01041851
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Fosamax	C				
			Lipitor	C				

Date:06/22/01ISR Number: 3749325-3Report Type:Periodic Company Report #WAES 01041867
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749330-7Report Type:Periodic Company Report #WAES 01041887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749332-0Report Type:Periodic Company Report #WAES 01041891
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Pyrexia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/01ISR Number: 3749333-2Report Type:Periodic Company Report #WAES 01041903
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Malaise	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749336-8Report Type:Periodic Company Report #WAES 01041910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Oedema Peripheral Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 12 DAY

Date:06/22/01ISR Number: 3749338-1Report Type:Periodic Company Report #WAES 01041912
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749339-3Report Type:Periodic Company Report #WAES 01041916
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Premarin	C				
			Aspirin	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749340-XReport Type:Periodic Company Report #WAES 01041917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749341-1Report Type:Periodic Company Report #WAES 01041919
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3749342-3Report Type:Periodic Company Report #WAES 01041944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749343-5Report Type:Periodic Company Report #WAES 01041957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3749344-7Report Type:Periodic Company Report #WAES 01041962
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749345-9Report Type:Periodic Company Report #WAES 01041988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749347-2Report Type:Periodic Company Report #WAES 01042004
Age:70 YR Gender:Male I/FU:I

Outcome	PT
	Dermatitis
	Dry Skin

	Pruritus						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Prinivil	C				
			Proscar	C				

Date:06/22/01ISR Number: 3749349-6Report Type:Periodic Company Report #WAES 01042031
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
			Calcium (Unspecified)	C				
			Estrogens (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3749351-4Report Type:Periodic Company Report #WAES 01042034
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia Face Oedema Increased Appetite Oedema Peripheral Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749353-8Report Type:Periodic Company Report #WAES 01042038
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Tinnitus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/01ISR Number: 3749354-XReport Type:Periodic Company Report #WAES 01042039
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Cytotec	C				
			Darvon	C				
			Fosamax	C				
			Plaquenil	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749356-3Report Type:Periodic Company Report #WAES 01042040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 MON
			Elavil	C				
			Lanoxin	C				
			Sinemet	C				

Date:06/22/01ISR Number: 3749358-7Report Type:Periodic Company Report #WAES 01042041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749362-9Report Type:Periodic Company Report #WAES 01042042
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 MON

Date:06/22/01ISR Number: 3749365-4Report Type:Periodic Company Report #WAES 01042043
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS	Merck Research			

Face Oedema
Oedema Peripheral
Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3749367-8Report Type:Periodic Company Report #WAES 01042054
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749368-XReport Type:Periodic Company Report #WAES 01042056
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper Faeces Discoloured Gastrointestinal Disorder Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atenolol	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749374-5Report Type:Periodic Company Report #WAES 01042058
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lortab	C				
			Norflex	C				

Date:06/22/01ISR Number: 3749377-0Report Type:Periodic Company Report #WAES 01042061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Protonix	C				
			Xanax	C				

Date:06/22/01ISR Number: 3749379-4Report Type:Periodic Company Report #WAES 01042063
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749381-2Report Type:Periodic Company Report #WAES 01042067
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema Face Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Advil	C				
			Celebrex	C				

Date:06/22/01ISR Number: 3749383-6Report Type:Periodic Company Report #WAES 01042069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Nausea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Guaifenesin	C				

Date:06/22/01ISR Number: 3749385-XReport Type:Periodic Company Report #WAES 01042072
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Tinnitus	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Fosamax	C				
Estrogens	C				

Date:06/22/01ISR Number: 3749387-3Report Type:Periodic Company Report #WAES 01042073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ziac	C				

Date:06/22/01ISR Number: 3749389-7Report Type:Periodic Company Report #WAES 01042078
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				

Date:06/22/01ISR Number: 3749391-5Report Type:Periodic Company Report #WAES 01042083
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Colace	C				
			Coumadin	C				
			Metrocream	C				
			Prevacid	C				
			Zocor	C				
			Amitriptyline	C				
			Colchicine (+)					
			Probenecid	C				
			Estradiol	C				
			Furosemide	C				
			Propafenone	C				

Date:06/22/01ISR Number: 3749394-0Report Type:Periodic Company Report #WAES 01042092
Age:73 YR Gender:Female I/FU:I

Outcome	PT
	Dyspnoea
	Headache
	Pain In Extremity

Palpitations

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749397-6Report Type:Periodic Company Report #WAES 01031758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Norvasc	C				
			Zoloft	C				
			Ibuprofen	C				

Date:06/22/01ISR Number: 3749399-XReport Type:Periodic Company Report #WAES 01031759
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749401-5Report Type:Periodic Company Report #WAES 01031763
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Lipitor	C		
			Acetaminophen (+)			
			Codeine	C		
			Enalapril	C		
			Indapamide	C		
			Isosorbide	C		
			Metoprolol	C		

Date:06/22/01ISR Number: 3749402-7Report Type:Periodic Company Report #WAES 01031771
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Diazide	C		
			Pepcid Ac	C		
			Premarin	C		
			Folic Acid	C		

			Methotrexate	C		
			Prednisone	C		
			Temazepam	C		

Date:06/22/01ISR Number: 3749404-0Report Type:Periodic Company Report #WAES 01031789
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dry Mouth Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Klonopin	C				
			Paxil	C				
			Zocor	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3749407-6Report Type:Periodic Company Report #WAES 01031791
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celelbrex	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749408-8Report Type:Periodic Company Report #WAES 01031801
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749410-6Report Type:Periodic Company Report #WAES 01031804
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Nervousness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749412-XReport Type:Periodic Company Report #WAES 01031807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aleve Unk	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749415-5Report Type:Periodic Company Report #WAES 01032126
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				
			Lipitor	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3749443-XReport Type:Periodic Company Report #WAES 01050584
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nausea		Atacand	C				
			Hydrocodone	C				

Date:06/22/01ISR Number: 3749448-9Report Type:Periodic Company Report #WAES 01050617
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Nausea						MG/DAILY/PO	
			Prilosec	C				
			Synthroid	C				
			Tiazac	C				
			Nitroglycerin	C				

Date:06/22/01ISR Number: 3749450-7Report Type:Periodic Company Report #WAES 01050629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Erythema	Professional					MG/DAILY/PO	
	Paraesthesia	Company Representative						

Date:06/22/01ISR Number: 3749454-4Report Type:Periodic Company Report #WAES 01050632
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Imitrex	C				

Date:06/22/01ISR Number: 3749458-1Report Type:Periodic Company Report #WAES 01050636
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Hallucination	Professional	Claritin	C				
	Muscular Weakness	Company Representative	Prempro	C				
			Amoxicillin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749462-3Report Type:Periodic Company Report #WAES 01050658
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Acetaminophen	C				
			Trihexyphenidyl Hydrochloride	C				

Date:06/22/01ISR Number: 3749466-0Report Type:Periodic Company Report #WAES 01050662
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:06/22/01ISR Number: 3749468-4Report Type:Periodic Company Report #WAES 01050664
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/22/01ISR Number: 3749471-4Report Type:Periodic Company Report #WAES 01050671
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/22/01ISR Number: 3749488-XReport Type:Periodic Company Report #WAES 01041742
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Lotensin	C				
			Norvasc	C				
			Ultram	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3749491-XReport Type:Periodic Company Report #WAES 01041798
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Throat Tightness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749492-1Report Type:Periodic Company Report #WAES 01041807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749497-0Report Type:Periodic Company Report #WAES 01041813
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PM/PO	
			Aleve	C				
			Darvon	C				
			Lanoxin	C				
			Norvasc	C				
			Toprol Xl Tablets	C				

Date:06/22/01ISR Number: 3749500-8Report Type:Periodic Company Report #WAES 01041820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Accupril	C				

Date:06/22/01ISR Number: 3749502-1Report Type:Periodic Company Report #WAES 01041823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749503-3Report Type:Periodic Company Report #WAES 01041824
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749504-5Report Type:Periodic Company Report #WAES 01041825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

			Salutensin	C
			Vitamins	C

Date:06/22/01ISR Number: 3749506-9Report Type:Periodic Company Report #WAES 01041826
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syphilis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749508-2Report Type:Periodic Company Report #WAES 01041831
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence Weight Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Pepcid	C				
			Premarin	C				
			Potassium	C				

Date:06/22/01ISR Number: 3749509-4Report Type:Periodic Company Report #WAES 01040940
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749511-2Report Type:Periodic Company Report #WAES 01040941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/1X/PO	

Date:06/22/01ISR Number: 3749513-6Report Type:Periodic Company Report #WAES 01040948
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749515-XReport Type:Periodic Company Report #WAES 01040951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25MG/DAILY/PO

Deseril	C
Premarin	C
Tricor	C
Zanaflex	C
Zocor	C
Zoloft	C
Lithium Salicylate	C

Date:06/22/01ISR Number: 3749517-3Report Type:Periodic Company Report #WAES 01040952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749519-7Report Type:Periodic Company Report #WAES 01040961
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cordarone	C				
			Coumadin	C				
			Levoxyl	C				
			Lotensin	C				
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749521-5Report Type:Periodic Company Report #WAES 01040963
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Fosamax C
Lipitor C
Norvasc C

Date:06/22/01ISR Number: 3749522-7Report Type:Periodic Company Report #WAES 01040964
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Lotensin C
Pravachol C
Risperdal C

Date:06/22/01ISR Number: 3749526-4Report Type:Periodic Company Report #WAES 01040968
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749528-8Report Type:Periodic Company Report #WAES 01040970
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749531-8Report Type:Periodic Company Report #WAES 01040971
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749534-3Report Type:Periodic Company Report #WAES 01040989
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

[Therapy
Unspecified] C
Propoxyphene
Napsylate C

Date:06/22/01ISR Number: 3749536-7Report Type:Periodic Company Report #WAES 01041010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749537-9Report Type:Periodic Company Report #WAES 01041023
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Cough							
	Dysphonia							
	Dyspnoea							
	Oedema Peripheral		Casodex	C				

Hyzaar	C
Lupron	C
Antineoplastic (Unspecified)	C
Ascorbic Acid	C
Aspirin	C
Verapamil	C
Vitamin E	C

Date:06/22/01ISR Number: 3749539-2Report Type:Periodic Company Report #WAES 01041024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749543-4Report Type:Periodic Company Report #WAES 01041032
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Oedema Peripheral Urticaria	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749546-XReport Type:Periodic Company Report #WAES 01041036
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

[Therapy
Unspecified] C

Date:06/22/01ISR Number: 3749549-5Report Type:Periodic Company Report #WAES 01041041
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis Exfoliative							
	Erythema							
	Paraesthesia		Desyrel	C				
			Prednisone	C				

Date:06/22/01ISR Number: 3749551-3Report Type:Periodic Company Report #WAES 01041042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749554-9Report Type:Periodic Company Report #WAES 01041050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749560-4Report Type:Periodic Company Report #WAES 01041054
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749562-8Report Type:Periodic Company Report #WAES 01041055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	3 WK
			Percocet	C				

Date:06/22/01ISR Number: 3749564-1Report Type:Periodic Company Report #WAES 01041061
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Flexeril	C	
Prilosec	C	
Prozac	C	
Hormonal Contraceptives	C	

Date:06/22/01ISR Number: 3749568-9Report Type:Periodic Company Report #WAES 01041062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO 2 DAY

Date:06/22/01ISR Number: 3749570-7Report Type:Periodic Company Report #WAES 01041066
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Date:06/22/01ISR Number: 3749573-2Report Type:Periodic Company Report #WAES 01041069
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Vioxx	PS	Merck Research			
	Oedema Peripheral	Professional			Laboratories Div			
	Pruritus				Merck Co Inc	ORAL	50	
	Weight Increased							
							MG/DAILY/PO	
			Amaryl	C				
			Avandia	C				
			Vivelle	C				

Date:06/22/01ISR Number: 3749575-6Report Type:Periodic Company Report #WAES 01041074
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	25	
		Representative						
							MG/DAILY/PO	
			Celebrex	C				
			Prilosec	C				
			Naproxen	C				

Date:06/22/01ISR Number: 3749578-1Report Type:Periodic Company Report #WAES 01041076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	PO	

Vasotec	C		
Furosemide	C		

Date:06/22/01ISR Number: 3749579-3Report Type:Periodic Company Report #WAES 01041082
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749581-1Report Type:Periodic Company Report #WAES 01041083
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749585-9Report Type:Periodic Company Report #WAES 01041086
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prozac	C				
			Xanax	C				

Date:06/22/01ISR Number: 3749587-2Report Type:Periodic Company Report #WAES 01041097
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749590-2Report Type:Periodic Company Report #WAES 01041098
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749593-8Report Type:Periodic Company Report #WAES 01041099
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

		Company Representative			Merck Co Inc	ORAL

PO

Date:06/22/01ISR Number: 3749596-3Report Type:Periodic Company Report #WAES 01041114
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Amaryl	C		
			Evista	C		
			Glucophage	C		
			Prilosec	C		
			Prinivil	C		
			Diltiazem	C		
			Doxazosin Mesylate	C		
			Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749600-2Report Type:Periodic Company Report #WAES 01041118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/01ISR Number: 3749603-8Report Type:Periodic Company Report #WAES 01041124
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Cardis	C				
			Prilosec	C				
			Zocor	C				
			[Therapy Unspecified]	C				
			Cyclobenzaprine Hydrochloride	C				
			Metoclopramide	C				
			Nortriptyline	C				

Date:06/22/01ISR Number: 3749606-3Report Type:Periodic Company Report #WAES 01041135
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749607-5Report Type:Periodic Company Report #WAES 01041162
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Dyspnoea						PO ; 50 MG	
	Muscular Weakness						DAILY PO; 25	
							MG DAILY	
			Avapro	C				
			Extra Strength Maalox	C				
			Verapamil	C				

Date:06/22/01ISR Number: 3749609-9Report Type:Periodic Company Report #WAES 01041165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Norvasc	C	
Pepcid	C	
Tylenol	C	
Zestril	C	

Date:06/22/01ISR Number: 3749612-9Report Type:Periodic Company Report #WAES 01041174
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified	C				

Date:06/22/01ISR Number: 3749614-2Report Type:Periodic Company Report #WAES 01041175
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Myalgia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Remeron	C			PO	
			[Therapy Unspecified]	C				
			Acetaminophen	C				
			Cimetidine	C				
			Simvastatin	C				

Date:06/22/01ISR Number: 3749617-8Report Type:Periodic Company Report #WAES 01041176
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research			

Urticaria Laboratories Div
Merck Co Inc ORAL
25 MG DAILY

PO

Dyazide	C	
Lipitor	C	
Synthroid	C	

Date:06/22/01ISR Number: 3749620-8Report Type:Periodic Company Report #WAES 01041182
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG DAILY

PO

Celebrex	C	
Lithium Carbonate	C	
Propranolol	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749622-1Report Type:Periodic Company Report #WAES 01041187
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749624-5Report Type:Periodic Company Report #WAES 01041188
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diovan	C				
			Hydrodiuril	C				
			Procardia	C				

Date:06/22/01ISR Number: 3749626-9Report Type:Periodic Company Report #WAES 01041189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3749629-4Report Type:Periodic Company Report #WAES 01041204
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder Vaginal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO
[Therapy
Unspecified] C

Date:06/22/01ISR Number: 3749630-0Report Type:Periodic Company Report #WAES 01041209
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Incontinence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Headache							
	Pruritus							
			Claritin	C				
			[Therapy Unspecified]	C				
			Diazepam	C				

Date:06/22/01ISR Number: 3749633-6Report Type:Periodic Company Report #WAES 01041215
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
	Pain In Extremity							

PO

	Aricept	C	
	Detrol	C	
	Premarin	C	
	Prilosec	C	
	Diltiazem	C	

Date:06/22/01ISR Number: 3749817-7Report Type:Periodic Company Report #WAES 01050201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema Peripheral		Indocin (Indomethacin)	C				

Date:06/22/01ISR Number: 3749818-9Report Type:Periodic Company Report #WAES 01050233
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Synthroid	C				
			Tenormin	C				

Date:06/22/01ISR Number: 3749819-0Report Type:Periodic Company Report #WAES 01050245
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Premarin	C				
			Ziac	C				

Date:06/22/01ISR Number: 3749820-7Report Type:Periodic Company Report #WAES 01050292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:06/22/01ISR Number: 3749821-9Report Type:Periodic Company Report #WAES 01050294
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Erythema	Professional					MG/DAILY/PO	
	Insomnia		[Therapy					
	Joint Stiffness		Unspecified]	C				
	Joint Swelling							
	Musculoskeletal Disorder							
	Pain							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3749822-0Report Type:Periodic Company Report #WAES 01050295
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3749823-2Report Type:Periodic Company Report #WAES 01050296
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/22/01ISR Number: 3749824-4Report Type:Periodic Company Report #WAES 01050309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/22/01ISR Number: 3749825-6Report Type:Periodic Company Report #WAES 01050318
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Actos	C
Hyzaar	C
Norvasc	C
Aspirin	C
Insulin	C

Date:06/22/01ISR Number: 3749826-8Report Type:Periodic Company Report #WAES 01050324
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/22/01ISR Number: 3750126-0Report Type:Periodic Company Report #WAES 01050172
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750127-2Report Type:Periodic Company Report #WAES 01050174
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Abnormal Faeces	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Synthroid	C				
			Zocor	C				

Date:06/22/01ISR Number: 3750128-4Report Type:Periodic Company Report #WAES 01050176
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3750129-6Report Type:Periodic Company Report #WAES 01050177
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ecotrin	C				

Date:06/22/01ISR Number: 3750130-2Report Type:Periodic Company Report #WAES 01050184
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750131-4Report Type:Periodic Company Report #WAES 01050198
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750132-6Report Type:Periodic Company Report #WAES 01050199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pigmentation Disorder Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750133-8Report Type:Periodic Company Report #WAES 01050200
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ativan	C				
			Lescol	C				

Date:06/22/01ISR Number: 3750134-XReport Type:Periodic Company Report #WAES 01050135
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750135-1Report Type:Periodic Company Report #WAES 01050139
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750136-3Report Type:Periodic Company Report #WAES 01050141
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5

MG/DAILY/PO

Aspirin C

Date:06/22/01ISR Number: 3750137-5Report Type:Periodic Company Report #WAES 01050149
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Claritin	C				
			Glucagon For Injestion (Lilly)	C				
			Glucophage	C				
			Humulin N	C				
			Prandin	C				
			Premarin	C				
			Alprazolam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750138-7Report Type:Periodic Company Report #WAES 01050152
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Sectral	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3750139-9Report Type:Periodic Company Report #WAES 01050159
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Norvasc	C				
			Vasotec	C				
			Zantac	C				
			Methotrexate	C				

Date:06/22/01ISR Number: 3750140-5Report Type:Periodic Company Report #WAES 01050162
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain Fluid Retention Proteinuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Renal Disorder		Hytrin	C				
			Neurontin	C				

Date:06/22/01ISR Number: 3750141-7Report Type:Periodic Company Report #WAES 01050163
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750142-9Report Type:Periodic Company Report #WAES 01050165
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prempro	C				
			Zanaflex	C				

Date:06/22/01ISR Number: 3750143-0Report Type:Periodic Company Report #WAES 01050167
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3750144-2Report Type:Periodic Company Report #WAES 01050060
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 MON

Date:06/22/01ISR Number: 3750145-4Report Type:Periodic Company Report #WAES 01050064
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Bleeding Periodontal Disease	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Lipitor	C				
			Chondroitin (+) Glucosamine	C				

Date:06/22/01ISR Number: 3750146-6Report Type:Periodic Company Report #WAES 01050067
Age:68 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	
			Premarin	C				
			Synthroid	C				

Aspirin	C
Calcium Carbonate (+) Vitamin D	C
Vitamin E	C
Vitamins (Unspecified)	C

Date:06/22/01ISR Number: 3750147-8Report Type:Periodic Company Report #WAES 01050070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750148-XReport Type:Periodic Company Report #WAES 01050071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage Platelet Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750149-1Report Type:Periodic Company Report #WAES 01050074
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750150-8Report Type:Periodic Company Report #WAES 01050104
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG BID PO	
			Darvocet-N	C				
			Deconamine	C				
			Flovent	C				
			Maxair	C				
			Nasacort	C				
			Nolvadex	C				
			Serevent	C				
			Singulair	C				
			Slo-Bid	C				
			[Therapy Unspecified]	C				
			Antineoplastic (Unspecified)	C				
			Ranitidine	C				

Date:06/22/01ISR Number: 3750151-XReport Type:Periodic Company Report #WAES 01050107
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG DAILY

PO

Altace	C
Paxil	C
Prevacid	C
Singulair	C
Ultram	C
Zyrtec	C
Acetaminophen (+)	
Dextropropoxyp	C
Alprazolam	C

Date:06/22/01ISR Number: 3750152-1Report Type:Periodic Company Report #WAES 01050108
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG DAILY

PO

Aricept	C
Esgic-Plus Tablets	C

Eskalith	C
Premarin	C
Prilosec	C
Furosemide	C
Levothyroxine	C
Nifedipine	C
Nortriptyline	C
Terazosin	C
Thiothixene	C

Date:06/22/01ISR Number: 3750153-3Report Type:Periodic Company Report #WAES 01050128
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/01ISR Number: 3750154-5Report Type:Periodic Company Report #WAES 01050007
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO
			Avapro	C				
			Amitriptyline	C				

Date:06/22/01ISR Number: 3750155-7Report Type:Periodic Company Report #WAES 01050010
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/01ISR Number: 3750156-9Report Type:Periodic Company Report #WAES 01050019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Eyelid Oedema					
	Fatigue					
	Fluid Retention					
	Oedema Peripheral		Inderal	C		
			Levsin	C		
			Premarin	C		
			Spironolactone	C		

Dose Duration

25 MG DAILY

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750157-0Report Type:Periodic Company Report #WAES 01050030
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Auricular Swelling							
	Basal Cell Carcinoma							
	Face Oedema		Claritin-D	C				
	Fatigue		Esgic-Plus Tablets	C				
	Nail Disorder		Gynodiol	C				
	Oedema Peripheral		Lortab	C				
			Norvasc	C				
			Prometrium	C				
			Amiloride	C				
			Glucosamine	C				
			Melatonin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3750158-2Report Type:Periodic Company Report #WAES 01050036
Age:86 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Intestinal Functional Disorder							
			Restoril	C				

Date:06/22/01ISR Number: 3750159-4Report Type:Periodic Company Report #WAES 01050037
Age:60 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Zocor	C				

Date:06/22/01ISR Number: 3750160-0Report Type:Periodic Company Report #WAES 01050039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								

Date:06/22/01ISR Number: 3750161-2Report Type:Periodic Company Report #WAES 01050042
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								10 DAY
			Glucophage	C				
			Percocet	C				
			Pravachol	C				

				Zocor	C		
				Aspirin	C		
				Lorazepam	C		

Date:06/22/01ISR Number: 3750162-4Report Type:Periodic Company Report #WAES 01050051
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Lortab	C				

Date:06/22/01ISR Number: 3750163-6Report Type:Periodic Company Report #WAES 01050057
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								3 MON

Date:06/22/01ISR Number: 3750164-8Report Type:Periodic Company Report #WAES 01042875
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspepsia Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
PO								
			Cozaar	C				

K Dur	C
Micronase	C
Pepcid	C
Synthroid	C
Zocor	C
Aspirin	C
Furosemide	C
Meclizine	C

Date:06/22/01ISR Number: 3750165-XReport Type:Periodic Company Report #WAES 01042880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY PO	

Date:06/22/01ISR Number: 3750166-1Report Type:Periodic Company Report #WAES 01042881
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/01ISR Number: 3750167-3Report Type:Periodic Company Report #WAES 01042889
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/22/01ISR Number: 3750168-5Report Type:Periodic Company Report #WAES 01042897
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oedema Peripheral Pain Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
SEE IMAGE						
			Coumadin	C		
			Prinivil	C		

Date:06/22/01ISR Number: 3750169-7Report Type:Periodic Company Report #WAES 01042910
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Gastrointestinal Disorder Myalgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG DAILY						

PO

Centrum Silver	C	
Darvocet-N	C	
Hyzaar	C	
Miacalcin	C	
Ocuvite	C	
Plavix	C	
Prevacid	C	
Zocor	C	
Aspirin	C	
Hypericin	C	
Lysine	C	
Nitroglycerin	C	
Vitamin E	C	

Date:06/22/01ISR Number: 3750170-3Report Type:Periodic Company Report #WAES 01042918
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Celebrex	C	
Flexeril	C	
Prozac	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750171-5Report Type:Periodic Company Report #WAES 01042919
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder Gait Disturbance	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
SEE IMAGE								
			Coumadin	C				
			Fosamax	C				
			Lipitor	C				
			Norvasc	C				
			Indapamide	C				

Date:06/22/01ISR Number: 3750172-7Report Type:Periodic Company Report #WAES 01042924
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
			Prempro	C				

Date:06/22/01ISR Number: 3750173-9Report Type:Periodic Company Report #WAES 01050005
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Constipation Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
PO								
	Pruritus		Ecotrin	C				
	Urinary Tract Infection		Norvasc	C				

Date:06/22/01ISR Number: 3750174-0Report Type:Periodic Company Report #WAES 01042768
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750175-2Report Type:Periodic Company Report #WAES 01042830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Muscle Rigidity Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Diazide	C				
			Verapamil	C				

Date:06/22/01ISR Number: 3750176-4Report Type:Periodic Company Report #WAES 01042832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG DAILY

PO

Ditropan	C
Flexeril	C
Fosamax	C
Maxalt (Rizatriptan Sulfate)	C
Ms Contn	C
Synthroid	C
Zantac	C
Zyrtec	C
Tamoxifen	C
Trazodone	C

Date:06/22/01ISR Number: 3750177-6Report Type:Periodic Company Report #WAES 01042834
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	

PO

Cipro	C

Date:06/22/01ISR Number: 3750178-8Report Type:Periodic Company Report #WAES 01042839
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PRN PO	

Glucosamine	C

Date:06/22/01ISR Number: 3750179-XReport Type:Periodic Company Report #WAES 01042852
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Atneolol	C				

Date:06/22/01ISR Number: 3750180-6Report Type:Periodic Company Report #WAES 01042866
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750181-8Report Type:Periodic Company Report #WAES 01042867
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG HS PO	
			Synthroid	C				

Date:06/22/01ISR Number: 3750182-XReport Type:Periodic Company Report #WAES 01042869
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
			Coreg	C			PO	
			Coumadin	C				
			Glucophage	C				
			Lanoxin	C				
			Pacerone	C				
			Zestril	C				
			Zocor	C				
			Aloopurinol	C				
			Furomsemide	C				
			Potasium Chloride	C				

Date:06/22/01ISR Number: 3750183-1Report Type:Periodic Company Report #WAES 01042872
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Lanoxin	C	
Serazone	C	
Atenolol	C	
Cimetidine	C	
Isosorbide	C	
Terazosin	C	
Triamcinolone	C	

Date:06/22/01ISR Number: 3750184-3Report Type:Periodic Company Report #WAES 01042444
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Fluctuation	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Blood Pressure Increased				Merck Co Inc	ORAL

PO

Accupril	C	
Hydrodiuril	C	
Antenolol	C	
Verapamil	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750185-5Report Type:Periodic Company Report #WAES 01042449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Diltiazem	C				

Date:06/22/01ISR Number: 3750186-7Report Type:Periodic Company Report #WAES 01042450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Eyelid Oedema Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Fosamax	C				
			Syntrhoid	C				

Date:06/22/01ISR Number: 3750187-9Report Type:Periodic Company Report #WAES 01042451
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Claritin	C				
			Elavil	C				
			Estrace	C				
			Procardia	C				
			Zantac	C				
			Gemfibrozil	C				
			...	C				

Date:06/22/01ISR Number: 3750188-0Report Type:Periodic Company Report #WAES 01042463
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750189-2Report Type:Periodic Company Report #WAES 01042468
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrasystoles	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3750190-9Report Type:Periodic Company Report #WAES 01042469
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3750191-0Report Type:Periodic Company Report #WAES 01042470
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750192-2Report Type:Periodic Company Report #WAES 01042507
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3750193-4Report Type:Periodic Company Report #WAES 01042520
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Hepatic Function Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Hyperbilirubinaemia Jaundice Myalgia Nausea Pyrexia	Company Representative			Merck Co Inc	

Date:06/22/01ISR Number: 3752104-4Report Type:Periodic Company Report #WAES 01032360
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gamma-Glutamyltransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5MG/TID/PO						
			Dantrium (Bencyclane Fumarate)	C		
			Fioricet Tablets	C		
			Valium	C		

Date:06/22/01ISR Number: 3752106-8Report Type:Periodic Company Report #WAES 01032396
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3752107-XReport Type:Periodic Company Report #WAES 01032406
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Blood Pressure Increased				Merck Co Inc	ORAL	25MG/DAILY/PO	
			Ecotrin	C				
			Vaigra	C				
			Hydrochlorothiazido (+) Triamter	C				

Date:06/22/01ISR Number: 3752109-3Report Type:Periodic Company Report #WAES01032409
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/PRN	

Date:06/22/01ISR Number: 3752111-1Report Type:Periodic Company Report #WAES 01032446
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Amaryl	C				
			Avandia	C				
			Glucophage	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Wellbutrin	C				

			Trazodone	C		

Date:06/22/01ISR Number: 3756107-5Report Type:Periodic Company Report #WAES 01032381
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Sweat Gland Disorder		Prevacid	SS		ORAL	30 MG/DAILY/PO	
			Lipitor	SS		ORAL	10 MG/DAILY/PO	
			[Therapy Unspecified]	SS		ORAL	625MG/TID/PO	
			Tab Zestoretic	SS		ORAL	DAILY/PO	

Date:06/22/01ISR Number: 3772315-1Report Type:Periodic Company Report #WAES 01042523
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	

MG/DAILY/PO

Date:06/22/01ISR Number: 3772317-5Report Type:Periodic Company Report #WAES 01042528
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772318-7Report Type:Periodic Company Report #WAES 01042529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection Rash Papular	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Ultram	C				

Date:06/22/01ISR Number: 3772319-9Report Type:Periodic Company Report #WAES 01042531
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Timodine	C				

Date:06/22/01ISR Number: 3772320-5Report Type:Periodic Company Report #WAES 01042533
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772321-7Report Type:Periodic Company Report #WAES 01042535
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tamoxifen	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3772322-9Report Type:Periodic Company Report #WAES 01042537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

				Fosamax	C		

Date:06/22/01ISR Number: 3772323-0Report Type:Periodic Company Report #WAES 01042538
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Chest Pain Eye Pain Neck Pain	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25/MG/DAILY/PO	
	Upper Respiratory Tract Infection		Flovent	C				
			Lotrel	C				
			Serevent	C				
			Tilade	C				
			Methtrexate	C				
			Prednisone	C				

Date:06/22/01ISR Number: 3772324-2Report Type:Periodic Company Report #WAES 01042539
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	1 MON
			Aerobid	C				
			Claritin	C				
			Coumadin	C				
			Detrol	C				
			Fioricet Tablets	C				
			Nasonex	C				
			Prilosec	C				
			Proventil	C				
			Singulair	C				
			Zocor	C				

Date:06/22/01ISR Number: 3772325-4Report Type:Periodic Company Report #WAES 01042541
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Sedation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Altace	C				
			Plendil	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772326-6Report Type:Periodic Company Report #WAES 01051819
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772327-8Report Type:Periodic Company Report #WAES 01051830
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772328-XReport Type:Periodic Company Report #WAES 01051836
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772329-1Report Type:Periodic Company Report #WAES 01051838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772330-8Report Type:Periodic Company Report #WAES 01051853
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research			

Laboratories Div
Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3772331-XReport Type:Periodic Company Report #WAES 01051854
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Oedema							
	Swelling							
			Diovan	C				
			Flovent	C				
			Singulair	C				
			Zocor	C				
			Oxazepam	C				

Date:06/22/01ISR Number: 3772332-1Report Type:Periodic Company Report #WAES 01051860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx [Therapy	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Unspecified] SS

Date:06/22/01ISR Number: 3772333-3Report Type:Periodic Company Report #WAES 01051876
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Drug Interaction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 DAY
			Demadex	SS				

Date:06/22/01ISR Number: 3772334-5Report Type:Periodic Company Report #WAES 01051879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772335-7Report Type:Periodic Company Report #WAES 01051885
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Percocet	C				
			Synthroid	C				
			Estradiol	C				

			Furosemide	C
			Ranitidine	C

Date:06/22/01ISR Number: 3772367-9Report Type:Periodic Company Report #WAES 01051954
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:06/22/01ISR Number: 3772368-0Report Type:Periodic Company Report #WAES 01051961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772369-2Report Type:Periodic Company Report #WAES 01051977
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772370-9Report Type:Periodic Company Report #WAES 01051978
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772371-0Report Type:Periodic Company Report #WAES 01051979
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772373-4Report Type:Periodic Company Report #WAES 01051980
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Avapro	C		
Lasix (Furosemide)	C		
Lescol	C		
Levoxyl	C		
Hydralazine	C		

Date:06/22/01ISR Number: 3772374-6Report Type:Periodic Company Report #WAES 01051983
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ogen	C				
			Prilosec	C				
			Zocor	C				
			Amitriptyline	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772375-8Report Type:Periodic Company Report #WAES 01051985
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Premarin	C				
			Spironolactone	C				

Date:06/22/01ISR Number: 3772377-1Report Type:Periodic Company Report #WAES 01051993
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PRN/PO	
			Fosamax	C				
			Norvasc	C				
			Toprol Xl Tablets	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/22/01ISR Number: 3772378-3Report Type:Periodic Company Report #WAES 01052000
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772379-5Report Type:Periodic Company Report #WAES 01051889
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS		ORAL	PO	
	Fatigue		Paxil	C				
			Vicodin Tablets	C				

Date:06/22/01ISR Number: 3772380-1Report Type:Periodic Company Report #WAES 01051892
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Health	Vioxx	PS		ORAL	25	
	Ecchymosis	Professional					MG/DAILY/PO	
	Pruritus		Thiamine	C				
			Zinc (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772382-5Report Type:Periodic Company Report #WAES 01051894
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Vioxx	PS		ORAL	PO	
	Pruritus		Effexor	C				
			Prempro	C				

Date:06/22/01ISR Number: 3772383-7Report Type:Periodic Company Report #WAES 01051896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:06/22/01ISR Number: 3772384-9Report Type:Periodic Company Report #WAES 01051898
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	3 MON

Date:06/22/01ISR Number: 3772385-0Report Type:Periodic Company Report #WAES 01050689
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO;

25

MG/DAILY/PO 7 DAY

Therapy Unspecified C

Date:06/22/01ISR Number: 3772386-2Report Type:Periodic Company Report #WAES 01051907
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Atacand	C				
			Toprol Xl Tablets	C				

Date:06/22/01ISR Number: 3772387-4Report Type:Periodic Company Report #WAES 01051909
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Lozol	C				

Date:06/22/01ISR Number: 3772388-6Report Type:Periodic Company Report #WAES 01051910
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS		ORAL	PO	

Date:06/22/01ISR Number: 3772389-8Report Type:Periodic Company Report #WAES 01051914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness Lip Dry Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	8 DAY

Date:06/22/01ISR Number: 3772390-4Report Type:Periodic Company Report #WAES 01050700
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772391-6Report Type:Periodic Company Report #WAES 01051922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	PO	
		Company Representative	Norvasc	C				
			Ogen	C				

			Trandate	C		

Date:06/22/01ISR Number: 3772392-8Report Type:Periodic Company Report #WAES 01050701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prevacid	C				
			Vasotec	C				

Date:06/22/01ISR Number: 3772393-XReport Type:Periodic Company Report #WAES 01050712
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Oedema Peripheral Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Sinequan	C				
			Xanax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772394-1Report Type:Periodic Company Report #WAES 01051292
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Loss Of Consciousness	Consumer	Tab Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Nuprin	C				
			Solaxin	C				

Date:06/22/01ISR Number: 3772395-3Report Type:Periodic Company Report #WAES 01050716
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772396-5Report Type:Periodic Company Report #WAES 01051296
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772397-7Report Type:Periodic Company Report #WAES 01050718
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:06/22/01ISR Number: 3772398-9Report Type:Periodic Company Report #WAES 01051297
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772399-0Report Type:Periodic Company Report #WAES 01050719
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Anxiety							
	Depression							
			Ativan	C				
			Zantac	C				
			Ziac	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772400-4Report Type:Periodic Company Report #WAES 01051306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772401-6Report Type:Periodic Company Report #WAES 01050720
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Asacol	C				

Date:06/22/01ISR Number: 3772402-8Report Type:Periodic Company Report #WAES 01051310
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK
			Zoloft	C				

Date:06/22/01ISR Number: 3772403-XReport Type:Periodic Company Report #WAES 01050727
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Evista	C	
Synthroid	C	
Calcium (+) Vitamin	C	
Glucosamine	C	

Date:06/22/01ISR Number: 3772404-1Report Type:Periodic Company Report #WAES 01051311
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Mass Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772405-3Report Type:Periodic Company Report #WAES 01051316
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra	C				

Ambien	C
Beconase Nasal Spray	C
Flovent	C
Ventolin Inhaler	C
Zantac	C
Lorazepam	C

Date:06/22/01ISR Number: 3772406-5Report Type:Periodic Company Report #WAES 01050735
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Hydrodiuril	C				
			Premarin	C				

Date:06/22/01ISR Number: 3772407-7Report Type:Periodic Company Report #WAES 01051318
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772408-9Report Type:Periodic Company Report #WAES 01051352
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Lip Dry	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div			

Pruritus Merck Co Inc ORAL
25

MG/DAILY/PO

Allegra	C
Cardizem	C
Flonase	C
Pravachol	C
Prevacid	C
Folic Acid	C
Niacin	C

Date:06/22/01ISR Number: 3772410-7Report Type:Periodic Company Report #WAES 01051361
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div	
	Gastritis				Merck Co Inc	ORAL

PO

Incur	C
Norvasc	C
Premarin	C
Prilosec	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772411-9Report Type:Periodic Company Report #WAES 01050737
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Hytrin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3772412-0Report Type:Periodic Company Report #WAES 01050739
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
			Therapy Unspecified	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3772413-2Report Type:Periodic Company Report #WAES 01050744
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772414-4Report Type:Periodic Company Report #WAES 01050745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lanoxin	C				

Date:06/22/01ISR Number: 3772415-6Report Type:Periodic Company Report #WAES 01050756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Rash	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 YR

Date:06/22/01ISR Number: 3772416-8Report Type:Periodic Company Report #WAES 01050760
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Corgard	C
Fosamax	C
Pravachol	C
Synthroid	C
Tylenol	C
Vicodin Tablets	C

Date:06/22/01ISR Number: 3772417-XReport Type:Periodic Company Report #WAES 01050763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772418-1Report Type:Periodic Company Report #WAES 01050765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772419-3Report Type:Periodic Company Report #WAES 01050770
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Lipitor	C				

			Ziac	C
			Aspirin	C

Date:06/22/01ISR Number: 3772420-XReport Type:Periodic Company Report #WAES 01050782
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772421-1Report Type:Periodic Company Report #WAES 01050783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772422-3Report Type:Periodic Company Report #WAES 01050784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772423-5Report Type:Periodic Company Report #WAES 01050786
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772424-7Report Type:Periodic Company Report #WAES 01050787
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772425-9Report Type:Periodic Company Report #WAES 01050788
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Representative

Date:06/22/01ISR Number: 3772426-0Report Type:Periodic Company Report #WAES 01050795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Neck Pain	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772427-2Report Type:Periodic Company Report #WAES 01050797
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772428-4Report Type:Periodic Company Report #WAES 01050798
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Swelling	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Prilosec	C				
			Propain Forte	C				
			Acetaminophen (+) Butalbital	C				

Date:06/22/01ISR Number: 3772429-6Report Type:Periodic Company Report #WAES 01050803
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	2 DAY

Date:06/22/01ISR Number: 3772430-2Report Type:Periodic Company Report #WAES 01050806
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772431-4Report Type:Periodic Company Report #WAES 01050819
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Claritin	C				

Date:06/22/01ISR Number: 3772432-6Report Type:Periodic Company Report #WAES 01050822
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772433-8Report Type:Periodic Company Report #WAES 01050837
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				
			Lipitor	C				
			Paxil	C				

Date:06/22/01ISR Number: 3772434-XReport Type:Periodic Company Report #WAES 01050844
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Tylenol Arthritis Extended Relie Composition	C				
			Unspecified	C				

Date:06/22/01ISR Number: 3772435-1Report Type:Periodic Company Report #WAES 01050845
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON
			Lipitor	C				
			Verapamil	C				

Date:06/22/01ISR Number: 3772436-3Report Type:Periodic Company Report #WAES 01050847
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Nicorette	SS				
			Premarin	C				
			Prozac	C				

Date:06/22/01ISR Number: 3772437-5Report Type:Periodic Company Report #WAES 01050850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria Oedema Peripheral Pigmentation Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAI/Y/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772438-7Report Type:Periodic Company Report #WAES 01050853
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pruritus Swelling Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestril	C				

Date:06/22/01ISR Number: 3772439-9Report Type:Periodic Company Report #WAES 01050857
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3772440-5Report Type:Periodic Company Report #WAES 01050859
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3772441-7Report Type:Periodic Company Report #WAES 01050969
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cytopec	C				

Date:06/22/01ISR Number: 3772442-9Report Type:Periodic Company Report #WAES 01050974
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Glossodynia							
	Lymphadenopathy							
	Oral Soft Tissue Disorder							
	Periodontal Disease							
	Tongue Disorder							

Date:06/22/01ISR Number: 3772443-0Report Type:Periodic Company Report #WAES 01050980
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	5 DAY

Flexeril C

Date:06/22/01ISR Number: 3772444-2Report Type:Periodic Company Report #WAES 01050985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Sustiva	C				

Date:06/22/01ISR Number: 3772445-4Report Type:Periodic Company Report #WAES 01050992
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3772446-6Report Type:Periodic Company Report #WAES 01050996
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Occult Blood	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Advil	C		
			Glucosamine	C		

Date:06/22/01ISR Number: 3772447-8Report Type:Periodic Company Report #WAES 01050999
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772448-XReport Type:Periodic Company Report #WAES 01051005
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Insomnia Nocturia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Combipatch	C				
			Combivent	C				
			Effexor	C				
			Fosamax	C				
			K-Dur	C				
			Salagen Tablets	C				

Serevent	C
Synthroid	C
Therapy Unspecified	C
Ascorbic Acid	C
Aspirin	C
Calcium	C
Phenobarbital	C
Vitamin E	C
Vitamins	C

Date:06/22/01ISR Number: 3772449-1Report Type:Periodic Company Report #WAES 01051007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772450-8Report Type:Periodic Company Report #WAES 01051008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							
	Dizziness							
	Oedema Peripheral							
	Pain In Extremity		Therapy Unspecified	C				
	Tinnitus		Estrogens	C				

Date:06/22/01ISR Number: 3772605-2Report Type:Periodic Company Report #WAES 01050871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Face Oedema					
	Fatigue					
25						
	Oedema Peripheral					
MG/DAILY/PO						
	Retching		Proscar	C		
	Salivary Hypersecretion		Zestril	C		

Date:06/22/01ISR Number: 3772607-6Report Type:Periodic Company Report #WAES 01050872
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						

Date:06/22/01ISR Number: 3772610-6Report Type:Periodic Company Report #WAES 01050874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3772611-8Report Type:Periodic Company Report #WAES 01050878
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aldoril	C				

Date:06/22/01ISR Number: 3772613-1Report Type:Periodic Company Report #WAES 01050908
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephritis Interstitial Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772614-3Report Type:Periodic Company Report #WAES 01050914
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer Rectal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab 0954-Binded Therapy Unk	C		ORAL	PO	
			Plavix	C				
			Ultram	C				

Date:06/22/01ISR Number: 3772627-1Report Type:Periodic Company Report #WAES 01050927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772629-5Report Type:Periodic Company Report #WAES 01050929
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772630-1Report Type:Periodic Company Report #WAES 01050936
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased Hypertriglyceridaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/01ISR Number: 3772632-5Report Type:Periodic Company Report #WAES 01050943
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Pruritus							
			Baycol	C				
			Darvon And Darvon Compound-65	C				
			Plaquenil	C				
			Prevacid	C				
			Prinivil	C				

Date:06/22/01ISR Number: 3772635-0Report Type:Periodic Company Report #WAES 01050953
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Myalgia							
	Oedema Peripheral							
			Lipitor	C				
			Prilosec	C				
			Xanax	C				

Date:06/22/01ISR Number: 3772644-1Report Type:Periodic Company Report #WAES 01051738
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Vioxx	PS	Merck Research			

Professional Laboratories Div
Merck Co Inc ORAL
12.5

MG/DAILY/PO
Zestril C

Date:06/22/01ISR Number: 3772645-3Report Type:Periodic Company Report #WAES 01051739
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough Dyspepsia Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3772646-5Report Type:Periodic Company Report #WAES 01051740
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Celebrex	C
			Lansoprazole	C

Date:06/22/01ISR Number: 3772647-7Report Type:Periodic Company Report #WAES 01051742
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772648-9Report Type:Periodic Company Report #WAES 01051743
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Methotrexate	C				

Date:06/22/01ISR Number: 3772649-0Report Type:Periodic Company Report #WAES 01051744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772651-9Report Type:Periodic Company Report #WAES 01051749
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
			Celebrex	C			

Date:06/22/01ISR Number: 3772652-0Report Type:Periodic Company Report #WAES 01051750
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772653-2Report Type:Periodic Company Report #WAES 01051752
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Dizziness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772655-6Report Type:Periodic Company Report #WAES 01051778
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							
	Rash Erythematous							
			Prempro	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772658-1Report Type:Periodic Company Report #WAES 01021319
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/22/01ISR Number: 3772659-3Report Type:Periodic Company Report #WAES 01021380
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Fosamax	C				
			Hydrea	C				
			Synthroid	C				
			Cyanocobalamin	C				
			Folic Acid	C				

Date:06/22/01ISR Number: 3772674-XReport Type:Periodic Company Report #WAES 01021405
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra D	C				
			Celebrex	C				
			Premarin	C				
			Xanax	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3772677-5Report Type:Periodic Company Report #WAES 01021406
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Trilistate Tablets/Liquid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772680-5Report Type:Periodic Company Report #WAES 01021419
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	50 MG/DAILY/PO	

SEE IMAGE

Date:06/22/01ISR Number: 3772682-9Report Type:Periodic Company Report #WAES 01021428
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acrochordon	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Blister							
	Gingival Hyperplasia							
	Haemorrhage							
	Inflammation		Menest	C				
	Mouth Ulceration		Prevacid	C				
	Oral Soft Tissue Disorder		Toprol Xl Tablets	C				
	Paraesthesia		Zocor	C				
	Toothache		Aspirin	C				
	Vasodilatation		Calcium (Unspecified) (+) Vitami	C				

Date:06/22/01ISR Number: 3772684-2Report Type:Periodic Company Report #WAES 01021429
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective							
			Ditropan Xl	C				
			Premarin	C				

Date:06/22/01ISR Number: 3772685-4Report Type:Periodic Company Report #WAES 01021448
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Gastrointestinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Premarin	C				

Date:06/22/01ISR Number: 3772687-8Report Type:Periodic Company Report #WAES 01021453
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety Hypercholesterolaemia Hypertension	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25/MG/BID/PO SEE IMAGE	
			Cipro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772688-XReport Type:Periodic Company Report #WAES 01021545
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia Tongue Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772705-7Report Type:Periodic Company Report #WAES 01021066
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				
			Lasix	C				
			Pravachol	C				
			Prilosec	C				
			Restoril	C				
			Tiazac	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Digoxin	C				
			Insulin	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3772708-2Report Type:Periodic Company Report #WAES 01021089
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspepsia Gastrointestinal Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Gastrooesophageal Reflux		Bentyl	C				

	Disease	Celebrex	C
	Nausea	Prevacid	C
	Pain		
	Vision Blurred		

Date:06/22/01ISR Number: 3772709-4Report Type:Periodic Company Report #WAES 01021108
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Vioxx	PS	Merck Research			
	Rash	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	50	MG/DAILY/PO
			Celebrex	C				
			Vicodin Tablets	C				

Date:06/22/01ISR Number: 3772712-4Report Type:Periodic Company Report #WAES 01021111
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			
					Laboratories Div			

Merck Co Inc ORAL
25 MG/BID/PO

Plaquenil	C	
Prednisone	C	

Date:06/22/01ISR Number: 3772714-8Report Type:Periodic Company Report #WAES 01021124
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Vioxx	PS	Merck Research			
	Hypertension	Professional			Laboratories Div			
	Palpitations	Company			Merck Co Inc	ORAL	50	
		Representative					MG/DAILY/PO	
			Lipitor	C				
			Tenormin	C				

Date:06/22/01ISR Number: 3772717-3Report Type:Periodic Company Report #WAES 01010447
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Vioxx	PS		ORAL	25 MG/HS/PO	
		Professional	Flexeril	C				

Date:06/22/01ISR Number: 3772718-5Report Type:Periodic Company Report #WAES 01010477
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS		ORAL	12.5	
		Health					MG/BID/PO	
		Professional	Atarax	C				
			Darvocet-N	C				
			Effexor	C				
			Flexeril	C				
			Humibid	C				

			Lactaid Caplets	C
			Sucraid	C
			Tofranil	C
			Urised Tablets	C
			Calcium Carbonate	C
			Vitamins (Unspecified)	C

Date:06/22/01ISR Number: 3772719-7Report Type:Periodic Company Report #WAES 01010505
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Night Sweats	Consumer	Vioxx	PS		ORAL	SEE IMAGE	
		Health Professional	Cataflam	C				
			Darvocet-N	C				
			Skelaxin	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3772720-3Report Type:Periodic Company Report #WAES 01010641
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO 14 DAY
Celebrex C

Date:06/22/01ISR Number: 3772721-5Report Type:Periodic Company Report #WAES 01010711
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research			
	Fatigue	Health			Laboratories Div			
	Rhinitis Allergic	Professional			Merck Co Inc	ORAL	25	MG/DAILY/PO
			Effexor	C				
			Norvasc	C				
			Zebeta	C				

Date:06/22/01ISR Number: 3772722-7Report Type:Periodic Company Report #WAES 01010734
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25MG/DAILY/PO	
			Estrace	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Relafen	C				
			Vasotec	C				
			Xanax	C				

Date:06/22/01ISR Number: 3772723-9Report Type:Periodic Company Report #WAES 01010771
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Vioxx	PS	Merck Research			
		Professional			Laboratories Div			

					Merck Co Inc	ORAL
PO						

Date:06/22/01ISR Number: 3772724-0Report Type:Periodic Company Report #WAES 01010811
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemorrhoids	Consumer	Vioxx	PS	Merck Research	
	Vascular Injury	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
PO						

Date:06/22/01ISR Number: 3772725-2Report Type:Periodic Company Report #WAES 01010814
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Musculoskeletal Pain	Health	Vioxx	PS	Merck Research	
	Oedema Peripheral	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
50 MG/PRN/PO						
		Representative	Norvasc	C		
			Ziac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772726-4Report Type:Periodic Company Report #WAES 01010815
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772731-8Report Type:Periodic Company Report #WAES 01021177
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain Headache Tinnitus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772732-XReport Type:Periodic Company Report #WAES 01021182
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
			Evista	C				
			Prinzide	C				
			Thyroid	C				

Date:06/22/01ISR Number: 3772734-3Report Type:Periodic Company Report #WAES 01021183
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:06/22/01ISR Number: 3772735-5Report Type:Periodic Company Report #WAES 01021185
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772736-7Report Type:Periodic Company Report #WAES 01021288
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/01ISR Number: 3772737-9Report Type:Periodic Company Report #WAES 01021294
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Oedema Peripheral	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atenolol	C				
			Nifedipine	C				

Date:06/22/01ISR Number: 3772738-0Report Type:Periodic Company Report #WAES 01020761
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Influenza Like Illness	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG, DAILY; PO	

Date:06/22/01ISR Number: 3772739-2Report Type:Periodic Company Report #WAES 01020762
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Faeces Discoloured	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY; PO	

			Methocarbamol	C		

Date:06/22/01ISR Number: 3772740-9Report Type:Periodic Company Report #WAES 01020775
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG, DAILY, PO	
			Hydrodiuril	C				
			Propranolol	C				

Date:06/22/01ISR Number: 3772742-2Report Type:Periodic Company Report #WAES 01020778
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Influenza Like Illness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	37.5 MG, DAILY, PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772744-6Report Type:Periodic Company Report #WAES 01020873
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY;	
	Aspartate Aminotransferase Increased		Allopurinol	SS			PO	
	Blood Alkaline Phosphatase Increased		Norvasc (Therapy Unspecified)	C				
			Aspirin	C				
			Colchicine	C				

Date:06/22/01ISR Number: 3772745-8Report Type:Periodic Company Report #WAES 01020885
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG, DAILY;	
	Oedema Peripheral	Health Professional					PO	
	Pollakiuria		Estrace	C				
			Levoxyl	C				
			Synthroid	C				
			Ibuprofen	C				

Date:06/22/01ISR Number: 3772746-XReport Type:Periodic Company Report #WAES 01020963
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Below Therapeutic	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50MG; DAILY;	

PO SEE IMAGE

	Tab Vioxx	SS		ORAL

25 MG/DAILY;

PO

	Prozac	SS		

20 MG, DAILY;

Date:06/22/01ISR Number: 3772747-1Report Type:Periodic Company Report #WAES 01020965
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25MG, DAILY;

PO

	Composition			
	Unspecified	C		
	Aspirin	C		
	Calcium (Unspecified)	C		
	Ibuprofen	C		
	Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772748-3Report Type:Periodic Company Report #WAES 01020972
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772749-5Report Type:Periodic Company Report #WAES 01021023
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG, DAILY, PO	

Date:06/22/01ISR Number: 3772750-1Report Type:Periodic Company Report #WAES 01051494
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anuria Fluid Retention	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/ DAILY/ PO; 2) 25 MG/Q4D/PO	
			Paxil	C				
			Prilosec	C				
			Zocor	C				

Date:06/22/01ISR Number: 3772751-3Report Type:Periodic Company Report #WAES 01051497
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Depression							

Date:06/22/01ISR Number: 3772752-5Report Type:Periodic Company Report #WAES 01051501
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Hallucination							
	Mental Impairment							
	Vision Blurred							
			Actonel	C				
			Duratuss	C				
			Maxair	C				
			Singulair	C				
			Acetaminophen (+) Hydrocodone Bi	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772753-7Report Type:Periodic Company Report #WAES 01051509
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772754-9Report Type:Periodic Company Report #WAES 01051514
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Folic Acid	C				
			Methotrexate	C				

Date:06/22/01ISR Number: 3772755-0Report Type:Periodic Company Report #WAES 01051516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772756-2Report Type:Periodic Company Report #WAES 01051517
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oral Soft Tissue Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/01ISR Number: 3772758-6Report Type:Periodic Company Report #WAES 01051518
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Klonopin	C		
			Neurontin	C		
			Prilosec	C		
			Risperdal	C		
			Aspirin	C		

Dose Duration

25

MG/DAILY/PO

Date:06/22/01ISR Number: 3772760-4Report Type:Periodic Company Report #WAES 01051519
Age:71 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Fluid Retention

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Evista	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772762-8Report Type:Periodic Company Report #WAES 01051520
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Acetaminophen	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3772765-3Report Type:Periodic Company Report #WAES 01051446
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Carita (Diltiazem Hydrochloride)	C				
			Cozaar	C				
			Hycroton	C				

K-Dur	C
Mevacor	C
Aspirin	C
Ca;Cium	C
Niacin	C

Date:06/22/01ISR Number: 3772767-7Report Type:Periodic Company Report #WAES 01051448
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Fatigue	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772768-9Report Type:Periodic Company Report #WAES 01051450
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Azmacort C

Date:06/22/01ISR Number: 3772770-7Report Type:Periodic Company Report #WAES 01051451
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukopenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772772-0Report Type:Periodic Company Report #WAES 01051452
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Dry	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dura-Vent	C				
			Xanax	C				

Date:06/22/01ISR Number: 3772774-4Report Type:Periodic Company Report #WAES 01051453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dermatitis							
	Diarrhoea							
	Dizziness							
	Fatigue		Darvocet-N	C				
			Diazide	C				

Date:06/22/01ISR Number: 3772775-6Report Type:Periodic Company Report #WAES 01051457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Chills	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:06/22/01ISR Number: 3772777-XReport Type:Periodic Company Report #WAES 01051465
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772779-3Report Type:Periodic Company Report #WAES 01051467
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Pain In Extremity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3772781-1Report Type:Periodic Company Report #WAES 01051492
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:06/22/01ISR Number: 3772783-5Report Type:Periodic Company Report #WAES 01051406
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain Breast Pain Dyspepsia Micturition Urgency	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	
	Renal Colic Urinary Incontinence		Celebrex	C				

Date:06/22/01ISR Number: 3772785-9Report Type:Periodic Company Report #WAES 01051407
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3772786-0Report Type:Periodic Company Report #WAES 01051411
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	

Date:06/22/01ISR Number: 3772787-2Report Type:Periodic Company Report #WAES 01051412
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall Headache Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 WK
			Norvasc	C				

		Paxil	C
		Prempro	C
		Valtrex	C
		Prednisone	C

Date:06/22/01ISR Number: 3772789-6Report Type:Periodic Company Report #WAES 01051415
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lasix	C				

Date:06/22/01ISR Number: 3772790-2Report Type:Periodic Company Report #WAES 01051418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Glucophage	C				
			Glipizide	C				

Date:06/22/01ISR Number: 3772792-6Report Type:Periodic Company Report #WAES 01051419
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
PO

Date:06/22/01ISR Number: 3772794-XReport Type:Periodic Company Report #WAES 01051428
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3772795-1Report Type:Periodic Company Report #WAES 01051433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Clonazepam	C				
			Propylthiouracil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772797-5Report Type:Periodic Company Report #WAES 01051441
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Cough Pyrexia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Antimicrobial	C				

Date:06/22/01ISR Number: 3772812-9Report Type:Periodic Company Report #WAES 00092105
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/AM/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/PM/PO	

Date:06/22/01ISR Number: 3772815-4Report Type:Periodic Company Report #WAES 00101534
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Abdominal Pain Nausea	Consumer	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	PO	
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3772816-6Report Type:Periodic Company Report #WAES 00102436
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 MON
	Rash							
	Rectal Haemorrhage							
	Urinary Incontinence		Hydrodiuril	C				
			Lopid	C				
			Lotensin	C				
			Prinivil	C				
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3772819-1Report Type:Periodic Company Report #WAES 00102528
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pain In Extremity							
			Carafate	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772820-8Report Type:Periodic Company Report #WAES 00102549
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral							
	Pigmentation Disorder							
	Weight Increased							

Date:06/22/01ISR Number: 3772822-1Report Type:Periodic Company Report #WAES 00102576
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
	Dizziness							
	Fluid Retention							
			Ecotrin	C				
			Tenormin	C				
			Zestril	C				

Date:06/22/01ISR Number: 3772824-5Report Type:Periodic Company Report #WAES 00110169
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Irritation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Keratoconjunctivitis							
	Sicca							
	Rash							
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3772826-9Report Type:Periodic Company Report #WAES 00110357
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Dizziness							
	Drug Ineffective				Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:06/22/01ISR Number: 3772827-0Report Type:Periodic Company Report #WAES 00110609
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Diarrhoea				Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Actos	C				
			Estraderm Transdermal System	C				
			Glucophage	C				
			Prilosec	C				
			Ziac	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772828-2Report Type:Periodic Company Report #WAES 00111068
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS	Merck Research			
	Asthenia	Health			Laboratories Div			
	Drug Ineffective	Professional			Merck Co Inc	ORAL	PO	
	Dyspepsia		Methylphenidate	C				
	Fatigue							
	Headache							

Date:06/22/01ISR Number: 3772832-4Report Type:Periodic Company Report #WAES 00011745
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx	PS		ORAL	12.5	MG/DAILY/PO
	Asthenia							
	Balance Disorder		Tab Vioxx 25 Mg	SS		ORAL	25	MG/DAILY/PO
	Depression							
	Dizziness		Klonopin	C				
	Fatigue		Plaquenil	C				
	Movement Disorder		Premarin	C				
	Muscle Rigidity		Serecor	C				
			Seroquel	C				
			Tylenol	C				
			[Therapy Unspecified]	C				
			Diphenhydramine	C				

Date:06/22/01ISR Number: 3772845-2Report Type:Periodic Company Report #WAES 00030041
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	PO	

	Malaise	Benadryl	C
		Lotensin	C
		Norvasc	C
		Prozac	C
		Singulair	C
		Ultram	C
		Ventolin	C
		Furosemide	C
		Theophylline	C

Date:06/22/01ISR Number: 3772846-4Report Type:Periodic Company Report #WAES 00041629
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Drug Ineffective		Prozac	C				
	Fatigue		Prozac	C				
	Sedation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772847-6Report Type:Periodic Company Report #WAES 00052690
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Ineffective	Health Professional						
	Gastrointestinal Disorder							
	Nausea		Tab Vioxx	SS		ORAL	PO	
			Tab Vioxx	SS		ORAL	PO	
			Xanax	C				
			Aspirin	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3772849-XReport Type:Periodic Company Report #WAES 00070839
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Photosensitivity Reaction							
			Lescol	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3772850-6Report Type:Periodic Company Report #WAES 00081280
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dermatitis							
	Paraesthesia							
	Pruritus							

	Urticaria		Tab Vioxx	SS		ORAL
PO						
			Penicillin	SS		
INJ						
			Estratab	C		
			Levothroid	C		
			Premarin	C		
			Synthroid	C		
			[Therapy Unspecified]	C		
			Flurazepam	C		

Date:06/22/01ISR Number: 3772852-XReport Type:Periodic Company Report #WAES 00081771
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Vioxx	PS		ORAL
PO						
	Blood Pressure Increased		Tab Vioxx 25 Mg	SS		ORAL
25						
	Fatigue					
MG/DAILY/PO						
	Insomnia		Xanax	C		
	Nervousness		Doxycycline	C		
	Pain		Prednisone	C		
	Pyrexia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3772854-3Report Type:Periodic Company Report #WAES 00082809
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/BID/PO	
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3772855-5Report Type:Periodic Company Report #WAES 00082973
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional Company Representative						

Date:06/22/01ISR Number: 3772857-9Report Type:Periodic Company Report #WAES 00092103
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

Date:06/22/01ISR Number: 3773196-2Report Type:Periodic Company Report #WAES 01020117
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID PO	
	Attention Deficit/Hyperactivity Disorder	Professional Company Representative	Caffeine	SS				
	Excitability							
	Nervousness							

Date:06/22/01ISR Number: 3773198-6Report Type:Periodic Company Report #WAES 01020196
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
	Fall	Health Professional	Detrol	C				
	Syncope		Vitamins	C				

Date:06/22/01ISR Number: 3773199-8Report Type:Periodic Company Report #WAES 01020546
Age:36 YR Gender:Female I/FU:F

Outcome	PT
	Constipation
	Disorientation
	Dyspepsia
	Feeling Abnormal

	Flatulence						
	Movement Disorder						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
							PO	
			Ativan	C				
			Wellbutrin	C				

Date:06/22/01ISR Number: 3773200-1Report Type:Periodic Company Report #WAES 01020619
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Dyspepsia	Health					PO	
	Pruritus	Professional	Datril	C				
			Evista	C				
			Levothyroid	C				
			Amitriptyline	C				
			Calcium	C				

Date:06/22/01ISR Number: 3773201-3Report Type:Periodic Company Report #WAES 01020660
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Centrum Silver	C				
			Vasotec	C				
			Amiodarone	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3773202-5Report Type:Periodic Company Report #WAES 01020667
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspepsia	Health					MG/DAILY/PO	
	Nausea	Professional	Relafen	C				
			Tegretol	C				
			Versene	C				
			Acetaminophen	C				
			Naproxen	C				

Date:06/22/01ISR Number: 3773203-7Report Type:Periodic Company Report #WAES 01020670
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional Company Representative	Prevacid	C				
			Oxycodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773258-XReport Type:Periodic Company Report #WAES 01051013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/22/01ISR Number: 3773261-XReport Type:Periodic Company Report #WAES 01051014
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/22/01ISR Number: 3773263-3Report Type:Periodic Company Report #WAES 01051015
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Drug Ineffective		Coumadin	C				
	Fatigue		Synthroid	C				
	Muscle Spasms		Hormones	C				
	Nausea							

Date:06/22/01ISR Number: 3773265-7Report Type:Periodic Company Report #WAES 01051016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health Professional	Tab Vioxx	PS		ORAL	PO	

Company
Representative

Date:06/22/01ISR Number: 3773267-0Report Type:Periodic Company Report #WAES 01051018
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vasculitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/22/01ISR Number: 3773268-2Report Type:Periodic Company Report #WAES 01051022
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773269-4Report Type:Periodic Company Report #WAES 01051026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	3 DAY
	Dizziness		Synthroid	C				
	Nausea		Esterogens	C				
	Oedema Peripheral							
	Pain In Extremity							
	Tinnitus							

Date:06/22/01ISR Number: 3773270-0Report Type:Periodic Company Report #WAES 01051030
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Blood Thyroid Stimulating Hormone Increased	Professional						
			Welchol 625mg	SS		ORAL	1875 MG/DAILY/PO	
	Fatigue							
			Synthroid	C				
			Synthroid	C				
			Synthroid	C				
			Pioglitazone Hydrochloride	C				

Date:06/22/01ISR Number: 3773271-2Report Type:Periodic Company Report #WAES 01051034
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 DAY
	Anxiety							

Date:06/22/01ISR Number: 3773288-8Report Type:Periodic Company Report #WAES 01051036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Company	Tab Vioxx 25mg	PS		ORAL	50 MG/DAILY/PO	
	C-Reactive Protein Increased	Representative Other						
	Dyspnoea							
	Ear Disorder							
	Fatigue							
	Hyperaesthesia							
	Joint Swelling							
	Pruritus							

Date:06/22/01ISR Number: 3773294-3Report Type:Periodic Company Report #WAES 01051103
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773298-0Report Type:Periodic Company Report #WAES 01051107
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3773300-6Report Type:Periodic Company Report #WAES 01051108
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Enbrel	C				
			Prednisone	C				

Date:06/22/01ISR Number: 3773301-8Report Type:Periodic Company Report #WAES 01051111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773304-3Report Type:Periodic Company Report #WAES 01051113
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/Q12H/PO	
			Zoloft	C				
			Amitriptyline	C				

Date:06/22/01ISR Number: 3773309-2Report Type:Periodic Company Report #WAES 01051115
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773312-2Report Type:Periodic Company Report #WAES 01051116
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Avapro	C	
Calan	C	
Norvasc	C	
Toprol Xl Tablets	C	

Date:06/22/01ISR Number: 3773315-8Report Type:Periodic Company Report #WAES 01051118
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

MG/DAILY/PO

Zocor	C	

Date:06/22/01ISR Number: 3773322-5Report Type:Periodic Company Report #WAES 01051119
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Adalat	C	
Pamelor	C	
Prilosec	C	

Date:06/22/01ISR Number: 3773328-6Report Type:Periodic Company Report #WAES 01051124
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	

Representative
MG/DAILY/PO
Nonsteroidal
Anti-Inflammatory C

Date:06/22/01ISR Number: 3773334-1Report Type:Periodic Company Report #WAES 01051165
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY

Date:06/22/01ISR Number: 3773337-7Report Type:Periodic Company Report #WAES 01051168
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773339-0Report Type:Periodic Company Report #WAES 01051178
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773341-9Report Type:Periodic Company Report #WAES 01051205
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Dysuria							
	Flushing							
	Genital Pruritus Female							
	Pain In Extremity		Serzone	C				
	Vaginal Infection		Alprazolam	C				
			Estradiol	C				

Date:06/22/01ISR Number: 3773355-9Report Type:Periodic Company Report #WAES 01051257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspepsia							
	Fatigue							

Date:06/22/01ISR Number: 3773357-2Report Type:Periodic Company Report #WAES 01051264
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Vioxx	PS	Merck Research			

		Professional Company Representative			Laboratories Div Merck Co Inc	ORAL

PO

Date:06/22/01ISR Number: 3773358-4Report Type:Periodic Company Report #WAES 01051279
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Betagen	C		
			Fosamax	C		
			Lipitor	C		
			Premarin	C		
			Univasc	C		
			Vicon-C	C		
			Aspirin	C		
			Folic Acid	C		
			Sulfasalazine	C		
			Vitamin E	C		

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773359-6Report Type:Periodic Company Report #WAES 01051280
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Ultram	C				
			Cortisone	C				

Date:06/22/01ISR Number: 3773360-2Report Type:Periodic Company Report #WAES 01051285
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Movement Disorder Muscle Rigidity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773361-4Report Type:Periodic Company Report #WAES 01051289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773392-4Report Type:Periodic Company Report #WAES 01051130
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Lipitor C
Viagra C

Date:06/22/01ISR Number: 3773394-8Report Type:Periodic Company Report #WAES 01051134
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/1X/PO	
			Novocain	C				
			Tylenol	C				

Date:06/22/01ISR Number: 3773397-3Report Type:Periodic Company Report #WAES 01051136
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Synthroid (Composition	C				

Unspecified) C

Date:06/22/01ISR Number: 3773398-5Report Type:Periodic Company Report #WAES 01051138
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	2 DAY
			Flonase	C				
			Fosamax	C				
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3773400-0Report Type:Periodic Company Report #WAES 01051141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Lotensin	C				

Date:06/22/01ISR Number: 3773402-4Report Type:Periodic Company Report #WAES 01051146
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Darvocet-N	C				

			Neurontin	C		
			Nifedicor	C		
			Prilosec	C		
			[Therapy Unspecified]	C		
			Metropolol	C		

Date:06/22/01ISR Number: 3773403-6Report Type:Periodic Company Report #WAES 01051154
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Diltiazem Hydrochloride	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773405-XReport Type:Periodic Company Report #WAES 01051156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773407-3Report Type:Periodic Company Report #WAES 01051158
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Localised Oedema Oedema Peripheral Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773408-5Report Type:Periodic Company Report #WAES 01051160
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Neurontin	C				
			Tylox	C				
			Trazodone	C				

Date:06/22/01ISR Number: 3773409-7Report Type:Periodic Company Report #WAES 01020743
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx	PS			ORAL
PO							
	Gastrointestinal Disorder		Tenormin	C			

Date:06/22/01ISR Number: 3773411-5Report Type:Periodic Company Report #WAES 01020759
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Oesophageal Disorder		Axid	C		
			Flomax (Morniflumate)	C		
			Isoptin	C		
			Prevacid	C		
			Zocor	C		
			Herbal Remedies (Unspecified)	C		

Date:06/22/01ISR Number: 3773417-6Report Type:Periodic Company Report #WAES 01052025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773420-6Report Type:Periodic Company Report #WAES 01052088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773425-5Report Type:Periodic Company Report #WAES 01052094
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773428-0Report Type:Periodic Company Report #WAES 01052095
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PRN/PO	

Date:06/22/01ISR Number: 3773439-5Report Type:Periodic Company Report #WAES 01052111
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/01ISR Number: 3773441-3Report Type:Periodic Company Report #WAES 01052153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773443-7Report Type:Periodic Company Report #WAES 01052154
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Asacol	C				
			Toradol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773445-0Report Type:Periodic Company Report #WAES 01052165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773449-8Report Type:Periodic Company Report #WAES 01052244
Age:90 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773450-4Report Type:Periodic Company Report #WAES 01060391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin Tablets	C				

Date:06/22/01ISR Number: 3773520-0Report Type:Periodic Company Report #WAES 01042408
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

			Exelon	C		
			Iron	C		

Date:06/22/01ISR Number: 3773521-2Report Type:Periodic Company Report #WAES 01042409
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Fatigue							
	Headache		Adderall Tablets	C				
	Pollakiuria							

Date:06/22/01ISR Number: 3773522-4Report Type:Periodic Company Report #WAES 01042412
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nail Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773523-6Report Type:Periodic Company Report #WAES 01042419
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Citracal	C				
			Evista	C				
			Norvasc	C				
			Ascorbic Acid	C				
			Glucosamine	C				
			Vitamin E	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3773524-8Report Type:Periodic Company Report #WAES 01042425
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia Eye Pruritus Face Oedema Lacrimation Increased	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Pharyngitis Rhinorrhoea		Elavil	C				
			Librium	C				
			Lopid	C				
			Pravachol	C				
			Prempro	C				
			Synthroid	C				

Date:06/22/01ISR Number: 3773525-XReport Type:Periodic Company Report #WAES 01042429
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache Tachycardia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25

MG/DAILY/PO

Date:06/22/01ISR Number: 3773526-1Report Type:Periodic Company Report #WAES 01042430
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Accutril	C				
			Duricef	C				

Date:06/22/01ISR Number: 3773527-3Report Type:Periodic Company Report #WAES 01042432
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia Dyspnoea Pharyngitis Throat Tightness	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Evista	C				

			Levoxyl	C
			Prevacid	C
			Calcium	C
			Phenobarbital	C

Date:06/22/01ISR Number: 3773528-5Report Type:Periodic Company Report #WAES 01042442
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Fosamax	C				
			Premarin	C				
			Provera	C				

Date:06/22/01ISR Number: 3773529-7Report Type:Periodic Company Report #WAES 01042443
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Aspirin	C				
			Glyburide	C				
			Ibuprofen	C				

Date:06/22/01ISR Number: 3773530-3Report Type:Periodic Company Report #WAES 01012372
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
	Drug Ineffective	Health			Laboratories Div			

		Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Coumadin	C		
			Lanoxin	C		
			Diltiazem	C		

Date:06/22/01ISR Number: 3773531-5Report Type:Periodic Company Report #WAES 01012475
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research	
	Pain	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Hydrodiuril	C		
			Neurontin	C		
			Potassium Chloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773532-7Report Type:Periodic Company Report #WAES 01012482
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Epigastric Discomfort Nausea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50	MG/DAILY/PO
			Prilosec	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3773533-9Report Type:Periodic Company Report #WAES 01012532
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO 1 DAY

Date:06/22/01ISR Number: 3773534-0Report Type:Periodic Company Report #WAES 01012564
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Inderal	C				

Date:06/22/01ISR Number: 3773535-2Report Type:Periodic Company Report #WAES 01012568
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity Pruritus Urticaria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773536-4Report Type:Periodic Company Report #WAES 01012595
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773537-6Report Type:Periodic Company Report #WAES 01012616
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Fluid Retention Pain		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

		Baycol	C
		Prinivil	C
		Aspirin	C
		Diazepam	C

Date:06/22/01ISR Number: 3773538-8Report Type:Periodic Company Report #WAES 01012668
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773539-XReport Type:Periodic Company Report #WAES 01012675
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Amaryl	C				
			Synthroid	C				
			Synvisc	C				
			Cortisone	C				
			Glucosamine	C				
			Insulin	C				

Date:06/22/01ISR Number: 3773540-6Report Type:Periodic Company Report #WAES 01011851
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness Neck Pain	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	
			Inderal	C				

			Proscar	C		

Date:06/22/01ISR Number: 3773541-8Report Type:Periodic Company Report #WAES 01011864
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/PO	
	Nausea							
	Swelling							
	Weight Increased		Xanax	C				

Date:06/22/01ISR Number: 3773542-XReport Type:Periodic Company Report #WAES 01011867
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773543-1Report Type:Periodic Company Report #WAES 01011980
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Disorder	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773544-3Report Type:Periodic Company Report #WAES 01012059
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer Health Professional	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dizziness							
	Fatigue							
	Feeling Abnormal		Actos	C				
	Fluid Retention		Glucophage	C				
	Nausea		K-Dur	C				
	Palpitations		Lasix (Furosemide)	C				
	Pigmentation Disorder		Lescol	C				
	Renal Colic		Robaxin	C				
	Sensation Of Heaviness		Vicodin Tablets	C				
			Verapamil	C				

Date:06/22/01ISR Number: 3773545-5Report Type:Periodic Company Report #WAES 01012065
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773546-7Report Type:Periodic Company Report #WAES 01012094
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pneumonia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div	
	Rib Fracture					
	Urinary Tract Infection				Merck Co Inc	ORAL
25 MG/BID/PO						
			Ceclor Cd	C		
			Diflucan	C		
			Hydromet	C		
			Levaquin	C		
			Tussafed	C		
			Vicodin Es Tablets	C		
			Acetaminophen (+)			
			Hydrocodone Bi	C		
			Albuterol	C		
			Clonazepam	C		
			Fluconazole	C		
			Ibuprofen	C		
			Orphenadrine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773547-9Report Type:Periodic Company Report #WAES 01012208
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS	Merck Research			
	Micturition Disorder	Health			Laboratories Div			
	Urticaria	Professional			Merck Co Inc	ORAL	25 MG/BID/PO	
			Evista	C				
			Lipitor	C				

Date:06/22/01ISR Number: 3773548-0Report Type:Periodic Company Report #WAES 01012237
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Tab Vioxx 25 Mg	PS	Merck Research			
	Tinnitus	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zithromax	C				
			Calcium	C				

Date:06/22/01ISR Number: 3773549-2Report Type:Periodic Company Report #WAES 01012328
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS	Merck Research			
		Professional			Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Vasotec	C				
			Celecoxib	C				

Date:06/22/01ISR Number: 3773550-9Report Type:Periodic Company Report #WAES 01051037
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Olfactory Nerve Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/01ISR Number: 3773551-0Report Type:Periodic Company Report #WAES 01051038
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prothrombin Time Prolonged	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Hytrin	C				
			Mevacor	C				
			Proventil	C				
			Salagen Tablets	C				
			Tenormin	C				
			Vanceril	C				
			Albuterol	C				
			Isosorbide	C				
			Theophylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773552-2Report Type:Periodic Company Report #WAES 01051040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	

Date:06/22/01ISR Number: 3773553-4Report Type:Periodic Company Report #WAES 01051047
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Celebrex	C				
			Centrum	C				
			Glucovance	C				
			Prinivil	C				
			Sythroid	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3773554-6Report Type:Periodic Company Report #WAES 01051048
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25M MG/UNK/PO	

Date:06/22/01ISR Number: 3773555-8Report Type:Periodic Company Report #WAES 01051068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			

Date:06/22/01ISR Number: 3773556-XReport Type:Periodic Company Report #WAES 01051071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773557-1Report Type:Periodic Company Report #WAES 01051081
Age:68 YR Gender:Female I/FU:I

Outcome	PT
	Bowel Sounds Abnormal Decreased Appetite Flatulence Increased Appetite

Malaise

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Celebrex	C				
	Norvasc	C				
	Furosemide	C				
	Vitamins (Unspecified)	C				

Date:06/22/01ISR Number: 3773558-3Report Type:Periodic Company Report #WAES 01051097
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dysgeusia							
	Increased Appetite							
	Weight Increased							

Date:06/22/01ISR Number: 3773559-5Report Type:Periodic Company Report #WAES 01051100
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Coronary Artery Disease							
			Dextropropoxyphene	C				
			Estrogens (Unspecified)	C				
			Warfarin	C				

Date:06/22/01ISR Number: 3773560-1Report Type:Periodic Company Report #WAES 01051791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773561-3Report Type:Periodic Company Report #WAES 01051793
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Pruritus Pruritus Genital	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773562-5Report Type:Periodic Company Report #WAES 01051795
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactose Intolerance	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773563-7Report Type:Periodic Company Report #WAES 01051796
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	

Date:06/22/01ISR Number: 3773564-9Report Type:Periodic Company Report #WAES 01051804
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dermatitis Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Azamacort	C				
			Proventil	C				

Date:06/22/01ISR Number: 3773565-0Report Type:Periodic Company Report #WAES 01051808
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
			Celexa	C		

Date:06/22/01ISR Number: 3773566-2Report Type:Periodic Company Report #WAES 01051810
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dermatitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Axid	C		
			Coumadin	C		
			Zocor	C		
			Atenolol	C		
			Diclofenac	C		
			Pentoxifylline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773567-4Report Type:Periodic Company Report #WAES 01051811
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Coumadin	C				
			Prinivil	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3773568-6Report Type:Periodic Company Report #WAES 01051812
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773569-8Report Type:Periodic Company Report #WAES 01051814
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan Sr	C				
			Fosamax	C				
			Hydrodiuril	C				
			Premarin	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3773571-6Report Type:Periodic Company Report #WAES 01042259
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50 MG/DAILY/PO	
			Premarin	C				

Date:06/22/01ISR Number: 3773572-8Report Type:Periodic Company Report #WAES 01042260
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nasacort	C				
			Premarin	C				
			Ziac	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773574-1Report Type:Periodic Company Report #WAES 01042263
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 50 MG/DAILY/PO	
			Evista	C				
			Ascorbic Acid	C				
			Calcium (Unspceified) (+)					
			Vitami	C				
			Chondroitin (+)					
			Glucosamine	C				

Date:06/22/01ISR Number: 3773576-5Report Type:Periodic Company Report #WAES 01042275
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Centrum Silver	C				
			Diazide	C				
			Glucophage	C				
			Lipitor	C				
			Neurontin	C				
			Synthroid	C				
			Tylenol	C				

Date:06/22/01ISR Number: 3773577-7Report Type:Periodic Company Report #WAES 01042279
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Diarrhoea Drug Ineffective Vomiting	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773578-9Report Type:Periodic Company Report #WAES 01042282
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cosopt	C				
			Timoptic-Xe	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773579-0Report Type:Periodic Company Report #WAES 01042283
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO; 25 MG/QOD/PO	
	Chest Pain							
	Dyspnoea							
			Coumadin	C				

Date:06/22/01ISR Number: 3773580-7Report Type:Periodic Company Report #WAES 01042287
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Calan	C				
			Lanoxin	C				
			Zocor	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3773581-9Report Type:Periodic Company Report #WAES 01042288
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	QOD/PO	
			Imdur	C				
			Tylenol	C				
			Zestril	C				
			Zocor	C				

Date:06/22/01ISR Number: 3773583-2Report Type:Periodic Company Report #WAES 01042292
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3773584-4Report Type:Periodic Company Report #WAES 01042181
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Glucotrol	C				
			Norvasc	C				
			Codeine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773586-8Report Type:Periodic Company Report #WAES 01042182
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	2 DAY

Date:06/22/01ISR Number: 3773587-XReport Type:Periodic Company Report #WAES 01042188
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Respiratory Disorder							
			Lasix (Furosemide)	C				
			Lisinopril	C				

Date:06/22/01ISR Number: 3773588-1Report Type:Periodic Company Report #WAES 01042195
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased	Professional						
		Company Representative						

Date:06/22/01ISR Number: 3773589-3Report Type:Periodic Company Report #WAES 01042204
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	25	

Chest Pain
MG/DAILY/PO
Dyspepsia
Extrasystoles
Palpitations

Lipitor	C
Plavix	C
Prilosec	C
Prozac	C
Hydroxychloroquine Sulfate	C

Date:06/22/01ISR Number: 3773591-1Report Type:Periodic Company Report #WAES 01042205
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773592-3Report Type:Periodic Company Report #WAES 01042211
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773593-5Report Type:Periodic Company Report #WAES 01042216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Vioxx	PS		ORAL	PO	
			Aspirin	C				

Date:06/22/01ISR Number: 3773597-2Report Type:Periodic Company Report #WAES 01042249
Age:91 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Back Pain							
	Dermatitis Exfoliative							
	Erythema							
	Face Oedema							
	Fatigue							
	Gastrointestinal Disorder							
	Hallucination							

Date:06/22/01ISR Number: 3773598-4Report Type:Periodic Company Report #WAES 01042254
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773601-1Report Type:Periodic Company Report #WAES 01042294
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cozaar	C				
			Lipitor	C				
			Proscar	C				
			Metoprolol	C				

Date:06/22/01ISR Number: 3773602-3Report Type:Periodic Company Report #WAES 01042300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Auricular Swelling Deafness Tinnitus	Consumer Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773603-5Report Type:Periodic Company Report #WAES 01042301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:06/22/01ISR Number: 3773604-7Report Type:Periodic Company Report #WAES 01042305
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Nail Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773605-9Report Type:Periodic Company Report #WAES 01042309
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Calcium	C				
			Vitamins	C				

Date:06/22/01ISR Number: 3773606-0Report Type:Periodic Company Report #WAES 01042311
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ BID/PO						
			Ultram (Therapy Unspecified)	C		

Date:06/22/01ISR Number: 3773608-4Report Type:Periodic Company Report #WAES 01042318
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysgeusia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY/ PO						
			Aciphex	C		
			Lopressor	C		
			Neurontin	C		
			Pepcid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773609-6Report Type:Periodic Company Report #WAES 01042319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Ziac	C				

Date:06/22/01ISR Number: 3773610-2Report Type:Periodic Company Report #WAES 01042320
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoma	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/ PO	
			[Therapy Unspcecified]	C				

Date:06/22/01ISR Number: 3773645-XReport Type:Periodic Company Report #WAES 01032317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Vicodin	C				

Date:06/22/01ISR Number: 3773646-1Report Type:Periodic Company Report #WAES 01032321
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea	Health	Vioxx	PS	Merck Research	
	Oedema	Professional			Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL

25 MG/DAILY/

PO

Hydrodiuril	C	
Lipitor	C	
Synthroid	C	

Date:06/22/01ISR Number: 3773651-5Report Type:Periodic Company Report #WAES 01032331
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Mouth	Consumer	Vioxx	PS	Merck Research	
	Sedation				Laboratories Div	
					Merck Co Inc	ORAL

50 MG/DAILY/

PO

Date:06/22/01ISR Number: 3773652-7Report Type:Periodic Company Report #WAES 01032332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Feeling Abnormal	Consumer	Vioxx	PS	Merck Research	
					Laboratories Div	
					Merck Co Inc	ORAL

PO

			Claritin	C
			Prevacid	C
			[Composition Unspecified]	C

Date:06/22/01ISR Number: 3773654-0Report Type:Periodic Company Report #WAES 01032335
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Hyzaar	C				
			Lipitor	C				
			Tenormin	C				
			Ultram	C				
			Potassium (Unspecified)	C				

Date:06/22/01ISR Number: 3773657-6Report Type:Periodic Company Report #WAES 01032336
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia Drug Ineffective Hair Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Lipitor	C				
			Prinivil	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3773662-XReport Type:Periodic Company Report #WAES 01032341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research			

	Faeces Discoloured	Health			Laboratories Div	
	Headache	Professional			Merck Co Inc	ORAL

12.5 MG/

DAILY/ PO

Diazide	C	
Hydrodiuril	C	
Tenormin	C	

Date:06/22/01ISR Number: 3773665-5Report Type:Periodic Company Report #WAES 01032343
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Drug Ineffective		Consumer	Vioxx	PS	Merck Research	
		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL

Dose Duration

PO

Oxycontin	C	
Therapy Unspecified	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773668-0Report Type:Periodic Company Report #WAES 01032351
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
			Darvocet	C				
			Premarin	C				
			Prometrium	C				
			Minocycline	C				

Date:06/22/01ISR Number: 3773669-2Report Type:Periodic Company Report #WAES 01032359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cardizem	C				
			Hydrodiuril	C				
			Prilosec	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3773686-2Report Type:Periodic Company Report #WAES 01011347
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Vioxx 12.5 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Inderal	C				
			Lanoxin	C				

Aspirin C

Date:06/22/01ISR Number: 3773688-6Report Type:Periodic Company Report #WAES 01011366
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773689-8Report Type:Periodic Company Report #WAES 01011435
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Pepcid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773690-4Report Type:Periodic Company Report #WAES 01011461
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Paranoid Personality Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Paxil	C				
			Aspirin	C				
			Atenolol	C				
			Docusate Sodium	C				
			Erythromycin	C				
			Ferrous Sulfate	C				
			Furosemide	C				
			Lisinopril	C				
			Nitroglycerin	C				
			Omeprazole	C				
			Potassium Chloride	C				
			Prednisolone	C				
			Thioridazine	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				
			Warfarin	C				

Date:06/22/01ISR Number: 3773692-8Report Type:Periodic Company Report #WAES 01011483
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haematochezia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773693-XReport Type:Periodic Company Report #WAES 01011750
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Emotional Disorder	Health Professional	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Plaquenil	C				
			Protonix	C				
			Tylenol With Codeine #3	C				
			Xanax	C				
			Prednisone	C				

Date:06/22/01ISR Number: 3773695-3Report Type:Periodic Company Report #WAES 01011761
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773696-5Report Type:Periodic Company Report #WAES 01011842
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773697-7Report Type:Periodic Company Report #WAES 01011843
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773699-0Report Type:Periodic Company Report #WAES 01011844
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773700-4Report Type:Periodic Company Report #WAES 01010837
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/PO

Date:06/22/01ISR Number: 3773702-8Report Type:Periodic Company Report #WAES 01010838
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lotrel	C				
			Prilosec	C				
			Timpotic-Xe	C				
			Lorazepam	C				

Date:06/22/01ISR Number: 3773708-9Report Type:Periodic Company Report #WAES 01010841
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773712-0Report Type:Periodic Company Report #WAES 01010872
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Trazodone	C				

Date:06/22/01ISR Number: 3773714-4Report Type:Periodic Company Report #WAES 01011091
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster Musculoskeletal Pain Paraesthesia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Rash Rash Papular		Aspirin	C				

Date:06/22/01ISR Number: 3773715-6Report Type:Periodic Company Report #WAES 01011109
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	4 WK
			Accupril	C				
			Hydrodiuril	C				
			Singulair	C				
			Nosteroidal Anti-Inflammatory	C				

Date:06/22/01ISR Number: 3773717-XReport Type:Periodic Company Report #WAES 01011242
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Inj Enbrel	SS			25 MG/2XW/INJ	
			Prevacid	C				

Date:06/22/01ISR Number: 3773718-1Report Type:Periodic Company Report #WAES 01011321
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAIILY/PO	
			Timoptic	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773719-3Report Type:Periodic Company Report #WAES 01011322
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Chest Pain	Health Professional						
	Drug Interaction							
			Vasotec	SS				
			Thyroxine	C				

Date:06/22/01ISR Number: 3773721-1Report Type:Periodic Company Report #WAES 01011332
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO; 25 MG DAILY PO	
	Hypoaesthesia							
			Cap Prevacid	SS		ORAL	30 MG/DAILY/PO	
			Synthroid	C				
			Amitriptyline Hydrochloride	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				
			Aspirin	C				
			Tylenol Arthritis Extended Relie	C				
			Tambocor	C				

Date:06/22/01ISR Number: 3773734-XReport Type:Periodic Company Report #WAES 01032134
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	7 DAY

Date:06/22/01ISR Number: 3773735-1Report Type:Periodic Company Report #WAES 01032139
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773736-3Report Type:Periodic Company Report #WAES 01032144
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Atrovent	C
Hydrodiuril	C
Prevacid	C
Albuterol	C

Date:06/22/01ISR Number: 3773738-7Report Type:Periodic Company Report #WAES 01032145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia Dizziness Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Gastrooesophageal Reflux Disease Headache Hypersomnia Muscular Weakness Pain Tinnitus		Aleve	C				

Date:06/22/01ISR Number: 3773740-5Report Type:Periodic Company Report #WAES 01032148
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritability	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO; 12.5 MG/QOD/PO	

Date:06/22/01ISR Number: 3773743-0Report Type:Periodic Company Report #WAES 01032149
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Flatulence Lip Disorder	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	Mouth Ulceration	Representative						
	Swelling		Tab Vioxx 25 Mg	SS		ORAL	25 MG/BID/PO; 25 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773744-2Report Type:Periodic Company Report #WAES 01032159
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Mucosal Eruption	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				
			Darvocet-N	C				
			Elavil	C				
			Macrodantin	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773745-4Report Type:Periodic Company Report #WAES 01032160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin Erythema	Company Representative Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773749-1Report Type:Periodic Company Report #WAES 01032163
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

Date:06/22/01ISR Number: 3773755-7Report Type:Periodic Company Report #WAES 01032164
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Levoxyl	C				
			Monopril	C				
			Premarin	C				
			Prilosec	C				
			Prozac	C				
			Methylclothiazide	C				
			Ranitidine	C				

Date:06/22/01ISR Number: 3773760-0Report Type:Periodic Company Report #WAES 01032172
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dyspepsia Fatigue	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Atenolol	C				

Date:06/22/01ISR Number: 3773761-2Report Type:Periodic Company Report #WAES 01032178
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773762-4Report Type:Periodic Company Report #WAES 01032209
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773763-6Report Type:Periodic Company Report #WAES 01032241
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Urinary Incontinence	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Norvasc	C				

Date:06/22/01ISR Number: 3773764-8Report Type:Periodic Company Report #WAES 01032248
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
			Actos	C				
			Coumadin	C				
			Glucophage	C				
			Neurontin	C				
			Premarin	C				
			Prilosec	C				
			Glyburide	C				

Date:06/22/01ISR Number: 3773765-XReport Type:Periodic Company Report #WAES 01032283
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Stiffness Musculoskeletal Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO

Date:06/22/01ISR Number: 3773766-1Report Type:Periodic Company Report #WAES 01032298
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	

PO

Date:06/22/01ISR Number: 3773767-3Report Type:Periodic Company Report #WAES 01032301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			Therapy Unspecified	C				

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773768-5Report Type:Periodic Company Report #WAES 01032307
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	PO
	Face Oedema	Health Professional						
	Orbital Oedema							
			Centrum	C				
			Vitamin E	C				

Date:06/22/01ISR Number: 3773769-7Report Type:Periodic Company Report #WAES 01032309
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Miacalcin	C				
			Monopril	C				
			Pepcid	C				
			Plendil	C				
			Amitriptyline	C				
			Aspirin	C				
			Methyldopa	C				
			Metoprolol	C				

Date:06/22/01ISR Number: 3773770-3Report Type:Periodic Company Report #WAES 01032448
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO

			Premarin	C
			Toprol Xl	C

Date:06/22/01ISR Number: 3773771-5Report Type:Periodic Company Report #WAES 01032460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Effect Decreased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ BID/						
PO						
			Glucophage	C		
			Lipitor	C		
			Zestril	C		

Date:06/22/01ISR Number: 3773772-7Report Type:Periodic Company Report #WAES 01032465
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urinary Tract Infection	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/ DAILY/						
PO						

	Prevacid	C	
	Ultram	C	
	Vistaril	C	

Date:06/22/01ISR Number: 3773774-0Report Type:Periodic Company Report #WAES 01032467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Neuropathy Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 DAY

Date:06/22/01ISR Number: 3773776-4Report Type:Periodic Company Report #WAES 01032472
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Face Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO 1 DAY
			Cortisone	C				
			Estrogens (Unspecified)	C				

Date:06/22/01ISR Number: 3773778-8Report Type:Periodic Company Report #WAES 01032474
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO
			Enbrel	C				

			Plaquenil	C
			Prednisone	C

Date:06/22/01ISR Number: 3773780-6Report Type:Periodic Company Report #WAES 01032485
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Pruritus							
	Skin Disorder							

Date:06/22/01ISR Number: 3773783-1Report Type:Periodic Company Report #WAES 01032490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Irritable Bowel Syndrome							
			Prilosec	C				
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773784-3Report Type:Periodic Company Report #WAES 01032491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3773785-5Report Type:Periodic Company Report #WAES 01032503
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Warfarin	C				

Date:06/22/01ISR Number: 3773806-XReport Type:Periodic Company Report #WAES 01051362
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/	PO

Date:06/22/01ISR Number: 3773807-1Report Type:Periodic Company Report #WAES 01051364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulse Abnormal	Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
25 MG/ DAILY/

PO 2 MON

Monopril	C
Aspirin	C
Metoprolol	C

Date:06/22/01ISR Number: 3773808-3Report Type:Periodic Company Report #WAES 01051372
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/ DAILY/

PO

Hydrodiuril	C
K-Dur	C
Lotrel	C
Premarin	C
Prilosec	C
Synthroid	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773809-5Report Type:Periodic Company Report #WAES 01051392
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Muscle Spasms							
	Sleep Disorder							
	Tinnitus		Evista	C				

Date:06/22/01ISR Number: 3773810-1Report Type:Periodic Company Report #WAES 01051396
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lipitor	C				
			Lopressor	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:06/22/01ISR Number: 3773811-3Report Type:Periodic Company Report #WAES 01051398
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/ DAILY/	PO
			Tenoretic	C				
			Aspirin	C				
			Calcium (Unspecified)	C				

Date:06/22/01ISR Number: 3773812-5Report Type:Periodic Company Report #WAES 01051399
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Diarrhoea							
			Levbid	C				
			Prinivil	C				
			Lorazepam	C				

Date:06/22/01ISR Number: 3773813-7Report Type:Periodic Company Report #WAES 01051400
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Paxil	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3773815-0Report Type:Periodic Company Report #WAES 01051403
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY/ PO	
	Ecchymosis							
	Skin Disorder							
	Swelling							
	Weight Increased		Actified	C				
			Premarin	C				

Date:06/22/01ISR Number: 3774318-XReport Type:Periodic Company Report #WAES 01042343
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Mucosal Ulceration							
			Evista	C				

Date:06/22/01ISR Number: 3774320-8Report Type:Periodic Company Report #WAES 01042344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Urine Abnormality							
			Ciproxin	C				
			Dilantin	C				
			Neurontin	C				
			Oxycontin	C				
			Oxyir	C				
			Paxil	C				
			Tagamet	C				

Topamax C

Date:06/22/01ISR Number: 3774322-1Report Type:Periodic Company Report #WAES 01042350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Estrogens (Unspecified)	C				
			Ibuprofen	C				

Date:06/22/01ISR Number: 3774324-5Report Type:Periodic Company Report #WAES 01042360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3774326-9Report Type:Periodic Company Report #WAES 01042362
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3774327-0Report Type:Periodic Company Report #WAES 01042368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Pruritus	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Celebrex	C				

Date:06/22/01ISR Number: 3774329-4Report Type:Periodic Company Report #WAES 01042372
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3774330-0Report Type:Periodic Company Report #WAES 01042391
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	

MG/DAILY/PO

Date:06/22/01ISR Number: 3774332-4Report Type:Periodic Company Report #WAES 01042404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Drug Ineffective Tachycardia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3774334-8Report Type:Periodic Company Report #WAES 01042405
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Hytrin	C				

Date:06/22/01ISR Number: 3774338-5Report Type:Periodic Company Report #WAES 01042321
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3774339-7Report Type:Periodic Company Report #WAES 01042322
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema Muscular Weakness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Fosamax	C				
			Levoxyl	C				
			Zocor	C				
			[Composition Unspecified]	C				
			Atenolol	C				

Date:06/22/01ISR Number: 3774340-3Report Type:Periodic Company Report #WAES 01042323
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PRN/PO	
			Glucotrol	C				
			Niaspan	C				

Date:06/22/01ISR Number: 3774341-5Report Type:Periodic Company Report #WAES 01042324
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cipro	C				
			Darvocet-N	C				
			Synthroid	C				
			Tylenol With Codeine #3	C				

Date:06/22/01ISR Number: 3774342-7Report Type:Periodic Company Report #WAES 01042328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Estradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/01ISR Number: 3774343-9Report Type:Periodic Company Report #WAES 01042332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/22/01ISR Number: 3774344-0Report Type:Periodic Company Report #WAES 01042333
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia Paraesthesia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lanoxin	C				
			Lescol	C				
			Norpace	C				

Date:06/22/01ISR Number: 3774345-2Report Type:Periodic Company Report #WAES 01042335
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Fluid Retention Oedema Weight Increased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Baycol	C				
			Darvocet-N	C				
			Motrin	C				
			Nasonex	C				
			Premarin	C				

Date:06/22/01ISR Number: 3774346-4Report Type:Periodic Company Report #WAES 01042338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective Pollakiuria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Zestril	C				

Date:06/22/01ISR Number: 3774347-6Report Type:Periodic Company Report #WAES 01042340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/01ISR Number: 3801057-9Report Type:Periodic Company Report #WAES 01061134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Abdominal Pain		Therapy Unspecified	C				

Date:06/25/01ISR Number: 3745805-5Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation		Vioxx	PS	Merck			
	Oedema Peripheral							

Date:06/25/01ISR Number: 3746232-7Report Type:Expedited (15-DaCompany Report #WAES 01041177
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/25/01ISR Number: 3746238-8Report Type:Expedited (15-DaCompany Report #WAES 01041177
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/25/01ISR Number: 3746244-3Report Type:Expedited (15-DaCompany Report #WAES 01042832
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Peripheral Embolism Peripheral Ischaemia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Ditropan	C				
			Flexeril	C				
			Fosamax	C				
			Maxzide	C				
			Ms Contin	C				
			Synthroid	C				
			Zantac	C				
			Zyrtec	C				
			Tamoxifen	C				
			Trazodone	C				

Date:06/25/01ISR Number: 3746256-XReport Type:Expedited (15-DaCompany Report #WAES 01031427
Age:64 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Distension	Health Professional Company	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
Alanine Aminotransferase Increased							
Anaemia	Representative						
Asthenia		Glucophage	C				
Back Pain		Lasix (Furosemide)	C				
Blood Albumin Decreased		Levaquin	C				
Blood Bilirubin Increased		Lopressor	C				
Blood Creatine Phosphokinase Increased		Procardia Xl	C				
Chest Pain		Vasotec	C				
Colitis		Voltaren-Xr	C				
Condition Aggravated		Zocor	C				
Decreased Appetite		Aspirin	C				
Diabetes Mellitus		Dipyridamole	C				
Dyspnoea		Glyburide	C				
Electrocardiogram Abnormal		Vitamin E	C				
Electrocardiogram Qt Prolonged							
Face Oedema							
Fatigue							
Fibrin D Dimer Increased							
Haematochezia							
Haematuria							
Hepatic Function Abnormal							
Hypertension							
International Normalised Ratio Decreased							
Intestinal Ischaemia							
Intrinsic Factor Antibody Positive							
Marrow Hyperplasia							
Nausea							
Oedema							
Pallor							
Periorbital Oedema							
Protein Total Decreased							
Proteinuria							
Prothrombin Time Prolonged							

Renal Failure Acute
Respiratory Rate
Increased
Stasis Dermatitis
Thrombocytopenia
Urinary Casts
Urinary Tract Infection
Urine Analysis Abnormal
Weight Decreased
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/01ISR Number: 3746264-9Report Type:Expedited (15-DaCompany Report #WAES 01041073
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Prerenal Failure	Health	Vioxx	PS	Merck Research			
Hospitalization -	Angina Pectoris	Professional			Laboratories Div			
Initial or Prolonged	Calcinosis				Merck Co Inc	ORAL	50	
	Cardiac Failure						MG/DAILY/PO	
	Congestive		Top Nitroglycerin	SS				
	Cardiomegaly		Tab Nitroglycerin	SS				
	Dizziness		Hyzaar	C				
	Dyspepsia		Lasix (Furosemide)	C				
	Feeling Hot		Lopressor	C				
	Fluid Retention		Synthroid	C				
	Flushing		Zocor	C				
	Hypertensive Crisis		Asprin	C				
	Orthopnoea							
	Pulmonary Oedema							
	Pyrexia							
	Renal Failure							
	Respiratory Rate Increased							

Date:06/25/01ISR Number: 3747372-9Report Type:Expedited (15-DaCompany Report #WAES 01069808
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Other			Laboratories Div			
Other	Haemoglobin Decreased				Merck Co Inc	ORAL	25MG/DAILY	
	Red Blood Cell Count Decreased		Tab Methotrexate Sodium	SS		ORAL	7.5 MG/WKY; PO	
			Tab Methotrexate Sodium	SS		ORAL	7.5 MG/WKY; PO	

			Cisapride	C		
			Isosorbide Mononitrate	C		

Date:06/25/01ISR Number: 3747381-XReport Type:Expedited (15-DaCompany Report #WAES 01068552
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Other				

Date:06/25/01ISR Number: 3747383-3Report Type:Expedited (15-DaCompany Report #WAES 01065112
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angioneurotic Oedema Dermatitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY;						
PO 22 DAY						
			Amlodipine	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/01ISR Number: 3747386-9Report Type:Expedited (15-DaCompany Report #WAES 01065076
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Tachycardia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	
			Ibuprofen	C				
			Insulin	C				
			Sildenafil Citrate	C				

Date:06/25/01ISR Number: 3747389-4Report Type:Expedited (15-DaCompany Report #WAES 01065069
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Dyspnoea	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	5 DAY
			Albuterol	C				
			Beclomethasone Dipropionate	C				
			Lactulose	C				
			Lansoprazole	C				

Date:06/25/01ISR Number: 3747393-6Report Type:Expedited (15-DaCompany Report #WAES 01065065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY;PO	

Atenolol	C
Bendroflumethiazide	C
Carbomer	C
Ranitidine	C

Date:06/25/01ISR Number: 3747394-8Report Type:Expedited (15-DaCompany Report #WAES 01063755
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY;	PO 8 DAY

Date:06/25/01ISR Number: 3747511-XReport Type:Expedited (15-DaCompany Report #WAES 01016031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Drug Level Below Therapeutic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	1 DAY
	Epilepsy Loss Of Consciousness		Tab Phenobarbital	SS		ORAL	50 MG/DAILY/	PO
			Leuprolide Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/01ISR Number: 3747512-1Report Type:Expedited (15-DaCompany Report #WAES 01025584
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram T Wave Inversion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	

Date:06/25/01ISR Number: 3747516-9Report Type:Expedited (15-DaCompany Report #WAES 01058647
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Costovertebral Angle Tenderness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID	3 DAY
	Nephritis Interstitial							
	Vomiting		Acetaminophen/Oxycodone Hydrochloride	C				
			Dimenhydrinate	C				
			Morphine	C				

Date:06/25/01ISR Number: 3747518-2Report Type:Expedited (15-DaCompany Report #WAES 01065015
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
Life-Threatening	Acute Respiratory Distress Syndrome							
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis		Prinivil	C				
	Blood Pressure Abnormal		Acetaminophen	C				
	Bone Pain		Beclomethasone Dipropionate	C				
	Calcinosis		Bendroflumethiazide	C				
	Cardio-Respiratory Arrest		Citalopram	C				
	Chest X-Ray Abnormal		Dienestrol	C				
	Coronary Artery Disease		Lactulose	C				
	Duodenal Ulcer		Lanolin (+) Mineral Oil (+) Petrolatum	C				
	Perforation							
	Fall							

	Oesophagitis		Levothyroxine Na	C
	Oliguria		Oxazepam	C
	Parkinsonism		Oxybutyninci	C
	Peritonitis		Temazepam	C
	Urine Flow Decreased			

Date:06/25/01ISR Number: 3747522-4Report Type:Expedited (15-DaCompany Report #WAES 01066026
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dermatitis	Foreign	Vioxx	PS	Merck Research Laboratories Div	
	Drug Hypersensitivity	Health				
	Renal Impairment	Professional			Merck Co Inc	ORAL
25 MG/DAILY 1 DAY						
			Fluindione	C		
			Irbesartan	C		
			Piretanide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/01ISR Number: 3747524-8Report Type:Expedited (15-DaCompany Report #WAES 01045536
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Status Asthmaticus	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	8 DAY
			Vasotec	C				
			Diltiazem	C				
			Isosorbide Dinitrate	C				
			Piretanide	C				
			Tetrazepam	C				
			Tramadol	C				

Date:06/25/01ISR Number: 3748499-8Report Type:Expedited (15-DaCompany Report #WAES 01069553
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic Pruritus Rash Generalised	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	
			Tab Placebo (Unspecified)	SS		ORAL	PO	619 DAY
			Bromhexine	C				
			Calcitonin	C				
			Cetirizine	C				
			Cinnarizine	C				
			Mizolastine	C				
			Prednisolone	C				
			Raloxifene	C				
			Ranitidine	C				
			Trimetazidine	C				

Date:06/26/01ISR Number: 3746162-0Report Type:Expedited (15-DaCompany Report #WAES 01041942
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Benign Oesophageal Neoplasm
	Blood Calcium Decreased
	Blood Pressure Increased
	Compression Fracture
	Condition Aggravated
	Difficulty In Walking
	Diverticulum
	Drug Effect Decreased
	Erosive Oesophagitis
	Gastritis
	Haemangioma Of Liver
	Hernia
	Herpes Virus Infection
	Hiatus Hernia
	Iron Deficiency Anaemia
	Kyphoscoliosis
	Melaena
	Neuralgia
	Oesophagitis
	Osteoporosis

	Osteoporotic Fracture						
	Pancreatic Disorder						
	Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pigmented Naevus		Fosamax	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS		ORAL	
			Vioxx	SS		ORAL	

Date:06/26/01ISR Number: 3747480-2Report Type:Direct Company Report #
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery		Vioxx	PS		ORAL	25 MG DAILY
	Atherosclerosis						ORALLY
			Zestril	C			
			Midrin	C			
			Fiorinal	C			

Date:06/26/01ISR Number: 3747788-0Report Type:Expedited (15-DaCompany Report #WAES 00102576
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO 2 DAY
	Fluid Retention						
	Oedema Peripheral						
			Ecotrin	C			
			Tenormin	C			
			Zestril	C			

Date:06/26/01ISR Number: 3747850-2Report Type:Expedited (15-DaCompany Report #WAES 01061322
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Cardiac Failure Renal Failure Respiratory Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

SEE IMAGE

Date:06/26/01ISR Number: 3747851-4Report Type:Expedited (15-DaCompany Report #WAES 01061553
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Ulcer Rectal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO						
			Coumadin	C		
			Flomax (Morniflumate)	C		
			K-Dur	C		
			Pravachol	C		
			Singulair	C		
			Furosemide	C		
			Verapamil	C		

Date:06/26/01ISR Number: 3747852-6Report Type:Expedited (15-DaCompany Report #WAES 01061583
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Swelling Urticaria	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Indocin (Indomethacin)	C				
			Composition Unspecified)	C				
			Allopurinol	C				

Date:06/26/01ISR Number: 3747853-8Report Type:Expedited (15-DaCompany Report #WAES 01061634
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Therapy Unspecified	C				
			Insulin	C				

Date:06/26/01ISR Number: 3747854-XReport Type:Expedited (15-DaCompany Report #WAES 01061690
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Ambien	C		
			Asacol	C		
			Norvasc	C		
			Premarin	C		

Date:06/26/01ISR Number: 3747855-1Report Type:Expedited (15-DaCompany Report #WAES 01061041
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG 50 MG/DAILY/PO						
			Cardizem	C		
			Prilosec	C		
			Tenormin	C		
			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/01ISR Number: 3747856-3Report Type:Expedited (15-DaCompany Report #WAES 01052465
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Colchicine	C				

Date:06/26/01ISR Number: 3747860-5Report Type:Expedited (15-DaCompany Report #WAES 01060481
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive Cardiomyopathy Respiratory Failure	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	
			Dyazide	C				
			Ocuvite	C				
			Prilosec	C				
			Prinivil	C				

Date:06/26/01ISR Number: 3747861-7Report Type:Expedited (15-DaCompany Report #WAES 01052647
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Failure Congestive Dyspnoea Oedema Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Novolin	C				
			Vicodin Tablets	C				

Date:06/26/01ISR Number: 3747862-9Report Type:Expedited (15-DaCompany Report #WAES 01041133
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck Research	
Hospitalization -	Haemorrhage	Professional			Laboratories Div	
Initial or Prolonged		Company			Merck Co Inc	ORAL
25						
Other		Representative				
MG/DAILY/PO						
			Hydrodiuril	C		
			Atenolol	C		
			Glyburide	C		

Date:06/26/01ISR Number: 3748004-6Report Type:Expedited (15-DaCompany Report #WAES 01068592
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Congestive	Health			Laboratories Div	
Initial or Prolonged	Pulmonary Oedema	Professional			Merck Co Inc	ORAL
25						

MG/DAILY/PO 22 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/01ISR Number: 3748006-XReport Type:Expedited (15-DaCompany Report #WAES 01068579
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Escherichia Sepsis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hctz/Triamterene	C				
			Aspirin	C				
			Valsartan	C				

Date:06/26/01ISR Number: 3748007-1Report Type:Expedited (15-DaCompany Report #WAES 01065141
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Vasotec	C				
			Zocor	C				
			Nizatidine	C				

Date:06/26/01ISR Number: 3748008-3Report Type:Expedited (15-DaCompany Report #WAES 01061765
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthma Blood Pressure Increased Blood Pressure Systolic	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MGDAILY/PO	80 DAY
Other	Inspiratory Decreased Blood Thyroid Stimulating Hormone Increased Bronchitis Cardiac Murmur		Becotide	C				
			Eltroxin	C				
			Klacid	C				
			Prozac	C				

Headache
Mitral Valve Incompetence
Nausea
Oedema
Pulmonary Oedema
Right Ventricular Failure
Sinus Bradycardia
Tricuspid Valve
Incompetence
Venous Pressure Jugular
Increased

Date:06/26/01ISR Number: 3748009-5Report Type:Expedited (15-DaCompany Report #WAES 01058587
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fluid Retention Weight Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
			Indapamide	C				
			Elavil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/01ISR Number: 3748010-1Report Type:Expedited (15-DaCompany Report #WAES 01035010
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Infection Pruritus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO	6 MON
			Acetaminophen	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Cinnarizine	C				
			Diazepam	C				
			Dicyclomine Hcl	C				
			Dihydrocodeine	C				
			Estrogens Conjuagated	C				
			Ibuprofen	C				
			Nitrazepam	C				
			Venlafaxine	C				

Date:06/26/01ISR Number: 3748029-0Report Type:Expedited (15-DaCompany Report #WAES 01048751
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Angina Pectoris Atrial Fibrillation Coronary Artery Disease	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	
		Other	Moduretic	C				
			Timoptic-Xe	C				
			Atenolol	C				
			Levothyroxine Na	C				

Date:06/26/01ISR Number: 3748506-2Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Faeces	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Life-Threatening	Activated Partial Thromboplastin Time							
Hospitalization -								
Initial or Prolonged	Prolonged	Representative						
Other	Biliary Cirrhosis Primary		Bactrim	C				
	Bilirubinuria		Calderol	C				
	Blood Creatinine Increased		Diflucan	C				
	Blood Sodium Decreased		Norvasc	C				
	Cholangitis		Os-Cal	C				
	Cholestasis		Procardia Xl	C				
	Condition Aggravated		Zoloft	C				
	Decreased Appetite		Cyclosporine	C				
	Diarrhoea		Ibuprofen	C				
	Eosinophil Count Increased		Prednisone	C				
	Hepatic Fibrosis							
	Hepatitis							
	Inflammation							
	Jaundice							
	Nausea							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/01ISR Number: 3748643-2Report Type:Expedited (15-DaCompany Report #WAES 01061308
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/26/01ISR Number: 3748644-4Report Type:Expedited (15-DaCompany Report #WAES 01061845
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/26/01ISR Number: 3748647-XReport Type:Expedited (15-DaCompany Report #WAES 01061610
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON
			Baycol	C				
			Cenestin	C				

Date:06/26/01ISR Number: 3748649-3Report Type:Expedited (15-DaCompany Report #WAES 01061687
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO 9 DAY
			Lasix (Furosemide)	C			

Date:06/26/01ISR Number: 3748651-1Report Type:Expedited (15-DaCompany Report #WAES 01061679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Systemic Lupus Erythematosus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Plaquenil	C				
			[Compostion Unspecified]	C				

Date:06/27/01ISR Number: 3748196-9Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dizziness Duodenal Ulcer Dyspepsia Faeces Discoloured

Gastric Ulcer

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx -Rofecoxib-	PS		ORAL	50MG DAILY	ORAL
			Atenolol	C				
			Claritin	C				

Date:06/27/01ISR Number: 3748387-7Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Vioxx 25mg Tabs	PS			12.5 MG QD	
Intervention to Prevent Permanent Impairment/Damage	Increased		Asa Ec	C				
			Synthroid	C				
			Metoprolol	C				
			Lasix	C				
			Isdn	C				
			Tamsulosin	C				
			Simvastatin	I				

Date:06/27/01ISR Number: 3748432-9Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Burning Sensation		Vioxx (25mg)	PS		ORAL	25MG PO QD	
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Asa	C				
Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage		Hydrocodone/Apap	C				

Date:06/27/01ISR Number: 3748436-6Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx (Mfd By Merck)	PS	Merck		SEE ITEM B5	4 MON
	Circulatory Collapse		Multivitamins And Mineral Supplements	C				
	Drug Withdrawal Syndrome		Vitamin B	C				
	Ecchymosis		Vitamin E	C				
	Feeling Abnormal		Calcium	C				
	Head Injury		Garlic	C				
	Headache		Some Herbal Supplements	C				
	Hyperhidrosis							
	Nausea							
	Nocturia							
	Syncope							
	Tremor							

Date:06/27/01ISR Number: 3749555-0Report Type:Periodic Company Report #2001011293-1
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Symptom	Consumer	Avandia	PS	Smithkline Beecham Pharmaceuticals		8 MILLIGRAMS	1.0 DAILY
	Oedema							
	Pulmonary Oedema							

				Vioxx (Rofecoxib)	SS	
				Avandia Smithline Beecham	SS	
4 MILLIGRAMS						
1.0 DAILY						
				Vioxx (Rofecoxib)	SS	
60 MILLIGRAMS						
				Synthroid (Levothyroxine Sodium)	C	
				Lopid (Gemfibrozil)	C	
				Insulin	C	
				Accupril (Quinapril)	C	
				Prilosec (Omeprazole)	C	
				Cenestin (Synthetic Conjugated Estrogens)	C	
				Amaryl (Glimepiride)	C	

Date:06/27/01ISR Number: 3749628-2Report Type:Expedited (15-DaCompany Report #WAES 01068762
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Circulatory Collapse	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Gastric Haemorrhage	Health			Laboratories Div	
Initial or Prolonged		Professional			Merck Co Inc	
			Aspirin	C		

Date:06/27/01ISR Number: 3749680-4Report Type:Expedited (15-DaCompany Report #WAES 01067005
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Drug Interaction	Company			Laboratories Div	
Other	Duodenal Ulcer	Representative			Merck Co Inc	ORAL
50 MG/DAILY						
	Melaena					
PO 91 DAY						
			Aspirin (+)			

Magnesium Oxide SS ORAL
160 MG/DAILY

PO

Cap Dipyridamole SS ORAL
400 MG/DAILY

PO 126 DAY

Date:06/27/01ISR Number: 3749685-3Report Type:Expedited (15-DaCompany Report #WAES 01069002
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Face Oedema	Foreign	Vioxx	PS	Merck Research	
	Hypertension	Other			Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL
25 MG/DAILY						
	Periorbital Oedema					
PO 1 DAY						
			Cobamamide	C		
			Diclofenac Na	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/01ISR Number: 3749686-5Report Type:Expedited (15-DaCompany Report #WAES 01069811
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Oedema Peripheral	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO
			Nonsteroidal Anti-Inflammatory Drug	C				
			Prednisone	C				
			Tramadol Hcl	C				

Date:06/27/01ISR Number: 3749687-7Report Type:Expedited (15-DaCompany Report #WAES 01045537
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma Status Asthmaticus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Fenoterol Hydrobromide (+) Ipratropium B	C				
			Fluticasone Propionate	C				
			Methylprednisolone	C				

Date:06/27/01ISR Number: 3749688-9Report Type:Expedited (15-DaCompany Report #WAES 01067504
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Confusional State	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

Disturbance In Attention Merck Co Inc ORAL
25 MG/DAILY
Mental Impairment
PO 8 DAY
Scotoma
Visual Acuity Reduced
Visual Field Defect

Date:06/27/01ISR Number: 3749689-0Report Type:Expedited (15-DaCompany Report #WAES 01068230
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 11 DAY
			Furosemide Sodium	C				
			Nitrazepam	C				

Date:06/27/01ISR Number: 3749696-8Report Type:Expedited (15-DaCompany Report #WAES 01065105
Age:76 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage Haemoglobin Decreased Oesophagitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Aspirin	SS		ORAL	75 MG/DAILY	
			Inj Suriclone	SS		SUBCUTANEOUS	75 MG/BID	2 DAY
			Amlodipine	C				
			Atenolol	C				
			Folic Acid	C				
			Isosorbide Mononitrate	C				
			Methotrexate	C				
			Nicorandil	C				
			Nizatidine	C				
			Prednisolone	C				

Date:06/27/01ISR Number: 3749697-XReport Type:Expedited (15-DaCompany Report #WAES 01065552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/27/01ISR Number: 3749698-1Report Type:Expedited (15-DaCompany Report #WAES 01065095
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Global Amnesia Memory Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	30 DAY
	Pulmonary Congestion		Prinivil	C				
			Aspirin	C				
			Atenolol	C				

Doxazosin	C
Insulin, Biphasic Isophane [Injection]	C
Isosorbide Mononitrate	C
Metformin	C

Date:06/27/01ISR Number: 3749699-3Report Type:Expedited (15-DaCompany Report #WAES 01063473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:06/27/01ISR Number: 3749700-7Report Type:Expedited (15-DaCompany Report #WAES 01063471
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div			

Merck Co Inc ORAL
12.5 MG BID ,

12.5 MG DAILY

Date:06/27/01ISR Number: 3749882-7Report Type:Expedited (15-DaCompany Report #WAES 01061424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Premarin	C				

Date:06/27/01ISR Number: 3750120-XReport Type:Expedited (15-DaCompany Report #WAES 01061254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/27/01ISR Number: 3750121-1Report Type:Expedited (15-DaCompany Report #WAES 01060986
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Cardiac Failure Congestive Feeling Cold Respiratory Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/27/01ISR Number: 3750122-3Report Type:Expedited (15-DaCompany Report #WAES 01060994
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Atrial Flutter Cardiac Failure Congestive	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY/ PO	
	Cardiomegaly Ejection Fraction Abnormal Pneumonia		Ascorbic Acid Aspirin Cyanocobalamin Vitamin E	C C C C				

Date:06/27/01ISR Number: 3750123-5Report Type:Expedited (15-DaCompany Report #WAES 01061012
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antinuclear Antibody Positive Blood Bilirubin Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Jaundice Liver Function Test Abnormal		Lozol Lisinopril	C C				

Date:06/27/01ISR Number: 3761456-0Report Type:Expedited (15-DaCompany Report #WAES 01069942
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Neck Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	2 DAY

Date:06/28/01ISR Number: 3749523-9Report Type:Expedited (15-DaCompany Report #WAES 01061868
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Coumadin	C				

Date:06/28/01ISR Number: 3749524-0Report Type:Expedited (15-DaCompany Report #WAES 01061839
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
		Representative	Coumadin	C				

Date:06/28/01ISR Number: 3749525-2Report Type:Expedited (15-DaCompany Report #WAES 01061806
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:06/28/01ISR Number: 3749529-XReport Type:Expedited (15-DaCompany Report #WAES 01061559
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache	Health	Vioxx	PS	Merck Research			
	Hypertension	Professional			Laboratories Div			
	Irritability				Merck Co Inc	ORAL	25 MG/DAILY/	
	Sinus Headache						PO	10 DAY
	Sinusitis		Minocin	C				
			Prevacid	C				
			Vasotec	C				
			Zocor	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:06/28/01ISR Number: 3749530-6Report Type:Expedited (15-DaCompany Report #WAES 01061393
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Death	Asthenia
Other	Cardio-Respiratory Arrest

		Cerebrovascular Accident Coronary Artery Disease Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall Myocardial Infarction Nausea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
		Sinus Tachycardia	Representative				
MG/DAILY/PO							
		Upper Gastrointestinal Haemorrhage		Chromagen	C		
				Imdur	C		
				Plavix	C		
				Toprol Xl	C		
				Zocor	C		

Date:06/28/01ISR Number: 3749923-7Report Type:Expedited (15-DaCompany Report #WAES 01061749
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Asthma Pulmonary Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:06/29/01ISR Number: 3750465-3Report Type:Expedited (15-DaCompany Report #WAES 01040811
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged Disability	Anxiety Blood Pressure Increased Condition Aggravated	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
Other	Diabetes Mellitus	Representative				
MG/DAILY/PO						
	Gastrooesophageal Reflux Disease Hepatitis Cholestatic		Prednisone	SS		
			Celebrex	C		
			Lipitor	C		
			Tylenol	C		
			...	C		
			Viagra	C		

			Lorazepam	C		
			Quinine Sulfate	C		

Date:06/29/01ISR Number: 3750528-2Report Type:Expedited (15-DaCompany Report #WAES 01065004
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	ORAL	
	Melaena		Aspirin	C				
			Citalopram	C				
			Prednisolone	C				

Date:06/29/01ISR Number: 3750529-4Report Type:Expedited (15-DaCompany Report #WAES 01035010
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	C-Reactive Protein Increased
	Dyspepsia

	Infection Inflammation Urticaria	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID/PO 6 MON
			Acetaminophen	C			
			Acetaminophen (+) Dihydrocodeine Bitartr	C			
			Aluminum Hydroxide/Magnesiun Carbonate	C			
			Cinnarizine	C			
			Diazepam	C			
			Dicyclomine	C			
			Dihydrocodeine	C			
			Estrogens, Conjugated	C			
			Ibuprofen	C			
			Nitrazepam	C			
			Venlafaxine	C			

Date:06/29/01ISR Number: 3750530-0Report Type:Expedited (15-DaCompany Report #WAES 01056536
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Drug Interaction Pancytopenia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY, PO
			Tab Methotrexate Sodium	SS		ORAL	10 MG/WKY, PO
			Aspirin	C			
			Digitalis	C			
			Estradiol	C			

Date:06/29/01ISR Number: 3750532-4Report Type:Expedited (15-DaCompany Report #WAES 01065127
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Duodenitis Haemorrhagic Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	
			Tramadol	C				

Date:06/29/01ISR Number: 3750533-6Report Type:Expedited (15-DaCompany Report #WAES 01061881
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysuria Micturition Disorder Urinary Incontinence	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Fosamax	C				

Lanoxin	C
Lasix (Furosemide)	C
Nexium	C
Singulair	C
Zyrtec	C
(Therapy Unspecified)	C
Calcium (Unspecified)	C
Vitamins (Unspecified)	C

Date:06/29/01ISR Number: 3750534-8Report Type:Expedited (15-DaCompany Report #WAES 01065573
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Other	Aspirin	C				

Date:06/29/01ISR Number: 3750561-0Report Type:Expedited (15-DaCompany Report #WAES 01040164
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Convulsion							
	Drug Interaction							
	Electroencephalogram							
	Abnormal		Levaquin	SS			500 MG/1X/	
	Hypersensitivity		Hormonal Contraceptives (Unspeci)	C				
	Loss Of Consciousness							
	Urticaria							

Date:06/29/01ISR Number: 3750562-2Report Type:Expedited (15-DaCompany Report #WAES 01052154
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Gastritis Erosive							
	Haematemesis							
	Haematocrit Decreased	Representative						
	Haemoglobin Decreased		Asacol	C				
	Mallory-Weiss Syndrome		Toradol	C				
	Melaena		Vicodin	C				
	Orthostatic Hypotension							
	Upper Gastrointestinal Haemorrhage							

Date:06/29/01ISR Number: 3750563-4Report Type:Expedited (15-DaCompany Report #WAES 01042538
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Arthralgia
	Chest Pain
	Eye Pain

		Myocardial Ischaemia Neck Pain Upper Respiratory Tract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infection	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Didronel	C		
				Flovent	C		
				Hydrodiuril	C		
				Lipitor	C		
				Lopressor	C		
				Lotrel	C		
				Prilosec	C		
				Serevent	C		
				Tilade	C		
				Methotrexate	C		
				Prednisone	C		
				..	C		
				..	C		

Date:06/29/01ISR Number: 3750564-6Report Type:Expedited (15-DaCompany Report #WAES 01060256
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Hypersensitivity Urinary Tract Disorder	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							

Date:06/29/01ISR Number: 3750565-8Report Type:Expedited (15-DaCompany Report #WAES 01052781
Age:67 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death Life-Threatening Hospitalization -		Mallory-Weiss Syndrome Myocardial Infarction Renal Failure Acute	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							

Initial or Prolonged	Retching
MG/DAILY/PO	
Other	Upper Gastrointestinal Haemorrhage
	Vomiting

Date:06/29/01ISR Number: 3750610-XReport Type:Expedited (15-DaCompany Report #WAES 01056107
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ecchymosis	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Gingival Bleeding	Health			Laboratories Div	
	Thrombocytopenia	Professional			Merck Co Inc	ORAL
12.5						
MG/DAILY; 25						
MG/DAILY; PO						
			Zocor	C		
			Acetaminophen	C		
			Acetylleucine	C		
			Betahistine Hydrochloride	C		
			Fosinopril Sodium	C		
			Ginkgo Biloba Extract	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/01ISR Number: 3750612-3Report Type:Expedited (15-DaCompany Report #WAES 01065015
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Acute Respiratory	Health			Laboratories Div			
Hospitalization -	Distress Syndrome	Professional			Merck Co Inc	ORAL	12.5	
Initial or Prolonged	Blood Pressure Abnormal						MG/DAILY; PO	
	Bone Pain		Prinivil	C				
	Cardio-Respiratory Arrest		Acetaminophen	C				
	Central Venous Pressure		Beclomethasone					
	Increased		Dipropionate	C				
	Chest Pain		Bendroflumethiazide	C				
	Condition Aggravated		Citalopram	C				
	Duodenal Perforation		Dienestrol	C				
	Duodenal Ulcer		Lactulose	C				
	Duodenal Ulcer		Lanolin (+) Mineral					
	Perforation		Oil (+) Petrolatum	C				
	Fall		Levothyroxine Na	C				
	Flatulence		Oxazepam	C				
	Oedema		Ocybutynincl	C				
	Oesophagitis		Temazepam	C				
	Oxygen Saturation							
	Abnormal							
	Parkinsonism							
	Peritonitis							
	Tenderness							
	Thyroid Disorder							
	Urine Flow Decreased							
	Vaginal Infection							
	Vaginal Prolapse							

Date:06/29/01ISR Number: 3750822-5Report Type:Expedited (15-DaCompany Report #WAES 01069552
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Burning Sensation	Health			Laboratories Div			
Initial or Prolonged	Dyspnoea	Professional			Merck Co Inc	ORAL	25 MG/DAILY	2 DAY
	Laryngeal Disorder		Acetaminophen (+)					

Laryngeal Oedema	Orphenadrine Citrate	C
Pruritus	Cyanocobalamin (+)	
Rash Generalised	Pyridoxine (+)	
	Thiami	C

Date:06/29/01ISR Number: 3752275-XReport Type:Periodic Company Report #A0144962A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Advair Diskus 100/50	PS	Glaxo Wellcome Inc	
RESPIRATORY						
	Constipation					
(INHALATION) 2 PUFF(S) /						
TWICE PER DAY						
/ INHALED						
			Rofecoxib			
			(Rofecoxib)	SS		
			...	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3750945-0Report Type:Expedited (15-DaCompany Report #WAES 01061715
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Health	Vioxx	PS	Merck Research			
	Dysphagia	Professional			Laboratories Div			
	Dyspnoea				Merck Co Inc	ORAL	PO	
	Hyperventilation		Celebrex	C				
	Laryngeal Oedema							
	Laryngospasm							
	Throat Tightness							
	Tremor							

Date:07/02/01ISR Number: 3750946-2Report Type:Expedited (15-DaCompany Report #WAES 01061736
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Hyperkalaemia	Professional			Laboratories Div			
	Malaise				Merck Co Inc	ORAL	PO	
	Renal Failure Acute		Nph Insulin	C				
			Digoxin	C				
			Diltiazem Maleate	C				
			Levothyroxine Sodium	C				
			Lisinopril	C				

Date:07/02/01ISR Number: 3750948-6Report Type:Expedited (15-DaCompany Report #WAES 01061771
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:07/02/01ISR Number: 3750951-6Report Type:Expedited (15-DaCompany Report #WAES 01061808
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/02/01ISR Number: 3750952-8Report Type:Expedited (15-DaCompany Report #WAES 01062067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3750953-XReport Type:Expedited (15-DaCompany Report #WAES 01041846
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Face Oedema Feeling Abnormal Oedema Peripheral Oral Pain Skin Exfoliation	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	1 WK

Date:07/02/01ISR Number: 3750954-1Report Type:Expedited (15-DaCompany Report #WAES 01040371
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction Neuropathy Peripheral Renal Failure Acute Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Neurontin	C				
			Non-Steroidal Anti-Inflammatory	C				

Date:07/02/01ISR Number: 3750956-5Report Type:Expedited (15-DaCompany Report #WAES 01060578
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Platelet Function Test Abnormal Post Procedural Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Flomax	C				
			Glucophage	C				

Prozac	C
Xanax	C
Aspirin	C
Furosemide	C
Hydrocodone	C
Isosorbide	C
Labetalol Hydrochloride	C
Minoxidil	C
Quinine Sulfate	C
Vitamins	C
Lipitor	C

Date:07/02/01ISR Number: 3750960-7Report Type:Expedited (15-DaCompany Report #WAES 01041823
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness Medication Error Migraine	Health Professional Company Representative	Vioxx Dyazide Synthroid	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3750961-9Report Type:Expedited (15-DaCompany Report #WAES 01042187
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				

Date:07/02/01ISR Number: 3750992-9Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Asthenia Atelectasis Biliary Cirrhosis Primary Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Condition Aggravated Cytomegalovirus Infection Depressed Level Of Consciousness Dyspnoea Failure To Thrive Haemorrhage Hepatic Failure Hepatotoxicity Hypotension Hypovolaemia International Normalised Ratio Decreased Nausea Pleural Effusion Pneumothorax	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other			Bactrim	C				
			Calderol	C				
			Diflucan	C				
			Norvasc	C				
			Os-Cal	C				
			Procardia Xl	C				
			Zoloft	C				
			Acetaminophen	C				
			Cyclosporine	C				
			Ibuprofen	C				
			Prednisone	C				

Prothrombin Time
Prolonged
Renal Failure
Renal Impairment
Respiratory Failure
Vascular Injury

Date:07/02/01ISR Number: 3750993-0Report Type:Expedited (15-DaCompany Report #WAES 01050194
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Change Of Bowel Habit Pancreatitis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
							(SEE IMAGE)	
			Advil	C				
			Naprosyn	C				
			Pulmicort	C				
			Serevent	C				
			Creatine	C				

				Vitamins (Unspecified)	C		

Date:07/02/01ISR Number: 3751005-5Report Type:Expedited (15-DaCompany Report #WAES 01061679
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Health	Vioxx	PS	Merck Research			
	Pruritus	Professional			Laboratories Div			
	Systemic Lupus	Company			Merck Co Inc	ORAL	25MG DAILY PO	
	Erythematosus	Representative	Plaquenil	C				
			Prednisone	C				

Date:07/02/01ISR Number: 3751013-4Report Type:Expedited (15-DaCompany Report #WAES 01061742
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health	Vioxx	PS	Merck Research			
	Drug Interaction	Professional			Laboratories Div			
	Gastrointestinal				Merck Co Inc	ORAL	PO	
	Haemorrhage		Warfarin	SS				
	International Normalised		Carafate	C				
	Ratio		Flomax	C				
	Syncope		Lasix	C				
			Prilosec	C				
			Zestril	C				
			Atenolol	C				
			Digoxin	C				
			Imipramine	C				
			Prednisone	C				

Date:07/02/01ISR Number: 3751014-6Report Type:Expedited (15-DaCompany Report #WAES 01062209
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Vioxx	PS	Merck Research			

Hospitalization - Initial or Prolonged	Ulcer				Laboratories Div Merck Co Inc	ORAL
25MG/DAILY/PO						
			Fosamax	C		
			Premarin	C		
			Zocor	C		

Date:07/02/01ISR Number: 3751015-8Report Type:Expedited (15-DaCompany Report #WAES 01062111
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Unstable Thrombosis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
		Representative	Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3751016-XReport Type:Expedited (15-DaCompany Report #WAES 01062064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease Myocardial Infarction	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/02/01ISR Number: 3751017-1Report Type:Expedited (15-DaCompany Report #WAES 01062108
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Haemodialysis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
			Femara	C				
			Prevacid	C				
			Valium	C				
			Zoloft	C				
			Hydroxyzine	C				

Date:07/02/01ISR Number: 3751018-3Report Type:Expedited (15-DaCompany Report #WAES 01062110
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Thrombosis	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
			Aspirin	C				

Date:07/02/01ISR Number: 3751020-1Report Type:Expedited (15-DaCompany Report #WAES 01062024
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
	Haematochezia		Coumadin	C			
	Pulmonary Oedema		Lasix	C			
			Digoxin	C			

Date:07/02/01ISR Number: 3751022-5Report Type:Expedited (15-DaCompany Report #WAES 01062132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/01ISR Number: 3751024-9Report Type:Expedited (15-DaCompany Report #WAES 01062109
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Procrit	C				
			Interferon (Unspecified)	C				

Date:07/02/01ISR Number: 3751234-0Report Type:Expedited (15-DaCompany Report #WAES 01055573
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:07/02/01ISR Number: 3751235-2Report Type:Expedited (15-DaCompany Report #WAES 01067910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:07/02/01ISR Number: 3751236-4Report Type:Expedited (15-DaCompany Report #WAES 01063518
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:07/02/01ISR Number: 3751245-5Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest X-Ray Abnormal Interstitial Lung Disease	Foreign Study	Arava	PS	Aventis Pharmaceuticals Inc	ORAL
10 VS 20 MG						
Disability		Health				
PO 106 DAY						
Other		Professional	Vioxx	SS		ORAL
25 MG QD PO 59 DAY						
		Other	Marcumar	C		
			Zocor	C		

Date:07/02/01ISR Number: 3751297-2Report Type:Expedited (15-DaCompany Report #WAES 00119134
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
	Asthenia
Other	Drug Interaction
	Haemodialysis

	Malaise						
	Necrosis						
	Nephritis Interstitial	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Normochromic Normocytic	Foreign	Vioxx	PS	Merck Research		
	Anaemia	Literature			Laboratories Div		
	Pallor	Health			Merck Co Inc	ORAL	12.5 MG/BID
	Renal Failure	Professional					PO
	Renal Interstitial	Company	Tab Enalapril	SS		ORAL	10 MG/DAILY
	Fibrosis	Representative					PO

Date:07/02/01ISR Number: 3751299-6Report Type:Expedited (15-DaCompany Report #WAES 01069552
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anaphylactic Shock	Foreign	Vioxx	PS	Merck Research		
Hospitalization -	Dermatitis	Health			Laboratories Div		
Initial or Prolonged	Dyspnoea	Professional			Merck Co Inc	ORAL	25 MG/DAILY
	Erythema						PO 2 DAY
	Laryngeal Oedema		Acetaminophen (+)				
	Laryngeal Pain		Orphenadrine Citrate	C			
	Paraesthesia		Cyanocobalamin (+)				
	Pruritus		Pyridoxine (+)				
	Rash Generalised		Thiami	C			

Date:07/02/01ISR Number: 3751300-XReport Type:Expedited (15-DaCompany Report #WAES 01059125
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Foreign	Vioxx	PS	Merck Research		
Initial or Prolonged	Cardiac Murmur	Health			Laboratories Div		
	Dizziness	Professional			Merck Co Inc	ORAL	25 MG/DAILY
	Dyspnoea Exertional						PO

Face Oedema
Fatigue
Gastritis Erosive
Gastrointestinal
Haemorrhage
Hiatus Hernia
Iron Deficiency Anaemia
Microcytic Anaemia
Normochromic Normocytic
Anaemia
Ph Urine Decreased
Pulmonary Granuloma

Date:07/03/01ISR Number: 3752527-3Report Type:Periodic Company Report #TAP2001Q00364
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhidrosis Drug Interaction Dyspnoea	Consumer Health Professional	Prevacid (Lansoprazole)	PS	Tap Pharmaceutical Products Inc	ORAL	30 MG, 1 IN 1 D, PER ORAL	
			Lipitor (Atorvastatin)	SS		ORAL	10 MG, 1 IN 1 D, PER ORAL	
			Wechol	SS		ORAL	625 MG, 3 IN 1 D, PER ORAL	

			Zestoretic (Prinzide)	SS	ORAL 1 IN 2 D, PER ORAL
			Vioxx (Rofecoxib)	SS	ORAL 0.5 TAB., 1 IN 1 D, PER ORAL
			Tricor (Fenofibrate)	C	ORAL

Date:07/03/01ISR Number: 3752575-3Report Type:Periodic Company Report #TAP2001Q00139
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Paraesthesia Oral Vasodilatation	Consumer	Prevacid	PS	Tap Pharmaceutical Products Inc	ORAL	30 MG, 1 IN 1 D, PER ORAL	
			Vioxx	SS		ORAL	PER ORAL	
			Synthroid (Levothyroxine Sodium)	C				
			Amitriptyline (Amitriptyline)	C				
			Aspirin (Acetylsalicylic Acid)	C				
			Tylenol Arthritis	C				
			Tambocor (Flecainide Acetate)	C				

Date:07/03/01ISR Number: 3754059-5Report Type:Periodic Company Report #TAP2000Q02641
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acne	Consumer	Prevacid	PS	Tap Pharmaceutical			

	Dermatitis				Products Inc	ORAL
30 MG 1 IN 1						
	Pruritus					
D PER ORAL						
			Vioxx	SS		ORAL
25 MG 2 IN 1						
D PER ORAL						
			Micro K	C		
			Plendil	C		
			Lopid	C		
			Lasix	C		
			Premarin	C		
			Glucotrol	C		
			Prozac	I		

Date:07/05/01ISR Number: 3752600-XReport Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chromaturia		Vioxx	PS		ORAL
25MG PO BID 6 MON						
Initial or Prolonged	Jaundice		Lisinopril	C		
			Lozre	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3752730-2Report Type:Expedited (15-DaCompany Report #WAES 01062483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/05/01ISR Number: 3752731-4Report Type:Expedited (15-DaCompany Report #WAES 01062234
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain Conduction Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG /DAILY/PO	
			Betapace	C				
			Prilosec	C				
			Zocor	C				

Date:07/05/01ISR Number: 3752733-8Report Type:Expedited (15-DaCompany Report #WAES 01040664
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delirium	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
			Interferon (Unspecified) Unk	SS			UNKNOWN	9,000, 000
			Benadryl	C				
			Imodium	C				
			L-Thyroxin	C				
			Mylanta & Mylanta Ds	C				
			Paxil	C				

			Tylenol	C		
			Ferrous Glycine Sulfate	C		

Date:07/05/01ISR Number: 3753073-3Report Type:Expedited (15-DaCompany Report #WAES 01069714
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Hydrocephalus	Foreign	Vioxx	PS	Merck Research	
Life-Threatening	Pneumonia	Health			Laboratories Div	
Hospitalization -		Professional			Merck Co Inc	ORAL
12.5 MG/DAILY						
Initial or Prolonged						
PO						
Disability			Digestive Enzymes (+) Pancreatin (+)			
			Sim	C		
			Donepezil Hydrochloride	C		
			Thiocolchicoside	C		
			Triflusal	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753082-4Report Type:Expedited (15-DaCompany Report #WAES 01068242
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Haemorrhage	Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	25 MG/DAILY	
Other								
PO								
			Tab Aspirin	SS		ORAL	100 MG/DAILY	
PO								
			Indapamide	C				
			Omega-3 Marine Triglycerides	C				

Date:07/05/01ISR Number: 3753084-8Report Type:Expedited (15-DaCompany Report #WAES 01069710
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Sepsis	Health			Laboratories Div			
Hospitalization -		Professional			Merck Co Inc	ORAL	50 MG/DAILY	
Initial or Prolonged								
PO								
Disability			Cefbuperazone	C				
			Vancomycin	C				

Date:07/05/01ISR Number: 3753085-XReport Type:Expedited (15-DaCompany Report #WAES 01069709
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bacterial Infection	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Intracranial Pressure	Health			Laboratories Div			
Hospitalization -	Increased	Professional			Merck Co Inc	ORAL	50 MG / DAILY	

Initial or Prolonged Sepsis
PO 6 DAY
Disability Pepcid C
Vancomycin C

Date:07/05/01ISR Number: 3753087-3Report Type:Expedited (15-DaCompany Report #WAES 01069708
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intracranial Pressure	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Increased	Health			Laboratories Div			
Hospitalization -	Nervous System Disorder	Professional			Merck Co Inc	ORAL	50 MG/DAILY	
Initial or Prolonged	Pneumonia							
PO							5	DAY
Disability			Dexamethasone	C				

Date:07/05/01ISR Number: 3753099-XReport Type:Expedited (15-DaCompany Report #WAES 01069712
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intracranial Pressure	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Increased	Health			Laboratories Div			
Hospitalization -	Nervous System Disorder	Professional			Merck Co Inc	ORAL	6	DAY
Initial or Prolonged	Sepsis		Cefbuperazone	C				
Disability			Vancomycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753203-3Report Type:Expedited (15-DaCompany Report #WAES 01070097
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer Perforation	Professional			Laboratories Div			
Initial or Prolonged		Company			Merck Co Inc	ORAL	25	
Disability		Representative					MG/DAILY/PO	
Other			Baycol	C				
			Claritin	C				
			Diovan	C				
			Estrace	C				
			Kerlone	C				
			Norvasc	C				
			Colonidine	C				

Date:07/05/01ISR Number: 3753213-6Report Type:Expedited (15-DaCompany Report #WAES 01069962
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Intravascular Coagulation	Health			Laboratories Div			
Hospitalization -	Haemorrhage Intracranial	Professional			Merck Co Inc	ORAL	25 MG/DAILY	27 DAY
Initial or Prolonged	Loss Of Consciousness		Tab Methotrexate					
	Pancytopenia		Sodium	SS		ORAL	27 DAY	
	Pyrexia							

Date:07/05/01ISR Number: 3753224-0Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Cardiomegaly	Health			Laboratories Div			
Initial or Prolonged	Cerebral Atrophy	Professional			Merck Co Inc	ORAL	12.5 MG/DAILY	2 MON
	Circulatory Collapse		Acetaminophen	C				

	Confusional State	Atenolol	C
	Duodenal Ulcer	Dipiproverine Dihcl	C
	Haemorrhage	Lactulose	C
	Fall		
	Haematemesis		
	Hypertension		
	Irritable Bowel Syndrome		
	Pulmonary Congestion		
	Pulmonary Embolism		
	Upper Gastrointestinal		
	Haemorrhage		
	Weight Decreased		

Date:07/05/01ISR Number: 3753225-2Report Type:Expedited (15-DaCompany Report #WAES 01065015
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Respiratory
Life-Threatening	Distress Syndrome
Hospitalization -	Bone Disorder
Initial or Prolonged	Bone Pain
	Cardio-Respiratory Arrest
	Duodenal Ulcer
	Perforation

		Fall Injury Oesophagitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Parkinson'S Disease Peritonitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY							
				Prinivil	C		
				Acetaminophen	C		
				Beclomethasone Dipropionate	C		
				Bendroflumethiazide	C		
				Citalopram	C		
				Dienestrol	C		
				Lactulose	C		
				Lanolin(+) Mineral Oil (+) Petrolatum	C		
				Levothyroxine Na	C		
				Oxazepam	C		
				Oxybutynincl	C		
				Temazepam	C		

Date:07/05/01ISR Number: 3753229-XReport Type:Expedited (15-DaCompany Report #WAES 01068241
Age:61 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Drug Interaction Renal Failure Acute Renal Papillary Necrosis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
Other				Tab Ibuprofen	SS		ORAL
400MG/TID							
				Noroxin	C		
				Acetaminophen	C		

Date:07/05/01ISR Number: 3753251-3Report Type:Expedited (15-DaCompany Report #WAES 01052786
Age:76 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization -		Abscess Asthenia	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

Initial or Prolonged	Blood Glucose Increased	Company			Merck Co Inc	ORAL
25						
Other	Chest Pain	Representative				
MG/DAILY/PO						
	Dizziness		Amaryl	C		
	Drug Level Below		Flomax			
	Therapeutic		(Morniflumate)	C		
	Faeces Discoloured		Keflex	C		
	Gastritis Haemorrhagic		Lanoxin	C		
	Gastroenteritis		Levoxyl	C		
	Helicobacter		Lipitor	C		
	Gastrointestinal		Nexium	C		
	Haemorrhage		Pletal	C		
	Groin Pain		Tenoretic	C		
	Haematemesis		Volmax	C		
	Hyperhidrosis		Isosorbide	C		
	Oedema Peripheral					
	Pallor					
	Renal Failure					

Date:07/05/01ISR Number: 3753257-4Report Type:Expedited (15-DaCompany Report #WAES 01062322
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Perforation Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/05/01ISR Number: 3753258-6Report Type:Expedited (15-DaCompany Report #WAES 01062336
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG, 25 MG/DAILY/PO	
			Ambien	C				

Date:07/05/01ISR Number: 3753261-6Report Type:Expedited (15-DaCompany Report #WAES 01062226
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis Influenza Like Illness	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allegra	C				
			Ceftin	C				
			Tylenol With Codeine #3	C				
			Zyrtec	C				
			Azithromycin	C				

Date:07/05/01ISR Number: 3753263-XReport Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Cardiac Disorder							
	Chest Pain							
	Dyspnoea							
	Sinus Arrest							
	Syncope							

Date:07/05/01ISR Number: 3753276-8Report Type:Expedited (15-DaCompany Report #WAES 01069758
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ascites	Foreign Literature Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 5 DAY
	Cardiac Disorder							
	Hepatic Cirrhosis							
	Hepatic Failure							
	Oedema Peripheral		Diclofenac	SS		ORAL	75 MG/DAILY	PO 2 DAY
	Osteoporosis							
	Renal Impairment		Spironolactone	C				
	Spinal Osteoarthritis							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753280-XReport Type:Expedited (15-DaCompany Report #WAES 01065004
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				
			Citalopram	C				
			Prednisolone	C				

Date:07/05/01ISR Number: 3753289-6Report Type:Expedited (15-DaCompany Report #WAES 01069817
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 32 DAY
			Acenocoumarol	SS		ORAL	PO	

Date:07/05/01ISR Number: 3753292-6Report Type:Expedited (15-DaCompany Report #WAES 01069141
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Aspirin	SS		ORAL	PO	

Date:07/05/01ISR Number: 3753293-8Report Type:Expedited (15-DaCompany Report #WAES 01068243
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Dreams	Foreign	Vioxx	PS	Merck Research	
	Nightmare	Other			Laboratories Div	
	Sleep Disorder				Merck Co Inc	ORAL
50 MG/DAILY 3 DAY						
			Calcium Carbonate			
			(+) Cholecalciferol	C		
			Raloxifene	C		

Date:07/05/01ISR Number: 3753294-XReport Type:Expedited (15-DaCompany Report #WAES 01069612
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardio-Respiratory Arrest	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Chest Pain	Health			Laboratories Div	
Initial or Prolonged	Gastric Ulcer	Professional			Merck Co Inc	
25 MG/DAILY						
Other	Myocardial Infarction		Aspirin	C		
	Pain In Extremity		Atorvastatin Calcium	C		
	Pseudomonas Infection		Diltiazem Hydrochloride	C		
			Vitamins (Unspecified)	C		
			Warfarin Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753295-1Report Type:Expedited (15-DaCompany Report #WAES 01065205
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea Visual Disturbance	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	13 DAY
			Aspirin	C				
			Omeprazole	C				

Date:07/05/01ISR Number: 3753297-5Report Type:Expedited (15-DaCompany Report #WAES 01069707
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Nervous System Disorder Vasospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	5 DAY
			Pepcid	C				
			Cefbuperazone	C				

Date:07/05/01ISR Number: 3753300-2Report Type:Expedited (15-DaCompany Report #WAES 01069713
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Hypernatraemia Intracranial Pressure Increased Nervous System Disorder	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	44 DAY
			Cefbuperazone	C				
			Dexamethasone	C				
			Vancomycin	C				

Date:07/05/01ISR Number: 3753303-8Report Type:Expedited (15-DaCompany Report #WAES 01061765
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthma Blood Pressure Increased Bronchitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	80 DAY
Other	Haemoglobin Decreased Headache Mitral Valve Incompetence Nausea Pulmonary Oedema Right Ventricular Failure Sinus Bradycardia Tricuspid Valve Incompetence Upper Respiratory Tract Infection		Becotide Eltroxin Klacid Prozac Rivotril Serevent Ventolin Estradiol	C C C C C C C C				

Date:07/05/01ISR Number: 3753329-4Report Type:Expedited (15-DaCompany Report #WAES 01062155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukaemia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Lasix	C		
			Zestril	C		
			Zocor	C		

Date:07/05/01ISR Number: 3753330-0Report Type:Expedited (15-DaCompany Report #WAES 01062274
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Bactroban	C				
			Cardizem Cd	C				
			Cozaar	C				
			Elocon	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Lopid	C				
			Lozol	C				
			Mavik	C				
			Plavix	C				
			Pravachol	C				
			Rezulin	C				
			Singulair	C				
			Testoderm	C				
			Viagra	C				
			Zocor	C				
			Aspirin	C				
			Insulin	C				
			Insulin Human	C				
			Insulin Human, Isophane	C				
			Vitamins	C				

Date:07/05/01ISR Number: 3753331-2Report Type:Expedited (15-DaCompany Report #WAES 01062543
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Nephropathy Toxic	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL PO

Date:07/05/01ISR Number: 3753337-3Report Type:Expedited (15-DaCompany Report #WAES 01055538
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Prostate Cancer Prostatic Specific Antigen Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		10 DAY

Date:07/05/01ISR Number: 3753341-5Report Type:Expedited (15-DaCompany Report #WAES 01035010
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	
	C-Reactive Protein Increased	Health Professional						
	Urticaria		Acetaminophen	C				
			Acetaminophen (+) Dihydrocodeine Bitartr	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Cinnarazine	C				
			Diazepam	C				
			Dicyclomine Hcl	C				
			Dihydrocodeine	C				
			Estrogens, Conjugated	C				
			Ibuprofen	C				
			Nitrazepam	C				
			Venlafaxine	C				

Date:07/05/01ISR Number: 3753342-7Report Type:Expedited (15-DaCompany Report #WAES 01069758
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	5 DAY
	Hepatic Failure	Literature						
	Renal Impairment	Health						
	Urine Sodium Decreased	Professional	Diclofenac	C				
	Weight Increased		Spironolactone	C				

Date:07/05/01ISR Number: 3753343-9Report Type:Expedited (15-DaCompany Report #WAES 01059604
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Asthma Blood Pressure Increased Blood Pressure Systolic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY 80 DAY						
Other	Inspiratory Decreased Bronchitis Cardiac Murmur Condition Aggravated Face Oedema Headache Mitral Valve Incompetence Nausea Oedema Oedema Peripheral Pulmonary Oedema Right Ventricular Failure Sinus Bradycardia Tricuspid Valve Incompetence Upper Respiratory Tract Infection Venous Pressure Jugular Increased		Albuterol Sulfate Beclomethasone Dipropionate Clonazepam Estradiol Fluoxetine Hcl Levothyroxine Na Salmeterol Xinafoate	C C C C C C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753464-0Report Type:Expedited (15-DaCompany Report #WAES 01060533
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Health	Vioxx	PS	Merck Research			
	Bronchospasm	Professional			Laboratories Div			
	Cholelithiasis	Company			Merck Co Inc	ORAL	50	
	Cough	Representative					MG/DAILY/PO	
	Dry Mouth		Allegra	C				
	Dyspnoea Exertional		Theo-Dur	C				
	Fatigue		Tylenol With Codeine					
	Hepatitis		#3	C				
	Jaundice Cholestatic		Xenical	C				
	Muscle Spasms							
	Oedema Peripheral							
	Pruritus							
	Skin Chapped							

Date:07/05/01ISR Number: 3753568-2Report Type:Expedited (15-DaCompany Report #WAES 01060669
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis	Health	Vioxx	PS	Merck Research			
Initial or Prolonged		Professional			Laboratories Div			
		Company			Merck Co Inc	ORAL	12.5	
		Representative					MG/DAILY/PO	

Date:07/05/01ISR Number: 3753569-4Report Type:Expedited (15-DaCompany Report #WAES 01040958
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence	Health	Vioxx	PS	Merck Research			
	Cardiac Failure	Professional			Laboratories Div			
	Congestive	Company			Merck Co Inc	ORAL	25	

	Cardiomegaly	Representative				
MG/DAILY/PO						
	Cardiomyopathy		Altace	C		
	Diarrhoea		Celebrex	C		
	Gynaecomastia		Lasix (Furosemide)	C		
	Mitral Valve Incompetence		Aspirin	C		
	Nocturia		Clonidine	C		
	Oedema Peripheral		Potassium	C		
	Weight Decreased					

Date:07/05/01ISR Number: 3753573-6Report Type:Expedited (15-DaCompany Report #WAES 01042857
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research	
	Ear Haemorrhage	Health			Laboratories Div	
	Excoriation	Professional			Merck Co Inc	ORAL
PO						
	Myalgia		Ocuvite	C		
	Orthostatic Hypotension		Zocor	C		
	Pain In Extremity		Antioxidants			
	Scab		(Unspecified)	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/01ISR Number: 3753600-6Report Type:Expedited (15-DaCompany Report #2001062001SE
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy	Foreign	Azulfidine	PS	Pharmacia And Upjohn Co			
	Colitis	Health						
	Diarrhoea Haemorrhagic	Professional	Ketoprofen	SS				
		Other	Rofecoxib	SS				

Date:07/05/01ISR Number: 3753712-7Report Type:Expedited (15-DaCompany Report #WAES 01067077
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Vioxx	PS	Merck Research Laboratories Div			
		Health						
		Professional			Merck Co Inc	ORAL	25 MG/DAILY	3 DAY

Date:07/05/01ISR Number: 3753714-0Report Type:Expedited (15-DaCompany Report #WAES 01067076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Vioxx	PS	Merck Research Laboratories Div			
		Health						
		Professional			Merck Co Inc		UNKNOWN	

Date:07/05/01ISR Number: 3753715-2Report Type:Expedited (15-DaCompany Report #WAES 01066045
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Anxiety	Other						
	Constipation				Merck Co Inc	ORAL	21	DAY
	Hallucination							

Date:07/05/01ISR Number: 3753717-6Report Type:Expedited (15-DaCompany Report #WAES 01059705
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury Road Traffic Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	43 DAY
			Hyaluronate Sodium	C				

Date:07/05/01ISR Number: 3753718-8Report Type:Expedited (15-DaCompany Report #WAES 01069711
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Pneumonia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG /DAILY	5 DAY
Disability			Cefbuperazone	C				
			Famotidine	C				
			Vancomycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/01ISR Number: 3753809-1Report Type:Expedited (15-DaCompany Report #WAES 01070029
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/06/01ISR Number: 3753818-2Report Type:Expedited (15-DaCompany Report #WAES 01062504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/06/01ISR Number: 3753821-2Report Type:Expedited (15-DaCompany Report #WAES 01062509
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Decreased Activity Decreased Appetite Sedation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Effexor	C				

Date:07/06/01ISR Number: 3753823-6Report Type:Expedited (15-DaCompany Report #WAES 01062382
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mallory-Weiss Syndrome Oesophageal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

		Representative	Singulair	C

Date:07/06/01ISR Number: 3753824-8Report Type:Expedited (15-DaCompany Report #WAES 01057519
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:07/06/01ISR Number: 3753860-1Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS		ORAL	25MG DAILY ORALLY [NOV 2000 (EARLY)]	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/01ISR Number: 3753992-8Report Type:Expedited (15-DaCompany Report #WAES 01062361
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG DAILY	PO
			Naproxen	C				

Date:07/06/01ISR Number: 3754627-0Report Type:Expedited (15-DaCompany Report #WAES 01065623
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 37 DAY

Date:07/09/01ISR Number: 3759244-4Report Type:Periodic Company Report #01RUSWE0100038
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Thyroid Stimulating Hormone Increased	Consumer Health Professional	Welchol	PS	Sankyo Pharma Inc	ORAL	1875 MG, QD, ORAL	
	Fatigue		Rofecoxib	SS		ORAL	50 MG, QD, ORAL	
			Pioglitazone	C				
			Synthroid (Levothyroxine Sodium)	C				

Date:07/09/01ISR Number: 3770077-5Report Type:Periodic Company Report #01RUSWE0100124
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anhidrosis	Consumer	Welchol	PS	Sankyo Pharma Inc	ORAL	625 MG, QD, ORAL	
	Drug Interaction	Other						
	Dyspnoea		Prevacid (Lansoprazole)	SS		ORAL	30 MG, QD, ORAL	
			Lipitor (Atorvastatin)	SS		ORAL	10 MG, QD, ORAL	
			Prinzide (Lisinopril, Hydrochlorothiazide)	SS		ORAL	1 TAB, QD, ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	0.5 TAB, QD, ORAL	

Date:07/10/01ISR Number: 3755558-2Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Foreign	Vioxx	PS	Merck Research			
	Cardiomegaly	Other			Laboratories Div			
	Circulatory Collapse				Merck Co Inc	ORAL	"SEE IMAGE"	2 MON
	Coronary Artery Disease		Actaminophen	C				
	Duodenal Ulcer		Atenolol	C				
	Gastrointestinal		Dipiproverine Dihcl	C				
	Haemorrhage		Lactulose	C				
	Haematemesis		...	C				
	Malaise							
	Pulmonary Congestion							
	Weight Decreased							

Date:07/10/01ISR Number: 3755566-1Report Type:Expedited (15-DaCompany Report #WAES 01055550
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness	Foreign	Vioxx	PS	Merck Research			
	Hypertensive Heart	Other			Laboratories Div			
	Disease				Merck Co Inc	ORAL	25 MG DAILY	3 DAY
	Nausea							
	Pulmonary Oedema							
	Shock							
	Ventricular Fibrillation							

Date:07/10/01ISR Number: 3755571-5Report Type:Expedited (15-DaCompany Report #WAES 01059708
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Endometrial Cancer	Other			Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY	15 DAY

Date:07/10/01ISR Number: 3755575-2Report Type:Expedited (15-DaCompany Report #WAES 01066116
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Drug Interaction	Other			Laboratories Div			
Initial or Prolonged	Drug Level Above				Merck Co Inc	ORAL	PO	5 DAY
	Therapeutic		Tab Vasotec	SS		ORAL	20 MG/DAILY, PO	
	Haemodialysis							
	Miosis		Tab Clorazepate					
	Overdose		Dipotassium	SS		ORAL	50 MG/DAILY, PO	
	Renal Failure Acute							
	Urine Analysis Abnormal		Cap Morphine	SS		ORAL	30 MG/BID,PO	12 DAY
			Atenolol	C				
			Clomipramine	C				
			Furosemide	C				
			Metformin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3755578-8Report Type:Expedited (15-DaCompany Report #WAES 01067811
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Body Temperature Increased Condition Aggravated Haemolysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 DAY

Date:07/10/01ISR Number: 3755580-6Report Type:Expedited (15-DaCompany Report #WAES 01063815
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Gastric Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Acetaminophen	C				
			Carbaspirin Calcium	C				
			Lactulose	C				
			Nadroparin	C				
			Thiamine Hydrochloride	C				

Date:07/10/01ISR Number: 3755582-XReport Type:Expedited (15-DaCompany Report #WAES 01069707
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Intracranial Pressure Increased Nervous System Disorder Vasospasm	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	5 DAY
Disability			Pepcid	C				
			Cefbuperazone	C				

Date:07/10/01ISR Number: 3755583-1Report Type:Expedited (15-DaCompany Report #WAES 01069708
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intracranial Pressure	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Increased	Health			Laboratories Div			
Hospitalization -	Nervous System Disorder	Professional			Merck Co Inc	ORAL	50	
Initial or Prolonged	Pneumonia							
MG/DAILY/PO	9	DAY						
Disability			Dexamethasone	C				

Date:07/10/01ISR Number: 3755585-5Report Type:Expedited (15-DaCompany Report #WAES 01069709
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intracranial Pressure	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Increased	Health			Laboratories Div			
Hospitalization -	Sepsis	Professional			Merck Co Inc	ORAL	50	
Initial or Prolonged								
MG/DAILY/PO	6	DAY						
Disability			Pepcid	C				
			Vancomycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3755757-XReport Type:Expedited (15-DaCompany Report #WAES 01052040
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dizziness							
	Malaise							
	Pain		Tab Vioxx 50 Mg	SS		ORAL	PO	
			Aspirin	C				
			Hormones (Unspecified)	C				

Date:07/10/01ISR Number: 3755758-1Report Type:Expedited (15-DaCompany Report #WAES 01061868
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriovenous Malformation	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
	International Normalised Ratio Increased							
	Prothrombin Time Prolonged		Coumadin	C				
	Upper Gastrointestinal Haemorrhage		Rythmol	C				
			Zestril	C				
			Digoxin	C				
			Nitroglycerin	C				

Date:07/10/01ISR Number: 3755759-3Report Type:Expedited (15-DaCompany Report #WAES 01010251
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Nausea							
	Weight Decreased							
			Celebrex	C				

Date:07/10/01ISR Number: 3755799-4Report Type:Expedited (15-DaCompany Report #WAES 01061126
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Ineffective Pain Renal Failure	Health Professional Company Representative	Tab Vioxx 50 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	100 MG/DAILY/PO	
			Demulen	C				

Date:07/10/01ISR Number: 3755800-8Report Type:Expedited (15-DaCompany Report #WAES 01061749
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Bronchospasm Pulmonary Hypertension	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3755801-XReport Type:Expedited (15-DaCompany Report #WAES 99121888
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister	Consumer	Vioxx	PS	Merck Research			
	Blood Pressure Increased	Health			Laboratories Div			
	Conjunctivitis	Professional			Merck Co Inc	ORAL	DAILY/PO	
	Diarrhoea		Lipitor	C				
	Ear Discomfort		Premarin	C				
	Ear Pain		Synthroid	C				
	Hearing Impaired		Zocor	C				
	Influenza Like Illness		[Composition					
	Meniere'S Disease		Unspecified]	C				
	Musculoskeletal Stiffness		Calcium Supplemenr					
	Nausea		(Composition	C				
	Pruritus		Vitamins	C				
	Tongue Ulceration							
	Vomiting							

Date:07/10/01ISR Number: 3755942-7Report Type:Expedited (15-DaCompany Report #WAES 01069710
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia	Foreign	Vioxx	PS	Merck Research			
Life-Threatening	Sepsis	Health			Laboratories Div			
Hospitalization -		Professional			Merck Co Inc	ORAL	50 MG/DAILY	
Initial or Prolonged			Cefbuperazone	C				
			Vancomycin	C				

Date:07/10/01ISR Number: 3756032-XReport Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL	50MG , 50MG	
Initial or Prolonged	Haemorrhage						HS ORAL	
			Aspirin	C				

Date:07/10/01ISR Number: 3756064-1Report Type:Expedited (15-DaCompany Report #WAES 01059705
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury Road Traffic Accident	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY,	
			Hyaluronate Sodium	C				

Date:07/10/01ISR Number: 3756065-3Report Type:Expedited (15-DaCompany Report #WAES 01065629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Blood Urea Increased Blood Uric Acid Increased Pneumonia Right Ventricular Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3756072-0Report Type:Expedited (15-DaCompany Report #WAES 01065632
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Drug Interaction Haematoma	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Haemoglobin Decreased		Enoxaparin	SS		INTRAVENOUS	0.8 ML/BID, IV	
	Haemorrhage Injury Scleral Disorder							

Date:07/10/01ISR Number: 3756073-2Report Type:Expedited (15-DaCompany Report #WAES 01067910
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Viral Infection	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	4 DAY

Date:07/10/01ISR Number: 3756093-8Report Type:Expedited (15-DaCompany Report #WAES 01069945
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAY, PO	
	Blood Lactate Dehydrogenase Increased		Plendil	C				
			Cilazapril	C				
	Chest Pain		Metformin Hcl	C				
	Muscular Weakness							

Date:07/10/01ISR Number: 3756094-XReport Type:Expedited (15-DaCompany Report #WAES 01076505
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/01ISR Number: 3756120-8Report Type:Expedited (15-DaCompany Report #WAES 01068579
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection Escherichia Sepsis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hctz/Triamterene	C				
			Aspirin	C				
			Valsartan	C				

Date:07/10/01ISR Number: 3756166-XReport Type:Expedited (15-DaCompany Report #WAES 01070101
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Blindness Condition Aggravated Eye Haemorrhage Histoplasmosis Vitrectomy	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/ DAILY PO	

Date:07/10/01ISR Number: 3756169-5Report Type:Expedited (15-DaCompany Report #WAES 01070098
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Nitro-Dur	C				
			Aspirin	C				
			Verapamil Hydrochloride	C				

Date:07/10/01ISR Number: 3756171-3Report Type:Expedited (15-DaCompany Report #WAES 01070315
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased Nephrolithiasis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Altace	C				
			Hydrodiuril	C				
			Proscar	C				

			Topril Xl Tablets	C		
			Aspirin	C		

Date:07/10/01ISR Number: 3756177-4Report Type:Expedited (15-DaCompany Report #WAES 01052040
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Dizziness					
	Malaise					
SEE IMAGE						
	Pain		Aspirin	C		
			Hormones (Unspecified)	C		

Date:07/10/01ISR Number: 3756289-5Report Type:Expedited (15-DaCompany Report #WAES 01050310
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Death	Basophil Count Abnormal
Hospitalization - Initial or Prolonged	Biliary Tract Disorder
	Cardiac Disorder
Disability	Cardiomyopathy
	Dermatitis
	Drug Hypersensitivity

		Eosinophilia Eosinophilic Myocarditis Eosinophilic Pneumonia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Disorder Hepatic Necrosis Hepatosplenomegaly	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO							
		Leukocytosis Lung Disorder Muscle Disorder Necrosis Pancreatic Disorder Renal Disorder Spleen Disorder	Representative	Correctol Laxative Tablets & Caplet Vicodin Tablets Codeine Excedrin Migraine Zoloft [Therapy Unpsecified] Atenolol	SS SS SS C C C C		

Date:07/10/01ISR Number: 3756311-6Report Type:Expedited (15-DaCompany Report #WAES 01062374
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5						
Other		Representative				
MG/DAILY/PO						
			Aspirin	C		

Date:07/10/01ISR Number: 3756313-XReport Type:Expedited (15-DaCompany Report #WAES 01062707
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
DAILY/PO						
			Prempor Ziac	C C		

Date:07/10/01ISR Number: 3756315-3Report Type:Expedited (15-DaCompany Report #WAES 01070214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Retinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	2 WK

Date:07/10/01ISR Number: 3756316-5Report Type:Expedited (15-DaCompany Report #WAES 01070213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Condition Aggravated Eye Haemorrhage Histoplasmosis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/01ISR Number: 3756536-XReport Type:Expedited (15-DaCompany Report #WAES 01075015
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/BID	PO 139 DAY
			Acetaminophen	C				
			Dihydrocodeine	C				

Date:07/10/01ISR Number: 3756539-5Report Type:Expedited (15-DaCompany Report #WAES 00119709
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Dizziness Headache Malaise	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PO	
			Elavil	C				
			Fosamax	C				
			Calcium (Carbonate/Gluconolac)	C				
			Calcium Lactate	C				

Date:07/10/01ISR Number: 3756540-1Report Type:Expedited (15-DaCompany Report #WAES 01069762
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/01ISR Number: 3756542-5Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			
Other	Cardiac Failure	Other			Merck Co Inc	ORAL	25 MG/DAILY	
	Cardiac Failure							
	Congestive							
	Fluid Overload		Beclomethasone Dipropionate	C				
			Hydrocortisone/Neomycinso4/Polymyxin Bso	C				
			Ispaghula Husk	C				
			Nystatin	C				

Date:07/10/01ISR Number: 3756627-3Report Type:Expedited (15-DaCompany Report #WAES 01010251
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Nausea							
	Weight Decreased				Merck Co Inc	ORAL	PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3756639-XReport Type:Expedited (15-DaCompany Report #WAES 01022160
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue Meningitis Aseptic Urinary Tract Infection	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	
			Nonsteroidal Anti-Inflammatory	C				

Date:07/10/01ISR Number: 3756884-3Report Type:Expedited (15-DaCompany Report #WAES 01062666
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased Chest Discomfort	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Agyrax (Meclizine Hydrochloride)	C				
			Hydrodiuril	C				
			K-Dur	C				
			Lipitor	C				
			Paxil	C				
			Vasotec	C				
			Estradiol	C				

Date:07/10/01ISR Number: 3756886-7Report Type:Expedited (15-DaCompany Report #WAES 01070024
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Vicoprofen	C				

Date:07/10/01ISR Number: 3756888-0Report Type:Expedited (15-DaCompany Report #WAES 01070039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agranulocytosis Bone Marrow Depression	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/10/01ISR Number: 3756919-8Report Type:Expedited (15-DaCompany Report #WAES 01070024
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Vicoprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3758901-3Report Type:Expedited (15-DaCompany Report #WAES 01075009
Age:76 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO 4 DAY
			Ranitidine	C				

Date:07/11/01ISR Number: 3755953-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised		Vioxx 12.5 Mg	PS			12.5 MG DAILY	
	Ratio Increased		Warfarin 2.5mg	SS			2.5MG QHS	

Date:07/12/01ISR Number: 3756885-5Report Type:Direct Company Report #
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia		Vioxx 25 Mg Merck	PS	Merck	ORAL	50 MG QD ORAL	
	Renal Failure Acute		Isordil	C				
			Levothyroxine	C				
			Digoxin	C				
			Aspirin	C				
			Prilosec	C				
			Lasix	C				
			Coumadin	C				
			Humabid	C				
			Baycol	C				
			Allopurinol	C				
			K-Dur	C				
			Ca++/Vitamin D	C				
			Prednisone	C				

			Colace	C		
			Serevent	C		
			Flovent	C		
			Atrovent	C		
			Metolazone	C		
			Albuterol	C		

Date:07/12/01ISR Number: 3757038-7Report Type:Direct Company Report #
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2-3 DAYS PTA	Cardiac Failure		Celebrex	PS		
Initial or Prolonged 2-3 DAYS PTA	Congestive		Vioxx	SS		
2WKS PTA	Condition Aggravated		Avandia	SS		
	Oedema		Asa	C		
			Lotensin	C		
			Lasix	C		
			Digoxin	C		
			Allopurnol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/01ISR Number: 3757066-1Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema		Rofecoxib (25mg)	PS			2 TAB EVERY	
	Urticaria						MORNING	
			Prazosin	C				
			Levothyroxine	C				
			Felodipine	C				
			Simvastatin	C				

Date:07/12/01ISR Number: 3757081-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx (25 Mg-Samples					
	Blood Pressure Decreased		Given At Another Md					
	Confusional State		Office)	PS		ORAL	25 MG PO QD	
	Dysarthria							
	Fatigue							

Date:07/13/01ISR Number: 3758351-XReport Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chromaturia		Vioxx (50mg)	PS		ORAL	PO QD	2 WK
	Decreased Appetite		Celexa	C				
	Faeces Pale							
	Fatigue							
	Myalgia							
	Pyrexia							

Date:07/13/01ISR Number: 3758516-7Report Type:Expedited (15-DaCompany Report #WAES 01075030
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
		Other					PO	140 DAY
			Acetaminophen/Codeine Phosphate	C				
			Diltiazem	C				
			Evening Primrose Oil	C				
			Garlic Extract	C				
			Insulin	C				
			Paroxetine	C				
			Tramadol	C				

Date:07/13/01ISR Number: 3758591-XReport Type:Expedited (15-DaCompany Report #WAES 01078509
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Humerus Fracture	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
							PO	
			Celecoxib	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/01ISR Number: 3758592-1Report Type:Expedited (15-DaCompany Report #WAES 01075036
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Gastric Ulcer						PO	
	Haemoglobin Decreased		Albuterol	C				
	Melaena		Aspirin	C				
			Furosemide	C				

Date:07/13/01ISR Number: 3758593-3Report Type:Expedited (15-DaCompany Report #WAES 01075033
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inappropriate Antidiuretic Hormone Secretion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5/DAILY PO	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Cetostearyl Alcohol					
			(+) Phenoxyethanol	C				
			Mineral Oil	C				
			Oxybutynincl	C				
			Paraffin	C				

Date:07/13/01ISR Number: 3758606-9Report Type:Expedited (15-DaCompany Report #WAES 01075034
Age:64 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Disability								
PO							31	DAY

Other				Acetaminophen/Codeine Phosphate	C		

Date:07/13/01ISR Number: 3758609-4Report Type:Expedited (15-DaCompany Report #WAES 01068592
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Atelectasis Cardiac Failure Congestive Fatigue Left Ventricular Failure Pleural Calcification Pleural Effusion Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG; DAILY;	PO 22 DAY

Date:07/13/01ISR Number: 3758610-0Report Type:Expedited (15-DaCompany Report #WAES 01058772
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Musculoskeletal Stiffness	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG; DAILY;	

PO

Date:07/13/01ISR Number: 3758729-4Report Type:Expedited (15-DaCompany Report #WAES 01070303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Aspirin	C				

Date:07/13/01ISR Number: 3758730-0Report Type:Expedited (15-DaCompany Report #WAES 01070329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Voltaren	C				

Date:07/13/01ISR Number: 3758731-2Report Type:Expedited (15-DaCompany Report #WAES 01062322
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Perforation Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/13/01ISR Number: 3758888-3Report Type:Expedited (15-DaCompany Report #WAES 01061715
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain Dysphagia Dyspnoea	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hyperventilation Laryngeal Oedema Laryngospasm Throat Tightness Tremor		Celebrex	C				

Date:07/13/01ISR Number: 3758935-9Report Type:Expedited (15-DaCompany Report #WAES 01065573
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Ischaemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/01ISR Number: 3759291-2Report Type:Expedited (15-DaCompany Report #WAES 01062109
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatine Increased Blood Urea Increased Dehydration	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25	MG/DAILY/PO
	Oral Intake Reduced	Representative						
	Pneumonia		Aredia	C				
	Upper Respiratory Tract Infection		Procrit	C				
			Interferon (Unspecified)	C				

Date:07/16/01ISR Number: 3759561-8Report Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Renal Failure	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5	MG/DAILY/PO
			Premarin	C				
			Ultran	C				

Date:07/16/01ISR Number: 3759562-XReport Type:Expedited (15-DaCompany Report #WAES 01070579
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Hydrodiuril	C				
			Lipitor	C				
			Atenolol	C				
			Clonidine	C				

Date:07/16/01ISR Number: 3759573-4Report Type:Expedited (15-DaCompany Report #WAES 01070621
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx	PS	Novartis			
	Haemoptysis	Professional			Pharmaceuticals Corp	ORAL	PO	
	Pneumonia		Tylenol	C				
	Weight Increased		Valium	C				
			Vicodin Tablets	C				
			Zestril	C				
			Zithromax	C				

Date:07/16/01ISR Number: 3759576-XReport Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Cardiac Arrest	Health			Laboratories Div			
	Chest Pain	Professional			Merck Co Inc	ORAL	PO	
	Dyspnoea							
	Sinus Arrest							
	Syncope							

Date:07/16/01ISR Number: 3759578-3Report Type:Expedited (15-DaCompany Report #WAES 01060669
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Faecal Occult Blood Positive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:07/16/01ISR Number: 3759579-5Report Type:Expedited (15-DaCompany Report #WAES 01061126
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Renal Failure	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	100 MG/DAILY/PO	
			Demulin	C				

Date:07/16/01ISR Number: 3759739-3Report Type:Expedited (15-DaCompany Report #WAES 01073471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
		Other	Aspirin	C				

Date:07/16/01ISR Number: 3759740-XReport Type:Expedited (15-DaCompany Report #WAES 01077008
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Haemorrhage Syncope Upper Gastrointestinal Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	14 DAY

Date:07/16/01ISR Number: 3759741-1Report Type:Expedited (15-DaCompany Report #WAES 01075533
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Pancytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	3 MON
		Other	Methotrexate	SS		ORAL	7.5 MG/WKY	
			Prinivil	C				
			Bromazepam	C				
			Calcium Carbonate (+) Etidronate Sodium	C				
			Folic Acid	C				
			Liotrix	C				
			Metoprolol Tartrate	C				
			Piretanide	C				

Ranitidine Hcl C

Date:07/16/01ISR Number: 3759742-3Report Type:Expedited (15-DaCompany Report #WAES 01073719
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Gastric Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/16/01ISR Number: 3759743-5Report Type:Expedited (15-DaCompany Report #WAES 01077252
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY	

Date:07/16/01ISR Number: 3759744-7Report Type:Expedited (15-DaCompany Report #WAES 01073487
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/16/01ISR Number: 3759818-0Report Type:Expedited (15-DaCompany Report #WAES 01073477
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			

Initial or Prolonged	Congestive Condition Aggravated	Consumer			Laboratories Div Merck Co Inc	ORAL
25MG/DAILY PO 2 MON						

Date:07/16/01ISR Number: 3759819-2Report Type:Expedited (15-DaCompany Report #WAES 01078526
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:07/16/01ISR Number: 3759821-0Report Type:Expedited (15-DaCompany Report #WAES 01036087
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Fatigue	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY PO						
	Haemoglobin Decreased					
	Melaena		Tab Acenocoumarol	SS		ORAL
PO (SEE IMAGE)						

Powd Aspirin SS ORAL
PO
Insulin C

Date:07/16/01ISR Number: 3759863-5Report Type:Expedited (15-DaCompany Report #WAES 01070611
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lodine	SS				

Date:07/16/01ISR Number: 3759939-2Report Type:Expedited (15-DaCompany Report #WAES 01061610
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	1 MON
			Baycol	C				
			Cenestin	C				

Date:07/16/01ISR Number: 3760647-2Report Type:Expedited (15-DaCompany Report #WAES 01058772
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache Musculoskeletal Stiffness	Foreign Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:07/18/01ISR Number: 3761097-5Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 MG PO BID	Abdominal Discomfort		Rofecoxib (Vioxx)	PS		ORAL
Initial or Prolonged	Anaemia		Digoxin	C		
	Confusional State		Atenolol	C		
	Haematoma		Kcl	C		
	Renal Failure Acute		Feso4	C		
	Therapeutic Agent		Famotidine	C		
	Toxicity		Alendronate	C		
			Caco3	C		
			Ntg	C		
			Furosemide	C		
			Atorvastatin	C		
			Dss	C		
			Candesartan	C		
			Heparin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3761707-2Report Type:Expedited (15-DaCompany Report #WAES 01062316
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Vioxx	PS	Merck Research			
Other	Haematemesis	Professional			Laboratories Div			
	Melaena	Company			Merck Co Inc	ORAL	50	
	Nausea	Representative					MG/DAILY/PO	

Date:07/19/01ISR Number: 3761727-8Report Type:Expedited (15-DaCompany Report #WAES 01078204
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign	Vioxx (Rofecoxib)	PS	Merck Research			
	Congestive	Health			Laboratories Div			
	Pulmonary Congestion	Professional			Merck Co Inc	ORAL	25 MG DAILY	
PO								14 DAY
			Aspirin	C				
			Atorvastatin Calcium	C				
			Bisoprolol Fumarate	C				
			Estradiol	C				

Date:07/19/01ISR Number: 3761728-XReport Type:Expedited (15-DaCompany Report #WAES 01075064
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Vioxx (Rofecoxib)	PS	Merck Research			
	Anorexia	Other			Laboratories Div			
					Merck Co Inc	ORAL	12.5 MG/DAILY	
PO								7 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				

Date:07/19/01ISR Number: 3761731-XReport Type:Expedited (15-DaCompany Report #WAES 01075067
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO
			Acetaminophen	C				
			Amlodipine	C				
			Bumetanide	C				
			Codeine Sulfate (+) Ipecac (+) Squill	C				
			Dihydrocodeine	C				
			Lactulose	C				
			Metoclopramide	C				
			Morphine	C				
			Morphineso4	C				
			Nystatin	C				
			Phenobarbital	C				
			Polyethylene Glycol	C				
			Prochlorperazine Maleate	C				
			Tramadol	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3761737-0Report Type:Expedited (15-DaCompany Report #WAES 01065623
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 36 DAY
			Aspirin	SS		ORAL	100 MG/DAILY	PO
			Lisinopril- Hctz	C				
			Methyldopa	C				
			Propafenone Hc1	C				

Date:07/19/01ISR Number: 3761739-4Report Type:Expedited (15-DaCompany Report #WAES 01079002
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated Eyelid Oedema Face Oedema	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	4 TABLET PO	561 DAY
	Oedema	Professional	Cyclobenzaprine Hcl	C				
			Folic Acid	C				
			Hydroxychloroquineso 4	C				
			Methotrexate	C				
			Naproxen	C				
			Prednisone	C				

Date:07/19/01ISR Number: 3761742-4Report Type:Expedited (15-DaCompany Report #WAES 01075024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive	Foreign Study	Vioxx	PS	Merck Research Laboratories Div			

		Health		Merck Co Inc	ORAL	
25 MG/DAILY						
		Professional				
PO	9 DAY					

Date:07/19/01ISR Number: 3761792-8Report Type:Expedited (15-DaCompany Report #WAES 01079505
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Dyspepsia Haematemesis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc			
PO	79 DAY							
			Vasotec	C				
			Aspirin	C				
			Fluoxetine	C				

Date:07/19/01ISR Number: 3761797-7Report Type:Expedited (15-DaCompany Report #WAES 01069962
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Death	Disseminated Intravascular Coagulation
Life-Threatening	Ecchymosis
Hospitalization - Initial or Prolonged	Epistaxis Haemorrhage Intracranial

		Haemorrhage Subcutaneous Loss Of Consciousness Mouth Ulceration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pancytopenia Pyrexia Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY							
PO	27 DAY						
				Tab Methotrexate Sodium	SS		ORAL
PO	27 DAY						

Date:07/19/01ISR Number: 3761798-9Report Type:Expedited (15-DaCompany Report #WAES 01079762
Age:30 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Atrophy Dermatitis Limb Deformity	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY							
PO		Pyrexia Tremor					

Date:07/19/01ISR Number: 3761990-3Report Type:Expedited (15-DaCompany Report #WAES 01070300
Age:63 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Anaemia Oedema	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25							
MG/DAILY/PO							
				Paxil	C		
				Premarin	C		
				Vitamins	C		

Date:07/19/01ISR Number: 3761992-7Report Type:Expedited (15-DaCompany Report #WAES 01070148
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY/PO	
	Blister							
	Bronchospasm							
	Diarrhoea							
	Headache							
	Nausea		Claritin	C				
	Rash Pruritic		Lodine	C				
	Urticaria		Motrin	C				
	Vomiting		Soma	C				
			Xanax	C				
			Aspirin	C				

Date:07/19/01ISR Number: 3761995-2Report Type:Expedited (15-DaCompany Report #WAES 01040371
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Neuropathy Peripheral							
	Renal Failure Acute							
			Celebrex	C				

			Neurontin	C
			Nonsteroidal Anti-Inflammatory	C

Date:07/19/01ISR Number: 3762001-6Report Type:Expedited (15-DaCompany Report #WAES 01070933
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Duodenitis Gastric Ulcer Gastritis Oesophagitis Upper Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/19/01ISR Number: 3762012-0Report Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Dizziness Drug Ineffective Hypertension Renal Impairment	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Premarin	C				
			Ultran	C				
			Atenolol	C				

Date:07/19/01ISR Number: 3762014-4Report Type:Expedited (15-DaCompany Report #WAES 01070670
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Heart Rate Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

	Orthostatic Hypotension				Merck Co Inc	ORAL
PO						
	Shock		Aggrenox	C		
			Tamoxifen	C		

Date:07/19/01ISR Number: 3762016-8Report Type:Expedited (15-DaCompany Report #WAES 01070318
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pneumonia Bacterial	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Klonopin	C		
			Lipitor	C		
			Zoloft	C		

Date:07/19/01ISR Number: 3762019-3Report Type:Expedited (15-DaCompany Report #WAES 01070532
Age:68 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
		Coumadin	C				
		Duragesic	C				
		Hydrodiuril	C				
		Mevacor	C				
		Synthroid	C				
		Vicodin Tablets	C				
		Allopurinol	C				
		Amlodipine Besylate	C				
		Trazodone	C				

Date:07/19/01ISR Number: 3762024-7Report Type:Expedited (15-DaCompany Report #WAES 01062509
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Decreased Activity Decreased Appetite Refusal Of Treatment By Patient Sedation	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Effexor	C				

Date:07/19/01ISR Number: 3762028-4Report Type:Expedited (15-DaCompany Report #WAES 01062513
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Pyrexia Renal Failure Acute Tremor	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 12.5 MG/DAILY/PO;	

2) 25

MG/DAILY/PO

	Vioxx	SS	ORAL

25MG DAILY PO

	Verelan	SS
	Prinvil	C

Date:07/19/01ISR Number: 3762032-6Report Type:Expedited (15-DaCompany Report #WAES 01070766
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO

	Celexa	C

Date:07/19/01ISR Number: 3762034-XReport Type:Expedited (15-DaCompany Report #WAES 01060862
Age:69 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Hypersensitivity Tongue Oedema	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:07/19/01ISR Number: 3762036-3Report Type:Expedited (15-DaCompany Report #WAES 01041531
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus Pancreatitis Chronic	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Daypro	C				
			Flexeril	C				
			Percocet	C				
			Relafen	C				
			Naproxen	C				

Date:07/19/01ISR Number: 3762037-5Report Type:Expedited (15-DaCompany Report #WAES 01042043
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension Eyelid Oedema Hypertension	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Insomnia Oedema Peripheral		Naprosyn	C				

Date:07/19/01ISR Number: 3762038-7Report Type:Expedited (15-DaCompany Report #WAES 01040958
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Disability	Congestive Cardiac Failure	Company			Merck Co Inc	ORAL	25 MG/DAILY/PO	
Other	Cardiac Murmur	Representative						
	Cardiomegaly		Altace	C				
	Cardiomyopathy		Celebrex	C				
	Diarrhoea		Lasix (Furosemide)	C				
	Ear Disorder		Aspirin	C				
	Gynaecomastia		Clonidine	C				
	Hypertension		Potassium	C				
	Mitral Valve Incompetence							
	Nocturia							

Date:07/19/01ISR Number: 3762039-9Report Type:Expedited (15-DaCompany Report #WAES 01071005
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Gastrointestinal Haemorrhage				Merck Co Inc	ORAL	25 MG/DAILY/PO	

			Allegra	C
			Combivent	C
			Coumadin	C
			Lanoxin	C
			Paxil	C
			Prinivil	C
			Synthroid	C
			Xanax	C
			Aspirin	C
			Doxepin	C

Date:07/19/01ISR Number: 3762057-0Report Type:Expedited (15-DaCompany Report #WAES 01070961
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hydrodiuril	C				
			Prinivil	C				
			Allopurinol	C				
			Atenolol	C				

Date:07/19/01ISR Number: 3762058-2Report Type:Expedited (15-DaCompany Report #WAES 01070579
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Dyspnoea	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Hydrodiuril	C				
			Lipitor	C				
			Atenolol	C				
			Clonidine	C				

Date:07/19/01ISR Number: 3762059-4Report Type:Expedited (15-DaCompany Report #WAES 01070883
Age:50 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
Other	Blood Pressure Fluctuation
	Cardiac Failure Congestive
	Cellulitis
	Chest Pain
	Difficulty In Walking
	Dyspnoea
	Dyspnoea Exacerbated
	Dyspnoea Exertional
	Fluid Overload
	Fluid Retention
	Lymphadenopathy
	Nephrotic Syndrome
	Oedema Peripheral
	Pallor

	Pulmonary Oedema Rales Scrotal Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Weight Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	MG/DAILY/PO
			Actos	C			
			Allegra	C			
			Avapro	C			
			Effexor	C			
			Flexeril	C			
			Humulin 70/30	C			
			Imitrex	C			
			Lipitor	C			
			Urispas	C			
			Viagra	C			
			Vicodin Tablets	C			
			Zyrtec	C			
			Aspirin	C			
			Atenolol	C			
			Cyclobenzaprine Hydrochloride	C			
			Furosemide	C			
			Ibuprofen	C			
			Niacin	C			
			Trazodone	C			

Date:07/19/01ISR Number: 3762063-6Report Type:Expedited (15-DaCompany Report #WAES 01062483
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Feeling Abnormal	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO

Date:07/19/01ISR Number: 3762064-8Report Type:Expedited (15-DaCompany Report #WAES 01040957
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx	PS	Merck Research			
Life-Threatening	Cardiac Failure	Professional			Laboratories Div			
Disability	Congestive	Company			Merck Co Inc	ORAL	25	
	Dyspnoea	Representative					MG/DAILY/PO	

Date:07/19/01ISR Number: 3762065-XReport Type:Expedited (15-DaCompany Report #WAES 01030399
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oral Intake Reduced	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Renal Failure Acute	Professional			Laboratories Div			
Other		Other			Merck Co Inc	ORAL	25	
							MG/DAILY/PO	
			Hydrodiuril	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3762066-1Report Type:Expedited (15-DaCompany Report #WAES 01042169
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Duodenitis	Professional			Laboratories Div			
Initial or Prolonged	Haematemesis	Company			Merck Co Inc	ORAL	25	
Other	Haematocrit Decreased	Representative					MG/DAILY/PO	
	Haemoglobin Decreased		Avandia	C				
	Melaena		Daypro	C				
	Upper Gastrointestinal		Fosamax	C				
	Haemorrhage		Lasix (Furosemide)	C				
			Lipitor	C				
			Plavix	C				
			Zestril	C				
			Aspirin	C				
			Potassium	C				

Date:07/19/01ISR Number: 3762067-3Report Type:Expedited (15-DaCompany Report #WAES 01070329
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Gastrointestinal	Professional			Laboratories Div			
	Haemorrhage	Company			Merck Co Inc	ORAL	25	
	Renal Failure Acute	Representative					MG/DAILY/PO	
			Voltaren	SS				
			Lasix (Furosemide)	C				
			Lopid	C				

Date:07/19/01ISR Number: 3762068-5Report Type:Expedited (15-DaCompany Report #WAES 01062374
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastrointestinal	Professional			Laboratories Div			

Initial or Prolonged	Haemorrhage	Company			Merck Co Inc	ORAL
25						
Other		Representative				
MG/DAILY/PO						
			Aspirin	SS		ORAL
81						
MG/DAILY/PO						
			Keflex	C		
			Atenolol	C		

Date:07/19/01ISR Number: 3762069-7Report Type:Expedited (15-DaCompany Report #WAES 01062226
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatitis	Health	Vioxx	PS	Merck Research	
	Influenza Like Illness	Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						
			Allegra	C		
			Ceftin	C		
			Tylenol W/ Codeine #3	C		
			Zyrtec	C		
			Azithromycin	C		

Date:07/19/01ISR Number: 3762070-3Report Type:Expedited (15-DaCompany Report #WAES 01052780
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
Other	Chronic Obstructive Pulmonary Disease	Other			Merck Co Inc	ORAL	50 MG/DAILY/PO	
	Duodenal Ulcer							
	Faeces Discoloured		Tab Aspirin	SS		ORAL	325 MG/DAILY/PO	
	Gastrointestinal							
	Haemorrhage		Indocin (Indomethacin)	C				
	Haematochezia							
	Oesophagitis							
	Pain							
	Vomiting							

Date:07/19/01ISR Number: 3762265-9Report Type:Expedited (15-DaCompany Report #WAES 01075086
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			
	Haemorrhage				Merck Co Inc	ORAL	25 MG/DAILY	
			Amlodipine	C				
			Aspirin/Dipyridamole	C				
			Fenofibrate	C				
			Oxybutynincl	C				

Date:07/19/01ISR Number: 3762266-0Report Type:Expedited (15-DaCompany Report #WAES 01075090
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis Ulcerative	Foreign Other	Vioxx	PS	Merck Research Laboratories Div			

					Merck Co Inc	ORAL
12.5 MG						
/DAILY						
			Insulin	C		
			Mesalamine	C		

Date:07/19/01ISR Number: 3762268-4Report Type:Expedited (15-DaCompany Report #WAES 01073484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Methotrexate	C		

Date:07/19/01ISR Number: 3762270-2Report Type:Expedited (15-DaCompany Report #WAES 01075559
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/BID						
			Bisoprolol Fumarate /Hctz	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3762271-4Report Type:Expedited (15-DaCompany Report #WAES 01073467
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/19/01ISR Number: 3762696-7Report Type:Expedited (15-DaCompany Report #WAES 01070915
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health Professional Company Representative	Tab Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/19/01ISR Number: 3762704-3Report Type:Expedited (15-DaCompany Report #GBR003987
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coma	Health Professional	Meridia	PS	Abbott Laboratories Pharmaceutical Products Div			
	Haemorrhagic Stroke							
	Overdose							
	Respiratory Depression		Propoxyphene	SS			65 MG OD	
	Sinus Tachycardia		Diazepam	SS				
	Suicide Attempt		Cyclobenzaprine	SS				
			Vioxx	SS				

Date:07/19/01ISR Number: 3762716-XReport Type:Expedited (15-DaCompany Report #WAES 01070662
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Consumer	Vioxx	PS	Merck Research Laboratories Div			
Hospitalization -	Haematemesis							

Initial or Prolonged Merck Co Inc ORAL
PO

Date:07/19/01ISR Number: 3762717-1Report Type:Expedited (15-DaCompany Report #WAES 01070676
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/19/01ISR Number: 3762718-3Report Type:Expedited (15-DaCompany Report #WAES 01061319
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG PRN PO	
Hospitalization - Initial or Prolonged	Chest Pain							
	Dyspnoea							
	Fatigue		Norvasc	C				
	Gastrointestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3762719-5Report Type:Expedited (15-DaCompany Report #WAES 01071190
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/19/01ISR Number: 3762720-1Report Type:Expedited (15-DaCompany Report #WAES 01051662
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukopenia	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
Other	Myelofibrosis							
	Neutropenia							
	Platelet Count Decreased	Representative					PO	
	Splenomegaly		Zithromax	C				

Date:07/19/01ISR Number: 3762721-3Report Type:Expedited (15-DaCompany Report #WAES 01071189
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/19/01ISR Number: 3762722-5Report Type:Expedited (15-DaCompany Report #WAES 01071039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div			
	Haemorrhage							

Melaena Merck Co Inc ORAL
PO

Date:07/19/01ISR Number: 3763053-XReport Type:Expedited (15-DaCompany Report #WAES 01043421
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Urticaria	Foreign	Vioxx	PS	Merck Research			
Other		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG/DAILY	15 DAY
			Irbesartan	C				

Date:07/19/01ISR Number: 3763056-5Report Type:Expedited (15-DaCompany Report #WAES 01065527
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Foreign	Vioxx	PS	Merck Research			
Initial or Prolonged	Vomiting	Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL	12.5 MG DAILY	
						PO	1	DAY
			Aspirin	C				
			Hydrochlorothiazide					
			(+) Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/01ISR Number: 3763057-7Report Type:Expedited (15-DaCompany Report #WAES 01078102
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Toxic Skin Eruption	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 24 DAY
			Tab Hydroxychloroquineso 4	SS		ORAL	200 MG/DAILY	PO 24 DAY

Date:07/19/01ISR Number: 3763058-9Report Type:Expedited (15-DaCompany Report #WAES 01078529
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celecoxib	C				

Date:07/19/01ISR Number: 3763059-0Report Type:Expedited (15-DaCompany Report #WAES 01069762
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Hospitalization - Initial or Prolonged	Loss Of Consciousness							
	Mental Impairment							
Disability	Renal Failure Acute							

Date:07/19/01ISR Number: 3763060-7Report Type:Expedited (15-DaCompany Report #WAES 00119134
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Asthenia	Literature						
Other	Drug Interaction	Health			Merck Co Inc	ORAL	12.5 MG/BID, PO	
	Haemodialysis	Professional						
	Hyperkalaemia	Other	Tab Enalapril	SS		ORAL	10 MG/DAILY, PO	
	Malaise							
	Metabolic Acidosis							
	Nausea							
	Nephritis Interstitial							
	Normochromic Normocytic Anaemia							
	Pallor							
	Proteinuria							
	Vomiting							
	White Blood Cells Urine Positive							

Date:07/19/01ISR Number: 3763068-1Report Type:Expedited (15-DaCompany Report #WAES 00119709
Age:71 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia Dizziness Headache	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO	16 DAY
	Malaise		Elavil	C				
			Fosamax	C				
			Calcium (Carbonate/Gluconolac)	C				
			Calcium Lactate	C				

Date:07/19/01ISR Number: 3763069-3Report Type:Expedited (15-DaCompany Report #WAES 01075012
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastroenteritis Helicobacter Melaena	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	

Date:07/19/01ISR Number: 3763071-1Report Type:Expedited (15-DaCompany Report #WAES 01075058
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Keratoconjunctivitis Sicca Vision Blurred	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	194 DAY

Date:07/20/01ISR Number: 3762622-0Report Type:Expedited (15-DaCompany Report #WAES 01079505
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	79 DAY
			Aspirin	C				
			Diclofenac	C				
			Enalapril Maleate	C				
			Fluoxetine	C				
			Furosemide	C				
			Omeprazole	C				

Date:07/20/01ISR Number: 3762630-XReport Type:Expedited (15-DaCompany Report #WAES 01061845
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
		Representative	Neurontin	C				

Date:07/20/01ISR Number: 3762632-3Report Type:Expedited (15-DaCompany Report #WAES 01070351
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Liver Function Test Abnormal Overdose	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	100 MG/DAILY/PO	1 MON

Date:07/20/01ISR Number: 3762636-0Report Type:Expedited (15-DaCompany Report #WAES 01071225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Embolism	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/20/01ISR Number: 3762638-4Report Type:Expedited (15-DaCompany Report #WAES 01071653
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Creatine Phosphokinase Increased Blood Glucose Decreased Dehydration Diarrhoea Hepatitis Thrombocytopenia	Health Professional Company Representative	Vioxx Tylenol	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/20/01ISR Number: 3762645-1Report Type:Expedited (15-DaCompany Report #WAES 01070883
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Albuminuria	Health	Vioxx	PS	Merck Research			
Hospitalization -	Benign Prostatic	Professional			Laboratories Div			
Initial or Prolonged	Hyperplasia	Company			Merck Co Inc	ORAL	25	
Other	Cardiac Failure	Representative					MG/DAILY/PO	
	Congestive		Actos	C				
	Cellulitis		Allegra	C				
	Condition Aggravated		Avapro	C				
	Hypoaesthesia		Effexor	C				
	Nephrotic Syndrome		Flexeril	C				
	Oedema		Humulin 70/30	C				
	Pulmonary Oedema		Imitrex	C				
	Pulse Pressure Decreased		Lipitor	C				
	Scrotal Swelling		Urispas	C				
			Viagra	C				
			Vicodin Tablets	C				
			Zyrtec	C				
			Aspirin	C				
			Atenolol	C				
			Cyclobenzaprine Hydrochloride	C				
			Furosemide	C				
			Ibuprofen	C				
			Niacin	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/01ISR Number: 3762656-6Report Type:Expedited (15-DaCompany Report #WAES 01070932
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Haemoglobin Decreased Thrombocythaemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Tab Prinivil Unk	SS				
			Hydrodiuril	C				
			Alprazolam	C				
			Atenolol	C				
			Pyridoxine	C				

Date:07/20/01ISR Number: 3762658-XReport Type:Expedited (15-DaCompany Report #WAES 01070150
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Increased Coma Dehydration Renal Failure Renal Failure Acute	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/20/01ISR Number: 3763000-0Report Type:Expedited (15-DaCompany Report #WAES 01058532
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia Hypoaesthesia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	2 DAY
			Acetaminophen	C				

Date:07/20/01ISR Number: 3763002-4Report Type:Expedited (15-DaCompany Report #WAES 01077268
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis Melaena Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	39 DAY
			Tab Acetaminophen	SS		ORAL	4000 MG/DAILY, PO	39 DAY

Date:07/20/01ISR Number: 3763003-6Report Type:Expedited (15-DaCompany Report #WAES 01073490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Oedema Peripheral	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Composition Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/01ISR Number: 3763005-XReport Type:Expedited (15-DaCompany Report #WAES 01073489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Oedema Peripheral		Composition Unspecified	C				

Date:07/20/01ISR Number: 3763007-3Report Type:Expedited (15-DaCompany Report #WAES 01077805
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Intestinal Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY, PO	3 WK
			Cortisone	SS			1 GM/DAILY	4 DAY

Date:07/23/01ISR Number: 3763480-0Report Type:Expedited (15-DaCompany Report #WAES 99061948
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apnoea Asthenia Atrioventricular Block Complete	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Back Pain		Rezulin 200 Mg	SS			200 MG/DAILY	
	Blood Triglycerides Increased		Flexeril Xenical	C C				
	Cardiac Arrest		Lipitor	C				
	Cardiomegaly		Sectral	C				

Cholelithiasis
Condition Aggravated
Diabetes Mellitus
Dyspnoea
Hepatic Congestion
Hepatic Steatosis
Hyperlipidaemia
Hypertriglyceridaemia
Ill-Defined Disorder
Malaise
Myocardial Infarction
Pericardial Effusion
Pleural Effusion
Pulmonary Embolism
Pulmonary Oedema
Respiratory Distress

Date:07/23/01ISR Number: 3763483-6Report Type:Expedited (15-DaCompany Report #WAES 01061322
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
	Fall	Health			Laboratories Div			
	Pain	Professional			Merck Co Inc	ORAL	SEE IMAGE	
	Renal Failure							
	Respiratory Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/01ISR Number: 3763484-8Report Type:Expedited (15-DaCompany Report #WAES 01051918
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haematocrit Decreased	Professional			Laboratories Div			
Initial or Prolonged	Haemoglobin Decreased				Merck Co Inc	ORAL	PO	
Other	Melaena		Cozaar	C				
	Platelet Count Decreased		Enturen	C				
	Red Blood Cell Count Decreased		Lipitor	C				
			Sectral	C				
	Ulcer Haemorrhage							
	White Blood Cell Count Decreased							

Date:07/23/01ISR Number: 3763530-1Report Type:Direct Company Report #
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression		Vioxx 25 Mg					
Life-Threatening	Mental Impairment		Rofecoxib	PS		ORAL	1 PO QD	
	Suicide Attempt		Paxil	C				
			Oxycontin	C				

Date:07/23/01ISR Number: 3763720-8Report Type:Expedited (15-DaCompany Report #WAES 01052332
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Hypomania	Health			Laboratories Div			
	Insomnia	Professional			Merck Co Inc	ORAL	PO	
	Mania		Thorazine	C				
			Zyprexa	C				

Date:07/23/01ISR Number: 3763727-0Report Type:Expedited (15-DaCompany Report #WAES 01071370
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/23/01ISR Number: 3763730-0Report Type:Expedited (15-DaCompany Report #WAES 01030393
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Blood Calcium Decreased
	Blood Chloride Decreased
Other	Blood Glucose Increased
	Drug Level Below Therapeutic
	Fall
	Femur Fracture
	Haematocrit Decreased
	Haemoglobin Decreased
	Nausea

		Tachycardia					
		Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		White Blood Cell Count Increased	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO							
				Ambien	C		
				Buspar	C		
				Flexeril	C		
				Lanoxin	C		
				Prilosec	C		
				Zantac	C		
				Insulin Human, Isophane	C		

Date:07/23/01ISR Number: 3763733-6Report Type:Expedited (15-DaCompany Report #WAES 01070740
Age:36 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Hypersensitivity	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Transient Ischaemic Attack					
50 MG/PRN/PO							
				Motrin	C		
				Prilosec	C		

Date:07/23/01ISR Number: 3763833-0Report Type:Expedited (15-DaCompany Report #001-0981-M0102484
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Consumer	Lipitor	PS	Pfizer Inc	ORAL
10 MG Initial or Prolonged (DAILY), PER		Decreased Appetite					
ORAL		Dehydration					
		Diarrhoea		Rofecoxib			

	Vomiting	(Rofecoxib)	SS	
	Weight Decreased	Nabumetone (Nabumetone)	SS	
		Omeprazole (Omeprazole)	SS	ORAL PER ORAL
		Lasix (Furosemide)	SS	ORAL PER ORAL
		Enalapril Maleate	C	
		Cyproheptadine	C	
		Metoccloprami de	C	

Date:07/23/01ISR Number: 3764011-1Report Type:Expedited (15-DaCompany Report #WAES 01079762
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive
	Dermatitis
	Microcytic Anaemia
	Nail Disorder
	Pyrexia
	Red Blood Cell Sedimentation Rate Increased
	Skin Disorder

Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Other					PO	18 DAY

Date:07/23/01ISR Number: 3764048-2Report Type:Expedited (15-DaCompany Report #WAES 01079805
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	19 DAY
	Faeces Discoloured		Acenocoumarol	C				
	Haemoglobin Decreased		Amiodarone	C				
	Hyperhidrosis		Candesartan	C				
	Pallor		Enalapril Maleate	C				
	Peptic Ulcer		Furosemide	C				
	Peptic Ulcer Haemorrhage		Spironolactone	C				
	Tachycardia							

Date:07/23/01ISR Number: 3764049-4Report Type:Expedited (15-DaCompany Report #WAES 01079004
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise Oliguria Renal Colic	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG	4 DAY
	Urine Abnormality		Aspirin	C				
			Cefixime	C				
			Dimethicone	C				
			Diosmin	C				

Date:07/23/01ISR Number: 3764056-1Report Type:Expedited (15-DaCompany Report #WAES 01079122
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Gastrointestinal Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	50 DAY
			(Therapy Unspecified)	SS		ORAL	PO	
			Acetylcysteine	C				
			Fluticasone Propionate	C				
			Paroxetine	C				
			Terbutaline Sulfate	C				

Date:07/23/01ISR Number: 3764058-5Report Type:Expedited (15-DaCompany Report #WAES 01075080
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal

Haemorrhage

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO	698 DAY					
			Zocor	C		
			Acetaminophen (+) Dihydrocodeine Bitartr	C		
			Betahistine Hydrochloride	C		
			Doxazosin	C		
			Fluticasone Propionate	C		
			Quinineso4	C		
			Ranitidine	C		

Date:07/23/01ISR Number: 3764059-7Report Type:Expedited (15-DaCompany Report #WAES 01075066
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Neutropenia	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO	9 DAY					
			Omeprazole Magnesium	SS		ORAL
20 MG/DAILY						
PO (SEE IMAGE)	5 DAY					
			Aluminumhydroxide/Mg Oh/Oxethazaine	C		
			Aspirin	C		
			Atorvastatin	C		
			Bendroflumethiazide	C		
			Cyclizine	C		

Danthron (+)	
Poloxamer 188	C
Diacetylmorphine	C
Ferrousso4	C
Hydromorphone	C
Lactulose	C
Methotrimeprazine	C
Metoclopramide	C
Morphineso4	C
Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C
Senna	C
Suriclone	C

Date:07/23/01ISR Number: 3764061-5Report Type:Expedited (15-DaCompany Report #WAES 01079120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Pharyngitis	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12,5 MG/DAILY	PO 8 DAY
			Pepcid	C				

			Acetaminophen	C		
			Dipyrone	C		

Date:07/23/01ISR Number: 3764062-7Report Type:Expedited (15-DaCompany Report #WAES 01075087
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	PO 11 DAY
			Levothyroxine Na	C				
			Omeprazole	C				
			Spironolactone	C				

Date:07/23/01ISR Number: 3764612-0Report Type:Expedited (15-DaCompany Report #WAES 01032487
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:07/23/01ISR Number: 3764613-2Report Type:Expedited (15-DaCompany Report #WAES 01052781
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Mallory-Weiss Syndrome Myocardial Infarction Renal Failure Acute Upper Gastrointestinal	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Other Haemorrhage

Date:07/23/01ISR Number: 3764614-4Report Type:Expedited (15-DaCompany Report #WAES 01060303
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Health			Laboratories Div			
Initial or Prolonged	Cardiomegaly	Professional			Merck Co Inc	ORAL	25	
Other	Liver Function Test						MG/DAILY/PO	
	Abnormal		Tab Arava	SS		ORAL	100	
	Weight Increased						MG/DAILY/PO	
			Tab Arava 20 Mg	SS		ORAL	20	
							MG/DAILY/PO	

Date:07/23/01ISR Number: 3764615-6Report Type:Expedited (15-DaCompany Report #WAES 01062513
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Haemorrhage	Health			Laboratories Div			
Other	Pyrexia	Professional			Merck Co Inc	ORAL	12.5	
	Renal Failure Acute						MG/DAILY/PO	
	Tremor		Tab Vioxx	SS		ORAL	25	

MG/DAILY/PO

			Lipitor	C		
			Prinivil	C		
			Verelan	C		

Date:07/23/01ISR Number: 3764618-1Report Type:Expedited (15-DaCompany Report #WAES 01061041
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	
			Cardizem	C				
			Prilozec	C				
			Tenormin	C				

Date:07/23/01ISR Number: 3764621-1Report Type:Expedited (15-DaCompany Report #WAES 01070933
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Diarrhoea Duodenitis Gastric Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Gastritis	Representative						
	Oesophagitis Upper Gastrointestinal Haemorrhage		Celebrex	C				
			Tylenol	C				

Date:07/23/01ISR Number: 3764623-5Report Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Chest Pain Dyspnoea Sinus Arrest Syncope	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/23/01ISR Number: 3764628-4Report Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Anorexia Cellulitis Melaena Nausea	Consumer Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY/PO	
Other	Pancreatitis Vomiting		Ativan Flexeril Valium	C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/01ISR Number: 3764631-4Report Type:Expedited (15-DaCompany Report #WAES 01070961
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Professional			Laboratories Div			
Initial or Prolonged	Haemorrhoids				Merck Co Inc	ORAL	12.5	
	Melaena						MG/DAILY/PO	
			Hydrodiuril	C				
			Prinivil	C				
			Allopurinol	C				
			Atenolol	C				

Date:07/23/01ISR Number: 3764634-XReport Type:Expedited (15-DaCompany Report #WAES 00121742
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck Research			
Hospitalization -	Congestive				Laboratories Div			
Initial or Prolonged	Syncope				Merck Co Inc	ORAL	12.5	
							MG/DAILY/PO	
			Tab Ziac	SS		ORAL	1	
							TABLET/DAILY/	
							PO	
			Fosamax	C				
			Glucophage	C				
			Xanax	C				
			Aspirin	C				
			Calcium (Unspecified) (+)					
			Vitami	C				
			Cyanocobalamin	C				

Date:07/23/01ISR Number: 3764639-9Report Type:Expedited (15-DaCompany Report #WAES 01051907
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Gastrointestinal Motility Disorder	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Arthrotec	C				
			Atacand	C				
			Avapro	C				
			Lipitor	C				
			Prilosec	C				
			Protonix	C				
			Toprol Xl Tablets	C				

Date:07/23/01ISR Number: 3764672-7Report Type:Expedited (15-DaCompany Report #WAES 01042497
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Tenderness Anaemia Arteriovenous Malformation Arthralgia Blood Glucose Increased

		Blood Pressure Decreased					
		Blood Urea Increased					
		Cardiac Murmur Functional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Creatine Phosphokinase Decreased	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO		Dehydration					
		Diarrhoea					
		Dizziness		Allegra	C		
		Electrocardiogram Abnormal		Fiorinal	C		
				Flexeril	C		
		Faeces Discoloured		Reglan	C		
		Gastrointestinal		Trental	C		
		Haemorrhage		Tylenol With Codeine #3	C		
		Haematochezia		Zestril	C		
		Haemorrhage		Quinine	C		
		Heart Rate Increased					
		Oesophagitis					
		Pallor					
		Rectal Haemorrhage					
		Respiratory Rate Increased					

Date:07/23/01ISR Number: 3764774-5Report Type:Expedited (15-DaCompany Report #WAES 01069762
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged Disability	Dialysis Loss Of Consciousness Renal Failure Acute	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:07/23/01ISR Number: 3764839-8Report Type:Expedited (15-DaCompany Report #WAES 01063421
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization -	Anaemia Gastrointestinal	Foreign Health	Vioxx	PS	Merck Research Laboratories Div	

Initial or Prolonged	Haemorrhage	Professional		Merck Co Inc	ORAL
PO 11 MON					
Other					

Date:07/25/01ISR Number: 3764162-1Report Type:Expedited (15-DaCompany Report #WAES 01041942
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Fosamax	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diverticulum		Vioxx	SS		ORAL
Other	Gastritis		Vioxx	SS		ORAL
	Gastrointestinal Disorder					
	Haemangioma Of Liver					
	Hiatus Hernia					
	Iron Deficiency Anaemia					
	Melaena					
	Neuralgia					
	Oesophagitis					
	Peptic Ulcer					
	Pigmented Naevus					
	Small Intestinal Obstruction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/01ISR Number: 3764326-7Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum		Ibuprofen 800mg	PS		ORAL	800MG Q8H	
	Faecal Occult Blood					ORAL		
	Positive		Vioxx 50mg	SS		ORAL	50MG QD ORAL	
	Gastric Ulcer		Coumadin	C				
	Haemoglobin Decreased		Heparin	C				

Date:07/25/01ISR Number: 3764345-0Report Type:Direct Company Report #
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL	50 MG DAILY	
Initial or Prolonged	Haemorrhage					ORAL		
	Ulcer							

Date:07/25/01ISR Number: 3765121-5Report Type:Expedited (15-DaCompany Report #WAES 01062064
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Disease	Professional			Laboratories Div			
	Myocardial Infarction	Company			Merck Co Inc	ORAL	PO	
		Representative						

Date:07/25/01ISR Number: 3765122-7Report Type:Expedited (15-DaCompany Report #WAES 01061997
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25 MG/DAILY

PO

	Nasonex	C	

Date:07/25/01ISR Number: 3765124-0Report Type:Expedited (15-DaCompany Report #WAES 01042504
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Gastroenteritis					
	Helicobacter					
	Upper Gastrointestinal	Representative				
	Haemorrhage		Beclovent	C		
			Vasotec	C		
			Zocor	C		
			Aspirin	C		
			Indapamide	C		

25 MG/DAILY/PO

Date:07/25/01ISR Number: 3765135-5Report Type:Expedited (15-DaCompany Report #WAES 01071938
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Drug Level Above Therapeutic

		Gastrointestinal Haemorrhage Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG, DAILY, PO							
				Coumadin	C		

Date:07/25/01ISR Number: 3765277-4Report Type:Expedited (15-DaCompany Report #WAES 01078561
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
10 DAY						

Date:07/25/01ISR Number: 3765279-8Report Type:Expedited (15-DaCompany Report #WAES 01079761
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Other	Abdominal Distension Abdominal Pain Erosive Duodenitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/BID 2 DAY						
	Flatulence Intestinal Ulcer		Tab Vioxx (Rofecoxib)	SS		ORAL
25 MG/DAILY 3 WK						
	Umbilical Cord Abnormality					

Date:07/25/01ISR Number: 3765281-6Report Type:Expedited (15-DaCompany Report #WAES 01078580
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Fosamax	C				
			Clonidine Hcl	C				
			Estrogens, Conjugated	C				
			Lisinopril	C				
			Lorazepam	C				
			Ramipril	C				
			Venlafaxine Hcl	C				

Date:07/25/01ISR Number: 3765324-XReport Type:Expedited (15-DaCompany Report #WAES 01041942
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Mass
Other	Abdominal Pain
	Anxiety
	Biopsy Site Unspecified
	Abnormal
	Blood Pressure Increased
	Diverticulum
	Erythema

		Gastritis Haemangioma Of Liver Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Iron Deficiency Anaemia	Health	Fosamax	PS	Merck And Co Inc	ORAL
10							
		Melaena	Professional				
MG/DAILY/PO							
		Oesophagitis	Company	Tab Vioxx	SS		ORAL
PO							
		Peptic Ulcer	Representative				
		Scan Abdomen Abnormal Skin Discolouration Small Intestinal Obstruction Trigeminal Neuralgia Vomiting					

Date:07/25/01ISR Number: 3765713-3Report Type:Expedited (15-DaCompany Report #WAES 01062625
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Atrial Fibrillation	Health	Vioxx	PS	Merck Research	
	Blood Pressure Increased	Professional			Laboratories Div	
		Company			Merck Co Inc	ORAL
PO						
		Representative	Tenormin	C		

Date:07/25/01ISR Number: 3765716-9Report Type:Expedited (15-DaCompany Report #WAES 01071225
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Disorder	Health	Vioxx	PS	Merck Research	
Initial or Prolonged	Embolism	Professional			Laboratories Div	
					Merck Co Inc	ORAL
PO						

Date:07/26/01ISR Number: 3766261-7Report Type:Expedited (15-DaCompany Report #WAES 01051820
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY/PO	
	Cardiac Failure							
	Fatigue							
	Oedema Peripheral		Lasix (Furosemide)	C				
	Weight Increased		Premarin	C				
			Tylenol	C				
			Atenolol	C				

Date:07/26/01ISR Number: 3766264-2Report Type:Expedited (15-DaCompany Report #WAES 01061679
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Systemic Lupus Erythematosus	Health Professional						
			Elavil	C				
			Plaquenil	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766272-1Report Type:Expedited (15-DaCompany Report #WAES 01062108
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia	Health	Vioxx	PS	Merck Research			
Hospitalization -	Blood Phosphorus	Professional			Laboratories Div			
Initial or Prolonged	Increased				Merck Co Inc	ORAL	25	
Disability	Dry Skin						MG/DAILY/PO	
Other	Fatigue		Femara	C				
	Haemodialysis		Prevacid	C				
	Hypocalcaemia		Valium	C				
	Nausea		Zaroxolyn	C				
	Normochromic Normocytic		Zoloft	C				
	Anaemia		Hydroxyzine	C				
	Oral Intake Reduced							
	Proteinuria							
	Rales							
	Renal Failure Acute							
	Renal Impairment							
	Skin Disorder							
	Skin Warm							
	Tenderness							
	Vomiting							
	Weight Decreased							
	White Blood Cell Count							
	Abnormal							

Date:07/26/01ISR Number: 3766273-3Report Type:Expedited (15-DaCompany Report #WAES 01077514
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Foreign	Tab Vioxx					
Initial or Prolonged	Blood Pressure Increased	Other	(Rofecoxib)	PS	Merck Research			
					Laboratories Div			
					Merck Co Inc	ORAL	25 MG/DAILY	
							PO	

Date:07/26/01ISR Number: 3766274-5Report Type:Expedited (15-DaCompany Report #WAES 01077513
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Amnesia Blood Pressure Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO						

Date:07/26/01ISR Number: 3766275-7Report Type:Expedited (15-DaCompany Report #WAES 01065552
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Aphasia Cerebrovascular Accident	Foreign Other	Tab Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO 5 MON						
			Crataegus	C		
			Estrogens	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766280-0Report Type:Expedited (15-DaCompany Report #WAES 01070932
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Drug Interaction							
	Haemoglobin Decreased		Tab Prinivil	SS				
	Myelodysplastic Syndrome		Hydrodiuril	C				
	Renal Impairment		Alprazolam	C				
	Thrombocythaemia		Atenolol	C				
			Pyridoxine	C				

Date:07/26/01ISR Number: 3766287-3Report Type:Expedited (15-DaCompany Report #WAES 01075158
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Allergic Granulomatous Angiitis Cutaneous Vasculitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Proctitis						PO	16 DAY
			Tab Fosamax (Alendronate Sodium)	SS		ORAL	10 MG/DAILY	
							PO	16 DAY
			Amlodipine Besylate	C				
			Fluticasone Propionate (+)					
			Salmeterol Xi	C				

Date:07/26/01ISR Number: 3766290-3Report Type:Expedited (15-DaCompany Report #WAES 01063473
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Asthenia Confusional State	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Fatigue	Professional			Merck Co Inc	ORAL
12.5 MG/DAILY						
	Gait Disturbance					
PO 31 DAY						
	Renal Failure Acute		Calcitriol	C		
			Perindopril Erbumine	C		

Date:07/26/01ISR Number: 3766297-6Report Type:Expedited (15-DaCompany Report #WAES 01068901
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Discomfort	Study			Laboratories Div	
	Ear Pain	Health			Merck Co Inc	ORAL
25 MG/DAILY						
	Rash Pruritic	Professional				
PO 36 DAY						
			Prinivil	C		
			Prazosin	C		
			Sennosides	C		
			Thymol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766413-6Report Type:Expedited (15-DaCompany Report #WAES 01077011
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	56 DAY
	Blood Folate Decreased	Other						
	Faecal Occult Blood							
	Positive							
	Haematemesis		Trimethoprim	SS		ORAL	160 MG/DAILY, PO	
	Oesophageal Candidiasis							
	Oesophageal Stenosis		Fosamax	C				
	Oesophageal Ulcer		Acetaminophen/Codeine Phosphate	C				
	Oesophagitis							
	Pancytopenia		Aspirin (+)					
	Upper Gastrointestinal Haemorrhage		Magnesium Oxide	C				
			Furosemide	C				

Date:07/26/01ISR Number: 3766414-8Report Type:Expedited (15-DaCompany Report #WAES 01063815
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	
	Duodenal Ulcer	Other						
	Gastric Ulcer							
			Acetaminophen	C				
			Carbaspirin Calcium	C				
			Lactulose	C				
			Nadroparin	C				
			Thiamine Hydrochloride	C				

Date:07/26/01ISR Number: 3766416-1Report Type:Expedited (15-DaCompany Report #WAES 01076037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abortion Induced Complications Of Maternal Exposure To Therapeutic Drugs Intra-Uterine Death Pregnancy	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	

Date:07/26/01ISR Number: 3766417-3Report Type:Expedited (15-DaCompany Report #WAES 01079708
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	16 DAY
		Other	Aspirin	C				
			Doxazosin Mesylate	C				
			Furosemide Sodium	C				
			Nabumetone	C				
			Piroxicam	C				
			Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/01ISR Number: 3766418-5Report Type:Expedited (15-DaCompany Report #WAES 01065213
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY, PO	
			Acetaminophen	C				
			Amlodipine	C				
			Bumetadine	C				
			Codeine Sulfate (+) Ipecac (+) Squill	C				
			Dihydrocodeine	C				
			Lactulose	C				
			Metoclopramide	C				
			Morphine	C				
			Morphineso4	C				
			Nystatin	C				
			Phenobarbital	C				
			Polyethylene Glycol	C				
			Prochlorperazine Maleate	C				
			Tramadol	C				
			Warfarin	C				

Date:07/26/01ISR Number: 3766439-2Report Type:Expedited (15-DaCompany Report #WAES 01075589
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
			[Therapy Unspecified]	C				

Date:07/26/01ISR Number: 3766440-9Report Type:Expedited (15-DaCompany Report #WAES 01075153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Dizziness	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:07/26/01ISR Number: 3766534-8Report Type:Expedited (15-DaCompany Report #WAES 01071955
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subarachnoid Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/26/01ISR Number: 3766536-1Report Type:Expedited (15-DaCompany Report #WAES 01071566
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Face Oedema Gastrointestinal

	Haemorrhage Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/PO
			[Therapy Unspecified]	C			

Date:07/26/01ISR Number: 3766579-8Report Type:Expedited (15-DaCompany Report #2001-07-0249
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Retinal Haemorrhage	Consumer	Nasonex	PS	Schering Plough Corp	NASAL	UNKNOWN NASAL SPRAY
			Vioxx (Rofecoxib) Tablets	SS		ORAL	UNKNOWN ORAL
			Vitamin Formulation	C			

Date:07/26/01ISR Number: 3766679-2Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Life-Threatening Hospitalization -	Activated Partial Thromboplastin Time Prolonged	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO
Initial or Prolonged	Ascites	Representative					
Other	Cytomegalovirus Infection		Aldactone	C			
	Duodenal Ulcer		Bactrim	C			
	Haematocrit Decreased		Calderol	C			
	Haemoglobin Decreased		Cellcept	C			
	Haemothorax		Compazine	C			
	Hepatic Failure		Diflucan	C			
	Hepatotoxicity		Norvasc	C			

	Hypotension	Os-Cal	C
	International Normalised	Phenergan	
	Ratio Increased	(Dibromopropamidine	
	Platelet Count Decreased	Is)	C
	Pneumonia	Prilosec	C
	Renal Failure	Zofran	C
	Renal Impairment	Zoloft	C
	Respiratory Failure	Acetaminophen	C
		Cyclosporine	C
		Ganciclovir	C
		Ibuprofen	C
		Prednisone	C

Date:07/27/01ISR Number: 3766498-7Report Type:Direct Company Report #
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx 25mg By Merck	PS	Merck	
25-50 MG QD						
Initial or Prolonged	Haemorrhage					
PRN PWK 4 MON						
	Medication Error		Recombinate	C		
			Bioclate	C		
			Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/01ISR Number: 3766815-8Report Type:Expedited (15-DaCompany Report #WAES 01071683
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
	Colitis Ulcerative							
	Gastrointestinal Haemorrhage		Neurontin	C				
	Infection		Oxycontin	C				
	Large Intestinal Ulcer							

Date:07/27/01ISR Number: 3767173-5Report Type:Expedited (15-DaCompany Report #WAES 01071996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	4 MON
	Meningitis Aseptic							
			Prednisone	C				

Date:07/27/01ISR Number: 3767292-3Report Type:Expedited (15-DaCompany Report #WAES 01073419
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
	Diarrhoea							
	Face Oedema							
	Vomiting							
			Tab Cephalexin	SS		ORAL	500 MG/TID PO	2 DAY
			Nitrofurantoin	C				

Date:07/27/01ISR Number: 3767293-5Report Type:Expedited (15-DaCompany Report #WAES 01075560
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Foreign	Vioxx	PS	Merck Research			
	Cardiovascular Disorder	Health			Laboratories Div			
	Drug Interaction	Professional			Merck Co Inc	ORAL	25-50 MG	
	Excitability		Tab Cabergoline	SS		ORAL	6 MG	
	Malaise		Benserazide Hydrochloride	C				

Date:07/27/01ISR Number: 3767294-7Report Type:Expedited (15-DaCompany Report #WAES 01075593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression	Foreign	Vioxx	PS	Merck Research			
		Health			Laboratories Div			
		Professional			Merck Co Inc	ORAL		
			Methotrexate Sodium	SS				

Date:07/27/01ISR Number: 3767295-9Report Type:Expedited (15-DaCompany Report #WAES 01079609
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Fluid Retention	Foreign
	Pulmonary Oedema	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	3 DAY
Acetaminophen/Propoxyphene Hydrochloride	C				

Date:07/27/01ISR Number: 3767296-0Report Type:Expedited (15-DaCompany Report #WAES 01079310
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Haematochezia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY	8 DAY

Date:07/27/01ISR Number: 3767297-2Report Type:Expedited (15-DaCompany Report #WAES 01076070
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY	4 DAY

Date:07/30/01ISR Number: 3767639-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased		Warfarin	PS		ORAL	2.5 MG/ QD/ ORAL	
			Rofecoxib	SS				

Date:07/30/01ISR Number: 3767656-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Asa Aspirin	PS		ORAL	81 MG/ QD / ORAL	
			Vioxx	SS		ORAL	50 MG/ QD/ ORAL	

Date:07/30/01ISR Number: 3767682-9Report Type:Expedited (15-DaCompany Report #WAES 01071862
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Dyspnoea Oedema Peripheral Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/01ISR Number: 3767850-6Report Type:Expedited (15-DaCompany Report #WAES 01079924
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Gastrointestinal Haemorrhage	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25-50MG MG/DAILY; PO	4 DAY
			Tab Fosamax (Alendronate Sodium)	SS		ORAL	10MG MG/DAILY, PO	4 DAY

Date:07/30/01ISR Number: 3768278-5Report Type:Expedited (15-DaCompany Report #2001COU1249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthritis	Consumer	Coumadin	PS	Dupont Merck Pharmaceutical Co	ORAL	PO	
	Ecchymosis Prothrombin Time Prolonged		Vioxx (Rofecoxib) Glucosamine Chondroitin Ds	SS C				

Date:07/30/01ISR Number: 3768854-XReport Type:Expedited (15-DaCompany Report #WAES 01070766
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dizziness Gastrointestinal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Celexa	C				

Date:07/30/01ISR Number: 3768855-1Report Type:Expedited (15-DaCompany Report #WAES 01070915
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:07/30/01ISR Number: 3768867-8Report Type:Expedited (15-DaCompany Report #WAES 01071681
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Dehydration Dermatitis Infection Leukocytosis Mental Impairment Petechiae	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO; 12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/01ISR Number: 3768949-0Report Type:Expedited (15-DaCompany Report #WAES 01045596
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	1 DAY
		Other	Vitamins (Unspecified)	C				

Date:07/30/01ISR Number: 3768950-7Report Type:Expedited (15-DaCompany Report #WAES 01058556
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Ph Increased Pco2 Increased Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	20 DAY
		Other	Herbs	C				

Date:07/30/01ISR Number: 3768969-6Report Type:Expedited (15-DaCompany Report #WAES 01075159
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Iron Deficiency Anaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		12.5 MG/DAILY	
	Microcytic Anaemia		Elavil	C				
			Acetaminophen/Codeine Phosphate	C				
			Aspirin	C				
			Heparinoid (+)					
			Salicylic Acid	C				
			Senna	C				

Date:07/30/01ISR Number: 3768973-8Report Type:Expedited (15-DaCompany Report #WAES 01067811
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coombs Direct Test Positive Haemolysis Pyrexia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	2	DAY

Date:07/31/01ISR Number: 3768334-1Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder		Rofecoxib	PS				

Date:07/31/01ISR Number: 3768534-0Report Type:Direct Company Report #
Age:20 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Delirium Dermatitis Hallucination, Visual Mental Disorder

	Pallor Speech Disorder Tonic Convulsion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx 50mg	PS		ORAL	50MG QD ORAL

Date:07/31/01ISR Number: 3777714-XReport Type:Periodic Company Report #2001056084US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Convulsion	Health	Celebrex	PS	Gd Searle And Co	ORAL	ORAL
		Professional	"Vioxx"	SS		ORAL	ORAL

Date:07/31/01ISR Number: 3777915-0Report Type:Periodic Company Report #2001058602US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastric Ulcer Rectal Haemorrhage	Consumer	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL
			Cardura (Doxazosin Mesilate)	SS		ORAL	4 MG, QD, ORAL
			"Vioxx"()	SS		ORAL	ORAL
			Adalat	C			
			Klonopin	C			
			Zantac	C			

Date:08/01/01ISR Number: 3768409-7Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Speech Disorder Thinking Abnormal		Vioxx (Med Returned To Merck In Las Vegas)	PS	Merck		
1 DAILY	4 DAY						

Date:08/01/01ISR Number: 3768932-5Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - PRIOR TO Initial or Prolonged ADMISSION	Blood Potassium Increased		Rofecoxib	PS		ORAL	25 MG PO BID,	
			Potassium Cl	SS		ORAL	80 MEQ QD PO	

Date:08/01/01ISR Number: 3769131-3Report Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaphylactic Reaction
Hospitalization -	Back Pain
Initial or Prolonged	Blood Potassium Increased
	Blood Thyroid Stimulating Hormone Increased
	Blood Urea Increased
	Cardiac Arrest
	Cardiac Disorder
	Coma

		Dyspnoea					
		Pain					
		Pulmonary Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder	Consumer	Vioxx 25 Mg	PS	Merck Research	
		Spleen Disorder	Health			Laboratories Div	
		Toxicologic Test Abnormal	Professional			Merck Co Inc	ORAL
SEE IMAGE							
		Tri-Iodothyronine Uptake	Other	Pravachol	C		
		Increased		Xanax	C		

Date:08/01/01ISR Number: 3769210-0Report Type:Expedited (15-DaCompany Report #WAES 01052086
Age:86 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Colitis Ischaemic	Consumer	Vioxx	PS	Merck Research	
		Drug Interaction				Laboratories Div	
						Merck Co Inc	ORAL
PO							
				Tab Fosamax	SS		ORAL
70 MG/WKY/PO							
				Avapro	C		
				Levoxyl	C		

Date:08/01/01ISR Number: 3769524-4Report Type:Expedited (15-DaCompany Report #WAES 01072144
Age:73 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident	Health	Vioxx	PS	Merck Research	
Hospitalization -		Fatigue	Professional			Laboratories Div	
Initial or Prolonged		Hemiparesis				Merck Co Inc	ORAL
12.5							
		Hypertension					
MG/DAILY/ORAL							
		Visual Disturbance		Daypro	C		
				Hydrodiuril	C		
				K-Dur	C		
				Premarin	C		
				Prozac	C		

Date:08/01/01ISR Number: 3769527-XReport Type:Expedited (15-DaCompany Report #WAES 01072258
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	1 YR
			Synthroid	C				
			Tylenol	C				
			Zestril	C				

Date:08/01/01ISR Number: 3769530-XReport Type:Expedited (15-DaCompany Report #WAES 01072100
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Cardizem	C				
			Cozaar	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/01ISR Number: 3769539-6Report Type:Expedited (15-DaCompany Report #WAES 01075201
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia Weight Increased	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	
ORAL			Acetaminophen	C				
			Beclomethasone Dipropionate	C				
			Levothyroxine Na	C				

Date:08/01/01ISR Number: 3769540-2Report Type:Expedited (15-DaCompany Report #WAES 01073542
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY	
ORAL								

Date:08/01/01ISR Number: 3769629-8Report Type:Expedited (15-DaCompany Report #WAES 01079609
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fluid Retention Pulmonary Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	3 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				

Date:08/01/01ISR Number: 3769630-4Report Type:Expedited (15-DaCompany Report #WAES 01079310
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rectal Haemorrhage	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	8 DAY

Date:08/01/01ISR Number: 3769631-6Report Type:Expedited (15-DaCompany Report #WAES 01079708
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	16 DAY
			Aspirin	C				
			Doxazosin Mesylate	C				
			Furosemide Sodium	C				
			Nabumetone	C				
			Piroxicam	C				
			Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/01ISR Number: 3769258-6Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Renal Failure Acute		Vioxx	PS				

Date:08/02/01ISR Number: 3773115-9Report Type:Periodic Company Report #2000COU0896
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Coumadin	PS	Dupont Merck Pharmaceutical Co	ORAL	0-7.5 MG DLY	
	Prothrombin Level Decreased		Vioxx (Rofecoxib)	SS		ORAL	PO	PO
	Prothrombin Level Increased		Lovenox (Heparin-Fraction, Sodium Salt)	C				
			(Iron)	C				
			(Fleet Enema)	C				
			Dulcolax (Bisacodyl)	C				
			Colace (Docusate Sodium)	C				

Date:08/03/01ISR Number: 3770209-9Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Vomiting		Eskalith 300mg Capsules	PS		ORAL	2 CAPSU	BID

ORAL

			Vioxx 25mg Tablets	SS		ORAL
1 TABLE						
DAILY ORAL						
			Levothyroid	C		

Date:08/03/01ISR Number: 3770825-4Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Vioxx 25 Mg	PS	Merck Research	
	Spinal Cord Disorder				Laboratories Div	
					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Delestrogen	C		
			Flexeril	C		
			Clonazepam	C		

Date:08/03/01ISR Number: 3770827-8Report Type:Expedited (15-DaCompany Report #WAES 01050310
Age:56 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Discomfort Blood Creatine Phosphokinase Increased	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Blood Creatine Phosphokinase Mb Increased Cardiac Tamponade Cardio-Respiratory Arrest Cardiomyopathy Disseminated Intravascular Coagulation Electrocardiogram St Segment Depression Eosinophilia Eosinophilic Myocarditis Eosinophilic Pneumonia Erythema Infectiosum Gastrointestinal Disorder Hepatic Necrosis Hepatitis Hepatosplenomegaly Leukocytosis Medication Error Pericardial Effusion Spleen Disorder	Representative	Correctol Laxative Tablets & Caplet Vicodin Tablets Codeine Excedrin Migraine Zoloft Atenololz	 SS SS C C C C				

Date:08/03/01ISR Number: 3770828-XReport Type:Expedited (15-DaCompany Report #WAES 01050354
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Anaemia Gastric Ulcer Haemorrhage Urinary Tract Infection	Health Professional Company Representative	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Aleve Amaryl Antivert	C C C				

Bactrim	C
Cartia (Diltiazem Hydrochloride)	C
Coumadin	C
Cozaar	C
Glucophage	C
Humulin N	C
Humulin R	C
Inderal	C
Lanoxin	C
Lasix (Furosemide)	C
Lipitor	C
Micro K	C
Oxycontin	C
Tricor	C
Lorazepam	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3770829-1Report Type:Expedited (15-DaCompany Report #WAES 01051781
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged SEE IMAGE	Blood Pressure Increased Cardiac Failure Congestive	Health Professional	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		
Other	Chest Pain Oxygen Saturation Decreased Pulmonary Oedema		Tylenol With Codeine #3 Zestril Acetaminophen (+) Hydrocodone Bi Aspirin Calcium Carbonate (+) Cholecalci Estradiol Folic Acid Glucosamine Sulfate Iron Medroxyprogesterone Acetate Melatonin Propranolol Vitamin E	 C C C C C C C C C C C C				

Date:08/03/01ISR Number: 3770830-8Report Type:Expedited (15-DaCompany Report #WAES 01061997
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhoids Rectal Haemorrhage	Consumer Health Professional	Vioxx 25 Mg	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Nasonex	C				

Date:08/03/01ISR Number: 3770831-XReport Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain Blood Pressure Increased Confusional State Fibromyalgia Muscle Spasms Myalgia Renal Failure	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Accupril	C				
			Calan Sr	C				
			Celebrex	C				
			Dyazide	C				
			Elavil	C				
			Flexeril	C				
			Plavix	C				
			Premarin	C				
			Ultram	C				
			Vicodin Tablets	C				
			Zoloft	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3770832-1Report Type:Expedited (15-DaCompany Report #WAES 01052332
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Abnormal	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Condition Aggravated	Other						
	Mania							
			Thorazine	C				
			Zyprexa	C				

Date:08/03/01ISR Number: 3770833-3Report Type:Expedited (15-DaCompany Report #WAES 01051532
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/BID/PO	
	Crying	Health Professional						
	Joint Stiffness							
	Liver Function Test		Darvocet-N	C				
	Abnormal		Zanaflex	C				
	Muscle Spasms		(Therapy Unspecified)	C				
	Tremor							

Date:08/03/01ISR Number: 3770834-5Report Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Atherosclerosis	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypertension	Company						
		Representative	Fiorinal	C				
			Midrin	C				
			Zestril (Composition Unspecified)	C				

Date:08/03/01ISR Number: 3770835-7Report Type:Expedited (15-DaCompany Report #WAES 01071862
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Dyspnoea Oedema Peripheral Palpitations	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/03/01ISR Number: 3770836-9Report Type:Expedited (15-DaCompany Report #WAES 01051404
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Upper Arthropathy Diverticulum Intestinal Drug Effect Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO (SEE IMAGE)	
	Duodenitis Gastritis Erosive Headache		Tylenol (Therapy Unspecified)	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3770837-0Report Type:Expedited (15-DaCompany Report #WAES 01072123
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Neutrophil Count Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	White Blood Cell Count Decreased	Company Representative			Merck Co Inc	ORAL	25 MG/DAILY/PO	1 WK

Date:08/03/01ISR Number: 3770900-4Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coordination Abnormal	Health	Vioxx 25 Mg	PS	Merck Research			
	Drug Interaction	Professional			Laboratories Div			
	Feeling Abnormal	Company			Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
	Gait Disturbance	Representative						
	Speech Disorder		Anafranil	SS				
	Vision Blurred		Lamictal	SS				
			Dipentum	SS				
			Zoloft	SS				
			Premarin	SS				
			Wellbutrin	SS				
			Klonopin	C				
			Motrin	C				

Date:08/03/01ISR Number: 3770975-2Report Type:Expedited (15-DaCompany Report #WAES 01072850
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Hospitalization - Initial or Prolonged	Blood Chloride Increased	Professional			Laboratories Div			
	Crepitations	Company			Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
Disability	Cyanosis	Representative						

Other	Decreased Appetite	Avandia	C
	Diabetic Nephropathy	Coumadin	C
	Dizziness	Elavil	C
	Hyperkalaemia	Lasix (Furosemide)	C
	Hypoglycaemia	Lotensin	C
	International Normalised	Synthroid	C
	Ratio Increased	Zestril	C
	Multiple Myeloma	Glipizide	C
	Nephritis Interstitial	Spironolactone	C
	Oedema	Theophylline	C
	Pain		
	Renal Failure Acute		
	Renal Tubular Necrosis		
	Umbilical Hernia		
	Venous Stasis		

Date:08/03/01ISR Number: 3770978-8Report Type:Expedited (15-DaCompany Report #WAES 01021197
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Disability	Blood Cholesterol
	Increased
	Feeling Abnormal
	Gastrointestinal
	Haemorrhage

	Haematuria						
	Headache						
	Hypergammaglobulinaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Benign Monoclonal	Consumer	Vioxx	PS	Merck Research		
	Hypertension				Laboratories Div		
	Oedema Peripheral				Merck Co Inc	ORAL	50
	Proteinuria						MG/DAILY/PO
	Renal Disorder		Claritin	C			
	Vision Blurred						

Date:08/03/01ISR Number: 3770979-XReport Type:Expedited (15-DaCompany Report #WAES 01072704
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Dermatitis	Consumer	Vioxx	PS	Merck Research		
Hospitalization -	Drug Interaction				Laboratories Div		
Initial or Prolonged					Merck Co Inc	ORAL	PO

Date:08/03/01ISR Number: 3770980-6Report Type:Expedited (15-DaCompany Report #WAES 01070101
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Blindness	Consumer	Vioxx	PS	Merck Research		
Other	Condition Aggravated	Health			Laboratories Div		
	Eye Haemorrhage	Professional			Merck Co Inc	ORAL	50
	Histoplasmosis						MG/DAILY/PO
	Vitrectomy						

Date:08/03/01ISR Number: 3771281-2Report Type:Expedited (15-DaCompany Report #WAES 01073560
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Dysphagia	Foreign	Vioxx	PS	Merck Research	
	Feeling Abnormal	Health			Laboratories Div	
	Mental Impairment	Professional			Merck Co Inc	ORAL
25 MG/DAILY 1 DAY						
	Migraine	Other				

Date:08/03/01ISR Number: 3771283-6Report Type:Expedited (15-DaCompany Report #WAES 01073558
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Dementia	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
		Other	Valproate	SS		ORAL
400 MG/DAILY						

Date:08/03/01ISR Number: 3771284-8Report Type:Expedited (15-DaCompany Report #WAES 01073559
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhagic Stroke	Foreign	Vioxx	PS	Merck Research	
Life-Threatening		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
37.5 MG/WKY						
		Other	Warfarin	SS		ORAL
3 MG/DAILY						
			Calcium Carbonate	C		
			Digoxin	C		

Estradiol	C
Estropipate	C
Hydroxocobalamin	C
Medroxyprogesterone Acetate	C

Date:08/03/01ISR Number: 3771285-XReport Type:Expedited (15-DaCompany Report #WAES 01073557
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	8 DAY
		Other	Acetaminophen	SS		ORAL	4000 MG/DAILY	16 DAY
			Trimethoprim	SS		ORAL	300 MG/DAILY	6 DAY
			Aspirin	C				
			Isorbide Mononitrate	C				
			Lisinopril	C				
			Metoprolol	C				

Date:08/03/01ISR Number: 3771288-5Report Type:Expedited (15-DaCompany Report #WAES 01056052
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms Pain	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	5 DAY

Date:08/03/01ISR Number: 3771289-7Report Type:Expedited (15-DaCompany Report #WAES 01035010
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angioneurotic Oedema C-Reactive Protein Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL 12.5 MG/BID ORAL
	Dyspepsia					
	Face Oedema Pruritus Urticaria		Acetaminophen	C		
			Acetaminophen (+) Dihydrocodeine Bitartr	C		
			Aluminum Hydroxide/Magnesium Carbonate	C		
			Cinnarizine	C		
			Diazepam	C		
			Dicyclomine Hcl	C		
			Dihydrocodeine	C		
			Estrogens, Conjugated	C		
			Ibuprofen	C		
			Nitrazepam	C		
			Venlafaxine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3771290-3Report Type:Expedited (15-DaCompany Report #WAES 01066026
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Dermatitis							
	Renal Impairment							
			Fluindione	C				
			Irbesartan	C				
			Piretanide	C				

Date:08/03/01ISR Number: 3771291-5Report Type:Expedited (15-DaCompany Report #WAES 01076524
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign Study Health	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	5 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Blood Ph Increased							
	Bronchospasm							
Other	Hypoxia	Professional	Tab Metoprolol	SS			7	DAY
		Other	Bendroflumethiazide	C				
			Insulin, Biphasic Isophane [Injection]	C				
			Insulin, Isophane	C				
			Leflunomide	C				
			Paroxetine	C				
			Prednisolone	C				

Date:08/03/01ISR Number: 3771306-4Report Type:Expedited (15-DaCompany Report #WAES 01058124
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Foreign Literature Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
	Gastrointestinal Haemorrhage							

Haematemesis
ORAL
Haemoglobin Decreased Diclofenac C
Heart Rate Increased Misoprostol C
Hypotension Naproxen C
Melaena

Date:08/03/01ISR Number: 3771309-XReport Type:Expedited (15-DaCompany Report #WAES 01073562
Age:73 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 3 DAY
	Cardiac Failure	Other						
	Congestive							
	Condition Aggravated							
	Dyspnoea		Cap Tramadol Hcl	SS		ORAL	150 MG DAILY	PO 3 DAY
	Oedema Peripheral							
			Inhl Formoterol Fumarate	SS		RESPIRATORY (INHALATION)	6 MICROGM/DAILY	INH
			Inhl Albuterol Sulfate	SS		RESPIRATORY (INHALATION)	INH	

Inhl Ipratropium Bromide SS
RESPIRATORY
(INHALATION) INH

Tab Furosemide SS ORAL
120 / DAILY
PO

Tab Potassium Chloride SS ORAL
600 MG DAILY
PO

Tab Prednisolone SS ORAL
12.5 / DAILY
PO

Date:08/03/01ISR Number: 3771310-6Report Type:Expedited (15-DaCompany Report #WAES 01073564
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Oedema Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	9 DAY
			Prednisolone	C				

Date:08/03/01ISR Number: 3771311-8Report Type:Expedited (15-DaCompany Report #WAES 01073555
Age:67 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG / DAILY PO	45 DAY

Date:08/03/01ISR Number: 3771312-XReport Type:Expedited (15-DaCompany Report #WAES 01079133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hiatus Hernia Melaena Oesophageal Ulcer Oesophagitis Upper Gastrointestinal Haemorrhage	Foreign Other	Vioxx Alprazolam Fluoxetine	PS C C	Merck Research Laboratories Div Merck Co Inc	ORAL ORAL	25 MG / DAILY	

Date:08/03/01ISR Number: 3771313-1Report Type:Expedited (15-DaCompany Report #WAES 01078128
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea Thrombocytopenia Vertigo	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY ORAL	2 DAY

Date:08/03/01ISR Number: 3771314-3Report Type:Expedited (15-DaCompany Report #WAES 01078612
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3771316-7Report Type:Expedited (15-DaCompany Report #WAES 01073556
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG / DAILY	31 DAY
			Tab Aspirin	SS		ORAL	150 MG/DAILY	
			Tab Atorvastatin	SS			40 MG / DAILY	
			Tab Captopril	SS			75 MG/ DAILY	
			Tab Furosemide	SS			160 MG/ DAILY	

Date:08/03/01ISR Number: 3771317-9Report Type:Expedited (15-DaCompany Report #WAES 01075220
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Duodenitis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	
			Amitriptyline	C				
			Carbamazepine	C				
			Codeine Phosphate	C				

Date:08/03/01ISR Number: 3771318-0Report Type:Expedited (15-DaCompany Report #WAES 01073565
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Muscular Weakness Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	

		Lisinopril	SS	ORAL
20 MG/DAILY 445 DAY				
		Levothyroxine Na	SS	ORAL
XX00 MICROM				
/DAILY				
		Amitriptyline Hcl	SS	ORAL
808 DAY				
		Chlorthalidone	SS	ORAL
2.5 MG /				
DAILY 78 DAY				
		Diazepam	SS	ORAL

Date:08/03/01ISR Number: 3771319-2Report Type:Expedited (15-DaCompany Report #WAES 01075219
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Angina Pectoris	Other			Laboratories Div	
Initial or Prolonged	Bacterial Infection				Merck Co Inc	ORAL
12.5 MG/						
	Gastric Ulcer					
DAILY						
	Gastroenteritis		Aspirin	SS		ORAL
150 MG/ DAILY						
	Helicobacter		Amlodipine	C		
	Gastrointestinal		Isosorbide			
	Haemorrhage		Mononitrate	C		
			Pravastatin Na	C		
			Ramipril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/01ISR Number: 3771320-9Report Type:Expedited (15-DaCompany Report #WAES 01075183
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hyponatraemia	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Inappropriate	Other			Laboratories Div			
Initial or Prolonged	Antidiuretic Hormone				Merck Co Inc	ORAL	18	DAY
	Secretion		Prinivil	C				
			Aspirin	C				
			Pravastatin Na	C				
			Prednisolone	C				
			Tramadol	C				

Date:08/03/01ISR Number: 3771337-4Report Type:Expedited (15-DaCompany Report #WAES 01063517
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Atrophy	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Confusional State	Other			Laboratories Div			
Initial or Prolonged	Dehydration				Merck Co Inc	ORAL	12.5 MG/DAILY	
Other	Dysphagia							
PO							48	DAY
	Pelvic Fracture		Digoxin	SS		ORAL		
SEE IMAGE							51	DAY
	Renal Impairment		Acetaminophen	C				
	Speech Disorder		Ascorbic Acid	C				
	Thyroid Disorder		Benserazadie Hyrdochloride (+)					
			Levodopa	C				
			Calcitrol	C				
			Calcium Carbonate	C				
			Clopidogrel Bisulfate	C				
			Gingko Biloba Extract	C				
			Karaya Gum	C				
			Mometasone Furoate	C				
			Pantoprazole Sodium	C				
			Sertraline Hcl	C				
			Telmisartan	C				
			Trimethoprim	C				

Date:08/06/01ISR Number: 3770966-1Report Type:Expedited (15-DaCompany Report #WAES 01072630
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/06/01ISR Number: 3771361-1Report Type:Expedited (15-DaCompany Report #WAES 01061890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/01ISR Number: 3771362-3Report Type:Expedited (15-DaCompany Report #WAES 01080010
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/06/01ISR Number: 3771363-5Report Type:Expedited (15-DaCompany Report #WAES 01072545
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pleural Effusion	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	DAILY/PO	

Date:08/06/01ISR Number: 3771556-7Report Type:Expedited (15-DaCompany Report #WAES 01059125
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anisocytosis	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
Other	Asthenia	Health Professional Other	Gramicidin/Neomycins o4/Polymyxin Bso4	C			PO	
	Cardiac Murmur							
	Dizziness							
	Dyspnoea							
	Dyspnoea Exertional							
	Face Oedema							
	Fatigue							
	Gastritis Erosive							
	Gastrointestinal Haemorrhage							
	Granuloma							
	Hiatus Hernia							
	Iron Deficiency Anaemia							
	Microcytic Anaemia							

Microcytosis
Normochromic Normocytic
Anaemia
Pruritus

Date:08/06/01ISR Number: 3771557-9Report Type:Expedited (15-DaCompany Report #WAES 01059125
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Face Oedema Pruritus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 75 DAY
			Gramicidin/Neomycins o4/Polymyxin Bso4	C				

Date:08/06/01ISR Number: 3771593-2Report Type:Expedited (15-DaCompany Report #WAES 01079007
Age: Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Disorder Dermatitis Eosinophil Count Increased Hepatitis Leukocytosis Mucosal Inflammation Myalgia Pyrexia Renal Failure Acute	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	5 DAY

Date:08/06/01ISR Number: 3771595-6Report Type:Expedited (15-DaCompany Report #WAES 01078238
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Gamma-Glutamyltransferase Increased Liver Disorder	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY, PO	12 DAY
			Tab Allopurinol	SS		ORAL	100 MG/DAILY,PO	22 DAY
			Vasotec	C				
			Diclofenac Na	C				

Date:08/06/01ISR Number: 3771596-8Report Type:Expedited (15-DaCompany Report #WAES 01076527
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Drug Level Above Therapeutic Renal Impairment	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO 11 DAY
			Acetaminophen	C			
			Amiloride Hydrochloride-Hctz	C			
			Amlodipine Besylate	C			
			Venlafaxine Hcl	C			

Date:08/06/01ISR Number: 3771603-2Report Type:Expedited (15-DaCompany Report #WAES 01076088
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	9 DAY
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Other						
	International Normalised Ratio Increased							
	Prothrombin Time Prolonged		Tab Acenocoumarol	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/01ISR Number: 3771604-4Report Type:Expedited (15-DaCompany Report #WAES 01076097
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Anorexia Nausea Vomiting	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/06/01ISR Number: 3771610-XReport Type:Expedited (15-DaCompany Report #WAES 01039126
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Face Oedema Pruritus	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG DAILY	ORAL 75 DAY
			Gramicidin/Neomycins o4/Polymyxin Bso4	C				

Date:08/06/01ISR Number: 3771613-5Report Type:Expedited (15-DaCompany Report #WAES 01079007
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Disorder Dermatitis Diarrhoea Eosinophil Count Increased Eosinophilia Hepatitis Leukocytosis Mucosal Inflammation Mucous Membrane Disorder Myalgia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	5 DAY

Pyrexia
Renal Failure Acute

Date:08/06/01ISR Number: 3771658-5Report Type:Expedited (15-DaCompany Report #WAES 01079605
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	PO 5 DAY
	Congestive	Health						
	Chest Pain	Professional						
	Dysphonia							
	Dyspnoea		Atorvastatin Calcium	C				
	Nausea		Captopril	C				
	Pharyngitis		Carbaspirin Calcium	C				
	Pharyngolaryngeal Pain		Diclofenac	C				
	Pulmonary Oedema		Digoxin	C				

Date:08/06/01ISR Number: 3771660-3Report Type:Expedited (15-DaCompany Report #WAES 01075267
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign	Vioxx	PS	Merck Research Laboratories Div			
	Renal Impairment	Other						

Merck Co Inc ORAL
12.5 MG/DAILY

PO 16 DAY

Aspirin	C
Dothiepin Hcl	C
Indapamide	C
Propranolol	C
Tetrabenazine	C

Date:08/06/01ISR Number: 3771662-7Report Type:Expedited (15-DaCompany Report #WAES 01059135
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research	
Hospitalization -	Congestive	Other			Laboratories Div	
Initial or Prolonged	Fluid Overload				Merck Co Inc	ORAL
12.5 MG/DAILY						
	Oedema					
PO 12 DAY						
	Renal Impairment		Cyclosporine	SS		ORAL
175 MG/DAILY						
PO						
			Prinivil	C		
			Amlodipine Besylate	C		
			Atorvastatin	C		
			Bisoprolol Fumarate	C		
			Calcium Carbonate (+) Cholecalciferol	C		
			Domperidone	C		
			Furosemide	C		
			Nitroglycerin	C		
			Prednisone	C		
			Ranitidine	C		
			Sulfamethoxazole/Trimethoprim	C		

Date:08/06/01ISR Number: 3771665-2Report Type:Expedited (15-DaCompany Report #WAES 01073487
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Life-Threatening Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5 MG/BID

PO

Date:08/06/01ISR Number: 3772241-8Report Type:Expedited (15-DaCompany Report #WAES 01040427
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Death	Accident	Health	Vioxx	PS	Merck Research	
Life-Threatening	Ascites	Professional			Laboratories Div	
Hospitalization -	Cytomegalovirus Infection	Company			Merck Co Inc	ORAL
Initial or Prolonged	Duodenal Ulcer	Representative				
Other	Haemorrhage		Tab Vioxx 25 Mg	SS		ORAL
	Hepatic Failure		Aldactone	C		
	Hypotension		Bactrim	C		
	Pleural Effusion		Calderol	C		
	Pneumonia		Cellcept	C		
	Pneumothorax		Compazine	C		
	Renal Impairment		Diflucan	C		
	Respiratory Failure		Norvasc	C		
			Os-Cal	C		
			Phenergan			

Dose Duration

25 MG/DAILY/PO

25MG/DAILY/PO

(Dibromopropamidine
Iso C
Prilosec C
Zofran C
Zoloft C
Acetaminophen C
Cyclosporine C
Ganciclovir C
Ibuprofen C
Prednisone C

Date:08/06/01ISR Number: 3772257-1Report Type:Expedited (15-DaCompany Report #WAES 01072862
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck Research			
Disability	Colonoscopy Abnormal	Professional			Laboratories Div			
	Erythema	Company			Merck Co Inc	ORAL	25	
	Gastrointestinal	Representative					MG/DAILY/PO	
	Haemorrhage		Tab Vioxx 12.5 Mg	SS		ORAL	25	
							MG/DAILY/PO	

Date:08/06/01ISR Number: 3772258-3Report Type:Expedited (15-DaCompany Report #WAES 01072679
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Haematochezia				Laboratories Div			
					Merck Co Inc	ORAL	25	
							MG/DAILY/PO	

Date:08/06/01ISR Number: 3772268-6Report Type:Expedited (15-DaCompany Report #WAES 01071955
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Subarachnoid Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:08/06/01ISR Number: 3772270-4Report Type:Expedited (15-DaCompany Report #WAES 01051577
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Gastric Haemorrhage Gastrointestinal Haemorrhage Haematocrit Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	C				

Date:08/06/01ISR Number: 3772363-1Report Type:Expedited (15-DaCompany Report #WAES 01072394
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Blood Pressure Increased

	Eructation						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL
			Vasotec	C			

Date:08/06/01ISR Number: 3772366-7Report Type:Expedited (15-DaCompany Report #WAES 01060705
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
		Company Representative	Prednisone	C			

Date:08/06/01ISR Number: 3772372-2Report Type:Expedited (15-DaCompany Report #WAES 01051918
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Haematocrit Decreased	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO
Other	Melaena		Cozaar	C			
	Platelet Count Decreased		Enturen	C			
	Red Blood Cell Count Decreased		Lipitor	C			
	White Blood Cell Count Decreased		Sectral	C			

Date:08/06/01ISR Number: 3772381-3Report Type:Expedited (15-DaCompany Report #WAES 01061041
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Orthopnoea	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Cardizem	C				
			Prilosec	C				
			Tenormin	C				

Date:08/07/01ISR Number: 3771421-5Report Type:Direct Company Report #
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx/ 50 Mg/ Merck	PS	Merck	ORAL	50 MG/ Q DAY/ ORAL	
	Blood Pressure Increased							
	Chest Discomfort							
	Chest Pain							
	Fatigue							
	Feeling Abnormal							
	Nausea							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/01ISR Number: 3771776-1Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased		Vioxx (Not Dispensed At This Pharmacy)	PS				

Date:08/09/01ISR Number: 3773908-8Report Type:Expedited (15-DaCompany Report #WAES 01078244
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc		25 MG/DAILY	15 DAY
	Periorbital Oedema	Other						
	Pruritus							
	Urticaria		Moduretic	C				
			Citalopram Hydrobromide	C				

Date:08/09/01ISR Number: 3773918-0Report Type:Expedited (15-DaCompany Report #WAES 01075066
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Neutropenia	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO (SEE IMAGE)	9 DAY
			Omeprazole Magnesium	SS		ORAL	20 MG/DAILY PO (SEE IMAGE)	5 DAY
			Aluminumhydroxide/Mg Oh/Oxethazaine	C				
			Aspirin	C				

Atorvastatin	C
Bendroflumethiazide	C
Cyclizine	C
Danthron (+)	
Poloxamer 188	C
Diacetylmorphine	C
Ferrousso4	C
Hydromorphone	C
Lactulose	C
Methotrimeprazine	C
Metoclopramide	C
Morphineso4	C
Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C
Senna	C
Suriclone	C

Date:08/09/01ISR Number: 3773954-4Report Type:Expedited (15-DaCompany Report #WAES 01085006
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Impairment	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

PO 23 DAY

22-Aug-2005 10:31 AM

				Elavil	C		
				Acetaminophen/Propoxyphene Hydrochloride	C		
				Atenolol	C		
				Bendroflumethiazide	C		

Date:08/09/01ISR Number: 3774184-2Report Type:Expedited (15-DaCompany Report #WAES 01075238
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea Dyspepsia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	11 DAY
			Vasotec	C				
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Digoxin	C				
			Furosemide	C				

Date:08/09/01ISR Number: 3774201-XReport Type:Expedited (15-DaCompany Report #WAES 01077015
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastroenteritis Helicobacter	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	9	DAY
	Oliguria	Other	Goserelin Acetate	C				
			Prednisolone	C				

Date:08/09/01ISR Number: 3774202-1Report Type:Expedited (15-DaCompany Report #WAES 01073489
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Large Cell Carcinoma Of The Respiratory Tract	Foreign Health	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged	Stage Unspecified	Professional			Merck Co Inc	ORAL
12.5 MG/DAILY						
	Pulmonary Oedema		Pepcid	C		
	Sternal Fracture		Atorvastatin Calcium	C		
			Paroxetine Hcl	C		

Date:08/09/01ISR Number: 3774203-3Report Type:Expedited (15-DaCompany Report #WAES 01076070
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diverticulum	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Gastrointestinal	Health			Laboratories Div	
	Haemorrhage	Professional			Merck Co Inc	ORAL
25 MG/DAILY 3 DAY						

Date:08/09/01ISR Number: 3774205-7Report Type:Expedited (15-DaCompany Report #WAES 01078612
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Blood Pressure Systolic
	Increased
	Coronary Artery

Atherosclerosis
Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	

Date:08/09/01ISR Number: 3774206-9Report Type:Expedited (15-DaCompany Report #WAES 01073490
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Left Ventricular Failure	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY	
			Pepcid	C				
			Vasotec	C				
			Atenolol	C				
			Digoxin	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Potassium Chloride	C				
			Warfarin	C				

Date:08/09/01ISR Number: 3774209-4Report Type:Expedited (15-DaCompany Report #WAES 01075066
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Neutropenia	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	
							PO	9 DAY
			Omeprazole Magnesium	SS		ORAL	20 MG/DAILY	
							PO (SEE	

IMAGE) 5 DAY

Aluminumhydroxide/Mg Oh/Oxethazaine	C
Aspirin	C
Atorvastatin	C
Bendroflumethiazide	C
Cyclizine	C
Danthron (+)	
Poloxamer 188	C
Diacetylmorphine	C
Ferrousso4	C
Hydromorphone	C
Lactulose	C
Methotrimeprazine	C
Metoclopramide	C
Morphineso4	C
Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C
Senna	C
Suriclone	C

Date:08/09/01ISR Number: 3774210-0Report Type:Expedited (15-DaCompany Report #WAES 01075183
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Inappropriate Antidiuretic Hormone Secretion	Foreign Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	18 DAY
			Prinivil	C				
			Aspirin	C				
			Pravastatin Na	C				
			Prednisolone	C				
			Tramadol	C				

Date:08/09/01ISR Number: 3774246-XReport Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia Coordination Abnormal Difficulty In Walking	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
	Disorientation	Representative						
	Drug Interaction		Anafranil	SS				
	Speech Disorder		Klonopin	SS				
	Vision Blurred		Lamictal	SS				
			Wellbutrin	SS				
			Dipentum	SS				
			Premarin	SS				
			Zoloft	SS				
			Coumadin	C				
			Motrin	C				
			Lithium Carbonate	C				

Date:08/09/01ISR Number: 3774272-0Report Type:Expedited (15-DaCompany Report #WAES 01080056
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Vioxx	PS	Merck Research			

Initial or Prolonged Haemorrhage Laboratories Div
Merck Co Inc ORAL

25

MG/DAILY/PO

Aspirin	SS
Advair Diskus	C
Deltasone	C
Nitrolingual	C
Norvasc	C
Premarin	C
Prevacid	C
Singulair	C
Albuterol	C
Amitriptyline Hydrochloride	C
Atenolol	C
Ibuprofen	C
Isosorbide Mononitrate	C
Ranitidine Hydrochloride	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3774273-2Report Type:Expedited (15-DaCompany Report #WAES 01072144
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck Research			
Hospitalization -	Fatigue	Professional			Laboratories Div			
Initial or Prolonged	Hemiparesis				Merck Co Inc	ORAL	12.5	
Other	Hypertension						MG/DAILY/ORAL	
	Visual Acuity Reduced		Prozac	SS			10 MG/DAILY/	
	Visual Field Defect		Daypro	C				
			Hydrodiuril	C				
			K-Dur	C				
			Lipitor	C				
			Premarin	C				
			Aspirin	C				
			Ramipril	C				

Date:08/09/01ISR Number: 3774274-4Report Type:Expedited (15-DaCompany Report #WAES 01060915
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck Research			
Initial or Prolonged	Blood Pressure Increased	Professional			Laboratories Div			
	Chest Pain				Merck Co Inc	ORAL	25	
	Dizziness						MG/DAILY/PO	
	Dyspnoea		Cozaar	C				
	Nausea		Lasix	C				
			Lipitor	C				
			Lopressor	C				
			Prilosec	C				
			Synthroid	C				

Date:08/09/01ISR Number: 3774275-6Report Type:Expedited (15-DaCompany Report #WAES 01080294
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Aspirin	C				

Date:08/09/01ISR Number: 3774287-2Report Type:Expedited (15-DaCompany Report #WAES 01075183
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Inappropriate Antidiuretic Hormone Secretion	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	18	DAY
			Prinivil	C				
			Aspirin	C				
			Pravastatin Na	C				
			Prednisolone	C				
			Tramadol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3774374-9Report Type:Expedited (15-DaCompany Report #WAES 01061306
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Aspirin	C				

Date:08/09/01ISR Number: 3774454-8Report Type:Expedited (15-DaCompany Report #WAES 01080181
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/09/01ISR Number: 3774455-XReport Type:Expedited (15-DaCompany Report #WAES 01080293
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/09/01ISR Number: 3774457-3Report Type:Expedited (15-DaCompany Report #WAES 01070670
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Pressure Increased	Health	Vioxx	PS	Merck Research		
Hospitalization -	Heart Rate Increased	Professional			Laboratories Div		
Initial or Prolonged	Orthostatic Hypotension				Merck Co Inc	ORAL	
PO							
	Shock		Aggrenox	C			
			Tamoxifen	C			

Date:08/09/01ISR Number: 3774458-5Report Type:Expedited (15-DaCompany Report #WAES 01080175
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Hospitalization -	Cardiac Failure	Consumer	Vioxx	PS	Merck Research		
Initial or Prolonged	Congestive				Laboratories Div		
					Merck Co Inc	ORAL	
PO							
			L-Thyroxin	C			
			Monopril	C			
			Pravachol	C			

Date:08/09/01ISR Number: 3774459-7Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Other	Convulsion	Consumer	Vioxx	PS	Merck Research		
	Spinal Disorder	Health			Laboratories Div		
		Professional			Merck Co Inc	ORAL	
25							

MG/DAILY/PO

	Wellbutrin	SS
UNKNOWN		
	Delestrogen	C
	Flexeril	C
	Lipitor	C
	Clonazepam	C

Date:08/09/01ISR Number: 3774518-9Report Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Coronary Artery Atherosclerosis Coronary Artery Disease	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						
	Hypertension Pulmonary Congestion	Representative	Fiorinal	C		
			Midrin	C		
			Zestril	C		
			[Composition Unspecified]	C		

Date:08/09/01ISR Number: 3774520-7Report Type:Expedited (15-DaCompany Report #WAES 01070662
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Hospitalization - Initial or Prolonged	Gastric Ulcer Haematemesis	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
PO						

Date:08/09/01ISR Number: 3774521-9Report Type:Expedited (15-DaCompany Report #WAES 01072916
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Systemic Lupus Erythematosus	Health Professional	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
PO
Evista C

Date:08/09/01ISR Number: 3774523-2Report Type:Expedited (15-DaCompany Report #WAES 01071133
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Immunoglobulin G Increased	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Chromaturia	Company			Merck Co Inc	ORAL	50	
	Constipation	Representative					MG/DAILY/PO	
	Cyst		Celexa	C				
	Cytomegalovirus Infection							
	Hepatitis							
	Pancreatic Disorder							
	Pyrexia							
	Scleral Discolouration							
	Spleen Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3774539-6Report Type:Expedited (15-DaCompany Report #WAES 01051918
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Dyspnoea	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
Other	Haematocrit Decreased Platelet Count Decreased Red Blood Cell Count Decreased White Blood Cell Count Decreased		Cozaar Enturen Lipitor Sectral	C C C C				

Date:08/09/01ISR Number: 3774540-2Report Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Atherosclerosis Coronary Artery Disease	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Hypertension Pulmonary Congestion	Representative	Fiorinal Midrin Zestril	C C C				

Date:08/09/01ISR Number: 3774572-4Report Type:Expedited (15-DaCompany Report #WAES 01070098
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 DAILY PO	
Other			Naprosyn Nitro-Dur Relafen Aspirin Ibuprofen	C C C C C				

				Verapamil Hydrochloride	C		

Date:08/09/01ISR Number: 3774574-8Report Type:Expedited (15-DaCompany Report #WAES 01072537
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Fluid Retention							
	Pharyngeal Oedema							
	Pulmonary Oedema		Avandia	C				
	Swelling		Glyburide	C				

Date:08/09/01ISR Number: 3774577-3Report Type:Expedited (15-DaCompany Report #WAES 01072233
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	PO

			Accupril	C		
			Caltrate	C		
			Lipitor	C		
			Norvasc	C		
			[Composition Unspecified]	C		
			Digoxin	C		

Date:08/09/01ISR Number: 3774580-3Report Type:Expedited (15-DaCompany Report #WAES 01072370
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Vioxx	PS	Merck Research	
	Difficulty In Walking	Health			Laboratories Div	
	Neuropathy Peripheral	Professional			Merck Co Inc	ORAL
SEE IMAGE						
	Oedema		Elavil	C		
	Tendon Injury		Neurontin	C		
	Weight Decreased		Premarin	C		
			Baclofen	C		
			Dicyclomine Hydrochloride	C		
			Methadone Hydrochloride	C		

Date:08/09/01ISR Number: 3774582-7Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Vioxx	PS	Merck Research	
	Spinal Disorder	Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Wellbutrin	SS		
UNKNOWN						
			Delestrogen	C		
			Flexeril	C		
			Lipitor	C		
			Clonazepam	C		

Date:08/09/01ISR Number: 3774586-4Report Type:Expedited (15-DaCompany Report #WAES 01051918
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Professional			Laboratories Div			
Initial or Prolonged	Dyspnoea				Merck Co Inc	ORAL	PO	
Other	Faeces Discoloured		Cozaar	C				
	Haematemesis		Enturen	C				
	Haematocrit Decreased		Lipitor	C				
	Haemoglobin Decreased		Sectral	C				
	Melaena							
	Red Blood Cell Count Decreased							
	White Blood Cell Count Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3774595-5Report Type:Expedited (15-DaCompany Report #WAES 01070098
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Health	Vioxx	PS	Merck Research			
Hospitalization -	Gastric Ulcer	Professional			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	12.5	
							Other	
							MG/DAILY/PO	
			Naprosyn	C				
			Nitro-Dur	C				
			Relafen	C				
			Aspirin	C				
			Ibuprofen	C				
			Verapamil Hydrochloride	C				

Date:08/09/01ISR Number: 3774632-8Report Type:Expedited (15-DaCompany Report #WAES 01072916
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Systemic Lupus	Health	Vioxx	PS	Merck Research			
	Erythematosus	Professional			Laboratories Div			
					Merck Co Inc	ORAL	PO	
			Evista	C				

Date:08/09/01ISR Number: 3774633-XReport Type:Expedited (15-DaCompany Report #WAES 01072486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Vioxx	PS	Merck Research			
Initial or Prolonged	Oedema Peripheral				Laboratories Div			
					Merck Co Inc	ORAL	PO	14 DAY

Date:08/09/01ISR Number: 3774634-1Report Type:Expedited (15-DaCompany Report #WAES 01072275
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Drug Level Below Therapeutic	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1) 25 MG/PRN/ORAL; 2) 25 MG/ BID/ ORAL ADMINISTRATIO	
			Ativan	C				
			Dilantin	C				
			Zoloft	C				

Date:08/09/01ISR Number: 3774649-3Report Type:Expedited (15-DaCompany Report #WAES 01080248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Disorder Ulcer	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3775194-1Report Type:Expedited (15-DaCompany Report #WAES 01080247
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Hypertension Pancreatitis Acute Urticaria	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	

Date:08/09/01ISR Number: 3775195-3Report Type:Expedited (15-DaCompany Report #WAES 01073490
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Condition Aggravated Left Ventricular Failure	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/ DAILY	
			Pepcid	C				
			Vasotec	C				
			Atenolol	C				
			Digoxin	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Potassium Chloride	C				
			Warfarin	C				

Date:08/09/01ISR Number: 3775196-5Report Type:Expedited (15-DaCompany Report #WAES 01080459
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatocellular Damage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/09/01ISR Number: 3775217-XReport Type:Expedited (15-DaCompany Report #WAES 01080123
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia Blood Pressure Increased Transient Ischaemic Attack	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG DAILY PO	

Date:08/09/01ISR Number: 3775262-4Report Type:Expedited (15-DaCompany Report #WAES 01075589
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1 TABLET/DAILY	11 DAY
			Trimipramine Maleate	SS		ORAL	1 TABLET/DAILY	11 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/01ISR Number: 3775396-4Report Type:Expedited (15-DaCompany Report #WAES 01085511
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure Hepatitis	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/09/01ISR Number: 3775401-5Report Type:Expedited (15-DaCompany Report #WAES 01045592
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphagia Nasopharyngitis Nervous System Disorder Oedema Mouth Pain Pharyngeal Oedema	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:08/09/01ISR Number: 3775402-7Report Type:Expedited (15-DaCompany Report #WAES 01075024
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive	Foreign Study Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	8 DAY

Date:08/09/01ISR Number: 3775403-9Report Type:Expedited (15-DaCompany Report #WAES 01088751
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Pancreatitis Renal Failure Chronic	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO	85 DAY					
			Acetaminophen/Codeine Phosphate	C		
			Allopurinol	C		
			Aspirin	C		
			Doxycycline	C		
			Folic Acid	C		
			Furosemide	C		
			Pantoprazole	C		

Date:08/09/01ISR Number: 3775404-0Report Type:Expedited (15-DaCompany Report #WAES 01086503
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Interaction Hyponatraemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO						
			Tab Furosemide	SS		ORAL
40 MG/DAILY						
PO						
			Acetaminophen	C		
			Metoclopramide Hydrochloride	C		

Potassium Chloride C

Date:08/13/01ISR Number: 3776205-XReport Type:Expedited (15-DaCompany Report #WAES 01080220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex Unk	SS				

Date:08/13/01ISR Number: 3776206-1Report Type:Expedited (15-DaCompany Report #WAES 01080219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Celebrex	SS				

Date:08/13/01ISR Number: 3776230-9Report Type:Expedited (15-DaCompany Report #WAES 00061932
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Pneumonitis Pruritus	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			[Therapy Unspecified]	C				

Date:08/13/01ISR Number: 3776231-0Report Type:Expedited (15-DaCompany Report #WAES 01070611
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lodine	SS				

Date:08/13/01ISR Number: 3776232-2Report Type:Expedited (15-DaCompany Report #WAES 01061715
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort Chest Pain Dysphagia	Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Dyspnoea Hyperventilation Laryngeal Oedema Laryngospasm Throat Tightness Tremor		Celebrex Levothyroxine Sodium	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/01ISR Number: 3776233-4Report Type:Expedited (15-DaCompany Report #WAES 01010971
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tenosynovitis	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Niacin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:08/13/01ISR Number: 3776234-6Report Type:Expedited (15-DaCompany Report #WAES 01080691
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure Renal Failure Acute	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Lasix (Furosemide)	C				

Date:08/13/01ISR Number: 3776235-8Report Type:Expedited (15-DaCompany Report #WAES 01080689
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Blood Creatinine Increased Cardiac Failure Congestive	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
	Dyspnoea		Lasix (Furosemide)	C				

Oedema Peripheral
Orthopnoea
Pleural Effusion

Date:08/13/01ISR Number: 3776237-1Report Type:Direct Company Report #
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective		Vioxx 12.5 Mg (Msd)	PS		
1 TAB QD						
			Diovan	C		
			Catapres	C		

Date:08/13/01ISR Number: 3776256-5Report Type:Direct Company Report #
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dementia		Vioxx (25mg)	PS		
25MG DAILY						
	Melaena					
	Peptic Ulcer					
	Syncope					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/01ISR Number: 3776995-6Report Type:Expedited (15-DaCompany Report #WAES 00105104
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
	Circulatory Collapse	Other				
	Dyspepsia					
	Gastritis		Acetaminophen/Codeine Phosphate	C		
	Gastroenteritis		Levothyroxine Na	C		
	Helicobacter		Ranitidine	C		
	Nausea		Temazepam	C		

Date:08/13/01ISR Number: 3776997-XReport Type:Expedited (15-DaCompany Report #WAES 01065632
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged	Foreign	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
		Other				
12.5 MG/DAILY 7 DAY						
	Drug Interaction		Enoxaparin	SS		
INTRAVENOUS 80 MG/BID						
	Eye Haemorrhage		Dipyrone	C		
	Haematoma		Furosemide/Spironolactone	C		
	Haemoglobin Decreased		Lactulose	C		
	Prothrombin Time Prolonged		Levothyroxine Na	C		
			Pantoprazole Sodium	C		

Date:08/13/01ISR Number: 3776998-1Report Type:Expedited (15-DaCompany Report #WAES 01085518
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Thrombocytopenia	Foreign Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
			Naloxone Hydrochloride (+)			
			Tilidine Hydr	C		

Date:08/13/01ISR Number: 3777000-8Report Type:Expedited (15-DaCompany Report #WAES 01075262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspnoea	Foreign	Vioxx	PS	Merck Research	
	Nasal Congestion	Other			Laboratories Div	
	Oedema Peripheral				Merck Co Inc	ORAL
25 MG DAILY						
PO						
			Acetaminophen (+)			
			Dihydrocodeine			
			Bitartrate	C		
			Atenolol	C		
			Clomipramine	C		
			Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/01ISR Number: 3777001-XReport Type:Expedited (15-DaCompany Report #WAES 01077502
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Alopecia	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged	Anaemia	Other			Laboratories Div	
Other	Eczema				Merck Co Inc	ORAL
	Inflammation		Aspirin	C		
	Malaise		Estriol	C		
	Pyrexia		Zaleplon	C		
	Rash Erythematous					
	Rash Pruritic					
	Weight Decreased					

Date:08/13/01ISR Number: 3777002-1Report Type:Expedited (15-DaCompany Report #WAES 01089605
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Peptic Ulcer Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
25 MG DAILY						
PO						

Date:08/13/01ISR Number: 3777019-7Report Type:Expedited (15-DaCompany Report #WAES 01073867
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx	PS	Merck Research	
Initial or Prolonged		Health			Laboratories Div	
		Professional			Merck Co Inc	ORAL
PO						
		Other				

Date:08/13/01ISR Number: 3777022-7Report Type:Expedited (15-DaCompany Report #WAES 01089606
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY PO	

Date:08/15/01ISR Number: 3777417-1Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Vioxx	PS		ORAL	25 MG QD PO	
Required	Increased		Captopril	SS		ORAL	25 MG BID PO	
Intervention to Prevent Permanent Impairment/Damage	Blood Urea Increased		Micro-K	SS				
			Lasix	C				
			Feso4	C				
			Doxepin	C				
			Miacalcin	C				
			Tylenol	C				
			Promethazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/01ISR Number: 3778149-6Report Type:Expedited (15-DaCompany Report #WAES 99122121
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Haemorrhage Diarrhoea Dizziness Eye Haemorrhage International Normalised Ratio Increased Prothrombin Time Prolonged	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Coumadin	C				

Date:08/15/01ISR Number: 3778153-8Report Type:Expedited (15-DaCompany Report #WAES 01061839
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Diverticulum Gastrointestinal Haemorrhage Haematochezia International Normalised Ratio Increased	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/BID/PO	
			Coumadin	C				

Date:08/15/01ISR Number: 3778155-1Report Type:Expedited (15-DaCompany Report #WAES 01080294
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haematoma Rectal Haemorrhage	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Synthroid	C				
			Aspirin	C				

Date:08/15/01ISR Number: 3778157-5Report Type:Expedited (15-DaCompany Report #WAES 01072486
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Oedema Peripheral	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:08/15/01ISR Number: 3778158-7Report Type:Expedited (15-DaCompany Report #WAES 01070961
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Melaena	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	SEE IMAGE	
			Hydrodiuril	C				
			Prinivil	C				
			Allopurinol	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/01ISR Number: 3778171-XReport Type:Expedited (15-DaCompany Report #WAES 01080319
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulation Time Shortened Embolism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Coumadin	C				

Date:08/15/01ISR Number: 3778212-XReport Type:Expedited (15-DaCompany Report #WAES 01080852
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulation Time Shortened Embolism	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/15/01ISR Number: 3778237-4Report Type:Expedited (15-DaCompany Report #WAES 01080837
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Demadex	C				

Date:08/15/01ISR Number: 3778239-8Report Type:Expedited (15-DaCompany Report #WAES 01080690
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Stevens-Johnson Syndrome	Health Professional	Vioxx	PS	Merck Research Laboratories Div			

Initial or Prolonged Merck Co Inc ORAL
12.5
Other
MG/DAILY/PO

Lasix (Furosemide)	C
Premarin	C
Pulmicort	C
Zestril	C

Date:08/15/01ISR Number: 3778328-8Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia		Vioxx 50 Mg Mrk #			
Hospitalization -			114	PS		ORAL
50 MG DAILY						
Initial or Prolonged						
PO						
Disability			Multivitamins	C		
Required			Aspirin	C		
Intervention to			Motrin	C		
Prevent Permanent			Plavix	I		
Impairment/Damage						

Date:08/15/01ISR Number: 3778336-7Report Type:Expedited (15-DaCompany Report #WAES 01085058
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia Fatigue Malaise	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY	91 DAY

Date:08/15/01ISR Number: 3778504-4Report Type:Expedited (15-DaCompany Report #WAES 01083456
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL		

Date:08/15/01ISR Number: 3778505-6Report Type:Expedited (15-DaCompany Report #WAES 01085050
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Impairment	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG DAILY	78 DAY
			Bendroflumethiazide	C				
			Clodronic Acid	C				
			Lansoprazole	C				
			Prednisolone	C				
			Tramadol	C				
			Valsartan	C				

Date:08/15/01ISR Number: 3778506-8Report Type:Expedited (15-DaCompany Report #WAES 01085522
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Pruritus Urticaria	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25MG/DAILY 34 DAY

Date:08/15/01ISR Number: 3778575-5Report Type:Expedited (15-DaCompany Report #WAES 01085533
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Mediastinitis Oesophageal Perforation	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	1TABLET/BID; PO 22 DAY

Date:08/15/01ISR Number: 3778576-7Report Type:Expedited (15-DaCompany Report #WAES 01088208
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Palpitations Tachycardia	Foreign Health Professional Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	50 MG/DAILY:PO 2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/01ISR Number: 3778577-9Report Type:Expedited (15-DaCompany Report #WAES 01077511
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biliary Tract Disorder Hepatitis Cholestatic Influenza Like Illness	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY: PO	25 DAY
			Domperidone	C				
			Estradiol Valerate	C				
			Lansoprazole	C				
			Lorazepam	C				
			Propafenone Hcl	C				

Date:08/15/01ISR Number: 3778578-0Report Type:Expedited (15-DaCompany Report #WAES 01083461
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Encephalopathy Hepatic Failure Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Respiratory Failure		Risedronate Sodium	SS		ORAL	30 MG/DAILY:PO	
			Allopurinol	C				
			Atorvastatin Calcium	C				
			Hydroxychloroquine So4	C				
			Raloxifene	C				
			Sertraline Hcl	C				
			Sulfasalazine	C				

Date:08/15/01ISR Number: 3778595-0Report Type:Expedited (15-DaCompany Report #WAES 01087505
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	C-Reactive Protein Increased Myalgia Purpura	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY 4 DAY

Date:08/15/01ISR Number: 3778632-3Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx 25 Mg Merck	PS	Merck	ORAL	25MG DAILY	
Hospitalization - Initial or Prolonged	Aphasia Blood Pressure Increased Coordination Abnormal Difficulty In Walking Dysphagia Dyspnoea Headache Nausea Palpitations Speech Disorder		Dipentum Lactimal Zoloft Anafranil Klonopin Premarin Wellbutrin	C C C C C C C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/01ISR Number: 3778649-9Report Type:Expedited (15-DaCompany Report #WAES 01085059
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis	Foreign	Vioxx	PS	Merck Research			
Hospitalization -		Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	25 MG/DAILY	
			Amlodipine	C				
			Furosemide	C				
			Lactulose	C				

Date:08/16/01ISR Number: 3778665-7Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Stress Disorder	Health	Vioxx	PS	Merck Research			
	Aphasia	Professional			Laboratories Div			
	Coordination Abnormal	Company			Merck Co Inc	ORAL	25 MG/DAILY/ORAL	
	Difficulty In Walking	Representative						
	Disorientation		Anafranil	SS				
	Drug Interaction		Klonopin	SS				
	Transient Ischaemic		Lamictal	SS				
	Attack		Wellbutrin	SS				
	Vision Blurred		Dipentum	SS				
			Premarin	SS				
			Zoloft	SS				
			Coumadin	C				
			Motrin	C				
			Lithium Carbonate	C				

Date:08/17/01ISR Number: 3779650-1Report Type:Expedited (15-DaCompany Report #WAES 01080727
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradyphrenia	Consumer	Vioxx	PS	Merck Research			
	Concussion				Laboratories Div			

	Confusional State				Merck Co Inc	ORAL
PO						
	Convulsion		Advil	C		
	Dysphemia		Prozac	C		

Date:08/17/01ISR Number: 3779701-4Report Type:Expedited (15-DaCompany Report #WAES 01051754
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Vioxx	PS	Merck Research Laboratories Div	
	Condition Aggravated					
	Fluid Retention				Merck Co Inc	ORAL
25						
	Irritable Bowel Syndrome					
MG/DAILY/PO						
	Oedema Peripheral		Vioxx	SS		ORAL
PO						
	Pulmonary Oedema		Avandia	SS		
8 MG/DAILY						
			Avandia	SS		
4 MG/DAILY						
			Accupril	C		
			Amaryl	C		
			Cenestin	C		
			Flexeril	C		
			Lopid	C		
			Prilosec	C		
			Synthroid	C		
			Ultram	C		

			Insulin	C		

Date:08/17/01ISR Number: 3779704-XReport Type:Expedited (15-DaCompany Report #WAES 01072258
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Cerebrovascular Accident	Consumer Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/ORAL 1 YR						
			Synthroid	C		
			Tylenol	C		
			Zestril	C		

Date:08/17/01ISR Number: 3779706-3Report Type:Expedited (15-DaCompany Report #WAES 01080114
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastrointestinal Haemorrhage	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY PO	Haematemesis	Representative				
	Haematochezia		Celebrex	C		

Date:08/17/01ISR Number: 3779801-9Report Type:Expedited (15-DaCompany Report #WAES 01080123
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Increased Orthostatic Hypotension Transient Ischaemic	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY/PO;	Attack	Representative				

25

MG/DAILY/PO;

50

			Flexeril	C		
			Soma	C		
			Ibuprofen	C		

Date:08/17/01ISR Number: 3779802-0Report Type:Expedited (15-DaCompany Report #WAES 01080123
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Aphasia Blood Pressure Increased Orthostatic Hypotension Transient Ischaemic Attack	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

25

MG/DAILY/PO;

50

			Flexeril	C		
			Soma	C		
			Ibuprofen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/01ISR Number: 3779835-4Report Type:Expedited (15-DaCompany Report #WAES 01080826
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Insomnia	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Actonel	C				
			Ambien	C				
			Demadex	C				
			Lasix (Furosemide)	C				
			Flavix	C				
			Zantac	C				
			Aspirin	C				
			Digoxin	C				
			Hydralazine	C				
			Nitroglycerin	C				
			Potassium Bromide	C				
			Prednisone	C				
			Spironolactone	C				

Date:08/17/01ISR Number: 3779836-6Report Type:Expedited (15-DaCompany Report #WAES 01080595
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastric Haemorrhage	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Allegra D	C				
			Prevacid	C				
			Clorazepate Dipotassium	C				

Date:08/17/01ISR Number: 3779837-8Report Type:Expedited (15-DaCompany Report #WAES 01080737
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Confusional State Palpitations	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
	Panic Attack	Representative	Celexa	C				
			Coumadin	C				
			Lasix (Furosemide)	C				
			Digoxin	C				

Date:08/17/01ISR Number: 3779841-XReport Type:Expedited (15-DaCompany Report #WAES 01011384
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyponatraemia	Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/PO	
			Tylenol	C				
			Capsaicin	C				
			Ferrous Sulfate	C				
			Lansoprazole	C				
			Simethicone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/01ISR Number: 3779842-1Report Type:Expedited (15-DaCompany Report #WAES 00121971
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hyponatraemia	Health Professional Company Representative	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Tylenol	C				
			Capsaicin	C				
			Ferrous Sulfate	C				
			Lansoprazole	C				
			Simethicone	C				

Date:08/17/01ISR Number: 3780224-7Report Type:Expedited (15-DaCompany Report #WAES 01087802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Epilepsy	Foreign Other	Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/17/01ISR Number: 3780225-9Report Type:Expedited (15-DaCompany Report #WAES 01085049
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Haemorrhage Gastroenteritis Helicobacter	Foreign Other	Vioxx (Rofecoxib)	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY PO	92 DAY
			Acetaminophen/Codeine Phosphate	C				
			Fluticasone Propionate	C				
			Loratadine	C				

			Salmeterol Xinafoate	C		

Date:08/17/01ISR Number: 3780239-9Report Type:Expedited (15-DaCompany Report #WAES 01073556
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
12.5 MG/DAILY						
PO 31 DAY						
			Aspirin	C		
			Atorvastatin	C		
			Captopril	C		
			Furosemide	C		

Date:08/17/01ISR Number: 3780241-7Report Type:Expedited (15-DaCompany Report #WAES 01079605
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive
	Chest Discomfort
	Dysphonia

	Nausea Pharyngitis Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY						
PO; 25						
MG/DAILY PO	5 DAY					
			Atorvastatin Calcium	C		
			Captopril	C		
			Carbaspirin Calcium	C		
			Diclofenac	C		
			Digoxin	C		

Date:08/17/01ISR Number: 3780242-9Report Type:Expedited (15-DaCompany Report #WAES 01085064
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Mallory-Weiss Syndrome Sepsis	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/PM PO	38 DAY					
			Acetaminophen (+) Dihydrocodeine Bitartr	C		
			Aluminum Hydroxide (+) Calcium Carbonate	C		
			Prednisolone	C		
			Rabeprazole Sodium	C		

Date:08/17/01ISR Number: 3780243-0Report Type:Expedited (15-DaCompany Report #WAES 01083704
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Hypoglycaemia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div	

Merck Co Inc ORAL
25 MG/DAILY

PO

Acenocoumarol	C
Folic Acid	C
Insulin, Biphasic Isophane (Injection)	C
Levobunolol Hcl	C

Date:08/17/01ISR Number: 3780244-2Report Type:Expedited (15-DaCompany Report #WAES 01085077
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Large Intestine Perforation	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL

12.5 MG/DAILY

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/01ISR Number: 3780246-6Report Type:Expedited (15-DaCompany Report #WAES 01086509
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Haemorrhage	Other			Laboratories Div			
Initial or Prolonged					Merck Co Inc	ORAL	12.5 MG/DAILY	
							PO	6 DAY
			Acetaminophen	C				
			Citalopram Hydrobromide	C				
			Furosemide	C				
			Oxycodone Hcl	C				

Date:08/17/01ISR Number: 3780248-XReport Type:Expedited (15-DaCompany Report #WAES 01073867
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS	Merck Research			
Initial or Prolonged		Health			Laboratories Div			
Congenital Anomaly		Professional			Merck Co Inc	ORAL	PO	
			Acetaminophen (+) Codeine	C				
			Hydroxychloroquineso 4	C				

Date:08/17/01ISR Number: 3780250-8Report Type:Expedited (15-DaCompany Report #WAES 01073489
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Vioxx	PS	Merck Research			
Hospitalization -	Congestive	Health			Laboratories Div			
Initial or Prolonged	Large Cell Carcinoma Of	Professional			Merck Co Inc	ORAL	12.5 MG/DAILY	
	The Respiratory Tract						PO	
	Stage Unspecified		Pepcid	C				

Metastases To Bone		Atorvastatin Calcium	C
Nausea		Paroxetine Hcl	C
Oedema Peripheral			
Pulmonary Oedema			
Sternal Fracture			

Date:08/17/01ISR Number: 3780251-XReport Type:Expedited (15-DaCompany Report #WAES 01073565
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscular Weakness Renal Failure Acute	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAY	PO 15 DAY
			Prinivil (Lisinopril)	SS		ORAL	20 MG/DAY PO	445 DAY
			Chlorthalidone	C				
			Levothyroxine Na	C				
			Lorazepam	C				
			Nortriptyline Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/01ISR Number: 3779779-8Report Type:Direct Company Report #
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity		Vioxx 25mg Merck	PS	Merck	ORAL	25 MG ONCE	
Hospitalization -	Thrombotic						DAILY ORAL	
Initial or Prolonged	Thrombocytopenic Purpura		Norflex	C				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:08/20/01ISR Number: 3779783-XReport Type:Direct Company Report #
Age:73 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS		ORAL	ORAL	
Hospitalization -	Haemorrhage		Acetazolamide	C				
Initial or Prolonged			Tylenol #3	C				

Date:08/20/01ISR Number: 3780163-1Report Type:Direct Company Report #USP 54231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Premarin	PS	Wyeth-Ayerst			
			Vioxx	SS	Merck & Co			
			Soma	SS	Wallace Labs			
			Celexa	SS	Forest			
			Allegra	SS	Aventis			

Date:08/21/01ISR Number: 3781437-0Report Type:Expedited (15-DaCompany Report #WAES 01081550
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Jaundice Liver Function Test Abnormal	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
	Rash Generalised	Representative				
MG/DAILY/PO						
			Celebrex	C		

Date:08/21/01ISR Number: 3781461-8Report Type:Expedited (15-DaCompany Report #WAES 01080812
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspnoea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Accolate	C		
			Azmacort	C		
			Nitro-Dur	C		
			Proventil	C		
			Furosemide	C		

Date:08/21/01ISR Number: 3781462-XReport Type:Expedited (15-DaCompany Report #WAES 01081114
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Epistaxis							
	Gastrointestinal Haemorrhage							
	Influenza Like Illness		Claritin	C				
	Jaundice		Keflex	C				
	Liver Disorder		Lipitor	C				
	Mouth Haemorrhage		Lopid	C				
			Maxalt (Rizatriptan Benzoate)	C				
			Premarin	C				
			Prevacid	C				
			Questran	C				
			Ultram	C				
			Vasotec	C				
			Xanax	C				
			Zoloft	C				
			Lorazepam	C				

Date:08/21/01ISR Number: 3781463-1Report Type:Expedited (15-DaCompany Report #WAES 01081491
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	

Date:08/21/01ISR Number: 3781465-5Report Type:Expedited (15-DaCompany Report #WAES 01081344
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck Research Laboratories Div			
	Gastrointestinal							

	Haemorrhage	Company			Merck Co Inc	ORAL
25 MG						
		Representative				
/DAILY/PO						
			Aspirin	C		

Date:08/21/01ISR Number: 3781473-4Report Type:Expedited (15-DaCompany Report #WAES 01081334
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck Research	
Hospitalization -					Laboratories Div	
Initial or Prolonged					Merck Co Inc	ORAL
25						
MG/DAILY/PO						
			Accupril	C		
			Calan Sr	C		
			Ditropan	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/21/01ISR Number: 3781474-6Report Type:Expedited (15-DaCompany Report #WAES 01081299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Tamoxifen	C				

Date:08/21/01ISR Number: 3781475-8Report Type:Expedited (15-DaCompany Report #WAES 01081006
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Pneumonia Rheumatoid Arthritis	Health Professional Company	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	12 DAY
	Systemic Lupus Erythematosus	Representative	Accupril	C				

Date:08/21/01ISR Number: 3781476-XReport Type:Expedited (15-DaCompany Report #WAES 01080962
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Pressure Increased Nausea	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Lipitor	C				
			Lotensin	C				
			Diazepam	C				
			Folic Acid	C				

Date:08/21/01ISR Number: 3781477-1Report Type:Expedited (15-DaCompany Report #WAES 01081391
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acidosis
	Asthenia
	Blood Pressure Decreased
	Decreased Appetite
	Dehydration
	Diarrhoea
	Dizziness
	Dyspnoea
	Epistaxis
	Gastroenteritis Proteus
	Hypertension
	International Normalised
	Ratio Increased
	Oral Intake Reduced
	Platelet Function Test
	Abnormal
	Proteus Infection
	Renal Atrophy
	Renal Failure Acute
	Streptococcal Infection

Urinary Tract Infection

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	25 MG/DAILY/PO	
			Lotensin	SS			40 MG/DAILY	
			Coumadin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:08/21/01ISR Number: 3781537-5Report Type:Expedited (15-DaCompany Report #WAES 01080879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ileitis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	4 WK

Date:08/21/01ISR Number: 3781538-7Report Type:Expedited (15-DaCompany Report #WAES 01081066
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
		Company Representative	Aldactone	C				
			Avapro	C				

Date:08/21/01ISR Number: 3781541-7Report Type:Expedited (15-DaCompany Report #WAES 01052339
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abdominal Pain	Consumer	Tab Vioxx 12.5-25 Mg	PS			ORAL
25 MG DAILY							
	Diarrhoea	Health					
PO							
	Flatulence	Professional	Flomax (Tamsulosin Hydrochloride)	C			
			Naprosyn	C			
			Prevacid	C			
			Ibuprofen	C			

Date:08/21/01ISR Number: 3781601-0Report Type:Expedited (15-DaCompany Report #WAES 01083449
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign	Tab Vioxx					
Other		Other	(Rofecoxib)	PS				

Date:08/21/01ISR Number: 3781602-2Report Type:Expedited (15-DaCompany Report #WAES 01085548
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fatigue	Foreign	Vioxx	PS		ORAL		
PO							14	DAY
Hospitalization -	Gastric Haemorrhage	Health	Hyzaar	C				
Initial or Prolonged	Melaena	Professional	Prednisone	C				
			Propranolol Hci	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/21/01ISR Number: 3781632-0Report Type:Expedited (15-DaCompany Report #WAES 01073558
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Dementia	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL	PO	
			Allopurinol	C				
			Propranolol Hcl	C				
			Valproate Sodium	C				
			Warfarin	C				

Date:08/22/01ISR Number: 3781721-0Report Type:Direct Company Report #
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Pulmonary Embolism		Vioxx	PS	Merck	ORAL	25 MG ONCE DAILY ORAL	

Date:08/22/01ISR Number: 3781899-9Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis Nausea		Rofecoxib (Vioxx)	PS				

Date:08/22/01ISR Number: 3781931-2Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Vioxx	PS		ORAL	25 MG PO	DAILY
	Confusional State							
	Hallucination		Donepozil	C				
			Mirtazapine	C				
			Lansoprazole	C				
			Citrucel	C				
			Ceftriaxone	C				
			Azithromycin	C				
			Alprazolam	C				

Date:08/22/01ISR Number: 3781943-9Report Type:Expedited (15-DaCompany Report #WAES 01050858
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Potassium Decreased
Hospitalization - Initial or Prolonged	Blood Sodium Decreased
	Body Temperature Increased
	Csf Glucose Abnormal
	Csf Lymphocyte Count Increased
	Csf Neutrophil Count

	Positive Csf Protein Increased Csf White Blood Cell Count Positive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25
	Haematocrit Decreased	Professional					MG/DAILY/PO
	Haemoglobin Decreased		Tylenol With Codeine				
	Headache		# 3	C			
	Meningitis Aseptic		Azathioprine	C			
	Nuclear Magnetic		Dietary Supplement				
	Resonance Imaging		(Unspecified)	C			
	Abnormal		Hydroxychloroquine				
	Photophobia		Sulfate	C			
	Red Blood Cells Csf		Prednisone	C			
	Positive						
	Vomiting						
	White Blood Cell Count						
	Decreased						

Date:08/22/01ISR Number: 3781944-0Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Haemorrhoids		Vioxx 25mg Merck	PS	Merck	ORAL	1-DAILY ORAL
	Rectal Haemorrhage		Vasotec	C			
			Lanoxin	C			
			Ranitidine	C			
			Aspirin	C			
			Ferrous Sulfate	C			
			Detrol	C			
			Decusate Sodium	C			

Date:08/22/01ISR Number: 3781957-9Report Type:Expedited (15-DaCompany Report #WAES 01042077
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25

Hospitalization - MG/DAILY/PO	Blood Glucose Increased	Professional		
Initial or Prolonged Disability	Blood Sodium Decreased		Keflex	SS
Other	Cardiac Failure		Calan Sr	C
	Congestive		Fosamax	C
	Fall		K-Dur	C
	Fluid Overload		Lozol	C
	Gastrointestinal		Prevacid	C
	Haemorrhage		Ibuprofen	C
	Oxygen Saturation Decreased			
	Pco2 Decreased			
	Pneumonia			
	Pulmonary Embolism			
	Pulmonary Oedema			
	Renal Failure Acute			
	Respiratory Failure			
	White Blood Cell Count Increased			

Date:08/22/01ISR Number: 3781959-2Report Type:Expedited (15-DaCompany Report #WAES 01051404
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Diverticulum Intestinal	Professional	Tylenol	C				
	Duodenitis		Therapy Unspecified	C				
	Gastritis Erosive							
	Headache							
	Osteoarthritis							
	Rotator Cuff Syndrome							
	Ultrasound Liver Abnormal							

Date:08/22/01ISR Number: 3781960-9Report Type:Expedited (15-DaCompany Report #WAES 01072916
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antibody Test Positive	Health	Tab Vioxx	PS		ORAL	PO	
	Antinuclear Antibody Positive	Professional	Evista	SS				
	Systemic Lupus Erythematosus							
	Systemic Lupus Erythematosus Rash							

Date:08/22/01ISR Number: 3781964-6Report Type:Expedited (15-DaCompany Report #WAES 01089714
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
Other		Professional						

Date:08/22/01ISR Number: 3782076-8Report Type:Expedited (15-DaCompany Report #WAES 01087802
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign Health Professional	Vioxx	PS		ORAL	25 MG/DAILY, PO	

Date:08/22/01ISR Number: 3782085-9Report Type:Expedited (15-DaCompany Report #WAES 01085560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia Sedation	Foreign Health Professional	Vioxx	PS		ORAL	PO	

Date:08/22/01ISR Number: 3782091-4Report Type:Expedited (15-DaCompany Report #WAES 01079007
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Blood Disorder Blood Lactate

	Dehydrogenase Increased Blood Urea Increased Dermatitis Diarrhoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Eosinophilia Haemoglobin Decreased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY 5 DAY
	Hepatitis Leukocytosis Liver Function Test Abnormal Mucosal Inflammation Pyrexia Renal Failure Acute	Professional					

Date:08/22/01ISR Number: 3782094-XReport Type:Expedited (15-DaCompany Report #WAES 01055553
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization -	Agranulocytosis Leukopenia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY
Initial or Prolonged	Thrombocytopenia	Professional	Tab Methotrexate	SS		ORAL	10 MG/WKY
		Other	Orso Penicillin (Unspecified)	SS		ORAL	10000 IU/TID 8 DAY
			Tab Prednisolone	SS		ORAL	7.5 MG

Date:08/22/01ISR Number: 3782109-9Report Type:Expedited (15-DaCompany Report #WAES 01081515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident	Health	Vioxx	PS		ORAL	25
		Professional					MG/DAILY/PO
		Company Representative					

Date:08/22/01ISR Number: 3782116-6Report Type:Expedited (15-DaCompany Report #WAES 01080757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	[Therapy Unspecified]	C				

Date:08/22/01ISR Number: 3782160-9Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Aphasia
	Asthenia
	Balance Disorder
	Blood Pressure Increased
	Confusional State
	Coordination Abnormal
	Difficulty In Walking
	Disorientation
	Dizziness
	Drug Interaction

		Dry Skin					
		Dysarthria					
		Dysphagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Emotional Distress	Professional				
MG/DAILY/ORAL							
		Feeling Abnormal	Company	Anafranil	SS		
25 MG/BID							
		Gait Disturbance	Representative	Klonopin	SS		
0.5 MG/BID							
		Headache		Lamictal	SS		
100 MG/BID							
		Mental Disorder		Wellbutrin	SS		
150 MG/BID							
		Mental Impairment		Dipentum	SS		
250 MG							
		Motor Dysfunction		Premarin	SS		
1.25 MG/DAILY							
		Respiratory Rate		Zoloft	SS		
100 MG/DAILY							
		Increased		Coumadin	C		
		Restlessness		Motrin	C		
		Skin Warm		Lithium Carbonate	C		
		Speech Disorder					
		Transient Ischaemic					
		Attack					
		Vision Blurred					

Date:08/22/01ISR Number: 3782162-2Report Type:Expedited (15-DaCompany Report #WAES 01038527
Age:52 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Carpal Tunnel Syndrome	Foreign	Tab Vioxx			
		Fluid Retention	Health	(Rofecoxib)	PS		ORAL
PO							
		Neuropathy Peripheral	Professional				
		Pain In Extremity					
		Pulmonary Oedema					
		Swelling					
		Tendonitis					
		Weight Increased					

Date:08/22/01ISR Number: 3782163-4Report Type:Expedited (15-DaCompany Report #WAES 01080919
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 7 DAY
	Leukopenia							
	Platelet Count Decreased							
	Pyrexia							

Date:08/22/01ISR Number: 3782165-8Report Type:Expedited (15-DaCompany Report #WAES 01073562
Age:73 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 3 DAY
	Cardiac Failure							
	Congestive							
	Condition Aggravated		Cap Tramadol Hcl	SS		ORAL	150 MG/DAILY	PO 3 DAY
	Dyspnoea							
	Oedema Peripheral		Albuterol Sulfate	C				
			Formoterol Fumarate	C				
			Furosemide	C				
			Ipratropium Bromide	C				
			Potassium Chloride	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/01ISR Number: 3782166-XReport Type:Expedited (15-DaCompany Report #WAES 01073867
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Increased	Foreign	Tab Vioxx					
	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Haemorrhage	Professional					PO	
			Acetaminophen (+)					
			Codeine	C				
			Hydrochloroquineso4	C				

Date:08/22/01ISR Number: 3782211-1Report Type:Expedited (15-DaCompany Report #WAES 01072862
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
Disability	Colonoscopy Abnormal	Professional	Glucophage	C				
	Gastrointestinal	Company	Zocor	C				
	Haemorrhage	Representative	Aspirin	C				
			Glyburide	C				

Date:08/22/01ISR Number: 3782212-3Report Type:Expedited (15-DaCompany Report #WAES 01080181
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:08/22/01ISR Number: 3782213-5Report Type:Expedited (15-DaCompany Report #WAES 01080595
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Chest Pain	Health	Allegra D	C				
	Gastrointestinal	Professional	Cardizem	C				
	Haemorrhage		Prevacid	C				
	Insomnia		Tranxene	C				
	Pallor		Zocor	C				
			Carbidopa (+)					
			Levodopa	C				
			Ibuprofen	C				

Date:08/22/01ISR Number: 3782214-7Report Type:Expedited (15-DaCompany Report #WAES 01080123
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Aphasia	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Blood Pressure Decreased	Professional	Flexeril	C				
Other	Blood Pressure Increased	Company	Percocet	C				
	Hypertension	Representative	Soma	C				
	Orthostatic Hypotension		Ibuprofen	C				
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/01ISR Number: 3782216-0Report Type:Expedited (15-DaCompany Report #WAES 01081420
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Albuterol	C				
			Ibuprofen	C				
			Theophylline	C				

Date:08/22/01ISR Number: 3782217-2Report Type:Expedited (15-DaCompany Report #WAES 01042842
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	4 MON
		Company Representative						

Date:08/22/01ISR Number: 3782234-2Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx 25 Mg	PS		ORAL	1 PER	ORAL
	Balance Disorder							
	Blood Pressure Increased							
	Disorientation							
	Dizziness							
	Dyspnoea							
	Fall							
	Fatigue							
	Laceration							
	Subcutaneous Haematoma							

Date:08/22/01ISR Number: 3782347-5Report Type:Expedited (15-DaCompany Report #WAES 01062543
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephropathy Toxic	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:08/22/01ISR Number: 3782348-7Report Type:Expedited (15-DaCompany Report #WAES 01071653
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Asthenia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL		
Initial or Prolonged	Blood Chloride Decreased		Aleve	C				
Other	Blood Glucose Decreased		Excedrin Extra-Strength	C				
	Dehydration		Tylenol	C				
	Diarrhoea		Tylenol With Codeine #3	C				
	Hepatitis		Aspirin	C				
	Leukopenia		Atenolol	C				
	Pain		Folic Acid	C				
	Pancytopenia		Pyridoxine	C				
	Renal Failure							
	Thrombocytopenia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/01ISR Number: 3782283-4Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lacrimation Increased Nausea Pruritus Urticaria Vomiting		Rofecoxib	PS				

Date:08/23/01ISR Number: 3782459-6Report Type:Direct Company Report #
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Disturbance		Vioxx	PS				

Date:08/23/01ISR Number: 3782763-1Report Type:Expedited (15-DaCompany Report #2001UW09975
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Drug Interaction Renal Failure	Foreign Health Professional Other	Zestril Vioxx	PS SS				

Date:08/27/01ISR Number: 3782980-0Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS				

Date:08/27/01ISR Number: 3782987-3Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Convulsion		Vioxx	SS				
	Fall		Celebrex	SS				
	Head Injury		Neurontin	C				
	Headache							
	Inflammation							
	Migraine							
	Mucous Membrane Disorder							
	Pruritus							
	Sinus Headache							
	Swelling							

Date:08/27/01ISR Number: 3783269-6Report Type:Expedited (15-DaCompany Report #WAES 01081866
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID/PO	
Hospitalization -	Increased	Professional						
Initial or Prolonged		Company						
Other		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/01ISR Number: 3783348-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx Merck	PS	Merck			
Hospitalization -			Glucophage	C				
Initial or Prolonged			Verapamil	C				
			Zocor	C				
			Toprol Xl	C				
			Diovan	C				
			Avandia	C				

Date:08/28/01ISR Number: 3783351-3Report Type:Direct Company Report #
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Hypersensitivity		Vioxx 12.5 And 50 Mg	PS		ORAL	12.5 ON 4/03	
Initial or Prolonged							ORAL, 50 MG	
							ON 4/09 ORAL	

Date:08/28/01ISR Number: 3783370-7Report Type:Direct Company Report #
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg	PS		ORAL	25 MG Q DAY	
							PO	2 MON
			Keflex	C				
			Prempro	C				
			Folic Acid	C				
			Atenolol	C				
			Lipitor	C				
			Asa	C				
			Methotrexate	C				
			Prilosec	C				

Date:08/28/01ISR Number: 3783903-0Report Type:Direct Company Report #
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS			UNKNOWN	
	Fatigue							
	Malaise							
	Weight Increased							

Date:08/28/01ISR Number: 3783912-1Report Type:Expedited (15-DaCompany Report #WAES 01070621
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Dyspnoea	Professional	Tylenol	C				
	Haemoptysis		Valium	C				
	Pneumonia		Vicodin Tablets	C				
	Pulmonary Fibrosis		Zestril	C				
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/01ISR Number: 3783938-8Report Type:Expedited (15-DaCompany Report #WAES 01081452
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
Hospitalization -	Dyspnoea							
Initial or Prolonged								

Date:08/28/01ISR Number: 3783940-6Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx (25mg)	PS		ORAL	25MG 1T PO QD	
Hospitalization -	Myocardial Infarction		Lipitor	C				
Initial or Prolonged			Atenolol	C				
Required			Ambien	C				
Intervention to			Allopurinol	C				
Prevent Permanent			Asa	C				
Impairment/Damage								

Date:08/28/01ISR Number: 3783971-6Report Type:Direct Company Report #
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis		Vioxx	PS		ORAL	ORAL	
Initial or Prolonged	Renal Failure Acute		Bactrim	C				
			Clotrimazole	C				
			Combivir	C				
			Indinavir	C				
			Prilosec	C				
			Lopid	C				
			Buspar	C				
			Pancrase	C				
			Inderal	C				
			Celexa	C				
			Depo-Testosterone	C				

				Elavil	C		
				Cardiazem	C		
				Colace	C		
				Zanaflex	C		

Date:08/28/01ISR Number: 3784159-5Report Type:Expedited (15-DaCompany Report #US008824
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Provigil	PS		ORAL	200 MG QD	
Initial or Prolonged	Dyspnoea	Professional				ORAL		
	Dysuria		Vioxx	SS		ORAL	12.5 MG QD	
	Fall					ORAL		
	Laceration		Betaseron	SS		SUBCUTANEOUS	3 CC QOD	
	Livedo Reticularis					SUBCUTANEOUS	1 YR	
	Mental Impairment		Wellbutrin	C				
	Oedema Peripheral		Procarin Patch	C				
	Rash Macular		Amantadine	C				
	Renal Disorder		Multivitamins	C				
	Serum Sickness							
	Status Epilepticus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/01ISR Number: 3784167-4Report Type:Expedited (15-DaCompany Report #WAES 01088234
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Diarrhoea	Health	(Rofecoxib)	PS		ORAL	5MG/DAILY PO	8 DAY
	Vomiting	Professional	Acetaminophen	C				
			Potassium (Unspecified)	C				
			Sulfamethoxazole/Trimethoprim	C				
			Suriclone	C				

Date:08/28/01ISR Number: 3784172-8Report Type:Expedited (15-DaCompany Report #WAES 01087802
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epilepsy	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/BID:PO	

Date:08/28/01ISR Number: 3784173-XReport Type:Expedited (15-DaCompany Report #WAES 01085533
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mediastinitis	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Oesophageal Perforation	Health	(Rofecoxib)	PS		ORAL	1 TABLET/BID:PO	22 DAY
	Pneumomediastinum	Professional						

Date:08/28/01ISR Number: 3784177-7Report Type:Expedited (15-DaCompany Report #WAES 01083717
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY: PO	
			Noroxin	C				
			Aspirin Calcium	C				
			Diazepam	C				
			Diclofenac Sodium (+) Misoprostol	C				
			Distigmine Bromide	C				
			Furosemide	C				
			Nitrazepam	C				

Date:08/28/01ISR Number: 3784180-7Report Type:Expedited (15-DaCompany Report #WAES 01075024
Age:55 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY:PO	8 DAY
			Acetaminophen/Codeine Phosphate	C				
			Citalopram Hydrobromide	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/01ISR Number: 3784217-5Report Type:Expedited (15-DaCompany Report #WAES 01072467
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health	Tab Vioxx	PS		ORAL	UNK/UNK/ORAL	
	Cardiomegaly	Professional	Ibuprofen	C				
	Coma							
	Coronary Artery Atherosclerosis							
	Gastritis Haemorrhagic							
	Glomerulonephritis Proliferative							
	Hepatic Congestion							
	Hepatic Steatosis							
	Myocardial Fibrosis							
	Nervous System Disorder							
	Pancreatic Disorder							
	Periportal Sinus Dilatation							
	Pulmonary Congestion							
	Pulmonary Oedema							
	Renal Disorder							
	Scar							
	Toxicologic Test Abnormal							

Date:08/28/01ISR Number: 3784223-0Report Type:Expedited (15-DaCompany Report #WAES 01081647
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:08/28/01ISR Number: 3784235-7Report Type:Expedited (15-DaCompany Report #WAES 01081792
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS	ORAL 25 MG/DAILY/PO
	Eye Disorder	Professional			
			Plavix(Composition Unspecified)	C	
			[Therapy Unspecified]	C	
			Aspirin	C	
			Nitroglycerin	C	

Date:08/28/01ISR Number: 3784241-2Report Type:Expedited (15-DaCompany Report #WAES 01030393
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accident
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased
Other	Blood Sodium Decreased
	Body Temperature Increased
	Diabetes Mellitus
	Gastrointestinal

		Haemorrhage Hip Fracture Hypoaesthesia Peripheral Coldness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Tab Vioxx 25 Mg	PS		ORAL
25							
			Professional				
MG/DAILY/PO							
			Other	Ambien	C		
				Buspar	C		
				Lanoxin	C		
				Prilosec	C		
				Zantac	C		
				Insulin Human, Isophane	C		
				Flexeril	C		

Date:08/28/01ISR Number: 3784245-XReport Type:Expedited (15-DaCompany Report #WAES 01081683
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Joint Swelling	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

Date:08/28/01ISR Number: 3784256-4Report Type:Expedited (15-DaCompany Report #WAES 01081879
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Dysarthria	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/AM/PO						
Hospitalization - Initial or Prolonged	Hallucination		Advair Diskus	C		
	Speech Disorder		Elavil	C		
	Throat Tightness		Neurontin	C		
	Transient Ischaemic Attack		Premarin	C		
			Singulair	C		
			Synthroid	C		
			Zoloft	C		
			Zyrtec	C		

			Albuterol	C		
			Medroxyprogesterone Acetate	C		

Date:08/28/01ISR Number: 3784257-6Report Type:Expedited (15-DaCompany Report #WAES 01065552
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Foreign	Tab Vioxx					
Hospitalization -	Cerebrovascular Accident	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Monoparesis							
PO								
			Cratageus	C				
			Estrogens	C				

Date:08/28/01ISR Number: 3784261-8Report Type:Expedited (15-DaCompany Report #WAES 01081866
Age:91 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG/BID/PO	3 DAY

Date:08/28/01ISR Number: 3784264-3Report Type:Expedited (15-DaCompany Report #WAES 01081066
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Aldactone	C				
			Avapro	C				

Date:08/28/01ISR Number: 3784484-8Report Type:Periodic Company Report #S01-USA-01356-01
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test Abnormal	Health Professional	Celexa (Citalopram Hydrobromide)	PS		ORAL	20 MG QD PO	
			Ambien (Zolpidem Tartrate)	SS		ORAL	10 MG QOD PO	
			Vioxx (Rofecoxib)	SS			25 MG QD	
			Simvastatin	C				
			Enalapril	C				
			Cyclophosphamide	C				
			Furosemide	C				
			Halcion (Triazolam)	C				

Date:08/29/01ISR Number: 3784136-4Report Type:Expedited (15-DaCompany Report #WAES 01085120
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:08/29/01ISR Number: 3785147-5Report Type:Expedited (15-DaCompany Report #WAES 01052758
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tamoxifen	C				

Date:08/29/01ISR Number: 3785299-7Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion Fall Head Injury Headache Increased Viscosity Of Bronchial Secretion Migraine

	Pruritus Sinus Headache Swelling	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Wellbutrin Tablet-Controlled Release (Bupropion Hydrochloride)	PS	Glaxosmithkline	ORAL	150 MG/ PER DAY / ORAL
			Rofecoxib (Formulation Unknown) (Rofecoxib)	SS			
			Celecoxib (Formulation Unknown) (Celecoxib)	C			
			Gabapentin	C			

Date:08/30/01ISR Number: 3785240-7Report Type:Direct Company Report #
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chest Pain		Vioxx (25mg) (Merck)	PS	Merck	ORAL	50 MG PO QD

Date:08/30/01ISR Number: 3785929-XReport Type:Direct Company Report #
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Renal Failure Acute		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG Q6H PRN ORAL
			Vasotec	SS		ORAL	5 MG QD ORAL
			Synthroid	C			
			Keflex	C			
			Flexeril	C			

Date:08/31/01ISR Number: 3786639-5Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Tongue Oedema		Celebrex 100 Mg (Pfizer)	PS	Pfizer	ORAL
100 MG PO BID						
			Vioxx	SS		
			Premarin	C		
			Asa	C		
			Hctz	C		
			Toprol Xl	C		
			Zocor	C		
			Claritin	C		
			Nasonex	C		
			Vitamin E	C		

Date:08/31/01ISR Number: 3786777-7Report Type:Expedited (15-DaCompany Report #WAES 01087802
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Epilepsy Migraine	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/BID						
		Professional				
PO						

Date:08/31/01ISR Number: 3786778-9Report Type:Expedited (15-DaCompany Report #WAES 01068528
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis	Foreign	Tab Vioxx					
Hospitalization -		Health	(Refecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional						
PO							3	DAY
			Ciprofloxacin Hydrochloride	C				
			Codeine	C				
			Diazepam	C				
			Oxazepam	C				
			Verapamil Hcl	C				
			Warfarin Sodium	C				

Date:08/31/01ISR Number: 3786780-7Report Type:Expedited (15-DaCompany Report #WAES 01075589
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx					
Initial or Prolonged	Gastrooesophageal Reflux	Health	(Rofecoxib)	PS		ORAL	1	
	Disease	Professional					TABLET/DAILY	
	Pancytopenia							
PO							11	DAY
	Weight Decreased		Tab Trimipramine Maleate	SS		ORAL	1	
							TABLET/DAILY	
PO							11	DAY

Date:08/31/01ISR Number: 3786792-3Report Type:Expedited (15-DaCompany Report #WAES 01035188
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Abnormal Dreams	Foreign	Tab Vioxx				
	Akathisia	Health	(Rofecoxib)	PS			ORAL
25 MG/DAILY 163 DAY							
	Pruritus	Professional	Ascorbic Acid (+)				
	Restless Legs Syndrome		Dimethyl Sulfone	C			
			Ethinyl				
			Estradiol/Norgestrel	C			
			Valerian	C			

Date:08/31/01ISR Number: 3786796-0Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation	Foreign	Tab Vioxx			
Initial or Prolonged	Cardiac Failure	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY 115 DAY						
Other	Congestive	Health	Beclomethasone			
	Fluid Retention	Professional	Dipropionate	C		
	International Normalised		Hydrocortisone/Neomy			
	Ratio Increased		cinso4/Polymyxin Bso	C		
	Weight Increased		Ispaghula Husk	C		
			Nystatin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3786799-6Report Type:Expedited (15-DaCompany Report #WAES 01073467
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					
Hospitalization -	Gastroenteritis	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	17 DAY
Initial or Prolonged	Helicobacter	Professional	Tab Aspirin Calcium	SS		ORAL	150 MG/DAILY	
			Zocor	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Irbesartan	C				

Date:08/31/01ISR Number: 3786802-3Report Type:Expedited (15-DaCompany Report #WAES 01083501
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL		
		Professional						

Date:08/31/01ISR Number: 3786808-4Report Type:Expedited (15-DaCompany Report #WAES 01089002
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Foreign	Tab Vioxx	PS		ORAL	25 MG PO	
	Paraesthesia	Other						
BATCH								
#HM77690							3	DAY
			Apazone	C				
			Bisoprolol Fumarate	C				
			Captopril	C				

Date:08/31/01ISR Number: 3786810-2Report Type:Expedited (15-DaCompany Report #WAES 01089615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Foreign	Tab Vioxx	PS		ORAL	50 MG DAILY	
Hospitalization -	Chest Pain	Other					ORAL; 25 MG	
Initial or Prolonged	Dyspnoea						DAILY ORAL	11 DAY
Disability	Face Oedema		Amoxicillin					
	Lower Respiratory Tract		Trihydrate (+)					
	Infection		Clavulanate P	C				
	Pleuritic Pain		Prednisone	C				

Date:08/31/01ISR Number: 3786812-6Report Type:Expedited (15-DaCompany Report #WAES 01076070
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis	Foreign	Vioxx (Rofecoxib)					
Initial or Prolonged	Gastrointestinal	Other	Tab	PS		ORAL	25 MG DAILY	
	Haemorrhage							
ORAL	3 DAY							
	Haemoglobin Decreased							

Date:08/31/01ISR Number: 3786817-5Report Type:Expedited (15-DaCompany Report #WAES 01089617
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism	Foreign	Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	1 DAY
Life-Threatening	Renal Failure	Other						
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:08/31/01ISR Number: 3786818-7Report Type:Expedited (15-DaCompany Report #WAES 01089138
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Impairment	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	
Hospitalization -		Other						
Initial or Prolonged							ORAL	1 DAY

Date:08/31/01ISR Number: 3786820-5Report Type:Expedited (15-DaCompany Report #WAES 01089307
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	2 MON
			Midazolam Hcl	C				

Date:08/31/01ISR Number: 3786822-9Report Type:Expedited (15-DaCompany Report #WAES 01089133
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Face Oedema	Foreign	Tab Vioxx				
	Oedema Peripheral	Other	(Rofecoxib)	PS			ORAL
PO 3 DAY							
	Oliguria						

Date:08/31/01ISR Number: 3786824-2Report Type:Expedited (15-DaCompany Report #WAES 01088591
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Foreign	Tab Vioxx			
Initial or Prolonged	Ulcer	Health	(Rofecoxib)	PS		ORAL
25 MG/BID PO						
		Professional				

Date:08/31/01ISR Number: 3786827-8Report Type:Expedited (15-DaCompany Report #WAES 01085173
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anorectal Disorder	Foreign	Tab Vioxx			
Initial or Prolonged	Gastrointestinal Ulcer	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
	Rectal Haemorrhage					
PO; 12.5						
MG/BID 18 DAY						
			Acetaminophen	C		
			Aspirin/Dipyridamole	C		
			Oxazepam	C		
			Tramadol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3786829-1Report Type:Expedited (15-DaCompany Report #WAES 01085170
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Doxazosin	C				
			Nifedipine	C				

Other
PO 41 DAY

Date:08/31/01ISR Number: 3786831-XReport Type:Expedited (15-DaCompany Report #WAES 01083716
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Exacerbated	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Fosamax	C				
			Acetylcysteine	C				
			Albuterol Sulfate	C				
			Calcium Carbonate	C				
			Captopril	C				
			Fluticasone Propionate	C				
			Ipratropium Bromide	C				
			Salmeterol Xinafoate	C				
			Sulfamethoxazole/Trimethoprim	C				
			Tramadol Hcl	C				
			Vitamin B Complex	C				

PO 1 DAY

Date:08/31/01ISR Number: 3786832-1Report Type:Expedited (15-DaCompany Report #WAES 01086028
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx					

Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Gastritis					
PO 5 DAY						
	Haematemesis		Acetaminophen/Propox			
	Melaena		yphene Hydrochloride	C		
	Petechiae					

Date:08/31/01ISR Number: 3786854-0Report Type:Expedited (15-DaCompany Report #WAES 01085576
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Agitation	Foreign	Tab Vioxx			
	Blood Pressure Increased	Consumer	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Eye Disorder					
PO 1 DAY						
	Melanodermia					
	Visual Disturbance					

Date:08/31/01ISR Number: 3786855-2Report Type:Expedited (15-DaCompany Report #WAES 01085573
Age:78 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angioneurotic Oedema Blood Creatinine Increased Blood Potassium Decreased Drug Interaction Haemoglobin Decreased	Foreign Other	Tab Vioxx (Rofecoxib) Tab Vasotec (Enalapril Maleate)	PS SS		ORAL ORAL	25 MG PO 5 MG PO	

Date:08/31/01ISR Number: 3786856-4Report Type:Expedited (15-DaCompany Report #WAES 01088237
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fixed Eruption	Foreign Other	Tab Vioxx (Rofecoxib) Acetaminophen	PS C		ORAL	SEE IMAGE	11 DAY

Date:08/31/01ISR Number: 3786857-6Report Type:Expedited (15-DaCompany Report #WAES 01088235
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise Nausea	Foreign Other	Tab Vioxx (Rofecoxib) Acetaminophen Calcium (Unspecified) (+) Vitamin D (Uns Ibuprofen Ranitidine Hcl	PS C C C C		ORAL	50 MG / DAILY PO	3 DAY

Date:08/31/01ISR Number: 3786859-XReport Type:Expedited (15-DaCompany Report #WAES 01085593
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma Circulatory Collapse Dermatitis Atopic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG / DAILY PO	

Date:08/31/01ISR Number: 3786861-8Report Type:Expedited (15-DaCompany Report #WAES 01088587
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Health Professional	Tab Vioxx (Rofecoxib) [Therapy Unspecified]	PS C		ORAL	SEE IMAGE	22 DAY

Date:08/31/01ISR Number: 3786895-3Report Type:Expedited (15-DaCompany Report #WAES 01085159
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx Prinivil Zocor	PS C C		ORAL	12.5 MG/DAILY	93 DAY

Amiodarone	C
Furosemide	C
Hydralazine	C
Isosorbide Mononitrate	C
Levothyroxine Na	C

Date:08/31/01ISR Number: 3786897-7Report Type:Expedited (15-DaCompany Report #WAES 01085157
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Foreign	Tab Vioxx	PS		ORAL	25 MG/DAILY	177 DAY
Initial or Prolonged	Oesophagitis	Other	Acetaminophen/Codein					
	Upper Gastrointestinal		e Phosphate	C				
	Haemorrhage		Albuterol Sulfate	C				
			Aluminum Hydroxide/Magnesium					
			Carbonate	C				
			Amitriptyline	C				
			Beclomethasone Dipropionate	C				
			Furosemide	C				
			Nifedipine	C				

Date:08/31/01ISR Number: 3786898-9Report Type:Expedited (15-DaCompany Report #WAES 01085139
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Tab Vioxx	PS		ORAL	12.5 MG/DAILY	398 DAY
	Faeces Discoloured	Other	Nitrazepam	C				
	Gastrointestinal Haemorrhage							

Date:08/31/01ISR Number: 3786900-4Report Type:Expedited (15-DaCompany Report #WAES 01085132
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Foreign	Tab Vioxx	PS		ORAL	12.5 MG/DAILY	3 DAY
Initial or Prolonged	Myocardial Infarction	Other	Aspirin	C				
Other	Pulmonary Oedema		Furosemide	C				
			Ibuprofen	C				
			Lansoprazole	C				
			Ramipril	C				

Date:08/31/01ISR Number: 3786950-8Report Type:Expedited (15-DaCompany Report #WAES 01085105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Immobile	Foreign	Tab Vioxx					
	Muscle Disorder	Health	(Rofecoxib)	PS		ORAL	12.5	
	Oedema Peripheral	Professional						
	Pain In Extremity						MG/DAILY, PO	6 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3786952-1Report Type:Expedited (15-DaCompany Report #WAES 01088239
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ascites	Foreign	Tab Vioxx					
	Oedema Peripheral	Health	(Rofecoxib)	PS		ORAL	25 MG/BID, PO	13 DAY
		Professional						

Date:08/31/01ISR Number: 3786953-3Report Type:Expedited (15-DaCompany Report #WAES 01085158
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena	Foreign	Tab Vioxx	PS		ORAL	12.5 MG/BID,	
Initial or Prolonged		Other					PO	9 DAY
			Furosemide	C				
			Metoprolol	C				
			Spironolactone	C				

Date:08/31/01ISR Number: 3786977-6Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Erosive	Health	Tab Vioxx 25 Mg	PS	Merck	ORAL	PO	
Hospitalization -	Gastrointestinal Disorder	Professional						
Initial or Prolonged	Gastrointestinal	Company						
Disability	Haemorrhage	Representative						
Other								

Date:08/31/01ISR Number: 3786980-6Report Type:Expedited (15-DaCompany Report #WAES 01082387
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 25 MG/BID/PO	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS	Merck	ORAL
Initial or Prolonged			Cardizem	C		
			Cozaar	C		
			Lanoxin	C		
			Lasix (Furosemide)	C		
			Plavix	C		
			Aspirin	C		
			Potassium (Unspecified)	C		

Date:08/31/01ISR Number: 3786981-8Report Type:Expedited (15-DaCompany Report #WAES 01082092
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - PO	Cardiac Disorder	Health	Tab Vioxx Unk	PS		ORAL
Initial or Prolonged	Gastric Ulcer	Professional	Ecotrin	C		

Date:08/31/01ISR Number: 3786988-0Report Type:Expedited (15-DaCompany Report #WAES 01010889
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Death	Abortion Spontaneous
Congenital Anomaly	Complications Of Maternal Exposure To Therapeutic Drugs

Pregnancy

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Vioxx Unk	PS	Merck	ORAL	PO	
		Professional	Correctol Laxative Tables & Cap	C				
			Acetaminophen	C				
			Calcium	C				

Date:08/31/01ISR Number: 3787011-4Report Type:Expedited (15-DaCompany Report #WAES 01082270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
		Professional						
		Company Representative						

Date:08/31/01ISR Number: 3787013-8Report Type:Expedited (15-DaCompany Report #WAES 01080757
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	No Adverse Drug Effect	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Therapy Unspecified	C				
		Company Representative						

Date:08/31/01ISR Number: 3787017-5Report Type:Expedited (15-DaCompany Report #WAES 01082552
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	

	Coagulation Time Shortened	Professional Company Representative

Date:08/31/01ISR Number: 3787018-7Report Type:Expedited (15-DaCompany Report #WAES 01061051
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, PM, PO	
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Hydrodiuril	C				
Other	Body Temperature Increased		Synthroid	C				
	Choking		Glyburide	C				
	Dry Mouth							
	Hypersensitivity							
	Speech Disorder							

Date:08/31/01ISR Number: 3787019-9Report Type:Expedited (15-DaCompany Report #WAES 01082507
Age:70 YR Gender:Male I/FU:I

Outcome	PT
Death	Retroperitoneal Haemorrhage
	Stupor

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	2 DAY

Date:08/31/01ISR Number: 3787020-5Report Type:Expedited (15-DaCompany Report #WAES 01082433
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:08/31/01ISR Number: 3787021-7Report Type:Expedited (15-DaCompany Report #WAES 01082439
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cerebrovascular Accident							
			Diazide	C				
			Plavix	C				

Date:08/31/01ISR Number: 3787022-9Report Type:Expedited (15-DaCompany Report #WAES 01082557
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:08/31/01ISR Number: 3787023-0Report Type:Expedited (15-DaCompany Report #WAES 01081864
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chromaturia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Feeling Abnormal		Metoprolol	C				

Date:08/31/01ISR Number: 3787024-2Report Type:Expedited (15-DaCompany Report #WAES 01081810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:08/31/01ISR Number: 3787025-4Report Type:Expedited (15-DaCompany Report #WAES 01082348
Age:98 YR Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
			Composition Unspecified	C				

Date:08/31/01ISR Number: 3787027-8Report Type:Expedited (15-DaCompany Report #WAES 01060440
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -		Health						
Initial or Prolonged		Professional	Accupril	C				
Other			Coumadin	C				
			Digitex	C				
			Lipitor	C				
			Xalatan	C				
			Atenolol	C				

Date:08/31/01ISR Number: 3787028-XReport Type:Expedited (15-DaCompany Report #WAES 01050820
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/PR PO	
Hospitalization -	Embolism	Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY	
Initial or Prolonged	Gastrointestinal						PO	
Other	Haemorrhage		Accupril	C				
	Haematochezia		Ecotrin	C				
	Myocardial Infarction		Estratest H.S.	C				
			Plavix	C				
			Pravachol	C				
			Synthroid	C				
			Metoprolol	C				

Date:08/31/01ISR Number: 3787029-1Report Type:Expedited (15-DaCompany Report #WAES 01052397
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Medication Error	Health Professional	Neurontin	C				
			Premarin	C				
			Vicodin Tablets	C				
			Colesevelam Hydrochloride	C				
			Nonsteroidal Anti-Inflammatory	C				
			Vitamins	C				

Date:08/31/01ISR Number: 3787030-8Report Type:Expedited (15-DaCompany Report #WAES 01060705
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative	Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3787031-XReport Type:Expedited (15-DaCompany Report #WAES 01061112
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Pruritus	Health					MG/DAILY/PO	
Initial or Prolonged	Urticaria	Professional	Covera-Hs	C				
	Vomiting		Glucophage	C				
			Hydrodiural	C				
			Prilosec	C				
			Vasotec	C				
			Gemfibrozil	C				
			Glyburide	C				

Date:08/31/01ISR Number: 3787032-1Report Type:Expedited (15-DaCompany Report #WAES 01080757
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Therapy Unspecified	C				
		Company						
		Representative						

Date:08/31/01ISR Number: 3787033-3Report Type:Expedited (15-DaCompany Report #WAES 01061116
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
Other	Haemorrhage	Company	K-Dur	C				
	Hiatus Hernia	Representative	Lasix (Furosemide)	C				
			Monopril	C				
			Proscar	C				

Date:08/31/01ISR Number: 3787035-7Report Type:Expedited (15-DaCompany Report #WAES 01082094
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional	Coumadin	C				
			Aspirin	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							
	Syncope							

Date:08/31/01ISR Number: 3787036-9Report Type:Expedited (15-DaCompany Report #WAES 01082105
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse	Health	Tab Vioxx Unk	PS		ORAL	50	
Initial or Prolonged	Suicide Attempt	Professional					TABLET/1X/PO	
			Tylenol Unk	SS				
UNKNOWN	30 TABLET/1X							
			Aspirin Unk	SS				
URETHRAL	30 TABLET/1X							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3787037-0Report Type:Expedited (15-DaCompany Report #WAES 01081863
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Increased	Professional	Celexa 20 Mg	SS		ORAL	20 MG/DAILY/PO	
	Aspartate Aminotransferase		Ambien 10 Mg	SS		ORAL	10 MG/QOD/PO	
	Increased		Tab Zocor 40 Mg	SS			UNKNOWN	40 MG /DAILY
	Blood Alkaline Phosphatase Increased		Halcion	C				
			Vasotec	C				
			Cyclophosphamide	C				
			Furosemide	C				

Date:08/31/01ISR Number: 3787038-2Report Type:Expedited (15-DaCompany Report #WAES 01082531
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypercalcaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Renal Failure Acute	Professional						
		Company Representative	Cardizem Cd	C				
			Isordil	C				
			Miacalcin	C				
			Prevacid	C				

Date:08/31/01ISR Number: 3787039-4Report Type:Expedited (15-DaCompany Report #WAES 01082532
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Haemorrhage	Professional						

Initial or Prolonged	Gastrointestinal Haemorrhage Haematocrit Decreased Prothrombin Time Prolonged Rectal Haemorrhage Vomiting	Company Representative	Aricept Paxil Sinemet	C C C

Date:08/31/01ISR Number: 3787040-0Report Type:Expedited (15-DaCompany Report #WAES 01070454
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased	Health Professional	Tab Viox 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cardiac Failure Congestive Condition Aggravated Gastrooesophageal Reflux Disease Pulmonary Oedema Renal Impairment	Company Representative	Acid -X Imdur Synthroid Zestril	C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3787041-2Report Type:Expedited (15-DaCompany Report #WAES 01082683
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Haematocrit Decreased	Professional					MG/DAILY/PO	
		Company Representative						

Date:08/31/01ISR Number: 3787049-7Report Type:Expedited (15-DaCompany Report #WAES 01081632
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastroduodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
		Company Representative	Aspirin	C				

Date:08/31/01ISR Number: 3787050-3Report Type:Expedited (15-DaCompany Report #WAES 01081913
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:08/31/01ISR Number: 3787067-9Report Type:Expedited (15-DaCompany Report #WAES 01052411
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Balance Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
	Blood Pressure Increased	Professional				
	Carotid Artery Stenosis	Company	Lasix (Furosemide)	C		
	Cerebrovascular Accident	Representative	Prilosec	C		
	Confusional State		Synthroid	C		
	Coronary Artery Disease		Potassium (Unspecified)	C		
	Difficulty In Walking					
	Headache					

Date:08/31/01ISR Number: 3787068-0Report Type:Expedited (15-DaCompany Report #WAES 01072862
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
Disability	Colonoscopy Abnormal	Professional						
	Erythema	Company	Tab Vioxx	SS		ORAL	12.5 MG/DAILY/PO	
	Gastrointestinal	Representative						
	Haemorrhage		Glucophage	C				
			Zocor	C				
			Aspirin	C				
			Glyburide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/01ISR Number: 3787069-2Report Type:Expedited (15-DaCompany Report #WAES 01081460
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/BID/PO	
	Decreased Appetite	Health	Tab Vioxx	SS		ORAL	25 MG/DAILY/PO	
	Nausea	Professional						
	Nervousness		Cardizem	C				
			Coumadin	C				
			Elavil	C				
			Lanoxin	C				
			Peri-Colace	C				
			Prinivil	C				
			Senokot (Sennosides)	C				
			Aspirin	C				

Date:08/31/01ISR Number: 3787070-9Report Type:Expedited (15-DaCompany Report #WAES 01060788
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional						
		Company Representative	Dyazide	C				
			Naprosyn	C				
			Prozac	C				
			Synthroid	C				
			Atenolol	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:08/31/01ISR Number: 3787071-0Report Type:Expedited (15-DaCompany Report #WAES 01052922
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25mg	PS		ORAL
PO						
Initial or Prolonged	Facial Palsy	Professional	Plaquenil	C		
	Sensation Of Heaviness	Company	Pravachol	C		
		Representative	Premphase	C		
			Calcium (Unspecified)	C		
			Folic Acid	C		
			Methotrexate	C		
			Vitamins (Unspecified)	C		

Date:08/31/01ISR Number: 3787075-8Report Type:Expedited (15-DaCompany Report #WAES 01082091
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Erosive Oesophagitis	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Gastritis	Professional				

Date:08/31/01ISR Number: 3787076-XReport Type:Expedited (15-DaCompany Report #WAES 01081992
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Cardiac Disorder	Health
Initial or Prolonged	Hypertension	Professional

		Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prinivil	C				

Date:08/31/01ISR Number: 3787077-1Report Type:Expedited (15-DaCompany Report #WAES 01081460
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Appetite	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/BID/PO;	
	Nausea						25MG/DAILY/PO	1 DAY
	Nervousness		Cardizem	C				
	Palpitations		Aspirin	C				
			Gastrointestinal Preparations	C				

Date:08/31/01ISR Number: 3787078-3Report Type:Expedited (15-DaCompany Report #WAES 01061041
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged		Health Professional	Antivert	C				
			Carafate	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Levoxyl	C				
			Ms Contin	C				
			Ogen	C				
			Prilosec	C				
			Tenormin	C				
			Digoxin	C				
			Furosemide	C				
			Injectable Gold					

(Unspecified)	C
Potassium (Unspecified)	C

Date:08/31/01ISR Number: 3787079-5Report Type:Expedited (15-DaCompany Report #WAES 00062473
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
Other	Bradycardia
	Brain Neoplasm
	Chills
	Decreased Activity
	Dizziness
	Fatigue
	Feeling Abnormal
	Feeling Jittery
	Gastrointestinal Disorder
	Ill-Defined Disorder
	Insomnia
	Muscle Spasms
	Myocardial Infarction
	Nausea

		Nervous System Disorder					
		Palpitations					
		Parkinson'S Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Vascular	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Disorder	Professional				
MG/DAILY/PO							
		Respiratory Disorder		Inj Cortisone	SS		
		Tremor		Ns Cortisone	SS		
		Visual Disturbance		Fosamax	C		
		Weight Decreased		Calcium Carbonate			
				(+) Vitamin D	C		
				Glucosamine	C		
				Vitamins			
				(Unespecified)	C		

Date:08/31/01ISR Number: 3787080-1Report Type:Expedited (15-DaCompany Report #WAES 00060809
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Chills	Consumer	Tab Vioxx 25mg	PS		ORAL
25 MG/BID/PO							
		Circulatory Collapse	Other	Calciuim			
		Drug Withdrawal Syndrome		(Unspecified)	C		
		Dyspepsia		Garlic Extract	C		
		Early Morning Awakening		Herbs (Unspecified)	C		
		Ecchymosis		Minerals			
		Fall		(Unspecified)	C		
		Feeling Hot And Cold		Vitamin B			
		Head Injury		(Unspecified)	C		
		Headache		Vitamin E	C		
		Hyperhidrosis		Vitamins	C		
		Nausea					
		Syncope					
		Tremor					

Date:08/31/01ISR Number: 3787081-3Report Type:Expedited (15-DaCompany Report #WAES 00062470
Age:75 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Anxiety	Consumer	Tab Vioxx 12.5 Mg	PS	ORAL PO
	Appetite Disorder		Inj Cortisone	SS	INJ
	Asthenia		Lanoxin	C	
	Chills		Aspirin	C	
	Gastrooesophageal Reflux Disease				
	Heart Rate Decreased				
	Ill-Defined Disorder				
	Nausea				
	Palpitations				
	Peripheral Vascular Disorder				
	Tremor				
	Vertigo				

Date:08/31/01ISR Number: 3787086-2Report Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Death	Coronary Artery Atherosclerosis

		Coronary Artery Disease Coronary Artery Occlusion Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Congestion	Health	Tab Vioxx	PS		ORAL
50							
		Ventricular Hypertrophy	Professional				
MG/DAILY/PO							
			Company	Tab Vioxx 25 Mg	SS		ORAL
25							
			Representative				
MG/DAILY/PO							
				Fiorinal	C		
				Midrin	C		
				Relafen	C		
				Zestril	C		
				Composition			
				Unspecified)			
				Capsaicin			
				Chondroitin Sulfate			
				Sodium Nitroglycerin	C		

Date:08/31/01ISR Number: 3788515-0Report Type:Expedited (15-DaCompany Report #WAES 01082089
Age:85 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Haematocrit Decreased	Health	Tab Vioxx	PS		ORAL
PO							
Initial or Prolonged		Haemoglobin Decreased	Professional	Aricept	C		
		Upper Gastrointestinal Haemorrhage					

Date:09/04/01ISR Number: 3786668-1Report Type:Direct Company Report #
Age:60 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Erythema		Vioxx	PS	Merck	ORAL
SEE IMAGE							
		Pruritus		Wellbutrin Xl	C		
				Allopurinol	C		
				Toprol Xl	C		

Saw Palmetto Extract C

Date:09/04/01ISR Number: 3786979-XReport Type:Expedited (15-DaCompany Report #WAES 01070027
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Impairment	Health	Tab Vioxx 25 Mg	PS	Merck	ORAL	25	
Initial or Prolonged	Vomiting	Professional					MG/DAILY/PO	
		Company Representative	Lasix (Furosemide) Unk	SS			40 MG/DAILY	

Date:09/04/01ISR Number: 3787823-7Report Type:Expedited (15-DaCompany Report #US008824
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Dyspnoea
	Dysuria
	Fall
	Laceration
	Livedo Reticularis
	Mental Impairment
	Oedema Peripheral

		Rash Macular Serum Sickness Status Epilepticus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Provigil	PS		ORAL
200 MG QD							
ORAL							
				Vioxx	SS		ORAL
12.5 MG QD							
ORAL							
				Betaseron	SS		
SUBCUTANEOUS	3 CC QOD						
SUBCUTANEOUS	1 YR						
				Wellbutrin	C		
				Procarin Patch	C		
				Amantadine	C		
				Multivitamins	C		

Date:09/04/01ISR Number: 3787997-8Report Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx 12.5mg	PS		ORAL
12.5MG 1 PO							
BID							

Date:09/04/01ISR Number: 3788023-7Report Type:Direct Company Report #
Age:45 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Chest Discomfort Chest Pain		Vioxx 25 Mg Merck & Co. Inc.	PS	Merck & Co. Inc.	ORAL
25 MG /ONCE							
DAILY/ ORAL		Dyspnoea					
		Heart Rate Increased		Nortriptyline	C		
		Oedema Peripheral		Prilosec	C		

Claritin	C
Trazodone	C
Imitrex	C
Ventolin Inhaler	C
Triamcinolone	C
Renova	C
Skelaxin	C
Otc Vitamins	C
Magnesium/Malcic Acid	C
Perdiem	C

Date:09/05/01ISR Number: 3788742-2Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematoma		Vioxx .25mg	PS			.25MG 1	
	Haemorrhagic Stroke						TABLET EVERY	
	Headache						DAY	
	Oedema Peripheral							

Date:09/05/01ISR Number: 3791697-8Report Type:Expedited (15-DaCompany Report #01081230
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Haemorrhage

		Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Enbrel 25 Mg	PS		
SUBCUTANEOUS	25 MG, BIW,						
SUBCUTANEOUS							
				Rofecoxib	SS		
				Prednisone	C		
				Fluoxetine	C		
				Methotrexate	C		

Date:09/06/01ISR Number: 3788557-5Report Type:Direct Company Report #
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Infarction		Vioxx (Merck And Co)	PS	Merck And Co	ORAL
12 1/ 2 -25MG						
Disability						
PO QD	2 YR					
Other						

Date:09/06/01ISR Number: 3789097-XReport Type:Expedited (15-DaCompany Report #PHEH2001US07100
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Difficulty In Walking	Consumer	Starlix(Nateglinide)			
	Drug Interaction	Company	Tablet	PS		ORAL
120 MG, TID,						
	Nausea	Representative				
ORAL						
	Vertigo		Vioxx (Rofecoxib)	SS		ORAL
ORAL	101 DAY					

Date:09/07/01ISR Number: 3789324-9Report Type:Direct Company Report #
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Respiratory Distress		Vioxx Msd	PS	Msd			
			Copd	C				
			Cad	C				
			Hypertension	C				

Date:09/07/01ISR Number: 3789338-9Report Type:Direct Company Report #
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	International Normalised		Vioxx	PS		ORAL	25 MG QD ORAL	
Intervention to	Ratio Increased		Coumadin	SS		ORAL	2 MG/ 4 MG	
Prevent Permanent	Weight Increased						X5/2/ORAL	
Impairment/Damage			Cardizem	C				
			Hctz	C				
			Synthroid	C				
			Dilantin	C				
			Hytrin	C				
			Lasix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3789516-9Report Type:Expedited (15-DaCompany Report #2001COU1249
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis Drug Interaction Ecchymosis Pain Prothrombin Time Prolonged	Health Professional	Coumadin (Crystalline Warfarin Sodium) Vioxx (Rofecoxib) (Glucosamine Chondroitin Ds)	PS SS C		ORAL	PO	

Date:09/07/01ISR Number: 3789526-1Report Type:Expedited (15-DaCompany Report #WAES 01086030
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional Other	Vioxx (Rofecoxib) Piroxicam	PS SS		ORAL ORAL	PO PO	44 DAY 2 DAY

Date:09/07/01ISR Number: 3789527-3Report Type:Expedited (15-DaCompany Report #WAES 01085121
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY PO	

Date:09/07/01ISR Number: 3789529-7Report Type:Expedited (15-DaCompany Report #WAES 01085184
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Malaise	Health						
PO								54 DAY
		Professional	Moduretic	C				
		Other	Acetaminophen/Codeine Phosphate	C				

Date:09/07/01ISR Number: 3789531-5Report Type:Expedited (15-DaCompany Report #WAES 01079702
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Health						
PO								
		Professional	Diclofenac	C				
		Other						

Date:09/07/01ISR Number: 3789572-8Report Type:Expedited (15-DaCompany Report #WAES 01089903
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
Initial or Prolonged		Professional						
PO								3 DAY
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3789624-2Report Type:Expedited (15-DaCompany Report #WAES 01081913
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Perforation	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Norvasc	C				
			Sinemet	C				
			Synthroid	C				

Date:09/07/01ISR Number: 3789643-6Report Type:Expedited (15-DaCompany Report #WAES 01085626
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
	Haemoglobin Decreased	Health Professional Other						

Date:09/07/01ISR Number: 3789647-3Report Type:Expedited (15-DaCompany Report #WAES 01085185
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	50 DAY
	Dyspnoea	Health Professional Other	Ibuprofen	C				
			Omeprazole	C				

Date:09/07/01ISR Number: 3789688-6Report Type:Expedited (15-DaCompany Report #WAES 01075538
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cortisol Abnormal	Foreign	Tab Vioxx					

Initial or Prolonged	Cardiomegaly	Health	(Rofecoxib)	PS		ORAL
PO 25MG/1X						
	Creatinine Renal Clearance Decreased	Professional	Atenolol	C		
	Dizziness					
	Fluid Retention					
	Headache					
	Hepatomegaly					
	Hyponatraemia					
	Limb Discomfort					
	Nausea					
	Oedema					
	Oedema Peripheral					
	Pleural Effusion					
	Vomiting					
	Weight Increased					

Date:09/07/01ISR Number: 3789692-8Report Type:Expedited (15-DaCompany Report #WAES 01083557
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Foreign	Tab Vioxx			
Initial or Prolonged	Haemorrhage	Health	(Rofecoxib)	PS		
		Professional	Aspirin	C		
			Celecoxib	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3789942-8Report Type:Expedited (15-DaCompany Report #WAES 01085593
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY,	
Initial or Prolonged	Circulatory Collapse	Health					PO	
	Dermatitis	Professional						
		Other						

Date:09/07/01ISR Number: 3789943-XReport Type:Expedited (15-DaCompany Report #WAES 01076088
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Herniation	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG, DAILY,	
Initial or Prolonged	Haemorrhagic Stroke	Professional					PO	8 DAY
	International Normalised	Other	Tab Acenocoumarol	SS		ORAL	4 MG, DAILY,	
	Ratio Increased						PO	
	Malaise		Dimethicone	C				
	Prothrombin Time							
	Prolonged							
	Vertigo							

Date:09/07/01ISR Number: 3789944-1Report Type:Expedited (15-DaCompany Report #WAES 01085518
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukaemia	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	Naloxone					
		Other	Hydrochloride (+)					
			Tilidine Hydr	C				

Date:09/07/01ISR Number: 3790066-4Report Type:Expedited (15-DaCompany Report #WAES 01082664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coordination Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
Hospitalization -	Fatigue						PO	
Initial or Prolonged	Haemorrhagic Stroke							
	Headache							
	Skin Discolouration							

Date:09/07/01ISR Number: 3790068-8Report Type:Expedited (15-DaCompany Report #WAES 01082393
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
Initial or Prolonged							PO; 25 MG/	
							QID/ PO	
			Inderal	C				
			Tussionex	C				
			Meprobamate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3790069-XReport Type:Expedited (15-DaCompany Report #WAES 01082715
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
	Feeling Abnormal							
			Prozac	C				
			Amitriptyline Hydrochloride	C				
			Phenobarbital	C				

Date:09/07/01ISR Number: 3790070-6Report Type:Expedited (15-DaCompany Report #WAES 01082590
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Blood Pressure Increased		Adalat	C				
			Glucophage	C				
			Lipitor	C				
			Monopril	C				
			Therapy Unspecified	C				
			Atenolol	C				

Date:09/07/01ISR Number: 3790071-8Report Type:Expedited (15-DaCompany Report #WAES 01082732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Coronary Artery Occlusion							
Disability			Lipitor	C				
			Neurontin	C				
			Aspirin	C				
			Vitamin B Complex	C				

Date:09/07/01ISR Number: 3790072-XReport Type:Expedited (15-DaCompany Report #WAES 01082564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, DAILY, PO	
			Capozide	C				
			Tylenol With Codeine #3	C				
			Captopril	C				
			Glyburide	C				

Date:09/07/01ISR Number: 3790076-7Report Type:Expedited (15-DaCompany Report #WAES 01082544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Urticaria	Professional						
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3790077-9Report Type:Expedited (15-DaCompany Report #WAES 00120395
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	5 DAY
Initial or Prolonged	Confusional State		Dialantin	SS				
	Convulsion		Glucophage	C				
			Hydrodiuril	C				
			Phenobarbital	C				

Date:09/07/01ISR Number: 3790078-0Report Type:Expedited (15-DaCompany Report #WAES 01061881
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysuria	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Muscle Spasms	Professional						
	Oliguria		Atacand	C				
	Urinary Incontinence		Fosamax	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Nesium	C				
			Singulair	C				
			Zyrtec	C				
			Calcium	C				
			Vitamins	C				

Date:09/07/01ISR Number: 3790079-2Report Type:Expedited (15-DaCompany Report #WAES 01072100
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomegaly	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Chest Pain	Health						
	Dyspnoea	Professional	Cozaar	C				
	Dyspnoea Paroxysmal		Glucophage	C				
	Nocturnal		Humulin 30/70	C				

	Exercise Test Abnormal	Tiazac	C
	Tenosynovitis	Xalatan	C
	Ventricular Hypertrophy	Zocor	C
		Aspirin	C
		Diltiazem Hydrochloride	C
		Nitroglycerin	C

Date:09/07/01ISR Number: 3790080-9Report Type:Expedited (15-DaCompany Report #WAES 01081992
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Hypertension	Professional					MG/DAILY/PO	
	Palpitations	Company Representative	Prinivil	C				

Date:09/07/01ISR Number: 3790081-0Report Type:Expedited (15-DaCompany Report #WAES 01081913
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Hospitalization -	Abdominal Pain	Health
Initial or Prolonged	Gastric Perforation	Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Norvasc	C		
			Sinemet	C		
			Synthroid	C		

Date:09/07/01ISR Number: 3790082-2Report Type:Expedited (15-DaCompany Report #WAES 00120395
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Confusional State	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PO	5 DAY					
Initial or Prolonged	Convulsion		Dialantin	C		
			Glucophage	C		
			Hydrodiuril	C		
			Phenobarbital	C		

Date:09/07/01ISR Number: 3790083-4Report Type:Expedited (15-DaCompany Report #WAES 01061881
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dysuria	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Muscle Spasms	Professional				
MG/DAILY/PO						
	Urinary Incontinence		Atacand	C		
			Fosamax	C		
			Lanoxin	C		
			Lasix (Furosemide)	C		
			Nexium	C		
			Singulair	C		
			Zyrtec	C		
			Calcium	C		
			Vitamins	C		

Date:09/07/01ISR Number: 3790084-6Report Type:Expedited (15-DaCompany Report #WAES 01072100
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomegaly	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Chest Pain	Health					MG/DAILY/PO	
	Dyspnoea	Professional	Cozaar	C				
			Glucophage	C				
			Humulin 30/70	C				
			Tiazac	C				
			Xalatan	C				
			Zocor	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Nitroglycerin	C				

Date:09/07/01ISR Number: 3790327-9Report Type:Expedited (15-DaCompany Report #WAES 01082627
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Discomfort	Health	Tab Vioxx	PS		ORAL	PO	
	Erythema	Professional						
	Irritability	Company						
	Perineal Pain	Representative						
	Thermal Burn							

Date:09/07/01ISR Number: 3790329-2Report Type:Expedited (15-DaCompany Report #WAES 01072268
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	50	
Hospitalization -	Anxiety Disorder	Professional					MG/DAILY/PO	
Initial or Prolonged	Chest Pain	Company	Exelon	C				
Other	Confusional State	Representative	Sinemet	C				
	Coordination Abnormal		Zocor	C				
	Crepitations		Aspirn	C				
	Ecchymosis		Diazepam	C				
	Electrocardiogram T Wave		Hydrochlorothiazide					
	Abnormal		(+) Triamter	C				
	Fall		Propranolol	C				
	Gait Disturbance							
	Gastric Ulcer							
	Hallucination, Auditory							
	Memory Impairment							
	Pallor							
	Pulse Absent							
	Renal Failure							
	Spinal Column Stenosis							
	Upper Gastrointestinal							
	Haemorrhage							

Date:09/07/01ISR Number: 3790330-9Report Type:Expedited (15-DaCompany Report #WAES 01082408
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Drug Effect Decreased						MG/DAILY/PO	
	Myocardial Infarction							

Date:09/07/01ISR Number: 3790331-0Report Type:Expedited (15-DaCompany Report #WAES 01082724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Cerebrovascular Accident						MG/DAILY/PO	
			Hydrodiuril	C				
			Lotensin	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/01ISR Number: 3790334-6Report Type:Expedited (15-DaCompany Report #WAES 01082779
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Faecal Incontinence							
	Headache		Claritin	C				
	Vomiting		Fosamax	C				
			Paxil	C				
			Prilosec	C				
			Procardia Xl	C				
			Atenolol	C				

Date:09/07/01ISR Number: 3790344-9Report Type:Expedited (15-DaCompany Report #WAES 01082615
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Influenza Like Illness							
Initial or Prolonged			Ambien	C				
			Norvasc	C				
			Prilosec	C				
			Doxazosin Mesylate	C				
			Famotidine	C				

Date:09/07/01ISR Number: 3790347-4Report Type:Expedited (15-DaCompany Report #WAES 01080252
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -	Periorbital Oedema	Professional						
Initial or Prolonged	Transient Ischaemic Attack	Company Representative						

Date:09/07/01ISR Number: 3790356-5Report Type:Expedited (15-DaCompany Report #WAES 01082469
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Tab Vioxx	PS		ORAL	PO	
	Pancreatitis	Professional	Naproxen	C				

Date:09/10/01ISR Number: 3790059-7Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx (25mg Po Qd)	PS		ORAL	25MG PO QD	
Initial or Prolonged	Gastrointestinal		Prinivil 20mg	SS			20MG BID	
	Haemorrhage		Kdur	C				
	Hyperkalaemia		Warfarin	C				
	Hypoglycaemia		Spironolactone	C				
	Renal Failure		Avandia	C				
	Rhabdomyolysis		Glipizide	C				
			Tricor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/01ISR Number: 3790784-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Post Procedural Complication		Vioxx 12.5 Merck	PS	Merck	
			Dynacirc	C		
	Pulmonary Embolism		Xanax	C		
	Sudden Death					

Date:09/11/01ISR Number: 3790969-0Report Type:Expedited (15-DaCompany Report #WAES 01081810
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaemia	Health	Tab Vioxx	PS		ORAL
PO						
	Bone Marrow Depression	Professional Company Representative				

Date:09/11/01ISR Number: 3790970-7Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastritis Erosive	Health	Tab Vioxx	PS		ORAL
SEE IMAGE						
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder	Professional Company Representative				
Disability	Gastrointestinal Haemorrhage					
Other						

Date:09/11/01ISR Number: 3790973-2Report Type:Expedited (15-DaCompany Report #WAES 01082507
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Nausea	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
Hospitalization -	Retroperitoneal	Professional				

Initial or Prolonged	Haemorrhage Stupor Vomiting	Company Representative

Date:09/11/01ISR Number: 3791266-XReport Type:Expedited (15-DaCompany Report #WAES 01088239
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Ascites Blood Magnesium Decreased Haemoglobin Decreased Oedema Peripheral Pleural Effusion Protein Total Decreased	Foreign Health Professional Other	Vioxx (Rofecoxib) Analgesic Or Anesthetic (Unspecified) Metoclopramide Hydrochloride Omeprazole Magnesium	PS SS C C		ORAL	25 MG/BID	

Date:09/11/01ISR Number: 3791268-3Report Type:Expedited (15-DaCompany Report #WAES 01089617
Age: Gender:Unknown I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Embolism	Foreign	Tab Vioxx					
	Renal Failure	Other	(Rofecoxib)	PS		ORAL	SEE IMAGE	1 DAY
			Estrogens (Unspecified)	C				

Date:09/11/01ISR Number: 3791274-9Report Type:Expedited (15-DaCompany Report #WAES 01085180
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenitis	Foreign	Tab Vioxx					
	Gastritis	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Gastrointestinal							
PO							184	DAY
	Haemorrhage		Aspirin	SS		ORAL	75 MG/DAILY	
PO							3	DAY
			Bicalutamide	C				
			Goserelin Acetate	C				
			Tamsulosin Hydrochloride	C				

Date:09/11/01ISR Number: 3791277-4Report Type:Expedited (15-DaCompany Report #WAES 01086054
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Dyspnoea							
PO							7	DAY
	Fatigue		Tab Acenocoumarol	SS		ORAL	PO	
	Pallor							

Date:09/11/01ISR Number: 3791281-6Report Type:Expedited (15-DaCompany Report #WAES 01089136
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	125 MG/DAILY	
Initial or Prolonged								
PO								319 DAY
			Ranitidine	C				

Date:09/11/01ISR Number: 3791285-3Report Type:Expedited (15-DaCompany Report #WAES 01086067
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypotension	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								
			Tab Candesartan Cilexetil	SS		ORAL	SEE IMAGE	
			Fenofibrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/01ISR Number: 3791289-0Report Type:Expedited (15-DaCompany Report #WAES 01088123
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 4 DAY
	Upper Gastrointestinal Haemorrhage		Aluminum Hydroxide/Aspirin/Mg Oxide	SS		ORAL	162 MG/DAILY	PO
			Tds Flurbiprofen	SS		TOPICAL		TOP

Date:09/11/01ISR Number: 3791291-9Report Type:Expedited (15-DaCompany Report #WAES 01089620
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness Neurosensory Tinnitus	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/1X PO	1 DAY

Date:09/12/01ISR Number: 3791837-0Report Type:Direct Company Report #
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx 12.5 Mg	PS		ORAL	12.5 MG ONE	PO BID

Date:09/12/01ISR Number: 3792178-8Report Type:Expedited (15-DaCompany Report #WAES 01075532
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema Multiforme	Foreign	Tab Vioxx	PS		ORAL	8	DAY
Initial or Prolonged	Petechiae	Health						
	Vasculitis	Professional						

Date:09/12/01ISR Number: 3792182-XReport Type:Expedited (15-DaCompany Report #WAES 01086060
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematoma	Foreign	Tab Vioxx	PS		ORAL	12.5 MG/DAILY	3 DAY
	Oedema	Consumer	Betahistine					
	Platelet Count Decreased		Hydrochloride	C				
	Rectal Haemorrhage		Ginkgo Biloba					
	Vertigo		Extract	C				
			Spironolactone	C				

Date:09/12/01ISR Number: 3792290-3Report Type:Expedited (15-DaCompany Report #WAES 01083061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/01ISR Number: 3792291-5Report Type:Expedited (15-DaCompany Report #WAES 01083173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative						

Date:09/12/01ISR Number: 3792296-4Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Foreign	Leflunomide	PS		ORAL	10 VS 20 MG PO	106 DAY
	Interstitial Lung Disease	Study						
Disability		Health	Vioxx	SS		ORAL	25 MG QD PO	59 DAY
Other		Professional	Marcumar	C				
		Other	Zocor	C				

Date:09/12/01ISR Number: 3792423-9Report Type:Expedited (15-DaCompany Report #WAES 01070915
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Professional Company Representative						
Other								

Date:09/12/01ISR Number: 3792453-7Report Type:Expedited (15-DaCompany Report #WAES 01079702
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis	Foreign Health Professional Other	Tab Vioxx (Rofecoxib) (Composition Unspecified)	PS		ORAL	25 MG/DAILY	
			Diclofenac	C				

Date:09/12/01ISR Number: 3792515-4Report Type:Direct Company Report #
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx (25mg)	PS			25MG	4 MON
Initial or Prolonged	Attack		Prevacid	C				
			Zoloft	C				
			Zanax	C				
			Asa	C				

Date:09/13/01ISR Number: 3792593-2Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx 12.5 Mg	PS			12.5 MG 1 QD	
Initial or Prolonged	Haematocrit Decreased		Asa	C				
			Ibuprofen	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/01ISR Number: 3792605-6Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eyelid Oedema		Vioxx	PS				10 DAYS
Initial or Prolonged	Face Oedema		Furosemide	C				
	Oedema Peripheral							
	Renal Failure Acute							
	Weight Increased							

Date:09/14/01ISR Number: 3793231-5Report Type:Direct Company Report #
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apathy		Vioxx 25 Mg	PS		ORAL	25 MG PO QD	
	Confusional State		Calar Sr	C				
	Decreased Activity		Synthroid	C				
	Disturbance In Attention		Limbitrol	C				
	Dizziness							

Date:09/14/01ISR Number: 3793583-6Report Type:Expedited (15-DaCompany Report #WAES 01090467
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Hospitalization -	Angina Unstable	Professional	Accupril	C				
Initial or Prolonged	Arrhythmia	Company	Lipitor	C				
Other	Arteriovenous	Representative	Lopressor	C				
	Malformation		Oxycontin	C				
	Blood Alkaline		Oxyir	C				
	Phosphatase Increased		Prilosec	C				
	Blood Glucose Increased		Vicodin Tablets	C				
	Blood Pressure Increased		Acetaminophen (+)					
	Cardiac Murmur		Hydrocodone	C				
	Condition Aggravated		Aspirin	C				
	Duodenitis		Clonazepam	C				
	Electrocardiogram St		Diltiazem					

	Segment Abnormal	Hydrochloride	C
	Gallop Rhythm Present	Nitroglycerin	C
	Gastritis		
	Gastritis Erosive		
	Gastroenteritis		
	Helicobacter		
	Gastrointestinal		
	Haemorrhage		
	Gastrooesophageal Reflux		
	Disease		
	Haematochezia		
	Haematocrit Decreased		
	Heart Rate Increased		
	Intervertebral Disc		
	Disorder		
	Myocardial Ischaemia		
	Oxygen Saturation		
	Decreased		
	Pallor		
	Pulse Pressure Decreased		
	Respiratory Rate		
	Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3793612-XReport Type:Expedited (15-DaCompany Report #WAES 01052077
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery	Health	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Atherosclerosis	Professional						
	Coronary Artery Disease	Company	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Fall	Representative						
	Hypertension		Fiorinal	C				
	Hypothalamo-Pituitary Disorders		Midrin	C				
			Relafen	C				
	Pulmonary Congestion		Zestril(Composition Unspecified					
			Capsaicin					
			Chondroitin Sulfate					
			Sodium Nitroglycerin	C				

Date:09/14/01ISR Number: 3793650-7Report Type:Expedited (15-DaCompany Report #WAES 01081632
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health	Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Perforation	Professional						
		Company	Vioxx 12.5 Mg	SS		ORAL	12.5 MG, DAILY, PO	
		Representative						
			Diovan	C				
			Fosamax	C				
			Lasix (Furosemide)	C				
			Aspirin	C				
			Calcium	C				
			Potassium (Unspecified)	C				

Date:09/14/01ISR Number: 3793651-9Report Type:Expedited (15-DaCompany Report #WAES 01082627
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation	Health	Vioxx 12.5 Mg	PS		ORAL	12.5 MG, DAILY, PO	
	Dermatitis	Professional						
	Erythema	Company	Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	
	Fungal Infection	Representative						
	Genital Pain Female		Diflucan	C				
	Herpes Zoster		Lamisil	C				
	Pain In Extremity		Premarin	C				
	Skin Irritation		Prilosec	C				
	Staphylococcal Scalded		Zyrtec	C				
	Skin Syndrome		Atenolol	C				
	Urinary Tract Infection		Hydralazine	C				
	Vulvitis		Hydrocortisone	C				
	Vulvovaginal Discomfort		Indapamide	C				

Date:09/14/01ISR Number: 3793652-0Report Type:Expedited (15-DaCompany Report #WAES 01090429
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Health	Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3793653-2Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fluid Retention	Consumer	Vioxx 285 Mg	PS		ORAL	25 MG, BID, PO	
	Pain	Health						
	Rhabdomyolysis	Professional	Darvocet-N	C				
	Weight Decreased		Klonopin	C				
			Naprosyn	C				
			Relafen	C				

Date:09/14/01ISR Number: 3793654-4Report Type:Expedited (15-DaCompany Report #WAES 01090017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx 25 Mg	PS		ORAL	PO	
	Palpitations							

Date:09/14/01ISR Number: 3793655-6Report Type:Expedited (15-DaCompany Report #WAES 01090007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/14/01ISR Number: 3793739-2Report Type:Expedited (15-DaCompany Report #WAES 01046556
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					

	Upper Gastrointestinal	Health	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
	Haemorrhage	Professional				
PO SEE IMAGE 22 DAY						
		Other	Tab Prednisolone	SS		ORAL
25 MG/DAILY						
PO						
			Tab Dipyridamole	SS		ORAL
400 MG PO						
			...	C		

Date:09/14/01ISR Number: 3793740-9Report Type:Expedited (15-DaCompany Report #WAES 01088632
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx			
Initial or Prolonged	Increased	Health	(Rofecoxib)	PS		
12.5 MG/DAILY 27 DAY						
	Chest Pain	Professional	Allopurinol	C		
		Other	Aspirin	C		
			Levothyroxine Na	C		
			Nifedipine	C		
			Omeprazole Magnesium	C		
			Paroxetine Hcl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3793741-0Report Type:Expedited (15-DaCompany Report #WAES 01085217
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Tab Vioxx (Rofecoxib)	SS				
			Amlodipine	C				
			Atenolol	C				
			Clopidogrel Bisulfate	C				
			Fluvastatin	C				
			Isosorbide Mononitrate	C				
			Omeprazole	C				
			Spirinolactone	C				
			Temazepam	C				

Date:09/14/01ISR Number: 3793742-2Report Type:Expedited (15-DaCompany Report #WAES 01085214
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	
Hospitalization - Initial or Prolonged			Gold Sodium Thiomalate	C				

Date:09/14/01ISR Number: 3793744-6Report Type:Expedited (15-DaCompany Report #WAES 01087027
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	22 DAY

			Tab Allopurinol	SS		ORAL
0.5						
TABLET/DAILY						
PO						
			Hyzaar	C		
			Cetirizine Hydrochloride	C		
			Doxazosin Mesylate	C		
			Furosemide	C		
			Levothyroxine Na	C		

Date:09/14/01ISR Number: 3793793-8Report Type:Expedited (15-DaCompany Report #WAES 01088237
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Eruption	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
SEE IMAGE 11 DAY						
			Acetaminophen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3793809-9Report Type:Expedited (15-DaCompany Report #WAES 01055146
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Perforation	Company	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Pancreatic Disorder	Representative	Acetaminophen	C				
			Atenolol	C				

Date:09/14/01ISR Number: 3793815-4Report Type:Expedited (15-DaCompany Report #WAES 01088254
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Skin Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
			Vasotec	C				
			Aspirin	C				
			Cyclophosphamide	C				
			Oxerutins	C				
			Prednisone	C				

Date:09/14/01ISR Number: 3793816-6Report Type:Expedited (15-DaCompany Report #WAES 01088624
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS		ORAL	PO	
Hospitalization -		Professional						
Initial or Prolonged								

Date:09/14/01ISR Number: 3793973-1Report Type:Expedited (15-DaCompany Report #WAES 01095008
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
	Cardiac Failure	Other	(Rofecoxib)	PS		ORAL	12.5 MG, BID, PO	
	Congestive							
			Albuterol Sulfate	C				
			Amiodarone	C				
			Budenoside	C				
			Digoxin	C				
			Furosemide	C				
			Gliclazide	C				
			Ipratropium Bromide	C				
			Irbesartan	C				
			Omeprazole	C				
			Prednisolone	C				
			Salmeterol	C				

Date:09/14/01ISR Number: 3793974-3Report Type:Expedited (15-DaCompany Report #WAES 01095521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Professional	Allopurinol	C				
			Amlodipine Besylate	C				

				Atorvastatin	C		
				Lisinopril	C		
				Phenprocoumon	C		

Date:09/14/01ISR Number: 3793984-6Report Type:Expedited (15-DaCompany Report #WAES 01055176
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Tab Vioxx					
Hospitalization -	Haemoglobin Abnormal	Other	(Rofecoxib)	PS		ORAL	25 MG, DAILY,	
Initial or Prolonged	Hypotension						PO	
	Upper Gastrointestinal		Prednisolone	SS		ORAL	5 MG, DAILY,	
	Haemorrhage						PO	
			Acetaminophen	C				
			Bisoprolol	C				
			Digoxin	C				
			Dihydrocodeine	C				
			Etidronate Disodium	C				
			Ferrous So4	C				
			Furosemide	C				
			Omeprazole	C				
			Ramipril	C				
			Spironolactone	C				
			Warfarin	C				

Date:09/14/01ISR Number: 3793986-XReport Type:Expedited (15-DaCompany Report #WAES 01076088
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Herniation	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG, DAILY,	
Initial or Prolonged	Haemorrhagic Stroke	Professional					PO	
	International Normalised	Other	Tab Acenocoumarol	SS		ORAL	4 MG, DAILY,	

		Ratio Increased					
PO							
		Malaise		Acetaminophen	C		
		Vertigo		Dimethicone	C		

Date:09/14/01ISR Number: 3793987-1Report Type:Expedited (15-DaCompany Report #WAES 01083604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haematemesis	Foreign	Tab Vioxx			
	Upper Gastrointestinal	Health	(Rofecoxib)	PS		ORAL
PO						
	Haemorrhage	Professional				

Date:09/14/01ISR Number: 3794025-7Report Type:Expedited (15-DaCompany Report #WAES 01099601
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Foreign	Tab Vioxx			
	Haemorrhage	Health	(Rofecoxib)	PS		ORAL
PO						
		Professional	[Therapy			
			Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3794028-2Report Type:Expedited (15-DaCompany Report #WAES 01045015
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Foreign	Tab Vioxx					
Hospitalization -	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	12.5 MG/	
Initial or Prolonged	Haemorrhage	Professional					DAILY /PO	2 MON
	Haematemesis	Other	Acetaminophen	C				
	Upper Gastrointestinal		Atenolol	C				
	Haemorrhage		Dipiproverine Dihcl	C				
			Lactulose	C				

Date:09/14/01ISR Number: 3794029-4Report Type:Expedited (15-DaCompany Report #WAES 01059553
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nephritis	Foreign	Tab Vioxx					
Initial or Prolonged	Proteinuria	Study	(Rofecoxib)	PS		ORAL	25	
		Health						
		Professional	Alfacalcidol	C			MG/DAILY/PO	
			Calcitonin	C				
			Diltiazem	C				
			Leflunomide	C				
			Levothyroxine Na	C				

Date:09/14/01ISR Number: 3794084-1Report Type:Expedited (15-DaCompany Report #WAES 01088132
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Foreign	Tab Vioxx					
Initial or Prolonged	Hypertensive Crisis	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	

Date:09/14/01ISR Number: 3794088-9Report Type:Expedited (15-DaCompany Report #WAES 01088623
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Life-Threatening	Ventricular Fibrillation	Other	(Rofecoxib)	PS		ORAL	PO	
Disability								

Date:09/14/01ISR Number: 3794090-7Report Type:Expedited (15-DaCompany Report #WAES 01088785
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Dermatitis	Consumer	(Rofecoxib)	PS				
	Gastrointestinal Disorder							
	Urinary Tract Infection							

Date:09/14/01ISR Number: 3794091-9Report Type:Expedited (15-DaCompany Report #WAES 01093409
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomyopathy	Foreign	Tab Vioxx					
Initial or Prolonged	Chest Pain	Other	(Rofecoxib)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3794178-0Report Type:Expedited (15-DaCompany Report #WAES 01071341
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Back Pain	Health						
	Burning Sensation	Professional						
	Candidiasis							
	Dysphagia							
	Dysphonia							
	Hearing Impaired							
	Oedema Mouth							
	Pruritus							
	Tenderness							
	Tongue Oedema							
	Vision Blurred							

Date:09/14/01ISR Number: 3794216-5Report Type:Expedited (15-DaCompany Report #WAES 01081114
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Consumer	Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Epistaxis						MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal		Claritin	C				
Other	Haemorrhage		Keflex	C				
	Haematemesis		Lipitor	C				
	Hepatic Failure		Lopid	C				
	Influenza Like Illness		Maxalt (Rizatriptan					
	Respiratory Arrest		Benzoate)	C				
			Premarin	C				
			Prevacid	C				
			Questran	C				
			Ultram	C				
			Vasotec	C				
			Xanax	C				
			Zoloft	C				
			Lorazepam	C				

Date:09/14/01ISR Number: 3794306-7Report Type:Expedited (15-DaCompany Report #WAES 01083147
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Dreams	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Insomnia		Herbs (Unspecified)	C				
	Suicidal Ideation							

Date:09/14/01ISR Number: 3794307-9Report Type:Expedited (15-DaCompany Report #WAES 01082868
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3794308-0Report Type:Expedited (15-DaCompany Report #WAES 01090004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/14/01ISR Number: 3794310-9Report Type:Expedited (15-DaCompany Report #WAES 01090096
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Nausea Oedema Peripheral Pulmonary Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

Date:09/14/01ISR Number: 3794316-XReport Type:Expedited (15-DaCompany Report #WAES 01083139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/14/01ISR Number: 3794320-1Report Type:Expedited (15-DaCompany Report #WAES 01083133
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Vision Blurred	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Baycol	C				
			Aspirin	C				

Date:09/14/01ISR Number: 3794322-5Report Type:Expedited (15-DaCompany Report #WAES 01090444
Age:100 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depressed Level Of	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Consciousness	Professional					MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Company Representative						
	Pneumonia							
Other	Post Procedural Complication							

Date:09/14/01ISR Number: 3794324-9Report Type:Expedited (15-DaCompany Report #WAES 01090267
Age:30 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
		Company Representative						

Date:09/14/01ISR Number: 3794326-2Report Type:Expedited (15-DaCompany Report #WAES 01090020
Age:30 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Wellbutrin	C				

Date:09/14/01ISR Number: 3794333-XReport Type:Expedited (15-DaCompany Report #WAES 01090044
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Full Blood Count Abnormal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:09/14/01ISR Number: 3794348-1Report Type:Expedited (15-DaCompany Report #WAES 01080123
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Blood Pressure Abnormal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Hypertension		Flexeril	C				
Other	Orthostatic Hypotension	Company Representative	Percocet	C				
	Transient Ischaemic Attack		Soma	C				
			Ibuprofen	C				

Date:09/14/01ISR Number: 3794349-3Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health Professional	Tab Vioxx 50 Mg, 25 Mg	PS		ORAL		
Hospitalization - SEE IMAGE	Gastritis Erosive							
Initial or Prolonged	Gastrointestinal Disorder	Company	Ceftin	C				

Disability	Gastrointestinal	Representative	Tylox	C
Other	Haemorrhage			

Date:09/14/01ISR Number: 3794350-XReport Type:Expedited (15-DaCompany Report #WAES 01083061
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:09/14/01ISR Number: 3794380-8Report Type:Expedited (15-DaCompany Report #WAES 01090322
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Myocardial Infarction	Professional					MG/BID/PO	
		Company Representative	Vicodin Tablets	C				

Date:09/14/01ISR Number: 3794382-1Report Type:Expedited (15-DaCompany Report #WAES 01090097
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Myocardial Infarction						MG/DAILY/PO	
			Plavix	C				
			Procardia	C				
			Aspirin	C				
			Atenolol	C				

Date:09/14/01ISR Number: 3794385-7Report Type:Expedited (15-DaCompany Report #WAES 01090033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
							MG/DAILY/PO	

Date:09/14/01ISR Number: 3794390-0Report Type:Expedited (15-DaCompany Report #WAES 01081006
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Autoimmune Hepatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	10 DAY
Initial or Prolonged	Back Pain	Professional	Accupril	C				
	Jaundice	Company						
	Pneumonia	Representative						
	Pyrexia							
	Thymus Disorder							

Date:09/14/01ISR Number: 3794392-4Report Type:Expedited (15-DaCompany Report #WAES 01082552
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coordination Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Hemiparesis	Professional					MG/DAILY/PO	
Initial or Prolonged	Simple Partial Seizures	Company	Aciphex	C				
	Transient Ischaemic Attack	Representative	Doxycycline	C				
			Ibuprofen	C				
	Visual Disturbance							

Date:09/14/01ISR Number: 3794401-2Report Type:Expedited (15-DaCompany Report #WAES 01090136
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	25	
Hospitalization -	Oedema Peripheral						MG/DAILY/PO	
Initial or Prolonged			Celebrex	C				
			Aspirin	C				

Date:09/14/01ISR Number: 3794404-8Report Type:Expedited (15-DaCompany Report #WAES 01090114
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Tab Vioxx	PS		ORAL	50	
		Professional					MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/01ISR Number: 3794405-XReport Type:Expedited (15-DaCompany Report #WAES 01090471
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:09/14/01ISR Number: 3794407-3Report Type:Expedited (15-DaCompany Report #WAES 01083164
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Blood Pressure Increased	Professional Company Representative						
	Herpes Zoster							
	Hypoaesthesia							

Date:09/14/01ISR Number: 3794408-5Report Type:Expedited (15-DaCompany Report #WAES 01090026
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction	Health	Tab Vioxx	PS		ORAL	50 MG/ DAILY/PO	
	Cerebrovascular Accident	Professional Company Representative						
	Hypertension							
	Hypoaesthesia							

Date:09/14/01ISR Number: 3794410-3Report Type:Expedited (15-DaCompany Report #WAES 01090439
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Chorea	Health	Tab Vioxx	PS		ORAL
12.5						
Initial or Prolonged		Professional				
MG/BID/PO						
		Company	Pacerone Unk	SS		
200 MG/DAILY/						
		Representative	Lipitor Unk	SS		
10 MG/ DAILY/						
			Allegra	C		
			Coumadin	C		
			Lasix (Furosemide)	C		
			Miacalcin	C		
			Digoxin	C		

Date:09/14/01ISR Number: 3794649-7Report Type:Expedited (15-DaCompany Report #WAES 01071039
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL
PO						
Hospitalization -	Faeces Discoloured					
Initial or Prolonged	Gastric Ulcer					
Disability	Haemorrhage					
Other						

Date:09/14/01ISR Number: 3794780-6Report Type:Expedited (15-DaCompany Report #WAES 01083051
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Other	Dialysis	Health
	Renal Failure	Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Tab Vioxx	PS		ORAL	PO	
	Atacand	C				
	Hydrodiuril	C				

Date:09/17/01ISR Number: 3793538-1Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Floxacillin Sodium	PS		ORAL	9	DAY
Initial or Prolonged	Increased		Leflunomide	SS		ORAL		
	Aspartate		Vioxx	SS		ORAL		
	Aminotransferase		Vasotec	SS	Merck & Co., Inc	ORAL	7	DAY
	Increased		Gabapentin	SS		ORAL		
	Blood Alkaline		Furosemide	SS		ORAL	7	DAY
	Phosphatase Increased		Metronidazole	SS		ORAL	9	DAY
	Blood Bilirubin Increased		Spironolactone	SS		ORAL		
	Blood Lactate		Folic Acid	C				
	Dehydrogenase Increased		Cisapride	C				
	Cardiomegaly		Albuterol Sulfate					
	Chest Pain		And Ipratropium					
	Culture Urine Positive		Bromide	C				
	Depressed Level Of		Calcium Carbonate					
	Consciousness		And Cholecalciferol	C				
	Ear Pain		Loperamide	C				
	Fatigue		Zolpidem Tartrate	C				
	Headache		Acetaminophen	C				
	Hypervolaemia		Morphine	C				
	Hypocalcaemia		Cetirizine					
	Infected Skin Ulcer		Hydrochloride	C				
	Liver Disorder		Lansoprazole	C				
	Metabolic Disorder		Morphine	C				
	Pharyngolaryngeal Pain		Prednisolone	C				
	Pleural Effusion		Vitamin E	C				
	Proteus Infection							
	Renal Failure Acute							

Date:09/17/01ISR Number: 3793946-9Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Warfarin	PS		ORAL	1-2MG QD	
Initial or Prolonged	Haematocrit Decreased						ORAL	
	International Normalised		Rofecoxib 25mg	SS		ORAL	50MG QD	
	Ratio Increased						ORAL	
			Ecasa	C				
			Dilt Cd	C				
			Isordil	C				
			Simvastatin	C				
			Metolazone	C				
			Lasix	C				
			Kcl	C				
			Losartan	C				
			Lansoprazole	C				
			Glyburide	C				
			Insulin	C				
			Vioxx	C				

Allopurinol	C
Colchicine	C
Vancenase Nasal Spray	C
Sennakot Qhs/Bisacodyl Prn	C

Date:09/17/01ISR Number: 3794201-3Report Type:Expedited (15-DaCompany Report #WAES 01090334
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Eye Pain							
	Rhinitis		Armour Thyroid Tablets	C				
			Pepcid	C				
			Prolex D	C				
			Estradiol	C				

Date:09/17/01ISR Number: 3794359-6Report Type:Expedited (15-DaCompany Report #WAES 01081992
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Heart Rate Increased							
	Hypertension	Company Representative	Prinivil	C				

Date:09/17/01ISR Number: 3794360-2Report Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Hospitalization - ; 25	Angiopathy	Health		
Initial or Prolonged MG/DAILY/PO	Back Pain	Professional		
	Blood Potassium Increased	Other	Pravachol	C
	Blood Thyroid Stimulating Hormone Increased		Xanax	C
	Blood Urea Increased			
	Cardiac Arrest			
	Cardiac Disorder			
	Coma			
	Dyspnoea			
	Pulmonary Congestion			
	Pulse Absent			
	Renal Disorder			
	Spleen Disorder			
	Toxicologic Test Abnormal			
	Tri-Iodothyronine Uptake Increased			

Date:09/17/01ISR Number: 3794365-1Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Aphasia

	Asthenia						
	Balance Disorder						
	Blood Pressure Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL
	Coordination Abnormal	Professional					
	Difficulty In Walking	Company	Anafranil Unk	SS			25 MG/BID
	Disorientation	Representative	Klonopin Unk	SS			0.5 MG/BID
	Dizziness		Lamictal Unk	SS			100 MG/BID
	Drug Interaction		Wellbutrin Sr Unk	SS			150 MG/BID
	Dry Skin		Dipentum Unk	SS			250 MG
	Dysarthria		Premarin Unk	SS			1.25 MG/DAILY
	Dysphagia		Zoloft Unk	SS			100 MG/DAILY
	Dyspnoea		Coumadin	C			
	Emotional Distress		Motrin	C			
	Headache		Lithium Carbonate	C			
	Mental Disorder						
	Motor Dysfunction						
	Respiratory Rate Increased						
	Restlessness						
	Skin Warm						
	Speech Disorder						
	Transient Ischaemic Attack						
	Vision Blurred						

Date:09/17/01ISR Number: 3794367-5Report Type:Expedited (15-DaCompany Report #WAES 01070766
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY
Initial or Prolonged	Dizziness	Health					
PO							

	Gastric Ulcer Haemorrhage	Professional	Celexa	C
	Gastrointestinal Haemorrhage			
	Haematocrit Decreased			
	Haemoglobin Decreased			

Date:09/17/01ISR Number: 3794368-7Report Type:Expedited (15-DaCompany Report #WAES 01090114
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY	PO

Date:09/17/01ISR Number: 3794370-5Report Type:Expedited (15-DaCompany Report #WAES 01082590
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL		PO
Initial or Prolonged	Hypertension	Health Professional	Adalat	C				
			Glucophage	C				
			Lipitor	C				
			Monopril	C				
			Atenolol	C				

Date:09/17/01ISR Number: 3794373-0Report Type:Expedited (15-DaCompany Report #WAES 01090322
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other		Professional					MG/BID/PO	
		Company Representative	Vicodin	C				

Date:09/17/01ISR Number: 3794375-4Report Type:Expedited (15-DaCompany Report #WAES 01090444
Age:100 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Depressed Level Of	Professional					MG/DAILY/PO	
Hospitalization -	Consciousness	Company						
Initial or Prolonged	Escherichia Infection	Representative						
Other	Gastric Ulcer Perforation							
	Hypertension							
	Myocardial Infarction							
	Oliguria							
	Pneumonia							
	Post Procedural Complication							

Date:09/17/01ISR Number: 3794515-7Report Type:Expedited (15-DaCompany Report #WAES 01090093
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Myocardial Infarction						MG/DAILY/PO	
Initial or Prolonged	Pneumonia							
	Respiratory Failure							

Date:09/17/01ISR Number: 3794546-7Report Type:Expedited (15-DaCompany Report #WAES 01068241
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Hospitalization -	Ovarian Cancer	Company	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Renal Failure Acute	Representative	Tab Ibuprofen	SS		ORAL	400 MG/TID PO	20 DAY
Other	Renal Papillary Necrosis		Noroxin	C				
			Acetaminophen	C				

Date:09/17/01ISR Number: 3794547-9Report Type:Expedited (15-DaCompany Report #WAES 01083557
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Tab Vioxx					
Hospitalization -	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Haemorrhage	Professional					PO	
	Melaena		Aspirin	SS		ORAL	100 MG/DAILY	
							PO	606 DAY
			Doxepin Hcl	C				
			Indapamide	C				
			Ranitidine Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/01ISR Number: 3794548-0Report Type:Expedited (15-DaCompany Report #WAES 01085105
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Disorder	Foreign	Tab Vioxx					
	Muscle Hypertrophy	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Myalgia	Professional					PO	
	Oedema Peripheral		Acetaminophen	C				
	Pain In Extremity		Ibuprofen	C				

Date:09/17/01ISR Number: 3794561-3Report Type:Expedited (15-DaCompany Report #WAES 01027276
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Foreign	Tab Vasotec					
Initial or Prolonged	Increased	Other	(Enalapril Maleate)	PS	Merck Sharp & Dohme	ORAL	20 MG/DAILY	
	Aspartate						PO	7 DAY
	Aminotransferase		Tab Vioxx					
	Increased		(Rofecoxib)	SS		ORAL	25 MG/DAILY	
	Blood Alkaline						PO	
	Phosphatase Increased		Cap Gabapentin	SS		ORAL	2400 MG/DAILY	
	Blood Bilirubin Increased						PO	
	Blood Creatinine		Tab Metronidazole	SS		ORAL	800 MG/DAILY	
	Increased						PO	9 DAY
	Blood Lactate		Tab Furosemide	SS			40 MG/DAILY	
	Dehydrogenase Increased						PO	7 DAY
	Blood Potassium Increased		Tab Floxacillin					
	C-Reactive Protein		Sodium	SS		ORAL	2200 MG/DAILY	
	Increased						PO	9 DAY

	Cardiomegaly	Tab Leflunomide	SS	ORAL
20 MG/DAILY				
	Chest Pain			
PO				
	Condition Aggravated	Tab Spironolactone	C	ORAL
50 MG/DAILY				
	Depressed Level Of			
PO				
	Consciousness	Acetaminophen	C	
	Ear Pain	Albuterol Sulfate		
	Electroencephalogram	(+) Ipratropium		
	Abnormal	Bromid	C	
	Fatigue	Calcium Carbonate		
	Headache	(+) Cholecalciferol	C	
	Hepatic Enzyme Increased	Cetirizine		
	Hypervolaemia	Hydrochloride	C	
	Hypocalcaemia	Cisapride	C	
	Liver Disorder	Folic Acid	C	
	Liver Function Test	Lansoprazole	C	
	Abnormal	Loperamide	C	
	Metabolic Disorder	Morphine	C	
	Pain	Morphine	C	
	Pharyngolaryngeal Pain	Prednisolone	C	
	Pleural Effusion	Vitamin E	C	
	Proteus Infection	Zolpidem Tartrate	C	
	Renal Disorder			
	Renal Failure			
	Urinary Tract Infection			
	Weight Decreased			
	Weight Increased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/01ISR Number: 3795962-XReport Type:Expedited (15-DaCompany Report #WAES 01099557
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -	Renal Failure	Health	(Rofecoxib)	PS		ORAL	1 TABLET,	
Initial or Prolonged	Toxic Epidermal	Professional					DAILY	1 MON
	Necrolysis							

Date:09/17/01ISR Number: 3795963-1Report Type:Expedited (15-DaCompany Report #WAES 01095585
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Foreign	Tab Vioxx					
	Sinus Tachycardia	Other	(Rofecoxib)	PS		ORAL	8	DAY

Date:09/17/01ISR Number: 3795965-5Report Type:Expedited (15-DaCompany Report #WAES 01095554
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	5 DAY
		Professional						

Date:09/17/01ISR Number: 3795966-7Report Type:Expedited (15-DaCompany Report #WAES 01099605
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Tenderness	Foreign	Tab Vioxx					
Hospitalization -	Dizziness	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	3 MON
Initial or Prolonged	Melaena	Professional	Terazosin					
Disability	Nausea		Hydrochloride	C				

Date:09/17/01ISR Number: 3795975-8Report Type:Expedited (15-DaCompany Report #WAES 01099804
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Impairment	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	37.5 MG PO	32 DAY
		Professional	Amlodipine Besylate	C				
			Indapamide	C				

Date:09/17/01ISR Number: 3795976-XReport Type:Expedited (15-DaCompany Report #WAES 01098208
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY Other PO	3 DAY
			Lactulose	C				
			Methadone Hcl	C				
			Oxazepam	C				
			Potassium Chloride	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/01ISR Number: 3795977-1Report Type:Expedited (15-DaCompany Report #WAES 01095551
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoimmune Disorder Blood Urea Increased Coagulopathy Gastric Ulcer Haemorrhage Thrombocytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	"UPPER LIMIT" PO	10 DAY

Date:09/18/01ISR Number: 3794951-9Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Rofecoxib	PS				

Date:09/19/01ISR Number: 3795410-XReport Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Vioxx (25mg Qd)	PS			25MG QD	

Date:09/20/01ISR Number: 3795718-8Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation White Blood Cell Count Increased		Vioxx	PS				

Date:09/20/01ISR Number: 3796360-5Report Type:Expedited (15-DaCompany Report #WAES 01082387
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Cardizem	C				
			Cozaar	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Plavix	C				
			Aspirin	C				
			Potassium (Unspecified)	C				

Date:09/20/01ISR Number: 3796363-0Report Type:Expedited (15-DaCompany Report #WAES 01072916
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Antibody Test Positive	Health	Tab Vioxx	PS		ORAL	PO	
	Antinuclear Antibody Positive	Professional	Evista	SS				
	Systemic Lupus Erythematosus Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/01ISR Number: 3796364-2Report Type:Expedited (15-DaCompany Report #WAES 01060773
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/20/01ISR Number: 3796373-3Report Type:Expedited (15-DaCompany Report #WAES 01090315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Confusional State							
	Depression		Cylert	C				
	Dizziness		Ditropan	C				
	Dysarthria		Nexium	C				
	Dyspnoea Exacerbated		Aspirin	C				
	Fatigue							
	Feeling Abnormal							
	Gastrointestinal Pain							
	Lethargy							
	Nausea							
	Pruritus							
	Skin Exfoliation							
	Suicidal Ideation							
	Tremor							
	Urinary Tract Infection							

Date:09/20/01ISR Number: 3796385-XReport Type:Expedited (15-DaCompany Report #WAES 01070915
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Hospitalization -	Dermatitis	Professional
MG/DAILY/PO		
Initial or Prolonged	Dermatitis Bullous	Company
	Face Oedema	Representative
	Hypersensitivity	
	Rash Macular	

Date:09/20/01ISR Number: 3796387-3Report Type:Expedited (15-DaCompany Report #WAES 01083051
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Confusional State	Professional					MG/DAILY/PO	
	Dialysis	Company	Atacand	C				
	Fluid Overload	Representative	Celebrex	C				
	Renal Failure		Colace	C				
			Darvocet-N	C				
			Detrol	C				
			Glucotrol	C				
			Hydrodiuril	C				
			Lipitor	C				
			Lotensin Hct	C				
			Motrin	C				
			Tranxene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/01ISR Number: 3796388-5Report Type:Expedited (15-DaCompany Report #WAES 01090093
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Myocardial Infarction	Health					MG/DAILY/PO	
Initial or Prolonged	Pneumonia	Professional	Antivert	C				
	Respiratory Failure		Donnatal	C				
			Prilosec	C				
			Tylenol With Codeine #3	C				

Date:09/20/01ISR Number: 3796430-1Report Type:Expedited (15-DaCompany Report #WAES 01080883
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Macular Oedema	Health	Vioxx 25 Mg	PS		ORAL	25	
	Visual Acuity Reduced	Professional					MG/DAILY/PO;	
		Company					PO	
		Representative	Celebrex	C				
			Lipitor	C				
			Prevacid	C				
			Singulair	C				
			Zocor	C				

Date:09/20/01ISR Number: 3796432-5Report Type:Expedited (15-DaCompany Report #WAES 01090315
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Anxiety						MG/DAILY/PO	
	Confusional State		Cylert	C				
	Depression		Ditropan	C				

Diarrhoea	Nexium	C
Dizziness	[Therapy	
Dysarthria	Unspecified]	C
Dyspnoea	Aspirin	C
Fatigue		
Feeling Abnormal		
Gastrointestinal Pain		
Lethargy		
Nausea		
Pain		
Pruritus		
Skin Exfoliation		
Suicidal Ideation		
Tremor		
Urinary Tract Infection		
Vision Blurred		

Date:09/20/01ISR Number: 3796434-9Report Type:Expedited (15-DaCompany Report #WAES 01083139
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic	Health	Vioxx	PS		ORAL	PO	
	Attack	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/01ISR Number: 3796439-8Report Type:Expedited (15-DaCompany Report #WAES 01062209
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Hospitalization -		Health						
Initial or Prolonged		Professional	Tab Fosamax 10 Mg	SS		ORAL	10 MG/DAILY/PO	
			Premarin	C				
			Zocor	C				

Date:09/20/01ISR Number: 3796460-XReport Type:Expedited (15-DaCompany Report #WAES 01095564
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Foreign	Tab Vioxx					
Initial or Prolonged	Intentional Misuse	Other	(Rofecoxib)	PS		ORAL	112. 5 MG PO	1 DAY
	Nausea							
	Suicide Attempt							

Date:09/20/01ISR Number: 3796484-2Report Type:Expedited (15-DaCompany Report #WAES 01099128
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	25 MG/DAILY	2 MON
	Cardiac Failure	Health	Fluticasone					
	Congestive	Professional	Propionate	C				
	Pruritus		Loratadine	C				
			Nystatin	C				
			Salmeterol	C				

Date:09/20/01ISR Number: 3796486-6Report Type:Expedited (15-DaCompany Report #WAES 01085215
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Dizziness	Other						
	Hyperhidrosis							
	Nausea							
	Syncope							

Date:09/20/01ISR Number: 3796488-XReport Type:Expedited (15-DaCompany Report #WAES 01096025
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign	Tab Vioxx (Rofecoxib)	PS			UNKNOWN	150 MG
	Overdose	Health						
	Pulmonary Oedema	Professional						
	Suicide Attempt							

Date:09/20/01ISR Number: 3796508-2Report Type:Expedited (15-DaCompany Report #WAES 01083061
Age: Gender:Female I/FU:F

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company

Representative

			Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx	PS		ORAL	PO	

Date:09/20/01ISR Number: 3796509-4Report Type:Expedited (15-DaCompany Report #WAES 01090068
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antiphospholipid Syndrome	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Disturbance In Attention						MG/DAILY/PO	
	Hypoaesthesia		Xanax	C				
	Speech Disorder							

Date:09/20/01ISR Number: 3796510-0Report Type:Expedited (15-DaCompany Report #WAES 01090701
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Cerebrovascular Accident							
	Ulcer Haemorrhage							

Date:09/20/01ISR Number: 3796511-2Report Type:Expedited (15-DaCompany Report #WAES 01091200
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Ulcer	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative						

Date:09/21/01ISR Number: 3796892-XReport Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS				
PRIOR TO ADM								
Hospitalization - Initial or Prolonged	Haemorrhage							

Date:09/21/01ISR Number: 3796975-4Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx (25 Mgm)	PS				
25MGM 1 QD								
Required			Glyburide	C				
Intervention to			Tylenol	C				
Prevent Permanent			Ventolin Inhaler	C				
Impairment/Damage			Flexeril	C				

Date:09/21/01ISR Number: 3797253-XReport Type:Expedited (15-DaCompany Report #WAES 01091111
Age: Gender: I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:09/21/01ISR Number: 3797256-5Report Type:Expedited (15-DaCompany Report #WAES 01091339
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/21/01ISR Number: 3797259-0Report Type:Expedited (15-DaCompany Report #WAES 01091114
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:09/21/01ISR Number: 3797339-XReport Type:Expedited (15-DaCompany Report #WAES 01095589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	PO	

Initial or Prolonged		Professional	Dipyrone	SS		ORAL
PO						
			Cortisone	C		

Date:09/21/01ISR Number: 3797349-2Report Type:Expedited (15-DaCompany Report #WAES 01095072
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx			
Hospitalization -	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Haemorrhage					
PO						
			Allopurinol	C		
			Amitriptyline	C		
			Amlodipine	C		
			Levothyroxine Na	C		
			Prednisolone	C		

Date:09/21/01ISR Number: 3797350-9Report Type:Expedited (15-DaCompany Report #WAES 01099943
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea	Foreign	Tab Vioxx			
Hospitalization -	Pruritus	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged						
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/01ISR Number: 3797361-3Report Type:Expedited (15-DaCompany Report #WAES 01097024
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Duodenal Ulcer	Foreign	Tab Vioxx			
	Haemorrhage	Other	(Rofecoxib)	PS	Merck Sharp & Dohme	
	Gastric Ulcer					

Date:09/21/01ISR Number: 3797432-1Report Type:Expedited (15-DaCompany Report #WAES 01090532
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL
25						
	Nausea	Other				
MG/DAILY/PO						
	Pain		Flonase	C		
	Scan Abdomen Abnormal		Motrin	C		
			Naprosyn	C		
			Premarin	C		
			Prilosec	C		
			Soma	C		
			Synthroid	C		
			Toprol Xl Tablets	C		
			Xanax	C		
			Xenical	C		
			Amitriptyline Hydrochloride	C		

Date:09/21/01ISR Number: 3797663-0Report Type:Expedited (15-DaCompany Report #WAES 01092098
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hyperkalaemia	Health	Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
Initial or Prolonged	Renal Failure	Professional				
PO						
		Company Representative				

Date:09/21/01ISR Number: 3797674-5Report Type:Expedited (15-DaCompany Report #WAES 01090674
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Heart Rate Decreased		Accupril	C				
	Hypotension		Ambien	C				
	Loss Of Consciousness		Inderal	C				
	Syncope		Lasix (Furosemide)	C				
			Prevacid	C				
			Tagamet	C				
			Toprol Xl Tablets	C				
			Ultram	C				
			Vasocon-A	C				
			Zoloft	C				
			[Therapy Unspecified]	C				
			Metoclopramide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/01ISR Number: 3797676-9Report Type:Expedited (15-DaCompany Report #WAES 01091337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative						

Date:09/21/01ISR Number: 3797678-2Report Type:Expedited (15-DaCompany Report #WAES 01091201
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Level Below	Professional					PO	
	Therapeutic		Dilantin	C				

Date:09/21/01ISR Number: 3797679-4Report Type:Expedited (15-DaCompany Report #WAES 01090935
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Loss Of Consciousness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Oedema Peripheral		Evista	C				
	Road Traffic Accident		Lasix (Furosemide)	C				
			Thyroid	C				

Date:09/21/01ISR Number: 3799854-1Report Type:Expedited (15-DaCompany Report #01090587
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Enbrel 25 Mg	PS		SUBCUTANEOUS	BIW,	

Initial or Prolonged	Atrial Fibrillation		
SUBCUTANEOUS			
	Atrial Tachycardia	Rofecoxib	SS
	Epistaxis	Celecoxib	SS
	Tremor	Omeprazole	C
		Naproxen	C
		Diazide	C

Date:09/24/01ISR Number: 3797556-9Report Type:Direct Company Report #
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx (25 Mg)	PS		ORAL	25 MG PO QD	
			Plaquenil	C				
			Premarin	C				

Date:09/24/01ISR Number: 3797730-1Report Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx 50mg Merck	PS	Merck	ORAL	50 MG QD ORAL	
Initial or Prolonged	Gastroenteritis							
	Helicobacter							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Haemorrhage							
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3797755-6Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Rofecoxib	PS				

Date:09/24/01ISR Number: 3797819-7Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx 25mg Merck	PS	Merck	ORAL	1/DAY/ORAL	

Date:09/24/01ISR Number: 3797841-0Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck	ORAL	25MG QD ORAL	
Hospitalization -	Upper Gastrointestinal		Elavil	C				
Initial or Prolonged	Haemorrhage		Sinemet	C				
Required			Neurontin	C				
Intervention to			Buspar	C				
Prevent Permanent			Synthroid	C				
Impairment/Damage			Ecotrin	C				

Date:09/24/01ISR Number: 3797946-4Report Type:Expedited (15-DaCompany Report #WAES 01091517
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3797947-6Report Type:Expedited (15-DaCompany Report #WAES 01091568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Hypertension	Professional Company Representative				

Date:09/24/01ISR Number: 3797953-1Report Type:Expedited (15-DaCompany Report #001-0906-M0100183
Age:70 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Asthenia
Other	Bradycardia
	Chest Pain

		Dyspnoea Electrocardiogram Qrs Complex Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram Qt Shortened		Accupril (Quinapril Hydrochloride)	PS		ORAL
20 MG							
		Electrocardiogram St Segment Abnormal					
(DAILY), PER							
		Electrocardiogram T Wave		Vioxx (Rofecoxib)	SS		ORAL
ORAL							
25 MG							
		Inversion					
(DAILY), PER							
		Eye Disorder					
ORAL							
		Hyperkalaemia Renal Impairment		Prednisone (Prednisone)	SS		
				(Isosorbide)	C		
				Lanoxin (Digoxin)	C		
				Synthroid (Levothyroxine Sodium)	C		
				Trileptal (Oxcarbazepine)	C		
				Atrovent (Ipratropium Bromide)	C		
				(Lorazepam)	C		
				(Oxygen Therapy) (Home)	C		

Date:09/24/01ISR Number: 3797960-9Report Type:Expedited (15-DaCompany Report #WAES 01091718
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3797961-0Report Type:Expedited (15-DaCompany Report #WAES 01091734
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3797989-0Report Type:Expedited (15-DaCompany Report #001-0981-M0106788
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Atorvastatin (Atorvastatin)	PS		ORAL	10 MG (DAILY), PER ORAL	
	Blood Creatinine Increased							
	Blood Urea Increased							
	Epistaxis		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG (DAILY) , PER ORAL	
	Post Procedural Haemorrhage							
	Tendonitis		Plavix (Clopidogrel)	SS		ORAL	(DAILY), PER ORAL	
			Unspecified Vitamins	C				

(Lansoprazole)	C
(Iron)	C
(Ascorbic Acid)	C
(Maxide)	C
(Lisinopril)	C

Date:09/24/01ISR Number: 3797996-8Report Type:Expedited (15-DaCompany Report #WAES 00092542
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Tab Vioxx	Unk	PS	ORAL	PO	
Initial or Prolonged	Hypersensitivity Pneumonia	Professional Company Representative						

Date:09/24/01ISR Number: 3797997-XReport Type:Expedited (15-DaCompany Report #WAES 01061308
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Depression Gastrointestinal Haemorrhage Hypertension Hypotension Syncope	Professional Company Representative						

Date:09/24/01ISR Number: 3797999-3Report Type:Expedited (15-DaCompany Report #WAES 01091301
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798000-8Report Type:Expedited (15-DaCompany Report #WAES 01091156
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Tab Voxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cerebrovascular Accident	Professional						
	Difficulty In Walking	Company						
	Dysarthria	Representative						
	Mydriasis							

Date:09/24/01ISR Number: 3798010-0Report Type:Expedited (15-DaCompany Report #WAES 01091499
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Congestive		Fosamax	C				
			Glucotrol	C				
			Norvasc	C				
			Ultram	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798026-4Report Type:Expedited (15-DaCompany Report #WAES 01097023
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased	Foreign	Tab Vioxx					
	Fluid Retention	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema							
							PO	12 DAY
	Renal Failure Acute		Acetaminophen/Codein					
	Weight Decreased		e Phosphate	C				
			Albuterol Sulfate	C				
			Amlodipine Besylate	C				
			Aspirin (+)					
			Magnesium Oxide	C				
			Atorvastatin					
			Calcium	C				
			Fluticasone					
			Propionate	C				
			Furosemide	C				
			Ipratropium Bromide	C				

Date:09/24/01ISR Number: 3798027-6Report Type:Expedited (15-DaCompany Report #WAES 01096521
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	5 DAY
			Furosemide	C				
			Lansoprazole	C				
			Methimazole	C				
			Morphineso4	C				

Date:09/24/01ISR Number: 3798028-8Report Type:Expedited (15-DaCompany Report #WAES 01096033
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Rhabdomyolysis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL

PO 2 DAY

Date:09/24/01ISR Number: 3798029-XReport Type:Expedited (15-DaCompany Report #WAES 01093476
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	Myocardial Infarction	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL
Hospitalization - Initial or Prolonged			Amiodarone	C		
			Quinapril Hcl	C		

Dose Duration
25 MG/AM PO

Date:09/24/01ISR Number: 3798030-6Report Type:Expedited (15-DaCompany Report #WAES 01085193
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Blood Alkaline Phosphatase Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
	Condition Aggravated	Professional				
	Gamma-Glutamyltransferase Increased		Acetaminophen/Codeine Phosphate	C		
	Hypergammaglobulinaemia					

Dose Duration
25 MG/DAILY
PO 12.5
MG/DAILY PO 39 DAY

			Ketoprofen	C
			Levothyroxine Na	C
			Nifedipine	C
			Prednisolone	C
			Tamoxifen Citrate	C
			Zolpidem Tartrate	C

Date:09/24/01ISR Number: 3798032-XReport Type:Expedited (15-DaCompany Report #WAES 01095566
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis	Foreign	Tab Vioxx					
	Renal Failure Acute	Literature	(Rofecoxib)	PS		ORAL	25 MG PO	5 DAY
	Renal Tubular Disorder	Health	Vasotec	C				
		Professional	Cyclosporine	C				
			Doxazosin	C				
			Furosemide	C				
			Ganciclovir	C				
			Metoprolol	C				
			Mycophenolate Mofetil	C				
			Pantoprazole	C				
			Prednisolone	C				

Date:09/24/01ISR Number: 3798050-1Report Type:Expedited (15-DaCompany Report #2001COU1517
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Study	Coumadin	PS		ORAL	PO	
Initial or Prolonged	Chest Discomfort	Health	Vioxx (Rofecoxib)	SS			25 MG	
	Confusional State	Professional	Asa (Acetylsalicylic Acid)	SS			81 MG	
	Culture Stool Positive							
	Gastric Ulcer							
	Haemoglobin Decreased							
	International Normalised Ratio Increased							

Date:09/24/01ISR Number: 3798179-8Report Type:Expedited (15-DaCompany Report #2001073066FR
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Conduction Disorder	Foreign Health Professional Other	Celebrex (Celecoxib) Capsule Rofecoxib (Rofecoxib)	PS SS		ORAL	ORAL	

Date:09/24/01ISR Number: 3798307-4Report Type:Direct Company Report #
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria		Rofecoxib (Merck)	PS	Merck	ORAL	25 MG 2-QD PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798387-6Report Type:Direct Company Report #
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	
			Asa	C				
			Simvastatin	C				

Date:09/24/01ISR Number: 3798515-2Report Type:Expedited (15-DaCompany Report #WAES 01075538
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cortisol Increased Cardiomegaly	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	1 DAY
	Creatinine Renal Clearance Decreased Dizziness Fluid Retention Gallbladder Disorder Glucocorticoids Increased Hepatomegaly Hyponatraemia Liver Disorder Nerve Root Lesion Oedema Pleural Effusion Uterine Disorder	Professional	Atenolol	C				

Date:09/24/01ISR Number: 3798521-8Report Type:Expedited (15-DaCompany Report #WAES 01085560
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness Hyponatraemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	
			Hydrodiuril	C				

Alfacalcidol	C
Amylase (+)	
Bromelains (+)	
Chymotrypsin	C
Betahistine Mesylate	C
Captopril	C
Ginkgo Biloba Extract	C
Risedronate Sodium	C

Date:09/24/01ISR Number: 3798533-4Report Type:Expedited (15-DaCompany Report #WAES 01093462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798580-2Report Type:Expedited (15-DaCompany Report #WAES 01076070
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulitis Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	3 DAY

Date:09/24/01ISR Number: 3798581-4Report Type:Expedited (15-DaCompany Report #WAES 01086060
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematoma Platelet Count Decreased	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	3 DAY
	Rectal Haemorrhage		Betahistine Hydrochloride	C				
			Ginkgo Biloba Extract	C				
			Spironolactone	C				

Date:09/24/01ISR Number: 3798624-8Report Type:Expedited (15-DaCompany Report #WAES 01095565
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign	Vioxx	PS		ORAL	25 MG	2 DAY
	Protein Total Decreased Renal Failure Acute	Literature Health Professional Other	Hydrodiuril	C				
			Acetaminophen	C				
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				
			Atorvastatin	C				
			Isosorbide Dinitrate	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3798656-XReport Type:Expedited (15-DaCompany Report #WAES 01081863
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Increased	Professional						
	Aspartate		Celexa 20 Mg	SS		ORAL	20 MG/HS/PO	
	Aminotransferase		Ambien 10 Mg	SS		ORAL	10 MG/QOD/PO	
	Increased		Tab Zocor 40 Mg	SS			40 MG/DAILY	
	Blood Alkaline		Halcion	C				
	Phosphatase Increased		Lasix (Furosemide)	C				
	Haematocrit Decreased		Prinivil	C				
			Cyclophosphamide	C				

Date:09/24/01ISR Number: 3798657-1Report Type:Expedited (15-DaCompany Report #WAES 01070101
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Other	Eye Haemorrhage	Health						
	Histoplasmosis	Professional	Actos	C				
	Neovascularisation		Amaryl	C				
	Visual Disturbance		Premarin	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798658-3Report Type:Expedited (15-DaCompany Report #WAES 01062024
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated	Health Professional	Tab Vioxx 12.5mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematochezia		Coumadin	C				
	Pulmonary Oedema		Darvocet-N	C				
			Lasix (Furosemide)	C				
			Tylenol Extra Stength	C				
			Calcium (Unspecified) (+) Vitami	C				
			Colchicine	C				
			Cyanocobalamin	C				
			Digoxin	C				
			Diltiazem Hydrochloride	C				
			Nitroglycerin	C				
			Potassium Chloride	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3798724-2Report Type:Periodic Company Report #WAES 01031303
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Orsu Vioxx 25 Mg	PS		ORAL	PO	
	Dyspepsia	Professional	Dexedrine	C				
	Energy Increased		Ornade Spansule	C				
			Vicodin Tablets	C				

Date:09/24/01ISR Number: 3798725-4Report Type:Periodic Company Report #WAES 01052710
Age:8 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Health	Orsu Vioxx 12.5 Mg	PS		ORAL
12.5						
		Professional				
MG/DAILY/PO						
			Histinex Hc	C		
			Zithromax	C		

Date:09/24/01ISR Number: 3798726-6Report Type:Periodic Company Report #WAES 01062156
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Orsu Vioxx 25 Mg	PS		ORAL
25						
	Dysphagia					
MG/DAILY/PO						
	Face Oedema		Lanoxin	C		
	Headache		Synthroid	C		
	Oedema Peripheral		Prednisone	C		

Date:09/24/01ISR Number: 3798727-8Report Type:Periodic Company Report #WAES 01042277
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Musculoskeletal Stiffness	Health				
MG/DAILY/PO;						
	Oedema Peripheral	Professional				
25 MG/PRN/PO						

	Aventyl	C
	Prinivil	C
	Valium	C
	Ventolin	C
	Aspirin	C

Date:09/24/01ISR Number: 3798728-XReport Type:Periodic Company Report #WAES 01042283
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO; 25 MG/QOD/PO	
	Chest Pain	Health						
	Dyspnoea	Professional	Coumadin	C				

Date:09/24/01ISR Number: 3798730-8Report Type:Periodic Company Report #WAES 01042301
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health						
		Professional	Amoxi	C				
			Avandia	C				
			Levoxyl	C				
			Normodyne	C				
			Premarin	C				

Date:09/24/01ISR Number: 3798732-1Report Type:Periodic Company Report #WAES 01042305
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Splinter Haemorrhages	Health						

		Professional	Tab Vioxx 50 Mg	SS		ORAL
50						
MG/DAILY/PO						

Date:09/24/01ISR Number: 3798733-3Report Type:Periodic Company Report #WAES 01042343
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash		Evista	C				

Date:09/24/01ISR Number: 3798734-5Report Type:Periodic Company Report #WAES 01042393
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
		Professional	Accupril	C			MG/DAILY/PO	
			Viagra	C				
			Aspirin	C				
			Atenolol	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798735-7Report Type:Periodic Company Report #WAES 01042408
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Exelon	C				
			Iron	C				

Date:09/24/01ISR Number: 3798736-9Report Type:Periodic Company Report #WAES 01042412
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nail Disorder							

Date:09/24/01ISR Number: 3798737-0Report Type:Periodic Company Report #WAES 01042442
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Uterine Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Advil	C				
			Fosamax	C				
			Premarin	C				
			Provera	C				

Date:09/24/01ISR Number: 3798738-2Report Type:Periodic Company Report #WAES 01042447
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				

			Glucophage	C		
			Hydrocodin	C		

Date:09/24/01ISR Number: 3798739-4Report Type:Periodic Company Report #WAES 01070791
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Hyperglycaemia							
			Darvon	C				
			Estrace	C				
			Glucophage	C				
			Lopressor	C				
			Tylenol	C				

Date:09/24/01ISR Number: 3798740-0Report Type:Periodic Company Report #WAES 01042523
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx	PS		ORAL	50MG/X1/PO	
	Dyspnoea	Professional						
	Hyperaesthesia							
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798741-2Report Type:Periodic Company Report #WAES 01042531
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Vomiting		Timodine	C				
			Tamoxifen	C				

Date:09/24/01ISR Number: 3798742-4Report Type:Periodic Company Report #WAES 01042535
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective	Professional						
			Claritin	C				
			Nolvadex	C				
			Desonide	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3798743-6Report Type:Periodic Company Report #WAES 01042569
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Parosmia	Professional						
		Company Representative						

Date:09/24/01ISR Number: 3798744-8Report Type:Periodic Company Report #WAES 01042573
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Back Pain	Health					MG/DAILY/PO	
	Contusion	Professional	Fosamax	C				
	Dizziness		Hydrodiuril	C				
	Fall		Estrogens	C				
	Fatigue							
	Feeling Cold							
	Injury							
	Skin Disorder							

Date:09/24/01ISR Number: 3798746-1Report Type:Periodic Company Report #WAES 01042691
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						
		Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798747-3Report Type:Periodic Company Report #WAES 01042707
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine	C				
			Ibuprofen	C				

Date:09/24/01ISR Number: 3798748-5Report Type:Periodic Company Report #WAES 01042852
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY PO	
			Atenolol	C				

Date:09/24/01ISR Number: 3798749-7Report Type:Periodic Company Report #WAES 01042867
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3798750-3Report Type:Periodic Company Report #WAES 01042872
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY PO	

				Cardura	C		
				Lanoxin	C		
				Serzone	C		
				Kalatan	C		
				Atenolol	C		
				Cimetidine	C		
				Isosorbide	C		
				Terazosin	C		
				Triamcinolone	C		

Date:09/24/01ISR Number: 3798751-5Report Type:Periodic Company Report #WAES 01051739
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia	Professional						
	Dyspnoea		Celebrex	C				

Date:09/24/01ISR Number: 3798752-7Report Type:Periodic Company Report #WAES 01070792
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	PO	
			Hyzaar	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798753-9Report Type:Periodic Company Report #WAES 01051740
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lansoprazole	C				

Date:09/24/01ISR Number: 3798754-0Report Type:Periodic Company Report #WAES 01070804
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health Professional	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Ascorbic Acid	C				
			Chondroitin (+) Glucosamine	C				
			Phentermine	C				

Date:09/24/01ISR Number: 3798755-2Report Type:Periodic Company Report #WAES 01051795
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactose Intolerance	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3798757-6Report Type:Periodic Company Report #WAES 01070810
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blister	Consumer	Vioxx 25 Mg	PS		ORAL
PO						
	Oral Soft Tissue Disorder					
	Skin Lesion					

Date:09/24/01ISR Number: 3798758-8Report Type:Periodic Company Report #WAES 01051810
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Pruritic	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Tab Vioxx 25 Mg	SS		ORAL
25						
MG/DAILY/PO						
			Axid	C		
			Coumadin	C		
			Voltaren	C		
			Zocor	C		
			Atenolol	C		
			Pentoxifylline	C		

Date:09/24/01ISR Number: 3798759-XReport Type:Periodic Company Report #WAES 01070812
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Haemorrhage	Health
		Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798760-6Report Type:Periodic Company Report #WAES 01051811
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Colonic Neoplasm	Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematochezia	Health						
	Rectal Haemorrhage	Professional	Ambien	C				
			Celebrex	C				
			Coumadin	C				
			Prinivil	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3798761-8Report Type:Periodic Company Report #WAES 01051823
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain	Health						
	Dyspepsia	Professional	Accupril	C				
	Dyspnoea		Calan	C				
	Erythema		Centrum	C				
	Painful Respiration		Combivent	C				
			Imdur	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Nitrostat	C				
			Prinivil	C				
			Prozac	C				
			Tenormin	C				
			Trental	C				

Tylenol	C
Vancenase Aq Nasal Spray	C
Allopurinol	C
Aspirin	C
Cyanocobalamin	C
Prednisone	C
Vitamin E	C

Date:09/24/01ISR Number: 3798762-XReport Type:Periodic Company Report #WAES 01070817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798764-3Report Type:Periodic Company Report #WAES 01051889
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Fatigue		Paxil	C				
			Vicodin Tablets	C				

Date:09/24/01ISR Number: 3798765-5Report Type:Periodic Company Report #WAES 01051892
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dry Skin	Professional					MG/DAILY/PO	
	Pruritus		Vitamin B Complex	C				
			Zinc	C				

Date:09/24/01ISR Number: 3798767-9Report Type:Periodic Company Report #WAES 01051898
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Health					MG/DAILY/PO	
		Professional						

Date:09/24/01ISR Number: 3798769-2Report Type:Periodic Company Report #WAES 01052000
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Oedema Professional
MG/DAILY/PO

Date:09/24/01ISR Number: 3798771-0Report Type:Periodic Company Report #WAES 01070818
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopause	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798772-2Report Type:Periodic Company Report #WAES 99121451
Age:16 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
	Leukocytosis	Health Professional	Advil	C				
			Motrin	C				
			Tylenol	C				
			Vicks Dayquil	C				
			Vicks Formula 44 Cold & Cough	C				
			Erythromycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798776-XReport Type:Periodic Company Report #WAES 01070822
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Joint Swelling							
			Premarin	C				
			Calcium	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3798778-3Report Type:Periodic Company Report #WAES 01070823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/ORAL	
			Celexa	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Inderal	C				
			Klonopin	C				
			Klor-Con	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3798779-5Report Type:Periodic Company Report #WAES 01051517
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798781-3Report Type:Periodic Company Report #WAES 01070839
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Faecal Incontinence							
			Monopril	C				
			Neurontin	C				

Date:09/24/01ISR Number: 3798782-5Report Type:Periodic Company Report #WAES 01051522
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798783-7Report Type:Periodic Company Report #WAES 01051527
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health	Tab Vioxx	PS		ORAL	PO	
	Urticaria	Professional Company Representative	Zyban	C				

Date:09/24/01ISR Number: 3798784-9Report Type:Periodic Company Report #WAES 01051574
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Detrol	C				
			Duradrin	C				
			Luvox	C				
			Premarin	C				
			Sonata	C				

Date:09/24/01ISR Number: 3798785-0Report Type:Periodic Company Report #WAES 01051593
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798786-2Report Type:Periodic Company Report #WAES 01070840
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Levoxyl	C				
			Mobic	C				
			Estradiol	C				

Date:09/24/01ISR Number: 3798787-4Report Type:Periodic Company Report #WAES 01051603
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Health Professional	Miacalcin	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3798788-6Report Type:Periodic Company Report #WAES 01070846
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Hydroxychloroquine Sulfate	C				
			Methotrexate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798789-8Report Type:Periodic Company Report #WAES 01051621
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Oedema Peripheral	Health Professional	Lipitor	C				
			Norvasc	C				
			Premarin	C				
			Vaseretic	C				

Date:09/24/01ISR Number: 3798790-4Report Type:Periodic Company Report #WAES 01070852
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS				
	Swelling		Celebrex	C				

Date:09/24/01ISR Number: 3798791-6Report Type:Periodic Company Report #WAES 01051633
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Glucophage	C				
			Theo-Dur	C				
			Vasotec	C				

Date:09/24/01ISR Number: 3798792-8Report Type:Periodic Company Report #WAES 01070881
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Jaundice	Professional				
MG/DAILY/PO						
	Pruritus		Augmentin	C		
			Cardizem Cd	C		
			Hytrin	C		
			Prilosec	C		
			Indapamide	C		

Date:09/24/01ISR Number: 3798793-XReport Type:Periodic Company Report #WAES 01051653
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
	Menstrual Disorder							

Date:09/24/01ISR Number: 3798794-1Report Type:Periodic Company Report #WAES 01070886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798795-3Report Type:Periodic Company Report #WAES 01051677
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Lasix (Furosemide)	C				
			Univasc	C				

Date:09/24/01ISR Number: 3798796-5Report Type:Periodic Company Report #WAES 01070894
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dry Mouth						MG/DAILY/PO	
	Keratoconjunctivitis							
	Sicca							
	Nausea							

Date:09/24/01ISR Number: 3798797-7Report Type:Periodic Company Report #WAES 00010421
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO ; 12.5	
	Oedema Peripheral						MG/DAILY/PO	
			Elavil	C				
			Fosamax	C				
			Mylanta & Mylanta Ds	C				
			Os-Cal	C				
			Cyanocobalamin	C				
			Vitamin E	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3798798-9Report Type:Periodic Company Report #WAES 00012540
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cardiomegaly							
	Headache		Estrogenic Preparations	C				
	Renal Disorder		Therapy Unspecified	C				

Date:09/24/01ISR Number: 3798799-0Report Type:Periodic Company Report #WAES 00020480
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhage							
			Aspirin Free Excedrin	C				
			Bentyl	C				
			Celebrex	C				
			Prevacid	C				
			Synthroid	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798800-4Report Type:Periodic Company Report #WAES 00021931
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO ;	
	Drug Ineffective							
	Headache		Advil, Cold And Sinus Caplets	C				
			Diovan	C				
			Plavix	C				
			Tylenol With Codeine	C				
			Aspirin	C				
			Folic Acid	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3798816-8Report Type:Periodic Company Report #WAES 01051407
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective	Health Professional	Premarin	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3798819-3Report Type:Periodic Company Report #WAES 01051418
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Coumadin	C				
			Glucophage	C				
			Glipizide	C				

Date:09/24/01ISR Number: 3798822-3Report Type:Periodic Company Report #WAES 01051433
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pharyngitis	Health						
	Pulmonary Congestion	Professional	Clonazepam	C				
			Propylthiouracil	C				

Date:09/24/01ISR Number: 3798825-9Report Type:Periodic Company Report #WAES 01051441
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cough	Health						
	Pyrexia	Professional	Antimicrobial (Unspecified)	C				

Date:09/24/01ISR Number: 3798828-4Report Type:Periodic Company Report #WAES 01051451
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukopenia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Lymphopenia	Health Professional						

Date:09/24/01ISR Number: 3798831-4Report Type:Periodic Company Report #WAES 01051453
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Diarrhoea	Health					MG/DAILY/PO	
	Dizziness	Professional	Celebrex	C				
	Dyspnoea		Darvocet-N	C				
	Fatigue		Diazide	C				
	Palpitations		Paxil	C				
	Panic Disorder		Vicodin Tablets	C				
	Rash		Nutritional Supplements	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3798833-8Report Type:Periodic Company Report #WAES 01051467
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Muscular Weakness	Health					MG/DAILY/PO	
	Myalgia	Professional	Bayer Aspirin	C				

Date:09/24/01ISR Number: 3798834-XReport Type:Periodic Company Report #WAES 01051492
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective	Professional						
			Celebrex	C				

Date:09/24/01ISR Number: 3798837-5Report Type:Periodic Company Report #WAES 01051494
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention	Other						
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/Q4D/PO	
			Paxil	C				
			Prilosec	C				
			Zocor	C				

Date:09/24/01ISR Number: 3798840-5Report Type:Periodic Company Report #WAES 01051501
Age:70 YR Gender:Female I/FU:F

Outcome	PT
	Confusional State
	Hallucination

	Hypoaesthesia Mental Impairment Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO
		Health Professional	Actonel	C			
			Duratuss	C			
			Maxair	C			
			Singulair	C			
			Acetaminophen (+)				
			Hydrocodone	C			

Date:09/24/01ISR Number: 3798845-4Report Type:Periodic Company Report #WAES 01050980
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Health Professional	Flexeril	C			

Date:09/24/01ISR Number: 3798848-XReport Type:Periodic Company Report #WAES 01051014
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Health Professional	Relafen	C			
			Furosemide	C			

Date:09/24/01ISR Number: 3798851-XReport Type:Periodic Company Report #WAES 01051081
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Abdominal Pain	Health				
MG/DAILY/PO						
	Appetite Disorder	Professional	Celebrex	C		
	Bowel Sounds Abnormal		Norvasc	C		
	Flatulence		Furosemide	C		
	Gastrointestinal Disorder		Vitamins			
	Increased Appetite		(Unspecified)	C		
	Malaise					

Date:09/24/01ISR Number: 3798853-3Report Type:Periodic Company Report #WAES 01051156
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Choking	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Dyspepsia	Health				
	Gastrointestinal Disorder	Professional				
	Gastrooesophageal Reflux					
	Disease					

Date:09/24/01ISR Number: 3798854-5Report Type:Periodic Company Report #WAES 01051165
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Feeling Abnormal	Professional					MG/DAILY/PO	
	Hallucination	Company	Lodine	C				
	Muscular Weakness	Representative						
	Transient Ischaemic Attack							

Date:09/24/01ISR Number: 3798855-7Report Type:Periodic Company Report #WAES 01051296
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health	Premarin	C				
		Professional	Synthroid	C				

Date:09/24/01ISR Number: 3798856-9Report Type:Periodic Company Report #WAES 01051310
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Zoloft	C				

Date:09/24/01ISR Number: 3798857-0Report Type:Periodic Company Report #WAES 01051372
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
	Weight Increased						
MG/DAILY/PO							
			Hydrodiuril	C			
			K-Dur	C			
			Lotrel	C			
			Premarin	C			
			Prilosec	C			
			Synthroid	C			

Date:09/24/01ISR Number: 3798858-2Report Type:Periodic Company Report #WAES 01051392
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
PO								
	Muscle Spasms		Evista	C				
	Sleep Disorder							
	Tinnitus							

Date:09/24/01ISR Number: 3798859-4Report Type:Periodic Company Report #WAES 01051399
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
PO								
	Diarrhoea		Levbid	C				
	Nausea		Prinivil	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3798861-2Report Type:Periodic Company Report #WAES 01050671
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased	Health Professional						
	Diarrhoea		Minocin	C				
			Premarin	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3798864-8Report Type:Periodic Company Report #WAES 01050727
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Synthroid	C				
			Calcium (Unspecified) (+)					
			Vitamin	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3798865-XReport Type:Periodic Company Report #WAES 01050760
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Corgard	C				
			Effexor Xr	C				
			Fosamax	C				
			Pravachol	C				
			Synthroid	C				

			Tylenol	C		
			Vicodin Tablets	C		

Date:09/24/01ISR Number: 3798867-3Report Type:Periodic Company Report #WAES 01050816
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Nausea	Health Professional	Aciphex	C				
			Flovent	C				

Date:09/24/01ISR Number: 3798869-7Report Type:Periodic Company Report #WAES 01050846
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Lipase Increased		Buspar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798870-3Report Type:Periodic Company Report #WAES 01050847
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
			Darvocet-N	C				
			Nicorette	C				
			Premarin	C				
			Prozac	C				

Date:09/24/01ISR Number: 3798872-7Report Type:Periodic Company Report #WAES 01050872
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798873-9Report Type:Periodic Company Report #WAES 01050936
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertriglyceridaemia							

Date:09/24/01ISR Number: 3798875-2Report Type:Periodic Company Report #WAES 00070214
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Vioxx 25 Mg	PS			ORAL
25							
	Constipation						
MG/DAILY/PO							
	Fatigue		Vioxx	SS			ORAL
12.5							

Date:09/24/01ISR Number: 3798876-4Report Type:Periodic Company Report #WAES 01050969
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vaginal Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Cytotec	C		

Date:09/24/01ISR Number: 3798878-8Report Type:Periodic Company Report #WAES 01050974
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gingival Disorder	Health				
MG/DAILY/PO						
	Glossodynia	Professional	Premarin	C		
	Lymphadenopathy		Visken	C		
	Oral Soft Tissue Disorder					
	Tongue Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798879-XReport Type:Periodic Company Report #WAES 00070569
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Gastric Ulcer	Health						
	Mouth Ulceration	Professional					12.5 MG	
	Oral Pain		Celebrex	C				
	Vaginal Discharge		Ecotrin	C				
			Fosamax	C				
			Miacalcin	C				
			Os-Cal D	C				
			Premarin	C				
			Vicodin Tablets	C				

Date:09/24/01ISR Number: 3798880-6Report Type:Periodic Company Report #WAES 00080979
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhage	Health						
	Infection	Professional	Accupril	C				
	Oedema Peripheral		Baycol	C				
	Skin Hyperpigmentation		Toprol Xl Tablets	C				
	Skin Lesion							

Date:09/24/01ISR Number: 3798881-8Report Type:Periodic Company Report #WAES 01050200
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Health						
		Professional	Ativan	C				

			Flexeril	C
			Percocet	C
			Diazepam	C
			Lescol	C

Date:09/24/01ISR Number: 3798882-XReport Type:Periodic Company Report #WAES 00081902
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	9 DAY
	Urinary Incontinence	Professional	Gerovital H3	C				
	Urine Flow Decreased		Calcium	C				
			Folic Acid	C				
			Vitamin E	C				
			Zinc	C				

Date:09/24/01ISR Number: 3798883-1Report Type:Periodic Company Report #WAES 01050233
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Professional						
		Company Representative	Lescol	C				
			Synthroid	C				
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798884-3Report Type:Periodic Company Report #WAES 00082135
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective						MG/DAILY/PO	
	Dyspnoea		Acular	C				
	Fatigue		Synthroid	C				
	Muscle Spasms		Timoptic	C				
	Vision Blurred		Glucosamine	C				

Date:09/24/01ISR Number: 3798885-5Report Type:Periodic Company Report #WAES 01050294
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health	Tab Vioxx 50 Mg	PS	Merck & Co., Inc.	ORAL	50	
		Professional					MG/DAILY/PO	
			Minocin	C				
			Prinivil	C				
			Tiazac	C				

Date:09/24/01ISR Number: 3798886-7Report Type:Periodic Company Report #WAES 00091159
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	25	
	Mouth Ulceration	Health					MG/DAILY/PO	
	Stomatitis	Professional	Hytrin	C				
			Levsin	C				
			Lotrisone	C				
			Mescolor	C				
			Cephalexin	C				
			Oxybutynin Chloride	C				

Date:09/24/01ISR Number: 3798887-9Report Type:Periodic Company Report #WAES 01050296
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3798888-0Report Type:Periodic Company Report #WAES 01050309
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx	PS	Merck & Co., Inc.	ORAL	PO	

Date:09/24/01ISR Number: 3798889-2Report Type:Periodic Company Report #WAES 00100997
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash		Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798892-2Report Type:Periodic Company Report #WAES 01050338
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Cough	Health						
	Dyspnoea	Professional	Diovan	C				
			Tiazac	C				
			[Therapy Unspecified]	C				
			Gemfibrozil	C				

Date:09/24/01ISR Number: 3798893-4Report Type:Periodic Company Report #WAES 00102436
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 12.5mg	PS		ORAL	50 MG/DAILY/PO	7 MON
	Hypersensitivity	Health						
	Polyuria	Professional	Hydrodiuril	C				
	Rash		Lopid	C				
	Rectal Haemorrhage		Lotensin	C				
	Urinary Incontinence		Prinivil	C				

Date:09/24/01ISR Number: 3798895-8Report Type:Periodic Company Report #WAES 01050339
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Rhinorrhoea							
			Zyrtec	C				

Date:09/24/01ISR Number: 3798896-XReport Type:Periodic Company Report #WAES 00120070
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 12.5mg	PS		ORAL	12.5 MG/DAILY/PO	
			Flonase	C				
			Mevacor	C				
			Pepcid	C				
			Premarin	C				
			Zestril	C				

Date:09/24/01ISR Number: 3798897-1Report Type:Periodic Company Report #WAES 00120524
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Urea Increased		Ambien	C				
	Hepatic Function Abnormal		Elavil	C				
	Renal Disorder		Flonase	C				
			Pepcid	C				
			Synthroid	C				
			Tenormin	C				
			Xanax	C				
			Allergic Extract	C				
			Trimethoprim	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798898-3Report Type:Periodic Company Report #WAES 01050552
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	PO	
	Headache	Health Professional	Diovan	C				
	Malaise		Provera	C				
	Nausea		Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3798899-5Report Type:Periodic Company Report #WAES 01050632
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Company Representative	Imitrex	C				

Date:09/24/01ISR Number: 3798901-0Report Type:Periodic Company Report #WAES 01050662
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS	Merck & Co., Inc.	ORAL	PO	
	Oedema	Professional Company Representative	[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3798903-4Report Type:Periodic Company Report #WAES 01050005
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
	Constipation	Health	Centrum	C		
	Oedema Peripheral	Professional	Ecotrin	C		
	Pruritus		Norvasc	C		
	Urinary Tract Infection		Chrondroitin (+)			
			Glucosamine	C		

Date:09/24/01ISR Number: 3798906-XReport Type:Periodic Company Report #WAES 01050019
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Eyelid Oedema	Health				
MG/DAILY/PO						
	Fatigue	Professional	Inderal	C		
	Fluid Retention		Levsin	C		
	Oedema Peripheral		Neurontin	C		
			Premarin	C		
			Pulmicort	C		
			Relafen	C		
			Aspirin	C		
			Spironolactonc	C		

Date:09/24/01ISR Number: 3798907-1Report Type:Periodic Company Report #WAES 01050128
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

Date:09/24/01ISR Number: 3798909-5Report Type:Periodic Company Report #WAES 01050139
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798911-3Report Type:Periodic Company Report #WAES 01050163
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective	Health Professional						

Date:09/24/01ISR Number: 3798913-7Report Type:Periodic Company Report #WAES 01050165
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Rash	Health Professional					MG/DAILY/PO	
			Elavil	C				
			Prempro	C				
			Zanaflex	C				

Date:09/24/01ISR Number: 3798915-0Report Type:Periodic Company Report #WAES 01050167
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional						

Date:09/24/01ISR Number: 3798916-2Report Type:Periodic Company Report #WAES 01050174
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Abdominal Pain							
	Abnormal Faeces		Darvocet-N	C				
			Synthroid	C				
			Zocor	C				

Date:09/24/01ISR Number: 3798917-4Report Type:Periodic Company Report #WAES 01050184
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	
	Pain	Health Professional						

Date:09/24/01ISR Number: 3798918-6Report Type:Periodic Company Report #WAES 01050198
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:09/24/01ISR Number: 3798919-8Report Type:Periodic Company Report #WAES 01031457
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Threapy Unspecified)	C				
			Methotrexate	C				

Date:09/24/01ISR Number: 3798920-4Report Type:Periodic Company Report #WAES 01031736
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Blood Thyroid Stimulating Hormone Increased	Professional					MG/DAILY/PO	
			Welchol 625 Mg	SS		ORAL	1875	
	Fatigue						MG/DAILY/PO	
			Synthroid	C				
			Pioglitazone Hydrochloride	C				

Date:09/24/01ISR Number: 3798921-6Report Type:Periodic Company Report #WAES 01032360
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/TID/PO	
			Dantrium (Bencyclane Fumarate)	C				
			Fioricet Tablets	C				
			Valium	C				

Date:09/24/01ISR Number: 3798922-8Report Type:Periodic Company Report #WAES 01032572
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia Pruritus	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Plaquenil	C				

Date:09/24/01ISR Number: 3798923-XReport Type:Periodic Company Report #WAES 01032884
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Crixivan	C				
			Retrovir	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798924-1Report Type:Periodic Company Report #WAES 01033056
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	1 MON
		Company Representative						

Date:09/24/01ISR Number: 3798925-3Report Type:Periodic Company Report #WAES 01034233
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Pruritus	Health Professional	Feldene	C				

Date:09/24/01ISR Number: 3798926-5Report Type:Periodic Company Report #WAES 01034246
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Health Professional	Therapy Unspecified	C				

Date:09/24/01ISR Number: 3798927-7Report Type:Periodic Company Report #WAES 01034252
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vaginal Haemorrhage	Health						

	Weight Increased	Professional	Menest	C
			Provera	C

Date:09/24/01ISR Number: 3798928-9Report Type:Periodic Company Report #WAES 01040044
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Fosamax	C				

Date:09/24/01ISR Number: 3798929-0Report Type:Periodic Company Report #WAES 01070710
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Cardura	C				
			Codin-P	C				
			Elavil	C				
			Flexeril	C				
			K-Dur	C				
			Mysoline	C				
			Prilosec	C				
			Reglan	C				
			Zoloft	C				

			Thyroid	C		

Date:09/24/01ISR Number: 3798930-7Report Type:Periodic Company Report #WAES 01070712
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Visual Disturbance		Cartia (Diltiazem Hydrochloride)	C				
			Monoket	C				

Date:09/24/01ISR Number: 3798931-9Report Type:Periodic Company Report #WAES 01070720
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798932-0Report Type:Periodic Company Report #WAES 01070723
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Malaise		Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Cardizem Cd	C				
			Detrol	C				
			Lac-Hydrin 12%	C				
			Miacalcin	C				
			Prilosec	C				
			Retin-A	C				
			Synthroid	C				

Timoptic	C
Vasotec	C
Xalatan	C

Date:09/24/01ISR Number: 3798933-2Report Type:Periodic Company Report #WAES 01070732
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798934-4Report Type:Periodic Company Report #WAES 01070734
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Phosphokinase Increased	Professional					MG/DAILY/PO	
	Influenza Like Illness		Claritin	C				
	Muscle Spasms							
	Muscular Weakness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3798935-6Report Type:Periodic Company Report #WAES 01070744
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Hyperhidrosis		Altace	C				
	Panic Disorder		Mirapex	C				
	Rash		Paxil	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3798936-8Report Type:Periodic Company Report #WAES 01070746
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Cozaar	C				
			Ibuprofen	C				

Date:09/24/01ISR Number: 3798937-XReport Type:Periodic Company Report #WAES 01070751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	11 DAY
	Dyspnoea							
	Headache		...	C				

Date:09/24/01ISR Number: 3798938-1Report Type:Periodic Company Report #WAES 01070753
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO
	Pain		Accupril	C		
			Caltrate	C		
			Centrum	C		
			Darvocet N	C		
			Fosamax	C		
			Protonix	C		
			Ascorbic Acid	C		
			Aspirin	C		
			Cholestyramine Resin	C		
			Ferrous Sulfate	C		

Date:09/24/01ISR Number: 3798939-3Report Type:Periodic Company Report #WAES 01070759
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	PRN/PO	
	Weight Increased							

Date:09/24/01ISR Number: 3798940-XReport Type:Periodic Company Report #WAES 01070763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Mouth Ulceration	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798941-1Report Type:Periodic Company Report #WAES 01070765
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urine Abnormality							
			Thyroid	C				

Date:09/24/01ISR Number: 3798942-3Report Type:Periodic Company Report #WAES 01070774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Zocor	C				

Date:09/24/01ISR Number: 3798943-5Report Type:Periodic Company Report #WAES 01070776
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	K-Dur	C				
			Lasix (Furosemide)	C				
			Lopressor	C				

				Zocor	C		
				Aspirin	C		

Date:09/24/01ISR Number: 3798944-7Report Type:Periodic Company Report #WAES 01070777
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3798945-9Report Type:Periodic Company Report #WAES 01070782
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3798947-2Report Type:Periodic Company Report #WAES 01070786
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Glossodynia							
	Mouth Ulceration		Estratest	C				
	Oral Pain		Flovent	C				

			Procardia	C		
			Provera	C		
			Serevent	C		

Date:09/24/01ISR Number: 3798948-4Report Type:Periodic Company Report #WAES 01070787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Back Pain		Celebrex	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3798949-6Report Type:Periodic Company Report #WAES 01070789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799004-1Report Type:Periodic Company Report #WAES 00120580
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervousness	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
			Plendil	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3799005-3Report Type:Periodic Company Report #WAES 00121481
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 50 Mg	PS	Merck & Co., Inc.	ORAL	50	
		Health					MG/DAILY/PO	
		Professional					SEE IMAGE	
			Celebrex	C				
			Naprosyn	C				

Date:09/24/01ISR Number: 3799006-5Report Type:Periodic Company Report #WAES 01010556
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS	Merck & Co., Inc.	ORAL	12.5	
	Rash	Health					MG/DAILY/PO	
		Professional	Paxil	C				
			Procardia Xl	C				
			Xanax	C				
			Potassium Chloride	C				

Date:09/24/01ISR Number: 3799007-7Report Type:Periodic Company Report #WAES 01010680
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Diarrhoea	Consumer
		Health

		Professional	Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL
15 MG/BID/PO						
			Coumadin	C		
			Lanoxin	C		
			Lasix	C		
			Neurontin	C		
			Prinivil	C		
			Tenormin	C		
			Allopurinol	C		

Date:09/24/01ISR Number: 3799008-9Report Type:Periodic Company Report #WAES 01010682
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gastrointestinal Disorder	Health				
MG/DAILY/PO						
		Professional	Cardura	C		
			Ziac	C		

Date:09/24/01ISR Number: 3799009-0Report Type:Periodic Company Report #WAES 01010790
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL
PO						
	Hypertension	Health	Ativan	C		
	Nervousness	Professional	Desyrel	C		
	Oedema Peripheral		Diovan	C		
			Miacalcin	C		
			Norvasc	C		
			Toprol Xl Tablets	C		
			(Therapy			
			Unspecified)	C		
			Aspirin	C		
			Calcium Carbonate			

			(+) Cholecalci	C

Date:09/24/01ISR Number: 3799010-7Report Type:Periodic Company Report #WAES 01011304
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 50 Mg	PS	Merck & Co., Inc.	ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799011-9Report Type:Periodic Company Report #WAES 01011310
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS	50 Mg/Daily/Po	ORAL	50 MG, 25 MG/DAILY/PO	
	Constipation	Health Professional						
	Feeling Abnormal		Darvon	C				
			Enulose	C				
			Prilosec	C				
			Reglan	C				
			Zoloft	C				
			Aspirin	C				

Magnesia (Milk Of) C

Date:09/24/01ISR Number: 3799012-0Report Type:Periodic Company Report #WAES 01011588
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Dizziness	Health						
	Ear Pain	Professional	Cardizem	C				
	Headache		Celebrex	C				
	Musculoskeletal Stiffness		Prilosec	C				
	Nausea		Prinivil	C				
			Zocor	C				

Date:09/24/01ISR Number: 3799013-2Report Type:Periodic Company Report #WAES 01012046
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Health						
		Professional	Flexeril	C				
			Premarin	C				
			Prinzide	C				
			Serzone	C				
			Ultram	C				
			Colonazepam	C				

Date:09/24/01ISR Number: 3799014-4Report Type:Periodic Company Report #WAES 01012327
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

		Health				
MG/DAILY/PO						
		Professional	Amidon	C		
			Vasotec	C		
			Zantac	C		
			Aspirin	C		
			Lorazepam	C		

Date:09/24/01ISR Number: 3799015-6Report Type:Periodic Company Report #WAES 01020191
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Fall		Evista	C				
			Prozac	C				
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799016-8Report Type:Periodic Company Report #WAES 01020451
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Wheezing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
MG/DAILY/PO								
		Professional	Diovan	C				

			Lipitor	C		

Date:09/24/01ISR Number: 3799017-XReport Type:Periodic Company Report #WAES 01020722
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Atacand	C				
			Premarin	C				
			Prilosec	C				
			Relafen	C				
			Tylenol Pm	C				

Date:09/24/01ISR Number: 3799018-1Report Type:Periodic Company Report #WAES 01020925
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Rash	Health Professional	Actos	C				
	Urticaria		Lotensin	C				
			Norvasc	C				
			Plendil	C				
			Premarin	C				
			Tylenol	C				
			Zocor	C				
			Calcium (Unspecified)	C				
			Parsley Concentrate	C				
			Ubidecarenone	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799019-3Report Type:Periodic Company Report #WAES 01021175
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Leukopenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lovenox	C				

Date:09/24/01ISR Number: 3799020-XReport Type:Periodic Company Report #WAES 01021231
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Lower	Consumer	Tab Vioxx	PS		ORAL	PO	
	Diarrhoea	Health Professional	Timoptic	C				
	Dyspepsia		Xalatan	C				
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799021-1Report Type:Periodic Company Report #WAES 01021503
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hepatomegaly	Health Professional	Premarin Vaginal Cream	C				
			Prempro	C				
			Ibuprofen	C				

Date:09/24/01ISR Number: 3799022-3Report Type:Periodic Company Report #WAES 01021844
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Cough							
	Pulmonary Congestion		Tylenol	C				
	Rhinorrhoea							
	Tinnitus							

Date:09/24/01ISR Number: 3799023-5Report Type:Periodic Company Report #WAES 01030031
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health Professional	Altace	C				
			Amaryl	C				
			Avandia	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Glucophage	C				
			Nasacort	C				
			Prempro	C				
			Zyrtec	C				

			Amitriptyline Hydrochloride	C		
			Aspirin	C		
			Niacin	C		
			Nonsteroidal Anti-Inflammatory D	C		

Date:09/24/01ISR Number: 3799087-9Report Type:Expedited (15-DaCompany Report #WAES 01098234
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Renal Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG / DAILY PO 34 DAY						
Disability						
Other			Amiloride Hydrochloride (+)			
			Atenolol (+)	C		
			Aspirin	C		
			Azathioprine Sodium	C		
			Cyclosporine	C		
			Torsemide	C		

Date:09/24/01ISR Number: 3799090-9Report Type:Expedited (15-DaCompany Report #WAES 01099005
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Phlebitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 16 DAY

Date:09/24/01ISR Number: 3799091-0Report Type:Expedited (15-DaCompany Report #WAES 01096054
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 10 DAY

Date:09/24/01ISR Number: 3799094-6Report Type:Expedited (15-DaCompany Report #WAES 01096048
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malaise Ventricular Fibrillation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO 4 DAY	

Date:09/24/01ISR Number: 3799097-1Report Type:Expedited (15-DaCompany Report #WAES 01099004
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Pulmonary Embolism	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	9 DAY

Date:09/24/01ISR Number: 3799111-3Report Type:Periodic Company Report #WAES 01080857
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Eyelid Oedema						MG/DAILY/PO	
	Oedema Peripheral		Prempro	C				
	Pollakiuria		Prilosec	C				
			Tylenol	C				

Date:09/24/01ISR Number: 3799119-8Report Type:Periodic Company Report #WAES 01070327
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Blood Pressure Increased	Health Professional	Darvocet-N	C				
			Fiorinal	C				
			Imodium	C				
			Loppressor	C				
			Pepcid	C				
			Prevacid	C				
			Robaxin	C				
			Tiazac	C				
			Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799123-XReport Type:Periodic Company Report #WAES 01061842
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	International Normalised Ratio Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Coumadin	C				
			Inderal	C				
			Lanoxin	C				
			Lasix (Furosemide Sodium)	C				
			Vasotec	C				
			Potassium	C				

Date:09/24/01ISR Number: 3799126-5Report Type:Periodic Company Report #WAES 01061451
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799128-9Report Type:Periodic Company Report #WAES 01061410
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799130-7Report Type:Periodic Company Report #WAES 01061269
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25; 50 MG/DAILY/PO	
	Myalgia	Health Professional	Midrin	C				
	Pain		Hydrocodone	C				

Date:09/24/01ISR Number: 3799134-4Report Type:Periodic Company Report #WAES 01052364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799155-1Report Type:Periodic Company Report #WAES 01040054
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Rash	Health Professional	Librax Capsules	C				

			Synthroid	C		
			Furosemide	C		
			Propranolol	C		

Date:09/24/01ISR Number: 3799158-7Report Type:Periodic Company Report #WAES 01040306
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
		Health					/ PO	
		Professional	Axid	C				
			Celebrex	C				
			Lipitor	C				

Date:09/24/01ISR Number: 3799161-7Report Type:Periodic Company Report #WAES 01040332
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
	Haematochezia						DAILY / PO	
			Ambien	C				
			Coumadin	C				
			Cozaar	C				
			Digitek	C				
			Lipitor	C				
			Tylenol Extra Strength	C				
			Verelan	C				
			Estradiol	C				
			Folic Acid	C				
			Methotrexate	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799164-2Report Type:Periodic Company Report #WAES 01040926
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Cardizem	C				
		Other						

Date:09/24/01ISR Number: 3799165-4Report Type:Periodic Company Report #WAES 01040951
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Oedema Peripheral	Professional					PO	
			Ambien	C				
			Deseril	C				
			Premarin	C				
			Serax	C				
			Toprol Xl Tablets	C				
			Tricor	C				
			Ultram	C				
			Zanaflex	C				
			Zocor	C				

			Zoloft	C		
			Lithium Salicylate	C		

Date:09/24/01ISR Number: 3799168-XReport Type:Periodic Company Report #WAES 01040989
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
			Propoxyphene Napsylate	C				

Date:09/24/01ISR Number: 3799172-1Report Type:Periodic Company Report #WAES 01041050
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799174-5Report Type:Periodic Company Report #WAES 01041114
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Oedema Peripheral	Health Professional						
			Amaryl	C				
			Evista	C				
			Glucophage	C				
			Prilosec	C				
			Prinivil	C				
			Diltiazem	C				

Doxazosin Mesylate	C		
Furosemide	C		

Date:09/24/01ISR Number: 3799178-2Report Type:Periodic Company Report #WAES 01041162
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Dyspnoea	Health Professional	Avapro	C				
	Muscular Weakness		Extra Strength					
	Pain		Maalox	C				

Date:09/24/01ISR Number: 3799181-2Report Type:Periodic Company Report #WAES 01041231
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799196-4Report Type:Periodic Company Report #WAES 01041242
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Headache	Professional						
	Influenza							
	Nausea							

Date:09/24/01ISR Number: 3799197-6Report Type:Periodic Company Report #WAES 01041309
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO;50	
	Haemorrhage	Health					MG/DAILY/PO	
		Professional	Toradol	C				

Date:09/24/01ISR Number: 3799198-8Report Type:Periodic Company Report #WAES 01041353
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Increased	Professional	[Therapy					
	Blood Urea Increased	Company	Unspecified]	C				
	Proteinuria	Representative						

Date:09/24/01ISR Number: 3799199-XReport Type:Periodic Company Report #WAES 01041355
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

		Health				
MG/DAILY/PO						
		Professional	Lopid	C		
			Questran	C		
			Veleran	C		
			Zantac	C		

Date:09/24/01ISR Number: 3799200-3Report Type:Periodic Company Report #WAES 01041394
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Pruritus	Health						
MG/DAILY/PO								
		Professional	Lotrel	C				
			Premarin	C				
			Synthroid	C				
			Tricor	C				
			Vaseline	C				
			Atenolol	C				
			Chlorthalidone	C				
			Insulin , Biphasic					
			Isophane [Inje	C				
			Nonsteroidal					
			Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799201-5Report Type:Periodic Company Report #WAES 01041439
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO;25MG/DAILY/PO	
	Hypoaesthesia	Company Representative						
			Aleve	C				
			Estratest H.S.	C				
			Synthroid	C				
			Xanax	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799202-7Report Type:Periodic Company Report #WAES 01041481
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799203-9Report Type:Periodic Company Report #WAES 01041484
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3799204-0Report Type:Periodic Company Report #WAES 01041798
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pharyngeal Oedema	Health						
	Throat Tightness	Professional						

Date:09/24/01ISR Number: 3799205-2Report Type:Periodic Company Report #WAES 01041842
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Arthralgia	Professional	Aleve	C				
	Joint Swelling	Company	Anaprox	C				
	Oedema Peripheral	Representative	Prilosec	C				

Date:09/24/01ISR Number: 3799208-8Report Type:Periodic Company Report #WAES 01042031
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/P0	
		Health						
		Professional	Calcijm (Unspecified)	C				
			Estrogens (Unspecified)	C				
			Vitamins					

(Unspecified) C

Date:09/24/01ISR Number: 3799210-6Report Type:Periodic Company Report #WAES 01042039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Contac (Chlorpheniramine Maleate (+)	SS			UNKNOWN	
			Celebrex	C				
			Cytotec	C				
			Darvon	C				
			Fosamax	C				
			Plaquenil	C				
			Zantac	C				

Date:09/24/01ISR Number: 3799212-XReport Type:Periodic Company Report #WAES 01042092
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea	Health						
	Headache	Professional						
	Pain In Extremity							
	Palpitations							

Date:09/24/01ISR Number: 3799216-7Report Type:Periodic Company Report #WAES 01042129
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
		Professional	[Therapy					
		Company	Unspecified]	C				

Representative

Date:09/24/01ISR Number: 3799219-2Report Type:Periodic Company Report #WAES 01042143
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness	Health						
	Eye Movement Disorder	Professional	Pentasa	C				
	Gait Disturbance							
	Gastritis							
	Insomnia							
	Oedema Peripheral							
	Pyrexia							
	Tinnitus							

Date:09/24/01ISR Number: 3799221-0Report Type:Periodic Company Report #WAES 01042147
Age:91 YR Gender:Female I/FU:F

Outcome	PT
	Asthenia
	Back Pain
	Erythema

	Face Oedema						
	Fatigue						
	Hypersensitivity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pneumonia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Skin Exfoliation						
			Actonel	C			
			Codeine Phosphate				
			(+) Promethazi	C			

Date:09/24/01ISR Number: 3799224-6Report Type:Periodic Company Report #WAES 01042163
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Health					
		Professional	Prozac	C			

Date:09/24/01ISR Number: 3799225-8Report Type:Periodic Company Report #WAES 01042170
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Diabetes Mellitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Non-Insulin-Dependent	Health					
		Professional	Climara	C			
			Coumadin	C			
			Glucovance	C			
			Lanoxin	C			
			Zestril	C			
			Zocor	C			
			Atenolol	C			
			Gemfibrozil	C			
			Nitroglycerin	C			

Date:09/24/01ISR Number: 3799227-1Report Type:Periodic Company Report #WAES 01042181
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
		Health Professional	Glucotrol	C				
			Norvasc	C				
			Codeine	C				

Date:09/24/01ISR Number: 3799229-5Report Type:Periodic Company Report #WAES 01042275
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Health Professional	Adalat Cc	C				
			Centrum Silver	C				
			Diazide	C				
			Fioricet Tablets	C				
			Fosamax	C				
			Glucophage	C				
			Lipitor	C				
			Lotrisone	C				
			Neurontin	C				

Ocuvite	C
Premarin	C
Provera	C
Synthroid	C
Tylenol Extra Strength	C
Ascorbic Acid	C
Aspirin	C
Calcium (Unspecified) (+)	
Vitai	C
Folic Acid	C
Pneumococcal Vaccine Polyvalent	C
Quinine Sulfate	C

Date:09/24/01ISR Number: 3799231-3Report Type:Periodic Company Report #WAES 01070054
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Paraesthesia		Femhrt	C				
	Weight Increased		Fosamax	C				
			Macrobid	C				
			Prevacid	C				

Date:09/24/01ISR Number: 3799235-0Report Type:Periodic Company Report #WAES 01070071
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3799236-2Report Type:Periodic Company Report #WAES 01070093
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Uterine Haemorrhage	Professional Company Representative	Estorgens (Unspecified)	C				

Date:09/24/01ISR Number: 3799237-4Report Type:Periodic Company Report #WAES 01070104
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Professional Company Representative	Periogard	C				
			Chlorhexidine	C				
			Doxycycline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799239-8Report Type:Periodic Company Report #WAES 01070130
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Oedema							
	Swelling		Lipitor	C				
			Prinzide	C				

Date:09/24/01ISR Number: 3799240-4Report Type:Periodic Company Report #WAES 01070133
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO
			Allegra D	C				
			Celexa	C				
			Detrol	C				
			L-Thyroxin	C				
			Prempro	C				
			Prilosec	C				
			Zocor	C				
			Atenolol	C				
			Doxepin	C				
			Hydroxyzine	C				

Date:09/24/01ISR Number: 3799241-6Report Type:Periodic Company Report #WAES 01070137
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Rash		Tab Vioxx 12.5 Mg	SS		ORAL	12.5	MG/DAILY/PO

			Norvasc	C		

Date:09/24/01ISR Number: 3799242-8Report Type:Periodic Company Report #WAES 01070151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alanine Aminotransferase	Health	Tab Vioxx 12.5 Mg	PS		
12.5 MG/PRN						
	Increased	Professional	Prevacid	C		
	Aspartate	Company	Glucosamine	C		
	Aminotransferase	Representative				
	Increased					
	Hepatic Function Abnormal					
	Hyperbilirubinaemia					

Date:09/24/01ISR Number: 3799245-3Report Type:Periodic Company Report #WAES 01070152
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL
PO						
		Health	Lipitor	SS		
		Professional	Diovan	C		
			Toprol Xl Tablets	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799255-6Report Type:Periodic Company Report #WAES 01070155
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY	/ PO
			Coreg	C				
			Cozaar	C				
			Zocor	C				

Date:09/24/01ISR Number: 3799257-XReport Type:Periodic Company Report #WAES 01070158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
	Urticaria						DAILY / PO	

Date:09/24/01ISR Number: 3799259-3Report Type:Periodic Company Report #WAES 01070159
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Altace	C				
			Astelin	C				
			Claritin	C				
			Flexeril	C				
			Lipitor	C				
			Synthroid	C				
			Zoloft	C				
			Aspirin	C				
			Dimethyl Sulfone (+)					
			Glucosamine	C				
			Insulin	C				

Date:09/24/01ISR Number: 3799261-1Report Type:Periodic Company Report #WAES 01070164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY; 25 MG / QOD / PO	
			Tylenol	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3799284-2Report Type:Periodic Company Report #WAES 01070168
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Tylenol	C				

Date:09/24/01ISR Number: 3799286-6Report Type:Periodic Company Report #WAES 01070170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY / PO	3 MON
	Drug Ineffective							

			Prilosec	C		

Date:09/24/01ISR Number: 3799288-XReport Type:Periodic Company Report #WAES 01070176
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Premarin	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3799290-8Report Type:Periodic Company Report #WAES 01070178
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Diarrhoea		Celebrex	C				
	Dizziness		Neurontin	C				
	Fatigue							
	Muscular Weakness							

Date:09/24/01ISR Number: 3799292-1Report Type:Periodic Company Report #WAES 01081001
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS			25 MG	
	Dyspnoea		Prevacid	C				

Date:09/24/01ISR Number: 3799293-3Report Type:Periodic Company Report #WAES 01070179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx	PS			ORAL
PO							

Date:09/24/01ISR Number: 3799294-5Report Type:Periodic Company Report #WAES 01081007
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Tylenol With Codeine #3	C				
			Valium	C				
			Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:09/24/01ISR Number: 3799295-7Report Type:Periodic Company Report #WAES 01081012
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799296-9Report Type:Periodic Company Report #WAES 01070180
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Actos	C				
			Amaryl	C				
			Lipitor	C				

Date:09/24/01ISR Number: 3799298-2Report Type:Periodic Company Report #WAES 01070181
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Tylenol	C				
			[Composition Unspecified]	C				

Date:09/24/01ISR Number: 3799300-8Report Type:Periodic Company Report #WAES 01081015
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Blood Bilirubin Increased		Coumadin	C				
	Blood Lactate Dehydrogenase Increased		Lanoxin	C				
	Haemolysis		Tricor	C				
	International Normalised Ratio Increased		Vicodin Tablets	C				
	Malaise		Furosemide	C				
			Isosorbide	C				
			Potassium Chloride	C				

Date:09/24/01ISR Number: 3799301-XReport Type:Periodic Company Report #WAES 01070185
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO; 50 MG/PO	10 DAY

Date:09/24/01ISR Number: 3799303-3Report Type:Periodic Company Report #WAES 01070186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799304-5Report Type:Periodic Company Report #WAES 01081016
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	BID PO	
	Dyspepsia		Flovent	C				
	Mouth Ulceration		Serevent	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799305-7Report Type:Periodic Company Report #WAES 01070187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advair	C				
			Cardura	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Pulmicort	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3799307-0Report Type:Periodic Company Report #WAES 01081018
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Theophylline	C				

Date:09/24/01ISR Number: 3799308-2Report Type:Periodic Company Report #WAES 01070189
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Flomax (Tamsulosin Hydrochloride)	C				

Date:09/24/01ISR Number: 3799310-0Report Type:Periodic Company Report #WAES 01081019
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
	Myalgia						PO	
			Avapro	C				
			Baycol	C				
			Pravachol	C				
			Proscar	C				
			Vicodin Tablets	C				

Date:09/24/01ISR Number: 3799311-2Report Type:Periodic Company Report #WAES 01070197
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO;	
	Increased	Professional					25 MG/DAILY/PO	1 WK
			Hytrin	C				
			Lanoxin	C				
			Vasotec	C				
			Zocor	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799312-4Report Type:Periodic Company Report #WAES 01081025
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799313-6Report Type:Periodic Company Report #WAES 01070199
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799314-8Report Type:Periodic Company Report #WAES 01081033
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Estrogen	C				
			....	C				

Date:09/24/01ISR Number: 3799316-1Report Type:Periodic Company Report #WAES 01081035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY PO	
			Depakote	C				

				Loxitane	C	
				Ritalin	C	
				Imipramine	C	
				Lorazepam	C	
				Oxazepam	C	

Date:09/24/01ISR Number: 3799317-3Report Type:Periodic Company Report #WAES 01081049
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Rash						MG/DAILY/PO	
			Ambien	C				
			Hydrocodone/Apap	C				
			Levoxyl	C				
			Premarin	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/24/01ISR Number: 3799318-5Report Type:Periodic Company Report #WAES 01081053
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

			Premarin	C		

Date:09/24/01ISR Number: 3799319-7Report Type:Periodic Company Report #WAES 01070201
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Goitre	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
		Health Professional	Aciphex	C				
			Cozaar	C				
			Flomax (Morniflumate)	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Clonazepam	C				

Date:09/24/01ISR Number: 3799321-5Report Type:Periodic Company Report #WAES 01081056
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Oedema Peripheral		Allegra	C				
			Therapy Unspecified	C				

Date:09/24/01ISR Number: 3799322-7Report Type:Periodic Company Report #WAES 01081059
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799323-9Report Type:Periodic Company Report #WAES 01081064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Middle Ear Effusion	Professional					MG/DAILY/PO	
	Pyrexia		Amitriptyline	C				

Date:09/24/01ISR Number: 3799324-0Report Type:Periodic Company Report #WAES 01081069
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Cartia (Diltiazem Hydrochloride)	C				
			Lopid	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799326-4Report Type:Periodic Company Report #WAES 01081071
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Urticaria							
			Lipitors	C				

Date:09/24/01ISR Number: 3799327-6Report Type:Periodic Company Report #WAES 01070206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative	[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799329-XReport Type:Periodic Company Report #WAES 01081074
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
			Lipitor	C				
			Levothyroxine Sodium	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3799331-8Report Type:Periodic Company Report #WAES 01081075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Tachycardia		Coumadin	C				
			Digoxin	C				

Date:09/24/01ISR Number: 3799332-XReport Type:Periodic Company Report #WAES 01070215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Celebrex	C				

Date:09/24/01ISR Number: 3799333-1Report Type:Periodic Company Report #WAES 01081079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Arthrotec	C				
			Glucovance	C				
			Hormones	C				

Date:09/24/01ISR Number: 3799334-3Report Type:Periodic Company Report #WAES 01070217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Vertigo	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799335-5Report Type:Periodic Company Report #WAES 01081081
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Levothyroxine Sodium	C				

Date:09/24/01ISR Number: 3799336-7Report Type:Periodic Company Report #WAES 01081083
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	

Date:09/24/01ISR Number: 3799337-9Report Type:Periodic Company Report #WAES 01070232
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799338-0Report Type:Periodic Company Report #WAES 01081094
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fatigue	Professional					MG/DAILY/PO	
	Oedema Peripheral		Baycol	C				
	Swelling		Evista	C				
			Flexeril	C				
			Toprol Xl Tablets	C				

Date:09/24/01ISR Number: 3799340-9Report Type:Periodic Company Report #WAES 01081098
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-25	
	Diarrhoea						MG/DAILY PO	
			Zocor	C				
			Atenolol	C				
			Chondroitin (+)					
			Glucosamine	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799342-2Report Type:Periodic Company Report #WAES 01081196
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799343-4Report Type:Periodic Company Report #WAES 01081107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799344-6Report Type:Periodic Company Report #WAES 01081137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799345-8Report Type:Periodic Company Report #WAES 01081140
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vision Blurred							
			Aciphex	C				
			Levbid	C				

			Miacalcin	C		
			Xalatan	C		

Date:09/24/01ISR Number: 3799346-XReport Type:Periodic Company Report #WAES 01081182
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Vioxx 25 Mg	PS		ORAL	25M	
							G/DAILY/PO	
			Antivert	C				
			Atacand	C				
			Avandia	C				
			Glucotrol	C				
			Lasix (Furosemide)	C				
			Zocor	C				

Date:09/24/01ISR Number: 3799347-1Report Type:Periodic Company Report #WAES 01081192
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx 25 Mg	PS		ORAL	25	
	Constipation						MG/DAILY/PO	
	Diarrhoea		Celebrex	C				
	Irritable Bowel Syndrome		Lasix (Furosemide)	C				
			Norvasc	C				

		Prevacid	C
		Serzone	C
		Warfarin	C

Date:09/24/01ISR Number: 3799348-3Report Type:Periodic Company Report #WAES 01070253
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:09/24/01ISR Number: 3799349-5Report Type:Periodic Company Report #WAES 01081197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative	Fosamax	C				

Date:09/24/01ISR Number: 3799350-1Report Type:Periodic Company Report #WAES 01081198
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Vitamins	C				

Date:09/24/01ISR Number: 3799351-3Report Type:Periodic Company Report #WAES 01081199
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional Company Representative						

Date:09/24/01ISR Number: 3799352-5Report Type:Periodic Company Report #WAES 01081200
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	12.5 MG	
	Headache	Professional					DAILY PO	:
	Musculoskeletal Stiffness						25 MG DAILY	
	Pain						PO	
			Allegra	C				
			Altace	C				
			Evista	C				
			Norvasc	C				
			Synthroid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799353-7Report Type:Periodic Company Report #WAES 01070255
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/PO	
	Hypertension	Professional Company Representative						

Date:09/24/01ISR Number: 3799354-9Report Type:Periodic Company Report #WAES 01081202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx	PS		ORAL	25 MG DAILY PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3799355-0Report Type:Periodic Company Report #WAES 01070278
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Keratoconjunctivitis							
	Sicca		Arava	C				

Date:09/24/01ISR Number: 3799356-2Report Type:Periodic Company Report #WAES 01081203
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	2 WK

	Dyspepsia	Professional	Lipitor	C		
	Nausea		Estrogens	C		

Date:09/24/01ISR Number: 3799357-4Report Type:Periodic Company Report #WAES 01070297
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Dizziness		Arapro	C				
	Fatigue							
	Nausea							

Date:09/24/01ISR Number: 3799358-6Report Type:Periodic Company Report #WAES 01081217
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Genital Haemorrhage	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
	Glossodynia						PO	
	Hypersensitivity		Darvocet-N	C				
	Oedema Genital		Zanaflex	C				
	Tongue Oedema							
	Vaginal Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799359-8Report Type:Periodic Company Report #WAES 01070298
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Musculoskeletal Stiffness						25 MG/DAILY/PO	
			Glucophage	C				
			Glyburide	C				

Date:09/24/01ISR Number: 3799361-6Report Type:Periodic Company Report #WAES 01081262
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Change Of Bowel Habit						PO	
	Face Oedema		Diovan	C				
	Fluid Retention		Dyazide	C				
	Weight Increased		Estrostep Fe	C				
			Glucophage	C				
			Hydergine	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Nexium	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Calcium (Unspecified) (+)					
			Vitamin	C				
			Chondroitin (+)					
			Glucosamine	C				
			Dimethyl Sulfone	C				

Date:09/24/01ISR Number: 3799362-8Report Type:Periodic Company Report #WAES 01081263
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/ DAILY / PO	
	Mouth Ulceration							
			Baycol	C				
			Lasix (Furosemide)	C				
			Doxazosin	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3799364-1Report Type:Periodic Company Report #WAES 01070302
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Zantac	C				
			Herbs	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799365-3Report Type:Periodic Company Report #WAES 01081283
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Hyzaar	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3799366-5Report Type:Periodic Company Report #WAES 01070304
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Lipitor	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3799367-7Report Type:Periodic Company Report #WAES 01081294
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx Unk	PS	Merck & Co., Inc.	ORAL	PO	

Date:09/24/01ISR Number: 3799369-0Report Type:Periodic Company Report #WAES 01081301
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25	

Professional
MG/DAILY/PO
Plaquenil C

Date:09/24/01ISR Number: 3799370-7Report Type:Periodic Company Report #WAES 01070305
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lanoxin	C				
			Lipitor	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/24/01ISR Number: 3799371-9Report Type:Periodic Company Report #WAES 01081307
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799374-4Report Type:Periodic Company Report #WAES 01070308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO
			Celebrex	C				

Date:09/24/01ISR Number: 3799375-6Report Type:Periodic Company Report #WAES 01081311
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	PO	
	Oedema Peripheral		Neurotin	C				
			Prozac	C	Merck & Co., Inc.	ORAL	PO	
			Wellbutrin	C				
			Morphine	C				

Date:09/24/01ISR Number: 3799378-1Report Type:Periodic Company Report #WAES 01081313
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.		25	MG/DAILY/PO

Date:09/24/01ISR Number: 3799379-3Report Type:Periodic Company Report #WAES 01070309
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Professional
MG/DAILY/PO

Date:09/24/01ISR Number: 3799381-1Report Type:Periodic Company Report #WAES 01081329
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS	Merck & Co., Inc.	ORAL	PO	

Date:09/24/01ISR Number: 3799383-5Report Type:Periodic Company Report #WAES 01081338
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Flatulence							
			Ismn	C				
			Metamucil	C				
			Protonix	C				
			Toprol Xl Tablets	C				
			Lactulose	C				

Date:09/24/01ISR Number: 3799384-7Report Type:Periodic Company Report #WAES 01081361
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
	Gastritis							

			Celebrex	C
			Lipitor	C
			Norvasc	C

Date:09/24/01ISR Number: 3799386-0Report Type:Periodic Company Report #WAES 01081363
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 50 Mg	PS	Merck & Co., Inc.	ORAL	50 MG/DAILY/PO	
			Anacin	C				
			Elavil	C				
			Tylenol	C				

Date:09/24/01ISR Number: 3799388-4Report Type:Periodic Company Report #WAES 01081370
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Health Professional Company Representative	Tab Vioxx Unk	PS	Merck & Co., Inc.	ORAL	PO	

Date:09/24/01ISR Number: 3799390-2Report Type:Periodic Company Report #WAES 01070312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Potassium	C				

Date:09/24/01ISR Number: 3799391-4Report Type:Periodic Company Report #WAES 01081510
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Urticaria	Professional Company Representative	Centrum	C				
			Synthroid	C				
			Calcium (Unspecified)	C				

Date:09/24/01ISR Number: 3799393-8Report Type:Periodic Company Report #WAES 01070324
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Menstrual Disorder							
			Ambien	C				
			Celebrex	C				
			Cortisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799395-1Report Type:Periodic Company Report #WAES 01070330
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	3 DAY
	Irritable Bowel Syndrome							

Date:09/24/01ISR Number: 3799397-5Report Type:Periodic Company Report #WAES 01081508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myalgia							
	Oedema Peripheral							
	Pruritus							
	Rash							
	Weight Increased							

Date:09/24/01ISR Number: 3799398-7Report Type:Periodic Company Report #WAES 01070336
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	5 DAY

Date:09/24/01ISR Number: 3799400-2Report Type:Periodic Company Report #WAES 01070338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Rash		Tylenol With Codeine #3	C				

				Valium	C		

Date:09/24/01ISR Number: 3799402-6Report Type:Periodic Company Report #WAES 01081410
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799403-8Report Type:Periodic Company Report #WAES 01081414
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG 1X PO	1 DAY
	Pain		[Composition Unspecified]	C				

Date:09/24/01ISR Number: 3799404-XReport Type:Periodic Company Report #WAES 01081430
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
	Headache						PO	
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799405-1Report Type:Periodic Company Report #WAES 01081448
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Prozac	C				

Date:09/24/01ISR Number: 3799406-3Report Type:Periodic Company Report #WAES 01081453
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Synthroid	C				

Date:09/24/01ISR Number: 3799407-5Report Type:Periodic Company Report #WAES 01081511
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
		Company Representative						

Date:09/24/01ISR Number: 3799408-7Report Type:Periodic Company Report #WAES 01081512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Libido Decreased	Health	Tab Vioxx	PS		ORAL		PO

			Professional Company Representative	Phenobarbital	C		

Date:09/24/01ISR Number: 3799409-9Report Type:Periodic Company Report #WAES 01081516
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3799410-5Report Type:Periodic Company Report #WAES 01070343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799411-7Report Type:Periodic Company Report #WAES 01070344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral							
			Levoxyl	C				
			Atenolol	C				
			Insulin	C				

Date:09/24/01ISR Number: 3799412-9Report Type:Periodic Company Report #WAES 01070416
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Musculoskeletal Stiffness							

Date:09/24/01ISR Number: 3799413-0Report Type:Periodic Company Report #WAES 01070418
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Jaundice							
	Nausea		Amaryl	C				
	Pyrexia		Avelox	C				
	Rash		Flomax (Morniflumate)	C				
			Glucophage	C				
			Lipitor	C				
			Nasonex	C				
			Aspirin	C				
			Hydrochlorthiazide (+) Spironol	C				

Date:09/24/01ISR Number: 3799414-2Report Type:Periodic Company Report #WAES 01070419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Chest Pain							
	Dyspnoea		Avapro	C				
	Oedema Peripheral		Cardura	C				
	Weight Increased		Lipitor	C				
			Pepcid	C				
			Allopurinol	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799415-4Report Type:Periodic Company Report #WAES 01070449
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Feeling Abnormal	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799416-6Report Type:Periodic Company Report #WAES 01070463
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hyzaar	C				
			Nolvadex	C				
			Norvasc	C				

Date:09/24/01ISR Number: 3799417-8Report Type:Periodic Company Report #WAES 01070465
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Pruritus							
			Cozaar	C				
			Hydrociuril	C				

Date:09/24/01ISR Number: 3799418-XReport Type:Periodic Company Report #WAES 01070480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	

Date:09/24/01ISR Number: 3799419-1Report Type:Periodic Company Report #WAES 01070482
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Vision Blurred	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/DAILY/PO 1 MON						
			Zestril	C		

Date:09/24/01ISR Number: 3799420-8Report Type:Periodic Company Report #WAES 01081600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Lymphoma	Health	Tab Vioxx	PS		ORAL
PO						
		Professional	Fosamax	C		
			Prilosec	C		
			Atenolol	C		

Date:09/24/01ISR Number: 3799421-XReport Type:Periodic Company Report #WAES 01070484
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Somnolence	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/HS/PO						
			Accupril	C		
			...	C		
			Digoxin	C		
			Felodipine	C		
			Furosemide	C		
			Glucosamine	C		
			Levothyroxine Sodium	C		
			Lovastatin	C		
			Manganese Sulfate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799423-3Report Type:Periodic Company Report #WAES 01070486
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Drug Ineffective		Albuterol	C				
	Muscle Spasms							
	Pain In Extremity							

Date:09/24/01ISR Number: 3799424-5Report Type:Periodic Company Report #WAES 01081604
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	4 DAY
	Headache							

Date:09/24/01ISR Number: 3799425-7Report Type:Periodic Company Report #WAES 01070489
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
			Carafate	C				
			Corgard	C				

Date:09/24/01ISR Number: 3799426-9Report Type:Periodic Company Report #WAES 01081554
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fluid Retention	Consumer	Tab Vioxx 12.5 Mg	PS	ORAL 12.5 MG/DAILY/PO
	Oedema Peripheral				
	Weight Increased		Hyzaar	C	
			Librax Capsules	C	
			Lipitor	C	
			Norvasc	C	
			Pepcid	C	
			Prandin	C	
			Tambocor	C	
			Tenormin	C	

Date:09/24/01ISR Number: 3799427-0Report Type:Periodic Company Report #WAES 01081517
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/PO	

Date:09/24/01ISR Number: 3799428-2Report Type:Periodic Company Report #WAES 01081536
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Abdominal Pain	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
PO						

Date:09/24/01ISR Number: 3799429-4Report Type:Periodic Company Report #WAES 01081559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Tab Celebrex 200 Mg	SS		
200 MG/DAILY						

Date:09/24/01ISR Number: 3799430-0Report Type:Periodic Company Report #WAES 01081573
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Paraesthesia					
MG/DAILY/PO						

Date:09/24/01ISR Number: 3799431-2Report Type:Periodic Company Report #WAES 01081586
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Epistaxis	Health	Tab Vioxx	PS		ORAL
PO						
		Professional	Nonsteroidal Anti-Inflammatory	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3799432-4Report Type:Periodic Company Report #WAES 01081633
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3799433-6Report Type:Periodic Company Report #WAES 01081636
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799434-8Report Type:Periodic Company Report #WAES 01070490
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash		Quinine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799435-XReport Type:Periodic Company Report #WAES 01081679
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Sinusitis		Bentyl	C				
			Buspar	C				
			Lo/Ovral	C				
			Prilosec	C				
			Stelazine	C				
			Tofranil	C				

Date:09/24/01ISR Number: 3799436-1Report Type:Periodic Company Report #WAES 01070492
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza	Consumer	Tab Vioxx Unk	PS		ORAL	50 MG/PO; 25 MG/PO	

Date:09/24/01ISR Number: 3799437-3Report Type:Periodic Company Report #WAES 01081661
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 DAY
			Vasotec	C				

Date:09/24/01ISR Number: 3799438-5Report Type:Periodic Company Report #WAES 01070497
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO; PO	
			Buspar	C				
			Zoloft	C				
			....	C				

Date:09/24/01ISR Number: 3799439-7Report Type:Periodic Company Report #WAES 01081659
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Artane	C				
			Deprinol	C				
			Lamuran	C				
			Sinemet	C				
			Skelaxin	C				

Date:09/24/01ISR Number: 3799440-3Report Type:Periodic Company Report #WAES 01070498
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dizziness		Inderal	C				
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799441-5Report Type:Periodic Company Report #WAES 01081657
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advair	C				
			Lotensin	C				
			Theo-Dur	C				
			Allopurinol	C				
			Cefadroxil	C				
			Doxycycline	C				

Date:09/24/01ISR Number: 3799442-7Report Type:Periodic Company Report #WAES 01070499
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	4 DAY
	Constipation	Health						
	Diarrhoea	Professional						

Date:09/24/01ISR Number: 3799443-9Report Type:Periodic Company Report #WAES 01081639
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Catapres	C				

Date:09/24/01ISR Number: 3799444-0Report Type:Periodic Company Report #WAES 01081640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
			Fosamax	C				

Date:09/24/01ISR Number: 3799445-2Report Type:Periodic Company Report #WAES 01070501
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Uterine Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Paxil	C				
			Prinivil	C				
			Insulin	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3799446-4Report Type:Periodic Company Report #WAES 01081648
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	4 DAY
	Feeling Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799447-6Report Type:Periodic Company Report #WAES 01081651
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG	
BID/PO								3 DAY

Date:09/24/01ISR Number: 3799448-8Report Type:Periodic Company Report #WAES 01081677
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Conjunctival Hyperaemia							
	Face Oedema							
	Headache							
	Skin Disorder							

Date:09/24/01ISR Number: 3799449-XReport Type:Periodic Company Report #WAES 01081680
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3799450-6Report Type:Periodic Company Report #WAES 01081774
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased							

			Cardis	C		
			Synthroid	C		
			Zocor	C		

Date:09/24/01ISR Number: 3799451-8Report Type:Periodic Company Report #WAES 01081768
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Corgard	C				

Date:09/24/01ISR Number: 3799452-XReport Type:Periodic Company Report #WAES 01081722
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Prevacid	C				
			Proscar	C				
			Protonix	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799453-1Report Type:Periodic Company Report #WAES 01081726
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
			Lasix (Furosemide)	C				
			Prinivil	C				
			Zocor	C				
			Zyrtec	C				

Date:09/24/01ISR Number: 3799454-3Report Type:Periodic Company Report #WAES 01081737
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haematochezia							

Date:09/24/01ISR Number: 3799455-5Report Type:Periodic Company Report #WAES 01081780
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nervousness							
			Lipitor	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3799456-7Report Type:Periodic Company Report #WAES 01081685
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Protein Total Decreased	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3799457-9Report Type:Periodic Company Report #WAES 01081693
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Somnolence					
MG/DAILY/PO						
			Requip	C		
			Sinemet	C		

Date:09/24/01ISR Number: 3799458-0Report Type:Periodic Company Report #WAES 01081761
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799459-2Report Type:Periodic Company Report #WAES 01081784
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Rectal Haemorrhage		Flexeril	C				
			Lo/Ovral 28 Tablets	C				

Date:09/24/01ISR Number: 3799460-9Report Type:Periodic Company Report #WAES 01070503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Prinivil	C				

Date:09/24/01ISR Number: 3799461-0Report Type:Periodic Company Report #WAES 01072711
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/24/01ISR Number: 3799462-2Report Type:Periodic Company Report #WAES 01072716
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:09/24/01ISR Number: 3799463-4Report Type:Periodic Company Report #WAES 01081831
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
			Diovan Hct	C				
			Nitrostat	C				
			Allopurinol	C				
			Hydrochlorothiazide (+) Triamterene	C				

Date:09/24/01ISR Number: 3799464-6Report Type:Periodic Company Report #WAES 01072749
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Erythema		Ambien	C				
	Hypersensitivity		Detrol	C				
	Pruritus		Evista	C				
			Lorcet 10/650	C				
			Neurontin	C				
			Nitroquick	C				

			Diazepam	C		

Date:09/24/01ISR Number: 3799465-8Report Type:Periodic Company Report #WAES 01072751
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
	Blood Urea Increased	Company	K-Dur	C				
	Blood Urea	Representative	Lasix (Furosemide)	C				
	Nitrogen/Creatinine Ratio		Allopurinol	C				
	Increased		Aspirin	C				
	Urine Potassium Increased		Insulin	C				
			Metoprolol	C				
			Thyroid	C				

Date:09/24/01ISR Number: 3799466-XReport Type:Periodic Company Report #WAES 01072755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Lip Disorder						MG/DAILY/PO	
	Palpitations							

Date:09/24/01ISR Number: 3799467-1Report Type:Periodic Company Report #WAES 01072760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Pravachol	C				

Date:09/24/01ISR Number: 3799468-3Report Type:Periodic Company Report #WAES 01072761
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Face Oedema	Professional					MG/DAILY/PO	
	Weight Increased		Prednisone	C				

Date:09/24/01ISR Number: 3799469-5Report Type:Periodic Company Report #WAES 01081790
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Health	Tab Vioxx 50 Mg	PS			50	
	Dizziness	Professional					MG/DAILY/UNK	
	Feeling Abnormal	Company	Toprol Xl Tablets	C				
	Nausea	Representative	Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799470-1Report Type:Periodic Company Report #WAES 01072772
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Flovent	C				
			K-Dur	C				
			Zantac	C				

Date:09/24/01ISR Number: 3799471-3Report Type:Periodic Company Report #WAES 01072773
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Accupril	C				
			Glucotrol Xl	C				
			Synthroid	C				
			Toprol Xl Tablets	C				

Date:09/24/01ISR Number: 3799472-5Report Type:Periodic Company Report #WAES 01072774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Asacol	C				
			Bentyl	C				
			Catapres	C				
			Klor-Con	C				
			Lasix (Furosemide)	C				
			Norvasc	C				
			Prandin	C				
			Prevacid	C				
			Trandate	C				

			Aspirin	C		
			Insulin	C		

Date:09/24/01ISR Number: 3799473-7Report Type:Periodic Company Report #WAES 01072777
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Tylenol	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799474-9Report Type:Periodic Company Report #WAES 01072787
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799475-0Report Type:Periodic Company Report #WAES 01081803
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Blood Pressure Increased							
SEE IMAGE								2 WK
	Dizziness		Altace	C				
	Drug Ineffective		Glucotrol	C				
	Dyspepsia		Zocor	C				
	Fatigue		Zyrtec	C				
	Muscular Weakness		Metoprolol	C				

Date:09/24/01ISR Number: 3799476-2Report Type:Periodic Company Report #WAES 01072789
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Infection							

Date:09/24/01ISR Number: 3799477-4Report Type:Periodic Company Report #WAES 01072792
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx	PS		ORAL	PO	
	Vomiting	Professional						

Date:09/24/01ISR Number: 3799478-6Report Type:Periodic Company Report #WAES 01081785
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Dyspepsia
MG/DAILY/PO

Fosamax C
Premarin C

Date:09/24/01ISR Number: 3799479-8Report Type:Periodic Company Report #WAES 01081786
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aggression	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Confusional State	Professional						
		Company Representative						

Date:09/24/01ISR Number: 3799480-4Report Type:Periodic Company Report #WAES 01072793
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Norvasc	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799481-6Report Type:Periodic Company Report #WAES 01081797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Company	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Hyperhidrosis	Representative						
	Nausea	Other						
	Pain							

Date:09/24/01ISR Number: 3799482-8Report Type:Periodic Company Report #WAES 01081800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Diarrhoea	Professional						

Date:09/24/01ISR Number: 3799483-XReport Type:Periodic Company Report #WAES 01072813
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage							

Date:09/24/01ISR Number: 3799484-1Report Type:Periodic Company Report #WAES 01081811
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Porphyria	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional						

Date:09/24/01ISR Number: 3799485-3Report Type:Periodic Company Report #WAES 01072819
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
			Lipitor	SS		ORAL	20 MG/DAILY/PO	
			Meridia	SS		ORAL	10 MG/DAILY/PO	
			Meridia	SS		ORAL	15 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799486-5Report Type:Periodic Company Report #WAES 01081813
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799487-7Report Type:Periodic Company Report #WAES 01081820
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799488-9Report Type:Periodic Company Report #WAES 01072820
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Swelling		Tab Synthroid	SS		ORAL	1 TABLET/DAILY/ PO	
			Vitamins (Unspecified)	SS		ORAL	DAILY/PO	
			Cap Meridia 10 Mg	SS		ORAL	10 MG/DAILY/PO	
			Cap Meridia	SS				

Date:09/24/01ISR Number: 3799489-0Report Type:Periodic Company Report #WAES 01072825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799490-7Report Type:Periodic Company Report #WAES 01080163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG BID PO	
	Paraesthesia		Allegra	C				

Date:09/24/01ISR Number: 3799491-9Report Type:Periodic Company Report #WAES 01080164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799492-0Report Type:Periodic Company Report #WAES 01072827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799493-2Report Type:Periodic Company Report #WAES 01080149
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Calan	C				
			Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799494-4Report Type:Periodic Company Report #WAES 01072830
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Actonel	C				
			Esgic-Plus Tablets	C				
			Timoptic-Xe	C				

Date:09/24/01ISR Number: 3799495-6Report Type:Periodic Company Report #WAES 01080151
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25mg	PS		ORAL	UNK/UNK/PO	
			Aspirin	C				

Date:09/24/01ISR Number: 3799496-8Report Type:Periodic Company Report #WAES 01080161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5mg	PS		ORAL	UNK PO	
	Upper Respiratory Tract Infection		Fosamax	C				
			Premarin	C				
	Vocal Cord Disorder		Therapy Unspecified	C				
			Triamterene	C				

Date:09/24/01ISR Number: 3799497-XReport Type:Periodic Company Report #WAES 01072835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50	

Dysgeusia
MG/DAILY/PO
Dyspnoea
Tremor

Guaifenex Pse	C
K-Dur	C
Remeron	C
Trimox	C
Wellbutrin	C

Date:09/24/01ISR Number: 3799498-1Report Type:Periodic Company Report #WAES 01080170
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Elavil	C				
			Fosamax	C				
			Lescol	C				
			Premarin	C				
			Atenolol	C				
			Progesterone	C				

Date:09/24/01ISR Number: 3799499-3Report Type:Periodic Company Report #WAES 01080171
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
			Tab Vioxx 50mg	SS		ORAL	50MG DAILY PO	

Accupril	C
Levoxyl	C
Proscar	C
Amiodarone Hydrochloride	C
Furosemide	C
Ibuprofen	C

Date:09/24/01ISR Number: 3799500-7Report Type:Periodic Company Report #WAES 01072852
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Panic Disorder	Professional Company Representative						

Date:09/24/01ISR Number: 3799501-9Report Type:Periodic Company Report #WAES 01080173
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Eruption	Health	Tab Vioxx Unk	PS		ORAL	UNK UNK PO	
	Skin Disorder	Professional	Tab Vioxx Unk	SS		ORAL	UNK UNK PO	
			Therapy Unspecified	C				

Date:09/24/01ISR Number: 3799502-0Report Type:Periodic Company Report #WAES 01072857
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx	PS		ORAL	PO	
	Chest Pain	Professional						
	Fatigue	Company Representative						

Date:09/24/01ISR Number: 3799503-2Report Type:Periodic Company Report #WAES 01072871
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gingival Disorder							
			Avandia	C				
			Diovan Hct	C				
			Norvasc	C				

Date:09/24/01ISR Number: 3799504-4Report Type:Periodic Company Report #WAES 01080176
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25mg	PS		ORAL	PRN PO	
	Paraesthesia	Health	Diovan	C				
	Pharyngitis	Professional	Fosamax	C				
	Rash		Lipitor	C				
			Prempro	C				
			Ziac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799505-6Report Type:Periodic Company Report #WAES 01072874
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799506-8Report Type:Periodic Company Report #WAES 01080180
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50MG DAILY PO	
	Fatigue		Tab Vioxx 25mg	SS		ORAL	25MG DAILY PO	
	Feeling Drunk		Chondroitin (+)					
	Libido Decreased		Glucosamine	C				
	Memory Impairment							
	Pollakiuria							

Date:09/24/01ISR Number: 3799507-XReport Type:Periodic Company Report #WAES 01072875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 50 Mg/37.5 Mg	PS		ORAL	SEE IMAGE	
	Oedema Peripheral		Darvocet-N	C				
			Sinequan	C				
			Ultram	C				
			Xanax	C				

Date:09/24/01ISR Number: 3799508-1Report Type:Periodic Company Report #WAES 01072876
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intestinal Functional Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Detrol	C				
			Imdur	C				
			Prilosec	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799509-3Report Type:Periodic Company Report #WAES 01080330
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Indocin (Indomethacin)	C				
			Therapy Unspecified	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799510-XReport Type:Periodic Company Report #WAES 01080234
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Decreased							
			Cosamin	C				
			Prinivil	C				
			Acetaminophen	C				
			Atenolol	C				
			Pyridoxine	C				
			Verapamil	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799511-1Report Type:Periodic Company Report #WAES 01080231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799512-3Report Type:Periodic Company Report #WAES 01080239
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Respiratory Disorder							

Date:09/24/01ISR Number: 3799513-5Report Type:Periodic Company Report #WAES 01080243
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799514-7Report Type:Periodic Company Report #WAES 01080260
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/'DAILY/PO	
			Hormone (Unspecified)	C				

Date:09/24/01ISR Number: 3799515-9Report Type:Periodic Company Report #WAES 01080310
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:09/24/01ISR Number: 3799516-0Report Type:Periodic Company Report #WAES 01080332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799517-2Report Type:Periodic Company Report #WAES 01080333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Drug Ineffective							

Date:09/24/01ISR Number: 3799518-4Report Type:Periodic Company Report #WAES 01072878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx 12.5 Mg/25 Mg	PS		ORAL	SEE IMAGE	4 MON
	Drug Ineffective		Prednisone	SS				
			Prednisone	SS				

Date:09/24/01ISR Number: 3799519-6Report Type:Periodic Company Report #WAES 01080335
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	2 WK

Date:09/24/01ISR Number: 3799520-2Report Type:Periodic Company Report #WAES 01072884
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799521-4Report Type:Periodic Company Report #WAES 01072887
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain							

Date:09/24/01ISR Number: 3799522-6Report Type:Periodic Company Report #WAES 01080400
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Rash						PO	
			Fosamax	C				
			Lopressor	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799523-8Report Type:Periodic Company Report #WAES 01080393
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Levoxyl	C				
			Premarin [Therapy Unspecified]	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799524-XReport Type:Periodic Company Report #WAES 01072893
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Parosmia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799525-1Report Type:Periodic Company Report #WAES 01080391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY	PO

Date:09/24/01ISR Number: 3799526-3Report Type:Periodic Company Report #WAES 01072902
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Blood Amylase Increased
MG/DAILY/PO
Breast Pain .. C
Drug Ineffective
Mouth Haemorrhage

Date:09/24/01ISR Number: 3799527-5Report Type:Periodic Company Report #WAES 01080357
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Flomax (Tamsulosin Hydrochloride	C				
			Glynase Prestab	C				
			Zestril	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799528-7Report Type:Periodic Company Report #WAES 01080337
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799529-9Report Type:Periodic Company Report #WAES 01080341
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Nolvadex	C				

Date:09/24/01ISR Number: 3799530-5Report Type:Periodic Company Report #WAES 01080382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL		
PO								

Date:09/24/01ISR Number: 3799531-7Report Type:Periodic Company Report #WAES 01080384
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Ibuprofen	C				

Date:09/24/01ISR Number: 3799532-9Report Type:Periodic Company Report #WAES 01080390
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Prevacid	C				

Date:09/24/01ISR Number: 3799533-0Report Type:Periodic Company Report #WAES 01080408
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Fall						PO	
	Nausea		Prozac	C				
	Oedema Peripheral		Lithium Aspartate	C				
	Rash							

Date:09/24/01ISR Number: 3799534-2Report Type:Periodic Company Report #WAES 01080554
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Avandia	C				
			Hyzaar	C				
			[Composition Unspecified]	C				
			Levothyroxine Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799535-4Report Type:Periodic Company Report #WAES 01080410
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx	PS		ORAL	PO	3 WK
		Professional Company Representative						

Date:09/24/01ISR Number: 3799536-6Report Type:Periodic Company Report #WAES 01080413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3799537-8Report Type:Periodic Company Report #WAES 01080419
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799538-XReport Type:Periodic Company Report #WAES 01080460
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Plavix	SS				

Date:09/24/01ISR Number: 3799539-1Report Type:Periodic Company Report #WAES 01080521
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG	DAILY PO
			Zocor	C				

Date:09/24/01ISR Number: 3799540-8Report Type:Periodic Company Report #WAES 01080534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Malaise							

Date:09/24/01ISR Number: 3799541-XReport Type:Periodic Company Report #WAES 01080536
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799542-1Report Type:Periodic Company Report #WAES 01080548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Influenza Like Illness							
	Oedema Peripheral							

Date:09/24/01ISR Number: 3799543-3Report Type:Periodic Company Report #WAES 01080552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799544-5Report Type:Periodic Company Report #WAES 01072915
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799545-7Report Type:Periodic Company Report #WAES 01072917
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Nausea							

Date:09/24/01ISR Number: 3799546-9Report Type:Periodic Company Report #WAES 01072918
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Paxil	C				
			Folic Acid	C				
			Prednisone	C				

Date:09/24/01ISR Number: 3799547-0Report Type:Periodic Company Report #WAES 01072920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799548-2Report Type:Periodic Company Report #WAES 01072926
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799549-4Report Type:Periodic Company Report #WAES 01072937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS				
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3799550-0Report Type:Periodic Company Report #WAES 01072938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS		ORAL	PO	
			(Composition Unspecified)	C				

Date:09/24/01ISR Number: 3799551-2Report Type:Periodic Company Report #WAES 01072942
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PM/PO	
			Avandia	C				
			Detrol La	C				
			Glucophage	C				
			Glucotrol	C				
			Lotensin	C				
			Nasonex	C				
			Synvisc	C				

Date:09/24/01ISR Number: 3799552-4Report Type:Periodic Company Report #WAES 01072944
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Fatigue
MG/DAILY/PO
Somnolence

Flexeril	C
Lipitor	C
Vivelle	C

Date:09/24/01ISR Number: 3799553-6Report Type:Periodic Company Report #WAES 01072945
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema							

Date:09/24/01ISR Number: 3799554-8Report Type:Periodic Company Report #WAES 01072951
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799555-XReport Type:Periodic Company Report #WAES 01072968
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Pollakiuria		Micardis	C				
			Synthroid	C				
			Amiodarone Hydrochloride	C				

Date:09/24/01ISR Number: 3799556-1Report Type:Periodic Company Report #WAES 01080008
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Norvasc	C				

Date:09/24/01ISR Number: 3799557-3Report Type:Periodic Company Report #WAES 01080012
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3799558-5Report Type:Periodic Company Report #WAES 01080589
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
	Pruritus Ani		Celebrex	C		
	Pruritus Genital		Lipitor	C		
			Miacalcin	C		
			Aspirin	C		

Date:09/24/01ISR Number: 3799559-7Report Type:Periodic Company Report #WAES 01080579
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Renal Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
PO						
			Cozaar	C		
			Estraderm	C		
			Provera	C		

Date:09/24/01ISR Number: 3799560-3Report Type:Periodic Company Report #WAES 01080565
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
			Adalat	C		
			Levothyroid	C		
			Premarin	C		
			Sinemet	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799561-5Report Type:Periodic Company Report #WAES 01080561
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PRN PO	

Date:09/24/01ISR Number: 3799562-7Report Type:Periodic Company Report #WAES 01080556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			[Therapy Unspecified]	C				
			Hydrocodone	C				

Date:09/24/01ISR Number: 3799563-9Report Type:Periodic Company Report #WAES 01080558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Headache							
	Upper Gastrointestinal Haemorrhage							

Date:09/24/01ISR Number: 3799564-0Report Type:Periodic Company Report #WAES 01080576
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Estrace	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3799565-2Report Type:Periodic Company Report #WAES 01080586
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Glucosamine	C				

Date:09/24/01ISR Number: 3799566-4Report Type:Periodic Company Report #WAES 01080588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Diarrhoea						PO	
			Aspirin	C				

Date:09/24/01ISR Number: 3799567-6Report Type:Periodic Company Report #WAES 01080591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799568-8Report Type:Periodic Company Report #WAES 01080748
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/DAILY/PO	
			Avandia	C				
			Diovan	C				
			Hydrodiuril	C				
			Synthroid	C				
			Chondroitin	C				

Date:09/24/01ISR Number: 3799569-XReport Type:Periodic Company Report #WAES 01080777
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Consumer	Tab Vioxx 25mg	PS		ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
	Toothache		Darvocet-N	C				
			Premarin	C				
			Provera	C				
			Albuterol	C				
			Temazepam	C				

Date:09/24/01ISR Number: 3799570-6Report Type:Periodic Company Report #WAES 01080807
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Combivent	C				
			Digitora	C				
			Tiazac	C				
			Spironolactone	C				
			Warfarin	C				

Date:09/24/01ISR Number: 3799571-8Report Type:Periodic Company Report #WAES 01080808
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25mg	PS		ORAL	25 MG/BID/PO	
	Hyperglycaemia	Professional	Hydrodiuril	C				
	Oedema Peripheral		Monopril	C				
	Pruritus		Prozac	C				
			Nadolol	C				

Date:09/24/01ISR Number: 3799572-XReport Type:Periodic Company Report #WAES 01080811
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Cozaar	C				
			K-Dur	C				
			Norvasc	C				
			Zoloft	C				
			Acetaminophen (+)					
			Hydrocodone Bi	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799573-1Report Type:Periodic Company Report #WAES 01080839
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 50 Mg	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799574-3Report Type:Periodic Company Report #WAES 01080846
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Visual Acuity Reduced							
		Company Representative	Skelaxin	C				

Date:09/24/01ISR Number: 3799575-5Report Type:Periodic Company Report #WAES 01080851
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Other	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Timoptic	C				

Date:09/24/01ISR Number: 3799576-7Report Type:Periodic Company Report #WAES 01080754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799577-9Report Type:Periodic Company Report #WAES 01080763
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Vioxx	PS		ORAL	UNK/UNK/PO	
	Bronchitis		Corzide Tablets	C				
	Respiratory Disorder		Synthroid	C				

Date:09/24/01ISR Number: 3799578-0Report Type:Periodic Company Report #WAES 01080019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Coumadin	C				

Date:09/24/01ISR Number: 3799579-2Report Type:Periodic Company Report #WAES 01080022
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Pletal	C				
			Pravachol	C				
			Zantac	C				
			Zoloft	C				

				(Therapy Unspecified)	C	
				Albuterol	C	
				Aspirin	C	

Date:09/24/01ISR Number: 3799580-9Report Type:Periodic Company Report #WAES 01080891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
			Tab Vioxx 50 Mg	SS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799581-0Report Type:Periodic Company Report #WAES 01080881
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	
	Fatigue		Prinivil	C				
			Zocor	C				
			Prednisone	C				

Date:09/24/01ISR Number: 3799582-2Report Type:Periodic Company Report #WAES 01080869
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	C		ORAL	12.5 MG BID PO	
			Norco	C				
			Prozac	C				

Date:09/24/01ISR Number: 3799583-4Report Type:Periodic Company Report #WAES 01080023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799584-6Report Type:Periodic Company Report #WAES 01080853
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Cardura	C				
			Persantine	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799585-8Report Type:Periodic Company Report #WAES 01080026
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
			Norvasc	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3799586-XReport Type:Periodic Company Report #WAES 01080883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Macular Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799587-1Report Type:Periodic Company Report #WAES 01080886
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Consumer	Tab Vioxx	PS		ORAL	UNK/UNK/PO	
			Triaminic Oral Drops Composition	C				
			Unspecified	C				

Date:09/24/01ISR Number: 3799588-3Report Type:Periodic Company Report #WAES 01080027
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

MG/DAILY/PO

			Urocit-K	C		
			Indapamide	C		

Date:09/24/01ISR Number: 3799589-5Report Type:Periodic Company Report #WAES 01080874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctivitis	Health	Tab Vioxx	PS		ORAL	UNK/UNK/PO	
		Professional Company Representative	Celebrex	C				

Date:09/24/01ISR Number: 3799590-1Report Type:Periodic Company Report #WAES 01080045
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799591-3Report Type:Periodic Company Report #WAES 01080858
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Corneal Abrasion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Antioxidants (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799592-5Report Type:Periodic Company Report #WAES 01080060
Age:9 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799593-7Report Type:Periodic Company Report #WAES 01080863
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

Date:09/24/01ISR Number: 3799594-9Report Type:Periodic Company Report #WAES 01080101
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

		Dyspepsia					
MG/DAILY/PO							
		Headache		Pepcid	C		
		Yawning		Toprol Xl Tablets	C		
				Zyrtec	C		
				Chlordiazepoxide Hydrochloride	C		
				Hydrochlorothiazide (+) Triamter	C		

Date:09/24/01ISR Number: 3799595-0Report Type:Periodic Company Report #WAES 01080867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3799596-2Report Type:Periodic Company Report #WAES 01080115
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Hyperkalaemia	Company Representative	Cordarone	C				
	Hyponatraemia		Imdur	C				
	Nausea		Lasix (Furosemide)	C				
			Metoprolol	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799597-4Report Type:Periodic Company Report #WAES 01080132
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 WK
			Lipitor	C				
			Premarin	C				

Date:09/24/01ISR Number: 3799598-6Report Type:Periodic Company Report #WAES 01080992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Norvasc	C				
			Prilosec	C				
			Ziac	C				

Date:09/24/01ISR Number: 3799599-8Report Type:Periodic Company Report #WAES 01080993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Allegra D	C				
			Prilosec	C				
			Albuterol	C				

Date:09/24/01ISR Number: 3799600-1Report Type:Periodic Company Report #WAES 01080134
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	5 WK

				Coumadin	C	
				Lasix (Furosemide)	C	
				Lopressor	C	
				Micro K	C	
				Vasotec	C	

Date:09/24/01ISR Number: 3799601-3Report Type:Periodic Company Report #WAES 01081000
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide)	C				

Date:09/24/01ISR Number: 3799602-5Report Type:Periodic Company Report #WAES 01080139
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Decreased							
			Zestril	C				
			Zocor	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799603-7Report Type:Periodic Company Report #WAES 01080972
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Lipitor	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799604-9Report Type:Periodic Company Report #WAES 01080144
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799605-0Report Type:Periodic Company Report #WAES 01080958
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dizziness						MG/DAILY/PO	
	Facial Pain		Digitex	C				
	Flushing		Prilosec	C				
	Nausea		Synthroid	C				
	Pruritus		Tylenol Arthritis Extended Relie	C				

Date:09/24/01ISR Number: 3799606-2Report Type:Periodic Company Report #WAES 01080148
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL

PO

Date:09/24/01ISR Number: 3799607-4Report Type:Periodic Company Report #WAES 01080960
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Toprol Xl	C				

Date:09/24/01ISR Number: 3799608-6Report Type:Periodic Company Report #WAES 01080971
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3799609-8Report Type:Periodic Company Report #WAES 01080973
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS			12.5 MG/DAILY	
	Mouth Ulceration		Cipro	C				

Date:09/24/01ISR Number: 3799610-4Report Type:Periodic Company Report #WAES 01081850
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:09/24/01ISR Number: 3799611-6Report Type:Periodic Company Report #WAES 01080977
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Estratab	C				

Date:09/24/01ISR Number: 3799612-8Report Type:Periodic Company Report #WAES 01080980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Libido Decreased							
	Respiratory Disorder							
	Weight Increased							

Date:09/24/01ISR Number: 3799613-XReport Type:Periodic Company Report #WAES 01081852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799614-1Report Type:Periodic Company Report #WAES 01081880
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Prilosec	C				
			Acetaminophen (+) Propoxyphene	C				
			Alprazolam	C				

Date:09/24/01ISR Number: 3799615-3Report Type:Periodic Company Report #WAES 01080706
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lotensin	C				

			Macrodantin	C		
			Potassium (Unspecified)	C		

Date:09/24/01ISR Number: 3799616-5Report Type:Periodic Company Report #WAES 01081889
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	22 DAY

Date:09/24/01ISR Number: 3799617-7Report Type:Periodic Company Report #WAES 01080677
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
			Avapro	C				
			Prilosec	C				
			Furosemide	C				
			Nifedipine	C				

Date:09/24/01ISR Number: 3799618-9Report Type:Periodic Company Report #WAES 01081896
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dyspnoea							
	Oedema Peripheral		Nolvadex	C				
			Percocet	C				

Date:09/24/01ISR Number: 3799619-0Report Type:Periodic Company Report #WAES 01080615
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
							PO	
			Lipitor	C				
			Prilosec	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3799620-7Report Type:Periodic Company Report #WAES 01081912
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Prinivil	C				
			Aspirin	C				
			Doxycycline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799621-9Report Type:Periodic Company Report #WAES 01080605
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Azmacort	C				
			Entex Pse	C				
			Maxair	C				
			Micardis	C				
			Pravachol	C				
			Theophylline	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3799622-0Report Type:Periodic Company Report #WAES 01080602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Mental Impairment		Baycol	C				
	Muscular Weakness		Prempro	C				
	Oedema Peripheral		Synthroid	C				

Date:09/24/01ISR Number: 3799623-2Report Type:Periodic Company Report #WAES 01080714
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	1 WK
			Astelin	C				
			Serevent	C				
			Tylenol With Codeine	C				
			Albuterol	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3799624-4Report Type:Periodic Company Report #WAES 01080600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Viagra	C				

Date:09/24/01ISR Number: 3799625-6Report Type:Periodic Company Report #WAES 01080635
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799626-8Report Type:Periodic Company Report #WAES 01080704
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Hypersensitivity		Xanax	C				
	Oedema Peripheral		Zoloft	C				

Date:09/24/01ISR Number: 3799627-XReport Type:Periodic Company Report #WAES 01080707
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Pain In Extremity							
			Ortho-Novum	C				

Date:09/24/01ISR Number: 3799628-1Report Type:Periodic Company Report #WAES 01081925
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Axid	C				

Date:09/24/01ISR Number: 3799629-3Report Type:Periodic Company Report #WAES 01081927
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Antigen Increased	Professional						

Date:09/24/01ISR Number: 3799630-XReport Type:Periodic Company Report #WAES 01080747
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				
			Dimethyl Sulfone	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3799631-1Report Type:Periodic Company Report #WAES 01081932
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hair Disorder							
			Allopurinol	C				
			Phenoxybenzamine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799632-3Report Type:Periodic Company Report #WAES 01080744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Depo-Provera	C				
			Synthroid	C				
			Zantac	C				
			Doxepin	C				

Date:09/24/01ISR Number: 3799633-5Report Type:Periodic Company Report #WAES 01081937
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
	Blood Urea Increased	Company	Diovan	C				
		Representative	Synthroid	C				
			Allopurinol	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3799634-7Report Type:Periodic Company Report #WAES 01080726
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/DAILY/PO	
							25	
							MG/DAILY/PO	
			Glucophage	C				
			Oxybutynin Chloride	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799635-9Report Type:Periodic Company Report #WAES 01081939
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799636-0Report Type:Periodic Company Report #WAES 01080731
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Corzide Tablets	C				
			Hydrodiuril	C				
			Lipitor	C				
			[Therapy Unspecified0	C				
			Glucosamine	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799637-2Report Type:Periodic Company Report # WAES 01081950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799638-4Report Type:Periodic Company Report #WAES 01080736
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lopressor	C				
			Xanax	C				
			Zestril	C				

Date:09/24/01ISR Number: 3799639-6Report Type:Periodic Company Report #WAES 01081956
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799640-2Report Type:Periodic Company Report #WAES 01080720
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	1 WK
	Oedema Peripheral Swelling		Vicodin Tablets	C				

Weight Increased

Date:09/24/01ISR Number: 3799641-4Report Type:Periodic Company Report #WAES 01082021
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Rash							
			Prinivil	C				
			Calcium (Unspecified)	C				

Date:09/24/01ISR Number: 3799642-6Report Type:Periodic Company Report #WAES 01082023
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO; 25 MG/PM/PO	
			Avalide	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799643-8Report Type:Periodic Company Report #WAES 01080716
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	PO	
	Neck Pain							

Date:09/24/01ISR Number: 3799644-XReport Type:Periodic Company Report #WAES 01080719
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
	Haemorrhage	Professional						

Date:09/24/01ISR Number: 3799645-1Report Type:Periodic Company Report #WAES 01082038
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Ziac	C				
			Zocor	C				

Date:09/24/01ISR Number: 3799646-3Report Type:Periodic Company Report #WAES 01080722
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:09/24/01ISR Number: 3799647-5Report Type:Periodic Company Report #WAES 01082050
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Eskalith Unk	SS				
			Sinement	C				

Date:09/24/01ISR Number: 3799648-7Report Type:Periodic Company Report #WAES 01080741
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Lanoxin	C				
			Lipitor	C				

Date:09/24/01ISR Number: 3799649-9Report Type:Periodic Company Report #WAES 01082052
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

			Fosamax	C		

Date:09/24/01ISR Number: 3799650-5Report Type:Periodic Company Report #WAES 01082054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase	Consumer	Tab Vioxx Unk	PS		ORAL	BID/PO	
	Increased Aspartate Aminotransferase Increased							

Date:09/24/01ISR Number: 3799651-7Report Type:Periodic Company Report #WAES 01082062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799653-0Report Type:Periodic Company Report #WAES 01082083
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/QOD/PO	
	Anxiety							
	Epistaxis							
	Mouth Haemorrhage		Claritin	C				
	Mouth Ulceration		Synthroid	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3799654-2Report Type:Periodic Company Report #WAES 01082100
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Percocet	C				

Date:09/24/01ISR Number: 3799656-6Report Type:Periodic Company Report #WAES 01082106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3799658-XReport Type:Periodic Company Report #WAES 01082112
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Urinary Retention	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799659-1Report Type:Periodic Company Report #WAES 01082154
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Back Pain							
	Dizziness							
	Headache							

Date:09/24/01ISR Number: 3799661-XReport Type:Periodic Company Report #WAES 01082174
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspnoea						MG/DAILY/PO	
	Pain		Cozaar	C				
	Respiratory Disorder		Hydrodiuril	C				
			K-Dur	C				
			Paxil	C				
			Prilosec	C				
			Antineoplastic (Unspecified)	C				
			Aspirin	C				
			Shark Cartilage	C				
			Deodorized (Fre	C				
			Trifolium	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799663-3Report Type:Periodic Company Report #WAES 01082300
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/QOD/PO
			Accolate	C				
			Flonase	C				
			Flovent	C				
			Serevent	C				
			Albuterol	C				

Date:09/24/01ISR Number: 3799665-7Report Type:Periodic Company Report #WAES 01082303
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nocturia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Actonel	C				
			Darvocet-N	C				
			Carbidopa (+)					
			Levodopa	C				
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799667-0Report Type:Periodic Company Report #WAES 01082306
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/PRN/PO	
			Actos	C				
			Glucophage	C				
			Lescol	C				

Date:09/24/01ISR Number: 3799668-2Report Type:Periodic Company Report #WAES 01082317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Procardia	C				

Date:09/24/01ISR Number: 3799670-0Report Type:Periodic Company Report #WAES 01082319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799671-2Report Type:Periodic Company Report #WAES 01082321
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799672-4Report Type:Periodic Company Report #WAES 01082322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799673-6Report Type:Periodic Company Report #WAES 01082323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799674-8Report Type:Periodic Company Report #WAES 01072516
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Positive	Professional					PO	
	Arthralgia	Other	[Therapy Unspecified]	C				
			Estradiol	C				

Date:09/24/01ISR Number: 3799675-XReport Type:Periodic Company Report #WAES 01082529
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799676-1Report Type:Periodic Company Report #WAES 01072503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	6 MON
	Palpitations		Glucotrol	C				
			Hydrodiuril	C				
			Premarin	C				
			Aspirin	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3799677-3Report Type:Periodic Company Report #WAES 01082530
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3799678-5Report Type:Periodic Company Report #WAES 01072498
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Back Pain		Advil	C				
	Pain In Extremity		Estrogens	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3799679-7Report Type:Periodic Company Report #WAES 01082676
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Dyspepsia	Professional					MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3799680-3Report Type:Periodic Company Report #WAES 01072475
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG	
	Drug Ineffective						/DAILY/PO	
			Neurontin	C				
			Norvasc	C				
			Plavix	C				
			Prilosec	C				

Zocor	C
Atenolol	C

Date:09/24/01ISR Number: 3799681-5Report Type:Periodic Company Report #WAES 01082677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Disorientation	Professional Company Representative						

Date:09/24/01ISR Number: 3799682-7Report Type:Periodic Company Report #WAES 01072444
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799683-9Report Type:Periodic Company Report #WAES 01082847
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3799684-0Report Type:Periodic Company Report #WAES 01072453
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
ORAL						

Date:09/24/01ISR Number: 3799685-2Report Type:Periodic Company Report #WAES 01072492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Tab Vioxx	PS		ORAL
PO						
	Nausea					

Date:09/24/01ISR Number: 3799686-4Report Type:Periodic Company Report #WAES 01083260
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:09/24/01ISR Number: 3799687-6Report Type:Periodic Company Report #WAES 01072493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
PO						
			Cardura	C		

			Atenolol	C		

Date:09/24/01ISR Number: 3799688-8Report Type:Periodic Company Report #WAES 01072499
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged	Lower Respiratory Tract						ORAL	
	Infection		[Composition					
	Upper Respiratory Tract		Unspecified]	C				
	Infection		Hydrochloroquine					
			Sulfate	C				

Date:09/24/01ISR Number: 3799689-XReport Type:Periodic Company Report #WAES 01070918
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective						MG/DAILY/PO	
	Hypertrophy Breast		Allegra	C				
	Oedema Peripheral		Lomotil	C				
			Provera	C				
			Thyroid Tablets Usp	C				
			Vasotec	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3799690-6Report Type:Periodic Company Report #WAES 01072517
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Coumadin	C				

Date:09/24/01ISR Number: 3799691-8Report Type:Periodic Company Report #WAES 01070928
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Hyperglycaemia	Health					MG/DAILY/PO	
	Nasal Congestion	Professional	Actos	C				
	Visual Disturbance		Glucophage	C				
			Glyburide	C				

Date:09/24/01ISR Number: 3799692-XReport Type:Periodic Company Report #WAES 01072659
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Haematochezia		Cordarone	C				
			Vasotec	C				
			Composition Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799693-1Report Type:Periodic Company Report #WAES 01070939
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Bronchitis	Health Professional	Actos	C				
	Cardiac Failure		Celebrex	C				
	Congestive		Glucophage	C				
	Dyspnoea		Glucotrol	C				
	Oedema Peripheral		Lipitor	C				
			Zyrtec	C				

Date:09/24/01ISR Number: 3799694-3Report Type:Periodic Company Report #WAES 01072638
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Urticaria		Estrace	C				
			Keflex	C				
			Lopressor	C				
			Lotensin	C				
			Zantac	C				

Date:09/24/01ISR Number: 3799695-5Report Type:Periodic Company Report #WAES 01070940
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Tab Vioxx Unk	PS			4	DAY

Date:09/24/01ISR Number: 3799696-7Report Type:Periodic Company Report #WAES 01072632
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/ PO						
			Motrin	C		
			Calcium	C		

Date:09/24/01ISR Number: 3799697-9Report Type:Periodic Company Report #WAES 01070941
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Oedema Peripheral	Health				
MG/DAILY/PO						
		Professional	Inj Synvisc 2 Ml	SS		
2 ML/1X/INJ						
			Avandia	C		
			Duratuss	C		
			Estrace	C		
			Humibid L.A.	C		
			Levothroid	C		
			Lipitor	C		
			Lozol	C		
			Paxil	C		
			Prilosec	C		
			Tabe	C		
			Glyburide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799698-0Report Type:Periodic Company Report #WAES 01072636
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Humibid	C				
			Lasix (Furosemide)	C				

Date:09/24/01ISR Number: 3799699-2Report Type:Periodic Company Report #WAES 01070942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngeal Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Urticaria							

Date:09/24/01ISR Number: 3799700-6Report Type:Periodic Company Report #WAES 01072644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3799701-8Report Type:Periodic Company Report #WAES 01072645
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				

Date:09/24/01ISR Number: 3799702-XReport Type:Periodic Company Report #WAES 01070947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Lortab	C				

Date:09/24/01ISR Number: 3799703-1Report Type:Periodic Company Report #WAES 01072657
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Feeling Abnormal		Estradiol	C				
	Headache							
	Hyperventilation							

Date:09/24/01ISR Number: 3799704-3Report Type:Periodic Company Report #WAES 01070949
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Tab Vioxx Unk	PS				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799705-5Report Type:Periodic Company Report #WAES 01072662
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

Date:09/24/01ISR Number: 3799706-7Report Type:Periodic Company Report #WAES 01070950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atenol	C				
			Detrol	C				
			Lescol	C				
			Prozac	C				

Date:09/24/01ISR Number: 3799707-9Report Type:Periodic Company Report #WAES 01072674
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3799708-0Report Type:Periodic Company Report #WAES 01072690
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799709-2Report Type:Periodic Company Report #WAES 01070951
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/PRN/PO	
			Alphagan	C				
			Ogen	C				

Date:09/24/01ISR Number: 3799710-9Report Type:Periodic Company Report #WAES 01072373
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urinary Tract Infection							
			Actonel	C				
			Fioricet Tablets	C				
			Prozac	C				
			Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799711-0Report Type:Periodic Company Report #WAES 01090447
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Face Oedema		Detrol	C				
	Oedema Peripheral		Plendil	C				
	Urinary Retention		Nitroglycerin	C				

Date:09/24/01ISR Number: 3799712-2Report Type:Periodic Company Report #WAES 01072320
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/ORAL	
			Humulin	C				
			Lo/Ovral	C				
			Prinivil	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3799713-4Report Type:Periodic Company Report #WAES 01070963
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

Date:09/24/01ISR Number: 3799714-6Report Type:Periodic Company Report #WAES 01072299
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Unevaluable Event	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO

Date:09/24/01ISR Number: 3799715-8Report Type:Periodic Company Report #WAES 01070987
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Drug Ineffective Gastrointestinal Disorder Tongue Disorder							

Date:09/24/01ISR Number: 3799716-XReport Type:Periodic Company Report #WAES 01072315
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3799717-1Report Type:Periodic Company Report #WAES 01071017
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Dyspepsia							
	Flatulence						12.5 MG PO	
			Centrum	C				
			Coumadin	C				
			Digitek	C				
			Keflex	C				
			Nexium	C				
			Cranberry Extract	C				

Date:09/24/01ISR Number: 3799718-3Report Type:Periodic Company Report #WAES 01072355
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	ORAL	
	Haemorrhage	Professional Company Representative						

Date:09/24/01ISR Number: 3799719-5Report Type:Periodic Company Report #WAES 01072363
Age:44 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS			25 MG/BID	

Date:09/24/01ISR Number: 3799720-1Report Type:Periodic Company Report #WAES 01071038
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50	
	Diarrhoea						MG/DAILY/PO	
			Estratest	C				
			Lozol	C				
			Prozac	C				
			Oxybutynin Chloride	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3799721-3Report Type:Periodic Company Report #WAES 01072364
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Oedema Peripheral						MG/DAILY/PO	
			Allegra	C				
			Estradiol	C				

Date:09/24/01ISR Number: 3799722-5Report Type:Periodic Company Report #WAES 01071061
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Vasotec	C				
			Vitamins					

(Unspecified) C

Date:09/24/01ISR Number: 3799723-7Report Type:Periodic Company Report #WAES 01072368
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
			Hyalgan	C				
			Plendil	C				

Date:09/24/01ISR Number: 3799724-9Report Type:Periodic Company Report #WAES 01072387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Drug Ineffective							
	Haemorrhage							
	Ulcer							

Date:09/24/01ISR Number: 3799725-0Report Type:Periodic Company Report #WAES 01071064
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nausea		Vicodin Tablets	C				
	Vomiting							

Date:09/24/01ISR Number: 3799726-2Report Type:Periodic Company Report #WAES 01072388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799727-4Report Type:Periodic Company Report #WAES 01071067
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799728-6Report Type:Periodic Company Report #WAES 01071072
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Chest Pain		Methotrexate	C				
	Heart Rate Irregular							

Date:09/24/01ISR Number: 3799729-8Report Type:Periodic Company Report #WAES 01072248
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Bone Cyst							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799730-4Report Type:Periodic Company Report #WAES 01071075
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ibuprofen	C				

Date:09/24/01ISR Number: 3799731-6Report Type:Periodic Company Report #WAES 01072252
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Rash	Professional	Celebrex	C				
			[Therapy Unspecified]	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3799732-8Report Type:Periodic Company Report #WAES 01072234
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	ORAL	
	Swelling	Health Professional	Paxil	C				
			Furosemide	C				
			Tamoxifen	C				

Date:09/24/01ISR Number: 3799733-XReport Type:Periodic Company Report #WAES 01071078
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
	Oesophageal Ulcer					
PO						
			Aspirin	SS		

Date:09/24/01ISR Number: 3799734-1Report Type:Periodic Company Report #WAES 01072230
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						

Date:09/24/01ISR Number: 3799735-3Report Type:Periodic Company Report #WAES 01071079
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oral Soft Tissue Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
		Professional				
PO						
			Lopressor Hct	C		
			Norvasc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799736-5Report Type:Periodic Company Report #WAES 01072232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anuria	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea							

Date:09/24/01ISR Number: 3799737-7Report Type:Periodic Company Report #WAES 01071081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Demadex	C				
			Premarin	C				
			Sinemet	C				
			Zestril	C				
			Acetaminophen (+) Hydrocodone	C				
			Potassium (Unspecified)	C				

Date:09/24/01ISR Number: 3799738-9Report Type:Periodic Company Report #WAES 01072239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 12.5 Mg	PS			37.5-50MG/DAILY	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799739-0Report Type:Periodic Company Report #WAES 01071085
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
	Nocturia						DAILY, PO; 25	
	Pain						MG/DAILY/PO	
			...	C				

Date:09/24/01ISR Number: 3799740-7Report Type:Periodic Company Report #WAES 01072242
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/DAILY/ORAL	
			Accupril	C				
			Lanoxin	C				

Date:09/24/01ISR Number: 3799741-9Report Type:Periodic Company Report #WAES 01072244
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Libido Decreased						MG/DAILY/ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799742-0Report Type:Periodic Company Report #WAES 01071087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, BID,	
	Oedema	Professional					PO	

Date:09/24/01ISR Number: 3799743-2Report Type:Periodic Company Report #WAES 01072245
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/ORAL	
		Professional	Skelaxin	C				

Date:09/24/01ISR Number: 3799744-4Report Type:Periodic Company Report #WAES 01072251
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799745-6Report Type:Periodic Company Report #WAES 01072281
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/DAILY/ORAL	
							12.5	

MG/DAILY/ORAL

ADMINISTRATIO

			Norvasc	C		
			Synthroid	C		
			Ziac	C		
			Zocor	C		

Date:09/24/01ISR Number: 3799746-8Report Type:Periodic Company Report #WAES 01072263
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Dry	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/ORAL

			Naprosyn	C		
			Os-Cal	C		
			Prempro	C		
			Prilosec	C		
			Salagen Tablets	C		
			Vicodin Tablets	C		
			Zoloft	C		
			[Therapy Unspecified]	C		
			Hydrocodone	C		
			Hydroxychloroquine Sulfate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3799747-XReport Type:Periodic Company Report #WAES 01072261
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Irritable Bowel Syndrome	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	50 MG/DAILY PO
			Prevacid	C				
			Xanax	C				

Date:09/24/01ISR Number: 3799748-1Report Type:Periodic Company Report #WAES 01071095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyanosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Pain							
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3799749-3Report Type:Periodic Company Report #WAES 01072253
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Gastrointestinal Disorder		Arthrotec	C				
			Diovan	C				
			Zantac	C				

Date:09/24/01ISR Number: 3799750-XReport Type:Periodic Company Report #WAES 01071097
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
			Lipitor	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3799751-1Report Type:Periodic Company Report #WAES 01072254
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Nasonex	C				

Date:09/24/01ISR Number: 3799752-3Report Type:Periodic Company Report #WAES 01071100
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3799753-5Report Type:Periodic Company Report #WAES 01072255
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/ORAL	
	Swelling	Professional						
			Effexor Xl	C				
			Flexeril	C				

Date:09/24/01ISR Number: 3799754-7Report Type:Periodic Company Report #WAES 01071101
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
		Professional						
		Company Representative						

Date:09/24/01ISR Number: 3799755-9Report Type:Periodic Company Report #WAES 01072267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3799756-0Report Type:Periodic Company Report #WAES 01071104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Laryngitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
PO						
			Glucophage	C		
			Atenolol	C		

Date:09/24/01ISR Number: 3799757-2Report Type:Periodic Company Report #WAES 01072272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
25								
MG/DAILY/PO								

Date:09/24/01ISR Number: 3799758-4Report Type:Periodic Company Report #WAES 01072280
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx	PS		ORAL		
PO								
		Professional						

Date:09/24/01ISR Number: 3799759-6Report Type:Periodic Company Report #WAES 01072285
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
25								
MG/DAILY/PO								

				[Therapy Unspecified]	C		

Date:09/24/01ISR Number: 3800029-8Report Type:Periodic Company Report #WAES 01072021
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Loestrin Fe	C				

Date:09/24/01ISR Number: 3800030-4Report Type:Periodic Company Report #WAES 01072022
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	1) 50 MG/DAILY/PO; 2) 25 MG/DAILY/PO	
	Face Oedema							
	Jaundice							
	Oedema Peripheral							
			Altace	C				
			Amaryl	C				
			Ambien	C				
			Avandia	C				
			Glucophage	C				
			Lopid	C				
			Nasonex	C				
			Zocor	C				
			Aspirin	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800031-6Report Type:Periodic Company Report #WAES 01072026
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/DAILY/PO; 2) 50 MG/DAILY/PO	
	Oedema Peripheral							
			Celebrex	C				
			Celexa	C				
			Glucotrol Xl	C				
			Lasix (Furosemide)	C				
			Maxzide	C				
			Neurontin	C				
			Premarin	C				
			Skelaxin	C				
			Alprazolam	C				
			Potassium (Unspecified)	C				

Date:09/24/01ISR Number: 3800033-XReport Type:Periodic Company Report #WAES 01072027
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Glucophage	C				

Prozac	C
Clonidine	C

Date:09/24/01ISR Number: 3800034-1Report Type:Periodic Company Report #WAES 01072036
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800036-5Report Type:Periodic Company Report #WAES 01072037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	1 WK

Date:09/24/01ISR Number: 3800037-7Report Type:Periodic Company Report #WAES 01072038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800039-0Report Type:Periodic Company Report #WAES 01072051
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company						

Representative

Date:09/24/01ISR Number: 3800040-7Report Type:Periodic Company Report #WAES 01072053
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800041-9Report Type:Periodic Company Report #WAES 01072072
Age:62 YR Gender:Female I/FU:U

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800043-2Report Type:Periodic Company Report #WAES 01071120
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspepsia						MG/DAILY/PO	
			Doxazosin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:09/24/01ISR Number: 3800044-4Report Type:Periodic Company Report #WAES 01071122
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Hyzaar	C				
			Prilosec	C				
			Vicodin Tablets	C				
			Zoloft	C				
			Alprazolam	C				
			Flurazepam	C				

Date:09/24/01ISR Number: 3800046-8Report Type:Periodic Company Report #WAES 01071128
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Oedema Peripheral						MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Lipitor	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3800047-XReport Type:Periodic Company Report #WAES 01071134
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800048-1Report Type:Periodic Company Report #WAES 01071135
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema Skin Lesion Swelling	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800050-XReport Type:Periodic Company Report #WAES 01071171
Age:57 YR Gender:Female I/FU:I

Outcome	PT
	Dizziness Face Oedema

	Flushing						
	Nausea						
	Somnolence	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Accupril	C				
			Combipatch	C				
			Prilosec	C				
			Synthroid	C				
			Metoprolol	C				

Date:09/24/01ISR Number: 3800052-3Report Type:Periodic Company Report #WAES 01071181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective							
	Headache							
	Nausea							

Date:09/24/01ISR Number: 3800053-5Report Type:Periodic Company Report #WAES 01052404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	3 DAY
	Dizziness							
	Headache							
	Nausea							
	Urinary Tract Disorder							
	Vomiting							

Date:09/24/01ISR Number: 3800055-9Report Type:Periodic Company Report #WAES 01071186
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health	Tab Vioxx	PS		ORAL	PRN/PO	
		Professional	Celebrex	C				
			Hydrodiuril	C				
			K Dur	C				
			Synthroid	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800056-0Report Type:Periodic Company Report #WAES 01052407
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral							
	Rash		Prozac	C				
	Urine Abnormality							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800057-2Report Type:Periodic Company Report #WAES 01071187
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800058-4Report Type:Periodic Company Report #WAES 01052409
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800059-6Report Type:Periodic Company Report #WAES 01071200
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Hyperhidrosis		Calan	C				
			Medrol	C				
			Neurontin	C				
			Serzone	C				
			Singulair	C				
			Ventolin	C				
			Zantac	C				

Date:09/24/01ISR Number: 3800061-4Report Type:Periodic Company Report #WAES 01052412
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abnormal Dreams	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Anxiety					
MG/DAILY/PO						
	Dyspnoea		Clonopin	C		
	Hallucination		Flexeril	C		
			Paxil	C		
			Aspirin	C		

Date:09/24/01ISR Number: 3800062-6Report Type:Periodic Company Report #WAES 01071205
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Diarrhoea					
MG/DAILY/PO						
			Mevacor	C		
			Prinivil	C		

Date:09/24/01ISR Number: 3800063-8Report Type:Periodic Company Report #WAES 01052413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Erythema					
MG/DAILY/PO 4 WK						
	Eyelid Oedema					
	Panic Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800065-1Report Type:Periodic Company Report #WAES 01071208
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG DAILY PO	
	Dizziness							
	Dysgeusia							
	Palpitations							
			Ambien	C				
			Flovent	C				
			Servent	C				

Date:09/24/01ISR Number: 3800066-3Report Type:Periodic Company Report #WAES 01052419
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/BID/PO; 2) 25 MG/DAILY/PO	
	Flatulence	Health Professional						
	Oedema Peripheral							
	Tachycardia							
	Weight Increased		Synthroid	C				

Date:09/24/01ISR Number: 3800067-5Report Type:Periodic Company Report #WAES 01071209
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/ORAL	
			Motrin	C				
			Toprol Xl Tablets	C				

Date:09/24/01ISR Number: 3800068-7Report Type:Periodic Company Report #WAES 01052421
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
			Darvocet-N	C				

Date:09/24/01ISR Number: 3800070-5Report Type:Periodic Company Report #WAES 01071210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	ORAL	

Date:09/24/01ISR Number: 3800071-7Report Type:Periodic Company Report #WAES 01052432
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/BID/PO;	
	Cardiac Murmur							
	Muscle Spasms						2) 25 MG/DAILY/PO	
	Oedema Peripheral		Effexor	C				

				Elavil	C		
				Medrol	C		
				Pravachol	C		
				Prempro	C		

Date:09/24/01ISR Number: 3800072-9Report Type:Periodic Company Report #WAES 01071214
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Alphagan	C				
			Cosopt	C				
			Fibercon	C				
			Luvox	C				
			Xalatan	C				

Date:09/24/01ISR Number: 3800074-2Report Type:Periodic Company Report #WAES 01052435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	1) PO; 2) PRN/PO - 1	YEAR

Date:09/24/01ISR Number: 3800075-4Report Type:Periodic Company Report #WAES 01071220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

	Professional	Evista	C
		Hydrochlorothiazide + Triamter	C
		Verapamil	C

Date:09/24/01ISR Number: 3800076-6Report Type:Periodic Company Report #WAES 01052436
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:09/24/01ISR Number: 3800078-XReport Type:Periodic Company Report #WAES 01072553
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Other	Tab Vioxx Unk	PS		ORAL	PO	
			Colace	C				
			Os-Cal	C				
			Pepcid	C				
			Plavix	C				
			Singulair	C				
			Volmax	C				

		Albuterol	C
		Prednisone	C
		Theophylline	C

Date:09/24/01ISR Number: 3800080-8Report Type:Periodic Company Report #WAES 01071227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx	PS				
			Hydrodiuril	C				

Date:09/24/01ISR Number: 3800081-XReport Type:Periodic Company Report #WAES 01072555
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Tab Vioxx Unk	PS		ORAL	50 MG/PRN/PO	
	Dizziness	Professional	Serzone	C				
	Paraesthesia							

Date:09/24/01ISR Number: 3800083-3Report Type:Periodic Company Report #WAES 01071228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3800084-5Report Type:Periodic Company Report #WAES 01072556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urine Flow Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Bentyl	C		

Date:09/24/01ISR Number: 3800085-7Report Type:Periodic Company Report #WAES 01071232
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx	PS		ORAL	PO	
	Skin Lesion	Professional						
	Swelling							

Date:09/24/01ISR Number: 3800087-0Report Type:Periodic Company Report #WAES 01072564
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
	Oliguria		Actos	C				
	Weight Increased		Prilosec	C				
			Atenolol	C				
			Doxazosin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800088-2Report Type:Periodic Company Report #WAES 01071237
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tylenol	C				

Date:09/24/01ISR Number: 3800089-4Report Type:Periodic Company Report #WAES 01072573
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-50 MG/DAILY/PO	
			Effexor	C				
			Fosamax	C				
			Folic Acid	C				

Date:09/24/01ISR Number: 3800090-0Report Type:Periodic Company Report #WAES 01072606
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fatigue							
	Haemorrhage							

Date:09/24/01ISR Number: 3800091-2Report Type:Periodic Company Report #WAES 01072618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PO	

Professional
Company
Representative

Date:09/24/01ISR Number: 3800092-4Report Type:Periodic Company Report #WAES 01072623
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx Unk	PS		ORAL	PO	1 YR
		Professional Company Representative						

Date:09/24/01ISR Number: 3800093-6Report Type:Periodic Company Report #WAES 01072625
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional Company Representative	Flexeril	C				
			Percocet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800094-8Report Type:Periodic Company Report #WAES 01072626
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Depression	Professional	Tab Vioxx	SS		ORAL	PO	
		Company Representative	Zoloft	C				

Date:09/24/01ISR Number: 3800160-7Report Type:Periodic Company Report #WAES 01071243
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tooth Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Celebrex	C				
			Estrogens (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800163-2Report Type:Periodic Company Report #WAES 01071248
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Health	Tab Vioxx	PS		ORAL	PO	
	Thrombocythaemia	Professional						

Date:09/24/01ISR Number: 3800165-6Report Type:Periodic Company Report #WAES 01071249
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO;	

50 MG/PRN/PO

				Vitamins (Unspecified)	C	

Date:09/24/01ISR Number: 3800168-1Report Type:Periodic Company Report #WAES 01071252
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800169-3Report Type:Periodic Company Report #WAES 01071253
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800170-XReport Type:Periodic Company Report #WAES 01071256
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	10 DAY
			Combivent	C				
			Glucophage	C				
			Prinivil	C				
			Triavil	C				
			Vanceril	C				
			Xanax	C				
			Albuterol	C				
			Ipratropium Bromide	C				
			Theophylline	C				

Date:09/24/01ISR Number: 3800171-1Report Type:Periodic Company Report #WAES 01071261
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Premarin	C				
			Alprazolam	C				

Date:09/24/01ISR Number: 3800173-5Report Type:Periodic Company Report #WAES 01071265
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
	Palpitations	Professional						
	Panic Disorder							

Date:09/24/01ISR Number: 3800175-9Report Type:Periodic Company Report #WAES 01071304
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhoids							
			Lipitor	C				
			Bisoprolol (+) Hydrochlorothiazi	C				

Date:09/24/01ISR Number: 3800177-2Report Type:Periodic Company Report #WAES 01071311
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800181-4Report Type:Periodic Company Report #WAES 01071315
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800183-8Report Type:Periodic Company Report #WAES 01071319
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3800184-XReport Type:Periodic Company Report #WAES 01071321
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Weight Decreased							

Date:09/24/01ISR Number: 3800185-1Report Type:Periodic Company Report #WAES 01071324
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50MG/DAILY /PO	
	Drug Interaction							
	Insomnia		Prozac Unk	SS			UNKNOWN	
	Mental Impairment							

Date:09/24/01ISR Number: 3800186-3Report Type:Periodic Company Report #WAES 01071326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	

MG/DAILY/PO 10 DAY

Date:09/24/01ISR Number: 3800188-7Report Type:Periodic Company Report #WAES 01071330
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Nausea							

Date:09/24/01ISR Number: 3800189-9Report Type:Periodic Company Report #WAES 01071331
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
			Celebrex	C				
			Norvasc	C				
			Zocor	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3800191-7Report Type:Periodic Company Report #WAES 01071332
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Diovan	C				
			Imdur	C				

Lasix (Furosemide)	C
Lopressor	C
Aspirin	C

Date:09/24/01ISR Number: 3800192-9Report Type:Periodic Company Report #WAES 01071336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800194-2Report Type:Periodic Company Report #WAES 01071339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800251-0Report Type:Periodic Company Report #WAES 01052051
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	2 WK
	Diarrhoea		Tab Vioxx	SS		ORAL	PO	
	Drug Ineffective		Prevacid	C				

Date:09/24/01ISR Number: 3800252-2Report Type:Periodic Company Report #WAES 01052061
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urinary Retention	Health Professional	Tab Vioxx 50mg	PS		ORAL 50 MG/DAILY/PO
			Avandia	C		
			Ecotrin	C		
			K-Dur	C		
			Premarin	C		
			Amoxicillin	C		
			Furosemide	C		
			Insulin	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:09/24/01ISR Number: 3800253-4Report Type:Periodic Company Report #WAES 01052063
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Fosamax	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800254-6Report Type:Periodic Company Report #WAES 01052070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				

Date:09/24/01ISR Number: 3800255-8Report Type:Periodic Company Report #WAES 01052073
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Flushing							
			Tab Vioxx	SS			12.5 MG/TID	
			Halcion	C				
			Xanax	C				

Date:09/24/01ISR Number: 3800256-XReport Type:Periodic Company Report #WAES 01052074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800257-1Report Type:Periodic Company Report #WAES 01052080
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Azoospermia	Consumer	Tab Vioxx Unk	PS			ORAL
PO							
			Claritin	C			
			Hydrodiuril	C			
			Protona	C			
			Atenolol	C			

Date:09/24/01ISR Number: 3800258-3Report Type:Periodic Company Report #WAES 01052084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral							
MG/DAILY/PO								
	Polyuria		Tab Vioxx	SS		ORAL	50	
MG/DAILY/PO	2	DAY						
			Tab Vioxx	SS		ORAL		
PO								

Date:09/24/01ISR Number: 3800259-5Report Type:Periodic Company Report #WAES 01052125
Age:71 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
MG/DALY/PO								
			Prilosec	C				
			Sular	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800260-1Report Type:Periodic Company Report #WAES 01052128
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							
	Tongue Ulceration		Estraderm	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Garlic Extract	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800261-3Report Type:Periodic Company Report #WAES 01052137
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Constipation							
	Diarrhoea		Premarin	C				
	Fatigue		Prinivil	C				
	Rhinorrhoea		Synthroid	C				

Date:09/24/01ISR Number: 3800262-5Report Type:Periodic Company Report #WAES 01052140
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			Premarin	C				
			Prevacid	C				

Date:09/24/01ISR Number: 3800264-9Report Type:Periodic Company Report #WAES 01052142
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Tab Vioxx	PS		ORAL	HS/PO	1 WK
			Hytrin	C				
			Klor-Con	C				
			Lasix	C				
			Pravachol	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3800266-2Report Type:Periodic Company Report #WAES 01052172
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800287-XReport Type:Periodic Company Report #WAES 01052173
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Alupent	C				
			Claritin	C				
			Glucotrol Xl	C				
			Prandin	C				
			Serevent	C				
			Singulair	C				
			Vanceril	C				
			Vanceril Double Strength	C				
			Naproxen	C				

Date:09/24/01ISR Number: 3800289-3Report Type:Periodic Company Report #WAES 01052174
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Meclizine	C				

Date:09/24/01ISR Number: 3800291-1Report Type:Periodic Company Report #WAES 01052177
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800292-3Report Type:Periodic Company Report #WAES 01052180
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Amaryl	C				
			Avandia	C				
			Lasix (Furosemide)	C				
			Prinivil	C				

Date:09/24/01ISR Number: 3800294-7Report Type:Periodic Company Report #WAES 01052181
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50mg	PS		ORAL	50 MG/DAILY/PO	
	Swelling							
			Fiorinal	C				
			Lorestat	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800296-0Report Type:Periodic Company Report #WAES 01052182
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Dyazide	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3800298-4Report Type:Periodic Company Report #WAES 01052184
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5	
	Dizziness						MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	25	
							MG/DAILY/PO	
			Therapy Unspecified	C				

Date:09/24/01ISR Number: 3800299-6Report Type:Periodic Company Report #WAES 01052186
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis B	Health	Tab Vioxx 50mg	PS		ORAL	50	
		Professional					MG/DAILY/PO	

Date:09/24/01ISR Number: 3800307-2Report Type:Periodic Company Report #WAES 01052190
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Vision Blurred	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/QOD/PO						
	Visual Disturbance					

Date:09/24/01ISR Number: 3800309-6Report Type:Periodic Company Report #WAES 01052192
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urticaria	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						

Date:09/24/01ISR Number: 3800310-2Report Type:Periodic Company Report #WAES 01052199
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Oedema Peripheral	Professional	Evista	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:09/24/01ISR Number: 3800311-4Report Type:Periodic Company Report #WAES 01052203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cardiac Disorder	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Dyspepsia		Tab Vioxx	SS		ORAL
50						
	Tachycardia					
MG/DAILY/PO						
			Darvocet-N	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800313-8Report Type:Periodic Company Report #WAES 01052207
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	4 DAY
			Mobic	C				

Date:09/24/01ISR Number: 3800315-1Report Type:Periodic Company Report #WAES 01052213
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prednisone	C				

Date:09/24/01ISR Number: 3800316-3Report Type:Periodic Company Report #WAES 01052271
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	SS				

Date:09/24/01ISR Number: 3800317-5Report Type:Periodic Company Report #WAES 01052279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800318-7Report Type:Periodic Company Report #WAES 01052283
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800319-9Report Type:Periodic Company Report #WAES 01052284
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
			Actonel	C				
			Baycol	C				
			Evista	C				

Date:09/24/01ISR Number: 3800320-5Report Type:Periodic Company Report #WAES 01052287
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Mobility Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800321-7Report Type:Periodic Company Report #WAES 01052296
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Pepcid Ac	C				
			Voltaren	C				
			Iron (Unspecified)	C				

Date:09/24/01ISR Number: 3800324-2Report Type:Periodic Company Report #WAES 01052297
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800327-8Report Type:Periodic Company Report #WAES 01052300
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea	Professional						
		Other						

Date:09/24/01ISR Number: 3800330-8Report Type:Periodic Company Report #WAES 01052301
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Cozaar	C				
			Glucophage	C				

Maxzide	C
Tenormin	C
Zocor	C
Levothyroxine	C
Magnesium (Unspecified)	C
Potassium (Unspecified)	C

Date:09/24/01ISR Number: 3800334-5Report Type:Periodic Company Report #WAES 01052303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hearing Impaired	Professional						
	Influenza Like Illness							
	Nervousness							

Date:09/24/01ISR Number: 3800338-2Report Type:Periodic Company Report #WAES 01052307
Age: Gender:Female I/FU:I

Outcome	PT
	Dyspepsia
	Face Oedema
	Headache
	Nasal Disorder

	Pruritus						
	Throat Tightness						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Colyte	C				
			Elavil	C				
			Fosamax	C				
			Provera	C				
			Calcium (Unspecified)	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3800340-0Report Type:Periodic Company Report #WAES 01052315
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Headache							
	Musculoskeletal Stiffness		Flexeril	C				
	Oedema Peripheral		Lipitor	C				
			Ultram	C				
			Voltaren	C				

Date:09/24/01ISR Number: 3800461-2Report Type:Periodic Company Report #WAES 01071341
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection	Consumer	Tab Vioxx	PS		ORAL	PO	
	Glossodynia							
	Tongue Oedema							

Date:09/24/01ISR Number: 3800462-4Report Type:Periodic Company Report #WAES 01071343
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800464-8Report Type:Periodic Company Report #WAES 01071361
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800466-1Report Type:Periodic Company Report #WAES 01071362
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800467-3Report Type:Periodic Company Report #WAES 01071368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:09/24/01ISR Number: 3800469-7Report Type:Periodic Company Report #WAES 01071369
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Blinded Therapy	C				

Date:09/24/01ISR Number: 3800470-3Report Type:Periodic Company Report #WAES 01071375
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
			Composition Unspecified)	C				

Date:09/24/01ISR Number: 3800471-5Report Type:Periodic Company Report #WAES 01071381
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Alopecia		Allopurinol	C				
	Diarrhoea							

Date:09/24/01ISR Number: 3800474-0Report Type:Periodic Company Report #WAES 01071382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx	PS		ORAL	PO	
			Darvocet-N	C				
			Vicoprofen	C				

Date:09/24/01ISR Number: 3800475-2Report Type:Periodic Company Report #WAES 01071383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS				
			Composition Unspecified)	C				

Date:09/24/01ISR Number: 3800477-6Report Type:Periodic Company Report #WAES 01071384
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800478-8Report Type:Periodic Company Report #WAES 01071385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800479-XReport Type:Periodic Company Report #WAES 01071387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Ultram	C				

Date:09/24/01ISR Number: 3800482-XReport Type:Periodic Company Report #WAES 01071388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800483-1Report Type:Periodic Company Report #WAES 01071391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Celebrex	C				

Date:09/24/01ISR Number: 3800484-3Report Type:Periodic Company Report #WAES 01071392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL
PO						
			Arthrotec	C		

Date:09/24/01ISR Number: 3800485-5Report Type:Periodic Company Report #WAES 01071395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL
PO						
			Darvocet-N	C		
			Daypro	C		
			Premarin	C		
			Prilosec	C		
			Zocor	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:09/24/01ISR Number: 3800486-7Report Type:Periodic Company Report #WAES 01071397
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL
DAILY/PO						
			Osteo-Bi-Flex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800487-9Report Type:Periodic Company Report #WAES 01071398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx	PS		PO	26	DAY
			Celebrex	SS				
			Ibuprofen	C				

Date:09/24/01ISR Number: 3800488-0Report Type:Periodic Company Report #WAES 01071401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800489-2Report Type:Periodic Company Report #WAES 01071406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Lipitor	C				
			Therapy Unspecified	C				

Date:09/24/01ISR Number: 3800490-9Report Type:Periodic Company Report #WAES 01071408
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	
			Ambien	C			PO	
			Detrol	C				
			Ecotrin	C				
			Hydrodiuril	C				

Lasix (Furosemide)	C
Lipitor	C
Prevacid	C
Synthroid	C
Vasotec	C
Calcium (Unspecified) (+)	
Magnes	C
Cyanocobalamin	C
Meprobamate	C
Vitamin B Complex	C

Date:09/24/01ISR Number: 3800491-0Report Type:Periodic Company Report #WAES 01071412
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
	Muscle Spasms						PO	
			Premarin	C				
			Provera	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800492-2Report Type:Periodic Company Report #WAES 01071413
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
	Abdominal Pain						PO	
	Oedema Peripheral		Ambien	C				
			Premarin	C				
			Acyclovir	C				
			Clonazepam	C				
			Folic Acid	C				

Date:09/24/01ISR Number: 3800493-4Report Type:Periodic Company Report #WAES 01071419
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/	
	Oedema Peripheral						PO	
	Weight Increased		Norvasc	C				
			Prinivil	C				

Date:09/24/01ISR Number: 3800494-6Report Type:Periodic Company Report #WAES 01071420
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Change Of Bowel Habit						PO	
	Dyspepsia		Allegra	C				
			Detrol La	C				
			Prozac	C				
			Estradiol	C				

Date:09/24/01ISR Number: 3800495-8Report Type:Periodic Company Report #WAES 01071422
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Oedema Peripheral						PO	
	Renal Pain		Claritin	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800496-XReport Type:Periodic Company Report #WAES 01071432
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:09/24/01ISR Number: 3800497-1Report Type:Periodic Company Report #WAES 01071472
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
	Back Pain						PO	
	Chest Pain		Neurontin	C				
			Prevacid	C				
			Sinemet	C				

				Xanax	C		
				Diltiazem Hydrochloride	C		

Date:09/24/01ISR Number: 3800498-3Report Type:Periodic Company Report #WAES 01071476
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY/ PO	
			Corgard	C				
			Diovan	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800499-5Report Type:Periodic Company Report #WAES 01071541
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Aspirin	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800500-9Report Type:Periodic Company Report #WAES 01071547
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /DAILY/PO	

		Professional	Tab Vioxx 12.5 Mg	SS		ORAL
12.5						
MG/BID/PO						
			Diazide	C		
			Zocor	C		

Date:09/24/01ISR Number: 3800501-0Report Type:Periodic Company Report #WAES 01071555
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dysuria	Consumer	Tab Vioxx Unk	PS		ORAL
50						
	Nocturia					
MG/DAILY/PO						
	Pollakiuria					

Date:09/24/01ISR Number: 3800502-2Report Type:Periodic Company Report #WAES 01071556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Dyspepsia					
MG/DAILY/PO 5 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800503-4Report Type:Periodic Company Report #WAES 01071558
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Faeces Discoloured							

Date:09/24/01ISR Number: 3800504-6Report Type:Periodic Company Report #WAES 01071561
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Muscular Weakness							
	Nausea		Lopressor	C				
			Tylenol	C				
			Xanax	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3800505-8Report Type:Periodic Company Report #WAES 01071565
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	BID/PO	
			Cozaar	C				
			Detrol	C				
			Dilantin	C				
			Norvasc	C				
			Pravachol	C				
			Clonidine	C				
			Furosemide	C				
			Nadolol	C				

Date:09/24/01ISR Number: 3800506-XReport Type:Periodic Company Report #WAES 01071583
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/[P	
	Dyspnoea		Detrol La	C				
	Fatigue		Fosamax	C				
	Feeling Abnormal							
	Musculoskeletal Stiffness							
	Pain							

Date:09/24/01ISR Number: 3800507-1Report Type:Periodic Company Report #WAES 01071585
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Simplex	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							

Date:09/24/01ISR Number: 3800508-3Report Type:Periodic Company Report #WAES 01071590
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Hallucination	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
50MG/DAILY/PO						

Date:09/24/01ISR Number: 3800509-5Report Type:Periodic Company Report #WAES 01071600
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dyspepsia	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3800510-1Report Type:Periodic Company Report #WAES 01071601
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Musculoskeletal Stiffness	Health	Tab Vioxx	PS		ORAL
PO						
	Myalgia	Professional Company Representative				

Date:09/24/01ISR Number: 3800511-3Report Type:Periodic Company Report #WAES 01071615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Insomnia	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:09/24/01ISR Number: 3800512-5Report Type:Periodic Company Report #WAES 01071616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oliguria		Darvocet-N	C				
			Colchicine	C				

Date:09/24/01ISR Number: 3800513-7Report Type:Periodic Company Report #WAES 01071617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	6 MON

Date:09/24/01ISR Number: 3800514-9Report Type:Periodic Company Report #WAES 01071619
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urinary Hesitation							

Date:09/24/01ISR Number: 3800515-0Report Type:Periodic Company Report #WAES 01071620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	2 MON

Date:09/24/01ISR Number: 3800516-2Report Type:Periodic Company Report #WAES 01071621
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800517-4Report Type:Periodic Company Report #WAES 01071623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal		Tab Vioxx	PS		ORAL	PO	
	Haemorrhage		Arthrotec	C				

Date:09/24/01ISR Number: 3800518-6Report Type:Periodic Company Report #WAES 01071624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800519-8Report Type:Periodic Company Report #WAES 01072073
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Hypersensitivity					
PO						
			Ambien	C		
			Armour Thyroid Tablets	C		
			Detrol	C		
			Diovan Hct	C		
			Prempro	C		
			Trazodone	C		

Date:09/24/01ISR Number: 3800520-4Report Type:Periodic Company Report #WAES 01072124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Respiratory Disorder	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL
PO						

Date:09/24/01ISR Number: 3800521-6Report Type:Periodic Company Report #WAES 01072128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthma	Consumer	Tab Vioxx Unk	PS		ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800522-8Report Type:Periodic Company Report #WAES 01072154
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx Unk	PS		ORAL	ORAL	
			Plaquenil	C				
			Prinivil	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Insulin	C				

Date:09/24/01ISR Number: 3800523-XReport Type:Periodic Company Report #WAES 01072169
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY	
	Oedema Peripheral					ORAL		
	Weight Increased		Aciphex	C				
			Celexa	C				
			Ultram	C				
			Cephalexin	C				
			Temazepam	C				

Date:09/24/01ISR Number: 3800524-1Report Type:Periodic Company Report #WAES 01072191
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800525-3Report Type:Periodic Company Report #WAES 01072205
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
	Urticaria						ORAL	
			Centrum	C				
			Detrol	C				
			Duragesic	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Lipitor	C				
			Atenolol	C				
			Calcium (Unspecified)	C				
			Isosorbide Mononitrate	C				

Date:09/24/01ISR Number: 3800526-5Report Type:Periodic Company Report #WAES 01072207
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Pruritus						PO	
	Rash		Coumadin	C				
			Flomax (Tamsulosin					

	Hydrochloride)	C
	Fosamax	C
	Lipitor	C
	Norvasc	C
	Sotalol Hydrochloride	C

Date:09/24/01ISR Number: 3800527-7Report Type:Periodic Company Report #WAES 01072217
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Pulse Pressure Increased						PO	
			Tab Zocor 40 Mg	SS			40 MG PM	
			Glucotrol Xl	C				
			Mavik	C				
			Tricor	C				
			Allopurinol	C				

Date:09/24/01ISR Number: 3800528-9Report Type:Periodic Company Report #WAES 01072229
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL	
			Lanoxin	C				
			Procardia	C				

Date:09/24/01ISR Number: 3800529-0Report Type:Periodic Company Report #WAES 01072396
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

			Flexeril	C		
			Percocet	C		

Date:09/24/01ISR Number: 3800530-7Report Type:Periodic Company Report #WAES 01072399
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Coagulopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Coumadin	C		
			Lanoxin	C		

Date:09/24/01ISR Number: 3800531-9Report Type:Periodic Company Report #WAES 01072402
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
			Tylenol With Codeine #3	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800532-0Report Type:Periodic Company Report #WAES 01072407
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	25MG/DAILY/PO
			Tylenol	C				
			Cyclobenzaprine Hydrochloride	C				

Date:09/24/01ISR Number: 3800533-2Report Type:Periodic Company Report #WAES 01072411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Colestid	C				
			Estraderm	C				
			Lipitor	C				
			Zyrtec	C				

Date:09/24/01ISR Number: 3800534-4Report Type:Periodic Company Report #WAES 01072420
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO, 50 MG/DAILY/PO	
	Pneumonitis							
			(Therapy Unspecified)	C				
			Naproxen	C				

Date:09/24/01ISR Number: 3800535-6Report Type:Periodic Company Report #WAES 01072425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL	
			Cardizem Cd	C				
			Cardura	C				
			Lipitor	C				
			Percodan	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3800536-8Report Type:Periodic Company Report #WAES 01072431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800537-XReport Type:Periodic Company Report #WAES 01072434
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 YR

Date:09/24/01ISR Number: 3800538-1Report Type:Periodic Company Report #WAES 01072443
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800539-3Report Type:Periodic Company Report #WAES 01072520
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800540-XReport Type:Periodic Company Report #WAES 01072525
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lozol	C				
			Pravachol	C				
			Prempro	C				

			Nadolol	C		

Date:09/24/01ISR Number: 3800541-1Report Type:Periodic Company Report #WAES 01072527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5 MG/BID/PO	

Date:09/24/01ISR Number: 3800542-3Report Type:Periodic Company Report #WAES 01072529
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Face Oedema							
			Tamoxifen	C				

Date:09/24/01ISR Number: 3800543-5Report Type:Periodic Company Report #WAES 01072530
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Flomax (Tamsulosin Hydrochloride)	C				

			Imodium	C		
			Librax Capsules	C		

Date:09/24/01ISR Number: 3800544-7Report Type:Periodic Company Report #WAES 01072538
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Increased						MG/DAILY/PO	
			Actos	C				
			Hydrodiuril	C				
			Prinivil	C				
			Protonix	C				
			Tricor	C				
			Zocor	C				
			Amitriptyline	C				
			Aspirin	C				
			Doxazosin	C				
			Insulin	C				
			Nifedipine	C				

Date:09/24/01ISR Number: 3800545-9Report Type:Periodic Company Report #WAES 01072539
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Nervousness	Health					MG/DAILY/PO	
	Oedema Peripheral	Professional	Fosamax	C				
	Rash		Lasix (Furosemide)	C				
	Tremor							
	Urticaria							

Date:09/24/01ISR Number: 3800546-0Report Type:Periodic Company Report #WAES 01072540
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Olfactory Nerve Disorder							
			Ziac	C				

Date:09/24/01ISR Number: 3800547-2Report Type:Periodic Company Report #WAES 01072548
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive	Professional						
	Drug Interaction	Company	[Composition					
	Renal Impairment	Representative	Unspecified] Unk	SS				

Date:09/24/01ISR Number: 3800548-4Report Type:Periodic Company Report #WAES 01072550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Hydrochloroquine Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800549-6Report Type:Periodic Company Report #WAES 01052936
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	PO
			Tenex	C				
			Vivelle	C				

Date:09/24/01ISR Number: 3800550-2Report Type:Periodic Company Report #WAES 01052964
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	25	MG/DAILY/PO
	Chest Pain	Professional						
	Colitis							
	Diarrhoea							
	Dizziness							
	Nausea							

Date:09/24/01ISR Number: 3800551-4Report Type:Periodic Company Report #WAES 01052966
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	DAILY/PO
	Mental Impairment							
	Speech Disorder		Atenolol	C				
			Disopyramide	C				

Date:09/24/01ISR Number: 3800552-6Report Type:Periodic Company Report #WAES 01052969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800553-8Report Type:Periodic Company Report #WAES 01052975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800554-XReport Type:Periodic Company Report #WAES 01060002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Nasal Congestion	Professional						
	Pharyngitis							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800555-1Report Type:Periodic Company Report #WAES 01060004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Vasotec	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800556-3Report Type:Periodic Company Report #WAES 01060005
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/PO	27 DAY
			Hytrin	C				
			Dextropropoxyphene	C				
			Ibuprofen	C				

Date:09/24/01ISR Number: 3800557-5Report Type:Periodic Company Report #WAES 01060008
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Aciphex	C				
			K-Dur	C				
			Lasix (Furosemide)	C				
			Pravachol	C				

Date:09/24/01ISR Number: 3800558-7Report Type:Periodic Company Report #WAES 01060020
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	10 DAY
	Paraesthesia	Professional	Buspar	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3800559-9Report Type:Periodic Company Report #WAES 01052833
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Fosamax	C				
			Toprol Xl Tablets	C				
			Calcium (Unspecified)	C				

Date:09/24/01ISR Number: 3800560-5Report Type:Periodic Company Report #WAES 01052840
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain In Extremity		Accolate	C				
			Atrovent	C				
			Proventil	C				
			Serevent	C				

Date:09/24/01ISR Number: 3800561-7Report Type:Periodic Company Report #WAES 01052845
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/DAILY/PO; 2) 50 MG/DAILY/PO	
	Rash							
			Vicodin Tablets	C				

Date:09/24/01ISR Number: 3800562-9Report Type:Periodic Company Report #WAES 01052847
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Tab Vioxx 50 Mg	PS		ORAL	1) 50 MG/DAILY/PO; 2) 25 MG/BID/PO; 3) 50	
	Pruritus	Professional						

Date:09/24/01ISR Number: 3800563-0Report Type:Periodic Company Report #WAES 01052858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral Swelling	Professional						

Date:09/24/01ISR Number: 3800564-2Report Type:Periodic Company Report #WAES 01052863
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Plaquenil	C				
			Remicade	C				
			Methotrexate	C				

Date:09/24/01ISR Number: 3800565-4Report Type:Periodic Company Report #WAES 01052869
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800566-6Report Type:Periodic Company Report #WAES 01052873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Palpitations		Tamoxifen	C				
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800567-8Report Type:Periodic Company Report #WAES 01052877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/DAILY/PO; 2) 25 MG/PRN/PO	
			Premarin	C				

Date:09/24/01ISR Number: 3800568-XReport Type:Periodic Company Report #WAES 01052883
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypersensitivity							
	Somnolence							
	Urinary Tract Infection							

Date:09/24/01ISR Number: 3800569-1Report Type:Periodic Company Report #WAES 01052766
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800572-1Report Type:Periodic Company Report #WAES 01052767
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800573-3Report Type:Periodic Company Report #WAES 01052785
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800574-5Report Type:Periodic Company Report #WAES 01052800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25/MG/DAILY/PO	
			Accupril	C				
			Glucophage	C				
			Toprol Xl Tablets	C				
			Estradiol	C				
			Glipizide	C				
			Medroxyprogesterone Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800575-7Report Type:Periodic Company Report #WAES 01052802
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Calan Sr	C				
			Cardura	C				
			Diovan Hct	C				
			Novolin 70/30	C				
			Xanax	C				
			Zantac	C				

Date:09/24/01ISR Number: 3800576-9Report Type:Periodic Company Report #WAES 01052806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Asthenia							
	Back Pain		Imitrex	C				
	Chest Pain		Ortho Cyclen	C				
	Fatigue		Oxycontin	C				
	Oedema Peripheral		Prevacid	C				
	Oliguria		Prozac	C				
	Vomiting							

Date:09/24/01ISR Number: 3800577-0Report Type:Periodic Company Report #WAES 01052818
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Glucophage	C				
			Toprol Xl Tablets	C				

			Zaroxolyn	C
			Zocor	C
			Furosemide	C
			Minoxidil	C

Date:09/24/01ISR Number: 3800578-2Report Type:Periodic Company Report #WAES 01052820
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO 3 DAY
			Prempro	C				
			Zestril	C				
			Aspirin	C				
			Diazepam	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:09/24/01ISR Number: 3800579-4Report Type:Periodic Company Report #WAES 01052824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800580-0Report Type:Periodic Company Report #WAES 01052828
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Pepcid	C				
			Premarin	C				
			Vasotec	C				
			Calcium	C				

Date:09/24/01ISR Number: 3800581-2Report Type:Periodic Company Report #WAES 01052735
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Paraesthesia						PO	
	Pharyngitis		Hydrodiruil	C				
			Tylenol	C				
			Zestril	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800582-4Report Type:Periodic Company Report #WAES 01052736
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx	PS		ORAL	PO	8 DAY
	Blood Pressure Increased							
	Dizziness							
	Palpitations							

Date:09/24/01ISR Number: 3800583-6Report Type:Periodic Company Report #WAES 01052739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800584-8Report Type:Periodic Company Report #WAES01052743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
	Diarrhoea						PO	
	Dyspnoea		Hydrodiuril	C				
	Face Oedema		Lotensin	C				
	Headache		Verapamil	C				
	Localised Oedema							
	Nausea							
	Oedema Peripheral							
	Oliguria							

Date:09/24/01ISR Number: 3800585-XReport Type:Periodic Company Report #WAES 01052748
Age:67 YR Gender: I/FU:I

Outcome	PT
	Asthenia
	Chest Pain

	Fatigue						
	Feeling Abnormal						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Fosamax	C				
			Allergenic Extract	C				
			Aspirin	C				
			Niacin	C				

Date:09/24/01ISR Number: 3800586-1Report Type:Periodic Company Report #WAES 01052751
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY/PO	
	Oedema Peripheral							
			Gluctrol Xl	C				
			Lanoxin	C				
			Lipitor	C				
			Lotrel	C				
			Niaspan	C				
			Resotril	C				
			Slow-K	C				
			Synthroid	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800587-3Report Type:Periodic Company Report #WAES 01052752
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Urticaria		Vasotec	C				
			Allopurinol	C				

Date:09/24/01ISR Number: 3800588-5Report Type:Periodic Company Report #WAES 01052754
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer Health Professional	Tab Vioxx 25 Mg Synthroid	PS C		ORAL	25 MG DIALY PO	

Date:09/24/01ISR Number: 3800589-7Report Type:Periodic Company Report #WAES 01052761
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Pain Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800590-3Report Type:Periodic Company Report #WAES 01052765
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
	Drug Ineffective						PO	
	Fatigue							

Date:09/24/01ISR Number: 3800591-5Report Type:Periodic Company Report #WAES 01052686
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
			Allegra	C				
			Lipitor	C				
			Norvasc	C				
			Tenormin	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800592-7Report Type:Periodic Company Report #WAES 01052694
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Sciatica						MG/DAILY/PO	
			Atenolol	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3800593-9Report Type:Periodic Company Report #WAES 01052695
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Health	Tab Vioxx 25 Mg	PS			ORAL
25							
	Blood Pressure Increased	Professional					
MG/DAILY/PO							
	Fatigue		Actos	C			
	Flushing		Glucophage	C			
	Oedema Peripheral						
	Tachycardia						

Date:09/24/01ISR Number: 3800596-4Report Type:Periodic Company Report #WAES 01052697
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Skin Lesion					
MG/DAILY/PO						
			Lipitor	C		
			Isosorbide	C		
			Ranitidine	C		

Date:09/24/01ISR Number: 3800598-8Report Type:Periodic Company Report #WAES 01052698
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Vaginal Infection					
MG/DAILY/PO						
			Cleocin	C		
			Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800599-XReport Type:Periodic Company Report #WAES 01052708
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Diarrhoea							
	Faeces Discoloured							

Date:09/24/01ISR Number: 3800601-5Report Type:Periodic Company Report #WAES 01052711
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Ultram	C				

Date:09/24/01ISR Number: 3800603-9Report Type:Periodic Company Report #WAES 01052714
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Ineffective						PO	
			Therapy Unspecified	C				
			Therapy Unspecified	C				
			Therapy Unspecified	C				
			Thyroid	C				

Date:09/24/01ISR Number: 3800605-2Report Type:Periodic Company Report #WAES 01052722
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS			ORAL
50							
	Hallucination						
MG/DAILY/PO							
	Hepatic Function Abnormal						
	Insomnia						

Date:09/24/01ISR Number: 3800606-4Report Type:Periodic Company Report #WAES 01052730
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vocal Cord Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
12.5 MG DAILY								
PO								
			Tab Vioxx 25 Mg	SS		ORAL		
25								
MG/DAILY/PO								
			Levoxyl	C				
			Protonix	C				

Date:09/24/01ISR Number: 3800608-8Report Type:Periodic Company Report #WAES 01052628
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
25								
	Oedema Peripheral							
MG/DAILY/PO								
			Diovan	C				
			Lozol	C				
			Prilosec	C				
			Serevent Disk	C				

				Singulair	C		
				Skelaxin	C		
				Zocor	C		
				Zyrtec	C		

Date:09/24/01ISR Number: 3800610-6Report Type:Periodic Company Report #WAES 01052631
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Nausea						MG/DAILY/PO	
	Pain		Darvocet-N	C				
			Evista	C				
			Procardia Xl	C				

Date:09/24/01ISR Number: 3800612-XReport Type:Periodic Company Report #WAES 01052637
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Miacalcin	C				
			Premarin	C				

Date:09/24/01ISR Number: 3800613-1Report Type:Periodic Company Report #WAES 01052640
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Hypertension	Professional					MG/DAILY/PO	
	Oedema Peripheral	Company	Premarin	C				
	Weight Increased	Representative						

Date:09/24/01ISR Number: 3800614-3Report Type:Periodic Company Report #WAES 01052648
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5; 25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3800617-9Report Type:Periodic Company Report #WAES 01052649
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health Professional	Tab Viox 12.5 Mg	PS		ORAL	12.5; 25 MG/DAILY/PO	
	Congestive Pulmonary Oedema	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800618-0Report Type:Periodic Company Report #WAES 01052665
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:09/24/01ISR Number: 3800620-9Report Type:Periodic Company Report #WAES 01052676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800622-2Report Type:Periodic Company Report #WAES 01052677
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hair Disorder		Diovan	C				
			Premarin	C				

Date:09/24/01ISR Number: 3800623-4Report Type:Periodic Company Report #WAES 01052683
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800625-8Report Type:Periodic Company Report #WAES 01052520
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800626-XReport Type:Periodic Company Report #WAES 01052522
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Tricor	C				
			Zocor	C				

Date:09/24/01ISR Number: 3800628-3Report Type:Periodic Company Report #WAES 01052527
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Migraine							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800629-5Report Type:Periodic Company Report #WAES 01052531
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Mevacor	C				
			Zantac	C				
			Allopurinol	C				
			Chlorthalidone	C				
			Glyburide	C				

Date:09/24/01ISR Number: 3800631-3Report Type:Periodic Company Report #WAES 01052532
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention Deficit/Hyperactivity Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention		Avandia	C				
	Insomnia		Coumadin	C				
	Weight Increased		Cozaar	C				
			Lanoxin	C				
			Lipitor	C				
			Metamucil	C				
			Novolin N	C				
			Surfak	C				
			Ultram	C				
			Furosemide	C				
			Potassium Chloride	C				
			Sulfasalazine	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3800633-7Report Type:Periodic Company Report #WAES 01052556
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Contusion	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3800636-2Report Type:Periodic Company Report #WAES 01052557
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Oedema	Professional Company Representative				

Date:09/24/01ISR Number: 3800638-6Report Type:Periodic Company Report #WAES 01052578
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ear Congestion	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Tinnitus					
MG/DAILY/PO						
			Lotrel	C		
			Nasonex	C		

			Patanol	C		
			Aspirin	C		

Date:09/24/01ISR Number: 3800641-6Report Type:Periodic Company Report #WAES 01052590
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company Representative	Tab Vioxx Unk	PS		PO		

Date:09/24/01ISR Number: 3800643-XReport Type:Periodic Company Report #WAES 01052623
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/PRN/PO	
			Digitek	C				
			Microzide	C				
			Prempro	C				
			Teveten (Eprosartan)	C				
			Verelan	C				
			Atenolol	C				
			Timolol Maleate	C				

Date:09/24/01ISR Number: 3800645-3Report Type:Periodic Company Report #WAES 01052482
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Steatosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Effexor Xr	C				

				Premarin	C		

Date:09/24/01ISR Number: 3800646-5Report Type:Periodic Company Report #WAES 01052485
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Flovent	C				
			Robaxin	C				
			Singulair	C				

Date:09/24/01ISR Number: 3800647-7Report Type:Periodic Company Report #WAES 01052491
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Other	Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	5 DAY
	Paraesthesia		Premarin	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800648-9Report Type:Periodic Company Report #WAES 01052492
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800649-0Report Type:Periodic Company Report #WAES 01052497
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	4 DAY
	Haemorrhage		Prinivil	C				

Date:09/24/01ISR Number: 3800651-9Report Type:Periodic Company Report #WAES 01052505
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea	Professional						
			Antimicrobial (Unspecified)	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3800652-0Report Type:Periodic Company Report #WAES 01052509
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Cosopt	C				
			Fosamax	C				
			Lanoxin	C				

			Prilosec	C		
			Aspirin	C		

Date:09/24/01ISR Number: 3800654-4Report Type:Periodic Company Report #WAES 01052513
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800655-6Report Type:Periodic Company Report #WAES 01052514
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Colestid	C				

Date:09/24/01ISR Number: 3800656-8Report Type:Periodic Company Report #WAES 01052515
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800658-1Report Type:Periodic Company Report #WAES 01052443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Nortriptyline	C				

Date:09/24/01ISR Number: 3800660-XReport Type:Periodic Company Report #WAES 01052452
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ativan	C				
			Zestril	C				
			Atenolol	C				
			Potassium (Unspecified)	C				

Date:09/24/01ISR Number: 3800661-1Report Type:Periodic Company Report #WAES 01052457
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO	
	Drug Ineffective	Health Professional						
	Palpitations							
			Atacand	C				
			Lipitor	C				

Date:09/24/01ISR Number: 3800662-3Report Type:Periodic Company Report #WAES 01052463
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Iron Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				

Date:09/24/01ISR Number: 3800666-0Report Type:Periodic Company Report #WAES 01052464
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain In Extremity							
			Vasotec	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3800667-2Report Type:Periodic Company Report #WAES 01052467
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	60 DAY
			Lanoxin	C				
			Tambocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800669-6Report Type:Periodic Company Report #WAES 01052469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800670-2Report Type:Periodic Company Report #WAES 01052471
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800671-4Report Type:Periodic Company Report #WAES 01052475
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Claritin	C				
			Paxil	C				
			Valium	C				
			Xanax	C				

Date:09/24/01ISR Number: 3800672-6Report Type:Periodic Company Report #WAES 01052477
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health	Tab Vioxx	PS		ORAL	PO	

		Professional	Cap Macrobid 100 Mg	SS		ORAL
100 MG/BID/PO						
			Imitrex	C		
			Inderal	C		

Date:09/24/01ISR Number: 3800675-1Report Type:Periodic Company Report #WAES 01052318
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperglycaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
MG/DAILY/PO						
			Inderal	C		
			Prempro	C		
			Tenormin	C		
			Aspirin	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3800677-5Report Type:Periodic Company Report #WAES 01052320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Hypoaesthesia					
MG/DAILY/PO						
	Pruritus		Clariitin	C		
			Femhrt	C		
			Flonase	C		

			Fosamax	C
			Synthroid	C
			Vitamins	C

Date:09/24/01ISR Number: 3800679-9Report Type:Periodic Company Report #WAES 01052321
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	
			Aciphex	C				
			Allegra	C				
			Inderal	C				
			Levaquin	C				
			Vicodin Tablets	C				
			Meprobamate	C				

Date:09/24/01ISR Number: 3800681-7Report Type:Periodic Company Report #WAES 01052328
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800682-9Report Type:Periodic Company Report #WAES 01052338
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25	

MG/DAILY/PO

			Tab Vioxx Unk	SS	ORAL
PO					
			Accupril	C	
			Cipro	C	
			Effexor	C	
			Lipitor	C	
			Norvasc	C	
			Pepcid	C	
			Toprol Xl Tablets	C	

Date:09/24/01ISR Number: 3800685-4Report Type:Periodic Company Report #WAES 01052340
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Dyschezia	Professional				
MG/DAILY/PO						
	Dyspepsia		Aggrenox	C		
			Caltrate 600 Plus			
			Vitamin D	C		
			Centrum	C		
			Hyzaar	C		
			Zocor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800686-6Report Type:Periodic Company Report #WAES 01052357
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder							

Date:09/24/01ISR Number: 3800688-XReport Type:Periodic Company Report #WAES 01052361
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
			Prilosec	SS				
			Miacalcin	C				
			Zocor	C				
			Soma	C				
			Nolvadex	C				

Date:09/24/01ISR Number: 3800689-1Report Type:Periodic Company Report #WAES 01052380
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Rash Papular	Health					MG/DAILY/PO	
		Professional	Deconamine	C				
			Relafen	C				
			Zantac	C				
			Trazodone	C				

Date:09/24/01ISR Number: 3800691-XReport Type:Periodic Company Report #WAES 01052437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Maxzide	C				

Date:09/24/01ISR Number: 3800693-3Report Type:Periodic Company Report #WAES 01052439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain							
	Palpitations		Premarin	C				
	Swelling							
	Tachycardia							

Date:09/24/01ISR Number: 3800695-7Report Type:Periodic Company Report #WAES 01052442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800698-2Report Type:Periodic Company Report #WAES 01050661
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800700-8Report Type:Periodic Company Report #WAES 01052023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800702-1Report Type:Periodic Company Report #WAES 01052031
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx	PS		ORAL	PO	
			Premarin	C				
			Clonidine	C				

Date:09/24/01ISR Number: 3800708-2Report Type:Periodic Company Report #WAES 01052032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence							
	Oedema Peripheral		Lipitor	C				
	Pain		Potachlor 10%	C				

Palpitations	Vasotec	C
Renal Disorder	Allopurinol	C
	Atenolol	C
	Furosemide	C
	Hydrochlorothiazide (+) Triamter	C

Date:09/24/01ISR Number: 3800709-4Report Type:Periodic Company Report #WAES 01052035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	

Date:09/24/01ISR Number: 3800710-0Report Type:Periodic Company Report #WAES 01052036
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Bronchitis	Professional						
	Dyspnoea							
	Hypertension							
	Oedema Peripheral							
	Pruritus							

Date:09/24/01ISR Number: 3800711-2Report Type:Periodic Company Report #WAES 01052038
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Deficit/Hyperactivity	Health					MG/DAILY/PO	
	Disorder	Professional	Claritin-D	C				
	Lactose Intolerance		Dhea	C				
	Nervousness							
	Paranoia							

Date:09/24/01ISR Number: 3800712-4Report Type:Periodic Company Report #WAES 01052039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Malaise						MG/DAILY/PO	2 DAY
	Nausea							
	Vertigo							
	Vomiting							

Date:09/24/01ISR Number: 3800713-6Report Type:Periodic Company Report #WAES 01052044
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Glucosamine	C				
			Warfarin	C				

Date:09/24/01ISR Number: 3800714-8Report Type:Periodic Company Report #WAES 01052045
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Pravachol	C				

Date:09/24/01ISR Number: 3800715-XReport Type:Periodic Company Report #WAES 01060454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Soma	C				
			Lithium Carbonate	C				

Date:09/24/01ISR Number: 3800716-1Report Type:Periodic Company Report #WAES 01060456
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lipitor	C				
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800717-3Report Type:Periodic Company Report #WAES 01060461
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Premarin	C				

Date:09/24/01ISR Number: 3800718-5Report Type:Periodic Company Report #WAES 01060462
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Glucophage	C				
			Hyzaar	C				
			Prandin	C				

Date:09/24/01ISR Number: 3800719-7Report Type:Periodic Company Report #WAES 01060463
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petechiae	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Serzone	C				

Date:09/24/01ISR Number: 3800720-3Report Type:Periodic Company Report #WAES 01060468
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

			Health			
MG/DAILY/PO						
			Professional	Diovan	C	
				Fosamax	C	

Date:09/24/01ISR Number: 3800721-5Report Type:Periodic Company Report #WAES 01060472
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gastrointestinal Disorder	Health				
MG/DAILY/PO						
	Malaise	Professional	Ativan	C		
	Pain		Lipitor	C		
	Paraesthesia		Prevacid	C		
	Pruritus		Trental	C		

Date:09/24/01ISR Number: 3800722-7Report Type:Periodic Company Report #WAES 01060477
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Bufferin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800723-9Report Type:Periodic Company Report #WAES 01060480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800724-0Report Type:Periodic Company Report #WAES 01060486
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) PO; 2)	
	Fatigue						12.5 MG/PRN	
			Buspar	C				
			Os-Cal	C				
			Doxepin	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3800726-4Report Type:Periodic Company Report #WAES 01060403
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3800727-6Report Type:Periodic Company Report #WAES 01060404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:09/24/01ISR Number: 3800729-XReport Type:Periodic Company Report #WAES 01060405
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3800731-8Report Type:Periodic Company Report #WAES 01060418
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised	Health	Tab Vioxx	PS		ORAL	PO	
	Ratio Increased Prothrombin Time Prolonged	Professional	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800733-1Report Type:Periodic Company Report #WAES 01060423
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Demadex	C				
			Zestril	C				
			Levothyroxine Sodium	C				
			Potassium Chloride	C				

Date:09/24/01ISR Number: 3800734-3Report Type:Periodic Company Report #WAES 01060444
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Elavil	C				
			Xanax	C				

Date:09/24/01ISR Number: 3800735-5Report Type:Periodic Company Report #WAES 01060445
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
	Mental Impairment		Chromagen Capsules	C				
			Coumadin	C				
			Covera-Hs	C				
			Monopril	C				
			Nasonex	C				
			Premarin	C				
			Prilosec	C				

Synthroid	C
Timoptic	C
Aspirin	C
Calcium (Unspecified)	C
Furosemide	C
Vitamin E	C

Date:09/24/01ISR Number: 3800737-9Report Type:Periodic Company Report #WAES 01060447
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Celebrex	SS				

Date:09/24/01ISR Number: 3800739-2Report Type:Periodic Company Report #WAES 01060452
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Somnolence		Accupril	C				
			Naprosyn	C				

Vitamins C

Date:09/24/01ISR Number: 3800741-0Report Type:Periodic Company Report #WAES 01060453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Ultram	C				

Date:09/24/01ISR Number: 3800820-8Report Type:Periodic Company Report #WAES 01060372
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx	PS		ORAL	UNK/UNK/PO	1 WK

Date:09/24/01ISR Number: 3800821-XReport Type:Periodic Company Report #WAES 01060375
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Drug Ineffective		Tylenol	C				
	Haematuria							

Date:09/24/01ISR Number: 3800822-1Report Type:Periodic Company Report #WAES 01060378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Micturition Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Synthroid	C		

Date:09/24/01ISR Number: 3800823-3Report Type:Periodic Company Report #WAES 01060379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Fosamax	C		
			Premarin	C		

Date:09/24/01ISR Number: 3800824-5Report Type:Periodic Company Report #WAES 01060380
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800825-7Report Type:Periodic Company Report #WAES 01060387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Tab Vioxx	PS		ORAL	UNK/UNK/PO	6 DAY
	Ecchymosis	Health	Tambocor	C				
	Oedema Peripheral	Professional						
	Renal Pain							

Date:09/24/01ISR Number: 3800826-9Report Type:Periodic Company Report #WAES 01060389
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Weight Increased							

Date:09/24/01ISR Number: 3800827-0Report Type:Periodic Company Report #WAES 01060395
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Muscle Spasms							
			Inderal	C				
			Lipitor	C				
			Periactine	C				

Date:09/24/01ISR Number: 3800828-2Report Type:Periodic Company Report #WAES 01060401
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Operative Haemorrhage	Health	Tab Vioxx	PS		ORAL	UNK/UNK/PO	

Professional
Company
Representative

Date:09/24/01ISR Number: 3800829-4Report Type:Periodic Company Report #WAES 01060402
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	UNK/UNK/PO	
	Congestive	Professional Company Representative						

Date:09/24/01ISR Number: 3800830-0Report Type:Periodic Company Report #WAES 01060340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	MG/PO	

Date:09/24/01ISR Number: 3800832-4Report Type:Periodic Company Report #WAES 01060352
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Oedema Peripheral	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Covera-Hs	C				
Evista	C				
Prilosec	C				
Reglan	C				
Synthroid	C				

Date:09/24/01ISR Number: 3800833-6Report Type:Periodic Company Report #WAES 01060353
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dizziness							
	Fatigue							

Date:09/24/01ISR Number: 3800834-8Report Type:Periodic Company Report #WAES 01060355
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Humibid	C				
			Premarin	C				

Date:09/24/01ISR Number: 3800835-XReport Type:Periodic Company Report #WAES 01060363
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional				

Date:09/24/01ISR Number: 3800836-1Report Type:Periodic Company Report #WAES 01060365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hyperglycaemia	Consumer	Tab Vioxx	PS		ORAL
PO						
	Oedema Peripheral					

Date:09/24/01ISR Number: 3800837-3Report Type:Periodic Company Report #WAES 01060367
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Lip Dry		Augmentin	C		
	Pruritus		Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800838-5Report Type:Periodic Company Report #WAES 01060368
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800839-7Report Type:Periodic Company Report #WAES 01060369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Levoxyl	C				
			Miacalcin	C				
			Tenormin	C				

Date:09/24/01ISR Number: 3800840-3Report Type:Periodic Company Report #WAES 01060288
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Bilirubin Increased Haematuria	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				

Date:09/24/01ISR Number: 3800841-5Report Type:Periodic Company Report #WAES 01060290
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	

Pain
Pain In Extremity

Date:09/24/01ISR Number: 3800842-7Report Type:Periodic Company Report #WAES 01060291
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Celebrex	C				
			Timoptic	C				

Date:09/24/01ISR Number: 3800843-9Report Type:Periodic Company Report #WAES 01060293
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Glucophage	C				
			Lipitor	C				
			Norvasc	C				
			Prevacid	C				
			Prinivil	C				
			Allopurinol	C				
			Nadolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800844-0Report Type:Periodic Company Report #WAES 01060308
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Zocor	C				

Date:09/24/01ISR Number: 3800845-2Report Type:Periodic Company Report #WAES 01060309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	1 WK
			Imitrex	C				

Date:09/24/01ISR Number: 3800846-4Report Type:Periodic Company Report #WAES 01060328
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malnutrition	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Metabolic Disorder							
	Weight Increased		Centrum Silver	C				
			Ditropan Xl	C				
			Hyzaar	C				
			Lipitor	C				
			Ogen	C				
			Lorazepam	C				
			Nifedipine	C				

Date:09/24/01ISR Number: 3800847-6Report Type:Periodic Company Report #WAES 01060329
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Diarrhoea						MG/DAILY/PO	
			Augmentin	C				
			Flonase	C				
			Pulmicort	C				
			Serevent	C				
			Singulair	C				

Date:09/24/01ISR Number: 3800848-8Report Type:Periodic Company Report #WAES 01060334
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Constipation		Excedrin					
	Fatigue		Extra-Strength	C				
	Somnolence		Imitrex	C				

Date:09/24/01ISR Number: 3800849-XReport Type:Periodic Company Report #WAES 01060337
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Gastrooesophageal Reflux						MG/DAILY/PO	
	Disease		Evista	C				

				Fosamax	C		

Date:09/24/01ISR Number: 3800850-6Report Type:Periodic Company Report #WAES 01061401
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800851-8Report Type:Periodic Company Report #WAES 01061402
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oral Soft Tissue Disorder							
			Fluocinolone Acetonide	C				

Date:09/24/01ISR Number: 3800852-XReport Type:Periodic Company Report #WAES 01061403
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Otitis Externa		Glucosamine	C				
	Rash							
	Tinea Pedis							

Date:09/24/01ISR Number: 3800853-1Report Type:Periodic Company Report #WAES 01061412
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Back Pain	Health Professional	Tab Vioxx	PS		ORAL PO

Date:09/24/01ISR Number: 3800854-3Report Type:Periodic Company Report #WAES 01061419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	2 WK
			Choletec	C				
			Hydrodiuril	C				
			Tenormin	C				

Date:09/24/01ISR Number: 3800855-5Report Type:Periodic Company Report #WAES 01061425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/OOD/PO	

Date:09/24/01ISR Number: 3800856-7Report Type:Periodic Company Report #WAES 01061430
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Armour Thyroid Tablets	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3800857-9Report Type:Periodic Company Report #WAES 01061433
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain	Health Professional	Tab Vioxx 50 Mg	SS		ORAL	PO	
			Estrace	C				
			Prilosec	C				
			Provera	C				
			Diazepam	C				
			Ibuprofen	C				
			Nortriptyline	C				

Date:09/24/01ISR Number: 3800858-0Report Type:Periodic Company Report #WAES 01061434
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800859-2Report Type:Periodic Company Report #WAES 01061435
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
	Pollakiuria		Penicillin	C				

Date:09/24/01ISR Number: 3800860-9Report Type:Periodic Company Report #WAES 01061437
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Actonel	C				
			Synthroid	C				
			Ultram	C				
			Ziac	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3800861-0Report Type:Periodic Company Report #WAES 01061443
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Arthralgia	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:09/24/01ISR Number: 3800862-2Report Type:Periodic Company Report #WAES 01061444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 50 Mg	PS			50MG/DAILY/	
	Rash		Synthroid	C				

Date:09/24/01ISR Number: 3800863-4Report Type:Periodic Company Report #WAES 01061448
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Tricor	C				
			Zantac	C				

Date:09/24/01ISR Number: 3800864-6Report Type:Periodic Company Report #WAES 01061449
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800865-8Report Type:Periodic Company Report #WAES 01061458
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800866-XReport Type:Periodic Company Report #WAES 01061459
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800867-1Report Type:Periodic Company Report #WAES 01061460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800868-3Report Type:Periodic Company Report #WAES 01061515
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tenormin	C				

Date:09/24/01ISR Number: 3800869-5Report Type:Periodic Company Report #WAES 01061549
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Swelling							
			Allegra D	C				
			Celexa	C				
			Detrol	C				
			L-Thyroxin	C				
			Prempro	C				
			Prilosec	C				
			Zocor	C				
			Atenolol	C				
			Doxepin	C				
			Furosemide	C				
			Hydroxyzine	C				

Date:09/24/01ISR Number: 3800870-1Report Type:Periodic Company Report #WAES 01061550
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Flushing	Professional	Estratest H.S.	C				
	Tinnitus		Prilosec	C				
			Synthroid	C				
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3800871-3Report Type:Periodic Company Report #WAES 01061560
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
			Cardizem	C				
			Prilosec	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Zocor	C				

Date:09/24/01ISR Number: 3800872-5Report Type:Periodic Company Report #WAES 01061568
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Fatigue							
	Oedema Peripheral							
	Rash							

Date:09/24/01ISR Number: 3800873-7Report Type:Periodic Company Report #WAES 01061569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Celexa	C				
			Prilosec	C				
			Isosorbide Mononitrate	C				

Date:09/24/01ISR Number: 3800874-9Report Type:Periodic Company Report #WAES 01061572
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Accupril	C				
			Actonel	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800875-0Report Type:Periodic Company Report #WAES 01061573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Tylenol	C				

Date:09/24/01ISR Number: 3800876-2Report Type:Periodic Company Report #WAES 01061577
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Blood Urea Increased							

Date:09/24/01ISR Number: 3800877-4Report Type:Periodic Company Report #WAES 01061578
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Pain	Health Professional	Ativan	C				
			Avapro	C				
			Lasix (Furosemide)	C				
			Imipramine	C				

Date:09/24/01ISR Number: 3800878-6Report Type:Periodic Company Report #WAES 01061581
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Lasix (Furosemide)	C				
			Clonazepam	C				
			Propranolol	C				

Date:09/24/01ISR Number: 3800879-8Report Type:Periodic Company Report #WAES 01061584
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prevacid	C				
			[Therapy Unspecified]	C				
			Insulin	C				

Date:09/24/01ISR Number: 3800880-4Report Type:Periodic Company Report #WAES 01061585
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Cardene-Sr	C				
			K-Dur	C				
			Lipitor	C				
			Zestril	C				
			Cortisone	C				
			Furosemide	C				

Date:09/24/01ISR Number: 3800881-6Report Type:Periodic Company Report #WAES 01061587
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Haemorrhagic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Faeces Discoloured						PO	
			Patanol	C				

Date:09/24/01ISR Number: 3800882-8Report Type:Periodic Company Report #WAES 01061590
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
		Professional					PO	
		Company Representative	Tylenol Arthritis Extended Relief	C				

Date:09/24/01ISR Number: 3800883-XReport Type:Periodic Company Report #WAES 01061592
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Company					PO	
		Representative	Humulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800884-1Report Type:Periodic Company Report #WAES 01061594
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Pain		Ativan	C				
			Atrovent	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Mysoline	C				
			Prevacid	C				
			Restoril	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800885-3Report Type:Periodic Company Report #WAES 01061597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematocrit Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Haemoglobin Decreased	Professional					PO	
	Mean Cell Haemoglobin Increased		Hyzaar	C				
	Red Blood Cell Count Decreased							
	Serum Ferritin Increased							

Date:09/24/01ISR Number: 3800886-5Report Type:Periodic Company Report #WAES 01061600
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pharyngeal Oedema		Allegra	C				
	Tongue Oedema		Avapro	C				
			Flexeril	C				
			Humibid	C				
			Lopressor	C				

				Premarin	C	
				Synthroid	C	
				Tiazac	C	
				Zoloft	C	
				Amitriptyline	C	
				Spironolactone	C	

Date:09/24/01ISR Number: 3800887-7Report Type:Periodic Company Report #WAES 01061604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Vomiting							
PO								113 DAY
			Xanax	C				
			Cimetidine	C				

Date:09/24/01ISR Number: 3800888-9Report Type:Periodic Company Report #WAES 01061605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Professional	Cardura	C				

			Lotensin	C		

Date:09/24/01ISR Number: 3800889-0Report Type:Periodic Company Report #WAES 01061608
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800890-7Report Type:Periodic Company Report #WAES 01061620
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Glucotrol	C				
			Lescol	C				
			Zestril	C				
			Zoloft	C				
			Benazepril Hydrochloride	C				
			Cyclobenzaprine Hydrochloride	C				
			Hydrocodone	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3800891-9Report Type:Periodic Company Report #WAES 01061624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg/50 Mg	PS		ORAL	PO	
	Anxiety							
	Asthenia		Hormonal Contraceptives	C				
	Blood Pressure Decreased							

Dyspepsia
Fatigue
Pain In Extremity
Urinary Tract Infection

Date:09/24/01ISR Number: 3800892-0Report Type:Periodic Company Report #WAES 01061630
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800893-2Report Type:Periodic Company Report #WAES 01061633
Age:51 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Confusional State
	Hypoaesthesia
	Mental Impairment

	Speech Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Claritin	C				
			Diovan	C				
			Lipitor	C				
			Premphase	C				
			Remeron	C				
			Zanaflex	C				
			Amitriptyline	C				

Date:09/24/01ISR Number: 3800894-4Report Type:Periodic Company Report #WAES 01061635
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dysgeusia		Xanax	C				
			Trazodone	C				

Date:09/24/01ISR Number: 3800895-6Report Type:Periodic Company Report #WAES 01061640
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800896-8Report Type:Periodic Company Report #WAES 01061641
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Constipation	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
	Dizziness						
MG/DAILY/PO							
	Drug Ineffective						

Date:09/24/01ISR Number: 3800897-XReport Type:Periodic Company Report #WAES 01061660
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
MG/DAILY/PO								
			Cyanocobalamin	C				
			Folic Acid	C				

Date:09/24/01ISR Number: 3800898-1Report Type:Periodic Company Report #WAES 01061662
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Haemorrhage							
MG/DAILY/PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800899-3Report Type:Periodic Company Report #WAES 01061683
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Musculoskeletal Stiffness	Professional Company Representative						

Date:09/24/01ISR Number: 3800900-7Report Type:Periodic Company Report #WAES 01060489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Tab Vioxx 50 Mg	SS		ORAL	PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3800901-9Report Type:Periodic Company Report #WAES 01060490
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3800902-0Report Type:Periodic Company Report #WAES 01060494
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:09/24/01ISR Number: 3800903-2Report Type:Periodic Company Report #WAES 01060496
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Urinary Tract Infection	Professional				
MG/DAILY/PO						
			Tab Vioxx 25 Mg	SS		
50 MG/PRN						
			Tab Vioxx	SS		
UNK/PRN						
			Claritin	C		
PRN						
			Dyazide	C		
			Synthroid	C		
			Tagamet	C		
			Atenolol	C		

Date:09/24/01ISR Number: 3800904-4Report Type:Periodic Company Report #WAES 01060498
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Pain					
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800905-6Report Type:Periodic Company Report #WAES 01060499
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Pravachol	C				
			Xanax	C				
			Metoprolol	C				

Date:09/24/01ISR Number: 3800906-8Report Type:Periodic Company Report #WAES 01060511
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Faeces Discoloured		Norvasc	C				
			Synthroid	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800907-XReport Type:Periodic Company Report #WAES 01060516
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Pravachol	C				
			Prilosec	C				
			Vioxx	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3800908-1Report Type:Periodic Company Report #WAES 01060521
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Interaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25
	Oedema Peripheral					MG/DAILY/PO
			Tab Vioxx	SS		ORAL 50 MG/DAILY/PO
			Lupron	SS		INJ
			[Therapy Unspecified]	C		

Date:09/24/01ISR Number: 3800909-3Report Type:Periodic Company Report #WAES 01060525
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800910-XReport Type:Periodic Company Report #WAES 01060540
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional Company
	Oedema	

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800911-1Report Type:Periodic Company Report #WAES 01060581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Vaseretic	C				
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3800912-3Report Type:Periodic Company Report #WAES 01060586
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			Dyazide	C				
			Elavil	C				
			Flonase	C				
			Miralax	C				
			Neurontin	C				
			Prilosec	C				
			Roxicet	C				
			Zocor	C				
			Diazepam	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800913-5Report Type:Periodic Company Report #WAES 01060589
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			....	C				

Date:09/24/01ISR Number: 3800914-7Report Type:Periodic Company Report #WAES 01060591
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Swelling		Coumadin	C				
			Cozaar	C				
			Pepcid	C				
			Ultram	C				
			Zoloft	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800915-9Report Type:Periodic Company Report #WAES 01060592
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800916-0Report Type:Periodic Company Report #WAES 01060600
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain In Extremity							

Date:09/24/01ISR Number: 3800917-2Report Type:Periodic Company Report #WAES 01060624
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Viral Infection	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Evista	C				
			Prilosec	C				

Date:09/24/01ISR Number: 3800918-4Report Type:Periodic Company Report #WAES 01060626
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/BID/PO	

Date:09/24/01ISR Number: 3800919-6Report Type:Periodic Company Report #WAES 01060627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health	Tab Vioxx	PS		ORAL	PO	
	Hypersensitivity	Professional	Celebrex	C				
	Lymphadenopathy	Company						
	Neck Mass	Representative						

Date:09/24/01ISR Number: 3800920-2Report Type:Periodic Company Report #WAES 01060628
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Appetite	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800921-4Report Type:Periodic Company Report #WAES 01060634
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dry Mouth							
	Fatigue							

Date:09/24/01ISR Number: 3800922-6Report Type:Periodic Company Report #WAES 01060636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Biaxin	C				

Date:09/24/01ISR Number: 3800923-8Report Type:Periodic Company Report #WAES 01060640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	
	Neck Pain	Health						
		Professional	Zocor	C				
			Zoloft	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3800924-XReport Type:Periodic Company Report #WAES 01060643
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Blood Pressure Increased		Detrol	C		
			Evista	C		
			Fosamax	C		
			Lipitor	C		
			Motrin	C		
			Synthroid	C		
			Vagipem	C		
			Calcium Citrate	C		
			Chondroitin (+)			
			Glucosamine	C		
			Doxepin	C		
			Folic Acid	C		
			Pyridoxine	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3800925-1Report Type:Periodic Company Report #WAES 01060646
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Buspar	C		
			Estrogens (Unspecified)	C		

Date:09/24/01ISR Number: 3800926-3Report Type:Periodic Company Report #WAES 01060650
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
	Drug Ineffective							

Date:09/24/01ISR Number: 3800927-5Report Type:Periodic Company Report #WAES 01060652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO; SEE IMAGE	
			Soma	C				
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3800928-7Report Type:Periodic Company Report #WAES 01060654
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
	Asthenia							
	Drug Ineffective							
	Fatigue		Cozaar	C				
	Pain In Extremity		Metoprolol	C				

Date:09/24/01ISR Number: 3800929-9Report Type:Periodic Company Report #WAES 01060655
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Blood Urea Increased							

Date:09/24/01ISR Number: 3800930-5Report Type:Periodic Company Report #WAES 01071665
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Blood Urea Increased							

Date:09/24/01ISR Number: 3800931-7Report Type:Periodic Company Report #WAES 01071671
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY / PO	

Date:09/24/01ISR Number: 3800932-9Report Type:Periodic Company Report #WAES 01071672
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prevacid	C				

			Tylenol Sinus	C		
			Zocor	C		

Date:09/24/01ISR Number: 3800933-0Report Type:Periodic Company Report #WAES 01071674
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Drug Ineffective		Baycol	C				
	Dyspepsia		Diovan	C				
	Oedema Peripheral		Flomax (Morniflumate)	C				
			Lasix (Furosemide)	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3800934-2Report Type:Periodic Company Report #WAES 01071679
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	PO	
			Prinzide	C				
			Trental	C				

Date:09/24/01ISR Number: 3800935-4Report Type:Periodic Company Report #WAES 01071684
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
			Celebrex	C				
			Zoloft	C				
			Composition Unspecified	C				

Date:09/24/01ISR Number: 3800936-6Report Type:Periodic Company Report #WAES 01071687
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Diarrhoea						PO	
	Nausea		Composition Unspecified	C				
			Nadolol	C				

Date:09/24/01ISR Number: 3800937-8Report Type:Periodic Company Report #WAES 01071692
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Rash		Hormones (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800938-XReport Type:Periodic Company Report #WAES 01071699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/ PO	

Date:09/24/01ISR Number: 3800939-1Report Type:Periodic Company Report #WAES 01071703
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	ORAL	
	Oedema Peripheral		Analgesic Or Anesthetic (Unspecifi	C				
	Tongue Oedema							

Date:09/24/01ISR Number: 3800940-8Report Type:Periodic Company Report #WAES 01071704
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	ORAL	
	Vertigo		Accupril	C				
			Buspar	C				

Date:09/24/01ISR Number: 3800941-XReport Type:Periodic Company Report #WAES 01071708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800942-1Report Type:Periodic Company Report #WAES 01071710
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO 10 DAY
			Provera	C				
			Synthroid	C				
			Estrogens	C				

Date:09/24/01ISR Number: 3800943-3Report Type:Periodic Company Report #WAES 01071715
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx	PS				

Date:09/24/01ISR Number: 3800944-5Report Type:Periodic Company Report #WAES 01071732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Tinnitus	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx	PS		

Date:09/24/01ISR Number: 3800945-7Report Type:Periodic Company Report #WAES 01071739
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oedema	Health Professional	Tab Vioxx	PS		ORAL
PO						

Date:09/24/01ISR Number: 3800946-9Report Type:Periodic Company Report #WAES 01071768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL
PO						
			Celebrex	C		

Date:09/24/01ISR Number: 3800947-0Report Type:Periodic Company Report #WAES 01071772
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
PO						
			Fosamax	C		

Date:09/24/01ISR Number: 3800948-2Report Type:Periodic Company Report #WAES 01071812
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:09/24/01ISR Number: 3800949-4Report Type:Periodic Company Report #WAES 01071820
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Synthroid	C				
			Zocor	C				
			Tamoxifen	C				

Date:09/24/01ISR Number: 3800950-0Report Type:Periodic Company Report #WAES 01071822
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ DAILY/ PO	
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800951-2Report Type:Periodic Company Report #WAES 01071826
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Musculoskeletal Stiffness	Health Professional	Levaquin	C				
	Oedema Peripheral							
	Paraesthesia							

Date:09/24/01ISR Number: 3800953-6Report Type:Periodic Company Report #WAES 01071847
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Eye Pain							
			Aleve	C				
			Lozol	C				
			Aspririn	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3800954-8Report Type:Periodic Company Report #WAES 01071850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Flexeril	C				

Date:09/24/01ISR Number: 3800955-XReport Type:Periodic Company Report #WAES 01071856
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fatigue						MG/DAILY/ORAL	
	Hyperhidrosis		Lasix (Furosemide)	C				
			Vasotec	C				
			Zoloft	C				
			Potassium (Unspecified)	C				

Date:09/24/01ISR Number: 3800956-1Report Type:Periodic Company Report #WAES 01071858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3800957-3Report Type:Periodic Company Report #WAES 01071859
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective						MG/DAILY/PO	
			Lanoxin	C				
			Composition Unspecified	C				

			Aspirin	C		
			Quinidine	C		
			Triamterene	C		

Date:09/24/01ISR Number: 3800958-5Report Type:Periodic Company Report #WAES 01071860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Haemorrhage	Professional Company Representative						

Date:09/24/01ISR Number: 3800959-7Report Type:Periodic Company Report #WAES 01071864
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Coumadin	C				

Date:09/24/01ISR Number: 3800960-3Report Type:Periodic Company Report #WAES 01071865
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Hyperhidrosis		Celebrex	C				
			Fosamax	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3800961-5Report Type:Periodic Company Report #WAES 01071874
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional Company Representative	Composition Unspecified	C				

Date:09/24/01ISR Number: 3800962-7Report Type:Periodic Company Report #WAES 01071876
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/ORAL	
		Professional Company Representative						

Date:09/24/01ISR Number: 3800963-9Report Type:Periodic Company Report #WAES 01071878
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800964-0Report Type:Periodic Company Report #WAES 01071881
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Headache						MG/DAILY/PO	
	Tongue Disorder		Darvocet-N	C				
	Vision Blurred		Lonox	C				
			Prevacid	C				
			Alprazolam	C				
			Dicyclomine Hydrochloride	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3800965-2Report Type:Periodic Company Report #WAES 01071918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS	Merck & Co., Inc.	ORAL	PO	
	Hypersensitivity	Health Professional						
	Nail Disorder							

Date:09/24/01ISR Number: 3800966-4Report Type:Periodic Company Report #WAES 01071934
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulopathy	Consumer	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25	
							MG/DAILY/PO	
			Altace	C				
			Lipitor	C				
			Prempro	C				
			Diltiazem Hydrochloride	C				

Date:09/24/01ISR Number: 3800967-6Report Type:Periodic Company Report #WAES 01071954
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3800968-8Report Type:Periodic Company Report #WAES 01071960
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Calan	C				
			Claritin	C				
			Coumadin	C				
			Lanoxin	C				
			Prinivil	C				

Date:09/24/01ISR Number: 3800969-XReport Type:Periodic Company Report #WAES 01071964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
	Faeces Discoloured							

Date:09/24/01ISR Number: 3800970-6Report Type:Periodic Company Report #WAES 01071973
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800971-8Report Type:Periodic Company Report #WAES 01071978
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Bronchitis							
			Glucosamine	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3800972-XReport Type:Periodic Company Report #WAES 01071985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Oral Soft Tissue Disorder	Professional	Dilantin	C				

	Paraesthesia	Premarin	C
		Prevacid	C
		Provera	C
		Zarontin	C
		Zyrtec	C
		Phenobarbital	C

Date:09/24/01ISR Number: 3800973-1Report Type:Periodic Company Report #WAES 01071988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25MG DAILY PO	

Date:09/24/01ISR Number: 3800974-3Report Type:Periodic Company Report #WAES 01071989
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Gait Disturbance							

Date:09/24/01ISR Number: 3800975-5Report Type:Periodic Company Report #WAES 01071995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	ORAL	3 DAY

Date:09/24/01ISR Number: 3800976-7Report Type:Periodic Company Report #WAES 01071998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS			PO	
			Therapy Unspecified	C				

Date:09/24/01ISR Number: 3800977-9Report Type:Periodic Company Report #WAES 01072003
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Fatigue	Professional	Zocor	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3800978-0Report Type:Periodic Company Report #WAES 01072007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY PO	
			Novolog	C				
			Zestril	C				

Date:09/24/01ISR Number: 3800979-2Report Type:Periodic Company Report #WAES 01072010
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Professional Company Representative	Ultram	C				

Date:09/24/01ISR Number: 3800980-9Report Type:Periodic Company Report #WAES 01072012
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Other	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
			Premarin	C				
			Ziac	C				

Date:09/24/01ISR Number: 3800981-0Report Type:Periodic Company Report #WAES 01072013
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50MG DAILY PO	
			Avandia	C				
			Dyazide	C				
			Glucophage	C				
			Lipitor	C				

			Thyrolar	C		

Date:09/24/01ISR Number: 3800982-2Report Type:Periodic Company Report #WAES 01072016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS			PO	

Date:09/24/01ISR Number: 3800983-4Report Type:Periodic Company Report #WAES 01071625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800984-6Report Type:Periodic Company Report #WAES 01071626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	ORAL	

Date:09/24/01ISR Number: 3800985-8Report Type:Periodic Company Report #WAES 01071627
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tongue Oedema							
			Digitek	C				
			Evista	C				
			Synthroid	C				
			Allopurinol	C				

			Furosemide	C		

Date:09/24/01ISR Number: 3800986-XReport Type:Periodic Company Report #WAES 01071628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Scar	Consumer	Tab Vioxx	PS		ORAL	ORAL	
	Skin Lesion							

Date:09/24/01ISR Number: 3800987-1Report Type:Periodic Company Report #WAES 01071629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Darvocet-N	C				

Date:09/24/01ISR Number: 3800988-3Report Type:Periodic Company Report #WAES 01071644
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/ORAL	
			Hytrin	C				
			Nolvadex	C				
			Norvasc	C				

				Prilosec	C		
				Atenolol	C		

Date:09/24/01ISR Number: 3800989-5Report Type:Periodic Company Report #WAES 01071646
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3800990-1Report Type:Periodic Company Report #WAES 01071651
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised	Health	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/PO	
Hospitalization -	Ratio Increased	Professional						
Initial or Prolonged	Prothrombin Time	Company	Coumadin	SS			7 MG/DAILY	
	Prolonged	Representative	Ibuprofen	SS				
			Hyzaar	C				
			Klonopin	C				
			Lopressor	C				
			Tricor	C				

Date:09/24/01ISR Number: 3800991-3Report Type:Periodic Company Report #WAES 01071652
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	PO	
	Depression							
	Weight Increased							

Date:09/24/01ISR Number: 3800992-5Report Type:Periodic Company Report #WAES 01071655
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Duodenitis	Professional					MG/DAILY/PO	
	Haemorrhage	Company	Aggrenox	C				
		Representative	Celexa	C				

Date:09/24/01ISR Number: 3800993-7Report Type:Periodic Company Report #WAES 01060662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspepsia							

Date:09/24/01ISR Number: 3800994-9Report Type:Periodic Company Report #WAES 01060665
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Diarrhoea						MG/DAILY/PO	
			Estrace	C				
			Salflex	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3800995-0Report Type:Periodic Company Report #WAES 01060668
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Laboratory Test Abnormal	Professional						
	Oedema	Company Representative						

Date:09/24/01ISR Number: 3800996-2Report Type:Periodic Company Report #WAES 01060670
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Orthostatic Hypotension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:09/24/01ISR Number: 3800997-4Report Type:Periodic Company Report #WAES 01060709
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Vision Blurred	Professional					MG/DAILY/PO	
		Company Representative	Vitamins	C				

Date:09/24/01ISR Number: 3800998-6Report Type:Periodic Company Report #WAES 01060717
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Drug Ineffective
Insomnia
Tinnitus

Date:09/24/01ISR Number: 3800999-8Report Type:Periodic Company Report #WAES 01060739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Sinusitis		Natol	C				
			Premarin	C				
			Urimax	C				

Date:09/24/01ISR Number: 3801000-2Report Type:Periodic Company Report #WAES 01060740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Myalgia		Diafen	C				
			Norvasc	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801001-4Report Type:Periodic Company Report #WAES 01060741
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Amitriptyline	C				

Date:09/24/01ISR Number: 3801002-6Report Type:Periodic Company Report #WAES 01060746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Pigmentation Disorder							
			Co-Proxamol	C				
			Lamaline	C				

Date:09/24/01ISR Number: 3801003-8Report Type:Periodic Company Report #WAES 01060754
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Maxzide	C				
			Premarin	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801004-XReport Type:Periodic Company Report #WAES 01060755
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glomerulonephritis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	50 MG DAILY	

	Urticaria	Health				
PO						
		Professional	Prinivil	C		

Date:09/24/01ISR Number: 3801005-1Report Type:Periodic Company Report #WAES 01060761
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Increased	Professional				
PO						
	Cardiac Failure		Maxzide Unk	SS		
DAILY						
	Congestive		A.S.A.	C		
			Fosamax	C		
			Premarin	C		
			Synthroid	C		
			Tenormin	C		
			Tylenol	C		

Date:09/24/01ISR Number: 3801006-3Report Type:Periodic Company Report #WAES 01060763
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gait Disturbance	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Oedema Peripheral					
PO						
			Norvasc	C		
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801007-5Report Type:Periodic Company Report #WAES 01060771
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
			Tetracycline	C				

Date:09/24/01ISR Number: 3801008-7Report Type:Periodic Company Report #WAES 01060786
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801009-9Report Type:Periodic Company Report #WAES 01060794
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801010-5Report Type:Periodic Company Report #WAES 01060813
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Oedema Peripheral						PO	
	Speech Disorder		Zyprexa	C				

			Clonazepam	C		
			Lithium Carbonate	C		

Date:09/24/01ISR Number: 3801011-7Report Type:Periodic Company Report #WAES 01060839
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Barrett'S Oesophagus						PO	
			Cozaar	C				
			Hydrodiuril	C				
			Prilosec	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801012-9Report Type:Periodic Company Report #WAES 01060841
Age:64 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Dyspepsia
	Dysphagia
	Fluid Retention

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Evista	C				
			Paxil	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801013-0Report Type:Periodic Company Report #WAES 01060861
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				
			Maxzide	C				
			Neurontin	C				
			Nexium	C				
			Niaspan	C				
			Paxil	C				
			Cephalexin	C				
			Lorazepam	C				

Date:09/24/01ISR Number: 3801014-2Report Type:Periodic Company Report #WAES 01060866
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cardura	C				
			Claritin	C				

Date:09/24/01ISR Number: 3801015-4Report Type:Periodic Company Report #WAES 01060868
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Malaise							
	Muscular Weakness		Dapsone	C				

Date:09/24/01ISR Number: 3801016-6Report Type:Periodic Company Report #WAES 01060870
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Blood Pressure Increased		[Composition Unspecified]	C				

Date:09/24/01ISR Number: 3801017-8Report Type:Periodic Company Report #WAES 01060873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801018-XReport Type:Periodic Company Report #WAES 01060876
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:09/24/01ISR Number: 3801019-1Report Type:Periodic Company Report #WAES 01060877
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Fosamax	C				
			Trazodone	C				

Date:09/24/01ISR Number: 3801020-8Report Type:Periodic Company Report #WAES 01060879
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea	Health Professional	Prevacid	C				
			[Therapy Unspecified]	C				
			Alprazolam	C				
			Temazepam	C				

Date:09/24/01ISR Number: 3801021-XReport Type:Periodic Company Report #WAES 01060883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
MG/DAILY/PO							

Date:09/24/01ISR Number: 3801022-1Report Type:Periodic Company Report #WAES 01060898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Nausea							
MG/DAILY/PO								
			Glucotrol	C				
			Lescol	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3801023-3Report Type:Periodic Company Report #WAES 01060904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
MG/DAILY/PO								
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801024-5Report Type:Periodic Company Report #WAES 01060905
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801025-7Report Type:Periodic Company Report #WAES 01060911
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Aspirin	C				
			Hydrochlorothiazide	C				

Date:09/24/01ISR Number: 3801026-9Report Type:Periodic Company Report #WAES 01060923
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Depression		Inderal	C				
	Fatigue		Premarin	C				

Date:09/24/01ISR Number: 3801027-0Report Type:Periodic Company Report #WAES 01060973
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Drug Reaction	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

	Nasal Congestion	Health
	Upper Respiratory Tract	Professional
	Infection	

Date:09/24/01ISR Number: 3801028-2Report Type:Periodic Company Report #WAES 01060985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3801029-4Report Type:Periodic Company Report #WAES 01060991
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Celebrex	C				
			Aspirin	C				
			Glucosaminie	C				
			Vitamins					

(Unspecified) C

Date:09/24/01ISR Number: 3801030-0Report Type:Periodic Company Report #WAES 01060996
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Evista	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801031-2Report Type:Periodic Company Report #WAES 01060998
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Musculoskeletal Stiffness	Professional	Tab Vioxx 25 Mg	SS		ORAL	25	MG/DAILY/PO 2 MON

Date:09/24/01ISR Number: 3801032-4Report Type:Periodic Company Report #WAES 01060999
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO 4 DAY
	Oedema Peripheral							
	Oliguria		Tab Vioxx	SS		ORAL	50 MG/PO	6 DAY
			Flexeril	C				
			Fosamax	C				

Date:09/24/01ISR Number: 3801033-6Report Type:Periodic Company Report #WAES 01061001
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hernia	Health	Profen Ii	C				
	Muscle Spasms	Professional	Zyrtec	C				
			....	C				
			Hormones	C				

Date:09/24/01ISR Number: 3801034-8Report Type:Periodic Company Report #WAES 01061003
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Hydrodiuril	C				
			Lipitor	C				
			Ogen	C				
			Synthroid	C				
			Vasotec	C				

Date:09/24/01ISR Number: 3801035-XReport Type:Periodic Company Report #WAES 01061017
Age:16 YR Gender:Female I/FU:I

Outcome	PT
	Electrocardiogram Qt Prolonged

Syncope

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Methotrexate	C				

Date:09/24/01ISR Number: 3801036-1Report Type:Periodic Company Report #WAES 01061018
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypersensitivity	Health Professional						
	Rash							

Date:09/24/01ISR Number: 3801037-3Report Type:Periodic Company Report #WAES 01061019
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lopressor	C				
			...	C				

Date:09/24/01ISR Number: 3801038-5Report Type:Periodic Company Report #WAES 01061022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Faeces Discoloured							

Company
Representative

Date:09/24/01ISR Number: 3801039-7Report Type:Periodic Company Report #WAES 01061023
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3801040-3Report Type:Periodic Company Report #WAES 01061024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801041-5Report Type:Periodic Company Report #WAES 01061026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	DAILY/PO	1 WK
			Diovan	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801042-7Report Type:Periodic Company Report #WAES 01061032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fatigue							
	Headache		Levoxyl	C				
			Tenormin	C				

Date:09/24/01ISR Number: 3801043-9Report Type:Periodic Company Report #WAES 01061033
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Amoram	C				
			Prinivil	C				
			Tiazac	C				

Date:09/24/01ISR Number: 3801044-0Report Type:Periodic Company Report #WAES 01061036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Palpitations							

Date:09/24/01ISR Number: 3801045-2Report Type:Periodic Company Report #WAES 01061043
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	

	Rash	Professional Company Representative	(Composition Unspecified)	C		

Date:09/24/01ISR Number: 3801046-4Report Type:Periodic Company Report #WAES 01061050
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				

Date:09/24/01ISR Number: 3801047-6Report Type:Periodic Company Report #WAES 01061059
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional						
			Allegra	C				
			Cardizem	C				
			Catapres Tts	C				
			Hydrodiuril	C				
			Nitrostat	C				
			Norvasc	C				
			Plavix	C				
			Prinivil	C				

Albuterol C

Date:09/24/01ISR Number: 3801048-8Report Type:Periodic Company Report #WAES 01061069
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801049-XReport Type:Periodic Company Report #WAES 01061070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Oedema							

Date:09/24/01ISR Number: 3801050-6Report Type:Periodic Company Report #WAES 01061106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801051-8Report Type:Periodic Company Report #WAES 01061113
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Congestive Professional
MG/DAILY/PO

Date:09/24/01ISR Number: 3801052-XReport Type:Periodic Company Report #WAES 01061117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx	PS		ORAL	50	
	Oedema	Professional						
		Company Representative						

MG/DAILY/PO

Date:09/24/01ISR Number: 3801053-1Report Type:Periodic Company Report #WAES 01061127
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
			Ortho-Prefest	C				

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801054-3Report Type:Periodic Company Report #WAES 01061128
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
PO								

Date:09/24/01ISR Number: 3801055-5Report Type:Periodic Company Report #WAES 01061130
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Urinary Tract Infection							
MG/DAILY/PO	4	DAY						

Date:09/24/01ISR Number: 3801056-7Report Type:Periodic Company Report #WAES 01061131
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
			Celebrex	C				
			Flovent	C				
			Lasix (Furosemide Sodium)	C				
			Lescol	C				
			Prinivil	C				
			Rhinocort	C				
			Serevent	C				
			Zyrtec	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3801058-0Report Type:Periodic Company Report #WAES 01061135
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Congestion	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3801059-2Report Type:Periodic Company Report #WAES 01061138
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Feeling Abnormal		Glucophage	C				
	Pain							
	Paraesthesia							

Date:09/24/01ISR Number: 3801060-9Report Type:Periodic Company Report #WAES 01061140
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Consumer	Tab Vioxx 50mg	PS		ORAL	50MG/DAILY/PO	
		Health Professional	Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801061-0Report Type:Periodic Company Report #WAES 01061141
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Nausea							

Date:09/24/01ISR Number: 3801062-2Report Type:Periodic Company Report #WAES 01061142
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Health	Tab Vioxx Mg	PS		ORAL	SEE IMAGE	
	Gastritis Erosive	Professional	Betagan	C				
	Sinusitis	Company	Diovan	C				
	Upper Gastrointestinal	Representative	Lorect 10/650	C				
	Haemorrhage		Vicodin Tuss					
	Upper Respiratory Tract		Expectorant	C				
	Infection		Aspirin	C				

Date:09/24/01ISR Number: 3801063-4Report Type:Periodic Company Report #WAES 01060026
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fluid Retention	Health					MG/DAILY/PO	
	Oedema Peripheral	Professional	Celebrex	C				
	Weight Increased							

Date:09/24/01ISR Number: 3801064-6Report Type:Periodic Company Report #WAES 01060029
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rales	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Wheezing					
MG/DAILY/PO						
			Aldactazide	C		
			Bumex	C		
			Cozaar	C		

Date:09/24/01ISR Number: 3801065-8Report Type:Periodic Company Report #WAES 01060032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL
PO 3 DAY						
			Ogen	C		

Date:09/24/01ISR Number: 3801066-XReport Type:Periodic Company Report #WAES 01060036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 50mg	PS		ORAL
50						
MG/DAILY/PO						
			[Composition Unspecified]	C		

Date:09/24/01ISR Number: 3801067-1Report Type:Periodic Company Report #WAES 01060037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ejaculation Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	MG/UNK/PO	4 DAY
			Diovan	C				
			Wellbutrin	C				

Date:09/24/01ISR Number: 3801068-3Report Type:Periodic Company Report #WAES 01060044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801069-5Report Type:Periodic Company Report #WAES 01060065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801070-1Report Type:Periodic Company Report #WAES 01060066
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company	Tab Vioxx 50 Mg [Composition Unspecified]	PS C		ORAL	PO	

Representative

Date:09/24/01ISR Number: 3801071-3Report Type:Periodic Company Report #WAES 01060067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801072-5Report Type:Periodic Company Report #WAES 01060068
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801078-6Report Type:Periodic Company Report #WAES 01060072
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
						PO		
			Cipro	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Humulin N	C				
			Lipitor	C				
			Proscar	C				
			Aspirin	C				
			Digoxin	C				
			Ginkgo Biloba Extract	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3801080-4Report Type:Periodic Company Report #WAES 01060076
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat		Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Ecchymosis		Anafranil	C				
	Nervousness		Celebrex	C				
	Scar		Clomipramine	C				
	Skin Ulcer							

Date:09/24/01ISR Number: 3801081-6Report Type:Periodic Company Report #WAES 01060107
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Chest Pain		Actonel	C				
	Face Oedema							
	Muscular Weakness							

Nausea
Rash

Date:09/24/01ISR Number: 3801083-XReport Type:Periodic Company Report #WAES 01060108
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Back Pain							
PO								1 MON
	Cognitive Disorder							
	Fatigue							
	Flatulence							

Date:09/24/01ISR Number: 3801085-3Report Type:Periodic Company Report #WAES 01060122
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5/25 Mg	PS		ORAL	PO	
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801086-5Report Type:Periodic Company Report #WAES 01060123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
	Swelling							

Date:09/24/01ISR Number: 3801087-7Report Type:Periodic Company Report #WAES 01060125
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			K-Dur	C				
			Lasix (Furosemide)	C				
			Levoxyl	C				
			Prinivil	C				
			Zocor	C				
			Aspirin	C				
			Estrogens	C				

Date:09/24/01ISR Number: 3801088-9Report Type:Periodic Company Report #WAES 01060131
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Dyspnoea							
	Muscular Weakness		Baycol	C				
	Pain In Extremity		Levoxyl	C				
			Lotrel	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:09/24/01ISR Number: 3801089-0Report Type:Periodic Company Report #WAES 01060135
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	

PO

Date:09/24/01ISR Number: 3801090-7Report Type:Periodic Company Report #WAES 01060143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:09/24/01ISR Number: 3801091-9Report Type:Periodic Company Report #WAES 01060156
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801092-0Report Type:Periodic Company Report #WAES 01060191
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Evista	C				
			Paxil	C				
			Verapamil Msd Lp	C				
			Trazodone	C				

Date:09/24/01ISR Number: 3801093-2Report Type:Periodic Company Report #WAES 01060192
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Weight Increased						PO	

Date:09/24/01ISR Number: 3801094-4Report Type:Periodic Company Report #WAES 01060196
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
							PO	
			Cipro	C				
			Climara	C				
			Dynabac	C				
			Elavil	C				
			Flexeril	C				
			Klonopin	C				
			Lomotil	C				
			Moduretic	C				
			Nulev	C				
			Phenergan (Promethazine Hydrochl	C				

			Xanax	C		
			Ascorbic Acid	C		
			Hyoscyamine	C		
			Vitamin B Complex	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3801095-6Report Type:Periodic Company Report #WAES 01060197
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
PO								
			Claritin D 24 Hour	C				
			Norvasc	C				
			Premarin	C				
			Sinemet	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801096-8Report Type:Periodic Company Report #WAES 01060201
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801098-1Report Type:Periodic Company Report #WAES 01060219
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Haemoptysis						PO	
			Darvocet-N	C				

Date:09/24/01ISR Number: 3801099-3Report Type:Periodic Company Report #WAES 01060226
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
		Health Professional					DAILY/ PO	
			Lipitor	C				
			Norvasc	C				
			Premarin	C				
			Synthroid	C				
			Toprol Xl	C				

Date:09/24/01ISR Number: 3801100-7Report Type:Periodic Company Report #WAES 01060227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG /	
	Dyspnoea						DAILY/ PO	
			Evista	C				
			Lipitor	C				
			Prilosec	C				
			Tenormin	C				

Date:09/24/01ISR Number: 3801102-0Report Type:Periodic Company Report #WAES 01060229
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Micturition Disorder	Professional	Norvasc	C				
			Prevacid	C				
			Atenolol	C				
			Imipramine	C				

Date:09/24/01ISR Number: 3801103-2Report Type:Periodic Company Report #WAES 01060263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Cozaar	C				

Tenormin C

Date:09/24/01ISR Number: 3801108-1Report Type:Periodic Company Report #WAES 01060268
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	17 DAY
	Dyspepsia							

Date:09/24/01ISR Number: 3801110-XReport Type:Periodic Company Report #WAES 01060269
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	
			Naprosyn	C				

Date:09/24/01ISR Number: 3801111-1Report Type:Periodic Company Report #WAES 01060270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	2 WK
			Synthroid	C				

Date:09/24/01ISR Number: 3801113-5Report Type:Periodic Company Report #WAES 01060276
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urticaria	Consumer	Tab Vioxx 50 Mg	PS			ORAL
PO							
			Synthroid	C			

Date:09/24/01ISR Number: 3801114-7Report Type:Periodic Company Report #WAES 01060277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
PO								
	Cardiac Failure Congestive							

Date:09/24/01ISR Number: 3801115-9Report Type:Periodic Company Report #WAES 01060278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase	Health	Tab Vioxx 50 Mg	PS		ORAL		
SEE IMAGE								
	Increased Aspartate Aminotransferase Increased	Professional	Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801117-2Report Type:Periodic Company Report #WAES 01060279
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	4 DAY
	Oedema Peripheral		Vasotec	C				
			Hydrochlorothiazide	C				
			Insulin	C				

Date:09/24/01ISR Number: 3801119-6Report Type:Periodic Company Report #WAES 01060282
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Haemorrhage							

Date:09/24/01ISR Number: 3801120-2Report Type:Periodic Company Report #WAES 01060285
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG	/DAILY/PO
			Percocet	C				
			Tylenol	C				

Date:09/24/01ISR Number: 3801122-6Report Type:Periodic Company Report #WAES 01060230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Mg	PS		ORAL	50 /DAILY/PO	
			Darvocet-N	C				
			Ultram	C				

Date:09/24/01ISR Number: 3801123-8Report Type:Periodic Company Report #WAES 01060232
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3801125-1Report Type:Periodic Company Report #WAES 01060233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Iritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801127-5Report Type:Periodic Company Report #WAES 01060240
Age:78 YR Gender:Female I/FU:I

Outcome	PT
	Asthenia
	Dysphonia
	Dyspnoea
	Fatigue

	Influenza						
	Nervousness						
	Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Vomiting						
			Advil	C			
			Calan	C			

Date:09/24/01ISR Number: 3801128-7Report Type:Periodic Company Report #WAES 01060242
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO
			Toprol Xl Tablets	C			

Date:09/24/01ISR Number: 3801129-9Report Type:Periodic Company Report #WAES 01060247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO

Date:09/24/01ISR Number: 3801130-5Report Type:Periodic Company Report #WAES 01060250
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
			Darvocet-N	C			

Date:09/24/01ISR Number: 3801132-9Report Type:Periodic Company Report #WAES 01060251
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Cenestin	C				
			Prometrium	C				
			Toprol Xl Tablets	C				
			Wellbutrin Sr	C				

Date:09/24/01ISR Number: 3801133-0Report Type:Periodic Company Report #WAES 01060252
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rectal Discharge		Synthroid	C				
			Calcium	C				

Date:09/24/01ISR Number: 3801135-4Report Type:Periodic Company Report #WAES 01060261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Glucophage	C				

Pravachol	C
Proscar	C
Atenolol	C
Nitroglycerin	C
Spironolactone	C
Verapamil	C

Date:09/24/01ISR Number: 3801137-8Report Type:Periodic Company Report #WAES 01061684
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801138-XReport Type:Periodic Company Report #WAES 01061689
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Glucotrol	C				
			Imdur	C				
			Kerlone	C				
			Lipitor	C				
			Norvasc	C				
			Protonix	C				

Date:09/24/01ISR Number: 3801140-8Report Type:Periodic Company Report #WAES 01061695
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Muscle Spasms	Consumer	Tab Vioxx 12.5 Mg	PS			ORAL
12.5MG/BID/PO							
			Cutivate	C			
			Premarin	C			
			Synthroid	C			
			Ranitidine	C			

Date:09/24/01ISR Number: 3801141-XReport Type:Periodic Company Report #WAES 01061704
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Weight Increased							
PO								

Date:09/24/01ISR Number: 3801142-1Report Type:Periodic Company Report #WAES 01061706
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx	PS		ORAL		
PO								
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801143-3Report Type:Periodic Company Report #WAES 01061726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801144-5Report Type:Periodic Company Report #WAES 01061730
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive Cardiomyopathy	Health Professional	Levoxyl	C				
			Ogen	C				
			Protonix	C				
			Provera	C				
			Prozac	C				
			Uniphyl	C				
			Ventilan (Albuterol)	C				
			Isosorbide	C				

Date:09/24/01ISR Number: 3801145-7Report Type:Periodic Company Report #WAES 01061731
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Garlic Extract	C				
			Vitamins	C				

Date:09/24/01ISR Number: 3801146-9Report Type:Periodic Company Report #WAES 01061734
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Phosphokinase Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ditropan	C				
			Paxil	C				
			Prempro	C				
			Prilosec	C				

Date:09/24/01ISR Number: 3801148-2Report Type:Periodic Company Report #WAES 01061744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bleeding Time Prolonged	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Ddavp	C				

Date:09/24/01ISR Number: 3801155-XReport Type:Periodic Company Report #WAES 01061750
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Estradiol	C				
			Norethindrone Acetate	C				

			Vitamins	C		

Date:09/24/01ISR Number: 3801160-3Report Type:Periodic Company Report #WAES 01061756
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
		Health Professional	Fosamax	C				

Date:09/24/01ISR Number: 3801162-7Report Type:Periodic Company Report #WAES 01061757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Lipitor	C				
			Prevacid	C				
			Wellbutrin	C				
			Zyprexa	C				

Date:09/24/01ISR Number: 3801163-9Report Type:Periodic Company Report #WAES 01061758
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO
	Feeling Hot							
	Flushing		Lipitor	C				
	Hypersensitivity		Allopurinol	C				

Date:09/24/01ISR Number: 3801164-0Report Type:Periodic Company Report #WAES 01061762
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention	Consumer	Tab Vioxx	PS		ORAL	PO	
	Deficit/Hyperactivity							
	Disorder							
	Dry Skin							
	Insomnia							
	Weight Increased							

Date:09/24/01ISR Number: 3801165-2Report Type:Periodic Company Report #WAES 01061787
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Levoxyl	C				
			Norvasc	C				
			Colchicine (+)					
			Probenecid	C				
			Furosemide	C				
			Indapamide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801166-4Report Type:Periodic Company Report #WAES 01061802
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:09/24/01ISR Number: 3801168-8Report Type:Periodic Company Report #WAES 01061803
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Increased Hepatic Haematoma Rib Fracture	Professional Company Representative						

Date:09/24/01ISR Number: 3801169-XReport Type:Periodic Company Report #WAES 01061804
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Dilantin	C				

Date:09/24/01ISR Number: 3801170-6Report Type:Periodic Company Report #WAES 01061824
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Murmur	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dizziness	Health					MG/DAILY/PO	
	Palpitations	Professional	Questran	C				

	Tachycardia		Diltiazem Maleate	C
			Doxepin	C
			Ranitidine	C

Date:09/24/01ISR Number: 3801171-8Report Type:Periodic Company Report #WAES 01061831
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Robaxin	C				

Date:09/24/01ISR Number: 3801172-XReport Type:Periodic Company Report #WAES 01061833
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801173-1Report Type:Periodic Company Report #WAES 01061838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801174-3Report Type:Periodic Company Report #WAES 01061841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801175-5Report Type:Periodic Company Report #WAES 01061844
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pharyngeal Oedema	Professional						
	Pruritus		Hyzaar	C				

Date:09/24/01ISR Number: 3801176-7Report Type:Periodic Company Report #WAES 01061847
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	
			Biaxin	C				

Claritin	C
Verelan	C

Date:09/24/01ISR Number: 3801177-9Report Type:Periodic Company Report #WAES 01061858
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	PO	
	Skin Disorder	Professional						

Date:09/24/01ISR Number: 3801178-0Report Type:Periodic Company Report #WAES 01061859
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801179-2Report Type:Periodic Company Report #WAES 01061866
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Oedema Peripheral		Fosamax	C				
	Panic Disorder		Prinizide	C				
			Prozac	C				
			Synthroid	C				
			Zocor	C				

Date:09/24/01ISR Number: 3801180-9Report Type:Periodic Company Report #WAES 01061867
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral		Allegra	C				
			Theragian Tablets					
			Advanced Formu	C				
			Zoloft	C				

Date:09/24/01ISR Number: 3801183-4Report Type:Periodic Company Report #WAES 01061872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Ineffective						PO	
	Nausea		Prevacid	C				
			Synthroid	C				
			Zocor	C				
			Aspirin	C				
			Insulin	C				

Date:09/24/01ISR Number: 3801184-6Report Type:Periodic Company Report #WAES 01061875
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG	
	Nausea						/DAILY/PO	
	Parosmia		Allegra	C				
			Centrum	C				
			Colestid	C				
			Gaviscon Antacid Tablets	C				
			Pravachol	C				
			Prilosec	C				
			Tums	C				
			Tylenol	C				
			Tylenol Pm	C				
			Zantac	C				
			Zestril	C				
			Chlorthalidone	C				
			Estradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801185-8Report Type:Periodic Company Report #WAES 01061878
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Health					PO	
		Professional	Celebrex	C				
			Lopid	C				

Date:09/24/01ISR Number: 3801187-1Report Type:Periodic Company Report #WAES 01061882
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Hypotension	Professional					MG/DAILY/PO	
	Muscular Weakness							
	Nausea							

Date:09/24/01ISR Number: 3801189-5Report Type:Periodic Company Report #WAES 01061885
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dizziness		Celebrex	C				
	Dyspepsia		Lotrel	C				
	Faeces Discoloured		Prilosec	C				
	Fall		Ultram	C				
	Lower Gastrointestinal		Vitamin E	C				
	Haemorrhage							
	Nausea							
	Syncope							
	Ulcer							

Date:09/24/01ISR Number: 3801191-3Report Type:Periodic Company Report #WAES 01061886
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
	Blood Urea Increased							

Date:09/24/01ISR Number: 3801192-5Report Type:Periodic Company Report #WAES 01061889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG DAILY PO	
	Pain In Extremity							

Date:09/24/01ISR Number: 3801193-7Report Type:Periodic Company Report #WAES 01061895
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801194-9Report Type:Periodic Company Report #WAES 01061896
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Lasix (Furosemide)	C				
			Procardia	C				
			Slow-K	C				
			Vasotec	C				

Date:09/24/01ISR Number: 3801196-2Report Type:Periodic Company Report #WAES 01061898
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx	PS		ORAL		
PO								
	Disease	Professional Company Representative						

Date:09/24/01ISR Number: 3801221-9Report Type:Periodic Company Report #WAES 01061899
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Full Blood Count Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			[Therapy Unspecified]	C				
			Iron (Unspecified)	C				

Date:09/24/01ISR Number: 3801223-2Report Type:Periodic Company Report #WAES 01061902
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Nausea						PO	
			Neurontin	C				

Date:09/24/01ISR Number: 3801224-4Report Type:Periodic Company Report #WAES 01061907
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
			Celebrex	C				
			Meridia	C				

Date:09/24/01ISR Number: 3801225-6Report Type:Periodic Company Report #WAES 01061910
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
		Health					PO	
		Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG BID PO	

Date:09/24/01ISR Number: 3801227-XReport Type:Periodic Company Report #WAES 01061911
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Oedema Peripheral						PO	
	Weight Increased		Flexeril	C				
			Oxycontin	C				
			Prozac	C				
			Buspirone Hydrochloride	C				
			Chlordiazepoxide Hydrochloride	C				
			Dicyclomine Hydrochloride	C				

Date:09/24/01ISR Number: 3801228-1Report Type:Periodic Company Report #WAES 01061915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3801229-3Report Type:Periodic Company Report #WAES 01061928
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Deficit/Hyperactivity						PO	
	Disorder		Avandia	C				
	Dry Skin		Coreg	C				
	Swelling		Coumadin	C				
			Cozaar	C				
			Lipitor	C				

Norvasc	C
Digoxin	C
Furosemide	C
Insulin	C
Potassium Chloride	C
Spironolactone	C
Sulfisoxazole	C

Date:09/24/01ISR Number: 3801232-3Report Type:Periodic Company Report #WAES 01061933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801233-5Report Type:Periodic Company Report #WAES 01061956
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eosinophil Count	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional	Plavix 75 Mg	SS			75 MG DAILY	
	Pruritus		Prilosec	C				
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801234-7Report Type:Periodic Company Report #WAES 01061961
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801238-4Report Type:Periodic Company Report #WAES 01061984
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Synthroid	C				
			Zocor	C				
			Chlordiazepoxide	C				

Date:09/24/01ISR Number: 3801240-2Report Type:Periodic Company Report #WAES 01061994
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801241-4Report Type:Periodic Company Report #WAES 01061999
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Contusion		Metabolife 356	C				
	Inflammation		Antioxidants (Unspecified)	C				
	Joint Effusion							

	Osteonecrosis	Fexofenadine	
	Red Blood Cell	Hydrochloride (+)	C
	Sedimentation Rate	Vitamins	
	Increased	(Unspecified)	C

Date:09/24/01ISR Number: 3801242-6Report Type:Periodic Company Report #WAES 01062005
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vaginal Haemorrhage	Health Professional	Acupril	C				
			Claritin	C				
			Elavil	C				
			Flexeril	C				
			Lasix (Furosemide)	C				
			Oxycontin	C				

Date:09/24/01ISR Number: 3801244-XReport Type:Periodic Company Report #WAES 01062008
Age:60 YR Gender:Female I/FU:I

Outcome	PT
	Blood Pressure Increased
	Dizziness
	Dyspepsia

	Vertigo						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Metamucil	C				
			Zocor	C				

Date:09/24/01ISR Number: 3801246-3Report Type:Periodic Company Report #WAES 01062015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Cough						MG/DAILY/PO	
	Drug Ineffective		Diovan	C				
	Fatigue		Miacalcin	C				
	Insomnia		Niaspan	C				
			Synthroid	C				
			Calcium (Unspecified)	C				
			Chrondroitin	C				
			Glucosamine	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3801248-7Report Type:Periodic Company Report #WAES 01062016
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Feeling Abnormal	Health Professional	Celebrex	C				
	Headache		[Composition Unspecified]	C				

Date:09/24/01ISR Number: 3801250-5Report Type:Periodic Company Report #WAES 01062019
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Ineffective		[Composition					
	Headache		Unspecified]	C				

Date:09/24/01ISR Number: 3801252-9Report Type:Periodic Company Report #WAES 01062025
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Tinnitus							
MG/DAILY/PO	2	DAY						
			Estrogens					
			(Unspecified)	C				

Date:09/24/01ISR Number: 3801253-0Report Type:Periodic Company Report #WAES 01062026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
			Synthroid	C				
			Tylenol	C				

			[Therapy Unspecified]	C		
			Methotrexate	C		

Date:09/24/01ISR Number: 3801258-XReport Type:Periodic Company Report #WAES 01062027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Infection							
	Petechiae		Premarin	C				
			Quinine	C				

Date:09/24/01ISR Number: 3801260-8Report Type:Periodic Company Report #WAES 01062030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	6 WK

Date:09/24/01ISR Number: 3801261-XReport Type:Periodic Company Report #WAES 01062031
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3801263-3Report Type:Periodic Company Report #WAES 01062039
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3801264-5Report Type:Periodic Company Report #WAES 01062046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Swelling							

Date:09/24/01ISR Number: 3801265-7Report Type:Periodic Company Report #WAES 01062047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801267-0Report Type:Periodic Company Report #WAES 01062058
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801269-4Report Type:Periodic Company Report #WAES 01062060
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypotension	Health	Tab Vioxx	PS		ORAL	PO	
	Muscular Weakness	Professional						
	Nausea							

Date:09/24/01ISR Number: 3801271-2Report Type:Periodic Company Report #WAES 01062062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801273-6Report Type:Periodic Company Report #WAES 01062063
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company	Tab Vioxx 25 Mg	PS		ORAL	PO	

Representative

Date:09/24/01ISR Number: 3801288-8Report Type:Periodic Company Report #WAES 01062065
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801290-6Report Type:Periodic Company Report #WAES 01062066
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Casodex	C				
			Demadex	C				
			Digoxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801291-8Report Type:Periodic Company Report #WAES 01062068
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	1 MON

Date:09/24/01ISR Number: 3801292-XReport Type:Periodic Company Report #WAES 01062099
Age:70 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Elavil	C				
			Glucophage	C				
			Humulin 70/30	C				
			Imdur	C				
			Nitroglycerin	C				
			Premarin	C				
			Prinivil	C				
			Zocor	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Metoprolol	C				
			Pentoxifylline	C				
			Vitamin E	C				

Date:09/24/01ISR Number: 3801293-1Report Type:Periodic Company Report #WAES 01062100
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Vioxx 25 Mg	PS		ORAL	25	

	Oedema					
MG/DAILY/PO						
			Nasacort	C		
			Premarin	C		
			Prilosec	C		
			Diazepam	C		
			Vitamin D (Unspecified)	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3801295-5Report Type:Periodic Company Report #WAES 01062102
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Health	Vioxx	PS		
	Drug Ineffective	Professional	Synvisc 2 Ml	SS		
2 ML/WKY/INJ						
	Joint Swelling		Prevacid	C		
	Synovial Disorder		Xylocaine	C		
			Glucosamine	C		
			Theophylline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801297-9Report Type:Periodic Company Report #WAES 01062118
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO, 25MG/PRN/PO	
	Dyspnoea							
			Diovan	C				
			Fosamax	C				
			Levothroid	C				
			Novadox	C				
			Ventolin	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801299-2Report Type:Periodic Company Report #WAES 01062120
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Asthenia	Health Professional	Cipro	C				
	Bronchitis		Evista	C				
	Chest Pain		Paxil	C				
	Dyspnoea		Tenormin	C				
	Faeces Discoloured							
	Fatigue							
	Headache							
	Speech Disorder							
	Wheezing							

Date:09/24/01ISR Number: 3801300-6Report Type:Periodic Company Report #WAES 01062121
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
			Aerobid	C				

			Covera-Hs	C		
			Mevacor	C		
			Serevent	C		
			(Therapy Unspecified)	C		

Date:09/24/01ISR Number: 3801302-XReport Type:Periodic Company Report #WAES 01062122
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Sedation		Cartia (Diltiazem Hydrochloride)	C				
	Weight Increased		Claritin	C				
			Coumadin	C				
			Cozaar	C				
			Fosamax	C				
			Hydrodiuril	C				
			Lanoxin	C				
			Paxil	C				
			Synthroid	C				
			(Therapy Unspecified)	C				

Date:09/24/01ISR Number: 3801305-5Report Type:Periodic Company Report #WAES 01062123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	MG/PO	
			Diovan	C				
			Evista	C				

Date:09/24/01ISR Number: 3801307-9Report Type:Periodic Company Report #WAES 01062125
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ QOD/ PO	

Date:09/24/01ISR Number: 3801308-0Report Type:Periodic Company Report #WAES 01062129
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lotensin	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801309-2Report Type:Periodic Company Report #WAES 01062131
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ AM/ PO	
		Health Professional	Avalide	C				

Date:09/24/01ISR Number: 3801310-9Report Type:Periodic Company Report #WAES 01062136
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY/ PO	
			Coumadin	C				
			Darvocet-N	C				

Date:09/24/01ISR Number: 3801312-2Report Type:Periodic Company Report #WAES 01062144
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Celebrex	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3801314-6Report Type:Periodic Company Report #WAES 01062146
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional Company Representative	Tab Vioxx 50 Mg	PS			50 MG/DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801315-8Report Type:Periodic Company Report #WAES 01062147
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Elavil	C				

Date:09/24/01ISR Number: 3801317-1Report Type:Periodic Company Report #WAES 01062152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prinzide	C				

Date:09/24/01ISR Number: 3801318-3Report Type:Periodic Company Report #WAES 01062161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG /DAILY/ PO	

Date:09/24/01ISR Number: 3801320-1Report Type:Periodic Company Report #WAES 01062162
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801322-5Report Type:Periodic Company Report #WAES 01062173
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Beconase	C				
			Hydrodiuril	C				
			Levothroid	C				
			Nitro-Bid	C				
			Provera	C				
			Pulmicort	C				
			Serevent	C				
			Aspirin	C				
			Clonidine	C				
			Folic Acid	C				
			Potassium (Unspecified)	C				
			Verapamil	C				

Date:09/24/01ISR Number: 3801324-9Report Type:Periodic Company Report #WAES 01062174
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801325-0Report Type:Periodic Company Report #WAES 01062208
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO; 50 MG PO	
	Dysphonia		Viagra	C				
	Fatigue		Chondroitin (+)					
	Oedema Peripheral		Glucosamine	C				
	Sweat Gland Disorder		Metoprolol	C				
			Mezereum	C				
			Noni	C				
			Quinine Sulfate	C				

Date:09/24/01ISR Number: 3801327-4Report Type:Periodic Company Report #WAES 01062222
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Urticaria	Professional					MG/DAILY/PO	
			Acupril	C				
			Accuretic	C				
			Celebrex	C				
			Detrol	C				
			Premarin	C				
			Provera	C				
			Verapamil Hydrochloride	C				

Date:09/24/01ISR Number: 3801328-6Report Type:Periodic Company Report #WAES 01062225
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				

			Valium	C
			Aspirin	C
			Verapamil Hydrochloride	C

Date:09/24/01ISR Number: 3801330-4Report Type:Periodic Company Report #WAES 01062232
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lung Neoplasm	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3801331-6Report Type:Periodic Company Report #WAES 01062233
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Dilacor Xr	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801333-XReport Type:Periodic Company Report #WAES 01062240
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Tab Vioxx 50 Mg	PS		ORAL	DAILY/PO	
			Prozac	C				
			Texofenadine Hydrochloride	C				
			Fluoxetine	C				
			Lansoprazole	C				
			Oxycodone	C				

Date:09/24/01ISR Number: 3801335-3Report Type:Periodic Company Report #WAES 01062241
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Zantac	C				
			Meclizine Hydrochloride	C				

Date:09/24/01ISR Number: 3801337-7Report Type:Periodic Company Report #WAES 01061146
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
							PO	1 DAY

Date:09/24/01ISR Number: 3801339-0Report Type:Periodic Company Report #WAES 01061150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						

Date:09/24/01ISR Number: 3801340-7Report Type:Periodic Company Report #WAES 01061153
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bladder Disorder	Health	Tab Vioxx	PS		ORAL
PO						
	Micturition Urgency	Professional				
	Pollakiuria	Company				
		Representative				

Date:09/24/01ISR Number: 3801342-0Report Type:Periodic Company Report #WAES 01061160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
	Weight Increased	Health	Allegra	C		
		Professional	Fosamax	C		
			Premarin	C		
			Prevacid	C		
			Synthroid	C		
			Zocor	C		
			Calcium Citrate	C		
			Iron	C		
			Magnesium Oxide	C		

			Vitamins	C		

Date:09/24/01ISR Number: 3801343-2Report Type:Periodic Company Report #WAES 01061161
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Premarin	C				
			Provera	C				
			Influenza Virus Vaccine	C				

Date:09/24/01ISR Number: 3801344-4Report Type:Periodic Company Report #WAES 01061162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/PO	
	Swelling	Health Professional	Aldactazide	C				
			Atenolol	C				
			Nonsteroidal Anti-Inflammatory D	C				

Date:09/24/01ISR Number: 3801345-6Report Type:Periodic Company Report #WAES 01061167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	

Date:09/24/01ISR Number: 3801346-8Report Type:Periodic Company Report #WAES 01061174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
			Monopril	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801347-XReport Type:Periodic Company Report #WAES 01061175
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ultram	SS				
			Claritin	C				
			Zestril	C				
			Fosamax	C				
			Ocupress	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801348-1Report Type:Periodic Company Report #WAES 01061177
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801351-1Report Type:Periodic Company Report #WAES 01061179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Company Representative	Therapy Unspecified	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801352-3Report Type:Periodic Company Report #WAES 01061182
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID PO	
			Paxil	C				
			Hydrochlorothiazide	C				
			Timolol	C				

Date:09/24/01ISR Number: 3801354-7Report Type:Periodic Company Report #WAES 01061183
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Pain
MG/DAILY/PO

Penlac	C
Premarin	C
Synthroid	C
Hydrochlorothiazide (+) Methyldo	C
Potassium Chloride	C

Date:09/24/01ISR Number: 3801356-0Report Type:Periodic Company Report #WAES 01061191
Age:83 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/PRN/PO	
		Professional	Cartia (Diltiazem Hydrochloride)	C				
			Evista	C				
			Oxycontin	C				
			Cyclobenzaprine Hydrochloride	C				

Date:09/24/01ISR Number: 3801359-6Report Type:Periodic Company Report #WAES 01061202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801361-4Report Type:Periodic Company Report #WAES 01061203
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3801362-6Report Type:Periodic Company Report #WAES 01061235
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Congestive	Health Professional Company Representative						

Date:09/24/01ISR Number: 3801363-8Report Type:Periodic Company Report #WAES 01061260
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:09/24/01ISR Number: 3801366-3Report Type:Periodic Company Report #WAES 01061261
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Professional

Date:09/24/01ISR Number: 3801368-7Report Type:Periodic Company Report #WAES 01061262
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Oedema	Professional Company Representative						

Date:09/24/01ISR Number: 3801370-5Report Type:Periodic Company Report #WAES 01061263
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx	PS		ORAL	PO	
	Hypertension	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801371-7Report Type:Periodic Company Report #WAES 01061266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801372-9Report Type:Periodic Company Report #WAES 01061270
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Blood Pressure Increased		Norvasc	C				
	Cough		Premarin	C				
	Dizziness		Atenolol	C				
	Drug Ineffective							
	Headache							
	Micturition Disorder							
	Muscle Spasms							
	Nausea							
	Rhinorrhoea							

Date:09/24/01ISR Number: 3801373-0Report Type:Periodic Company Report #WAES 01061274
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lamisil	C				
			Paxil	C				
			Zantac	C				
			Oxycodone	C				

Date:09/24/01ISR Number: 3801375-4Report Type:Periodic Company Report #WAES 01061275
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Fatigue	Health Professional	Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3801376-6Report Type:Periodic Company Report #WAES 01061278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Drug Ineffective						MG/DAILY/PO	
	Weight Increased		Inderal	C				

Date:09/24/01ISR Number: 3801378-XReport Type:Periodic Company Report #WAES 01061282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50	
	Chest Pain						MG/DAILY/PO	
	Dyspepsia		Corticosteroids (Unspecified)	C				
	Dyspnoea							
	Flatulence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801381-XReport Type:Periodic Company Report #WAES 01061283
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
	Rectal Haemorrhage	Professional						

Date:09/24/01ISR Number: 3801383-3Report Type:Periodic Company Report #WAES 01061288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Musculoskeletal Pain		Benadryl	C				
	Oedema Peripheral		Plaquenil	C				
			Synthroid	C				
			Tylenol	C				
			Zocor	C				
			Acebutolol	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3801384-5Report Type:Periodic Company Report #WAES 01061294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:09/24/01ISR Number: 3801389-4Report Type:Periodic Company Report #WAES 01061297
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache	Consumer	Tab Vioxx 12.5 Mg	PS			ORAL
PO	10 DAY						
			Atenolol	C			

Date:09/24/01ISR Number: 3801390-0Report Type:Periodic Company Report #WAES 01061299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
			Maxzide	C		
			Plavix	C		
			Tiazac	C		
			Zantac	C		
			Zocor	C		

Date:09/24/01ISR Number: 3801391-2Report Type:Periodic Company Report #WAES 01061300
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
			Zyloprim	C		
			[Composition Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801393-6Report Type:Periodic Company Report #WAES 01061309
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801394-8Report Type:Periodic Company Report #WAES 01061310
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	
			Klonopin	C				
			Lorcet	C				
			Premarin	C				
			Prevacid	C				
			Prozac	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3801396-1Report Type:Periodic Company Report #WAES 01061312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	
			Soma	C				

Date:09/24/01ISR Number: 3801398-5Report Type:Periodic Company Report #WAES 01061315
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
	Headache						/ PO	
			Buspar	C				
			Mestinon	C				
			Prozac	C				
			Sinemet	C				
			[Therapy Unspecified]	C				
			Iron (Unspecified)	C				
			Vitamin B (Unspecified)	C				

Date:09/24/01ISR Number: 3801400-0Report Type:Periodic Company Report #WAES 01061316
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Alesse	C				
			Claritin-D	C				
			Hormonal Contraceptives (Unspeci	C				

Date:09/24/01ISR Number: 3801402-4Report Type:Periodic Company Report #WAES 01061318
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY / PO	

Date:09/24/01ISR Number: 3801405-XReport Type:Periodic Company Report #WAES 01061323
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	
	Dyspnoea							
	Fatigue		Chlordiazachel	C				
	Mouth Ulceration		Prevacid	C				
			Zocor	C				

Date:09/24/01ISR Number: 3801406-1Report Type:Periodic Company Report #WAES 01061325
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO, 50 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased							
			Coumadin	C				
			Plavix	C				
			(Therapy Unspecified)	C				
			Rifampin	C				

Date:09/24/01ISR Number: 3801407-3Report Type:Periodic Company Report #WAES 01061327
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Influenza Like Illness						MG/DAILY/PO	

Date:09/24/01ISR Number: 3801408-5Report Type:Periodic Company Report #WAES 01061331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Maxzide	C				

Date:09/24/01ISR Number: 3801410-3Report Type:Periodic Company Report #WAES 01061332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective						MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801412-7Report Type:Periodic Company Report #WAES 01061344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	12 DAY
	Drug Ineffective							

Date:09/24/01ISR Number: 3801414-0Report Type:Periodic Company Report #WAES 01061345
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	BID/PO	

Date:09/24/01ISR Number: 3801416-4Report Type:Periodic Company Report #WAES 01061354
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Doxepin	C				
			Methotrexate	C				

Date:09/24/01ISR Number: 3801417-6Report Type:Periodic Company Report #WAES 01061383
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Pain In Extremity		Altace	C				
			Caltrate 600 Plus					

				Vitamin D	C		
				Lipitor	C		
				Synthroid	C		
				Toprol Xl Tablets	C		
				Ascorbic Acid	C		
				Vitamin E	C		

Date:09/24/01ISR Number: 3801419-XReport Type:Periodic Company Report #WAES 01061386
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							

Date:09/24/01ISR Number: 3801421-8Report Type:Periodic Company Report #WAES 01061400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendon Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO, 25 MG/DAILY/PO	
			Actos	C				
			Paxil	C				
			Cimetidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801424-3Report Type:Periodic Company Report #WAES 01070509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

Date:09/24/01ISR Number: 3801426-7Report Type:Periodic Company Report #WAES 01070512
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Cardura	C				
			Lipitor	C				
			Norvasc	C				
			(Composition Unspecified)	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801428-0Report Type:Periodic Company Report #WAES 01070515
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO 4 DAY
			Requip	C				
			Sinemet	C				

Date:09/24/01ISR Number: 3801429-2Report Type:Periodic Company Report #WAES 01070529
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ogen	C				
			(Therapy Unspecified)	C				
			Thyroid	C				

Date:09/24/01ISR Number: 3801432-2Report Type:Periodic Company Report #WAES 01070538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801433-4Report Type:Periodic Company Report #WAES 01070567
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Depression							
	Weight Increased							

Date:09/24/01ISR Number: 3801435-8Report Type:Periodic Company Report #WAES 01070578
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hepatic Function Abnormal							
	Swelling		Meridia	C				
	Weight Increased		Prilosec	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Viagra	C				
			Xenical	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801436-XReport Type:Periodic Company Report #WAES 01070580
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801438-3Report Type:Periodic Company Report #WAES 01070599
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Back Pain		Aleve	C				
	Dysuria		Coumadin	C				
	Haematuria		Detrol	C				
	Urinary Incontinence		Lanoxin	C				
			Procardia Xl	C				
			Xalatan	C				
			Metoprolol	C				

			Ranitidine	C		

Date:09/24/01ISR Number: 3801439-5Report Type:Periodic Company Report #WAES 01070600
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tinnitus							
	Vision Blurred							
			Actos	C				
			Coreg	C				
			Coumadin	C				
			Digitek	C				
			Humulin N	C				
			Lipitor	C				
			Dextropropoxyphene	C				
			Furosemide	C				
			Gemfibrozil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801442-5Report Type:Periodic Company Report #WAES 01070604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Tab Vioxx	PS				

Date:09/24/01ISR Number: 3801443-7Report Type:Periodic Company Report #WAES 01070605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:09/24/01ISR Number: 3801444-9Report Type:Periodic Company Report #WAES 01070614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25	
	Oliguria						MG/DAILY/PO/S	

EE IMAGE

Date:09/24/01ISR Number: 3801445-0Report Type:Periodic Company Report #WAES 01070624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Company
Representative

Date:09/24/01ISR Number: 3801446-2Report Type:Periodic Company Report #WAES 01070632
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Pain		Fosamax	C				
			Zocor	C				

Date:09/24/01ISR Number: 3801447-4Report Type:Periodic Company Report #WAES 01070633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801448-6Report Type:Periodic Company Report #WAES 01070639
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801449-8Report Type:Periodic Company Report #WAES 01070640
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Influenza Like Illness							

Date:09/24/01ISR Number: 3801450-4Report Type:Periodic Company Report #WAES 01070641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Asacol	C				
			Prempro	C				

Date:09/24/01ISR Number: 3801451-6Report Type:Periodic Company Report #WAES 01070650
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Urine Abnormality		Zocor	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801456-5Report Type:Periodic Company Report #WAES 01062505
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Neurontin	C				

				Prozac	C		
				Analgesic Or Anesthetic (Unspeci	C		
				Prednisone	C		
				Vitamin E	C		
				Vitamins (Unspecified)	C		

Date:09/24/01ISR Number: 3801457-7Report Type:Periodic Company Report #WAES 01062591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	
	Pain							

Date:09/24/01ISR Number: 3801458-9Report Type:Periodic Company Report #WAES 01062599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lodine Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801460-7Report Type:Periodic Company Report #WAES 01062507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Depentum	C				
			Lotensin	C				
			Pravachol	C				
			Premarin	C				
			Insulin	C				

Date:09/24/01ISR Number: 3801461-9Report Type:Periodic Company Report #WAES 01062601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluid Retention							
	Oedema Peripheral							
	Weight Increased							

Date:09/24/01ISR Number: 3801463-2Report Type:Periodic Company Report #WAES 01062512
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Red Blood Cell Count	Health	Tab Vioxx	PS		ORAL	PO	
	Decreased	Professional						
	Thrombocytopenia							

Date:09/24/01ISR Number: 3801464-4Report Type:Periodic Company Report #WAES 01062602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801465-6Report Type:Periodic Company Report #WAES 01062514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypersensitivity	Professional Company Representative	Aspirin	C				

Date:09/24/01ISR Number: 3801467-XReport Type:Periodic Company Report #WAES 01062604
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Flexeril	C				
			Levoxyl	C				
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801469-3Report Type:Periodic Company Report #WAES 01062606
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801470-XReport Type:Periodic Company Report #WAES 01062542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO;	
	Drug Ineffective	Company Representative					25 MG/DAILY/PO	
	Oedema							
			Celebrex	C				
			Aspirin	C				

Date:09/24/01ISR Number: 3801472-3Report Type:Periodic Company Report #WAES 01062608
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801473-5Report Type:Periodic Company Report #WAES 01062568
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abnormal Faeces	Consumer	Tab Vioxx 50mg	PS		ORAL
50						
MG/DAILY/PO						
			Hydrodiuril	C		
			Premarin	C		
			Tenormin	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3801475-9Report Type:Periodic Company Report #WAES 01062612
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Asthenia	Health				
MG/BID/PO						
	Fatigue	Professional	Dyazide	C		
	Insomnia		Lipitor	C		
	Malaise		Ogen	C		
	Nervousness		Prilosec	C		
			Singulair	C		
			Synthroid	C		
			Tenormin	C		
			Tylenol	C		
			Alprazolam	C		
			Ascorbic Acid	C		
			Aspirin	C		
			Calcium (Unspecified)	C		
			Folic Acid	C		
			Vitamin B	C		
			Vitamin E	C		

				Vitamins	C		

Date:09/24/01ISR Number: 3801477-2Report Type:Periodic Company Report #WAES 01062569
Age:81 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Evista	C				
			Prevacid	C				
			Lorazepam	C				
			Verapamil Hydrochloride	C				
			Vitamin D (Unspecified)	C				

Date:09/24/01ISR Number: 3801478-4Report Type:Periodic Company Report #WAES 01062616
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Erythema		Evista	C				
	Oedema Peripheral							
	Skin Hypopigmentation							

Date:09/24/01ISR Number: 3801480-2Report Type:Periodic Company Report #WAES 01062621
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Oedema							
	Urinary Tract Disorder							

Date:09/24/01ISR Number: 3801481-4Report Type:Periodic Company Report #WAES 01062574
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Rofecoxib	PS		ORAL	PO	
			Tab Ultram 50 Mg	SS		ORAL	10 MG/Q12H/PO; 50 MG/TID/PO	
			Amlodipine	C				
			Atracurium Besylate	C				
			Lansoprazole	C				

Date:09/24/01ISR Number: 3801483-8Report Type:Periodic Company Report #WAES 01062623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801484-XReport Type:Periodic Company Report #WAES 01062579
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Faeces Discoloured							
	Haemorrhage		Celexa	C				
	Ulcer		Claritin	C				
			Flonase	C				
			Flovent	C				
			Neurontin	C				
			Nitrostat	C				
			Prempro	C				
			Zanaflex	C				
			Albuterol	C				
			Bumetanide	C				
			Potassium Chloride	C				
			Prednisone	C				
			Timolol	C				

Date:09/24/01ISR Number: 3801485-1Report Type:Periodic Company Report #WAES 01062627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Altace	C				
			Diovan	C				
			Insulin	C				

Date:09/24/01ISR Number: 3801487-5Report Type:Periodic Company Report #WAES 01062633
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	1 MON

Date:09/24/01ISR Number: 3801488-7Report Type:Periodic Company Report #WAES 01062590
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Periostat	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3801491-7Report Type:Periodic Company Report #WAES 01062634
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
			Fosamax	C				

Date:09/24/01ISR Number: 3801492-9Report Type:Periodic Company Report #WAES 01062638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY PO	
	Rash							

Atenol	C
Synthroid	C
Aspirin	C
Vitamins (Unspecified)	C

Date:09/24/01ISR Number: 3801493-0Report Type:Periodic Company Report #WAES 01070652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:09/24/01ISR Number: 3801494-2Report Type:Periodic Company Report #WAES 01070654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash		Estrogens	C				

Date:09/24/01ISR Number: 3801495-4Report Type:Periodic Company Report #WAES 01062642
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Tab Vioxx 50 Mg	PS			50 MG	
	Asthenia							
	Chest Pain							
	Depression							
	Dysphoria							
	Fatigue							
	Fluid Retention							
	Hepatic Pain							
	Insomnia							
	Pruritus							

Date:09/24/01ISR Number: 3801497-8Report Type:Periodic Company Report #WAES 01062651
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
		Company Representative	Prinivil	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3801498-XReport Type:Periodic Company Report #WAES 01070658
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL		
PO								
	Oedema Peripheral		Caltrate	C				

			Novex	C
			Prevacid	C
			Serevent	C
			Oxygen	C

Date:09/24/01ISR Number: 3801500-5Report Type:Periodic Company Report #WAES 01062654
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Dizziness						PO	
	Fatigue		Avapro	C				
	Hypokinesia		Hydrodiuril	C				
	Influenza		Lipitor	C				
	Pain		Prempro	C				
	Vertigo		Prevacid	C				
			Alprazolam	C				

Date:09/24/01ISR Number: 3801501-7Report Type:Periodic Company Report #WAES 01062655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
	Joint Range Of Motion Decreased		Naproxen	C				
	Musculoskeletal Stiffness							

Date:09/24/01ISR Number: 3801504-2Report Type:Periodic Company Report #WAES 01062656
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Oedema		Prempro	C				
			Restoril	C				

			Calcium (Unspecified)	C		
			Vitamin E	C		

Date:09/24/01ISR Number: 3801505-4Report Type:Periodic Company Report #WAES 01062659
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Premarin	C				
			Calcium (Unspecified)	C				
			Chondroitin (+) Glucosamine	C				
			Vitamin B Complex	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801507-8Report Type:Periodic Company Report #WAES 01062691
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Headache							
	Nausea		Atenolol	C				
			Hydrochlorothiazide (+) Triamterene	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3801510-8Report Type:Periodic Company Report #WAES 01062692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801511-XReport Type:Periodic Company Report #WAES 01062708
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Activity	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Decreased Appetite	Professional	Effexor	C				
	Somnolence							

Date:09/24/01ISR Number: 3801512-1Report Type:Periodic Company Report #WAES 01070665
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Constipation							

	Dizziness		Detrol	C

Date:09/24/01ISR Number: 3801514-5Report Type:Periodic Company Report #WAES 01062709
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Claritin	C				
			Fosamax	C				
			Lanoxin	C				
			Synthroid	C				
			Furosemide	C				
			Propranolol	C				

Date:09/24/01ISR Number: 3801515-7Report Type:Periodic Company Report #WAES 01070666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Professional						
			Niferex Forte	C				
			Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801516-9Report Type:Periodic Company Report #WAES 01070004
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3801518-2Report Type:Periodic Company Report #WAES 01070005
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Pravachol	C				
			Aspirin	C				
			Atenolol	C				
			Phenobarbital	C				

Date:09/24/01ISR Number: 3801519-4Report Type:Periodic Company Report #WAES 01070668
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Arthrotec	C				
			Lipitor	C				
			Lotrel	C				
			Prilosec	C				

Date:09/24/01ISR Number: 3801522-4Report Type:Periodic Company Report #WAES 01070006
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Pruritus						MG/DAILY/PO	
	Rash		Hydro-Diuril	C				
			Norvasc	C				
			Premarin	C				
			Prilosec	C				

Date:09/24/01ISR Number: 3801523-6Report Type:Periodic Company Report #WAES 01070669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Phosphokinase Increased	Health					MG/DAILY/PO	
	Hyperkalaemia	Professional	Axid Unk	SS				
			Coumadin	C				
			Lipitor	C				
			Allopurinol	C				
			Sotalol Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801526-1Report Type:Periodic Company Report #WAES 01070017
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx 25 Mg	PS			UNKNOWN	25 MG/DAILY
		Professional Company Representative	[Therapy Unspecified	C				

Date:09/24/01ISR Number: 3801527-3Report Type:Periodic Company Report #WAES 01070671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
	Paraesthesia							
			Lanoxin	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Indapamine	C				
			Methrotrexate	C				

Date:09/24/01ISR Number: 3801528-5Report Type:Periodic Company Report #WAES 01070018
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pharyngitis		Synthroid	C				

Date:09/24/01ISR Number: 3801530-3Report Type:Periodic Company Report #WAES 01070677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Health	Tab Vioxx Unk	PS			ORAL
PO							
		Professional Company Representative					

Date:09/24/01ISR Number: 3801531-5Report Type:Periodic Company Report #WAES 01070709
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
MG/DAILY/PO								
			Tylenol	C				

Date:09/24/01ISR Number: 3801532-7Report Type:Periodic Company Report #WAES 01070025
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25mg	PS		ORAL	25	
	Rash	Professional						
MG/DAILY/PO								
	Urticaria		Cardura	C				
			Dilacor Xr	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801533-9Report Type:Periodic Company Report #WAES 01070031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			Estrogens (Unspecified)	C				
			Glucosamine	C				

Date:09/24/01ISR Number: 3801534-0Report Type:Periodic Company Report #WAES 01062247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Calan	C				
			Diazide	C				
			K-Dur	C				
			Lasix (Furosemide)	C				
			Lescol	C				

Date:09/24/01ISR Number: 3801535-2Report Type:Periodic Company Report #WAES 01070036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801537-6Report Type:Periodic Company Report #WAES 01062252
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Allegra	C				
			Premarin	C				

			Dapsone	C		

Date:09/24/01ISR Number: 3801538-8Report Type:Periodic Company Report #WAES 01070040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				

Date:09/24/01ISR Number: 3801539-XReport Type:Periodic Company Report #WAES 01070043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prozac	C				
			[Therapy Unspecified]	C				
			Albuterol	C				
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801540-6Report Type:Periodic Company Report #WAES 01062255
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Isordil	C				
			Zestril	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801541-8Report Type:Periodic Company Report #WAES 01070046
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/ DAILY / PO	

Date:09/24/01ISR Number: 3801542-XReport Type:Periodic Company Report #WAES 01062257
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Irritability							
			Meridia 10 Mg	SS		ORAL	10 MG/DAILY/PO	
			Aciphex	C				
			Flonase	C				
			Lipitor	C				
			Zyrtec	C				
			Atenolol	C				

Date:09/24/01ISR Number: 3801543-1Report Type:Periodic Company Report #WAES 01070048
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3801545-5Report Type:Periodic Company Report #WAES 01062259
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Fatigue		Norvasc	C				
	Muscular Weakness		Tapazole	C				

Date:09/24/01ISR Number: 3801546-7Report Type:Periodic Company Report #WAES 01070049
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG / DAILY / PO	
		Company Representative	Brevital Sodium	C				
			Versed	C				
			Fentanyl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801547-9Report Type:Periodic Company Report #WAES 01062260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Drug Ineffective							
	Dyspepsia							
	Nausea							
	Vertigo							

Date:09/24/01ISR Number: 3801548-0Report Type:Periodic Company Report #WAES 01070051
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional Company Representative	Vioxx	PS		ORAL	PO	
	Gastrointestinal Haemorrhage		[Therapy Unspecified] Unk	SS				

Date:09/24/01ISR Number: 3801549-2Report Type:Periodic Company Report #WAES 01062268
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801550-9Report Type:Periodic Company Report #WAES 01070053
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal	Health	Vioxx	PS		ORAL
PO						
	Haemorrhage	Professional Company Representative	[Therapy Unspecified]	C		

Date:09/24/01ISR Number: 3801551-0Report Type:Periodic Company Report #WAES 01062277
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Rash							
MG/DAILY/PO								

Date:09/24/01ISR Number: 3801552-2Report Type:Periodic Company Report #WAES 01062278
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Erosive	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
MG/DAILY/PO								
			Detrol	C				
			Hydrodiuril	C				
			Zocor	C				
			Aspirin	C				
			Glyburide	C				
			Metoprolol	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801553-4Report Type:Periodic Company Report #WAES 01062279
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dizziness						MG/DAILY/PO	
	Hearing Impaired		Effexor Xr	C				
			Evista	C				
			Fosamax	C				

Date:09/24/01ISR Number: 3801554-6Report Type:Periodic Company Report #WAES 01062280
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Accupril	C				
			Levoxyl	C				
			Ocuflox	C				
			Hydrochlorothiaxide (+)Triamter	C				

Date:09/24/01ISR Number: 3801555-8Report Type:Periodic Company Report #WAES 01062287
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Chest Pain						MG/DAILY/PO	
	Gastrooesophageal Reflux Disease		Lipitor	C				
			Prilosec	C				
	Hiatus Hernia		Synthroid	C				
			Timoptic	C				
			Xalatan	C				

Date:09/24/01ISR Number: 3801556-XReport Type:Periodic Company Report #WAES 01062288
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO,	
	Drug Ineffective						50MG/DAILY/PO	
			Claritin	C				
			Gastrocrom	C				
			Ortho-Prefest	C				
			Zantac	C				
			Naproxen	C				

Date:09/24/01ISR Number: 3801557-1Report Type:Periodic Company Report #WAES 01062295
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801558-3Report Type:Periodic Company Report #WAES 01062318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG /DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3801559-5Report Type:Periodic Company Report #WAES 01062319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchospasm	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 WK
		Company Representative						

Date:09/24/01ISR Number: 3801560-1Report Type:Periodic Company Report #WAES 01062323
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx 12.5 Mg, Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO SEE IMAGE	

Date:09/24/01ISR Number: 3801561-3Report Type:Periodic Company Report #WAES 01062329
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Celexa	C				

Date:09/24/01ISR Number: 3801562-5Report Type:Periodic Company Report #WAES 01062331
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	6 MON
			Diovan	C				
			Premarin	C				
			Synthroid	C				

Date:09/24/01ISR Number: 3801700-4Report Type:Periodic Company Report #WAES 01062333
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Covera-Hs	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801706-5Report Type:Periodic Company Report #WAES 01062335
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fatigue							
	Sinus Disorder		Dyazide	C				

Date:09/24/01ISR Number: 3801708-9Report Type:Periodic Company Report #WAES 01062338
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Cyst	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Renal Cyst		Neurontin	C				

Date:09/24/01ISR Number: 3801711-9Report Type:Periodic Company Report #WAES 01062343
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	2 YR
	Gastrooesophageal Reflux Disease		Celexa	C				
			Synthroid	C				
	Tinnitus		Wellbutrin	C				
			Doxepin Hydrochloride	C				
			Estrogens (Unspecified)	C				

Date:09/24/01ISR Number: 3801716-8Report Type:Periodic Company Report #WAES 01062345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Avapro	C		

Date:09/24/01ISR Number: 3801718-1Report Type:Periodic Company Report #WAES 01062346
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Lidex	C		
			Pragmazone	C		
			Prempro	C		
			Sinutab Regular Strength Tablets	C		
			Synthroid	C		
			Tylenol	C		

Date:09/24/01ISR Number: 3801720-XReport Type:Periodic Company Report #WAES 01062347
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Actigall	C		
			Calderol	C		

				Diazide	C		
				Lopressor	C		
				Premarin	C		
				Prevacid	C		
				Tagamet	C		
				Folic Acid	C		

Date:09/24/01ISR Number: 3801721-1Report Type:Periodic Company Report #WAES 01062349
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ogen	C				
			Synthroid	C				
			Zocor	C				
			Ranitidine	C				

Date:09/24/01ISR Number: 3801724-7Report Type:Periodic Company Report #WAES 01062351
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Klonopin	C				
			Neurontin	C				
			Prozac	C				
			Wellbutrin	C				
			[Therapy Unspecified]	C				

Date:09/24/01ISR Number: 3801726-0Report Type:Periodic Company Report #WAES 01062352
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Timoptic	C				
			Antineoplastic (Unspecified)	C				

Date:09/24/01ISR Number: 3801801-0Report Type:Periodic Company Report #WAES 01062353
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx	PS		ORAL	PO	1 MON
	Pharyngitis		Darvocet-N	C				
	Rhinorrhoea		Ogen	C				
	Throat Tightness		Thyrolar	C				

Date:09/24/01ISR Number: 3801803-4Report Type:Periodic Company Report #WAES 01062355
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801804-6Report Type:Periodic Company Report #WAES 01062356
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801806-XReport Type:Periodic Company Report #WAES 01062362
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801807-1Report Type:Periodic Company Report #WAES 01062364
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx	PS		ORAL	12.5 OR 25 MG/DAILY/PO	
	Epistaxis							
	Haematocrit Decreased		Imdur	C				
	Red Blood Cell Count Decreased		Norvasc	C				
			Atenolol	C				
	Thrombocytopenia		Nonsteroidal Anti-Inflammatory	C				

Date:09/24/01ISR Number: 3801809-5Report Type:Periodic Company Report #WAES 01062365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Neuralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Lipitor	C		
			Calcium (Unspecified)	C		

Date:09/24/01ISR Number: 3801810-1Report Type:Periodic Company Report #WAES 01062372
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastritis	Health Professional						
	Oedema Peripheral							

Date:09/24/01ISR Number: 3801812-5Report Type:Periodic Company Report #WAES 01062378
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
			Arthrotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801813-7Report Type:Periodic Company Report #WAES 01062383
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Diarrhoea	Professional						
	Epigastric Discomfort	Company						
	Nausea	Representative						

Date:09/24/01ISR Number: 3801815-0Report Type:Periodic Company Report #WAES 01062427
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:09/24/01ISR Number: 3801818-6Report Type:Periodic Company Report #WAES 01062428
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Asacol	C				
			Atrovent	C				
			Flovent	C				
			Synthroid	C				
			Atenolol	C				
			Betamethasone Clobetasol Propionate	C				
			Fluconazole	C				
			Hydrochlorothiazide (+) Trimaterene	C				
			Ketoconazole	C				

			Labetaolol Hydrochloride	C		
			Methocarbamaol	C		
			Quinine Sulfate	C		

Date:09/24/01ISR Number: 3801820-4Report Type:Periodic Company Report #WAES 01062430
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Swelling							
			Fosamax	C				
			Synthroid	C				
			Zocor	C				
			Enalapril Maleate	C				

Date:09/24/01ISR Number: 3801821-6Report Type:Periodic Company Report #WAES 01062431
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Hepatic Function Abnormal		Estraderm	C				
			Provera	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801823-XReport Type:Periodic Company Report #WAES 01062439
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Cyclobenzaprine Hcl 10 Mg	SS		ORAL	10 MG/HS/PO	

Date:09/24/01ISR Number: 3801824-1Report Type:Periodic Company Report #WAES 01062481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Company Representative Other	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801826-5Report Type:Periodic Company Report #WAES 01062485
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:09/24/01ISR Number: 3801827-7Report Type:Periodic Company Report #WAES 01062487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hormones					

			(Unspecified)	C		

Date:09/24/01ISR Number: 3801829-0Report Type:Periodic Company Report #WAES 01062488
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health	Tab Vioxx	PS		ORAL	PO	
	Visual Acuity Reduced	Professional	Benadryl	C				
			Fosamax	C				
			Hydrodiuril	C				
			Lomotil	C				
			Ocupress	C				
			Prempro	C				
			Trusopt	C				
			Xalatan	C				
			Methotrexate	C				
			Pilocarpine	C				

Date:09/24/01ISR Number: 3801831-9Report Type:Periodic Company Report #WAES 01062498
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Steatorrhoea	Health	Hydrodiuril	C				
	Weight Increased	Professional	Premarin	C				
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3801833-2Report Type:Periodic Company Report #WAES 10162499
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Upper Respiratory Tract Infection		Claritin	C				

Date:09/24/01ISR Number: 3804472-2Report Type:Periodic Company Report #WAES 01071834
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:09/24/01ISR Number: 3804474-6Report Type:Periodic Company Report #WAES 01071835
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Health Professional	Celebrex	C				
			Vitamins (Unspecified)	C				

Date:09/24/01ISR Number: 3804475-8Report Type:Periodic Company Report #WAES 01071836
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

				Estrace	C	
				Maxzide	C	
				Synthroid	C	
				Potassium Chloride	C	

Date:09/24/01ISR Number: 3804477-1Report Type:Periodic Company Report #WAES 01071837
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Dysgeusia		Advil	C				
	Nausea							
	Olfactory Nerve Disorder							

Date:09/24/01ISR Number: 3804478-3Report Type:Periodic Company Report #WAES 01071838
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PRN/PO	
	Diarrhoea		Ativan	C				
			Mobic	C				
			Nexium	C				
			Prilosec	C				
			Herbs	C				
			Minerals	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/01ISR Number: 3804499-0Report Type:Periodic Company Report #WAES 01071843
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Estrogens	C				

Date:09/24/01ISR Number: 3804500-4Report Type:Periodic Company Report #WAES 01071844
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
			Celestone	C			PO	

Date:09/24/01ISR Number: 3804502-8Report Type:Periodic Company Report #WAES 01071846
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Hypoacusis		Pravachol	SS				
	Hypoaesthesia		Flovent	C				
	Memory Impairment		Nexium	C				
	Visual Disturbance		Zocor	C				

Date:09/24/01ISR Number: 3805294-9Report Type:Periodic Company Report #WAES 01062272
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:09/24/01ISR Number: 3808771-XReport Type:Periodic Company Report #WAES 01060344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accuretic	C				
			Allegra	C				
			Celebrex	C				
			Inderal	C				
			Lipitor	C				

Date:09/24/01ISR Number: 3813113-XReport Type:Periodic Company Report #NSADSS2001018862
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Hypertension	Health Professional	Remicade (5 Mg/Ml Lyophilized Powder) (Infliximab, Recombinant)	PS	Centocor	INTRAVENOUS	IV	
			Vioxx (Rofecoxib)	SS				
			Prednisone (Prednisone)	C				
			Mtx (Methotrexate Sodium)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/01ISR Number: 3798150-6Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Platelet Count Decreased		Celebrex (200 Mg) -					
Hospitalization -			11-20- 1 1/2 Mths	PS				
1 A DAY							2	MON
Initial or Prolonged			Vioxx 25					
			1-12-01-03-23-01	SS				
1 A DAY								

Date:09/25/01ISR Number: 3799146-0Report Type:Expedited (15-DaCompany Report #2001-NO-00020
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Persantine					
Initial or Prolonged	Duodenal Ulcer	Other	Tablets/200	PS				
200/TWICE								
DAILY/NR							4	MON
			Vioxx	SS		ORAL		
50 MG/PO								
			Albyl E	SS		ORAL		
160 MG/PO								

Date:09/25/01ISR Number: 3800005-5Report Type:Expedited (15-DaCompany Report #001-0981-M0107668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm	Consumer	Atorvastatin					
Initial or Prolonged	Cardiac Valve Disease		(Atorvastatin)	PS				
Other	Pain		(Celecoxib)	SS				
	Vulval Disorder		(Rofecoxib)	SS				

Date:09/25/01ISR Number: 3800775-6Report Type:Expedited (15-DaCompany Report #2001073354US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Aneurysm	Other	Celebrex (Celecoxib) Capsule	PS				
Other	Vulval Disorder		Lipitor (Atorvastatin)	SS				
			Vioxx ()	SS				

Date:09/26/01ISR Number: 3798774-6Report Type:Direct Company Report #
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria		Warfarin 5 MG QD	PS				
			Rofecoxib	SS				
			Digoxin	C				
			Ipratropium	C				
			Metoprolol	C				
			Adalat Cc	C				

Date:09/26/01ISR Number: 3799170-8Report Type:Expedited (15-DaCompany Report #2001068668US
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Other	Alanine Aminotransferase Increased
	Aspartate Aminotransferase

	Blood Alkaline Phosphatase Increased Liver Function Test	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abnormal Nephrotic Syndrome	Health Professional	Ambien (Zolpidem Tartrate) Tablet	PS		ORAL	10 MG, QOD, ORAL
			Celexa (Citalopram Hydrobromide)	SS		ORAL	20 MG, QD, ORAL
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, QD, ORAL
			Simvastatin (Simvastatin)	C			
			Enalapril (Enalapril)	C			
			Cyclophosphamide	C			
			Furosemide	C			
			Halcion	C			

Date:09/26/01ISR Number: 3799396-3Report Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS		ORAL	25 MG PO QD
Initial or Prolonged	Non-Insulin-Dependent						(PRIOR TO
	Gastrointestinal						ADM)
	Haemorrhage		Celebrex	SS		ORAL	200 MG PO QD
	Hypotension						(PRIOR TO
	Myocardial Infarction						ADM)

Date:09/26/01ISR Number: 3800164-4Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS		ORAL	25MG PO QD	
Hospitalization -	Haemorrhage		Coumadin	SS			1MG QD	
Initial or Prolonged			Lopressor	C				
Required			Prozac	C				
Intervention to			Lanoxin	C				
Prevent Permanent			Vancomycin	C				
Impairment/Damage			Tylenol	C				
			Darvocet N	C				
			Prevacid	C				

Date:09/26/01ISR Number: 3800286-8Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS		ORAL	25 MG/ QD/	
Initial or Prolonged	Rectal Haemorrhage							
ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/01ISR Number: 3801713-2Report Type:Direct Company Report #
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Rofecoxib 25mg Merck	PS	Merck	ORAL	1T QD PO	

Date:09/27/01ISR Number: 3801775-2Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bacteria Sputum	Foreign	Leflunomide	PS		ORAL	10 VS 20 MG	
Initial or Prolonged	Identified	Study					PO	106 DAY
Disability	Cardiac Disorder	Health	Vioxx	SS		ORAL	25 MG QD PO	59 DAY
Other	Cystitis Escherichia	Professional	Marcumar	C				
	Haemophilus Infection	Other	Zocor	C				
	Interstitial Lung Disease		Furosemide	C				
	Left Ventricular Failure		Aldactone	C				
	Pneumonia		---Proxin	C				
	Respiratory Failure		Sotalol	C				
	Staphylococcal Infection		Lasix	C				
	Ventricular Fibrillation		Seresta	C				
	Ventricular Tachycardia		Prednison	C				
			Atrovent	C				
			Normison	C				

Date:09/28/01ISR Number: 3801736-3Report Type:Expedited (15-DaCompany Report #WAES 01092933
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cyst	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
		Professional					PO	
		Company Representative						

Date:09/28/01ISR Number: 3802044-7Report Type:Direct Company Report #
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Chest Pain		Vioxx	PS		
ONCE DAILY						
	Condition Aggravated					
	Gastrooesophageal Reflux Disease					
	Mitral Valve Prolapse					
	Palpitations					
	Ulcer					

Date:10/01/01ISR Number: 3802317-8Report Type:Direct Company Report #
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Fluid Retention		Vioxx	PS		
25 MG ONCE						
	Oedema Peripheral					
DAILY 6 MON						
	Pleural Effusion		Ventolin Inhaler	C		
	Weight Increased		Albuterol	C		
			Lasix	C		
			Potassium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3802328-2Report Type:Expedited (15-DaCompany Report #WAES 01062513
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Dialysis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
Initial or Prolonged	Eosinophil Count	Health	Lipitor	C				
	Increased	Professional	Norvasc	C				
	Glomerulonephritis		Prinivil	C				
	Haemorrhage		Verelan	C				
	Lung Infiltration							
	Pyrexia							
	Renal Failure Acute							
	Tremor							
	Vasculitis Necrotising							

Date:10/01/01ISR Number: 3802330-0Report Type:Expedited (15-DaCompany Report #WAES 01091892
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO, 25 MG/PO	
	Condition Aggravated	Professional	Arthrotec	C				
	Gastritis		Claritin	C				
	Oedema Peripheral		Premarin	C				
	Palpitations		Prilosec	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Tussionex	C				
			Cephalexin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:10/01/01ISR Number: 3802331-2Report Type:Expedited (15-DaCompany Report #WAES 01092105
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis	Health	Tav Vioxx 50 Mg	PS		ORAL	50	

Initial or Prolonged		Haematoma	Professional				
MG/DAILY/PO							
		Post Procedural Haemorrhage Vomiting	Company Representative	Lasix (Furosemide)	C		

Date:10/01/01ISR Number: 3802332-4Report Type:Expedited (15-DaCompany Report #WAES 01083065
Age:81 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Coagulopathy	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Other		International Normalised	Professional				
MG/DAILY/PO							
		Ratio Increased	Company Representative	Coumadin (Therapy Unspecified)	C C		

Date:10/01/01ISR Number: 3802333-6Report Type:Expedited (15-DaCompany Report #WAES 01092218
Age:93 YR Gender:Female I/FU:I

Outcome	PT
Other	Aphasia
	Disorientation
	Hypertension

	Speech Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
			Prilosec	C			
			Zoloft	C			
			Zyrtec	C			
			Aspirin	C			
			Thyroid	C			

Date:10/01/01ISR Number: 3802341-5Report Type:Expedited (15-DaCompany Report #WAES 01092092
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Choking Sensation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO
	Oedema Peripheral						
			Prilosec	C			
			Procardia Xl	C			
			Methylphenidate	C			
			Trazodone	C			

Date:10/01/01ISR Number: 3803068-6Report Type:Expedited (15-DaCompany Report #WAES 01086021
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abortion Spontaneous	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO 7 DAY
	Complications Of Maternal	Other					
	Exposure To Therapeutic Drugs		Acetaminophen	C			
			Alprazolam	C			
			Hormonal Contraceptives (Unspecified)	C			

Date:10/01/01ISR Number: 3803070-4Report Type:Expedited (15-DaCompany Report #WAES 01093711
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged								
PO								199 DAY
			Tab Aspirin	SS		ORAL	80 MG/DAILY	
PO								
			Betahistine Hydrochloride	C				
			Oxazepam	C				
			Vitamin A	C				

Date:10/01/01ISR Number: 3803071-6Report Type:Expedited (15-DaCompany Report #WAES 01096073
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Gastritis Erosive	Other	(Rofecoxib)	PS		ORAL		
PO								9 DAY
			Buflomedil Hcl	C				
			Furosemide/Spironolactone	C				

			Gliclazide	C		
			Lorazepam	C		
			Molsidomine	C		
			Ranitidine Hcl	C		

Date:10/01/01ISR Number: 3803072-8Report Type:Expedited (15-DaCompany Report #WAES 01096076
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Fibrillation Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
PO 5 YR						
			Aspirin	C		
			Metformin	C		
			Pentoxifylline	C		

Date:10/01/01ISR Number: 3803073-XReport Type:Expedited (15-DaCompany Report #WAES 01097050
Age:96 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Upper Gastrointestinal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Haemorrhage					
PO						
			Propecia	C		
			Citalopram Hydrobromide	C		
			Lactulose	C		

Date:10/01/01ISR Number: 3803259-4Report Type:Expedited (15-DaCompany Report #WAES 01093504
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angina Pectoris Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		

Date:10/01/01ISR Number: 3803260-0Report Type:Expedited (15-DaCompany Report #WAES 01096083
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:10/01/01ISR Number: 3803262-4Report Type:Expedited (15-DaCompany Report #WAES 01095131
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ecchymosis	Foreign	Tab Vioxx					
	Oedema Peripheral	Other	(Rofecoxib)	PS		ORAL	28 DAY	
			Tab Vioxx (Rofecoxib)	SS		ORAL	12.5 MG/DAILY	27 DAY
			Acetaminophen	C				
			Chloroquineso4	C				
			Paroxetine Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3803263-6Report Type:Expedited (15-DaCompany Report #WAES 01055008
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bacterial Infection	Foreign	Tab Vioxx					
Hospitalization -	Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Perforation		Acetaminophen	C				
	Pneumonia		Calcium Carbonate	C				
	Renal Failure		Prednisolone	C				
	Sepsis							

Date:10/01/01ISR Number: 3803304-6Report Type:Expedited (15-DaCompany Report #WAES 01098755
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	12.5 MG	
		Professional						
							/DAILY	

Date:10/01/01ISR Number: 3803306-XReport Type:Expedited (15-DaCompany Report #WAES 01096048
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malaise	Foreign	Tab Vioxx					
	Ventricular Fibrillation	Other	(Rofecoxib)	PS		ORAL	12.5 MG /BID	5 DAY
			Vasotec	C				
			Acebutolol	C				
			Acenocoumarol	C				
			Furosemide	C				
			Nilutamide	C				

Date:10/01/01ISR Number: 3804117-1Report Type:Expedited (15-DaCompany Report #WAES 01080248
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Corneal Ulcer	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Injury	Professional						
Other	Retinal Disorder	Company						
	Ulcer	Representative						

Date:10/01/01ISR Number: 3804118-3Report Type:Expedited (15-DaCompany Report #WAES 01091989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:10/01/01ISR Number: 3804119-5Report Type:Expedited (15-DaCompany Report #WAES 01092540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Consumer	Vioxx	PS		ORAL	PO	
	Chest Pain							
	Oedema							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3804120-1Report Type:Expedited (15-DaCompany Report #WAES 01092529
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:10/01/01ISR Number: 3804121-3Report Type:Expedited (15-DaCompany Report #WAES 01091990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer Company Representative	Vioxx	PS		ORAL	PO	

Date:10/01/01ISR Number: 3804128-6Report Type:Expedited (15-DaCompany Report #WAES 01092427
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:10/01/01ISR Number: 3804129-8Report Type:Expedited (15-DaCompany Report #WAES 01092426
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company	Tab Vioxx	PS		ORAL	PO	

Representative

Date:10/01/01ISR Number: 3804130-4Report Type:Expedited (15-DaCompany Report #WAES 01092380
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged Disability								

Date:10/01/01ISR Number: 3804139-0Report Type:Expedited (15-DaCompany Report #WAES 01092498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Company Representative	Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/01ISR Number: 3804154-7Report Type:Expedited (15-DaCompany Report #WAES 01092598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:10/01/01ISR Number: 3804163-8Report Type:Expedited (15-DaCompany Report #WAES 01092507
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Health	Vioxx	PS		ORAL	25	
Other	Congestive	Professional					MG/DAILY/PO	
	Fluid Retention	Company	Accupril	C				
	Insomnia	Representative	Cardizem Cd	C				
	Renal Failure		Lanoxin	C				
			Lasix (Furosemide)	C				
			Os-Cal	C				
			Plaquenil	C				
			Zantac	C				
			Colchicine	C				
			Doxepin	C				
			Glyburide	C				
			Prednisone	C				
			Temazepam	C				

Date:10/01/01ISR Number: 3804164-XReport Type:Expedited (15-DaCompany Report #WAES 01083061
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased	Health	Vioxx	PS		ORAL	25	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Aciphex	C				

Other	International Normalised Ratio Increased	Representative	Coumadin	C
			Humulin N	C
			Humulin R	C
			Lasix (Furosemide)	C
			Neurontin	C
			Serevent	C
			Singulair	C

Date:10/01/01ISR Number: 3804165-1Report Type:Expedited (15-DaCompany Report #WAES 01091201
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Drug Level Below Therapeutic	Professional						
	Medication Error		Dilantin	C				

Date:10/01/01ISR Number: 3804292-9Report Type:Expedited (15-DaCompany Report #WAES 01082531
Age:89 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Arrhythmia	Professional					MG/DAILY/PO	
	Blood Culture Positive	Company	Ns Miacalcin 1 Dose	SS			1 DOSE/DAILY/	
	Dyspepsia	Representative	Calcium 600 Mg	SS			600 MG/BID/	
	Fungal Infection		Cardizem Cd	C				
	Hypercalcaemia		Isordil	C				
	Hypertension		Metamucil	C				
	Hypovolaemia		Prevacid	C				
	Infection		Tylenol Arthritis					
	Mental Impairment		Extended Relie	C				
	Myelodysplastic Syndrome							
	Oesophagitis							
	Pleural Effusion							
	Renal Failure Acute							
	Urinary Tract Infection							

Date:10/01/01ISR Number: 3804302-9Report Type:Expedited (15-DaCompany Report #WAES 01082715
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Feeling Abnormal						MG/DAILY/PO	
			Prozac	C				
			Amitriptyline Hydrochloride	C				
			Phenobarbital	C				

Date:10/01/01ISR Number: 3804303-0Report Type:Expedited (15-DaCompany Report #WAES 01090096
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dizziness Heart Rate Decreased Lethargy Nausea Pulmonary Oedema Swelling	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						

Date:10/02/01ISR Number: 3802663-8Report Type:Expedited (15-DaCompany Report #WAES 01100033
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Myocardial Infarction		Vioxx Lipitor [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL

Date:10/02/01ISR Number: 3802664-XReport Type:Expedited (15-DaCompany Report #WAES 01100007
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebrovascular Accident Paralysis		Vioxx Coumadin	PS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/01ISR Number: 3803279-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS		ORAL	25 PO QD	
			Physical Therapy	C				

Date:10/02/01ISR Number: 3803406-4Report Type:Direct Company Report #
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS			25MG QD	4 DAY
Initial or Prolonged	Haematemesis		Ibuprofen (Otc)	SS			600MG QD ?	
			Aspirin	SS			650 Q 4 HR	

Date:10/02/01ISR Number: 3803407-6Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Pain		Vioxx	PS			50 QD	5 MON
Initial or Prolonged	Haematemesis		Ibuprofen (400 Q6h)	SS			400 Q 6H PRN	3 MON
	Haematuria		Apap	C				
			Felodipine	C				
			Cytotec	C				
			Atorvastatin	C				
			Risperidone	C				
			Buspar	C				
			Trazodone	C				
			Diazepam	C				

Date:10/02/01ISR Number: 3803512-4Report Type:Direct Company Report #
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25 Merck	PS	Merck	ORAL	1 DAILY ORAL	
Initial or Prolonged	Hypoaesthesia Transient Ischaemic Attack Vertigo		Flonase	C				

Date:10/02/01ISR Number: 3803514-8Report Type:Expedited (15-DaCompany Report #WAES 01096057
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health Professional	(Rofecoxib)	PS		ORAL		

Date:10/02/01ISR Number: 3803516-1Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer		Rofecoxib 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	
	Perforation							

Date:10/02/01ISR Number: 3803517-3Report Type:Expedited (15-DaCompany Report #WAES 01096055
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	17 DAY	
			Aspirin Lysine	C				
			Fenofibrate	C				

Date:10/02/01ISR Number: 3803622-1Report Type:Expedited (15-DaCompany Report #WAES 01075532
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Multiforme	Foreign	Tab Vioxx					
	Petechiae	Health	(Rofecoxib)	PS		ORAL	8 DAY	
	Vasculitis	Professional	Hydrochlorothiazide	SS				

Date:10/02/01ISR Number: 3803624-5Report Type:Expedited (15-DaCompany Report #WAES 01095650
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein	Foreign	Tab Vioxx					
	Increased	Health	(Rofecoxib)	PS		ORAL		
	Eczema	Professional						
	Hepatic Function Abnormal							
	Lymphadenopathy							
	Skin Disorder							

Date:10/02/01ISR Number: 3803631-2Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx 25 Mg/Ml	PS		ORAL	25 MG DAY	
						ORAL		

Date:10/02/01ISR Number: 3803688-9Report Type:Expedited (15-DaCompany Report #WAES 01088623
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Foreign	Tab Vioxx					
Life-Threatening	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Hemiplegia	Professional						
PO								
Initial or Prolonged								
Disability								

Date:10/02/01ISR Number: 3803690-7Report Type:Expedited (15-DaCompany Report #WAES 01099908
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Renal Tubular Necrosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/1X PO	

Date:10/02/01ISR Number: 3803693-2Report Type:Expedited (15-DaCompany Report #WAES 01085221
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	
			Acetaminophen/Codeine Phosphate	C				
			Dihydrocodeine	C				

Date:10/02/01ISR Number: 3803695-6Report Type:Expedited (15-DaCompany Report #WAES 01095099
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Cardiac Failure Congestive Condition Aggravated Coronary Artery Disease	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	18 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Candesartan	C				
			Furosemide	C				
			Insulin Human	C				
			Insulin Human, Isophane	C				
			Isosorbide					

Mononitrate	C
Lacidipine	C
Psyllium Husk	C
Sotalol Hydrochloride	C

Date:10/02/01ISR Number: 3803708-1Report Type:Expedited (15-DaCompany Report #WAES 01099309
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Disability								
PO							1	DAY
			Tab Cephradine	SS		ORAL	500 MG/DAILY	
PO							1	DAY

Date:10/02/01ISR Number: 3803710-XReport Type:Expedited (15-DaCompany Report #WAES 01073484
Age:82 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Foreign	Tab Vioxx					
	Mucosal Inflammation	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Mucous Membrane Disorder	Professional						
PO								
	Pancytopenia		Methotrexate	SS		ORAL	80 MG/WKY	31 MON
			Acetaminophen	C				

Date:10/02/01ISR Number: 3803719-6Report Type:Expedited (15-DaCompany Report #WAES 01016171
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Foreign	Tab Vioxx					
	Electroencephalogram	Study	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Abnormal	Health						
PO								109 DAY
	Epilepsy	Professional	Cetirizine	C				
	Hallucination		Ferrouss04	C				
	Nausea		Omeprazole	C				

Date:10/02/01ISR Number: 3803721-4Report Type:Expedited (15-DaCompany Report #WAES 01098546
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS		ORAL		
PO								
		Professional						

Date:10/02/01ISR Number: 3803723-8Report Type:Expedited (15-DaCompany Report #WAES 01088623
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Foreign	Tab Vioxx					
Life-Threatening	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -		Professional						
Initial or Prolonged								
Disability								

Date:10/02/01ISR Number: 3803733-0Report Type:Expedited (15-DaCompany Report #WAES 01098166
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Tab Vioxx					
	Hypertensive Crisis	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Malaise							
PO							4	DAY
			Amisulpride	C				
			Hydrochlorothiazide					
			(+) Valsartan	C				
			Propranolol Hcl	C				

Date:10/02/01ISR Number: 3803736-6Report Type:Expedited (15-DaCompany Report #WAES 01096051
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL		
PO							35	DAY

			Bromazepam	C		
			Fluoxetine Hcl	C		
			Polyethylene Glycol 4000	C		
			Spironolactone	C		

Date:10/02/01ISR Number: 3803738-XReport Type:Expedited (15-DaCompany Report #WAES 01095127
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	PO 2 DAY
			Acetaminophen	C				

Date:10/02/01ISR Number: 3803739-1Report Type:Expedited (15-DaCompany Report #WAES 01095112
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Syncope Vomiting	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG AM PO	

Date:10/02/01ISR Number: 3803743-3Report Type:Expedited (15-DaCompany Report #WAES 01095107
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage Oesophageal Ulcer	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	7 DAY
			Etidronate Disodium	C				
			Nifedipine	C				
			Temazepam	C				

Date:10/02/01ISR Number: 3803757-3Report Type:Expedited (15-DaCompany Report #WAES 01095109
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	233 DAY
			Bendroflumethiazide	C				
			Chlorpheniramine Maleate	C				

Date:10/02/01ISR Number: 3803759-7Report Type:Expedited (15-DaCompany Report #WAES 01095092
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Urticaria	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	229 DAY
	Vision Blurred		Acetaminophen/Propoxyphene Hydrochloride	C				

Date:10/02/01ISR Number: 3803927-4Report Type:Expedited (15-DaCompany Report #WAES 01091754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	

Date:10/02/01ISR Number: 3803928-6Report Type:Expedited (15-DaCompany Report #WAES 01091979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Other	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:10/02/01ISR Number: 3803929-8Report Type:Expedited (15-DaCompany Report #WAES 01092094
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agranulocytosis	Health	Tab Vioxx Unk	PS		ORAL	UNK/DAILY/PO	
Initial or Prolonged	Bile Duct Obstruction	Professional Company Representative						

Date:10/02/01ISR Number: 3803930-4Report Type:Expedited (15-DaCompany Report #WAES 01092186
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	15 DAY
Initial or Prolonged	Hyperhidrosis Nausea							

Date:10/02/01ISR Number: 3804059-1Report Type:Expedited (15-DaCompany Report #WAES 01072100
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomegaly	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Chest Pain	Health					MG/DAILY/PO	
	Condition Aggravated	Professional	Cozaar	C				
	Coronary Artery Disease		Glucophage	C				
	Drug Hypersensitivity		Humulin 30/70	C				
	Dyspnoea		Tiazac	C				
	Dyspnoea Paroxysmal		Xalatan	C				
	Nocturnal		Zocor	C				
	Tenosynovitis		Aspirin	C				
	Ventricular Hypertrophy		Diltiazem Hydrochloride	C				
			Nitroglycerin	C				

Date:10/02/01ISR Number: 3804060-8Report Type:Expedited (15-DaCompany Report #WAES 01081460
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO;	
	Decreased Appetite	Health					25	
	Drug Hypersensitivity	Professional					MG/DAILY/PO	
	Nausea		Cardizem	C				
			Coumadin	C				
			Elavil	C				
			Lanoxin	C				

Peri-Colace	C
Prinivil	C
Senokot (Sennosides)	C
Aspirin	C

Date:10/02/01ISR Number: 3804304-2Report Type:Expedited (15-DaCompany Report #WAES 01092114
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Tinnitus						MG/DAILY/PO	
Disability			Aspirin	C				

Date:10/02/01ISR Number: 3804306-6Report Type:Expedited (15-DaCompany Report #WAES 01092191
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged								

Date:10/02/01ISR Number: 3804307-8Report Type:Expedited (15-DaCompany Report #WAES 01092506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	[Therapy Unspecified]	C				

Date:10/02/01ISR Number: 3804308-XReport Type:Expedited (15-DaCompany Report #WAES 01091935
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
Other		Professional Company Representative						

Date:10/02/01ISR Number: 3804309-1Report Type:Expedited (15-DaCompany Report #WAES 01092088
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:10/02/01ISR Number: 3804344-3Report Type:Expedited (15-DaCompany Report #WAES 01079556
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Tab Vioxx					
Hospitalization -		Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Health						
PO							544	DAY
Disability		Professional	Tab Placebo					

				(Unspecified)	SS		ORAL
PO	98	DAY					
				Mevacor	C		
				Aspirin	C		
				Diltiazem Hydrochloride	C		
				Sulfasalazine	C		

Date:10/02/01ISR Number: 3804347-9Report Type:Expedited (15-DaCompany Report #WAES 01098544
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:10/02/01ISR Number: 3804349-2Report Type:Expedited (15-DaCompany Report #WAES 01098173
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oliguria	Foreign	Tab Vioxx					
	Renal Impairment	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Weight Increased	Professional					PO	
			Vasotec	C				
			Amlodipine	C				
			Nitroglycerin	C				

Date:10/02/01ISR Number: 3805507-3Report Type:Expedited (15-DaCompany Report #WAES 01095647
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	1 WK
		Professional						

Date:10/02/01ISR Number: 3805526-7Report Type:Expedited (15-DaCompany Report #WAES 01052432
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO,	
	Decreased	Health					25	
	Cardiac Murmur	Professional					MG/DAILY/PO	
	Muscle Spasms		Effexor	C				
	Oedema Peripheral		Elavil	C				
			Medrol	C				
			Pravachol	C				
			Prempro	C				

Date:10/02/01ISR Number: 3805529-2Report Type:Expedited (15-DaCompany Report #WAES 01083164
Age:28 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
	Blood Pressure Increased
	Chest Pain
	Dyspnoea
	Hemiparesis
	Herpes Zoster

	Hypoaesthesia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO

Date:10/02/01ISR Number: 3805531-0Report Type:Expedited (15-DaCompany Report #WAES 01090471
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Fibrosis	Health Professional Company Representative	Tav Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Disability	Haematoma						
Other	International Normalised Ratio Increased		Coumadin	C			
			Klonopin	C			
			Oxycontin	C			
			Xanax	C			

Date:10/02/01ISR Number: 3805540-1Report Type:Expedited (15-DaCompany Report #WAES 01090439
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chorea	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID PO
	Diabetes Mellitus						
	Drug Interaction		Pacerone Unk	SS			200 MG DAILY
	Overdose		Lipitor Unk	SS			10 MG DAILY
			Allegra	C			
			Coumadin	C			
			Lasix (Furosemide)	C			
			Miacalcin	C			
			Digoxin	C			

Date:10/02/01ISR Number: 3805541-3Report Type:Expedited (15-DaCompany Report #WAES 01072716
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Amoxicillin	C				

Date:10/02/01ISR Number: 3805549-8Report Type:Expedited (15-DaCompany Report #WAES 01091200
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Perforation	Professional					PO	
Initial or Prolonged	Pulmonary Embolism	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/01ISR Number: 3805593-0Report Type:Expedited (15-DaCompany Report #WAES 01092315
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Duodenal Ulcer	Health					PO	
	Gastrooesophageal Reflux	Professional	Isoptin Sr 120 Mg	SS		ORAL	120 MG DAILY	
	Disease						PO	
	Hiatus Hernia		Mavik 2 Mg	SS		ORAL	2 MG DAILY PO	
			Celexa	C				
			Zocor	C				
			Vitamin E	C				

Date:10/02/01ISR Number: 3805595-4Report Type:Expedited (15-DaCompany Report #WAES 01092120
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Alopecia						MG/DAILY/PO	
	Convulsion		Allegra	C				
	Fluid Retention		Tylenol Extra					
	Gastrointestinal Disorder		Strength	C				
	Onychorrhexis		Zocor	C				
			Alprazolam	C				
			Furosemide	C				

Date:10/02/01ISR Number: 3805978-2Report Type:Periodic Company Report #2001018254-1
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Avandia Smithkline					
	Dyspnoea		Beecham	PS	Smithkline Beecham	ORAL	4 MILLIGRAMS	

Gastritis
1.0 DAILY
Oedema Peripheral
ORAL
Pulmonary Oedema
Vioxx (Rofecoxib)
Merck & Co. SS
25 MILLIGRAMS

1.0 DAILY
Lasix (Furosemide) C
Atacand (Candesartan Cilexetil) C
Zocor (Simvastatin) C
Glucotrol (Glipizide) C
Antivert (Meclizine) C

Date:10/02/01ISR Number: 3806087-9Report Type:Expedited (15-DaCompany Report #WAES 01095126
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
PO								10 DAY
			Atenolol	C				
			Estradiol Valerate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/01ISR Number: 3803322-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS		ORAL	25 MG QD PO	
Initial or Prolonged	Increased		Furosemide	SS			80 MG QD	
	Blood Pressure Decreased		Lisinopril	C				
	Condition Aggravated		Atenolol	C				
	Dyspnoea		Allopurinol	C				
	Dyspnoea Exertional		Amitriptyline	C				
	Hypovolaemia		Spironolactone	C				
	Oedema							
	Renal Failure Acute							

Date:10/03/01ISR Number: 3803435-0Report Type:Expedited (15-DaCompany Report #WAES 01100093
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/01ISR Number: 3803440-4Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
Hospitalization -	Decreased Activity		[Therapy					
Initial or Prolonged	Gastric Haemorrhage		Unspecified]	C				

Date:10/03/01ISR Number: 3803441-6Report Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 29 DAY	Oedema Peripheral	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 24 DAY	Rash Pustular	Professional	Hydroxyurea	SS		ORAL
			Dipyrone	C		ORAL
29 DAY						
			Mercaptopurine	C		ORAL
3 YR						
			Omeprazole	C		ORAL
1138 DAY						

Date:10/03/01ISR Number: 3803442-8Report Type:Expedited (15-DaCompany Report #WAES 01105001
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/03/01ISR Number: 3804543-0Report Type:Expedited (15-DaCompany Report #WAES 01092825
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged MG/DAILY/PO		Professional				
			Avandia	C		
			Celexa	C		
			Flovent	C		
			Foradil	C		
			Glucophage	C		

Lopressor	C
Patanol	C
Plavix	C
Prilosec	C
Prinivil	C
Reglan	C
Zocor	C
Albuterol	C
Aspirin	C

Date:10/03/01ISR Number: 3806809-7Report Type:Expedited (15-DaCompany Report #WAES 01099147
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral	Foreign	Tab Vioxx					
	Embolism Venous	Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	1 DAY
	Vasodilatation	Professional	Os Carteolol Hcl	SS		OPHTHALMIC		
	Visual Disturbance							

Date:10/03/01ISR Number: 3806845-0Report Type:Expedited (15-DaCompany Report #WAES 01095138
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Rectal Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	23 DAY
			Dothiepin Hcl	C				

Date:10/03/01ISR Number: 3806846-2Report Type:Expedited (15-DaCompany Report #WAES 01095145
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Tab Vioxx					
	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Gastric Haemorrhage		Aluminum					

	Gastrooesophageal Reflux Disease	Hydroxide/Magnesium Carbonate	C
		Aspirin	C
		Bendroflumethiazide	C
		Fluoxetine	C
		Isosorbide Mononitrate	C

Date:10/03/01ISR Number: 3807436-8Report Type:Expedited (15-DaCompany Report #WAES 01092212
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aspiration Pleural Cavity	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure		Detrol	C				
	Congestive		Lasix (Furosemide)	C				
	Chest Pain							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/01ISR Number: 3803952-3Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous		Vioxx	PS		ORAL	25 MG PO QD	
	Rash Maculo-Papular		Prednisone	C				
			Colvite	C				
			Paxil	C				
			Diovan	C				
			Prevacid	C				
			Tylenol	C				
			Ferrous Sequels	C				
			Albuterol	C				
			Flonase	C				
			Atrovent	C				

Date:10/04/01ISR Number: 3804052-9Report Type:Expedited (15-DaCompany Report #WAES 01100237
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/04/01ISR Number: 3804053-0Report Type:Expedited (15-DaCompany Report #WAES 01100363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Embolism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Initial or Prolonged	Ulcer Haemorrhage		[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				

Date:10/04/01ISR Number: 3804054-2Report Type:Expedited (15-DaCompany Report #WAES 01109103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/04/01ISR Number: 3804057-8Report Type:Expedited (15-DaCompany Report #WAES 01106009
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	56	DAY
	Cardiac Arrest	Professional	Alfuzosin Hydrochloride	C		ORAL		
	Coronary Artery Disease		Acetaminophen	C		ORAL		
			Pantoprazole	C		ORAL		

Date:10/04/01ISR Number: 3804058-XReport Type:Expedited (15-DaCompany Report #WAES 01100246
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Zestril	C				
			Glipizide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/01ISR Number: 3804424-2Report Type:Direct Company Report #
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Vioxx 25 Mg Q Day	PS			25 MG Q DAY	
	Hypersensitivity		...	C				
	Myocardial Infarction		...	C				
	Respiratory Arrest		Hctz	C				
	Vomiting		Atenolol	C				
			Prevacid	C				

Date:10/04/01ISR Number: 3804536-3Report Type:Expedited (15-DaCompany Report #WAES 01092663
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Encephalitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QID/PO	
	Encephalopathy	Professional						
	Medication Error							

Date:10/04/01ISR Number: 3804539-9Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral							
	Pain							
	Peripheral Vascular							
	Disorder							

Date:10/04/01ISR Number: 3804540-5Report Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Bradycardia	Consumer	Tab Vioxx	PS		ORAL
DAILY/PO						
Initial or Prolonged	Chest Pain					
	Dizziness					
	Dyspnoea					
	Fatigue					
	Sinus Arrest					

Date:10/04/01ISR Number: 3805205-6Report Type:Expedited (15-DaCompany Report #WAES 01096091
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Exfoliative	Foreign	Tab Vioxx					
Initial or Prolonged	Oedema Peripheral	Company	(Rofecoxib)	PS		ORAL	PO	1 DAY
	Oral Mucosal Eruption	Representative						

Date:10/04/01ISR Number: 3805215-9Report Type:Expedited (15-DaCompany Report #WAES 01093462
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12. 5 MG	
	Haemorrhage							
DAILY PO								
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/01ISR Number: 3805217-2Report Type:Expedited (15-DaCompany Report #WAES 01099557
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	1 TABLET	
Initial or Prolonged	Renal Failure						DAILY PO	1 MON
	Toxic Epidermal Necrolysis							

Date:10/04/01ISR Number: 3805218-4Report Type:Expedited (15-DaCompany Report #WAES 01095565
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Tab Vioxx					
	Renal Failure Acute	Literature	(Rofecoxib)	PS		ORAL	25 MG PO	3 DAY
		Other	Hydrodiuril	C				
			Acetaminophen	C				
			Allopurinol	C				
			Aspirin	C				
			Atenolol	C				
			Atorvastatin	C				
			Glimepiride	C				
			Isosorbide Dinitrate	C				
			Ranitidine	C				

Date:10/04/01ISR Number: 3805222-6Report Type:Expedited (15-DaCompany Report #WAES 01086054
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ascites	Foreign	Tab Vioxx					
Life-Threatening	Atrial Fibrillation	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
Hospitalization -	Duodenal Ulcer							
PO								12 DAY
Initial or Prolonged	Haemorrhage		Tab Acenocoumarol	SS		ORAL	PO	

	Dyspnoea		Propafenone	C			
	Metastatic Neoplasm						
	Peritoneal Disorder						

Date:10/04/01ISR Number: 3805240-8Report Type:Expedited (15-DaCompany Report #WAES 01096057
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased Blood Creatine Phosphokinase Increased Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:10/04/01ISR Number: 3805299-8Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastritis Erosive	Professional						
	Gastrointestinal Disorder	Company	Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
Disability	Gastrointestinal Haemorrhage	Representative						
Other			Ceftin	C				

				Tylox	C		

Date:10/04/01ISR Number: 3805301-3Report Type:Expedited (15-DaCompany Report #WAES 01080727
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Vioxx	PS		ORAL	PO	
	Bradyphrenia	Health	Advil	C				
	Concussion	Professional	Effexor	C				
	Confusional State		Prozac	C				
	Convulsion		Xanax	C				
	Dizziness							
	Fall							
	Haematoma							
	Headache							
	Syncope							

Date:10/04/01ISR Number: 3805302-5Report Type:Expedited (15-DaCompany Report #WAES 01061804
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Vioxx	PS		ORAL	PO	
Hospitalization -	Epilepsy	Professional	Dilantin	C				
Initial or Prolonged	Hemiplegia		Tranxene	C				
Disability								
Other								

Date:10/04/01ISR Number: 3805304-9Report Type:Expedited (15-DaCompany Report #WAES 01081864
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chromaturia	Consumer	Vioxx	PS		ORAL	PO	
	Medication Error	Health	Metoprolol 50 Mg	SS				
25 MG/DAILY								

			Professional	Lotensin	SS		
20 MG/BID							
				Celebrex	SS		
				Levoxyl	C		
				Zyrtec	C		

Date:10/04/01ISR Number: 3805306-2Report Type:Expedited (15-DaCompany Report #WAES 01090439
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chorea	Health	Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Diabetes Mellitus	Professional					MG/BID/PO	
	Drug Interaction	Company	Pacerone	SS			200 MG/DAILY	
	Dysarthria	Representative	Lipitor	SS			10 MG/DAILY	
	Overdose		Allegra	C				
			Coumadin	C				
			Lasix (Furosemide)	C				
			Miacalcin	C				
			Digoxin	C				

Date:10/04/01ISR Number: 3805308-6Report Type:Expedited (15-DaCompany Report #WAES 01090471
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fibrosis	Health	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haematoma	Professional					MG/DAILY/PO	
Other	International Normalised	Company	Coumadin	C				
	Ratio Increased	Representative	Klonopin	C				
	Post Procedural		Neurontin	C				
	Complication		Oxycontin	C				
	Thrombocythaemia		Xanax	C				

Date:10/04/01ISR Number: 3805523-1Report Type:Expedited (15-DaCompany Report #WAES 01092336
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oesophageal Haemorrhage	Consumer	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged							MG/DAILY/PO	
			Calcium Carbonate	C				
			Raloxifene	C				

Date:10/04/01ISR Number: 3805555-3Report Type:Expedited (15-DaCompany Report #WAES 01099742
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fall	Foreign	Tab Vioxx					
Initial or Prolonged	Spinal Compression	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	44 DAY
	Fracture							

Date:10/04/01ISR Number: 3805557-7Report Type:Expedited (15-DaCompany Report #WAES 01093503
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:10/04/01ISR Number: 3805559-0Report Type:Expedited (15-DaCompany Report #WAES 01099409
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:10/04/01ISR Number: 3805584-XReport Type:Expedited (15-DaCompany Report #WAES 01095566
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis	Foreign	Tab Vioxx					
	Oedema	Literature	(Rofecoxiv)	PS		ORAL	25 MG PO	5 DAY
	Renal Artery Stenosis		Vasotec	C				
	Renal Disorder		Cyclosporine	C				
	Renal Failure Acute		Doxazosin	C				
	Renal Tubular Disorder		Epoetin	C				
			Furosemide	C				
			Ganciclovir	C				
			Metoprolol	C				
			Moxonidine	C				

			Mycophenolate Mofetil	C		
			Pantoprazole	C		
			Prednisolone	C		

Date:10/04/01ISR Number: 3805592-9Report Type:Expedited (15-DaCompany Report #WAES 01092837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/DAILY/PO	18 MON
			Fosamax	C				
			Prempro	C				

Date:10/04/01ISR Number: 3806066-1Report Type:Expedited (15-DaCompany Report #WAES 01092836
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Plaquenil	C				

Date:10/05/01ISR Number: 3804662-9Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/01ISR Number: 3804663-0Report Type:Expedited (15-DaCompany Report #WAES 01103401
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Ulcer Haemorrhage		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		

Date:10/05/01ISR Number: 3804684-8Report Type:Expedited (15-DaCompany Report #WAES 01109801
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Other	Electrocardiogram St Segment Depression Ventricular Arrhythmia Ventricular Extrasystoles		Ibuprofen Diclofenac	C C		ORAL ORAL		

Date:10/05/01ISR Number: 3805362-1Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization - Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aphasia		Vioxx	PS			2.5MG ONCE	
Cerebrovascular Accident						DAILY 25MG 2	
Hypertension						WKS AS NEEDED	
Immobile						FOR GOUT	
		Allopurinol	C				
		Colchicine	C				

Date:10/05/01ISR Number: 3806847-4Report Type:Expedited (15-DaCompany Report #WAES 01095171
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse	Foreign	Tab Vioxx					
	Dizziness	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Feeling Abnormal						PO	
	Syncope		Diclofenac	C				

Date:10/05/01ISR Number: 3807449-6Report Type:Expedited (15-DaCompany Report #WAES 01092770
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:10/05/01ISR Number: 3808365-6Report Type:Expedited (15-DaCompany Report #WAES 01078619
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Foreign Health	Tab Vioxx (Rofecoxib)	PS	Merck Sharp & Dohme	ORAL	25 MG/DAILY	
	Petechiae	Professional						
PO							64	DAY
	Platelet Count Decreased		Irbesartan	C				

Date:10/05/01ISR Number: 3808366-8Report Type:Expedited (15-DaCompany Report #WAES 01095171
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Foreign	Tab Vioxx					
	Feeling Abnormal	Other	(Rofecoxib)	PS	Merck Sharp & Dohme	ORAL	25 MG/DAILY	
	Syncope							
PO								
			Diclofenac	C				

Date:10/05/01ISR Number: 3808367-XReport Type:Expedited (15-DaCompany Report #WAES 01078619
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Foreign Health	Tab Vioxx (Rofecoxib)	PS	Merck Sharp & Dohme	ORAL	25 MG/DAILY	
	Petechiae	Professional						
PO							64	DAY
	Platelet Count Decreased		Irbesartan	C				

Date:10/08/01ISR Number: 3805074-4Report Type:Expedited (15-DaCompany Report #WAES 01100368
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		171 DAY
Initial or Prolonged	Congestive		Vioxx	SS		ORAL		15 DAY
			Meridia	C				
			Cardura	C				
			Lotensin	C				
			Viagra	C				

Date:10/08/01ISR Number: 3805076-8Report Type:Expedited (15-DaCompany Report #WAES 01100365
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Paxil	C		ORAL		125 DAY
Initial or Prolonged			Aspirin	C				
Disability								
Other								

Date:10/08/01ISR Number: 3805088-4Report Type:Expedited (15-DaCompany Report #WAES 01107501
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Syncope							

Date:10/08/01ISR Number: 3805089-6Report Type:Expedited (15-DaCompany Report #WAES 01105020
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY

	Anorexia		Bendroflumethiazide	C	ORAL
	Dysphagia		Diazepam	C	ORAL
	Gastrooesophageal Reflux Disease		Acetaminophen And Dihydrocodeine Bitartrate	C	ORAL
	Vomiting		Amitriptyline	C	ORAL

Date:10/09/01ISR Number: 3805686-8Report Type:Expedited (15-DaCompany Report #WAES 01100511
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/09/01ISR Number: 3805687-XReport Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/09/01ISR Number: 3805691-1Report Type:Expedited (15-DaCompany Report #WAES 01105025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	92	DAY
	Haemorrhage		Tramadol	C		ORAL	134	DAY
	Mallory-Weiss Syndrome							
	Vomiting							

Date:10/09/01ISR Number: 3805695-9Report Type:Expedited (15-DaCompany Report #WAES 01100719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/09/01ISR Number: 3805698-4Report Type:Expedited (15-DaCompany Report #WAES 01105034
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	387	DAY
Initial or Prolonged			Levothyroxine Sodium	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:10/10/01ISR Number: 3806282-9Report Type:Expedited (15-DaCompany Report #WAES 01100581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806286-6Report Type:Expedited (15-DaCompany Report #WAES 01100584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806287-8Report Type:Expedited (15-DaCompany Report #WAES 01100582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806288-XReport Type:Expedited (15-DaCompany Report #WAES 01100538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806289-1Report Type:Expedited (15-DaCompany Report #WAES 01100585
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3806291-XReport Type:Expedited (15-DaCompany Report #WAES 01100583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806293-3Report Type:Expedited (15-DaCompany Report #WAES 01100586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:10/10/01ISR Number: 3806295-7Report Type:Expedited (15-DaCompany Report #WAES 01100589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806296-9Report Type:Expedited (15-DaCompany Report #WAES 01100587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806297-0Report Type:Expedited (15-DaCompany Report #WAES 01100588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806298-2Report Type:Expedited (15-DaCompany Report #WAES 01100594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806299-4Report Type:Expedited (15-DaCompany Report #WAES 01100590
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806300-8Report Type:Expedited (15-DaCompany Report #WAES 01100591
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806302-1Report Type:Expedited (15-DaCompany Report #WAES 01100595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/10/01ISR Number: 3806304-5Report Type:Expedited (15-DaCompany Report #WAES 01100592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806306-9Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	YR
	Dyspnoea		Provigil	SS		ORAL	6 MON	
	Dysuria		Betaseron	SS				
	Fall		Wellbutrin	C				
	Laceration		Prednisone	C				
	Livedo Reticularis		[Therapy Unspecified]	C				
	Mental Impairment		Amantadine Hydrochloride	C				
	Multiple Sclerosis		Procuren	C				
	Oedema Peripheral		Vitamins (Unspecified)	C				
	Rash Macular							
	Serum Sickness							
	Status Epilepticus							

Date:10/10/01ISR Number: 3806307-0Report Type:Expedited (15-DaCompany Report #WAES 01100758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		

	Blood Pressure Increased	Ultram	C
	Oedema	Imitrex	C
	Optic Neuropathy		

Date:10/10/01ISR Number: 3806309-4Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Intestinal Obstruction		Vasotec	C		ORAL
Initial or Prolonged	Intestinal Perforation		Lipitor	C		
Disability			Ziac	C		
			Aspirin	C		

Date:10/10/01ISR Number: 3806310-0Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Face Oedema
Initial or Prolonged	Idiopathic
	Thrombocytopenic Purpura
	Periorbital Haematoma

	Post Procedural Haematoma Post Procedural Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Naprosyn	C				

Date:10/10/01ISR Number: 3806312-4Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus Inadequate Control		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806318-5Report Type:Expedited (15-DaCompany Report #WAES 01100593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/01ISR Number: 3806502-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx 25 Mg Merck	PS	Merck			
			Lipitor	C				
			Ambien	C				
			Protonix	C				
			Carafate	C				
			Norvasc	C				
			Darvocet-N	C				
			Demerol	C				

Date:10/10/01ISR Number: 3807534-9Report Type:Expedited (15-DaCompany Report #WAES 01097807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	25	
	Ulcer	Professional					MG/DAILY/PO	
			Fenofibrate	C				
			Flavon Glycoside (+)					
			Ginkgo Biloba Extra	C				
			Homeopathic					
			Medications	C				
			Sodium Fluoride	C				

Date:10/10/01ISR Number: 3807536-2Report Type:Expedited (15-DaCompany Report #WAES 01096544
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Crying	Foreign	Tab Vioxx					
	Depression	Other	(Rofecoxib)	PS		ORAL	25	
	Nausea						MG/DAILY/PO	2 DAY
			Amiloride					
			Hydrochloride-Hctz	C				
			Aspirin	C				

			Atenolol	C		
			Felodipine	C		
			Sulfasalazine	C		

Date:10/10/01ISR Number: 3807540-4Report Type:Expedited (15-DaCompany Report #WAES 01096543
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Oedema Peripheral Weight Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	PO 11 DAY
			Bedroflumethiazide/Kcl	C				
			Prednisolone	C				

Date:10/10/01ISR Number: 3807541-6Report Type:Expedited (15-DaCompany Report #WAES 01096102
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 6 DAY
			Cozaar	C				
			Atenolol (+) Nifedipine	C				
			Fenofibrate	C				
			Furosemide	C				
			Metformin	C				
			Tramadol	C				

Date:10/10/01ISR Number: 3807557-XReport Type:Expedited (15-DaCompany Report #WAES 01098253
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Drug Interaction Gastrointestinal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
50 MG/DAILY Other PO 4 DAY	Haemorrhage					
	Prothrombin Time		Tab Nimesulide	SS		ORAL
100 MG/1X PO 1 DAY						
	Prolonged		Tab Phenprocoumon	SS		ORAL
PO						

Date:10/10/01ISR Number: 3807560-XReport Type:Expedited (15-DaCompany Report #WAES 01099006
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematuria	Foreign Health	Tab Vioxx (Rofecoxib)	PS		
22 DAY						
		Professional	Fosamax	C		
			Calcium Carbonate (+) Calcium			
			Glubionate	C		
			Glucametacin	C		
			Piroxicam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3807566-0Report Type:Expedited (15-DaCompany Report #WAES 01085511
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure	Foreign	Tab Vioxx					
	Hepatitis	Health	(Rofecoxib)	PS		ORAL		
		Professional						

Date:10/10/01ISR Number: 3807571-4Report Type:Expedited (15-DaCompany Report #WAES 01088623
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Foreign	Tab Vioxx					
Life-Threatening	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Hemiplegia	Professional	Cyclobenzaprine Hcl	C				
Initial or Prolonged			Raloxifene	C				
Disability								

Date:10/10/01ISR Number: 3807973-6Report Type:Expedited (15-DaCompany Report #WAES 01096097
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Foreign	Tab Vioxx					
Initial or Prolonged	Diverticulum Intestinal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	37 DAY
	Gastrointestinal		Proscar	C				
	Haemorrhage		Trusopt	C				
	Rectal Haemorrhage		Acetaminophen (+)					
			Caffeine (+)					
			Carbaspir	C				
			Candesartan					
			Cilexetil	C				
			Diacerein	C				
			Ketoprofen	C				
			Nystatin/Triamcinolo					
			ne Acetonide	C				

Date:10/10/01ISR Number: 3807974-8Report Type:Expedited (15-DaCompany Report #WAES 01096097
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Tab Vioxx					
	Diverticulum Intestinal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	37 DAY
	Gastrointestinal		Proscar	C				
	Haemorrhage		Trusopt	C				
	Rectal Haemorrhage		Acetaminophen (+)					
			Caffeine (+)					
			Carbaspir	C				
			Candesartan					
			Cilexetil	C				
			Diacerein	C				
			Ketoprofen	C				
			Nystatin/Triamcinolone Acetonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3807975-XReport Type:Expedited (15-DaCompany Report #WAES 01096064
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
	Renal Impairment		Elavil	C				
	Thrombocytopenia		Acetaminophen (+)					
			Belladonna (+)					
			Caffein	C				
			Aspirin Lysine	C				
			Azathioprine	C				
			Benzbromarone	C				
			Bisoprolol Fumarate	C				
			Cyclosporine	C				
			Fluoxetine Hcl	C				
			Furosemide	C				
			Levothyroxine Na	C				
			Omeprazole Sodium	C				
			Oxazepam	C				
			Pravastatin Na	C				
			Prednisolone Sodium Metasulfobenzoate	C				
			Valpromide	C				

Date:10/10/01ISR Number: 3807976-1Report Type:Expedited (15-DaCompany Report #WAES 01093542
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Foreign	Tab Vioxx					
	Pruritus	Consumer	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	4 DAY
	Pulmonary Oedema		Albuterol Sulfate	C				
	Urinary Retention		Calcitriol	C				
	Urine Potassium Decreased		Fluticasone Propionate (+)					
			Salmeterol Xl	C				
			Fosinopril Sodium (+)					
			Hydrochlorothiazid	C				
			Ipratropium Bromide	C				
			Prednisolone	C				

			Theophylline	C		

Date:10/10/01ISR Number: 3807978-5Report Type:Expedited (15-DaCompany Report #WAES 01096083
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	
			Acebutolol	C				
			Althiazide/Spironolactone	C				
			Molsidomine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3807979-7Report Type:Expedited (15-DaCompany Report #WAES 01103401
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY PO	
			Apsirin	C				

Date:10/10/01ISR Number: 3807980-3Report Type:Expedited (15-DaCompany Report #WAES 01109103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:10/10/01ISR Number: 3807981-5Report Type:Expedited (15-DaCompany Report #WAES 01106009
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY PO	56 DAY
			Acetaminophen	C				
			Alfuzosin Hydrochloride	C				
			Pantoprazole	C				

Date:10/10/01ISR Number: 3807986-4Report Type:Expedited (15-DaCompany Report #WAES 01095049
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Inflammation	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	1) 12.5 MG/DAILY; 2) 25 MG/DAILY	2 MON

Date:10/10/01ISR Number: 3807987-6Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Myocardial Infarction	Health Professional Other	Tab Placebo (Unspecified)	SS		ORAL		
			Insulin	C				

Date:10/10/01ISR Number: 3807988-8Report Type:Expedited (15-DaCompany Report #WAES 01095182
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenitis Haemorrhagic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	10 DAY
			Aspirin	C				
			Bendroflumethiazide	C				

			Ramipril	C		

Date:10/10/01ISR Number: 3807989-XReport Type:Expedited (15-DaCompany Report #WAES 01097319
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Tab Vioxx					
	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	156 DAY
	Gastroenteritis	Professional						
	Helicobacter	Other						
	Syncope							

Date:10/10/01ISR Number: 3808001-9Report Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis	Foreign	Tab Vioxx					
	Oedema Peripheral	Company	(Rofecoxib)	PS		ORAL	PO	29 DAY
	Rash Pustular	Representative	Hydroxyurea	SS		ORAL	PO	24 DAY
			Dipyrone	C				
			Merceptopurine	C				
			Omeprazole	C				

Date:10/10/01ISR Number: 3808003-2Report Type:Expedited (15-DaCompany Report #WAES 01105001
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	12.5-25	
		Professional						
							MG/DAILY PO	

Date:10/10/01ISR Number: 3808005-6Report Type:Expedited (15-DaCompany Report #WAES 01095184
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 60 DAY
			Acetaminophen	C				

Date:10/10/01ISR Number: 3808006-8Report Type:Expedited (15-DaCompany Report #WAES 01098260
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 7 DAY
	Face Oedema							
	Oedema Peripheral							
	Urine Abnormality		Amlodipine Besylate	C				
			Aspirin	C				
			Citalopram Hydrobromide	C				
			Enalapril Maleate	C				
			Insulin, Biphasic Isophane (Injection)	C				
			Magnesium Aspartate	C				
			Metformin Hcl	C				

			Torsemide	C		

Date:10/10/01ISR Number: 3808009-3Report Type:Expedited (15-DaCompany Report #WAES 01097813
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Vasoretic	C				
			Zocor	C				
			Allopurinol	C				
			Furosemide Sodium	C				
			Isosorbide Mononitrate	C				
			Metformin Hcl	C				
			Phenprocoumon	C				
			Repaglinide	C				
			Tramadol Hcl	C				

Date:10/10/01ISR Number: 3808272-9Report Type:Expedited (15-DaCompany Report #WAES 01090505
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer Health Professional	Tax Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Vicodin Tablets	C				

Date:10/10/01ISR Number: 3808286-9Report Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Consumer	Tab Vioxx	PS		ORAL	DAILY, PO	
	Chest Pain							
	Dizziness							

Dyspnoea
Sinus Arrest

Date:10/10/01ISR Number: 3808337-1Report Type:Expedited (15-DaCompany Report #WAES 01100246
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
Initial or Prolonged			Zestril	C				
			Glipizide	C				

Date:10/10/01ISR Number: 3808338-3Report Type:Expedited (15-DaCompany Report #WAES 01081600
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Pain
	Arthralgia
	Atelectasis
	Bronchospasm
	Chills
	Diffuse Large B-Cell Lymphoma

		Gastric Cancer					
		Hepatic Cyst					
		Hepatic Steatosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Stiffness	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY							
		Non-Hodgkin'S Lymphoma	Professional				
PO							
		Pyrexia		Fosamax	C		
		Weight Increased		Prilosec	C		
				Atenolol	C		

Date:10/10/01ISR Number: 3809130-6Report Type:Expedited (15-DaCompany Report #WAES 01100237
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death	Company	Tab Vioxx	PS		ORAL
PO							
			Representative				

Date:10/10/01ISR Number: 3809134-3Report Type:Expedited (15-DaCompany Report #WAES 01100093
Age: Gender:Unknown I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Arrest	Health	Tab Vioxx	PS		ORAL
PO							
			Professional				
			Company				
			Representative				

Date:10/10/01ISR Number: 3809135-5Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:76 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Asthenia	Consumer	Tab Vioxx	PS		ORAL
PO							
Hospitalization -		Colonic Haemorrhage					
Initial or Prolonged		Decreased Activity					

Gastric Haemorrhage

Date:10/10/01ISR Number: 3809136-7Report Type:Expedited (15-DaCompany Report #WAES 01093319
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive Dyspnoea	Professional Company Representative						

Date:10/10/01ISR Number: 3809137-9Report Type:Expedited (15-DaCompany Report #WAES 01093163
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Eye Haemorrhage		Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3809138-0Report Type:Expedited (15-DaCompany Report #WAES 01093161
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:10/10/01ISR Number: 3809169-0Report Type:Expedited (15-DaCompany Report #WAES 01093175
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	UNK/UNK/PO	
			Coumadin	C				
			Lanoxin	C				
			Therapy Unspecified	C				
			Insulin	C				

Date:10/10/01ISR Number: 3809171-9Report Type:Expedited (15-DaCompany Report #WAES 01092842
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Consumer	Tab Vioxx 12.5-25 Mg	PS		ORAL	12.5-25	
	Myeloid Metaplasia	Health					MG/DAILY/PO	
		Professional	Dyazide	C				
			Flexeril	C				
			Fosamax	C				
			Synthroid	C				
			Ultram	C				
			Potassium	C				
			Spironolactone	C				

Date:10/10/01ISR Number: 3809179-3Report Type:Expedited (15-DaCompany Report #WAES 01090114
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Vioxx	PS		ORAL	50 MG/ DAILY / PO	

Date:10/10/01ISR Number: 3809180-XReport Type:Expedited (15-DaCompany Report #WAES 01090674
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apnoea	Consumer	Vioxx	PS		ORAL	25 MG/ PO	
	Atrophy		Accupril	C				
	Blood Pressure Decreased		Ambien	C				
	Brain Damage		Dilantin	C				
	Cerebrovascular Accident		Inderal	C				
	Condition Aggravated		Lasix (Furosemide)	C				
	Heart Rate Decreased		Percocet	C				
	Loss Of Consciousness		Prevacid	C				
	Neck Pain		Tagamet	C				
	Pain In Extremity		Toprol Xl Tablets	C				
	Syncope		Ultram	C				
			Vasocon-A	C				
			Zoloft	C				
			Metoclopramide	C				

			Nitroglycerin	C		
			Potassium	C		

Date:10/10/01ISR Number: 3809181-1Report Type:Expedited (15-DaCompany Report #WAES 01100363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage	Consumer	Vioxx	PS		ORAL	DAILY / PO	
Initial or Prolonged								

Date:10/10/01ISR Number: 3809182-3Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Vioxx	PS		ORAL	PO	

Date:10/10/01ISR Number: 3809183-5Report Type:Expedited (15-DaCompany Report #WAES 01081980
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea Increased	Health	Vioxx	PS		ORAL	50 MG/ DAILY	
Initial or Prolonged	Faecal Occult Blood	Professional					/ PO	
Other	Positive	Other	Ambien	C				
	Gastric Ulcer		Catapres	C				
	Gastrointestinal		Mysoline	C				
	Haemorrhage		Paxil	C				
	Melaena		Sectral	C				
			Tylenol	C				
			Nitroglycerin	C				

Date:10/10/01ISR Number: 3809186-0Report Type:Expedited (15-DaCompany Report #WAES 01090023
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Vioxx	PS		ORAL	25	
	Vertigo	Health					MG/DAILY/PO	
		Professional	Celebrex	C				
			Claritin	C				

Date:10/10/01ISR Number: 3809187-2Report Type:Expedited (15-DaCompany Report #WAES 01051556
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Delirium	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Delusion	Professional					MG/DAILY/PO/2	
	Disorientation						MONTH	
			Ditropan	C				
			Pravachol	C				
			Zocor	C				
			Aspirin	C				
			Calcium	C				
			Candesartan					
			Cilexetil	C				
			Nonsteroidal					
			Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3809188-4Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cerebrovascular Accident	Health					MG/DAILY/PO	
	Embolism	Professional	Provera	SS				
	Headache		Capozide	C				
	Hemianopia Homonymous		Tylenol With Codeine #3	C				
	Hyporeflexia		Captopril	C				
	Meningioma		Cisapride	C				
			Glyburide	C				

Date:10/10/01ISR Number: 3809221-XReport Type:Expedited (15-DaCompany Report #WAES 01092951
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Transient Ischaemic						MG/DAILY/PO	
	Attack		Coumadin	SS				
			Tiazac	C				
			Zestril	C				
			Digoxin	C				

Date:10/10/01ISR Number: 3809222-1Report Type:Expedited (15-DaCompany Report #WAES 01100007
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Cardiac Septal	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Defect		Coumadin	C				
	Cerebrovascular Accident							

Date:10/10/01ISR Number: 3809223-3Report Type:Expedited (15-DaCompany Report #WAES 01100033
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Myocardial Infarction		Lipitor	C				
			..	C				

Date:10/10/01ISR Number: 3809224-5Report Type:Expedited (15-DaCompany Report #WAES 01090505
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Health					MG/DAILY/PO	
		Professional	Vicodin Tablets	C				

Date:10/10/01ISR Number: 3809225-7Report Type:Expedited (15-DaCompany Report #WAES 01090315
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Distension
	Anxiety
	Arthralgia
	Condition Aggravated

	Confusional State						
	Depression						
	Diarrhoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Drug Hypersensitivity	Health					
	Dysarthria	Professional	Cylert	C			
	Dyspnoea		Ditropan	C			
	Fatigue		Nexium	C			
	Feeling Jittery		Aspirin	C			
	Gastrointestinal Pain		..	C			
	Lethargy						
	Lyme Disease						
	Myalgia						
	Nausea						
	Pain						
	Pruritus						
	Skin Exfoliation						
	Speech Disorder						
	Suicidal Ideation						
	Urinary Tract Infection						
	Vision Blurred						

Date:10/10/01ISR Number: 3809226-9Report Type:Expedited (15-DaCompany Report #WAES 01082732
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Initial or Prolonged	Back Pain	Health					
Disability	Chest Pain	Professional	Celexa	C			
	Coronary Artery Occlusion		Lipitor	C			
	Ecchymosis		Neurontin	C			
	Hypertension		Theragran Tablets				
	Myocardial Ischaemia		Advanced Formu	C			
	Pharyngolaryngeal Pain		Xanax	C			
			Aspirin	C			
			Vitamin B Complex	C			
			Vitamin E	C			

Date:10/10/01ISR Number: 3809253-1Report Type:Expedited (15-DaCompany Report #WAES 01092529
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:10/10/01ISR Number: 3809254-3Report Type:Expedited (15-DaCompany Report #WAES 01090322
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Other	Myocardial Infarction	Professional					MG/BID/PO	
		Company Representative Other	Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3809255-5Report Type:Expedited (15-DaCompany Report #WAES 00060809
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Chills	Other	Calcium	C				
	Drug Withdrawal Syndrome		Garlic Extract	C				
	Dyspepsia		Herbs	C				
	Ecchymosis		Minerals	C				
	Fall		Vitamin B	C				
	Feeling Abnormal		Vitamin E	C				
	Feeling Hot And Cold		Vitamins	C				
	Head Injury							
	Headache							
	Hyperhidrosis							
	Medication Error							
	Nausea							
	Nocturia							
	Syncope							
	Tremor							

Date:10/10/01ISR Number: 3809257-9Report Type:Expedited (15-DaCompany Report #WAES 01072442
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL	
Hospitalization -	Anxiety	Professional						
Initial or Prolonged	Aphasia	Company	Anafranil	SS			25 MG/BID	
Other	Asthenia	Representative	Klonopin	SS			0.5 MG/BID	
	Balance Disorder		Lamictal	SS			100 MG/BID	
	Blood Pressure Systolic		Wellbutrin Sr	SS			150 MG/BID	
	Increased		Dipentum	SS			250 MG	
	Confusional State		Premarin	SS			1.25 MG/DAILY	

	Coordination Abnormal	Zoloft	SS
100 MG/DAILY			
	Difficulty In Walking	Coumadin	C
	Disorientation	Motrin	C
	Dizziness	Lithium Carbonate	C
	Drug Interaction		
	Dysphagia		
	Dyspnoea		
	Emotional Distress		
	Fear		
	Gait Disturbance		
	Headache		
	Nausea		
	Palpitations		
	Restlessness		
	Speech Disorder		
	Transient Ischaemic		
	Attack		
	Vision Blurred		

Date:10/10/01ISR Number: 3809258-0Report Type:Expedited (15-DaCompany Report #WAES 01090701
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Brain Damage		Aspirin	C				
	Cerebrovascular Accident							
	Ulcer Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/10/01ISR Number: 3809613-9Report Type:Expedited (15-DaCompany Report #001-0945-M0101181
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Decreased	Health	Neurontin					
Hospitalization -	Bone Pain	Professional	(Gabapentin)	PS		ORAL	600 MG BID	
Initial or Prolonged	Coma						PER ORAL	
Other	Ecchymosis		Vioxx (Rofecoxib)	SS			25 MG	
	Fall		(Methadone)	C				
	Inflammation		Fosamax (Alendronate Sodium)	C				
	Loss Of Consciousness		Nasal Calcitonin (Calcitonin)	C				

Date:10/10/01ISR Number: 3809699-1Report Type:Expedited (15-DaCompany Report #WAES 01092507
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Congestive	Professional					MG/DAILY/PO	
	Condition Aggravated	Company	Accupril	C				
	Insomnia	Representative	Cardizem Cd	C				
	Renal Failure		Lanoxin	C				
			Lasix (Furosemide)	C				
			Os-Cal	C				
			Plaquenil	C				
			Zantac	C				
			Colchicine	C				
			Doxepin	C				
			Glyburide	C				
			Prednisone	C				
			Temazepam	C				

Date:10/10/01ISR Number: 3809704-2Report Type:Expedited (15-DaCompany Report #WAES 01070658
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breath Sounds Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cor Pulmonale	Health					MG/DAILY/PO	
	Dyspnoea	Professional	Caltrate	C				
	Dyspnoea Exertional		Entex	C				
	Fluid Overload		Norvasc	C				
	Oedema Peripheral		Novex	C				
	Pulmonary Congestion		Prevacid	C				
			Serevent	C				
			Vanceril	C				
			Albuterol	C				
			Aspirin	C				
			Oxygen	C				
			Vitamins	C				

Date:10/11/01ISR Number: 3806949-2Report Type:Expedited (15-DaCompany Report #WAES 01100560
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Tachycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged		Professional	Diocyclin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/01ISR Number: 3806957-1Report Type:Expedited (15-DaCompany Report #WAES 01100761
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/01ISR Number: 3806960-1Report Type:Expedited (15-DaCompany Report #WAES 01103707
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/01ISR Number: 3807310-7Report Type:Direct Company Report #
Age:70.5 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioplasty		Vioxx 12.5 Mg	PS			12.5 MG 1 EVERY AM	Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage

Date:10/11/01ISR Number: 3807311-9Report Type:Direct Company Report #
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25mg	PS		ORAL	25MG PO QD	
	Congestive		Zaroxylen	C				
	Renal Failure Acute		Lasix	C				
			Toprol	C				
			Atrovent	C				

			Albuterol	C		
			Levaquin	C		
			Laroxin	C		
			Buspar	C		
			Anoxyl	C		
			Xanax	C		

Date:10/11/01ISR Number: 3807678-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haematuria		Vioxx	PS		
25MG ONCE						
	Ketonuria					
DAILY						
	Micturition Urgency		Hydroxychloroquine	C		
	Prostatitis		Methotrexate	C		
	Proteinuria		Leflunomide	C		
	Renal Papillary Necrosis		Azathioprine	C		
			Folic Acid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/01ISR Number: 3807696-3Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS		ORAL	25 PO QD	
	Arrhythmia Supraventricular							

Date:10/12/01ISR Number: 3807824-XReport Type:Expedited (15-DaCompany Report #WAES 01109711
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Weight Increased							

Date:10/12/01ISR Number: 3807830-5Report Type:Expedited (15-DaCompany Report #WAES 01100460
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Difficulty In Walking							
Disability	Osteoarthritis							
	Ulcer							
	Ulcer Haemorrhage							

Date:10/12/01ISR Number: 3807832-9Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Conjunctival Hyperaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Idiopathic		Naprosyn	C				
	Thrombocytopenic Purpura							
	Oedema							
	Periorbital Haematoma							
	Post Procedural							

Haemorrhage
Skin Discolouration

Date:10/12/01ISR Number: 3807833-0Report Type:Expedited (15-DaCompany Report #WAES 01100365
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		Aspirin	C				
			Neurontin	C				
Disability			Paxil	C				
Other								

Date:10/12/01ISR Number: 3807835-4Report Type:Expedited (15-DaCompany Report #WAES 01105540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eosinophilia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3807836-6Report Type:Expedited (15-DaCompany Report #WAES 01101302
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/01ISR Number: 3807839-1Report Type:Expedited (15-DaCompany Report #WAES 01101257
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tinnitus		Diovan	C				
			Synthroid	C				
			Coumadin	C				
			Diazide	C				
			Estradiol	C				

Date:10/12/01ISR Number: 3807840-8Report Type:Expedited (15-DaCompany Report #WAES 01105059
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Urticaria		Prochlorperazine Maleate	C		ORAL		
			Fexofenadine Hydrochloride	C		ORAL		
			Ibuprofen	C		ORAL		

Date:10/12/01ISR Number: 3807843-3Report Type:Expedited (15-DaCompany Report #WAES 01101099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/01ISR Number: 3807844-5Report Type:Expedited (15-DaCompany Report #WAES 01109115
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Varices		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization - Initial or Prolonged	Haemorrhage Varices Oesophageal		Vioxx	SS		ORAL		
			Rabeprazole Sodium	C		ORAL		
Other			Acetaminophen	C		ORAL		
			Captopril And Hydrochlorothiazide	C		ORAL		

Date:10/12/01ISR Number: 3807845-7Report Type:Expedited (15-DaCompany Report #WAES 01109904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Peptic Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
			Fosamax	SS		ORAL	3	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3807846-9Report Type:Expedited (15-DaCompany Report #WAES 01109101
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:10/12/01ISR Number: 3808489-3Report Type:Expedited (15-DaCompany Report #WAES 01093409
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Disability	Bundle Branch Block Right		Zocor	C				
	Intermittent Claudication		Candesartan Cilexetil	C				
	Laryngeal Cancer							

Date:10/12/01ISR Number: 3808789-7Report Type:Expedited (15-DaCompany Report #200120667FR
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Other	Furosemide (Lasilix 40 Mg) Tablets	PS		ORAL	40 MG QD PO	
			Tramadol Hydrochloride Capsules	SS		ORAL	200 MG BID PO	6 DAY
			Tenordate Capsules	SS		ORAL	2 U PO	
			Rofecoxib (Vioxx)	SS		ORAL	PO	6 DAY
			Metformin Hydrochloride (Glucophage 850 Mg)	C				
			Losartan Potassium (Cozaar)	C				
			Fenofibrate (Lipanthyl)	C				

				*	C		
				*	C		
				*	C		

Date:10/12/01ISR Number: 3808835-0Report Type:Expedited (15-DaCompany Report #WAES 01093038
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eye Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/PO	
Hospitalization -	Gastrointestinal							
Initial or Prolonged	Haemorrhage		Coumadin	SS				
	Haemorrhage		Asacol	C				
	Prothrombin Time Abnormal		Estrogens	C				
	Urinary Tract Disorder							

Date:10/12/01ISR Number: 3808987-2Report Type:Expedited (15-DaCompany Report #HQ6700403OCT2001
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Cordarone					
Initial or Prolonged	Drug Interaction	Professional	(Amiodarone, Tablet)	PS		ORAL	200 MG 1X PER 1 DAY	366 DAY
	Muscular Weakness	Other						
	Renal Failure Acute		Vioxx (Rofecoxib,					
	Rhabdomyolysis		Tablet)	SS		ORAL	25 MG 1X PER	

1 DAY 366 DAY

Zocor (Simvastatin)	SS		ORAL

80 MG 1X PER

1 DAY 46 DAY

Lasix (Furosemide)	C
Aas (Acetylsalicylic Acid)	C
Marcoumar (Phenprocoumon)	C
Zestril (Lisinopril)	C

Date:10/12/01ISR Number: 3809001-5Report Type:Expedited (15-DaCompany Report #WAES 01098331
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Hypertensive Crisis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL

Dose Duration
25 MG/DAILY 8 DAY

Date:10/12/01ISR Number: 3809035-0Report Type:Expedited (15-DaCompany Report #WAES 01095677
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Convulsion	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL

Dose Duration
PO 3 MON

Date:10/12/01ISR Number: 3809037-4Report Type:Expedited (15-DaCompany Report #WAES 01033627
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Activated Partial Thromboplastin Time	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL

Dose Duration
25 MG/DAILY

	Prolonged	Professional		
PO				
	Ecchymosis		Acetaminophen	C
			Atorvastatin Calcium	C
			Betamethasone	C
			Calcitriol	C
			Calcium Carbonate	C
			Chloramphenicol	C
			Docusate Sodium (+)	
			Senna	C
			Dothiepin Hcl	C
			Ferrousso4	C
			Furosemide Sodium	C
			Hydroxocobalamin	C
			Levothyroxine Na	C
			Nizatidine	C
			Omeprazole Magnesium	C
			Oxazepam	C
			Potassium Chloride	C
			Prednisone	C
			Promethazine Hcl	C
			Temazepam	C

Date:10/12/01ISR Number: 3809102-1Report Type:Expedited (15-DaCompany Report #WAES 01095039
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse	Foreign	Vioxx	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Myocardial Ischaemia	Study						
PO								224 DAY
Other		Health Professional	Placebo (Unspecified)	C				

Date:10/12/01ISR Number: 3809106-9Report Type:Expedited (15-DaCompany Report #WAES 01109801
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Foreign	Tab Vioxx					
Other	Electrocardiogram	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Abnormal	Professional						
PO								1 DAY
	Electrocardiogram St Segment Depression	Other	Diclofenac	C				
			Ibuprofen	C				
	Ventricular Arrhythmia							
	Ventricular Extrasystoles							

Date:10/12/01ISR Number: 3809113-6Report Type:Expedited (15-DaCompany Report #WAES 01093476
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Tab Vioxx					
Initial or Prolonged	Atrial Fibrillation	Health	(Rofecoxib)	PS		ORAL	25 MG/AM PO	
	Chest Pain	Professional	Amiodarone	C				
	Heart Rate Irregular		Quinapril Hc1	C				
	Myocardial Infarction							

Date:10/12/01ISR Number: 3809436-0Report Type:Expedited (15-DaCompany Report #WAES 01072989
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Literature	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Health					MG/DAILY/PO	
	Cardiac Murmur	Professional	Elavil	C				
	Cells In Urine		Vasotec	C				
	Diabetes Mellitus		Aspirin	C				
	Electrolyte Imbalance		Carvedilol	C				
	Haematocrit Decreased		Epoetin	C				
	Haemoglobin Decreased		Ferrous Sulfate	C				
	Hypertension		Furosemide	C				
	Pco2 Decreased		Glyburide	C				
	Renal Failure Acute							
	Urinary Casts							

Date:10/12/01ISR Number: 3809438-4Report Type:Expedited (15-DaCompany Report #WAES 01091156
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other		Professional					MG/DAILY/PO	
		Company	Cardizem	C				
		Representative	Glucotrol Xl	C				
			Lopid	C				
			Plaquenil	C				

				Remicade	C		
				Folic Acid	C		

Date:10/12/01ISR Number: 3809439-6Report Type:Expedited (15-DaCompany Report #WAES 00040938
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Ratio Increased	Professional					MG/DAILY/PO	
	Prothrombin Time Prolonged	Company Representative	Coumadin	C				

Date:10/12/01ISR Number: 3809441-4Report Type:Expedited (15-DaCompany Report #WAES 01091517
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:10/12/01ISR Number: 3809443-8Report Type:Expedited (15-DaCompany Report #WAES 01060986
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Consumer	Vioxx	PS		ORAL	25 MG/1X/PO	
Life-Threatening	Congestive	Health	Keflex	C				
	Chest Pain	Professional	Robitussin Dac	C				
	Feeling Cold							
	Pneumonia							

Date:10/12/01ISR Number: 3809445-1Report Type:Expedited (15-DaCompany Report #WAES 01091560
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis	Health Professional	Vioxx	PS		ORAL	50 MG/DAILY/PO	
Disability								
Other								

Date:10/12/01ISR Number: 3809446-3Report Type:Expedited (15-DaCompany Report #WAES 01082423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO; PO,PO	
Initial or Prolonged	Condition Aggravated	Health Professional	Cartia (Diltiazem Hydrochloride)	C				
	Heart Rate Increased		Claritin	C				
			Lasix (Furosemide)	C				
			Prilosec	C				
			Tropel Xl Tablets	C				
			Estradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3809447-5Report Type:Expedited (15-DaCompany Report #WAES 01100368
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS			12.5	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO;	
		Company					15MG/DAILY/PO	
		Representative	Cardura	C				
			Lotensin	C				
			Meridia	C				
			Viagra	C				

Date:10/12/01ISR Number: 3809450-5Report Type:Expedited (15-DaCompany Report #WAES 01100365
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Congestive	Professional					MG/DAILY/PO	
Initial or Prolonged			Paxil	C				
Disability			Aspirin	C				
Other								

Date:10/12/01ISR Number: 3809462-1Report Type:Expedited (15-DaCompany Report #WAES 01062513
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Allergic Granulomatous	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Angiitis	Health	Lipitor	C				
	Anaemia	Professional	Norvasc	C				
	Arthralgia		Prinivil	C				
	Arthritis		Verelan	C				
	Asthenia							
	Blood Glucose Increased							
	Crohn'S Disease							

Dialysis
Dyspnoea
Eosinophilic Pneumonia
Gastritis
Glomerulonephritis
Haemorrhage
Lung Infiltration
Nausea
Pyrexia
Red Blood Cell
Sedimentation Rate
Increased
Renal Failure Acute
Tremor
Vasculitis

Date:10/12/01ISR Number: 3809728-5Report Type:Expedited (15-DaCompany Report #WAES 00060408
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Electrocardiogram Qrs
Hospitalization -	Complex Prolonged
Initial or Prolonged	Electrocardiogram T Wave
	Peaked
	Haematocrit Decreased

		Haemodialysis					
		Haemoglobin Decreased					
		Hyperkalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperphosphataemia	Literature	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY							
		Renal Failure Acute	Health				
PO							
			Professional	Glyburide	C		
				Oxybutynin Choloride	C		
				Ranitidine	C		
				Sodium Bicarbonate	C		
				Vitamins	C		

Date:10/12/01ISR Number: 3809744-3Report Type:Expedited (15-DaCompany Report #WAES 01080358
Age:63 YR Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure Acute	Literature	Tab Vioxx	PS		ORAL
PO							
			Health Professional	Diuretic	C		

Date:10/12/01ISR Number: 3809873-4Report Type:Expedited (15-DaCompany Report #2000COU1548
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Gastrooesophageal Reflux Disease	Consumer	Coumadin (Crystalline Warfarin Sodium)	PS		ORAL
PO							
		International Normalised Ratio Decreased		Neurontin (Gabapentin)	SS		
		Prothrombin Time Shortened		Tegretol (Carbamazepine)	SS		
		Transient Ischaemic Attack		Dilantin (Phenytoin Sodium)	SS		
		Trigeminal Neuralgia		Ni (Baclofen)	SS		
				Vioxx (Rofecoxib)	SS		
				Lanoxin (Digoxin)	SS		
				Ni Verapamil	SS		

			Lipitor (Atorvastatin Calcium)	SS		
			Ni Other (S) - Unspecified	SS		

Date:10/12/01ISR Number: 3809886-2Report Type:Expedited (15-DaCompany Report #WAES 01072990
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia	Literature	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Initial or Prolonged	Diarrhoea	Health					PO	
Other	Electrolyte Imbalance	Professional	Prinivil	C				
	Hypotension		Acetaminophen	C				
	Hypovolaemia		Aspirin	C				
	Nephropathy Toxic		Atenolol	C				
	Renal Failure Acute		Ferrous Sulfate	C				
			Furosemide	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/01ISR Number: 3810672-8Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Neurontin (Gabapentin)	PS		ORAL	300 MG PER	
Other	Blood Pressure Increased							
	Dry Mouth							
	Dysarthria		Vioxx (Rofecoxib)	SS				
	Dysuria		Zanaflex (Tizanidine)	SS				
	Fatigue							
	Miosis							
	Nausea							

Date:10/15/01ISR Number: 3809574-2Report Type:Expedited (15-DaCompany Report #200011757DDC
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Barrett'S Oesophagus	Foreign	Leflunomide	PS			20 MG QD	
	Condition Aggravated	Study	Vioxx	SS		ORAL	25 MG/DAY PO	
	Gastritis Erosive	Health	Meticorten	SS		ORAL	5 MG/DAY PO	
	Hiatus Hernia	Professional	Higroton	C				
	Hypertension	Other	Ranitidine	C				
	Oesophagitis							

Date:10/16/01ISR Number: 3809191-4Report Type:Expedited (15-DaCompany Report #WAES 01101289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/01ISR Number: 3809192-6Report Type:Expedited (15-DaCompany Report #WAES 01101028
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Facial Palsy		Ditropan	C		ORAL		
			Fosamax	C		ORAL		
			Prempro	C		ORAL		

Date:10/16/01ISR Number: 3809193-8Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Convulsion		Provigil	SS		ORAL		
	Dyspnoea		Amantadine					
	Dysuria		Hydrochloride	SS				
	Fall		Betaseron	SS				
SUBCUTANEOUS		YR						
	Laceration		Wellbutrin	C				
	Livedo Reticularis		[Therapy					6 MON
	Mental Impairment		Unspecified]	C				
	Oedema Peripheral		Procuren	C				
	Rash Macular		Prednisone	C				
	Serum Sickness		Vitamins					
	Status Epilepticus		(Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3809198-7Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/01ISR Number: 3809200-2Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Intestinal Obstruction		Vasotec	C		ORAL		
Disability	Large Intestine Perforation		Lipitor	C				
			Ziac	C				
			Aspirin	C				

Date:10/16/01ISR Number: 3809201-4Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Coumadin	C				
			[Therapy Unspecified]	C				

Date:10/16/01ISR Number: 3809202-6Report Type:Expedited (15-DaCompany Report #WAES 01105090
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Inhibition		Ethynodiol Diacetate	SS				
	Menstruation Irregular		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
	Unintended Pregnancy		Amitriptyline	C		ORAL		

Date:10/16/01ISR Number: 3809204-XReport Type:Expedited (15-DaCompany Report #WAES 01105541
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Non-Hodgkin'S Lymphoma		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Sulpiride	C				

Date:10/16/01ISR Number: 3809206-3Report Type:Expedited (15-DaCompany Report #WAES 01109609
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3809209-9Report Type:Expedited (15-DaCompany Report #WAES 01108204
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Renal Tubular Disorder		Vioxx	SS		ORAL		31 DAY

Date:10/16/01ISR Number: 3809210-5Report Type:Expedited (15-DaCompany Report #WAES 01106035
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/16/01ISR Number: 3809213-0Report Type:Expedited (15-DaCompany Report #WAES 01105084
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		82 DAY
	Bronchospasm							
	Hypertension							

Date:10/16/01ISR Number: 3809216-6Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Prednisone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Leflunomide	C		ORAL		

Date:10/16/01ISR Number: 3809220-8Report Type:Expedited (15-DaCompany Report #WAES 01108210
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	C		ORAL		
			Diclofenac	C		ORAL		
			Ibuprofen	C		ORAL		
			Acetaminophen	C		RECTAL		
			Adrenal Cortical Extract And Heparinoid And Salicylic Acid	C		TOPICAL		
			Orlistat	C		ORAL		
			Flupentixol Hydrochloride And Melitracen Hydrochloride	C		ORAL		
			Hypericin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3809751-0Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain In Extremity		Vioxx (25mg)	PS		ORAL	25MG PO	

Date:10/16/01ISR Number: 3809865-5Report Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ageusia		Vioxx 25mg Merck	PS	Merck		25MG 1 TABLE	
Hospitalization -	Dizziness						DAILY	
Initial or Prolonged	Headache							
	Hypoaesthesia							
	Nausea							
	Vomiting							

Date:10/16/01ISR Number: 3809869-2Report Type:Direct Company Report #
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mouth Ulceration		Rofecoxib Merck	PS	Merck	ORAL	ORAL	
Initial or Prolonged	Penile Ulceration		Naproxen	C				
Required	Skin Discolouration							
Intervention to	Skin Exfoliation							
Prevent Permanent	Skin Ulcer							
Impairment/Damage								

Date:10/16/01ISR Number: 3810059-8Report Type:Expedited (15-DaCompany Report #WAES 01107501
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased	Foreign	Tab Vioxx					

Initial or Prolonged	Syncope	Health Professional	(Rofecoxib)	PS		ORAL

Date:10/16/01ISR Number: 3810060-4Report Type:Expedited (15-DaCompany Report #WAES 01098258
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthma	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY 6 DAY						
			Zocor	C		
			Aspirin	C		
			Lisinopril-Hctz	C		

Date:10/16/01ISR Number: 3810090-2Report Type:Expedited (15-DaCompany Report #WAES 01065629
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Atrial Fibrillation
Hospitalization -	Blood Creatinine
Initial or Prolonged	Increased
	Blood Urea Increased
	Bronchitis
	Bronchopneumonia
	Chest Pain

		Heart Rate Increased Oedema Peripheral Pulmonary Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Right Ventricular Failure	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG / BID							
			Professional	Vasotec	C		
				Zocor	C		
				Aspirin	C		
				Bromazepam	C		
				Furosemide/Spironolactone	C		
				Metoprolol Succinate	C		

Date:10/16/01ISR Number: 3810092-6Report Type:Expedited (15-DaCompany Report #WAES 01105020
Age:67 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Pain Upper Anorexia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 - 25							
		Dysphagia					
MG/DAILY	18 DAY						
		Gastrooesophageal Reflux Disease Vomiting		Acetaminophen (+) Dihydrocodeine Bitartr	C		
				Amitriptyline	C		
				Bendroflumethiazide	C		
				Diazepam	C		

Date:10/16/01ISR Number: 3810093-8Report Type:Expedited (15-DaCompany Report #WAES 01096549
Age:91 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Melaena Oesophageal Stenosis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY	17 DAY						
			Professional				

Date:10/16/01ISR Number: 3810094-XReport Type:Expedited (15-DaCompany Report #WAES 01096507
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced	Foreign	Tab Vioxx					
Hospitalization -	Complications Of Maternal	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Exposure To Therapeutic	Professional	Acetaminophen	C				
	Drugs		Tramadol	C				
	Pregnancy							

Date:10/16/01ISR Number: 3810111-7Report Type:Expedited (15-DaCompany Report #WAES 01105034
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								387 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Levothyroxine Na	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3810112-9Report Type:Expedited (15-DaCompany Report #WAES 01105025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Haemoglobin						PO	92 DAY
	Haemoglobin Decreased		Tramadol	C				
	Mallory-Weiss Syndrome							
	Vomiting							

Date:10/16/01ISR Number: 3810113-0Report Type:Expedited (15-DaCompany Report #WAES 01096098
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Leukopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Neutropenia		Fluindione	C				
			Furosemide	C				
			Nifedipine	C				
			Omeprazole Sodium	C				
			Spironolactone	C				

Date:10/16/01ISR Number: 3810114-2Report Type:Expedited (15-DaCompany Report #WAES 01096088
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Decreased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	8 DAY	
	Gastric Ulcer Haemorrhage		Digoxin	C				
	Gastroenteritis		Ginkgo Biloba Extract	C				
	Helicobacter		Glipizide	C				
	Haematemesis		Levothyroxine Na	C				
	Haemoglobin Decreased							
	Heart Rate Increased							
	Melaena							

Date:10/16/01ISR Number: 3810127-0Report Type:Expedited (15-DaCompany Report #WAES 01096781
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Peptic Ulcer Perforation	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	25 MG / DAILY	
Initial or Prolonged								
PO							5	DAY
			Elavil	C				
			Acetaminophen	C				
			Albuterol (+)					
			Ipratropium Bromide	C				
			Aspirin	C				
			Cephalexin	C				
			Dalteparin Sodium	C				
			Ferrousso4	C				
			Roxithromycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3810195-6Report Type:Expedited (15-DaCompany Report #WAES 01100758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema	Professional	Imitrex	C				
	Optic Neuropathy		Ultram	C				

Date:10/16/01ISR Number: 3810382-7Report Type:Expedited (15-DaCompany Report #WAES 01100587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Myocardial Infarction							

Date:10/16/01ISR Number: 3810383-9Report Type:Expedited (15-DaCompany Report #WAES 01100588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tasb Vioxx Unk	PS		ORAL	PO	
	Myocardial Infarction							

Date:10/16/01ISR Number: 3810385-2Report Type:Expedited (15-DaCompany Report #WAES 01100589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810387-6Report Type:Expedited (15-DaCompany Report #WAES 01100590
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810388-8Report Type:Expedited (15-DaCompany Report #WAES 01100591
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810390-6Report Type:Expedited (15-DaCompany Report #WAES 01100592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810397-9Report Type:Expedited (15-DaCompany Report #WAES 01100593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810399-2Report Type:Expedited (15-DaCompany Report #WAES 01100594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Blood Pressure Increased							

Date:10/16/01ISR Number: 3810401-8Report Type:Expedited (15-DaCompany Report #WAES 01100595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Other	Myocardial Infarction							

Date:10/16/01ISR Number: 3810410-9Report Type:Expedited (15-DaCompany Report #WAES 01100585
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810415-8Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Inadequate Control	Professional Company Representative						

Date:10/16/01ISR Number: 3810416-XReport Type:Expedited (15-DaCompany Report #WAES 01100538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810418-3Report Type:Expedited (15-DaCompany Report #WAES 01100581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810420-1Report Type:Expedited (15-DaCompany Report #WAES 01100582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810422-5Report Type:Expedited (15-DaCompany Report #WAES 01100583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/01ISR Number: 3810423-7Report Type:Expedited (15-DaCompany Report #WAES 01100584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810425-0Report Type:Expedited (15-DaCompany Report #WAES 01100511
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810433-XReport Type:Expedited (15-DaCompany Report #WAES 01100719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:10/16/01ISR Number: 3810524-3Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Conjunctival Hyperaemia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Idiopathic Thrombocytopenic Purpura		Naprosyn	C				
	Oedema							
	Post Procedural							

Complication
Post Procedural
Haemorrhage
Skin Discolouration
Wound Secretion

Date:10/16/01ISR Number: 3810525-5Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis	Health	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Intestinal Obstruction	Professional						
Disability	Large Intestine		Lipitor	C				
	Perforation		Vasotec	C				
			Ziac	C				
			Aspirin	C				

Date:10/16/01ISR Number: 3810527-9Report Type:Expedited (15-DaCompany Report #WAES 01071681
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Confusional State
	Dehydration
	Dermatitis

	Hypotension						
	Leukocytosis						
	Mental Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Petechiae	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE
	Polymyalgia Rheumatica	Professional					

Date:10/16/01ISR Number: 3810528-0Report Type:Expedited (15-DaCompany Report #WAES 01092218
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5
	Cerebrovascular Accident	Professional					MG/DAILY/PO
	Disorientation		Prilosec	C			
	Hypertension		Zoloft	C			
	Speech Disorder		Zytrec	C			
	Transient Ischaemic		Aspirin	C			
	Attack		Thyroid	C			

Date:10/16/01ISR Number: 3810532-2Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5
Initial or Prolonged	Convulsion	Professional					MG/DAILY/PO
	Dyspnoea		Provigil 200mg	SS		ORAL	200
	Dysuria						MG/DAILY/PO
	Fall		Betaseron	SS		SUBCUTANEOUS	QOD/SC
	Laceration		Procuren	C			
	Livedo Reticularis		Wellbutrin	C			
	Mental Impairment		Therapy Unspecified	C			
	Oedema Peripheral		Amantadine				
	Rash Macular		Hydrochloride	C			

Serum Sickness		Prednisone	C
Status Epilepticus		Vitamins (Unspecified)	C

Date:10/16/01ISR Number: 3810547-4Report Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Myocardial Infarction	Professional						
	Thrombosis		Atenolol	C				

Date:10/16/01ISR Number: 3810632-7Report Type:Expedited (15-DaCompany Report #WAES 01100586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	18 MON

Date:10/16/01ISR Number: 3810957-5Report Type:Expedited (15-DaCompany Report #WAES 01092191
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder
	Gastrointestinal

Perforation
Ulcer Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Health					MG/DAILY/PO	
Professional						

Date:10/17/01ISR Number: 3809986-7Report Type:Expedited (15-DaCompany Report #WAES 01106030
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Pancreatitis							

Date:10/17/01ISR Number: 3809988-0Report Type:Expedited (15-DaCompany Report #WAES 01109115
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -	Varices Oesophageal		Vioxx	SS		ORAL		
Initial or Prolonged	Varicose Vein		Rabeprazole Sodium	C		ORAL		
			Acetaminophen	C		ORAL		
			Captopril And Hydrochlorothiazide	C		ORAL		

Date:10/17/01ISR Number: 3809990-9Report Type:Expedited (15-DaCompany Report #WAES 01101626
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Haemorrhage		Prevacid	C				
	Ulcer		Lasix (Furosemide)	C				

			Potassium (Unspecified)	C		
			Pravachol	C		

Date:10/17/01ISR Number: 3809997-1Report Type:Expedited (15-DaCompany Report #WAES 01105060
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
	Oedema Peripheral		Warfarin	C		ORAL		
	Rectal Haemorrhage		Verapamil	C		ORAL		
			Hydroxyzine	C		ORAL		
			Estradiol	C		TOPICAL		

Date:10/17/01ISR Number: 3810000-8Report Type:Expedited (15-DaCompany Report #WAES 01101630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Limb Injury		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Pulmonary Embolism		Coumadin	C				
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/01ISR Number: 3810001-XReport Type:Expedited (15-DaCompany Report #WAES 01101051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Coumadin	C				
			[Therapy Unspecified]	C				

Date:10/17/01ISR Number: 3810002-1Report Type:Expedited (15-DaCompany Report #WAES 01105563
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Dysphagia							
	Urticaria							

Date:10/17/01ISR Number: 3810003-3Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Fluid Retention		Naprosyn	C				
	Idiopathic Thrombocytopenic Purpura							
	Ocular Hyperaemia							
	Periorbital Haematoma							
	Post Procedural Haemorrhage							

Date:10/17/01ISR Number: 3810004-5Report Type:Expedited (15-DaCompany Report #WAES 01106038
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Flushing		Vioxx	PS	Merck & Co., Inc	ORAL
29 DAY						
Hospitalization -	Malaise		Sotalol			
Initial or Prolonged	Sciatica		Hydrochloride	SS		ORAL
	Torsade De Pointes		Flurbiprofen	C		ORAL
	Tremor		Atorvastatin Calcium	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Quinapril Hydrochloride	C		ORAL

Date:10/17/01ISR Number: 3810006-9Report Type:Expedited (15-DaCompany Report #WAES 01106043
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
27 DAY						
Initial or Prolonged			Vioxx	SS		ORAL
			Quinapril Hydrochloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/01ISR Number: 3810009-4Report Type:Expedited (15-DaCompany Report #WAES 01102188
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Lanoxin	SS		ORAL		
Initial or Prolonged	Therapeutic Agent		Rythmol	C		ORAL		
	Toxicity		K-Dur	C		ORAL		
			Neurontin	C		ORAL		
			Betapace	C				
			Vicodin Tablets	C				
			Ambien	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Vitamins (Unspecified)	C				

Date:10/17/01ISR Number: 3810010-0Report Type:Expedited (15-DaCompany Report #WAES 01108156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Oedema							

Date:10/17/01ISR Number: 3810255-XReport Type:Direct Company Report #
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Gleevec	PS	Novartis	ORAL	400MG PO QD	
Intervention to	Increased		Cytarabine	SS				
INTRAVENOUS							100MG IV QD	
Prevent Permanent	Blood Urea Increased		Vioxx	SS		ORAL	25MG PO BID	
Impairment/Damage								

Date:10/17/01ISR Number: 3810747-3Report Type:Direct Company Report #
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck	ORAL	25MG QD ORAL	
Initial or Prolonged	Cardiac Failure		Avandia	C				
	Congestive		Vasotec	C				
	Chest Pain							
	Dyspnoea Exertional							
	Gastrointestinal Disorder							
	Oedema Peripheral							
	Weight Increased							

Date:10/17/01ISR Number: 3810825-9Report Type:Expedited (15-DaCompany Report #HQ7066112OCT2001
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Bundle Branch Block Right
Initial or Prolonged	Cardiomegaly
	Chest Pain
	Cough
	Dyspnoea
	Electrocardiogram
	Abnormal
	Jaundice

Pulmonary Embolism

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Temesta (Lorazepam, Tablet)	PS		ORAL	2.5 MG 1X PER 1 DAY	
Other	Chondrosulf (Chondroitin Sulfate Sodium,)	SS			1.2 G 1X PER 1 DAY	
	Etioven (Naftazone,)	SS			30 MG 1X PER 1 DAY	
	Sectral "May & Baker Ltd" (Acebutolol Hydrochloride,)	SS			100 MG 1X PER 1 DAY	
	Vioxx (Rofecoxib, Tablet)	SS			25 MG 1X PER 1 DAY	10 DAY

Date:10/17/01ISR Number: 3810857-0Report Type:Expedited (15-DaCompany Report #ZANA000857 (0)
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL	4 MG DAILY	
	Fatigue	Health						
Other	Oedema Peripheral	Professional				ORAL		
	Sinus Bradycardia	Distributor	Vioxx (Rofecoxib)	SS		ORAL	25 MG DAILY	

ORAL

Date:10/17/01ISR Number: 3811049-1Report Type:Direct Company Report #
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	

Date:10/17/01ISR Number: 3811090-9Report Type:Direct Company Report #
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal		Vioxx	PS		ORAL	25 MG PO BID	
	Haemorrhage		Asa	SS		ORAL	81 MG PO QD	
			Wellbutrin	C				
			Sinemet	C				
			Tylenol	C				
			Cardura	C				
			Imipramine	C				
			Stool Softener	C				
			Laxative	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3810788-6Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Vioxx	SS		ORAL		
	Respiratory Arrest		Prevacid	C				
	Vomiting		Atenolol	C				
			Hydrodiuril	C				

Date:10/18/01ISR Number: 3810795-3Report Type:Expedited (15-DaCompany Report #WAES 01100511
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/01ISR Number: 3810811-9Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Celebrex	SS				
	Blood Pressure Increased							
	Exsanguination							
	Haemorrhage							
	Large Intestinal Ulcer							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							

Date:10/18/01ISR Number: 3810813-2Report Type:Expedited (15-DaCompany Report #WAES 01101985
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dry Skin		Vioxx	PS	Merck & Co., Inc	ORAL		
	Skin Exfoliation		Bactrim	C				

				Lactulose	C		
				Colace	C		

Date:10/18/01ISR Number: 3810816-8Report Type:Expedited (15-DaCompany Report #WAES 01108135
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Hypertensive Crisis		Vioxx	SS		ORAL		3 DAY
	Oedema Peripheral							

Date:10/18/01ISR Number: 3810817-XReport Type:Expedited (15-DaCompany Report #WAES 01105136
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		302 DAY
Initial or Prolonged	Haemorrhage		Amlodipine	C		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3810821-1Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Leflunomide	C		ORAL		

Date:10/18/01ISR Number: 3811134-4Report Type:Direct Company Report #
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain		Vioxx 50 Mg	PS			50 MG X 3 DAY THEN 25 MG Q DAY	
	Cholelithiasis							
	Duodenal Ulcer							
	Perforation		Toradol 60 Mg Im Q 8 Hours X 3 On Previous Admit	SS		INTRAMUSCULAR	60 MG IM Q 8 HOURS X 3 DOSES	
	Fluid Retention							
	Haemorrhage							
	Ileus Paralytic							
			Insulin	C				
			Diflucan	C				
			Lortab	C				
			Cyclobenzapril	C				
			Neurontin	C				
			Glucophage	C				

Date:10/18/01ISR Number: 3811165-4Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastrointestinal		Vioxx	PS		ORAL
PO PREADM						
Initial or Prolonged	Haemorrhage					

Date:10/18/01ISR Number: 3811205-2Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diverticulitis		Vioxx	PS		ORAL
PO						
Initial or Prolonged	Haematochezia					

Date:10/18/01ISR Number: 3811207-6Report Type:Expedited (15-DaCompany Report #WAES 01076037
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abortion	Foreign	Tab Vioxx			
Hospitalization -	Complications Of Maternal	Health	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Initial or Prolonged	Exposure To Therapeutic Drugs	Professional				
	Intra-Uterine Death					
	Menorrhagia					
	Menstrual Disorder					
	Pregnancy					

Date:10/18/01ISR Number: 3811210-6Report Type:Expedited (15-DaCompany Report #WAES 01099004
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Other	(Rofecoxib)	PS		ORAL	50 MG PO	9 DAY

Date:10/18/01ISR Number: 3811234-9Report Type:Expedited (15-DaCompany Report #WAES 01095530
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Foreign	Tab Vioxx					
Life-Threatening	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	12.5 MG/BID	258 DAY
Hospitalization - Initial or Prolonged	Multi-Organ Failure	Professional	Benserazide Hydrochloride (+)					
	Upper Gastrointestinal Haemorrhage		Levodopa	C				
			Captopril	C				
			Thioridazine Hydrochloride	C				
			Torsemide	C				

Date:10/18/01ISR Number: 3811236-2Report Type:Expedited (15-DaCompany Report #WAES 01035062
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Encephalopathy	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Hepatic Failure	Other	(Rofecoxib)	PS		ORAL		
Other								

Date:10/18/01ISR Number: 3811238-6Report Type:Expedited (15-DaCompany Report #WAES 01109904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Haemoglobin Decreased	Foreign	Tab Vioxx			
	Peptic Ulcer Haemorrhage	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY 3 WK						
			Tab Fosamax			
			(Alendronate Sodium)	SS		ORAL
10 MG/DAILY 3 WK						

Date:10/18/01ISR Number: 3811239-8Report Type:Expedited (15-DaCompany Report #WAES 01109115
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Bleeding Varicose Vein	Foreign	Tab Vioxx			
Hospitalization -	Oesophageal Haemorrhage	Health	(Rofecoxib)	PS		ORAL
12.5						
Initial or Prolonged	Varices Oesophageal	Professional				
MG/DAILY:						
Other						
12.5 MG/Q12H 2 WK						
			Acetaminophen	C		
			Captopril/Hctz	C		
			Rabeprazole Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3811240-4Report Type:Expedited (15-DaCompany Report #WAES 01105059
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Tab Vioxx					
Hospitalization -	Urticaria	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	2 DAY
Initial or Prolonged			Fexofenadine Hydrochloride	C				
			Ibuprofen	C				
			Prochlorperazine Maleate	C				

Date:10/18/01ISR Number: 3811241-6Report Type:Expedited (15-DaCompany Report #WAES 01105540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Eosinophilia							

Date:10/18/01ISR Number: 3811243-XReport Type:Expedited (15-DaCompany Report #WAES 01109101
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	5 DAY

Date:10/18/01ISR Number: 3811251-9Report Type:Expedited (15-DaCompany Report #WAES 01093718
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Serotonin Syndrome	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

PO
Tab Paroxetine Hcl SS ORAL
20 MG/BID PO 75 DAY

Date:10/18/01ISR Number: 3811259-3Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS			50MG ONCE	
Hospitalization -	Perforation						DAILY	
Initial or Prolonged			Aspirin	SS				
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:10/18/01ISR Number: 3811261-1Report Type:Direct Company Report #
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise		Vioxx	PS		ORAL	1 PER DAY	
	Nausea							

-ORALLY TOOK

2-3 DAYS 3 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3811348-3Report Type:Expedited (15-DaCompany Report #WAES 01109711
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Weight Increased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	8 DAY

Date:10/18/01ISR Number: 3811349-5Report Type:Expedited (15-DaCompany Report #WAES 01103707
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:10/18/01ISR Number: 3811501-9Report Type:Expedited (15-DaCompany Report #WAES 00050132
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased	Health	Tab Vioxx	PS		ORAL PO		
	Drug Interaction Dysphagia Hallucination Psychotic Disorder Tachycardia	Professional Other	Zanaflex	SS				

Date:10/18/01ISR Number: 3811547-0Report Type:Expedited (15-DaCompany Report #WAES 01100761
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO		

Date:10/18/01ISR Number: 3811549-4Report Type:Expedited (15-DaCompany Report #WAES 01100560
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tachycardia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Diocyclin	C				

Date:10/18/01ISR Number: 3811550-0Report Type:Expedited (15-DaCompany Report #WAES 00110998
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Confusional State	Other						
Disability	Embolism		Motrin	C				
Other	Fatigue		Percocet	C				
	Haemorrhagic Stroke							
	Headache							
	Medication Error							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/01ISR Number: 3811551-2Report Type:Expedited (15-DaCompany Report #WAES 00050131
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia	Health	Tab Vioxx	PS		ORAL	PO	
	Chest Pain	Professional	Zanaflex	SS				
	Dizziness	Other	Maxalt (Rizatriptan Benzoate	C				
	Drug Interaction							
	Hypotension							

Date:10/18/01ISR Number: 3811553-6Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conjunctival Hyperaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Cyanosis	Professional					PO	
	Fluid Retention		Naprosyn	C				
	Haemorrhage							
	Idiopathic							
	Thrombocytopenic Purpura							
	Platelet Count Decreased							
	Procedural Site Reaction							
	Swelling							

Date:10/18/01ISR Number: 3811554-8Report Type:Expedited (15-DaCompany Report #WAES 01072772
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Health					PO	
		Professional	Altace	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Flovent	C				
			Fosamax	C				

K-Dur	C
Lasix (Furosemide)	C
Lopressor	C
Zantac	C
Aspirin	C
Digoxin	C

Date:10/18/01ISR Number: 3811561-5Report Type:Expedited (15-DaCompany Report #WAES 01101302
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/18/01ISR Number: 3811563-9Report Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Constipation
Hospitalization - Initial or Prolonged	Diverticulum
	Dizziness

Rectal Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Study	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Health					PO; 25	
Professional					MG/DAILY /PO	
	Tab Placebo (Unspecified) Unk	SS		ORAL	PO	
	Acetaminophen Unk	SS		ORAL	325 MG	
					/PRN/PO	
	Tears Naturale	C				
	Tubex	C				
	Vasocon-A	C				
	Aspirin	C				
	Folic Acid	C				
	Methotrexate	C				

Date:10/18/01ISR Number: 3811571-8Report Type:Expedited (15-DaCompany Report #WAES 01100365
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Belligerence	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Cardiac Failure	Professional					MG/DAILY/PO	
Initial or Prolonged	Congestive	Company	Neurontin	C				
Disability		Representative	Paxil	C				
Other			Aspirin	C				

Date:10/18/01ISR Number: 3811750-XReport Type:Expedited (15-DaCompany Report #WAES 01062364
Age:96 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia Haemolytic
	Autoimmune

Anisocytosis
Antibody Test Positive
Blood Pressure Decreased
Breath Sounds Decreased
Cardiac Arrest
Cardiac Failure
Congestive
Cardiac Murmur
Chest Pain
Condition Aggravated
Dyspnoea
Ecchymosis
Epistaxis
Faecal Occult Blood
Positive
Fall
Haemorrhage Subcutaneous
Idiopathic
Thrombocytopenic Purpura
Nausea
Petechiae
Platelet Function Test
Abnormal
Pleural Effusion
Poikilocytosis
Reticulocytosis

Skin Lesion

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
12.5 OR 25 MG/DAILY/PO		Health Professional	Tab Vioxx	PS		ORAL
			Celebrex	C		
			Imdur	C		
			Norvasc	C		
			Ogen	C		
			Prilosec	C		
			Atenolol	C		
			Atenolol	C		
			Isosorbide	C		
			Nitroglycerin	C		
			Nonsteroidal Anti-Inflammatory	C		
			Vitamins	C		

Date:10/18/01ISR Number: 3811781-XReport Type:Expedited (15-DaCompany Report #WAES 01081114
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
Hospitalization - Initial or Prolonged	Epistaxis	Health Professional						
Other	Gastrointestinal Haemorrhage		Claritin	C				
	Hepatic Failure		Keflex	C				
	Influenza Like Illness		Maxalt (Rizatriptan Benzoate)	C				
	Oesophageal Varices Haemorrhage		Premarin	C				
	Portal Hypertension		Prevacid	C				
	Respiratory Arrest		Questran	C				
	Retching		Ultram	C				
			Vasotec	C				
			Xanax	C				
			Zoloft	C				
			Lorazepam	C				

Date:10/18/01ISR Number: 3811782-1Report Type:Expedited (15-DaCompany Report #WAES 01062226
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Gallbladder Disorder	Professional	Allegra	C				
	Hepatic Steatosis		Ceftin	C				
	Hepatitis		Tylenol With Codeine #3	C				
	Infectious Mononucleosis		Zyrtec	C				
	Influenza Like Illness		Azithromycin	C				
	Polyp							

Date:10/18/01ISR Number: 3811783-3Report Type:Expedited (15-DaCompany Report #WAES 01070915
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Stevens-Johnson Syndrome	Professional					PO	
Initial or Prolonged		Company						
Other		Representative						

Date:10/18/01ISR Number: 3811784-5Report Type:Expedited (15-DaCompany Report #WAES 01100460
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Osteoarthritis Ulcer							
Disability	Ulcer Haemorrhage							

Date:10/18/01ISR Number: 3811785-7Report Type:Expedited (15-DaCompany Report #WAES 01101099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
		Company Representative						

Date:10/18/01ISR Number: 3811786-9Report Type:Expedited (15-DaCompany Report #WAES 01101257
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Tinnitus							
			Coumadin	C				
			Diazide	C				
			Diovan	C				
			Synthroid	C				
			Estradiol	C				

Date:10/19/01ISR Number: 3811281-7Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fluid Retention Hypernatraemia Renal Failure		Vioxx	PS				

Date:10/19/01ISR Number: 3811291-XReport Type:Direct Company Report #
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx 25 Mg	PS			25 MG QD	
	Burning Sensation		Aspirin 325 Mg	SS			325 MG QD	
	Faeces Discoloured Fatigue Gastrointestinal Haemorrhage Lethargy							

Date:10/19/01ISR Number: 3811293-3Report Type:Direct Company Report #
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis		Vioxx 25 Mg	PS			25 MG QD	2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/01ISR Number: 3811294-5Report Type:Direct Company Report #
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Faeces		Vioxx	PS			25 MG QD	
Initial or Prolonged	Asthenia							
	Chromaturia							
	Fatigue							
	Jaundice							
	Nausea							

Date:10/19/01ISR Number: 3811302-1Report Type:Expedited (15-DaCompany Report #WAES 01102196
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoglycaemia		Mestinon	C				
			Prevacid	C				
			Estrace	C				
			Elavil	C				

Date:10/19/01ISR Number: 3811304-5Report Type:Expedited (15-DaCompany Report #WAES 01106017
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Cardiac Disorder		Chondroitin Sulfate					
	Cardiomegaly		Sodium	C		ORAL		
	Chest Pain		Naftazone	C		ORAL		
	Coronary Artery Disease		Lorazepam	C		ORAL		
	Cough		Acebutolol					
	Dyspnoea		Hydrochloride	C		ORAL		
	Electrocardiogram T Wave							
	Inversion							
	Hypokinesia							
	Pulmonary Embolism							
	Ventricular Hypertrophy							

Date:10/19/01ISR Number: 3811305-7Report Type:Expedited (15-DaCompany Report #WAES 01101028
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Ditropan	C		ORAL		
			Fosamax	C		ORAL		
			Prempro	C		ORAL		

Date:10/19/01ISR Number: 3811430-0Report Type:Expedited (15-DaCompany Report #WAES 01102263
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Hospitalization -	Hypoaesthesia		Flexeril	C				
Initial or Prolonged	Pain		Combivent	C				
	Shock		Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/01ISR Number: 3811432-4Report Type:Expedited (15-DaCompany Report #WAES 01101639
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dislocation Of Sternum		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematocrit Decreased		Coumadin	SS				
	Haemoglobin Decreased		Coumadin	SS				
	Haemothorax		Lasix (Furosemide)	C				
	International Normalised		Lopressor	C				
	Ratio Increased		Percocet	C				
	Medication Error		Colace	C				
	Platelet Count Decreased		Potassium Chloride	C				
	Prothrombin Time		Zantac	C				
	Prolonged		Xanax	C				
	White Blood Cell Count		Robitussin	C				
	Increased		Metamucil	C				

Date:10/19/01ISR Number: 3811489-0Report Type:Direct Company Report #
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Vioxx	PS			25 MG 1 X	DAILY
	Blood Pressure Increased							
	Eyelid Disorder		Zoloft	C				
	Joint Stiffness		Librox	C				
	Lethargy		Zantac	C				
	Pain In Extremity		Axid	C				
	Weight Increased							

Date:10/19/01ISR Number: 3812665-3Report Type:Expedited (15-DaCompany Report #200120869FR
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Thrombosis Ischaemic Stroke Myocardial Infarction	Foreign Other	Heparin-Fraction, Sodium Salt (Lovenox) Solution For Injection	PS		SUBCUTANEOUS	40 MG QD SC	5 DAY

				Rofecoxib (Vioxx) Tablets	SS	ORAL
25 MG QD PO						
				Pamidronate Disodium (Aredia) Solution For Injection	SS	
INTRAVENOUS	30 MG QD IV	1	DAY			
				Prednisone (Cortancyl 20 Mg) Tablets	SS	ORAL
10 MG QD PO						
				Paracetamol (Dafalgan) Capsules	SS	ORAL
1000 MG TID						
PO	6	DAY				
				Meprobamate, Aceprometazine (Mepronizine)	C	
				Bromazepam (Lexomil)	C	
				Calcifediol (Dedrogyl)	C	
				Ketoprofen (Profenid)	C	
				Calcium Phosphate (Ostram)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/01ISR Number: 3812681-1Report Type:Expedited (15-DaCompany Report #WAES 01105060
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration	Foreign	Tab Vioxx					
	Oedema Peripheral	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Peripheral Embolism							
PO								31 DAY
	Rectal Haemorrhage		Estradiol	C				
			Hydroxyzine	C				
			Verapamil	C				
			Warfarin	C				

Date:10/19/01ISR Number: 3812684-7Report Type:Expedited (15-DaCompany Report #WAES 01106035
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:10/19/01ISR Number: 3812689-6Report Type:Expedited (15-DaCompany Report #WAES 01108210
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Acetaminophen	C				
			Adrenal Cortical Extract (+)					
			Heparinoid	C				
			Celecoxib	C				
			Diclofenac	C				
			Flupentixol Hydrochloride (+)					
			Melitracen	C				
			Hyperican	C				

			Ibuprofen	C		
			Orlistat	C		

Date:10/19/01ISR Number: 3812712-9Report Type:Expedited (15-DaCompany Report #WAES 01105084
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension	Foreign	Tab Vioxx					
	Bronchospasm	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	82 DAY
	Hypertension							

Date:10/19/01ISR Number: 3812714-2Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional	Leflunomide	C				
			Prednisone	C				
			Tramadol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/01ISR Number: 3812723-3Report Type:Expedited (15-DaCompany Report #WAES 01109115
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Varices	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	12.5	
Initial or Prolonged		Professional					MG/DAILY;	
							12.5 MG/Q12H	2 WK
			Acetaminophen	C				
			Captopril/Hctz	C				
			Rabeprazole Sodium	C				

Date:10/19/01ISR Number: 3812785-3Report Type:Expedited (15-DaCompany Report #WAES 01105090
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Tab Vioxx					
	Menstrual Disorder	Other	(Rofecoxib)	PS		ORAL	12.5 - 25 MG	
	Pregnancy On Oral							
	Contraceptive		Ethynodiol Diacetate	SS			DAILY	
			Acetaminophen (+)					
			Dihydrocodeine					
			Bitartr	C				
			Amitriptyline	C				

Date:10/19/01ISR Number: 3812786-5Report Type:Expedited (15-DaCompany Report #WAES 01105541
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Non-Hodgkin'S Lymphoma	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL		
		Professional	Aspirin	C				
			Sulpiride	C				

Date:10/19/01ISR Number: 3812787-7Report Type:Expedited (15-DaCompany Report #WAES 01108204
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria Renal Tubular Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	31 DAY

Date:10/19/01ISR Number: 3812820-2Report Type:Expedited (15-DaCompany Report #WAES 01109609
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain Dyspnoea Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:10/22/01ISR Number: 3812065-6Report Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Condition Aggravated		Vioxx 25 Mg Msd	PS	Msd	AURICULAR (OTIC)	25 MG/QD/AURICUL	

AR (OTIC)

Detrol	C	
Lanoxin	C	
Lasix	C	
Iron	C	
Nitroglycerin Sl	C	

Date:10/22/01ISR Number: 3812576-3Report Type:Expedited (15-DaCompany Report #WAES 01101289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Consumer	Tab Vioxx	PS	Merck & Co., Inc.	ORAL	PO	

Date:10/22/01ISR Number: 3812580-5Report Type:Expedited (15-DaCompany Report #WAES 01082552
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS	Merck & Co., Inc.	ORAL	25 MG/DAILY/PO	
Hospitalization -	Convulsion	Professional						
Initial or Prolonged	Coordination Abnormal	Company	Aciphex	C				
Other	Csf Lymphocyte Count	Representative	Lortab	C				
	Increased		Doxycycline	C				
	Dizziness		Ibuprofen	C				
	Encephalitic Infection							
	Encephalitis Viral							
	Hemiplegia							
	Meningitis							
	Paralysis							
	Red Blood Cells Csf Positive							
	Transient Ischaemic Attack							
	Visual Field Defect							

Date:10/22/01ISR Number: 3812657-4Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Intestinal Obstruction	Professional						
Initial or Prolonged	Large Intestine		Lipitor	C				
Disability	Perforation		Vasotec	C				
			Ziac	C				
			Aspirin	C				

Date:10/22/01ISR Number: 3812658-6Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Convulsion
	Dyspnoea
	Dysuria
	Fall
	Fatigue
	Laceration
	Mental Impairment
	Serum Sickness

Status Epilepticus

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Provigil 200 Mg	SS		ORAL	200 MG/DAILY/PO	
			Betaseron	SS		SUBCUTANEOUS	QOD/SC	
			Amantadine Hydrochloride	SS				
			Procuren	C				
			Wellbutrin	C				
			Prednisone	C				
			Vitamins	C				

Date:10/22/01ISR Number: 3812780-4Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:10/22/01ISR Number: 3812784-1Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rectal Haemorrhage		Coumadin	C				

Date:10/22/01ISR Number: 3812808-1Report Type:Expedited (15-DaCompany Report #WAES 01101626
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	4 DAY
	Ulcer		Lasix (Furosemide)	C				
			Pravachol	C				
			Prevacid	C				
			Potassium (Unspecified)	C				

Date:10/22/01ISR Number: 3812809-3Report Type:Expedited (15-DaCompany Report #WAES 01092218
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Disorientation	Professional					MG/DAILY/PO	
	Hypertension		Prilosec	C				
	Speech Disorder		Zoloft	C				
			Zyrtec	C				
			Aspirin	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/01ISR Number: 3812811-1Report Type:Expedited (15-DaCompany Report #WAES 01101028
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Ditropan	C				
			Fosamax	C				
			Prempro	C				

Date:10/22/01ISR Number: 3813344-9Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx (50 Mg Tab)	PS		ORAL	25MG QD PO	
	Oedema							

Date:10/22/01ISR Number: 3813360-7Report Type:Expedited (15-DaCompany Report #WAES 01090674
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Brain Damage		Accupril	C				
	Cerebral Atrophy		Ambien	C				
	Cerebrovascular Accident		Dilantin	C				
	Heart Rate Decreased		Inderal	C				
	Loss Of Consciousness		Lasix (Furosemide)	C				
	Neck Pain		Percocet	C				
	Pain In Extremity		Prevacid	C				
	Respiratory Arrest		Tagamet	C				
	Syncope		Toprol Xl Tablets	C				
			Ultram	C				
			Vasocon-A	C				
			Zoloft	C				
			Metoclopramide	C				
			Nitroglycerin	C				

				Potassium (Unspecified)	C		

Date:10/22/01ISR Number: 3813362-0Report Type:Expedited (15-DaCompany Report #WAES 01093161
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative	Celebrex	C				

Date:10/22/01ISR Number: 3813781-2Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	5 DAY
	Myocardial Infarction		Enoxaparin	C				
			Acetaminophen	C		ORAL	INTRAVENOUS	1 DAY
			Pamidronate Disodium	C				
			Prednisone	C		ORAL	6 DAY	
			Vitamin D					

				(Unspecified)	C		ORAL
				Calcium Phosphate, Tribasic	C		ORAL
				Bromazepam	C		ORAL
				Acepromet azine Maleate And Meprobamate	C		ORAL
				Ketoprofen	C		
INTRAMUSCULAR	5	DAY					

Date:10/22/01ISR Number: 3813782-4Report Type:Expedited (15-DaCompany Report #WAES 01107025
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia Asthenia Blood Albumin Increased C-Reactive Protein Increased Duodenal Ulcer Gastric Ulcer Gastroenteritis Helicobacter Haematochezia Red Blood Cell Sedimentation Rate Increased		Vioxx	PS	Merck & Co., Inc	

Date:10/22/01ISR Number: 3813785-XReport Type:Expedited (15-DaCompany Report #WAES 01102000
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
			Ranitidine	C		
			[Therapy Unspecified]	C		

Date:10/22/01ISR Number: 3813788-5Report Type:Expedited (15-DaCompany Report #WAES 01101988
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Buspar	C				
Other	Simple Partial Seizures		Zoloft	C				

Date:10/22/01ISR Number: 3813792-7Report Type:Expedited (15-DaCompany Report #WAES 01105001
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		34 DAY
Hospitalization - Initial or Prolonged	Perforation		Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/01ISR Number: 3811928-5Report Type:Expedited (15-DaCompany Report #A0155443A
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Wellbutrin	PS	Glaxo Wellcome	ORAL	150MG Per day	
Initial or Prolonged	Convulsion		Vioxx	SS				
Other	Fall		Celebrex	SS				14 DAY
	Head Injury		Neurontin	C		ORAL	300MG Four	
	Headache						times per day	YR
	Inflammation							
	Migraine							
	Mucous Membrane Disorder							
	Paralysis							
	Pruritus							
	Sinus Headache							
	Sinus Polyp							
	Swelling							

Date:10/23/01ISR Number: 3812237-0Report Type:Expedited (15-DaCompany Report #WAES 01102892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural							
	Complication							
	Post Procedural							
	Haemorrhage							

Date:10/23/01ISR Number: 3812241-2Report Type:Expedited (15-DaCompany Report #WAES 01100093
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							

Date:10/23/01ISR Number: 3812248-5Report Type:Expedited (15-DaCompany Report #WAES 01105069
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Tongue Disorder		Vioxx	SS		ORAL	9	MON
			Pilocarpine	C			OPHTHALMIC	
			Timoptic	C			OPHTHALMIC	
			Furosemide	C		ORAL		
			Ranitidine	C		ORAL		
			Proscar	C		ORAL		
			Tramadol	C		ORAL		

Date:10/23/01ISR Number: 3812249-7Report Type:Expedited (15-DaCompany Report #WAES 01101944
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/01ISR Number: 3812252-7Report Type:Expedited (15-DaCompany Report #WAES 01102117
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C				
Initial or Prolonged			Toprol Xl Tablets	C				
			Prempro	C				

Date:10/23/01ISR Number: 3812254-0Report Type:Expedited (15-DaCompany Report #WAES 01105086
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Acetaminophen And Codeine Phosphate	C				

Date:10/23/01ISR Number: 3813871-4Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	13 DAY	
Hospitalization -	Distress Syndrome		Vasotec	C		ORAL		
Initial or Prolonged	Colitis		Vasotec	C				
Disability	Large Intestine		Lipitor	C				
	Perforation		Vasotec	C		ORAL		
	Sepsis		Aspirin	C				
	Small Intestinal		Zebeta	C				
	Obstruction							

Date:10/23/01ISR Number: 3813875-1Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy					

				Unspecified]	C		

Date:10/23/01ISR Number: 3813886-6Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY
			Atenolol	C				

Date:10/23/01ISR Number: 3813890-8Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atacand	C				
			Lopid	C				
			Aspirin	C				
			Glucosamine	C				
			Sudafed	C				
			Benadryl	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/01ISR Number: 3813895-7Report Type:Expedited (15-DaCompany Report #WAES 01102188
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Lanoxin	SS		ORAL		
Initial or Prolonged	Therapeutic Agent		Rythmol	C		ORAL		
	Toxicity		K-Dur	C		ORAL		
			Neurontin	C		ORAL		
			Betapace	C				
			Vicodin Tablets	C				
			Ambien	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Vitamins (Unspecified)	C				

Date:10/23/01ISR Number: 3813899-4Report Type:Expedited (15-DaCompany Report #WAES 01102421
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Theophylline	SS				
			Albuterol	C				

Date:10/23/01ISR Number: 3813902-1Report Type:Expedited (15-DaCompany Report #WAES 01108566
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS		ORAL		
1 YR								

Date:10/23/01ISR Number: 3814041-6Report Type:Expedited (15-DaCompany Report #2001073066FR
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Arrest	Foreign	Celebrex (Celecoxib)			
	Conduction Disorder	Health	Capsule	PS		ORAL 200 MG, BID,
	Drug Ineffective	Professional				ORAL
	Myocardial Infarction	Other	Rofecoxib (Rofecoxib)	SS		ORAL QD, ORAL
			Nexen (Nimesulide)	SS		ORAL BID, ORAL
			Salazopyrine	C		
			Xatral (Alfuzosin)	C		
			Eupantol	C		
			Dafalgan	C		

Date:10/23/01ISR Number: 3814279-8Report Type:Expedited (15-DaCompany Report #2001UW13224
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization -	Abdominal Pain Upper	Health	Nolvadex "Zeneca"	PS		ORAL 20 MG QD PO
Initial or Prolonged	Cellulitis	Professional	Vioxx	SS		
	Erythema Multiforme					
	Gastrooesophageal Reflux Disease					
	Oesophagitis					
	Stevens-Johnson Syndrome					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/01ISR Number: 3812904-9Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atacand	C				
Initial or Prolonged			Lopid	C				
Disability			Aspirin	C				
Other			Glucosamine	C				
			Sudafed	C				
			Benadryl	C				
			Atenolol	C				
			Hydrodiuril	C				

Date:10/24/01ISR Number: 3812906-2Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc			
	Oedema Peripheral							
	Pain							

Date:10/24/01ISR Number: 3812907-4Report Type:Expedited (15-DaCompany Report #WAES 01106029
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
132 DAY								
Initial or Prolonged	Haematemesis		Doxazosin	C		ORAL		
	Rectal Haemorrhage		Aluminum Hydroxide And Magnesium Carbonate	C		ORAL		
			Lorazepam	C		ORAL		

Date:10/24/01ISR Number: 3812910-4Report Type:Expedited (15-DaCompany Report #WAES 01105548
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vasotec	C		ORAL		
			Elavil	C		ORAL		
Disability			Metoprolol Tartrate	C		ORAL		

Date:10/24/01ISR Number: 3812914-1Report Type:Expedited (15-DaCompany Report #WAES 01105565
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Diarrhoea		Flecainide Acetate	C				
			Atorvastatin Calcium	C				
			Certoparin Sodium	C				

Date:10/24/01ISR Number: 3812915-3Report Type:Expedited (15-DaCompany Report #WAES 01102011
Age:62 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Stress		Zyrtec	C				
			[Therapy Unspecified]	C				

Date:10/24/01ISR Number: 3812916-5Report Type:Expedited (15-DaCompany Report #WAES 01105082
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	221	DAY
Initial or Prolonged	Melaena		Acetaminophen And Codeine Phosphate	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Thiamine	C		ORAL		

Date:10/24/01ISR Number: 3812917-7Report Type:Expedited (15-DaCompany Report #WAES 01102240
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	SS		ORAL		

Date:10/24/01ISR Number: 3812918-9Report Type:Expedited (15-DaCompany Report #WAES 01106029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	132	DAY
	Haematemesis		Doxazosin	C		ORAL		
	Rectal Haemorrhage		Aluminum Hydroxide And Magnesium Carbonate	C		ORAL		

			Lorazepam	C		ORAL

Date:10/24/01ISR Number: 3812920-7Report Type:Expedited (15-DaCompany Report #WAES 01105157
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
			Bendroflumethiazide	C		ORAL		

Date:10/24/01ISR Number: 3812921-9Report Type:Expedited (15-DaCompany Report #WAES 01108158
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		
			Piroxicam	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/01ISR Number: 3812922-0Report Type:Expedited (15-DaCompany Report #WAES 01106060
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Weight Increased		Metformin	C		ORAL		
			Acetaminophen	C		ORAL		

Date:10/24/01ISR Number: 3812924-4Report Type:Expedited (15-DaCompany Report #WAES 01107505
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiomegaly		Prinivil	C		ORAL		
Initial or Prolonged	Chest X-Ray Abnormal		Althiazide And					
Other	Pulmonary Congestion		Spironolactone	C		ORAL		
	Pulmonary Oedema		Felodipine And					
			Metoprolol Succinate	C		ORAL		

Date:10/24/01ISR Number: 3813379-6Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis		Vioxx	PS		ORAL		
25 MGM PO QD								
Initial or Prolonged	Gastrointestinal		Aspirin	SS				
	Haemorrhage		Levoxyl	SS				
			Amitryptiline	SS				
			Asa	SS				

Date:10/24/01ISR Number: 3813949-5Report Type:Expedited (15-DaCompany Report #WAES 01106038
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Flushing	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
PO							29	DAY

Hospitalization -	Malaise	Health	Sotalol				
Initial or Prolonged	Torsade De Pointes	Professional	Hydrochloride	SS			ORAL
240 MG DAILY							
	Tremor	Other					
PO							
			Atorvastatin Calcium	C			
			Flurbiprofen	C			
			Levothyroxine Na	C			
			Quinapril Hcl	C			

Date:10/24/01ISR Number: 3813950-1Report Type:Expedited (15-DaCompany Report #WAES 01108156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Oedema	Health						
PO							2	DAY
		Professional						
		Other						

Date:10/24/01ISR Number: 3813952-5Report Type:Expedited (15-DaCompany Report #WAES 01105563
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Other	Chills
	Dysphagia

Urticaria

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY PO	11 DAY

Date:10/24/01ISR Number: 3813955-0Report Type:Expedited (15-DaCompany Report #WAES 01106030
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	3 DAY
	Pancreatitis	Health Professional Other						

Date:10/24/01ISR Number: 3814001-5Report Type:Expedited (15-DaCompany Report #WAES 01106043
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO ; 25 MG/DAILY PO	27 DAY
			Quinapril Hcl	C				

Date:10/24/01ISR Number: 3814019-2Report Type:Expedited (15-DaCompany Report #WAES 01096781
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Peptic Ulcer Perforation	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY 5 DAY						
Hospitalization -		Health	Elavil	C		
Initial or Prolonged		Professional	Acetaminophen	C		
		Other	Albuterol (+)			
			Ipratropium Bromide	C		
			Aspirin	C		
			Cephalexin	C		
			Dalteparin Sodium	C		
			Ferrous S04	C		
			Roxithromycin	C		

Date:10/24/01ISR Number: 3814077-5Report Type:Expedited (15-DaCompany Report #WAES 01105136
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Foreign	Tab Vioxx			
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
25 MG DAILY						
PO 302 DAY						
			Acetaminophen	C		
			Amlodipine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/01ISR Number: 3814188-4Report Type:Expedited (15-DaCompany Report #PERI00201004247
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign	Coversyl (Perindopril)	PS		ORAL	4 MG QD PO	
	Renal Failure Chronic	Health						
		Professional	Vioxx (Rofecoxib)	SS		ORAL	25 MG QD PO	
		Other	Pravastatin (Pravastatin Sodium)	C				
			Allopurinol	C				
			Molsidomine	C				
			Moduretic	C				
			Oxis (Formoterol)	C				
			Fluticasone	C				

Date:10/24/01ISR Number: 3814363-9Report Type:Expedited (15-DaCompany Report #WAES 01101028
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Facial Palsy	Professional						
	Hyperhidrosis		Ditropan	C				
			Fosamax	C				
			Prempro	C				

Date:10/24/01ISR Number: 3814367-6Report Type:Expedited (15-DaCompany Report #WAES 01082590
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertension	Health						
		Professional	Glucophage	C				
			Lipitor	C				
			Monopril	C				

			Atenolol	C		
			Therapeutic			
			Unespecific	C		

Date:10/24/01ISR Number: 3814370-6Report Type:Expedited (15-DaCompany Report #WAES 01061779
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
Initial or Prolonged	Chest Pain							
	Dizziness							
	Dyspnoea							
	Palpitations							
	Respiratory Rate Increased							
	Sinus Arrest							
	Syncope							

Date:10/24/01ISR Number: 3814590-0Report Type:Expedited (15-DaCompany Report #USA020423
Age:11 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Miosis	Other	Meridia	PS				
	Mydriasis		Lotronex (Alosetron)	SS				
	Sedation		Phenergan	SS				
			Vioxx	SS				
			Ultram	SS				
			Prozac	SS				
			Prilosec	SS				

Date:10/24/01ISR Number: 3814630-9Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conjunctival Hyperaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Idiopathic	Professional					MG/DAILY/PO	
	Thrombocytopenic Purpura		Naprosyn	C				
	Post Procedural Haemorrhage							
	Skin Discolouration							
	Swelling							

Date:10/24/01ISR Number: 3814633-4Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Rectal Haemorrhage		Coumadin	C				
			(Therapy Unspecified)	C				

Date:10/24/01ISR Number: 3814635-8Report Type:Expedited (15-DaCompany Report #WAES 99091937
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease Myocardial Infarction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:10/24/01ISR Number: 3814931-4Report Type:Expedited (15-DaCompany Report #PHRM2001FR02291
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia Cerebral Artery Embolism Cerebral Artery Thrombosis	Foreign Health Professional Other	Aredia (Disodium Pamidronate) Solution For Infusion	PS		INTRAVENOUS	INTRAVENOUS	
	Confusional State Myocardial Infarction Myocardial Ischaemia Osteoporotic Fracture Speech Disorder		Vioxx (Rofecoxib) Tablet	SS		ORAL	25 MG, QD, ORAL	
			Lovenex (Heparin-Fraction, Sodium Salt) Solution For Injection	SS		SUBCUTANEOUS	40 MG, QD, SUBCUTANEOUS	

Dafalgan (Paracetamol) Capsule, 500mg	SS	ORAL	1 G, TID, ORAL
Cortancyl (Prednisone) Tablet, 20mg	SS	ORAL	10 MG, QD, ORAL
Mepronizine (Aceprometazine, Meprobamate) Tablet	C		
Lexomil (Bromazepam)	C		
Dedrogyl (Calcifediol) Solution	C		
Ostram	C		

Date:10/24/01ISR Number: 3814990-9Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
Other	Dyspnoea	Professional	Hydrodiuril	C				
	Multiple Allergies	Company	Prevacid	C				
	Myocardial Infarction	Representative	Atenolol	C				
	Nausea							
	Vomiting							

Date:10/24/01ISR Number: 3814992-2Report Type:Expedited (15-DaCompany Report #WAES 01102263
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Hypoaesthesia	Professional						

Initial or Prolonged	Pain In Extremity	Company	Combivent	C
	Shock	Representative	Flexeril	C
			Albuterol	C

Date:10/24/01ISR Number: 3814993-4Report Type:Expedited (15-DaCompany Report #WAES 01101985
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Exfoliative	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Dry Skin	Professional	Bactrim	C				
			Colace	C				
			Lactulose	C				

Date:10/24/01ISR Number: 3814994-6Report Type:Expedited (15-DaCompany Report #WAES 01102196
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health	Orsu Vioxx 12.5 Mg	PS		ORAL	12.5	
	Hypoglycaemia	Professional					MG/DAILY/PO	
		Company	Elavil	C				
		Representative	Estrace	C				
			Mestinon	C				
			Prevacid	C				

Date:10/24/01ISR Number: 3815247-2Report Type:Expedited (15-DaCompany Report #WAES 01102892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inflammation	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG /	
	Post Procedural	Professional					DAILY/ PO	
	Complication	Company						
	Post Procedural	Representative						
	Haemorrhage							

Date:10/24/01ISR Number: 3815252-6Report Type:Expedited (15-DaCompany Report #WAES 01100511
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:10/24/01ISR Number: 3815263-0Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort	Consumer	Tab Vioxx	PS		ORAL	PO	
	Arrhythmia		Celebrex	SS				
	Blood Pressure Increased							
	Exsanguination							
	Large Intestinal Ulcer							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							

Date:10/24/01ISR Number: 3815269-1Report Type:Expedited (15-DaCompany Report #WAES 01101630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Pulmonary Embolism	Consumer	Tab Vioxx 25 Mg	PS		ORAL		1 MON
Initial or Prolonged			Celebrex	C				
			Coumadin	C				

Date:10/24/01ISR Number: 3815313-1Report Type:Expedited (15-DaCompany Report #WAES 01076037
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Missed	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Hospitalization - PO	Complications Of Maternal	Health						
Initial or Prolonged	Exposure To Therapeutic	Professional						
	Drugs	Other						
	Intra-Uterine Death							
	Menorrhagia							
	Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/01ISR Number: 3815622-6Report Type:Expedited (15-DaCompany Report #WAES 01106017
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block	Foreign	Tab Vioxx					
	Cardiomegaly	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	10 DAY
	Chest Pain		Acebutolol					
	Cough		Hydrochloride	C				
	Dyspnoea		Chondroitin Sulfate					
	Pulmonary Embolism		Sodium	C				
	Right Ventricular Failure		Lorazepam	C				
	Ventricular Hypertrophy		Naftazone	C				

Date:10/24/01ISR Number: 3815628-7Report Type:Expedited (15-DaCompany Report #WAES 01108135
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Tab Vioxx					
	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY;	
	Oedema Peripheral	Professional					25 MG/DAILY	3 DAY

Date:10/24/01ISR Number: 3815630-5Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional	Leflunomide	C				
			Prednisone	C				
			Tramadol Hcl	C				

Date:10/24/01ISR Number: 3815702-5Report Type:Expedited (15-DaCompany Report #WAES 01095589
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL		
Initial or Prolonged	Pruritus	Professional	Dipyrone	SS		ORAL	1000 MG; 500 MG	1 DAY

Date:10/24/01ISR Number: 3815705-0Report Type:Expedited (15-DaCompany Report #WAES 01107025
Age:89 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Asthenia Blood Albumin Decreased Blood Creatinine Increased Blood Urea Increased C-Reactive Protein Increased Duodenal Ulcer Gastric Ulcer Gastroenteritis Helicobacter Haematochezia Melaena

		Red Blood Cell Sedimentation Rate Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		White Blood Cell Count Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		

Date:10/24/01ISR Number: 3815706-2Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
			Acepromatazine Maleate (+)			
			Meprobamate	C		
			Acetaminophen	C		
			Bromazepam	C		
			Calcium Phosphate, Tribasic	C		
			Enoxaparin	C		
			Ketoprofen	C		
			Pamidronate Disodium	C		
			Prednisone	C		
			Vitamin D (Unspecified)	C		

Date:10/25/01ISR Number: 3813976-8Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/25/01ISR Number: 3813979-3Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						

Date:10/25/01ISR Number: 3813980-XReport Type:Expedited (15-DaCompany Report #WAES 01102394
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL
3 MON						
Initial or Prolonged	Distress Syndrome		Norvasc	C		
	Oedema Peripheral		Percocet	C		
	Pericardial Effusion		Prozac	C		
	Pleural Effusion		Neurontin	C		
			Prilosec	C		

Date:10/25/01ISR Number: 3813983-5Report Type:Expedited (15-DaCompany Report #WAES 01102407
Age:59 YR Gender:Female I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Dizziness
	Hypertension

	Nausea						
	Oedema Peripheral						
	Parkinsonian Gait	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C				
			Clonidine	C				

Date:10/25/01ISR Number: 3813984-7Report Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS		ORAL		
			Coumadin	C				
			[Therapy Unspecified]	C				
OPHTHALMIC								
			[Therapy Unspecified]	C				

Date:10/25/01ISR Number: 3813988-4Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Toxicity		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Mental Impairment		Dilantin	SS				

Date:10/25/01ISR Number: 3813990-2Report Type:Expedited (15-DaCompany Report #WAES 01107918
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			

Date:10/25/01ISR Number: 3813992-6Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
	Distress Syndrome		Captopril	C		ORAL	1	DAY
	Condition Aggravated		Calcium Carbonate	C		ORAL	25	DAY
	Scleroderma		Prednisolone	C		ORAL	25	DAY
			Piprinhydrinate	C		ORAL	26	DAY
			Aluminum Hydroxide And Magnesium Carbonate	C		ORAL	26	DAY
			Fosamax	C		ORAL	25	DAY
			[Composition Unspecified]	C		ORAL	26	DAY

Date:10/25/01ISR Number: 3813995-1Report Type:Expedited (15-DaCompany Report #WAES 01108577
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/01ISR Number: 3813997-5Report Type:Expedited (15-DaCompany Report #WAES 01105125
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
	Dyspnoea		Ibuprofen	C		ORAL	113 DAY	
			Moduretic	C		ORAL	17 DAY	

Date:10/25/01ISR Number: 3814679-6Report Type:Direct Company Report #
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL	ORAL	
Initial or Prolonged	Haemorrhage		Aspirin	SS		ORAL	ORAL	

Date:10/25/01ISR Number: 3814702-9Report Type:Direct Company Report #
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure		Rofecoxib	PS		ORAL	25MG BID PO	
Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/26/01ISR Number: 3814789-3Report Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Atenolol	C		
			Motrin	C		
9 DAY						

Date:10/26/01ISR Number: 3814792-3Report Type:Expedited (15-DaCompany Report #WAES 01103289
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/26/01ISR Number: 3814794-7Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Gemfibrozil	C		
	Headache					
	Hypertensive Crisis					

Date:10/26/01ISR Number: 3814799-6Report Type:Expedited (15-DaCompany Report #WAES 01109003
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY						
	Purpura					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/01ISR Number: 3814800-XReport Type:Expedited (15-DaCompany Report #WAES 01107052
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asphyxia		Vioxx	PS	Merck & Co., Inc			8 DAY
Initial or Prolonged	Deep Vein Thrombosis		Estradiol Valerate	C				
Other	Dyspnoea							

Date:10/26/01ISR Number: 3814801-1Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Prednisone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Leflunomide	C		ORAL		

Date:10/26/01ISR Number: 3814805-9Report Type:Expedited (15-DaCompany Report #WAES 01108213
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
	Diarrhoea		Glyburide	C		ORAL		
	Dizziness							
	Vomiting							

Date:10/26/01ISR Number: 3814811-4Report Type:Expedited (15-DaCompany Report #WAES 01109139
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged								

Date:10/26/01ISR Number: 3814828-XReport Type:Expedited (15-DaCompany Report #WAES 01103082
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prothrombin Time Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Premarin	C				
			Levoxyl	C				

Date:10/26/01ISR Number: 3814829-1Report Type:Expedited (15-DaCompany Report #WAES 01106063
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Creatinine Renal Clearance Decreased		Verapamil Hydrochloride	SS		ORAL		
			Bisoprolol Fumarate	C		ORAL	32	DAY
	Fall		Alprazolam	C		ORAL		
	Orthostatic Hypotension		Paroxetine	C		ORAL		
	Sinus Bradycardia		Elavil	C		ORAL		
			Trihexyphenidyl Hydrochloride	C		ORAL		
			[Therapy Unspecified]	C		ORAL		

			Acetaminophen	C		ORAL

Date:10/26/01ISR Number: 3814832-1Report Type:Expedited (15-DaCompany Report #WAES 01103352
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Vascular Purpura		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Vasculitis		Methylprednisolone	C		
			Enbrel	C		
			Methotrexate	C		

Date:10/26/01ISR Number: 3814833-3Report Type:Expedited (15-DaCompany Report #WAES 01104365
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Ill-Defined Disorder		Bisoprolol And Hydrochlorothiazide	C		
			Aspirin	C		

Date:10/26/01ISR Number: 3814835-7Report Type:Expedited (15-DaCompany Report #WAES 01103397
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/26/01ISR Number: 3814836-9Report Type:Expedited (15-DaCompany Report #WAES 01105220
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
Other			Promethazine	C		ORAL
			Cephalexin	C		ORAL
6 DAY						

	Ibuprofen	C	ORAL
13 DAY			
	Carbamazepine	C	ORAL
	Omeprazole	C	ORAL
	Insulin, Biphasic Isophane [Injection]	C	
	Nitroglycerin	C	
SUBLINGUAL			
	Salmeterol Xinafoate	C	
RESPIRATORY			
(INHALATION)			
	Albuterol Sulfate	C	
RESPIRATORY			
(INHALATION)			
	Fluticasone Propionate	C	
RESPIRATORY			
(INHALATION)			
	Irbesartan	C	ORAL
	Acetaminophen And Codeine Phosphate	C	ORAL

Date:10/26/01ISR Number: 3814841-2Report Type:Expedited (15-DaCompany Report #WAES 01107919
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Macroglossia Rash Papular

	Salivary Gland Enlargement						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc		7	DAY

Date:10/26/01ISR Number: 3814843-6Report Type:Expedited (15-DaCompany Report #WAES 01106093
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Aspirin	C		ORAL		

Date:10/26/01ISR Number: 3814844-8Report Type:Expedited (15-DaCompany Report #WAES 01109711
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Weight Increased							

Date:10/26/01ISR Number: 3814845-XReport Type:Expedited (15-DaCompany Report #WAES 01109115
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Varices		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -	Haemorrhage		Vioxx	SS		ORAL		
Initial or Prolonged			Rabeprazole Sodium	C		ORAL		
			Acetaminophen	C		ORAL		
			Captopril And Hydrochlorothiazide	C		ORAL		

Date:10/26/01ISR Number: 3815748-7Report Type:Expedited (15-DaCompany Report #WAES 01102000
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Ranitidine	C				

Date:10/26/01ISR Number: 3815752-9Report Type:Expedited (15-DaCompany Report #WAES 01108566
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	1 YR

Date:10/26/01ISR Number: 3815753-0Report Type:Expedited (15-DaCompany Report #WAES 01081006
Age:22 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Autoimmune Hepatitis
	Back Pain
	Jaundice
	Pneumonia

		Pyrexia					
		Thymus Disorder					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Tab Vioxx 25mg	PS		ORAL
PO	10 DAY						
			Professional Company Representative	Accupril	C		

Date:10/26/01ISR Number: 3815754-2Report Type:Expedited (15-DaCompany Report #WAES 01081460
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
	Decreased Appetite	Health	Cardizem	C		
	Drug Hypersensitivity	Professional	Coumadin	C		
	Feeling Abnormal		Elavil	C		
	Nausea		Lanoxin	C		
	Nervousness		Peri-Colace	C		
			Prinivil	C		
			Senokot (Sennosides)	C		
			Aspirin	C		

Date:10/26/01ISR Number: 3815755-4Report Type:Expedited (15-DaCompany Report #WAES 01102188
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Prerenal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Bradycardia	Professional				
MG/DAILY/PO						
Initial or Prolonged	Renal Impairment	Company	Tab Lanoxin 0.25 Mg	SS		ORAL
0.25						
	Therapeutic Agent	Representative				
MG/DAILY/PO						
	Toxicity		Ambien	C		
			Betapace	C		
			K-Dur	C		
			Neurontin	C		

				Rythmol	C		
				Vicodin Tablets	C		
				Ascorbic Acid	C		
				Vitamin E	C		
				Vitamins (Unspecified)	C		

Date:10/26/01ISR Number: 3815763-3Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Acute Abdomen	Professional						
Initial or Prolonged Disability	Acute Respiratory Distress Syndrome		Lipitor	C				
			Vasotec	C				
	Colitis		Vasotec	C				
	Colitis Ulcerative		Zebeta	C				
	Diarrhoea		Aspirin	C				
	Large Intestine Perforation							
	Retching							
	Sepsis							
	Small Intestinal Obstruction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/01ISR Number: 3815833-XReport Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Drug Effect Decreased	Foreign Health Professional Other	Tab Vioxx (Rofecoxib) [Therapy Unspecified]	PS C		ORAL	PO	

Date:10/26/01ISR Number: 3815841-9Report Type:Expedited (15-DaCompany Report #WAES 01105001
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO 25 MG/DAILY	34 DAY

Date:10/26/01ISR Number: 3816064-XReport Type:Expedited (15-DaCompany Report #WAES 01061804
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Aphasia Apraxia Blood Alkaline Phosphatase Increased Brain Scan Abnormal Cerebral Atrophy Dysarthria Dysphagia Escherichia Infection Gait Disturbance Hemiparesis Hypertonia Muscle Twitching	Health Professional	Tab Vioxx Dilantin Tranxene	PS C C	Merck & Co., Inc.	ORAL	PO	

Simple Partial Seizures
Urinary Tract Infection

Date:10/26/01ISR Number: 3816113-9Report Type:Expedited (15-DaCompany Report #WAES 01092527
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Red Blood Cell Sedimentation Rate Increased	Health Professional	Synthroid	C				
			Atenolol	C				
	Swelling							
	Urticaria							

Date:10/26/01ISR Number: 3816115-2Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Atacand	C				
			Benadryl	C				
			Lopid	C				

			Sudafed	C		
			Aspirin	C		
			Atenolol	C		
			Glucosamine	C		

Date:10/26/01ISR Number: 3816117-6Report Type:Expedited (15-DaCompany Report #WAES 01102421
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx	PS		ORAL	PO	
			Theophylline	SS				
			Albuterol	C				

Date:10/26/01ISR Number: 3816248-0Report Type:Expedited (15-DaCompany Report #WAES 01082433
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:10/26/01ISR Number: 3816249-2Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	PO
			Atenolol	C				

Date:10/26/01ISR Number: 3816302-3Report Type:Expedited (15-DaCompany Report #WAES 01101988
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Convulsion		Buspar	C				
Other	Simple Partial Seizures		Zoloft	C				

Date:10/26/01ISR Number: 3816303-5Report Type:Expedited (15-DaCompany Report #WAES 01101639
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged	Cough	Professional	Coumadin 5 Mg	SS			5 MG/HS	
	Dislocation Of Sternum	Company	Colace	C				
	Dyspnoea	Representative	Lasix (Furosemide)	C				
	Haematocrit Decreased		Lopressor	C				
	Haemothorax		Metamucil	C				
	International Normalised		Percocet	C				
	Ratio Increased		Robitussin	C				
	Medication Error		Xanax	C				
	Platelet Count Decreased		Zantac	C				
	Prothrombin Time		Potassium Chloride	C				
	Prolonged							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/01ISR Number: 3816431-4Report Type:Expedited (15-DaCompany Report #WAES 01097024
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Haemorrhage Gastric Ulcer	Foreign Health Professional Other	Rofecoxib	PS				

Date:10/26/01ISR Number: 3816492-2Report Type:Expedited (15-DaCompany Report #WAES 01047006
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroduodenal Ulcer Gastrointestinal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 6 DAY
		Other	Acetaminophen/ Codeine Phosphate	C				
			Carisoprodol	C				
			Oxazepam	C				

Date:10/26/01ISR Number: 3816496-XReport Type:Expedited (15-DaCompany Report #WAES 00106119
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Osteonecrosis	Foreign Study	Tab Rofecoxib	PS		ORAL	12.5 MG/DAILY	PO 132 DAY
Disability		Health Professional	Cicletanine	C				
			Methyclothiazide (+) Triamterene	C				
			Simvastatin	C				

Date:10/26/01ISR Number: 3822259-1Report Type:Expedited (15-DaCompany Report #2001-10-0725
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Adhesions	Study	Vioxx (Rofecoxib)					
	Ammonia Increased	Health	Tablets	PS		ORAL	25 MG QD	
	Change Of Bowel Habit	Professional	Peg-Intron					
	Condition Aggravated		(Peginterferon					
	Diarrhoea		Alfa-2b) Injectable					
	Diverticulitis		Powder	SS		SUBCUTANEOUS	150 MCG-UNK/W	
	Irritable Bowel Syndrome					SUBCUTANEOUS		
	Nausea		Ribavirin Capsules	SS		ORAL	0.8 GM-UNK QD	
	Neurogenic Bladder					ORAL		
	Neutropenia		Neupogen	C				
	Urinary Retention		...	C				
	Vomiting		Lactulose	C				
			Ambien (Zolpidem Tartrate)	C				
			Vitamin C	C				
			Topamax	C				
			Diovan	C				
			Imodium	C				
			Demerol	C				
			Multivitamins	C				
			Vitamin E	C				
			Dilantin	C				
			Ativan	C				

			...	C		
			Phenergan	C		
			Neurontin	C		

Date:10/29/01ISR Number: 3815771-2Report Type:Expedited (15-DaCompany Report #WAES 01107919
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc			7 DAY
Initial or Prolonged	Macroglossia							
	Rash Papular							
	Salivary Gland							
	Enlargement							

Date:10/29/01ISR Number: 3816606-4Report Type:Expedited (15-DaCompany Report #WAES 01106060
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema	Foreign	Tab Vioxx					
Initial or Prolonged	Weight Increased	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
			Acetaminophen	C				
			Metformin	C				

Date:10/29/01ISR Number: 3816608-8Report Type:Expedited (15-DaCompany Report #WAES 01105565
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Foreign	Tab Vioxx					
Initial or Prolonged	Diarrhoea	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY
		Professional	Atorvastatin Calcium	C				
			Certoparin Sodium	C				
			Flecainide Acetate	C				

Date:10/29/01ISR Number: 3816610-6Report Type:Expedited (15-DaCompany Report #WAES 01108158
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Crm Piroxicam	SS				

Date:10/29/01ISR Number: 3816613-1Report Type:Expedited (15-DaCompany Report #WAES 01105157
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Fluctuation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	27 DAY
	Hypertension		Bendroflumethiazide	C				

Date:10/29/01ISR Number: 3816622-2Report Type:Expedited (15-DaCompany Report #WAES 01105548
Age:46 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged Disability	Coronary Artery Disease Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	19 MON
			Elavil	C				
			Vasotec	C				
			Metoprolol Tartrate	C				

Date:10/29/01ISR Number: 3816636-2Report Type:Expedited (15-DaCompany Report #WAES 01105086
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Other		Health					PO	
		Professional Other	Acetaminophen/Codeine Phosphate	C				

Date:10/29/01ISR Number: 3816638-6Report Type:Expedited (15-DaCompany Report #WAES 01106029
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	
	Haematemesis	Consumer					PO	132 DAY
	Rectal Haemorrhage Upper Gastrointestinal Haemorrhage	Other	Aluminum Hydroxide/Magnesium Carbonate	C				
			Doxazosin	C				
			Lorazepam	C				

Date:10/29/01ISR Number: 3817002-6Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Rofecoxib 25mg	PS		ORAL	25MG ONCE	
Hospitalization -	Intestinal Ulcer						DAILY ORAL	
Initial or Prolonged								

Date:10/29/01ISR Number: 3817037-3Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Tab Vioxx Unk	PS				
	Oedema Peripheral	Professional						
	Pain	Company						
		Representative						

Date:10/29/01ISR Number: 3817038-5Report Type:Expedited (15-DaCompany Report #WAES 01102117
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -							MG/DAILY/PO	
Initial or Prolonged								
			Prempro	C				
			Synthroid	C				
			Tropol Xl Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/01ISR Number: 3817050-6Report Type:Expedited (15-DaCompany Report #WAES 01102011
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG /DAILY/PO	
Disability			Zyrtec	C				

Date:10/29/01ISR Number: 3817080-4Report Type:Expedited (15-DaCompany Report #WAES 01101944
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
			Aspirin	C				

Date:10/29/01ISR Number: 3817101-9Report Type:Expedited (15-DaCompany Report #WAES 01102240
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Tab Zocor	SS		ORAL	PO	

Date:10/29/01ISR Number: 3817164-0Report Type:Expedited (15-DaCompany Report #WAES 01105069
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Foreign	Tab Vioxx					
	Obstructive Airways	Other	(Rofecoxib)	PS		ORAL	12.5	

Disorder
MG/DAILY, PO 10 DAY
Tongue Disorder Tab Vioxx SS ORAL
PO 10 DAY
Proscar C
Timoptic C
Furosemide C
Pilocarpine C
Ranitidine C
Tramadol C

Date:10/29/01ISR Number: 3817167-6Report Type:Expedited (15-DaCompany Report #WAES 01105082
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	221 DAY
			Acetaminophen/Codeine Phosphate	C				
			Bendroflumethiazide	C				
			Thiamine	C				

Date:10/29/01ISR Number: 3817188-3Report Type:Expedited (15-DaCompany Report #WAES 01107505
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Atrial Fibrillation Cardiomegaly Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Prinivil	C				
			Althiazide/Spironola					

			ctone	C
			Felodipine/Metoprolo l Succinate	C

Date:10/29/01ISR Number: 3821494-6Report Type:Expedited (15-DaCompany Report #01090568
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased	Health	Enbrel 25 Mg	PS				
SUBCUTANEOUS							25 MG, BIW,	
Initial or Prolonged	Gastric Haemorrhage	Professional						
SUBCUTANEOUS								
Other	Gastritis		Rofecoxib	SS				
Required	Hypokalaemia		Alendronate	C				
Intervention to	Hypotension		Prednisone	C				
Prevent Permanent	Ileus Paralytic		Potassium Chloride	C				
Impairment/Damage	Osteomyelitis		Aciphex	C				
	Staphylococcal Infection		Lisinopril	C				
	Toe Amputation		Digoxin	C				
			Furosemide	C				
			Warfarin	C				
			Iron	C				
			Oyster Shell Calcium	C				

Date:10/30/01ISR Number: 3816793-8Report Type:Expedited (15-DaCompany Report #WAES 01104726
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
							1	WK
			Proctium	C				
			Folic Acid	C				
			Prednisone	C				

Date:10/30/01ISR Number: 3816799-9Report Type:Expedited (15-DaCompany Report #WAES 01101214
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Hallucination, Visual

Date:10/30/01ISR Number: 3816803-8Report Type:Expedited (15-DaCompany Report #WAES 01104756
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
Initial or Prolonged	Oedema Peripheral							

Date:10/30/01ISR Number: 3817314-6Report Type:Direct Company Report #
Age:48 YR Gender:Female I/FU:I

Outcome	PT
Disability	Confusional State
Required	Dizziness
Intervention to	Hypertension
Prevent Permanent	Mental Impairment
Impairment/Damage	Movement Disorder
	Oedema Peripheral
	Tinnitus
	Tremor

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 25 Mg	PS		ORAL	25-50 MG	DAILY ORAL
	Diovan	C				
	Prozac	C				
	Ventylin	C				
	Flovent	C				
	Hydrocholthiazide	C				

Date:10/31/01ISR Number: 3817428-0Report Type:Expedited (15-DaCompany Report #WAES 01106065
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lipase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pancreatitis		Vioxx	SS		ORAL	DAY	
			Mebeverine Hydrochloride	C		ORAL		
			Chlordiazepoxide Hydrochloride And Clidinium Bromide	C		ORAL		
			Acetaminophen	C		ORAL		
			Fenofibrate	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		

Date:10/31/01ISR Number: 3817429-2Report Type:Expedited (15-DaCompany Report #WAES 01107308
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Gabapentin	C				
			Norfloxacin	C				
			Flunitrazepam	C				
			Esomeprazole					

			Magnesium	C		

Date:10/31/01ISR Number: 3817436-XReport Type:Expedited (15-DaCompany Report #WAES 01102749
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Level Above		Dilantin	SS				
	Therapeutic							
	Drug Toxicity							
	Mental Impairment							

1 YR

Date:10/31/01ISR Number: 3817439-5Report Type:Expedited (15-DaCompany Report #WAES 01103045
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3817440-1Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	MON	
Hospitalization - Initial or Prolonged	Asthenia		[Therapy Unspecified]	C				
	Diverticulum		Xanax	C				
	Faeces Discoloured		Premarin	C				
	Gastritis		Tenormin	C				
	Gastrointestinal		Norvasc	C				
	Haemorrhage		Lasix (Furosemide)	C				
	Haematochezia		Os-Cal + D	C				
	Haemorrhoids		Ms Contin	C				
	Hiatus Hernia		Vicodin Es Tablets	C				
	International Normalised Ratio Increased		Aspirin	C				
	White Blood Cell Count Increased							

Date:10/31/01ISR Number: 3817442-5Report Type:Expedited (15-DaCompany Report #WAES 01104757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/31/01ISR Number: 3817443-7Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Hospitalization - Initial or Prolonged	Acute Abdomen		Vasotec	C		ORAL		
	Acute Respiratory		Vasotec	C		ORAL		
Disability	Distress Syndrome		Vasotec	C				
	Colitis		Lipitor	C				
	Diarrhoea		Aspirin	C				
	Diverticulum		Zebeta	C				
	Intestinal Dilatation							

Intestinal Obstruction
Intestinal Perforation
Large Intestine
Perforation
Megacolon
Purulence
Retching
Sepsis

Date:10/31/01ISR Number: 3817445-0Report Type:Expedited (15-DaCompany Report #WAES 01108176
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3817446-2Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
	Distress Syndrome		Captopril	C		ORAL	1	DAY
	Condition Aggravated		Calcium Carbonate	C		ORAL	25	DAY
	Dyspnoea Exacerbated		Prednisolone	C		ORAL	25	DAY
	Scleroderma		Piprinhydrinate	C		ORAL	26	DAY
			Aluminum Hydroxide And Magnesium Carbonate	C		ORAL	26	DAY
			Fosamax	C		ORAL	25	DAY
			Penicillamine	C		ORAL	24	DAY

Date:10/31/01ISR Number: 3817448-6Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/31/01ISR Number: 3817452-8Report Type:Expedited (15-DaCompany Report #WAES 01106106
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Headache		Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL		
	Injection Site Haemorrhage							
	Red Blood Cells Csf							

Positive

Date:10/31/01ISR Number: 3817453-XReport Type:Expedited (15-DaCompany Report #WAES 01105172
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Alkaline Phosphatase Increased		Elavil	C		ORAL		
	Blood Bilirubin Increased		Acetaminophen And Codeine Phosphate	C		ORAL		
	Gamma-Glutamyltransferase Increased							

Date:10/31/01ISR Number: 3818318-XReport Type:Expedited (15-DaCompany Report #11032299
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropod Bite	Foreign	Hydrea Caps					
	Oedema	Health	(Hydroxyurea)	PS		ORAL	500 MILLIGRAM, 2/1 DAY ORAL	
	Pyrexia	Professional						
	Rash Pustular	Company						
	Skin Disorder	Representative	Vioxx (Rofecoxib)	SS				
		Other	Novalgin (Dipyrone)	SS				
			Purinethol (6-Mercaptopurine)	SS				
			Omeprazole					

			(Omeprazole)	C		
			Zyloric (Allopurinol)	C		
			Duragesic (Fentanyl Nitrate)	C		

Date:10/31/01ISR Number: 3818614-6Report Type:Expedited (15-DaCompany Report #WAES 01085193
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alkaline Phosphatase Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Condition Aggravated		Acetaminophen/Codeine Phosphate	C				
	Gamma-Glutamyltransferase Increased		Ketoprofen	C				
	Hypergammaglobulinaemia		Levothyroxine Na	C				
	Liver Function Test Abnormal		Nifedipine	C				
			Prednisolone	C				
	Metastases To Bone		Tamoxifen Citrate	C				
	Metastases To Liver		Zolpidem Tartrate	C				
	Metastases To Lung							

Date:10/31/01ISR Number: 3818618-3Report Type:Expedited (15-DaCompany Report #WAES 01105125
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bronchospasm Dyspnoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	15 DAY
			Moduretic	C				
			Ibuprofen	C				

Date:10/31/01ISR Number: 3818619-5Report Type:Expedited (15-DaCompany Report #WAES 01105220
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma	Foreign	Tab Vioxx					

Other	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY 8 DAY					
		Acetaminophen/Codeine Phosphate	C		
		Albuterol Sulfate	C		
		Carbamazepine	C		
		Cephalexin	C		
		Fluticasone Propionate	C		
		Ibuprofen	C		
		Insulin, Biphasic Isophane (Injection)	C		
		Irbesartan	C		
		Nitroglycerin	C		
		Omeprazole	C		
		Promethazine	C		
		Salmeterol Xinafoate	C		

Date:10/31/01ISR Number: 3818662-6Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Leflunomide	C				
			Prednisone	C				
			Tramadol Hcl	C				

Date:10/31/01ISR Number: 3818670-5Report Type:Expedited (15-DaCompany Report #WAES 01106029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 132 DAY
	Haematemesis							
	Rectal Haemorrhage							
	Upper Gastrointestinal Haemorrhage		Aluminum Hydroxide/Magnesium Carbonate	C				
			Doxazosin	C				
			Lorazepam	C				

Date:10/31/01ISR Number: 3818675-4Report Type:Expedited (15-DaCompany Report #WAES 01106063
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health Professional	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY,	PO
	Creatinine Renal Clearance Decreased	Other	Verapamil Hcl	SS		ORAL	120 MG/BID,	PO

	Fall	Elavil	C
	Orthostatic Hypotension	Acetimanophen	C
	Sinus Bradycardia	Alprazolam	C
		Bisoprolol Fumarate	C
		Paroxetine	C
		Trihexyphenidyl Hcl	C

Date:10/31/01ISR Number: 3818680-8Report Type:Expedited (15-DaCompany Report #WAES 01106093
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Health Professional Other	Aspirin	C				

Date:10/31/01ISR Number: 3818711-5Report Type:Expedited (15-DaCompany Report #WAES 01108213
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	50 MG/BID	2 DAY
	Diarrhoea	Health Professional Other	Glyburide	C				
	Dizziness							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3818712-7Report Type:Expedited (15-DaCompany Report #WAES 01088603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cough	Foreign	Vioxx (Rofecoxib)	PS		ORAL	1) 25 MG/	
Hospitalization -	Dizziness	Health					DAILY; 2) 50	
Initial or Prolonged	Fluid Retention	Professional					MG/ DAILY;	
	Medication Error	Other					3) 125	
	Weight Increased						MG/DAILY	3 DAY
			Oxycodone Hcl	C				

Date:10/31/01ISR Number: 3818713-9Report Type:Expedited (15-DaCompany Report #WAES 01078612
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Systolic	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Increased	Health						
Initial or Prolonged	Coronary Artery Disease	Professional						
	Hyperhidrosis	Other						
	Myocardial Infarction							
	Nausea							

Date:10/31/01ISR Number: 3818718-8Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Ischaemia	Foreign	Tab Vioxx					
Hospitalization -	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Headache	Professional	Gemfibrozil	C				
	Hypertensive Crisis							

Date:10/31/01ISR Number: 3818719-XReport Type:Expedited (15-DaCompany Report #WAES 01096781
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Perforation	Company	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Peritonitis	Representative						
PO							5	DAY
	Respiratory Arrest		Elavil	C				
	Urinary Tract Infection		Acetaminophen	C				
			Albuterol (+)					
			Ipratropium Bromide	C				
			Aspirin	C				
			Cephalexin	C				
			Dalteparin Sodium	C				
			Ferrousso4	C				
			Roxithromycin	C				

Date:10/31/01ISR Number: 3818723-1Report Type:Expedited (15-DaCompany Report #WAES 01107919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Macroglossia	Foreign	Tab Vioxx					
Initial or Prolonged	Oedema	Health	(Rofecoxib)	PS				
7								DAY
	Rash Papular	Professional						
	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3818767-XReport Type:Expedited (15-DaCompany Report #WAES 01109115
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Hospitalization - ; 12.5	Varices Oesophageal	Health						
Initial or Prolonged MG/Q12H :		Professional						
		Other						
PO							2	WK
			Acetaminophen	C				
			Captopril/Hctz	C				
			Rabeprazole Sodium	C				

Date:10/31/01ISR Number: 3818772-3Report Type:Expedited (15-DaCompany Report #WAES 01109711
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Weight Increased	Health						
PO							8	DAY
		Professional						
		Other						

Date:10/31/01ISR Number: 3818814-5Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Distress Syndrome	Health						
PO							27	DAY
	Condition Aggravated	Professional	Fosamax	C				
	Scleroderma	Other	(Composition Unspecified)	C				
			Aluminum Hydroxide/Magnesium					

Carbonate	C
Calcium Carbonate	C
Captopril	C
Piprinhydrinate	C
Prednisolone	C

Date:10/31/01ISR Number: 3818827-3Report Type:Expedited (15-DaCompany Report #WAES 01085626
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Platelet Count Decreased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25-50 MG PO	

Date:10/31/01ISR Number: 3818829-7Report Type:Expedited (15-DaCompany Report #WAES 01095554
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatic Pseudocyst Pancreatitis Acute	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	5 DAY

Date:10/31/01ISR Number: 3818835-2Report Type:Expedited (15-DaCompany Report #WAES 01095589
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Pruritus	Professional	Dipyrone	SS		ORAL	SEE IMAGE	1 DAY
		Other	Cortisone	C				
			Fluticasone Propionate (+)					
			Salmeterol	C				
			Prednisone	C				
			Theophylline	C				

Date:10/31/01ISR Number: 3818961-8Report Type:Expedited (15-DaCompany Report #WAES 01103289
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:10/31/01ISR Number: 3818962-XReport Type:Expedited (15-DaCompany Report #WAES 01102774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:10/31/01ISR Number: 3818964-3Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Drug Toxicity	Health	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Laboratory Test Abnormal	Professional			
MG/DAILY/PO					
		Company	Dilantin 300 Mg	SS	
300 MG/DAILY					
		Representative			

Date:10/31/01ISR Number: 3818967-9Report Type:Expedited (15-DaCompany Report #WAES 01103046
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dysuria	Study	Tab Vioxx	PS		ORAL
PO 1 DAY						
Initial or Prolonged	Haemorrhage	Consumer				
Other	Penis Disorder					

Date:10/31/01ISR Number: 3818971-0Report Type:Expedited (15-DaCompany Report #2000COU1548
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Gastrooesophageal Reflux
Initial or Prolonged	Disease
	International Normalised
	Ratio Decreased
	Medication Error
	Prothrombin Time
	Shortened

	Transient Ischaemic Attack Trigeminal Neuralgia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Coumadin (Crystalline Warfarin Sodium)	PS		ORAL	PO	
			Neurontin (Gabapentin)	SS				
			Tegretol (Carbamazepine)	SS				
			Ni (Baclofen)	SS				
			Vioxx (Rofecoxib)	SS				
			Lanoxin (Digoxin)	SS				
			Ni (Verapamil)	SS				
			Lipitor(Atorvastatin Sodium)	SS				
			Ni (Other (S) - Unspecified)	SS				
			Ni(Baclofen)	SS				
			Dilantin(Phenytoin Sodium)	SS				

Date:10/31/01ISR Number: 3818996-5Report Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Professional						
			Motrin	C				
			Atenolol	C				

Date:10/31/01ISR Number: 3819007-8Report Type:Expedited (15-DaCompany Report #WAES 01081679
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrospinal Fluid	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

	Leakage	Health			
MG/DAILY/PO					
	Cough	Professional	Bentyl	C	
	Headache		Buspar	C	
	Postnasal Drip		Lo/Ovral	C	
			Prilosec	C	
			Stelazine	C	
			Tofranil	C	

Date:10/31/01ISR Number: 3819008-XReport Type:Expedited (15-DaCompany Report #WAES 01082423
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
Initial or Prolonged	Palpitations	Health	Tab Vioxx 25 Mg	SS		ORAL
PO						
		Professional	Tab Vioxx 50 Mg	SS		ORAL
PO						
			Cartia (Diltiazem Hydrochloride)	C		
			Claritin	C		
			Lasix (Furosemide)	C		
			Prilosec	C		
			Toprol Xl Tablets	C		
			Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3819010-8Report Type:Expedited (15-DaCompany Report #WAES 01072394
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Pressure Increased	Professional					MG/DAILY/PO	
	Burning Sensation		Vasotec	C				
	Eructation		Vasotec	C				
	Gastrointestinal Disorder		[Composition Unspecified]	C				

Date:10/31/01ISR Number: 3819013-3Report Type:Expedited (15-DaCompany Report #WAES 01092825
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG	
Initial or Prolonged		Professional					DAILY/PO	
		Company Representative	Avandia	C				
			Celexa	C				
			Flovent	C				
			Foradil	C				
			Glucophage	C				
			Lopressor	C				
			Patanol	C				
			Plavix	C				
			Prilosec	C				
			Prinivil	C				
			Reglan	C				
			Zocor	C				
			Albuterol	C				
			Aspirin	C				

Date:10/31/01ISR Number: 3819016-9Report Type:Expedited (15-DaCompany Report #WAES 01090594
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Amnesia	Company	Tab Vioxx Unk	PS		ORAL
PO						
	Loss Of Consciousness	Representative				
	Sexual Assault Victim	Other				
	Vaginal Haemorrhage					

Date:10/31/01ISR Number: 3819023-6Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Blood Glucose Increased	Health				
MG/DAILY/PO						
	Blood Pressure Increased	Professional	Provera Unk	SS		
	Cerebral Infarction		Capozide	C		
	Cerebrovascular Accident		Tylenol With Codeine			
	Confusional State		#3	C		
	Headache		Captopril	C		
	Hemianopia Homonymous		Cisapride	C		
	Hemiparesis		Glyburide	C		
	Hyporeflexia					
	Meningioma					
	Visual Disturbance					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3819025-XReport Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;PO	
			Coumadin	C				

Date:10/31/01ISR Number: 3819026-1Report Type:Expedited (15-DaCompany Report #WAES 01102394
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral		Neurontin	C				
	Pericardial Effusion		Norvasc	C				
	Pleural Effusion		Percocet	C				
			Prilosec	C				
			Prozac	C				

Date:10/31/01ISR Number: 3819028-5Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Company Representative	Atacand	C				
Disability			Benadryl	C				
Other			Hydrodiuril	C				
			Lopid	C				
			Sudafed	C				
			Aspirin	C				

				Atenolol	C		
				Glucosamine	C		

Date:10/31/01ISR Number: 3819030-3Report Type:Expedited (15-DaCompany Report #WAES 01092951
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cerebrovascular Disorder	Health Professional	Coumadin	SS			3 MG/DAILY	
	Condition Aggravated		Celebrex	C				
	Prothrombin Time Prolonged		Effexor Xr	C				
	Transient Ischaemic Attack		Tiazac	C				
			Zestril	C				
			Digoxin	C				

Date:10/31/01ISR Number: 3819031-5Report Type:Expedited (15-DaCompany Report #WAES 01092825
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Avandia	C				
			Celexa	C				
			Flovent	C				

Foradil	C
Glucophage	C
Lopressor	C
Patanol	C
Plavix	C
Prilosec	C
Prinivil	C
Reglan	C
Zocor	C
Albuterol	C
Aspirin	C

Date:10/31/01ISR Number: 3819033-9Report Type:Expedited (15-DaCompany Report #WAES 01103352
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Purpura						MG/DAILY/PO	
	Vasculitis		Enbrel	C				
			Methotrexate	C				
			Methylprednisolone	C				

Date:10/31/01ISR Number: 3819058-3Report Type:Expedited (15-DaCompany Report #WAES 01100093
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
	Cardiac Failure	Professional						
	Congestive	Company						
		Representative						

Date:10/31/01ISR Number: 3819059-5Report Type:Expedited (15-DaCompany Report #WAES 01090044
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blood Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
		Health				
MG/DAILY/PO						
		Professional	Indocin (Indomethacin Sodium)	C		

Date:10/31/01ISR Number: 3819060-1Report Type:Expedited (15-DaCompany Report #WAES 01093319
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Congestive	Professional				
MG/DAILY/PO						
	Condition Aggravated	Company	Accupril	C		
	Pulmonary Oedema	Representative	Actos	C		
			Aldactone	C		
			Lasix (Furosemide)	C		
			Lipitor	C		
			Plavix	C		
			Digoxin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3819063-7Report Type:Expedited (15-DaCompany Report #WAES 01103082
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prothrombin Time Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Pulmonary Embolism	Professional					MG/DAILY/PO	
Initial or Prolonged			Levoxyl	C				
			Premarin	C				

Date:10/31/01ISR Number: 3819067-4Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Erosive	Health	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Gastrointestinal Disorder	Professional	...	SS				
Initial or Prolonged	Gastrointestinal	Company	Ceftin	C				
Disability	Haemorrhage	Representative	Tylox	C				
Other								

Date:10/31/01ISR Number: 3819093-5Report Type:Expedited (15-DaCompany Report #WAES 01104365
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Nausea		Aspirin	C				
			Bisoprolol (+) Hydrochlorothiazide	C				

Date:10/31/01ISR Number: 3819094-7Report Type:Expedited (15-DaCompany Report #WAES 01091979
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:10/31/01ISR Number: 3819095-9Report Type:Expedited (15-DaCompany Report #WAES 01060653
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Condition Aggravated	Health	Tab Vioxx	PS		ORAL
PO						
	Pancreatitis	Professional				

Date:10/31/01ISR Number: 3819097-2Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional				

Date:10/31/01ISR Number: 3819104-7Report Type:Expedited (15-DaCompany Report #WAES 01103397
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/01ISR Number: 3819105-9Report Type:Expedited (15-DaCompany Report #WAES 01102407
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Dizziness						PO	
	Hypertension		Toprol Xl Tablets	C				
	Nausea		Clonidine	C				
	Oedema Peripheral							
	Parkinsonian Gait							
	Weight Increased							

Date:10/31/01ISR Number: 3819160-6Report Type:Expedited (15-DaCompany Report #WAES 01035062
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Foreign	Tab Vioxx					
Hospitalization -	Encephalopathy	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Hepatic Failure	Professional						
Disability								
Other								

Date:10/31/01ISR Number: 3819161-8Report Type:Expedited (15-DaCompany Report #WAES 01107052
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asphyxia	Foreign	Tab Vioxx					
Initial or Prolonged	Deep Vein Thrombosis	Other	(Rofecoxib)	PS			25 MG/DAILY	8 DAY
Other	Dyspnoea		Estradiol Valerate	C				

Date:10/31/01ISR Number: 3819193-XReport Type:Expedited (15-DaCompany Report #WAES 01109003
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	2 DAY

Date:10/31/01ISR Number: 3819194-1Report Type:Expedited (15-DaCompany Report #WAES 01109139
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	2 DAY

Date:10/31/01ISR Number: 3819196-5Report Type:Expedited (15-DaCompany Report #WAES 01107918
Age:94 YR Gender:Male I/FU:I

Outcome	PT
Death	Alanine Aminotransferase Increased Aplastic Anaemia Aspartate Aminotransferase Increased Epistaxis

		Fatigue					
		Infection					
		Pancytopenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pharyngolaryngeal Pain	Foreign	Tab Vioxx			
		Pyrexia	Health	(Rofecoxib)	PS		
		Toxic Epidermal	Professional				
		Necrolysis					

Date:10/31/01ISR Number: 3819198-9Report Type:Expedited (15-DaCompany Report #WAES 01108577
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Disorder	Foreign	Tab Vioxx			
Initial or Prolonged			Health	(Rofecoxib)	PS		ORAL
PO							
			Professional				

Date:10/31/01ISR Number: 3819814-1Report Type:Periodic Company Report #2001072716US
Age:67 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)			
		Diarrhoea		Capsule	PS		ORAL
ORAL	122 DAY						
		Electrocardiogram		Vioxx ()	SS		ORAL
ORAL							
		Abnormal		Risedronic Acid			
		Malaise		(Risedronic Acid)	C		
				Budesonide	C		
				Fluticasone			
				(Fluticasone)	C		

Date:10/31/01ISR Number: 3820299-XReport Type:Periodic Company Report #2001065172US
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure	Health	Celebrex (Celecoxib)			

		Professional	Capsule	PS
			Vioxx	SS

Date:10/31/01ISR Number: 3821165-6Report Type:Periodic Company Report #2001070038US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Consumer	Celebrex(Celecoxib)					
	Pruritus		Capsule	PS		ORAL	ORAL	
	Urticaria		"Vioxx" ()	SS		ORAL	ORAL	

Date:11/01/01ISR Number: 3818207-0Report Type:Expedited (15-DaCompany Report #WAES 01105233
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	113 DAY	
Hospitalization - Initial or Prolonged	Oesophageal Ulcer Haemorrhage		Cozaar	C		ORAL		
			Doxazosin	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Folic Acid	C		ORAL		
			Methotrexate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/01ISR Number: 3818208-2Report Type:Expedited (15-DaCompany Report #WAES 01103111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased Cardiac Disorder Overdose		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/01/01ISR Number: 3818209-4Report Type:Expedited (15-DaCompany Report #WAES 01106293
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		

Date:11/01/01ISR Number: 3818211-2Report Type:Expedited (15-DaCompany Report #WAES 01103573
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc			

Date:11/01/01ISR Number: 3818217-3Report Type:Expedited (15-DaCompany Report #WAES 01106492
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/01ISR Number: 3818222-7Report Type:Expedited (15-DaCompany Report #WAES 01106107
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	

Initial or Prolonged	Peritonitis		Acetaminophen	C		ORAL
			Diacerein	C		ORAL
			Meloxicam	C		ORAL
			Omeprazole Sodium	C		ORAL

Date:11/01/01ISR Number: 3818226-4Report Type:Expedited (15-DaCompany Report #WAES 01104651
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/01ISR Number: 3818228-8Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Cognitive Disorder							
	Embolism							
	Feeling Abnormal							
	Lethargy							
	Mental Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/01ISR Number: 3818232-XReport Type:Expedited (15-DaCompany Report #WAES 01100033
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Malaise		Lipitor	C				
	Myocardial Infarction							

Date:11/01/01ISR Number: 3818233-1Report Type:Expedited (15-DaCompany Report #WAES 01106116
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Gliclazide	C		ORAL		

Date:11/01/01ISR Number: 3818238-0Report Type:Expedited (15-DaCompany Report #WAES 01106102
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
2 DAY								
Initial or Prolonged	Urinary Retention		Dothiepin Hydrochloride	C		ORAL		
			Valpromide	C		ORAL		
			Clorazepate Dipotassium	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:11/01/01ISR Number: 3818240-9Report Type:Expedited (15-DaCompany Report #WAES 01108588
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
			Omeprazole Magnesium	C		ORAL		

Date:11/01/01ISR Number: 3818242-2Report Type:Expedited (15-DaCompany Report #WAES 01106292
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Asthenia		Flexeril	C				
Other	Cardiac Failure		Celebrex	C				
	Congestive							
	Cough							
	Lung Neoplasm Malignant							
	Pneumonia							
	Pulmonary Oedema							
	Tachycardia							

Date:11/01/01ISR Number: 3818246-XReport Type:Expedited (15-DaCompany Report #WAES 01108587
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Pantoprazole Sodium	C		ORAL		
	Nausea							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/01ISR Number: 3818250-1Report Type:Expedited (15-DaCompany Report #WAES 01109312
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Skin Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Thermal Burn							

Date:11/01/01ISR Number: 3819872-4Report Type:Direct Company Report #
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Kidney Small		Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Renal Disorder						ORAL	
	Renal Failure Chronic		Synthroid	C				
	Renal Vessel Disorder		Aspirin	C				
			Lipitor	C				

Date:11/01/01ISR Number: 3819879-7Report Type:Direct Company Report #
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx 25mg Merck	PS	Merck	ORAL	25 MG PRN	
						ORAL		

Date:11/01/01ISR Number: 3819894-3Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx 25 Mg Merck	PS	Merck		1TABLE DAILY	
Hospitalization -	Renal Cell Carcinoma		Norvasc	C				
Initial or Prolonged	Stage Unspecified							

Disability
Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:11/02/01ISR Number: 3818837-6Report Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Life-Threatening	Haemorrhage							

Date:11/02/01ISR Number: 3818843-1Report Type:Expedited (15-DaCompany Report #WAES 01104488
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:11/02/01ISR Number: 3818845-5Report Type:Expedited (15-DaCompany Report #WAES 01104254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Hypovolaemia Renal Tubular Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/01ISR Number: 3818850-9Report Type:Expedited (15-DaCompany Report #WAES 01105248
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Verapamil	C		ORAL		
			Salmeterol	C				
			Levothyroxine Sodium	C				

Date:11/02/01ISR Number: 3818851-0Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Periorbital Oedema Pulmonary Oedema Rash Generalised Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL	48	HR

Date:11/02/01ISR Number: 3818855-8Report Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage Syncope		Vioxx Aspirin Paxil Disopyramide Levothyroxine Sodium	PS C C C C	Merck & Co., Inc	ORAL

Date:11/02/01ISR Number: 3818857-1Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Conjunctival Hyperaemia Haemorrhage Idiopathic Thrombocytopenic Purpura Periorbital Haematoma Skin Discolouration Swelling		Vioxx Naprosyn Fludarabine	PS C C	Merck & Co., Inc	ORAL		10 DAY

Date:11/02/01ISR Number: 3818858-3Report Type:Expedited (15-DaCompany Report #WAES 01107522
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/01ISR Number: 3818873-XReport Type:Expedited (15-DaCompany Report #WAES 01104365
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Asthenia		Ziac	C				
	Diverticulum		Aspirin	C				
	Dyspnoea							
	Fatigue							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							
	Sinusitis							

Date:11/02/01ISR Number: 3818880-7Report Type:Expedited (15-DaCompany Report #WAES 01104872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Aspirin	C				
	Myocardial Infarction							
	Renal Failure							

Date:11/02/01ISR Number: 3818884-4Report Type:Expedited (15-DaCompany Report #WAES 01106442
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatic Function Abnormal							
	Nausea							
	Vomiting							

Date:11/02/01ISR Number: 3819674-9Report Type:Expedited (15-DaCompany Report #WAES 01106492
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
	Upper Gastrointestinal Haemorrhage	Company Representative				

Date:11/02/01ISR Number: 3820547-6Report Type:Expedited (15-DaCompany Report #001-0902-M0100101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Hospitalization - Initial or Prolonged	Blindness	Consumer	Nardil (Phenelzine Sulfate)	PS		
Other	Blood Pressure Abnormal		Accupril (Quinapril Hydrochloride)	SS		ORAL 10 MG (DAILY), PER ORAL
	Coma					
	Diabetes Mellitus					
	Drug Toxicity					
	Loss Of Consciousness					
	Migraine		Vitamins Nos	SS		
	Salivary Hypersecretion		Vioxx (Rofecoxib)	SS		
			Promethazine Hydrochloride	C		
			Unspecified Medications For Diabetes	C		

		Paracetamol	C
		Paracetamol, Oxycodone Hydrochloride	C
		Pethidine Hydrochloride	C

Date:11/05/01ISR Number: 3819706-8Report Type:Expedited (15-DaCompany Report #WAES 01109354
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Pain							
	Purulence							

Date:11/05/01ISR Number: 3819712-3Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dyspnoea		Vioxx	SS		ORAL		
	Hypersensitivity		Prevacid	C				
	Multiple Allergies		Atenolol	C				
	Myocardial Infarction		Hydrodiuril	C				
	Sudden Death							
	Vomiting							

Date:11/05/01ISR Number: 3819719-6Report Type:Expedited (15-DaCompany Report #WAES 01106429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thinking Abnormal							

Date:11/05/01ISR Number: 3819722-6Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State		Enoxaparin	C			SUBCUTANEOUS	5 DAY
	Ischaemic Stroke		Acetaminophen	C		ORAL		6 DAY
	Myocardial Infarction		Pamidronate Disodium	C			INTRAVENOUS	1 DAY
	Myocardial Ischaemia		Prednisone	C		ORAL		
			Vitamin D (Unspecified)	C		ORAL		
			Calcium Phosphate, Tribasic	C		ORAL		
			Bromazepam	C		ORAL		
			Acepromazine Maleate And Meprobamate	C		ORAL		
			Ketoprofen	C			INTRAMUSCULAR	5 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/01ISR Number: 3819726-3Report Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Coumadin	C				
			[Therapy Unspecified]	C				
OPHTHALMIC								
			[Therapy Unspecified]	C				

Date:11/05/01ISR Number: 3819727-5Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/01ISR Number: 3819729-9Report Type:Expedited (15-DaCompany Report #WAES 01106495
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	11 MON	

Date:11/05/01ISR Number: 3819734-2Report Type:Expedited (15-DaCompany Report #WAES 01101604
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Abdominal Tenderness		Vioxx	SS		ORAL	4 DAY	
	Asthenia		Skelaxin	C			11 DAY	

Other	Blood Pressure Systolic	Lortab	C
11 DAY			
	Increased	Tums	C
	Chest Discomfort	Aleve	C
	Duodenitis		
	Dyspnoea		
	Faecal Occult Blood		
	Positive		
	Gastric Ulcer		
	Gastrointestinal		
	Haemorrhage		
	Haematemesis		
	Heart Rate Increased		
	Hiatus Hernia		
	Melaena		
	Nausea		
	Oesophagitis		
	Pallor		
	Red Blood Cell Count		
	Abnormal		

Date:11/05/01ISR Number: 3819737-8Report Type:Expedited (15-DaCompany Report #WAES 01102000
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tremor		[Therapy					

		Unspecified]	C
		Ranitidine [Therapy Unspecified]	C

Date:11/05/01ISR Number: 3820622-6Report Type:Expedited (15-DaCompany Report #WAES 01106293
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/PO	
			Aspirin	C				

Date:11/05/01ISR Number: 3821966-4Report Type:Expedited (15-DaCompany Report #EMADSS2001006180
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Health Professional	Topalgic (Unspecified) (Tramadol Hydrochloride)	PS		ORAL	400 MG, DAILY, ORAL	
			Lasilix (Furosemide)	SS				
			Tenordate (Nif-Ten)	SS				
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, 4 IN 1 DAILY, ORAL	
			Glucophage (Metformin Hydrochloride)	C				
			Cozaar (Losartan Potassium)	C				
			Lipanthyl (Fenofibrate)	C				

Date:11/05/01ISR Number: 3822331-6Report Type:Expedited (15-DaCompany Report #HQ7654625OCT2001
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Detensiel (Bisoprolol, Tablet)	PS		ORAL	10 MG 1X PER	
Other	Bradycardia	Other						1 DAY 4 WK
	Fall Orthostatic Hypotension		Isoptin (Verapamil Hydrochloride)	SS		ORAL	240 MG 1X PER	
								1 DAY 2 YR
			Vioxx (Rofecoxib, Tablet)	SS		ORAL	1 DF	
			Xanax (Alprazolam)	C				
			Deroxat (Paroxetine Hydrochloride)	C				
			Laroxyl (Amitriptyline Hydrochloride)	C				
			Trihexyphenidyl Hydrochloride (Trihexyphenidyl Hydrochloride)	C				
			Sulfarlem (Anethole Trithione)	C				

				Efferalgan (Paracetamol)	C		

Date:11/06/01ISR Number: 3820458-6Report Type:Expedited (15-DaCompany Report #WAES 01109145
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		452 DAY
Disability	Cerebrovascular Accident		Dexamethasone Sodium Phosphate	SS		INTRAMUSCULAR		
Other	Hip Fracture							
	Sepsis		Diuretic (Unspecified)	C				
	Urinary Tract Infection							

Date:11/06/01ISR Number: 3820460-4Report Type:Expedited (15-DaCompany Report #WAES 01105676
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/06/01ISR Number: 3820463-XReport Type:Expedited (15-DaCompany Report #WAES 01101099
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/06/01ISR Number: 3820468-9Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 48 HR	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Oedema					
	Pulmonary Oedema					
	Rash Generalised					
	Vomiting					

Date:11/06/01ISR Number: 3820473-2Report Type:Expedited (15-DaCompany Report #WAES 01115001
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability 10 DAY	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL
	Agitation		Ranitidine	C		ORAL
	Mental Disorder		Acetaminophen And Codeine Phosphate	C		
			Isosorbide Mononitrate	C		ORAL
			Aspirin	C		ORAL
			Amiloride Hydrochloride And Furosemide	C		ORAL
			Loratadine	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/01ISR Number: 3821469-7Report Type:Expedited (15-DaCompany Report #FRA002759
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health	Isoptine 120mg (Immediate Release)	PS		ORAL	240 MG OD PO	2 YR
	Fall	Professional	Vioxx	SS		ORAL	1 DF OD PO	
	Orthostatic Hypotension	Other	Detensiel	SS		ORAL	1 DF OD PO	
			Xanax	SS		ORAL	3 DF OD PO	2 YR
			Deroxat	SS		ORAL	1 DF OD PO	
			Laroxyl	SS		ORAL	0.5 DF OD PO	2 YR

Date:11/07/01ISR Number: 3821081-XReport Type:Expedited (15-DaCompany Report #WAES 01106035
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Initial or Prolonged	Congestive Myocardial Infarction		Urapidil	C		ORAL		

Date:11/07/01ISR Number: 3821083-3Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	23 DAY	
Initial or Prolonged	Blood Pressure Decreased Cardiovascular Disorder Heart Rate Increased Hyperhidrosis Upper Gastrointestinal Haemorrhage							

Date:11/07/01ISR Number: 3821776-8Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Coumadin	PS		ORAL	5 MG QD ORAL	
Initial or Prolonged	International Normalised		Vioxx	SS			ONCE	
	Ratio Increased		Vioxx	C				

Date:11/07/01ISR Number: 3822418-8Report Type:Expedited (15-DaCompany Report #WAES 01103045
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:11/07/01ISR Number: 3822500-5Report Type:Expedited (15-DaCompany Report #WAES 01100033
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Malaise	Health	Lipitor	C				
	Myocardial Infarction	Professional						

Date:11/07/01ISR Number: 3822503-0Report Type:Expedited (15-DaCompany Report #WAES 01082678
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Gastritis Erosive	Professional					MG/DAILY/PO;	
Initial or Prolonged	Gastrointestinal Disorder	Company					25	
Disability	Gastrointestinal	Representative					MG/DAILY/PO	
Other	Haemorrhage		Ceftin	C				
			Tylox	C				

Date:11/07/01ISR Number: 3822577-7Report Type:Expedited (15-DaCompany Report #WAES 01100707
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conjunctival Hyperaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haematoma	Professional					MG/DAILY/PO	
Other	Idiopathic		Naprosyn	C				
	Thrombocytopenic Purpura		Fludarabine	C				
	Post Procedural							
	Haemorrhage							
	Procedural Site Reaction							
	Skin Discolouration							

Date:11/07/01ISR Number: 3822578-9Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Computerised Tomogram	Health					MG/DAILY/PO	
	Abnormal	Professional	Provera	SS				
	Haemorrhagic Stroke		Capozide	C				

	Loss Of Consciousness		Tylenol With Codeine #3	C
			Captopril	C
			Cisapride	C
			Glyburide	C

Date:11/07/01ISR Number: 3822580-7Report Type:Expedited (15-DaCompany Report #WAES 01104365
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Asthenia	Health					MG/DAILY/PO	
	Diverticulum Intestinal	Professional	Ziac	C				
	Dyspnoea		Aspirin	C				
	Fatigue							
	Gastric Ulcer							
	Sinusitis							

Date:11/07/01ISR Number: 3822582-0Report Type:Expedited (15-DaCompany Report #WAES 00082175
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Circulatory Collapse

	Dyspnoea						
	Dyspnoea Exertional						
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pulmonary Embolism	Health	Tab Vioxx 25 Mg	PS		ORAL	25
	Syncope	Professional					MG/DAILY/PO
	Tachycardia		Prempro	C			
			Tenormin	C			

Date:11/07/01ISR Number: 3822586-8Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25
Initial or Prolonged	Blood Pressure Increased	Health					MG/DAILY/PO
	Cerebral Infarction	Professional	Provera	SS			
	Depressed Level Of Consciousness		Capozide	C			
			Tylenol With Codeine #3	C			
	Haemorrhagic Stroke		Captopril	C			
	Headache		Cisapride	C			
	Hemiparesis		Glyburide	C			
	Loss Of Consciousness						

Date:11/07/01ISR Number: 3822590-XReport Type:Expedited (15-DaCompany Report #WAES 00082175
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Activated Partial	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Hospitalization -	Thromboplastin Time	Professional					MG/DAILY/PO
Initial or Prolonged	Prolonged		Prempro	C			
Other	Circulatory Collapse		Tenormin	C			
	Hyperhidrosis						
	Pulmonary Embolism						
	Syncope						
	Tachycardia						

Date:11/07/01ISR Number: 3823254-9Report Type:Expedited (15-DaCompany Report #WAES 01091935
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
Other	Myocardial Infarction	Professional Company Representative						

Date:11/07/01ISR Number: 3823255-0Report Type:Expedited (15-DaCompany Report #WAES 01091935
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
Other	Myocardial Infarction	Professional Company Representative						

Date:11/07/01ISR Number: 3823256-2Report Type:Expedited (15-DaCompany Report #WAES 01101604
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Tenderness	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Abnormal Faeces	Professional					MG/DAILY/PO	
Initial or Prolonged	Asthenia	Company	Aleve	C				
Other	Back Pain	Representative	Lortab	C				
	Blood Pressure Increased		Skelaxin	C				
	Chest Discomfort		Tums	C				
	Condition Aggravated							
	Duodenitis							
	Dyspnoea							
	Faeces Discoloured							
	Frequent Bowel Movements							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							
	Heart Rate Increased							
	Hiatus Hernia							
	Nausea							
	Oesophagitis							
	Pallor							
	Scleral Disorder							
	Vomiting							

Date:11/07/01ISR Number: 3823259-8Report Type:Expedited (15-DaCompany Report #WAES 01106442
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eosinophilia	Health	Tab Vioxx	PS		ORAL	PO	
	Hepatic Function Abnormal	Professional						
	Nausea							
	Vomiting							

Date:11/07/01ISR Number: 3823260-4Report Type:Expedited (15-DaCompany Report #WAES 01104872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage Myocardial Infarction Renal Failure	Professional Company Representative	Aspirin	C				

Date:11/07/01ISR Number: 3823271-9Report Type:Expedited (15-DaCompany Report #WAES 01104651
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:11/07/01ISR Number: 3823276-8Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Eyelid Oedema	Professional						
	Pulmonary Oedema	Company						
	Rash Generalised	Representative						
	Vomiting							

Date:11/07/01ISR Number: 3823277-XReport Type:Expedited (15-DaCompany Report #WAES 01104488
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
Other	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:11/07/01ISR Number: 3823278-1Report Type:Expedited (15-DaCompany Report #WAES 01104254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Hypovolaemia	Professional						
	Renal Failure	Company						
	Renal Tubular Necrosis	Representative						

Date:11/07/01ISR Number: 3823281-1Report Type:Expedited (15-DaCompany Report #WAES 01103111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Blood Potassium Decreased	Consumer	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Cardiac Disorder		[Therapy Unspecified]	C		

Date:11/07/01ISR Number: 3823282-3Report Type:Expedited (15-DaCompany Report #WAES 01104757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
Initial or Prolonged						
PO						

Date:11/07/01ISR Number: 3823345-2Report Type:Expedited (15-DaCompany Report #WAES 01108587
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain Upper	Foreign	Tab Vioxx			
	Headache	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Nausea		Pantoprazole Sodium	C		
	Vertigo					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/01ISR Number: 3823347-6Report Type:Expedited (15-DaCompany Report #WAES 01106102
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Urinary Retention	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	2	DAY
			Acetaminophen/Codeine Phosphate	C				
			Clorazepate Dipotassium	C				
			Dothiepin Hcl	C				
			Valpromide	C				

Date:11/07/01ISR Number: 3823349-XReport Type:Expedited (15-DaCompany Report #WAES 01108588
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Omeprazole Magnesium	C				

Date:11/07/01ISR Number: 3823350-6Report Type:Expedited (15-DaCompany Report #WAES 01107522
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:11/07/01ISR Number: 3823376-2Report Type:Expedited (15-DaCompany Report #WAES 01106107
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation Peritonitis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Professional

PO 30 DAY

Acetaminophen	C
Diacerein	C
Meloxicam	C
Omeprazole Sodium	C

Date:11/07/01ISR Number: 3823377-4Report Type:Expedited (15-DaCompany Report #WAES 01103573
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Glomerulonephritis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:11/07/01ISR Number: 3823380-4Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Asthenia
	Diverticulum Intestinal
	Faeces Discoloured
	Gastrointestinal

		Haemorrhage Haematochezia Haemorrhoids Melanosis Coli	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
MG/DAILY/PO							
				Lasix (Furosemide)	C		
				Ms Contin	C		
				Norvasc	C		
				Os-Cal + D	C		
				Premarin	C		
				Tenormin	C		
				Vicodin Es Tablets	C		
				Xanax	C		
				Aspirin	C		

Date:11/07/01ISR Number: 3823416-0Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Respiratory Distress Syndrome	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY	27 DAY						
		Condition Aggravated Dyspnoea Exacerbated Scleroderma	Professional	Fosamax	C		
				Aluminum Hydroxide/Magnesium Carbonate	C		
				Calcium Carbonate	C		
				Captopril	C		
				Penicillamine	C		
				Piprinhydrinate	C		
				Prednisolone	C		

Date:11/07/01ISR Number: 3823417-2Report Type:Expedited (15-DaCompany Report #WAES 01095049
Age:35 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Eye Inflammation	Foreign	Tab Vioxx			

	Iritis	Health	(Rofecoxib)	PS		ORAL
12.5MG/DAILY;						
	Pupillary Disorder	Professional				
25						
MG/DAILY/PO						

Date:11/07/01ISR Number: 3823430-5Report Type:Expedited (15-DaCompany Report #WAES 01106116
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diabetes Mellitus	Foreign	Tab Vioxx			
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL
PO						
		Professional	Gliclazide	C		

Date:11/07/01ISR Number: 3823432-9Report Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Foreign	Tab Vioxx			
Life-Threatening	Haemorrhage	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
		Professional				
PO 8 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/01ISR Number: 3823436-6Report Type:Expedited (15-DaCompany Report #WAES 01109354
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Pain Purulence Ulcer	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY

Date:11/07/01ISR Number: 3823438-XReport Type:Expedited (15-DaCompany Report #WAES 01095551
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - PO Initial or Prolonged	Blood Urea Increased Coagulopathy Gastric Haemorrhage Gastric Ulcer Gastrointestinal Haemorrhage Thrombocytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	UPPER LIMIT	10 DAY

Date:11/07/01ISR Number: 3823443-3Report Type:Expedited (15-DaCompany Report #WAES 01105248
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	7 DAY
			Albuterol	C				
			Levothyroxine Na	C				
			Salmetrerol	C				
			Verapamil	C				

Date:11/07/01ISR Number: 3823459-7Report Type:Expedited (15-DaCompany Report #WAES 01106106
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Encephalopathy Headache	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	16 DAY
	Injection Site Haemorrhage	Professional	Aspirin/Caffeine/Propoxyphene Hcl	C				

Date:11/07/01ISR Number: 3823468-8Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:11/07/01ISR Number: 3823528-1Report Type:Expedited (15-DaCompany Report #WAES 01109312
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Staphylococcal Scalded Skin Syndrome	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID PO	8 DAY
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/01ISR Number: 3824263-6Report Type:Expedited (15-DaCompany Report #WAES 01105233
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophageal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5	
Initial or Prolonged								
							MG/DAILY, PO	113 DAY
			Cozaar	C				
			Doxazosin	C				
			Folic Acid	C				
			Levothyroxine Na	C				
			Methotrexate	C				

Date:11/07/01ISR Number: 3824267-3Report Type:Expedited (15-DaCompany Report #WAES 01105172
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Foreign	Tab Vioxx					
	Increased	Other	(Rofecoxib)	PS		ORAL	25	
	Anorexia							
							MG/DAILY/PO	
	Blood Alkaline		Elavil	C				
	Phosphatase Increased		Acetaminophen/Codein					
	Blood Bilirubin Increased		e Phosphate	C				
	Gamma-Glutamyltransferase							
	Increased							
	Hepatic Function Abnormal							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Weight Decreased							

Date:11/07/01ISR Number: 3824271-5Report Type:Expedited (15-DaCompany Report #WAES 01108176
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					

Initial or Prolonged	Melaena	Other	(Rofecoxib)	PS		ORAL
25 MG/PRN, PO						
Other	Myocardial Infarction					

Date:11/07/01ISR Number: 3824281-8Report Type:Expedited (15-DaCompany Report #HQ7654625OCT2001
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine	Health	Detensiel			
Initial or Prolonged	Increased	Professional	(Bisoprolol, Tablet)	PS		ORAL
10 MG 1X PER						
Other	Bradycardia	Other				
1 DAY ORAL 4 WK						
	Fall		Isoptin (Verapamil			
	Orthostatic Hypotension		Hydrochloride,)	SS		ORAL
240 MG 1X PER						
1 DAY ORAL						
			Vioxx (Rofecoxib,			
			Tablet)	SS		ORAL
1 DF ORAL						
			Xanax (Alprazolam)	C		
			Deroxat (Paroxetine			
			Hydrochloride)	C		
			Laroxyl			
			(Amitriptyline			
			Hydrochloride)	C		
			Trihexyphenidyl			
			Hydrochloride			

	(Trihexyphenidyl Hydrochloride)	C
	Sulfarlem (Anethole Trithione)	C
	Efferalgan (Paracetamol)	C

Date:11/07/01ISR Number: 3824324-1Report Type:Expedited (15-DaCompany Report #WAES 01081790
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 50 Mg	PS			50 MG/DAILY	
	Confusional State	Professional	Toprol Xl Tablets	SS			SEE IMAGE	
	Dizziness	Company	Estrogens					
	Dizziness Postural	Representative	(Unspecified)	C				
	Feeling Abnormal							
	Heart Rate Decreased							
	Influenza							
	Nausea							

Date:11/07/01ISR Number: 3824339-3Report Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Gastric Ulcer	Professional					MG/DAILY/PO	
	Gastrointestinal		Paxil	C				
	Haemorrhage		Aspirin	C				
	Melaena		Disopyramide	C				
	Syncope		Levothyroxine Sodium	C				

Date:11/07/01ISR Number: 3824340-XReport Type:Expedited (15-DaCompany Report #WAES 01106292
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Asthenia	Professional				
MG/DAILY/PO						
Other	Cardiac Failure	Company	Celebrex	C		
	Congestive	Representative	Flexeril	C		
	Cough					
	Lung Neoplasm Malignant					
	Pneumonia					
	Pulmonary Oedema					
	Tachycardia					

Date:11/07/01ISR Number: 3824341-1Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Embolism	Consumer	Tab Vioxx	PS		ORAL
PO						
	Lethargy	Company				
	Nervous System Disorder	Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/01ISR Number: 3824342-3Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Acute Abdomen	Professional					MG/DAILY/PO	
Initial or Prolonged	Acute Respiratory		Lipitor	C				
Disability	Distress Syndrome		Vasotec	C				
	Diarrhoea		...	C				
	Diverticulum		...	C				
	Large Intestine		Zebeta	C				
	Perforation		Aspirin	C				
	Megacolon							
	Purulence							
	Retching							
	Sepsis							
	Small Intestinal							
	Obstruction							

Date:11/07/01ISR Number: 3824343-5Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Drug Level Above	Professional					MG/DAILY/PO	
	Therapeutic	Company	Dilantin 300 Mg	SS			300 MG/DAILY	
	Mental Impairment	Representative						

Date:11/08/01ISR Number: 3821816-6Report Type:Direct Company Report #
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Renal Failure Acute		Rofecoxib-Vioxx-	PS		ORAL	QD ORAL	
Intervention to			Ranitidine	C				

Prevent Permanent Impairment/Damage				Metoprolol	C		

Date:11/08/01ISR Number: 3821886-5Report Type:Expedited (15-DaCompany Report #WAES 01110189
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspepsia		Premarin	C				
	Viral Infection							

Date:11/08/01ISR Number: 3821887-7Report Type:Expedited (15-DaCompany Report #WAES 01110337
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure		Lasix (Furosemide)	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3821892-0Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypoaesthesia							

Date:11/08/01ISR Number: 3821895-6Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
Other	Distress Syndrome		Captopril	C		ORAL		1 DAY
	Cardiomegaly		Calcium Carbonate	C		ORAL		25 DAY
	Condition Aggravated		Prednisolone	C		ORAL		25 DAY
	Myopathy		Piprinhydrinate	C		ORAL		26 DAY
	Pericardial Effusion Pleural Effusion Pulmonary Oedema		Aluminum Hydroxide And Magnesium Carbonate	C		ORAL		26 DAY
	Scleroderma		Fosamax	C		ORAL		25 DAY
			Penicillamine	C		ORAL		24 DAY
			Aminophylline	C		PARENTERAL		DAY
			Furosemide	C		INTRAVENOUS		
			Blood, Plasma	C		INTRAVENOUS DRIP		

Date:11/08/01ISR Number: 3821896-8Report Type:Expedited (15-DaCompany Report #WAES 01103290
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharyngeal Oedema		Vioxx	PS	Merck & Co., Inc		2	DAY
	Tongue Disorder		Vivelle	C				
	Urticaria		Paxil	C				
			Vitamins (Unspecified)	C				

Date:11/08/01ISR Number: 3821897-XReport Type:Expedited (15-DaCompany Report #WAES 01102196
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoglycaemia		Mestinon	C				
			Prevacid	C				
			Estrace	C				
			Elavil	C				

Date:11/08/01ISR Number: 3821898-1Report Type:Expedited (15-DaCompany Report #WAES 01105259
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Carbamazepine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3821901-9Report Type:Expedited (15-DaCompany Report #WAES 01110494
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
	Autoimmune		Vioxx	SS		ORAL	14	DAY
			Vioxx	SS		ORAL	14	DAY
			Zyrtec	C				
			Entex	C				
			Flonase	C				
			Serevent	C				

Date:11/08/01ISR Number: 3821903-2Report Type:Expedited (15-DaCompany Report #WAES 01119753
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/01ISR Number: 3821904-4Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Blood Pressure Decreased Cardiovascular Disorder Heart Rate Increased Hyperhidrosis Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	23	DAY

Date:11/08/01ISR Number: 3821908-1Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/01ISR Number: 3821914-7Report Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Mucosal Lesion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Aspirin	C				
			Paxil	C				
	Melaena		Disopyramide	C				
	Syncope		Levothyroxine Sodium	C				

Date:11/08/01ISR Number: 3821915-9Report Type:Expedited (15-DaCompany Report #WAES 01105082
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		221 DAY
	Melaena		Acetaminophen And Codeine Phosphate	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Thiamine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3821916-0Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Oedema Peripheral		Vioxx	SS		ORAL		28 DAY

Date:11/08/01ISR Number: 3821918-4Report Type:Expedited (15-DaCompany Report #WAES 01106093
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		28 DAY
Initial or Prolonged	Gastritis		Aspirin	SS		ORAL		
	Haemoglobin Decreased		Lacidipine	C		ORAL		
	Melaena		Zopiclone	C		ORAL		
	Rectal Haemorrhage		Hydroxyzine Hydrochloride	C		ORAL		

Date:11/08/01ISR Number: 3821921-4Report Type:Expedited (15-DaCompany Report #WAES 01110175
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Adderall Tablets	C				
Other								

Date:11/08/01ISR Number: 3821922-6Report Type:Expedited (15-DaCompany Report #WAES 01115523
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Livedo Reticularis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Rheumatoid Factor Positive		Vioxx [Therapy Unspecified]	SS C		ORAL		

Date:11/08/01ISR Number: 3822355-9Report Type:Direct Company Report #
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Infection		Vioxx 25mg	PS			25MG ONCE	
Initial or Prolonged	Oedema Peripheral						BEFORE BED	

Date:11/08/01ISR Number: 3822359-6Report Type:Direct Company Report #
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg Merck	PS	Merck	ORAL	25MG 2X DAY	
Hospitalization -							ORALLY	
Initial or Prolonged			Multi-Vit	C				
Required			Estrogen	C				
Intervention to			Guiafenisin	C				
Prevent Permanent								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/01ISR Number: 3822888-5Report Type:Expedited (15-DaCompany Report #200120976EU
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased	Foreign Other	Leflunomide (Arava) Tablets	PS		ORAL	20 MG / DAY	
	Cardiac Failure						PO	
	Chest Pain		Metronidazole (Flagyl)	SS				
	Depressed Level Of Consciousness		Metronidazole (Flagyl)	SS		ORAL	800 MG / DAY	
	Hepatic Enzyme Increased							
	Renal Failure Acute						PO	15 DAY
			Flucloxacillin Sodium (Heracillin)	SS				
			Flucloxacillin Sodium (Heracillin)	SS			2.2 G/DAY	15 DAY
			Rofecoxib (Vioxx)	SS			25 MG/ DAY	
			Enalapril Maleate (Renitec)	SS		ORAL	20MG/DAY PO	7 DAY
			Spironolactone	SS		ORAL	50 MG/DAY PO	
			Furosemide (Furix)	SS		ORAL	40 MG/DAY PO	7 DAY
			Gabapentin (Neurontin)	SS		ORAL	QD PO	
			Folic Acid, Calcium Phosphate (Folacin)	C				
			Vitamin E	C				
			Morfin	C				
			Prednisolon	C				
			Cisapride (Prepulsid)	C				
			Cetirizine (Zyrlex)	C				
			Morphine Sulfate (Dolcontin)	C				
			Lansoprazole (Lanzo)	C				

Date:11/08/01ISR Number: 3823047-2Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Blood Pressure Decreased Cardiovascular Disorder Heart Rate Increased Hyperhidrosis Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 23 DAY

Date:11/09/01ISR Number: 3822726-0Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Prednisone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Leflunomide	C		ORAL		

Date:11/09/01ISR Number: 3822727-2Report Type:Expedited (15-DaCompany Report #WAES 01115033
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/09/01ISR Number: 3822735-1Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Embolism Lethargy		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

Date:11/09/01ISR Number: 3822737-5Report Type:Expedited (15-DaCompany Report #WAES 01110508
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/01ISR Number: 3822739-9Report Type:Expedited (15-DaCompany Report #WAES 01100109
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	

Date:11/09/01ISR Number: 3822743-0Report Type:Expedited (15-DaCompany Report #WAES 01110767
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Covera-Hs	C				
			Tenormin	C				

Date:11/09/01ISR Number: 3822830-7Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				

Date:11/09/01ISR Number: 3822833-2Report Type:Expedited (15-DaCompany Report #WAES 01103731
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
411 DAY								
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena		Acenocoumarol	SS		ORAL		
			Perindopril Erbumine	C		ORAL		
			Furosemide	C		ORAL		
			Formoterol Fumarate	C				

RESPIRATORY

(INHALATION)

			Budesonide	C		
RESPIRATORY						
(INHALATION)						
			Mirtazapine	C		ORAL
			Lactulose	C		ORAL
			Methimazole	C		ORAL
			Zopiclone	C		ORAL

Date:11/09/01ISR Number: 3822953-2Report Type:Direct Company Report #
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Nausea		"Vioxx"	PS		ORAL
PO						

Date:11/12/01ISR Number: 3822989-1Report Type:Expedited (15-DaCompany Report #WAES 01101950
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
328 DAY						
Initial or Prolonged	Blood Pressure Systolic		Captopril	C		ORAL
	Increased		Inderal	C		ORAL
	Cataract		Detrol La	C		ORAL
	Dizziness		Excedrin			
	Dyspnoea		(Acetaminophen (+)			
	Endoscopy		Caffeine)	C		
	Endoscopy Abnormal		Atrovent	C		
	Faecal Occult Blood		Vitamin E	C		
	Positive		Centrum	C		ORAL
	Gastrointestinal		[Therapy			
	Haemorrhage		Unspecified]	C		
	Haematemesis					
	Haematocrit Decreased					
	International Normalised					
	Ratio Decreased					
	Pallor					
	Platelet Count Decreased					
	Tachycardia					
	Tenderness					

Vomiting

Date:11/12/01ISR Number: 3822990-8Report Type:Expedited (15-DaCompany Report #WAES 01103289
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/01ISR Number: 3822992-1Report Type:Expedited (15-DaCompany Report #WAES 01115035
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Death		Levothyroxine Sodium	C		ORAL		
			Prednisolone	C		ORAL		
			Lactulose	C		ORAL		
			Loperamide	C				
			Lorazepam	C				
			Acetaminophen	C				

Date:11/12/01ISR Number: 3822993-3Report Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Leukopenia		Acetaminophen	C		ORAL		
	Thrombocytopenia		Ibuprofen	C		ORAL		
			[Therapy Unspecified]	C				
			Amoxicillin	C		ORAL		

OPHTHALMIC

Date:11/12/01ISR Number: 3822995-7Report Type:Expedited (15-DaCompany Report #WAES 01106442
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatic Function Abnormal		Excedrin					
	Nausea		(Acetaminophen (+)					
	Vomiting		Aspirin (+)					
			Caffeine)	C				
			Zantac	C				

Date:11/12/01ISR Number: 3822998-2Report Type:Expedited (15-DaCompany Report #WAES 01116024
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Duodenitis		Vioxx	SS		ORAL		11 DAY
	Necrosis		Molsidomine	C		ORAL		
	Oesophagitis		Amlodipine	C		ORAL		
	Vomiting		Zolpidem Tartrate	C		ORAL		
			Fosinopril Sodium	C		ORAL		

Date:11/12/01ISR Number: 3822999-4Report Type:Expedited (15-DaCompany Report #WAES 01110878
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
			Niaspan	C		
			Altace	C		
			Zoloft	C		
			Lipitor	C		
			Aciphex	C		
			Neurontin	C		

Date:11/12/01ISR Number: 3823005-8Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Increased		Atacand	C		
	Cerebrovascular Accident		Lopid	C		
Disability	Hemiparesis		Aspirin	C		
Other	Hyperglycaemia		Glucosamine	C		
	Hyperlipidaemia		Sudafed	C		
	Renal Impairment		Benadryl	C		
	Weight Decreased		Atenolol	C		
			Atenolol	C		

				Hydrodiuril	C		
				Atacand Plus	C		

Date:11/12/01ISR Number: 3823006-XReport Type:Expedited (15-DaCompany Report #WAES 01101944
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Diarrhoea		Aspirin	C				
			Glucophage	C				
			Ativan	C				
			Questran	C				

Date:11/12/01ISR Number: 3823009-5Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
			Vioxx	SS		ORAL	1	WK
			Dipyrone	C				
			Captopril	C				

Date:11/12/01ISR Number: 3823010-1Report Type:Expedited (15-DaCompany Report #WAES 01119801
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Other	Tachycardia							

Date:11/12/01ISR Number: 3823016-2Report Type:Expedited (15-DaCompany Report #WAES 01110972
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemiparesis Speech Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY

Date:11/12/01ISR Number: 3823017-4Report Type:Expedited (15-DaCompany Report #WAES 01110855
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/01ISR Number: 3823018-6Report Type:Expedited (15-DaCompany Report #WAES 01110854
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/01ISR Number: 3823670-5Report Type:Expedited (15-DaCompany Report #WAES 01106429
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour Cerebrovascular Disorder

Thinking Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx	PS		ORAL	PO	

Date:11/12/01ISR Number: 3823674-2Report Type:Expedited (15-DaCompany Report #WAES 01106495
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:11/12/01ISR Number: 3823757-7Report Type:Expedited (15-DaCompany Report #WAES 01072772
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cardiac Disorder	Health Professional	Flomax (Tamsulosin Hydrochloride)	C				
	Cardiac Failure Congestive		Flovent	C				
	Cardiomegaly		Fosamax	C				
	Coronary Artery Disease		Tylenol	C				
	Dyspnoea Exertional		Zantac	C				
	Ejection Fraction Abnormal							
	Electrocardiogram Abnormal							
	Fluid Retention							
	Hypokinesia							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Pulmonary Function Test Decreased							
	Upper Respiratory Tract Infection							

Ventricular Extrasystoles

Date:11/12/01ISR Number: 3823768-1Report Type:Expedited (15-DaCompany Report #WAES 01092186
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Hyperhidrosis	Health	Lotrel	C				
Other	Nausea	Professional						

Date:11/12/01ISR Number: 3823769-3Report Type:Expedited (15-DaCompany Report #WAES 01090944
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Condition Aggravated	Professional	Daypro	C				
Initial or Prolonged	Gastritis	Company						
Other	Gastrointestinal	Representative						
	Haemorrhage							
	Haematemesis							

Date:11/12/01ISR Number: 3823771-1Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx 12.5mg	PS		ORAL	SEE IMAGE	
Other	Condition Aggravated	Professional	Hydrodiuril	C				
	Dyspnoea	Company	Prevacid	C				
	Multiple Allergies	Representative	Atenolol	C				
	Myocardial Infarction							
	Nausea							
	Respiratory Arrest							
	Sudden Death							
	Vomiting							

Date:11/12/01ISR Number: 3823774-7Report Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged							MG/DAILY/PO	
			Coumadin	C				
			[Therapy					
			Unspecified]	C				
			....	C				

Date:11/12/01ISR Number: 3823776-0Report Type:Expedited (15-DaCompany Report #WAES 01102000
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective	Health					MG/DAILY/PO	
	Tremor	Professional	[Therapy					
			Unspecified]	C				
			[Therapy					
			Unspecified]	C				

			Ranitidine	C			

Date:11/12/01ISR Number: 3824666-XReport Type:Expedited (15-DaCompany Report #2001078865SE
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased	Foreign Other	Spironolakton Nm Pharma (Spironolactone) Tablet	PS			50 MG/DAY	
	Depressed Level Of Consciousness							
	Gamma-Glutamyltransferase Increased		Gabapentin (Gabapentin)	SS		(CAPS)	2.4 MG/DAY	
	Hepatic Enzyme Increased							
	Infected Skin Ulcer		Furosemide (Furosemide)	SS			40 MG/DAY	
	Metabolic Disorder							
	Renal Failure Acute		Enalapril (Enalapril)	SS			20 MG/DAY	
	Sedation							
			Rofecoxib (Rofecoxib)	SS			25 MG/DAY	
			Metronidazole (Metronidazole)	SS			800 MG/DAY	
			Flucloxacillin (Flucloxacillin)	SS			2.2 G/DAY	
			Leflunomide					

				(Leflunomide)	SS	
20 MG/DAY						
				Folic Acid	C	
				Tocopherol (Tocopherol)	C	
				Paracetamol	C	
				Prednisolon	C	
				Morphine	C	
				Cisapride (Cisapride)	C	
				Cetrizin (Cefatrizine Propyleglycolate Sulfate)	C	
				Dolcontin (Morphine Sulfate)	C	
				Zolpidem (Zolpidem)	C	
				Calcium	C	
				Loperamide (Loperamide)	C	
				Ipratropium Bromide	C	
				Lansoprazole	C	

Date:11/12/01ISR Number: 3824685-3Report Type:Expedited (15-DaCompany Report #WAES 01109145
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema	Foreign	Tab Vioxx					
Disability	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	25 MG/Q12H	452 DAY
Other	Hip Fracture	Professional	Inj Dexamethasone					
	Sepsis		Sodium Phosphate	SS		INTRAMUSCULAR		
	Tachypnoea		Diuretic					
	Urinary Tract Infection		(Unspecified)	C				

Date:11/12/01ISR Number: 3824715-9Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia	Foreign	Tab Vioxx					

Initial or Prolonged	Cerebrovascular Accident	Other	(Rofecoxib)	PS	ORAL
25 MG/DAILY					
	Confusional State		Acepromet azine		
	Electroencephalogram		Maleate (+)		
	Abnormal		Meprobamate	C	
	Myocardial Infarction		Acetaminophen	C	
			Bromazepam	C	
			Calcium Phosphate,		
			Tribasic	C	
			Enoxaparin	C	
			Ketoprofen	C	
			Pamidronate Disodium	C	
			Prednisone	C	
			Vitamin D		
			(Unspecified)	C	

Date:11/12/01ISR Number: 3824726-3Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender: I/FU:I

Outcome	PT	Report Source
Other	Myocardial Infarction	Foreign
		Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:11/13/01ISR Number: 3823106-4Report Type:Expedited (15-DaCompany Report #WAES 01104756
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged	Haemorrhage Intracranial Metastasis Oedema Peripheral							

Date:11/13/01ISR Number: 3823108-8Report Type:Expedited (15-DaCompany Report #WAES 01108158
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Piroxicam	SS		TOPICAL		

Date:11/13/01ISR Number: 3823109-XReport Type:Expedited (15-DaCompany Report #WAES 01106030
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Initial or Prolonged	Pancreatitis		Proscar	C		ORAL		

Date:11/13/01ISR Number: 3823110-6Report Type:Expedited (15-DaCompany Report #WAES 01111018
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:11/13/01ISR Number: 3823113-1Report Type:Expedited (15-DaCompany Report #WAES 01115006
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Grand Mal Convulsion		Acetaminophen	C		ORAL		
			Carbamazepine	C		ORAL		
			Estradiol	C		TOPICAL		

Date:11/13/01ISR Number: 3823114-3Report Type:Expedited (15-DaCompany Report #WAES 01115547
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Liposarcoma							
	Renal Cell Carcinoma							
	Stage Unspecified							
	Renal Cyst							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/01ISR Number: 3823118-0Report Type:Expedited (15-DaCompany Report #WAES 01115061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Haematoma Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/13/01ISR Number: 3823265-3Report Type:Expedited (15-DaCompany Report #A124517
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria	Foreign Health Professional	Feldene Capsules	PS				
			Rofecoxib	SS		ORAL	PRN:ORAL	

Date:11/13/01ISR Number: 3824018-2Report Type:Direct Company Report #
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Cell Carcinoma		Vioxx 25 Mg	PS		ORAL	25MG 1T QD PO	
Hospitalization - Initial or Prolonged	Stage Unspecified		Norvasc	C				
			Monopril	C				
			Maxzide	C				

Date:11/14/01ISR Number: 3823611-0Report Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Vioxx	SS		ORAL		
	Cerebrovascular Accident		Xalatan	C			OPHTHALMIC	
			Atenolol	C				
			Verapamil	C				

			Hydrodiuril	C		
			Zocor	C		
			Prinivil	C		

Date:11/14/01ISR Number: 3823612-2Report Type:Expedited (15-DaCompany Report #WAES 01106292
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 14 DAY	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Flexeril	C		
Other	Congestive		Celebrex	C		
	Cardiomegaly		Nonsteroidal			
	Cough		Anti-Inflammatory			
	Dyspnoea		Drug (Unspecified)	C		
	Inappropriate					
	Antidiuretic Hormone					
	Secretion					
	Lung Adenocarcinoma					
	Oedema Peripheral					
	Pneumonia					
	Pulmonary Oedema					
	Tachycardia					

Date:11/14/01ISR Number: 3823615-8Report Type:Expedited (15-DaCompany Report #WAES 01116510
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:11/14/01ISR Number: 3823616-XReport Type:Expedited (15-DaCompany Report #WAES 01118119
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Oedema		Clonidine Hydrochloride	C				
	Renal Disorder		Hydroxychloroquine Sulfate	C				
			Ramipril	C				
			Timoptic	C				
			Aspirin	C				
			Rabeprazole Sodium	C				

Date:11/14/01ISR Number: 3823621-3Report Type:Expedited (15-DaCompany Report #WAES 01111153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Haemorrhage							

Date:11/14/01ISR Number: 3823622-5Report Type:Expedited (15-DaCompany Report #WAES 01115015
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL	146	DAY

	Dyspnoea		Levothyroxine Sodium	C
	Headache			
	Palpitations			
	Tremor			

Date:11/14/01ISR Number: 3823623-7Report Type:Expedited (15-DaCompany Report #WAES 01115052
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Circulatory Collapse	Professional	[Therapy			
Initial or Prolonged	Head Injury		Unspecified]	SS		
	Hypotension		[Therapy			
	Loss Of Consciousness		Unspecified]	C		
	Ventricular Hypertrophy		Aspirin	C		

Date:11/14/01ISR Number: 3824696-8Report Type:Direct Company Report #
Age:97 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Cardiac Failure
Initial or Prolonged	Congestive

		Cardiomegaly Dyspnoea Pleural Effusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx Msd	PS	Msd	ORAL
25MG PO QD							
~1WK DURATION	1 WK						
				Levothyroxine	C		
				Digoxin	C		
				Glucotrol Xl	C		
				Claritin	C		
				Celexa	C		

Date:11/14/01ISR Number: 3825132-8Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Diarrhoea	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Eyelid Oedema	Professional				
	Pulmonary Oedema	Company				
	Rash Generalised	Representative				
	Vomiting					

Date:11/14/01ISR Number: 3825138-9Report Type:Expedited (15-DaCompany Report #WAES 01081460
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
	Atrial Fibrillation	Health	Cardizem	C		
	Decreased Appetite	Professional	Coumadin	C		
	Drug Hypersensitivity		Elavil	C		
	Feeling Abnormal		Lanoxin	C		
	Nausea		Peri-Colace	C		
	Palpitations		Prinivil	C		
			Senokot (Sennosides)	C		
			Aspirin	C		

Date:11/14/01ISR Number: 3825139-0Report Type:Expedited (15-DaCompany Report #WAES 01103290
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nasopharyngeal Disorder	Health	Tab Vioxx 25 Mg	PS			25 MG	
	Tongue Disorder	Professional					MG/DAILY	
	Urticaria	Company Representative	Paxil	C				
			Vivelle	C				
			Vitamins(Unspecified)	C				

Date:11/14/01ISR Number: 3825169-9Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral	Professional						
	Pain In Extremity	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3825170-5Report Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Gastric Mucosal Lesion	Professional					MG/DAILY/PO	
	Syncope		Paxil	C				
			Aspirin	C				
			Disopyramide	C				
			Levothyroxine Sodium	C				

Date:11/14/01ISR Number: 3825189-4Report Type:Expedited (15-DaCompany Report #WAES 01110494
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Haemolytic	Health	Tab Vioxx	PS		ORAL	PO	
	Autoimmune	Professional	Entex	C				
			Flonase	C				
			Serevent	C				
			Zyrtec	C				

Date:11/14/01ISR Number: 3825191-2Report Type:Expedited (15-DaCompany Report #WAES 01102196
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health	Orsu Vioxx 12.5 Mg	PS		ORAL	12.5	
	Hypoglycaemia	Professional					MG/BID/PO	
		Company Representative	Elavil	C				
			Estrace	C				
			Mestinon	C				
			Prevacid	C				

Date:11/14/01ISR Number: 3825198-5Report Type:Expedited (15-DaCompany Report #WAES 01110337
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Condition Aggravated		Lasix (Furosemide)	C				
	Renal Failure		(Therapy Unspecified)	C				

Date:11/14/01ISR Number: 3825318-2Report Type:Expedited (15-DaCompany Report #WAES 01107919
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Foreign	Vioxx (Rofecoxib)	PS			7	DAY
Initial or Prolonged	Oedema	Health						
	Oral Soft Tissue Disorder	Professional						
	Rash Papular	Other						
	Salivary Gland Disorder							
	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3825329-7Report Type:Expedited (15-DaCompany Report #WAES 01104726
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 WK
			Proctium	C				
			Folic Acid	C				
			Prednisone	C				

Date:11/14/01ISR Number: 3825330-3Report Type:Expedited (15-DaCompany Report #WAES 01082484
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg/12.5mg	PS		ORAL	25 MG/12.5 MG	
	Headache							
	Oedema	Company Representative	Talacen	C				
			(Composition Unspecified)	C				
			Alprazolam	C				

Date:11/14/01ISR Number: 3825437-0Report Type:Expedited (15-DaCompany Report #US008824
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Provigil	PS		ORAL	200 MG QD ORAL	
	Convulsion							
	Dyspnoea		Vioxx	SS		ORAL	12.5 MG QD ORAL	
	Dysuria							
	Fall		Betaseron	SS		SUBCUTANEOUS	3 CC QOD, SUBCUTANEOUS	1 YR
	Head Injury							

	Hyperreflexia	Wellbutrin	C
	Laceration	Procarin Patch	C
	Livedo Reticularis	Amantadine	C
	Mental Impairment	Multivitamins	C
	Oedema Peripheral		
	Rash Macular		
	Status Epilepticus		

Date:11/14/01ISR Number: 3825439-4Report Type:Expedited (15-DaCompany Report #WAES 01082868
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Cerebrovascular Accident							
	Confusional State		Prilosec	C				
	Decreased Activity							
	Dyspnoea							
	Memory Impairment							
	Vision Blurred							

Date:11/14/01ISR Number: 3825557-0Report Type:Expedited (15-DaCompany Report #WAES 01101214
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Cerebral Infarction	Health Professional Company
	Hallucination	

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	

Date:11/14/01ISR Number: 3825592-2Report Type:Expedited (15-DaCompany Report #WAES 01090026
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Cerebrovascular Accident	Professional						
	Hypertension	Company						
	Hypoaesthesia	Representative						

Date:11/14/01ISR Number: 3825594-6Report Type:Expedited (15-DaCompany Report #WAES 00030223
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Study	Tab Mk-0966 25 Mg					
Hospitalization -	Dyspnoea	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Joint Swelling	Professional						
Disability	Mitral Valve Disease		Coumadin	C				
	Oedema		Lopressor	C				
	Ventricular Tachycardia		Vasotec	C				
			Ascorbic Acid	C				
			Calcium Carbonate	C				
			Furosemide	C				
			Vitamin D	C				
			Vitamin E	C				
			Vitamins	C				

Date:11/14/01ISR Number: 3825595-8Report Type:Expedited (15-DaCompany Report #WAES 00074037
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Study	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional	Tab 0954-Blinded Therapy Unk	SS		ORAL	PO	
			Fosamax	C				
			Hydrodiuril	C				
			Propecia	C				
			Chondroitin Sulfate	C				
			Darvocet N	C				
			Glucosamine	C				
			Prednisone	C				
			Terazosin	C				

Date:11/14/01ISR Number: 3825600-9Report Type:Expedited (15-DaCompany Report #WAES 01092218
Age:93 YR Gender:Female I/FU:F

Outcome	PT
Other	Abnormal Behaviour
	Aggression
	Aphasia
	Blood Pressure Increased
	Coma
	Confusional State

		Decreased Appetite					
		Disorientation					
		Ecchymosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Excoriation	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Faecal Incontinence	Professional				
MG/DAILY/PO							
		Fall		Ativan	C		
		Inappropriate Affect		Darvocet-N	C		
		Listless		Prilosec	C		
		Restlessness		Zoloft	C		
		Sedation		Zyrtec	C		
		Urinary Incontinence		...	C		
				Aspirin	C		
				Thyroid	C		

Date:11/14/01ISR Number: 3825726-XReport Type:Expedited (15-DaCompany Report #WAES 01082423
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety Disorder	Consumer	Tab Vioxx	PS		ORAL
SEE IMAGE							
Initial or Prolonged		Atrial Fibrillation	Health	Cartia (Diltiazem			
		Blood Pressure Increased	Professional	Hydrochloride)	C		
		Palpitations		Claritin	C		
				Lasix (Furosemide)	C		
				Prilosec	C		
				Toprol Xl Tablets	C		
				Estradiol	C		

Date:11/14/01ISR Number: 3825729-5Report Type:Expedited (15-DaCompany Report #WAES 01082868
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
Other		Cerebrovascular Accident					
MG/DAILY/PO							
		Confusional State		Prilosec	C		
		Dyspnoea					

Memory Impairment
Vision Blurred

Date:11/14/01ISR Number: 3825741-6Report Type:Expedited (15-DaCompany Report #WAES 01090534
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Health	Tab Vioxx	PS		ORAL	25	
Other	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company Representative	Coumadin	C				

Date:11/14/01ISR Number: 3825757-XReport Type:Expedited (15-DaCompany Report #WAES 01101099
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3825764-7Report Type:Expedited (15-DaCompany Report #WAES 01104756
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage Intracranial	Health	Tab Vioxx	PS		ORAL	PO	18 DAY
Initial or Prolonged	Oedema Peripheral	Professional						

Date:11/14/01ISR Number: 3825772-6Report Type:Expedited (15-DaCompany Report #WAES 01110189
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Dyspepsia							
Initial or Prolonged	Pericardial Disease		Premarin	C				
	Viral Infection							

Date:11/14/01ISR Number: 3825774-XReport Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Hospitalization -	Hypoaesthesia							
Initial or Prolonged								

Date:11/14/01ISR Number: 3825780-5Report Type:Expedited (15-DaCompany Report #WAES 01110175
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional	Adderall Tablets	C				
Other								

Date:11/14/01ISR Number: 3826170-1Report Type:Expedited (15-DaCompany Report #WAES 01115001
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Behaviour	Foreign	Tab Vioxx					
	Agitation	Company	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Mental Disorder	Representative						
						PO		10 DAY
			Acetaminophen/Codeine Phosphate	C				
			Amiloride Hydrochloride (+) Furosemide	C				
			Aspirin	C				
			Isosorbide Mononitrate	C				
			Loratadine	C				
			Ranitidine	C				

Date:11/14/01ISR Number: 3826176-2Report Type:Expedited (15-DaCompany Report #WAES 01105676
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3826223-8Report Type:Expedited (15-DaCompany Report #WAES 01119753
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:11/14/01ISR Number: 3826229-9Report Type:Expedited (15-DaCompany Report #WAES 01105259
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	1 TABLET/DAILY	
			Carbamazepine	C				

Date:11/14/01ISR Number: 3826230-5Report Type:Expedited (15-DaCompany Report #WAES 01115523
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cutaneous Vasculitis Rheumatoid Factor Positive	Foreign Health Professional	Tab Vioxx (Rofecoxib) Therapy Unspecified	PS C		ORAL	SEE IMAGE	

Date:11/14/01ISR Number: 3826231-7Report Type:Expedited (15-DaCompany Report #WAES 01103731
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization -	Abdominal Pain Gastrointestinal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	411 DAY

Initial or Prolonged	Haemorrhage		Tab Acenocoumarol	SS		ORAL
1 TABLET/PRN						
			Budenoside	C		
			Formoterol Fumarate	C		
			Furosemide	C		
			Lactulose	C		
			Methimazole	C		
			Mirtazapine	C		
			Perindopril Erbumine	C		
			Zopiclone	C		

Date:11/14/01ISR Number: 3826274-3Report Type:Expedited (15-DaCompany Report #WAES 01106065
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancreatitis	Foreign	Tab Vioxx			
		Health	(Rofecoxib)	PS		ORAL
12.5 MG DAILY						
		Professional				
PO						
			Acetaminophen	C		
			Chlordiazepoxide			
			Hcl/Clidinium			
			Bromide	C		
			Fenofibrate	C		
			Lorazepam	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3826325-6Report Type:Expedited (15-DaCompany Report #WAES 01047305
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena Thrombocytopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 21 DAY

Date:11/14/01ISR Number: 3826327-XReport Type:Expedited (15-DaCompany Report #WAES 01076088
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Herniation	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Cheyne-Stokes Respiration	Health	(Rofecoxib)	PS		ORAL	25MG/DAILY	
	Corneal Reflex Decreased	Professional						PO 8 DAY
	Drug Interaction	Other	Tab Acenocoumarol	SS		ORAL	4 MG/DAILY	
	Haemorrhagic Stroke							PO
	International Normalised Ratio Increased		Acetaminophen	C				
			Dimethicone	C				
	Malaise							
	Mydriasis							
	Nystagmus							
	Pupillary Reflex Impaired							
	Sedation							
	Vertigo							
	Vomiting							

Date:11/14/01ISR Number: 3826337-2Report Type:Expedited (15-DaCompany Report #WAES 01107308
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

PO

Esomeprazole		
Magnesium	C	
Flunitrazepam	C	
Gabapentin	C	
Norfloxacin	C	

Date:11/14/01ISR Number: 3826341-4Report Type:Expedited (15-DaCompany Report #WAES 01085105
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Disorder	Foreign	Tab Vioxx					
	Muscle Hypertrophy	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Myalgia	Professional					PO	
	Oedema Peripheral		Acetaminophen	C				
	Pain In Extremity		Ibuprofen	C				

Date:11/14/01ISR Number: 3826343-8Report Type:Expedited (15-DaCompany Report #WAES 01059109
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Duodenitis
Hospitalization -	Gastric Ulcer
Initial or Prolonged	Gastric Ulcer Haemorrhage
	Gastrointestinal

Haemorrhage
Hiatus Hernia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO
	Gemfibrozil	C				

Date:11/14/01ISR Number: 3826389-XReport Type:Expedited (15-DaCompany Report #WAES 01085105
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Laboratory Test Abnormal	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/UNK	PO
	Muscle Disorder							
	Oedema Peripheral							
	Pain In Extremity		Acetaminophen	C				
			Ibuprofen	C				

Date:11/14/01ISR Number: 3826421-3Report Type:Expedited (15-DaCompany Report #WAES 01115033
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:11/14/01ISR Number: 3826422-5Report Type:Expedited (15-DaCompany Report #WAES 01059109
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Duodenitis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Gastric Ulcer							

Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional					
PO							
	Hiatus Hernia		Gemfibrozil	C			

Date:11/14/01ISR Number: 3826526-7Report Type:Expedited (15-DaCompany Report #WAES 01106035
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx					
Initial or Prolonged	Congestive	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Myocardial Infarction	Professional						
PO							31	DAY
			Urapidil	C				

Date:11/14/01ISR Number: 3826565-6Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25	
Initial or Prolonged		Professional						
MG/DAILY/PO								
		Other	Leflunomide	C				
			Prednisone	C				
			Tramadol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/01ISR Number: 3826569-3Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 23 DAY
	Blood Pressure Decreased							
	Cardiovascular Disorder							
	Heart Rate Increased							
	Hyperhidrosis							
	Hypovolaemic Shock							
	Upper Gastrointestinal Haemorrhage							

Date:11/14/01ISR Number: 3826571-1Report Type:Expedited (15-DaCompany Report #WAES 01104914
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	27 DAY
Other	Anaemia							
	Cardiomegaly		Fosamax	C				
	Chest X-Ray Abnormal		Aluminum Hydroxide/Magnesium Carbonate	C				
	Condition Aggravated		Aminophylline	C				
	Dyspnoea Exacerbated		Blood,Plasma	C				
	Pericardial Effusion		Calcium Carbonate	C				
	Pleural Effusion		Captopril	C				
	Pulmonary Oedema		Furosemide	C				
	Scleroderma		Penicillamine	C				
			Piprinhydrinate	C				
			Prednisolone	C				

Date:11/14/01ISR Number: 3826573-5Report Type:Expedited (15-DaCompany Report #WAES 01105082
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY PO	221 DAY
			Acetaminophen/Codeine Phosphate	C				
			Bendroflumethiazide	C				
			Thiamine	C				

Date:11/14/01ISR Number: 3826574-7Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Drug Ineffective Haemorrhage Intracranial Oedema Peripheral	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO 25MG/DAILY PO	14 DAY

Date:11/14/01ISR Number: 3826575-9Report Type:Expedited (15-DaCompany Report #WAES 01106093
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastritis Rectal Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 28 DAY
			Powd Aspirin	SS		ORAL	75 MG/DAILY	PO
			Hydroxyzine Hydrochloride	C				
			Lacidipine	C				
			Zopiclone	C				

Date:11/15/01ISR Number: 3824494-5Report Type:Expedited (15-DaCompany Report #WAES 01104872
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Aspirin	C				
	Bundle Branch Block Left		Plendil	C				
	Cardiac Failure		Plendil	C				
	Congestive		Inderal	C				
	Chest Pain		Zocor	C				
	Coma		Celexa	C				
	Duodenal Ulcer		Isordil	C				
	Haemorrhage		Celebrex	C				
	Ejection Fraction Abnormal							
	Gastroenteritis							
	Helicobacter							
	Myocardial Infarction							
	Renal Failure							

Date:11/15/01ISR Number: 3824497-0Report Type:Expedited (15-DaCompany Report #WAES 01110863
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lamictal	C				
			Lamictal	C				
			Keppra	C				
			Celexa	C				
			Allegra	C				

Date:11/15/01ISR Number: 3824499-4Report Type:Expedited (15-DaCompany Report #WAES 01115569
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/01ISR Number: 3824500-8Report Type:Expedited (15-DaCompany Report #WAES 01116509
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		
			Potassium Chloride	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Aspirin	C		ORAL		
			Furosemide	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Gemfibrozil	C		ORAL		
			Ramipril	C		ORAL		
			Glimepiride	C		ORAL		

Date:11/15/01ISR Number: 3824501-XReport Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
30 DAY								
Initial or Prolonged	Drug Interaction		Carbamazepine	SS		ORAL		
	Drug Level Below		Elavil	C		ORAL		
	Therapeutic		Alprazolam	C		ORAL		

Date:11/15/01ISR Number: 3824502-1Report Type:Expedited (15-DaCompany Report #WAES 01115070
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
15 DAY								
	Faeces Pale		Gold Sodium					
	Headache		Thiomalate	C				
INTRAMUSCULAR								
	Vomiting		Ranitidine	C		ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Estradiol And Norethindrone Acetate	C		ORAL		

Date:11/15/01ISR Number: 3824503-3Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
			Sulfasalazine	C				

Date:11/15/01ISR Number: 3824504-5Report Type:Expedited (15-DaCompany Report #WAES 01111179
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS		ORAL	7	DAY
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Congestive		Depakote	C				
Other	Confusional State		Zoloft	C				
	Hyponatraemia		Baclofen	C				
	Pleural Effusion		Toprol Xl Tablets	C		ORAL		
			Tegretol	C				
			Zantac	C				
			Valium	C				

			Zocor	C		

Date:11/15/01ISR Number: 3824508-2Report Type:Expedited (15-DaCompany Report #WAES 01116008
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 278 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Spironolactone And Althiazide	C		ORAL
			Propranolol	C		ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
			Hyaluronic Acid	C		
PARENTERAL						

Date:11/15/01ISR Number: 3824509-4Report Type:Expedited (15-DaCompany Report #WAES 01111217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 DAY	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Loss Of Consciousness					
	Tremor					

Date:11/15/01ISR Number: 3824510-0Report Type:Expedited (15-DaCompany Report #WAES 01111500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
	Rectal Haemorrhage		Vioxx	SS		ORAL
			Avalox	C		
			Rhinocort	C		
			Qvar	C		
			Combivent	C		
			Monopril	C		
			Toprol Xl Tablets	C		

				Depo-Medrol	C		
				Lomotil	C		
				Imodium	C		

Date:11/15/01ISR Number: 3824515-XReport Type:Expedited (15-DaCompany Report #WAES 01115068
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Other	Face Oedema Pharyngeal Oedema							

Date:11/15/01ISR Number: 3824519-7Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/01ISR Number: 3824944-4Report Type:Direct Company Report #
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx 25 Mg	PS			1 DAILY	
	Sudden Death							

Date:11/16/01ISR Number: 3824957-2Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
Other								

Date:11/16/01ISR Number: 3824964-XReport Type:Expedited (15-DaCompany Report #WAES 01105676
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Hydrochlorothiazide And Triamterene	C		ORAL		

Date:11/16/01ISR Number: 3824968-7Report Type:Expedited (15-DaCompany Report #WAES 01115558
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/01ISR Number: 3824970-5Report Type:Expedited (15-DaCompany Report #WAES 01118542
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/01ISR Number: 3825427-8Report Type:Direct Company Report #
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Oral Pain		Vioxx 50mg Merck-Medco	PS	Merck-Medco	ORAL	50MG QD ORAL	
			Viagra	C				
			Flomax	C				
			Tylenol #3	C				

Date:11/16/01ISR Number: 3825813-6Report Type:Expedited (15-DaCompany Report #WAES 01110508
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:11/16/01ISR Number: 3825814-8Report Type:Expedited (15-DaCompany Report #WAES 01100109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:11/16/01ISR Number: 3825816-1Report Type:Expedited (15-DaCompany Report #WAES 01110854
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:11/16/01ISR Number: 3825817-3Report Type:Expedited (15-DaCompany Report #WAES 01110855
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:11/16/01ISR Number: 3825915-4Report Type:Expedited (15-DaCompany Report #WAES 01110767
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Palpitations		Covera-Hs	C				
			Tenormin	C				

Date:11/16/01ISR Number: 3825916-6Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Coumadin	C				

Date:11/16/01ISR Number: 3825985-3Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx 25 Mg	PS		ORAL	PO QD	
	Duodenal Ulcer		Prednisone 50 Mg	SS			50 MG QD X 7	
	Haemorrhage						D	
	Shock		Cozaar	C				
	Syncope		Bumex	C				
			Lanoxin	C				
			Klor Con	C				

				Premarin	C		
				Lotensin	C		

Date:11/16/01ISR Number: 3826309-8Report Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aplasia Pure Red Cell Aplastic Anaemia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ PRN	
	Asthenia	Professional	Acetaminophen	C				
	Leukopenia		Amoxicillin	C				
	Pallor		Ibuprofen	C				

Date:11/16/01ISR Number: 3826373-6Report Type:Expedited (15-DaCompany Report #WAES 01116024
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Duodenitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY/PO; 25 MG/DAILY	5 DAY
	Necrosis							
	Oesophagitis							
	Vomiting		Amlodipine	C				
			Fosinopril Sodium	C				
			Molsidomine	C				
			Zolpidem Tartrate	C				

Date:11/16/01ISR Number: 3826919-8Report Type:Expedited (15-DaCompany Report #WAES 01115547
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Liposarcoma	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Renal Cyst	Professional						

Other

Date:11/16/01ISR Number: 3826922-8Report Type:Expedited (15-DaCompany Report #WAES 01115061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Embolism	Health						
	Haematoma	Professional						
	Haemorrhage	Other						

Date:11/16/01ISR Number: 3826926-5Report Type:Expedited (15-DaCompany Report #WAES 01115006
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5	
		Health						
		Professional	Acetaminophen	C			MG/DAILY, PO	2 DAY
		Other	Carbamazepine	C				
			Estradiol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/01ISR Number: 3826950-2Report Type:Expedited (15-DaCompany Report #WAES 01115035
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Tab Vioxx					
	Sudden Death	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Acetaminophen	C				
			Lactulose	C				
			Levothyroxine Na	C				
			Loperamide	C				
			Lorazepam	C				
			Prednisolone	C				

Date:11/16/01ISR Number: 3826952-6Report Type:Expedited (15-DaCompany Report #WAES 01119801
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Tab Vioxx					
Other	Hypertension	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	13 DAY
	Tachycardia	Professional						

Date:11/16/01ISR Number: 3826955-1Report Type:Expedited (15-DaCompany Report #WAES 01095601
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eczema	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	12.5 MG/BID	15 DAY
		Professional	Captopril	C				
			Cerivastatin Sodium	C				
			Furosemide	C				
			Insulin	C				
			Pentaerythritol Tetranitrate	C				

Date:11/16/01ISR Number: 3826973-3Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	1 WK
			Captopril	C				
			Dipyrone	C				

Date:11/16/01ISR Number: 3827363-XReport Type:Expedited (15-DaCompany Report #WAES 01111018
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:11/16/01ISR Number: 3827471-3Report Type:Expedited (15-DaCompany Report #WAES 01110878
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia	Consumer	Tab Vioxx	PS		ORAL	25 MG DAIL PO	
			Aciphex	C				
			Altace	C				

			Lipitor	C
			Neurontin	C
			Niaspan	C
			Zoloft	C

Date:11/16/01ISR Number: 3827472-5Report Type:Expedited (15-DaCompany Report #WAES 01101950
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Tenderness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Asthenia	Professional					PO	
	Cataract	Company	Atrovent	C				
	Dizziness	Representative	Centrum	C				
	Dyspnoea		Detrol La	C				
	Faecal Occult Blood		Excedrin					
	Positive		(Acetaminophen (+)					
	Gastrointestinal Ulcer		Caff	C				
	Haematemesis		Inderal	C				
	Haematocrit Decreased		Captopril	C				
	International Normalised		Vitamin E	C				
	Ratio Decreased							
	Pallor							
	Platelet Count Decreased							
	Respiratory Rate							
	Increased							
	Tachycardia							
	Upper Gastrointestinal							
	Haemorrhage							

Date:11/19/01ISR Number: 3825357-1Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Pancreatitis		Vioxx	SS		ORAL	1	WK
			Dipyrone	C				
			Captopril	C				

			Aceclofenac	C		

Date:11/19/01ISR Number: 3825365-0Report Type:Expedited (15-DaCompany Report #WAES 01115559
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 YR	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Sedation		Estrogens (Unspecified)	C		
	Transient Ischaemic Attack					
	Visual Disturbance					

Date:11/19/01ISR Number: 3825367-4Report Type:Expedited (15-DaCompany Report #WAES 01106060
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased
	Condition Aggravated
	Heart Rate Irregular

	Hypothyroidism						
	Oedema						
	Weight Increased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Acetaminophen	C		ORAL		
			Metformin	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:11/19/01ISR Number: 3825369-8Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:11/19/01ISR Number: 3825849-5Report Type:Expedited (15-DaCompany Report #WAES 01111442
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/01ISR Number: 3825872-0Report Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
	Chest Wall Pain		Hyzaar	C		ORAL		
	Duodenitis		Alprazolam	C		ORAL		
	Melaena		Amlodipine Besylate	C		ORAL		

Date:11/20/01ISR Number: 3826255-XReport Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11591633
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema		Lopril Tabs 25 Mg	PS	Apothecon	ORAL		
30 DAY								
Initial or Prolonged	Prurigo		Fucidine	SS				
	Pruritus		Vioxx	SS				
	Purpura		Cleridium	SS				
			Vancomycin	SS				

Date:11/20/01ISR Number: 3826442-0Report Type:Expedited (15-DaCompany Report #WAES 01119126
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Omeprazole	C		ORAL		
	Deep Vein Thrombosis		Deflazacort	C		ORAL		
			Calcifediol	C		ORAL		
			Cyproterone Acetate	C		ORAL		
			Triptorelin Acetate	C				
INTRAMUSCULAR								
			Calcium Carbonate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/01ISR Number: 3826443-2Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		136 DAY
Initial or Prolonged	Necrosis		Diacerein	C		ORAL		
	Necrotising Fasciitis		Isradipine	C		ORAL		
	Skin Lesion		Ibuprofen	C		ORAL		

Date:11/20/01ISR Number: 3826444-4Report Type:Expedited (15-DaCompany Report #WAES 01115113
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
			Metformin	C		ORAL		
			Gliclazide	C		ORAL		
			Atenolol	C		ORAL		
			Nifedipine	C		ORAL		

Date:11/20/01ISR Number: 3826446-8Report Type:Expedited (15-DaCompany Report #WAES 01111885
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Hepatic Encephalopathy							
	Renal Failure Acute							

Date:11/20/01ISR Number: 3826447-XReport Type:Expedited (15-DaCompany Report #WAES 01103082
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prothrombin Time Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Embolism		Premarin	C				
Initial or Prolonged			Levoxyl	C				

Date:11/20/01ISR Number: 3826448-1Report Type:Expedited (15-DaCompany Report #WAES 01100719
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	42 DAY	
Initial or Prolonged			Zocor	C				
Disability			Prevacid	C				
Other								

Date:11/20/01ISR Number: 3826449-3Report Type:Expedited (15-DaCompany Report #WAES 01112063
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Cardiac Failure
Initial or Prolonged	Congestive
	Cardiovascular Disorder
	Chronic Obstructive
	Airways Disease
	Exacerbated
	Condition Aggravated
	Erythema
	Hypertension

Oedema Peripheral

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	58	DAY
			Lotensin	C		ORAL		
			Combivent	C				
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				
			Lasix (Furosemide)	C				
			Aspirin	C		ORAL		
			Verapamil	C		ORAL		
			Lanoxin	C		ORAL		
			Potassium Chloride	C		ORAL		

Date:11/20/01ISR Number: 3826450-XReport Type:Expedited (15-DaCompany Report #WAES 01107819
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Condition Aggravated							

Date:11/20/01ISR Number: 3826451-1Report Type:Expedited (15-DaCompany Report #WAES 01115563
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Composition Unspecified]	C				

Date:11/20/01ISR Number: 3826452-3Report Type:Expedited (15-DaCompany Report #WAES 01111486
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS		ORAL

Date:11/20/01ISR Number: 3826454-7Report Type:Expedited (15-DaCompany Report #WAES 01112052
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/20/01ISR Number: 3826459-6Report Type:Expedited (15-DaCompany Report #WAES 01119005
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorectal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Diarrhoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/01ISR Number: 3826467-5Report Type:Expedited (15-DaCompany Report #WAES 01119138
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Enalapril Maleate	C		ORAL		
			Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Aspirin	C		ORAL		
			Calcium Carbonate And Calcium Glubionate	C		ORAL		
			Risedronate Sodium	C		ORAL		

Date:11/20/01ISR Number: 3826468-7Report Type:Expedited (15-DaCompany Report #WAES 01115114
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Other	Melaena		Proscar	C		ORAL		
			Allopurinol	C		ORAL		
			Doxazosin	C		ORAL		
			Acetaminophen	C		ORAL		

Date:11/20/01ISR Number: 3827405-1Report Type:Direct Company Report #
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking		Rofecoxib Tablets (Merck)	PS	Merck		12.5MG	QD
	Hyperhidrosis							
	Nausea		Fioricet	C				
			Aspirin	C				
			Diltiazem	C				

Date:11/20/01ISR Number: 3827465-8Report Type:Direct Company Report #
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx	PS		ORAL	25 MG PO	
Hospitalization -	Purulence							
DAILY							1	MON
Initial or Prolonged								

Date:11/20/01ISR Number: 3827923-6Report Type:Expedited (15-DaCompany Report #200120976EU
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Abnormal
	Aspartate
	Aminotransferase Abnormal
	Blood Alkaline
	Phosphatase Increased
	Blood Potassium Decreased
	Blood Potassium Increased
	Cardiac Failure
	Chest Pain
	Depressed Level Of

Dose	Duration		Consciousness Fluid Overload Hepatic Enzyme Increased Liver Function Test	Report Source	Product	Role	Manufacturer	Route
			Abnormal Localised Infection	Foreign Other	Leflunomide (Arava) Tablets	PS		ORAL
20 MG/DAY PO								
			Metabolic Disorder Pain Renal Failure Acute Weight Increased		Metronidazole (Flagyl)	SS		
					Metronidazole (Flagyl)	SS		ORAL
800 MG/DAY PO	15	DAY						
					Flucloxacillin Sodium (Heracillin)	SS		
					Flucloxacillin Sodium (Heracillin)	SS		
2.2. G/DAY	15	DAY						
					Rofecoxib (Vioxx)	SS		
25 MG/DAY								
					Enalapril Maleate (Renitec)	SS		ORAL
20 MG/DAY PO	1	WK						
					Spironolactone	SS		ORAL
50 MG/DAY PO								
					Furosemide (Furix)	SS		ORAL
40 MG/DAY PO	1	WK						
					Gabapentin (Neurontin)	SS		ORAL
QD PO								
					Folic Acid, Calcium Phosphate (Folacin)	C		
					Vitamin E	C		
					Morfin	C		
					Prednisolon	C		
					Cisapride (Prepulsid)	C		
					Cetirizine (Zyrlex)	C		
					Morphine Sulfate (Dolcontin)	C		
					Lansoprazole (Lanzo)	C		

Date:11/20/01ISR Number: 3828022-XReport Type:Expedited (15-DaCompany Report #01P-056-0112914-00
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bladder Disorder Oedema Peripheral Scrotal Oedema	Foreign Health Professional Other	Tranxene(Clorazepate Dipotassium) (Clorazepate Dipotassium)	PS		ORAL	75 MG, PER ORAL	
			Valpromide	SS		ORAL	3 UNIT, PER ORAL	
			Dosulepin	SS		ORAL	150 MG, PER ORAL	
			Rofecoxib	SS		ORAL	1 UNIT, PER ORAL	
			Panadeine Co	SS		ORAL	6 UNIT, PER ORAL	

Date:11/20/01ISR Number: 3828213-8Report Type:Expedited (15-DaCompany Report #WAES 01072716
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
			Amoxicillin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/01ISR Number: 3828214-XReport Type:Expedited (15-DaCompany Report #WAES 01072370
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Difficulty In Walking	Health Professional	Elavil	C				
	Loss Of Control Of Legs		Neurontin	C				
	Neuritis		Premarin	C				
	Oedema		Baclofen	C				
	Tendon Injury		Dicyclomine Hydrochloride	C				
	Weight Decreased		Methadone Hydrochloride	C				

Date:11/20/01ISR Number: 3828215-1Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other PO	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
	Hypoaesthesia							
	Oedema Peripheral							
	Pain							
	Peripheral Circulatory Failure							

Date:11/20/01ISR Number: 3828224-2Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other PO	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL		
	Embolism	Health Professional						
	Lethargy							

Date:11/20/01ISR Number: 3828225-4Report Type:Expedited (15-DaCompany Report #WAES 01103289
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
	Embolism	Professional Company Representative						
	Lethargy							

Date:11/20/01ISR Number: 3828226-6Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase Increased
Hospitalization - Initial or Prolonged	Cerebral Infarction
Disability	Depression
Other	Difficulty In Walking
	Dysphagia
	Embolic Stroke
	High Density Lipoprotein Decreased
	Hyperglycaemia
	Hyperlipidaemia
	Renal Impairment

	Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Atacand	C				
			Atacand Plus	C				
			Benadryl	C				
			Hydrodiuril	C				
			Lopid	C				
			Sudafed	C				
			Aspirin	C				
			Atenolol	C				
			Glucosamine	C				

Date:11/20/01ISR Number: 3828230-8Report Type:Expedited (15-DaCompany Report #WAES 01101944
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Diarrhoea	Health Professional	Ativan	C				
			Glucophage	C				
			Questran	C				
			Aspirin	C				

Date:11/20/01ISR Number: 3828231-XReport Type:Expedited (15-DaCompany Report #WAES 01072370
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Difficulty In Walking	Health Professional	Elavil	C				
	Oedema		Neurontin	C				
	Weight Decreased		Premarin	C				
			Baclofen	C				

				Dicyclomine Hydrochloride	C		
				Methadone Hydrochloride	C		

Date:11/20/01ISR Number: 3828232-1Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Cardio-Respiratory Arrest	Health					MG/DAILY/PO	
Initial or Prolonged	Headache	Professional	Claritin	C				
	Hypertension		Deltasone	C				
			K-Dur	C				
			Lasix	C				
			Plavix	C				
			Alprazolam	C				
			Atenolol	C				
			Captopril	C				
			Carbidopa (+) Levodopa	C				
			Clonazepam	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/01ISR Number: 3827631-1Report Type:Expedited (15-DaCompany Report #WAES 01115092
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Hydrocortisone	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		

Date:11/21/01ISR Number: 3827632-3Report Type:Expedited (15-DaCompany Report #WAES 01116057
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/01ISR Number: 3827634-7Report Type:Expedited (15-DaCompany Report #WAES 01119009
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
			Pepcid	C		ORAL		
			Oxazepam	C		ORAL		
			Piracetam	C		ORAL		
			Dipyrone	C		RECTAL		
			Hematoporphyrin	C		ORAL		

Date:11/21/01ISR Number: 3827638-4Report Type:Expedited (15-DaCompany Report #WAES 01111888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lortab	C				

Shock

Date:11/21/01ISR Number: 3827904-2Report Type:Direct Company Report #
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Decreased Activity		Docetaxel	PS		
INTRAVENOUS DOCETAXEL						
Initial or Prolonged	Muscular Weakness					
35MG/M2 IV						
Disability	Myalgia					
WEEKLY						
			Tiazac	C		
			Insulin	C		
			Compazine	C		
			Vioxx	I		
			Alegra	I		

Date:11/21/01ISR Number: 3828537-4Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Grand Mal Convulsion	Consumer	Tab Vioxx Unk	PS		ORAL
DAILY/PO						
			Sulfasalazine	C		

Date:11/21/01ISR Number: 3828538-6Report Type:Expedited (15-DaCompany Report #WAES 01111217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Loss Of Consciousness Tremor	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:11/21/01ISR Number: 3828644-6Report Type:Expedited (15-DaCompany Report #WAES 01111442
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:11/21/01ISR Number: 3828920-7Report Type:Expedited (15-DaCompany Report #WAES 01116510
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	Disability

Date:11/21/01ISR Number: 3828922-0Report Type:Expedited (15-DaCompany Report #WAES 01115052
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Essential Hypertension Fall Head Injury Hypotension Loss Of Consciousness Ventricular Hypertrophy	Other	(Rofecoxib)	PS		ORAL		
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:11/21/01ISR Number: 3828924-4Report Type:Expedited (15-DaCompany Report #WAES 01115015
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse	Foreign	Tab Vioxx					
	Dyspnoea	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	146 DAY
	Headache	Professional	Levothyroxine Na	C				
	Palpitations							
	Tremor							

Date:11/21/01ISR Number: 3828927-XReport Type:Expedited (15-DaCompany Report #WAES 01116008
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	278 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Althiazide/Spironolactone	C				
			Hyaluronic Acid	C				
			Propranolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/01ISR Number: 3828945-1Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Hypertension Pancreatitis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 WK
			Aceclofenac	C				
			Captopril	C				
			Dipyrone	C				

Date:11/21/01ISR Number: 3828946-3Report Type:Expedited (15-DaCompany Report #WAES 01106060
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Condition Aggravated Oedema Weight Increased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 5 DAY
			Acetaminophen	C				
			Levothyroxine Na	C				
			Metformin	C				

Date:11/21/01ISR Number: 3828947-5Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO

Date:11/21/01ISR Number: 3828948-7Report Type:Expedited (15-DaCompany Report #WAES 01105676
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	25 MG/BID PO	
Initial or Prolonged		Professional	Hctz/Triamterene	C				

Date:11/21/01ISR Number: 3828952-9Report Type:Expedited (15-DaCompany Report #WAES 01118119
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Foreign	Tab Vioxx					
	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema	Professional						
PO							9	DAY
	Renal Disorder		Timoptic	C				
			Aspirin	C				
			Clonidine Hcl	C				
			Hydroxychloroquine So4	C				
			Rabeprazole Sodium	C				
			Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/01ISR Number: 3828956-6Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
Hospitalization -	Congestive	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Myocardial Infarction	Health						
PO							297	DAY
Disability		Professional	Tab Placebo					
			(Unspecified)	SS		ORAL	PO	297 DAY
			Insulin	C				

Date:11/21/01ISR Number: 3828957-8Report Type:Expedited (15-DaCompany Report #WAES 01106030
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
PO							3	DAY
			Proscar	C				

Date:11/21/01ISR Number: 3828958-XReport Type:Expedited (15-DaCompany Report #WAES 01108158
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Urticaria	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/PRN PO	
		Professional	Crum Piroxicam	SS				
TOPICAL							TOP	

Date:11/21/01ISR Number: 3829135-9Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly		Vioxx (Dose Unknown)	PS				
	Chest X-Ray Abnormal		Actos	C				
	Diaphragmatic Disorder		Coumadin	C				
	Dyspnoea		Zocor	C				
	Oedema Peripheral		Insulin	C				
	Oxygen Saturation Decreased		Wellbutrin	C				

Date:11/21/01ISR Number: 3829309-7Report Type:Expedited (15-DaCompany Report #WAES 01110863
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Celexa	C				
			Keppra	C				
			Lamictal	C				

Date:11/21/01ISR Number: 3829310-3Report Type:Expedited (15-DaCompany Report #WAES 01111179
Age:61 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Atrial Fibrillation	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	
Cardiac Failure	Professional	Depakote	C				
Congestive		Tegretol	C				
Confusional State		Toprol Xl Tablets	C				
Heart Rate Increased		Valium	C				
Hyponatraemia		Zantac	C				
Pleural Effusion		Zocor	C				
		Zoloft	C				
		Baclofen	C				

Date:11/21/01ISR Number: 3829324-3Report Type:Expedited (15-DaCompany Report #WAES 01111500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
	Rectal Haemorrhage	Professional					DAILY/PO	
		Company Representative	Avalox	C				
			Combivent	C				
			Depo-Medrol	C				
			Imodium	C				
			Lomotil	C				
			Monopril	C				
			Qvar	C				
			Rhinocort	C				
			Toprol Xl	C				

Date:11/21/01ISR Number: 3829465-0Report Type:Expedited (15-DaCompany Report #WAES 01082423
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	1) PO; 2) 25	
Initial or Prolonged	Atrial Fibrillation	Health					MG/DAILY/PO;	

	Blood Pressure Increased	Professional			
3) PO					
	Condition Aggravated		Cardizem	C	
	Heart Rate Increased		Claritin	C	
	Heart Rate Irregular		Lasix (Furosemide)	C	
	Palpitations		Prilosec	C	
			Toprol Xl Tablets	C	
			Estradiol	C	

Date:11/21/01ISR Number: 3829466-2Report Type:Expedited (15-DaCompany Report #WAES 01082557
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Ulcer Haemorrhage	Company	Axid	C				
Other		Representative						

Date:11/21/01ISR Number: 3829467-4Report Type:Expedited (15-DaCompany Report #WAES 00060809
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Chills	Health	Calcium	C				
	Circulatory Collapse	Professional	Garlic Extract	C				
	Drug Withdrawal Syndrome	Other	Herbs	C				
	Dyspepsia		Minerals	C				
	Ecchymosis		Vitamin B	C				
	Fall		Vitamin E	C				
	Feeling Abnormal		Vitamins	C				
	Feeling Hot And Cold							
	Head Injury							
	Headache							
	Hyperhidrosis							
	Medication Error							
	Nausea							
	Nocturia							
	Syncope							
	Tremor							

Date:11/21/01ISR Number: 3829469-8Report Type:Expedited (15-DaCompany Report #WAES 01102891
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Professional					MG/DAILY/PO	
	Pain In Extremity	Company Representative						

Date:11/21/01ISR Number: 3829548-5Report Type:Direct Company Report #
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS				
			Skelexan	C				

Date:11/21/01ISR Number: 3829594-1Report Type:Expedited (15-DaCompany Report #WAES 01102728
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolic Stroke	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Hydrodiuril	C				
			Prinivil	C				
			Xalatan	C				
			Zocor	C				
			Atenolol	C				
			Verapamil	C				

Date:11/21/01ISR Number: 3829595-3Report Type:Expedited (15-DaCompany Report #WAES 01106292
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Cardiac Failure
Other	Congestive

		Cardiomegaly					
		Cough					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inappropriate	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Antidiuretic Hormone	Professional				
MG/DAILY/PO							
		Secretion	Company	Celebrex	C		
		Lobar Pneumonia	Representative	Flexeril	C		
		Lung Adenocarcinoma		Nonsteroidal			
		Oedema Peripheral		Anti-Inflammatory	C		
		Pulmonary Oedema					
		Tachycardia					

Date:11/21/01ISR Number: 3829596-5Report Type:Expedited (15-DaCompany Report #WAES 01050629
Age:41 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Paraesthesia	Professional				
MG/DAILY/PO							
		Pruritus	Company				
		Rash Erythematous	Representative				

Date:11/21/01ISR Number: 3829597-7Report Type:Expedited (15-DaCompany Report #WAES 01104756
Age:74 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Brain Neoplasm	Health	Tab Vioxx	PS		ORAL
PO/18 DAY							
Initial or Prolonged		Haemorrhage Intracranial	Professional				
		Metastasis					
		Oedema Peripheral					

Date:11/21/01ISR Number: 3829599-0Report Type:Expedited (15-DaCompany Report #WAES 01104872
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Asthenia		Celebrex	C				
	Bundle Branch Block Left		Celexa	C				
	Cardiac Failure		Inderal	C				
	Congestive		Isordil	C				
	Chest Pain		Plendil	C				
	Coma		Zocor	C				
	Confusional State		Aspirin	C				
	Duodenal Ulcer							
	Haemorrhage							
	Ejection Fraction							
	Abnormal							
	Gastroenteritis							
	Helicobacter							
	Myocardial Infarction							
	Renal Failure							

Date:11/21/01ISR Number: 3829609-0Report Type:Expedited (15-DaCompany Report #WAES 01061779
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bradycardia
	Chest Pain

Dizziness
Dyspnoea
Fatigue | Report Source | Product | Role | Manufacturer | Route | Dose | Duration
Sinus Arrest | Consumer | Tab Vioxx | PS | | ORAL | DAILY, PO
Syncope

Date:11/21/01ISR Number: 3829611-9Report Type:Expedited (15-DaCompany Report #WAES 01050629
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Rash Pruritic	Professional Company Representative						

Date:11/21/01ISR Number: 3829778-2Report Type:Expedited (15-DaCompany Report #WAES 01092426
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:11/21/01ISR Number: 3830170-5Report Type:Expedited (15-DaCompany Report #WAES 01099147
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral	Foreign	Tab Vioxx					
	Eye Disorder	Other	(Rofecoxib)	PS		ORAL	50 MG/DAILY, PO	1 DAY
	Hypotension							

	Intraocular Pressure Increased		Carteolol Hc1	C			
	Vascular Anomaly						
	Visual Disturbance						

Date:11/21/01ISR Number: 3830177-8Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
Hospitalization -	Congestive	Study	(Rofecoxib)	PS		ORAL	PO	297 DAY
Initial or Prolonged Disability	Myocardial Infarction	Other	Insulin	C				

Date:11/21/01ISR Number: 3830220-6Report Type:Expedited (15-DaCompany Report #WAES 01115558
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:11/21/01ISR Number: 3830222-XReport Type:Expedited (15-DaCompany Report #WAES 01115559
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 YR
			Estrogens (Unspecified)	C				

Date:11/21/01ISR Number: 3830226-7Report Type:Expedited (15-DaCompany Report #WAES 01118542
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged		Health Professional	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO

Date:11/21/01ISR Number: 3830239-5Report Type:Expedited (15-DaCompany Report #WAES 01115068
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Foreign	Tab Vioxx					
Other	Face Oedema	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Pharyngeal Oedema							
PO	14 DAY							

Date:11/21/01ISR Number: 3830242-5Report Type:Expedited (15-DaCompany Report #WAES 01115070
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Tab Vioxx					

	Faeces Pale	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
	Headache					
PO 15 DAY						
	Vomiting		Acetaminophen (+) Dihydrocodeine Bitartr	C		
			Estradiol / Norethindrone Acetate	C		
			Gold Sodium Thiomalate	C		
			Ranitidine	C		

Date:11/21/01ISR Number: 3830395-9Report Type:Expedited (15-DaCompany Report #WAES 01115569
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hepatitis Cholestatic	Foreign	Tab Vioxx			
Hospitalization -		Other	(Rofecoxib)	PS		ORAL
PO						
Initial or Prolonged						

Date:11/21/01ISR Number: 3830397-2Report Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Bipolar Disorder
Initial or Prolonged	Condition Aggravated

		Drug Interaction Drug Level Below Therapeutic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY							
PO	30 DAY						
				Cap Sr Carbamazepine	SS		ORAL
200 MG/DAILY							
PO							
				Elavil	C		
				Alprazolam	C		

Date:11/21/01ISR Number: 3830400-XReport Type:Expedited (15-DaCompany Report #WAES01116509
Age:64 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Palpitations	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY							
PO							
				Amlodipin Besylate	C		
				Aspirin	C		
				Furosemide	C		
				Gemfibrozil	C		
				Glimepiride	C		
				Metoprolol Tartrate	C		
				Potassium Chloride	C		
				Ramipril	C		

Date:11/21/01ISR Number: 3830474-6Report Type:Expedited (15-DaCompany Report #WAES 01111153
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Brain Damage	Consumer	Tab Vioxx Unk	PS		ORAL
PO							
Hospitalization -		Cerebrovascular Accident					

Initial or Prolonged Gastric Haemorrhage

Date:11/21/01ISR Number: 3830495-3Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-25	
Initial or Prolonged	Thromboplastin Time	Professional					MG/DAILY/PO	
Disability	Prolonged	Other						
Other	Antinuclear Antibody Positive							
	Cardiolipin Antibody Positive							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Coordination Abnormal							
	Extensor Plantar Response							
	Hemiparesis							
	Hyperreflexia							
	International Normalised Ratio Decreased							
	Laboratory Test Abnormal							
	Movement Disorder							
	Sensation Of Heaviness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828691-4Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	144 DAY	
Hospitalization -	Increased		Atacand	C				
Initial or Prolonged	Aspiration		Lopid	C				
Disability	Blood Cholesterol		Aspirin	C				
Other	Increased		Osteo-Bi-Flex	C				
	Brain Neoplasm		Sudafed	C				
	Cardiac Murmur		Benadryl	C				
	Cardiomegaly		Atenolol	C				
	Cerebral Infarction		Atenolol	C				
	Cerebral Ischaemia		Hydrodiuril	C				
	Coordination Abnormal		Atacand Plus	C				
	Dizziness		Gastrointestinal					
	Dysarthria		Preparations					
	Dysphagia		(Unspecified)	C				
	Embolic Stroke							
	Facial Palsy							
	Hemiparesis							
	Hyperglycaemia							
	Hyperlipidaemia							
	Mood Swings							
	Oedema Peripheral							
	Pain In Extremity							
	Renal Impairment							
	Sensory Disturbance							

Date:11/26/01ISR Number: 3828694-XReport Type:Expedited (15-DaCompany Report #WAES 01110175
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Adderall Tablets	C				
Other								

Date:11/26/01ISR Number: 3828695-1Report Type:Expedited (15-DaCompany Report #WAES 01106309
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828708-7Report Type:Expedited (15-DaCompany Report #WAES 01112418
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828710-5Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828714-2Report Type:Expedited (15-DaCompany Report #WAES 01117510
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		DAY
Initial or Prolonged	Perforation		Vioxx	SS		ORAL	2	DAY
	Peritonitis		Citalopram Hydrobromide	C		ORAL		
			Fosamax	C		ORAL		
			Carvedilol	C		ORAL		
			Althiazide And Spironolactone	C		ORAL		
			Haloperidol	C		ORAL		
			Ranitidine	C		ORAL		

Date:11/26/01ISR Number: 3828715-4Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Diarrhoea		Irbesartan	C				
Initial or Prolonged	Dyspnoea		Lipitor	C				
	Erythema		Xanax	C				
	Face Oedema		Paxil	C				
	Hypersensitivity							
	Pneumonia							
	Pulmonary Oedema							
	Pyrexia							
	Rales							
	Rash Generalised							
	Tachycardia							
	Tachypnoea							
	Vomiting							
	White Blood Cell Count Increased							

Date:11/26/01ISR Number: 3828717-8Report Type:Expedited (15-DaCompany Report #WAES 01101985
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dermatitis Exfoliative		Vioxx	PS	Merck & Co., Inc	ORAL
			Bactrim	C		
			Lactulose	C		
			Colace	C		
			Folic Acid	C		
			Thiamine	C		
			Vitamins (Unspecified)	C		

Date:11/26/01ISR Number: 3828718-XReport Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 236 DAY	Gastric Mucosal Lesion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Haemorrhage		Aspirin	C		
	Syncope		Paxil	C		
			Disopyramide	C		
			Levothyroxine Sodium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828719-1Report Type:Expedited (15-DaCompany Report #WAES 01112803
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
			Prevacid	C				

Date:11/26/01ISR Number: 3828722-1Report Type:Expedited (15-DaCompany Report #WAES 01112372
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828723-3Report Type:Expedited (15-DaCompany Report #WAES 01112151
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Artery Embolism		[Therapy Unspecified]	C				
			Coumadin	C				

Date:11/26/01ISR Number: 3828724-5Report Type:Expedited (15-DaCompany Report #WAES 01113442
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc			

Date:11/26/01ISR Number: 3828726-9Report Type:Expedited (15-DaCompany Report #WAES 01113464
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc			22 DAY
Initial or Prolonged	Gastritis		Acetaminophen And Codeine Phosphate	C		ORAL		
	Gastrointestinal Haemorrhage		Celecoxib	C		ORAL		
	Varices Oesophageal							

Date:11/26/01ISR Number: 3828728-2Report Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C				

Date:11/26/01ISR Number: 3828729-4Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Erythema
Initial or Prolonged	Pruritus
	Purpura

Skin Reaction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Captopril	SS		ORAL	30	DAY
	Fusidate Sodium	SS		ORAL	40	DAY
	Dipyridamole	SS		ORAL	38	DAY
	Vancomycin	SS				
INTRAVENOUS					40	DAY

Date:11/26/01ISR Number: 3828730-0Report Type:Expedited (15-DaCompany Report #WAES 01113463
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ramipril	C				
			Lansoprazole	C				
			Atorvastatin Calcium	C				
			Acetaminophen And Codeine Phosphate	C				
			Metformin Hydrochloride	C		ORAL		

Date:11/26/01ISR Number: 3828731-2Report Type:Expedited (15-DaCompany Report #WAES 01112455
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Photopsia		Vioxx	SS		ORAL	3	WK
	Vitreous Detachment		Pravachol	C				
			Premarin	C				
			Provera	C				
			Calcium (Unspecified) And Vitamin D					

			(Unspecified)	C		
			Vitamins			
			(Unspecified)	C		
			Synthroid	C		
			Flexeril	C		
			Diazepam	C		

Date:11/26/01ISR Number: 3828738-5Report Type:Expedited (15-DaCompany Report #WAES 01100373
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Faeces		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Vasotec	C				
	Congestive		Lanoxin	C				
	Coordination Abnormal		Ranitidine	C				
	Frequent Bowel Movements		Aspirin	C				
	Haematochezia		Ferrous Sulfate	C				
	Haemorrhage		Detrol	C				
	Haemorrhoids		Docusate Sodium	C				
	Pain In Extremity							
	Sepsis							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828739-7Report Type:Expedited (15-DaCompany Report #WAES 01119144
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Artery Thrombosis Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc			

Date:11/26/01ISR Number: 3828744-0Report Type:Expedited (15-DaCompany Report #WAES 01113481
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Faeces Discoloured Haematemesis		Ramipril	C				
			Hydrochlorothiazide And Triamterene	C				
			Furosemide Sodium	C				

Date:11/26/01ISR Number: 3828745-2Report Type:Expedited (15-DaCompany Report #WAES 01112545
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Blood Pressure Increased Decreased Activity Eyelid Ptosis Lethargy Middle Insomnia Pain In Extremity Thermal Burn Weight Increased		Ibuprofen	C				

Date:11/26/01ISR Number: 3828746-4Report Type:Expedited (15-DaCompany Report #WAES 01110972
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Initial or Prolonged	Blood Pressure Increased		Naprosyn	C				
	Cerebrovascular Accident		Neurontin	C				
	Haematocrit Decreased		Lortab	C				
	Haematuria		Chondroitin And Glucosamine	C				
	Haemoglobin Decreased		Paxil	C				
	Hemiparesis		Naprosyn	C				
	Hyperreflexia							
	Hypertonia							
	Oedema							

Date:11/26/01ISR Number: 3828750-6Report Type:Expedited (15-DaCompany Report #WAES 01112521
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Vioxx	SS		ORAL		
Initial or Prolonged	Pulmonary Embolism		Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828752-XReport Type:Expedited (15-DaCompany Report #WAES 01112431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828753-1Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828754-3Report Type:Expedited (15-DaCompany Report #WAES 01112451
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Valve Disease Bundle Branch Block Right Hypertension Mitral Valve Disease Myocardial Infarction Precerebral Artery Occlusion Pulmonary Embolism Sudden Death		Vioxx Dynacirc Xanax Buspar	PS C C C	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828758-0Report Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx Lipitor [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL		

Date:11/26/01ISR Number: 3828759-2Report Type:Expedited (15-DaCompany Report #WAES 01113472
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc			39 DAY
Initial or Prolonged			Aspirin Calcium	SS				

Date:11/26/01ISR Number: 3828760-9Report Type:Expedited (15-DaCompany Report #WAES 01113465
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Colchicine	C				
			Acetaminophen	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3828763-4Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
Initial or Prolonged	Pancreatitis		Vioxx	SS		ORAL		1 WK
			Dipyrone	C				
			Captopril	C				
			Aceclofenac	C				

Date:11/26/01ISR Number: 3828764-6Report Type:Expedited (15-DaCompany Report #WAES 01113482
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Ranitidine Hydrochloride	C		ORAL		
			Prazosin Hydrochloride	C		ORAL		

Date:11/26/01ISR Number: 3829253-5Report Type:Direct Company Report #
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised		Vioxx 25mg	PS		ORAL	25MG PO QD	
	Ratio Increased		Warfarin	C				

Date:11/26/01ISR Number: 3829671-5Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Consumer	Tab Vioxx 285 Mg	PS		ORAL	25 MG/BID/PO	

Initial or Prolonged	Burning Sensation	Health	Tab Vioxx 25 Mg	SS	ORAL
25 MG/PRN/PO					
	Chondropathy	Professional			
; 25					
	Compression Fracture				
MG/PRN/PO ;					
	Condition Aggravated				
PO					
	Difficulty In Walking		Darvocet-N	SS	
	Fluid Retention		Klonopin	SS	
	Headache		Relafen	SS	
	Hypotonia		Naprosyn	SS	
	Neuropathy Peripheral				
	Pain				
	Rhabdomyolysis				
	Weight Decreased				

Date:11/26/01ISR Number: 3829675-2Report Type:Expedited (15-DaCompany Report #2001USA01458
Age:54 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Chronic Obstructive
	Pulmonary Disease
	Decreased Appetite
	Dehydration
	Depression
	Dermatitis
	Diarrhoea
	Ejection Fraction

		Abnormal Eosinophil Count Increased					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension	Study	Plavix	PS		ORAL
75 MG QD PO							
		Lethargy		Vioxx	SS		
50 MG DAILY							
		Metabolic Acidosis		Coumadin	C		
		Myalgia		Flovent	C		
		Myocardial Infarction		Prednisone	C		
		Oedema Peripheral		Lanoxin	C		
		Oral Intake Reduced		Synthroid	C		
		Pain In Extremity					
		Petechiae					
		Pyrexia					
		Renal Failure Acute					
		Sepsis					
		Systemic Lupus Erythematosus					
		Vasculitis					

Date:11/26/01ISR Number: 3830026-8Report Type:Expedited (15-DaCompany Report #WAES 01111172
Age:54 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Distension	Study	Tab Vasotec 20 Mg	PS		ORAL
20							
Initial or Prolonged		Pain	Health				
MG/DAILY/PO							
		Pyelonephritis	Professional	Tab Pravachol 20 Mg	SS		
20 MG/DAILY							
		Rhabdomyolysis		Tab Vioxx	SS		ORAL
25							
MG/DAILY/PO							
				Lopid	SS		
600 MG/BID							
				Aleve	C		
				Avandia	C		
				Celexa	C		
				Elavil	C		
				Glucophage	C		
				Glynase Prestab			

				Tablets	C		
				Levaquin	C		
				Stadol	C		
				Aspirin	C		

Date:11/26/01ISR Number: 3830033-5Report Type:Expedited (15-DaCompany Report #WAES 01103082
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prothrombin Time Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Pulmonary Embolism	Professional					MG/DAILY/PO	
Initial or Prolonged			Levoxyl	C				
			Premarin	C				

Date:11/26/01ISR Number: 3830041-4Report Type:Expedited (15-DaCompany Report #WAES 01092842
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Consumer	Tab Vioxx 12.5-25 Mg	PS		ORAL	12.5-25	
Other	Bone Marrow Depression	Health					MG/DAILY/PO	
	Myelodysplastic Syndrome	Professional	Dyazide	C				
			Flexeril	C				
			Fosamax	C				

		Synthroid	C
		Ultram	C
		Potassium (Unspecified)	C
		Spironolactone	C

Date:11/26/01ISR Number: 3830044-XReport Type:Expedited (15-DaCompany Report #WAES 01111885
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	5 DAY
	Hepatic Encephalopathy							
	Renal Failure Acute	Company Representative						

Date:11/26/01ISR Number: 3830064-5Report Type:Expedited (15-DaCompany Report #WAES 01091032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive							

Date:11/26/01ISR Number: 3830243-7Report Type:Expedited (15-DaCompany Report #PHRM2001FR02516
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression	Foreign Health Professional Other	Tegretol Lp (Carbamazepine) Extended Release, Tablet	PS		ORAL	200 MG/DAY, ORAL	
	Drug Interaction							
	Drug Level Below Therapeutic							
			Vioxx (Rofecoxib)	SS		ORAL	25 MG/DAY,	

ORAL

			Laroxyl (Amtriptyline Hydrochloride)	C		
			Xanax (Alprazolam) Tablet	C		

Date:11/26/01ISR Number: 3830249-8Report Type:Expedited (15-DaCompany Report #WAES 01099742
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Compression Fracture	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Fall	Health						
PO								44 DAY
	Spinal Fracture	Professional						
		Other						

Date:11/26/01ISR Number: 3830258-9Report Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	21 DAY
	Chest Pain	Health	Hyzaar	C				
	Duodenitis	Professional	Alprazolam	C				
	Melaena	Other	Amlodipine Besylate	C				

Date:11/26/01ISR Number: 3830259-0Report Type:Expedited (15-DaCompany Report #WAES 01115113
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus	Foreign	Tab Vioxx					
	Inadequate Control	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional					PO	
		Other	Atenolol	C				
			Gliclazide	C				
			Metformin	C				
			Nifedipine	C				

Date:11/26/01ISR Number: 3830260-7Report Type:Expedited (15-DaCompany Report #WAES 01119126
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Thrombosis	Health					PO	
	Deep Vein Thrombosis	Professional	Calcifediol	C				
	Transient Ischaemic	Other	Calcium Carbonate	C				
	Attack		Cyproterone Acetate	C				
			Deflazacort	C				
			Omeprazole	C				
			Triptorelin Acetate	C				

Date:11/26/01ISR Number: 3830273-5Report Type:Expedited (15-DaCompany Report #WAES 01100719
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
Disability			Prevacid	C				
Other			Zocor	C				

Date:11/26/01ISR Number: 3830292-9Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Laceration Necrotising Fasciitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	136 DAY
			Diacerein	C				
			Ibuprofen	C				
			Isradipine	C				

Date:11/26/01ISR Number: 3830354-6Report Type:Expedited (15-DaCompany Report #WAES 01107819
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Weight Increased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	4	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/01ISR Number: 3830358-3Report Type:Expedited (15-DaCompany Report #WAES 01091032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Congestive							

Date:11/26/01ISR Number: 3830376-5Report Type:Expedited (15-DaCompany Report #PHRM2001FR02528
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erysipelas	Foreign	Icaz Lp(Isradipine)					
	Laceration	Health	Slow Release					
	Necrotising Fasciitis	Professional	Capsules	PS		ORAL	ORAL	
		Other	Art 50(Diacerein)	SS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	ORAL	
			Advil	C				

Date:11/27/01ISR Number: 3829709-5Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Prednisone	C			6	DAY
	Haemorrhage		Cozaar	C				
	Hypotension		Bumex	C				
	Syncope		Lanoxin	C				
			Klor-Con	C				
			Premarin	C				
			Lotensin	C				

Date:11/27/01ISR Number: 3829710-1Report Type:Expedited (15-DaCompany Report #WAES 01115115
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Vasotec	C		ORAL		

Date:11/27/01ISR Number: 3829711-3Report Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Initial or Prolonged	Rash Pustular		Hydroxyurea	SS		ORAL	24	DAY
			Dipyrone	C		ORAL	29	DAY
			Mercaptopurine	C		ORAL	3	YR
			Omeprazole	C		ORAL	1138	DAY

Date:11/27/01ISR Number: 3829715-0Report Type:Expedited (15-DaCompany Report #WAES 01111158
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angiopathy
Initial or Prolonged	Arteriosclerosis
Other	Balance Disorder
	Cerebral Infarction
	Cerebral Ischaemia

	Cerebrovascular Accident						
	Headache						
	Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nuclear Magnetic		Vioxx	PS	Merck & Co., Inc	ORAL	512 DAY
	Resonance Imaging		Flonase	C			RESPIRATORY
	Abnormal						(INHALATION)
	Sinus Bradycardia						
	Transient Ischaemic						
	Attack						
	Vertigo						

Date:11/27/01ISR Number: 3829721-6Report Type:Expedited (15-DaCompany Report #WAES 01119147
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY
Initial or Prolonged	Increased		Aceclofenac	SS		ORAL	
	Aspartate		Diclofenac Sodium	SS		ORAL	
	Aminotransferase		Atenolol	C		ORAL	
	Increased		Aspirin	C		ORAL	
	Drug Interaction		Digoxin	C		ORAL	
	Renal Impairment						
	Right Ventricular Failure						

Date:11/27/01ISR Number: 3829724-1Report Type:Expedited (15-DaCompany Report #WAES 01106107
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY
Hospitalization -	Perforation		Acetaminophen	C		ORAL	
Initial or Prolonged	Peritonitis		Diacerein	C		ORAL	
			Meloxicam	C		ORAL	
			Omeprazole Sodium	C		ORAL	

Date:11/27/01ISR Number: 3829728-9Report Type:Expedited (15-DaCompany Report #WAES 01112803
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
			Prevacid	C				

Date:11/27/01ISR Number: 3829729-0Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Initial or Prolonged	Purpura		Captopril	SS		ORAL	30	DAY
	Skin Reaction		Fusidate Sodium	SS		ORAL	40	DAY
			Dipyridamole	SS		ORAL	38	DAY
			Vancomycin	SS		INTRAVENOUS	40	DAY

Date:11/27/01ISR Number: 3829730-7Report Type:Expedited (15-DaCompany Report #WAES 01115610
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
	Oedema Peripheral							

Date:11/27/01ISR Number: 3829731-9Report Type:Expedited (15-DaCompany Report #WAES 01113498
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema		Vioxx	PS	Merck & Co., Inc			

Date:11/27/01ISR Number: 3829733-2Report Type:Expedited (15-DaCompany Report #WAES 01119307
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Disability								

Date:11/27/01ISR Number: 3829734-4Report Type:Expedited (15-DaCompany Report #WAES 01115558
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Captopril	C		ORAL		
			Furosemide	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		
			Phenprocoumon	C		ORAL		
			Glyburide	C		ORAL	2	MON
			Rosiglitazone					

			Maleate	C	ORAL

Date:11/27/01ISR Number: 3830445-XReport Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention		Vioxx	PS		
	Weight Increased		Insulin	C		
			Latanoprost	C		
			Warfarin	C		
			Atorvastatin	C		
			Ntg	C		
			Kcl	C		
			Lisinopril	C		
			Atenolol	C		
			Digoxin	C		
			Gabapentin	C		
			Felodipine	C		
			Ferrous Sulfate	C		
			Alprazolam	C		
			Rabeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/01ISR Number: 3830475-8Report Type:Expedited (15-DaCompany Report #WAES 01111486
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:11/27/01ISR Number: 3830477-1Report Type:Expedited (15-DaCompany Report #WAES 01111888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Loss Of Consciousness							
	Shock		Lortab	C				

Date:11/27/01ISR Number: 3830522-3Report Type:Expedited (15-DaCompany Report #WAES 01112052
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:11/27/01ISR Number: 3830753-2Report Type:Expedited (15-DaCompany Report #2001-07-0249
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue Retinal Haemorrhage	Consumer	Nasonex (Mometasone Furoate) Nasal Suspension	PS		NASAL	50 MCG QD NASAL SPRAY	
			Vioxx (Rofecoxib)					

			Tablets	SS		ORAL
25 MG QD ORAL						
			Vitamin Formulation	C		
			Ogen	C		
			Levothyroxine	C		
			Nasonex (Mometasone Furoate)	C		

Date:11/27/01ISR Number: 3831044-6Report Type:Direct Company Report #
Age:78 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Culture Positive		Potassium Sulfate	PS			10MEG QD	
	Culture Urine Positive		Rofecoxib-Vioxx	SS			25MG BID	
	Escherichia Infection							
	Fall							
	Haemodialysis							
	Hyperkalaemia							
	Intervertebral Disc Disorder							
	Mental Impairment							
	Renal Failure Acute							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/27/01ISR Number: 3831074-4Report Type:Expedited (15-DaCompany Report #WAES 01112063
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25	Bronchospasm	Health	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged MG/DAILY/PO	Cardiac Failure	Professional				
	Congestive		Combivent	C		
	Chronic Obstructive		Lanoxin	C		
	Pulmonary Disease		Lasix (Furosemide)	C		
	Condition Aggravated		Lotensin	C		
	Dyspnoea		Aspirin	C		
	Erythema		Calcium			
	Hypertension		(Unspecified) (+)			
	Hypertensive Heart		(Vitami	C		
	Disease		Potassium Chloride	C		
	Oedema Peripheral		Verapamil	C		
	Tachycardia					
	Tachypnoea					

Date:11/27/01ISR Number: 3831151-8Report Type:Expedited (15-DaCompany Report #WAES 01116057
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx			
Initial or Prolonged	Congestive	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY,						
PO						

Date:11/27/01ISR Number: 3831152-XReport Type:Expedited (15-DaCompany Report #WAES 01115092
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Upper Gastrointestinal	Foreign	Tab Vioxx			
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
PO 13 DAY						
Initial or Prolonged			Calcium Carbonate			
			(+) Cholecalciferon	C		

			Hydrocortisone	C		
			Levothyroxine Na	C		

Date:11/27/01ISR Number: 3831189-0Report Type:Expedited (15-DaCompany Report #WAES 01119009
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY 20 DAY						
			Pepcid	C		
			Dipyrone	C		
			Hematoporphyrin	C		
			Oxazepam	C		
			Piracetam	C		

Date:11/27/01ISR Number: 3831541-3Report Type:Expedited (15-DaCompany Report #WAES 01119138
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Myocardial Infarction	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
		Professional				
PO						
		Other	Tab Vioxx			

(Rofecoxib) SS ORAL
25 MG/DAILY

PO

Risedronate Sodium C
Spironolactone C
Aspirin C
Calcium Carbonate +
Calcium Lactobionate C
Enalapril Maleate C
Furosemide C

Date:11/27/01ISR Number: 3831542-5Report Type:Expedited (15-DaCompany Report #WAES 01119005
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorectal Disorder	Foreign	Tab Vioxx					
	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	1 DAY

Date:11/27/01ISR Number: 3831556-5Report Type:Expedited (15-DaCompany Report #WAES 01115114
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
Other	Melaena		(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
							PO	14 DAY

Proscar C
Acetaminophen C
Allopurinol C
Doxazosin C

Date:11/28/01ISR Number: 3830663-0Report Type:Expedited (15-DaCompany Report #WAES 01115619
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Tachyarrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY

Date:11/28/01ISR Number: 3830667-8Report Type:Expedited (15-DaCompany Report #WAES 01118587
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depression Drug Toxicity Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/28/01ISR Number: 3830670-8Report Type:Expedited (15-DaCompany Report #WAES 01115033
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3830672-1Report Type:Expedited (15-DaCompany Report #WAES 01100560
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Echocardiogram Abnormal Electrocardiogram St Segment Depression Hepatic Steatosis Hyperhidrosis Mitral Valve Disease Pulmonary Valve Incompetence Sinus Tachycardia Supraventricular Tachycardia Vasodilatation Ventricular Hypertrophy		Vioxx Diocyclin	PS C	Merck & Co., Inc	ORAL		

Date:11/28/01ISR Number: 3830674-5Report Type:Expedited (15-DaCompany Report #WAES 01113476
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc			
			Quinapril Hydrochloride	C				
			Metformin Hydrochloride	C				
			Gliclazide	C				
			Hydrodiuril	C				
			Aspirin	C				
			Estradiol	C				
TOPICAL								
			Fluticasone Propionate	C				
			Latanoprost	C				
OPHTHALMIC								
			Latanoprost	C				
OPHTHALMIC								

Date:11/28/01ISR Number: 3830677-0Report Type:Expedited (15-DaCompany Report #WAES 01113172
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
786 DAY						
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C		
	Myocardial Infarction		Kaon	C		
	Upper Gastrointestinal Haemorrhage		Norvasc	C		
			Isorbid	C		
			Bumex	C		
			Synthroid	C		
			Paxil	C		
			Elavil	C		
			Lamisil	C		
			Darvocet-N	C		
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/28/01ISR Number: 3830679-4Report Type:Expedited (15-DaCompany Report #WAES 01113456
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Haematemesis		Aspirin	SS		ORAL		
	Melaena							

Date:11/28/01ISR Number: 3830681-2Report Type:Expedited (15-DaCompany Report #WAES 01113294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral							

Date:11/28/01ISR Number: 3830682-4Report Type:Expedited (15-DaCompany Report #WAES 01105547
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
	Dizziness		Captopril	C		ORAL		21 DAY
	Myositis		Captopril	C		ORAL		
	Neutropenia		Hydrochlorothiazide	C		ORAL		21 DAY
	Thrombocytopenia		Pantoprazole Sodium	C		ORAL		21 DAY
			Aspirin	C		ORAL		21 DAY
			Aspirin	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		21 DAY
			Isosorbide Mononitrate	C		ORAL		

Date:11/28/01ISR Number: 3830684-8Report Type:Expedited (15-DaCompany Report #WAES 01113462
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C				
			Diazepam	C		ORAL		
			Moclobemide	C		ORAL		

Date:11/28/01ISR Number: 3830685-XReport Type:Expedited (15-DaCompany Report #WAES 01113468
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Circulatory Collapse		Aspirin	SS		ORAL		
	Faeces Discoloured		Fish Oil (Unspecified)	C		ORAL		
	Rectal Haemorrhage							

Date:11/28/01ISR Number: 3830686-1Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Drug Interaction
	Drug Level Above Therapeutic
Disability	

	Drug Toxicity Dysarthria Gait Disturbance	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Mental Impairment		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
			Dilantin	SS			YR
			Premarin	C			
			Vicodin Es Tablets	C		ORAL	

Date:11/28/01ISR Number: 3830687-3Report Type:Expedited (15-DaCompany Report #WAES 01113484
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Olsalazine Sodium	C		ORAL	
			Paroxetine Hydrochloride	C			
			Quinine	C			
			Temazepam	C			
			Aspirin	C			

Date:11/28/01ISR Number: 3830688-5Report Type:Expedited (15-DaCompany Report #WAES 01113483
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY

Date:11/28/01ISR Number: 3830689-7Report Type:Expedited (15-DaCompany Report #WAES 01119138
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	251 DAY
Hospitalization -	Myocardial Infarction		Vasotec	C		ORAL	

Initial or Prolonged			Furosemide	C		ORAL
285 DAY						
			Spironolactone	C		ORAL
285 DAY						
			Aspirin	C		ORAL
285 DAY						
			Calcium Carbonate And Calcium Glubionate	C		ORAL
			Risedronate Sodium	C		ORAL

Date:11/28/01ISR Number: 3830690-3Report Type:Expedited (15-DaCompany Report #WAES 01119311
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Influenza Like Illness		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Tachycardia							

Date:11/28/01ISR Number: 3830691-5Report Type:Expedited (15-DaCompany Report #WAES 01113485
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc			
	Hemiparesis		Prednisolone	C				
			Ranitidine Hydrochloride	C		ORAL		
			Aspirin	C				

			Furosemide Sodium	C		
			Amiodarone Hydrochloride	C		
			Nitroglycerin	C		
			Digoxin	C		

Date:11/28/01ISR Number: 3830692-7Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged Disability	Dysphasia Dyspraxia							

Date:11/28/01ISR Number: 3830693-9Report Type:Expedited (15-DaCompany Report #WAES 01118272
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis Bacterial		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Diarrhoea		Floxacillin Sodium	SS			INTRAVENOUS	7 DAY
	Purpura Staphylococcal Infection		Ciprofloxacin Hydrochloride	C		ORAL		2 DAY
			Epoetin Alfa	C			INTRAVENOUS	
			Aspirin	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Rifampin	C		ORAL		1 DAY
			Aluminum Chlorohydrate	C		ORAL		
			Acetaminophen	C		ORAL		
			Vasotec	C		ORAL		
			Iron (Unspecified)	C			INTRAVENOUS	
			Cefuroxime Sodium	C			INTRAVENOUS	2 DAY

Date:11/28/01ISR Number: 3830694-0Report Type:Expedited (15-DaCompany Report #WAES 01113471
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		647 DAY
Initial or Prolonged	Rectal Haemorrhage		Aspirin	SS		ORAL		43 DAY
			Methotrexate Sodium	SS				
			Prednisolone	SS		ORAL		
			Omeprazole	C		ORAL		
			Levothyroxine Sodium	C				
			Furosemide Sodium	C				
			Calcitriol	C				
			Pravastatin Sodium	C				
			Mianserin Hydrochloride	C				
			Acetaminophen	C				

Date:11/28/01ISR Number: 3830695-2Report Type:Expedited (15-DaCompany Report #WAES 01113478
Age:85 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Duodenal Ulcer Haemorrhage

	Haemoglobin Decreased Melaena						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
			Aspirin And Dipyridamole	SS			17	DAY
			Metoprolol Tartrate	C				
			Acetaminophen	C				

Date:11/28/01ISR Number: 3830696-4Report Type:Expedited (15-DaCompany Report #WAES 01113486
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscular Weakness		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Renal Failure Acute		Lisinopril	SS			445	DAY
			Levothyroxine Sodium	C				
			Nortriptyline Hydrochloride	C			77	DAY
			Chlorthalidone	C			78	DAY
			Lorazepam	C				

Date:11/28/01ISR Number: 3830698-8Report Type:Expedited (15-DaCompany Report #WAES 01113477
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Clopidogrel Bisulfate	SS				
	Haemolytic Uraemic Syndrome		Trandolapril	C		ORAL		
	Microangiopathic Haemolytic Anaemia		Ranitidine	C		ORAL		
	Renal Failure Acute							
	Thrombocytopenia							

Date:11/29/01ISR Number: 3831479-1Report Type:Expedited (15-DaCompany Report #WAES 01112063
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL		58 DAY
Initial or Prolonged	Cardiac Failure		Lotensin	C		ORAL		
	Congestive		Combivent	C				
	Chronic Obstructive		Calcium					
	Pulmonary Disease		(Unspecified) And					
	Condition Aggravated		Vitamin D					
	Gram Stain Positive		(Unspecified)	C				
	Hypertension		Lasix (Furosemide)	C				
	Left Ventricular Failure		Aspirin	C		ORAL		
	Sputum Abnormal		Verapamil	C		ORAL		
	Tachycardia		Lanoxin	C		ORAL		
	Tachypnoea		Potassium Chloride	C		ORAL		
	Vasodilatation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/01ISR Number: 3831480-8Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Disorder		Aspirin	C				

Date:11/29/01ISR Number: 3831482-1Report Type:Expedited (15-DaCompany Report #WAES 01101364
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	94	DAY
Other	Abdominal Tenderness		Lasix (Furosemide)	C				
	Cardiac Failure							
	Congestive							
	Dyspnoea							
	Oedema							

Date:11/29/01ISR Number: 3831484-5Report Type:Expedited (15-DaCompany Report #WAES 01113180
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS		ORAL	1	MON
	Dysuria		Hyzaar	C				
	Face Oedema		Premarin	C				
	Oedema		Klor-Con	C				
	Oliguria		Synthroid	C				
	Weight Increased							

Date:11/29/01ISR Number: 3831486-9Report Type:Expedited (15-DaCompany Report #WAES 01104345
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL
18 DAY						
Other	Blood Urea Increased		Lasix (Furosemide)	C		
	Cardiac Failure		Flomax			
	Congestive		(Morniflumate)	C		
			Cozaar	C		
			Aspirin	C		
			Insulin	C		

Date:11/29/01ISR Number: 3831487-0Report Type:Expedited (15-DaCompany Report #WAES 01105541
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis		Vioxx	PS	Merck & Co., Inc	ORAL
83 DAY						
Initial or Prolonged			Aspirin	C		ORAL
			Sulpiride	C		ORAL

Date:11/29/01ISR Number: 3831491-2Report Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
			[Therapy Unspecified]	C				

Date:11/29/01ISR Number: 3831492-4Report Type:Expedited (15-DaCompany Report #WAES 01113459
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/01ISR Number: 3831493-6Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS		ORAL		
	Visual Disturbance		Catapres	C				
			Lasix (Furosemide)	C				

Date:11/29/01ISR Number: 3831496-1Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				

Date:11/29/01ISR Number: 3831498-5Report Type:Expedited (15-DaCompany Report #WAES 01113466
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dysphonia	Vioxx	PS	Merck & Co., Inc
Other	Hemiparesis	Methotrexate	C	
	Hypertension	Aspirin	C	
		Atorvastatin Calcium	C	
		Prinivil	C	
		Omeprazole Magnesium	C	
		Estrogens, Conjugated And Medroxyprogesterone Acetate	C	

Date:11/29/01ISR Number: 3831499-7Report Type:Expedited (15-DaCompany Report #WAES 01113458
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/01ISR Number: 3831500-0Report Type:Expedited (15-DaCompany Report #WAES 01113081
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Medical Device Complication Syncope Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/01ISR Number: 3831501-2Report Type:Expedited (15-DaCompany Report #WAES 01119136
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Furosemide	C				
			Lisinopril	C				
			Digoxin	C				
			Nitroglycerin	C				
			Acenocoumarol	C				
			Gliclazide	C				

Date:11/29/01ISR Number: 3831502-4Report Type:Expedited (15-DaCompany Report #WAES 01113472
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc			39 DAY
	Gastroenteritis Helicobacter		Aspirin Calcium	SS				

Date:11/29/01ISR Number: 3831503-6Report Type:Expedited (15-DaCompany Report #WAES 01113470
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
	Dizziness		Aspirin	SS				

	Duodenal Ulcer		Digoxin	C
	Gastric Ulcer		Felodipine	C
	Melaena		Levothyroxine Sodium	C
	Rectal Haemorrhage			
	Syncope			

Date:11/29/01ISR Number: 3831504-8Report Type:Expedited (15-DaCompany Report #WAES 01113487
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Haematemesis		Aspirin	C				

Date:11/29/01ISR Number: 3831505-XReport Type:Expedited (15-DaCompany Report #WAES 01115120
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Heparin	SS				
	Myocardial Infarction		Prednisolone	C				
			Methotrexate	C				

				[Therapy Unspecified]	C		

Date:11/29/01ISR Number: 3831507-3Report Type:Expedited (15-DaCompany Report #WAES 01113489
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mallory-Weiss Syndrome		Alcohol	SS				
			Aspirin	SS				
			Quinapril Hydrochloride	C				
			Spironolactone	C				
			Pyridoxine Hydrochloride	C				
			Zocor	C				
			Folic Acid	C				
			Omeprazole	C				

Date:11/29/01ISR Number: 3831508-5Report Type:Expedited (15-DaCompany Report #WAES 01113467
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Aspirin	SS		ORAL		
	Melaena		Clavulanate Potassium And Ticarcillin Disodium	C			INTRAVENOUS	13 DAY
			Doxycycline Hyclate	C		ORAL	11 DAY	
			Metoclopramide Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		
			Morphine Sulfate	C				

Date:11/29/01ISR Number: 3831509-7Report Type:Expedited (15-DaCompany Report #WAES 01113495
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Optic Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		261 DAY
	Neuropathy Optic Neuritis		Allopurinol	C				

Date:11/29/01ISR Number: 3831510-3Report Type:Expedited (15-DaCompany Report #WAES 01113494
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		DAY
Initial or Prolonged	Congestive Oedema		Warfarin [Composition	C				
	Pulmonary Oedema		Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/01ISR Number: 3831511-5Report Type:Expedited (15-DaCompany Report #WAES 01118584
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	C-Reactive Protein Increased		Acetaminophen And Codeine Phosphate	C				
	Decreased Activity							
	Oliguria							
	Pneumonia							
	Respiratory Failure							
	Uterine Contractions During Pregnancy							

Date:11/29/01ISR Number: 3832724-9Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Consumer	Neurontin					
	Blood Pressure Increased	Health	(Gabapentin)	PS		ORAL	600 MG (BID),	
Disability	Depressed Level Of	Professional					PER ORAL	
Other	Consciousness		Vioxx (Rofecoxib)	SS				
	Dry Mouth		Zanaflex					
	Dysarthria		(Tizanidine)	SS				
	Dysuria							
	Fatigue							
	Gait Disturbance							
	Lethargy							
	Miosis							
	Nausea							
	Sedation							

Date:11/30/01ISR Number: 3832183-6Report Type:Expedited (15-DaCompany Report #WAES 01119146
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
47 DAY						
	Hypertension		Hydrodiuril	SS		ORAL
	Oedema		Acetaminophen [Therapy Unspecified]	C		ORAL
				C		ORAL
			Diazepam	C		ORAL

Date:11/30/01ISR Number: 3832187-3Report Type:Expedited (15-DaCompany Report #WAES 01119144
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebral Artery Thrombosis Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	

Date:11/30/01ISR Number: 3832196-4Report Type:Expedited (15-DaCompany Report #WAES 01113498
Age:50 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Macular Oedema		Vioxx [Composition Unspecified]	PS	Merck & Co., Inc	
				C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3832198-8Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Diabetes Mellitus Inadequate Control		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/01ISR Number: 3832202-7Report Type:Expedited (15-DaCompany Report #WAES 01113220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/01ISR Number: 3832206-4Report Type:Expedited (15-DaCompany Report #WAES 01113132
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dry Mouth Ear Discomfort Epistaxis Headache Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/01ISR Number: 3832207-6Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anal Stenosis		Claritin	C				
	Aortic Valve Incompetence		Sulindac	C				
	Aortic Valve Sclerosis		Motrin	C				
	Calcinosis		Plaquenil	C				
	Cardiac Disorder		Tagamet	C				
	Cardiomegaly		Lipitor	C				
	Chest Pain		Aspirin	C		ORAL		
	Diverticulum		Synthroid	C				

Dizziness	Zocor	C	ORAL
Ejection Fraction			
Abnormal			
Flatulence			
Gastric Ulcer Haemorrhage			
Haemorrhage			
Hepatic Steatosis			
Hypokinesia			
Left Ventricular Failure			
Melaena			
Mitral Valve Incompetence			
Muscle Spasms			
Portal Hypertension			
Rectal Haemorrhage			
Renal Cyst			
Tricuspid Valve Incompetence			
Varices Oesophageal			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3832210-6Report Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Arrest		Cozaar	C		ORAL		
Hospitalization -	Duodenal Ulcer		Bumex	C		ORAL		
Initial or Prolonged	Haemorrhage		Lanoxin	C		ORAL		
Disability	Exsanguination		Klor-Con	C		ORAL		
Other	Haematochezia		Premarin	C		ORAL		
	Hypotension		Lotensin	C		ORAL		
	Syncope		Prednisone	C				

6 DAY

Date:11/30/01ISR Number: 3832508-1Report Type:Direct Company Report #
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS				
Initial or Prolonged	Oedema Peripheral		Lanoxin	C				
	Orthopnoea		Claritin	C				
			Spironolactone	C				
			Avapro	C				

Date:11/30/01ISR Number: 3832958-3Report Type:Expedited (15-DaCompany Report #WAES 99091791
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	
Hospitalization -	Dyspepsia	Professional	Toprol Xl Tablets					
Initial or Prolonged	Nausea	Company	12.5 Mg	SS			12.5 MG/	
Other		Representative					DAILY	

Date:11/30/01ISR Number: 3832976-5Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Aspiration
Other	Asthenia
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Murmur
	Cardiomegaly
	Cerebral Infarction
	Cerebral Ischaemia
	Coordination Abnormal
	Decreased Activity
	Dizziness
	Dysarthria
	Dysphagia
	Embolic Stroke
	Embolism
	Facial Palsy
	Feeling Abnormal
	Hemiparesis

		Hemiplegia					
		Hyperglycaemia					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Hyporeflexia	Professional				
MG/DAILY/PO							
		Laryngeal Disorder	Company	Atacand	C		
		Oedema Peripheral	Representative	Atacand Plus	C		
		Pain In Extremity		Benadryl	C		
		Paraesthesia		Hydrodiuril	C		
		Renal Impairment		Lopid	C		
		Tenderness		Osteo-Bi-Flex	C		
		Weight Decreased		Sudafed	C		
				Aspirin	C		
				Atenolol	C		
				Gastrointestinal			
				Preparations	C		

Date:11/30/01ISR Number: 3833021-8Report Type:Expedited (15-DaCompany Report #WAES 01112431
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Multi-Organ Failure	Health	Tab Vioxx	PS		ORAL
50 MG/1X/PO							
		Post Procedural	Professional				
		Complication	Company				
		Renal Failure	Representative				

Date:11/30/01ISR Number: 3833022-XReport Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Myocardial Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL
50 MG, DAILY,							
Initial or Prolonged			Professional				
PO							
			Company	Lipitor	C		
			Representative	[Therapy			
				Unspecified]	C		

Date:11/30/01ISR Number: 3833029-2Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged								

Date:11/30/01ISR Number: 3833030-9Report Type:Expedited (15-DaCompany Report #WAES 01112803
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG,DAILY, PO	
Hospitalization - Initial or Prolonged			Prevacid	C				
			[Therapy Unspecified]	C				

Date:11/30/01ISR Number: 3833199-6Report Type:Expedited (15-DaCompany Report #WAES 01117510
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Peritonitis							
PO							2	DAY
			Fosamax	C				
			Althiazide/Spironolactone	C				
			Carvedilol	C				
			Citalopram Hydrobromide	C				
			Haloperidol	C				
			Ranitidine	C				

Date:11/30/01ISR Number: 3833200-XReport Type:Expedited (15-DaCompany Report #WAES 01113463
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								
			Acetaminophen/Codeine Phosphate	C				
			Atorvastatin Calcium	C				
			Lansoprazole	C				
			Metformin Hcl	C				
			Ramipril	C				

Date:11/30/01ISR Number: 3833201-1Report Type:Expedited (15-DaCompany Report #WAES 01113442
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS				

Professional

Date:11/30/01ISR Number: 3833215-1Report Type:Expedited (15-DaCompany Report #WAES 01119144
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Artery Thrombosis Cerebral Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:11/30/01ISR Number: 3833270-9Report Type:Expedited (15-DaCompany Report #WAES 01110175
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx Adderall Tablets	PS C		ORAL PO		
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3833310-7Report Type:Expedited (15-DaCompany Report #WAES 01113464
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastritis	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	22 DAY
	Gastrointestinal Haemorrhage		Acetaminophen/Codeine Phosphate	C				
			Celecoxib	C				

Date:11/30/01ISR Number: 3833313-2Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Panniculitis Pruritus	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	24 DAY	
	Purpura		Tab Captopril	SS		ORAL	25 MG/DAILY	30 DAY
	Skin Reaction		Tab Fusidate Sodium	SS		ORAL	250 MG/DAILY	40 DAY
			Tab Dipyridamole	SS		ORAL	38 DAY	
			Inj Vancomycin	SS		INTRAVENOUS		40 DAY

Date:11/30/01ISR Number: 3833334-XReport Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO		
			[Therapy Unspecified]	C				

Date:11/30/01ISR Number: 3833347-8Report Type:Expedited (15-DaCompany Report #WAES 01112455
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	3 WK
	Hypertensive Crisis		Flexeril	C				
	Vitreous Detachment		Pravachol	C				
			Premarin	C				
			Provera	C				
			Synthroid	C				
			Calcium (+) Vitamin	C				
			Diazepam	C				
			Vitamins	C				

Date:11/30/01ISR Number: 3833355-7Report Type:Expedited (15-DaCompany Report #WAES 01106309
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						
	Gastrointestinal	Company						
	Haemorrhage	Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3833356-9Report Type:Expedited (15-DaCompany Report #WAES 01112418
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:11/30/01ISR Number: 3833357-0Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:11/30/01ISR Number: 3833358-2Report Type:Expedited (15-DaCompany Report #WAES 01112151
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Embolism	Company Representative	Coumadin	C				

Date:11/30/01ISR Number: 3833377-6Report Type:Expedited (15-DaCompany Report #WAES 01112372
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:11/30/01ISR Number: 3833386-7Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Gastrointestinal	Professional					PO	
	Haemorrhage	Company	Bumex	C				
	Haematochezia	Representative	Cozaar	C				
	Hypotension		Klor-Con	C				
	Syncope		Lanoxin	C				
			Lotensin	C				
			Premarin	C				
			Prednisone	C				

Date:11/30/01ISR Number: 3833389-2Report Type:Expedited (15-DaCompany Report #WAES 01106165
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Bronchospasm
Hospitalization -	Diarrhoea
Initial or Prolonged	Drug Hypersensitivity
	Pneumonia
	Pulmonary Oedema
	Rales
	Tachycardia

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative	Lipitor	C				
			Paxil	C				
			Xanax	C				
			Irbesartan	C				

Date:11/30/01ISR Number: 3833493-9Report Type:Expedited (15-DaCompany Report #WAES 01106306
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Mucosal Lesion	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal	Professional						
	Haemorrhage		Paxil	C				
	Melaena		Aspirin	C				
	Syncope		Disopyramide	C				
			Levothyroxine Sodium	C				

Date:11/30/01ISR Number: 3833497-6Report Type:Expedited (15-DaCompany Report #WAES 01101985
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Exfoliative	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Rash Generalised	Professional	Bactrim	C				
			Colace	C				
			Folic Acid	C				
			Lactulose	C				
			Thiamine	C				
			Vitamins (Unspecified)	C				

Date:11/30/01ISR Number: 3833501-5Report Type:Expedited (15-DaCompany Report #WAES 00091412
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dysuria							
	Faecal Incontinence							
	Joint Stiffness							
	Paralysis							

Date:11/30/01ISR Number: 3833597-0Report Type:Expedited (15-DaCompany Report #WAES 01088587
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Condition Aggravated	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY PO ; 25 MG/DAILY PO	21 DAY
			Hyzaar	C				
			Diltiazem Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3833650-1Report Type:Expedited (15-DaCompany Report #WAES 01100373
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematochezia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Disability	Haemorrhoids	Other						
	Rectal Haemorrhage		Detrol	C				
			Lanoxin	C				
			Vasotec	C				
			Aspirin	C				
			Docusate Sodium	C				
			Ferrous Sulfate	C				
			Ranitidine	C				

Date:11/30/01ISR Number: 3833651-3Report Type:Expedited (15-DaCompany Report #WAES 01083073
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Cardiomegaly	Professional						
	Mitral Valve Incompetence	Company						
	Pericardial Effusion	Representative						
	Ventricular Hypertrophy							

Date:11/30/01ISR Number: 3833653-7Report Type:Expedited (15-DaCompany Report #WAES 01112545
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	6 MON
	Arthritis							
	Blood Pressure Increased		Ibuprofen	C				
	Lethargy							
	Lid Lag							
	Pain In Extremity							

Weight Increased

Date:11/30/01ISR Number: 3833654-9Report Type:Expedited (15-DaCompany Report #WAES 01112451
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Health	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Aortic Valve Sclerosis	Professional						
	Arteriovenous Fistula		Buspar	C				
	Bundle Branch Block Right		Dynacirc	C				
	Calcinosis		Xanax	C				
	Hypertension							
	Insomnia							
	Knee Arthroplasty							
	Mitral Valve Disease							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Precerebral Artery Occlusion							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/01ISR Number: 3833656-2Report Type:Expedited (15-DaCompany Report #WAES 01112521
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Health	Vioxx	PS		ORAL	DAILY/PO	
Hospitalization - Initial or Prolonged	Dyspnoea Pulmonary Embolism	Professional	Estrogens	C				

Date:11/30/01ISR Number: 3833657-4Report Type:Expedited (15-DaCompany Report #WAES 01111158
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis Cerebral Infarction	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Headache Hypoaesthesia Sinus Bradycardia Transient Ischaemic Attack Vertigo	Other	Flonase	C				

Date:11/30/01ISR Number: 3833816-0Report Type:Expedited (15-DaCompany Report #WAES 01115115
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	2 DAY
			Vasotec	C				

Date:11/30/01ISR Number: 3833817-2Report Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Oedema Peripheral	Foreign	Tab Vioxx			
Initial or Prolonged	Rash Pustular	Other	(Rofecoxib)	PS		ORAL
25 MG/BID PO 29 DAY						
			Hydroxyurea	SS		ORAL
PO 24 DAY						
			Dipyrone	C		
			Mercaptopurine	C		
			Omeprazole	C		

Date:11/30/01ISR Number: 3833821-4Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension	Foreign	Tab Vioxx			
Initial or Prolonged	Pancreatitis	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
PO 1 WK						
			Aceclofenac	C		
			Captopril	C		
			Dipyrone	C		

Date:11/30/01ISR Number: 3833823-8Report Type:Expedited (15-DaCompany Report #WAES 01088587
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Hospitalization -	Atrial Fibrillation	Foreign
Initial or Prolonged		Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 21 DAY
Hyzaar	C				
Diltiazem Hydrochloride	C				

Date:11/30/01ISR Number: 3833829-9Report Type:Expedited (15-DaCompany Report #WAES 01113482
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	PO
			Prazosin	C				
			Ranitidine Hcl	C				

Date:11/30/01ISR Number: 3833831-7Report Type:Expedited (15-DaCompany Report #WAES 01113472
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS			12.5 MG/DAILY	39 DAY
			Aspirin Calcium	SS			150 MG/DAILY	

Date:11/30/01ISR Number: 3833834-2Report Type:Expedited (15-DaCompany Report #WAES 01113481
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	15 DAY
			Hctz/Triamterene	C				
			Furosemide Sodium	C				
			Ramipril	C				

Date:11/30/01ISR Number: 3833848-2Report Type:Expedited (15-DaCompany Report #WAES 01113465
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Acetaminophen	C				
			Aspirin	C				
			Colchicine	C				

Date:11/30/01ISR Number: 3834454-6Report Type:Expedited (15-DaCompany Report #WAES 01110972
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bacteriuria Blood Albumin Abnormal Blood Creatinine Abnormal

		Blood Glucose Abnormal Blood Pressure Increased Carotid Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL
DAILY/PO							
		Haematocrit Decreased	Professional	Lortab	C		
		Haematuria	Company	Naprosyn	C		
		Haemoglobin Abnormal	Representative	Neurontin	C		
		Pco2 Abnormal		Paxil	C		
		Platelet Count Abnormal		Chondroitin (+)			
		Protein Total Abnormal		Glucosamine	C		
		White Blood Cell Count Abnormal					
		White Blood Cells Urine Positive					

Date:11/30/01ISR Number: 3854338-7Report Type:Periodic Company Report #CIP01002049
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Interaction	Consumer	Actonel	PS		ORAL
5 MG DAILY,						
	Dyspepsia					
ORAL						
	Oral Discomfort		Vioxx (Rofecoxib)	SS		ORAL
EVERY OTHER						
DAY, ORAL						
			Apap	C		
			Calcium	C		
			Multivit (Vitamins Nos)	C		

Date:12/03/01ISR Number: 3832813-9Report Type:Expedited (15-DaCompany Report #WAES 01114270
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Complications Of Maternal		Vioxx	PS	Merck & Co., Inc	
2 DAY						

Other	Exposure To Therapeutic	Vioxx	SS	
7 DAY				
	Drugs			
	Congenital Anomaly			
	Congenital Central			
	Nervous System Anomaly			
	Congenital Intestinal			
	Malformation			
	Developmental Delay			
	Intestinal Obstruction			
	Pregnancy			

Date:12/03/01ISR Number: 3832816-4Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypoaesthesia							
Initial or Prolonged	Nausea							
	Paraesthesia							

Date:12/03/01ISR Number: 3832818-8Report Type:Expedited (15-DaCompany Report #WAES 01106429
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour Cerebral Ischaemia Mental Impairment Thinking Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/01ISR Number: 3832819-XReport Type:Expedited (15-DaCompany Report #WAES 01113727
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		241 DAY
			Aspirin	C		ORAL		
			Prednisolone	C		ORAL		
			Budesonide	C				

RESPIRATORY

(INHALATION)

Date:12/03/01ISR Number: 3832823-1Report Type:Expedited (15-DaCompany Report #WAES 01119854
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
			Vioxx	SS		ORAL		3 DAY

Date:12/03/01ISR Number: 3832826-7Report Type:Expedited (15-DaCompany Report #WAES 01115187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		223 DAY

Hospitalization - Initial or Prolonged	Large Intestinal Ulcer		Metoprolol	C	ORAL
	Rectal Haemorrhage		Isosorbide Mononitrate	C	ORAL
			Bendroflumethiazide	C	ORAL
			Allopurinol	C	ORAL
			Zocor	C	ORAL
			Nicorandil	C	ORAL

Date:12/03/01ISR Number: 3832828-0Report Type:Expedited (15-DaCompany Report #WAES 01116082
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Tinnitus		Heptaminol Hydrochloride	C		ORAL		
			Celecoxib	C		ORAL		

Date:12/03/01ISR Number: 3832829-2Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Systemic Lupus Erythematosus		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/01ISR Number: 3832830-9Report Type:Expedited (15-DaCompany Report #WAES 01114421
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Xanax	C				
	Heart Rate Irregular		Zocor	C				
	Oedema Peripheral		Ultram	C				
	Wheezing		Ecotrin	C				
			Zoloft	C				
			Norvasc	C				
			Atenolol	C				
			Imdur	C				
			Premarin	C				
			Zantac	C				
			Digitek	C				
			Prinivil	C				
			Synthroid	C				
			Lasix (Furosemide)	C				
			Doxepin	C				
			Trazodone	C				
			Meclizine	C				

Date:12/03/01ISR Number: 3847295-0Report Type:Periodic Company Report #01080617
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Consumer	Enbrel 25 Mg	PS				
SUBCUTANEOUS							25 MG, BIW,	
	Conjunctivitis							
SUBCUTANEOUS								
	Diabetes Mellitus		Rofecoxib	SS				
25 MG, QD								
	Multiple Myeloma		Viamin B Complex	C				
	Oedema Peripheral		Rosiglitazone	C				
			Colestipol	C				

Date:12/04/01ISR Number: 3833093-0Report Type:Direct Company Report #
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Atrial Fibrillation		Vioxx 50 Mg	PS		ORAL	1 PO QHS	
Intervention to Prevent Permanent Impairment/Damage	Cardiac Failure Congestive Renal Failure Acute		Vasotec 5mg	SS		ORAL	1 PO BID	11 YR

Date:12/04/01ISR Number: 3833508-8Report Type:Expedited (15-DaCompany Report #WAES 01105565
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY	
	Atrial Fibrillation		Flecainide Acetate	C		ORAL		
	Diarrhoea		Atorvastatin Calcium	C		ORAL		
			Certoparin Sodium	C			17 DAY	
			Escin	C		ORAL		
			Liotrix	C		ORAL		
			Magnesium Oxide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3833511-8Report Type:Expedited (15-DaCompany Report #WAES 01113494
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization - Initial or Prolonged	Congestive		Digoxin	C		ORAL		
Disability			Warfarin	C		ORAL		
			Fosinopril Sodium	C				
			Pravastatin Sodium	C				
			Amlodipine Besylate	C				
			Metformin Hydrochloride	C				
			Insulin Lispro, Biphasic Isophane [Injection]	C				
			Allopurinol	C				
			Fosamax	C				
			Calcitriol	C				

Date:12/04/01ISR Number: 3833512-XReport Type:Expedited (15-DaCompany Report #WAES 01117280
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		65 DAY
Initial or Prolonged	Hypertension		Amlodipine Besylate	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Ramipril	C				
			Atorvastatin Calcium	C				
			Aspirin	C				
			Insulin, Biphasic Isophane [Injection]	C				

Date:12/04/01ISR Number: 3833513-1Report Type:Expedited (15-DaCompany Report #WAES 01102263
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardio-Respiratory Arrest	Vioxx	PS	Merck & Co., Inc	ORAL
17 DAY					
Hospitalization - Initial or Prolonged	Compartment Syndrome	Flexeril	C		
	Peripheral Embolism	Combivent	C		
	Rhabdomyolysis	Albuterol	C		
	Shock				

Date:12/04/01ISR Number: 3833518-0Report Type:Expedited (15-DaCompany Report #WAES 01113466
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dysphonia		Vioxx	PS	Merck & Co., Inc	
	Hemiparesis		Methotrexate	C		
	Hypertension		Aspirin	C		
			Atorvastatin Calcium	C		
			Prinivil	C		
			Omeprazole Magnesium	C		
			Estrogens, Conjugated And Medroxyprogesterone Acetate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3833519-2Report Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Disturbance In Attention		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/04/01ISR Number: 3833520-9Report Type:Expedited (15-DaCompany Report #WAES 01115179
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease Gastrointestinal Haemorrhage		Vioxx Calcium Carbonate Cyanocobalamin Mesalamine Methotrexate	PS C C C C	Merck & Co., Inc			

Date:12/04/01ISR Number: 3833521-0Report Type:Expedited (15-DaCompany Report #WAES 01117028
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Choking Sensation		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Deep Vein Thrombosis		Estradiol Valerate	C				YR
Other	Difficulty In Walking Dyspnoea							

Date:12/04/01ISR Number: 3833522-2Report Type:Expedited (15-DaCompany Report #WAES 01116085
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Hospitalization -			Dihydroergotamine					
Initial or Prolonged			Mesylate	C			1	DAY

			Pyrantel Pamoate	C		ORAL
1 DAY						
			Clonazepam	C		ORAL
			Phenobarbital	C		ORAL
			Carbamazepine	C		ORAL

Date:12/04/01ISR Number: 3833524-6Report Type:Expedited (15-DaCompany Report #WAES 01117524
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/04/01ISR Number: 3833527-1Report Type:Expedited (15-DaCompany Report #WAES 01118279
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 4 DAY	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Mucosal Ulceration					
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834046-9Report Type:Direct Company Report #
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx (25 Mg) Merck	PS	Merck	ORAL	ONCE A DAY PO	
	Fatigue						ONE DOSE ONLY	
	Nausea		Ddavp	C				
	Pollakiuria							

Date:12/04/01ISR Number: 3834455-8Report Type:Expedited (15-DaCompany Report #WAES 01096011
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Tab Vioxx					
	Bone Marrow Disorder	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Drug Toxicity	Professional					PO	1 MON
	Fatigue		Acetaminophen	C				
	Macrocytosis		Celecoxib	C				
	Neutropenia		Pygeum Africanum					
	Pancytopenia		Extract	C				
	Purpura							

Date:12/04/01ISR Number: 3834463-7Report Type:Expedited (15-DaCompany Report #WAES 01113476
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign	Tab Vioxx					
	Hypoxia	Other	(Rofecoxib)	PS			12.5 MG /	
	Pulmonary Embolism						DAILY	
			Hydrodiuril	C				
			Aspirin	C				
			Estradiol	C				
			Fluticasone					
			Propionate	C				

				Gliclazide	C		
				Latanoprost	C		
				Metformin Hcl	C		
				Quinapril Hcl	C		

Date:12/04/01ISR Number: 3834465-0Report Type:Expedited (15-DaCompany Report #WAES 01118587
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Toxicity	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
PO						

Date:12/04/01ISR Number: 3834471-6Report Type:Expedited (15-DaCompany Report #WAES 01113485
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder Hemiparesis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		
			Amiodarone Hydrochloride	C		
			Aspirin	C		
			Digoxin	C		
			Furosemide Sodium	C		

			Nitroglycerin	C		
			Prednisolone	C		

Date:12/04/01ISR Number: 3834473-XReport Type:Expedited (15-DaCompany Report #WAES 01113486
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscular Weakness Renal Failure Acute Ultrasound Kidney	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 15 DAY
	Abnormal		Lisinopril	SS			20 MG/DAILY	
			Chlorthalidone	C				
			Levothyroxine Na	C				
			Lorazepam	C				
			Nortriptyline Hcl	C				

Date:12/04/01ISR Number: 3834474-1Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Disability Dysphasia Dyspraxia Speech Disorder	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 DAY

Date:12/04/01ISR Number: 3834476-5Report Type:Expedited (15-DaCompany Report #WAES 01118272
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Staphylococcal Infection
PO 7 DAY

Inj Flocacillin Sodium	SS

INTRAVENOUS 2000 MG/DAILY

IV 7 DAY

Vasotec	C
Acetaminophen	C
Alumimum Chlorohydrate	C
Amlodipine Besylate	C
Aspirin	C
Cefuroxime Sodium	C
Ciprofloxacin Hydrochloride	C
Epoetin Alfa	C
Iron (Unspecified)	C
Rifampin	C

Date:12/04/01ISR Number: 3834478-9Report Type:Expedited (15-DaCompany Report #WAES01119311
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cough Influenza Like Illness Tachycardia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

PO 1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834479-0Report Type:Expedited (15-DaCompany Report #WAES 01113484
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured	Foreign	Tab Vioxx					
	Gastric Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Haematemesis						PO	
	Upper Gastrointestinal Haemorrhage		Aspirin	C				
			Olsalazone Sodium	C				
			Paroxetine Hc1	C				
			Quinine	C				
			Temazepam	C				

Date:12/04/01ISR Number: 3834481-9Report Type:Expedited (15-DaCompany Report #WAES 01113478
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Haemorrhage						PO	12 DAY
	Epigastric Discomfort		Aspirin/Dipyridamole	SS			17 DAY	
	Melaena							

Date:12/04/01ISR Number: 3834482-0Report Type:Expedited (15-DaCompany Report #WAES 01113477
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Anaemia	Other	(Rofecoxib)	PS		ORAL	PO	
	Diarrhoea		Ranitidine	C				
	Haemolytic Uraemic Syndrome		Trandolapril	C				
	Renal Failure Acute							
	Thrombocytopenia							

Date:12/04/01ISR Number: 3834484-4Report Type:Expedited (15-DaCompany Report #WAES 01113459
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/04/01ISR Number: 3834486-8Report Type:Expedited (15-DaCompany Report #WAES 01119146
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	47 DAY
	Hypertension							
	Hypotension							
	Oedema		Tab Hydrodiuril (Hydrochlorothiazide)	SS		ORAL	PO	
			Acetaminophen	C				
			Diazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834493-5Report Type:Expedited (15-DaCompany Report #WAES 01096054
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Foreign	Tab Vioxx					
Hospitalization -	Infarction	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Cardio-Respiratory Arrest							
PO							4	DAY
	Hypotension							

Date:12/04/01ISR Number: 3834514-XReport Type:Expedited (15-DaCompany Report #WAES 01119138
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Tab Vioxx					
Hospitalization -	Ventricular Hypertrophy	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional						
PO							251	DAY
			Vasotec	C				
			Aspirin	C				
			Calcium Carbonate (=) Calcium Glubionate	C				
			Furosemide	C				
			Risedronate Sodium	C				
			Spironolactone	C				

Date:12/04/01ISR Number: 3834550-3Report Type:Expedited (15-DaCompany Report #WAES 01106107
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Perforation	Health	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	29 DAY
Initial or Prolonged	Peritonitis	Professional	Acetaminophen	C				
			Diacerein	C				
			Meloxicam	C				
			Omeprazole Sodium	C				

Date:12/04/01ISR Number: 3834551-5Report Type:Expedited (15-DaCompany Report #WAES 01115558
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional	Amlodipine Besylate	C				
			Captopril	C				
			Furosemide	C				
			Glyburide	C				
			Isosorbide Dinitrate	C				
			Phenprocoumon	C				
			Rosiglitazone Maleate	C				

Date:12/04/01ISR Number: 3834552-7Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Condition Aggravated
Initial or Prolonged	Erythema Induratum
	Panniculitis

		Pruritus Purpura Skin Lesion	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Staphylococcal Infection	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	24 DAY
				Tab Captopril	SS		ORAL	25 MG/DAILY	
								PO	30 DAY
				Tab Fusidate Sodium	SS		ORAL	250 MG/DAILY	
								PO	40 DAY
				Tab Dipyridamole	SS		ORAL	PO	38 DAY
				Inj Vancomycin	SS			INTRAVENOUS	IV 40 DAY

Date:12/04/01ISR Number: 3834553-9Report Type:Expedited (15-DaCompany Report #WAES 01115033
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/04/01ISR Number: 3834571-0Report Type:Expedited (15-DaCompany Report #2001073066FR
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign Other	Celebrex (Celecoxib) Capsule	PS		ORAL	200 MG, BID, ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	QD, ORAL	

			Nexen (Nimesulide)	SS			ORAL
BID, ORAL							
			Xatral (Alfuzosin)	C			
			Eupantol	C			
			Dafalgan	C			
			Salazopyrine	C			

Date:12/04/01ISR Number: 3834590-4Report Type:Expedited (15-DaCompany Report #WAES01096011
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia	Foreign	Tab Vioxx			
	Fatigue	Other	(Rofecoxib)	PS		ORAL
12.5						
	Macrocytosis					
MG/DAILY, PO 1 MON						
	Pancytopenia		Acetaminophen	C		
	Purpura		Celecoxib	C		
			Pygeum Africanum			
			Extract	C		

Date:12/04/01ISR Number: 3834593-XReport Type:Expedited (15-DaCompany Report #WAES 01119136
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx			
Initial or Prolonged	Congestive	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Condition Aggravated					
PO						
			Acenocoumarol	C		
			Digoxin	C		
			Furosemide	C		
			Gliclazide	C		

			Liisnopril	C		
			Nitroglycerin	C		

Date:12/04/01ISR Number: 3834598-9Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Myocardial Infarction	Professional	Heparin [Therapy Unspecified]	SS				
			Methotrexate	C				
			Prednisolone	C				

Date:12/04/01ISR Number: 3834600-4Report Type:Expedited (15-DaCompany Report #WAES 01118584
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Laboratory Test Abnormal	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Oliguria	Health	(Rofecoxib)	PS		ORAL	PO	4 DAY
	Pneumonia	Professional	Acetaminophen/Codeine Phosphate	C				
	Respiratory Failure							
	Urine Osmolarity Increased							

Date:12/04/01ISR Number: 3834602-8Report Type:Expedited (15-DaCompany Report #WAES 01113495
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Optic Ischaemic Neuropathy	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Optic Neuritis	Professional					PO	261 DAY
			Allopurinol	C				

Date:12/04/01ISR Number: 3834603-XReport Type:Expedited (15-DaCompany Report #WAES 01113494
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	
	Oedema	Professional					PO	
	Pulmonary Oedema		[Composition Unspecified]	C				
			Warfarin	C				

Date:12/04/01ISR Number: 3834604-1Report Type:Expedited (15-DaCompany Report #WAES 01113489
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mallory-Weiss Syndrome	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Alcohol	SS				
			Aspirin	SS			100 MG/DAILY	
			Zocor	C				
			Folic Acid	C				

			Omeprazole	C
			Pyridoxine Hcl	C
			Quinapril Hcl	C
			Spironolactone	C

Date:12/04/01ISR Number: 3834606-5Report Type:Expedited (15-DaCompany Report #WAES 01113487
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Haematemesis							
PO							8	DAY
	Melaena		Aspirin	C				

Date:12/04/01ISR Number: 3834608-9Report Type:Expedited (15-DaCompany Report #WAES 01113470
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Dizziness	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Duodenal Ulcer							
PO							93	DAY
	Gastric Ulcer		Aspirin	SS			0.5/DAILY	
	Melaena		Digoxin	C				
	Rectal Haemorrhage		Felodipine	C				
	Syncope		Levothyroxine Na	C				

Date:12/04/01ISR Number: 3834609-0Report Type:Expedited (15-DaCompany Report #WAES 01113466
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysphonia	Foreign	Tab Vioxx					
Initial or Prolonged	Hemiparesis	Other	(Rofecoxib)	PS			25 MG/DAILY	

Other	Hypertension	Prinivil	C
	Paresis	Aspirin	C
	Vocal Cord Disorder	Atorvastatin Calcium	C
		Estrogens, Conjugated (+)	
		Medroxyprogest	C
		Methotrexate	C
		Omeprazole Magnesium	C

Date:12/04/01ISR Number: 3834649-1Report Type:Expedited (15-DaCompany Report #11591633
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Induratum	Foreign	Lopril Tabs 25 Mg					
	Pruritus	Health	(Captopril)	PS		ORAL	25 MILLIGRAM,	
	Purpura	Professional					1/1 DAY	
		Company					ORAL	
		Representative	Fucidine (Fusidic					
		Other	Acid)	SS				
			Vioxx (Rofecoxib)	SS				
			Cleridium (Dipyridamole)	SS				
			Vancomycin (Vancomycin Hcl)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834658-2Report Type:Expedited (15-DaCompany Report #2001USA01458
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Study	Plavix	PS		ORAL	75 MG QD PO	
Initial or Prolonged	Infarction		Vioxx	SS		ORAL	50 MG DAILY	
	Amnesia						PO	
	Antinuclear Antibody		Treatment B					
	Positive		(Gatifloxacin/Placeb					
	Antiphospholipid		o)	SS				
	Antibodies Positive		Treatment A (Statin)					
	Arthralgia		Pravastatin Or					
	Blood Pressure Systolic		Atorvastatin	SS		ORAL	40 MG DAILY	
	Decreased						PO	
	Chest Pain		Coumadin	C				
	Chronic Obstructive		Thyroid	C				
	Pulmonary Disease		Flovent	C				
	Complement Factor		Lanoxin	C				
	Decreased		Prednisone	C				
	Decreased Appetite							
	Dehydration							
	Depression							
	Diarrhoea							
	Eosinophil Count							
	Increased							
	Fat Embolism							
	Fatigue							
	Hypotension							
	Lethargy							
	Metabolic Acidosis							
	Myalgia							
	Nausea							
	Oedema Peripheral							
	Oral Intake Reduced							
	Pain In Extremity							
	Pericardial Effusion							
	Pericarditis							
	Pyrexia							
	Rash							
	Renal Failure Acute							
	Splinter Haemorrhages							

Systemic Lupus
Erythematosus
Thrombotic
Thrombocytopenic Purpura
Vasculitis

Date:12/04/01ISR Number: 3834666-1Report Type:Expedited (15-DaCompany Report #WAES 01112949
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Study	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Health	Celebrex	C				
	Congestive	Professional	Galantamine	C				
	Cardiomegaly							
	Mitral Valve Incompetence							
	Pulmonary Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834676-4Report Type:Expedited (15-DaCompany Report #WAES 01090532
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea	Other						
	Dyspepsia		Flonase	C				
	Ejection Fraction Decreased		Motrin	C				
	Weight Increased		Naprosyn	C				
			Premarin	C				
			Prilosec	C				
			Soma	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Xanax	C				
			Xenical	C				
			Amitriptyline Hydrochloride	C				

Date:12/04/01ISR Number: 3834679-XReport Type:Expedited (15-DaCompany Report #WAES 99091791
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Health	Tab Vioxx 50 Mg/25					
Hospitalization - SEE IMAGE	Dyspepsia	Professional	Mg	PS		ORAL		
Initial or Prolonged	Nausea	Company	Toprol Xl Tablets					
Disability		Representative	12.5 Mg	C		ORAL	12.5 MG/DAILY/PO	
Other								
			(Composition Unspecified)	C				
			Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:12/04/01ISR Number: 3834731-9Report Type:Expedited (15-DaCompany Report #WAES 01113180
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dyspnoea							
	Dysuria		Tab Vioxx 25 Mg	SS		ORAL	28 MG/DAILY/PO	
	Face Oedema							
	Oedema		Hyzaar	C				
	Weight Increased		Klor-Con	C				
			Premarin	C				
			Synthroid	C				

Date:12/04/01ISR Number: 3834732-0Report Type:Expedited (15-DaCompany Report #WAES 01113081
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Pacemaker Malfunction	Consumer	Tab Vioxx	PS		ORAL	PO	
	Syncope							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834735-6Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Cerebrovascular Accident							
	Visual Disturbance		Tab Vioxx	SS		ORAL	25 MG/DAILY/PO	
			Catapres	C				
			Lasix (Furosemide)	C				

Date:12/04/01ISR Number: 3834737-XReport Type:Expedited (15-DaCompany Report #WAES 01104345
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Increased	Health						
	Blood Glucose Increased	Professional	Cozaar	C				
	Blood Urea Increased		Flomax					
	Cardiac Failure		(Morniflumate)	C				
	Congestive		Lasix (Furosemide)	C				
	Chest X-Ray Abnormal		Aspirin	C				
	Dyspnoea		Insulin	C				
	Fluid Retention							
	Joint Swelling							
	Oedema Peripheral							

Date:12/04/01ISR Number: 3834827-1Report Type:Expedited (15-DaCompany Report #WAES 01119144
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Infarction	Foreign	Tab Vioxx					
	Cerebral Thrombosis	Other	(Rofecoxib)	PS				

Date:12/04/01ISR Number: 3834829-5Report Type:Expedited (15-DaCompany Report #WAES 01113498
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:12/04/01ISR Number: 3834831-3Report Type:Expedited (15-DaCompany Report #WAES 01088603
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cough	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Dizziness	Health Professional	(Rofecoxib)	PS		ORAL	100 MG/DAILY, PO	
	Fluid Retention							
Disability	Medication Error		Celecoxib	C				
Other	Respiratory Disorder		Oxycodone Hcl	C				
	Weight Increased							

Date:12/04/01ISR Number: 3834834-9Report Type:Expedited (15-DaCompany Report #WAES 01095677
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Foreign	Tab Vioxx					
Hospitalization -	Grand Mal Convulsion	Other	(Rofecoxib)	PS		ORAL	PO	3 MON
Initial or Prolonged	Petit Mal Epilepsy		Aspirin	C				
Other			Glyburide	C				

Date:12/04/01ISR Number: 3834835-0Report Type:Expedited (15-DaCompany Report #WAES 01113483
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign	Tab Vioxx					
			(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
							PO	7 DAY

Date:12/04/01ISR Number: 3834836-2Report Type:Expedited (15-DaCompany Report #WAES 01119147
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Aspartate							
							PO	16 DAY
	Aminotransferase		Aceclofenac	SS		ORAL	100 MG/DAILY,	
	Increased							
							PO	
	Drug Interaction		Tab Diclofenac Na	SS		ORAL	150 MG/DAILY,	
	Renal Impairment							
							PO	
	Right Ventricular Failure		Aspirin	C				
			Atenolol	C				
			Digoxin	C				

Date:12/04/01ISR Number: 3834838-6Report Type:Expedited (15-DaCompany Report #WAES 01119307
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Disability							PO	8 DAY

Date:12/04/01ISR Number: 3834849-0Report Type:Expedited (15-DaCompany Report #WAES 01113471
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancytopenia Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	647 DAY
			Cap Aspirin	SS		ORAL		
			Methotrexate Sodium	SS			10 MG/1X	43 DAY
			Prednisolone	SS			15 MG/DAILY	
			Acetaminophen	C				
			Calcitriol	C				
			Furosemide Sodium	C				
			Levothyroxine Na	C				
			Mianserin Hcl	C				
			Omeprazole	C				
			Pravastatin Na	C				

Date:12/04/01ISR Number: 3834854-4Report Type:Expedited (15-DaCompany Report #WAES 01113468
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Circulatory Collapse	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY	
	Faeces Discoloured							
	Melaena		Aspirin	SS		ORAL	100 MG/DAILY	
	Rectal Haemorrhage Syncope		Fish Oil (Unspecified)	C				

Date:12/04/01ISR Number: 3834855-6Report Type:Expedited (15-DaCompany Report #WAES 01113462
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cervical Myelopathy	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY	
			Acetaminophen/Codeine Phosphate	C				
			Diazepam	C				
			Moclobemide	C				

Date:12/04/01ISR Number: 3834856-8Report Type:Expedited (15-DaCompany Report #WAES 01113456
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epigastric Discomfort Gastric Ulcer	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	200 MG/DAILY	11 DAY
	Haematemesis		Aspirin	SS		ORAL	200 MG/DAILY	
	Melaena Upper Gastrointestinal Haemorrhage							

Date:12/04/01ISR Number: 3834857-XReport Type:Expedited (15-DaCompany Report #WAES 01105547
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Tab Vioxx					
	Blood Creatine	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Phosphokinase Increased		Aspirin	C				
	Blood Lactate		Captopril	C				
	Dehydrogenase Increased		Hydrochlorothiazide	C				
	Decreased Appetite		Isosorbide					
	Dizziness		Mononitrate	C				
	Gait Disturbance		Pantoprazole Sodium	C				
	Myositis							
	Neutropenia							
	Pain In Extremity							
	Thrombocytopenia							
	White Blood Cell Count Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834861-1Report Type:Expedited (15-DaCompany Report #WAES 01105541
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	1 TABLET/DAILY	83 DAY
			Aspirin	C				
			Sulpiride	C				

Date:12/04/01ISR Number: 3834862-3Report Type:Expedited (15-DaCompany Report #WAES 01112854
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Arthritis	Health Professional						
	Atelectasis		Tab Acetaminophen					
Disability	Blood Creatine		Unk	SS		ORAL	325 MG/PRN/PO	
	Phosphokinase Increased		Effexor	C				
	Calcinosis		Zocor	C				
	Coronary Artery Disease		Aspirin	C				
	Dyspnoea							
	Hyperhidrosis							
	Myocardial Infarction							
	Nausea							
	Osteoarthritis							
	Sudden Cardiac Death							
	Ventricular Tachycardia							

Date:12/04/01ISR Number: 3834863-5Report Type:Expedited (15-DaCompany Report #WAES 01113472
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					

Initial or Prolonged	Gastroenteritis	Other	(Rofecoxib)	PS
12.5 MG/DAILY 39 DAY				
	Helicobacter		Aspirin Calcium	SS

Date:12/04/01ISR Number: 3834908-2Report Type:Expedited (15-DaCompany Report #WAES 01113172
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
50						
Hospitalization -	Haemorrhage	Professional				
MG/DAILY/PO						
Initial or Prolonged	Myocardial Infarction	Company	Bumex	C		
		Representative	Darvocet-N	C		
			Elavil	C		
			Isorbid	C		
			Kaon	C		
			Lamisil	C		
			Norvasc	C		
			Paxil	C		
			Synthroid	C		
			Aspirin	C		
			Calcium			
			(Unspecified) (+)			
			Vitami	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3834910-0Report Type:Expedited (15-DaCompany Report #WAES 01113294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Congestive	Professional						
	Condition Aggravated	Company Representative						

Date:12/04/01ISR Number: 3834913-6Report Type:Expedited (15-DaCompany Report #WAES 01101364
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Other	Abdominal Tenderness	Professional					PO	
	Cardiac Failure	Company Representative	Lasix (Furosemide)	C				
	Congestive							
	Dyspnoea							
	Oedema							

Date:12/04/01ISR Number: 3834914-8Report Type:Expedited (15-DaCompany Report #WAES 01112803
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Pulmonary Oedema	Professional					PO	
Initial or Prolonged		Company Representative	Prevacid	C				
			...	C				

Date:12/04/01ISR Number: 3834949-5Report Type:Expedited (15-DaCompany Report #WAES 01112949
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Study	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Health	Celebrex	C				
	Congestive	Professional	Galantamine	C				
	Cardiomegaly							
	Mitral Valve Incompetence							
	Pulmonary Hypertension							

Date:12/04/01ISR Number: 3834986-0Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Coumadin	C				

Date:12/04/01ISR Number: 3834988-4Report Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Lipitor	C				

Date:12/04/01ISR Number: 3834990-2Report Type:Expedited (15-DaCompany Report #WAES 01082092
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Epigastric Discomfort	Professional					MG/DAILY/PO	
	Faecal Occult Blood		Tab Ecotrin 325 Mg	SS		ORAL	325	
	Positive						MG/DAILY/PO	
	Gastric Ulcer		Ecotrin	C				
	Normochromic Normocytic Anaemia							

Date:12/04/01ISR Number: 3835008-8Report Type:Expedited (15-DaCompany Report #WAES 01090096
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Heart Rate Decreased	Professional					MG/DAILY/PO	
	Lethargy	Company						
	Nausea	Representative						
	Pulmonary Oedema							
	Swelling							

Date:12/04/01ISR Number: 3835141-0Report Type:Expedited (15-DaCompany Report #WAES 01112063
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Gram Stain Negative		Combivent	C				
	Gram Stain Positive		Lanoxin	C				
	Haematocrit Increased		Lasix (Furosemide)	C				

	Hypertension		Lotensin	C
	Joint Swelling		Aspirin	C
	Sputum Culture Positive		Calcium (+) Vitami	C
	Tachycardia		Potassium Chloride	C
	Tachypnoea		Verapamil	C
	Venous Pressure Jugular Increased			
	Weight Increased			
	Wheezing			
	White Blood Cell Count Increased			

Date:12/04/01ISR Number: 3835168-9Report Type:Expedited (15-DaCompany Report #WAES 01020940
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
Initial or Prolonged	Headache	Health Professional	Xalatan	C				
	Hypertension		Calcium	C				
	Ligament Sprain		Vitamin D	C				
	Mental Disorder		Vitamins	C				
	Myalgia							
	Neck Pain							
	Rotator Cuff Syndrome							
	Tachycardia							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3835179-3Report Type:Expedited (15-DaCompany Report #WAES 01100560
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diastolic Dysfunction	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
Initial or Prolonged	Electrocardiogram St	Health					PO	
	Segment Depression	Professional	Diocyclin	C				
	Heart Rate Increased							
	Hepatic Steatosis							
	Hyperhidrosis							
	Mitral Valve Disease							
	Pulmonary Valve							
	Incompetence							
	Supraventricular							
	Tachycardia							
	Ventricular Hypertrophy							

Date:12/04/01ISR Number: 3835185-9Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Albumin Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Calcium Abnormal	Professional					MG/DAILY/PO	
Disability	Blood Calcium Decreased	Company	Dilantin 400 Mg	SS			400 MG/DAILY	
	Blood Potassium Abnormal	Representative	Premarin	C				
	Blood Sodium Abnormal		Vicodin Es Tablets	C				
	Drug Interaction							
	Drug Level Above							
	Therapeutic							
	Drug Toxicity							
	Dysarthria							
	Gait Disturbance							
	Laboratory Test Abnormal							
	Mental Status Changes							
	Pco2 Abnormal							
	Protein Total Abnormal							

Date:12/04/01ISR Number: 3835187-2Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Cardiac Disorder	Professional Company Representative	Aspirin	C				

Date:12/04/01ISR Number: 3835274-9Report Type:Expedited (15-DaCompany Report #WAES 01115610
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Oedema Peripheral	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	43 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/01ISR Number: 3835275-0Report Type:Expedited (15-DaCompany Report #WAES 01115619
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Tachyarrhythmia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	30 DAY

Date:12/04/01ISR Number: 3838520-0Report Type:Expedited (15-DaCompany Report #WAES 01113458
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/05/01ISR Number: 3834215-8Report Type:Expedited (15-DaCompany Report #WAES 01106309
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Hospitalization - Initial or Prolonged	Haemorrhage Gastrointestinal Haemorrhage		Hytrin Celebrex	C C		ORAL		

Date:12/05/01ISR Number: 3834218-3Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY	
Hospitalization - Initial or Prolonged	Ventricular Fibrillation							

Date:12/05/01ISR Number: 3834224-9Report Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Arrest		Prednisone	SS				
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Cozaar	C		ORAL		
Disability	Haemorrhage		Bumex	C		ORAL		
Other	Exsanguination		Lanoxin	C		ORAL		
	Haemorrhage		Klor-Con	C		ORAL		
	Syncope		Premarin	C		ORAL		
			Lotensin	C		ORAL		

Date:12/05/01ISR Number: 3834229-8Report Type:Expedited (15-DaCompany Report #WAES 01114658
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Paxil	C				
			Verapamil Msd Lp	C				
			Humulin N	C				
			Metoprolol Tartrate	C				
			Digitek	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/01ISR Number: 3834235-3Report Type:Expedited (15-DaCompany Report #WAES 01120162
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			[Therapy Unspecified]	C				
			Aspirin	C				

Date:12/05/01ISR Number: 3834240-7Report Type:Expedited (15-DaCompany Report #WAES 01115610
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Pulmonary Congestion		Isosorbide Mononitrate	C				
			Molsidomine	C				
			Metoprolol	C				
			Aspirin	C				

Date:12/05/01ISR Number: 3834241-9Report Type:Expedited (15-DaCompany Report #WAES 01110337
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Condition Aggravated		Lasix (Furosemide)	C				
	Renal Failure		[Therapy Unspecified]	C				

Date:12/05/01ISR Number: 3834244-4Report Type:Expedited (15-DaCompany Report #WAES 01119854
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mitral Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Initial or Prolonged	Productive Cough		Vioxx	SS			ORAL
3 DAY							
	Tachycardia						
	Throat Tightness						

Date:12/05/01ISR Number: 3834871-4Report Type:Expedited (15-DaCompany Report #WAES 01081983
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25-50	
	Blood Pressure Increased	Professional					M/DAILY/PO	
	Cardiac Flutter	Other						
	Chest Discomfort							
	Chest Pain							
	Fatigue							
	Palpitations							

Date:12/05/01ISR Number: 3834891-XReport Type:Expedited (15-DaCompany Report #WAES 01113220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/01ISR Number: 3834892-1Report Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Cardiac Arrest	Professional					MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Company Representative	Bumex	C				
Disability	Haemorrhage		Cozaar	C				
Other	Exsanguination		Klor-Con	C				
	Haematochezia		Lanoxin	C				
	Hypotension		Lotensin	C				
	Syncope		Premarin	C				
			Prednisone	C				

Date:12/05/01ISR Number: 3835015-5Report Type:Expedited (15-DaCompany Report #WAES 01119854
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tachycardia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	

PO; 25

MG/DAILY PO 3 DAY

Date:12/05/01ISR Number: 3835017-9Report Type:Expedited (15-DaCompany Report #WAES 01113132
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dry Mouth	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Ear Discomfort							
	Ear Pain	Professional					PO	
	Epistaxis							
	Headache							
	Heart Rate Increased							

Tachycardia

Date:12/05/01ISR Number: 3835489-XReport Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Metabolic Acidosis		Vioxx	PS		ORAL	25MG PO QD	6 MON
Hospitalization - Initial or Prolonged	Nephritis Interstitial		Lithium	C				
	Renal Failure Acute		Zoloft	C				
			Atorvastatin	C				
			Synthroid	C				
			Aciphex	C				
			Topamax	C				
			Lasix	C				
			Potassium	C				
			Zithromax	C				

Date:12/06/01ISR Number: 3834994-XReport Type:Expedited (15-DaCompany Report #WAES 01120328
Age:34 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Activated Partial Thromboplastin Time Prolonged
Other	

		Blood Pressure Increased Cyst Haematocrit Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemoglobin Decreased		Coumadin	SS		
		Heart Rate Increased International Normalised Ratio Increased Metrorrhagia Oedema Pain Pelvic Mass Post Procedural Haemorrhage Prothrombin Time Prolonged Respiratory Rate Increased Seroma Tenderness Vaginal Haemorrhage Vaginal Laceration White Blood Cell Count Increased					

Date:12/06/01ISR Number: 3835000-3Report Type:Expedited (15-DaCompany Report #WAES 01102623
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Aspiration
Hospitalization - Initial or Prolonged	Asthenia Atrial Fibrillation Blood Chloride Decreased Blood Chloride Increased Blood Lactic Acid Increased Blood Potassium Increased Blood Sodium Decreased Blood Thyroid Stimulating Hormone Increased Body Temperature Increased Cardiac Disorder Cardiomegaly

Chest X-Ray Abnormal
Diabetes Mellitus
Dialysis
Electrocardiogram
Abnormal
Electrocardiogram T Wave
Inversion
Epistaxis
Faecal Occult Blood
Positive
Faecaloma
Gait Disturbance
Gallbladder Disorder
Haematocrit Decreased
Hypokalaemia
Hypoxia

		Lethargy					
		Lung Disorder					
		Lung Infiltration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Malaise		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Glucophage	SS		
		Myocardial Ischaemia		Rinatec	C		
		Pallor		Avapro	C		
		Pco2 Decreased		Flexeril	C		
		Pleural Effusion		Synthroid	C		
		Pneumonia Aspiration					
		Pulmonary Congestion					
		Renal Failure Acute					
		Sedation					
		Sinus Arrhythmia					
		Sinus Tachycardia					
		Staphylococcal Infection					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		White Blood Cell Count					
		Increased					

Date:12/06/01ISR Number: 3835001-5Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
Initial or Prolonged		Drug Toxicity		Dilantin	SS		
YR							
Disability		Dysarthria		Premarin	C		
		Gait Disturbance		Vicodin Es Tablets	C		ORAL
		Mental Impairment					
		Movement Disorder					
		Multiple Sclerosis					
		Nervous System Disorder					

Date:12/06/01ISR Number: 3835003-9Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Myocardial Infarction		Zantac	C				
Other			Avandia	C				

Date:12/06/01ISR Number: 3835004-0Report Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
	Chest Pain		Hyzaar	C		ORAL		
	Diverticulum Duodenal		Alprazolam	C		ORAL		
	Gastritis		Amlodipine Besylate	C		ORAL		
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/01ISR Number: 3835006-4Report Type:Expedited (15-DaCompany Report #WAES 01120117
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/01ISR Number: 3836203-4Report Type:Direct Company Report #
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Post Procedural Haemorrhage		Vioxx (50 Mg)	PS		ORAL	50MG 1 PO DAY	

Date:12/06/01ISR Number: 3836210-1Report Type:Direct Company Report #
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Post Procedural Haemorrhage		Vioxx 50 Mg	PS			50 MG ONE DOSE	

Date:12/06/01ISR Number: 3836211-3Report Type:Direct Company Report #
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Post Procedural Haemorrhage		Vioxx	PS			50 MGM ONE DOSE	

Intervention to
Prevent Permanent
Impairment/Damage

Date:12/06/01ISR Number: 3836311-8Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angiopathy		Vioxx (25mg.) -					
	Burning Sensation		(Merck + Co. Inc.)	PS	Merck And Co Inc	ORAL	25MG 1 PILL	
	Hypoaesthesia						PER DAY BY	
	Joint Swelling						MOUTH	
	Pain In Extremity		Procardia Xl	C				
	Rash		Valium	C				
			Zantac	C				
			Premarin	C				
			Vitamin E	C				

Date:12/06/01ISR Number: 3836570-1Report Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Other	Disturbance In Attention	Health
	Loss Of Employment	Professional
	Memory Impairment	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	

Date:12/06/01ISR Number: 3836572-5Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Ventricular Fibrillation	Company Representative						

Date:12/06/01ISR Number: 3836576-2Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Hospitalization - Initial or Prolonged	Hypoaesthesia Nausea Paraesthesia							

Date:12/06/01ISR Number: 3836945-0Report Type:Expedited (15-DaCompany Report #WAES 01117524
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:12/06/01ISR Number: 3836946-2Report Type:Expedited (15-DaCompany Report #WAES 01115179
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease Gastrointestinal	Foreign Other	Tab Vioxx (Rofecoxib)	PS			12.5 MG/DAILY	
	Haemorrhage		Calcium Carbonate	C				
			Cyanocobalamin	C				
			Mesalamine	C				
			Methotrexate	C				

Date:12/06/01ISR Number: 3837163-2Report Type:Expedited (15-DaCompany Report #EMADSS2001004548
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required	Dyspnoea Pneumonitis	Foreign Health Professional	Zydol (Tablet) (Tramadol Hydrochloride)	PS			DOSAGE VARIED FROM 50 MG - 100 MG DAILY	
Intervention to Prevent Permanent Impairment/Damage			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG, ORAL	
			Amlodipine (Amlodipine)	C				
			Bumetanide (Bumetanide)	C				
			Paracetamol					

(Paracetamol)	C
Dihydrocodeine (Dihydrocodeine)	C
Lactulose (Lactulose)	C
Simple Linctus (Simple Linctus)	C
Oramorph (Morphine Sulfate)	C
Nystatin (Nystatin)	C
Movicol (Movicol)	C
Metoclopramide (Metoclopramide)	C

Date:12/06/01ISR Number: 3837199-1Report Type:Expedited (15-DaCompany Report #WAES 01120328
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Adhesions	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Abdominal Pain	Professional					MG/DAILY/PO	
Other	Activated Partial Thromboplastin Time Prolonged	Company Representative	Coumadin	SS				
	Back Pain							
	Blood Potassium Decreased							
	Blood Pressure Systolic Increased							
	Gastrointestinal Disorder							
	Haematoma							
	Haemorrhage							
	Heart Rate Increased							
	Inflammation							
	International Normalised Ratio Increased							
	Oedema							
	Post Procedural Complication							
	Post Procedural Haemorrhage							
	Postoperative Adhesion							
	Prothrombin Time Prolonged							
	Respiratory Rate							

Increased
Seroma
Suprapubic Pain
Suture Rupture
Vaginal Haemorrhage
Wheezing
White Blood Cell Count
Increased

Date:12/06/01ISR Number: 3837350-3Report Type:Expedited (15-DaCompany Report #WAES 01118279
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Ulceration Mucosal Ulceration	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	4 DAY
Other		Professional						

Date:12/06/01ISR Number: 3837351-5Report Type:Expedited (15-DaCompany Report #WAES01117028
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choking Sensation Deep Vein Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	8 DAY
Other	Difficulty In Walking Dyspnoea		Estradiol Valerate	C				

Date:12/06/01ISR Number: 3837352-7Report Type:Expedited (15-DaCompany Report #WAES 01116085
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaphylactic Shock	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	1 DOSE /DAILY	14 DAY
			Carbamazepine	C				
			Clonazepam	C				
			Dihydroergotamine Mesylate	C				
			Phenobarbital	C				

Date:12/06/01ISR Number: 3839103-9Report Type:Expedited (15-DaCompany Report #WAES 01090519
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Wall Pain Dizziness	Consumer Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea Musculoskeletal Pain	Professional	Effexor	C				
			Salagen Tablets	C				
			Prednisone	C				

Date:12/06/01ISR Number: 3839105-2Report Type:Expedited (15-DaCompany Report #WAES 01106429
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Cerebral Ischaemia							
	Thinking Abnormal							

Date:12/06/01ISR Number: 3851952-XReport Type:Periodic Company Report #WAES 01103305
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
		Professional					/PO	
			V211-Blinded Therapy	SS				
			Climara	C				
			Elavil	C				
			Glucophage	C				
			Lipitor	C				
			Nasocort	C				
			Sectral	C				
			Synthroid	C				
			Allopurinol	C				
			Calcium	C				
			Glucosamine	C				
			Magnesium	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/01ISR Number: 3835628-0Report Type:Expedited (15-DaCompany Report #WAES 01103573
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc			

Date:12/07/01ISR Number: 3835632-2Report Type:Expedited (15-DaCompany Report #WAES 01118186
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Nimesulide	SS				
	Hyperhidrosis							

Date:12/07/01ISR Number: 3835635-8Report Type:Expedited (15-DaCompany Report #WAES 01115035
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL	58 DAY	
	Sudden Death		Prednisolone	C		ORAL		
			Lactulose	C		ORAL		
			Lofepramine Hydrochloride	C				
			Levothyroxine Sodium	C		ORAL		
			Lorazepam	C		ORAL		
			Acetaminophen	C				

Date:12/07/01ISR Number: 3835637-1Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	17 DAY	
			Atenolol	C				

Date:12/07/01ISR Number: 3835638-3Report Type:Expedited (15-DaCompany Report #WAES 01117026
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Oesophageal Haemorrhage		Felodipine	C		ORAL		
	Oesophageal Ulcer		Enoxaparin	C				

Date:12/07/01ISR Number: 3835640-1Report Type:Expedited (15-DaCompany Report #WAES 01114529
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diaphragmatic Paralysis							
	Dyspnoea							

Date:12/07/01ISR Number: 3835641-3Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Distress Syndrome		Vasotec	C		ORAL		
Appendix Disorder		Vasotec	C		ORAL		
Colitis		Vasotec	C				
Colonic Haemorrhage		Lipitor	C				
Colonic Polyp		Aspirin	C				
Diverticulum		Zebeta	C				
Fibrosis							
Gastrointestinal Disorder							
Gastrointestinal Gangrene							
Gastrointestinal Necrosis							
Ileitis							
Ileus Paralytic							
Large Intestinal Ulcer							
Large Intestine							
Perforation							
Megacolon							
Oedema							
Oliguria							
Purulence							
Retching							
Sepsis							
Skin Discolouration							
Small Intestinal							
Obstruction							
White Blood Cell Count							
Increased							

Date:12/07/01ISR Number: 3835643-7Report Type:Expedited (15-DaCompany Report #WAES 01110855
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/01ISR Number: 3835644-9Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS		ORAL		
	Photopsia		Catapres	C				
	Visual Disturbance		Lasix (Furosemide)	C				

Date:12/07/01ISR Number: 3835646-2Report Type:Expedited (15-DaCompany Report #WAES 01114487
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Csf White Blood Cell Count Positive		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/01ISR Number: 3835647-4Report Type:Expedited (15-DaCompany Report #WAES 01115183
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Nausea		Amiloride Hydrochloride And Furosemide	C		ORAL		
	Vomiting							

Date:12/07/01ISR Number: 3835648-6Report Type:Expedited (15-DaCompany Report #WAES 01115181
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Urticaria		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
			Albuterol	C		RESPIRATORY (INHALATION)		
			Metformin	C		ORAL		
			Clonazepam	C		ORAL		
			Latanoprost	C		OPHTHALMIC		

Date:12/07/01ISR Number: 3835650-4Report Type:Expedited (15-DaCompany Report #WAES 01115185
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
			Zocor	C		ORAL		

Date:12/07/01ISR Number: 3835652-8Report Type:Expedited (15-DaCompany Report #WAES 01115182
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL	250	DAY
			Atenolol	C		ORAL		
			Aspirin	C		ORAL		
			Cozaar	C		ORAL		
			Amlodipine	C		ORAL		

Date:12/07/01ISR Number: 3835653-XReport Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Systemic Lupus Erythematosus		Vioxx	PS	Merck & Co., Inc	ORAL	TOPICAL	
			Levothyroxine Sodium	C				
			Omeprazole	C				
			Ibuprofen	C				
			Hydroxychloroquine Sulfate	C				

Date:12/07/01ISR Number: 3835655-3Report Type:Expedited (15-DaCompany Report #WAES 01115184
Age:59 YR Gender:Female I/FU:I

Outcome	PT
Other	Change Of Bowel Habit
	Ileus Paralytic

Rectal Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/01ISR Number: 3835658-9Report Type:Expedited (15-DaCompany Report #WAES 01120286
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	10 WK	
Initial or Prolonged	Cardiac Failure		Diuretic					
Other	Oedema Peripheral		(Unspecified)	C				
	Ventricular Arrhythmia		[Therapy Unspecified]	C				

Date:12/07/01ISR Number: 3835659-0Report Type:Expedited (15-DaCompany Report #WAES 01120365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Cirrhosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/07/01ISR Number: 3835660-7Report Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
Hospitalization -								
Initial or Prolonged								

Date:12/07/01ISR Number: 3835662-0Report Type:Expedited (15-DaCompany Report #WAES 01125515
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Lactic Acidosis							
	Myocarditis							
	Renal Failure Acute							

Date:12/07/01ISR Number: 3835663-2Report Type:Expedited (15-DaCompany Report #WAES 01125524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/01ISR Number: 3835665-6Report Type:Expedited (15-DaCompany Report #WAES 01126008
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	63	DAY
			Spironolactone	C		ORAL		
			Clonidine	C		ORAL		
			Acetaminophen	C		ORAL		
			Cifenline Succinate	C		ORAL		

				Lacidipine	C		ORAL

Date:12/07/01ISR Number: 3835667-XReport Type:Expedited (15-DaCompany Report #WAES 01126517
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Dyspnoea		Glyburide	C		ORAL		

Date:12/07/01ISR Number: 3835668-1Report Type:Expedited (15-DaCompany Report #WAES 01128201
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
			Levothyroxine Sodium	C		ORAL		

Date:12/07/01ISR Number: 3836758-XReport Type:Expedited (15-DaCompany Report #WAES 01115195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
	Systemic Lupus Erythematosus	Health Professional Other						

Date:12/07/01ISR Number: 3836784-0Report Type:Expedited (15-DaCompany Report #WAES 01116082
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

		Tinnitus	Health			
PO	4 DAY					
			Professional	Celecoxib	C	
			Other	Heptaminol Hcl	C	

Date:12/07/01ISR Number: 3836789-XReport Type:Expedited (15-DaCompany Report #WAES 01113727
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 ML/DAILY						
Initial or Prolonged		Other				
PO	241 DAY					
			Aspirin	C		
			Budesonide	C		
			Prednisolone	C		

Date:12/07/01ISR Number: 3836790-6Report Type:Expedited (15-DaCompany Report #WAES 01113498
Age:50 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Macular Oedema	Foreign	Vioxx (Rofecoxib)	PS		
Initial or Prolonged		Health				
		Professional				
		Other				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/01ISR Number: 3836804-3Report Type:Expedited (15-DaCompany Report #WAES 01117280
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Hypertension	Consumer					PO	65 DAY
		Other	Amlodipine Besylate	C				
			Aspirin	C				
			Atorvastatin Calcium	C				
			Furosemide	C				
			Insulin, Biphasic Isophane[Injection]	C				
			Isosorbide Mononitrate	C				
			Ramipril	C				

Date:12/07/01ISR Number: 3837135-8Report Type:Expedited (15-DaCompany Report #WAES 01092315
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Duodenal Ulcer	Health					MG/DAILY/PO	
	Gastrooesophageal Reflux	Professional	Isoptin Sr 120 Mg	SS		ORAL	120	
	Disease						MG/DAILY/PO	
	Hiatus Hernia		Mavik 2 Mg	SS		ORAL	2 MG/DAILY/PO	
	Inflammation		Celexa	C				
			Zocor	C				
			Vitamin E	C				

Date:12/07/01ISR Number: 3837156-5Report Type:Expedited (15-DaCompany Report #WAES 01082094
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Faeces Discoloured	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Fall	Professional				
MG/DAILY/PO						
	Gastric Ulcer		Cardura	C		
	Gastrointestinal		Coumadin	C		
	Haemorrhage		Hyzaar	C		
	Haematocrit Decreased		Lipitor	C		
	Haemoglobin Decreased		Aspirin	C		
	Melaena		Atenolol	C		
	Syncope					

Date:12/07/01ISR Number: 3837645-3Report Type:Expedited (15-DaCompany Report #WAES 01105565
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arrhythmia	Foreign	Tab Vioxx			
	Atrial Fibrillation	Health	(Rofecoxib)	PS		ORAL
25 MG DAILY						
	Diarrhoea	Professional				
PO 2 DAY						
			Mg Oxide	C		
			Atorvastatin Calcium	C		
			Certoparin Sodium	C		
			Escin	C		
			Flecainide Acetate	C		
			Liotrix	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/01ISR Number: 3837739-2Report Type:Expedited (15-DaCompany Report #WAES 01096073
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastritis Erosive	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	9 DAY
		Professional Company Representative	Buflomedil Hcl	C				
			Furosemide/Spironolactone	C				
		Other	Gliclazide	C				
			Lorazepam	C				
			Molsidomine	C				
			Ranitidine Hcl	C				

Date:12/07/01ISR Number: 3837744-6Report Type:Expedited (15-DaCompany Report #WAES 01115187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Inflammation Large Intestinal Ulcer Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	223 DAY
			Zocor	C				
			Allopurinol	C				
			Bendroflumethiazide	C				
			Isosorbide Mononitrate	C				
			Metoprolol	C				
			Nicorandil	C				

Date:12/07/01ISR Number: 3838190-1Report Type:Expedited (15-DaCompany Report #WAES 01114421
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure Congestive	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

	Heart Rate Irregular	Digitek	C
	Oedema Peripheral	Ecotrin	C
	Wheezing	Imdur	C
		Lasix (Furosemide)	C
		Norvasc	C
		Premarin	C
		Prinivil	C
		Synthroid	C
		Ultram	C
		Xanax	C
		Zantac	C
		Zocor	C
		Zoloft	C
		Atenolol	C
		Doxepin	C
		Meclizine	C
		Trazodone	C

Date:12/07/01ISR Number: 3838217-7Report Type:Expedited (15-DaCompany Report #WAES 01114270
Age: Gender:Female I/FU:I

Outcome	PT
Congenital Anomaly	Complications Of Maternal
Other	Exposure To Therapeutic

	Drugs Congenital Central Nervous System Anomaly Foetal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intestinal Obstruction	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO;	
	Limb Malformation Pregnancy Ultrasound Antenatal Screen Abnormal						25 MG/DAILY/PO	

Date:12/07/01ISR Number: 3839021-6Report Type:Expedited (15-DaCompany Report #WAES 01082089
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Aricept	C				
	Haematocrit Decreased		Asacol	C				
	Haemoglobin Decreased		Prevacid	C				

Date:12/07/01ISR Number: 3839022-8Report Type:Expedited (15-DaCompany Report #WAES 01100956
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Hemiparesis	Professional						
Disability		Company Representative						

Date:12/07/01ISR Number: 3839310-5Report Type:Expedited (15-DaCompany Report #WAES 01100341
Age:79 YR Gender:Male I/FU:F

Outcome PT

Life-Threatening Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Lower Aortic Atherosclerosis Colonic Polyp Confusional State Dilatation Ventricular Diverticulum Eructation Flatulence Frequent Bowel Movements Gastric Hyperplasia Gastritis Gastrointestinal Haemorrhage Haematochezia Haematocrit Decreased Haemoglobin Decreased Haemorrhage Haemorrhoids Hepatic Steatosis Liver Disorder Melaena Mitral Valve Incompetence Portal Hypertensive Gastropathy Rectal Haemorrhage Renal Cyst

	Tricuspid Valve Incompetence						
	Varices Oesophageal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Hypokinesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,
		Health					PO
		Professional	Claritin	C			
			Lipitor	C			
			Motrin	C			
			Plaquenil	C			
			Synthroid	C			
			Tagamet	C			
			Zocor	C			
			Aspirin	C			
			Sulindac	C			

Date:12/10/01ISR Number: 3836589-0Report Type:Expedited (15-DaCompany Report #WAES 01111885
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Initial or Prolonged	Hyperplasia		Isordil	C			
	Cardiac Failure		Inderal	C			
	Congestive		Lasix (Furosemide)	C			
	Coma		Aldactone	C			
	Fluid Overload		Glyburide	C			
	Hepatic Encephalopathy		Avandia	C			
	Hypotension						
	Obstructive Uropathy						
	Renal Failure						
	Respiratory Failure						

Date:12/10/01ISR Number: 3836591-9Report Type:Expedited (15-DaCompany Report #WAES 01111158
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL	512 DAY

Initial or Prolonged	Hypoaesthesia		Flonase	C		
RESPIRATORY						
Other	Nuclear Magnetic					
(INHALATION)						
	Resonance Imaging					
	Abnormal					
	Sinus Bradycardia					
	Transient Ischaemic					
	Attack					
	Vertigo					

Date:12/10/01ISR Number: 3836592-0Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Aldosterone		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Increased		Valsartan	SS		
	Blood Creatinine					
	Increased					
	Nephropathy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/01ISR Number: 3836593-2Report Type:Expedited (15-DaCompany Report #WAES 01120336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Intestinal Perforation		Coumadin	C				
			[Therapy Unspecified]	C				

Date:12/10/01ISR Number: 3836595-6Report Type:Expedited (15-DaCompany Report #WAES 01120249
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/01ISR Number: 3836596-8Report Type:Expedited (15-DaCompany Report #WAES 01127001
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Suicidal Ideation		Zopiclone	C		ORAL		
			Estradiol Valerate	C		ORAL		

Date:12/10/01ISR Number: 3836598-1Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
			Sulfasalazine	C				

Date:12/10/01ISR Number: 3836603-2Report Type:Expedited (15-DaCompany Report #WAES 01127801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc			

Date:12/10/01ISR Number: 3836604-4Report Type:Expedited (15-DaCompany Report #WAES 01127803
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
			Furosemide Sodium	C				
			Insulin	C				
			Vasotec	C				

Date:12/10/01ISR Number: 3836608-1Report Type:Expedited (15-DaCompany Report #WAES 01125004
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	4	WK
	Urticaria		Estrogens, Conjugated	C				
			Buprenorphine Hydrochloride	C				
			Clopidrogel	C				
			Diazepam	C				

			Atorvastatin	C		
			Acetaminophen And Propoxyphene Hydrochloride	C		
			Fexofenadine	C		
			Nitroglycerin	C		
			Albuterol	C		

Date:12/10/01ISR Number: 3836612-3Report Type:Expedited (15-DaCompany Report #WAES 01120354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/01ISR Number: 3836614-7Report Type:Expedited (15-DaCompany Report #WAES 01126014
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Ramipril	C		ORAL		
			Digoxin	C		ORAL		
			Furosemide	C		ORAL		
			Fluindione	C		ORAL		

Date:12/10/01ISR Number: 3836615-9Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Disorder Sarcoma		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Corticosteroids (Unspecified)	C		ORAL		

Date:12/10/01ISR Number: 3836617-2Report Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8	WK
	Drug Ineffective		Vioxx	SS		ORAL	1	WK
			Motrin	C				
			Lotensin	C				
			Lipitor	C				
			Paxil	C				
			Norvasc	C				
			Atenolol	C				
			Zyrtec	C				
			Ambien	C				
			Prevacid	C				
			Vicodin Tablets	C		ORAL		
			Plavix	C				

Date:12/10/01ISR Number: 3836619-6Report Type:Expedited (15-DaCompany Report #WAES 01125533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/01ISR Number: 3836621-4Report Type:Expedited (15-DaCompany Report #WAES 01128758
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
99 DAY								
Initial or Prolonged								

Date:12/10/01ISR Number: 3836622-6Report Type:Expedited (15-DaCompany Report #WAES 01128502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS		ORAL		
	Drug Ineffective							
	Medication Error							
	Multiple Sclerosis							
	Oesophageal Varices							
	Haemorrhage							
	Overdose							
	Spinal Cord Injury							

Date:12/10/01ISR Number: 3836623-8Report Type:Expedited (15-DaCompany Report #WAES 01128508
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
8 DAY								
Initial or Prolonged			Celecoxib	C		ORAL		
			Celecoxib	C		ORAL		

Date:12/10/01ISR Number: 3836624-XReport Type:Expedited (15-DaCompany Report #WAES 01125010
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Acetaminophen And Codeine Phosphate	C		ORAL		
Other			Tramadol	C		ORAL		

Date:12/10/01ISR Number: 3853021-1Report Type:Periodic Company Report #WAES 01052491
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO; 50 MG/BID/PO	
	Paraesthesia	Professional						
		Other						
			Buspar	C				
			Premarin	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3836981-4Report Type:Expedited (15-DaCompany Report #WAES 01105069
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Macroglossia		Vioxx	SS		ORAL	9	MON
			Pilocarpine	C		OPHTHALMIC		
			Timoptic	C		OPHTHALMIC		
			Furosemide	C		ORAL		
			Ranitidine	C		ORAL		
			Proscar	C		ORAL		
			Tramadol	C		ORAL		

Date:12/11/01ISR Number: 3836984-XReport Type:Expedited (15-DaCompany Report #WAES 01111164
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Blood Pressure Systolic		Detrol	C				
Other	Increased		Lanoxin	C				
	Bundle Branch Block Right		Lasix (Furosemide)	C				
	Cardiac Failure		Iron (Unspecified)	C				
	Congestive		Nitroglycerin	C		SUBLINGUAL		
	Condition Aggravated		Equate	C				
	Dyspnoea							
	Erythema							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Heart Rate Increased							
	Oedema Peripheral							
	Orthopnoea							
	Pruritus							
	Sinus Arrhythmia							
	Vasodilatation							

Date:12/11/01ISR Number: 3836985-1Report Type:Expedited (15-DaCompany Report #WAES 01120649
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged			Axid	C				
			Synthroid	C				
			Prednisone	C				
			Methotrexate	C				
			Folic Acid	C				
			Aspirin	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Vitamins (Unspecified)	C				
			Calcium (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3836986-3Report Type:Expedited (15-DaCompany Report #WAES 01115559
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nuclear Magnetic Resonance Imaging Abnormal Transient Ischaemic Attack Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
			Estrogens (Unspecified)	C				

Date:12/11/01ISR Number: 3836988-7Report Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Embolism Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:12/11/01ISR Number: 3836990-5Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/01ISR Number: 3836994-2Report Type:Expedited (15-DaCompany Report #WAES 01120919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Estrogens (Unspecified)	C				

Date:12/11/01ISR Number: 3837004-3Report Type:Expedited (15-DaCompany Report #WAES 01115660
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Autoantibody Positive		Diclofenac	SS		ORAL		
	Thrombocytopenia		Hydrochlorothiazide And Irbesartan	C		ORAL		
			Estradiol Valerate And Estriol And Levonorgestrel	C		ORAL		

Date:12/11/01ISR Number: 3837005-5Report Type:Expedited (15-DaCompany Report #WAES 01120620
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy							
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3837006-7Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Embolism		Vioxx	PS		ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/11/01ISR Number: 3837007-9Report Type:Expedited (15-DaCompany Report #WAES 01125551
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Methotrexate	C				

Date:12/11/01ISR Number: 3837009-2Report Type:Expedited (15-DaCompany Report #WAES 01123426
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc			
	Feeling Abnormal							
	Sinus Bradycardia							
	Tunnel Vision							

Date:12/11/01ISR Number: 3837013-4Report Type:Expedited (15-DaCompany Report #WAES 01127804
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc			
Hospitalization - Initial or Prolonged								

Date:12/11/01ISR Number: 3837014-6Report Type:Expedited (15-DaCompany Report #WAES 01128755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemarthrosis		Vioxx	PS	Merck & Co., Inc	ORAL		2 WK
Initial or Prolonged	Haemorrhage		Warfarin	C				
	International Normalised Ratio Increased		Celecoxib	C				

Date:12/11/01ISR Number: 3838239-6Report Type:Direct Company Report #
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
Hospitalization -	Congestive							
Initial or Prolonged	Fluid Retention		Norvasc	C				
			Prozac	C				
			Levoxyl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3838251-7Report Type:Expedited (15-DaCompany Report #WAES 01110337
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Renal Failure		Lasix (Furosemide)	C				

Date:12/11/01ISR Number: 3838253-0Report Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Cardiac Arrest	Professional					MG/DAILY/PO	
Hospitalization -	Duodenal Ulcer	Company	Prednisone Unk	SS			50 MG / DAILY	
Initial or Prolonged	Haemorrhage	Representative	Bumex	C				
Disability	Haematochezia		Cozaar	C				
Other	Syncope		Klor-Con	C				
			Lanoxin	C				
			Lotensin	C				
			Premarin	C				

Date:12/11/01ISR Number: 3838257-8Report Type:Expedited (15-DaCompany Report #WAES 01102263
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Compartment Syndrome	Professional					MG/DAILY/PO	
Initial or Prolonged	Femoral Artery Occlusion	Company	Combivent	C				
	Hypoaesthesia	Representative	Flexeril	C				
	Pain In Extremity		Albuterol	C				
	Post Procedural Complication							

Pulse Absent
Rhabdomyolysis
Shock

Date:12/11/01ISR Number: 3838308-0Report Type:Expedited (15-DaCompany Report #WAES 01082091
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Bacteraemia
	Cholecystitis Acute
	Convulsion
	Duodenal Ulcer
	Encephalopathy
	Fatigue
	Fungal Infection
	Gangrene
	Gastric Ulcer
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haematoma
	Mental Impairment
	Multi-Organ Failure
	Neoplasm Malignant

	Oesophageal Ulcer						
	Pneumonia Aspiration						
	Respiratory Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rhonchi	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE
		Professional	Toradol 30 Mg	SS			30 MG/Q6H/INJ
			Prevacid	C			

Date:12/11/01ISR Number: 3838309-2Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Calcium Decreased	Health	Vioxx 25 Mg	PS		ORAL	25
Initial or Prolonged	Drug Interaction	Professional					MG/DAILY/PO
Disability	Drug Level Increased	Company	Dilantin 400 Mg	SS			400 MG/DAILY
	Drug Toxicity	Representative	Premarin	C			
	Dysarthria		Vicodin Es	C		ORAL	
	Gait Disturbance						
	Hypogammaglobulinaemia						
	Mental Status Changes						
	Movement Disorder						

Date:12/11/01ISR Number: 3838323-7Report Type:Expedited (15-DaCompany Report #WAES 01114658
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Haemorrhage	Consumer	Vioxx 25 Mg	PS		ORAL	25
Hospitalization -							MG/DAILY/PO
Initial or Prolonged			Digitek	C			
			Humulin N	C			
			Paxil	C			
			Verapamil	C	Msd Lp		
			Metoprolol Tartrate	C			

Date:12/11/01ISR Number: 3838328-6Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complex Regional Pain	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Syndrome	Health						
	Condition Aggravated	Professional	Prinzide	C				
	Muscular Weakness		Chondroitin (+)					
	Oedema Peripheral		Glucosamine	C				
	Pain		Herbs	C				
	Paraesthesia							
	Post Procedural Complication							

Date:12/11/01ISR Number: 3838366-3Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Infarction	Professional					PO	
Other	Coronary Artery Disease		Avandia	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3838405-XReport Type:Expedited (15-DaCompany Report #2014962
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Disorder	Health Professional	Oxycontin Cr (Oxycodone Hydrochloride)	PS		ORAL	560 MG Q12H	
Other	Blood Testosterone Decreased							
	Electroencephalogram						PO	1 YR
	Abnormal		Neurontin (Gabapentin)	SS		ORAL	2100 MG HS PO	
	Grand Mal Convulsion							
	Hypothyroidism		Vioxx (Rofecoxib)	SS		ORAL	PO	
	Oedema Peripheral		Celebrex (Celecoxib)	SS		ORAL	PO	
	Pain In Extremity		Dalmane (Flurazepam)	C				
	Polycythaemia Vera		Folic Acid	C				
			Prozac (Fluoxetine)	C				
			Vistaril (Hydroxizine Pamoate)	C				
			Synthroid (Levothyroxine)	C				
			Lasix (Furosemide)	C				
			Aspirin (Acetylsalicylic Acid)	C				
			Multivitamin	C				
			Colace (Docusate)	C				

Date:12/11/01ISR Number: 3838730-2Report Type:Expedited (15-DaCompany Report #WAES 01120117
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pulmonary Embolism							

Date:12/11/01ISR Number: 3838732-6Report Type:Expedited (15-DaCompany Report #WAES 01102623
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Acidosis
Hospitalization - Initial or Prolonged	Aspiration
	Asthenia
	Atrial Fibrillation
	Blood Albumin Abnormal
	Blood Chloride Abnormal
	Blood Creatine Phosphokinase Abnormal
	Blood Culture Positive
	Blood Glucose Abnormal
	Blood Lactic Acid Abnormal
	Blood Sodium Abnormal
	Blood Thyroid Stimulating Hormone Increased
	Cardiomegaly
	Dialysis
	Dilatation Atrial
	Electrocardiogram St-T Segment Abnormal
	Electrocardiogram T Wave Inversion

	Epistaxis						
	Faecal Occult Blood						
	Faecaloma	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gait Disturbance	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Gallbladder Disorder	Health					
	Haematocrit Decreased	Professional	Glucophage Unk	SS			1000 MG/BID/UNK
	Hypokalaemia						
	Hypoxia		Avapro	C			
	Lethargy		Flexeril	C			
	Lung Infiltration		Rinatec	C			
	Malaise		Synthroid	C			
	Mitral Valve Incompetence						
	Myocardial Ischaemia						
	Pco2 Abnormal						
	Platelet Count Abnormal						
	Pleural Effusion						
	Pneumonia Aspiration						
	Pulmonary Oedema						
	Pulmonary Vascular Disorder						
	Renal Failure Acute						
	Renal Tubular Necrosis						
	Scan Abdomen Abnormal						
	Scoliosis						
	Sinus Tachycardia						
	Somnolence						
	Staphylococcal Infection						
	Tricuspid Valve Incompetence						
	Vascular Calcification						
	Ventricular Extrasystoles						
	Ventricular Hypokinesia						
	White Blood Cell Count Increased						

Date:12/11/01ISR Number: 3838735-1Report Type:Expedited (15-DaCompany Report #WAES 01120162
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Other		Professional				
MG/DAILY/PO						
		Company Representative	Aspirin	C		

Date:12/11/01ISR Number: 3838737-5Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Atenolol	C		

Date:12/11/01ISR Number: 3838792-2Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:72 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure Congestive	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Myocardial Infarction	Health Professional	Tab Placebo	SS		ORAL	PO	297 DAY
		Insulin, Biphasic Isophane [Injection]	C				
		Insulin, Biphasic Isophane [Injection]	C				

Date:12/11/01ISR Number: 3838907-6Report Type:Expedited (15-DaCompany Report #WAES 01118186
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Gastric Ulcer Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Hyperhidrosis	Professional					PO	15 DAY
			Tab Nimesulide	SS				

Date:12/11/01ISR Number: 3838909-XReport Type:Expedited (15-DaCompany Report #WAES 01117026
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Oesophageal Haemorrhage	Foreign Company	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oesophageal Ulcer	Representative					PO	1 DAY
	Upper Gastrointestinal Haemorrhage		Enoxaparin	C				
			Felodipine	C				

Date:12/11/01ISR Number: 3838976-3Report Type:Expedited (15-DaCompany Report #WAES 01106309
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal	Company	Celebrex	C				
	Haemorrhage	Representative	Hytrin	C				

Date:12/11/01ISR Number: 3838986-6Report Type:Expedited (15-DaCompany Report #WAES 01115035
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Tab Vioxx					
	Emotional Distress	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Pain							
PO								58 DAY
	Sudden Death		Acetaminophen	C				
			Lactulose	C				
			Levothyroxine Na	C				
			Lofepramine Hcl	C				
			Lorazepam	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3838987-8Report Type:Expedited (15-DaCompany Report #WAES 01103573
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glomerulonephritis	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:12/11/01ISR Number: 3838988-XReport Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	21 DAY
	Chest Pain							
	Diverticulum Duodenal		Hyzaar	C				
	Gastroduodenitis		Alprazolam	C				
	Melaena		Amlodipine Besylate	C				

Date:12/11/01ISR Number: 3838989-1Report Type:Expedited (15-DaCompany Report #WAES 01038527
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Carpal Tunnel Syndrome	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Decreased Activity							
	Disorientation							
	Fluid Retention							
	Median Nerve Lesion							
	Oedema							
	Pain In Extremity							
	Pulmonary Oedema							
	Swelling							
	Tendonitis							
	Weight Increased							

Date:12/11/01ISR Number: 3839003-4Report Type:Expedited (15-DaCompany Report #WAES 01119854
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Rupture Nasopharyngeal Disorder Obstruction Tachycardia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	PO 1 DAY

Date:12/11/01ISR Number: 3839004-6Report Type:Expedited (15-DaCompany Report #WAES 01115610
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Oedema Peripheral Pulmonary Congestion	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 WK
		Other	Aspirin	C				
			Isosorbide Mononitrate	C				
			Metoprolol	C				
			Mosidomine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3839007-1Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Cardiac Failure Congestive	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	S5 MG/DAILY	297 DAY
Initial or Prolonged Disability	Myocardial Infarction	Health Professional	Placebo (Unspecified)	SS		ORAL	297 DAY	
			Insulin, Biphasic Isophane [Injection]	C				

Date:12/11/01ISR Number: 3839019-8Report Type:Expedited (15-DaCompany Report #WAES 01038527
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bedridden Carpal Tunnel Syndrome Condition Aggravated Disorientation Fluid Retention Neuropathy Oedema Oedema Peripheral Pain In Extremity Pulmonary Oedema Respiratory Disorder Swelling Tendonitis Weight Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:12/11/01ISR Number: 3839046-0Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Cardiac Failure Congestive	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	

Initial or Prolonged	Myocardial Infarction	Health				
PO 297 DAY						
Disability		Professional	Tab Placebo (Unspecified)	SS		ORAL
PO 297 DAY						
			Insulin	C		

Date:12/11/01ISR Number: 3839047-2Report Type:Expedited (15-DaCompany Report #WAES 01113466
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dysphonia	Foreign	Tab Vioxx			
Initial or Prolonged	Hemiparesis	Other	(Rofecoxib)	PS		
25 MG DAILY						
	Hypertension		Prinivil	C		
			Aspirin	C		
			Atorvastatin Calcium	C		
			Estrogens, Conjugated (+)			
			Medroxyprogest	C		
			Methotrexate	C		
			Omeprazole Magnesium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/01ISR Number: 3839048-4Report Type:Expedited (15-DaCompany Report #WAES 01113494
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
Hospitalization -	Congestive	Health	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged		Professional						
PO							8	DAY
Disability			Fosamax	C				
			Allopurinol	C				
			Amlodipine Besylate	C				
			Calcitriol	C				
			Digoxin	C				
			Fosinopril Sodium	C				
			Insulin Lispro, Biphasic Isophane [Injec	C				
			Metformin Hcl	C				
			Pravastatin Na	C				
			Warfarin	C				

Date:12/12/01ISR Number: 3837664-7Report Type:Expedited (15-DaCompany Report #WAES 01120364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Vioxx	SS		ORAL		

Date:12/12/01ISR Number: 3837667-2Report Type:Expedited (15-DaCompany Report #WAES 01120577
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Embolism		Premarin	C				
	Fatigue		Cytomel	C				
	Hemiparesis		Fosamax	C				
	Hemiplegia		Potassium (Unspecified)	C				
	Urinary Tract Infection							

Date:12/12/01ISR Number: 3837669-6Report Type:Expedited (15-DaCompany Report #WAES 01103289
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/12/01ISR Number: 3837670-2Report Type:Expedited (15-DaCompany Report #WAES 01120553
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/12/01ISR Number: 3838927-1Report Type:Direct Company Report #
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Urinary Tract Infection		Vioxx	PS			AS NEEDED FOR PAIN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/01ISR Number: 3838996-9Report Type:Direct Company Report #
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 50 Mg	PS			1 DAILY	
Hospitalization -			Tenormin	C				
Initial or Prolonged			Monopril	C				
Required			Clonidine Tts-2	C				
Intervention to			Aspirin	C				
Prevent Permanent			Lipitor	C				
Impairment/Damage								

Date:12/12/01ISR Number: 3839014-9Report Type:Direct Company Report #
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum		Vioxx (25mg)	PS		ORAL	25MG PO Q	
Initial or Prolonged	Gastritis						DAY/ TOOK	
Required	Gastrointestinal						PRIOR TO	
Intervention to	Haemorrhage						ADMISSION	
Prevent Permanent	Gastrointestinal Necrosis		Metoclopramide	C				
Impairment/Damage			Carafate	C				
			Doxepin	C				
			Zestril	C				
			Ntg	C				

Date:12/12/01ISR Number: 3839468-8Report Type:Expedited (15-DaCompany Report #001-0981-M0109332
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Atorvastatin					
	Joint Swelling		(Atorvastatin)	PS		ORAL	10 MG	
	Oedema Peripheral							
							(DAILY), PER	

Poor Peripheral
ORAL
Circulation (Rofecoxib) SS ORAL
25 MG

(DAILY), PER

ORAL
(Acetylsalicylic
Acid) C
(Tocopherol) C
(Metoprolol) C
(Zinc) C
(Selenium) C
(Serenoa Repens) C
(Ascorbic Acid) C
(Ubicarenone) C

Date:12/12/01ISR Number: 3839959-XReport Type:Expedited (15-DaCompany Report #046-0945-M0100062
Age: Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Other

PT
Blood Alkaline
Phosphatase Increased
Cardiac Failure
Chest Pain
Depressed Level Of
Consciousness
Fluid Retention
Infected Skin Ulcer

		Liver Function Test Abnormal Metabolic Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute Skin Ulcer Weight Increased	Foreign Consumer	Neurontin Tablets(Gabapentin)	PS		ORAL
2.4 GM (DAILY), PER ORAL							
				Furix(Furosemide)	SS		ORAL
40 MG (DAILY), PER ORAL							
				Spironolakton(Spironolactone)	SS		ORAL
50 MG (DAILY), PER ORAL							
				Renitec (Enalapril Maleate)	SS		ORAL
20 MG (DAILY), PER ORAL							
				Vioxx(Rofecoxib)	SS		ORAL
25 MG (DAILY), PER ORAL							
				Flagyl(Metronidazole)	SS		ORAL
800 MG (DAILY), PER ORAL							
				Heracillin(Flucloxacillin Sodium)	SS		ORAL
PER ORAL							

Arava(Leflunomide)	SS		ORAL

20 MG

(DAILY), PER

ORAL

Folic Acid, Calcium Phosphate	C
Tocopheryl Acetate	C
Paracetamol	C
Prednisolone	C
Morphine	C
Cisapride	C
Cetirizine	C
Morphine Sulfate	C
Lansoprazole	C
Zolpidem Tartrate	C
Loperamide	C
Calcium Carbonate	C
Ipratropium Bromide, Salbutamol Sulfate	C

Date:12/12/01ISR Number: 3840002-7Report Type:Expedited (15-DaCompany Report #PHBS2001NO12060
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Insufficiency Nephropathy Pyrexia Red Blood Cell Sedimentation Rate Increased	Foreign Other	Diovan (Valsartan) Vioxx (Rofecoxib)	PS SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/01ISR Number: 3840246-4Report Type:Expedited (15-DaCompany Report #WAES 01120919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Pulmonary Embolism	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Estrogens (Unspecified)	C				

Date:12/13/01ISR Number: 3838572-8Report Type:Expedited (15-DaCompany Report #WAES 01120970
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive Pulmonary Oedema							

Date:12/13/01ISR Number: 3838575-3Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Wheezing		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			[Therapy Unspecified]	C				

Date:12/13/01ISR Number: 3838581-9Report Type:Expedited (15-DaCompany Report #WAES 01110189
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspepsia		Premarin	C				
Initial or Prolonged	Viral Pericarditis							

Date:12/13/01ISR Number: 3838584-4Report Type:Expedited (15-DaCompany Report #WAES 01120917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS		ORAL		

Date:12/13/01ISR Number: 3838589-3Report Type:Expedited (15-DaCompany Report #WAES 01123436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intra-Abdominal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/01ISR Number: 3838590-XReport Type:Expedited (15-DaCompany Report #WAES 01125539
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Interaction		Diclofenac Sodium	SS		RECTAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/01ISR Number: 3838592-3Report Type:Expedited (15-DaCompany Report #WAES 01129109
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Hypertension		Vasotec	SS		ORAL		
	Left Ventricular Failure							

Date:12/13/01ISR Number: 3838596-0Report Type:Expedited (15-DaCompany Report #WAES 01112151
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL	228	DAY
Initial or Prolonged	Hemianopia		Coumadin	C				
Disability	Precerebral Artery		Actos	C				
Other	Occlusion		Fluoxetine	C				
	Retinal Artery Thrombosis		Furosemide	C				
			Toprol Xl Tablets	C				
			Allopurinol	C				
			Lanoxin	C				
			Cozaar	C				

Date:12/13/01ISR Number: 3838597-2Report Type:Expedited (15-DaCompany Report #WAES 01129111
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY
	Dyspnoea		Acetaminophen And					
	Stridor		Codeine Phosphate	SS		ORAL	17	DAY
			Flexeril	SS		ORAL	17	DAY
			Captopril	C		ORAL		
			Chlorthalidone	C		ORAL		

Date:12/13/01ISR Number: 3838598-4Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Drug Level Above		Dilantin	SS				YR
Disability	Therapeutic		Premarin	C				
	Drug Toxicity		Vicodin Es Tablets	C		ORAL		
	Dysarthria							
	Gait Disturbance							
	Movement Disorder							
	Pco2 Decreased							

Date:12/13/01ISR Number: 3838599-6Report Type:Expedited (15-DaCompany Report #WAES 01126518
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Respiratory Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Throat Tightness							
Initial or Prolonged	Tongue Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/01ISR Number: 3838602-3Report Type:Expedited (15-DaCompany Report #WAES 01129110
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Hospitalization - Initial or Prolonged	Epistaxis Haemoglobin Decreased International Normalised Ratio Increased		Acenocoumarol	SS		ORAL		

Date:12/13/01ISR Number: 3838603-5Report Type:Expedited (15-DaCompany Report #WAES 01128122
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coombs Positive Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY

Date:12/13/01ISR Number: 3838604-7Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Hospitalization - Initial or Prolonged	Congestive Weight Increased		Calcium (Unspecified) Paxil	C C				

Date:12/13/01ISR Number: 3838607-2Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON
Life-Threatening Hospitalization -	Congestive							

Initial or Prolonged

Date:12/13/01ISR Number: 3838610-2Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -	Congestive		Vioxx	SS		ORAL	4	WK
Initial or Prolonged	Dyspepsia		Vitamins					
	Dyspnoea		(Unspecified)	C				
	Weight Increased		Aspirin	C				

Date:12/13/01ISR Number: 3838611-4Report Type:Expedited (15-DaCompany Report #WAES 01120364
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/01ISR Number: 3840111-2Report Type:Direct Company Report #
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx Merck & Co.	PS	Merck & Co	ORAL	1 X DAILY	
Initial or Prolonged	Coronary Artery Occlusion						ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea Exertional							

Date:12/14/01ISR Number: 3839185-4Report Type:Expedited (15-DaCompany Report #WAES 01101988
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Pain		Buspar	C				
	Coma		Zoloft	C				
	Convulsion							
	Electrocardiogram Abnormal							
	Fatigue							
	Feeling Hot							
	Hyperhidrosis							
	Lethargy							
	Pco2 Decreased							
	Platelet Count Increased							
	Po2 Decreased							
	Simple Partial Seizures							
	White Blood Cell Count Increased							

Date:12/14/01ISR Number: 3839187-8Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	

	Cerebrovascular Accident	Allopurinol	C
	Visual Disturbance		
	Visual Field Defect		

Date:12/14/01ISR Number: 3839192-1Report Type:Expedited (15-DaCompany Report #WAES 01120967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/01ISR Number: 3839432-9Report Type:Expedited (15-DaCompany Report #046-0945-M0100062
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased
Other	Blood Creatinine Increased
	Blood Potassium Increased
	Cardiac Failure
	Chest Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Depressed Level Of Consciousness Infected Skin Ulcer Liver Function Test Abnormal Oedema Pain Weight Increased	Foreign Consumer	Neurontin Tablets (Gabapentin)	PS		ORAL
2.4 GM (DAILY), PER ORAL							
				Furix (Furosemide)	SS		ORAL
40 MG (DAILY), PER ORAL							
				Spironolakton (Spironolactone)	SS		ORAL
50 MG (DAILY), PER ORAL							
				Renitec (Enalapril Maleate)	SS		ORAL
20 MG (DAILY), PER ORAL							
				Vioxx (Rofecoxib)	SS		ORAL
25 MG (DAILY), PER ORAL							
				Flagyl (Metronidazole)	SS		ORAL
800 MG (DAILY), PER ORAL							
				Heracillin (Flucloxacillin			

				Sodium)	SS		ORAL
PER ORAL							
				Arava (Leflunomide)	SS		ORAL
20 MG							
(DAILY), PER							
ORAL							
				Folic Acid, Calcium Phosphate	C		
				Tocopheryl Acetate	C		
				Paracetamol	C		
				Prednisolone	C		
				Morphine	C		
				Cisapride	C		
				Cetirizine	C		
				Morphine Sulfate	C		
				Lansoprazole	C		
				Zolpidem Tartrate	C		
				Loperamide	C		
				Calcium Carbonate	C		
				Ipratropium Bromide, Salbutamol Sulfate	C		

Date:12/14/01ISR Number: 3840478-5Report Type:Expedited (15-DaCompany Report #PHRM2001FR02730
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactic Shock	Foreign Health Professional	Diergo Spray (Dihydroergotamine Mesilate) Spray	PS		
Other						
RESPIRATORY						
(INHALATION) INHALATION		Other				
			Vioxx (Rofecoxib)	SS		ORAL
1 DF, QD,						
ORAL						
			Combantrin (Pyrantel Embonate Tablet)	SS		ORAL
6 DF PER DAY,						
ORAL						

				Rivotril	C		
				Gardenal	C		
				Tegretol	C		

Date:12/17/01ISR Number: 3839521-9Report Type:Expedited (15-DaCompany Report #WAES 01125576
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/01ISR Number: 3839534-7Report Type:Expedited (15-DaCompany Report #WAES 01127801
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia Large Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc			

Date:12/17/01ISR Number: 3839541-4Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
Initial or Prolonged	Pancreatitis Acute		Vioxx	SS		ORAL	10	DAY
			Dipyrone	C		ORAL		
			Captopril	C		ORAL		
			Aceclofenac	C				
			Furosemide	C		ORAL		

Date:12/17/01ISR Number: 3839542-6Report Type:Expedited (15-DaCompany Report #WAES 01116057
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Aortic Valve Stenosis Cardiac Failure Congestive Dyspnoea Exacerbated Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/17/01ISR Number: 3839544-XReport Type:Expedited (15-DaCompany Report #WAES 01110863
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
			Lamictal	C		
			Lamictal	C		
			Keppra	C		
			Celexa	C		
			Allegra	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/01ISR Number: 3839545-1Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -	Infarction		Zantac	C				
Initial or Prolonged	Coronary Artery Occlusion		Avandia	C				
Other								

Date:12/17/01ISR Number: 3839547-5Report Type:Expedited (15-DaCompany Report #WAES 01118542
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Silent Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS		ORAL	17	DAY
Initial or Prolonged			Calcium Carbonate And Etidronate Sodium	C				

Date:12/17/01ISR Number: 3839549-9Report Type:Expedited (15-DaCompany Report #WAES 01115547
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liposarcoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Cyst		Bromazepam	C				
YR								
			Fenoterol Hydrobromide And Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)	YR							
			Citalopram Hydrobromide	C				
YR								
			Vasotec	C		ORAL		
YR								

			Amlodipine Besylate	C			
YR							
			Tramadol Hydrochloride	C			ORAL
YR							
			Allopurinol	C			
YR							

Date:12/17/01ISR Number: 3839550-5Report Type:Expedited (15-DaCompany Report #WAES 01125035
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	13 DAY	
	Dyspnoea		Carbomer	C			OPHTHALMIC	
	Oedema Peripheral		Temazepam	C				
			Levothyroxine Sodium	C				
			Timoptic	C			OPHTHALMIC	
			Benzyl Alcohol And Benzyl Benzoate And Benzyl Cinnamate And Lanolin And Zinc Oxide	C			TOPICAL	
			Acetaminophen And Dihydrocodeine Bitartrate	C				
			Sertraline	C				
			Methotrexate	C				
			Folic Acid	C				
			Dihydrocodeine	C				
			Amiloride					

			Hydrochloride And Furosemide	C		
			Sulfasalazine	C		

Date:12/17/01ISR Number: 3839554-2Report Type:Expedited (15-DaCompany Report #WAES 01126038
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged			Clopidogrel Bisulfate	C		ORAL		

Date:12/17/01ISR Number: 3839555-4Report Type:Expedited (15-DaCompany Report #WAES 01120434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nervous System Disorder							
	Pain							
	Shock							

Date:12/17/01ISR Number: 3839557-8Report Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Hyponatraemia		Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C		ORAL	5	DAY
	Metabolic Acidosis							
	Oral Intake Reduced							
	Pleural Effusion							
	Pulmonary Congestion		Dipyrone	C		ORAL	3	DAY
	Renal Failure Acute		Fentanyl	C		TOPICAL		
	Urinary Tract Infection		Valerian	C		ORAL	3	DAY

	Vomiting			Lactulose	C
1 DAY					
				Certoparin Sodium	C
SUBCUTANEOUS		6	DAY		
				Furosemide And Penbutolol Sulfate	C
1 DAY					
				Cerivastatin Sodium	C
7 DAY					
				Fosamax	C
1 DAY					
				Methylprednisolone	C
2 DAY					
				Methylprednisolone	C
1 DAY					
				Nitroxoline	C
2 DAY					
				Nitroxoline	C
1 DAY					
				Furosemide And Penbutolol Sulfate	C
6 DAY					
				Tramadol Hydrochloride	C
1 DAY					
				Dimenhydrinate	C
INTRAVENOUS		1	DAY		
				Piritramide	C
INTRAVENOUS					
1 DAY					
				Diclofenac	C
RECTAL		2	DAY		
				Diuretic (Unspecified)	C
				Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C

	ORAL
	ORAL
	ORAL
	ORAL
	ORAL
	ORAL
	ORAL
	ORAL
	ORAL
	DRIP

Date:12/17/01ISR Number: 3839558-XReport Type:Expedited (15-DaCompany Report #WAES 01120569
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Dyazide	C				
	Haematemesis							
	Haemorrhagic Stroke							

Date:12/17/01ISR Number: 3839561-XReport Type:Expedited (15-DaCompany Report #WAES 01125028
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Date:12/17/01ISR Number: 3839564-5Report Type:Expedited (15-DaCompany Report #WAES 01127804
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc			
Hospitalization - Initial or Prolonged			[Composition Unspecified]	C				

Date:12/17/01ISR Number: 3839567-0Report Type:Expedited (15-DaCompany Report #WAES 01113727
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	241	DAY
			Aspirin	C		ORAL		
			Prednisolone	C		ORAL		
			Budesonide	C				
			RESPIRATORY (INHALATION)					

Date:12/17/01ISR Number: 3839572-4Report Type:Expedited (15-DaCompany Report #WAES 01110508
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/01ISR Number: 3839576-1Report Type:Expedited (15-DaCompany Report #WAES 01126008
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		63 DAY
Initial or Prolonged	Coronary Artery Stenosis		Spironolactone	C		ORAL		
			Clonidine	C		ORAL		
			Acetaminophen	C		ORAL		
			Cifenline Succinate	C		ORAL		
			Lacidipine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/01ISR Number: 3839579-7Report Type:Expedited (15-DaCompany Report #WAES 01120813
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/01ISR Number: 3839919-9Report Type:Direct Company Report #
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx 25 Mg Qd					
Hospitalization -	Cardio-Respiratory Arrest		(Merck)	PS	Merck	ORAL	25 MG QD PO	
Initial or Prolonged	Duodenal Ulcer		Asa 325 Mg Qd	SS		ORAL	325 MG QD PO	
Required Intervention to Prevent Permanent Impairment/Damage	Haemorrhage		Kcl	C				
			Tegretol	C				
			Nortriptyline	C				

Date:12/17/01ISR Number: 3840106-9Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Prerenal Failure		Zestril	PS		ORAL	20MG PO QD	
Initial or Prolonged			Vioxx	SS		ORAL	2.5 PO QD	

Date:12/17/01ISR Number: 3840582-1Report Type:Expedited (15-DaCompany Report #WAES 01115559
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Foreign	Tab Vioxx					
Initial or Prolonged	Somnolence	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

		Transient Ischaemic	Professional				
PO	1 YR						
		Attack		Estrogens			
		Visual Disturbance		(Unspecified)	C		

Date:12/17/01ISR Number: 3840594-8Report Type:Expedited (15-DaCompany Report #WAES 01111164
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Bundle Branch Block Right	Professional					MG/DAILY/PO	
Other	Cardiac Failure	Other	Detrol	C				
	Congestive		Equate	C				
	Carotid Bruit		Lanoxin	C				
	Chest Pain		Lasix (Furosemide)	C				
	Gastritis		Iron	C				
	Heart Rate Increased		Nitroglycerin	C				
	Hypertension							
	Pruritus							
	Rash							
	Upper Gastrointestinal							
	Haemorrhage							
	Vasodilatation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/01ISR Number: 3840595-XReport Type:Expedited (15-DaCompany Report #WAES 00095116
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Tab Vioxx					
Hospitalization -	Cardiac Failure	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	15 DAY
Initial or Prolonged	Congestive		Diclofenac Na	SS		ORAL		
	Duodenal Ulcer		Atenolol	C				
	Haemorrhage		Digoxin	C				
	Large Intestine		Furosemide	C				
	Perforation		Warfarin	C				
	Left Ventricular Failure							
	Myocardial Infarction							

Date:12/17/01ISR Number: 3840596-1Report Type:Expedited (15-DaCompany Report #WAES 01115181
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urticaria	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5MG/DAILY	6 DAY
			Albuterol	C				
			Beclomethasone Dipropionate	C				
			Clonazepam	C				
			Latanoprost	C				
			Metformin	C				

Date:12/17/01ISR Number: 3840597-3Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS				
	Nephropathy		Valsartan	SS				
	Renal Disorder							

Date:12/17/01ISR Number: 3840599-7Report Type:Expedited (15-DaCompany Report #WAES 01115183
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Foreign	Tab Vioxx					
	Nausea	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	4 DAY
	Vomiting		Amiloride Hydrochloride (+) Furosemide	C				

Date:12/17/01ISR Number: 3840600-0Report Type:Expedited (15-DaCompany Report #WAES 01115184
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Barium Enema Abnormal	Foreign	Tab Vioxx					
	Change Of Bowel Habit	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Clonic Convulsion							
	Gastrointestinal Disorder							
	Rectal Haemorrhage							
	X-Ray Gastrointestinal Tract Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/01ISR Number: 3840601-2Report Type:Expedited (15-DaCompany Report #WAES 01125515
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Failure	Foreign	Tab Vioxx					
	Lactic Acidosis	Other	(Rofecoxib)	PS		ORAL	25 MG	2 DAY
	Myocarditis							
	Renal Failure Acute							

Date:12/17/01ISR Number: 3840602-4Report Type:Expedited (15-DaCompany Report #WAES 01126008
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	63 DAY
			Acetaminophen	C				
			Cifenline Succinate	C				
			Clonidine	C				
			Lecidipine	C				
			Spironolactone	C				

Date:12/17/01ISR Number: 3840603-6Report Type:Expedited (15-DaCompany Report #WAES 01128201
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Weight Increased	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/BID	6 DAY
			Levothyroxine Na	C				

Date:12/17/01ISR Number: 3840604-8Report Type:Expedited (15-DaCompany Report #WAES 01127001
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression	Foreign	Tab Vioxx					

	Suicidal Ideation	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY 1 WK						
			Estradiol Valerate	C		
			Zopiclone	C		

Date:12/17/01ISR Number: 3840612-7Report Type:Expedited (15-DaCompany Report #WAES 01128508
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pulmonary Oedema	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY 8 DAY						
Initial or Prolonged		Health Professional Other	Celecoxib	C		

Date:12/17/01ISR Number: 3840614-0Report Type:Expedited (15-DaCompany Report #WAES 01128502
Age: Gender:Male I/FU:I

Outcome	PT
Other	Condition Aggravated
	Dizziness
	Drug Ineffective
	Multiple Sclerosis
	Oesophageal Varices
	Haemorrhage

	Overdose Spinal Cord Injury						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/BID
		Consumer Other					

Date:12/17/01ISR Number: 3840616-4Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Sarcoma	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID
Initial or Prolonged		Health Professional	Corticosteroids (Unspecified)	C			
		Other	Methotrexate	C			

Date:12/17/01ISR Number: 3840617-6Report Type:Expedited (15-DaCompany Report #WAES 01125004
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaphylactic Shock	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY
Initial or Prolonged	Urticaria	Consumer	Acetaminophen/Propoxyphene Hydrochloride	C			
		Other	Albuterol	C			
			Atorvastatin	C			
			Buprenorphine Hcl	C			
			Clopidogrel	C			
			Diazepam	C			
			Estrogens, Conjugated	C			
			Fexofenadine	C			
			Nitroglycerin	C			

Date:12/17/01ISR Number: 3840619-XReport Type:Expedited (15-DaCompany Report #WAES 01126014
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	8 DAY
			Digoxin	C				
			Fluindione	C				
			Furosemide	C				
			Ramipril	C				

Date:12/17/01ISR Number: 3840620-6Report Type:Expedited (15-DaCompany Report #WAES 01120354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive Cardiomyopathy	Company Representative						

Date:12/17/01ISR Number: 3840657-7Report Type:Expedited (15-DaCompany Report #WAES 01125533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:12/17/01ISR Number: 3840658-9Report Type:Expedited (15-DaCompany Report #WAES 01128758
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	99 DAY

Date:12/17/01ISR Number: 3840664-4Report Type:Expedited (15-DaCompany Report #WAES 01115185
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	12 DAY
			Zocor	C				

Date:12/17/01ISR Number: 3840666-8Report Type:Expedited (15-DaCompany Report #WAES 01125524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:12/17/01ISR Number: 3840667-XReport Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	4	DAY
Initial or Prolonged		Professional						

Date:12/17/01ISR Number: 3840669-3Report Type:Expedited (15-DaCompany Report #WAES 01127801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Foreign	Tab Vioxx					
	Perforation	Health	(Rofecoxib)	PS				
		Professional						

Date:12/17/01ISR Number: 3840670-XReport Type:Expedited (15-DaCompany Report #WAES 01115182
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain In Extremity	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG/BID	250 DAY
			Cozaar	C				
			Amlodipine	C				
			Aspirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/01ISR Number: 3840692-9Report Type:Expedited (15-DaCompany Report #WAES 01115010
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Tab Vioxx					
Other		Other	(Rofecoxib)	PS		ORAL	12.5	

MG/DAILY, PO

Date:12/17/01ISR Number: 3840746-7Report Type:Expedited (15-DaCompany Report #WAES 01111885
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Coma	Company	Aldactone	C				
	Hepatic Encephalopathy	Representative	Avandia	C				
	Hypotension		Inderal	C				
	Obstructive Uropathy		Isordil	C				
	Renal Failure		Lasix (Furosemide)	C				
	Respiratory Failure		Glyburide	C				
	Urinary Retention							

Date:12/17/01ISR Number: 3840749-2Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	1) 12.5	
	Hypertension						MG/DAILY/PO;	
	Visual Disturbance						2) 25	
							MG/DAILY/PO	
			Catapres	C				
			Lasix (Furosemide)	C				

Date:12/17/01ISR Number: 3840757-1Report Type:Expedited (15-DaCompany Report #WAES 01090315
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Distension
	Anxiety
	Arthralgia
	Condition Aggravated
	Confusional State
	Depression
	Diarrhoea
	Dizziness
	Dysarthria
	Dyspnoea
	Fatigue
	Feeling Abnormal
	Gastrointestinal Disorder
	Gastrointestinal Pain
	Lyme Disease
	Myalgia
	Nausea
	Pruritus
	Skin Exfoliation
	Speech Disorder
	Suicidal Ideation
	Urinary Tract Infection

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Health Professional	Cylert	C				
	Ditropan	C				
	Nexium	C				
	Aspirin	C				

Date:12/17/01ISR Number: 3840777-7Report Type:Expedited (15-DaCompany Report #WAES 01111158
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder	Health	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Cerebrovascular Accident	Professional						
Other	Headache	Other	Flonase	C				
	Hypoaesthesia							
	Infarction							
	Sinus Bradycardia							
	Transient Ischaemic Attack							
	Vertigo							

Date:12/17/01ISR Number: 3840781-9Report Type:Expedited (15-DaCompany Report #WAES 01114529
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma	Consumer	Tab Vioxx	PS		ORAL	PO	
	Diaphragmatic Paralysis							
	Difficulty In Walking							
	Dyspnoea							

Date:12/17/01ISR Number: 3840782-0Report Type:Expedited (15-DaCompany Report #WAES 01120286
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased	Health	Vioxx	PS		ORAL	DAILY/PO	10 WK
Initial or Prolonged	Cardiac Failure	Professional	Diuretic	C				
Other	Decreased Activity							
	Oedema Peripheral							
	Ventricular Arrhythmia							

Date:12/17/01ISR Number: 3840789-3Report Type:Expedited (15-DaCompany Report #WAES 01120649
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel Syndrome	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Initial or Prolonged								
			Axid	C				
			Synthroid	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Folic Acid	C				
			Methotrexate	C				

			Prednisone	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:12/17/01ISR Number: 3840795-9Report Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Drug Ineffective						50 MG/DAILY/PO	1 WK
			Ambien	C				
			Lipitor	C				
			Lotensin	C				
			Motrin	C				
			Norvasc	C				
			Paxil	C				
			Plavix	C				
			Prevacid	C				
			Vicodin Tablets	C				
			Zyrtec	C				
			Atenolol	C				

Date:12/17/01ISR Number: 3840858-8Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Lower
Disability	Acute Respiratory Distress Syndrome
	Appendix Disorder
	Blood Pressure Systolic Decreased
	Colitis

Colonic Haemorrhage
Diarrhoea
Diverticulum
Ileal Ulcer
Ileitis
Ileus Paralytic
Large Intestinal Ulcer
Large Intestine
Perforation
Necrotising Colitis
Paralysis
Pseudopolyposis
Retching
Septic Shock
Skin Discolouration
Small Intestinal
Obstruction
Splenic Rupture
White Blood Cell Count
Increased
X-Ray Gastrointestinal

Tract Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Vasotec	C				
			Zebeta	C				
			Aspirin	C				

Date:12/17/01ISR Number: 3840863-1Report Type:Expedited (15-DaCompany Report #WAES 01120249
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/17/01ISR Number: 3840889-8Report Type:Expedited (15-DaCompany Report #WAES 01126517
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea Dyspnoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	15 DAY
			Glyburide	C				

Date:12/17/01ISR Number: 3840894-1Report Type:Expedited (15-DaCompany Report #WAES 01127803
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS			
25 MG			Vasotec	C			
			Furosemide Sodium	C			
			Insulin	C			

Date:12/17/01ISR Number: 3840904-1Report Type:Expedited (15-DaCompany Report #WAES 01125010
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Other	Haemorrhage	Health Professional Other	Acetaminophen/Codeine Phosphate	C				
			Tramadol	C				

Date:12/17/01ISR Number: 3840906-5Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Systemic Lupus Erythematosus	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Hydroxychloroquineso4	C				
			Ibuprofen	C				

				Levothyroxine Na	C		
				Omeprazole	C		

Date:12/17/01ISR Number: 3840908-9Report Type:Expedited (15-DaCompany Report #WAES 01105069
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	10 DAY
	Tongue Disorder	Health	Proscar	C				
	Tongue Oedema	Professional	Timoptic	C				
		Other	Furosemide	C				
			Pilocarpine	C				
			Ranitidine	C				
			Tramadol	C				

Date:12/17/01ISR Number: 3840915-6Report Type:Expedited (15-DaCompany Report #WAES 01055030
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bite	Foreign	Tab Vioxx					
	Tongue Oedema	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional						
PO								10 DAY
		Company	Tab Proscar					
		Representative	(Finasteride)	SS		ORAL	5 MG/AM PO	
			Timoptic	C				
			Furosemide	C				
			Pilocarpine	C				
			Ranitidine	C				
			Tramadol	C				

Date:12/17/01ISR Number: 3840916-8Report Type:Expedited (15-DaCompany Report #WAES 00095116
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Failure	Foreign	Tab Vioxx			
Hospitalization -	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Initial or Prolonged	Congestive	Professional				
PO 15 DAY						
	Duodenal Ulcer	Company	Diclofenac Na	SS		ORAL
PO						
	Haemorrhage	Representative	Atenolol	C		
	Large Intestine		Digoxin	C		
	Perforation		Furosemide	C		
	Left Ventricular Failure		Warfarin	C		
	Myocardial Infarction					

Date:12/17/01ISR Number: 3840934-XReport Type:Expedited (15-DaCompany Report #WAES 01110855
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Meningitis	Other	Tab Vioxx	PS		ORAL
PO						

Date:12/17/01ISR Number: 3841104-1Report Type:Expedited (15-DaCompany Report #WAES 01120336
Age: Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional	Coumadin	C				
	Iatrogenic Injury	Company	Therapy Unspecified	C				
	Intestinal Perforation	Representative						

Date:12/17/01ISR Number: 3841105-3Report Type:Expedited (15-DaCompany Report #WAES 01120365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Cirrhosis	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:12/17/01ISR Number: 3841106-5Report Type:Expedited (15-DaCompany Report #WAES 01114487
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Csf White Blood Cell	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Count Positive	Professional						

Date:12/17/01ISR Number: 3841108-9Report Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Embolism	Professional	Therapy Unspecified	C				
	Haemorrhage	Company Representative						

Date:12/17/01ISR Number: 3841109-0Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Grand Mal Convulsion		Sulfasalazine	C				

Date:12/17/01ISR Number: 3841110-7Report Type:Expedited (15-DaCompany Report #WAES 01091935
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/17/01ISR Number: 3841642-1Report Type:Direct Company Report #
Age:55 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage
	Haematochezia
	Hypotension

Loss Of Consciousness

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck	ORAL	25MG QD ORAL	
			Zanaflex	C				
			Vicodin	C				
			Robaxin	C				
			Nephro-Vit	C				
			Ees Elixir	C				

Date:12/17/01ISR Number: 3841722-0Report Type:Direct Company Report #
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous		Vioxx (Rofecoxib)	PS		ORAL	25MG QD PO	
	Rash Macular							

Date:12/17/01ISR Number: 3843618-7Report Type:Expedited (15-DaCompany Report #01081230
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Enbrel 25 Mg	PS			SUBCUTANEOUS	25 MG, BIW,
Initial or Prolonged	Operative Haemorrhage	Health					SUBCUTANEOUS	
		Professional	Rofecoxib	SS				
			Prednisone	C				
			Fluoxetine	C				
			Methotrexate	C				

Date:12/18/01ISR Number: 3840424-4Report Type:Expedited (15-DaCompany Report #WAES 01115523
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Blister		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Livedo Reticularis	Vioxx	SS	ORAL
	Rheumatoid Factor	Digitoxin	C	ORAL
	Positive	Torsemide	C	ORAL
		Enalapril Maleate	C	ORAL
		Sotalol Hydrochloride	C	ORAL
		Omeprazole	C	ORAL

Date:12/18/01ISR Number: 3840426-8Report Type:Expedited (15-DaCompany Report #WAES 01128509
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/18/01ISR Number: 3840767-4Report Type:Direct Company Report #
Age:53 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Cardiovascular Disorder
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Coagulopathy
	Confusional State

		Memory Impairment					
		Paralysis					
		Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx (Merck)	PS	Merck	
1@ DAY	14 MON						
		Attack					

Date:12/18/01ISR Number: 3841603-2Report Type:Direct Company Report #
Age:83 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chills		Aspirin Geneva Pharm	PS	Geneva Pharm	ORAL
326 MG DAILY							
Initial or Prolonged		Haemorrhage					
PO							
Other		Pyrexia		Vioxx	SS		ORAL
25 MG DAILY							
Required		Rectal Haemorrhage					
PO							
Intervention to				Prevacid	C		
Prevent Permanent				Mercatopurine	C		
Impairment/Damage				Lopressor	C		
				Glucotrol	I		

Date:12/18/01ISR Number: 3841914-0Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Carpal Tunnel Syndrome	Consumer	Vioxx 25 Mg	PS		ORAL
25							
		Condition Aggravated	Health				
MG/DAILY/PO							
		Muscular Weakness	Professional	Prinzide	C		
		Oedema Peripheral		Therapy Unspecified	C		
		Paraesthesia		Chondroitin (+)			
				Glucosamine	C		
				Herbs (Unspecified)	C		

Date:12/19/01ISR Number: 3841212-5Report Type:Expedited (15-DaCompany Report #WAES 01118279
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mouth Ulceration	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Mucosal Ulceration	Professional	Tramadol Hydrochloride	C		ORAL	5	DAY
Other								

Date:12/19/01ISR Number: 3841213-7Report Type:Expedited (15-DaCompany Report #WAES 01127265
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Initial or Prolonged	Diarrhoea	Professional	Ranitidine Hydrochloride	SS				
			Felodipine And Metoprolol Succinate	C				
			Estriol	C				
			Furosemide Sodium	C				
			Propoxyphene Napsylate	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3841214-9Report Type:Expedited (15-DaCompany Report #WAES 01126027
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Confusional State	Professional	Vioxx	SS		ORAL		
	Hallucination		Calcium Dobesilate	C		ORAL		
			Trimebutine	C		ORAL		

Date:12/19/01ISR Number: 3841216-2Report Type:Expedited (15-DaCompany Report #WAES 01115547
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liposarcoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Cyst Ruptured	Professional	Bromazepam	C				YR
	Renal Disorder		Fenoterol Hydrobromide And Ipratropium Bromide	C		RESPIRATORY		(INHALATION) YR
			Citalopram Hydrobromide	C				YR
			Vasotec	C		ORAL		YR
			Amlodipine Besylate	C				YR
			Tramadol Hydrochloride	C		ORAL		YR
			Allopurinol	C				YR

Date:12/19/01ISR Number: 3841219-8Report Type:Expedited (15-DaCompany Report #WAES 01120620
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiomyopathy Hypertension Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/19/01ISR Number: 3841576-2Report Type:Expedited (15-DaCompany Report #WAES 01125577
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/19/01ISR Number: 3841578-6Report Type:Expedited (15-DaCompany Report #WAES 01126530
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Generalised Exanthematous Pustulosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/19/01ISR Number: 3841582-8Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Sarcoma		Vioxx	PS	Merck & Co., Inc	ORAL	61	DAY
Initial or Prolonged			Vioxx	SS		ORAL	163	DAY
			Vioxx	SS		ORAL		

				Methotrexate	C		ORAL
				Prednisone	C		ORAL

Date:12/19/01ISR Number: 3841583-XReport Type:Expedited (15-DaCompany Report #WAES 01125533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/19/01ISR Number: 3842131-0Report Type:Expedited (15-DaCompany Report #PHFR2001GB03402
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Diclofenac					
Life-Threatening	Duodenal Ulcer	Health	Sodium(Diclofenac					
Hospitalization -	Haemorrhage	Professional	Sodium)	PS		ORAL		
ORAL								
Initial or Prolonged	Intestinal Perforation	Other	Rofecoxib(Rofecoxib)	SS				
12.5 MG/DAY								
	Left Ventricular Failure		Atenolol	C				
	Myocardial Infarction		Frusemide	C				
			Warfarin (Warfarin)	C				
			Digoxin	C				

Date:12/19/01ISR Number: 3842215-7Report Type:Expedited (15-DaCompany Report #WAES 01128122
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia Haemolytic	Foreign	Tab Vioxx					
Initial or Prolonged	Autoimmune		(Rofecoxib)	PS		ORAL		
12.5								
	Coombs Direct Test							
MG/DAILY; PO 8 DAY								
	Positive							
	Coombs Indirect Test							
	Positive							

Date:12/19/01ISR Number: 3842220-0Report Type:Expedited (15-DaCompany Report #WAES 01129110
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Hospitalization -	Epistaxis		(Rofecoxib)	PS		ORAL	PO	22 DAY
Initial or Prolonged			Tab Acenocoumarol	SS		ORAL	12 MG/WKY; PO	

Date:12/19/01ISR Number: 3842221-2Report Type:Expedited (15-DaCompany Report #WAES 01129111
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Foreign	Tab Vioxx					
	Dyspnoea		(Rofecoxib)	PS		ORAL	12.5	
	Stridor						MG/DAILY; PO	17 DAY
			Tab Acetaminophen/Codeine Phosphate	SS		ORAL	4 TABLET;	
							DAILY; PO	17 DAY
			Tab Flexeril (Cyclobenzaprine Hcl)	SS		ORAL	10	
							MG/DAILY;PO	17 DAY

				Captopril	C		
				Chlorthalidone	C		

Date:12/19/01ISR Number: 3842229-7Report Type:Expedited (15-DaCompany Report #WAES 01126518
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Respiratory Distress	Foreign	Tab Vioxx					
Hospitalization -	Throat Tightness	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Tongue Oedema							
PO								

Date:12/19/01ISR Number: 3842231-5Report Type:Expedited (15-DaCompany Report #WAES 01123436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hysterectomy	Foreign	Tab Vioxx					
Initial or Prolonged	Intra-Abdominal	Health	(Rofecoxib)	PS		ORAL		
PO								
	Haemorrhage	Professional						

Date:12/19/01ISR Number: 3842234-0Report Type:Expedited (15-DaCompany Report #WAES 01123426
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Foreign	Tab Vioxx					
Initial or Prolonged	Feeling Abnormal	Health	(Rofecoxib)	PS				
	Sinus Bradycardia	Professional						
	Tunnel Vision							

Date:12/19/01ISR Number: 3842242-XReport Type:Expedited (15-DaCompany Report #WAES 01128755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign	Tab Vioxx				
	Haemorrhage	Consumer	(Rofecoxib)	PS			ORAL
12.5 MG DAILY							
	International Normalised						
PO 2 WK							
	Ratio Increased		Celecoxib	C			
			Warfarin	C			

Date:12/19/01ISR Number: 3842250-9Report Type:Expedited (15-DaCompany Report #WAES 01129109
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Tab Vioxx					
	Hypertension	Other	(Rofecoxib)	PS		ORAL		
25 MG/DAILY	8 DAY							
	Left Ventricular Failure		Vasotec (Enalapril					
			Maleate)	SS		ORAL		
20 MG/DAILY								

Date:12/19/01ISR Number: 3842337-0Report Type:Expedited (15-DaCompany Report #WAES 01120917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx Unk	PS		ORAL		
25 MG/UNK/PO;								
	Transient Ischaemic	Professional						
50 MG/UNK/PO								
	Attack	Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3842338-2Report Type:Expedited (15-DaCompany Report #WAES 01120970
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Pulmonary Oedema	Company Representative						

Date:12/19/01ISR Number: 3842344-8Report Type:Expedited (15-DaCompany Report #WAES 01110189
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Dyspepsia	Health					MG/DAILY/PO	
Initial or Prolonged	Viral Infection	Professional	Premarin	C				

Date:12/19/01ISR Number: 3842351-5Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Congestive	Professional					PO	
Initial or Prolonged	Weight Increased		Paxil	C				
			Calcium (Unspecified)	C				

Date:12/19/01ISR Number: 3842352-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01264
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Pancytopenia	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional	Flexeril	C		
		Company	Pepcid	C		
		Representative				

Date:12/19/01ISR Number: 3842404-1Report Type:Expedited (15-DaCompany Report #WAES 01125539
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx			
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL
PO						
Initial or Prolonged		Professional	Supp Diclofenac Na	SS		
RECTAL RECT						

Date:12/19/01ISR Number: 3842409-0Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Wheezing	Foreign	Tab Vioxx			
		Health	(Rofecoxib)	PS		ORAL
PRN						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3842417-XReport Type:Expedited (15-DaCompany Report #WAES 01115660
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Antibody Test Positive Thrombocytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	
			Tab Diclofenac	SS		ORAL	100 MG, PO	
			Estradiol Valerate (+) Estriol (+) Levon Hydrochlorothiazide (+) Irbesartan	C C				

Date:12/19/01ISR Number: 3842419-3Report Type:Expedited (15-DaCompany Report #WAES 01125551
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign Health Professional	Tab Vioxx (Rofecoxib) 25 Mg/Daily	PS		ORAL	25 MG/DAILY, PO	
			Methotrexate	C				

Date:12/19/01ISR Number: 3842560-5Report Type:Expedited (15-DaCompany Report #049-0981-M0100914
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukopenia Thrombocytopenia	Foreign Health Professional	Atorvastatin (Atorvastatin)	PS		ORAL	20 MG Other (DAILY), PER Required ORAL	

Intervention to Prevent Permanent Impairment/Damage			Azathioprine (Azathioprine)	SS			ORAL
100 MG (DAILY), PER ORAL							
			Rofecoxib (Rofecoxib)	SS			ORAL
25 MG (DAILY), PER ORAL							
			Ranitidine Hydrochlroide	C			
			Heparin-Fraction, Sodium Salt	C			
			Ranitidine Hydrochloride	C			

Date:12/19/01ISR Number: 3842571-XReport Type:Expedited (15-DaCompany Report #WAES 01103289
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3842577-0Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Thrombosis	Professional Company Representative						

Date:12/19/01ISR Number: 3842593-9Report Type:Expedited (15-DaCompany Report #WAES 01120620
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Congestive Cardiomyopathy	Professional Company Representative						
	Hypertension							

Date:12/19/01ISR Number: 3842647-7Report Type:Expedited (15-DaCompany Report #2001-07-0249
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Consumer	Nasonex (Mometasone Furoate) Nasal Suspension	PS			50 MCG QD*	NASAL SPRAY
	Retinal Haemorrhage	Health Professional						
			Vioxx (Rofecoxib) Tablets	SS		ORAL	25 MG QD ORAL	
			Vitamin Formulation	C				
			Ogen	C				
			Levothyroxine	C				

Date:12/19/01ISR Number: 3842730-6Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Hypertension	Professional						
	Visual Field Defect	Company Representative	Allopurinol	C				

Date:12/19/01ISR Number: 3842734-3Report Type:Expedited (15-DaCompany Report #WAES 01120967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/19/01ISR Number: 3842736-7Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional						

Date:12/19/01ISR Number: 3842739-2Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG ; 25	
Hospitalization -	Congestive	Professional					MG : DAILY/PO 4	WK
Initial or Prolonged	Dyspepsia		Aspirin	C				
	Dyspnoea		Vitamins					
	Weight Increased		(Unspecified)	C				

Date:12/19/01ISR Number: 3842743-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA01201
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Effexor Xr	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:12/19/01ISR Number: 3842833-6Report Type:Expedited (15-DaCompany Report #001-0981-M0109542
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Atorvastatin					

Hospitalization -	Platelet Count Decreased	(Atorvastatin)	PS	ORAL
20 MG				
Initial or Prolonged	Red Blood Cell Count			
(DAILY), PER				
Other	Decreased			
ORAL				
	Systemic Lupus	(Rofecoxib)	SS	
	Erythematosus	(Paroxetine		
	T-Cell Lymphoma	Hydrochloride)	SS	
		(Zolpidem Tartrate)	C	
		(Paracetamol,		
		Dextropropoxyphene)	C	
		(Hyoscyamine)	C	
		(Acetylsalicylic		
		Acid)	C	

Date:12/19/01ISR Number: 3842859-2Report Type:Expedited (15-DaCompany Report #001-0902-M0100101
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Bipolar Disorder
Initial or Prolonged	Blindness
Other	Blood Pressure Increased
	Depressed Level Of
	Consciousness
	Diabetes Mellitus
	Drug Toxicity
	Loss Of Consciousness

		Migraine Osteoarthritis Salivary Hypersecretion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer Health Professional	Nardil (Phenelzine Sulfate)	PS		
				Accupril (Quinapril Hydrochloride)	SS		ORAL
10 MG (DAILY), PER ORAL							
				Vioxx (Rofecoxib)	SS		
25 MG (QD)							
				(Promethazine Hydrochloride)	C		
				(Codeine Phosphate, Paracetamol)	C		
				(Paracetamol, Oxycodone Hydrochloride)	C		
				(Pethidine Hydrochloride)	C		
				(Vitamins Nos)	C		
				Unspecified Medications For Diabetes	C		
				(Cyanocobalamin)	C		

Date:12/19/01ISR Number: 3842971-8Report Type:Expedited (15-DaCompany Report #WAES 01120364
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Transient Ischaemic Attack	Health Professional	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY PO SEE IMAGE							
			Company Representative				

Date:12/19/01ISR Number: 3842973-1Report Type:Expedited (15-DaCompany Report #WAES 01120577
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Cerebrovascular Accident		Cytomel	C				
	Fatigue		Fosamax	C				
	Paralysis		Premarin	C				
	Thrombosis		Potassium	C				
	Urinary Tract Infection							

Date:12/19/01ISR Number: 3842974-3Report Type:Expedited (15-DaCompany Report #WAES 01120553
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/01ISR Number: 3849086-3Report Type:Expedited (15-DaCompany Report #WAES 01127804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Perforation	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:12/20/01ISR Number: 3842003-1Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -	Congestive		Vioxx	SS		ORAL	4	WK
Initial or Prolonged	Dyspepsia Weight Increased		Vitamins (Unspecified) Aspirin	C C				

Date:12/20/01ISR Number: 3842005-5Report Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Heparin Low Molecular Weight [Therapy Unspecified]	SS C		ORAL		

Date:12/20/01ISR Number: 3842011-0Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage Myocardial Infarction		Heparin Prednisolone	SS C				

			Methotrexate	C		
			[Therapy			
			Unspecified]	C		

Date:12/20/01ISR Number: 3842013-4Report Type:Expedited (15-DaCompany Report #WAES 01120967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/20/01ISR Number: 3842044-4Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Dysphasia Dyspraxia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3842051-1Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Life-Threatening	Congestive							
Hospitalization - Initial or Prolonged	Condition Aggravated							

Date:12/20/01ISR Number: 3842265-0Report Type:Direct Company Report #
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pharyngeal Oedema		Rofecoxib	PS				
			Niacin	C				
			Colestipol Hcl	C				
			Fexofenadine Hcl	C				
			Gabapentin	C				
			Aloh/Mgoh/Simth Xtra Strength	C				
			Paroxetine Hcl	C				
			Celecoxib	C				
			Rabeprazole Na	C				
			Zolpidem Tartrate	C				
			Oxyodone 5mg/Acetaminophen	C				

Date:12/20/01ISR Number: 3843131-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01314
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pulmonary Embolism		Coumadin	C				

Date:12/20/01ISR Number: 3843137-8Report Type:Expedited (15-DaCompany Report #WAES 01112151
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hemianopia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Retinal Artery Embolism	Professional					MG/DAILY/PO	
Disability		Company	Actos	C				
Other		Representative	Coumadin	C				
			Cozaar	C				
			Lanoxin	C				
			Toprol Xl Tablets	C				
			Allopurinol	C				
			Fluoxetine	C				
			Furosemide	C				

Date:12/20/01ISR Number: 3843142-1Report Type:Expedited (15-DaCompany Report #WAES 01120569
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Haemorrhage	Professional	Dyazide	C				
	Haematemesis							
	Haemorrhagic Stroke							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3843144-5Report Type:Expedited (15-DaCompany Report #WAES 01091718
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/20/01ISR Number: 3843164-0Report Type:Expedited (15-DaCompany Report #WAES 01126008
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Arterial Stenosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG/DAILY	63 DAY
			Acetaminophen	C				
			Cifenline Succinate	C				
			Clonidine	C				
			Lacidipine	C				
			Spironolactone	C				

Date:12/20/01ISR Number: 3843174-3Report Type:Expedited (15-DaCompany Report #WAES 01115523
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Cutaneous Vasculitis Haemorrhage Subcutaneous	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO ; 25 MG/DAILY PO	
			Digitoxin	C				
			Enalapril Maleate	C				
			Omeprazole	C				
			Sotalol Hydrochloride	C				
			Torsemide	C				

Date:12/20/01ISR Number: 3843233-5Report Type:Expedited (15-DaCompany Report #WAES 01125035
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia	Foreign	Tab Vioxx					
	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Oedema Peripheral							
PO							13	DAY
			Timoptic	C				
			Acetaminophen (+)					
			Dihydrocodeine					
			Bitartr	C				
			Amiloride					
			Hydrochloride (+)					
			Furosemide	C				
			Benzyl Alcohol (+)					
			Benzyl Benzoate (+)					
			B	C				
			Carbomer	C				
			Dihydrocodeine	C				
			Folic Acid	C				
			Levothyroxine Na	C				
			Methotrexate	C				
			Sertraline	C				

			Sulfasalazine	C		
			Temazepam	C		

Date:12/20/01ISR Number: 3843236-0Report Type:Expedited (15-DaCompany Report #WAES 01127801
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematochezia	Foreign	Tab Vioxx			
Initial or Prolonged	Intestinal Ulcer	Health	(Rofecoxib)	PS		
		Professional				

Date:12/20/01ISR Number: 3843238-4Report Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemodialysis	Foreign	Tab Vioxx			
Hospitalization -	Hyponatraemia	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Metabolic Acidosis	Professional				
PO 4 DAY						
	Oral Intake Reduced		Diuretic			
	Pleural Effusion		(Unspecified)	C		
	Pulmonary Congestion		Nonsteroidal			
	Renal Failure Acute		Anti-Inflammatory			
	Urinary Tract Infection		Drug (Unspecifie	C		
	Vomiting		Fosamax	C		
			Calcium Gluconate			
			(+) Calcium			
			Phosphate	C		
			Cerivastatin Sodium	C		
			Certoparin Sodium	C		
			Diclofenac	C		
			Dimenhydrinate	C		
			Dipyrone	C		
			Fentanyl	C		
			Furosemide (+)			
			Penbutolol Sulfate	C		
			Lactulose	C		
			Methylprednisolone	C		
			Nitroxoline	C		
			Piritramide	C		

			Tramadol Hcl	C		
			Valerian	C		

Date:12/20/01ISR Number: 3843243-8Report Type:Expedited (15-DaCompany Report #WAES 01098555
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Fatigue	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	325 MG/ PO	
	Somnolence	Professional Other	Lorazepam	SS		ORAL	2.0 MG/ PO	

Date:12/20/01ISR Number: 3843311-0Report Type:Expedited (15-DaCompany Report #WAES 01128509
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

PO

Date:12/20/01ISR Number: 3843320-1Report Type:Expedited (15-DaCompany Report #WAES 01113727
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 ML/DAILY	
			Aspirin	C				
			Budesonide	C				
			Prednisolone	C				

PO 241 DAY

Date:12/20/01ISR Number: 3843322-5Report Type:Expedited (15-DaCompany Report #WAES 01120813
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	

Date:12/20/01ISR Number: 3843345-6Report Type:Expedited (15-DaCompany Report #WAES 01127804
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Perforation	Foreign Other	Tab Vioxx (Rofecoxib)	PS				
Hospitalization - Initial or Prolonged			(Composition Unspecified)	C				

Date:12/20/01ISR Number: 3843347-XReport Type:Expedited (15-DaCompany Report #WAES 01115547
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Condition Aggravated Liposarcoma Renal Cyst Sarcoma	Foreign Other	Tab Vioxx (Rofecoxib) Vasotec Allopurinol Amlodipine Besylate Bromazepam Citalopram Hydrobromide Fenoterol Hydrobromide (+) Ipratropium B Tramadol Hcl	PS C C C C C C C		ORAL

Date:12/20/01ISR Number: 3843349-3Report Type:Expedited (15-DaCompany Report #WAES 01116057
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged 12.5 MG/DAILY	Aortic Valve Stenosis Cardiac Failure Congestive Dyspnoea Mitral Valve Incompetence	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3843352-3Report Type:Expedited (15-DaCompany Report #WAES 01118542
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Foreign	Tab Vioxx					
Hospitalization -	Infarction	Other	(Rofecoxib)	PS		ORAL	25	
Initial or Prolonged							MG/DAILY/50	
							MG/DAILY	17 DAY
			Calcium Carbonate (+) Etidronate Sodium	C				

Date:12/20/01ISR Number: 3843353-5Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Foreign	Tab Vioxx					
Initial or Prolonged	Pancreatitis Acute	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	10 DAY
			Aceclofenac	C				
			Captopril	C				
			Dipyrene	C				
			Furosemide	C				

Date:12/20/01ISR Number: 3843399-7Report Type:Expedited (15-DaCompany Report #WAES 0112ITA08130
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	50 MG/DAILY	60 DAY
	Haematemesis		Amiloride Hydrochloride-Hctz	C				
	Melaena		Aspirin	C				
	Myocardial Infarction		Bromazepam	C				
	Upper Gastrointestinal Haemorrhage		Isosorbide Dinitrate	C				

Date:12/20/01ISR Number: 3843651-5Report Type:Expedited (15-DaCompany Report #WAES 01112438
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Stenosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Hospitalization -	Myocardial Infarction	Professional					PO	
Initial or Prolonged			Avandia	C				
Other			Zantac	C				

Date:12/20/01ISR Number: 3843652-7Report Type:Expedited (15-DaCompany Report #WAES 01110863
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
		Professional					PO	
			Allegra	C				
			Celexa	C				
			Keppra	C				
			Lamictal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3843653-9Report Type:Expedited (15-DaCompany Report #WAES 01120434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Decreased Activity							
	Injury							
	Nervous System Disorder							
	Neuralgia							
	Shock							

Date:12/20/01ISR Number: 3843656-4Report Type:Expedited (15-DaCompany Report #WAES 01070532
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Tab Voxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -		Health					MG/BID/PO	
Initial or Prolonged		Professional	Cordarone	C				
Disability			Coumadin	C				
			Duragesic	C				
			Hydrodiuril	C				
			Monopril	C				
			Synthroid	C				
			Vicodine Tablets	C				
			Zocor	C				
			Allopurinol	C				
			Amlodipine Besylate	C				
			Trazodone	C				

Date:12/20/01ISR Number: 3843657-6Report Type:Expedited (15-DaCompany Report #WAES 01110508
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	

Company
Representative

Date:12/20/01ISR Number: 3843677-1Report Type:Expedited (15-DaCompany Report #WAES 01101988
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hyperhidrosis	Health Professional	Buspar	C				
	Memory Impairment		Zoloft	C				
	Nystagmus							
	Pain							
	Simple Partial Seizures							

Date:12/20/01ISR Number: 3843680-1Report Type:Expedited (15-DaCompany Report #WAES 01120364
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 50 MG/DIALY/PO	
		Company Representative						
			...	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/01ISR Number: 3843682-5Report Type:Expedited (15-DaCompany Report #WAES 01102749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged	Drug Toxicity	Professional	Dilantin 400 Mg	SS			400 MG/DAILY	
Disability	Dysarthria	Company	Premarin	C				
	Gait Disturbance	Representative	Vicodin Es Tablets	C				
	Mental Status Changes							
	Nervous System Disorder							

Date:12/20/01ISR Number: 3843730-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01616
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Pharyngeal Oedema	Professional					MG/DAILY/PO	
	Throat Tightness	Company	Claritin	C				
		Representative	Metamucil	C				
			Pravachol	C				
			Allergenic Extract	C				
			Aspirin	C				

Date:12/20/01ISR Number: 3843791-0Report Type:Expedited (15-DaCompany Report #WAES 01125028
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Health						
							PO	15 DAY
		Professional						
		Other						

Date:12/20/01ISR Number: 3843792-2Report Type:Expedited (15-DaCompany Report #WAES 01126038
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	7 DAY
	Cerebrovascular Accident	Health						
	Facial Palsy	Professional	Clopidogrel Bisulfate	C				
		Other						

Date:12/20/01ISR Number: 3843793-4Report Type:Expedited (15-DaCompany Report #WAES 01125576
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Health						
		Professional						
		Other						

Date:12/20/01ISR Number: 3843869-1Report Type:Expedited (15-DaCompany Report #WAES 01070532
Age:68 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Health					MG/BID/PO	
		Professional	Cordarone	C				
			Coumadin	C				
			Duragesic	C				
			Hydrodiuril	C				
			Monopril	C				
			Synthroid	C				
			Vicodin Tablets	C				
			Zocor	C				
			Allopurinol	C				
			Amlodipine Besylate	C				
			Trazodone	C				

Date:12/21/01ISR Number: 3842986-XReport Type:Expedited (15-DaCompany Report #WAES 01126014
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged			Ramipril	C		ORAL		
			Digoxin	C		ORAL		
			Furosemide	C		ORAL		
			Fluindione	C		ORAL		

Date:12/21/01ISR Number: 3842990-1Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Initial or Prolonged	Chest Pain		Allopurinol	C				
Other	Hemianopia							
	Thrombotic Stroke							

Date:12/21/01ISR Number: 3843003-8Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
			Atenolol	C				

Date:12/21/01ISR Number: 3843004-XReport Type:Expedited (15-DaCompany Report #WAES 01102374
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Erythema Multiforme		Nolvadex	C				
	Gastrooesophageal Reflux Disease		Flexeril	C		ORAL		
	Herpes Simplex							
	Mouth Ulceration							
	Oesophagitis							
	Stevens-Johnson Syndrome							
	Varicella							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/01ISR Number: 3843011-7Report Type:Expedited (15-DaCompany Report #WAES 01108566
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/01ISR Number: 3843012-9Report Type:Expedited (15-DaCompany Report #WAES 01120249
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/01ISR Number: 3843013-0Report Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Hyponatraemia		Furosemide And Penbutolol Sulfate	C		ORAL	1	DAY
	Metabolic Acidosis							
	Oedema		Furosemide And Penbutolol Sulfate	C		ORAL	6	DAY
	Oligodipsia							
	Oral Intake Reduced		Cerivastatin Sodium	C		ORAL	7	DAY
	Pleural Effusion		Nitroxoline	C		ORAL	1	DAY
	Pulmonary Congestion		Nitroxoline	C		ORAL	2	DAY
	Pyrexia		Methylprednisolone	C		ORAL	1	DAY
	Renal Failure Acute		Methylprednisolone	C		ORAL	2	DAY
	Urinary Tract Infection		Fosamax	C		ORAL	1	DAY
	Vomiting		Calcium Gluconate And Calcium Phosphate Tribasic					

			And Cholecalciferol	C	ORAL
5 DAY					
			Dipyrone	C	ORAL
3 DAY					
			Fentanyl	C	
TOPICAL					
			Valerian	C	ORAL
3 DAY					
			Lactulose	C	
1 DAY					
			Certoparin Sodium	C	
SUBCUTANEOUS	6	DAY			
			Tramadol Hydrochloride	C	ORAL
1 DAY					
			Dimenhydrinate	C	
INTRAVENOUS	1	DAY			
			Piritramide	C	
INTRAVENOUS					
					DRIP
1 DAY					
			Diclofenac	C	
RECTAL	2	DAY			
			Diuretic (Unspecified)	C	
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C	

Date:12/21/01ISR Number: 3843014-2Report Type:Expedited (15-DaCompany Report #WAES 01127803
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Heart Valve Operation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged			Furosemide Sodium	C		
			Insulin	C		
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/01ISR Number: 3843016-6Report Type:Expedited (15-DaCompany Report #WAES 01125551
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Methotrexate	C				

Date:12/21/01ISR Number: 3843018-XReport Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

Date:12/21/01ISR Number: 3843019-1Report Type:Expedited (15-DaCompany Report #WAES 01125021
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Endoscopy Upper Gastrointestinal Tract		Fosamax	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL	8	DAY
	Abnormal Gastrooesophageal Reflux Disease		Doxazosin	C		ORAL		
			Aspirin	C		ORAL		
			Ergocalciferol	C				
	Haemangioma							
	Haematemesis							
	Oesophagitis							
	Telangiectasia							

Date:12/21/01ISR Number: 3843031-2Report Type:Expedited (15-DaCompany Report #WAES 01115619
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Hospitalization -	Hypertension		Ferrous Sulfate And					

Initial or Prolonged	Tachyarrhythmia		Folic Acid	C		ORAL
48 DAY						
	Tachycardia Paroxysmal		Tolperisone Hydrochloride	C		ORAL
42 DAY						
			Metoprolol Succinate	C		ORAL
26 DAY						
			Teicoplanin	C		
PARENTERAL	8 DAY					
			Fentanyl	C		
TOPICAL	23 DAY					
			Dalteparin Sodium	C		
SUBCUTANEOUS						
			Ciprofloxacin Hydrochloride	C		ORAL

Date:12/21/01ISR Number: 3843032-4Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coronary Artery Disease		Aspirin	C		
Initial or Prolonged						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/01ISR Number: 3843035-XReport Type:Expedited (15-DaCompany Report #WAES 01105075
Age:0 DY Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 DAY	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Caesarean Section		Amitriptyline	C		
1 WK	Complications Of Maternal		Clonazepam	C		
	Exposure To Therapeutic Drugs		Tramadol	C		
	Foetal Distress Syndrome		Acetaminophen And Propoxyphene Hydrochloride	C		
	Platelet Count Decreased		Morphine	C		
	Premature Baby		Labetalol Hydrochloride	C		
			Lactulose	C		
			Diclofenac	C		
			Nifedipine	C		
			Ferrous Sulfate	C		
			Ranitidine	C		
			Betamethasone	C		

Date:12/21/01ISR Number: 3843036-1Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS		ORAL
	Hypertension		Catapres	C		
			Lasix (Furosemide)	C		

Date:12/21/01ISR Number: 3843037-3Report Type:Expedited (15-DaCompany Report #WAES 01106114
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 212 DAY	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Melaena		Metformin	C		ORAL
			Gliclazide	C		ORAL

Ticlopidine Hydrochloride	C	ORAL
Benazepril Hydrochloride	C	ORAL
Nafronyl Oxalate	C	ORAL
Buflomedil Hydrochloride	C	ORAL
Zocor	C	ORAL

Date:12/21/01ISR Number: 3843039-7Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Blood Sodium Decreased Blood Urea Increased Hypertension Nausea Pancreatitis Acute Red Blood Cell Count Decreased Vomiting

		White Blood Cell Count Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
18	DAY						
				Vioxx	SS		ORAL
10	DAY						
				Dipyrone	C		ORAL
				Captopril	C		ORAL
				Aceclofenac	C		
				Furosemide	C		ORAL

Date:12/21/01ISR Number: 3843040-3Report Type:Expedited (15-DaCompany Report #WAES 01105075
Age:31 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
25	DAY						
		Caesarean Section		Amitriptyline	C		
		Complications Of Maternal		Clonazepam	C		
1	WK						
		Exposure To Therapeutic		Tramadol	C		
		Drugs		Acetaminophen And			
		Foetal Distress Syndrome		Propoxyphene			
		Platelet Count Decreased		Hydrochloride	C		
		Premature Baby		Morphine	C		
				Labetalol			
				Hydrochloride	C		
				Lactulose	C		
				Diclofenac	C		
				Nifedipine	C		
				Ferrous Sulfate	C		
				Ranitidine	C		
				Betamethasone	C		

Date:12/21/01ISR Number: 3843041-5Report Type:Expedited (15-DaCompany Report #WAES 01115015
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL
146 DAY						
	Dyspnoea		Levothyroxine Sodium	C		
	Headache					
	Palpitations					
	Tremor					

Date:12/21/01ISR Number: 3843710-7Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Sudden Death		Vioxx 25mgs Merck	PS	Merck	ORAL
25MGS QD ORAL						
			Prednisone	C		
			Triamcinolone	C		

Date:12/24/01ISR Number: 3843662-XReport Type:Direct Company Report #
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx 25mg Merck Co	PS	Merck Co	
25MG 1 TAB						
Initial or Prolonged	Blood Pressure Increased					
DAILY 30 DAY						
	Headache					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/01ISR Number: 3843953-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA02091
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemodialysis	Health	Tab Vioxx 50 Mg	PS		ORAL	50MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Renal Failure Acute	Professional Company Representative						
	Rhabdomyolysis							
Disability								
Other								

Date:12/26/01ISR Number: 3844099-XReport Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/26/01ISR Number: 3844100-3Report Type:Expedited (15-DaCompany Report #WAES 01111179
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	SS		ORAL	7	DAY
Other	Congestive		Depakote	C				
	Confusional State		Zoloft	C				
	Dyspnoea		Baclofen	C				
	Ejection Fraction		Toprol Xl Tablets	C		ORAL		
	Decreased		Tegretol	C				
	Hyponatraemia		Zantac	C				
	Pleural Effusion		Valium	C				
	Pneumonia		Zocor	C				
	Staphylococcal Infection							

Date:12/26/01ISR Number: 3844102-7Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged	Congestive Weight Increased		Calcium (Unspecified)	C				
			Paxil	C				
			Celebrex	C				

Date:12/26/01ISR Number: 3844104-0Report Type:Expedited (15-DaCompany Report #WAES 01129111
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY
	Dyspnoea Stridor		Acetaminophen And Codeine Phosphate	SS		ORAL	17	DAY
			Flexeril	SS		ORAL	17	DAY
			Captopril	C		ORAL		
			Chlorthalidone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/01ISR Number: 3844105-2Report Type:Expedited (15-DaCompany Report #WAES 01116082
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoacusis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Tinnitus		Heptaminol Hydrochloride	C		ORAL		
			Celecoxib	C		ORAL		
			Benfluorex Hydrochloride	C		ORAL		

Date:12/26/01ISR Number: 3844281-1Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Ec Asa 81mg	PS			81MG QD	
Hospitalization -	Haemorrhage		Vioxx 12.5mg	SS			12.5MG QD	
Initial or Prolonged								

Date:12/26/01ISR Number: 3844283-5Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive		Vioxx (12.5mg Qd)	PS			12.5MG QD	
Initial or Prolonged	Gastrointestinal Disorder		Asa(225mg Qd)					
	Gastrointestinal		Enteric	SS			225MG QD	
	Haemorrhage							
	Inflammation							
	Peptic Ulcer							

Date:12/26/01ISR Number: 3844284-7Report Type:Direct Company Report #
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS		ORAL	12.5MG QD PO	

Date:12/26/01ISR Number: 3845216-8Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Blood Pressure Increased
Disability	Confusional State
Other	Difficulty In Walking
	Dysarthria
	Dysuria
	Fatigue
	Gait Disturbance
	Hemiparesis
	Lethargy
	Loss Of Consciousness
	Memory Impairment
	Mental Status Changes
	Miosis
	Nausea
	Photophobia
	Somnolence

Speech Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health	Neurontin (Gabapentin)	PS		ORAL	300 MG (ONCE), PER ORAL	
Professional	Vioxx (Rofecoxib)	SS		ORAL	50 MG (ONCE), PER ORAL	
	Zanaflex (Tizanidine)	SS		ORAL	2 MG (ONCE), PER ORAL	
	(Clopidogrel)	C				

Date:12/27/01ISR Number: 3844551-7Report Type:Expedited (15-DaCompany Report #WAES 01109101
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:12/27/01ISR Number: 3844552-9Report Type:Expedited (15-DaCompany Report #WAES 01102011
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Stress		Zyrtec	C				
Other			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3844558-XReport Type:Expedited (15-DaCompany Report #WAES 01107522
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flupentixol Hydrochloride And Melitracen Hydrochloride	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Moduretic	C		ORAL		
			Allopurinol	C		ORAL		
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		

Date:12/27/01ISR Number: 3844569-4Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Celebrex	C		ORAL		
Other	Ventricular Fibrillation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3845106-0Report Type:Expedited (15-DaCompany Report #2001086222FR
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo Vomiting	Foreign Health Professional	Cytotec (Misoprostol) Tablet	PS		ORAL	200 UG, QD, ORAL	
		Other	Dhea (Prasterone)	SS		ORAL	50 MG/DAY, ORAL	
			Sermion (Nicergoline)	SS				
			Ciflox (Ciprofloxacin)	SS				
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Aspegic	C				
			Phakan (Aminoacetic Acid, Glutamic Acid)	C				
			Ideos	C				
			Atepadene (Adenosine Phosphate, Sodium Salt)	C				
			Tanakan	C				
			Bisoprolol (Bisoprolol)	C				
			Hyzaar	C				
			Vitamins	C				

Date:12/27/01ISR Number: 3845322-8Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Arrhythmia
	Blood Creatine Phosphokinase Abnormal
	Blood Creatine Phosphokinase Increased
	Blood Pressure Increased

Cardiac Arrest
Dizziness
Duodenal Ulcer
Haemorrhage
Electrocardiogram
Abnormal
Electrocardiogram St
Segment Depression
Electrocardiogram T Wave
Inversion
Exsanguination
Faecal Occult Blood
Positive
Gastrointestinal
Haemorrhage
Head Injury
Hypotension
Laboratory Test Abnormal
Loss Of Consciousness
Platelet Count Increased
Prothrombin Time Abnormal
Respiratory Rate

	Increased						
	Syncope						
	Thrombosis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY; PO
		Company Representative Distributor	Bumex	C			
			Cozaar	C			
			Klor-Con	C			
			Lanoxin	C			
			Lasix (Furosemide)	C			
			Lotensin	C			
			Premarin	C			
			Aspirin	C			
			Prednisone	C			

Date:12/27/01ISR Number: 3845353-8Report Type:Expedited (15-DaCompany Report #WAES 01112949
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Study	Tab Vioxx Unk	PS		ORAL	PO
	Cardiac Failure	Health Professional	Celebrex	C			
	Congestive		Galantamine	C			
	Dilatation Atrial						
	Dyspnoea						
	Fatigue						
	Mitral Valve Incompetence						
	Oedema						
	Pulmonary Hypertension						

Date:12/27/01ISR Number: 3845442-8Report Type:Expedited (15-DaCompany Report #WAES 01091124
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25
	Syncope Vasovagal	Health					MG/DAILY/PO

Professional	Acular	C
	Celebrex	C
	Ocuflox	C
	Prinivil	C
	Tenormin	C

Date:12/27/01ISR Number: 3845443-XReport Type:Expedited (15-DaCompany Report #WAES 01112854
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Akinesia
Initial or Prolonged	Aortic Valve
Disability	Calcification
	Arthritis
	Blood Pressure Increased
	Cardiac Disorder
	Chest X-Ray Abnormal
	Dyskinesia
	Dyspnoea
	Hyperhidrosis
	Middle Insomnia
	Myocardial Infarction

	Nausea Pain Spinal Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Tachycardia	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Health Professional	Tab Acetaminophen	SS		ORAL	325 MG/PRN/PO
			Effexor	C			
			Zocor	C			
			Aspirin	C			

Date:12/27/01ISR Number: 3845444-1Report Type:Expedited (15-DaCompany Report #WAES 01101868
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Sudden Cardiac Death	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Health Professional Other	Atenolol	C			

Date:12/27/01ISR Number: 3845462-3Report Type:Expedited (15-DaCompany Report #WAES 01102374
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cellulitis	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO
	Erythema Multiforme						
	Gastrooesophageal Reflux Disease		Flexeril	C			
			Nolvadex	C			
	Herpes Simplex						
	Oesophagitis						
	Stevens-Johnson Syndrome						

Date:12/27/01ISR Number: 3845463-5Report Type:Expedited (15-DaCompany Report #WAES 01120249
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hemiparesis	Professional Company Representative						

Date:12/27/01ISR Number: 3845464-7Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3845465-9Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Hemianopia	Professional						
	Pain	Company Representative	Allopurinol	C				
	Thrombotic Stroke							
	Visual Disturbance							

Date:12/27/01ISR Number: 3845468-4Report Type:Expedited (15-DaCompany Report #WAES 01072951
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholecystectomy	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Cholecystitis	Professional	Ambien	C				
			Exelon	C				
			Flovent	C				
			Nasocort	C				
			Norco	C				
			Premarin	C				
			Prevacid	C				
			Serevent	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3845535-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA01597
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Tab Hyzaar	PS		ORAL	PO	
		Professional	Tab Vioxx	SS		ORAL	PO	
		Company Representative						

Date:12/27/01ISR Number: 3845541-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA02134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
		Company Representative	[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3845542-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3845544-6Report Type:Expedited (15-DaCompany Report #WAES 0112USA01466
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Palpitations	Health	Coumadin	C				
Other	Sick Sinus Syndrome	Professional	Niaspan	C				
	Ventricular Extrasystoles		Timoptic	C				

			Xalatan	C
			Zebeta	C
			Zocor	C
			Digoxin	C

Date:12/27/01ISR Number: 3845552-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA01440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral	Health	Tab Vioxx	PS		ORAL	PO	
	Cerebrovascular Accident	Professional Company Representative						

Date:12/27/01ISR Number: 3845553-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01494
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Migration Of Implant	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Vomiting						MG/DAILY/PO	
			Glucophage	C				
			Hydrodiuril	C				
			Lasix (Furosemide)	C				
			Ocuvite	C				
			Prevacid	C				
			Diltiazem Malate	C				
			Quinine	C				
			Vitamin B (Unspecified)	C				

Date:12/27/01ISR Number: 3845584-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA02133
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Headache	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Malaise	Professional				
MG/DAILY/PO						
	Musculoskeletal Stiffness	Company	Advil	C		
	Vomiting	Representative	Tylenol	C		
			Dimethyl Sulfone	C		
			Estrogens			
			(Unspecified)	C		

Date:12/27/01ISR Number: 3845586-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL
50						
Hospitalization -						
MG/DAILY/PO						
Initial or Prolonged			Tab Vioxx 50 Mg	SS		ORAL
50						
Disability						
MG/DAILY/PO						
			Accupril	C		
			Imdur	C		
			Lasix (Furosemide)	C		
			Levoxyl	C		
			Prempro	C		
			Slow-K	C		
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3845587-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01647
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Transient Ischaemic Attack		Premarin	C				
			Prozac	C				

Date:12/27/01ISR Number: 3845719-6Report Type:Expedited (15-DaCompany Report #WAES 0112USA01319
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 MON
	Urticaria							
		Company Representative	Composition Unspecified	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3845720-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01194
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bradycardia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Life-Threatening	Cardiac Arrest							
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Carbatrol	C				
	Dialysis		Prinivil	C				
	Renal Failure		Digoxin	C				
			Torsemide	C				

Date:12/27/01ISR Number: 3845746-9Report Type:Expedited (15-DaCompany Report #WAES 01120967
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3845747-0Report Type:Expedited (15-DaCompany Report #WAES 01112889
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Deep Vein Thrombosis	Professional	Therapy Unspecified]	SS		ORAL	PO	
	Embolism Haemorrhage	Company Representative	Heparin Low Molecular Weight	SS				

Date:12/27/01ISR Number: 3845748-2Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Cardiac Failure
Hospitalization -	Congestive
Initial or Prolonged	Dyspepsia
	Respiratory Disorder

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; 25 MG DAILY/PO	4 WK
	Aspirin	C				
	Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3845749-4Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health Professional	Tab Vioxx	PS		ORAL	PO	
Life-Threatening	Congestive Condition Aggravated							
Hospitalization - Initial or Prolonged								

Date:12/27/01ISR Number: 3845784-6Report Type:Expedited (15-DaCompany Report #WAES 01062513
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Allergic Granulomatous Angiitis
	Anaemia
	Antineutrophil Cytoplasmic Antibody Positive
	Bacteria Urine Identified
	Blood Albumin Abnormal
	Blood Alkaline Phosphatase Increased
	Blood Bicarbonate Abnormal

Blood Calcium Abnormal
Blood Ph Decreased
Blood Phosphorus
Blood Potassium Abnormal
Blood Sodium Abnormal
Blood Urine Present
Cardiac Failure
Congestive
Cardiomegaly
Coronary Artery Disease
Culture Urine Positive
Cystitis Escherichia
Diabetes Mellitus
Diabetes Mellitus
Inadequate Control
Dialysis
Enterococcal Infection
Eosinophil Count
Increased
Glomerulonephritis Acute
Glycosylated Haemoglobin
Increased
Haemorrhage

		Hypoxia					
		Immunoglobulins					
		Interstitial Lung Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Laboratory Test Abnormal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Leukopenia	Health				
MG/BID/PO							
		Lipase Increased	Professional	Lipitor	C		
		Lung Infiltration		Norvasc	C		
		Necrosis		Prilosec	C		
		Oedema Peripheral		Prinivil	C		
		Pco2 Abnormal		Verelan	C		
		Po2 Abnormal		Aspirin	C		
		Pulmonary Oedema		Glyburide	C		
		Pyrexia					
		Red Blood Cell Count					
		Abnormal					
		Red Blood Cell					
		Sedimentation Rate					
		Abnormal					
		Renal Failure Acute					
		Tremor					
		Vasculitis					

Date:12/27/01ISR Number: 3845825-6Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Pain	Consumer	Tab Vioxx 285 Mg	PS		ORAL
25 MG/BID/PO							
Initial or Prolonged		Chondropathy	Health	Darvocet	SS		
		Difficulty In Walking	Professional	Klonopin	SS		
		Fluid Retention		Relafen	SS		
		Headache		Naprosyn	SS		
		Intestinal Ulcer					
		Muscular Weakness					
		Neuropathy Peripheral					
		Pain					
		Rhabdomyolysis					
		Weight Increased					

Date:12/27/01ISR Number: 3845826-8Report Type:Expedited (15-DaCompany Report #WAES 99110468
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Study	Tab Vioxx	PS		ORAL	5 MG ; 50MG : DAILY/PO	
	Diplopia	Health Professional						
	Dizziness		Acetaminophen 325 Mg	SS			PRN	
			Tab Placebo	SS		ORAL	2 TABLET/DAILY/ PO	
			Tab Placebo	SS		ORAL	3 TABLET/DAILY/ PO	
			Elavil	C				
			Flexeril	C				
			Lotensin	C				
			Panalgesic Gold Cream	C				
			Synthroid	C				
			Ventolin	C				
			[Composition					

			Unspecified]	C		
			Acetaminophen	C		
			Glyburide	C		
			Leflunomide	C		
			Methotrexate	C		
			Theophylline	C		

Date:12/27/01ISR Number: 3845879-7Report Type:Expedited (15-DaCompany Report #WAES 01115547
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Foreign	Tab Vioxx					
	Liposarcoma	Health	(Rofecoxib)	PS		ORAL	PO	
	Renal Cyst	Professional	Vasotec	C				
	Renal Cyst Ruptured		Allopurinol	C				
			Amlodipine Besylate	C				
			Bromazepam	C				
			Citalopram Hydrobromide	C				
			Fenoterol Hydrobromide (+)					
			Ipratropium B	C				
			Tramadol Hcl	C				

Date:12/27/01ISR Number: 3845880-3Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Sarcoma	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	SEE IMAGE	163 DAY
		Professional	Methotrexate	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3845883-9Report Type:Expedited (15-DaCompany Report #WAES 0112DNK06548
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY PO 45 DAY						
			Aspirin	C		
			Citalopram	C		
			Hydroxocobalamin	C		

Date:12/27/01ISR Number: 3845884-0Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06062
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Vertigo Vomiting	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL
PO						
			Nicergoline	SS		ORAL
PO						
			Ciprofloxacin Hydrochloride	SS		
			Misoprostol	SS		ORAL
PO						
			Hyzaar	C		
			Aspirin Lysine	C		
			Bisoprolol	C		
			Ginkgo Biloba			

			Extract	C		
			Prasterone	C		

Date:12/27/01ISR Number: 3845885-2Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05086
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Foreign	Tab Vioxx					
	Hallucination, Visual	Company	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Pain	Representative						
PO							16	DAY
	Renal Impairment		Acetaminophen/Codein					
	Urinary Tract Infection		e Phosphate	C				
	Visual Disturbance		Cimetidine	C				
			Furosemide	C				
			Oxybutynin Cl	C				
			Quinine So4	C				

Date:12/27/01ISR Number: 3845899-2Report Type:Expedited (15-DaCompany Report #WAES 0112PRT09004
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Subarachnoid Haemorrhage	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	PO	

Date:12/27/01ISR Number: 3845947-XReport Type:Expedited (15-DaCompany Report #WAES 01127803
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG	
Hospitalization - Initial or Prolonged	Congestive	Health	Vasotec	C				
		Professional	Furosemide Sodium	C				
		Other	Insulin	C				

Date:12/27/01ISR Number: 3845957-2Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06051
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Phlebitis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	92 DAY
Initial or Prolonged	Pulmonary Embolism	Health Professional Other	Fenofibrate	C				

Date:12/27/01ISR Number: 3845959-6Report Type:Expedited (15-DaCompany Report #WAES 01125577
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Small Intestinal Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
Initial or Prolonged	Haemorrhage	Health Professional Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3845978-XReport Type:Expedited (15-DaCompany Report #WAES 0112NLD03710
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/27/01ISR Number: 3845979-1Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05078
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	29 DAY
			Amiloride Hydrochloride (+) Furosemide	C				
			Clopidogrel Bisulfate	C				
			Digoxin	C				
			Isosorbide Mononitrate	C				

Date:12/27/01ISR Number: 3845991-2Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05085
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	8 DAY
			Acetaminophen/Codeine Phosphate	C				
			Sulfasalazine	C				

Date:12/27/01ISR Number: 3845994-8Report Type:Expedited (15-DaCompany Report #WAES 01125533
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:12/27/01ISR Number: 3845996-1Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Health Professional Other	Heparin (Therapy Unspecified)	SS				
	Myocardial Infarction		Methotrexate	C				
			Prednisolone	C				

Date:12/27/01ISR Number: 3846006-2Report Type:Expedited (15-DaCompany Report #WAES01126027
Age:82 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Confusional State

Hallucination

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG/DAILY	2 DAY
	Calcium Dobesilate	C				
	Trimebutine	C				

Date:12/27/01ISR Number: 3846008-6Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06049
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pleural Effusion	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	2 DAY
	Pulmonary Oedema	Health Professional Other	Acetaminophen	C				
			Oxazepam	C				
			Pantoprazole	C				
			Trimetazidine	C				

Date:12/27/01ISR Number: 3846010-4Report Type:Expedited (15-DaCompany Report #WAES 01127265
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 29 DAY Initial or Prolonged	Diarrhoea	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
		Health Professional Other	Ranitidine Hcl	SS				
			Aspirin	C				
			Estriol	C				
			Felodipine/Metoprolol Succinate	C				
			Furosemide Sodium	C				
			Propoxyphene Napsylate	C				

Date:12/27/01ISR Number: 3846022-0Report Type:Expedited (15-DaCompany Report #WAES 01108566
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	

Date:12/27/01ISR Number: 3846024-4Report Type:Expedited (15-DaCompany Report #WAES 01125538
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemodialysis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	4 DAY
Hospitalization - Initial or Prolonged	Hyponatraemia							
	Metabolic Acidosis		Diuretic (Unspecified)	SS				
	Oedema		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	SS				
	Oliguria		Fosamax	C				
	Oral Intake Reduced		Calcium Gluconate (+) Calcium Phosphate	C				
	Pleural Effusion							
	Pulmonary Congestion							
	Renal Failure							
	Urinary Tract Infection							
	Vomiting							

Cerivastatin Sodium	C
Certoparin Sodium	C
Diclofenac	C
Dimenhydrinate	C
Dipyrone	C
Fentanyl	C
Furosemide (+)	
Penbutolol Sulfate	C
...	C
Lactulose	C
Methylprednisolone	C
...	C
Nitroxoline	C
...	C
Piritramide	C
Tramadol Hcl	C
Valerian	C

Date:12/27/01ISR Number: 3846026-8Report Type:Expedited (15-DaCompany Report #WAES 01125551
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Methotrexate	C				

Date:12/27/01ISR Number: 3846030-XReport Type:Expedited (15-DaCompany Report #WAES 01126014
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	8 DAY
			Digoxin	C				
			Fluindione	C				
			Furosemide	C				
			Ramipril	C				

Date:12/27/01ISR Number: 3846031-1Report Type:Expedited (15-DaCompany Report #WAES 01118279
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Ulceration Mucosal Ulceration	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	5 DAY
Other	Urethral Disorder	Professional	Tramadol Hcl	C				

Date:12/27/01ISR Number: 3846085-2Report Type:Expedited (15-DaCompany Report #WAES 01126530
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Generalised Exanthematous Pustulosis	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3846087-6Report Type:Expedited (15-DaCompany Report #WAES 01125021
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Foreign	Fosamax					
	Oesophagitis	Health	(Alendronate Sodium)	PS		ORAL	70 MG/WKY PO	
	Telangiectasia	Professional	Vioxx (Rofecoxib)	SS		ORAL	12.5 MG/DAILY	
	Upper Gastrointestinal	Other						
	Haemorrhage		Aspirin	C			PO	8 DAY
			Doxazosin	C				
			Ergocalciferol	C				

Date:12/27/01ISR Number: 3846089-XReport Type:Expedited (15-DaCompany Report #WAES 0112FRA06077
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Health						
							PO	3 WK
		Professional	Methotrexate	SS		ORAL	PO	
		Other						

Date:12/27/01ISR Number: 3846184-5Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Tab Vioxx					
Initial or Prolonged	Dysphasia	Other	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
Disability	Dyspraxia						PO	
	Muscle Disorder							
	Speech Disorder							

Date:12/27/01ISR Number: 3847689-3Report Type:Periodic Company Report #WAES 01080857
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Eyelid Oedema						MG/DAILY/PO	
	Oedema Peripheral		Prempro	C				
	Pollakiuria		Prilosec	C				
			Tylenol	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3847691-1Report Type:Periodic Company Report #WAES 01080115
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyponatraemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Nausea	Professional					MG/DAILY/PO	
	Renal Failure	Company	Cardarone	C				
		Representative	Imdur	C				
			Lasix (Furosemide)	C				
			Metoprolol	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3847692-3Report Type:Periodic Company Report #WAES 01112794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS			25	
Initial or Prolonged		Professional					MG/DAILY/UNK	
		Company Representative						

Date:12/27/01ISR Number: 3847693-5Report Type:Periodic Company Report #WAES 01111226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/UNK/PO	
Initial or Prolonged	Haemorrhage	Professional	Coumadin	C				
		Company Representative						

Date:12/27/01ISR Number: 3847694-7Report Type:Periodic Company Report #WAES 01111203
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	10 DAY
		Company Representative						

Date:12/27/01ISR Number: 3847697-2Report Type:Periodic Company Report #WAES 01111205
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL 50 MG/DAILY/PO

Date:12/27/01ISR Number: 3847701-1Report Type:Periodic Company Report #WAES 01111175
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Health Professional Company Representative	Tab Vioxx Unk Celebrex Therapy Unspecified	PS SS C		ORAL PO		

Date:12/27/01ISR Number: 3847704-7Report Type:Periodic Company Report #WAES 01110831
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 12.5 Mg Prevacid Aspirin	PS C C		ORAL 12.5 MG/DAILY/PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3847725-4Report Type:Periodic Company Report #WAES 01110465
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged	Haemorrhage	Professional					PO	
		Company Representative	Aspirin	C				

Date:12/27/01ISR Number: 3847727-8Report Type:Periodic Company Report #WAES 01110334
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
		Professional					MG/DAILY/PO	

Date:12/27/01ISR Number: 3847756-4Report Type:Periodic Company Report #WAES 01110270
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test Abnormal	Health	Tab Vioxx	PS		ORAL	PO	
	Renal Failure	Professional Company Representative						

Date:12/27/01ISR Number: 3847759-XReport Type:Periodic Company Report #WAES 01110168
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx	PS			PO	
		Professional						

Company
Representative

Date:12/27/01ISR Number: 3847765-5Report Type:Periodic Company Report #WAES 01110169
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3847767-9Report Type:Periodic Company Report #WAES 01106347
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3847769-2Report Type:Periodic Company Report #WAES 01104899
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	

Date:12/27/01ISR Number: 3847770-9Report Type:Periodic Company Report #WAES 01104737
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional	Imuran (Azathioprine)	C				
			Prozac	C				

Date:12/27/01ISR Number: 3847771-0Report Type:Periodic Company Report #WAES 01104546
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Coumadin	C				

Date:12/27/01ISR Number: 3847772-2Report Type:Periodic Company Report #WAES 01104507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							

Cardiovascular Disorder
Oedema
Renal Failure

Date:12/27/01ISR Number: 3847773-4Report Type:Periodic Company Report #WAES 01104508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3847776-XReport Type:Periodic Company Report #WAES 01104510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3848368-9Report Type:Periodic Company Report #WAES 01104511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848369-0Report Type:Periodic Company Report #WAES 01104513
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Other	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848370-7Report Type:Periodic Company Report #WAES 01104514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848371-9Report Type:Periodic Company Report #WAES 01104516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Fluctuation					
	Cardiovascular Disorder					
	Oedema					
	Renal Failure					

Date:12/27/01ISR Number: 3848372-0Report Type:Periodic Company Report #WAES 01104517
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Fluctuation					
	Cardiovascular Disorder					
	Oedema					
	Renal Failure					

Date:12/27/01ISR Number: 3848373-2Report Type:Periodic Company Report #WAES 01104518
Age: Gender: I/FU:I

Outcome	PT
Other	Blood Pressure
	Fluctuation
	Cardiovascular Disorder

Oedema
Renal Failure

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3848374-4Report Type:Periodic Company Report #WAES 01104521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848375-6Report Type:Periodic Company Report #WAES 01104522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848376-8Report Type:Periodic Company Report #WAES 01104497
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							

Renal Failure

Date:12/27/01ISR Number: 3848377-XReport Type:Periodic Company Report #WAES 01104499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848378-1Report Type:Periodic Company Report #WAES 01104500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3848379-3Report Type:Periodic Company Report #WAES 01104502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848380-XReport Type:Periodic Company Report #WAES 01104503
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848381-1Report Type:Periodic Company Report #WAES 01104504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848382-3Report Type:Periodic Company Report #WAES 01104477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL
PO						
	Fluctuation					
	Cardiovascular Disorder					
	Oedema					
	Renal Failure					

Date:12/27/01ISR Number: 3848383-5Report Type:Periodic Company Report #WAES 01104484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL
PO						
	Fluctuation					
	Cardiovascular Disorder					
	Oedema					
	Renal Failure					

Date:12/27/01ISR Number: 3848384-7Report Type:Periodic Company Report #WAES 01104485
Age: Gender:Female I/FU:I

Outcome	PT
Other	Blood Pressure
	Fluctuation
	Cardiovascular Disorder

Oedema
Renal Failure

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3848385-9Report Type:Periodic Company Report #WAES 01104486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	

Fluctuation
Cardiovascular Disorder
Oedema
Renal Failure

Date:12/27/01ISR Number: 3848386-0Report Type:Periodic Company Report #WAES 01104487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	

Fluctuation
Cardiovascular Disorder
Oedema
Renal Failure

Date:12/27/01ISR Number: 3848387-2Report Type:Periodic Company Report #WAES 01104489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	

Fluctuation
Cardiovascular Disorder
Oedema

Renal Failure

Date:12/27/01ISR Number: 3848388-4Report Type:Periodic Company Report #WAES 01104490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848389-6Report Type:Periodic Company Report #WAES 01104491
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3848390-2Report Type:Periodic Company Report #WAES 01104492
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848391-4Report Type:Periodic Company Report #WAES 01104495
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:12/27/01ISR Number: 3848392-6Report Type:Periodic Company Report #WAES 01104344
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Joint Crepitation		Premarin	C				
	Neck Pain		Prozac	C				
	Oedema Peripheral		Vicodin Tablets	C				
	Pain In Extremity							
	Rash							
	Traumatic Arthropathy							

Date:12/27/01ISR Number: 3848393-8Report Type:Periodic Company Report #WAES 01104246
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Renal Failure Acute	Professional Company Representative						

Date:12/27/01ISR Number: 3848394-XReport Type:Periodic Company Report #WAES 01102874
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3848395-1Report Type:Periodic Company Report #WAES 01102851
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	
Infusion (Form) Nafcillin Na	SS		INTRAVENOUS	IV	

Date:12/27/01ISR Number: 3848396-3Report Type:Periodic Company Report #WAES 01102757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3848397-5Report Type:Periodic Company Report #WAES 01102374
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Oesophagitis		Flexeril	C				
	Stevens-Johnson Syndrome		Nolvadex	C				

Date:12/27/01ISR Number: 3848398-7Report Type:Periodic Company Report #WAES 01102195
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Nephritis Interstitial Renal Failure Acute	Health Professional	Tab Vioxx 12.5mg	PS		ORAL	25 MG/DAILY/PO	

Initial or Prolonged	Company	Catapres	C
Disability	Representative	K-Dur	C
Other		Lasix (Furosemide)	C
		Lotensin	C
		Clonidine	C
		Insulin	C
		Nonsteroidal Anti-Inflammatory	C

Date:12/27/01ISR Number: 3848399-9Report Type:Periodic Company Report #WAES 01101834
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/PRN/PO	
Initial or Prolonged	Haemorrhage	Professional	Cardura	C				
			Coumadin	C				
			Darvocet-N	C				
			Hydrodiuril	C				
			Proscar	C				
			Vicoprofen	C				
			Nitroglycerin	C				
			Yohimbine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3848400-2Report Type:Periodic Company Report #WAES 01101631
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Claritin	C				
			Darvocet-N	C				
			Diflucan	C				
			Hydrodiuril	C				
			Prilosec	C				
			Voltaren	C				
			Methotrexate	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3848401-4Report Type:Periodic Company Report #WAES 01101622
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	3 MON
		Professional						
		Company						
		Representative						

Date:12/27/01ISR Number: 3848402-6Report Type:Periodic Company Report #WAES 01100417
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:12/27/01ISR Number: 3848403-8Report Type:Periodic Company Report #WAES 01100151
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL	25-50	
Hospitalization -	Gastric Ulcer	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal Haemorrhage	Company Representative	Ambien	C				
			Darvocet-N	C				
			Lipitor	C				
			Trandate	C				
			Potassium (Unspecified)	C				

Date:12/27/01ISR Number: 3848404-XReport Type:Periodic Company Report #WAES 01092826
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage		Effexor	C				
			Neurontin	C				
			Aspirin	C				
			Atenolol	C				
			Baclofen	C				
			Magnesium (Unspecified)	C				

			Quinine	C		

Date:12/27/01ISR Number: 3848405-1Report Type:Periodic Company Report #WAES 01092555
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged							MG/DAILY/PO	
			Norvasc	C				
			Plaquenil	C				
			Prempro	C				
			Doxepin	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3848406-3Report Type:Periodic Company Report #WAES 01092333
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Buspar	C				
		Representative	Elavil	C				
			Klonopin	C				
			Neurontin	C				
			Sinemet	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3848407-5Report Type:Periodic Company Report #WAES 01092227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						

Company
Representative

Date:12/27/01ISR Number: 3848479-8Report Type:Periodic Company Report #WAES 01091856
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

Date:12/27/01ISR Number: 3848480-4Report Type:Periodic Company Report #WAES 01091807
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Caltrate	C		
			Diovan Hct	C		
			Norvasc	C		
			Prempro	C		
			Aspirin	C		

			Labetalol Hydrochloride	C		
			Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3848481-6Report Type:Periodic Company Report #WAES 01090291
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	Initial or Prolonged
			Betapace	C				
			Vasotec	C				
			Zocor	C				

Date:12/27/01ISR Number: 3848482-8Report Type:Periodic Company Report #WAES 01090131
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Oedema Peripheral							
			Claritin	C				
			Coumadin	C				
			Cozaar	C				
			Esgic-Plus Tablets	C				
			Amiodarone	C				
			Diazepam	C				
			Metoprolol	C				
			Ranitidine	C				

Date:12/27/01ISR Number: 3848483-XReport Type:Periodic Company Report #WAES 01083042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company Representative				

Date:12/27/01ISR Number: 3848484-1Report Type:Periodic Company Report #WAES 01083004
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Dizziness					
MG/BID/PO						
	Fluid Retention		Synthroid	C		
	Oedema					

Date:12/27/01ISR Number: 3848485-3Report Type:Periodic Company Report #WAES 01082743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension	Consumer	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Health Professional Other				

Date:12/27/01ISR Number: 3855437-6Report Type:Periodic Company Report #WAES 01092889
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx	PS		ORAL	UNK/ DAILY / PO	

Date:12/27/01ISR Number: 3855438-8Report Type:Periodic Company Report #WAES 01092890
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx Unk	PS		ORAL	UNK/ PO	
	Pain In Extremity	Professional						

Date:12/27/01ISR Number: 3855439-XReport Type:Periodic Company Report #WAES 01092892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health	Tab Vioxx 12.5mg	PS		ORAL	UNK/PO	6 MON
		Professional						

Date:12/27/01ISR Number: 3855440-6Report Type:Periodic Company Report #WAES 01092934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health	Tab Vioxx 25 Mg	PS		ORAL	UNK/ PO	
	Infection	Professional Company Representative						

Date:12/27/01ISR Number: 3855441-8Report Type:Periodic Company Report #WAES 01092941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/ PO	

Date:12/27/01ISR Number: 3855442-XReport Type:Periodic Company Report #WAES 01092943
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Oedema							
			Prilosec	C				
			Sular	C				
			Vicodin	C				
			Xalatan	C				
			Calcium And Magnes	C				
			Chromium Picolinate	C				
			Lecithin	C				
			Linseed Oil	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855443-1Report Type:Periodic Company Report #WAES 01092944
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG BID PO	
	Pollakiuria		Levoxyl	C				
			Plaquenil	C				
			Pravachol	C				
			Prempro	C				
			Baclofen	C				

Date:12/27/01ISR Number: 3855451-0Report Type:Periodic Company Report #WAES 01093009
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Prinivil	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3855455-8Report Type:Periodic Company Report #WAES 01093011
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Date:12/27/01ISR Number: 3855461-3Report Type:Periodic Company Report #WAES 01093031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Erosive	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3855695-8Report Type:Periodic Company Report #WAES 01092823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Varicose Vein		Lipitor	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3855697-1Report Type:Periodic Company Report #WAES 01092827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative	Sudafed	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855699-5Report Type:Periodic Company Report #WAES 01092828
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3855701-0Report Type:Periodic Company Report #WAES 01092835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Fatigue		Celebrex	C				
	Hypertension		Diovan	C				
			Furosemide	C				
			Nadolol	C				

Date:12/27/01ISR Number: 3855704-6Report Type:Periodic Company Report #WAES 01092843
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3855706-XReport Type:Periodic Company Report #WAES 01092853
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Palpitations	Professional					
MG/DAILY/PO							
	Ventricular Extrasystoles		Tab Vioxx 50 Mg	SS			ORAL
50							
MG/DAILY/PO							
			Altace	C			
			Digoxin	C			
			Vitamins (Unspecified)	C			
			Aspirin	C			
			Lipitor	C			

Date:12/27/01ISR Number: 3855728-9Report Type:Periodic Company Report #WAES 01092854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Zestril	SS				
			Prilosec	C				

Date:12/27/01ISR Number: 3855729-0Report Type:Periodic Company Report #WAES 01092870
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx	PS		ORAL	PO	
	Nausea	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855732-0Report Type:Periodic Company Report #WAES 01092874
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Rash		Lipitor	C				
			Norvasc	C				
			Hydroxychloroquine Sulfate	C				

Date:12/27/01ISR Number: 3855735-6Report Type:Periodic Company Report #WAES 01092879
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Paxil	C				
			Premarin	C				
			Prilosec	C				
			Serevent Disk	C				
			Acetaminophen (+) Codeine Phosph	C				

Date:12/27/01ISR Number: 3855738-1Report Type:Periodic Company Report #WAES 01092511
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Swelling							

Date:12/27/01ISR Number: 3855742-3Report Type:Periodic Company Report #WAES 01092519
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Gastrointestinal Disorder		Celebrex	C				
	Mouth Ulceration		Maalox	C				
	Nausea		Tylenol	C				
	Oral Soft Tissue Disorder		Aspirin	C				
			Hormones	C				

Date:12/27/01ISR Number: 3855744-7Report Type:Periodic Company Report #WAES 01092520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Diarrhoea		Aceon	C				
			Terazosin Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855746-0Report Type:Periodic Company Report #WAES 01092524
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional Company Representative	Lasix (Furosemide)	C				
			Aspirin	C				
			Spironolactone	C				

Date:12/27/01ISR Number: 3855748-4Report Type:Periodic Company Report #WAES 01092525
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Increased	Professional Company Representative	Hydrodiuril	C				
			Imdur	C				
			Rythmol	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3855750-2Report Type:Periodic Company Report #WAES 01092528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3855753-8Report Type:Periodic Company Report #WAES 01092534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL
PO						
	Oesophageal Pain		Mylanta & Mylanta Ds	C		
			Oxycontin	C		
			Prempro	C		
			Synthroid	C		
			Zantac	C		
			Aspirin	C		
			Atenolol	C		
			Calcium	C		

Date:12/27/01ISR Number: 3855768-XReport Type:Periodic Company Report #WAES 01092536
Age:97 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

Date:12/27/01ISR Number: 3855770-8Report Type:Periodic Company Report #WAES 01092544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Fosamax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855771-XReport Type:Periodic Company Report #WAES 01092557
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Acupril	C				
			Coreg	C				
			Dermadex	C				
			Fosamax	C				
			Carbamazepine	C				
			Potassium (Unspecified)	C				

Date:12/27/01ISR Number: 3855926-4Report Type:Periodic Company Report #WAES 01091853
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 50mg	PS		ORAL	50MG /1X/PO	
			Calan	C				
			Hytrin	C				
			Relafen	C				
			Singulair	C				
			Tylenol	C				
			Zestril	C				
			Albuterol	C				
			Ranitidine	C				

Date:12/27/01ISR Number: 3855929-XReport Type:Periodic Company Report #WAES 01091858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Tab Vioxx Unk	PS		ORAL	50MG DAILY	
	Hyperbilirubinaemia						POSEE IMAGE	5 DAY
	Jaundice							

Nausea
Pruritus
Vomiting

Date:12/27/01ISR Number: 3855931-8Report Type:Periodic Company Report #WAES 01091859
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Joint Swelling		Prempro	C				
			Restoril	C				

Date:12/27/01ISR Number: 3855932-XReport Type:Periodic Company Report #WAES 01091862
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluid Retention		Baycol	C				
	Nausea		Pravachol	C				
	Rash		Zocor	C				
	Weight Increased		Aspirin	C				
			Calcium	C				
			Metoprolol	C				

Propafenone	C
Vitamin	C

Date:12/27/01ISR Number: 3855934-3Report Type:Periodic Company Report #WAES 01091868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx Unk	PS			PO	
	Tremor	Professional Company Representative						

Date:12/27/01ISR Number: 3855935-5Report Type:Periodic Company Report #WAES 01091873
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Deafness							

Date:12/27/01ISR Number: 3855936-7Report Type:Periodic Company Report #WAES 01091874
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx Unk	PS		ORAL	50MG PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3855938-0Report Type:Periodic Company Report #WAES 01091879
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG DAILY PO						
	Feeling Abnormal		Cozaar	C		
			Provera	C		
			Synthroid	C		
			Ascorbic Acid	C		
			Estrogens	C		
			Garlic Extrac	C		
			Lecithin	C		
			Spironolactone	C		
			Vitamins	C		

Date:12/27/01ISR Number: 3855940-9Report Type:Periodic Company Report #WAES 01091900
Age:61 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855943-4Report Type:Periodic Company Report #WAES 01091901
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Claritin	C				
			Flonase	C				
			Imodium	C				
			Levoxyl	C				
			Ziac	C				

Date:12/27/01ISR Number: 3855946-XReport Type:Periodic Company Report #WAES 01091770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	

Date:12/27/01ISR Number: 3855948-3Report Type:Periodic Company Report #WAES 01091779
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Retention	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3855950-1Report Type:Periodic Company Report #WAES 01091782
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Alkaline Phosphatase Increased	Health Professional Company	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3855952-5Report Type:Periodic Company Report #WAES 01091824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Pain	Professional	Tab Vioxx 25 Mg	SS		ORAL	50 MG DAILY PO	
			Ascorbic Acid	C				
			Hormonal Contraceptives	C				
			Vitamins	C				

Date:12/27/01ISR Number: 3855953-7Report Type:Periodic Company Report #WAES 01091825
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	4 DAY
	Lacrimation Increased	Professional	Accupril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855954-9Report Type:Periodic Company Report #WAES 01091832
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Pruritus		Synthroid	C				
			Calcium	C				

Date:12/27/01ISR Number: 3855955-0Report Type:Periodic Company Report #WAES 01091835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	UNK PO	

Date:12/27/01ISR Number: 3855956-2Report Type:Periodic Company Report #WAES 01091836
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
			Baycol	C				
			Pravachol	C				

Date:12/27/01ISR Number: 3855957-4Report Type:Periodic Company Report #WAES 01091844
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Dyspepsia		Tenormin	C				
			Hydrochlorothiazide And Triamterene	C				

Date:12/27/01ISR Number: 3855960-4Report Type:Periodic Company Report #WAES 01091850
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	UNK BID PO	
	Congestive Face Oedema Oedema Peripheral							

Date:12/27/01ISR Number: 3855964-1Report Type:Periodic Company Report #WAES 01091601
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Ativan	C				
			Celebrex	C				
			Detrol	C				
			Elavil	C				
			Evista	C				
			Lipitor	C				
			Microzide	C				
			Plendil	C				
			Synthroid	C				
			Toprol Xl Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3855966-5Report Type:Periodic Company Report #WAES 01091604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Plaquenil	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3855969-0Report Type:Periodic Company Report #WAES 01091609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Tinnitus	Company Representative						

Date:12/27/01ISR Number: 3855970-7Report Type:Periodic Company Report #WAES 01091620
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Fatigue		Meridia	SS		ORAL	15 MG/DAILY/PO	
	Nervousness							
			Synthroid	SS		ORAL	50 MICROGM/DAILY	

/PO

			Lorazepam	SS	ORAL
1 MG/BID/PO					
			Wellbutrin	SS	ORAL
150					
MG/DAILY/PO					

Date:12/27/01ISR Number: 3855972-0Report Type:Periodic Company Report #WAES 01091649
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspepsia						MG/DAILY/PO	
	Muscular Weakness		Ambien	C				
	Nausea		Procardia Xl	C				
			Theo-24	C				
			Zocor	C				
			Aspirin	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3855973-2Report Type:Periodic Company Report #WAES 01091650
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Vasotec	C				
			Vivelle-Dot	C				
			Medroxyprogesterone					

Acetate C

Date:12/27/01ISR Number: 3855978-1Report Type:Periodic Company Report #WAES 01091697
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3855994-XReport Type:Periodic Company Report #WAES 01091709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Vioxx	PS		ORAL	PO	
	Oedema							

Date:12/27/01ISR Number: 3855996-3Report Type:Periodic Company Report #WAES 01091710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Humulin	C				
			Cephalexin	C				
			Nortriptyline	C				
			Propoxphyene Napsylate	C				

Date:12/27/01ISR Number: 3855998-7Report Type:Periodic Company Report #WAES 01091712
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Swelling	Health	Tab Vioxx 25 Mg	PS			ORAL
PO							
		Professional	Detrol	C			

Date:12/27/01ISR Number: 3856007-6Report Type:Periodic Company Report #WAES 01091383
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Company	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
		Representative				

Date:12/27/01ISR Number: 3856009-XReport Type:Periodic Company Report #WAES 01091390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL
PO						
			Composition Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856010-6Report Type:Periodic Company Report #WAES 01091400
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/UNK/PO	1 WK
	Drug Ineffective		Clinoril	C				
	Fatigue							
	Somnolence							
	Speech Disorder							

Date:12/27/01ISR Number: 3856011-8Report Type:Periodic Company Report #WAES 01091406
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocythaemia	Consumer	Tab Vioxx 25 Mg	PS			25 MG/PRN/UNK	
			Fosamax	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3856013-1Report Type:Periodic Company Report #WAES 01091411
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/UNK/PO	
	Pigmentation Disorder	Professional	Pepcid Ac	C				
			Thyrolar	C				

Date:12/27/01ISR Number: 3856014-3Report Type:Periodic Company Report #WAES 01091412
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Constipation							
PO								

Date:12/27/01ISR Number: 3856015-5Report Type:Periodic Company Report #WAES 01091414
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Nausea	Health Professional	Femara	C				

Date:12/27/01ISR Number: 3856017-9Report Type:Periodic Company Report #WAES 01091443
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							
			Atenolol	C				

Date:12/27/01ISR Number: 3856018-0Report Type:Periodic Company Report #WAES 01091444
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				

				Ogen	C	
				Prinzide	C	
				Therapy Unspecified	C	
				Medroxyprogesterone Acetate	C	

Date:12/27/01ISR Number: 3856020-9Report Type:Periodic Company Report #WAES 01091466
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness	Health Professional						
	Dyspepsia		Coumadin	C				
	Mouth Haemorrhage		Tiazac	C				
	Nausea		Composition Unspecified	C				
	Vomiting							

Date:12/27/01ISR Number: 3856055-6Report Type:Periodic Company Report #WAES 01082897
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	PO	
	Pollakiuria		Lipitor	C				

Date:12/27/01ISR Number: 3856056-8Report Type:Periodic Company Report #WAES 01082902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Tab Vioxx	PS		ORAL	25 MG/ PO	
			Evista	C				
			Miacalcin	C				

Date:12/27/01ISR Number: 3856057-XReport Type:Periodic Company Report #WAES 01082904
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	PO	2 DAY
	Tongue Disorder	Health Professional	Tab Vioxx	SS		ORAL	PO	10 DAY

Date:12/27/01ISR Number: 3856058-1Report Type:Periodic Company Report #WAES 01082905
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/ PO	
	Face Oedema							
	Pruritus		Prozac	C				
	Rash							
	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856059-3Report Type:Periodic Company Report #WAES 01082918
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Tab Vioxx	PS		ORAL	25 MG/ DAILY / PO	
			Celebrex	C				
			Cosoft	C				

Date:12/27/01ISR Number: 3856060-XReport Type:Periodic Company Report #WAES 01082921
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	50 MG/ DAILY/ PO	
	Nausea							
	Urine Abnormality		Prinzide	C				
			Prozac	C				
			Synthroid	C				
			Zocor	C				
			Furosemide	C				

Date:12/27/01ISR Number: 3856061-1Report Type:Periodic Company Report #WAES 01082923
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/ PO	
	Faeces Discoloured							
	Oedema Peripheral		Covera-Hs	C				
	Rash		Miacalcin	C				
	Vaginal Infection		Perdiem Fiber	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:12/27/01ISR Number: 3856062-3Report Type:Periodic Company Report #WAES 01082924
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/ BID/ PO	
	Cough							
	Diarrhoea		Claritin-D	C				
	Dizziness		Paxil	C				
	Dyspepsia		Premarin	C				
	Fatigue		Zestril	C				
	Headache							
	Oedema Peripheral							
	Productive Cough							
	Weight Increased							

Date:12/27/01ISR Number: 3856063-5Report Type:Periodic Company Report #WAES 01082931
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	25 MG / DAILY / PO	
	Somnolence							
			Coreg	C				
			Plavix	C				
			Proscar	C				
			Furosemide	C				

				Terazosin Hydrochloride	C		

Date:12/27/01ISR Number: 3856064-7Report Type:Periodic Company Report #WAES 01082932
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx	PS		ORAL	25 MG/ AM/ PO	
	Nausea		Hyzaar	C				
			Timoptic-Xe	C				
			Verapamil	C				

Date:12/27/01ISR Number: 3856065-9Report Type:Periodic Company Report #WAES 01082548
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Plaquenil	C				

Date:12/27/01ISR Number: 3856066-0Report Type:Periodic Company Report #WAES 01082549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	30 DAY
			Aldactone	C				
			Demadex	C				
			Levoxyl	C				
			Lipitor	C				
			Monopril	C				
			...Orvasc	C				
			...Revacid	C				
			Zoloft	C				
			Isosorbide					

				Mononitrate	C		

Date:12/27/01ISR Number: 3856067-2Report Type:Periodic Company Report #WAES 01082566
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856068-4Report Type:Periodic Company Report #WAES 01082568
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Tightness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Palpitations	Health					PO	
	Supraventricular Tachycardia	Professional	Claritin	C				
			Equate	C				
			Fosamax	C				
			Paxil	C				
			Prilosec	C				
			...Rocardia	C				
			...Spirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856069-6Report Type:Periodic Company Report #WAES 01082571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856070-2Report Type:Periodic Company Report #WAES 01082581
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Influenza Like Illness							
			Combivent	C				
			Darvocet-N	C				
			Imdur	C				
			Methotrexate (Methotrexate Sodium)	C				
			Toprol Xl Tablets	C				
			Xanax	C				
			Aspirin	C				
			Nitroglycerin	C				

Date:12/27/01ISR Number: 3856071-4Report Type:Periodic Company Report #WAES 01082588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Disease	Health						
		Professional	Prevacid	C				
			Hormonal Contrceptives (Unspec	C				

Date:12/27/01ISR Number: 3856072-6Report Type:Periodic Company Report #WAES 01082603
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional	Eurax	C				
	Pelvic Pain	Company	Prempro	C				
	Skin Disorder	Representative	Betamethasone	C				
	Thrombosis							

Date:12/27/01ISR Number: 3856073-8Report Type:Periodic Company Report #WAES 01082604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actonel	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856074-XReport Type:Periodic Company Report #WAES 01082607
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3856075-1Report Type:Periodic Company Report #WAES 01080440
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer Health Professional	Tab Vioxx	PS				
			Tab Zocor 20 Mg	SS		ORAL	20 MG, DAILY, PO	
			Centrum	C				
			Glucophage	C				
			Lotensin	C				
			Motrin	C				
			Metoprolol	C				
			Oxybutynin Chloride	C				
			Vitamin E	C				

Date:12/27/01ISR Number: 3856076-3Report Type:Periodic Company Report #WAES 01082193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Company Representative Other	Tab Vioxx	PS		ORAL	25 MG, DAILY, PO	

Date:12/27/01ISR Number: 3856077-5Report Type:Periodic Company Report #WAES 01082195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Other	Tab Vioxx	PS		ORAL	PO	
	Panic Disorder							

Date:12/27/01ISR Number: 3856078-7Report Type:Periodic Company Report #WAES 01082199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	4 DAY
		Professional	Thyroid	C				

Date:12/27/01ISR Number: 3856079-9Report Type:Periodic Company Report #WAES 01082203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856080-5Report Type:Periodic Company Report #WAES 01082209
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	25 MG, BID,	
	Retching							
PO								
			Celebrex	C				
			Prinivil	C				
			Glyburide	C				
			Ranitidine	C				
			Verapamil	C				

Date:12/27/01ISR Number: 3856081-7Report Type:Periodic Company Report #WAES 01082216
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG, DAILY,	
PO								4 DAY
			Cordarone	C				
			Cozaar	C				
			Inderal	C				
			Lopid	C				
			Prilosec	C				
			Procan-Sr	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856082-9Report Type:Periodic Company Report #WAES 01082223
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG, DAILY,	
PO								
			Trazodone	C				

Date:12/27/01ISR Number: 3856083-0Report Type:Periodic Company Report #WAES 01082236
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG, DAILY, PO	
			Doxycycline	C				

Date:12/27/01ISR Number: 3856084-2Report Type:Periodic Company Report #WAES 01082243
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25 MG, DAILY, PO	
			Xanax	C				

Date:12/27/01ISR Number: 3856085-4Report Type:Periodic Company Report #WAES 01081000
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856086-6Report Type:Periodic Company Report #WAES 01081053
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vocal Cord Disorder	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:12/27/01ISR Number: 3856087-8Report Type:Periodic Company Report #WAES 01081064
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Middle Ear Effusion							
	Pyrexia		Amitriptyline	C				

Date:12/27/01ISR Number: 3856088-XReport Type:Periodic Company Report #WAES 01081071
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Urticaria							
			Lipitor	C				

Date:12/27/01ISR Number: 3856089-1Report Type:Periodic Company Report #WAES 01081081
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Thyroid Stimulating	Consumer	Tab Vioxx	PS		ORAL	25	

Hormone Decreased
MG/DAILY/PO
Somnolence Levothyroxine Sodium C

Date:12/27/01ISR Number: 3856090-8Report Type:Periodic Company Report #WAES 01081182
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Gastritis		Antivert	C				
			Atacand	C				
			Avandia	C				
			Glucotrol	C				
			Hyzaar	C				
			Lasix (Furosemide)	C				
			Zocor	C				

Date:12/27/01ISR Number: 3856091-XReport Type:Periodic Company Report #WAES 01081200
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO ;	
	Headache	Professional						
	Musculoskeletal Stiffness						25 MG/DAILY/PO	
	Pain							
			Allegra	C				
			Altace	C				
			Evista	C				

			Norvasc	C
			Synthroid	C
			Atenolol	C

Date:12/27/01ISR Number: 3856092-1Report Type:Periodic Company Report #WAES 01081301
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Plaquenil	C				

Date:12/27/01ISR Number: 3856093-3Report Type:Periodic Company Report #WAES 01081307
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO ;	
	Chest Pain	Company Representative					25 MG/Q3D/PO ; 25 MG/QOD/PO	

Date:12/27/01ISR Number: 3856094-5Report Type:Periodic Company Report #WAES 01081313
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856095-7Report Type:Periodic Company Report #WAES 01080600
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Viagra	C				

Date:12/27/01ISR Number: 3856096-9Report Type:Periodic Company Report #WAES 01080706
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Viox 25 Mg	PS		ORAL	PO	
		Health Professional	Lotensin	C				
			Macrodantin	C				
			Therapy Unspecified	C				
			Potassium (Unspecified)	C				

Date:12/27/01ISR Number: 3856097-0Report Type:Periodic Company Report #WAES 01080736
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Vision Blurred		Lopressor	C				
			Xanax	C				

				Zestril	C		

Date:12/27/01ISR Number: 3856098-2Report Type:Periodic Company Report #WAES 01080846
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Macular Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vision Blurred	Professional						
	Visual Acuity Reduced	Company Representative	Skelaxin	C				

Date:12/27/01ISR Number: 3856099-4Report Type:Periodic Company Report #WAES 01080851
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperaesthesia	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Timoptic	C				

Date:12/27/01ISR Number: 3856103-3Report Type:Periodic Company Report #WAES 01080853
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 50MG DAILY PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Cardura	C				

				Celebrex	C		
				Nexium	C		
				Persantine	C		
				Prilosec	C		

Date:12/27/01ISR Number: 3856108-2Report Type:Periodic Company Report #WAES 01080874
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Oedema	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Celebrex	C				

Date:12/27/01ISR Number: 3856130-6Report Type:Periodic Company Report #WAES 01080972
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer Health	Tab Vioxx 25 Mg; 50 Mg	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
		Professional						
			Lipitor	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856135-5Report Type:Periodic Company Report #WAES 01080977
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menopausal Symptoms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
		Health Professional	Estratab	C				

Date:12/27/01ISR Number: 3856140-9Report Type:Periodic Company Report #WAES 01080980
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Libido Decreased	Health Professional						
	Respiratory Disorder		Hydrodiuril	C				
	Weight Increased		Prinivil	C				

Date:12/27/01ISR Number: 3856195-1Report Type:Periodic Company Report #WAES 01080318
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856196-3Report Type:Periodic Company Report #WAES 01080330
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Professional
MG/DAILY/PO

Indocin (Indomethacin)	C
Therapy Unspecified	C
Verapamil	C

Date:12/27/01ISR Number: 3856197-5Report Type:Periodic Company Report #WAES 01080333
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective							

Date:12/27/01ISR Number: 3856198-7Report Type:Periodic Company Report #WAES 01080382
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856199-9Report Type:Periodic Company Report #WAES 01080390
Age:70 YR Gender:Female I/FU:F

Outcome	PT
	Asthenia
	Fatigue

	Fluid Retention Weight Increased					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Prevacid	C		
			Calcium (Unspecified)	C		
			Chondroitin (+) Glucosamine	C		
			Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3856200-2Report Type:Periodic Company Report #WAES 01080393
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Levoxyl	C		
			Premarin	C		
			Therapy Unspecified	C		
			Atenolol	C		

Date:12/27/01ISR Number: 3856201-4Report Type:Periodic Company Report #WAES 01080410
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Asthma	Health	Tab Vioxx	PS		ORAL
PO	3 WK					
		Professional Company Representative				

Date:12/27/01ISR Number: 3856202-6Report Type:Periodic Company Report #WAES 01080534
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Malaise							

Date:12/27/01ISR Number: 3856203-8Report Type:Periodic Company Report #WAES 01080556
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
		Health Professional	Therapy Unspecified	C				
			Hydrocodone	C				

Date:12/27/01ISR Number: 3856204-XReport Type:Periodic Company Report #WAES 01080565
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Health Professional	Adalat	C				
			Levothroid	C				

			Premarin	C		
			Sinemet	C		

Date:12/27/01ISR Number: 3856205-1Report Type:Periodic Company Report #WAES 01072793
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3856206-3Report Type:Periodic Company Report #WAES 01072876
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/BID/PO; 2) 50 MG/DAILY/PO	
			Detrol	C				
			Imdur	C				
			Prilosec	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3856207-5Report Type:Periodic Company Report #WAES 01072887
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain	Health	Ditropan	C				

	Professional	Prempro	C
		Protonix	C
		Vicodin Tablets	C
		Levothyroxine Sodium	C

Date:12/27/01ISR Number: 3856208-7Report Type:Periodic Company Report #WAES 01072893
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Olfactory Nerve Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Skin Odour Abnormal	Health					MG/DAILY/PO	
	Urine Abnormality	Professional						

Date:12/27/01ISR Number: 3856209-9Report Type:Periodic Company Report #WAES 01080026
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Epistaxis	Health					MG/DAILY/PO	
		Professional	Norvasc	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856210-5Report Type:Periodic Company Report #WAES 01080027
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Urocit-K	C				
			Indapamide	C				

Date:12/27/01ISR Number: 3856211-7Report Type:Periodic Company Report #WAES 01080132
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 WK
		Health Professional	Lipitor	C				
			Premarin	C				

Date:12/27/01ISR Number: 3856212-9Report Type:Periodic Company Report #WAES 01080148
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema	Company Representative						

Date:12/27/01ISR Number: 3856213-0Report Type:Periodic Company Report #WAES 01080231
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Company
Representative

Date:12/27/01ISR Number: 3856214-2Report Type:Periodic Company Report #WAES 01080243
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PRN/PO	
		Professional						
		Company						
		Representative						

Date:12/27/01ISR Number: 3856215-4Report Type:Periodic Company Report #WAES 01072053
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
		Professional						
		Company	Hydrodiuril	C			PO	
		Representative	K-Dur	C				
			Lasix	C				
			Aspirin	C				
			Digoxin	C				
			Quinine Sulfate	C				

Date:12/27/01ISR Number: 3856216-6Report Type:Periodic Company Report #WAES 01072229
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
		Health						
ORAL								
		Professional	Lanoxin	C				
			Procardia	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3856217-8Report Type:Periodic Company Report #WAES 01072254
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Weight Increased	Health						
PO								
		Professional	Nasonex	C				

Date:12/27/01ISR Number: 3856218-XReport Type:Periodic Company Report #WAES 01072255
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY,	
	Headache	Professional						
PO								
	Muscular Weakness		Effexor Xr	C				
	Nausea		Elavil	C				
	Pain							
	Swelling							
	Vision Blurred							

Date:12/27/01ISR Number: 3856219-1Report Type:Periodic Company Report #WAES 01072527
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, BID, PO	
	Nausea	Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	

Date:12/27/01ISR Number: 3856220-8Report Type:Periodic Company Report #WAES 01072530
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
		Health Professional	Flomax (Tamsulosin Hydrochloride)	C				
			Fosamax	C				
			Imodium	C				
			Librax Capsules	C				
			Os-Cal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856221-XReport Type:Periodic Company Report #WAES 01072618
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx	PS		ORAL	25 MG, DAILY, PO	1 DAY
		Company Representative	Tab Vioxx	SS		ORAL	50, 1X, PO	1 DAY
			Claritin	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3856222-1Report Type:Periodic Company Report #WAES 01072644
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
		Company Representative	Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	

Date:12/27/01ISR Number: 3856223-3Report Type:Periodic Company Report #WAES 01072659
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Haematochezia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, DAILY, PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY,	

PO

			Cordarone	C		
			Composition			
			Unspecified	C		
			Vasotec	C		

Date:12/27/01ISR Number: 3856224-5Report Type:Periodic Company Report #WAES 01072761
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Face Oedema	Professional						
PO								
	Muscle Tightness		Amoxicillin	C				
	Oedema Peripheral		Clarithromycin	C				
	Weight Increased		Lansoprazole	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3856225-7Report Type:Periodic Company Report #WAES 01071395
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Darvocet-N	C				
			Daypro	C				
			Premarin	C				
			Prilosec	C				
			Zocor	C				
			Nonsteroidal Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856226-9Report Type:Periodic Company Report #WAES 01071601
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Myalgia	Professional Company Representative						

Date:12/27/01ISR Number: 3856227-0Report Type:Periodic Company Report #WAES 01071623
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage		Arthrotec	C				

Date:12/27/01ISR Number: 3856228-2Report Type:Periodic Company Report #WAES 01071625
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
		Health Professional						

Date:12/27/01ISR Number: 3856229-4Report Type:Periodic Company Report #WAES 01071672
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Tightness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) PO; 2)	
	Oedema Peripheral	Health					25 MG/QOD/PO	
		Professional	Prevacid	C				
			Tylenol Sinus	C				

				Zocor	C		

Date:12/27/01ISR Number: 3856230-0Report Type:Periodic Company Report #WAES 01071710
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Provera	C				
			Synthroid	C				
			Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3856231-2Report Type:Periodic Company Report #WAES 01071836
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Estrace	C				
			Maxzide	C				
			Synthroid	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856232-4Report Type:Periodic Company Report #WAES 01071865
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Ineffective		Celebrex	C				
	Hyperhidrosis		Fosamax	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3856233-6Report Type:Periodic Company Report #WAES 01072036
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856234-8Report Type:Periodic Company Report #WAES 01072037
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Health					MG/DAILY/PO	
	Weight Increased	Professional	Actonel	C				
			Ambien	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3856235-XReport Type:Periodic Company Report #WAES 01070759
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL
PRN/PO						
	Fluid Retention	Health				
	Weight Increased	Professional				

Date:12/27/01ISR Number: 3856236-1Report Type:Periodic Company Report #WAES 01070812
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
PO						
	Haemorrhage	Professional				
		Company				
		Representative				

Date:12/27/01ISR Number: 3856237-3Report Type:Periodic Company Report #WAES 01070928
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Dysphonia	Health				
MG/DAILY/PO						
	Hyperglycaemia	Professional	Actos	C		
	Nasal Congestion		Glucophage	C		
			Glyburide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856238-5Report Type:Periodic Company Report #WAES 01071128
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Fluid Retention	Health						
	Oedema Peripheral	Professional	Lasix (Furosemide)	C				
			Lipitor	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3856239-7Report Type:Periodic Company Report #WAES 01071134
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856240-3Report Type:Periodic Company Report #WAES 01071210
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx	PS		ORAL	ORAL	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856241-5Report Type:Periodic Company Report #WAES 01071332
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO
			Diovan	C		
			Imdur	C		
			Lasix (Furosemide)	C		
			Lopressor	C		
			Aspirin	C		

Date:12/27/01ISR Number: 3856242-7Report Type:Periodic Company Report #WAES 01071362
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Health Professional						

Date:12/27/01ISR Number: 3856243-9Report Type:Periodic Company Report #WAES 01071384
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856244-0Report Type:Periodic Company Report #WAES 01071391
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Celebrex	C				

Date:12/27/01ISR Number: 3856245-2Report Type:Periodic Company Report #WAES 01090062
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Voixx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aricept	C				
			Darvocet-N	C				
			Detrol	C				
			Dilacor Xr	C				
			Synthroid	C				
			Zoloft (Therapy Unspecified)	C				
			Trazodone Hydrochloride	C				

Date:12/27/01ISR Number: 3856246-4Report Type:Periodic Company Report #WAES 01090063
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lipitor	C				
			Prilosec	C				
			Zocor	C				

Date:12/27/01ISR Number: 3856247-6Report Type:Periodic Company Report #WAES 01090066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Penicillin (Unspecified)	C				

Date:12/27/01ISR Number: 3856248-8Report Type:Periodic Company Report #WAES 01090074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Glucophage	C				
			Vasotec	C				

Date:12/27/01ISR Number: 3856249-XReport Type:Periodic Company Report #WAES 01090075
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dyspepsia	Health						
	Joint Swelling	Professional	Motrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856250-6Report Type:Periodic Company Report #WAES 01090080
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856251-8Report Type:Periodic Company Report #WAES 01090094
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856252-XReport Type:Periodic Company Report #WAES 01090095
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Discomfort	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856253-1Report Type:Periodic Company Report #WAES 01090101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:12/27/01ISR Number: 3856254-3Report Type:Periodic Company Report #WAES 01090123
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Celebrex	C				
			Celexa	C				
			Clonidine	C				
			Furosemide	C				
			Verapamil	C				

Date:12/27/01ISR Number: 3856255-5Report Type:Periodic Company Report #WAES 01092002
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	
			Celebrex	C				
			Cytotec	C				
			Pepcid	C				

Date:12/27/01ISR Number: 3856256-7Report Type:Periodic Company Report #WAES 01092004
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY;	
ORAL								

Date:12/27/01ISR Number: 3856257-9Report Type:Periodic Company Report #WAES 01092014
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/	
PO								

Date:12/27/01ISR Number: 3856258-0Report Type:Periodic Company Report #WAES 01092021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
PO		Company Representative						

Date:12/27/01ISR Number: 3856259-2Report Type:Periodic Company Report #WAES 01092030
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY;	
PO								

			Tab Vioxx 25 Mg	C		ORAL
25 MG/DAILY;						
PO						
			Atrovent	C		
			Nexium	C		
			Nolvadex	C		
			Paxil	C		
			Alprazolam	C		
			Clonidine	C		
			Gemfibrozil	C		
			Theophylline	C		

Date:12/27/01ISR Number: 3856260-9Report Type:Periodic Company Report #WAES 01092042
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY;						
		Professional				
PO						

Date:12/27/01ISR Number: 3856261-0Report Type:Periodic Company Report #WAES 01092045
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY;						
	Myalgia					
PO						
	Oedema Peripheral		Glucophage	C		
			Humulin 70/30	C		
			Levoxyl	C		
			Pravachol	C		

Pulmicort	C
Albuterol	C
Hydrochlorothiazide (+) Lisinopr	C

Date:12/27/01ISR Number: 3856262-2Report Type:Periodic Company Report #WAES 01092089
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856263-4Report Type:Periodic Company Report #WAES 01092090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			Aspirin	C				

Date:12/27/01ISR Number: 3856264-6Report Type:Periodic Company Report #WAES 01092101
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Engorgement	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	
	Breast Pain							
			Dilantin	C				
			Prevacid	C				
			Zyrtec	C				

Date:12/27/01ISR Number: 3856265-8Report Type:Periodic Company Report #WAES 01093055
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Plaquenil	C				
			Synthroid	C				
			Atenolol	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3856266-XReport Type:Periodic Company Report #WAES 01093032
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Exfoliation	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856267-1Report Type:Periodic Company Report #WAES 01093034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	12.5	
	Confusional State						MG/DAILY/PO	
	Fatigue		Bentyl	C				
	Memory Impairment		Lipitor	C				
	Oedema Peripheral		Tagamet	C				
	Somnolence		Insulin	C				
	Weight Increased							

Date:12/27/01ISR Number: 3856268-3Report Type:Periodic Company Report #WAES 01093035
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25	
	Drug Ineffective						MG/DAILY/PO	
			Avapro	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Aspirin	C				
			Verapamil	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3856269-5Report Type:Periodic Company Report #WAES 01093036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	PO	
			[Composition Unspecified]	C				

Date:12/27/01ISR Number: 3856270-1Report Type:Periodic Company Report #WAES 01093037
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Retching							

Date:12/27/01ISR Number: 3856271-3Report Type:Periodic Company Report #WAES 01093045
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Fatigue							
	Headache		Pulmicort	C				
	Musculoskeletal Stiffness		Xopenex	C				
			Zyrtec	C				

Date:12/27/01ISR Number: 3856272-5Report Type:Periodic Company Report #WAES 01093049
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea		Hydrodiuril	C				

			Micro K	C		
			Tenormin	C		

Date:12/27/01ISR Number: 3856273-7Report Type:Periodic Company Report #WAES 01093052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Other	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856274-9Report Type:Periodic Company Report #WAES 01093054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Diovan	C				
			Prozac	C				
			Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3856275-0Report Type:Periodic Company Report #WAES 01112422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856276-2Report Type:Periodic Company Report #WAES 01112428
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Fatigue		Tab Vioxx 25 Mg	SS		ORAL	25 MG, QOD, PO	
	Tachycardia							
			Claritin	C				
			Maxzide	C				
			Norvasc	C				
			Premarin	C				

Date:12/27/01ISR Number: 3856277-4Report Type:Periodic Company Report #WAES 01112436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856278-6Report Type:Periodic Company Report #WAES 01112440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856279-8Report Type:Periodic Company Report #WAES 01112477
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Respiratory Disorder							
	Wheezing							

Date:12/27/01ISR Number: 3856280-4Report Type:Periodic Company Report #WAES 01112506
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856281-6Report Type:Periodic Company Report #WAES 01112507
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Odour Abnormal	Health Professional	Tab Vioxx	PS		ORAL	PO	

Company
Representative

Date:12/27/01ISR Number: 3856282-8Report Type:Periodic Company Report #WAES 01112508
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856283-XReport Type:Periodic Company Report #WAES 01112510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856284-1Report Type:Periodic Company Report #WAES 01112609
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/	PO
			Accupril	C				
			Ambien	C				
			Pravachol	C				
			Chlordiazepoxide	C				

Date:12/27/01ISR Number: 3856285-3Report Type:Periodic Company Report #WAES 01112277
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Flushing	Professional						
	Oedema Peripheral							

Date:12/27/01ISR Number: 3856286-5Report Type:Periodic Company Report #WAES 01112278
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Professional					MG/DAILY/PO	
			Atenolol	C				
			Galantamine Hydrobromide	C				
			Nitroglycerin	C				

Date:12/27/01ISR Number: 3856287-7Report Type:Periodic Company Report #WAES 01112298
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS			ORAL
50 MG/PRN/PO							
	Weight Increased		Lortab	C			
			Nasonex	C			
			Norvasc	C			
			Premarin	C			
			Prilosec	C			
			Ziac	C			
			Calcium (Unspecified)	C			
			Fluoxetine	C			
			Vitamins (Unspecified)	C			

Date:12/27/01ISR Number: 3856288-9Report Type:Periodic Company Report #WAES 01112315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Dyspepsia					
	Hypoaesthesia					
	Malaise					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856289-0Report Type:Periodic Company Report #WAES 01112369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:12/27/01ISR Number: 3856290-7Report Type:Periodic Company Report #WAES 01112371
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856291-9Report Type:Periodic Company Report #WAES 01112377
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health Professional	Tab Vioxx 25 Mg; 50 Mg	PS		ORAL	PO SEE IMAGE	
		Company Representative						

Date:12/27/01ISR Number: 3856292-0Report Type:Periodic Company Report #WAES 01112400
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	UNK; 25; 50	

MG/DAILY/PO

Allegra	C
Combipatch	C
Combivent	C
Flonase	C
Flovent	C
Lipitor	C
Ultram	C
Vaseretic	C
Carisoprodol	C

Date:12/27/01ISR Number: 3856293-2Report Type:Periodic Company Report #WAES 01112414
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856294-4Report Type:Periodic Company Report #WAES 01112419
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 WK

Date:12/27/01ISR Number: 3856295-6Report Type:Periodic Company Report #WAES 01111907
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856296-8Report Type:Periodic Company Report #WAES 01111908
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856297-XReport Type:Periodic Company Report #WAES 01111909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fatigue							

Date:12/27/01ISR Number: 3856298-1Report Type:Periodic Company Report #WAES 01111963
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Altace	C				
			Trusopt	C				
			Xalatan	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				

Date:12/27/01ISR Number: 3856299-3Report Type:Periodic Company Report #WAES 01112057
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Aleve	C				

Date:12/27/01ISR Number: 3856300-7Report Type:Periodic Company Report #WAES 01112173
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856301-9Report Type:Periodic Company Report #WAES 01112202
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Hallucination		Synthroid	C				
			Zestoretic	C				

Date:12/27/01ISR Number: 3856302-0Report Type:Periodic Company Report #WAES 01112212
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Pruritus							

Date:12/27/01ISR Number: 3856303-2Report Type:Periodic Company Report #WAES 01112227
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856304-4Report Type:Periodic Company Report #WAES 01112264
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Cozaar	C				
			Detrol	C				
			Levaquin	C				

Mevacor	C
Ophtosol	C
Singulair	C
Synthroid	C
Albuterol	C
Diazepam	C
Nystatin	C
Prednisone	C

Date:12/27/01ISR Number: 3856305-6Report Type:Periodic Company Report #WAES 01110658
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856306-8Report Type:Periodic Company Report #WAES 01110682
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856307-XReport Type:Periodic Company Report #WAES 01110697
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856308-1Report Type:Periodic Company Report #WAES 01110700
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Flovent	C				
			Norvasc	C				
			Os-Cal	C				
			Aspirin	C				
			Glucosamine	C				
			Metoprolol	C				

Date:12/27/01ISR Number: 3856309-3Report Type:Periodic Company Report #WAES 01110702
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Glossodynia		Fosamax	C				
			Xanax	C				
			Zoloft	C				

Date:12/27/01ISR Number: 3856310-XReport Type:Periodic Company Report #WAES 01110709
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO	

Date:12/27/01ISR Number: 3856311-1Report Type:Periodic Company Report #WAES 01110710
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Hypoaesthesia		Celexa	C				
			Hydrodiuril	C				
			Prilosec	C				
			Atenolol	C				
			Lorazepam	C				

Date:12/27/01ISR Number: 3856312-3Report Type:Periodic Company Report #WAES 01110716
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856313-5Report Type:Periodic Company Report #WAES 01110718
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional						
			Avandia	C				

Date:12/27/01ISR Number: 3856314-7Report Type:Periodic Company Report #WAES 01110735
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO;	
	Weight Increased						25 MG/DAILY/PO	
			Claritin	C				
			Premarin	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3856315-9Report Type:Periodic Company Report #WAES 01083071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:12/27/01ISR Number: 3856316-0Report Type:Periodic Company Report #WAES 01083072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856317-2Report Type:Periodic Company Report #WAES 01083074
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856318-4Report Type:Periodic Company Report #WAES 01083075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
	Vaginal Infection	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856319-6Report Type:Periodic Company Report #WAES 01083083
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856320-2Report Type:Periodic Company Report #WAES 01083110
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856321-4Report Type:Periodic Company Report #WAES 01083112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Palpitations							

Date:12/27/01ISR Number: 3856322-6Report Type:Periodic Company Report #WAES 01083128
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Zocor	C				

Date:12/27/01ISR Number: 3856323-8Report Type:Periodic Company Report #WAES 01083148
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Other	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	7 DAY
	Depression							
	Fatigue		Celebrex	C				
			Claritin	C				
			Digitek	C				
			Flomax (Morniflumate)	C				
			K-Dur	C				
			...Ynthroid	C				
			...Oloft	C				
			Albuterol	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856324-XReport Type:Periodic Company Report #WAES 01083149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856325-1Report Type:Periodic Company Report #WAES 01083150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Flomax (Tamsulosin Hydrochloride)	C				

Date:12/27/01ISR Number: 3856326-3Report Type:Periodic Company Report #WAES 01083152
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx	PS		ORAL	PRN	

Date:12/27/01ISR Number: 3856327-5Report Type:Periodic Company Report #WAES 01083160
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Celebrex	C				
			Clonidine	C				

Date:12/27/01ISR Number: 3856328-7Report Type:Periodic Company Report #WAES 01083167
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Avapro	C				
			Coumadin	C				

Norvasc	C
Trental	C
Tricor	C
Tylenol Sinus	C
Digoxin	C

Date:12/27/01ISR Number: 3856329-9Report Type:Periodic Company Report #WAES 01083169
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856330-5Report Type:Periodic Company Report #WAES 01083176
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Neurontin	C				
			Toprol Xl Tablets	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856331-7Report Type:Periodic Company Report #WAES 01083193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anuria	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856332-9Report Type:Periodic Company Report #WAES 01083195
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	
			Norvasc	C				
			Calcium (Unspecified)	C				

Date:12/27/01ISR Number: 3856333-0Report Type:Periodic Company Report #WAES 01083200
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856334-2Report Type:Periodic Company Report #WAES 01083201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Professional
MG/DAILY/PO
Company
Representative

Date:12/27/01ISR Number: 3856335-4Report Type:Periodic Company Report #WAES 01102443
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx Unk Effexor	PS C		ORAL	PO	

Date:12/27/01ISR Number: 3856336-6Report Type:Periodic Company Report #WAES 01102473
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856337-8Report Type:Periodic Company Report #WAES 01102492
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Cystitis	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx Unk	PS		ORAL
PO						

Date:12/27/01ISR Number: 3856338-XReport Type:Periodic Company Report #WAES 01102495
Age:77 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Proteinuria	Consumer	Tab Vioxx 12.5mg	PS		ORAL
12.5MG DAILY						
	Renal Impairment					
PO						
			Allegra	C		
			Flonase	C		
			Hytrin	C		
			Mevacor	C		
			Micro K	C		
			Prinivil	C		
			Synthroid	C		
			Indapamide	C		

Date:12/27/01ISR Number: 3856339-1Report Type:Periodic Company Report #WAES 01102547
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dyspepsia	Consumer	Tab Vioxx 12.5mg	PS		ORAL
12.5MG DAILY						
	Tachycardia					
PO						

Date:12/27/01ISR Number: 3856340-8Report Type:Periodic Company Report #WAES 01102549
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Erythema	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG DAILY PO						
	Hyperaesthesia					
	Skin Warm					

Date:12/27/01ISR Number: 3856341-XReport Type:Periodic Company Report #WAES 01102551
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG DAILY PO						
	Nocturia		Allegra	C		
			Verapamil	C		

Date:12/27/01ISR Number: 3856342-1Report Type:Periodic Company Report #WAES 01102558
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG DAILY PO						
			Celexa	C		
			Chlorazepate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856343-3Report Type:Periodic Company Report #WAES 01102559
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Fatigue						SEE IMAGE	
	Muscular Weakness		Ranitidine	C				
	Musculoskeletal Stiffness							

Date:12/27/01ISR Number: 3856344-5Report Type:Periodic Company Report #WAES 01102560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	1 MON
	Diarrhoea							
	Rash							

Date:12/27/01ISR Number: 3856345-7Report Type:Periodic Company Report #WAES 01102402
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased	Professional						
			Elavil	C				
			Hydrodiuril	C				
			Synthroid	C				
			Zoloft	C				

Date:12/27/01ISR Number: 3856346-9Report Type:Periodic Company Report #WAES 01102403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Consumer	Tab Vioxx 50 Mg	PS		
50 MG/QOD						

Date:12/27/01ISR Number: 3856347-0Report Type:Periodic Company Report #WAES 01102406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
SEE IMAGE						
	Haemorrhage	Professional Company Representative				

Date:12/27/01ISR Number: 3856348-2Report Type:Periodic Company Report #WAES 01102416
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
			Synthroid	C		
			Glucosamine	C		
			Vitamin E	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856349-4Report Type:Periodic Company Report #WAES 01102417
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856350-0Report Type:Periodic Company Report #WAES 01102419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856351-2Report Type:Periodic Company Report #WAES 01102423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Paraesthesia							
			Norvasc	C				
			Premarin	C				
			Prevacid	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856352-4Report Type:Periodic Company Report #WAES 01102426
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

			Flonase	C		
			Lanoxicaps	C		

Date:12/27/01ISR Number: 3856353-6Report Type:Periodic Company Report #WAES 01102429
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3856354-8Report Type:Periodic Company Report #WAES 01102440
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Atorvent	C				
			Centrum Silver	C				
			Flovent	C				
			Lasix (Furosemide)	C				
			Mevacor	C				
			Proventil	C				
			Xanax	C				
			Calcium	C				

				Diltiazem Hydrochloride	C		

Date:12/27/01ISR Number: 3856355-XReport Type:Periodic Company Report #WAES 01102351
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Erythema							
	Pruritus		Dilantin	C				
			Fosamax	C				
			Miacalcin	C				
			Ogen	C				
			Os-Cal+D	C				
			Plavix	C				
			Slow Fe	C				
			Melatonin	C				

Date:12/27/01ISR Number: 3856356-1Report Type:Periodic Company Report #WAES 01102372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx	PS		ORAL		DAILY/PO

Date:12/27/01ISR Number: 3856357-3Report Type:Periodic Company Report #WAES 01102376
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Flatulence							
			Alegan S	C				
			Azopt Drops	C				
			Betagan	C				

				Enduron	C		
				Lipitor	C		
				Rescula	C		

Date:12/27/01ISR Number: 3856358-5Report Type:Periodic Company Report #WAES 01102382
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Composition					
		Company	Unspecified	C				
		Representative						

Date:12/27/01ISR Number: 3856359-7Report Type:Periodic Company Report #WAES 01102385
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lasix (Furosemide)	C				
			Paxil	C				
			Pravachol	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3856360-3Report Type:Periodic Company Report #WAES 01102386
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856361-5Report Type:Periodic Company Report #WAES 01102388
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Accupril	C				
			Klor-Con	C				
			Lasix (Furosemide)	C				
			Levothyroid	C				
			Oxycontin	C				
			Diltiazem Hydrochloride	C				

Date:12/27/01ISR Number: 3856362-7Report Type:Periodic Company Report #WAES 01102390
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Gastric Ulcer		Tylenol	C				

Date:12/27/01ISR Number: 3856363-9Report Type:Periodic Company Report #WAES 01102392
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Levoxyl	C				
			Lotrel	C				

Date:12/27/01ISR Number: 3856364-0Report Type:Periodic Company Report #WAES 01102399
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Gastrointestinal Disorder						MG/DAILY/PO	
	Nausea		Tylenol With Codeine #3	C				

Date:12/27/01ISR Number: 3856365-2Report Type:Periodic Company Report #WAES 01102246
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856366-4Report Type:Periodic Company Report #WAES 01102262
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Congestive	Professional					MG/DAILY/PO	
	Hypertension		Lortab	C				
			Sonata	C				

Date:12/27/01ISR Number: 3856367-6Report Type:Periodic Company Report #WAES 01102269
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Claritin	C				
			Fioricet Tablets	C				
			Levoxyl	C				
			Premarin	C				
			Serzone	C				
			Zocor	C				
			Lorazepam	C				

Date:12/27/01ISR Number: 3856368-8Report Type:Periodic Company Report #WAES 01102274
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3856369-XReport Type:Periodic Company Report #WAES 01102284
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Ultram	C				

Date:12/27/01ISR Number: 3856370-6Report Type:Periodic Company Report #WAES 01102285
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dysgeusia						MG/DAILY/PO	
			Flomax (Tamsulosin Hydrochloride	C				
			Chondroitin (+) Glucosamine	C				
			Cyanocobalamin	C				
			Hydrochlorothiazide (+) Triamter	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856371-8Report Type:Periodic Company Report #WAES 01102289
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Celexa	C				
			Neurontin	C				

Date:12/27/01ISR Number: 3856372-XReport Type:Periodic Company Report #WAES 01102333
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Valtrex	C				

Date:12/27/01ISR Number: 3856373-1Report Type:Periodic Company Report #WAES 01102345
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/DAILY/PO; 2) 50 MG/DAILY/PO	
			Claritin	C				
			Lasix (Furosemide)	C				
			Nasonex	C				
			Skelaxin	C				
			Tylenol	C				

Date:12/27/01ISR Number: 3856374-3Report Type:Periodic Company Report #WAES 01102350
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Hydrodiuril	C				
			Prinivil	C				
			Aspirin	C				
			Potassium Chloride	C				
			Propranolol	C				

Date:12/27/01ISR Number: 3856375-5Report Type:Periodic Company Report #WAES 01110975
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856376-7Report Type:Periodic Company Report #WAES 01110976
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Hypertension	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Monopril	C		

Date:12/27/01ISR Number: 3856377-9Report Type:Periodic Company Report #WAES 01110978
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO	Hypertension	Professional				
		Company Representative	Monopril	C		
			Premarin	C		
			Clonidine	C		
			Labetalol Hydrochloride	C		
			Oxybutynin Hydrochloride	C		

Date:12/27/01ISR Number: 3856378-0Report Type:Periodic Company Report #WAES 01110999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Paraesthesia	Health	Tab Vioxx	PS		ORAL
50 MG/ DAILY / PO	Rash	Professional				
		Company Representative				

Date:12/27/01ISR Number: 3856379-2Report Type:Periodic Company Report #WAES 01111017
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/ DAILY/ PO	
			Lasix (Furosemide)	C				
			Norco	C				
			Prilosec	C				
			Prinzide	C				
			Prozac	C				
			Synthroid	C				
			Albuterol	C				
			Diltiazem Hydrochloride	C				
			Estradiol	C				

Date:12/27/01ISR Number: 3856380-9Report Type:Periodic Company Report #WAES 01111019
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/ PO	
			Imitrex	C				
			Ascorbic Acid	C				
			Herbs (Unspecified)	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856381-0Report Type:Periodic Company Report #WAES 01111021
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/	
	Dizziness						PO	
	Vision Blurred		Allegra	C				
			Avalide	C				
			Nasocort	C				
			Toprol Xl Tablets	C				
			Zoloft	C				

Date:12/27/01ISR Number: 3856382-2Report Type:Periodic Company Report #WAES 01111029
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	50 MG/ DAILY/	
	Fatigue						PO	
	Flatulence							
	Nausea							

Date:12/27/01ISR Number: 3856383-4Report Type:Periodic Company Report #WAES 01111044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/	
							PO	
			Hyzaar	C				
			Tylenol	C				

Date:12/27/01ISR Number: 3856384-6Report Type:Periodic Company Report #WAES 01111050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/	
	Diarrhoea						DAILY/ PO	
	Face Oedema		Tylenol	C				
	Headache							
	Oedema Peripheral							
	Urine Abnormality							

Date:12/27/01ISR Number: 3856385-8Report Type:Periodic Company Report #WAES 01110842
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Glucosamine	C				

Date:12/27/01ISR Number: 3856386-XReport Type:Periodic Company Report #WAES 01110843
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/PO	
	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856387-1Report Type:Periodic Company Report #WAES 01110845
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Plavix	C				

Date:12/27/01ISR Number: 3856389-5Report Type:Periodic Company Report #WAES 01110858
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3856394-9Report Type:Periodic Company Report #WAES 01110861
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Glucosamine	C				

Date:12/27/01ISR Number: 3856400-1Report Type:Periodic Company Report #WAES 01110874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Immunodeficiency	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856403-7Report Type:Periodic Company Report #WAES 01110876
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Blood Pressure Increased							
	Fatigue							
	Nausea							
	Pain							

Date:12/27/01ISR Number: 3856407-4Report Type:Periodic Company Report #WAES 01110880
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Nexium	C				
			Viagra	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856411-6Report Type:Periodic Company Report #WAES 01110884
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856413-XReport Type:Periodic Company Report #WAES 01110971
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	4 WK
		Company Representative	Zocor	C				

Date:12/27/01ISR Number: 3856416-5Report Type:Periodic Company Report #WAES 01090906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Effexor	C				
			Estrogens	C				

Date:12/27/01ISR Number: 3856417-7Report Type:Periodic Company Report #WAES 01090908
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Geographic	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856418-9Report Type:Periodic Company Report #WAES 01090914
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Hypertension							
	Oedema Peripheral		Diovan	C				
	Tachycardia		Lasix (Furosemide)	C				
			Tenormin	C				

Date:12/27/01ISR Number: 3856423-2Report Type:Periodic Company Report #WAES 01090924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Norvasc	C				
			Calcium	C				
			Vitamins	C				

Date:12/27/01ISR Number: 3856426-8Report Type:Periodic Company Report #WAES 01090926
Age: Gender:Female I/FU:I

Outcome	PT
	Feeling Abnormal
	Muscle Spasms
	Musculoskeletal Stiffness
	Paraesthesia

	Swelling					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Tab Vioxx	PS		ORAL
PRN/PO						
			Prednisone	C		

Date:12/27/01ISR Number: 3856430-XReport Type:Periodic Company Report #WAES 01090927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hyperhidrosis	Consumer	Tab Vioxx	PS		ORAL
25						
	Nausea					
MG/DAILY/PO						
	Tachycardia					

Date:12/27/01ISR Number: 3856432-3Report Type:Periodic Company Report #WAES 01090930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Asthenia	Consumer	Tab Vioxx	PS		ORAL
PO						
	Extrasystoles		Cardizem	C		
	Fatigue					
	Nausea					
	Pulse Pressure Decreased					

Date:12/27/01ISR Number: 3856436-0Report Type:Periodic Company Report #WAES 01090942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Alopecia	Consumer	Tab Vioxx	PS		ORAL
PO						
			Prevacid	C		

Date:12/27/01ISR Number: 3856438-4Report Type:Periodic Company Report #WAES 01090943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Disorder	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	20 DAY
	Facial Palsy							
	Lacrimation Increased							
	Vision Blurred							

Date:12/27/01ISR Number: 3856441-4Report Type:Periodic Company Report #WAES 01090945
Age:65 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856444-XReport Type:Periodic Company Report #WAES 01111053
Age: Gender: I/FU:I

Outcome	PT
	Blood Creatine Phosphokinase Increased

Hepatic Function Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856447-5Report Type:Periodic Company Report #WAES 01111057
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856448-7Report Type:Periodic Company Report #WAES 01111059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Consumer	Tab Vioxx	PS				

Date:12/27/01ISR Number: 3856449-9Report Type:Periodic Company Report #WAES 01111069
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
	Vomiting		Altace	C				

Date:12/27/01ISR Number: 3856451-7Report Type:Periodic Company Report #WAES 01111075
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS				
	Contusion		Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3856454-2Report Type:Periodic Company Report #WAES 01111078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vision Blurred							

Date:12/27/01ISR Number: 3856457-8Report Type:Periodic Company Report #WAES 01111084
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulitis	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	1 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856460-8Report Type:Periodic Company Report #WAES 01111097
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx	PS		ORAL	DAILY; PO	
	Pruritus		Amaryl	C				
	Rash		Avandia	C				
	Swelling		Glucophage	C				
			Macrobid	C				
			Prempro	C				

Date:12/27/01ISR Number: 3856463-3Report Type:Periodic Company Report #WAES 01111108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856465-7Report Type:Periodic Company Report #WAES 01111143
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Avapro	C				
			Cordarone	C				
			Coumadin	C				
			Flomax (Morniflumate)	C				
			Purinethol	C				
			Ultram	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3856509-2Report Type:Periodic Company Report #WAES 01110737
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Other	Tab Vioxx Unk	PS		ORAL	ORAL	
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3856516-XReport Type:Periodic Company Report #WAES 01110741
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive		Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856519-5Report Type:Periodic Company Report #WAES 01110749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Azulfidine	C				
			Betoptic	C				
			Morphine	C				

			Prednisone	C		
			Warfarin Sodium	C		

Date:12/27/01ISR Number: 3856540-7Report Type:Periodic Company Report #WAES 01110750
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			Hydrodiuril	C				
			Zocor	C				
			Atenolol	C				
			Vitamins (Unspecified0	C				

Date:12/27/01ISR Number: 3856541-9Report Type:Periodic Company Report #WAES 01110762
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Skin Disorder							
			Copoten	C				
			Coumadin	C				
			Nolvadex	C				

Date:12/27/01ISR Number: 3856542-0Report Type:Periodic Company Report #WAES 01110768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	50 MG/UNK PO	
	Fatigue		Advair	C				
	Nausea		Estratest	C				
	Pruritus		Neurontin	C				
			Norco	C				
			Prevacid	C				

Prozac	C
Singulair	C
Wellbutrin	C
Albuterol	C
Lorazepam	C
Morphine	C
Trazodone	C

Date:12/27/01ISR Number: 3856543-2Report Type:Periodic Company Report #WAES 01110770
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856544-4Report Type:Periodic Company Report #WAES 01110773
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856546-8Report Type:Periodic Company Report #WAES 01110774
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Celexa	C				
			Ocupress	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3856548-1Report Type:Periodic Company Report #WAES 01110787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Oedema Peripheral							
	Weight Increased		Bumex	C				

Date:12/27/01ISR Number: 3856573-0Report Type:Periodic Company Report #WAES 01093289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Premarin	C				
			Prilosec	C				
			Ultram	C				
			Zoloft	C				

Date:12/27/01ISR Number: 3856578-XReport Type:Periodic Company Report #WAES 01100004
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Excoriation	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Pruritus	Professional	Claritin-D	C				
	Rash		Covera-Hs	C				
			Flortal	C				
			Healthy Womann Soy Menopause	C				
			Humibid L.A.	C				
			Oxycontin	C				
			Pravachol	C				
			Prevacid	C				
			Cimicifuga	C				

Date:12/27/01ISR Number: 3856588-2Report Type:Periodic Company Report #WAES 01100009
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856591-2Report Type:Periodic Company Report #WAES 01100018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Isoptin Sr	C				
			Pepcid	C				

Date:12/27/01ISR Number: 3856599-7Report Type:Periodic Company Report #WAES 01100026
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Diarrhoea	Professional	Hydrodiuril	C				
	Dyspnoea		Synthroid	C				

Date:12/27/01ISR Number: 3856601-2Report Type:Periodic Company Report #WAES 01100028
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Estratest	C				
			Fosamax	C				
			Prometrium	C				

Date:12/27/01ISR Number: 3856604-8Report Type:Periodic Company Report #WAES 01100039
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

			Ativan	C
			Hydrocodone/Apap	C

Date:12/27/01ISR Number: 3856606-1Report Type:Periodic Company Report #WAES 01100046
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral							
MG/DAILY/PO								
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3856616-4Report Type:Periodic Company Report #WAES 01100061
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Flushing							
MG/DAILY/PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856624-3Report Type:Periodic Company Report #WAES 01100066
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856628-0Report Type:Periodic Company Report #WAES 01100383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	C				
			Glucophage	C				

Date:12/27/01ISR Number: 3856632-2Report Type:Periodic Company Report #WAES 01100386
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Tachycardia							
	Tinnitus							
	Weight Increased							

Date:12/27/01ISR Number: 3856635-8Report Type:Periodic Company Report #WAES 01100387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO

Date:12/27/01ISR Number: 3856638-3Report Type:Periodic Company Report #WAES 01100390
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder Joint Swelling	Health Professional	Tab Vioxx 25 Mg; 50 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
			Nexium	C				

Date:12/27/01ISR Number: 3856641-3Report Type:Periodic Company Report #WAES 01100398
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856643-7Report Type:Periodic Company Report #WAES 01100399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Erectile Dysfunction	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
PO						

Date:12/27/01ISR Number: 3856644-9Report Type:Periodic Company Report #WAES 01100410
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL
PO						

Date:12/27/01ISR Number: 3856645-0Report Type:Periodic Company Report #WAES 01100416
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Aciphex	C		
			Miacalcin	C		
			Toprol Xl Tablets	C		
			Tylenol	C		

Date:12/27/01ISR Number: 3856646-2Report Type:Periodic Company Report #WAES 01100424
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Dyazide	C		
			Tenormin	C		

Date:12/27/01ISR Number: 3856647-4Report Type:Periodic Company Report #WAES 01100433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive Oedema Peripheral		Aleve	C				

Date:12/27/01ISR Number: 3856648-6Report Type:Periodic Company Report #WAES 01090029
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Tightness	Consumer	Tab Vioxx	PS		ORAL	50 MG, DAILY, PO	
	Oedema Peripheral							
			Tab Vioxx	SS		ORAL	25 MG, DAILY, PO	
			Tab Vioxx	SS		ORAL	50 MG, DAILY, PO	
			Lipitor	C				
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856649-8Report Type:Periodic Company Report #WAES 01090031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:12/27/01ISR Number: 3856656-5Report Type:Periodic Company Report #WAES 01090035
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856659-0Report Type:Periodic Company Report #WAES 01090037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3856663-2Report Type:Periodic Company Report #WAES 01090039
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Malaise		Coumadin	C				

	Nausea		Maxzide	C			

Date:12/27/01ISR Number: 3856666-8Report Type:Periodic Company Report #WAES 01090040
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG, DAILY,	
	Back Pain	Health					PO	
	Fatigue	Professional	Darvocet-N	C				
	Hypoaesthesia		Remeron	C				
	Muscular Weakness		Zestril	C				
	Pain In Extremity							

Date:12/27/01ISR Number: 3856675-9Report Type:Periodic Company Report #WAES 01090045
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
							PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856679-6Report Type:Periodic Company Report #WAES 01090046
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG,BID, PO	
	Musculoskeletal Stiffness		Tab Vioxx 50 Mg	SS		ORAL	50 MG, DAILY, PO	
	Oral Soft Tissue Disorder							
			Diovan	C				
			Norvasc	C				
			Guaifenesin	C				
			Synthroid	C				
			Hydrodiuril	C				
			Fosamax	C				

Date:12/27/01ISR Number: 3856686-3Report Type:Periodic Company Report #WAES 01090059
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
		Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG, DAILY, PO	
			Accupril	C				
			Celebrex	C				
			Claritin	C				
			Demadex	C				
			Effexor Xr	C				
			Elavil	C				
			Meridia	C				
			Pepcid	C				
			Prempro	C				
			Doxycycline	C				

			Minocycline	C		

Date:12/27/01ISR Number: 3856687-5Report Type:Periodic Company Report #WAES 01090060
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral	Health Professional	Actos	C				

Date:12/27/01ISR Number: 3856695-4Report Type:Periodic Company Report #WAES 01083202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY	/ PO
			Furosemide	C				

Date:12/27/01ISR Number: 3856698-XReport Type:Periodic Company Report #WAES 01083204
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Oedema	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx	PS		ORAL
25 MG/ DAILY/							
PO							

Date:12/27/01ISR Number: 3856710-8Report Type:Periodic Company Report #WAES 01083208
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Effect Decreased	Health	Tab Vioxx	PS		ORAL
50 MG/ DAILY/						
		Professional				
PO						
			Tab Vioxx	SS		ORAL
25 MG /						
DAILY/ PO						
			Tab Vioxx	SS		ORAL
50 MG/ DAILY/						
PO						
			Celebrex	C		

Date:12/27/01ISR Number: 3856714-5Report Type:Periodic Company Report #WAES 01083223
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dysuria	Consumer	Tab Vioxx	PS		ORAL
25 MG/ DAILY/						
	Vision Blurred					
PO						
			Anaspaz	C		
			Deconamine	C		
			Menest	C		
			Nasonex	C		
			Pravachol	C		
			Prilosec	C		

			Xanax	C		
			Zyrtec	C		

Date:12/27/01ISR Number: 3856721-2Report Type:Periodic Company Report #WAES 01083259
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Consumer	Tab Vioxx	PS		
	Dyspepsia					
	Hypoaesthesia					
	Muscle Spasms					

Date:12/27/01ISR Number: 3856727-3Report Type:Periodic Company Report #WAES 01083261
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Palpitations	Consumer	Tab Vioxx	PS		ORAL
25 MG/ DAILY/						
PO						
			Seroquel	C		
			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856732-7Report Type:Periodic Company Report #WAES 01083300
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/	
	Dizziness						PO	
	Fatigue		Paxil	C				
	Gastrointestinal Disorder		Prilosec	C				
	Muscular Weakness		Requip	C				
			Sinemet	C				
			Clonazepam	C				

Date:12/27/01ISR Number: 3856736-4Report Type:Periodic Company Report #WAES 01090016
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx	PS		ORAL	HS/ PO	
	Gait Disturbance							
	Hypoaesthesia							
	Influenza Like Illness							

Date:12/27/01ISR Number: 3856741-8Report Type:Periodic Company Report #WAES 01090018
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/	
							PO	
			Atenolol	C				

Date:12/27/01ISR Number: 3856745-5Report Type:Periodic Company Report #WAES 01090024
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	50 MG/ DAILY/	
	Lower Gastrointestinal Haemorrhage						PO	2 DAY

Date:12/27/01ISR Number: 3856746-7Report Type:Periodic Company Report #WAES 01102883
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haematochezia		Aleve	C				
			Ditropan Xl	C				
			Fosamax	C				
			Nitrostat	C				
			Prilosec	C				
			Zocor	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856747-9Report Type:Periodic Company Report #WAES 01102887
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Nervousness	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Soma	C		

Date:12/27/01ISR Number: 3856748-0Report Type:Periodic Company Report #WAES 01102888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Visual Disturbance	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:12/27/01ISR Number: 3856749-2Report Type:Periodic Company Report #WAES 01102890
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Dyspnoea	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:12/27/01ISR Number: 3856750-9Report Type:Periodic Company Report #WAES 01102894
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pyuria	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company				

Date:12/27/01ISR Number: 3856751-0Report Type:Periodic Company Report #WAES 01102940
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Zyrtec	C				
			Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3856753-4Report Type:Periodic Company Report #WAES 01103013
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Lescol	C				
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856754-6Report Type:Periodic Company Report #WAES 01103017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856756-XReport Type:Periodic Company Report #WAES 01103036
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lupron	C				

Date:12/27/01ISR Number: 3856757-1Report Type:Periodic Company Report #WAES 01103043
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gait Disturbance							
	Oedema Peripheral		Aricept	C				
	Palmar Erythema		Proscar	C				

Date:12/27/01ISR Number: 3856759-5Report Type:Periodic Company Report #WAES 01102875
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx	PS		ORAL	DAILY;PO	
			Hydrochlorothiazid + Triamter	C				
			Plendil	C				

				Paxil	C		

Date:12/27/01ISR Number: 3856761-3Report Type:Periodic Company Report #WAES 01102854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY; PO	

Date:12/27/01ISR Number: 3856762-5Report Type:Periodic Company Report #WAES 01102863
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx	PS		ORAL	QOD; PO	
	Dyspepsia		Actonel 5 Mg	SS			5 MG/DAILY/	
	Oral Pain		Apap	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856764-9Report Type:Periodic Company Report #WAES 01102869
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	
			Avapro	C				
			Celexa	C				
			Coumadin	C				
			Digitek	C				
			Premarin	C				
			Seroquel	C				
			Ascorbic Acid	C				
			Calcium (Unspecified) (=)					
			Vitami	C				
			Folic Acid	C				
			Orphenadrine	C				
			Pyridoxine	C				
			Vitamine E	C				

Date:12/27/01ISR Number: 3856765-0Report Type:Periodic Company Report #WAES 01102766
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	DAILY; PO	

Date:12/27/01ISR Number: 3856767-4Report Type:Periodic Company Report #WAES 01102776
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Claritin-D	C				
			Darvocet-N	C				
			Flonase	C				
			Fluocinonide	C				

Date:12/27/01ISR Number: 3856768-6Report Type:Periodic Company Report #WAES 01102729
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Zocor	C				

Date:12/27/01ISR Number: 3856770-4Report Type:Periodic Company Report #WAES 01102735
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure	Health	Tab Vioxx	PS		ORAL	PO	
	Fluctuation	Professional Company Representative	(Composition Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856775-3Report Type:Periodic Company Report #WAES 01102741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advair	C				
			Nexium	C				
			Singulair	C				

Date:12/27/01ISR Number: 3856777-7Report Type:Periodic Company Report #WAES 01102746
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY; PO	
			Altace	C				
			Darvocet-N	C				
			Glucophage	C				
			Peridex	C				
			Zocor	C				
			Aspirin	C				
			Glyburide	C				
			Metoprolol	C				

Date:12/27/01ISR Number: 3856780-7Report Type:Periodic Company Report #WAES 01102561
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea		Aricept	C				
	Tachycardia		Diovan	C				
			Flomax (Morniflumate)	C				
			Flonase	C				

		Prevacid	C
		Pulmicort	C
		Serevent	C
		Albuterol	C

Date:12/27/01ISR Number: 3856782-0Report Type:Periodic Company Report #WAES 01102565
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	5 DAY
	Dyspepsia							
	Flatulence		Tab Vioxx	SS			DAILY/PO	
	Nausea							

Date:12/27/01ISR Number: 3856784-4Report Type:Periodic Company Report #WAES 01102571
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Drug Ineffective		Tab Vioxx	SS			PO	
	Ulcer		Aldactone	C				
	Upper Gastrointestinal		Plendil	C				
	Haemorrhage		Tylenol With Codeine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856786-8Report Type:Periodic Company Report #WAES 01102580
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
			Lipitor	C				
			Rythmol	C				
			Allopurinol	C				
			Hydroxyurea	C				

Date:12/27/01ISR Number: 3856790-XReport Type:Periodic Company Report #WAES 01102582
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Morbilliform	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	
			...	C				

Date:12/27/01ISR Number: 3856798-4Report Type:Periodic Company Report #WAES 01102588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856805-9Report Type:Periodic Company Report #WAES 01102602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

MG/DAILY/PO

Date:12/27/01ISR Number: 3856808-4Report Type:Periodic Company Report #WAES 01102669
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dizziness						MG/DAILY/PO	
	Headache		Claritin	C				
			Fosamax	C				
			Hydrodiuril	C				
			Synthroid	C				
			Zestril	C				
			Zocor	C				
			Quinine	C				

Date:12/27/01ISR Number: 3856815-1Report Type:Periodic Company Report #WAES 01102674
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO ;

12.5

MG/BID/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856816-3Report Type:Periodic Company Report #WAES 01102704
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
	Weight Increased		Avandia	C				
			Coreg	C				
			Cozaar	C				
			Digitek	C				
			Premphase	C				
			Furosemide	C				
			Glyburide	C				
			Nitroglycerin	C				
			Potassium Chloride	C				

Date:12/27/01ISR Number: 3856818-7Report Type:Periodic Company Report #WAES 01092683
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fatigue		Prilosec	C				

Date:12/27/01ISR Number: 3856819-9Report Type:Periodic Company Report #WAES 01092694
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pharyngeal Oedema							
	Urticaria		Paxil	C				

Date:12/27/01ISR Number: 3856821-7Report Type:Periodic Company Report #WAES 01092699
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Dyspepsia		Atacand	C				
	Faeces Discoloured		Paxil	C				
			Prevacid	C				
			Synthroid	C				
			Alprazolam	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856870-9Report Type:Periodic Company Report #WAES 01092734
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3856875-8Report Type:Periodic Company Report #WAES 01092748
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Prempro	C				

			Synthroid	C
			Atenolol	C

Date:12/27/01ISR Number: 3856876-XReport Type:Periodic Company Report #WAES 01092751
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Ibuprofen	C				

Date:12/27/01ISR Number: 3856878-3Report Type:Periodic Company Report #WAES 01092802
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain		Lipitor	C				
			Prinivil	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3856879-5Report Type:Periodic Company Report #WAES 01092803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Pain In Extremity						MG/DAILY/PO	

Date:12/27/01ISR Number: 3856880-1Report Type:Periodic Company Report #WAES 01092804
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cholecystitis							
	Gait Disturbance							
	Gastrointestinal Disorder							
	Liver Disorder							
	Pain In Extremity							
	Swelling							

Date:12/27/01ISR Number: 3856881-3Report Type:Periodic Company Report #WAES 01092815
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Field Defect	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Lipitor	C				
			Norvasc	C				

Date:12/27/01ISR Number: 3856958-2Report Type:Periodic Company Report #WAES 01092656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	10 DAY
	Visual Disturbance	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856961-2Report Type:Periodic Company Report #WAES 01092660
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG	MG/DAILY/PO
	Hypersensitivity							
			Prilosec	C				
			Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3856963-6Report Type:Periodic Company Report #WAES 01092662
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
		Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25	MG/DAILY/PO
			Premarin	C				
			Lorazepam	C				

Date:12/27/01ISR Number: 3856966-1Report Type:Periodic Company Report #WAES 01092665
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	25	MG/DAILY/PO
	Pruritus							
			Vioxx	SS		ORAL	50	MG/DAILY/PO
			Zoloft	C				

Lorazepam C

Date:12/27/01ISR Number: 3856970-3Report Type:Periodic Company Report #WAES 01092666
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3856973-9Report Type:Periodic Company Report #WAES 01092667
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Herpetiformis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856974-0Report Type:Periodic Company Report #WAES 01092671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856976-4Report Type:Periodic Company Report #WAES 01092677
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Anorexia							
PO								

Date:12/27/01ISR Number: 3856978-8Report Type:Periodic Company Report #WAES 01092681
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
MG/DAILY/PO								

Date:12/27/01ISR Number: 3856980-6Report Type:Periodic Company Report #WAES 01092682
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
		Professional	Hyoscyamine	C				

Date:12/27/01ISR Number: 3856984-3Report Type:Periodic Company Report #WAES 01092560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional						
MG/DAILY/PO	2	DAY						

Date:12/27/01ISR Number: 3856986-7Report Type:Periodic Company Report #WAES 01092595
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3856995-8Report Type:Periodic Company Report #WAES 01092596
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 50 Mg	PS		ORAL	1X/PO	1 DAY

Date:12/27/01ISR Number: 3856997-1Report Type:Periodic Company Report #WAES 01092602
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Blood Urea Increased	Company Representative	Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Arthrotec	C				
			Nonsteroidal Anti-Inflammatory	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3856999-5Report Type:Periodic Company Report #WAES 01092620
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Centrum Silver	C				
			Monopril	C				
			Norvasc	C				
			Zebeta	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3857001-1Report Type:Periodic Company Report #WAES 01092636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prempro	C				

Date:12/27/01ISR Number: 3857003-5Report Type:Periodic Company Report #WAES 01092640
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3857005-9Report Type:Periodic Company Report #WAES 01092642
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/AM/PO	
			Accupril	C				
			Celebrex	C				
			Pravachol	C				
			Starlix	C				
			Synthroid	C				
			Aspirin	C				
			Insulin	C				

Date:12/27/01ISR Number: 3857006-0Report Type:Periodic Company Report #WAES 01092643
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Urticaria		Tenormin	C				
			Xalatan	C				

Date:12/27/01ISR Number: 3857009-6Report Type:Periodic Company Report #WAES 01092647
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tylenol With Codeine					

			#2	C		
			Zantac	C		
			Atenolol	C		

Date:12/27/01ISR Number: 3857016-3Report Type:Periodic Company Report #WAES 01092193
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Azmacort	C				
			Cozaar	C				
			Prevacid	C				
			Zocor	C				
			Albuterol	C				
			Aspirin	C				
			Trazodone	C				

Date:12/27/01ISR Number: 3857028-XReport Type:Periodic Company Report #WAES 01092199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857029-1Report Type:Periodic Company Report #WAES 01092204
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO	
			Accupril	C				
			Phenobarbital	C				
			Vitamins					

				(Unspecified)	C		

Date:12/27/01ISR Number: 3857030-8Report Type:Periodic Company Report #WAES 01092214
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857031-XReport Type:Periodic Company Report #WAES 01092219
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dizziness		Buspar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857032-1Report Type:Periodic Company Report #WAES 01092226
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advil	C				

Date:12/27/01ISR Number: 3857033-3Report Type:Periodic Company Report #WAES 01092228
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ear Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Tinnitus							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Humibid	C				

Date:12/27/01ISR Number: 3857034-5Report Type:Periodic Company Report #WAES 01092229
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	50 MG/PRN/PO	
			Trazodone	C				

Date:12/27/01ISR Number: 3857035-7Report Type:Periodic Company Report #WAES 01111684
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Accutane	C				
			Minocycline	C				

Date:12/27/01ISR Number: 3857036-9Report Type:Periodic Company Report #WAES 01092232
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Depression							
	Dizziness							
	Malaise							

Date:12/27/01ISR Number: 3857037-0Report Type:Periodic Company Report #WAES 01111687
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Somnolence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857038-2Report Type:Periodic Company Report #WAES 01092235
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

Date:12/27/01ISR Number: 3857039-4Report Type:Periodic Company Report #WAES 01111715
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Calculus Urinary	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Effexor Xr	C				
			Hydrochloride/Apap	C				

Date:12/27/01ISR Number: 3857040-0Report Type:Periodic Company Report #WAES 01111725
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Prevacid	C				
			Zyrtec	C				
			Diazepam	C				

Date:12/27/01ISR Number: 3857041-2Report Type:Periodic Company Report #WAES 01090281
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 DAY

Date:12/27/01ISR Number: 3857042-4Report Type:Periodic Company Report #WAES 01111734
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Oedema Peripheral							

Date:12/27/01ISR Number: 3857043-6Report Type:Periodic Company Report #WAES 01090286
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Temperature Intolerance	Professional						

Date:12/27/01ISR Number: 3857044-8Report Type:Periodic Company Report #WAES 01111735
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857045-XReport Type:Periodic Company Report #WAES 01111749
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857046-1Report Type:Periodic Company Report #WAES 01111750
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/PO	

Date:12/27/01ISR Number: 3857047-3Report Type:Periodic Company Report #WAES 01111752
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857048-5Report Type:Periodic Company Report #WAES 01090303
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:12/27/01ISR Number: 3857049-7Report Type:Periodic Company Report #WAES 01111754
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:12/27/01ISR Number: 3857050-3Report Type:Periodic Company Report #WAES 01090305
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Cozaar	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857051-5Report Type:Periodic Company Report #WAES 01090307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857052-7Report Type:Periodic Company Report #WAES 01090310
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prilosec	C				
			Toprol Xl Tablets	C				
			Zestril	C				
			Zocor	C				

Date:12/27/01ISR Number: 3857053-9Report Type:Periodic Company Report #WAES 01090314
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857054-0Report Type:Periodic Company Report #WAES 01090319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3857055-2Report Type:Periodic Company Report #WAES 01090325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dry Mouth		Triamterene	C				

Date:12/27/01ISR Number: 3857056-4Report Type:Periodic Company Report #WAES 01090329
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Coreg	C				
			Fosamax	C				
			Synthroid	C				
			Zocor	C				

Date:12/27/01ISR Number: 3857057-6Report Type:Periodic Company Report #WAES 01110579
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Contusion	Health
	Menstrual Disorder	Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857058-8Report Type:Periodic Company Report #WAES 01110580
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative	Toradol	C				

Date:12/27/01ISR Number: 3857059-XReport Type:Periodic Company Report #WAES 01110581
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative Other						

Date:12/27/01ISR Number: 3857060-6Report Type:Periodic Company Report #WAES 01110628
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:12/27/01ISR Number: 3857061-8Report Type:Periodic Company Report #WAES 01110629
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Health	Tab Vioxx	PS		ORAL	PO	
	Skin Exfoliation	Professional Company Representative						

Date:12/27/01ISR Number: 3857062-XReport Type:Periodic Company Report #WAES 01110630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Tab Vioxx	PS		ORAL	PO	
	Drug Interaction	Professional Company Representative	Xenical	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857063-1Report Type:Periodic Company Report #WAES 01110631
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857064-3Report Type:Periodic Company Report #WAES 01110633
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tinnitus							
			Allegra	C				
			Amaryl	C				
			Avandia	C				
			K-Dur	C				
			Zoloft	C				
			Furosemide	C				
			Terazosin Hydrochloride	C				

Date:12/27/01ISR Number: 3857065-5Report Type:Periodic Company Report #WAES 01090152
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zocor	C				

Date:12/27/01ISR Number: 3857066-7Report Type:Periodic Company Report #WAES 01090160
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Lip Dry						MG/DAILY/PO	
	Mouth Ulceration		Avapro	C				
			Prempro	C				
			Prilosec	C				
			Synthroid	C				
			Zyrtec	C				
			Hydrochlorothiazide	C				
			Nifedipine	C				

Date:12/27/01ISR Number: 3857067-9Report Type:Periodic Company Report #WAES 01090162
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/BID/PO	
			Prempro	C				
			Theragran-M	C				
			Ascorbic Acid	C				
			Calcium (Unspecified					
			(+) Vitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857068-0Report Type:Periodic Company Report #WAES 01090176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx	PS		ORAL	PO	
	Paraesthesia	Professional Company Representative						

Date:12/27/01ISR Number: 3857069-2Report Type:Periodic Company Report #WAES 01090177
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 25 Mg	PS				
			Accupril	C				
			Norvasc	C				

Date:12/27/01ISR Number: 3857070-9Report Type:Periodic Company Report #WAES 01090193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	6 MON
			(Therapy Unspecified)	C				

Date:12/27/01ISR Number: 3857071-0Report Type:Periodic Company Report #WAES 01090216
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857072-2Report Type:Periodic Company Report #WAES 01090230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional						

Date:12/27/01ISR Number: 3857073-4Report Type:Periodic Company Report #WAES 01090239
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Lower Gastrointestinal Haemorrhage		Aciphex	C				
			Premarin	C				
			Zoloft	C				
			Clonazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857074-6Report Type:Periodic Company Report #WAES 01090242
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dyspepsia							
	Epigastric Discomfort		Hyzaar	C				
			Synvisc	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3857075-8Report Type:Periodic Company Report #WAES 01091233
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Ear Pain		Celexa	C				
	Fatigue		Klonopin	C				
	Hypoaesthesia		Nexium	C				
	Myalgia							
	Pain In Extremity							
	Pharyngitis							

Date:12/27/01ISR Number: 3857076-XReport Type:Periodic Company Report #WAES 01110636
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Celebrex	C				
			Miacalcin	C				
			Nasacort	C				
			Prempro	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3857077-1Report Type:Periodic Company Report #WAES 01091234
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857078-3Report Type:Periodic Company Report #WAES 01110646
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Insomnia		Fosamax	C				
			Ziac	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857079-5Report Type:Periodic Company Report #WAES 01091235
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857080-1Report Type:Periodic Company Report #WAES 01110448
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx	PS		ORAL	50 MG/PO	

Date:12/27/01ISR Number: 3857081-3Report Type:Periodic Company Report #WAES 01091236
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857082-5Report Type:Periodic Company Report #WAES 01110480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857083-7Report Type:Periodic Company Report #WAES 01091244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857084-9Report Type:Periodic Company Report #WAES 01091268
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Diarrhoea							
	Weight Increased		Flonase	C				
			Levoxyl	C				
			Norvasc	C				
			Prinivil	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857085-0Report Type:Periodic Company Report #WAES 01110489
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
			Hydrocortisone	C				
			Methotrexate	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3857086-2Report Type:Periodic Company Report #WAES 01091276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Nausea							
			Imitrex	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3857087-4Report Type:Periodic Company Report #WAES 01110495
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Headache							
	Weight Increased							

Date:12/27/01ISR Number: 3857088-6Report Type:Periodic Company Report #WAES 01091291
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermal Cyst	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Rash Papular	Professional					
MG/DAILY/PO							
		Company	Cozaar	C			
		Representative	Aspirin	C			

Date:12/27/01ISR Number: 3857089-8Report Type:Periodic Company Report #WAES 01091314
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Intolerance							

Date:12/27/01ISR Number: 3857090-4Report Type:Periodic Company Report #WAES 01091380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Flomax (Tamsulosin Hydrochloride0	C				
			Pepcid	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857091-6Report Type:Periodic Company Report #WAES 01091030
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY;	
			Relafen	C				
			Labetalol Hyrochloride	C				

Date:12/27/01ISR Number: 3857092-8Report Type:Periodic Company Report #WAES 01091038
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG, DAILY;	
			Desyrel	C				
			Estratest	C				
			Vasotec	C				

Date:12/27/01ISR Number: 3857093-XReport Type:Periodic Company Report #WAES 01091040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Consumer	Tab Vioxx	PS		ORAL		

Date:12/27/01ISR Number: 3857094-1Report Type:Periodic Company Report #WAES 01091042
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY;						
PO						

Date:12/27/01ISR Number: 3857095-3Report Type:Periodic Company Report #WAES 01091090
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY;						
	Erythema					
PO						
	Pharyngeal Oedema		Cardizem Cd	C		
	Pharyngitis		Aspirin	C		

Date:12/27/01ISR Number: 3857096-5Report Type:Periodic Company Report #WAES 01091105
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Liver Disorder	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857097-7Report Type:Periodic Company Report #WAES 01091112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Haemorrhage	Professional Company Representative						

Date:12/27/01ISR Number: 3857098-9Report Type:Periodic Company Report #WAES 01091141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx	PS		ORAL	PO	
			Fosamax	C				

Date:12/27/01ISR Number: 3857099-0Report Type:Periodic Company Report #WAES 01091142
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3857100-4Report Type:Periodic Company Report #WAES 01091145
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3857101-6Report Type:Periodic Company Report #WAES 01092368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	2 WK
		Company Representative						

Date:12/27/01ISR Number: 3857102-8Report Type:Periodic Company Report #WAES 01092372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atenolol	C				

Date:12/27/01ISR Number: 3857103-XReport Type:Periodic Company Report #WAES 01092377
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857104-1Report Type:Periodic Company Report #WAES 01092391
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3857105-3Report Type:Periodic Company Report #WAES 01092403
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Activella	C				
			Allegra	C				
			Aygestin	C				
			Hydrocodone/Apa	C				
			Micardis	C				
			Mirapex	C				
			Prempro	C				
			Ultram	C				
			Zocor	C				
			Zoloft	C				
			Zyrtec	C				
			Cephalexin	C				
			Doxepin Hydrochloride	C				
			Estradiol	C				
			Estrogens (Unspecified)	C				
			Estropipate	C				
			Ketorolac	C				

Date:12/27/01ISR Number: 3857106-5Report Type:Periodic Company Report #WAES 01110506
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:12/27/01ISR Number: 3857107-7Report Type:Periodic Company Report #WAES 01092428
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857108-9Report Type:Periodic Company Report #WAES 01110510
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Rash		Tab Vioxx 50 Mg	SS		ORAL	50	

MG/DAILY/PO

Hydrodiuril	C	
Levothroid	C	
Prempro	C	

Date:12/27/01ISR Number: 3857109-0Report Type:Periodic Company Report #WAES 01092457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea							
	Oedema Peripheral							
	Tachycardia							

Date:12/27/01ISR Number: 3857110-7Report Type:Periodic Company Report #WAES 01110513
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx	PS		ORAL	PO	
	Renal Pain		Climara	C				

Date:12/27/01ISR Number: 3857111-9Report Type:Periodic Company Report #WAES 01092466
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional	Diovan	SS				
	Blood Urea Increased	Company Representative	Glucovance	C				

Date:12/27/01ISR Number: 3857112-0Report Type:Periodic Company Report #WAES 01110534
Age:74 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			K-Dur	C				
			Acetaminophen (+) Hydrocodone	C				
			Estradiol	C				
			Furosemide	C				

Date:12/27/01ISR Number: 3857113-2Report Type:Periodic Company Report #WAES 01092497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Gastrointestinal Haemorrhage	Consumer Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857114-4Report Type:Periodic Company Report #WAES 01110542
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857115-6Report Type:Periodic Company Report #WAES 01110555
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Eye Disorder		Armour Thyroid					
	Headache		Tablets	C				
			Prilosec	C				
			Prozac	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Atenolol	C				
			Calcium	C				
			Hydrochlorothiazide (+) Triamter	C				
			Magnesium	C				
			Vitamin E	C				
			Zinc	C				

Date:12/27/01ISR Number: 3857116-8Report Type:Periodic Company Report #WAES 01092510
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857117-XReport Type:Periodic Company Report #WAES 01091723
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Inadequate Control		Insulin	C				

Date:12/27/01ISR Number: 3857118-1Report Type:Periodic Company Report #WAES 01091724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Change Of Bowel Habit	Professional					MG/DAILY/PO	
		Company Representative	Premarin (Therapy Unspecified)	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:12/27/01ISR Number: 3857119-3Report Type:Periodic Company Report #WAES 01110037
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857120-XReport Type:Periodic Company Report #WAES 01091725
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Flexeril	C				

Date:12/27/01ISR Number: 3857121-1Report Type:Periodic Company Report #WAES 01110038
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857122-3Report Type:Periodic Company Report #WAES 01091731
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Methadone Hydrochloride	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3857123-5Report Type:Periodic Company Report #WAES 01110057
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS			ORAL 25 MG/DAILY/PO

Date:12/27/01ISR Number: 3857124-7Report Type:Periodic Company Report #WAES 01110082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857125-9Report Type:Periodic Company Report #WAES 01110156
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Amaryl	C				
			Claritin	C				
			Flomax (Morniflumate)	C				
			Flovent	C				
			Norvasc	C				
			Prevacid	C				
			Serevent	C				

Sonata C

Date:12/27/01ISR Number: 3857126-0Report Type:Periodic Company Report #WAES 01110182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:12/27/01ISR Number: 3857127-2Report Type:Periodic Company Report #WAES 01110187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857128-4Report Type:Periodic Company Report #WAES 01091732
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health	Tab Vioxx	PS		ORAL	PO	
	Systemic Lupus Erythematosus	Professional	Rythmol	SS			UNKNOWN	

Date:12/27/01ISR Number: 3857129-6Report Type:Periodic Company Report #WAES 01110190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:12/27/01ISR Number: 3857130-2Report Type:Periodic Company Report #WAES 01110231
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857131-4Report Type:Periodic Company Report #WAES 01091736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Erythema							
	Pruritus		Valium	C				
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857132-6Report Type:Periodic Company Report #WAES 01091742
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857133-8Report Type:Periodic Company Report #WAES 01110267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Haemorrhage	Professional Company Representative						

Date:12/27/01ISR Number: 3857134-XReport Type:Periodic Company Report #WAES 01091744
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
	Nausea		Percocet	C				
	Respiratory Disorder		Prilosec	C				
			Hydrocodone	C				

Date:12/27/01ISR Number: 3857135-1Report Type:Periodic Company Report #WAES 01091746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS			60 DAY	
	Musculoskeletal Stiffness		Naprosyn	C				

	Paraesthesia		Prednisone	C			

Date:12/27/01ISR Number: 3857136-3Report Type:Periodic Company Report #WAES 01104820
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857137-5Report Type:Periodic Company Report #WAES 01091750
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema							
			Cardura	C				
			Timoptic	C				
			Hydrochlorothiazide (+) Triamter	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857138-7Report Type:Periodic Company Report #WAES 01104868
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dementia	Literature	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Depression	Health Professional	Tab Aricept 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Drug Interaction		Tab Effexor Xr 75 Mg	SS		ORAL	75 MG/PM/PO	
	Insomnia		Cap Vitamin E 1000 Iu	SS		ORAL	1000 IU/BID/PO	
			Tab Premarin 0.625 Mg	SS		ORAL	0.625 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857139-9Report Type:Periodic Company Report #WAES 01104884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857140-5Report Type:Periodic Company Report #WAES 01091468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857141-7Report Type:Periodic Company Report #WAES 01104886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857142-9Report Type:Periodic Company Report #WAES 01091497
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Baycol	C				
			Celebrex	C				
			Fosamax	C				
			Lodine Xl	C				
			Paxil	C				
			Prilosec	C				
			Synthroid	C				
			Ultram	C				
			Lorazepam	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857143-0Report Type:Periodic Company Report #WAES 01104894
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857144-2Report Type:Periodic Company Report #WAES 01091522
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Ulcerative	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Hormonal Contraceptive (Unspeci	C				

Date:12/27/01ISR Number: 3857145-4Report Type:Periodic Company Report #WAES 01104897
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Plaquenil	C				
			Synthroid	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3857146-6Report Type:Periodic Company Report #WAES 01106159
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Arthralgia
MG/DAILY/PO 3 YR
Dizziness Tylenol C
Nausea Ranitidine C
Pain In Extremity
Rash
Rash Macular
Vomiting

Date:12/27/01ISR Number: 3857147-8Report Type:Periodic Company Report #WAES 01091525
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	25	
	Urticaria	Professional					MG/DAILY/PO	
			Ibuprofen	C				

Date:12/27/01ISR Number: 3857148-XReport Type:Periodic Company Report #WAES 01106177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Emotional Disorder	Professional	Cipro	C				
			Glucophage	C				
			Pravachol	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857149-1Report Type:Periodic Company Report #WAES 01106179
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactation Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
			Ortho Tri-Cyclen	C				

Date:12/27/01ISR Number: 3857150-8Report Type:Periodic Company Report #WAES 01106180
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857151-XReport Type:Periodic Company Report #WAES 01104496
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
			Andro/Fem	C				

Date:12/27/01ISR Number: 3857152-1Report Type:Periodic Company Report #WAES 01104404
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS		ORAL	25	
	Dyspepsia						MG/DAILY/PO	
	Fatigue		Glucotrol Xl	C				
	Muscular Weakness		Neurontin	C				
			Pravachol	C				
			Prilosec	C				
			Alprazolam	C				

Date:12/27/01ISR Number: 3857153-3Report Type:Periodic Company Report #WAES 01104415
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3857154-5Report Type:Periodic Company Report #WAES 01104437
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857155-7Report Type:Periodic Company Report #WAES 01104438
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857156-9Report Type:Periodic Company Report #WAES 01104459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx	PS			50 MG/DAILY	
			Tricor	C				
			Triamterene	C				

Date:12/27/01ISR Number: 3857157-0Report Type:Periodic Company Report #WAES 01104462
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857158-2Report Type:Periodic Company Report #WAES 01091534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 MON
			Prevacid	C				
			Prinivil	C				

Verapamil C

Date:12/27/01ISR Number: 3857159-4Report Type:Periodic Company Report #WAES 01104464
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857160-0Report Type:Periodic Company Report #WAES 01091551
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Os-Cal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857161-2Report Type:Periodic Company Report #WAES 01104465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857162-4Report Type:Periodic Company Report #WAES 01091554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma	Foreign Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857163-6Report Type:Periodic Company Report #WAES 01104469
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857164-8Report Type:Periodic Company Report #WAES 01091563
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Professional
MG/DAILY/PO
Premarin C

Date:12/27/01ISR Number: 3857165-XReport Type:Periodic Company Report #WAES 01091570
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Gastrointestinal Disorder						50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857166-1Report Type:Periodic Company Report #WAES 01091598
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857167-3Report Type:Periodic Company Report #WAES 01112615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

			Lescol	C		

Date:12/27/01ISR Number: 3857168-5Report Type:Periodic Company Report #WAES 01112624
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857169-7Report Type:Periodic Company Report #WAES 01112625
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
	Hypersensitivity		Prilosec	C				
	Hypertension		Therapy Unspecified	C				
			Estrogens (Unspecified)	C				
			Propranolol	C				

Date:12/27/01ISR Number: 3857170-3Report Type:Periodic Company Report #WAES 01112626
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857171-5Report Type:Periodic Company Report #WAES 01112629
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence							
	Gastritis		Prevacid	C				
	Gastrointestinal Disorder		Thyroid	C				

Date:12/27/01ISR Number: 3857172-7Report Type:Periodic Company Report #WAES 01104647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857173-9Report Type:Periodic Company Report #WAES 01112633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857174-0Report Type:Periodic Company Report #WAES 01104649
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lachydrin	C				
			Prevacid	C				
			Atenolol (+)					
			Chlorthalidone	C				
			Lorazepam	C				

Date:12/27/01ISR Number: 3857175-2Report Type:Periodic Company Report #WAES 01112639
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Palpitations		Protonix	C				

Date:12/27/01ISR Number: 3857176-4Report Type:Periodic Company Report #WAES 01112640
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Glucophage	C				
			Mevacor	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3857177-6Report Type:Periodic Company Report #WAES 01104650
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
PO						
	Haemorrhage	Professional Company Representative				

Date:12/27/01ISR Number: 3857178-8Report Type:Periodic Company Report #WAES 01104716
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL
PO						
	Pruritus		Celebrex	C		
			Lipitor	C		
			Maxzide	C		
			Norvasc	C		
			Toprol Xl Tablets	C		
			[Therapy Unspecified]	C		

Date:12/27/01ISR Number: 3857179-XReport Type:Periodic Company Report #WAES 01104719
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Ecchymosis	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS			25 MG/DAILY	
Klonopin	C				
Motrin	C				
Voltaren	C				

Date:12/27/01ISR Number: 3857180-6Report Type:Periodic Company Report #WAES 01112664
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Darvocet-N	C				
			Orphenadrine Citrate	C				

Date:12/27/01ISR Number: 3857181-8Report Type:Periodic Company Report #WAES 01104722
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx	PS		ORAL	25 MG/ DAILY/	
	Vaginal Discharge						PO	
			Detrol	C				
			Lasix (Furosemide)	C				
			Prozac	C				
			Synthroid	C				
			Trental	C				
			Vicodin Tablets	C				
			Clonidine	C				
			Dextromethorphan Hydrobromide	C				
			Potassium (Unspecified)	C				

Date:12/27/01ISR Number: 3857182-XReport Type:Periodic Company Report #WAES 01112702
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder		Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857183-1Report Type:Periodic Company Report #WAES 01104725
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
			Aspirin	C				

Date:12/27/01ISR Number: 3857184-3Report Type:Periodic Company Report #WAES 01104729
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Toprol Xl Tablets	C				

				Xanax	C		
				Zoloft	C		

Date:12/27/01ISR Number: 3857185-5Report Type:Periodic Company Report #WAES 01104738
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:12/27/01ISR Number: 3857186-7Report Type:Periodic Company Report #WAES 01104747
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Tab Vioxx	PS		ORAL	12.MG/DAILY/PO	
	Gastrointestinal Ulcer							
			Zestril	C				

Date:12/27/01ISR Number: 3857187-9Report Type:Periodic Company Report #WAES 01104525
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Increased							
	Drug Interaction		Accupril	SS				
			Coumadin	C				
			Lanoxin	C				
			Lipitor	C				

Date:12/27/01ISR Number: 3857188-0Report Type:Periodic Company Report #WAES 01104528
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Levothroid	C				
			Neurontin	C				
			Zocor	C				
			Cyanocobalamin	C				

Date:12/27/01ISR Number: 3857189-2Report Type:Periodic Company Report #WAES 01104506
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain In Extremity							
			Flomax (Morniflumate)	C				
			Synthroid	C				
			Clioquinol (+) Hydrocortisone	C				
			Nystatin (+) Triamcinolone Aceto	C				

			Quinine Sulfate	C		

Date:12/27/01ISR Number: 3857190-9Report Type:Periodic Company Report #WAES 01104548
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Valium	C				

Date:12/27/01ISR Number: 3857191-0Report Type:Periodic Company Report #WAES 01104549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence							
			Methotrexate (Methotrexate Sodium)	C				
			Synthroid	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3857192-2Report Type:Periodic Company Report #WAES 01104553
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857193-4Report Type:Periodic Company Report #WAES 01104554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857194-6Report Type:Periodic Company Report #WAES 01104570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857195-8Report Type:Periodic Company Report #WAES 01104579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857196-XReport Type:Periodic Company Report #WAES 01104600
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857197-1Report Type:Periodic Company Report #WAES 01103383
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Gastric Disorder							

Date:12/27/01ISR Number: 3857198-3Report Type:Periodic Company Report #WAES 01103399
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Fatigue		Enbrel	C				
	Pharyngitis		Premarin	C				
			Methotrexate	C				

Date:12/27/01ISR Number: 3857199-5Report Type:Periodic Company Report #WAES 01104242
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Post Procedural	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Company Representative						

Date:12/27/01ISR Number: 3857200-9Report Type:Periodic Company Report #WAES 01104255
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3857201-0Report Type:Periodic Company Report #WAES 01104266
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Drug Intolerance		Lasix (Furosemide)	C				
	Dyspepsia		Minitran	C				
	Feeling Cold		Tiazac	C				
	Feeling Hot		Ultram	C				
	Pain In Extremity		Valium	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857202-2Report Type:Periodic Company Report #WAES 01104267
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Daranide	C				
			Nasacort	C				
			Prilosec	C				
			Tylenol	C				
			Belladonna	C				

Date:12/27/01ISR Number: 3857203-4Report Type:Periodic Company Report #WAES 01104268
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Consumer	Tab Vioxx	PS		ORAL	PO/ PRN	
	Increased		Evista	C				
	Blood Urea Increased		Leucovorin	C				
	Renal Disorder		Norvasc	C				
			Zaroxyl	C				
			Labetalol Hydrochloride	C				
			Methotrexate	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3857204-6Report Type:Periodic Company Report #WAES 01104270
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857205-8Report Type:Periodic Company Report #WAES 01104277
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Epigastric Discomfort							

Date:12/27/01ISR Number: 3857206-XReport Type:Periodic Company Report #WAES 01104336
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Lamisil	C				
			Estradiol	C				

Date:12/27/01ISR Number: 3857207-1Report Type:Periodic Company Report #WAES 01092257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retching	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857208-3Report Type:Periodic Company Report #WAES 01092268
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oral Soft Tissue Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857209-5Report Type:Periodic Company Report #WAES 01092288
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857210-1Report Type:Periodic Company Report #WAES 01092320
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dysgeusia		Synthroid	C				
	Dyspepsia							
	Nausea							

Date:12/27/01ISR Number: 3857211-3Report Type:Periodic Company Report #WAES 01092330
Age:53 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	

MG/DAILY/PO

Beconase	C
Climara	C
Zomig	C
Zyrtec	C

Date:12/27/01ISR Number: 3857212-5Report Type:Periodic Company Report #WAES 01092352
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:12/27/01ISR Number: 3857213-7Report Type:Periodic Company Report #WAES 01092357
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Fatigue	Health Professional	Vitamins	C				
	Headache							
	Musculoskeletal Stiffness							
	Neck Pain							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857214-9Report Type:Periodic Company Report #WAES 01092358
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Neurontin	C				
			Vicodin Tablets	C				

Date:12/27/01ISR Number: 3857215-0Report Type:Periodic Company Report #WAES 01092359
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lotensin	C				

Date:12/27/01ISR Number: 3857216-2Report Type:Periodic Company Report #WAES 01092366
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	30 DAY
			Advil	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:12/27/01ISR Number: 3857217-4Report Type:Periodic Company Report #WAES 01092110
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	

		Haemorrhage	Professional Company Representative				

Date:12/27/01ISR Number: 3857218-6Report Type:Periodic Company Report #WAES 01092116
Age:81 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route	Dose
		Gastrointestinal Disorder	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO
				Prinivil	C			

Date:12/27/01ISR Number: 3857219-8Report Type:Periodic Company Report #WAES 01092119
Age:80 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route	Dose
		Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
		Flatulence						
		Nausea		Enduron	C			
				Fosamax	C			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857220-4Report Type:Periodic Company Report #WAES 01092167
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	DAILY/PO
			Levothyroxine Sodium	C				

Date:12/27/01ISR Number: 3857221-6Report Type:Periodic Company Report #WAES 01092172
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Premphase	C				
			Prilosec	C				
			Atenolol	C				
			Folic Acid	C				
			Methotrexate	C				

Date:12/27/01ISR Number: 3857222-8Report Type:Periodic Company Report #WAES 01092174
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Nausea		Aspirin	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3857223-XReport Type:Periodic Company Report #WAES 01092176
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Drug Ineffective		Depakote	C		
			Lipitor	C		
			Monopril	C		
			Thorazine	C		
			Aspirin	C		
			Phenobarbital	C		

Date:12/27/01ISR Number: 3857224-1Report Type:Periodic Company Report #WAES 01092180
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PRN/PO						
	Tongue Disorder					

Date:12/27/01ISR Number: 3857225-3Report Type:Periodic Company Report #WAES 01092182
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY						
	Headache	Health				
PO						
	Malaise	Professional	Cetapril	C		
			K-Dur	C		
			Ascorbic Acid	C		
			Aspirin	C		

Indapamide	C
Sulfinpyrazone	C
Verapamil	C
Vitamin E	C

Date:12/27/01ISR Number: 3857226-5Report Type:Periodic Company Report #WAES 01092192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Oedema Peripheral		Celebrex	C				
			Paxil	C				
			Zanaflex	C				

Date:12/27/01ISR Number: 3857227-7Report Type:Periodic Company Report #WAES 01091927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857228-9Report Type:Periodic Company Report #WAES 01091928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Urea Increased	Company Representative						
	Oedema Peripheral							

Date:12/27/01ISR Number: 3857229-0Report Type:Periodic Company Report #WAES 01091955
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/1X/PO	

Date:12/27/01ISR Number: 3857230-7Report Type:Periodic Company Report #WAES 01091960
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx	PS		ORAL	PO	
	Pruritus		Accupril	C				
	Skin Disorder		Flomax (Tamsulosin Hydrochloride	C				
			Micardis	C				
			Prilosec	C				
			Zocor	C				
			Zyrtec	C				
			Acebutolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857231-9Report Type:Periodic Company Report #WAES 01091970
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Nausea		Lopressor	C				
	Oedema Peripheral		Motrin	C				
	Rash		Tylenol	C				
	Weight Increased		Zocor	C				
			Aspirin	C				
			Propafenone	C				
			Itamins	C				

Date:12/27/01ISR Number: 3857232-0Report Type:Periodic Company Report #WAES 01091976
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Psoriasis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Prilosec	C				
			Atenolol	C				
			Folic Acid	C				
			Methotrexate	C				
			Hyroid	C				

Date:12/27/01ISR Number: 3857233-2Report Type:Periodic Company Report #WAES 01091977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Epigastric Discomfort		Buspar	C				
			Depakote	C				
			Effexor	C				

			Neuroton	C		

Date:12/27/01ISR Number: 3857234-4Report Type:Periodic Company Report #WAES 01091991
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857235-6Report Type:Periodic Company Report #WAES 01091995
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vomiting							
			Buspar	C				
			Compazine	C				
			Corzide Tablets	C				
			Depakote	C				
			Lorestat	C				
			Paxil	C				
			Phenergan Syrup	C				
			Sinemet	C				

Zomax C

Date:12/27/01ISR Number: 3857236-8Report Type:Periodic Company Report #WAES 01091998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional Company Representative	Glucophage	C				

Date:12/27/01ISR Number: 3857237-XReport Type:Periodic Company Report #WAES 01101842
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:12/27/01ISR Number: 3857238-1Report Type:Periodic Company Report #WAES 01101870
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

Date:12/27/01ISR Number: 3857239-3Report Type:Periodic Company Report #WAES 01101872
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857240-XReport Type:Periodic Company Report #WAES 01101884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Lesion	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857241-1Report Type:Periodic Company Report #WAES 01101905
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased Blood Urea Increased	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857242-3Report Type:Periodic Company Report #WAES 01101924
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypoaesthesia							
			Accupril	C				
			Flonase	C				
			Prempro	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3857243-5Report Type:Periodic Company Report #WAES 01101957
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	
	Cardiac Disorder							
	Dyspnoea							
	Fatigue							
	Malaise							
	Weight Increased							

Date:12/27/01ISR Number: 3857244-7Report Type:Periodic Company Report #WAES 01101958
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							

Date:12/27/01ISR Number: 3857245-9Report Type:Periodic Company Report #WAES 01101962
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cholestasis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3857246-0Report Type:Periodic Company Report #WAES 01101963
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Celebrex	C				
			Cozaar	C				
			Lasix (Furosemide)	C				
			Zocor	C				
			Atenolol	C				
			Potassium	C				

Date:12/27/01ISR Number: 3857247-2Report Type:Periodic Company Report #WAES 01101623
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Change Of Bowel Habit	Professional						
	Diarrhoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857248-4Report Type:Periodic Company Report #WAES 01101619
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Obesity	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Glucophage	C				
			Maxzide	C				
			Norflex	C				
			Ultram	C				
			Zocor	C				
			Albuterol	C				
			Estrogens (Unspecified)	C				
			Hyoscyamine	C				

Date:12/27/01ISR Number: 3857249-6Report Type:Periodic Company Report #WAES 01101634
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25mg	PS		ORAL	PRN/PO	
		Health Professional	Hytrin	C				
			Prevacid	C				
			Questram	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3857250-2Report Type:Periodic Company Report #WAES 01101669
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage Ulcer	Company Representative						

Date:12/27/01ISR Number: 3857251-4Report Type:Periodic Company Report #WAES 01101671
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857252-6Report Type:Periodic Company Report #WAES 01101672
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857253-8Report Type:Periodic Company Report #WAES 01101686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857254-XReport Type:Periodic Company Report #WAES 01101690
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Back Pain		Prilosec	C				
	Chest Pain							
	Fatigue							
	Flushing							
	Hyperhidrosis							
	Oedema Peripheral							

Date:12/27/01ISR Number: 3857255-1Report Type:Periodic Company Report #WAES 01101789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Consumer	Tab Vioxx	PS		ORAL	PO	
	Phosphokinase Increased		Actonel	C				
			Phenobarbital	C				

Date:12/27/01ISR Number: 3857256-3Report Type:Periodic Company Report #WAES 01101796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857257-5Report Type:Periodic Company Report #WAES 01101457
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	
			Tab Estrogens (Unspecified) Unk	SS				
			Norflex	C				
			Ultram	C				

Date:12/27/01ISR Number: 3857258-7Report Type:Periodic Company Report #WAES 01101468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857259-9Report Type:Periodic Company Report #WAES 01101529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
		Company Representative						

Date:12/27/01ISR Number: 3857260-5Report Type:Periodic Company Report #WAES 01101540
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Disorder							
			Altace	C				
			Lasix (Furosemide)	C				
			Lotrel	C				
			Premarin	C				
			Protonix	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Ginkgo Biloba Extract	C				
			Potassium Chloride	C				

Date:12/27/01ISR Number: 3857261-7Report Type:Periodic Company Report #WAES 01101547
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857262-9Report Type:Periodic Company Report #WAES 01101558
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				

Date:12/27/01ISR Number: 3857263-0Report Type:Periodic Company Report #WAES 01101561
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Lotrel	C				
			Skelaxin	C				
			Atenolol	C				
			Nifedipine	C				

Date:12/27/01ISR Number: 3857264-2Report Type:Periodic Company Report #WAES 01101568
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Tab Vioxx Unk Celebrex	PS C		ORAL	PO	

Date:12/27/01ISR Number: 3857265-4Report Type:Periodic Company Report #WAES 01101569
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma Blood Pressure Increased Dizziness Dyspepsia Muscle Spasms Nasal Congestion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857266-6Report Type:Periodic Company Report #WAES 01101618
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased Tooth Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3857267-8Report Type:Periodic Company Report #WAES 01101273
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bradycardia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Heart Rate Irregular	Professional				
MG/DAILY/PO						
	Myalgia		Zocor	C		
			Cyclosporine	C		

Date:12/27/01ISR Number: 3857268-XReport Type:Periodic Company Report #WAES 01101278
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
			Tab Vioxx 25 Mg	SS		ORAL
PO						
			Lipitor	C		
			Lozol	C		
			Xalatan	C		
			Atenolol	C		

Date:12/27/01ISR Number: 3857269-1Report Type:Periodic Company Report #WAES 01101284
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Glucophage	C		
			Lipitor	C		
			Therapy Unspecified	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857270-8Report Type:Periodic Company Report #WAES 01101299
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Clonidine	C				

Date:12/27/01ISR Number: 3857271-XReport Type:Periodic Company Report #WAES 01101310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rectal Haemorrhage							

Date:12/27/01ISR Number: 3857272-1Report Type:Periodic Company Report #WAES 01101339
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Aldactazine	C				
			Labetalol Hydrochloride	C				

Date:12/27/01ISR Number: 3857273-3Report Type:Periodic Company Report #WAES 01101365
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3857274-5Report Type:Periodic Company Report #WAES 01101368
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Headache							

Date:12/27/01ISR Number: 3857275-7Report Type:Periodic Company Report #WAES 01101449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Oesophageal Obstruction		Tab Vioxx 25 Mg	SS		ORAL	PO	

Date:12/27/01ISR Number: 3857276-9Report Type:Periodic Company Report #WAES 01101453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857277-0Report Type:Periodic Company Report #WAES 01101216
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Therapy Unspecified	C				

Date:12/27/01ISR Number: 3857278-2Report Type:Periodic Company Report #WAES 01101217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Swelling	Professional Company Representative						

Date:12/27/01ISR Number: 3857279-4Report Type:Periodic Company Report #WAES 01101219
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nephritis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3857280-0Report Type:Periodic Company Report #WAES 01101221
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Company
Representative

Date:12/27/01ISR Number: 3857281-2Report Type:Periodic Company Report #WAES 01101244
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							

Date:12/27/01ISR Number: 3857282-4Report Type:Periodic Company Report #WAES 01101247
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Rash							
			Allegra	C				
			Prinzide	C				
			Proscar	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857283-6Report Type:Periodic Company Report #WAES 01101253
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:12/27/01ISR Number: 3857284-8Report Type:Periodic Company Report #WAES 01101263
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO;	
		Company Representative					25 MG/DAILY/PO;	
							12.5	

Date:12/27/01ISR Number: 3857285-XReport Type:Periodic Company Report #WAES 01101264
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:12/27/01ISR Number: 3857286-1Report Type:Periodic Company Report #WAES 01101268
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Headache	Health					MG/DAILY/PO	
		Professional	Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3857287-3Report Type:Periodic Company Report #WAES 01103331
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx	PS		ORAL	12.5	
	Hypoaesthesia	Professional					MG/BID/PO	
	Oedema Peripheral		Tab Vioxx 12.5 Mg	SS		ORAL	12.5	
	Pain						MG/DAILY/PO	
	Rash		Pravachol	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Atenolol	C				
			Folic Acid	C				
			Niacin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857288-5Report Type:Periodic Company Report #WAES 01103333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pigmentation Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
			Monopril	C				

Date:12/27/01ISR Number: 3857289-7Report Type:Periodic Company Report #WAES 01103337
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia		Hydrodiuril	C				
			Synthroid	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3857290-3Report Type:Periodic Company Report #WAES 01103341
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx	PS		ORAL	PO	
	Pruritus	Professional	Glucotrol Xl	C				
	Swelling	Company						
	Urticaria	Representative						

Date:12/27/01ISR Number: 3857291-5Report Type:Periodic Company Report #WAES 01103343
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx	PS		ORAL	PO	
			Synthroid	C				

Date:12/27/01ISR Number: 3857292-7Report Type:Periodic Company Report #WAES 01103360
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Elavil	C				
			Lipitor	C				

Date:12/27/01ISR Number: 3857293-9Report Type:Periodic Company Report #WAES 01103362
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3857294-0Report Type:Periodic Company Report #WAES 01103366
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia Tendonitis	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	

			Tab Vioxx 25 Mg	SS		ORAL
25						
MG/DAILY/PO						
			Fosamax	C		
			Tums	C		
			Aspartame	C		
			Sodium Fluoride	C		

Date:12/27/01ISR Number: 3857295-2Report Type:Periodic Company Report #WAES 01103375
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Back Pain	Consumer	Tab Vioxx	PS		ORAL
25						
MG/DAILY/PO						
			Darvocet-N	C		
			Fosamax	C		
			Prempro	C		
			Soma	C		
			Aspirin	C		
			Calcium (Unspecified)	C		
			Clonazepam	C		
			Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3857296-4Report Type:Periodic Company Report #WAES 01103376
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx	PS		ORAL
PO						
	Fatigue					
	Myalgia					
	Weight Increased					

Date:12/27/01ISR Number: 3857995-4Report Type:Periodic Company Report #WAES 01111413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
	Drug Ineffective		Therapy Unspecified	C				
	Eyelid Oedema							
	Face Oedema							
	Fluid Retention							
	Pollakiuria							
	Pruritus							

Date:12/27/01ISR Number: 3857996-6Report Type:Periodic Company Report #WAES 01111415
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3857997-8Report Type:Periodic Company Report #WAES 01111481
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Lipitor	C				
			Maxzide	C				
			Glipizide	C				
			Oxybutynin Chloride	C				

Date:12/27/01ISR Number: 3857998-XReport Type:Periodic Company Report #WAES 01111485
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Faeces Discoloured							
	Gastrointestinal Disorder							

Date:12/27/01ISR Number: 3857999-1Report Type:Periodic Company Report #WAES 01111492
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
			Arthrotec	C				
			Detrol La	C				
			Estradiol	C				
			Verapamil	C				

Date:12/27/01ISR Number: 3858000-6Report Type:Periodic Company Report #WAES 01111493
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Alrex	C				
			Augmentan	C				
			Carafate	C				
			Chlorazepate	C				
			Nasocort	C				
			Paxil	C				
			Serzone	C				

Date:12/27/01ISR Number: 3858001-8Report Type:Periodic Company Report #WAES 01111499
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Contusion	Professional					MG/DAILY/PO	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858002-XReport Type:Periodic Company Report #WAES 01111598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858003-1Report Type:Periodic Company Report #WAES 01111666
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858004-3Report Type:Periodic Company Report #WAES 01111667
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				

Date:12/27/01ISR Number: 3858005-5Report Type:Periodic Company Report #WAES 01111252
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Pharyngeal Ulceration		Premarin	C				
			Zantac	C				
			Aspirin	C				

			Vitamins	C		

Date:12/27/01ISR Number: 3858006-7Report Type:Periodic Company Report #WAES 01111255
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							
	Oedema Peripheral		Aricept	C				
			Plavix	C				
			Tylenol	C				
			Aspirin	C				
			Atenolol	C				
			Codeine (+) Salicylic Acid	C				
			Isosorbide Dinitrate	C				
			Nitroglycerin	C				
			Trazodone	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858007-9Report Type:Periodic Company Report #WAES 01111266
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Celebrex	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3858008-0Report Type:Periodic Company Report #WAES 01111274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Enzyme Abnormality	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:12/27/01ISR Number: 3858009-2Report Type:Periodic Company Report #WAES 01111275
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3858010-9Report Type:Periodic Company Report #WAES 01111276
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Back Pain	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:12/27/01ISR Number: 3858011-0Report Type:Periodic Company Report #WAES 01111338
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/	
	Oedema Peripheral						DAILY/PO	
			Lopressor	C				
			Monopril	C				
			Ogen	C				
			Zocor	C				
			Famotidine	C				
			Hydrochlorothiazide/ Triamter	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858012-2Report Type:Periodic Company Report #WAES 01111367
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:12/27/01ISR Number: 3858013-4Report Type:Periodic Company Report #WAES 01111380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pigmentation Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	1 WK
			Estrogens (Unspecified)	C				
			Methylprednisolone	C				

Date:12/27/01ISR Number: 3858014-6Report Type:Periodic Company Report #WAES 01111394
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
			Lortab	C				
			Levodopa	C				

Date:12/27/01ISR Number: 3858109-7Report Type:Periodic Company Report #WAES 01111213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aspirin	C				

				Vitamins (Unspecified)	C	

Date:12/27/01ISR Number: 3858110-3Report Type:Periodic Company Report #WAES 01111214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858111-5Report Type:Periodic Company Report #WAES 01111194
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Hytrin	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Proscar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858112-7Report Type:Periodic Company Report #WAES 01111200
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Pain In Extremity		Diovan	C				
			Estrace	C				
			Imdur	C				
			Lipitor	C				
			Maxzide	C				
			Nexium	C				
			Norvasc	C				
			Tenormin	C				

Date:12/27/01ISR Number: 3858113-9Report Type:Periodic Company Report #WAES 01111152
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Aricept	C				
			Lipitor	C				
			Lopid	C				
			Nitrostat	C				

Date:12/27/01ISR Number: 3858114-0Report Type:Periodic Company Report #WAES 01111155
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chorea	Health Professional	Tab Vioxx Unk	PS				

Date:12/27/01ISR Number: 3858115-2Report Type:Periodic Company Report #WAES 01111156
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sleep Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3858116-4Report Type:Periodic Company Report #WAES 01111231
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Hytrin	C				
			Tylenol With Codeine	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858117-6Report Type:Periodic Company Report #WAES 01111239
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	
	Musculoskeletal Stiffness	Professional						
	Paraesthesia		Diflucan	C				
	Rash							

Date:12/27/01ISR Number: 3858118-8Report Type:Periodic Company Report #WAES 01111250
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Urticaria							

Date:12/27/01ISR Number: 3858119-XReport Type:Periodic Company Report #WAES 01082480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Drug Ineffective							
	Fall							

Date:12/27/01ISR Number: 3858120-6Report Type:Periodic Company Report #WAES 01082485
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/Q8H/PO	
			Monopril	C				

Date:12/27/01ISR Number: 3858121-8Report Type:Periodic Company Report #WAES 01082520
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Headache		Glucotrol Xl	C				
	Oedema		Lozol	C				
	Oedema Peripheral		Ascorbic Acid	C				
			Aspirin	C				
			Beta Carotene	C				
			Vitamin E	C				

Date:12/27/01ISR Number: 3858122-XReport Type:Periodic Company Report #WAES 01082521
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actonel	C				
			Diovan	C				
			Drisdol	C				
			Premarin Vaginal Cream	C				
			Tiazac	C				
			Aspirin	C				

				Atenolol	C	
				Trazodone	C	
				Vitamin E	C	
				Vitamins (Unspecified)	C	

Date:12/27/01ISR Number: 3858123-1Report Type:Periodic Company Report #WAES 01082536
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lenoxin	C				

Date:12/27/01ISR Number: 3858124-3Report Type:Periodic Company Report #WAES 01082538
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

Date:12/27/01ISR Number: 3858125-5Report Type:Periodic Company Report #WAES 01082539
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Malaise	Health Professional						
			Allopurinol Msd	C				
			Avandia	C				
			Cozaar	C				
			Glucophage	C				
			Prempro	C				
			Tricor	C				

			Glipizide	C

Date:12/27/01ISR Number: 3858126-7Report Type:Periodic Company Report #WAES 01082541
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Bowel Sounds Abnormal							
	Chest Pain		Elavil	C				
	Faeces Discoloured		Lortab	C				
	Fatigue		Lotrel	C				
			Nexium	C				
			Aspirin	C				
			Oxygen	C				

Date:12/27/01ISR Number: 3858127-9Report Type:Periodic Company Report #WAES 01082543
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858128-0Report Type:Periodic Company Report #WAES 01082547
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO ; PO	

Date:12/27/01ISR Number: 3858129-2Report Type:Periodic Company Report #WAES 01090250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Feeling Drunk							
	Muscular Weakness							

Date:12/27/01ISR Number: 3858130-9Report Type:Periodic Company Report #WAES 01090256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Tab Vioxx	PS		ORAL	PO	
	Paraesthesia		Allegra	C				
			Evista	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3858131-0Report Type:Periodic Company Report #WAES 01090262
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Pruritus							
			Zantac	C				

Date:12/27/01ISR Number: 3858132-2Report Type:Periodic Company Report #WAES 01090263
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Avandia	C				
			Cardizem Cd	C				
			Cozaar	C				
			Glucotrol	C				
			Lipitor	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3858133-4Report Type:Periodic Company Report #WAES 01090270
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Pain In Extremity		Avandia	C				
			Prinivil	C				
			Aspirin	C				
			Digoxin	C				
			Sotalol Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858134-6Report Type:Periodic Company Report #WAES 01090272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25MG/UNK/PO; 50MG/UNK/PO	
			[Composition Unspecified]	C				
			Allopurinol	C				

Date:12/27/01ISR Number: 3858135-8Report Type:Periodic Company Report #WAES 01090275
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY/PO	
	Dizziness							
	Weight Increased		Celebrex	C				
			Fosamax	C				

Date:12/27/01ISR Number: 3858136-XReport Type:Periodic Company Report #WAES 01090276
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858137-1Report Type:Periodic Company Report #WAES 01090278
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	25	

		Fatigue					
MG/DAILY/PO	1	MON					
		Joint Swelling		Celebrex	C		
		Oedema Peripheral		Hyzaar	C		
				Lipitor	C		
				Lupron	C		

Date:12/27/01ISR Number: 3858138-3Report Type:Periodic Company Report #WAES 01090279
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx	PS		ORAL	PO	
			Prilosec	C				
			Synthroid	C				
			Zoloft	C				
			Estrogens (Unspecified)	C				
			Lorazepam	C				

Date:12/27/01ISR Number: 3858139-5Report Type:Periodic Company Report #WAES 01091151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Coumadin	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858140-1Report Type:Periodic Company Report #WAES 01091155
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 50 Mg	PS		ORAL	100	
	Oedema Peripheral	Professional					MG/DAILY/PO	
	Weight Increased		Effexor	C				
			Hydrodiuril	C				
			Zestril	C				

Date:12/27/01ISR Number: 3858141-3Report Type:Periodic Company Report #WAES 01091187
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3858142-5Report Type:Periodic Company Report #WAES 01091190
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Serevent	C				
			Zocor	C				

Date:12/27/01ISR Number: 3858143-7Report Type:Periodic Company Report #WAES 01091192
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO 10 DAY

Date:12/27/01ISR Number: 3858144-9Report Type:Periodic Company Report #WAES 01091193
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858145-0Report Type:Periodic Company Report #WAES 01091196
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
	Mouth Ulceration							
			Premarin	C				
			Provera	C				
			Synthroid	C				
			[Therapy Unspecified]	C				
			Calcium (Unspecified)	C				

				Vitamin E	C		
				Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3858146-2Report Type:Periodic Company Report #WAES 01091198
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Aspirin	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3858147-4Report Type:Periodic Company Report #WAES 01091199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858148-6Report Type:Periodic Company Report #WAES 01091223
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fatigue							
	Weight Increased							

Date:12/27/01ISR Number: 3858149-8Report Type:Periodic Company Report #WAES 01090744
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/ PO	

Date:12/27/01ISR Number: 3858150-4Report Type:Periodic Company Report #WAES 01090747
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	25 MG/ DAILY/ PO	
			Actos	C				
			Celebrex	C				
			Glucotrol Xl	C				
			Mavik	C				
			Os-Cal	C				
			Premarin	C				
			Prevacid	C				
			Prilosec	C				
			Synthroid	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858151-6Report Type:Periodic Company Report #WAES 01090750
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858152-8Report Type:Periodic Company Report #WAES 01090751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858153-XReport Type:Periodic Company Report #WAES 01090767
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25-50 MG/ DAILY/	PO
			Desyrel	C				
			Evista	C				
			Exelon	C				
			Wellbutrin Sr	C				

Date:12/27/01ISR Number: 3858154-1Report Type:Periodic Company Report #WAES 01090782
Age:78 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Nocturia	Consumer	Tab Vioxx	PS		ORAL
12.5 MG/						
	Oliguria					
DAILY/ PO						
	Pollakiuria		Avandia	C		
			Cozaar	C		
			Glucophage	C		
			Procardia Xl	C		
			Toprol Xl Tablets	C		
			Lorazepam	C		

Date:12/27/01ISR Number: 3858155-3Report Type:Periodic Company Report #WAES 01090815
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Paraesthesia	Consumer	Tab Vioxx	PS		ORAL
25 MG/ DAILY/						
PO						
			Coreg	C		
			Synthroid	C		
			Zocor	C		
			Diazepam	C		
			Spironolactone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858156-5Report Type:Periodic Company Report #WAES 01090823
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858157-7Report Type:Periodic Company Report #WAES 01090826
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	12.5 MG/ DAILY/ PO	
			Estrace	C				

Date:12/27/01ISR Number: 3858158-9Report Type:Periodic Company Report #WAES 01090829
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Irritability							

Date:12/27/01ISR Number: 3858228-5Report Type:Periodic Company Report #WAES 01101119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company	Coumadin	C				

Date:12/27/01ISR Number: 3858230-3Report Type:Periodic Company Report #WAES 01101125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Joint Swelling							
	Mobility Decreased							
	Muscle Spasms							

Date:12/27/01ISR Number: 3858233-9Report Type:Periodic Company Report #WAES 01101135
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder		Ditropan Xl	C				
	Nervousness		Imodium A-D	C				
	Urinary Tract Disorder		Prevacid	C				
			Diazepam	C				
			Isosorbide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858235-2Report Type:Periodic Company Report #WAES 01101163
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Memory Impairment		Claritin	C				
			Coumadin	C				
			Darvocet-N	C				
			Elavil	C				
			Premarin	C				

Date:12/27/01ISR Number: 3858237-6Report Type:Periodic Company Report #WAES 01101169
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Combivent	C				
			Duratuss	C				
			Elavil	C				
			Evista	C				
			Flonase	C				
			Lipitor	C				
			Prilosec	C				
			Prinivil	C				
			Synthroid	C				
			Vanceril	C				
			Zyrtec	C				
			Theophylline	C				

Date:12/27/01ISR Number: 3858239-XReport Type:Periodic Company Report #WAES 01101183
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Nitropatch	C				

			Norvasc	C
			Prilosec	C
			Xanax	C

Date:12/27/01ISR Number: 3858241-8Report Type:Periodic Company Report #WAES 01101193
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Prevacid	C				
			Estradiol	C				
			Hydrochlorothiazide (+) Triamter	C				
			Hydroxychloroquine Sulfate	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858243-1Report Type:Periodic Company Report #WAES 01101197
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Lipitor	C				

Date:12/27/01ISR Number: 3858245-5Report Type:Periodic Company Report #WAES 01101212
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:12/27/01ISR Number: 3858246-7Report Type:Periodic Company Report #WAES 01101215
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyuria	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3858248-0Report Type:Periodic Company Report #WAES 01100990
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Professional						
			Ultram	C				

				Medroxyprogesterone Acetate	C		
				Propoxyphene Napsylate	C		

Date:12/27/01ISR Number: 3858250-9Report Type:Periodic Company Report #WAES 01100997
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Flonase	C				
			Zyrtec	C				
			Hydrochlorothiazide (+) Triamter	C				
			Hydroxyzine	C				

Date:12/27/01ISR Number: 3858251-0Report Type:Periodic Company Report #WAES 01101012
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858252-2Report Type:Periodic Company Report #WAES 01101037
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Headache							

Date:12/27/01ISR Number: 3858253-4Report Type:Periodic Company Report #WAES 01101040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858254-6Report Type:Periodic Company Report #WAES 01101042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Proteinuria	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858255-8Report Type:Periodic Company Report #WAES 01101060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haemoptysis							

Date:12/27/01ISR Number: 3858256-XReport Type:Periodic Company Report #WAES 01101082
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx	PS		ORAL	50 MG/PO	
			Hydrodiuril	C				
			Lipitor	C				
			Lotrel	C				
			Tenex	C				
			Aspirin	C				
			Atenolol	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3858258-3Report Type:Periodic Company Report #WAES 01101084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Diarrhoea							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858260-1Report Type:Periodic Company Report #WAES 01101117
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Loestrin	C				
			Glucosamine	C				

Date:12/27/01ISR Number: 3858342-4Report Type:Periodic Company Report #WAES 01103231
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Dyspepsia		Flovent	C				
	Hypersomnia		Ventilan (Albuterol)	C				
	Insomnia							
	Nausea							

Date:12/27/01ISR Number: 3858343-6Report Type:Periodic Company Report #WAES 01103242
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858344-8Report Type:Periodic Company Report #WAES 01103260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858345-XReport Type:Periodic Company Report #WAES 01103280
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Synthroid	C				
			Atenolol	C				
			Hydrochlorothiazidce (+) Triamter	C				
			Potassium Chloride	C				
			Ranitidine	C				
			Tamoxifen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858346-1Report Type:Periodic Company Report #WAES 01103285
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Headache							
			Synvisc	C				
			Nortriptyline	C				

Date:12/27/01ISR Number: 3858347-3Report Type:Periodic Company Report #WAES 01103288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858348-5Report Type:Periodic Company Report #WAES 01103293
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Catapres Tts	C				
			Elocon	C				
			Lipitor	C				
			Nolvadex	C				

Date:12/27/01ISR Number: 3858349-7Report Type:Periodic Company Report #WAES 01103294
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Flatulence
MG/DAILY/PO

Diovan	C
Donnatal	C
Prilosec	C
Procardia	C
Synthroid	C
Amiodarone	C
Diazepam	C

Date:12/27/01ISR Number: 3858350-3Report Type:Periodic Company Report #WAES 01103297
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							

Date:12/27/01ISR Number: 3858351-5Report Type:Periodic Company Report #WAES 01103329
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Renal Pain							
			Celebrex	C				

Date:12/27/01ISR Number: 3858352-7Report Type:Periodic Company Report #WAES 01103196
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Hydrodiuril	C				
			Tiazac	C				
			Pancrelipase	C				
			Potassium Chloride	C				

Date:12/27/01ISR Number: 3858353-9Report Type:Periodic Company Report #WAES 01103063
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	1 DAY
	Headache							
	Musculoskeletal Stiffness							

Date:12/27/01ISR Number: 3858354-0Report Type:Periodic Company Report #WAES 01103073
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Consumer	Tab Vioxx	PS		ORAL	PO	
			Neurontin	C				
			Remeron	C				
			Senokot(Senna)	C				
			Zantac	C				
			Morphine	C				
			Trazodone	C				

Date:12/27/01ISR Number: 3858355-2Report Type:Periodic Company Report #WAES 01103110
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PRN/PO	
			Zocor	C				

Date:12/27/01ISR Number: 3858356-4Report Type:Periodic Company Report #WAES 01103116
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Professional	Flomax (Tamsulosin Hydrochloride)	C				
			Lescol	C				
			Neurontin	C				

Date:12/27/01ISR Number: 3858357-6Report Type:Periodic Company Report #WAES 01103140
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mental Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Sexual Relationship Change		Wellbutrin	C				
			Hydrochlorothiazide (+) Triamter	C				

				Methylprednisolone	C		

Date:12/27/01ISR Number: 3858358-8Report Type:Periodic Company Report #WAES 01103143
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
			Flonase	C				
			Glucophage	C				
			Lasix (Furosemide)	C				

Date:12/27/01ISR Number: 3858359-XReport Type:Periodic Company Report #WAES 01103180
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858360-6Report Type:Periodic Company Report #WAES 01103182
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Creatinine Renal Clearance Increased							

Date:12/27/01ISR Number: 3858361-8Report Type:Periodic Company Report #WAES 01103183
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Health	Tab Vioxx 25 Mg	PS		ORAL 25
		Professional				MG/DAILY/PO
			Prilosec	C		
			Atenolol	C		

Date:12/27/01ISR Number: 3858362-XReport Type:Periodic Company Report #WAES 01090633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Tinnitus	Company Representative						

Date:12/27/01ISR Number: 3858363-1Report Type:Periodic Company Report #WAES 01090634
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO SEE IMAGE	
	Intervertebral Disc Displacement	Health Professional	Tab Vioxx 25 Mg	SS		ORAL	PO	
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858364-3Report Type:Periodic Company Report #WAES 01090640
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Norvasc	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3858365-5Report Type:Periodic Company Report #WAES 01090643
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Creatine	Health						
	Phosphokinase Increased	Professional	Ultram	C				

Date:12/27/01ISR Number: 3858366-7Report Type:Periodic Company Report #WAES 01090644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3858367-9Report Type:Periodic Company Report #WAES 01090648
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspnoea							

Fatigue
Headache
Oedema Peripheral

Date:12/27/01ISR Number: 3858368-0Report Type:Periodic Company Report #WAES 01090657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Zoloft	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3858369-2Report Type:Periodic Company Report #WAES 01090662
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Celebrex	C				
			Premarin	C				
			Progesterone	C				
			Triamterene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858370-9Report Type:Periodic Company Report #WAES 01090676
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858371-0Report Type:Periodic Company Report #WAES 01090680
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Muscular Weakness							
	Palpitations		Synthroid	C				

Date:12/27/01ISR Number: 3858372-2Report Type:Periodic Company Report #WAES 01090522
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fatigue							
	Nocturia		Premarin	C				
	Oedema Peripheral		Zoloft	C				

Date:12/27/01ISR Number: 3858373-4Report Type:Periodic Company Report #WAES 01090526
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

	Pigmentation Disorder	Skelaxin	C
		Synthroid	C
		Atenolol	C

Date:12/27/01ISR Number: 3858374-6Report Type:Periodic Company Report #WAES 01090529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25 MG/DAILY/PO; 2) 25 MG/PM/PO	
	Fatigue							
	Insomnia							

Date:12/27/01ISR Number: 3858375-8Report Type:Periodic Company Report #WAES 01090530
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858376-XReport Type:Periodic Company Report #WAES 01090541
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Allegra-D	C				
			Dyazide	C				
			Fosamax	C				
			K-Dur	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3858377-1Report Type:Periodic Company Report #WAES 01090557
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858378-3Report Type:Periodic Company Report #WAES 01090573
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:12/27/01ISR Number: 3858379-5Report Type:Periodic Company Report #WAES 01090626
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased	Health Professional						

Date:12/27/01ISR Number: 3858380-1Report Type:Periodic Company Report #WAES 01090627
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3858381-3Report Type:Periodic Company Report #WAES 01090628
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphoedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actonel	C				
			Cozaar	C				
			Hydrodiuril	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858382-5Report Type:Periodic Company Report #WAES 01090476
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pyrexia							
	Vision Blurred		Naproxen	C				

Date:12/27/01ISR Number: 3858383-7Report Type:Periodic Company Report #WAES 01090480
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Health						
		Professional	Lipitor	C				
			Quinine Sulfate	C				
			Triamterene	C				

Date:12/27/01ISR Number: 3858384-9Report Type:Periodic Company Report #WAES 01090485
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypoaesthesia	Health						
		Professional						

Date:12/27/01ISR Number: 3858385-0Report Type:Periodic Company Report #WAES 01090496
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hyperkalaemia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO
			Ativan	C			
			Coumadin	C			
			Glucophage	C			
			Neurontin	C			
			Ultram	C			

Date:12/27/01ISR Number: 3858386-2Report Type:Periodic Company Report #WAES 01090497
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Glucosamine	C				

Date:12/27/01ISR Number: 3858387-4Report Type:Periodic Company Report #WAES 01090499
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858388-6Report Type:Periodic Company Report #WAES 01090500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Ativan	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3858389-8Report Type:Periodic Company Report #WAES 01090502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Klonopin	C				
			Ms Contin	C				
			Soma	C				

Date:12/27/01ISR Number: 3858390-4Report Type:Periodic Company Report #WAES 01090509
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			Warfarin Sodium	C				

Date:12/27/01ISR Number: 3858391-6Report Type:Periodic Company Report #WAES 01090518
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Evoxac	C				
			Premarin	C				

Date:12/27/01ISR Number: 3858392-8Report Type:Periodic Company Report #WAES 01090339
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY/PO	

Date:12/27/01ISR Number: 3858393-XReport Type:Periodic Company Report #WAES 01090344
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
			Chromagen Capsules	C				
			Gluctorol Xl	C				
			Humulin N	C				
			Humulin R	C				
			Hyzaar	C				

Severent	C
Clonazepam	C
Pentoxifylline	C
Terazosin Hydrochloride	C
Furosemide	C

Date:12/27/01ISR Number: 3858394-1Report Type:Periodic Company Report #WAES 01090380
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY; PO	

Date:12/27/01ISR Number: 3858395-3Report Type:Periodic Company Report #WAES 01090392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	

Date:12/27/01ISR Number: 3858396-5Report Type:Periodic Company Report #WAES 01090394
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	

Date:12/27/01ISR Number: 3858397-7Report Type:Periodic Company Report #WAES 01090427
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
	Dizziness							
	Feeling Hot		Centrum	C				
	Flushing		Digtek	C				
			Prilosec	C				
			Synthroid	C				
			Tylenol Arthritis Extended Relieve	C				
			Therapy Unspecified	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3858398-9Report Type:Periodic Company Report #WAES 01090431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858399-0Report Type:Periodic Company Report #WAES 01090446
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Eye Disorder		Zocor	C				
	Eye Pruritus							
	Hypoaesthesia							
	Paraesthesia							

Date:12/27/01ISR Number: 3858400-4Report Type:Periodic Company Report #WAES 01090451
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
	Sweat Gland Disorder						PO	
			Norvasc	C				
			Prinivil	C				
			Glyburide	C				
			Hydrochlorothiazide + Triamter	C				
			Metoprolol Tartrate	C				

Date:12/27/01ISR Number: 3858401-6Report Type:Periodic Company Report #WAES 01090452
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	PO	
	Weight Increased		Therapy Unspecified	C				

Date:12/27/01ISR Number: 3858402-8Report Type:Periodic Company Report #WAES 01082981
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Nausea						MG/DAILY/PO	
	Palpitations							
	Tachycardia							

Date:12/27/01ISR Number: 3858403-XReport Type:Periodic Company Report #WAES 01082987
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/DAILY/PO	
			Coumadin	C				
			Zocor	C				

Date:12/27/01ISR Number: 3858404-1Report Type:Periodic Company Report #WAES 01083008
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Haemorrhage	Professional					MG/DAILY/PO	
	Hiatus Hernia	Company	Tab Fosamax Unk	SS		ORAL	WKY/PO	
		Representative						

Date:12/27/01ISR Number: 3858405-3Report Type:Periodic Company Report #WAES 01083015
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cozaar	C				
			Levothroid	C				
			Norvasc	C				
			Prempro	C				

Date:12/27/01ISR Number: 3858406-5Report Type:Periodic Company Report #WAES 01083016
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Confusional State	Professional						
	Hallucination		Prilosec	C				
			Tenormin	C				
			Aspirin	C				
			Nifedipine	C				

Date:12/27/01ISR Number: 3858407-7Report Type:Periodic Company Report #WAES 01083018
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Increased	Professional						
	Blood Urea Increased		Lipitor	C				
	Creatinine Renal		Maxzide	C				
	Clearance Increased		Theophylline	C				
	Hepatic Function Abnormal							
	Pigmentation Disorder							

Date:12/27/01ISR Number: 3858408-9Report Type:Periodic Company Report #WAES 01083032
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858409-0Report Type:Periodic Company Report #WAES 01083041
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Paxil	C				
			Verapamil	C				

Date:12/27/01ISR Number: 3858410-7Report Type:Periodic Company Report #WAES 01083043
Age:63 YR Gender:Female I/FU:I

Outcome	PT
	Bronchitis
	Cough
	Sinusitis

	Sputum Abnormal						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) PO; 2) 12.5 MG/DAILY/PO
			Caltrate	C			
			Centrum Silver	C			
			Ditropan	C			
			Estrace	C			
			Fosamax	C			
			Synthroid	C			

Date:12/27/01ISR Number: 3858411-9Report Type:Periodic Company Report #WAES 01083046
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO
			Hydrodiuril	C			
			Premarin	C			
			Zantac	C			

Date:12/27/01ISR Number: 3858412-0Report Type:Periodic Company Report #WAES 01082871
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Heart Rate Irregular	Consumer	Tab Vioxx	PS		ORAL	50 MG DAILY
	Oedema Peripheral						PO
			Lanoxil	C			
			Levoxyl	C			

Date:12/27/01ISR Number: 3858413-2Report Type:Periodic Company Report #WAES 01082872
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oral Pain							
			Arimidex	C				
			Aspirin	C				
			Tamoxifen	C				

Date:12/27/01ISR Number: 3858414-4Report Type:Periodic Company Report #WAES 01082875
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Flutter	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea	Professional						
	Haematocrit Decreased		Calan	C				

Date:12/27/01ISR Number: 3858415-6Report Type:Periodic Company Report #WAES 01082876
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Facial Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	TAB VIOXX 12.5 MG/BID/PO	
	Neck Pain							

			Verapamil	C		

Date:12/27/01ISR Number: 3858416-8Report Type:Periodic Company Report #WAES 01082880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858417-XReport Type:Periodic Company Report #WAES 01082886
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Cardizem Cd	C				
			Diovan Hct	C				
			Prozac	C				

Date:12/27/01ISR Number: 3858418-1Report Type:Periodic Company Report #WAES 01082890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Candidiasis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fungal Infection							
	Vaginal Pain		Tylenol Arthritis Extended Relie	C				

Date:12/27/01ISR Number: 3858419-3Report Type:Periodic Company Report #WAES 01082893
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS			ORAL
PO							
	Facial Pain						

Date:12/27/01ISR Number: 3858420-XReport Type:Periodic Company Report #WAES 01082894
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abnormal Faeces	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Back Pain		Combivent	C		
	Blood Pressure Increased		Effexor	C		
			Neurontin	C		
			Pepcid	C		
			Prevacid	C		
			Relafen	C		
			Acetaminophen (+)			
			Propoxyphene	C		
			Aspirin	C		
			Bisoprolol (+)			
			Hydrochlorothiazi	C		
			Folic Acid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858421-1Report Type:Periodic Company Report #WAES 01082895
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Rash	Professional					MG/DAILY/PO	
	Wheezing		Effexor Xr	C				
			Premarin	C				
			Prinzide	C				
			Serax	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3858422-3Report Type:Periodic Company Report #WAES 01082764
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Gastrooesophageal Reflux						MG/DAILY/PO	
	Disease		Actonel	C				
			Cardizem Cd	C				
			Prevacid	C				

Date:12/27/01ISR Number: 3858423-5Report Type:Periodic Company Report #WAES 01082773
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional						

Date:12/27/01ISR Number: 3858424-7Report Type:Periodic Company Report #WAES 01082793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858425-9Report Type:Periodic Company Report #WAES 01082812
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Muscular Weakness		Arava	C				
			Humibid	C				
			Theo-Dur	C				
			Albuterol	C				

Date:12/27/01ISR Number: 3858426-0Report Type:Periodic Company Report #WAES 01082815
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/ PO; 25 MGDAILY/PO	
			Diovan	C				
			Flonase	C				
			Fosamax	C				
			Albuterol	C				

			Prednisone	C		
			Theophylline	C		

Date:12/27/01ISR Number: 3858427-2Report Type:Periodic Company Report #WAES 01082817
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx	PS		ORAL	PO	
			Allegra	C				
			Pulmicort	C				
			Rhinocort Aqua	C				

Date:12/27/01ISR Number: 3858428-4Report Type:Periodic Company Report #WAES 01082839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858429-6Report Type:Periodic Company Report #WAES 01082844
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3858430-2Report Type:Periodic Company Report #WAES 01082848
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

				Accupril	C		
				Celebrex	C		
				Coreg	C		
				Dermadex	C		
				Fosamax	C		
				Carbamazepine	C		
				Potassium (Unspecified)	C		

Date:12/27/01ISR Number: 3858431-4Report Type:Periodic Company Report #WAES 01082854
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	2 DAY
			Hydrochlorothiazide (+) Triamter	C				

Date:12/27/01ISR Number: 3858432-6Report Type:Periodic Company Report #WAES 01100836
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO,	
			Tab. Vioxx 12.5 Mg / Daily / Po	SS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858433-8Report Type:Periodic Company Report # WAES 01100886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3858434-XReport Type:Periodic Company Report #WAES 01100935
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Butazolidin (Phenylbutazone Sodi	C				

Date:12/27/01ISR Number: 3858435-1Report Type:Periodic Company Report #WAES 01100937
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Paraesthesia		Aspirin	C				

Date:12/27/01ISR Number: 3858436-3Report Type:Periodic Company Report #WAES 01100938
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:12/27/01ISR Number: 3858437-5Report Type:Periodic Company Report #WAES 01100944
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain In Extremity							
	Palpitations							

Date:12/27/01ISR Number: 3858438-7Report Type:Periodic Company Report #WAES 01100958
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/BID/PO	
	Ventricular Extrasystoles	Professional	Theo-Dur	C				
			Zestoretic	C				

Date:12/27/01ISR Number: 3858439-9Report Type:Periodic Company Report #WAES01100960
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Rash	Consumer
		Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS			25 MG/DAILY	
Claritin-D	C				

Date:12/27/01ISR Number: 3858440-5Report Type:Periodic Company Report #WAES 01100972
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Prevachol	C				
			Prempro	C				
			Tenormin	C				

Date:12/27/01ISR Number: 3858441-7Report Type:Periodic Company Report #WAES 01100975
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Throat Tightness							
			Amaryl	C				
			Avandia	C				
			Digitek	C				
			Flomax (Morniflumate)	C				
			Prilosec	C				
			Toprol Xl Tablets	C				
			Hyoscyamine	C				

Date:12/27/01ISR Number: 3858442-9Report Type:Periodic Company Report #WAES 01100714
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Tab Vioxx 25mg	PS		ORAL	25MG/DAILY PO	
	Diarrhoea		Cardura	C				
	Dyspnoea		Paxil	C				
	Haemorrhoids							
	Vomiting							
	Weight Decreased							

Date:12/27/01ISR Number: 3858443-0Report Type:Periodic Company Report #WAES 01100732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG /DAILY/PO	
			Ziac	C				
			Triamterene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858444-2Report Type:Periodic Company Report #WAES 01100733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG /DAILY	/PO

Date:12/27/01ISR Number: 3858445-4Report Type:Periodic Company Report #WAES 01100751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Cenestin	C				
			K-Dur	C				
			Lotensin	C				
			Tagamet	C				
			Wellbutrin	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3858446-6Report Type:Periodic Company Report #WAES 01100759
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	1 MON
			Estradiol	C				
			Progesterone	C				

Date:12/27/01ISR Number: 3858447-8Report Type:Periodic Company Report #WAES 01100781
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG BID PO	

	Oedema Peripheral	Diovan	C
	Weight Increased	Diovan Hct	C
		Atenolol	C

Date:12/27/01ISR Number: 3858448-XReport Type:Periodic Company Report #WAES 01100783
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Pruritus		Norvasc	C				
	Rash							
	Urticaria							

Date:12/27/01ISR Number: 3858449-1Report Type:Periodic Company Report #WAES 01100804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858450-8Report Type:Periodic Company Report #WAES 01100810
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Photopsia	Professional Company Representative						

Date:12/27/01ISR Number: 3858451-XReport Type:Periodic Company Report #WAES 01100833
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 50mg	PS		ORAL	PO	
	Congestive Pericardial Disease	Professional Company Representative						

Date:12/27/01ISR Number: 3858452-1Report Type:Periodic Company Report #WAES 01100554
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx 12.5mg	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3858453-3Report Type:Periodic Company Report #WAES 01100561
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Professional Company Representative	Asacol	C				
			Elavil	C				
			Flovent	C				

			Prevacid	C		
			Proventil	C		
			Benzonatate	C		
			Estradiol	C		
			Famotidine	C		
			Insulin	C		
			Losartan Potassium	C		
			Metformin Hydrochloride	C		

Date:12/27/01ISR Number: 3858454-5Report Type:Periodic Company Report #WAES 01100569
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Glucophage	C				
			Questran	C				
			Timoptic	C				
			Xalatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858455-7Report Type:Periodic Company Report #WAES 01100570
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rectal Haemorrhage		Zofran	C				
			Allopurinol	C				
			Prednisone	C				
			Ranitidine	C				
			Warfarin	C				

Date:12/27/01ISR Number: 3858456-9Report Type:Periodic Company Report #WAES 01100571
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Voltaren	SS				
			Premarin	C				

Date:12/27/01ISR Number: 3858457-0Report Type:Periodic Company Report #WAES 01100577
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Pharyngeal Oedema		Zestril	C				
	Pruritus							
	Rash							

Date:12/27/01ISR Number: 3858458-2Report Type:Periodic Company Report #WAES 01100596
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

	Eye Disorder		Imdur	C
			Maxzide	C

Date:12/27/01ISR Number: 3858459-4Report Type:Periodic Company Report #WAES 01100598
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50mg	PS		ORAL	PO	
	Eye Disorder		Lipitor	C				
	Musculoskeletal Stiffness		Prinivil	C				

Date:12/27/01ISR Number: 3858460-0Report Type:Periodic Company Report #WAES 01100599
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Diarrhoea	Health	Claritin	C				
	Dyspnoea	Professional	Synthroid	C				
			Tylenol	C				
			Antimicrobial	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3858461-2Report Type:Periodic Company Report #WAES 01100660
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Phlebitis	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health Professional Company Representative	Therapy Unspecified	C				

Date:12/27/01ISR Number: 3863926-3Report Type:Periodic Company Report #WAES 01100436
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3863945-7Report Type:Periodic Company Report #WAES 01100226
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863947-0Report Type:Periodic Company Report #WAES 01100256
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Pyrexia		Tylenol	C				
	Tendonitis							

Date:12/27/01ISR Number: 3863949-4Report Type:Periodic Company Report #WAES 01100261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stress Fracture	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863950-0Report Type:Periodic Company Report #WAES 01100266
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863952-4Report Type:Periodic Company Report #WAES 01100438
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							
			Ogen	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3863953-6Report Type:Periodic Company Report #WAES 01100269
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863954-8Report Type:Periodic Company Report #WAES 01100452
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Fatigue		Diazide	C				
			Tenormin	C				

Date:12/27/01ISR Number: 3863956-1Report Type:Periodic Company Report #WAES 01100453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Erythema							
	Rash		Hyzaar	C				
			Ridaura	C				

Date:12/27/01ISR Number: 3863957-3Report Type:Periodic Company Report #WAES 01100462
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Influenza Like Illness	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
		Professional				
MG/DAILY/PO						

Date:12/27/01ISR Number: 3863958-5Report Type:Periodic Company Report #WAES 01100297
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
		Health				
PO						
		Professional	Avapro	C		
			Cortiron	C		
			Hydrodiuril	C		
			Plendil	C		
			Synthroid	C		

Date:12/27/01ISR Number: 3863960-3Report Type:Periodic Company Report #WAES 01100469
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Liver Tenderness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3863962-7Report Type:Periodic Company Report #WAES 01100318
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863963-9Report Type:Periodic Company Report #WAES 01100499
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Flovent	C				
			Nasacort Aq	C				
			Norflex	C				
			Iron (Unspecified)	C				

Date:12/27/01ISR Number: 3863965-2Report Type:Periodic Company Report #WAES 01100541
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/UNK/PO	
	Dysphagia	Health Professional						
	Feeling Abnormal							
	Joint Crepitation							

Date:12/27/01ISR Number: 3863966-4Report Type:Periodic Company Report #WAES 01100328
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx Unk	PS		ORAL	PO	

Drug Intolerance

Date:12/27/01ISR Number: 3863967-6Report Type:Periodic Company Report #WAES 01100547
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dizziness		Imodium	C				
	Feeling Hot And Cold							
	Headache							
	Hyperhidrosis							
	Nausea							

Date:12/27/01ISR Number: 3863969-XReport Type:Periodic Company Report #WAES 01100549
Age:73 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863970-6Report Type:Periodic Company Report #WAES 01100330
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863972-XReport Type:Periodic Company Report #WAES 01100331
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

PO

Date:12/27/01ISR Number: 3863973-1Report Type:Periodic Company Report #WAES 01100332
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder							
	Oedema Peripheral							

Date:12/27/01ISR Number: 3863974-3Report Type:Periodic Company Report #WAES 01100350
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863977-9Report Type:Periodic Company Report #WAES 01100353
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
			Colestid	C				
			Flonase	C				
			Fosamax	C				
			Imodium	C				
			Lotrel	C				
			Maxizide	C				
			Zantac	C				

Date:12/27/01ISR Number: 3863978-0Report Type:Periodic Company Report #WAES 01100069
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS			50 MG/DAILY/	
			Celebrex	C				
			Ultram	C				
			Zanaflex	C				

Date:12/27/01ISR Number: 3863979-2Report Type:Periodic Company Report #WAES 01100356
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/ PRN/ PO	
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3863980-9Report Type:Periodic Company Report #WAES 01100357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	
			Vitamins	C				

Date:12/27/01ISR Number: 3863981-0Report Type:Periodic Company Report #WAES 01100089
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Premarin	C				

Date:12/27/01ISR Number: 3863982-2Report Type:Periodic Company Report #WAES 01100364
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health Professional						

Date:12/27/01ISR Number: 3863983-4Report Type:Periodic Company Report #WAES 01100090
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyst	Health Professional	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:12/27/01ISR Number: 3863984-6Report Type:Periodic Company Report #WAES 01100367
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25 MG/ DAILY/ PO	

Date:12/27/01ISR Number: 3863985-8Report Type:Periodic Company Report #WAES 01100107
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863986-XReport Type:Periodic Company Report #WAES 01100369
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Hypertension	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx Mg	PS		ORAL
25 MG/ DAILY / PO	5	DAY					
				Tab Vioxx	SS		ORAL
25 MEQ/ DAILY/ PO	5	DAY					
				Valium	C		

Date:12/27/01ISR Number: 3863987-1Report Type:Periodic Company Report # WAES 01100108
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863988-3Report Type:Periodic Company Report #WAES 01100375
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3863989-5Report Type:Periodic Company Report #WAES 01100377
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	

Professional
Company
Representative

Date:12/27/01ISR Number: 3863990-1Report Type:Periodic Company Report #WAES 01100118
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS			25 MG/DAILY	
			Fosamax	C				
			Albuterol	C				
			Atenolol	C				
			Diazepam	C				
			Meclizine	C				

Date:12/27/01ISR Number: 3863991-3Report Type:Periodic Company Report #WAES 01106451
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3863992-5Report Type:Periodic Company Report #WAES 01100120
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Glucophage	C				
			Glynase Prestab Tablets	C				
			Lopid	C				
			Pletal	C				
			Prilosec	C				
			Prinivil	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3863994-9Report Type:Periodic Company Report #WAES 01106452
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Diarrhoea	Professional Company Representative						

Date:12/27/01ISR Number: 3863995-0Report Type:Periodic Company Report #WAES 01100179
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lescol	C				
			Lopressor	C				
			Prozac	C				
			Sinemet	C				

Date:12/27/01ISR Number: 3863996-2Report Type:Periodic Company Report #WAES 01106475
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
PO								
			Cozaar	C				
			Fosamax	C				
			Penlac	C				
			Plendil	C				
			Synthroid	C				
			Betamethasone Dipropionate (+) C	C				

Date:12/27/01ISR Number: 3863999-8Report Type:Periodic Company Report #WAES 01106484
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Avandia	C				
			Avapro	C				
			Coumadin	C				
			Demadex	C				

Digitek	C
Ecotrin	C
Glucophage	C
Lipitor	C
Neurontin	C
Norvasc	C
Pepcid	C
Synthroid	C
Estropipate	C
Vitamin B Complex	C
Vitamin E	C

Date:12/27/01ISR Number: 3864000-2Report Type:Periodic Company Report #WAES 01106485
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lymphadenopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Nasal Dryness		Flexeril	C				
	Pharyngitis		Calcium (Unspecified)	C				
			Potassium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864001-4Report Type:Periodic Company Report #WAES 01100189
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PRN/PO; 25 MG/DAILY/PO	
			Dilacor Xr	C				
			Vasotec	C				

Date:12/27/01ISR Number: 3864002-6Report Type:Periodic Company Report #WAES 01110003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Company Representative Other	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864005-1Report Type:Periodic Company Report #WAES 01100225
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864006-3Report Type:Periodic Company Report #WAES 01110010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG BID PO	
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864007-5Report Type:Periodic Company Report #WAES 01110014
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Haemoptysis		Lorcet Plus	C				
			Mevacor	C				

Date:12/27/01ISR Number: 3864009-9Report Type:Periodic Company Report #WAES 01110019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864010-5Report Type:Periodic Company Report #WAES 01093176
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
		Company Representative	Estratest	C				
			Glucotrol	C				
			Humulin	C				
			Zestril	C				

Date:12/27/01ISR Number: 3864011-7Report Type:Periodic Company Report #WAES 01110036
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PRN PO	
	Nausea							

Date:12/27/01ISR Number: 3864013-0Report Type:Periodic Company Report #WAES 01106363
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3864014-2Report Type:Periodic Company Report #WAES 01093186
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
	Influenza Like Illness		Synthroid	C				
	Nausea		Aspirin	C				

Date:12/27/01ISR Number: 3864015-4Report Type:Periodic Company Report #WAES 01106364
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Health Professional	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864016-6Report Type:Periodic Company Report #WAES 01106365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	3 DAY
		Company Representative						

Date:12/27/01ISR Number: 3864018-XReport Type:Periodic Company Report #WAES 01106367
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	6 DAY
	Tachycardia							

Date:12/27/01ISR Number: 3864019-1Report Type:Periodic Company Report #WAES 01106368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3864021-XReport Type:Periodic Company Report #WAES 01106377
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

			Professional				
MG/DAILY/PO							
				Aricept	C		
				Fosamax	C		
				Zocor	C		

Date:12/27/01ISR Number: 3864022-1Report Type:Periodic Company Report #WAES 01093195
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Hypoaesthesia						PO	
	Palpitations		Allopurinol	C				

Date:12/27/01ISR Number: 3864023-3Report Type:Periodic Company Report #WAES 01106395
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS			25 MG/DAILY	
		Professional	Accupril	C				
			Glucotrol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864025-7Report Type:Periodic Company Report #WAES 01106441
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx	PS		ORAL	DAILY/PO	
	Fatigue	Professional	Estratest	C				
	Nervousness		Nexium	C				
	Pruritus		Skelaxin	C				
	Rash		Soma	C				
	Urticaria		Synthroid	C				
			Vicodin Tablets	C				
			Diltiazem Malate	C				
			Nonsteroidal Anti-Inflamatory	C				

Date:12/27/01ISR Number: 3864026-9Report Type:Periodic Company Report #WAES 01106448
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional						
	Blood Urea Increased	Company Representative						

Date:12/27/01ISR Number: 3864027-0Report Type:Periodic Company Report #WAES 01106449
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Discharge	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Calcium	C				
			Vitamins	C				

Date:12/27/01ISR Number: 3864028-2Report Type:Periodic Company Report #WAES 01093199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Levoxyl	C				

Date:12/27/01ISR Number: 3864029-4Report Type:Periodic Company Report #WAES 01093203
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
	Clearance Decreased	Professional						
	Drug Ineffective	Company Representative						

Date:12/27/01ISR Number: 3864032-4Report Type:Periodic Company Report #WAES 01110789
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864033-6Report Type:Periodic Company Report #WAES 01110790
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/UNK/PO	5 DAY

Date:12/27/01ISR Number: 3864034-8Report Type:Periodic Company Report #WAES 01110800
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Drug Ineffective		Cardizem Cd	C				
			Vasotec	C				
			Zocor	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864036-1Report Type:Periodic Company Report #WAES 01093281
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	DAILY PO	
	Gastrointestinal Disorder		Prinivil	C				
			Urecholine	C				

Date:12/27/01ISR Number: 3864038-5Report Type:Periodic Company Report #WAES 01110818
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional						

Company
Representative

Date:12/27/01ISR Number: 3864039-7Report Type:Periodic Company Report #WAES 01093282
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								2 WK

Date:12/27/01ISR Number: 3864040-3Report Type:Periodic Company Report #WAES 01110819
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/UNK/PO	
	Asthenia							
	Fatigue		Fosamax	C				
	Mental Impairment		Premarin	C				
			[Composition Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864041-5Report Type:Periodic Company Report #WAES 01110822
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864042-7Report Type:Periodic Company Report #WAES 01110824
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urine Abnormality							
			Glyburide	C				

Date:12/27/01ISR Number: 3864043-9Report Type:Periodic Company Report #WAES 01110832
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Other	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864044-0Report Type:Periodic Company Report #WAES 01110836
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Company Representative						

Date:12/27/01ISR Number: 3864045-2Report Type:Periodic Company Report #WAES 01110841
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fungal Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Norvasc	C				
			Xanax	C				
			Zoloft	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3864046-4Report Type:Periodic Company Report #WAES 01104341
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Musculoskeletal Stiffness							
			Lipitor	C				

Date:12/27/01ISR Number: 3864047-6Report Type:Periodic Company Report #WAES 01104342
Age:35 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Distension
	Pollakiuria

Urinary Retention

	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

Date:12/27/01ISR Number: 3864048-8Report Type:Periodic Company Report #WAES 01104361
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
SEE IMAGE								
			Tab Vioxx 50 Mg	SS		ORAL	50	MG/DAILY/PO
			Beclovent	C				
			Flexeril	C				

Date:12/27/01ISR Number: 3864049-XReport Type:Periodic Company Report #WAES 01104363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864050-6Report Type:Periodic Company Report #WAES 01104364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Cozaar	C				
			Hytrin	C				
			Probenemid	C				

Date:12/27/01ISR Number: 3864052-XReport Type:Periodic Company Report #WAES 01104367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ibuprofen	SS				
			Hydrodiuril	C				
			Tylenol	C				
			Zantac	C				
			Zestril	C				
			Zocor	C				

Date:12/27/01ISR Number: 3864053-1Report Type:Periodic Company Report #WAES 01104374
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	3 DAY
			Atarax	C				

			Dilantin	C		
			Elocon	C		
			Neurontin	C		

Date:12/27/01ISR Number: 3864054-3Report Type:Periodic Company Report #WAES 01104376
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral	Professional Company Representative						

Date:12/27/01ISR Number: 3864057-9Report Type:Periodic Company Report #WAES 01104383
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Synthroid	C				
			Tylenol	C				

Date:12/27/01ISR Number: 3864058-0Report Type:Periodic Company Report #WAES 01104402
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Baclofen	C				

Date:12/27/01ISR Number: 3864064-6Report Type:Periodic Company Report #WAES 01081785
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia	Health Professional	Fosamax	C				
			Premarin	C				

Date:12/27/01ISR Number: 3864066-XReport Type:Periodic Company Report #WAES 01081852
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Health Professional						

Date:12/27/01ISR Number: 3864067-1Report Type:Periodic Company Report #WAES 01093283
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertrophy Breast	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Urinary Incontinence							
			Darvocet-N	C				

Premarin	C
Prilosec	C
Salagen Tablets [Therapy Unspecified]	C
Ephalexin	C

Date:12/27/01ISR Number: 3864068-3Report Type:Periodic Company Report #WAES 01081889
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864069-5Report Type:Periodic Company Report #WAES 01093286
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Nausea		Hyzaar	C				
			Nolvadex	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3864070-1Report Type:Periodic Company Report #WAES 01081937
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Urea Increased	Company Representative	Diovan	C				
			Synthroid	C				
			Allopurinol	C				

				Aspirin	C		

Date:12/27/01ISR Number: 3864071-3Report Type:Periodic Company Report #WAES 01082050
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Tremor							
			Eskalith	SS		ORAL	12.5 MG/DAILY/PO	
			Sinemet	C				
			Tums	C				
			Ultram	C				

Date:12/27/01ISR Number: 3864073-7Report Type:Periodic Company Report #WAES 01082052
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urticaria							
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				

Date:12/27/01ISR Number: 3864074-9Report Type:Periodic Company Report #WAES 01082062
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain							
	Sciatica		Celebrex	C				

Date:12/27/01ISR Number: 3864075-0Report Type:Periodic Company Report #WAES 01082083
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO	
	Anxiety	Health	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Aphthous Stomatitis	Professional						
	Conversion Disorder		Claritin	C				
	Depression		Estrace	C				
	Epistaxis		Provera	C				
	Mouth Haemorrhage		Synthroid	C				
	Mouth Ulceration							
	Tremor							

Date:12/27/01ISR Number: 3864077-4Report Type:Periodic Company Report #WAES 01082529
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3864078-6Report Type:Periodic Company Report #WAES 01093288
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
	Blood Pressure Increased						PO	
	Gastrointestinal Disorder		Synthroid	C				
	Nausea		Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3864079-8Report Type:Periodic Company Report #WAES 01093161
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative	Celebrex	C				

Date:12/27/01ISR Number: 3864080-4Report Type:Periodic Company Report #WAES 01081370
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864082-8Report Type:Periodic Company Report #WAES 01081410
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocythaemia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864083-XReport Type:Periodic Company Report #WAES 01093056
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Paxil	C				
			Serzone	C				
			Tylenol Extra Strength	C				
			Xanax	C				
			Calcium (Unspecified)	C				

Date:12/27/01ISR Number: 3864084-1Report Type:Periodic Company Report #WAES 01081453
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased	Health Professional	Synthroid	C				

Date:12/27/01ISR Number: 3864085-3Report Type:Periodic Company Report #WAES 01093062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Fatigue							
	Palpitations							

Date:12/27/01ISR Number: 3864086-5Report Type:Periodic Company Report #WAES 01093071
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Extendryl	C				
			Levoxyl	C				
			Ogen	C				
			Pravachol	C				

Date:12/27/01ISR Number: 3864089-0Report Type:Periodic Company Report #WAES 01081508
Age: Gender:Female I/FU:F

Outcome	PT
	Hypersensitivity
	Myalgia
	Oedema Peripheral
	Pruritus
	Rash

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864090-7Report Type:Periodic Company Report #WAES 01093075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864091-9Report Type:Periodic Company Report #WAES 01081633
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864092-0Report Type:Periodic Company Report #WAES 01093084
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder Haematochezia Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; 25	

MG/DAILY/PO

Date:12/27/01ISR Number: 3864094-4Report Type:Periodic Company Report #WAES 01081636
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QQD/PO	
		Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/WKY/PO	

Date:12/27/01ISR Number: 3864096-8Report Type:Periodic Company Report #WAES 01093121
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864098-1Report Type:Periodic Company Report #WAES 01081640
Age: Gender:Female I/FU:F

Outcome	PT	Report Source
	Abdominal Pain	Consumer Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	
Fosamax	C				

Date:12/27/01ISR Number: 3864099-3Report Type:Periodic Company Report #WAES 01093144
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO; 25	
	Oedema Peripheral						MG/DAILY/PO	
			Prilosec	C				

Date:12/27/01ISR Number: 3864101-9Report Type:Periodic Company Report #WAES 01081648
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Feeling Abnormal	Health					MG/DAILY/PO	4 DAY
		Professional						

Date:12/27/01ISR Number: 3864102-0Report Type:Periodic Company Report #WAES 01081661
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Vasotec	C				

Date:12/27/01ISR Number: 3864103-2Report Type:Periodic Company Report #WAES 01093145
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aricept	C				
			Effexor	C				
			Pamine Bromide	C				
			Prilosec	C				
			Relafen	C				

Date:12/27/01ISR Number: 3864105-6Report Type:Periodic Company Report #WAES 01081780
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nervousness	Health Professional	Lipitor	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864106-8Report Type:Periodic Company Report #WAES 01093168
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864108-1Report Type:Periodic Company Report #WAES 01093170
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO;	
	Pain	Health Professional					25 MG/DAILY/PO	
			Claritin	C				
			Prozac	C				
			Estrogens (Unspecified)	C				

Date:12/27/01ISR Number: 3864111-1Report Type:Periodic Company Report #WAES 01102218
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864115-9Report Type:Periodic Company Report #WAES 01102228
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Cardizem	C				
			Flomax (Tamsulosin Hydrochloride	C				
			Hytrin	C				
			Tenormin	C				
			Tequin	C				

Date:12/27/01ISR Number: 3864120-2Report Type:Periodic Company Report #WAES 01102231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS			25 MG/PRN/UNK	

Date:12/27/01ISR Number: 3864122-6Report Type:Periodic Company Report #WAES 01102235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Dyspepsia		Lotrel	C				
			Allopurinol	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864124-XReport Type:Periodic Company Report #WAES 01102236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased							
			A.S.A.	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864126-3Report Type:Periodic Company Report #WAES 01070312
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional	[Therapy Unspecified]	C				
			Potassium (Unspecified)	C				

Date:12/27/01ISR Number: 3864128-7Report Type:Periodic Company Report #WAES 01070416
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertension	Health Professional	Toprol Xl Tablets	C				
	Musculoskeletal Stiffness		Folic Acid	C				
			Methotrexate	C				

Date:12/27/01ISR Number: 3864129-9Report Type:Periodic Company Report #WAES 01070464
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
		Professional	Elavil	C			MG/DAILY/PO	
			Premarin	C				
			Prinivil	C				
			Serevent	C				
			Diltiazem Hydrochloride	C				
			Folic Acid	C				

Date:12/27/01ISR Number: 3864131-7Report Type:Periodic Company Report #WAES 01070529
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Ogen	C				
			[Therapy Unspecified]	C				
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864133-0Report Type:Periodic Company Report #WAES 01070567
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Depression	Health						
	Weight Increased	Professional	Xenical	C				

Date:12/27/01ISR Number: 3864134-2Report Type:Periodic Company Report #WAES 01070614
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO; 12.5 MG/QOD/PO;12.5 MG/DAILY/PO	
	Oedema Peripheral							
	Oliguria							
			Celebrex	C				
			Verapamil Msd Lp	C				
			Digoxin	C				
			Oxycodone	C				

Date:12/27/01ISR Number: 3864135-4Report Type:Periodic Company Report #WAES 01070632
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Pain		Fosamax	C				
			Zocor	C				

Date:12/27/01ISR Number: 3864137-8Report Type:Periodic Company Report #WAES 01070671
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Health					MG/DAILY/PO	
		Professional	Lanoxin	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Indapamide	C				
			Methotrexate	C				

Date:12/27/01ISR Number: 3864138-XReport Type:Periodic Company Report #WAES 01102124
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Diovan Hct	C				
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864139-1Report Type:Periodic Company Report #WAES 01070746
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health Professional	Cozaar	C				
			Ibuprofen	C				

Date:12/27/01ISR Number: 3864140-8Report Type:Periodic Company Report #WAES 01070753
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain	Health Professional	Accupril	C				
			Caltrate	C				
			Centrum	C				
			Darvocet-N	C				
			Fosamax	C				
			Protonix	C				
			[Therapy Unspecified]	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Cholestyramine Resin	C				
			Ferrous Sulfate	C				

Date:12/27/01ISR Number: 3864141-XReport Type:Periodic Company Report #WAES 01062427
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
		Health Professional					PO	

Date:12/27/01ISR Number: 3864142-1Report Type:Periodic Company Report #WAES 01102125
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Maxzide	C				

Date:12/27/01ISR Number: 3864143-3Report Type:Periodic Company Report #WAES 01062431
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY; PO	
	Back Pain	Health Professional						
	Hepatic Function Abnormal		Estraderm	C				
			Prempro	C				
			Provera	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864144-5Report Type:Periodic Company Report #WAES 01102161
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864145-7Report Type:Periodic Company Report #WAES 01062487
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
		Health Professional	Hormones (Unspecified)	C			PO	

Date:12/27/01ISR Number: 3864146-9Report Type:Periodic Company Report #WAES 01102187
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus	Company Representative	Aspirin	C				

Date:12/27/01ISR Number: 3864147-0Report Type:Periodic Company Report #WAES 01062616
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Conjunctival Hyperaemia	Consumer	Tab Vioxx 25 Mg	PS			ORAL
PO; 25 MG; PO							
	Erythema	Health	Evista	C			
	Oedema Peripheral	Professional					
	Skin Hypopigmentation						

Date:12/27/01ISR Number: 3864148-2Report Type:Periodic Company Report #WAES 01102191
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ecchymosis	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

Date:12/27/01ISR Number: 3864149-4Report Type:Periodic Company Report #WAES 01062633
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL
PO 1 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864150-0Report Type:Periodic Company Report #WAES 01062709
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorectal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID; PO	
	Asthenia	Health	Claritin	C				
	Fatigue	Professional	Fosamax	C				
	Haemorrhage		Lanoxin	C				
			Synthroid	C				
			Furosemide	C				
			Propranolol	C				

Date:12/27/01ISR Number: 3864151-2Report Type:Periodic Company Report #WAES 01070130
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
	Oedema Peripheral	Health					PO	
	Swelling	Professional	Lipitor	C				
			Prinzide	C				

Date:12/27/01ISR Number: 3864152-4Report Type:Periodic Company Report #WAES 01101838
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
	Mental Impairment		Demerol	C				
			Hydrocortone	C				

Date:12/27/01ISR Number: 3864154-8Report Type:Periodic Company Report #WAES 01070189
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Prostatic Specific	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL 12.5
	Antigen Increased	Health				MG/DAILY; PO
		Professional	Flomax (Tamsulosin Hydrochloride)	C		

Date:12/27/01ISR Number: 3864155-XReport Type:Periodic Company Report #WAES 01101797
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO
	Medication Residue		Coumadin	C		
			Hydrodiuril	C		
			Valium	C		
			Calcium (Unspecified)	C		
			Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3864156-1Report Type:Periodic Company Report #WAES 01070278
Age:78 YR Gender:Male I/FU:F

Outcome	PT
	Dry Mouth
	Keratoconjunctivitis

Sicca

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
		Health Professional	Arava	C			PO	

Date:12/27/01ISR Number: 3864158-5Report Type:Periodic Company Report #WAES 01070308
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY;	
		Health Professional	Celebrex	C			PO	

Date:12/27/01ISR Number: 3864159-7Report Type:Periodic Company Report #WAES 01101799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864160-3Report Type:Periodic Company Report #WAES 01101803
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864161-5Report Type:Periodic Company Report #WAES 01101805
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Tab Vioxx 25 Mg	PS			25	
	Cough						MG/DAILY/PO	
	Eye Disorder		Advair	C				
	Pain							

Date:12/27/01ISR Number: 3864162-7Report Type:Periodic Company Report #WAES 01101808
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Lipitor	C				
			Lortab	C				
			Oxycontin	C				
			Soma	C				
			Insulin	C				

Date:12/27/01ISR Number: 3864165-2Report Type:Periodic Company Report #WAES 01101815
Age:60 YR Gender:Male I/FU:I

Outcome	PT
	Dyspnoea
	Oedema Peripheral

	Speech Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864166-4Report Type:Periodic Company Report #WAES 01061585
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Cardene Sr	C				
			K-Dur	C				
			Lipitor	C				
			Zestril	C				
			Cortisone	C				
			Furosemide	C				

Date:12/27/01ISR Number: 3864167-6Report Type:Periodic Company Report #WAES 01101816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise		Tab Vioxx	PS		ORAL	PO	
			Tab Clinoril Unk	SS				

Date:12/27/01ISR Number: 3864169-XReport Type:Periodic Company Report #WAES 01061590
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Haematoma	Professional					
MG/DAILY/PO;							
	Pigmentation Disorder	Company					
50							
	Post Procedural	Representative					
MG/DAILY/PO							
	Haemorrhage		Cosamin	C			
			Tylenol Arthritis				
			Extended Relie	C			
			[Composition				
			Unspecified]	C			
			...	C			

Date:12/27/01ISR Number: 3864170-6Report Type:Periodic Company Report #WAES 01101817
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
PO								
	Thrombosis							

Date:12/27/01ISR Number: 3864171-8Report Type:Periodic Company Report #WAES 01061624
Age:37 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Anxiety
	Asthenia

	Blood Pressure Decreased						
	Dyspepsia						
	Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50
	Oedema Peripheral	Health					MG/DAILY/PO;
	Pain In Extremity	Professional					25
	Urinary Tract Infection						MG/DAILY/PO
			Hormonal Contraceptive (Unspeci	C			

Date:12/27/01ISR Number: 3864173-1Report Type:Periodic Company Report #WAES 01061744
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Bleeding Time Prolonged	Health	Tab Vioxx 25 Mg	PS		ORAL	PO
		Professional					

Date:12/27/01ISR Number: 3864174-3Report Type:Periodic Company Report #WAES 01061867
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Eyelid Oedema	Consumer	Tab Vioxx	PS		ORAL	PO
	Oedema Peripheral		Allegra	C			
			Theragran Tablets Advanced Form	C			
			Zoloft	C			

Date:12/27/01ISR Number: 3864177-9Report Type:Periodic Company Report #WAES 01101828
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Infection	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	1) 12.5 MG/DAILY/PO; 2) 25 MG/DAILY/PO	
	Keratoconjunctivitis							
	Sicca							
	Sinusitis							
	Upper Respiratory Tract Infection		Flexeril	C				
			Lipitor	C				
			Zyrtec	C				
			Calcium (Unspecified)	C				
			Ranitidine Hydrochloride	C				
			Vitamin E	C				

Date:12/27/01ISR Number: 3864178-0Report Type:Periodic Company Report #WAES 01061994
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Motrin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864180-9Report Type:Periodic Company Report #WAES 01062099
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO	
		Health Professional						
			Aciphex	C				
			Elavil	C				
			Glucophage	C				
			Humulin 70/30	C				
			Imdur	C				
			Nitroglycerin	C				
			Remarin	C				
			Prinivil	C				
			Zocor	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Metoprolol	C				
			Pentoxifylline	C				
			Vitamin E	C				

Date:12/27/01ISR Number: 3864184-6Report Type:Periodic Company Report #WAES 01062222
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							
	Urticaria							
			Accupril	C				
			Accuretic	C				
			Celebrex	C				
			Detrol	C				
			Premarin	C				
			Verapamil Hydrochloride	C				

Date:12/27/01ISR Number: 3864187-1Report Type:Periodic Company Report #WAES 01062272
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864189-5Report Type:Periodic Company Report #WAES 01062318
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion		Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864190-1Report Type:Periodic Company Report #WAES 01060741
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Drug Ineffective	Consumer
	Dyspepsia	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
Amitriptyline	C				

Date:12/27/01ISR Number: 3864191-3Report Type:Periodic Company Report #WAES 01060841
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Dysphagia		Evista	C				
	Fluid Retention		Paxil	C				
	Weight Increased		Atenolol	C				

Date:12/27/01ISR Number: 3864193-7Report Type:Periodic Company Report #WAES 01060911
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Syncope	Professional						
			Tab Hydroduril Unk	SS				
			Prinivil	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864195-0Report Type:Periodic Company Report #WAES 01061003
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25 MG/DAILY/PO	
			Hydrodiuril	C				
			Lipitor	C				
			Ogen	C				
			Synthroid	C				
			Vasotec	C				

Date:12/27/01ISR Number: 3864196-2Report Type:Periodic Company Report #WAES 01061018
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypersensitivity							
	Rash							

Date:12/27/01ISR Number: 3864198-6Report Type:Periodic Company Report #WAES 01061103
Age:46 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Dyspepsia

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Health Professional	Neurontin	C				
	Paxil	C				
	Prilosec	C				
	Ultram	C				
	Wellbutrin Sr	C				
	Carisoprodol	C				
	Estradiol	C				
	Prednisone	C				
	Trazodone	C				

Date:12/27/01ISR Number: 3864200-1Report Type:Periodic Company Report #WAES 01061183
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Pain	Health Professional	Penlac	C				
			Premarin	C				
			Synthroid	C				
			Hydrochlorothiazide	C				
			Potassium Chloride	C				

Date:12/27/01ISR Number: 3864202-5Report Type:Periodic Company Report #WAES 01061354
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Mouth Ulceration							
			Methotrexate 2.5 Mg	SS		ORAL	10 MG/WKY/PO	
			Citracal	C				
			Prempro	C				
			Doxepin	C				

				Folic Acid	C		

Date:12/27/01ISR Number: 3864203-7Report Type:Periodic Company Report #WAES 01061383
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional	Altace	C				
	Pain In Extremity		Caltrate 600 Plus Vitamin D	C				
			Lipitor	C				
			Synthroid	C				
			Toprol Xl Tablets	C				
			Ascorbic Acid	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864205-0Report Type:Periodic Company Report #WAES 01061412
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Baycol	C				
			Estratest	C				
			Diltiazem Hydrochloride	C				

Date:12/27/01ISR Number: 3864208-6Report Type:Periodic Company Report #WAES 01052695
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Blood Pressure Increased	Professional					MG/DAILY/PO	
	Fatigue		Actos	C				
	Flushing		Glucophage	C				
	Oedema Peripheral							
	Tachycardia							

Date:12/27/01ISR Number: 3864209-8Report Type:Periodic Company Report #WAES 01052800
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Health					MG/DAILY/PO	
		Professional	Accupril	C				
			Glucophage	C				
			Toprol Xl Tablets	C				
			Estradiol	C				
			Glipizide	C				
			Medroxyprogesterone Acetate	C				

Date:12/27/01ISR Number: 3864210-4Report Type:Periodic Company Report #WAES 01060036
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
		Health					MG/DAILY/PO	
		Professional	Composition					
			Unspecified	C				

Date:12/27/01ISR Number: 3864211-6Report Type:Periodic Company Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO SEE IMAGE	
	Neurodermatitis	Health	Anafranil	C				
		Professional	Celebrex	C				
			Lidex	C				

Date:12/27/01ISR Number: 3864212-8Report Type:Periodic Company Report #WAES 01060192
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
	Weight Increased						PO	

Date:12/27/01ISR Number: 3864213-XReport Type:Periodic Company Report #WAES 01060240
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspnoea						MG/DAILY/PO	
	Fatigue		Advil	C				
	Influenza		Calan	C				
	Nervousness							
	Pruritus							
	Tremor							
	Vocal Cord Disorder							
	Vomiting							

Date:12/27/01ISR Number: 3864214-1Report Type:Periodic Company Report #WAES 01060334
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Constipation	Health	Excedrin					
	Drug Ineffective	Professional	Extra-Strength	C				
	Fatigue		Imitrex	C				
	Somnolence							

Date:12/27/01ISR Number: 3864215-3Report Type:Periodic Company Report #WAES 01060521
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Health					MG/DAILY/PO	
		Professional					SEE IMAGE	
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3864216-5Report Type:Periodic Company Report #WAES 01060588
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
		Health					MG/DAILY/PO	
		Professional	Allegra	C				
			Prinivil	C				
			Propranolol Hydrochloride	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864217-7Report Type:Periodic Company Report #WAES 01060589
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea	Health Professional						

Date:12/27/01ISR Number: 3864218-9Report Type:Periodic Company Report #WAES 01050770
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Health Professional	Lipitor	C				
			Ziac	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864219-0Report Type:Periodic Company Report #WAES 01050936
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertriglyceridaemia	Health Professional						

Date:12/27/01ISR Number: 3864221-9Report Type:Periodic Company Report #WAES 01051205
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

	Dysuria	Health				
MG/DAILY/PO						
	Flushing	Professional	Serzone	C		
	Genital Pruritus Female		Alprazolam	C		
	Pain In Extremity		Estradiol	C		
	Urine Flow Decreased					
	Vaginal Infection					

Date:12/27/01ISR Number: 3864222-0Report Type:Periodic Company Report #WAES 01051352
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Lip Dry	Health				
MG/DAILY/PO						
	Nausea	Professional	Allegra	C		
	Pruritus		Cardizem	C		
			Flonase	C		
			Pravachol	C		
			Prevacid	C		
			Folic Acid	C		
			Niacin	C		

Date:12/27/01ISR Number: 3864223-2Report Type:Periodic Company Report #WAES 01101965
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Oedema Peripheral					
MG/DAILY/PO						

		Accupril	C
		Glucophage	C
		Nadolol	C

Date:12/27/01ISR Number: 3864224-4Report Type:Periodic Company Report #WAES 01051527
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health	Tab Vioxx	PS		ORAL	PO	
	Urticaria	Professional Company Representative	Zyban	C				

Date:12/27/01ISR Number: 3864226-8Report Type:Periodic Company Report #WAES 01051634
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea	Health Professional	Avandia	C				
			Humulin	C				
			K-Dur	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Digoxin	C				

Date:12/27/01ISR Number: 3864227-XReport Type:Periodic Company Report #WAES 01101976
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Weight Increased		Inderal	C				

Date:12/27/01ISR Number: 3864228-1Report Type:Periodic Company Report #WAES 01051838
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3864229-3Report Type:Periodic Company Report #WAES 01101987
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Headache							
	Insomnia							
	Swelling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864231-1Report Type:Periodic Company Report #WAES 01102017
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864232-3Report Type:Periodic Company Report #WAES 01052128
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Health Professional						
	Tongue Disorder		Estraderm	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Garlic Extract	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864234-7Report Type:Periodic Company Report #WAES 01052491
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional Other	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO; 50 MG/BID/PO	
	Paraesthesia							
			Buspar	C				
			Premarin	C				
			Zoloft	C				

Date:12/27/01ISR Number: 3864235-9Report Type:Periodic Company Report #WAES 01102023
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Headache						MG/DAILY/PO	
			Glucophage Xr	C				
			Humalog	C				
			Prozac	C				
			Rythmol	C				
			Zocor	C				

Date:12/27/01ISR Number: 3864236-0Report Type:Periodic Company Report # WAES 01052542
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective	Health					MG/DAILY/PO	
	Fluid Retention	Professional	Ambien	C				
			Cordarone	C				
			Elavil	C				
			Fosamax	C				
			Hydrocodone/Apap	C				
			Lasix (Furosemide	C				
			Prilosec	C				

		Proventil Inhaler	C
		Serevent	C
		Singulair	C
		Synthroid	C
		Vitamins (Unspecified)	C

Date:12/27/01ISR Number: 3864238-4Report Type:Periodic Company Report #WAES 01102051
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Other	Tab Vioxx	PS		ORAL	PO	
			Niaspan	C				
			Synthroid	C				
			Zocor	C				
			Enalapril Maleate	C				

Date:12/27/01ISR Number: 3864240-2Report Type:Periodic Company Report #WAES 01102052
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864241-4Report Type:Periodic Company Report #WAES 01102054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Fluctuation	Company Representative	Composition Unspecified	C				

Date:12/27/01ISR Number: 3864243-8Report Type:Periodic Company Report #WAES 01040828
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Atarax	C				
			Flonase	C				
			Miacalcin	C				
			Seconal Sodium	C				
			Ventolin	C				
			Wellbutrin	C				
			[Therapy Unspecified]	C				
			Calcium (Unspecified)	C				

Date:12/27/01ISR Number: 3864244-XReport Type:Periodic Company Report #WAES 01040968
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864246-3Report Type:Periodic Company Report #WAES 01041436
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS			PO	
	Haemorrhage	Professional						
	Oedema	Company						
	Ulcer	Representative						

Date:12/27/01ISR Number: 3864247-5Report Type:Periodic Company Report #WAES 01102118
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Maxzide	C				
			Toprol Xl Tablets	C				
			Zoloft	C				
			Echinacea	C				
			Estradiol	C				

Date:12/27/01ISR Number: 3864248-7Report Type:Periodic Company Report #WAES 01041720
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Asthenia	Health						
	Fatigue	Professional	Actos	C				
	Fluid Retention		Cozaar	C				
	Swelling		Lasix (Furosemide)	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3864249-9Report Type:Periodic Company Report #WAES 01102120
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Pruritus							
			Prilosec	C				
			Zoloft	C				
			Furosemide	C				

Date:12/27/01ISR Number: 3864250-5Report Type:Periodic Company Report #WAES 01041742
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Oedema Peripheral	Health Professional	Hytrin	C				
			Lotensin	C				
			Norvasc	C				
			Ultram	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864251-7Report Type:Periodic Company Report #WAES 01042160
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	24MG/DAILY/PO	
	Rash	Professional	Darvocet-N	C				
			Zestoretic	C				

Date:12/27/01ISR Number: 3864252-9Report Type:Periodic Company Report #WAES 01111755
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3864254-2Report Type:Periodic Company Report #WAES 01042391
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral							

Date:12/27/01ISR Number: 3864255-4Report Type:Periodic Company Report #WAES 01042658
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Vision Blurred							

Date:12/27/01ISR Number: 3864257-8Report Type:Periodic Company Report #WAES 01050067
Age:68 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tachycardia							
			Premarin	C				
			Synthroid	C				
			Aspirin	C				
			Calcium Carbonate (+) Vitamin D	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864259-1Report Type:Periodic Company Report #WAES 01050163
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;PO	
	Blood Creatinine Increased	Professional						
	Blood Pressure Increased							
	Drug Ineffective							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864260-8Report Type:Periodic Company Report #WAES 01111762
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864261-XReport Type:Periodic Company Report #WAES 00072670
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fibromyalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral							
	Pain							
	Weight Increased							

Date:12/27/01ISR Number: 3864262-1Report Type:Periodic Company Report #WAES 01111813
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Oedema Peripheral							

Date:12/27/01ISR Number: 3864264-5Report Type:Periodic Company Report #WAES 00080498
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO; 25 MG/DAILY/PO	
	Tremor							
			Flovent	C				

				Percocet	C	
				Serevent	C	
				Ultram	C	
				Zocor	C	
				Prednisone	C	

Date:12/27/01ISR Number: 3864265-7Report Type:Periodic Company Report #WAES 01111815
Age:34 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Influenza Like Illness							
			Flexeril	C				
			Vicodin Tablets	C				

Date:12/27/01ISR Number: 3864266-9Report Type:Periodic Company Report #WAES 00090137
Age:69 YR Gender:Male I/FU:F

Outcome	PT
	Abnormal Faeces
	Aspartate Aminotransferase Increased
	Cardiac Murmur
	Creatinine Renal Clearance Increased
	Haematuria

	Insomnia						
	Pain						
	Penile Discharge	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Penile Swelling	Consumer	Tab Vioxx	PS		ORAL	PO
	Proteinuria	Health	Celebrex	C			
	Renal Cyst	Professional	Hytrin	C			
	Testicular Disorder		Naprosyn	C			
			Relafen	C			
			Aspirin	C			
			Cimetidine	C			
			Vitamins	C			

Date:12/27/01ISR Number: 3864269-4Report Type:Periodic Company Report #WAES 01111853
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haematuria	Health	Tab Vioxx 25 Mg	PS		ORAL	25
		Professional					MG/DAILY/PO
			Claritin	C			
			Zocor	C			

Date:12/27/01ISR Number: 3864270-0Report Type:Periodic Company Report #WAES 00091585
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO
	Alopecia		Cardizem	C			
			Coumadin	C			
			Procrit	C			

Date:12/27/01ISR Number: 3864271-2Report Type:Periodic Company Report #WAES 01111855
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864274-8Report Type:Periodic Company Report #WAES 01111863
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	2 DAY
			Celebrex	C				
			Covera-Hs	C				
			Premarin	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3864275-XReport Type:Periodic Company Report #WAES 00110472
Age:75 YR Gender:Male I/FU:F

Outcome	PT
	Appetite Disorder
	Diarrhoea
	Dyspepsia

	Gastrointestinal Haemorrhage Pulmonary Congestion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Tab Vioxx	PS		ORAL	PO
			Zocor	C			

Date:12/27/01ISR Number: 3864278-5Report Type:Periodic Company Report #WAES 01111869
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ PO

Date:12/27/01ISR Number: 3864279-7Report Type:Periodic Company Report #WAES 01010482
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO;
		Health Professional Company Representative					PO

Date:12/27/01ISR Number: 3864280-3Report Type:Periodic Company Report #WAES 01111878
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
			Detrol La	C			
			Ditropan Xl	C			

				Imitrex	C		
				Prevacid	C		
				Tambocor	C		

Date:12/27/01ISR Number: 3864281-5Report Type:Periodic Company Report #WAES 01021104
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Headache		Azulfidine	C				
	Pain In Extremity		Elavil	C				

Date:12/27/01ISR Number: 3864283-9Report Type:Periodic Company Report #WAES 01111904
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx	PS		ORAL	QOD/PO	
	Dyspepsia		Actonel 5 Mg	SS			5 MG/DAILY	
	Oral Pain		Apap	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864284-0Report Type:Periodic Company Report #WAES 01032922
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dysphonia						MG/DAILY/PO	
			Avapro	C				
			Detrol	C				
			Lipitor	C				
			Norvasc	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3864285-2Report Type:Periodic Company Report #WAES 01040465
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Health					MG/DAILY/PO	
		Professional	Didronel	C				
			Estraderm	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3864288-8Report Type:Periodic Company Report #WAES 01040728
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:12/27/01ISR Number: 3864352-3Report Type:Periodic Company Report #WAES 01082703
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Cytomel	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3864355-9Report Type:Periodic Company Report #WAES 01082714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3864369-9Report Type:Periodic Company Report #WAES 01082716
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Actonel	C				
			Caltrate	C				
			Norvasc	C				
			Prempro	C				

			Zestril	C		
			Aspirin	C		
			Metoprolol	C		
			Vitamin E	C		

Date:12/27/01ISR Number: 3864381-XReport Type:Periodic Company Report #WAES 01082722
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Therapy Unspecified	C				
			Folic Acid	C				
			Ranitidine	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864385-7Report Type:Periodic Company Report #WAES 01082733
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS				
			Aleve	C				
			Cardizem Cd	C				
			Hydrodiuril	C				
			Lipitor	C				
			Therapy Unspecified	C				

Date:12/27/01ISR Number: 3864387-0Report Type:Periodic Company Report #WAES 01082736
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased	Health Professional						
	Fatigue							
	Oedema Peripheral							

Date:12/27/01ISR Number: 3864389-4Report Type:Periodic Company Report #WAES 01082740
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arteriovenous Malformation	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864390-0Report Type:Periodic Company Report #WAES 01082750
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Weight Increased	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864393-6Report Type:Periodic Company Report #WAES 01082752
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				
			Thyroid	C				

Date:12/27/01ISR Number: 3864394-8Report Type:Periodic Company Report #WAES 01082760
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
			Flonase	C				
			Hydrodiuril	C				
			Tiazac	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864398-5Report Type:Periodic Company Report #WAES 01082609
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864400-0Report Type:Periodic Company Report #WAES 01082610
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Heart Rate Irregular	Health	Tab Vioxx 12.5 Mg	PS		ORAL
PO ; PO						
	Palpitations	Professional Company Representative	[Composition Unspecified]	C		

Date:12/27/01ISR Number: 3864402-4Report Type:Periodic Company Report #WAES 01082611
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Lipitor	C		
			Premarin	C		
			Medroxyprogesterone Acetate	C		

Date:12/27/01ISR Number: 3864405-XReport Type:Periodic Company Report #WAES 01082634
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Muscular Weakness	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Urinary Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864407-3Report Type:Periodic Company Report #WAES 01082635
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO ; PO	
	Asthenia		Daypro	C				
	Chills							
	Dehydration							
	Diarrhoea							
	Drug Ineffective							
	Dyspepsia							
	Dysphagia							
	Eye Disorder							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Influenza Like Illness							
	Muscular Weakness							
	Pyrexia							
	Rash							
	Vomiting							
	Weight Decreased							

Date:12/27/01ISR Number: 3864409-7Report Type:Periodic Company Report #WAES 01082639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864411-5Report Type:Periodic Company Report #WAES 01082662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional Company	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864413-9Report Type:Periodic Company Report #WAES 01082694
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 WK
	Nausea		Synthroid	C				
			Zocor	C				

Date:12/27/01ISR Number: 3864415-2Report Type:Periodic Company Report #WAES 01082698
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Vertigo	Health	Fosamax	C				
	Vestibular Disorder	Professional	Hydrodiuril	C				
			Levoxyl	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864416-4Report Type:Periodic Company Report #WAES 01082701
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:12/27/01ISR Number: 3864419-XReport Type:Periodic Company Report #WAES 01082420
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hyperhidrosis							
	Nausea		Ultran	C				

Date:12/27/01ISR Number: 3864421-8Report Type:Periodic Company Report #WAES 01082432
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Nausea		Zantac	C				

Date:12/27/01ISR Number: 3864423-1Report Type:Periodic Company Report #WAES 01082436
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12/5 Mg	PS		ORAL	12.5 MG /DAILY/PO	
	Nausea	Health Professional	Actonel	C				

				Prempro	C		

Date:12/27/01ISR Number: 3864425-5Report Type:Periodic Company Report #WAES 01082441
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pulmonary Congestion	Health Professional	Calan	C				
			Premarin	C				

Date:12/27/01ISR Number: 3864427-9Report Type:Periodic Company Report #WAES 01082442
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Chest Pain							
	Choking							
	Headache							
	Pain In Extremity							
	Pollakiuria							
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864428-0Report Type:Periodic Company Report #WAES 01082447
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Lipitor	C				
			Lopressor	C				
			Aspirin	C				

Date:12/27/01ISR Number: 3864430-9Report Type:Periodic Company Report #WAES 01082450
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Cortisone	C				

Date:12/27/01ISR Number: 3864431-0Report Type:Periodic Company Report #WAES 01082463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cozaar	C				

Date:12/27/01ISR Number: 3864432-2Report Type:Periodic Company Report #WAES 01082465
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	1 YR
	Respiratory Disorder		Celebrex	C				

Date:12/27/01ISR Number: 3864437-1Report Type:Periodic Company Report #WAES 01082478
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Disorder		Benadryl	C				
	Skin Lesion							

Date:12/27/01ISR Number: 3864445-0Report Type:Periodic Company Report #WAES 01082378
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Feeling Abnormal						MG/DAILY/PO	

Date:12/27/01ISR Number: 3864448-6Report Type:Periodic Company Report #WAES 01082380
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Health					MG/DAILY/PO	
		Professional	Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864451-6Report Type:Periodic Company Report #WAES 01082388
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Blood Urea Increased							
	Renal Disorder							

Date:12/27/01ISR Number: 3864454-1Report Type:Periodic Company Report #WAES 01082391
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Muscle Spasms		Hydrodiuril	C				
			Clonidine	C				
			Potassium	C				

Date:12/27/01ISR Number: 3864458-9Report Type:Periodic Company Report #WAES 01082397
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Insomnia	Health					MG/DAILY/PO	
		Professional	Glucovance	C				
			Insulin	C				

Date:12/27/01ISR Number: 3864461-9Report Type:Periodic Company Report #WAES 01082404
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	

	Wheezing	Health					
MG/DAILY/PO							
		Professional	Insulin	C			

Date:12/27/01ISR Number: 3864464-4Report Type:Periodic Company Report #WAES 01082410
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Urine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional	Centrum	C				
			Fosamax	C				
			Slow-Mag	C				
			Univasc	C				
			Aspirin	C				
			Calcium	C				
			Methotrexate	C				
			Sulfasalazine	C				

Date:12/27/01ISR Number: 3864465-6Report Type:Periodic Company Report #WAES 01082411
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Haemorrhage	Professional						
MG/DAILY/PO								
	Gastrointestinal Ulcer	Company Representative	Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864466-8Report Type:Periodic Company Report #WAES 01082412
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Heart Rate Irregular		Actonel	C				
			Pravachol	C				
			Hydrocortisone	C				

Date:12/27/01ISR Number: 3864470-XReport Type:Periodic Company Report #WAES 01082414
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness	Health Professional						
	Gastrointestinal Disorder		Aricept	C				
	Nausea		Lipitor	C				
			Synthroid	C				

Date:12/27/01ISR Number: 3864471-1Report Type:Periodic Company Report #WAES 01082264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864472-3Report Type:Periodic Company Report #WAES 01082273
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Eye Pain					
MG/DAILY/PO						
	Migraine					

Date:12/27/01ISR Number: 3864474-7Report Type:Periodic Company Report #WAES 01082356
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
			Pravachol	C		

Date:12/27/01ISR Number: 3864476-0Report Type:Periodic Company Report #WAES 01082365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Thrombosis	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

Date:12/27/01ISR Number: 3864478-4Report Type:Periodic Company Report #WAES 01082367
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Feeling Abnormal		Celebrex	C		
	Weight Increased		Diovan	C		

Atenolol C

Date:12/27/01ISR Number: 3864483-8Report Type:Periodic Company Report #WAES 01082370
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864486-3Report Type:Periodic Company Report #WAES 01082371
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864488-7Report Type:Periodic Company Report #WAES 01082373
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Bradycardia							
	Confusional State							
	Fatigue							

Date:12/27/01ISR Number: 3864491-7Report Type:Periodic Company Report #WAES 01082374
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
MG/DAILY/PO							
			Ativan	C			
			Zoloft	C			

Date:12/27/01ISR Number: 3864492-9Report Type:Periodic Company Report #WAES 01082375
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspepsia							
	Nausea							

Date:12/27/01ISR Number: 3864495-4Report Type:Periodic Company Report #WAES 01104748
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Chest Pain						MG/DAILY/PO	
	Palpitations							
			Celexa	C				
			Premarin	C				
			Provera	C				
			Tylenol	C				
			Vicodin	C				

Albuterol C

Date:12/27/01ISR Number: 3864497-8Report Type:Periodic Company Report #WAES 01104750
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx	PS		ORAL	PO	
	Gait Disturbance	Professional Company Representative	Glucophage	SS				

Date:12/27/01ISR Number: 3864498-XReport Type:Periodic Company Report #WAES 01104752
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx	PS		ORAL	DAILY PO	

Date:12/27/01ISR Number: 3864500-5Report Type:Periodic Company Report #WAES 01104775
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Lipitor	C				

Date:12/27/01ISR Number: 3864502-9Report Type:Periodic Company Report #WAES 01104779
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Dizziness
MG/DAILY/PO
Dyspnoea
Feeling Abnormal
Headache
Musculoskeletal Stiffness

Date:12/27/01ISR Number: 3864504-2Report Type:Periodic Company Report #WAES 01104780
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Buspar	C				
			Serzone	C				

Date:12/27/01ISR Number: 3864505-4Report Type:Periodic Company Report #WAES 01104782
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Tab Vioxx	PS		ORAL	DAILY PO	
	Muscle Spasms							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864507-8Report Type:Periodic Company Report #WAES 01104787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864509-1Report Type:Periodic Company Report #WAES 01104792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864510-8Report Type:Periodic Company Report #WAES 01104798
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	PO	12.5 MG DAILY
			Hyzaar	C				
			Ultram	C				
			Clorazepate Dipotassium	C				
			Methotrexate	C				
			Prednisone	C				

Date:12/27/01ISR Number: 3864515-7Report Type:Periodic Company Report #WAES 01106188
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Diarrhoea							
	Drug Ineffective							

Dyspepsia

Date:12/27/01ISR Number: 3864517-0Report Type:Periodic Company Report #WAES 01106201
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864520-0Report Type:Periodic Company Report #WAES 01106282
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864523-6Report Type:Periodic Company Report #WAES 01106285
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Viagra	C				

			Cimetidine	C		
			Terazosin Hydrochloride	C		
			Verapamil	C		

Date:12/27/01ISR Number: 3864524-8Report Type:Periodic Company Report #WAES 01106288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3864525-XReport Type:Periodic Company Report #WAES 01106333
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Ineffective		Dilantin	C				
			Prinivil	C				
			Calcium (Unspecified)	C				
			Triamterene	C				
			Vitamins (Unspecified)	C				

Date:12/27/01ISR Number: 3864527-3Report Type:Periodic Company Report #WAES 01106335
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3864530-3Report Type:Periodic Company Report #WAES 01106336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864531-5Report Type:Periodic Company Report #WAES 01106337
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Alesse	C				
			Effexor Xr	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864534-0Report Type:Periodic Company Report #WAES 01106346
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Depression		Wellbutrin	C				
	Drug Ineffective							
	Panic Disorder							

Date:12/27/01ISR Number: 3864538-8Report Type:Periodic Company Report #WAES 01110294
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Fatigue	Professional					PO	
		Company Representative						

Date:12/27/01ISR Number: 3864541-8Report Type:Periodic Company Report #WAES 01110336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:12/27/01ISR Number: 3864544-3Report Type:Periodic Company Report #WAES 01110339
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Prilosec	C		
			Xanax	C		
			Vitamins (Unspecified)	C		

Date:12/27/01ISR Number: 3864546-7Report Type:Periodic Company Report #WAES 01110362
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864548-0Report Type:Periodic Company Report #WAES 01110391
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Aclovate	C				
			Cozaar	C				
			Rythmol	C				
			Synthroid	C				
			Tenormin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864550-9Report Type:Periodic Company Report #WAES 01110393
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Atacand	C				
			Claritin	C				
			Ditropan Xl	C				
			Premarin	C				
			Atenolol	C				

Date:12/27/01ISR Number: 3864551-0Report Type:Periodic Company Report #WAES 01110412
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Evista	C				
			Fosamax	C				
			Hyzaar	C				
			Lipitor	C				
			Prilosec	C				
			Synthroid	C				
			Welchol	C				

Date:12/27/01ISR Number: 3864553-4Report Type:Periodic Company Report #WAES 01110426
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Celebrex	C				

Date:12/27/01ISR Number: 3864554-6Report Type:Periodic Company Report #WAES 01110429
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Lanoxin	C				
			Lipitor	C				
			Micronase	C				
			Theo-24	C				
			Zoloft	C				
			Metoprolol	C				
			Ranitidine	C				
			Temazepam	C				
			Thyroid	C				

Date:12/27/01ISR Number: 3864555-8Report Type:Periodic Company Report #WAES 01110435
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864557-1Report Type:Periodic Company Report #WAES 01113365
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Prilosec	C				

Date:12/27/01ISR Number: 3864559-5Report Type:Periodic Company Report #WAES 01113384
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864560-1Report Type:Periodic Company Report #WAES 01114213
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional	Tab Vioxx	PS		PO		

Date:12/27/01ISR Number: 3864562-5Report Type:Periodic Company Report #WAES 01114390
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:12/27/01ISR Number: 3864563-7Report Type:Periodic Company Report #WAES 01114602
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea							
	Oedema Peripheral							
	Tachycardia							

Date:12/27/01ISR Number: 3864565-0Report Type:Periodic Company Report #WAES 01114674
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
	Skin Disorder	Professional Company Representative						

Date:12/27/01ISR Number: 3864568-6Report Type:Periodic Company Report #WAES 01120070
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health	Tab Vioxx	PS		ORAL	PO	
	Hypertension	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864569-8Report Type:Periodic Company Report #WAES 00012540
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Breast Disorder							
	Cardiomegaly		[Therapy Unspecified]	C				
	Headache		[Therapy Unspecified]	C				
	Renal Disorder		[Therapy Unspecified]	C				
			Estrogenic Preparations (Composi	C				

Date:12/27/01ISR Number: 3864571-6Report Type:Periodic Company Report #WAES 00040255
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Electroencephalogram	Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
	Abnormal	Company						
	Migraine	Representative	Inderal	C				
	Paraesthesia		Prilosec	C				
			Toprol Xl Tablets	C				

Date:12/27/01ISR Number: 3864573-XReport Type:Periodic Company Report #WAES 00070214
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Constipation							

	Fatigue	Tab Vioxx 12.5 Mg	SS	ORAL PO
	Oedema Peripheral	Tab Vioxx 25 Mg	SS	ORAL 25 MG/DAILY/PO
	Polyuria			
	Renal Pain	[Therapy Unspecified]	C	

Date:12/27/01ISR Number: 3864576-5Report Type:Periodic Company Report #WAES 01112886
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864579-0Report Type:Periodic Company Report #WAES 01112906
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx	PS		ORAL PO		
	Dyspepsia	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864581-9Report Type:Periodic Company Report #WAES 01112907
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Effexor	SS				

Date:12/27/01ISR Number: 3864582-0Report Type:Periodic Company Report #WAES 01112908
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx	PS		ORAL	25 MG/ PO	
	Drug Interaction	Professional	Ultram	SS				
	Fatigue	Company	Zanaflex	SS				
		Representative	Neurontin	SS				

Date:12/27/01ISR Number: 3864584-4Report Type:Periodic Company Report #WAES 01112932
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness	Health	Tab Vioxx	PS		ORAL	PO	
	Diplopia	Professional						

Date:12/27/01ISR Number: 3864587-XReport Type:Periodic Company Report #WAES 01112946
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis Erosive	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal	Professional						
	Haemorrhage	Company	Elavil	C				

Representative	Neurontin	C
	Prevacid	C
	Vicodin Tablets	C
	Zanaflex	C

Date:12/27/01ISR Number: 3864589-3Report Type:Periodic Company Report #WAES 01112952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Disorder							
	Nausea							
	Pain							

Date:12/27/01ISR Number: 3864590-XReport Type:Periodic Company Report #WAES 01112979
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864593-5Report Type:Periodic Company Report #WAES 01113089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864594-7Report Type:Periodic Company Report #WAES 01113337
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Epogen	C				
			Vasotec	C				
			Allopurinol	C				

Date:12/27/01ISR Number: 3864875-7Report Type:Periodic Company Report #WAES 01112798
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864879-4Report Type:Periodic Company Report #WAES 01112801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	

	Professional Company Representative	Tylenol With Codeine #3 Unk	SS

Date:12/27/01ISR Number: 3864886-1Report Type:Periodic Company Report #WAES 01112802
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3864887-3Report Type:Periodic Company Report #WAES 01112814
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO;	
		Professional Company Representative					PO	
			Hytrin	C				
			Inderal	C				

Date:12/27/01ISR Number: 3864888-5Report Type:Periodic Company Report #WAES 01112817
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864889-7Report Type:Periodic Company Report #WAES 01112822
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864891-5Report Type:Periodic Company Report #WAES 01112834
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:12/27/01ISR Number: 3864892-7Report Type:Periodic Company Report #WAES 01112865
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Allegra-D	C				
			Ambien	C				
			Elavil	C				
			Nasonex	C				

Soriatane	C
Zoloft	C
Estradiol	C

Date:12/27/01ISR Number: 3864898-8Report Type:Periodic Company Report #WAES 01112866
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864900-3Report Type:Periodic Company Report #WAES 01112885
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	

Date:12/27/01ISR Number: 3864904-0Report Type:Periodic Company Report #WAES 01112795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864908-8Report Type:Periodic Company Report #WAES 01112705
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Abdominal Pain							
			Coumadin	C				
			Duragesic	C				
			Neurontin	C				
			Synthroid	C				
			Amitriptyline	C				
			Famotidine	C				
			Gemfibrozil	C				

Date:12/27/01ISR Number: 3864912-XReport Type:Periodic Company Report #WAES 01112707
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Disorder							
			Efexor	C				
			Ranitidine	C				

Date:12/27/01ISR Number: 3864913-1Report Type:Periodic Company Report #WAES 01112720
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864922-2Report Type:Periodic Company Report #WAES 01112768
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	
			Celebrex	SS		ORAL	DAILY/PO	
			Aciphex	C				
			Medrol	C				
			Plaquenil	C				
			Prempro	C				

Date:12/27/01ISR Number: 3864930-1Report Type:Periodic Company Report #WAES 01112769
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO;	
	Diarrhoea						25 MG/DAILY/PO	
			Covera-Hs	C				
			Fosamax	C				
			Synthroid	C				
			Volmax	C				
			Cimetidine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/01ISR Number: 3864933-7Report Type:Periodic Company Report #WAES 01112770
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Darvocet-N	C				
			Detrol	C				
			Imodium A-D	C				
			Ogen	C				
			Prevacid	C				
			Provera	C				
			Fluoxetine Hydrochloride	C				
			Lorazepam	C				
			Trazodone	C				

Date:12/27/01ISR Number: 3864935-0Report Type:Periodic Company Report #WAES 01112773
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Tab Vioxx	PS		ORAL	PO; 25 MG/DAILY/PO	
	Face Oedema							
	Oedema							
			Cozaar	C				
			Fosamax	C				
			Ogen	C				
			Prilosec	C				
			Synthroid	C				
			Zocor	C				
			Calcium (Unspecified)	C				
			Metoprolol	C				

Date:12/27/01ISR Number: 3864937-4Report Type:Periodic Company Report #WAES 01112792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
	Renal Disorder	Company Representative						

Date:12/27/01ISR Number: 3864938-6Report Type:Periodic Company Report #WAES 01112793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
		Professional Company Representative						

Date:12/27/01ISR Number: 3864942-8Report Type:Periodic Company Report #WAES 01090683
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Feeling Abnormal	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
50 MG/PRN/PO						

Date:12/27/01ISR Number: 3864944-1Report Type:Periodic Company Report #WAES 01090686
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Gastrointestinal Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						

Date:12/27/01ISR Number: 3864946-5Report Type:Periodic Company Report #WAES 01090688
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL
PO						
			Celebrex	C		

Date:12/27/01ISR Number: 3864948-9Report Type:Periodic Company Report #WAES 01090696
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Nizoral	C		
			Phenergen (Promethazine Hydrochl	C		
			Prilosec	C		
			Relenza	C		

				Zyrtec	C		

Date:12/27/01ISR Number: 3864952-0Report Type:Periodic Company Report #WAES 01090699
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS				
			Premarin	C				
			Prilosec	C				
			Gemfibrozil	C				

Date:12/27/01ISR Number: 3864954-4Report Type:Periodic Company Report #WAES 01090709
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:12/27/01ISR Number: 3864957-XReport Type:Periodic Company Report #WAES 01090714
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

	Cartia (Diltiazem Hydrochloride)	C
	Diamox	C
	K-Dur	C
	Lanoxin	C
	Pravachol	C
	Prinivil	C

Date:12/27/01ISR Number: 3864961-1Report Type:Periodic Company Report #WAES 01090733
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	

Date:12/27/01ISR Number: 3864967-2Report Type:Periodic Company Report #WAES 01090739
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO;	

Date:12/27/01ISR Number: 3864969-6Report Type:Periodic Company Report #WAES 01090742
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dizziness							
	Nausea							
			Arthrotec	C				
			Claritin	C				
			Dyazide	C				
			Ogen	C				
			Prevacid	C				

			Synthroid	C
			Vasotec	C

Date:12/28/01ISR Number: 3845016-9Report Type:Expedited (15-DaCompany Report #WAES 01103260
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 14 DAY	Blood Calcium Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 103 DAY	Blood Creatinine Abnormal		Vioxx	SS		ORAL
	Blood Urea Abnormal		Persantine	C		ORAL
	Dizziness					
	Fatigue					
	Gastric Ulcer Haemorrhage					
	Gastritis Erosive					
	Gastroduodenitis					
	Gastrointestinal Haemorrhage					
	Haematocrit Abnormal					
	Haemoglobin Abnormal					
	Melaena					
	Platelet Count Abnormal					
	White Blood Cell Count Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/01ISR Number: 3845023-6Report Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/28/01ISR Number: 3845024-8Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Inappropriate		Vioxx	PS	Merck & Co., Inc	ORAL		
41 DAY								
Initial or Prolonged	Antidiuretic Hormone		Bendroflumethiazide	C				
Other	Secretion		Isosorbide					
	Pleural Effusion		Mononitrate	C				
	Renal Impairment		Bisoprolol	C				
			Omeprazole	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				

Date:12/28/01ISR Number: 3845032-7Report Type:Expedited (15-DaCompany Report #WAES 01118587
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Toxicity		Vioxx	SS		ORAL		
1 DAY								

Date:12/28/01ISR Number: 3845034-0Report Type:Expedited (15-DaCompany Report #WAES 01125016
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Benserazide Hydrochloride And					

			Levodopa	C		ORAL

Date:12/28/01ISR Number: 3846491-6Report Type:Expedited (15-DaCompany Report #200111235BFR
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dizziness	Foreign	Ciflox			
Initial or Prolonged	Vertigo	Health	(Ciprofloxacin)	PS		
	Vomiting	Professional	Sermion			
		Other	(Nicergoline)	SS		
			Cytotec			
			(Misoprostol)	SS		
			Vioxx (Rofecoxib)	SS		
			Aspegic	C		
			Phakan	C		
			Ideos	C		
			Tanakan	C		
			Chondrosulf	C		
			Dhea	C		
			Cardentiel	C		
			Hyzaar	C		
			Cryogest	C		
			Cardentiel	C		

				Atepedene	C		
				Vitamins A C E	C		

Date:12/28/01ISR Number: 3846956-7Report Type:Expedited (15-DaCompany Report #PHNU2001DE02940
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Stevens-Johnson Syndrome	Foreign Study Health Professional Other	Hydergin (Co-Dergocrine Mesylate)	PS			INTRAVENOUS	SEE IMAGE
			Heparin (Heparin Sodium) Ampoule	SS			INTRAVENOUS	SEE IMAGE
			Fenistil (Dimetindene Maleate) Solution For Injection	SS			INTRAVENOUS	SEE IMAGE
			Insulin Human (Insulin Human) Solution For Injection	SS			INTRAVENOUS	SEE IMAGE
			Combactam (Sulbactam Sodium) Solution For Injection	SS			INTRAVENOUS	1 G, TID,
			Dormicum For Injection (Midazolam Hydrochloride) Solution For Injection	SS			INTRAVENOUS	SEE IMAGE
			Cordanum Sugar-Coated Tablet (Talinolol)	SS		ORAL	SEE IMAGE	
			Fentanyl (Fentanyl) Solution For Injection	SS			INTRAVENOUS	1.5MG/DAY,

INTRAVENOUS		Konakion (Phytomenadione) Solution For Injection	SS		
INTRAVENOUS	1 DF, QD,				
INTRAVENOUS		Paracefan (Clonidine Hydrochloride) Solution For Injection	SS		ORAL
1.05 MG/DAY,					
ORAL		Aminoplasmal (Amino Acids Nos) Solution For Injection	SS		
INTRAVENOUS	1 DF, QD,				
INTRAVENOUS		Pavulon (Pancuronium Bromide)	SS		
INTRAVENOUS	SEE IMAGE				
		Kalymin "Asta Medica Awd" (Pyridostigmine Bromide) Solution For Injection	SS	Asta Medica	
INTRAVENOUS	30 MG, QD,				
INTRAVENOUS		Furesis Comp (Furosemide, Triamterene) Tablet	SS		ORAL
SEE IMAGE					

Ampho-Moronal (Amphotericin B) Suspension SS ORAL
2 ML, 6QD,
ORAL

Paracetamol (Paracetamol) Tablet SS ORAL
1 G,
ONCE/SINGE,
ORAL

Espumisan (Dimeticone) Emulsion SS ORAL
2 ML, 6QD,
ORAL

Dopacard (Dopexamine Hydrochloride) Solution For Injection SS
INTRAVENOUS 100 MG, QD,
INTRAVENOUS

Berlosin S (Metamizole Sodium) Solution For Injection SS
INTRAVENOUS 1 DF,
ONCE/SINGLE,
INTRAVENOUS

Sinophenin (Promazine Phosphate) SS
INTRAVENOUS 3 DF/DAY,
INTRAVENOUS

Diflucan (Fluconazole) SS ORAL
80 MG/DAY,
ORAL

Aspisol

(Acetylsalicylate Lysine) Solution For Injection SS

INTRAVENOUS 1 DF, QD,

INTRAVENOUS

Pipril S (Piperacillin Sodium) Solution For Injection, 3g SS

INTRAVENOUS 3 G, BID,

INTRAVENOUS

Prednisolut (Prednisolone Sodium Succinate) Solution For Injection SS

INTRAVENOUS 25 MG, BID,

INTRAVENOUS

Intralipid (Soya Oil, Lecithin) Solution For Infusion SS

INTRAVENOUS 1 DF, QD,

INTRAVENOUS

Panthenol (Panthenol) Solution SS

INTRAVENOUS 4 DF, QID,

INTRAVENOUS

Ulcogant Suspension (Sucralfate) SS ORAL

5 ML, 6QD,

ORAL

Cerucal (Metoclopramide Hydrochloride) Solution For Injection SS

INTRAVENOUS 1 DF, TID,

INTRAVENOUS						
		Inzolen	SS			
INTRAVENOUS	1 DF, QD,					
INTRAVENOUS						
		Aminophylline (Aminophylline) Tablet	SS			ORAL
SEE IMAGE						
		Vitalipid Solution (Vitamins Nos)	SS			
INTRAVENOUS	1 DF, QD,					
INTRAVENOUS						
		Soluvit (Vitamins Nos)	SS			
INTRAVENOUS	1 DF, QD,					
INTRAVENOUS						
		Vioxx Tablet, 12.5mg	SS			ORAL
SEE IMAGE						
		Nimotop (Nimodipine) Solution	SS			
INTRAVENOUS	1 DF, QD,					
INTRAVENOUS						
		Ketanest (Ketamine) Solution	SS			
INTRAVENOUS	3 G, QD,					
INTRAVENOUS						
		Bifiteral "Solvay Arzneimittel" (Lactulose) Syrup	SS	Solvay		ORAL
.5 ML, TID,						
ORAL						
		Furesis (Furosemide) Solution	SS			
INTRAVENOUS	SEE IMAGE					
		Mucosolvan (Ambroxol Hydrochloride) Solution For Injection	SS			
INTRAVENOUS	3 G, QD,					
INTRAVENOUS						

		Luminal (Phenobarbital) Soluti	SS
INTRAVENOUS	SEE IMAGE		
		Osmofundin (Sodium Acetate Trihydrate)	C
		Eufibron Suppository	C
		Arterenol (Norepinephrine Hydrochloride) Solution For Injection	C
		Addel N (Zinc Chloride, Selenide Sodium, Manganese Chloride, Ferrous Chloride, Copper	C
		Theophylline Tablet	C
		Glucose Solution For Infusion	C
		Indometacin Tablet	C
		....	C
		Normabrain Solution For Infusion	C
		Calcium Solution For Injection	C
		Tregor (Amantadine Sulfate) Solution For Infusion	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/01ISR Number: 3845701-9Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Thrombosis		Vioxx	SS		ORAL		

Date:12/31/01ISR Number: 3845707-XReport Type:Expedited (15-DaCompany Report #WAES 01115523
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS		ORAL		
	Livedo Reticularis		Digitoxin	C		ORAL		
	Rheumatoid Factor Positive		Torsemide	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		

Date:12/31/01ISR Number: 3846074-8Report Type:Direct Company Report #CTU 157990
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Vioxx	PS		ORAL	PO, 1 DOSE	
	Respiratory Disorder							

Date:12/31/01ISR Number: 3846114-6Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ammonia Increased		Vioxx	PS		ORAL	25MG PO QD	PTA
	Hepatic Encephalopathy							
	Lethargy		Duragesic	C				

	Vomiting		Celexa	C
			Trazodone	C
			Lasix	C
			Kcl	C
			Neuronitin	C
			Melatonin	C

Date:12/31/01ISR Number: 3846673-3Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05146
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dehydration	Foreign	Vioxx (Rofecoxib)	PS		ORAL
SEE IMAGE 10 DAY						
	Incontinence	Other	Atenolol	C		
	Oedema Peripheral		Calcium Carbonate			
	Weight Decreased		(+) Cholecalciferol	C		
			Omeprazole	C		
			Warfarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/01ISR Number: 3846683-6Report Type:Expedited (15-DaCompany Report #WAES 01107522
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Thrombocytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Moduretic	C				
			Allopurinol	C				
			Bisoprolol Fumarate	C				
			Flupentixol Hydrochloride (+)					
			Melitracen	C				
			Naloxone Hydrochloride (+)					
			Tilidine Hydr	C				
			Omeprazole	C				

Date:12/31/01ISR Number: 3846696-4Report Type:Expedited (15-DaCompany Report #WAES 01107522
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Thrombocytopenia	Health Professional	Moduretic	C				
			Allopurinol	C				
			Bisoprolol Fumarate	C				
			Flupentixol Hydrochloride (+)					
			Melitracen	C				
			Naloxone Hydrochloride (+)					
			Tilidine Hydr	C				
			Omeprazole	C				

Date:12/31/01ISR Number: 3846714-3Report Type:Expedited (15-DaCompany Report #200111235BFR
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Foreign	Ciflox					

Initial or Prolonged	Vertigo Vomiting	Health Professional Other	(Ciprofloxacin) Sermion (Nicergoline) Cytotec (Misoprostol) Vioxx (Rofecoxib) Aspegic Phakan Ideos Tanakan Chondrosulf Dhea Cardentiel Hyzaar Cryogest Atepedene Vitamins A C E	PS SS SS SS C C C C C C C C C C C

Date:12/31/01ISR Number: 3846767-2Report Type:Expedited (15-DaCompany Report #WAES 01048107
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma Mouth Haemorrhage Oral Mucosal Petechiae Petechiae Skin Disorder Thrombocytopenia	Foreign Other	Tab Vioxx (Rofecoxib) Atenolol/Chlorthalidone Lomefloxacin Hydrochloride	PS C C		ORAL	25 MG/DAILY	PO 5 DAY

Date:12/31/01ISR Number: 3846814-8Report Type:Expedited (15-DaCompany Report #WAES 01115015
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse Dyspnoea Headache Palpitations Tremor	Foreign Health Professional Other	Tab Vioxx (Rofecoxib) Levothyroxine Na	PS C		ORAL	12.5 MG/DAILY	PO 146 DAY

Date:12/31/01ISR Number: 3846841-0Report Type:Expedited (15-DaCompany Report #WAES 01113079
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension Visual Disturbance	Consumer	Tab Vioxx 12.5mg Catapres Lasix (Furosemide)	PS C C		ORAL	12.5 MG/DAILY/PO ; 25 MG/DAILY/PO	

Date:12/31/01ISR Number: 3846859-8Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05087
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Hyponatraemia	Health	Acetaminophen/Propox					
Disability	Inappropriate	Professional	yphene Hydrochloride	C				
Other	Antidiuretic Hormone	Other	Bendroflumethiazide	C				
	Secretion		Bisoprolol	C				
	Malaise		Isosorbide					
	Vomiting		Mononitrate	C				
			Omeprazole	C				

Date:12/31/01ISR Number: 3846861-6Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05110
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/BID	6 WK
Hospitalization -	International Normalised	Health	Acetaminophen	C				
Initial or Prolonged	Ratio Increased	Professional	Warfarin	C				
	Renal Failure Acute	Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/01ISR Number: 3846863-XReport Type:Expedited (15-DaCompany Report #WAES 01106114
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	212 DAY
Initial or Prolonged	Melaena	Health Professional Other	Zocor	C				
			Benazepril Hcl	C				
			Buflomedil Hcl	C				
			Gliclazide	C				
			Metformin	C				
			Nafronyl Oxalate	C				
			Ticlopidine Hydrochloride	C				

Date:12/31/01ISR Number: 3846865-3Report Type:Expedited (15-DaCompany Report #WAES 01105075
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID	25 DAY
Initial or Prolonged	Caesarean Section	Health Professional Other	Acetaminophen/Propoxyphene Hydrochloride	C				
	Complications Of Maternal Exposure To Therapeutic Drugs		Amitriptyline	C				
			Betamethasone	C				
	Foetal Distress Syndrome		Clonazepam	C				
	Maternal Drugs Affecting Foetus		Diclofenac	C				
			Ferrouss04	C				
	Platelet Count Decreased		Labetalol Hcl	C				
	Premature Baby		Lactulose	C				
			Morphine	C				
			Nifedipine	C				
			Ranitidine	C				
			Tramadol	C				

Date:12/31/01ISR Number: 3846877-XReport Type:Expedited (15-DaCompany Report #WAES 01115619
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx					

Hospitalization -	Hypertension	Health	(Rofecoxib)	PS	ORAL
25 MG/DAILY					
Initial or Prolonged	Tachyarrhythmia	Professional			
PO 30 DAY					
			Ciprofloxacin Hydrochloride	C	
			Dalteparin Sodium	C	
			Fentanyl	C	
			Ferrousso4/Folic Acid	C	
			Metoprolol Succinate	C	
			Teicoplainin	C	
			Tolperisone Hcl	C	

Date:12/31/01ISR Number: 3846879-3Report Type:Expedited (15-DaCompany Report #WAES 01119123
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Glucose Increased
Initial or Prolonged	Blood Sodium Decreased
	Hypertension
	Pancreatitis Acute
	Red Blood Cell Count

Decreased
White Blood Cell Count
Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	25MG/DAILY PO 10 DAY
	Aceclofenac	C				
	Captopril	C				
	Dipyrone	C				
	Furosemide	C				

Date:12/31/01ISR Number: 3846945-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage	Consumer Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:12/31/01ISR Number: 3847064-1Report Type:Expedited (15-DaCompany Report #WAES 01102011
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY; PO	
Other			Zyrtec	C				

Date:12/31/01ISR Number: 3847131-2Report Type:Expedited (15-DaCompany Report #WAES 01112634
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Health	Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Coronary Artery Disease	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Aspirin	C				
Other		Representative						

Date:12/31/01ISR Number: 3847134-8Report Type:Expedited (15-DaCompany Report #WAES 0112USA01616
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Vioxx 25 Mg	PS		ORAL	25	
	Throat Tightness	Professional					MG/DAILY/PO	
		Company	Claritin	C				
		Representative	Metamucil	C				
			Pravachol	C				
			Allergenic Extract	C				
			Aspirin	C				

Date:12/31/01ISR Number: 3847137-3Report Type:Expedited (15-DaCompany Report #WAES 01111179
Age:61 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health	Vioxx	PS		ORAL	50	
	Cardiac Failure	Professional					MG/DAILY/PO	
	Congestive		Depakote	C				
	Confusional State		Tegretol	C				
	Hyponatraemia		Toprol Xl Tablets	C				
	Pleural Effusion		Valium	C				
	Pneumonia		Zantac	C				
	Staphylococcal Infection		Zocor	C				
			Zoloft	C				
			Baclofen	C				

Date:12/31/01ISR Number: 3847139-7Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health	Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	

Date:12/31/01ISR Number: 3847143-9Report Type:Expedited (15-DaCompany Report #WAES 01090534
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Gastrointestinal	Health					MG/DAILY/PO;	
Initial or Prolonged	Haemorrhage	Professional					25	
Other		Company					MG/DAILY/PO	
		Representative	Coumadin	C				

Date:12/31/01ISR Number: 3847147-6Report Type:Expedited (15-DaCompany Report #WAES 01092825
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company	Avandia	C				
		Representative	Celexa	C				
			Flovent	C				
			Foradil	C				
			Glucophage	C				
			Lopressor	C				
			Patanol	C				
			Plavix	C				
			Prilosec	C				
			Prinivil	C				
			Reglan	C				
			Zocor	C				
			Albuterol	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/01ISR Number: 3847150-6Report Type:Expedited (15-DaCompany Report #WAES 00111760
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Blood Pressure Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Gastric Ulcer	Health Professional	Ecotrin	C				
	Haematemesis		Flomax (Tamsulosin Hydrochloride)	C				
	Helicobacter Infection		Lopressor	C				
	Mallory-Weiss Syndrome		Maalox	C				
	Melaena		Proscar	C				
	Syncope		Zantac	C				
	Upper Gastrointestinal Haemorrhage		Zestril	C				

Date:12/31/01ISR Number: 3847253-6Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged Other	Myocardial Infarction	Company Representative	Celebrex	C				
	Ventricular Fibrillation							

Date:12/31/01ISR Number: 3847549-8Report Type:Direct Company Report #
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hypersensitivity		Vioxx 12.5mg Merck	PS	Merck	ORAL	1 DAILY	
			Betamethasone Dipropionate Ointment	C				

Date:01/02/02ISR Number: 3847385-2Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization -	Arrhythmia
Initial or Prolonged	Atrioventricular Block
	First Degree
	Blood Pressure Diastolic
	Decreased
	Blood Pressure Systolic
	Increased
	Cardiac Arrest
	Dizziness
	Duodenal Ulcer
	Haemorrhage
	Electrocardiogram St
	Segment Abnormal
	Electrocardiogram St
	Segment Depression
	Electrocardiogram T Wave
	Inversion
	Exsanguination
	Fall
	Haematemesis
	Haematochezia

		Head Injury Hypotension Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Rate	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY							
		Increased	Professional				
PO							
		Syncope	Company	Bumex	C		
		Thrombosis	Representative	Cozaar	C		
				Klor-Con	C		
				Lanoxin	C		
				Lasix (Furosemide)	C		
				Lotensin	C		
				Premarin	C		
				Aspirin	C		
				Prednisone	C		

Date:01/02/02ISR Number: 3847425-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA02436
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Congestive					
MG/DAILY/PO						
Initial or Prolonged	Dyspnoea					
Disability	Oedema Peripheral					
	Protein Urine Present					
	Pulmonary Oedema					

Date:01/02/02ISR Number: 3847426-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA02168
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Convulsion	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged		Professional				
MG/DAILY/PO						
			Fibercon	C		
			Nexium	C		

			Levothyroxine Sodium	C		

Date:01/02/02ISR Number: 3847427-4Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Congestive	Professional					MG/DAILY/PO	
Initial or Prolonged	Weight Increased		Celebrex	C				
			Paxil	C				
			Calcium	C				

Date:01/02/02ISR Number: 3847428-6Report Type:Expedited (15-DaCompany Report #WAES 0112USA01264
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Flexeril	C				
		Company Representative	Pepcid	C				

Date:01/02/02ISR Number: 3847438-9Report Type:Expedited (15-DaCompany Report #WAES 01116082
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Tinnitus	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	4 DAY
			Benfluorex Hcl	C				
			Celecoxib	C				
			Heptaminol Hcl	C				

Date:01/02/02ISR Number: 3847439-0Report Type:Expedited (15-DaCompany Report #WAES 01129111
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough Dyspnoea Stridor	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	17 DAY
			Tab Acetaminophen/Codeine Phosphate	SS		ORAL	4 TABLET/DAILY PO	17 DAY
			Tab Flexeril (Cyclobenzaprine Hcl)	SS		ORAL	10 MG/DAILY PO	17 DAY
			Captopril	C				
			Chlorthalidone	C				

Date:01/02/02ISR Number: 3847440-7Report Type:Expedited (15-DaCompany Report #WAES 01109101
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness Unilateral	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY PO	5 DAY

Date:01/02/02ISR Number: 3847452-3Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06075
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Sudden Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	113 DAY
			Aspirin Lysine	C				
			Fenofibrate	C				
			Flecainide Acetate	C				
			Hydrochlorothiazide (+) Irbesartan	C				
			Paroxetine	C				
			Tramadol Hcl	C				
			Uridine 5' -Triphosphate	C				
			Zolpidem Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/02/02ISR Number: 3847455-9Report Type:Expedited (15-DaCompany Report #WAES 0112CAN08592
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Atrophy	Literature						
	Blood Thyroid Stimulating	Other					PO	
	Hormone Decreased		Tab Celecoxib	SS		ORAL	100 MG/DAILY	
	Computerised Tomogram						PO	2 WK
	Abnormal		Cilazapril	C				
	Confusional State		Estrogens, Conjugated	C				
	Delirium		Furosemide	C				
	Disorientation		Levothyroxine Na	C				
	Hallucinations, Mixed		Nizatidine	C				
	Mental Disorder		Sotalol Hydochloride	C				
	Periventricular Leukomalacia							

Date:01/02/02ISR Number: 3847459-6Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06079
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	16 DAY
	Duodenal Ulcer	Other						
	Haemorrhage		Tab Fluindione	SS		ORAL	25 MG/DAILY	
	Dyspnoea						PO	
	Haemoglobin Decreased							
	International Normalised Ratio Increased							

Date:01/02/02ISR Number: 3847460-2Report Type:Expedited (15-DaCompany Report #WAES 0112DEU05629
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	
	Protein C Decreased						PO; 12.5 MG DAILY	
			Levothyroxine Na	C				

Date:01/02/02ISR Number: 3847484-5Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06094
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Amiodarone	C				
			Furosemide	C				
			Nitroglycerin	C				
			Rabeprazole Sodium	C				
			Telmisartan	C				
			Zolpidem Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/02/02ISR Number: 3847662-5Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05117
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	2 MON
Other			Aspirin	C				
			Quinine	C				

Date:01/03/02ISR Number: 3847318-9Report Type:Expedited (15-DaCompany Report #WAES 01117524
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Rofecoxib	PS	Merck & Co., Inc	ORAL		

Date:01/03/02ISR Number: 3847321-9Report Type:Expedited (15-DaCompany Report #WAES 01102623
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acidosis
Hospitalization - Initial or Prolonged	Asthenia
	Atrial Fibrillation
	Blood Albumin Abnormal
	Blood Chloride Abnormal
	Blood Creatine Phosphokinase Abnormal
	Blood Glucose Abnormal
	Blood Ketone Body Present
	Blood Sodium Abnormal
	Blood Thyroid Stimulating Hormone Increased
	Cardiomegaly
	Chest X-Ray Abnormal
	Computerised Tomogram Abnormal
	Dialysis
	Dilatation Atrial
	Electrocardiogram St-T Segment Abnormal
	Electrocardiogram T Wave

Inversion
Epistaxis
Faecal Occult Blood
Positive
Faecaloma
Gait Disturbance
Gallbladder Disorder
Haematocrit Decreased
Hypokalaemia
Hypoxia
Laboratory Test Abnormal
Lethargy
Lung Infiltration
Mitral Valve Incompetence
Myocardial Ischaemia
Myoglobin Blood Increased
Pallor
Pco2 Abnormal
Platelet Count Abnormal
Pleural Effusion

		Pneumonia Aspiration					
		Pulmonary Oedema					
		Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scoliosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Somnolence		Glucophage	SS		
		Staphylococcal Sepsis		Avapro	C		
		Tachycardia		Rinatec	C		
		Tricuspid Valve		Flexeril	C		
		Incompetence		Synthroid	C		
		Troponin I					
		Vascular Calcification					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					

Date:01/03/02ISR Number: 3847326-8Report Type:Expedited (15-DaCompany Report #WAES 01110854
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/03/02ISR Number: 3847327-XReport Type:Expedited (15-DaCompany Report #WAES 01111159
Age:73 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
Hospitalization -		Blood Pressure Systolic		Aspirin	C		
Initial or Prolonged		Decreased		Aspirin	C		
		Gastrointestinal		Elavil	C		
		Haemorrhage		Norvasc	C		
				[Therapy			
				Unspecified]	C		
				Levoxyl	C		
				Rowasa	C		

Date:01/03/02ISR Number: 3847331-1Report Type:Expedited (15-DaCompany Report #WAES 01125539
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Interaction		Diclofenac Sodium	SS				
RECTAL							1	DAY
Initial or Prolonged	Hypotension		Diclofenac Sodium	SS				
RECTAL								
	Pulse Absent		Methimazole	C				
			Phenprocoumon	C		ORAL		

Date:01/03/02ISR Number: 3847995-2Report Type:Expedited (15-DaCompany Report #HQ7066112OCT2001
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right	Health	Temesta (Lorazepam,					
Initial or Prolonged	Cardiomegaly	Professional	Tablet)	PS		ORAL		
3 MG 1 X PER								
	Chest Pain	Other						
1 DAY ORAL								
	Cough		Chondrosulf					
	Dyspnoea		(Chondroitin Sulfate					
	Electrocardiogram		Sodium,)	SS				
1 G 1X PER 1								
	Abnormal							
DAY								
	Jaundice		Sectral (Acebutolol					
	Pulmonary Embolism		Hydrochloride,					

				Capsule)	SS		
100 MG 1X PER 1 DAY							
				Vioxx (Rofecoxib, Tablet)	SS		
25 MG 1X PER 1 DAY	10 DAY						
				Etioven (Naftazone,)	C		
30 MG 1X PER 1 DAY							

Date:01/03/02ISR Number: 3848216-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA03021
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Palpitations	Professional						
		Company Representative						

Date:01/04/02ISR Number: 3848121-6Report Type:Expedited (15-DaCompany Report #WAES 01120286
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	10 WK	
Hospitalization -	Cardiac Failure		Vioxx	SS		ORAL	10 WK	
Initial or Prolonged	Hypertension		Diuretic (Unspecified)	C				
Other	Oedema Peripheral		[Therapy Unspecified]	C				
	Ventricular Arrhythmia							

Date:01/04/02ISR Number: 3848124-1Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Akinesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Prednisone	C		ORAL		
	Blood Cholesterol Increased		Tramadol Hydrochloride	C		ORAL		
	Blood Creatine Phosphokinase Increased		Leflunomide	C		ORAL		
	Cardiac Disorder							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Ejection Fraction Decreased							
	High Density Lipoprotein Decreased							
	Hypokinesia							
	Hypotension							
	Low Density Lipoprotein Increased							
	Malaise							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Neck Pain							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/02ISR Number: 3848132-0Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Life-Threatening	Congestive							
Hospitalization - Initial or Prolonged								

Date:01/04/02ISR Number: 3848133-2Report Type:Expedited (15-DaCompany Report #WAES 01108577
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Paroxetine Hydrochloride	C				
			Estrogens, Conjugated	C				

Date:01/04/02ISR Number: 3848610-4Report Type:Direct Company Report #CTU 158365
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Exertional		Vioxx	PS				
PRN								
	Fatigue		Nexium	C				
	Oedema							

Date:01/04/02ISR Number: 3848741-9Report Type:Direct Company Report #CTU 158384 E
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx 1 A Day 12.5 Mg	PS		ORAL		
	Haematochezia							
BY MOUTH Required	Heart Rate Increased		Celebrex 2 A Day 100					

Intervention to Prevent Permanent Impairment/Damage | Mg 1 Week A Dose | SS

Date:01/04/02ISR Number: 3848914-5Report Type:Expedited (15-DaCompany Report #WAES 01118587
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Toxicity	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	1 DAY

Date:01/04/02ISR Number: 3848967-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA02870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	PO	
	Paralysis	Professional						
	Pruritus							

Date:01/04/02ISR Number: 3848969-8Report Type:Expedited (15-DaCompany Report #WAES 0112USA02467
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Zantac	C				

Date:01/04/02ISR Number: 3849036-XReport Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention	Health	Tab Vioxx	PS		ORAL	PO	
	Memory Impairment	Professional Company Representative						

Date:01/04/02ISR Number: 3849037-1Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Thrombosis	Health	Tab Vioxx	PS		ORAL	PO	
Other	Lung Neoplasm Malignant	Professional Company Representative						

Date:01/04/02ISR Number: 3849039-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA01494
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vomiting	Consumer	Tab Vioxx	PS		ORAL	25	

Initial or Prolonged
MG/DAILY/PO

Glucophage	C
Hydrodiuril	C
Lasix (Furosemide)	C
Ocuvite	C
Prevacid	C
Dltiazem Malate	C
Quinine	C
Vitamin B	C

Date:01/04/02ISR Number: 3849043-7Report Type:Expedited (15-DaCompany Report #WAES 01103260
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Dizziness
	Faecal Occult Blood Positive
	Fatigue
	Gastritis Erosive
	Gastroduodenitis
	Gastroenteritis
	Helicobacter Gastrointestinal
	Haemorrhage
	Melaena

	White Blood Cell Count Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional Company Representative	Tab Vioxx	PS		ORAL	SEE IMAGE	
			Persantine	C				

Date:01/04/02ISR Number: 3849045-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA01597
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional Company Representative	Tab Hyzaar 50-12.5 Mg	PS		ORAL	50-12.5 MG/DAILY/PO	
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide Sodium)	C				
			Micro K	C				
			Nitrostat	C				
			Synthroid	C				

Date:01/04/02ISR Number: 3849054-1Report Type:Expedited (15-DaCompany Report #WAES 0112USA02294
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Computerised Tomogram							
	Abnormal		Avandia	C				
	Dizziness		Elavil	C				
	Haematochezia		Humalog	C				
	Haemorrhage		Humulin Nph	C				

	Headache		Prilosec	C
	Hemiparesis		Prinivil	C
	Iron Deficiency		Aspirin	C
			Vitamins (Unspecified)	C

Date:01/04/02ISR Number: 3849191-1Report Type:Expedited (15-DaCompany Report #WAES 0112USA02378
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged	Congestive Cardiomyopathy	Professional	Cardizem Cd	C				
	Ejection Fraction Decreased		Coumadin	C				
	Pulmonary Oedema		Evista	C				
			Lipitor	C				
			Miacalcin	C				

Date:01/04/02ISR Number: 3849198-4Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06088
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Atrioventricular Block
Hospitalization -	Conduction Disorder
Initial or Prolonged	Gastrointestinal Disorder

	Heart Rate Decreased						
	Hepatic Enzyme Increased						
	Malaise	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Syncope	Foreign	Tab Vioxx				
		Health	(Rofecoxib)	PS		ORAL	6 WK
		Professional	Atorvastatin	C			
			Celiprolol	C			
			Piribedil	C			

Date:01/04/02ISR Number: 3849199-6Report Type:Expedited (15-DaCompany Report #WAES 0112DEU05633
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chills	Foreign	Tab Vioxx				
	Nausea	Consumer	(Rofecoxib)	PS		ORAL	25 MG/DAILY 1 DAY
	Swelling						
	Tongue Oedema						

Date:01/04/02ISR Number: 3849211-4Report Type:Expedited (15-DaCompany Report #WAES 0112BEL07521
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Aplastic Anaemia	Foreign	Tab Vioxx				
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	PO 4 WK
Initial or Prolonged	Pneumonia	Professional					

Date:01/04/02ISR Number: 3849212-6Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06080
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx				
Initial or Prolonged	Faeces Discoloured	Other	(Rofecoxib)	PS		ORAL	PO 16 DAY
	Gastric Ulcer		Aspirin Lysine	C			

	Haematemesis
	Haemoglobin Decreased
	Upper Gastrointestinal
	Haemorrhage

Date:01/04/02ISR Number: 3849217-5Report Type:Expedited (15-DaCompany Report #WAES 01125016
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Benserazide Hydrochloride (+) Levodopa	C				

Date:01/04/02ISR Number: 3849219-9Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Inappropriate Antidiuretic Hormone Secretion
Other	

	Pleural Effusion Renal Impairment						
		Report Source	Product	Role	Manufacturer	Route	Dose
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY
PO	41 DAY						
			Acetaminophen/ Propoxyphene Hydrochloride	C			
			Bendroflumetniazide	C			
			Bisoprolol	C			
			Isosorbide Mononitrate	C			
			Omeprazole	C			

Date:01/04/02ISR Number: 3849221-7Report Type:Expedited (15-DaCompany Report #WAES 0112POL09813
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY	
PO	3 DAY							
			Tab Vioxx (Rofecoxib)	SS		ORAL	12.5 MG/ DAILY PO	2 DAY

Date:01/04/02ISR Number: 3849249-7Report Type:Expedited (15-DaCompany Report #WAES 01058683
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Cerebrovascular Accident	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
Disability	Diabetes Mellitus		Clopidogrel					

			Bisulfate	C		
			Diltiazem Hydrochloride	C		
			Glyburide	C		
			Metformun Hcl	C		
			Omeprazole Magnesium	C		

Date:01/07/02ISR Number: 3848743-2Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization -	Congestive		Vioxx	SS		ORAL		353 DAY
Initial or Prolonged	Dyspepsia		Ferrous Sulfate	C				
Other	Dyspnoea		Ecotrin	C				
	Fluid Overload		K-Dur	C				
	Weight Increased		Lasix (Furosemide)	C				

Date:01/07/02ISR Number: 3848744-4Report Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Thrombosis		Atenolol	C				
	Dyspnoea		Motrin	C				
	Myocardial Infarction						9	DAY

Date:01/07/02ISR Number: 3848745-6Report Type:Expedited (15-DaCompany Report #WAES 01113172
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	878	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Aspirin	C				
	Upper Gastrointestinal Haemorrhage		Kaon	C				
			Norvasc	C				
			Isorbid	C				
			Bumex	C				
			Synthroid	C				
			Paxil	C				
			Elavil	C				
			Lamisil	C				
			Darvocet-N	C				
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				

Date:01/07/02ISR Number: 3848752-3Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		Os-Cal D	C				
	Chest X-Ray Abnormal		Paxil	C				
							182	DAY
	Pleural Effusion		Paxil	C				

	Weight Increased		Celebrex	C		
			Fosamax	C		ORAL

Date:01/07/02ISR Number: 3848756-0Report Type:Expedited (15-DaCompany Report #WAES 01115660
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Autoimmune		Diclofenac	SS		ORAL
	Thrombocytopenia		Hydrochlorothiazide			
	Epistaxis		And Irbesartan	C		ORAL
	Melaena		Estradiol Valerate			
	Petechiae		And Estriol And			
			Levonorgestrel	C		ORAL

Date:01/07/02ISR Number: 3849452-6Report Type:Expedited (15-DaCompany Report #WAES 0201NLD00001
Age:68 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Betaxolol Hcl	C				
			Latanoprost	C				

Date:01/07/02ISR Number: 3849454-XReport Type:Expedited (15-DaCompany Report #WAES 0112NLD03710
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	PO	

Date:01/07/02ISR Number: 3849611-2Report Type:Expedited (15-DaCompany Report #200111235BFR
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Foreign	Ciflox					
Initial or Prolonged	Vertigo	Health	(Ciprofloxacin)	PS				
	Vomiting	Professional	Sermion					
		Other	(Nicergoline)	SS				
			Cytotec					
			(Misoprostol)	SS				
			Vioxx (Rofecoxib)	SS				
			Dhea	SS		ORAL	50 MG DAILY	
						ORAL		
			Aspegic	C				
			Phakan	C				
			Ideos	C				
			Tanakan	C				
			Chondrosulf	C				
			Cardentiel	C				
			Hyzaar	C				
			Cryogest	C				

Atepedene	C
Vitamins A C E	C
Cozaar	C
Rocephine	C
Tavanic	C

Date:01/07/02ISR Number: 3849820-2Report Type:Direct Company Report #CTU 158580
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 50mg Merck	PS	Merck	ORAL	50MG DAILY	
Hospitalization -	Thrombosis							
Initial or Prolonged								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/02ISR Number: 3850189-8Report Type:Direct Company Report #CTU 158555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx Merck	PS	Merck	ORAL	QD ORAL	
Initial or Prolonged	Haemorrhage		Aspirin 81mg Bayer	SS	Bayer	ORAL	81MG QD ORAL	

Date:01/07/02ISR Number: 3850444-1Report Type:Direct Company Report #CTU 158529
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck	ORAL	QD ORAL	
Initial or Prolonged	Haemorrhage		Aspirin	SS	Bayer	ORAL	81MG QD ORAL	

Date:01/08/02ISR Number: 3849269-2Report Type:Expedited (15-DaCompany Report #WAES 01111226
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Coumadin	C				
Initial or Prolonged								

Date:01/08/02ISR Number: 3849757-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA01384
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:01/08/02ISR Number: 3849758-0Report Type:Expedited (15-DaCompany Report #WAES 01111159
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Blood Pressure Systolic							
	Decreased	Other	Elavil	C				
	Diverticulitis		Levoxyl	C				
	Gastrointestinal Haemorrhage		Norvasc	C				
			Rowasa	C				
			Aspirin	C				

Date:01/08/02ISR Number: 3849777-4Report Type:Expedited (15-DaCompany Report #WAES 01117524
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Tab Rofecoxib	PS		ORAL	PO	

Date:01/08/02ISR Number: 3849840-8Report Type:Expedited (15-DaCompany Report #WAES 01081790
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 50 Mg	PS			50 MG/DAILY/	
	Confusional State	Professional	Toprol Xl Tablets 25					
	Dizziness	Company	Mg	SS			1) 25	
	Drug Toxicity	Representative					MG/HS/UNK;	
	Feeling Abnormal						2) 50	
	Heart Rate Decreased						MG/HS/UNK	
	Influenza		Estrogens					
	Nausea		(Unspecified)	C				
	Syncope							

Date:01/08/02ISR Number: 3849843-3Report Type:Expedited (15-DaCompany Report #WAES 01110854
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:01/08/02ISR Number: 3849845-7Report Type:Expedited (15-DaCompany Report #WAES 01120286
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	1) 25	
Hospitalization -	Cardiac Failure	Professional					MG/DAILY/PO;	
Initial or Prolonged	Decreased Activity						2) 50	

Other Hypertension
MG/DAILY/PO

Oedema Peripheral Diuretic
Ventricular Arrhythmia (Unspecified) C

Date:01/08/02ISR Number: 3850102-3Report Type:Expedited (15-DaCompany Report #WAES 01125539
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG DAILY	
Initial or Prolonged		Professional					PO	
		Other	Supp Diclofenac Na	SS		RECTAL	100 MG/DAILY	
						RECT	1	DAY
			Methimazole	C				
			Phenprocoumon	C				

Date:01/08/02ISR Number: 3850105-9Report Type:Expedited (15-DaCompany Report #WAES 01106034
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Aortic Valve Incompetence
Hospitalization -	Arteriosclerotic
Initial or Prolonged	Retinopathy
	Atherosclerosis
	Coronary Artery Stenosis
	Ejection Fraction
	Decreased
	Hypotension

	Malaise Mitral Valve Incompetence Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Hypertrophy	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY PO
		Other	Leflunomide	C			
			Prednisone	C			
			Tramadol Hcl	C			

Date:01/08/02ISR Number: 3850108-4Report Type:Direct Company Report #CTU 158590
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Oedema		Vioxx (25mg)	PS		ORAL	25MG DAILY ORALLY
			Actos	C			
			Lipitor	C			
			Aspirin	C			
			Centrum Vit	C			

Date:01/08/02ISR Number: 3850116-3Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06105
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Face Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	1 DOSE/DAILY 8 DAY
			Cap Omeprazole	SS		ORAL	10 MG/DAILY 8 DAY

Date:01/08/02ISR Number: 3850211-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA02467
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Maxzide	C				
			Plavix	C				
			Zantac	C				

Date:01/08/02ISR Number: 3850213-2Report Type:Expedited (15-DaCompany Report #WAES 01102623
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acidosis
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Blood Chloride Decreased
	Blood Culture Positive
	Blood Potassium Increased
	Blood Sodium Decreased
	Blood Thyroid Stimulating Hormone Increased
	Cardiomegaly
	Diabetes Mellitus
	Dialysis
	Echocardiogram Abnormal
	Electrocardiogram Abnormal

		Electrocardiogram T Wave Inversion					
		Epistaxis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Faecaloma	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Gait Disturbance	Health				
MG/DAILY/PO							
		Gallbladder Disorder	Professional	Glucophage Unk	SS		
1000							
		Hypokalaemia					
MG/BID/UNK							
		Hypoxia		Avapro	C		
		Malaise		Flexeril	C		
		Pallor		Rinatec	C		
		Pneumonia Aspiration		Synthroid	C		
		Pulmonary Oedema					
		Renal Failure Acute					
		Scoliosis					
		Sinus Tachycardia					
		Staphylococcal Infection					
		Supraventricular Extrasystoles					
		Tricuspid Valve Incompetence					
		White Blood Cell Count Increased					

Date:01/08/02ISR Number: 3850244-2Report Type:Expedited (15-DaCompany Report #WAES 01115523
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Blister Cutaneous Vasculitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY							
		Livedo Reticularis					
PO							
		Rheumatoid Factor Positive		Digitoxin	C		
				Enalapril Maleate	C		
				Omeprazole	C		
				Sotalol Hydrochloride	C		
				Torsemide	C		

Date:01/08/02ISR Number: 3850856-6Report Type:Expedited (15-DaCompany Report #WAES 00067514
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	PO
			Candesartan Cilexetil	C				
			Cyproterone Acetate (+) Estradiol Valera	C				
			Levothyroxine Na	C				
			Valerian	C				

Date:01/08/02ISR Number: 3850888-8Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06099
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Coordination Abnormal
	Headache

	Somnolence Tinnitus Vertigo	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY 15 DAY
			Acetaminophen	C			
			Atorvastatin Calcium	C			
			Prazepam	C			
			Sulpiride	C			
			Zolpidem Tartrate	C			

Date:01/08/02ISR Number: 3850907-9Report Type:Expedited (15-DaCompany Report #WAES 0112BEL07518
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY
Other		Professional	Aspirin	C			
			Pravastatin Na	C			
			Telmisartan	C			

Date:01/09/02ISR Number: 3849640-9Report Type:Expedited (15-DaCompany Report #WAES 01115659
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
Initial or Prolonged	Hypertensive Crisis		Isosorbide Dinitrate	C		ORAL	
Disability	Transient Ischaemic Attack		Theophylline	C		ORAL	
			Budesonide And Formoterol Fumarate	C		ORAL	
			Cholecalciferol	C		ORAL	
			Fosamax	C		ORAL	
			Celecoxib	C		ORAL	125 DAY

Date:01/09/02ISR Number: 3849641-0Report Type:Expedited (15-DaCompany Report #WAES 01125524
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/09/02ISR Number: 3851084-0Report Type:Direct Company Report #CTU 158828
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rectal Haemorrhage		Vioxx (25 Mg Tab)	PS				
			Atenolol	C				
			Felodipine	C				
			Cilostazol	C				

Date:01/10/02ISR Number: 3850996-1Report Type:Direct Company Report #CTU 158755
Age:52 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Occlusion		Vioxx (25mg)	PS		ORAL	25MG 1/DAY PO	
	Myocardial Infarction							
	Pain							

Date:01/10/02ISR Number: 3851103-1Report Type:Expedited (15-DaCompany Report #046-0945-M0100018
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased	Foreign Consumer	Neurontin Tablets (Gabapentin)	PS		ORAL	2400 MG (DAILY), PER ORAL	
Other	Blood Potassium Increased							
	Cardiac Failure							
	Chest Pain		Furosemide	SS		ORAL	40 MG (DAILY), PER ORAL	
	Depressed Level Of Consciousness							
	Electroencephalogram Abnormal		Spironolactone	SS		ORAL	50 MG (DAILY), PER ORAL	
	Infected Skin Ulcer							
	Liver Disorder		Enalapril Maleate	SS		ORAL	20 MG (DAILY), PER ORAL	
	Liver Function Test Abnormal							
	Metabolic Disorder		Rofecoxib	SS		ORAL	25 MG (DAILY), PER ORAL	
	Renal Failure Acute							
	Skin Ulcer							

	Weight Increased	Metronidazole	SS	ORAL 800 MG (DAILY), PER ORAL
		Flucloxacillin Sodium	SS	ORAL PER ORAL
		Leflunomide	SS	ORAL 20 MG (DAILY), PER ORAL
		Folic Acid, Calcium Phosphate	C	
		Tocopheryl Acetate	C	
		Paracetamol	C	
		Prednisolone	C	
		Morphine	C	
		Cisapride	C	
		Cetirizine	C	
		Morphine Sulfate	C	
		Lansoprazole	C	
		Zolpidem Tartrate	C	
		Loperamide	C	
		Calcium Carbonate	C	
		Combivent (Ipratropium Bromide, Salbutamol Sulfate)	C	

Date:01/10/02ISR Number: 3851435-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01647
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Electroencephalogram

		Abnormal Transient Ischaemic Attack					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Tab Vioxx 25 Mg/12.5 Mg	PS		ORAL
SEE IMAGE							
				Premarin	C		
				Prozac	C		

Date:01/10/02ISR Number: 3851437-0Report Type:Expedited (15-DaCompany Report #WAES 01113172
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Lower Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
Hospitalization -	Haemorrhage	Professional	Bumex	C		
Initial or Prolonged	Myocardial Infarction	Company	Darvocet-N	C		
	Upper Gastrointestinal	Representative	Elavil	C		
	Haemorrhage		Isorbid	C		
			Kaon	C		
			Lamisil	C		
			Norvasc	C		
			Paxil	C		
			Synthroid	C		
			Aspirin	C		
			Calcium (Unspecified) (+)			
			Vitami	C		

Date:01/10/02ISR Number: 3851438-2Report Type:Expedited (15-DaCompany Report #WAES 01120940
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Congestive	Professional				
MG/DAILY/PO						
Initial or Prolonged	Pleural Effusion		Celebrex	C		
	Weight Increased		Fosamax	C		
			Os-Cal D	C		

			Paxil	C		

Date:01/10/02ISR Number: 3851439-4Report Type:Expedited (15-DaCompany Report #WAES 01120943
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	1) 12.5 MG/DAILY/PO;	
Hospitalization - Initial or Prolonged	Congestive	Professional					2) 25 MG/DAILY/PO	
Other	Dyspepsia							
	Fluid Overload							
	Weight Increased		Ecotrin	C				
			K-Dur	C				
			Lasix (Furosemide)	C				
			Ferrous Sulfate	C				

Date:01/10/02ISR Number: 3851440-0Report Type:Expedited (15-DaCompany Report #WAES 01120910
Age:85 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:01/10/02ISR Number: 3851441-2Report Type:Expedited (15-DaCompany Report #WAES 01100552
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Enzymes Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Chest Discomfort	Professional						
	Chest Pain		Motrin	C				
	Coronary Artery Thrombosis		Atenolol	C				
	Dyspnoea							
	Myocardial Infarction							

Date:01/10/02ISR Number: 3851651-4Report Type:Expedited (15-DaCompany Report #2001086222FR
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo Vomiting	Foreign Health	Cytotec (Misoprostol) Tablet	PS		ORAL	200 UG, QD, ORAL	
		Professional						
		Other	Dhea(Prasterone)	SS		ORAL	50MG/DAY, ORAL	
			Sermion(Nicergoline)	SS				
			Ciflox(Ciprofloxacin)	SS				
			Rofecoxib(Rofecoxib)	SS		ORAL	ORAL	
			Aspegic	C				

Phakan (Aminoacetic Acid, Glutamic Acid)	C
Ideos	C
Atepadine (Adenosine Phosphate, Sodium Salt)	C
Tanakan	C
Bisoprolol (Bisoprolol)	C
Hyzaar	C
Vitamins	C
Kliogest (Norethisterone Acetate)	C

Date:01/10/02ISR Number: 3851698-8Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06062
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vertigo	Foreign	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Vomiting	Health	Nicergoline	SS		ORAL	PO	
		Professional	Ciprofloxacin					
		Other	Hydrochloride	SS		ORAL	PO	
			Misoprostol	SS		ORAL	PO	
			Hyzaar	C				
			Aspirin Lysine	C				

				Bisoprolol	C		
				Gingko Biloba Extract	C		
				Prasterone	C		

Date:01/10/02ISR Number: 3851699-XReport Type:Expedited (15-DaCompany Report #WAES 01108577
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Dilatation	Foreign	Vioxx	PS		ORAL	25 MG/DAILY,	
Hospitalization -	Pulmonary Oedema	Health					PO	
Initial or Prolonged		Professional	Estrogens Conjugated	C				
		Other	Paroxetine Hcl	C				

Date:01/10/02ISR Number: 3851700-3Report Type:Expedited (15-DaCompany Report #WAES 01066026
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash	Foreign	Tab Vioxx					
Initial or Prolonged	Renal Impairment	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
		Professional						
PO							1	DAY
		Other	Fluindione	C				
			Irbesartan	C				
			Piretanide	C				

Date:01/10/02ISR Number: 3851728-3Report Type:Expedited (15-DaCompany Report #WAES 0112ESP09133
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aplasia Pure Red Cell	Foreign	Tab Vioxx					
Hospitalization -	Aplastic Anaemia	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged								
PO								

Date:01/10/02ISR Number: 3852148-8Report Type:Direct Company Report #CTU 158939
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx 25 Mg By Merck	PS	Merck	ORAL	25 MG ONCE PO QD	
	Glossodynia							
	Mouth Ulceration							

Date:01/11/02ISR Number: 3851135-3Report Type:Expedited (15-DaCompany Report #WAES 01112369
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Pulmonary Oedema
Hospitalization - Initial or Prolonged	Blood Creatinine Decreased
	Blood Ph Increased
	Blood Pressure Systolic Increased
	Blood Urea Decreased
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly

		Chest Pain					
		Diarrhoea					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pco2 Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
		Po2 Decreased		Estrogens			
		Thyroid Neoplasm		(Unspecified)	C		
				Synthroid	C		
				Lipitor	C		
				Atenolol	C		
				Vitamin E	C		
				Calcium			
				(Unspecified)	C		
				Prevacid	C		

Date:01/11/02ISR Number: 3851139-0Report Type:Expedited (15-DaCompany Report #WAES 01102188
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aortic Valve Sclerosis		Lanoxin	SS		ORAL
Initial or Prolonged		Atrial Fibrillation		Rythmol	C		ORAL
		Bradycardia		K-Dur	C		ORAL
		Dilatation Atrial		Neurontin	C		ORAL
		Dizziness		Betapace	C		
		Drug Toxicity		Vicodin Tablets	C		
		Dyspnoea		Ambien	C		
		Electrocardiogram St-T		Vitamin E	C		
		Change		Ascorbic Acid	C		
		Mitral Valve Incompetence		Vitamins			
		Renal Failure		(Unspecified)	C		
		Renal Impairment					
		Sick Sinus Syndrome					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					

Date:01/11/02ISR Number: 3851800-8Report Type:Expedited (15-DaCompany Report #WAES 01111226
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Coumadin	C				

Date:01/11/02ISR Number: 3851801-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA00138
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	PO	
	Sudden Death							

Date:01/11/02ISR Number: 3851802-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA00380
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acidosis	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Blood Creatinine Increased	Professional Company	Celebrex	SS				
	Blood Urea Increased	Representative						

Date:01/11/02ISR Number: 3851803-3Report Type:Expedited (15-DaCompany Report #WAES 0112USA02378
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Congestive Cardiomyopathy	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged	Pulmonary Oedema	Professional Company Representative	Cardizem Cd	C				
			Coumadin	C				
			Evista	C				
			Lipitor	C				
			Miacalcin	C				

Date:01/11/02ISR Number: 3851825-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA00124
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Colonic Polyp	Health	Ecotrin	C				
	Dyspnoea	Professional	Lasix (Furosemide)	C				
	Faeces Discoloured		Nitro-Bid	C				
	Gastric Polyps		Norvasc	C				
	Haemoglobin Decreased		Atenolol	C				
	Haemorrhage		Glyburide	C				

Date:01/11/02ISR Number: 3851826-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00205
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis	Consumer	Tab Vioxx 25 Mg	PS			25 MG/DAILY	
	Nausea							

Date:01/11/02ISR Number: 3851827-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA00207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Impaired Healing	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Advair	C				
			Celexa	C				
			Evista	C				
			Prevacid	C				
			Furosemide	C				
			Lorazepam	C				
			Theophylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/02ISR Number: 3851856-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01264
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Evista	C				
			Flexeril	C				
			Pepcid Ac	C				

Date:01/11/02ISR Number: 3851970-1Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Decreased	Consumer	Vioxx	PS		ORAL	25 MG/DAILY;	
Hospitalization -	Blood Pressure Decreased	Health Professional					PO	
Initial or Prolonged	Bundle Branch Block		Lasix	SS			40 MG/BID/	
	Cardiac Disorder		Ativan	C				
	Cardiac Failure		Claritan	C				
	Congestive		Deltasone	C				
	Cardio-Respiratory Arrest		Flonase	C				
	Cardiomegaly		K-Dur	C				
	Chest Pain		Nitropatch	C				
	Condition Aggravated		Paxil	C				
	Coronary Artery Occlusion		Pepcid	C				
	Fall		Plavix	C				
	Haematocrit Decreased		Ritalin	C				
	Headache		Zocor	C				
	Heart Rate Decreased		Alprazolam	C				
	Lethargy		Aspirin	C				
	Movement Disorder		Atenolol	C				
	Neutrophil Count		Captopril	C				
	Decreased		Carbidopa(+)					
	Oxygen Saturation		Levodopa	C				
	Decreased		Clonazepam	C				
	Pallor		Codeine	C				
	Pulmonary Oedema		Ibuprofen	C				
	Respiratory Distress		Methylphenidate	C				

	Syncope		Nitroglycerin	C
	Tachycardia		Quinine	C
	White Blood Cell Count Increased			

Date:01/11/02ISR Number: 3851980-4Report Type:Expedited (15-DaCompany Report #WAES 01115660
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Epistaxis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Melaena	Professional	Tab Diclofenac	SS		ORAL	100 MG	
	Petechiae Thrombocytopenia		Estradiol Valerate (+) Estriol (+) Levon	C				
			Hydrochlorothiazide (+) Irbesartan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/02ISR Number: 3851981-6Report Type:Expedited (15-DaCompany Report #WAES 01098253
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	4 DAY
Other	Gastrointestinal		Tab Nimesulide	SS		ORAL	100 MG/1X	1 DAY
	Haemorrhage		Tab Phenprocoumon	SS		ORAL	PRN	
	Prothrombin Time Prolonged							

Date:01/11/02ISR Number: 3852101-4Report Type:Expedited (15-DaCompany Report #WAES 0201ITA00005
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis Acute	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization - Initial or Prolonged		Other					PO	
			Cap Hctz / Spironolactone	SS		ORAL	25/25 MG/ BID	
							PO	17 DAY
			Tab Zofenopril Calcium	SS		ORAL	30 MG/DAILY	
							PO	12 DAY

Date:01/11/02ISR Number: 3852106-3Report Type:Expedited (15-DaCompany Report #WAES 0112ESP09136
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					

Hospitalization - Pulmonary Oedema Other (Rofecoxib) PS ORAL
25 MG/DAILY
Initial or Prolonged Renal Impairment
PO 22 DAY
Tab Calcium
Carbonate (+)
Cholecalciferol SS ORAL
1

TABLET/DAILY

PO 22 DAY
Albuterol Sulfate C
Amlodipine C
Cinitapride C
Fluticasone
Propionate (+)
Salmeterol Xi C
Omeprazole C
Prednisone C

Date:01/11/02ISR Number: 3852108-7Report Type:Expedited (15-DaCompany Report #WAES 0112CHL00005
Age:82 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Life-Threatening Gastric Ulcer Haemorrhage Foreign Tab Vioxx
Hospitalization - Other (Rofecoxib) PS ORAL
25 MG/DAILY
Initial or Prolonged
PO 6 DAY
Indapamide C
Losartan Potassium C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/02ISR Number: 3852109-9Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06103
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Blood Creatine Phosphokinase Increased Blood Pressure Systolic Increased Confusional State Hallucination, Visual Headache Insomnia Logorrhoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 83 DAY

Date:01/11/02ISR Number: 3852139-7Report Type:Direct Company Report #CTU 158932
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx 25 Mg	PS		ORAL	25 MG QD ORAL	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haematochezia		Aspirin 81 Mg	SS		ORAL	81 MG QD ORAL	

Date:01/14/02ISR Number: 3852343-8Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00007
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	100 DAY
			Aspirin	C				
			Azathioprine	C				

			Isosorbide Mononitrate	C		

Date:01/14/02ISR Number: 3852345-1Report Type:Expedited (15-DaCompany Report #WAES 01115659
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY 15 DAY						
Disability	Facial Paresis	Professional	Fosamax	C		
	Hypertensive Crisis	Other	Budesonide (+)			
	Transient Ischaemic Attack		Formoterol Fumarate	C		
			Celecoxib	C		
			Cholecalciferol	C		
			Isosorbide Dinitrate	C		
			Theophylline	C		

Date:01/14/02ISR Number: 3852633-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA00710
Age:80 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG	
	Hyponatraemia	Professional					DIALY/PO	
	Inappropriate Antidiuretic Hormone Secretion	Company Representative	Therapy Unspecified	C				

Date:01/14/02ISR Number: 3852889-2Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Hospitalization - Initial or Prolonged	Dyspnoea	Health Professional						
	Hyperventilation							
	Hypoaesthesia							
	Nausea							
	Respiratory Alkalosis							

Date:01/14/02ISR Number: 3852916-2Report Type:Expedited (15-DaCompany Report #WAES 0112NLD03710
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	TAB VIOXX (ROFECOXIB) PO	

Date:01/14/02ISR Number: 3852920-4Report Type:Expedited (15-DaCompany Report #WAES 01125524
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Macular Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:01/15/02ISR Number: 3853023-5Report Type:Expedited (15-DaCompany Report #WAES 01105545
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	White Blood Cell Count Decreased		Aspirin	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		
			Ramipril	C		ORAL		
			Sitosterols	C		ORAL		

Date:01/15/02ISR Number: 3853024-7Report Type:Expedited (15-DaCompany Report #WAES 01127505
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

26 DAY

Date:01/15/02ISR Number: 3853175-7Report Type:Direct Company Report #CTU 159214
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 50 Mg	PS			5 MG PER DAY	
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/15/02ISR Number: 3853176-9Report Type:Direct Company Report #CTU 159215
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Post Procedural		Vioxx	PS			1 A DAY	
Hospitalization - Initial or Prolonged	Complication							
	Pulmonary Thrombosis							
Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis							

Date:01/15/02ISR Number: 3853252-0Report Type:Expedited (15-DaCompany Report #WAES 01112369
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Cardiac Failure	Professional						
	Congestive	Company	Lipitor	C				
	Cardiomegaly	Representative	Prevacid	C				
	Chest Pain		Synthroid	C				
	Condition Aggravated		Atenolol	C				
	Diarrhoea		Calcium	C				
	Fluid Retention		Estrogens	C				

	Mitral Valve Incompetence	Vitamin E	C
	Oedema		
	Post Procedural		
	Complication		
	Thyroid Neoplasm		

Date:01/15/02ISR Number: 3853269-6Report Type:Expedited (15-DaCompany Report #WAES 01102188
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Prerenal Failure
Hospitalization -	Aortic Valve Incompetence
Initial or Prolonged	Aortic Valve Sclerosis
	Arrhythmia
	Supraventricular
	Atrial Fibrillation
	Bradycardia
	Dilatation Atrial
	Dizziness
	Dyspnoea
	Mitral Valve Incompetence
	Renal Impairment
	Supraventricular

	Extrasystoles Tachycardia Therapeutic Agent Toxicity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Extrasystoles	Health	Tab Vioxx 25 Mg	PS		ORAL	25
	Ventricular Hypertrophy	Professional					MG/DAILY/PO
	Ventricular Hypokinesia	Company	Tab Lanoxin 0.25 Mg	SS		ORAL	0.25
		Representative					MG/DAILY/PO
			Ambien	C			
			Betapace	C			
			K-Dur	C			
			Neurontin	C			
			Rythmol	C			
			Vicodin Tablets	C			
			Ascorbic Acid	C			
			Vitamin E	C			
			Vitamins (Unspecified)	C			

Date:01/15/02ISR Number: 3853271-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00581
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Ulcer	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO
Initial or Prolonged			L-Thyroxin	C			

Date:01/15/02ISR Number: 3853394-XReport Type:Direct Company Report #CTU 159308
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Depression		Volterin 75mg	PS		ORAL	ORAL
Hospitalization -	Eating Disorder		Celebrex	SS			
Initial or Prolonged	Gastrointestinal Disorder		Vioxx 25mgs	SS			
Disability	Scar						
Other							

Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:01/15/02ISR Number: 3853449-XReport Type:Expedited (15-DaCompany Report #WAES 0201FRA00021
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Diverticulum	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	12 DAY
	Rectal Haemorrhage		Powd Aspirin Lysine	SS		ORAL	100 MG/DAILY	
			Acetaminophen	C			PO	
			Amiodarone Hydrochloride	C				
			Benserazide Hydrochloride (+) Levodopa	C				
			Furosemide	C				
			Lercanidipine Hydrochloride	C				
			Melilot	C				
			Molsidomine	C				

				Nitroglycern	C		
				Pipemidic Acid Trihydrate	C		
				Triemtazidine Hydrochloride	C		

Date:01/15/02ISR Number: 3853557-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA00592
Age:95 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged			Flomax (Tamsulosin Hydrochloride)	C				
			Plavix	C				
			Proscar	C				
			Protonix	C				
			Synthroid	C				

Date:01/15/02ISR Number: 3853558-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA00513
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Perforation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Haematochezia							
	Haemorrhage		Coumadin	C				
			Cozaar	C				
			Lasix (Furosemide)	C				
			Cortisone	C				

Date:01/16/02ISR Number: 3853941-8Report Type:Direct Company Report #CTU 159367
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Renal Failure Acute		Vioxx 25 Mg Qd	PS		ORAL
25 MG QD PO						
Initial or Prolonged			Altace 10 Mg Qd	SS		ORAL
10 MG QD PO						

Date:01/17/02ISR Number: 3853399-9Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Heparin	SS		
	Myocardial Infarction		Prednisolone	C		
			Methotrexate	C		
			[Therapy			
			Unspecified]	C		

Date:01/17/02ISR Number: 3853400-2Report Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Aplastic Anaemia
	Asthenia
	Cardiac Murmur

	Leukopenia						
	Oral Discomfort						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Urinary Tract Infection		Acetaminophen	C		ORAL		
			Ibuprofen	C		ORAL		
			Timoptic	C				
OPHTHALMIC								
			Amoxicillin	C		ORAL		
			Aceclofenac	C		ORAL		
			Hidrosmin	C		ORAL		
			Glucosamine Sulfate	C				
			Pepcid	C				

Date:01/17/02ISR Number: 3853401-4Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
30 DAY								
Initial or Prolonged	Chest Pain		Allopurinol	C				
Disability	Hemianopia							
Other	Hypertension							
	Thrombotic Stroke							
	Visual Disturbance							

Date:01/17/02ISR Number: 3854012-7Report Type:Direct Company Report #CTU 159492
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx-Mg25-Merck	PS	Merck			
1 DAILY								
Initial or Prolonged	Antisocial Behaviour							
Disability	Chest Discomfort							
	Convulsion							
	Depression							
	Disturbance In Attention							
	Headache							
	Insomnia							
	Social Avoidant Behaviour							

Suicidal Ideation
Tinnitus

Date:01/17/02ISR Number: 3854182-0Report Type:Expedited (15-DaCompany Report #WAES 01095585
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Foreign	Tab Vioxx					
Hospitalization -	First Degree	Company	(Rofecoxib)	PS		ORAL	PO	30 DAY
Initial or Prolonged	Cardiac Failure	Representative						
	Cardiomegaly							
	Encephalopathy							
	Face Oedema							
	Headache							
	Supraventricular							
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/17/02ISR Number: 3854932-3Report Type:Expedited (15-DaCompany Report #WAES 0112USA01201
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Cerebrovascular Accident	Professional						
Initial or Prolonged	Hemiplegia	Company	Effexor Xr	C				
Disability		Representative	Premarin	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:01/17/02ISR Number: 3854935-9Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/PO	
Hospitalization -	Arrhythmia	Professional						
Initial or Prolonged	Cardiac Arrest	Company	Bumex	C				
	Culture Stool Positive	Representative	Cozaar	C				
	Dizziness		Klor-Con	C				
	Duodenal Ulcer		Lanoxin	C				
	Electrocardiogram		Lasix (Furosemide)	C				
	Abnormal		Lotensin	C				
	Gastrointestinal Disorder		Premarin	C				
	Gastrointestinal		Aspirin	C				
	Haemorrhage		Prednisone	C				
	Head Injury							
	Heart Rate Increased							
	Hypotension							
	Loss Of Consciousness							
	Syncope							
	Thrombosis							

Date:01/17/02ISR Number: 3854984-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00618
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:01/17/02ISR Number: 3854986-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00697
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Diarrhoea Lethargy Nausea Pain Rectal Haemorrhage Vomiting	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:01/17/02ISR Number: 3854990-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA01374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Myocardial Infarction	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Taba Vioxx	PS		ORAL
PO						

Date:01/17/02ISR Number: 3855041-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA00729
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Rectal Haemorrhage	Consumer	Tab Vioxx 25mg	PS		ORAL
25						
Initial or Prolonged	Urinary Incontinence					
MG/DAILY/PO						
			Lachydrin	C		
			Miralax	C		
			Norvasc	C		
			Prilosec	C		
			Aspirin	C		

Date:01/17/02ISR Number: 3855042-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA00640
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Colonic Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
Initial or Prolonged						

Date:01/17/02ISR Number: 3855073-1Report Type:Expedited (15-DaCompany Report #WAES 01090709
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Drug Effect Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
Other	Oedema Peripheral	Professional				
PO						
			Celebrex	C		

Date:01/17/02ISR Number: 3855086-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00038
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria Wheezing	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG, PO	4 DAY
		Professional	Temazepam	C				
		Other	Terbinafine	C				

Date:01/17/02ISR Number: 3855092-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Cardiac Failure Congestive	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG, PO	7 DAY
	Fluid Retention	Professional	Zocor	C				
		Other	Furosemide	C				
			Levothyroxine	C				

Date:01/18/02ISR Number: 3854105-4Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypercoagulation		Effexor	C				
	Mitral Valve Prolapse		Zoloft	C				
			Elavil	C				

Date:01/18/02ISR Number: 3854171-6Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Distress Syndrome		Paxil	C				
	Deep Vein Thrombosis		Xanax	C				
	Gangrene		Estrogens					
	International Normalised		(Unspecified)	C				
	Ratio Increased		[Therapy					
	Lung Neoplasm Malignant		Unspecified]	C				
	Pulmonary Embolism							

Date:01/18/02ISR Number: 3854244-8Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Headache		Gemfibrozil	C				
	Hypertensive Crisis							
	Transient Ischaemic Attack							

Date:01/18/02ISR Number: 3854245-XReport Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged	Asthenia	Acetaminophen	C	ORAL
	Cardiac Murmur	Ibuprofen	C	ORAL
	Leukopenia	Timoptic	C	
OPHTHALMIC				
	Oral Discomfort	Amoxicillin	C	ORAL
	Pallor	Aceclofenac	C	ORAL
	Tachycardia	Hidrosmin	C	ORAL
	Thrombocytopenia	Glucosamine Sulfate	C	ORAL
	Urinary Tract Infection	Pepcid	C	ORAL

Date:01/18/02ISR Number: 3854248-5Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
Hospitalization - Initial or Prolonged	Thromboplastin Time
	Prolonged
	Anaemia
	Asthenia
	Faeces Discoloured
	Gastritis
	Gastrointestinal

		Haemorrhage Haematochezia Hiatus Hernia White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
MON							
				[Therapy Unspecified]	C		
				Xanax	C		
				Premarin	C		
				Tenormin	C		
				Norvasc	C		
				Lasix (Furosemide)	C		
				Os-Cal + D	C		
				Ms Contin	C		
				Vicodin Es Tablets	C		
				Aspirin	C		

Date:01/18/02ISR Number: 3854251-5Report Type:Expedited (15-DaCompany Report #WAES 01114270
Age:0 DY Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Bradycardia Foetal		Vioxx	PS	Merck & Co., Inc	
2	DAY						
Congenital Anomaly		Caesarean Section		Vioxx	SS		
7	DAY						
		Complications Of Maternal Exposure To Therapeutic Drugs Congenital Anomaly Congenital Bowing Of Long Bones Congenital Brain Damage Duodenal Atresia Foetal Disorder Hydrocephalus Intestinal Obstruction Lower Limb Deformity Maternal Drugs Affecting Foetus Multiple Cardiac Defects Pregnancy Talipes					

Date:01/18/02ISR Number: 3855789-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA00377
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:01/18/02ISR Number: 3855804-0Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00026
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	1 DOSE/DAILY PO	4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/02ISR Number: 3855867-2Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00030
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/TID	13 DAY
			Tab Clopidogrel Bisulfate	SS		ORAL	75 MG/DAILY	4 DAY

Date:01/18/02ISR Number: 3855869-6Report Type:Expedited (15-DaCompany Report #WAES 01105545
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia White Blood Cell Count Decreased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Aspirin	C				
			Isosorbide Dinitrate	C				
			Ramipril	C				
			Sitosterols	C				

Date:01/18/02ISR Number: 3855873-8Report Type:Expedited (15-DaCompany Report #WAES 01127505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO; 12.5 MG/DAILY	26 DAY

Date:01/18/02ISR Number: 3855874-XReport Type:Expedited (15-DaCompany Report #WAES 0112CAN08539
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	
			Calcium Carbonate (+) Etidronate Sodium	C				

Date:01/18/02ISR Number: 3855875-1Report Type:Expedited (15-DaCompany Report #WAES 0201PRT00002
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Diarrhoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	1 DAY
			Lornoxicam	SS		ORAL	8 MG/BID PO	3 DAY
			Lornoxicam	SS		ORAL	8MG/1X	3 DAY

Date:01/18/02ISR Number: 3855876-3Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00034
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY PO	
			Albuterol	C				

Amlodipine Besylate	C
Fluticasone Propionate (+)	
Salmeterol Xi	C
Zolpidem Tartrate	C

Date:01/21/02ISR Number: 3854416-2Report Type:Expedited (15-DaCompany Report #304687
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Stevens-Johnson Syndrome	Foreign	Dormicum	PS	Roche	
START DATE						
PRIOR TO 27						
NOV 2000.						
			Konakion	SS	Roche	
START DATE						
PRIOR TO 27						
NOV 2000.						
			Panthenol	SS	Roche	
START DATE						
PRIOR TO 27						
NOV 2000.						
ONGOING ON 25						
DEC 2000.						
			Heparin	SS	Roche	
			Arterenol	SS		
1 DAY						
			Osmofundin	SS		
1 DAY						
			Theophyllin	SS		
START DATE						
PRIOR TO 27						
NOV 2000.						

	Indometacin	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Eufibron	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Dopacard	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Nutritional Supplement	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Nimotop	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Fentanyl	SS	Roche
START DATE			
PRIOR TO 27			
NOV 2000.			
	Luminal	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Ketanest	SS	
START DATE			
PRIOR TO 27			
NOV 2000.			
	Cordanum	SS	
START DATE			
PRIOR TO 27			

NOV 2000.

START DATE

PRIOR TO 27

NOV 2000.

START DATE

PRIOR TO 27

Bifiteral	SS
Pipril	SS

NOV 2000.

START DATE

PRIOR TO 27

NOV 2000.

ONGOING ON 25

DEC 2000.

Combactam	SS
Human Insulin	SS
Mucosolvan	SS
Prednisolut	SS
Hydergin	SS
Intralipid	SS
Ulcogant	SS

ONGOING ON 25 DEC 2000.	Cerucal	SS	
START DATE PRIOR TO 27 NOV 2000.	Addel	SS	
START DATE PRIOR TO 27 NOV 2000.	Osmotan	SS	
START DATE PRIOR TO 27 NOV 2000.	Furesis	SS	
	Inzolen	SS	
	Aminophyllin	SS	
25 DAY	Vitalipid	SS	
	Soluvit	SS	
	Vioxx	SS	
25 DAY	Multivitamin	SS	Roche
23 DAY	Paracefan	SS	
	Aminoplasmal	SS	
	Pavulon	SS	
4 DAY	Pyridostigmine Bromide	SS	Roche
13 DAY	Furesis Comp	SS	
19 DAY	Ampho Moronal	SS	
12 DAY	Paracetamol	SS	Roche
16 DAY	Fenistil	SS	
	Espumisan	SS	
ONGOING ON 25 DEC 2000.	Sinophenin	SS	
1 DAY			

		Berlosin	SS
1	DAY		
		Diflucan	SS
6	DAY		
		Aspisol	SS
1	DAY		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/02ISR Number: 3854596-9Report Type:Expedited (15-DaCompany Report #WAES 01102443
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Tolerance Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Effexor	C				

Date:01/21/02ISR Number: 3854597-0Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 30 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Allopurinol	C				
Disability	Feeling Abnormal		Vitamins					
Other	Hemianopia Homonymous		(Unspecified)	C				
	Hypertension							
	Thinking Abnormal							

Date:01/21/02ISR Number: 3854598-2Report Type:Expedited (15-DaCompany Report #WAES 01111157
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 9 DAY	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Avandia	C		ORAL		
	Congestive		Vasotec	C		ORAL		
	Chest Pain							
	Dyspnoea Exertional							
	Oedema Peripheral							
	Sensation Of Pressure							
	Weight Increased							

Date:01/21/02ISR Number: 3854609-4Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00054
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Depressed Level Of		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Consciousness		Vioxx	SS		ORAL
	Impaired Driving Ability					
	Orthostatic Hypotension					

Date:01/21/02ISR Number: 3854612-4Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00036
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Disability			Vioxx	SS		ORAL	169	DAY

Date:01/21/02ISR Number: 3854614-8Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00026
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	431	DAY
Initial or Prolonged	Cardiac Failure		Zopiclone	C				
			Acetylcysteine	C				
			Terbutaline Sulfate	C				
			Acetaminophen And Codeine Phosphate	C				

			Lansoprazole	C		
			Tolterodine Tartrate	C		
			Fluticasone Propionate And Salmeterol Xinafoate	C		

Date:01/21/02ISR Number: 3854619-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/02ISR Number: 3855195-5Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00050
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON
			Pravastatin Sodium	C		ORAL		
			Nitrendipine	C		ORAL		
			Acetaminophen	C		ORAL		
			Diosmin	C		ORAL		

Date:01/22/02ISR Number: 3855201-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Rash Erythematous Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/02ISR Number: 3855204-3Report Type:Expedited (15-DaCompany Report #WAES 0112USA02467
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged	Duodenal Ulcer		Zantac	C				
Other	Hiatus Hernia		Plavix	C				
	Melaena		Maxzide	C				
	Oesophageal Stenosis		Catapres	C				
	Upper Gastrointestinal Haemorrhage		Darvocet-N	C		ORAL		

Date:01/22/02ISR Number: 3855501-1Report Type:Expedited (15-DaCompany Report #WAES 0112USA01647
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Electroencephalogram Abnormal		Vioxx	SS		ORAL		
			Vioxx	SS		ORAL		
	Transient Ischaemic Attack		Premarin	C				
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3855502-3Report Type:Expedited (15-DaCompany Report #WAES 01105545
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		
			Ramipril	C		ORAL		
			Sitosterols	C		ORAL		

Date:01/22/02ISR Number: 3855503-5Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00049
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Acetaminophen	C		ORAL		
			Oxazepam	C		ORAL		
			[Therapy Unspecified]	C				

Date:01/22/02ISR Number: 3855504-7Report Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8	WK
	Drug Ineffective		Vioxx	SS		ORAL	1	WK
			Motrin	C				
			Lotensin	C				
			Lipitor	C				
			Paxil	C				
			Norvasc	C				
			Atenolol	C				
			Zyrtec	C				
			Ambien	C				
			Prevacid	C				
			Vicodin Tablets	C		ORAL		
			Plavix	C				

Date:01/22/02ISR Number: 3855506-0Report Type:Expedited (15-DaCompany Report #WAES 0201AUT00006
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisolone	SS				
			Phenprocoumon	C				

Date:01/22/02ISR Number: 3855507-2Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00138
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	126 DAY	
Hospitalization - Initial or Prolonged	Perforation		Vioxx	SS		ORAL	84 DAY	
			Albuterol	C			RESPIRATORY (INHALATION)	
			Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)	
			Acetaminophen And					

		Codeine Phosphate	C
		Lactulose	C
		Senna	C

Date:01/22/02ISR Number: 3855508-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA01207
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Coumadin	C				
Initial or Prolonged	Swelling							
	Tongue Haemorrhage							

Date:01/22/02ISR Number: 3855509-6Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	69	DAY
Hospitalization -	Cerebrovascular Accident		Prempro	C				
Initial or Prolonged			Lasix (Furosemide)	C				
Disability			Slow-K	C				
			Levoxyl	C				
			Imdur	C				
			Synthroid	C				
			Accupril	C				
			Mobic	C				
							2	WK

Date:01/22/02ISR Number: 3855511-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA01976
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Congestive							

Date:01/22/02ISR Number: 3855512-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		53 DAY
Initial or Prolonged								

Date:01/22/02ISR Number: 3855513-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Haematochezia		[Therapy					
	Malaise		Unspecified]	C				
	Wrist Fracture							

Date:01/22/02ISR Number: 3856100-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01819
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3856101-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
			Daypro	C				
			Avandia	C				

Date:01/22/02ISR Number: 3856102-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA01821
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diplopia		Coumadin	C				
	Dizziness		Aspirin	C				
	Fatigue		Zestril	C				
	Haemorrhage Intracranial		Norvasc	C				
			Digoxin	C				
			Tricor	C				
			Hydrocodone	C				
			Glucophage	C				
			Lipitor	C				
			Atenolol	C				
			Desyrel	C				
			Vitamins (Unspecified)	C				

Date:01/22/02ISR Number: 3856950-8Report Type:Direct Company Report #CTU 159696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Vioxx 25 Mg Tabs					
	Blood Creatinine		Merck	PS	Merck			
25 MG QD								
	Increased		Pepcid	C				
	Blood Potassium Increased							
	Renal Failure Acute							

Date:01/22/02ISR Number: 3857636-6Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:01/22/02ISR Number: 3857711-6Report Type:Expedited (15-DaCompany Report #WAES 01075012
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Helicobacter Infection	Professional						
			Loperamide	C			PO	191 DAY
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3857713-XReport Type:Expedited (15-DaCompany Report #WAES 01085616
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Foreign	Tab Vioxx					
	Arrhythmia	Health	(Rofecoxib)	PS		ORAL	25 MG/BID PO	2 MON
	Hypertension	Professional	Ascorbic Acid (+)					
	Tachycardia		Aspirin	C				
			Hops (+) Passiflora					
			(+) Valerian	C				
			Hyaluronate Sodium	C				
			Ibuprofen Lysine	C				
			Magnesium	C				
			Pantoprazole Sodium	C				
			Sodium Fluoride	C				

Date:01/22/02ISR Number: 3857735-9Report Type:Expedited (15-DaCompany Report #WAES 0201ZAF00004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscle Atrophy	Foreign	Tab Vioxx					
Initial or Prolonged	Muscular Weakness		(Rofecoxib)	PS		ORAL	PO	
	Myopathy		Zocor	C				
			Aspirin	C				
			Furosemide Sodium	C				
			Metformin Hcl	C				
			Potassium (Unspecified)	C				
			Ramipril	C				

Date:01/22/02ISR Number: 3857737-2Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00012
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	C-Reactive Protein		(Rofecoxib)	PS		ORAL	12.5	

Increased
MG/DAILY; PO 29 DAY
Diarrhoea Haemorrhagic

Aspirin	C
Estriol	C
Furosemid	C
Ibuprofen	C

Date:01/22/02ISR Number: 3857739-6Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00039
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL
			Dietary Supplement (Unspecified)	SS		ORAL
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Estrogens, Conjugated	C		

Dose Duration
12.5
MG/DAILY; PO
PO 2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3857740-2Report Type:Expedited (15-DaCompany Report #WAES 01075012
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Helicobacter Infection	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY; PO	191 DAY
			Loperamide	C				
			Temazepam	C				

Date:01/22/02ISR Number: 3857951-6Report Type:Expedited (15-DaCompany Report #WAES 0201NLD00013
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
	Blood Creatine Phosphokinase Increased		Folic Acid	C				
	Myocardial Infarction		Vitamin A	C				
			Viamin E	C				
			Zolpidem Tartrate	C				
			Zopiclone	C				

Date:01/22/02ISR Number: 3857955-3Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00039
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Atrial Fibrillation	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
Disability	Electrocardiogram						9	DAY
	Repolarisation Abnormality							
	Heart Rate Increased							
	Heart Rate Irregular							

Sick Sinus Syndrome
Sinoatrial Block
Supraventricular
Extrasystoles
Tricuspid Valve
Incompetence

Date:01/22/02ISR Number: 3857957-7Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lower Gastrointestinal	Foreign	Tab Vioxx					
Life-Threatening	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional						
			Tab Phenprocoumon	SS		ORAL	PO	
			Buprenorphine Hcl	C				
			Calcium Carbonate					
			(-) Cholecalciferol	C				
			Melperone Hcl	C				
			Paroxetine Hcl	C				

Date:01/22/02ISR Number: 3857960-7Report Type:Expedited (15-DaCompany Report #WAES 0201CHE00003
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Humerus Fracture	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	PO

Date:01/22/02ISR Number: 3858104-8Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06084
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Bullous Face Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY
	Leukocytosis		Calcium Carbonate	C				
	Pyrexia		Fenofibrate	C				
	Toxic Skin Eruption		Irbesartan	C				
			Levothyroxine Na	C				

Date:01/22/02ISR Number: 3858175-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA00786
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage Pneumonia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Imdur	C				
			Lasix (Furosemide)	C				
			Toprol Xl Tablets	C				
			Potassium	C				

Date:01/22/02ISR Number: 3858193-0Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Initial or Prolonged	Blood Pressure Increased	Professional					PO	
Disability	Chest Pain	Company	Allopurinol	C				
Other	Hemianopia Homonymous	Representative						
	Thrombotic Stroke							
	Visual Disturbance							

Date:01/22/02ISR Number: 3858222-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00885
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haematochezia						MG/DAILY/PO	
	Headache		Catapres Tts	C				
	Nausea		Darvocet-N	C				
	Oedema Peripheral		Levoxyl	C				
	Vomiting		Premarin	C				
			Theo-Dur	C				

Date:01/22/02ISR Number: 3858265-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA01018
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Condition Aggravated	Health					MG/DAILY/PO	
	Electrocardiogram T Wave	Professional	Blinded Therapy	SS		ORAL	PO	
	Abnormal							
	Ileus Paralytic							
	Nausea							
	Urticaria							

Date:01/22/02ISR Number: 3858284-4Report Type:Expedited (15-DaCompany Report #PHEH2002US00582
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Lamisil (Terbinafine					
	Migraine	Professional	Hydrochloride)					
	Palpitations		Tablet	PS		ORAL	250	
	Vision Blurred							
							MG,QD,ORAL	
			Vioxx (Rofecoxib	SS				

Date:01/22/02ISR Number: 3858298-4Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Foreign	Tab Vioxx					
	Complications Of Maternal	Consumer	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	2 YR
	Exposure To Therapeutic							
	Drugs							
	Maternal Drugs Affecting							
	Foetus							
	Pregnancy							

Date:01/22/02ISR Number: 3858599-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01207
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Haemorrhage	Professional						
Initial or Prolonged	Swelling	Company	Coumadin	C				
	Tongue Haemorrhage	Representative						

Date:01/22/02ISR Number: 3858671-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00377
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional						
		Company Representative						

Date:01/22/02ISR Number: 3858673-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative	[Therapy Unspecified]	C				

Date:01/22/02ISR Number: 3858691-XReport Type:Expedited (15-DaCompany Report #WAES 01051780
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Hernia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Anaemia	Professional Company Representative						
Other	Arthralgia		Allegra	C				
	Aspiration Pleural Cavity Abnormal		Correctol (Docusate Sodium)	C				
	Diabetes Mellitus		Glucophage	C				
	Inadequate Control		Aspirin	C				
	Duodenal Ulcer		Glyburide	C				
	Ileus Paralytic							
	Joint Effusion							
	Lung Infiltration							
	Oedema Peripheral							
	Platelet Count Decreased							
	Tachycardia							
	Upper Gastrointestinal Haemorrhage							
	Venous Stasis							

Date:01/22/02ISR Number: 3858955-XReport Type:Expedited (15-DaCompany Report #WAES 0112FRA06103
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Foreign	Tab Vioxx					

Initial or Prolonged	Blood Creatine	Other	(Rofecoxib)	PS			ORAL
25 MG/DAILY							
	Phosphokinase Increased						
PO	83 DAY						
	Confusional State						
	Hallucination, Visual						
	Headache						
	Insomnia						

Date:01/22/02ISR Number: 3858956-1Report Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aplasia Pure Red Cell	Foreign	Tab Vioxx			
Initial or Prolonged	Aplastic Anaemia	Other	(Rofecoxib)	PS		ORAL
25 MG/PRN PO						
	Asthenia		Pepcid	C		
	Cardiac Murmur		Timoptic	C		
	Condition Aggravated		Aceclofenac	C		
	Leukopenia		Acetaminophen	C		
	Oral Pain		Amoxicillin	C		
	Tachycardia		Glucosamine Sulfate	C		
	Thrombocytopenia		Hidrosmin	C		
	Urinary Tract Infection		Ibuprofen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/02ISR Number: 3858957-3Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Myocardial Infarction		Heparin (Therapy Unspecified)	SS				
			Methotrexate	C				
			Prednisolone	C				

Date:01/22/02ISR Number: 3858959-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:01/23/02ISR Number: 3856106-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA03016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Right		Atenolol	C		ORAL		
	Chest Pain		Glucosamine	C		ORAL		
	Chronic Obstructive Airways Disease Exacerbated		Zantac	C		ORAL		
			Vitamins (Unspecified)	C		ORAL		
	Constipation		Vitamin B Complex	C		ORAL		
	Duodenal Ulcer		Ascorbic Acid	C		ORAL		
	Haemorrhage		Garlic Extract	C				
	Faecal Incontinence		Ginkgo Biloba Extract	C		ORAL		
	Gastric Polyps							
	Gastritis Erosive		Calcium (Unspecified)	C		ORAL		
	Hypotension							
	Lethargy		Chromium Polynicotinate	C		ORAL		
	Pallor							

	Reflux Oesophagitis		Medrol Dosepak	C		
			Aspirin	C		
			Vitamin E	C		
			Levaquin	C		
			Flexeril	C		ORAL
			Prednisone	C		
			Darvocet-N	C		

Date:01/23/02ISR Number: 3856107-0Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00032
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 DAY	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypertension		Desmopressin	SS		
	Hyponatraemia		Terbutaline Sulfate	C		
	Nausea		Omeprazole Magnesium	C		
			Budesonide	C		
			Estradiol	C		
			Tibolone	C		
			Karaya Gum	C		
			Cortisone Acetate	C		

			Levothyroxine Sodium	C		
			Vitamin E	C		
			Acetaminophen And Propoxyphene Hydrochloride	C		
			Cisapride	C		
			Aspirin	C		

Date:01/23/02ISR Number: 3856109-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged			Paxil	C				
			Tylenol Extra Strength	C				

Date:01/23/02ISR Number: 3856187-2Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00159
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	46 DAY	
Initial or Prolonged	Haemorrhage							
Other								

Date:01/23/02ISR Number: 3856193-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02041
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Alphagan	C				
Initial or Prolonged			Serevent	C				
			Flovent	C				

Date:01/23/02ISR Number: 3856893-XReport Type:Expedited (15-DaCompany Report #2002-01-0096
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Thalomid					
Hospitalization -	Convulsion		(Thalidomide 50 Mg)					
Initial or Prolonged	Glomerulonephritis		Capsules	PS		ORAL	200 MG/DAY	
	Impaired Gastric Emptying							
	Intracranial Aneurysm		Rofecoxib Tablets	SS		ORAL	ORAL	
	Rash		Lopressor	C				
	Vomiting		Norvasc	C				
			Imdur	C				
			Cardura	C				
			Aspirin	C				
			Lasix	C				
			Pepcid	C				
			Duragesic	C				
			Lortab	C				
			Reglan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/02ISR Number: 3858197-8Report Type:Direct Company Report #CTU 159767
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Behaviour		Vioxx	PS	Merck		MG25	1 DAILY
Initial or Prolonged	Anorexia							
Disability	Chest Discomfort							
	Convulsion							
	Depression							
	Disturbance In Attention							
	Insomnia							
	Sensation Of Pressure							
	Suicidal Ideation							
	Tinnitus							

Date:01/23/02ISR Number: 3858705-7Report Type:Expedited (15-DaCompany Report #WAES 0112BEL07521
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alanine Aminotransferase	Foreign	Tab Vioxx					
Hospitalization -	Increased	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Aplastic Anaemia	Professional						
PO	34 WK							
	Aspartate		Cetirizine					
	Aminotransferase		Hydrochloride	C				
	Increased		Fluticasone					
	Bilirubin Conjugated		Propionate	C				
	Increased		Nadroparin	C				
	Blood Alkaline		Omeprazole	C				
	Phosphatase Increased		Salmeterol Xinafoate	C				
	Blood Bilirubin Increased		Zafirlukast	C				
	Blood Lactate							
	Dehydrogenase Increased							
	Chest X-Ray Abnormal							
	Haemolytic Anaemia							
	Hypotension							
	Musculoskeletal Stiffness							
	Photophobia							
	Platelet Count Decreased							
	Subarachnoid Haemorrhage							
	White Blood Cell Count							

Decreased

Date:01/23/02ISR Number: 3859325-0Report Type:Expedited (15-DaCompany Report #WAES 01120914
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Distress Syndrome	Professional	Paxil	C				
	Deep Vein Thrombosis	Company	Xanax	C				
	Gangrene	Representative	Estrogens (Unspecified)	C				
	International Normalised Ratio Abnormal							
	Lung Neoplasm Malignant							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/02ISR Number: 3859383-3Report Type:Expedited (15-DaCompany Report #WAES 01110732
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Effexor	C				
			Elavil	C				
			Zoloft	C				

Date:01/23/02ISR Number: 3859384-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA02091
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Glycogen Storage Disease	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Type V	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemodialysis	Company						
Disability	Renal Failure Acute	Representative						
Other	Rhabdomyolysis							

Date:01/23/02ISR Number: 3859385-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA02870
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	PO	
	Back Pain	Professional						
	Monoplegia							
	Oedema Peripheral							
	Pruritus							

Date:01/23/02ISR Number: 3860008-1Report Type:Direct Company Report #CTU 159884
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus		Vioxx 25 Mg	PS			25 MG	ONCE A DAY

Date:01/24/02ISR Number: 3857008-4Report Type:Expedited (15-DaCompany Report #WAES 01119005
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorectal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Diarrhoea							

Date:01/24/02ISR Number: 3857012-6Report Type:Expedited (15-DaCompany Report #WAES 01105086
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL	59	DAY
Other			Acetaminophen And Codeine Phosphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/02ISR Number: 3857014-XReport Type:Expedited (15-DaCompany Report #WAES 01127801
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Large Intestinal Ulcer		Aspirin	C				
			Hydrochlorothiazide And Valsartan	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Nicorandil	C		ORAL		

Date:01/24/02ISR Number: 3858787-2Report Type:Expedited (15-DaCompany Report #001-0981-M0109542
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bone Marrow Disorder	Consumer	Atorvastatin					
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Health	(Atorvastatin)	PS		ORAL	20 MG DAILY, PER ORAL	
	Haemorrhage	Professional						
Other	Mobility Decreased		(Rofecoxib)	SS		ORAL	25 MG (TWICE DAILY), PER ORAL	
	Pain							
	Pain In Extremity							
	Platelet Count Decreased		(Paroxetine Hydrochloride)	SS				
	Red Blood Cell Count Decreased		(Zolpidem Tartrate)	C				
	Systemic Lupus Erythematosus		(Hyoscyamine Sulfate)	C				
	T-Cell Lymphoma		(Propoxyphen)	C				
			(Toprol)	C				
			(Prednisone)	C				
			(Rabeprazole Sodium)	C				
			(Hyoscyamine)	C				
			(Aetylsalicylic Acid)	C				

Date:01/24/02ISR Number: 3858857-9Report Type:Expedited (15-DaCompany Report #WAES 01114270
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bradycardia Foetal	Consumer	Tab Vioxx 50 Mg	PS		TRANSPLACENTAL	50 MG/BID/PO	
Congenital Anomaly	Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Congenital Hydrocephalus Congenital Intestinal Malformation Foetal Disorder Heart Disease Congenital Limb Malformation Maternal Drugs Affecting Foetus Pregnancy Respiratory Tract Malformation Talipes	Health Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/02ISR Number: 3859015-4Report Type:Expedited (15-DaCompany Report #WAES 01100037
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Asthenia	Health						
Initial or Prolonged	Diverticulum Intestinal	Professional	Lasix (Furosemide)	C				
	Gastritis		Ms Contin	C				
	Gastrointestinal		Norvasc	C				
	Haemorrhage		Os-Cal + D	C				
	Haemorrhoids		Premarin	C				
	Hiatus Hernia		Tenormin	C				
	Melanosis Coli		Vicodin Es Tablets	C				
			Xanax (Therapy Unspecified)	C				
			Aspirin	C				

Date:01/24/02ISR Number: 3860183-9Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -	Headache	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Hypertensive Crisis	Professional	Gemfibrozil	C				

Date:01/24/02ISR Number: 3860184-0Report Type:Expedited (15-DaCompany Report #WAES 01119121
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aplastic Anaemia	Foreign	Tab Vioxx					
Hospitalization -	Oral Discomfort	Health	(Rofecoxib)	PS		ORAL	25 MG/PRN PO	
Initial or Prolonged	Oral Pain	Professional	Pepcid	C				
	Urinary Tract Infection	Company	Timoptic	C				
		Representative	Aceclofenac	C				
			Acetaminophen	C				
			Amoxicillin	C				

Glucosamine Sulfate	C
Hidrosmin	C
Ibuprofen	C

Date:01/24/02ISR Number: 3860186-4Report Type:Expedited (15-DaCompany Report #WAES 0112ESP09133
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aplastic Anaemia	Foreign Company Representative	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:01/24/02ISR Number: 3860192-XReport Type:Expedited (15-DaCompany Report #2001061170SE
Age:79 YR Gender:Female I/FU:I

Outcome	PT
Death	Acidosis
	Alanine Aminotransferase Increased
	Aortic Atherosclerosis
	Aortic Valve Stenosis
	Arrhythmia

		Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Alkaline Phosphatase Increased	Foreign Health Professional	Spirolakton Nm Pharma(Spirolactone) Tablet, 50mg	PS		
50 MG, QD							
		Blood Glucose Increased	Other	Cardizem Retard (Diltiazem, Diltiazem) Tablet, Extended Release	SS		
		Blood Lactate Dehydrogenase Increased					
		Blood Pressure Decreased					
0.27 G, QD							
		Blood Sodium Decreased		Rofecoxib (Rofecoxib) 12.5 Mg	SS		
		Bradycardia					
12.5 MG, QD							
		Cardiac Arrest		Sotalol (Sotalol)	SS		
80 MG, QD							
		Cardiac Failure		Paracetamol	C		
		Cold Sweat		Calcium	C		
		Creatine Urine Increased		Colecalciferol	C		
		Dizziness		Antifoam Trinitrate	C		
		Glomerular Filtration		Flunitrazepam	C		
		Rate Decreased		Simvastatin (Simvastatin)	C		
		Haemoglobin Decreased					
		Hepatic Enzyme Increased		Isosorbide Mononitrate	C		
		Hyperkalaemia					
		Kidney Small		Acetylsalicylic Acid	C		
		Pulmonary Congestion		Etidronate Disodium	C		
		Renal Arteriosclerosis					
		Renal Failure					
		Renal Function Test Abnormal					

Date:01/24/02ISR Number: 3861963-6Report Type:Periodic Company Report #2001USA01327
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia	Health	Plavix	PS		ORAL
75 MG QD PO						
Initial or Prolonged	Gastrointestinal	Professional	Vioxx	SS		ORAL
25 MG QD PO						
	Haemorrhage	Company Representative	Synthroid	C		
			Lasix	C		

			K-Dur	C		
			Cardura	C		
			Tiazac	C		
			Zestril	C		
			Prevacid	C		
			Chromagen	C		

Date:01/24/02ISR Number: 3861964-8Report Type:Periodic Company Report #2001USA01328
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Plavix	PS		ORAL
75 MG QD PO						
Initial or Prolonged	Gastrointestinal	Professional	Vioxx	SS		ORAL
25 MG QD PO						
	Haemorrhage	Company	Visken	C		
	Haematemesis	Representative	Fosamax	C		
			Aspirin	C		
			Zyloprim	C		
			Maxzide	C		

Date:01/25/02ISR Number: 3857976-0Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00166
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea Increased		Vioxx	PS	Merck & Co., Inc	ORAL		503 DAY
Initial or Prolonged	Haemoglobin Decreased		Aspirin	SS		ORAL		48 DAY
	Melaena		Furosemide	C		ORAL		
			Prochlorperazine Maleate	C		ORAL		
			Ursodiol	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		
			Fenoterol Hydrobromide And Ipratropium Bromide	C				
RESPIRATORY (INHALATION)								

Date:01/25/02ISR Number: 3857982-6Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00138
Age:75 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		126 DAY
Hospitalization -	Perforation		Vioxx	SS		ORAL		84 DAY
Initial or Prolonged			Albuterol	C				
RESPIRATORY (INHALATION)								
			Beclomethasone Dipropionate	C				
RESPIRATORY (INHALATION)								
			Acetaminophen And Codeine Phosphate	C				
			Lactulose	C				
			Senna	C				

Date:01/25/02ISR Number: 3857985-1Report Type:Expedited (15-DaCompany Report #WAES 0201GRC00004
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Life-Threatening	Pulmonary Embolism		Glimepiride	C				
Hospitalization - Initial or Prolonged	Renal Failure		Metformin Hydrochloride	C				
			Gemfibrozil	C				
			Allopurinol	C				
			Piracetam	C				
			Cilazapril	C				

Date:01/25/02ISR Number: 3857987-5Report Type:Expedited (15-DaCompany Report #WAES 0201ESP00029
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		601 DAY

Date:01/25/02ISR Number: 3857994-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				

Atacand	C
Flovent	C
Combivent	C
Zoloft	C
Coreg	C
Plavix	C
Aspirin	C
Vitamin E	C

Date:01/25/02ISR Number: 3860372-3Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00050
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 17 MON
			Acetaminophen	C				
			Diosmin	C				
			Nitrendipine	C				
			Pravastatin Na	C				

Date:01/25/02ISR Number: 3860376-0Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00017
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Eczema Epistaxis Pyrexia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				23 DAY

Date:01/25/02ISR Number: 3860598-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA01495
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Chest Pain	Health	Tab Vioxx	PS		ORAL
PO						
		Professional	Coumadin	C		

Date:01/25/02ISR Number: 3860599-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00828
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety	Consumer	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Cardiac Failure					
Disability	Congestive					
	Stress					

Date:01/25/02ISR Number: 3860600-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00837
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Epistaxis		Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Accupril	C		
			Premarin	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/02ISR Number: 3860601-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA01163
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adenocarcinoma	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Anaemia Haemolytic	Health Professional						
	Autoimmune							
	Haemorrhage							
	Headache							
	Metastasis							
	Neck Pain							
	Paraesthesia							

Date:01/25/02ISR Number: 3860602-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01250
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:01/25/02ISR Number: 3860606-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA01496
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Clinoril	C				
			Motrin	C				
			Voltaren	C				

Date:01/25/02ISR Number: 3860613-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA02467
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
Other	Hiatus Hernia	Company	Catapres	C		
	Oesophageal Stenosis	Representative	Darvocet-N	C		
			Maxzide	C		
			Plavix	C		
			Zantac	C		

Date:01/25/02ISR Number: 3860614-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA01017
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain	Study	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Gastritis	Health	Blinded Therapy	C		
	Gastrointestinal	Professional				
	Haemorrhage					
	Post Procedural					
	Complication					

Date:01/25/02ISR Number: 3860771-XReport Type:Expedited (15-DaCompany Report #WAES 01111157
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Chest Pain	Other	Avandia	C				
	Weight Increased		Vasotec	C				

Date:01/25/02ISR Number: 3860918-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00083
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Mouth Ulceration	Foreign	Tab Vioxx					
	Rash Generalised	Health	(Rofecoxib)	PS		ORAL	12.5	
		Professional					MG/DAILY, PO	7 DAY
		Other	Beclomethasone					
			Dipropionate	C				
			Nabumetone	C				

Date:01/25/02ISR Number: 3860919-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00054
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Foreign	Tab Vioxx					
Other	Depressed Level Of	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Consciousness	Professional					PO	
	Orthostatic Hypotension	Other						

Date:01/25/02ISR Number: 3860921-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00036
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Foreign	Vioxx	PS		ORAL	1 DOSE/DAILY,	
Disability		Health					PO	10 DAY
		Professional						
		Other						

Date:01/25/02ISR Number: 3860924-0Report Type:Expedited (15-DaCompany Report #WAES 01085616
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Foreign	Tab Vioxx					
	Anxiety Disorder	Health	(Rofecoxib)	PS		ORAL	25 MG/BID PO	2 MON
	Arrhythmia	Professional	Ascorbic Acid (+)					
	Hypertension		Aspirin	C				
	Tachycardia		Hops (+) Passiflora					
			(+) Valerian	C				
			Hyaluronate Sodium	C				
			Ibuprofen Lysine	C				
			Magnesium (Unspecified)	C				
			Pantoprazole Sodium	C				
			Sodium Fluoride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/02ISR Number: 3860937-9Report Type:Expedited (15-DaCompany Report #WAES 01085616
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder	Foreign	Tab Vioxx					
	Arrhythmia	Health	(Rofecoxib)	PS		ORAL	25 MG/BID PO	2 MON
	Hypertension	Professional	Ascorbic Acid (+)					
	Tachycardia		Aspirin	C				
			Hops (+) Passiflora					
			(+) Valerian	C				
			Hyaluronate Sodium	C				
			Ibuprofen Lysine	C				
			Magnesium					
			(Unspecified)	C				
			Pantoprazole Sodium	C				
			Sodium Fluoride	C				

Date:01/25/02ISR Number: 3860944-6Report Type:Expedited (15-DaCompany Report #WAES 01088623
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Foreign	Tab Vioxx					
Life-Threatening	Coronary Artery Embolism	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Embolic Stroke						PO	
Initial or Prolonged	Hemiplegia		Cyclobenzaprine Hcl	C				
Disability			Raloxifene	C				

Date:01/25/02ISR Number: 3860958-6Report Type:Expedited (15-DaCompany Report #WAES 01037335
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Hospitalization -	Alanine Aminotransferase	Health	Spironolactone	SS		ORAL	50 MG/DAILY	
Initial or Prolonged	Increased	Professional	Diltiazem					

	Aortic Valve Stenosis	Other	Hydrochloride	SS	ORAL 270 MG/DAILY
	Aspartate Aminotransferase Increased		Sotalol Hydrochloride	SS	ORAL 80 MG/DAILY
	Blood Alkaline Phosphatase Increased		Zocor	C	
	Blood Calcium Decreased		Acetaminophen/Propoxyphene Hydrochloride	C	
	Blood Glucose Increased		Aspirin	C	
	Blood Lactate Dehydrogenase Increased		Calcium Carbonate (+) Cholecalciferol	C	
	Blood Pressure Decreased		Etidronate Disodium	C	
	Blood Sodium Decreased		Flunitrazepam	C	
	Bradyarrhythmia		Isosorbide	C	
	Bradycardia		Nitroglycerni	C	
	Cardiac Arrest		Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C	
	Cardiac Failure		Simethicone	C	
	Congestive Condition Aggravated				
	Haemoglobin Decreased				
	Hyperkalaemia				
	Kidney Small				
	Myocardial Infarction				
	Pulmonary Congestion				
	Renal Failure				

Date:01/25/02ISR Number: 3860960-4Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00026
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	431 DAY
Initial or Prolonged	Cardiac Failure Congestive	Health Professional Other	Acetaminophen/Codeine Phosphate	C				
			Acetylcysteine	C				
			Fluticasone Propionate (+) Salmeterol Xi	C				
			Lansoprazole	C				
			Terbutaline Sulfate	C				
			Tolterodine Tartrate	C				
			Zopiclone	C				

Date:01/25/02ISR Number: 3861417-7Report Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	(SEE IMAGE) 76 DAY
	Drug Ineffective							
			Ambien	C				
			Lipitor	C				
			Lotensin	C				
			Motrin	C				
			Norvasc	C				
			Paxil	C				
			Plavix	C				
			Prevacid	C				
			Vicodin Tablets	C				
			Zyrtec	C				
			Atenolol	C				

Date:01/25/02ISR Number: 3861421-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA01647
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx	PS			25	
Initial or Prolonged	Transient Ischaemic						MG/DAILY/PO	
	Attack							
(SEE IMAGE)								
			Premarin	C				
			Prozac	C				

Date:01/25/02ISR Number: 3861422-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Cerebrovascular Accident						MG/DAILY/PO	
Initial or Prolonged			Accupril	C				
			Imdur	C				
			Lasix	C				
			Levoxyl	C				
			Mobic	C				
			Prempro	C				
			Slow-K	C				

				Synthroid	C		

Date:01/25/02ISR Number: 3861431-1Report Type:Expedited (15-DaCompany Report #WAES 01102443
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Tolerance Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Effexor	C				

Date:01/25/02ISR Number: 3861483-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA01251
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Hypoaesthesia	Professional	Vasotec	C				

Date:01/25/02ISR Number: 3861484-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional Company Representative						

Date:01/25/02ISR Number: 3861485-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Rash Pruritic Professional
MG/DAILY/PO

Date:01/25/02ISR Number: 3861493-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA01214
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:01/25/02ISR Number: 3861693-0Report Type:Expedited (15-DaCompany Report #WAES 01105545
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Aspirin	C				
			Isosorbide Dinitrate	C				
			Ramipril	C				
			Sitosterols	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/02ISR Number: 3861694-2Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00049
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	3 MON
			(Therapy Unspecified)	C				
			Acetaminophen	C				
			Oxazepam	C				

Date:01/25/02ISR Number: 3862159-4Report Type:Expedited (15-DaCompany Report #WAES 01120956
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health	Tab Viox 12.5mg	PS		ORAL	12.5 MG/DAILY/PO	
	Cerebral Infarction	Professional						
Disability	Chest Pain	Company Representative	Allopurinol	C				
Other	Hemianopia Homonymous Thrombotic Stroke		Vitamins	C				

Date:01/25/02ISR Number: 3862161-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lipitor	C				
			Norvasc	C				
			Synthroid	C				
			Aspirin	C				

Date:01/25/02ISR Number: 3863129-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01207
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Swelling	Company	Coumadin	C				
	Tongue Haemorrhage	Representative						

Date:01/25/02ISR Number: 3863130-9Report Type:Expedited (15-DaCompany Report #WAES 01092114
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Tinnitus	Health					MG/DAILY/PO	
Disability		Professional	Aspirin	C				

Date:01/25/02ISR Number: 3864287-6Report Type:Expedited (15-DaCompany Report #2001-10-0725
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Adhesions
Initial or Prolonged	Abdominal Pain
	Abnormal Faeces
	Ammonia Increased
	Diarrhoea

	Diverticulitis						
	Dysuria						
	Irritable Bowel Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neurogenic Bladder	Study	Vioxx (Rofecoxib)				
	Neutropenia	Health	Tablets	PS		ORAL	25 MG QD ORAL
	Urinary Retention	Professional	Peg-Intron				
	Urinary Tract Infection		(Peginterferon				
	Vomiting		Alfa-2b) Injectable				
			Powder	SS		SUBCUTANEOUS	150 MCG-UNK/W SUBCUTANEO
			Ribavirin Capsules	SS		ORAL	0.8 GM-UNK QD ORAL
			Neupogen	C			
			Phenergan	C			
			Neurontin	C			
			Ativan	C			
			Lactulose	C			
			Dilantin	C			
			Ambien (Zolpidem Tartrate)	C			
			Vitamin E	C			
			Vitamin C	C			
			Multivitamins	C			
			Topamax	C			
			Demerol	C			
			Imodium	C			
			Diovan	C			

Date:01/28/02ISR Number: 3858798-7Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
	Myocardial Infarction		Relafen	C			
	Swelling		Celebrex	C			

Date:01/28/02ISR Number: 3858800-2Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00067
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		DAY
Initial or Prolonged	Hyponatraemia		Venlafaxine Hydrochloride	SS		ORAL		

Date:01/28/02ISR Number: 3858804-XReport Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Acute Respiratory
Initial or Prolonged	Distress Syndrome
Disability	Appendix Disorder
	Colitis
	Colon Gangrene
	Colonic Haemorrhage
	Colonic Polyp
	Diverticulum
	Gastrointestinal Disorder

		Ileus Paralytic					
		Intestinal Dilatation					
		Intestinal Perforation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
13	DAY						
		Necrotising Colitis		Vasotec	C		ORAL
		Oedema		Vasotec	C		
		Oliguria		Lipitor	C		
		Purulence		Vasotec	C		ORAL
		Retching		Aspirin	C		
		Septic Shock		Zebeta	C		
		Skin Discolouration					
		Spleen Disorder					

Date:01/28/02ISR Number: 3858805-1Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Faeces Discoloured		Vioxx	PS		ORAL
Initial or Prolonged		Malaise		Fosamax	C	Merck & Co., Inc	ORAL

Date:01/28/02ISR Number: 3858806-3Report Type:Expedited (15-DaCompany Report #WAES 01114637
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Haemorrhage		Advil	C		
Other		Ulcer					

Date:01/28/02ISR Number: 3858808-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
70	DAY						

Hospitalization - 8 DAY	Arthritis	Actonel	SS
Initial or Prolonged Disability	Cardiomyopathy	Klor-Con	C
	Dyspnoea	[Therapy Unspecified]	C
	Ejection Fraction Decreased	Pyridoxine	C
	Embolic Stroke	Fish Oil (Unspecified)	C
	Joint Stiffness	Vitamins (Unspecified)	C
	Myocarditis	Slow-K	C
	Viral Infection	Os-Cal	C
		Imipramine	C
		Lasix (Furosemide)	C
		Prempro	C
		Levoxyl	C
		Imdur	C
		Synthroid	C
		Accupril	C
		Mobic	C

2 WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/02ISR Number: 3858809-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02526
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		271 DAY
	Haemorrhage		Zantac	C				
	Syncope		Doxepin Hydrochloride	C				
			Hydrocodone	C				
			Acetaminophen	C				

Date:01/28/02ISR Number: 3858811-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Myocardial Infarction							
	Oedema Peripheral							

Date:01/28/02ISR Number: 3858813-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA01214
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
	Rectal Haemorrhage							
	Ulcer							

Date:01/28/02ISR Number: 3858814-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01815
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Daypro	C				
			Avandia	C				

Date:01/28/02ISR Number: 3858815-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Calcium (Unspecified)	C				

Date:01/28/02ISR Number: 3858860-9Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11673936
Age:44 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Distension
	Abdominal Pain
	Abdominal Pain Upper
	Arthralgia
	Arthritis
	Back Pain
	Breast Cellulitis
	Cerumen Impaction

		Cervicitis					
		Condition Aggravated					
		Costochondritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Glucophage	PS	Bristol-Myers Squibb	
		Diarrhoea				Company	ORAL
		Dyspareunia		Rezulin	SS		ORAL
		Dyspnoea		Vioxx	SS		ORAL
		Dysuria		Zocor	SS		ORAL
		Fibrocystic Breast					
		Disease					
		Flushing					
		Gastrooesophageal Reflux					
		Disease					
		Goitre					
		Haemorrhoids					
		Headache					
		Hepatic Steatosis					
		Hepatocellular Damage					
		Hyperlipidaemia					
		Hypertension					
		Hypoglycaemia					
		Mastitis					
		Nausea					
		Obesity					
		Otitis Media					
		Pain In Extremity					
		Pharyngitis					
		Pollakiuria					
		Pyrexia					
		Sinusitis					
		Suprapubic Pain					
		Tachycardia					
		Upper Respiratory Tract					
		Infection					
		Vaginal Candidiasis					
		Vaginal Discharge					
		Vaginal Infection					
		Vomiting					

Date:01/28/02ISR Number: 3859049-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 15 DAY	Cerebrovascular Accident	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Transient Ischaemic Attack	Valium	C		
		Fosamax	C		ORAL
		Soma	C		
		Lasix (Furosemide)	C		
		Calcium Carbonate	C		
		L-Thyroxin	C		
		Oxycontin	C		
		Quinine	C		
		Cozaar	C		
		Dilacor Xr	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/02ISR Number: 3859053-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02324
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Thromboplastin Time		Intetrix	C			4	DAY
Initial or Prolonged	Abnormal		Flagyl	C			4	DAY
Disability	Blood Fibrinogen Abnormal		Buscopan	C			7	DAY
Other	Mesenteric Occlusion		Debridat	C			4	DAY
	Portal Vein Thrombosis		Ciprobay	C			8	DAY
			Contralac	C			6	DAY
			Feldene	C			1	DAY
			Zantac	C			1	DAY
			Tarivid	C			1	DAY

Date:01/28/02ISR Number: 3861328-7Report Type:Periodic Company Report #USA 020427
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse	Health	Meridia	PS				
Initial or Prolonged	Somnolence	Professional	Lotronex (Alosetron)	SS				
Required		Other	Phenergan	SS				
Intervention to			Vioxx	SS				
Prevent Permanent			Ultram	SS				
Impairment/Damage			Prozac	SS				
			Prilosec	SS				

Date:01/28/02ISR Number: 3862144-2Report Type:Direct Company Report #CTU 160251
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Mental Impairment		Vioxx(25mg)	PS		
25MG ONCE DAILY 2 WK						

Date:01/28/02ISR Number: 3863716-1Report Type:Expedited (15-DaCompany Report #NSADSS2002001976
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Blood Alkaline Phosphatase Increased	Foreign Study Health Professional	Remicade(5 Mg/Ml Lyophilized Powder)(Infliximab, Recombinant)	PS		
INTRAVENOUS 1 IN 1 DAILY, IV						
			Placebo(Placebo)	SS		
INTRAVENOUS 1 IN 1 DAILY, IV						
			Vioxx(Rofecoxib)	SS		ORAL
25 MG, 1 IN 1 DAILY, ORAL						
			Tramadol Hydrochloride Ir(Tablet)(Tramadol Hydrochloride)	SS		
150 MG, 1 IN 1 DAILY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3859557-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hemianopia Homonymous		Vioxx	PS	Merck & Co., Inc	ORAL		126 DAY
Initial or Prolonged	Transient Ischaemic		Acetaminophen And					
Other	Attack		Codeine Phosphate	C		ORAL		

Date:01/29/02ISR Number: 3859558-3Report Type:Expedited (15-DaCompany Report #WAES 01127512
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paraesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/02ISR Number: 3859559-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00228
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		24 DAY
Initial or Prolonged	Haemoglobin Decreased		Anastrozole	C				
			Morphine	C				
			Omeprazole	C				
			Cyclizine	C				
			Quinine	C				
			Temazepam	C				
			Medroxyprogesterone Acetate	C				

Date:01/29/02ISR Number: 3859560-1Report Type:Expedited (15-DaCompany Report #WAES 01105563
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY

	Pruritus		Vioxx	SS		ORAL
1 DAY						
	Urticaria		Diclofenac	C		
PARENTERAL						

Date:01/29/02ISR Number: 3859561-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02655
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis		Vioxx	SS		ORAL
	Peptic Ulcer		Aspirin And			
	Upper Gastrointestinal		Oxycodone			
	Haemorrhage		Hydrochloride	C		ORAL
15 YR						
			Omeprazole	C		
			Clonazepam	C		

Date:01/29/02ISR Number: 3859565-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3859882-4Report Type:Expedited (15-DaCompany Report #WAES 01118615
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Incomplete		Vioxx	PS	Merck & Co., Inc			
	Drug Interaction		Ethinyl Estradiol					
	Hydrops Foetalis		And Norgestimate	SS				
			Flexeril	SS				

Date:01/29/02ISR Number: 3859885-XReport Type:Expedited (15-DaCompany Report #WAES 01125533
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL		474 DAY
	Increased							
	Condition Aggravated							
	Dyspnoea							
	Pulmonary Embolism							
	Pulmonary Hypertension							

Date:01/29/02ISR Number: 3859886-1Report Type:Expedited (15-DaCompany Report #WAES 01118615
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Ethinyl Estradiol					
	Haemorrhage		And Norgestimate	SS		ORAL		
	Hydrops Foetalis		Flexeril	SS		ORAL		
	Pregnancy							

Date:01/29/02ISR Number: 3859890-3Report Type:Expedited (15-DaCompany Report #WAES 0201CAN00091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/02ISR Number: 3859893-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02710
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:01/29/02ISR Number: 3859896-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02405
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Clonic Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Grand Mal Convulsion		Coumadin	C				
			Digoxin	C				
			Lasix (Furosemide)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3859897-6Report Type:Expedited (15-DaCompany Report #WAES 0201BEL00011
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aortic Atherosclerosis		Prasterone	SS		ORAL		
Other	Atherosclerosis		Aspirin	C		ORAL		
	Carotid Artery Stenosis		Cerivastatin	C		ORAL		
	Hypertension							

Date:01/29/02ISR Number: 3859898-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA00513
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Toxicity		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Gastric Ulcer		Coumadin	SS				
	Gastrointestinal		Lasix (Furosemide)	C				
	Haemorrhage		Cortisone	C				
PARENTERAL							1	DAY
	Haematochezia		Cozaar	C		ORAL		
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Oesophageal Ulcer							

Date:01/29/02ISR Number: 3859902-7Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00078
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization -	Haemodialysis		Spironolactone	C		ORAL	900	DAY
Initial or Prolonged	Hyperkalaemia		Perindopril	C		ORAL	900	DAY
	Renal Failure Acute		Cystine	C		ORAL	5	DAY

Date:01/29/02ISR Number: 3861135-5Report Type:Expedited (15-DaCompany Report #WAES 01048107
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Haemorrhage	Foreign	Tab Vioxx					
	Petechiae	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
	Thrombocytopenia		Atenolol/Chlorthalidone	C				
			Lomefloxacin Hydrochloride	C				

Date:01/29/02ISR Number: 3861630-9Report Type:Expedited (15-DaCompany Report #WAES 01081114
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Alcoholic Liver Disease
Hospitalization - Initial or Prolonged	Anaemia
	Ascites
	Blood Alcohol Increased
	Cardio-Respiratory Arrest
	Cholestasis
	Coagulopathy
	Condition Aggravated
	Contusion
	Dehydration
	Diarrhoea

		Encephalopathy					
		Epistaxis					
		Gallbladder Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PRN/PO							
		Hepatic Failure	Health	Claritin	C		
		Hepatic Steatosis	Professional	Keflex	C		
		Hepatitis Alcoholic		Maxalt (Rizatriptan			
		Hepatomegaly		Benzoate)	C		
		Hyponatraemia		Premarin	C		
		Hypotension		Prevacid	C		
		Influenza Like Illness		Questran	C		
		International Normalised		Soma	C		
		Ratio Increased		Ultram	C		
		Mouth Haemorrhage		Vasotec	C		
		Oedema Peripheral		Xanax	C		
		Oesophageal Varices		Zoloft	C		
		Haemorrhage		Lorazepam	C		
		Portal Hypertension					
		Prothrombin Time					
		Prolonged					
		Rectal Haemorrhage					
		Respiratory Arrest					
		Retching					
		Spider Naevus					
		Upper Gastrointestinal					
		Haemorrhage					

Date:01/29/02ISR Number: 3861789-3Report Type:Direct Company Report #CTU 160319
Age:72 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required		Colitis Ischaemic		Vioxx 25 Mg	PS		ORAL
25 MG ONE PO							
Intervention to							
Q D							
Prevent Permanent				Zestril	C		
Impairment/Damage				Aspirin	C		

Date:01/29/02ISR Number: 3861928-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA01815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional	Avandia	C				
			Daypro	C				

Date:01/29/02ISR Number: 3861929-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA01819
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged								

Date:01/29/02ISR Number: 3862049-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02041
Age:82 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Alphagan	C				
			Flovent	C				
			Serevent	C				

Date:01/29/02ISR Number: 3862227-7Report Type:Expedited (15-DaCompany Report #WAES 0201SWE00032
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	8 DAY
	Hypertension							
	Hyponatraemia		Ns Desmopressin	SS				
	Nausea		Acetaminophen/Propoxyphene Hydrochloride	C				
			Aspirin	C				
			Budesonide	C				
			Cisapride	C				
			Cortisone Acetatec	C				
			Estradiol	C				
			Karaya Gum	C				
			Levothyroxine Na	C				
			Omeprazole Magnesium	C				
			Terbutaline Sulfate	C				
			Tibolone	C				
			Vitamin E	C				

Date:01/29/02ISR Number: 3862230-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00138
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Perforation	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5	
Hospitalization -								

Initial or Prolonged
MG/DAILY; 25

MG DAILY; PO 846 DAY

Acetaminophen/Codeine Phosphate	C
Albuterol	C
Beclomethasone Dipropionate	C
Lactulose	C
Senna	C

Date:01/29/02ISR Number: 3862244-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00159
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY Other PO	46 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3862248-4Report Type:Expedited (15-DaCompany Report #WAES 0201AUT00006
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Foreign	Tab Vioxx	PS		ORAL	25 MG DAILY	
Initial or Prolonged		Other					PO	
			Prednisolone	SS				
			Phenprocoumon	C				

Date:01/29/02ISR Number: 3862658-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Fall							
	Haematochezia							
	Wrist Fracture							

Date:01/29/02ISR Number: 3862660-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged							MG/DAILY/PO	

Date:01/29/02ISR Number: 3862662-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA01976
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Congestive	Professional					
MG/DAILY/PO 2 DAY							
		Company Representative					

Date:01/29/02ISR Number: 3862663-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged						
MG/DAILY/PO						
			Paxil	C		
			Tylenol Extra Strength	C		

Date:01/29/02ISR Number: 3862664-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA01821
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diplopia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Dizziness					
PO						
	Fatigue		Coumadin	C		
	Haemorrhage Intracranial		Desyrel	C		
			Glucophage	C		
			Lipitor	C		
			Norvasc	C		
			Tricor	C		
			Zestril	C		

			Aspirin	C		
			Atenolol	C		
			Digoxin	C		
			Hydrocodone	C		
			Vitamins (Unspecified)	C		

Date:01/29/02ISR Number: 3862678-0Report Type:Expedited (15-DaCompany Report #001-0981-M0109332
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Atorvastatin					
	Drug Ineffective	Health	(Atorvastatin)	PS		ORAL	10 MG	
	Fatigue	Professional					(DAILY), PER	
	Groin Pain						ORAL	
	Myocardial Infarction		(Rofecoxib)	SS		ORAL	25 MG	
	Oedema Peripheral						(DAILY), PER	
	Pain In Extremity						ORAL	
	Peripheral Vascular Disorder		(Acetylsalicylic Acid)	C				
			(Tocopherol)	C				
			(Metoprolol)	C				
			(Zinc)	C				
			(Selenium)	C				
			(Serenoa Repens)	C				
			(Asorbic Acid)	C				
			(Ubidecarenone0	C				

Date:01/29/02ISR Number: 3863124-3Report Type:Expedited (15-DaCompany Report #WAES 0112USA03016
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

Initial or Prolonged PO	Bundle Branch Block Right	Professional		
	Chest Pain	Company Representative	Darvocet-N	C
	Chronic Obstructive Airways Disease Exacerbated		Flexeril	C
			Levaquin	C
			Medrol Dosepak	C
	Constipation		Zantac	C
	Dizziness		Ascorbic Acid	C
	Drug Effect Decreased		Aspirin	C
	Duodenal Ulcer		Atenolol	C
	Haemorrhage		Calcium (Unspecified)	C
	Dyspnoea			
	Gastric Polyps		Chromium Polynicotinate	C
	Gastritis Erosive		Garlic Extract	C
	Hypotension		Ginkgo Biloba Extract	C
	Reflux Oesophagitis		Glucosamine	C
			Prednisone	C
			Vitamin B Complex	C
			Vitamin E	C
			Vitamins (Unspecified)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/02ISR Number: 3903540-4Report Type:Periodic Company Report #A130239
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Tikosyn Capsules	PS		ORAL	1.00 MG	
	Rash	Professional					TOTAL:BID:ORA	
	Urticaria						L	
			Clinoril	SS				
			Protonix	SS				
			Vioxx	SS		ORAL	ORAL	
			Cardura	C				
			Lisinopril	C				
			Coumadin	C				

Date:01/30/02ISR Number: 3860251-1Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	41 DAY	
Initial or Prolonged	Increased		Bendroflumethiazide	C				
Disability	Hyponatraemia		Isosorbide					
Other	Inappropriate		Mononitrate	C				
	Antidiuretic Hormone		Bisoprolol	C				
	Secretion		Omeprazole	C				
	Malaise		Acetaminophen And					
	Malignant Pleural		Propoxyphene					
	Effusion		Hydrochloride	C				
	Renal Impairment							
	Vomiting							

Date:01/30/02ISR Number: 3860255-9Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05087
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Increased	Bendroflumethiazide	C	ORAL
Disability	Hyponatraemia	Isosorbide		
Other	Inappropriate	Mononitrate	C	ORAL
	Antidiuretic Hormone	Bisoprolol	C	ORAL
	Secretion	Omeprazole	C	
	Malignant Pleural	Acetaminophen And		
	Effusion	Propoxyphene		
	Nausea	Hydrochloride	C	
	Renal Impairment			
	Vomiting			

Date:01/30/02ISR Number: 3860481-9Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00060
Age:90 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Atrioventricular Block
Initial or Prolonged	First Degree
	Atrophy
	Dyspnoea
	Face Oedema
	Fall
	Generalised Oedema
	Haematuria
	Kidney Enlargement

	Oedema Peripheral						
	Pleural Effusion						
	Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ultrasound Kidney		Vioxx	PS	Merck & Co., Inc	ORAL	134	DAY
	Abnormal		Cyamemazine	C		ORAL		
	Urinary Retention		Aspirin Lysine	C		ORAL		
			Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL		
			Amlodipine	C		ORAL		

Date:01/30/02ISR Number: 3860485-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged	Thrombosis		Ziac	C				

Date:01/30/02ISR Number: 3860486-8Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00210
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	805	DAY
Other	Haemorrhage		Fosamax	C		ORAL		
	Iron Deficiency Anaemia		Aspirin	C		ORAL	162	DAY
	Melaena		Vitamin E Acetate	C		ORAL		
			Ascorbic Acid	C		ORAL		
			Acetaminophen	C		ORAL		

Date:01/30/02ISR Number: 3860487-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00216
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 627 DAY	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Aspirin	SS		ORAL
			Zopiclone	C		ORAL
			Quinine	C		ORAL
			Tamsulosin Hydrochloride	C		ORAL
			Furosemide	C		ORAL
			Isosorbide Mononitrate	C		ORAL
			Betahistine Hydrochloride	C		ORAL

Date:01/30/02ISR Number: 3860489-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 9 DAY	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Aspirin	C		
Other			Calcium (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/02ISR Number: 3860490-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01819
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Infection Phlebitis Superficial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	4 MON	

Date:01/30/02ISR Number: 3862138-7Report Type:Expedited (15-DaCompany Report #WAES 01105086
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Foreign	Tab Vioxx					
Other		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
PO								59 DAY
		Other	Acetaminophen / Codeine Phosphate	C				

Date:01/30/02ISR Number: 3862139-9Report Type:Expedited (15-DaCompany Report #WAES 01127801
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia Large Intestinal Ulcer	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
PO								
		Other	Aspirin	C				
			Atorvastatin Calcium	C				
			Hydrochlorothiazide (+) Valsartan	C				
			Nicorandil	C				

Date:01/30/02ISR Number: 3862321-0Report Type:Expedited (15-DaCompany Report #049-0981-M0200071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Atorvastatin					
	Myositis	Health	(Atorvastatin)	PS		ORAL	PER ORAL	
	Pulmonary Embolism	Professional	(Rofecoxib					
	Pulmonary Hypertension		(Rofecoxib)	SS		ORAL	25 MG	
							(DAILY), PER	
							ORAL	

Date:01/30/02ISR Number: 3862332-5Report Type:Expedited (15-DaCompany Report #WAES 01119005
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorectal Disorder	Foreign	Tab Vioxx					
	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
							PO	1 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/02ISR Number: 3861025-8Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06075
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		113 DAY
	Sudden Death		Flecainide Acetate	C		ORAL		
			Aspirin Lysine	C		ORAL		
			Fenofibrate	C		ORAL		
			Paroxetine	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Uridine 5'-Triphosphate	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		

Date:01/31/02ISR Number: 3861201-4Report Type:Expedited (15-DaCompany Report #WAES 01103401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:01/31/02ISR Number: 3861205-1Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
			Sulfasalazine	C				

Date:01/31/02ISR Number: 3861206-3Report Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged			Lipitor	C		
			[Therapy Unspecified]	C		

Date:01/31/02ISR Number: 3861211-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA00640
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/02ISR Number: 3861213-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA03065
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/02ISR Number: 3862413-6Report Type:Expedited (15-DaCompany Report #00GB-10015
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Foreign	Voltarol (Diclofenac					
Hospitalization -	Cardiac Failure	Health	Sodium) Unknown	PS		ORAL	ORAL	
Initial or Prolonged	Duodenal Ulcer	Professional	Vioxx (Rofecoxib)					
	Haemorrhage	Other	Unknown	SS		ORAL	MG,	
	Gastrointestinal						ONCE/SINGLE,	
	Perforation						ORAL	
	Myocardial Infarction		Warfarin	C				
			Frusemide					
			(Furosemide)	C				
			Atenolol (Atenolol)	C				
			Digoxin	C				

Date:01/31/02ISR Number: 3862770-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Congestive	Professional						
	Myocardial Infarction							
	Oedema Peripheral							

Date:01/31/02ISR Number: 3862771-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Haemorrhage						MG/DAILY/PO	
			Aspirin	C				
			Calcium	C				

Date:01/31/02ISR Number: 3862772-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02526
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Haemorrhage		Zantac	C				
	Syncope		Acetaminophen	C				
			Doxepin Hydrochloride	C				
			Hydrocodone	C				

Date:01/31/02ISR Number: 3862802-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Combivent	C				
			Coreg	C				
			Flovent	C				
			Lipitor	C				
			Plavix	C				

			Zoloft	C		
			Aspirin	C		
			Vitamin E	C		

Date:01/31/02ISR Number: 3862806-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Malaise						MG?DAILY/PO	
			Foamax	C				

Date:01/31/02ISR Number: 3862822-5Report Type:Expedited (15-DaCompany Report #WAES 01100737
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Abdominal Pain	Professional					MG/DAILY/PO	
Initial or Prolonged	Abdominal Pain Lower		Lipitor	C				
Disability	Acute Respiratory		Vasotec	C				
	Distress Syndrome		Zebeta	C				
	Appendix Disorder		Aspirin	C				
	Blood Pressure Decreased							
	Colitis Ulcerative							
	Colon Gangrene							
	Diarrhoea							
	Diverticulum							
	Fibrosis							
	Haemorrhage							
	Ileal Ulcer							
	Ileitis							
	Large Intestine							
	Perforation							
	Necrotising Colitis							
	Oliguria							
	Post Procedural							
	Complication							

Pseudopolyposis
Retching
Septic Shock
Skin Discolouration
Spleen Disorder
White Blood Cell Count
Increased

Date:01/31/02ISR Number: 3862855-9Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00067
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Hyponatraemia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Tab Venlafaxine Hcl	SS		ORAL	75 MG	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/02ISR Number: 3862866-3Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00138
Age:75 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Perforation	Other	(Rofecoxib)	PS		ORAL	12.5	
Initial or Prolonged							MG/DAILY, PO;	
							25 MG/DAILY,	
							PO	846 DAY
			Acetaminophen/Codein					
			e Phosphate	C				
			Albuterol	C				
			Beclomethasone					
			Dipropionate	C				
			Lactulose	C				
			Senna	C				

Date:01/31/02ISR Number: 3862926-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Dyspnoea	Health						
Initial or Prolonged	Ejection Fraction	Professional	Actonel	SS			MG/DAILY/PO	
Disability	Decreased		Accupril	C				
	Embolic Stroke		Imdur	C				
	Facial Paresis		Klor-Con	C				
	Hemiparesis		Lasix (Furosemide)	C				
	Myocarditis		Levoxyl	C				
	Viral Infection		Mobic	C				
			Os-Cal	C				
			Prempro	C				
			Slow-K	C				
			Synthroid	C				
			Therapy Unspecified	C				
			Fish Oil	C				
			Imipramine	C				

			Pyridoxine	C		
			Vitamins	C		

Date:01/31/02ISR Number: 3862937-1Report Type:Expedited (15-DaCompany Report #WAES 01114637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO 3 DAY						
Other		Company Representative	Advil	C		

Date:01/31/02ISR Number: 3862941-3Report Type:Expedited (15-DaCompany Report #001-0945-M0101181
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accidental Exposure
Initial or Prolonged	Bone Pain
	Contusion
	Depressed Level Of Consciousness
	Fall

	Hypoglycaemia Inflammation Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Medication Error Respiratory Rate Increased	Health Professional	Neurontin (Gabapentin)	PS		ORAL	600 MG (BID, PER ORAL
			Vioxx (Rofecoxib)	SS			25 MG (DAILY)
			(Glibenclamide)	SS		ORAL	(ONE DOSE), PER ORAL
			(Methadone)	C			
			Fosamax (Alendronate Sodium)	C			
			Nasal Calcitonin (Calcitonin)	C			
			Paracetamol	C			
			Enalapril	C			

Date:01/31/02ISR Number: 3863068-7Report Type:Expedited (15-DaCompany Report #WAES 0201GRC00004
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Life-Threatening Hospitalization -	Blood Pressure Decreased Erythema Face Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG / DAILY PO 3 DAY
Initial or Prolonged	Hypersensitivity Pruritus Pulmonary Embolism Renal Failure		Allopurinol	C			
			Cilazapril	C			
			Gemfibrozil	C			
			Glimepiride	C			
			Metformin Hcl	C			
			Piracetam	C			

Date:01/31/02ISR Number: 3863072-9Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00166
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Increased Haemoglobin Decreased Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG / DAILY PO	503 DAY
			Aspirin	SS		ORAL	75 MG/DAILY PO	48 DAY
			Citalopram Hydrobromide	C				
			Fenoterol Hydrobromide (+) Ipratropium B	C				
			Furosemide	C				
			Prochlorperazine Maleate	C				
			Ursodiol	C				

Date:01/31/02ISR Number: 3863074-2Report Type:Expedited (15-DaCompany Report #WAES 0201ESP00029
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	601 DAY

Date:01/31/02ISR Number: 3863269-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01815
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Congestive	Professional					PO	
			Avandia	C				
			Daypro	C				

Date:01/31/02ISR Number: 3863272-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01214
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	125 MG DAILY	
Initial or Prolonged	Rectal Haemorrhage						PO	
	Ulcer							

Date:01/31/02ISR Number: 3863273-XReport Type:Expedited (15-DaCompany Report #WAES 01102774
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myocardial Infarction		Celebrex	C				
	Swelling		Relafen	C				

Date:02/01/02ISR Number: 3861623-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00261
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Dibucaine Hydrochloride And					

				Framycetin Sulfate And Hydrocortisone	C		
RECTAL							

Date:02/01/02ISR Number: 3861624-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA01797
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Congestive		Coumadin	C		ORAL
	Ejection Fraction		Coumadin	C		ORAL
	Decreased		Celexa	C		ORAL
	Hepatomegaly		Estrace	C		ORAL
	Liver Function Test		Aspirin	C		ORAL
	Abnormal					
	Pleural Effusion					
	Pulmonary Oedema					
	Rales					

Date:02/01/02ISR Number: 3861626-7Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Arrest	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Myocardial Infarction		Celebrex	C		ORAL		
	Ventricular Fibrillation							

Date:02/01/02ISR Number: 3861628-0Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00229
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY
Hospitalization -	Chills	Professional	Sulfasalazine	SS		ORAL	41	DAY
Initial or Prolonged	Endocarditis		Naproxen	C		ORAL		
	Malaise							
	Neutropenia							
	Neutrophilia							
	Pulse Pressure Increased							
	Pyrexia							

Date:02/01/02ISR Number: 3861860-6Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Provigil	SS		ORAL		
	Dysuria		Amantadine					
	Fall		Hydrochloride	SS				
	Laceration		Betaseron	SS				
SUBCUTANEOUS	YR							
	Livedo Reticularis		Wellbutrin	C				
	Mental Impairment		[Therapy				6	MON
	Nuclear Magnetic		Unspecified]	C				
	Resonance Imaging Brain		Procuren	C				
	Abnormal		Prednisone	C				
	Oedema Peripheral		Vitamins					

	Rash Macular		(Unspecified)	C		
	Reflexes Abnormal					
	Serum Sickness					
	Status Epilepticus					

Date:02/01/02ISR Number: 3861862-XReport Type:Expedited (15-DaCompany Report #WAES 0112USA02294
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebral Haemorrhage		Humulin Nph	C		
PARENTERAL						
	Convulsion		Humalog	C		
PARENTERAL						
	Dizziness		Avandia	C		
	Faecal Occult Blood		Prinivil	C		
	Positive		Prilosec	C		
	Haemorrhage Intracranial		Elavil	C		
	Headache		Vitamins			
	Iron Deficiency		(Unspecified)	C		
	Rash					
	Rectal Haemorrhage					
	Red Blood Cell					
	Sedimentation Rate					
	Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/02ISR Number: 3861864-3Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00162
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
	C-Reactive Protein		Phenprocoumon	C		ORAL		
	Increased Haemorrhage Purpura Sepsis		Spironolactone	C				
			Omeprazole	C				
			Naloxone Hydrochloride And Tilidine Hydrochloride	C				
			Prednisolone	C				

Date:02/01/02ISR Number: 3863366-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Transient Ischaemic Attack	Company Representative	Cozaar	C				
			Dilacor Xr	C				
			Fosamax	C				
			L-Thyroxin	C				
			Lasix (Furosemide)	C				
			Oxycontin	C				
			Soma	C				
			Valium	C				
			Calcium Carbonate	C				
			Quinine	C				

Date:02/01/02ISR Number: 3863370-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS		ORAL	PO	

Date:02/01/02ISR Number: 3863372-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02655
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Peptic Ulcer Haemorrhage	Literature	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged		Health Professional	Aspirin (+)					
			Oxycodone Hydrochlor	C				
			Clonazepam	C				
			Omeprazole	C				

Date:02/01/02ISR Number: 3863390-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00513
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Toxicity	Consumer	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional						
	Oesophageal Ulcer Haemorrhage		Coumadin	SS				
			Cozaar	C				
			Lasix (Furosemide)	C				
			Cortisone	C				

Date:02/01/02ISR Number: 3863415-6Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Complex Regional Pain	Health					MG/DAILY/PO	
	Syndrome	Professional	Prinzide	C				
	Condition Aggravated		Chondroitin (+)					
	Muscular Weakness		Glucosamine	C				
	Oedema Peripheral		Herbs	C				
	Pain							
	Paraesthesia							
	Peripheral Coldness							

Date:02/01/02ISR Number: 3863509-5Report Type:Expedited (15-DaCompany Report #WAES 00050809
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Study	Tab Vioxx	PS		ORAL	25	
Initial or Prolonged	Atrophy	Health					MG/DAILY/PO	
	Colonoscopy Abnormal	Professional	Tab Acetaminophen	SS		ORAL	325 MG/PRN/PO	
	Diarrhoea		Combivent	C				
	Dizziness		Methotrexate	C				
	Gastrointestinal Disorder							
	Lipoma							
	Lower Gastrointestinal							
	Haemorrhage							
	Nausea							
	Oesophagitis							
	Oral Intake Reduced							
	Orthostatic Hypotension							
	Vomiting							

Date:02/01/02ISR Number: 3863511-3Report Type:Expedited (15-DaCompany Report #WAES 00060894
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Study	Tab Naproxen 500 Mg	PS		ORAL	500 MG	
Initial or Prolonged	Gastritis	Health					/BID/PO	
	Haemoglobin Decreased	Professional	Tab Vioxx 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Nausea		Tab Acetaminophen					
	Upper Gastrointestinal		325 Mg	SS		ORAL	325 MG/PRN/PO	
	Haemorrhage		Novolin N	C				
	Vomiting		Atenolol (+)					
			Chlorthalidone	C				
			Aurothioglucose	C				
			Furosemide	C				
			Metolazone	C				
			Potassium Chloride	C				
			Prednisone	C				
			Tramadol	C				

Date:02/01/02ISR Number: 3863527-7Report Type:Expedited (15-DaCompany Report #WAES 00031887
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Other	Duodenal Ulcer
	Gastric Ulcer
	Gastrointestinal

Haemorrhage
Pleural Infection
Pneumonia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Study	Tab Naproxen 500 Mg	PS		ORAL	500 M	
Health					G/BID/PO	
Professional	Tab Vioxx 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Tab Acetaminophen Unk	SS			325 MG/PRN	
	Percocet	C				
	Plaquenil	C				
	Rocephin	C				
	Vantin	C				
	Vioxx	C				
	Methotrexate	C				
	Nifedipine	C				

Date:02/01/02ISR Number: 3863529-0Report Type:Expedited (15-DaCompany Report #WAES 00060894
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Study	Tab Naproxen 500 Mg	PS		ORAL	500 MG/BID/PO	
Initial or Prolonged	Gastritis	Health	Tab Vioxx 5 Mg	SS		ORAL	5 MG/DAILY/PO	
	Haemoglobin Decreased	Professional	Tab Acetaminophen 325 Mg	SS		ORAL	325 MG/PRN/PO	
	Upper Gastrointestinal Haemorrhage		Novolin N	C				
			Atenolol (+) Chlorthalidone	C				
			Aurothioglucose	C				
			Furosemide	C				
			Metolazone	C				
			Potassium Chloride	C				
			Prednisone	C				
			Tramadol	C				

Date:02/01/02ISR Number: 3864404-8Report Type:Expedited (15-DaCompany Report #WAES 01125533
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Tab Vioxx					
	Dyspnoea	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	474 DAY
	Pulmonary Embolism	Professional						
	Pulmonary Hypertension	Other						

Date:02/01/02ISR Number: 3864406-1Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
Disability	Blood Creatinine Increased
Other	Condition Aggravated
	Drug Ineffective
	Hyponatraemia
	Inappropriate Antidiuretic Hormone Secretion
	Malignant Neoplasm Of Pleura

		Nausea Renal Impairment Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY	41 DAY						
			Professional Other	Acetaminophen/Propox yphene Hydrochloride	C		
				Bendroflumethiazide	C		
				Bisoprolol	C		
				Isosorbide Mononitrate	C		
				Omeprazole	C		

Date:02/01/02ISR Number: 3864410-3Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05087
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Drug Withdrawal Syndrome	Foreign	Tabb Vioxx			
Initial or Prolonged	Hyponatraemia	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Disability	Inappropriate		Acetaminophen/Pronox			
Other	Antidiuretic Hormone		yphene Hydrochloride	C		
	Secretion		Bendroflumethiazidie	C		
	Malignant Neoplasm Of		Bisoprolol	C		
	Pleura		Isosorbide			
	Malignant Pleural		Mononitrate	C		
	Effusion		Omeprazole	C		
	Nausea					
	Renal Impairment					
	Vomiting					

Date:02/01/02ISR Number: 3864420-6Report Type:Expedited (15-DaCompany Report #WAES 01105563
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dysphagia	Foreign	Tab Vioxx			
	Pruritus	Health	(Rofecoxib)	PS		ORAL
SEE IMAGE	10 DAY					
	Urticaria	Professional	Diclofenac	C		

Date:02/01/02ISR Number: 3864424-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02324
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial	Foreign	Tab Vioxx					
Hospitalization -	Thromboplastin Time	Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	6 DAY
Initial or Prolonged	Prolonged	Professional	Buscopan	C				
Disability	Blood Fibrinogen		Ciprobay	C				
Other	Increased		Contralac	C				
	Mesenteric Occlusion		Debridat	C				
	Mesenteric Vascular		Feldene	C				
	Insufficiency		Flagyl	C				
	Portal Vein Thrombosis		Intetrix	C				
			Tarivid	C				
			Zantac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/02ISR Number: 3864426-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemianopia Homonymous Transient Ischaemic Attack	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	126 DAY
Other			Acetaminophen/Codeine Phosphate	C				

Date:02/01/02ISR Number: 3864429-2Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00228
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	24 DAY
			Anastrozole	C				
			Cyclizine	C				
			Medroxyprogesterone Acetate	C				
			Morphine	C				
			Omeprazole	C				
			Quinine	C				
			Temazepam	C				

Date:02/01/02ISR Number: 3864496-6Report Type:Expedited (15-DaCompany Report #WAES 01099742
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Lumbar Vertebral Fracture Spinal Compression Fracture	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	16 DAY

Date:02/01/02ISR Number: 3868243-3Report Type:Expedited (15-DaCompany Report #WAES 01127512
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paraesthesia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:02/04/02ISR Number: 3862470-7Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cutaneous Lupus Erythematosus		Vioxx	PS	Merck & Co., Inc	ORAL	TOPICAL	
			Levothyroxine Sodium	C				
			Omeprazole	C				
			Ibuprofen	C				
			Hydroxychloroquine Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/02ISR Number: 3862472-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA03329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/02ISR Number: 3862473-2Report Type:Expedited (15-DaCompany Report #WAES 0201MEX00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	MON	

Date:02/04/02ISR Number: 3862478-1Report Type:Expedited (15-DaCompany Report #WAES 0201AUS00106
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL	42	DAY

Date:02/04/02ISR Number: 3862480-XReport Type:Expedited (15-DaCompany Report #WAES 01120620
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Chloride Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine Abnormal		Cardizem Cd	C				
	Blood Potassium Abnormal		Lipitor	C				
	Blood Sodium Abnormal		Evista	C				
	Bundle Branch Block Left							
	Cardiac Failure							
	Congestive							
	Congestive Cardiomyopathy							
	Crepitations							
	Dyspnoea							
	Ejection Fraction							

	Decreased Gallop Rhythm Present Hypertension International Normalised Ratio Abnormal Left Ventricular Failure Nausea Pco2 Abnormal Pulmonary Oedema Tachycardia

Date:02/04/02ISR Number: 3862481-1Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06088
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Atrioventricular Block Blood Lactate Dehydrogenase Increased

	Gamma-Glutamyltransferase Increased						
	Gastrointestinal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Heart Rate Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	24 DAY
	Malaise		Celiprolol	C		ORAL	
	Syncope		Atorvastatin	C		ORAL	
			Piribedil	C		ORAL	

Date:02/04/02ISR Number: 3862486-0Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00068
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Initial or Prolonged	Hallucination, Visual		Zolpidem Tartrate	C		ORAL	1 DAY
	Metastases To Central Nervous System		Dihydroergotamine Mesylate	C		ORAL	1 DAY
	Speech Disorder		Antineoplastic (Unspecified)	C			1 DAY

Date:02/04/02ISR Number: 3862487-2Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00225
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Tongue Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS		ORAL	
			Ibuprofen	C		ORAL	

Date:02/04/02ISR Number: 3862499-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA03320
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	

Initial or Prolonged	Atrial Fibrillation		Trental	C
	Chest Discomfort		Inderal	C
	Dyspnoea		Vicodin Tablets	C
	Hypertension		Claritin	C

Date:02/04/02ISR Number: 3862502-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged	Diverticulitis		Vioxx	SS		ORAL	9	DAY
	Orthostatic Hypotension		Tylenol Arthritis					
	Rectal Haemorrhage		Extended Relief	C				
	Tachycardia		Paxil	C				
			Paxil	C			7	DAY
			Zoloft	C				
			Prinzide	C				

Date:02/04/02ISR Number: 3865007-1Report Type:Expedited (15-DaCompany Report #A126732
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Drug Interaction
Initial or Prolonged	Hypoglycaemia

	Malaise						
	Oedema Peripheral						
	Syncope Vasovagal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign	Norvasc Tablets	PS			5.00 MG
		Health					TOTAL:DAILY
		Professional	Rofecoxib	SS			
			Gliclazide	C			
			Buflomedil	C			
			Prazosin	C			
			Furosemide	C			

Date:02/04/02ISR Number: 3878596-8Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00005
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain	Foreign	Tab Vioxx				
Hospitalization -	Blood Creatine	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY
Initial or Prolonged	Phosphokinase Increased	Professional					PO
Disability	Chills		Clonazepam	C			
	Discomfort		Moclobemide	C			
	Multi-Organ Failure						
	Necrotising Fasciitis						
	Platelet Count Abnormal						
	Streptococcal Sepsis						
	Vomiting						

Date:02/05/02ISR Number: 3863420-XReport Type:Expedited (15-DaCompany Report #WAES 01125014
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Blood Bilirubin Increased		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
Hospitalization -	Blood Glucose Increased		Hydroflumethiazide				
Initial or Prolonged	Circulatory Collapse		And Spironolactone	C			
	Depressed Level Of		Propranolol	C			
	Consciousness		Acetaminophen	C			

	Hyponatraemia		Diuretic			
	Syncope		(Unspecified)	C		

Date:02/05/02ISR Number: 3863421-1Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Dysphasia Dyspraxia					

Date:02/05/02ISR Number: 3863428-4Report Type:Expedited (15-DaCompany Report #WAES 01115091
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain Collapse Of Lung Dyspnoea Lower Respiratory Tract Infection Pleuritic Pain Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
			Azathioprine [Therapy Unspecified]	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/02ISR Number: 3863903-2Report Type:Expedited (15-DaCompany Report #2002090788GB
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence	Foreign	Salazopyrin(Sulfasalazine) Tablet	PS		ORAL	1G, BID, ORAL	
Hospitalization -	Chills	Health						
Initial or Prolonged	Endocarditis	Professional	Rofecoxib(Rofecoxib)	SS		ORAL	25 MG, QD, ORAL	
	Neutrophilia	Other						
	Pyrexia		Naproxen	C				

Date:02/05/02ISR Number: 3865315-4Report Type:Direct Company Report #CTU 160882
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx 25mg 1 Per Day	PS			25MG 1 PER DAY	7 MON
	Chest Pain							
	Flatulence							
	Hypoaesthesia							
	Paraesthesia							

Date:02/05/02ISR Number: 3865691-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Thrombosis	Professional						
			Ziac	C				

Date:02/05/02ISR Number: 3865692-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colectomy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haematochezia						MG/DAILY/PO	
Other			Aspirin	C				
			Calcium (Unspecified)	C				

Date:02/05/02ISR Number: 3865963-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA03329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Company Representative						

Date:02/05/02ISR Number: 3865984-9Report Type:Expedited (15-DaCompany Report #WAES 01112810
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/02ISR Number: 3865987-4Report Type:Expedited (15-DaCompany Report #WAES 01120333
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Myocardial Infarction	Company					MG/DAILY/PO	
Initial or Prolonged	Ventricular Fibrillation	Representative	Celebrex	C				
Other								

Date:02/05/02ISR Number: 3865989-8Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06075
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Vioxx (Rofecoxib)	PS		ORAL	113 DAY	
	Sudden Death	Health	Aspirin Lysine	C				
		Professional	Fenobibrate	C				
		Other	Flecainide Acetate	C				
			Hydrochlorothiazide					
			(+) Irbesartan	C				
			Paroxetine	C				
			Tramadol Hcl	C				
			Uridine 5'					
			-Triphosphate	C				
			Zolpidem Tartrate	C				

Date:02/05/02ISR Number: 3865993-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01797
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Congestive	Professional					MG/DAILY/PO	
	Dyspnoea	Company	Celexa	C				
	Ejection Fraction	Representative	Coumadin	C				
	Decreased		Estrace	C				
	Hepatomegaly		Aspirin	C				

Liver Function Test
Abnormal
Pitting Oedema
Pleural Effusion
Pulmonary Oedema
Rales
Weight Decreased

Date:02/05/02ISR Number: 3866004-2Report Type:Expedited (15-DaCompany Report #WAES 01103401
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	
			Aspirin	C				

Date:02/05/02ISR Number: 3866006-6Report Type:Expedited (15-DaCompany Report #WAES 01073471
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

			Aspirin	C		

Date:02/05/02ISR Number: 3866009-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR 00229
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence	Foreign	Tab Vioxx					
Hospitalization -	C-Reactive Protein	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Increased							
PO							41	DAY
	Chills		Sulfasalazine	SS		ORAL	1 GM/BID, PO	41 DAY
	Endocarditis		Naproxen	C				
	Malaise							
	Neutrophilia							
	Pulse Abnormal							
	Pyrexia							

Date:02/05/02ISR Number: 3866011-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00261
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Foreign	Tab Vioxx					
	Headache	Other	(Rofecoxib)	PS		ORAL	12.5 MG	
							DAILY, PO	
			Dibucaine Hydrochloride (+) Framycetin S	C				

Date:02/05/02ISR Number: 3866025-XReport Type:Expedited (15-DaCompany Report #WAES0201USA00640
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Colonic Haemorrhage	Health					
MG/DAILY/PO							
		Professional					

Date:02/05/02ISR Number: 3866531-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01819
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx	PS		ORAL		
PO								
Initial or Prolonged	Haemorrhage							
	Infection							
	Phlebitis Superficial							
	Thrombosis							

Date:02/05/02ISR Number: 3866538-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA03065
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL		
PO								
Initial or Prolonged		Professional						
		Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/02ISR Number: 3866553-7Report Type:Expedited (15-DaCompany Report #WAES 01111406
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY PO	
			Sulfasalazine	C				

Date:02/05/02ISR Number: 3866610-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00216
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastritis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	627 DAY
			Aspirin	SS		ORAL	75 MG/DAILY	
			Betahistine Hydrochloride	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Quinine	C				
			Tamsulosin Hydrochloride	C				
			Zopiclone	C				

Date:02/05/02ISR Number: 3866611-7Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00210
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Anaemia Fatigue	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Gastrointestinal Haemorrhage Melaena Pallor						PO	805 DAY
			Fosamax	C				
			Acetaminophen	C				
			Ascorbic Acid	C				
			Aspirin	C				

			Vitamin E Acetate	C		

Date:02/05/02ISR Number: 3866613-0Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00060
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrioventricular Block	Foreign	Tab Vioxx			
Initial or Prolonged	First Degree	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY 134 DAY						
	Dyspnoea		Amlodipine	C		
	Face Oedema		Aspirin Lysine	C		
	Fall		Aspirin/Caffeine/Pro			
	Generalised Oedema		poxphene Hcl	C		
	Haematuria		Cyamemazine	C		
	Kidney Enlargement					
	Pleural Effusion					
	Renal Atrophy					
	Renal Failure Acute					
	Urinary Retention					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/02ISR Number: 3866635-XReport Type:Expedited (15-DaCompany Report #WAES 0201MEX00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	PO MON

Date:02/05/02ISR Number: 3866743-3Report Type:Expedited (15-DaCompany Report #EMADSS2002000599
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine	Foreign Health Professional	Fentanyl (Fentanyl)	PS		TRANSDERMAL	100 MCG, TRANSD	DAY(S),
	Increased Constipation							
	Duodenal Ulcer		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG, DAY(S),	
	Vomiting							
			Finasteride (Finasteride)	C				
			Docusate (Docusate)	C				
			Senna (Senna)	C				
			Enalapril (Enalapril)	C				
			Beclometasone (Beclometasone)	C				

Date:02/06/02ISR Number: 3864304-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02710
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:02/06/02ISR Number: 3864313-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Attack		Aggrenox	C				
			Pravachol	C				

Date:02/06/02ISR Number: 3864314-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00249
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral		Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc			

Date:02/06/02ISR Number: 3864315-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Flutter Haemorrhage Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/02ISR Number: 3864673-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00274
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Congestive		Zestril	C		ORAL		
			Glucophage	C		ORAL		
Other			Diabeta	C		ORAL		
			Norvasc	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Digoxin	C		ORAL		

Date:02/06/02ISR Number: 3864679-5Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00152
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	256	DAY
	Ulcer		[Therapy Unspecified]	C		ORAL		

Date:02/06/02ISR Number: 3865505-0Report Type:Direct Company Report #CTU 161076
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Polyp		Vioxx 25mg	PS		ORAL	25MG	QD PO
Initial or Prolonged	Diverticulum Intestinal		Aggrenox 200mg	SS		ORAL	200MG	PO
	Duodenal Ulcer						TID	
	Gastrointestinal Haemorrhage							

Date:02/06/02ISR Number: 3865519-0Report Type:Direct Company Report #CTU 161074
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Duodenal Ulcer Perforation		Vioxx	PS				3 WK

Date:02/07/02ISR Number: 3865551-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA00513
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Asthenia Blood Folate Abnormal Blood Glucose Increased Blood Urea Increased Contusion Drug Interaction Drug Toxicity Gastric Ulcer Gastrointestinal Haemorrhage Haematochezia International Normalised

	Ratio Increased						
	Melaena						
	Oesophageal Ulcer						
	Orthostatic Hypotension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Polyp		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
	Prothrombin Time		Lasix (Furosemide)	C			
	Prolonged		Cortisone	C			
PARENTERAL							1 DAY
	Tremor		Cozaar	C		ORAL	
	White Blood Cell Count		Coumadin	I			
	Increased		Coumadin	I			

Date:02/07/02ISR Number: 3865556-6Report Type:Expedited (15-DaCompany Report #WAES 01126038
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
Initial or Prolonged	Cerebrovascular Accident		Clopidogrel				
Disability	Difficulty In Walking		Bisulfate	C		ORAL	
	Hemiparesis						
	Monoparesis						

Date:02/07/02ISR Number: 3865557-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL	11 MON
			Lamictal	C			
			Mysoline	C			
			Premarin	C			

Date:02/07/02ISR Number: 3865631-6Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - 163 DAY	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Heparin	SS		
	Myocardial Infarction		Prednisolone	C		
			Methotrexate [Therapy Unspecified]	C C		

Date:02/07/02ISR Number: 3865633-XReport Type:Expedited (15-DaCompany Report #WAES 0112GBR05146
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other 10 DAY	Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL
	Oedema Peripheral		Vioxx	SS		ORAL
	Urinary Incontinence		Atenolol	C		ORAL
	Weight Decreased		Omeprazole	C		ORAL
			Warfarin	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/02ISR Number: 3865636-5Report Type:Expedited (15-DaCompany Report #WAES 01120970
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Coumadin	C				
	Dyspnoea		Digoxin	C				
	Dyspnoea Exertional		Diltiazem Msd	C				
	Dyspnoea Paroxysmal							
	Nocturnal							
	Joint Swelling							
	Pulmonary Oedema							
	Weight Increased							

Date:02/07/02ISR Number: 3865637-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemia							
	Maculopathy							
	Retinal Haemorrhage							
	Retinal Vein Thrombosis							

Date:02/07/02ISR Number: 3865638-9Report Type:Expedited (15-DaCompany Report #WAES 0201PRT00009
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Periorbital Oedema		Pravastatin Sodium	C		ORAL		
			Allopurinol	C		ORAL		
			Glucosamine Sulfate	C		ORAL		

Date:02/07/02ISR Number: 3865640-7Report Type:Expedited (15-DaCompany Report #WAES 0201MEX00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		MON

Date:02/07/02ISR Number: 3865641-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA00640
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder Condition Aggravated Diverticulum Haemorrhage Lower Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/02ISR Number: 3865642-0Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00003
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Tremor		Vioxx Morphine Sulfate	PS C	Merck & Co., Inc	ORAL		

Elavil	C
Acetaminophen	C
Omeprazole Magnesium	C
Hydrochlorothiazide And Triamterene	C

Date:02/07/02ISR Number: 3865643-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00319
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Fluctuation							
	Brain Scan Abnormal							
	Cerebrovascular Accident							
	Drug Ineffective							

Date:02/07/02ISR Number: 3865644-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00050
Age:100 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization -								
Initial or Prolonged								

Date:02/07/02ISR Number: 3865645-6Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00003
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness							
	Intracranial Aneurysm							

Date:02/07/02ISR Number: 3865647-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/02ISR Number: 3866399-XReport Type:Direct Company Report #CTU 161179
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Rhabdomyolysis		Vioxx 12.5 Mg Merck	PS	Merck	ORAL	12.5 MG QD	
			Motrin	C				
			Habitrol	C				
			Tylenol #3	C				

Date:02/07/02ISR Number: 3866411-8Report Type:Direct Company Report #CTU 161196
Age:57 YR Gender:Female I/FU:I

Outcome
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation		Vioxx (25mgm Po					
	Extrasystoles		Daily) Merck	PS	Merck	ORAL	25MGM DAILY &	
	Ventricular Extrasystoles						PRN ORAL	
			E-Stim	C				

Date:02/07/02ISR Number: 3866621-XReport Type:Expedited (15-DaCompany Report #WAES 0112USA02294
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Convulsion	Professional					MG/DAILY/PO	
	Coordination Abnormal	Company	Avandia	C				
	Dizziness	Representative	Elavil	C				
	Faecal Occult Blood		Humalog	C				
	Positive		Humulin Nph	C				
	Haemorrhage Intracranial		Prilosec	C				
	Headache		Prinivil	C				
	Hemiparesis		Vitamins					
	Iron Deficiency		(Unspecified)	C				
	Rash							
	Rectal Haemorrhage							

Date:02/07/02ISR Number: 3866623-3Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Convulsion	Professional					MG/DAILY/PO	
	Dyspnoea		Provigil 200 Mg	SS		ORAL	200	

		Dysuria					
MG/DAILY/PO							
		Fall		Betaseron Unk	SS		
SUBCUTANEOUS	QOD/SC						
		Laceration		Amantadine Hydrochloride Unk	SS		
		Mental Impairment		Procuren	C		
		Oedema Peripheral		Wellbutrin	C		
		Serum Sickness		(Therapy Unspecified)	C		
		Status Epilepticus		Prednisone	C		
				Vitamins (Unspecified)	C		

Date:02/07/02ISR Number: 3867058-XReport Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Study	Tab Vioxx 12.5 Mg	PS		ORAL	SEE ATTACHED	
Hospitalization - Initial or Prolonged	Constipation	Health Professional	Tab Placebo (Unspecified) Unk	SS		ORAL	PO	
	Diverticulum							
	Dizziness		Acetaminophen Unk	SS		ORAL	325 MG/PRN/PO	
	Rectal Haemorrhage		Tears Naturale	C				
			Tubex	C				
			Vasocon-A	C				
			Aspirin	C				
			Folic Acid	C				
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/02ISR Number: 3867297-8Report Type:Expedited (15-DaCompany Report #WAES 01037307
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Diarrhoea Haemorrhagic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 6 WK
			Cap Ketoprofen	SS		ORAL	PO	
			Tab Sulfasalazine	SS		ORAL	PO	24 DAY

Date:02/07/02ISR Number: 3867301-7Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00162
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister C-Reactive Protein	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/BID PO	
	Increased Haemorrhage Purpura Sepsis White Blood Cell Count Increased	Professional	Naloxone Hydrochloride (+)					
			Tilidine Hydr	C				
			Omeprazole	C				
			Phenprocoumon	C				
			Prednisolone	C				
			Spironolactone	C				

Date:02/08/02ISR Number: 3865845-5Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05110
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	6 WK	
Hospitalization - Initial or Prolonged	Diarrhoea Fatigue		Acetaminophen	C		ORAL	144 DAY	
			Warfarin	C		ORAL		
	International Normalised Ratio Increased							

Renal Failure Acute
Vomiting

Date:02/08/02ISR Number: 3865850-9Report Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/02ISR Number: 3865853-4Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00139
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage Melaena		Melperone Hydrochloride	C		ORAL		

Date:02/08/02ISR Number: 3865858-3Report Type:Expedited (15-DaCompany Report #WAES 0202ESP00013
Age:77 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	158	DAY
	Gastritis Erosive		Methylprednisolone	SS		ORAL		
	Gastrointestinal		Aspirin	SS		ORAL		
	Haemorrhage		Omeprazole	C		ORAL		
	Haematocrit Decreased		Methotrexate	C		ORAL		
	Haemoglobin Decreased		Propranolol Hydrochloride	C		ORAL		

Date:02/08/02ISR Number: 3866056-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00294
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Feeling Abnormal							
	Headache							
	Mood Altered							

Date:02/08/02ISR Number: 3866060-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA01163
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adenocarcinoma		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Anaemia Haemolytic							
	Autoimmune							
	Contusion							
	Haemorrhage							
	Headache							
	Metastases To Bone Marrow							
	Neck Pain							
	Paraesthesia							

Date:02/08/02ISR Number: 3866061-3Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00095
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Irbesartan	C		ORAL		
	Cardioactive Drug Level Increased		Fluindione	C		ORAL		
			Digoxin	C		ORAL		
	Haemodialysis		Pravastatin Sodium	C		ORAL		
	Haemoglobin Decreased							
	International Normalised Ratio Increased							
	Kidney Small							
	Renal Failure Acute							
	Renal Tubular Necrosis							

Date:02/08/02ISR Number: 3866065-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00719
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Hospitalization - Initial or Prolonged	Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/02ISR Number: 3866066-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00490
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/02ISR Number: 3866664-6Report Type:Direct Company Report #CTU 161287
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphthous Stomatitis		Vioxx 25mg Merck	PS	Merck	ORAL	25 MG QD AT	HS ORAL
			Multivitamin	C				

Date:02/08/02ISR Number: 3867259-0Report Type:Direct Company Report #CTU 161250
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute		Refecoxib	PS		ORAL	PO	
	Septic Shock							

Date:02/08/02ISR Number: 3867657-5Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06088
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	24 DAY
Hospitalization - Initial or Prolonged	Increased Aspartate Aminotransferase Increased	Health Professional Other	Atorvastatin	C				
			Celiprolol`	C				
			Piribedil	C				
	Atrioventricular Block							
	Blood Lactate Dehydrogenase Increased							

Gamma-Glutamyltransferase
Increased
Gastrointestinal Disorder
Heart Rate Decreased
Malaise
Syncope

Date:02/08/02ISR Number: 3867661-7Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Systemic Lupus Erythematosus	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional Other	Hydroxychloroquineso 4	C				
			Ibuprofen	C				
			Levothyroxine Na	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/02ISR Number: 3867808-2Report Type:Expedited (15-DaCompany Report #WAES 01075012
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Helicobacter Infection	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 191 DAY
	Melaena		Loperamide Temazepam	C C				

Date:02/08/02ISR Number: 3867828-8Report Type:Expedited (15-DaCompany Report #WAES 01115091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atelectasis Collapse Of Lung	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Condition Aggravated Lower Respiratory Tract Infection Pneumonia Systemic Lupus Erythematosus	Professional	Azathioprine	C				

Date:02/08/02ISR Number: 3867829-XReport Type:Expedited (15-DaCompany Report #WAES 01125014
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Bilirubin Increased Blood Glucose Increased Blood Potassium Decreased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 1 DAY
			Diuretic Acetaminophen Hydroflumethiazide (+) Spironolactone Propranolol	C C C C				

Blood Urea Increased
Circulatory Collapse
Depressed Level Of Consciousness
Haematocrit Decreased
Hyponatraemia
Red Blood Cell Count Decreased
Syncope

Date:02/08/02ISR Number: 3868280-9Report Type:Expedited (15-DaCompany Report #WAES 01099409
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/02ISR Number: 3868509-7Report Type:Expedited (15-DaCompany Report #WAES 01120620
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Left	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Cardiac Failure	Professional	Cardizem Cd	C				
	Congestive	Company	Evista	C				
	Congestive Cardiomyopathy	Representative	Lipitor	C				
	Crepitations							
	Dyspnoea							
	Gallop Rhythm Present							
	Hypertension							
	Nausea							
	Pco2 Decreased							
	Pulmonary Oedema							
	Tachycardia							
	Ventricular Hypokinesia							

Date:02/08/02ISR Number: 3868531-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Flutter	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Ulcer Haemorrhage	Company Representative						

Date:02/08/02ISR Number: 3868533-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Attack	Professional					MG/DAILY/PO	
		Company	Aggrenox	C				
		Representative	Pravachol	C				

Date:02/08/02ISR Number: 3868535-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00249
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS			25 MG/DAILY	
Initial or Prolonged		Professional Company Representative	[Composition Unspecified]	C				

Date:02/08/02ISR Number: 3868569-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
Initial or Prolonged	Dizziness	Health					PO	
	Fatigue	Professional	Paxil	C				
	Rectal Haemorrhage		Prinzide	C				
	Tachycardia		Tylenol Arthritis Extended Relief	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/02ISR Number: 3868576-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA03320
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Pressure Increased	Professional					MG/DAILY/PO	
			Claritin	C				
			Inderal	C				
			Trental	C				
			Vicodin Tablets	C				

Date:02/08/02ISR Number: 3868621-2Report Type:Expedited (15-DaCompany Report #WAES 0201AUS00106
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Insomnia	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Consumer						
PO							42	DAY
		Other						

Date:02/08/02ISR Number: 3868622-4Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00068
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination, Visual	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Metastases To Central	Consumer						
PO							3	DAY
	Nervous System	Other	Antineoplastic					
	Recurrent Cancer		(Unspecified)	C				
	Speech Disorder		Dihydroergotamine					
			Mesylate	C				
			Zolpidem Tartrate	C				

Date:02/08/02ISR Number: 3868623-6Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00225
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tongue Oedema	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID PO ; PO	
			Ibuprofen	C				

Date:02/08/02ISR Number: 3868624-8Report Type:Expedited (15-DaCompany Report #WAES 01115133
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysphasia	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	1 DAY
	Dyspraxia							
Disability								

Date:02/08/02ISR Number: 3868633-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02710
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/02ISR Number: 3866416-7Report Type:Expedited (15-DaCompany Report #WAES 01107308
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Gabapentin	C				
			Flunitrazepam	C				
			Esomeprazole					
			Magnesium	C				

Date:02/11/02ISR Number: 3866424-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Epistaxis		Vioxx	SS		ORAL		
	Renal Failure							

Date:02/11/02ISR Number: 3866425-8Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS		ORAL		
Initial or Prolonged	Diarrhoea		Fosamax	C	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Vitamins					
	Faeces Discoloured		(Unspecified)	C				
	Gastric Ulcer		Calcitonin	C				
	Malaise		Vitamin E	C				
			[Therapy					
			Unspecified]	C				
			[Therapy					
			Unspecified]	C				

Date:02/11/02ISR Number: 3866510-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00338
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Heart Rate Decreased		Vioxx Premarin	PS C	Merck & Co., Inc	ORAL		

Date:02/11/02ISR Number: 3866511-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA01319
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON
	Drug Hypersensitivity		One-A-Day Women'S	C				
			Ortho-Cyclen	C				
			Darvocet-N	C				

Date:02/11/02ISR Number: 3866512-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA00058
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Other	Chromaturia
	Dizziness
	Dyspepsia
	Hepatitis

	Hepatotoxicity Jaundice Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Congestion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pseudoephedrine Hydrochloride	SS				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
			Synthroid	C				

Date:02/11/02ISR Number: 3866513-6Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/02ISR Number: 3866515-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
			Dalteparin Sodium	C		SUBCUTANEOUS		
			Aspirin	C		ORAL		

Date:02/11/02ISR Number: 3866516-1Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00005
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Multi-Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Necrotising Fasciitis Renal Impairment Respiratory Failure		Prednisolone	C				

Date:02/11/02ISR Number: 3866518-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Rash Erythematous Rash Pruritic Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/02ISR Number: 3868123-3Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00152
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5-25 MG PO	256 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/02ISR Number: 3868137-3Report Type:Expedited (15-DaCompany Report #WAES 0202ESP00013
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	PO	158 DAY
Initial or Prolonged	Gastric Ulcer		Tab					
	Gastrointestinal		Methylprednisolone	SS		ORAL	6 MG DAILY PO	
	Haemorrhage		Cap Aspirin	SS		ORAL	150 MG DAILY	
							PO	
			Methotrexate	C				
			Omeprazole	C				
			Propranolol Hcl	C				

Date:02/11/02ISR Number: 3868438-9Report Type:Expedited (15-DaCompany Report #EPOS00302000384
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Disorder	Foreign	Eprosartan					
	Osteoarthritis	Study	(Eprosartan)	PS		ORAL	600 MG DAILY	
	Paresis	Health					PO	
		Professional	Vioxx 25 (Rofecoxib)	SS		ORAL	25 MG DAILY	
		Other					PO	
			Ass (Acetylsalicylic Acid)	C				

Date:02/11/02ISR Number: 3868462-6Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00050
Age:100 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Foreign	Tab Vioxx					

Hospitalization -	Upper Gastrointestinal	Other	(Rofecoxib)	PS		ORAL
PO 10 DAY						
Initial or Prolonged	Haemorrhage					

Date:02/11/02ISR Number: 3868463-8Report Type:Expedited (15-DaCompany Report #WAES 0201PRT00009
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema Peripheral	Foreign	Tab Vioxx			
	Periorbital Oedema	Other	(Rofecoxib) Batch #			
			Hn13420	PS		ORAL
25 MG/DAILY						
PO 3 DAY						
			Allopurinol	C		
			Glucosamine Sulfate	C		
			Pravastatin Na	C		

Date:02/11/02ISR Number: 3868492-4Report Type:Expedited (15-DaCompany Report #WAES 0112GBR05110
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atrial Fibrillation	Foreign	Tab Vioxx			
Hospitalization -	Diarrhoea	Company	(Rofecoxib)	PS		ORAL
12.5 MG/BID						
Initial or Prolonged	Fatigue	Representative				
PO 6 WK						
	International Normalised		Acetaminophen	C		
	Ratio Increased		Warfarin	C		
	Renal Failure Acute					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/02ISR Number: 3868495-XReport Type:Expedited (15-DaCompany Report #WAES 0112GBR05146
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dehydration	Foreign	Tab Vioxx					
	Incontinence	Company	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema Peripheral	Representative					PO, 12.5	
	Polyuria						MG/DAILY PO	10 DAY
	Weight Decreased		Atenolol	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Omeprazole	C				
			Warfarin	C				

Date:02/11/02ISR Number: 3868498-5Report Type:Expedited (15-DaCompany Report #WAES 01115120
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Myocardial Infarction	Professional					PO	163 DAY
			Heparin (Therapy Unspecified)	SS				
			Methotrexate	C				
			Prednisolone	C				

Date:02/11/02ISR Number: 3868548-6Report Type:Expedited (15-DaCompany Report #WAES 0201MEX00007
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
		Professional						

Date:02/11/02ISR Number: 3868591-7Report Type:Expedited (15-DaCompany Report #WAES 01126038
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
Disability		Professional	Clopidogrel Bisulfate	C				

Date:02/11/02ISR Number: 3868894-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA00513
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Asthenia
	Blood Urea Increased
	Colonic Polyp
	Drug Interaction
	Drug Toxicity
	Faeces Discoloured
	Gastric Ulcer
	Gastrointestinal Haemorrhage

	Haematochezia						
	Haemorrhage						
	International Normalised	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ratio Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Melaena	Health					MG/DAILY/PO	
	Oesophageal Ulcer	Professional	Coumadin	C				
	Tremor		Cozaar	C				
	White Blood Cell Count		Lasix (Furosemide)	C				
	Increased		Cortisone	C				

Date:02/11/02ISR Number: 3869015-6Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00003
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Foreign	Tab Vioxx					
Initial or Prolonged	Tremor	Health	(Rofecoxib)	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Elavil	C				
			Hctz/Triamerene	C				
			Acetaminophen	C				
			Morphineso4	C				
			Omeprazole Magnesium	C				

Date:02/11/02ISR Number: 3869016-8Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00139
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	25	
Initial or Prolonged	Melaena	Professional					MG/DAILY/PO	
			Melperone Hcl	C				

Date:02/11/02ISR Number: 3869018-1Report Type:Expedited (15-DaCompany Report #WAES 0101CAN00003
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Dizziness Intracranial Aneurysm	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY;PO	

Date:02/11/02ISR Number: 3869109-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA00640
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage Condition Aggravated Diverticulum	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:02/11/02ISR Number: 3869138-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00274
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Congestive	Professional						
Other		Company Representative	Diabeta	C				
			Glucophage	C				

				Lasix (Furosemide)	C	
				Norvasc	C	
				Zestril	C	
				Digoxin	C	

Date:02/11/02ISR Number: 3869140-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	11 MON
			Lamictal	C				
			Mysoline	C				
			Premarin	C				

Date:02/11/02ISR Number: 3869685-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00319
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	2 MON
	Computerised Tomogram Abnormal							

Date:02/11/02ISR Number: 3869686-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Maculopathy							
	Retinal Haemorrhage							
	Retinal Vein Thrombosis							

Date:02/11/02ISR Number: 3869687-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Discomfort	Health Professional						

Date:02/11/02ISR Number: 3869690-6Report Type:Expedited (15-DaCompany Report #WAES 01114385
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disturbance In Attention	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Loss Of Employment	Professional						
	Memory Impairment	Company Representative						

Date:02/11/02ISR Number: 3869691-8Report Type:Expedited (15-DaCompany Report #WAES 01120970
Age:76 YR Gender:Female I/FU:F

Outcome	PT
	Cardiac Failure Congestive

Pulmonary Oedema

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Coumadin	C				
			Diltiazem Msd	C				
			Digoxin	C				

Date:02/12/02ISR Number: 3866843-8Report Type:Expedited (15-DaCompany Report #WAES 0201NLD00001
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased Aspartate Aminotransferase Increased Blood Cholesterol Increased Blood Creatine Phosphokinase Mb Increased Blood Lactate Dehydrogenase Increased Myocardial Infarction		Betaxolol Hydrochloride	C			OPHTHALMIC	
			Latanoprost	C			OPHTHALMIC	

Date:02/12/02ISR Number: 3866845-1Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL	136 DAY	
	Necrotising Fasciitis		Diacerein	C		ORAL		
	Skin Lesion		Isradipine	C		ORAL		
			Ibuprofen	C		ORAL		

Date:02/12/02ISR Number: 3866847-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00015
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Localised Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			Hyzaar	SS		ORAL	MON	

Date:02/12/02ISR Number: 3866855-4Report Type:Expedited (15-DaCompany Report #306506
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Rocaltrol	PS	Roche			
Initial or Prolonged	Dehydration		Vioxx	SS				
	Lethargy		Fosamax	SS				
	Nausea		Cartia (Aspirin)	SS				
	Sinus Bradycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/02ISR Number: 3867034-7Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Professional	Gemfibrozil	C				
	Headache							
	Hypertensive Crisis							

Date:02/12/02ISR Number: 3867035-9Report Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Life-Threatening	Haemorrhage	Professional						
	Post Procedural Haemorrhage							

Date:02/12/02ISR Number: 3867036-0Report Type:Expedited (15-DaCompany Report #WAES 01128509
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
		Professional	Cozaar	C				
			Diltiazem Hydrochloride	C				
			Nitrazepam	C				
			Diazepam	C				

Date:02/12/02ISR Number: 3867037-2Report Type:Expedited (15-DaCompany Report #WAES 01105162
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Marrow Depression		Metronidazole	C				

	Pancytopenia		Mercaptopurine	C
52 DAY				
			Acetaminophen And Propoxyphene Hydrochloride	C

Date:02/12/02ISR Number: 3867040-2Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00030
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	
	Ecchymosis		Warfarin	SS		
	Epistaxis					
	Gingival Bleeding					
	Prothrombin Level Decreased					

Date:02/12/02ISR Number: 3867042-6Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Drug Interaction

		International Normalised Ratio Increased Prothrombin Level	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
44	DAY						
				Warfarin	SS		ORAL
				Digoxin	C		ORAL
				Furosemide	C		ORAL
				Folic Acid	C		ORAL
				Methotrexate	C		ORAL
				Prednisolone	C		ORAL
				Quinine Sulfate	C		ORAL
				Prinivil	C		ORAL
				Acetaminophen	C		ORAL

Date:02/12/02ISR Number: 3867044-XReport Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Warfarin Sodium	SS		ORAL

Date:02/12/02ISR Number: 3867048-7Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspnoea		Amlodipine Besylate	SS		
	International Normalised Ratio Increased		Atorvastatin Calcium	SS		
	Prothrombin Level Decreased		Celecoxib	SS		
			Paroxetine Hydrochloride	SS		
			Warfarin Sodium	SS		
			Prazosin Hydrochloride	C		
			Irbesartan	C		
			Digoxin	C		
			Oxycodone Hydrochloride	C		
			Calcitriol	C		

			Diazepam	C		

Date:02/12/02ISR Number: 3867049-9Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00036
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 7 DAY	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	International Normalised Ratio Increased		Warfarin	SS		
			Sodium Bicarbonate	C		ORAL
	Prothrombin Level Decreased		Norfloxacin	C		

Date:02/12/02ISR Number: 3867051-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00099
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Other	Difficulty In Walking
	Oedema Peripheral

	Swelling						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:02/12/02ISR Number: 3867053-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00659
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/12/02ISR Number: 3867056-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00855
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Face Oedema							
	Gastrointestinal Motility Disorder							
	Pain							
	Renal Disorder							
	Skin Discolouration							

Date:02/12/02ISR Number: 3867710-6Report Type:Direct Company Report #CTU 161421
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx 50mg Merck And					
Required	Arthritis		Co Inc	PS	Merck And Co Inc			
09/17/2001								
Intervention to	Hepatocellular Damage							
09/20/2001								
Prevent Permanent Impairment/Damage	Liver Function Test Abnormal							

Pain

Date:02/13/02ISR Number: 3867851-3Report Type:Expedited (15-DaCompany Report #WAES 0202AUT00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 14 DAY	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged			Pantoprazole Sodium	SS		
			Citalopram Hydrobromide	C		
			Amlodipine Besylate	C		
			Hydrochlorothiazide And Ramipril	C		

Date:02/13/02ISR Number: 3867855-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypertension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/02ISR Number: 3868370-0Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		44 DAY
Initial or Prolonged	Drug Interaction		Warfarin	SS		ORAL		
	International Normalised		Acetaminophen	C		ORAL		
	Ratio Increased		Digoxin	C		ORAL		
	Prothrombin Level		Furosemide	C		ORAL		
	Decreased		Folic Acid	C		ORAL		
	Prothrombin Time		Methotrexate	C		ORAL		
	Prolonged		Prednisolone	C		ORAL		
			Quinine Sulfate	C		ORAL		
			Prinivil	C		ORAL		

Date:02/14/02ISR Number: 3868374-8Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00036
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	International Normalised		Warfarin	SS				
	Ratio Increased		Sodium Bicarbonate	C		ORAL		
	Prothrombin Level		Norfloxacin	C				
	Decreased							
	Prothrombin Time							
	Prolonged							

Date:02/14/02ISR Number: 3868377-3Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Warfarin Sodium	SS		ORAL		

Date:02/14/02ISR Number: 3868716-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00722
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Life-Threatening	Dyspnoea		Vioxx	SS		ORAL	10	DAY
Hospitalization - Initial or Prolonged			Norgesic (Aspirin (+) Caffeine (+) Orphenadrine Citrate)	C				
			Cyanocobalamin	C				

Date:02/14/02ISR Number: 3868780-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Inderal	C				
			Claritin-D	C				
			Humibid	C				
			Prevacid	C				
			Nasonex	C				
			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/02ISR Number: 3868787-4Report Type:Expedited (15-DaCompany Report #WAES 01120825
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Pulmonary Embolism		Vioxx	SS		ORAL		
			Premarin	C				
			Betapace	C				

Date:02/14/02ISR Number: 3868790-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Phenobarbital	C				
			Primidone	C				

Date:02/14/02ISR Number: 3869880-2Report Type:Direct Company Report #CTU 161626
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Rofecoxib	PS				
	Myocardial Infarction		Methotrexate	C				
	Vasculitis Cerebral		Folic Acid	C				

Date:02/14/02ISR Number: 3870032-0Report Type:Direct Company Report #CTU 161646
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Vioxx 50 Mg	PS		ORAL	50 MG TID	
Intervention to	Increased							
Prevent Permanent	Blood Urea Increased		Fexofenadine	C				
Impairment/Damage			Novolin	C				
			Prempro	C				

Ranitidine	C
Prochlorperazine	C
Glucophage	C
Carbidopa/Levodopa	C
Clonazepam	C
Bupropoin	C
Simvastatin	C
Lisinopril	C
Paroxetine	C
Docusate Sodium	C
Ferrous Sulfate	C
Avandia	C
Amlodipine	C
Erythropoetin	C
Erythropoetin Alpha	C

Date:02/14/02ISR Number: 3870081-2Report Type:Expedited (15-DaCompany Report #WAES 01107308
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	
			Esomeprazole					

22-Aug-2005 10:31 AM
Page: 4936

			Magnesium	C
			Flunitrazepam	C
			Gabapentin	C

Date:02/14/02ISR Number: 3870307-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Dialysis	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Epistaxis							
	Renal Disorder							

Date:02/14/02ISR Number: 3870309-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Diarrhoea							
	Faeces Discoloured		Fosamax	C				
	Gastric Ulcer		Therapy Unspecified	C				
			Calcitonin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:02/14/02ISR Number: 3870310-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA01163
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adenocarcinoma	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Anaemia Haemolytic	Health						
	Autoimmune	Professional						
	Contusion							
	Haemorrhage							

Headache
Metastasis
Neck Pain
Paraesthesia

Date:02/15/02ISR Number: 3869228-3Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00017
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
			Fluoxetine	C		ORAL		
			Lorazepam	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Raloxifene	C		ORAL		
			Ciprofibrate	C		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/02ISR Number: 3869229-5Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00152
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		256 DAY
	Helicobacter Infection		[Therapy Unspecified]	C		ORAL		
	Ulcer							

Date:02/15/02ISR Number: 3869230-1Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/02ISR Number: 3869232-5Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dry Mouth		[Composition Unspecified]	C				
			Paroxetine Hydrochloride	C				

Date:02/15/02ISR Number: 3869236-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00110
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Hypertension							
	Nausea							
	Paraesthesia							

Date:02/15/02ISR Number: 3869273-8Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11713591
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Aprovel	PS	Bristol-Myers Squibb Company	ORAL		
Hospitalization - Initial or Prolonged	Condition Aggravated							
	Drug Interaction		Vioxx	SS				5 DAY
	Haematochezia		Previscan	C				
	Haemoptysis		Previscan	C				
	Oliguria		Hemigoxine Nativelle	C			0.125 mg	
	Renal Failure Acute		Hemigoxine Nativelle	C			0.125 mg	
			Vasten Tabs 20 Mg	C	Bristol-Myers Squibb Company			

Date:02/15/02ISR Number: 3869412-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA01138
Age:58 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/02ISR Number: 3869734-1Report Type:Direct Company Report #CTU 161713
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hypertension		Vioxx 25mg	PS		ORAL	25MG Q BID	
Intervention to	Renal Artery Stenosis							
Prevent Permanent Impairment/Damage	Renal Failure Chronic Renal Impairment							

Date:02/15/02ISR Number: 3870982-5Report Type:Expedited (15-DaCompany Report #306506
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Dehydration Lethargy Nausea Sinus Bradycardia	Foreign Other	Rocaltrol (Calcitriol) Vioxx (Rofecoxib) Fosamax (Alendronate Sodium) Cartia (Aspirin) (Aspirin)	PS SS SS SS		ORAL	100 MG DAILY ORAL	

Date:02/15/02ISR Number: 3871146-1Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00015
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Localised Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib) Tab Hyzarr (Losartan Potassium-Hctz)	PS SS		ORAL ORAL	25MG/DAILY PO PO	3 DAY MON

Date:02/15/02ISR Number: 3871147-3Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00005
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Multi-Organ Failure	Foreign	Tab Vioxx					
Hospitalization -	Necrotising Fasciitis	Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Renal Impairment	Professional						
	Respiratory Failure							

Date:02/15/02ISR Number: 3871148-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:02/15/02ISR Number: 3871149-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25MG/DAILY PO	6 DAY
		Professional	Aspirin	C				
			Dalteparin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/02ISR Number: 3871329-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00058
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hepatitis	Professional						
	Hepatitis B Antibody Positive	Company Representative	Pseudoephedrine Hcl	SS				
	Hepatotoxicity		Synthroid	C				
	Sinus Congestion		Nonsteroidal Anti-Inflammatory	C				
	Weight Decreased							

Date:02/15/02ISR Number: 3871354-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00338
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Heart Rate Decreased		Premarin	C				

Date:02/15/02ISR Number: 3871411-8Report Type:Expedited (15-DaCompany Report #WAES 0201NLD00001
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Increased	Company	(Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
	Aspartate	Representative						
	Aminotransferase Increased		Betaxolol Hcl	C				
			Latanoprost	C				
	Blood Cholesterol Increased							
	Myocardial Infarction							

Date:02/15/02ISR Number: 3871414-3Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Necrotising Fasciitis	Foreign Company	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	136 DAY
		Representative	Diacerein	C				
			Ibuprofen	C				
			Isradipine	C				

Date:02/15/02ISR Number: 3871460-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash Papular							
	Rash Pruritic							
	Urticaria							

Date:02/15/02ISR Number: 3871463-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA01319
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Anaphylactic Reaction	Health Professional

Company Representative	Product	Role	Manufacturer	Route	Dose	Duration
	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Darvocet-N	C				
	One-A-Day Women'S	C				
	Ortho-Cylcen	C				

Date:02/19/02ISR Number: 3870320-8Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Amlodipine Besylate	SS				
	International Normalised Ratio Increased		Atorvastatin Calcium	SS				
	Prothrombin Level Decreased		Celecoxib	SS				
			Paroxetine Hydrochloride	SS				
			Warfarin Sodium	SS				
			Prazosin Hydrochloride	C				
			Irbesartan	C				
			Digoxin	C				
			Oxycodone Hydrochloride	C				
			Calcitriol	C				
			Diazepam	C				

Date:02/19/02ISR Number: 3870325-7Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00030
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc			
	Ecchymosis		Warfarin	SS				
	Epistaxis							
	Gingival Bleeding							
	Prothrombin Level							

Decreased

Date:02/19/02ISR Number: 3870326-9Report Type:Expedited (15-DaCompany Report #WAES 0202NOR00013
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer		Lisinopril-Bc	C		ORAL		
	Gastrointestinal Haemorrhage		Furosemide	C		ORAL		
			Nitrofurantoin	C		ORAL		
			Ferrous Sulfate	C		ORAL		

Date:02/19/02ISR Number: 3870327-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Cerebrovascular Accident		Valium	C				
	Paronychia		Fosamax	C		ORAL		
	Transient Ischaemic		Soma	C				
	Attack		Lasix (Furosemide)	C				
			Calcium Carbonate	C		ORAL		
			L-Thyroxin	C		ORAL		
			Oxycontin	C				
			Quinine Sulfate	C				
			Cozaar	C		ORAL		
			Dilacor Xr	C				
			Atrovent	C				
RESPIRATORY								
(INHALATION)								
			Celebrex	C				

Date:02/19/02ISR Number: 3870328-2Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00019
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Lercanidipine Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Quinine And Thiamine	C				
			Oxybutynin Chloride	C		ORAL		

Date:02/19/02ISR Number: 3870329-4Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00018
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myeloid Leukaemia		Vioxx	PS	Merck & Co., Inc	ORAL	56	WK
Initial or Prolonged			Ciprofibrate	C				

			Risedronate Sodium	C		

Date:02/19/02ISR Number: 3870337-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00147
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 134 DAY	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Prednisolone	SS		ORAL
Other			Azathioprine	C		ORAL
			Bendroflumethiazide	C		ORAL
			Omeprazole	C		ORAL

Date:02/19/02ISR Number: 3870540-2Report Type:Expedited (15-DaCompany Report #WAES 0112USA02870
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Monoplegia Oedema Peripheral Pruritus	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/02ISR Number: 3870542-6Report Type:Expedited (15-DaCompany Report #WAES 01110555
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Headache	Professional	Prilosec	C				
	Retinal Artery Embolism		Atenolol	C				
			Hydrochlorothiazide And Triamterene	C				
			Prozac	C				
			Armour Thyroid Tablets	C				
			Aspirin	C				
			Vitamin E	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Magnesium (Unspecified)	C				
			Zinc (Unspecified)	C				

Date:02/19/02ISR Number: 3870547-5Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00293
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
	Congestive		Ranitidine	C		ORAL	55	DAY
	Gastrointestinal Haemorrhage							
	Haemoglobin Abnormal							
	Myocardial Infarction							

Date:02/19/02ISR Number: 3870550-5Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Erythema Induratum		Vioxx	PS	Merck & Co., Inc	ORAL
24 DAY						
Initial or Prolonged	Pruritus		Captopril	SS		ORAL
30 DAY						
	Purpura		Fusidate Sodium	SS		ORAL
40 DAY						
			Dipyridamole	SS		ORAL
38 DAY						
			Vancomycin	SS		
INTRAVENOUS		40 DAY				

Date:02/19/02ISR Number: 3870551-7Report Type:Expedited (15-DaCompany Report #WAES 01110878
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Niaspan	C		
			Altace	C		
			Zoloft	C		
			Lipitor	C		
			Aciphex	C		
			Neurontin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/02ISR Number: 3870555-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00151
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		441 DAY
Hospitalization - Initial or Prolonged			Bisoprolol Fumarate	C				
Disability			Captopril	C				
Other			Aluminum Hydroxide And Magnesium Carbonate	C				
			Heparinoid And Salicylic Acid	C				
			Digoxin	C				
			Furosemide	C				
			Atorvastatin	C				
			Aspirin	C				
			Acetaminophen And Codeine Phosphate	C				
			Doxazosin Mesylate	C				

Date:02/19/02ISR Number: 3870558-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Difficulty In Walking		Vioxx	SS		ORAL		
	Epistaxis							
	Ill-Defined Disorder							
	Renal Failure							

Date:02/19/02ISR Number: 3870559-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00187
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		315 DAY
	Spinal Disorder		Anastrozole	C		ORAL		
			Dihydrocodeine	C		ORAL		

		Levothyroxine Sodium	C	ORAL
		Sertraline	C	ORAL
		Lansoprazole	C	ORAL
		Acetaminophen	C	ORAL
		Beclomethasone Dipropionate	C	

RESPIRATORY

(INHALATION)

Date:02/19/02ISR Number: 3870560-8Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		

Date:02/19/02ISR Number: 3870561-XReport Type:Expedited (15-DaCompany Report #WAES 0112USA01494
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Medical Device Complication

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Hydrodiuril	C				
			Prevacid	C				
			Lasix (Furosemide)	C				
			Quinine	C				
			Glucophage	C				
			Diltiazem Malate	C				
			Vitamin B (Unspecified)	C				
			Ocuvite	C				

Date:02/19/02ISR Number: 3870563-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00165
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Initial or Prolonged	Condition Aggravated		Clotrimazole	C			VAGINAL	
	Urticaria		Insulin Human	C				
			Minocycline	C				
			Amphotericin B	C				
			Insulin, Isophane	C				

Date:02/19/02ISR Number: 3870564-5Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00029
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Exanthem		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pruritus							

Date:02/19/02ISR Number: 3870565-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00102
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx Etidronate Disodium	PS C	Merck & Co., Inc	ORAL		

Date:02/19/02ISR Number: 3871812-8Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00294
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Disorder Headache Mood Altered	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 6 DAY

Date:02/19/02ISR Number: 3872458-8Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00095
Age:73 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Blood Ph Decreased Drug Ineffective Drug Level Increased Haemodialysis Hypertension

	Kidney Small Oliguria Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Failure Acute Renal Tubular Necrosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY 5 DAY
	Urinary Tract Disorder		Digoxin	C			
			Fluinidione	C			
			Irbesartan	C			
			Pravastatin Na	C			

Date:02/19/02ISR Number: 3872781-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00490
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident	Company Representative Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO

Date:02/19/02ISR Number: 3872782-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA00719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO

Date:02/19/02ISR Number: 3872900-2Report Type:Expedited (15-DaCompany Report #WAES 01092606
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Drug Screen Positive	Health	Tab Vioxx	PS		ORAL	PO

Overdose	Professional	Tab Dizocilpine Maleate	SS

Date:02/20/02ISR Number: 3871013-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Anaemia
	Anxiety
	Asthenia
	Blood Pressure Increased
	Chills
	Cough
	Decreased Activity
	Dizziness
	Fatigue
	Gastrointestinal
	Haemorrhage
	Haematochezia
	Haemorrhoids
	Mental Disorder
	Nausea
	Orthostatic Hypotension
	Pallor

		Pyrexia					
		Rectal Haemorrhage					
		Sleep Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
		Tenderness		Vioxx	SS		ORAL
		Urinary Tract Infection		Tylenol Arthritis Extended Relief	C		
				Paxil	C		
				Paxil	C		
7	DAY						
				Zoloft	C		
				Zoloft	C		
13	DAY						
				Ascorbic Acid	C		
				Vitamin E	C		
				Vitamin B (Unspecified)	C		
				Motrin	C		
				[Therapy Unspecified]	C		
				[Therapy Unspecified]	C		
				Flonase	C		
				Aspirin	C		

Date:02/20/02ISR Number: 3871014-5Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06062
Age:91 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL
		Vomiting		Prasterone	SS		ORAL
				Nicergoline	SS		ORAL
				Ciprofloxacin Hydrochloride	SS		ORAL
				Misoprostol	SS		ORAL
				Aspirin Lysine	C		ORAL
				Ginkgo Biloba Extract	C		
				Hyzaar	C		ORAL
				Bisoprolol	C		ORAL
				Ascorbic Acid And Cysteine And			

Glutamic Acid And Glycine And Pyridoxine	C
Calcium (Unspecified) And Vitamin D (Unspecified)	C
Adenosine Triphosphate	C
Vitamin A	C
Ascorbic Acid	C
Vitamin E	C
Chondroitin Sulfate Sodium	C
Estradiol And Norethindrone Acetate	C
Ceftriaxone Sodium	C
Levofloxacin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3871015-7Report Type:Expedited (15-DaCompany Report #WAES 01120825
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Pulmonary Embolism		Vioxx	SS		ORAL		
			Premarin	C				
			Betapace	C				

Date:02/20/02ISR Number: 3871016-9Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc			

Date:02/20/02ISR Number: 3871022-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00099
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Oedema Peripheral							

Date:02/20/02ISR Number: 3871024-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00659
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Amitriptyline	C				
			Aricept	C				
			Tramadol	C				
			Hypericin	C				
			Melatonin	C				
			Chondroitin And Glucosamine	C				

				[Therapy Unspecified]	C		

Date:02/20/02ISR Number: 3872603-4Report Type:Direct Company Report #CTU 161878
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia		Vioxx	PS	Merck	ORAL	1 PER DAY	
	Dry Mouth						25MG ORAL	
	Feeling Abnormal		Hctz	C				
	Hallucination, Visual		Premarin	C				
	Lip Dry		Aspirin	C				
	Musculoskeletal Stiffness		Calcium	C				
	Nervousness		Vit E	C				
	Oedema Peripheral		Multi Vit	C				
	Pain							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3872615-0Report Type:Direct Company Report #CTU 161899
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis		Vioxx	PS		ORAL	25 MG PO BID	
Initial or Prolonged			Neurontin	C				
			Aciphex	C				
			Neurontin	C				
			Tums	C				

Date:02/20/02ISR Number: 3872634-4Report Type:Direct Company Report #CTU 161929
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intestinal Perforation		Aspirin 365mg	PS		ORAL	365MG DAILY	
						ORAL		
			Vioxx 25mg Merck	SS	Merck	ORAL	25MG DAILY	
						ORAL		

Date:02/20/02ISR Number: 3872826-4Report Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Study	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Condition Aggravated	Health					MG/DAILY/PO	
Initial or Prolonged	Constipation	Professional	Tab Placebo	SS		ORAL	PO	
	Diverticulum		Acetaminophen	SS		ORAL	325 MG/PRN/PO	
	Dizziness		Hydrodiuril	C				
	Gastric Ulcer		Tears Naturale	C				
	Gastrointestinal		Tubex	C				
	Haemorrhage		Vasocon-A	C				

	Iron Deficiency Anaemia	Aspirin	C
	Malnutrition	Folic Acid	C
	Rectal Haemorrhage	Methotrexate	C

Date:02/20/02ISR Number: 3872829-XReport Type:Expedited (15-DaCompany Report #WAES 01082868
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Dyspnoea	Health Professional	Prilosec	C			MG/DAILY/PO	

Date:02/20/02ISR Number: 3872891-4Report Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation	Study	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Diverticulum	Health Professional					MG/DAILY/PO;	
Initial or Prolonged	Dizziness						25MG/DAILY/PO	
	Gastric Ulcer		Tab Placebo (Unspecified) Unk	SS		ORAL	PO	
	Gastrointestinal							
	Haemorrhage		Acetaminophen Unk	SS		ORAL	325 MG/PRN/PO	
	Iron Deficiency Anaemia		Hydrodiuril	C				
	Malnutrition		Tears Naturale	C				
	Rectal Haemorrhage		Tubex	C				
			Vasocon-A	C				
			Aspirin	C				

			Folic Acid	C		
			Methotrexate	C		

Date:02/20/02ISR Number: 3872976-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Claritin-D	C				
			Darvocet-N	C				
			Humibid	C				
			Inderal	C				
			Nasonex	C				
			Prevacid	C				

Date:02/20/02ISR Number: 3872980-4Report Type:Expedited (15-DaCompany Report #WAES 01120825
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	50 MG/ DAILY/	
	Pulmonary Embolism						PO/ 1 YEAR	
			Betapace	C				
			Premarin	C				

Date:02/20/02ISR Number: 3873008-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02405
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Clonic Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
Initial or Prolonged	Grand Mal Convulsion	Professional	Coumadin	C				
			Lasix (Furosemide)	C				
			Digoxin	C				

Date:02/20/02ISR Number: 3873022-7Report Type:Expedited (15-DaCompany Report #WAES 01092114
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Tinnitus	Health					MG/DAILY/PO	
Disability		Professional	Aspirin	C				

Date:02/20/02ISR Number: 3873456-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00659
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	50 MG/ DAILY/	
Initial or Prolonged		Professional					PO	

Date:02/20/02ISR Number: 3873458-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00855
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Arrest
	Face Oedema

		Intestinal Functional Disorder					
		Lip Discolouration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain	Consumer	Tab Vioxx	PS		ORAL
PO							
		Pharyngeal Oedema					
		Renal Disorder					

Date:02/20/02ISR Number: 3873461-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02710
Age: Gender:Unknown I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death	Health	Tab Vioxx 50 Mg	PS		ORAL
PO							
Hospitalization -			Professional				
Initial or Prolonged			Company				
			Representative				

Date:02/20/02ISR Number: 3873512-7Report Type:Expedited (15-DaCompany Report #WAES 01095112
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Circulatory Collapse	Foreign	Tab Vioxx			
Initial or Prolonged		Dizziness	Health	(Rofecoxib)	PS		ORAL
25 MG/AM							
Other		Syncope	Professional	Diclofenac	C		
		Vomiting	Other				

Date:02/20/02ISR Number: 3873559-0Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00017
Age:46 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Pancytopenia	Foreign	Tab Vioxx			
			Health	(Rofecoxib)	PS		ORAL
25 MG/ DAILY							
			Professional				
PO	7 MON						

		Other	Acetaminophen	C
			Ciprofibrate	C
			Fluoxetine	C
			Lorazepam	C
			Raloxifene	C
			Sotalol Hydrochloride	C

Date:02/20/02ISR Number: 3873562-0Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00110
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	5 DAY
	Hypertension	Health						
	Nausea	Professional						
	Paraesthesia	Other						

Date:02/20/02ISR Number: 3873580-2Report Type:Expedited (15-DaCompany Report #WAES 01128509
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	10 DAY

	Cozaar	C
	Diazepam	C
	Diltiazem Hydrochloride	C
	Nitrazepam	C

Date:02/20/02ISR Number: 3873587-5Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00036
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG / DAILY	7 DAY
			Warfarin	SS			25 MG/DAILY	
	Prothrombin Level Decreased		Norfloxacin	C				
			Sodium Bicarbonate	C				

Date:02/20/02ISR Number: 3873588-7Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Intracranial	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	37.5 MG / WKY PO	
			Warfarin Sodium	SS		ORAL	3 MG/DAILY PO	

Date:02/20/02ISR Number: 3873589-9Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /	

		International Normalised				
DAILY PO	44 DAY					
		Ratio Increased		Warfarin	SS	ORAL
2.5 MG/DAILY						
		Prothrombin Level				
PO						
		Decreased		Prinivil	C	
				Acetaminophen	C	
				Digoxin	C	
				Folic Acid	C	
				Furosemide	C	
				Methotrexate	C	
				Prednisolone	C	
				Quinineso4	C	

Date:02/20/02ISR Number: 3873624-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
		Company	Phenobarbital	C		
		Representative	Primidone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3873625-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Hypertension							

Date:02/20/02ISR Number: 3873764-3Report Type:Expedited (15-DaCompany Report #WAES 01092114
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Tinnitus	Health						
Disability		Professional	Aspirin	C				

Date:02/20/02ISR Number: 3873874-0Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Foreign	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Dyspnoea		Amlodipine Besylate	SS			10 MG/DAILY	
	International Normalised		Atorvastatin Calcium	SS			10 MG/DAILY	
	Ratio Increased		Celecoxib	SS			400 MG/DAILY	
	Prothrombin Level		Paroxetine Hcl	SS			20 MG/DAILY	
	Decreased		Warfarin Sodium	SS			25 MG/DAILY	
	Prothrombin Time		Calcitriol	C				
	Prolonged		Diazepam	C				
			Digoxin	C				
			Irbesartan	C				
			Oxycodone Hcl	C				

Prazosin Hcl C

Date:02/20/02ISR Number: 3873880-6Report Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colonic Haemorrhage	Foreign	Tab Vioxx					
Life-Threatening	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	8 DAY
	Haemorrhage							

Date:02/20/02ISR Number: 3873881-8Report Type:Expedited (15-DaCompany Report #WAES 01109133
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -	Hypertensive Crisis	Health	(Rofecoxib)	PS		ORAL		
Initial or Prolonged		Professional	Gemfibrozil	C				

Date:02/20/02ISR Number: 3873885-5Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
	Prothrombin Time							
PO								44 DAY
	Prolonged		Warfarin	SS		ORAL	2.5 MG /	

DAILY PO

	Prinivil	C
	Acetaminophen	C
	Digoxin	C
	Folic Acid	C
	Furosemide	C
	Methotrexate	C
	Prednisolone	C
	Quinineso4	C

Date:02/20/02ISR Number: 3873886-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00099
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Foreign	Tab Vioxx					
	Oedema Peripheral	Other	(Rofecoxib)	PS		ORAL	12.5 MG /	
DAILY PO								5 DAY

Date:02/20/02ISR Number: 3873889-2Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00036
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx					
Initial or Prolonged	Prothrombin Level	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Decreased							
PO								7 DAY
			Warfarin	SS			25 MG/DAILY	
			Norfloxacin	C				
			Sodium Bicarbonate	C				

Date:02/20/02ISR Number: 3874032-6Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cerebral Haemorrhage	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
37.5 MG/WKY						
			Warfarin Sodium	SS		ORAL
3 MG/DAILY						

Date:02/20/02ISR Number: 3874033-8Report Type:Expedited (15-DaCompany Report #WAES 0201CAN00091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deafness Unilateral	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL

Date:02/20/02ISR Number: 3874042-9Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Convulsion	Foreign	Tab Vioxx			
	Dry Mouth	Consumer	(Rofecoxib)	PS		ORAL
25 MG/BID						
			Paroxetine Hcl	C		

Date:02/20/02ISR Number: 3874044-2Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:02/20/02ISR Number: 3874054-5Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00030
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Tab Vioxx					
	Ecchymosis	Other	(Rofecoxib)	PS				
	Epistaxis		Warfarin	SS				
	Gingival Bleeding						3 MG/DAILY	
	Prothrombin Level Decreased							
	Prothrombin Time Prolonged							
	Purpura							

Date:02/20/02ISR Number: 3874058-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00722
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort	Foreign	Tab Vioxx					
Life-Threatening	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	20 DAY	
Hospitalization - Initial or Prolonged			Norgesic (Aspirin (+) Caffeine (+) Orphe	C				
			Cyanocobalamin	C				

Date:02/20/02ISR Number: 3874060-0Report Type:Expedited (15-DaCompany Report #WAES 0202AUT00005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	14 DAY
			Pantoprazole Sodium	SS				
			Amlodipine Besylate	C				
			Citalopram Hydrobromide	C				
			Hydrochlorothiazide (+) Ramipril	C				

Date:02/20/02ISR Number: 3874064-8Report Type:Expedited (15-DaCompany Report #WAES 01105162
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia Pancytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY	
			Acetaminophen/ Propoxyphene Hydrochloride	C				
			Mercaptopurine	C				
			Metronidazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3874074-0Report Type:Expedited (15-DaCompany Report #WAES 0201BEL00011
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amaurosis Fugax Carotid Artery Occlusion	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
Other	Carotid Artery Stenosis	Professional	Tab Prasterone	SS		ORAL	12 MG PO	
	Hypertension		Aspirin	C				
			Cerivastatin	C				

Date:02/20/02ISR Number: 3874077-6Report Type:Expedited (15-DaCompany Report #WAES 01118615
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Incomplete Abortion Spontaneous	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Drug Interaction Haemorrhage Pregnancy On Oral Contraceptive Retained Products Of Conception	Professional	Ethinyl Estradiol/Norgestimate	SS		ORAL		
			Tab Flexeril (Cyclobenzaprine Hcl) 10 Mg/Prn	SS		ORAL	PO	
	Ultrasound Antenatal Screen Abnormal							

Date:02/20/02ISR Number: 3874081-8Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00078
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Bradycardia Hyperkalaemia Renal Impairment	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	5 DAY
			Cystine	C				
			Perindopril	C				

			Spironolactone	C		

Date:02/21/02ISR Number: 3871342-3Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
	International Normalised Ratio Decreased		Warfarin Sodium	SS		ORAL

Date:02/21/02ISR Number: 3871344-7Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 44 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Interaction		Warfarin	SS		ORAL
	International Normalised Ratio Increased		Digoxin	C		ORAL
			Furosemide	C		ORAL
	Prothrombin Level Decreased		Folic Acid	C		ORAL
			Methotrexate	C		ORAL
			Prednisolone	C		ORAL
			Quinine Sulfate	C		ORAL
			Prinivil	C		ORAL
			Acetaminophen	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/02ISR Number: 3871346-0Report Type:Expedited (15-DaCompany Report #WAES 01113294
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/21/02ISR Number: 3871347-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00722
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Exposure		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Life-Threatening	Chest Discomfort		Vioxx	SS		ORAL	10	DAY
Hospitalization - Initial or Prolonged	Dyspnoea		Norgesic (Aspirin (+) Caffeine (+) Orphenadrine Citrate)	C				
	Renal Failure		Cyanocobalamin	C				

Date:02/21/02ISR Number: 3871348-4Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Amlodipine Besylate	SS				
	International Normalised Ratio Increased		Atorvastatin Calcium	SS				
	Prothrombin Level Decreased		Celecoxib	SS				
			Paroxetine Hydrochloride	SS				
			Warfarin Sodium	SS				
			Prazosin Hydrochloride	C				
			Irbesartan	C				
			Digoxin	C				
			Oxycodone Hydrochloride	C				
			Calcitriol	C				
			Diazepam	C				

Date:02/21/02ISR Number: 3871353-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA01645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:02/21/02ISR Number: 3871617-8Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Blood Albumin Decreased
Hospitalization - Initial or Prolonged	Blood Immunoglobulin A Decreased
	Blood Immunoglobulin G Increased
	Blood Immunoglobulin M Decreased
	Blood Urea Increased
	Haematocrit Decreased

		Haemoglobin Decreased					
		Hypergammaglobulinaemia					
		Benign Monoclonal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Immunoglobulins Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Laboratory Test Abnormal		Acetaminophen And			
		Lymphocyte Count Abnormal		Oxycodone			
		Multiple Myeloma		Hydrochloride	C		ORAL
		Neutrophil Count Abnormal		Calcium Carbonate			
		Protein Urine Present		And Etidronate			
		Red Blood Cell Count		Sodium	C		
		Decreased		Atorvastatin Calcium	C		
		Serum Ferritin Decreased		Celecoxib	C		
41	DAY						

Date:02/21/02ISR Number: 3871619-1Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00008
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hemiplegia		Amphetamine And			
Initial or Prolonged			Phenobarbital	C		ORAL
Disability			Benserazide			
			Hydrochloride And			
			Levodopa	C		ORAL
			Ergoloid Mesylates	C		ORAL
			Propranolol			
			Hydrochloride	C		ORAL
			Bezafibrate	C		ORAL
			Fentanyl	C		
TOPICAL						

Date:02/21/02ISR Number: 3871621-XReport Type:Expedited (15-DaCompany Report #WAES 0202ZAF00011
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Disorientation		Ramipril	C		ORAL
			Glimepiride	C		ORAL

Date:02/21/02ISR Number: 3872734-9Report Type:Direct Company Report #CTU 162006
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS			50MG QD	
Initial or Prolonged	Diarrhoea							
GREATER THAN								
	Faecal Occult Blood							
6 MONTHS								
	Positive							
	Faeces Discoloured							
	Haemoglobin Decreased							
	Melaena							

Date:02/21/02ISR Number: 3873443-2Report Type:Expedited (15-DaCompany Report #2002090788GB
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Aortic Valve Incompetence
Hospitalization -	Chills
Initial or Prolonged	Endocarditis
	Neutrophilia

Pyrexia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Salazopyrin (Sulfasalazine) Tablet	PS		ORAL	1 G, BID,	
Other						
	Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, QD,	
	Naproxen	C				

Date:02/22/02ISR Number: 3871949-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00131
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	122 DAY	
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Professional	Aspirin	SS		ORAL		
			Betahistine Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Spironolactone	C		ORAL		

Date:02/22/02ISR Number: 3871950-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02112
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc			

Date:02/22/02ISR Number: 3871952-3Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00011
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/02ISR Number: 3871960-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA01530
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
			Cardizem	C				
			Tambocor	C				
			Aspirin	C				

Date:02/22/02ISR Number: 3871961-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA01537
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diclofenac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/02ISR Number: 3872184-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00019
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Lercanidipine Hydrochloride	C		ORAL		
	Melaena		Tramadol Hydrochloride	C		ORAL		
			Quinine And Thiamine	C				
			Oxybutynin Chloride	C		ORAL		

Date:02/22/02ISR Number: 3872186-9Report Type:Expedited (15-DaCompany Report #WAES 01105180
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness		Vioxx	SS		ORAL		
	Orthostatic Hypotension		Aspirin	C		ORAL		

Date:02/22/02ISR Number: 3872189-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA02168
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Grand Mal Convulsion		Nexium	C				3 DAY
			Levothyroxine Sodium	C				
			Fibercon	C				

Date:02/22/02ISR Number: 3872190-0Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00162
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholinesterase		Phenprocoumon	C		ORAL		3 MON

Abnormal	Spironolactone	C
C-Reactive Protein Increased	Omeprazole	C
Clostridium Colitis	Naloxone Hydrochloride And Tilidine Hydrochloride	C
Culture Wound Positive	Prednisolone	C
Disseminated Intravascular Coagulation		
Exanthem		
Impaired Healing		
International Normalised Ratio Increased		
Klebsiella Infection		
Neutrophil Toxic Granulation Present		
Oedema Peripheral		
Petechiae		
Platelet Count Increased		
Staphylococcal Infection		
Stenotrophomonas Infection		

Date:02/22/02ISR Number: 3872193-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Difficulty In Walking Epistaxis Haemorrhage Renal Disorder		Vioxx	SS		ORAL		

Date:02/22/02ISR Number: 3872196-1Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00088
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged	Cardiac Arrest							

Date:02/22/02ISR Number: 3872198-5Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00091
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/02ISR Number: 3872199-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00030
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization -	Haemoglobin Decreased		Omeprazole	C		ORAL		8 DAY
Initial or Prolonged	Shock		Felodipine	C		ORAL		
			Simvastatin	C		ORAL		

			Estradiol And Medroxyprogesterone Acetate	C			ORAL
			Naftazone	C			ORAL

Date:02/22/02ISR Number: 3872201-2Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00031
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonoscopy Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Large Intestinal Ulcer Loss Of Consciousness Rectal Haemorrhage Shock		Acetaminophen	C		ORAL		

Date:02/22/02ISR Number: 3872204-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA01890
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Memory Impairment Subdural Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL	69	DAY
			Naprosyn	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/02ISR Number: 3872208-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA01722
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bilirubinuria		Vioxx	PS	Merck & Co., Inc	ORAL		
	Liver Disorder		Lipitor	SS				
	Liver Function Test Abnormal		Corticosteroids (Unspecified)	C				

Date:02/22/02ISR Number: 3874683-9Report Type:Expedited (15-DaCompany Report #WAES 00033093
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Literature	Tab Vioxx	PS		ORAL	25 MG/PO	
		Health Professional Company Representative	Therapy Unspecified	C				
			Chlorpheniramine Maleate	C				
			Fluticasone Propionate	C				
			Pseudoephedrine	C				

Date:02/22/02ISR Number: 3874769-9Report Type:Expedited (15-DaCompany Report #WAES 01072444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/22/02ISR Number: 3874772-9Report Type:Expedited (15-DaCompany Report #WAES 01072443
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Myocardial Infarction							

Date:02/22/02ISR Number: 3874775-4Report Type:Expedited (15-DaCompany Report #WAES 01072444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:02/22/02ISR Number: 3875335-1Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00152
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Ulcer Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5-25 MG	
	Helicobacter Infection	Professional					PO	256 DAY
		Other						

Date:02/24/02ISR Number: 3872650-2Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00081
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder		Metformin	C				
			Doxazosin Mesylate	C				

			Hydrochlorothiazide And Valsartan	C		
			Carvedilol	C		

Date:02/24/02ISR Number: 3872652-6Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00225
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tongue Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C		ORAL		

Date:02/24/02ISR Number: 3872654-XReport Type:Expedited (15-DaCompany Report #WAES 0202BEL00020
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/02ISR Number: 3872659-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
79 DAY								
Initial or Prolonged	Arrhythmia		[Composition					
	Asthenia		Unspecified]	C				
PARENTERAL								
	Bronchitis							
	Cardiac Flutter							
	Depressed Level Of Consciousness							
	Duodenal Ulcer Haemorrhage							
	Dysstasia							
	Erosive Duodenitis							
	Fatigue							
	Gastric Ulcer							
	Gastrointestinal Haemorrhage							

Heart Rate Irregular
Hyperhidrosis
Influenza Like Illness
Sensitivity Of Teeth
Syncope

Date:02/24/02ISR Number: 3872660-5Report Type:Expedited (15-DaCompany Report #WAES 0202ZAF00010
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/02ISR Number: 3872664-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Inderal	C				
			Claritin-D	C				
			Humibid	C				

Prevacid	C
Nasonex	C
Darvocet-N	C
Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C

Date:02/25/02ISR Number: 3873129-4Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		135 DAY
Life-Threatening	Arrhythmia		Prednisone	SS				6 DAY
Hospitalization - Initial or Prolonged	Asthenia		Cozaar	C				
Disability	Atrioventricular Block		Bumex	C				
Other	First Degree		Lanoxin	C				
	Blood Pressure Increased		Klor-Con	C				
	Cardiac Arrest		Premarin	C				
	Dizziness		Lotensin	C				
	Duodenal Ulcer		Lasix (Furosemide)	C				
	Haemorrhage		Aspirin	C				
	Electrocardiogram St Segment Depression							
	Electrocardiogram T Wave Inversion							
	Faecal Occult Blood Positive							
	Fall							
	Gastrointestinal Haemorrhage							
	Haematocrit Decreased							
	Heart Rate Increased							
	Hypoaesthesia							
	Hypotension							
	Loss Of Consciousness							
	Respiratory Rate Increased							
	Syncope							

Date:02/25/02ISR Number: 3873130-0Report Type:Expedited (15-DaCompany Report #WAES 0202POL00010
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Hypersensitivity Oedema Peripheral Rash Tongue Oedema	Professional	Vioxx	SS		ORAL		

Date:02/25/02ISR Number: 3873131-2Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00012
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Cardiac Failure Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/02ISR Number: 3873133-6Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00005
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Axillary Pain	Professional	Moclobemide	C		ORAL		
Initial or Prolonged	Blood Creatine		Clonazepam	C		ORAL		
Disability	Phosphokinase Increased							
	Chest Wall Pain							
	Multi-Organ Failure							
	Necrotising Fasciitis							
	Platelet Count Decreased							
	Streptococcal Sepsis							
	White Blood Cell Count Increased							

Date:02/25/02ISR Number: 3873134-8Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00020
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Orthostatic Hypotension	Health	Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	
Initial or Prolonged	Pneumonia	Professional	Aspirin	SS		ORAL		
	Purpura		Cinnarizine	SS		ORAL		
	Renal Failure Acute		Amiloride Hydrochloride And Hydrochlorothiazide	SS		ORAL		
			Amiloride Hydrochloride And Hydrochlorothiazide	SS		ORAL	DAY	

Date:02/25/02ISR Number: 3873139-7Report Type:Expedited (15-DaCompany Report #WAES 0202NOR00019
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Potassium Increased		Prinivil	C				
	Blood Pressure Decreased		Furosemide	C				
	Gastric Ulcer		Metoprolol Tartrate	C				

	Melaena	Iron (Unspecified)	C
		Digitoxin	C
		Acetaminophen And Codeine Phosphate	C
		Flunitrazepam	C
		Insulin Human, Isophane	C
		Cetirizine Hydrochloride	C
		Isosorbide Mononitrate	C

Date:02/25/02ISR Number: 3873141-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA01670
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/02ISR Number: 3873145-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/02ISR Number: 3873429-8Report Type:Direct Company Report #CTU 162141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthma		Vioxx	PS		ORAL	12.5MG PO	Intervention to Prevent Permanent Impairment/Damage

Date:02/25/02ISR Number: 3873934-4Report Type:Expedited (15-DaCompany Report #WAES 01090334
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Eye Pain							
	Nystagmus		Armour Thyroid					
	Rhinitis		Tablets	C				
			Pepcid	C				
			Prolex D	C				
			Estradiol	C				

Date:02/25/02ISR Number: 3874133-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00147
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Foreign	Tab Vioxx					

Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Other						
PO	134 DAY					
			Prednisolone	SS		ORAL
VARIABLE PO						
			Azathioprine	C		
			Bendroflumethiazide	C		
			Omeprazole	C		

Date:02/25/02ISR Number: 3874135-6Report Type:Expedited (15-DaCompany Report #WAES 0202NOR00013
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia	Foreign	Tab Vioxx			
Hospitalization -	Gastric Ulcer	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Gastrointestinal					
PO						
	Haemorrhage		Lisinopril-Bc	C		
			Ferrousso4	C		
			Furosemide	C		
			Nitrofurantoin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/02ISR Number: 3874140-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00019
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Melaena	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG /DAILY	
			Lercanidipine Hydrochloride	C				
			Oxybutynin Cl	C				
			Quinine/Thiamine	C				
			Tramadol Hcl	C				

Date:02/25/02ISR Number: 3874143-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00018
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Myeloid Leukaemia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	56 WK
	Nausea	Professional	Ciprofibrate	C				
			Risedronate Sodium	C				

Date:02/25/02ISR Number: 3874146-0Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Dyspnoea		Amlodipine Besylate	SS			10MG/DAILY	
	International Normalised Ratio Increased		Atorvastatin Calcium1	SS			10 MG/DAILY	
	Prothrombin Level		Celecoxib	SS			400 MG/DAILY	
	Decreased		Paroxetine Hcl	SS			20MG/DAILY	

			Warfarin Sodium	SS		
25 MG/DAILY						
			Calcitriol	C		
			Diasepam	C		
			Digoxin	C		
			Irbesartan	C		
			Oxycodone Hcl	C		
			Prazosin Hcl	C		

Date:02/25/02ISR Number: 3874147-2Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00030
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction	Foreign	Tab Vioxx			
Initial or Prolonged	Ecchymosis	Other	(Rofecoxib)	PS		
	Epistaxis		Warfarin	SS		
3 MG/DAILY						
	Gingival Bleeding					
	International Normalised					
	Ratio Increased					
	Purpura					

Date:02/25/02ISR Number: 3874334-3Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00006
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anxiety

Hypertension

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign	Vioxx	PS		ORAL	50 MG/DAILY	
Study						
Health Professional	Tab Placebo (Unspecified)	SS		ORAL	PO	
	Hctz/Triamterene	C				
	Prinivil	C				
	Aspirin	C				
	Calcium Carbonate	C				
	Cyanocobalamin	C				
	Folic Acid	C				
	Folic Acid (+) Iron (Unspecified) (+) Vi	C				
	Infliximab	C				
	Methotrexate	C				
	Prednisolone	C				
	Propranolol	C				
	Tibolone	C				
	Tramadol Hcl	C				

Date:02/25/02ISR Number: 3874365-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cerebrovascular Accident	Professional					MG/DAILY/PO	
Disability	Paronychia	Company	Atrovent	C				
Other	Transient Ischaemic Attack	Representative	Celebrex	C				
			Cozaar	C				
			Dilacor Xr	C				
			Fosamax	C				
			L-Thyroxin	C				
			Lasix (Furosemide)	C				
			Oxycontin	C				
			Soma	C				
			Valium	C				

Calcium Carbonate	C
Quinine Sulfate	C

Date:02/25/02ISR Number: 3874368-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA01138
Age:58 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:02/25/02ISR Number: 3874995-9Report Type:Direct Company Report #CTU 162253
Age:71 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required

Intervention to
Prevent Permanent
Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure		Vioxx 40mg?	PS				1 PER
Congestive							

Date:02/25/02ISR Number: 3875134-0Report Type:Direct Company Report #CTU 162227
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Potassium Increased		Vioxx	PS	Merck			
			Norvasc	C				
			Glucophage Xr	C				
			Darvocet-N 100	C				
			Imdur	C				
			Sliding Scale Insulin	C				
			Premarin	C				
			Glucotrol Xl	C				
			Plavix	C				
			Norvasc	C				
			Novolin 70/30 Insulin	C				
			Lasix	C				
			Altace	C				
			Mom	C				

Date:02/26/02ISR Number: 3873648-0Report Type:Expedited (15-DaCompany Report #WAES 01111500
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Vioxx	SS		ORAL	7	DAY
			Avalox	C				
			Rhinocort	C				
			Qvar	C				
			Combivent	C				
			Monopril	C				

Toprol Xl Tablets	C
Depo-Medrol	C
Lomotil	C
Imodium	C
Celebrex	C

Date:02/26/02ISR Number: 3873651-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA01448
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
	Asthenia
	Chills
	Cold Sweat
	Dehydration
	Dizziness
	Dyspepsia
	Feeling Cold

		Headache					
		Hypoaesthesia					
		Migraine	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Intake Reduced		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain					
		Pyrexia					
		Renal Neoplasm					
		Stress					
		Visual Disturbance					
		Vomiting					

Date:02/26/02ISR Number: 3873652-2Report Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Cardiac Arrest		Prednisone	SS		
6 DAY						
Hospitalization -	Duodenal Ulcer		Cozaar	C		ORAL
Initial or Prolonged	Haemorrhage		Bumex	C		ORAL
Disability	Exsanguination		Lanoxin	C		ORAL
Other	Haematochezia		Klor-Con	C		ORAL
	Haemorrhage		Premarin	C		ORAL
	Syncope		Lotensin	C		ORAL

Date:02/26/02ISR Number: 3873693-5Report Type:Expedited (15-DaCompany Report #WAES 01111442
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/26/02ISR Number: 3873697-2Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blood Albumin Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Disability	Multiple Myeloma Osteopenia Osteoporosis Red Blood Cell Count Decreased	Professional	Acetaminophen And Oxycodone Hydrochloride Calcium Carbonate And Etidronate Sodium Atorvastatin Calcium Celecoxib	C C C C		ORAL

41 DAY

Date:02/26/02ISR Number: 3873700-XReport Type:Expedited (15-DaCompany Report #WAES 0202CAN00088
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Life-Threatening Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Cardiac Arrest	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/02ISR Number: 3873702-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA01537
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive	Professional	Vioxx	SS		ORAL		
			Diclofenac	C				

Date:02/26/02ISR Number: 3893152-3Report Type:Periodic Company Report #CAPTOPRL2001-00354
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pruritus	Foreign	Lopril (Captopril)	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Skin Reaction	Health					PO	
		Professional	Fucidine	SS				
			Vioxx	SS				
			Cleridium	SS				
			Vancomycine	SS				

Date:02/27/02ISR Number: 3874114-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2 MON	
Initial or Prolonged	Asthenia							
	Blood Pressure							
	Fluctuation							
	Cerebrovascular Accident							
	Computerised Tomogram							
	Abnormal							
	Coordination Abnormal							
	Coronary Artery Stenosis							
	Drug Ineffective							
	Gait Disturbance							
	Hyperreflexia							
	International Normalised							
	Ratio Decreased							

Peroneal Nerve Palsy
Prothrombin Time
Prolonged
Ventricular Hypertrophy

Date:02/27/02ISR Number: 3874115-0Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00235
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/27/02ISR Number: 3874116-2Report Type:Expedited (15-DaCompany Report #WAES 0202SWE00026
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
4 WK								
Initial or Prolonged	Dyspnoea		Acetaminophen	C				
	Gastric Ulcer		Clarithromycin	C				
	Haemoglobin Decreased		Propranolol Hydrochloride	C				
			Allopurinol	C				

				Lansoprazole	C		

Date:02/27/02ISR Number: 3874117-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Melaena		Pergolide	C		ORAL
Initial or Prolonged	Pneumonia		Temazepam	C		
	Upper Gastrointestinal		Carbidopa And			
	Haemorrhage		Levodopa	C		
			Ipratropium Bromide	C		
RESPIRATORY						
(INHALATION)						
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Scopolamine	C		

Date:02/27/02ISR Number: 3874119-8Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dyspnoea					
Initial or Prolonged	Hyperventilation					
	Hypoaesthesia					
	Nausea					
	Respiratory Alkalosis					

Date:02/27/02ISR Number: 3874121-6Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00138
Age:74 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Peritonitis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Small Intestinal					

Initial or Prolonged Perforation

Date:02/27/02ISR Number: 3874124-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA00207
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Impaired Healing		Vioxx	PS	Merck & Co., Inc	ORAL
			Lorazepam	C		
			Advair	C		
			Prevacid	C		
			Celexa	C		
			Furosemide	C		
			Theophylline	C		
			Evista	C		

Date:02/27/02ISR Number: 3874386-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 MON	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Tolerance		Ziac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/02ISR Number: 3874387-2Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Restenosis		Dalteparin Sodium	C		SUBCUTANEOUS		
	Myocardial Infarction		Aspirin	C		ORAL		

Date:02/27/02ISR Number: 3874388-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA03021
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Palpitations		Toprol Xl Tablets	C				
			Prevacid	C				

Date:02/27/02ISR Number: 3874389-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02036
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Lasix (Furosemide)	C				
	Dyspnoea		Lanoxin	C				
	Fluid Overload		Avandia	C				
			Zaroxolyn	C				
			Aspirin	C				
			Niferex	C				
			Insulin	C				
			Insulin	C				

Date:02/27/02ISR Number: 3874391-4Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00153
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL
17 DAY						
Hospitalization -			Captopril	C		ORAL
Initial or Prolonged			Bisoprolol	C		ORAL

Date:02/27/02ISR Number: 3874393-8Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Citalopram Hydrobromide	C		ORAL

Date:02/27/02ISR Number: 3874399-9Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00265
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY						
Initial or Prolonged	Melaena		Acetaminophen	C		ORAL
Disability			Fluoxetine	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/02ISR Number: 3874855-3Report Type:Direct Company Report #CTU 162432
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Rofecoxib	PS		ORAL	25MG PO BID	
Initial or Prolonged	Fatigue		Prednisone	SS		ORAL	10MG PO QD	
Required	Haematocrit Abnormal		Aspirin (Excedrin)	SS		ORAL	1 TAB PO BID	
Intervention to	Haemoglobin Abnormal		Atorvastatin	C				
Prevent Permanent	Nocturia		Zolpidem	C				
Impairment/Damage	Platelet Count Decreased		Atorvastatin	C				
	Pollakiuria		Percocet					
	Rectal Haemorrhage		(Acetaminophen/Oxyco					
	Vomiting		done)	C				
	Weight Decreased							

Date:02/27/02ISR Number: 3875945-1Report Type:Direct Company Report #CTU 162433
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arterial Occlusive		Vioxx	PS				
25MG								
	Disease							
	Cardio-Respiratory Arrest							
	Cholelithiasis							
	Cold Sweat							
	Dyspepsia							
	Dyspnoea							
	Nausea							
	Pulmonary Oedema							
	Urinary Incontinence							
	Weight Increased							

Date:02/27/02ISR Number: 3875999-2Report Type:Direct Company Report #CTU 162479
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort		Ibuprofen	PS				

			Vioxx	SS		
			Ultram	SS		

Date:02/27/02ISR Number: 3876023-8Report Type:Direct Company Report #CTU 162488
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine		Vioxx 25mg Merck	PS	Merck	ORAL
25MG QD ORAL						
Initial or Prolonged	Increased		Cipro	C		
	Renal Failure Acute		Lomotil	C		
			Senekot	C		

Date:02/28/02ISR Number: 3875104-2Report Type:Expedited (15-DaCompany Report #WAES 0202NLD00091
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Omeprazole	C		ORAL
Initial or Prolonged			Furosemide	C		ORAL
			Carbaspirin Calcium	C		ORAL
			Isosorbide Mononitrate	C		ORAL

			Lisinopril	C		ORAL
			Isosorbide Dinitrate	C		ORAL
			Goserelin Acetate	C		
PARENTERAL						

Date:02/28/02ISR Number: 3875376-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00200
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
36 DAY						
Initial or Prolonged	Decubitus Ulcer		Fosamax	C		ORAL
18 DAY						
	Gastric Haemorrhage		Calcium Carbonate			
	Haemoglobin Decreased		And Cholecalciferol	C		ORAL
			Citalopram	C		ORAL
			Metformin	C		ORAL
			Gliclazide	C		ORAL
			Ibuprofen	C		

Date:02/28/02ISR Number: 3875377-6Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00034
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Balance Disorder		Losartan Potassium	PS		ORAL
Hospitalization -	Condition Aggravated		Furosemide Sodium	SS		ORAL
Initial or Prolonged	Dehydration		Diclofenac Sodium	SS		ORAL
	Drug Interaction		Vioxx	SS	Merck & Co., Inc	ORAL
	Metabolic Acidosis		Metformin			
	Po2 Increased		Hydrochloride	SS		ORAL
	Renal Failure Acute		Acenocoumarol	C		ORAL
	Vomiting		Itraconazole	C		ORAL
2 DAY						
			Omeprazole Sodium	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Amlodipine Besylate	C		ORAL
			Miglitol	C		ORAL

Date:02/28/02ISR Number: 3875379-XReport Type:Expedited (15-DaCompany Report #WAES 0202MEX00017
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Deflazacort	C				
Initial or Prolonged			Pepcid	C		ORAL		

Date:02/28/02ISR Number: 3875381-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA01256
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Fosamax	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Faeces Discoloured		Fosamax	SS		ORAL		
	Gastric Ulcer		Vioxx	SS				
	Gastric Ulcer Haemorrhage		Plavix	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased							
	Melaena							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3875384-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/28/02ISR Number: 3875385-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA02325
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Hyponatraemia		Levodopa	C				
			Minipress	C				
			Zoloft	C				

Date:02/28/02ISR Number: 3875386-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00256
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Other	Drug Interaction		Lithium Carbonate	SS		ORAL		
	Drug Level Increased		Sulfasalazine	C		ORAL		
	Therapeutic Agent		Methotrexate Sodium	C		ORAL		
	Toxicity		Oxybutynin Chloride	C		ORAL		
	Tremor							
	Vomiting							

Date:02/28/02ISR Number: 3875388-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA02014
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Blood Urea Increased							
	Oedema							

Tachycardia

Date:02/28/02ISR Number: 3875393-4Report Type:Expedited (15-DaCompany Report #WAES 0112DEU05629
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Vioxx	SS		ORAL		
Initial or Prolonged	Attention		Levothyroxine Sodium	C		ORAL		
	Deficit/Hyperactivity							
	Disorder							
	Coronary Artery							
	Thrombosis							
	Dyspnoea							
	Echocardiogram Abnormal							
	Hypokinesia							
	Myocardial Infarction							
	Protein S Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3875394-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA02447
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Other	Dysgeusia		Lotrel	C				
	Gingival Pain		Zocor	C				
	Glossodynia		Hydrodiuril	C				
	Hypoaesthesia Oral		Aspirin	C				
			Glucosamine	C				
			Ascorbic Acid	C				

Date:02/28/02ISR Number: 3875397-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA02439
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Plavix	C				
			Aspirin	C				
			Tenormin	C				
			Prevacid	C				
			Ativan	C				
			Pravachol	C				
			Zoloft	C				
			Neurontin	C				
			Demadex	C				
			Plaquenil	C				
			Elavil	C				
			Colestid	C				

Date:02/28/02ISR Number: 3875398-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:02/28/02ISR Number: 3875402-2Report Type:Expedited (15-DaCompany Report #WAES 0202ITA00068
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Urticaria		Paroxetine Hydrochloride	C				
			Zocor	C				
			Tribenoside	C				
			Diclofenac	C				

Date:02/28/02ISR Number: 3875403-4Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00118
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3875404-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA02045
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Increased		Lipitor	SS				
	Anorexia		Lipitor	SS				10 DAY
	Arterial Disorder		Prednisone	C				
	Aspartate							
	Aminotransferase							
	Increased							
	Biopsy Site Unspecified							
	Abnormal							
	Blood Alkaline							
	Phosphatase Increased							
	Blood Bilirubin Increased							
	Chromaturia							
	Headache							
	Hypercholesterolaemia							
	Pain In Extremity							
	Pelvic Pain							
	Platelet Count Increased							
	Pyrexia							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Temporal Arteritis							
	Tendonitis							

Date:02/28/02ISR Number: 3875745-2Report Type:Direct Company Report #CTU 162507
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS		ORAL		VIOXX? PO
Initial or Prolonged	Dyspnoea		Lasix 40 Mg					
	Fall		(Generic)	SS		ORAL		LASIX 40MG
	Oedema Peripheral							
								PO, INCREASED

TO 80 MG

Cozaar	C
Allopurinol	C
Klotrix	C
Digoxin	C
Premarin	C
Sular	C
Synthroid	C
Trandate	C
Glynase	C
Zantac	C
Plavix	C
Amitriptyline	C

Date:02/28/02ISR Number: 3875767-1Report Type:Direct Company Report #CTU 162503
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice Cholestatic		Vioxx	PS		ORAL	25 PO QD	1 YR
Initial or Prolonged			Plaquenil	SS		ORAL	400MG PO QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3875769-5Report Type:Direct Company Report #CTU 162505
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx 12.5mg	PS			12.5MG QD	1 WK
Initial or Prolonged	Coordination Abnormal		Methotrexate	C				
	Hypoaesthesia		Coumadin	C				
	Paraesthesia		Calcium Plus Vit D	C				
	Posture Abnormal		Multivitamin	C				

Date:02/28/02ISR Number: 3875770-1Report Type:Direct Company Report #CTU 162506
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS		ORAL	250MG QD PO	1 WK
Initial or Prolonged	Hypertension		Furosemide (40mg Mwf)	SS		ORAL	40MG PO MWF	
	Loss Of Consciousness		Prilosec	C				

Date:02/28/02ISR Number: 3876400-5Report Type:Expedited (15-DaCompany Report #WAES 0112FRA06062
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vertigo	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
Initial or Prolonged	Vomiting	Other	Prasterone	SS		ORAL		
			Nicergoline	SS		ORAL		
			Misoprostol	SS		ORAL		
			Ciprofloxacin Hydrochloride	C		ORAL		
			Hyzaar	C				
			Adenosine Triphosphate	C				
			Ascorbic Acid	C				
			Ascorbic Acid (+) Cysteine (+)					

Glutamic	C
Aspirin Lysine	C
Bisoprolol	C
Calcium Unspecified (+) Vitamin D (Uns	C
Ceftriaxone Sodium	C
Chondroitin Sulfate Sodium	C
Estradiol Norethindrone Acetate	C
Gingko Biloba Extract	C
Levofloxacin	C
Vitamin A	C
Vitamin E	C

Date:02/28/02ISR Number: 3876402-9Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00099
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Difficulty In Walking	Foreign
	Oedema Peripheral	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	5 DAY

Date:02/28/02ISR Number: 3876406-6Report Type:Expedited (15-DaCompany Report #WAES 01085105
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myogelosis Oedema Peripheral Pain In Extremity	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Acetaminophen	C				
			Ibruprofen	C				

Date:02/28/02ISR Number: 3876481-9Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00008
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Hemiplegia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY PO	
			Amphetamine (+) Phenobarbital Benserazide Hydrochloride (+)	C				
			Levodopa	C				
			Bezafibrate	C				
			Ergoloid Mesylates	C				
			Fentanyl	C				
			Propranolol Hcl	C				

Date:02/28/02ISR Number: 3876486-8Report Type:Expedited (15-DaCompany Report #WAES 01085105
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Disorder	Foreign	Tab Vioxx					
	Myogelosis	Health	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
	Oedema Peripheral	Professional					PO	
	Pain In Extremity		Acetaminophen	C				
			Ibuprofen	C				

Date:02/28/02ISR Number: 3876487-XReport Type:Expedited (15-DaCompany Report #WAES 0202AUS00033
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Literature	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Dyspnoea						PO	
	International Normalised		Amlodipine Besylate	SS		ORAL	10 MG DAILY	
	Ratio Increased						PO	
	Prothrombin Level		Atorvastatin Calcium	SS			10 MG DAILY	
	Decreased		Celecoxib	SS			400 MG DAILY	
			Paroxetine Hcl	SS			20 MG DAILY	
			Warfarin Sodium	SS			25 MG DAILY	
			Calcitriol	C				

			Diazepam	C
			Digoxin	C
			Irbesartan	C
			Oxycodone	C
			Prazosin Hcl	C

Date:02/28/02ISR Number: 3876489-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00722
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain	Foreign	Tab Vioxx					
Life-Threatening	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	PO	
Hospitalization -	Renal Failure		Norgesic (Aspirin					
Initial or Prolonged	Respiratory Fume		(+) Cafeine (+)					
	Inhalation Disorder		Orphe	C				
	Sense Of Oppression		Cyanocobalamin	C				

Date:02/28/02ISR Number: 3876490-XReport Type:Expedited (15-DaCompany Report #WAES 0202AUS00031
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage	Foreign	Tab Vioxx					
	Haemorrhage Intracranial	Literature	(Rofecoxib)	PS		ORAL	37.5 MG/WKY	
		Other					PO	
			Warfarin Sodium	SS		ORAL	3 MG/DAILY PO	

Date:02/28/02ISR Number: 3876491-1Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00025
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Literature	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	

International Normalised Other
PO 44 DAY
Ratio Increased Warfarin SS ORAL
2.5 MG DAILY
Prothrombin Level
PO
Decreased Prinivil C
Acetaminophen C
Digoxin C
Folic Acid C
Furosemide C
Methotrexate C
Prednisolone C
Quinineso4 C

Date:02/28/02ISR Number: 3877200-2Report Type:Expedited (15-DaCompany Report #WAES 01113294
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	50	
	Congestive	Professional					MG/DAILY/PO	
	Oedema Peripheral	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3877201-4Report Type:Expedited (15-DaCompany Report #WAES 01120825
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Pulmonary Embolism	Health Professional	Tab Vioxx	SS		ORAL	50 MG/DAILY/PO	1 YR
			Betapace	C				
			Premarin	C				

Date:02/28/02ISR Number: 3877203-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Anaemia	Health Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/PRN/PO	
	Asthenia		Flonase	C				
	Conjunctival Discolouration		Motrin	C				
	Constipation		Paxil	C				
	Cough		Tylenol Arthritis Extended Relief	C				
	Dizziness		Zoloft	C				
	Fatigue		[Therapy Unspecified]	C				
	Haematochezia		Ascorbic Acid	C				
	Insomnia		Aspirin	C				
	Intestinal Obstruction		Vitamin B (Unspecified)	C				
	Lower Gastrointestinal Haemorrhage		Vitamin E	C				
	Orthostatic Hypotension							
	Platelet Count Decreased							
	Rectal Haemorrhage							
	Tachycardia							
	Thrombosis							

Date:02/28/02ISR Number: 3877205-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00659
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Infarction	Professional					MG/DAILY/PO	
	Coronary Artery Occlusion		Aricept	C				
	Coronary Artery Stenosis		[Therapy Unspecified]	C				
			Amitriptyline	C				
			Chondroitin (+) Glucosamine	C				
			Hypericin	C				
			Melatonin	C				
			Tramadol	C				

Date:02/28/02ISR Number: 3877354-8Report Type:Expedited (15-DaCompany Report #PHBS2002CH02620
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Foreign	Voltaren (Diclofenac Sodium)	PS		ORAL	50 MG/DAY,	
Hospitalization -	Metabolic Acidosis	Health						
Initial or Prolonged	Renal Failure Acute	Professional					ORAL	
	Vomiting	Other	Metformin					

	(Metformin)	SS	ORAL 2550 MG/DAY, ORAL
	Vioxx (Rofecoxib)	SS	ORAL 25 MG/DAY, ORAL
	Cosaar (Losartan Potassium)	SS	ORAL 50 MG/DAY, ORAL
	Lasix (Furosemide)	SS	ORAL 40 MG/DAY, ORAL
	Sintrom	C	
	Sporanox G (Itraconazole)	C	
	Antra (Omeprazole)	C	
	Levothyroxine Sodium	C	
	Norvasc	C	
	Diastabol (Miglitol)	C	

Date:02/28/02ISR Number: 3877664-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00102
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
			Etidronate Disodium	C				

Date:02/28/02ISR Number: 3877665-6Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00165
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Foreign	Tab Vioxx					

Initial or Prolonged	Urticaria	Other	(Rofecoxib)	PS		ORAL
1 OR 2 DAILY						
DOSE PO 24 DAY						
			Amphotericin B	C		
			Clotrimazole	C		
			Insulin Human	C		
			Insulin, Isophane	C		
			Minocycline	C		

Date:02/28/02ISR Number: 3877666-8Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00151
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastritis Haemorrhagic	Foreign	Tab Vioxx			
Hospitalization -		Other	(Rofecoxib)	PS		ORAL
2 DOSE/DAILY						
Initial or Prolonged						
PO						
Disability			Acetaminophen/Codein			
			e Phosphate	C		
			Aluninum			
			Hydroxide/Magnesium			
			Carbonate	C		
			Aspirin	C		
			Atorvastatin	C		
			Bisoprolol Fumarate	C		
			Captopril	C		
			Digoxin	C		
			Doxazosin Mesylate	C		
			Furosemide	C		
			Heparinoid (+)			

Salicylic Acid C

Date:02/28/02ISR Number: 3877667-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00293
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Dyspnoea	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 55 DAY
	Gastrointestinal Haemorrhage Haemoglobin Decreased Myocardial Infarction		Ranitidine	C				

Date:02/28/02ISR Number: 3877668-1Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:02/28/02ISR Number: 3877950-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA02112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer	Health Professional	Tab Vioxx Unk	PS				

Date:02/28/02ISR Number: 3877952-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA01537
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL PO
			Diclofenac	C		

Date:02/28/02ISR Number: 3877955-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA01530
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 YR
			Cardizem	C				
			Tambocor	C				
			Aspirin	C				

Date:02/28/02ISR Number: 3877960-0Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Arteriosclerosis	Health Professional						
	Cardio-Respiratory Arrest		Lasix 40 Mg	SS			40 MG/BID	
	Headache		Ativan	C				

Claritin	C
Deltasone	C
Flonase	C
K-Dur	C
Nitropatch	C
Paxil	C
Pepcid	C
Plavix	C
Ritalin	C
Zocor	C
Alprazolam	C
Aspirin	C
Atenolol	C
Captopril	C
Carbidopa (+)	
Levodopa	C
Clonazepam	C
Codeine	C
Ibuprofen	C
Methylphenidate	C
Nitroglycerin	C
Quinine	C

Date:02/28/02ISR Number: 3877980-6Report Type:Expedited (15-DaCompany Report #WAES 01110878
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Altace	C				
			Lipitor	C				
			Neurontin	C				
			Niaspan	C				
			Zoloft	C				

Date:02/28/02ISR Number: 3877985-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA01494
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Foreign Body Trauma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Medical Device							
	Complication		Glucophage	C				
	Vomiting		Hydrodiuril	C				
			Lasix (Furosemide)	C				
			Ocuvite	C				
			Prevacid	C				
			Diltiazem Malate	C				
			Quinine	C				
			Vitamin B (Unspecified)	C				

Date:02/28/02ISR Number: 3877990-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Dialysis
	Difficulty In Walking

		Epistaxis					
		Medication Error					
		Renal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE							

Date:02/28/02ISR Number: 3878061-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA01645
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Renal Failure	Consumer	Tab Vioxx	PS		ORAL
PO							
Other							

Date:02/28/02ISR Number: 3878187-9Report Type:Expedited (15-DaCompany Report #WAES 01110555
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Eye Haemorrhage	Health				
MG/DAILY/PO							
		Headache	Professional	Armour Thyroid			
		Retinal Artery Embolism		Tablets	C		
				Prilosec	C		
				Prozac	C		
				Ascorbic Acid	C		
				Aspirin	C		
				Atenolol	C		
				Calcium (Unspecified)	C		
				Hydrochlorothiazide (+) Triameterene	C		
				Magnesium (Unspecified)	C		
				Vitamin E	C		
				Zinc (Unspecified)	C		

Date:02/28/02ISR Number: 3878190-9Report Type:Expedited (15-DaCompany Report #WAES 0112USA02870
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Monoparesis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional						
	Pruritus							

Date:02/28/02ISR Number: 3878256-3Report Type:Expedited (15-DaCompany Report #WAES 0202ZAF00011
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Foreign	Tab Vioxx					
	Disorientation	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
		Professional						
			Glimepiride	C				
			Ramipril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3878599-3Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Albumin Decreased	Foreign	Tab Vioxx					
Hospitalization -	Haematocrit Decreased	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Haemoglobin Decreased	Professional	Acetaminophen/Ocxyco					
	Hypergammaglobulinaemia		done Hydrochloride	C				
	Multiple Myeloma		Atorvastatin Calcium	C				
	Osteopenia		Calcium Carbonate					
	Platelet Count Abnormal		(+) Etidronate					
	Red Blood Cell Count		Sodium	C				
	Decreased		Celecoxib	C				

Date:02/28/02ISR Number: 3878601-9Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00011
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Tab Vioxx					
	Congestive	Health	(Rofecoxib)	PS		ORAL		
		Professional						

Date:02/28/02ISR Number: 3878603-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00131
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Hospitalization -	Duodenal Ulcer	Other	(Rofecoxib)	PS			OPHTHALMIC	12.5 MG/DAILY 122 DAY
Initial or Prolonged	Haemorrhage		Aspirin	SS		ORAL	75 MG/DAILY	
			Batahistine					
			Hydrochloride	C				
			Furosemide	C				
			Spironolactone	C				

Date:02/28/02ISR Number: 3878609-3Report Type:Expedited (15-DaCompany Report #WAES 01116043
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema Induratum	Foreign	Tab Vioxx					
	Panniculitis	Other	(Rofecoxib)	PS		ORAL	24 DAY	
	Pruritus		Tab Captopril	SS		ORAL	25 MG/DAILY	30 DAY
	Purpura		Tab Fusidate Sodium	SS		ORAL	250 MG	40 DAY
			Tab Dipyridamole	SS		ORAL	38 DAY	
			Inj Vancomycin	SS			INTRAVENOUS	40 DAY

Date:02/28/02ISR Number: 3878860-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00187
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis	Foreign	Tab Vioxx					
	Upper Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5-25	
	Haemorrhage						MG/DAILY PO	315 DAY
			Acetaminophen	C				
			Anastrozole	C				
			Beclomethasone Dipropionate	C				
			Dihydrocodeine	C				
			Lansoprazole	C				

			Levothyroxine Na	C		
			Sertraline	C		

Date:02/28/02ISR Number: 3878862-6Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:02/28/02ISR Number: 3878863-8Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00029
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Exanthem	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/01/02ISR Number: 3876104-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/02ISR Number: 3876105-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Asthenia		Valium	C				
Disability	Atherosclerosis		Fosamax	C		ORAL		
Other	Carotid Artery Disease		Soma	C				

	Cerebrovascular Accident		Lasix (Furosemide)	C		
	Dermatitis		Calcium Carbonate	C		ORAL
	Eczema		L-Thyroxin	C		ORAL
	Left Ventricular Failure		Oxycontin	C		
	Paronychia		Quinine Sulfate	C		
	Transient Ischaemic		Cozaar	C		ORAL
	Attack		Dilacor Xr	C		
			Atrovent	C		
RESPIRATORY						
(INHALATION)						
			Celebrex	C		

Date:03/01/02ISR Number: 3876106-2Report Type:Expedited (15-DaCompany Report #WAES 0202SGP00001
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypotension		Indapamide	C		ORAL
	Hypovolaemia		Calcium			
	Pulse Pressure Decreased		(Unspecified)	C		
	Vomiting		Nonsteroidal			
			Anti-Inflammatory			
			Drug (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/02ISR Number: 3876113-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02596
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased							
	Melaena							
	Occult Blood Positive							
	Rectal Haemorrhage							

Date:03/01/02ISR Number: 3878406-9Report Type:Expedited (15-DaCompany Report #PHEH2002US00582
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health	Lamisil (Terbinafine					
	Dizziness	Professional	Hydrochloride)					
	Flushing		Tablet	PS		ORAL	250 MG, QD,	
	Migraine							
	Palpitations		Vioxx(Roffecoxib)	SS				
	Vision Blurred							

Date:03/02/02ISR Number: 3876184-0Report Type:Expedited (15-DaCompany Report #WAES 01125515
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization -	Atrioventricular Block		Ibuprofen	SS		ORAL		
Initial or Prolonged	Second Degree		Metoprolol Succinate	C		ORAL		
	Bradyarrhythmia		Metildigoxin	C		ORAL		
	Coagulopathy		Spironolactone	C		ORAL		
	Duodenal Ulcer		Clopidogrel					
	Dyspnoea		Bisulfate	C		ORAL		
	Hepatic Failure		Furosemide	C		ORAL		
	Lactic Acidosis		Iron (Unspecified)	C		ORAL		
	Myocarditis							
	Renal Failure Acute							

Thrombocytopenia
White Blood Cell Count
Increased

Date:03/04/02ISR Number: 3876466-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11744158
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Electrolyte Imbalance		Glucophage	PS	Bristol-Myers Squibb Company	ORAL		
Hospitalization - Initial or Prolonged	Lactic Acidosis							
	Renal Failure Acute		Voltarene	SS				
			Vioxx	SS				
			Cozaar	SS	Bristol-Myers Squibb Company			
			Lasix	SS				
			Sintrom	C				
			Sporanox	C				
			Antra	C				
			Eltroxin	C				
			Norvasc	C				
			Diastabol	C				

Date:03/04/02ISR Number: 3876549-7Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Albuminuria		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Albumin Decreased		Acetaminophen And Oxycodone Hydrochloride	C		ORAL		
	Blood Glucose Increased		Calcium Carbonate And Etidronate Sodium	C				
	Blood Immunoglobulin A Decreased		Atorvastatin Calcium	C				
	Blood Immunoglobulin G Increased		Celecoxib	C				
	Blood Immunoglobulin M Decreased							
	Haematocrit Decreased							
	Immunoglobulins Abnormal							
	Lymphocyte Count Decreased							
	Multiple Myeloma							
	Neutrophil Count Decreased							
	Platelet Count Abnormal							
	Red Blood Cell Count Abnormal							
	White Blood Cell Count Abnormal							

41 DAY

Date:03/04/02ISR Number: 3876553-9Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00263
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Zolmitriptan	C		ORAL		
	Gastritis		Acetaminophen And Aspirin And Caffeine	C		ORAL		
	Haemoglobin Decreased		Diclofenac	C		ORAL		

Date:03/04/02ISR Number: 3876605-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vicodin Tablets	C				

Date:03/04/02ISR Number: 3876612-0Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Necrotising Fasciitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		136 DAY
	Skin Lesion	Professional	Diacerein	C		ORAL		
	Wound		Isradipine	C		ORAL		
			Ibuprofen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/02ISR Number: 3876695-8Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00297
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Haemorrhage		Paroxetine	C		ORAL		
			Cholecalciferol And Calcium Carbonate	C		ORAL		

Date:03/04/02ISR Number: 3877305-6Report Type:Direct Company Report #CTU 162607
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Rofecoxib	PS		ORAL	25MG ORALLY ,	
	Congestive							DAILY
	Condition Aggravated		Calcium Carbonate	C				
	Dyspnoea Exertional		Digoxin	C				
	Oedema Peripheral		Furosemide	C				
	Weight Increased		Mesalamine	C				
			Potassium Chloride	C				
			Cyanocobalamine	C				
			Famotidine	C				
			Levothyroxine	C				
			Multivitamin	C				
			Raloxifene	C				
			Warfarin	C				

Date:03/04/02ISR Number: 3878162-4Report Type:Expedited (15-DaCompany Report #WAES 01071996
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache	Consumer	Tab Vioxx	PS		ORAL	PO	4 MON
Initial or Prolonged	Meningitis Aseptic	Health Professional	Imuran (Azathioprine)	C				
			Prednisone	C				

Date:03/04/02ISR Number: 3878174-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Stenosis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	2 MON
	Cerebrovascular Accident	Health						
	Drug Ineffective	Professional						
	Labile Blood Pressure							
	Ventricular Hypertrophy							
	Vertebrobasilar Insufficiency							

Date:03/04/02ISR Number: 3878226-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA00207
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hip Surgery	Health	Tab Vioxx	PS		ORAL	PO	
	Impaired Healing	Professional	Advair	C				
			Celexa	C				
			Evista	C				
			Prevacid	C				
			Furosemide	C				

Lorazepam	C
Theophylline	C

Date:03/04/02ISR Number: 3878227-7Report Type:Expedited (15-DaCompany Report #WAES 01110183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Hospitalization - Initial or Prolonged	Dyspnoea Hyperventilation Hypoaesthesia Nausea Respiratory Alkalosis	Health Professional						

Date:03/04/02ISR Number: 3878234-4Report Type:Expedited (15-DaCompany Report #WAES 00091412
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Decreased Activity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Difficulty In Walking	Health Professional						
	Diplegia Dysuria Faecal Incontinence Joint Stiffness Neuropathy Peripheral							

Date:03/04/02ISR Number: 3878235-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA01537
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	12.5 MG/DAILY/PO;	

		Company				
SEE IMAGE						
		Representative	Diclofenac	C		

Date:03/04/02ISR Number: 3878272-1Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Complex Regional Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Other	Syndrome	Health				
MG/DAILY/PO						
	Muscular Weakness	Professional	Prinzide	C		
	Oedema Peripheral		Chondroitin (+)			
	Paraesthesia		Glucosamine	C		
	Peripheral Coldness		Herbs (Unspecified)	C		
	Poor Peripheral					
	Circulation					

Date:03/04/02ISR Number: 3878275-7Report Type:Expedited (15-DaCompany Report #WAES 01111442
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastric Ulcer Perforation	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
		Health				
		Professional				

Date:03/04/02ISR Number: 3878552-XReport Type:Expedited (15-DaCompany Report #WAES 0202SWE00026
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	4 WK
	Dyspnoea		Acetaminophen	C				
	Gastric Ulcer		Allopurinol	C				
	Haemoglobin Decreased		Clarithromycin	C				
			Lansoprazole	C				
			Propranolol Hcl	C				

Date:03/04/02ISR Number: 3878598-1Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00020
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Orthostatic Hypotension Pneumonia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	34 DAY
	Purpura	Professional	Tab Aspirin	SS		ORAL	100 MG/DAILY	PO
	Rash	Other						
	Renal Failure Acute		Cinnarizine	SS		ORAL	PO	
			Tab Amiloride Hydrochloride-Hctz	SS		ORAL	50+5 MG/DAILY	PO DAY

Date:03/04/02ISR Number: 3878600-7Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00081
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Cyst Renal Disorder	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional	Carvedilol	C				

				Doxazosin Mesylate	C		
				Hydrochlorothiazide (+) Valsartan	C		
				Metformin	C		

Date:03/04/02ISR Number: 3878639-1Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00031
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Large Intestinal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	PO	3 DAY
Initial or Prolonged	Loss Of Consciousness		Acetaminophen	C				
	Rectal Haemorrhage							
	Shock							

Date:03/04/02ISR Number: 3878640-8Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00030
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis	Foreign	Tab Vioxx					
Hospitalization -	Shock	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Upper Gastrointestinal							
	Haemorrhage		Estradiol (+) Medroxyprogesterone Acetat	C			PO	8 DAY
			Felodipine	C				

				Naftazone	C		
				Omeprazole	C		
				Simvastatin	C		

Date:03/04/02ISR Number: 3878664-0Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00019
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					
	Melaena	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
PO								
			Lercanidipine					
			Hydrochloride	C				
			Oxybutyninc1	C				
			Quinine/Thiamine	C				
			Tramadol Hcl	C				

Date:03/04/02ISR Number: 3878691-3Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00088
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Foreign	Tab Vioxx					
Life-Threatening	Infarction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Cardiac Arrest	Professional						
PO								
Initial or Prolonged								

Date:03/04/02ISR Number: 3878696-2Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00088
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Foreign	Tab Vioxx					
Life-Threatening	Infarction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

Hospitalization - Cardiac Arrest Professional
PO
Initial or Prolonged

Date:03/04/02ISR Number: 3878700-1Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Albumin Decreased	Foreign	Tab Vioxx					
Disability	Multiple Myeloma	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional						
PO								
			Acetaminophen/Oxycodone Hydrochloride	C				
			Atorvastatin Calcium	C				
			Calcium Carbonate (+) Etidronate Sodium	C				
			Celecoxib	C				

Date:03/04/02ISR Number: 3878730-XReport Type:Expedited (15-DaCompany Report #WAES 01114348
Age:82 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening

Hospitalization - Initial or Prolonged Disability	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Cardiac Arrest	Professional					MG/DAILY/PO	
	Duodenal Ulcer	Company	Prednisone	SS			50 MG/DAILY	
	Haemorrhage	Representative	Bumex	C				
	Exsanguination		Cozaar	C				
	Haematochezia		Klor-Con	C				
	Syncope		Lanoxin	C				
			Lotensin	C				
			Premarin	C				

Date:03/04/02ISR Number: 3878736-0Report Type:Expedited (15-DaCompany Report #WAES 01111500
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rectal Haemorrhage	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
		Professional					MG/DAILY/PO;	
		Company					12.5	
		Representative					MG/WKY/PO	
			Avalox	C				
			Celebrex	C				
			Combivent	C				
			Depo-Medrol	C				
			Imodium	C				
			Lomotil	C				
			Monopril	C				
			Qvar	C				
			Rhinocort	C				
			Toprol Xl Tablets	C				

Date:03/04/02ISR Number: 3878740-2Report Type:Expedited (15-DaCompany Report #WAES 01112833
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Life-Threatening	Arrhythmia
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree
Disability	Cardiac Arrest
Other	Dizziness
	Duodenal Ulcer Haemorrhage
	Electrocardiogram Abnormal
	Electrocardiogram St Segment Abnormal
	Electrocardiogram St Segment Depression
	Electrocardiogram T Wave Inversion
	Extrasystoles
	Faecal Occult Blood Positive
	Fall
	Gastrointestinal Haemorrhage
	Haematemesis

		Head Injury Hypotension International Normalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ratio Abnormal	Health	Tab Vioxx	PS		ORAL
25							
		Loss Of Consciousness	Professional				
MG/DAILY/PO							
		Prothrombin Time	Company	Prednisone 50 Mg	SS		
50 MG/DAILY							
		Prolonged	Representative	Bumex	C		
		Syncope		Cozaar	C		
				Klor-Con	C		
				Lanoxin	C		
				Lasix (Furosemide)	C		
				Lotensin	C		
				Premarin	C		
				Aspirin	C		

Date:03/04/02ISR Number: 3878782-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Initial or Prolonged			Professional				
MG/DAILY/PO							
			Company	Claritin-D	C		
			Representative	Darvocet-N	C		
				Humibid	C		
				Inderal	C		
				Nasonex	C		
				Prevacid	C		
				Nonsteroidal			
				Anti-Inflammatory	C		

Date:03/04/02ISR Number: 3878852-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Anaemia	Consumer	Tab Vioxx 50 Mg	PS		ORAL
PO						
Initial or Prolonged	Asthenia	Health	[Composition			
	Bronchitis	Professional	Unspecified]	C		
	Cardiac Flutter					
	Duodenal Ulcer					
	Haemorrhage					
	Faeces Discoloured					
	Fatigue					
	Gastric Ulcer					
	Gastrointestinal					
	Haemorrhage					
	Heart Rate Irregular					
	Hyperhidrosis					
	Influenza Like Illness					
	Melaena					
	Syncope					

Date:03/04/02ISR Number: 3878858-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA01890
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Memory Impairment	Professional				
MG/DAILY/PO						
	Subdural Haematoma		Naprosyn	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/02ISR Number: 3878861-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA01722
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bilirubin Urine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Liver Disorder	Professional					MG/DAILY/PO	
	Liver Function Test		Lipitor 10 Mg	SS		ORAL	10	
	Abnormal						MG/DAILY/PO	
			Corticosteroids	C				

Date:03/04/02ISR Number: 3878882-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02146
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Difficulty In Walking	Health						
	Epistaxis	Professional						
	Haemorrhage							
	Ill-Defined Disorder							
	Medication Error							
	Renal Disorder							

Date:03/04/02ISR Number: 3878884-5Report Type:Expedited (15-DaCompany Report #WAES 0112USA02168
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Grand Mal Convulsion	Professional					MG/DAILY;PO	
			Fibercon	C				
			Nexium	C				
			Levothyroxine Sodium	C				

Date:03/04/02ISR Number: 3878897-3Report Type:Expedited (15-DaCompany Report #WAES 0202ZAF00010
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL		

Date:03/04/02ISR Number: 3878899-7Report Type:Expedited (15-DaCompany Report #WAES 0202AUS00091
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Myalgia	Consumer Other						

Date:03/04/02ISR Number: 3878919-XReport Type:Expedited (15-DaCompany Report #WAES 01071996
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Consumer	Tab Vioxx	PS		ORAL	PO	4 MON
		Health Professional	Imuran (Azathioprine)	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/02ISR Number: 3878934-6Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00235
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:03/04/02ISR Number: 3878944-9Report Type:Expedited (15-DaCompany Report #WAES 01065095
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Foreign	Tab Vioxx					
	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	30 DAY
	Global Amnesia		Prinivil	C				
	Memory Impairment		Aspirin	C				
	Pulmonary Congestion		Atenolol	C				
			Doxazosin	C				
			Insulin, Biphasic Isophane (Injection)	C				
			Isosorbide Mononitrate	C				
			Metformin	C				

Date:03/04/02ISR Number: 3878950-4Report Type:Expedited (15-DaCompany Report #WAES 01105180
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased	Foreign	Tab Vioxx					
Other	Orthostatic Hypotension	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional					PO ; 25	
		Other					MG/DAILY	
			Aspirin	C				

Date:03/04/02ISR Number: 3878955-3Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00138
Age:74 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peritonitis	Foreign	Tab Vioxx					
Hospitalization -	Small Intestinal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Perforation							

Date:03/04/02ISR Number: 3878971-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00225
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tongue Oedema	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/BID PO	
			Ibuprofen	C				

Date:03/04/02ISR Number: 3878972-3Report Type:Expedited (15-DaCompany Report #WAES 01065213
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonitis	Foreign	Tab Vioxx					
Initial or Prolonged	Pulmonary Oedema	Health	(Rofecoxib)	PS		ORAL	12.5	
Other		Professional					MG/DAILY; PO	

			Tramadol Hcl	SS	ORAL
50-100					
MG/DAILY; PO	14	DAY			
			Acetaminophen	C	
			Amlodipine	C	
			Bumetanide	C	
			Codeine Sulfate (+) Ipecac (+) Squill	C	
			Dihydrocodeine	C	
			Lactulose	C	
			Metoclopramide	C	
			Morphine	C	
			Morphines04	C	
			Nystatin	C	
			Phenobarbital	C	
			Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C	
			Prochlorperazine Maleate	C	
			Warfarin	C	

Date:03/04/02ISR Number: 3878974-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemoglobin Abnormal	Foreign	Tab Vioxx			
Hospitalization -	Melaena	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Initial or Prolonged	Pneumonia					
PO						
	Underweight		Albuterol	C		
	Upper Gastrointestinal Haemorrhage		Carbidopa/Levodopa	C		
			Ipratropium Bromide	C		
			Pergolide	C		
			Scopolamine	C		
			Temazepam	C		

Date:03/04/02ISR Number: 3879086-9Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00162
Age:72 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive Bacterial Infection Blood Blister C-Reactive Protein Increased Clostridium Colitis Diarrhoea Differential White Blood Cell Count Abnormal Exanthem International Normalised Ratio Decreased Klebsiella Infection Oedema Peripheral Petechiae Prothrombin Level Decreased Purpura Rheumatoid Factor Positive

		Sepsis Staphylococcal Infection Stenotrophomonas	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infection White Blood Cell Count	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
50 MG/BID							
		Increased	Professional	Naloxone Hydrochloride (+)			
				Tilidine Hydr	C		
				Omeprazole	C		
				Phenprocoumon	C		
				Prednisolone	C		
				Spironolactone	C		

Date:03/04/02ISR Number: 3879089-4Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00020
Age:50 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Agranulocytosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL

Date:03/04/02ISR Number: 3879563-0Report Type:Direct Company Report #CTU 162677
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Pollakiuria		Vioxx (25mg Tabs)	PS		ORAL
25MG PO QD							

Date:03/05/02ISR Number: 3877459-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA01890
Age:73 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
69 DAY							
Initial or Prolonged		Memory Impairment		Naprosyn	C		
Other		Subdural Haematoma		Premarin	C		

				Glucosamine	C		
				Vitamins (Unspecified)	C		

Date:03/05/02ISR Number: 3877676-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/05/02ISR Number: 3877678-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA01314
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coagulopathy		Coumadin	C				
	Pulmonary Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/02ISR Number: 3877680-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
			Atacand	C				
			Flovent	C				
			Combivent	C				
			Zoloft	C				
			Coreg	C				
			Plavix	C				
			Aspirin	C				
			Vitamin E	C				

Date:03/05/02ISR Number: 3877681-4Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00229
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		41 DAY
Hospitalization -	C-Reactive Protein		Sulfasalazine	SS		ORAL		41 DAY
Initial or Prolonged	Increased		Naproxen	C		ORAL		
	Chills							
	Endocarditis							
	Neutrophilia							
	Pulse Pressure Increased							
	Pyrexia							
	White Blood Cell Count Abnormal							

Date:03/05/02ISR Number: 3877683-8Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00130
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Methocarbamol	C				
			Carbamazepine	C				

				Acetaminophen And Codeine Phosphate	C		

Date:03/05/02ISR Number: 3877684-XReport Type:Expedited (15-DaCompany Report #WAES 0202CAN00129
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anuria	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Blood Urine Present	Professional	Naproxen	SS			2	DAY
	Renal Tubular Necrosis		Dimenhydrinate	C		PARENTERAL		
	Rhabdomyolysis		Acetaminophen And Codeine Phosphate	C		ORAL		
	Urinary Casts							
	White Blood Cells Urine		Lorazepam	C		SUBLINGUAL		
	Positive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/02ISR Number: 3877685-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02526
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		271 DAY
Other	Syncope		Zantac	C				
	Upper Gastrointestinal		Doxepin					
	Haemorrhage		Hydrochloride	C				
			Hydrocodone	C				
			Acetaminophen	C				

Date:03/05/02ISR Number: 3877686-3Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00128
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paralysis	Health	Vioxx	PS		ORAL		
		Professional	Tizanidine					
			Hydrochloride	SS		ORAL		9 WK
			Tolterodine Tartrate	C	Merck & Co., Inc	ORAL		

Date:03/05/02ISR Number: 3877687-5Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00133
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Appetite	Professional	Risedronate Sodium	SS		ORAL		
	Diarrhoea Haemorrhagic		Aspirin	SS		ORAL		1 YR
	Dizziness		Meperidine					
	Duodenal Ulcer		Hydrochloride	C		ORAL		
	Gastrointestinal		Salcatonin	C				RESPIRATORY
	Haemorrhage							(INHALATION)
	Haemoglobin Decreased		Vitamins					
	Nausea		(Unspecified)	C				
	Respiratory Arrest		Calcium Carbonate	C				
	Weight Decreased		Acetaminophen	C				

			Vitamin D (Unspecified)	C		
			Goserelin Acetate	C		
SUBCUTANEOUS						

Date:03/05/02ISR Number: 3877688-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00044
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Initial or Prolonged	Difficulty In Walking		Phenytoin	SS		ORAL		
	Drug Interaction		Aspirin	C		ORAL		
	Drug Level Above Therapeutic							
	Insomnia							

Date:03/05/02ISR Number: 3877691-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02041
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Pruritus		Aricept	C		ORAL		
	Rash Generalised		Actonel	C		ORAL		
			Paxil	C		ORAL		

				Cyanocobalamin	C		
PARENTERAL							
				Celebrex	C		

Date:03/05/02ISR Number: 3877693-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00009
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/05/02ISR Number: 3879187-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Thrombosis	Professional					MG/DAILY/PO	
			Ziac	C				

Date:03/05/02ISR Number: 3879192-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02036
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Fluid Overload	Company	Avandia	C				
		Representative	Lanoxin	C				
			Lasix (Furosemide)	C				
			Niferex	C				
			Zaroxolyn	C				
			Aspirin	C				
			Insulin	C				

Date:03/05/02ISR Number: 3879283-2Report Type:Expedited (15-DaCompany Report #WAES 00091412
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dysuria	Health Professional						
	Faecal Incontinence							
	Joint Stiffness							
	Neuropathy Peripheral							
	Paralysis							
	Paralytic Disability							
	Peripheral Vascular Disorder							
	Visual Acuity Reduced							

Date:03/05/02ISR Number: 3879314-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA01256
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Faeces Discoloured
	Gastric Haemorrhage
	Gastric Ulcer
	Haematocrit Decreased
	Haemoglobin Decreased
	Hypotension

	Melaena Syncope						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Fosamax 70 Mg	PS		ORAL	70 MG/WKY/PO	
		Professional	Tab Vioxx	SS				
			Plavix	C				
			Aspirin	C				

Date:03/05/02ISR Number: 3879320-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA01448
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	2	
Hospitalization -	Abdominal Pain						TABLET/1X/PO	
Initial or Prolonged	Asthenia							
	Chills							
	Cold Sweat							
	Dehydration							
	Dizziness							
	Dyspepsia							
	Eating Disorder							
	Haematemesis							
	Headache							
	Hypoaesthesia							
	Pain							
	Pyrexia							
	Renal Neoplasm							
	Stress							
	Tremor							
	Visual Disturbance							
	Vomiting							
	Weight Decreased							

Date:03/05/02ISR Number: 3879321-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA03021
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Aortic Valve Disease	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Atrial Fibrillation	Professional				
MG/DAILY/PO						
	Bicuspid Aortic Valve	Company	Prevacid	C		
	Palpitations	Representative	Toprol Xl Tablets	C		

Date:03/05/02ISR Number: 3879710-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA01670
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company				
		Representative				

Date:03/05/02ISR Number: 3879711-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization -	Cardiovascular Disorder	Health
Initial or Prolonged		Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx	PS		ORAL
PO						

Date:03/05/02ISR Number: 3880134-0Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00012
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx			
Initial or Prolonged	Congestive	Health	(Rofecoxib)	PS		ORAL
4 DAY						
	Pulmonary Oedema	Professional				

Date:03/05/02ISR Number: 3880248-5Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00153
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Hypertensive Crisis	Foreign	Tab Vioxx			
Hospitalization -		Health	(Rofecoxib)	PS		ORAL
25MG/DAILY	17 DAY					
Initial or Prolonged		Professional	Bisoprolol	C		
			Captopril	C		

Date:03/05/02ISR Number: 3880249-7Report Type:Expedited (15-DaCompany Report #WAES 0202NLD00091
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx			
Hospitalization -	Congestive	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Oedema		Carbaspirin Calcium	C		
			Furosemide	C		
			Goserelin Acetate	C		
			Isosorbide Dinitrate	C		
			Isorbide Monitrate	C		

			Lisinopril	C		
			Omeprazole	C		

Date:03/05/02ISR Number: 3880250-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00265
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG /DAILY	30 DAY
Disability								
			Acetaminophen	C				
			Fluoxetine	C				

Date:03/05/02ISR Number: 3880252-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Citalopram Hydrobromide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/02ISR Number: 3880253-9Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Restenosis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	6 DAY
	Myocardial Infarction	Professional	Aspirin	C				
			Dalteparin Sodiium	C				

Date:03/05/02ISR Number: 3880432-0Report Type:Expedited (15-DaCompany Report #WAES 0112DEU05629
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Foreign	Tab Vioxx					
Hospitalization -	Blood Test Abnormal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Chest X-Ray Abnormal						PO ; 12.5	
	Myocardial Infarction						MG/DAILY PO	
	Protein S Decreased		Levothyroxine Na	C				
	Ventricular Hypokinesia							

Date:03/05/02ISR Number: 3880516-7Report Type:Expedited (15-DaCompany Report #WAES 0202NOR00019
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Blood Potassium Increased	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Faecal Occult Blood						PO	
	Positive		Prinivil	C				
	Gastric Ulcer		Acetaminophen/Codein					
	Hypotension		e Phosphate	C				
	Melaena		Cetirizine					
	Red Blood Cell Count		Hydrochloride	C				
	Decreased		Digitoxin	C				
			Flunitrazepam	C				

Furosemide	C
Insulin Human, Isophane	C
Iron (Unspecified)	C
Isosorbide Mononitrate	C
Metoprolol Tartrate	C

Date:03/05/02ISR Number: 3880522-2Report Type:Expedited (15-DaCompany Report #WAES 0202POL00010
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema Hypersensitivity Oedema Peripheral Rash Tongue Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	PO 1 DAY

Date:03/05/02ISR Number: 3889276-7Report Type:Periodic Company Report #01080617
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Other	Angioneurotic Oedema Conjunctivitis

		Diabetes Mellitus Multiple Myeloma Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Enbrel 25 Mg	PS		
SUBCUTANEOUS	25 MG, BIW,						
			Health				
SUBCUTANEOUS							
			Professional	Rofecoxib	SS		
25 MG, QD							
				Vitamin B Complex	C		
				Rosiglitazone	C		
				Colestipol	C		

Date:03/06/02ISR Number: 3877988-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00038
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Congestive	Professional	Vioxx	SS		ORAL
				Lipitor	C		
				[Composition			
				Unspecified]	C		

Date:03/06/02ISR Number: 3877989-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00074
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/06/02ISR Number: 3878324-6Report Type:Expedited (15-DaCompany Report #WAES 0112BEL07521
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Death	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Aplastic Anaemia
	Aspartate

Aminotransferase
Increased
Bilirubin Conjugated
Increased
Blood Alkaline
Phosphatase Increased
Blood Bilirubin Increased
Blood Lactate
Dehydrogenase Increased
Blood Urea Increased
C-Reactive Protein
Increased
Crepitations
Epistaxis
Eyelid Oedema
Haemolytic Anaemia
Hypotension
Musculoskeletal Stiffness
Petechiae
Photophobia
Platelet Count Decreased
Subarachnoid Haemorrhage
Wheezing
White Blood Cell Count

Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY
	Salmeterol Xinafoate	C		RESPIRATORY (INHALATION)		
	Fluticasone Propionate	C		RESPIRATORY (INHALATION)		
	Omeprazole	C		ORAL		
	Zafirlukast	C		ORAL		
	Nadroparin	C		PARENTERAL	11	DAY
	Nadroparin	C		PARENTERAL	32	DAY
	Cetirizine Hydrochloride	C		ORAL		

Date:03/06/02ISR Number: 3878332-5Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00068
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Eye Disorder		Zolpidem Tartrate	C		ORAL	1	DAY
	Hallucination, Visual		Dihydroergotamine Mesylate	C		ORAL	1	DAY
	Metastases To Central Nervous System		Antineoplastic (Unspecified)	C			1	DAY
	Speech Disorder							

Date:03/06/02ISR Number: 3878335-0Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Provigil	SS		ORAL		
	Dyspnoea		Amantadine Hydrochloride	SS				
	Dysuria		Betaseron	SS				
	Fall		Wellbutrin	C				
	Head Injury		[Therapy Unspecified]	C				
	Hyperreflexia		Procuren	C				
	Laceration		Prednisone	C				
	Mental Status Changes		Vitamins (Unspecified)	C				
	Serum Sickness							
	Status Epilepticus							

SUBCUTANEOUS

6 YR MON

Date:03/06/02ISR Number: 3878338-6Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00050
Age:100 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Melaena		Acetaminophen And Propoxyphene Napsylate	C				

9 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/02ISR Number: 3878339-8Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00126
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/06/02ISR Number: 3878341-6Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Increased		Fenofibrate	C		ORAL		
Disability	Hypertension		Trimetazidine					
	Renal Artery Stenosis		Hydrochloride	C		ORAL		
	Retinal Vascular		Budesonide	C				
RESPIRATORY								
	Occlusion							
(INHALATION)								
			Salmeterol Xinafoate	C				
RESPIRATORY								
(INHALATION)								

Date:03/06/02ISR Number: 3878343-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00030
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Haemorrhage	Professional	Ketoprofen	SS		ORAL		
Initial or Prolonged	Haematemesis		Omeprazole	C		ORAL	8	DAY
	Haemoglobin Decreased		Felodipine	C		ORAL		
	Shock		Zocor	C		ORAL		
			Estradiol And Medroxyprogesterone Acetate	C		ORAL		
			Naftazone	C		ORAL		

Date:03/06/02ISR Number: 3878345-3Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00131
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cognitive Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Dementia		Aspirin	C		ORAL		
	Memory Impairment		Glucosamine	C		ORAL		

Date:03/06/02ISR Number: 3878349-0Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00015
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Frequent Bowel Movements		Isosorbide					
Other	Large Intestinal Ulcer		Mononitrate	C				
	Rectal Haemorrhage		Allopurinol	C				
			Bendroflumethiazide	C				
			Lansoprazole	C				
			Zocor	C		ORAL		
			Nicorandil	C				
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/02ISR Number: 3878354-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Depressed Level Of Consciousness Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/02ISR Number: 3879205-4Report Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Life-Threatening	Haemorrhage							

Date:03/07/02ISR Number: 3879211-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02844
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL		
			Proscar	C				
			Hytrin	C				
			Lipitor	C				

Date:03/07/02ISR Number: 3879410-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA00365
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
Disability	Haemoglobin Decreased	Professional	Prevacid	C				
Other	Platelet Disorder		Arthrotec	C				

Date:03/07/02ISR Number: 3879416-8Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhagic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Oedema Peripheral	Professional	Vioxx	SS		ORAL		28 DAY
			Estrogens, Conjugated And Medrogestone	C				
			Ibuprofen	C		TOPICAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:03/07/02ISR Number: 3879417-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00056
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Peritonitis	Professional	Acetaminophen	C		ORAL		
Initial or Prolonged			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Diosmin	C		ORAL		
			Trimetazidine					

			Hydrochloride	C		ORAL
			Phenobarbital	C		ORAL

Date:03/07/02ISR Number: 3879421-1Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00014
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Agitation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Confusional State	Professional	Acetaminophen And Oxycodone			
	Flushing					
			Hydrochloride	C		ORAL

Date:03/07/02ISR Number: 3879423-5Report Type:Expedited (15-DaCompany Report #WAES 0203SWE00003
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 507 DAY	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Methotrexate Sodium	C		
			Prednisolone	C		
			Carbamazepine	C		

Date:03/07/02ISR Number: 3879424-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00099
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 58 DAY	Angiogram Abnormal	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angiopathy		[Therapy Unspecified]	C		
	Cardio-Respiratory Arrest					
	Cholelithiasis					
	Cold Sweat					
	Dyspepsia					
	Dyspnoea					
	Malaise					
	Pulmonary Oedema					
	Weight Increased					

Date:03/07/02ISR Number: 3879427-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Arthralgia		[Therapy			
	Dialysis		Unspecified]	SS		
	Drug Interaction		Insulin	C		
	Kidney Transplant		Imuran			
	Rejection		(Azathioprine)	C		
	Myalgia		Prednisone	C		
	Pain		Lasix (Furosemide)	C		
	Rash		Cyclosporine	C		
	Skin Disorder		Clonidine	C		
			Norvasc	C		
			Toprol Xl Tablets	C		
			Zebeta	C		
			Cyclobenzaprine			
			Hydrochloride	C		
			Vitamin B			
			(Unspecified)	C		
			Celebrex	C		

			Lipitor	C		
			Clonazepam	C		
			Zemplar	C		

Date:03/07/02ISR Number: 3879429-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA00347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Other	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/02ISR Number: 3880735-XReport Type:Expedited (15-DaCompany Report #WAES 01125515
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					
Hospitalization -	Atrioventricular Block	Health	(Rofecoxib)	PS		ORAL	25 MG BID PO	1 DAY
Initial or Prolonged	Second Degree	Professional	Ibuprofen	SS		ORAL	400 MG BID PO	
	Bradyarrhythmia	Other						
	Disseminated		Clopidogrel					
	Intravascular Coagulation		Bisulfate	C				
	Duodenal Ulcer		Furosemide	C				
	Dyspnoea		Iron (Unspecified)	C				
	Hepatic Failure		Metildigoxin	C				
	Lactic Acidosis		Metoprolol Succinate	C				
	Myocarditis		Spironolactone	C				
	Renal Failure Acute							
	Thrombocytopenia							
	White Blood Cell Count Increased							

Date:03/07/02ISR Number: 3880756-7Report Type:Expedited (15-DaCompany Report #WAES 0202MEX00017
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Tab Vioxx					

Hospitalization -		Other	(Rofecoxib)	PS			ORAL
25 MG/DAILY							
Initial or Prolonged							
PO							
			Pepcid	C			
			Deflazacort	C			

Date:03/07/02ISR Number: 3880764-6Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Necrotising Fasciitis	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL		
PO							136	DAY
			Diacerein	C				
			Ibuprofen	C				
			Isradipine	C				

Date:03/07/02ISR Number: 3880765-8Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00057
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Multiple Myeloma	Foreign	Tab Vioxx					
Disability		Other	(Rofecoxib)	PS		ORAL		
25 MG/DAILY								

PO

	Acetaminophen/Oxycodone Hydrochloride	C
	Atorvastatin Calcium	C
	Calcium Carbonate (+) Etidronate Sodium	C
	Celecoxib	C

Date:03/07/02ISR Number: 3880773-7Report Type:Expedited (15-DaCompany Report #WAES 0202SGP00001
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration	Foreign	Tab Vioxx					
	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Hypotension							
PO								
	Hypovolaemia		Calcium (Unspecified)	C				
	Pulse Pressure Decreased		Indapamide	C				
	Vomiting		Nonsteroidal Anti-Inflammatory Drug (Uns	C				

Date:03/07/02ISR Number: 3880781-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA02014
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Fluctuation	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema							
PO							5	DAY
	Pulse Pressure Abnormal							
	Tachycardia							

Date:03/07/02ISR Number: 3880803-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00263
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Faeces Discoloured Gastritis Haemoglobin Decreased	Foreign Other	Tab Vioxx (Rofecoxib) Acetaminophen-Aspirin-Caffeine Diclofenac Zolmitriptan	PS C C C		ORAL	25 MG/DAILY	

Date:03/07/02ISR Number: 3881055-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx 25 Mg Vicodin Tablets	PS C		ORAL	25 MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/02ISR Number: 3881057-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/07/02ISR Number: 3881074-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02752
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Atherosclerosis	Professional					MG/DAILY/PO	
Disability	Carotid Artery Disease	Company	Atrovent	C				
Other	Cerebrovascular Accident	Representative	Celebrex	C				
	Echocardiogram Abnormal		Cozaar	C				
	Eczema		Dilacor Xr	C				
	Nuclear Magnetic		Fosamax	C				
	Resonance Imaging		L-Thyroxin	C				
	Abnormal		Lasix (Furosemide)	C				
	Transient Ischaemic		Oxycontin	C				
	Attack		Soma	C				
	Ultrasound Scan Abnormal		Valium	C				
	Ventricular Hypokinesia		Calcium Carbonate	C				
			Quinine Sulfate	C				

Date:03/07/02ISR Number: 3881241-9Report Type:Expedited (15-DaCompany Report #WAES 0202ITA00068
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Foreign	Tab Vioxx					
Initial or Prolonged	Urticaria	Health	(Rofecoxib)	PS		ORAL	25 MG/DIALY,	
		Professional					PO	
			Zocor	C				
			Diclofenac	C				
			Paroxetine Hcl	C				

Trigenoside C

Date:03/07/02ISR Number: 3881243-2Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00118
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:03/07/02ISR Number: 3881249-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00256
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Other	Drug Level Increased	Other	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
	Drug Toxicity							
PO								30 DAY
			Lithiumco3	SS		ORAL	600 MG/DAILY	
PO								
			Methotrexate Sodium	C				
			Oxybutynincl	C				
			Sulfasalazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/02ISR Number: 3881250-XReport Type:Expedited (15-DaCompany Report #WAES 0202CHE00034
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Balance Disorder	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Metabolic Acidosis						PO	
	Renal Failure Acute		Tab Losartan					
	Vomiting		Potassium	SS		ORAL	50 MG/DAILY	
							PO	
			Furosemide Sodium	SS		ORAL	40 MG/DAILY	
							PO	
			Diclofenac Na	SS		ORAL	50 MG/DAILY	
							PO	
			Metformin Hcl	SS		ORAL	2550	
							MG/DAILY/PO	
			Acenocoumarol	C				
			Amlodipine Besylate	C				
			Itraconazole	C				
			Levothyroxine Na	C				
			Miglitol	C				
			Omeprazole Sodium	C				

Date:03/07/02ISR Number: 3881251-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00200
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx					
Initial or Prolonged	Decubitus Ulcer	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Gastric Haemorrhage							
PO							36	DAY
	Haemoglobin Decreased		Fosamax	C				

			Calcium Carbonate			
			(+) Cholecalciferol	C		
			Citalopram	C		
			Gliclazide	C		
			Ibuprofen	C		
			Metformin	C		

Date:03/07/02ISR Number: 3881307-3Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Foreign	Leflunomide	PS		ORAL	10 VS 20 MG	
Initial or Prolonged	Cardiac Asthma	Study					PO	15 WK
Disability	Cardiac Disorder	Health	Vioxx	SS		ORAL	25 MG QD PO	8 WK
Other	Cardiac Failure	Professional	Marcumar	C				
	Cystitis Escherichia	Other	Zocor	C				
	Interstitial Lung Disease		Furosemide	C				
	Pneumonia Haemophilus		Aldactone	C				
	Pneumonia Klebsiella		Losec	C				
	Pneumonia Pneumococcal		Ciproxin	C				
	Respiratory Failure		Sotalol	C				
	Staphylococcal		Lasix	C				
	Bacteraemia		Seresta	C				
	Ventricular Fibrillation		Prednison	C				
	Ventricular Tachycardia		Atrovent	C				
			Normison	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/02ISR Number: 3881321-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA02439
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAIILY/PO	Hospitalization - Initial or Prolonged
			Ativan	C				
			Colestid	C				
			Demadex	C				
			Elavil	C				
			Neurontin	C				
			Plaquenil	C				
			Plavix	C				
			Pravachol	C				
			Prevacid	C				
			Tenormin	C				
			Zoloft	C				
			Aspirin	C				

Date:03/07/02ISR Number: 3881322-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02325
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health	Tab Vioxx 50 Mg	PS		ORAL	50MG/DAILY; PO	4 MON
	Hyponatraemia	Professional						
			Minipress	C				
			Zoloft	C				
			Levodopa	C				

Date:03/07/02ISR Number: 3881324-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02045
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	

Initial or Prolonged	Increased	Professional		
PO				
	Aspartate		Lipitor	SS
	Aminotransferase		Prednisone	C
	Increased			
	Blood Alkaline			
	Phosphatase Increased			
	Blood Bilirubin Increased			
	Chromaturia			
	Decreased Appetite			
	Fibrosis			
	Headache			
	Pyrexia			
	Temporal Arteritis			
	Tendonitis			
	Thrombocythaemia			

Date:03/07/02ISR Number: 3881347-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA02375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Health	Tab Vioxx 50 Mg	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

Date:03/07/02ISR Number: 3881437-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA02596
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faecal Occult Blood	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Positive	Professional					MG/DAILY/PO	
	Haematemesis		Aspirin	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Melaena							

Date:03/07/02ISR Number: 3881688-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA02447
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia	Other	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Dysgeusia						MG/DAILY/PO	
	Gingival Pain		Hydrodiuril	C				
	Glossodynia		Lotrel	C				
	Hypoaesthesia Oral		Zocor	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Glucosamine	C				

Date:03/07/02ISR Number: 3881699-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:03/08/02ISR Number: 3879825-7Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Other	Coronary Artery Disease		Relafen	C				
	Coronary Artery Stenosis		Celebrex	C				
	Dyspnoea		Xanax	C				
	Ejection Fraction Decreased		Aspirin	C				
			Mepergan	C				
	Electrocardiogram Q Wave Abnormal		Amitriptyline	C				
	Electrocardiogram T Wave Abnormal							
	Fluid Retention							
	Hypoaesthesia							
	Myocardial Infarction							
	Nausea							
	Sensation Of Heaviness							
	Sensation Of Pressure							
	Swelling							
	Ventricular Hypokinesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/02ISR Number: 3879829-4Report Type:Expedited (15-DaCompany Report #WAES 0112CAN08629
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/02ISR Number: 3880111-XReport Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis		Ethinyl Estradiol And Levonorgestrel	PS		ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY

Date:03/08/02ISR Number: 3880118-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00016
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:03/08/02ISR Number: 3880921-9Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00297
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Calcium Carbonate (+) Cholecalciferol	C				
			Paroxetine	C				

Date:03/08/02ISR Number: 3882118-5Report Type:Expedited (15-DaCompany Report #2002095652US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Renal Failure	Consumer Company	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL	
		Representative	Deltasone (Prednisone) Tablet	SS		ORAL	ORAL	
			Insulin (Insulin)	SS				
			Imuran (Azathioprine)	SS				
			Lasix (Furosemide)	SS				
			Cyclosporine (Ciclosporin)	SS				
			Clonidine (Clonidine)	SS				
			Norvasc (Amlodipine Besilate)	SS				
			Toprool ()	SS				
			Zebeta (Bisoprolol Fumarate)	SS				
			Cyclobenzaprine (Cyclobenzaprine)	SS				
			B Complex (Pyridoxine Hydrochloride, Thiamine Hydrochloride,	SS				

	Vioxx ()	SS
	Lipitor (Atorvastatin)	SS
	Clonazepam (Clonazepam)	SS

Date:03/08/02ISR Number: 3888360-1Report Type:Periodic Company Report #WAES 01010994
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Prinivil 10 Mg	PS		ORAL	10 MG, DAILY,	
	Cough	Professional					PO	
			Tab Vioxx 25 Mg	SS		ORAL	PO	
			Cardura	C				
			Ogen	C				
			Prilosec	C				
			Zyrtec	C				

Date:03/11/02ISR Number: 3880575-1Report Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8 WK	
	Drug Ineffective		Vioxx	SS		ORAL	1 WK	
			Motrin	C				
			Lotensin	C			OPHTHALMIC	
			Lipitor	C		ORAL		
			Paxil	C		ORAL		
			Norvasc	C		ORAL		
			Atenolol	C				
			Zyrtec	C		ORAL		
			Ambien	C				
			Prevacid	C		ORAL		
			Vicodin Tablets	C		ORAL		
			Plavix	C		ORAL		

Date:03/11/02ISR Number: 3880586-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00855
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Constipation							
	Face Oedema							
	Lip Discolouration							
	Oral Soft Tissue Disorder							
	Pain							
	Poisoning							
	Renal Disorder							

Date:03/11/02ISR Number: 3880808-1Report Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Chest Pain
	Diverticulum Duodenal
	Gastroduodenitis

Melaena

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
			Hyzaar	C		ORAL		
			Alprazolam	C		ORAL		
			Amlodipine Besylate	C		ORAL		

Date:03/11/02ISR Number: 3880810-XReport Type:Expedited (15-DaCompany Report #WAES 0203CAN00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/02ISR Number: 3880811-1Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/02ISR Number: 3880812-3Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Leukopenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/02ISR Number: 3880816-0Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/02ISR Number: 3880817-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA01002
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization - Initial or Prolonged	Hypertensive Crisis		Cozaar	C				
	Malaise		Atenolol	C				
Disability			Claritin	C				

Date:03/11/02ISR Number: 3881127-XReport Type:Direct Company Report #CTU 163120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Right		Vioxx	PS	Merk		1 A DAY	
	Condition Aggravated							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/02ISR Number: 3881615-6Report Type:Direct Company Report #CTU 163193
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthenia		Rofecoxib 25 Mg	PS		ORAL	25MG QD ORAL	
Intervention to Prevent Permanent Impairment/Damage	Diarrhoea Fatigue Vomiting							

Date:03/11/02ISR Number: 3882029-5Report Type:Expedited (15-DaCompany Report #WAES 01085193
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alkaline	Foreign	Tab Vioxx					
Hospitalization -	Phosphatase Increased	Health	(Rofecoxib)	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Condition Aggravated	Professional	Acetaminophen/Codein					
Disability	Gamma-Glutamyltransferase		e Phosphate	C				
Other	Increased		Ketoprofen	C				
	Hypergammaglobulinaemia		Ketoprofen	C				
	Malaise		Levothyroxine Na	C				
	Metastases To Bone		Nifedipine	C				
	Metastases To Liver		Prednisolone	C				
	Metastases To Lung		Tamoxifen Citrate	C				
	Pneumothorax		Zolpidem Tartrate	C				

Date:03/11/02ISR Number: 3882091-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
		Company Representative						

Date:03/11/02ISR Number: 3882093-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00009
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:03/11/02ISR Number: 3882094-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA00074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/11/02ISR Number: 3882095-7Report Type:Expedited (15-DaCompany Report #WAES 0112USA01314
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypercoagulation	Health Professional	Coumadin	C				
	Pulmonary Embolism							

Date:03/11/02ISR Number: 3882284-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00229
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence	Foreign	Tab Vioxx					
Hospitalization -	C-Reactive Protein	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Increased						PO	
	Chills		Sulfasalazine	SS		ORAL	1 GM/BID PO	41 DAY
	Endocarditis		Naproxen	C				
	Neutrophilia							
	Pulse Pressure Increased							
	Pyrexia							
	White Blood Cell Count Abnormal							

Date:03/11/02ISR Number: 3882286-5Report Type:Expedited (15-DaCompany Report #WAES 01085193
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Alkaline	Foreign	Tab Vioxx					
Hospitalization -	Phosphatase Increased	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Condition Aggravated	Professional					PO	
Disability	Gamma-Glutamyltransferase		Acetamionphen/Codein					
Other	Increased		e Phosphate	C				
	Hypergammaglobulinaemia		Ketoprofen	C				
	Malaise		Levothyroxine Na	C				
	Metastases To Bone		Nifedipine	C				
	Metastases To Liver		Prednisolone	C				
	Metastases To Lung		Tamoxifen Citrate	C				
	Pneumothorax		Zolpidem Tartrate	C				

Date:03/11/02ISR Number: 3882289-0Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00129
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anuria	Foreign	Tab Vioxx			
	Haematuria	Other	(Rofecoxib)	PS		ORAL
25 MG/ DAILY						
	Proteinuria					
PO 4 DAY						
	Pyuria		Naproxen	SS		
375 MG TID						
	Renal Tubular Necrosis		Acetaminophen/Codein			
	Rhabdomyolysis		e Phosphate	C		
	Urinary Casts		Dimenhydrinate	C		
	White Blood Cells Urine		Lorazepam	C		
	Positive					

Date:03/11/02ISR Number: 3882291-9Report Type:Expedited (15-DaCompany Report #WAES0202CAN00128
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Paralysis	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
PO						
			Tizanidine			
			Hydrochloride	SS		ORAL
8 MG/DAILY PO						
			Tolterodine Tartrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/02ISR Number: 3882375-5Report Type:Expedited (15-DaCompany Report #WAES 01011435
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Pressure Increased						MG/DAILY/PO	
	Drug Ineffective		Tab Vioxx 12.5 Mg	SS			12.5	
							MG/DAILY/PO	
			Pepcid	C				
			Glucosamine	C				

Date:03/11/02ISR Number: 3882378-0Report Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Study	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Constipation	Health	Tab Placebo	SS		ORAL	PO	
Initial or Prolonged	Diverticulitis	Professional	Acetaminophen	SS		ORAL	...MG, PRN,	
	Diverticulum						PO	
	Dizziness		Hydrodiuril	C				
	Gastric Ulcer		Tears Naturale	C				
	Gastrointestinal		Tubex	C				
	Haemorrhage		Vasocon-A	C				
	Iron Deficiency Anaemia		Aspirin	C				
	Malnutrition		Folic Acid	C				
	Rectal Haemorrhage		Methotrexate	C				

Date:03/11/02ISR Number: 3882384-6Report Type:Expedited (15-DaCompany Report #WAES 00060598
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - SEE IMAGE	Gastrooesophageal Reflux	Consumer	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged	Disease	Company Representative				

Date:03/11/02ISR Number: 3882386-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	3	DAY
Initial or Prolonged	Congestive	Professional Company Representative	Lipitor	C				

Date:03/11/02ISR Number: 3882387-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA02041
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Drug Ineffective	Professional					MG/DAILY/PO	
	Oral Mucosal Eruption	Company	Actonel	C				
	Pruritus	Representative	Aricept	C				
	Rash Generalised		Celebrex	C				
			Paxil	C				
			Cyanocobalamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/02ISR Number: 3882402-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02526
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Syncope	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Upper Gastrointestinal Haemorrhage	Health Professional	Zantac	C				
			Acetaminophen	C				
			Doxepin Hydrochloride	C				
			Hydrocodone	C				

Date:03/11/02ISR Number: 3882404-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Combivent	C				
			Coreg	C				
			Flovent	C				
			Lipitor	C				
			Plavix	C				
			Zoloft	C				
			Aspirin	C				
			Vitamin E	C				

Date:03/11/02ISR Number: 3882440-2Report Type:Expedited (15-DaCompany Report #WAES 01011435
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	

			Tqab Vioxx 12.5 Mg	SS		ORAL
12.5 MG,						
DAILY, PO						
			Pepcid	C		
			Glucosamine	C		

Date:03/11/02ISR Number: 3882443-8Report Type:Expedited (15-DaCompany Report #0960039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Constipation	Study	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG,						
Hospitalization -	Diverticulum	Health				
DAILY, PO						
Initial or Prolonged	Dizziness	Professional	Tab Vioxx 25 Mg	SS		ORAL
25 MG, DAILY,						
	Gastric Ulcer					
PO						
	Gastrointestinal		Tab Placebo			
	Haemorrhage		(Unspecified)	SS		ORAL
PO						
	Iron Deficiency Anaemia		Acetaminophen	SS		ORAL
325 MG, PRN,						
	Malnutrition					
PO						
	Rectal Haemorrhage		Hydrodiuril	C		
			Tears Naturale	C		
			Tubex	C		
			Vasocon-A	C		
			Aspirin	C		
			Folic Acid	C		
			Methotrexate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/02ISR Number: 3882447-5Report Type:Expedited (15-DaCompany Report #WAES 00060598
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease		Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:03/11/02ISR Number: 3882545-6Report Type:Expedited (15-DaCompany Report #WAES 01092870
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Diverticulum Intestinal Gastrointestinal Obstruction Gastrointestinal Stenosis Nausea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/11/02ISR Number: 3882547-XReport Type:Expedited (15-DaCompany Report #WAES 01092870
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Obstruction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/12/02ISR Number: 3881536-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Haemoptysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/12/02ISR Number: 3881539-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Platelet Count Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/12/02ISR Number: 3881581-3Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/12/02ISR Number: 3881585-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension Asthenia Back Pain Blood Sodium Decreased Blood Urea Decreased Bowel Sounds Abnormal Breath Sounds Decreased

		Cardiac Murmur					
		Chills					
		Crepitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS		ORAL
		Dizziness		Ecotrin	SS		
		Dyspepsia		Fosamax	C	Merck & Co., Inc	ORAL
		Dysstasia		Vitamins			
		Frequent Bowel Movements		(Unspecified)	C		
		Gastric Mucosal		Calcitonin	C		
		Hypertrophy		[Therapy			
		Gastric Ulcer		Unspecified]	C		
		Gastritis		Tylenol Extra			
		Gastrointestinal		Strength	C		
		Haemorrhage		Caltrate	C		
		Haematocrit Decreased		Miacalcin	C		
		Haemoglobin Decreased		Vitamin E	C		
		Haemorrhoids		Atenolol	C		
		Malaise		Ultram	C		ORAL
		Mucous Membrane Disorder					
		Myalgia					
		Nausea					
		Pallor					
		White Blood Cell Count					
		Increased					

Date:03/12/02ISR Number: 3881594-1Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00007
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 17 DAY		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Hydrochlorothiazide And Lisinopril	C		ORAL
				Amlodipine Besylate	C		ORAL
				Glyburide And Metformin Hydrochloride	C		ORAL
				Digoxin	C		ORAL

Date:03/12/02ISR Number: 3881595-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00431
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cartilage Injury		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Chest Pain							
	Decreased Activity							
	Dyspnoea							
	Fall							

Date:03/12/02ISR Number: 3881596-5Report Type:Expedited (15-DaCompany Report #WAES 0203POL00003
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged								
Other								

Date:03/12/02ISR Number: 3881607-7Report Type:Direct Company Report #CTU 163185
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Rofecoxib	PS		ORAL	QD ORAL	

Date:03/12/02ISR Number: 3881616-8Report Type:Direct Company Report #CTU 163194
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Rofecoxib	PS		ORAL	QD ORAL	

Date:03/12/02ISR Number: 3882295-6Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00126
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/12/02ISR Number: 3882298-1Report Type:Expedited (15-DaCompany Report #WAES 0112CAN08629
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tinnitus	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	

Date:03/12/02ISR Number: 3882300-7Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00014
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Confusional State	Health	Acetaminophen/Oxycod					
	Flushing	Professional	one Hydrochloride	C				
		Other						

Date:03/12/02ISR Number: 3882301-9Report Type:Expedited (15-DaCompany Report #WAES 0203SWE00003
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	507 DAY
Initial or Prolonged		Health	Carbamazepine	C				
		Professional	Methotrexate	C				
		Other	Prednisolone	C				

Date:03/12/02ISR Number: 3882325-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00050
Age:100 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematemesis	Foreign	Tab Vioxx					
	Melaena	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Upper Gastrointestinal	Professional						
	Haemorrhage		Acetaminophen (+) Propoxyphene Napsylate	C				

Date:03/12/02ISR Number: 3882330-5Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00131
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cognitive Disorder	Foreign	Tab Vioxx					
	Dementia	Other	(Rofecoxib)	PS		ORAL	25 MG PO	3 MON
	Memory Impairment		Aspirin	C				
			Glucosamine	C				

Date:03/12/02ISR Number: 3882338-XReport Type:Expedited (15-DaCompany Report #WAES 01103733
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Foreign	Tab Vioxx					
Life-Threatening	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	8 DAY

Date:03/12/02ISR Number: 3882352-4Report Type:Expedited (15-DaCompany Report #WAES 0112BEL07521
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Death	Alanine Aminotransferase
Hospitalization -	Increased

Initial or Prolonged	Aplastic Anaemia Aspartate Aminotransferase Increased Bilirubin Conjugated Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Blood Urea Increased C-Reactive Protein Increased Crepitations Epistaxis Eyelid Oedema Haemolytic Anaemia Hypotension Interstitial Lung Disease Petechiae Platelet Count Decreased Subarachnoid Haemorrhage Transfusion Reaction Wheezing

	White Blood Cell Count Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY
			Cetirizine Hdyrochloride	C			
			Fluticasone Propionate	C			
			Nadroparin	C			
			Omeprazole	C			
			Salmeterol Xinafoate	C			
			Zafirlukast	C			

Date:03/12/02ISR Number: 3882446-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00099
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cholelithiasis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Cold Sweat						
	Dyspepsia						
	Malaise						
	Pulmonary Oedema						
	Weight Increased						

Date:03/12/02ISR Number: 3882449-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Anxiety	Consumer	Tab Vioxx	PS		ORAL	PO
	Arthralgia		Celebrex	C			
	Complications Of Transplant Surgery		Imuran (Azathioprine)	C			
	Dialysis		Lasix (Furosemide)	C			
	Drug Interaction		Lipitor	C			
	Haemorrhage		Norvasc	C			

	Injury	Toprol Xl Tablets	C
	Myalgia	Zebeta	C
	Pain	Zemplar	C
	Rash	Clonazepam	C
	Renal Failure	Clonidine	C
	Skin Disorder	Cyclobenzaprine Hydrochloride	C
		Cyclosporine	C
		Insulin	C
		Prednisone	C
		Vitamin B	C

Date:03/12/02ISR Number: 3882467-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00365
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Disability	Haemoglobin Decreased	Professional						
Other	Platelet Count Abnormal	Company	Arthrotec	C				
	Platelet Function Test Abnormal	Representative	Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/02ISR Number: 3882582-1Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Tab Vioxx					
	Drug Ineffective	Other	(Rofecoxib)	PS		ORAL	SEE IMAGE	14 DAY
	Haemorrhage Intracranial		Acetaminophen/Codein					
	Haemorrhagic Stroke		e Phosphate	C				
	Muscle Injury		Estrogens,					
	Oedema Peripheral		Conjugated (+)					
			Medrogestone	C				
			Ibuprofen	C				

Date:03/12/02ISR Number: 3882593-6Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00056
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Peritonitis	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional					PO	
			Acetaminophen	C				
			Acetaminophen/Propox					
			yphene Hydrochloride	C				
			Diosmin	C				
			Phenobarbital	C				
			Trimetazidine					
			Hydrochloride	C				

Date:03/12/02ISR Number: 3882754-6Report Type:Expedited (15-DaCompany Report #WAES 01095589
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Health	(Rofecoxib)	PS		ORAL	PO	
	Drug Hypersensitivity	Professional	Cortisone	C				
	Dyspnoea	Other	Dipyrone	C				

	Pruritus		Fluticasone Propionate (+) Salmeterol	C		
			Prednisone	C		
			Theophylline	C		

Date:03/12/02ISR Number: 3882755-8Report Type:Expedited (15-DaCompany Report #WAES 01063755
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colonic Haemorrhage	Foreign	Tab Vioxx					
Life-Threatening	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Haemorrhage	Professional						
PO							8	DAY
	Intestinal Stoma Site Bleeding	Other						

Date:03/12/02ISR Number: 3882756-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00030
Age:63 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Endoscopy Upper Gastrointestinal Tract Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 8 DAY
	Gastric Haemorrhage		Ketoprofen	SS		ORAL	PO	
	Haematemesis		Zocor	C				
	Haemoglobin Decreased		Estradiol (+) Medroxyprogesterone Acetat	C				
	Shock		Felodipine	C				
	Upper Gastrointestinal Haemorrhage		Naftazone	C				
			Omeprazole	C				

Date:03/12/02ISR Number: 3882757-1Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00068
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Visual Metastases To Central Nervous System	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 3 DAY
	Speech Disorder		Antineoplastic Dihydroergotamine Mesylate	C				
			Zolpidem Tartrate	C				

Date:03/12/02ISR Number: 3882764-9Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00015
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Frequent Bowel Movements	Foreign Other	Vioxx	PS		ORAL	12.5 MG/DAILY PO	

Other	Gastrointestinal Ulcer	Zocor	C
	Large Intestinal Ulcer	Allopurinol	C
	Rectal Haemorrhage	Bendroflumethiazide	C
		Isosorbide Mononitrate	C
		Lansoprazole	C
		Metoprolol	C
		Nicorandil	C

Date:03/12/02ISR Number: 3882786-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Depressed Level Of Consciousness	Company Representative						
	Gastric Haemorrhage							

Date:03/12/02ISR Number: 3882787-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02844
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urine Present	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
Initial or Prolonged								

		Hytrin	C
		Lipitor	C
		Proscar	C

Date:03/12/02ISR Number: 3882811-4Report Type:Expedited (15-DaCompany Report #WAES 01112854
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Akinesia	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Aortic Valve Disease	Health					MG/DAILY/PO	
Initial or Prolonged	Cardiac Enzymes Increased	Professional	Tab Acetaminophen					
Disability	Coronary Artery Disease		Unk	SS		ORAL	325 MG/PRN/PO	
	Dilatation Atrial		Effexor	C				
	Dilatation Ventricular		Zocor	C				
	Dyskinesia		Aspirin	C				
	Dyspnoea							
	Dyspnoea Exertional							
	Ejection Fraction Decreased							
	Fatigue							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Neoplasm Prostate							
	Pleural Effusion							
	Pulmonary Hypertension							
	Pulmonary Oedema							
	Scar							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							
	Ventricular Tachycardia							

Date:03/12/02ISR Number: 3882812-6Report Type:Expedited (15-DaCompany Report #WAES 01100711
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Initial or Prolonged	Convulsion	Professional				
MG/DAILY/PO						
	Dyspnoea		Provigil 200 Mg	SS		ORAL
200						
	Dysuria					
MG/DAILY/PO						
	Fall		Betaseron Unk	SS		
SUBCUTANEOUS QOD/SC						
	Hyperreflexia		Amantadine			
	Laceration		Hydrochloride Unk	SS		
	Mental Impairment		Procuren	C		
	Serum Sickness		Wellbutrin	C		
	Skin Injury		Prednisone	C		
	Status Epilepticus		Vitamins			
			(Unspecified)	C		

Date:03/12/02ISR Number: 3882852-7Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Coronary Artery Stenosis
Initial or Prolonged	Fluid Retention
Other	Myocardial Infarction
	Nausea
	Swelling

Ventricular Hypokinesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx	PS		ORAL	PO	
	Celebrex	C				
	Mepergan	C				
	Relafen	C				
	Xanax	C				
	Amitriptyline	C				
	Aspirin	C				

Date:03/12/02ISR Number: 3882858-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/12/02ISR Number: 3882887-4Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Abnormal
	Aggression
	Atrioventricular Block
	Complete
	Blood Bicarbonate
	Abnormal
	Blood Chloride Abnormal
	Blood Creatinine Abnormal
	Blood Glucose Abnormal
	Blood Ph Abnormal
	Blood Potassium Abnormal
	Blood Sodium Abnormal
	Blood Urea Abnormal
	Bundle Branch Block Left
	Cardiac Failure
	Congestive

Cardio-Respiratory Arrest
Cardiomegaly
Chest Pain
Crepitations
Dyspnoea
Electrocardiogram
Abnormal
Electrocardiogram Poor
R-Wave Progression
Haematocrit Abnormal
Haemoglobin Abnormal
Headache
Heart Rate Decreased
Hypertension
Hypotension
International Normalised
Ratio Abnormal
Lethargy
Lymphocyte Count Abnormal
Myoglobin Blood Increased

		Neutrophil Count Abnormal					
		Oxygen Saturation Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pco2 Abnormal	Consumer	Tab Vioxx 25mg	PS		ORAL
25 MG/DAILY/PO							
		Platelet Count Abnormal	Health				
		Po2 Abnormal	Professional	Lasix 40 Mg	SS		
49 MG/BID							
		Prothrombin Time Abnormal		Ativan	C		
		Pulmonary Oedema		Claritin	C		
		Red Blood Cell		Deltasone	C		
		Sedimentation Rate		Flonase	C		
		Increased		K-Dur	C		
		Respiratory Distress		Klonopin	C		
		Respiratory Rate		Nitropatch	C		
		Increased		Paxil	C		
		Syncope		Pepcid	C		
		Tachycardia		Plavix	C		
		White Blood Cell Count		Ritalin	C		
		Abnormal		Sinemet	C		
				Zocor	C		
				Alprazolam	C		
				Aspirin	C		
				Atenolol	C		
				Captopril	C		
				Codeine	C		
				Ibuprofen	C		
				Methylphenidate	C		
				Nitroglycerin	C		
				Quinine	C		

Date:03/12/02ISR Number: 3882939-9Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Hypertension	Foreign	Tab Vioxx			
		Retinal Vascular	Other	(Rofecoxib)	PS		ORAL
PO	15 DAY						
Disability		Occlusion		Budesonide	C		
				Fenofibrate	C		
				Salmeterol Xinafoate	C		
				Trimetazidine			

				Hydrochloride	C		

Date:03/13/02ISR Number: 3881960-4Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00066
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:03/13/02ISR Number: 3881964-1Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00035
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Ulcer		Acetaminophen	C		ORAL		
	Helicobacter Pylori Identification Test Positive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/02ISR Number: 3881967-7Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:03/13/02ISR Number: 3881971-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Epistaxis							
	Eye Haemorrhage							
	Eye Inflammation							
	Macular Degeneration							

Date:03/13/02ISR Number: 3881973-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/13/02ISR Number: 3882050-7Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00130
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL		
		Other	Acetaminophen (+) Methocarbamol	C				
			Acetaminophen/Codeine Phosphate	C				
			Carbamazepine	C				

Date:03/13/02ISR Number: 3882053-2Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00133
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Foreign	Tab Vioxx					
	Decreased Appetite	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Dizziness						PO	
	Duodenal Ulcer		Risederonate Sodium	SS		ORAL	5 MG/DAILY PO	
	Gastrointestinal		Tab Aspirin	SS		ORAL	80 MG/DAILY	
	Haemorrhage						PO	
	Haematochezia		Acetaminophen	C				
	Haemoglobin Decreased		Calcium Carbonate	C				
	Nausea		Goserelin Acetate	C				
	Respiratory Arrest		Meperidine Hc1	C				
	Weight Decreased		Salcatonin	C				
			Vitamin D (Unspecified)	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/02ISR Number: 3882055-6Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00044
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Balance Disorder Disturbance In Attention	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	4 MON
	Drug Interaction		Phenytoin	SS		ORAL	PO	
	Drug Level Increased Fatigue Gait Disturbance Mental Impairment		Aspirin	C				

Date:03/13/02ISR Number: 3883233-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00855
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Consumer	Tab Vioxx	PS		ORAL	PO	
	Constipation Face Oedema Oral Mucosal Discolouration Pain Renal Disorder Skin Discolouration							

Date:03/13/02ISR Number: 3883269-1Report Type:Expedited (15-DaCompany Report #WAES 01112854
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma Blood Pressure Increased	Health Professional	Tab Acetaminophen	SS		ORAL	325 MG/PRN/PO	

Disability	Cardiac Murmur	Effexor	C
	Cardiomyopathy	Zocor	C
	Dyspnoea	Aspirin	C
	Dyspnoea Exertional		
	Electrocardiogram T Wave		
	Inversion		
	Fatigue		
	Hyperhidrosis		
	Nausea		
	Pain		
	Ventricular Tachycardia		

Date:03/13/02ISR Number: 3883271-XReport Type:Expedited (15-DaCompany Report #WAES 01114623
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	1 WK
	Drug Ineffective		Ambien	C				
			Lipitor	C				
			Lotensin	C				
			Motrin	C				
			Norvasc	C				
			Paxil	C				
			Plavix	C				
			Prevacid	C				
			Vicodin Tablets	C				

			Zyrtec	C		
			Atenolol	C		

Date:03/13/02ISR Number: 3883651-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00016
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 DAY

Date:03/13/02ISR Number: 3883652-4Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY;	PO 8 DAY
			Tab Ethinyl Estradiol (+) Levonorgestrel	SS		ORAL	0.15/0.03 MG/DAILY	PO

Date:03/13/02ISR Number: 3883653-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00035
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Osteoarthritis Paresis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG PO	86 DAY
			Eprosartan	SS		ORAL	600 MG PO	

Date:03/14/02ISR Number: 3882369-XReport Type:Direct Company Report #CTU 163368
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Subcutaneous		Vioxx	PS		ORAL	12.5MG ONCE A DAY ORAL	

Date:03/14/02ISR Number: 3882511-0Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00060
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Death	Angiopathy
Life-Threatening	Blood Lactate
Hospitalization - Initial or Prolonged	Dehydrogenase Increased
	Brain Oedema
	C-Reactive Protein Increased
	Cardiac Failure
	Disseminated Intravascular Coagulation
	Erythema
	Fatigue
	Gastrointestinal Haemorrhage
	Haematemesis

	Hypersensitivity						
	Influenza Like Illness						
	Leukocytoclastic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vasculitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Multi-Organ Failure	Professional	Penicillin				
	Necrosis		(Unspecified)	SS			INTRAVENOUS
	Pain		Aspirin	SS		ORAL	
	Pruritus		Allopurinol	C		ORAL	
	Rectal Haemorrhage		Bisoprolol Fumarate	C		ORAL	
	Shock		Acetylcysteine	C		ORAL	
	Spleen Disorder						
	Viral Infection						

Date:03/14/02ISR Number: 3882512-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00030
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY
Hospitalization -	Haemorrhage		Aspirin Lysine	SS		ORAL	2439 DAY
Initial or Prolonged	Femoral Neck Fracture						
	Gastric Ulcer						
	Gastrointestinal						
	Haemorrhage						
	Hypovolaemic Shock						
	Intestinal Ischaemia						
	Oesophagitis						

Date:03/14/02ISR Number: 3884895-6Report Type:Expedited (15-DaCompany Report #NSADSS2002001976
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cholelithiasis	Foreign	Remicade (5 Mg/Ml				
Initial or Prolonged		Study	Lyophilized Powder)				
		Health	(Infliximab,				
		Professional	Recombinant)	PS			INTRAVENOUS 1 IN 1 DAILY,

IV

Placebo (Unspecified) (Placebo) SS

INTRAVENOUS 1 IN 1 DAILY,

IV

Vioxx (Rofecoxib) SS ORAL

25 MG, 1 IN 1

DAILY, ORAL

Tramadol Hydrochloride Ir (Tablet) (Tramadol Hydrochloride) SS

150 MG, 1 IN

1 DAILY

Date:03/15/02ISR Number: 3883082-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01158
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Tightness Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/02ISR Number: 3883083-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01174
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rash Generalised		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tylenol With Codeine #3	C				

Date:03/15/02ISR Number: 3883102-8Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00012
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc			4 DAY
Initial or Prolonged	Hypersensitivity							
	Oedema							
	Skin Discolouration							

Date:03/15/02ISR Number: 3883104-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00044
Age:53 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Respiratory Disorder							

Date:03/15/02ISR Number: 3883165-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Urticaria							

Date:03/15/02ISR Number: 3883166-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS		ORAL		
Initial or Prolonged	Fall		Vicodin Tablets	C				

Date:03/15/02ISR Number: 3883167-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colectomy		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Initial or Prolonged	Haematochezia		Aspirin	C				
Other			Calcium (Unspecified)	C				

Date:03/15/02ISR Number: 3883170-3Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Pulmonary Oedema
Initial or Prolonged	Akinesia
	Coronary Artery
	Restenosis

	Coronary Artery Stenosis Echocardiogram Abnormal Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
			Dalteparin Sodium	C		SUBCUTANEOUS		
			Aspirin	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Perindopril Erbumine	C		ORAL		
			Nitroglycerin	C				

Date:03/15/02ISR Number: 3883173-9Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Thrombosis Myocardial Infarction		Ethinyl Estradiol And Levonorgestrel	SS		ORAL		

Date:03/15/02ISR Number: 3883175-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00048
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
	Face Oedema		Vioxx	SS		ORAL		
	Oedema Peripheral		Bromelains	C		ORAL		
	Somnolence Tongue Oedema		Magnesium (Unspecified)	C		ORAL		

Date:03/15/02ISR Number: 3883178-8Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00011
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	67	DAY

Initial or Prolonged	Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Condition Aggravated Gamma-Glutamyltransferase Increased Jaundice Malaise Osteoarthritis Vomiting	Atorvastatin Calcium Amlodipine Besylate	C C	ORAL ORAL

Date:03/15/02ISR Number: 3883182-XReport Type:Expedited (15-DaCompany Report #WAES 0203DEU00074
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Death	Cardiac Failure Acute
Life-Threatening	Coma Condition Aggravated Haematocrit Decreased Haemodialysis

	Haemoglobin Decreased						
	Platelet Count Abnormal						
	Renal Impairment	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Urinary Tract Infection		Aspirin	SS		ORAL		
	White Blood Cell Count		Molsidomine	SS		ORAL		
	Abnormal		Fentanyl	SS		TOPICAL		
			Furosemide	SS		ORAL		
			Insulin, Biphasic					
			Isophane [Injection]	C		SUBCUTANEOUS		
			Digitoxin	C		ORAL		

Date:03/15/02ISR Number: 3883183-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Dysphagia							
	Gingivitis							
	Pharyngolaryngeal Pain							
	Tongue Discolouration							
	Tongue Disorder							

Date:03/15/02ISR Number: 3883188-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00392
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diarrhoea		Vioxx	SS		ORAL		
Other	Gastric Haemorrhage		Hydrocortone	C				
	Gastrointestinal Pain							
	Oral Intake Reduced							

Date:03/15/02ISR Number: 3883496-3Report Type:Direct Company Report #CTU 163506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx 25mg Merck & Company Inc	PS	Merck & Company Inc			
Congenital Anomaly	Arrhythmia							
SEE IMAGE								
Required Intervention to Prevent Permanent Impairment/Damage	Dizziness							
	Dyspnoea							
	Flushing							
	Headache							
	Pain In Extremity							
	Palpitations							

Date:03/15/02ISR Number: 3883536-1Report Type:Direct Company Report #CTU 163521
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG QD ORAL	
Initial or Prolonged	Dyspnoea		Aspirin 325 Mg	SS		ORAL	650 MG QD ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Gastritis							
	Oesophageal Ulcer							
	Upper Gastrointestinal Haemorrhage							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/02ISR Number: 3884231-5Report Type:Direct Company Report #CTU 163480
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx 12.5mg	PS			1T Q D	12 DAY
Initial or Prolonged			Lorazepam	C				

Date:03/15/02ISR Number: 3884606-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00431
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fall							
	Limb Injury							
	Respiratory Disorder							

Date:03/15/02ISR Number: 3884648-9Report Type:Expedited (15-DaCompany Report #WAES 0203POL00003
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tachycardia	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional						
PO							7	DAY
Other								

Date:03/15/02ISR Number: 3884649-0Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00007
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

Professional
PO 17 DAY

Amlodipine Besylate	C
Digoxin	C
Glyburide (+) Metformin Hydrochloride	C
Lisinopril-Hctz	C

Date:03/15/02ISR Number: 3884650-7Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/15/02ISR Number: 3884654-4Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Leukopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/02ISR Number: 3884655-6Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/15/02ISR Number: 3884657-XReport Type:Expedited (15-DaCompany Report #WAES 0203CAN00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/15/02ISR Number: 3884658-1Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/15/02ISR Number: 3884807-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Haemoptysis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/15/02ISR Number: 3884808-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00334
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation	Study	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Nausea	Health						
Other	Pain	Professional	Lortab	C				
	Post Procedural		Premarin	C				
	Cellulitis		Desflurane	C				
	Postoperative Infection		Fentanyl	C				
	Wound Drainage		Midazolam	C				
			Morphine Sulfate	C				
			Nitrous Oxide	C				
			Ondansetron	C				
			Propofol	C				
			Rocuronium Bromide	C				

Date:03/15/02ISR Number: 3884867-1Report Type:Expedited (15-DaCompany Report #EMADSS2002001611
Age:82 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Atrial Fibrillation
	Confusional State
	Electrocardiogram
	Repolarisation

	Abnormality Epistaxis Extrapyramidal Disorder Fall	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	General Physical Health Deterioration Haemorrhagic Stroke Hypertension	Foreign Health Professional	Tramadol (Unspecified) (Tramadol Hydrochloride)	PS		ORAL	SEE IMAGE	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Corvasal (Molsidomine)	C				
			Triatec Faibe (Ramipril)	C				
			Allopurinol (Allopurinol)	C				
			Digoxine (Digoxin)	C				
			Haldol Faible (Haloperidol)	C				
			Lexomidl (Bromazepam)	C				
			Tradyferon (Ferrous Sulfate)	C				
			Dicynone (Etamsilate)	C				

Date:03/15/02ISR Number: 3884909-3Report Type:Expedited (15-DaCompany Report #WAES 01073719
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Gastric Haemorrhage Gastric Perforation	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/15/02ISR Number: 3884910-XReport Type:Expedited (15-DaCompany Report #WAES 01119004
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					

	Chest Pain	Other	(Rofecoxib)	PS		ORAL
25 MG PO 21 DAY						
	Diverticulum Duodenal		Hyzaar	C		
	Gastroduodenitis		Alprazolam	C		
	Melaena		Amlodipine Besylate	C		

Date:03/15/02ISR Number: 3885025-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01002
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypertensive Crisis	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
Hospitalization -		Professional	Claritin	C		
Initial or Prolonged		Company	Cozaar	C		
Disability		Representative	Atenolol	C		

Date:03/15/02ISR Number: 3885028-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization -	Chest Pain	Consumer
Initial or Prolonged	Platelet Count Decreased	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:03/18/02ISR Number: 3883835-3Report Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY	
Initial or Prolonged	Pyrexia		Hydroxyurea	SS		ORAL	24 DAY	
	Rash Pustular		Dipyrone	C		ORAL	29 DAY	
			Mercaptopurine	C		ORAL	3 YR	
			Omeprazole	C		ORAL	1138 DAY	

Date:03/18/02ISR Number: 3883837-7Report Type:Expedited (15-DaCompany Report #WAES 01106017
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Chest Pain		Chondroitin Sulfate Sodium	C		ORAL		
	Coronary Artery Disease		Naftazone	C		ORAL		
	Cough		Lorazepam	C		ORAL		
	Dilatation Ventricular		Acebutolol Hydrochloride	C		ORAL		
	Dyspnoea							
	Electrocardiogram Abnormal							
	Electrocardiogram T Wave Inversion							
	Pulmonary Embolism							
	Ventricular Hypertrophy							
	Ventricular Hypokinesia							

Date:03/18/02ISR Number: 3883838-9Report Type:Expedited (15-DaCompany Report #WAES 01105259
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Carbamazepine	C				

Date:03/18/02ISR Number: 3883839-0Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Ischaemia		Enoxaparin	C			SUBCUTANEOUS	5 DAY
	Cerebrovascular Accident		Acetaminophen	C		ORAL	6 DAY	
	Confusional State		Pamidronate Disodium	C			INTRAVENOUS	1 DAY
	Myocardial Infarction		Prednisone	C		ORAL		
			Vitamin D (Unspecified)	C		ORAL		
			Calcium Phosphate, Tribasic	C		ORAL		
			Bromazepam	C		ORAL		
			Aceprometazine Maleate And Meprobamate	C		ORAL		

				Ketoprofen	C		
INTRAMUSCULAR		5	DAY				

Date:03/18/02ISR Number: 3883840-7Report Type:Expedited (15-DaCompany Report #WAES 01115006
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Grand Mal Convulsion		Carbamazepine	C		ORAL		
			Estradiol	C		TOPICAL		
			Acetaminophen	C		ORAL		

Date:03/18/02ISR Number: 3883843-2Report Type:Expedited (15-DaCompany Report #WAES 01106063
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
	Creatinine Renal Clearance Decreased		Verapamil Hydrochloride	SS		ORAL		
			Bisoprolol Fumarate	C		ORAL		
	Fall		Alprazolam	C		ORAL		
	Orthostatic Hypotension		Paroxetine	C		ORAL		
	Sinus Bradycardia		Elavil	C		ORAL		
			Trihexyphenidyl Hydrochloride	C		ORAL		
			[Therapy Unspecified]	C		ORAL		
			Acetaminophen	C		ORAL		

Date:03/18/02ISR Number: 3883844-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	79	DAY

Initial or Prolonged	Asthenia	Professional	[Composition	
Other	Bronchitis		Unspecified]	C
PARENTERAL				
	Cardiac Flutter		Aspirin	C
1 DAY				
	Duodenal Ulcer			
	Haemorrhage			
	Duodenitis			
	Faeces Discoloured			
	Fatigue			
	Gastritis Erosive			
	Gastrointestinal			
	Haemorrhage			
	Haematemesis			
	Heart Rate Irregular			
	Hyperhidrosis			
	Influenza Like Illness			
	Melaena			
	Orthostatic Hypotension			
	Sensitivity Of Teeth			
	Shock			
	Syncope			
	Upper Gastrointestinal			
	Haemorrhage			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/02ISR Number: 3883845-6Report Type:Expedited (15-DaCompany Report #WAES 0203MYS00008
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Face Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Lethargy	Professional				
	Oedema					
	Oedema Peripheral					
	Periorbital Oedema					
	Somnolence					

Date:03/18/02ISR Number: 3883910-3Report Type:Expedited (15-DaCompany Report #WAES 01106009
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
56 DAY						
	Mydriasis		Alfuzosin Hydrochloride	C		ORAL
			Acetaminophen	C		ORAL
			Pantoprazole	C		ORAL

Date:03/18/02ISR Number: 3883911-5Report Type:Expedited (15-DaCompany Report #WAES 01112431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/18/02ISR Number: 3883917-6Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00027
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
	Face Oedema		Risperidone	C		ORAL
	Tongue Oedema		Lactulose	C		
			Senna	C		

Anastrozole	C			ORAL
Morphine Sulfate	C			

Date:03/18/02ISR Number: 3883921-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00583
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Zocor	PS	Merck & Co., Inc	ORAL
	Aspartate Aminotransferase Increased		Zocor	SS		ORAL
	Blood Cholesterol Increased		Vioxx	SS		ORAL
	Blood Triglycerides Increased		Tylenol With Codeine	SS		
	Pancreatitis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/02ISR Number: 3883925-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Haemoptysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/02ISR Number: 3883926-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Digoxin	SS				
			Lopressor	SS				
			Hydrodiuril	SS				
			Indocin (Indomethacin)	SS				
			Metoprolol	SS				
			Toprol Xl Tablets	SS				
			Coumadin	SS				
			Lotensin	SS				

Date:03/18/02ISR Number: 3884193-0Report Type:Direct Company Report #CTU 163580
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haemoglobin Decreased Melaena		Rofecoxib	PS				
			Hyzaar	C				
			Vicodin	C				
			Elavil	C				
			Thyroid	C				
			Premarin	C				
			C	C				

Date:03/18/02ISR Number: 3884195-4Report Type:Direct Company Report #CTU 163581
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Rofecoxib	PS		ORAL	25MG PO QD	
Initial or Prolonged	Gastritis		Lopressor	C				
	Haematocrit Abnormal		Evista	C				
	Melaena		Lasix	C				
	Tachycardia		Kdur	C				
	Ulcer		Albuterol	C				

Date:03/18/02ISR Number: 3884197-8Report Type:Direct Company Report #CTU 163582
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Renal Artery		Rofecoxib	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Atherosclerosis		Colchicine	C				
	Renal Failure Acute		Gemfibrozil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/02ISR Number: 3884198-XReport Type:Direct Company Report #CTU 163583
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Rofecoxib	PS				
	Gastrointestinal Haemorrhage		Aspirin	SS				

Date:03/18/02ISR Number: 3884199-1Report Type:Direct Company Report #CTU 163584
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Rofecoxib	PS				
	Hepatitis Acute		Risperidol	C				
	Hypokalaemia		Seroquel	C				
	Vomiting							

Date:03/18/02ISR Number: 3884842-7Report Type:Expedited (15-DaCompany Report #THQ2002A00340
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cutaneous Lupus Erythematosus	Health Professional	Lansoprazole (Lansoprazole)	PS				78 DAY
	Skin Necrosis		Sulphasalazine (Sulfasalazine)	SS		ORAL	2 G	
			Rofecoxib (Rofecoxib)	SS		ORAL	12.5 MG; 25 MG	624 DAY
			Ferrous Fumarate (Ferrous Fumarate)	C				
			Paracetamol (Paracetamol)	C				
			Tramadol (Tramadol)	C				

Date:03/19/02ISR Number: 3884408-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00009
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Myocardial Infarction							

Date:03/19/02ISR Number: 3884569-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA01861
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Gastrointestinal Ulcer		Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	C				
			Motrin	C				
			Plavix	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/02ISR Number: 3884572-1Report Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bipolar Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Condition Aggravated		Carbamazepine	SS		ORAL		
	Drug Interaction		Elavil	C		ORAL		
	Drug Level Below Therapeutic		Alprazolam	C		ORAL		

Date:03/19/02ISR Number: 3884573-3Report Type:Expedited (15-DaCompany Report #WAES 01117510
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		DAY
Initial or Prolonged	Duodenal Ulcer		Vioxx	SS		ORAL		2 DAY
	Perforation		Citalopram Hydrobromide	C		ORAL		
	Oesophagitis		Fosamax	C		ORAL		
	Peritonitis		Carvedilol	C		ORAL		
			Althiazide And Spironolactone	C		ORAL		
			Haloperidol	C		ORAL		
			Ranitidine	C		ORAL		

Date:03/19/02ISR Number: 3884575-7Report Type:Expedited (15-DaCompany Report #WAES 01104344
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS		ORAL		
	Hepatitis B		Premarin	C				
	Joint Crepitation		Prozac	C				
	Neck Pain		Vicodin Tablets	C				
	Oedema Peripheral		Serzone	C				
	Pain In Extremity							

Date:03/19/02ISR Number: 3884576-9Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00131
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:03/19/02ISR Number: 3884580-0Report Type:Expedited (15-DaCompany Report #WAES 01113180
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS		ORAL	1	MON
	Face Oedema		Hyzaar	C				
	Oedema		Premarin	C				
	Oedema Peripheral		Klor-Con	C				
	Oliguria		Synthroid	C				
	Weight Increased		Cozaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/02ISR Number: 3884587-3Report Type:Expedited (15-DaCompany Report #WAES 0203SWE00003
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		507 DAY
Initial or Prolonged			Methotrexate Sodium	C				
			Prednisolone	C				
			Carbamazepine	C				

Date:03/19/02ISR Number: 3884593-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA01866
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Non-Cardiogenic Pulmonary							
Other	Oedema							
	Respiratory Distress							

Date:03/19/02ISR Number: 3884694-5Report Type:Direct Company Report #CTU 163669
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Depression		Vioxx	PS		ORAL	25MG PO QD	
Intervention to	Hyperkalaemia							
Prevent Permanent	Psychotic Disorder							
Impairment/Damage								

Date:03/19/02ISR Number: 3885492-9Report Type:Expedited (15-DaCompany Report #WAES 0203CAN00050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Foreign	Tab Vioxx					
		Consumer	(Rofecoxib)	PS		ORAL	PO	2 MON

Date:03/19/02ISR Number: 3885517-0Report Type:Expedited (15-DaCompany Report #WAES 01058223
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Drug Interaction Fatigue Oedema Peripheral Sinus Bradycardia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 5 DAY
			Tab Tizanidine	SS		ORAL	4 MG/DAILY	5 DAY

Date:03/19/02ISR Number: 3885607-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00060
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Death	Back Pain
Life-Threatening	Blood Creatinine Increased
Hospitalization - Initial or Prolonged	Blood Lactate Dehydrogenase Increased Blood Urea Increased Brain Oedema C-Reactive Protein Increased

	Capillary Leak Syndrome						
	Carcinoid Syndrome						
	Disseminated	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Intravascular Coagulation	Foreign	Tab Vioxx				
	Erythema	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY
	Gastrointestinal						PO
	Haemorrhage		Penicillin				
	Henoch-Schonlein Purpura		(Unspecified)	SS		INTRAVENOUS	20 MEGA
	Hypersensitivity						IU/DAILY IV
	Influenza Like Illness		Aspirin	SS		ORAL	100 MG/DAILY
	Multi-Organ Failure						PO
	Pruritus		Acetylcysteine	C			
	Rectal Haemorrhage		Allopurinol	C			
	Sciatica		Bisoprolol Fumarate	C			
	Vasculitis						
	Viral Infection						
	White Blood Cell Count Increased						

Date:03/19/02ISR Number: 3885608-4Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00030
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx				
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	PO 11 DAY
Initial or Prolonged	Gastric Ulcer Haemorrhage		Aspirin Lysine	SS		ORAL	325 MG/DAILY
	Hypovolaemic Shock						PO 2439 DAY
	Intestinal Ischaemia						
	Lower Limb Fracture						
	Mesenteric Vascular Insufficiency						
	Oesophagitis						

Date:03/19/02ISR Number: 3885849-6Report Type:Expedited (15-DaCompany Report #WAES 01092233
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Carpal Tunnel Syndrome	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Condition Aggravated	Health					MG/DAILY/PO	
	Pain In Extremity	Professional	Prinzide	C				
	Post Procedural		Chondroitin (+)					
	Complication		Glucosamine	C				
	Rheumatoid Arthritis		Herbs	C				

Date:03/19/02ISR Number: 3885912-XReport Type:Expedited (15-DaCompany Report #EMADSS2002001728
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Foreign	Durogesic (50 Mcg/Hr					
	Coronary Artery	Health	Patch) (Fentanyl)	PS				
TRANSDERMAL							50 MCG/H, 1	
	Insufficiency	Professional						
IN 72								
	Renal Impairment							
HOUR(S),								
	Urinary Tract Infection							
TRANSD								
			Vioxx (Rofecoxib)	SS		ORAL		
12.5 MG, 2 IN								
1 DAY(S),								
ORAL								
			Ass (Acetylsalicylic Acid)	C				

Berlinsulin (Insulin Zinc Suspension)	C
Furesis (Furosemide)	C
Corvaton (Molsidomine)	C
Digitoxin (Digitoxin)	C

Date:03/19/02ISR Number: 3886077-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Contusion							
	Epistaxis							
	Eye Inflammation							
	Macular Degeneration							
	Scotoma							

Date:03/19/02ISR Number: 3886078-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/19/02ISR Number: 3886102-7Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00066
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:03/19/02ISR Number: 3886103-9Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00035
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Ulcer Helicobacter Pylori Identification Test Positive	Foreign Health Professional	Tab Vioxx (Rofecoxib) Acetaminophen	PS C		ORAL	25 MG DAILY PO	

Date:03/19/02ISR Number: 3886104-0Report Type:Expedited (15-DaCompany Report #WAES 0112USA01427
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Asthenia Blood Pressure Decreased Bowel Sounds Abnormal Breath Sounds Decreased Chills Convulsion Diarrhoea

	Dizziness						
	Dyspepsia						
	Faeces Discoloured	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Frequent Bowel Movements	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Gastric Ulcer	Health					
	Gastrointestinal	Professional	Ecotrin 1 Tablet	SS			1 TABLET/DAILY
	Haemorrhage						
	Haematochezia		Caltrate	C			
	Haematocrit Decreased		Fosamax	C			
	Haemoglobin Decreased		Miacalcin	C			
	Haemorrhoids		Tylenol Extra Strength	C			
	Helicobacter Infection		Ultram	C			
	Malaise		Atenolol	C			
	Melaena		Calcitonin	C			
	Myalgia		Vitamin E	C			
	Nausea		Vitamins	C			
	Pallor						
	White Blood Cell Count Increased						

Date:03/19/02ISR Number: 3886205-7Report Type:Direct Company Report #CTU 163748
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine		Vioxx 25mg	PS		ORAL	25MG QD ORAL
	Increased		Methylprednisone	C			
	Blood Urea Increased		Bacitracin	C			
			Flovent Ihn	C			
			Combivent Inh	C			
			Salmeterol	C			
			Naphazoline	C			
			Livostin	C			
			Zyrtec	C			
			Tamoxifen	C			
			Diphenhydramine	C			
			Raberazole	C			
			Calan Sr	C			
			Alprazolam	C			

				Aerobid Inh	C		
				Cyclobenzaprine	C		
				Darvocet N100	C		
				Ferrous Sulfate	C		
				Fleet Phos	C		

Date:03/19/02ISR Number: 3886255-0Report Type:Direct Company Report #CTU 163719
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Anxiety		Vioxx 50mg	PS		ORAL	50MG QD ORAL	
Intervention to Prevent Permanent Impairment/Damage	Nervousness		Nystatin	C				
	Palpitations		Nasonex Spray	C				
			Triamcinolone Inh	C				
			Albuterol Inh	C				
			Timolol	C				
			Asa	C				
			Verapamil	C				
			Simvastatin	C				
			Glimeperide	C				
			Metformin	C				

				Gemfibrozil	C		
				Lisinopril	C		

Date:03/20/02ISR Number: 3884897-XReport Type:Expedited (15-DaCompany Report #WAES 0203ZAF00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/20/02ISR Number: 3884900-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/20/02ISR Number: 3884902-0Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00004
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage Haemoglobin Decreased International Normalised Ratio Increased Melaena		Vioxx Celecoxib Warfarin Sodium Digitoxin Furosemide	PS SS SS C C	Merck & Co., Inc			WK

Date:03/20/02ISR Number: 3884907-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA01868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 1 DAY	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diarrhoea Haemorrhagic					

Date:03/20/02ISR Number: 3885113-5Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00124
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastritis Erosive		Aspirin	SS		ORAL
	Gastritis Haemorrhagic		Fosamax	SS		ORAL
	Haematemesis		Naloxone			
	Haematocrit Decreased		Hydrochloride And			
	Haemoglobin Decreased		Tilidine			
			Hydrochloride	C		ORAL
			Zocor	C		ORAL
			Hyzaar	C		ORAL
			Tetrazepam	C		ORAL
			Nitrendipine	C		ORAL

Date:03/20/02ISR Number: 3885115-9Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00011
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Delirium		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY

Date:03/20/02ISR Number: 3886186-6Report Type:Expedited (15-DaCompany Report #PHRM2001FR02528
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Necrotising Fasciitis	Foreign Health Professional	Icaz Lp (Isradipine) Slow Release Capsules	PS		ORAL		
		Other	Art 50 (Diacerein)	SS		ORAL		
			Vioxx (Rofecoxib)	SS		ORAL		
			Advil	C				

Date:03/20/02ISR Number: 3886194-5Report Type:Direct Company Report #CTU 163816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY	
			Finasteride	C				
			Folic Acid	C				
			Simvastatin	C				
			Trazodone	C				
			Warfarin	C				

Date:03/20/02ISR Number: 3886311-7Report Type:Expedited (15-DaCompany Report #EMADSS2002001611
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Epistaxis Extrapyramidal Disorder Fall Haemorrhagic Stroke Hypertension	Foreign Health Professional	Tramadol (Unspecified) (Tramadol Hydrochloride)	PS		ORAL	1) 100 MG, DAILY, ORAL; 2) 150 MG, DAILY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Corvasal (Molsidomine)	C				
			Triatec Faible (Ramipril)	C				
			Allopurinol (Allopurinol)	C				
			Digoxine (Digoxin)	C				
			Haldol Faible (Haloperidol)	C				
			Lexomil (Bromazepam)	C				
			Tardyferon (Ferrous Sulfate)	C				
			Dicynone (Etamsilate)	C				

Date:03/20/02ISR Number: 3886440-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01861
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Excedrin					
Other	Gastrointestinal Ulcer	Company	(Acetaminophen (+)					
		Representative	Aspi	C				
			Motrin	C				
			Plavix	C				
			Therapy Unspecified	C				

Date:03/21/02ISR Number: 3885647-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Enbrel	C				
			Methotrexate	C				

Date:03/21/02ISR Number: 3885960-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00017
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	11	MON
			Lamictal	C				
			Mysoline	C				
			Premarin	C				

Date:03/21/02ISR Number: 3885961-1Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00056
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Peritonitis		Acetaminophen	C		ORAL		

Initial or Prolonged	Acetaminophen And Propoxyphene Hydrochloride	C	ORAL
	Diosmin	C	ORAL
	Trimetazidine Hydrochloride	C	ORAL
	Phenobarbital	C	ORAL

Date:03/21/02ISR Number: 3885963-5Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
Other	Coronary Artery Disease
	Coronary Artery Stenosis
	Dyspnoea
	Ejection Fraction Decreased
	Electrocardiogram Qrs Complex Abnormal
	Electrocardiogram T Wave Abnormal
	Fluid Retention

		Myocardial Infarction					
		Nausea					
		Sensation Of Heaviness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Hypokinesia		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
				Relafen	C		
				Celebrex	C		
				Xanax	C		
				Aspirin	C		
				Mepergan	C		
				Amitriptyline	C		

Date:03/21/02ISR Number: 3885964-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA01249
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Infection		Vioxx	PS	Merck & Co., Inc	ORAL
2	WK						
		Pain		[Therapy			
		Vaginal Haemorrhage		Unspecified]	C		
				Micro K	C		
				Tylenol With Codeine #4	C		
				Lasix (Furosemide)	C		
				Cardizem Cd	C		
				Lanoxin	C		
				Uniphyl	C		
				Aerobid-M	C		
				Desyrel	C		
				Colace	C		
				Dalmane	C		
				Metamucil	C		
				Mylanta & Mylanta Ds	C		
				Prilosec	C		
				Travatan	C		
				Allopurinol	C		

Date:03/21/02ISR Number: 3885965-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00392
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS		ORAL		
	Faeces Discoloured		Vioxx	SS				
	Gastric Haemorrhage		Hydrocortone	C				
	Gastrointestinal Pain							
	Operative Haemorrhage							
	Oral Intake Reduced							
	Syncope							

Date:03/21/02ISR Number: 3885966-0Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00143
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/02ISR Number: 3885967-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00144
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fentanyl	C		TOPICAL		
			Dipyrone	C		ORAL		
			Ranitidine Hydrochloride	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Captopril	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Prednisolone	C		ORAL		

Date:03/21/02ISR Number: 3885969-6Report Type:Expedited (15-DaCompany Report #WAES 0203CHE00021
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Coordination Abnormal		Cosopt	C		ORAL		
Other	Speech Disorder		Aspirin	C		ORAL		
	Vertigo		Magnesium (Unspecified)	C		ORAL		
			Fish Oil (Unspecified)	C		ORAL		

Date:03/21/02ISR Number: 3885970-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoptysis							

Date:03/21/02ISR Number: 3885971-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA01607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Chest Pain Dyspnoea Gastric Haemorrhage Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/02ISR Number: 3885973-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01805
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS		ORAL		
			Glucosamine	C				
			Chondroitin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/02ISR Number: 3886383-XReport Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-10415024
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Digoxin	PS	Regulatory Health Authority Brazil			
Hospitalization - Initial or Prolonged	Low Cardiac Output Syndrome		Enalapril	SS		ORAL		
Disability	Renal Failure		Rofecoxib	SS				
	Renal Failure Chronic		Spironolactone	SS				
			Furosemide	SS				
			Hydrochlorothiazide	SS				
			Atorvastatin	C				
			Warfarin	C				
			Milrinone	C		INTRAVENOUS		
			Docusate Calcium	C				
			Sennosides	C				
			Temazepam	C				
			Carbamazepine	C				
			Allopurinol	C				
			Nitroglycerin Patch	C				
			Clotrimazole Cream	C				
			Diphenhydramine	C				

Date:03/22/02ISR Number: 3886637-7Report Type:Expedited (15-DaCompany Report #WAES 01100237
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/02ISR Number: 3886670-5Report Type:Expedited (15-DaCompany Report #WAES 01120336
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Coumadin	C				
	Intestinal Perforation		[Therapy					
Other			Unspecified]	C				

Date:03/22/02ISR Number: 3886671-7Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00012
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Cardiac Failure		Digoxin	C		ORAL		
	Congestive		Perindopril	C		ORAL		
			Bumetanide	C		ORAL		
			Acetylcysteine	C		ORAL		
			Methylprednisolone	C		ORAL		
			Acenocoumarol	C		ORAL		

Date:03/22/02ISR Number: 3886673-0Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00011
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Breath Sounds Decreased
	Cardiac Disorder
	Cardiac Failure

		Cardiomegaly Chronic Obstructive Airways Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Exacerbated Rhonchi Venous Pressure Jugular Increased Ventricular Hypertrophy Wheezing		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/22/02ISR Number: 3886675-4Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - WK	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Zolpidem Tartrate	C		ORAL
			Antimicrobial (Unspecified)	C		

Date:03/22/02ISR Number: 3886770-XReport Type:Expedited (15-DaCompany Report #WAES 01105153
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS		ORAL
Disability						

Date:03/22/02ISR Number: 3886772-3Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00162
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Clostridium Colitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Nausea		Aspirin	SS		ORAL
			Cefpodoxime Proxetil	SS		ORAL
6 DAY						
			Etilefrine			

			Hydrochloride	C		ORAL
			Ginkgo Biloba Extract	C		ORAL
			Dihydroergotamine	C		ORAL
			Verapamil Hydrochloride	C		ORAL

Date:03/22/02ISR Number: 3886774-7Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rhabdomyosarcoma		Vioxx	PS	Merck & Co., Inc	ORAL		61 DAY
Initial or Prolonged			Vioxx	SS		ORAL		163 DAY
			Vioxx	SS		ORAL		
			Methotrexate	C		ORAL		
			Prednisone	C		ORAL		

Date:03/22/02ISR Number: 3886778-4Report Type:Expedited (15-DaCompany Report #WAES 0202MEX00017
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Deflazacort	C		ORAL		
Initial or Prolonged			Pepcid	C		ORAL		
			Aspirin	C		ORAL		

Date:03/22/02ISR Number: 3886779-6Report Type:Expedited (15-DaCompany Report #WAES 01120919
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Dyspnoea		Vioxx	SS		ORAL	25	DAY
Initial or Prolonged	Oxygen Saturation		Estinyl	C				
Other	Decreased		Provera	C				
	Pulmonary Embolism		Daypro	C				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C			15	YR
			Soma	C				
			Tylenol With Codeine #3	C				
			Inderal La	C				
			Nortriptyline	C				
			Capoten	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Midrin	C				

Date:03/22/02ISR Number: 3886783-8Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00160
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Hydrochlorothiazide And Valsartan	PS		ORAL		
Hospitalization -	Cholelithiasis							

Initial or Prolonged	Cholestasis		Melperone	SS		ORAL
	Drug Interaction		Metoprolol	SS		ORAL
	Nausea		Nitrendipine	SS		ORAL
	Post Procedural		Nitrendipine	SS		ORAL
	Complication		Vioxx	SS	Merck & Co., Inc	ORAL
	Renal Disorder		Famotidine	C		ORAL
	Renal Failure Acute		Prednisolone	C		ORAL
	Vomiting		Omeprazole	C		ORAL
			Cisapride	C		ORAL

Date:03/22/02ISR Number: 3886785-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Pancreatic Cyst		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/02ISR Number: 3886795-4Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/02ISR Number: 3886798-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02034
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Distress Syndrome		Vioxx	SS				
549 DAY								
Initial or Prolonged	Acute Respiratory Failure		Tylenol	C		ORAL		
Disability	Back Pain Cardiac Failure Congestive Condition Aggravated Congestive Cardiomyopathy Dyspnoea							

Date:03/26/02ISR Number: 3888108-0Report Type:Expedited (15-DaCompany Report #WAES 01120365
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Cirrhosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/26/02ISR Number: 3888110-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA00618
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/26/02ISR Number: 3888137-7Report Type:Expedited (15-DaCompany Report #WAES 01125014
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Increased Aspartate Aminotransferase Increased		Hydroflumethiazide And Spironolactone	C				
	Blood Bilirubin Increased		Propranolol	C				
	Circulatory Collapse		Acetaminophen	C				
	Depressed Level Of Consciousness		Diuretic (Unspecified)	C				
	Hyponatraemia							
	Red Blood Cell Count Decreased							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/02ISR Number: 3888138-9Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00008
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Phenytoin Sodium	C		ORAL		

Date:03/26/02ISR Number: 3888139-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrapyramidal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Tardive Dyskinesia							

Date:03/26/02ISR Number: 3888140-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02180
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Prinivil	C		ORAL		
	Rash		Metoprolol	C				
	Tachycardia							

Date:03/26/02ISR Number: 3888141-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02065
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Diarrhoea							
	Meningitis							
	Nausea							
	Upper Respiratory Tract Infection							

Date:03/26/02ISR Number: 3888144-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Platelet Count Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/26/02ISR Number: 3888146-8Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00177
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Face Oedema		Bisoprolol Fumarate	C		ORAL		
			Ranitidine	C		ORAL		
			Prednisolone	C		ORAL		

Date:03/26/02ISR Number: 3888148-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00146
Age:90 YR Gender:Female I/FU:I

Outcome
Hospitalization - Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON
	Gastrointestinal Ulcer		Vioxx	SS		ORAL		
	Hypertension		Vioxx	SS		ORAL		
			Aspirin	SS		ORAL		
			Metoprolol	C				
			Lisinopril	C				
			Magnesium Aspartate And Potassium Aspartate	C				
			Candesartan Cilexetil	C				
			Nebivolol Hydrochloride	C				

Date:03/26/02ISR Number: 3888156-0Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00018
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aplasia		Vioxx	PS	Merck & Co., Inc	ORAL	56	WK
Initial or Prolonged	Dizziness		Ciprofibrate	C		ORAL	8	YR
	Drug Eruption		Risedronate Sodium	C		ORAL		
	Haemoglobin Decreased		Oxybutynin Chloride	C		ORAL		
	Idiopathic Thrombocytopenic Purpura							
	Myeloid Leukaemia							
	Nausea							
	Pyrexia							
	White Blood Cell Count Decreased							

Date:03/26/02ISR Number: 3888311-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower

Initial or Prolonged	Abdominal Tenderness
	Anaemia
	Asthenia
	Blood Creatinine Abnormal
	Blood Urea Abnormal
	Constipation
	Cough
	Diverticulum Intestinal
	Haemorrhagic
	Dizziness
	Fatigue
	Gastrointestinal
	Haemorrhage
	Haematochezia
	Haemorrhoids
	Insomnia
	International Normalised
	Ratio Decreased
	Intestinal Obstruction
	Intestinal Stenosis
	Orthostatic Hypotension

		Rectal Haemorrhage Tachycardia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
				Vioxx	SS		ORAL
				Tylenol Arthritis Extended Relief	C		
				Paxil	C		
7	DAY						
				Paxil	C		
13	DAY						
				Zoloft	C		
20	DAY						
				Zoloft	C		
19	DAY						
				Ascorbic Acid	C		
				Vitamin E	C		
				Vitamin B (Unspecified)	C		
				Motrin	C		
				[Therapy Unspecified]	C		
				[Therapy Unspecified]	C		
				Flonase	C		
				Aspirin	C		

Date:03/26/02ISR Number: 3888312-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA00837
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL
		Nephrolithiasis		Premarin	C		
				Accupril	C		
				Methotrexate	C		

Date:03/26/02ISR Number: 3888313-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA01537
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Vioxx	SS		ORAL		3 DAY
Initial or Prolonged			Diclofenac	C				

Date:03/26/02ISR Number: 3888315-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02439
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		70 DAY
Hospitalization -	Muscle Twitching		Zoloft	C				
Initial or Prolonged	Pruritus		Neurontin	C				
	Rash		Demadex	C				
	Vomiting		Plavix	C				
			Tenormin	C				
			Ativan	C				
			Pravachol	C				
			Prevacid	C				
			Aspirin	C				
			Plaquenil	C				
			Elavil	C				
			Colestid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/02ISR Number: 3888317-0Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Composition					
Hospitalization -			Unspecified]	C				
Initial or Prolonged								

Date:03/26/02ISR Number: 3888320-0Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Insulin	C				
SUBCUTANEOUS								
Initial or Prolonged								

Date:03/26/02ISR Number: 3888322-4Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00107
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Depression							
	Hyperacusis							
	Overdose							
	Persecutory Delusion							

Date:03/26/02ISR Number: 3888323-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02040
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diverticulum		Acetaminophen	C				
	Dizziness		Furosemide	C				
	Gastritis Erosive		Calcium Acetate	C				
	Gastrointestinal		Nephrocaps	C				

Haemorrhage
Haemoglobin Decreased
Haemoptysis
Hypotension
International Normalised
Ratio Decreased
Melaena
Rectal Haemorrhage

Date:03/26/02ISR Number: 3888326-1Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00018
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Ulcer		Moduretic	C		ORAL		
Initial or Prolonged	Gastrointestinal		Nitrazepam	C		ORAL		
	Haemorrhage		Ferrous Sulfate	C				
			Acetaminophen	C				
			Acetaminophen And Codeine Phosphate	C				
			Omeprazole Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/02ISR Number: 3888330-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/26/02ISR Number: 3888332-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02150
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastroduodenal Ulcer		[Therapy Unspecified]	C				
	Helicobacter Infection		Ibuprofen	C				
	Upper Gastrointestinal Haemorrhage							

Date:03/26/02ISR Number: 3888333-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02213
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
			Dilantin	C				
			Thiamine	C				
			Folic Acid	C				
			Proscar	C				
			Zestril	C				
			Potassium Chloride	C				
			Furosemide	C				

Date:03/26/02ISR Number: 3889764-3Report Type:Direct Company Report #CTU 164234
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Nausea		Vioxx 50mg Tab	PS				
	Vomiting		Terazosin Hcl	C				
			Fexofenadine Hcl	C				
			Rabeprazole Na	C				

				Sildenafil Citrate	C		
				Glipizide	C		
				Nifedipine (Adalat Cc)	C		
				Atenolol	C		
				Venlafaxine	C		
				Clonazepam	C		
				Trazodone Hcl	C		
				Acetaminophen	C		
				Gemfibrozil	C		

Date:03/26/02ISR Number: 3889777-1Report Type:Direct Company Report #CTU 164236
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Lip Ulceration		Vioxx	PS				
	Rash		Gabapentin	C				
			Nortriptyline Hcl	C				
			Acetaminophen	C				
			Salsalate	C				
			Tramadol Hcl	C				

	Acetaminophen 325mg W/Codeine	C
	Epi-Pen	C

Date:03/26/02ISR Number: 3889800-4Report Type:Direct Company Report #CTU 164223
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Haematemesis		Vioxx	PS		ORAL	25 MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Melaena		Prednisone	SS		ORAL	20 MG PO QD	

Date:03/27/02ISR Number: 3889018-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA02291
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	
	Haemorrhage		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				

Date:03/27/02ISR Number: 3889019-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01002
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization - Initial or Prolonged Disability	Hypertensive Crisis		Cozaar	C				
			Atenolol	C				
			Claritin	C				

Date:03/27/02ISR Number: 3889020-3Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00017
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	118 DAY	
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vasoretic	C		ORAL		
	Haemorrhage		Furosemide	C		ORAL		
	Haematemesis		Trusopt	C				
	Helicobacter Pylori		Latanoprost	C				
	Identification Test		Cyanocobalamin	C				
	Positive		Zopiclone	C		ORAL		
			Iron (Unspecified)	C				

Date:03/27/02ISR Number: 3889372-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA02294
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Convulsion
	Coordination Abnormal
	Dizziness
	Haematochezia
	Haemorrhage Intracranial
	Headache
	Hemiparesis

	Iron Deficiency Anaemia						
	Rash						
	Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Humulin Nph	C			PARENTERAL
			Humalog	C			PARENTERAL
			Avandia	C			
			Prinivil	C			
			Prilosec	C			
			Elavil	C			
			Vitamins (Unspecified)	C			

Date:03/27/02ISR Number: 3889374-8Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	97 DAY
Initial or Prolonged	Thrombosis		Citalopram Hydrobromide	C		ORAL	
	Myocardial Infarction		Citalopram Hydrobromide	C		ORAL	

Date:03/27/02ISR Number: 3889377-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00340
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	2 WK
Initial or Prolonged	Increased		Vioxx	SS		ORAL	
	Dehydration						
	Nausea						
	Vomiting						

Date:03/27/02ISR Number: 3889384-0Report Type:Expedited (15-DaCompany Report #WAES 0203ISR00008
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Haemoglobin Decreased							

Date:03/27/02ISR Number: 3890296-7Report Type:Direct Company Report #CTU 164261
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx 25 Mg	PS		ORAL	1 PO QD	

Date:03/27/02ISR Number: 3890709-0Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00131
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	1 DAY
		Health Professional Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/02ISR Number: 3890713-2Report Type:Expedited (15-DaCompany Report #WAES 01106009
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Mydriasis	Health						
PO								56 DAY
		Professional	Acetaminophen	C				
		Other	Alfuzosin Hydrochloride	C				
			Pantoprazole	C				

Date:03/27/02ISR Number: 3890714-4Report Type:Expedited (15-DaCompany Report #WAES 01073719
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Gastric Haemorrhage	Health						
	Gastric Perforation	Professional						
	Iatrogenic Injury	Other						
	Proctitis							

Date:03/27/02ISR Number: 3890719-3Report Type:Expedited (15-DaCompany Report #WAES0203GBR00027
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Face Oedema	Other						
	Tongue Oedema							
PO								1 DAY
			Anastrozole	C				
			Lactulose	C				
			Morphineso4	C				
			Risperidone	C				
			Senna	C				

Date:03/27/02ISR Number: 3890724-7Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00004
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Foreign Other	Vioxx (Rofecoxib)	PS				
	Haemoglobin Decreased		Celecoxib	SS				
	International Normalised Ratio Increased		Warfarin Sodium	SS				
	Melaena		Digitoxin	C				
			Furosemide	C				

Date:03/27/02ISR Number: 3890726-0Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00012
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Akinesia	Foreign	Tab Vioxx					
	Cardiac Disorder	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Coronary Artery	Professional					PO	6 DAY
	Restenosis		Aspirin	C				
	Myocardial Infarction		Dalteparin Sodium	C				
	Pulmonary Oedema		Nitroglycerin	C				
			Perindopril Erbumine	C				
			Pravastatin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/02ISR Number: 3890727-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY, PO	8 DAY
	Myocardial Infarction	Professional						
			Tab Ethinyl Estradiol (+) Levonorgestrel	SS		ORAL	0.15/0.03 MG/DAILY, PO	

Date:03/27/02ISR Number: 3890751-XReport Type:Expedited (15-DaCompany Report #WAES 01106001
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID	29 DAY
	Pyrexia	Other						
	Rash Pustular		Tab Hydroxyurea	SS		ORAL	500 MG/BID	24 DAY
			Dipyrone	C				
			Mercaptopurine	C				
			Omeprazole	C				

Date:03/27/02ISR Number: 3890752-1Report Type:Expedited (15-DaCompany Report #WAES 01105259
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	1 TABLET/DAILY	
		Professional						
			Carbamazepine	C				

Date:03/27/02ISR Number: 3890753-3Report Type:Expedited (15-DaCompany Report #WAES 01115006
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy	Foreign	Tab Vioxx					
	Grand Mal Convulsion	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	2 DAY
			Acetaminophen	C				
			Carbamazepine	C				
			Estradiol	C				

Date:03/27/02ISR Number: 3890754-5Report Type:Expedited (15-DaCompany Report #WAES 01106063
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Tab Vioxx					
Initial or Prolonged	Increased	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Bradycardia		Tab Verapamil Hcl	SS		ORAL	120 MG/BID	
	Fall		Elavil	C				
	Orthostatic Hypotension		Therapy Unspecified	C				
			Acetaminophen	C				
			Alprazolam	C				
			Bisoprolol Fumarate	C				
			Paroxetine	C				
			Trihexyphenidyl Hcl	C				

Date:03/27/02ISR Number: 3890755-7Report Type:Expedited (15-DaCompany Report #WAES 01106021
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Tab Vioxx					
	Confusional State	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Ischaemic Stroke		Acepromazine					
	Myocardial Infarction		Maleate (+)					
			Meprobamate	C				
			Acetaminophen	C				
			Bromazepam	C				
			Calcium Phosphate, Tribasic	C				
			Enoxaparin	C				
			Ketoprofen	C				
			Pamidronate Disodium	C				
			Prednisone	C				
			Vitamin D	C				

Date:03/27/02ISR Number: 3890756-9Report Type:Expedited (15-DaCompany Report #WAES 01106017
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Right	Foreign	Tab Vioxx					
	Chest Pain	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	10 DAY
	Cough		Acebutolol					
	Dyspnoea		Hydrochloride	C				
	Pulmonary Embolism		Chondroitin Sulfate					
	Ventricular Hypertrophy		Sodium	C				
	Ventricular Hypokinesia		Lorazepam	C				
			Naftazone	C				

Date:03/27/02ISR Number: 3890818-6Report Type:Expedited (15-DaCompany Report #WAES 0203MYS00008
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Foreign	Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	

		Face Oedema	Health				
PO							
		Fatigue	Professional				
		Oedema	Other				
		Oedema Peripheral					
		Somnolence					

Date:03/27/02ISR Number: 3890917-9Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Foreign	Vioxx (Rofecoxib)	PS		ORAL
	Cerebrovascular Accident	Health				
		Professional				
		Other				

Date:03/27/02ISR Number: 3891005-8Report Type:Expedited (15-DaCompany Report #PHNU2002DE01089
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Blood Pressure Decreased
	Cardiovascular Disorder

		Drug Interaction Fluid Imbalance Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Procedural Complication Renal Failure Vomiting	Foreign Study Health Professional	Co-Diovan (Hydrochlorothiazide , Valsartan) Film-Coated Tablet	PS		ORAL
1 DF, QD,							
ORAL			Other				
				Melperone (Melperone) Film-Coated Tablet, 25 Mg	SS		ORAL
25 MG, QD,							
ORAL							
				Metoprolol "Ratiopharm' (Metoprolol Tartrate) Tablet, 50 Mg	SS	Ratiopharm	ORAL
50 MG, QD,							
ORAL							
				Nitrendipine "Ratiopharm" Tablet, 10 Mg	SS	Ratiopharm	ORAL
10 MG, BID,							
ORAL							
				Vioxx (Rofecoxib) Tablet, 25 Mg	SS		ORAL
25 MG, BID,							
ORAL							
				Antra (Omeprazole) Tablet	C		
				Famotidine Film-Coated Tablet	C		
				Prednisolon Tablet	C		
				Propulsin (Cisapride (Monohydrate) Tablet	C		

Date:03/27/02ISR Number: 3891028-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA01360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myocardial Infarction		Tab Digoxin	SS				
			Lopressor	SS				
			Tab Hydrodiuril	SS				
			Indocin (Indomethacin)	SS				
			Metoprolol	SS				
			Toprol Xl Tablets	SS				
			Coumadin	SS				
			Lotensin	SS				

Date:03/27/02ISR Number: 3891039-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:I

Outcome	PT
Other	Drug Ineffective
	Dysphagia
	Erythema
	Mouth Injury
	Pharyngolaryngeal Pain
	Tongue Disorder

Tongue Oedema

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

Date:03/27/02ISR Number: 3891043-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02350
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haematochezia						MG/DAILY/PO	
Other			Aspirin	C				
			Calcium	C				

Date:03/27/02ISR Number: 3891049-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA00583
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Health	Tab Zocor	PS		ORAL	10	
Initial or Prolonged	Increased	Professional					MG/DAILY/PO	
	Aspartate		Tab Vioxx	SS		ORAL	PO	
	Aminotransferase		Tylenol With Codeine	SS				
	Increased							
	Blood Cholesterol							
	Increased							
	Blood Triglycerides							
	Increased							
	Pancreatitis							

Date:03/27/02ISR Number: 3891050-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemoptysis	Professional					MG/DAILY/PO	
		Company Representative						

Date:03/27/02ISR Number: 3891051-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Hospitalization -	Increased	Professional					PO; 25 MG	
Initial or Prolonged	Myocardial Infarction	Company					DAILY PO	
		Representative	Vicodin	C				

Date:03/27/02ISR Number: 3891052-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Bronchitis
Other	Cardiac Flutter
	Duodenal Ulcer

		Haemorrhage					
		Erosive Duodenitis					
		Gastric Ulcer					
		Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis	Consumer	Tab Vioxx 50 Mg	PS		ORAL
PO							
		Heart Rate Irregular	Health	Aspirin	C		
		Influenza Like Illness	Professional				
		Melaena					
		Orthostatic Hypotension					
		Sensitivity Of Teeth					
		Syncope					
		Toothache					

Date:03/27/02ISR Number: 3891053-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA01968
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Rash Erythematous	Professional				
MG/DAILY/PO						
	Rash Pruritic					
	Urticaria					

Date:03/27/02ISR Number: 3891054-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00392
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper	Consumer	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Diarrhoea		Hydrocortone	C		
Other	Gastric Haemorrhage					
	Gastrointestinal Disorder					

Date:03/27/02ISR Number: 3891056-3Report Type:Expedited (15-DaCompany Report #WAES 01113180
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Dyspnoea	Health	Cozaar	C				
	Dysuria	Professional	Hyzaar	C				
	Face Oedema		Klor-Con	C				
	Oedema Peripheral		Premarin	C				
	Urine Flow Decreased		Synthroid	C				
	Weight Increased							

Date:03/27/02ISR Number: 3891057-5Report Type:Expedited (15-DaCompany Report #WAES 01104344
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Headache	Health	Premarin	C				
	Hepatitis B	Professional	Prozac	C				
	Neck Pain		Serzone	C				
	Oedema Peripheral		Vicodin Tablets	C				
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/02ISR Number: 3891058-7Report Type:Expedited (15-DaCompany Report #WAES 00091412
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Diplegia	Health					PO	
	Dysuria	Professional						
	Faecal Incontinence							
	Neuropathy Peripheral							

Date:03/27/02ISR Number: 3891059-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00009
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	25	
		Professional					MG/DAILY/PO	
		Company Representative						

Date:03/27/02ISR Number: 3891060-5Report Type:Expedited (15-DaCompany Report #WAES 01112431
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Renal Failure	Professional						
		Company Representative						

Date:03/27/02ISR Number: 3891067-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01866
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx 50 Mg	PS			ORAL
50 MG / PO							
Initial or Prolonged		Professional					
Other		Company					
		Representative					

Date:03/27/02ISR Number: 3891068-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA01868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Diarrhoea Haemorrhagic	Professional				
MG/DAILY/PO						
		Company				
		Representative				

Date:03/27/02ISR Number: 3891140-4Report Type:Periodic Company Report #HQ3002609JUL2001
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Consumer	Lodine (Etodolac,			
Initial or Prolonged	Haemorrhage		Unspec)	PS		
			Vioxx (Rofecoxib,			
			Tablet)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/02ISR Number: 3891209-4Report Type:Expedited (15-DaCompany Report #WAES 01096102
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	6 DAY
			Cozaar	C				
			Atenolol (+) Nifedipine	C				
			Fenofibrate	C				
			Furosemide	C				
			Metformin	C				
			Tramadol	C				

Date:03/27/02ISR Number: 3891212-4Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gamma-Glutamyltransferase Increased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/PO	86 DAY
	Muscle Disorder	Other	Eprosartan	SS		ORAL	600 MG/PO	
	Osteoarthritis Paralysis		Aspirin	C				

Date:03/27/02ISR Number: 3891216-1Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Congestive	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	297 DAY
	Chest Pain	Health	Tab Placebo	SS		ORAL	297 DAY	
Disability	Dyspnoea	Professional	Insulin, Biphasic					
	Joint Swelling		Isophane (Injection)	C				

Myocardial Infarction

Date:03/27/02ISR Number: 3891376-2Report Type:Expedited (15-DaCompany Report #WAES 01117510
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oesophagitis						PO	2 DAY
	Peritonitis		Fosamax	C				
			Althiazide/Spironolactone	C				
			Carvedilol	C				
			Citalopram Hydrobromide	C				
			Haloperidol	C				
			Ranitidine	C				

Date:03/27/02ISR Number: 3891379-8Report Type:Expedited (15-DaCompany Report #WAES 0203SWE00003
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Other	Tab Vioxx	PS		ORAL	25 MG/DAILY	PO 507 DAY

			Carbamazepine	C		
			Methotrexate Sodium	C		
			Prednisolone	C		

Date:03/27/02ISR Number: 3891384-1Report Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder Condition Aggravated	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Depression							
PO								30 DAY
	Drug Interaction		Cap Sr Carbamazepine	SS		ORAL	200 MG/DAILY	
PO								
			Elavil	C				
			Alprazolam	C				

Date:03/27/02ISR Number: 3891390-7Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00011
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Aspartate							
PO								67 DAY
	Aminotransferase Increased		Amlodipine Besylate	C				
			Atorvastatin Calcium	C				
	Blood Alkaline Phosphatase Increased							
	Hepatic Function Abnormal							
	Jaundice							
	Malaise							
	Osteoarthritis							
	Vomiting							

Date:03/27/02ISR Number: 3891394-4Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00074
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Foreign	Tab Vioxx					
Life-Threatening	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	12.5 MG/BID	
	Haematocrit Decreased						PO	6 DAY
	Haemodialysis		Tab Aspirin	SS		ORAL	100 MG/DAILY	
	Haemoglobin Decreased						PO	
	Malaise		Tab Molsidomine	SS		ORAL	12 MG/DAILY	
	Oral Intake Reduced						PO	
	Platelet Count Abnormal		Top Fentanyl	SS			TOPICAL	50/ HOUR
	Renal Impairment						MICROGM TOP	
	Somnolence		Furosemide	SS		ORAL	PO	
	Urinary Tract Infection		Digitoxin	C				
	White Blood Cell Count Abnormal		Insulin, Biphasic Isophane [Injection]	C				

Date:03/27/02ISR Number: 3891398-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00048
Age:40 YR Gender:Male I/FU:I

Outcome	PT
Other	Confusional State
	Face Oedema

	Oedema Peripheral Somnolence Tongue Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ TID PO/ DAILY
			Bromelains	C			
			Magnesium (Unspecified)	C			

Date:03/28/02ISR Number: 3890097-XReport Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	41 DAY
Initial or Prolonged	General Physical Health		Bendroflumethiazide	C			
Disability	Deterioration		Isosorbide				
Other	Hyponatraemia		Mononitrate	C			
	Inappropriate		Bisoprolol	C			
	Antidiuretic Hormone		Omeprazole	C			
	Secretion		Acetaminophen And				
	Malaise		Propoxyphene				
	Malignant Pleural		Hydrochloride	C			
	Effusion						
	Nausea						
	Renal Impairment						
	Vomiting						

Date:03/28/02ISR Number: 3890099-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Infarction		Inderal La	C			
	Angina Pectoris		Claritin-D	C			
							1758 DAY
	Mitral Valve Incompetence		Humibid	C			

	Tricuspid Valve Incompetence		Prevacid	C		
			Nasonex	C		
764 DAY						
			Darvocet-N	C		
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		

Date:03/28/02ISR Number: 3890100-7Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00199
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
113 DAY						
Hospitalization -	Dyspnoea		Elavil	C		ORAL
Initial or Prolonged	Gastrointestinal Disorder		Levothyroxine Sodium	C		ORAL
	Malaise		Levothyroxine Sodium	C		ORAL
			Cetirizine Hydrochloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3890101-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA01158
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/02ISR Number: 3890102-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02485
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/02ISR Number: 3890103-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02203
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/02ISR Number: 3890104-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02433
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Overdose		[Therapy Unspecified]	SS				
	Pulmonary Congestion		Soma	C				
			Methadone Hydrochloride	C				
			Wellbutrin	C				
			Elavil	C		ORAL		

Date:03/28/02ISR Number: 3890105-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Enbrel	C				
			Methotrexate	C				
			Celebrex	C				
			Folic Acid	C				

PARENTERAL

Date:03/28/02ISR Number: 3890109-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02567
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pepcid	C				
			Furosemide	C				
			Pravachol	C				
			Synthroid	C				
			Nifedipine	C				
			Zyrtec	C				
			Accupril	C				
			Glucophage	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3890505-4Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Life-Threatening	Haemorrhage		Phenprocoumon	SS		ORAL		
			Buprenorphine Hydrochloride	C				
			Melperone Hydrochloride	C				
			Calcium Carbonate And Cholecalciferol	C				
			Paroxetine Hydrochloride	C				

Date:03/28/02ISR Number: 3890508-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00583
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Zocor	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased		Zocor	SS		ORAL		
	Blood Cholesterol Increased		Vioxx	SS		ORAL		
	Blood Lactate Dehydrogenase Increased		Tylenol With Codeine	SS				
	Blood Triglycerides Increased		Premarin	C				
	Gamma-Glutamyltransferase Increased							
	Pancreatitis							

Date:03/28/02ISR Number: 3890510-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged		Prilosec	C	
		Cocaine	C	

Date:03/28/02ISR Number: 3890515-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02543
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Circulatory Collapse		Clozaril	C		
	Gait Disturbance		Clonazepam	C		
			Paxil	C		

Date:03/28/02ISR Number: 3891885-6Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00011
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Confusional State	Foreign Health Professional
	Delirium	

Other

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID; PO	8 DAY

Date:03/28/02ISR Number: 3891897-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00124
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Gastritis Haemorrhagic	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/PRN PO	
			Aspirin	SS		ORAL	100 MG/DAILY PO	
			Tab Fosamax (Alendronate Sodium)	SS		ORAL	10 MG/DAILY PO	
			Hyzaar	C				
			Zocor	C				
			Naloxone Hydrochloride	C				
			Nitrendipine	C				
			Tetrazepam	C				

Date:03/28/02ISR Number: 3892089-3Report Type:Direct Company Report #CTU 164463
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Musculoskeletal Stiffness Nausea		Vioxx	PS		ORAL	1 DAILY ORAL	

Date:03/28/02ISR Number: 3892223-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Thrombosis	Professional					PO	
		Company Representative	Enbrel	C				
			Methotrexate	C				

Date:03/28/02ISR Number: 3918554-8Report Type:Periodic Company Report #WAES 0202USA00413
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx	PS		ORAL	25 MG/BID/PO	
			L-Thyroxin	C				
			Lotensin	C				
			Paxil	C				
			Zocor	C				
			Hydrochlorothiazide (+) Triamter	C				
			Oxybutynin Chloride	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3918555-XReport Type:Periodic Company Report #WAES 0202USA00423
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atrovent	C				
			Combivent	C				
			Dynacirc	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Treiamter	C				

Date:03/28/02ISR Number: 3918556-1Report Type:Periodic Company Report #WAES 0202USA00473
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3918557-3Report Type:Periodic Company Report #WAES 0202USA00477
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
			Calan Sr	C				
			Ditropan	C				
			Prempro	C				

Date:03/28/02ISR Number: 3918558-5Report Type:Periodic Company Report #WAES 0202USA00486
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Cardura	C				
			Hydrodiuril	C				
			Imuran (Azathioprine)	C				
			Lipitor	C				
			Lopressor	C				
			Lotrel	C				
			Pepcid	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3918559-7Report Type:Periodic Company Report #WAES 0202USA00488
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3918560-3Report Type:Periodic Company Report #WAES 0202USA00489
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Viox 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Nausea		Cyclobenzaprine Hydrochloride	C				
	Oedema Peripheral							

Date:03/28/02ISR Number: 3918561-5Report Type:Periodic Company Report #WAES 0202USA00247
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Tab Vioxx	PS		ORAL	DAILY/PO	
	Petechiae	Professional	Premarin	C				
	Pruritus	Company	Toradol	C				
	Rash	Representative	Iron(Unspecified)	C				
	Swelling							

Date:03/28/02ISR Number: 3918562-7Report Type:Periodic Company Report #WAES 0202USA00253
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Dizziness						MG/DAILY/PO	
	Nausea		Fosamax	C				
	Retching		Estradiol	C				

Date:03/28/02ISR Number: 3918563-9Report Type:Periodic Company Report #WAES 0202USA00264
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

Dyspepsia

Date:03/28/02ISR Number: 3918629-3Report Type:Periodic Company Report #WAES 0202USA00513
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3918640-2Report Type:Periodic Company Report #WAES 0202USA00517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3918644-XReport Type:Periodic Company Report #WAES 0202USA00562
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Hyperkalaemia	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3918649-9Report Type:Periodic Company Report #WAES 0202USA00576
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PRN PO	
	Haematochezia		Premarin	C				
			Synthroid	C				

Date:03/28/02ISR Number: 3918655-4Report Type:Periodic Company Report #WAES 0202USA00592
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
	Dysuria	Professional Company Representative						

Date:03/28/02ISR Number: 3918661-XReport Type:Periodic Company Report #WAES 0202USA00594
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal	Company	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Haemorrhage	Representative					PO	
		Other						

Date:03/28/02ISR Number: 3918666-9Report Type:Periodic Company Report #WAES 0202USA00597
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Rash	Professional Company Representative	Premarin	C				

Date:03/28/02ISR Number: 3918672-4Report Type:Periodic Company Report #WAES 0202USA00343
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	PO
			Premarin	C				

Date:03/28/02ISR Number: 3918674-8Report Type:Periodic Company Report #WAES 0202USA00349
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3918675-XReport Type:Periodic Company Report #WAES 0202USA00355
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea		Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Dyspepsia						PO	
	Oedema Peripheral		Accupril	C				
			Estring	C				
			Evista	C				
			Miacalcin	C				
			Pravachol	C				
			Synthroid	C				
			Tiazac	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3918676-1Report Type:Periodic Company Report #WAES 0202USA00266
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Headache						MG/DAILY/PO	1 WK
			Hytrin	C				
			Hyzaar	C				
			Norvasc	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3918677-3Report Type:Periodic Company Report #WAES 0202USA00267
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Detrol	C				

			Estratest	C		
			Flovent	C		
			Lamisil	C		
			Prevacid	C		
			Synthroid	C		
			Topamax	C		
			Albuterol	C		
			Alprazolam	C		
			Atenolol	C		

Date:03/28/02ISR Number: 3918678-5Report Type:Periodic Company Report #WAES 0202USA00304
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				

Date:03/28/02ISR Number: 3918679-7Report Type:Periodic Company Report #WAES 0202USA00312
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Coagulopathy	Health Professional

		Company Representative					
			Product	Role	Manufacturer	Route	Dose	Duration
			Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3918680-3Report Type:Periodic Company Report #WAES 0202USA00314
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3918681-5Report Type:Periodic Company Report #WAES 0202USA00332
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Compazine	C				
			Flexeril	C				
			Norvasc	C				
			Oxycontin	C				
			Paxil	C				
			Zestril	C				
			Doxepin	C				
			Potassium	C				

Date:03/28/02ISR Number: 3918682-7Report Type:Periodic Company Report #WAES 0202USA00340
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Creatinine	Health	Tab Vioxx	PS		ORAL
SEE IMAGE						
	Increased	Professional				
	Dehydration					
	Nausea					
	Vomiting					

Date:03/28/02ISR Number: 3918683-9Report Type:Periodic Company Report #WAES 0202USA00161
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Neoplasm	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG /						
		Professional				
DAILY/ PO						

Date:03/28/02ISR Number: 3918684-0Report Type:Periodic Company Report #WAES 0202USA00166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gastritis					
MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3918685-2Report Type:Periodic Company Report #WAES 0202USA00170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
	Feeling Abnormal		Glucophage	C				
	Swelling		Lipitor	C				
	Throat Tightness							

Date:03/28/02ISR Number: 3919786-5Report Type:Periodic Company Report #WAES 0202USA00972
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	2 MON
			Salsalate	C				

Date:03/28/02ISR Number: 3919916-5Report Type:Periodic Company Report #WAES 0201USA02931
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Glucophage Xr	C				
			Neurontin	C				

Date:03/28/02ISR Number: 3919917-7Report Type:Periodic Company Report #WAES 0201USA02942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

	Congestive	Professional					
MG/DAILY/PO							
		Company Representative					

Date:03/28/02ISR Number: 3919918-9Report Type:Periodic Company Report #WAES 0201USA02977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Renal Disorder	Consumer	Tab Vioxx	PS		ORAL
PO						
			Lipitor	C		
			Travatan	C		
			Zestril	C		

Date:03/28/02ISR Number: 3919919-0Report Type:Periodic Company Report #WAES 0201USA02979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PRN/PO						

SEE IMAGE

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919920-7Report Type:Periodic Company Report #WAES 0201USA02982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Celebrex	C				
			Trandate	C				

Date:03/28/02ISR Number: 3919921-9Report Type:Periodic Company Report #WAES 0201USA02994
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919922-0Report Type:Periodic Company Report #WAES 0201USA02999
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO
			Neurontin	C				

Date:03/28/02ISR Number: 3919923-2Report Type:Periodic Company Report #WAES 0201USA03002
Age:24 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	

	Haemorrhage	Professional Company Representative					

Date:03/28/02ISR Number: 3919924-4Report Type:Periodic Company Report #WAES 0201USA03005
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydroxyzine	C				

Date:03/28/02ISR Number: 3919925-6Report Type:Periodic Company Report #WAES 0201USA03006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Flomax (Morniflumate)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919926-8Report Type:Periodic Company Report #WAES 0201USA03082
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Pepcid	C				
			Pulmicort Turbuhaler	C				
			Ultram	C				
			Viagra	C				
			Zocor	C				
			Allopurinol	C				

Date:03/28/02ISR Number: 3919927-XReport Type:Periodic Company Report #WAES 0201USA03095
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Skin Exfoliation							
			Caltrate	C				
			Coumadin	C				
			Klor-Con	C				
			Lipitor	C				
			Synthroid	C				
			Furosemide	C				

Date:03/28/02ISR Number: 3919928-1Report Type:Periodic Company Report #WAES 0201USA03099
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	

Date:03/28/02ISR Number: 3919929-3Report Type:Periodic Company Report #WAES 0201USA03105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919930-XReport Type:Periodic Company Report #WAES 0201USA03106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Face Oedema	Professional					PO	
	Oedema Peripheral		Sarafem	C				

Date:03/28/02ISR Number: 3919931-1Report Type:Periodic Company Report #WAES 0201USA02554
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Hallucination	Professional					PO	
	Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919932-3Report Type:Periodic Company Report #WAES 0201USA02555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Keratoconjunctivitis						PO	
	Sicca		Synthroid	C				
	Oedema Peripheral		Carisoprodol	C				
	Upper Respiratory Tract Infection							

Date:03/28/02ISR Number: 3919933-5Report Type:Periodic Company Report #WAES 0201USA02559
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Compartment Syndrome	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral	Professional Company Representative						

Date:03/28/02ISR Number: 3919934-7Report Type:Periodic Company Report #WAES 0201USA02569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG UNK PO	
			Fosamax	C				

Date:03/28/02ISR Number: 3919935-9Report Type:Periodic Company Report #WAES 0201USA02575
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Discolouration	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG DAILY	

PO

Date:03/28/02ISR Number: 3919936-0Report Type:Periodic Company Report #WAES 0201USA02587
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Pain							
			Estratest	C				
			Fosamax	C				
			Medroxyprogesterone Acetate	C				

Date:03/28/02ISR Number: 3919937-2Report Type:Periodic Company Report #WAES 0201USA02591
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919938-4Report Type:Periodic Company Report #WAES 0201USA02594
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Flexeril	C				

Date:03/28/02ISR Number: 3919939-6Report Type:Periodic Company Report #WAES 0201USA02603
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Pharyngeal Oedema		Anzemet	C				
	Vomiting		Augmentin	C				
			Bromfed	C				
			Cardura	C				
			Celebrex	C				
			Compazine	C				
			Darvocet-N	C				
			Daypro	C				
			Demerol	C				
			Elavil	C				
			Glucophage	C				
			Glucotrol Xl	C				
			Kefzol	C				
			Motrin	C				
			Naprosyn	C				
			Pepcid	C				
			Rezulin	C				
			Roxicet	C				
			Toradol	C				
			Trimox	C				
			Veetids	C				
			Vicodin Tablets	C				
			Acetaminophen (+)					
			Hydrocodone Bi	C				
			Amoxicillin	C				
			Diclofenac	C				
			Gastrointestinal					
			Preparations	C				
			Penicillin G Sodium	C				

			Sulfamethoxazole (+)			
			Trimethopri	C		

Date:03/28/02ISR Number: 3919940-2Report Type:Periodic Company Report #WAES 0201USA02605
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx	PS		ORAL	PO	
			Accupril	C				
			Actos	C				
			Allegra	C				
			Catapres	C				
			Centrum Silver	C				
			Claritin	C				
			Fe-Tinic	C				
			Humulin	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Niferex	C				

Paxil	C
Pce	C
Premarin	C
Rezulin	C
Tagamet	C
Zaroxolyn	C

Date:03/28/02ISR Number: 3919941-4Report Type:Periodic Company Report #WAES 0201USA02508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919942-6Report Type:Periodic Company Report #WAES 0201USA02517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional	Tab Vioxx	PS		ORAL	PRN/PO	

Date:03/28/02ISR Number: 3919943-8Report Type:Periodic Company Report #WAES 0201USA02518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919944-XReport Type:Periodic Company Report #WAES 0201USA02537
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Gastrointestinal Haemorrhage Haematochezia Vomiting	Professional Company Representative				

Date:03/28/02ISR Number: 3919945-1Report Type:Periodic Company Report #WAES 0201USA02540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Rectal Haemorrhage	Professional				
MG/DAILY/PO						

Date:03/28/02ISR Number: 3919946-3Report Type:Periodic Company Report #WAES 0201USA02545
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Hyperhidrosis					
MG/DAILY/PO						
	Paraesthesia		Aciphex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919947-5Report Type:Periodic Company Report #WAES 0201USA02548
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Coumadin	C				

Date:03/28/02ISR Number: 3919948-7Report Type:Periodic Company Report #WAES 0201USA02549
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY /PO	
	Oedema Peripheral		Norvasc	C				

Date:03/28/02ISR Number: 3919949-9Report Type:Periodic Company Report #WAES 0201USA02551
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx Unk	PS		ORAL	25MG/PO	

Date:03/28/02ISR Number: 3919950-5Report Type:Periodic Company Report #WAES 0201USA02346
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG /DAILY/PO	
			Accupril	C				
			Cenestin	C				
			Lasix (Furosemide)	C				
			Zocor	C				

Date:03/28/02ISR Number: 3919951-7Report Type:Periodic Company Report #WAES 0201USA02377
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3919952-9Report Type:Periodic Company Report #WAES 0201USA02402
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS	`	ORAL	25 MG; DAILY/PO; SEE IMAGE	
		Other						
			Premarin	C				
			Serozone	C				
			Ultram	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919953-0Report Type:Periodic Company Report #WAES 0201USA02406
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx Unk	PS		ORAL	1/2 TABLET	
	Palpitations						/DAILY/PO	
			Premo	C				
			Aspirin	C				
			Glucosamine	C				
			Linseed Oil	C				

Date:03/28/02ISR Number: 3919954-2Report Type:Periodic Company Report #WAES 0201USA02410
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Pain In Extremity		Hydrocodone	C				

Date:03/28/02ISR Number: 3919955-4Report Type:Periodic Company Report #WAES 0201USA02423
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Hypertension						MG/DAILY/PO	
			Atacand	C				
			Cardizem	C				
			Lipitor	C				
			Microzide	C				

Date:03/28/02ISR Number: 3919956-6Report Type:Periodic Company Report #WAES 0201USA02427
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Celebrex	C				
			Levoxyl	C				
			Prilosec	C				
			Provigil	C				
			Zocor	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3919957-8Report Type:Periodic Company Report #WAES 0201USA02457
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ecotrin	C				
			Inderal	C				
			Lasix (Furosemide)	C				
			Nitrolingual	C				
			Nitrostat	C				
			Os-Cal	C				
			Synthroid	C				
			Zithromax	C				
			Potassium Chloride	C				
			Vitamin E	C				

Date:03/28/02ISR Number: 3919958-XReport Type:Periodic Company Report #WAES 0201USA02487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema							
	Swelling		Premarin	C				
			Valtrex	C				
			Zyrtec	C				

Date:03/28/02ISR Number: 3919959-1Report Type:Periodic Company Report #WAES 0201USA02253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Insomnia		Norvasc	C				
			Premarin	C				
			Prilosec	C				
			Tenormin	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3919960-8Report Type:Periodic Company Report #WAES 0201USA02258
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional						
	Rash							

Date:03/28/02ISR Number: 3919961-XReport Type:Periodic Company Report #WAES 0201USA02263
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919962-1Report Type:Periodic Company Report #WAES 0201USA02278
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Ear Infection Pulmonary Congestion Sinusitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3919963-3Report Type:Periodic Company Report #WAES 0201USA02279
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Captopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919964-5Report Type:Periodic Company Report #WAES 0201USA02287
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Myokymia	Professional	Celebrex	C				
			Synthroid	C				
			Vicodin Tablets	C				

Date:03/28/02ISR Number: 3919965-7Report Type:Periodic Company Report #WAES 0201USA02293
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:03/28/02ISR Number: 3919966-9Report Type:Periodic Company Report #WAES 0201USA02294
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Lipitor	C				
			Nexium	C				
			Synthroid	C				
			Estradiol	C				
			Hydralazine	C				

Date:03/28/02ISR Number: 3919967-0Report Type:Periodic Company Report #WAES 0201USA02328
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
	Dyspepsia					
PO						
	Faeces Discoloured		Colbenemid	C		
	Haematochezia		Darvocet-N	C		
			Kerlone	C		
			Lipitor	C		
			Norvasc	C		
			One-A-Day Essential			
			Vitmains	C		
			Aspirin	C		

Date:03/28/02ISR Number: 3919968-2Report Type:Periodic Company Report #WAES 0201USA02343
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG,DAILY,						
		Professional				
PO						
			[Composition			
			Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919969-4Report Type:Periodic Company Report #WAES 0201USA02187
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
		Company Representative	Neurontin	C				
			[Therapeutic Unspecified]	C				

Date:03/28/02ISR Number: 3919970-0Report Type:Periodic Company Report #WAES 0201USA02209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx	PS		ORAL	PO	
	Hypothyroidism		Duratuss G	C				
			Klonopin	C				
			Nasarel	C				
			Plaquenil	C				
			Prempro	C				
			Pulmicort	C				
			Synthroid	C				
			Veralan	C				
			Zoloft	C				

Date:03/28/02ISR Number: 3919971-2Report Type:Periodic Company Report #WAES 0201USA02211
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
			Amaryl	C				
			Avandia	C				
			Glucophage	C				
			Ziac	C				

			Tamoxifen	C		

Date:03/28/02ISR Number: 3919972-4Report Type:Periodic Company Report #WAES 0201USA02213
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	25 MG, DAILY,	
	Rash						PO	
			Accupril	C				
			Maxzide	C				
			Norvasc	C				
			Premarin	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3919973-6Report Type:Periodic Company Report #WAES 0201USA02214
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
							PO	
			Paxil	C				
			Premarin	C				
			Toprol Xl Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919974-8Report Type:Periodic Company Report #WAES 0201USA02217
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
							PO	
			Celebrex	C				
			Celexa	C				
			Glucophage Xr	C				
			Prilosec	C				
			Synthroid	C				
			Clonazepam	C				
			Metoclopramide Hydrochloride	C				
			Metoprolol	C				

Date:03/28/02ISR Number: 3919975-XReport Type:Periodic Company Report #WAES 0201USA02223
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Oedema Peripheral	Health					PO	
	Weight Increased	Professional	Avandia	C				
			Diabeta	C				
			Glucophage Xr	C				
			Lipitor	C				
			Metoprolol	C				

Date:03/28/02ISR Number: 3919976-1Report Type:Periodic Company Report #WAES 0201USA02229
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal	Health	Tab Vioxx	PS		ORAL	PO	
	Clearance Increased	Professional Company						

Representative

Date:03/28/02ISR Number: 3919977-3Report Type:Periodic Company Report #WAES 0201USA02233
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3919978-5Report Type:Periodic Company Report #WAES 0201USA02237
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO;	
	Chest Pain	Health Professional					12.5 MG/DAILY/PO	
			Caltrate	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919979-7Report Type:Periodic Company Report #WAES 0201USA02152
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Synthroid	C				
			Folic Acid	C				
			Spironolactone	C				

Date:03/28/02ISR Number: 3919980-3Report Type:Periodic Company Report #WAES 0201USA02176
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
	Urticaria		Hydrodiuril	C				
			Ogen	C				

Date:03/28/02ISR Number: 3919981-5Report Type:Periodic Company Report #WAES 0201USA02181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Count Decreased	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	

Date:03/28/02ISR Number: 3919982-7Report Type:Periodic Company Report #WAES 0201USA02040
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Actos	C				
			Glucotrol Xl	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Prilosec	C				
			Prinivil	C				
			Tiazac	C				
			Guanfacine	C				
			Potassium Chloride	C				

Date:03/28/02ISR Number: 3919983-9Report Type:Periodic Company Report #WAES 0201USA02055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3919984-0Report Type:Periodic Company Report #WAES 0201USA02065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Drug Ineffective	Consumer
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	2 WK

Date:03/28/02ISR Number: 3919985-2Report Type:Periodic Company Report #WAES 0201USA02083
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Acivir	C				
			Cardura	C				
			Imodium	C				

Date:03/28/02ISR Number: 3919986-4Report Type:Periodic Company Report #WAES 0201USA02088
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Keratoconjunctivitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/UNK/PO	
	Sicca		Premarin	C				
			Synthroid	C				
			Vitamins	C				

Date:03/28/02ISR Number: 3919987-6Report Type:Periodic Company Report #WAES 0201USA02089
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain							
	Skin Nodule		Glucophage	C				

Date:03/28/02ISR Number: 3919988-8Report Type:Periodic Company Report #WAES 0201USA02110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3919989-XReport Type:Periodic Company Report #WAES 0201USA02131
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	1 DAY

Date:03/28/02ISR Number: 3919990-6Report Type:Periodic Company Report #WAES 0201USA02143
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Norvasc	C				

				Premarin	C	
				Prinivil	C	
				Synthroid	C	
				Hydrochlorothiazide (+) Triamter	C	

Date:03/28/02ISR Number: 3919991-8Report Type:Periodic Company Report #WAES 0201USA02150
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celexa	C				
			Desyrel	C				
			Ms Contin	C				
			Percocet	C				
			Prilosec	C				

Date:03/28/02ISR Number: 3919992-XReport Type:Periodic Company Report #WAES 0201USA01942
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO	

Date:03/28/02ISR Number: 3919993-1Report Type:Periodic Company Report #WAES 0201USA01958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prempro	C				

Date:03/28/02ISR Number: 3919994-3Report Type:Periodic Company Report #WAES 0201USA01959
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3919995-5Report Type:Periodic Company Report #WAES 0201USA01966
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Clonopin	C				
			Prozac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3919996-7Report Type:Periodic Company Report #WAES 0201USA01969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:03/28/02ISR Number: 3919997-9Report Type:Periodic Company Report #WAES 0201USA00762
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Coumadin	C				

Date:03/28/02ISR Number: 3919998-0Report Type:Periodic Company Report #WAES 0201USA00763
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Triamterene	C				

Date:03/28/02ISR Number: 3919999-2Report Type:Periodic Company Report #WAES 0201USA00772
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Face Oedema							
	Fluid Retention							

Nausea
Pruritus
Rash
Weight Increased

Date:03/28/02ISR Number: 3920000-5Report Type:Periodic Company Report #WAES 0201USA00784
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920001-7Report Type:Periodic Company Report #WAES 0201USA00819
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Fosamax	C				
			Cyanocobalamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920002-9Report Type:Periodic Company Report #WAES 0201USA00824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Procardia	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3920003-0Report Type:Periodic Company Report #WAES 0201USA00827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Haematochezia							

Date:03/28/02ISR Number: 3920004-2Report Type:Periodic Company Report #WAES 0201USA00840
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920005-4Report Type:Periodic Company Report #WAES 0201USA00851
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Cipro	C				
			Fosamax	C				
			Sporanox	C				

				Amoxicillin	C		

Date:03/28/02ISR Number: 3920006-6Report Type:Periodic Company Report #WAES 0201USA00881
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:03/28/02ISR Number: 3920007-8Report Type:Periodic Company Report #WAES 0202USA00977
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Professional	Norvasc	C				
			Prempro	C				
			Prilosec	C				
			Calcium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920008-XReport Type:Periodic Company Report #WAES 0202USA00980
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25MG DAILY PO	
			Avandia	C				
			Effexor	C				
			Glucotrol	C				
			Prempro	C				
			Prevacid	C				
			Prinivil	C				
			Metoprolol Tartrate	C				

Date:03/28/02ISR Number: 3920009-1Report Type:Periodic Company Report #WAES 0202USA00987
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx	PS		ORAL	PO	
	Nausea							

Date:03/28/02ISR Number: 3920010-8Report Type:Periodic Company Report #WAES 0202USA00990
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Congestive	Professional	Premarin	C				
	Drug Interaction		Prilosec	C				
	Oedema Peripheral		Prozac	C				
			Acyclovir	C				
			Ampicillin	C				

Date:03/28/02ISR Number: 3920011-XReport Type:Periodic Company Report #WAES 0202USA00999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Tegretol Unk	SS				
		Company Representative	Mysoline	C				

Date:03/28/02ISR Number: 3920012-1Report Type:Periodic Company Report #WAES 0202USA01001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
			Coumadin	C				
			Lanoxin	C				
			Persantine	C				

Date:03/28/02ISR Number: 3920013-3Report Type:Periodic Company Report #WAES 0202USA01010
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	12.5MG-25MG	
		Professional					DAILY PO	

Date:03/28/02ISR Number: 3920014-5Report Type:Periodic Company Report #WAES 0202USA01011
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Hyperpigmentation	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG PRN PO	

Date:03/28/02ISR Number: 3920015-7Report Type:Periodic Company Report #WAES 0202USA01017
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Date:03/28/02ISR Number: 3920016-9Report Type:Periodic Company Report #WAES 0201USA01972
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coagulopathy	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG, PO	
	Haemorrhage	Professional Company Representative						

Date:03/28/02ISR Number: 3920017-0Report Type:Periodic Company Report #WAES 0201USA01978
Age:80 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920018-2Report Type:Periodic Company Report #WAES 0201USA01980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo	Health Professional Company Representative	Tab Vioxx 25	PS		ORAL	SEE IMAGE	

Date:03/28/02ISR Number: 3920019-4Report Type:Periodic Company Report #WAES 0201USA02011
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Viox 12.5 Mg	PS		ORAL	12.5 MG, BID, PO	
	Heart Rate Irregular							
	Hypertension							
	Syncope							

Date:03/28/02ISR Number: 3920021-2Report Type:Periodic Company Report #WAES 0201USA02034
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920022-4Report Type:Periodic Company Report #WAES 0201USA01835
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Aspartate Aminotransferase Increased	Company Representative	Niacin 500 Mg	SS		ORAL	DAILY, PO	
			Altace	C				
			Claritin	C				
			Tessalon	C				
			Aspirin	C				
			Vitamin E	C				

Date:03/28/02ISR Number: 3920024-8Report Type:Periodic Company Report #WAES 0201USA01842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Drug Ineffective							
	Heart Rate Irregular							

Date:03/28/02ISR Number: 3920026-1Report Type:Periodic Company Report #WAES 0201USA01844
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, AM, PO	
	Diarrhoea							
	Dizziness		Glucophage	C				
	Fatigue		Prevacid	C				
	Nausea		Carisoprodol	C				

Date:03/28/02ISR Number: 3920028-5Report Type:Periodic Company Report #WAES 0201USA01845
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Allegra	C				

Date:03/28/02ISR Number: 3920030-3Report Type:Periodic Company Report #WAES 0201USA01853
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional						

Date:03/28/02ISR Number: 3920031-5Report Type:Periodic Company Report #WAES 0201USA01878
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920033-9Report Type:Periodic Company Report #WAES 0201USA01889
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hearing Impaired	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Nonsteroidal Anti-Inflammatory	C				

Date:03/28/02ISR Number: 3920034-0Report Type:Periodic Company Report #WAES 0201USA01909
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx Unk	PS		ORAL	25 MG/PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3920036-4Report Type:Periodic Company Report #WAES 0201USA01922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 WK
		Professional Company Representative						

Date:03/28/02ISR Number: 3920038-8Report Type:Periodic Company Report #WAES 0201USA01929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

			Corgard	C		
			Prinzide	C		

Date:03/28/02ISR Number: 3920039-XReport Type:Periodic Company Report #WAES 0201USA01530
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Avandia	C				
			Glucophage	C				
			Humalog	C				
			Levoxyl	C				
			Nitroquick	C				
			Tricor	C				
			Glyburide	C				
			Verapamil	C				

Date:03/28/02ISR Number: 3920040-6Report Type:Periodic Company Report #WAES 0201USA01534
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Weight Increased							
			Atacand	C				

	Lipitor	C
	Prilosec	C
	Atenolol	C

Date:03/28/02ISR Number: 3920042-XReport Type:Periodic Company Report #WAES 0201USA01536
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Tremor		Diovan	C				
			Prevacid	C				
			Dicyclomine Hydrochloride	C				

Date:03/28/02ISR Number: 3920043-1Report Type:Periodic Company Report #WAES 0201USA01643
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/PO	

Date:03/28/02ISR Number: 3920046-7Report Type:Periodic Company Report #WAES 0201USA01807
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Lower Gastrointestinal Haemorrhage							

Date:03/28/02ISR Number: 3920049-2Report Type:Periodic Company Report #WAES 0201USA01808
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Singulair	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3920052-2Report Type:Periodic Company Report #WAES 0201USA01810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 YR
			Mevacor	C				
			Norvasc	C				
			Tylenol Extra Strength	C				
			Furosemide	C				

Date:03/28/02ISR Number: 3920055-8Report Type:Periodic Company Report #WAES 0201USA01813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
			Coumadin	C				

			Lasix (Furosemide Sodium)	C		

Date:03/28/02ISR Number: 3920057-1Report Type:Periodic Company Report #WAES 0201USA01820
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Dizziness		Centrum Silver	C				
	Dyspepsia		Cozaar	C				
	Epistaxis		Niaspan	C				
	Haemorrhage		Os-Cal	C				
	Headache		Albuterol	C				
	Oedema Peripheral		Estradiol	C				
	Rectal Haemorrhage		Hydrochlorothiazide (+) Triamter	C				
	Upper Respiratory Tract Infection		Nadolol	C				
			Spironolactone	C				

Date:03/28/02ISR Number: 3920058-3Report Type:Periodic Company Report #WAES 0201USA01824
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Aspartate Aminotransferase Increased		Vicodin Tablets	C				
			Estrogens (Unspecified)	C				

Date:03/28/02ISR Number: 3920060-1Report Type:Periodic Company Report #WAES 0201USA01406
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Diarrhoea					
MG/DAILY/PO						
			Therapy Unspecified	C		

Date:03/28/02ISR Number: 3920062-5Report Type:Periodic Company Report #WAES 0201USA01408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Nausea	Consumer	Tab Vioxx	PS		ORAL
25 MG/PO						

Date:03/28/02ISR Number: 3920063-7Report Type:Periodic Company Report #WAES 0202USA00843
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Tylenol	C		

Date:03/28/02ISR Number: 3920064-9Report Type:Periodic Company Report #WAES 0201USA01410
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3920066-2Report Type:Periodic Company Report #WAES 0201USA01426
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	
	Urticaria	Health Professional	Vitamins [Unspecified]	SS				
			Ibuprofen	C				

Date:03/28/02ISR Number: 3920068-6Report Type:Periodic Company Report #WAES 0201USA01430
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective		Darvocet-N	C				
	Muscle Disorder							

Date:03/28/02ISR Number: 3920069-8Report Type:Periodic Company Report #WAES 0202USA00862
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY;PO	
	Joint Swelling		Agenerase	C				

				Diflucan	C		
				Epivir	C		
				Percocet	C		
				Psorcon	C		
				Restoril	C		
				Vitamins (Unspecified)	C		

Date:03/28/02ISR Number: 3920071-6Report Type:Periodic Company Report #WAES 0201USA01446
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea							
			Evista	C				
			Librax Capsules	C				
			Mevacor	C				
			Prilosec	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920072-8Report Type:Periodic Company Report #WAES 0201USA01447
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Arthrotec	C				
			Celebrex	C				

Date:03/28/02ISR Number: 3920073-XReport Type:Periodic Company Report #WAES 0201USA01449
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS		ORAL	PO	
		Professional	Lipitor	C				
			Tricor	C				
			Allopurinol	C				

Date:03/28/02ISR Number: 3920075-3Report Type:Periodic Company Report #WAES 0201USA01458
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx	PS		ORAL	PO	
	Disease	Professional						

Date:03/28/02ISR Number: 3920076-5Report Type:Periodic Company Report #WAES 0202USA002874
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Disorder	Professional	Celebrex	C				

Date:03/28/02ISR Number: 3920077-7Report Type:Periodic Company Report #WAES 0201USA01475
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920079-0Report Type:Periodic Company Report #WAES 0201USA01355
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Nausea						PO	
	Somnolence		Premarin	C				
			Synthroid	C				
			Ranitidine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920080-7Report Type:Periodic Company Report #WAES 0202USA00905
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx	PS		ORAL	25MG, DAILY;	
	Disorientation						PO	
	Memory Impairment		Proscar	C				
			Vitamins	C				

Date:03/28/02ISR Number: 3920081-9Report Type:Periodic Company Report #WAES 0201USA01362
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920083-2Report Type:Periodic Company Report #WAES 0201USA01365
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngeal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Lipitor	C				
			Premarin	C				
			Timoptic-Xe	C				
			Vivelle	C				

Date:03/28/02ISR Number: 3920084-4Report Type:Periodic Company Report #WAES 0201USA01366
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

PO

			Prempro	C		

Date:03/28/02ISR Number: 3920086-8Report Type:Periodic Company Report #WAES 0201USA01372
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disturbance In Attention	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Feeling Abnormal	Health						
PO								
	Photopsia	Professional	Allegra	C				
			Centrum Silver	C				
			Citrical	C				
			Humalog	C				
			Hydrodiuril	C				
			Nph Insulin	C				
			Pepcid	C				
			Valium	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3920087-XReport Type:Periodic Company Report #WAES 0202USA00943
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx	PS		ORAL		
PO								
			Ambien	C				
			Atarax	C				

			Ativan	C		
			Elavil	C		

Date:03/28/02ISR Number: 3920088-1Report Type:Periodic Company Report #WAES 0201USA01377
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypertension	Professional Company Representative						

Date:03/28/02ISR Number: 3920089-3Report Type:Periodic Company Report #WAES 0202USA00944
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/AM/PO	
			Claritin	C				
			Miacalcin	C				
			Mirapex	C				
			Prilosec	C				
			Remeron	C				
			Zoloft	C				
			Albuterol	C				
			Buspirone Hydrochloride	C				
			Isosorbide Monitrate	C				
			Lorazepam	C				
			Meclizine Hydrochloride	C				
			Potassium Chloride	C				
			Quinine Sulfate	C				

Date:03/28/02ISR Number: 3920090-XReport Type:Periodic Company Report #WAES 0202USA00947
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG, DAILY;	
PO								
			Allegra	C				
			Hytrin	C				
			Lipitor	C				
			Locoid	C				
			Skelaxin	C				

Date:03/28/02ISR Number: 3920091-1Report Type:Periodic Company Report #WAES 0202USA00953
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG, DAILY;	
PO								
			Advil	C				
			Diovan Hct	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920092-3Report Type:Periodic Company Report #WAES 0202USA00968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	25MG, PRN; PO	
			Betoptic S	C				
			Synthroid	C				
			Xalatan	C				
			Pilocarpine	C				

Date:03/28/02ISR Number: 3920093-5Report Type:Periodic Company Report #WAES 0202USA00970
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PRN; PO	
	Rectal Haemorrhage		[Composition Unspecified]	C				

Date:03/28/02ISR Number: 3920095-9Report Type:Periodic Company Report #WAES 0202USA00806
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PRN/PO	
			Ativan	C				
			Plendil	C				
			Sinemet	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3920097-2Report Type:Periodic Company Report #WAES 0201USA01378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	

Professional
PO
Company
Representative

Date:03/28/02ISR Number: 3920098-4Report Type:Periodic Company Report #WAES 0202USA00807
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920100-XReport Type:Periodic Company Report #WAES 0201USA01379
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG / PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920101-1Report Type:Periodic Company Report #WAES 0201USA01380
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain In Extremity							
	Paraesthesia		Synthroid	C				
			Verelan	C				

Date:03/28/02ISR Number: 3920103-5Report Type:Periodic Company Report #WAES 0202USA00821
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920104-7Report Type:Periodic Company Report #WAES 0201USA01402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	

Date:03/28/02ISR Number: 3920105-9Report Type:Periodic Company Report #WAES 0201USA01249
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO 2 WK

Aerobid-M	C
Cardizem Cd	C
Colace	C
Dalmane	C
Desyrel	C
Lanoxin	C
Lasix (Furosemide)	C
Metamucil	C
Micro K	C
Mylanta & Mylanta Ds	C
Prilosec	C
Travatan	C
Tylenol With Codeine #4	C
Uniphyl (Therapy Unspecified)	C
Allopurinol	C

Date:03/28/02ISR Number: 3920106-0Report Type:Periodic Company Report #WAES 0202USA00823
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920107-2Report Type:Periodic Company Report #WAES 0201USA01253
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Gastritis		Darvocet-N	C				
			Hydrodiuril	C				
			Zoloft	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3920109-6Report Type:Periodic Company Report #WAES 0201USA01255
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY	/ PO

Date:03/28/02ISR Number: 3920110-2Report Type:Periodic Company Report #WAES 0201USA01259
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Pain		Lipitor	C				
			Prempro	C				
			Tiazac	C				
			Zyrtec	C				

Date:03/28/02ISR Number: 3920111-4Report Type:Periodic Company Report #WAES 0202USA00825
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:03/28/02ISR Number: 3920113-8Report Type:Periodic Company Report #WAES 0201USA01275
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Fluid Retention							

MG/BID/PO

Date:03/28/02ISR Number: 3920115-1Report Type:Periodic Company Report #WAES 0201USA01286
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25	
			Arthrotec	C				
			Celebrex	C				
			Dilantin	C				
			Duragesic	C				
			Kayexalate	C				
			Phoslo	C				
			Prilosec	C				
			Tylenol With Codeine	C				
			Viagra	C				
			Calcitriol	C				

MG/DAILY/PO

Doxazosin	C	
Metoclopramide Hydrochloride	C	

Date:03/28/02ISR Number: 3920116-3Report Type:Periodic Company Report #WAES 0202USA00826
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	7 DAY

Date:03/28/02ISR Number: 3920118-7Report Type:Periodic Company Report #WAES 0201USA01287
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	

Date:03/28/02ISR Number: 3920119-9Report Type:Periodic Company Report #WAES 0202USA00830
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Dizziness		Diltiazem Hydrochloride	C				

Date:03/28/02ISR Number: 3920120-5Report Type:Periodic Company Report #WAES 0201USA01298
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920121-7Report Type:Periodic Company Report #WAES 0201USA01301
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Back Pain							
	Chest Pain							
	Dyspnoea							
	Facial Pain							
	Neck Pain							

Date:03/28/02ISR Number: 3920122-9Report Type:Periodic Company Report #WAES 0202USA00832
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Analysis Abnormal	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Glucovance	C				
			Lipitor	C				
			Cortisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920123-0Report Type:Periodic Company Report #WAES 0201USA01318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920124-2Report Type:Periodic Company Report #WAES 0201USA01168
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased		Cenestin	C				
			Nexium	C				
			Provera	C				
			Zocor	C				
			Zyrtec	C				

Date:03/28/02ISR Number: 3920125-4Report Type:Periodic Company Report #WAES 0201USA01172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920126-6Report Type:Periodic Company Report #WAES 0202USA00838
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx	PS			ORAL
25 MG/PO							
			Pulmicort	C			
			Zantac	C			
			Zoloft	C			
			Therapy Unspecified	C			

Date:03/28/02ISR Number: 3920127-8Report Type:Periodic Company Report #WAES 0201USA01173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920128-XReport Type:Periodic Company Report #WAES 0201USA01184
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Face Oedema							
	Pharyngeal Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920129-1Report Type:Periodic Company Report #WAES 0201USA01186
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Renal Pain	Consumer	Tab Vioxx 25 Mg; 12.5 Mg	PS		ORAL	25 MG/DAILY/PO;	SEE IMAGE
			Altace	C				
			Combivent	C				
			Coumadin	C				
			Flovent	C				
			Lasix (Furosemide)	C				
			Norvasc	C				
			Prilosec	C				
			Rubesol	C				
			Singulair	C				
			Alprazolam	C				
			Potassium (Unspecified)	C				
			Sotalol Hydrochloride	C				

Date:03/28/02ISR Number: 3920130-8Report Type:Periodic Company Report #WAES 0202USA00839
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Oxycodone	SS				
			...	C				

Date:03/28/02ISR Number: 3920131-XReport Type:Periodic Company Report #WAES 0201USA01189
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Headache	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
	Tinnitus						
MG/DAILY/PO							
			Aspirin	C			
			Glyburide	C			
			Metoprolol	C			
			Vitamins (Unspecified)	C			

Date:03/28/02ISR Number: 3920148-5Report Type:Periodic Company Report #WAES 0202USA00660
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Fatigue					
MG/DAILY/PO						
	Muscular Weakness		Plaquenil	C		
			Salagen Tablets	C		
			Plaquenil	C		
			Salagen Tablets	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920156-4Report Type:Periodic Company Report #WAES 0202USA00666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/PO	
			Maxzide	C				
			(Therapy Unspecified)	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3920161-8Report Type:Periodic Company Report #WAES 0202USA00678
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	
	Vision Blurred							

Date:03/28/02ISR Number: 3920166-7Report Type:Periodic Company Report #WAES 0202USA00686
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920171-0Report Type:Periodic Company Report #WAES 0202USA00689
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920174-6Report Type:Periodic Company Report #WAES 0202USA00731
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3920180-1Report Type:Periodic Company Report #WAES 0202USA00740
Age:66 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920184-9Report Type:Periodic Company Report #WAES 0202USA00787
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	[Composition Unspecified]	C				

Date:03/28/02ISR Number: 3920187-4Report Type:Periodic Company Report #WAES 0202USA00598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Hydrodiuril	C				
			Protonix	C				
			Synthroid	C				

Date:03/28/02ISR Number: 3920189-8Report Type:Periodic Company Report #WAES 0202USA00606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
	Myalgia							
			Pravachol	C				
			Tricor	C				

Date:03/28/02ISR Number: 3920193-XReport Type:Periodic Company Report #WAES 0202USA00607
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sweat Gland Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Lipitor	C				
			Toprol Xl Tablets	C				
			Zestril	C				

Date:03/28/02ISR Number: 3920195-3Report Type:Periodic Company Report #WAES 0202USA00608
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cardizem Cd	C				
			Coumadin	C				
			Humalog	C				
			Imdur	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Nitro-Spray	C				
			Proventil	C				
			Starlix	C				

Date:03/28/02ISR Number: 3920199-0Report Type:Periodic Company Report #WAES 0202USA00616
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920204-1Report Type:Periodic Company Report #WAES 0202USA00619
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
			Viagra	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3920211-9Report Type:Periodic Company Report #WAES 0202USA00620
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920215-6Report Type:Periodic Company Report #WAES 0202USA00627
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lipitor	C				
			Procardia	C				

Date:03/28/02ISR Number: 3920218-1Report Type:Periodic Company Report #WAES 0202USA00651
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
	Bronchitis						
MG/DAILY/PO							
	Cough		Therapy Unspecified	C			
	Pneumonitis						
	Swelling						

Date:03/28/02ISR Number: 3920222-3Report Type:Periodic Company Report #WAES 0202USA00652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Other	Tab Vioxx 25mg	PS		ORAL
25						
MG/DAILY/PO						

Date:03/28/02ISR Number: 3920224-7Report Type:Periodic Company Report #WAES 0202USA00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Lipitor	C		
			Norvasc	C		
			Toprol Xl Tablets	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920226-0Report Type:Periodic Company Report #WAES 0202USA00496
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5 MG/DAILY/PO; 25 MG/PRN/PO	
			Acupril	C				
			Lopressor	C				

Date:03/28/02ISR Number: 3920227-2Report Type:Periodic Company Report #WAES 0202USA00028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3920230-2Report Type:Periodic Company Report #WAES 0202USA00031
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 MON
			[Composition Unspecified]	C				

Date:03/28/02ISR Number: 3920232-6Report Type:Periodic Company Report #WAES 0202USA00500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Olfactory Nerve Disorder		Therapy Unspecified	C				

Date:03/28/02ISR Number: 3920233-8Report Type:Periodic Company Report #WAES 0202USA00033
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3920235-1Report Type:Periodic Company Report #WAES 0202USA00056
Age:78 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Prempro	C				
			Synthroid	C				
			Tylenol	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920238-7Report Type:Periodic Company Report #WAES 0202USA00057
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hallucination							
	Speech Disorder		Aciphex	C				
			Acular	C				
			Hydrodiuril	C				
			Lopressor	C				
			Penicillin Vk	C				
			Potassium Chloride	C				
			Prednisone	C				

Date:03/28/02ISR Number: 3920241-7Report Type:Periodic Company Report #WAES 0202USA00504
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Zyrtec	C				

Date:03/28/02ISR Number: 3920242-9Report Type:Periodic Company Report #WAES 0201USA03267
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Propranolol	C				

Date:03/28/02ISR Number: 3920245-4Report Type:Periodic Company Report #WAES 0201USA03268
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	25 MG/BID/PO	

Date:03/28/02ISR Number: 3920247-8Report Type:Periodic Company Report #WAES 0201USA03275
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
	Rash							

Date:03/28/02ISR Number: 3920249-1Report Type:Periodic Company Report #WAES 0201USA03278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920255-7Report Type:Periodic Company Report #WAES 0201USA03309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Blood Pressure Increased							
	Dizziness							
	Drug Ineffective							
	Headache							
	Nausea							
	Urine Abnormality							

Date:03/28/02ISR Number: 3920257-0Report Type:Periodic Company Report #WAES 0202USA00123
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Oxycontin	C				
			Zocor	C				
			[Therapy Unspecified]	C				
			Temazepam	C				

Date:03/28/02ISR Number: 3920259-4Report Type:Periodic Company Report #WAES 0201USA03330
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lescol	C				
			Paxil	C				

Date:03/28/02ISR Number: 3920260-0Report Type:Periodic Company Report #WAES 0201USA03336
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Tab Vioxx Unk	PS				
OPHTHALMIC						PO		
		Professional	Gabitril	C				
			Zoloft	C				

Date:03/28/02ISR Number: 3920263-6Report Type:Periodic Company Report #WAES 0201USA03339
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL		
PO								
		Professional						

Date:03/28/02ISR Number: 3920264-8Report Type:Periodic Company Report #WAES 0202USA00125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx Unk	PS		ORAL		
PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920265-XReport Type:Periodic Company Report #WAES 0201USA03340
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920267-3Report Type:Periodic Company Report #WAES 0201USA03358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	DALY/PO	
	Constipation							
	Eating Disorder							
	Gastrointestinal Disorder							

Date:03/28/02ISR Number: 3920268-5Report Type:Periodic Company Report #WAES 0201USA03114
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG /	
	Dyspnoea						DAILY / PO	1 YR
	Palpitations		Prilosec	C				
			Estrogens	C				

Date:03/28/02ISR Number: 3920271-5Report Type:Periodic Company Report #WAES 0202USA00152
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, PO	
			Paxil	C				

Date:03/28/02ISR Number: 3920272-7Report Type:Periodic Company Report #WAES 0201USA03144
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920274-0Report Type:Periodic Company Report #WAES 0201USA03189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920276-4Report Type:Periodic Company Report #WAES 0201USA03190
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
	Oedema Peripheral		Celebrex	C				
			Diovan	C				
			Norvasc	C				
			Premarin	C				
			Prometrium	C				

Zestril C

Date:03/28/02ISR Number: 3920277-6Report Type:Periodic Company Report #WAES 0202USA00514
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			[Therapy Unspecified)	C				

Date:03/28/02ISR Number: 3920280-6Report Type:Periodic Company Report #WAES 0201USA03192
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Pain							
	Urogenital Haemorrhage							

Date:03/28/02ISR Number: 3920282-XReport Type:Periodic Company Report #WAES 0202USA00156
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3920283-1Report Type:Periodic Company Report #WAES 0201USA03198
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Prinivil	C
Toprol Xl Tablets	C
Zantac	C
Zocor	C
Glyburide	C

Date:03/28/02ISR Number: 3920285-5Report Type:Periodic Company Report #WAES 0201USA03200
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Demadex	C
K-Dur	C
Premarin	C
Folic Acid	C
Methitural Sodium	C

Date:03/28/02ISR Number: 3920286-7Report Type:Periodic Company Report #WAES 0202USA00157
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Irritability							

MG/DAILY/PO

Prevacid C

Date:03/28/02ISR Number: 3920288-0Report Type:Periodic Company Report #WAES 0201USA03204
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920289-2Report Type:Periodic Company Report #WAES 0202USA00159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emotional Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Irritability							
			Prilosec	C				

Date:03/28/02ISR Number: 3920290-9Report Type:Periodic Company Report #WAES 0201USA03225
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dyspnoea							
	Face Oedema							
	Urine Abnormality							

Date:03/28/02ISR Number: 3920291-0Report Type:Periodic Company Report #WAES 0201USA03360
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Date:03/28/02ISR Number: 3920293-4Report Type:Periodic Company Report #WAES 0201USA03231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Mouth Ulceration							
	Urticaria							

Date:03/28/02ISR Number: 3920294-6Report Type:Periodic Company Report #WAES 0201USA02612
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920296-XReport Type:Periodic Company Report #WAES 0202USA00001
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Allegra	C				

			Coreg	C		
			Lipitor	C		
			Aspirin	C		
			Digoxin	C		

Date:03/28/02ISR Number: 3920297-1Report Type:Periodic Company Report #WAES 0201USA02624
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Lescol	C				
			Norvasc	C				
			Premarin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:03/28/02ISR Number: 3920299-5Report Type:Periodic Company Report #WAES 0201USA02641
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920301-0Report Type:Periodic Company Report #WAES 0202USA00005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Cipro	C				
			Macrobid	C				

Date:03/28/02ISR Number: 3920302-2Report Type:Periodic Company Report #WAES 0201USA02646
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract	Health	Tab Vioxx	PS		ORAL	PO	
	Infection	Professional Company Representative						

Date:03/28/02ISR Number: 3920322-8Report Type:Periodic Company Report #WAES 0201USA02647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG 1X PO	
	Attack	Professional Company Representative	Aggrenox	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920324-1Report Type:Periodic Company Report #WAES 0202USA00175
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Somnolence						PO	1 WK
	Vision Blurred		Lasix (Furosemide)	C				
			Plavix	C				
			Allopurinol	C				
			Diltiazem Bhydrochloride	C				

Date:03/28/02ISR Number: 3920325-3Report Type:Periodic Company Report #WAES 0201USA02650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920326-5Report Type:Periodic Company Report #WAES 0201USA02654
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO; 12. 4 MG	
			Aspirin	C				
			Indapamide	C				
			Reserpine	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3920328-9Report Type:Periodic Company Report #WAES 0202USA00185
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
						PO		
			Tamoxifen	C				

Date:03/28/02ISR Number: 3920329-0Report Type:Periodic Company Report #WAES 0201USA02660
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Headache							
	Musculoskeletal Stiffness					PO		

Date:03/28/02ISR Number: 3920331-9Report Type:Periodic Company Report #WAES 0201USA02666
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920333-2Report Type:Periodic Company Report #WAES 0201USA02686
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx Unknown	PS		ORAL	25 MG DAILY	
	Muscular Weakness						PO	
	Pain In Extremity		Lasix (Furosemide)	C				
			Procardia	C				
			Vasotec	C				
			Glyburide	C				
			Sulfur	C				

Date:03/28/02ISR Number: 3920335-6Report Type:Periodic Company Report #WAES 0202USA00189
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	

Date:03/28/02ISR Number: 3920336-8Report Type:Periodic Company Report #WAES 0201USA02691
Age:45 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
		Company Representative	Nexium	C				

Date:03/28/02ISR Number: 3920338-1Report Type:Periodic Company Report #WAES 0202USA00192
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Conjunctival Hyperaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Somnolence						PO	
			Synthroid	C				

Date:03/28/02ISR Number: 3920339-3Report Type:Periodic Company Report #WAES 0201USA02693
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Professional					PO	
		Company Representative	Insulin	C				

Date:03/28/02ISR Number: 3920340-XReport Type:Periodic Company Report #WAES 0201USA02705
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg, 50 Mg, 12.5 Mg	PS		ORAL	25 MG DAILY	
	Contusion						PO, 50 MG	
	Tachycardia						DAILY PO,	
							12.5 MG DAILY	
							PO	
			Accupril	C				
			Celebrex	C				

Centrum	C
Elavil	C
Levothroid	C
Tylenol	C
Ascorbic Acid	C
Atenolol	C
Calcium (Unspecified) (+)	
Vitamin	C
Estropipate	C
Lorazepam	C

Date:03/28/02ISR Number: 3920343-5Report Type:Periodic Company Report #WAES 0202USA00194
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Hypertension	Professional					PO	
	Memory Impairment	Company Representative						

Date:03/28/02ISR Number: 3920345-9Report Type:Periodic Company Report #WAES 0201USA02707
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:03/28/02ISR Number: 3920347-2Report Type:Periodic Company Report #WAES 0202USA00204
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

Professional
PO

Date:03/28/02ISR Number: 3920350-2Report Type:Periodic Company Report #WAES 0202USA00228
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3920351-4Report Type:Periodic Company Report #WAES 0201USA02722
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920355-1Report Type:Periodic Company Report #WAES 0201USA02724
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920357-5Report Type:Periodic Company Report #WAES 0202USA00059
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
							PO	
			Dextrol La	C				
			Fosamax	C				
			Levoxyl	C				
			Norvasc	C				
			Questran Light	C				
			Calcium (Unspecified)	C				
			Dicyclomine Hydrochloride	C				
			Temazepam	C				
			Vitamin D (Unspecified)	C				

Date:03/28/02ISR Number: 3920359-9Report Type:Periodic Company Report #WAES 0201USA02725
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920360-5Report Type:Periodic Company Report #WAES 0201USA02751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	
	Muscular Weakness	Company Representative	Cenestin	C				
			Diovan	C				
			Lipitor	C				
			Plaquenil	C				
			Prometrium	C				
			Tricor	C				
			[Therapy Unspecified]	C				

Date:03/28/02ISR Number: 3920363-0Report Type:Periodic Company Report #WAES 0202USA00097
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920364-2Report Type:Periodic Company Report #WAES 0201USA02753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Increased	Professional					MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3920366-6Report Type:Periodic Company Report #WAES 0201USA02754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Vomiting	Professional					MG/DAILY/PO	2 DAY
		Company Representative						

Date:03/28/02ISR Number: 3920367-8Report Type:Periodic Company Report #WAES 0202USA00115
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG AM PO	
	Dizziness		Centrum	C				
	Dyspepsia		Fosamax	C				
	Fall		Levoxyl	C				
	Headache							

Date:03/28/02ISR Number: 3920370-8Report Type:Periodic Company Report #WAES 0201USA02755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal	Health	Tab Vioxx Unk	PS			ORAL
UNK/DAILY/PO 2 WK							
	Haemorrhage	Professional Company Representative	[Therapy Unspecified]	C			

Date:03/28/02ISR Number: 3920372-1Report Type:Periodic Company Report #WAES 0201USA02775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL
PO						
		Company Representative				

Date:03/28/02ISR Number: 3920376-9Report Type:Periodic Company Report #WAES 0201USA02776
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920381-2Report Type:Periodic Company Report #WAES 0201USA02783
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Change Of Bowel Habit		Fosamax	C				
	Flatulence		Requip	C				
			Sinemet Cr	C				
			Zoloft	C				

Date:03/28/02ISR Number: 3920385-XReport Type:Periodic Company Report #WAES 0201USA02803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY	
	Vision Blurred	Professional						
		Company Representative						

Date:03/28/02ISR Number: 3920388-5Report Type:Periodic Company Report #WAES 0201USA02813
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3920391-5Report Type:Periodic Company Report #WAES 0201USA02817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Darnocet-N	C				
			Micronase	C				

				Paxil	C		
				Aspirin	C		
				Metoprolol	C		

Date:03/28/02ISR Number: 3920392-7Report Type:Periodic Company Report #WAES 0201USA02821
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG DAILY	
		Health					PO	
		Professional	Premarin	C				
			Prinzide	C				
			Nitrofurantoin	C				
			Vitamins	C				

Date:03/28/02ISR Number: 3920394-0Report Type:Periodic Company Report #WAES 0201USA02822
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Drug Ineffective		Aspirin	C				
			Terazosin Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920396-4Report Type:Periodic Company Report #WAES 0201USA02843
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY	
	Dyspepsia							
PO								

Date:03/28/02ISR Number: 3920398-8Report Type:Periodic Company Report #WAES 0201USA02853
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 25mg	PS		ORAL		
PO								
		Professional						

Date:03/28/02ISR Number: 3920399-XReport Type:Periodic Company Report #WAES 0201USA02854
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx	PS		ORAL		
PO								
	Weight Increased	Professional						

Date:03/28/02ISR Number: 3920401-5Report Type:Periodic Company Report #WAES 0201USA02912
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY	
PO								
	Dyspepsia		Lopressor Hct	C				
	Rectal Haemorrhage							
	Vomiting							

Date:03/28/02ISR Number: 3920455-6Report Type:Periodic Company Report #WAES 0201USA03015
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Paraesthesia		Benemid	C				

Date:03/28/02ISR Number: 3920459-3Report Type:Periodic Company Report #WAES 0201USA03027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ PRN/ PO	

Date:03/28/02ISR Number: 3920460-XReport Type:Periodic Company Report #WAES 0201USA03028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920462-3Report Type:Periodic Company Report #WAES 0201USA03042
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
PO								
			Evista	C				

Date:03/28/02ISR Number: 3920464-7Report Type:Periodic Company Report #WAES 0201USA03055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL		
PO								

Date:03/28/02ISR Number: 3920467-2Report Type:Periodic Company Report #WAES 0201USA03058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Paraesthesia							
PO								
			Synthroid	C				
			Therapy Unspecified	C				

Date:03/28/02ISR Number: 3920468-4Report Type:Periodic Company Report #WAES 0201USA03062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL		
PO								

Professional
Company
Representative

Date:03/28/02ISR Number: 3920484-2Report Type:Periodic Company Report #WAES 0201USA03063
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mobility Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Myalgia	Professional						
PO								3 DAY
	Oedema Peripheral	Company Representative						

Date:03/28/02ISR Number: 3920488-XReport Type:Periodic Company Report #WAES 0201USA03067
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Fatigue	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3920490-8Report Type:Periodic Company Report #WAES 0201USA03076
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 1 Tablet	PS		ORAL	1 TABLET/	DAILY/ PO
			Premarin	C				

Date:03/28/02ISR Number: 3923311-2Report Type:Periodic Company Report #WAES 0202USA01903
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tremor	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923314-8Report Type:Periodic Company Report #WAES 0112USA02469
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx 25 Mg	PS		ORAL	PO	
			Diazide	C				
			Lipitor	C				
			Zestril	C				

Date:03/28/02ISR Number: 3923316-1Report Type:Periodic Company Report #WAES 0202USA01707
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Health Professional Company	Tab Vioxx	PS		ORAL	PO	

Representative

Date:03/28/02ISR Number: 3923319-7Report Type:Periodic Company Report #WAES 0202USA01708
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ibuprofen	C				

Date:03/28/02ISR Number: 3923321-5Report Type:Periodic Company Report #WAES 0112USA02207
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Pruritus		Atacand	C				

Date:03/28/02ISR Number: 3923323-9Report Type:Periodic Company Report #WAES 0112USA02243
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx	PS		ORAL	PO	
		Professional	Baycol	C				
			Flomax (Tamsulosin					

				Hydrochlroide)	C		
				Prilosec	C		

Date:03/28/02ISR Number: 3923324-0Report Type:Periodic Company Report #WAES 0202USA01712
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Professional Company Representative	Wellbutrin	C				

Date:03/28/02ISR Number: 3923326-4Report Type:Periodic Company Report #WAES 0112USA02244
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Evista	C				
			Prevacid	C				
			Prilosec	C				
			Imipramine	C				

Date:03/28/02ISR Number: 3923328-8Report Type:Periodic Company Report #WAES 0202USA01719
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:03/28/02ISR Number: 3923329-XReport Type:Periodic Company Report #WAES 0112USA02275
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx 25 Mg	PS		ORAL	PO	
			Alphagan	C				
			Prevacid	C				
			Pilocarpine	C				

Date:03/28/02ISR Number: 3923330-6Report Type:Periodic Company Report #WAES 0202USA01725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5mg	PS		ORAL	SEE IMAGE	
		Professional Company Representative						

Date:03/28/02ISR Number: 3923331-8Report Type:Periodic Company Report #WAES 0202USA01733
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx	PS		ORAL	PO	
	Rash	Professional Company Representative	Diovan Hct	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923332-XReport Type:Periodic Company Report #WAES 0112USA02276
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923333-1Report Type:Periodic Company Report #WAES 0112USA02278
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cystitis							
			Prilosec	C				
			Proctocort	C				
			Synvisc	C				
			Zocor	C				
			Zyrtec	C				
			Nabumetone	C				

Date:03/28/02ISR Number: 3923334-3Report Type:Periodic Company Report #WAES 0202USA01735
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lipitor	C				
			Procardia Xl	C				
			Tricor	C				

Date:03/28/02ISR Number: 3923335-5Report Type:Periodic Company Report #WAES 0112USA02281
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923336-7Report Type:Periodic Company Report #WAES 0202USA01736
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperkalaemia	Health Professional	Tab Vioxx 25 Mg Diuretic (Unspecified)	PS C		ORAL	25 MG/BID/PO	

Date:03/28/02ISR Number: 3923337-9Report Type:Periodic Company Report #WAES 0112USA02295
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923338-0Report Type:Periodic Company Report #WAES 0202USA01747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923339-2Report Type:Periodic Company Report #WAES 0112USA02520
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Almodet (Methyldopate Hydrochloride)	C				
			Axid	C				
			Trileptal	C				
			Wellbutrin	C				
			Clonazepam	C				
			Cyclobenzaprine Hydrochloride	C				
			Ibuprofen	C				
			Nortriptyline	C				
			Trazodone	C				

Date:03/28/02ISR Number: 3923340-9Report Type:Periodic Company Report #WAES 0112USA02525
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Diovan Hct	C				
			Estratest	C				
			Lipitor	C				
			Prilosec	C				

Date:03/28/02ISR Number: 3923341-0Report Type:Periodic Company Report #WAES 0112USA02312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Herpetiformis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY, PO	
			Prempro	C				
			Synthroid	C				
			Toprol Xl Tabelts	C				
			Zocor	C				
			Aspirin	C				
			Folic Acid	C				
			Isosorbide	C				

Date:03/28/02ISR Number: 3923342-2Report Type:Periodic Company Report #WAES 0112USA02313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Protonix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923343-4Report Type:Periodic Company Report #WAES 0112USA02314
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Gastric Neoplasm	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
	Gastrooesophageal Reflux Disease	Professional					PO	
			Avapro	C				
			Prilosec	C				
			Synthroid	C				
			Zocor	C				

Date:03/28/02ISR Number: 3923344-6Report Type:Periodic Company Report #WAES 0112USA02348
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:03/28/02ISR Number: 3923345-8Report Type:Periodic Company Report #WAES 0112USA02352
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY,	
	Dyspepsia	Professional					PO	
	Nausea							

Date:03/28/02ISR Number: 3923346-XReport Type:Periodic Company Report #WAES 0112USA02384
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:03/28/02ISR Number: 3923347-1Report Type:Periodic Company Report #WAES 0112USA02455
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY,	
	Chest Pain	Health					PO	
	Diarrhoea	Professional	Buspar	C				
	Dizziness		Lamisil	C				
	Dyspnoea							
	Nausea							
	Pharyngeal Oedema							
	Pruritus							
	Urticaria							

Date:03/28/02ISR Number: 3923348-3Report Type:Periodic Company Report #WAES 0112USA02464
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Abdominal Pain	Health					MG/DAILY/PO	
	Flatulence	Professional	Ambien	C				
	Laboratory Test Abnormal		Avandia	C				

Coumadin	C
Glucotrol Xl	C
Hydrodiuril	C
Lipitor	C
Neurontin	C
Protonix	C
Toprol Xl Tablets	C
Zestril	C

Date:03/28/02ISR Number: 3923349-5Report Type:Periodic Company Report #WAES 0112USA02713
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Bullous	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Pruritus	Professional						
	Rash	Company						
	Skin Disorder	Representative						

Date:03/28/02ISR Number: 3923350-1Report Type:Periodic Company Report #WAES 0112USA02766
Age:65 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Flatulence							
	Insomnia		Buspar	C				
	Musculoskeletal Stiffness		Nexium	C				
	Upper Respiratory Tract Infection		Xanax	C				

Date:03/28/02ISR Number: 3923351-3Report Type:Periodic Company Report #WAES 0112USA02484
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO ;	

25 MG/PO

		Celebrex	C
		Aspirin	C

Date:03/28/02ISR Number: 3923352-5Report Type:Periodic Company Report #WAES 0112USA02486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstrual Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923353-7Report Type:Periodic Company Report #WAES 0112USA02493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder	Professional	Celebrex	C				
	Oedema Peripheral		Zyprexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923354-9Report Type:Periodic Company Report #WAES 0112USA02494
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Aspartate Aminotransferase Increased		Nexium	C				
	Gastrooesophageal Reflux Disease							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Night Sweats							
	Oedema Peripheral							
	Pain							
	Pyrexia							
	Weight Increased							

Date:03/28/02ISR Number: 3923355-0Report Type:Periodic Company Report #WAES 0112USA02496
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY/PO	3 DAY
			Plavix	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3923356-2Report Type:Periodic Company Report #WAES 0112USA02498
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923357-4Report Type:Periodic Company Report #WAES 0112USA02504
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923358-6Report Type:Periodic Company Report #WAES 0112USA02507
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							
			Tab Fosamax 10 Mg	SS		ORAL	10 MG/DAILY/PO	
			Lipitor 10 Mg	SS			10 MG/ DAILY	
			Premarin	C				
			Provera	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923367-7Report Type:Periodic Company Report #WAES 0201USA00518
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Flatulence							
			Lipitor	C				
			Lotrel	C				
			Persantine	C				
			Premarin	C				
			Prilosec	C				

Date:03/28/02ISR Number: 3923368-9Report Type:Periodic Company Report #WAES 0201USA00521
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Coumadin	C				

Date:03/28/02ISR Number: 3923370-7Report Type:Periodic Company Report #WAES 0201USA00529
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923371-9Report Type:Periodic Company Report #WAES 0201USA00391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Disorder	Professional						

Date:03/28/02ISR Number: 3923372-0Report Type:Periodic Company Report #WAES 0201USA00431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
			Asacol	C				
			Bentyl	C				
			Fosamax	C				
			Miacalcin	C				
			Plaquenil	C				
			Premarin	C				
			Ultram	C				
			Verapamil	C				

Date:03/28/02ISR Number: 3923373-2Report Type:Periodic Company Report #WAES 0201USA00434
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertrophy Breast							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923374-4Report Type:Periodic Company Report #WAES 0201USA00447
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Discolouration	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923375-6Report Type:Periodic Company Report #WAES 0201USA00465
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:03/28/02ISR Number: 3923376-8Report Type:Periodic Company Report #WAES 0201USA00470
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
			Doryx	C				
			Lachydrin	C				
			Maxzide	C				
			Prilosec	C				
			Zocor	C				

Date:03/28/02ISR Number: 3923489-0Report Type:Periodic Company Report #WAES 0201USA00630
Age:56 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Vioxx	PS			ORAL
25							
MG/DAILY/PO							
			Accupril	C			
			Norvasc	C			
			Hydrochlorothiazide (+) Triamter	C			
			Metoprolol	C			

Date:03/28/02ISR Number: 3923491-9Report Type:Periodic Company Report #WAES 0201USA00634
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Movement Disorder	Health Professional	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923492-0Report Type:Periodic Company Report #WAES 0201USA00648
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Feeling Cold							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923494-4Report Type:Periodic Company Report #WAES 0201USA00651
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Vioxx	PS		ORAL	PO	
	Depression	Health	Lortab	C				
	Dyskinesia Oesophageal	Professional	Ultram	C				
	Gastrooesophageal Reflux Disease							

Date:03/28/02ISR Number: 3923495-6Report Type:Periodic Company Report #WAES 0201USA00502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Urine	Consumer	Tab Vioxx	PS		ORAL	25	
	Increased						MG/DAILY/PO	4 WK
			Atenolol	C	Msd			
			Ativan	C				
			Remeron	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:03/28/02ISR Number: 3923496-8Report Type:Periodic Company Report #WAES 0201USA00504
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Vioxx	PS		ORAL	12.5	
	Rash						MG/DAILY/PO	
	Urine Abnormality		Flonase	C				
			Fosamax	C				

Date:03/28/02ISR Number: 3923498-1Report Type:Periodic Company Report #WAES 0201USA00508
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Muscular Weakness							
	Syncope							

Date:03/28/02ISR Number: 3923499-3Report Type:Periodic Company Report #WAES 0201USA00509
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS		ORAL	PO	
	Diarrhoea		Lanoxin	C				
			Tylenol	C				
			Vasotec	C				

Date:03/28/02ISR Number: 3923501-9Report Type:Periodic Company Report #WAES 0201USA00510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	SEE IMAGE	
			Gastrointestinal Preparations	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923503-2Report Type:Periodic Company Report #WAES 0201USA00516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Nasal Polyps							

Date:03/28/02ISR Number: 3923506-8Report Type:Periodic Company Report #WAES 0202USA01357
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/PO	
	Vaginal Ulceration							
			Lipitor	C				
			Synthroid	C				
			Tenormin	C				

Date:03/28/02ISR Number: 3923507-XReport Type:Periodic Company Report #WAES 0202USA01399
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 WK
	Nausea							
	Somnolence		Orsu Vioxx 25 Mg	SS		ORAL	25 MG/ DAILY/PO	
			Synthroid	C				
			Pilocarpine	C				
			Protein	C				

Date:03/28/02ISR Number: 3923508-1Report Type:Periodic Company Report #WAES 0202USA01404
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Oedema Peripheral	Professional					PO	2 WK
			Hydro-Diuril	C				

Date:03/28/02ISR Number: 3923509-3Report Type:Periodic Company Report #WAES 0202USA01405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Consumer	Vioxx	PS		ORAL	12.5 MG/	
	Phosphokinase Increased						DAILY/ PO	

Date:03/28/02ISR Number: 3923510-XReport Type:Periodic Company Report #WAES 0202USA01406
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923511-1Report Type:Periodic Company Report #WAES 0202USA01407
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Vioxx	PS		ORAL	25 MG/ DAILY/ PO	

Date:03/28/02ISR Number: 3923512-3Report Type:Periodic Company Report #WAES 0202USA01420
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx	PS		ORAL	PO	
	Urticaria		Premarin	C				
			Provera	C				

Date:03/28/02ISR Number: 3923513-5Report Type:Periodic Company Report #WAES 0202USA01432
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health Professional	Vioxx	PS		ORAL	25 MG/ DAILY/ PO	
	Hypersensitivity							
	Weight Increased		Persantine	C				
			Hydroxyurea	C				

Date:03/28/02ISR Number: 3923514-7Report Type:Periodic Company Report #WAES 0202USA01459
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	PO	
			Celebrex	C				
			Claritin	C				

				Cutivate	C	
				Lipitor	C	
				Paxil	C	
				Prinivil	C	
				Alprazolam	C	
				Ranitidine	C	

Date:03/28/02ISR Number: 3923515-9Report Type:Periodic Company Report #WAES 0202USA01165
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Vioxx	PS		ORAL	12.5 MG/ BID/ PO; 12.5 MG/DAILY/PO; 25 MG/PO	18 MON
	Back Pain							
			Cardizem	C				
			Diovan	C				
			Zyloprim	C				

Date:03/28/02ISR Number: 3923526-3Report Type:Periodic Company Report #WAES 0202USA01169
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Covera-Hs	C				

		Flonase	C
		Levoxyl	C
		Lipitor	C
		Paxil	C
		Prempro	C
		Prevacid	C
		Temazepam	C

Date:03/28/02ISR Number: 3923527-5Report Type:Periodic Company Report #WAES 0202USA01212
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923528-7Report Type:Periodic Company Report #WAES 0202USA01214
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Skin Disorder							
	Vision Blurred		Anusol-Hc 2.5% Cream	C				
			Lipitor	C				
			Isosorbide Mononitrate	C				
			Metoprolol Tartrate	C				

Date:03/28/02ISR Number: 3923529-9Report Type:Periodic Company Report #WAES 0202USA01216
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	MG/UNK/PO	
			Augmentin	C				

			Ceftin	C
			Paxil	C
			Nortriptyline	C
			Prednisone	C

Date:03/28/02ISR Number: 3923530-5Report Type:Periodic Company Report #WAES 0202USA01247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	

Date:03/28/02ISR Number: 3923531-7Report Type:Periodic Company Report #WAES 0202USA01268
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Centrum Silver	C				
			Ecotrin	C				

Date:03/28/02ISR Number: 3923532-9Report Type:Periodic Company Report #WAES 0202USA01269
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923533-0Report Type:Periodic Company Report #WAES 0202USA01292
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Dyspepsia						; 25	
	Headache						MG/DAILY/PO	
	Movement Disorder		Fibercon	C				
	Nausea		Premarin	C				
			Synthroid	C				
			Atenolol	C				
			Vitamin D (Unspecified)	C				

Date:03/28/02ISR Number: 3923534-2Report Type:Periodic Company Report #WAES 0202USA01293
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg / 25 Mg	PS		ORAL	12.5 MG/DAILY/PO ; 25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923535-4Report Type:Periodic Company Report #WAES 0202USA01333
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health	Tab Vioxx	PS		ORAL	DAILY/PO	
	Gastrointestinal Haemorrhage	Professional Company Representative						

Date:03/28/02ISR Number: 3923563-9Report Type:Periodic Company Report #WAES 0202USA01106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	4 DAY
	Dyspepsia							
			Diovan	C				
			Premarin	C				
			Synthroid	C				
			Clonidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923564-0Report Type:Periodic Company Report #WAES 0202USA01112
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Celebrex	C				

Date:03/28/02ISR Number: 3923565-2Report Type:Periodic Company Report #WAES 0202USA01118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional	Aspirin	SS				

Date:03/28/02ISR Number: 3923566-4Report Type:Periodic Company Report #WAES 0202USA01122
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
	Rash							

Date:03/28/02ISR Number: 3923567-6Report Type:Periodic Company Report #WAES 0202USA01127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional						

Date:03/28/02ISR Number: 3923568-8Report Type:Periodic Company Report #WAES 0202USA01135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	3 DAY
	Mouth Haemorrhage		Aldomet (Methydopa)	C				
	Pain		Azmacort	C				
			Paxil	C				
			Trazodone	C				

Date:03/28/02ISR Number: 3923569-XReport Type:Periodic Company Report #WAES 0202USA01140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urine Abnormality	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Tylenol	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923570-6Report Type:Periodic Company Report #WAES 0202USA01147
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epididymitis	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	5 DAY

Date:03/28/02ISR Number: 3923571-8Report Type:Periodic Company Report #WAES 0202USA01149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923572-XReport Type:Periodic Company Report #WAES 0202USA01161
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Haematochezia							
			Premarin	C				

Date:03/28/02ISR Number: 3923585-8Report Type:Periodic Company Report #WAES 01102406
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:03/28/02ISR Number: 3923586-XReport Type:Periodic Company Report #WAES 01102191
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ecchymosis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923587-1Report Type:Periodic Company Report #WAES 01102284
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	30 DAY
		Health Professional	Ultram	C				

Date:03/28/02ISR Number: 3923588-3Report Type:Periodic Company Report #WAES 01102333
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Valtrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923589-5Report Type:Periodic Company Report #WAES 01102392
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Levoxyl	C				
			Lotrel	C				

Date:03/28/02ISR Number: 3923590-1Report Type:Periodic Company Report #WAES 01102399
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Gastrointestinal Disorder						MG/DAILY/PO	
	Nausea		Tylenol With Codeine #3	C				

Date:03/28/02ISR Number: 3923592-5Report Type:Periodic Company Report #WAES 01103297
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Diarrhoea	Health					MG/DAILY/PO	
	Nausea	Professional						

Date:03/28/02ISR Number: 3923594-9Report Type:Periodic Company Report #WAES 01103333
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pigmentation Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health	Monopril	C				

Professional

Date:03/28/02ISR Number: 3923596-2Report Type:Periodic Company Report #WAES 01103343
Age:74 YR Gender:Not SpecifiI/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Synthroid	C				

Date:03/28/02ISR Number: 3923599-8Report Type:Periodic Company Report #WAES 01104374
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Malaise	Professional					MG/DAILY/PO	5 DAY
			Atarax	C				
			Dilantin	C				
			Elocon	C				
			Neurontin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923602-5Report Type:Periodic Company Report #WAES 01100783
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspnoea	Health					MG/DAILY/PO	
	Pruritus	Professional	Norvasc	C				
	Urticaria							

Date:03/28/02ISR Number: 3923604-9Report Type:Periodic Company Report #WAES 01100810
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Health	Tab Vioxx 12.5 Mg	PS			12.5; 25	
	Anxiety	Professional					MG/DAILY/PO	
	Insomnia	Company	Lipitor	C				
	Photopsia	Representative	Norvasc	C				

Date:03/28/02ISR Number: 3923608-6Report Type:Periodic Company Report #WAES 01100836
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:03/28/02ISR Number: 3923610-4Report Type:Periodic Company Report #WAES 01092843
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	

Date:03/28/02ISR Number: 3923612-8Report Type:Periodic Company Report #WAES 01092874
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Professional					MG/DAILY/PO	
	Rash	Other	Lipitor	C				
			Medrol	C				
			Norvasc	C				
			Plaquenil	C				

Date:03/28/02ISR Number: 3923616-5Report Type:Periodic Company Report #WAES 01093034
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Confusional State						MG/DAILY/PO	
	Fatigue		Bentyl	C				
	Memory Impairment		Lipitor	C				
	Oedema Peripheral		Tagamet	C				
	Somnolence		Insulin	C				
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923618-9Report Type:Periodic Company Report #WAES 01093054
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
		Health Professional	Diovan	C				
			Ortho-Prefest	C				
			Prozac	C				

Date:03/28/02ISR Number: 3923620-7Report Type:Periodic Company Report #WAES 01093170
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5; 25	
	Pain	Health Professional					MG/DAILY/PO	
			Claritin	C				
			Prozac	C				
			Estrogens (Unspecified)	C				

Date:03/28/02ISR Number: 3923621-9Report Type:Periodic Company Report #WAES 01100009
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923623-2Report Type:Periodic Company Report #WAES 01100061
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Flushing	Health				
MG/DAILY/PO						
		Professional	Dovonex	C		
			Haley'S M-O	C		
			Hydrodiuril	C		
			Synthroid	C		
			Topamax	C		
			Zocor	C		
			Clobetasol Propionate	C		
			Estrogens (Unspecified)	C		

Date:03/28/02ISR Number: 3923625-6Report Type:Periodic Company Report #WAES 0201USA00692
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Actos	C		
			Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923626-8Report Type:Periodic Company Report #WAES 0201USA00716
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	PO	
	Abdominal Pain		Cap Celebrex	SS		ORAL	PO	
	Erosive Oesophagitis							
	Weight Decreased							

Date:03/28/02ISR Number: 3923627-XReport Type:Periodic Company Report #WAES 0201USA00722
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:03/28/02ISR Number: 3923629-3Report Type:Periodic Company Report #WAES 0201USA00723
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Antimicrobial	C				
		Company						
		Representative						

Date:03/28/02ISR Number: 3923631-1Report Type:Periodic Company Report #WAES 0201USA00753
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

MG/DAILY/PO

Adalat	C
Plavix	C
Zocor	C
Ascorbic Acid	C
Vitamin E	C

Date:03/28/02ISR Number: 3923633-5Report Type:Periodic Company Report #WAES 0201USA00534
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923634-7Report Type:Periodic Company Report #WAES 0201USA00589
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pneumonia							

Diovan	C
Synthroid	C
Bumetanide	C
Estradiol	C
Ranitidine	

				Hydrochloride	C		

Date:03/28/02ISR Number: 3923636-0Report Type:Periodic Company Report #WAES 0201USA00591
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Aricept	C				
			Effexor	C				
			Prilosec	C				
			Ginkgo Biloba Extract	C				
			Glucosamine	C				
			Linseed Oil	C				
			Vitamin E	C				

Date:03/28/02ISR Number: 3923637-2Report Type:Periodic Company Report #WAES 0201USA00612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS				DAILY
			Ambien	C				
			Celexa	C				
			Plavix	C				
			Premarin	C				
			Prilosec	C				
			Soma	C				
			Toprol Xl Tablets	C				
			Valium	C				
			Zestril	C				
			Oxybutynin Chloride	C				

Date:03/28/02ISR Number: 3923639-6Report Type:Periodic Company Report #WAES 0201USA00624
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional	Lescol	C				
			Premarin	C				
			Zoloft	C				

Date:03/28/02ISR Number: 3923655-4Report Type:Periodic Company Report #WAES 0201USA00890
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
			Ambien	C				
			Flonase	C				
			Guaifed	C				
			Levoxyl	C				
			Zithromax	C				
			Clonazepam	C				
			Estradiol	C				
			Sodium Fluoride	C				

Date:03/28/02ISR Number: 3923677-3Report Type:Periodic Company Report #WAES 0201USA00892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923679-7Report Type:Periodic Company Report #WAES 0201USA00914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	PO
			Tab Vioxx 25 Mg	SS		ORAL	25 MG/ QOD/	PO
			Aspirin	C				
			Calcium	C				
			Garlic Extract	C				
			Vitamins	C				

Date:03/28/02ISR Number: 3923682-7Report Type:Periodic Company Report #WAES 0201USA00915
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	PO
		Health Professional	Alrex	C				
			Corgard	C				
			Dilantin	C				
			Dyazide	C				
			Lipitor	C				

			Norvasc	C		
			Prinivil	C		
			Synthroid	C		
			Ferrous Gluconate	C		

Date:03/28/02ISR Number: 3923683-9Report Type:Periodic Company Report #WAES 0201USA00653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diverticulum Intestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Gastrointestinal						PO	
	Haemorrhage		Norvasc	C				
			Prilosec	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3923686-4Report Type:Periodic Company Report #WAES 0201USA00655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
							PO	
			Diovan	C				
			Lipitor	C				
			Prilosec	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923689-XReport Type:Periodic Company Report #WAES 0201USA00667
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	50 MG/ DAILY/	
	Hair Disorder	Health Professional	Tab Vioxx	SS		ORAL	50 MG/ PRN/	
			Prempro	C				

Date:03/28/02ISR Number: 3923691-8Report Type:Periodic Company Report #WAES 0201USA00675
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923694-3Report Type:Periodic Company Report #WAES 0201USA00691
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	

Date:03/28/02ISR Number: 3923697-9Report Type:Periodic Company Report #WAES 01090823
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional	Celebrex	C		

Date:03/28/02ISR Number: 3923699-2Report Type:Periodic Company Report #WAES 01090924
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Myalgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO; 25 MG						
		Health				
DAILY PO						
		Professional	Norvasc	C		
			Calcium (Unsepecified)	C		
			Vitamins (Unspecified)	C		

Date:03/28/02ISR Number: 3923701-8Report Type:Periodic Company Report #WAES 01081268
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Swelling	Health	Tab Vioxx 25 Mg	PS		ORAL
24 MG DAILY						
		Professional				
PO						
			Allegra	C		
			Allegra-D	C		
			Levaquin	C		
			Nolvadex	C		
			Zocor	C		
			Nitrofurantoin	C		

			Nortriptyline	C
			Verapamil	C

Date:03/28/02ISR Number: 3923703-1Report Type:Periodic Company Report #WAES 01081332
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PRN PO;	
	Blood Pressure Increased	Health					50 MG PRN PO	
	Oedema Peripheral	Professional	Cardura	C				
	Peripheral Vascular Disorder		Fosamax	C				
			Ventolin	C				
			Xanax	C				
			Calcium (Unspecified)	C				
			Indapamide	C				
			Vitamin E	C				

Date:03/28/02ISR Number: 3923704-3Report Type:Periodic Company Report #WAES 0202USA02016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3923705-5Report Type:Periodic Company Report #WAES 01081508
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Myalgia	Health						
	Oedema Peripheral	Professional						

Pruritus
Rash
Stasis Dermatitis
Weight Increased

Date:03/28/02ISR Number: 3923707-9Report Type:Periodic Company Report #WAES 0202USA01764
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema							
	Weight Increased		Diurite	C				
			Flexeril	C				
			Norvasc	C				
			Clonazepam	C				

Date:03/28/02ISR Number: 3923708-0Report Type:Periodic Company Report #WAES 01081554
Age:76 YR Gender:Male I/FU:F

Outcome PT
Fluid Retention
Oedema Peripheral

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	PO
			Hyzaar	C				
			Librax Capsules	C				
			Lipitor	C				
			Norvasc	C				
			Pepcid	C				
			Prandin	C				
			Tambocor	C				
			Tenormin	C				

Date:03/28/02ISR Number: 3923709-2Report Type:Periodic Company Report #WAES 0202USA01777
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923710-9Report Type:Periodic Company Report #WAES 01081639
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Oedema Peripheral						PO	
			Catapres	C				
			Chondroitin (+) Glucosamine	C				

Date:03/28/02ISR Number: 3923711-0Report Type:Periodic Company Report #WAES 0202USA01778
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	

Date:03/28/02ISR Number: 3923712-2Report Type:Periodic Company Report #WAES 01082021
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
		Health					PO	
		Professional	Prinivil	C				
			Calcium (Unspecified)	C				

Date:03/28/02ISR Number: 3923714-6Report Type:Periodic Company Report #WAES 0202USA01784
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Musculoskeletal Chest						MG/DAILY/PO	
	Pain		Cozaar	C				
			Effexor	C				
			Exelon	C				

			Norvasc	C		
			Synthroid	C		
			Isosorbide Mononitrate	C		

Date:03/28/02ISR Number: 3923715-8Report Type:Periodic Company Report #WAES 01082306
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Actos	C				
			Glucophage	C				
			Lsecol	C				

Date:03/28/02ISR Number: 3923716-XReport Type:Periodic Company Report #WAES 0202USA01801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Zyprexa	C				

Date:03/28/02ISR Number: 3923717-1Report Type:Periodic Company Report #WAES 01082339
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
	Pruritus	Health						
	Rash	Professional	Amaryl	C				
			Avandia	C				
			Evista	C				

Levbid	C
Lufyllin Gg	C
Zocor	C
Allopurinol	C

Date:03/28/02ISR Number: 3923719-5Report Type:Periodic Company Report #WAES 01103282
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia	Health Professional	Femhrt	C				

Date:03/28/02ISR Number: 3923720-1Report Type:Periodic Company Report #WAES 01103242
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923722-5Report Type:Periodic Company Report #WAES 01103231
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness	Other						
	Dyspepsia		Flovent	C				
	Hypersomnia		Ventilan (Albuterol)	C				
	Insomnia							
	Nausea							

Date:03/28/02ISR Number: 3923724-9Report Type:Periodic Company Report #WAES 01103196
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dyspnoea	Professional						
			Hydrodiuril	C				
			Tiazac	C				
			Pancrelipase	C				
			Potassium Chloride	C				

Date:03/28/02ISR Number: 3923725-0Report Type:Periodic Company Report #WAES 01103043
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chills	Health						
	Hyperaesthesia	Professional	Advil	C				
	Malaise		Aricept	C				
	Movement Disorder		Nexium	C				
	Oedema Peripheral		Aspirin	C				
	Palmar Erythema							

Date:03/28/02ISR Number: 3923727-4Report Type:Periodic Company Report #WAES 01102890
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923728-6Report Type:Periodic Company Report #WAES 0202USA01802
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923729-8Report Type:Periodic Company Report #WAES 01104747
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Haemorrhage	Health						
	Gastric Ulcer	Professional	Celebrex	SS				
	Weight Decreased		Zestril	C				

Date:03/28/02ISR Number: 3923730-4Report Type:Periodic Company Report #WAES 0202USA01807
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
			Flomax (Morniflumate)	C				
			Nexium	C				
			Proscar	C				
			Zocor	C				
			Atenolol	C				
			Nitroglycerin	C				

Date:03/28/02ISR Number: 3923731-6Report Type:Periodic Company Report #WAES 01104752
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Drug Ineffective		Composition Unspecified	C				

Date:03/28/02ISR Number: 3923733-XReport Type:Periodic Company Report #WAES 01104775
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Hypertension	Health					MG/DAILY/PO	
	Muscle Spasms	Professional	Lipitor	C				

Date:03/28/02ISR Number: 3923734-1Report Type:Periodic Company Report #WAES 0202USA01818
Age:59 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Dyazide	C				
			Evista	C				
			Atenolol	C				
			Glucosamine	C				

Date:03/28/02ISR Number: 3923735-3Report Type:Periodic Company Report #WAES 01104779
Age:40 YR Gender:Male I/FU:F

Outcome	PT
	Blood Pressure Increased
	Dizziness
	Dyspnoea

Feeling Abnormal
Headache
Musculoskeletal Stiffness

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923736-5Report Type:Periodic Company Report #WAES 0202USA01898
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	6 WK

Date:03/28/02ISR Number: 3923743-2Report Type:Periodic Company Report #WAES 01092677
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY PO	
	Anorexia	Health Professional						
	Nausea							

Date:03/28/02ISR Number: 3923744-4Report Type:Periodic Company Report #WAES 01092656
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Visual Disturbance							

Date:03/28/02ISR Number: 3923745-6Report Type:Periodic Company Report #WAES 01092640
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
			Lipitor	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923747-XReport Type:Periodic Company Report #WAES 01092391
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
			Allegra	C				
			Dyazide	C				
			Premarin	C				
			Prilosec	C				

Date:03/28/02ISR Number: 3923748-1Report Type:Periodic Company Report #WAES 01092330
Age:53 YR Gender:Female I/FU:F

Outcome	PT
	Oedema Peripheral
	Pain

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Health Professional					PO, 50 MG DAILY PO	
	Beconase	C				
	Climara	C				
	Premarin	C				
	Relafen	C				
	Serevent	C				
	Vancenase	C				
	Zomig	C				
	Zyrtec	C				

Date:03/28/02ISR Number: 3923750-XReport Type:Periodic Company Report #WAES 01092193
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Health Professional					PO	
			Atrovent	C				
			Azmacort	C				
			Cozaar	C				
			Prevacid	C				
			Zocor	C				
			Albuterol	C				
			Aspirin	C				
			Trazodone	C				

Date:03/28/02ISR Number: 3923754-7Report Type:Periodic Company Report #WAES 01100120
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25 MG DAILY
	Oedema Peripheral	Health				PO
		Professional	Glucophage	C		
			Glynase Prestab Tablets	C		
			Ismo	C		
			Lopid	C		
			Pletal	C		
			Prilosec	C		
			Prinivil	C		
			Toprol Xl Tablets	C		

Date:03/28/02ISR Number: 3923757-2Report Type:Periodic Company Report #WAES 01100256
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polymyalgia Rheumatica	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY PO, 25 MG DAILY PO	
		Health						
		Professional	Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923760-2Report Type:Periodic Company Report #WAES 01100318
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia	Health Professional						

Date:03/28/02ISR Number: 3923764-XReport Type:Periodic Company Report #WAES 01106188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Diarrhoea	Health Professional	Composition Unspecified	C				
	Drug Ineffective							
	Dyspepsia							

Date:03/28/02ISR Number: 3923767-5Report Type:Periodic Company Report #WAES 01106179
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lactation Disorder	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
			Ortho Tri Cyclen	C				

Date:03/28/02ISR Number: 3923768-7Report Type:Periodic Company Report #WAES 01104798
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Drug Ineffective							
	Flushing		Hyzaar	C				
			Nexium	C				

Tazobac	C
Tranxene	C
Ultram	C
Methotrexate	C
Prednisone	C

Date:03/28/02ISR Number: 3923771-7Report Type:Periodic Company Report #WAES 01104792
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Codeine	C				

Date:03/28/02ISR Number: 3923773-0Report Type:Periodic Company Report #WAES 01104787
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Diverticulum Intestinal	Health Professional						
	Lactose Intolerance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923774-2Report Type:Periodic Company Report #WAES 01110339
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Prilosec	C				
			Xanax	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923776-6Report Type:Periodic Company Report #WAES 01110426
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Celebrex	C				

Date:03/28/02ISR Number: 3923777-8Report Type:Periodic Company Report #WAES 01110435
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	

Date:03/28/02ISR Number: 3923778-XReport Type:Periodic Company Report #WAES 01110495
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abnormal Dreams	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25
	Headache	Health				MG/DAILY/PO
	Weight Increased	Professional				

Date:03/28/02ISR Number: 3923779-1Report Type:Periodic Company Report #WAES 01110658
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3923780-8Report Type:Periodic Company Report #WAES 01101842
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923782-1Report Type:Periodic Company Report #WAES 01110294
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG	
	Fatigue	Professional					DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3923783-3Report Type:Periodic Company Report #WAES 01110221
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS		ORAL	25	
	Drug Ineffective	Professional					MG/DAILY/PO	
	Oedema Peripheral		Aciphex	C				
			Allegra	C				
			Arava	C				
			Leucovorin	C				
			Alprazolam	C				
			Carisoprodol	C				
			Furosemide	C				
			Quinine Sulfate	C				

Date:03/28/02ISR Number: 3923784-5Report Type:Periodic Company Report #WAES 01102050
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY	
	Oedema Peripheral	Professional					PO	
			Celebrex	C				
			Neurontin	C				
			Nonsteroidal Anti-Inflammatory D	C				

Date:03/28/02ISR Number: 3923785-7Report Type:Periodic Company Report #WAES 01102084
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx 25mg	PS		ORAL	DAILY PO	
	Polymyalgia Rheumatica	Professional	Synthroid	C				
	Temporal Arteritis		Calcium	C				

Date:03/28/02ISR Number: 3923786-9Report Type:Periodic Company Report #WAES 01100332
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Consumer	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Disorder							
	Oedema Peripheral							

Date:03/28/02ISR Number: 3923787-0Report Type:Periodic Company Report #WAES 01100356
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Blood Pressure Increased	Consumer
	Oedema Peripheral	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25mg	PS		ORAL	25-50MG PRN	PO
Premarin	C				
Synthroid	C				
Aspirin	C				
Triamterene	C				

Date:03/28/02ISR Number: 3923788-2Report Type:Periodic Company Report #WAES 01110038
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease	Health	Vioxx	PS		ORAL	PO	
	Mouth Ulceration	Professional						
	Oral Mucosal Discolouration	Company Representative						
	Pain							

Date:03/28/02ISR Number: 3923790-0Report Type:Periodic Company Report #WAES 01100357
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
		Health	Tab Vioxx	SS		ORAL	PO	
		Professional	Vitamins Unspecified	C				

Date:03/28/02ISR Number: 3923791-2Report Type:Periodic Company Report #WAES 01110768
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthenia	Consumer	Tab Vioxx	PS		ORAL
50 MG PO						
	Fatigue	Health	Advair	C		
	Nausea	Professional	Estratest	C		
	Pruritus		Ms Contin	C		
			Neurontin	C		
			Norco	C		
			Prevacid	C		
			Prozac	C		
			Singulair	C		
			Wellbutrin	C		
			Albuterol	C		
			Lorazepam	C		
			Trazodone	C		

Date:03/28/02ISR Number: 3923793-6Report Type:Periodic Company Report #WAES 01100416
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Urinary Tract Infection	Consumer	Tab Vioxx 25mg	PS		ORAL
PO						
		Health	Aciphex	C		
		Professional	Miacalcin	C		
			Toprol Xl	C		
			Tylenol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923794-8Report Type:Periodic Company Report #WAES 01100462
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Influenza Like Illness	Professional						
	Malaise							
	Pulmonary Congestion							

Date:03/28/02ISR Number: 3923796-1Report Type:Periodic Company Report #WAES 01100660
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Phlebitis	Health	Tab Vioxx	PS			PO	
		Professional						
		Company						
		Representative						

Date:03/28/02ISR Number: 3923797-3Report Type:Periodic Company Report #WAES 01100732
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Health	Ziac	C				
		Professional	Triamterene	C				

Date:03/28/02ISR Number: 3923799-7Report Type:Periodic Company Report #WAES 01101263
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
		Professional						
							MG/DAILY/PO	

		Company Representative	Tab Vioxx 25 Mg	SS			ORAL 25 MG/DAILY/PO
			Tab Vioxx 12.5 Mg	SS			ORAL 12.5 MG/DAILY/PO

Date:03/28/02ISR Number: 3923801-2Report Type:Periodic Company Report #WAES 01101336
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Hypertension		Acton	C				
	Oedema		Demadex	C				
			Depakote	C				
			Prazil	C				

Date:03/28/02ISR Number: 3923803-6Report Type:Periodic Company Report #WAES 01101623
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Change Of Bowel Habit							
	Diarrhoea							

Date:03/28/02ISR Number: 3923804-8Report Type:Periodic Company Report #WAES 01110770
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923806-1Report Type:Periodic Company Report #WAES 01110824
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urine Abnormality	Health Professional	Glyburide	C				

Date:03/28/02ISR Number: 3923807-3Report Type:Periodic Company Report #WAES 01101672
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	International Normalised Ratio Increased	Professional Company Representative						

Date:03/28/02ISR Number: 3923810-3Report Type:Periodic Company Report #WAES 01110842
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health						

		Professional	Glucosamine	C
			Naproxen	C

Date:03/28/02ISR Number: 3923812-7Report Type:Periodic Company Report #WAES 01101797
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Medication Residue	Health Professional	Coumadin	C				
			Hydrodiuril	C				
			Valium	C				
			Calcium	C				
			Vitamins	C				

Date:03/28/02ISR Number: 3923813-9Report Type:Periodic Company Report #WAES 01110971
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Rash						PO	
		Company Representative	Zocor	C				

Date:03/28/02ISR Number: 3923816-4Report Type:Periodic Company Report #WAES 01101805
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accommodation Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cough							
	Ear Pain		Advair	C				

Date:03/28/02ISR Number: 3923817-6Report Type:Periodic Company Report #WAES 01111019
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG /DAILY /PO	
		Health						
		Professional	Imitrex	C				
			Ascorbic Acid	C				
			Herbs (Unspecified)`	C				
			Vitamin E	C				

Date:03/28/02ISR Number: 3923819-XReport Type:Periodic Company Report #WAES 01111029
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Epigastric Discomfort	Health						
	Fatigue	Professional						
	Flatulence							
	Nausea							

Date:03/28/02ISR Number: 3923820-6Report Type:Periodic Company Report #WAES 01101838
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
	Mental Disorder		Demerol	C				
			Hydrocortone	C				

Date:03/28/02ISR Number: 3923821-8Report Type:Periodic Company Report #WAES 01102571
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Drug Ineffective		Tab Vioxx Unk	SS		ORAL	PO	
	Ulcer		Aldactone	C				
	Upper Gastrointestinal		Plendil	C				
	Haemorrhage		Tylenol With Codeine	C				

Date:03/28/02ISR Number: 3923824-3Report Type:Periodic Company Report #WAES 01110750
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
		Health					PO, 25 MG	
		Professional					DAILY PO	
			Hydrodiuril	C				
			Zocor	C				
			Atenolol	C				

				Vitamins (Unspecified)	C		

Date:03/28/02ISR Number: 3923825-5Report Type:Periodic Company Report #WAES 01102674
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/BID/PO	

Date:03/28/02ISR Number: 3923827-9Report Type:Periodic Company Report #WAES 01110749
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
		Health Professional	Azulfidine	C				
			Betoptic	C				
			Morphine	C				
			Prednisone	C				
			Warfarin Sodium	C				

Date:03/28/02ISR Number: 3923828-0Report Type:Periodic Company Report #WAES 01102776
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

			Claritin-D	C
			Darvocet-N	C
			Flonase	C
			Fluocinonide	C

Date:03/28/02ISR Number: 3923831-0Report Type:Periodic Company Report #WAES 01111069
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hiatus Hernia	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG PO	
	Nausea Oesophagitis Vomiting	Health Professional	Altace	C				

Date:03/28/02ISR Number: 3923834-6Report Type:Periodic Company Report #WAES 01104570
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Health	Tab Vioxx	PS		ORAL	PO	
	Hallucination	Professional Company Representative	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923836-XReport Type:Periodic Company Report #WAES 01111252
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PRN PO	
	Oral Soft Tissue Disorder	Health Professional	Premarin	C				
	Pharyngeal Ulceration		Zantac	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923839-5Report Type:Periodic Company Report #WAES 01111275
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
		Company Representative						

Date:03/28/02ISR Number: 3923840-1Report Type:Periodic Company Report #WAES 01104609
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Climara	C				
			Flexeril	C				
			Norco	C				
			Prozac	C				
			Zocor	C				
			Furosemide	C				

Date:03/28/02ISR Number: 3923843-7Report Type:Periodic Company Report #WAES 01111394
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Health						
PO								
		Professional	Lortab	C				
			Levodopa	C				

Date:03/28/02ISR Number: 3923844-9Report Type:Periodic Company Report #WAES 01104528
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
MG/DAILY/PO								
		Professional	Coumadin	C				
			Levothroid	C				
			Neurontin	C				
			Zocor	C				
			Cyanocobalamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923847-4Report Type:Periodic Company Report #WAES 01111724
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Blood Pressure Increased	Health					PO; 12.5 MG;	
	Bradycardia	Professional					25 MG	
	Chest Pain		Nexium	C				
	Headache		Niaspan	C				
	Nausea		Norvasc	C				
	Vomiting		Synthroid	C				
			Bumetanide	C				

Date:03/28/02ISR Number: 3923850-4Report Type:Periodic Company Report #WAES 01104469
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Visual Disturbance	Health					MG/DAILY/PO	
		Professional	Synthroid	C				
			Zestoretic	C				

Date:03/28/02ISR Number: 3923851-6Report Type:Periodic Company Report #WAES 01111752
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3923853-XReport Type:Periodic Company Report #WAES 01111815
Age:34 YR Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Influenza Like Illness						PO	
			Flexeril	C				
			Vicodin Tablets	C				

Date:03/28/02ISR Number: 3923855-3Report Type:Periodic Company Report #WAES 01104464
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:03/28/02ISR Number: 3923857-7Report Type:Periodic Company Report #WAES 01104462
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923858-9Report Type:Periodic Company Report #WAES 01111853
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Clritin	C				
			Zocor	C				

Date:03/28/02ISR Number: 3923861-9Report Type:Periodic Company Report #WAES 01106201
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							

Date:03/28/02ISR Number: 3923863-2Report Type:Periodic Company Report #WAES 01112508
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lip Disorder	Health Company Representative	Tab Vioxx	PS		ORAL	PO	
	Mouth Ulceration							

Date:03/28/02ISR Number: 3923865-6Report Type:Periodic Company Report #WAES 01112625
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
	Hypersensitivity	Health	Prilosec	C				

	Labile Hypertension	Professional	Estrogens	C
			Propranolol	C

Date:03/28/02ISR Number: 3923866-8Report Type:Periodic Company Report #WAES 01106204
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Cartia (Diltiazem Hydrochloride)	C				
			Detrol La	C				
			Premarin	C				

Date:03/28/02ISR Number: 3923869-3Report Type:Periodic Company Report #WAES 01112639
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Palpitations	Health					MG/DAILY/PO	
		Professional	Protonix	C				

Date:03/28/02ISR Number: 3923871-1Report Type:Periodic Company Report #WAES 01106337
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Alesse	C				
			Effexor Xr	C				

Date:03/28/02ISR Number: 3923873-5Report Type:Periodic Company Report #WAES 01112702
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hair Disorder	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923874-7Report Type:Periodic Company Report #WAES 01106449
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Discharge	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923876-0Report Type:Periodic Company Report #WAES 01110036
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Nausea							

Date:03/28/02ISR Number: 3923877-2Report Type:Periodic Company Report #WAES 01112769
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Abdominal Pain	Health	Volmax 4 Mg	SS			4 MG/BID	
	Diarrhoea	Professional	Covera	C				
	Flatulence		Fosamax	C				
			Synthroid	C				
			Cimetidine Hydrochloride	C				

Date:03/28/02ISR Number: 3923880-2Report Type:Periodic Company Report #WAES 01114390
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923881-4Report Type:Periodic Company Report #WAES 0112USA02128
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
		Health Professional Company Representative						

Date:03/28/02ISR Number: 3923882-6Report Type:Periodic Company Report #WAES 99061831
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Pain		Hytrin	C				
	Vertigo		Lipitor	C				
			Prilosec	C				
			Zocor	C				
			Aspirin	C				

Date:03/28/02ISR Number: 3923898-XReport Type:Periodic Company Report #WAES 01113004
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Constipation						PO	
	Erythema		Prevacid	C				
	Pruritus							

Date:03/28/02ISR Number: 3923905-4Report Type:Periodic Company Report #WAES 01120090
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY PO	
	Tinnitus		Estring	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3923908-XReport Type:Periodic Company Report #WAES 01120091
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
			Isosorbide Dinitrate	C				
			Propranolol	C				

Date:03/28/02ISR Number: 3923910-8Report Type:Periodic Company Report #WAES 01120108
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Oedema							

Elavil	C
Lipitor	C
Synthroid	C
Atenolol	C
Hydrochlorothiazide (+) Triamter	C

Date:03/28/02ISR Number: 3923914-5Report Type:Periodic Company Report #WAES 01120115
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923915-7Report Type:Periodic Company Report #WAES 01120133
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Petechiae						PO	
			Lotensin	C				
			Ranitidine	C				
			Verapamil	C				

Date:03/28/02ISR Number: 3923919-4Report Type:Periodic Company Report #WAES 01120211
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cognitive Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Ineffective						PO	
			Allegra	C				

			Celebrex	C
			Synthroid	C
			Xalatan	C
			Etodolac	C

Date:03/28/02ISR Number: 3923920-0Report Type:Periodic Company Report #WAES 01120214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Health						
PO								
		Professional	Arthrotec	C				
			Pravachol	C				
			Voltaren	C				
			Diclofenac	C				
			Diuretic (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923923-6Report Type:Periodic Company Report #WAES 01120216
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO 4 DAY
			Advil	C				

Date:03/28/02ISR Number: 3923935-2Report Type:Periodic Company Report #WAES 01120228
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG PO	
	Back Pain		Glucophage	C				
	Dizziness		Glucotrol Xl	C				
	Fatigue		Levothroid	C				
	Nausea		Captopril	C				
	Urinary Tract Infection		Gemfibrozil	C				

Date:03/28/02ISR Number: 3923938-8Report Type:Periodic Company Report #WAES 0112USA02859
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celexa	C				

Date:03/28/02ISR Number: 3923941-8Report Type:Periodic Company Report #WAES 0112USA02871
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Swelling	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Weight Increased					
MG/DAILY/PO						
			Celebrex	C		

Date:03/28/02ISR Number: 3923942-XReport Type:Periodic Company Report #WAES 0112USA02527
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Celebrex	C		
			Coumadin	C		
			Esgic-Plus Tablet	C		
			Hydrodiuril	C		
			Uniximе	C		
			Sotalol Hydrochloride	C		
			Thyroid	C		

Date:03/28/02ISR Number: 3923943-1Report Type:Periodic Company Report #WAES 0112USA02569
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source
	Diarrhoea	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	150 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923945-5Report Type:Periodic Company Report #WAES 0112USA02633
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Headache		Atenolol	C				

Date:03/28/02ISR Number: 3923947-9Report Type:Periodic Company Report #WAES 0112USA02629
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:03/28/02ISR Number: 3923948-0Report Type:Periodic Company Report #WAES 0112USA02646
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Face Oedema		Verapamil Msd Lp	C				
	Headache		Imipramine	C				
	Oedema Peripheral		Triamterene	C				

Date:03/28/02ISR Number: 3923950-9Report Type:Periodic Company Report #WAES 0112USA02651
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	2 MON
			Accupril	C				

Date:03/28/02ISR Number: 3923952-2Report Type:Periodic Company Report #WAES 0112USA02664
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Lipitor	C				
			Premarin	C				

Date:03/28/02ISR Number: 3923955-8Report Type:Periodic Company Report #WAES 0112USA02680
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923962-5Report Type:Periodic Company Report #WAES 0201USA00924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Tremor		Norvasc	C				
			Premarin	C				
			Ultram	C				
			Thyroid	C				

Date:03/28/02ISR Number: 3923965-0Report Type:Periodic Company Report #WAES 0201USA00939
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Neurontin	C				
			Vasotec	C				

Date:03/28/02ISR Number: 3923967-4Report Type:Periodic Company Report #WAES 0201USA00941
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Eating Disorder							
	Gastritis		Accupril	C				
	Gastrointestinal Disorder		Atenolol	C				

Date:03/28/02ISR Number: 3923969-8Report Type:Periodic Company Report #WAES 0201USA00948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Breast Disorder	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25 MG/PO							
	Breast Pain		Cytotec	C			
			Lipitor	C			
			Atenolol	C			
			Astradiol	C			
			Hydrochlorothiazide				
			Triamter	C			

Date:03/28/02ISR Number: 3923971-6Report Type:Periodic Company Report #WAES 0201USA00965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Synthroid	C		
			Theophylline	C		

Date:03/28/02ISR Number: 3923972-8Report Type:Periodic Company Report #WAES 0201USA01012
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Lopressor Hct	C		
			Climicifuga	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923973-XReport Type:Periodic Company Report #WAES 0201USA01013
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dysgeusia							
			Allegra	C				
			Fosamax	C				
			Calcium	C				

Date:03/28/02ISR Number: 3923976-5Report Type:Periodic Company Report #WAES 0201USA01022
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Headache							

Date:03/28/02ISR Number: 3923978-9Report Type:Periodic Company Report #WAES 0201USA01028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923981-9Report Type:Periodic Company Report #WAES 0201USA00889
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3923985-6Report Type:Periodic Company Report #WAES 0202USA01022
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx Unk	PS		ORAL	12.5-25 MG/DAILY/PO	
			Calcium(Unspecified)	C				
			Glucosamine	C				
			Ubidecarenone	C				

Date:03/28/02ISR Number: 3923987-XReport Type:Periodic Company Report #WAES 0202USA01024
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:03/28/02ISR Number: 3923989-3Report Type:Periodic Company Report #WAES 0202USA01028
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3923992-3Report Type:Periodic Company Report #WAES 0202USA01036
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:03/28/02ISR Number: 3923993-5Report Type:Periodic Company Report #WAES 0202USA01053
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Feeling Abnormal							

Date:03/28/02ISR Number: 3923996-0Report Type:Periodic Company Report #WAES 0202USA01063
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Potaba	C				
			Prinivil	C				

Date:03/28/02ISR Number: 3923999-6Report Type:Periodic Company Report #WAES 0202USA01070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional Company	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Representative

Date:03/28/02ISR Number: 3924002-4Report Type:Periodic Company Report #WAES 0202USA01091
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Compartment Syndrome	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:03/28/02ISR Number: 3924004-8Report Type:Periodic Company Report #WAES 0202USA01102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Celebrex	C				
			Mobic	C				
			Aspirin	C				
			Gemfibrozil	C				
			Niacin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3924008-5Report Type:Periodic Company Report #WAES 0202USA01104
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Nexium	C				

Date:03/28/02ISR Number: 3925617-XReport Type:Periodic Company Report #WAES 0201USA01206
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epigastric Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY / PO	
	Faeces Discoloured	Health Professional						
	Gastrooesophageal Reflux Disease		Fosamax	C				
			Tums	C				
	Nausea		Tylenol	C				
			Aspirin	C				
			Ibuprofen	C				
			Vitamins (Unspecified)	C				

Date:03/28/02ISR Number: 3925618-1Report Type:Periodic Company Report #WAES 0201USA01209
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	

Date:03/28/02ISR Number: 3925620-XReport Type:Periodic Company Report #WAES 0201USA01219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx	PS		ORAL	PO	3 DAY
			Os-Cal	C				
			Plendil	C				
			Singulair	C				
			Folic Acid	C				
			Methotrexate	C				
			Naproxen	C				
			Prednisone	C				
			Vitamin D (Unspecified)	C				

Date:03/28/02ISR Number: 3925621-1Report Type:Periodic Company Report #WAES 0201USA01241
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG /DAILY	
	Tongue Discolouration	Health Professional Company Representative					/ PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3925622-3Report Type:Periodic Company Report #WAES 0201USA01100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx	PS		ORAL	PO	
			Vicodin Tablets	C				

Date:03/28/02ISR Number: 3925623-5Report Type:Periodic Company Report #WAES 0201USA01102
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/28/02ISR Number: 3925625-9Report Type:Periodic Company Report #WAES 0201USA01107
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blister							
	Glossodynia		Lopressor Hct	C				

Date:03/28/02ISR Number: 3925626-0Report Type:Periodic Company Report #WAES 0201USA01117
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Altace	C				
			Fosamax	C				
			Lunipax	C				
			Plavix	C				
			Atenolol	C				

Date:03/28/02ISR Number: 3925628-4Report Type:Periodic Company Report #WAES 0201USA01118
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	
	Tachycardia						/ PO	
			Ativan	C				
			Durolax	C				
			Monopril	C				
			Prevacid	C				
			Roxicodone	C				

Date:03/28/02ISR Number: 3925629-6Report Type:Periodic Company Report #WAES 0201USA01146
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3925742-3Report Type:Periodic Company Report #WAES 0202USA01476
Age:70 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:03/28/02ISR Number: 3925743-5Report Type:Periodic Company Report #WAES 0202USA01482
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Therapy Unspecified	C				

Date:03/28/02ISR Number: 3925744-7Report Type:Periodic Company Report #WAES 0202USA01487
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Nitroglycerin Prolongate	C				
			Zocor	C				
			Propranolol	C				

Date:03/28/02ISR Number: 3925745-9Report Type:Periodic Company Report #WAES 0202USA01495
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Cardiovascular Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gait Disturbance					
MG/DAILY/PO						
	Muscle Spasms		Depakote	C		
	Swelling		Hydrochlorothiazide (+) Triamter	C		
			Minocycline	C		

Date:03/28/02ISR Number: 3925746-0Report Type:Periodic Company Report #WAES 0202USA01503
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Shock	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
	Swelling	Professional				
MG/DAILY/PO						
		Company Representative	Procardia Xl	C		

Date:03/28/02ISR Number: 3925747-2Report Type:Periodic Company Report #WAES 0202USA01505
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
		Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3925748-4Report Type:Periodic Company Report #WAES 0202USA01509
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Quinine	C				
			Ranitidine	C				

Date:03/28/02ISR Number: 3925749-6Report Type:Periodic Company Report #WAES 0202USA01520
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cranial Nerve Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Glucophage	C				
			Lescol	C				
			Insulin	C				

Date:03/28/02ISR Number: 3925750-2Report Type:Periodic Company Report #WAES 0202USA01521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:03/28/02ISR Number: 3925751-4Report Type:Periodic Company Report #WAES 0202USA01336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PRN/PO	
		Company Representative						

Date:03/28/02ISR Number: 3925752-6Report Type:Periodic Company Report #WAES 0202USA01705
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	1 MON
			Maxide	C				

Date:03/28/02ISR Number: 3925753-8Report Type:Periodic Company Report #WAES 0202USA01540
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	1 DAY
			Fosamax	C				

Date:03/28/02ISR Number: 3925754-XReport Type:Periodic Company Report #WAES 0202USA01544
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Ms Contin	C				
			Valium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3925755-1Report Type:Periodic Company Report #WAES 0202USA01548
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Maxzide	C				
			Triavil	C				
			Zocor	C				

Date:03/28/02ISR Number: 3925756-3Report Type:Periodic Company Report #WAES 0202USA01552
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/	
	Diarrhoea						DAILY/PO	
	Haemorrhage		Lopressor	C				
			Zocor	C				
			Tamoxifen	C				

Date:03/28/02ISR Number: 3925757-5Report Type:Periodic Company Report #WAES 0202USA01553
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	6 MON
			Celebrex	C				
			Estrogens	C				

Date:03/28/02ISR Number: 3925758-7Report Type:Periodic Company Report #WAES 0202USA01556
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG /PRN/PO	

				Fosamax	C		
				Premarin	C		
				Prevacid	C		
				Provera	C		

Date:03/28/02ISR Number: 3925759-9Report Type:Periodic Company Report #WAES 0202USA01557
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Cardene	C				
			Lipitor	C				
			Potassium	C				

Date:03/28/02ISR Number: 3925760-5Report Type:Periodic Company Report #WAES 0202USA01563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	1 MON
			Zestril	C				
			Chlorothiazide	C				
			Thyroid	C				
			Verapamil Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/02ISR Number: 3925761-7Report Type:Periodic Company Report #WAES 0202USA01570
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:03/28/02ISR Number: 3941121-7Report Type:Periodic Company Report #WAES 0202USA01662
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
			Lotrel	C				
			Oxycontin	C				
			Pravachol	C				
			Terazosin Hydrochloride	C				

Date:03/28/02ISR Number: 3941122-9Report Type:Periodic Company Report #WAES 0202USA01671
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/PO	
	Paraesthesia							
	Vision Blurred							

Date:03/28/02ISR Number: 3941123-0Report Type:Periodic Company Report #WAES 0202USA01672
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3941124-2Report Type:Periodic Company Report #WAES 0202USA01673
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Rash		Effexor	C				
			Inderal	C				
			Trazodone	C				

Date:03/28/02ISR Number: 3941125-4Report Type:Periodic Company Report #WAES 0202USA01682
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Infection	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Ultram	C				
			Valium	C				

Date:03/28/02ISR Number: 3941126-6Report Type:Periodic Company Report #WAES 0202USA01683
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:03/28/02ISR Number: 3941127-8Report Type:Periodic Company Report #WAES 0202USA01688
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	8 WK
	Blood Pressure Increased							
	Eyelid Oedema		Imdur	C				
	Fatigue		Prilosec	C				
	Headache		Zocor	C				
	Photopsia							

Date:03/28/02ISR Number: 3941128-XReport Type:Periodic Company Report #WAES 0202USA01693
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
	Tachycardia		Celebrex	C				
			Tylenol With Codeine #3	C				
			Ultram	C				

Date:03/29/02ISR Number: 3891457-3Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00082
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Spironolactone	C		ORAL		
	Heart Rate Increased		Ferrous Sulfate	C				
	Respiratory Rate Increased		Acetaminophen And Propoxyphene Hydrochloride	C				
			Grape Seeds	C		ORAL		
			Nifedipine	C		ORAL		
			Enoxaparin	C				
			Aceprometazine Maleate And Meprobamate	C				

Date:03/29/02ISR Number: 3891459-7Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00080
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pancreatitis Acute		Piroxicam	SS		ORAL		
	Renal Failure Acute		Ibuprofen	SS		ORAL		
			Diclofenac	SS		ORAL		
			Phloroglucinol And Trimethylphloroglucinol	C		ORAL		

			Morphine	C		ORAL

Date:03/29/02ISR Number: 3891460-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Lipitor	C		
			Atacand	C		
			Flovent	C		
			Combivent	C		
			Zoloft	C		
			Coreg	C		
			Plavix	C		
			Aspirin	C		
			Vitamin E	C		

Date:03/29/02ISR Number: 3891462-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Vioxx	SS		ORAL
1 DAY						
Initial or Prolonged	Cardiogenic Shock		Vicodin Tablets	C		
	Coronary Artery Disease		Valtrex	C		
	Coronary Artery Occlusion		Medrol Dosepak	C		
	Renal Failure Acute		Vasotec	C		
	Vomiting		Aspirin	C		
			Clonidine	C		
			Lasix (Furosemide)	C		
			Atenolol	C		
			Norvasc	C		

Date:03/29/02ISR Number: 3891463-9Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00093
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization - 86 DAY	Anaemia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Iron Abnormal	Caffeine And			
	Hiatus Hernia	Phenobarbital	C		ORAL
	Mean Cell Volume	Oxazepam	C		ORAL
	Decreased	Betahistine			
		Hydrochloride	C		ORAL
		Piribedil	C		
		Aspirin Lysine	C		ORAL
		Omeprazole	C		ORAL

Date:03/29/02ISR Number: 3891465-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02074
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Alopecia Totalis		Vioxx	PS	Merck & Co., Inc	ORAL
154 DAY						
			Claritin-D	C		ORAL
			Centrum	C		ORAL
			Albuterol	C		ORAL
			Vanceril	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3891466-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02512
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
			Topamax	C				
			Depakote	C				

Date:03/29/02ISR Number: 3891468-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02960
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ambien	C				

Date:03/29/02ISR Number: 3891469-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/29/02ISR Number: 3891472-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02620
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Premarin	C				
			Lipitor	C				
			Vitamins (Unspecified)	C				
			Aspirin	C				

Date:03/29/02ISR Number: 3891476-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02598
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/02ISR Number: 3891477-9Report Type:Expedited (15-DaCompany Report #WAES 0203SGP00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			

Date:03/29/02ISR Number: 3891478-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02515
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Skin Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3891479-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pyrexia		Lanoxin	C				
			Accupril	C				
			Aspirin	C				
			Singulair	C				

Date:03/29/02ISR Number: 3891480-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		
			Wellbutrin	C				

Date:03/29/02ISR Number: 3891481-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02603
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/02ISR Number: 3891482-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abnormal		Prevacid	C				
	Meningitis		Prilosec	C				

Date:03/29/02ISR Number: 3891484-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02947
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection Brain Abscess Spinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK

Date:03/29/02ISR Number: 3891486-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02626
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/02ISR Number: 3891879-0Report Type:Direct Company Report #CTU 164515
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx (Rofecoxib) 25mg Tablet Mfg: Merck + Co	PS	Merck +Co	ORAL	1 TABLET EVERY 25MG	3 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3891929-1Report Type:Direct Company Report #CTU 164498
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Temporal Arteritis Transient Ischaemic Attack		Vioxx. 25 Mg	PS			1 QD	2 WEEKS

Date:03/29/02ISR Number: 3891940-0Report Type:Direct Company Report #CTU 164489
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Difficulty In Walking Ear Infection Herpes Zoster Meningitis Viral Upper Respiratory Tract Infection		Vioxx 25mg Merck	PS	Merck		ONE PER DAY	

Date:03/29/02ISR Number: 3892095-9Report Type:Direct Company Report #CTU 164466
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Meningitis		Vioxx	PS			1 DAILY	

Date:03/29/02ISR Number: 3892096-0Report Type:Direct Company Report #CTU 164467
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx 25mg	PS			1 TABLE AS NEEDED	

Date:03/29/02ISR Number: 3892442-8Report Type:Direct Company Report #CTU 164598
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx 50mg Merck	PS	Merck		ONCE DAILY	
	Sudden Death							

Date:03/29/02ISR Number: 3892460-XReport Type:Direct Company Report #CTU 164609
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Meningitis		Vioxx	PS		ORAL	1 PILL AS NEEDED ORAL	
Hospitalization - Initial or Prolonged								

Date:03/29/02ISR Number: 3892473-8Report Type:Direct Company Report #CTU 164614
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrospinal Fluid Leakage		Vioxx Merck	PS	Merck			
Hospitalization - Initial or Prolonged	Meningitis							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/02ISR Number: 3892703-2Report Type:Direct Company Report #CTU 164585
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache		Vioxx 50mg Merck	PS	Merck	ORAL	1 TAB ONCE	
Initial or Prolonged	Musculoskeletal Stiffness						PER ORAL	
	Pyrexia							
	Vomiting							

Date:03/29/02ISR Number: 3896582-9Report Type:Periodic Company Report #WAES 0201USA02388
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal	Health	Orsu Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Prozac	C				
			Doxepin Hydrochloride	C				

Date:03/30/02ISR Number: 3892718-4Report Type:Direct Company Report #CTU 164587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Celebrex	PS		ORAL	STANDARD ORAL	
	Back Pain		Vioxx	SS		ORAL	STANDARD ORAL	
	Fall							
	Hypothyroidism							
	Medication Error							
	Meningitis Viral							

Date:04/01/02ISR Number: 3892163-1Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation Peritonitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flupentixol Decanoate	C		INTRAMUSCULAR		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL	22	DAY
			Diclofenac Sodium	C		ORAL	17	DAY
			Ranitidine	C		ORAL		

Date:04/01/02ISR Number: 3892166-7Report Type:Expedited (15-DaCompany Report #WAES 0203AUT00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/02ISR Number: 3892167-9Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00131
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock Carotid Artery Stenosis Syncope		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3892265-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA01146
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anger Hallucination, Auditory Hallucination, Visual		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:04/01/02ISR Number: 3892266-1Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00033
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:04/01/02ISR Number: 3893215-2Report Type:Expedited (15-DaCompany Report #WAES 01085193
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Anxiety Blood Alkaline Phosphatase Increased Gamma-Glutamyltransferase Increased Hypergammaglobulinaemia Malaise Metastases To Liver Pneumothorax	Foreign Other	Tab Vioxx (Rofecoxib) 25 MG/DAILY PO ; 12.5 MG / DAILY PO Acetaminophen / Codeine Phosphate Ketoprofen Levothyroxine Na Nifedipine Prednisolone Tamoxifen Citrate Zolpidem Tartrate	PS C C C C C C C		ORAL		

Date:04/01/02ISR Number: 3893221-8Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO WK
			Antimicrobial	C				
			Zolpidem Tartrate	C				

Date:04/01/02ISR Number: 3893222-XReport Type:Expedited (15-DaCompany Report #WAES 0202BEL00011
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Cardiomegaly Chronic Obstructive Airways Disease Exacerbated Oedema Peripheral	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3893232-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01249
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	14 DAY
	Pain							
	Vaginal Haemorrhage		Aerobid-M	C				
			Cardizem Cd	C				
			Colace	C				
			Dalmane	C				
			Desyrel	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				
			Metamucil	C				
			Micro K	C				
			Mylanta & Mylanta Ds	C				
			Prilosec	C				
			Travatan	C				
			Tylenol With Codeine #4	C				
			Uniphyl	C				
			Allopurinol	C				

Date:04/01/02ISR Number: 3893233-4Report Type:Expedited (15-DaCompany Report #WAES 01102774
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease	Consumer	Tab Vioxx	PS		ORAL	PO	
Other	Coronary Artery Stenosis		Celebrex	C				
	Dyspnoea		Mepergan	C				
	Ejection Fraction Abnormal		Relafen	C				
	Fluid Retention		Xanax	C				
	Hypoaesthesia		Amitriptyline	C				
	Myocardial Infarction		Aspirin	C				
	Nausea							
	Swelling							
	Ventricular Hypokinesia							

Date:04/01/02ISR Number: 3893234-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA01627
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Back Pain	Health					MG/DAILY/PO	
Other	Chest Pain	Professional	Actos	C				
			Avalide	C				
			Covera-Hs	C				
			Flomax (Tamsulosin Hydrochloride	C				
			Glucovance	C				
			Lipitor	C				
			Nitrostat	C				
			Plavix	C				
			Sinemet	C				
			Ultracef	C				
			Atenolol	C				
			Glyburide	C				
			Isosorbide Dinitrate	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3893235-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01805
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Pancreatitis	Professional	Chondroitin	C				
	Pyrexia	Company Representative	Glucosamine	C				

Date:04/01/02ISR Number: 3893245-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Chest Pain	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged	Platelet Count Decreased	Company Representative						

Date:04/01/02ISR Number: 3893276-0Report Type:Expedited (15-DaCompany Report #WAES 99080555
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 12.5 MG DAILY	Meningitis Aseptic	Literature	Vioxx 12.5 Mg	PS		ORAL		
Initial or Prolonged PO		Health						
		Professional	Zoloft	C				
		Company Representative	Atenolol	C				

Date:04/01/02ISR Number: 3893277-2Report Type:Expedited (15-DaCompany Report #WAES 99081150
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 12.5	Meningitis Aseptic	Literature	Vioxx 12.5mg	PS		ORAL		

Initial or Prolonged Health
MG/DAILY/PO
Professional B Vitamins C

Date:04/01/02ISR Number: 3893278-4Report Type:Expedited (15-DaCompany Report #WAES 00050141
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Literature	Vioxx 12.5mg	PS		ORAL	12.5 MG	DAILY/PO
	Meningitis Aseptic	Health Professional	Ibuprofen 200 Mg	SS		ORAL	200-600	MG/PRN/PO
Disability	Mental Status Changes		Midrin	C				
			Paxil	C				
			Vicodin Tablets	C				

Date:04/01/02ISR Number: 3893279-6Report Type:Expedited (15-DaCompany Report #WAES 99080718
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Alveolitis
Hospitalization - Initial or Prolonged	Anxiety
	Aphasia
	Cerebrovascular Accident
	Convulsion
	Csf Neutrophil Count

	Positive Csf Test Abnormal Csf White Blood Cell Count Positive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased Activity	Literature	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO:
	Dehydration	Health					
	Depressed Level Of Consciousness	Professional Company					12.5MG/DAILY/ PO
	Depression	Representative					
	Drug Intolerance		Flovent	C			
	Electroencephalogram		Limbitrol Tablets	C			
	Abnormal		Plaquenil	C			
	Encephalopathy		Prilosec	C			
	Meningitis		Singulair	C			
	Meningitis Aseptic		Xanax	C			
	Mental Status Changes		Albuterol	C			
	Pneumonia		Prednisone	C			
	Respiratory Distress						
	Sepsis						
	Transient Ischaemic Attack						
	Upper Respiratory Tract Infection						

Date:04/01/02ISR Number: 3893365-0Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00012
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema Cardiac Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY PO
	Congestive						
			Acenocoumarol	C			
			Acetylcysteine	C			
			Bumetanide	C			
			Digoxin	C			
			Methylprednisolone	C			
			Perindopril	C			

Date:04/01/02ISR Number: 3893366-2Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00056
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Foreign	Tab Vioxx					
Hospitalization -	Peritonitis	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
Initial or Prolonged								
PO								
			Acetaminophen	C				
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Diosmin	C				
			Phenobarbital	C				
			Trimetazidine Hydrochloride	C				

Date:04/01/02ISR Number: 3893371-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00044
Age:53 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism	Foreign	Tab Vioxx					
	Respiratory Disorder	Other	(Rofecoxib)	PS		ORAL		
PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3893373-XReport Type:Expedited (15-DaCompany Report #WAES 0203DEU00146
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastric Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	
Other	Hypertensive Crisis		Tab Aspirin	SS		ORAL	PO	
			Candesartan Cilexetil	C				
			Lisinopril	C				
			Magnesium Aspartate (+) Potassium Aspart	C				
			Metoprolol	C				
			Nebivolol Hydrochloride	C				

Date:04/01/02ISR Number: 3893375-3Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00177
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Face Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG PO	
			Bisoprolol Fumarate	C				
			Prednisolone	C				
			Ranitidine	C				

Date:04/01/02ISR Number: 3893381-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrapyramidal Disorder	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ 1X/ PO	
	Tardive Dyskinesia	Professional Company Representative						

Date:04/01/02ISR Number: 3893382-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02180
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Headache		Prinivil	C				
	Rash		Metoprolol	C				
	Tachycardia							

Date:04/01/02ISR Number: 3893384-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02065
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Diarrhoea							
	Meningitis							
	Nausea							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3893396-0Report Type:Expedited (15-DaCompany Report #WAES 01100237
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/01/02ISR Number: 3893406-0Report Type:Expedited (15-DaCompany Report #WAES 01120365
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Cirrhosis	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/01/02ISR Number: 3893409-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA00618
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:04/01/02ISR Number: 3893447-3Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00020
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia Hypertension Hypertensive Crisis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/01/02ISR Number: 3893458-8Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00012
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Erythema Hypersensitivity	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	4 DAY

Date:04/01/02ISR Number: 3893523-5Report Type:Expedited (15-DaCompany Report #WAES 01120336
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage Intestinal Perforation	Professional Company	Coumadin	C				
Other		Representative	Therapy Unspecified	C				

Date:04/01/02ISR Number: 3893524-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00392
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Upper Angiopathy Diarrhoea Gastrointestinal Haemorrhage

		Haematochezia Haemorrhage Oral Intake Reduced	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope	Consumer	Tab Vioxx	PS		ORAL
PO							
				Hydrocortisone	C		

Date:04/01/02ISR Number: 3893525-9Report Type:Expedited (15-DaCompany Report #WAES 0202USA00017
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO 11 MON						
		Professional	Lamictal	C		
			Mysoline	C		
			Premarin	C		

Date:04/01/02ISR Number: 3893556-9Report Type:Expedited (15-DaCompany Report #WAES 99111023
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Decreased	Literature	Tab Vioxx 25 Mg	PS		ORAL
50						
	Chills	Health				
MG/DAILY/PO						
	Csf Neutrophil Count Positive	Professional				
	Csf Protein Increased					
	Csf Test Abnormal					
	Csf White Blood Cell Count Positive					
	Dizziness					
	Extensor Plantar Response					
	Headache					
	Insomnia					
	Lymphocyte Count Decreased					
	Medication Error					

Meningism
Meningitis Aseptic
Musculoskeletal Stiffness
Nausea
Night Sweats
Pain
Red Blood Cells Csf
Positive
Respiratory Rate
Increased
Subarachnoid Haemorrhage

Date:04/01/02ISR Number: 3893605-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01000
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemoptysis	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/02ISR Number: 3893608-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA01607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Chest Pain Dyspnoea Gastric Haemorrhage Gastritis Erosive	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/01/02ISR Number: 3893610-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA01174
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rash	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Tylenol With Codeine #3	C				

Date:04/01/02ISR Number: 3893611-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA01158
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:04/01/02ISR Number: 3893617-4Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00143
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG/DAILY	

Date:04/01/02ISR Number: 3893619-8Report Type:Expedited (15-DaCompany Report #WAES 0203CHE00021
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder Coordination Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	1 DAY
Other	Speech Disorder Vertigo		Cosopt	C				
			Aspirin	C				
			Fish Oil (Unspecified)	C				
			Magnesium (Unspecified)	C				

Date:04/01/02ISR Number: 3893620-4Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00144
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Captopril	C				
			Dipyrone	C				
			Fentanyl	C				
			Hydrochlorothiazide	C				

			Prednisolone	C		
			Ranitidine Hcl	C		
			Zolpidem Tartrate	C		

Date:04/01/02ISR Number: 3893625-3Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00008
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								2 DAY
			Phenytoin Sodium	C				

Date:04/01/02ISR Number: 3893636-8Report Type:Expedited (15-DaCompany Report #WAES 01096083
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
PO								
			Acebutolol	C				
			Althiazide / Spironolactone	C				
			Molsidomine	C				

Date:04/02/02ISR Number: 3892838-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02405
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase Increased
Hospitalization - Initial or Prolonged	Arrhythmia
Disability	Blood Albumin Abnormal
Other	Blood Alkaline Phosphatase Increased

Blood Bilirubin Increased
Blood Bilirubin
Unconjugated Increased
Blood Calcium Decreased
Blood Osmolarity
Decreased
Blood Thyroid Stimulating
Hormone Abnormal
Blood Urea Increased
Clonic Convulsion
Csf Glucose Increased
Depressed Level Of
Consciousness
Difficulty In Walking
Drug Level Below
Therapeutic
Dyskinesia
Encephalopathy
Grand Mal Convulsion
Hyperglycaemia
International Normalised
Ratio Abnormal
Postictal State

		Prostatic Specific Antigen Increased					
		Sedation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Shift To The Left		Vioxx	PS	Merck & Co., Inc	ORAL
		White Blood Cell Count Increased		Coumadin	C		
				Digoxin	C		
				Lasix (Furosemide)	C		
				Depakote	C		
1	DAY						
				Reglan	C		

Date:04/02/02ISR Number: 3893027-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA00207
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Hip Surgery		Vioxx	PS	Merck & Co., Inc	ORAL
		Impaired Healing		Lorazepam	C		
				Advair	C		
RESPIRATORY							
(INHALATION)							
				Prevacid	C		
				Celexa	C		
				Furosemide	C		
				Theophylline	C		
				Evista	C		

Date:04/02/02ISR Number: 3893028-1Report Type:Expedited (15-DaCompany Report #WAES 01106116
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
				Gliclazide	C		ORAL

Date:04/02/02ISR Number: 3893029-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Norvasc	C				
	Myocardial Infarction		Lopressor	C				
	Ocular Hyperaemia		Prinivil	C				
			Premarin	C				

Date:04/02/02ISR Number: 3893039-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00259
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased							
	Blood Alkaline Phosphatase Increased							
	Cholelithiasis							
	Gamma-Glutamyltransferase Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/02ISR Number: 3893042-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02887
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:04/02/02ISR Number: 3893047-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/02/02ISR Number: 3893048-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA03150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				
			Lasix (Furosemide)	C				
			Digoxin	C				
			Coumadin	C				
			Potassium (Unspecified)	C				
			Nexium	C				
			Zestoretic	C				
			Toprol Xl Tablets [Composition Unspecified]	C				
			Thyroid	C				

Date:04/02/02ISR Number: 3893050-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00014
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS		ORAL
			Sinemet	C		
			Prevacid	C		
			Singulair	C		
			Norvasc	C		
			Toprol Xl Tablets	C		
			Combivent	C		
			Serevent	C		
			Flovent	C		

Date:04/02/02ISR Number: 3893275-9Report Type:Direct Company Report #CTU 164688
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Epistaxis		Vioxx 25mg	PS		
1 TABLE DAY						
Initial or Prolonged	Meningitis Viral					

Date:04/02/02ISR Number: 3893699-XReport Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemolytic Anaemia	Foreign	Tab Vioxx					
Hospitalization -	Jaundice	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged							PO	
			Insulin	C				

Date:04/02/02ISR Number: 3893700-3Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00017
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					
Hospitalization -	Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL	25 MG/BID PO	118 DAY
Initial or Prolonged	Haemorrhage		Trusopt	C				
	Haematemesis		Vasoretic	C				
	Helicobacter Pylori		Cyanocobalamin	C				
	Identification Test		Furosemide	C				
	Positive		Iron	C				
	Upper Gastrointestinal		Latanoprost	C				
	Haemorrhage		Zopiclone	C				

Date:04/02/02ISR Number: 3893701-5Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					
Life-Threatening	Shock	Other	(Rofecoxib)	PS		ORAL	PO	
Hospitalization -			(Composition					
Initial or Prolonged			Unspecified)	SS				

Date:04/02/02ISR Number: 3893704-0Report Type:Expedited (15-DaCompany Report #WAES 0203NOR00018
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					
Hospitalization -	Gastric Ulcer	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Gastrointestinal						PO	
	Haemorrhage		Moduretic	C				
			Acetaminophen	C				
			Acetaminohen/Codeine Phosphate	C				
			Ferrousso4	C				
			Nitrazepam	C				
			Omeprazole Magnesium	C				

Date:04/02/02ISR Number: 3893705-2Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00107
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Foreign	Tab Vioxx					
Other	Delusion	Other	(Rofecoxib)	PS		ORAL	PO	
	Depression							
	Hyperacusis							
	Overdose							

Date:04/02/02ISR Number: 3893844-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	
		Other						

Date:04/02/02ISR Number: 3894014-8Report Type:Expedited (15-DaCompany Report #WAES 01099742
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Foreign	Tab Vioxx					
	Joint Sprain	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Lumbar Vertebral Fracture	Professional						
	Muscle Strain						PO	16 DAY
	Spinal Compression							
	Fracture							

Date:04/02/02ISR Number: 3894093-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02213
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Swelling	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	
			Dilantin	C				
			Proscar	C				
			Zestril	C				
			Folic Acid	C				
			Furosemide	C				
			Potassium Chloride	C				
			Thiamine	C				

Date:04/02/02ISR Number: 3894094-XReport Type:Direct Company Report #CTU 164825
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx 25mg Merck	PS	Merck		ONCE DAILY	
Hospitalization -	Drug Interaction		Lotrel 5/10mg	SS			ONCE DAILY	
Initial or Prolonged	Gastric Ulcer							
Disability	Heart Rate Decreased							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:04/02/02ISR Number: 3894096-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02150
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bacterial Infection	Literature	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Duodenal Ulcer	Health Professional						
	Gastritis		[Therapy Unspecfied]	C				
	Gastrointestinal Infection		Ibuprofen	C				
	Upper Gastrointestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/02ISR Number: 3894097-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02040
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum	Literature	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Dizziness	Health					MG/DAILY/PO	
	Gastritis Erosive	Professional	Nephrocaps	C				
	Gastrointestinal		Acetaminophen	C				
	Haemorrhage		Calcium Acetate	C				
	Haemoglobin Decreased		Furosemide	C				
	Haemoptysis							
	Hypotension							
	Melaena							
	Polyp							
	Thrombosis							

Date:04/02/02ISR Number: 3894240-8Report Type:Direct Company Report #CTU 164812
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anovulatory Cycle		Vioxx Merck	PS	Merck	ORAL	PRN ORAL	
	Menstrual Disorder							

Date:04/03/02ISR Number: 3893574-0Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Late Onset		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS		ORAL		
	Wheezing		[Therapy Unspecified]	C				

Date:04/03/02ISR Number: 3893578-8Report Type:Expedited (15-DaCompany Report #WAES 0203AUS00140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc			

Date:04/03/02ISR Number: 3893579-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	90 DAY	
Hospitalization - Initial or Prolonged			Tenormin	C				
Other			Monopril	C				
			Clonidine	C				
			Aspirin	C				
			Lipitor	C				

Date:04/03/02ISR Number: 3893583-1Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Blood Pressure Decreased
	Heart Rate Increased
	Hyperhidrosis

	Shock Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY

Date:04/03/02ISR Number: 3893584-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA01002
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization -	First Degree		Cozaar	C				
Initial or Prolonged	Cold Sweat		Atenolol	C				
Disability	Hypertension		Claritin	C				
Other	Hypertensive Crisis		Ginkgo Biloba					
	Pain In Extremity		Extract	C				
	Supraventricular		Aspirin	C				
	Extrasystoles							

Date:04/03/02ISR Number: 3893714-3Report Type:Expedited (15-DaCompany Report #WAES 0203DNK00014
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	45	DAY
Initial or Prolonged	Weight Increased		Vioxx	SS		ORAL	23	DAY
Disability			Aspirin	C		ORAL		
			Bendroflumethiazide	C		ORAL		

Date:04/03/02ISR Number: 3893716-7Report Type:Expedited (15-DaCompany Report #WAES 0203DNK00013
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY

Initial or Prolonged	Oedema Peripheral	Acetaminophen	C		ORAL
		Tramadol	C		ORAL
YR					
		Prednisolone	C		ORAL
		Fenoterol Hydrobromide And Ipratropium Bromide	C		
		Salmeterol Xinafoate	C		
		Furosemide	C		ORAL
		Spironolactone	C		ORAL
		Methimazole	C		ORAL

Date:04/03/02ISR Number: 3893719-2Report Type:Expedited (15-DaCompany Report #WAES 0203PRT00007
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
16 DAY								
Initial or Prolonged	Gastrointestinal		Thiocolchicoside	C		ORAL		
16 DAY								
	Haemorrhage							
	Haematemesis							
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3893720-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA03168
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adrenal Insufficiency		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Other	Hyperkalaemia		Furosemide	C				
	Renal Failure Acute							

Date:04/03/02ISR Number: 3893723-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrapyramidal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Tardive Dyskinesia							

Date:04/03/02ISR Number: 3894051-3Report Type:Direct Company Report #CTU 164831
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx- I Was On The Smallest Dosage	PS				
	Blood Pressure Decreased							
	Dizziness							
	Gastric Ulcer Haemorrhage		Lipitor	C				
	Melaena		Claritin-D	C				
	Upper Gastrointestinal Haemorrhage		Fosamax	C				
			Calcium /W D	C				
	Vomiting		Multivitamin	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3894573-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02034
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Acute Respiratory	Health	Tab Vioxx 25 Mg/50mg	PS		ORAL
25						
Hospitalization -	Distress Syndrome	Professional				
MG/DAILY/PO,						
Initial or Prolonged	Acute Respiratory Failure	Company				
50						
Disability	Back Pain	Representative				
MG/DAILY/PO						
	Cardiac Failure		Tylenol	C		
	Congestive					
	Condition Aggravated					
	Congestive Cardiomyopathy					

Date:04/03/02ISR Number: 3894960-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00018
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myeloid Leukaemia	Foreign	Tab Vioxx			
Initial or Prolonged	Aplasia	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Dizziness					
PO 56 WK						
	Nausea		Ciprofibrate	C		
			Oxybutynincl	C		
			Risedronate Sodium	C		

Date:04/03/02ISR Number: 3894961-7Report Type:Expedited (15-DaCompany Report #WAES 01125014
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aspartate	Foreign	Tab Vioxx					
Hospitalization -	Aminotransferase	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Increased							
PO								1 DAY
	Blood Bilirubin Increased		Diuretic					
	Blood Potassium Decreased		(Unspecified)	SS				
	Blood Urea Increased		Acetaminophen	C				
	Hyponatraemia		Hydroflumethiazide					
	Syncope		(+) Spironolactone	C				
			Propranolol	C				

Date:04/03/02ISR Number: 3894963-0Report Type:Expedited (15-DaCompany Report #WAES 0202MEX00017
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged								
PO								
			Pepcid	C				
			Aspirin	C				
			Deflazacort	C				

Date:04/03/02ISR Number: 3894965-4Report Type:Expedited (15-DaCompany Report #WAES 01126013
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Sarcoma	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								163 DAY
			Methotrexate	C				
			Prednisone	C				

Date:04/03/02ISR Number: 3894971-XReport Type:Expedited (15-DaCompany Report #WAES 0203DEU00167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatic Cyst	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:04/03/02ISR Number: 3894973-3Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00162
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Clostridium Colitis Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
			Tab Aspirin	SS		ORAL	100 MG/DAILY PO	
			Tab Cefpodoxime Proxetil	SS		ORAL	200 MG/BID PO	6 DAY
			Dihydroergotamine	C				
			Etilefrine Hydrochloride	C				
			Ginkgo Biloba					

			Extract	C
			Verapamil Hcl	C

Date:04/03/02ISR Number: 3894975-7Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00160
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased	Foreign	Tab Vioxx					
Hospitalization -	Cardiovascular Disorder	Other	(Rofecoxib)	PS		ORAL	25 MG/BID PO	
Initial or Prolonged	Cholelithiasis		Tab					
	Cholestasis		Hydrochlorothiazide					
	Drug Interaction		(+) Valsartan	SS		ORAL	12.5/80	
	Renal Failure Acute						MG/DAILY PO	
	Vomiting		Tab Melperone	SS		ORAL	25 MG/DAILY	
							PO	
			Tab Metoprolol	SS		ORAL	50 MG/DAILY	
							PO	
			Tab Nitrendipine	SS		ORAL	10 MG/BID PO	
			Cisapride	C				
			Famotidine	C				
			Omeprazole	C				
			Prednisolone	C				

Date:04/03/02ISR Number: 3894979-4Report Type:Expedited (15-DaCompany Report #WAES 01105153
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscle Spasms	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	SEE IMAGE	
Disability		Professional						

Date:04/03/02ISR Number: 3895005-3Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Cardiac Arrest Conduction Disorder	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:04/03/02ISR Number: 3895029-6Report Type:Expedited (15-DaCompany Report #WAES 01120919
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization - Initial or Prolonged Other	Dyspnoea Oxygen Saturation Decreased Pulmonary Embolism	Professional Company Representative	Capoten	C				
			Daypro	C				
			Estinyl	C				
			Inderal La	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Midrin	C				
			Provera	C				
			Soma	C				
			Tylenol With Codeine #3	C				
			Nonsteroidal Anti-Inflammatory	C				

				Nortriptyline	C		

Date:04/03/02ISR Number: 3895118-6Report Type:Periodic Company Report #WAES 01120219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO Initial or Prolonged	Dizziness	Consumer	Tab Vioxx	PS		ORAL		

Date:04/03/02ISR Number: 3895119-8Report Type:Periodic Company Report #WAES 0112USA02895
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO, 25 MG/DAILY/PO	
		Health Professional						
			Lipitor	C				
			Prinivil	C				
			Synthroid	C				
			Folic Acid	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3895120-4Report Type:Periodic Company Report #WAES 0112USA02380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:04/03/02ISR Number: 3895121-6Report Type:Periodic Company Report #WAES 0201USA00240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3895122-8Report Type:Periodic Company Report #WAES 0201USA00569
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3895123-XReport Type:Periodic Company Report #WAES 0201USA01885
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Impairment	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:04/03/02ISR Number: 3895124-1Report Type:Periodic Company Report #WAES 0201USA01376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Tylenol Herbs (Unspecified)	C C				

Date:04/03/02ISR Number: 3895125-3Report Type:Periodic Company Report #WAES 0201USA01215
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional						

Date:04/03/02ISR Number: 3895126-5Report Type:Periodic Company Report #WAES 0201USA01026
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactoid Reaction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional	Tylenol Wih Codeine	SS		ORAL	PO	

Other			Cap Prevacid 30 Mg	SS		ORAL
30 MG/1X/PO						
			Levaquin	SS		ORAL
PO						

Date:04/03/02ISR Number: 3895127-7Report Type:Periodic Company Report #WAES 0201USA00711
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged		Professional				
MG/BID/PO						
		Company	Flovent	C		
		Representative	Naprosyn	C		
			Serevent	C		
			Singulair	C		
			Prednisone	C		

Date:04/03/02ISR Number: 3895128-9Report Type:Periodic Company Report #WAES 0202USA01549
Age:13 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaphylactic Reaction	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3895129-0Report Type:Periodic Company Report #WAES 0202USA02071
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company Representative	Plendil	C				
			Prozac	C				

Date:04/03/02ISR Number: 3895130-7Report Type:Periodic Company Report #WAES 01091807
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Arthrotec	C				
			Caltrate	C				
			Diovan Hct	C				
			Norvasc	C				
			Prempro	C				
			Aspirin	C				
			Labetalol Hydrochloride	C				
			Vitamins (Unspecified)	C				

Date:04/03/02ISR Number: 3895131-9Report Type:Periodic Company Report #WAES 01102757
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Health Professional Company Representative						

Date:04/03/02ISR Number: 3895132-0Report Type:Periodic Company Report #WAES 01110465
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Other	Gastrointestinal Haemorrhage	Professional Company Representative	Aspirin 325 Mg	SS			326 MG	
			Aspirin 81 Mg	SS			81 MG/DAILY	
			Zantac	C				

Date:04/03/02ISR Number: 3895133-2Report Type:Periodic Company Report #WAES 01110334
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3895134-4Report Type:Periodic Company Report #WAES 01110831
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company	Aspirin 325 Mg	SS			325 MG	
		Representative	Prevacid	C				
			Prilosec	C				

Date:04/03/02ISR Number: 3895135-6Report Type:Periodic Company Report #WAES 01111203
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Perforation	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional					MG/DAILY/PO	
	Oesophageal Ulcer Haemorrhage	Company Representative	Therapy Unspecified	C				

Date:04/03/02ISR Number: 3895136-8Report Type:Periodic Company Report #WAES 01112794
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Aricept	C				
			Duragesic	C				
			Elavil	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Lopressor	C				
			Protonix	C				
			Aspirin	C				

Potassium Chloride C

Date:04/03/02ISR Number: 3895137-XReport Type:Periodic Company Report #WAES 0112USA02092
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:04/03/02ISR Number: 3895138-1Report Type:Periodic Company Report #WAES 0112USA02186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3895139-3Report Type:Periodic Company Report #WAES 0201USA02479
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fatigue	Professional					MG/DAILY/PO	
	Hypertension	Company						
	Oedema Peripheral	Representative						

Date:04/03/02ISR Number: 3895140-XReport Type:Periodic Company Report #WAES 0201USA02497
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Tab Vioxx	PS		ORAL	PO	
	Nausea		Cozaar	C				
			Prilosec	C				

Date:04/03/02ISR Number: 3895141-1Report Type:Periodic Company Report #WAES 0201USA02935
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Respiratory Tract	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50MG/DAILY/PO	
Initial or Prolonged	Infection							

Date:04/03/02ISR Number: 3895142-3Report Type:Periodic Company Report #WAES 0201USA02842
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Perforation	Professional					MG/DAILY/PO	
Initial or Prolonged		Company						

Other Representative

Date:04/03/02ISR Number: 3895143-5Report Type:Periodic Company Report #WAES 0202USA00038
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						
	Renal Failure	Company						
		Representative						

Date:04/03/02ISR Number: 3895144-7Report Type:Periodic Company Report #WAES 0202USA00685
Age:55 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:04/03/02ISR Number: 3895145-9Report Type:Periodic Company Report #WAES 0202USA00664
Age: Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization -	Gastric Ulcer Haemorrhage	Health
Initial or Prolonged		Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3895146-0Report Type:Periodic Company Report #WAES 0202USA01472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3895147-2Report Type:Periodic Company Report #WAES 0201USA00078
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	International Normalised Ratio Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Intra-Abdominal Haemorrhage		Celebrex	C				
			Cogentin	C				
			Haldol	C				
			Carbamazepine	C				
			Ferrous Sulfate	C				
			Lithium Carbonate	C				
			Warfarin	C				

Date:04/03/02ISR Number: 3895148-4Report Type:Periodic Company Report #WAES 0112USA02325
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Librax Capsules C

Date:04/03/02ISR Number: 3895149-6Report Type:Periodic Company Report #WAES 0201USA01867
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other								

Date:04/03/02ISR Number: 3895150-2Report Type:Periodic Company Report #WAES 0201USA01979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia	Health Professional	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Company Representative						

Date:04/03/02ISR Number: 3895151-4Report Type:Periodic Company Report #WAES 0201USA01829
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Renal Failure Acute	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx	PS		ORAL
PO						

Date:04/03/02ISR Number: 3895152-6Report Type:Periodic Company Report #WAES 01120319
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
			Lopressor	C		

Date:04/03/02ISR Number: 3895153-8Report Type:Periodic Company Report #WAES 01120564
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Renal Failure	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Professional				
		Company				
		Representative				

Date:04/03/02ISR Number: 3895154-XReport Type:Periodic Company Report #WAES 0112USA01204
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
		Company				
		Representative				

Date:04/03/02ISR Number: 3895155-1Report Type:Periodic Company Report #WAES 0112USA01232
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Health Professional	Doxazosin 1 Mg	SS			1 MG/HS	
Other			Tab Prinzide 20/25 Mg	C			20/25 MG/AM	
			Advair	C				
			Ambien	C				
			Claritin	C				
			Estradiol	C				
			Minerals (+) Vitam	C				

Date:04/03/02ISR Number: 3895156-3Report Type:Periodic Company Report #WAES 0112USA01626
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactoid Reaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3895375-6Report Type:Expedited (15-DaCompany Report #WAES 01035256
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Hyponatraemia	Foreign Other	Tab Vioxx (Refecoxib)	PS		ORAL	12.5 MG/DAILY	PO 1 DAY
			Hydroflumethiazide (+) Spironolactone	C				
			Propranolol	C				

Date:04/03/02ISR Number: 3897423-6Report Type:Expedited (15-DaCompany Report #WAES 0203AUS00140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:04/03/02ISR Number: 3920132-1Report Type:Periodic Company Report #WAES 01120335
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
		Company Representative	Chondroitin	C				

Date:04/03/02ISR Number: 3920133-3Report Type:Periodic Company Report #WAES 01120349
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25 MG DAILY							
	Nausea						
PO							
			Moduretic	C			
			[Therapy				
			Unspecified]	C			
			Aspirin	C			

Date:04/03/02ISR Number: 3920135-7Report Type:Periodic Company Report #WAES 01120356
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Epistaxis					
PO						
	Fatigue		Aricept	C		
			Flomax (Tamsulosin			
			Hydrochloride	C		

Date:04/03/02ISR Number: 3920137-0Report Type:Periodic Company Report #WAES 01120361
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Anxiety	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Asthenia	Professional				
PO						
	Confusional State					
	Fatigue					

Date:04/03/02ISR Number: 3920139-4Report Type:Periodic Company Report #WAES 01120362
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO

Date:04/03/02ISR Number: 3920140-0Report Type:Periodic Company Report #WAES 01120367
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
	Blood Pressure Increased							
	Diarrhoea							
	Dizziness							
	Dyspepsia							
	Fatigue							
	Muscular Weakness							
	Nausea							

Date:04/03/02ISR Number: 3920142-4Report Type:Periodic Company Report #WAES 01120369
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO ; 50 MG DAILY PO	2 DAY

Date:04/03/02ISR Number: 3920143-6Report Type:Periodic Company Report #WAES 01120374
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Respiratory Distress						PO	

Date:04/03/02ISR Number: 3920145-XReport Type:Periodic Company Report #WAES 01120408
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Professional					PO	
			Atenolol	C				
			Phentermine	C				

Date:04/03/02ISR Number: 3920147-3Report Type:Periodic Company Report #WAES 01120413
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
		Professional	Estratest	C				
			Prozac	C				
			Remeron	C				
			Diazepam	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920150-3Report Type:Periodic Company Report #WAES 01120575
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Headache							
			Citracal	C				
			Fosamax	C				
			Prempro	C				
			Prilosec	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920152-7Report Type:Periodic Company Report #WAES 01120590
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920153-9Report Type:Periodic Company Report #WAES 01120602
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Vioxx	PS		ORAL	PO	
			Darvocet-N	C				
			Paxil	C				
			Ultram	C				
			Cyclobenzaprine Hydrochloride	C				

Date:04/03/02ISR Number: 3920155-2Report Type:Periodic Company Report #WAES 01120605
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920157-6Report Type:Periodic Company Report #WAES 01120609
Age:87 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY / PO	
			Aricept	C				
			Armour Thyroid Tablets	C				
			Detrol La	C				
			Paxil	C				
			Sular	C				
			Ranitidine	C				

Date:04/03/02ISR Number: 3920158-8Report Type:Periodic Company Report #WAES 01120610
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Oedema		Hyzaar	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920160-6Report Type:Periodic Company Report #WAES 01120614
Age:77 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920162-XReport Type:Periodic Company Report #WAES 01120621
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920164-3Report Type:Periodic Company Report #WAES 01120665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Glucovance	C				
			Hyzaar	C				
			Levothroid	C				
			Norvasc	C				
			Paxil	C				
			Toprol Xl	C				

Date:04/03/02ISR Number: 3920165-5Report Type:Periodic Company Report #WAES 01120673
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Infection	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Sinus Disorder	Professional				
MG/DAILY/PO						
	Sinusitis		Lopressor	C		
			Mevacor	C		

Date:04/03/02ISR Number: 3920168-0Report Type:Periodic Company Report #WAES 0202USA02069
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
PO						

Date:04/03/02ISR Number: 3920169-2Report Type:Periodic Company Report #WAES 0202USA01919
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
PO						
			Artane	C		
			Intal	C		
			Neurontin	C		
			Premarin	C		
			Vancenase	C		
			Chlorpheniramine			

				Maleate	C	

Date:04/03/02ISR Number: 3920172-2Report Type:Periodic Company Report #WAES 0202USA01929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920173-4Report Type:Periodic Company Report #WAES 0202USA01941
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, PO	
	Dyspepsia							
	Nausea							

Date:04/03/02ISR Number: 3920175-8Report Type:Periodic Company Report #WAES 0202USA01956
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
			Avapro	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3920177-1Report Type:Periodic Company Report #WAES 0202USA01957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920178-3Report Type:Periodic Company Report #WAES 0202USA01993
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pemphigus	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920179-5Report Type:Periodic Company Report #WAES 0202USA01994
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920182-5Report Type:Periodic Company Report #WAES 0202USA02004
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
							PO	
			Climara	C				
			Fosamax	C				
			Hyoscyamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920183-7Report Type:Periodic Company Report #WAES 0202USA02015
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
	Weight Increased						DAILY, PO	
			Antivert	C				
			Centrum	C				
			Tylenol	C				

Date:04/03/02ISR Number: 3920198-9Report Type:Periodic Company Report #WAES 01081140
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	25	
	Vision Blurred	Health					MG/DAILY/PO	
	Visual Acuity Reduced	Professional	Aciphex	C				
			Levbid	C				
			Miacalcin	C				
			Xalatan	C				

Date:04/03/02ISR Number: 3920203-XReport Type:Periodic Company Report #WAES 01081262
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx	PS		ORAL	25	
	Dyspepsia	Health					MG/DAILY/PO	
	Face Oedema	Professional	Diovan	C				
	Fluid Retention		Dyazide	C				
	Weight Increased		Estrostep Fe	C				
			Glucophage	C				
			Hydergine	C				
			Lasix (Purosemide)	C				
			Lipitor	C				

Nexium	C
Synthroid	C
Toprol Xl Tablets	C
Calcium (+) Vitami	C
Chondroitin (+)	
Glucosamine	C
Dimethyl Sulfone	C

Date:04/03/02ISR Number: 3920205-3Report Type:Periodic Company Report #WAES 00022271
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Nasal Congestion							
	Nausea		Nasacort	C				
	Weight Increased							

Date:04/03/02ISR Number: 3920206-5Report Type:Periodic Company Report #WAES 00072358
Age:62 YR Gender:Female I/FU:F

Outcome	PT
	Gastrointestinal Disorder
	Gingivitis
	Headache

	Herpes Simplex						
	Nausea						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting	Health	Tab Vioxx	PS		ORAL	75	MG/DAILY/PO
	Weight Increased	Professional						
			Tab Vioxx	SS		ORAL	12.5	MG/QQD/PO
			Tab Vioxx	C		ORAL	25	MG/DAILY/PO
			Synthroid	C				
			Estrogenic Preparations	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920208-9Report Type:Periodic Company Report #WAES 00080849
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	12.5	MG/DAILY/PO 3 MON
	Hallucination							
	Insomnia		Tab Vioxx	SS		ORAL	25	MG/DAILY/PO
	Nausea							
	Pruritus		Darvocet-N	C				
	Rash		Estratab	C				
	Urticaria		Lamisil	C				
	Vertigo		Lopid	C				
			Premarin	C				
			Robaxin	C				
			Synthroid	C				
			Estrogens	C				

Date:04/03/02ISR Number: 3920209-0Report Type:Periodic Company Report #WAES 00091475
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faecal Incontinence	Consumer	Tab Vioxx	PS		ORAL	25	
	Micturition Disorder						MG/DAILY/PO	
	Musculoskeletal Stiffness							

Date:04/03/02ISR Number: 3920212-0Report Type:Periodic Company Report #WAES 00101334
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	25	
	Micturition Urgency						MG/DAILY/PO	
	Pollakiuria		Proscar	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3920214-4Report Type:Periodic Company Report #WAES 00111328
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Drug Ineffective		Klonopin	C				
	Fatigue		Medrol Dosepak	C				
	Pain		Nardil	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920217-XReport Type:Periodic Company Report #WAES 00111896
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Literature	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	1 MON
	Paraesthesia	Health Professional	Estrogens, Conjugated	C				
			Fexofenadine	C				
			Fluticasone Propionate	C				
			Paroxetine	C				
			Sumatriptan	C				
			Zolpidem Tartrate	C				

Date:04/03/02ISR Number: 3920221-1Report Type:Periodic Company Report #WAES 01011721
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention	Health Professional	Prilosec	C				
			Valium	C				

Date:04/03/02ISR Number: 3920225-9Report Type:Periodic Company Report #WAES 01082716
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Actonel	C				
			Caltrate	C				
			Norvasc	C				
			Prempro	C				

				Zestril	C		
				Aspirin	C		
				Metoprolol	C		
				Vitamin E	C		

Date:04/03/02ISR Number: 3920228-4Report Type:Periodic Company Report #WAES 01082784
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fluid Retention	Health					MG/DAILY/PO	
	Oliguria	Professional	Inderide Tablets	C				
	Weight Increased		Zocor	C				

Date:04/03/02ISR Number: 3920231-4Report Type:Periodic Company Report #WAES 01042834
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg/ 50					
	Headache		Mg	PS		ORAL	SEE IMAGE	
			Cipro	C				
			Naprosyn	C				
			Norvasc	C				
			Premarin	C				

			Hyoscyamine Sulfate	C		

Date:04/03/02ISR Number: 3920236-3Report Type:Periodic Company Report #WAES 01060240
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dysphonia	Health					MG/DAILY/PO	
	Dyspnoea	Professional	Advil	C				
	Fatigue		Calan	C				
	Influenza Like Illness							
	Nervousness							
	Pruritus							
	Tremor							
	Vomiting							

Date:04/03/02ISR Number: 3920239-9Report Type:Periodic Company Report #WAES 01061867
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema Peripheral	Health	Allegra	C				
		Professional	Theragran Tablets					
			Advanced Form	C				
			Zoloft	C				

Date:04/03/02ISR Number: 3920243-0Report Type:Periodic Company Report #WAES 01070823
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50	
							MG/DAILY/ORAL	
			Celexa	C				

			Darvocet-N	C		
			Hydrodiuril	C		
			Inderal	C		
			Klonopin	C		
			Klor-Con	C		
			Synthroid	C		

Date:04/03/02ISR Number: 3920246-6Report Type:Periodic Company Report #WAES 01071985
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Mouth Ulceration	Professional	Dilantin	C				
	Paraesthesia		Premarin	C				
			Prevacid	C				
			Provera	C				
			Zarontin	C				
			Zyrtec	C				
			Phenobarbital	C				

Date:04/03/02ISR Number: 3920253-3Report Type:Periodic Company Report #WAES 01072363
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Diarrhoea	Health Professional						
	Tachycardia							

Date:04/03/02ISR Number: 3920256-9Report Type:Periodic Company Report #WAES 01072364
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Fluid Retention	Health Professional						
	Oedema Peripheral		Allegra	C				
	Weight Increased		Estradiol	C				

Date:04/03/02ISR Number: 3920261-2Report Type:Periodic Company Report #WAES 01080132
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Articular Disc Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 WK
	Pain	Health Professional	Lipitor	C				
	Urticaria		Premarin	C				

Date:04/03/02ISR Number: 3920266-1Report Type:Periodic Company Report #WAES 01092176
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Ineffective	Health Professional	Depakote	C				
			Lipitor	C				

Monopril	C		
Thorazine	C		
Aspirin	C		
Phenobarbital	C		

Date:04/03/02ISR Number: 3920270-3Report Type:Periodic Company Report #WAES 01092182
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Headache	Health						
	Malaise	Professional	Cetapril	C				
			K-Dur	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Indapamide	C				
			Sulfinpyrazone	C				
			Verapamil	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920275-2Report Type:Periodic Company Report #WAES 01082932
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Nausea		Hyzaar	C				
			Timoptic-Xe	C				
			Verapamil	C				

Date:04/03/02ISR Number: 3920278-8Report Type:Periodic Company Report #WAES 01090325
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	DAILY/PO	
	Mouth Ulceration	Other	Triamterene	C				

Date:04/03/02ISR Number: 3920279-XReport Type:Periodic Company Report #WAES 01090427
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness	Health						
	Drug Ineffective	Professional	Centrum	C				
	Dyspnoea		Digitek	C				
	Feeling Hot		Prilosec	C				
	Flushing		Synthroid	C				
	Headache		Tylenol Arthritis Extended Relie	C				
			Aspirin	C				
			Therapy Unspecified	C				

Date:04/03/02ISR Number: 3920287-9Report Type:Periodic Company Report #WAES 01090502
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Discharge	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/.DAILY/PO	
			Klonopin	C				
			Ms Contin	C				
			Soma	C				

Date:04/03/02ISR Number: 3920292-2Report Type:Periodic Company Report #WAES 01090693
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia	Health Professional	Androderm	C				
			Benzamycin Topical Gel	C				
			Celebrex	C				
			Cipro	C				
			Flonase	C				
			Doxycycline	C				
			Terazosin Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920298-3Report Type:Periodic Company Report #WAES 01090733
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920300-9Report Type:Periodic Company Report #WAES 01090747
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actos	C				
			Celebrex	C				
			Glucotrol Xl	C				
			Indocin (Indomethacine Sodium)	C				
			Mavik	C				
			Os-Cal	C				
			Premarin	C				
			Prevacid	C				
			Prilosec	C				
			Synthroid	C				
			Metoprolol	C				

Date:04/03/02ISR Number: 3920304-6Report Type:Periodic Company Report #WAES 01090767
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Desyrel	C				
			Evista	C				
			Exelon	C				

				Wellbutrin Sr	C		

Date:04/03/02ISR Number: 3920307-1Report Type:Periodic Company Report #WAES 01120674
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dehydration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Asoirin	C				

Date:04/03/02ISR Number: 3920309-5Report Type:Periodic Company Report #WAES 01120678
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
	Nausea							
			Prinivil	C				
			Zocor	C				
			Corticosteroids (Unspecified)	C				
			Spironolactone	C				

Date:04/03/02ISR Number: 3920312-5Report Type:Periodic Company Report #WAES 01120679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920314-9Report Type:Periodic Company Report #WAES 01120692
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	3 WK
			Thyroid Tablets Usp	C				
			(Therapy Unspecified)	C				

Date:04/03/02ISR Number: 3920316-2Report Type:Periodic Company Report #WAES 01120697
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Pain In Extremity		Ativan	C				
			Prilosec	C				
			Penicillin (Unspecified)	C				

Date:04/03/02ISR Number: 3920318-6Report Type:Periodic Company Report #WAES 01120706
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Crying	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
	Depression	Professional	Elavil	C		
	Face Oedema		Premphase	C		

Date:04/03/02ISR Number: 3920319-8Report Type:Periodic Company Report #WAES 01120715
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
	Pain	Professional	Lipitor	C		
	Rheumatoid Arthritis					

Date:04/03/02ISR Number: 3920320-4Report Type:Periodic Company Report #WAES 01120718
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

Date:04/03/02ISR Number: 3920321-6Report Type:Periodic Company Report #WAES 01120739
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Rash	Health
		Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
PO						
			(Therapy Unspecified)	C		

Date:04/03/02ISR Number: 3920323-XReport Type:Periodic Company Report #WAES 01120766
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Arava	C		
			Celexa	C		
			Estrace	C		
			Neurontin	C		
			Sinemet	C		
			Vasotec	C		
			Aspirin	C		
			Hydrochlorothiazide + Triamter	C		
			Hydroxycloroquine Sulfate	C		
			Lithium Carbonate	C		
			Sodium Chloride	C		
			Trazodone	C		

Date:04/03/02ISR Number: 3920327-7Report Type:Periodic Company Report #WAES 01113227
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PO						
			Ditropan	C		
			Tegretol	C		
			Warfarin	C		

Date:04/03/02ISR Number: 3920330-7Report Type:Periodic Company Report #WAES 01112945
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920332-0Report Type:Periodic Company Report #WAES 01112961
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Dizziness		Lipitor	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3920334-4Report Type:Periodic Company Report #WAES 01112967
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx Unk	PS		ORAL	PRN/PO	
	Red Blood Cell Abnormality		Procrit	C				

Date:04/03/02ISR Number: 3920337-XReport Type:Periodic Company Report #WAES 01112970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Blinded Therapy Unk	SS				

Date:04/03/02ISR Number: 3920344-7Report Type:Periodic Company Report #WAES 01112972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920346-0Report Type:Periodic Company Report #WAES 01112973
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PO	

Date:04/03/02ISR Number: 3920348-4Report Type:Periodic Company Report #WAES 01112978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Myalgia	Professional					MG/DAILY/PO	

Date:04/03/02ISR Number: 3920352-6Report Type:Periodic Company Report #WAES 01112992
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Feeling Abnormal						MG/DAILY/PO	
	Haemorrhage		Amaryl	C				
	Mental Impairment		Premarin	C				
	Muscular Weakness		Synthroid	C				
	Oedema Peripheral		Methylprednisolone	C				
	Swelling							
	Vision Blurred							

Date:04/03/02ISR Number: 3920356-3Report Type:Periodic Company Report #WAES 01112998
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	PO	
	Skin Lesion		Digoxin	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920378-2Report Type:Periodic Company Report #WAES 0201USA00471
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
	Neuralgia		Darvocet-N	C				
			Premarin	C				
			Amitriptyline	C				
			Phenobarbital	C				

Date:04/03/02ISR Number: 3920379-4Report Type:Periodic Company Report #WAES 0201USA00478
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tenormin	C				

Date:04/03/02ISR Number: 3920384-8Report Type:Periodic Company Report #WAES 0201USA00498
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gingival Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Mouth Ulceration	Health Professional	Fosamax	C				

Date:04/03/02ISR Number: 3920390-3Report Type:Periodic Company Report #WAES 0201USA00500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
		Health Professional	Cardizem	C		
			Estrace	C		
			Pyridium	C		
			Zoloft	C		
			Acyclovir	C		
			Aspirin	C		
			Calcium(Unspecified)	C		
			Progesterone	C		
			Vitamin E	C		

Date:04/03/02ISR Number: 3920393-9Report Type:Periodic Company Report #WAES 0201USA00328
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Influenza Like Illness	Health Professional	Tab Vioxx Unk	PS		ORAL
MG/UNK/PO						

Date:04/03/02ISR Number: 3920395-2Report Type:Periodic Company Report #WAES 0201USA00330
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
	Muscle Spasms		Accupril	C		
			Celebrex	C		
			Glucophage	C		

Prempro	C
Zocor	C
Glyburide	C

Date:04/03/02ISR Number: 3920400-3Report Type:Periodic Company Report #WAES 0201USA00331
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920402-7Report Type:Periodic Company Report #WAES 0201USA00347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920403-9Report Type:Periodic Company Report #WAES 0201USA00365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	1 WK
	Platelet Disorder	Professional						
		Company Representative	Prevacid	C				

Date:04/03/02ISR Number: 3920406-4Report Type:Periodic Company Report #WAES 0201USA00368
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO	Neck Pain					

Date:04/03/02ISR Number: 3920408-8Report Type:Periodic Company Report #WAES 0112USA02980
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Lotrel	C				
			Zocor	C				

Date:04/03/02ISR Number: 3920410-6Report Type:Periodic Company Report #WAES 0112USA02994
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920412-XReport Type:Periodic Company Report #WAES 0112USA02775
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Choking						PO	
	Eye Oedema		Nexium	C				
	Eye Pain							

Date:04/03/02ISR Number: 3920413-1Report Type:Periodic Company Report #WAES 0112USA02781
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Haemorrhage						PO	
			Neurontin	C				
			Ziac	C				
			Allopurinol	C				

Date:04/03/02ISR Number: 3920414-3Report Type:Periodic Company Report #WAES 0112USA02791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Tab Vioxx Unk	PS		ORAL	DAILY PO	

Date:04/03/02ISR Number: 3920415-5Report Type:Periodic Company Report #WAES 0112USA02832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

PO

Date:04/03/02ISR Number: 3920417-9Report Type:Periodic Company Report #WAES 0112USA02849
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Piloerection	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Rash	Professional	Insulin	C		
			Vitamins (Unspecified)	C		

Date:04/03/02ISR Number: 3920418-0Report Type:Periodic Company Report #WAES0112USA02850
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Vaginal Haemorrhage					
PO						
			Synthroid	C		
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920419-2Report Type:Periodic Company Report #WAES 0112USA02857
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Dizziness							
PO								16 DAY
	Dyspepsia		Potassium (Unspecified)	C				
	Rectal Haemorrhage							

Date:04/03/02ISR Number: 3920420-9Report Type:Periodic Company Report #WAES 0112USA02858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx Unk	PS		ORAL		
PO								

Date:04/03/02ISR Number: 3920442-8Report Type:Periodic Company Report #WAES 01120231
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gout	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Lopressor	C				
			Prinizide	C				

Date:04/03/02ISR Number: 3920492-1Report Type:Periodic Company Report #WAES 01111050
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG/DAILY/	
	Diarrhoea							
PO								

	Face Oedema		Tylenol	C			
	Headache						
	Oedema Peripheral						
	Urine Abnormality						

Date:04/03/02ISR Number: 3920494-5Report Type:Periodic Company Report #WAES 01120248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Maxzide	C				

Date:04/03/02ISR Number: 3920496-9Report Type:Periodic Company Report #WAES01111044
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	12.5MG PO	
		Health Professional	Tab Vioxx 25mg	SS		ORAL	25MG DAILY PO	
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920500-8Report Type:Periodic Company Report #WAES01111869
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Health Professional						

Date:04/03/02ISR Number: 3920501-XReport Type:Periodic Company Report #WAES 01120250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:04/03/02ISR Number: 3920504-5Report Type:Periodic Company Report #WAES 01112202
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Delirium	Other	Ativan	C				
	Delusion		Synthroid	C				
	Feeling Abnormal		Zestoretic	C				
	Hallucination							

Date:04/03/02ISR Number: 3920506-9Report Type:Periodic Company Report #WAES 01112227
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Date:04/03/02ISR Number: 3920507-0Report Type:Periodic Company Report #WAES 01120251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Vioxx	PS		ORAL	PO	
	Increased	Professional Company Representative						

Date:04/03/02ISR Number: 3920509-4Report Type:Periodic Company Report #WAES 01112277
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 12.5mg	PS		ORAL	12.5MG BID PO	
	Facial Pain	Professional					DAILY	
	Flushing							
	Headache							
	Oedema Peripheral							
	Paraesthesia							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920512-4Report Type:Periodic Company Report #WAES 01120255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoglycaemia	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Metoprolol	C				

Date:04/03/02ISR Number: 3920513-6Report Type:Periodic Company Report #WAES 01112377
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	PO	
			Tab Vioxx 50 Mg	SS		ORAL	PO	

Date:04/03/02ISR Number: 3920514-8Report Type:Periodic Company Report #WAES 01112414
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920515-XReport Type:Periodic Company Report #WAES 01112436
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Professional
Company
Representative

Date:04/03/02ISR Number: 3920516-1Report Type:Periodic Company Report #WAES 01120258
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Chest Pain		Ultram	C				
	Tachycardia							

Date:04/03/02ISR Number: 3920517-3Report Type:Periodic Company Report #WAES 01112477
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG DAILY	
	Respiratory Disorder	Health					PO	
	Wheezing	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920518-5Report Type:Periodic Company Report #WAES 01113330
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Other	Tab Vioxx 25 Mg	PS				
	Dyspnoea		Flovent	C				
	Pruritus		Serevent	C				
			Zantac	C				
			Albuterol	C				

Date:04/03/02ISR Number: 3920519-7Report Type:Periodic Company Report #WAES 01112507
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Olfactory Nerve Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25MGDAILY PO	
	Skin Odour Abnormal	Professional Company Representative						

Date:04/03/02ISR Number: 3920520-3Report Type:Periodic Company Report #WAES 01120262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Jaundice							
	Pruritus		Premarin	C				

Date:04/03/02ISR Number: 3920521-5Report Type:Periodic Company Report #WAES 01113073
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg, 25mg	PS		ORAL	50	

MG/DAILY/PO;

SEE IMAGE

Atenolol	C	
Thyroid	C	

Date:04/03/02ISR Number: 3920522-7Report Type:Periodic Company Report #WAES 0202USA02145
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920523-9Report Type:Periodic Company Report #WAES 0202USA02018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	1) 12.5 MG/DAILY/PO; 25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920524-0Report Type:Periodic Company Report #WAES 01120291
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	
	Fatigue	Professional						
	Oedema Peripheral							
	Somnolence							

Date:04/03/02ISR Number: 3920525-2Report Type:Periodic Company Report #WAES 0202USA02021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:04/03/02ISR Number: 3920526-4Report Type:Periodic Company Report #WAES 01120332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Dyspnoea	Professional						
	Nausea							
	Nervousness							

Date:04/03/02ISR Number: 3920527-6Report Type:Periodic Company Report #WAES 0202USA02023
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	

	Dizziness	Professional				
PO						
	Feeling Abnormal	Company	Axid	C		
	Pain In Extremity	Representative	Premarin	C		
			Tenormin	C		
			Xanax	C		
			Zoloft	C		
			Aspirin	C		
			Calcium (Unspecified)	C		

Date:04/03/02ISR Number: 3920528-8Report Type:Periodic Company Report #WAES 0202USA02024
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
		Professional						
MG/DAILY/PO								
			Motrin	C				
			Prozac	C				

Date:04/03/02ISR Number: 3920529-XReport Type:Periodic Company Report #WAES 01113074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
MG/DAILY/PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920530-6Report Type:Periodic Company Report #WAES 0112USA01187
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920531-8Report Type:Periodic Company Report #WAES 01113078
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS			25 MG/DAILY	
	Diarrhoea							
	Dizziness							

Date:04/03/02ISR Number: 3920532-XReport Type:Periodic Company Report #WAES 0202USA02037
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
	Vertigo							

Date:04/03/02ISR Number: 3920533-1Report Type:Periodic Company Report #WAES 0202USA02047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920534-3Report Type:Periodic Company Report #WAES 01113086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920535-5Report Type:Periodic Company Report #WAES 0202USA02048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920536-7Report Type:Periodic Company Report #WAES 0201USA01147
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Platelet Disorder	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920537-9Report Type:Periodic Company Report #WAES 01113178
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Weight Increased							
			Calan Sr	C				
			Maxzide	C				
			Meridia	C				
			Nizoral 2% Shampoo	C				
			Patanol	C				

Date:04/03/02ISR Number: 3920538-0Report Type:Periodic Company Report #WAES 0202USA02055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Upper Respiratory Tract Infection							
			Hydrodiuril	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920539-2Report Type:Periodic Company Report #WAES 01113210
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
			Coreg	C				
			Coumadin	C				
			Lanoxin	C				
			Lasix (Furosemide0	C				
			Lipitor	C				
			Zaroxolyn	C				
			Zestril	C				

				Aspirin	C		
				Potassium (Unspecified0	C		

Date:04/03/02ISR Number: 3920540-9Report Type:Periodic Company Report #WAES 0202USA02060
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteonecrosis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3920541-0Report Type:Periodic Company Report #WAES 0201USA01151
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920542-2Report Type:Periodic Company Report #WAES 01113218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920543-4Report Type:Periodic Company Report #WAES 0201USA01155
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prozac	C				

Date:04/03/02ISR Number: 3920544-6Report Type:Periodic Company Report #WAES 00020849
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Nausea		Celebrex	C				
	Pruritus		Skelatin	C				
			Synthroid	C				
			Tylenol	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920545-8Report Type:Periodic Company Report #WAES 01113222
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

				Premarin	C		
				Procardia	C		
				Prednisone	C		
				Thyroid	C		

Date:04/03/02ISR Number: 3920546-XReport Type:Periodic Company Report #WAES 00021274
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg, 50 Mg	PS		ORAL	25 MG/DAILY/PO ; 50 MG/DAILY/PO	
		Company Representative						
			Enbrel	C				
			Plaquenil	C				
			Folic Acid	C				
			Levothyroxine Sodium	C				
			Methotrexate	C				
			Sulfamethazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920547-1Report Type:Periodic Company Report #WAES 0201USA01159
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Dyspepsia		Maxzide	C				
			Premarin	C				

Date:04/03/02ISR Number: 3920548-3Report Type:Periodic Company Report #WAES 01113223
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/PO	
	Nausea		Ambien	C				
	Pain		Estrace	C				
			Synthroid	C				

Date:04/03/02ISR Number: 3920549-5Report Type:Periodic Company Report #WAES 0202USA02072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920550-1Report Type:Periodic Company Report #WAES 0202USA02073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920552-5Report Type:Periodic Company Report #WAES 0201USA01033
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920553-7Report Type:Periodic Company Report #WAES 0202USA02092
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Ambien	C				
			Evista	C				
			Lipitor	C				
			Miacalcin	C				
			Norvasc	C				
			Terazosin Hydrochloride	C				

Date:04/03/02ISR Number: 3920554-9Report Type:Periodic Company Report #WAES 0201USA01034
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinorrhoea	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920555-0Report Type:Periodic Company Report #WAES 0202USA02096
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920556-2Report Type:Periodic Company Report #WAES 0201USA01056
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Vioxx 50 Mg	PS		ORAL	50 MG/PRN/PO	

Date:04/03/02ISR Number: 3920557-4Report Type:Periodic Company Report #WAES 0202USA02098
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920558-6Report Type:Periodic Company Report #WAES 0201USA01057
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS		ORAL	50 MG/PO	3 MON

Date:04/03/02ISR Number: 3920559-8Report Type:Periodic Company Report #WAES 0201USA01060
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Migraine							
			Prempro	C				
			Sudafed	C				

Date:04/03/02ISR Number: 3920560-4Report Type:Periodic Company Report #WAES 0201USA01067
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Throat Tightness	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920561-6Report Type:Periodic Company Report #WAES 0112USA03046
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
			Prinivil	C				

Date:04/03/02ISR Number: 3920562-8Report Type:Periodic Company Report #WAES 0202USA02101
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Glucovance	C				
			Prinivil	C				

Date:04/03/02ISR Number: 3920565-3Report Type:Periodic Company Report #WAES 0201USA00007
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Health Professional	Tab Vioxx 25mg	PS		ORAL	SEE IMAGE	
	Oral Pain		Accupril	C				
	Oral Soft Tissue Disorder		Lipitor	C				

Date:04/03/02ISR Number: 3920566-5Report Type:Periodic Company Report #WAES 0202USA02139
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Rash		Ambien 10 Mg	SS		ORAL	10 MG/HS/PO	

			Evista	C		
			Os-Cal	C		

Date:04/03/02ISR Number: 3920567-7Report Type:Periodic Company Report #WAES 0202USA02142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional						

Date:04/03/02ISR Number: 3920568-9Report Type:Periodic Company Report #WAES 0201USA00011
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Prevacid	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920569-0Report Type:Periodic Company Report #WAES 0112USA02874
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Prinivil	SS				
			Hydrodiuril	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920570-7Report Type:Periodic Company Report #WAES 0112USA02879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920572-0Report Type:Periodic Company Report #WAES 0112USA02903
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920573-2Report Type:Periodic Company Report #WAES 0112USA02947
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Date:04/03/02ISR Number: 3920574-4Report Type:Periodic Company Report #WAES 0112USA02973
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	
			Potassium	C				

Date:04/03/02ISR Number: 3920576-8Report Type:Periodic Company Report #WAES 0112USA02976
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5mg	PS		ORAL	25MG DAILY PO	
	Vaginal Haemorrhage							

Date:04/03/02ISR Number: 3920579-3Report Type:Periodic Company Report #WAES 0112USA02977
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Appetite Disorder	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG DAILY PO	
	Dry Mouth							
	Thirst		Amiloride Hcl W/ Hctz	C				
			Captoril	C				

Date:04/03/02ISR Number: 3920581-1Report Type:Periodic Company Report #WAES 0201USA00062
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			Tab Vioxx 50 Mg	SS		ORAL	PO	
			Coumadin	C				
			Atenolol	C				

				Folic Acid	C		
				Niacin	C		

Date:04/03/02ISR Number: 3920583-5Report Type:Periodic Company Report #WAES 0201USA00065
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG PO	
			Aspirin	C				
			Insulin	C				

Date:04/03/02ISR Number: 3920585-9Report Type:Periodic Company Report #WAES 0201USA00071
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Hair Disorder					PO		
			Estrogens	C				

Date:04/03/02ISR Number: 3920587-2Report Type:Periodic Company Report #WAES 0112USA03004
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920589-6Report Type:Periodic Company Report #WAES 0112USA03005
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dizziness	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25 MG DAILY							
	Vaginal Haemorrhage						
PO							
			Vitamins	C			

Date:04/03/02ISR Number: 3920591-4Report Type:Periodic Company Report #WAES 0112USA03007
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL		
PO								
		Professional						

Date:04/03/02ISR Number: 3920594-XReport Type:Periodic Company Report #WAES 0112USA03022
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Health	Tab Vioxx	PS		ORAL		
SEE IMAGE								
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920597-5Report Type:Periodic Company Report #WAES 0112USA03026
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
	Hypertension	Professional						
		Company Representative	Lopressor	C				
			Therapy Unspecified	C				

Date:04/03/02ISR Number: 3920600-2Report Type:Periodic Company Report #WAES 0112USA03031
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health	Tab Vioxx	PS		ORAL		
		Professional Company Representative						

Date:04/03/02ISR Number: 3920602-6Report Type:Periodic Company Report #WAES 0112USA03033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL		
			Paxil	SS				

Date:04/03/02ISR Number: 3920604-XReport Type:Periodic Company Report #WAES 0201USA00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
			Excedrin (Acetaminophen (+)					

			Caff	C		

Date:04/03/02ISR Number: 3920606-3Report Type:Periodic Company Report #WAES 0201USA00122
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Zoloft	C				

Date:04/03/02ISR Number: 3920609-9Report Type:Periodic Company Report #WAES 0201USA00136
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920610-5Report Type:Periodic Company Report #WAES 0201USA00013
Age:64 YR Gender:Female I/FU:I

Outcome	PT
	Abdominal Distension
	Dyspnoea

Heart Rate Irregular

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	6 DAY
			Fosamax	C				

Date:04/03/02ISR Number: 3920611-7Report Type:Periodic Company Report #WAES 0201USA00016
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	25 MG/DAILY/PO	
	Arthropathy							
	Oedema Peripheral		Diovan	C				
			K-Dur	C				
			Lasix(Furosemide)	C				
			Synthroid	C				

Date:04/03/02ISR Number: 3920612-9Report Type:Periodic Company Report #WAES0201USA00018
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Medrol Dosepak	C				

Date:04/03/02ISR Number: 3920613-0Report Type:Periodic Company Report #WAES 0201USA00025
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Haematuria	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:04/03/02ISR Number: 3920615-4Report Type:Periodic Company Report #WAES 0201USA00039
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
			Allegra	C		
			Prilosec	C		
			Serzone	C		
			Metoprolol	C		
			Sulfasalazine	C		

Date:04/03/02ISR Number: 3920617-8Report Type:Periodic Company Report #WAES 01021100
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Genital Haemorrhage	Consumer	Tab Vioxx 12.5mg	PS		ORAL
12.5MG DAILY						
	Wheezing					
PO						
			Proscar	C		
			Prozac	C		
			Risperdal	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920618-XReport Type:Periodic Company Report #WAES 0201USA00044
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
			Norvasc	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3920619-1Report Type:Periodic Company Report #WAES 01032922
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Viox 25mg	PS		ORAL	25MG DAILY PO	
	Dysphonia		Tab Vioxx 25mg	SS		ORAL	25MG DAILY PO	
			Avapro	C				
			Detrol	C				
			Lipitor	C				
			Norvasc	C				
			Prilosec	C				
			Ultram	C				

Date:04/03/02ISR Number: 3920620-8Report Type:Periodic Company Report #WAES 0201USA00045
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920621-XReport Type:Periodic Company Report #WAES 0202USA02148
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Aspirin	C				
			Quinine Sulfate	C				
			Ranitidine	C				

Date:04/03/02ISR Number: 3920627-0Report Type:Periodic Company Report #WAES 0112USA01387
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920630-0Report Type:Periodic Company Report #WAES 0202USA02230
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiovascular Disorder	Health Professional Company Representative	Tab Viox 25mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920632-4Report Type:Periodic Company Report #WAES 0112USA01188
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health	Tab Vioxx	PS		ORAL	PO	
	Gynaecomastia	Professional Company Representative						

Date:04/03/02ISR Number: 3920634-8Report Type:Periodic Company Report #WAES 0202USA02291
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:04/03/02ISR Number: 3920639-7Report Type:Periodic Company Report #WAES 0202USA02313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Professional Company Representative						

Date:04/03/02ISR Number: 3920640-3Report Type:Periodic Company Report #WAES 0112USA01189
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Company
Representative

Date:04/03/02ISR Number: 3920641-5Report Type:Periodic Company Report #WAES 0202USA02316
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health	Tab Vioxx	PS		ORAL	PO	
	Urinary Retention	Professional Company Representative						

Date:04/03/02ISR Number: 3920643-9Report Type:Periodic Company Report #WAES 0202USA02692
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920644-0Report Type:Periodic Company Report #WAES 0112USA01191
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920646-4Report Type:Periodic Company Report #WAES 020USA02761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Oedema	Company Representative						

Date:04/03/02ISR Number: 3920648-8Report Type:Periodic Company Report #WAES 0203USA00350
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:04/03/02ISR Number: 3920649-XReport Type:Periodic Company Report #WAES 0112USA01200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Company
Representative

Date:04/03/02ISR Number: 3920651-8Report Type:Periodic Company Report #WAES 0112USA01549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change Of Bowel Habit	Consumer	Tab Vioxx 12.5 Mg	PS			12.5 MG/BID/	
	Constipation						; 12.5 MG /	
							DAILY	
			Gastrointestinal Preparations	C				
			Insulin	C				

Date:04/03/02ISR Number: 3920654-3Report Type:Periodic Company Report #WAES 0112USA01231
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	5 DAY
	Oedema Peripheral		Cozaar	C				
			Norvasc	C				
			Furosemide	C				
			Lorazepam	C				
			Potassium Chloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920656-7Report Type:Periodic Company Report #WAES 0112USA01276
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Swelling							

Date:04/03/02ISR Number: 3920657-9Report Type:Periodic Company Report #WAES 0112USA01283
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY / PO	2 MON
		Company Representative						

Date:04/03/02ISR Number: 3920658-0Report Type:Periodic Company Report #WAES 0112USA01257
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	5 DAY
	Blood Pressure Increased	Health Professional	Atenolol	C				

Date:04/03/02ISR Number: 3920659-2Report Type:Periodic Company Report #WAES 0112USA01300
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/ PO	2 DAY
	Anxiety		Maxzide	C				

Atenolol C

Date:04/03/02ISR Number: 3920660-9Report Type:Periodic Company Report #WAES 0112USA01311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:04/03/02ISR Number: 3920662-2Report Type:Periodic Company Report #WAES 0112USA01266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920663-4Report Type:Periodic Company Report #WAES 0112USA01356
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920665-8Report Type:Periodic Company Report #WAES 0112USA01362
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY / PO	
	Chest Pain							

Date:04/03/02ISR Number: 3920667-1Report Type:Periodic Company Report #WAES 0112USA01368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920668-3Report Type:Periodic Company Report #WAES 0112USA01272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Other	Tab Vioxx	PS		ORAL	PO	
	Dizziness		Activella	C				
	Fatigue		Prozac	C				
	Headache		Vicodin Tablets	C				
	Tachycardia		Trazadone	C				

Date:04/03/02ISR Number: 3920670-1Report Type:Periodic Company Report #WAES 0112USA01385
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920671-3Report Type:Periodic Company Report #WAES 0112USA01386
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Tongue Oedema	Professional Company Representative						

Date:04/03/02ISR Number: 3920672-5Report Type:Periodic Company Report #WAES 0112USA01273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
	Rectal Haemorrhage	Professional						

Date:04/03/02ISR Number: 3920673-7Report Type:Periodic Company Report #WAES 0112USA01641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920676-2Report Type:Periodic Company Report #WAES 0112USA01409
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Health	Tab Vioxx	PS		ORAL	PO	6 DAY
	Myositis	Professional						
	Vasculitis	Company						
		Representative						

Date:04/03/02ISR Number: 3920677-4Report Type:Periodic Company Report #WAES 0112USA01421
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Flushing		Centrum	C				
			Evista	C				
			Nasacort Aq	C				
			Prilosec	C				

Date:04/03/02ISR Number: 3920679-8Report Type:Periodic Company Report #WAES 0112USA01423
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Micturition Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			One-A-Day Essential Vitamins	C				
			Prozac	C				
			Aspirin	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3920681-6Report Type:Periodic Company Report #WAES 0112USA01426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920683-XReport Type:Periodic Company Report #WAES 0112USA01448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis Ulcerative	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral		Synthroid	C				
	Urinary Hesitation		Atenolol	C				
			Verapamil	C				

Date:04/03/02ISR Number: 3920684-1Report Type:Periodic Company Report #WAES 0112USA01483
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	
		Health Professional	Celebrex	C				
			Cozaar	C				
			Pepcid	C				
			Allopurinol	C				

			Chlorzoxazone	C		
			Colchicine	C		
			Nortriptyline	C		

Date:04/03/02ISR Number: 3920685-3Report Type:Periodic Company Report #WAES 0201USA00372
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Therapy Unspecified	C				
			Calcium Unspecified	C				
			Enalapril Maleate	C				
			Glucosamine	C				
			Prednisone	C				

Date:04/03/02ISR Number: 3920686-5Report Type:Periodic Company Report #WAES 0201USA00373
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx Unk	PS			3	DAY
	Oedema Peripheral		Actos	C				
	Pain In Extremity		Coumadin	C				
	Renal Disorder		Diovan	C				
			Lanoxin	C				
			Toprol Xl Tablets	C				
			Furosemide	C				

Date:04/03/02ISR Number: 3920687-7Report Type:Periodic Company Report #WAES 0201USA00379
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Evista	C				

Serzone	C
Propoxyphene Hydrochloride	C
Triazolam	C

Date:04/03/02ISR Number: 3920688-9Report Type:Periodic Company Report #WAES 0201USA00384
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:04/03/02ISR Number: 3920690-7Report Type:Periodic Company Report #WAES 0201USA00228
Age: Gender:Female I/FU:I

Outcome	PT
	Blindness
	Chest Pain
	Feeling Abnormal
	Heart Rate Irregular

Muscular Weakness
Paraesthesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Premarin	C				

Date:04/03/02ISR Number: 3920692-0Report Type:Periodic Company Report #WAES 0201USA00236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920695-6Report Type:Periodic Company Report #WAES 0112USA01517
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920697-XReport Type:Periodic Company Report #WAES 0201USA00259
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920698-1Report Type:Periodic Company Report #WAES 0112USA01521
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	

Date:04/03/02ISR Number: 3920700-7Report Type:Periodic Company Report #WAES 0112USA01527
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastric Disorder							
	Headache		Colestid	C				
	Joint Swelling		Fosamax	C				
			Spectazole	C				
			Tenoretic	C				
			Ascorbic Acid	C				
			Calcium	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920702-0Report Type:Periodic Company Report #WAES 0201USA00264
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Other	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Norpace-Norpace Cr	C				
			Prilosec	C				

			Toprol Xl Tablets	C

Date:04/03/02ISR Number: 3920704-4Report Type:Periodic Company Report #WAES 0112USA01753
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Diarrhoea							
	Nausea		Diovan	C				
			Premarin	C				
			Synthroid	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920705-6Report Type:Periodic Company Report #WAES 0201USA00269
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Elavil	C				
			Lipitor	C				
			Restoril	C				
			Acetaminophen (+) Butalbital	C				
			Metoprolol	C				
			Nortriptyline Hydrochloride	C				

Date:04/03/02ISR Number: 3920706-8Report Type:Periodic Company Report #WAES 0112USA01754
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Platelet Count Decreased	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:04/03/02ISR Number: 3920708-1Report Type:Periodic Company Report #WAES 0112USA01555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthma	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:04/03/02ISR Number: 3920710-XReport Type:Periodic Company Report #WAES 0112USA01572
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Musculoskeletal Stiffness	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Pain	Professional				
MG/DAILY/PO						
	Pruritus	Company	Biaxin	C		
	Rash	Representative	Tylenol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920711-1Report Type:Periodic Company Report #WAES 0201USA00272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920712-3Report Type:Periodic Company Report #WAES 0112USA01573
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody	Health Professional	Tab Vioxx	PS		ORAL	25 MG/PO	
	Positive Hepatic Function Abnormal Systemic Lupus Erythematosus	Company Representative						

Date:04/03/02ISR Number: 3920713-5Report Type:Periodic Company Report #WAES 0112USA01574
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920715-9Report Type:Periodic Company Report #WAES 0112USA01594
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Accupril	C				
			Arthotec	C				

Glucophage Xr	C
Levoxyl	C
Ultram	C
Glyburide	C

Date:04/03/02ISR Number: 3920716-0Report Type:Periodic Company Report #WAES 0112USA01595
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920717-2Report Type:Periodic Company Report #WAES 0112USA01617
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920718-4Report Type:Periodic Company Report #WAES 0201USA01084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920719-6Report Type:Periodic Company Report #WAES 0112USA01638
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Blister	Health Professional						
	Fatigue		Avapro	C				
	Nervousness		Zyrtec	C				

Date:04/03/02ISR Number: 3920723-8Report Type:Periodic Company Report #WAES 0201USA01088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
			Estrace	C				
			Lescol	C				

Date:04/03/02ISR Number: 3920724-XReport Type:Periodic Company Report #WAES 0112USA01814
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/BID/PO	Depression					

Date:04/03/02ISR Number: 3920725-1Report Type:Periodic Company Report #WAES 0201USA01097
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Fatigue						PO	
	Hyperhidrosis		Flexeril	C				
	Liver Tenderness		Guaifenex La	C				
			Neurontin	C				
			Premarin	C				
			Wellbutrin Sr	C				
			Zyrtec	C				
			Ch Ondroitin (+)					
			Glucosamine	C				
			Folic Acid	C				
			Timolol	C				
			Trazodone	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920726-3Report Type:Periodic Company Report #WAES 0201USA01098
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphthous Stomatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Oral Infection							

Date:04/03/02ISR Number: 3920727-5Report Type:Periodic Company Report #WAES 0112USA01817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Paraesthesia							
	Pruritus		Altace	C				
	Rash		Fosamax	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920728-7Report Type:Periodic Company Report #WAES 0201USA00967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Fatigue	Professional					PO	
	Influenza Like Illness	Company						
	Muscular Weakness	Representative						

Date:04/03/02ISR Number: 3920729-9Report Type:Periodic Company Report #WAES 0201USA00969
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

		Pain In Extremity	Professional				
PO							
			Company Representative				

Date:04/03/02ISR Number: 3920731-7Report Type:Periodic Company Report #WAES 0112USA01652
Age:44 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG /PO							
		Cold Sweat					
		Diarrhoea					
		Inflammation					
		Insomnia					
		Myalgia					
		Paraesthesia					
		Peripheral Coldness					
		Pruritus					

Date:04/03/02ISR Number: 3920732-9Report Type:Periodic Company Report #WAES 0112USA01664
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL
PO							
				Celebrex	C		

Date:04/03/02ISR Number: 3920734-2Report Type:Periodic Company Report #WAES 0201USA00970
Age:90 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920735-4Report Type:Periodic Company Report #WAES 0112USA01671
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	15 MG /DAILY/PO	2 WK

Date:04/03/02ISR Number: 3920737-8Report Type:Periodic Company Report #WAES 0201USA00974
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-25 MG DAILY PO	
		Health Professional	Evista	C				
			Fosamax	C				
			Prilosec	C				
			Diclofenac Sodium	C				

Date:04/03/02ISR Number: 3920738-XReport Type:Periodic Company Report #WAES 0112USA01680
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Tab Vioxx 25 Mg	SS		ORAL	25MG/DAILY /PO	
			Premarin	C				

Date:04/03/02ISR Number: 3920740-8Report Type:Periodic Company Report #WAES 0112USA01690
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vision Blurred							

Date:04/03/02ISR Number: 3920742-1Report Type:Periodic Company Report #WAES0112USA01696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG /DAILY/PO	
	Sinusitis							
			Avonex	C				
			Nasacort Aq	C				
			Neurontin	C				
			Valium	C				
			Nortriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920743-3Report Type:Periodic Company Report #WAES 0201USA00979
Age:75 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920745-7Report Type:Periodic Company Report #WAES 0112USA01700
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920746-9Report Type:Periodic Company Report #WAES 0201USA00982
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
			Migrazone	C				
			Neurontin	C				
			Paxil	C				
			Premarin	C				
			Protonix	C				
			Skelaxin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3920747-0Report Type:Periodic Company Report #WAES 0112USA01744
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Autoimmune Disorder	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	

Date:04/03/02ISR Number: 3920749-4Report Type:Periodic Company Report #WAES 01120536
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920751-2Report Type:Periodic Company Report #WAES 01120545
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	'Tab Vioxx 12.5mg	PS		ORAL	12.5MG /DAILY	
	Gastritis						PO	
	Upper Gastrointestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920752-4Report Type:Periodic Company Report #WAES 01120548
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920758-5Report Type:Periodic Company Report #WAES 01120550
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920767-6Report Type:Periodic Company Report #WAES 01120551
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920780-9Report Type:Periodic Company Report #WAES 01120552
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920788-3Report Type:Periodic Company Report #WAES 01120554
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920791-3Report Type:Periodic Company Report #WAES 01120555
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920792-5Report Type:Periodic Company Report #WAES 01120558
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Tab Prinivil	SS		ORAL	PO	
		Company Representative						

Date:04/03/02ISR Number: 3920794-9Report Type:Periodic Company Report #WAES 01120560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Health	Tab Vioxx	PS		ORAL	50MG DAILY PO	
		Professional	Pravachol	C				
		Company Representative						

Date:04/03/02ISR Number: 3920795-0Report Type:Periodic Company Report #WAES 0112USA01922
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Disease	Professional						

Date:04/03/02ISR Number: 3920796-2Report Type:Periodic Company Report #WAES 01120414
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:04/03/02ISR Number: 3920797-4Report Type:Periodic Company Report #WAES 0112USA01923
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Increased	Professional Company Representative	Celebrex	C				

Date:04/03/02ISR Number: 3920798-6Report Type:Periodic Company Report #WAES 0112USA01761
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Fioricet Tablets	C				
			Imitrex	C				
			Nasonex	C				
			Synthroid	C				
			Buspirone Hydrochloride	C				
			Diazepam	C				
			Estradiol	C				
			Sucralfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920799-8Report Type:Periodic Company Report #WAES 01120439
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Hiccups		Lipitor	C				
			Plavix	C				
			Prinivil	C				

Date:04/03/02ISR Number: 3920800-1Report Type:Periodic Company Report #WAES 0112USA01762
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAI.Y/PO	
			Nexium 40 Mg	SS			40 MG/DAILY	
			Lotrel	C				
			Zocor	C				
			Doxazosin	C				
			Ranitidine	C				

Date:04/03/02ISR Number: 3920801-3Report Type:Periodic Company Report #WAES 01120441
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Lipitor	C				
			Nexium	C				
			Aspirin	C				
			Verapamil	C				

Date:04/03/02ISR Number: 3920802-5Report Type:Periodic Company Report #WAES 0112USA01767
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actos	C				
			Diovan	C				
			Hydrodiuril	C				
			Niaspan	C				
			Norvasc	C				
			Prilosec	C				
			Toprol Xl Tablets	C				
			Sotalol Hydrochloride	C				

Date:04/03/02ISR Number: 3920803-7Report Type:Periodic Company Report #WAES 01120464
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

Date:04/03/02ISR Number: 3920804-9Report Type:Periodic Company Report #WAES 01120465
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920805-0Report Type:Periodic Company Report #WAES 01120467
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920806-2Report Type:Periodic Company Report #WAES 0112USA01772
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Combivent	C				
			Coreg	C				
			Flovent	C				
			Lipitor	C				
			Norvasc	C				
			Vasotec	C				

Date:04/03/02ISR Number: 3920807-4Report Type:Periodic Company Report #WAES 01120469
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920808-6Report Type:Periodic Company Report #WAES 0112USA01775
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Weight Increased		Toprol Xl	C				
			Digoxin	C				
			Hydrochlorothiazide	C				
			Minoxidil	C				

Date:04/03/02ISR Number: 3920809-8Report Type:Periodic Company Report #WAES 0112USA01805
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
	Blood Pressure Increased	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920810-4Report Type:Periodic Company Report #WAES 0112USA01811
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Blood Pressure Increased							
	Dyspepsia		Atenolol	C				
	Pollakiuria							

Date:04/03/02ISR Number: 3920811-6Report Type:Periodic Company Report #WAES 0112USA01813
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	1 WK
			Ativan	C				
			Hydrodiuril	C				
			Nexium	C				
			Prinivil	C				

Date:04/03/02ISR Number: 3920812-8Report Type:Periodic Company Report #WAES 01120472
Age:72 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Lortab	C				
			Nexium	C				
			Zocor	C				

				Zyrtec	C		

Date:04/03/02ISR Number: 3920813-XReport Type:Periodic Company Report #WAES 01114287
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Acetaminophen (+) Hydrocodone Bi	C				
			Spironolactone	C				

Date:04/03/02ISR Number: 3920814-1Report Type:Periodic Company Report #WAES 0112USA02296
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920815-3Report Type:Periodic Company Report #WAES 01113240
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	DAILY/PO
			Ambien	C				
			Hydrocortone	C				
			Imodium	C				
			Paregoric Usp	C				
			Plendil	C				
			Toprol Xl Tablets	C				
			Zantac	C				

Date:04/03/02ISR Number: 3920816-5Report Type:Periodic Company Report #WAES 0112USA02306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Aspirin	C				

Date:04/03/02ISR Number: 3920817-7Report Type:Periodic Company Report #WAES 01120485
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
	Tongue Ulceration						PO	
	Weight Increased		Hytrin	C				
			Prilosec	C				
			Acetazolamide	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Saw Palmetto	C				

			Spironolactone	C
			Thyroid	C
			Vitamin E	C

Date:04/03/02ISR Number: 3920818-9Report Type:Periodic Company Report #WAES 0112USA02131
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Hydrodiuril	C				
			Synthroid	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3920819-0Report Type:Periodic Company Report #WAES 01120534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920820-7Report Type:Periodic Company Report #WAES 0112USA02150
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Novadex	C				
			Xanax	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920821-9Report Type:Periodic Company Report #WAES 01113245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Professional						

Date:04/03/02ISR Number: 3920822-0Report Type:Periodic Company Report #WAES 01113247
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Prinzide	C				

Date:04/03/02ISR Number: 3920823-2Report Type:Periodic Company Report #WAES 01113249
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intestinal Obstruction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea	Professional						
	Vomiting							

Date:04/03/02ISR Number: 3920824-4Report Type:Periodic Company Report #WAES 01113255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
			Fosamax	C				
			Miacalcin	C				
			Premarin	C				

Date:04/03/02ISR Number: 3920825-6Report Type:Periodic Company Report #WAES 01113288
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Claritin	C				
			Diovan	C				
			Premarin	C				
			Provera	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920826-8Report Type:Periodic Company Report #WAES 01113305
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Neurontin	C				

Date:04/03/02ISR Number: 3920827-XReport Type:Periodic Company Report #WAES 01113308
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							

Date:04/03/02ISR Number: 3920828-1Report Type:Periodic Company Report #WAES 01113315
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG/DAILY/PO	
			Methylprednisolone Sodium Succin	C				

Date:04/03/02ISR Number: 3920830-XReport Type:Periodic Company Report #WAES 0112USA02155
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Herpes Zoster	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Ayr	C		
			Duratuss	C		
			Nasocort	C		

Date:04/03/02ISR Number: 3920835-9Report Type:Periodic Company Report #WAES 01113393
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash	Consumer	Tab Vioxx Unk	PS		ORAL
PO						

Date:04/03/02ISR Number: 3920836-0Report Type:Periodic Company Report #WAES 0112USA02160
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hypoaesthesia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
			Cozaar	C		
			Duratuss G	C		

Date:04/03/02ISR Number: 3920840-2Report Type:Periodic Company Report #WAES 01113396
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						

Tab
Hydroxychloroquineso
4 200mg SS
200 MG /BID

Date:04/03/02ISR Number: 3920842-6Report Type:Periodic Company Report #WAES 0112USA02171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
			Alcaine	C				
			Calcium	C				
			Glucosamine	C				
			Potassium	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920845-1Report Type:Periodic Company Report #WAES 01114212
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Gastrointestinal Disorder	Professional						

Date:04/03/02ISR Number: 3920848-7Report Type:Periodic Company Report #WAES 0112USA02173
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Rexan (Acyclovir)	C				
			Doxycycline	C				

Date:04/03/02ISR Number: 3920850-5Report Type:Periodic Company Report #WAES 01114234
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920854-2Report Type:Periodic Company Report #WAES 01114235
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG /DAILY/PO	

Date:04/03/02ISR Number: 3920856-6Report Type:Periodic Company Report #WAES 0112USA02177
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinusitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 WK
			Aciphex	C				

Duratuss G C

Date:04/03/02ISR Number: 3920860-8Report Type:Periodic Company Report #WAES 01114237
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx Unk	PS		ORAL	BID/PO	

Date:04/03/02ISR Number: 3920861-XReport Type:Periodic Company Report #WAES 0112USA02192
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Claritin	C				
			Menest	C				
			Synthroid	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920863-3Report Type:Periodic Company Report #WAES 01114254
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920864-5Report Type:Periodic Company Report #WAES 01091090
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25MG DAILY PO						
	Erythema	Health	Buspar	C		
	Pharyngeal Oedema	Professional	Cardizem Cd	C		
	Pharyngitis		Aspirin	C		

Date:04/03/02ISR Number: 3920865-7Report Type:Periodic Company Report #WAES 01114258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG						
	Fatigue					
/DAILY/PO						
	Headache		Amibid La	C		
	Jaundice		Elavil	C		
	Nausea		Lotensin	C		
	Neck Pain		Terazosin			
	Rash		Hydrochloride	C		
			Thyroid	C		

Date:04/03/02ISR Number: 3920866-9Report Type:Periodic Company Report #WAES 01114268
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Pain In Extremity					
MG/DAILY/PO						
			Tab Zocor Unk	SS		

			Oxycodone	C

Date:04/03/02ISR Number: 3920867-0Report Type:Periodic Company Report #WAES 01114285
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Increased	Professional Company Representative						

Date:04/03/02ISR Number: 3920869-4Report Type:Periodic Company Report #WAES 01091190
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Serevent	C				
			Zocor	C				

Date:04/03/02ISR Number: 3920873-6Report Type:Periodic Company Report #WAES 01091443
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Health Professional	Aspirin	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3920876-1Report Type:Periodic Company Report #WAES 01120954
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Circulatory Collapse	Consumer	Tab Vioxx 25 Mg	PS			ORAL
PO 2 YR							
	Upper Limb Fracture						

Date:04/03/02ISR Number: 3920877-3Report Type:Periodic Company Report #WAES 01120962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Aciphex	C		
			Diovan	C		
			Pravachol	C		
			Propranolol	C		

Date:04/03/02ISR Number: 3920878-5Report Type:Periodic Company Report #WAES 01120965
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Mouth Ulceration	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920879-7Report Type:Periodic Company Report #WAES 01120977
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3920880-3Report Type:Periodic Company Report #WAES 01091444
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Health Professional	Fosamax	C				
			Ogen	C				
			Prinzide	C				
			Medroxyprpgesterone Acetate	C				

Date:04/03/02ISR Number: 3920881-5Report Type:Periodic Company Report #WAES 01120979
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atacand	C				
			Celebrex	C				
			Lipitor	C				
			Zoloft	C				
			Atenolol	C				
			Clonazepam	C				

Date:04/03/02ISR Number: 3920882-7Report Type:Periodic Company Report #WAES 01120989
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Flatulence						MG/DAILY/PO	
			Nexium	C				
			Premarin	C				
			Zestril	C				

Date:04/03/02ISR Number: 3920883-9Report Type:Periodic Company Report #WAES 01121002
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	5 DAY
	Oedema	Professional	Celebrex	C				

Date:04/03/02ISR Number: 3920884-0Report Type:Periodic Company Report #WAES 01091497
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Health Professional	Baycol	C				
			Celebrex	C				
			Fosamax	C				
			Synthroid	C				

			Lorazepam	C		
			Metoprolol	C		
			Ultram	C		
			Lodine Xl	C		
			Paxil	C		
			Prilosec	I		

Date:04/03/02ISR Number: 3920885-2Report Type:Periodic Company Report #WAES 01091598
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	

Date:04/03/02ISR Number: 3920886-4Report Type:Periodic Company Report #WAES 01121023
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Fosamax	C				
			Synthroid	C				
			Folic Acid	C				
			Metoprolol Tartrate	C				
			Quinine Sulfate	C				

Date:04/03/02ISR Number: 3920887-6Report Type:Periodic Company Report #WAES 01091601
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Dizziness		Ativan	C				
	Drug Ineffective		Celebrex	C				
			Detrol	C				

Elavil	C
Evista	C
Lipitor	C
Microzide	C
Plendil	C
Synthroid	C
Toprol Xl Tablets	C

Date:04/03/02ISR Number: 3920888-8Report Type:Periodic Company Report #WAES 0112USA01055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Jaundice	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920889-XReport Type:Periodic Company Report #WAES 01091650
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Professional	Vasotec	C				
			Vivelle-Dot	C				
			Medroxyprogesterone Acetate	C				

Date:04/03/02ISR Number: 3920890-6Report Type:Periodic Company Report #WAES 0112USA01057
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Tab Vioxx Unk	PS				
	International Normalised Ratio Increased	Professional	Coumadin	C				
		Company Representative						

Date:04/03/02ISR Number: 3920891-8Report Type:Periodic Company Report #WAES 01091707
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY PO	
	Disease	Professional						
	Nausea		Lanoxin	C				
			Premarin	C				
			Tylenol With Codeine #3	C				

Date:04/03/02ISR Number: 3920892-XReport Type:Periodic Company Report #WAES 01114291
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Intolerance	Health Professional	Vioxx	PS			ORAL PO

Date:04/03/02ISR Number: 3920893-1Report Type:Periodic Company Report #WAES 01091723
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diabetes Mellitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK PO	
	Inadequate Control	Health Professional	Insulin	C				

Date:04/03/02ISR Number: 3920894-3Report Type:Periodic Company Report #WAES 01092174
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Nausea		Aspirin	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3920895-5Report Type:Periodic Company Report #WAES 01114295
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920896-7Report Type:Periodic Company Report #WAES 01114298
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3920897-9Report Type:Periodic Company Report #WAES 01114347
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance	Health Professional	Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY	
	Hyperhidrosis						PO	
	Nausea		Fioricet Tablets	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				

Date:04/03/02ISR Number: 3920898-0Report Type:Periodic Company Report #WAES 01114395
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Dyspepsia		Effexor Xr	C				
	Nausea		Levoxyl	C				

				Atenolol	C		

Date:04/03/02ISR Number: 3920899-2Report Type:Periodic Company Report #WAES 01114400
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Vioxx 50 Mg	PS		ORAL	50MG DAILY PO	
			Tab Vioxx 12.5 Mg	SS		ORAL	12.5MG DAILY PO	
			Accupril	C				
			Humulin	C				
			Lipitor	C				
			Doxazosin	C				
			Ranitidine	C				

Date:04/03/02ISR Number: 3920900-6Report Type:Periodic Company Report #WAES 01114429
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Vioxx 25 Mg	PS		ORAL	25MG PRN PO	
	Headache		Caltrate And Vitamin D	C				
	Pruritus		Citrucel	C				
	Rash		Diimethyl Sulfone And Glucosamine	C				

			Estradiol	C		
			Vitamins	C		

Date:04/03/02ISR Number: 3920901-8Report Type:Periodic Company Report #WAES 01114432
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Dyspepsia						PO	
			Buspar	C				
			Fosamax	C				
			Nexium	C				
			Premarin	C				
			Quinine Sulfate	C				

Date:04/03/02ISR Number: 3920902-XReport Type:Periodic Company Report #WAES 01114465
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Vioxx 12.5 Mg	PS		ORAL	DAILY PO	
			Fosamax	C				
			Synthroid	C				
			Minerals	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3920903-1Report Type:Periodic Company Report #WAES 01114479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Consumer	Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
	Disease							
	Increased Appetite							

Date:04/03/02ISR Number: 3921010-4Report Type:Periodic Company Report #WAES 0112USA02195
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Ulcer							
			Hydrodiuril	C				
			Lipitor	C				
			Zestril	C				
			Allopurinol	C				
			Diltiazem Hydrochloride	C				
			Glucosamine	C				

Date:04/03/02ISR Number: 3921011-6Report Type:Periodic Company Report #WAES 0112USA02203
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cheilitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Dilantin	C				
			Fosamax	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921012-8Report Type:Periodic Company Report #WAES 0112USA02043
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:04/03/02ISR Number: 3921013-XReport Type:Periodic Company Report #WAES 0112USA02046
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prevacid	C				
			Synthroid	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:04/03/02ISR Number: 3921014-1Report Type:Periodic Company Report #WAES 0112USA02049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Company Representative Other	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	6 DAY

Date:04/03/02ISR Number: 3921015-3Report Type:Periodic Company Report #WAES 0112USA02057
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	

		Professional	Celebrex	C		

Date:04/03/02ISR Number: 3921016-5Report Type:Periodic Company Report #WAES 0112USA02067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:04/03/02ISR Number: 3921017-7Report Type:Periodic Company Report #WAES 0112USA02093
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative	Proscar	C				
			Allopurinol	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3921018-9Report Type:Periodic Company Report #WAES 0112USA02101
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Gastrointestinal Disorder							
	Hypoaesthesia							
	Swelling							

Date:04/03/02ISR Number: 3921019-0Report Type:Periodic Company Report #WAES 0112USA02112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
	Urticaria	Professional Company Representative						

Date:04/03/02ISR Number: 3921020-7Report Type:Periodic Company Report #WAES 0112USA02020
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Feeling Abnormal		Premarin	C				

Date:04/03/02ISR Number: 3921021-9Report Type:Periodic Company Report #WAES 0112USA02030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	

Musculoskeletal Stiffness
PO

Date:04/03/02ISR Number: 3921022-0Report Type:Periodic Company Report #WAES 0112USA01818
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx	PS		ORAL	PO	
			Celebrex	C				
			Duragesic	C				
			Lotrel	C				
			Oxycontin	C				
			Etodolac	C				

Date:04/03/02ISR Number: 3921023-2Report Type:Periodic Company Report #WAES 0112USA01849
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
	Hypertension		Tab Vioxx 12.5 Mg	SS		ORAL	12.5 MG/DAILY/PO	
			Claritin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921024-4Report Type:Periodic Company Report #WAES 0112USA01854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Faeces	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lotensin	C				

Date:04/03/02ISR Number: 3921025-6Report Type:Periodic Company Report #WAES 0112USA01866
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Claritin	C				
			Flonase	C				

Date:04/03/02ISR Number: 3921026-8Report Type:Periodic Company Report #WAES 0112USA01883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pharyngeal Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Tongue Oedema							

Date:04/03/02ISR Number: 3921027-XReport Type:Periodic Company Report #WAES 0112USA01886
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Weight Increased							
			Accupril	C				
			Flovent	C				
			K-Dur	C				

			Norvasc	C		
			Serevent	C		
			Furosemide	C		
			Glyburide	C		

Date:04/03/02ISR Number: 3921028-1Report Type:Periodic Company Report #WAES 0112USA01891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Centrum Silver	C				
			Elavil	C				
			Premarin	C				
			Ziac	C				
			Vitamin E	C				

Date:04/03/02ISR Number: 3921029-3Report Type:Periodic Company Report #WAES 0112USA01896
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921030-XReport Type:Periodic Company Report #WAES 0112USA02114
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Diarrhoea							
			Avapro	C				
			Hydrodiuril	C				
			Miacalcin	C				

Date:04/03/02ISR Number: 3921031-1Report Type:Periodic Company Report #WAES 0112USA02116
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Estropipate	C				

Date:04/03/02ISR Number: 3921032-3Report Type:Periodic Company Report #WAES 0112USA01954
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Urticaria							

Date:04/03/02ISR Number: 3921033-5Report Type:Periodic Company Report #WAES 0112USA01981
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
	Arthralgia					
			Aciphex	C		
			Ambien	C		
			Celebrex	C		
			Citracal	C		
			Darvocet-N	C		
			Flomax (Tamsulosin Hydrochloride)	C		

Date:04/03/02ISR Number: 3921034-7Report Type:Periodic Company Report #WAES 0112USA01987
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Fatigue							

Date:04/03/02ISR Number: 3921035-9Report Type:Periodic Company Report #WAES 0112USA01992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx	PS		ORAL	PO	1 DAY
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921036-0Report Type:Periodic Company Report #WAES 0112USA01999
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Altace	C				
			Zantac	C				
			Verapamil	C				

Date:04/03/02ISR Number: 3921037-2Report Type:Periodic Company Report #WAES 0112USA02011
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	DAILY PO	
	Urticaria							

Date:04/03/02ISR Number: 3921038-4Report Type:Periodic Company Report #WAES 0112USA02012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Duragesic	C				
			Lopid	C				
			Synthroid	C				

Date:04/03/02ISR Number: 3921039-6Report Type:Periodic Company Report #WAES 0112USA02016
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Professional
MG/DAILY/PO
Company
Representative

Date:04/03/02ISR Number: 3921040-2Report Type:Periodic Company Report #WAES 01114480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3921041-4Report Type:Periodic Company Report #WAES 01114484
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3921042-6Report Type:Periodic Company Report #WAES 01114486
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921043-8Report Type:Periodic Company Report #WAES 01114496
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	PO	
	Face Oedema	Professional						
	Oedema Peripheral	Company Representative						

Date:04/03/02ISR Number: 3921044-XReport Type:Periodic Company Report #WAES 01114497
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercholesterolaemia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Low Density Lipoprotein Increased		Prinzide	C				
			Synthroid	C				

Date:04/03/02ISR Number: 3921045-1Report Type:Periodic Company Report #WAES 01114507
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Vertigo							

Date:04/03/02ISR Number: 3921046-3Report Type:Periodic Company Report #WAES 01114513
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Efudex	C				

Date:04/03/02ISR Number: 3921047-5Report Type:Periodic Company Report #WAES 01114518
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Professional					MG/DAILY/PO	
			Paxil	C				

Date:04/03/02ISR Number: 3921048-7Report Type:Periodic Company Report #WAES 01114530
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
							MG/DAILY/PO	

Date:04/03/02ISR Number: 3921049-9Report Type:Periodic Company Report #WAES 01114535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation	Health	Tab Vioxx	PS		ORAL	PO	
	Drug Withdrawal Syndrome	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921050-5Report Type:Periodic Company Report #WAES 01114569
Age:61 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Toprol Xl Tablets	C				

Date:04/03/02ISR Number: 3921051-7Report Type:Periodic Company Report #WAES 01114605
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Blocadren	C				
			Estrace	C				
			Neurontin	C				

Date:04/03/02ISR Number: 3921052-9Report Type:Periodic Company Report #WAES 01114607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain In Extremity	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3921053-0Report Type:Periodic Company Report #WAES 01114612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	PRN/PO	
	Dyspepsia	Professional						
	Oedema Peripheral							

Date:04/03/02ISR Number: 3921054-2Report Type:Periodic Company Report #WAES 01114616
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Evista	C				

Date:04/03/02ISR Number: 3921055-4Report Type:Periodic Company Report #WAES 01114626
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuromyopathy	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3921056-6Report Type:Periodic Company Report #WAES 01114627
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921057-8Report Type:Periodic Company Report #WAES 01114640
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Paraesthesia							
			Claritin-D	C				

Date:04/03/02ISR Number: 3921058-XReport Type:Periodic Company Report #WAES 01114648
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Fosamax	C				

Date:04/03/02ISR Number: 3921059-1Report Type:Periodic Company Report #WAES 01114664
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Claritin	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3921060-8Report Type:Periodic Company Report #WAES 01120822
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS			ORAL
PO							
	Dyspnoea						
	Headache						
	Muscle Spasms						
	Neck Pain						
	Paraesthesia						

Date:04/03/02ISR Number: 3921061-XReport Type:Periodic Company Report #WAES 01120902
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fatigue						MG/DAILY/PO	
	Malaise		L-Thyroxin	C				
	Nausea		Normi-Nox	C				
	Oedema							

Date:04/03/02ISR Number: 3921062-1Report Type:Periodic Company Report #WAES 01120913
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
							MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921063-3Report Type:Periodic Company Report #WAES 01120916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3921064-5Report Type:Periodic Company Report #WAES 01120930
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
	Oedema Peripheral							

Date:04/03/02ISR Number: 3921065-7Report Type:Periodic Company Report #WAES 01120935
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							

Date:04/03/02ISR Number: 3921066-9Report Type:Periodic Company Report #WAES 01120938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3921067-0Report Type:Periodic Company Report #WAES 01120946
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dizziness							
	Headache		Coumadin	C				
			Plendil	C				

Date:04/03/02ISR Number: 3921068-2Report Type:Periodic Company Report #WAES 01120949
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3921069-4Report Type:Periodic Company Report #WAES 01120952
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Muscular Weakness							
	Nausea		Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921990-7Report Type:Periodic Company Report #WAES 0112USA01275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	11 DAY
	Drug Ineffective		Procardia	C				

Date:04/03/02ISR Number: 3921991-9Report Type:Periodic Company Report #WAES 0112USA01128
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3921992-0Report Type:Periodic Company Report #WAES 0112USA01133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 MON
			Glucotrol	C				

Date:04/03/02ISR Number: 3921993-2Report Type:Periodic Company Report #WAES 0112USA01135
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	

Date:04/03/02ISR Number: 3921994-4Report Type:Periodic Company Report #WAES 0112USA01143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx	PS		ORAL	50 MG/PO	
			Norvasc	C				
			Aspirin	C				
			Atenolol	C				

Date:04/03/02ISR Number: 3921996-8Report Type:Periodic Company Report #WAES 0112USA01150
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Sular	C				
			Chlorthalidone	C				

Date:04/03/02ISR Number: 3921997-XReport Type:Periodic Company Report #WAES 0112USA01154
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3921999-3Report Type:Periodic Company Report #WAES 0112USA01162
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health	Tab Vioxx	PS		ORAL	PO	
	Neck Mass	Professional						

Date:04/03/02ISR Number: 3922001-XReport Type:Periodic Company Report #WAES 0112USA01169
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	MG/DAILY/PO
	Oedema Peripheral							
			Estrace	C				
			Rhinocort	C				
			Singulair	C				
			Zyrtec	C				
			Guaifenesin	C				

Date:04/03/02ISR Number: 3922002-1Report Type:Periodic Company Report #WAES 0112USA01172
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO

Date:04/03/02ISR Number: 3922004-5Report Type:Periodic Company Report #WAES 01091873
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Deafness Health
MG/DAILY/PO
Professional Therapy Unspecified C

Date:04/03/02ISR Number: 3922006-9Report Type:Periodic Company Report #WAES 01091858
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	5 DAY
	Hyperbilirubinaemia	Professional						
	Jaundice							
	Nausea							
	Pruritus							
	Vomiting							

Date:04/03/02ISR Number: 3922008-2Report Type:Periodic Company Report #WAES 01092681
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
		Professional						

MG/DAILY/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3922010-0Report Type:Periodic Company Report #WAES 01092683
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Fatigue		Prilosec	C				
			Therapy Unspecified	C				

Date:04/03/02ISR Number: 3922014-8Report Type:Periodic Company Report #WAES 01092734
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia	Professional						

Date:04/03/02ISR Number: 3922016-1Report Type:Periodic Company Report #WAES 01092802
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Pain		Lipitor	C				
			Prinivil	C				
			Aspirin	C				

Date:04/03/02ISR Number: 3922018-5Report Type:Periodic Company Report #WAES 01091725
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Flexeril	C				

Date:04/03/02ISR Number: 3922020-3Report Type:Periodic Company Report #WAES 01091750
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional	Cardura	C				
			Timoptic	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3922024-0Report Type:Periodic Company Report #WAES 01091824
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Pain		Ascorbic Acid	C				
			Hormonal Contraceptive	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3922027-6Report Type:Periodic Company Report #WAES 01091844
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Abdominal Pain	Health	Tenormin	C				
	Dyspepsia	Professional	Hydrochlorothiazide (+) Triamter	C				

Date:04/03/02ISR Number: 3922030-6Report Type:Periodic Company Report #WAES 01114667
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celexa	C				
			Neurontin	C				
			Prempro	C				
			Prilosec	C				
			Seroquel	C				
			Synthroid	C				
			Wellbutrin Sr	C				
			Glyburide	C				

Date:04/03/02ISR Number: 3922032-XReport Type:Periodic Company Report #WAES 01114678
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional	Coumadin	C				

Date:04/03/02ISR Number: 3922033-1Report Type:Periodic Company Report #WAES 01114726
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/03/02ISR Number: 3922035-5Report Type:Periodic Company Report #WAES 01114774
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Methotrexate	C				

Date:04/03/02ISR Number: 3922036-7Report Type:Periodic Company Report #WAES 01120050
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Claritin-D	C				
			Estratest	C				
			Vitamins	C				

Date:04/03/02ISR Number: 3922038-0Report Type:Periodic Company Report #WAES 01120055
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 MON
	Urinary Tract Infection							

Date:04/03/02ISR Number: 3922040-9Report Type:Periodic Company Report #WAES 01120060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Myalgia							
	Paraesthesia							

Date:04/03/02ISR Number: 3922042-2Report Type:Periodic Company Report #WAES 01120065
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Calcium	C				

Date:04/03/02ISR Number: 3922044-6Report Type:Periodic Company Report #WAES 01120066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Fosamax	C				

Date:04/03/02ISR Number: 3922046-XReport Type:Periodic Company Report #WAES 01120067
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ PRN / PO	
		Company Representative	Allegra	C				
			Neurontin	C				
			Premarin	C				
			Prozac	C				

Date:04/03/02ISR Number: 3922049-5Report Type:Periodic Company Report #WAES 01120777
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Consumer	Tab Vioxx	PS		ORAL	PO	
	Sleep Attacks							

Date:04/03/02ISR Number: 3922051-3Report Type:Periodic Company Report #WAES 01120781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
			Thyroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3922052-5Report Type:Periodic Company Report #WAES 01120790
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Hydroduiril	C				
			Proscar	C				
			Zestril	C				

Date:04/03/02ISR Number: 3922054-9Report Type:Periodic Company Report #WAES 01120792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3922055-0Report Type:Periodic Company Report #WAES 01120798
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
	Abdominal Pain		Valium	C				
	Anxiety		Vicodin Tablets	C				
	Cholelithiasis							
	Disorientation							
	Dizziness							
	Flatulence							
	Headache							
	Tachycardia							

Date:04/03/02ISR Number: 3922057-4Report Type:Periodic Company Report #WAES 01120799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
	Blood Pressure Increased	Professional				
MG/DAILY/PO						
	Liver Disorder	Company				
	Renal Disorder	Representative				

Date:04/03/02ISR Number: 3922058-6Report Type:Periodic Company Report #WAES 01120805
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Rash					
MG/DAILY/PO						
			Hydroduiril	C		
			Lorazepam	C		

Date:04/03/02ISR Number: 3922060-4Report Type:Periodic Company Report #WAES 01120808
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL
SEE IMAGE						
	Joint Swelling		Aciphex	C		
			Norvasc	C		
			Vivelle	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3922063-XReport Type:Periodic Company Report #WAES 01120810
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Estrace	C				

Date:04/03/02ISR Number: 3922065-3Report Type:Periodic Company Report #WAES 01120816
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Vaginal Haemorrhage	Company Representative						

Date:04/03/02ISR Number: 3922068-9Report Type:Periodic Company Report #WAES 0201USA00206
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Headache		Darvocet-N	C				
	Syncope		Lotensin	C				
			Prilosec	C				
			Zocor	C				
			Folic Acid	C				
			Methotrexate	C				

Date:04/03/02ISR Number: 3922070-7Report Type:Periodic Company Report #WAES 0201USA00213
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Chest Pain	Health	Tab Vioxx 25 Mg	PS			ORAL
25 MG/1X/PO							
		Professional	Nitroquick	C			

Date:04/03/02ISR Number: 3922073-2Report Type:Periodic Company Report #WAES 0201USA00224
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Health Professional	Mobic	C				
			Xanax	C				
			Zoloft	C				

Date:04/03/02ISR Number: 3922074-4Report Type:Periodic Company Report #WAES 0201USA00084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:04/03/02ISR Number: 3922077-XReport Type:Periodic Company Report #WAES 0201USA00089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:04/03/02ISR Number: 3922078-1Report Type:Periodic Company Report #WAES 0201USA00100
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Dilantin	C				
			Sinemet	C				

Date:04/03/02ISR Number: 3922080-XReport Type:Periodic Company Report #WAES 0201USA00101
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Dyspnoea	Consumer	Tab Vioxx 25 Mg, 12.5 Mg	PS		ORAL	SEE IMAGE	
	Oedema Peripheral		Premarin	C				
			Prilosec	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Niacin	C				
			Vitamin E	C				

Date:04/03/02ISR Number: 3922082-3Report Type:Periodic Company Report #WAES 0201USA00104
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
MG/DAILY/PO							

Date:04/03/02ISR Number: 3922084-7Report Type:Periodic Company Report #WAES 0201USA00106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/03/02ISR Number: 3922087-2Report Type:Periodic Company Report #WAES 0201UDA00107
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Synthroid	C				

Date:04/03/02ISR Number: 3922094-XReport Type:Periodic Company Report #WAES 0201USA00295
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
	Pain	Health
	Pruritus	Professional
	Rash	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3922096-3Report Type:Periodic Company Report #WAES 0201USA00308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/03/02ISR Number: 3922098-7Report Type:Periodic Company Report #WAES 0201USA00313
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tongue Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
			Tab Buspirone Hcl 15 Mg	SS		ORAL	15 MG DAILY PO	
			Tab Estradiol 1 Mg	SS		ORAL	1 MG DAILY PO	
			Tab Diazepam 5 Mg	SS		ORAL	5 MG BID PO	
			Tab Effexor 200 Mg	SS		ORAL	200 MG DAILY PO	
			Tab Synthroid Unk	SS		ORAL	DAILY PO	
			Tab Acetaminophen/Butalb					

ital/Caffeine/Unk SS ORAL
PRN PO

Tab Roxidodone Unk SS ORAL
PRN PO

Inj Dilaudid Unk SS
INTRAVENOUS PRN IV

Date:04/03/02ISR Number: 3922109-9Report Type:Periodic Company Report #WAES 0201USA00159
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:04/03/02ISR Number: 3922110-5Report Type:Periodic Company Report #WAES 0201USA00164
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
							PO	
			Synthroid	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/02ISR Number: 3922113-0Report Type:Periodic Company Report #WAES 0201USA00172
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Plavix	C				
			Prevacid	C				
			Toprol Xl Tablets	C				
			Tricor	C				
			Zaroxolyn	C				
			Nitroglycerin	C				
			Spironolactone	C				

Date:04/03/02ISR Number: 3922115-4Report Type:Periodic Company Report #WAES 0201USA00173
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY PO	
	Dyspepsia							

Date:04/03/02ISR Number: 3922117-8Report Type:Periodic Company Report #WAES 0201USA00179
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
		Company Representative	Claritin	C				

Date:04/03/02ISR Number: 3922118-XReport Type:Periodic Company Report #WAES 0201USA00188
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO

Date:04/03/02ISR Number: 3922119-1Report Type:Periodic Company Report #WAES 0201USA00189
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Cozaar	C				
			Clonidine	C				
			Terazosin Hydrochloride	C				

Date:04/04/02ISR Number: 3894037-9Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00028
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Dehydration Feeling Cold		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3894423-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894426-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Attack		Aggrenox	C		ORAL		
			Pravachol	C				

Date:04/04/02ISR Number: 3894427-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00154
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Cirrhosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oesophageal Haemorrhage		[Therapy Unspecified]	C				

Date:04/04/02ISR Number: 3894431-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00243
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Bronchopneumonia		Digitoxin	C		ORAL		
	Duodenitis		Dipyrone	C		ORAL		
	Gastric Ulcer		Torsemide	C		ORAL		
	Gastritis		Tramadol Hydrochloride	C		ORAL		
	Gastritis Erosive							
	Gastroenteritis							
	Helicobacter							

Gastrointestinal
Haemorrhage
Haematemesis
Hiatus Hernia
Left Ventricular Failure
Pulmonary Congestion
Reflux Oesophagitis

Date:04/04/02ISR Number: 3894434-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Inadequate Control		Insulin	C				
SUBCUTANEOUS								
Initial or Prolonged	Fatigue							
	Haemolytic Anaemia							
	Jaundice							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3894435-3Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00227
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Other			Pantoprazole	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C				
			Folic Acid	C				
			Lactulose	C				
			Ferrous Sulfate	C				
			Aspirin	C				
			Quinine	C				
			Isosorbide Mononitrate	C				

Date:04/04/02ISR Number: 3894439-0Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00093
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		86 DAY
Initial or Prolonged	Asthenia		Oxazepam	C		ORAL		
	Hiatus Hernia		Betahistine Hydrochloride	C		ORAL		
			Aspirin Lysine	C		ORAL		
			Omeprazole	C		ORAL		
			Caffeine And Phenobarbital	C		ORAL		
			Piribedil	C				

Date:04/04/02ISR Number: 3894440-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Lactate Dehydrogenase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Enbrel	C				
PARENTERAL								

	Blood Urine Present		Methotrexate	C		
	Culture Urine Positive		Celebrex	C		
	Haematocrit Decreased		Folic Acid	C		
	Oedema Peripheral					
	Protein Urine Present					
	Streptococcal Infection					
	Thrombosis					
	White Blood Cells Urine Positive					

Date:04/04/02ISR Number: 3894441-9Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00041
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema							
	Oliguria							
	Renal Failure							
	Weight Increased							

Date:04/04/02ISR Number: 3894444-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Balance Disorder Csf White Blood Cell Count Positive Ear Pain Facial Palsy Fall Meningitis Aseptic Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894445-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:04/04/02ISR Number: 3894446-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal Meningitis		Vioxx Prevacid Prilosec	PS C C	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894448-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA03144
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx Nexium Estrace	PS C C	Merck & Co., Inc	ORAL		

Megace	C
Zestril	C
Isosorbide Mononitrate	C
Synthroid	C
Zaroxolyn	C
Toprol Xl Tablets	C
Lasix (Furosemide)	C
Acetaminophen And Hydrocodone Bitartrate	C
Potassium Chloride	C
Neurontin	C
Wellbutrin	C
Plavix	C

Date:04/04/02ISR Number: 3894450-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				

				Lopressor	C		
				Prinivil	C		
				Premarin	C		

Date:04/04/02ISR Number: 3894453-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA03213
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Lescol	C		ORAL		
	Platelet Function Test		Flomax					
	Abnormal		(Morniflumate)	C		ORAL		
			Vitamins					
			(Unspecified)	C		ORAL		
			Timoptic	C				
OPHTHALMIC								

Date:04/04/02ISR Number: 3894454-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA03281
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Meningitis		Vioxx	SS		ORAL		
			Synthroid	C				
			Xanax	C				

Date:04/04/02ISR Number: 3894457-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA03299
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Attack							

Date:04/04/02ISR Number: 3894458-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894460-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA03309
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894461-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00014
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
	Cerebrovascular Accident		Sinemet	C				
			Prevacid	C				
			Singulair	C				
			Norvasc	C				

Toprol Xl Tablets	C
Combivent	C
Serevent	C
Flovent	C

Date:04/04/02ISR Number: 3894464-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3894467-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00063
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/02ISR Number: 3895590-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02947
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacterial Infection Brain Abscess Spinal Disorder	Consumer	Tab Vioxx	PS		ORAL PO		

Date:04/04/02ISR Number: 3895598-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Meningitis	Health Professional Company	Tab Vioxx	PS		ORAL PO		

Representative

Date:04/04/02ISR Number: 3895599-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02960
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Ill-Defined Disorder						MG/DAILY/PO	
	Meningitis		Ambien	C				
	Pyrexia							

Date:04/04/02ISR Number: 3895601-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02603
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3895603-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02515
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Livedo Reticularis	Health	Tab Vioxx	PS		ORAL		
Initial or Prolonged		Professional Company Representative						

Date:04/04/02ISR Number: 3895605-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02626
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Meningitis	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged								

Date:04/04/02ISR Number: 3895624-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02598
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Meningitis	Consumer	Tab Vioxx 50 Mg	PS		ORAL		
Initial or Prolonged								

Date:04/04/02ISR Number: 3895629-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02485
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Upper Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:04/04/02ISR Number: 3895630-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02512
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx Unk	PS		ORAL	50 MG/UNK/PO	
			Depakote	C				
			Topamax	C				

Date:04/04/02ISR Number: 3895633-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged			Wellbutrin	C				

Date:04/04/02ISR Number: 3895668-2Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00199
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Foreign	Tab Vioxx					
Hospitalization -	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	12.5 MG	113 DAY
Initial or Prolonged	Gastrointestinal Disorder		Elavil	C				
	Malaise		Cetirizine Hydrochloride	C				

			Levothyroxine Na	C		

Date:04/04/02ISR Number: 3895812-7Report Type:Expedited (15-DaCompany Report #WAES 0203AUT00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pneumonia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID/PO	

Date:04/04/02ISR Number: 3895813-9Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00082
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema Cardiac Enzymes Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY/ PO	15 DAY
			Acepromazine Maleate (+) Meprobamate	C				
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Enoxaparin	C				
			Ferrousso4	C				
			Grape Seeds	C				
			Nifedipine	C				
			Spironolactone	C				

Date:04/04/02ISR Number: 3895816-4Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00080
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis Pancreatitis Acute	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

	Renal Failure Acute		Tab Piroxicam	SS		ORAL
PO						
			Tab Ibuprofen	SS		ORAL
PO						
			Tab Diclofenac	SS		ORAL
PO						
			Morphine	C		
			Phloroglucinol (+) Trimethylphlorogluci n	C		

Date:04/04/02ISR Number: 3895817-6Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Ulcer Perforation	Foreign	Tab Vioxx			
	Peritonitis	Other	(Rofecoxib)	PS		ORAL
25						
MG/DAILY/PO						
			Acetaminophen (+) Dihydrocodeine Bitartr	C		
			Diclofenac Na	C		
			Flupentixol Decanoate	C		
			Ranitidine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3895864-4Report Type:Expedited (15-DaCompany Report #WAES 0203SGP00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:04/04/02ISR Number: 3895879-6Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00093
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Asthenia	Other	(Rofecoxib)	PS		ORAL	86	DAY
	Hiatus Hernia		Aspirin Lysine	C				
			Betahistine Hydrochloride	C				
			Caffeine (+) Phenobarbital	C				
			Omeprazole	C				
			Oxazepam	C				
			Piribedil	C				

Date:04/04/02ISR Number: 3895882-6Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disseminated Intravascular Coagulation	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	97	DAY
	Myocardial Infarction		Citalopram Hydrobromide	C				

Date:04/04/02ISR Number: 3895883-8Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia General Physical Health	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	41 DAY
Disability Other	Deterioration Inappropriate Antidiuretic Hormone Secretion Malaise Malignant Neoplasm Of Pleura Malignant Pleural Effusion Renal Impairment		Acetaminophen/Propoxyphene Hydrochloride Bendroflumethiazide Bisoprolol Isosorbide Mononitrate Omeprazole	C C C C C				

Date:04/04/02ISR Number: 3895884-XReport Type:Expedited (15-DaCompany Report #WAES 0203ISR00008
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haemoglobin Decreased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3895893-0Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression	Foreign	Tab Vioxx					
Life-Threatening	Lower Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Haemorrhage							
PO								9 DAY
	Prothrombin Time		Tab Phenprocoumon	SS		ORAL	1.5 MG/DAILY	
	Shortened							
PO								
			Buprenorphine Hcl	C				
			Calcium Carbonate					
			(+) Cholecalciferol	C				
			Melperone Hcl	C				
			Paroxetine Hcl	C				

Date:04/04/02ISR Number: 3895963-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02433
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Tab Vioxx	PS		ORAL	PO	
	Overdose	Professional	Therapy Unspecified	SS				
	Pulmonary Congestion		Elavil	C				
			Soma	C				
			Wellbutrin	C				
			Methadone Hydrochloride	C				

Date:04/04/02ISR Number: 3895964-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00583
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Health	Tab Zocor	PS		ORAL	10	
Initial or Prolonged	Increased	Professional					MG/DAILY/PO	

	Aspartate		Tab Vioxx	SS		ORAL
PO						
	Aminotransferase		Tylenol With Codeine	SS		
	Increased		Premarin	C		
	Blood Lactate					
	Dehydrogenase Increased					
	Blood Triglycerides					
	Increased					
	Gamma-Glutamyltransferase					
	Increased					
	Hypercholesterolaemia					
	Pancreatitis					

Date:04/04/02ISR Number: 3895967-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA02628
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arterial Occlusive	Health	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
Hospitalization -	Disease	Professional	Lasix (Furosemide)	C		
Initial or Prolonged	Cardiogenic Shock	Company	Medrol Dosepak	C		
	Coronary Artery Disease	Representative	Norvasc	C		
	Coronary Artery Occlusion		Valtrex	C		
	Ejection Fraction		Vasotec	C		
	Decreased		Vicodin Tablets	C		
	Myocardial Infarction		Aspirin	C		
	Renal Failure Acute		Atenolol	C		
			Clonidine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3895970-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperhidrosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Pyrexia		Accupril	C				
			Lanoxin	C				
			Singulair	C				
			Aspirin	C				

Date:04/04/02ISR Number: 3895981-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02203
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						

Date:04/04/02ISR Number: 3895992-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02620
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Increased	Consumer	Tab Vioxx	PS		ORAL	50 MG, DAILY,	
Initial or Prolonged	Hypertension						PO	
			Lipitor	C				
			Premarin	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:04/04/02ISR Number: 3896022-XReport Type:Direct Company Report #CTU 165034
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Depression	Vioxx	PS		ORAL
1 X DAY, ORAL					
Initial or Prolonged	Lethargy				
	Migraine				
	Musculoskeletal Stiffness				
	Pain In Extremity				
	Vomiting				

Date:04/04/02ISR Number: 3896025-5Report Type:Direct Company Report #CTU 165036
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product			Role	Manufacturer	Route
Dose	Duration							
Life-Threatening	Confusional State		Vioxx	12.5mg	Merck	PS	Merck	ORAL
12.5MG DAILY								
Hospitalization -	Diabetes Mellitus							
ORAL								
Initial or Prolonged	Disorientation							
Disability	Dizziness							
Required	Emotional Distress							
Intervention to	Headache							
Prevent Permanent	Malaise							
Impairment/Damage	Memory Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/02ISR Number: 3896036-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02074
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia Totalis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Centrum	C				
			Claritin-D	C				
			Vanceril	C				
			Albuterol	C				

Date:04/04/02ISR Number: 3896076-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Meningitis		Prevacid	C				
			Prilosec	C				

Date:04/04/02ISR Number: 3896093-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA01158
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myalgia	Consumer	Vioxx	PS		ORAL	PO	
		Health Professional						

Date:04/04/02ISR Number: 3896096-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Thrombosis	Health	Vioxx	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company	Celebrex	C		
		Representative	Enbrel	C		
			Folic Acid	C		
			Methotrexate	C		

Date:04/04/02ISR Number: 3896097-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00340
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration	Health	Vioxx	PS		ORAL
12.5						
Initial or Prolonged	Nausea	Professional				
MG/DAILY/PO						
	Vomiting					

Date:04/04/02ISR Number: 3896098-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02567
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Consumer	Vioxx	PS		ORAL
25						
MG/DAILY/PO						
			Accupril	C		
			Glucophage	C		
			Pepcid	C		
			Pravachol	C		

			Synthroid	C
			Zyrtec	C
			Furosemide	C
			Nifedipine	C

Date:04/04/02ISR Number: 3896222-9Report Type:Direct Company Report #CTU 165050
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other Required Intervention to Prevent Permanent Impairment/Damage	Meningitis		Vioxx 25 Mg 1a Day Merck Drug	PS	Merck Drug			

Date:04/04/02ISR Number: 3896224-2Report Type:Direct Company Report #CTU 165051
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperaesthesia		Vioxx	PS		TAKEN AS INSTR.		
Other SAMPLED FROM PCP	Meningitis Aseptic							
	Muscle Spasms							
	Musculoskeletal Stiffness							
	Neck Pain		Prevacid	C				
	Pain		Cozaar	C				
			Aspirin	C				
			Flexeril	C				

Date:04/04/02ISR Number: 3896418-6Report Type:Expedited (15-DaCompany Report #WAES 0112USA02294
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Convulsion	Health	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Dizziness	Professional			
MG/DAILY/PO					
	Haemorrhagic Stroke	Company	Avandia	C	
	Headache	Representative	Elavil	C	
	Iron Deficiency Anaemia		Humalog	C	
	Rash		Humulin Nph	C	
	Rectal Haemorrhage		Prilosec	C	
			Prinivil	C	
			Vitamins	C	

Date:04/04/02ISR Number: 3896432-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
	Angina Pectoris
	Blood Cholesterol
	Abnormal
	High Density Lipoprotein
	Abnormal
	Low Density Lipoprotein
	Abnormal

		Tricuspid Valve Incompetence Ventricular Hypokinesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO							
			Company Representative	Claritin-D	C		
				Darvocet-N	C		
				Humibid	C		
				Inderal La	C		
				Nasonex	C		
				Prevacid	C		
				Nonsteroidal Anti-Inflammatory	C		

Date:04/05/02ISR Number: 3894818-1Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL
70 DAY						
Hospitalization -	Dyspnoea		Actonel	SS		
8 DAY						
Initial or Prolonged	Ejection Fraction		Prempro	C		
Disability	Decreased		Levoxyl	C		
	Embolic Stroke		Imipramine	C		
	Facial Paresis		Pyridoxine	C		
	Myocarditis		Vitamins (Unspecified)	C		
			Fish Oil (Unspecified)	C		
			[Therapy Unspecified]	C		
			Os-Cal	C		
			Synthroid	C		
			Mobic	C		
2 WK						

Date:04/05/02ISR Number: 3895213-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA00837
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nephrolithiasis		Premarin	C				
			Accupril	C				
			Methotrexate	C				

Date:04/05/02ISR Number: 3895216-7Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00069
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased							
	Blood Alkaline Phosphatase Increased							
	Cholestasis							
	Gamma-Glutamyltransferase Increased							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/02ISR Number: 3895220-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Platelet Count Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/02ISR Number: 3895223-4Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/02ISR Number: 3895932-7Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00131
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock Carotid Artery Stenosis Syncope	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	1 DAY

Date:04/05/02ISR Number: 3895989-3Report Type:Direct Company Report #CTU 165012E
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Unevaluable Event		Vioxx 25 Mg	PS			1 A DAY	

Date:04/05/02ISR Number: 3896056-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02405
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase Increased
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased
Disability	Blood Chloride Decreased
Other	Blood Cortisol Increased
	Blood Osmolarity Decreased
	Blood Urea Increased
	Clonic Convulsion
	Depressed Level Of Consciousness
	Difficulty In Walking
	Drug Level Below Therapeutic
	Dyskinesia
	Dysphonia
	Encephalopathy
	Fall
	Gait Disturbance
	Grand Mal Convulsion

		Head Injury					
		Heart Rate Irregular					
		Hyperglycaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyponatraemia	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG AM PO							
		Hyporeflexia	Professional	Coumadin	C		
		Movement Disorder		Depakote	C		
		Prostatic Specific		Lasix (Furosemide)	C		
		Antigen Increased		Reglan	C		
		Sedation		Digoxin	C		
		White Blood Cell Count					
		Increased					
		X-Ray Abnormal					

Date:04/05/02ISR Number: 3896060-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA01146
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anger	Health	Tab Vioxx 25 Mg	PS		ORAL
25MG BID PO							
Initial or Prolonged		Hallucinations, Mixed	Professional				
			Company				
			Representative				

Date:04/05/02ISR Number: 3896079-6Report Type:Expedited (15-DaCompany Report #A207250
Age:39 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Foreign	Viagra Tablets	PS		ORAL
50.00 MG							
Initial or Prolonged		Intestinal Ischaemia	Consumer				
TOTAL; PRN;							
ORAL							
				Rofecoxib	SS		ORAL
PRN; ORAL							
				Rilmenidine	C		
				Celiprolol	C		

Date:04/05/02ISR Number: 3896115-7Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00043
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Phlebothrombosis	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG /DAILY	528 DAY

Date:04/05/02ISR Number: 3896212-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Deep Vein Thrombosis	Health Professional	Tab Vioxx	PS		ORAL		
Initial or Prolonged		Company Representative	Prilosec	C				
			Cocaine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/02ISR Number: 3896214-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02543
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Health	Tab Vioxx	PS		ORAL		
Other	Gait Disturbance	Professional	Clozaril	C				
			Paxil	C				
			Clonazepam	C				

Date:04/05/02ISR Number: 3896367-3Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00033
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	2 DAY

Date:04/05/02ISR Number: 3896369-7Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00043
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Phlebothrombosis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	528 DAY

Date:04/05/02ISR Number: 3896421-6Report Type:Expedited (15-DaCompany Report #WAES 00100365
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Back Pain	Health
MG/DAILY/PO		
	Chondropathy	Professional
	Condition Aggravated	
	Difficulty In Walking	
	Dyspnoea	
	Fatigue	
	Fluid Retention	
	Headache	
	Intervertebral Disc	
	Disorder	
	Muscle Disorder	
	Muscular Weakness	
	Neuralgia	
	Neuropathy Peripheral	
	Pain	
	Rhabdomyolysis	
	Spinal Compression	
	Fracture	
	Weight Decreased	
	Weight Increased	

Date:04/05/02ISR Number: 3896425-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic	Consumer	Tab Vioxx Unk	PS		ORAL	25	
	Attack							
MG/DAILY/PO								
			Atacand	C				

Combivent	C
Coreg	C
Flovent	C
Lipitor	C
Plavix	C
Zoloft	C
Aspirin	C
Vitamin E	C

Date:04/05/02ISR Number: 3897071-8Report Type:Expedited (15-DaCompany Report #A207016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional	Zyrtec Tablets	PS				
			Vioxx	SS				
			Prozac	SS				

Date:04/06/02ISR Number: 3897527-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00014
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Diastolic Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Systolic Increased	Health Professional	Combivent	C				
	Cerebrovascular Accident		Flovent	C				
			Norvasc	C				
			Prevacid	C				
			Serevent	C				
			Sinemet	C				
			Singulair	C				
			Toprol Xl	C				

Date:04/08/02ISR Number: 3895760-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00082
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY						
Hospitalization - Initial or Prolonged	Chest Discomfort		Spironolactone	C		ORAL
	Heart Rate Increased		Ferrous Sulfate	C		
	Respiratory Rate Increased		Acetaminophen And Propoxyphene Hydrochloride	C		
			Grape Seeds	C		ORAL
			Nifedipine	C		ORAL
			Enoxaparin	C		
			Aceprometazine Maleate And Meprobamate	C		

Date:04/08/02ISR Number: 3895762-6Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00003
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Idiopathic Capillaritis		Vioxx	PS	Merck & Co., Inc	ORAL
59 DAY						
	Purpura		Vioxx	SS		ORAL
			Acetaminophen And Propoxyphene			

			Hydrochloride	C		ORAL

Date:04/08/02ISR Number: 3895765-1Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00017
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/02ISR Number: 3895767-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anal Haemorrhage Colitis Ischaemic		Vioxx Celiprolol Hydrochloride Rilmenidene Sildenafil Citrate	PS C C C	Merck & Co., Inc	ORAL	7	DAY

Date:04/08/02ISR Number: 3895772-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00512
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Oedema Psoriasis Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/02ISR Number: 3895913-3Report Type:Expedited (15-DaCompany Report #WAES 0204PRT00001
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:04/08/02ISR Number: 3895914-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00255
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/02ISR Number: 3895916-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02636
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Temperature Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Burning Sensation		Oxycodone	C				
	Chest Discomfort		[Therapy Unspecified]	C				
	Cough		Valium	C				
	Dyspnoea							
	Headache							
	Joint Stiffness							
	Musculoskeletal Stiffness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/02ISR Number: 3895917-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00124
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Ecotrin	C				
	Dyspnoea		Glyburide	C				
	Faeces Discoloured		Atenolol	C				
	Gastric Polypectomy		Norvasc	C				
	Gastrointestinal		Lasix (Furosemide)	C				
	Haemorrhage		Nitro-Bid	C				
	Haemoglobin Decreased							

Date:04/08/02ISR Number: 3895919-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00271
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:04/08/02ISR Number: 3896788-9Report Type:Direct Company Report #CTU 165205
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Rofecoxib	PS				

Date:04/08/02ISR Number: 3896791-9Report Type:Direct Company Report #CTU 165208
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Rofecoxib	PS			QD	
			Enalapril	SS				
			Metolazone	C				
			Levofloxacin	C				

Date:04/08/02ISR Number: 3896792-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:04/08/02ISR Number: 3896812-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Disease Recurrence	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Myocardial Infarction	Professional					PO	
			Lopressor	C				
			Norvasc	C				
			Premarin	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/02ISR Number: 3896815-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02887
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vascular	Consumer	Tab Vioxx	PS		ORAL	PO	
	Thrombosis		[Composition Unspecified]	C				

Date:04/08/02ISR Number: 3896830-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA03299
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 25	Transient Ischaemic	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Attack	Professional					MG/DAILY/PO	1 YR
		Company Representative						

Date:04/08/02ISR Number: 3896832-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA03281
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 25	Meningitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged							MG/DAILY/PO	
			Synthroid	C				
			Xanax	C				

Date:04/08/02ISR Number: 3896834-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Grand Mal Convulsion	Health	Tab Vioxx	PS		ORAL	PO	

Initial or Prolonged Professional Company Representative

Date:04/08/02ISR Number: 3896835-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA03309
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/08/02ISR Number: 3896839-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/08/02ISR Number: 3896840-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00063
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/08/02ISR Number: 3896842-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Balance Disorder Ear Pain Eating Disorder Facial Palsy Fall Meningitis Aseptic Weight Decreased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	

Date:04/08/02ISR Number: 3896845-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/08/02ISR Number: 3896846-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA03144
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS	ORAL 25 MG/PO
			Estrace	C	
			Lasix (Furosemide)	C	
			Megace	C	
			Neurontin	C	
			Nexium	C	
			Plavix	C	
			Synthroid	C	
			Toprol Xl Tablets	C	
			Wellbutrin	C	
			Zaroxolyn	C	
			Zestril	C	
			Acetaminophen (+) Hydrocodone Bi	C	
			Isosorbide Mononitrate	C	
			Potassium Chloride	C	

Date:04/08/02ISR Number: 3896926-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA03213
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Disability	Contusion	Health
	Haemorrhage	Professional
	Platelet Disorder	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Flomax (Morniflumate)	C				
Lescol	C				
Timoptic	C				
Vitamins	C				

Date:04/08/02ISR Number: 3896937-2Report Type:Expedited (15-DaCompany Report #A207205
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Somnolence	Foreign Consumer	Zoloft Tablets	PS		ORAL	50.00 MG TOTAL DAILY	ORAL
			Rofecoxib	SS		ORAL	25.00 MG TOTAL DAILY	ORAL
			Pantoprazole	C				
			Hydrochlorothiazide	C				

Date:04/08/02ISR Number: 3896957-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA00207
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Impaired Healing	Other	Tab Vioxx	PS		ORAL	PO	
			Advair	C				
			Celexa	C				

Date:04/08/02ISR Number: 3897027-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01002
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Health	Tab Vioxx 25mg	PS		ORAL	25 MG BID PO	
Hospitalization - Initial or Prolonged	First Degree Hypertension	Professional Company	Claritin	C				
Disability	Hypertensive Crisis	Representative	Cozaar	C				
Other	Supraventricular Extrasystoles		Aspirin	C				
			Atenolol	C				
			Gingko Biloba Extract	C				

Date:04/08/02ISR Number: 3897035-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00014
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG DAILY PO	
			Combivent	C				
			Flovent	C				
			Norvasc	C				
			Prevacid	C				
			Serevent	C				
			Sinemet	C				
			Singulair	C				

				Toprol Xl Tablets	C		

Date:04/08/02ISR Number: 3897037-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Hospitalization -		Professional						
Initial or Prolonged		Other	Lipitor	C				
Other			Monopril	C				
			Tenormin	C				
			Aspirin	C				
			Clonidine	C				

Date:04/08/02ISR Number: 3897038-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA03150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Cardiac Pacemaker							
	Insertion		Coumadin	C				
			Lasix (Furosemide)	C				
			Nexium	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Zestoretic	C				
			Digoxin	C				
			Potassium (Unspecified)	C				
			Thyroid	C				

Date:04/08/02ISR Number: 3897093-7Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Late Onset	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO; PRN PO;	
			Therapy Unspecified	C				

Date:04/08/02ISR Number: 3897097-4Report Type:Expedited (15-DaCompany Report #WAES 01106116
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Gliclazide	C				

Date:04/08/02ISR Number: 3897099-8Report Type:Expedited (15-DaCompany Report #WAES 01118525
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Blood Pressure Decreased
	Haemodynamic Instability
	Heart Rate Increased
	Hyperhidrosis

		Hypovolaemic Shock Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/BID; PO	11 DAY						

Date:04/08/02ISR Number: 3897426-1Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00259
Age:65 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alanine Aminotransferase	Foreign	Tab Vioxx			
Initial or Prolonged		Increased	Health	(Rofecoxib)	PS		ORAL
PO							
		Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Gamma-Glutamyltransferase Increased Hepatic Function Abnormal	Professional				

Date:04/08/02ISR Number: 3897440-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00243
Age:87 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Bronchopneumonia	Foreign	Tab Vioxx			
Hospitalization -		Duodenitis	Other	(Rofecoxib)	PS		ORAL
25 MG DAILY							
Initial or Prolonged		Gastric Ulcer					
PO							
		Gastritis Erosive		Digitoxin	C		
		Gastritis Haemorrhagic		Dipyrone	C		
		Gastroenteritis		Torsemide	C		
		Helicobacter		Tramadol Hcl	C		
		Gastrointestinal Haemorrhage					
		Left Ventricular Failure					
		Pulmonary Congestion					

Reflux Oesophagitis

Date:04/08/02ISR Number: 3897441-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00227
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anal Haemorrhage	Foreign	Tab Vioxx					
Other	Rectal Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	22 DAY
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Aspirin	C				
			Ferrousso4	C				
			Folic Acid	C				
			Isosorbide Mononitrate	C				
			Lactulose	C				
			Pantoprazole	C				
			Quinine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/02ISR Number: 3897795-2Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00041
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema	Foreign	Tab Vioxx					
	Oliguria	Other	(Rofecoxib)	PS		ORAL	PO	
	Renal Failure							
	Weight Increased							

Date:04/08/02ISR Number: 3897991-4Report Type:Expedited (15-DaCompany Report #A204966
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus	Health	Glucotrol Xl					
Initial or Prolonged	Gastroenteritis	Professional	Extended Release					
Required	Hypovolaemia		Tablets	PS		ORAL	5.00 MG	
Intervention to	Malabsorption						TOTAL;DAILY;O	
Prevent Permanent	Medication Error						RAL	
Impairment/Damage	Renal Failure Acute		Glucophage	SS		ORAL	3000.00 MG	
							TOTAL;DAILY;O	
							RAL	
			Naproxen	SS		ORAL	DAILY;ORAL	
			Vioxx	SS				
			Atacand	C				
			Hydrochlorothiazide	C				
			Actos	C				
			Aspirin	C				
			Humulin R	C				

Date:04/08/02ISR Number: 3898177-XReport Type:Direct Company Report #CTU 165172
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Duodenal Ulcer		Vioxx 25mg	PS		ORAL	25 MG, BID, ORAL	
			Molindone	C				
			Benztropine	C				
			Chlorpromazine	C				
			Phenytoin	C				
			Lorazepam	C				
			Clonidine Patch	C				
			Docusate	C				
			Acetaminophen	C				
			Ibuprofen	C				

Date:04/08/02ISR Number: 3898178-1Report Type:Direct Company Report #CTU 165173
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Vioxx 12.5 Mg					
Hospitalization -	Coma		Merck	PS	Merck	ORAL	12.5 MG,	
Initial or Prolonged	Confusional State						DAILY, ORAL	
Disability	Depressed Level Of		Avandia	C				
Required	Consciousness		Glucophage	C				
Intervention to	Dizziness		Diabeta	C				
Prevent Permanent	Encephalitis		Tenomin	C				
Impairment/Damage	Meningitis Viral		Prilosec	C				
	Schizophreniform Disorder							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/02ISR Number: 3898376-7Report Type:Direct Company Report #CTU 165198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Rofecoxib 25 Mg Merck	PS	Merck	ORAL	25 MG QD & PRN ORAL	
			Azathiprine 50 Mg Geq	SS		ORAL	50 MG BID ORAL	

Date:04/09/02ISR Number: 3896239-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02624
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL	1 MON	
Hospitalization - Initial or Prolonged	Oedema Peripheral		Lasix (Furosemide)	C				
	Pericardial Effusion		Cytomel	C				
Disability			Unithroid	C				
Other			Zyrtec	C				
			Maxzide	C				
			Celexa	C				
			Flonase	C			RESPIRATORY (INHALATION)	
			Celebrex	C				

Date:04/09/02ISR Number: 3896245-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	

Initial or Prolonged	Increased	Digoxin	SS	ORAL
10 DAY				
	Cardiac Failure	[Therapy		
	Confusional State	Unspecified]	SS	ORAL
7 DAY				
	Crepitations	Midamor	C	
	Disorientation	Lisuride Maleate	C	ORAL
	Dyspnoea	Fluindione	C	
	Hallucination	Lansoprazole	C	ORAL
	Pyrexia	Polyethylene Glycol		
	Rales	3350 And Potassium		
		Chloride And Sodium		
		Bicarbonate And		
		Sodium Chloride	C	ORAL
		Paraffin	C	ORAL
		Buflomedil		
		Hydrochloride	C	ORAL
		Clomipramine		
		Hydrochloride	C	ORAL
		Benserazide		
		Hydrochloride And		
		Levodopa	C	ORAL
		Amlodipine	C	ORAL
		Furosemide	C	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/02ISR Number: 3896246-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00012
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Cardiac Failure		Nadolol	C		ORAL		
	Congestive		Molsidomine	C		ORAL		
	Dyspnoea		Tramadol	C		ORAL		
			Nadolol	C		ORAL		
			Diacerein	C		ORAL		

Date:04/09/02ISR Number: 3896249-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
			Herbs (Unspecified)	C				
	Laboratory Test Abnormal							
	Lung Infiltration							
	Po2 Abnormal							
	Productive Cough							
	Red Blood Cell Sedimentation Rate Increased							
	Respiratory Disorder							
	Respiratory Failure							

Date:04/09/02ISR Number: 3896511-8Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00041
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oliguria							
	Renal Failure							
	Weight Increased							

Date:04/09/02ISR Number: 3896514-3Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00001
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
Initial or Prolonged	Melaena		Ranitidine Hydrochloride	C		ORAL		

Date:04/09/02ISR Number: 3896517-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00387
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Meningitis Viral							

Date:04/09/02ISR Number: 3897176-1Report Type:Direct Company Report #CTU 165298
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephrotic Syndrome		Vioxx 25mg	PS		ORAL	25MG PO QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/02ISR Number: 3897411-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Aggrenox	C				
			Pravachol	C				

Date:04/09/02ISR Number: 3897412-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00154
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Cirrhosis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Oesophageal Haemorrhage	Professional						

Date:04/09/02ISR Number: 3897413-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02050
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Cardiovascular Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:04/09/02ISR Number: 3897525-4Report Type:Expedited (15-DaCompany Report #WAES 0112USA01784
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	

Hospitalization - MG/DAILY/PO	Embolic Stroke	Health		
Initial or Prolonged Disability	Myocarditis	Professional	Actonel Unk	SS
			Levoxyl	C
			Mobic	C
			Os-Cal	C
			Prempro	C
			Synthroid	C
			Fish Oil (Unspecified)	C
			Imipramine	C
			Pyridoxine	C
			Vitamins (Unspecified)	C

Date:04/09/02ISR Number: 3897530-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Headache	Professional					MG/DAILY/PO	
	Myocardial Infarction		Lopressor	C				
	Ocular Hyperaemia		Norvasc	C				
			Premarin	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/02ISR Number: 3897532-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Function Test	Consumer	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Abnormal						MG/DAILY/PO	
	Meningitis		Prevacid	C				
			Prilosec	C				

Date:04/09/02ISR Number: 3897550-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Movement Disorder	Health	Tab Vioxx 50 Mg	PS		ORAL	50MG/1X/PO	
	Paralysis	Professional Company Representative						

Date:04/09/02ISR Number: 3897747-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00093
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx					
Initial or Prolonged	Asthenia	Health	(Rofecoxib)	PS		ORAL	12.5	
	Blood Iron Increased	Professional						
MG/DAILY, PO	86	DAY						
	Hiatus Hernia		Aspirin Lysine	C				
	Mean Cell Volume Decreased		Betahistine Hydrochloride	C				
			Caffeine (+) Phenobarbital	C				
			Omeprazole	C				
			Oxazepam	C				
			Piribedil	C				

Date:04/09/02ISR Number: 3897750-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus	Foreign	Tab Vioxx					
Hospitalization -	Inadequate Control	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Haemolytic Anaemia	Professional	Insulin	C				
		Other						

Date:04/09/02ISR Number: 3897840-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA01864
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Thromboplastin Time	Professional					MG/DAILY/PO	
	Prolonged	Company	Celebrex	C				
	Cardiolipin Antibody	Representative	Enbrel	C				
	Positive		Folic Acid	C				
	Culture Urine Positive		Methotrexate	C				
	Laboratory Test Abnormal							
	Oedema Peripheral							
	Streptococcal Infection							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/02ISR Number: 3897902-1Report Type:Expedited (15-DaCompany Report #S02-FRA-00583-01
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Foreign	Seropram (Citalopram					
Hospitalization -		Health	Hydrobromide)	PS		ORAL	20 MG QD PO	
Initial or Prolonged		Professional	Seropram (Citalopram					
		Other	Hydrobromide)	SS		ORAL	10 MG QD PO	
			Rofecoxib	SS				

Date:04/09/02ISR Number: 3899765-7Report Type:Expedited (15-DaCompany Report #02040111
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage	Foreign	Enbrel 25 Mg	PS				
SUBCUTANEOUS							25 MG, BIW,	
Initial or Prolonged		Health						
SUBCUTANEOUS								
		Professional	Rofecoxib	SS				
			Ibuprofen	SS				

Date:04/10/02ISR Number: 3896990-6Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00044
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY	
	Dyspnoea		Aspirin	C		ORAL		
	Joint Swelling		Levothyroxine Sodium	C		ORAL		
	Orthopnoea		Cimetidine	C		ORAL		
			Betahistine Hydrochloride	C		ORAL		

Date:04/10/02ISR Number: 3896991-8Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00028
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization -	Duodenal Ulcer		Aspirin	SS		ORAL		24 DAY
Initial or Prolonged	Haemorrhage		Nadroparin Calcium	SS				
SUBCUTANEOUS								15 DAY
	Endoscopy Abnormal		Ramipril	C		ORAL		
	Erosive Oesophagitis							
	Faecal Occult Blood Positive							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hiatus Hernia							
	Mallory-Weiss Syndrome							
	Melaena							

Date:04/10/02ISR Number: 3896992-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00465
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/02ISR Number: 3897211-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00338
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Feeling Abnormal		Premarin	C				
Other	Heart Rate Decreased							
	Infection							

Date:04/10/02ISR Number: 3897213-4Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Idiopathic		Vioxx	PS	Merck & Co., Inc	ORAL		
							6	DAY
Initial or Prolonged	Thrombocytopenic Purpura		Zolpidem Tartrate	C		ORAL		
			Antimicrobial (Unspecified)	C				

Date:04/10/02ISR Number: 3897215-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00194
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
							4	DAY
Initial or Prolonged	Dyspepsia		Dyazide	C		ORAL		
	Global Amnesia		Allegra	C				
	Hypertension		Zantac	C				
			Caltrate	C				
			Celebrex	C				

Date:04/10/02ISR Number: 3897216-XReport Type:Expedited (15-DaCompany Report #WAES 01109103
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:04/10/02ISR Number: 3897221-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Increased		Digoxin	SS		ORAL		10 DAY
	Cardiac Failure		[Therapy					
	Confusional State		Unspecified]	SS		ORAL		7 DAY
	Crepitations		Midamor	C				
	Disorientation		Lisuride Maleate	C		ORAL		
	Drug Toxicity		Fluindione	C				
	Dyspnoea		Lansoprazole	C		ORAL		
	Hallucination		Polyethylene Glycol					
	Pyrexia		3350 And Potassium					
	Rales		Chloride And Sodium					
			Bicarbonate And					
			Sodium Chloride	C		ORAL		
			Paraffin	C		ORAL		
			Buflomedil					
			Hydrochloride	C		ORAL		
			Clomipramine					
			Hydrochloride	C		ORAL		

		Benserazide Hydrochloride And Levodopa	C	ORAL
		Amlodipine	C	ORAL
		Furosemide	C	ORAL

Date:04/10/02ISR Number: 3897226-2Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00006
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Oedema Peripheral		Acenocoumarol	C		ORAL		
	Weight Increased		Chlorthalidone	C		ORAL		

Date:04/10/02ISR Number: 3897230-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/10/02ISR Number: 3897234-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00783
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Cozaar	C		ORAL		
			Atenolol	C				

Date:04/10/02ISR Number: 3897235-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Encephalitis		Vioxx	PS	Merck & Co., Inc	ORAL
41 DAY						
			Estrogens (Unspecified)	C		
			Tylenol Pm	C		
			Prilosec	C		
			Zyrtec	C		

Date:04/10/02ISR Number: 3898129-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA03168
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Hyperkalaemia	Literature	Tab Vioxx 50 Mg	PS		ORAL
50						
Other	Mucosal Dryness	Health				
MG/DAILY/PO 2 WK						
	Renal Failure Acute	Professional Company Representative	Furosemide	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/02ISR Number: 3898343-3Report Type:Expedited (15-DaCompany Report #WAES 0203DNK00014
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Weight Increased	Foreign Other	Tab Vioxx (Rofecoxib) 25 Mg	PS		ORAL	12.5 MG/DAILY	23 DAY
Disability			Aspirin	C				
			Bendroflumethiazide	C				

Date:04/10/02ISR Number: 3898345-7Report Type:Expedited (15-DaCompany Report #WAES 0203DNK00013
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	17 DAY
			Acetaminophen	C				
			Fenoterol Hydrobromide (+)					
			Ipratropium B	C				
			Furosemide	C				
			Methimazole	C				
			Prednisolone	C				
			Salmeterol Xinafoate	C				
			Spironolactone	C				
			Tramadol	C				

Date:04/10/02ISR Number: 3898348-2Report Type:Expedited (15-DaCompany Report #WAES 0203PRT00007
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Haematemesis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	16 DAY
	Melaena Upper Gastrointestinal Haemorrhage		Thiocolchicoside	C				

Date:04/10/02ISR Number: 3898381-0Report Type:Expedited (15-DaCompany Report #HQ3002609JUL2001
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum	Health Professional	Lodine (Etodolac)	PS		ORAL	400 MG DAILY, ORAL	
	Dyspnoea							
	Gastritis		Vioxx (Rofecoxib, Tablet)	SS				
	Gastritis Erosive		Norvasc (Amlodipine Besilate)	C				
	Gastrointestinal Haemorrhage		Lasix (Furosemide)	C				
	Hypochromic Anaemia		Ecotrin (Acetylsalicylic Acid)	C				
	Melaena		Prilosec (Omeprazole)	C				
			Potassiuim (Potassium0	C				
			Zocor (Simvastatin0	C				
			Darvocet-N (Dextropropoxyphene/ Paracetamol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/10/02ISR Number: 3898584-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02624
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Joint Swelling	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Oedema Peripheral	Professional					MG/DAILY/PO	
Initial or Prolonged	Pericardial Effusion	Company	Celebrex	C				
Disability		Representative	Celexa	C				
Other			Cytomel	C				
			Flonase	C				
			Lasix (Furosemide)	C				
			Maxzide	C				
			Unithroid	C				
			Zyrtec	C				

Date:04/10/02ISR Number: 3899379-9Report Type:Direct Company Report #CTU 165433
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx 12.5mg Merck & Co. Inc.	PS	Merck & Co. Inc.	ORAL	2 PILLS	
							DAILY ORAL	

Date:04/10/02ISR Number: 3899555-5Report Type:Direct Company Report #CTU 165444
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25mg	PS			25MG QD 047	18 MON
Hospitalization -	Congestive		Glucophage	C				
Initial or Prolonged	Cardiomyopathy		Nexium	C				
Disability	Chest Pain		Reglan	C				
Required	Cough							
Intervention to	Dyspnoea							
Prevent Permanent	Gastrooesophageal Reflux							
Impairment/Damage	Disease							

Hiatus Hernia
Kidney Infection
Mass
Wheezing

Date:04/11/02ISR Number: 3897697-1Report Type:Expedited (15-DaCompany Report #WAES 0203KOR00137
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eyelid Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Face Oedema							
	Oedema Peripheral							

Date:04/11/02ISR Number: 3897937-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00006
Age:85 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage
	Gastrointestinal Ulcer
	Haematemesis
	Loss Of Consciousness
	Melaena

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Zocor	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL	1	DAY
			Aspirin Lysine	C		ORAL		
			Celiprolol Hydrochloride	C				
			Omeprazole	C		ORAL		
			Nifedipine	C		ORAL		
			Budesonide	C				
			Hydrochlorothiazide And Valsartan	C		ORAL		
			Ambroxol	C				
			Nitroglycerin	C				
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		

Date:04/11/02ISR Number: 3897938-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Attack		Aggrenox	C		ORAL		
			Pravachol	C				

Date:04/11/02ISR Number: 3897939-2Report Type:Expedited (15-DaCompany Report #WAES 0204DNK00002
Age:98 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Hospitalization - Initial or Prolonged			Aspirin	C	ORAL
			Quinine Hydrochloride	C	ORAL
			Acetaminophen	C	ORAL

Date:04/11/02ISR Number: 3897944-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00015
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia Disorientation Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:04/11/02ISR Number: 3897945-8Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00006
Age:70 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure Congestive

Pleural Effusion
Ventricular Tachycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
	Furosemide	C		ORAL		
	Isosorbide Mononitrate	C		ORAL		
	Atorvastatin	C		ORAL		
	Digoxin	C		ORAL		
	Captopril	C		ORAL		

Date:04/11/02ISR Number: 3897946-XReport Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Irbesartan	SS		ORAL		
	Hyperkalaemia		Furosemide And Spironolactone	SS		ORAL		
Other			Fentanyl	C		TOPICAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Alendronate Sodium	C		ORAL		
			Glimepiride	C		ORAL		
			Oxybutynin Chloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Bromazepam	C		ORAL		
			Paraffin	C		ORAL		
			Nadroparin	C		PARENTERAL		

Date:04/11/02ISR Number: 3897947-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00704
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Dilantin	C				
			Lasix (Furosemide)	C				

			Prevacid	C		
			Mysoline	C		

Date:04/11/02ISR Number: 3897950-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00010
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C		ORAL		
	Haematemesis		Aspirin	C		ORAL		
	Haemoglobin Decreased		Calcium (Unspecified) And Vitamin D (Unspecified)	C				
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/02ISR Number: 3897951-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00691
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/02ISR Number: 3897952-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	
Hospitalization - Initial or Prolonged	Congestive Renal Failure		[Therapy Unspecified]	C				
Other								

Date:04/11/02ISR Number: 3898675-9Report Type:Direct Company Report #CTU 165523
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Duodenal Ulcer Perforation		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY ORAL	

Date:04/11/02ISR Number: 3898720-0Report Type:Direct Company Report #CTU 165512
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure Acute		Vioxx	PS				
			Ace Inhibitor Zestril 20mg Po Qd	SS				

Date:04/11/02ISR Number: 3898975-2Report Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaphylactic Reaction
Hospitalization - Initial or Prolonged	Anxiety
	Asthenia
	Atherosclerosis
	Back Pain
	Blood Cholesterol Increased
	Blood Potassium Increased
	Blood Pressure Increased
	Cardiac Arrest
	Coma
	Coronary Artery Stenosis
	Depression
	Dizziness
	Dyspepsia
	Dysphonia
	Dyspnoea
	Insomnia
	Myositis
	Panic Attack
	Pharyngolaryngeal Pain
	Pulmonary Congestion

		Pulse Absent					
		Pupil Fixed					
		Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE							
		Spleen Disorder	Health	Lipitor	C		
		Tremor	Professional	Lodine	C		
		Tri-Iodothyronine	Other	Pravachol	C		
		Increased		Premarin	C		
				Xanax	C		

Date:04/11/02ISR Number: 3899142-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA00837
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/							
		Nephrolithiasis					
DAILY/PO							
				Accupril	C		
				Premarin	C		
				Methotrexate	C		

Date:04/11/02ISR Number: 3899150-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00512
Age:63 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
Initial or Prolonged		Psoriasis	Professional				
MG/DAILY/PO							
		Rash Generalised	Company				
		Urticaria	Representative				

Date:04/11/02ISR Number: 3899180-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA00153
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Platelet Count Decreased	Company Representative						

Date:04/11/02ISR Number: 3899612-3Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00017
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Foreign	Tab Vioxx					
Initial or Prolonged	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	25 MG	
		Professional						

Date:04/11/02ISR Number: 3899618-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic	Foreign	Tab Vioxx					
Initial or Prolonged	Mesenteric Vascular	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Insufficiency	Professional	Celiprolol Hcl	C				
			Rilmenidene	C				
			Sildenafil Citrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/02ISR Number: 3899619-6Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00016
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:04/11/02ISR Number: 3899634-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00082
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Enzymes Increased	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Fibrin D Dimer Increased	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	15 DAY
	Pulmonary Oedema							
			Acepromazine Maleate (+) Meprobamate	C				
			Acetaminopne/Propoxyphene Hydrochloride	C				
			Ferrous S04	C				
			Grape Seeds	C				
			Nifedipine	C				
			Spironolactone	C				
			Enoxaparin	C				

Date:04/11/02ISR Number: 3899875-4Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00003
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Capillary Disorder	Foreign	Tab Vioxx					
	Dry Skin	Other	(Rofecoxib)	PS		ORAL	25 MG/ DAILY/ PO	59 DAY
	Purpura							
	Rash		Acetaminophen/Propoxyphene Hydrochloride	C				

Date:04/11/02ISR Number: 3899876-6Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00069
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Cholestasis Gamma-Glutamyltransferase Increased Pruritus	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY/ PO	

Date:04/11/02ISR Number: 3903309-0Report Type:Expedited (15-DaCompany Report #01090587
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Atrial Fibrillation

		Atrial Tachycardia					
		Epistaxis					
		Sciatica	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Treatment Noncompliance	Consumer	Enbrel 25 Mg	PS		
SUBCUTANEOUS	BIW,						
		Tremor	Health				
SUBCUTANEOUS							
			Professional	Rofecoxib	SS		
				Celecoxib	SS		
				Omeprazole	C		
				Naproxen	C		
				Diazide	C		

Date:04/12/02ISR Number: 3898896-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00720
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cryptogenic Organizing	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Pneumonia	Professional	Premarin	C		
Initial or Prolonged	Viral Infection					

Date:04/12/02ISR Number: 3898897-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hyperhidrosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Nausea	Professional	Lanoxin	C		
	Pyrexia		Accupril	C		
	Vomiting		Aspirin	C		
			Singulair	C		
			Tylox	C		
			Cartia (Diltiazem Hydrochloride)	C		
			Serevent	C		
RESPIRATORY						
(INHALATION)						

Date:04/12/02ISR Number: 3898899-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00857
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/02ISR Number: 3898926-0Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11798485
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Dysphagia Gastrointestinal Pain Mucosal Inflammation Nausea Pain	Health Professional	Cisplatin	PS	Bristol-Myers Squibb Company	INTRAVENOUS	Week 6 (25 Feb 2002) held due to abnormal lab values.	5 WK
	Renal Failure Acute		Taxol Inj	SS	Bristol-Myers Squibb Company	INTRAVENOUS	Week 6 (25 Feb 2002) held due to abnormal lab values.	5 WK

			Herceptin	SS	
			Radiation Therapy	SS	
5 WK					
			Famvir	SS	
Dose first					
decreased					
then					
discontinued.					
			Vioxx	SS	
			Zofran	C	
			Compazine	C	
			Nexium	C	
			Lorazepam	C	
			Oxycodone	C	
			Senokot	C	

Date:04/12/02ISR Number: 3898969-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
97 DAY								
Initial or Prolonged	Coronary Artery Thrombosis Myocardial Infarction	Professional	Citalopram Hydrobromide	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		

Date:04/12/02ISR Number: 3898970-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/02ISR Number: 3898971-5Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00007
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Cardiac Failure	Professional	Vioxx	SS		ORAL		
			Tramadol Hydrochloride	C		ORAL	8	DAY
			Gabapentin	C		ORAL	8	DAY
			Acetaminophen	C		ORAL	8	DAY
			Acenocoumarol	C		ORAL		
			Insulin	C		SUBCUTANEOUS		

Date:04/12/02ISR Number: 3898972-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/02ISR Number: 3899938-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00012
Age:80 YR Gender:Male I/FU:I

Outcome	PT
Other	Atrial Fibrillation
	Cardiac Failure

Congestive

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	3 MON
Professional	Diacerein	C				
Other	Molsidomine	C				
	Nadolol	C				
	Tramadol	C				

Date:04/12/02ISR Number: 3899958-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Blood Urea Decreased		Digoxin	SS		ORAL	0.25 MG/DAILY	10 DAY
	C-Reactive Protein Increased		[Therapy Unspecified] Unk	SS		ORAL		7 DAY
	Confusional State		Midamor	C				
	Crepitations		Amlodipine	C				
	Disorientation		Benserazide Hydrochloride (+)					
	Dyspnoea							
	Hallucination		Levodopa	C				
	Pyrexia		Buflomedil Hcl	C				
	Rales		Clomipramine Hcl	C				
			Fluindione	C				
			Furosemide	C				
			Lansoprazole	C				
			Lisuride Maleate	C				
			Paraffin	C				
			Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C				

Date:04/12/02ISR Number: 3899982-6Report Type:Direct Company Report #CTU 165658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx 25mg	PS			25MG DAILY	
Initial or Prolonged	Gastrointestinal Haemorrhage							

Date:04/12/02ISR Number: 3900108-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02636
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Temperature	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Increased	Health					PO	
	Burning Sensation	Professional	Valium	C				
	Chest Discomfort		[Therapy					
	Cough		Unspecified]	C				
	Dyspnoea		Oxycodone	C				
	Headache							
	Joint Stiffness							
	Musculoskeletal Stiffness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/02ISR Number: 3900109-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome Red Blood Cell Sedimentation Rate Increased Respiratory Failure	Health Professional	Tab Vioxx Unk Herbs (Unspecified)	PS C		ORAL	PO	

Date:04/12/02ISR Number: 3900119-5Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00001
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 16 DAY
			Ranitidine Hcl	C				

Date:04/12/02ISR Number: 3900120-1Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00044
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Dyspnoea Joint Swelling	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 5 DAY
	Orthopnoea		Aspirin	C				
			Betahistine Hydrochloride	C				
			Cimetidine	C				
			Levothyroxine Na	C				

Date:04/12/02ISR Number: 3900123-7Report Type:Expedited (15-DaCompany Report #WAES 0204PRT00001
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	5 DAY

Date:04/12/02ISR Number: 3900493-XReport Type:Expedited (15-DaCompany Report #200211335FR
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Furosemide (Lasilix Faible) Tablets	PS		ORAL	20 MG BID PO	
	Blood Fibrinogen Increased		Propofan Tablets	SS		ORAL	PO	1 WK
	Blood Lactate Dehydrogenase Increased		Amiloride Hydrochloride (Modamide) Tablets	SS		ORAL	2.5 MG QD PO	
	Confusional State Cyanosis		Rofecoxib (Vioxx) Tablets	SS		ORAL	1 U QD PO	1 WK
	Inflammation Overdose		Digoxin (Digoxine Nativelle) Tablets	SS		ORAL	0.25 MG QD PO	10 DAY
	Pyrexia Renal Impairment		Amlodipine Besilate (Amlor) Capsule	SS		ORAL	5 MG QD PO	
			Lansoprazole					

(Lanzor)	C
Levodopa, Benserazide Hydrochloride (Modopar)	C
Lisuride Maleate (Dopergin)	C
Clomipramine Hydrochloride (Anafranil 10 Mg)	C
Fluindione (Previscan)	C
Buflomedil Hydrochloride (Fonzylane)	C
Paraffin, Liquid (Lubentyl)	C
Soidum Bicarbonate, Potassium Chloride, Sodium Chloride, Macrogol (Movicol)	C

Date:04/12/02ISR Number: 3900635-6Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00041
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral Oliguria Renal Failure Weight Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/12/02ISR Number: 3900643-5Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00028
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Drug Interaction Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	15 DAY

Erosive Oesophagitis Tab Aspirin SS ORAL
300 MG/DAILY
Faecal Occult Blood
PO 24 DAY
Positive Inj Nadroparin
Haematocrit Decreased Calcium SS
SUBCUTANEOUS 0.3 ML/DAILY
Haemoglobin Decreased
SC 15 DAY
Hiatus Hernia Ramipril C
Mallory-Weiss Syndrome
Melaena
Mucosal Inflammation

Date:04/12/02ISR Number: 3900747-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00271
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Meningitis	Health	Tab Vioxx	PS		ORAL
PO	2 MON					
	Spinal Disorder	Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/02ISR Number: 3900791-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00255
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:04/12/02ISR Number: 3900797-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA00124
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Colonic Polyp	Health	Ecotrin	C				
	Dyspnoea	Professional	Lasix (Furosemide)	C				
	Faeces Discoloured		Nitro-Bid	C				
	Gastric Polyps		Norvasc	C				
	Gastrointestinal		Atenolol	C				
	Haemorrhage		Glyburide	C				
	Haemoglobin Decreased							

Date:04/12/02ISR Number: 3900799-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00465
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:04/12/02ISR Number: 3900801-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00387
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Diplopia	Consumer	Tab Vioxx 25 Mg	PS	ORAL
25 MG PRN PO					
Initial or Prolonged	Eye Disorder				
	Meningitis Viral				

Date:04/15/02ISR Number: 3899889-4Report Type:Direct Company Report #CTU 165702
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Distension		Vioxx 25mg Merck	PS	Merck	ORAL
1 TAB DAILY						
Initial or Prolonged	Chest Discomfort					
ORAL						
	Chest Pain					
	Dyspepsia					
	Dyspnoea					
	Feeling Hot					
	Palpitations					
	Syncope					

Date:04/15/02ISR Number: 3900323-6Report Type:Direct Company Report #CTU 165670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Meningitis		Vioxx	PS		ORAL
25MG PO QD						
Initial or Prolonged						
(PRIOR TO						

HOSPITAL

STAY)

Date:04/15/02ISR Number: 3900378-9Report Type:Direct Company Report #CTU 165725
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx 25mg 1 Daily	PS		ORAL	25MG 1 DAILY	
	Fatigue						PO	
	Headache		Flonase	C				
	Nausea		Paxil	C				
			..	C				

Date:04/15/02ISR Number: 3900764-7Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00006
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Foreign	Tab Vioxx					
Initial or Prolonged	Cardiac Failure	Other	(Rofecoxib)	PS		ORAL	25 MG/TID PO	14 DAY
	Congestive		Atorvastatin	C				
			Captopril	C				
			Digoxin	C				
			Furosemide	C				
			Isosorbide Monoitrate	C				

Date:04/15/02ISR Number: 3900766-0Report Type:Expedited (15-DaCompany Report #WAES 0204DNK00002
Age:98 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged								
PO							6	DAY
			Acetaminophen	C				

			Aspirin	C		
			Quinine Hcl	C		

Date:04/15/02ISR Number: 3900767-2Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatinine	Foreign	Tab Vioxx			
Hospitalization -	Increased	Health	(Rofecoxib)	PS		ORAL
50 MG/DAILY						
Initial or Prolonged	Hyperkalaemia	Professional	Tab Irbesartan	SS		ORAL
300 MG/DAILY						
Other		Other	Tab			
			Furosemide/Spironola			
			ctone	SS		ORAL
20/50						
MG/DAILY						
			Alendronate Sodium	C		
			Bromazepam	C		
			Calcium Carbonate			
			(+) Cholecalciferol	C		
			Fentanyl	C		
			Glimepiride	C		
			Nadroparin	C		
			Oxybutynincl	C		
			Pantoprazole	C		
			Paraffin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/02ISR Number: 3900769-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00015
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	1 DAY

Date:04/15/02ISR Number: 3900777-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Blood Urea Increased		Digoxin	SS		ORAL	0.25 MG/DAILY	10 DAY
	C-Reactive Protein		Therapy Unspecified	SS		ORAL	7	DAY
	Increased		Midamor	C				
	Confusional State		Amlodipine	C				
	Disorientation		Benserazide Hydrochloride (+)					
	Drug Effect Decreased		Levodopa	C				
	Drug Level Increased		Buflomedil Hcl	C				
	Dyspnoea		Clomipramine Hcl	C				
	Hallucination		Fluindione	C				
	Pyrexia		Furosemide	C				
	Rales		Lansoprazole	C				
			Lisuride Maleate	C				
			Paraffin	C				
			Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C				

Date:04/15/02ISR Number: 3900783-0Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00010
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					

Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Haematemesis					
PO 4 DAY						
	Haemoglobin Decreased		Aspirin	C		
	Melaena		Calcium (Unspecified) (+)			
			Vitamin D (Uns	C		

Date:04/15/02ISR Number: 3900784-2Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00006
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Foreign	Tab Vioxx			
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Gastrointestinal Ulcer					
PO 1 DAY						
	Haematemesis		Zocor	C		
	Hiatus Hernia		Acetaminophen/Codein			
	Loss Of Consciousness		e Phosphate	C		
	Melaena		Ambroxol	C		
			Aspirin Lysine	C		
			Budesonide	C		
			Celiprolol Hcl	C		
			Hydrochlorothiazide (+) Valsartan	C		
			Nifedipine	C		

Nitroglycerin	C
Omeprazole	C
Polyethylene Glycol 3350/Kcl/Nahc03/Nac1	C

Date:04/15/02ISR Number: 3900988-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/15/02ISR Number: 3900991-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Encephalitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			Prilosec	C				
			Tylenol Pm	C				
			Zyrtec	C				
			Estrogens (Unspecified)	C				

Date:04/15/02ISR Number: 3900995-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00783
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Congestive		Cozaar	C				
			Atenolol	C				

Date:04/15/02ISR Number: 3901002-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nausea	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Vomiting	Professional					MG/DAILY/PO	
			Accupril	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Lanoxin	C				
			Serevent	C				
			Singulair	C				
			Tylox	C				
			Aspirin	C				

Date:04/15/02ISR Number: 3901005-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00250
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Attack						MG/DAILY/PO	
			Aggrenox	C				
			Pravachol	C				

Date:04/15/02ISR Number: 3901255-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00338
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged	Chest Pain	Health	Premarin	C				
Other	Heart Rate Decreased	Professional						
	Infection							

Date:04/15/02ISR Number: 3901256-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00194
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Global Amnesia	Professional					MG/DAILY/PO	
	Hypertension	Company	Allegra	C				
		Representative	Caltrate	C				
			Celebrex	C				
			Dyazide	C				
			Zantac	C				

Date:04/15/02ISR Number: 3901288-3Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00006
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign	Tab Vioxx					
	Oedema Peripheral	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Weight Increased	Professional						
PO	5	DAY						
			Acenocoumarol	C				
			Chlorthalidone	C				

Date:04/15/02ISR Number: 3901290-1Report Type:Expedited (15-DaCompany Report #WAES 0203KOR00137
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Oedema	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema Peripheral	Professional						
PO							15	DAY

Date:04/15/02ISR Number: 3901366-9Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	6 DAY
			Antimicrobial (Unspecified)	C				
			Zolpidem Tartrate	C				

Date:04/15/02ISR Number: 3901368-2Report Type:Expedited (15-DaCompany Report #WAES 01109103
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/02ISR Number: 3901420-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00720
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cryptogenic Organizing	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Hospitalization - Initial or Prolonged	Pneumonia Viral Infection	Professional Company Representative	Premarin	C				

Date:04/15/02ISR Number: 3901422-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00857
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx Unk	PS		ORAL	50 MG/QOD/PO	
		Professional Company Representative						

Date:04/15/02ISR Number: 3901424-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00801
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Hospitalization - Initial or Prolonged Other	Congestive Renal Failure	Professional Company Representative						

Date:04/15/02ISR Number: 3901426-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00704
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/DAILY/PO	
	Pulmonary Thrombosis		Dilantin	C				

		Thrombosis		Lasix (Furosemide)	C		
				Mysoline	C		
				Prevacid	C		

Date:04/15/02ISR Number: 3901487-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00691
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/15/02ISR Number: 3901522-XReport Type:Expedited (15-DaCompany Report #001-0981-M0201960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Atrovastatin (Atorvastatin)	PS				
			Gabapentin	SS				
			Rofecoxib	SS				

Date:04/15/02ISR Number: 3901524-3Report Type:Expedited (15-DaCompany Report #WAES 00110224
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
Hospitalization - Initial or Prolonged	Arthropathy	Health Professional Other	Lipitor	C				
	Atherosclerosis		Lodine	C				
	Blood Thyroid Stimulating Hormone Increased		Pravachol	C				
			Premarin	C				
	Cardiac Arrest		Xanax	C				
	Coma							
	Coronary Artery Stenosis							
	Dyspnoea							
	Laboratory Test Abnormal							
	Myocardial Fibrosis							
	Pulmonary Congestion							
	Pulmonary Haemorrhage							
	Renal Disorder							
	Spleen Congestion							
	Toxicologic Test Abnormal							
	Tri-Iodothyronine Uptake Increased							

Date:04/16/02ISR Number: 3899822-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00020
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Haemorrhage		Fluindione	C		ORAL		
	Haematemesis		Fluindione	C		ORAL		
	Haemoglobin Decreased		Furosemide	C		ORAL		
	Melaena							
	Oesophageal Ulcer							

Date:04/16/02ISR Number: 3899826-2Report Type:Expedited (15-DaCompany Report #WAES 0204ITA00002
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 15 DAY	Anaemia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer Haemorrhage	Metformin Hydrochloride	C		
	Gastric Ulcer Haemorrhage	Zocor	C		ORAL
		Lacidipine	C		
		Ramipril	C		
		Chlorthalidone And Oxprenolol Hydrochloride	C		
		Aluminum Hydroxide And Aspirin And Magnesium Oxide	C		

Date:04/16/02ISR Number: 3899829-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00982
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Evista	C		
			Lipitor	C		
			Synthroid	C		

			Skelaxin	C		
			Valium	C		
			[Therapy Unspecified]	C		

Date:04/16/02ISR Number: 3899830-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01074
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Respiratory Disorder		Synthroid	C				

Date:04/16/02ISR Number: 3899833-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01381
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema		Vioxx	SS		ORAL		
	Palpitations		Celebrex	C				
			[Therapy Unspecified]	C				
			Valdecoxib	C				

Date:04/16/02ISR Number: 3899838-9Report Type:Expedited (15-DaCompany Report #WAES 0204MEX00005
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Hospitalization -	Cerebral Haemorrhage		Ciprofloxacin					
Initial or Prolonged	Convulsion		Hydrochloride	C		ORAL	10	DAY
Other	Cyanosis							
	Euphoric Mood							
	Headache							
	Photophobia							

Date:04/16/02ISR Number: 3899839-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA01001
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Disability	Increased		Betapace	C		ORAL		
Other	Blood Potassium Increased		Diovan Hct	C		ORAL		
	Blood Urea Increased							
	Dehydration							
	Dyspnoea							
	Hypoxia							
	Oedema Peripheral							
	Pitting Oedema							
	Polyuria							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3899840-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zyrtec	C				

Date:04/16/02ISR Number: 3899843-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00403
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Ulcer		Diovan	C				
	Vaginal Haemorrhage		Protonix	C				
			Nexium	C				

Date:04/16/02ISR Number: 3899848-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3899849-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:04/16/02ISR Number: 3899852-3Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00069
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Cholelithiasis Cholestasis Gamma-Glutamyltransferase Increased Pruritus

Date:04/16/02ISR Number: 3899853-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3899854-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00002
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Condition Aggravated		Aspirin	C		ORAL		
Initial or Prolonged	Myocardial Infarction		Molsidomine	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		
			Hyzaar	C		ORAL		
			Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		

Date:04/16/02ISR Number: 3899857-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3899859-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:04/16/02ISR Number: 3899860-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Peritonitis							

Date:04/16/02ISR Number: 3899863-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3899864-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization - Initial or Prolonged	Gastric Haemorrhage							

Date:04/16/02ISR Number: 3899867-5Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00010
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Vasotec	SS		ORAL		
	Drug Interaction		Furosemide	SS		ORAL		
	Pulmonary Oedema		Tramadol Hydrochloride	C		ORAL		
	Troponin I Increased		Insulin, Biphasic					

				Isophane [Injection]	C		
SUBCUTANEOUS							
				Clorazepate Dipotassium	C		ORAL

Date:04/16/02ISR Number: 3899868-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01090
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Rash		Celebrex	C				

Date:04/16/02ISR Number: 3899870-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Convulsion		Estrogens (Unspecified)	C				
	Disturbance In Attention		Tylenol Pm	C				
	Encephalitis Herpes		Prilosec	C				
	Speech Disorder		Zyrtec	C				
	Vision Blurred							
	Visual Disturbance							

Date:04/16/02ISR Number: 3900187-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900188-2Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Initial or Prolonged	Retinal Vascular	Fenofibrate	C		ORAL
Disability	Occlusion	Trimetazidine			
	Thrombosis	Hydrochloride	C		ORAL
	Visual Acuity Reduced	Budesonide	C		
RESPIRATORY					
(INHALATION)					
		Salmeterol Xinafoate	C		
RESPIRATORY					
(INHALATION)					

Date:04/16/02ISR Number: 3900189-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900190-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
7 DAY								
Initial or Prolonged	Grand Mal Convulsion		Vioxx	SS		ORAL		
70 DAY								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3900191-2Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00003
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Idiopathic Capillaritis		Vioxx	PS	Merck & Co., Inc	ORAL		59 DAY
	Purpura		Vioxx	SS		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:04/16/02ISR Number: 3900269-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1758 DAY
	Mitral Valve Incompetence		Inderal La	C				
	Myocardial Infarction		Claritin-D	C				
	Oedema		Humibid	C				
	Palpitations		Prevacid	C				
	Tricuspid Valve Incompetence		Nasonex	C				764 DAY
	Ventricular Hypokinesia		Darvocet-N	C				
	Weight Increased		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				

Date:04/16/02ISR Number: 3900274-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900414-XReport Type:Expedited (15-DaCompany Report #WAES 0204DEU00084
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stress Ulcer Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900416-3Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00068
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apathy		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Clonic Convulsion		Lithium Carbonate	SS		ORAL		
	Drug Toxicity		Levothyroxine Sodium	C				
	Gait Disturbance		Hydrochlorothiazide And Ramipril	C		ORAL		
	Hypertonia		Allopurinol	C		ORAL		
	Mood Altered		Elavil	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Ferrous Glycine Sulfate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3900418-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Anaemia		Vioxx	SS		ORAL		
	Anxiety		Tylenol Arthritis					
	Arthritis		Extended Relief	C				
	Asthenia		Paxil	C				7 DAY
	Blood Pressure Increased		Paxil	C				13 DAY
	Connective Tissue		Zoloft	C				20 DAY
	Disorder		Zoloft	C				19 DAY
	Constipation		Ascorbic Acid	C				
	Cough		Vitamin E	C				
	Decreased Activity		Vitamin B					
	Diverticulitis		(Unspecified)	C				
	Dizziness		Motrin	C				
	Fatigue		[Therapy					
	Haemorrhoids		Unspecified]	C				
	Insomnia		[Therapy					
	Lower Gastrointestinal		Unspecified]	C				
	Haemorrhage		Flonase	C				
	Orthostatic Hypotension		Aspirin	C				
	Rectal Haemorrhage							
	Tachycardia							
	Urinary Tract Infection							

Date:04/16/02ISR Number: 3900423-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA01670
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Peptic Ulcer Haemorrhage							
Initial or Prolonged								

Date:04/16/02ISR Number: 3900426-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00034
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastasis		Vioxx	PS	Merck & Co., Inc			

Date:04/16/02ISR Number: 3900429-1Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00006
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Haematemesis		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc			

Date:04/16/02ISR Number: 3900438-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3900441-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900444-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01368
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Vioxx	SS		ORAL	1	MON
			Lipitor	C				
			Accupril	C				
			Amaryl	C				
			Imdur	C				
			Coumadin	C				
			Atenolol	C				
			L-Thyroxin	C				
			Pletal	C				

Date:04/16/02ISR Number: 3900445-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01400
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900446-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00971
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/02ISR Number: 3900668-XReport Type:Direct Company Report #CTU 165766
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx 25 Mg Po Qd	PS		ORAL	25 MG PO QD	
Initial or Prolonged	Haemorrhage		Prednisone	SS				
	Oesophageal Ulcer		Lorazepam	C				
	Oesophagitis		Apap	C				
			Paxil	C				

Date:04/16/02ISR Number: 3900721-0Report Type:Direct Company Report #CTU 165779
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS			50MG 1 X/DAY	
Hospitalization -	Status Epilepticus		Vioxx	SS			25MG 1 X/DAY	
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/02ISR Number: 3901199-3Report Type:Direct Company Report #CTU 165795
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx (Rofecoxib)					
Hospitalization -	Meningitis Aseptic		-Merck	PS	Merck			
PT TOOK THE								
Initial or Prolonged	Mental Status Changes							
DRUG ON/OFF								
	Renal Failure							
FOR ~1 YR							1	YR
	Respiratory Failure							
	Thrombotic							
	Thrombocytopenic Purpura							

Date:04/17/02ISR Number: 3900918-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
2							MON	
Initial or Prolonged	Disorientation		[Therapy					
	Fluid Retention		Unspecified]	C				
	Medication Error							
	Memory Impairment							

Date:04/17/02ISR Number: 3900924-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01649
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Perforated Ulcer		Vioxx	SS		ORAL		
			Diovan Hct	C				
			Fosamax	C		ORAL		
			Timoptic	C				
OPHTHALMIC								

Date:04/17/02ISR Number: 3900926-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Renal Failure Acute							

Date:04/17/02ISR Number: 3900928-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01653
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Aspirin	SS				
Initial or Prolonged								

Date:04/17/02ISR Number: 3901088-4Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00016
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/17/02ISR Number: 3901089-6Report Type:Expedited (15-DaCompany Report #WAES 01126027
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Confusional State		Vioxx	SS		ORAL		
	Hallucination		Calcium Dobesilate	C		ORAL		
	Mental Impairment		Trimebutine	C		ORAL		

Date:04/17/02ISR Number: 3901094-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02927
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Haematemesis							
	Haematochezia							

Date:04/17/02ISR Number: 3901101-4Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		25 DAY
Initial or Prolonged	Increased		Lithium Sulfate	SS		ORAL		
	Depressed Level Of		Zolpidem Tartrate	C				
	Consciousness		Levothyroxine Sodium	C				
	Drug Level Increased		Lofepramine					
	Extrapyramidal Disorder		Hydrochloride	C				
			Dipyridamole	C				
			Calcium Carbonate And Cholecalciferol	C				
			Tramadol Hydrochloride	C				

Date:04/17/02ISR Number: 3901104-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/02ISR Number: 3901430-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Convulsion Dizziness Headache		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/02ISR Number: 3901431-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01554
Age:79 YR Gender:Male I/FU:I

Outcome	PT
Other	Coronary Artery Disease Electrocardiogram Abnormal Exercise Test Abnormal

Fatigue
Malaise

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	[Therapy Unspecified]	C				
	Zocor	C				
	[Therapy Unspecified]	C				
	Androgel	C				
	Aspirin	C				
	Vitamins (Unspecified)	C				

Date:04/18/02ISR Number: 3901642-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02065
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Diarrhoea							
	Meningitis Aseptic							
	Nausea							
	Upper Respiratory Tract Infection							

Date:04/18/02ISR Number: 3901645-5Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00138
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

Date:04/18/02ISR Number: 3901647-9Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00140
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Internal Injury		Vioxx	PS	Merck & Co., Inc			

Date:04/18/02ISR Number: 3901648-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Extrapyramidal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Tardive Dyskinesia							
Other								

Date:04/18/02ISR Number: 3901650-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02189
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage Visual Acuity Reduced		Vioxx Aciphex Flomax (Morniflumate)	PS C C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/02ISR Number: 3901654-6Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Corticosteroids (Unspecified)	C				
			Antimicrobial (Unspecified)	C				

Date:04/18/02ISR Number: 3901655-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/18/02ISR Number: 3901658-3Report Type:Expedited (15-DaCompany Report #WAES 0204NLD00012
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	38	DAY
Initial or Prolonged	Gastrooesophageal Reflux Disease		Cisapride	C		ORAL		

Date:04/18/02ISR Number: 3901659-5Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00006
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Haematemesis		[Therapy Unspecified]	C				

Date:04/18/02ISR Number: 3901661-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mental Impairment		Dyazide	C				
	Mental Status Changes							
	Renal Failure							
	Thrombotic							
	Thrombocytopenic Purpura							

Date:04/18/02ISR Number: 3902946-7Report Type:Expedited (15-DaCompany Report #HQ3002609JUL2001
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Diverticulum
	Dyspnoea
	Gastritis Erosive
	Gastrointestinal
	Haemorrhage
	Hypochromic Anaemia
	Lacunar Infarction
	Melaena

Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Lodine (Etodolac, Unspec)	PS		ORAL	400MG, DAILY,	ORAL
	Vioxx (Rofecoxib, Tablet)	SS				
	Norvasc (Amlodipine Besilate)	C				
	Lasix (Furosemide)	C				
	Ecotrin (Acetylsalicylic Acid)	C				
	Prilosec (Omeprazole)	C				
	Potassium (Potassium)	C				
	Zocor (Simvastatin)	C				
	Darvocet-N (Dextropropoxyphene/ Paracetamol)	C				

Date:04/18/02ISR Number: 3903272-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Affect Lability	Health Professional	Tab Vioxx	PS		ORAL		
Initial or Prolonged	Balance Disorder		Prilosec	C				
	Convulsion		Tylenol Pm	C				
	Disturbance In Attention		Zyrtec	C				
	Encephalitis		Estrogens	C				
	Speech Disorder							
	Vision Blurred							
	Visual Acuity Reduced							

Date:04/18/02ISR Number: 3903768-3Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Retinal Vascular Occlusion	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 15 DAY
			Budesonide	C				
			Fenofibrate	C				
			Salmeterol Xinafoate	C				
			Trimetazidine Hydrochloride	C				

Date:04/18/02ISR Number: 3903769-5Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00003
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Capillary Disorder Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO ; UNK PO 59 DAY
			Acetaminophen/Propoxyphen Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/02ISR Number: 3903771-3Report Type:Expedited (15-DaCompany Report #WAES 0203ITA00069
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bile Duct Stone Cholestasis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO

Date:04/18/02ISR Number: 3903772-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00002
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Atrial Fibrillation Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Hyzaar	C				
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Insulin, Biphasic Isophane (Injection)	C				
			Molsidomine	C				

Date:04/19/02ISR Number: 3902225-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01962
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/02ISR Number: 3902226-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01961
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cold Sweat		Bufferin	C		ORAL		
Other	Gastrointestinal Haemorrhage							

Date:04/19/02ISR Number: 3902228-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01258
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:04/19/02ISR Number: 3902229-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/02ISR Number: 3902230-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01960
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Aspirin	C				
			Viagra	C				
			Vitamins (Unspecified)	C				
			Calcium (Unspecified)	C				
			Relafen	C				

87 DAY

Date:04/19/02ISR Number: 3902232-5Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation Peritonitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flupentixol Decanoate	C		INTRAMUSCULAR		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL	22	DAY
			Diclofenac Sodium	C		ORAL	17	DAY
			Ranitidine	C		ORAL		

Date:04/19/02ISR Number: 3902584-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY; PO	

Date:04/19/02ISR Number: 3902684-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01860
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
	Food Allergy		Vioxx	SS		ORAL		
	Influenza Like Illness							

Date:04/19/02ISR Number: 3902685-2Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00007
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Urticaria							

Date:04/19/02ISR Number: 3902687-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hydrodiuril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/02ISR Number: 3902688-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/02ISR Number: 3902689-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01892
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/02ISR Number: 3902690-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01858
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/02ISR Number: 3902694-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01951
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/02ISR Number: 3903830-5Report Type:Direct Company Report #CTU 166141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG QD PO	
Hospitalization - Initial or Prolonged								

Date:04/19/02ISR Number: 3903860-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEK00014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	2 MON

Date:04/19/02ISR Number: 3903863-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	

Date:04/19/02ISR Number: 3903864-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
Death	Death	Foreign Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:04/19/02ISR Number: 3903871-8Report Type:Direct Company Report #CTU 166186
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypotension		Warfarin	PS			4MG QD	
Initial or Prolonged	Upper Gastrointestinal		Rofecoxib	SS			25MG QD	
	Haemorrhage		Isordil	C				
			Feso4	C				
			Digoxin	C				
			Lisinopril	C				
			Kcl	C				
			Paroxetine	C				
			Diltiazem	C				
			Metoprolol	C				
			Furosemide	C				
			Glyburide	C				
			Insulin Nph	C				

Date:04/19/02ISR Number: 3903878-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Ulcer Perforation	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	6 MON
	Peritonitis	Professional						

Date:04/19/02ISR Number: 3903879-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization -	Cardiovascular Disorder Gastric Haemorrhage	Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	Initial or Prolonged

Date:04/19/02ISR Number: 3903880-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.6 MG/DAILY, PO	1 MON

Date:04/19/02ISR Number: 3903881-0Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00010
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Acute Pulmonary Oedema Blood Creatinine Abnormal Blood Urea Abnormal

Drug Interaction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Vasotec (Enalapril Maleate)	SS		ORAL	20 MG/DAILY,PO	
			Tab Furosemide	SS		ORAL	40 MG/DAILY, PO	
			Clorazepate Dipotassium	C				
			Insulin, Biphasic Isophane [Injection]	C				
			Tremadol Hcl	C				

Date:04/19/02ISR Number: 3903882-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	

Date:04/19/02ISR Number: 3903883-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	

Date:04/19/02ISR Number: 3903932-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02227
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Abdominal Pain Lower	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Anaemia	Health Professional	Flonase	C				
	Asthenia		Motrin	C				
	Connective Tissue Disorder		Paxil	C				
			Tylenol Arthritis Extended Relie	C				
	Constipation		Zoloft	C				
	Cough		Ascorbic Acid	C				
	Decreased Activity		Aspirin	C				
	Diverticulitis		Vitamin B (Unspecified)	C				
	Dizziness		Vitamin E	C				
	Haematochezia							
	Haemorrhoids							
	Inflammation							
	Insomnia							
	Orthostatic Hypotension							
	Peptic Ulcer Haemorrhage							
	Rectal Haemorrhage							
	Tachycardia							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/02ISR Number: 3903933-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01090
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Rash						MG/DAILY/PO	
			Celebrex	C				

Date:04/19/02ISR Number: 3903934-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Grand Mal Convulsion	Professional						

Date:04/19/02ISR Number: 3903940-2Report Type:Expedited (15-DaCompany Report #WAES 01072443
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myocardial Infarction	Other						

Date:04/19/02ISR Number: 3903954-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA01670
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Peptic Ulcer Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative						

Date:04/19/02ISR Number: 3904353-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	PO

Date:04/22/02ISR Number: 3903778-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA01805
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Initial or Prolonged	Increased		Vioxx	SS		ORAL	2 WK	
Other	Heart Rate Decreased		Glucosamine	C				
	Murphy'S Sign Positive		Chondroitin	C				
	Pancreatitis		Tagamet	C				
	Pyrexia							

Date:04/22/02ISR Number: 3903780-4Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Retinal Artery Thrombosis		Fenofibrate	C		ORAL		
	Retinal Vascular Occlusion		Trimetazidine Hydrochloride	C		ORAL		
			Budesonide	C				
RESPIRATORY (INHALATION)								
			Salmeterol Xinafoate	C				
RESPIRATORY (INHALATION)								

Date:04/22/02ISR Number: 3903782-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00022
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Peritonitis							

Date:04/22/02ISR Number: 3903783-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00042
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:04/22/02ISR Number: 3903785-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01250
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Chest Discomfort Dyspepsia Dyspnoea Heart Rate Increased Syncope		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/02ISR Number: 3903786-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01257
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident Thrombosis		Vioxx Monopril Norvasc Glynase Prestab Tablets Lipitor Potassium (Unspecified) Estradiol Deserol	PS C C C C C C C	Merck & Co., Inc	ORAL

Date:04/22/02ISR Number: 3903943-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:04/22/02ISR Number: 3903944-XReport Type:Expedited (15-DaCompany Report #WAES 0204GBR00059
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	41 DAY	
Hospitalization - Initial or Prolonged	Haematemesis		Lansoprazole	C		ORAL		
	Haemoglobin Abnormal		Acetaminophen And Codeine Phosphate	C		ORAL		
	Ill-Defined Disorder							

Date:04/22/02ISR Number: 3903947-5Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00008
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Jaundice		Vioxx	SS				
	Laryngitis		Amoxicillin Trihydrate And Clavulanate Potassium	SS		ORAL	11 DAY	
	Liver Disorder							
	Oesophagitis							
	Pruritus							
			Esomeprazole Magnesium	SS		ORAL	46 DAY	

Date:04/22/02ISR Number: 3903948-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02154
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged 1 DAY	Face Oedema Oedema		Vioxx Morphine Lasix (Furosemide) Toprol Xl Tablets Altace	PS C C C C	Merck & Co., Inc	ORAL

Date:04/22/02ISR Number: 3904427-3Report Type:Direct Company Report #CTU 166314
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Urea Increased		Vioxx	PS		ORAL	1 PO QD	
Intervention to Prevent Permanent Impairment/Damage	Contusion Fatigue							

Date:04/22/02ISR Number: 3904441-8Report Type:Direct Company Report #CTU 166311
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Confusional State Coordination Abnormal Hallucination Spinal Compression

	Fracture					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx-25 Mg-Merck	PS	Merck	
ONE 25MG 1X						
DAY						
			Digoxin	C		
			Miacalcin	C		
			Nitroglycerine	C		
			Lasix	C		
			Premarin	C		
			Pravachol	C		
			Pepcid	C		
			Lotrel	C		
			Plavix	C		
			Levoxyl	C		
			Vit B-12	C		

Date:04/22/02ISR Number: 3904450-9Report Type:Direct Company Report #CTU 166296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Lenticular Opacities		Vioxx	PS		
			Allegra	SS		
			Prilosec	SS		

Date:04/22/02ISR Number: 3904553-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01554
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Coronary Artery Disease	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Fatigue	Professional				
MG/DAILY/PO						
	Malaise		Angrogel	C		
			Zocor	C		
			[Therapy Unspecified]	C		
			Aspirin	C		

			Vitamins (Unspecified)	C		

Date:04/22/02ISR Number: 3904556-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
Initial or Prolonged	Chest Pain							

Date:04/22/02ISR Number: 3904617-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cardiac Valve Disease	Professional					MG/DAILY/PO	
	Myocardial Infarction	Company	Claritin-D	C				
	Oedema	Representative	Darvocet-N	C				
	Palpitations		Humibid	C				
	Ventricular Hypokinesia		Inderal La	C				
	Weight Increased		Nasonex	C				

				Prevacid	C		
				Nonsteroidal Anti-Inflammatory	C		

Date:04/22/02ISR Number: 3904654-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01381
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Drug Effect Decreased							
	Oedema	Company Representative	Tab Vioxx	SS		ORAL	PO	
	Palpitations		Celebrex	C				
			Valdecoxib	C				

Date:04/22/02ISR Number: 3904658-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00403
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urine Present	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haematochezia		Diovan	C				
	Ulcer		Nexium	C				
	Vaginal Haemorrhage		Protonix	C				

Date:04/22/02ISR Number: 3904660-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
		Company Representative	Zyrtec	C				

Date:04/22/02ISR Number: 3904661-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/22/02ISR Number: 3904664-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01001
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Disability	Increased	Professional					PO	
Other	Blood Potassium Increased	Company	Betapace	C				
	Blood Urea Increased	Representative	Diovan Hct	C				
	Dyspnoea							
	Hypoxia							
	Oedema Peripheral							
	Pitting Oedema							
	Polyuria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/02ISR Number: 3904667-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00982
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional	Evista	C				
		Company	Lipitor	C				
		Representative	Skelaxin	C				
			Synthroid	C				
			Valium	C				

Date:04/22/02ISR Number: 3904669-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01074
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/ BID/	
Initial or Prolonged	Respiratory Disorder						PO	
			Synthroid	C				

Date:04/22/02ISR Number: 3904711-3Report Type:Expedited (15-DaCompany Report #WAES 99091937
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Infarction	Health						
	Angina Unstable	Professional						
	Blood Pressure Increased							
	Chest Pain							
	Coronary Artery Occlusion							
	Dyspepsia							
	Eructation							
	Gastroduodenitis							
	Gastrointestinal Disorder							
	Laboratory Test Abnormal							
	Oesophagitis							

Date:04/22/02ISR Number: 3904717-4Report Type:Expedited (15-DaCompany Report #WAES 01072444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Cerebrovascular Accident							
	Injury							

Date:04/22/02ISR Number: 3904721-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01653
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Myocardial Infarction	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Aspirin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/02ISR Number: 3904724-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01649
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Perforated Ulcer		Diovan Hct	C				
			Fosamax	C				
			Timoptic	C				

Date:04/22/02ISR Number: 3904735-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01368
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25; 50 MG/DAILY/PO	
	Drug Ineffective							
			Accupril	C				
			Amaryl	C				
			Coumadin	C				
			Imdur	C				
			L-Thyroxin	C				
			Lipitor	C				
			Pletal	C				
			Atenolol	C				

Date:04/22/02ISR Number: 3904737-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01400
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Meningitis	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged								

Date:04/22/02ISR Number: 3904740-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rash Generalised							

Date:04/22/02ISR Number: 3904743-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/22/02ISR Number: 3904744-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
	Convulsion							
	Decreased Activity							
	Dizziness							
	Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/02ISR Number: 3904746-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00971
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/22/02ISR Number: 3904782-4Report Type:Expedited (15-DaCompany Report #WAES 01072444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:04/22/02ISR Number: 3904784-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02927
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	

Date:04/22/02ISR Number: 3904802-7Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY;	

Depressed Level Of
PO 25 DAY
Consciousness Tab Lithiumso4 SS ORAL
42 MG/DAILY,
Drug Level Increased
PO
Extrapyramidal Disorder Calcium Carbonate
(+) Cholecalciferol C
Dipyridamole C
Levothyroxine Na C
Lofepramine Hcl C
Tramadol Hcl C
Zolpidem Tartrate C

Date:04/22/02ISR Number: 3904822-2Report Type:Expedited (15-DaCompany Report #WAES 01126027
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Agitation	Foreign	Tab Vioxx			
Initial or Prolonged	Confusional State	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY 2 DAY						
	Hallucination	Professional	Calcium Dobesilate	C		
			Trimebutine	C		

Date:04/22/02ISR Number: 3904824-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00016
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Loss Of Consciousness	Foreign
	Syncope	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	1 DAY

Date:04/22/02ISR Number: 3904835-0Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00006
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Haematemesis	Foreign Health Professional	Tab Vioxx (Rofecoxib) [Therapy Unspecified]	PS C				

Date:04/22/02ISR Number: 3904836-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00034
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Carcinoma Cell Type Unspecified Stage Iv	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS			25 MG DAILY	

Date:04/22/02ISR Number: 3904837-4Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00084
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stress Ulcer Ulcer Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/22/02ISR Number: 3904838-6Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00068
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apathy	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG BID	PO 6 DAY
	Clonic Convulsion							
	Dehydration							
	Drug Interaction		Tab Cr Lithiumco3	SS		ORAL	600 MG DAILY	PO
	Gait Disturbance							
	Hypertonia		Elavil	C				
	Mood Altered		Allopurinol	C				
	Oligodipsia		Bisoprolol Fumarate	C				
	Therapeutic Agent		Ferrous Glycine Sulfate	C				
	Toxicity		Hydrochlorothiazide (+) Ramipril	C				
			Levothyroxine Na	C				

Date:04/22/02ISR Number: 3904846-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Coagulopathy
	Coronary Artery Stenosis
	Coronary Artery

Thrombosis
Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	97 DAY
		Other	Citalopram Hydrobromide	C				
			Citalopram Hydrobromide	C				

Date:04/22/02ISR Number: 3904900-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:04/22/02ISR Number: 3904901-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:04/22/02ISR Number: 3904903-3Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00007
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema	Foreign	Tab Vioxx					
	Cardiac Failure	Other	(Rofecoxib)	PS		ORAL	5	DAY
	Congestive		Acenocoumarol	C				

Acetaminophen	C
Gabapentin	C
Insulin	C
Tramadol Hcl	C

Date:04/22/02ISR Number: 3904905-7Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00020
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY
	Haematemesis	Professional	Fluindione	C				
	Haemoglobin Decreased		Furosemide	C				
	Melaena							
	Oesophageal Ulcer Haemorrhage							

Date:04/22/02ISR Number: 3905035-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01107
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Brain Oedema

		Disorientation Fluid Retention Medication Error	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
25 MG DAILY			Health Professional	Tab Vioxx 25 Mg	PS		ORAL
PO	2 MON		Company Representative	[Therapy Unspecified]	C		

Date:04/22/02ISR Number: 3905036-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bradycardia	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
Initial or Prolonged	Renal Failure Acute	Professional				
PO 5 DAY						
		Company Representative				

Date:04/22/02ISR Number: 3905077-5Report Type:Expedited (15-DaCompany Report #WAES 0204MEX00005
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebral Haemorrhage	Foreign	Tab Vioxx			
Hospitalization -	Convulsion	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY 14 DAY						
Initial or Prolonged		Professional	Ciprofloxacin			
Other			Hydrochloride	C		

Date:04/22/02ISR Number: 3905422-0Report Type:Expedited (15-DaCompany Report #WAES 0204IT00002
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Foreign	Tab Vioxx			

Initial or Prolonged	Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY 15 DAY						
	Haemorrhage		Zocor	C		
	Gastric Ulcer Haemorrhage		Aluminum Hydroxide/Aspirin/ Mg Oxide	C		
			Chlorthalidone (+) Oxprenolol Hydrochlor	C		
			Lacidipine	C		
			Meformin Hcl	C		
			Ramipril	C		

Date:04/23/02ISR Number: 3904565-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02283
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Haemoglobin Decreased					
Initial or Prolonged	Ulcer Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3904567-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:04/23/02ISR Number: 3904569-2Report Type:Expedited (15-DaCompany Report #WAES 0203KOR00137
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Face Oedema							
	Oedema Peripheral							

Date:04/23/02ISR Number: 3904570-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02293
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
Other			Advil	C				

Date:04/23/02ISR Number: 3904576-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02294
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
	Photosensitivity Reaction							

Date:04/23/02ISR Number: 3904949-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01044
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
	Congestive		Prednisone	C		ORAL		
			Procardia Xl	C		ORAL		
			Fosamax	C		ORAL		
			Synthroid	C		ORAL		
			Lanoxin	C		ORAL		
			Demadex	C				
			Nexium	C				
			Coumadin	C				

Date:04/23/02ISR Number: 3904955-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00980
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatine		Vioxx	SS		ORAL		
	Phosphokinase Increased		Claritin	C		ORAL		
	Hypoaesthesia		Flonase	C				
RESPIRATORY								
	Myalgia							
(INHALATION)								
	Myopathy		Niaspan	C		ORAL		
	Pain		Topamax	C		ORAL		
	Paraesthesia		Meclizine	C		ORAL		
37 DAY								

				Neurontin	C		ORAL
37 DAY							
				Clonazepam	C		ORAL
				Doxepin	C		ORAL
				Lipitor	C		
				Testosterone	C		
				Darvocet-N	C		

Date:04/23/02ISR Number: 3904957-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Affect Lability		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Balance Disorder		Estrogens			
	Blindness		(Unspecified)	C		
	Convulsion		Tylenol Pm	C		
	Encephalitis		Prilosec	C		
	Encephalitis Herpes		Zyrtec	C		
	Meningitis Aseptic					
	Meningitis Viral					
	Speech Disorder					
	Vision Blurred					
	Visual Disturbance					

Date:04/23/02ISR Number: 3904962-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL
26 DAY						
Hospitalization -	Lower Gastrointestinal		Lipitor	C		
Initial or Prolonged	Haemorrhage		Thyroid	C		

Date:04/23/02ISR Number: 3904964-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL

Other				Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		
				Ibuprofen	C		
				[Therapy Unspecified]	C		

Date:04/23/02ISR Number: 3904965-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Monoplegia Sensory Loss		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/23/02ISR Number: 3904966-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02134
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3904968-9Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Increased Blood Ph Decreased		Irbesartan	SS		ORAL		
Other	Drug Interaction		Furosemide And Spironolactone	SS		ORAL		
	Electrocardiogram T Wave Peaked		Calcium Carbonate	C		ORAL		
	Hyperkalaemia		Alendronate Sodium	C		ORAL		
			Glimepiride	C		ORAL		
			Oxybutynin Chloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Bromazepam	C		ORAL		
			Paraffin	C		ORAL		
			Nadroparin	C		SUBCUTANEOUS		
			Cholecalciferol	C		ORAL		
			Agar	C		ORAL		
			Phenolphthalein	C				
			Fentanyl	C		TOPICAL		

Date:04/23/02ISR Number: 3905269-5Report Type:Direct Company Report #CTU 166414
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Arteritis		Levaquin 500mg Qd	PS		ORAL	500MG IV PO	
Required	Renal Impairment						QD	6 DAY
Intervention to Prevent Permanent Impairment/Damage	Renal Necrosis		Motrin	SS				
			Vioxx 12.5 Mg Q Am	SS		ORAL	12.5 MG PO QD	
			Celexa	C				
			Prilosec	C				
			Hctz	C				
			Trileptal	C				

Date:04/23/02ISR Number: 3905546-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Mental Impairment Mental Status Changes Renal Failure Thrombocytopenic Purpura	Professional	Dyazide	C				

Date:04/23/02ISR Number: 3905547-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3905551-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01962
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Oedema	Professional Company Representative						

Date:04/23/02ISR Number: 3905554-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01961
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Cold Sweat	Professional						
Initial or Prolonged	Gastrointestinal	Company	Bufferin	C				
Other	Haemorrhage	Representative						
	Haematemesis							
	Post Procedural Complication							

Date:04/23/02ISR Number: 3905557-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01960
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -		Professional						
Initial or Prolonged		Company	Relafen	C				
		Representative	Viagra	C				
			Aspirin	C				
			Calcium	C				
			Vitamins	C				

Date:04/23/02ISR Number: 3905580-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02197
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Extrapyramidal Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/1XPO	
Hospitalization - Initial or Prolonged	Tardive Dyskinesia	Professional						
Other		Company Representative						

Date:04/23/02ISR Number: 3905582-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02065
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Diarrhoea	Health						
	Meningitis Aseptic	Professional						
	Nausea							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3905644-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aciphex	C				
			Flomax (Morniflumate)	C				

Date:04/23/02ISR Number: 3905649-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01258
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Aspirin	C				

Date:04/23/02ISR Number: 3905650-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:04/23/02ISR Number: 3905934-XReport Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Foreign	Tab Vioxx					

	Peritonitis	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY,						
		Professional				
PO						
		Other	Acetaminophen (+)			
			Dihydrocodeine			
			Bitartr	C		
			Diclofenac Na	C		
			Flupentixol			
			Decanoate	C		
			Ranitidine	C		

Date:04/23/02ISR Number: 3905935-1Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00006
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY,						
Initial or Prolonged	Haematemesis	Health				
PO 1 WK						
		Professional	(Therapy			
		Other	Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/23/02ISR Number: 3905966-1Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00140
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	

Date:04/23/02ISR Number: 3905970-3Report Type:Direct Company Report #CTU 166490
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Urine Present		Vioxx 25mg Merck And Co	PS	Merck And Co		1 PER	
	Calculus Bladder							
	Cardiac Murmur		Acetemonphin	C				
	Pain		Glucosamine					
	Sinus Arrhythmia		Chondratin	C				

Date:04/23/02ISR Number: 3905971-5Report Type:Direct Company Report #CTU 166492
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Dexamethasone	PS				
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haemorrhage		Rofecoxib	SS				

Date:04/23/02ISR Number: 3906059-XReport Type:Expedited (15-DaCompany Report #2002094318US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib					

	Dermatitis	Health	) Capsule	PS
	Hypersensitivity	Professional	Vioxx()	SS
	Lung Disorder			

Date:04/23/02ISR Number: 3906076-XReport Type:Expedited (15-DaCompany Report #WAES 0204CAN00138
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pancreatitis Acute	Foreign	Vioxx (Rofecoxib)	PS		ORAL
PO 10 DAY						
Initial or Prolonged		Health				
		Professional				
		Other				

Date:04/23/02ISR Number: 3906080-1Report Type:Expedited (15-DaCompany Report #WAES 0204NLD00012
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG/ DAILY						
Initial or Prolonged	Gastrooesophageal Reflux	Health				
PO 38 DAY						
	Disease	Professional	Cisapride	C		
		Other				

Date:04/23/02ISR Number: 3906083-7Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Disorder	Foreign	Vioxx (Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged		Health Professional Other	Antimicrobial	C				
			Corticosteroids	C				

Date:04/23/02ISR Number: 3906663-9Report Type:Expedited (15-DaCompany Report #200211120EU
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal	Foreign	Furosemide (Seguril)	PS		ORAL	40 MG/DAY PO	
Hospitalization -	Blood Urea Abnormal		Rofecoxib (Vioxx)	SS				
Initial or Prolonged	Drug Interaction		Enalapril	SS		ORAL	20 MG/DAY PO	
	Pulmonary Oedema		Tramadol Hydrochloride (Adolonta)	C				
			Biphasic Insulin	C				
			Clorazepate Dipotassium (Tranxilium)	C				

Date:04/24/02ISR Number: 3905729-7Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00006
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY	
	Oedema Peripheral		Acenocoumarol	C		ORAL		
	Weight Increased		Chlorthalidone	C		ORAL		

Date:04/24/02ISR Number: 3905730-3Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00112
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antibody Test Positive		Vioxx	PS	Merck & Co., Inc	ORAL		2 WK
Initial or Prolonged	Basophilia		Diclofenac Sodium	C		ORAL		1 WK
	Fatigue							
	Flatulence							
	Hepatic Necrosis							
	Hepatic Steatosis							
	Hepatitis							
	High Density Lipoprotein Increased							

Date:04/24/02ISR Number: 3905731-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00043
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Phosphokinase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		425 DAY
Initial or Prolonged	Myalgia		Tamsulosin Hydrochloride	C		ORAL		2252 DAY
			Amlodipine	C		ORAL		
			Aspirin Lysine	C		ORAL		
			Ifenprodil Tartrate	C				
			Glyburide	C				
			Lercanidipine					

		Hydrochloride	C
		Methylprednisolone	C
		Alfuzosin Hydrochloride	C

Date:04/24/02ISR Number: 3905733-9Report Type:Expedited (15-DaCompany Report #WAES 0204ZAF00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression Fatigue	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3905734-0Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00045
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Colitis Ischaemic Rectal Haemorrhage		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		

Date:04/24/02ISR Number: 3905735-2Report Type:Expedited (15-DaCompany Report #WAES 0204PRT00002
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Colitis Ischaemic		Omeprazole	C		ORAL	3	MON
	Colonic Haemorrhage		Alprazolam	C		ORAL	1	YR
	Crohn'S Disease		Amlodipine	C		ORAL	1	YR
	Enterobacter Infection Inflammatory Bowel Disease Leukocytosis Necrosis							

Pallor

Date:04/24/02ISR Number: 3905794-7Report Type:Expedited (15-DaCompany Report #WAES 01129110
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Hospitalization - Initial or Prolonged	Epistaxis Haemoglobin Decreased International Normalised Ratio Increased		Acenocoumarol	SS		ORAL		

Date:04/24/02ISR Number: 3905797-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00167
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatic Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/02ISR Number: 3905798-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00659
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Contusion							
	Epistaxis							
	Eye Inflammation							
	Macular Degeneration							
	Retinal Haemorrhage							

Date:04/24/02ISR Number: 3905800-XReport Type:Expedited (15-DaCompany Report #WAES 0203GBR00158
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Duodenal Ulcer		Aspirin	C				
Initial or Prolonged	Perforation		Quinine Sulfate	C				
	Oesophageal Ulcer		Felodipine	C				
	Peritonitis		Levothyroxine Sodium	C				
			Furosemide	C				

Date:04/24/02ISR Number: 3905801-1Report Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY
Initial or Prolonged	Increased		Bendroflumethiazide	C				
Disability	Drug Ineffective		Isosorbide					
Other	Hyponatraemia		Mononitrate	C				
	Inappropriate		Bisoprolol	C				
	Antidiuretic Hormone		Omeprazole	C				
	Secretion		Acetaminophen And					
	Malignant Pleural		Propoxyphene					
	Effusion		Hydrochloride	C				
	Metastasis							
	Nausea							
	Neoplasm Malignant							

Renal Impairment
Vomiting

Date:04/24/02ISR Number: 3905804-7Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00104
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL
			Amoxicillin Trihydrate And Clavulanate Potassium	SS		
			Corticosteroids (Unspecified)	C		

Date:04/24/02ISR Number: 3905806-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02433
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Overdose		[Therapy					
	Pulmonary Congestion		Unspecified]	SS				
			Soma	C				
			Methadone					
			Hydrochloride	C				
			Wellbutrin	C				
			Elavil	C		ORAL		

Date:04/24/02ISR Number: 3905808-4Report Type:Expedited (15-DaCompany Report #WAES 0204NOR00012
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc			
	Haematemesis							
	Melaena							

Date:04/24/02ISR Number: 3905809-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Csf Protein Increased		Dyazide	C				
	Csf White Blood Cell		Atenolol	C				
	Count Positive		[Therapy					
	Haemodialysis		Unspecified]	C				
	Haemorrhage Intracranial							
	Mental Status Changes							
	Renal Failure Acute							
	Respiratory Failure							
	Thrombocytopenia							
	Thrombotic							
	Thrombocytopenic Purpura							

Date:04/24/02ISR Number: 3905811-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stress		Vioxx	SS		ORAL		
	Transient Ischaemic Attack		Plavix	C				

Date:04/24/02ISR Number: 3905812-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02261
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/02ISR Number: 3905813-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02431
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3905815-1Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization -	Increased		Irbesartan	SS		ORAL		
Initial or Prolonged	Blood Ph Decreased		Furosemide And					
Other	Drug Interaction		Spironolactone	SS		ORAL		
	Electrocardiogram T Wave		Fentanyl	C		TOPICAL		
	Peaked		Calcium Carbonate	C		ORAL		
	Hyperkalaemia		Alendronate Sodium	C		ORAL		
			Glimepiride	C		ORAL		
			Oxybutynin Chloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Bromazepam	C		ORAL		
			Paraffin	C		ORAL		
			Nadroparin	C		SUBCUTANEOUS		
			Cholecalciferol	C		ORAL		
			Agar	C		ORAL		
			Phenolphthalein	C				

Date:04/24/02ISR Number: 3905816-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hip Fracture		Vioxx	PS	Merck & Co., Inc			4 MON
Initial or Prolonged	Stress Ulcer							

Date:04/24/02ISR Number: 3905817-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00050
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3905820-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02543
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Circulatory Collapse		Clozaril	C				
	Gait Disturbance		Clonazepam	C				
			Paxil	C				

Date:04/24/02ISR Number: 3905821-7Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00128
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Diarrhoea		Doxycycline	SS		ORAL	4	DAY
	Renal Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/02ISR Number: 3905822-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Dyspnoea Haemoglobin Decreased Palpitations Red Blood Cell Abnormality		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		6 YR

Date:04/24/02ISR Number: 3905823-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02179
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3905824-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02212
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3905826-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02208
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ejection Fraction Decreased Myocardial Infarction		Vioxx Adderall Tablets	PS C	Merck & Co., Inc	ORAL		

Date:04/24/02ISR Number: 3906258-7Report Type:Direct Company Report #CTU 166553
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis		Coumadin Dupont	PS	Dupont	ORAL		
Hospitalization -	Haematochezia		Vioxx Merck	SS	Merck	ORAL		
Initial or Prolonged	Haemoptysis							
Required	Mouth Haemorrhage							
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:04/25/02ISR Number: 3906144-2Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00095
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Pulmonary Oedema
Hospitalization -	Blood Ph Decreased
Initial or Prolonged	Blood Pressure Increased
	Drug Level Increased
	Dyspnoea
	Haemodialysis
	Haemoglobin Abnormal
	International Normalised

		Ratio Increased					
		Oliguria					
		Oxygen Saturation Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Po2 Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Renal Failure Acute		Irbesartan	C		ORAL
		Renal Tubular Necrosis		Fluindione	C		ORAL
				Digoxin	C		ORAL
				Pravastatin Sodium	C		ORAL

Date:04/25/02ISR Number: 3906145-4Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
75	DAY						
Life-Threatening		Gastritis Haemorrhagic		Isosorbide			
Hospitalization -		Polymyositis		Mononitrate	C		ORAL
19	DAY						
Initial or Prolonged		Shock Haemorrhagic		Furosemide	C		ORAL
19	DAY						
				Ramipril	C		ORAL
19	DAY						
				Sotalol Hydrochloride	C		ORAL
19	DAY						
				Tramadol Hydrochloride	C		ORAL
19	DAY						
				Prednisone	C		ORAL
65	DAY						
				Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL
				Pantoprazole Sodium	C		ORAL
32	DAY						

Date:04/25/02ISR Number: 3906146-6Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated Gastric Ulcer Perforation Peritonitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flupentixol Decanoate	C		INTRAMUSCULAR		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL	22	DAY
			Diclofenac Sodium	C		ORAL	17	DAY
			Ranitidine	C		ORAL		

Date:04/25/02ISR Number: 3906147-8Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/02ISR Number: 3906152-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02353
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Angioneurotic Oedema Chest Discomfort Chest Pain Dyspnoea Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/02ISR Number: 3906153-3Report Type:Expedited (15-DaCompany Report #WAES 0204NZL00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc			
	Sciatic Nerve Neuropathy		Aspirin	C				

Date:04/25/02ISR Number: 3906155-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02362
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/02ISR Number: 3906519-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cachexia		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Life-Threatening	Condition Aggravated							
Hospitalization - Initial or Prolonged	Hepatic Neoplasm Malignant							
Disability	Metastases To Central Nervous System							

Date:04/25/02ISR Number: 3906530-0Report Type:Expedited (15-DaCompany Report #WAES 0204FIN00008
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Melaena		Acetaminophen	C		ORAL		
			Rivastigmine	C		ORAL		
			Risperidone	C		ORAL	15	DAY
			Zopiclone	C		ORAL		
			Etilefrine					

			Hydrochloride	C		ORAL

Date:04/25/02ISR Number: 3906532-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01721
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 DAY	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Disease		Diovan	C		
	Myocardial Infarction		Norvasc	C		
			Glucophage	C		

Date:04/25/02ISR Number: 3906534-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02483
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/02ISR Number: 3906544-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00857
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/02ISR Number: 3907496-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01858
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:04/25/02ISR Number: 3907497-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01860
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Tab Vioxx	PS		ORAL	PO	30 DAY
Initial or Prolonged	Hypersensitivity	Professional	...	C				
	Influenza Like Illness	Company Representative						
	Rash							

Date:04/25/02ISR Number: 3907498-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company Representative						

Date:04/25/02ISR Number: 3907499-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01892
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:04/25/02ISR Number: 3907500-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction	Health	Tab Vioxx	PS		ORAL	PO	
	Hypoaesthesia	Professional Company Representative	Hydrodiuril	C				
	Transient Ischaemic Attack							

Date:04/25/02ISR Number: 3907507-1Report Type:Direct Company Report #CTU 166688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Gastrointestinal Haemorrhage		Vioxx Merck	PS	Merck			
			Aspirin	C				

Date:04/25/02ISR Number: 3907659-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00022
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer Peritonitis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 6 MON
		Other						

Date:04/25/02ISR Number: 3907660-XReport Type:Expedited (15-DaCompany Report #WAES 0202FRA00047
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 15 DAY
Disability	Hypertension							
	Retinal Vascular Occlusion	Other	Budesonide	C				
			Fenofibrate	C				
			Salmeterol Xinafoate	C				
			Trimetazidine Hydrochloride	C				

Date:04/25/02ISR Number: 3907710-0Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00007
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Urticaria	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO 9 DAY
		Other						

Date:04/25/02ISR Number: 3907718-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00042
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Maculo-Papular	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 2 DAY

Date:04/25/02ISR Number: 3907739-2Report Type:Expedited (15-DaCompany Report #WAES 0204ZAF00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Marrow Depression Fatigue	Foreign Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY; ORAL	

Date:04/25/02ISR Number: 3907791-4Report Type:Expedited (15-DaCompany Report #USA-2002-0000725
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Oliguria Urinary Tract Infection	Health Professional	Oxycontin Tablets (Oxycodon Hydrochloride) Cr Tablet	PS		ORAL	ORAL	

			Vioxx (Rofecoxib) Tablet	SS		ORAL ORAL
			Nifedipine Tablet	C		
			Atenolol Hydrochloride (Atenolol Hydrochloride)	C		

Date:04/25/02ISR Number: 3907865-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01951
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:04/25/02ISR Number: 3907867-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01257
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Embolism	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Deserol	C				
			Glynase Prestab Tablets	C				
			Lipitor	C				
			Monopril	C				
			Norvasc	C				
			Estradiol	C				
			Potassium (Unspecified)	C				

Date:04/25/02ISR Number: 3907870-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01250
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Dyspepsia Dyspnoea Heart Rate Increased Syncope	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:04/25/02ISR Number: 3907880-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA01805
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Abdominal Distension Abdominal Pain Upper Abdominal Tenderness Back Pain Bowel Sounds Abnormal Decreased Appetite Heart Rate Decreased Murphy'S Sign Positive Nausea Pancreatitis

		Pyrexia Respiratory Rate Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		White Blood Cell Count Increased	Health Professional Company	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO; 25 MG/QOD/PO							
			Representative	Tagamet	C		
				Chondroitin	C		
				Glucosamine	C		

Date:04/26/02ISR Number: 3906847-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/26/02ISR Number: 3906849-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02575
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
			Orudis	C		

Date:04/26/02ISR Number: 3906850-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00229
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening 41 DAY	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - 41 DAY	Chills		Sulfasalazine	SS		ORAL
Initial or Prolonged	Endocarditis Neutrophilia Pulse Pressure Increased		Naproxen	C		ORAL

Date:04/26/02ISR Number: 3906855-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02717
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907135-8Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00034
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Balance Disorder Dizziness Drug Interaction Electrolyte Imbalance Metabolic Acidosis Renal Failure Acute Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Cozaar	SS		ORAL		
			Furosemide Sodium	SS		ORAL		
			Diclofenac Sodium	SS		ORAL		
			Metformin Hydrochloride	SS		ORAL		
			Acenocoumarol	C		ORAL		
			Itraconazole	C		ORAL	2	DAY
			Omeprazole Sodium	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Amlodipine Besylate	C		ORAL		

			Miglitol	C		ORAL

Date:04/26/02ISR Number: 3907137-1Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00033
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:04/26/02ISR Number: 3907140-1Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00066
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Respiratory Disorder		[Therapy Unspecified]	C				

Date:04/26/02ISR Number: 3907144-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:04/26/02ISR Number: 3907145-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cachexia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Condition Aggravated		Hydrodiuril	C		ORAL	548	DAY
	Lung Carcinoma Cell Type		Fosinopril Sodium	C		ORAL	548	DAY

Disability	Unspecified Stage Iv		Atorvastatin Calcium	C		ORAL
1050 DAY						
			Bisoprolol Fumarate	C		ORAL
1488 DAY						
			Methylprednisolone	C		ORAL
37 DAY						

Date:04/26/02ISR Number: 3907148-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01872
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional				

Date:04/26/02ISR Number: 3907149-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01090
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rash	Professional	Celebrex	C		

Date:04/26/02ISR Number: 3907150-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02474
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Health	Vioxx	PS		ORAL
367 DAY						
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
367 DAY						

Insulin	C
Hydrocodin	C
Glucophage	C
Plavix	C
Captopril Msd	C
Pravachol	C

Date:04/26/02ISR Number: 3907152-8Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Hyperhidrosis							

Date:04/26/02ISR Number: 3907153-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00061
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident	Professional	Doxazosin	SS		ORAL		
	Weight Increased							

Date:04/26/02ISR Number: 3907158-9Report Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Vestibular Neuronitis							

Date:04/26/02ISR Number: 3907159-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Distress Syndrome Lung Infiltration Po2 Increased Productive Cough Pulmonary Arterial Wedge Pressure Increased Purulence Red Blood Cell Sedimentation Rate Increased Respiratory Failure	Professional	Herbs (Unspecified)	C

Date:04/26/02ISR Number: 3907160-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional	Vioxx Hydrodiuril	PS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3907161-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907162-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02428
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fall Hypoaesthesia Monoplegia		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907163-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02431
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907165-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02612
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Obstruction Surgery Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907166-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02630
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged	Pulmonary Embolism Thrombosis Urinary Tract Disorder	Vioxx Neurontin Atenolol Folic Acid	PS C C C	Merck & Co., Inc	ORAL

Date:04/26/02ISR Number: 3907167-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02565
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/02ISR Number: 3907168-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Bacterial		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3907405-3Report Type:Direct Company Report #CTU 166712
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx 25mg					
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease		Publix-Vioxx Bran Label	PS	Publix-Vioxx Bran Label	ORAL	25MG QID ORAL	
Required	Pulmonary Embolism							
Intervention to Prevent Permanent Impairment/Damage	Rhinitis		Aerobid Inh	C				
	Status Asthmaticus		Ventolin Inh	C				
			Lopressor	C				
			Vivele Estrogen Patch	C				
			Nexium	C				
			Dilantin	C				
			Topomax	C				

Date:04/26/02ISR Number: 3907572-1Report Type:Direct Company Report #CTU 166670
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx 25mg Merck	PS	Merck	ORAL	1 2 X DAY	
	Angioneurotic Oedema						ORAL	
	Chest Discomfort							

Date:04/26/02ISR Number: 3907866-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01124
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Health	Tab Vioxx	PS		ORAL	PO	
	Cardiac Failure	Professional	...	SS				
	Medication Error	Company Representative						

Date:04/26/02ISR Number: 3908005-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx Unk	PS		ORAL	PO	
Other	Perforation	Professional Company Representative	Ibuprofen Nonsteroidal Anti-Inflammatory	C C				

Date:04/26/02ISR Number: 3908077-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02283
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ PO	
Hospitalization - Initial or Prolonged	Haemorrhage Gastrointestinal Ulcer Haemoglobin Decreased	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3908091-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02134
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Tab Vioxx Unk	PS		ORAL	PO	
Other		Professional Company Representative						

Date:04/26/02ISR Number: 3908092-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Monoplegia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Sensory Loss							

Date:04/26/02ISR Number: 3908143-3Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00059
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	
Hospitalization -	Blood Electrolytes	Health					PO	41 DAY
Initial or Prolonged	Abnormal	Professional	Acetaminophen/Codein					
	Blood Urea Abnormal	Other	e Phosphate	C				
	Haematemesis		Lansoprazole	C				
	Haemoglobin Abnormal							
	Ill-Defined Disorder							

Date:04/26/02ISR Number: 3908150-0Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Creatinine	Foreign	Vioxx (Rofecoxib)	PS	ORAL 50 MG DAILY
Hospitalization -	Increased	Health			
PO 4 DAY					
Initial or Prolonged	Blood Ph Decreased	Professional	Irbesartan	SS	ORAL 300 MG DAILY
Other	Drug Interaction	Other			
PO					
	Electrocardiogram T Wave Amplitude Increased		Furospir (Furosemide/Spironolactone)	SS	ORAL 20+50 MG
	Hyperkalaemia				
					DAILY PO
			Agar	C	
			Alendronate Sodium	C	
			Bromazepam	C	
			Calcium Carbonate	C	
			Cholecalciferol	C	
			Fentanyl	C	
			Glimepiride	C	
			Nadroparin	C	
			Oxybutynin Cl	C	
			Pantoprazole	C	
			Paraffin	C	
			Phenolphthalein	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3908152-4Report Type:Expedited (15-DaCompany Report #WAES 0203KOR00137
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Oedema	Foreign	Tab Vioxx					
	Face Oedema	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema Peripheral							
PO							15	DAY

Date:04/26/02ISR Number: 3908639-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00334
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis	Study	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Constipation	Health					MG/DAILY/PO	
Other	Nausea	Professional	Lortab	C				
	Pain		Premarin	C				
	Post Procedural		Desflurane	C				
	Complication		Fentanyl	C				
	Post Procedural Discharge		Midazolam	C				
	Postoperative Infection		Morphine Sulfate	C				
	Wound Dehiscence		Nitrous Oxide	C				
			Ondansetron	C				
			Propofol	C				
			Rocuronium Bromide	C				

Date:04/26/02ISR Number: 3908728-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02154
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
Initial or Prolonged	Swelling						PO	
			Altace	C				
			Lasix (Furosemide)	C				
			Toprol Ix Tablets	C				

			Morphine	C		

Date:04/26/02ISR Number: 3908732-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01044
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Congestive	Professional						
	Joint Swelling	Company	Coumadin	C				
		Representative	Demadex	C				
			Fosamax	C				
			Lanoxin	C				
			Nexium	C				
			Procardia Xl	C				
			Synthroid	C				
			Prednisone	C				

Date:04/26/02ISR Number: 3908733-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Life-Threatening	Colitis	Health
Hospitalization -	Lower Gastrointestinal	Professional
Initial or Prolonged	Haemorrhage	Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Lipitor	C				
Thyroid	C				

Date:04/26/02ISR Number: 3908734-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00980
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Creatine	Professional						
	Phosphokinase Increased	Company	Claritin	C				
	Hypoaesthesia	Representative	Darvocet-N	C				
	Myalgia		Flonase	C				
	Myopathy		Lipitor	C				
	Pain		Neurontin	C				
	Paraesthesia		Niaspan	C				
			Topamax	C				
			Clonazepam	C				
			Doxepin	C				
			Meclizine	C				
			Testosterone	C				

Date:04/26/02ISR Number: 3908745-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02294
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	
	Photosensitivity Reaction	Professional						
	Skin Discolouration	Company						
		Representative						

Date:04/26/02ISR Number: 3908746-6Report Type:Expedited (15-DaCompany Report #WAES 0204 USA02083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	(Therapy Unspecified)	C				

Date:04/26/02ISR Number: 3908748-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02293
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Perforated Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Advil	C				
Other			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/02ISR Number: 3909035-6Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00112
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basophilia	Foreign	Tab Vioxx					
Initial or Prolonged	Epstein-Barr Virus	Health	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Antibody Positive	Professional						
PO							2	WK
	Fatigue		Diclofenac Na	C				
	Flatulence							
	Hepatic Steatosis							

Date:04/26/02ISR Number: 3909039-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00045
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Vioxx	PS		ORAL		
PO							6	MON
Initial or Prolonged	Colitis Ischaemic	Health	Nonsteroidal					
	Rectal Haemorrhage	Professional	Anti-Inflammatory					
		Other	Drug (Uns	C				

Date:04/26/02ISR Number: 3909041-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00043
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine	Foreign	Vioxx (Rofecoxib)	PS		ORAL		
PO								
Initial or Prolonged	Phosphokinase Increased	Health	Alfuzosin					
	Myalgia	Professional	Hydrochloride	C				
		Other	Amlodipine	C				
			Aspirin Lysine	C				
			Glyburide	C				
			Ifenprodil Tartrate	C				
			Lercanidipine					
			Hydrochloride	C				
			Methylprednisolone	C				
			Tamsulosin					
			Hydrochloride	C				

Date:04/26/02ISR Number: 3909043-5Report Type:Expedited (15-DaCompany Report #WAES 0204PRT00002
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased	Foreign Literature	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 5 DAY
	Enterocolitis							
	Haemorrhagic	Other						
	Leukocytosis		Alprazolam	C				
			Amlodipine	C				
			Omeprazole	C				

Date:04/26/02ISR Number: 3909051-4Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00008
Age:61 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Blood Alkaline

	Phosphatase Increased Blood Bilirubin Increased Condition Aggravated Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal Jaundice	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Laryngitis Oesophagitis Pruritus		Amoxicillin Trihydrate (+) Clavulanate Potassium	SS			11	DAY
			Tab Esomeprazole Magnesium	SS		ORAL	PO	46 DAY

Date:04/29/02ISR Number: 3907775-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:04/29/02ISR Number: 3907776-8Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Idiopathic		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Thrombocytopenic Purpura		Sodium Feredetate	C		ORAL	47	DAY
			Opium	C		ORAL	5	DAY
			Furosemide	C		ORAL	47	DAY
			Warfarin	C		ORAL	47	DAY
			Prednisolone	C		ORAL		
			Rutin	C		ORAL		
			Misoprostol	C		ORAL		
			Antimicrobial					

			(Unspecified)	C		ORAL

Date:04/29/02ISR Number: 3907778-1Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00188
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Pioglitazone			
	Angina Pectoris		Hydrochloride	SS		
2 MON						
	Cardiac Failure		Zocor	C		ORAL
	Congestive		Glyburide	C		ORAL
	Coronary Artery Disease		Diltiazem			
	Disease Progression		Hydrochloride	C		ORAL
	Fluid Overload		Perindopril Erbumine	C		ORAL
	Hypertension		Atenolol	C		ORAL
			Hydrodiuril	C		ORAL
			Isosorbide Dinitrate	C		

Date:04/29/02ISR Number: 3908334-1Report Type:Direct Company Report #CTU 166754
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL
50MG 1 DAILY						
Hospitalization -	Pulmonary Oedema					
PO						
Initial or Prolonged			Zestril	C		
			Lopressor	C		

Cardizem -Cd C

Date:04/29/02ISR Number: 3909285-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02362
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/29/02ISR Number: 3909308-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02353
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Angioneurotic Oedema Chest Discomfort Chest Pain Dysuria	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/BID/PO	

Date:04/29/02ISR Number: 3909322-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:04/29/02ISR Number: 3909324-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02717
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Gastrointestinal	Health	Tab Vioxx Unk	PS			ORAL
PO							
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative					

Date:04/29/02ISR Number: 3909326-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02575
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
			Orudis	C		

Date:04/29/02ISR Number: 3909328-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02483
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3909331-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00857
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	50 MG/QOD/PO	

Date:04/29/02ISR Number: 3909338-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02179
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Viral	Consumer Company Representative	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	

Date:04/29/02ISR Number: 3909412-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02353
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Shock Angioneurotic Oedema Chest Discomfort Chest Pain Dysuria	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/BID/PO	

Date:04/29/02ISR Number: 3909414-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02431
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Myocardial Infarction	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

			Company Representative				

Date:04/29/02ISR Number: 3909415-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02261
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx 25mg	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:04/29/02ISR Number: 3909416-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02212
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	(Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3909523-2Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Auricular Swelling	Health	Celebrex	SS				
	Burning Sensation	Professional	Anafranil	C				
	Cardiac Disorder		Lidex	C				
	Condition Aggravated							
	Dermatitis Exfoliative							
	Drug Hypersensitivity							
	Epidermal Naevus							
	Erythema							
	Excoriation							
	Inflammation							
	Lung Disorder							
	Lymphatic Disorder							
	Nervous System Disorder							
	Neurodermatitis							
	Oedema							
	Oedema Peripheral							
	Otitis Externa							
	Pain							
	Pruritus							
	Rash Macular							
	Scab							
	Scar							
	Skin Discolouration							
	Skin Necrosis							
	Skin Papilloma							
	Skin Ulcer							
	Sleep Disorder							
	Urticaria							
	White Blood Cell Count							
	Abnormal							

Date:04/29/02ISR Number: 3909540-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Affect Lability	Health	Tab Vioxx Unk	PS		ORAL	PO	

Initial or Prolonged	Balance Disorder	Professional	Prilosec	C
	Blindness Transient	Company	Tylenol Pm	C
	Convulsion	Representative	Zyrtec	C
	Csf Lymphocyte Count		Estrogens	
	Increased		(Unspecified)	C
	Disturbance In Attention			
	Encephalitis			
	Encephalitis Herpes			
	Meningitis			
	Night Blindness			
	Speech Disorder			
	Visual Acuity Reduced			

Date:04/29/02ISR Number: 3909543-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01721
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Arterial Occlusive
Initial or Prolonged	Disease

Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG	/DAILY/PO
			Norvasc	C				
			Glucophage	C				
			Diovan	C				

Date:04/29/02ISR Number: 3909548-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Dyspnoea Exertional		Aspirin	C				
	Palpitations							

Date:04/29/02ISR Number: 3909575-XReport Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Consumer	Tab Vioxx 50mg	PS		ORAL	50	
Hospitalization -	Anorexia	Health					MG/DAILY/PO	
Initial or Prolonged	Cellulitis	Professional	Ativan	C				
Disability	Ileus Paralytic	Other	Flexeril	C				
Other	Melaena		Valium	C				
	Pancreatitis							
	Peripancreatic Fluid Collection							
	Weight Decreased							

Date:04/29/02ISR Number: 3909610-9Report Type:Expedited (15-DaCompany Report #WAES 01095039
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol Increased	Foreign Study	Vioxx	PS		ORAL	25 MG/DAILY, PO	254 DAY
Hospitalization - Initial or Prolonged	Chest Pain Circulatory Collapse Dyspnoea Exercise Tolerance Decreased Hyposthenuria Influenza Like Illness Myocardial Ischaemia	Health Professional	Placebo	C				

Date:04/29/02ISR Number: 3909614-6Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3909615-8Report Type:Expedited (15-DaCompany Report #WAES 0204FIN00008
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/1X,PO	10 DAY
			Acetaminophen	C				
			Etilefrine Hydrochloride	C				
			Risperidone	C				
			Rivastigmine	C				
			Zopiclone	C				

Date:04/29/02ISR Number: 3909617-1Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00229
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aortic Valve Incompetence Chills Endocarditis Laboratory Test Abnormal Neutrophilia Pulse Pressure Increased Pyrexia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	41 DAY
			Sulfasalazine	SS		ORAL	1 GM/BID	41 DAY
			Naproxen	C				

Date:04/29/02ISR Number: 3909620-1Report Type:Expedited (15-DaCompany Report #WAES 01049108
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Thrombosis Limb	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Hydrodiuril	C				
			Lacidipine	C				
			Omeprazole	C				

Date:04/29/02ISR Number: 3909627-4Report Type:Expedited (15-DaCompany Report #A208918
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Fibrinogen Increased	Foreign Health Professional	Norvasc Tablets	PS		ORAL	5.00 MG TOTAL:DAILY:ORAL	
	Dehydrogenase Increased	Other	Digoxine	SS		ORAL	0.25 MG TOTAL:DAILY:ORAL	
	C-Reactive Protein Increased							
	Cardiac Failure		Amiloride	SS		ORAL	DAILY:ORAL	
	Confusional State		Rofecoxib	SS		ORAL	25.00 MG TOTAL:DAILY:ORAL	
	Crepitations							
	Cyanosis							
	Disorientation		Furosemide	C				
	Dyspnoea		Benserazide	C				
	Hallucination		Lisuride	C				
	Inflammation		Clomipramine	C				
	Overdose		Fluindione	C				
	Prothrombin Time Prolonged		Buflomedil	C				
			Lansoprazole	C				
	Pyrexia		Paraffine	C				
	Renal Impairment		Sodium Carbonate	C				
	Sleep Disorder		Propofan Tablets					

			(Acetamin/Caffeine/D extropropoxy)	C		

Date:04/29/02ISR Number: 3909709-7Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Rofecoxib	PS		ORAL	25 MG/DAILY	
Hospitalization -	Congestive	Study						
PO								189 DAY
Initial or Prolonged	Myocardial Infarction	Other	Tab Placebo	SS		ORAL		
PO								189 DAY
Disability	Vomiting		Insulin, Bisphasic Isophane [Injection]	C				
			Insulin, Bisphasic Isophane [Injection]	C				

Date:04/29/02ISR Number: 3909711-5Report Type:Expedited (15-DaCompany Report #WAES 01095039
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol	Foreign	Tab Mk-0966 Vioxx	PS		ORAL	25 MG/DAILY	
Hospitalization -	Increased	Study						
PO								254 DAY
Initial or Prolonged	Chest Pain	Other	Placebo	C				
	Circulatory Collapse							
	Dyspnoea							
	Exercise Tolerance Decreased							
	Hyposthenuria							
	Hypotension							
	Influenza Like Illness							
	Myocardial Ischaemia							

Date:04/29/02ISR Number: 3909713-9Report Type:Expedited (15-DaCompany Report #WAES 01049109
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	170 DAY
Initial or Prolonged			Hydrodiuril	C				
			Acetaminophen	C				
			Lacidipine	C				

Date:04/29/02ISR Number: 3909718-8Report Type:Expedited (15-DaCompany Report #WAES 0204NOR00012
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Foreign	Tab Vioxx					
	Haematemesis	Other	(Rofecoxib)	PS				
	Melaena							

Date:04/29/02ISR Number: 3909719-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hip Fracture	Foreign	Tab Vioxx					
Initial or Prolonged	Stress Ulcer	Health	(Rofecoxib)	PS			12.5 MG/	
		Professional						
DAILY							4	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3909723-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cachexia	Foreign	Tab Vioxx					
Life-Threatening	Condition Aggravated	Health	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	2 MON
Hospitalization - Initial or Prolonged	Hepatic Neoplasm Malignant	Professional						
Disability	Metastases To Central Nervous System							

Date:04/29/02ISR Number: 3909724-3Report Type:Expedited (15-DaCompany Report #WAES 0204NZL00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Foreign	Tab Vioxx					
	Sciatica	Consumer	(Rofecoxib)	PS				
			Aspirin	C				

Date:04/29/02ISR Number: 3909729-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea		Aspirin	C				
	Palpitations							

Date:04/29/02ISR Number: 3909744-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00659
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion	Consumer	Tab Vioxx	PS		ORAL	PO	
	Epistaxis							
	Eye Inflammation							

Macular Degeneration
Retinal Haemorrhage
Scotoma

Date:04/29/02ISR Number: 3909745-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02433
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Tab Vioxx	PS		ORAL	PO	
	Overdose	Professional	...	SS				
	Pulmonary Congestion		Elavil	C				
			Soma	C				
			Wellbutrin	C				
			Methadone Hydrochloride	C				

Date:04/29/02ISR Number: 3909749-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion
	Csf Protein Increased
	Csf White Blood Cell

		Count Positive					
		Haemodialysis					
		Haemorrhage Intracranial					
		Mental Status Changes	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute	Health	Tab Vioxx	PS		ORAL
PO							
		Respiratory Failure	Professional	Dyazide	C		
		Thrombotic		...	C		
		Thrombocytopenic Purpura		Atenolol	C		

Date:04/29/02ISR Number: 3909763-2Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Antinuclear Antibody	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO, SEE							
		Positive	Health				
IMAGE							
		Anxiety	Professional	Celebrex Unk	SS		
		Auricular Swelling		Anafranil	C		
		Condition Aggravated		Lidex	C		
		Drug Hypersensitivity					
		Eczema					
		Epidermal Naevus					
		Excoriation					
		Neurodermatitis					
		Otitis Externa					
		Scar					
		Skin Papilloma					
		Skin Ulcer					
		Sleep Disorder					

Date:04/29/02ISR Number: 3909824-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00158
Age:83 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia	Foreign	Tab Vioxx			
Hospitalization -		Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL
12.5 MG/ BID/							
Initial or Prolonged		Perforation					
PO							

	Oesophageal Ulcer		Aspirin	C
	Peritonitis		Felodipine	C
			Furosemide	C
			Levothyroxine Na	C
			Quinineso4	C

Date:04/29/02ISR Number: 3910069-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02543
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Tab Vioxx Unk	PS		ORAL	PO	
Other	Circulatory Collapse	Professional	Clozaril	C				
	Gait Disturbance		Paxil	C				
			Clonazepam	C				

Date:04/29/02ISR Number: 3910070-2Report Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	
	Abdominal Pain	Health					PO	
	Anorexia	Professional	Ativan	C				
	Cellulitis	Other	Flexeril	C				
	Melaena		Valium	C				
	Pancreatitis							
	Vomiting							
	Weight Decreased							

Date:04/29/02ISR Number: 3910072-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02208
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged			Adderalltablets	C				

Date:04/29/02ISR Number: 3910073-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Stress	Consumer	Tab Vioxx 25 Mg	PS		ORAL	1) 25	
Initial or Prolonged	Transient Ischaemic						MG/DAILY/PO;	
	Attack						2) 25 MG/	
							BID/ PO	
			Plavix	C				

Date:04/29/02ISR Number: 3910317-2Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00128
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration	Foreign	Tab Vioxx					
	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	PO	4 DAY
	Renal Impairment		Doxycycyline	SS		ORAL	12.5 MG/DAILY	PO 4 DAY

Date:04/29/02ISR Number: 3910319-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00050
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intestinal Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	PO	

Date:04/29/02ISR Number: 3910351-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hip Fracture	Foreign	Tab Vioxx					
Initial or Prolonged	Stress Ulcer	Health	(Rofecoxib)	PS			12.5 MG/DAILY	4 MON
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3910353-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00050
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:04/29/02ISR Number: 3910355-XReport Type:Expedited (15-DaCompany Report #WAES 0204GBR00128
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration	Foreign	Tab Vioxx					
	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	PO	4 DAY
	Renal Impairment		Doxycycline	SS		ORAL	12.5 MG/DAILY, PO	4 DAY

Date:04/29/02ISR Number: 3910356-1Report Type:Expedited (15-DaCompany Report #WAES 0204NOR00012
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Foreign	Tab Vioxx					
	Haematemesis	Other	(Rofecoxib)	PS				
	Melaena							

Date:04/29/02ISR Number: 3910372-XReport Type:Expedited (15-DaCompany Report #WAES 01125033
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Foreign	Tab Vioxx					
	Drug Ineffective	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	41 DAY
Disability	Hyponatraemia	Professional	Acetaminophen/Propox					

Other	Inappropriate Antidiuretic Hormone Secretion Malaise Malignant Pleural Effusion Nausea Renal Impairment Vomiting	Other	yhpene Hydrochloride Bendroflumethiazide Bisoprolol Isosorbide Mononitrate Omeprazole	C C C C C

Date:04/29/02ISR Number: 3910375-5Report Type:Expedited (15-DaCompany Report #WAES 01129110
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Drug Interaction Epistaxis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		22 DAY
Initial or Prolonged	Haemoglobin Decreased International Normalised Ratio Increased		Tab Acenocoumarol	SS		ORAL	12 MG/WKY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3910379-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00167
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatic Cyst	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	

Date:04/29/02ISR Number: 3910395-0Report Type:Expedited (15-DaCompany Report #WAES 00079140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Gastric Ulcer	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	17 DAY
	Gastrointestinal Haemorrhage		Fluoxetine	SS		ORAL	20 MG/DAILY, PO	
	Haemoglobin Decreased							

Date:04/29/02ISR Number: 3910396-2Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00104
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatocellular Damage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	2-4 TABLET, PO	
			Amoxicillin Trihydrate (_) Clavulanate Potassium	SS				
			Corticosteroids (Unspecified)	C				

Date:04/29/02ISR Number: 3910398-6Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00014
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY, PO	4 DAY
	Drug Interaction							
Other	Electrocardiogram T Wave Peaked		Irbesartan	SS		ORAL	300 MG/DAILY, PO	
	Hyperkalaemia		Furosemide/Spironolactone	SS		ORAL	20 + 50 MG/DAILY, PO	
			Agar	C				
			Alendronate Sodium	C				
			Bromazepam	C				
			Calcium Carbonate	C				
			Cholecalciferol	C				
			Fentanyl	C				
			Glimepiride	C				
			Oxybutynincl	C				
			Pantoprazole	C				
			Paraffin	C				
			Phenolphthalein	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/02ISR Number: 3910402-5Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Foreign	Tab Vioxx					
	Gastric Ulcer Perforation	Other	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
	Peritonitis							
PO								
			Acetaminophen (+) Dihydrocodeine Bitartr	C				
			Diclofenac Na	C				
			Flupentixol Decanoate	C				
			Ranitidine	C				

Date:04/29/02ISR Number: 3910404-9Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx					
Life-Threatening	Gastritis Haemorrhagic	Health	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
Hospitalization -	Shock Haemorrhagic	Professional						
PO							75	DAY
Initial or Prolonged			Nonsteroidal Anti-Inflammatory Drug	SS		ORAL		
PO								
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Pantoprazole Sodium	C				
			Prednisone	C				
			Ramipril	C				
			Sotalol Hydrochloride	C				
			Tramadol Hcl	C				

Date:04/29/02ISR Number: 3910405-0Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00095
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Foreign	Tab Vioxx					
Hospitalization -	Blood Ph Decreased	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Cardioactive Drug Level							
PO							5	DAY
	Increased		Digoxin	C				
	Dyspnoea		Fluindione	C				
	Haemodialysis		Irbesartan	C				
	Haemoglobin Decreased		Pravastatin Na	C				
	Oliguria							
	Po2 Decreased							
	Renal Failure Acute							
	Renal Tubular Necrosis							

Date:04/29/02ISR Number: 3910414-1Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00006
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign	Tab Vioxx					
	Oedema Peripheral	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Weight Increased	Professional						
PO							5	DAY
			Acenocoumarol	C				

Chlorthalidone C

Date:04/29/02ISR Number: 3910939-9Report Type:Expedited (15-DaCompany Report #WEAS00079140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Hospitalization -	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged	Haemorrhage							
PO								17 DAY
			Fluoxetine	SS		ORAL	20 MG/DAILY	
PO								

Date:04/29/02ISR Number: 3910945-4Report Type:Expedited (15-DaCompany Report #WAES 0204NZL00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Nerve Compression	Consumer	(Rofecoxib)	PS				
			Aspirin	C				

Date:04/29/02ISR Number: 3911201-0Report Type:Expedited (15-DaCompany Report #NSADSS2002009867
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Remicade (5mg/Ml					
Initial or Prolonged	Acute Myocardial	Study	Lyophilized Powder					
Other	Infarction	Health	)(Infliximab,					
Required	Blood Glucose Increased	Professional	Recombinant)	PS				
INTRAVENOUS							300 MG	, 1 IN
Intervention to	Bronchospasm							
1 TIME(S), IV								
Prevent Permanent	Bundle Branch Block Left		Vioxx (Rofecoxib)	SS				
25 , DAILY								
Impairment/Damage	Cardiac Failure		Methotrexate					

	Congestive	(Methotrexate0	SS
7.5 MG, 1 IN			
	Cardiotoxicity		
1 WEEK			
	Cyanosis	Feldene (Piroxicam)	C
	Cyanosis Central	Enconcor	C
	Dehydration	Dilutol(Torsemide)	C
	Duodenal Ulcer	Karvia	C
	Haemorrhage	Isocover	C
	Haematocrit Decreased	Pulmicort	
	Haemoptysis	(Budesonide)	C
	Heart Rate Increased	Atrovent(Ipratropium	
	Hypoventilation	Bromide)	C
	Intercostal Retraction	Nitroderm (Glyceryl	
	Left Ventricular Failure	Trinitrate)	C
	Melaena	Plenur (Lithium	
	Mucous Membrane Disorder	Carbonate)	C
	Myocardial Ischaemia	Oxis (Formoterol)	C
	Pallor		
	Pulmonary Fibrosis		
	White Blood Cell Count		
	Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/02ISR Number: 3908341-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Balsalazide Disodium	C		ORAL		
Initial or Prolonged			Valdecoxib	C				
Other								

Date:04/30/02ISR Number: 3908431-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01105
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Malaise		Vioxx	SS		ORAL		
	Pain In Extremity							
	Rhabdomyolysis							

Date:04/30/02ISR Number: 3908433-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02939
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization -	Renal Failure Acute		Naprosyn	C				
Initial or Prolonged			Vicodin Tablets	C				
Other								

Date:04/30/02ISR Number: 3908436-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02938
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	389	DAY
			Fiorinal	C				
			Synthroid	C				
			Prozac	C				

			Estrace	C		
			Moduretic	C		

Date:04/30/02ISR Number: 3908437-1Report Type:Expedited (15-DaCompany Report #WAES 0204PER00005
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY						
Hospitalization -	Infarction		Renitec (Enalapril			
Initial or Prolonged			Maleate)	C		ORAL
			Aspirin	C		ORAL
			Amlodipine Besylate	C		ORAL

Date:04/30/02ISR Number: 3908445-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA01518
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cyanopsia		Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						
	Optic Disc Drusen		Celebrex	C		
	Vision Blurred					
	Visual Disturbance					

Date:04/30/02ISR Number: 3908447-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00014
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Carbamazepine	C		ORAL		
			Fentanyl	C				
			Acetaminophen	C		ORAL		

Date:04/30/02ISR Number: 3908449-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00711
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebral Ischaemia		Glucophage	C				
Other	Confusional State		Micronase	C				
	Dysphagia		Avandia	C				
	Erosive Duodenitis		Prednisone	C				
	Gastritis		Lipitor	C				
	Haematocrit Decreased		Cardizem	C				
	Haemoglobin Decreased		Methotrexate	C				
	Herpes Simplex							
	Meningitis Aseptic							
	Nausea							
	Oesophageal Candidiasis							
	Reflux Oesophagitis							
	Salivary Hypersecretion							
	Stomatitis							
	Upper Respiratory Tract Infection							
	White Blood Cell Count Decreased							

Date:04/30/02ISR Number: 3908451-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02941
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		[Therapy					
	Oesophageal Ulcer		Unspecified]	C				

Upper Gastrointestinal
Haemorrhage

Date:04/30/02ISR Number: 3908455-3Report Type:Expedited (15-DaCompany Report #WAES 01105162
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bone Marrow Depression		Metronidazole	C				
Initial or Prolonged	Pancytopenia		Mercaptopurine	C				
52 DAY								
			Acetaminophen And Propoxyphene Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/02ISR Number: 3908662-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:04/30/02ISR Number: 3908663-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00119
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Hospitalization - Initial or Prolonged								

Date:04/30/02ISR Number: 3908664-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00204
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/30/02ISR Number: 3908665-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:04/30/02ISR Number: 3908667-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:04/30/02ISR Number: 3908670-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00034
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disease Progression Lung Neoplasm Malignant Metastasis		Vioxx	PS	Merck & Co., Inc			

Date:04/30/02ISR Number: 3908671-0Report Type:Expedited (15-DaCompany Report #WAES 0204AUT00005
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Impaired Healing		Metformin Hydrochloride	C				
	Multi-Organ Failure		Insulin	C				
	Myelodysplastic Syndrome							
	Myeloid Leukaemia							

Date:04/30/02ISR Number: 3908672-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02418
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Vioxx	PS	Merck & Co., Inc			

Date:04/30/02ISR Number: 3908673-4Report Type:Expedited (15-DaCompany Report #WAES 0204ITA00056
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/30/02ISR Number: 3908674-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02163
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

Date:04/30/02ISR Number: 3908675-8Report Type:Expedited (15-DaCompany Report #WAES 0204ISR00007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:04/30/02ISR Number: 3908676-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02179
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/30/02ISR Number: 3908677-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02418
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Induced Complications Of Maternal Exposure To Therapeutic Drugs Maternal Death Affecting Foetus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/30/02ISR Number: 3908682-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02859
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/02ISR Number: 3908684-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY
Initial or Prolonged	Dizziness		Taxol	C				
	Hypoaesthesia		Estradiol	C				
	Paraesthesia							
	Toxicologic Test Abnormal							

Date:04/30/02ISR Number: 3909579-7Report Type:Direct Company Report #CTU 166936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic		Vioxx	PS				
Initial or Prolonged								

Date:04/30/02ISR Number: 3910278-6Report Type:Expedited (15-DaCompany Report #A209127
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration	Foreign	Vibramycin Capsules	PS		ORAL		ORAL
	Diarrhoea	Health	Vioxx (Rofecoxib)	SS		ORAL		ORAL
	Renal Impairment	Professional						
		Other						

Date:04/30/02ISR Number: 3910617-6Report Type:Expedited (15-DaCompany Report #001-0981-M0201960
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm	Consumer	Atorvastatin					
Life-Threatening	Convulsion		(Atorvastatin)	PS		ORAL		PER ORAL

Hospitalization -	Difficulty In Walking		Gabapentin	SS		ORAL
PER ORAL						
Initial or Prolonged	Lung Neoplasm Malignant		Rofecoxib	SS		ORAL
PER ORAL						
Other	Metastases To Bone		Phenobarbital	SS		
	Metastases To Liver		Valproate Semisodium	C		
	Metastases To Spine					
	Muscular Weakness					
	Myalgia					
	Rash					
	Somnolence					
	Tremor					

Date:04/30/02ISR Number: 3911395-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 50 Mg	PS		ORAL
50 MG DAILY						
Hospitalization -		Professional				
PO						
Initial or Prolonged		Company	Balsalazide Disodium	C		
Other		Representative	Valdecoxib	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/02ISR Number: 3909163-5Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00130
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Respiratory Distress	Professional	Flurbiprofen	C		ORAL		
Initial or Prolonged			Acetaminophen	C		ORAL		
			Lansoprazole	C		ORAL		

Date:05/01/02ISR Number: 3909164-7Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00146
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident	Professional	Atenolol	C		ORAL		
Initial or Prolonged			Psyllium Husk	C		ORAL		

Date:05/01/02ISR Number: 3909166-0Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00174
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/01/02ISR Number: 3909169-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	26 DAY	
Hospitalization -	Lower Gastrointestinal	Professional	Lipitor	C				
Initial or Prolonged	Haemorrhage		Thyroid	C				

Date:05/01/02ISR Number: 3909171-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional	Vioxx Hydrodiuril	PS C	Merck & Co., Inc	ORAL		

Date:05/01/02ISR Number: 3909174-XReport Type:Expedited (15-DaCompany Report #WAES 0203BEL00024
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Laryngeal Oedema Loss Of Consciousness Rash Generalised		Acetaminophen And Codeine Phosphate	C		ORAL		

Date:05/01/02ISR Number: 3909426-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA02844
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematuria Haemorrhage		Vioxx Proscar	PS C	Merck & Co., Inc	ORAL		
Other			Hytrin Lipitor Prevacid	C C C		ORAL ORAL ORAL		

			Prilosec	C		ORAL
			Lasix (Furosemide)	C		ORAL

Date:05/01/02ISR Number: 3909428-7Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00138
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged			Fenofibrate	C		ORAL		
			Hydromorphone	C				

Date:05/01/02ISR Number: 3909431-7Report Type:Expedited (15-DaCompany Report #WAES 0202POL00010
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Hypersensitivity		Vioxx	SS		ORAL		
	Oedema Peripheral							
	Rash							
	Tongue Oedema							

Date:05/01/02ISR Number: 3909432-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00070
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL	519	DAY
Initial or Prolonged	Interstitial Lung Disease		Infliximab	SS				
INTRAVENOUS	23 DAY							
			Methotrexate Sodium	SS		ORAL	152	DAY

Date:05/01/02ISR Number: 3909436-6Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00141
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
			Tramadol	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:05/01/02ISR Number: 3909437-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02770
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dehydration		Lithium Carbonate	SS				
	Dizziness							
	Nausea							
	Toxicologic Test Abnormal							

Date:05/01/02ISR Number: 3909440-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00846
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Confusional State
	Meningitis

Myalgia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
			Prednisone	C		ORAL		
			Plaquenil	C		ORAL		
			Protonix	C				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
			Naproxen	C				

Date:05/01/02ISR Number: 3909441-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02752
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/01/02ISR Number: 3910521-3Report Type:Direct Company Report #CTU 167100
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased		Vioxx 25 Mg Merck And Co.	PS	Merck And Co.		25 MG ONCE DAILY	
			Dm	C				
			Htn	C				
			Dyslipidemia	C				

Date:05/01/02ISR Number: 3911498-7Report Type:Expedited (15-DaCompany Report #A209103
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Rhabdomyolysis	Foreign	Norvasc Tablets	PS	ORAL
ORAL					
Initial or Prolonged		Health	Tamsulosine	SS	ORAL
ORAL					
Required		Professional	Rofecoxib	SS	ORAL
ORAL					
Intervention to		Other	Kardegic	SS	ORAL
ORAL					
Prevent Permanent			Ifenprodil	C	
Impairment/Damage			Glibenclamide	C	
			Lercanidipine	C	
			Methylprednisolone	C	
			Alfuzosine	C	

Date:05/02/02ISR Number: 3909796-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Asthenia
Other	Blood Urea Increased
	Bronchitis
	Cardiac Disorder
	Cough
	Diarrhoea
	Dizziness
	Duodenal Ulcer

	Haemorrhage						
	Duodenitis						
	Dysstasia						
	Faecal Occult Blood	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Positive	Health	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
	Faeces Discoloured	Professional	Vioxx	SS		ORAL	62	DAY
	Fatigue		[Composition					
	Feeling Hot And Cold		Unspecified]	C		PARENTERAL		
	Gastritis Erosive		Aspirin	C			1	DAY
	Gastrointestinal		Estrogens					
	Haemorrhage		(Unspecified)	C		TOPICAL		
	Haematemesis		Bactrim	C		ORAL		
	Haematocrit Decreased		Tums	C		ORAL		
	Haemoglobin Decreased		Humibid	C		ORAL		
	Hyperhidrosis		Guaifenesin	C		ORAL		
	Influenza Like Illness		Nasonex	C		RESPIRATORY		
	Melaena					(INHALATION)		
	Orthostatic Hypotension							
	Sinus Congestion							
	Syncope							
	Thrombosis							
	Toothache							

Date:05/02/02ISR Number: 3909798-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc			

Date:05/02/02ISR Number: 3909799-1Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00171
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hypertensive Crisis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
		Professional				

Date:05/02/02ISR Number: 3909801-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/02/02ISR Number: 3909803-0Report Type:Expedited (15-DaCompany Report #WAES 01116008
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 278 DAY	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Althiazide And Spironolactone	C		ORAL
			Propranolol	C		ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
			Hyaluronic Acid	C		
PARENTERAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/02ISR Number: 3909806-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Femur Fracture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:05/02/02ISR Number: 3909812-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA03192
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS		ORAL		
	Headache		Vioxx	SS		ORAL		
	Hypertension							
	Tachycardia							

Date:05/02/02ISR Number: 3910022-2Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Hyperhidrosis							

Date:05/02/02ISR Number: 3910025-8Report Type:Expedited (15-DaCompany Report #WAES 0204ISR00007
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:05/02/02ISR Number: 3910028-3Report Type:Expedited (15-DaCompany Report #WAES 0204NLD00016
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Cholecalciferol	C		ORAL		
	Paraesthesia		Perindopril Erbumine	C		ORAL		
			Pamidronic Acid	C		INTRAVENOUS	DRIP	

Date:05/02/02ISR Number: 3910029-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA01976
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Congestive		Premarin	C				
Other	Oxygen Saturation		Zantac	C				
	Decreased		Synthroid	C				
			Serzone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/02ISR Number: 3910031-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00061
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged	Hemiparesis		Doxazosin	SS		ORAL		
Disability	Hypertension							
	Monoplegia							
	Weight Increased							

Date:05/02/02ISR Number: 3910032-5Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00016
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Haematuria		Warfarin Sodium	SS		ORAL		
			Nitroglycerin	C				
			Ergoloid Mesylates	C				
			Atenolol	C				
			Simvastatin	C				
			Isosorbide Mononitrate	C				

Date:05/02/02ISR Number: 3910034-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02208
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ejection Fraction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Decreased		Adderall Tablets	C				
Disability	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							

Date:05/02/02ISR Number: 3910040-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00151
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dysuria							
	Headache							
	Hypoaesthesia							
	Memory Impairment							
	Meningitis Viral							
	Occult Blood Positive							
	Paraesthesia							
	Pollakiuria							
	Urinary Incontinence							

Date:05/02/02ISR Number: 3911455-0Report Type:Direct Company Report #CTU 167192
Age: Gender:Female I/FU:I

Outcome	PT
Death	Blood Pressure Decreased
Life-Threatening	Cardio-Respiratory Arrest
Hospitalization - Initial or Prolonged	Chest Pain
	Haemodynamic Instability
	Myocardial Infarction
	Small Intestinal

Haemorrhage

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
			Flurbiprofen 100 Mg Tab	PS		ORAL
100MG PO BID						
			Vioxx 25mg Tablets	SS		ORAL
25 MG PO BID						
			Integrilin	SS		
INTRAVENOUS	15.8 MG IV 12					
MCG/KG/MIN						
			Lovenox	SS		
SUBCUTANEOUS	70MG SQ X 1					
			Fragmin 10,000 Units	SS		
SUBCUTANEOUS	10,000 UNITS					
SQ Q 12 H						
			Aspirin 325 Mg Tablets	SS		ORAL
325 MG PO QD						
			Tricor	C		
			Diltiazem	C		
			Aceon 8 Mg	C		
			Synthroid	C		
			Hydrocodone/Apap	C		
			Insulin	C		
			Morphine	C		
			Reglan 5 Mg Iv	C		
			Nitroglycerin	C		

Date:05/02/02ISR Number: 3911457-4Report Type:Direct Company Report #CTU 167193
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Distension		Vioxx	PS		
Hospitalization -	Anaemia		Prevacid	C		
Initial or Prolonged	Decreased Appetite		Klor-Con	C		
Required	Depressed Level Of		Verapamil	C		
Intervention to	Consciousness		Magnesium Oxide	C		
Prevent Permanent	Dysarthria		Colchine	C		
Impairment/Damage	Gastrointestinal		Hydrochlorothiazide	C		
	Haemorrhage					

Hepatic Encephalopathy
Hepatic Failure
Kidney Small
Mental Status Changes
Renal Failure Acute
Renal Tubular Necrosis
Sepsis
Urinary Tract Infection

Date:05/02/02ISR Number: 3911926-7Report Type:Expedited (15-DaCompany Report #001-0981-M0201152
Age: Gender:Male I/FU:F

Outcome PT
Disability Anxiety
Other Arthralgia
Asthenia
Blood Parathyroid Hormone
Increased
Complications Of
Transplant Surgery
Drug Interaction
Erythema Multiforme
Haemorrhage
Iatrogenic Injury

		Injury Myalgia Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash Renal Failure	Consumer Health	Atovastatin (Atorvastatin)	PS		ORAL
20 MG(DAILY),							
		Skin Disorder	Professional				
PER ORAL							
				Amlodipine (Amlopidine)	SS		
10 MG (DAILY)							
				Celecoxib (Celecoxib)	SS		
				Clonazepam (Clonazepam)	SS		
				Cyclobenzaprine (Cyclobenzaprine)	SS		
				B Complex (Pyridoxine Hydrochloride, Thiamine Hydrochloride,	SS		
				Rofecoxib (Rofecoxib)	SS		
				Paricalcitol	SS		
				(Various Medications)	SS		
				(Humulin N) (Insulin Human Injection, Isophane)	SS		
				Imuran (Azathioprine)	SS		
				Prednisone (Prednisone)	SS		
				Furosemide (Furosemide)	SS		
				Cyclosporine (Ciclosporin)	SS		
				Clonidine (Clonidine)	SS		
				Metoprolol Succinate (Metoprolol Succinate)	SS		
				Bisoprolol Fumarate (Bisoprolol Fumarate)	SS		

Date:05/03/02ISR Number: 3910323-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02189
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Sensation In Eye		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Aciphex	C				
	Drug Ineffective		Flomax					
	Scintillating Scotoma		(Morniflumate)	C				
	Vitreous Floaters							
	Vitreous Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/02ISR Number: 3910326-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				

Date:05/03/02ISR Number: 3911693-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01518
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chromatopsia	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Congenital Eye Naevus	Health					PO	
	Vision Blurred	Professional	Celebrex	C				
	Visual Disturbance							

Date:05/03/02ISR Number: 3911694-9Report Type:Expedited (15-DaCompany Report #WAES0204USA02938
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis	Health	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Professional					PO	
		Company Representative	Estrace	C				
			Fiorinal	C				
			Moduretic	C				
			Prozac	C				
			Synthroid	C				

Date:05/03/02ISR Number: 3911761-XReport Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vertigo	Foreign	Tab Vioxx					

Initial or Prolonged Vestibular Neuronitis Other (Rofecoxib) PS ORAL
12.5 MG/DAILY

PO

Date:05/03/02ISR Number: 3911764-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 3 MON

Date:05/03/02ISR Number: 3911767-0Report Type:Expedited (15-DaCompany Report #WAES 0203ESP00033
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 6 DAY

Date:05/03/02ISR Number: 3911779-7Report Type:Expedited (15-DaCompany Report #WAES 0204AUSA00153
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Hyperhidrosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 DAY

Date:05/03/02ISR Number: 3911786-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecchymosis Thrombocytopenic Purpura	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO 5 DAY	
			Antimicrobial (Unspecified)	C				
			Furosemide	C				
			Misoprostol	C				
			Opium	C				
			Prednisolone	C				
			Rutin	C				
			Sodium Feredetate	C				
			Warfarin	C				

Date:05/03/02ISR Number: 3911792-XReport Type:Expedited (15-DaCompany Report #WAES 01025277
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea Difficulty In Walking Drug Ineffective	Foreign Consumer	Tab Vioxx (Rofecoxib) Batch # 205137	PS		ORAL	25 MG/DAILY	PO 5 WK
			Aspirin	C				
			Indapamide	C				
			Omeprazole	C				

			Perindopril	C		

Date:05/03/02ISR Number: 3911960-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Hemiparesis	Professional Company Representative						

Date:05/03/02ISR Number: 3911961-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02428
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fall	Consumer	Tab Vioxx	PS		ORAL	PO	
	Monoplegia		Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/02ISR Number: 3912010-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02612
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Surgery	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer Haemorrhage							
	Haemorrhage							

Date:05/03/02ISR Number: 3912011-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Bacterial	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:05/03/02ISR Number: 3912012-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02565
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Other	Tab Vioxx	PS		ORAL	PO	

Date:05/03/02ISR Number: 3912013-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02630
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Thrombosis	Professional					MG/DAILY/PO	
Initial or Prolonged	Urinary Tract Disorder		Neurontin	C				
			Atenolol	C				
			Folic Acid	C				

Date:05/03/02ISR Number: 3912014-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02474
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Captopril Msd	C				
			Glucophage	C				
			Hydrocodin	C				
			Plavix	C				
			Pravachol	C				
			Insulin	C				

Date:05/03/02ISR Number: 3912029-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02939
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company	Naprosyn	C				
Other		Representative	Vicodin	C				

Date:05/03/02ISR Number: 3912031-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00711
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Biopsy Tongue Abnormal	Professional	Avandia	C				
Disability	Cerebral Atrophy	Company	Glucophage	C				
Other	Cerebral Ischaemia	Representative	Lipitor	C				
	Cerebrovascular Disorder		Micronase	C				
	Computerised Tomogram		Methotrexate	C				
	Abnormal		Prednisone	C				
	Confusional State							
	Coordination Abnormal							
	Dysarthria							
	Dysphagia							
	Erosive Duodenitis							
	Gastritis							
	Herpangina							
	Herpes Virus Infection							
	Laboratory Test Abnormal							
	Meningitis Aseptic							
	Mouth Ulceration							
	Nausea							
	Nuclear Magnetic							
	Resonance Imaging Brain							
	Abnormal							
	Oesophageal Candidiasis							
	Oral Pain							
	Productive Cough							
	Reflux Oesophagitis							
	Stomatitis							
	Upper Respiratory Tract							
	Infection							

Date:05/03/02ISR Number: 3912033-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02941
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Health	Tab Vioxx	PS		ORAL	PO	
	Haemoglobin Decreased	Professional						
	Oesophageal Ulcer	Company						

	Upper Gastrointestinal Haemorrhage	Representative

Date:05/03/02ISR Number: 3912051-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Attack	Professional Company Representative	Hydrodiuril	C				

Date:05/03/02ISR Number: 3912054-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02431
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source
Death	Cardiac Disorder	Health
	Myocardial Infarction	Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx Unk	PS		ORAL
PO							

Date:05/03/02ISR Number: 3912057-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01872
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative				

Date:05/03/02ISR Number: 3912058-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01090
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Rash	Health				
MG/DAILY/PO						
		Professional	Celebrex	C		

Date:05/03/02ISR Number: 3912071-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Respiratory	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Distress Syndrome	Professional	Herbs	C		
	Interstitial Lung Disease					
	Laboratory Test Abnormal					
	Lung Infiltration					
	Po2 Decreased					

Productive Cough
Red Blood Cell
Sedimentation Rate
Increased
Respiratory Failure
Sputum Purulent

Date:05/03/02ISR Number: 3912073-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01105
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	250MG/DAILY/P	
Initial or Prolonged	Gastrointestinal Disorder	Professional					O ; 50	
	Malaise	Company					MG/DAILY/PO	
	Medication Error	Representative						
	Rhabdomyolysis							

Date:05/03/02ISR Number: 3912078-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00334
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Cellulitis
Initial or Prolonged	Constipation
Other	Flatulence

	Nausea Pain Post Procedural	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Complication	Study	Tab Vioxx 50 Mg	PS		ORAL	50
	Postoperative Infection	Health					MG/DAILY/PO
	Pruritus	Professional	Claritin	C			
	Purulence		Lortab	C			
	Wound Dehiscence		Premarin	C			
	Wound Drainage		Reglan	C			
			Desflurane	C			
			Fentanyl	C			
			Midazolam	C			
			Morphine Sulfate	C			
			Nitrous Oxide	C			
			Ondansetron	C			
			Propofol	C			
			Rocuronium Bromide	C			
			Simethicone	C			

Date:05/03/02ISR Number: 3912160-7Report Type:Expedited (15-DaCompany Report #WAES 0204PER00005
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Myocardial	Foreign	Tab Vioxx				
Hospitalization -	Infarction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY
Initial or Prolonged		Professional					
PO							15 DAY
			Renitec (Enalparil Maleate)	C			
			Amlodipine Besylate	C			
			Aspirin	C			

Date:05/03/02ISR Number: 3912172-3Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00188
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris	Foreign	Tab Vioxx				

Initial or Prolonged	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Congestive	Professional				
PO						
	Coronary Artery Disease		Pioglitazone Hcl	SS		
45 MG 2 MON						
	Fluid Overload		Hydrodiuril	C		
	Hypertension		Zocor	C		
	Myocardial Infarction		Atenolol	C		
	Orthopnoea		Diltiazem Hydrochloride	C		
			Glyburide	C		
			Isosorbide Dinitrate	C		
			Perindopril Erbumine	C		

Date:05/03/02ISR Number: 3912186-3Report Type:Expedited (15-DaCompany Report #WAES 01105162
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aplastic Anaemia	Foreign	Tab Vioxx			
Hospitalization -	Bone Marrow Depression	Health	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Initial or Prolonged	Pancytopenia	Professional				
PO						
			Acetaminophen/Propoxyphene Hydrochloride	C		
			Mercaptopurine	C		

				Metronidazole	C		

Date:05/03/02ISR Number: 3912196-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00014
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant	Foreign	Tab Vioxx					
Disability		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Acetaminophen	C				
			Carbamazepine	C				
			Fentanyl	C				

Date:05/03/02ISR Number: 3912197-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	3 MON

Date:05/03/02ISR Number: 3912200-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00061
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Ischaemia	Foreign	Tab Vioxx					
	Cerebrovascular Accident	Other	(Rofecoxib)	PS		ORAL		
	Weight Increased		Tab Doxazosin	SS		ORAL		

Date:05/03/02ISR Number: 3912227-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00003
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cachexia	Foreign	Tab Vioxx					

Hospitalization -	Lung Carcinoma Cell Type	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Unspecified Stage Iv	Professional	Hydrodiuril	C		
Disability	Neoplasm Malignant		Atorvastatin Calcium	C		
			Bisoprolol Fumarate	C		
			Fosinopril Sodium	C		
			Methyl-Prednisolone	C		

Date:05/03/02ISR Number: 3912228-5Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00066
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dyspnoea	Foreign	Tab Vioxx			
Hospitalization -	Respiratory Disorder	Health	(Rofecoxib)	PS		ORAL
2						
Initial or Prolonged		Professional				
TABLET/DAILY						
			[Therapy Unspecified]	C		

Date:05/03/02ISR Number: 3912230-3Report Type:Expedited (15-DaCompany Report #WAES 0202CHE00034
Age:90 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction Metabolic Acidosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Renal Failure Acute		Tab Cozaar (Losartan Potassium)	SS		ORAL	50 MG/DAILY	
			Diclofenac Sodium	SS		ORAL	50 MG/DAILY	
			Metformin Hcl	SS		ORAL	2550 MG/DAILY	
			Furosemide Sodium	SS		ORAL	40 MG/DAILY	
			Acenocoumarol	C				
			Omeprazole Sodium	C				
			Amlodipine Besylate	C				
			Itraconazole	C				
			Miglitol	C				
			Levothyroxine Na	C				

Date:05/03/02ISR Number: 3912261-3Report Type:Expedited (15-DaCompany Report #S02-FRA-00583-01
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Coronary Artery Thrombosis	Foreign Health	Seropram (Citalopram Hydrobromide)	PS		ORAL	20 MG QD PO	
Initial or Prolonged	Myocardial Infarction	Professional Other	Seropram (Citalopram Hydrobromide)	SS		ORAL	10 MG QD PO	
			Rofecoxib	SS				

Date:05/04/02ISR Number: 3910873-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00019
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/02ISR Number: 3910883-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Emotional Disorder		Estrogens			
	Encephalitis		(Unspecified)	C		
	Meningitis Aseptic		Tylenol Pm	C		
			Prilosec	C		
			Zyrtec	C		

Date:05/04/02ISR Number: 3910884-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA03071
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
4 MON						
Initial or Prolonged	Drug Interaction		Vioxx	SS		ORAL
4 MON						
	Fluid Retention		Cyclosporine	SS		
	Pneumonia		Prednisone	C		
			[Therapy			
			Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/02ISR Number: 3910885-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA03166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				

Date:05/04/02ISR Number: 3910886-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Rosaprostol	C				

Date:05/04/02ISR Number: 3910887-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Balsalazide Disodium	C		ORAL		
Initial or Prolonged			Valdecoxib	C				
Other								

Date:05/04/02ISR Number: 3910888-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA03129
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Suicidal Ideation		Vioxx	SS		ORAL	8	DAY
			Vioxx	SS		ORAL	21	DAY

Date:05/04/02ISR Number: 3910889-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA03106
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Decreased Activity Difficulty In Walking Flat Affect		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/02ISR Number: 3910890-4Report Type:Expedited (15-DaCompany Report #WAES 0204ZAF00011
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Quinapril					
Initial or Prolonged			Hydrochloride	C		ORAL		
Disability			Bisoprolol Fumarate	C		ORAL		
Other			Spironolactone	C		ORAL		

Date:05/04/02ISR Number: 3910891-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA03150
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Advil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/02ISR Number: 3910893-XReport Type:Expedited (15-DaCompany Report #WAES 0203GBR00158
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anaemia		Aspirin	C				
	Duodenal Ulcer		Quinine Sulfate	C				
	Perforation		Felodipine	C				
	Knee Operation		Levothyroxine Sodium	C				
	Oesophageal Ulcer		Furosemide	C				
	Peritonitis							

Date:05/04/02ISR Number: 3910894-1Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00212
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	6	WK
	Haemorrhage		Vioxx	SS		ORAL		
	Overdose							

Date:05/04/02ISR Number: 3910895-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal							

Date:05/04/02ISR Number: 3910896-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00007
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Gold Sodium					

			Thiomalate	C		
INTRAMUSCULAR						
			Doxazosin	C		
			Bendroflumethiazide	C		

Date:05/04/02ISR Number: 3910898-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Haemorrhage		Coumadin	C		

Date:05/04/02ISR Number: 3910899-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Nizatidine	C		ORAL
			Furosemide	C		ORAL
			Amiloride	C		ORAL
			Digoxin	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/02ISR Number: 3910900-4Report Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Ibuprofen	C		ORAL		
			[Therapy Unspecified]	C				

Date:05/06/02ISR Number: 3911552-XReport Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vestibular Neuronitis		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY

Date:05/06/02ISR Number: 3911554-3Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00222
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Disability								
Other								

Date:05/06/02ISR Number: 3911557-9Report Type:Expedited (15-DaCompany Report #WAES 0204NZL00015
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc			
	Nerve Compression		Aspirin	C				
			Naproxen	C				

Date:05/06/02ISR Number: 3911558-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/02ISR Number: 3911559-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Post Procedural Complication Respiratory Disorder Respiratory Failure		Vioxx	SS		ORAL		
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
			Ibuprofen	C				
			[Therapy Unspecified]	C				

Date:05/06/02ISR Number: 3911565-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA00282
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysphonia		Coumadin	C				
Other	Haematemesis		Cortisone	C				
	Haemorrhage Subcutaneous							
	Heart Rate Irregular							
	Memory Impairment							

Date:05/07/02ISR Number: 3911888-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00018
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/02ISR Number: 3911889-4Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00015
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged			Isosorbide Mononitrate	C		ORAL		
			Amoxicillin Trihydrate And Clavulanate Potassium	C		ORAL	8	DAY
			Aspirin	C		ORAL		
			Furosemide	C		ORAL		
			Ramipril	C		ORAL		
			Digitoxin	C		ORAL		

Date:05/07/02ISR Number: 3911890-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00011
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive Pulmonary Disease		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:05/07/02ISR Number: 3911891-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA03260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged	Myocardial Infarction Pain							

Date:05/07/02ISR Number: 3911946-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00038
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema		Captopril	C		ORAL		
	Pulmonary Oedema		Nifedipine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3911947-4Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00056
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Hyzaar	C		ORAL		

Date:05/07/02ISR Number: 3911951-6Report Type:Expedited (15-DaCompany Report #WAES 0204KOR00081
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	46	DAY

Date:05/07/02ISR Number: 3911953-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02752
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/02ISR Number: 3912895-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00034
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Carcinoma Cell Type Unspecified Stage Iv	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG DAILY	

Date:05/07/02ISR Number: 3912904-4Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00174
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Chest Pain	Foreign	Tab Vioxx			
	Fatigue	Consumer	(Rofecoxib)	PS		ORAL
25 MG DAILY						
	Myocardial Infarction					
PO						

Date:05/07/02ISR Number: 3912906-8Report Type:Direct Company Report #CTU 167471
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS		
Initial or Prolonged	Haemorrhage					

Date:05/07/02ISR Number: 3912908-1Report Type:Direct Company Report #CTU 167972
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure Acute		Zocor	PS		
Initial or Prolonged	Rhabdomyolysis		Vioxx	SS		

Date:05/07/02ISR Number: 3912909-3Report Type:Direct Company Report #CTU 167436
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Blister
	Face Oedema

Pruritus
Rash Macular
Urticaria

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS			TWICE DAILY	

Date:05/07/02ISR Number: 3912910-XReport Type:Expedited (15-DaCompany Report #WAES 0204GBR00130
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Distress	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged			Acetaminophen	C				
			Flurbiprofen	C				
			Lansoprazole	C				

Date:05/07/02ISR Number: 3912942-1Report Type:Expedited (15-DaCompany Report #WAES 0204ISR00007
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	1 DAY

Date:05/07/02ISR Number: 3912946-9Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00153
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Hyperhidrosis	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
							PO	1 DAY

Date:05/07/02ISR Number: 3912967-6Report Type:Expedited (15-DaCompany Report #WAES 0204NLD00016
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign	Tab Vioxx					
	Hypertension	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Paraesthesia							
PO								
			Cholecalciferol	C				
			Pamidronic Acid	C				
			Perindopril Erbumine	C				

Date:05/07/02ISR Number: 3912988-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Disability								
PO							1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3912990-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00119
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional						
PO	3	MON						

Date:05/07/02ISR Number: 3912992-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO	6	MON						

Date:05/07/02ISR Number: 3912993-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO	1	MON						

Date:05/07/02ISR Number: 3912994-9Report Type:Expedited (15-DaCompany Report #WAES 0204ISR00007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

PO 1 DAY

Date:05/07/02ISR Number: 3912995-0Report Type:Expedited (15-DaCompany Report #WAES 0204ITA00056
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:05/07/02ISR Number: 3913039-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS			25 MG/DAILY	

Date:05/07/02ISR Number: 3913090-7Report Type:Expedited (15-DaCompany Report #WAES 0202POL00010
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 1 DAY
	Hypersensitivity							
	Oedema Peripheral							
	Rash							
	Tongue Oedema							

Date:05/07/02ISR Number: 3913093-2Report Type:Expedited (15-DaCompany Report #WAES 01116008
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 278 DAY
			Acetaminophen/ Propoxyphene Hydrochloride	C				
			Althiazide/ Spironolactone	C				
			Hyaluronic Acid	C				
			Propranolol	C				

Date:05/07/02ISR Number: 3913122-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00061
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign	Tab Vioxx					
	Gait Disturbance	Other	(Rofecoxib)	PS		ORAL		PO 13 DAY
Disability	Hemiparesis		Tab Doxazosin	SS		ORAL		PO
	Hypertension							
	Ischaemic Stroke							
	Monoplegia							
	Weight Increased							

Date:05/07/02ISR Number: 3913149-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00070
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoxia	Foreign	Tab Vioxx					
	Interstitial Lung Disease	Other	(Rofecoxib)	PS		ORAL	37.5 MG/DAILY,	PO 519 DAY

			Methotrexate Sodium	SS		ORAL
5 MG, DAILY,						
PO	152 DAY					

Date:05/07/02ISR Number: 3913150-0Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00171
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Hypertensive Crisis	Foreign	Tab Vioxx			
		Health	(Rofecoxib)	PS		ORAL
50 MG, DAILY,						
		Professional				
PO	6 DAY					

Date:05/07/02ISR Number: 3913187-1Report Type:Expedited (15-DaCompany Report #WAES 0204AUT00005
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Condition Aggravated	Foreign	Tab Vioxx			
Hospitalization -	Multi-Organ Failure	Other	(Rofecoxib)	PS		ORAL
25 MG						
Initial or Prolonged	Myelodysplastic Syndrome		Insulin	C		
	Myeloid Leukaemia		Metformin Hcl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3913233-5Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00138
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG/DAILY	10 DAY
			Fenofibrate	C				
			Hydromorphone	C				

Date:05/07/02ISR Number: 3913242-6Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00016
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematoma	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG/DAILY	31 DAY
	Haematuria	Other						
			Warfarin Sodium	SS		ORAL		
			Atenolol	C				
			Ergoloid Mesylates	C				
			Isosorbide Mononitrate	C				
			Nitroglycerin	C				
			Simvstatin	C				

Date:05/07/02ISR Number: 3913327-4Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00146
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Other						
	Hypertension							
			Atenolol	C				
			Psyllium Husk	C				

Date:05/07/02ISR Number: 3913332-8Report Type:Expedited (15-DaCompany Report #WAES 0203BEL00024
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema Cardio-Respiratory Arrest	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID/PO	1 DAY
	Loss Of Consciousness	Professional	Acetaminophen/Codein e Phosphate	C				

Date:05/07/02ISR Number: 3913459-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Femoral Neck Fracture Femur Fracture	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	2 MON

Date:05/07/02ISR Number: 3913460-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3913461-9Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00141
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	9 DAY
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Tramadol	C				

Date:05/07/02ISR Number: 3913501-7Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Auricular Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Cardiac Disorder	Health Professional	Celebrex	SS				
	Eczema		Anafranil	C				
	Epidermal Naevus		Lidex	C				
	Excoriation							
	Hypersensitivity							
	Inflammation							
	Nervousness							
	Neurodermatitis							
	Otitis Externa							
	Pain							
	Rash Macular							
	Respiratory Disorder							
	Scar							
	Skin Necrosis							
	Skin Papilloma							
	Skin Ulcer							

Date:05/07/02ISR Number: 3913525-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02163
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastroenteritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged Professional
MG/DAILY/PO
Company
Representative

Date:05/07/02ISR Number: 3913578-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02067
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Transient Ischaemic	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Attack	Professional	Hydrodiuril	C		
		Company				
		Representative				

Date:05/07/02ISR Number: 3913579-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG						
Hospitalization -	Haemorrhage	Professional				
/DAILY/PO						
Initial or Prolonged		Company	Lipitor	C		
		Representative	Thyroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3913581-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02179
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Viral	Company Representative Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:05/07/02ISR Number: 3913655-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA01976
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Other	Congestive Oxygen Saturation Decreased	Company Representative	Premarin	C				
			Serzone	C				
			Synthroid	C				
			Zantac	C				

Date:05/07/02ISR Number: 3913656-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02208
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Myocardial Infarction	Health Professional	Adderall Tablets	C				

Date:05/07/02ISR Number: 3913657-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02189
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abnormal Sensation In Eye	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Blindness Unilateral	Health				
MG/DAILY/PO						
	Vitreous Haemorrhage	Professional	Aciphex	C		
			Flomax			
			(Morniflumate)	C		

Date:05/07/02ISR Number: 3913666-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02844
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematuria	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY,						
Initial or Prolonged		Health				
PO						
Other		Professional	Hytrin	C		
			Lasix (Furosemide)	C		
			Lipitor	C		
			Prevacid	C		
			Prilosec	C		
			Proscar	C		

Date:05/07/02ISR Number: 3913814-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00151
Age:44 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Blood Urine Present
Initial or Prolonged	Coma
Other	Convulsion

		Dysuria Headache Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Memory Impairment	Health	Vioxx 50 Mg	PS		ORAL
50							
		Meningitis Viral	Professional				
MG/DAILY/PO							
		Paraesthesia	Company				
		Pollakiuria	Representative				
		Urinary Incontinence					

Date:05/07/02ISR Number: 3913852-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02418
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abortion	Health	Tab Vioxx	PS		
PO							
		Complications Of Maternal	Professional				
		Exposure To Therapeutic					
		Drugs					
		Maternal Drugs Affecting					
		Foetus					

Date:05/07/02ISR Number: 3913918-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00204
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dyspepsia	Health	Vioxx 25 Mg	PS		ORAL
25							
		Pruritus	Professional				
MG/DAILY/PO							

Date:05/07/02ISR Number: 3913922-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02859
Age:75 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Haemorrhage	Health	Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Ulcer	Professional				
MG/DAILY/PO 2 WK						
		Company				
		Representative				

Date:05/07/02ISR Number: 3913923-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Dizziness	Professional				
MG/DAILY/PO						
	Hypoaesthesia	Company	Taxol	C		
	Paraesthesia	Representative	Estradiol	C		

Date:05/07/02ISR Number: 3913930-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhage	Health	Tab Vioxx	PS		ORAL
PO						
		Professional	Coumadin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/02ISR Number: 3913966-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02752
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:05/07/02ISR Number: 3913970-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00649
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Tab Voxx 50 Mg	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Asthenia	Health	Bactrim	C				
Other	Blood Albumin Decreased	Professional	Humibid	C				
	Bronchitis		Nasonex	C				
	Cardiac Flutter		Tums	C				
	Cardiovascular Disorder		Aspirin	C				
	Duodenal Ulcer		Estrogens	C				
	Haemorrhage		Guaifenesin	C				
	Duodenitis							
	Gastritis Erosive							
	Gastrointestinal Disorder							
	Headache							
	Hyperhidrosis							
	Influenza Like Illness							
	Sensitivity Of Teeth							
	Sinusitis							
	Skin Papilloma							
	Tachycardia							
	Thrombosis							
	Upper Gastrointestinal Haemorrhage							

Date:05/07/02ISR Number: 3914668-7Report Type:Expedited (15-DaCompany Report #NSADSS2002014331
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoxia Lung Disorder	Foreign Health Professional	Remicade (5 Mg/Ml Lyophilized Powder) (Infliximab, Recombinant)	PS		INTRAVENOUS	5 MG/KG, 1 IN 1 TIME (S), IV	
			Methotrexate (Methotrexate)	SS		ORAL	5 MG WEEKLY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	37.5 MG, DAILY, ORAL	
			Corticosteroid Nos (Corticosteroid Nos)	C				

Date:05/07/02ISR Number: 3915181-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02770
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Dehydration

	Dizziness Nausea						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lithiumco3 Unk	SS				

Date:05/07/02ISR Number: 3915182-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00846
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Depressed Level Of Consciousness	Company Representative	Plaquenil	C				
	Meningitis		Protonix	C				
			Naproxen	C				
			Nonsteroidal Anti-Inflammatory	C				
			Prednisone	C				

Date:05/07/02ISR Number: 3915184-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA03192
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health Professional	Tab Vioxx 50 Mg 25 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO; PO	
	Dyspnoea	Company Representative						
	Headache							
	Hypertension							
	Tachycardia							

Date:05/08/02ISR Number: 3912365-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY
Hospitalization - Initial or Prolonged	Dizziness	Professional	Taxol	C				
	Drug Screen Positive		Estradiol	C				
	Headache		Premarin	C				
	Hypoaesthesia		Darvocet-N	C				
	Paraesthesia							

Date:05/08/02ISR Number: 3912366-7Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis Necrotising		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/08/02ISR Number: 3912368-0Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00060
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged			Carbamazepine	C		ORAL		11 DAY
			Hydrochlorothiazide And Lisinopril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/02ISR Number: 3912370-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00038
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Congestive	Professional	Vioxx	SS		ORAL		
			Lipitor	C				
			[Composition Unspecified]	C				

Date:05/08/02ISR Number: 3912615-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02293
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Abdominal Rigidity		Aspirin	C				
Initial or Prolonged	Blood Albumin Abnormal		Advil	C				
Disability	Blood Urea Abnormal		Aldoril	C		ORAL		
Other	Duodenal Ulcer		Norvasc	C				
	Perforation		Premarin	C				
	Gastric Ulcer Perforation		Vitamins (Unspecified)	C				
	Gastrointestinal Necrosis		Caltrate + D	C				
	Inflammation		Propacet	C				
	Laboratory Test Abnormal							
	Medication Error							
	Myocardial Infarction							
	Peritonitis							
	Protein Total Abnormal							
	Urinary Incontinence							
	Urine Ketone Body Present							
	Vomiting							

Date:05/08/02ISR Number: 3912616-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00015
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lung Disorder							
	Sepsis							

Date:05/08/02ISR Number: 3912617-9Report Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo Vestibular Neuronitis		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY

Date:05/08/02ISR Number: 3912619-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		26 DAY
Hospitalization - Initial or Prolonged	Lower Gastrointestinal Haemorrhage		Lipitor Thyroid	C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/02ISR Number: 3912620-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00711
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Confusional State		Glucophage	C				
Disability	Dysphagia		Micronase	C				
Other	Erosive Duodenitis		Avandia	C				
	Gastritis		Prednisone	C				
	Haematocrit Decreased		Lipitor	C				
	Haemoglobin Abnormal		Cardizem	C				
	Herpetic Stomatitis		Methotrexate	C				
	Meningitis Aseptic							
	Nuclear Magnetic Resonance Imaging Abnormal							
	Oesophageal Candidiasis							
	Reflux Oesophagitis							
	Upper Respiratory Tract Infection							
	White Blood Cell Count Decreased							

Date:05/08/02ISR Number: 3912621-0Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00003
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
Other	Hypocoagulable State		Acenocoumarol	SS		ORAL	6	YR
			Fluticasone Propionate And Salmeterol Xinafoate	C		RESPIRATORY (INHALATION)	16	MON
			Desogestrel	C		ORAL	2	YR
			Homeopathic Medications (Unspecified)	C		ORAL		

Date:05/08/02ISR Number: 3912623-4Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00024
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lower Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
	Infection		Ipratropium Bromide	C			RESPIRATORY (INHALATION)	
	Oedema Peripheral							
			Albuterol	C			RESPIRATORY (INHALATION)	
			Beclomethasone Dipropionate	C				
			Furosemide	C		ORAL		
			Furosemide	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/02ISR Number: 3912624-6Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00033
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage		Prednisone	C		ORAL		
			[Therapy Unspecified]	C		ORAL		

Date:05/08/02ISR Number: 3912625-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA00521
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
4 DAY								
Initial or Prolonged	Facial Palsy		Celebrex	C				
	Hypertension		Norvasc	C				
			Atenolol	C				
			Clonidine	C				
			Lasix (Furosemide)	C				
			Neurontin	C				
			Insulin	C				
			Levaquin	C				
			Synthroid	C				
			Prinivil	C				
			Metformin	C				
			Coumadin	C				
			Magnesium Oxide	C				

Date:05/08/02ISR Number: 3912626-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA00132
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Coumadin	C				
Initial or Prolonged								

Date:05/08/02ISR Number: 3912628-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00580
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Jaundice		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:05/08/02ISR Number: 3912685-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA00778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/02ISR Number: 3913870-8Report Type:Direct Company Report #CTU 167598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Level Increased		Vioxx 25mg By Other					
	Drug Toxicity		Physician	PS				
Q DAY DATE 2/								

Date:05/09/02ISR Number: 3913298-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02717
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage	Professional						
Initial or Prolonged								

Date:05/09/02ISR Number: 3913302-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01192
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
39 DAY								
Other	Cerebrovascular Accident		Vioxx	SS				
	Convulsion		Lorcet 10/650	C				
	Discomfort		Soma	C				
	Dizziness		Hydrocodone	C				
	Headache		Vicodin Es Tablets	C		ORAL		
	Hypertension		Flexeril	C		ORAL		
	Insomnia		Naprosyn	C				
	Intervertebral Disc Disorder							
	Intervertebral Disc Protrusion							
	Joint Range Of Motion Decreased							
	Mobility Decreased							
	Musculoskeletal Stiffness							
	Neck Pain							
	Pain							
	Paraesthesia							

		Pruritus					
		Radiculopathy					

Date:05/09/02ISR Number: 3913308-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA03106
Age:80 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Coordination Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Difficulty In Walking		Vioxx	SS		ORAL
209 DAY							
		Drug Ineffective					
		Flat Affect					
		Hypoaesthesia					

Date:05/09/02ISR Number: 3913312-2Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00003
Age:77 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Melaena	Professional	Aspirin	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3913326-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00782
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/02ISR Number: 3913536-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00017
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/02ISR Number: 3913538-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hallucination, Olfactory		Vioxx	SS		ORAL	1	MON
	Nervous System Disorder		Vioxx	SS		ORAL	1	YR
	Prescribed Overdose		[Composition Unspecified]	C				

Date:05/09/02ISR Number: 3913541-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01353
Age:97 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage		Warfarin Sodium	C				
Hospitalization -			Prednisone	C				
Initial or Prolonged			Prozac	C				
Other			Digoxin	C		ORAL		
			Altace	C				
			Lasix (Furosemide)	C				
			Minitran	C				

Date:05/09/02ISR Number: 3913543-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00016
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Fibrosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/02ISR Number: 3913545-5Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00013
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS		ORAL	15 YR	
			Captopril And Hydrochlorothiazide	C		ORAL	15 YR	
			Diltiazem Hydrochloride	C		ORAL	15 YR	
			Theophylline	C		ORAL	20 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3913548-0Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00012
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	MON
Life-Threatening	Perforation		Aspirin	C		ORAL		
Hospitalization -	Gastric Ulcer Perforation							
Initial or Prolonged	Peritonitis							
Disability								
Other								

Date:05/09/02ISR Number: 3913549-2Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Pioglitazone Hydrochloride	C		ORAL		

Date:05/09/02ISR Number: 3913550-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00018
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL		
							1	WK
Initial or Prolonged	Condition Aggravated		Vioxx	SS		ORAL		
	Cytomegalovirus Infection		Mesalamine	C				
	Drug Effect Decreased							

Date:05/09/02ISR Number: 3913553-4Report Type:Expedited (15-DaCompany Report #WAES 0205KOR00005
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypovolaemic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
							82	DAY

Date:05/09/02ISR Number: 3913555-8Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00006
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		40 DAY
Initial or Prolonged	Oedema		Aspirin	C				
			Estriol	C				
			Karaya Gum	C				
			Furosemide	C				
			Acetaminophen And Codeine Phosphate	C				
			Methenamine Hippurate	C				
			Digoxin	C				
			Renitec (Enalapril Maleate)	C				
			Loperamide Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3913557-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA00950
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ivth Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:05/09/02ISR Number: 3913558-3Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00003
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin Human, Isophane	C				
			Lisinopril	C				
			Aspirin	C				
			Insulin Lispro	C				

Date:05/09/02ISR Number: 3913559-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/02ISR Number: 3913562-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA00862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/02ISR Number: 3914367-1Report Type:Direct Company Report #CTU 167745
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx 50mg-Merck	PS	Merck	ORAL	50MG PO QD	3 DAY
Initial or Prolonged	Cerebral Infarction		Amlodipine	C				
Disability	Facial Palsy		Clonidine	C				
			Furosemide	C				

Date:05/09/02ISR Number: 3914368-3Report Type:Direct Company Report #CTU 167747
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx 50mg-Merck	PS	Merck	ORAL	50MG PO QD	1 DAY
	Headache							
	Hypertension							

Date:05/09/02ISR Number: 3914375-0Report Type:Direct Company Report #CTU 167720
Age:55 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Required Intervention to Prevent Permanent Impairment/Damage	Meningitis Bacterial Meningococcal Infection		Vioxx	PS		ORAL	25MG 1/DAY ORAL 25MG 2/DAY ORAL	
			Lipitor	C				
			Plumacort	C				
			Rhinocort Acqua	C				
			Albuterol	C				

Date:05/09/02ISR Number: 3914386-5Report Type:Direct Company Report #CTU 167715
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Platelet Count Decreased		Vioxx 25mg	PS		ORAL	1 TAB PO QD	
			Synthroid	C				
			Pravachol	C				
			Donnatal	C				
			Quinine Sulfate	C				

Date:05/09/02ISR Number: 3914408-1Report Type:Direct Company Report #CTU 167809
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Rectal Haemorrhage		Vioxx	PS			12.5 MG ONCE DAILY	3 WK
			Vasotec	C				
			Allegra	C				
			Tylenol	C				

Date:05/09/02ISR Number: 3914748-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA03260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Myocardial Infarction							
	Pain							

Date:05/09/02ISR Number: 3914948-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Balsalazide Disodium	C				
Other		Representative	Valdecoxib	C				

Date:05/09/02ISR Number: 3914951-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA00843
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Balance Disorder
Initial or Prolonged	Blindness Transient

	Csf Lymphocyte Count Increased						
	Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Emotional Disorder	Health	Tab Vioxx	PS		ORAL	PO
	Encephalitis	Professional	Prilosec	C			
	Grand Mal Convulsion	Company	Tylenol Pm	C			
	Meningitis Aseptic	Representative	Zyrtec	C			
	Pleocytosis		Estrogens	C			
	Speech Disorder						
	Vision Blurred						

Date:05/09/02ISR Number: 3915092-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Back Pain	Consumer	Tab Vioxx	PS		ORAL	PO
Initial or Prolonged	Chest Discomfort	Health					
	Chest Pain	Professional					

Date:05/09/02ISR Number: 3915093-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Gastric Ulcer Perforation	Health	Tab Vioxx	PS		ORAL	25 MG/PO; SEE
Hospitalization -	Respiratory Failure	Professional					IMAGE
Initial or Prolonged		Company	Ibuprofen	C			
		Representative	Nonsteroidal				
			Anti-Inflammatory	C			

Date:05/09/02ISR Number: 3915101-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA03071
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Drug Interaction Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
			Cyclosporine	SS		
			Therapy Unspecified	C		
			Prednisone	C		

Date:05/09/02ISR Number: 3915103-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA03129
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Depression Suicidal Ideation	Consumer	Tab Vioxx 50 Mg	PS		ORAL 50 MG/DAILY/PO
			Tab Vioxx 25 Mg	SS		ORAL 25 MG/DAILY/PO

Date:05/09/02ISR Number: 3915109-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA03166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL PO
			Celebrex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3915272-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Nausea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Rosaprostol	C				

Date:05/09/02ISR Number: 3915273-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA03150
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Advil	C				

Date:05/09/02ISR Number: 3915274-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA00358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal	Professional Company Representative						

Date:05/09/02ISR Number: 3915275-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	

Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative	Coumadin	C

Date:05/09/02ISR Number: 3915297-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA00282
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Dysphonia		Coumadin	C				
Other	Haematemesis		Cortisone	C				
	Haemorrhage Subepidermal							
	Heart Rate Irregular							
	Memory Impairment							

Date:05/09/02ISR Number: 3915335-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA03106
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective							
	Flat Affect							
	Sensory Loss							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3915340-XReport Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Hospitalization -	Melaena	Health					PO	
Initial or Prolonged	Pancreatic Disorder	Professional	Ativan	C				
Disability	Pancreatitis	Other	Flexeril	C				
Other	Weight Decreased		Valium	C				

Date:05/09/02ISR Number: 3915359-9Report Type:Expedited (15-DaCompany Report #WAES 0204NZL00015
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Nerve Compression	Consumer	(Rofecoxib)	PS			12.5 MG/DAILY	
	Sciatica		Aspirin	C				
			Naproxen	C				

Date:05/09/02ISR Number: 3915375-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00018
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	25	
							MG/DAILY/PO	

Date:05/09/02ISR Number: 3915377-0Report Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vertigo	Foreign	Tab Vioxx					

Initial or Prolonged	Vestibular Neuronitis	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
PO 3 DAY						

Date:05/09/02ISR Number: 3915390-3Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Upper Gastrointestinal	Foreign	Tab Vioxx			
Initial or Prolonged	Haemorrhage	Other	(Rofecoxib)	PS		ORAL
12.5 MG DAILY						
PO						
			Amiloride	C		
			Digoxin	C		
			Furosemide	C		
			Nizatidine	C		

Date:05/09/02ISR Number: 3915392-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00019
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Foreign	Tab Vioxx			
		Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3915393-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00007
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Bendroflumethiazide	C				
			Doxazosin	C				
			Gold Sodium Thiomalate	C				
			Methotrexate	C				

Date:05/09/02ISR Number: 3915431-3Report Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL		
Hospitalization - Initial or Prolonged		Health Professional	Ibuprofen	C				

Date:05/09/02ISR Number: 3915433-7Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00212
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
	Prescribed Overdose	Professional					PO	6 WK

Date:05/09/02ISR Number: 3915435-0Report Type:Expedited (15-DaCompany Report #WAES 0204ZAF00011
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Foreign	Tab Vioxx					

Hospitalization -		Other	(Rofecoxib)	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
Disability			Bisoprolol Fumarate	C		
Other			Quinapril Hcl	C		
			Spironolactone	C		

Date:05/09/02ISR Number: 3915439-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00158
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Duodenal Ulcer	Foreign	Tab Vioxx			
Hospitalization -	Perforation	Other	(Rofecoxib)	PS		ORAL
12.5						
Initial or Prolonged	Oesophageal Ulcer					
MG/BID/PO						
	Peritonitis		Aspirin	C		
			Felodipine	C		
			Furosemide	C		
			Levothyroxine Na	C		
			Quinine So4	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/02ISR Number: 3915469-6Report Type:Expedited (15-DaCompany Report #WAES 01079556
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Tab Vioxx					
Hospitalization -		Study	(Rofecoxib)	PS		ORAL	25	
Initial or Prolonged		Other					MG/DAILY/PO	542 DAY
Disability			Tab Placebo					
			(Unspecified)	SS		ORAL	PO	98 DAY
			Mevacor	C				
			Aspirin	C				
			Diltiazem					
			Hydrochloride	C				
			Sulfasalazine	C				

Date:05/09/02ISR Number: 3915482-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00015
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged								
PO	5 DAY							
			Amoxicillin					
			(Trihydrate (+)					
			Clavulanate P	C				
			Aspirin	C				
			Digitoxin	C				
			Furosemide	C				
			Isosorbide					
			Mononitrate	C				
			Ramipril	C				

Date:05/09/02ISR Number: 3915506-9Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00222
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disease Recurrence	Foreign	Tab Vioxx					
Life-Threatening	Myocardial Infarction	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Disability		Professional						
Other								

Date:05/09/02ISR Number: 3915507-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00011
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive Pulmonary Disease	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		
			Therapy Unspecified	C				

Date:05/10/02ISR Number: 3913792-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Balsalazide Disodium	C		ORAL		
			Valdecoxib	C				
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/02ISR Number: 3913795-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00984
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
	Meningitis Aseptic		Flexeril	C				
	Petechiae							

Date:05/10/02ISR Number: 3913800-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Lopid	C				
			Inderal	C				
			Allegra	C				
			Premarin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				
			Plavix	C				
			Zestril	C				
			Metformin	C				
			Folic Acid	C				
			Mobic	C				
			Wellbutrin	C				

Date:05/10/02ISR Number: 3913803-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02362
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				
			Darvocet-N	C				
			Aspirin	C				
			Prilosec	C				

Date:05/10/02ISR Number: 3913805-8Report Type:Expedited (15-DaCompany Report #WAES 0205SGP00001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc			
Hospitalization -	Infarction		Spironolactone	C				
Initial or Prolonged	Gastric Ulcer		Clopidogrel					
	Gastrointestinal		Bisulfate	C				
	Haemorrhage		Ramipril	C				
	Hypotension		Isosorbide Dinitrate	C				
			Atorvastatin Calcium	C				

Date:05/10/02ISR Number: 3913972-6Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00222
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		693 DAY
Life-Threatening	Infarction		Atorvastatin Calcium	C				196 DAY
Disability	Aortic Aneurysm Rupture		Indocin					
Other	Intracranial Aneurysm		(Indomethacin)	C				4997 DAY
	Myocardial Ischaemia		Acetaminophen And					

		Codeine Phosphate	C
		Quinapril Hydrochloride	C
1381 DAY			
		Metoprolol	C
988 DAY			

Date:05/10/02ISR Number: 3913982-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01721
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Diovan	C				
Disability			Norvasc	C				
Other			Glucophage	C				

Date:05/10/02ISR Number: 3913984-2Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/02ISR Number: 3913985-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebellar Artery		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - INTRAVENOUS	Thrombosis		Globulin, Immune	C				
Initial or Prolonged	Cerebrovascular Accident							

Date:05/10/02ISR Number: 3913989-1Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00073
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Blood Pressure Decreased							
	Nausea							

Date:05/10/02ISR Number: 3913990-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00047
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	121	DAY
	Palpitations		Aspirin	C				
			Levothyroxine Sodium	C				
			Diltiazem Hydrochloride	C				
			Ramipril	C				
			Betaxolol Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/02ISR Number: 3913992-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemiparesis							
	Mental Impairment							

Date:05/10/02ISR Number: 3913994-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01097
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastrointestinal		Lipitor	C				
Initial or Prolonged	Haemorrhage		Norvasc	C				
Other	Myocardial Infarction		Coumadin	C				
			Lasix (Furosemide)	C				

Date:05/10/02ISR Number: 3913995-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01111
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/02ISR Number: 3913997-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crying		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Depression		Insulin, Biphasic Isophane [Injection]	C				
			Lisinopril	C				
			Atorvastatin	C				

Date:05/13/02ISR Number: 3914771-1Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Dyspnoea	Professional	Phenprocoumon	SS		ORAL		
	Gastrointestinal		Buprenorphine					
	Haemorrhage		Hydrochloride	C				
	International Normalised		Melperone					
	Ratio Increased		Hydrochloride	C				
	Prothrombin Time Abnormal		Calcium Carbonate					
	Pulmonary Oedema		And Cholecalciferol	C				
			Paroxetine					
			Hydrochloride	C				

Date:05/13/02ISR Number: 3914773-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01075
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
							30	DAY
Hospitalization -	Dementia		Vioxx	SS		ORAL		
Initial or Prolonged	Meningitis Aseptic							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/02ISR Number: 3914776-0Report Type:Expedited (15-DaCompany Report #WAES 0205POL00003
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Exacerbated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
		Professional	Vioxx	SS		ORAL	1	DAY
			Singulair	C			4	WK
			Formoterol Fumarate	C			RESPIRATORY (INHALATION)	3 MON
			Theophylline	C		ORAL	6	MON
			Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)	1 YR
			Hydroxyzine	C			2	MON
			Acetaminophen	C			3	MON

Date:05/13/02ISR Number: 3915059-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA01868
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Dehydration	Professional	Lorazepam	C		ORAL		
	Diarrhoea Haemorrhagic		Paxil	C		ORAL		
	Rectal Haemorrhage							

Date:05/13/02ISR Number: 3915060-1Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00018
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Bone Marrow Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Hospitalization -		Professional	Cozaar	C			
Initial or Prolonged		Company	Tolterodine Tartrate	C			
		Representative					

Date:05/13/02ISR Number: 3915061-3Report Type:Expedited (15-DaCompany Report #WAES 0205PER00002
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conjunctival Oedema	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Initial or Prolonged	Eye Inflammation							

Date:05/13/02ISR Number: 3915066-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00521
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
Initial or Prolonged	Cerebral Infarction	Professional	Celebrex	C				
			Norvasc	C				
			Atenolol	C				
			Atenolol	C				
			Clonidine	C				
			Lasix (Furosemide)	C				
			Lasix (Furosemide)	C				
			Neurontin	C				
			Insulin	C				
			Levaquin	C				
			Synthroid	C				
			Prinivil	C				

				Metformin	C		
				Coumadin	C		
				Magnesium Oxide	C		
				Nitroglycerin	C		
TOPICAL							

Date:05/13/02ISR Number: 3915068-6Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Systemic Lupus	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Erythematosus	Professional	Levothyroxine Sodium	C				
			Omeprazole	C				
			Ibuprofen	C				
TOPICAL								
			Hydroxychloroquine Sulfate	C				

Date:05/13/02ISR Number: 3915069-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Olfactory	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose	Professional	Vioxx	SS		ORAL	1	MON
	Temporal Lobe Epilepsy		Vioxx	SS		ORAL	1	YR
			[Composition Unspecified]	C				

Date:05/13/02ISR Number: 3915071-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01273
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/02ISR Number: 3915072-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01187
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				
			Atenolol	C				
			Isosorbide Mononitrate	C				
			Zoloft	C				
			Synthroid	C				
			Norvasc	C				
			Diclofenac	C				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				

Date:05/13/02ISR Number: 3915075-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01127
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/02ISR Number: 3915533-1Report Type:Expedited (15-DaCompany Report #2002104923US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intestinal Obstruction	Consumer	Arthrotec (Diclofenac Sodium, Misoprostol) Tablet	PS		ORAL	ORAL	
			Celebrex (Celecoxib) Capsule	SS				
			Vioxx ()	SS				

Date:05/13/02ISR Number: 3915539-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Thrombosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Cerebrovascular Accident	Professional						
Initial or Prolonged		Company Representative	Globulin, Immune	C				

Date:05/13/02ISR Number: 3915900-6Report Type:Direct Company Report #CTU 167900
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Rofecoxib 25mg Merck	PS	Merck	ORAL	25 MG QD ORAL	
Initial or Prolonged	Increased		Pcn G Potassium	C				
	Blood Potassium Increased		Oxycodone	C				
	Blood Urea Increased		Methadone	C				

Date:05/13/02ISR Number: 3915956-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02752
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Ulcer Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL

50 MG/DAILY/PO

Date:05/13/02ISR Number: 3915987-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00038
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO 25 MG/DAILY PO	3 DAY
			Lipitor (Composition Unspecified)	C				

Date:05/13/02ISR Number: 3916176-6Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis Necrotising	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:05/13/02ISR Number: 3916179-1Report Type:Expedited (15-DaCompany Report #WAES 0204KOR00081
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY/PO	

Date:05/13/02ISR Number: 3916405-9Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY	
	Oedema							
	Pulmonary Oedema		Captopril	C				
			Nifedipine	C				

Date:05/13/02ISR Number: 3916407-2Report Type:Expedited (15-DaCompany Report #WAES 0204CHE00056
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
			Hyzaar	C				

Date:05/13/02ISR Number: 3916408-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00060
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	3 DAY
			Carbamazepine	C				

				Lisinopril-Hctz	C		

Date:05/13/02ISR Number: 3916434-5Report Type:Direct Company Report #CTU 167989
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blister		Rofecoxib	PS		
	Chills					
	Rash					
	Swelling					

Date:05/13/02ISR Number: 3916596-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Dizziness	Professional				
MG/DAILY/PO						
Initial or Prolonged	Drug Screen Positive	Company	Darvocet-N	C		
	Headache	Representative	Premarin	C		
	Hypoaesthesia		Taxol	C		
	Paraesthesia		Estradiol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3915513-6Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00171
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
		Professional	Gabapentin	C		ORAL		
			Metoprolol Succinate	C		ORAL		

Date:05/14/02ISR Number: 3915516-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Iatrogenic Injury							
	Monoplegia							
	Phlebitis							
	Sensory Loss							
	Thermal Burn							
	Thrombosis							

Date:05/14/02ISR Number: 3915521-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01326
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/14/02ISR Number: 3915702-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00783
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive	Professional	Cozaar	C		ORAL		
	Cardiomegaly		Atenolol	C				
			Klor-Con	C				
			Ativan	C				

Neurontin	C
Aldactazide	C
Prozac	C
Serevent	C
Atrovent	C
Ambien	C

Date:05/14/02ISR Number: 3915704-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00053
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Biliary Colic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Pancreatitis	Professional						

Date:05/14/02ISR Number: 3915705-6Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00076
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged		Professional	Flupirtine Maleate	C		ORAL		

Date:05/14/02ISR Number: 3915707-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/14/02ISR Number: 3915708-1Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00008
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc			

Date:05/14/02ISR Number: 3915709-3Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00007
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc			

Date:05/14/02ISR Number: 3915710-XReport Type:Expedited (15-DaCompany Report #WAES 0205GBR00077
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Thinking Abnormal		Tramadol Hydrochloride	C		ORAL		

Date:05/14/02ISR Number: 3915712-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01311
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Gastrointestinal Haemorrhage	Health Professional	Vioxx Coumadin	PS C	Merck & Co., Inc	ORAL

Date:05/14/02ISR Number: 3916551-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02293
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL
25						
Hospitalization -	Blood Glucose Increased	Professional				
MG/DAILY/PO						
Initial or Prolonged	Blood Pressure Increased	Company	Advil	C		
Disability	Blood Urea Increased	Representative	Aldoril	C		
Other	Diverticulitis		Caltrate + D	C		
	Duodenal Ulcer		Norvasc	C		
	Perforation		Premarin	C		
	Haematocrit Decreased		Propacet	C		
	Intestinal Ischaemia		Aspirin	C		
	Myocardial Infarction		Vitamins	C		
	Nausea					
	Peritonitis					
	Respiratory Rate Increased					
	Urinary Incontinence					
	Urine Ketone Body Present					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3916558-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Fluid Retention	Professional					MG/DAILY/PO	
		Company Representative						

Date:05/14/02ISR Number: 3916559-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA00782
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:05/14/02ISR Number: 3916565-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
		Company Representative						

Date:05/14/02ISR Number: 3916566-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA00950
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Ivth Nerve Paralysis	Health	Tab Vioxx	PS			ORAL
PO							
		Professional Company Representative	Therapy Unspecified	C			

Date:05/14/02ISR Number: 3916567-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Company	Tab Vioxx	PS		ORAL		
PO								
		Representative Other						

Date:05/14/02ISR Number: 3916571-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02717
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx	PS		ORAL		
PO								
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3916582-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA00984
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL	25-50	
Initial or Prolonged	Petechiae	Professional					MG/DAILY/PO	
		Company Representative	Flexeril	C				

Date:05/14/02ISR Number: 3916643-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Balsalazide Disodium	C				
Other			Valdecoxib	C				

Date:05/14/02ISR Number: 3916655-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02362
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Coumadin	C				
			Darvocet-N	C				
			Prilosec	C				
			Aspirin	C				

Date:05/14/02ISR Number: 3916681-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01192
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Back Pain	Consumer	Tab Vioxx 25 Mg	PS	ORAL
1) 25					
Other	Blood Pressure Increased				
MG/DAILY/PO;					
	Cerebrovascular Accident				
2) 25-50					
	Convulsion				
MG/PRN/UNK					
	Discomfort		Flexeril	C	
	Dizziness		Lorcet 10/650	C	
	Headache		Naprosyn	C	
	Insomnia		Soma	C	
	Intervertebral Disc		Vicodin Es Tablets	C	
	Disorder		Hydrocodone	C	
	Intervertebral Disc				
	Protrusion				
	Joint Range Of Motion				
	Decreased				
	Musculoskeletal Stiffness				
	Pain				
	Paraesthesia				
	Pruritus				
	Radiculopathy				

Date:05/14/02ISR Number: 3916695-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:I

Outcome	PT
Other	Convulsion
	Hallucination, Olfactory

Muscle Spasms

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO; 25	

Date:05/14/02ISR Number: 3916697-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Inderal	C				
			Mobic	C				
			Plavix	C				
			Premarin	C				
			Wellbutrin	C				
			Zestril	C				
			Folic Acid	C				
			Metformin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:05/14/02ISR Number: 3916698-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01353
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Upper Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Life-Threatening	Haemorrhage	Professional				
MG/DAILY/PO						
Hospitalization -		Company	Altace	C		
Initial or Prolonged		Representative	Lasix (Furosemide)	C		
Other			Minitran	C		
			Prozac	C		
			Digoxin	C		
			Prednisone	C		
			Warfarin Sodium	C		

Date:05/14/02ISR Number: 3916705-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00132
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Upper Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Hospitalization -	Haemorrhage	Professional	Coumadin	C		
Initial or Prolonged		Company				
		Representative				

Date:05/14/02ISR Number: 3916706-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02079
Age:70 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Lower Gastrointestinal	Professional					PO	
	Haemorrhage	Company	Lipitor	C				
		Representative	Thyroid	C				

Date:05/14/02ISR Number: 3916707-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00711
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Brain Scan Abnormal	Professional	Avandia	C				
Disability	Cerebral Atrophy	Company	Cardizem	C				
Other	Cerebral Ischaemia	Representative	Glucophage	C				
	Confusional State		Lipitor	C				
	Coordination Abnormal		Micronase	C				
	Dysarthria		Methotrexate	C				
	Dysphagia		Prednisone	C				
	Electroencephalogram Abnormal							
	Erosive Duodenitis							
	Gastritis							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Meningitis Aseptic							
	Mouth Ulceration							
	Nausea							
	Nervous System Disorder							
	Oesophageal Candidiasis							
	Oral Pain							
	Productive Cough							
	Reflux Oesophagitis							
	Stomatitis							
	Tongue Ulceration							
	Upper Respiratory Tract Infection							
	Viral Infection							
	White Blood Cell Count							

Decreased

Date:05/14/02ISR Number: 3916708-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA03106
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coordination Abnormal	Consumer	Tab Vioxx Unk	PS		ORAL	PO : 25	
	Difficulty In Walking	Other					MG/DAILY/PO	
	Drug Ineffective							
	Hypoaesthesia							
	Sensory Loss							

Date:05/14/02ISR Number: 3916759-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00521
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebral Infarction
	Cerebral Ischaemia

	Chest Pain						
	Facial Palsy						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea	Health	Tab Vioxx	PS		ORAL	50
	Vomiting	Professional					MG/DAILY/PO
		Company Representative	Celebrex	C			
			Coumadin	C			
			Lasix (Furosemide)	C			
			Levaquin	C			
			Neurontin	C			
			Norvasc	C			
			Prinivil	C			
			Synthroid	C			
			Atenolol	C			
			Clonidine	C			
			Insulin	C			
			Magnesium Oxide	C			
			Metformin	C			

Date:05/14/02ISR Number: 3916766-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA00580
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Aspartate	Health	Vioxx 50 Mg	PS		ORAL	50
	Aminotransferase	Professional					MG/DAILY/PO
	Increased						
	Blood Alkaline						
	Phosphatase Increased						
	Blood Bilirubin Increased						
	Jaundice						

Date:05/14/02ISR Number: 3916843-4Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00006
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Uric Acid Increased	Foreign	Tab Vioxx				

Initial or Prolonged	C-Reactive Protein	Other	(Rofecoxib)	PS	ORAL
25 MG/DAILY					
	Increased				
PO 40 DAY					
	Cardiac Failure		Renitec (Enalapril Maleate)	C	
	Lung Infiltration		Acetaminophen/Codeine Phosphate	C	
	Red Blood Cell Sedimentation Rate Increased		Aspirin	C	
			Digoxin	C	
			Estriol	C	
			Furosemide	C	
			Karaya Gum	C	
			Loperamide Hcl	C	
			Methenamine Hippurate	C	

Date:05/14/02ISR Number: 3916844-6Report Type:Expedited (15-DaCompany Report #WAES 0202BEL00006
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Angina Pectoris Hypertension	Foreign Study Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Mk-0966	PS		ORAL	50 MG/DAILY	PO
Tab Placebo (Unspecified)	SS		ORAL		PO
Hctz/Trimterene	C				
Prinivil	C				
Aspirin	C				
Calcium Carbonate	C				
Cyanocobalamin	C				
Folic Acid	C				
Folic Acid (+) Iron (Unspecified) (+) Vi	C				
Infliximab	C				
Methotrexate	C				
Prednisolone	C				
Propranol	C				
Tibolone	C				
Tramadol Hcl	C				

Date:05/14/02ISR Number: 3916848-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00016
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Fibrosis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
		Professional						

Date:05/14/02ISR Number: 3916849-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00017
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm	Foreign	Tab Vioxx					

		Health	(Rofecoxib)	PS			ORAL
25 MG/DAILY							
		Professional					
PO							

Date:05/14/02ISR Number: 3916856-2Report Type:Expedited (15-DaCompany Report #WAES 0205KOR00005
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypovolaemic Shock	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL		
12.5 MG/DAILY								
		Professional						
PO							82	DAY

Date:05/14/02ISR Number: 3916857-4Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00003
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL		
PO								
			Aspirin	C				
			Insulin Human,					
			Isophane	C				
			Insulin Lispro	C				
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3916865-3Report Type:Expedited (15-DaCompany Report #WAES 0204GRC00013
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO
			Tab Aspirin	SS		ORAL	100 MG/DAILY	PO
								15 YR
			Captopril/Hctz	C				
			Diltiazem Hydrochloride	C				
			Theophylline	C				

Date:05/14/02ISR Number: 3916870-7Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00003
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Melaena	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Tab Aspirin	SS		ORAL	100 MG/DAILY	PO

Date:05/14/02ISR Number: 3916874-4Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		PO
			Pioglitazone Hcl	C				

Date:05/14/02ISR Number: 3916877-XReport Type:Expedited (15-DaCompany Report #WAES 0204SGP00008
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo Vestibular Neuronitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/ DAILY PO	3 DAY

Date:05/14/02ISR Number: 3916933-6Report Type:Expedited (15-DaCompany Report #001-0981-M0202377
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Drug Hypersensitivity	Consumer	Atorvastatin (Atorvastatin)	PS		ORAL	20 MG (DAILY), PER ORAL	
Other	Gout Liver Function Test Abnormal Myocardial Infarction Swelling Thyroid Disorder Thyroid Neoplasm Weight Increased		Clopidogrel Rofecoxib Digoxin Imipramine Captopril Propranolol Potassium Chloride Lansoprazole Allopurinol Isosorbide	SS SS C C C C C C C C				

				Actos	C	
				Levothyroine Sodium	C	
				Furosemide	C	

Date:05/14/02ISR Number: 3916999-3Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00003
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypocoagulable State	Foreign	Tab Vioxx					
Other	International Normalised	Other	(Rofecoxib)	PS		ORAL	75 MG/DAILY	
	Ratio Increased							
PO							18	DAY
			Tab Acenocoumarol	SS		ORAL	PRN PO	6 YR
			Desogestrel	C				
			Fluticasone Propionate (+) Salmeterol Xi	C				
			Homeopathic Medications (Unspecified)	C				

Date:05/14/02ISR Number: 3917011-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00015
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cellulitis	Foreign	Tab Vioxx					
	Lung Disorder	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	Sepsis							
PO								

Date:05/14/02ISR Number: 3917053-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00024
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lower Respiratory Tract	Foreign	Tab Vioxx					

	Infection	Other	(Rofecoxib)	PS		ORAL
12.5 MG PO 12 DAY						
	Oedema Peripheral		Acetaminophen/Codeine Phosphate	C		
			Albuterol	C		
			Beclomethasone Dipropionate	C		
			Furosemide	C		
			Furosemide	C		
			Ipratropium Bromide	C		

Date:05/14/02ISR Number: 3917055-0Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00033
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal	Foreign	Tab Vioxx			
Life-Threatening	Haemorrhage	Health	(Rofecoxib)	PS		ORAL
PO						
		Professional	Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/02ISR Number: 3917112-9Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00012
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Life-Threatening	Perforation	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	3 MON
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation		Aspirin	C				
Disability	Peritonitis							
Other								

Date:05/14/02ISR Number: 3917120-8Report Type:Expedited (15-DaCompany Report #WAES 0205SGP00001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Foreign	Tab Vioxx					
Hospitalization -	Infarction	Other	(Rofecoxib)	PS				
Initial or Prolonged	Gastric Ulcer		Atorvastatin Calcium	C				
	Gastrointestinal		Clopidogrel					
	Haemorrhage		Bisulfate	C				
	Helicobacter Infection		Isorbide Dinitrate	C				
	Hypotension		Ramipril	C				
			Spironolactone	C				

Date:05/14/02ISR Number: 3917121-XReport Type:Expedited (15-DaCompany Report #WAES 0205GBR00018
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative	Foreign	Tab Vioxx					
Initial or Prolonged	Cytomegalovirus Colitis	Literature	(Rofecoxib)	PS		ORAL	12.5	
	Disease Recurrence	Other					MG/DAILY; 25	
	Drug Ineffective						MG/DAILY	1 WK
			Mesalamine	C				

Date:05/15/02ISR Number: 3916250-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA03071
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Overload		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Pulmonary Congestion		Vioxx	SS		ORAL		
			Gengraf	SS				
			Prednisone	C				
			[Therapy Unspecified]	C				
			Cytovene Capsules	C				

Date:05/15/02ISR Number: 3916254-1Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Aspirin	C		ORAL		
Disability								

Date:05/15/02ISR Number: 3916261-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00862
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/02ISR Number: 3916266-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Gastrointestinal Haemorrhage Myocardial Infarction Nausea Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/02ISR Number: 3916267-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01500
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/02ISR Number: 3916268-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01383
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bleeding Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
	Subdural Haematoma		Vioxx	SS		ORAL		
			Ginkgo Biloba Extract	SS				
			Zestril	C				
			Glyburide	C				
			Ginseng	C				
			Fish Oil					

			(Unspecified)	C		ORAL
			Vitamin E	C		
			Vitamins (Unspecified)	C		

Date:05/16/02ISR Number: 3916604-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Liver Function Test	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abnormal		Prevacid	C		
	Meningitis		Prilosec	C		

Date:05/16/02ISR Number: 3916605-8Report Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Necrotising Fasciitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
136 DAY						
Initial or Prolonged		Professional	Diacerein	C		ORAL
			Isradipine	C		ORAL

			Ibuprofen	C		ORAL

Date:05/16/02ISR Number: 3916606-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged		Professional	Ziac	C				

Date:05/16/02ISR Number: 3916607-1Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00069
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Thrombosis Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/02ISR Number: 3916610-1Report Type:Expedited (15-DaCompany Report #WAES 0205PRT00001
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glossitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	52	DAY
	Stomatitis	Professional	Vioxx	SS		ORAL		
			Tiapride Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		
			Cyanocobalamin And Pyridoxine And Thiamine	C		ORAL		

Date:05/16/02ISR Number: 3916613-7Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00040
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urinary Retention		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
			Fluoxetine Hydrochloride	C				
			Gabapentin	C				
			Estrogens, Conjugated	C				
			Fluticasone Propionate	C				
			Albuterol	C				
			Temazepam	C				

Date:05/16/02ISR Number: 3916615-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Premarin	C				
	Back Pain		Dyazide	C				
			Atenolol	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Ambien	C				

				Lonox	C		

Date:05/16/02ISR Number: 3916717-9Report Type:Expedited (15-DaCompany Report #WAES 0205NLD00007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/02ISR Number: 3916720-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01262
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hepatic Failure		Paxil	C				
			[Composition Unspecified]	C				

Date:05/16/02ISR Number: 3916722-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01542
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
			Aspirin	C				
			Zoloft	C				
			Paxil	C				

Date:05/16/02ISR Number: 3916723-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc		2	WK

Date:05/16/02ISR Number: 3916724-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus							

Date:05/16/02ISR Number: 3916725-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/02ISR Number: 3916726-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/02ISR Number: 3917564-4Report Type:Direct Company Report #CTU 168218
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Asthenia Depression Diarrhoea Haematochezia Intervertebral Disc Degeneration		Vioxx 25mg Tab (Merc) Eckerd Vioxx 12.5mg Tab Merc Eckerd	PS SS	(Merc) Eckerd Merc Eckerd		1 TAB DAILY 1 TAB DAILY	

Date:05/16/02ISR Number: 3917650-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01273
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:05/16/02ISR Number: 3917655-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01127
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
		Professional				
		Company				
		Representative				

Date:05/16/02ISR Number: 3917687-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01097
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastritis	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Gastrointestinal	Professional				
MG/DAILY/PO						
Initial or Prolonged	Haemorrhage		Coumadin	C		
Other	Haematocrit Decreased		Lasix (Furosemide)	C		
	Myocardial Infarction		Lipitor	C		
			Norvasc	C		

Date:05/16/02ISR Number: 3917706-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01326
Age: Gender: I/FU:I

Outcome	PT	Report Source
Death	Death	Health
		Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	

Date:05/16/02ISR Number: 3917712-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01111
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:05/16/02ISR Number: 3917716-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Olfactory	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Temporal Lobe Epilepsy	Professional	[Composition Unspecified]	C				

Date:05/16/02ISR Number: 3917718-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA00521
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Blood Pressure Increased							
	Cerebral Infarction		Celebrex	C				
	Chest Pain		Coumadin	C				
	Dyspnoea		Lasix (Furosemide)	C				
	Facial Palsy		Levaquin	C				

Nausea	Neurontin	C
Vomiting	Norvasc	C
	Prinivil	C
	Synthroid	C
	Atenolol	C
	Clonidine	C
	Insulin	C
	Magnesium Oxide	C
	Metformin	C
	Nitroglycerin	C

Date:05/16/02ISR Number: 3917721-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Hypoaesthesia							
	Monoplegia							
	Phlebitis							
	Sensory Loss							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/02ISR Number: 3917732-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01075
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Dementia							
Initial or Prolonged	Meningitis Aseptic							
Disability								

Date:05/16/02ISR Number: 3917769-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA01868
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
Initial or Prolonged	Dehydration	Professional						
	Diarrhoea Haemorrhagic	Company	Paxil	C				
	Rectal Haemorrhage	Representative	Lorazepam	C				

Date:05/16/02ISR Number: 3917786-2Report Type:Direct Company Report #CTU 168209
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG QD	
Initial or Prolonged								
			Aspirin 81 Mg	SS		ORAL	81 MG BID	

Date:05/16/02ISR Number: 3917832-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01187
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Prevacid	C				
			Synthroid	C				
			Zoloft	C				
			Atenolol	C				
			Diclofenac	C				
			Isosorbide Mononitrate	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:05/16/02ISR Number: 3917872-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01721
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Hospitalization - Initial or Prolonged	Myocardial Infarction						PO	
Disability			Diovan	C				
Other			Glucophage	C				
			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/02ISR Number: 3917875-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Judgement Impaired	Professional					PO	
		Company Representative						

Date:05/16/02ISR Number: 3918108-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01044
Age:11 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Study	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Blood Pressure Decreased	Health					MG/DAILY/PO	
Initial or Prolonged	Faeces Discoloured	Professional	Inj Blinded Therapy	SS			INTRAVENOUS	IV
Other	Gastrointestinal		Atarax	C				
	Haemorrhage		Flagyl	C				
	Haematemesis		Megace	C				
	Headache		Smz-Tmp	C				
	Pyrexia		Cytarabine	C				
	Vomiting		Daunorubicin	C				
			Etoposide	C				
			Meropenem	C				
			Tobramycin	C				
			Topiramate	C				
			Vancomycin	C				

Date:05/16/02ISR Number: 3918265-9Report Type:Expedited (15-DaCompany Report #WAES 0205PER00002
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Conjunctival Oedema	Foreign	Tab Vioxx					
Initial or Prolonged	Eye Inflammation	Consumer	(Rofecoxib)	PS		ORAL	25 MG /DAILY	3 DAY

Date:05/16/02ISR Number: 3918385-9Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00073
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Foreign	Tab Vioxx					
	Blood Pressure Decreased	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Nausea							
PO							2	DAY
	Paraesthesia Oral							

Date:05/16/02ISR Number: 3918387-2Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL		
PO								

Date:05/16/02ISR Number: 3918391-4Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL		
25 MG	PO						3	DAY

			Atorvastatin	C		
			Insulin, Biphasic Isophane [Injection]	C		
			Lisinopril	C		

Date:05/16/02ISR Number: 3918393-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00047
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	121 DAY
	Palpitations	Health Professional Other	Aspirin	C				
			Betaxolol Hcl	C				
			Diltiazem Hydrochloride	C				
			Levothyroxine Na	C				
			Ramipril	C				

Date:05/16/02ISR Number: 3918394-XReport Type:Expedited (15-DaCompany Report #WAES 0205POL00003
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Exacerbated	Foreign	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	1 DAY
		Health Professional Other	Singulair	C				
			Acetaminophen	C				
			Beclomethasone Dipropionate	C				
			Formoterol Fumarate	C				
			Hydroxyzine	C				
			Theophylline	C				

Date:05/16/02ISR Number: 3918405-1Report Type:Expedited (15-DaCompany Report #WAES 01079556
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Tab Vioxx					

Hospitalization -	Electrocardiogram	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY 542 DAY						
Initial or Prolonged	Abnormal	Health	Tab Placebo			
Disability		Professional	(Unspecified)	SS		ORAL
98 DAY						
		Other	Vevacor	C		
			Aspirin	C		
			Diltiazem Hydrochloride	C		
			Sulfasalazine	C		

Date:05/16/02ISR Number: 3918419-1Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Systemic Lupus	Foreign	Tab Vioxx			
	Erythematosus	Health	(Rofecoxib)	PS		ORAL
12.5						
		Professional				
MG/DAILY/PO 5 MON						
			Hydroxychloroquineso 4	C		
			Ibuprofen	C		
			Levothyroxine Na	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/02ISR Number: 3918422-1Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00171
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY/PO	3 DAY
			Gabapentin	C				
			Metoprolol Succinate	C				

Date:05/16/02ISR Number: 3918441-5Report Type:Expedited (15-DaCompany Report #WAES 0204CAN00222
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Foreign Health	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	693 DAY
Disability	Aortic Aneurysm Rupture	Professional	Indocin (Indomethacin)	C				
Other	Blood Triglycerides Increased	Other	Acetaminophen /Codeine Phosphate	C				
	Cardio-Respiratory Arrest		Atorvastatin Calcium	C				
	Circulatory Collapse		Metoprolol	C				
	Coma		Quinapril Hcl	C				
	Disease Recurrence							
	Intracranial Aneurysm							
	Myocardial Ischaemia							
	Pupil Fixed							

Date:05/16/02ISR Number: 3918442-7Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Depression	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5MG/DILY, PO	
Life-Threatening	Haemoglobin Decreased							
	International Normalised							

	Ratio Increased	Other	Tab Phenprocoumon	SS		ORAL
1.5 MG/DAILY,						
	Pain In Extremity					
PO						
	Phlebothrombosis		Buprenorphine Hcl	C		
	Prothrombin Time Abnormal		Calcium Carbonate			
	Pulmonary Oedema		(+) Cholecalciferol	C		
	Small Intestinal		Melperone Hcl	C		
	Haemorrhage		Paroxetine Hcl	C		

Date:05/16/02ISR Number: 3918463-4Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00018
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bone Marrow Depression	Foreign	Tab Vioxx			
Hospitalization -		Health	(Rofecoxib)	PS		ORAL
25 MG DAILY						
Initial or Prolonged		Professional				
PO 2 YR						
			Cozaar	C		
			Tolterodine Tartrate	C		

Date:05/17/02ISR Number: 3917073-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
	Asthenia	Professional	Taxol	C				
	Cerebrovascular Accident		Estradiol	C				
	Crying		Premarin	C				
	Dizziness		Darvocet-N	C				
	Drug Screen Positive							
	Headache							
	Hypoaesthesia							
	Hypokalaemia							
	Paraesthesia							

Date:05/17/02ISR Number: 3917074-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00106
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Rupture	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening		Professional						

Date:05/17/02ISR Number: 3917075-6Report Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fluid Overload	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypotension	Professional	Diclofenac Sodium	C				
INTRAMUSCULAR							1	DAY
Initial or Prolonged	Leukocytosis		Irbesartan	C		ORAL	10	DAY
	Metabolic Acidosis		Indomethacin	C		ORAL	1	DAY
	Renal Failure Acute							
	Sepsis							

Date:05/17/02ISR Number: 3917079-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00836
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Congestive	Professional	Vioxx	SS		ORAL	1	MON
Initial or Prolonged	Chest Pain		Coumadin	C				
Disability	Condition Aggravated		Prilosec	C				
Other	Hypoxia		Amiodarone	C				
	Pulmonary Fibrosis		Allegra	C				
			Zestril	C				

Date:05/17/02ISR Number: 3917080-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/17/02ISR Number: 3917081-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/02ISR Number: 3917377-3Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc			
	Nephropathy		Valsartan	SS				

Date:05/17/02ISR Number: 3917382-7Report Type:Expedited (15-DaCompany Report #WAES 0203KOR00129
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Ulcer		Vioxx	SS		ORAL	8	DAY
Initial or Prolonged			Vioxx	SS		ORAL	8	DAY
			Propranolol Hydrochloride	C		ORAL		
			Furosemide Sodium	C		ORAL		
			[Composition Unspecified]	C		ORAL		
			Spironolactone	C			12	DAY
			Silibinin	C			12	DAY

Date:05/17/02ISR Number: 3917383-9Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00073
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Angioneurotic Oedema		Hormonal Contraceptives (Unspecified)	C		ORAL		
	Nausea							
	Orthostatic Hypotension							

Date:05/17/02ISR Number: 3917386-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							
	Myocardial Infarction							

Date:05/17/02ISR Number: 3917388-8Report Type:Expedited (15-DaCompany Report #WAES 0205SGP00002
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemarthrosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON

Date:05/17/02ISR Number: 3917392-XReport Type:Expedited (15-DaCompany Report #WAES 0205GBR00089
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Acetaminophen And Codeine Phosphate	SS		ORAL		1 DAY
	Dyspnoea							
	Syncope							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/02ISR Number: 3917393-1Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00008
Age:50 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc			4 WK

Date:05/17/02ISR Number: 3917394-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01951
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Perforated Ulcer		[Therapy Unspecified]	C				

Date:05/17/02ISR Number: 3917395-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00082
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lethargy		Calcium Carbonate And Cholecalciferol	C		ORAL		
			Fosamax	C		ORAL		
			Methotrexate Sodium	C		ORAL		
			Prednisolone	C		ORAL		
			Folic Acid	C		ORAL		

Date:05/17/02ISR Number: 3917399-2Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00007
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc			14 DAY

Date:05/17/02ISR Number: 3917404-3Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00006
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Full Blood Count Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/17/02ISR Number: 3917407-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01970
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Oedema Peripheral							
Other	Urticaria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/02ISR Number: 3918535-4Report Type:Direct Company Report #CTU 168390
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Loss Of Consciousness		Vioxx	PS		ORAL	1 DAILY ORAL	
	Photopsia							

Date:05/20/02ISR Number: 3918512-3Report Type:Direct Company Report #CTU 168331
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Disorder		Vioxx Oral 25 Mg. 2 X Days	PS		ORAL	25MG 2 X DAYS	
	Headache							
Other							ORAL	

Date:05/20/02ISR Number: 3918545-7Report Type:Direct Company Report #CTU 168345
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx (Concern Order Of Mix With) Benadryl 50mg For 3 Months Described	PS				
Hospitalization - Initial or Prolonged	Back Pain							
	Blood Urine Present							
Required	Chest Pain			SS				
50MG								
Intervention to Prevent Permanent Impairment/Damage	Dizziness							
	Dyspnoea							
	Faeces Discoloured							
	Gastrointestinal Disorder							
	Gastrointestinal Haemorrhage							
	Headache							
	Lung Disorder							
	Lung Infection							
	Migraine							
	Muscle Spasms							
	Pulmonary Oedema							
	Rash							

Renal Pain
Scar
Skin Ulcer
Tongue Oedema
Urinary Tract Infection

Date:05/20/02ISR Number: 3918574-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY	
Initial or Prolonged			Sodium Feredetate	C		ORAL	47 DAY	
			Opium	C		ORAL	5 DAY	
			Furosemide	C		ORAL	47 DAY	
			Warfarin	C		ORAL	47 DAY	
			Prednisolone	C		ORAL		
			Rutin	C		ORAL		
			Misoprostol	C		ORAL		
			Antimicrobial (Unspecified)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/02ISR Number: 3918575-5Report Type:Expedited (15-DaCompany Report #WAES 01106102
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Urinary Retention		Dothiepin Hydrochloride	C		ORAL		
			Valpromide	C		ORAL		
			Clorazepate Dipotassium	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:05/20/02ISR Number: 3918576-7Report Type:Expedited (15-DaCompany Report #WAES 01116085
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization -			Dihydroergotamine Mesylate	C				1 DAY
Initial or Prolonged			Pyrantel Pamoate	C		ORAL		1 DAY
			Clonazepam	C		ORAL		
			Phenobarbital	C		ORAL		
			Carbamazepine	C		ORAL		

Date:05/20/02ISR Number: 3918581-0Report Type:Expedited (15-DaCompany Report #WAES 0205COL00005
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Purpura		Vioxx	PS	Merck & Co., Inc			1 WK
Initial or Prolonged			Diltiazem Malate	C				
Disability			Aspirin	C				
			Isosorbide Mononitrate	C				

Date:05/20/02ISR Number: 3918647-5Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00011
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis Necrotising		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/02ISR Number: 3918648-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01653
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Aspirin	SS				

Date:05/20/02ISR Number: 3918650-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01368
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
	Drug Ineffective
	Therapeutic Response Decreased

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Vioxx	SS		ORAL	1	MON
			Lipitor	C				
			Accupril	C				
			Amaryl	C				
			Imdur	C				
			Coumadin	C				
			Atenolol	C				
			L-Thyroxin	C				
			Pletal	C				

Date:05/20/02ISR Number: 3918651-7Report Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bipolar Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Initial or Prolonged	Drug Interaction		Carbamazepine	SS		ORAL		
			Elavil	C		ORAL		
			Alprazolam	C		ORAL		

Date:05/20/02ISR Number: 3918652-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02938
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	389	DAY
			Fiorinal	C				
			Synthroid	C				
			Prozac	C				
			Estrace	C				
			Moduretic	C				

Date:05/20/02ISR Number: 3918653-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00240
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Somnolence		Zanaflex	C		ORAL		
			Baclofen	C		ORAL		

Date:05/20/02ISR Number: 3918657-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA03150
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	General Symptom		Premarin	C				
			Lasix (Furosemide)	C				
			Digoxin	C				
			Coumadin	C				
			Potassium (Unspecified)	C				
			Nexium	C				
			Zestoretic	C				
			Toprol Xl Tablets [Composition	C				

			Unspecified]	C		
			Thyroid	C		

Date:05/20/02ISR Number: 3918658-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Iatrogenic Injury							
	Monoplegia							
	Phlebitis							
	Sensory Loss							
	Thermal Burn							
	Thrombosis							

Date:05/20/02ISR Number: 3918662-1Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00116
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyponatraemia		Vioxx	PS	Merck & Co., Inc	ORAL		
9 DAY								
Initial or Prolonged	Somnolence		Oxazepam	SS		ORAL		
1 DAY								
			Clomipramine Hydrochloride	SS		ORAL		
			Ranitidine	C		ORAL		

Date:05/20/02ISR Number: 3918663-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/02ISR Number: 3918664-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chorea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Lansoprazole	C		ORAL		
			Lactulose	C		ORAL		
			Senna	C		ORAL		

Date:05/20/02ISR Number: 3918668-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/02ISR Number: 3918669-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/02ISR Number: 3918670-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01629
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Premarin	C		ORAL		
			Ginkgo Biloba Extract	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Centrum	C		ORAL		

Date:05/20/02ISR Number: 3918869-3Report Type:Direct Company Report #CTU 168430
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorectal Disorder		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG ONCE	
Initial or Prolonged	Blood Glucose Abnormal						DAILY ORAL	
Disability	Glucose Urine Present		Soma 250 Mg Watson					
	Hydrocele		Lab	SS	Watson Lab	ORAL	250 MG AT	
	Lymphadenopathy						NIGHT ORAL	
	Oedema Genital Swelling							

Date:05/20/02ISR Number: 3918876-0Report Type:Direct Company Report #CTU 168434
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS		ORAL	25 MG QD ORAL	
Initial or Prolonged	Hyponatraemia		Hctz	C				
			Nortrptyline	C				
			Edepryl	C				

Date:05/20/02ISR Number: 3919140-6Report Type:Direct Company Report #CTU 168340
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vaginal Haemorrhage		Celebrex	PS		ORAL	1 TAB DAILY BY MOUTH/ AFTER 3 MONTHS AFTER 10 DAYS	
			Vioxx	SS		ORAL	25 MG 1 TAB DAILY BY MOUTH	

Date:05/20/02ISR Number: 3919760-9Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Insufficiency Nephropathy	Foreign Health Professional Other	Vioxx (Rofecoxib) Valsartan	PS SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/02ISR Number: 3919027-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02956
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/21/02ISR Number: 3919036-XReport Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fluid Overload		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - INTRAMUSCULAR	Hypotension		Diclofenac Sodium	C			1	DAY
Initial or Prolonged	Leukocytosis		Irbesartan	C		ORAL	10	DAY
	Metabolic Acidosis		Indocin (Indomethacin)	C		ORAL	1	DAY
	Renal Failure Acute							
	Sepsis		[Therapy Unspecified]	C		ORAL		

Date:05/21/02ISR Number: 3919041-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/21/02ISR Number: 3919198-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00063
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Consciousness Fluctuating		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Tachycardia		Propranolol Hydrochloride	C				
			Levothyroxine Sodium	C				

				Estrogens, Conjugated And Medroxyprogesterone Acetate	C		
				Calcium Carbonate	C		

Date:05/21/02ISR Number: 3919209-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			

Date:05/22/02ISR Number: 3919697-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lopid	C				
			Inderal	C				
			Allegra	C				
			Premarin	C				
			Vitamin E	C				
			Vitamins					

(Unspecified)	C
Plavix	C
Zestril	C
Metformin	C
Folic Acid	C
Mobic	C
Wellbutrin	C

Date:05/22/02ISR Number: 3919701-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02437
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hidradenitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:05/22/02ISR Number: 3919702-6Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	75	DAY
Life-Threatening	Gastritis Haemorrhagic		Isosorbide Mononitrate	C		ORAL	19	DAY
Hospitalization - Initial or Prolonged	Shock Haemorrhagic		Furosemide	C		ORAL	65	DAY
			Ramipril	C		ORAL	65	DAY
			Sotalol Hydrochloride	C		ORAL	19	DAY
			Tramadol Hydrochloride	C		ORAL	19	DAY
			Prednisone	C		ORAL	65	DAY
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		
			Pantoprazole Sodium	C		ORAL	32	DAY

Date:05/22/02ISR Number: 3919876-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02947
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abscess	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged	Back Pain	Professional	Zyvox	C				
	Myelitis Transverse		Clindamycin	C				
Disability			Anaptivan	C				
Other								

Date:05/22/02ISR Number: 3919878-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00693
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Hospitalization - Initial or Prolonged	Respiratory Distress	Professional	Aleve	C				
			Ibuprofen	C				
Other			Vicodin Tablets	C				

Date:05/22/02ISR Number: 3919882-2Report Type:Expedited (15-DaCompany Report #WAES 0203BEL00009
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort							
	Confusional State							
	Fluid Retention							
	Hyponatraemia							
	Incontinence							
	Nausea							
	Petit Mal Epilepsy							
	Transient Ischaemic Attack							
	Vertigo							

Date:05/22/02ISR Number: 3919884-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00980
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatine Phosphokinase Increased		Vioxx	SS		ORAL		
			Claritin	C		ORAL		
	Hypoaesthesia		Flonase	C				
RESPIRATORY (INHALATION)	Muscular Weakness							
	Myalgia		Niaspan	C		ORAL		
	Myopathy		Topamax	C		ORAL		
	Pain		Meclizine	C		ORAL	37	DAY
	Paraesthesia		Neurontin	C		ORAL	37	DAY
			Clonazepam	C		ORAL		
			Doxepin	C		ORAL		
			Lipitor	C				
			Testred	C				
			Darvocet-N	C				
			Fosamax	C		ORAL		
			Vitamin E	C				
			Ascorbic Acid	C				
			Vitamins (Unspecified)	C				

			Ubiquinones (Unspecified)	C		
			Glucosamine	C		

Date:05/22/02ISR Number: 3919889-5Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00013
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Diarrhoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Haemoglobin Abnormal		Furosemide Sodium	C		
	Vomiting		Nitroglycerin	C		
			Atenolol	C		
			Zolpidem Tartrate	C		

Date:05/22/02ISR Number: 3919891-3Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00106
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Microcytic Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Aspirin	C		ORAL

		Etidronate Disodium	C	ORAL
		Omeprazole	C	ORAL
		Senna	C	
		Amiloride Hydrochloride And Furosemide	C	
		Psyllium Husk	C	
		Dihydrocodeine	C	

Date:05/22/02ISR Number: 3919892-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01719
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Coma	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Medication Error		Lithium Carbonate	SS		
	Oedema Peripheral		Paxil	SS		
	Speech Disorder		Glucophage	C		
			Glucotrol	C		
			Prilosec	C		
			Lipitor	C		
			Metamucil	C		
			[Therapy Unspecified]	C		

Date:05/22/02ISR Number: 3919893-7Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00003
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Insulin Human, Isophane	C		
			Lisinopril	C		
			Aspirin	C		
			Insulin Lispro	C		

Date:05/22/02ISR Number: 3919894-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01111
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Back Pain Gastrointestinal Disorder Herpes Zoster	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919895-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919899-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3919900-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01988
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919901-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919902-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919903-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919904-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01984
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919905-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01989
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919906-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02378
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Symptom		Prempro	C				
			Synthroid	C				
			Aspirin	C				

Date:05/22/02ISR Number: 3919907-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3919908-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919909-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919910-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919911-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919912-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919913-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3919914-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/22/02ISR Number: 3920074-1Report Type:Direct Company Report #CTU 168685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking		Vioxx	PS		ORAL	25MG PO	
	Lethargy							
	Meningitis Aseptic							
	Muscle Rigidity							
	Nervous System Disorder							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3921080-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01311
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:05/22/02ISR Number: 3921263-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Health	Tab Vioxx	PS		ORAL	PO	2 WK
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus	Professional						

Date:05/22/02ISR Number: 3921319-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage Gastrointestinal Ulcer	Professional Company Representative						

Date:05/22/02ISR Number: 3921322-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Retinal Vein Thrombosis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL

25 MG/DAILY/PO

Date:05/22/02ISR Number: 3921344-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Pulmonary Embolism							

Date:05/22/02ISR Number: 3921476-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA00836
Age:74 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Blood Creatine Increased
Hospitalization - Initial or Prolonged	Blood Urea Increased
	Cardiac Failure
Disability	Congestive
Other	Chest Pain
	Condition Aggravated

Hypoxia
Pulmonary Fibrosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO; 25 MG/DAILY/PO	
Company Representative	Allegra	C				
	Coumadin	C				
	Prilosec	C				
	Zestril	C				
	Amiodarone	C				

Date:05/22/02ISR Number: 3921477-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01542
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Paxil	C				
			Zoloft	C				
			Aspirin	C				

Date:05/22/02ISR Number: 3921486-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:05/22/02ISR Number: 3921544-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00862
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Health	Tab Vioxx	PS		ORAL	PO	
	Meningitis	Professional Company Representative Other						

Date:05/22/02ISR Number: 3921546-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02401
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Thrombosis	Professional					MG/DAILY/PO	
			Ziac	C				

Date:05/22/02ISR Number: 3921548-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01262
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Consumer	Tab Vioxx	PS		ORAL	PO	
Other	Hepatic Failure		Paxil	C				

Date:05/22/02ISR Number: 3921550-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02874
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Function Test	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
Initial or Prolonged	Abnormal						PO	
	Malaise		Prevacid	C				
	Meningitis		Prilosec	C				

Date:05/22/02ISR Number: 3921554-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA03071
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG; 50 MG	
Initial or Prolonged	Increased	Health					/ DAILY/ PO	
	Drug Interaction	Professional	Gengraf	SS				
	Dyspnoea		Cytovene Capsules	C				
	Fluid Overload		Prednisone	C				
	Pulmonary Congestion							
	Weight Increased							

Date:05/22/02ISR Number: 3921559-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01500
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myocardial Infarction							

Date:05/22/02ISR Number: 3921564-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Abdominal Adhesions	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/ DAILY/						
	Abdominal Pain					
PO						
			Ambien	C		
			Dyazide	C		
			Lasix (Furosemide)	C		
			Lonox	C		
			Micro K	C		
			Premarin	C		
			Atenolol	C		

Date:05/22/02ISR Number: 3921570-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Fatigue					
	Full Blood Count					
	Decreased					
	Haematochezia					
	Haemorrhage					
	Malaise					
	Myocardial Infarction					
	Nausea					
	Pallor					
	Syncope					

Date:05/22/02ISR Number: 3921573-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01383
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Literature	Tab Vioxx Unk	PS		ORAL	DAILY/ PO	
Initial or Prolonged	Bleeding Time Abnormal	Health	Ginkgo Biloba					
	Drug Interaction	Professional	Extract 253.4 Mg	SS			253.4 MG/	
	Gait Disturbance						DAILY	
	Head Injury		Zestril	C				
	Hemiparesis		Fish Oil	C				
	Subdural Haematoma		Ginseng	C				
			Glyburide	C				
			Vitamin E	C				
			Vitamins	C				

Date:05/22/02ISR Number: 3921673-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00783
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Congestive	Health					PO	
	Cardiomegaly	Professional	Aldactazide	C				
	Dyspnoea		Ambien	C				
	Fluid Overload		Ativan	C				
	Oedema		Atrovent	C				
			Cozaar	C				
			Klor-Con	C				
			Neurontin	C				
			Prozac	C				
			Serevent	C				
			Atenolol	C				

Date:05/22/02ISR Number: 3921736-2Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00007
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:05/22/02ISR Number: 3921739-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00077
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Thinking Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	8 DAY
			Tramadol Hcl	C				

Date:05/22/02ISR Number: 3922132-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional Company Representative	Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3922198-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02888
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Behaviour	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Arthritis	Professional						
Initial or Prolonged	Asthenia	Company	Darvocet-N	C				
	Balance Disorder	Representative	Premarin	C				
	Cerebrovascular Accident		Taxol	C				
	Crying		Estradiol	C				
	Dizziness							
	Drug Screen Positive							
	Haemoglobin Decreased							
	Headache							
	Hypoaesthesia							
	Hypoaesthesia Oral							
	Hypokalaemia							
	Hyporeflexia							
	Paraesthesia							
	Physical Examination Abnormal							
	Sensation Of Heaviness							
	Sensory Disturbance							
	Vertigo Positional							
	Visual Disturbance							

Date:05/22/02ISR Number: 3922341-4Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00008
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:05/22/02ISR Number: 3922377-3Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00040
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Condition Aggravated Urinary Retention	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG DAILY PO 10 DAY						
			Albuterol	C		
			Estrogens, Conjugated	C		
			Fluoxetine Hcl	C		
			Fluticasone Propionate	C		
			Gabapentin	C		
			Temazepam	C		

Date:05/22/02ISR Number: 3922378-5Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00069
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Coronary Artery Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
PO						
	Fall Resuscitation Ventricular Fibrillation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3922482-1Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00053
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Biliary Colic	Foreign	Tab Vioxx					
	Pancreatitis	Health	(Rofecoxib)	PS		ORAL	PO	2 DAY
		Professional						

Date:05/22/02ISR Number: 3922485-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00106
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Rupture	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
		Professional						
PO								

Date:05/22/02ISR Number: 3922493-6Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00076
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Foreign	Tab Vioxx					
Initial or Prolonged	Cerebrovascular Accident	Health	(Rofecoxib)	PS		ORAL	PO	2 DAY
	Hyperhidrosis	Professional	Flupirtine Maleate	C				

Date:05/22/02ISR Number: 3922590-5Report Type:Expedited (15-DaCompany Report #WAES 0205PRT00001
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glossitis	Foreign	Tab Vioxx					
	Stomatitis	Other	(Rofecoxib)	PS		ORAL	25 MG PO	52 DAY
			Cyanocobalamin (+)					
			Pyridoxine (+) Thiam	C				

				Omeprazole	C		
				Tiapride Hydrochloride	C		

Date:05/22/02ISR Number: 3922625-XReport Type:Expedited (15-DaCompany Report #WAES 01116031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Necrotising Fasciitis Skin Lesion	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL		136 DAY
			Diacerein	C				
			Ibuprofen	C				
			Isradipine	C				

Date:05/22/02ISR Number: 3922641-8Report Type:Expedited (15-DaCompany Report #WAES 0205NLD00007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3922642-XReport Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
Disability		Professional	Aspirin	C				

Date:05/22/02ISR Number: 3922662-5Report Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fluid Overload	Foreign	Tab Vioxx					
Hospitalization -	Hypotension	Other	(Rofecoxib)	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Leukocytosis		Diclofenac Na	C				
	Metabolic Acidosis		Indomethacin	C				
	Renal Failure Acute		Irbesartan	C				
	Sepsis							

Date:05/22/02ISR Number: 3922706-0Report Type:Expedited (15-DaCompany Report #A04200200079
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cystitis	Foreign	Plavix (Clopidogrel					
Hospitalization -	Toxic Epidermal	Health	Sulfate)	PS		ORAL	75 MG OD,	
Initial or Prolonged	Necrolysis	Professional						
ORAL							5	DAY
		Other	Novalgin (Metamizole Sodium) Solution 500 Mg/Ml	SS		ORAL	50 GTT QID,	
ORAL							29	DAY
			(Acetylsalicylic Acid) Tablet 100 Mg	SS		ORAL		
			(Diazepam) Solution	SS			1	DAY

Vioxx (Rofecoxib)
Tablet 25 Mg SS ORAL
25 MG OD,

ORAL 11 DAY

(Norepinephrine)
Solution SS
INTRAVENOUS INTRAVENOUS

NOS 1 DAY

Xylocain (Lidicaine
Hydrochloride)
Solution SS
SUBCUTANEOUS SUBCUTANEOUS 1 DAY

Catapresan
(Clonidine) Solution SS
INTRAVENOUS INTRAVENOUS

NOS 1 DAY

Euglucon
(Glibenclamide)
Tablet 3.5 Mg SS ORAL
3.5 MG TID,

ORAL

Noctamid
(Lormetazepam)
Tablet 1 Mg SS ORAL
1 MG BID,

ORAL 1 DAY

Acetylsalicylic Acid C ORAL
4 DAY

Contrast Medium
Solution C
INTRAVENOUS INTRAVENOUS

NOS 1 DAY

Tavegil (Clemastine) C
Ortho-Gnest Vaginal
Suppository

(Estriol)	C
Corvaton Retard (Molsidomine)	C
Durogesic Plaster (Fentanyl)	C
Insulin (Insulin)	C
Fragmin P (Heparin-Fraction, Sodium Salt)	C
Decortin (Prednisone)	C
Unat 10 (Torasemide)	C
Mono Mack Depot (Isosorbide Mononitrate)	C
Antra Mups 20 (Omeprazole)	C
Calcium Effervescent Tablet (Calcium)	C
Glucose 5% (Glucose)	C
Ringer Solution	C
Cotrim	C
Solu-Decortin 100 Mg (Prednisolone Sodium Succinate)	C

Date:05/23/02ISR Number: 3920623-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00026
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	42	DAY
Other	Vertigo		Lisinopril	C		ORAL		
			Amiodarone Hydrochloride	C		ORAL		

Date:05/23/02ISR Number: 3920624-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00118
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Hospitalization -
Initial or Prolonged
Disability

Date:05/23/02ISR Number: 3920626-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		
			Wellbutrin	C				

Date:05/23/02ISR Number: 3920628-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00119
Age:95 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Salcatonin	C		ORAL		

Date:05/23/02ISR Number: 3920629-4Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00047
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chromaturia		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Pleural Infection							

Date:05/23/02ISR Number: 3920631-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00140
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	179	DAY
Hospitalization -			Aspirin	C		ORAL	609	DAY
Initial or Prolonged			Bendroflumethiazide	C		ORAL		

Date:05/23/02ISR Number: 3920633-6Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:05/23/02ISR Number: 3920635-XReport Type:Expedited (15-DaCompany Report #WAES 0205KOR00035
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling		Vioxx	PS	Merck & Co., Inc	ORAL	75	DAY

Date:05/23/02ISR Number: 3920636-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00138
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - RESPIRATORY Initial or Prolonged (INHALATION)	Pulmonary Disease		Ipratropium Bromide	C				
Other			Dothiepin Hydrochloride	C		ORAL		
			Ramipril	C		ORAL		
			Albuterol RESPIRATORY (INHALATION)	C				
			Tibolone	C		ORAL		
			Nifedipine	C		ORAL		
			Aspirin	C		ORAL		

Date:05/23/02ISR Number: 3920638-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA03065
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive

Drug Ineffective
Prescribed Overdose

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Vioxx	SS		ORAL	11	DAY

Date:05/23/02ISR Number: 3920653-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Premarin	C				
	Back Pain		Dyazide	C				
			Atenolol	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Ambien	C				
			Lonox	C				

Date:05/23/02ISR Number: 3920968-7Report Type:Direct Company Report #CTU 168743
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG	QD
Initial or Prolonged	Haemorrhage							
ORAL								

Date:05/23/02ISR Number: 3920980-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00513
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged	Meningitis Aseptic							

Other	Papilloedema
	Retinal Disorder

Date:05/23/02ISR Number: 3920981-XReport Type:Expedited (15-DaCompany Report #WAES 0204SWE00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Haematuria		Warfarin Sodium	SS		ORAL		
	Subcutaneous Haematoma		Nitroglycerin	C				
			Ergoloid Mesylates	C				
			Atenolol	C				
			Simvastatin	C				
			Isosorbide Mononitrate	C				

Date:05/23/02ISR Number: 3920982-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00044
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		175 DAY
			Fosinopril Sodium	SS		ORAL		

Date:05/23/02ISR Number: 3920984-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02180
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Prinivil	C		ORAL		
	Rash		Metoprolol	C				
	Tachycardia							

Date:05/23/02ISR Number: 3920986-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02620
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Palpitations		Premarin	C				
			Lipitor	C				
			Vitamins (Unspecified)	C				
			Aspirin	C				

Date:05/23/02ISR Number: 3920987-0Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged			Celiprolol Hydrochloride	C				
			Rilmenidene	C				
			Sildenafil Citrate	C				

Date:05/23/02ISR Number: 3920990-0Report Type:Expedited (15-DaCompany Report #WAES 0203CHE00021
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Initial or Prolonged	Cerebrovascular Disorder		Aspirin	C	ORAL
Other	Facial Paresis		Magnesium (Unspecified)	C	ORAL
	Transient Ischaemic Attack		Fish Oil (Unspecified)	C	ORAL
	Vertigo		Cosopt	C	ORAL

Date:05/23/02ISR Number: 3920991-2Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00018
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged			Cozaar	C				
			Tolterodine Tartrate	C				

Date:05/23/02ISR Number: 3920992-4Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00130
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Cerebral Infarction		Cosyntropin	C				
INTRAVENOUS							3	DAY
			Enoxaparin Sodium	C				
SUBCUTANEOUS							6	DAY

				Vitamins (Unspecified)	C		
INTRAVENOUS	3	DAY					
				Vitamin B (Unspecified)	C		
INTRAVENOUS							
				Pentoxifylline	C		
INTRAVENOUS							
				Metoclopramide	C		ORAL
2	DAY						
				Ranitidine	C		ORAL
6	DAY						
				Tilidine Hydrochloride	C		ORAL
6	DAY						
				Tolperisone Hydrochloride	C		ORAL
6	DAY						
				Elavil	C		ORAL
3	DAY						

Date:05/23/02ISR Number: 3920993-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02705
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Outlet		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Initial or Prolonged	Obstruction		Zocor	C		ORAL	75	DAY
	Gastritis							

Date:05/23/02ISR Number: 3920996-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01074
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Respiratory Disorder		Synthroid	C				

Date:05/23/02ISR Number: 3920997-3Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00026
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Drug Interaction		Ibuprofen	SS		ORAL	8	DAY
	Haematemesis		Aspirin	SS		ORAL		
	Malaise		Dipyrone	C		ORAL	7	DAY
	Shock		Irbesartan	C		ORAL		
			Molsidomine	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Amiodarone	C		ORAL		

Date:05/23/02ISR Number: 3920998-5Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		

Date:05/23/02ISR Number: 3920999-7Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00092
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Left Ventricular Failure		Amlodipine Besylate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/02ISR Number: 3921000-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00123
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
	Upper Gastrointestinal		Aspirin	SS		ORAL		22 DAY
	Haemorrhage		Acetaminophen And Codeine Phosphate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		
			Cefuroxime	C			INTRAVENOUS	3 DAY
			Prochlorperazine Maleate	C			INTRAMUSCULAR	1 DAY
			Furosemide	C				1 DAY

Date:05/23/02ISR Number: 3921001-3Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00162
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization - Initial or Prolonged	Perforation		Vioxx	SS		ORAL		

Date:05/23/02ISR Number: 3921003-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00142
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/23/02ISR Number: 3921004-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anuria		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Life-Threatening	Cardiovascular Disorder		Sirdalud	C		ORAL		
Hospitalization -	Diarrhoea		Coltramyl	C		ORAL		
Initial or Prolonged	Electric Shock		Mydocalm	C		ORAL		
	Fatigue		[Therapy					
	Heart Rate Decreased		Unspecified]	C				
	Hypotension		[Composition					
	Loss Of Consciousness		Unspecified]	C				
	Pulmonary Oedema							
	Shock							
	Ventricular Fibrillation							

Date:05/23/02ISR Number: 3921006-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00118
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	50	DAY
Hospitalization -			Digoxin	C		ORAL		
Initial or Prolonged			Enalapril Maleate	C		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/02ISR Number: 3921787-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01970
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Oedema Peripheral	Professional					MG/DAILY/PO	
Initial or Prolonged	Urticaria	Company						
Other		Representative						

Date:05/23/02ISR Number: 3921989-0Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	PO	5 DAY
			Antimicrobial	C				
			Furosemide	C				
			Misoprostol	C				
			Opium	C				
			Prednisolone	C				
			Rutin	C				
			Sodium Feredetate	C				
			Warfarin	C				

Date:05/23/02ISR Number: 3921995-6Report Type:Expedited (15-DaCompany Report #WAES 01116085
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	1 DOSE/DAILY	
Initial or Prolonged								
			Carbamazepine	C			PO	14 DAY
			Clonazepam	C				
			Dihydroergotamine Mesylate	C				

			Phenobarbital	C		
			Pyrantel Pamoate	C		

Date:05/23/02ISR Number: 3921998-1Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00007
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				14 DAY

Date:05/23/02ISR Number: 3922000-8Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00073
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Angioneurotic Oedema							
	Nausea						PO	2 DAY
	Orthostatic Hypotension		Hormonal Contraceptives	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/02ISR Number: 3922019-7Report Type:Expedited (15-DaCompany Report #WAES 01106102
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Urinary Retention	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Acetaminophen/Codeine Phosphate	C				
			Clorazepate Dipotassium	C				
			Dothiepin Hcl	C				
			Valpromide	C				

Date:05/23/02ISR Number: 3922021-5Report Type:Expedited (15-DaCompany Report #WAES 0205DNK00008
Age:50 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS			4	WK
Disability								

Date:05/23/02ISR Number: 3922028-8Report Type:Expedited (15-DaCompany Report #WAES 0205COL00005
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura	Foreign Health	Tab Vioxx (Rofecoxib)	PS			1	WK
Disability		Professional	Aspirin	C				
			Diltiazem Maleate	C				
			Isosorbide Mononitrate	C				

Date:05/23/02ISR Number: 3922029-XReport Type:Expedited (15-DaCompany Report #WAES 0203KOR00129
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage	Foreign	Tab Vioxx					
Hospitalization -	Ulcer	Health	(Rofecoxib)	PS		ORAL	SEE IMAGE	8 DAY
Initial or Prolonged		Professional	Furosemide Sodium	C				
			Propranolol Hcl	C				
			Silibinin	C				
			Spironolactone	C				

Date:05/23/02ISR Number: 3922037-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00082
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Foreign	Tab Vioxx					
Initial or Prolonged	Lethargy	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Fosamax	C			PO	
			Calcium Carbonate (+) Cholecalciferol	C				
			Folic Acid	C				
			Methotrexate Sodium	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/02ISR Number: 3922039-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00089
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ PO	
	Dyspnoea Syncope Vomiting		Acetaminophen / Codeine Phosphate	SS		ORAL	30/500 PO	1 DAY

Date:05/23/02ISR Number: 3922041-0Report Type:Expedited (15-DaCompany Report #WAES 0205SGP00002
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemarthrosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	3 MON

Date:05/23/02ISR Number: 3922047-1Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00006
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Full Blood Count Decreased	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	

Date:05/23/02ISR Number: 3922200-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01951
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Perforated Ulcer	Professional				
MG/DAILY/PO						
Initial or Prolonged		Company Representative				

Date:05/23/02ISR Number: 3922206-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Myocardial Infarction	Professional				
MG/DAILY/PO						
Initial or Prolonged		Company Representative				

Date:05/23/02ISR Number: 3922212-3Report Type:Expedited (15-DaCompany Report #WAES 01010253
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Abdominal Rigidity
Initial or Prolonged	Abdominal Tenderness
Disability	Alanine Aminotransferase
Other	Increased
	Anorexia
	Blood Chloride Decreased
	Chills
	Computerised Tomogram

	Abnormal						
	Decreased Appetite						
	Diarrhoea						
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ileus Paralytic	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50
	Melaena	Health					MG/DAILY/PO
	Mucous Membrane Disorder	Professional	Ativan	C			
	Pallor	Other	Flexeril	C			
	Pancreatic Disorder		Valium	C			
	Pancreatitis						
	Pco2 Decreased						
	Physical Examination						
	Abnormal						
	Weight Decreased						

Date:05/24/02ISR Number: 3921654-XReport Type:Expedited (15-DaCompany Report #WAES 0205AUS00074
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		
			Naproxen	C			

Date:05/24/02ISR Number: 3921657-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/24/02ISR Number: 3921658-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx Nonsteroidal	PS	Merck & Co., Inc	ORAL	
	Gastrointestinal Ulcer Perforation		Anti-Inflammatory Drug (Unspecified)	C			

Date:05/24/02ISR Number: 3921951-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00024
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		122 MON
			Vioxx	SS		ORAL		
			Metoprolol Tartrate	SS				

Date:05/24/02ISR Number: 3921955-5Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		97 DAY
Initial or Prolonged	Myocardial Infarction		Citalopram Hydrobromide	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3921956-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00220
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Coordination Abnormal		Vioxx	SS		ORAL		
Disability	Hallucination		Prilosec	C				
			Lasix (Furosemide)	C				
			Humulin 70/30	C				
			Magnesium (Unspecified)	C				
			Fosamax	C		ORAL		
			Allopurinol	C				
			Nadolol	C				
			Digoxin	C				
			Miacalcin	C				
			Nitroglycerin	C				
			Premarin	C				
			Pravachol	C				
			Pepcid	C		ORAL		
			Lotrel	C				
			Plavix	C				
			Levoxyl	C				
			Cyanocobalamin	C				

Date:05/24/02ISR Number: 3921958-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02859
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Diltiazem Msd	C				
Initial or Prolonged	Ulcer		Allopurinol	C				
Disability			Lasix (Furosemide)	C				
Other			Aspirin	C				
			Sinemet	C				
			Pravachol	C				
			Xalatan	C				
			Alphagan	C				

Date:05/24/02ISR Number: 3921959-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA02760
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Protonix	C				
	Faecal Occult Blood Positive		Centrum	C				
	Gastric Outlet Obstruction							
	Muscle Spasms							
	Vomiting							

Date:05/24/02ISR Number: 3921963-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00110
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3921964-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization - Initial or Prolonged	Mental Status Changes		Dyazide	C				
	Renal Failure Acute		Atenolol	C				
	Respiratory Failure		[Therapy Unspecified]	C				
	Thrombocytopenia							

Date:05/24/02ISR Number: 3921965-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00859
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Rash Erythematous		[Therapy Unspecified]	C				

Date:05/24/02ISR Number: 3921967-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke		Soma	C		ORAL		
Disability	Hemiparesis							
Other	Hypertension							
	Mental Impairment							

Date:05/24/02ISR Number: 3921968-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age:0 DY Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc			
			Zostrix	C				
			Vitamins					

			(Unspecified)	C		

Date:05/24/02ISR Number: 3921972-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00141
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/02ISR Number: 3921974-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zostrix	C		TOPICAL		
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3921978-6Report Type:Expedited (15-DaCompany Report #WAES 0205NOR00012
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Aspirin And Magnesium Oxide	C				
	Melaena		Citalopram Hydrobromide	C				
	Oesophagitis		Vasotec	C				
			Furosemide	C				
			Nitrazepam	C				

Date:05/24/02ISR Number: 3921983-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysstasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Darvocet-N	C				
	Sensory Disturbance							
	Visual Field Defect							

Date:05/24/02ISR Number: 3922463-8Report Type:Direct Company Report #CTU 168907
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Vioxx 25 Or 50	PS			1 DOSE	
	Psychomotor Hyperactivity							
	Swelling							

Date:05/24/02ISR Number: 3922464-XReport Type:Direct Company Report #CTU 168908
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Energy Increased		Vioxx 25mg	PS		ORAL	25MG PO X 1	

	Insomnia						
SINGLE DOSE							
	Psychomotor Hyperactivity						

Date:05/24/02ISR Number: 3922484-5Report Type:Direct Company Report #CTU 168922
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx 50 Mg	PS			1 QD	
Initial or Prolonged	Haemorrhage							

Date:05/24/02ISR Number: 3922488-2Report Type:Direct Company Report #CTU 168924
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg Qd	PS				
			Luvox	C				
			Nortriptyline	C				
			Remeron	C				
			Ambien	C				
			Levoxyl	C				
			Methylprednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3922496-1Report Type:Direct Company Report #CTU 168930
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Rofecoxib	PS			50 MG QDAY	
	Cardio-Respiratory Arrest		Naproxen	SS			500 MG PRN UP TO TID 500	
	Gastrointestinal							
	Haemorrhage						BID	
			Clozapine	SS			250 Q HS	
			Chlorpromazine	SS			200 Q HS	
			Mvi/Folic Ac	C				
			Levothyroxine	C				
			Chlorzoxazone	C				
			Gabapentin	C				
			Nefazodone	C				
			Clonazepam	C				
			Oxycodone Cr	C				
			Vit C	C				

Date:05/24/02ISR Number: 3922879-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:05/24/02ISR Number: 3922895-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Tab Vioxx	PS				

Myocardial Ischaemia

Date:05/24/02ISR Number: 3922897-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02437
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hidradenitis	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:05/24/02ISR Number: 3922910-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02956
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3922961-7Report Type:Expedited (15-DaCompany Report #WAES 01100908
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Study	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Constipation	Health					MG/DAILY/PO	
Initial or Prolonged	Diverticulitis	Professional	Tab Vioxx 25 Mg	SS		ORAL	25	
	Diverticulum						MG/DAILY/PO	
	Dizziness		Tab Placebo	SS		ORAL	PO	
	Gastric Ulcer		Acetaminophen	SS		ORAL	325 MG/PRN/PO	
	Gastrointestinal		Hydrodiuril	C				
	Haemorrhage		Tears Naturale	C				
	Iron Deficiency Anaemia		Tubex	C				
	Malnutrition		Vasocon-A	C				
	Rectal Haemorrhage		Aspirin	C				
			Folic Acid	C				
			Methotrexate	C				

Date:05/24/02ISR Number: 3922964-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Disability			Allegra	C				
			Inderal	C				
			Lopid	C				
			Mobic	C				
			Plavix	C				
			Premarin	C				
			Wellbutrin	C				
			Zestril	C				
			Folic Acid	C				
			Metformin	C				
			Vitamin E	C				

			Vitamins	C		

Date:05/24/02ISR Number: 3922975-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA03150
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25	Cardiac Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
Initial or Prolonged						
MG/DAILY/PO						
			Coumadin	C		
			Lasix (Furosemide)	C		
			Nexium	C		
			Premarin	C		
			Toprol Xl Tablets	C		
			Zestoretic	C		
			Digoxin	C		
			Potassium	C		
			Thyroid	C		

Date:05/24/02ISR Number: 3923008-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02938
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Epistaxis	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Estrace	C		
			Fiorinal	C		
			Moduretic	C		
			Prozac	C		
			Synthroid	C		

Date:05/24/02ISR Number: 3923015-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01653
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Gastric Ulcer Haemorrhage	Professional				
MG/DAILY/PO						
Initial or Prolonged	Myocardial Infarction	Company	Aspirin Unk	SS		
	Thrombosis	Representative				

Date:05/24/02ISR Number: 3923017-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death	Company	Tab Vioxx	PS		ORAL
PO						
		Representative				
		Other				

Date:05/24/02ISR Number: 3923018-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01368
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY						
	Drug Ineffective	Other				
PO ; 50						
	Weight Increased					
MG/DAILY PO						
			Accupril	C		
			Amaryl	C		
			Coumadin	C		
			Imdur	C		
			L-Thyroxin	C		
			Lipitor	C		
			Pletal	C		
			Atenolol	C		

Date:05/24/02ISR Number: 3923020-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00240
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Muscular Weakness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Somnolence	Health				
MG/DAILY/PO						
		Professional	Zanaflex	C		
			Baclofen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3923022-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/24/02ISR Number: 3923025-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/24/02ISR Number: 3923026-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01629
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Professional	Centrum	C				
			Premarin	C				
			Calcium (Unspecified)	C				
			Ginkgo Biloba Extract	C				

Date:05/24/02ISR Number: 3923051-XReport Type:Expedited (15-DaCompany Report #WAES 01097024
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Haemorrhage Gastric Ulcer	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:05/24/02ISR Number: 3923054-5Report Type:Expedited (15-DaCompany Report #WAES 01069553
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic	Foreign	Tab Mk-0966	PS		ORAL	50 MG/DAILY	
		Study						
PO								642 DAY
		Health	Tab Placebo	SS		ORAL		
PO								642 DAY
		Professional	Bromhexine	C				
		Other	Calcitonin	C				
			Cetirizine	C				
			...	C				
			Cinnarizine	C				
			Mizolastine	C				
			Prednisolone	C				
			Raloxifene	C				
			Ranitidine	C				
			Trimetazidine	C				

Date:05/24/02ISR Number: 3923055-7Report Type:Expedited (15-DaCompany Report #WAES 01069553
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic	Foreign	Tab Mk-0966	PS		ORAL	50 MG/DAILY	
	Rash Generalised	Study						
PO								642 DAY
		Other	Tab Placebo					

			(Unspecified)	SS		ORAL
PO	642 DAY					
			Bromhexine	C		
			Calcitonin	C		
			Cetirizine	C		
			Cinnarizine	C		
			Mizolastine	C		
			Prednisolone	C		
			Raloxifene	C		
			Ranitidine	C		
			Trimetazidine	C		

Date:05/24/02ISR Number: 3923064-8Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Ulcer Haemorrhage	Foreign	Tab Vioxx			
Life-Threatening	Gastritis Haemorrhagic	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Hospitalization -	Polymyositis					
PO 75 DAY						
Initial or Prolonged	Shock Haemorrhagic		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	SS		ORAL
PO						
			Furosemide	C		
			Isosorbide Mononitrate	C		
			Pantoprazole Sodium	C		
			Prednisone	C		
			Ramipril	C		
			Sotalol Hydrochloride	C		
			Tramadol Hcl	C		

Date:05/24/02ISR Number: 3923065-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02173
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Distension	Study	Tab Vioxx 25 Mg	PS		ORAL
25						

Initial or Prolonged		Abdominal Pain	Health			
MG/DAILY/PO						
		Dysuria	Professional	Inhl Blinded Therapy		
		Gastric Outlet		Unk	SS	
RESPIRATORY						
		Obstruction				
(INHALATION)	INH					
		Nausea				
		Peptic Ulcer				
		Pneumonia Aspiration				
		Small Intestinal				
		Obstruction				
		Vomiting				
		White Blood Cell Count				
		Increased				

Date:05/24/02ISR Number: 3923074-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO							
		Hypoaesthesia					
		Monoplegia					
		Phlebitis					
		Sensory Loss					
		Thrombosis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3923082-XReport Type:Expedited (15-DaCompany Report #WAES 01116033
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bipolar Disorder	Foreign	Tab Vioxx					
	Condition Aggravated	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Depression							
							PO	30 DAY
	Drug Interaction		Cap Sr Carbamazepine	SS		ORAL	200 MG/DAILY	
	Drug Level Decreased							
							PO	
			Elavil	C				
			Alprazolam	C				

Date:05/24/02ISR Number: 3923085-5Report Type:Expedited (15-DaCompany Report #WAES 0204MYS00003
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fluid Overload	Foreign	Tab Vioxx					
Hospitalization - Initial or Prolonged	Hypotension	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Leukocytosis	Professional					PO	
	Metabolic Acidosis		Indocin					
	Renal Failure Acute		(Indomethacin)	C				
	Sepsis		Diclofenac Na	C				
			Irbesartan	C				

Date:05/24/02ISR Number: 3923104-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chorea	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
							PO	
			Acetaminophen	C				

				Lactulose	C		
				Lansoprazole	C		
				Senna	C		

Date:05/24/02ISR Number: 3923106-XReport Type:Expedited (15-DaCompany Report #WAES 0205AUS00063
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Consciousness Fluctuating	Foreign	Tab Vioxx					
	Feeling Abnormal	Consumer	(Rofecoxib)	PS		ORAL	12.5	
	Tachycardia							
							MG/DAILY PO	1 DAY
			Calcium Carbonate	C				
			Estrogens, Conjugated (+)					
			Medroxyprogest	C				
			Levothyroxine Na	C				
			Propranolol Hcl	C				

Date:05/24/02ISR Number: 3923109-5Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00065
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Foreign	Tab Vioxx					
Initial or Prolonged	Respiratory Disorder	Study	(Rofecoxib)	PS		ORAL	PO	7 DAY
		Health Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/02ISR Number: 3923111-3Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00116
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Hyponatraemia Sleep Disorder	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 9 DAY
	Somnolence		Oxazepam	SS		ORAL	PO	1 DAY
			Clomipramine Hcl	SS		ORAL	PO	
			Ranitidine	C				

Date:05/24/02ISR Number: 3923254-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00011
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis Necrotising	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/ DAILY	PO

Date:05/28/02ISR Number: 3922992-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02353
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Anaphylactic Shock Angioneurotic Oedema Chest Pain Dyspnoea Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/28/02ISR Number: 3922993-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization -	Grand Mal Convulsion		Vioxx	SS		ORAL		70 DAY
Initial or Prolonged	Status Epilepticus							

Date:05/28/02ISR Number: 3922999-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Increased		Digoxin	SS		ORAL		10 DAY
	Confusional State		[Therapy					
	Disorientation		Unspecified]	SS		ORAL		7 DAY
	Drug Level Increased		Midamor	C				
	Hallucination		Lisuride Maleate	C		ORAL		
			Fluindione	C				
			Lansoprazole	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		
			Paraffin	C		ORAL		
			Buflomedil Hydrochloride	C		ORAL		
			Clomipramine					

Hydrochloride	C		ORAL
Benserazide Hydrochloride And Levodopa	C		ORAL
Amlodipine	C		ORAL
Furosemide	C		ORAL

Date:05/28/02ISR Number: 3923000-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Akathisia		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Facial Palsy		Vioxx	SS		ORAL		3 DAY
Disability	Fall		Vioxx	SS		ORAL		
	Fracture Nonunion		Vioxx	SS		ORAL		7 DAY
	Haematochezia		Aristocort	C		PARENTERAL		1 DAY
	Haemorrhagic Stroke		Ziac	C		ORAL		
	Radius Fracture		Hyzaar	C		ORAL		
			Zoloft	C		ORAL		
			Tiazac	C				

Date:05/28/02ISR Number: 3923004-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00152
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
	Cardiac Failure		Mometasone Furoate	C				
	Congestive		Psyllium Husk	C		ORAL		

Date:05/28/02ISR Number: 3923005-3Report Type:Expedited (15-DaCompany Report #WAES 0205MYS00002
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL 3 DAY

Date:05/28/02ISR Number: 3923006-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01961
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Blood Pressure Decreased
	Blood Urea Increased
Disability	Cold Sweat
Other	Dizziness
	Duodenal Ulcer
	Duodenitis
	Gastritis Erosive
	Haematemesis
	Haematocrit Decreased
	Haemoglobin Decreased
	Hyperhidrosis
	Hypoaesthesia
	Hypovolaemia
	Loss Of Consciousness
	Melaena
	Movement Disorder
	Musculoskeletal Stiffness

		Nausea					
		Prothrombin Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Retching		Bufferin	C		ORAL
		Tachycardia					
		Upper Gastrointestinal Haemorrhage					

Date:05/28/02ISR Number: 3923009-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Lower Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Coumadin	C		

Date:05/28/02ISR Number: 3923010-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02970
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1 MON						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Warfarin	C		
			Vasotec	C		
			Triazolam	C		

Date:05/28/02ISR Number: 3923011-9Report Type:Expedited (15-DaCompany Report #WAES 0205NOR00013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
93 DAY						
	Dyspnoea		Aspirin And Magnesium Oxide	C		ORAL
	Faeces Discoloured		Amlodipine Besylate	C		ORAL
	Gastrointestinal Haemorrhage		Vasotec	C		ORAL

Date:05/28/02ISR Number: 3923014-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02257
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Motrin	C				
			Atenolol	C				
			Carbidopa And Levodopa	C				
			Dyazide	C				

Date:05/28/02ISR Number: 3923318-5Report Type:Periodic Company Report #WAES 0112USA02477
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Klonopin	C				
			Tranxene	C				
			Diazepam	C				
			Diflunisal	C				

Temazepam C

Date:05/28/02ISR Number: 3923369-0Report Type:Periodic Company Report #WAES 0201USA00528
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tongue Disorder	Health Professional	Lipitor	C				

Date:05/28/02ISR Number: 3923405-1Report Type:Direct Company Report #CTU 169038
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx 12.5mg Merck And Co	PS	Merck And Co	ORAL	12.5MG DAILY ORAL	
	Dizziness							
	Headache							
	Irritability							
	Muscle Spasms							
	Nausea							
	Vision Blurred							

Date:05/28/02ISR Number: 3923536-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00120
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	36 DAY	
			Lansoprazole	C		ORAL	62 DAY	
			Pergolide	C		ORAL	62 DAY	
			Benserazide	C		ORAL	141 DAY	

			Furosemide	C			ORAL
652 DAY							
			Warfarin	C			ORAL
141 DAY							

Date:05/28/02ISR Number: 3923539-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00025
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Headache		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Musculoskeletal Stiffness		Premarin	C		ORAL
Other			[Composition Unspecified]	C		

Date:05/28/02ISR Number: 3923540-8Report Type:Expedited (15-DaCompany Report #WAES 0203AUS00140
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Initial or Prolonged	Dyspnoea		Amlodipine Besylate	C		ORAL
2568 DAY						
	Pulmonary Oedema					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/02ISR Number: 3923542-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged			Celiprolol Hydrochloride	C				
			Rilmenidene	C				
			Sildenafil Citrate	C				

Date:05/28/02ISR Number: 3923543-3Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00020
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Haemorrhage		Fluindione	C		ORAL		
	Oesophageal Ulcer		Fluindione	C		ORAL		
			Furosemide	C		ORAL		

Date:05/28/02ISR Number: 3923545-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01769
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY
Initial or Prolonged								

Date:05/28/02ISR Number: 3923546-9Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00012
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Life-Threatening	Duodenal Ulcer		Aspirin	SS		ORAL		
Hospitalization -	Perforation							

Initial or Prolonged Disability		Gastric Ulcer Perforation Necrosis Oral Intake Reduced Peritonitis					

Date:05/28/02ISR Number: 3923548-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02583
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Mental Status Changes					

Date:05/28/02ISR Number: 3923549-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebellar Artery		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Thrombosis		Globulin, Immune	SS		
INTRAVENOUS							
Initial or Prolonged		Cerebellar Infarction		Globulin, Immune	SS		
INTRAVENOUS							
		Cerebrovascular Accident					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/02ISR Number: 3923550-0Report Type:Expedited (15-DaCompany Report #WAES 0205FRA00035
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Diarrhoea		Celecoxib	SS		ORAL		2 DAY
	Nausea		Thiocolchicoside	C		ORAL		2 DAY
	Renal Failure Acute							
	Vomiting							

Date:05/28/02ISR Number: 3923551-2Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00048
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Decreased Activity		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Deep Vein Thrombosis		Ciprofloxacin	C		ORAL		
			Cloxacillin Sodium	C		ORAL		
			Fluvoxamine Maleate	C		ORAL		

Date:05/28/02ISR Number: 3923552-4Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00159
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
	Hypertension		Amitriptyline	C		ORAL		
			Vasotec	C		ORAL		
			Atenolol	C		ORAL		
			Indapamide	C		ORAL		
			Omeprazole	C		ORAL		

Date:05/28/02ISR Number: 3923554-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00168
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ranitidine	C		ORAL		
			Lisinopril	C		ORAL		
			Aspirin	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Quinine Sulfate	C				

Date:05/28/02ISR Number: 3923558-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02573
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Paraesthesia Mucosal		Vioxx	PS	Merck & Co., Inc	ORAL		
			Soma	C				
			Ultram	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/02ISR Number: 3923559-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:05/28/02ISR Number: 3923560-3Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00016
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Initial or Prolonged	Gastrointestinal		Fosamax	SS		ORAL	19	DAY
Disability	Haemorrhage		Acetaminophen	C		ORAL	19	DAY
	Melaena							

Date:05/28/02ISR Number: 3923561-5Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00020
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/28/02ISR Number: 3923769-9Report Type:Direct Company Report #CTU 169031
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Impaired Healing		Vioxx Standard	PS		ORAL	1 TABLE ONCE	
	Mouth Ulceration							

PER ORAL

Date:05/28/02ISR Number: 3923841-3Report Type:Direct Company Report #CTU 169028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache		Vioxx	PS		ORAL	25 MG PO 1 QD	
Initial or Prolonged Other	Meningitis Aseptic							

Date:05/28/02ISR Number: 3941119-9Report Type:Periodic Company Report #WAES 0202USA01756
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:05/29/02ISR Number: 3924115-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00284
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
			Gastrointestinal Preparations (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3924517-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00050
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intestinal Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:05/29/02ISR Number: 3924526-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Coumadin	C				
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:05/29/02ISR Number: 3924527-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00162
Age:98 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tramadol	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		
			Acetaminophen	C		ORAL		
			Senna	C		ORAL		

Date:05/29/02ISR Number: 3924529-5Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00038
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY

	Asthenia		Rutin	C			ORAL
2478 DAY							
	Duodenal Ulcer		Tramadol				
	Haemorrhage		Hydrochloride	C			ORAL
15 DAY							
	Hypotension						
	Vertigo						

Date:05/29/02ISR Number: 3924531-3Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00052
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Hospitalization -	Haemorrhage		Carbidopa And			
Initial or Prolonged	Shock		Levodopa	C		
1 YR						
			Paroxetine			
			Hydrochloride	C		
1 YR						
			Nitroglycerin	C		
1 YR						
			Valsartan	C		
			Furosemide	C		
			Benserazide			
			Hydrochloride And			
			Levodopa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3924532-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00173
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY
	Rectal Haemorrhage		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Psyllium Husk	C		ORAL		

Date:05/29/02ISR Number: 3924534-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00174
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Aspirin	SS		ORAL		

Date:05/29/02ISR Number: 3924535-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00176
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL	186	DAY
			Vioxx	SS		ORAL		
			Acetaminophen	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		

Date:05/29/02ISR Number: 3924538-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00163
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/29/02ISR Number: 3925213-4Report Type:Direct Company Report #CTU 169112
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardio-Respiratory Arrest		Vioxx	PS			50 MG ONCE QD	

Date:05/29/02ISR Number: 3925276-6Report Type:Direct Company Report #CTU 169087
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Vioxx	PS				

Date:05/29/02ISR Number: 3925925-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3925927-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925928-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925929-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925931-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01984
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925932-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925934-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925940-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925941-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925942-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3925944-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3925993-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA01074
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pneumonia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Respiratory Disorder						MG/BID/PO	
			Synthroid	C				

Date:05/29/02ISR Number: 3926002-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02180
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Consumer	Tab Vioxx	PS		ORAL	PO	
	Headache		Prinivil	C				
	Rash		Metoprolol	C				
	Tachycardia							

Date:05/29/02ISR Number: 3926029-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02620
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Increased	Consumer	Vioxx	PS		ORAL	50	
Initial or Prolonged	Hypertension						MG/DAILY/PO	
			Lipitor	C				
			Premarin	C				

				Aspirin	C		
				Vitamins	C		

Date:05/29/02ISR Number: 3926067-2Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00047
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia Pleural Infection	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY

Date:05/29/02ISR Number: 3926122-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02705
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/PO	
	Gastritis	Company Representative	Zocor	C				

Date:05/29/02ISR Number: 3926123-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926124-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Gastric Ulcer Perforation	Health Professional Company Representative	Tab Vioxx 50 Mg Nonsteroidal Anti-Inflammatory	PS C		ORAL	50 MG/DAILY/PO	

Date:05/29/02ISR Number: 3926186-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00118
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulum Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib) Acetaminophen Digoxin Enalapril Maleate	PS C C C		ORAL	12.5 MG / DAILY PO	50 DAY

Date:05/29/02ISR Number: 3926189-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00123
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
	Gastric Ulcer	Other	(Rofecoxib)	PS		ORAL	50 MG/PO	19 DAY
	Upper Gastrointestinal		Aspirin	SS		ORAL	150 MG/PO	22 DAY
	Haemorrhage		Acetaminophen / Codeine Phosphate	C				
			Cefuroxime	C				
			Furosemide	C				
			Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C				
			Prochlorperazine Maleate	C				

Date:05/29/02ISR Number: 3926190-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00142
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926194-XReport Type:Expedited (15-DaCompany Report #WAES 0205SWE00013
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea	Foreign	Tab Vioxx					
	Electrocardiogram Qt Prolonged	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
	Electrocardiogram T Wave Abnormal		Atenolol	C				
			Furosemide Sodium	C				
	Haemoglobin Abnormal		Nitroglycerin	C				
	Vomiting		Zolpidem Tartrate	C				
	White Blood Cell Count Abnormal							

Date:05/29/02ISR Number: 3926195-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00106
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Microcytic Anaemia	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Aspirin	C				
			Dihydrocodeine	C				
			Etidronate Disodium	C				
			Omeprazole	C				
			Psyllium Husk	C				
			Senna	C				

Date:05/29/02ISR Number: 3926196-3Report Type:Expedited (15-DaCompany Report #WAES 0203BEL00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Tab Vioxx					
	Chest Discomfort	Health	(Refecoxib)	PS		ORAL		
	Confusional State	Professional						

Encephalopathy
Fluid Retention
Hyponatraemia
Incontinence
Nausea
Petit Mal Epilepsy
Transient Ischaemic
Attack
Vertigo

Date:05/29/02ISR Number: 3926197-5Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00074
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS				
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3926199-9Report Type:Expedited (15-DaCompany Report #WAES 0205KOR00035
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 75 DAY

Date:05/29/02ISR Number: 3926203-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00026
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Foreign	Tab Vioxx					
Other	Vertigo	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	42 DAY
		Professional	Amiodarone Hydrochloride	C				
			Lisinopril	C				

Date:05/29/02ISR Number: 3926205-1Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	PO	18 MON
		Professional						

Date:05/29/02ISR Number: 3926209-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00138
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Obstructive	Foreign	Tab Vioxx					
Hospitalization -	Airways Disease	Other	(Rofecoxib)	PS		ORAL	12.5 MG/1X PO	1 DAY

Initial or Prolonged	Exacerbated		Albuterol	C
Other			Aspirin	C
			Dothiepin Hci	C
			Ipratropium Bromide	C
			Nifedipine	C
			Ramipril	C
			Tibolone	C

Date:05/29/02ISR Number: 3926221-XReport Type:Expedited (15-DaCompany Report #WAES 0205DEU00130
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis	Foreign	Tab Vioxx					
	Carotid Artery Occlusion	Health	(Rofecoxib)	PS		ORAL	12.5 MG/BID,	
	Cerebral Infarction	Professional						
		Other	Elavil	C			PO	6 DAY
			Cosyntropin	C				
			Enoxaparin Sodium	C				
			Metoclopramide	C				
			Pentoxifylline	C				
			Rantidine	C				
			Tilidine Hydrochloride	C				
			Tolperisone Hcl	C				
			Vitamin B (Unspecified)	C				

				Vitamins (Unspecified)	C		

Date:05/29/02ISR Number: 3926222-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00140
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage	Foreign	Tab Vioxx					
Hospitalization -		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Initial or Prolonged								
PO								179 DAY
			Aspirin	C				
			Bendroflumethiazide	C				

Date:05/29/02ISR Number: 3926224-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00044
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Chronic	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	12.5	
		Professional						
MG/DAILY, PO								175 DAY
		Other	Tab Fosinopril					
			Sodium	SS		ORAL	20 MG/DAILY,	
PO								

Date:05/29/02ISR Number: 3926274-9Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00092
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Left Ventricular Failure	Health						
PO								6 DAY

		Professional	Amlodipine Besylate	C
		Other		

Date:05/29/02ISR Number: 3926276-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Life-Threatening	Fatigue	Health					PO	2 DAY
Hospitalization - Initial or Prolonged	Heart Rate Decreased	Professional	Coltramyl	C				
	Hypotension	Other	Mydocalm	C				
	Loss Of Consciousness		Sirdalud	C				
	Organ Failure		....	C				
	Pulmonary Oedema		Therapy Unspeciried	C				
	Shock							
	Ventricular Fibrillation							

Date:05/29/02ISR Number: 3926278-6Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00026
Age:94 YR Gender:Female I/FU:I

Outcome	PT
Death	Abdominal Pain
	Drug Interaction
	Gastric Ulcer
	Haematemesis
	Ileus Paralytic

Malaise
Shock

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY, PO	3 DAY
Other	Tab Ibuprofen	SS		ORAL	1200 MG/DAILY, PO	8 DAY
	Aspirin	SS		ORAL	100 MG/DAILY, PO	
	Amiodarone	C				
	Irbesartan	C				
	Molsidomine	C				
	Zolpidem Tartrate	C				

Date:05/29/02ISR Number: 3926281-6Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00162
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Perforation	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY, PO	14 DAY

Date:05/29/02ISR Number: 3926393-7Report Type:Expedited (15-DaCompany Report #WAES 01088603
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Cough Dizziness	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	100 MG/DAILY	

Initial or Prolonged	Fluid Retention	Professional				
PO						
Disability	Medication Error		Celecoxib	C		
Other	Respiratory Disorder		Oxycodone Hcl	C		
	Weight Increased					

Date:05/29/02ISR Number: 3926464-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926465-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926466-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01989
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926467-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01988
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926468-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:05/29/02ISR Number: 3926474-8Report Type:Expedited (15-DaCompany Report #WAES 0203CHE00021
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	1 DAY
Other	Coordination Abnormal	Other						
	Facial Paresis		Cosopt	C				
	Speech Disorder		Aspirin	C				
	Vertigo		Fish Oil (Unspecified)	C				
			Magnesium (Unspecified)	C				

Date:05/29/02ISR Number: 3926475-XReport Type:Expedited (15-DaCompany Report #WAES 01088603
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cough	Foreign	Tab Vioxx					
Hospitalization -	Dizziness	Health	(Rofecoxib)	PS		ORAL	100 MG /DAILY	
Initial or Prolonged	Fluid Retention	Professional	Celecoxib	C				
Disability	Medication Error		Oxycodone Hcl	C				

Other	Respiratory Disorder Weight Increased					

Date:05/29/02ISR Number: 3926542-0Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00018
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Bone Marrow Depression	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 YR
Initial or Prolonged		Professional	Cozaar	C				
			Tolterodine Tartrate	C				

Date:05/29/02ISR Number: 3926543-2Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00010
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
Disability		Professional	Aspirin	C				

Date:05/29/02ISR Number: 3926544-4Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Albumin Urine Present	Foreign	Tab Vioxx					
	Blood Pressure Systolic	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	31 DAY
	Increased		Warfarin Sodium	SS		ORAL		
	Haematoma		Atenolol	C				
	Haematuria		Ergoloid Mesylates	C				
	Haemorrhage Subcutaneous		Isosorbide Mononitrate	C				
			Nitroglycerin	C				
			Simvastatin	C				

Date:05/29/02ISR Number: 3926545-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG/DAILY	7 DAY
		Professional Other	Celiprolol Hcl	C				
			Rilmenidene	C				
			Sildenafil Citrate	C				

Date:05/29/02ISR Number: 3926627-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA00513
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
Other	Meningitis Aseptic	Professional Company Representative						
	Nausea							
	Optic Nerve Disorder							
	Pain							
	Papilloedema							
	Retinal Haemorrhage							
	Visual Disturbance							
	Vomiting							

Date:05/29/02ISR Number: 3926649-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01719
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Consumer	Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Medication Error		Lithiumco3	SS				
	Mutism		Paxil	SS				
	Oedema Peripheral		Glucophage	C				
			Glucotrol	C				
			Lipitor	C				
			Metamucil	C				
			Prilosec	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3926651-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00693
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Oedema Peripheral	Professional					MG/DAILY/PO	
Initial or Prolonged	Pharyngeal Oedema	Company	Aleve	C				
Other	Rash	Representative	Vicodin Tablets	C				
	Respiratory Distress		Ibuprofen	C				
	Throat Tightness							
	Tongue Oedema							

Date:05/29/02ISR Number: 3926653-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02378
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal Disorder		Prempro	C				
			Synthroid	C				
			Aspirin	C				

Date:05/30/02ISR Number: 3925398-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03162
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal	Professional						
	Haemorrhage							
	Gastrointestinal Ulcer							

Date:05/30/02ISR Number: 3925400-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hallucination, Olfactory	Health	Vioxx	PS	Merck & Co., Inc	ORAL	17 DAY
	Temporal Lobe Epilepsy	Professional	Vioxx	SS		ORAL	36 DAY
			Vioxx	SS		ORAL	441 DAY
			[Composition Unspecified]	C			

Date:05/30/02ISR Number: 3925404-2Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00035
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Duodenal Ulcer	Professional	Acetaminophen	C		ORAL		
			Viloxazine Hydrochloride	C		ORAL		

Date:05/30/02ISR Number: 3925405-4Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00078
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization -	Haemodialysis	Professional	Spironolactone	C		ORAL	900	DAY
Initial or Prolonged	Hyperkalaemia		Perindopril	C		ORAL	900	DAY
	Renal Failure Acute		Cystine	C		ORAL	5	DAY

Date:05/30/02ISR Number: 3925765-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00091
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Insulin, Neutral	C				
			Insulin, Isophane	C				
			Insulin, Isophane	C				
			Chlorthalidone	C				
			Lisinopril	C				
			Atorvastatin Calcium	C				
			Warfarin	C				
			Isosorbide Mononitrate	C				
			Digoxin	C				

Date:05/30/02ISR Number: 3925766-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00117
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
			Lansoprazole	C		ORAL		
			Furosemide	C		ORAL		
			Vasotec	C		ORAL		
			Molsidomine	C		ORAL		
			Fenofibrate	C		ORAL		
			Salmeterol Xinafoate	C		ORAL		
			Budesonide	C				

RESPIRATORY

(INHALATION)

Date:05/30/02ISR Number: 3925767-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Percocet	C				

Other	Difficulty In Walking	Omega-3	C
	Discomfort	Ginkgo Biloba	
	Hypoaesthesia	Extract	C
	Monoplegia		
	Pain In Extremity		
	Phlebitis		
	Sensory Loss		
	Thermal Burn		
	Thrombosis		

Date:05/30/02ISR Number: 3925768-XReport Type:Expedited (15-DaCompany Report #WAES 0204BEL00110
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/02ISR Number: 3925769-1Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00164
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Tinnitus		Tramadol Hydrochloride	C		PARENTERAL	2	DAY

Date:05/30/02ISR Number: 3925772-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA01871
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Amylase Increased		Prednisone	SS				
	Blood Pressure Decreased		Prinivil	C				
	Gastritis Haemorrhagic		Metoprolol	C				
	Gastrointestinal		Synthroid	C				
	Haemorrhage		Plaquenil	C				
	Haematemesis							
	Heart Rate Increased							
	Hiatus Hernia							
	Renal Impairment							

Date:05/30/02ISR Number: 3925775-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00188
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Oil Of Peppermint	C				
			Zolmitriptan	C		ORAL		

Date:05/30/02ISR Number: 3925778-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00189
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
16 DAY						
	Left Ventricular Failure		Isosorbide Mononitrate	C		ORAL
			Cozaar	C		ORAL
			Furosemide	C		ORAL
			Acetaminophen	C		ORAL

Date:05/30/02ISR Number: 3925779-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Respiratory Failure		Vioxx	SS		ORAL
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		
			Ibuprofen	C		
			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/02ISR Number: 3925783-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction Prescribed Overdose							

Date:05/30/02ISR Number: 3926384-6Report Type:Direct Company Report #CTU 169216
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx 25mg Merck	PS	Merck	ORAL	25MG 1 PER	DAY ORAL
	Haemorrhagic Stroke							
	Loss Of Consciousness		Paxil	C				
	Myocardial Infarction		Atenolol	C				
			Primidone	C				
			Fosomax	C				

Date:05/30/02ISR Number: 3926695-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03165
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhage	Professional						
Other	Rectal Haemorrhage	Company Representative	Carafate	C				
			Digestive Enzymes (+) Pancreatin	C				
			Glyburide	C				

Date:05/30/02ISR Number: 3926708-XReport Type:Expedited (15-DaCompany Report #2002AP01362
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma	Foreign	Felodipine	PS			5 MG DAILY	
Initial or Prolonged		Health	Chlortetracycline	SS			25 MG DAILY	
		Professional	Rofecoxib	SS			300 MG DAILY	
		Other	Enoxaparin	SS			120 MG DAILY	
			Irbesartan	C				
			Simvastatin	C				
			Aspirin "Bayer"	C				
			Ranitidine	C				

Date:05/30/02ISR Number: 3927467-7Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Antinuclear Antibody
	Positive
	Anxiety
	Arthropod Bite
	Auricular Swelling
	Biopsy Skin Abnormal
	Burning Sensation
	Cardiac Disorder
	Dermatitis Contact
	Drug Hypersensitivity
	Eczema

	Epidermal Naevus						
	Erythema						
	Excoriation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hyperkeratosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE
	Hypersensitivity	Health	Celebrex	SS			
	Inflammation	Professional	Anafranil	C			
	Injury		Lidex	C			
	Insomnia						
	Laboratory Test Abnormal						
	Lung Disorder						
	Mycosis Fungoides						
	Nasal Oedema						
	Necrosis						
	Nervousness						
	Neurodermatitis						
	Pain						
	Pityriasis Rubra Pilaris						
	Pruritus						
	Rash						
	Rash Erythematous						
	Rash Macular						
	Rash Scaly						
	Scar						
	Skin Papilloma						
	Skin Ulcer						
	Urticaria Papular						

Date:05/30/02ISR Number: 3927501-4Report Type:Expedited (15-DaCompany Report #WAES 0201USA03065
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO
	Cardiomegaly	Company					
	Heart Rate Increased	Representative					

Date:05/30/02ISR Number: 3927502-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01111
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Back Pain	Professional						
	Gastrointestinal Disorder	Company						
	Herpes Zoster	Representative						

Date:05/30/02ISR Number: 3927503-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00980
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Blood Creatine	Professional						
	Phosphokinase Increased	Company	Claritin	C			MG/DAILY/PO	
	Hypoaesthesia	Representative	Darvocet-N	C				
	Myalgia		Flonase	C				
	Myopathy		Fosamax	C				
	Pain		Lipitor	C				
	Paraesthesia		Neurontin	C				
			Niaspan	C				

Testred	C
Topamax	C
Ascorbic Acid	C
Clonazepam	C
Doxepin	C
Glucosamine	C
Meclizine	C
Ubiquinones	C
Vitamin E	C
Vitamins	C

Date:05/30/02ISR Number: 3927504-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged		Health Professional	Wellbutrin	C				

Date:05/30/02ISR Number: 3927505-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02947
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Hypoaesthesia	Health Professional	Anaptivan	C				
Initial or Prolonged	Intraspinal Abscess		Zyvox	C				
Disability	Myelitis Transverse		Clindamycin	C				
Other	Pain							

Date:05/30/02ISR Number: 3927723-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Adhesions	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

	Abdominal Pain	Other				
MG/DAILY/PO						
			Ambien	C		
			Dyazide	C		
			Lasix (Furosemide)	C		
			Lonox	C		
			Micro K	C		
			Premarin	C		
			Atenolol	C		

Date:05/30/02ISR Number: 3927730-XReport Type:Expedited (15-DaCompany Report #WAES 01059553
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Proteinuria	Foreign	Tab Viox (Rofecoxib)	PS		ORAL
25 MG /DAILY 262 DAY						
Initial or Prolonged		Study	Tab Placebo			
		Other	(Unspecified)	SS		ORAL
			Calcitonin	C		
			Diltiazem	C		
			Leflunomide	C		
			Levothyroxine Na	C		
			Alfacalcidol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/02ISR Number: 3927732-3Report Type:Expedited (15-DaCompany Report #WAES 00095116
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	15 DAY
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Health Professional	Diclofenac Na	SS		ORAL		
	Intestinal Perforation	Other	Atenolol	C				
	Myocardial Infarction		Digoxin	C				
	Ventricular Failure		Furosemide	C				
			Warfarin	C				

Date:05/30/02ISR Number: 3927759-1Report Type:Expedited (15-DaCompany Report #WAES 0205SWE00003
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Tab Vioxx (Rofecoxib)	PS		ORAL		
			Aspirin	C				
			Insulin Human, Isophane	C				
			Insulin Lispro	C				
			Lisinopril	C				

Date:05/30/02ISR Number: 3927762-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00119
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Foreign	Tab Vioxx					
Life-Threatening		Health	(Rofecoxib)	PS			25MG DAILY PO	3 MON
Hospitalization - Initial or Prolonged		Professional	Salcatonin	C				

Date:05/30/02ISR Number: 3927812-2Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00118
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25MG/DAILY PO	1 MON

Date:05/31/02ISR Number: 3926238-5Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00030
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Life-Threatening Hospitalization - Initial or Prolonged	Haemorrhage Femur Fracture Gastric Ulcer Haemorrhage Hypovolaemic Shock Intestinal Ischaemia Multi-Organ Failure Oesophagitis Renal Impairment Septic Shock Shock Haemorrhagic	Professional	Aspirin Lysine	SS		ORAL	2439 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3926243-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02515
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Celexa	C				
Other	Dyspnoea		Diphenhydramine	C		ORAL		
	Hypoaesthesia		Lorazepam	C		ORAL		
	Livedo Reticularis		Flexeril	C		ORAL		
	Paraesthesia							
	Tachycardia							

Date:05/31/02ISR Number: 3926246-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02768
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/02ISR Number: 3926247-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Neurontin	C				
Disability								
Other								

Date:05/31/02ISR Number: 3926248-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA03053
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Pletal	C				
	Gastrointestinal Ulcer		Aspirin	C				
			Lopid	C				

			Digoxin	C		
			Zocor	C		
			Ambien	C		
			Colchicine	C		
			Norflex	C		
			Acetaminophen And Hydrocodone Bitartrate	C		
			Glucosamine	C		

Date:05/31/02ISR Number: 3926249-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03392
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Post Procedural		Vicodin Tablets	C				
Disability	Haemorrhage		Amoxicillin	C				
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3926486-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00095
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization - Initial or Prolonged	Gastric Haemorrhage		Spironolactone	C		ORAL		
	Gastric Ulcer		Molsidomine	C		ORAL		
	Haematocrit Decreased		Propoxyphene Hydrochloride	C		ORAL		
	Haemoglobin Decreased		Dipyridamole	C		ORAL		
	Hip Fracture		Metoclopramide Hydrochloride	C		ORAL		
	Melaena		Tramadol Hydrochloride	C		ORAL		

Date:05/31/02ISR Number: 3926487-6Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00076
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Hyperhidrosis		Flupirtine Maleate	C		ORAL	2	DAY

Date:05/31/02ISR Number: 3926489-XReport Type:Expedited (15-DaCompany Report #WAES 0204AUS00157
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malignant Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Haemorrhage		Candesartan Cilexetil	C				
			Quinapril Hydrochloride	C				
			Atorvastatin Calcium	C				
			Estradiol	C				
			Nicotine	C				

Date:05/31/02ISR Number: 3926494-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	164 DAY	
	Appendicectomy		Decadron					
	Asthenia		(Dexamethasone)	C		ORAL	10 DAY	
	Difficulty In Walking		Prilosec	C				
	Fatigue		Singulair	C		ORAL		
	Lethargy		Serevent	C				
	Muscle Rigidity		Bromfed	C				
	Nervous System Disorder							
	Vertigo							

Date:05/31/02ISR Number: 3926496-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00018
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL	1 WK	
Initial or Prolonged	Cytomegalovirus Infection		Vioxx	SS		ORAL		
	Drug Ineffective		Mesalamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3926505-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02439
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Gastrointestinal Haemorrhage		Vioxx Plavix	PS SS	Merck & Co., Inc	ORAL		

Date:05/31/02ISR Number: 3926919-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01769
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Scan Abnormal Csf Lymphocyte Count Increased Csf White Blood Cell Count Positive Eye Movement Disorder Haemoglobin Decreased Lymphocyte Count Decreased Meningitis Aseptic Migraine Pain Photophobia Syncope White Blood Cell Count Increased	Consumer Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	

Date:05/31/02ISR Number: 3926922-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02583
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Carotid Artery Disease Cerebral Ischaemia Memory Impairment	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Mental Status Changes
Myocardial Infarction

Date:05/31/02ISR Number: 3926924-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02573
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Fatigue						MG/DAILY/PO	
	Meningitis		Soma	C				
	Paraesthesia		Ultram	C				
			Atenolol	C				

Date:05/31/02ISR Number: 3926946-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Tab Vioxx Unk	PS		ORAL	PO	1 YR
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3926948-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysstasia	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Fatigue		Darvocet-N	C				
	Feeling Abnormal							

Date:05/31/02ISR Number: 3926949-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA00859
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Erythematous	Health	Tab Vioxx 25 Mg	PS		ORAL		
	Rash Pruritic	Professional						
		Company Representative						

Date:05/31/02ISR Number: 3926961-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02350
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia	Health	Tab Vioxx 25 Mg	PS		ORAL		
Hospitalization -	Circulatory Collapse	Professional						
Initial or Prolonged	Delusion	Company	Soma	C				
Disability	Depression	Representative						
Other	Dysarthria							
	Fall							
	Gastrooesophageal Reflux Disease							
	Haematoma							
	Haemorrhagic Stroke							
	Hallucination, Auditory							
	Hemiparesis							
	Hypertension							
	Middle Insomnia							

Movement Disorder
Nervous System Disorder
Pain In Extremity
Polytraumatism
Pyrexia

Date:05/31/02ISR Number: 3927001-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01393
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Tab Vioxx Unk	PS		ORAL	PO	1 YR
Hospitalization - Initial or Prolonged	Csf Protein Increased	Professional	Dyazide	C				
	Haemodialysis		Atenolol	C				
	Haemorrhage Intracranial							
	Meningitis Aseptic							
	Mental Status Changes							
	Renal Failure Acute							
	Respiratory Failure							
	Thrombotic							
	Thrombocytopenic Purpura							

Date:05/31/02ISR Number: 3927003-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02353
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization - Initial or Prolonged	Angioneurotic Oedema Chest Discomfort Chest Pain Dyspnoea Dysuria							

Date:05/31/02ISR Number: 3927004-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01319
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Complications Of Maternal Exposure To Therapeutic Drugs Intra-Uterine Death Maternal Drugs Affecting Foetus Pregnancy	Professional	Zostrix Vitamins(Unspecified)	C C				

Date:05/31/02ISR Number: 3927005-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02859
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal Ulcer	Company	Alphagan	C				
Disability		Representative	Diltiazem Msd	C				
Other			Lasix(Furosemide)	C				
			Pravachol	C				
			Sinemet	C				
			Xalatan	C				

			Allopurinol	C		
			Aspirin	C		

Date:05/31/02ISR Number: 3927006-0Report Type:Expedited (15-DaCompany Report #WAES 01071186
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haematuria	Health	Tab Vioxx 25 Mg	PS		ORAL
PRN/PO						
	Urinary Retention	Professional	Cardura	C		
			Celebrex	C		
			Hydrodiuril	C		
			K-Dur	C		
			Levoxyl	C		
			Synthroid	C		
			Aspirin	C		
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3927007-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebellar Artery	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Thrombosis	Professional					MG/DAILY/PO	
Initial or Prolonged	Cerebrovascular Accident	Company Representative	Inj Globulin, Immune Unk	SS				

INTRAVENOUS SEE IMAGE

Date:05/31/02ISR Number: 3927008-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction	Health	Tab Vioxx 50 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Grand Mal Convulsion	Professional						
Initial or Prolonged	Status Epilepticus							

Date:05/31/02ISR Number: 3927011-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA02760
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Blood Pressure Systolic Increased	Professional	Centrum	C				
	Choking	Company Representative	Protonix	C				
	Colonic Polyp							
	Duodenal Ulcer							
	Gastric Outlet Obstruction							
	Hiatus Hernia							
	Intestinal Obstruction							
	Scar							
	Ulcer Haemorrhage							

Date:05/31/02ISR Number: 3927012-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA00220
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Tab Vioxx	PS		ORAL	12.5	
Initial or Prolonged	Coordination Abnormal	Professional					MG/DAILY/PO	
Disability	Hallucination	Company	Tab Vioxx	SS		ORAL	25	
	Spinal Cord Compression	Representative					MG/DAILY/PO	
			Fosamax	C				
			Humulin 70/30	C				
			Lasix (Furosemide)	C				
			Levoxyl	C				
			Lotrel	C				
			Miacalcin	C				
			Pepcid	C				
			Plavix	C				
			Pravachol	C				
			Premarin	C				
			Prilosec	C				
			Allopurinol	C				
			Cyanocobalamin	C				
			Digoxin	C				
			Magnesium	C				
			Nadolol	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3927013-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02970
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 MON
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company Representative	Vasotec	C				
			Triazolam	C				
			Warfarin	C				

Date:05/31/02ISR Number: 3927014-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02257
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Dyazide	C				
			Motrin	C				
			Atenolol	C				
			Carbidopa (+) Levodopa	C				

Date:05/31/02ISR Number: 3927086-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01961
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DILY/PO	
Hospitalization - Initial or Prolonged	Convulsion	Professional Company Representative	Bufferin	C				
Disability	Duodenal Ulcer							
Other	Haemorrhage							
	Exsanguination							
	Gastritis Erosive							
	Hypoaesthesia							
	Hypotension							
	Hypovolaemia							

Hypoxia
Joint Stiffness
Loss Of Consciousness
Movement Disorder
Renal Tubular Necrosis
Respiratory Failure
Retching
Upper Gastrointestinal
Haemorrhage

Date:05/31/02ISR Number: 3927114-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00025
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Other		Company Representative	Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3927122-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lower Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:05/31/02ISR Number: 3927197-1Report Type:Expedited (15-DaCompany Report #WAES 01070611
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Dyspnoea	Health	Lodine Unk	SS		ORAL	400	
	Gastritis	Professional					MG/DAILY/PO	
	Gastritis Erosive		Darvocet-N	C				
	Gastrointestinal Disorder		Ecotrin	C				
	Gastrointestinal		Lasix (Furosemide)	C				
	Haemorrhage		Norvasc	C				
	Hypochromic Anaemia		Prilosec	C				
	Lacunar Infarction		Zocor	C				
	Myocardial Infarction		Potassium	C				

Date:05/31/02ISR Number: 3927199-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00141
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
		Professional Other						

Date:05/31/02ISR Number: 3927201-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00152
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation	Foreign	Tab Vioxx					
	Cardiac Failure	Health	(Rofecoxib)	PS		ORAL	12.5 MG/ PO	17 DAY
	Congestive	Professional	Mometasone Furoate	C				
		Other	Psyllium Husk	C				

Date:05/31/02ISR Number: 3927202-2Report Type:Expedited (15-DaCompany Report #WAES 0205MYS00002
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
		Professional					PO	3 DAY
		Other						

Date:05/31/02ISR Number: 3927203-4Report Type:Expedited (15-DaCompany Report #WAES 0205NOR00013
Age: Gender: I/FU:I

Outcome	PT
Disability	Angina Pectoris
	Dyspnoea

		Faeces Discoloured Fatigue Gastrointestinal Haemorrhage Haemoglobin Decreased	Report Source Foreign Health Professional Other	Product Tab Vioxx (Rofecoxib)	Role PS	Manufacturer	Route ORAL
Dose 12.5 MG/DAILY	Duration PO 93 DAY						
				Vasotec	C		
				Amlodipine Besylate	C		
				Aspirin (+) Magnesium Oxide	C		

Date:05/31/02ISR Number: 3927214-9Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00020
Age:35 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Drug Ineffective	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY							

Date:05/31/02ISR Number: 3927215-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00168
Age:69 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest Rectal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG							
				Aspirin	C		
				Lisinopril	C		
				Quinines04	C		
				Ranitidine	C		
				Acetaminophen/ Propoxyphene Hydrochloride	C		

Date:05/31/02ISR Number: 3927216-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00159
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Foreign	Tab Vioxx					
	Hypertension	Other	(Rofecoxib)	PS		ORAL	12.5 MG	8 DAY
			Vasotec	C				
			Amitriptyline	C				
			Atenolol	C				
			Indapamide	C				
			Omeprazole	C				

Date:05/31/02ISR Number: 3927217-4Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00110
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx					
Initial or Prolonged	Congestive	Other	(Rofecoxib)	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/02ISR Number: 3927218-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00024
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo	Foreign	Tab Viox (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	122 MON
		Other	Metropolol Tartrate	SS			100MG	

Date:05/31/02ISR Number: 3927219-8Report Type:Expedited (15-DaCompany Report #WAES 0205NOR00012
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
	Gastric Ulcer	Other	(Rofecoxib)	PS		ORAL	12,5 MG/DAILY	
	Haemoglobin Decreased		Vasotec	C				
	Melaena		Aspirin(+) Magnesium					
	Oesophagitis		Oxide	C				
			Citalopram					
			Hydrobrmoide	C				
			Furosemide	C				
			Nitrazepam	C				

Date:05/31/02ISR Number: 3927228-9Report Type:Expedited (15-DaCompany Report #WAES 0205FRA00035
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Diarrhoea	Other	(Rofecoxib)	PS		ORAL	PO	2 DAY
	Nausea		Celecoxib	SS			2 DAY	
	Renal Failure Acute		Thiocolchicoside	SS		ORAL	4 MG/TID; PO	2 DAY
	Vomiting							

Date:05/31/02ISR Number: 3927229-0Report Type:Expedited (15-DaCompany Report #WAES 0205ESP00048
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY;	PO
			Ciprofloxacin	C				
			Cloxacillin Sodium	C				
			Fluvoxamine Maleate	C				

Date:05/31/02ISR Number: 3927348-9Report Type:Expedited (15-DaCompany Report #200113181EU
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
	Bacteriuria
Disability	Blood Culture Positive
Other	Cardiac Asthma
	Cardiac Failure
	Escherichia Infection
	Haemophilus Infection
	Interstitial Lung Disease
	Klebsiella Infection
	Pneumococcal Infection
	Respiratory Failure
	Staphylococcal Infection

Ventricular Fibrillation
Ventricular Tachycardia

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
10 MG/DAY PO	106 DAY	Foreign	Leflunomide Tablets	PS		ORAL
25 MG QD PO	59 DAY	Study	Vioxx	SS		ORAL
		Health Professional Other	Marcumar	C		
			Zocor	C		
			Furosemide	C		
			Aldactone	C		
			Losec	C		
			Ciproxin	C		
			Sotalol	C		
			Lasix	C		
			Seresta	C		
			Prednison	C		
			Atrovent	C		
			Normison	C		

Date:05/31/02ISR Number: 3927425-2Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	7 DAY
	Cardiac Failure		Digoxin	SS		ORAL	0.25 MG/DAILY	10 DAY
	Confusional State Disorientation		[Therapy Unspecified]	SS		ORAL	7 DAY	
	Drug Level Increased		Midamor	C				
	Dyspnoea		Amlodipine	C				
	Hallucination		Benserazide Hydrochloride (+)					
	Pyrexia		Levodopa	C				
			Buflomedil Hcl	C				
			Clomipramine Hcl	C				
			Fluindione	C				
			Furosemide	C				
			Lansoprazole	C				
			Lisuride Maleate	C				

			Paraffin	C		
			Polyethylene Glycol 3350/Kcl/Nahco3/Nacl	C		

Date:05/31/02ISR Number: 3927428-8Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis Myocardial Infarction	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	97	DAY
		Professional Other	Citalopram Hydrobromide	C				

Date:05/31/02ISR Number: 3927429-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00020
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Gastrointestinal Haemorrhage

	Haemoglobin Decreased Hiatus Hernia Oesophageal Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY
		Professional	Fluindione	C				
			Furosemide	C				

Date:05/31/02ISR Number: 3927431-8Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00001
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	3 DAY
		Professional	Celiprolol Hcl	C				
		Other	Rilmenidene	C				
			Sildenafil Citrate	C				

Date:05/31/02ISR Number: 3927478-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia
Disability	Anaemia
	Arthralgia
	Arthropathy
	Asthenia
	Back Injury
	Balance Disorder
	Blood Pressure Diastolic Decreased
	Brain Scan Abnormal
	Bundle Branch Block Left
	Bursitis
	Cardiovascular Disorder
	Cerebral Haemorrhage
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease

Discomfort
Dizziness
Facial Paresis
Fall
Haematochezia
Haematocrit Decreased
Hemiparesis
Hyperaesthesia
Hypertension
Hypoaesthesia
Injury
Malaise
Movement Disorder
Myoglobin Blood Increased
Osteoarthritis
Pharyngitis
Radius Fracture
Respiratory Rate
Increased
Sinus Bradycardia

		Tendonitis Thrombocytopenia Wrist Deformity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Wrist Fracture	Consumer	Tab Vioxx	PS		ORAL
25 MG/PO ; 50							
			Health				
MG/DAILY/PO ;							
			Professional				
25 MG/DAILY /							
PO ; 12.5							
MG/BID/PO							
				Aristocort	C		
				Hyzaar	C		
				Tiazac	C		
				Ziac	C		
				Zoloft	C		

Date:05/31/02ISR Number: 3927640-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00120
Age:78 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure	Foreign	Tab Vioxx			
			Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY,							
			Professional				
PO	36 DAY						
				Benserazide	C		
				Furosemide	C		
				Lansoprazole	C		
				Pergolide	C		
				Warfarin	C		

Date:05/31/02ISR Number: 3927641-XReport Type:Expedited (15-DaCompany Report #WAES 0203AUS00140
Age:94 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation	Foreign	Tab Vioxx			

Initial or Prolonged	Pulmonary Oedema	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY,						
PO 6 DAY						
			Amlodipine Besylate	C		

Date:05/31/02ISR Number: 3927643-3Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00016
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspepsia	Foreign	Tab Vioxx			
Initial or Prolonged	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY,						
Disability	Haemorrhage	Professional				
PO 19 DAY						
	Melaena		Tab Fosamax			
			(Alendronate Sodium)	SS		ORAL
10 MG/DAILY,						
PO 19 DAY						
			Acetaminophen	C		

Date:05/31/02ISR Number: 3927645-7Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00012
Age:95 YR Gender:Female I/FU:F

Outcome	PT
Death	Anorexia
Life-Threatening	Duodenal Ulcer
Hospitalization -	Perforation
Initial or Prolonged	Eating Disorder
Disability	Gastric Ulcer Perforation

		Pain Peritonitis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY, PO	3 MON						
				Tab Aspirin	SS		ORAL
80 MG/DAILY, PO							

Date:05/31/02ISR Number: 3927647-0Report Type:Expedited (15-DaCompany Report #WAES 01095168
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - SEE IMAGE	189 DAY	Angina Pectoris Blood Creatine	Foreign Study	Tab Vioxx (Rofecoxib)	PS	ORAL
Initial or Prolonged Disability SEE IMAGE	189 DAY	Phosphokinase Increased Cardiac Failure	Other	Tab Placebo (Unspecified)	SS	ORAL
		Congestive Chest Pain Myocardial Infarction Vomiting		Insulin Biphasic Isophane (Injection)	C	

Date:05/31/02ISR Number: 3927678-0Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged PO	97 DAY	Coronary Artery Stenosis Disseminated	Foreign Other	Tab Vioxx (Rofecoxib)	PS	ORAL
		Intravascular Coagulation Myocardial Infarction Thrombosis		Citalopram Hydrobromide	C	

Date:05/31/02ISR Number: 3927680-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Confusional State							
PO								7 DAY
	Disorientation		Digoxin	SS		ORAL	0.25 MG DAILY	
	Drug Level Increased							
PO								10 DAY
	Dyspnoea		Midamor	C				
	Hallucination		Amlodipine	C				
	Pyrexia		Benserazide Hydrochloride (+) Levodopa	C				
			Buflomedil Hci	C				
			Clomipramine Hci	C				
			Fluindione	C				
			Furosemide	C				
			Lansoprazole	C				
			Lisuride Maleate	C				
			Paraffin	C				
			Polyethylene Glycol 3350/Kcl/Nahco3/Naci	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/02ISR Number: 3926742-XReport Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11882214
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenic Purpura	Health Professional	Coumadine	PS	Bristol-Myers Squibb Company	ORAL	47 DAY	
			Ferrostrane	SS		ORAL	47 DAY	
			Vioxx	SS		ORAL	5 DAY	
			Lamaline	SS		ORAL	5 DAY	
			Lasilix	SS		ORAL	20 ("Lasilex Fabile")-40 MG	47 DAY
			Solupred	C			10 YR	
			Esberiven	C				
			Cytotec	C				
			Antibiotic	C				

Date:06/03/02ISR Number: 3926749-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02553
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort Abdominal Distension Abdominal Pain Upper Constipation Dehydration Diverticulum Diverticulum Intestinal Duodenitis Faecal Occult Blood Positive Faeces Discoloured Fall Gastric Outlet Obstruction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Septra	C				

Gastric Ulcer Haemorrhage
Haemorrhoids
Nausea
Oral Intake Reduced
Vomiting

Date:06/03/02ISR Number: 3926758-3Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00129
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prescribed Overdose	Health	Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	
		Professional	Sumatriptan Succinate	C				
			Clomipramine Hydrochloride	C				

Date:06/03/02ISR Number: 3926854-0Report Type:Direct Company Report #CTU 169352
Age:85 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to

Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Prerenal Failure		Vioxx	PS		ORAL	ORAL	
	Renal Failure Acute		Lisinopril	SS		ORAL	ORAL	
			Levaquin	C				
			Norvasc	C				
			Actos	C				
			Glyburide	C				
			Glucophage	C				
			Digoxin	C				

Date:06/03/02ISR Number: 3926963-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
			Atacand	C				
			Flovent	C				
			Combivent	C				
			Zoloft	C				
			Coreg	C				
			Plavix	C				
			Aspirin	C				
			Vitamin E	C				

Date:06/03/02ISR Number: 3926965-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		
			Wellbutrin	C				

Date:06/03/02ISR Number: 3926966-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Dysphagia							
	Gingival Disorder							
	Pharyngolaryngeal Pain							
	Tongue Disorder							
	Tongue Oedema							

Date:06/03/02ISR Number: 3926967-3Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00041
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
Initial or Prolonged Disability			Acetaminophen	C		ORAL		

Date:06/03/02ISR Number: 3926968-5Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00284
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
			Gastrointestinal Preparations (Unspecified)	C				

Date:06/03/02ISR Number: 3926969-7Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00117
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
			Lansoprazole	C		ORAL		
			Furosemide	C		ORAL		
			Vasotec	C		ORAL		
			Molsidomine	C		ORAL		
			Fenofibrate	C		ORAL		
			Salmeterol Xinafoate	C		ORAL		
			Budesonide	C				

RESPIRATORY

(INHALATION)

Date:06/03/02ISR Number: 3926970-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Grand Mal Convulsion		Vioxx	SS		ORAL	70	DAY
Initial or Prolonged	Status Epilepticus							

Date:06/03/02ISR Number: 3926974-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00201
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena							

Date:06/03/02ISR Number: 3926975-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01262
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hepatic Failure		Paxil	C				
			[Composition Unspecified]	C				

Date:06/03/02ISR Number: 3928387-4Report Type:Expedited (15-DaCompany Report #2002AP01361
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Muscular Weakness Renal Failure Acute	Foreign Health Professional

Other

Product	Role	Manufacturer	Route	Dose	Duration
Zestril	PS			20 MG DAILY	
Vioxx	SS			12.5 MG DAILY	
Oroxine	C				
Allegron	C				
Chlorthalidone	C				
Ativan	C				

Date:06/04/02ISR Number: 3927311-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Aleve	C		ORAL		
	Congestive		Vicodin Tablets	C		ORAL		
	Coronary Artery Disease		Oxycontin	C		ORAL		
	Myocardial Infarction		Ultram	C		ORAL		
	Pneumonia		Ceftin	C		ORAL		
	Ventricular Fibrillation		Mevacor	C		ORAL		
			Aspirin	C		ORAL		
			Lipitor	C		ORAL		
			[Therapy Unspecified]	C		TOPICAL		

Date:06/04/02ISR Number: 3927314-3Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00139
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Melperone Hydrochloride	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

Date:06/04/02ISR Number: 3927316-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA01861
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Gastrointestinal Ulcer		Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	C				
			Motrin	C				
			Plavix	C				
			[Therapy Unspecified]	C				

Date:06/04/02ISR Number: 3927317-9Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00151
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrotic Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	4 WK	
			Piroxicam	SS		ORAL	2 WK	
			Dipiproverine					

			Dihydrochloride	C		

Date:06/04/02ISR Number: 3927319-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00194
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Acuity Reduced		[Therapy Unspecified]	C				

Date:06/04/02ISR Number: 3927321-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY
Hospitalization - Initial or Prolonged	Infarction							
	Brain Death							
	Prescribed Overdose							

Date:06/04/02ISR Number: 3927322-2Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00066
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Aspirin	C				

Date:06/04/02ISR Number: 3927507-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00213
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
	Gastrooesophageal Reflux Disease	Professional	Acetaminophen And Dihydrocodeine					

	Peptic Ulcer		Bitartrate	C		ORAL
	Vomiting					

Date:06/04/02ISR Number: 3927508-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01963
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
	Grand Mal Convulsion	Professional	Vioxx	SS		ORAL		
	Leukopenia							
	Liver Function Test Abnormal							
	Malaise							
	Nuclear Magnetic Resonance Imaging Brain Abnormal							
	Splenomegaly							
	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/02ISR Number: 3927510-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA02867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Aldactone	C				
			Tegretol	C				
			Nortriptyline	C				

Date:06/04/02ISR Number: 3927516-6Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00052
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Haemorrhage Shock		Carbidopa And Levodopa	C			1	YR
			Paroxetine Hydrochloride	C			1	YR
			Nitroglycerin	C			1	YR
			Valsartan	C				
			Furosemide	C				
			Benserazide Hydrochloride And Levodopa	C				
			Digoxin	C				

Date:06/04/02ISR Number: 3927517-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Distress Syndrome	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Herbs (Unspecified)	C				
Hospitalization - Initial or Prolonged	Lung Infiltration Respiratory Failure							
Disability								

Date:06/04/02ISR Number: 3927518-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03359
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:06/04/02ISR Number: 3927519-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Difficulty In Walking Dyspnoea	Consumer	Vioxx Diltiazem Hydrochloride	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/02ISR Number: 3927521-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02437
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Hidradenitis	Professional						

Date:06/04/02ISR Number: 3927524-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA03549
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				
			Quinine Sulfate	C				
			Zyrtec	C				

Date:06/04/02ISR Number: 3928166-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	PO	
Life-Threatening		Professional	Coumadin	C				
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:06/04/02ISR Number: 3928168-1Report Type:Expedited (15-DaCompany Report #WAES 0203USA02051
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Olfactory	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Temporal Lobe Epilepsy	Professional						

Date:06/04/02ISR Number: 3928270-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03162
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company						
	Gastrointestinal Ulcer	Representative						

Date:06/04/02ISR Number: 3928822-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03053
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage						MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal Ulcer		Ambien	C				
			Lopid	C				
			Norflex	C				
			Pletal	C				
			Zocor	C				
			Acetaminophen (+)					
			Hydrocodone	C				
			Aspirin	C				

		Colchicide	C
		Digoxin	C
		Glucosamine	C

Date:06/04/02ISR Number: 3928825-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA03185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Anxiety	Professional					MG/DAILY/PO	
Initial or Prolonged	Dizziness	Company	Neurontin	C				
Disability	Neck Pain	Representative						
Other								

Date:06/04/02ISR Number: 3928829-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02280
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Health	Tab Vioxx	PS		ORAL	25 MG/PO; 50	
Hospitalization -	Respiratory Failure	Professional					MG/PO	
Initial or Prolonged		Company	Ibuprofen	C				
		Representative	Nonsteroidal					
			Anti-Inflammatory	C				

Date:06/04/02ISR Number: 3928830-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02515
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Tab Vioxx	PS		ORAL	50	
Initial or Prolonged	Dyspnoea	Professional					MG/DAILY/PO	
Other	Gait Disturbance	Company	Celexa	C				
	Hypoaesthesia	Representative	Flexeril	C				

	Livedo Reticularis		Diphenhydramine	C
	Paraesthesia		Lorazepam	C
	Tachycardia			

Date:06/04/02ISR Number: 3929057-9Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00052
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
Initial or Prolonged	Melaena	Professional	Benserazide					
	Shock	Other	Hydrochloride (+)					
			Levodopa	C				
			Carbidopa/Levodopa	C				
			Furosemide	C				
			Nitroglycerin	C				
			Paroxetine Hcl	C				
			Valsartan	C				

Date:06/04/02ISR Number: 3929058-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00174
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis	Foreign	Tab Vioxx					
	Melaena	Health	(Rofecoxib)	PS		ORAL	12.5 MG	
		Professional	Aspirin	SS		ORAL	75 MG/AM	
		Other						

Date:06/04/02ISR Number: 3929059-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00173
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Lower	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG	41 DAY
	Colitis Ulcerative	Health	Acetaminophen/Propox					
	Rectal Haemorrhage	Professional	yphen Hydrochloride	C				
		Other	Psyllium Husk	C				

Date:06/04/02ISR Number: 3929060-9Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00163
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
	Perforation	Other	(Rofecoxib)	PS		ORAL	12.5 MG	

Date:06/04/02ISR Number: 3929061-0Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00038
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Foreign	Tab Vioxx					
	Asthenia	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	14 DAY
	Duodenal Ulcer	Professional	Rutin	C				

	Haemorrhage	Other	Tramadol Hc1	C
	Hypotension			
	Vertigo			

Date:06/04/02ISR Number: 3929062-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00162
Age:98 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Foreign	Tab Vioxx					
	Haemorrhage	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional	Acetaminophen	C				
		Other	Amiloride					
			Hydrochloride (+)					
			Furosemide	C				
			Senna	C				
			Tramadol	C				

Date:06/04/02ISR Number: 3929073-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00176
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vasculitis	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG PO	186 DAY
			Acetaminophen	C				
			Amiloride					

				Hydrochloride (+)			
				Furosemide	C		

Date:06/04/02ISR Number: 3929136-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00117
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Foreign	Tab Vioxx					
	Pulmonary Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	8 MON
		Professional	Vasotec	C				
			Budesonide	C				
			Fenofibrate	C				
			Furosemide	C				
			Lansoprazole	C				
			Molsidomine	C				
			Salmeterol Xinafoate	C				

Date:06/04/02ISR Number: 3929139-1Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00164
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Foreign	Tab (Vioxx)					
	Tinnitus	Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY/PO	6 DAY
		Professional						
			Tramadol Hcl	C				

Date:06/04/02ISR Number: 3929140-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00189
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated	Foreign	Tab Vioxx					
	Left Ventricular Failure	Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	16 DAY
			Cozaar	C				
			Acetaminophen	C				
			Furosemide	C				

			Isosorbide Mononitrate	C		

Date:06/04/02ISR Number: 3929142-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00188
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aspartate Aminotransferase Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	
	Fatigue		Oil Of Peppermint	C				
			Zolmitriptan	C				

Date:06/04/02ISR Number: 3929143-3Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00091
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoglycaemia	Foreign Health	Tab Vioxx (Rofecoxib)	PS		INTRAVENOUS	SEE IMAGE	
		Professional	Atorvastatin Calcium	C				
			Chlorthalidone	C				
			Digoxin	C				
			Insulin, Isophane	C				

Insulin, Neutral	C
Isosorbide Mononitrate	C
Lisinopril	C
Warfarin	C

Date:06/04/02ISR Number: 3929144-5Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00110
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	10 MON
Initial or Prolonged		Professional						

Date:06/04/02ISR Number: 3929145-7Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00030
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Life-Threatening	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	11 DAY	
Hospitalization -	Femur Fracture		Aspirin Lysine	SS		ORAL	325 MG/DAILY	2439 DAY
Initial or Prolonged	Gastric Ulcer Haemorrhage							
	Hypovolaemic Shock							
	Intestinal Ischaemia							
	Multi-Organ Failure							
	Oesophagitis							
	Renal Impairment							
	Septic Shock							
	Shock Haemorrhagic							

Date:06/04/02ISR Number: 3929174-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02768
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO

Date:06/04/02ISR Number: 3929175-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Myocardial Infarction	Professional Company Representative						

Date:06/04/02ISR Number: 3929177-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
	Back Pain
Other	Difficulty In Walking
	Hypoaesthesia

	Iatrogenic Injury						
	Monoplegia						
	Pain In Extremity	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Phlebitis	Consumer	Tab Vioxx 25mg	PS		ORAL	PO
	Sensory Loss	Health	Omega-3	C			
	Thermal Burn	Professional	Percocet	C			
	Thrombosis		Ginkgo Biloba Extract	C			

Date:06/04/02ISR Number: 3929217-7Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00050
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain	Foreign	Tab Vioxx				
Hospitalization -	Intestinal Infarction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY
Initial or Prolonged		Professional					

Date:06/04/02ISR Number: 3929220-7Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00035
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia	Foreign	Tab Vioxx				
Initial or Prolonged	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY
	Helicobacter Infection	Professional	Acetaminophen	C			
			Viloxazine Hcl	C			

Date:06/04/02ISR Number: 3929221-9Report Type:Expedited (15-DaCompany Report #WAES 0201FRA00078
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Bradycardia	Foreign	Tab Vioxx				
Hospitalization -	Haemodialysis	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY 5 DAY
Initial or Prolonged	Hyperkalaemia		Cystine	C			

	Renal Failure Acute		Perindropril	C
			Spironolactone	C

Date:06/04/02ISR Number: 3929869-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03392
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Pharyngeal Haemorrhage	Professional					MG/DAILY/PO	
Disability	Post Procedural	Company	Vicodin Tablets	C				
Other	Haemorrhage	Representative	Amoxicillin	C				

Date:06/04/02ISR Number: 3929882-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA01871
Age:54 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
	Blood Amylase Increased
	Blood Pressure Decreased
	Body Temperature
	Decreased
	Dysstasia

	Gastritis Haemorrhagic						
	Heart Rate Increased						
	Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oliguria	Health	Tab Vioxx	PS		ORAL	PO	
	Renal Impairment	Professional	Prednisone 10 Mg	SS			10 MG/DAILY	
	Upper Gastrointestinal Haemorrhage	Company Representative	Plaquenil	C				
			Prinivil	C				
	Viral Infection		Synthroid	C				
			Metoprolol	C				

Date:06/05/02ISR Number: 3927967-XReport Type:Expedited (15-DaCompany Report #WAES 0205FRA00061
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	78	DAY
Initial or Prolonged	International Normalised Ratio Increased	Professional	Acenocoumarol	SS				
			Amiodarone Hydrochloride	C				
			Digoxin	C				
			Allopurinol	C				
			Felodipine	C				

Date:06/05/02ISR Number: 3927970-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain	Professional						

Date:06/05/02ISR Number: 3927974-7Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Arthralgia Difficulty In Walking Dyspnoea Face Oedema Oropharyngeal Swelling Palpitations Sensation Of Heaviness Tongue Oedema Vision Blurred

Date:06/05/02ISR Number: 3927977-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00220
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Reflux Oesophagitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Professional	Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/02ISR Number: 3927978-4Report Type:Expedited (15-DaCompany Report #WAES 0205FRA00060
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged		Professional	Warfarin Sodium	C				
			Cicletanine Hydrochloride	C		ORAL		
			Acetaminophen And Belladonna And Caffeine And Opium	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Lansoprazole	C		ORAL		
			Bromazepam	C		ORAL		
			Adenosine Phosphate	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		
			Ambroxol	C		ORAL		

Date:06/05/02ISR Number: 3927980-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA03593
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization -			Prinivil	C		ORAL		
Initial or Prolonged			Propranolol	C				
			Zocor	C		ORAL		
			Cartia (Diltiazem Hydrochloride)	C				
			Metoprolol Tartrate	C				

Date:06/05/02ISR Number: 3930350-4Report Type:Expedited (15-DaCompany Report #N134750
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy Disorientation Drug Ineffective Gastrointestinal Haemorrhage Haematocrit Decreased Leukopenia Mucosal Membrane Hyperplasia Myocardial Infarction Platelet Count Decreased	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG/2 DAYS - TIME TO ONSET : 2 DAYS	2 DAY
			Asa - (Acetylsalicylic Acid)	SS		ORAL	325 MG/ 6 DAYS - TIME TO ONSET : 6 DAYS	6 DAY
			Methylprednisolone	SS			250 MG/ 2 DAYS - TIME TO ONSET : 2 DAYS	2 DAY
			Nsaid'S - Rofecoxib	SS		ORAL	25MG/ 1 DAY - TIME TO ONSET : 3	

DAYS 1 DAY

	Serumlipidreducing Agents	SS

3 DAYS -

TIME TO ONSET

: 5 DAYS 3 DAY

	Heparin	C
	Zantac (Ranitidine Hydrochloride)	C
	Vitamin E	C
	Levofloxacin	C
	Haldol (Haloperidol)	C
	Terazosin	C
	Diphenhydramine	C
	Metoprolol	C

Date:06/05/02ISR Number: 3932164-8Report Type:Expedited (15-DaCompany Report #NSADSS2002009867
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial	Foreign	Remicade (5 Mg/Ml			
Hospitalization -	Infarction	Study	Lyphilized Powder)			
Initial or Prolonged	Blood Glucose Increased	Health	(Infliximab,			
Other	Bronchospasm	Professional	Recombinant)	PS		
INTRAVENOUS 300 MG, 1 IN						
Required	Bundle Branch Block Left					
1 TIME(S), IV						
Intervention to	Cardiac Failure		Vioxx (Rofecoxib)	SS		
25, DAILY						
Prevent Permanent	Congestive		Methotrexate			
Impairment/Damage	Condition Aggravated		(Methotrexate)	SS		
7.5 MG, 1 IN						
	Cyanosis					
1 WEEK(S)						
	Drug Toxicity		Feldene (Piroxicam)	C		
	Duodenal Ulcer		Enconcor	C		
	Haemorrhage		Dilutol (Torsemide)	C		
	Dyspnoea		Karvia	C		
	Left Ventricular Failure		Isocover	C		
	Pulmonary Fibrosis		Pulmicort(Budesonide			
	White Blood Cell Count		)	C		
	Increased		Atrovent			

				(Ipratropium Bromide)	C		
				Nitroderm (Glyceryl Trinitrate)	C		
				Plenur (Lithium Carbonate)	C		
				Oxis (Formoterol)	C		

Date:06/06/02ISR Number: 3928644-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00121
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
		Professional	Flunitrazepam	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Risperidone	C		ORAL		
			Cholecalciferol	C		ORAL		
			Acetaminophen And Aspirin And Caffeine And Codeine Phosphate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/02ISR Number: 3928648-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02941
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Duodenitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		[Therapy Unspecified]	C				
	Oesophageal Ulcer		Zestril	C				
	Upper Gastrointestinal Haemorrhage		Chondroitin And Glucosamine	C				

Date:06/06/02ISR Number: 3928663-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA03417
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardio-Respiratory Arrest		Naproxen	SS				
	Gastric Haemorrhage		Clozapine	SS				
			Naproxen	SS			1	DAY
			Chlorpromazine	SS				
			Folic Acid	C				
			Vitamins (Unspecified)	C				
			Levothyroxine Sodium	C				
			Chlorzoxazone	C				
			Gabapentin	C		ORAL		
			Gabapentin	C		ORAL		
			Nefazodone Hydrochloride	C		ORAL		
			Clonazepam	C				
			Oxycodone	C				
			Oxycodone	C				
			Ascorbic Acid	C				

Date:06/06/02ISR Number: 3928665-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	
3 WK						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional				

Date:06/06/02ISR Number: 3928666-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA03554
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Paxil	C		
Disability						

Date:06/06/02ISR Number: 3928667-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA03466
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
			Risperdal	C		
			Codeine	C		
			[Therapy			

Unspecified] C

Date:06/06/02ISR Number: 3928668-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03555
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Fosamax	C		ORAL

Date:06/06/02ISR Number: 3928672-6Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adrenal Insufficiency	Health	Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Blood Creatinine Increased	Professional	Valsartan	SS		
	Nephropathy					

Date:06/06/02ISR Number: 3928674-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03418
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Pulmonary Fibrosis		Vioxx	PS	Merck & Co., Inc	ORAL
Other			Premarin	C		
			Provera	C		
			Voltaren	C		
			Dilantin	C		
			Claritin	C		
			Actonel	C		
			Effexor	C		
			Lamictal	C		
			Paxil	C		

Date:06/06/02ISR Number: 3928675-1Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00002
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Thrombocytopenia		Fosamax	C		ORAL		DAY

Date:06/06/02ISR Number: 3928683-0Report Type:Expedited (15-DaCompany Report #WAES 01105153
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscle Spasms	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional	Vioxx	SS		ORAL		17 DAY
Disability			Citalopram Hydrobromide	C				
			Isosorbide Mononitrate	C				
			Levothyroxine Sodium	C				
			Vitamin B (Unspecified)	C				
			Furosemide	C				
			Gastrointestinal Preparations (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/02ISR Number: 3928687-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA03550
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged	Diarrhoea	Professional	Celexa	C				
	Nausea							
	Vomiting							

Date:06/06/02ISR Number: 3928930-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA00335
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:06/06/02ISR Number: 3928933-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
			Atacand	C				
			Flovent	C				
			Combivent	C				
			Zoloft	C				
			Coreg	C				
			Plavix	C				
			Aspirin	C				
			Vitamin E	C				

Date:06/06/02ISR Number: 3928934-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00269
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Gastrointestinal	Aspirin	C
	Haemorrhage	Levoxyl	C
	Ulcer	Nifedipine	C
		Lipitor	C
		Hydrodiuril	C

Date:06/06/02ISR Number: 3928937-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA03162
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Celebrex	C				
Other								

Date:06/06/02ISR Number: 3929853-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02553
Age:79 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Arthralgia
	Asthenia

		Blood Albumin Abnormal					
		Blood Creatinine Abnormal					
		Blood Glucose Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Urea Abnormal	Health	Tab Vioxx	PS		ORAL
PO							
		Chest Wall Pain	Professional	Septra	C		
		Dehydration					
		Discomfort					
		Diverticulum					
		Duodenal Stenosis					
		Duodenitis					
		Eating Disorder					
		Erythema					
		Faeces Discoloured					
		Fall					
		Flatulence					
		Gastric Ulcer Haemorrhage					
		Gastrointestinal					
		Obstruction					
		Haemorrhage					
		Haemorrhoids					
		Hiatus Hernia					
		Platelet Count Decreased					
		Retching					
		White Blood Cell Count					
		Abnormal					

Date:06/06/02ISR Number: 3929854-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PM/PO							
		Asthenia	Professional	Bromfed	C		
		Difficulty In Walking		Decadron			
		Dysstasia		(Dexamethasone)	C		
		Fatigue		Prilosec	C		
		Lethargy		Serevent	C		
		Muscle Rigidity		Singulair	C		
		Nervous System Disorder					
		Vertigo					

Date:06/06/02ISR Number: 3930108-6Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00157
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malignant Hypertension Retinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY, PO	
			Atorvastatin Calcium	C				
			Candesartan Cilexetil	C				
			Estradiol	C				
			Nicotine	C				
			Quinapril Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/02ISR Number: 3930112-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02439
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health	Tab Vioxx	PS		ORAL	PRN/PO	
	Dizziness	Professional	Plavix 75 Mg	SS				
	Faeces Discoloured	Company						
	Gastrointestinal	Representative						
	Haemorrhage							

Date:06/06/02ISR Number: 3930223-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00018
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Biopsy Rectum Abnormal	Literature	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Colitis Ulcerative	Other						
	Condition Aggravated						PO; 25 MG/DAILY PO	1 WK
	Cytomegalovirus Antigen Positive		Mesalamine	C				
	Cytomegalovirus Infection							
	Drug Ineffective							
	Frequent Bowel Movements							
	Haematochezia							
	Laboratory Test Abnormal							
	Sigmoidoscopy Abnormal							

Date:06/06/02ISR Number: 3930224-9Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00076
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Foreign	Tab Vioxx					
Hospitalization -	Cerebrovascular Accident	Other	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
Initial or Prolonged	Hyperhidrosis							
							PO	2 DAY

			Flupirtine Maleate	C		

Date:06/06/02ISR Number: 3930225-0Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00095
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Fall	Foreign	Tab Vioxx			
Hospitalization -	Gastric Haemorrhage	Other	(Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
Initial or Prolonged	Gastric Ulcer					
PO 4 MON						
	Hip Fracture		Dipyridamole	C		
	Melaena		Metoclopramide			
			Hydrochloride	C		
			Molsidomine	C		
			Propoxyphene Hcl	C		
			Spironolactone	C		
			Tramadol Hcl	C		

Date:06/06/02ISR Number: 3930570-9Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00129
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Prescribed Overdose	Foreign	Tab Vioxx			
		Health	(Rofecoxib)	PS		ORAL
25 MG/BID, PO 20 DAY						
		Professional	Clomipramine Hcl	C		

				Sumatriptan Succinate	C		

Date:06/07/02ISR Number: 3929277-3Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Systemic Lupus		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Erythematosus		Levothyroxine Sodium	C				
			Omeprazole	C				
			Ibuprofen	C				
TOPICAL			Hydroxychloroquine Sulfate	C				

Date:06/07/02ISR Number: 3929278-5Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00011
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS		ORAL		
Initial or Prolonged	Complete		Acetazolamide	C	Merck & Co., Inc	ORAL	3	DAY
	Fatigue							
	Palpitations							

Date:06/07/02ISR Number: 3929281-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA01381
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS		ORAL		
Other	Hypertension		Celebrex	C				
	Oedema		[Therapy Unspecified]	C				
			Bextra	C				

Date:06/07/02ISR Number: 3929282-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
			Lopressor	C				
			Prinivil	C				
			Premarin	C				

Date:06/07/02ISR Number: 3929283-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Pulmonary Oedema
Life-Threatening	Anuria
Hospitalization - Initial or Prolonged	Diarrhoea
	Heart Rate Decreased
	Hypotension
	Loss Of Consciousness
	Organ Failure
	Shock

Ventricular Arrhythmia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Sirdalud	C		ORAL		
			Coltramyl	C		ORAL		
			Mydocalm	C		ORAL		
			[Therapy Unspecified]	C				
			[Composition Unspecified]	C				

Date:06/07/02ISR Number: 3929284-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cognitive Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemiparesis		Lopid	C				
	Ischaemic Stroke		Inderal	C				
	Migraine		Allegra	C				
	Transient Ischaemic Attack		Premarin	C		ORAL		
			Vitamin E	C				
			Vitamins (Unspecified)	C				
			Plavix	C				
			Zestril	C				
			Metformin	C				
			Folic Acid	C				
			Mobic	C				
			Wellbutrin	C				

Date:06/07/02ISR Number: 3929286-4Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00139
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
	Abdominal Pain Upper		Etidronate Disodium	C		ORAL		

Date:06/07/02ISR Number: 3929288-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00231
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations		Pepcid	C		ORAL		
			Glucotrol Xl	C				
			Vitamins (Unspecified)	C				

Date:06/07/02ISR Number: 3929290-6Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00003
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Exanthem		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/02ISR Number: 3929292-XReport Type:Expedited (15-DaCompany Report #WAES 0206NOR00001
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Hospitalization - Initial or Prolonged	Haematemesis		Aspirin And Magnesium Oxide	SS		ORAL		
	Hypotension		Clarithromycin	C		ORAL		
	Melaena		Lisinopril	C		ORAL		
	Myocardial Infarction		Senna	C		ORAL		
			Furosemide	C		ORAL		
			Nitrazepam	C		ORAL		
			Fusidic Acid	C		OPHTHALMIC		
			Metoclopramide Hydrochloride	C		ORAL		
			Lactulose	C				
			Acetaminophen	C		ORAL		
			Minerals (Unspecified) And Vitamins (Unspecified)	C		ORAL		
			Estradiol	C		ORAL		

Date:06/07/02ISR Number: 3929428-0Report Type:Direct Company Report #CTU 169698
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Prerenal Failure		Vioxx 25 Mg	PS		ORAL	25MG DAILY ORAL	
	Cardiac Failure							
	Congestive		Pletal 100 Mg	SS		ORAL	100MG TWICE DAILY ORAL	
			Toprol Xl	C				
			Lanoxin	C				
			Zocor	C				
			Procardia	C				

Date:06/07/02ISR Number: 3930587-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03359
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Hypertension	Professional Company Representative						

Date:06/07/02ISR Number: 3930588-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02867
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Health	Tab Vioxx 25 Mg ;					
	Deep Vein Thrombosis	Professional	Unk	PS		ORAL	PO ; PO	
			Aldactone	C				
			Tegretol	C				
			Nortriptyline	C				

Date:06/07/02ISR Number: 3930589-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA03593
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Tab Vioxx Unk	PS		ORAL	1	
Hospitalization -	Myocardial Infarction						TABLET/DAILY/	
Initial or Prolonged							PO	
			Cartia (Diltiazem Hydrochloride)	C				
			Prinivil	C				
			Zocor	C				
			Metoprolol Tartrate	C				
			Propranolol	C				

Date:06/07/02ISR Number: 3930590-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01088
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Health					MG/DAILY/PO	
		Professional						

Date:06/07/02ISR Number: 3930592-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02437
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Hidradenitis	Professional					MG/DAILY/PO	
	Rash	Company Representative						

Date:06/07/02ISR Number: 3930595-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01963
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO ;	
	Grand Mal Convulsion	Professional						
	Leukopenia	Company						
	Liver Function Test Abnormal	Representative						
	Malaise							
	Nuclear Magnetic Resonance Imaging Abnormal							
	Splenomegaly							
	Viral Infection							

Date:06/07/02ISR Number: 3930597-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Respiratory Distress Syndrome
Life-Threatening	Dyspnoea
Hospitalization - Initial or Prolonged	Lung Disorder
Disability	Lung Infiltration
	Productive Cough
	Pulmonary Arterial Wedge

	Pressure Increased Red Blood Cell Sedimentation Rate Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Respiratory Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO
			Herbs	C			

Date:06/07/02ISR Number: 3930704-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO
	Difficulty In Walking Dyspnoea		Diltiazem Hydrochloride	C			

Date:06/07/02ISR Number: 3930916-1Report Type:Expedited (15-DaCompany Report #WAES 0205FRA00060
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO 22 DAY
			Acetaminophen (+)				
			Belladonna (+)				
			Caffein	C			
			Adenosine Phosphate	C			
			Ambroxol	C			
			Bromazepam	C			
			Chondroitin Sulfate Sodium	C			
			Cicletanine Hcl	C			
			Lansoprazole	C			
			Sotalol Hydrochloride	C			
			Tamsulosin Hydrochloride	C			
			Trimetazidine				

Hydrochloride	C
Warfarin Sodium	C

Date:06/07/02ISR Number: 3930929-XReport Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Arthralgia Difficulty In Walking Dyspnoea Face Oedema Oropharyngeal Swelling Palpitations Sensation Of Heaviness Tongue Oedema Vision Blurred	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/02ISR Number: 3930933-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00213
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux Disease	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Peptic Ulcer							
PO							55	DAY
			Acetaminophen (+) Dihydrocodeine Bitartr	C				

Date:06/07/02ISR Number: 3930945-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00220
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Reflux Oesophagitis	Foreign	Tab Vioxx					
Hospitalization -	Upper Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	12.5 MG/ PO	
Initial or Prolonged	Haemorrhage		Aspirin	C				

Date:06/07/02ISR Number: 3930960-4Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00041
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Cancer	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	16 DAY
Disability		Professional	Acetaminophen	C				

Date:06/07/02ISR Number: 3930961-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00201
Age:71 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					

Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena	Other	(Rofecoxib)	PS		ORAL 1 WK

Date:06/07/02ISR Number: 3930963-XReport Type:Expedited (15-DaCompany Report #WAES 0205GBR00194
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Blindness Transient Visual Acuity Reduced	Foreign Health Professional	Tab Vioxx (Rofecoxib) Therapy Unspecified	PS C		ORAL

Date:06/07/02ISR Number: 3930964-1Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00151
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Nephrotic Syndrome	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL 25 MG/DAILY 4 WK
		Professional	Tab Piroxicam	SS		ORAL 2 WK
			Dipiproverine Dihcl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/02ISR Number: 3930966-5Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00066
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	1 DAY
			Aspirin	C				

Date:06/07/02ISR Number: 3931062-3Report Type:Expedited (15-DaCompany Report #WAES 0205FRA00061
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction International Normalised Ratio Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	78	DAY
	Phlebitis		Acenocoumarol	SS				
			Allopurinol	C				
			Amiodarone Hydrochloride	C				
			Digoxin	C				
			Felodipine	C				

Date:06/07/02ISR Number: 3931063-5Report Type:Expedited (15-DaCompany Report #WAES 0205IT00052
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	
Hospitalization - Initial or Prolonged	Melaena						PO	5 DAY
	Shock		Benserazide Hydrochloride (+)					
			Levodopa	C				
			Carbidopa/Levodopa	C				
			Digoxin	C				
			Furosemide	C				
			Nitroglycerin	C				
			Paroxetine Hcl	C				

				Valsartan	C		

Date:06/07/02ISR Number: 3931091-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Hospitalization - Initial or Prolonged								

Date:06/07/02ISR Number: 3931092-1Report Type:Expedited (15-DaCompany Report #N134750
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Disorientation	Health Professional	Plavix (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG, ORAL	2 DAY
	Drug Ineffective							
	Gastrointestinal							
	Haemorrhage		Asa-(Acetylsalicylic Acid)	SS		ORAL	325 MG, ORAL	6 DAY
	Leukopenia							
	Myocardial Infarction							
	White Blood Cell Count		Methylprednisolone	SS			250MG	2 DAY
	Decreased		Nsaid'S (Rofecoxib)	SS		ORAL	25MG, ORAL	1 DAY

				Serumlipidreducing Agents	SS		
3	DAY						
				Heparin	C		
				Zantac (Ranitidine Hydrochloride)	C		
				Vitamin E	C		
				Levofloxacin	C		
				Haldol (Haloperidol)	C		
				Terazosin	C		
				Diphenhydramine	C		
				Metoprolol	C		

Date:06/07/02ISR Number: 3931245-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA03549
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Zyrtec	C				
			Quinine Sulfate	C				

Date:06/10/02ISR Number: 3929967-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00462
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/02ISR Number: 3929970-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00226
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventricular Extrasystoles		Doxazosin	C		ORAL		

Doxazosin	C			ORAL
Bendroflumethiazide	C			ORAL

Date:06/10/02ISR Number: 3929971-4Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Oedema							

Date:06/10/02ISR Number: 3929976-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA00328
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Prinivil	C				
			Prilosec	C				
			Flomax (Tamsulosin Hydrochloride)	C				
			Urocit-K	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/02ISR Number: 3929977-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA00272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/02ISR Number: 3929978-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01372
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dehydration Fatigue Gastrointestinal Haemorrhage Laboratory Test Abnormal Malaise Myocardial Infarction Nausea Syncope	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/02ISR Number: 3929985-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00015
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Spironolactone	C		ORAL		
			Althiazide And Spironolactone	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:06/10/02ISR Number: 3929987-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension	Professional	Sodium Folate	C				
Disability			Goserelin Acetate	C				
			Cyproterone Acetate	C				
			Methotrexate	C				

Date:06/10/02ISR Number: 3929990-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00227
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	19 DAY	
	Melaena	Professional						

Date:06/10/02ISR Number: 3929991-XReport Type:Expedited (15-DaCompany Report #WAES 0205AUS00153
Age:54 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Occlusion	Health Professional	Vioxx	PS	Merck & Co., Inc			

Date:06/10/02ISR Number: 3929997-0Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00003
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholestasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	84 DAY	
Initial or Prolonged	Hepatocellular Damage	Professional						
	Liver Function Test Abnormal							

Date:06/10/02ISR Number: 3930000-7Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00026
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amyotrophic Lateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL	294 DAY	
	Sclerosis	Professional	Irbesartan	C		ORAL		

Date:06/10/02ISR Number: 3930085-8Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11882214
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura		Coumadine	PS	Bristol-Myers Squibb Company	ORAL	47 DAY	
Initial or Prolonged								
			Vioxx	SS		ORAL	5 DAY	
			Lamaline	SS		ORAL	5 DAY	
			Lasilix	SS		ORAL	20 ("Lasilex Fabile")-40 MG	47 DAY
			Ferrostrane	C		ORAL	47 DAY	
			Solupred	C			10 YR	
			Esberiven	C				

			Cytotec	C		
			Antibiotic	C		

Date:06/10/02ISR Number: 3930253-5Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00076
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Diltiazem Hydrochloride	C		ORAL
			Allopurinol	C		ORAL
			Ramipril	C		ORAL
			Nebivolol Hydrochloride	C		ORAL
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL

Date:06/10/02ISR Number: 3930254-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00212
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
68 DAY						
	Inadequately Controlled		Bendroflumethiazide	C		ORAL
			Alendronic Acid	C		ORAL
			Atenolol	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/02ISR Number: 3930256-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Rosaprostol	C				
	Nausea		Lasix (Furosemide)	C		ORAL		
			Zestril	C		ORAL		
			Digoxin	C		ORAL		
			Glucosamine	C				

Date:06/10/02ISR Number: 3930260-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00754
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
			Vioxx	SS		ORAL		

Date:06/10/02ISR Number: 3930265-1Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00010
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
Initial or Prolonged	Gastrointestinal Necrosis		Diacerein	C				

Date:06/10/02ISR Number: 3930853-2Report Type:Direct Company Report #CTU 169792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Rofecoxib 25mg	PS		ORAL	SEE IMAGE	
Initial or Prolonged	Congestive							
	Cough							
	Dyspnoea							

Date:06/11/02ISR Number: 3930715-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01326
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/11/02ISR Number: 3930720-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01097
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Lipitor	C				
			Univasc	C				
Other	Myocardial Infarction		Coumadin	C				
			Lasix (Furosemide)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/02ISR Number: 3930724-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03554
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL	4	DAY
Disability			Paxil	C				

Date:06/11/02ISR Number: 3930726-5Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial Thromboplastin Time Prolonged	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C		ORAL		
	Acute Myocardial Infarction		Acetaminophen And Hydrocodone Bitartrate	C		ORAL		
	Alanine Aminotransferase Increased		Zydone	C		ORAL		
			Pertussin N	C		ORAL		
	Anaphylactic Reaction		Accolate	C		ORAL		
	Arrhythmia		Claritin	C		ORAL		
	Blood Pressure Increased		Pravachol	C		ORAL		
	Cardiac Arrest		Paxil	C		ORAL		
	Cardiac Disorder		Flonase	C		ORAL		
	Cardio-Respiratory Arrest		Toradol	C		ORAL		
	Circulatory Collapse		Remeron	C		ORAL		
	Condition Aggravated		Nystatin	C		ORAL		
	Contusion		Biaxin	C		ORAL		
	Exsanguination		Depo-Provera	C		INTRAMUSCULAR		
	Gastrointestinal Disorder		Hydrocortisone Acetate	C				
	Gastrointestinal Haemorrhage		Skelaxin	C		ORAL		
	Haematemesis		Tequin	C		ORAL		
	International Normalised Ratio Increased		Alupent	C		RESPIRATORY (INHALATION)		
	Large Intestinal Ulcer		Serevent	C		RESPIRATORY (INHALATION)		
	Haemorrhage							

	Oedema	Flovent	C	
RESPIRATORY				
	Oesophageal Ulcer			
(INHALATION)				
	Haemorrhage	Buspar	C	ORAL
	Platelet Count Decreased	Lipitor	C	ORAL
	Prothrombin Time	Amaryl	C	ORAL
	Prolonged	Percocet	C	ORAL
	Rib Fracture	Pramoxine		
	Sudden Cardiac Death	Hydrochloride	C	
TOPICAL				
		Premarin	C	ORAL
		Proventil	C	
RESPIRATORY				
(INHALATION)				
		Demerol	C	ORAL
		Alprazolam	C	ORAL
		Carisoprodol	C	ORAL
		Aquaphor	C	
		Promethazine	C	

Date:06/11/02ISR Number: 3930727-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea	Professional	Roxilox	SS		ORAL		
	Pyrexia		Serevent	C				
RESPIRATORY								
	Vomiting							
(INHALATION)								
			Lanoxin	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Accupril	C				
			Aspirin	C				
			Singulair	C				

Date:06/11/02ISR Number: 3930729-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA01448
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization -	Abdominal Pain Upper	Professional						
Initial or Prolonged	Asthenia							
	Chills							
	Cold Sweat							
	Dehydration							
	Diarrhoea							
	Dizziness							
	Feeling Cold							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							
	Haematuria							
	Intestinal Obstruction							
	Ketonuria							
	Leukocytosis							
	Mallory-Weiss Syndrome							
	Migraine							
	Oesophagitis							
	Oral Intake Reduced							
	Pyrexia							

Renal Neoplasm
Tremor
Visual Acuity Reduced
Vomiting
Weight Decreased

Date:06/11/02ISR Number: 3931011-8Report Type:Direct Company Report #CTU 169860
Age:61 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Hyperkalaemia		Vioxx 25	PS		ORAL	PO QD	
Intervention to Prevent Permanent Impairment/Damage			Oscal & D	C				
			Mvi	C				
			Amitriptyline	C				
			***	C				
			Fosamax	C				

Date:06/11/02ISR Number: 3931096-9Report Type:Expedited (15-DaCompany Report #WAES 0206DNK00007
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		214 DAY
Hospitalization - Initial or Prolonged	Haemorrhage	Professional	Zocor	C				
			Acetaminophen	C				
			Quinine Hydrochloride	C				
			Propoxyphene Hydrochloride	C				
			Oxazepam	C				

Date:06/11/02ISR Number: 3931098-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00050
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Metoprolol	C		ORAL		
			Prinivil	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:06/11/02ISR Number: 3931101-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00313
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		561 DAY
	Congestive		Methadone Hydrochloride	C		ORAL		
			Norco	C		ORAL		
			Soma	C		ORAL		
			Effexor Xr	C		ORAL		

Date:06/11/02ISR Number: 3931102-1Report Type:Expedited (15-DaCompany Report #WAES 0206DNK00009
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Gastritis	Professional	Vioxx	SS		ORAL	44	DAY
			Celecoxib	SS		ORAL	8	DAY

Date:06/11/02ISR Number: 3931105-7Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00021
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged	Melaena	Professional	Anastrozole	C		ORAL		
			Omeprazole	C		ORAL		
			Bumetanide	C		ORAL		
			Acetaminophen	C		ORAL		
			Diazepam	C		ORAL		
			Amiloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/02ISR Number: 3931107-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00417
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	C				
			Lanoxin	C				
			Prevacid	C				

Date:06/11/02ISR Number: 3931108-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00368
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Panic Attack	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
	Suicidal Ideation		Estrace	C				
	Thyroid Function Test Abnormal		Toprol Xl Tablets	C				
			Synthroid	C				

Date:06/11/02ISR Number: 3931110-0Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00010
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Ascites		Diacerein	C				
	Condition Aggravated							
	Gastrointestinal Necrosis							
	Pancreatitis							

Date:06/11/02ISR Number: 3931114-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage							

Date:06/11/02ISR Number: 3931115-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00662
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		121 DAY
Initial or Prolonged	Oedema Peripheral		Aspirin	C				
			Vitamin E	C				
			Prilosec	C				

Date:06/11/02ISR Number: 3933285-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 50 Mg	PS				
PRN							3	WK
Hospitalization -	Gastrointestinal	Professional						
Initial or Prolonged	Haemorrhage	Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/02ISR Number: 3933287-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03555
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Fosamax	C				

Date:06/11/02ISR Number: 3933288-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03550
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Diarrhoea	Professional					MG/DAILY/PO	3 MON
	Nausea		Celexa	C				
	Vomiting							

Date:06/11/02ISR Number: 3933417-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03417
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apnoea	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Arrhythmia	Professional					MG/DAILY/PO	
	Cardiac Arrest		Naproxen Unk	SS			SEE IMAGE	
	Gastric Haemorrhage		Clozapine Unk	SS			250 MG/HS	
	Haematocrit Abnormal		Chlorpromazine Unk	SS			200 MG/HS	
	Haemoglobin Abnormal		Ascorbic Acid	C				
	Platelet Count Abnormal		Chlorzoxazone	C				
	Red Blood Cell Count Abnormal		Clonazepam	C				
			Folic Acid	C				
	Weight Decreased		Gabapentin	C				

	White Blood Cell Count		Levothyroxine Sodium	C
	Abnormal		Nefazodone Hydrochloride	C
			Oxycodone	C
			Vitamins	C

Date:06/11/02ISR Number: 3933418-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03418
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Antibody Test Positive	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other	Blood Carbon Monoxide	Professional					MG/DAILY/PO	
	Decreased		Actonel	C				
	Cough		Claritin	C				
	Dyspnoea		Dilantin	C				
	Fatigue		Effexor	C				
	Inflammation		Lamictal	C				
	Influenza Like Illness		Paxil	C				
	Lung Infiltration		Premarin	C				
	Parotid Gland Enlargement		Provera	C				
	Pulmonary Congestion		Voltaren	C				
	Pulmonary Fibrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/02ISR Number: 3933419-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA03466
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Risperdal	C				
			Codeine	C				

Date:06/11/02ISR Number: 3933420-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03554
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Low Density Lipoprotein	Professional					MG/DAILY/PO	
Disability	Decreased	Company Representative	Paxil	C				

Date:06/11/02ISR Number: 3933728-8Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00002
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma	Foreign	Tab Vioxx					
Initial or Prolonged	Thrombocytopenia	Health	(Rofecoxib)	PS		ORAL	PO	MON
		Professional	Fosamax	C				

Date:06/11/02ISR Number: 3933753-7Report Type:Expedited (15-DaCompany Report #WAES 01105153
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscle Spasms	Foreign	Tab Vioxx					
Initial or Prolonged		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

Disability Professional
PO; 12.5

MG/DAILY PO 17 DAY

Citalopram	C
Furosemide	C
Gastrointestinal Preparations (Unspecified)	C
Isosorbide Mononitrate	C
Levothyroxine Na	C
Vitamin B (Unspecified)	C

Date:06/11/02ISR Number: 3933755-0Report Type:Expedited (15-DaCompany Report #WAES 01117030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adrenal Insufficiency Blood Creatinine Increased Nephropathy	Foreign Other	Tab Vioxx (Rofecoxib) Valsartan	PS SS		

Date:06/11/02ISR Number: 3933757-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00121
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Influenza	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG DAILY	PO 10 DAY
			Acetaminophen (+) Aspirin - (+)					
			Caffeine	C				
			Cholecalciferol	C				
			Flunitrazepam	C				
			Paroxetine Hcl	C				
			Risperidone	C				

Date:06/11/02ISR Number: 3934996-9Report Type:Expedited (15-DaCompany Report #NSADSS2002001976
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased Cholelithiasis	Foreign Study Health Professional	Remicade (5 Mg/Ml Lyophilized Powder) (Infliximab, Recombinant)	PS		INTRAVENOUS	5 MG/KG, 1 IN 1 DAILY, IV	
			Vioxx (Rofecoxib)	SS		INTRAVENOUS	25 MG, 1 IN 1 DAILY, IV	
			Tramadol Hydrochloride Ir (Tablet) (Tramadol Hydrochloride)	SS			150 MG, 1 IN 1 DAILY	

Date:06/12/02ISR Number: 3931567-5Report Type:Direct Company Report #CTU 169915
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Anaemia Bone Marrow Depression Cardiac Failure Congestive Cerebrovascular Accident Confusional State Endocarditis Flushing Gastrointestinal Haemorrhage Hypertension Liver Disorder Liver Function Test Abnormal Pancytopenia Pruritus Pulmonary Oedema Rash Renal Disorder Vomiting		Vioxx-25mg-Merck And Co	PS	Merck And Co		1 DAILY	

Date:06/12/02ISR Number: 3931848-5Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Arthralgia Difficulty In Walking Dyspnoea Face Oedema Oropharyngeal Swelling Palpitations Sensation Of Heaviness Tongue Oedema Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/02ISR Number: 3931849-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Viral		Vioxx Wellbutrin	PS C	Merck & Co., Inc	ORAL		

Date:06/12/02ISR Number: 3931850-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02261
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	6	WK

Date:06/12/02ISR Number: 3931853-9Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00020
Age:79 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
77 DAY						
Hospitalization - Initial or Prolonged	Haemorrhage		Acetaminophen	C		ORAL
	Oesophagitis		Amiloride Hydrochloride And Furosemide	C		ORAL
			Dihydrocodeine	C		ORAL

Date:06/12/02ISR Number: 3931854-0Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00007
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Ulcer		Aspirin And Magnesium Oxide	SS		
	Melaena		Metoprolol Tartrate	C		
			Amlodipine Besylate	C		
			Timolol Maleate	C		
OPHTHALMIC						
			Zopiclone	C		
			Sennosides	C		
			Nitroglycerin	C		
			Diazepam	C		
			Aluminum Hydroxide And Magnesium			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Carbonate And
Magnesium Hydroxide C

Date:06/12/02ISR Number: 3931924-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01250
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia							
	Dyspnoea							
	Syncope							
	Tachycardia							

Date:06/12/02ISR Number: 3931925-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02756
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hypertension		Vioxx	SS		ORAL		
	Joint Swelling							
	Malaise							
	Rheumatoid Factor Positive							
	Soft Tissue Inflammation							
	Swelling							

Date:06/12/02ISR Number: 3931929-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02123
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	80 DAY	
Other	Confusional State							
	Dizziness							
	Hallucination, Visual							
	Nausea							

Date:06/12/02ISR Number: 3931930-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA00358
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal							

Date:06/12/02ISR Number: 3931934-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
	Back Pain
Other	Difficulty In Walking
	Hypoaesthesia
	Iatrogenic Injury
	Monoplegia
	Pain In Extremity
	Phlebitis
	Road Traffic Accident

	Sensory Loss Thermal Burn Thrombosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Percocet	C			
			Omega-3	C			
			Ginkgo Biloba Extract	C			

Date:06/12/02ISR Number: 3931936-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA00611
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Disturbance In Attention Hypoaesthesia Pain Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/12/02ISR Number: 3931937-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA00877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/12/02ISR Number: 3931941-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA00642
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cystitis Drug Exposure During Pregnancy Pain Pregnancy Vomiting In Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL	3 WK

Date:06/12/02ISR Number: 3931942-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00711
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C				

Date:06/12/02ISR Number: 3931944-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00033
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Interaction		Aspirin	SS		ORAL		
			Bisoprolol And Hydrochlorothiazide	SS		ORAL		
			Molsidomine	C		ORAL		

Date:06/12/02ISR Number: 3931950-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02438
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Weight Decreased		Folic Acid	C		ORAL		
			Oxycontin	C		ORAL		
			Prednisone	C		ORAL		
			Pepcid	C				
			Mercaptopurine	C		ORAL		

Date:06/12/02ISR Number: 3931952-1Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00039
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoantibody Positive		Vioxx	PS	Merck & Co., Inc	ORAL	748	DAY
	Blood Lactate Dehydrogenase Increased							
	Myelodysplastic Syndrome							

Date:06/12/02ISR Number: 3932881-XReport Type:Expedited (15-DaCompany Report #PHNU2001DE02756
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Foreign	Diovan(Valsartan)	PS		ORAL	80 MG, QD,	ORAL
	Pain In Extremity	Health Professional	Vioxx (Rofecoxib)	SS		ORAL	ORAL	
		Other	Wobenzym (Enzymes Nos)	C				
			Crataegutt (Crataegus Extract)	C				

Date:06/12/02ISR Number: 3933208-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00269
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastrointestinal		Hydrodiuril	C				
	Haemorrhage		Levoxyl	C				
	Haematemesis		Lipitor	C				
	Ulcer		Aspirin	C				
			Nifedipine	C				

Date:06/12/02ISR Number: 3933209-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00231
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5	
Initial or Prolonged	Palpitations						MG/DAILY/PO	
			Glucotrol Xl	C				
			Pepcid	C				
			Vitamins	C				

Date:06/12/02ISR Number: 3933283-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02941
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer	Professional	Zestril	C				
Disability	Gastrooesophageal Reflux	Company	Chondroitin (+)					
	Disease	Representative	Glucosamine	C				
	Hiatus Hernia							
	Oesophageal Ulcer							
	Upper Gastrointestinal							
	Haemorrhage							

Date:06/12/02ISR Number: 3933680-5Report Type:Expedited (15-DaCompany Report #WAES 0204GBR00139
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Abdominal Pain Upper	Other	(Rofecoxib)	PS		ORAL	25 MG/UNK PO	26 DAY
			Etidronate Disodium	C				

Date:06/12/02ISR Number: 3933681-7Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00003
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Exanthem	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
							PO	9 DAY

Date:06/12/02ISR Number: 3933683-0Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00001
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abdominal Pain	Foreign	Tab Vioxx			
Hospitalization -	Anaemia	Other	(Rofecoxib)	PS		ORAL
PO 6 MON						
Initial or Prolonged	Blood Albumin Increased		Aspirin (+)			
	Blood Creatinine		Magnesium Oxide	SS		ORAL
PO						
	Increased		Acetaminophen	C		
	Blood Glucose Increased		Clarithromycin	C		
	Blood Potassium Increased		Estradiol	C		
	Fibrin D Dimer Increased		Furosemide	C		
	Gastrointestinal		Fusidic Acid	C		
	Haemorrhage		Lactulose	C		
	Haematemesis		Lisinopril	C		
	Hypotension		Metoclopramide			
	Melaena		Hydrochloride	C		
	Myocardial Infarction		Minerals			
	Pulmonary Congestion		(Unspecified) (+)			
	White Blood Cell Count		Vitamins (Uns	C		
	Increased		Nitrazepam	C		
			Senna	C		

Date:06/12/02ISR Number: 3933684-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00335
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaphylactic Shock	Foreign	Tab Vioxx			
		Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						

PO 4 DAY

Date:06/13/02ISR Number: 3932256-3Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00141
Age:75 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/02ISR Number: 3932386-6Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Fluindione	SS		ORAL		
	International Normalised Ratio Increased							

Date:06/13/02ISR Number: 3932632-9Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00003
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum		Acetaminophen	C				
	Dizziness		Furosemide	C				
	Gastritis Erosive		Vitamins (Unspecified)	C				
	Haemoglobin Decreased		Calcium Acetate	C				
	Upper Gastrointestinal Haemorrhage							

Date:06/13/02ISR Number: 3932634-2Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00004
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged		Haemoglobin Decreased		Ibuprofen	C		ORAL
7 MON							
		Helicobacter Infection					
		Upper Gastrointestinal Haemorrhage					

Date:06/13/02ISR Number: 3932640-8Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY							
Initial or Prolonged		Drug Interaction		Phenobarbital	SS		ORAL
				Phenobarbital	SS		ORAL
				Furosemide	C		
				Potassium Chloride	C		
				Nicergoline	C		
				Trimetazidine Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/02ISR Number: 3932647-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00595
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:06/13/02ISR Number: 3933752-5Report Type:Direct Company Report #CTU 170101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Chest Pain		Vioxx 25mg	PS		ORAL	ONE TABLE	
Intervention to	Cough						ONCE DAILY	
Prevent Permanent	Dyspnoea						ORAL	
Impairment/Damage								

Date:06/13/02ISR Number: 3933858-0Report Type:Periodic Company Report #2001UW16304
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenia	Health	Prilosec	PS				
Initial or Prolonged		Professional	Vioxx	SS				
			Cardizem	C				
			Prevacid	C				

Date:06/13/02ISR Number: 3933985-8Report Type:Expedited (15-DaCompany Report #WAES 01115195
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Antinuclear Antibody	Foreign	Tab Vioxx					
	Positive	Health	(Rofecoxib)	PS		ORAL	12.5	
	Cutaneous Lupus	Professional						
MG/DAILY;PO							5	MON

	Erythematosus		Hydroxychloroquines0			
			4	C		
			Ibupprofen	C		
			Levothyroxine Na	C		
			Omeprazole	C		

Date:06/13/02ISR Number: 3933987-1Report Type:Expedited (15-DaCompany Report #WAES0205USA02292
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema	Foreign	Tab Vioxx					
Life-Threatening	Anuria	Health	(Rofecoxib)	PS		ORAL	25	
Hospitalization -	Atrioventricular Block	Professional					MG/DAILY;PO	2 DAY
Initial or Prolonged	Diarrhoea		Coltramyl	C				
	Fatigue		Mydocalm	C				
	Heart Rate Decreased		Sirdalud	C				
	Hypotension							
	Loss Of Consciousness							
	Mydriasis							
	Myocardial Infarction							
	Organ Failure							
	Pallor							
	Pulmonary Oedema							
	Shock							
	Ventricular Arrhythmia							
	Ventricular Fibrillation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/02ISR Number: 3933989-5Report Type:Expedited (15-DaCompany Report #WAES 0203ZAF00011
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Complete	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY;PO	
	Fatigue	Professional						
	Palpitations		Acetazolamide	C				

Date:06/13/02ISR Number: 3934335-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA01381
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Atrial Fibrillation	Professional	Bextra	C				
Other	Atrial Tachycardia	Company	Celebrex	C				
	Chest Pain	Representative						
	Drug Effect Decreased							
	Hypertension							
	Oedema							

Date:06/13/02ISR Number: 3934337-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic	Consumer	Tab Vioxx Unk	PS		ORAL	25MG/DAILY/PO	
	Attack		Atacand	C				
			Combivent	C				
			Coreg	C				
			Flovent	C				
			Lipitor	C				
			Plavix	C				
			Zoloft	C				
			Aspirin	C				
			Vitamin E	C				

Date:06/13/02ISR Number: 3934341-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA03162
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Faeces	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Dyspepsia	Professional Company Representative	Celebrex	C				
Other	Gastric Ulcer Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:06/13/02ISR Number: 3934343-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02922
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lopressor	C				
			Norvasc	C				
			Premarin	C				
			Prinivil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/02ISR Number: 3934455-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00564
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiogram Cerebral	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Abnormal	Professional					MG/DAILY/PO	
Disability	Asthenia		Allegra	C				
	Balance Disorder		Inderal	C				
	Blood Pressure Increased		Lopid	C				
	Brain Scan Abnormal		Mobic	C				
	Cognitive Disorder		Plavix	C				
	Conversion Disorder		Premarin	C				
	Depression		Wellbutrin	C				
	Diabetes Mellitus		Zestril	C				
	Non-Insulin-Dependent		Folic Acid	C				
	Difficulty In Walking		Metformin	C				
	Emotional Disorder		Vitamin E	C				
	Headache		Vitamins					
	Hemiparesis		(Unspecified)	C				
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Memory Impairment							
	Migraine							
	Nuclear Magnetic							
	Resonance Imaging							
	Abnormal							
	Paraesthesia							
	Sarcoidosis							
	Sensory Disturbance							
	Speech Disorder							
	Transient Ischaemic							
	Attack							

Date:06/14/02ISR Number: 3933188-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Life-Threatening	Anaphylactic Shock		Sirdalud	C		ORAL		

Hospitalization - Initial or Prolonged	Anuria Diarrhoea Heart Rate Decreased Hypotension Loss Of Consciousness Organ Failure Shock Ventricular Arrhythmia	Coltramyl Mydocalm [Therapy Unspecified] [Composition Unspecified]	C C C C	ORAL ORAL

Date:06/17/02ISR Number: 3934831-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00754
Age:41 YR Gender:Male I/FU:I

Outcome	PT
Other	Atrial Fibrillation Blood Pressure Systolic Decreased Cardiac Flutter Chest Discomfort Heart Rate Irregular Tachycardia

		Tricuspid Valve Incompetence					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
SEE IMAGE			Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL

Date:06/17/02ISR Number: 3934841-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA01448
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL
2							
Hospitalization -		Chills	Health				
TABLET/1X/PO							
Initial or Prolonged		Cold Sweat	Professional				
		Dehydration					
		Diarrhoea					
		Dizziness					
		Gastric Ulcer					
		Gastrointestinal					
		Haemorrhage					
		Haematemesis					
		Hiatus Hernia					
		Hypoaesthesia					
		Leukocytosis					
		Mallory-Weiss Syndrome					
		Melaena					
		Migraine					
		Oesophagitis					
		Pyrexia					
		Renal Cell Carcinoma					
		Stage Unspecified					
		Small Intestinal					
		Obstruction					
		Stress					
		Tremor					
		Vomiting					
		Weight Decreased					
		White Blood Cell Count					
		Increased					

Date:06/17/02ISR Number: 3935289-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02710
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Potassium Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea	Professional						
		Company Representative	Lasix (Furosemide)	C				
			Zestril	C				
			Digoxin	C				
			Glucosamine	C				
			Rosaprostol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935290-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02622
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperhidrosis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Nausea	Professional					MG/DAILY/PO	
Initial or Prolonged	Pyrexia		Cap Roxilox 5/500 Mg	SS		ORAL	5/500 MG	
Other	Vomiting						Q4H/PO	
			Accupril	C				
			Cartia (Diltiazem Hydrochloride)	C				
			Lanoxin	C				
			Serevent	C				
			Singulair	C				
			Aspirin	C				

Date:06/17/02ISR Number: 3935291-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01097
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Coumadin	C				
Other	Haematocrit Decreased	Representative	Lasix (Furosemide)	C				
	Myocardial Infarction		Lipitor	C				
			Univasc	C				

Date:06/17/02ISR Number: 3935302-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00462
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatitis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Company
Representative

Date:06/17/02ISR Number: 3935304-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00272
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
		Company Representative						

Date:06/17/02ISR Number: 3935358-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01311
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Haemorrhage	Professional	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935359-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00056
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/02ISR Number: 3935360-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01096
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	60 DAY	
Other	Gastritis	Professional						
	Pain							

Date:06/17/02ISR Number: 3935361-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00041
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Joint Swelling	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	
	Rash	Professional	Acetaminophen And					
	Somnolence		Codeine Phosphate	C		ORAL		

Date:06/17/02ISR Number: 3935362-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/02ISR Number: 3935366-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01204
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Necrosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rhabdomyolysis Sepsis							

Date:06/17/02ISR Number: 3935367-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01009
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/02ISR Number: 3935382-8Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00037
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Meningitis Osteomyelitis		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	

Date:06/17/02ISR Number: 3935387-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA00958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/02ISR Number: 3935413-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01326
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/17/02ISR Number: 3935416-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01372
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Dehydration Fatigue Gastrointestinal Haemorrhage Myocardial Infarction Nausea Pallor Syncope	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/17/02ISR Number: 3935432-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Transient Ischaemic	Consumer	Tab Vioxx	PS	ORAL
25 MG, DAILY,					
	Attack				
PO					
			Atacand	C	
			Combivent	C	
			Coreg	C	
			Flovent	C	
			Lipitor	C	
			Plavix	C	
			Zoloft	C	
			Aspirin	C	
			Vitamin E	C	

Date:06/17/02ISR Number: 3935433-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
	Dysphagia					
PO						
	Gingival Disorder					
	Pharyngolaryngeal Pain					
	Tongue Discolouration					
	Tongue Disorder					
	Tongue Oedema					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935434-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged		Health Professional	Wellbutrin	C				

Date:06/17/02ISR Number: 3935435-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction	Health Professional	Tab Vioxx 50 Mg; 25 Mg	PS		ORAL	SEE IMAGE	
Hospitalization -	Grand Mal Convulsion							
Initial or Prolonged	Status Epilepticus							

Date:06/17/02ISR Number: 3935436-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA01861
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage		Excedrin					
Other	Gastrointestinal Ulcer	Company Representative	(Acetaminophen (+)					
			Aspi	C				
			Motrin	C				
			Plavix	C				

Date:06/17/02ISR Number: 3935451-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00328
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Hospitalization -
MG/DAILY/PO
Initial or Prolonged

Flomax (Tamsulosin Hydrochloride	C	
Prilosec	C	
Prinivil	C	
Urocit-K	C	

Date:06/17/02ISR Number: 3935456-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00284
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Foreign	Tab Vioxx					
	Gastrointestinal	Health	(Rofecoxib)	PS		ORAL		
	Carcinoma	Professional	[Therapy Unspecified]	C				
			Gastrointestinal Preparations (Unspecifi	C				

Date:06/17/02ISR Number: 3935457-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00117
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Life-Threatening	Acute Pulmonary Oedema	Foreign
		Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	8 MON
Vasotec	C				
Budesonide	C				
Fenofibrate	C				
Furosemide	C				
Lansoprazole	C				
Molsidomine	C				
Salmeterol Xinafoate	C				

Date:06/17/02ISR Number: 3935460-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02876
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Viral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged	Nausea	Health	Wellbutrin	C				
	Oral Intake Reduced	Professional						
	Vomiting							

Date:06/17/02ISR Number: 3935461-5Report Type:Expedited (15-DaCompany Report #WAES 0201DEU00139
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional	Amitriptyline Hydrochloride	C				
			Melperone Hcl	C				

Date:06/17/02ISR Number: 3935475-5Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00010
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Gastrointestinal Necrosis	Foreign Health Professional	Tab Vioxx (Rofecoxib) Diacerein	PS C		ORAL	25 MG/DAILY	16 DAY

Date:06/17/02ISR Number: 3935478-0Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00153
Age:54 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Occlusion	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:06/17/02ISR Number: 3935480-9Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00003
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholestasis Hepatocellular Damage Hepatotoxicity	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	84 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935481-0Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00026
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amyotrophic Lateral Sclerosis	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
			Irbesartan	C			PO	294 DAY

Date:06/17/02ISR Number: 3935487-1Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00010
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Intestinal Ascites	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG /DAILY	10 DAY
	Condition Aggravated Gastrointestinal Necrosis Pancreatitis Acute		Diacerein	C				

Date:06/17/02ISR Number: 3935489-5Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Arthralgia Difficulty In Walking Dyspnoea Face Oedema Oropharyngeal Swelling Palpitations Pharyngeal Oedema Sensation Of Heaviness Tongue Oedema Vision Blurred	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:06/17/02ISR Number: 3935498-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00076
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign	Tab Vioxx					
	Medication Error	Other	(Rofecoxib)	PS		ORAL	1 DOSE/DAILY	
			Acetaminophen (+) Dihydrocodeine Bitartr	C				
			Allopurinol	C				
			Diltiazem Hydrochloride	C				
			Nebivolol Hydrochloride	C				
			Ramipril	C				

Date:06/17/02ISR Number: 3935499-8Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00212
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Inadequately Controlled	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG	68 DAY
			Alendronic Acid	C				

			Atenolol	C		
			Bendroflumethiazide	C		

Date:06/17/02ISR Number: 3935501-3Report Type:Expedited (15-DaCompany Report #WAES 01059553
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Proteinuria	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 262 DAY
		Health Professional	Tab Placebo (Unspecified)	SS		ORAL	PO	
			Alfacalcidol	C				
			Calcitonin	C				
			Diltiazem	C				
			Leflunomide	C				
			Levothyroxine Na	C				

Date:06/17/02ISR Number: 3935511-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00662
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Oedema Peripheral						MG/DAILY/PO	
			Prilosec	C				
			Aspirin	C				
			Vitamin E	C				

Date:06/17/02ISR Number: 3935515-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA00313
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Congestive	Professional				
MG/DAILY/PO						
Other	Oedema Peripheral		Effexor Xr	C		
			Norco	C		
			Soma	C		
			Methadone Hydrochloride	C		

Date:06/17/02ISR Number: 3935519-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00368
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Panic Attack	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/HS/PO						
	Suicidal Ideation		Estrace	C		
	Thyroid Disorder		Synthroid	C		
			Toprol Xl Tablets	C		

Date:06/17/02ISR Number: 3935521-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00417
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
			Fosamax	C		

			Lanoxin	C
			Prevacid	C

Date:06/17/02ISR Number: 3935530-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Haemorrhage	Professional Company Representative						

Date:06/17/02ISR Number: 3935536-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02261
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Life-Threatening	Haemorrhage	Professional					MG/DAILY/PO	6 WK
Hospitalization - Initial or Prolonged		Company Representative						

Date:06/17/02ISR Number: 3935542-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03554
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	4 DAY
Initial or Prolonged		Professional	Paxil	C				
Disability		Company Representative						

Date:06/17/02ISR Number: 3935602-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01262
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Other	Hepatic Failure		Paxil	C				

Date:06/17/02ISR Number: 3935673-0Report Type:Expedited (15-DaCompany Report #WAES 00095116
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Foreign	Tab Vioxx					
Life-Threatening	Duodenal Ulcer	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
Hospitalization -	Haemorrhage	Professional						
Initial or Prolonged	Large Intestine	Other	Diclofenac Na	SS		ORAL	PO	15 DAY
	Perforation		Atenolol	C				
	Left Ventricular Failure		Digoxin	C				
	Myocardial Infarction		Furosemide	C				
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935719-XReport Type:Expedited (15-DaCompany Report #2002-BP-02682AU (0)
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Haemorrhage	Other	Asasantin Sr(Kar) (Acetylsalicylic Acid, Dipyridamole)	PS		ORAL	400/ 50MG PO	2 WK
			Vioxx (Ta)	SS		ORAL	25 MG (1 IN 1 D) PO	DAY
			Betaloc (Metoprolol Tartrate) (Nr)	C				
			Panadol (Paracetamol) (Nr)	C				

Date:06/17/02ISR Number: 3935754-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00015
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	1 DAY
			Althiazide/Spironolactone	C				
			Metformin Hcl	C				
			Spironolactone	C				

Date:06/17/02ISR Number: 3935758-9Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Hypertension	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Cyproterone Acetate	C				
			Goserelin Acetate	C				
			Methotrexate	C				
			Sodium Folate	C				

Date:06/17/02ISR Number: 3935888-1Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00007
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Chest Pain	Other	(Rofecoxib)	PS		ORAL	PO	
	Gastric Ulcer		Tab Aspirin (+)					
	Melaena		Magnesium Oxide	SS				
			Aluminum Hydroxide					
			(+) Magnesium					
			Carbona	C				
			Amlodipine Besylate	C				
			Diazepam	C				
			Metoprolol Tartrate	C				
			Nitroglycerin	C				
			Sennosides	C				
			Timolol Maleate	C				
			Zopiclone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3935890-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00020
Age:79 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG, PO	77 DAY
Initial or Prolonged	Oesophagitis		Acetaminophen	C				
			Amiloride Hydrochloride (+)					
			Furosemide	C				
			Dihidhydrocodeine	C				

Date:06/17/02ISR Number: 3935892-3Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00050
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Stenosis	Foreign	Tab Vioxx					
Initial or Prolonged	Myocardial Infarction	Other	(Rofecoxib)	PS		ORAL	PO	
			Prinivil	C				
			Aspirin	C				
			Metoprolol	C				
			Pravastatin Na	C				

Date:06/17/02ISR Number: 3935893-5Report Type:Expedited (15-DaCompany Report #WAES 0206DNK00007
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged							PO	214 DAY
			Zocor	C				
			Acetaminophen	C				
			Oxazepam	C				
			Proposxyphene Hcl	C				
			Quinine Hcl	C				

Date:06/17/02ISR Number: 3935894-7Report Type:Expedited (15-DaCompany Report #WAES 0206DNK00009
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Gastritis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	SEE IMAGE	44 DAY
			Cap Celecoxib	SS		ORAL	200 MG/DAILY PO	8 DAY

Date:06/17/02ISR Number: 3935896-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00021
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG PO	14 DAY
			Acetaminophen	C				
			Amiloride	C				
			Anastrozole	C				
			Bumetanide	C				
			Diazepam	C				
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3936044-3Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00227
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Tab Vioxx					
	Melaena	Other	(Rofecoxib)	PS		ORAL	25MG/ PO	19 DAY

Date:06/17/02ISR Number: 3936047-9Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Tab Vioxx					
	Oedema	Consumer	(Rofecoxib)	PS		ORAL	PO	10 DAY

Date:06/17/02ISR Number: 3936057-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00226
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ventricular Extrasystoles	Foreign	Tab Vioxx					
		Other	(Rofecoxib)	PS		ORAL	12.5 MG/ BID	
							PO	
			Bendroflumethiazide	C				
			Doxazosin	C				

Date:06/17/02ISR Number: 3936501-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Benign Lung Neoplasm	Consumer	Tab Viox 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Bronchitis	Health						
Initial or Prolonged	Bronchopneumonia	Professional	Aleve	C				

Cardiac Failure
Congestive
Cardiomyopathy
Coronary Artery Disease
Electrocardiogram
Abnormal
Fungal Infection
Haematocrit Decreased
Haemoglobin Decreased
Hypoxia
Laboratory Test Abnormal
Mobility Decreased
Myocardial Infarction
Oxygen Saturation
Decreased
Pleural Effusion
Postoperative Fever
Postoperative Wound
Complication
Pulmonary Oedema
Sinus Tachycardia
Ventricular Fibrillation
Wound Secretion

Ceftin	C
Lipitor	C
Mevacor	C
Oxycontin	C
Ultram	C
Vicodin Tablets	C
Aspirin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3937601-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cough	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Ineffective		Vioxx	SS		ORAL
	Dysphonia					
	Headache					
	Meningitis Viral					
	Musculoskeletal Stiffness					
	Thirst					

Date:06/17/02ISR Number: 3937602-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain	Professional	Percocet	C		
Other	Difficulty In Walking		Omega-3	C		
	Hypoaesthesia		Ginkgo Biloba			
	Monoplegia		Extract	C		
	Pain In Extremity					
	Phlebitis					
	Sensory Loss					

Date:06/17/02ISR Number: 3937641-1Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Initial or Prolonged			Zolpidem Tartrate	C		ORAL
			Antimicrobial			
			(Unspecified)	C		

Date:06/17/02ISR Number: 3937645-9Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Drug Interaction		Vioxx	SS		ORAL		3 DAY
	Haematemesis		Fluindione	C		ORAL		
	International Normalised Ratio Increased		Fluindione	C		ORAL		

Date:06/17/02ISR Number: 3937647-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00040
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Methotrexate	C		ORAL		
			Folic Acid	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Cyproterone Acetate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/02ISR Number: 3937650-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00036
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	98	DAY
Hospitalization - Initial or Prolonged	Melaena		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
	Pain		Furosemide	C		ORAL		
			Isosorbide	C		ORAL		

Date:06/17/02ISR Number: 3937651-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA01018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/18/02ISR Number: 3934283-9Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00003
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum		Acetaminophen	C				
	Gastritis Erosive		Furosemide	C				
	Haematemesis		Vitamins (Unspecified)	C				
	Upper Gastrointestinal Haemorrhage		Calcium Acetate	C				

Date:06/18/02ISR Number: 3934284-0Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00004
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Upper Gastrointestinal		Ibuprofen	C		ORAL	7	MON

Haemorrhage

Date:06/18/02ISR Number: 3934290-6Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00006
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness		Vioxx	SS		ORAL
14 DAY						
Disability	Drug Ineffective		Drospirenone And			
	Fatigue		Ethinyl Estradiol	C		
	Gamma-Glutamyltransferase		Celecoxib	C		
	Increased		Diclofenac Sodium	C		
	Haemoglobin Decreased		Acetaminophen	C		
	Headache					
	Hepatomegaly					
	Infection					
	Nausea					
	Pain In Extremity					
	Pyrexia					
	Red Blood Cell					
	Sedimentation Rate					
	Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/02ISR Number: 3935934-5Report Type:Expedited (15-DaCompany Report #200115144BWH
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Baycol (Cerivastatin Sodium)	PS		ORAL	0.4MG DAILY, ORAL	
	Haemoglobin Decreased	Health						
	Myopathy	Professional						
	Nausea		Prinzide	SS				
	Red Blood Cell Count Decreased		Demadex (Torasemide)	SS				
			Vioxx (Rofecoxib)	SS				
	Renal Failure Acute		Ultram	C				
	Tendon Disorder		Welchol	C				
	Vomiting		Verapamil	C				
			Thyroid	C				
			Cardizem	C				
			Kay Ciel	C				
			Prilosec	C				
			Singulair	C				
			Nasacort	C				
			Azmacort	C				
			Insulin	C				
			Apcpc	C				
			Metamucil	C				
			Milk Of Magnesia	C				

Date:06/18/02ISR Number: 3936151-5Report Type:Expedited (15-DaCompany Report #2002-DE-01186YA (0)
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia	Other	Omix (Tamsulosin) (Nr) (Tamsulosin Hydrochloride)	PS		ORAL	0.4 MG PO	
			Coumadine (Warfarin Sodium) (Nr)	SS		ORAL	ANZ PO	
			Tenstaten (Cicletanine) (Nr)	SS		ORAL	2 ANZ PO	
			Vioxx (Nr)	SS		ORAL	1 ANZ PO	21 DAY

Lamaline (Lamaline) (Nr)	SS				ORAL
PO	10	YR			
Sotalex (Sotalol Hydrochloride) (Nr)	SS				ORAL
PO					
Trimetazidine Hydrochloride (Trimetazidine) (Nr)	C				
Lansoprazole (Lansoprazole) (Nr)	C				
Bromazepam (Bromazepam) (Nr)	C				
Adenosine Phosphate (Adenosine Phosphate) (Nr)	C				
Chondroitin Sulfate Sodium (Chondroitin Sulfate Sodium)	C				
Ambroxol Hydrochloride (Ambroxol Hydrochloride) (Nr)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3935305-1Report Type:Direct Company Report #CTU 170398
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chromaturia		Vioxx 25mg	PS		ORAL	25MG DAILY	
	Fatigue					ORAL		
	Hepatitis		Aciphex 20mg	SS		ORAL	20MG DAILY	
						ORAL		

Date:06/19/02ISR Number: 3935390-7Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00092
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL	67 DAY	
			Amlodipine Besylate	C		ORAL		

Date:06/19/02ISR Number: 3935392-0Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia							
	Difficulty In Walking							
	Dyspnoea							
	Face Oedema							
	Oropharyngeal Swelling							
	Palpitations							
	Sensation Of Heaviness							
	Tongue Oedema							
	Vision Blurred							

Date:06/19/02ISR Number: 3935395-6Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00025
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	General Physical Health		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
Hospitalization - Initial or Prolonged	Deterioration Myocardial Infarction		Betahistine Hydrochloride	C		ORAL		
			Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY (INHALATION)								
			Omeprazole	C		ORAL		
			Singulair	C		ORAL		

Date:06/19/02ISR Number: 3935398-1Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00068
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Weight Increased		Aspirin And Dipyridamole	C		ORAL		
			Zocor	C		ORAL		
			Vasotec	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3935399-3Report Type:Expedited (15-DaCompany Report #WAES 0206ESP00028
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
	Haematemesis		Diclofenac Sodium	C				
	Myocardial Infarction		Verapamil	C		ORAL		

Date:06/19/02ISR Number: 3935400-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00032
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		59 DAY
Initial or Prolonged	Melaena		Aspirin Lysine	SS		ORAL		
			Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C		ORAL		59 DAY
			Auranofin	C		ORAL		
			Simvastatin	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		

Date:06/19/02ISR Number: 3935401-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Paraesthesia							

Date:06/19/02ISR Number: 3935402-0Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00026
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 5 DAY	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Indapamide	C		ORAL

Date:06/19/02ISR Number: 3935404-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA01198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Vioxx	SS		ORAL
	Inflammation					

Date:06/19/02ISR Number: 3935405-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01680
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain		Embeline E	C		
TOPICAL						
			Protopic	C		
TOPICAL						
			Estrace	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3935706-1Report Type:Direct Company Report #CTU 170516
Age:86 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Cardio-Respiratory Arrest Gastric Ulcer Gastrointestinal Haemorrhage Haematocrit Decreased Myocardial Infarction		Vioxx	PS				

Date:06/19/02ISR Number: 3936355-1Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00003
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp Diverticulum Intestinal Dizziness Gastritis Erosive Haemoglobin Abnormal Upper Gastrointestinal Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	PO
			Ca Acetate	C				
			Acetaminophen	C				
			Furosemide	C				
			Vitamins (Unspecified)	C				

Date:06/19/02ISR Number: 3936357-5Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00004
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Duodenal Ulcer Haemoglobin Decreased Helicobacter Pylori Identification Test Positive Upper Gastrointestinal Haemorrhage	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Ibuprofen	C				

Date:06/19/02ISR Number: 3936359-9Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	1) 100 MG/DAILY; 2) 50 MG/DAILY	8 DAY
	Drug Interaction	Health						
	Drug Level Decreased	Professional	Phenobarbital	SS		ORAL		
			Furosemide	C				
			Nicergoline	C				
			Potassium Chloride	C				
			Trimetazidine Hydrochloride	C				

Date:06/19/02ISR Number: 3936416-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema Anaemia Anaphylactic Shock Anuria Cardio-Respiratory Arrest Coma Diarrhoea Fatigue Haematemesis Hypotension Loss Of Consciousness Organ Failure Pallor Ventricular Fibrillation	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	2 DAY
			Coltramyl	C				
			Mydocalm	C				
			Sirdalud	C				
			Composition Unspecified	C				
			Therapy Unspecified	C				

Date:06/19/02ISR Number: 3936424-6Report Type:Expedited (15-DaCompany Report #HQ6700403OCT2001
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Condition Aggravated Drug Interaction Muscular Weakness Renal Failure Acute	Health Professional Other	Cordarone (Amiodarone , Tablet)	PS		ORAL	200 MG 1X PER 1 DAY	366 DAY
	Rhabdomyolysis		Vioxx (Rofecoxib, Tablet)	SS		ORAL	25 MG 1X PER 1 DAY	366 DAY
			Zocor (Simvastatin)	SS		ORAL	80 MG 1X PER 1 DAY	46 DAY
			Lasix (Furosemide)	C				
			Cardioaspirin (Acetylsalicylic Acid)	C				
			Mascoumar					

			(Phenprocoumon)	C
			Zestril (Lisinopril)	C

Date:06/19/02ISR Number: 3936492-1Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00141
Age:75 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:06/19/02ISR Number: 3936498-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00039
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoantibody Positive Blood Lactate Dehydrogenase Increased Myelodysplastic Syndrome	Foreign Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	748 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3936500-8Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00033
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Tab Vioxx					
Hospitalization -	Blood Pressure Systolic	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Increased	Professional					PO	
	Chest Pain	Other	Tab Aspirin	SS		ORAL	150 MG/DAILY	
	Creatine Phosphokinase						PO	
	Decreased		Tab Bisoprolol/Hctz	SS		ORAL	5/12/5	
	Drug Interaction						MG/DAILY PO	
	Electrocardiogram St		Molsidomine	C				
	Segment Depression							
	Epistaxis							
	Feeling Abnormal							
	Haemoglobin Decreased							
	Hyperhidrosis							
	Injection Site							
	Haemorrhage							
	Petechiae							
	Shock							
	White Blood Cell Count							
	Increased							

Date:06/19/02ISR Number: 3936503-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG DAILY	
	International Normalised	Professional					PO	
	Ratio Increased	Other	Fluindione	SS		ORAL	PO	

Date:06/19/02ISR Number: 3936585-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:06/19/02ISR Number: 3936589-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00711
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Attack	Professional	Zocor	C				

Date:06/19/02ISR Number: 3936592-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00642
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cystitis	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	3 WK
Initial or Prolonged	Drug Exposure During Pregnancy Pregnancy Vomiting In Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3936784-6Report Type:Expedited (15-DaCompany Report #WAES 01080220
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged			Celebrex	SS				

Date:06/19/02ISR Number: 3936786-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01250
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Dyspepsia						MG/DAILY/PO	
	Dyspnoea							
	Heart Rate Increased							
	Syncope							

Date:06/19/02ISR Number: 3936788-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Difficulty In Walking	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Hypoaesthesia	Health	Omega-3	C				
Other	Iatrogenic Injury	Professional	Percocet	C				
	Monoplegia		Ginkgo Biloba					
	Phlebitis		Extract	C				
	Sensory Loss							
	Thermal Burn							

Date:06/19/02ISR Number: 3936805-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02756
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Arthralgia	Health	Tab Vioxx 25 Mg ; 50			
Other	Hypertension	Professional	Mg	PS		ORAL
25						
	Inflammation					
MG/DAILY/PO ;						
	Joint Swelling					
50 MG/PO						
	Malaise					
	Rheumatoid Arthritis					
	Swelling					

Date:06/19/02ISR Number: 3936812-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02123
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/AM/PO						
Other	Confusional State	Health				
	Dizziness	Professional				
	Hallucination, Visual					
	Nausea					

Date:06/19/02ISR Number: 3936814-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00611
Age:41 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia

	Disturbance In Attention Hypoaesthesia Paralysis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO

Date:06/19/02ISR Number: 3936825-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA00358
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal	Professional Company Representative						

Date:06/19/02ISR Number: 3937879-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02438
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Peptic Ulcer	Professional						
	Weight Decreased	Company Representative	Oxycontin	C				
			Pepcid	C				
			Folic Acid	C				
			Mercaptopurine	C				
			Prednisone	C				

Date:06/19/02ISR Number: 3937886-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00595
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Bradycardia	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY/PO 3 DAY						

Date:06/19/02ISR Number: 3938259-7Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Blood Creatinine Increased		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:06/19/02ISR Number: 3938261-5Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/02ISR Number: 3938262-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00008
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Hepatitis Oesophagitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/19/02ISR Number: 3938264-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01431
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oedema Peripheral		Premarin	C				

Date:06/19/02ISR Number: 3938267-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01441
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/19/02ISR Number: 3938269-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/19/02ISR Number: 3957453-2Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00153
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						
	Myocardial Ischaemia		Fluticasone Propionate And Salmeterol Xinafoate	C		
	Nausea					
	Vomiting					
			Albuterol Sulfate	C		
RESPIRATORY						
(INHALATION)						

Date:06/19/02ISR Number: 3957457-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death		Celebrex	C		
	Gastrointestinal Haemorrhage					

Date:06/19/02ISR Number: 3987709-9Report Type:Periodic Company Report #WAES 0203USA00254
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Rash Pruritic	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/PRN/PO						
			Fosamax	C		
			Premarin	C		

			Provera	C		

Date:06/20/02ISR Number: 3935908-4Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00085
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dialysis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Intentional Misuse	Professional						
	Renal Failure							

Date:06/20/02ISR Number: 3938635-2Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Drug Interaction	Professional	Phenobarbital	SS		ORAL		
	Drug Level Decreased		Phenobarbital	SS		ORAL		
			Furosemide	C				
			Potassium Chloride	C				
			Nicergoline	C				
			Trimetazidine Hydrochloride	C				

Date:06/21/02ISR Number: 3936810-4Report Type:Direct Company Report #CTU 170651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS		ORAL	25 MG QD PO	
			Albuterol Inhaler	C				

Date:06/21/02ISR Number: 3937202-4Report Type:Direct Company Report #CTU 170714
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain		Zanaflex	PS				
	Blood Pressure Increased		Vioxx	SS				
	Ear Infection							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Sinusitis							
	Tinnitus							
	Visual Acuity Reduced							
	Weight Increased							

Date:06/21/02ISR Number: 3937418-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Consumer	Vioxx	PS		ORAL	PO	
	Thrombosis	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/02ISR Number: 3937420-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA00871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/21/02ISR Number: 3937454-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Operation	Consumer	Orsu Vioxx 25/5 Mg/Ml	PS		ORAL	25 MG/ML/DAILY/PO	

Date:06/21/02ISR Number: 3937457-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Swelling	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/21/02ISR Number: 3937550-8Report Type:Expedited (15-DaCompany Report #WAES 01080219
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Arterial Occlusive Disease Atherosclerosis Blood Urea Increased

Bronchospasm
Cardiac Disorder
Cardiac Failure
Congestive
Cardiac Murmur
Carotid Artery Stenosis
Carotid Bruit
Cerebrovascular Disorder
Cholelithiasis
Chronic Obstructive
Airways Disease
Exacerbated
Contrast Media Reaction
Coronary Artery Disease
Cranial Nerve Disorder
Difficulty In Walking
Dysphonia
Dyspnoea Exacerbated
Hypertension
Hyporeflexia
Intermittent Claudication
Iron Deficiency Anaemia
Lung Disorder
Mental Status Changes
Muscle Atrophy
Pain In Extremity

		Peripheral Vascular Disorder Pulse Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO							
		Respiratory Rate Decreased Sinus Tachycardia Subclavian Artery Stenosis Temperature Regulation Disorder Vascular Graft Occlusion Ventricular Hypokinesia White Blood Cells Urine Positive	Health Professional	Celebrex	SS		

Date:06/21/02ISR Number: 3937617-4Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00003
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Colonic Polyp	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL
12.5 MG/DAILY						
	Diverticulum	Professional	Ca Acetate	C		
	Gastric Haemorrhage	Other	Acetaminophen	C		
	Gastritis Erosive		Furosemide	C		
	Haemoglobin Decreased		Vitamins	C		
	Upper Gastrointestinal Haemorrhage		...	C		

Date:06/21/02ISR Number: 3937621-6Report Type:Expedited (15-DaCompany Report #WAES 0206CHN00004
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Duodenal Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Haemoglobin Decreased Helicobacter Pylori Identification Test	Health Professional Other	Ibuprofen	C		

Positive
Upper Gastrointestinal
Haemorrhage

Date:06/21/02ISR Number: 3937626-5Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00037
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Osteomyelitis	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG	16 DAY
Disability		Professional Other						

Date:06/21/02ISR Number: 3937627-7Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00006
Age:18 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Dizziness
Disability	Fatigue

		Gamma-Glutamyltransferase Increased					
		Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache	Foreign	Tab Vioxx			
		Hepatomegaly	Consumer	(Rofecoxib)	PS		ORAL
SEE IMAGE	14 DAY						
		Infection		Acetaminophen	C		
		Nausea		Celecoxib	C		
		Pain In Extremity		Diclofenac Na	C		
		Pyrexia		Drospirenone (+)			
		Red Blood Cell		Ethinyl Estradiol	C		
		Sedimentation Rate					
		Increased					

Date:06/21/02ISR Number: 3937856-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01204
Age:36 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Necrosis	Health	Tab Vioxx 50 Mg	PS		ORAL
50							
Hospitalization -		Rhabdomyolysis	Professional				
MG/DAILY/PO							
Initial or Prolonged		Streptococcal Sepsis					

Date:06/21/02ISR Number: 3938056-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aphonia	Consumer	Tab Vioxx 12.5 Mg,			
Initial or Prolonged		Cough		25 Mg	PS		ORAL
SEE IMAGE							
		Disorientation					
		Dizziness					
		Dysphonia					
		Headache					
		Immune System Disorder					
		Malaise					
		Meningitis Viral					
		Musculoskeletal Stiffness					
		Nausea					

Thirst
Vision Blurred

Date:06/21/02ISR Number: 3938060-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Back Pain	Health	Omega-3	C				
Other	Discomfort	Professional	Percocet	C				
	Hypoaesthesia		Ginkgo Biloba					
	Monoplegia		Extract	C				
	Pain In Extremity							
	Phlebitis							
	Sensory Loss							
	Thermal Burn							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/02ISR Number: 3938062-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01311
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional	Coumadin	C				
	Haematochezia	Company						
	Vomiting	Representative						

Date:06/21/02ISR Number: 3938139-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01096
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia	Foreign	Tab Vioxx					
Other	Gastritis	Health	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
	Pain	Professional						
PO							60	DAY

Date:06/21/02ISR Number: 3938148-8Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00041
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Joint Swelling	Foreign	Tab Vioxx					
	Rash	Other	(Rofecoxib)	PS		ORAL	12.5 MG/BID	
	Somnolence							
PO							7	DAY
			Acetaminophen/Codeine Phosphate	C				

Date:06/21/02ISR Number: 3938153-1Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00036
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Foreign	Tab Vioxx					

Hospitalization -	Haemorrhage	Other	(Rofecoxib)	PS			ORAL
12.5 MG/ PO 98 DAY							
Initial or Prolonged	Melaena		Acetaminophen/Propoxyphene Hydrochloride	C			
			Furosemide	C			
			Isosorbide	C			

Date:06/21/02ISR Number: 3938155-5Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00056
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	PO	
		Professional						

Date:06/21/02ISR Number: 3938173-7Report Type:Expedited (15-DaCompany Report #2001085935US
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypotension	Consumer	Celebrex(Celecoxib)					
Initial or Prolonged	Myocarditis	Health	Capsule	PS		ORAL	200 MG, BID,	
	Upper Gastrointestinal	Professional					ORAL	
	Haemorrhage		Vioxx(Rofecoxib)	SS				
			Clonidine	C				
			Avapro (Irbesartan)	C				
			Demadex (Torasemide)	C				

Lipitor (Atorvastatin)	C	
Premarin (Estrogens Conjugated)	C	
Ultram (Tramadol Hydrochloride)	C	
Neurontin (Gabapentin)	C	
Zanaflex (Tizanidine Hydrochloride)	C	

Date:06/21/02ISR Number: 3938346-3Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00043
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenic Purpura	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, DAILY, PO	6 DAY
			Antimicrobial (Unspecified)	C				
			Zolpidem Tartrate	C				

Date:06/21/02ISR Number: 3938348-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, DAILY, PO	3 DAY
	Drug Interaction							
	Haematemesis							
	International Normalised Ratio Increased		Fluindione	SS		ORAL	PO	

Date:06/21/02ISR Number: 3938351-7Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00040
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident Transient Ischaemic Attack	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG, PO	
			Acetaminophen/Propoxyphene Hydrochloride	C				
			Cyproterone Acetate	C				
			Folic Acid	C				
			,Ethotrexate	C				

Date:06/21/02ISR Number: 3938673-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01327
Age:56 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Dizziness	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/02ISR Number: 3938675-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01452
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/21/02ISR Number: 3938677-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00051
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional						
	Large Intestine Perforation							

Date:06/21/02ISR Number: 3938678-9Report Type:Expedited (15-DaCompany Report #WAES 01098248
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Zocor	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Failure	Professional	Rofecoxib	SS		ORAL		
Disability	Rhabdomyolysis		Amiodarone Hydrochloride	C		ORAL		
Other			Furosemide Sodium	C		ORAL		
			Aspirin	C		ORAL		
			Phenprocoumon	C		ORAL		
			Lisinopril	C		ORAL		

Date:06/21/02ISR Number: 3957526-4Report Type:Expedited (15-DaCompany Report #WAES 01110165
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plaquenil	C				
	Premature Rupture Of Membranes		Methotrexate	C				

Date:06/21/02ISR Number: 3957527-6Report Type:Expedited (15-DaCompany Report #WAES 01110165
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Nasal Septum Disorder		Vioxx	PS	Merck & Co., Inc			
			Plaquenil	C				
			Methotrexate	C				

Date:06/21/02ISR Number: 3957528-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Disability	Drug Ineffective		Advil	C				
Other	Stomatitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/02ISR Number: 3957530-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02655
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prilosec	C				
Initial or Prolonged			Cocaine	C				
Disability								
Other								

Date:06/21/02ISR Number: 3957532-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02483
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
							24	DAY
Initial or Prolonged	Haemorrhage		Diovan	C		ORAL		
Other			Potassium (Unspecified)	C		ORAL		
			Lasix (Furosemide)	C		ORAL		

Date:06/21/02ISR Number: 3957535-5Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00033
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
							226	DAY
Life-Threatening	Haemorrhage		Prednisolone	SS		ORAL		
	Shock		Levothyroxine Sodium	C		ORAL		
			Captopril	C		ORAL		
			Ranitidine	C		ORAL		

Date:06/21/02ISR Number: 3957536-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA00293
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 9 DAY	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hallucination, Visual Sleep Attacks					

Date:06/21/02ISR Number: 3957540-9Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00097
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dyspnoea		Primidone	C		ORAL
			Phenytoin	C		ORAL
			Potassium Chloride	C		ORAL
			Doxycycline	C		ORAL
			Terbutaline Sulfate	C		
RESPIRATORY						
(INHALATION)						
			Fluticasone Propionate And Salmeterol Xinafoate	C		
			Bendroflumethiazide	C		
			Metoclopramide Hydrochloride	C		
			Quinine Sulfate	C		
			Prednisolone	C		
			Fosamax	C		ORAL

			Albuterol Sulfate	C		
RESPIRATORY						
(INHALATION)						
			Ipratropium Bromide	C		
RESPIRATORY						
(INHALATION)						

Date:06/21/02ISR Number: 3957542-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00077
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faecal Occult Blood		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Positive		Clopidogrel					
Initial or Prolonged	Hyperkalaemia		Bisulfate	C		ORAL		
Disability	Renal Impairment		Aspirin	C		ORAL		
			Warfarin	C		ORAL		
			Acetaminophen	C		ORAL		
			Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Zocor	C		ORAL		
			Isosorbide					
			Mononitrate	C		ORAL		
			Allopurinol	C		ORAL		
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Nitroglycerin	C				
			Potassium Chloride	C		ORAL		

Date:06/21/02ISR Number: 3957543-4Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00024
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged			Cyanocobalamin	C				
							1	MON

Date:06/21/02ISR Number: 3957544-6Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00025
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY
Initial or Prolonged	Duodenal Ulcer		Reviparin Sodium	C		PARENTERAL		
	Haemorrhage							

Date:06/22/02ISR Number: 3937000-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01708
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Headache		Prednisone	C				
	Myocardial Infarction							

Date:06/22/02ISR Number: 3937001-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01821
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
Hospitalization -	Influenza Like Illness
Initial or Prolonged	Rash

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
			Soma	C				
			Darvocet-N	C				
			Xanax	C				
			Prozac	C				
			[Therapy Unspecified]	C				

Date:06/22/02ISR Number: 3937005-0Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00083
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophageal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged	Syncope		Hyzaar	C		ORAL		

Date:06/22/02ISR Number: 3937009-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intraventricular		Vioxx	PS	Merck & Co., Inc	ORAL	65	DAY
Initial or Prolonged	Haemorrhage Subarachnoid Haemorrhage		Vioxx	SS		ORAL		

Date:06/22/02ISR Number: 3937014-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Aldactone	C				

			Tegretol	C		
			Nortriptyline	C		

Date:06/22/02ISR Number: 3937015-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01902
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Hypersensitivity Hypertension							

Date:06/22/02ISR Number: 3937016-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA01901
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Vioxx	SS		ORAL		
	Fatigue		Methotrexate	C		PARENTERAL		
			Aspirin	C				
			Paxil	C				
			Hydrochlorothiazide	C				
			Potassium					

(Unspecified)	C		
Xanax	C		
Singulair	C		ORAL

Date:06/22/02ISR Number: 3937018-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01743
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Hypertension		Digoxin	C				

Date:06/22/02ISR Number: 3937019-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Coumadin	C				
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:06/22/02ISR Number: 3937021-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peripheral Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Vioxx	SS		ORAL		
			Vioxx	SS		ORAL		

Date:06/22/02ISR Number: 3937022-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01148
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

				Ibuprofen	C		

Date:06/22/02ISR Number: 3937026-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	164	DAY
	Lethargy		Decadron					
	Muscle Rigidity		(Dexamethasone)	C		ORAL	10	DAY
	Nervous System Disorder		Prilosec	C				
	Vertigo		Singulair	C		ORAL		
			Serevent	C				
			Bromfed	C				

Date:06/23/02ISR Number: 3937031-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01959
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zestril	SS				

				Aspirin	SS		
				Digoxin	C		
				Zoloft	C		
				Blinded Therapy	C		ORAL
				Blinded Therapy	C		ORAL
35 DAY							

Date:06/24/02ISR Number: 3937686-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02970
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
1 MON						
Hospitalization -	Cerebrovascular Accident		Coumadin	C		
Initial or Prolonged	Ecchymosis		Vasotec	C		
Disability	Gastrointestinal		Triazolam	C		
Other	Haemorrhage					
	International Normalised					
	Ratio Increased					
	Soft Tissue Haemorrhage					

Date:06/24/02ISR Number: 3937692-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA03162
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY						
	Gastritis		Vioxx	SS		ORAL
	Irritable Bowel Syndrome		Naprosyn	C		
	Pruritus Generalised		Atacand	C		ORAL
	Urticaria		Toprol Xl Tablets	C		ORAL
			Zocor	C		ORAL
			Zoloft	C		
			Celebrex	C		

Date:06/24/02ISR Number: 3937693-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02583
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic Increased Carotid Artery Disease Confusional State Ischaemia Memory Impairment Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:06/24/02ISR Number: 3937698-8Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00031
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Epistaxis		Acenocoumarol	SS		ORAL		
	International Normalised Ratio Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/02ISR Number: 3937699-XReport Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Drug Interaction		Vioxx	SS		ORAL		3 DAY
	Haematemesis		Fluindione	SS		ORAL		
	International Normalised Ratio Increased		Fluindione	SS		ORAL		

Date:06/24/02ISR Number: 3937700-3Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00036
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		98 DAY
Hospitalization -	Haemorrhage		Acetaminophen And					
Initial or Prolonged	Melaena		Propoxyphene Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Isosorbide	C		ORAL		

Date:06/24/02ISR Number: 3941740-8Report Type:Expedited (15-DaCompany Report #NSADSS2002009867
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Foreign	Remicade (5 Mg/Ml					
Hospitalization -	Infarction	Study	Lyophilized					
Initial or Prolonged	Blood Glucose Increased	Health	Powder)(Infliximab,					
Other	Bronchospasm	Professional	Recombinant)	PS				
INTRAVENOUS							300 MG, 1 IN	
Required	Bundle Branch Block Left							
							1 TIME(S), IV	
Intervention to	Cardiac Failure		Vioxx (Rofecoxib)	SS				
							25, DAILY	
Prevent Permanent	Congestive		Methotrexate					
Impairment/Damage	Cardiotoxicity		(Methotrexate)	SS				
							7.5 MG, 1 IN	

Dehydration
1 WEEK(S)
Duodenal Ulcer
Haemorrhage
General Physical Health
Deterioration
Haemoptysis
Heart Rate Increased
Hyperhidrosis
Hypoventilation
Intercostal Retraction
Lung Crepitation
Oxygen Saturation
Decreased
Pallor
Pulmonary Fibrosis
Rales
White Blood Cell Count
Increased

Lithium (Lithium)	SS
Mellaril(Thioridazine Hydrochloride)	SS
Feldene(Piroxicam)	C
Enconcor	C
Dilutol(Torsemide)	C
Karvia	C
Isocover	C
Pulmicort(Budesonide)	C
Atrovent(Ipratropium Bromide)	C
Nitroderm(Glyceryl Trinitrate)	C
Oxis (Formoterol)	C

Date:06/25/02ISR Number: 3938377-3Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00130
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
	Cerebral Infarction		Cosyntropin	C				
INTRAVENOUS							3 DAY	
			Enoxaparin Sodium	C				
SUBCUTANEOUS							6 DAY	

			Vitamins (Unspecified)	C		
INTRAVENOUS	3	DAY				
			Vitamin B (Unspecified)	C		
INTRAVENOUS						
			Pentoxifylline	C		
INTRAVENOUS						
			Metoclopramide	C		ORAL
2	DAY					
			Ranitidine	C		ORAL
6	DAY					
			Tilidine Hydrochloride	C		ORAL
6	DAY					
			Tolperisone Hydrochloride	C		ORAL
6	DAY					
			Elavil	C		ORAL
3	DAY					

Date:06/25/02ISR Number: 3938379-7Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	75	DAY
Life-Threatening	Blood Pressure Decreased		Isosorbide Mononitrate	C		ORAL		
Hospitalization -	Cardiovascular Disorder						19	DAY
Initial or Prolonged	Gastric Ulcer Haemorrhage		Furosemide	C		ORAL	65	DAY
	Gastritis Haemorrhagic		Ramipril	C		ORAL	65	DAY
	Shock Haemorrhagic		Sotalol Hydrochloride	C		ORAL	19	DAY
			Tramadol Hydrochloride	C		ORAL	19	DAY
			Prednisone	C		ORAL	65	DAY
			Nonsteroidal Anti-Inflammatory					

			Drug (Unspecified)	C		ORAL
			Pantoprazole Sodium	C		ORAL

32 DAY

Date:06/25/02ISR Number: 3938380-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01820
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain		Corgard	C		
	Influenza Like Illness		Hydrodiuril	C		ORAL
	Migraine		[Therapy			
	Pharyngitis Streptococcal		Unspecified]	C		
PARENTERAL						

Date:06/25/02ISR Number: 3938381-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02768
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Disability						
Other						

Date:06/25/02ISR Number: 3938383-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00109
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Gastrointestinal

	Haemorrhage						
	Peptic Ulcer						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Aricept	C		ORAL		
			Risperdal	C		ORAL		
			Hydrodiuril	C				
			Peri-Colace	C				
			Levoxyl	C				
			Vasotec	C				
			Aspirin	C				
			Ferrous Sulfate	C		ORAL		
			Zoloft	C		ORAL		
			Protein (Unspecified)	C				

Date:06/25/02ISR Number: 3938387-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Barrett'S Oesophagus							
	Gastritis							
	Hiatus Hernia							
	Oesophageal Disorder							
	Orthostatic Hypotension							
	Prostatic Specific Antigen Increased							
	Vertigo							

Date:06/25/02ISR Number: 3938389-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00125
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/25/02ISR Number: 3938710-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00085
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Aortic Valve Incompetence		[Therapy Unspecified]	C		ORAL		
	Dialysis							
	Gastritis							
	Hepatitis A Antibody Positive							
	Intentional Misuse							
	Nephritis Interstitial							
	Oedema Peripheral							
	Renal Failure							

Date:06/25/02ISR Number: 3938712-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03185
Age:47 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Neurontin	C				
	Back Pain							
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Hyperhidrosis							
	Neck Pain							

Date:06/25/02ISR Number: 3938714-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00131
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening	Shock		Torsemide	SS		ORAL	3	DAY
			Vasotec	SS		ORAL	3	DAY
			Phenprocoumon	C		ORAL		
			Glyburide	C		ORAL		
			Acetyldigoxin	C		ORAL		
			Verapamil	C				
			Spironolactone And Furosemide	C		ORAL		

Date:06/25/02ISR Number: 3938721-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01882
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS		ORAL		

Date:06/25/02ISR Number: 3938726-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01879
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/25/02ISR Number: 3938730-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02143
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/25/02ISR Number: 3938731-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02149
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer		Zocor	C		ORAL		
			Plavix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/02ISR Number: 3939437-3Report Type:Expedited (15-DaCompany Report #WAES 01098248
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Tab Zocor					
	Renal Failure	Other	(Simvastatin)	PS		ORAL	80 MG/DAILY	
Disability	Rhabdomyolysis							
PO								46 DAY
Other			Tab Rofecoxib	SS		ORAL	25 MG/DAILY	
PO								366 DAY
			Amiodarone Hydrochloride	C				
			Aspirin	C				
			Furosemide Sodium	C				
			Lisinopril	C				
			Phenprocoumon	C				

Date:06/25/02ISR Number: 3939458-0Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00153
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Occlusive Disease	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	9 DAY
	Atherosclerosis	Professional	Albuterol Sulfate	C				
	Coronary Artery Occlusion		Fluticasone Propionate (+)					
	Myocardial Ischaemia							
	Nausea		Salmeterol Xi	C				
	Vomiting							

Date:06/25/02ISR Number: 3939461-0Report Type:Expedited (15-DaCompany Report #WAES 01065141
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electroencephalogram Abnormal	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY	17 DAY

	Hallucination, Visual		Alendronate Sodium	C		
			Enalapril Maleate	C		
			Nizatidine	C		
			Simvastatin	C		

Date:06/25/02ISR Number: 3939471-3Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00097
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia Dyspnoea	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
			Fosamax	C				
			Albuterol Sulfate	C				
			Bendroflumethiazide	C				
			Doxycycline	C				
			Fluticasone Propionate (+) Salmeterol Xi	C				
			Ipratropium Bromide	C				
			Metoclopramide Hydrochloride	C				
			Phenytoin	C				
			Potassium Chloride	C				
			Prednisolone	C				
			Primidone	C				

				Quinines04	C		
				Terbutaline Sulfate	C		

Date:06/25/02ISR Number: 3939474-9Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00077
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faecal Occult Blood	Foreign	Tab Vioxx					
Hospitalization -	Positive	Other	(Rofecoxib)	PS		ORAL	12.5 MG/PM	4 DAY
Initial or Prolonged	Hyperkalaemia		Zocor	C				
Disability	Renal Impairment		Acetaminophen	C				
			Albuterol	C				
			Allopurinol	C				
			Aspirin	C				
			Clopidogrel Bisulfate	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				
			Nitroglycerin	C				
			Potassium Chloride	C				
			Spironolactone	C				
			Warfarin	C				

Date:06/25/02ISR Number: 3939478-6Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00024
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Foreign	Tab Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	14 DAY
			Cyanocobalamin	C				

Date:06/25/02ISR Number: 3939480-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00051
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Foreign Health	Tab Vioxx (Rofecoxib)	PS			ORAL
25 MG/DAILY 7 DAY							
	Large Intestine Perforation	Professional					

Date:06/25/02ISR Number: 3939489-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00068
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Face Oedema	Foreign	Tab Vioxx			
	Oedema	Other	(Rofecoxib)	PS		ORAL
12.5 MG / PO 15 DAY						
	Oedema Peripheral		Vasotec	C		
	Weight Increased		Zocor	C		
			Aspirin / Dipyridamole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/02ISR Number: 3939491-9Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00085
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis Intentional Misuse Renal Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	200 MG PO	1 WK

Date:06/25/02ISR Number: 3939494-4Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign Other	Tab Vioxx (Rofecoxib)	PS				

Date:06/25/02ISR Number: 3939506-8Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00033
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Gastrointestinal Haemorrhage Shock	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	226 DAY
			Tab Prednisolone	SS		ORAL	PO	
			Captopril	C				
			Levothyroxine Na	C				
			Ranitidine	C				

Date:06/25/02ISR Number: 3939546-9Report Type:Expedited (15-DaCompany Report #WAES 01055067
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hallucination, Visual	Foreign	Tab Vioxx					

		Health	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
		Professional				
PO	17 DAY					
		Other	Alendronate Sodium	C		
			Enalapril Maleate	C		
			Nizatidine	C		
			Simvastatin	C		

Date:06/25/02ISR Number: 3939723-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02483
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25mg	PS		ORAL
25MG/DAILY/PO						
Initial or Prolonged	Haemorrhage	Professional	Diovan	C		
Other	Haemoglobin Decreased	Company	Lasix (Furosemide)	C		
		Representative	Potassium			
			(Unspecified)	C		

Date:06/25/02ISR Number: 3939724-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00293
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hallucination, Visual	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
Initial or Prolonged	Sudden Onset Of Sleep	Professional				
MG/DAILY/PO						
	Thinking Abnormal	Company	...	C		
	Vascular Injury	Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/02ISR Number: 3939725-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA01191
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25	
Disability	Drug Ineffective	Health					MG/DAILY/PO	
Other	Stomatitis	Professional	Advil	C				

Date:06/25/02ISR Number: 3939726-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02655
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcohol Poisoning	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization -	Alcoholic Hangover	Professional	Prilosec	C				
Initial or Prolonged	Deep Vein Thrombosis	Company	Cocaine	C				
Disability	Drug Screen Positive	Representative						
Other								

Date:06/25/02ISR Number: 3939728-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx Unk	PS		ORAL	PO	
Other	Gastrointestinal Haemorrhage	Professional Company Representative	Celebrex	C				

Date:06/25/02ISR Number: 3939737-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01327
Age:56 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Tab Vioxx Unk	PS		ORAL	PO	

Initial or Prolonged	Dizziness	Professional Company Representative

Date:06/25/02ISR Number: 3939738-9Report Type:Expedited (15-DaCompany Report #WAES 01110165
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Complications Of Maternal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Exposure To Therapeutic Drugs	Professional	Plaquenil	C				
			Methotrexate	C				
	Congenital Nose Malformation							
	Maternal Drugs Affecting Foetus							
	Pregnancy							
	Premature Baby							
	Premature Rupture Of Membranes							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/02ISR Number: 3939739-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01452
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/25/02ISR Number: 3939908-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Paraesthesia	Health Professional	Vioxx Unk	PS		ORAL	PO	

Date:06/25/02ISR Number: 3939929-7Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00025
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Tab Vioxx					
	Duodenal Ulcer	Other	(Rofecoxib)	PS		ORAL	25 MG/BID	21 DAY
	Haemorrhage		Reviparin Sodium	C				

Date:06/25/02ISR Number: 3939981-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01680
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain							
			Embeline E	C				
			Estrace	C				

Protopic C

Date:06/25/02ISR Number: 3939983-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/25/02ISR Number: 3939985-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01441
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephrolithiasis	Consumer	Vioxx	PS		ORAL	PO	

Date:06/25/02ISR Number: 3939988-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01431
Age:54 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction	Consumer	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Oedema Peripheral							
			Premarin	C				

Date:06/25/02ISR Number: 3939989-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Gastroenteritis	Health	Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company Representative						

Date:06/25/02ISR Number: 3940002-2Report Type:Expedited (15-DaCompany Report #2002-BP-02682AU(1)
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Other	Asasantin Sr (Kar) (Acetylsalicylic	PS		ORAL	500/50MG	2 WK
	Duodenal Ulcer							
	Haemorrhage		Vioxx (Ta)	SS		ORAL	25 MG (1 IN 1 D)	11 DAY
			Betaloc (Metoprolol Tartrate) (Nr)	C				
			Panadol (Paracetamol) (Nr)	C				

Date:06/25/02ISR Number: 3940140-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00032
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS			25 MG, DAILY, PO	
			Aspirin Lysine	SS		ORAL	160 MG, DAILY, PO	
			Acetaminphen (+)					
			Caffeine (+)					
			Propoxyph	C				
			Auranofin	C				
			Simvastatin	C				
			Verapamil Hcl	C				

Date:06/25/02ISR Number: 3940141-6Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00008
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Hepatitis Oesophagitis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	

Date:06/25/02ISR Number: 3940142-8Report Type:Expedited (15-DaCompany Report #WAES 0206ESP00028
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastritis	Foreign	Tab Vioxx					
	Myocardial Infarction	Consumer	(Rofecoxib)	PS		ORAL	25 MG, DAILY,	
							PO	10 DAY
			Diclofenac Na	C				
			Verapamil	C				

Date:06/25/02ISR Number: 3940143-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Foreign	Tab Vioxx					
	Increased	Health	(Rofecoxib)	PS		ORAL	PO	
		Professional	[Therapy					
			Unspecified]	C				

Date:06/25/02ISR Number: 3940156-8Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00025
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	General Physical Health	Foreign	Tab Vioxx					
Hospitalization -	Deterioration	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	32 DAY
Initial or Prolonged	Myocardial Infarction	Professional	Singulair	C				
			Betahistine Hydrochloride	C				
			Fluticasone Propionate (+) Salmeterol Xi	C				
			Omeprazole	C				

Date:06/25/02ISR Number: 3940157-XReport Type:Expedited (15-DaCompany Report #WAES 0205AUS00092
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Left Ventricular Failure	Foreign	Tab Vioxx					
	Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	67 DAY
		Professional	Amlodipine Besylate	C				

Date:06/25/02ISR Number: 3940158-1Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Foreign	Tab Vioxx					
Initial or Prolonged	Arthralgia	Consumer	(Rofecoxib)	PS		ORAL		
	Difficulty In Walking							
	Dyspnoea							
	Face Oedema							
	Oropharyngeal Swelling							
	Palpitations							
	Pharyngeal Oedema							
	Sensation Of Heaviness							
	Tongue Oedema							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/02ISR Number: 3940159-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion Drug Interaction	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	1) 100 MG/DAILY; 2) 50 MG DAILY	8 DAY
			Phenobarbital	SS		ORAL		
			Furosemide	C				
			Nicergoline	C				
			Potassium Chloride	C				
			Trimetazidine Hydrochloride	C				

Date:06/25/02ISR Number: 3940166-0Report Type:Expedited (15-DaCompany Report #WAES 0206ITA00026
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	5 DAY
			Indapamide	C				

Date:06/25/02ISR Number: 3940168-4Report Type:Expedited (15-DaCompany Report #WAES 01080220
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
	Chest Pain	Health Professional	Allegra	C				
	Coronary Artery Disease		Celebrex	C				
	Coronary Artery Stenosis		Celexa	C				
	Dyskinesia		Glucovance	C				
	Dyspnoea		Plavix	C				
	Dyspnoea Exertional		Pravachol	C				

	Gastrooesophageal Reflux	Prinivil	C
	Disease	Toprol Xl Tablets	C
	Hypertension	Zantac	C
	Myocardial Ischaemia	Zestril	C
	Nausea	Aspirin	C

Date:06/25/02ISR Number: 3982276-8Report Type:Periodic Company Report #WAES 0201USA02388
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperglycaemia	Health Professional	Orsu Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Liq Fluoxetine Hcl 40 Mg	SS		ORAL	40 MG/DAILY/PO	
			Liq Doxepin Hcl 20 Mg	SS		ORAL	20 MG/DAILY/PO	

Date:06/26/02ISR Number: 3939517-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA01845
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Erythematous		Vioxx	PS		ORAL		8 DAY
Initial or Prolonged			Duragesic	C	Merck & Co., Inc	TOPICAL		
Other			Celebrex	C				

Date:06/26/02ISR Number: 3939518-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00032
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		59 DAY
Initial or Prolonged	Melaena		Aspirin Lysine	SS		ORAL		
			Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C		ORAL		59 DAY
			Auranofin	C		ORAL		
			Simvastatin	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		

Date:06/26/02ISR Number: 3939521-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA00964
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
	Headache		Mobic	C		ORAL		56 DAY
	Syncope		Celebrex	C		ORAL		16 DAY

Date:06/26/02ISR Number: 3939747-XReport Type:Expedited (15-DaCompany Report #WAES 0206NOR00006
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Vioxx	SS		ORAL		
14 DAY								
Disability	Fatigue		Drospirenone And					
	Gamma-Glutamyltransferase		Ethinyl Estradiol	C				
	Increased		Celecoxib	C				
	Haemoglobin Decreased		Diclofenac Sodium	C				
	Headache		Acetaminophen	C				
	Hepatomegaly							
	Nausea							
	Pain In Extremity							
	Pyrexia							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							

Date:06/26/02ISR Number: 3939752-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA03165
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Duodenal Ulcer
Hospitalization -	Gastric Ulcer
Initial or Prolonged	Gastritis Erosive
Other	Gastrointestinal

	Haemorrhage Orthostatic Hypotension Shock						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Carafate	C				
			Digestive Enzymes And Pancreatin	C				
			Glyburide	C				

Date:06/26/02ISR Number: 3939753-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02268
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cough Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cardizem	C				
			Prinivil	C		ORAL		
			Altace	C				
			[Therapy Unspecified]	C				

Date:06/26/02ISR Number: 3939772-9Report Type:Expedited (15-DaCompany Report #WAES 0206BEL00005
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diaphragmatic Hernia Oesophagitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	SS		ORAL		476 DAY
Other			Fluticasone Propionate	C				
RESPIRATORY (INHALATION)								
			Zocor	C		ORAL		
			Albuterol	C				
RESPIRATORY (INHALATION)								
			Felodipine	C		ORAL		

Date:06/26/02ISR Number: 3939773-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA03359
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
			Diuretic (Unspecified)	C				
			Methotrexate Sodium	C				
			Prednisone	C				
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3940116-7Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00144
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		214 DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation		Metoprolol	C		ORAL		
	Peritonitis		Metoprolol	C				INTRAVENOUS
			Repaglinide	C		ORAL		214 DAY
			Amlodipine	C		ORAL		214 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3940117-9Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00140
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	80	DAY

Date:06/27/02ISR Number: 3940129-5Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00124
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/02ISR Number: 3940131-3Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00120
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Dyspepsia		Acetaminophen And Codeine Phosphate	C		ORAL	12	DAY
			Sotalol Hydrochloride	C		ORAL		
			Methyldopa	C		ORAL		
			Aspirin	C		ORAL		

Date:06/27/02ISR Number: 3940135-0Report Type:Expedited (15-DaCompany Report #WAES 0206FIN00003
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Swelling		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Weight Increased		Tizanidine	C		ORAL		

Date:06/27/02ISR Number: 3940137-4Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00029
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
			Zocor	C		ORAL		
			Aspirin	C		ORAL		
			Atenolol And Chlorthalidone	C		ORAL		
			Cholecalciferol	C		ORAL		
			Calcium (Unspecified)	C		ORAL		

Date:06/27/02ISR Number: 3940144-1Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00058
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
	Face Oedema		Vasotec	C		ORAL		
			Vinburnine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3940147-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Drug Interaction		Phenobarbital	SS		ORAL		
			Phenobarbital	SS		ORAL		
			Furosemide	C				
			Potassium Chloride	C				
			Nicergoline	C				
			Trimetazidine Hydrochloride	C				

Date:06/27/02ISR Number: 3940148-9Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00056
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:06/27/02ISR Number: 3940231-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00109
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Chloride Increased		Ferrous Sulfate	C		ORAL		
Initial or Prolonged	Blood Creatinine		Zoloft	C		ORAL		
Other	Increased		Aricept	C		ORAL		
	Blood Potassium Increased		Hydrodiuril	C		ORAL		
	Blood Urea Increased		Levoxyl	C				
	Coma		Aspirin	C				
	Confusional State		Vasotec	C				
	Gastrointestinal		Peri-Colace	C				
	Haemorrhage		Risperdal	C		ORAL		
	Peptic Ulcer		Protein (Unspecified)	C				
	Protein Total Decreased		Magnesia [Milk Of]	C				
	White Blood Cell Count Increased							

Date:06/27/02ISR Number: 3940236-7Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00148
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Melaena		Acetaminophen	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:06/27/02ISR Number: 3940237-9Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00158
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Polyps		Indapamide And Perindopril Erbumine	C		ORAL		
	Rectal Haemorrhage		Furosemide Sodium	C				
			Domperidone	C				

		Omeprazole Magnesium	C	
		Dipyridamole	C	
		Calcium Carbonate	C	
		Ergocalciferol	C	
		Glimepiride	C	ORAL
		Isosorbide Mononitrate	C	ORAL

Date:06/27/02ISR Number: 3940240-9Report Type:Expedited (15-DaCompany Report #WAES 0206CAN00143
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arthralgia Arthritis Reactive Erythema Joint Swelling		Vioxx Analgesic Or Anesthetic (Unspecified) [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL

Date:06/27/02ISR Number: 3940242-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00039
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 728 DAY	Autoantibody Positive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Lactate Dehydrogenase Increased Myelodysplastic Syndrome		Methylprednisolone	C		

Date:06/27/02ISR Number: 3940243-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/27/02ISR Number: 3940245-8Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00126
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Bradycardia		Atenolol	C		ORAL		
			Ciprofibrate	C		ORAL		

Date:06/27/02ISR Number: 3940246-XReport Type:Expedited (15-DaCompany Report #WAES 0206CHE00028
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	98	DAY
			Fosamax	C		ORAL		
			Moduretic	C		ORAL		
			Valsartan	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3940247-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02340
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged			Diovan Hct	C				
			Digoxin	C				
			Metoprolol	C				
			Prinivil	C		ORAL		
			Prevacid	C				

Date:06/27/02ISR Number: 3940248-3Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00135
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastrointestinal		Indomethacin	SS		ORAL		
Initial or Prolonged	Haemorrhage							
	Large Intestinal Ulcer							

Date:06/27/02ISR Number: 3940249-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02194
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/02ISR Number: 3940251-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02573
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Paraesthesia		Soma	C				
			Ultram	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3940252-5Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00128
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tendon Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	442	DAY
			Levofloxacin	SS		ORAL	4	DAY
			Prednisolone	C		ORAL		

Date:06/27/02ISR Number: 3940723-1Report Type:Direct Company Report #CTU 171089
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS				
	Hypertension		Glucophage	C				
			Pravachol	C				
			Lotensin/Hydrochlorothiazide	C				
			Metoprolol	C				
			Multivitamin	C				
			Flomax	C				
			Urecholine	C				
			Viagra	C				

				Xenical	C		

Date:06/27/02ISR Number: 3940815-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Health	Tab Vioxx 25 Mg, Unk	PS		ORAL	PO	
	Deep Vein Thrombosis	Professional	Aldactone	C				
			Tegretol	C				
			Nortriptyline	C				

Date:06/27/02ISR Number: 3940820-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	PO	
Life-Threatening		Professional	Coumadin	C				
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:06/27/02ISR Number: 3940822-4Report Type:Expedited (15-DaCompany Report #WAES 01072467
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Cardiac Disorder	Health						
	Coma	Professional	Ibuprofen	C				
	Coronary Artery Atherosclerosis							
	Gastritis Haemorrhagic							
	Glomerulosclerosis							
	Hepatic Congestion							

Hepatic Steatosis
Pulmonary Congestion
Pulmonary Oedema
Rib Fracture
Scar

Date:06/27/02ISR Number: 3940847-9Report Type:Direct Company Report #CTU 171041
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx 25mg	PS		ORAL	25MG QD PO	
			Albuterol Inhaler	C				

Date:06/27/02ISR Number: 3940851-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01879
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3940858-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01882
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Oedema	Professional	Celebrex	SS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3941269-7Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00131
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coagulopathy	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID	3 DAY
Life-Threatening	Hepatic Failure	Health	Torsemide	SS		ORAL	10 MG/DAILY	3 DAY
	Shock	Professional	Vasotec (Enalapril					
		Other	Maleate)	SS		ORAL	2.5 MG DAILY	3 DAY
			Acetyldigoxin	C				
			Furosemide/Spironolactone	C				
			Glyburide	C				
			Phenprocoumon	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3941287-9Report Type:Expedited (15-DaCompany Report #WAES 01096011
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Macrocytosis	Foreign	Tab Vioxx					
	Pancytopenia	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
		Professional						
		Other	Acetaminophen	C			PO	1 MON
			Celecoxib	C				

				Pygeum Africanum Extract	C		

Date:06/27/02ISR Number: 3941366-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01708
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Tab Vioxx	PS		ORAL	PO	
	Headache		Prednisone	C				
	Myocardial Infarction							

Date:06/27/02ISR Number: 3941369-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Peripheral Embolism	Professional						
	Post Procedural Complication							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3941372-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01901
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Faeces Discoloured		Paxil	C				
	Fatigue		Singulair	C				
			Xanax	C				
			Aspirin	C				
			Hydrochlorothiazide	C				
			Methotrexate	C				
			Potassium (Unspecified)	C				

Date:06/27/02ISR Number: 3941376-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01959
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Study	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Mobility Decreased	Health	Zestril 5 Mg	SS			5 MG/DAILY	
	Rectal Haemorrhage	Professional	Blinded Therapy 2 Mg	SS		ORAL	SEE IMAGE	
			Aspirin	SS				
			Zoloft	C				
			Digoxin	C				

Date:06/27/02ISR Number: 3941378-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01821
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Influenza Like Illness						MG/DAILY/PO	6 MON
Initial or Prolonged	Rash		Darvocet-N	C				
	Vomiting		Prozac	C				
			Soma	C				

			Xanax	C
			Therapy Unspecified	C

Date:06/27/02ISR Number: 3941380-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage Intracranial							
	Infection							
	Somnolence							
	Subarachnoid Haemorrhage							

Date:06/27/02ISR Number: 3941389-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA03185
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization -	Anxiety
Initial or Prolonged	Back Pain
Disability	Chest Pain
Other	Dizziness
	Dyspnoea
	Hyperhidrosis

	Neck Pain						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Neurontin	C				

Date:06/27/02ISR Number: 3941399-XReport Type:Expedited (15-DaCompany Report #WAES 0202BEL00083
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophageal Haemorrhage	Foreign	Tab Vioxx					
Hospitalization -	Syncope	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	1 MON
Initial or Prolonged			Hyzaar	C				

Date:06/27/02ISR Number: 3941407-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01845
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Stevens-Johnson Syndrome	Health	Vioxx	PS		ORAL	50 MG/PO	
Initial or Prolonged		Professional	Celebrex	C				
Other		Company Representative	Duragesic	C				

Date:06/27/02ISR Number: 3941431-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA00964
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Health	Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Chest Pain	Professional						

	Headache	Company	Celebrex	C
	Syncope	Representative	Mobic	C

Date:06/27/02ISR Number: 3941452-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02149
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Ulcer	Professional					MG/DAILY/PO	
		Company Representative	Plavix	C				
			Zocor	C				

Date:06/27/02ISR Number: 3941454-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02143
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Transplant	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3941478-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA03070
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health	Vioxx Unk	PS		ORAL	PO	
Life-Threatening	Refusal Of Treatment By Patient	Professional	Coumadin	C				
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:06/27/02ISR Number: 3941484-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PM/PO	
	Appendicectomy	Professional	Bromfed	C				
	Asthenia		Decadron					
	Difficulty In Walking		(Dexamethasone)	C				
	Fatigue		Prilosec	C				
	Lethargy		Serevent	C				
	Muscle Rigidity		Singulair	C				
	Nervous System Disorder							
	Vertigo							

Date:06/27/02ISR Number: 3941525-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01148
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Tab Vioxx	PS		ORAL	PO	
			Ibuprofen	C				

Date:06/27/02ISR Number: 3941529-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01902
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage						MG/DAILY/PO	
Initial or Prolonged	Hypersensitivity							

Date:06/27/02ISR Number: 3941531-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA01743
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Professional					MG/DAILY/PO	
	Hypertension	Company Representative	Digoxin	C				

Date:06/27/02ISR Number: 3941797-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00032
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Foreign	Tab Vioxx					
Initial or Prolonged	Melaena	Other	(Rofecoxib)	PS		ORAL	25	
							MG/DAILY/PO	59 DAY
			Aspirin Lysine	SS		ORAL	160	

MG/DAILY/PO

Acetaminophen (+)	
Caffeine (+)	
Propoxyph	C
Auranofin	C
Simvastatin	C
Verapamil Hcl	C

Date:06/27/02ISR Number: 3941801-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00031
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Epistaxis International Normalised Ratio Increased	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
			Acenocoumarol	SS		ORAL	PO	

Date:06/27/02ISR Number: 3941805-0Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00085
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Anxiety Aortic Valve Incompetence Diabetes Mellitus Gastritis Haemodialysis Hepatitis A Antibody Positive Hypertension Intentional Misuse Intercapillary Glomerulosclerosis Nephritis Interstitial Oedema Peripheral Renal Failure Acute	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	200 MG	1 WK

Date:06/27/02ISR Number: 3943158-0Report Type:Periodic Company Report #WAES 0204USA02864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943159-2Report Type:Periodic Company Report #WAES 0204USA02800
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943160-9Report Type:Periodic Company Report #WAES 0204USA02593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3943161-0Report Type:Periodic Company Report #WAES 0204USA02378
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional	Aspirin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/27/02ISR Number: 3943162-2Report Type:Periodic Company Report #WAES 0204USA02299
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company Representative	Cardizem Cd	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3943163-4Report Type:Periodic Company Report #WAES 0204USA02282
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AILY/PO	

Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative	Celebrex	C
			Fosamax	C
Other			Vasotec	C

Date:06/27/02ISR Number: 3943164-6Report Type:Periodic Company Report #WAES 0204USA02167
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Company	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhage	Representative						
		Other	Aspirin	C				

Date:06/27/02ISR Number: 3943165-8Report Type:Periodic Company Report #WAES 0204USA02081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943166-XReport Type:Periodic Company Report #WAES 0204USA01873
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:06/27/02ISR Number: 3943167-1Report Type:Periodic Company Report #WAES 0204USA01854
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged		Company Representative						

Date:06/27/02ISR Number: 3943168-3Report Type:Periodic Company Report #WAES 0204USA01751
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:06/27/02ISR Number: 3943169-5Report Type:Periodic Company Report #WAES 0204USA01727
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	

Company
Representative

Date:06/27/02ISR Number: 3943170-1Report Type:Periodic Company Report #WAES 0204USA01705
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Amaryl	C				
			Glucophage	C				
			Monopril	C				
			Zocor	C				
			Chlorthalidone	C				
			Probenecid	C				

Date:06/27/02ISR Number: 3943171-3Report Type:Periodic Company Report #WAES 0204USA01388
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PRN/PO	

Date:06/27/02ISR Number: 3943172-5Report Type:Periodic Company Report #WAES 0204USA01391
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Tab Vioxx Unk Zestril	PS C		ORAL	PO	

Date:06/27/02ISR Number: 3943173-7Report Type:Periodic Company Report #WAES 0204USA01303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943174-9Report Type:Periodic Company Report #WAES 0204USA01296
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:06/27/02ISR Number: 3943175-0Report Type:Periodic Company Report #WAES 0204USA01285
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Blood Urine Present	Consumer	Tab Vioxx 12.5 Mg; 25 Mg	PS		ORAL	12.5	

Drug Ineffective
MG/DAILY/PO;
Renal Failure Acute
SEE IMAGE

Actos	C
Allegra	C
Glucophage Xr	C
Zocor	C
Allopurinol	C
Aspirin	C
Gemfibrozil	C
Metoprolol	C

Date:06/27/02ISR Number: 3943176-2Report Type:Periodic Company Report #WAES 0204USA01122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Prednisone	C				

Date:06/27/02ISR Number: 3943177-4Report Type:Periodic Company Report #WAES 0204USA01123
Age: Gender: I/FU:I

Outcome	PT	Report Source
Other	Meningitis Aseptic	Health Professional

			Company Representative				
				Product	Role	Manufacturer	Route
Dose	Duration						
				Tab Vioxx	PS		ORAL
PO							

Date:06/27/02ISR Number: 3943178-6Report Type:Periodic Company Report #WAES 0204USA00995
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company	Actos	C		
		Representative	Aldactone	C		
			Feosol	C		
			Glucophage	C		
			Glucotrol	C		
			Lasix (Furosemide)	C		
			Neurontin	C		
			Prevacid	C		
			Ternormin	C		

Date:06/27/02ISR Number: 3943179-8Report Type:Periodic Company Report #WAES 0204USA00939
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Nephritis Interstitial	Health	Tab Vioxx 50mg	PS		ORAL
50						
Hospitalization -	Renal Failure Acute	Professional				
MG/DAILY/PO						
Initial or Prolonged		Company	Celebrex	C		
Disability		Representative	Hyzaar	C		

Date:06/27/02ISR Number: 3943180-4Report Type:Periodic Company Report #WAES 0204USA00892
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Inderal	C				
			Premarin	C				
			Zomax	C				

Date:06/27/02ISR Number: 3943181-6Report Type:Periodic Company Report #WAES 0204USA00833
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Oedema	Company Representative						

Date:06/27/02ISR Number: 3943182-8Report Type:Periodic Company Report #WAES 0204USA00731
Age: Gender: I/FU:I

Outcome	PT	Report Source
Other	Leukopenia	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 DAY

Date:06/27/02ISR Number: 3943183-XReport Type:Periodic Company Report #WAES 0204USA00737
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Perforation	Consumer Other	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943184-1Report Type:Periodic Company Report #WAES 0204USA00517
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Aspirin	PS C		ORAL	PO	

Date:06/27/02ISR Number: 3943185-3Report Type:Periodic Company Report #WAES 0204USA00510
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg Accupril Lipitor Toprol Xl Tablets	PS C C C		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3943186-5Report Type:Periodic Company Report #WAES 0204USA00174
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943187-7Report Type:Periodic Company Report #WAES 0204USA00169
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	SS				
			Guaifenex Pse	C				
			Potassium Chloride	C				
			Lotensin	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943188-9Report Type:Periodic Company Report #WAES 0205USA00750
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	3=25M G/DAILY/PO	
		Company Representative	Estrogens	C				

Date:06/27/02ISR Number: 3943189-0Report Type:Periodic Company Report #WAES 0205USA00725
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged			Atacand	C				
			Dyazide	C				
			Lipitor	C				
			Clorazepate Dipotassium	C				

Date:06/27/02ISR Number: 3943190-7Report Type:Periodic Company Report #WAES 0205USA00584
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	3 DAY
		Professional Company Representative	Zoloft	C				

Date:06/27/02ISR Number: 3943191-9Report Type:Periodic Company Report #WAES 0205USA00545
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943192-0Report Type:Periodic Company Report #WAES 0205USA00502
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	
	Gastrointestinal Haemorrhage		Coumadin	C				

Date:06/27/02ISR Number: 3943193-2Report Type:Periodic Company Report #WAES 0205USA00287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943194-4Report Type:Periodic Company Report #WAES 0205USA00105
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG / DAILY / PO ; 25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3943195-6Report Type:Periodic Company Report #WAES 0205USA00112
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943196-8Report Type:Periodic Company Report #WAES 0204USA02966
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Trimox	C				

Date:06/27/02ISR Number: 3943197-XReport Type:Periodic Company Report #WAES 0204USA02943
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Haemorrhage	Professional				
MG/DAILY/PO						
Initial or Prolonged			Buspar	C		
Other			Demerol	C		
			Tegretol	C		
			Zyrtec	C		
			Lorazepam	C		

Date:06/27/02ISR Number: 3943198-1Report Type:Periodic Company Report #WAES 0204USA00123
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Consumer	Tab Vioxx 12.5mg	PS		ORAL
SEE IMAGE						
		Health	Celebrex	C		
		Professional	Premarin	C		
			Zestril	C		

Date:06/27/02ISR Number: 3943199-3Report Type:Periodic Company Report #WAES 0204USA00036
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertension	Health	Tab Vioxx	PS		ORAL
PO						
	Renal Failure Acute	Professional	Darvocet-N	C		
		Company	Atenolol	C		
		Representative	Prednisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943200-7Report Type:Periodic Company Report #WAES 0203USA03263
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Bactrim	C				
		Company	Decadron					
		Representative	(Dexamethasone					
			Sodium)	C				
			Proscar	C				
			Allopurinol	C				

Date:06/27/02ISR Number: 3943201-9Report Type:Periodic Company Report #WAES 0203USA03215
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged	Gastrointestinal	Professional	(Therapy					
Disability	Haemorrhage	Company	Unspecified)	C				
Other		Representative						

Date:06/27/02ISR Number: 3943202-0Report Type:Periodic Company Report #WAES 0203USA03206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other		Company	Synthroid	C				
		Representative	Xanax	C				

Date:06/27/02ISR Number: 3943203-2Report Type:Periodic Company Report #WAES 0203USA03210
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative	Glucophage	C				

Date:06/27/02ISR Number: 3943204-4Report Type:Periodic Company Report #WAES 0203USA03179
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3943205-6Report Type:Periodic Company Report #WAES 0203USA03169
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Literature	Tab Vioxx 25mg	PS		ORAL	PO	21 DAY
		Health	Hydrodiuril	C				
		Professional Company Representative	Furosemide	C				

Date:06/27/02ISR Number: 3943206-8Report Type:Periodic Company Report #WAES 0203USA03167
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Literature	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	28 DAY
	Renal Failure Acute	Health Professional Company Representative	Metoprolol	C				

Date:06/27/02ISR Number: 3943207-XReport Type:Periodic Company Report #WAES 0203USA03029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tab Flexeril 10mg	SS		ORAL	10 MG/TID/PO	
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3943208-1Report Type:Periodic Company Report #WAES 0203USA02968
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY /PO	

Date:06/27/02ISR Number: 3943209-3Report Type:Periodic Company Report #WAES 0203USA02914
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3943210-XReport Type:Periodic Company Report #WAES 0203USA02494
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE,PO	
		Health Professional	Lasix (Furosemide)	C				
			Lipitor	C				
			Paxil	C				
			Procardia Xl	C				
			Synthroid	C				
			Tenormin	C				

Date:06/27/02ISR Number: 3943211-1Report Type:Periodic Company Report #WAES 0203USA02484
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Confusional State
	Hypoaesthesia

Musculoskeletal Stiffness

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Lipitor	C				

Date:06/27/02ISR Number: 3943212-3Report Type:Periodic Company Report #WAES 0203USA02182
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
Hospitalization -		Professional						
Initial or Prolonged		Company	Advil	C				
Disability		Representative	Aleve	C				
Other			Glutofac	C				
			Inderal	C				
			Lopressor	C				
			Nexium	C				
			Spironolactone	C				

Date:06/27/02ISR Number: 3943213-5Report Type:Periodic Company Report #WAES 0203USA01161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx	PS		ORAL		PO
Initial or Prolonged		Professional Company Representative						

Date:06/27/02ISR Number: 3943214-7Report Type:Periodic Company Report #WAES 0203USA00599
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Pravachol	C				
Other		Representative	Folic Acid	C				

Date:06/27/02ISR Number: 3943215-9Report Type:Periodic Company Report #WAES 0203USA00312
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:06/27/02ISR Number: 3943216-0Report Type:Periodic Company Report #WAES 0203USA00255
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	

Date:06/27/02ISR Number: 3943217-2Report Type:Periodic Company Report #WAES 0203USA00192
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:06/27/02ISR Number: 3943259-7Report Type:Periodic Company Report #WAES 0202USA00664
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative						

Date:06/27/02ISR Number: 3943260-3Report Type:Periodic Company Report #WAES 0202USA00038
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage Renal Failure	Professional Company Representative						

Date:06/27/02ISR Number: 3943261-5Report Type:Periodic Company Report #WAES 0201USA02754
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50	

	Nausea	Professional					
MG/DAILY/PO							
	Vomiting	Company Representative	Ambien	C			
			Triphasil	C			

Date:06/27/02ISR Number: 3943262-7Report Type:Periodic Company Report #WAES 0201USA01026
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactoid Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other			Tab Tylenol With Codeine	SS		ORAL	PRN/PO	
			Cap Prevacid 30 Mg	SS		ORAL	30 MG/1X/PO	
			Levaquin 500 Mg	SS		INTRAVENOUS	500	MG/DAILY/IV
			Dilantin	C				

Date:06/27/02ISR Number: 3943263-9Report Type:Periodic Company Report #WAES 0201USA00508
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	
	Loss Of Consciousness	Health					MG/DAILY/PO	
	Nausea	Professional	Tab Vioxx 25 Mg	SS		ORAL	PO	
			Darvocet-N	C				

Flexeril	C
Glucophage	C
Miacalcin	C
Monopril	C
Zocor	C
Digoxin	C
Glyburide	C

Date:06/27/02ISR Number: 3943264-0Report Type:Periodic Company Report #WAES 0201USA00377
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3943265-2Report Type:Periodic Company Report #WAES 0205USA02833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Tab Fosamax	SS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3943266-4Report Type:Periodic Company Report #WAES 0205USA02967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Aspirin	C				
		Company	Prednisone	C				

Representative

Date:06/27/02ISR Number: 3943267-6Report Type:Periodic Company Report #WAES 0205USA02829
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Avandia	C				
Other		Representative	Zocor	C				
			Insulin	C				

Date:06/27/02ISR Number: 3943268-8Report Type:Periodic Company Report #WAES 0205USA02000
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastroduodenal Ulcer	Health	Tab Vioxx	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company						
		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943269-XReport Type:Periodic Company Report #WAES 0205USA01967
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional Company Representative	Demerol	C				

Date:06/27/02ISR Number: 3943270-6Report Type:Periodic Company Report #WAES 0205USA01722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	10 MON
		Professional Company Representative						

Date:06/27/02ISR Number: 3943271-8Report Type:Periodic Company Report #WAES 0205USA01702
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertension	Professional Company Representative						
	Oedema		Glucovance	C				
	Renal Impairment		Propranolol Hydrochloride	C				

Date:06/27/02ISR Number: 3943272-XReport Type:Periodic Company Report #WAES 0205USA01566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL
50 MG/DAILY/PO 1 YR		Professional Company Representative	(Therapy Unspecified)	C		

Date:06/27/02ISR Number: 3943273-1Report Type:Periodic Company Report #WAES 0205USA01285
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
Initial or Prolonged	Haemorrhage	Professional Company Representative	Coumadin	C		

Date:06/27/02ISR Number: 3943274-3Report Type:Periodic Company Report #WAES 0205USA01195
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 Initial or Prolonged MG/DAILY/PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3943275-5Report Type:Periodic Company Report #WAES 0205USA01178
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3943276-7Report Type:Periodic Company Report #WAES 0205USA01174
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:06/27/02ISR Number: 3943277-9Report Type:Periodic Company Report #WAES 0205USA01160
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Accupril	C				
			Celebrex	C				
			Oxacillin Sodium	C				

Date:06/27/02ISR Number: 3943278-0Report Type:Periodic Company Report #WAES 0205USA01013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation	Health Professional Company Representative	Tab Vioxx Unk	PS			ORAL UNK/UNK/PO

Date:06/27/02ISR Number: 3943288-3Report Type:Periodic Company Report #WAES 0203USA00117
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Haemorrhage		Ambien	C				
			Evista	C				
			Prevacid	C				
			Zoloft	C				
			Zyrtec-D	C				

Date:06/27/02ISR Number: 3943289-5Report Type:Periodic Company Report #WAES 0202USA02351
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3943290-1Report Type:Periodic Company Report #WAES 0202USA02228
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:06/27/02ISR Number: 3943291-3Report Type:Periodic Company Report #WAES 0203USA01867
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	Kefzol	SS				

Date:06/27/02ISR Number: 3943292-5Report Type:Periodic Company Report #WAES 0203USA01779
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional Company Representative	Digitex	C			MG/DAILY/PO	
			Tricor	C				
			Trazodone	C				

Date:06/27/02ISR Number: 3943293-7Report Type:Periodic Company Report #WAES 0203USA01760
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
		Company Representative				

Date:06/27/02ISR Number: 3943294-9Report Type:Periodic Company Report #WAES 0203USA01640
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						

Date:06/27/02ISR Number: 3943295-0Report Type:Periodic Company Report #WAES 0203USA01348
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Diarrhoea	Health				
MG/DAILY/PO						
	Fluid Retention	Professional	Fosamax	C		
	Oedema Peripheral		Glucophage	C		
			Levoxyl	C		
			Lidoderm	C		
			Lomotil	C		
			Micro K	C		
			Neurontin	C		

Premarin	C
Tenormin	C
Ultracef	C
Zocor	C
Zomig	C
Allopurinol	C
Furosemide	C

Date:06/27/02ISR Number: 3978224-7Report Type:Periodic Company Report #WAES 0204USA00712
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lung Disorder	Health	Tab Vioxx	PS		ORAL	PO	
	Pleural Effusion	Professional Company Representative						

Date:06/27/02ISR Number: 3978227-2Report Type:Periodic Company Report #WAES 0204USA00714
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Swelling		Elmiron	SS				
	Weight Increased		Tab Elavil	SS		ORAL	PO	
			Ziac	C				

Date:06/27/02ISR Number: 3978230-2Report Type:Periodic Company Report #WAES 0204USA00726
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Company
Representative

Date:06/27/02ISR Number: 3978232-6Report Type:Periodic Company Report #WAES 0204USA00741
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dysuria							
			Ambien	C				
			Endocet	C				

Date:06/27/02ISR Number: 3978233-8Report Type:Periodic Company Report #WAES 0204USA00745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Ultram 50 Mg	SS		ORAL	200-300 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978239-9Report Type:Periodic Company Report #WAES 0204USA00748
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	C				

Date:06/27/02ISR Number: 3978240-5Report Type:Periodic Company Report #WAES 0204USA00750
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Augmentin	C				
			Cefalexin	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3978241-7Report Type:Periodic Company Report #WAES 0204USA00754
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978242-9Report Type:Periodic Company Report #WAES 0204USA00788
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/ PO	
	Prothrombin Level Increased		Cardizem Cd	C				
			Coumadin	C				
			Demadex	C				

Digitek	C
K-Dur	C
Miacalcin	C
Propylthiouracil	C

Date:06/27/02ISR Number: 3978250-8Report Type:Periodic Company Report #WAES 0204USA00790
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urticaria							

Date:06/27/02ISR Number: 3978254-5Report Type:Periodic Company Report #WAES 0204USA00796
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Ziac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978257-0Report Type:Periodic Company Report #WAES 0204USA00808
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Flomax (Morinflumate)	C				
			Prilosec	C				
			Prinivil	C				
			Urocit-K	C				
			Aspirin	C				
			Digoxin	C				
			Silver Protein, Mild	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3978260-0Report Type:Periodic Company Report #WAES 0204USA00820
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978261-2Report Type:Periodic Company Report #WAES 0204USA00828
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Coumadin	C				
			Lipitor	C				
			Toprol Xl Tablets	C				
			Ultram	C				
			Digoxin	C				

Date:06/27/02ISR Number: 3978265-XReport Type:Periodic Company Report #WAES 0204USA00835
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Hot	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Paraesthesia		Diovan	C				
			Norvasc	C				
			Estrogens	C				
			Thyroid	C				

Date:06/27/02ISR Number: 3978268-5Report Type:Periodic Company Report #WAES 0204USA00836
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Daypo	C				
			Neurontin	C				
			Prilosec	C				
			Cyclobenzaprine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978271-5Report Type:Periodic Company Report #WAES 0204USA00837
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Amgien	C				
			Endocet	C				

Date:06/27/02ISR Number: 3978274-0Report Type:Periodic Company Report #WAES 0204USA00845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO; 25 MG	

Date:06/27/02ISR Number: 3978276-4Report Type:Periodic Company Report #WAES 0204USA00852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema							
	Weight Increased		Neurontin	C				
			Amitripytline	C				

Date:06/27/02ISR Number: 3978279-XReport Type:Periodic Company Report #WAES 0204SUA00858
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Health Professional	Tab Vioxx Unk	PS			ORAL
25 MG/DAILY/PO; 12.5 MG/DAILY/PO							
			Dyazide	C			

Date:06/27/02ISR Number: 3978282-XReport Type:Periodic Company Report #WAES 0203USA00878
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25mg	PS		ORAL	25, 50	
	Panic Attack	Health Professional					MG/DAILY/PO	4 MON

Date:06/27/02ISR Number: 3978285-5Report Type:Periodic Company Report #WAES 0203USA00881
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	SEE IMAGE	
	Myalgia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978288-0Report Type:Periodic Company Report #WAES 0203USA00891
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/BID/PO	

Date:06/27/02ISR Number: 3978289-2Report Type:Periodic Company Report #WAES 0203USA00892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
			Calan	C				
			Lipitor	C				
			Maxzide	C				
			Tylenol	C				

Date:06/27/02ISR Number: 3978290-9Report Type:Periodic Company Report #WAES 0203USA00907
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Herpes Zoster	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Nitro-Dur	C				
			Prevacid	C				
			Vicodin Tablets	C				
			Bumetanide	C				
			Diltiazem Hydrochloride	C				
			Fluoxetine	C				
			Magnesium Oxide	C				

Date:06/27/02ISR Number: 3978291-0Report Type:Periodic Company Report #WAES 0203USA00913
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978292-2Report Type:Periodic Company Report #WAES 0203USA00927
Age:47 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Rash	Professional	Arthrotec	C				
	Swelling		Celexa	C				
			Prevacid	C				
			Synthroid	C				
			Acetaminophen (+)					
			Hydrocodone Bi	C				

Date:06/27/02ISR Number: 3978295-8Report Type:Periodic Company Report #WAES 0203USA00935
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Amaryl	C				
			Hydrodiuril	C				

			Levaquin	C		
			Fluoxetine	C		

Date:06/27/02ISR Number: 3978299-5Report Type:Periodic Company Report #WAES 0203USA00946
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Atacand	C				

Date:06/27/02ISR Number: 3978302-2Report Type:Periodic Company Report #WAES 0203USA00947
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3978306-XReport Type:Periodic Company Report #WAES 0204USA01113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Abnormal Pruritus	Company Representative						
	Rash Erythematous							

Date:06/27/02ISR Number: 3978309-5Report Type:Periodic Company Report #WAES 0204USA01114
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978312-5Report Type:Periodic Company Report #WAES 0204USA01115
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Neurontin	C				
			Ultracet	C				
			Zocor	C				
			Isosorbide	C				

Date:06/27/02ISR Number: 3978315-0Report Type:Periodic Company Report #WAES 0204USA01116
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypoaesthesia							
	Paraesthesia							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978318-6Report Type:Periodic Company Report #WAES 0204USA01148
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dyspepsia							
			Coumadin	C				
			Diovan	C				
			Hydrodiuril	C				
			Prinivil	C				

Date:06/27/02ISR Number: 3978321-6Report Type:Periodic Company Report #WAES 0204USA01159
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Actos	C				
			Claritin	C				
			Diovan	C				
			Klor-Con	C				
			Xalatan	C				
			Calcium (Unspecified)	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3978324-1Report Type:Periodic Company Report #WAES 0204USA01161
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Ditropan	C				

Date:06/27/02ISR Number: 3978327-7Report Type:Periodic Company Report #WAES 0204USA01162
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Fosamax	C				

Date:06/27/02ISR Number: 3978328-9Report Type:Periodic Company Report #WAES 0204USA01174
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3978329-0Report Type:Periodic Company Report #WAES 0204USA01179
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Arthrotec	C				

			Celebrex	C		

Date:06/27/02ISR Number: 3978330-7Report Type:Periodic Company Report #WAES 0203USA00618
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Alphagan	C				
			Lotemax	C				

Date:06/27/02ISR Number: 3978331-9Report Type:Periodic Company Report #WAES 0203USA00625
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy	Consumer	Tab Vioxx 25mg	PS		ORAL	PO	
	Drug Ineffective	Health	Zoloft	C				
	Pain In Extremity	Professional						

Date:06/27/02ISR Number: 3978332-0Report Type:Periodic Company Report #WAES 0203USA00626
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Pain						MG/DAILY/PO	
			Diovan Hct	C				
			Prilosec	C				
			Zocor	C				

Date:06/27/02ISR Number: 3978333-2Report Type:Periodic Company Report #WAES 0203USA00632
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978334-4Report Type:Periodic Company Report #WAES 0203USA00634
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Joint Swelling		Celebrex	C				

Date:06/27/02ISR Number: 3978335-6Report Type:Periodic Company Report #WAES 0203USA00648
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nocturia							
	Urine Flow Decreased		Claritin	C				
			Monopril	C				
			Zocor	C				
			Fluoxetine	C				
			Ranitidine	C				
			Terazosin					

				Hydrochloride	C		
				Verapamil Hydrochloride	C		

Date:06/27/02ISR Number: 3978336-8Report Type:Periodic Company Report #WAES 0203USA00712
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Viagra	C				
			Zocor	C				
			Levothyroxine Sodium	C				

Date:06/27/02ISR Number: 3978337-XReport Type:Periodic Company Report #WAES 0203USA00730
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978338-1Report Type:Periodic Company Report #WAES 0203USA00733
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Headache							
	Tinnitus		Diovan	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3978339-3Report Type:Periodic Company Report #WAES 0203USA00876
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3978340-XReport Type:Periodic Company Report #WAES 0203USA00481
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx	PS		ORAL	25MG/DAILY;	
	Prescribed Overdose	Health					PO	
		Professional	Tab Vioxx	SS		ORAL	50 MG; BID;	
		Company					PO	
		Representative	Dilantin	C				

Date:06/27/02ISR Number: 3978341-1Report Type:Periodic Company Report #WAES 0203USA00499
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Vioxx	PS		ORAL	25 MG; DAILY;	
	Congestive	Professional					PO	

Pepcid	C
Calcium Carbonate	C
Cyanocobalamin	C
Digoxin	C
Furosemide	C
Levothyroxine Sodium	C
Mesalamine	C
Potassium Chloride	C
Raloxifene	C
Vitamins (Unspecified)	C
Warfarin	C
...	C

Date:06/27/02ISR Number: 3978342-3Report Type:Periodic Company Report #WAES 0203USA00504
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Vioxx	PS		ORAL	25MG; DAILY;	
PO								
			Accuretic	C				
			Lanoxin	C				
			Neurotonin Capsules	C				
			Bisoprolol Fumarate	C				
			Doxazosin Mesylate	C				
			Metformin	C				
			Prednisone	C				

Date:06/27/02ISR Number: 3978343-5Report Type:Periodic Company Report #WAES 0203USA00591
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Vioxx	PS		ORAL	25MG; DAILY;	
	Decreased							
PO								
			Metadate	C				
			Lithium Carbonate	C				

Date:06/27/02ISR Number: 3978344-7Report Type:Periodic Company Report #WAES 0203USA00605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3978345-9Report Type:Periodic Company Report #WAES 0203USA00606
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5mg	PS		ORAL	PO	
	Fluid Retention		Tab Vioxx	SS		ORAL	25 MG/UNK; PO	
	Oedema Peripheral		Tab Vioxx	SS		ORAL	50 MG/UNK; PO	
			Aciphex	C				
			Astelin	C				
			Avandia	C				
			Diosmol	C				
			Lasix (Furosemide)	C				

Lipitor	C
Protopic	C
Tearisol	C
Temaril	C
Ascorbic Acid	C
Aspirin	C
Insulin	C
Linseed Oil	C
Vitamins (Unspecified)	C

Date:06/27/02ISR Number: 3978346-0Report Type:Periodic Company Report #WAES 0203USA00608
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS		ORAL	25 MG/DAILY;	
	Nail Disorder							
PO								
			Glucophage	C				
			Norvasc	C				
			Premarin	C				

Date:06/27/02ISR Number: 3978347-2Report Type:Periodic Company Report #WAES 0203USA00610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Vioxx 25 Mg	PS		ORAL	50 MG;DAILY;	
	Decreased							
PO								

Date:06/27/02ISR Number: 3978348-4Report Type:Periodic Company Report #WAES 0203USA00612
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG; DAILY;	

Hypoaesthesia
PO
Nausea

Date:06/27/02ISR Number: 3978349-6Report Type:Periodic Company Report #WAES 0203USA00617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG; DAILY;	
PO								

Date:06/27/02ISR Number: 3978350-2Report Type:Periodic Company Report #WAES 0204USA00860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL		
PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978351-4Report Type:Periodic Company Report #WAES 0204USA00861
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:06/27/02ISR Number: 3978352-6Report Type:Periodic Company Report #WAES 0204USA00872
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Decreased						PO	
			Ecotrin	C				
			Calcium (Unspecified)	C				
			Nadolol	C				
			Vitamin E	C				

Date:06/27/02ISR Number: 3978353-8Report Type:Periodic Company Report #WAES 0203USA00964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	General Symptom	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral							
	Paraesthesia							

Date:06/27/02ISR Number: 3978354-XReport Type:Periodic Company Report #WAES 0203USA00965
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Rash	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative				

Date:06/27/02ISR Number: 3978355-1Report Type:Periodic Company Report #WAES 0203USA00968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Unevaluable Event	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional Company Representative	Bactrim	C		

Date:06/27/02ISR Number: 3978356-3Report Type:Periodic Company Report #WAES 0203USA00979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Bundle Branch Block Right	Consumer	Tab Vioxx 50 Mg	PS		ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978357-5Report Type:Periodic Company Report #WAES 0203USA00999
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Hypertension	Professional					MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3978358-7Report Type:Periodic Company Report #WAES 0203USA01003
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:06/27/02ISR Number: 3978359-9Report Type:Periodic Company Report #WAES 0203USA01054
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Swelling						MG/DAILY/PO	
			Azelex	C				
			Hydrodiuril	C				
			Penlac	C				
			Premarin	C				
			Prevacid	C				
			Synthroid	C				
			Zocor	C				

Date:06/27/02ISR Number: 3978360-5Report Type:Periodic Company Report #WAES 0203USA01056
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Singulair	C				

Date:06/27/02ISR Number: 3978361-7Report Type:Periodic Company Report #WAES 0203USA01059
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Aerobid	C				
			Celexa	C				
			Lipitor	C				
			Norvasc	C				
			Nortriptyline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978362-9Report Type:Periodic Company Report #WAES 0203USA01072
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978736-6Report Type:Periodic Company Report #WAES 0204USA00965
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Claritin-D	C				
			Nexium	C				
			Provigil	C				
			Baclofen	C				

Date:06/27/02ISR Number: 3978742-1Report Type:Periodic Company Report #WAES 0204USA00970
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978747-0Report Type:Periodic Company Report #WAES 0204USA00973
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic Attack	Consumer Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

		Professional	Prilosec	C

Date:06/27/02ISR Number: 3978749-4Report Type:Periodic Company Report #WAES 0204USA00993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3978753-6Report Type:Periodic Company Report #WAES 0204USA01018
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Tylenol Arthritis Extended Relie	C				
			Glucosamine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978757-3Report Type:Periodic Company Report #WAES 0204USA01070
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Skin	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral		Celebrex	C				

Date:06/27/02ISR Number: 3978760-3Report Type:Periodic Company Report #WAES 0204USA01078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Company	Tab Vioxx	PS		ORAL	PO	
		Representative Other	Therapy Unspecified	C				

Date:06/27/02ISR Number: 3978763-9Report Type:Periodic Company Report #WAES 0204USA01093
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/	
	Oedema Peripheral	Professional					DAILY/PO	
		Company Representative	Fosamax	C				
			Levoxyl	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/27/02ISR Number: 3978769-XReport Type:Periodic Company Report #WAES 0204USA01100
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	

	Tinnitus	Professional					
PO							
		Company	Lipitor	C			
		Representative	Toprol Xl Tablets	C			

Date:06/27/02ISR Number: 3978771-8Report Type:Periodic Company Report #WAES 0204USA01112
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Bone Pain							
PO								
			Premarin	C				
			Prilosec	C				
			Provera	C				
			Colchicine	C				

Date:06/27/02ISR Number: 3978774-3Report Type:Periodic Company Report #WAES 0203USA01075
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapy Non-Responder	Health	Tab Vioxx	PS		ORAL		
PO								
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978776-7Report Type:Periodic Company Report #WAES 0203USA01080
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Pepcid	C				
			Prempro	C				
			Serevent	C				
			Singulair	C				
			Tiazac	C				
			Zyrtec	C				
			Albuterol	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3978778-0Report Type:Periodic Company Report #WAES 0203USA01088
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx	PS		ORAL	PO	
	Bronchitis	Professional						
	Upper Respiratory Tract Infection	Company Representative						

Date:06/27/02ISR Number: 3978782-2Report Type:Periodic Company Report #WAES 0203USA01089
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Health	Tab Vioxx	PS		ORAL	PO	
	Bronchitis	Professional						
	Upper Respiratory Tract Infection	Company Representative						

Date:06/27/02ISR Number: 3978786-XReport Type:Periodic Company Report #WAES 0203USA01141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Musculoskeletal Stiffness							
			Flomax (Tamsulosin Hydrochloride)	C				

Date:06/27/02ISR Number: 3978791-3Report Type:Periodic Company Report #WAES 0203USA01146
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978794-9Report Type:Periodic Company Report #WAES 0203USA01154
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Lasix (Furosemide)	C				
			Potassium	C				
			Vitamin E	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978800-1Report Type:Periodic Company Report #WAES 0203USA01164
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978805-0Report Type:Periodic Company Report #WAES 0203USA01167
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Periorbital Oedema		Estrace	C				
			Lipitor	C				

Date:06/27/02ISR Number: 3978806-2Report Type:Periodic Company Report #WAES 0203USA01170
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Skin Exfoliation							
			Os-Cal Plus	C				
			Diltiazem Hydrochloride	C				

Date:06/27/02ISR Number: 3978807-4Report Type:Periodic Company Report #WAES 0205USA00356
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urogenital Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	50 MG/ PO	

Date:06/27/02ISR Number: 3978808-6Report Type:Periodic Company Report #WAES 0205USA00359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3978809-8Report Type:Periodic Company Report #WAES 0205USA00444
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bone Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 - 25 MG/PRN/PO	
	Chills							
	Muscle Spasms		Ambien	C				
			Levoxyl	C				
			Nifedipine	C				
			Oxazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978810-4Report Type:Periodic Company Report #WAES 0205USA00511
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Sleep Walking							
			Hytrin	C				
			Prinivil	C				
			Furosemide	C				
			Propranolol Hydrochloride	C				

Date:06/27/02ISR Number: 3978811-6Report Type:Periodic Company Report #WAES 0205USA00512
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lipitor	C				
			Prilosec	C				
			Zestril	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3978813-XReport Type:Periodic Company Report #WAES 0205USA00515
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Polyps	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Peptic Ulcer							
			Altace	C				
			Evista	C				
			Lipitor	C				
			Premarin Vaginal Cream	C				
			Ziac	C				

Date:06/27/02ISR Number: 3978814-1Report Type:Periodic Company Report #WAES 0205USA00528
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mobility Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							

Date:06/27/02ISR Number: 3978815-3Report Type:Periodic Company Report #WAES 0205USA00536
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978816-5Report Type:Periodic Company Report #WAES 0205USA00552
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Consumer	Tab Vioxx	PS		ORAL	PO	
			Augmentin	C				

				Protonix	C	
				Wellbutrin	C	

Date:06/27/02ISR Number: 3978817-7Report Type:Periodic Company Report #WAES 0205USA00559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Decreased		Tylenol	C				

Date:06/27/02ISR Number: 3978821-9Report Type:Periodic Company Report #WAES 0204USA02050
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO; 50 MG/DAILY/PO	
			Depakote	C				
			Zantac	C				
			Calcium	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3978827-XReport Type:Periodic Company Report #WAES 0204USA02058
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978830-XReport Type:Periodic Company Report #WAES 0204USA02059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Memory Impairment							
			Clarinex	C				
			Effexor	C				
			Hytrin	C				
			Hyzaar	C				
			Lipitor	C				
			Norvasc	C				
			Prevacid	C				
			Tylenol	C				

Date:06/27/02ISR Number: 3978833-5Report Type:Periodic Company Report #WAES 0204USA02066
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Company Representative Other	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978835-9Report Type:Periodic Company Report #WAES 0204USA02069
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
	Increased	Professional					PO	
	Blood Urea Increased		Prilosec	C				
	Headache		Zestril	C				
	Hypertension							

Date:06/27/02ISR Number: 3978838-4Report Type:Periodic Company Report #WAES 0204USA02076
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	4 DAY
			Penicillin	C				

Date:06/27/02ISR Number: 3978841-4Report Type:Periodic Company Report #WAES 0204USA02078
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Macular	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Rash Pruritic						MG/DAILY/PO	

Date:06/27/02ISR Number: 3978845-1Report Type:Periodic Company Report #WAES 0204USA02084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional						
		Company						

Date:06/27/02ISR Number: 3978848-7Report Type:Periodic Company Report #WAES 0204USA02089
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Carita (Diltiazem Hydrochlride)	C				
			Detrol	C				
			Fosamax	C				
			Prinivil	C				

Date:06/27/02ISR Number: 3978850-5Report Type:Periodic Company Report #WAES 0204USA02099
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Allegra	C				
			Detrol	C				
			Unithroid	C				
			Zocor	C				
			Fluoxetine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978880-3Report Type:Periodic Company Report #WAES 0204USA02400
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978882-7Report Type:Periodic Company Report #WAES0204USA02414
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978885-2Report Type:Periodic Company Report #WAES 0204USA02442
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	

Date:06/27/02ISR Number: 3978888-8Report Type:Periodic Company Report #WAES 0204USA02444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blindness Influenza Like Illness Skin Lesion	Consumer	Tab Vioxx	PS				

Date:06/27/02ISR Number: 3978892-XReport Type:Periodic Company Report #WAES 0204USA02453
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
	Diarrhoea						DAILY; PO	
	Oedema Peripheral		Acetaminophen (+) Hydrocodone	C				

Date:06/27/02ISR Number: 3978896-7Report Type:Periodic Company Report #WAES 0204USA02459
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphonia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
	Lymphadenopathy						PO	
	Oedema Peripheral		Prilosec	C				
			Procardia	C				
			Redux	C				
			Isosorbide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978902-XReport Type:Periodic Company Report #WAES 0204USA02464
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
PO								
			Timoptic	C				
			Tylenol	C				
			Phenobarbital	C				

Date:06/27/02ISR Number: 3978911-0Report Type:Periodic Company Report #WAES 0204USA02465
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
PO								
			Cozaar	C				
			Lipitor	C				
			Synthroid	C				
			Tamoxifen	C				

Date:06/27/02ISR Number: 3978918-3Report Type:Periodic Company Report #WAES 0204USA02468
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
	Confusional State							
PO								
	Hepatitis		Duragesic	C				
	Insomnia		Zoloft	C				
	Pneumonia		Oxycodone	C				
	Upper Respiratory Tract Infection							

Date:06/27/02ISR Number: 3978923-7Report Type:Periodic Company Report #WAES 0204USA02481
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Hydrodiuril	C				
			Tiazac	C				
			Zestril	C				

Date:06/27/02ISR Number: 3978927-4Report Type:Periodic Company Report #WAES 0204USA02287
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3978931-6Report Type:Periodic Company Report #WAES 0204USA02296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/ PO	
	Nausea	Professional						
		Company Representative	Advil	C				
			Flexeril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978933-XReport Type:Periodic Company Report #WAES 0204USA02345
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978936-5Report Type:Periodic Company Report #WAES 0204USA02354
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rheumatoid Arthritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Amaryl	C				

Date:06/27/02ISR Number: 3978942-0Report Type:Periodic Company Report #WAES 0204USA02366
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:06/27/02ISR Number: 3978945-6Report Type:Periodic Company Report #WAES 0204USA02367
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	

Date:06/27/02ISR Number: 3978952-3Report Type:Periodic Company Report #WAES 0204USA02370
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978955-9Report Type:Periodic Company Report #WAES 0204USA02371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978958-4Report Type:Periodic Company Report #WAES 0204USA02374
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	PO	
	Liver Function Test Abnormal	Professional Company Representative						
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978961-4Report Type:Periodic Company Report #WAES 0204USA02383
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
		Company Representative	Lipitor	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3978967-5Report Type:Periodic Company Report #WAES 0204USA02205
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	/PO
	Anorexia							
			Premarin	C				

Date:06/27/02ISR Number: 3978979-1Report Type:Periodic Company Report #WAES 0204USA02209
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Tab Vioxx	PS		ORAL	PO	
	Somnolence	Professional Company Representative	Zanaflex	SS				

Date:06/27/02ISR Number: 3978981-XReport Type:Periodic Company Report #WAES 0204USA02214
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Confusional State	Health	Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY;						
	Hallucination	Professional				
PO						
	Memory Impairment	Company Representative	Dexedrine	C		
			Imdur	C		
			Plavix	C		
			Prilosec	C		
			Vasotec	C		
			Zocor	C		
			Aspirin	C		
			Atenolol	C		
			Imipramine	C		

Date:06/27/02ISR Number: 3978982-1Report Type:Periodic Company Report #WAES 0204USA00911
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
PO						
			Detrol La	C		
			Digitek	C		
			Fosamax	C		
			Ocuvite	C		
			Ogen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3978985-7Report Type:Periodic Company Report #WAES 0204USA02218
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Medication Error		Advair Diskus	C				
			Atrovent	C				
			....	C				
			Ginkobil	C				
			Lamisil	C				
			Paxil	C				
			Protonix	C				
			Singulair	C				
			Tenormin	C				

Date:06/27/02ISR Number: 3978986-9Report Type:Periodic Company Report #WAES 0204USA02221
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3978987-0Report Type:Periodic Company Report #WAES 0204USA02229
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Diovan	C				
			Prempro	C				
			Synthroid	C				
			Zocor	C				

Date:06/27/02ISR Number: 3978989-4Report Type:Periodic Company Report #WAES 0204USA00922
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY,						
PO						
			Avandia	C		
			Fosamax	C		
			Glucophage	C		
			Zocor	C		
			Glipizide	C		
			Hydrochlorothiazide (+) Triamter	C		
			Potassium Chloride	C		

Date:06/27/02ISR Number: 3978990-0Report Type:Periodic Company Report #WAES 0204USA02234
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL
SEE IMAGE, PO						
	Joint Swelling		.....	C		
	Weight Increased		Metrogel	C		
			One-A-Day Essential Vitamins	C		
			Premarin	C		
			Provera	C		

Viactiv Soft Calcium Chews	C
Aspirin	C
Tetracycline	C
Vitamin E	C

Date:06/27/02ISR Number: 3978993-6Report Type:Periodic Company Report #WAES 0204USA02248
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhoids							
	Insomnia		Lantus	C				
	Joint Swelling		Zocor	C				
	Muscle Spasms		Ramipril	C				
	Nasal Congestion							
	Oedema Peripheral							

Date:06/27/02ISR Number: 3978994-8Report Type:Periodic Company Report #WAES 0204USA00930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3978998-5Report Type:Periodic Company Report #WAES 0204USA02270
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	White Blood Cell Count Decreased		Paxil	C				

Date:06/27/02ISR Number: 3979001-3Report Type:Periodic Company Report #WAES 0204USA00934
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979005-0Report Type:Periodic Company Report #WAES 0204USA02286
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG; DAILY;	
	Pruritus	Professional					PO	
		Company Representative						

Date:06/27/02ISR Number: 3979007-4Report Type:Periodic Company Report #WAES 0204USA00937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979010-4Report Type:Periodic Company Report #WAES 0204USA02110
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/PO	
			Tab Arava 100 Mg	SS		ORAL	100 MG/DAILY/PO	
			Tab Arava 20 Mg	SS		ORAL	20 MG/DAILY/PO	
			Prednisone	C				

Date:06/27/02ISR Number: 3979014-1Report Type:Periodic Company Report #WAES 0204USA00945
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glaucoma	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, BID, PO	
		Company Representative	Dyazide	C				
			Levothyroid	C				
			Nevacor	C				
			Norvasc	C				
			Prilosec	C				
			Trusopt	C				
			Xalatan	C				
			Nitroglycerin	C				

Date:06/27/02ISR Number: 3979015-3Report Type:Periodic Company Report #WAES 0204USA02128
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO						
			Prinivil	C		
			Acetaminophen	C		
			Atenolol	C		
			Methotrexate	C		
			Oxaprozin	C		

Date:06/27/02ISR Number: 3979016-5Report Type:Periodic Company Report #WAES 0204USA02150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	
	Swelling							

Date:06/27/02ISR Number: 3979018-9Report Type:Periodic Company Report #WAES 0204USA00964
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Headache							
			Ambien	C				
			Inderal	C				
			Klonopin	C				
			Prilosec	C				
			Robaxin	C				
			Seroquel	C				

Synthroid	C
Zyrtec	C
Therapy Unspecified	C

Date:06/27/02ISR Number: 3979019-0Report Type:Periodic Company Report #WAES 0204USA02156
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3979021-9Report Type:Periodic Company Report #WAES 0204USA02158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3979023-2Report Type:Periodic Company Report #WAES 0204USA02160
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979025-6Report Type:Periodic Company Report #WAES 0204USA02168
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Diarrhoea							
	Dyspepsia							
	Pruritus							
	Rash Generalised							

Date:06/27/02ISR Number: 3979027-XReport Type:Periodic Company Report #WAES 0204USA02188
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eyelid Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	3 DAY

Date:06/27/02ISR Number: 3979029-3Report Type:Periodic Company Report #WAES 0204USA02197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979031-1Report Type:Periodic Company Report #WAES 0204USA02204
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Avapro	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3979037-2Report Type:Periodic Company Report #WAES 0205USA02056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Skelaxin	C				
			Hormonal Contraceptives	C				

Date:06/27/02ISR Number: 3979039-6Report Type:Periodic Company Report #WAES 0205USA02057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979042-6Report Type:Periodic Company Report #WAES 0205USA02058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS				

Date:06/27/02ISR Number: 3979045-1Report Type:Periodic Company Report #WAES 0205USA02059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979047-5Report Type:Periodic Company Report #WAES 0205USA02060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979049-9Report Type:Periodic Company Report #WAES 0205USA02061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979051-7Report Type:Periodic Company Report #WAES 0205USA02062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979053-0Report Type:Periodic Company Report #WAES 0205USA02063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979056-6Report Type:Periodic Company Report #WAES 0205USA02064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979057-8Report Type:Periodic Company Report #WAES 0205USA02065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tax Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979663-0Report Type:Periodic Company Report #WAES 0112USA02806
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Dizziness	Health					PO	
	Headache	Professional	Actonel	C				
			Celebrex	C				
			Fosamax	C				
			Lasix (Furosemide)	C				
			Slow-K	C				
			Synthroid	C				
			Ultracet	C				
			Ultram	C				

Date:06/27/02ISR Number: 3979681-2Report Type:Periodic Company Report #WAES 0201USA00013
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY,	
	Arrhythmia							
PO								6 DAY
	Dyspnoea		Fosamax	C				
	Heart Rate Irregular							

Date:06/27/02ISR Number: 3979685-XReport Type:Periodic Company Report #WAES 0201USA00172
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Hyperglycaemia	Health						
PO								
	Oedema Peripheral	Professional	Plavix	C				
			Prevacid	C				
			Toprol Xl Tablets	C				
			Tricor	C				
			Zaroxolyn	C				
			Nitroglycerin	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979688-5Report Type:Periodic Company Report #WAES 0201USA00236
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Medication Residue	Professional	Coumadin	C				
			Klor-Con	C				
			Oxycontin	C				
			Amitriptyline	C				
			Atenolol (+) Chlorthalidone	C				

Date:06/27/02ISR Number: 3979694-0Report Type:Periodic Company Report #WAES 0201USA00295
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG,PRN,PO	
	Pruritus	Professional						
	Rash	Company Representative						

Date:06/27/02ISR Number: 3979701-5Report Type:Periodic Company Report #WAES 0201USA00314
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, DAILY, PO	
		Health Professional	Accupril	C				
			Celebrex	C				
			Dantrium (Dantrolene Sodium)	C				
			Zanaflex	C				

Date:06/27/02ISR Number: 3979706-4Report Type:Periodic Company Report #WAES 0201USA00434
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Engorgement	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Fluid Retention	Health					PO	
	Flushing	Professional						
	Oedema Peripheral							
	Weight Increased							

Date:06/27/02ISR Number: 3979711-8Report Type:Periodic Company Report #WAES 0201USA00440
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
	Blood Pressure Increased	Health					PO	
	Oedema	Professional	Accupril	C				
			Premarin	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979719-2Report Type:Periodic Company Report #WAES 0204USA00307
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/BID/PO	
			Cozaar	C				
			Ditropan	C				
			Evista	C				
			Prilosec	C				
			Diltiazem Hydrochloride	C				
			Hydrochlorothiazide (+) Triamter	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3979725-8Report Type:Periodic Company Report #WAES 0204USA00311
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Fluid Retention	Professional						
	Weight Increased	Company Representative						

Date:06/27/02ISR Number: 3979729-5Report Type:Periodic Company Report #WAES 0204USA00312
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979732-5Report Type:Periodic Company Report #WAES 0204USA00338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
	Fatigue	Company					
MG/DAILY/PO							
	Tachycardia	Representative	Avapro	C			
	Weight Increased		Lipitor	C			
			Metoprolol	C			

Date:06/27/02ISR Number: 3979736-2Report Type:Periodic Company Report #WAES 0204USA00382
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Injury	Consumer	Tab Vioxx	PS		ORAL
PO						
		Other				

Date:06/27/02ISR Number: 3979750-7Report Type:Periodic Company Report #WAES 0204USA00394
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hepatitis C	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO 5 MON						
			Allopurinol	C		
			Nefazodone Hydrochloride	C		
			Risperidone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979758-1Report Type:Periodic Company Report #WAES 0204USA00399
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Celebrex	C				

Date:06/27/02ISR Number: 3979762-3Report Type:Periodic Company Report #WAES 0204USA00411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DALY/PO	

Date:06/27/02ISR Number: 3979767-2Report Type:Periodic Company Report #WAES 0204USA00417
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979807-0Report Type:Periodic Company Report #WAES 0203USA01578
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3979810-0Report Type:Periodic Company Report #WAES 0203USA01606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dysphonia		Vasotec	C				
	Influenza Like Illness							

Date:06/27/02ISR Number: 3979812-4Report Type:Periodic Company Report #WAES 0203USA01612
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bundle Branch Block Left	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Chest Pain	Professional	Coumadin	C				
	Electrocardiogram St Segment Depression		[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3979815-XReport Type:Periodic Company Report #WAES 0203USA01644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nail Disorder		Avandia	C				
			Hydrodiuril	C				

			Premarin	C		
			Naproxen	C		

Date:06/27/02ISR Number: 3979818-5Report Type:Periodic Company Report #WAES 0203USA01647
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3979820-3Report Type:Periodic Company Report #WAES 0203USA01655
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prempro	SS				

Date:06/27/02ISR Number: 3979825-2Report Type:Periodic Company Report #WAES 0203USA01671
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Consumer	Tab Vioxx	PS		ORAL	PO	
	Psychotic Disorder		Xanax	C				

Date:06/27/02ISR Number: 3979827-6Report Type:Periodic Company Report #WAES 0203USA01672
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
							50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3979833-1Report Type:Periodic Company Report #WAES 0203USA01673
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rash		Cozaar	C				
			Hydrodiuril	C				
			Nasonex	C				
			Norvasc	C				
			Plendil	C				
			Premarin	C				
			Medroxyprogesterone Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3979836-7Report Type:Periodic Company Report #WAES 0203USA01674
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	No Adverse Drug Effect	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Altace	C				
			Arthrotec	C				

Date:06/27/02ISR Number: 3981070-1Report Type:Periodic Company Report #WAES 0202USA02637
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Aspirin	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3981071-3Report Type:Periodic Company Report #WAES 0202USA02639
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Allegra	C				
			Fosamax	C				
			Lonox	C				
			Prilosec	C				
			Zocor	C				
			Doxazosin	C				
			Hydroxyzine	C				

Date:06/27/02ISR Number: 3981072-5Report Type:Periodic Company Report #WAES 0202USA02651
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Betapace	C				
			Cozaar	C				
			Ecotrin	C				

Date:06/27/02ISR Number: 3981074-9Report Type:Periodic Company Report #WAES 0202USA02654
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased		Celebrex	C				
			Norvasc	C				
			Prevacid	C				
			Zocor	C				
			Acebutolol	C				
			Nitroglycerin	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981077-4Report Type:Periodic Company Report #WAES 0202USA02656
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
	Oedema Peripheral							
			Ambien	C				
			Elavil	C				
			Imitrex	C				
			Prevacid	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3981078-6Report Type:Periodic Company Report #WAES 0202USA02658
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Drug Ineffective							
			Didronel	C				
			Evista	C				
			Prilosec	C				
			Cimetidine	C				

Date:06/27/02ISR Number: 3981081-6Report Type:Periodic Company Report #WAES 0202USA02661
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Dry Throat							
	Dyspnoea							

Date:06/27/02ISR Number: 3981083-XReport Type:Periodic Company Report #WAES 0202USA02664
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Insomnia	Professional						
	Pain	Company	Centrum	C				
	Paraesthesia	Representative	Atenolol	C				

Date:06/27/02ISR Number: 3981086-5Report Type:Periodic Company Report #WAES 0202USA02673
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Decreased Appetite							
	General Symptom		Tylenol	C				
	Haematochezia							

Date:06/27/02ISR Number: 3981088-9Report Type:Periodic Company Report #WAES 0202USA02688
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Company	Tab Vioxx	PS		ORAL	PO	
		Representative						
		Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981090-7Report Type:Periodic Company Report #WAES 0203USA02067
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Auricular Swelling	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Erythema	Professional						
	Eyelid Oedema		Adalat	C				
	Face Oedema							
	Pruritus							
	Rash Papular							
	Swelling							
	Urticaria							

Date:06/27/02ISR Number: 3981094-4Report Type:Periodic Company Report #WAES 0203USA02082
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Pain							
			Accupril	C				
			Allegra	C				
			Evista	C				
			Hydrodiuril	C				
			Gemfibrozil	C				
			Ranitidine	C				

Date:06/27/02ISR Number: 3981097-XReport Type:Periodic Company Report #WAES 0203USA02094
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3981100-7Report Type:Periodic Company Report #WAES 0203USA02114
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-25 MG/DAILY/PO	
			Levoxyl	C				
			Mysoline	C				
			Paxil	C				
			Atenolol	C				
			Diazepam	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3981102-0Report Type:Periodic Company Report #WAES 0203USA02116
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Darvocet-N	C				
			Dilantin Kapseals	C				
			Diovan	C				
			Xalatan	C				
			Phenobarbital	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981104-4Report Type:Periodic Company Report #WAES 0203USA02117
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Celebrex	C				
			Fosamax	C				

Date:06/27/02ISR Number: 3981106-8Report Type:Periodic Company Report #WAES 0203USA02118
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
							MG/DAILY/PO	
			Lotensin	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3981107-XReport Type:Periodic Company Report #WAES 0203USA02123
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	

Date:06/27/02ISR Number: 3981110-XReport Type:Periodic Company Report #WAES 0203USA02142
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Professional
MG/DAILY/PO

Cenestin	C	
Hydrodiuril	C	
Zyrtec	C	

Date:06/27/02ISR Number: 3981114-7Report Type:Periodic Company Report #WAES 0203USA02145
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
	Dyspepsia	Professional						
	Swelling		Nexium	C				

Date:06/27/02ISR Number: 3981115-9Report Type:Periodic Company Report #WAES 0203USA01434
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
		Professional						
			Miacalcin	C				
			Nasonex	C				
			Prilosec	C				
			Synthroid	C				
			Tricor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981116-0Report Type:Periodic Company Report #WAES 0203USA01462
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
							PO; 25 MG	
							DAILY PO	
			Fosamax	C				
			Prevacid	C				
			Calcium (Unspecified)	C				

Date:06/27/02ISR Number: 3981118-4Report Type:Periodic Company Report #WAES 0203USA01464
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Gastrooesophageal Reflux						PO	
	Disease		Claritin	C				
			Hydrodiuril	C				
			Prilosec	C				
			Zocor	C				
			Diltiazem Hydrochloride	C				

Date:06/27/02ISR Number: 3981122-6Report Type:Periodic Company Report #WAES 0203USA01467
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	
	Headache						PO	
	Influenza Like Illness							

Date:06/27/02ISR Number: 3981125-1Report Type:Periodic Company Report #WAES 0203USA01477
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Abnormal	Consumer	Tab Vioxx	PS		ORAL	PO	
	Haemoglobin Abnormal		Procrit	C				
	Laboratory Test Abnormal		Acetaminophen	C				
	Lipid Metabolism Disorder		Alendronate Sodium	C				
	Thyroid Disorder		Levothyroxine Sodium	C				

Date:06/27/02ISR Number: 3981136-6Report Type:Periodic Company Report #WAES 0203USA01481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981139-1Report Type:Periodic Company Report #WAES 0203USA01494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981141-XReport Type:Periodic Company Report #WAES 0203USA01499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								

Date:06/27/02ISR Number: 3981142-1Report Type:Periodic Company Report #WAES 0203USA01501
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Vomiting							
PO								

Date:06/27/02ISR Number: 3981144-5Report Type:Periodic Company Report #WAES 0203USA01515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO		Company Representative						

Date:06/27/02ISR Number: 3981670-9Report Type:Periodic Company Report #WAES 0204USA03093
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rhinitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Sinus Congestion							
MG/DAILY/PO								

			Prilosec	C
			Pulmicort Turbuhaler	C
			Rhinocort Aqua	C
			Singulair	C
			Hydrochlorothiazide (+) Triamter	C

Date:06/27/02ISR Number: 3981671-0Report Type:Periodic Company Report #WAES 0204USA03105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg; 25 Mg	PS		ORAL	12.5 MG/DAILY/PO; 25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3981672-2Report Type:Periodic Company Report #WAES 0204USA03108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Carafate	C				
			Prevacid	C				
			Ibuprofen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981673-4Report Type:Periodic Company Report #WAES 0204USA03117
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Synthroid	C				

Date:06/27/02ISR Number: 3981674-6Report Type:Periodic Company Report #WAES 0204USA03122
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981675-8Report Type:Periodic Company Report #WAES 0204USA03124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981676-XReport Type:Periodic Company Report #WAES 0204USA03126
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Company
Representative

Date:06/27/02ISR Number: 3981677-1Report Type:Periodic Company Report #WAES 0204USA03128
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Health Professional	Tab Vioxx 50 Mg Vicocin Tablets	PS C		ORAL	50 MG/HS/PO	

Date:06/27/02ISR Number: 3981678-3Report Type:Periodic Company Report #WAES 0204USA03135
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea Dyspepsia	Consumer	Tab Vioxx 25 Mg; 50mg	PS		ORAL	25 MG/DAILY/PO;	

SEE IMAGE

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981679-5Report Type:Periodic Company Report #WAES 0204USA03138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Fall							
	Feeling Drunk							
	Heart Rate Increased							

Date:06/27/02ISR Number: 3981680-1Report Type:Periodic Company Report #WAES 0204USA01182
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Hyzaar	C				
			Norvasc	C				
			Prempro	C				
			Prilosec	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3981681-3Report Type:Periodic Company Report #WAES 0204USA01186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	25	MG/DAILY/PO
	Eye Swelling							
	Medication Error							
	Pain							

Date:06/27/02ISR Number: 3981682-5Report Type:Periodic Company Report #WAES 0204USA01195
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Cough							
	Upper Respiratory Tract Infection		Mirapex	C				
			Premarin	C				
	Wheezing		Calcium Carbonate	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3981683-7Report Type:Periodic Company Report #WAES 0204USA01228
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981684-9Report Type:Periodic Company Report #WAES 0204USA01231
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Aspirin	C				

				Glucosamine	C		
				Niacin	C		

Date:06/27/02ISR Number: 3981685-0Report Type:Periodic Company Report #WAES 0204USA01232
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
			Combivent	C				
			Flovent	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3981686-2Report Type:Periodic Company Report #WAES 0204USA01241
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Vioxx	PS		ORAL	25	MG/DAILY/PO
	Diplopia							
	Dizziness		Levoxyl	C				
			Lipitor	C				
			Tenormin	C				
			Zantac	C				

Date:06/27/02ISR Number: 3981687-4Report Type:Periodic Company Report #WAES 0204USA01242
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	MG/DAILY/PO
			Augmentin	C				

Date:06/27/02ISR Number: 3981688-6Report Type:Periodic Company Report #WAES 0204USA01245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG BID	
	Fatigue		Prevacid	C				
	Nausea							
	Pollakiuria							

Date:06/27/02ISR Number: 3981689-8Report Type:Periodic Company Report #WAES 0204USA01246
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	18 DAY
	Joint Swelling		Synthroid	C				
			Tiazac	C				

Date:06/27/02ISR Number: 3981690-4Report Type:Periodic Company Report #WAES 0202USA02690
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

		Fosamax	C
		Premarin	C
		Herbs (Unspecified)	C

Date:06/27/02ISR Number: 3981691-6Report Type:Periodic Company Report #WAES 0202USA02691
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO;	
		Health					50 MG/QOD/PO	
		Professional	Lipitor	C				
			Lopressor	C				
			Nexium	C				
			Tavist	C				
			Tylenol	C				
			Ultram	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3981692-8Report Type:Periodic Company Report #WAES 0202USA02693
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981693-XReport Type:Periodic Company Report #WAES 0202USA02700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Company	Tab Vioxx 25 Mg	PS		ORAL	PO	1 DAY
		Representative	Motrin	C				
		Other						

Date:06/27/02ISR Number: 3981694-1Report Type:Periodic Company Report #WAES 0202USA02715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Dyspnoea						MG/DAILY/PO	

Date:06/27/02ISR Number: 3981695-3Report Type:Periodic Company Report #WAES 0202USA02728
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Keppra	C				
			Ortho Cyclen	C				
			Provigil	C				
			Wellbutrin	C				
			Carbamazepine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981696-5Report Type:Periodic Company Report #WAES 0202USA02752
Age:7 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981697-7Report Type:Periodic Company Report #WAES 0202USA02755
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Plaquenil	C				

Date:06/27/02ISR Number: 3981698-9Report Type:Periodic Company Report #WAES 0202USA02767
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatomegaly	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Liver Tenderness						MG/DAILY/PO	
			Tylenol Unk	SS				
			Alcohol Unk	SS				
			Humulin	C				
			Norvasc	C				
			Nitroglycerin	C				

Date:06/27/02ISR Number: 3981699-0Report Type:Periodic Company Report #WAES 0202USA02785
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Tab Vioxx 25 Mg	PS		ORAL	25	

Hypertension
MG/DAILY/PO 12 MON

Date:06/27/02ISR Number: 3981700-4Report Type:Periodic Company Report #WAES 0205USA01393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981701-6Report Type:Periodic Company Report #WAES 0205USA01412
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
			Premarin	C				

Date:06/27/02ISR Number: 3981702-8Report Type:Periodic Company Report #WAES 0205USA01422
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Cardiac Failure Congestive	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx Unk	PS		ORAL
PO						

Date:06/27/02ISR Number: 3981703-XReport Type:Periodic Company Report #WAES 0205USA01435
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rash Generalised	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
			Aciphex	C		
			Celexa	C		

Date:06/27/02ISR Number: 3981704-1Report Type:Periodic Company Report #WAES 0205USA01439
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Joint Swelling					
MG/DAILY/PO						
	Oedema Peripheral		Tab Fosamax 70 Mg	SS		ORAL
70 MG/WK/PO						
			Dyazide	C		
			Monopril	C		
			Tylenol	C		
			Zocor	C		

Date:06/27/02ISR Number: 3981705-3Report Type:Periodic Company Report #WAES 0205USA01441
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Pressure Decreased	Other	Tab Vioxx Unk	PS		ORAL
PO						

Date:06/27/02ISR Number: 3981706-5Report Type:Periodic Company Report #WAES 0205USA01450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ibuprofen	C				

Date:06/27/02ISR Number: 3981707-7Report Type:Periodic Company Report #WAES 0205USA01453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3981708-9Report Type:Periodic Company Report #WAES 0205USA01475
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
		Professional	Pravachol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3981711-9Report Type:Periodic Company Report #WAES 0205USA01508
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Glossitis		Prilosec	C				
	Tongue Oedema							

Date:06/27/02ISR Number: 3982156-8Report Type:Periodic Company Report #WAES 0205USA02293
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Bextra	C				

Date:06/27/02ISR Number: 3982157-XReport Type:Periodic Company Report #WAES 0205USA2298
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Corticosteroids	C				

Date:06/27/02ISR Number: 3982158-1Report Type:Periodic Company Report #WAES 0205USA02308
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/HS/PO	

				Tylenol Pm	C		

Date:06/27/02ISR Number: 3982159-3Report Type:Periodic Company Report #WAES 0205USA02313
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Skin Warm							
			Cartia (Diltiazem Hydrochloride)	C				
			Flovent	C				
			Serevent	C				
			Albuterol	C				
			Isosorbide Mononitrate	C				
			Theophylline	C				

Date:06/27/02ISR Number: 3982160-XReport Type:Periodic Company Report #WAES 0205USA02319
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hiatus Hernia		Cartia (Diltiazem Hydrochloride)	C				

Claritin	C
Fosamax	C
Levoxyl	C
Prempro	C
Prevacid	C

Date:06/27/02ISR Number: 3982161-1Report Type:Periodic Company Report #WAES 0205USA02369
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Pepcid	C				
			Allopurinol	C				

Date:06/27/02ISR Number: 3982162-3Report Type:Periodic Company Report #WAES 0205USA02372
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actos	C				
			Diovan	C				
			Lipitor	C				

Date:06/27/02ISR Number: 3982163-5Report Type:Periodic Company Report #WAES 0205USA02383
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982164-7Report Type:Periodic Company Report #WAES 0205USA02403
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cold Sweat	Health	Tab Vioxx	PS		ORAL	PO	
	Muscle Rigidity	Professional Company Representative						
	Nausea							
	Syncope							
	Tremor							

Date:06/27/02ISR Number: 3982165-9Report Type:Periodic Company Report #WAES 0205USA02409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982166-0Report Type:Periodic Company Report #WAES 0204USA02889
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased		Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3982167-2Report Type:Periodic Company Report #WAES 0204USA02892
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
			Combivent	C				
			Prinzide	C				
			Serevent Inhalation Aerosol	C				
			Zocor	C				

Date:06/27/02ISR Number: 3982168-4Report Type:Periodic Company Report #WAES 0204USA02895
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Diovan Hct	C				
			Doxil	C				
			Fosamax	C				
			Norvasc	C				
			Zocor	C				
			Aspirin	C				
			Estradiol	C				

Date:06/27/02ISR Number: 3982169-6Report Type:Periodic Company Report #WAES 0204USA02935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982170-2Report Type:Periodic Company Report #WAES 0204USA02936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal	Health Professional Company Representative Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982171-4Report Type:Periodic Company Report #WAES 0204USA02937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Aspartate Aminotransferase Increased	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; 25MG/QOD/PO	

Date:06/27/02ISR Number: 3982172-6Report Type:Periodic Company Report #WAES 0204USA02942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Inflammatory Bowel Disease	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Small Intestinal Haemorrhage		Zocor	C				
	Small Intestinal Obstruction							

Date:06/27/02ISR Number: 3982173-8Report Type:Periodic Company Report #WAES 0204USA02945
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pleural Effusion	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Levoxyl	C				

Date:06/27/02ISR Number: 3982174-XReport Type:Periodic Company Report #WAES 0204USA02948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL
12.5 MG/PO						

Date:06/27/02ISR Number: 3982175-1Report Type:Periodic Company Report #WAES 0204USA02951
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25-50						
MG/DAILY/PO						
			Ogen	C		
			Prinivil	C		

Date:06/27/02ISR Number: 3982178-7Report Type:Periodic Company Report #WAES 0204USA02957
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Weight Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Diovan	C		
			Miacalcin	C		
			Chlorthalidone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982180-5Report Type:Periodic Company Report #WAES 0204USA02959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia	Consumer	Tab Vioxx	PS				
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Dyspnoea							
	Oedema							

Date:06/27/02ISR Number: 3982181-7Report Type:Periodic Company Report #WAES 0204USA02965
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Donnatal	C				
			Norvasc	C				
			Paxil	C				
			Chlorthalidone	C				
			Potassium Chloride	C				

Date:06/27/02ISR Number: 3982184-2Report Type:Periodic Company Report #WAES 0204USA02970
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Incoherent	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Coumadin	C				
			Lopressor	C				
			Sinemet	C				
			Digoxin	C				
			Diltiazem Hydrochloride	C				

Date:06/27/02ISR Number: 3982186-6Report Type:Periodic Company Report #WAES 0204USA02985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	

Date:06/27/02ISR Number: 3982189-1Report Type:Periodic Company Report #WAES 0204USA02986
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation	Health	Tab Vioxx	PS		ORAL	PO	
	Urine Amphetamine Positive	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982191-XReport Type:Periodic Company Report #WAES 0204USA02988
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982193-3Report Type:Periodic Company Report #WAES 0204USA02993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premenstrual Syndrome	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY /PO	

Date:06/27/02ISR Number: 3982195-7Report Type:Periodic Company Report #WAES 0204USA02996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982197-0Report Type:Periodic Company Report #WAES 0204USA02999
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	

Company
Representative

Date:06/27/02ISR Number: 3982203-3Report Type:Periodic Company Report #WAES 0204USA03002
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Euphoric Mood	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25 MG/PRN/PO; 50 MG/PRN/PO	

Date:06/27/02ISR Number: 3982204-5Report Type:Periodic Company Report #WAES 0204USA03005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pitting Oedema	Consumer Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982206-9Report Type:Periodic Company Report #WAES 0204USA03011
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25-50 Mg	PS		ORAL	25-50 MG	DAILY PO
			Benadryl	C				
			Norvasc	C				
			Pravachol	C				
			Aspirin	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3982207-0Report Type:Periodic Company Report #WAES 0204USA03020
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	

Date:06/27/02ISR Number: 3982210-0Report Type:Periodic Company Report #WAES 0204USA03022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Heart Rate Irregular	Company Representative						

Date:06/27/02ISR Number: 3982211-2Report Type:Periodic Company Report #WAES 0204USA03028
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
PO						
			Actonel	C		
			Dyazide	C		

Date:06/27/02ISR Number: 3982213-6Report Type:Periodic Company Report #WAES 0204USA03029
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Myalgia	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:06/27/02ISR Number: 3982216-1Report Type:Periodic Company Report #WAES 0204USA03034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Haematoma	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL
PO						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982218-5Report Type:Periodic Company Report #WAES 0204USA03051
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982219-7Report Type:Periodic Company Report #WAES 0204USA03090
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
							PO	
			Premarin	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3982222-7Report Type:Periodic Company Report #WAES 0205USA02005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982224-0Report Type:Periodic Company Report #WAES 0205USA02007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982226-4Report Type:Periodic Company Report #WAES 0205USA02008
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Adverse Event Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3982227-6Report Type:Periodic Company Report #WAES 0205USA02011
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Adverse Event Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3982228-8Report Type:Periodic Company Report #WAES 0205USA02012
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Adverse Event Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3982230-6Report Type:Periodic Company Report #WAES 0205USA02014
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Adverse Event Consumer Tab Vioxx Unk PS ORAL
PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982232-XReport Type:Periodic Company Report #WAES 0205USA02016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982235-5Report Type:Periodic Company Report #WAES 0205USA02017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982237-9Report Type:Periodic Company Report #WAES 0205USA02018
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3982240-9Report Type:Periodic Company Report #WAES 0205USA02021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative	Aspirin	C				
		Other						

Date:06/27/02ISR Number: 3982277-XReport Type:Periodic Company Report #WAES 0204USA03142
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Transient Ischaemic Attack							

Date:06/27/02ISR Number: 3982278-1Report Type:Periodic Company Report #WAES 0204USA03146
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Oedema Peripheral		Benadryl	C				
			Inderal	C				
			Lasix (Furosemide)	C				

Date:06/27/02ISR Number: 3982279-3Report Type:Periodic Company Report #WAES 0204USA03154
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Detrol	C				

			Atenolol	C		

Date:06/27/02ISR Number: 3982280-XReport Type:Periodic Company Report #WAES 0204USA03155
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hair Growth Abnormal							
			Fosamax	C				
			Prednisone	C				

Date:06/27/02ISR Number: 3982281-1Report Type:Periodic Company Report #WAES 0204USA03159
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Covera-Hs	C				

Date:06/27/02ISR Number: 3982282-3Report Type:Periodic Company Report #WAES 0204USA03162
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Irritable Bowel Syndrome							
			Atacand	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3982283-5Report Type:Periodic Company Report #WAES 0204USA03170
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hytrin	C				
			Synthroid	C				
			Furosemide	C				
			Megetrol Acetate	C				
			Potassium Chloride	C				

Date:06/27/02ISR Number: 3982284-7Report Type:Periodic Company Report #WAES 0204USA03189
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
			Climara	C				
			Synthroid	C				
			Univasc	C				
			Bupropion Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982285-9Report Type:Periodic Company Report #WAES 0204USA03191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982286-0Report Type:Periodic Company Report #WAES 0204USA03219
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982295-1Report Type:Periodic Company Report #WAES 0203USA01908
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO; 25 MG/DAILY/PO	11 DAY
	Oedema Peripheral							
	Pruritus							
			Synthroid	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3982296-3Report Type:Periodic Company Report #WAES 0203USA01921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	

Date:06/27/02ISR Number: 3982297-5Report Type:Periodic Company Report #WAES 0203USA01925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Lipitor	C				
			Estrogens (Unspecified)	C				

Date:06/27/02ISR Number: 3982298-7Report Type:Periodic Company Report #WAES 0203USA01926
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oligomenorrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3982299-9Report Type:Periodic Company Report #WAES 0203USA01929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Rash Macular							

Date:06/27/02ISR Number: 3982300-2Report Type:Periodic Company Report #WAES 0203USA01940
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982301-4Report Type:Periodic Company Report #WAES 0203USA01947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3982302-6Report Type:Periodic Company Report #WAES 0203USA01957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Anxiety	Company Representative						

Date:06/27/02ISR Number: 3982303-8Report Type:Periodic Company Report #WAES 0203USA01968
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapy Non-Responder	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3982304-XReport Type:Periodic Company Report #WAES 0203USA01980
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Enulose	C				
			Norvasc	C				
			Proscar	C				
			Zestril	C				
			Amitriptyline	C				

Date:06/27/02ISR Number: 3983010-8Report Type:Periodic Company Report #WAES 0204USA03272
Age:62 YR Gender:Female I/FU:I

Outcome	PT
	Medication Error
	Pruritus
	Rash Generalised

	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5-25MG	DAILY PO
			Levoxyl	C				
			Premarin	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3983013-3Report Type:Periodic Company Report #WAES 0204USA03282
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50MG DAILY PO	
	Cardiac Flutter		Tab Vioxx 25mg	SS			25MG DAILY PO	
			Claritin	C				
			Premarin	C				
			Vitamins	C				
			Tylenol	C				
			Calcium	I				

Date:06/27/02ISR Number: 3983017-0Report Type:Periodic Company Report #WAES 0204USA03286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx	PS		ORAL	PO	
			Allegra-D 60/120 Mg	SS		ORAL	PO	
			Tab Allegra 180 Mg	SS		ORAL	PO	
			Flonase	SS				
			Alcohol	SS				

Date:06/27/02ISR Number: 3983020-0Report Type:Periodic Company Report #WAES 0205USA00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50MG DAILY PO	

Date:06/27/02ISR Number: 3983026-1Report Type:Periodic Company Report #WAES 0205USA00063
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
			Paxil	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3983030-3Report Type:Periodic Company Report #WAES 0205USA00082
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
			Glucophage	C				
			Glucotrol	C				

				Premarin	C	
				Hydroxychloroquine Sulfate	C	
				Verapamil	C	

Date:06/27/02ISR Number: 3983031-5Report Type:Periodic Company Report #WAES 0205USA00091
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG DAILY PO	
		Professional	Diovan	C				
			Prempro	C				

Date:06/27/02ISR Number: 3983034-0Report Type:Periodic Company Report #WAES 0205USA00094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort	Company	Tab Vioxx	PS		ORAL	PO	
		Representative						
		Other						

Date:06/27/02ISR Number: 3983037-6Report Type:Periodic Company Report #WAES 0205USA00098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG DAILY PO	
	Memory Impairment	Professional						
		Company	Tab Vioxx 25mg	SS		ORAL	25MG DAILY PO	
		Representative						

Date:06/27/02ISR Number: 3983039-XReport Type:Periodic Company Report #WAES 0205USA00102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 50mg	PS		ORAL	50MG DAILY PO	
	Drug Ineffective							
	Overdose							

Date:06/27/02ISR Number: 3983875-XReport Type:Periodic Company Report #WAES 0203USA01331
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Darvocet-N	C				
		Company Representative						

Date:06/27/02ISR Number: 3983880-3Report Type:Periodic Company Report #WAES 0203USA01343
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	12.5-25MG	
		Health					/DAILY/PO	
		Professional	Hydrodiuril	C				
			Prinivil	C				

			Prozac	C		

Date:06/27/02ISR Number: 3983883-9Report Type:Periodic Company Report #WAES 0203USA01345
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25MG	
	Joint Swelling	Health					/DAILY/PO	
	Oedema Peripheral	Professional	Actonel	C				
			Ambien	C				
			Premarin	C				
			Prevacid	C				
			Calcium	C				
			Glucosamine	C				
			Ursodiol	C				

Date:06/27/02ISR Number: 3983887-6Report Type:Periodic Company Report #WAES 0203USA01394
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25MG	
							/DAILY/PO	
			Lozol	C				
			Micronase	C				

Date:06/27/02ISR Number: 3983890-6Report Type:Periodic Company Report #WAES 0203USA01401
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25MG	
							/DAILY/PO	
			Hydrodiuril	C				

Date:06/27/02ISR Number: 3983897-9Report Type:Periodic Company Report #WAES 0203USA01412
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Consumer	Tab Vioxx	PS		ORAL	PO	
			Norvac	C				
			Synthroid	C				
			Vasotec	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3983900-6Report Type:Periodic Company Report #WAES 0203USA01418
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyuria	Consumer	Tab Vioxx	PS		ORAL	PO	
			Cardura	C				
			Detrol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983907-9Report Type:Periodic Company Report #WAES 0203USA01424
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	25MG	
	Ill-Defined Disorder	Health					/DAILY/PO	
	Pain	Professional	Actonel	C				
	Pain In Extremity		Dilantin	C				
	Pruritus		Mysoline	C				
			Premarin	C				
			Prevacid	C				
			Relafen	C				
			Remeron	C				
			Senokot(Senna)	C				

Date:06/27/02ISR Number: 3983908-0Report Type:Periodic Company Report #WAES 0203USA01428
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	12.5MG/DAILY/	
		Professional					PO	
			Cardizem Cd	C				
			Claritin	C				

Date:06/27/02ISR Number: 3983910-9Report Type:Periodic Company Report #WAES 0203USA01430
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health	Tab Vioxx 25mg	PS		ORAL	25-50MG	
		Professional					/DAILY/PO	

Date:06/27/02ISR Number: 3983911-0Report Type:Periodic Company Report #WAES 0203USA01519
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Disorder	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
		Company Representative						

Date:06/27/02ISR Number: 3983912-2Report Type:Periodic Company Report #WAES 0203USA01520
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25mg	PS			PO	
	Ear Disorder		Flonase	C				
			Hytrin	C				
			Maxzide	C				

Date:06/27/02ISR Number: 3983913-4Report Type:Periodic Company Report #WAES 0203USA01526
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx	PS		ORAL	PO	
	Myalgia		Hytrin	C				
			Amitriptyline	C				
			Carisoprodol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983914-6Report Type:Periodic Company Report #WAES 0203USA01533
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx 25mg	PS			25MG DAILY PO	

Date:06/27/02ISR Number: 3983916-XReport Type:Periodic Company Report #WAES 0203USA01537
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 50mg	PS		ORAL	50MG DAILY PO	
	Disorientation		Wellbutrin Sr	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3983917-1Report Type:Periodic Company Report #WAES 0203USA01539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Pain		Enbrel	C				

Date:06/27/02ISR Number: 3983919-5Report Type:Periodic Company Report #WAES 0203USA01544
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG BID PO	
			Avapro	C				
			Prevacid	C				
			Isosorbide Mononitrate	C				

			Thiothixene	C		

Date:06/27/02ISR Number: 3983921-3Report Type:Periodic Company Report #WAES 0203USA01549
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Dysgeusia		Azopt Drops	C				
			Bumex	C				
			Monopril	C				
			Nexium	C				
			Procardia Xl	C				

Date:06/27/02ISR Number: 3983922-5Report Type:Periodic Company Report #WAES 0203USA01551
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Hypersensitivity	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983924-9Report Type:Periodic Company Report #WAES 0203USA01559
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS			PO	

Date:06/27/02ISR Number: 3983925-0Report Type:Periodic Company Report #WAES 0202USA00177
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Therapeutic Response						PO, SEE IMAGE	
	Unexpected		Glucotrol	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3983926-2Report Type:Periodic Company Report #WAES 0202USA02190
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Halitosis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
							PO	
			Aerolate	C				

Date:06/27/02ISR Number: 3983927-4Report Type:Periodic Company Report #WAES 0202USA02197
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diplopia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Drug Ineffective						PO	

			Azmacort	C		
			Cozaar	C		
			Norvasc	C		
			Plavix	C		
			Aspirin	C		
			Prednisone	C		

Date:06/27/02ISR Number: 3983929-8Report Type:Periodic Company Report #WAES 0202USA02204
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO		Company Representative	Klonopin	C				
			Lipitor	C				
			Prevacid	C				
			Senokot (Senna)	C				
			Ultram	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3983930-4Report Type:Periodic Company Report #WAES 0202USA02222
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983931-6Report Type:Periodic Company Report #WAES 0202USA02223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983932-8Report Type:Periodic Company Report #WAES 0202USA02240
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Hyzaar	C				
			Estradiol	C				

Date:06/27/02ISR Number: 3983933-XReport Type:Periodic Company Report #WAES 0202USA02251
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Prinivil	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3983934-1Report Type:Periodic Company Report #WAES 0202USA02255
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

	Drug Intolerance	Professional					
PO							
	Oedema Peripheral			Actos	C		
	Weight Increased			Cozaar	C		
				Humulin	C		
				Lozol	C		
				Prempro	C		
				Prinivil	C		
				Clonidine	C		

Date:06/27/02ISR Number: 3983936-5Report Type:Periodic Company Report #WAES 0202USA02256
Age:72 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3983937-7Report Type:Periodic Company Report #WAES 0205USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983939-0Report Type:Periodic Company Report #WAES 0205USA02029
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983941-9Report Type:Periodic Company Report #WAES 0205USA02030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983942-0Report Type:Periodic Company Report #WAES 0205USA02031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983943-2Report Type:Periodic Company Report #WAES 0205USA02035
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intestinal Polyp	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983944-4Report Type:Periodic Company Report #WAES 0205USA02037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Unevaluable Event Consumer Tab Vioxx PS ORAL
PO

Date:06/27/02ISR Number: 3983946-8Report Type:Periodic Company Report #WAES 0205USA02038
Age:82 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Drug Ineffective Consumer Tab Vioxx 25 Mg PS ORAL
25

MG/DAILY/PO

Date:06/27/02ISR Number: 3983947-XReport Type:Periodic Company Report #WAES 0205USA02039
Age: Gender:Unknown I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Unevaluable Event Consumer Tab Vioxx PS ORAL
PO

Date:06/27/02ISR Number: 3983948-1Report Type:Periodic Company Report #WAES 0205USA02040
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Gastric Disorder Consumer Tab Vioxx PS ORAL
PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983949-3Report Type:Periodic Company Report #WAES 0205USA02041
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983951-1Report Type:Periodic Company Report #WAES 0205USA02043
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983952-3Report Type:Periodic Company Report #WAES 0205USA02044
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983954-7Report Type:Periodic Company Report #WAES 0205USA02046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983956-0Report Type:Periodic Company Report #WAES 0205USA02048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983962-6Report Type:Periodic Company Report #WAES 0205USA02049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983963-8Report Type:Periodic Company Report #WAES 0205USA02050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983964-XReport Type:Periodic Company Report #WAES 0205USA02052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983966-3Report Type:Periodic Company Report #WAES 0205USA02053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983968-7Report Type:Periodic Company Report #WAES 0205USA02054
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Singulair	C				

Date:06/27/02ISR Number: 3983969-9Report Type:Periodic Company Report #WAES 0205USA02055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983972-9Report Type:Periodic Company Report #WAES 0205USA01720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983973-0Report Type:Periodic Company Report #WAES 0205USA01721
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983974-2Report Type:Periodic Company Report #WAES 0205USA01723
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/PO	

Date:06/27/02ISR Number: 3983976-6Report Type:Periodic Company Report #WAES 0205USA01727
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983977-8Report Type:Periodic Company Report #WAES 0205USA01788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983979-1Report Type:Periodic Company Report #WAES 0205USA01793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx Unk	PS				

Date:06/27/02ISR Number: 3983980-8Report Type:Periodic Company Report #WAES 0205USA01794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983981-XReport Type:Periodic Company Report #WAES 0205USA01796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983984-5Report Type:Periodic Company Report #WAES 0205USA01797
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3983985-7Report Type:Periodic Company Report #WAES 0205USA01812
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
	Depression		Fiorinal	C		
	Night Sweats		Humibid	C		
			Hydrodiuril	C		
			Premarin	C		
			Ultram	C		
			Xanax	C		
			Desipramine Hydrochloride	C		

Date:06/27/02ISR Number: 3983994-8Report Type:Periodic Company Report #WAES 0203USA02354
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Parotid Gland Enlargement	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

Date:06/27/02ISR Number: 3983996-1Report Type:Periodic Company Report #WAES 0203USA02360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3983997-3Report Type:Periodic Company Report #WAES 0203USA02367
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chromaturia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3983998-5Report Type:Periodic Company Report #WAES 0203USA02370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dry Skin							
	Euphoric Mood							
	Hair Disorder							
	Hangover							
	Medication Error							
	Nail Disorder							

Date:06/27/02ISR Number: 3984000-1Report Type:Periodic Company Report #WAES 0203USA02375
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984001-3Report Type:Periodic Company Report #WAES 0203USA02380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health	Tab Vioxx	PS		ORAL	PO	

	Professional Company Representative	Ecotrin	C

Date:06/27/02ISR Number: 3984003-7Report Type:Periodic Company Report #WAES 0203USA02387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Dry Mouth	Health Professional	Accolate	C				
	Hypoaesthesia		Advair	C				
			Evista	C				
			Maxair	C				
			Moduretic	C				
			Ibuprofen	C				

Date:06/27/02ISR Number: 3984004-9Report Type:Periodic Company Report #WAES 0203USA02399
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984005-0Report Type:Periodic Company Report #WAES 0203USA02402
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Gastrointestinal Disorder	Professional						

Date:06/27/02ISR Number: 3984006-2Report Type:Periodic Company Report #WAES 0203USA02404
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Claritin-D	C				
			Famodine	C				
			Nasonex	C				
			Skelaxin	C				
			Ultram	C				
			Zoloft	C				
			Zyprexa	C				
			Acetaminophen (+)					
			Hydrocodone	C				

Date:06/27/02ISR Number: 3984007-4Report Type:Periodic Company Report #WAES 0202USA02259
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Arthrotec	C				

Date:06/27/02ISR Number: 3984009-8Report Type:Periodic Company Report #WAES 0202USA02298
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY/PO						
			Tab Vioxx 25 Mg	SS		ORAL
25 MG/DAILY/PO						
			Insulin	C		

Date:06/27/02ISR Number: 3984010-4Report Type:Periodic Company Report #WAES 0202USA02299
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL
PO						
	Epistaxis		Cap Celebrex 200 Mg	SS		
200 MG/DAILY						
			Inj Cortisone Unk	SS		
INJ						
			Acetaminophen	C		
			Calcuim Carbonate	C		
			Chondroitin	C		
			Raloxifene	C		
			Verapamil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984011-6Report Type:Periodic Company Report #WAES 0202USA02334
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Memory Impairment		Lipitor	C				
	Pollakiuria		Vasotec	C				

Date:06/27/02ISR Number: 3984012-8Report Type:Periodic Company Report #WAES 0202USA02340
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Amaryl	C				
			Nadolol	C				

Date:06/27/02ISR Number: 3984013-XReport Type:Periodic Company Report #WAES 0202USA02380
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
	Joint Swelling		Evista	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3984014-1Report Type:Periodic Company Report #WAES 0202USA02382
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
			Diovan	C				
			Ogen	C				

Date:06/27/02ISR Number: 3984015-3Report Type:Periodic Company Report #WAES 0202USA02383
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/PO	
			Aspirin	C				
			..	C				

Date:06/27/02ISR Number: 3984016-5Report Type:Periodic Company Report #WAES 0202USA02387
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Fluctuation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dysphagia		Celebrex	C				
	Dyspnoea		Mirapex	C				
	Muscular Weakness		Norvasc	C				
	Tremor		Prinivil	C				
			Atenolol	C				
			Lorazepam	C				
			Temazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984017-7Report Type:Periodic Company Report #WAES 0202USA02388
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Other	Bayer Aspirin	C				
			Claritin	C				
			Delestrogen	C				
			Dovonex	C				
			Lasix (Furosemide)	C				
			Slow-K	C				
			Synthroid	C				
			Ultravate	C				

Date:06/27/02ISR Number: 3984018-9Report Type:Periodic Company Report #WAES 0203USA02263
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984019-0Report Type:Periodic Company Report #WAES 0203USA02266
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapy Non-Responder	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prempro	C				
			Ultram	C				
			Zocor	C				
			Buspirone Hydrochloride	C				
			Trazodone	C				

Date:06/27/02ISR Number: 3984020-7Report Type:Periodic Company Report #WAES 0203USA02269
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema	Professional						
			Lipitor	C				
			Atenolol	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3984021-9Report Type:Periodic Company Report #WAES 0203USA02270
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984022-0Report Type:Periodic Company Report #WAES 0203USA02281
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984023-2Report Type:Periodic Company Report #WAES 0203USA02315
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activated Partial Thromboplastin Time Prolonged	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984024-4Report Type:Periodic Company Report #WAES 0203USA02335
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Diarrhoea		Catapres Tts	C				
			Diovan	C				
			Fosamax	C				
			Humibid L.A.	C				
			Lozol	C				
			Nasacort Aq	C				
			Patanol	C				
			Verelan	C				
			Aspirin	C				
			Calcium + Vitami	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3984025-6Report Type:Periodic Company Report #WAES 0203USA02341
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Other	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984026-8Report Type:Periodic Company Report #WAES 0203USA02348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Depo-Provera	C				

Date:06/27/02ISR Number: 3984027-XReport Type:Periodic Company Report #WAES 0203USA02352
Age: Gender:Female I/FU:I

Outcome	PT
	Hallucination
	Nervousness

	Nightmare Personality Change						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Tab Vioxx	PS		ORAL	PO

Date:06/27/02ISR Number: 3984028-1Report Type:Periodic Company Report #WAES 01081639
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Oedema Peripheral	Health Professional	Catapres	C			
			Chondroitin (+) Glucosamine	C			

Date:06/27/02ISR Number: 3984029-3Report Type:Periodic Company Report #WAES 01090039
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Diarrhoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO
	Nausea		Coumadin	C			
			Maxzide	C			

Date:06/27/02ISR Number: 3984030-XReport Type:Periodic Company Report #WAES 01090530
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO
	Haemorrhage	Professional Company Representative					

Date:06/27/02ISR Number: 3984031-1Report Type:Periodic Company Report #WAES 01091030
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Diarrhoea	Professional					MG/DAILY/PO	
			Celebrex	C				
			Relafen	C				
			Labetalol Hydrochloride	C				

Date:06/27/02ISR Number: 3984032-3Report Type:Periodic Company Report #WAES 01100118
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	24	
		Health					MG/DAILY/PO	
		Professional	Ambien	C				
			Fosamax	C				
			Albuterol	C				
			Atenolol	C				
			Diazepam	C				
			Meclizine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984033-5Report Type:Periodic Company Report #WAES 01100423
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Actos	C				
			Cardura	C				
			Dynacirc	C				
			Glucophage	C				
			K-Dur	C				
			Lanoxicaps	C				
			Lipitor	C				
			Prandin	C				
			Prinivil	C				
			Probenecid	C				
			Sotalol Hydrochloride	C				

Date:06/27/02ISR Number: 3984034-7Report Type:Periodic Company Report #WAES 01100778
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dizziness	Health Professional						
	Gait Disturbance		Fosamax	C				
	Malaise		Prilosec	C				
	Tachycardia		Nortriptyline	C				
	Vertigo							

Date:06/27/02ISR Number: 3984035-9Report Type:Periodic Company Report #WAES 01100972
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

	Fluid Retention	Health				
MG/DAILY/PO						
	Oedema Peripheral	Professional	Elavil	C		
			Levsinex Timecaps	C		
			Pravachol	C		
			Prempro	C		
			Tenormin	C		

Date:06/27/02ISR Number: 3984036-0Report Type:Periodic Company Report #WAES 01100997
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Diarrhoea	Professional						
MG/DAILY/PO								
	Nausea		Dyazide	C				
			Evista	C				
			Flonase	C				
			Zyrtec	C				
			Hydroxyzine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984037-2Report Type:Periodic Company Report #WAES 01101568
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx Unk	PS		ORAL	PO	
	General Symptom	Professional	Celebrex	C				

Date:06/27/02ISR Number: 3984098-0Report Type:Periodic Company Report #WAES 0205USA00724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Decreased Appetite	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/HS/PO;	
	Diarrhoea						25 MG/HS/PO	10 DAY
	Dyspnoea							
	Nausea							

Date:06/27/02ISR Number: 3984099-2Report Type:Periodic Company Report #WAES 0205USA00728
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prevacid	C				

Date:06/27/02ISR Number: 3984100-6Report Type:Periodic Company Report #WAES 0205USA00741
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS			25 MG/DAILY/	
			Tab Hyzaar	SS		ORAL	DAILY/PO	

Celebrex	C
Norvasc	C
Atenolol	C

Date:06/27/02ISR Number: 3984101-8Report Type:Periodic Company Report #WAES 0205USA00743
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

Date:06/27/02ISR Number: 3984102-XReport Type:Periodic Company Report #WAES 0205USA00745
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
	Oedema	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984103-1Report Type:Periodic Company Report #WAES 0205USA00756
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Doxepin	C				

Date:06/27/02ISR Number: 3984104-3Report Type:Periodic Company Report #WAES 0205USA00759
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage Gastrointestinal Ulcer Vomiting	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984105-5Report Type:Periodic Company Report #WAES 0205USA00761
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984106-7Report Type:Periodic Company Report #WAES 0205USA00779
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3984107-9Report Type:Periodic Company Report #WAES 0205USA02411
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Joint Swelling							
PO								
	Weight Increased		Prinivil	C				
			Glipizide	C				
			Metformin	C				

Date:06/27/02ISR Number: 3984108-0Report Type:Periodic Company Report #WAES 0205USA02424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL		
PO								
		Health Professional						

Date:06/27/02ISR Number: 3984109-2Report Type:Periodic Company Report #WAES 0205USA02440
Age: Gender:Male I/FU:I

Outcome	PT
	Hypoaesthesia
	Impaired Driving Ability

	Vision Blurred					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/HS/PO						
		Professional Company Representative				

Date:06/27/02ISR Number: 3984110-9Report Type:Periodic Company Report #WAES 0205USA02441
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypoaesthesia	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/HS/ PO						
	Impaired Driving Ability	Professional Company Representative				
	Vision Blurred					

Date:06/27/02ISR Number: 3984111-0Report Type:Periodic Company Report #WAES 0205USA02442
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Conjunctival Hyperaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/						
	Eye Pruritus					
PO						
	Nausea		Levoxyl	C		
			Zocor	C		
			Captopril	C		

Date:06/27/02ISR Number: 3984112-2Report Type:Periodic Company Report #WAES 0205USA02501
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/ DAILY/						

Rash

PO

Celebrex	C
Diabeta	C
Dilantin	C
Premarin	C
Synthroid	C
Potassium Chloride	C

Date:06/27/02ISR Number: 3984113-4Report Type:Periodic Company Report #WAES 0205USA02503
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	

PO

Altace	C
Cozaar	C
Demadex	C
Detrol La	C
Digitek	C
Flovent	C
Norvasc	C
Zaroxolyn	C
Colchicine	C
Potassium Chloride	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984114-6Report Type:Periodic Company Report #WAES 0205USA02506
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Feeling Hot						PO	
			Levoxyl	C				

Date:06/27/02ISR Number: 3984115-8Report Type:Periodic Company Report #WAES 0205USA02645
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx	PS		ORAL	DAILY/ PO	
	Oedema Peripheral							

Date:06/27/02ISR Number: 3984116-XReport Type:Periodic Company Report #WAES 0205USA02674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Syndrome	Health	Tab Vioxx	PS		ORAL	PO	
	Fatigue	Professional						
	Lethargy	Company Representative						

Date:06/27/02ISR Number: 3984117-1Report Type:Periodic Company Report #WAES 0205USA00563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3984118-3Report Type:Periodic Company Report #WAES 0205USA00566
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/WKY/PO	
			Magnesium Stereate	SS				
			Prilosec	C				

Date:06/27/02ISR Number: 3984119-5Report Type:Periodic Company Report #WAES 0205USA00574
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Naprosyn	C				
			Neurontin	C				
			Tricor	C				
			Zoloft	C				
			Alprazolam	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984120-1Report Type:Periodic Company Report #WAES 0205USA00585
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Level Increased	Professional						
	Extrapyramidal Disorder		Clozapine	SS				
			Olanzapine	SS				
			Biaxin	C				
			Phenergan With Codeine	C				

Date:06/27/02ISR Number: 3984121-3Report Type:Periodic Company Report #WAES 0205USA00587
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3984122-5Report Type:Periodic Company Report #WAES 0205USA00632
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3984123-7Report Type:Periodic Company Report #WAES 0205USA00652
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Antivert	C				
			Valium	C				

Date:06/27/02ISR Number: 3984124-9Report Type:Periodic Company Report #WAES 0205USA00714
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative	Celebrex	C				

Date:06/27/02ISR Number: 3984125-0Report Type:Periodic Company Report #WAES 0205USA00723
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5-25 MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984126-2Report Type:Periodic Company Report #WAES 0204USA01261
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
	Malaise		Hyzaar	C				
	Nervousness		Vicodin Tablets	C				
	Panic Disorder		Xanax	C				
			Propanolol	C				

Date:06/27/02ISR Number: 3984127-4Report Type:Periodic Company Report #WAES 0204USA01263
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Feeling Abnormal							
	Hallucination, Olfactory		Celebrex	C				
	Psychomotor Hyperactivity		Cortisone	C				

Date:06/27/02ISR Number: 3984128-6Report Type:Periodic Company Report #WAES 0204USA01265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Muscle Spasms							
	Nausea	Company Representative	Advil	C				

Date:06/27/02ISR Number: 3984129-8Report Type:Periodic Company Report #WAES 0204USA01269
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO

Date:06/27/02ISR Number: 3984130-4Report Type:Periodic Company Report #WAES 0204USA01271
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO		
	Pain							
	Rash Scaly							

Date:06/27/02ISR Number: 3984131-6Report Type:Periodic Company Report #WAES 0204USA01277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984132-8Report Type:Periodic Company Report #WAES 0204USA01280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984133-XReport Type:Periodic Company Report #WAES 0204USA01299
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accupril	C				
			Advair	C				
			Clarinex	C				
			Coreg	C				
			Nexium	C				
			Prempro	C				

Date:06/27/02ISR Number: 3984134-1Report Type:Periodic Company Report #WAES 0204USA01301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Swelling	Company Representative						

Date:06/27/02ISR Number: 3984135-3Report Type:Periodic Company Report #WAES 0204USA01302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain Lower	Health	Tab Vioxx	PS		ORAL
PO						
	Diarrhoea	Professional Company Representative				

Date:06/27/02ISR Number: 3984136-5Report Type:Periodic Company Report #WAES 0205USA00783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ulcer	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:06/27/02ISR Number: 3984137-7Report Type:Periodic Company Report #WAES 0205USA00784
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Fosamax	C		
			Premarin	C		
			Prevacid	C		
			Prinivil	C		
			Aspirin	C		
			Doxazosin	C		
			Vitamin E	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984138-9Report Type:Periodic Company Report #WAES 0205USA00788
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chromaturia	Health	Tab Vioxx	PS		ORAL	PO	
	Urine Odour Abnormal	Professional Company Representative						

Date:06/27/02ISR Number: 3984139-0Report Type:Periodic Company Report #WAES 0205USA00810
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Gastrooesophageal Reflux Disease						MG/DAILY/PO	
			Fosamax	C				
			Levothroid	C				
			Lovastatin	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3984140-7Report Type:Periodic Company Report #WAES 0205USA00812
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Urticaria						MG/DAILY/PO	1 DAY
			Allegra	C				
			Androgel	C				
			Effexor	C				
			Hydrodiuril	C				
			Vasotec	C				
			Wellbutrin Sr	C				
			Zocor	C				

Date:06/27/02ISR Number: 3984141-9Report Type:Periodic Company Report #WAES 0205USA00814
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	BID/PO	
	Medication Error		Aciphex	C				
	Pain In Extremity		Arthrotec	C				
			Climara	C				
			Ultram	C				
			Vasotec	C				
			Zebeta	C				
			Oxazepam	C				

Date:06/27/02ISR Number: 3984142-0Report Type:Periodic Company Report #WAES 0205USA00817
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nail Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				
			Ecotrin	C				
			Synvisc	C				
			Glucosamine	C				

			Vitamins (Unspecified)	C		

Date:06/27/02ISR Number: 3984143-2Report Type:Periodic Company Report #WAES 0205USA00820
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Fluid Retention							
	Oliguria		Atenol	C				
	Renal Impairment		Hydrodiuril	C				
			Norvasc	C				
			Pepcid	C				
			Premarin	C				
			Tofranil	C				
			Tylenol Pm	C				
			Calcium (Unspecified)	C				
			Potassium Chloride	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3984144-4Report Type:Periodic Company Report #WAES 0205USA00826
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Miacalcin	C				
			Premphase	C				

Date:06/27/02ISR Number: 3984145-6Report Type:Periodic Company Report #WAES 0205USA00830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health	Tab Vioxx	PS		ORAL	PO	1 WK
	Rash Generalised	Professional Company Representative						

Date:06/27/02ISR Number: 3984146-8Report Type:Periodic Company Report #WAES 01101569
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthma	Health						
	Blood Pressure Increased	Professional						
	Dizziness							
	Dyspepsia							
	Haematochezia							
	Nasal Congestion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984147-XReport Type:Periodic Company Report #WAES 01102017
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Cardizem	C				
			Imdur	C				
			Pepcid	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3984148-1Report Type:Periodic Company Report #WAES 01102120
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg; 50					
	Pruritus	Health	Mg	PS		ORAL	25 MG/DAILY/PO;	
	Rash	Professional						
	Urticaria						50 MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Prilosec	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3984149-3Report Type:Periodic Company Report #WAES 01102352
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Health						
		Professional						

Date:06/27/02ISR Number: 3984150-XReport Type:Periodic Company Report #WAES 01103140
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Change In Sustained	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Attention	Health					MG/DAILY/PO	
	Libido Decreased	Professional	Wellbutrin	C				
			Hydrochlorothiazide (+) Triamter	C				
			Methylprednisolone	C				

Date:06/27/02ISR Number: 3984151-1Report Type:Periodic Company Report #WAES 01103183
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Blood Pressure	Professional					MG/DAILY/PO	
	Fluctuation		Celebrex	C				
			Prilosec	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984152-3Report Type:Periodic Company Report #WAES 01104266
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain	Health Professional						
	Drug Intolerance		Lasix (Furosemide)	C				
	Dyspepsia		Minitran	C				
	Feeling Hot And Cold		Tiazac	C				
	Hyperhidrosis		Ultram	C				
	Pain In Extremity		Valium	C				
	Vomiting		Zantac	C				

Date:06/27/02ISR Number: 3984153-5Report Type:Periodic Company Report #WAES 01104404
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Discomfort	Health Professional						
	Diarrhoea		Glucotrol Xl	C				
	Dyspepsia		Neurontin	C				
	Muscular Weakness		Pravachol	C				
			Prilosec	C				
			Alprazolam	C				

Date:06/27/02ISR Number: 3984154-7Report Type:Periodic Company Report #WAES 01104570
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Delusion	Health Professional	Tab Vioxx	PS		ORAL	PO	
	Hallucination	Company Representative	Celebrex	C				

Date:06/27/02ISR Number: 3984155-9Report Type:Periodic Company Report #WAES 01104647
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	

Date:06/27/02ISR Number: 3984156-0Report Type:Periodic Company Report #WAES 0205USA01147
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	25 MG/BID/PO	
			Avonex	C				
			Ditropan	C				

Date:06/27/02ISR Number: 3984157-2Report Type:Periodic Company Report #WAES 0205USA01159
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984158-4Report Type:Periodic Company Report #WAES 0205USA01168
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx	PS		ORAL	PO	
			Neurontin	C				

Date:06/27/02ISR Number: 3984159-6Report Type:Periodic Company Report #WAES 0205USA01176
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased Blood Urea Increased	Professional Company Representative	Celexa	C				

Date:06/27/02ISR Number: 3984160-2Report Type:Periodic Company Report #WAES 0205USA01194
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Pravachol	C				
			Zoloft	C				
			Acetaminophen (+) Codeine	C				
			Atenolol	C				
			Potassium Chloride	C				

Date:06/27/02ISR Number: 3984161-4Report Type:Periodic Company Report #WAES 0205USA01199
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Alopecia	Consumer	Tab Vioxx	PS		ORAL
25 MG/DAILY/PO						
			Azmacort	C		
			Fosamax	C		
			Serevent	C		

Date:06/27/02ISR Number: 3984162-6Report Type:Periodic Company Report #WAES 0205USA01251
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Drug Effect Decreased							
			Ditropan Xl	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3984163-8Report Type:Periodic Company Report #WAES 0205USA01252
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Dyspepsia		Flonase	C				
			Fosamax	C				
			Synthroid	C				

			Zyrtec	C		
			Trazodone	C		

Date:06/27/02ISR Number: 3984164-XReport Type:Periodic Company Report #WAES 0205USA01258
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx	PS		ORAL	PO	
			Hydrodiuril	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3984807-0Report Type:Periodic Company Report #WAES 0205USA01266
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ogen	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3984808-2Report Type:Periodic Company Report #WAES 0205USA01272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	4 DAY
		Company Representative						

Date:06/27/02ISR Number: 3984810-0Report Type:Periodic Company Report #WAES 0205USA01277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg & 50 Mg	PS		ORAL	50 & 25 MG/DAILY/PO	
	Frequent Bowel Movements							
	Gastric Haemorrhage							
	Haemorrhage		Norvas	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3984816-1Report Type:Periodic Company Report #WAES 0205USA01291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Plendil	C				

Date:06/27/02ISR Number: 3984817-3Report Type:Periodic Company Report #WAES 0205USA01301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
	Asthma	Health Professional Company
	Dyspnoea	

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 50 Mg	PS		ORAL	50 MG/1X/PO	

Date:06/27/02ISR Number: 3984818-5Report Type:Periodic Company Report #WAES 0205USA01304
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor Unk	SS			UNK/UNK/UNK	

Date:06/27/02ISR Number: 3984820-3Report Type:Periodic Company Report #WAES 0205USA01325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health Professional	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Company Representative	Aldactone	C				
			Ativan	C				
			Lasix (Furosemide)	C				
			Neurontin	C				
			Tylenol	C				
			Urecholine	C				
			Zyprexa	C				
			Hydrocodone	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3984822-7Report Type:Periodic Company Report #WAES 0205USA01345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional Company Representative	[Composition Unspecified]	C				

Date:06/27/02ISR Number: 3984824-0Report Type:Periodic Company Report #WAES 0205USA01367
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	

Date:06/27/02ISR Number: 3984829-XReport Type:Periodic Company Report #WAES 0205USA01379
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Congestive	Professional Company Representative	Diuretic (Unspecified)	C				
			Ibuprofen	C				

Date:06/27/02ISR Number: 3984834-3Report Type:Periodic Company Report #WAES 0205USA01077
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY; PO	
			Protonix	C				

Date:06/27/02ISR Number: 3984836-7Report Type:Periodic Company Report #WAES 0205USA01098
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Potassium Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;PO	2 WK
		Company Representative	[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3984839-2Report Type:Periodic Company Report #WAES 0205USA01102
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY; PO	
	Oedema Peripheral							
	Pain In Extremity		Levothroid	C				
			Premarin	C				
			Ultram	C				
			Acetaminophen (+) Hydrocodone	C				
			Diazepam	C				

Date:06/27/02ISR Number: 3984841-0Report Type:Periodic Company Report #WAES 0205USA01104
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY;	
						PO		
			Prilosec	C				
			Zocor	C				
			Alprazolam	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3984845-8Report Type:Periodic Company Report #WAES 0205USA01109
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:06/27/02ISR Number: 3984853-7Report Type:Periodic Company Report #WAES 0205USA01129
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Psoriasis	Health
		Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984858-6Report Type:Periodic Company Report #WAES 0205USA01131
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			Corticosteroids	C				

Date:06/27/02ISR Number: 3984864-1Report Type:Periodic Company Report #WAES 0205USA01140
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984866-5Report Type:Periodic Company Report #WAES 0205USA01143
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3984867-7Report Type:Periodic Company Report #WAES 0205USA01144
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
			Altace	C				
			Cardizem	C				
			Hydrodiuril	C				
			Lasix (Furosemide)	C				
			Lipitor	C				

Date:06/27/02ISR Number: 3984869-0Report Type:Periodic Company Report #WAES 0205USA01034
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Decreased		Ambien	C				
			Depakote	C				
			Lamictal	C				
			Lipitor	C				
			Pepcid	C				
			Prempro	C				
			Vasotec	C				
			[Therapy Unspecified]	C				
			Chlordiazepoxide					

				Hydrochloride	C		

Date:06/27/02ISR Number: 3984871-9Report Type:Periodic Company Report #WAES 0205USA01036
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
			Adalat Cc	C				
			Aggrenox	C				
			Ziac	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3984876-8Report Type:Periodic Company Report #WAES 0205USA01041
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Centrum Silver	C				
			Flomax (Tamsulosin Hydrochloride	C				
			Hydrodiuril	C				
			Aspirin	C				
			Ranitidine	C				

Date:06/27/02ISR Number: 3984880-XReport Type:Periodic Company Report #WAES 0205USA01042
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG BID PO	
	Decreased		Fosamax	C				
			Lipitor	C				

Date:06/27/02ISR Number: 3984883-5Report Type:Periodic Company Report #WAES 0205USA01043
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Lethargy						PO	
	Mental Impairment		Estrogens (Unspecified)	C				

Date:06/27/02ISR Number: 3984885-9Report Type:Periodic Company Report #WAES 0205USA01046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
		Company Representative					PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984889-6Report Type:Periodic Company Report #WAES 0205USA01053
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984896-3Report Type:Periodic Company Report #WAES 0205USA01057
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
	Congestive	Professional					PO	6 WK
		Company Representative	Aleve	C				

Date:06/27/02ISR Number: 3984901-4Report Type:Periodic Company Report #WAES 0205USA01058
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx	PS		ORAL	25 MG PO	
	Erythema		Allegra	C				
	Eye Irritation		Hydrodiuril	C				
			Zestril	C				
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3984908-7Report Type:Periodic Company Report #WAES 0205USA01073
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health	Tab Vioxx	PS		ORAL	PO	

Professional

Date:06/27/02ISR Number: 3984916-6Report Type:Periodic Company Report #WAES 0201USA00528
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Glossodynia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tongue Disorder	Health Professional	Lipitor	C				

Date:06/27/02ISR Number: 3984921-XReport Type:Periodic Company Report #WAES 0201USA00589
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pneumonia	Health Professional	Diovan	C				
			Synthroid	C				
			Bumetanide	C				
			Estradiol	C				
			Ranitidine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984923-3Report Type:Periodic Company Report #WAES 0201USA00692
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Glucose Increased	Health Professional	Actos	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3984929-4Report Type:Periodic Company Report #WAES 0201USA00722
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984934-8Report Type:Periodic Company Report #WAES 0201USA00762
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO; 50 MG/DAILY/PO	
	Gastrointestinal Haemorrhage		Coumadin	C				

Date:06/27/02ISR Number: 3984944-0Report Type:Periodic Company Report #WAES 0201USA00772
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Fluid Retention	Consumer	Tab Vioxx 50 Mg	PS		ORAL
50						
	Hypersensitivity	Health				
MG/DAILY/PO						
		Professional				

Date:06/27/02ISR Number: 3984950-6Report Type:Periodic Company Report #WAES 0201USA00851
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Alopecia	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Therapeutic Response	Professional				
MG/DAILY/PO						
	Decreased		Cipro	C		
			Fosamax	C		
			Sporanox	C		
			Amoxicillin	C		

Date:06/27/02ISR Number: 3984957-9Report Type:Periodic Company Report #WAES 0201USA00948
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Breast Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Breast Tenderness	Health				
MG/DAILY/PO						
		Professional	Cytotec	C		
			Lipitor	C		
			Atenolol	C		
			Estradiol	C		
			Hydrochlorothiazide			

(+) Triamter C

Date:06/27/02ISR Number: 3984961-0Report Type:Periodic Company Report #WAES 0201USA00965
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Prevacid	C				
			Synthroid	C				
			Theophylline	C				

Date:06/27/02ISR Number: 3984967-1Report Type:Periodic Company Report #WAES 0201USA00970
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyponatraemia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3984977-4Report Type:Periodic Company Report #WAES 01104716
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage		Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
	Oedema Peripheral							
	Pruritus		Celebrex	C				
	Rash		Lipitor	C				
			Maxzide	C				
			Norvasc	C				
			Toprol Xl Tablets [Therapy	C				

				Unspecified]	C		

Date:06/27/02ISR Number: 3984986-5Report Type:Periodic Company Report #WAES 01104798
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
	Drug Ineffective	Professional					DAILY, PO	
	Erythema		Hyzaar	C				
			Nexium	C				
			Tazorac	C				
			Tranxene	C				
			Ultram	C				
			Methotrexate	C				
			Prednisone	C				

Date:06/27/02ISR Number: 3984990-7Report Type:Periodic Company Report #WAES 01110057
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	
		Professional					PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3984997-XReport Type:Periodic Company Report #WAES 01110391
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, BID,	PO
			Aclovate	C				
			Cozaar	C				
			Rythmol	C				
			Synthroid	C				
			Tenormin	C				

Date:06/27/02ISR Number: 3985001-XReport Type:Periodic Company Report #WAES 01110631
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	PO
	Muscle Spasms	Professional						
		Company Representative						

Date:06/27/02ISR Number: 3985004-5Report Type:Periodic Company Report #WAES 01110971
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY,	PO
	Pruritus	Professional						
		Company Representative	Lopid	C				

Date:06/27/02ISR Number: 3985016-1Report Type:Periodic Company Report #WAES 01112227
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Health	Tab Vioxx	PS		ORAL	25 MG, DAILY,	
	Decreased	Professional					PO	

Date:06/27/02ISR Number: 3985017-3Report Type:Periodic Company Report #WAES 01112400
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, PRN,	
		Health					PO	
		Professional	Tab Vioxx	SS		ORAL	25 MG, PRN,	
							PO	
			Tab Vioxx 50 Mg	SS		ORAL	50 MG, PRN,	
							PO	
			Allegra	C				
			Combipatch	C				
			Combivent	C				
			Flonase	C				
			Flovent	C				
			Lipitor	C				
			Ultram	C				
			Vaseretic	C				
			Carisoprodol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985019-7Report Type:Periodic Company Report #WAES 01112978
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
	Aspartate Aminotransferase Increased		Nicotine	C				
	Blood Creatine Phosphokinase Increased							
	Muscular Weakness							
	Myalgia							

Date:06/27/02ISR Number: 3985020-3Report Type:Periodic Company Report #WAES 01113247
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Prinzide	C				

Date:06/27/02ISR Number: 3985022-7Report Type:Periodic Company Report #WAES 0112USA02101
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG DAILY	
	Gastrointestinal Disorder	Health Professional					PO	
	Hypoaesthesia		Prevacid	C				
	Malaise		Zocor	C				
	Pain		Zoloft	C				
	Swelling							

Date:06/27/02ISR Number: 3985024-0Report Type:Periodic Company Report #WAES 0112USA02125
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985026-4Report Type:Periodic Company Report #WAES 0112USA02278
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Cystitis		Prilosec	C				
			Proctocort	C				
			Synvisc	C				
			Zocor	C				
			Zyrtec	C				
			Nabumetone	C				

Date:06/27/02ISR Number: 3985028-8Report Type:Periodic Company Report #WAES 0112USA02314
Age:69 YR Gender:Female I/FU:F

Outcome	PT
	Benign Gastric Neoplasm
	Gastric Ulcer
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Professional	Tab Vioxx	SS		ORAL	PO	
		Avapro	C				
		Prilosec	C				
		Aspirin	C				
		Synthroid	C				
		Zocor	I				

Date:06/27/02ISR Number: 3985032-XReport Type:Periodic Company Report #WAES 0112USA02348
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3985034-3Report Type:Periodic Company Report #WAES 0112USA02504
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3985037-9Report Type:Periodic Company Report #WAES 0112USA02524
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Health	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Dizziness	Professional	Singulair	C				
	Vertigo		Chondroitin (+)					

			Glucosamine	C		

Date:06/27/02ISR Number: 3985039-2Report Type:Periodic Company Report #WAES 0112USA02527
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
			Celebrex	C				
			Coumadin	C				
			Esgic-Plus	C				
			Hydrodiuril	C				
			Uniximе	C				
			Sotalol Hydrochloride	C				
			Thyroid	C				

Date:06/27/02ISR Number: 3985042-2Report Type:Periodic Company Report #WAES 0112USA02713
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis Contact	Health	Tab Vioxx	PS		ORAL	PO	
	Fungal Rash	Professional						
	Pruritus	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985055-0Report Type:Periodic Company Report #WAES 0205USA01818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985056-2Report Type:Periodic Company Report #WAES 0205USA01824
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	

Date:06/27/02ISR Number: 3985057-4Report Type:Periodic Company Report #WAES 0205USA01833
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985058-6Report Type:Periodic Company Report #WAES 0205USA01835
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence							
	Gastrointestinal Pain		Aciphex	C				
	Oedema Peripheral		Centrum	C				

				Inderal	C	
				Docusate Sodium	C	

Date:06/27/02ISR Number: 3985060-4Report Type:Periodic Company Report #WAES 0205USA01841
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx Unk	PS			OPHTHALMIC	PO
		Professional Company Representative						

Date:06/27/02ISR Number: 3985061-6Report Type:Periodic Company Report #WAES 0205USA01842
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG / DAILY	/ PO
	Therapeutic Response							
	Decreased		Coumadin	C				
			Verapamil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985062-8Report Type:Periodic Company Report #WAES 0205USA01843
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash							

Date:06/27/02ISR Number: 3985063-XReport Type:Periodic Company Report #WAES 0205USA01846
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Fosamaxx	C				
			Composition Unspecified	C				

Date:06/27/02ISR Number: 3985065-3Report Type:Periodic Company Report #WAES 0205USA01847
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3985067-7Report Type:Periodic Company Report #WAES 0205USA01858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Aspartate	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Aminotransferase Increased	Professional	Composition Unspecified	C		

Date:06/27/02ISR Number: 3985069-0Report Type:Periodic Company Report #WAES 0205USA01860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Medication Residue	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
			Folic Acid 1 Mg	SS		
1 MG/DAILY						
			Adalat	C		
			Darvocet-N	C		
			Isordil	C		
			Klor-Con	C		
			Lasix (Furosemide)	C		
			Levoxyl	C		
			Protonix	C		
			Restoril	C		
			Zoloft	C		
			Dicyclomine Hydrochloride	C		
			Hydroxyzine	C		
			Metoprolol Tartrate	C		
			Pyridoxine	C		

Date:06/27/02ISR Number: 3985071-9Report Type:Periodic Company Report #WAES 0205USA01863
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Oedema Peripheral		Clonazepam	C				
	Urinary Tract Infection		Vitamins	C				
	Vascular Injury							

Date:06/27/02ISR Number: 3985074-4Report Type:Periodic Company Report #WAES 0205USA01864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia Oral	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3985076-8Report Type:Periodic Company Report #WAES 0205USA01868
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lipitor	C				
			Quinine Sulfate	C				

Date:06/27/02ISR Number: 3985078-1Report Type:Periodic Company Report #WAES 0205USA01869
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS			ORAL
25							
MG/DAILY/PO							
			Aspirin	C			

Date:06/27/02ISR Number: 3985079-3Report Type:Periodic Company Report #WAES 0205USA01878
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Tab Vioxx 50 Mg	PS		ORAL		
50								
	Dysgeusia							
MG/DAILY/PO								
			Tab Vioxx 25 Mg	SS		ORAL		
25								
MG/DAILY/PO								
			Avapro	C				
			Lotrial	C				

Date:06/27/02ISR Number: 3985081-1Report Type:Periodic Company Report #WAES 0205USA01879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL		
12.5								
	Drug Ineffective							
MG/DAILY';								
	Fatigue							
12.5								
MG/BID/PO								
			Lanoxin	C				
			Plavix	C				
			Proscar	C				

Aspirin	C
Atenolol	C
Vitamin B	C
Vitamin E	C

Date:06/27/02ISR Number: 3985082-3Report Type:Periodic Company Report #WAES 0205USA01887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Ear Infection		Vitamins	C				
	Hypoacusis							
	Medication Error							

Date:06/27/02ISR Number: 3985083-5Report Type:Periodic Company Report #WAES 0205USA01888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoacusis	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985085-9Report Type:Periodic Company Report #WAES 0205USA01889
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PM/PO	
	Haemorrhage	Professional	Cipro	C				
		Company	Flagyl	C				
		Representative						

Date:06/27/02ISR Number: 3985098-7Report Type:Periodic Company Report #WAES 0203USA00299
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Health	Vioxx	PS		ORAL	25MG/DAILY/PO	
	Decreased	Professional						

Date:06/27/02ISR Number: 3985099-9Report Type:Periodic Company Report #WAES 0203USA00300
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3985100-2Report Type:Periodic Company Report #WAES 0203USA00303
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Somnolence						MG/DAILY/PO	
			Aciphex	C				
			Buspar	C				
			Lipitor	C				
			Prilosec	C				
			Xanax	C				
			Zoloft	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985101-4Report Type:Periodic Company Report #WAES 0203USA00304
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Bilirubin Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Prothrombin Level Increased	Professional	Diuretic (Unspecified)	C				

Date:06/27/02ISR Number: 3985103-8Report Type:Periodic Company Report #WAES 0203USA00315
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea	Health						
	Flatulence	Professional						

Date:06/27/02ISR Number: 3985105-1Report Type:Periodic Company Report #WAES 0203USA00319
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nightmare	Health	Tab Vioxx 25mg	PS		ORAL	PRN/PO	
		Professional Other	Sinemet	C				

Date:06/27/02ISR Number: 3985107-5Report Type:Periodic Company Report #WAES 0203USA00320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						
		Company						

Representative

Date:06/27/02ISR Number: 3985109-9Report Type:Periodic Company Report #WAES 0203USA00322
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Company	Tab Vioxx	PS		ORAL	PO	
		Representative						
		Other						

Date:06/27/02ISR Number: 3985111-7Report Type:Periodic Company Report #WAES 0203USA00329
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Disorder	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Lamisil 250 Mg	SS			250 MG/DAILY	
			Elocon	C				
			Prempro	C				
			Synthroid	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985112-9Report Type:Periodic Company Report #WAES 0203USA00330
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Professional						
			Allegra	C				
			Buspar	C				
			Effexor Xr	C				
			Imitrex	C				
			Levaquin	C				
			Premarin	C				
			Prozac	C				
			Singulair	C				
			Acetaminophen + Codeine	C				
			Albuterol	C				

Date:06/27/02ISR Number: 3985115-4Report Type:Periodic Company Report #WAES 0203USA00331
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3985117-8Report Type:Periodic Company Report #WAES 0203USA00341
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY PO	
	Dysphagia							
	Hiccups							

Date:06/27/02ISR Number: 3985119-1Report Type:Periodic Company Report #WAES 0203USA00342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	PO

Date:06/27/02ISR Number: 3985120-8Report Type:Periodic Company Report #WAES 0203USA00370
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985122-1Report Type:Periodic Company Report #WAES 0203USA00373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Prozac	C				

Date:06/27/02ISR Number: 3985124-5Report Type:Periodic Company Report #WAES 0203USA00374
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carotid Artery Occlusion	Health	Tab Vioxx Unk	PS		ORAL	DAILY PO	
	Dizziness	Professional	Diltiazem Hydrochloride	C				
	Heart Rate Decreased							

Date:06/27/02ISR Number: 3985126-9Report Type:Periodic Company Report #WAES 0203USA00379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Decreased						PO	

Date:06/27/02ISR Number: 3985128-2Report Type:Periodic Company Report #WAES 0203USA00382
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angioneurotic Oedema	Consumer	Tab Vioxx	PS		ORAL	PO	
	Extrasystoles	Health Professional						
	Fluid Retention							
	Food Allergy							
	Oedema Peripheral							
	Weight Increased							

Date:06/27/02ISR Number: 3985131-2Report Type:Periodic Company Report #WAES 0203USA00390
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	

Professional
PO

Lescol	C	
Levothyroid	C	
Tenormin	C	

Date:06/27/02ISR Number: 3985133-6Report Type:Periodic Company Report #WAES 0203USA00406
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PO	
			Saw Palmetto	C				

Date:06/27/02ISR Number: 3985134-8Report Type:Periodic Company Report #WAES 0203USA00408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Estrogens	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985136-1Report Type:Periodic Company Report #WAES 0203USA00411
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Viox 25mg	PS		ORAL	25MG/DAILY/PO	
	Chondropathy		Vivelle	C				

Date:06/27/02ISR Number: 3985137-3Report Type:Periodic Company Report #WAES 0203USA00418
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3985138-5Report Type:Periodic Company Report #WAES 0203USA00429
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Celebrex	PS C		ORAL	PO	

Date:06/27/02ISR Number: 3985139-7Report Type:Periodic Company Report #WAES 0203USA00430
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985140-3Report Type:Periodic Company Report #WAES 0203USA00435
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Accidental Overdose	Consumer	Tab Vioxx 4 Tablet	PS		ORAL	4 TABLET/1X/PO	
	Dyspepsia							
	Headache							

Date:06/27/02ISR Number: 3985141-5Report Type:Periodic Company Report #WAES 0203USA00439
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985142-7Report Type:Periodic Company Report #WAES 0203USA00440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3985143-9Report Type:Periodic Company Report #WAES 0203USA00442
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	2 DAY
	Increased Blood Urea Increased	Professional Company Representative	Covera-Hs	C				

Date:06/27/02ISR Number: 3985144-0Report Type:Periodic Company Report #WAES 0203USA00451
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
			Vitamins	C				

Date:06/27/02ISR Number: 3985145-2Report Type:Periodic Company Report #WAES 0203USA01795
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Palpitations							
			Detrol	C				
			Tarazodone	C				

Date:06/27/02ISR Number: 3985146-4Report Type:Periodic Company Report #WAES 0203USA01804
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Pain							

Date:06/27/02ISR Number: 3985148-8Report Type:Periodic Company Report #WAES 0203USA01814
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Celebrex	C				

Date:06/27/02ISR Number: 3985156-7Report Type:Periodic Company Report #WAES 0203USA01829
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:06/27/02ISR Number: 3985157-9Report Type:Periodic Company Report #WAES 0203USA01842
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Swelling	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Hydrodiuril	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985158-0Report Type:Periodic Company Report #WAES 0203USA01874
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Imdur	C				
			Zocor	C				

Date:06/27/02ISR Number: 3985159-2Report Type:Periodic Company Report #WAES 0203USA01877
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Ambien	C				
			Fosamax	C				
			Alprazolam	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3985160-9Report Type:Periodic Company Report #WAES 0203USA01881
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985161-0Report Type:Periodic Company Report #WAES 0203USA001904
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25
	Rash	Health				MG/DAILY/PO
		Professional	Miralax	C		
			Nexium	C		
			Pepcid	C		
			Nystatin	C		

Date:06/27/02ISR Number: 3985162-2Report Type:Periodic Company Report #WAES 0203USA01907
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Drug Effect Decreased							

Date:06/27/02ISR Number: 3985848-XReport Type:Periodic Company Report #WAES 0205USA01161
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Decreased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Drug Interaction		Levoxyl	C				
			Zestril	C				
			Insulin	C				

Date:06/27/02ISR Number: 3985944-7Report Type:Periodic Company Report #WAES 0204USA01722
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
	Heart Rate Increased		Prozac	C				

Date:06/27/02ISR Number: 3985946-0Report Type:Periodic Company Report #WAES 0204USA01725
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Calcitonin	C				

Date:06/27/02ISR Number: 3985947-2Report Type:Periodic Company Report #WAES 0204USA01728
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	12.5 M/BID/PO; SEE IMAGE	
	Gastric Ulcer							
	Pain							
			Claritin-D	C				
			Tamoxifen	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3985948-4Report Type:Periodic Company Report #WAES 0204USA01738
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Pressure Increased	Consumer	Tab Vioxx	PS			ORAL
25 MG/PRN/PO							
			Elavil	C			
			Zestril	C			

Date:06/27/02ISR Number: 3985950-2Report Type:Periodic Company Report #WAES 0204USA01747
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	PO	
			Sudafed	C				

Date:06/27/02ISR Number: 3985951-4Report Type:Periodic Company Report #WAES 0204USA01750
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	;25MG DAILY
			Zocor	C				

Date:06/27/02ISR Number: 3985952-6Report Type:Periodic Company Report #WAES 0204USA01755
Age:81 YR Gender:Female I/FU:I

Outcome	PT
	Feeling Abnormal
	Nausea

Overdose

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx	PS		ORAL	25 MG/BID/PO	
			Nasonex	C				
			Acetaminophen (+)Hydrocodone	C				

Date:06/27/02ISR Number: 3985953-8Report Type:Periodic Company Report #WAES 0204USA01780
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985954-XReport Type:Periodic Company Report #WAES 0204USA01824
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Citracal	C				
			Detrol	C				
			Ascorbic Acid	C				

Date:06/27/02ISR Number: 3985981-2Report Type:Periodic Company Report #WAES 0204USA01829
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased	Consumer	Tab Vioxx	PS		ORAL	50	

MG/DAILY/PO;

SEE IMAGE

Altace	C
Cardizem	C
Glucophage Xr	C

Date:06/27/02ISR Number: 3985983-6Report Type:Periodic Company Report #WAES 0204USA01840
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx	PS		ORAL	25 MG/PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3985984-8Report Type:Periodic Company Report #WAES 0204USA01845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Fentanyl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985986-1Report Type:Periodic Company Report #WAES 0204USA01846
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Haematuria	Professional						
			Levlen	C				
			Prozac	C				

Date:06/27/02ISR Number: 3985987-3Report Type:Periodic Company Report #WAES 0204USA01857
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	25 MG/BID/PO;	
	Chest Pain	Professional					SEE IMAGE	
	Dyspnoea	Company Representative	Lotensin	C				
			Colchicine	C				

Date:06/27/02ISR Number: 3985988-5Report Type:Periodic Company Report #WAES 0204USA01859
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3985990-3Report Type:Periodic Company Report #WAES 0204USA01868
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL
PO						
		Professional Company Representative				

Date:06/27/02ISR Number: 3985991-5Report Type:Periodic Company Report #WAES 0204USA01877
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Health	Tab Vioxx	PS		ORAL
PO						
	Dizziness	Professional Company Representative				
	Nausea					

Date:06/27/02ISR Number: 3985992-7Report Type:Periodic Company Report #WAES 0204USA01882
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL
25 MG/BID/PO						
	Fatigue		Hydrodiuril	C		
	Oedema Peripheral		Erythromycin	C		
	Throat Irritation					
	Tongue Ulceration					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3985993-9Report Type:Periodic Company Report #WAES 0204USA01887
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx	PS		ORAL	PO	1 YR

Date:06/27/02ISR Number: 3985995-2Report Type:Periodic Company Report #WAES 0204USA01894
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3985996-4Report Type:Periodic Company Report #WAES 0204USA01897
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
			Pepcid	C				
			Premarin	C				
			Synthroid	C				
			Zocor	C				

Date:06/27/02ISR Number: 3985997-6Report Type:Periodic Company Report #WAES 0204USA01900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea		Aspirin	C				
	Face Oedema							
	Oedema Peripheral							

Date:06/27/02ISR Number: 3985998-8Report Type:Periodic Company Report #WAES 0204USA01904
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menorrhagia	Consumer	Tab Vioxx	PS		ORAL	25MG/DAILY/PO	
			Hydrodiuril	C				
			Motrin	C				
			Prozac	C				
			Robaxin	C				
			Vasotec	C				

Date:06/27/02ISR Number: 3985999-XReport Type:Periodic Company Report #WAES 0204USA01947
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG IV	
	Oedema Peripheral						/DAILY /PO	
			Ecotrin	C				
			Hydrodiuril	C				
			Monopril	C				
			Penlac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986000-4Report Type:Periodic Company Report #WAES 0204USA01957
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Health Professional Company Representative	Tab Vioxx 25mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986004-1Report Type:Periodic Company Report #WAES 0204USA01989
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY	
	Dry Mouth	Health Professional					/PO	
	Dysgeusia		Accolate	C				
	Hypoaesthesia		Advair	C				
	Paraesthesia		Evista	C				
			Maxair	C				
			Moduretic	C				
			Ibuprofen	C				

Date:06/27/02ISR Number: 3986005-3Report Type:Periodic Company Report #WAES 0204USA02028
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS		ORAL	PO	
	Visual Acuity Reduced							

Date:06/27/02ISR Number: 3986006-5Report Type:Periodic Company Report #WAES 0204USA02039
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abnormal Faeces	Consumer	Tab Vioxx 25mg	PS		ORAL
PRN PO						
	Haematochezia					

Date:06/27/02ISR Number: 3986010-7Report Type:Periodic Company Report #WAES 0204USA02042
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL
12.5MG						
	Hyperventilation					
/BID/PO						
			Aciphex	C		
			Benemid	C		
			Prozac	C		

Date:06/27/02ISR Number: 3986011-9Report Type:Periodic Company Report #WAES 0205USA01518
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Diarrhoea					
MG/DAILY/PO						
	Frequent Bowel Movements		Accupril	C		
			Digitek	C		
			Lipitor	C		
			Toprol Xl Tablets	C		
			Amitriptyline	C		

			Aspirin	C
			Diazepam	C
			Folic Acid	C
			Furosemide	C
			Nifedipine	C

Date:06/27/02ISR Number: 3986012-0Report Type:Periodic Company Report #WAES 0205USA01535
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Glucose Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Insulin	C				

Date:06/27/02ISR Number: 3986013-2Report Type:Periodic Company Report #WAES 0205USA01545
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advair	C				
			Lipitor	C				
			Albuterol	C				
			Triamterene	C				

Date:06/27/02ISR Number: 3986014-4Report Type:Periodic Company Report #WAES 0205USA01547
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Fosamax	C				
			Pamelor	C				

Date:06/27/02ISR Number: 3986015-6Report Type:Periodic Company Report #WAES 0205USA01560
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
			Lipitor	C				
			Synthroid	C				
			Hydrochlorothiazide	C				

Date:06/27/02ISR Number: 3986016-8Report Type:Periodic Company Report #WAES 0205USA01570
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/TID/PO	
	Pain	Professional						
	Prescribed Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986017-XReport Type:Periodic Company Report #WAES 0205USA01577
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986018-1Report Type:Periodic Company Report #WAES 0205USA01606
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50 MG/DAILY/PO	
	Vision Blurred							
			Claritin	C				
			Climara	C				
			Urised Tablets	C				
			Zocor	C				
			Amitriptyline	C				
			Aspirin	C				
			Calcium (Unspecified)	C				
			Garlic Extract	C				
			Magnesium (Unspecified)	C				
			Vitamin B Complex	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3986019-3Report Type:Periodic Company Report #WAES 0205USA01618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986020-XReport Type:Periodic Company Report #WAES 0205USA01627
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Serevent	C				
			Albuterol	C				
			Furosemide	C				
			Glyburide	C				

Date:06/27/02ISR Number: 3986022-3Report Type:Periodic Company Report #WAES 0205USA00847
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Wellbutrin	C				

Date:06/27/02ISR Number: 3986023-5Report Type:Periodic Company Report #WAES 0205USA00848
Age:58 YR Gender:Female I/FU:I

Outcome	PT
	Fatigue
	Headache

Joint Swelling
Paraesthesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx	PS		ORAL	25	MG/DAILY/PO

Date:06/27/02ISR Number: 3986024-7Report Type:Periodic Company Report #WAES 0205USA00866
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986025-9Report Type:Periodic Company Report #WAES 0205USA00880
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional	Prinivil	C				
	Blood Pressure Increased							
	Blood Urea Increased							

Date:06/27/02ISR Number: 3986026-0Report Type:Periodic Company Report #WAES 0205USA00881
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysgeusia	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Mouth Ulceration		Niaspan	C				
	Tongue Ulceration							

Date:06/27/02ISR Number: 3986027-2Report Type:Periodic Company Report #WAES 0205USA00886
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO;	
	Drug Ineffective	Professional						
	Hallucination						50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986028-4Report Type:Periodic Company Report #WAES 0205USA00899
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx Unk	PS		ORAL	25 MG/PO	
	Rash Pruritic							

Date:06/27/02ISR Number: 3986029-6Report Type:Periodic Company Report #WAES 0205USA00917
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Dyazide	C				

Lopid	C
Prinivil	C
Oxazepam	C

Date:06/27/02ISR Number: 3986030-2Report Type:Periodic Company Report #WAES 0205USA00956
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Menstruation Irregular	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986031-4Report Type:Periodic Company Report #WAES 0205USA00964
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986032-6Report Type:Periodic Company Report #WAES 0205USA01652
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Abdominal Pain Upper Fluid Retention Oedema Peripheral Weight Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986033-8Report Type:Periodic Company Report #WAES 0205USA01660
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
	Blood Urea Increased	Professional Company Representative	Lipitor	C				
			Niaspan	C				
			Tricor	C				
			Zocor	C				

Date:06/27/02ISR Number: 3986034-XReport Type:Periodic Company Report #WAES 0205USA01675
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urine Present	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Norvasc	C				
			Proscar	C				
			Zestril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986035-1Report Type:Periodic Company Report #WAES 0205USA01676
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Psychomotor Hyperactivity							
			Aciphex	C				
			Claritin	C				
			Diovan Hct	C				
			Flonase	C				
			Premphase	C				

Date:06/27/02ISR Number: 3986036-3Report Type:Periodic Company Report #WAES 0205USA01682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Petechiae	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Rash Erythematous	Professional	Prilosec	C				
			Zestril	C				

Date:06/27/02ISR Number: 3986037-5Report Type:Periodic Company Report #WAES 0205USA01685
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/PRN/PO	

Date:06/27/02ISR Number: 3986038-7Report Type:Periodic Company Report #WAES 0205USA01694
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Mass	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
		Professional						

Date:06/27/02ISR Number: 3986039-9Report Type:Periodic Company Report #WAES 0205USA01708
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pollakiuria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Urine Flow Decreased							
			Altace	C				
			Diprivan	C				
			Entex	C				
			Norvasc	C				
			Plavix	C				
			Vicoprofen	C				
			Zoloft	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3986040-5Report Type:Periodic Company Report #WAES 0205USA01715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Sodium Decreased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Tegretol (Therapy Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986041-7Report Type:Periodic Company Report #WAES 0205USA01717
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	UNK/UNK/PO	
	Constipation		Lipitor	C				
	Fatigue		Zileuton	C				
	Nervousness							
	Paraesthesia							
	Somnolence							

Date:06/27/02ISR Number: 3986042-9Report Type:Periodic Company Report #WAES 0205USA00968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986043-0Report Type:Periodic Company Report #WAES 0205USA00971
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Throat Tightness							
			Cardizem	C				
			Coumadin	C				
			Levothroid	C				
			Zantac	C				
			Nitroglycerin	C				

Date:06/27/02ISR Number: 3986044-2Report Type:Periodic Company Report #WAES 0205USA00985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Swelling	Consumer	Tab Vioxx	PS		ORAL
PO						

Date:06/27/02ISR Number: 3986045-4Report Type:Periodic Company Report #WAES 0205USA01007
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Myalgia	Consumer	Tab Vioxx	PS		ORAL
PO						
			Verapamil	C		

Date:06/27/02ISR Number: 3986046-6Report Type:Periodic Company Report #WAES 0205USA01011
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Deafness	Consumer	Tab Vioxx	PS		ORAL
25						
	Medication Error					
MG/DAILY/PO;						
	Tinnitus					
SEE IMAGE						
			Antivert	C		
			Estrogens (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986048-XReport Type:Periodic Company Report #WAES 0205USA01019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL		
	Gastrooesophageal Reflux Disease		Atarax	C				
			Prevacid	C				
	Oedema Peripheral		Aspirin	C				

Date:06/27/02ISR Number: 3986049-1Report Type:Periodic Company Report #WAES 0205USA01022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986050-8Report Type:Periodic Company Report #WAES 0205USA01023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
			Calcium	C				
			Vitamin E	C				

Date:06/27/02ISR Number: 3986051-XReport Type:Periodic Company Report #WAES 0205USA01029
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO;	

SEE IMAGE

Date:06/27/02ISR Number: 3986052-1Report Type:Periodic Company Report #WAES 0204USA00070
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	
			[Therapy Unspecified]	C				

Date:06/27/02ISR Number: 3986053-3Report Type:Periodic Company Report #WAES 0204USA00087
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986054-5Report Type:Periodic Company Report #WAES 0204USA00091
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Consumer	Tab Vioxx	PS		ORAL	25 MG BID PO	
	Muscle Rigidity		Amaryl	C				
	Muscular Weakness		Centrum Silver	C				

Depakote	C
Ferricon	C
Glucophage	C
Hydrodiuril	C
Levothroid	C
Lipitor	C
Prinivil	C
Sular	C
Ticlid	C
Toprol Xl Tablets	C
Calcium (Unspecified)	C
Terazosin Hydrochloride	C

Date:06/27/02ISR Number: 3986055-7Report Type:Periodic Company Report #WAES 0204USA00093
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Fosamax	C				

Date:06/27/02ISR Number: 3986056-9Report Type:Periodic Company Report #WAES 0204USA00099
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Maxzide	C				
			Ascorbic Acid	C				
			Garlic Extract	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3986057-0Report Type:Periodic Company Report #WAES 0204USA00104
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Evista	C				
			Imitrex	C				
			Vagifem	C				
			Clonazepam	C				

Date:06/27/02ISR Number: 3986058-2Report Type:Periodic Company Report #WAES 0204USA00109
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Confusional State	Consumer	Tab Vioxx	PS		ORAL	12.5 MG DAILY	
	Somnolence							
PO								
			Detrol	C				
			Paxil	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986059-4Report Type:Periodic Company Report #WAES 0204USA00111
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Accolate	C				

Date:06/27/02ISR Number: 3986060-0Report Type:Periodic Company Report #WAES 0204USA00112
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Cozaar	C				
			Levoxyl	C				
			Lipitor	C				
			Paxil	C				
			Prilosec	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3986061-2Report Type:Periodic Company Report #WAES 0204USA00117
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986062-4Report Type:Periodic Company Report #WAES 0204USA02664
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Pain	Professional Company Representative						

Date:06/27/02ISR Number: 3986063-6Report Type:Periodic Company Report #WAES 0204USA02677
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Sinus Disorder	Professional Company Representative						

Date:06/27/02ISR Number: 3986064-8Report Type:Periodic Company Report #WAES 0204USA02679
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986065-XReport Type:Periodic Company Report #WAES 0204USA02690
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			K-Dur	C				
			Monopril-Hct	C				
			Zocor	C				
			Glucosamine	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3986066-1Report Type:Periodic Company Report #WAES 0204USA02708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx Unk	PS		ORAL	25 MG/UNK/PO	
	Haemorrhage	Professional Company Representative	Aspirin	C				

Date:06/27/02ISR Number: 3986067-3Report Type:Periodic Company Report #WAES 0204USA02713
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Retinal Haemorrhage	Professional Company Representative	Estrogens (Unspecified)	C				

Date:06/27/02ISR Number: 3986068-5Report Type:Periodic Company Report #WAES 0204USA02720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Neck Pain							

Date:06/27/02ISR Number: 3986069-7Report Type:Periodic Company Report #WAES 0204USA02722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Migraine	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
			Arthrotec	C				
			Celebrex	C				
			Ibuprofen	C				

Date:06/27/02ISR Number: 3986070-3Report Type:Periodic Company Report #WAES 0204USA02731
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health Professional	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Celexa	C				
			Evista	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986071-5Report Type:Periodic Company Report #WAES 0204USA00129
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cyst	Consumer	Tab Vioxx	PS		ORAL	50 MG/PO	
			Verapamil	C				

Date:06/27/02ISR Number: 3986072-7Report Type:Periodic Company Report #WAES 0204USA00131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Methacycline	C				

Date:06/27/02ISR Number: 3986073-9Report Type:Periodic Company Report #WAES 0204USA00139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx	PS		ORAL	25	
	Pruritus						MG/DAILY/PO	
	Urticaria		Cardizem	C				
			Zebeta	C				

Date:06/27/02ISR Number: 3986074-0Report Type:Periodic Company Report #WAES 0204USA00144
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	25	
	Pain In Extremity						MG/DAILY/PO	

Date:06/27/02ISR Number: 3986075-2Report Type:Periodic Company Report #WAES 0204USA00148
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/ PO	
			Prevacid	C				
			Trental	C				

Date:06/27/02ISR Number: 3986076-4Report Type:Periodic Company Report #WAES 0204USA00166
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Nexium	C				
			Prempro	C				
			Xalatan	C				

Date:06/27/02ISR Number: 3986077-6Report Type:Periodic Company Report #WAES 0204USA00179
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Allegra	C				
			Loestrin Fe	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986078-8Report Type:Periodic Company Report #WAES 0204USA00206
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypersensitivity	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986079-XReport Type:Periodic Company Report #WAES 0204USA00211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Company Representative Other	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986080-6Report Type:Periodic Company Report #WAES 0204USA00231
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Constipation	Health Professional	Ambien	C				
	Diarrhoea		Cataplam (Diclofenac Potassium)	C				
	Dyspepsia		Digitek	C				
	Pruritus		Glucophage	C				
			Paxil	C				
			Starlix	C				
			Doxazosin	C				
			Enalapril Maleate	C				

Date:06/27/02ISR Number: 3986608-6Report Type:Periodic Company Report #WAES 0203USA02215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx	PS		ORAL	PO	
	Rash	Professional Company Representative						

Date:06/27/02ISR Number: 3986609-8Report Type:Periodic Company Report #WAES 0203USA02221
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lopid	C				
			Prinivil	C				
			Zocor	C				

Date:06/27/02ISR Number: 3986610-4Report Type:Periodic Company Report #WAES 0203USA02223
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Inderal	C				
			Prilosec	C				

Doxepin C

Date:06/27/02ISR Number: 3986611-6Report Type:Periodic Company Report #WAES 0203USA02224
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Fluid Retention	Professional	Tab Vioxx 25 Mg	SS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3986612-8Report Type:Periodic Company Report #WAES 0203USA02236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prostatic Specific Antigen Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986613-XReport Type:Periodic Company Report #WAES 0203USA02238
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Purpura	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
			Altace	C				
			Neurontin	C				
			Prempro	C				

Date:06/27/02ISR Number: 3986614-1Report Type:Periodic Company Report #WAES 0203USA02239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Health	Tab Vioxx	PS		ORAL	PO	
	Diarrhoea	Professional						

Date:06/27/02ISR Number: 3986615-3Report Type:Periodic Company Report #WAES 0203USA02244
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3986616-5Report Type:Periodic Company Report #WAES 0203USA02251
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986617-7Report Type:Periodic Company Report #WAES 0203USA02253
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sedation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Valium	C				
			Albuterol	C				
			Hydrocodone	C				

Date:06/27/02ISR Number: 3986628-1Report Type:Periodic Company Report #WAES 0202USA02392
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986629-3Report Type:Periodic Company Report #WAES 0202USA02394
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydrodiuril	C				
			Lotensin	C				
			Plendil	C				
			Premarin	C				
			Medroxyprogesterone Acetate	C				

Date:06/27/02ISR Number: 3986630-XReport Type:Periodic Company Report #WAES 0202USA02404
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective	Professional						
			Actos	C				
			Altace	C				
			Glucotrol Xl	C				
			Lipitor	C				
			Allopurinol	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3986631-1Report Type:Periodic Company Report #WAES 0202USA02405
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Drug Tolerance Decreased	Professional						

Date:06/27/02ISR Number: 3986632-3Report Type:Periodic Company Report #WAES 0202USA02406
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986633-5Report Type:Periodic Company Report #WAES 0202USA02407
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Gastrooesophageal Reflux Disease	Professional					MG/DAILY/PO	
			Darvocet-N	C				
			Effexor Xr	C				
			Estratest	C				
			Nexium	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3986634-7Report Type:Periodic Company Report #WAES 0202USA02411
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3986635-9Report Type:Periodic Company Report #WAES 0202USA02493
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Advair	C				
			Combivent	C				
			Loperyl	C				
			Nexium	C				
			Norvasc	C				
			Premarin	C				
			Proventil	C				
			Singulair	C				
			Aspirin	C				
			Atenolol	C				

				Vitamin E	C		

Date:06/27/02ISR Number: 3986636-0Report Type:Periodic Company Report #WAES 0202USA02496
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flatulence	Health Professional	Altace	C				
			Ambien	C				
			Fosamax	C				
			Nexium	C				
			Norvasc	C				
			Synthroid	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3986637-2Report Type:Periodic Company Report #WAES 0202USA02498
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986662-1Report Type:Periodic Company Report #WAES 0203USA02407
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986663-3Report Type:Periodic Company Report #WAES 0203USA02412
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Arthrotec	C				
			Neurontin	C				
			Provera	C				
			Sonata	C				
			Ultram	C				
			Diazepam	C				
			Estradiol	C				

Date:06/27/02ISR Number: 3986664-5Report Type:Periodic Company Report #WAES 0203USA02441
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986665-7Report Type:Periodic Company Report #WAES 0203USA02445
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx	PS		ORAL PO

Date:06/27/02ISR Number: 3986666-9Report Type:Periodic Company Report #WAES 0203USA02642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Pain	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986667-0Report Type:Periodic Company Report #WAES 0203USA02452
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	International Normalised Ratio Increased	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL PO		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986668-2Report Type:Periodic Company Report #WAES 0203USA02645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986669-4Report Type:Periodic Company Report #WAES 0203USA02453
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986670-0Report Type:Periodic Company Report #WAES 0203USA02647
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986671-2Report Type:Periodic Company Report #WAES 0203USA02472
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
	Urticaria	Professional	Plavix	SS		ORAL	75	

Other
MG/DAILY/PO
Premarin C

Date:06/27/02ISR Number: 3986672-4Report Type:Periodic Company Report #WAES 0203USA02663
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Darvocet-N	C				
			Premarin	C				
			Buspirone Hydrochloride	C				
			Propranolol	C				

Date:06/27/02ISR Number: 3986673-6Report Type:Periodic Company Report #WAES 0203USA02487
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Gastrointestinal Ulcer	Company Representative	[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986674-8Report Type:Periodic Company Report #WAES 0203USA02496
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactoid Reaction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986675-XReport Type:Periodic Company Report #WAES 0203USA02670
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Incontinence	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986676-1Report Type:Periodic Company Report #WAES 0203USA02679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Face Oedema Pharyngolaryngeal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986677-3Report Type:Periodic Company Report #WAES 0203USA02499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaphylactic Reaction Chest Discomfort Drug Tolerance Decreased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986678-5Report Type:Periodic Company Report #WAES 0203USA02685
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Fosamax	C				
			Sporanox	C				

Date:06/27/02ISR Number: 3986681-5Report Type:Periodic Company Report #WAES 0203USA02717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986682-7Report Type:Periodic Company Report #WAES 0203USA02901
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Rash		Tab Vioxx 25 Mg	SS		ORAL	PO	
			Allegra	C				

		Lipitor	C
		Synthroid	C
		Alprazolam	C
		Prednisone	C

Date:06/27/02ISR Number: 3986685-2Report Type:Periodic Company Report #WAES 0203USA02590
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
		Health Professional	Hydrodiuril	C				
			Premarin	C				
			Prevacid	C				
			Synthroid	C				
			Prednisone	C				

Date:06/27/02ISR Number: 3986686-4Report Type:Periodic Company Report #WAES 0203USA02593
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS		ORAL	25 MG / DAILY / PO	
	Contusion	Health Professional	Bactrim	C				
	Drug Ineffective		Sudil	C				
	Excoriation		Hydrocodone	C				
	Fall							
	Haematoma							
	Joint Sprain							
	Neck Pain							
	Pain In Extremity							
	Tendonitis							

Date:06/27/02ISR Number: 3986687-6Report Type:Periodic Company Report #WAES 0203USA02596
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eructation	Consumer	Vioxx	PS		ORAL	PO	
	Increased Appetite							

Date:06/27/02ISR Number: 3986689-XReport Type:Periodic Company Report #WAES 0203USA02618
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health	Vioxx Unk	PS		ORAL	PO	
	Diplopia	Professional	Norvasc	C				
	Dizziness							
	Neurological Symptom							
	Vomiting							

Date:06/27/02ISR Number: 3986691-8Report Type:Periodic Company Report #WAES 0203USA02621
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Vioxx	PS		ORAL	50 MG / DAILY	
	Back Pain						/ PO ; 50	
	Myalgia						MG/PRN/PO	

			Hyzaar	C		
			Aspirin	C		
			Isosorbide	C		

Date:06/27/02ISR Number: 3986692-XReport Type:Periodic Company Report #WAES 0203USA02628
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Vioxx	PS		ORAL	PO	
	Rash Macular		Dilantin	C				
			Hydrodiuril	C				
			Neurontin	C				
			Os-Cal	C				
			Percocet	C				
			Protonix	C				
			Serzone	C				
			Vival	C				

Date:06/27/02ISR Number: 3986694-3Report Type:Periodic Company Report #WAES 0203USA02629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polymyalgia Rheumatica	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986696-7Report Type:Periodic Company Report #WAES 0203USA02630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Disorientation							
			Celebrex	C				
			Diflucan	C				

Date:06/27/02ISR Number: 3986697-9Report Type:Periodic Company Report #WAES 0203USA02635
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health	Vioxx	PS		ORAL	25 MG / DAILY	
	Hypersomnia	Professional					/ PO	
	Pain		Premarin	C				
			Synthroid	C				
			Oxybutynin Chloride	C				

Date:06/27/02ISR Number: 3986699-2Report Type:Periodic Company Report #WAES 0203USA02639
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx	PS		ORAL	12.5	
	Headache						MG/DAILY/PO ;	
							25	
							MG/DAILY/PO	
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986701-8Report Type:Periodic Company Report #WAES 0203USA02500
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendon Rupture	Consumer	Tab Vioxx	PS		ORAL	12.5 MG DAILY	PO 10 DAY
			Glucotrol	C				
			Lipitor	C				

Date:06/27/02ISR Number: 3986703-1Report Type:Periodic Company Report #WAES 0203USA02507
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986705-5Report Type:Periodic Company Report #WAES 0203USA02509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Company Representative Other	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986706-7Report Type:Periodic Company Report #WAES 0203USA02532
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Health	Tab Vioxx	PS		ORAL	25-50 MG	

Professional
DAILY PO

	Levoxyl	C
	Estropipate	C
	Hydroxychloroquine Sulfate	C

Date:06/27/02ISR Number: 3986708-0Report Type:Periodic Company Report #WAES 0203USA02547
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3986709-2Report Type:Periodic Company Report #WAES 0203USA02555
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activated Partial Thromboplastin Time Prolonged	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986712-2Report Type:Periodic Company Report #WAES 0203USA02580
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Chest Pain		Vitamins					
	Headache		(Unspecified)	C				
	Nausea							

Date:06/27/02ISR Number: 3986713-4Report Type:Periodic Company Report #WAES 0203USA02584
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	PO
			Oxycontin	C				
			Percocet	C				

Date:06/27/02ISR Number: 3986714-6Report Type:Periodic Company Report #WAES 0203USA02587
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	PO

Date:06/27/02ISR Number: 3986715-8Report Type:Periodic Company Report #WAES 0203USA02588
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Kidney Infection	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	

Therapeutic Response
PO
Decreased Ambien C
Nexium C
Premarin C

Date:06/27/02ISR Number: 3986717-1Report Type:Periodic Company Report #WAES 0204USA02732
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Rash	Professional						
		Company Representative	Zoloft	C				

Date:06/27/02ISR Number: 3986719-5Report Type:Periodic Company Report #WAES 0204USA02743
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 DAY
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986720-1Report Type:Periodic Company Report #WAES 0204USA02746
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Vioxx	PS		ORAL	25 MG/PO	
	Oral Mucosal Blistering							
	Rash							
	Swelling							

Date:06/27/02ISR Number: 3986722-5Report Type:Periodic Company Report #WAES 0204USA02763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	BID/PO	
			Fosamax	C				

Date:06/27/02ISR Number: 3986723-7Report Type:Periodic Company Report #WAES 0204USA02767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Oedema	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3986725-0Report Type:Periodic Company Report #WAES 0204USA02768
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Screen Positive	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986727-4Report Type:Periodic Company Report #WAES 0204USA02769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Vioxx	PS		ORAL	25 MG/BID/PO	

Date:06/27/02ISR Number: 3986729-8Report Type:Periodic Company Report #WAES 0204USA02775
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	1 TABLET/DAILY/PO	1 MON
			Glucotrol	C				

Date:06/27/02ISR Number: 3986730-4Report Type:Periodic Company Report #WAES 0204USA02781
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Gastrooesophageal Reflux Disease		Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986732-8Report Type:Periodic Company Report #WAES 0204USA02823
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test	Health	Vioxx	PS		ORAL	50 MG/3XW/PO	
	Abnormal	Professional						

Date:06/27/02ISR Number: 3986741-9Report Type:Periodic Company Report #WAES 0203USA03286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS		ORAL	50 MG/DAILY/PO	7 WK
		Professional						

Date:06/27/02ISR Number: 3986743-2Report Type:Periodic Company Report #WAES 0203USA03287
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Vioxx	PS		ORAL	PO	
		Professional						

Date:06/27/02ISR Number: 3986746-8Report Type:Periodic Company Report #WAES 0203USA03294
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Swelling	Consumer	Vioxx	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986747-XReport Type:Periodic Company Report #WAES 0203USA03307
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Health Professional Company Representative	Vioxx	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	

Date:06/27/02ISR Number: 3986750-XReport Type:Periodic Company Report #WAES 0203USA03310
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Vioxx	PS		ORAL	PO	
	Swelling		Insulin	C				

Date:06/27/02ISR Number: 3986753-5Report Type:Periodic Company Report #WAES 0203USA03323
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Cortisone (Cortisone Acetate)	C				
			Florinef Acetate	C				
			Fosamax	C				
			Premarin	C				
			Medroxyprogesterone					

Acetate C

Date:06/27/02ISR Number: 3986756-0Report Type:Periodic Company Report #WAES 0203USA03324
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986757-2Report Type:Periodic Company Report #WAES 0203USA03339
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Synthroid	C				
			Zocor	C				
			Allopurinol	C				
			Indapamide	C				

Date:06/27/02ISR Number: 3986760-2Report Type:Periodic Company Report #WAES 0204USA00001
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Ulcer Haemorrhage							
			Elavil	C				

Date:06/27/02ISR Number: 3986761-4Report Type:Periodic Company Report #WAES 0204USA00008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Vioxx	PS		ORAL	PO	
	Rash	Professional Company Representative						

Date:06/27/02ISR Number: 3986780-8Report Type:Periodic Company Report #WAES 0201USA03358
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Vioxx	PS		ORAL	12.5MG/DAILY/	
	Abdominal Pain	Health					PO	
	Bladder Disorder	Professional	Celebrex	C				
	Constipation		Miacalcin	C				
	Diarrhoea		Ultram	C				
	Eating Disorder		Zoloft	C				
	Gastrointestinal Disorder		Acetaminophen	C				

Date:06/27/02ISR Number: 3986781-XReport Type:Periodic Company Report #WAES 0202USA00056
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source
	Dermatitis Contact	Consumer
	Joint Swelling	Health

Professional

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx	PS		ORAL	50 MG/DAILY/PO	
Celebrex	C				
Prempro	C				
Synthroid	C				
Tylenol	C				
Vicodin Tablets	C				
Vitamins	C				

Date:06/27/02ISR Number: 3986783-3Report Type:Periodic Company Report #WAES 0202USA00057
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Dysphonia	Health Professional	Aciphex	C				
	Hallucination		Acular	C				
	Oedema Peripheral		Ascriptin	C				
			Didronel	C				
			Hydrodiuril	C				
			Lopressor	C				
			Penicillin Vk	C				
			Estropipate	C				
			Methotrexate	C				
			Potassium Chloride	C				
			Prednisone	C				
			Progesterone	C				

Date:06/27/02ISR Number: 3986785-7Report Type:Periodic Company Report #WAES 0202USA00115
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	
	Diarrhoea	Health	Centrum	C				

	Dizziness	Professional	Fosamax	C
	Dyspepsia	Company	Levoxyl	C
	Fall	Representative		
	Headache			

Date:06/27/02ISR Number: 3986791-2Report Type:Periodic Company Report #WAES 0202USA00175
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoptysis	Consumer	Vioxx	PS		ORAL	25	
	Somnolence	Health					MG/DAILY/PO	1 WK
	Vision Blurred	Professional	Lasix (Furosemide)	C				
			Plavix	C				
			Allopurinol	C				
			Diltiazem Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986792-4Report Type:Periodic Company Report #WAES 0202USA00247
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fear	Health	Vioxx Unk	PS		ORAL	DAILY/PO	
	Petechiae	Professional	Premarin	C				
	Pruritus	Company	Toradol	C				
	Rash	Representative	Iron	C				
	Swelling							

Date:06/27/02ISR Number: 3986793-6Report Type:Periodic Company Report #WAES 0202USA00343
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Vioxx	PS		ORAL	12.5	
		Health					MG/DAILY/PO	
		Professional	Premarin	C				
			Naproxen	C				

Date:06/27/02ISR Number: 3986794-8Report Type:Periodic Company Report #WAES 0202USA00355
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Vioxx	PS		ORAL	25	
	Diarrhoea						MG/DAILY/PO	
	Joint Swelling		Accupril	C				
			Estring	C				
			Evista	C				
			Miacalcin	C				
			Pravachol	C				
			Synthroid	C				
			Tiazac	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3986795-XReport Type:Periodic Company Report #WAES 0202USA00420
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Pain	Consumer Health Professional	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
			Cartia (Diltiazem Hydrochloride)	C				
			Coumadin	C				
			Bumetanide	C				

Date:06/27/02ISR Number: 3986796-1Report Type:Periodic Company Report #WAES 0202USA00423
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer Health Professional	Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral		Atrovent	C				
			Combivent	C				
			Dynacirc	C				
			Zoloft	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3986798-5Report Type:Periodic Company Report #WAES 0201USA03062
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3986799-7Report Type:Periodic Company Report #WAES 0201USA03067
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3986800-0Report Type:Periodic Company Report #WAES 0201USA03095
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Skin Exfoliation	Health Professional	Caltrate	C			MG/DAILY/PO	
			Coumadin	C				
			Klor-Con	C				
			Lipitor	C				
			Synthroid	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3986801-2Report Type:Periodic Company Report #WAES 0201USA03099
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986802-4Report Type:Periodic Company Report #WAES 0201USA03191
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Iron Deficiency Anaemia	Professional						
			Nasonex	C				
			Nexium	C				
			Pepcid	C				
			Premarin	C				
			Bisoprolol Fumarate	C				

Date:06/27/02ISR Number: 3986803-6Report Type:Periodic Company Report #WAES 0201USA03275
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Health						
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986804-8Report Type:Periodic Company Report #WAES 0201USA03278
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral	Professional					MG/DAILY/PO	
	Swelling	Company Representative						

Date:06/27/02ISR Number: 3986805-XReport Type:Periodic Company Report #WAES 0201USA03309
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Blood Pressure Increased	Health					MG/BID/PO	
	Dizziness	Professional						
	Drug Ineffective							
	Dry Mouth							
	Gastrooesophageal Reflux Disease							
	Headache							
	Myalgia							
	Nausea							
	Urine Odour Abnormal							

Date:06/27/02ISR Number: 3986806-1Report Type:Periodic Company Report #WAES 0201USA03336
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
		Professional					MG/DAILY/PO	
			Gabitril	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3986807-3Report Type:Periodic Company Report #WAES 0201USA02427
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Other	Celebrex	C				
			Levoxyl	C				
			Prilosec	C				
			Provigil	C				
			Zocor	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3986808-5Report Type:Periodic Company Report #WAES 0201USA02487
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Oedema							
	Swelling		Premarin	C				
			Valtrex	C				
			Zyrtec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986810-3Report Type:Periodic Company Report #WAES 0201USA02548
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Laboratory Test Abnormal	Consumer	Tab Vioxx	PS		ORAL	PO	
			Coumadin	C				

Date:06/27/02ISR Number: 3986811-5Report Type:Periodic Company Report #WAES 0201USA02551
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986812-7Report Type:Periodic Company Report #WAES 0201USA02722
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3986813-9Report Type:Periodic Company Report #WAES 0201USA02725
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Dyspnoea Exertional							
	Palpitations		Celebrex	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/27/02ISR Number: 3986815-2Report Type:Periodic Company Report #WAES 0201USA02751
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO;1	
	Muscular Weakness	Company Representative					2.5 MG/DAILY/PO;	
							50	
			Cenestan	C				
			Diovan	C				
			Lipitor	C				
			Plaquenil	C				
			Prometrium	C				
			Tricor	C				

Date:06/27/02ISR Number: 3986816-4Report Type:Periodic Company Report #WAES 0201USA02803
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mydriasis	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Pharyngeal Oedema	Company Representative						
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3986818-8Report Type:Periodic Company Report #WAES 0201USA02977
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lipitor	C				
			Travatan	C				
			Zestril	C				

Date:06/27/02ISR Number: 3986819-XReport Type:Periodic Company Report #WAES 0201USA02994
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3987567-2Report Type:Periodic Company Report #WAES 0201USA01959
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
		Company Representative	Celebrex	C				

Date:06/27/02ISR Number: 3987569-6Report Type:Periodic Company Report #WAES 0201USA01972
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Haemorrhage	Health	Tab Vioxx 50 Mg	PS			ORAL
50							
	Haemorrhagic Disorder	Professional					
MG/DAILY/PO;							
		Company					
25							
		Representative					
MG/DAILY/PO							

Date:06/27/02ISR Number: 3987572-6Report Type:Periodic Company Report #WAES 0201USA02011
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
	Heart Rate Irregular					
MG/BID/PO						
	Hypertension		Celebrex	C		
	Syncope					

Date:06/27/02ISR Number: 3987573-8Report Type:Periodic Company Report #WAES 0201USA02143
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Nausea	Health				
MG/DAILY/PO						
		Professional	Dyazide	C		
			Norvasc	C		
			Premarin	C		
			Prinivil	C		
			Synthroid	C		
			Metoprolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987574-XReport Type:Periodic Company Report #WAES 0201USA02150
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Swelling	Professional					MG/DAILY/PO	
			Celebrex	C				
			Celexa	C				
			Desyrel	C				
			Ms Contin	C				
			Percocet	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3987575-1Report Type:Periodic Company Report #WAES 0201USA02209
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Interaction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Hypothyroidism		Duratuss G	C				
			Klonopin	C				
			Nasarel	C				
			Plaquenil	C				
			Prempro	C				
			Pulmicort	C				
			Synthroid	C				
			Veralan	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3987576-3Report Type:Periodic Company Report #WAES 0201USA02213
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	25	
	Nausea	Health					MG/DAILY/PO	
	Rash	Professional	Accupril	C				

	Urticaria		Maxzide	C		
			Norvasc	C		
			Premarin	C		
			Atenolol	C		

Date:06/27/02ISR Number: 3987577-5Report Type:Periodic Company Report #WAES 0201USA02214
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tremor							
			Paxil	C				
			Premarin	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3987578-7Report Type:Periodic Company Report #WAES 0201USA02410
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pain In Extremity							
			Hydrocodone	C				

Date:06/27/02ISR Number: 3987579-9Report Type:Periodic Company Report #WAES 0201USA02423
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Hypertension							
			Atacand	C				
			Cardizem	C				
			Lipitor	C				
			Microzide	C				

Date:06/27/02ISR Number: 3987580-5Report Type:Periodic Company Report #WAES 0201USA01034
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haematuria							
	Rhinorrhoea	Company Representative						

Date:06/27/02ISR Number: 3987581-7Report Type:Periodic Company Report #WAES 0201USA01084
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Residue	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3987582-9Report Type:Periodic Company Report #WAES 0201USA01151
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis	Health	Tab Vioxx	PS		ORAL	50 MG/3XW/PO	
	Pulmonary Embolism	Professional Company Representative	Diovan	C				
			Pamelor	C				
			Prempro	C				
			Singulair	C				
			Ziac	C				

Date:06/27/02ISR Number: 3987583-0Report Type:Periodic Company Report #WAES 0201USA01159
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Drug Ineffective							
	Dyspepsia		Maxzide	C				
			Premarin	C				

Date:06/27/02ISR Number: 3987584-2Report Type:Periodic Company Report #WAES 0201USA01206
Age:84 YR Gender:Male I/FU:F

Outcome	PT
	Abdominal Pain Upper
	Faeces Discoloured
	Gastrooesophageal Reflux Disease

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
Health Professional	Fosamax	C				
	Tums	C				
	Tylenol	C				
	Aspirin	C				
	Ibuprofen	C				
	Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3987585-4Report Type:Periodic Company Report #WAES 0201USA01286
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25	MG/DAILY/PO
	Oesophagitis							
			Arthotec	C				
			Celebrex	C				
			Dilantin	C				
			Duragesic	C				
			Fosamax	C				
			Kayexalate	C				
			Phoslo	C				
			Prilosec	C				
			Tylenol With Codeine	C				
			Viagra	C				
			Calcitrol	C				
			Doxazosin	C				
			Metoclopramide Hydrochloride	C				

Date:06/27/02ISR Number: 3987586-6Report Type:Periodic Company Report #WAES 0201USA01362
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flushing	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Rosacea						MG/DAILY/PO	
			Relafen	C				

Date:06/27/02ISR Number: 3987587-8Report Type:Periodic Company Report #WAES 0201USA01366
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Celebrex	C				
			Feldene	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987588-XReport Type:Periodic Company Report #WAES 0201USA01530
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Health Professional	Avandia	C				
			Glucophage	C				
			Humalog	C				
			Levoxyl	C				
			Nitroquick	C				
			Tricor	C				
			Glyburide	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3987589-1Report Type:Periodic Company Report #WAES 0201USA01942
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO	
			Aerobid	C				
			Fosamax	C				
			Serevent	C				

Date:06/27/02ISR Number: 3987590-8Report Type:Periodic Company Report #WAES 0205USA02066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987591-XReport Type:Periodic Company Report #WAES 0205USA02068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Injury Consumer Tab Vioxx PS ORAL
PO

Date:06/27/02ISR Number: 3987592-1Report Type:Periodic Company Report #WAES 0205USA02069
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Injury Consumer Tab Vioxx PS ORAL
PO

Date:06/27/02ISR Number: 3987593-3Report Type:Periodic Company Report #WAES 0205USA02070
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Injury Consumer Tab Vioxx PS ORAL
PO

Date:06/27/02ISR Number: 3987594-5Report Type:Periodic Company Report #WAES 0205USA02072
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Injury Consumer Tab Vioxx PS ORAL
PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987595-7Report Type:Periodic Company Report #WAES 0205USA02073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987596-9Report Type:Periodic Company Report #WAES 0205USA02074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987597-0Report Type:Periodic Company Report #WAES 0205USA02075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987598-2Report Type:Periodic Company Report #WAES 02050USA02076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987599-4Report Type:Periodic Company Report #WAES 0205USA02077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987600-8Report Type:Periodic Company Report #WAES 0205USA01890
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	12.5 MG/ PO; 25 MG/ PO	

Date:06/27/02ISR Number: 3987601-XReport Type:Periodic Company Report #WAES 0205USA01929
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987602-1Report Type:Periodic Company Report #WAES 0205USA01942
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ PRN/PO	
			Allegra	C				
			Nasonex	C				

Premarin	C
Synthroid	C
Hydrochlorothiazide (+) Triamter	C

Date:06/27/02ISR Number: 3987603-3Report Type:Periodic Company Report #WAES 0205USA01948
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Toprol Xl	C				
			Quinine Sulfate	C				

Date:06/27/02ISR Number: 3987604-5Report Type:Periodic Company Report #WAES 0205USA01956
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987605-7Report Type:Periodic Company Report #WAES 0205USA01964
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	6 MON
	Pulmonary Hypertension	Company Representative						

Date:06/27/02ISR Number: 3987606-9Report Type:Periodic Company Report #WAES 0205USA01977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987607-0Report Type:Periodic Company Report #WAES 0205USA01978
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987608-2Report Type:Periodic Company Report #WAES 0205USA01979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987609-4Report Type:Periodic Company Report #WAES 0205USA01980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987641-0Report Type:Periodic Company Report #WAES 0204USA00235
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25-50 MG/DAILY/PO	
	Diarrhoea							
			Glucophage Xr	C				
			Lescol	C				
			Indapamide	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3987648-3Report Type:Periodic Company Report #WAES 0204USA00236
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Pain In Extremity		Hydrodiuril	C				
			Pravachol	C				
			Prevacid	C				
			Calcium Carbonate	C				
			Doxazosin	C				

Date:06/27/02ISR Number: 3987657-4Report Type:Periodic Company Report #WAES 0204USA00238
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
	Fatigue	Health						
	Rash	Professional	Celebrex	C				
	Somnolence		Syn-Rx Tablets	C				
	Swelling							

Date:06/27/02ISR Number: 3987661-6Report Type:Periodic Company Report #WAES 0204USA00247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Avandia	C				
			Glucophage	C				
			Glucotrol	C				
			Lanoxin	C				
			Lipitor	C				
			Aspirin	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3987672-0Report Type:Periodic Company Report #WAES 0204USA00251
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Buttock Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
	Hypoaesthesia		Fiorinal	C				
			Tenormin	C				
			Tranxene	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987680-XReport Type:Periodic Company Report #WAES 0204USA00268
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3987681-1Report Type:Periodic Company Report #WAES 0204USA00272
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987682-3Report Type:Periodic Company Report #WAES 0204USA00276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alanine Aminotransferase Increased	Health Professional	Tab Vioxx	PS		ORAL	50 MG/DAILY/ PO	
	Aspartate Aminotransferase Increased	Company Representative						

Date:06/27/02ISR Number: 3987683-5Report Type:Periodic Company Report #WAES 0204USA00290
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987684-7Report Type:Periodic Company Report #WAES 0204USA00306
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Celebrex	C				
			Evista	C				
			Clonidine	C				
			Dicyclomine Hydrochloride	C				

Date:06/27/02ISR Number: 3987685-9Report Type:Periodic Company Report #WAES 0203USA02025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987686-0Report Type:Periodic Company Report #WAES 0203USA02026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	ORAL	

Date:06/27/02ISR Number: 3987687-2Report Type:Periodic Company Report #WAES 0203USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987688-4Report Type:Periodic Company Report #WAES 0203USA02029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987689-6Report Type:Periodic Company Report #WAES 0203USA02032
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Fatigue							
	Headache							
	Muscular Weakness							

Date:06/27/02ISR Number: 3987690-2Report Type:Periodic Company Report #WAES 0203USA02036
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Diastolic Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987691-4Report Type:Periodic Company Report #WAES 0203USA02038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987692-6Report Type:Periodic Company Report #WAES 0203USA02050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 12.5 Mg; 25 Mg	PS		ORAL	POSEIMAGE	

Date:06/27/02ISR Number: 3987693-8Report Type:Periodic Company Report #WAES 0203USA02060
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/QID/PO	
	Tachycardia		Azulfindine	C				
			Enbrel	C				

Klonopin	C
Neurontin	C
Plaquenil	C
Ultram	C
Zithromax	C
Folic Acid	C
Methotrexate	C

Date:06/27/02ISR Number: 3987694-XReport Type:Periodic Company Report #WAES 0203USA02066
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Frequent Bowel Movements	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Weight Decreased							
			Composition Unspecified	C				
			Calcium (Unspecified)	C				

Date:06/27/02ISR Number: 3987695-1Report Type:Periodic Company Report #WAES 0203USA00205
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987696-3Report Type:Periodic Company Report #WAES 0203USA00206
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/SEE IMAGE	
			Vicodin Tablets	C				

Date:06/27/02ISR Number: 3987697-5Report Type:Periodic Company Report #WAES 0203USA00207
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987698-7Report Type:Periodic Company Report #WAES 0203USA00208
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Ery-Tab	C				
			Famvir	C				
			Flexeril	C				
			Ultram	C				
			Fluoxetine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987699-9Report Type:Periodic Company Report #WAES 0203USA00211
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	
	Pruritus							
			Ambien	C				
			Armour Thyroid Tablets	C				
			Cipro	C				
			Darvocet-N	C				
			Hyzaar	C				
			Plavix	C				
			Prilosec	C				
			Uniphyl	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3987700-2Report Type:Periodic Company Report #WAES 0203USA00229
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Tab Vioxx	PS		ORAL	PO	
	Depression	Professional						
	General Symptom	Company Representative						

Date:06/27/02ISR Number: 3987701-4Report Type:Periodic Company Report #WAES 0203USA00233
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Memory Impairment	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3987702-6Report Type:Periodic Company Report #WAES 0203USA00236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987703-8Report Type:Periodic Company Report #WAES 0203USA00237
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash Papular							
			Androgel	SS			5 GM/DAILY	

Date:06/27/02ISR Number: 3987704-XReport Type:Periodic Company Report #WAES 0203USA00243
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Flushing							
			Metoprolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987705-1Report Type:Periodic Company Report #WAES 0203USA00245
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Flatulence	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Nasonex	C				
			Nizoral 2% Shampoo	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3987706-3Report Type:Periodic Company Report #WAES 0203USA00246
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemoglobin Abnormal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/PO	
	Oedema Peripheral							
			Protonix	C				
			Zantac	C				

Date:06/27/02ISR Number: 3987707-5Report Type:Periodic Company Report #WAES 0203USA00248
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rectal Haemorrhage							

Date:06/27/02ISR Number: 3987708-7Report Type:Periodic Company Report #WAES 0203USA00253
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Aciphex	C		
			Actonel	C		
			Claritin	C		
			Levoxyl	C		
			Nolvadex	C		
			Prinivil	C		
			Serevent	C		
			Singulair	C		
			Zocor	C		

Date:06/27/02ISR Number: 3987710-5Report Type:Periodic Company Report #WAES 0203USA00259
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Gastrooesophageal Reflux					
MG/DAILY/PO						
	Disease		Detrol La	C		
			Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987711-7Report Type:Periodic Company Report #WAES 0203USA00274
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Pruritic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
			Calan	C				
			Catapres	C				
			Prempro	C				
			Zocor	C				

Date:06/27/02ISR Number: 3987712-9Report Type:Periodic Company Report #WAES 0203USA00278
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Headache		Premarin	C				
	Musculoskeletal Stiffness							

Date:06/27/02ISR Number: 3987713-0Report Type:Periodic Company Report #WAES 0203USA00284
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral		Indocin (Indomethacin)	C				

Date:06/27/02ISR Number: 3987714-2Report Type:Periodic Company Report #WAES 0203USA00291
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	1 WK
	Headache		Ultram	C				

Date:06/27/02ISR Number: 3987715-4Report Type:Periodic Company Report #WAES 0203USA03159
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urine Present	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Norvasc	C				
			Serevent	C				

Date:06/27/02ISR Number: 3987716-6Report Type:Periodic Company Report #WAES 0203USA03165
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional	Avapro	C				
			Celebrex	C				

Date:06/27/02ISR Number: 3987717-8Report Type:Periodic Company Report #WAES 0203USA03170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987718-XReport Type:Periodic Company Report #WAES 0203USA03174
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapy Non-Responder	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987719-1Report Type:Periodic Company Report #WAES 0203USA03194
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Prevacid	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3987720-8Report Type:Periodic Company Report #WAES 0203USA03195
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Faeces Discoloured							
	Haemoglobin Decreased							
	Occult Blood Positive							

Date:06/27/02ISR Number: 3987721-XReport Type:Periodic Company Report #WAES 0203USA03211
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Company
Representative

Date:06/27/02ISR Number: 3987722-1Report Type:Periodic Company Report #WAES 0203USA03219
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE, PO	
	Haemorrhage	Professional Company Representative						

Date:06/27/02ISR Number: 3987723-3Report Type:Periodic Company Report #WAES 0203USA03220
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health	Tab Vioxx 12.5mg	PS		ORAL	SEE IMAGE	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987724-5Report Type:Periodic Company Report #WAES 0203USA03221
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3987725-7Report Type:Periodic Company Report #WAES 0202USA02931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987726-9Report Type:Periodic Company Report #WAES 0202USA02933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Fluid Retention	Company Representative						
	Gastric Disorder							
	Oedema Peripheral							
	Weight Increased							

Date:06/27/02ISR Number: 3987727-0Report Type:Periodic Company Report #WAES 0202USA02935
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Oedema Peripheral	Company Representative						
	Weight Increased							

Date:06/27/02ISR Number: 3987728-2Report Type:Periodic Company Report #WAES 0203USA00012
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3987729-4Report Type:Periodic Company Report #WAES 0203USA00013
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Ibuprofen	C				

Date:06/27/02ISR Number: 3987730-0Report Type:Periodic Company Report #WAES 0203USA00014
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation	Health Professional	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987731-2Report Type:Periodic Company Report #WAES 0203USA00023
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
			Arava	C				

Date:06/27/02ISR Number: 3987732-4Report Type:Periodic Company Report #WAES 0203USA00030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3987733-6Report Type:Periodic Company Report #WAES 0203USA00047
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Asthenia							
	Joint Swelling							
	Muscular Weakness							
	Pharyngolaryngeal Pain							

Date:06/27/02ISR Number: 3987734-8Report Type:Periodic Company Report #WAES 0203USA00051
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomatitis	Health Professional Company	Tab Vioxx Unk Therapy Unspecified	PS C		ORAL	PO	

Representative

Date:06/27/02ISR Number: 3987735-XReport Type:Periodic Company Report #WAES 0203USA03055
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Dyspepsia						PO	
	Somnolence		Ambien	C				
			Claritin	C				
			Combivent	C				
			Skelaxin	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3987736-1Report Type:Periodic Company Report #WAES 0203USA03059
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Vertigo	Health					PO	
		Professional	Tricor	C				
			Vasotec	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987737-3Report Type:Periodic Company Report #WAES 0203USA03061
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Fosamax	C				
			Nexium	C				
			Ultram	C				
			Amitriptyline	C				
			Aspirin	C				
			Atenolol	C				
			Iron (Unspecified)	C				
			Lactulose	C				
			Quinine Sulfate	C				

Date:06/27/02ISR Number: 3987738-5Report Type:Periodic Company Report #WAES 0203USA03126
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Consumer	Tab Vioxx	PS		ORAL	PO	6 MON

Date:06/27/02ISR Number: 3987739-7Report Type:Periodic Company Report #WAES 0203USA03127
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Back Pain	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG BID	
	Headache	Professional					PO	3 WK
	Neck Pain							

Date:06/27/02ISR Number: 3987740-3Report Type:Periodic Company Report #WAES 0203USA03129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
							PO	
			Accupril	C				
			Amaryl	C				

Date:06/27/02ISR Number: 3987741-5Report Type:Periodic Company Report #WAES 0203USA03135
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	1 MON

Date:06/27/02ISR Number: 3987742-7Report Type:Periodic Company Report #WAES 0203USA03143
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG PRN PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987743-9Report Type:Periodic Company Report #WAES 0203USA03149
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	PO
			Synthroid	C				
			Estradiol	C				

Date:06/27/02ISR Number: 3987744-0Report Type:Periodic Company Report #WAES 0203USA03158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987745-2Report Type:Periodic Company Report #WAES 0202USA02832
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG BID PO	
			Tab Vioxx 25mg	SS		ORAL	25MG DAILY PO	
			Celexa	C				
			Prevacid	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3987746-4Report Type:Periodic Company Report #WAES 0202USA 02837
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Pruritus	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG /UNK/ PO						
	Rash Erythematous		Lipitor	C		

Date:06/27/02ISR Number: 3987747-6Report Type:Periodic Company Report #WAES 0202USA02843
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention	Health	Tab Vioxx 25mg	PS		ORAL
25MG DAILY PO						
	Swelling	Professional	Tab Vioxx 25mg	SS		ORAL
12.5MG DAILY						
PO						

Date:06/27/02ISR Number: 3987748-8Report Type:Periodic Company Report #WAES 0202USA02849
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

Date:06/27/02ISR Number: 3987749-XReport Type:Periodic Company Report #WAES 0202USA02886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Discomfort	Consumer	Tab Vioxx 25mg	PS		ORAL
25MG BID PO						
	Stomach Discomfort					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987750-6Report Type:Periodic Company Report #WAES 0202USA02910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987751-8Report Type:Periodic Company Report #WAES 0202USA02912
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987752-XReport Type:Periodic Company Report #WAES 0202USA02926
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG DAILY PO	
	Headache		Elavil	C				
	Nausea		Miacalcin	C				
	Somnolence		Prempro	C				
	Weight Increased		Prilosec	C				
			Ultram	C				
			Diazepam	C				
			Prednisone	C				

Date:06/27/02ISR Number: 3987753-1Report Type:Periodic Company Report #WAES 0202USA02927
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG PRN PO	
	Heart Rate Irregular		Betoptic	C				
			Norvasc	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3987754-3Report Type:Periodic Company Report #WAES 0202USA02930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Company	Tab Vioxx	PS		ORAL	PO	
	Alopecia	Representative						

Date:06/27/02ISR Number: 3987755-5Report Type:Periodic Company Report #WAES 0203USA01990
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987756-7Report Type:Periodic Company Report #WAES 0203USA01992
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Pruritus	Professional	Aciphex	C				
			Ambien	C				
			Celebrex	C				
			Neurontin	C				
			Prilosec	C				
			Zocor	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3987757-9Report Type:Periodic Company Report #WAES 0203USA01996
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
	Drug Intolerance	Professional						

Date:06/27/02ISR Number: 3987758-0Report Type:Periodic Company Report #WAES 0203USA02016
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Dry Mouth	Health					PO	
	Hyperhidrosis	Professional	Allegra	C				
	Nausea		Botox	C				
	Nervousness		Climara	C				
	Tremor		Darvocet-N	C				
			Lipitor	C				
			Wellbutrin Sr	C				

Date:06/27/02ISR Number: 3987759-2Report Type:Periodic Company Report #WAES 0203USA02018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	
		Other						

Date:06/27/02ISR Number: 3987760-9Report Type:Periodic Company Report #WAES 0203USA02020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS				

Date:06/27/02ISR Number: 3987761-0Report Type:Periodic Company Report #WAES 0203USA02021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987762-2Report Type:Periodic Company Report #WAES 0203USA02022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987763-4Report Type:Periodic Company Report #WAES 0203USA02023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987764-6Report Type:Periodic Company Report #WAES 0203USA02024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987765-8Report Type:Periodic Company Report #WAES 0202USA02510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral Weight Increased	Consumer	Tab Vioxx 12.5 Mg; 25mg; 50 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987766-XReport Type:Periodic Company Report #WAES 0202USA02532
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO
			Clonazepam	C		
			Vitamins (Unspecified)	C		

Date:06/27/02ISR Number: 3987767-1Report Type:Periodic Company Report #WAES 0202USA02533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Constipation	Consumer	Tab Vioxx 25 Mg	PS		ORAL PO
	Diarrhoea		Vicodin Tablets	C		
	Dyspepsia		Zestril	C		
			Zocor	C		

Date:06/27/02ISR Number: 3987768-3Report Type:Periodic Company Report #WAES 0202USA02543
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
	Hyperglycaemia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3987769-5Report Type:Periodic Company Report #WAES 0202USA02549
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987770-1Report Type:Periodic Company Report #WAES 0202USA02553
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gingival Pain							
	Glossodynia							

Date:06/27/02ISR Number: 3987771-3Report Type:Periodic Company Report #WAES 0202USA02561
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hytrin	C				

Date:06/27/02ISR Number: 3987772-5Report Type:Periodic Company Report #WAES 0202USA02569
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3987773-7Report Type:Periodic Company Report #WAES 0202USA02577
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Zestril	C				

Date:06/27/02ISR Number: 3987774-9Report Type:Periodic Company Report #WAES 0202USA02578
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Eye Swelling							
	Face Oedema		Betapace	C				
	Oedema Peripheral		Cozaar	C				
	Vision Blurred		Klor-Con	C				
			Lipitor	C				
			Hydrochlorothiazide (+) Triamter	C				
			Lorazepam	C				

Date:06/27/02ISR Number: 3988353-XReport Type:Periodic Company Report #WAES 0203USA02972
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

				Asacol	C	

Date:06/27/02ISR Number: 3988356-5Report Type:Periodic Company Report #WAES 0203USA02982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988357-7Report Type:Periodic Company Report #WAES 0203USA02984
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urticaria	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
			Estrace	C				
			Prilosec	C				
			Prometrium	C				
			Zoloft	C				

Date:06/27/02ISR Number: 3988360-7Report Type:Periodic Company Report #WAES 0203USA02988
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tachycardia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988361-9Report Type:Periodic Company Report #WAES 0203USA02993
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25MG/DAILY/PO						
	Dizziness		Ambien	C		
	Dry Mouth		Prevacid	C		
	Hyperhidrosis		Ultram	C		

Date:06/27/02ISR Number: 3988364-4Report Type:Periodic Company Report #WAES 0203USA02995
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Eye Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Headache	Health				
MG/DAILY/PO						
		Professional	Atarax	C		
			Xanax	C		
			Zoloft	C		

Date:06/27/02ISR Number: 3988367-XReport Type:Periodic Company Report #WAES 0203USA03007
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Drug Intolerance	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
		Professional				
MG/DAILY/PO						
			Digitek	C		
			Monopril	C		

		Prilosec	C
		Atenolol	C
		Furosemide	C

Date:06/27/02ISR Number: 3988369-3Report Type:Periodic Company Report #WAES 0203USA03038
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988371-1Report Type:Periodic Company Report #WAES 0203USA03040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988374-7Report Type:Periodic Company Report #WAES 0203USA03048
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Balance Disorder	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Headache							
			Actonel	C				
			Cosopt	C				
			Miacalcin	C				
			Prinzide	C				

Date:06/27/02ISR Number: 3988382-6Report Type:Periodic Company Report #WAES 0203USA01268
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Zoloft	C				

Date:06/27/02ISR Number: 3988384-XReport Type:Periodic Company Report #WAES 0203USA01269
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988386-3Report Type:Periodic Company Report #WAES 0203USA01270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy Peripheral	Health	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
	Paraesthesia	Professional						
			Singulair	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988387-5Report Type:Periodic Company Report #WAES 0203USA01276
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intraocular Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	25 MG/PRN/PO	

Date:06/27/02ISR Number: 3988388-7Report Type:Periodic Company Report #WAES 0203USA01293
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx	PS		ORAL	50 MG/DAILY/PO	
			Lipitor	C				
			Pindolol	C				

Date:06/27/02ISR Number: 3988389-9Report Type:Periodic Company Report #WAES 0203USA01294
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	25 MG/BID/PO	
			Paxil	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3988390-5Report Type:Periodic Company Report #WAES 0203USA1297
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	25	

MG/DAILY/PO

			Claritin	C		
			Fosamax	C		
			Zocor	C		
			Propranolol	C		

Date:06/27/02ISR Number: 3988391-7Report Type:Periodic Company Report #WAES 0203USA01300
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Akathisia	Consumer	Tab Vioxx	PS		ORAL	25	
	Insomnia							
MG/DAILY/PO								
			Mag-Ox 400 Tablets	C				
			Tiazac	C				
			Tricor	C				
			Clonazepam	C				
			Cyclobenzaprine Hydrochloride	C				

Date:06/27/02ISR Number: 3988392-9Report Type:Periodic Company Report #WAES 0203USA01307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx	PS		ORAL	PO	
	Dyspepsia		Allegra	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988395-4Report Type:Periodic Company Report #WAES0203USA01308
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PRN/PO	
		Professional	Anaprox	C				
			Claritin	C				
			Nasarel	C				
			Pravachol	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3988396-6Report Type:Periodic Company Report #WAES 0203USA02146
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Celexa	C				
			Depakote	C				
			Humulin N	C				
			Premarin	C				
			Prilosec	C				
			Zoloft	C				
			Clorazepate Dipotassium	C				
			Trazodone	C				

Date:06/27/02ISR Number: 3988397-8Report Type:Periodic Company Report #WAES 0203USA02162
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Malaise	Consumer	Tab Vioxx	PS		ORAL	PO	
	Muscular Weakness							

Date:06/27/02ISR Number: 3988398-XReport Type:Periodic Company Report #WAES 0203USA02181
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO	
	Dyspepsia		Fosamax	C				
			Premarin	C				

Date:06/27/02ISR Number: 3988399-1Report Type:Periodic Company Report #WAES 0203USA02185
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Disorder	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Paraesthesia							
			Prinzide	C				

Date:06/27/02ISR Number: 3988400-5Report Type:Periodic Company Report #WAES 0203USA02186
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Haematuria	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	PO	6 MON

Date:06/27/02ISR Number: 3988401-7Report Type:Periodic Company Report #WAES 0203USA02188
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Anorexia	Health Professional	[Therapy Unspecified]	C				
	Faeces Discoloured		Clindamycin	C				
	Headache							
	Nausea							

Date:06/27/02ISR Number: 3988402-9Report Type:Periodic Company Report #WAES 0203USA02190
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Diarrhoea							
	Headache		Ativan	C				
	Tinnitus		Doxepin	C				

Date:06/27/02ISR Number: 3988403-0Report Type:Periodic Company Report #WAES 0203USA02194
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO;	
	Frequent Bowel Movements							

25

MG/DAILY/PO 10 DAY

Date:06/27/02ISR Number: 3988404-2Report Type:Periodic Company Report #WAES 0203USA02202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	25 MG/1X/PO	
	Weight Increased	Professional						

Date:06/27/02ISR Number: 3988405-4Report Type:Periodic Company Report #WAES 0203USA02209
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx	PS		ORAL	12.5 MG/QID/PO	
	Tachycardia	Professional						

Date:06/27/02ISR Number: 3988407-8Report Type:Periodic Company Report #WAES 0203USA01189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
			Lipirtor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988408-XReport Type:Periodic Company Report #WAES 0203USA01194
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG, BID, PO	

Date:06/27/02ISR Number: 3988409-1Report Type:Periodic Company Report #WAES 0203USA01202
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY, PO	
			Advair	C				
			Buspar	C				
			Hydroriuril	C				
			Prozac	C				
			Albuterol	C				

Date:06/27/02ISR Number: 3988410-8Report Type:Periodic Company Report #WAES 0203USA01206
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PRN, PO	
	Rectal Tenesmus		Vasotec	C				
			Zocor	C				
			Megestrol Acetate	C				

Date:06/27/02ISR Number: 3988411-XReport Type:Periodic Company Report #WAES 0203USA01226
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	

Date:06/27/02ISR Number: 3988412-1Report Type:Periodic Company Report #WAES 0203USA01229
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Fosamax	C				

Date:06/27/02ISR Number: 3988413-3Report Type:Periodic Company Report #WAES 0203USA01232
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Tenderness	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, DAILY, PO	
	Dyspepsia							
	Erythema		Tab Vioxx 25 Mg	SS		ORAL	25 MG, DAILY, PO	
	Face Oedema							
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988415-7Report Type:Periodic Company Report #WAES 0203USA01248
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx	PS		ORAL	PO	
			Capoten	C				
			Celebrex	C				
			Estrogens (Unspecified)	C				
			Fish Oil (Unspecified)	C				
			Ibuprofen	C				
			Shark Cartilage, Dedorized Fe	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3988417-0Report Type:Periodic Company Report #WAES 0203USA01252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx	PS		ORAL	PO	10 DAY
	Urticaria		Fosamax [Composition Unspecified]	C				

Date:06/27/02ISR Number: 3988419-4Report Type:Periodic Company Report #WAES 0203USA01254
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Tendency To	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG, PRN, PO	
	Bruise	Professional						
		Company Representative						

Date:06/27/02ISR Number: 3988421-2Report Type:Periodic Company Report #WAES 0204USA00430
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral		Nystatin	C				

Date:06/27/02ISR Number: 3988424-8Report Type:Periodic Company Report #WAES 0204USA00433
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988425-XReport Type:Periodic Company Report #WAES 0204USA00436
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Pruritus							
			Carmol 40	C				

				Ocuvite	C		
				Acetaminophen (+) Propoxyphene	C		
				Alprazolam	C		
				Glyburide	C		

Date:06/27/02ISR Number: 3988427-3Report Type:Periodic Company Report #WAES 0204USA00464
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Abnormal	Professional						
	Oedema							
	Renal Disorder							
	Weight Increased							

Date:06/27/02ISR Number: 3988430-3Report Type:Periodic Company Report #WAES 0204USA00471
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:06/27/02ISR Number: 3988436-4Report Type:Periodic Company Report #WAES 0204USA00482
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
		Professional						
			Fosamax	C				
			Lipitor	C				

				Nexium	C		
				Singulair	C		
				Lorazepam	C		

Date:06/27/02ISR Number: 3988438-8Report Type:Periodic Company Report #WAES 0204USA00499
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx	PS			UNKNOWN	25
	Nausea						MG/DAILY/UNK	
			Fosamax	C				
			Oxybutynin Chloride	C				

Date:06/27/02ISR Number: 3988439-XReport Type:Periodic Company Report #WAES 0204USA00504
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
			Actos	C				
			Demadex	C				
			Ecotrin	C				
			Hydrodiuril	C				

Ascorbic Acid	C
Glyburide	C
Vitamin E	C
Vitamins (Unspecified)	C

Date:06/27/02ISR Number: 3988441-8Report Type:Periodic Company Report #WAES 0204USA00507
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY PO	
	Vaginal Haemorrhage		Coumadin	C				
			Acetaminophen	C				

Date:06/27/02ISR Number: 3988442-XReport Type:Periodic Company Report #WAES 0204USA00514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erectile Dysfunction		Tab Vioxx Unk	PS		ORAL	DAILY/PO	

Date:06/27/02ISR Number: 3988444-3Report Type:Periodic Company Report #WAES 0204USA00515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 WK
		Company Representative						

Date:06/27/02ISR Number: 3988445-5Report Type:Periodic Company Report #WAES 0204USA00519
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased	Other	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988447-9Report Type:Periodic Company Report #WAES 0204USA00647
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx	PS		ORAL	PO	4 MON
	Swelling							

Date:06/27/02ISR Number: 3988448-0Report Type:Periodic Company Report #WAES 0204USA00655
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Cardizem	C				
			Inderal	C				
			Maxzide	C				
			Tylenol	C				
			Potassium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988451-0Report Type:Periodic Company Report #WAES 0204USA00656
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Creatinine Renal Clearance Increased	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988453-4Report Type:Periodic Company Report #WAES 0204USA00660
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988454-6Report Type:Periodic Company Report #WAES 0204USA00662
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988455-8Report Type:Periodic Company Report #WAES 0204USA00665
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50	

MG/DAILY/PO

			Estrogens (Unspecified)	C		

Date:06/27/02ISR Number: 3988456-XReport Type:Periodic Company Report #WAES 0204USA00671
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Loss Of Consciousness	Consumer	Tab Vioxx Unk	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3988458-3Report Type:Periodic Company Report #WAES 0204USA00675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Depakote	C				
			Effexor	C				
			Norvasc	C				
			Premarin	C				
			Toprol Xl Tablets	C				
			Xanax	C				
			Zyrtec	C				
			Progesterone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988459-5Report Type:Periodic Company Report #WAES 0204USA00682
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988460-1Report Type:Periodic Company Report #WAES 0204USA00683
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg; 50 Mg	PS		ORAL	25 MG/DAILY/PO; 50 MG/DAILY/PO	4 DAY

Date:06/27/02ISR Number: 3988461-3Report Type:Periodic Company Report #WAES 0204USA00685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988463-7Report Type:Periodic Company Report #WAES 0204USA00686
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clonic Convulsion	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	7 DAY
	Fall	Professional	Altace	C				

	Speech Disorder		Glucophage	C		
			Lipitor	C		
			Lopressor	C		
			Aspirin	C		

Date:06/27/02ISR Number: 3988464-9Report Type:Periodic Company Report #WAES 0204USA00689
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3988474-1Report Type:Periodic Company Report #WAES 0204USA00692
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Contusion	Professional					MG/DAILY/PO	
			Advil	C				
			Prempro	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988475-3Report Type:Periodic Company Report #WAES 0204USA00699
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Potassium Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional	Lipitor	C				
			Synthroid	C				
			Methotrexate	C				

Date:06/27/02ISR Number: 3988477-7Report Type:Periodic Company Report #WAES 0204USA00703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg;					
	Heart Rate Increased		25 Mg	PS		ORAL	PO; PO	
			Prempro	C				

Date:06/27/02ISR Number: 3988478-9Report Type:Periodic Company Report #WAES 0204USA00009
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Dysphonia							

Date:06/27/02ISR Number: 3988480-7Report Type:Periodic Company Report #WAES 0204USA00011
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
			Avandia	C				
			Evista	C				
			Glucophage	C				
			Lipitor	C				

				Aspirin	C		

Date:06/27/02ISR Number: 3988481-9Report Type:Periodic Company Report #WAES 0204USA00019
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Weight Increased		Accupril	C				
			Coreg	C				
			Coumadin	C				
			Glucophage	C				
			Humulin	C				
			Lasix (Furosemide)	C				
			Lanoxin	C				
			Zocor	C				
			Zyloprim	C				
			Nitroglycerin	C				

Date:06/27/02ISR Number: 3988482-0Report Type:Periodic Company Report #WAES 0204USA00022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988483-2Report Type:Periodic Company Report #WAES 0204USA00024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988485-6Report Type:Periodic Company Report #WAES 0204USA00033
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988486-8Report Type:Periodic Company Report #WAES 0204USA00046
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
	Headache							

Date:06/27/02ISR Number: 3988488-1Report Type:Periodic Company Report #WAES 0204USA00064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:06/27/02ISR Number: 3988489-3Report Type:Periodic Company Report #WAES 0204USA00065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Contusion	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988490-XReport Type:Periodic Company Report #WAES 0204USA00067
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988491-1Report Type:Periodic Company Report #WAES 0204USA02605
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988492-3Report Type:Periodic Company Report #WAES 0204USA02611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988493-5Report Type:Periodic Company Report #WAES 0204USA02614
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	1 WK
		Company Representative						

Date:06/27/02ISR Number: 3988494-7Report Type:Periodic Company Report #WAES 0204USA02616
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Squamous Cell Carcinoma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Darvocet	C				
			Valium	C				

Date:06/27/02ISR Number: 3988495-9Report Type:Periodic Company Report #WAES 0204US02620
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	

Congestive Professional Company Representative

Date:06/27/02ISR Number: 3988496-0Report Type:Periodic Company Report #WAES 0204USA02624
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive	Professional Company Representative						

Date:06/27/02ISR Number: 3988497-2Report Type:Periodic Company Report #WAES 0204USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988498-4Report Type:Periodic Company Report #WAES 0204USA02633
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional	Amaryl	C				
			Armour Thyroid Tablets	C				
			Detrol La	C				
			Glucophage Xr	C				
			Hydra-Zide	C				
			Zocor	C				

Date:06/27/02ISR Number: 3988499-6Report Type:Periodic Company Report #WAES 0204USA02637
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Joint Swelling		Femhrt	C				
	Oedema Peripheral		Prinivil	C				
			Rantidine-Bc	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3988500-XReport Type:Periodic Company Report #WAES 0204USA02646
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Syncope							
			Fosamax	C				
			Lipitor	C				
			Travatan	C				

Date:06/27/02ISR Number: 3988501-1Report Type:Periodic Company Report #WAES 0203USA01756
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Health	Tab Vioxx	PS		ORAL	PO	
	Hypoaesthesia	Professional						
	Paraesthesia							

Date:06/27/02ISR Number: 3988503-5Report Type:Periodic Company Report #WAES 0203USA01759
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG; DAILY;	
		Professional					PO	

Date:06/27/02ISR Number: 3988511-4Report Type:Periodic Company Report #WAES 0203USA01761
Age: Gender:Male I/FU:I

Outcome	PT
	Chest Discomfort
	Drug Effect Decreased
	Infection

	Palpitations						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988516-3Report Type:Periodic Company Report #WAES 0203USA01768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
	Urticaria		Cardizem	C				
			Nitro-Dur	C				
			Vicodin Tablets	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3988521-7Report Type:Periodic Company Report #WAES 0203USA01771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Paraesthesia		Claritin	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3988526-6Report Type:Periodic Company Report #WAES 0203USA01777
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
	Haemorrhage	Professional	Aspirin	C				
		Company Representative	Nonsteroidal Anti-Inflammatory	C				

Date:06/27/02ISR Number: 3988533-3Report Type:Periodic Company Report #WAES 0203USA01778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS			25 MG	
	Dry Mouth		Accolate	C				
	Paraesthesia		Advair	C				
			Evista	C				
			Maxair	C				

Date:06/27/02ISR Number: 3988542-4Report Type:Periodic Company Report #WAES 0203USA01782
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bladder Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG; DAILY;	
	Pollakiuria						PO	
			Fosamax	C				
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988545-XReport Type:Periodic Company Report #WAES 0203USA01783
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematochezia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG; DAILY;	
PO								

Date:06/27/02ISR Number: 3988547-3Report Type:Periodic Company Report #WAES 0203USA01785
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Breast Malformation	Consumer	Tab Vioxx	PS		ORAL		
PO								
	Joint Swelling							

Date:06/27/02ISR Number: 3988553-9Report Type:Periodic Company Report #WAES 0203USA00053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25 DAILY PO	

Date:06/27/02ISR Number: 3988554-0Report Type:Periodic Company Report #WAES 0203USA00066
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux	Health	Tab Vioxx	PS		ORAL		
PO								
	Disease	Professional						

Date:06/27/02ISR Number: 3988555-2Report Type:Periodic Company Report #WAES 0203USA00068
Age:80 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Tolerance Decreased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Celebrex	C				
			Zocor	C				

Date:06/27/02ISR Number: 3988556-4Report Type:Periodic Company Report #WAES 0203USA00075
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrooesophageal Reflux Disease	Other	Tab Vioxx	PS		ORAL	25 MG DAILY PO	
			Allegra	C				

Date:06/27/02ISR Number: 3988558-8Report Type:Periodic Company Report #WAES 0203USA00078
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988559-XReport Type:Periodic Company Report #WAES 0203USA00079
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Elavil	C				
			Hydrodiuril	C				
			Plavix	C				
			Premarin	C				
			Prozac	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3988560-6Report Type:Periodic Company Report #WAES 0203USA00082
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Hypersensitivity	Other	Tab Vioxx	PS		ORAL	12.5 MG DAILY	
			Allegra-D	C			PO	
			Premarin	C				
			Synthroid	C				
			Zoloft	C				
			Carisoprodol	C				

Date:06/27/02ISR Number: 3988562-XReport Type:Periodic Company Report #WAES 0203USA00085
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Food Interaction	Consumer	Tab Vioxx	PS		ORAL	PRN PO	
	Tongue Discolouration		[Composition Unspecified]	SS				

Date:06/27/02ISR Number: 3988565-5Report Type:Periodic Company Report #WAES 0203USA00089
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Other	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988567-9Report Type:Periodic Company Report #WAES 0203USA00121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Finger Deformity	Consumer	Tab Vioxx	PS		ORAL	PO	3 DAY
	Pruritus							

Date:06/27/02ISR Number: 3988568-0Report Type:Periodic Company Report #WAES 0203USA03224
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus Generalised	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Rash	Health Professional	Hydrodiuril	C				
			Norvasc	C				
			Premarin	C				
			Zocor	C				
			Medroxyprogesterone Acetate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988569-2Report Type:Periodic Company Report #WAES 0203USA03235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3988570-9Report Type:Periodic Company Report #WAES 0203USA03241
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema Peripheral						MG/DAILY/PO	
			Prilosec	C				
			Zyrtec	C				
			Phenobarbital	C				

Date:06/27/02ISR Number: 3988572-2Report Type:Periodic Company Report #WAES 0203USA03246
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Therapeutic Response						MG/DAILY/PO	
	Decreased		Actonel	C				
			Advair	C				
			Norvasc	C				
			Pravachol	C				
			Premarin	C				
			Prilosec	C				
			Atenolol	C				
			Lorazepam	C				
			Medroxyprogesterone Acetate	C				

Date:06/27/02ISR Number: 3988573-4Report Type:Periodic Company Report #WAES 0203USA03255
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Hallucination		Diovan	C				
			Fibercon	C				
			Prempro	C				
			Zanaflex	C				

Date:06/27/02ISR Number: 3988575-8Report Type:Periodic Company Report #WAES 0203USA03262
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3988576-XReport Type:Periodic Company Report #WAES 0203USA03269
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3988577-1Report Type:Periodic Company Report #WAES 0203USA03272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3988579-5Report Type:Periodic Company Report #WAES 0203USA03273
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Musculoskeletal Stiffness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Neck Pain	Health Professional						
	Photophobia		Claritin	C				
			Elocon	C				
			Hydrodiuril	C				
			Nasonex	C				
			Premarin	C				
			Prevacid	C				
			Synthroid	C				
			Aspirin	C				
			Metoprolol	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3988581-3Report Type:Periodic Company Report #WAES 0203USA03277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Paraesthesia							
	Visual Disturbance		Percocet	C				

Date:06/27/02ISR Number: 3988583-7Report Type:Periodic Company Report #WAES 0203USA00311
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health Professional Company Representative	Tab Vioxx	PS		ORAL	SEE IMAGE	
			Celebrex	C				

Date:06/27/02ISR Number: 3988584-9Report Type:Periodic Company Report #WAES 0203USA01878
Age:53 YR Gender: I/FU:I

Outcome	PT	Report Source
	Abdominal Pain Upper	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx	PS		ORAL	SEE IMAGE	

Date:06/27/02ISR Number: 3988586-2Report Type:Periodic Company Report #WAES 0203USA02450
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Aspirin	C				

Date:06/27/02ISR Number: 3988587-4Report Type:Periodic Company Report #WAES 0203USA03027
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Health	Tab Vioxx	PS		ORAL	PO	
	Dyspnoea Nasal Congestion Periorbital Oedema Swelling	Professional Company Representative	Inj Allergenic Extract	SS				

Date:06/27/02ISR Number: 3989358-5Report Type:Periodic Company Report #WAES 0202USA00489
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
	Joint Swelling	Health					PO	
	Nausea	Professional	Cyclobenzaprine Hydrochloride	C				

Date:06/27/02ISR Number: 3989359-7Report Type:Periodic Company Report #WAES 0202USA00504
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG DAILY	
PO								
			Zyrtec	C				

Date:06/27/02ISR Number: 3989360-3Report Type:Periodic Company Report #WAES 0202USA00597
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Health	Tab Vioxx	PS		ORAL	25 MG DAILY	
	Rash Macular	Professional						
PO								
		Company Representative	Premarin	C				
			Calcium (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989361-5Report Type:Periodic Company Report #WAES 0202USA00608
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health	Tab Vioxx	PS		ORAL	25 MG DAILY	
	Pulmonary Oedema	Professional					PO	
			Cardizem Cd	C				
			Coumadin	C				
			Humalog	C				
			Imdur	C				
			Lasix (Furosemide)	C				
			Nitro-Spray	C				
			Proventil	C				
			Starlix	C				

Date:06/27/02ISR Number: 3989362-7Report Type:Periodic Company Report #WAES 0202USA00619
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
		Health Professional	Viagra	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3989363-9Report Type:Periodic Company Report #WAES 0202USA00627
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx	PS		ORAL	PO	
			Lipitor	C				
			Procardia	C				

Date:06/27/02ISR Number: 3989364-0Report Type:Periodic Company Report #WAES 0202USA00660
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	12.5 MG DAILY	
	Muscular Weakness	Other					PO	
			Plaquenil	C				
			Salagen Tablets	C				

Date:06/27/02ISR Number: 3989365-2Report Type:Periodic Company Report #WAES 0202USA00666
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematuria	Consumer	Tab Vioxx	PS		ORAL	25 MG PO	
			Maxzide	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:06/27/02ISR Number: 3989366-4Report Type:Periodic Company Report #WAES 0202USA00678
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Health	Tab Vioxx	PS		ORAL	25 MG DAILY	
	Vision Blurred	Professional					PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989367-6Report Type:Periodic Company Report #WAES 0202USA00686
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989368-8Report Type:Periodic Company Report #WAES 0205USA02116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989369-XReport Type:Periodic Company Report #WAES 0205USA02117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989370-6Report Type:Periodic Company Report #WAES 0205USA02119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989371-8Report Type:Periodic Company Report #WAES 0205USA02120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3989372-XReport Type:Periodic Company Report #WAES 0205USA02121
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3989373-1Report Type:Periodic Company Report #WAES 0205USA02122
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:06/27/02ISR Number: 3989374-3Report Type:Periodic Company Report #WAES 0205USA02123
Age:70 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Stomach Discomfort Consumer Tab Vioxx PS ORAL
25

MG/DAILY/PO

Celebrex C
Lotensin Hct C
Prilosec C
Zocor C
Atenolol C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989375-5Report Type:Periodic Company Report #WAES 0205USA02124
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989376-7Report Type:Periodic Company Report #WAES 0205USA02126
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO; 50 MG/DAILY/PO	
	Diarrhoea							
	Drug Ineffective		Zocor	C				
	Intraocular Pressure Increased		Acetaminophen (+) Hydrocodone	C				
	Nausea		Chondroitin (+) Glucosamine	C				
			Prednisone	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3989377-9Report Type:Periodic Company Report #WAES 0205USA02127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989378-0Report Type:Periodic Company Report #WAES 0205USA02104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989379-2Report Type:Periodic Company Report #WAES 0205USA02106
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989380-9Report Type:Periodic Company Report #WAES 0205USA02107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		OROPHARINGEAL	PO	

Date:06/27/02ISR Number: 3989381-0Report Type:Periodic Company Report #WAES 0205USA02108
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989382-2Report Type:Periodic Company Report #WAES 0205USA02109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989383-4Report Type:Periodic Company Report #WAES 0205USA02110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989384-6Report Type:Periodic Company Report #WAES 0205USA02112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989385-8Report Type:Periodic Company Report #WAES 0205USA02113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989386-XReport Type:Periodic Company Report #WAES 0205USA02114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989387-1Report Type:Periodic Company Report #WAES 0205USA02115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989388-3Report Type:Periodic Company Report #WAES 0205USA02078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989389-5Report Type:Periodic Company Report #WAES 0205USA02079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989390-1Report Type:Periodic Company Report #WAES 0205USA02080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Ta Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989391-3Report Type:Periodic Company Report #WAES 0205USA02081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989392-5Report Type:Periodic Company Report #WAES 0205USA02082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989393-7Report Type:Periodic Company Report #WAES 0205USA02083
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989394-9Report Type:Periodic Company Report #WAES 0205USA02084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989395-0Report Type:Periodic Company Report #WAES 0205USA02086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989396-2Report Type:Periodic Company Report #WAES 0205USA02088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989397-4Report Type:Periodic Company Report #WAES 0205USA02089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989398-6Report Type:Periodic Company Report #WAES 0205USA02090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989399-8Report Type:Periodic Company Report #WAES 0205USA02092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989400-1Report Type:Periodic Company Report #WAES 0205USA02093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Oestrogen Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Breast Engorgement	Professional						
	Breast Pain		Allopurinol	SS				
	Drug Interaction		Celebrex	C				

Date:06/27/02ISR Number: 3989401-3Report Type:Periodic Company Report #WAES 0205USA02094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989402-5Report Type:Periodic Company Report #WAES 0205USA02095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989403-7Report Type:Periodic Company Report #WAES 0205USA02096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989404-9Report Type:Periodic Company Report #WAES 0205USA02097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989405-0Report Type:Periodic Company Report #WAES 0205USA02098
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989406-2Report Type:Periodic Company Report #WAES 0205USA02100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989407-4Report Type:Periodic Company Report #WAES 0205USA02103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989408-6Report Type:Periodic Company Report #WAES 0204USA02488
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myalgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Neck Pain		Paxil	C				
	Pain In Extremity							

Date:06/27/02ISR Number: 3989409-8Report Type:Periodic Company Report #WAES 0204USA02490
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Attack						MG/DAILY/PO	
			Bentyl	C				
			Coumadin	C				
			Lanoxin	C				
			Maxzide	C				
			Vasotec	C				

Date:06/27/02ISR Number: 3989410-4Report Type:Periodic Company Report #WAES 0204USA02493
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urine Present	Other	Tab Vioxx 25 Mg	PS		ORAL	25	
	Renal Disorder						MG/DAILY/PO	
			Accuretic	C				
			Claritin	C				

Date:06/27/02ISR Number: 3989411-6Report Type:Periodic Company Report #WAES 0204USA02497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Accupril	C				

Date:06/27/02ISR Number: 3989412-8Report Type:Periodic Company Report #WAES 0204USA02498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 3989413-XReport Type:Periodic Company Report #WAES 0204USA02499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Ulcer	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Haemorrhage	Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3989414-1Report Type:Periodic Company Report #WAES 0204USA02500
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Covera-Hs	C				
			Diovan	C				
			Lasix (Furosemide Sodium)	C				
			Synthroid	C				
			Glyburide	C				
			Potassium	C				

Date:06/27/02ISR Number: 3989415-3Report Type:Periodic Company Report #WAES 0204USA02522
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Ambien	C				
			K-Dur	C				
			Lipitor	C				
			Norvasc	C				
			Captopril (+) Hydrochlorothiazid	C				

Date:06/27/02ISR Number: 3989416-5Report Type:Periodic Company Report #WAES 0204USA02539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989417-7Report Type:Periodic Company Report #WAES 0204USA02604
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Level Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Tegretol	C				

Date:06/27/02ISR Number: 3989418-9Report Type:Periodic Company Report #WAES 0205USA02128
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989419-0Report Type:Periodic Company Report #WAES 0205USA02129
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort	Consumer	Vioxx	PS		ORAL	12.5 MG/DAILY/PO	
			Hyzaar	C				
			Norvasc	C				
			Plavix	C				
			Zoloft	C				
			Atenolol	C				

Levothyroxine Sodium	C
Ranitidine	C

Date:06/27/02ISR Number: 3989420-7Report Type:Periodic Company Report #WAES 0205USA02130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989421-9Report Type:Periodic Company Report #WAES 0205USA02131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989422-0Report Type:Periodic Company Report #WAES 0205USA02132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989423-2Report Type:Periodic Company Report #WAES 0205USA02133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989424-4Report Type:Periodic Company Report #WAES 0205USA02134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989425-6Report Type:Periodic Company Report #WAES 0205USA02136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989426-8Report Type:Periodic Company Report #WAES 0205USA02137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3989427-XReport Type:Periodic Company Report #WAES 0205USA02138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Unevaluable Event	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990118-XReport Type:Periodic Company Report #WAES 0202USA00731
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
	Tinnitus	Professional Company Representative	Lipitor	C				

Date:06/27/02ISR Number: 3990121-XReport Type:Periodic Company Report #WAES 0202USA00807
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5MG/DAILY/	
		Health					PO	
		Professional						

Date:06/27/02ISR Number: 3990129-4Report Type:Periodic Company Report #WAES 0202USA00826
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Dreams	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional						

Date:06/27/02ISR Number: 3990131-2Report Type:Periodic Company Report #WAES 0202USA00838
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25 MG/PO	
		Health	Pulmicort	C				
		Professional	Zantac	C				
			Zoloft	C				

			Therapy Unspecified	C

Date:06/27/02ISR Number: 3990134-8Report Type:Periodic Company Report #WAES 0202USA00944
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/AM/PO	
	Flushing	Health Professional	Claritin	C				
	Pruritus		Miacalcin	C				
			Mirapex	C				
			Prilosec	C				
			Remeron	C				
			Zoloft	C				
			Albuterol	C				
			Buspirone Hydrochloride	C				
			Isosorbine Mononitrate	C				
			Lorazepam	C				
			Meclizine Hydrochloride	C				
			Potassium Chloride	C				
			Quinine Sulfate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990137-3Report Type:Periodic Company Report #WAES 0202USA00977
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Tinnitus							
			Norvasc	C				
			Prempro	C				
			Prilosec	C				
			Calcium	C				

Date:06/27/02ISR Number: 3990140-3Report Type:Periodic Company Report #WAES 0202USA00980
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
			Avandia	C				
			Effexor	C				
			Glucotrol	C				
			Prempro	C				
			Prevacid	C				
			Prinivil	C				
			Metoprolol Tartrate	C				

Date:06/27/02ISR Number: 3990143-9Report Type:Periodic Company Report #WAES 0202USA01011
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Skin Hyperpigmentation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
		Health Professional						

Date:06/27/02ISR Number: 3990146-4Report Type:Periodic Company Report #WAES 0202USA01017
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amenorrhoea	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3990149-XReport Type:Periodic Company Report #WAES 0202USA01028
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Health Professional	Tab Vioxx	PS		ORAL	PO	
			Celebrex	C				

Date:06/27/02ISR Number: 3990152-XReport Type:Periodic Company Report #WAES 0202USA01070
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
			Therapy Unspecified	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990154-3Report Type:Periodic Company Report #WAES 0202USA01091
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Compartment Syndrome	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional	Tab Vioxx 50 Mg	SS		ORAL	PO	
		Company Representative						

Date:06/27/02ISR Number: 3990159-2Report Type:Periodic Company Report #WAES 0202USA01106
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	4 DAY
	Dyspepsia	Health Professional	Diovan	C				
			Premarin	C				
			Synthroid	C				
			Clonidine	C				

Date:06/27/02ISR Number: 3990161-0Report Type:Periodic Company Report #WAES 0202USA01212
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3990162-2Report Type:Periodic Company Report #WAES 0202USA01405
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Blood Creatine Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE						
		Health Professional				

Date:06/27/02ISR Number: 3990163-4Report Type:Periodic Company Report #WAES 0202USA01420
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pruritus	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Rash Erythematous	Health				
MG/DAILY/PO						
	Urticaria	Professional	Premarin	C		
			Provera	C		

Date:06/27/02ISR Number: 3990166-XReport Type:Periodic Company Report #WAES 0202USA01495
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cardiovascular Disorder	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
	Dizziness	Health				
MG/DAILY/PO						
	Drug Interaction	Professional	Adalat Cc	C		
	Gait Disturbance		Depakote	C		
	Muscle Spasms		Maxzide	C		
	Swelling		Nexium	C		
			Minocycline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990171-3Report Type:Periodic Company Report #WAES 0202USA01520
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cranial Nerve Disorder	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Glucophage	C				
			Lescol	C				
			Insulin	C				

Date:06/27/02ISR Number: 3990173-7Report Type:Periodic Company Report #WAES 0202USA01563
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	1 MON
		Health Professional	Zestril	C				
			Chlorothiazide	C				
			Thyroid	C				
			Verapamil Hydrochloride	C				

Date:06/27/02ISR Number: 3990175-0Report Type:Periodic Company Report #WAES 0202USA01578
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral	Health Professional	Prilosec	C				
			Tylenol	C				
			Zyrtec	C				
			Phenobarbital	C				

Date:06/27/02ISR Number: 3990177-4Report Type:Periodic Company Report #WAES 0203USA00128
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Scab	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
		Professional	Demadex	C			MG/DAILY/PO	
			Norvasc	C				
			Sonata	C				
			Synthroid	C				
			Potassium Chloride	C				

Date:06/27/02ISR Number: 3990178-6Report Type:Periodic Company Report #WAES 0203USA00132
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Psychomotor Hyperactivity	Professional					MG/DAILY/PO	

Date:06/27/02ISR Number: 3990179-8Report Type:Periodic Company Report #WAES 0203USA00158
Age: Gender:Female I/FU:I

Outcome	PT
	Incision Site Haemorrhage
	Pigmentation Disorder
	Rash Macular

	Raynaud'S Phenomenon Tenderness					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						
		Professional	Synthroid	C		

Date:06/27/02ISR Number: 3990180-4Report Type:Periodic Company Report #WAES 0203USA00160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Face Oedema	Consumer	Tab Vioxx Unk	PS		ORAL
UNK/UNK/PO						

Date:06/27/02ISR Number: 3990181-6Report Type:Periodic Company Report #WAES 0203USA00165
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Memory Impairment	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 & 12.5						
	Vitreous Floaters					
MG/DAILY/PO						
			[Composition			
			Unspecified]	C		
			Chondroitin	C		
			Glucosamine	C		

Date:06/27/02ISR Number: 3990182-8Report Type:Periodic Company Report #WAES 0203USA00167
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Oedema	Health	Tab Vioxx 12.5 Mg	PS		ORAL
UNK/UNK/PO						
		Professional				
		Company				
		Representative				

Date:06/27/02ISR Number: 3990183-XReport Type:Periodic Company Report #WAES 0203USA00179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/BID/PO	
	Mucosal Inflammation	Professional	Tamiflu	C				
		Company Representative	Z-Pak	C				

Date:06/27/02ISR Number: 3990184-1Report Type:Periodic Company Report #WAES 0202USA01662
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	2 DAY
	Decreased Appetite	Health	Lotrel	C				
	Gastrointestinal Disorder	Professional	Oxycontin	C				
	Nausea		Pravachol	C				
			Terazosin Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990185-3Report Type:Periodic Company Report #WAES 0203USA00184
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	30 DAY
	Pruritus							
			Elavil	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3990186-5Report Type:Periodic Company Report #WAES 0202USA01671
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/PO	
	Paraesthesia							
	Vision Blurred							

Date:06/27/02ISR Number: 3990187-7Report Type:Periodic Company Report #WAES 0203USA00195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
		Professional						
		Company						
		Representative						

Date:06/27/02ISR Number: 3990188-9Report Type:Periodic Company Report #WAES 0203USA00202
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Discomfort	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Professional
MG/DAILY/PO

Cardizem	C
Celebrex	C
Glucophage	C
Lescol	C
Prilosec	C
Nonsteroidal Anti-Inflammatory	C

Date:06/27/02ISR Number: 3990189-0Report Type:Periodic Company Report #WAES 0202USA01672
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3990190-7Report Type:Periodic Company Report #WAES 0202USA01673
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Swelling	Consumer	Tab Vioxx	PS		ORAL	PO	
	Rash		Effexor	C				
			Inderal	C				
			Trazodone	C				

Date:06/27/02ISR Number: 3990191-9Report Type:Periodic Company Report #WAES 0202USA01707
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
		Professional Company Representative	Prevacid	C				

Date:06/27/02ISR Number: 3990192-0Report Type:Periodic Company Report #WAES 0202USA01712
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Professional Company Representative	Wellbutrin	C				

Date:06/27/02ISR Number: 3990193-2Report Type:Periodic Company Report #WAES 0202USA01725
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO, SEE IMAGE	
	Headache	Professional Company Representative						
	Oedema Peripheral							

Date:06/27/02ISR Number: 3990194-4Report Type:Periodic Company Report #WAES 0205USA00114
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG;	

Professional
DAILY; PO

Date:06/27/02ISR Number: 3990195-6Report Type:Periodic Company Report #WAES 0202USA01735
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO; SEE IMAGE	
			Lipitor	C				
			Procardia Xl	C				
			Tricor	C				

Date:06/27/02ISR Number: 3990196-8Report Type:Periodic Company Report #WAES 0205USA00119
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Extremity Mass	Consumer	Tab Vioxx	PS		ORAL	PO	
			Claritin	C				

Date:06/27/02ISR Number: 3990197-XReport Type:Periodic Company Report #WAES 0205USA00122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG; DAILY;	

ORAL

			Zestril	C		
			Hydrochlorothiazide	C		

Date:06/27/02ISR Number: 3990198-1Report Type:Periodic Company Report #WAES 0205USA00131
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Disorder	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG; DAILY;	
			Premarin	C				

Date:06/27/02ISR Number: 3990199-3Report Type:Periodic Company Report #WAES 0202USA01737
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dizziness							
	Nausea							

Date:06/27/02ISR Number: 3990200-7Report Type:Periodic Company Report #WAES 0205USA00142
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG; DAILY; PO	

Date:06/27/02ISR Number: 3990201-9Report Type:Periodic Company Report #WAES 0202USA01785
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Blood Pressure Increased							
			Caltrate	C				
			Menest	C				
			Monopril-Hct	C				
			Zocor	C				

Date:06/27/02ISR Number: 3990202-0Report Type:Periodic Company Report #WAES 0205USA00143
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal	Health	Tab Vioxx 25mg	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:06/27/02ISR Number: 3990203-2Report Type:Periodic Company Report #WAES 0205USA00146
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Pale	Consumer	Tab Vioxx 25mg	PS		OPHTHALMIC	PO	16 DAY
			Prilosec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990204-4Report Type:Periodic Company Report #WAES 0205USA00147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG, DAILY;	
PO								
			Iron	C				

Date:06/27/02ISR Number: 3990215-9Report Type:Periodic Company Report #WAES 0205USA00186
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance	Health	Tab Vioxx 25mg	PS		ORAL	25 MG DAILY;	
PO		Professional						
			Prilosec	C				
			Enalapril Maleate	C				
			Isosorbide Monitrate	C				

Date:06/27/02ISR Number: 3990219-6Report Type:Periodic Company Report #WAES 0205USA00197
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY;	
PO	Abnormal							
			Aricept	C				
			Effexor Xr	C				
			Prilosec	C				

Date:06/27/02ISR Number: 3990225-1Report Type:Periodic Company Report #WAES 0205USA02194
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 G/DAILY/PO	
			Coumadin	C				
			Detrol La	C				
			Paxil	C				
			Toprol Xl Tablets	C				

Date:06/27/02ISR Number: 3990240-8Report Type:Periodic Company Report #WAES 0205USA02203
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Consumer	Tab Vioxx	PS		ORAL	PO	
	Oedema Peripheral		Prempro	C				
			Prinivil	C				
			Hydroxychloroquine Sulfate	C				
			Labetalol Hydrochloride	C				

Date:06/27/02ISR Number: 3990246-9Report Type:Periodic Company Report #WAES 0205USA02206
Age: Gender: I/FU:I

Outcome	PT	Report Source
	Post Procedural Haemorrhage	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx	PS		ORAL
PO						

Date:06/27/02ISR Number: 3990247-0Report Type:Periodic Company Report #WAES 0205USA02207
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Retinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL
PO						

Date:06/27/02ISR Number: 3990249-4Report Type:Periodic Company Report #WAES 0205USA02224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Glucose Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/						
DAILY/PO						
			Cozaar	C		
			Plavix	C		
			Proscar	C		
			Allopurinol	C		
			Potassium (Unspecified)	C		

Date:06/27/02ISR Number: 3990251-2Report Type:Periodic Company Report #WAES 0205USA02228
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						

Pain
MG/DAILY/PO

Fosamax	C	
Lasix (Furosemide)	C	
Thyroid	C	

Date:06/27/02ISR Number: 3990255-XReport Type:Periodic Company Report #WAES 0205USA02243
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Urea Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Mevacor	C				

Date:06/27/02ISR Number: 3990256-1Report Type:Periodic Company Report #WAES 0205USA02264
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Erythema	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Fatigue						MG/DAILY/PO	
	Oedema Peripheral							
	Pruritus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990257-3Report Type:Periodic Company Report #WAES 0205USA02268
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990258-5Report Type:Periodic Company Report #WAES 0205USA02270
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Swelling							
			Norvasc	C				
			Plavix	C				
			Remeron	C				
			Zocor	C				

Date:06/27/02ISR Number: 3990260-3Report Type:Periodic Company Report #WAES 00072225
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional						
		Company Representative	Alcohol	SS				

Date:06/27/02ISR Number: 3990261-5Report Type:Periodic Company Report #WAES 00091403
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL PO
	Abnormal Faeces					
	Constipation					
	Fatigue					
	Headache					
	Hypoaesthesia					
	Oedema Peripheral					
	Pain					
	Pain In Extremity					
	Paraesthesia					
	Swelling					
	Weight Increased					

Date:06/27/02ISR Number: 3990263-9Report Type:Periodic Company Report #WAES 00111328
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO; SEE IMAGE	
	Drug Effect Decreased	Health Professional						
	Pain							
			Klonopin	C				
			Medrol Dosepak	C				
			Nardil	C				
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990264-0Report Type:Periodic Company Report #WAES 01010060
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Congestive Hypertension	Professional Company Representative						

Date:06/27/02ISR Number: 3990266-4Report Type:Periodic Company Report #WAES 01032144
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Gastrointestinal Disorder						MG/DAILY/PO	
			Atrovent	C				
			Hydrodiuril	C				
			Prevacid	C				
			Albuterol	C				
			Diazepam	C				
			Naproxen	C				

Date:06/27/02ISR Number: 3990267-6Report Type:Periodic Company Report #WAES 01050661
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gestational Diabetes	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Haemorrhage	Professional					MG/DAILY/PO	
	Hepatic Function Abnormal							

Date:06/27/02ISR Number: 3990269-XReport Type:Periodic Company Report #WAES 01050700
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3990271-8Report Type:Periodic Company Report #WAES 01052039
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	2 DAY
	Malaise							
	Nausea							
	Vertigo							
	Vomiting							

Date:06/27/02ISR Number: 3990272-XReport Type:Periodic Company Report #WAES 01060870
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Pressure Increased							
	Drug Ineffective		Diovan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990274-3Report Type:Periodic Company Report #WAES 01081107
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Catapres	C				
			Parafon Forte	C				
			Robaxin	C				
			Tylenol	C				
			Ultram	C				

Date:06/27/02ISR Number: 3990277-9Report Type:Periodic Company Report #WAES 0205USA02140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990279-2Report Type:Periodic Company Report #WAES 0205USA02141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990280-9Report Type:Periodic Company Report #WAES 0205USA02143
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990282-2Report Type:Periodic Company Report #WAES 0205USA02144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990283-4Report Type:Periodic Company Report #WAES 0205USA02145
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
	Hypertension							
			Claritin	C				

Date:06/27/02ISR Number: 3990285-8Report Type:Periodic Company Report #WAES 0205USA02146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990286-XReport Type:Periodic Company Report #WAES 0205USA02169
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Triglycerides	Health	Tab Vioxx	PS		ORAL	PO	
	Increased	Professional Company Representative						

Date:06/27/02ISR Number: 3990288-3Report Type:Periodic Company Report #WAES 0205USA02187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990289-5Report Type:Periodic Company Report #WAES 0205USA02191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990290-1Report Type:Periodic Company Report #WAES 0205USA02192
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photopsia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Norvasc	C				
			Synthroid	C				
			Metoprolol	C				

Date:06/27/02ISR Number: 3990318-9Report Type:Periodic Company Report #WAES 0202USA02004
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased Tendency To Bruise	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Climara	C				
			Fosamax	C				
			Hyoscyamine	C				

Date:06/27/02ISR Number: 3990319-0Report Type:Periodic Company Report #WAES 0202USA02055
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Upper Respiratory Tract Infection	Health Professional	Hydrodiuril	C				
			Atenolol	C				

Date:06/27/02ISR Number: 3990320-7Report Type:Periodic Company Report #WAES 0202USA02083
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	
	Muscle Spasms	Health Professional	Advil	C				

Tricor	C
Zocor	C
Aspirin	C
Glucosamine	C
Vitamins (Unspecified)	C

Date:06/27/02ISR Number: 3990321-9Report Type:Periodic Company Report #WAES 0202USA02096
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema	Professional						
			Celebrex	C				

Date:06/27/02ISR Number: 3990322-0Report Type:Periodic Company Report #WAES 0202USA02098
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO;	
	Joint Swelling	Professional						
	Oedema Peripheral						12.5 MG/DAILY/PO	
			Ibuprofen	C				

Date:06/27/02ISR Number: 3990323-2Report Type:Periodic Company Report #WAES 0202USA02142
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Consumer	Tab Vioxx	PS		ORAL	PO	
	Congestive	Health						

Professional

Date:06/27/02ISR Number: 3990324-4Report Type:Periodic Company Report #WAES 99071697
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/UNK/PO	
	Dizziness							
	Drug Ineffective		Diovan	C				
			Klonopin	C				
			Lozol	C				
			Mirapex	C				
			Voltaren	C				
			Zyloprim	C				
			B Vitamins	C				
			Nonsteroidal Anti-Inflammatory	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3990325-6Report Type:Periodic Company Report #WAES 01082525
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source
	Macular Oedema	Health Professional
	Visual Acuity Reduced	

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
25						
MG/DAILY/PO						
			Celebrex	C		
			Singulair	C		
			Singulair	C		

Date:06/27/02ISR Number: 3990326-8Report Type:Periodic Company Report #WAES 0112USA02128
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Drug Effect Decreased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
		Health Professional				
		Company Representative				

Date:06/27/02ISR Number: 3990327-XReport Type:Periodic Company Report #WAES 0202USA02899
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Palpitations	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
	Supraventricular	Professional				
MG/DAILY/PO						
	Extrasystoles	Company Representative	Prilosec	SS		

Date:06/27/02ISR Number: 3990328-1Report Type:Periodic Company Report #WAES 0205USA02714
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

	Cardiac Failure	Health	Tab Vioxx Unk	PS			ORAL
PO							
	Congestive	Professional Company Representative					

Date:06/27/02ISR Number: 3990329-3Report Type:Periodic Company Report #WAES 0205USA02832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Headache	Professional					MG/DAILY/PO	
	Nausea	Company Representative						

Date:06/27/02ISR Number: 3990330-XReport Type:Periodic Company Report #WAES 0205USA03388
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
	Dyspnoea	Professional					MG/DAILY/PO	
	Feeling Abnormal	Company Representative						
	Headache							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990331-1Report Type:Periodic Company Report #WAES 0205USA03404
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Oedema Peripheral	Professional						
	Pain	Company Representative						

Date:06/27/02ISR Number: 3990332-3Report Type:Periodic Company Report #WAES 0206USA00434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:06/27/02ISR Number: 3990333-5Report Type:Periodic Company Report #WAES 0206USA00811
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company Representative						

Date:06/27/02ISR Number: 3990334-7Report Type:Periodic Company Report #WAES 0206USA00905
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	PO	

Professional
Company
Representative

Date:06/27/02ISR Number: 3990335-9Report Type:Periodic Company Report #WAES 0206USA01380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990336-0Report Type:Periodic Company Report #WAES 00022271
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Constipation	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Drug Ineffective							
	Nasal Congestion		Nasacort	C				
	Nausea		Zocor	C				
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990337-2Report Type:Periodic Company Report #WAES 00040255
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Electroencephalogram	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Abnormal	Professional	Inderal	C				
	Migraine	Company	Prilosec	C				
		Representative	Toprol Xl Tablets	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3990346-3Report Type:Periodic Company Report #WAES 0203USA02918
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	4 DAY
	Dyspepsia							
			Levothroid	C				
			Premarin	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3990347-5Report Type:Periodic Company Report #WAES 0203USA02921
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Dry Throat							
	Oedema Peripheral		Mirapex	C				
			Prempro	C				
			Synthroid	C				

Date:06/27/02ISR Number: 3990348-7Report Type:Periodic Company Report #WAES 0203USA02923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cough	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990349-9Report Type:Periodic Company Report #WAES 0203USA02926
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza Like Illness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Nasopharyngitis		Accupril	C				
			Atenolol	C				
			Gemfibrozil	C				

Date:06/27/02ISR Number: 3990350-5Report Type:Periodic Company Report #WAES 0203USA02934
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blister							
	Nail Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990351-7Report Type:Periodic Company Report #WAES 0203USA02939
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyp	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Vaginal Haemorrhage	Professional						

Date:06/27/02ISR Number: 3990352-9Report Type:Periodic Company Report #WAES 0203USA02953
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx	PS		ORAL	PO; PRN PO	
			Covera-Hs	C				
			Estrace	C				
			Protonix	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:06/27/02ISR Number: 3990353-0Report Type:Periodic Company Report #WAES 0203USA02958
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
		Professional	Elavil	C				
		Company	Nasonex	C				
		Representative	Premarin	C				
			Prozac	C				

Date:06/27/02ISR Number: 3990354-2Report Type:Periodic Company Report #WAES 0203USA02969
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL

PO; 50

MG/DAILY/PO 1 YR

Date:06/27/02ISR Number: 3990355-4Report Type:Periodic Company Report #WAES 0203USA02971
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Aggression	Health	Tab Vioxx	PS		ORAL
	Blood Pressure Decreased	Professional				
	Dysarthria					

Dose Duration

PO

Date:06/27/02ISR Number: 3990356-6Report Type:Periodic Company Report #WAES 0202USA02788
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL

Dose Duration

25

MG/DAILY/PO

Date:06/27/02ISR Number: 3990357-8Report Type:Periodic Company Report #WAES 0202USA02791
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
	Fungal Infection	Health	Tab Vioxx 25 Mg	PS		ORAL
		Professional	Lipitor	C		

Dose Duration

25 MG/PRN/PO

			Premarin	C
			Aspirin	C
			Atenolol	C

Date:06/27/02ISR Number: 3990358-XReport Type:Periodic Company Report #WAES 0202USA02795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Function Abnormal	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990359-1Report Type:Periodic Company Report #WAES 0202USA02800
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Tab Vioxx Unk	PS		ORAL	BID/PO	
	Chills	Health Professional	Cartia (Aspirin)	C				
	Diarrhoea		Lasix (Furosemide)	C				
	Drug Ineffective		Levoxyl	C				
	Gastrointestinal Disorder		Zocor	C				
	Vomiting							

Date:06/27/02ISR Number: 3990360-8Report Type:Periodic Company Report #WAES 0202USA02801
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
	Cough		Premarin	C				
	Dizziness							
	Nasopharyngitis							

Date:06/27/02ISR Number: 3990361-XReport Type:Periodic Company Report #WAES 0202USA02805
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neck Mass	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Oedema Peripheral							
	Weight Increased		Vasotec	C				
			Amiodarone	C				
			Aspirin	C				
			Vitamins	C				

Date:06/27/02ISR Number: 3990362-1Report Type:Periodic Company Report #WAES 0202USA02812
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Erythematous	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
			Vicodin Tablets	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990363-3Report Type:Periodic Company Report #WAES 0202USA02814
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Joint Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Corgard	C				

Date:06/27/02ISR Number: 3990364-5Report Type:Periodic Company Report #WAES 0202USA02816
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Tylenol	C				
			Vitamin E	C				

Date:06/27/02ISR Number: 3990365-7Report Type:Periodic Company Report #WAES 0202USA02822
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chromaturia	Health	Tab Vioxx Unk	PS		ORAL	1X/PO	
	Jaundice	Professional Company Representative	Tylenol Unk	SS				
			Vicodin Tablets	C				

Date:06/27/02ISR Number: 3990382-7Report Type:Periodic Company Report #WAES 0203USA01681
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx	PS		ORAL	PO	

Professional

Date:06/27/02ISR Number: 3990383-9Report Type:Periodic Company Report #WAES 0203USA01683
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health	Tab Vioxx 12.5 Mg	PS		ORAL	SEE IMAGE	
		Professional	...	C				
			Celebrex	C				
			Ditropan Xl	C				
			Lipitor	C				
			Norvasc	C				
			Prilosec	C				
			Atenolol	C				
			Metoclopramide Hydrochloride	C				

Date:06/27/02ISR Number: 3990384-0Report Type:Periodic Company Report #WAES 0203USA01690
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Health	Tab Vioxx	PS		ORAL	PO	
	Drug Ineffective	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3990385-2Report Type:Periodic Company Report #WAES 0203USA01702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Disorder	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3990386-4Report Type:Periodic Company Report #WAES 0203USA01723
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Limb Injury		Detrol La	C				
			Flomax (Tamsulosin Hydrochloride	C				
			Synthroid	C				
			Zocor	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Calcium	C				
			Diltiazem Hydrochloride	C				
			Folic Acid	C				
			Potassium Gluconate	C				
			Pyridoxine	C				
			Vitamin E	C				

Date:06/27/02ISR Number: 3990387-6Report Type:Periodic Company Report #WAES 0203USA01727
Age:85 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dry Mouth	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Dry Throat						PO	
	Lacrimation Increased		Lanoxin	C				

	Nausea		Patanol	C
	Paraesthesia		Zestoretic	C
			Meclizine Hydrochloride	C
			Pentoxifylline	C
			Triamcinolone Acetonide	C

Date:06/27/02ISR Number: 3990388-8Report Type:Periodic Company Report #WAES 0203USA01739
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthma	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
PO								
			Allegra	C				
			Darvocet-N	C				
			Flomax (Morniflumate)	C				
			Glucotrol Xl	C				
			Norvasc	C				
			Proscar	C				
			Serevent Disk	C				
			Vasotec	C				

			Albuterol	C		
			Potassium Chloride	C		

Date:06/27/02ISR Number: 3990389-XReport Type:Periodic Company Report #WAES 0203USA01740
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/	
	Hyperaesthesia						PO	
	Oral Pain		Coreg	C				
			Digitek	C				
			Humulin 70/30	C				
			Oxycontin	C				
			Prilosec	C				
			Vasotec	C				
			Zoloft	C				
			Isosorbide Mononitrate	C				
			Lactulose	C				

Date:06/27/02ISR Number: 3990390-6Report Type:Periodic Company Report #WAES 0203USA01742
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Palpitations	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/	
							PO	
			Arava	C				
			Estrace	C				
			Fosamax	C				
			Os-Cal	C				
			Chondroitin (+) Glucosamine	C				
			Iron (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3990391-8Report Type:Periodic Company Report #WAES 0203USA01754
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991562-7Report Type:Periodic Company Report #WAES 0204USA02832
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eye Swelling	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Face Oedema							
	Oedema Peripheral Swelling		Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3991563-9Report Type:Periodic Company Report #WAES 0204USA02835
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Consumer	Tab Vioxx	PS		ORAL	PO	
			Glucophage	C				

Date:06/27/02ISR Number: 3991564-0Report Type:Periodic Company Report #WAES 0204USA02838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991565-2Report Type:Periodic Company Report #WAES 0204USA02848
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991566-4Report Type:Periodic Company Report #WAES 0204USA02853
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ageusia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Nexium	C				
			Prempro	C				
			Robaxin	C				
			Hydrocortisone	C				

Date:06/27/02ISR Number: 3991567-6Report Type:Periodic Company Report #WAES 0204USA02863
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS			25 MG/DAILY	

Date:06/27/02ISR Number: 3991568-8Report Type:Periodic Company Report #WAES 0204USA02865
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991569-XReport Type:Periodic Company Report #WAES 0204USA02866
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3991570-6Report Type:Periodic Company Report #WAES 0204USA02869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Disorder	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991571-8Report Type:Periodic Company Report #WAES 0204USA02875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Microcytic Anaemia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Health Professional Company Representative	Lipitor	SS				

Date:06/27/02ISR Number: 3991572-XReport Type:Periodic Company Report #WAES 0204USA01305
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister	Health Professional Company Representative	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Furuncle							
	Rash		Glucophage Xr	C				

Date:06/27/02ISR Number: 3991573-1Report Type:Periodic Company Report #WAES 0204USA01309
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	

Somnolence
MG/DAILY/PO

Hyzaar	C
Procardia Xl	C
Rythmol	C
Xanax	C
Zoloft	C

Date:06/27/02ISR Number: 3991574-3Report Type:Periodic Company Report #WAES 0204USA01318
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Epistaxis							

Claritin-D 12 Hour	C
Cozaar	C
Premarin	C
Synthroid	C

Date:06/27/02ISR Number: 3991575-5Report Type:Periodic Company Report #WAES 0204USA01321
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Advair	C
Allegra	C
Evista	C

				Prilosec	C	
				Prozac	C	
				Synvisc	C	
				Albuterol	C	
				Gemfibrozil	C	

Date:06/27/02ISR Number: 3991576-7Report Type:Periodic Company Report #WAES 0204USA01323
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prinivil	C				
			Amitriptyline	C				
			Atenolol	C				
			Hyoscyamine	C				
			Metronidazole	C				
			Ranitidine	C				

Date:06/27/02ISR Number: 3991577-9Report Type:Periodic Company Report #WAES 0204USA01328
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Prilosec	C				
			Prinivil	C				
			Zocor	C				

Date:06/27/02ISR Number: 3991578-0Report Type:Periodic Company Report #WAES 0204USA01363
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Urinary Incontinence	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
		Company	Foradil	C		
		Representative	Singulair	C		

Date:06/27/02ISR Number: 3991579-2Report Type:Periodic Company Report #WAES 0204USA01366
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Headache	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO						
		Professional	Prilosec	C		
		Company	Prednisone	C		
		Representative	Vitamin D (Unspecified)	C		

Date:06/27/02ISR Number: 3991580-9Report Type:Periodic Company Report #WAES 0204USA01370
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG / DAILY						
	Abnormal Faeces					
/ PO						
			Herbs (Unspecified)	C		
			Vitamins			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Unspecified) C

Date:06/27/02ISR Number: 3991581-0Report Type:Periodic Company Report #WAES 0204USA01379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3991582-2Report Type:Periodic Company Report #WAES 0205USA00207
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Abnormal	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3991583-4Report Type:Periodic Company Report #WAES 0205USA00208
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
	Oedema							

Date:06/27/02ISR Number: 3991584-6Report Type:Periodic Company Report #WAES 0205USA00222
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fluid Retention	Consumer	Tab Vioxx	PS		ORAL	25MG DAILY PO	
	Pitting Oedema		Actos	C				
	Swelling		Advair Diskus	C				
			Humulin	C				
			Levoxyl	C				
			Lipitor	C				
			Prevacid	C				
			Allopurinol	C				
			Captopril	C				
			Furosemide	C				
			Isosorbide	C				
			Potassium Chloride	C				
			Propranolol	C				

Date:06/27/02ISR Number: 3991585-8Report Type:Periodic Company Report #WAES 0205USA00228
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Tab Vioxx	PS		ORAL	12.5MG DAILY PO	
	Sleep Disorder							
			Aciphex	C				
			Synthroid	C				
			Atenolol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3991586-XReport Type:Periodic Company Report #WAES 0205USA00255
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Systolic	Health	Tab Vioxx	PS			PO	
	Increased	Professional Company Representative						

Date:06/27/02ISR Number: 3991587-1Report Type:Periodic Company Report #WAES 0205USA00260
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic	Consumer	Tab Vioxx	PS		ORAL	PO	
	Attack							
	Visual Disturbance							

Date:06/27/02ISR Number: 3991588-3Report Type:Periodic Company Report #WAES 0205USA00274
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bronchitis	Consumer	Tab Vioxx	PS		ORAL	12.5MG DAILY	
	Face Oedema						PO	
	Neck Mass		Avalide	C				
	Rash		Prevacid	C				
			Toprol Xl	C				
			Valium	C				
			Globulin, Immune	C				

Date:06/27/02ISR Number: 3991589-5Report Type:Periodic Company Report #WAES 0205USA00283
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Gamma-Glutamyltransferase	Health	Tab Vioxx	PS			ORAL
50MG DAILY PO							
	Increased	Professional	Tab Vioxx 25mg	SS			ORAL
25MG DAILY PO							
	Malaise		Immodium	C			
	Neuropathy Peripheral		Vitamins	C			

Date:06/27/02ISR Number: 3991590-1Report Type:Periodic Company Report #WAES 0205USA00285
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cough	Health	Tab Vioxx	PS		ORAL
12.5MG DAILY						
	Pyrexia	Professional				
PO						
	Wheezing	Company Representative	Hyzaar	C		
			Zocor	C		

Date:06/27/02ISR Number: 3991591-3Report Type:Periodic Company Report #WAES 0205USA00286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Diastolic	Health	Tab Vioxx	PS		ORAL
PO						
	Increased	Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993197-9Report Type:Periodic Company Report #WAES 0204USA01394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive	Health Professional Company Representative	Tab Vioxx 25 Mg	PS				

Date:06/27/02ISR Number: 3993200-6Report Type:Periodic Company Report #WAES0204USA01403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/ DAILY	
	Drug Ineffective						PO	

Date:06/27/02ISR Number: 3993203-1Report Type:Periodic Company Report #WAES0204USA01405
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993207-9Report Type:Periodic Company Report #WAES0204USA01407
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993209-2Report Type:Periodic Company Report #WAES0204USA01408
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/	
	Oedema Peripheral	Professional					DAILY/PO	
	Weight Increased	Company Representative	Synthroid	C				

Date:06/27/02ISR Number: 3993212-2Report Type:Periodic Company Report #WAES0204USA01413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking	Health	Tab Vioxx	PS		ORAL	PO	
		Professional	Estrace	C				
			Paxil	C				
			Prilosec	C				
			Synthroid	C				
			Doxycycline	C				
			Vitamins (Unspecified)	C				

Date:06/27/02ISR Number: 3993213-4Report Type:Periodic Company Report #WAES0204USA01416
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Photosensitivity Reaction	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3993215-8Report Type:Periodic Company Report #WAES0204USA01419
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Hydroxyzine Hydrochloride	C				
			Theophylline	C				

Date:06/27/02ISR Number: 3993217-1Report Type:Periodic Company Report #WAES0204USA01431
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:06/27/02ISR Number: 3993219-5Report Type:Periodic Company Report #WAES0204USA01440
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Somnolence							
			Flomax (Morniflumate)	C				

Date:06/27/02ISR Number: 3993227-4Report Type:Periodic Company Report #WAES 0204USA01454
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993230-4Report Type:Periodic Company Report #WAES 0204USA01491
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993231-6Report Type:Periodic Company Report #WAES 0204USA01499
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
			Evista	C				
			Foradil	C				
			Uniphyl	C				
			Diltiazem Hydrochloride	C				

Date:06/27/02ISR Number: 3993233-XReport Type:Periodic Company Report #WAES 0204USA01507
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tinnitus	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Premarin	C				

Date:06/27/02ISR Number: 3993234-1Report Type:Periodic Company Report #WAES 0204USA01511
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	
			Percocet	C				
			Hydralazine Hydrochloride (+)	C				
			Ranitidine	C				

Date:06/27/02ISR Number: 3993236-5Report Type:Periodic Company Report #WAES 0204USA01521
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Rash		Neurontin	C				
			Paxil	C				
			Alprazolam	C				
			Hydrocodone	C				

Date:06/27/02ISR Number: 3993237-7Report Type:Periodic Company Report #WAES 0204USA01527
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dysphagia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nasopharyngeal Disorder							

Date:06/27/02ISR Number: 3993238-9Report Type:Periodic Company Report #WAES 0204USA01528
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993239-0Report Type:Periodic Company Report #WAES 0204USA01529
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cystitis	Consumer	Tab Vioxx	PS		ORAL	PO	5 DAY
	Kidney Infection		Synthroid	C				
			Vasotec	C				
			Estrone	C				
			Lorazepam	C				

Date:06/27/02ISR Number: 3993240-7Report Type:Periodic Company Report #WAES 0204USA01530
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nephrolithiasis							

Date:06/27/02ISR Number: 3993241-9Report Type:Periodic Company Report #WAES 0205USA00289
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx	PS		ORAL	25 MG PO	
			Aleve	C				
			Motrin	C				
			Hormoral Contraceptives	C				
			Naproxen	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:06/27/02ISR Number: 3993242-0Report Type:Periodic Company Report #WAES 0205USA00290
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Potassium Increased	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Corticosteroids	C				

Date:06/27/02ISR Number: 3993243-2Report Type:Periodic Company Report #WAES 0205USA00293
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hallucination	Health	Tab Vioxx	PS			PO	
		Professional Company Representative						

Date:06/27/02ISR Number: 3993244-4Report Type:Periodic Company Report #WAES 0205USA00296
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage	Health	Tab Vioxx 25mg	PS		ORAL	PO	
		Professional Company Representative	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993245-6Report Type:Periodic Company Report #WAES 0205USA00313
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Tab Vioxx	PS		ORAL	25MG DAILY PO	
			Elavil	C				

Date:06/27/02ISR Number: 3993246-8Report Type:Periodic Company Report #WAES 0205USA00316
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	BID PO	
			Premarin	C				
			Hydrochlorothiazide	C				
			Methotrexate	C				
			Prilosec	I				

Date:06/27/02ISR Number: 3993247-XReport Type:Periodic Company Report #WAES 0205USA00317
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension	Consumer	Tab Vioxx	PS		ORAL	PO	
	Abdominal Pain Upper		Allegra	C				
			Levsin	C				

Date:06/27/02ISR Number: 3993248-1Report Type:Periodic Company Report #WAES 0205USA00335
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Vioxx	PS		ORAL	25MG DAILY PO	
	Weight Increased		Lipitor	C				
			Premarin	C				
			Hydrochlorothiazide					

(+) Valsarta C

Date:06/27/02ISR Number: 3993250-XReport Type:Periodic Company Report #WAES 0205USA00353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Phlebitis Superficial	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993251-1Report Type:Periodic Company Report #WAES 0205USA00354
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension	Health Professional Company Representative	Vioxx	PS		ORAL	50MG DAILY PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993255-9Report Type:Periodic Company Report #WAES 0204USA01535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/QOD/PO	
			Aciphex	C				
			Lescol	C				
			Verapamil	C				

Date:06/27/02ISR Number: 3993259-6Report Type:Periodic Company Report #WAES 0204USA01539
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993260-2Report Type:Periodic Company Report #WAES 0204USA01541
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Face Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG	
	Oedema Peripheral	Professional					/DAILY/PO	2 WK

Date:06/27/02ISR Number: 3993262-6Report Type:Periodic Company Report #WAES 0204USA01543
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Optic Nerve Disorder		Pravachol	C				

Date:06/27/02ISR Number: 3993263-8Report Type:Periodic Company Report #WAES 0204USA01546
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	12.5 MG/DAILY/PO	
	Dyspepsia							
	Liver Function Test		Celexa	C				
	Abnormal		Premarin	C				
	Medication Error		Synthroid	C				
	Nausea							
	Urinary Tract Infection							

Date:06/27/02ISR Number: 3993265-1Report Type:Periodic Company Report #WAES 0204USA01557
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Effexor	C				
			Tranxene	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993267-5Report Type:Periodic Company Report #WAES 0204USA01565
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993270-5Report Type:Periodic Company Report #WAES 0204USA01570
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angiopathy	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
	Hypertension		Centrum Silver	C				
	Memory Impairment		Paxil	C				
			Remeron	C				
			Serevent	C				
			Zestril	C				
			Zoloft	C				
			Alprazolam	C				
			Aspirin	C				
			Calcium	C				
			Vitamin D	C				
			Vitamen E	C				
			Zinc	C				

Date:06/27/02ISR Number: 3993272-9Report Type:Periodic Company Report #WAES 0204USA01571
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx; Tab Vioxx 25 Mg	PS		ORAL	PO; SEE IMAGE	
			Claritin	C				
			Prempro	C				

Date:06/27/02ISR Number: 3993283-3Report Type:Periodic Company Report #WAES 0204USA01575
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993285-7Report Type:Periodic Company Report #WAES 0204USA01586
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health Professional Company Representative	Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993288-2Report Type:Periodic Company Report #WAES 0204USA01588
Age:40 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Health	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Gastrointestinal Pain	Professional				PO		
		Company Representative						

Date:06/27/02ISR Number: 3993290-0Report Type:Periodic Company Report #WAES 0204USA01611
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash	Other	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993291-2Report Type:Periodic Company Report #WAES 0204USA01616
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling	Health	Vioxx	PS		ORAL	PO	
		Professional	Celebrex	C				
			Seroquel	C				
			Zoloft	C				
			Butalbital	C				
			Clonazepam	C				
			Furosemide	C				

Date:06/27/02ISR Number: 3993294-8Report Type:Periodic Company Report #WAES 0204USA01633
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression	Consumer	Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	

Influenza Like Illness
PO

	Ultram	C	
	Acetaminophen (+) Hydrocodone Bitartrate	C	

Date:06/27/02ISR Number: 3993306-1Report Type:Periodic Company Report #WAES 0204USA01646
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
PO								
			Allegra	C				
			Diprolene Af Cream	C				
			Fosamax	C				

Date:06/27/02ISR Number: 3993311-5Report Type:Periodic Company Report #WAES 0204USA01665
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG PM PO	
	Rash Scaly		Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 3993313-9Report Type:Periodic Company Report #WAES 0204USA01667
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Burning Sensation	Consumer	Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Dyspepsia						PO	
	Haematochezia		Azulfidine	C				
			Celexa	C				
			Coumadin	C				
			Demadex	C				
			K-Dur	C				
			Mavik	C				
			Toprol Xl Tablets	C				
			Xanax	C				

Date:06/27/02ISR Number: 3993316-4Report Type:Periodic Company Report #WAES 0204USA01713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuropathy	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993370-XReport Type:Periodic Company Report #WAES 0204USA01714
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mouth Ulceration	Consumer	Vioxx 25 Mg	PS		ORAL	PO	

Date:06/27/02ISR Number: 3993954-9Report Type:Periodic Company Report #WAES 0205USA00755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gynaecomastia	Health Professional Company Representative	Vioxx	PS		ORAL	PO	

Date:06/27/02ISR Number: 3997007-5Report Type:Periodic Company Report #WAES 0112USA02126
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Somnolence	Consumer Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	

Date:06/27/02ISR Number: 4001470-3Report Type:Periodic Company Report #WAES 0205USA00565
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Therapeutic Response	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	
	Decreased							
			Motrin	C				
			Prempro	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/02ISR Number: 4001775-6Report Type:Periodic Company Report #WAES 0203USA02646
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:06/27/02ISR Number: 4004339-3Report Type:Periodic Company Report #WAES 0204USA02709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:06/28/02ISR Number: 3940808-XReport Type:Expedited (15-DaCompany Report #WAES 01113486
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscular Weakness	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Initial or Prolonged	Renal Failure Acute	Professional	Lisinopril	SS			445 DAY	
			Levothyroxine Sodium	C				
			Nortriptyline Hydrochloride	C			77 DAY	
			Chlorthalidone	C			78 DAY	
			Lorazepam	C				

Date:06/28/02ISR Number: 3940810-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Death Gastrointestinal Haemorrhage	Celebrex	C

Date:06/28/02ISR Number: 3940811-XReport Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Activated Partial Thromboplastin Time Prolonged Acute Myocardial Infarction Alanine Aminotransferase Increased Anaphylactic Reaction Arrhythmia Blood Pressure Increased Cardiac Arrest Chronic Obstructive Pulmonary Disease Contusion Exsanguination Gastrointestinal Disorder Gastrointestinal Haemorrhage Haematemesis International Normalised

		Ratio Increased					
		Large Intestinal Ulcer					
		Haemorrhage					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophageal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage		Celebrex	C		ORAL
		Platelet Count Decreased		Acetaminophen And			
		Pleuritic Pain		Hydrocodone			
		Prothrombin Time		Bitartrate	C		ORAL
		Prolonged		Zydone	C		ORAL
		Rib Fracture		Pertussin N	C		ORAL
		Sudden Cardiac Death		Accolate	C		ORAL
				Claritin	C		ORAL
				Pravachol	C		ORAL
				Paxil	C		ORAL
				Flonase	C		ORAL
				Toradol	C		ORAL
				Remeron	C		ORAL
				Nystatin	C		ORAL
				Biaxin	C		ORAL
				Depo-Provera	C		
INTRAMUSCULAR							
				Hydrocortisone			
				Acetate	C		
				Skelaxin	C		ORAL
				Tequin	C		ORAL
				Alupent	C		
RESPIRATORY							
(INHALATION)							
				Serevent	C		
RESPIRATORY							
(INHALATION)							
				Flovent	C		
RESPIRATORY							
(INHALATION)							
				Buspar	C		ORAL
				Lipitor	C		ORAL
				Amaryl	C		ORAL
				Percocet	C		ORAL
				Pramoxine			
				Hydrochloride	C		
TOPICAL							
				Premarin	C		ORAL

			Proventil	C		
RESPIRATORY						
(INHALATION)						
			Demerol	C		ORAL
			Alprazolam	C		ORAL
			Carisoprodol	C		ORAL
			Aquaphor	C		
			Promethazine	C		

Date:06/28/02ISR Number: 3940813-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:06/28/02ISR Number: 3940817-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebellar Artery Thrombosis

Cerebrovascular Accident

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Globulin, Immune	SS			INTRAVENOUS	
			Globulin, Immune	SS			INTRAVENOUS	

Date:06/28/02ISR Number: 3940823-6Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00117
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiomyopathy		Metformin Hydrochloride	C				
	Fluid Retention		Gliclazide	C				
			Prazosin Hydrochloride	C				
			Furosemide	C				
			Echinacea	C				

Date:06/28/02ISR Number: 3941041-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Sodium Folate	C				
Disability			Goserelin Acetate	C				
Other			Cyproterone Acetate	C				
			Methotrexate	C				

Date:06/28/02ISR Number: 3941043-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction

Date:06/28/02ISR Number: 3941045-5Report Type:Expedited (15-DaCompany Report #WAES 0206ESP00028
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Myocardial Infarction		Diclofenac Sodium	C				
			Verapamil	C		ORAL		

Date:06/28/02ISR Number: 3941048-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00150
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Morphine Sulfate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/02ISR Number: 3941050-9Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00013
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Stenosis		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Gastrointestinal		Celecoxib	SS		
	Haemorrhage		Pantoprazole Sodium	C		

Date:06/28/02ISR Number: 3941058-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00067
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Generalised Oedema		Furosemide	C		ORAL

Date:06/28/02ISR Number: 3941059-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02213
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anorexia		Lasix (Furosemide			
Other	Anxiety		Sodium)	C		ORAL
	Asthenia		Levaquin	C		
	Atrial Flutter		Coreg	C		
	Cardiac Failure		Micro K	C		
	Congestive		[Therapy			
	Cardiomegaly		Unspecified]	C		
	Dyspnoea		Synthroid	C		
	Electrocardiogram St-T		Folic Acid	C		
	Change		Glucophage	C		
	Fatigue		Glyburide	C		
	Hypoglycaemia					
	Nasopharyngitis					
	Orthopnoea					
	Productive Cough					
	Supraventricular					
	Extrasystoles					
	Upper Respiratory Tract					
	Infection					
	Ventricular Extrasystoles					

Date:06/28/02ISR Number: 3941063-7Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00064
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Gastrointestinal Ulcer Melaena		Acetaminophen	C				

Date:06/28/02ISR Number: 3941065-0Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Drug Interaction		Phenobarbital	SS		ORAL		
			Phenobarbital	SS		ORAL		
			Furosemide	C				
			Potassium Chloride	C				

			Nicergoline	C		
			Trimetazidine Hydrochloride	C		

Date:06/28/02ISR Number: 3941067-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00066
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		45 DAY
Initial or Prolonged	Renal Impairment		Hydrochlorothiazide And Irbesartan	SS		ORAL		45 DAY
			Digoxin	C		ORAL		
			Aspirin Lysine	C		ORAL		
			Allopurinol	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Ginkgo Biloba Extract	C		ORAL		

Date:06/28/02ISR Number: 3941068-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		[Therapy Unspecified]	C				
	Coma							
	Transient Ischaemic Attack							

Date:06/28/02ISR Number: 3941120-5Report Type:Periodic Company Report #WAES 0202USA01578
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL		25-50

MG/DAILY/PO

Prilosec	C
Tylenol	C
Zyrtec	C
Phenobarbital	C

Date:06/28/02ISR Number: 3941917-1Report Type:Expedited (15-DaCompany Report #001-0981-M0201152
Age: Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
Other	Arthralgia
	Blood Parathyroid Hormone
	Increased
	Dialysis
	Drug Interaction
	Erythema Multiforme
	Haemorrhage
	Iatrogenic Injury
	Kidney Transplant
	Rejection
	Movement Disorder
	Myalgia

		Pain Rash Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Disorder Surgical Procedure	Consumer Health	Atorvastatin (Atorvastatin)	PS		ORAL
20 MG (DAILY)							
		Repeated	Professional				
ORAL							
				Amlodipine (Amlodipine)	SS		
10 MG (DAILY)							
				Celecoxib (Celecoxib)	SS		
				Clonazepam (Clonazepam)	SS		
				Cyclobenzaprine (Clyclobenzaprine)	SS		
				B Complex (Becosym Forte)	SS		
				Rofecoxib (Rofecoxib)	SS		
				Paricalcitol (Paricalcitol)	SS		
INTRAVENOUS	INTRAVENOUS						
				(Various Medications)	SS		
				(Humulin N) (Insulin Human Injection, Isophane)	SS		
SUBCUTANEOUS	SUBCUTANEOUS						
				Imuran (Azathioprine)	SS		
				Prednisone (Prednisone)	SS		
				Furosemide (Furosemide)	SS		
				Cyclosporine (Ciclosporin)	SS		
				Clonidine (Clonidine)	SS		
				Metoprolol Succinate (Metoprolol Succinate)	SS		
				Bisoprolol Fumarte (Bisoprolol Fumarte)	SS		

Date:06/28/02ISR Number: 3941922-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Barrett'S Oesophagus							
	Gastritis							
	Hiatus Hernia							
	Orthostatic Hypotension							
	Prostatic Specific Antigen Increased							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/02ISR Number: 3941958-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA01820
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Chest Pain						MG/DAILY/PO	
	Influenza Like Illness		Corgard	C				
	Migraine		Hydrodiuril	C				
	Pharyngitis Streptococcal							

Date:06/28/02ISR Number: 3941960-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA00109
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company	Aricept	C				
	Peptic Ulcer	Representative	Hydrodiuril	C				
			Levoxyl	C				
			Peri-Colace	C				
			Risperdal	C				
			Vasotec	C				
			Zoloft	C				
			Aspirin	C				
			Ferrous Sulfate	C				
			Protein	C				

Date:06/28/02ISR Number: 3942291-7Report Type:Periodic Company Report #300708
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nausea	Health	Xeloda					
Initial or Prolonged	Palmar-Plantar	Professional	(Capecitabine) 500					
Disability	Erythrodysaesthesia		Mg	PS		ORAL	4 GRAM DAILY	

	Syndrome			ORAL
	Skin Ulcer Vomiting	Coumadin (Warfarin Sodium)	SS	ORAL
		K-Dur (Potassium Chloride)	SS	ORAL 16 MEQ 2 PER DAY ORAL
		Nexium (Esomeprazole)	SS	ORAL 30 MG DAILY ORAL
		Oxycontin (Oxycodone)	SS	ORAL 120 MG 3 PER DAY ORAL
		Zyrtec (Cetirizine Hydrochloride)	SS	ORAL 20 MG DAILY ORAL
		Roxicodone (Oxycodone Hydrochloride)	SS	ORAL 5 MG 1 PER PRN ORAL
		Buspar (Buspirone Hydrochloride)	SS	ORAL 50 MG 2 PER DAY ORAL
		Lasix (Furosemide)	SS	ORAL 40 MG DAILY ORAL
		Remeron (Mirtazapine)	SS	ORAL 30 MG DAILY

ORAL

Ativan (Lorazepam)	SS	ORAL	1 MG 1 PER PRN ORAL
Phenergan (Promethazine Hydrochloride)	SS	ORAL	25 MG 1 PER PRN ORAL
Vioxx (Rofecoxib)	SS	ORAL	25 MG 1 PER PRN ORAL
Zofran (Ondansetron Hydrochloride)	SS	ORAL	8 MG 1 PER PRN ORAL
Carafate (Sucralfate)	SS	ORAL	1 PER 4 HOUR ORAL

Date:06/28/02ISR Number: 3943488-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00125
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:07/01/02ISR Number: 3941600-2Report Type:Expedited (15-DaCompany Report #WAES 01098248
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscular Weakness		Zocor	PS	Merck & Co., Inc	ORAL	46	DAY

Initial or Prolonged	Renal Failure		Rofecoxib	SS	ORAL
366 DAY					
Disability	Rhabdomyolysis		Amiodarone		
Other			Hydrochloride	C	ORAL
366 DAY					
			Furosemide Sodium	C	ORAL
			Aspirin	C	ORAL
			Phenprocoumon	C	ORAL
			Lisinopril	C	ORAL

Date:07/01/02ISR Number: 3941604-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02108
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocarditis		Celebrex	SS		ORAL
	Ulcer		Clonidine	C		
	Upper Gastrointestinal		Avapro	C		
	Haemorrhage		Demadex	C		
			Lipitor	C		
			Premarin	C		
			Ultram	C		
			Neurontin	C		
			Zanaflex	C		

Date:07/01/02ISR Number: 3941605-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA00950
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Ivth Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL
			Coumadin	C		

				Lipitor	C		
				Monopril	C		

Date:07/01/02ISR Number: 3941608-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02885
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pyelonephritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure Acute		[Therapy					
Initial or Prolonged	Renal Tubular Necrosis		Unspecified]	C				
Disability	Tubulointerstitial		[Therapy					
Other	Nephritis		Unspecified]	C				
	Urosepsis		Verapamil	C				
			Plaquenil	C				
			Plaquenil	C				

Date:07/01/02ISR Number: 3941613-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00595
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:07/01/02ISR Number: 3941614-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA02620
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/02ISR Number: 3941619-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02360
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Ms Contin	C				

				Metaphyllin	C		

Date:07/01/02ISR Number: 3941860-8Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00024
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/02ISR Number: 3941868-2Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00051
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged			Lorazepam	C				
			Acetaminophen And Codeine Phosphate	C				
			Smectite	C				

Date:07/01/02ISR Number: 3941869-4Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00180
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged								

Date:07/01/02ISR Number: 3941870-0Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc			
	Blood Pressure Increased							
	Fluid Retention							
	Migraine							
	Oedema Peripheral							
	Weight Increased							

Date:07/01/02ISR Number: 3941875-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01627
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lopid	C				

Date:07/01/02ISR Number: 3941877-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA02437
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/02ISR Number: 3941879-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02027
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:07/01/02ISR Number: 3941880-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombotic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/02ISR Number: 3942060-8Report Type:Direct Company Report #CTU 171295
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy Bradycardia Cardiac Arrest Hyperkalaemia Renal Failure Acute		Rofecoxib 25 Mg	PS		ORAL	PO QD	2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/02ISR Number: 3942071-2Report Type:Direct Company Report #CTU 171323
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx 25mg Merck	PS	Merck	ORAL	1 TABLE PER	
Hospitalization -	Chest Discomfort						DAY ORAL	
Initial or Prolonged	Hypoaesthesia							
Required	Muscle Tightness							
Intervention to	Throat Tightness							
Prevent Permanent								
Impairment/Damage								

Date:07/01/02ISR Number: 3942452-7Report Type:Direct Company Report #CTU 171352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Dalteparin	PS				
SUBCUTANEOUS							2500 UNITS SQ	
Initial or Prolonged	Gastric Ulcer							
QD								
Required	Gastritis Erosive		Rofecoxib	SS		ORAL		
25-50MG PO QD								
Intervention to	Injection Site		Metoprolol	C				
Prevent Permanent	Haemorrhage		Sertraline	C				
Impairment/Damage	Melaena		Fosamax	C				
			Digoxin	C				

Date:07/01/02ISR Number: 3944077-6Report Type:Periodic Company Report #TAP2001Q02885
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactoid Reaction	Health	Prevacid					
Initial or Prolonged		Professional	(Lansoprazole) (30					
Required			Milligram, Capsules)	PS		ORAL		
30 MG, ONCE,								
Intervention to								
ORAL								
Prevent Permanent			Levaquin					

Impairment/Damage

(Levofloxacin)
(Injection For
Infusion) SS

INTRAVENOUS 500 MG, 1 IN

1 D,

INTRAVENOUS

Tylenol With Codeine
(Panadeine Co)
(Tablets) SS (Panadeine Co) ORAL

Q4HOURS AS

NEEDED, ORAL

Vioxx (Rofecoxib) SS ORAL

25 MG, 1 N 1

D, ORAL

Date:07/02/02ISR Number: 3942513-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942516-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA03555
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Mallory-Weiss Syndrome		Fosamax	SS		ORAL		
Other			Accupril	C		ORAL		
			Procardia	C		ORAL		
			Neurontin	C		ORAL		
			Doxepin	C		ORAL		
			Prilosec	C		ORAL		
			Aspirin	C				

Date:07/02/02ISR Number: 3942517-XReport Type:Expedited (15-DaCompany Report #WAES 0206PRT00002
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Hypertension		Hydrochlorothiazide And Irbesartan	SS		ORAL		

Date:07/02/02ISR Number: 3942518-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00249
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cholecystitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL	168	DAY
Hospitalization -	Gastric Ulcer		Celebrex	C				
Initial or Prolonged	Gastrointestinal		Nexium	C				
Disability	Haemorrhage		Nadolol	C				
Other	Platelet Count Increased		Hydrodiuril	C				
	Weight Decreased		Iron (Unspecified)	C				

Date:07/02/02ISR Number: 3942519-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Premarin	C				
	Back Pain		Dyazide	C				
			Atenolol	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Ambien	C				
			Lonox	C				

Date:07/02/02ISR Number: 3942520-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00175
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS		ORAL		
			Hydroxychloroquine Sulfate	C				
			[Therapy Unspecified]	C				
			Citalopram Hydrobromide	C				
			Folic Acid	C				

				Methotrexate	C		

Date:07/02/02ISR Number: 3942523-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/02/02ISR Number: 3942524-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02699
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/02/02ISR Number: 3942525-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01204
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rhabdomyolysis Sepsis							

Date:07/02/02ISR Number: 3942526-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02492
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain Dyspnoea Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/02/02ISR Number: 3942551-XReport Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Foreign	Tab Vioxx					
Life-Threatening	Aortic Valve Sclerosis	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Blood Pressure Decreased	Professional						
PO								75 DAY
Initial or Prolonged	Coronary Artery Atherosclerosis	Other	Nonsteroidal Anti-Inflammatory Drug	SS		ORAL	PO	
	Emphysema							
	Gastric Ulcer Haemorrhage		Furosemide	C				
	Gastritis Haemorrhagic		Isosorbide Mononitrate	C				
	Heart Rate Decreased		Pantoprazole Sodium	C				
	Mitral Valve Sclerosis		Prednisone	C				
	Pulmonary Hypertension		Ramipril	C				
	Shock Haemorrhagic		Sotalol Hydrochloride	C				
			Tramadol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942595-8Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00130
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis	Foreign	Tab Vioxx					
	Carotid Artery Occlusion	Other	(Rofecoxib)	PS		ORAL	12.5 MG/BID	6 DAY
	Carotid Artery Stenosis		Elavil	C				
	Cerebral Artery Occlusion		Cosyntropin	C				
	Cerebral Infarction		Enoxaparin Sodium	C				
	Hemiparesis		Metoclopramide	C				
			Pentoxifylline	C				
			Ranitidine	C				
			Tilidine Hydrochloride	C				
			Tolperisone Hcl	C				
			Vitamin B	C				
			Vitamins	C				

Date:07/02/02ISR Number: 3942626-5Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00019
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Tab Vioxx					
Initial or Prolonged	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	6 DAY
	Haematemesis	Professional	Fluindione	SS		ORAL		
	International Normalised Ratio Increased							

Date:07/02/02ISR Number: 3942629-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00036
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Tab Vioxx					
Hospitalization -	Melaena	Other	(Rofecoxib)	PS		ORAL	12.5 MG/	98 DAY
Initial or Prolonged			Acetaminophen/Propoxyphene Hydrochloride	C				
			Furosemide	C				

			Isosorbide	C			

Date:07/02/02ISR Number: 3942631-9Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00110
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Foreign	Tab Vioxx					
Life-Threatening	Aortic Valve Sclerosis	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Blood Pressure Decreased	Professional						
PO								75 DAY
Initial or Prolonged	Coronary Artery	Other	Nonsteroidal					
	Atherosclerosis		Anti-Inflammatory					
	Emphysema		Drug	SS		ORAL	PO	
	Gastric Ulcer Haemorrhage		Furosemide	C				
	Gastritis Haemorrhagic		Isosorbide					
	Mitral Valve Sclerosis		Mononitrate	C				
	Pulmonary Hypertension		Pantoprazole Sodium	C				
	Shock Haemorrhagic		Prednisone	C				
			Ramipril	C				
			Sotalol					
			Hydrochloride	C				
			Tramadol Hcl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942633-2Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00130
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis	Foreign	Tab Vioxx					
	Carotid Artery Occlusion		(Rofecoxib)	PS		ORAL	12.5 MG/BID	6 DAY
	Carotid Artery Stenosis		Elavil	C				
	Cerebral Infarction		Cosyntropin	C				
	Hemiparesis		Enoxaparin Sodium	C				
			Metoclopramide	C				
			Pentoxifylline	C				
			Ranitidine	C				
			Tilidine Hydrochloride	C				
			Tolperisone Hcl	C				
			Vitamin B (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:07/02/02ISR Number: 3942681-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02768
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional						
Disability		Company						
Other		Representative						

Date:07/02/02ISR Number: 3942683-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02970
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	1 MON
Hospitalization -	Cerebrovascular Accident	Professional						

Initial or Prolonged	Ecchymosis	Company	Coumadin	C
Disability	Gastrointestinal	Representative	Vasotec	C
Other	Haemorrhage		Triazolam	C
	International Normalised			
	Ratio Increased			
	Soft Tissue Haemorrhage			

Date:07/02/02ISR Number: 3942686-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02583
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Increased	Professional					PO	
	Carotid Artery Disease	Company						
	Confusional State	Representative						
	Ischaemia							
	Memory Impairment							
	Mental Status Changes							
	Microangiopathy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942688-5Report Type:Expedited (15-DaCompany Report #WAES 0204USA03162
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/	
	Gastritis	Health					PO	
	Irritable Bowel Syndrome	Professional	Atacand	C				
	Pruritus		Celebrex	C				
	Urticaria		Naprosyn	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Zoloft	C				

Date:07/02/02ISR Number: 3942693-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA03162
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
	Irritable Bowel Syndrome	Health	Atacand	C				
	Pruritus Generalised	Professional	Celebrex	C				
	Urticaria		Naprosyn	C				
			Toprol Xl Tablets	C				
			Zocor	C				
			Zoloft	C				

Date:07/02/02ISR Number: 3942695-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02583
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Disease	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Confusional State	Professional					PO	
	Ischaemia	Company						
	Memory Impairment	Representative						
	Mental Status Changes							

Date:07/02/02ISR Number: 3942698-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02970
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Cerebrovascular Accident	Professional						
PO								1 MON
Initial or Prolonged	Ecchymosis	Company	Coumadin	C				
Disability	Gastrointestinal	Representative	Vasotec	C				
Other	Haemorrhage		Triazolam	C				
	Haemorrhage							
	International Normalised							
	Ratio Increased							

Date:07/02/02ISR Number: 3942699-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02768
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional						
PO								
Disability		Company						
Other		Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3942953-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Cardiomegaly	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged	Cardiomyopathy Coronary Artery Disease Coronary Artery Occlusion Hypokinesia Myocardial Infarction Pulmonary Congestion		[Therapy Unspecified]	C				

Date:07/02/02ISR Number: 3942973-7Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort Alanine Aminotransferase Increased Anaphylactic Reaction Anion Gap Increased Anisocytosis Aspartate Aminotransferase Abnormal Back Injury Back Pain Blood Albumin Decreased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Blood Calcium Abnormal Blood Chloride Increased Blood Creatinine Abnormal Blood Glucose Abnormal Blood Potassium Increased Blood Pressure Increased Blood Sodium Increased Blood Urea Abnormal Cardiac Arrest Circulatory Collapse Contusion Cough Exsanguination

Gastrointestinal
Haemorrhage
Haematemesis
Haematocrit Decreased
Haemoglobin Decreased
International Normalised
Ratio Increased
Large Intestinal Ulcer
Haemorrhage
Macrocytosis
Monocyte Count Decreased
Myocardial Infarction
Neutrophil Count Abnormal
Oedema
Oesophageal Ulcer
Haemorrhage
Pco2 Abnormal
Platelet Count Decreased

		Protein Total Decreased					
		Prothrombin Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Red Blood Cell Count	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO							
		Decreased	Health	Accolate	C		
		Regurgitation Of Food	Professional	Alupent	C		
		Respiratory Arrest		Amaryl	C		
		Rib Fracture		Aquaphor	C		
		Sudden Cardiac Death		Biaxin	C		
		White Blood Cell Count		Buspar	C		
		Increased		Celebrex	C		
				Claritin	C		
				Demerol	C		
				Depo-Provera	C		
				Flonase	C		
				Flovent	C		
				Lipitor	C		
				Paxil	C		
				Percocet	C		
				Pertussin N	C		
				Pravachol	C		
				Premarin	C		
				Proventil	C		
				Remeron	C		
				Serevent	C		
				Skelaxin	C		
				Trquin	C		
				Toradol	C		
				Zydone	C		
				Acetaminophen (+)			
				Hydrocodone	C		
				Alprazolam	C		
				Carisoprodol	C		
				Hydrocortisone Acetate	C		
				Nystatin	C		
				Pramoxine Hydrochloride	C		
				Promethazine	C		

Date:07/02/02ISR Number: 3943338-4Report Type:Expedited (15-DaCompany Report #WAES 0204AUS00158
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Haemorrhage	Foreign	Tab Vioxx					
	Gastric Polyps	Health	(Rofecoxib)	PS		ORAL	12.5 MG/DAILY	
	Haemoglobin Abnormal	Professional					PO	
	Rectal Haemorrhage		Calcium Carbonate	C				
			Dipyridamole	C				
			Domperidone	C				
			Ergocalciferol	C				
			Furosemide Sodium	C				
			Glimepiride	C				
			Indapamide (+)					
			Perindopril Erbumine	C				
			Isosorbide					
			Mononitrate	C				
			Omeprazole Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3943339-6Report Type:Expedited (15-DaCompany Report #WAES 0206CAN00143
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Arthritis Reactive	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	PO	
	Erythema Joint Swelling	Professional	Therapy Unspecified	C				
			Analgesic Or Anesthetic	C				

Date:07/02/02ISR Number: 3943340-2Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00135
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Diverticulum Intestinal Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	
	Haemoglobin Decreased		Cap Indomethacin	SS		ORAL	25 MG/DAILY	
	Laboratory Test Abnormal						PO	
	Large Intestinal Ulcer							

Date:07/02/02ISR Number: 3943341-4Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00028
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Condition Aggravated	Foreign Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Professional					PO	98 DAY
			Fosamax	C				
			Moduretic	C				
			Valsartan	C				

Date:07/02/02ISR Number: 3943353-0Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00126
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Bradycardia	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/UNK PO	10 DAY
			Atenolol	C				
			Ciprofibrate	C				

Date:07/02/02ISR Number: 3943354-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00128
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Tendon Disorder	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/UNK PO	442 DAY
			Levofloxacin	SS		ORAL	500 MG/UNK PO	4 DAY

Date:07/02/02ISR Number: 3943355-4Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00148
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Melaena	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY PO	8 DAY

			Acetaminophen	C		
			Acetaminophen/Propoxyphene Hydrochloride	C		

Date:07/02/02ISR Number: 3943356-6Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00117
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Foreign	Tab Vioxx					
Disability	Dyspnoea	Consumer	(Rofecoxib)	PS		ORAL	25 MG/BID PO	
	Fluid Retention		Echinacea	C				
			Furosemide	C				
			Gliclazide	C				
			Metformin Hcl	C				
			Prazosin Hcl	C				

Date:07/02/02ISR Number: 3943381-5Report Type:Expedited (15-DaCompany Report #WAES 01073565
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscular Weakness	Foreign	Tab Vioxx					
	Renal Failure Acute	Health	(Rofecoxib)	PS		ORAL	12.5 MG DAILY	
		Professional					PO	
		Other	Lisinopril	SS		ORAL	20 MG DAILY	
							PO	445 DAY
			Chlorthalidone	C				
			Levothyroxine Na	C				
			Lorazepam	C				
			Nortriptyline Hcl	C				

Date:07/02/02ISR Number: 3943477-8Report Type:Expedited (15-DaCompany Report #2002-DE-01311DE (0)
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cystitis Erythema Toxic Epidermal Necrolysis	Health Professional	Catapresan (Clonidine Hcl)	PS			INTRAVENOUS	IV
			Novalgin (Metamizole Sodium) (Nr)	SS		ORAL	PO	
			Euglukon N (Glibenclamide) (Nr)	SS				
			Vioxx (Specific Antirheumatic Agents) (Nr)	SS		ORAL	PO	
			Noradrenalin (Norepinephrine) (Nr)	SS			INTRAVENOUS	IV ONCE
			Contrast Media (Contrast Media) (Nr)	SS			INTRAVENOUS	IV ONCE
			Noctamid (Lormetazepam) (Nr)	SS		ORAL	PO ONCE	
			Xylocain (Lidocaine Hydrochloride) (Nr)	SS			SUBCUTANEOUS	SC ONCE
			Diazepam (Diazepam) (Nr)	SS			INTRAVENOUS	IV ONCE
			Plavix 75 (Clopidogrel) (Nr)	SS		ORAL	PO	
			Corvaton					

(Molsidomine) (Nr)	C
Durogesic (Fentanyl) (Tts)	C
Insulin (Insulin) (Nr)	C
Fragmin (Hepatin-Fraction, Sodium Salt) (Nr)	C
Decortin (Prednisone) (Nr)	C
Unat 10 (Torasemide) (Nr)	C
Mono Mack (Isosorbide Mononitrate) (Nr)	C
Antra Mups (Omeprazole) (Nr)	C
Ca (Calcium)	C
Insulin	C
Glucose 5%	C
Ringers Solution	C

Date:07/02/02ISR Number: 3943543-7Report Type:Direct Company Report #CTU 171536
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Photosensitivity Reaction		Vioxx 25 Mg	PS		ORAL	25 MG QD PO	

Date:07/02/02ISR Number: 3943591-7Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00039
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Autoantibody Positive Blood Lactate Dehydrogenase Increased Cold Agglutinins Positive Gastritis Erosive Haematocrit Decreased	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5-25 MG	728 DAY

Haematoma
Haemoglobin Decreased
Mean Cell Haemoglobin
Concentration Increased
Mean Cell Volume
Increased
Myelodysplastic Syndrome
Platelet Count Decreased
White Blood Cell Count
Decreased

Date:07/02/02ISR Number: 3943592-9Report Type:Expedited (15-DaCompany Report #WAES 01113486
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscular Weakness Renal Failure Acute	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	15 DAY
			Lisinopril	SS			20 MG/DAILY	445 DAY
			Chlorthalidone	C				

			Levothyroxine Na	C		
			Lorazepam	C		
			Nortriptyline Hcl	C		

Date:07/02/02ISR Number: 3943597-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02340
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Swelling	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Oedema Peripheral						MG/DAILY/PO	
			Diovan Hct	C				
			Prevacid	C				
			Prinivil	C				
			Digoxin	C				
			Metoprolol	C				

Date:07/02/02ISR Number: 3943603-0Report Type:Expedited (15-DaCompany Report #WAES 01073565
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscular Weakness	Foreign	Tab Vioxx					
	Renal Failure Acute	Other	(Rofecoxib)	PS		ORAL	12.5MG/DAILY	
							PO	
			Lisinopril	SS		ORAL	20 MG/DAILY	
							PO	445 DAY
			Chlorthalidone	C				
			Levothyroxine Na	C				
			Lorazepam	C				
			Nortriptyline Hc1	C				

Date:07/02/02ISR Number: 3943615-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Cerebrovascular Accident							
	Dizziness							
	Joint Swelling							
	Oedema Peripheral							
	Renal Disorder							

Date:07/02/02ISR Number: 3943617-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02194
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Tab Vioxx	PS		ORAL	PO	
	Embolism	Professional						

Date:07/02/02ISR Number: 3943789-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Tab Vioxx	PS		ORAL	PO	
Other	Gastrointestinal Haemorrhage	Professional Company Representative	Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/02ISR Number: 3943794-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01406
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebellar Infarction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cerebral Thrombosis	Professional					MG/DAILY/PO	
	Cerebrovascular Accident	Company	Inj Globulin, Immune	SS		INTRAVENOUS	40 G/MTH/IV	
	Dizziness	Representative	Inj Globulin, Immune					
	Nausea		10 Gm	SS		INTRAVENOUS	10 GM/MTH/IV	

Date:07/02/02ISR Number: 3943797-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA00109
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Blood Chloride Increased	Professional					MG/DAILY/PO	
Initial or Prolonged	Blood Creatinine Abnormal	Company	Aricept	C				
Other	Blood Potassium Increased	Representative	Hydrodiuril	C				
	Blood Urea Abnormal		Levoxyl	C				
	Coma		Peri-Colace	C				
	Confusional State		Risperdal	C				
	Gastrointestinal		Vasotec	C				
	Haemorrhage		Zoloft	C				
	Mucosal Dryness		Aspirin	C				
	Peptic Ulcer		Ferrous Sulfate	C				
	Protein Total Decreased		Magnesia (Milk Of)	C				
	White Blood Cell Count Abnormal		Protein	C				

Date:07/02/02ISR Number: 3943800-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02573
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Asthenia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Fatigue					
MG/DAILY/PO						
	Meningitis		Soma	C		
	Paraesthesia		Ultram	C		
			Atenolol	C		

Date:07/03/02ISR Number: 3942951-8Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00031
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
54 DAY						
Initial or Prolonged	Angina Unstable	Professional	Vioxx	SS		ORAL
	Cardiac Failure		Hydrochlorothiazide And Lisinopril	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL
			Acetaminophen	C		ORAL
			Citalopram Hydrobromide	C		ORAL
			Nitroglycerin	C		
TOPICAL						

Date:07/03/02ISR Number: 3942954-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01556
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Other		Professional						

Date:07/03/02ISR Number: 3942961-0Report Type:Expedited (15-DaCompany Report #WAES 0206NOR00013
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Initial or Prolonged	Haemoglobin Decreased		Estradiol Valerate	C		ORAL		
	Melaena		Doxazosin Mesylate	C		ORAL		

Date:07/03/02ISR Number: 3943151-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02766
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Evista	C				
			Synthroid	C				

Date:07/03/02ISR Number: 3943153-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA00042
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/02ISR Number: 3943154-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/02ISR Number: 3943155-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA00096
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Hospitalization - Initial or Prolonged	Congestive Coma							

Date:07/03/02ISR Number: 3943156-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA00035
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/02ISR Number: 3943157-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA00140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/02ISR Number: 3944291-XReport Type:Expedited (15-DaCompany Report #WAES 0206NOR00006
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign	Tab Vioxx					
	Dizziness	Consumer	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
Disability	Fatigue	Other						
	Gamma-Glutamyltransferase Increased		Acetaminophen	C			PO	
			Celecoxib	C				
	Haemoglobin Decreased		Diclofenac Na	C				
	Headache		Drospirenone (+) Ethinyl Estradiol	C				
	Hepatomegaly							
	Nausea							
	Pain In Extremity							
	Pyrexia							
	Red Blood Cell Sedimentation Rate Increased							

Date:07/03/02ISR Number: 3944294-5Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Tab Vioxx					
	Drug Interaction	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Drug Level Below Therapeutic	Professional					PO	8 DAY
			Phenobarbital	SS		ORAL	SEE IMAGE	
			Furosemide	C				

			Nicergoline	C		
			Potassium Chloride	C		
			Trimetazidine Hydrochloride	C		

Date:07/03/02ISR Number: 3944314-8Report Type:Expedited (15-DaCompany Report #WAES0206BEL00005
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diaphragmatic Hernia	Foreign	Vioxx (Rofecoxib)	PS		ORAL
25 MG / DAILY						
Initial or Prolonged	Oesophagitis	Health				
/ PO						
Other		Professional	Tab Fosamax			
		Other	(Alendronate Sodium)	SS		ORAL
10						
MG/DAILY/PO 476 DAY						
			Zocor	C		
			Albuterol	C		
			Felodipine	C		
			Fluticasone Propionate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/02ISR Number: 3944315-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00144
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Gastric Ulcer Perforation	Health						
PO								214 DAY
Initial or Prolonged	Peritonitis	Professional	Amlodipine	C				
	Sepsis	Other	Metoprolol	C				
			Repaglinide	C				

Date:07/03/02ISR Number: 3944317-3Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00140
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Health						
PO								80 DAY
		Professional						
		Other						

Date:07/03/02ISR Number: 3944407-5Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00029
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Foreign	Tab Vioxx					
		Health	(Rofecoxib)	PS		ORAL	25 MG/ DAILY/	
		Professional						
PO								11 DAY
			Zocor	C				
			Aspirin	C				
			Atenolol/Chlorthalid one	C				
			Calcium (Unspecified)	C				
			Cholecalciferol	C				

Date:07/03/02ISR Number: 3944422-1Report Type:Expedited (15-DaCompany Report #WAES 02206FRA00056
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

Date:07/03/02ISR Number: 3944426-9Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00058
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema	Foreign	Tab Vioxx					
	Face Oedema	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	13 DAY
		Professional	Vasotec	C				
			Vinburnine	C				

Date:07/03/02ISR Number: 3944462-2Report Type:Expedited (15-DaCompany Report #WAES 0206FIN00003
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Swelling	Foreign	Tab Vioxx					
	Weight Increased	Other	(Rofecoxib)	PS		ORAL	50 MG DAILY	
							PO	5 DAY

Tizanidine C

Date:07/03/02ISR Number: 3944712-2Report Type:Expedited (15-DaCompany Report #2002PK00622
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erythema	Foreign	Xylocain	PS				
	Post Procedural Complication	Other	Antra Mups	SS		ORAL	20 MG DAILY PO	
	Toxic Epidermal Necrolysis		Tavegil	SS		ORAL	2 DF DAILY PO	
			Ortho-Gynest	SS		VAGINAL	1 DF DAILY VG	
			Corvaton "Aventis Pharma"	SS	Aventis Pharma	ORAL	8 MG DAILY PO	
			Novalgin	SS		ORAL	50 GTT QID PO	
			Durogesic	SS		CUTANEOUS	125 UG Q72H CU	3 DAY
			Durogesic	SS		CUTANEOUS	50 UG Q72H CU	3 DAY
			Durogesic	SS		CUTANEOUS	75 UG Q72H CU	3 DAY
			Durogesic	SS		CUTANEOUS	100 UG Q72H CU	3 DAY
			Durogesic	SS		CUTANEOUS	150 UG Q72H CU	3 DAY
			Insulin	SS				
			Insulin	SS				
			Fragmin	SS			1 DF QD SQ	
			Decortin	SS		ORAL	80 MG QD PO	
			Decortin	SS		ORAL	60 MG QD PO	

Decortin	SS		ORAL
50 MG QD PO			
Decortin	SS		ORAL
40 MG QD PO			
Unat	SS		ORAL
5 MG QD PO			
Mono Mack	SS		
Euglucon N	SS		
3 DF DAILY			
Ass "Ct-Arzneimittel"	SS		ORAL
100 MG QD PO			
Ass "Ct-Arzneimittel"	SS		ORAL
100 MG QD PO			
Vioxx	SS		ORAL
25 MG QD PO			
Catapresan	SS		
Noradrenalin	SS		
Contrast Medium	SS		
Noctamid-1	SS		ORAL
1 MG BID PO			
Diazepam	SS		
Plavix	SS		ORAL
75 MG QD PO			
Calcium	C		
Glucose 5%	C		
Cotrim	C		
Ringer "Biosedra"	C		

Date:07/03/02ISR Number: 3944744-4Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00120
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea	Foreign	Tab Vioxx					
	Dyspepsia	Other	(Rofecoxib)	PS		ORAL	12.5 MG/BID	12 DAY
			Acetaminophen/Codeine Phosphate	C				
			Aspirin	C				
			Methyldopa	C				
			Sotalol					

				Hydrochloride	C	

Date:07/03/02ISR Number: 3944745-6Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL		

Date:07/03/02ISR Number: 3944865-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03359
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic	Health	Vioxx Unk	PS		ORAL	PO	
	Increased Cerebrovascular Accident Hypertension	Professional Company Representative	....	C				
			Diuretic(Unspecified)	C				
			Methotrexate Sodium	C				
			Prednisone	C				

Date:07/03/02ISR Number: 3944867-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA03165
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional						
Other	Gastric Ulcer Haemorrhage	Company	Carafate	C				
	Gastritis Erosive	Representative	Digestive Enzymes(+)					
			Pancreatin	C				
			Glyburide	C				

Date:07/03/02ISR Number: 3944914-5Report Type:Expedited (15-DaCompany Report #A-US2001-00176
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Blood Creatinine Increased Blood Potassium Increased Blood Urea Increased Cardiac Failure Drug Level Above Therapeutic Dyspnoea Fluid Retention International Normalised Ratio Increased Laboratory Test Abnormal Malaise Renal Impairment Syncope Ventricular Hypokinesia Weight Increased	Study Health Professional	Tracleer (Bosentan Tablet 62.5 Mg)Tracleer(Bosentan)Tablet Vioxx (Rofecoxib) Digoxin (Digoxin) Coumadin (Warfarin Sodium) Lasix(Furosemide)	PS SS C C C		ORAL	62.5 MG, BID, ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/02ISR Number: 3945034-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02268
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Altace	C				
			Cardizem	C				
			Prinivil	C				

Date:07/04/02ISR Number: 3944118-6Report Type:Expedited (15-DaCompany Report #A-US2001-00176
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Study	Tracleer (Bosentan					
	Cardiac Failure	Health	Tablet 62.5 Mg)					
	Congestive	Professional	Tablet	PS		ORAL	62.5 MG, BID, ORAL	
	Dyspnoea Exacerbated							
	Fluid Retention		Vioxx (Rofecoxib)	SS				
	Renal Impairment		Digoxin	C				
	Syncope		Coumadin (Warfarin Sodium)	C				
			Lasix (Furosemide)	C				

Date:07/05/02ISR Number: 3943863-6Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00194
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dizziness		Aspirin	SS		ORAL		
	Duodenitis		Ibuprofen	SS		ORAL		
	Gastric Ulcer Haemorrhage		Propranolol Hydrochloride	C		ORAL		
	Gastric Ulcer		Pantoprazole Sodium	C		ORAL		
	Helicobacter							
	Gastritis Erosive							
	Haematocrit Decreased							

Haemoglobin Decreased

Date:07/05/02ISR Number: 3943866-1Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00008
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		371 DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C				
Other								

Date:07/05/02ISR Number: 3943867-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA03631
Age: Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Arrhythmia
	Cardiac Disorder
	Difficulty In Walking
	Discomfort
	Dyspnoea
	General Physical Health

	Deterioration						
	Headache						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
			Diltiazem Hydrochloride	C				

Date:07/05/02ISR Number: 3943868-5Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00175
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS		ORAL	284	DAY
Hospitalization -	Liver Function Test		Flupirtine Maleate	SS	Merck & Co., Inc	ORAL	109	DAY
Initial or Prolonged	Abnormal							

Date:07/05/02ISR Number: 3943869-7Report Type:Expedited (15-DaCompany Report #WAES 0205ITA00052
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Crepitations		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Duodenal Ulcer		Sinemet	C			1	YR
Initial or Prolonged	Haemorrhage		Paroxetine Hydrochloride	C			1	YR
	Dyspnoea							
	Fatigue		Nitroglycerin	C			1	YR
	Haemoglobin Decreased		Valsartan	C				
	Micturition Disorder		Furosemide	C				
	Oedema Peripheral		Benserazide Hydrochloride And Levodopa	C				
	Shock		Digoxin	C				
			Aspirin	C				

Date:07/05/02ISR Number: 3943873-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease Coronary Artery Occlusion		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:07/05/02ISR Number: 3943875-2Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00013
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Perforation Gastric Ulcer Gastrointestinal Necrosis Intestinal Ischaemia		Vioxx Etanercept Cortisone	SS C C		ORAL		

Date:07/05/02ISR Number: 3943877-6Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Sodium Folate	C		ORAL		
			Goserelin Acetate	C				
Disability			Cyproterone Acetate	C		ORAL		
Other			Methotrexate	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:07/05/02ISR Number: 3943879-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00040
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Folic Acid	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Cyproterone Acetate	C		ORAL		

Date:07/05/02ISR Number: 3943883-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA00232
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	139	DAY
			Prinivil	C		ORAL		
			Megestrol Acetate	C				
			Furosemide	C				
			Norvasc	C				
			Zoloft	C				

Date:07/05/02ISR Number: 3943884-3Report Type:Expedited (15-DaCompany Report #WAES 0207ITA00003
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Melaena							

Date:07/05/02ISR Number: 3943886-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA00167
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Oxycontin	C				

Date:07/05/02ISR Number: 3943888-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA00252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/02ISR Number: 3944910-8Report Type:Expedited (15-DaCompany Report #WAES 01072467
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/ORAL	
	Coma	Health Professional	Ibuprofen	C				
	Coronary Artery Atherosclerosis							
	Gastritis Haemorrhagic							
	Glomerulosclerosis							
	Hepatic Congestion							
	Hepatic Steatosis							
	Myocardial Fibrosis							
	Pancreatic Disorder							
	Pulmonary Congestion							
	Pulmonary Oedema							

Date:07/05/02ISR Number: 3944968-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA00950
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplopia	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
	Ivth Nerve Paralysis		Coumadin	C				
		Company Representative	Lipitor	C				
			Monopril	C				

Date:07/05/02ISR Number: 3944969-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00595
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:07/05/02ISR Number: 3945644-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombotic Stroke	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/05/02ISR Number: 3945664-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01627
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL	
		Company Representative	Lopid	C				

Date:07/05/02ISR Number: 3945686-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Embolism Myocardial Infarction	Other	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/05/02ISR Number: 3945689-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02885
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Hospitalization - Initial or Prolonged	Biopsy Kidney Abnormal	Professional Company Representative	[Therapy Unspecified] Unk	SS				
Disability	Blood Culture Positive		Plaquenil	C				
Other	Blood Potassium Increased		Verapamil	C				
	Bradycardia							
	Cold Sweat							
	Colitis							
	Condition Aggravated							
	Cyanosis							
	Diverticulum Intestinal							
	Dyspnoea							
	Escherichia Infection							
	Fibrosis							
	Gastritis							
	Haematocrit Decreased							
	Hypertension							
	Inflammation							
	Mitral Valve Incompetence							
	Pulmonary Valve Incompetence							
	Pyelonephritis							
	Renal Cyst							
	Renal Failure Acute							
	Renal Tubular Disorder							
	Tricuspid Valve Incompetence							
	Tubulointerstitial Nephritis							
	Urosepsis							

Date:07/05/02ISR Number: 3945692-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02620
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Disorder							

Date:07/05/02ISR Number: 3945694-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02360
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Metaphyllin	C				
			Ms Contin	C				

Date:07/05/02ISR Number: 3945695-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02108
Age:61 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Haemorrhage
	Hypotension
	Myocardial Infarction
	Myocarditis
	Ulcer
	Upper Gastrointestinal

Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Celebrex Unk	SS		ORAL	200 MG/BID/PO	
			Avapro	C				
			Demadex	C				
			Lipitor	C				
			Neurontin	C				
			Premarin	C				
			Ultram	C				
			Zanaflex	C				
			Clonidine	C				

Date:07/05/02ISR Number: 3945699-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02027
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Treatment Noncompliance	Health Professional						

Date:07/05/02ISR Number: 3945701-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02437
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/05/02ISR Number: 3945727-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02213
Age:75 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Asthenia

Other	Atrial Flutter Blood Thyroid Stimulating Hormone Increased Cardiac Failure Congestive Cardiomegaly Ejection Fraction Decreased Electrocardiogram St-T Change Fatigue Heart Rate Increased Hypertension Hypertensive Heart Disease Hypoglycaemia Joint Swelling Obstructive Airways Disorder Respiratory Rate Increased Supraventricular Extrasystoles Upper Respiratory Tract

Infection
Ventricular Extrasystoles

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Company Representative	Coreg	C				
	Glucophage	C				
	Lasix (Furosemide Sodium)	C				
	Levaquin	C				
	Micro K	C				
	Synthroid	C				
	Folic Acid	C				
	Glyburide	C				

Date:07/05/02ISR Number: 3945729-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia	Consumer	Tab Vioxx	PS		ORAL	PO	
	Asthenia	Company Representative						
	Coma							
	Oral Intake Reduced							
	Transient Ischaemic Attack							

Date:07/05/02ISR Number: 3945754-3Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS				
	Blood Pressure Increased							
	Fluid Retention							
	Joint Swelling							
	Migraine							
	Weight Increased							

Date:07/05/02ISR Number: 3946041-XReport Type:Expedited (15-DaCompany Report #WAES 01098248
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Renal Failure	Foreign Other	Tab Zocor (Simvastatin)	PS		ORAL	80 MG/DAILY	46 DAY
Disability	Rhabdomyolysis		Tab Rofecoxib	SS		ORAL	25 MG DAILY	
Other							PO	366 DAY
			Amiodarone Hydrochloride	C				
			Aspirin	C				
			Furosemide Sodium	C				
			Lisinopril	C				
			Phenprocoumon	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/02ISR Number: 3946060-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00067
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Foreign	Tab Vioxx					
	Dyspnoea	Other	(Rofecoxib)	PS		ORAL	PO	
	Generalised Oedema		Furosemide	C				

Date:07/05/02ISR Number: 3946065-2Report Type:Expedited (15-DaCompany Report #WAES 0206CHE00024
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Foreign	Tab Vioxx					
	Haematemesis	Other	(Rofecoxib)	PS		ORAL	150 MG/DAILY	
	Mucous Membrane Disorder						PO	
	Overdose							

Date:07/05/02ISR Number: 3946070-6Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00051
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Foreign	Tab Vioxx					
Hospitalization -		Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional						
							PO	7 DAY
			Acetaminophen/Codeine Phosphate	C				
			Lorazepam	C				
			Smectite	C				

Date:07/05/02ISR Number: 3946083-4Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00180
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Foreign	Tab Vioxx(Rofecoxib)	PS		ORAL	PO	
Life-Threatening	Oedema Peripheral	Other						
Hospitalization - Initial or Prolonged								

Date:07/05/02ISR Number: 3946086-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00150
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Acetaminophen/Codein e Phosphate	C				
			Calcium Carbonate (+) Cholecalciferol	C				
			Morphineso4	C				

Date:07/05/02ISR Number: 3946362-0Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00013
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Duodenal Stenosis Gastrointestinal

	Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign Health Professional	Tab Vioxx (Rofecoxib) Pantoprazole Sodium	PS C				

Date:07/05/02ISR Number: 3946363-2Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00064
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	15 DAY
	Dyspnoea		Acetaminophen	C				
	Fatigue							
	Gastrointestinal Ulcer							
	Melaena							

Date:07/05/02ISR Number: 3946365-6Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00066
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	45 DAY	
	Blood Creatinine Increased		Hydrochlorothiazide (+) Irbesartan	SS		ORAL	45 DAY	
	Renal Impairment		Allopurinol	C				
			Aspirin Lysine	C				
			Digoxin	C				
			Fluoxetine Hcl	C				
			Ginkgo Biloba Extract	C				

Date:07/05/02ISR Number: 3946391-7Report Type:Expedited (15-DaCompany Report #WAES 01023401
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyoderma Gangrenosum	Foreign	Tab Mk-0966	PS		ORAL	50 MG/DAILY	409 DAY
Initial or Prolonged		Study	Placebo	SS				409 DAY
		Health Professional Other	Hydroxychloroquine So4	C				

Date:07/05/02ISR Number: 3946422-4Report Type:Expedited (15-DaCompany Report #WAES 0206ESP00028
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Gastritis	Health					PO	10 DAY
	Haematemesis	Professional	Diclofenac Na	C				
	Heart Rate Increased	Other	Verapamil	C				
	Myocardial Infarction							
	Pericardial Haemorrhage							
	Vomiting							

Date:07/05/02ISR Number: 3946425-XReport Type:Expedited (15-DaCompany Report #WAES 0203GBR00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Foreign	Vioxx					
Hospitalization -	Hypertension	Health	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged		Professional					PO	
Disability		Other	Cyproterone Acetate	C				
Other			Goserelin Acetate	C				
			Methotrexate	C				
			Sodium Folate	C				

Date:07/05/02ISR Number: 3946428-5Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Convulsion	Health					PO	7 DAY
	Drug Interaction	Professional	Phenobarbital	SS		ORAL	SEE IMAGE	
	Drug Level Below Therapeutic	Other	Furosemide	C				
			Nicergoline	C				
			Potassium Chloride	C				
			Trimetazidine Hydrochloride	C				

Date:07/05/02ISR Number: 3946430-3Report Type:Expedited (15-DaCompany Report #WAES 01023401
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chills	Foreign	Tab Mk-0966	PS		ORAL	50 MG/DAILY	409 DAY
Initial or Prolonged	Pyoderma Gangrenosum	Study	Placebo					
	Pyrexia	Health	(Unspecified)	SS			409 DAY	
	Wound Infection	Professional	Hydroxychloroquine					

		Other	So4	C

Date:07/08/02ISR Number: 3944262-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/02ISR Number: 3944263-5Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00058
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
	Face Oedema	Professional	Vasotec	C		ORAL		
	Herpes Zoster Ophthalmic		Vinburnine	C		ORAL		
	Photosensitivity Reaction							

Date:07/09/02ISR Number: 3944935-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA00294
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/02ISR Number: 3944938-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA00185
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/02ISR Number: 3945163-7Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00048
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depressed Level Of		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Consciousness		Bromelains	C		ORAL	42	DAY
	Dizziness		Magnesium					
	Face Oedema		(Unspecified)	C		ORAL	57	DAY
	Illusion		Arnica	C		ORAL	6	DAY
	Tongue Oedema							

Date:07/09/02ISR Number: 3945165-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	269	DAY
Initial or Prolonged	Drug Ineffective		Vioxx	SS		ORAL	166	DAY
	Dysphonia		Claritin-D	C		ORAL		
	Headache		Tums	C				
	Meningitis Viral		Lorcet 10/650	C				
	Musculoskeletal Stiffness		Ultracet	C		ORAL		
	Photopsia							
	Sinusitis							
	Thirst							
	Upper Respiratory Tract Infection							

Date:07/09/02ISR Number: 3945170-4Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00056
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glimepiride	C		ORAL		
			Digoxin	C		ORAL		
			Benfluorex Hydrochloride	C		ORAL		
			Acenocoumarol	C		ORAL		

Date:07/09/02ISR Number: 3945171-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01732
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/02ISR Number: 3945172-8Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00031
Age:40 YR Gender:Female I/FU:I

Outcome	PT
Other	Asthenia
	Chest Pain

	Constipation						
	Diarrhoea						
	Flatulence	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Pollakiuria						
	Somnolence						

Date:07/09/02ISR Number: 3945174-1Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00037
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
Initial or Prolonged	Osteomyelitis							
Disability								

Date:07/09/02ISR Number: 3945175-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00016
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Drug Interaction		Phenobarbital	SS		ORAL		
			Phenobarbital	SS		ORAL		
			Phenobarbital	SS		ORAL		
			Furosemide	C				
			Potassium Chloride	C				
			Nicergoline	C				
			Trimetazidine Hydrochloride	C				

Date:07/09/02ISR Number: 3945179-0Report Type:Expedited (15-DaCompany Report #WAES 0207ESP00007
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 1 YR	Haematemesis	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Melaena	Vaseretic	C		
		Diltiazem Hydrochloride	C		

Date:07/09/02ISR Number: 3945181-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00109
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastritis		Aspirin	SS		
Initial or Prolonged	Gastrointestinal		Levoxyl	C		
Disability	Haemorrhage		Ferrous Sulfate	C		ORAL
Other	Peptic Ulcer		Protein (Unspecified)	C		
			Risperdal	C		ORAL
			Peri-Colace	C		
			Hydrodiuril	C		ORAL
			Aricept	C		ORAL
			Magnesia [Milk Of]	C		
			Zoloft	C		ORAL
			Vasotec	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/02ISR Number: 3945183-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01431
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	257	DAY
Hospitalization - Initial or Prolonged	Dyspepsia		Premarin	C				
Other	Myocardial Infarction							
	Oedema Peripheral							

Date:07/09/02ISR Number: 3945192-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00426
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/02ISR Number: 3945456-3Report Type:Direct Company Report #CTU 171904
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL	25MG PO QD	
Hospitalization - Initial or Prolonged			Clopidogrel	C				
			Captopril	C				
			Heparin	C				
			Nitroglycerin	C				

Date:07/09/02ISR Number: 3945457-5Report Type:Direct Company Report #CTU 171905
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 12.5mg Tabs	PS		ORAL	12.5MG PO QD	
			Asa	C				
			Zyrtec	C				
			Prozac	C				

			Lasix	C		
			Glimepiride	C		
			Ativan	C		
			Lopressor	C		
			Ntg	C		
			Protonix	C		
			Kcl	C		
			Zocor	C		
			Apap	C		
			Reglan	C		
			Morphine	C		
			Promethasine	C		

Date:07/09/02ISR Number: 3945709-9Report Type:Direct Company Report #CTU 171867
Age:8 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Rofecoxib	PS		ORAL	12.5 MG PO QD	
	Increased		Sucralfate	C				
	Gastritis		Ranitidine	C				
			Oxybutynin	C				
			Ceftazidime	C				
			Metronidazole	C				
			Omeprazole	C				

				Fluconazole	C		
				Ampicillin	C		

Date:07/09/02ISR Number: 3945908-6Report Type:Direct Company Report #CTU 171922
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis		Rofecoxib (Vioxx)	PS		ORAL	12.5MG PO	
	Upper Gastrointestinal						BID, 25MG PO	
	Haemorrhage						BID	
			Clozaril	C				
			Depakote	C				
			Klonopin	C				
			Premarin	C				
			Levothroxine	C				
			Benztropine	C				
			Atenolol	C				
			Prolixin	C				
			Vit E	C				
			Glucosamine	C				
			Detrol	C				
			Pei Colace	C				
			Ddavp	C				
			Tums	C				

Date:07/09/02ISR Number: 3947156-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Cardiomegaly	Health	[Therapy					
	Carotid Artery Stenosis	Professional	Unspecified]	C				
	Coronary Artery Disease							
	Hypoventilation							
	Loss Of Consciousness							
	Myocardial Infarction							
	Pleural Effusion							

Pneumothorax

Date:07/09/02ISR Number: 3947159-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA00249
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anaemia
Disability	Asthenia
Other	Bile Duct Obstruction
	Blood Alkaline
	Phosphatase Increased
	Blood Potassium Increased
	Candidiasis
	Cholecystitis Acute
	Decreased Appetite
	Faeces Discoloured
	Gastric Ulcer
	Gastrointestinal
	Haemorrhage

		Hypertension					
		Leukocytosis					
		Lipase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Melaena	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/BID/PO							
		Metabolic Acidosis	Professional	Celebrex	C		
		Pallor	Company	Hydrodiuril	C		
		Peptic Ulcer	Representative	Nexium	C		
		Platelet Count Increased		Iron	C		
		Respiratory Rate		Nadolol	C		
		Increased					
		Weight Decreased					

Date:07/10/02ISR Number: 3945843-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02474
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
367 DAY						
			Plavix	C		
			Glucophage	C		
			Insulin	C		
			Hydrocodin	C		
			Captopril	C		
			Pravachol	C		

Date:07/10/02ISR Number: 3945852-4Report Type:Expedited (15-DaCompany Report #WAES 0207CHE00015
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
	Liver Disorder		Aspirin	SS		ORAL
1 YR						
			Atorvastatin Calcium	SS		ORAL
378 DAY						
			Bisoprolol Fumarate	C		ORAL
1 YR						

Date:07/10/02ISR Number: 3945854-8Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Dyspnoea							
	Ear Pain							
	Insomnia							
	Laryngeal Disorder							
	Tongue Blistering							
	Tongue Oedema							

Date:07/10/02ISR Number: 3945857-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00532
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Zocor	PS	Merck & Co., Inc	ORAL		
	Hepatic Failure		Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/02ISR Number: 3946120-7Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Akathisia		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Facial Palsy		Vioxx	SS		ORAL		3 DAY
Disability	Fall		Vioxx	SS		ORAL		
	Fracture Nonunion		Vioxx	SS		ORAL		7 DAY
	Haematochezia		Aristocort	C			PARENTERAL	1 DAY
	Haemorrhagic Stroke		Ziac	C		ORAL		
	Radius Fracture		Hyzaar	C		ORAL		
			Zoloft	C		ORAL		
			Tiazac	C				

Date:07/10/02ISR Number: 3946122-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02599
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Back Pain		Keflex	C				
	Claustrophobia		Micronor	C		ORAL		
	Dyspnoea							
	Pharyngolaryngeal Pain							

Date:07/10/02ISR Number: 3946125-6Report Type:Expedited (15-DaCompany Report #WAES 0205AUS00153
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
	Atherosclerosis		Fluticasone					
	Myocardial Ischaemia		Propionate And					
	Nausea		Salmeterol Xinafoate	C			RESPIRATORY	

	Vomiting						
(INHALATION)							
			Albuterol Sulfate	C			
RESPIRATORY							
(INHALATION)							
			Acetaminophen And Codeine Phosphate	C			ORAL
			Budesonide	C			

Date:07/10/02ISR Number: 3946128-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00127
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nail Discolouration		Vioxx	PS	Merck & Co., Inc	ORAL	197	DAY
	Nail Disorder		Climara	C		ORAL		
			Reglan	C		ORAL		
			Xanax	C		ORAL		
			Klonopin	C		ORAL		

Date:07/10/02ISR Number: 3946137-2Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00048
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Folic Acid	C		ORAL		
			Morphine Sulfate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/02ISR Number: 3946140-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA00526
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	31	WK
Initial or Prolonged	Haematemesis		Hyzaar	C				
	Ulcer							

Date:07/10/02ISR Number: 3946141-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA00523
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vasotec	C				
			Estrogens (Unspecified)	C				
			Neurontin	C				

Date:07/10/02ISR Number: 3946256-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA03555
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine Abnormal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Urea Increased	Professional					MG/DAILY/PO	
Other	Faeces Discoloured	Company	Tab Fosamax 70 Mg	SS		ORAL	70 MG/WKY/PO	
	Fatigue	Representative	Accupril	C				
	Gastric Ulcer		Neurontin	C				
	Gastric Ulcer Haemorrhage		Prilosec	C				
	Haematemesis		Procardia	C				
	Haematocrit Decreased		Aspirin	C				
	Haemoglobin Decreased		Doxepin	C				
	Heart Rate Increased							
	Mallory-Weiss Syndrome							
	Nausea							
	Osteoporosis							
	Pallor							

Date:07/10/02ISR Number: 3946392-9Report Type:Direct Company Report #CTU 171949
Age:97 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure		Cozaar 100 Mg Qd	PS				
			Vioxx	SS				

Date:07/10/02ISR Number: 3946516-3Report Type:Direct Company Report #CTU 172006
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS				

Date:07/11/02ISR Number: 3946618-1Report Type:Expedited (15-DaCompany Report #WAES 0207ISR00008
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/02ISR Number: 3946621-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01839
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peripheral Embolism		Vioxx	PS		ORAL		
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Cozaar	C		ORAL		
			Prempro	C				
			Pyridoxine	C				
			Cyanocobalamin	C				
			Folic Acid	C				
			Vitamin E	C				
			Imitrex	C				
			Zestril	C				
			Aspirin	C				
			Chondroitin And Glucosamine	C				

Date:07/11/02ISR Number: 3946622-3Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rheumatoid Arthritis		Ibuprofen	C				
			Ibuprofen	C				

Date:07/11/02ISR Number: 3946623-5Report Type:Expedited (15-DaCompany Report #WAES 0206PRT00002
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Hypertension		Hydrochlorothiazide And Irbesartan	SS		ORAL		

Date:07/11/02ISR Number: 3946625-9Report Type:Expedited (15-DaCompany Report #WAES 0204DEU00084
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Stress Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	28 DAY	
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Clomipramine	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Flupirtine	C		ORAL	30 DAY	

Date:07/11/02ISR Number: 3946629-6Report Type:Expedited (15-DaCompany Report #WAES 0207ESP00018
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventricular Arrhythmia		Bisoprolol Fumarate	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/02ISR Number: 3946899-4Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00107
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Life-Threatening			Lorazepam	C		ORAL		
Hospitalization - Initial or Prolonged			Omeprazole	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		

Date:07/11/02ISR Number: 3946903-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00284
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/02ISR Number: 3948601-9Report Type:Expedited (15-DaCompany Report #HQ3150509JUL2002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder	Health Professional Other	Protium (Pantoprazole, Unspec)	PS			"A WHILE"	
	Hepatocellular Damage							
	Jaundice		Vioxx (Rofecoxib, Tablet)	SS			ONCE DAILY	

Date:07/11/02ISR Number: 3950247-3Report Type:Expedited (15-DaCompany Report #WAES 01080220
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blepharitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Cardiac Disorder	Health		
MG/DAILY/PO				
	Cartilage Injury	Professional	Celebrex Unk	SS
	Chest Pain		Allegra	C
	Chondromalacia		Celexa	C
	Diabetes Mellitus		Pravachol	C
	Diverticulum		Prinivil	C
	Drug Ineffective		Toprol Xl Tablets	C
	Haemoglobin Decreased		Zantac	C
	Nausea		Zestril	C
	Osteoarthritis		Aspirin	C
	Sinus Arrhythmia			
	Sinus Bradycardia			
	Synovitis			
	Vertigo			

Date:07/11/02ISR Number: 3950304-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	No Adverse Drug Effect	Consumer	Vioxx	PS		ORAL
PO						
Initial or Prolonged		Health				
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/02ISR Number: 3950308-9Report Type:Expedited (15-DaCompany Report #WAES 01080219
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged	Blood Pressure Increased	Health	Celebrex Unk	SS				
Disability	Body Temperature	Professional	Amaryl	C				
	Decreased		Darvocet-N	C				
	Cardiac Disorder		Humulin	C				
	Cardiac Murmur		Neurontin	C				
	Carotid Bruit		Peri-Colace	C				
	Cholelithiasis		Aspirin	C				
	Dyspnoea Exacerbated		Verapamil	C				
	Femoral Bruit		Vitamins					
	Hypersensitivity		(Unspecified)	C				
	Hyporeflexia							
	Intermittent Claudication							
	Muscle Atrophy							
	Myocardial Ischaemia							
	Post Procedural							
	Complication							
	Pulse Absent							
	Renal Failure							
	Subclavian Artery							
	Stenosis							
	Tinnitus							
	Vascular Graft Occlusion							
	Ventricular Hypokinesia							

Date:07/12/02ISR Number: 3947518-3Report Type:Expedited (15-DaCompany Report #WAES 0207CAN00029
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/02ISR Number: 3947522-5Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00065
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Lansoprazole	C		ORAL
			Acetaminophen And Codeine Phosphate	C		ORAL
			Penicillamine	C		ORAL

Date:07/12/02ISR Number: 3947669-3Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00078
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
	Oedema Peripheral		Tramadol Hydrochloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/02ISR Number: 3947678-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA00707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Drug Interaction		Norvasc	SS				
			Captopril	SS				
			Tenormin	SS				
			Lipitor	C				
			Aspirin	C				

Date:07/12/02ISR Number: 3949010-9Report Type:Expedited (15-DaCompany Report #001-0981-M0201152
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Atorvastatin					
Other	Arthralgia	Health	(Atorvastatin)	PS		ORAL	20 MG DAILY,	
	Dialysis	Professional						
	Drug Interaction		Amlodipine	SS			10 MG	
	Erythema Multiforme		Celecoxib					
	Haemorrhage		(Celecoxib)	SS				
	Myalgia		Clonazepam					
	Pain		(Clonazepam)	SS				
	Paresis		Cyclobenzaprine					
	Rash		(Cyclobenzaprine)	SS				
	Renal Failure		B Complex (Becosym					
	Restless Legs Syndrome		Forte)	SS				
	Skin Disorder		Rofecoxib					
			(Rofecoxib)	SS				
			Paricalcitol					
			(Paricalcitol)	SS				
INTRAVENOUS	INTRAVENOUS							
			Various Medications	SS				
			Humulin N (Insulin					
			Human Injection,					
			Isophane)	SS				
SUBCUTANEOUS	SUBCUTANEOUS							
			Imuran					
			(Azathioprine)	SS				

Prednisone (Prednisone)	SS
Furosemide (Furosemide)	SS
Cyclosporine (Ciclosporin)	SS
Clonidine (Clonidine)	SS
Metoprolol Succinate (Metoprolol Succinate)	SS
Bisoprolol Fumarate (Bisoprolol Fumarate)	SS

Date:07/15/02ISR Number: 3948042-4Report Type:Expedited (15-DaCompany Report #WAES 0207MYS00005
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Duodenitis
	Gastric Haemorrhage
	Oesophageal Ulcer

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:07/15/02ISR Number: 3948044-8Report Type:Expedited (15-DaCompany Report #WAES 0205ZAF00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Full Blood Count Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Antineoplastic (Unspecified)	SS				

INTRAVENOUS

Date:07/15/02ISR Number: 3948045-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00140
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
Hospitalization -			Nifedipine	C		ORAL		
Initial or Prolonged								

Date:07/15/02ISR Number: 3948050-3Report Type:Expedited (15-DaCompany Report #WAES 0207SWE00003
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ventricular Extrasystoles	Health	Vioxx	PS	Merck & Co., Inc	ORAL	79	DAY
Initial or Prolonged		Professional						

Date:07/15/02ISR Number: 3948237-XReport Type:Expedited (15-DaCompany Report #WAES 0207GBR00076
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL	79 DAY	
			Furosemide	C		ORAL		
			Omeprazole	C		ORAL		

Date:07/15/02ISR Number: 3948238-1Report Type:Expedited (15-DaCompany Report #WAES 01113486
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscular Weakness		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Initial or Prolonged	Renal Failure Acute		Lisinopril	SS			445 DAY	
			Levothyroxine Sodium	C				
			Nortriptyline Hydrochloride	C			77 DAY	
			Chlorthalidone	C			78 DAY	
			Lorazepam	C				

Date:07/15/02ISR Number: 3948239-3Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00087
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/15/02ISR Number: 3948240-XReport Type:Expedited (15-DaCompany Report #WAES 0204CAN00153
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/02ISR Number: 3948241-1Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00002
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL	90	DAY
Initial or Prolonged	Thrombocytopenia		Fosamax	SS		ORAL	90	DAY

Date:07/15/02ISR Number: 3948242-3Report Type:Expedited (15-DaCompany Report #WAES 0207NZL00024
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematemesis		Warfarin	C		ORAL		
			Atorvastatin	C		ORAL		
			Cilazapril	C		ORAL		
			Furosemide	C		ORAL		

Date:07/15/02ISR Number: 3948243-5Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00066
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
	Faeces Discoloured		[Therapy Unspecified]	C		

Date:07/15/02ISR Number: 3948245-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01879
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Faecal Occult Blood		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Ulcer Haemorrhage		Temazepam	C		
Disability	Haematemesis		Avandia	C		
Other	Haematocrit Decreased		Epogen	C		
	Haemoglobin Decreased		Iron (Unspecified)	C		
	Hypovolaemia		Tums	C		
	Oedema		Nephrocaps	C		
	Pulse Abnormal		Lopid	C		
			Lipitor	C		
			Neurontin	C		
			Aspirin	C		
			Oxygen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/02ISR Number: 3948246-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01883
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Vioxx	SS		ORAL		
Other	Congestive		Buspar	C		ORAL		
	Hypertension		Synthroid	C				
			Norvasc	C				
			Zestril	C				
			Atenolol	C				

Date:07/15/02ISR Number: 3948247-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Aleve	C		ORAL		
	Blood Sodium Decreased		Vicodin Tablets	C		ORAL		
	Bronchitis		Oxycontin	C		ORAL		
	Cardiac Failure		Ultram	C		ORAL		
	Congestive		Ceftin	C		ORAL		
	Cardiomegaly		Mevacor	C		ORAL		
	Cardiomyopathy		Aspirin	C		ORAL		
	Coronary Artery Disease		Lipitor	C		ORAL		
	Drug Effect Decreased		[Therapy					
	Haemoglobin Abnormal		Unspecified]	C				
TOPICAL								
	Hypochromasia							
	Immobile							
	Insomnia							
	Laboratory Test Abnormal							
	Myocardial Infarction							
	Oedema Peripheral							
	Onychomycosis							
	Pleural Effusion							
	Pneumonia							
	Pulmonary Embolism							
	Pulmonary Oedema							
	Red Blood Cell Count Decreased							
	Sinus Tachycardia							
	Ventricular Extrasystoles							

Ventricular Fibrillation
Ventricular Hypokinesia

Date:07/15/02ISR Number: 3948248-4Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00018
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hypoglycaemia		Althiazide And			
Initial or Prolonged	Lactic Acidosis		Spironolactone	SS		ORAL
	Renal Failure Acute		Metformin			
			Hydrochloride	SS		ORAL
			Colchicine	SS		ORAL
			Colchicine And			
			Opium, Powdered And			
			Tiemonium			
			Methylsulfate	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/02ISR Number: 3948547-6Report Type:Direct Company Report #CTU 172322
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx 25mg Qd	PS		ORAL	25MG QD PO	
			Zestril	C				
			Serevent	C				
			Flovent	C				
			Prilosec	C				

Date:07/16/02ISR Number: 3948719-0Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00098
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Electrocardiogram Change		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Hyperventilation							
	Palpitations							

Date:07/16/02ISR Number: 3948720-7Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00008
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	118	DAY
	Gastric Ulcer		Aspirin And Magnesium Oxide	C		ORAL		
	Haemoglobin Decreased		Acetaminophen	C				
	Melaena		Amlodipine Besylate	C				
	Syncope		Tramadol Hydrochloride	C				
			Zopiclone	C				

Date:07/16/02ISR Number: 3948721-9Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00088
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Increased Blood Pressure Increased Fluid Retention Oedema		Vioxx	SS		ORAL		

Date:07/16/02ISR Number: 3948726-8Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY
Initial or Prolonged	Haemoglobin Decreased Melaena		Aspirin And Magnesium Oxide	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Fosamax	C				
			Calcium (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3948727-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA00269
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastrointestinal		Aspirin	C				
Initial or Prolonged	Haemorrhage		Levoxyl	C				
Other	Peptic Ulcer		Procardia Xl	C				
			Lipitor	C				
			Hydrodiuril	C				

Date:07/16/02ISR Number: 3948731-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA01031
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Death							
	Hypertension							
	Rash							
	Tinnitus							
	Toothache							
	Weight Increased							

Date:07/16/02ISR Number: 3948732-3Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00102
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage							
Initial or Prolonged								

Date:07/16/02ISR Number: 3948733-5Report Type:Expedited (15-DaCompany Report #WAES 0207CHE00025
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 9 DAY	Dermatitis Bullous	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Clavulanate Potassium And Amoxicillin Trihydrate	SS		ORAL
Other		Clarithromycin	SS		ORAL
9 DAY		Tizanidine	C		ORAL
8 DAY		Atenolol	C		
		Aspirin	C		
		Esomeprazole Magnesium	C		
		Pravastatin Sodium	C		
		Mianserin Hydrochloride	C		

Date:07/16/02ISR Number: 3948734-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA00621
Age:40 YR Gender:Male I/FU:I

Outcome	PT
Other	Erectile Dysfunction
	Gastrointestinal Haemorrhage
	Haemochromatosis

Suicidal Ideation

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			Percocet	C				
			Valium	C				

Date:07/16/02ISR Number: 3948735-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA00994
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Neurontin	C				
	Feeling Abnormal		[Therapy Unspecified]	C				

Date:07/16/02ISR Number: 3948737-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA01011
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	84	DAY
Initial or Prolonged	Melaena		Aspirin	C				

Date:07/16/02ISR Number: 3948875-4Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00101
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Increased	Professional	Tramadol Hydrochloride	C				
Disability			Torsemide	C				
			Metoclopramide	C				
			Fenoterol Hydrobromide	C				

				Budesonide	C		
				Calcium Carbonate And Cholecalciferol And Sodium (Unspecified)	C		
				Insulin Human	C		
				Certoparin Sodium	C		
				Levothyroxine Sodium	C		
				Aspirin	C		
				Isosorbide Dinitrate	C		
				Dihydrotachysterol	C		ORAL

Date:07/16/02ISR Number: 3948876-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02360
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Ms Contin	C		
			Metaphyllin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3948877-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Cardiomegaly Carotid Artery Stenosis Chest Pain Chest X-Ray Abnormal Coronary Artery Disease Coronary Artery Occlusion Dyspnoea Exertional Electrocardiogram St Segment Abnormal Heart Rate Decreased Influenza Like Illness Ischaemic Cardiomyopathy Loss Of Consciousness		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:07/16/02ISR Number: 3948879-1Report Type:Expedited (15-DaCompany Report #WAES 01105017
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Late Onset	Health Professional	Vioxx Vioxx [Therapy Unspecified]	PS SS C	Merck & Co., Inc	ORAL ORAL		

Date:07/16/02ISR Number: 3948880-8Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00031
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Epistaxis International Normalised Ratio Increased	Health Professional	Vioxx Acenocoumarol	PS SS	Merck & Co., Inc	ORAL ORAL		

Date:07/16/02ISR Number: 3948882-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03593
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction	Professional	Cartia (Diltiazem					
Initial or Prolonged			Hydrochloride)	C				
			Prinivil	C		ORAL		
			Zocor	C		ORAL		
			Propranolol	C				
			Metoprolol Tartrate	C				

Date:07/16/02ISR Number: 3948883-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01017
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoaesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Paraesthesia	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3948888-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA00512
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
Other	Paraesthesia Oral		Flexeril	C				
	Tongue Coated							
	Tongue Oedema							

Date:07/16/02ISR Number: 3948893-6Report Type:Expedited (15-DaCompany Report #WAES 0207ISR00008
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged								

Date:07/16/02ISR Number: 3948894-8Report Type:Expedited (15-DaCompany Report #WAES 0207NZL00024
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematemesis		Warfarin	C		ORAL		
			Atorvastatin	C		ORAL		
			Cilazapril	C		ORAL		
			Furosemide	C		ORAL		

Date:07/16/02ISR Number: 3948897-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00929
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oxygen Saturation		Avandia	C				
	Decreased		Glyburide	C				
			Metformin	C				
			Vitamins					

			(Unspecified)	C		
			Lasix (Furosemide)	C		
			Potassium Chloride	C		
			Baycol	C		
			Synthroid	C		

Date:07/16/02ISR Number: 3948901-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA00526
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	29	WK
Initial or Prolonged	Gastritis		Hyzaar	C				
	Haematemesis							
	Haemorrhage							

Date:07/16/02ISR Number: 3948902-4Report Type:Expedited (15-DaCompany Report #WAES 0207AUS00071
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc			
			Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3948904-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA01097
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Methotrexate	C				
Initial or Prolonged			Arava	C				
Disability								

Date:07/16/02ISR Number: 3949096-1Report Type:Direct Company Report #CTU 172370
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Rofecoxib	PS			25MG QD	2 WK
Initial or Prolonged	Fluid Retention		Warfarin	C				
Required			Aldactazide	C				
Intervention to			Furosemide	C				
Prevent Permanent			Candesartan	C				
Impairment/Damage			Metoprolol Xl	C				
			Potassium	C				

Date:07/16/02ISR Number: 3949109-7Report Type:Direct Company Report #CTU 172390
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Morphine	PS			INTRAVENOUS	6MG IM X 1
Initial or Prolonged	Dizziness		Rofecoxib	SS		ORAL	50MG PO X 1	
Required	Hyperhidrosis							
Intervention to	Loss Of Consciousness							
Prevent Permanent	Tachycardia							
Impairment/Damage	Vomiting							

Date:07/16/02ISR Number: 3949111-5Report Type:Direct Company Report #CTU 172394
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Rofecoxib	PS		ORAL	25MG PO QD	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Blood Potassium Increased		Amiodarone	C				
	Cardiac Failure		Aspirin	C				
	Congestive		Cyanocobalamin	C				
	Fatigue		Famotidine	C				
	Haemodialysis		Ferrous Sulfate	C				
	Lethargy		Furosemide	C				
	Renal Impairment		Metoprolol	C				
	Treatment Noncompliance		Mult Vit	C				
	Weight Increased		Nystatin	C				
			Ramipril	C				
			Panafil	C				
			Simvastatin	C				
			Valsartan	C				

Date:07/16/02ISR Number: 3949137-1Report Type:Direct Company Report #CTU 172362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer		Vioxx	PS			25 MG QD	
	Gastrointestinal		Aspirin	SS			325 MG QD	
	Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/02ISR Number: 3949378-3Report Type:Direct Company Report #CTU 172419
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - 1 A DAY Initial or Prolonged Disability Other	Cerebrovascular Accident Nerve Injury		Vioxx 25mg Merck And Co	PS	Merck And Co			

Date:07/16/02ISR Number: 3950316-8Report Type:Expedited (15-DaCompany Report #2002050989
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Foreign	Atorvastatin					
	Hepatotoxicity	Health	(Atorvastatin)	PS		ORAL	20 MG	ORAL
	Liver Disorder	Professional	Rofecoxib	SS		ORAL	25 MG	ORAL
	Liver Function Test Abnormal	Other	Acetylsalicylic Acid	C				
			Bisoprolol Fumarate	C				

Date:07/17/02ISR Number: 3949623-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA00231
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive	Professional	Pepcid	C		ORAL		
	Dyspnoea		Glucotrol Xl	C				
	Malaise		Vitamins					
	Myocardial Ischaemia		(Unspecified)	C				
	Palpitations							

Date:07/18/02ISR Number: 3950130-3Report Type:Expedited (15-DaCompany Report #WAES 0207NZL00027
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C		ORAL		
			Beclomethasone Dipropionate	C				
RESPIRATORY (INHALATION)								
			Albuterol	C				
RESPIRATORY (INHALATION)								

Date:07/18/02ISR Number: 3950138-8Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00098
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Electrocardiogram Change		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Hyperventilation							
	Palpitations							

Date:07/18/02ISR Number: 3950409-5Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00030
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eczema		Zocor	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Ketoprofen	SS		ORAL		

				Rofecoxib	SS		ORAL

Date:07/19/02ISR Number: 3950891-3Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00105
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Upper Gastrointestinal Haemorrhage		Aspirin	C		ORAL		
			Furosemide	C		ORAL		
			Ramipril	C		ORAL		
			Risedronate Sodium	C		ORAL		

Date:07/19/02ISR Number: 3950892-5Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00106
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/02ISR Number: 3950893-7Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00013
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Perforation		Vioxx	SS		ORAL	4	DAY
Initial or Prolonged	Gastric Ulcer		Diclofenac Sodium	SS				
	Gastrointestinal Necrosis		Etanercept	C		SUBCUTANEOUS		
	Haemoglobin Decreased		Cortisone	C				
	Hepatic Enzyme Increased		Prednisolone	C		ORAL	1	DAY
	Hypertension		Esomeprazole					
	Intestinal Ischaemia		Magnesium	C				
	Musculoskeletal Disorder		Omeprazole	C				
	White Blood Cell Count Increased		Prednisone	C				
			Cholecalciferol	C				
			Butylscopolamine Bromide	C				

Calcium (Unspecified)	C		
Ferrous Glycine Sulfate	C		

Date:07/19/02ISR Number: 3950895-0Report Type:Expedited (15-DaCompany Report #WAES 0207MYS00005
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Gastric Haemorrhage Oesophageal Ulcer Vomiting		Tramadol Hydrochloride	C		ORAL		
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/02ISR Number: 3950896-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA01216
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lovenox	C				

Date:07/19/02ISR Number: 3950897-4Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00108
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		
87 DAY								

Date:07/19/02ISR Number: 3950898-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA01266
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Nausea		Meclizine	C				
Initial or Prolonged	Stomach Discomfort		Acetaminophen And Propoxyphene Hydrochloride	C				
			Accuretic	C				
			Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	C				

Date:07/19/02ISR Number: 3950902-5Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00104
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitic Rash		Vioxx	PS	Merck & Co., Inc	ORAL		
147 DAY								

Date:07/19/02ISR Number: 3950904-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA00836
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Atacand	C				
			Ranitidine	C				
			Hydrochlorothiazide And Triamterene	C				
			Diazepam	C				
			Enbrel	C				

Date:07/19/02ISR Number: 3950906-2Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00129
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
			Sumatriptan Succinate	C				
			Clomipramine Hydrochloride	C				

Date:07/19/02ISR Number: 3950993-1Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00111
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Femoral Neck Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged		Professional	Vioxx	SS		ORAL		

Date:07/19/02ISR Number: 3950994-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc			
	Coronary Artery Disease							
	Heart Rate Irregular							

Date:07/19/02ISR Number: 3950995-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	164	DAY
	Appendicectomy	Professional	Decadron					
	Asthenia		(Dexamethasone)	C		ORAL	10	DAY
	Difficulty In Walking		Prilosec	C				
	Electrocardiogram		Singulair	C		ORAL		
	Abnormal		Serevent	C				
	Fatigue		Bromfed	C				
	Lethargy							
	Muscle Rigidity							
	Nervous System Disorder							
	Oedema Peripheral							
	Vertigo							

Date:07/19/02ISR Number: 3950996-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA01107
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Oedema Confusional State Fluid Retention Medication Error	Health Professional	Vioxx [Therapy Unspecified] [Therapy Unspecified]	PS SS C	Merck & Co., Inc	ORAL		

Date:07/19/02ISR Number: 3951002-0Report Type:Expedited (15-DaCompany Report #WAES 0206MYS00013
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Gastrointestinal Infection Vomiting		Vioxx Omeprazole Vitamins (Unspecified)	PS C C	Merck & Co., Inc	ORAL ORAL	1 DAY	

Date:07/19/02ISR Number: 3951010-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA01287
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/02ISR Number: 3951314-0Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00036
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Initial or Prolonged		Professional	Althiazide And Spironolactone	C		ORAL		
			Fluindione	C				
			Trimetazidine Hydrochloride	C				

Date:07/22/02ISR Number: 3951316-4Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00038
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Escherichia Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Nephritis Interstitial	Professional	Clocinizine	SS		ORAL		13 DAY
	Nephrotic Syndrome		Pholcodine	SS		ORAL		13 DAY
	Renal Failure Acute		Tramadol Hydrochloride	SS		ORAL		20 DAY
			Ibuprofen	SS		ORAL		2 DAY
			Althiazide And Spironolactone	SS		ORAL		145 DAY
			Potassium Bitartrate And Sodium Bicarbonate	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Nomegestrol	C		ORAL		
			Polyethylene Glycol 4000	C		ORAL		
			Bezafibrate	C		ORAL		

Date:07/22/02ISR Number: 3951318-8Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00036
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Consumer	Vioxx	PS	Merck & Co., Inc			
	Blood Pressure Increased							
	Fluid Retention							
	Joint Swelling							
	Migraine							
	Weight Increased							

Date:07/22/02ISR Number: 3951319-XReport Type:Expedited (15-DaCompany Report #WAES 01104899
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cellulitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation		Synthroid	C				
			Prozac	C				
			Pepcid	C				
			Lasix (Furosemide)	C				
			Aspirin	C				
			Diovan	C				
			Lipitor	C				
			Remeron	C				
			K-Dur	C				
			Serevent	C				

			Isordil	C		

Date:07/22/02ISR Number: 3951321-8Report Type:Expedited (15-DaCompany Report #WAES 0207BEL00032
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Malaise	Professional	Eprosartan	C		ORAL
	Syncope		Insulin, Biphasic			
	Trifascicular Block		Isophane [Injection]	C		
SUBCUTANEOUS						
			Nifedipine	C		ORAL
			Furosemide	C		ORAL

Date:07/22/02ISR Number: 3951325-5Report Type:Expedited (15-DaCompany Report #WAES 0207CHE00028
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Pulmonary Embolism	Professional	Infliximab	SS		
PARENTERAL	1 DAY					
			Prednisone	C		ORAL
			Methotrexate	C		ORAL

Date:07/22/02ISR Number: 3951326-7Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00012
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastroduodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
MON						
Initial or Prolonged	Haemoglobin Decreased	Professional	Warfarin Sodium	C		
	Melaena		Acetaminophen	C		ORAL
			Ketoprofen	C		
TOPICAL						
			Lansoprazole	C		ORAL

Date:07/22/02ISR Number: 3951327-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA01084
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		332 DAY
Other	Dyspnoea	Professional	Levoxyl	C				
	Urticaria		E-Mycin	C				
			Plaquenil	C				
			Estropipate	C				
			Cycrin	C				
			Prilosec	C				
			Pepcid Ac	C				
			Zyrtec	C				
			[Therapy Unspecified]	C				

Date:07/22/02ISR Number: 3951328-0Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00013
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Professional	Aspirin And Magnesium Oxide	C				YR
	Melaena							
	Syncope		Hydrochlorothiazide					

And Valsartan	C		
Nitroglycerin	C		ORAL
Metoprolol Tartrate	C		ORAL
Zocor	C		ORAL

Date:07/22/02ISR Number: 3951332-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA01463
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Operative Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/02ISR Number: 3951477-7Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11945748
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoglycaemia		Glucophage Tabs 850 Mg	PS	Bristol-Myers Squibb Company	ORAL		
Other	Lactic Acidosis		Spiroctazine	SS		ORAL		
	Renal Failure Acute		Vioxx	SS		ORAL		
			Colchicine	SS		ORAL		
			Colchimax	C				

Dose Regimen:

3 tabs/day

during 3

days, then 2

tabs/3

Date:07/22/02ISR Number: 3951480-7Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00151
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ascites		Piroxicam	SS		ORAL		

Initial or Prolonged	Blood Cholesterol	Allopurinol	C	ORAL
Other	Increased	Colchicine	C	ORAL
	Blood Pressure Increased	Lansoprazole	C	ORAL
	Dizziness	Atorvastatin Calcium	C	ORAL
	Glomerulonephritis			
	Minimal Lesion			
	Nephrotic Syndrome			
	Oedema			
	Pleural Effusion			
	Weight Increased			

Date:07/22/02ISR Number: 3951482-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aphonia
Initial or Prolonged	Csf White Blood Cell
	Count Positive
	Dizziness
	Drug Ineffective
	Headache
	Immune System Disorder
	Malaise
	Musculoskeletal Stiffness

		Nausea					
		Photopsia					
		Polydipsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thirst		Vioxx	PS	Merck & Co., Inc	ORAL
269	DAY						
		Upper Respiratory Tract		Vioxx	SS		ORAL
166	DAY						
		Infection		Claritin-D	C		ORAL
				Tums	C		
				Lorcet 10/650	C		
				Ultracet	C		ORAL
				Ketorolac	C		
6	DAY						
				Hydrocodone	C		
				Bextra	C		

Date:07/22/02ISR Number: 3951486-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Dermatop	C		
		Blood Creatinine		Zocor	C		ORAL
		Increased		Zantac	C		ORAL
		Cardiomegaly					
		Chest X-Ray Abnormal					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Dilatation Ventricular					
		Heart Rate Decreased					
		Influenza Like Illness					
		Inner Ear Disorder					
		Ischaemic Cardiomyopathy					
		Loss Of Consciousness					
		Monocyte Count Increased					
		Ventricular Hypokinesia					

Date:07/22/02ISR Number: 3951487-XReport Type:Expedited (15-DaCompany Report #WAES 01112978
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Habitrol	C				
			Motrin	C				

Date:07/22/02ISR Number: 3951490-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00175
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS		ORAL	284	DAY
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic		Flupirtine Maleate	SS	Merck & Co., Inc	ORAL	109	DAY

Date:07/22/02ISR Number: 3951492-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA01475
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Haemorrhage		Furosemide	C				
	Medication Error		Prilosec	C				

			Verapamil	C		
			Warfarin	C		
			Potassium Chloride	C		
			Digitek	C		

Date:07/22/02ISR Number: 3951497-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA00035
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Synthroid	C				

Date:07/22/02ISR Number: 3951500-XReport Type:Expedited (15-DaCompany Report #WAES 0207DEU00126
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apathy		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization -	Aphasia		Vioxx	SS		ORAL	8	DAY
Initial or Prolonged	Blood Pressure Decreased		Diclofenac Sodium	C		ORAL		
	Dysstasia		Dipyrone	C		ORAL		
	Haemodialysis		Vasotec	C		ORAL	12	DAY
	Oral Intake Reduced		[Therapy					
	Renal Failure Acute		Unspecified]	C				
	Rhabdomyolysis		Flupirtine Maleate	C				
	Somnolence							

Date:07/22/02ISR Number: 3951502-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA01390
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death							
Initial or Prolonged	Infection							
	Large Intestine							
	Perforation							

Date:07/22/02ISR Number: 3951504-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA01537
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Iron Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
	Fatigue		Synthroid	C		
	Full Blood Count Decreased		Gemfibrozil	C		
			Nexium	C		
			Lipitor	C		
			Neurontin	C		

Date:07/22/02ISR Number: 3951505-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA01614
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Ulcer		Prilosec	C		
	Oedema Peripheral		Atenolol	C		
			Folic Acid	C		
			Tylenol	C		

			Propulsid	C		
			Hydrochlorothiazide And Triamterene	C		

Date:07/22/02ISR Number: 3952554-7Report Type:Expedited (15-DaCompany Report #2002115325NO
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Upper Alanine Aminotransferase Increased	Foreign Health Professional	Fragmin (Dalteparin Sodium) Solution, Sterile	PS		SUBCUTANEOUS	5000 IU, QD,	
	Anaemia	Other				SUBCUTANEOUS		
	Aspartate Aminotransferase Abnormal		Prednisolon (Prednisolone)	SS		ORAL	6 MG, ORAL	
	Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased		Albyl-E (Acetylsalicylic Acid, Magnesium Oxide)	SS		ORAL	75 MG, QD,	
	Blood Amylase Increased Blood Bicarbonate Abnormal		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, QD,	
	Blood Glucose Abnormal Electrocardiogram St Segment Elevation Electrocardiogram T Wave Peaked Faecal Occult Blood Positive Gastrointestinal Haemorrhage Hyperkalaemia Metabolic Acidosis Myocardial Infarction Po2 Abnormal Renal Failure Acute Shock		Aprovel (Irbesartan)	C				

Date:07/23/02ISR Number: 3951820-9Report Type:Expedited (15-DaCompany Report #WAES 0207MYS00005
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Duodenitis Gastric Haemorrhage Inflammation Oesophageal Ulcer Vomiting	Professional	Nonsteroidal Anti-Inflammatory Drug (Unspecified)	SS		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:07/23/02ISR Number: 3951825-8Report Type:Direct Company Report #CTU 172725
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased		Vioxx	PS			25MG QD	
Initial or Prolonged	Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/02ISR Number: 3951827-1Report Type:Expedited (15-DaCompany Report #WAES 0207NLD00012
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C		ORAL		
			Hydroxychloroquine Sulfate	C		ORAL		
			Omeprazole	C		ORAL		
			Lisinopril	C		ORAL		

Date:07/23/02ISR Number: 3951830-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA01601
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/23/02ISR Number: 3951831-3Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00048
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Spironolactone And Althiazide	C		ORAL		
			Bezafibrate	C		ORAL		
			Tramadol	C		ORAL		
			Bromazepam	C		ORAL		

Date:07/23/02ISR Number: 3952016-7Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00109
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/23/02ISR Number: 3952018-0Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00147
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Haematemesis		Dextromoramide	C		ORAL		
	Oral Discomfort		Morphine Sulfate	C		ORAL	3	DAY
	Vulval Disorder		Floxacillin	C		ORAL	8	DAY

Date:07/23/02ISR Number: 3952020-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA01560
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/02ISR Number: 3952024-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA01427
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			Synthroid	C				
			Flonase	C				
			Clarinex	C				

Date:07/24/02ISR Number: 3952566-3Report Type:Direct Company Report #CTU 172876
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pain In Extremity		Vioxx	PS		ORAL	25 MG PO QD	
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:07/24/02ISR Number: 3952659-0Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
	Cardiomegaly		Zantac	C		ORAL		
	Coronary Artery Disease							
	Coronary Artery Occlusion							

Date:07/24/02ISR Number: 3952661-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 2 DAY	Akathisia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 3 DAY	Anaemia	Vioxx	SS		ORAL
Disability 7 DAY	Asthenia	Vioxx	SS		ORAL
	Balance Disorder	Vioxx	SS		ORAL
PARENTERAL	Blood Pressure Increased 1 DAY	Aristocort	C		
	Bundle Branch Block Left	Ziac	C		ORAL
	Dizziness	Hyzaar	C		ORAL
	Facial Palsy	Zoloft	C		ORAL
INTRAMUSCULAR	Faecal Occult Blood	Toradol	C		
	Positive				
	Fall				
	Fracture Nonunion				
	Haemorrhagic Stroke				
	Myoglobin Blood Increased				
	Radius Fracture				
	Sinus Bradycardia				
	Thrombocytopenia				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/02ISR Number: 3952664-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA01402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Coronary Artery Atherosclerosis Myocardial Infarction							

Date:07/24/02ISR Number: 3952733-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02485
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	136	DAY
Initial or Prolonged Disability	Haemorrhage		Aspirin	C				

Date:07/24/02ISR Number: 3952734-0Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00140
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
Hospitalization - Initial or Prolonged			Nifedipine	C		ORAL		YR

Date:07/24/02ISR Number: 3952736-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01379
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive		Ibuprofen	C				
			Ultram	C				
			Insulin	C				
			Allegra	C				

			Captopril	C		
			Famotidine	C		
			Flonase	C		
			Lasix (Furosemide)	C		
			Potassium Chloride	C		
			Nexium	C		
			Premarin	C		
			Celexa	C		

Date:07/24/02ISR Number: 3952737-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA01249
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Infection		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Pain		[Therapy Unspecified]	C				
	Vaginal Haemorrhage		Micro K	C				
			Tylenol With Codeine #4	C				
			Lasix (Furosemide)	C				
			Cardizem Cd	C				
			Lanoxin	C				
			Uniphyl	C				
			Aerobid-M	C				

			Desyrel	C		
			Colace	C		
			Dalmane	C		
			Metamucil	C		
			Mylanta & Mylanta Ds	C		
			Prilosec	C		
			Travatan	C		
			Allopurinol	C		

Date:07/24/02ISR Number: 3952748-0Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00028
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	
94 DAY						
			Omeprazole	C		
			Acetaminophen	C		

Date:07/24/02ISR Number: 3952751-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA01759
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
	Difficulty In Walking		Allegra	C		
	Mania		Atenolol	C		
			Oxycontin	C		
			Paxil	C		
			Trazodone	C		
			Lithium Citrate	C		
			Klonopin	C		

Date:07/24/02ISR Number: 3952884-9Report Type:Direct Company Report #CTU 172816
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea		Rofecoxib	PS		
Initial or Prolonged	Joint Swelling		Carvedilol	C		
			Isosorbide	C		

			Vitamin E	C		
			Aspirin	C		
			Tamsulosin	C		
			Lisinopril	C		

Date:07/24/02ISR Number: 3952907-7Report Type:Direct Company Report #CTU 172881
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx 25 Mg Tabs	PS		ORAL	1 TAB PO QD	
Initial or Prolonged	Difficulty In Walking		Imdur	C				
	Hyperkalaemia		Lopressor	C				
	Renal Failure Acute		Lasix	C				
			Diltiazem	C				
			Synthroid	C				
			Oxycontin	C				
			Neurontin	C				
			Ec Asa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/02ISR Number: 3953642-1Report Type:Expedited (15-DaCompany Report #2001085935US
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypotension	Consumer	Celebrex (Celecoxib)				200 MG, BID , ORAL	
	Myocardial Infarction	Health	Capsule	PS		ORAL		
	Myocarditis	Professional						
	Ulcer Haemorrhage		Vioxx (Rofecoxib)	SS				
	Upper Gastrointestinal Haemorrhage		Clonidine	C				
			Avapro (Irbesartan)	C				
			Demadex (Torasemide)	C				
			Lipitor (Atorvastatin)	C				
			Premarin (Estrogens Conjugated)	C				
			Ultram (Tramadol Hydrochloride)	C				
			Neurontin (Gabapentin)	C				
			Zanaflex (Tizanidine Hydrochloride)	C				

Date:07/25/02ISR Number: 3953040-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01443
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Premarin	C				
	Back Pain		Dyazide	C				
			Atenolol	C				
			Lasix (Furosemide)	C				
			Micro K	C				
			Ambien	C				
			Lonox	C				

Date:07/25/02ISR Number: 3953043-6Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00014
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		MON
	Melaena		Warfarin Sodium	C				YR
	Ulcer Haemorrhage		Acetaminophen	C				YR

Date:07/25/02ISR Number: 3953045-XReport Type:Expedited (15-DaCompany Report #WAES 0207DEU00159
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/02ISR Number: 3953046-1Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00011
Age:85 YR Gender:Female I/FU:I

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage
	Hyperkalaemia

	Metabolic Acidosis Renal Failure Acute						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisolone	SS				
			Aspirin And Magnesium Oxide	SS		ORAL	11	DAY
			Dalteparin Sodium	SS			SUBCUTANEOUS	11 DAY
			Dalteparin Sodium	SS			SUBCUTANEOUS	22 DAY
			Hydrochlorothiazide And Irbesartan	C		ORAL		

Date:07/25/02ISR Number: 3953047-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00096
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Coma		[Therapy Unspecified]	C				

Date:07/25/02ISR Number: 3953049-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA01097
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Methotrexate	C				
Disability			Arava	C				

Date:07/25/02ISR Number: 3953051-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA01597
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Haematochezia Syncope Vomiting		Vioxx Librium	PS C	Merck & Co., Inc	ORAL		

Date:07/25/02ISR Number: 3953268-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00138
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/02ISR Number: 3953271-XReport Type:Expedited (15-DaCompany Report #WAES 0207BRA00035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Respiratory Failure		Corticosteroids (Unspecified)	C				
Other						DRIP	INTRAVENOUS	
			Dexamethasone	C			INTRAMUSCULAR	
			Aminophylline	C			INTRAVENOUS	

Date:07/25/02ISR Number: 3953274-5Report Type:Expedited (15-DaCompany Report #WAES 0207BEL00043
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Breast Tenderness		Estradiol And Norethindrone Acetate	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Aspirin	C		ORAL		
			Cerivastatin	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		
			Isradipine	C		ORAL		

Date:07/25/02ISR Number: 3953279-4Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00166
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/02ISR Number: 3953280-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA01583
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS		ORAL		
	Congestive		Avandia	SS				
			Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Lipitor	C				
			Combivent	C				
			Glucagon	C				
			Depakote	C				
			Flovent	C				
			Glucophage Xr	C				
			Diovan	C				
			[Therapy Unspecified]	C				
			Serevent Disk	C				

Date:07/25/02ISR Number: 3953284-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:07/25/02ISR Number: 3953285-XReport Type:Expedited (15-DaCompany Report #WAES 0207GBR00165
Age:79 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx [Therapy Unspecified] [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/02ISR Number: 3953711-6Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00011
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		WK
Hospitalization - Initial or Prolonged	Infarction		Prednisolone	SS				
	Anaemia		Aspirin And Magnesium Oxide	SS		ORAL		11 DAY
	Gastrointestinal							
	Haemorrhage		Dalteparin Sodium	SS			SUBCUTANEOUS	22 DAY
	Hyperkalaemia		Dalteparin Sodium	SS			SUBCUTANEOUS	11 DAY
	Metabolic Acidosis		Hydrochlorothiazide And Irbesartan	C		ORAL		
	Renal Failure Acute							

Date:07/26/02ISR Number: 3953718-9Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00144
Age:7 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Potassium Chloride	C				

Date:07/26/02ISR Number: 3953934-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02108
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypotension		Celebrex	SS		ORAL		
	Myocarditis		Clonidine	C				
	Ulcer		Avapro	C				
	Upper Gastrointestinal		Demadex	C				
	Haemorrhage		Lipitor	C				
			Premarin	C				
			Ultram	C				
			Neurontin	C				
			Zanaflex	C				

Date:07/26/02ISR Number: 3954301-1Report Type:Direct Company Report #CTU 173009
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx 50mg	PS		ORAL	50MG QD ORAL	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage		Simvistatin	C				
			Levothyroxine	C				
			Vicodin	C				
			Gabapentin	C				
			Imipramine	C				

Date:07/26/02ISR Number: 3956127-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Asthma
	Calcinosis
	Cardiac Disorder
	Cardiomegaly

	Chest X-Ray Abnormal						
	Coronary Artery Disease						
	Coronary Artery Occlusion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea Exertional	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG PRN PO
	Echocardiogram Abnormal	Health	Dermatop	C			
	Hypokinesia	Professional	Zantac	C			
	Influenza Like Illness		Zocor	C			
	Pulmonary Congestion						

Date:07/29/02ISR Number: 3954444-2Report Type:Expedited (15-DaCompany Report #WAES 01105179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Drug Effect Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY
Initial or Prolonged	Haemorrhagic Stroke	Professional	Vioxx	SS		ORAL	28 DAY
	Muscle Injury		Estrogens, Conjugated And				
	Oedema Peripheral		Medrogestone	C			
	Sciatica		Ibuprofen	C			TOPICAL
			Acetaminophen And Codeine Phosphate	C		ORAL	

Date:07/29/02ISR Number: 3954445-4Report Type:Expedited (15-DaCompany Report #WAES 0207ITA00043
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY
	Melaena						

Date:07/29/02ISR Number: 3954446-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02224
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident Difficulty In Walking Dizziness Hypoaesthesia Joint Swelling Movement Disorder Oedema Peripheral Pain In Extremity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/29/02ISR Number: 3954597-6Report Type:Direct Company Report #CTU 173075
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx 25mg Longs	PS	Longs	ORAL	25 TO DAILY	
Initial or Prolonged	Blood Triglycerides						ORAL	
Required	Increased							
Intervention to	Heart Rate Increased							
Prevent Permanent								
Impairment/Damage								

Date:07/29/02ISR Number: 3954624-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02080
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Gastrointestinal Haemorrhage		Naprosyn	C				
			Ibuprofen	C				

Date:07/29/02ISR Number: 3954631-3Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00137
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Sodium Decreased		Vasotec	C		ORAL		
	Blood Urea Increased		Baclofen	C		ORAL		
	Diarrhoea		Trospium Chloride	C		ORAL		
	Large Intestine Perforation		Memantine Hydrochloride	C		ORAL		
	Red Blood Cell Sedimentation Rate Abnormal		Hydrodiuril	C		ORAL		
	White Blood Cell Count Increased		Minerals (Unspecified) And Vitamins (Unspecified)	C		ORAL		
			Bisacodyl	C		RECTAL		
			Globulin, Immune	C				

Date:07/29/02ISR Number: 3954636-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA02379
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Aspirin	C				
	Gastritis		Synthroid	C				
Other								

Date:07/29/02ISR Number: 3956142-8Report Type:Expedited (15-DaCompany Report #2002116411FR
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysuria	Foreign	Aldactazine(Spironolactone, Althiazide)					
	Headache	Health						
	Hyponatraemia	Professional	Tablet	PS		ORAL	1 DF, EVERY 2	DAYS, ORAL
	Nephritis Interstitial	Other						
	Nephrotic Syndrome		Topalgic(Tramadol Hydrochloride)	SS		ORAL	ORAL	
	White Blood Cell Count Increased		Vioxx(Rofecoxib)	SS		ORAL	25 MG, QD,	ORAL
			Denoral(Cloxinizine Hydrochloride, Buzepide Metiodide)	SS		ORAL	ORAL	
			Ergix(Ibuprofen)	SS		ORAL	200 MG, ORAL	
			Befizal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/02ISR Number: 3955162-7Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophagitis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Bendroflumethiazide	C		ORAL		
Initial or Prolonged			Atenolol	C		ORAL		
			Temazepam	C		ORAL		
			Dihydrocodeine	C		ORAL		

Date:07/30/02ISR Number: 3955330-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02066
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Plavix	C				
			Synthroid	C				
			Zocor	C		ORAL		
			Folic Acid	C				

Date:07/30/02ISR Number: 3955332-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombotic Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/30/02ISR Number: 3955533-9Report Type:Direct Company Report #CTU 173175
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum		Vioxx	PS		ORAL	25MG QD PO	2 WK
Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis		Asa (Aspirin)	C				
			Skelaxin	C				
			Dcn-100 (Darvocet					

			N-100)	C		
			Norvasc	C		
			Levoxyl	C		

Date:07/30/02ISR Number: 3955553-4Report Type:Direct Company Report #CTU 173181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematemesis		Vioxx	PS		ORAL
25 MG TAB PO						
Initial or Prolonged			Ancef	C		
Required			Morphine	C		
Intervention to			Darvocet N	C		
Prevent Permanent			Serax	C		
Impairment/Damage			Lovenox	C		
			Asa	C		
			Humalog	C		
			Glargine	C		
			Prinivil	C		
			Zyprexa	C		

Date:07/30/02ISR Number: 3957383-6Report Type:Expedited (15-DaCompany Report #2002100722CA
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Granuloma Annulare	Foreign Health Professional	Celebrex (Celecoxib) Capsule	PS		ORAL	100 MG, QD, ORAL	
		Other	Rofecoxib (Rofecoxib)	SS				
			Premarin (Estrogens Conjugated)	C				
			Synthroid (Levothyroxine Sodium)	C				
			Pantoloc "Byk" (Pantoprazole Sodium)	C				
			Efexor Xl (Venlafaxine Hydrochloride)	C				

Date:07/31/02ISR Number: 3955649-7Report Type:Expedited (15-DaCompany Report #WAES 0207BEL00032
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Malaise		Eprosartan	C		ORAL		
	Syncope		Insulin, Biphasic Isophane [Injection]	C			SUBCUTANEOUS	
			Nifedipine	C		ORAL		
			Furosemide	C		ORAL		

Date:07/31/02ISR Number: 3955651-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA02205
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Cardiac Failure Congestive						

Date:07/31/02ISR Number: 3955882-4Report Type:Expedited (15-DaCompany Report #WAES 0205DEU00162
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
Hospitalization - Initial or Prolonged			Aspirin	C		ORAL		
			Vaseretic	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:07/31/02ISR Number: 3955889-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA00328
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Prinivil	C				
			Prilosec	C				
			Flomax (Tamsulosin					

			Hydrochloride)	C		
			Urocit-K	C		

Date:07/31/02ISR Number: 3955892-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA03436
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Jaundice							
	Liver Disorder							
	Renal Impairment							

Date:07/31/02ISR Number: 3955893-9Report Type:Expedited (15-DaCompany Report #WAES 0207KOR00077
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			[Composition Unspecified]	C		ORAL	5	DAY
			Dexamethasone	C			INTRAMUSCULAR	1 DAY
			Levothyroxine Sodium	C		ORAL		
			[Composition Unspecified]	C			RECTAL	
			[Composition Unspecified]	C		ORAL		
			Aluminum Hydroxide And Magnesium Hydroxide And Simethicone	C		ORAL		
			Aspergillus Oryzae Extract And Pancreatin	C		ORAL		
			Cimetidine	C		ORAL		

Date:07/31/02ISR Number: 3955896-4Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00167
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspepsia		Aspirin	SS				
			Omeprazole	C		ORAL		
			Atenolol	C		ORAL		
			Vasotec	C		ORAL		
			Orlistat	C		ORAL		
			Erythromycin Ethylsuccinate	C				
			Coal Tar And Juniper Tar And Oleyl Alcohol	C				
			Quinine Sulfate	C		ORAL		
			Influenza Virus Vaccine	C				
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Furosemide	C		ORAL		
			Gliclazide	C		ORAL		
			Hydrargaphen	C				
TOPICAL								
			Urea	C				
			[Therapy					

			Unspecified]	C		

Date:07/31/02ISR Number: 3955897-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA02339
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Other	Death							

Date:07/31/02ISR Number: 3955898-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA01560
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				
			Asacol	C				
			Insulin	C				
			Zestril	C				
			[Therapy Unspecified]	C				

Date:07/31/02ISR Number: 3955899-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02405
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/31/02ISR Number: 3955931-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
	Arterial Occlusive	Health Professional	Zantac	C				
			Zocor	C				

Disease
Arthralgia
Asthenia
Cardiomegaly
Carotid Artery Stenosis
Chest Pain
Coronary Artery Disease
Dyspnoea Exertional
Echocardiogram Abnormal
Heart Rate Decreased
Hyperhidrosis
Influenza Like Illness
Loss Of Consciousness
Nausea
Vascular Calcification

Date:07/31/02ISR Number: 3955932-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia
	Anaemia
Disability	Asthenia

		Balance Disorder					
		Bundle Branch Block Left					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Condition Aggravated	Consumer	Tab Vioxx	PS		ORAL
SEE IMAGE							
		Discomfort	Health	Aristocort	C		
		Dizziness	Professional	Hyzaar	C		
		Electroencephalogram		Toradol	C		
		Abnormal		Ziac	C		
		Facial Palsy		Zoloft	C		
		Faecal Occult Blood					
		Positive					
		Fall					
		Haemoglobin Decreased					
		Haemorrhage Intracranial					
		Head Injury					
		Heart Rate Decreased					
		Hypertension					
		Injury					
		Malaise					
		Myoglobin Blood Increased					
		Radius Fracture					
		Respiratory Rate					
		Increased					
		Sinus Bradycardia					
		Tendonitis					
		Thrombocytopenia					
		Wrist Deformity					

Date:08/01/02ISR Number: 3956287-2Report Type:Direct Company Report #CTU 173342
Age:86 YR Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Creatinine		Vioxx	PS		ORAL
PO QD							
Initial or Prolonged		Increased					
		Blood Urea Increased					
		Cardiac Failure					
		Congestive					
		Pulmonary Oedema					

Date:08/01/02ISR Number: 3956301-4Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00211
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Phosphokinase Increased		Tramadol Hydrochloride	C		PARENTERAL		
	Bronchospasm							
	Hepatitis		Metoclopramide Hydrochloride	C		PARENTERAL		
	Hypotension							
	Respiratory Failure		Fenofibrate	C				YR
	Somnolence							
	White Blood Cell Count Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/02ISR Number: 3956303-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02450
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged			Toprol Xl Tablets	C				
			Lipitor	C				
			Nitropaste	C				
			Cardura	C				

Date:08/01/02ISR Number: 3956305-1Report Type:Expedited (15-DaCompany Report #WAES 0207DNK00013
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Hospitalization -	Helicobacter		Citalopram					
Initial or Prolonged	Gastric Ulcer Perforation		Hydrobromide	C		ORAL		
			Oxycodone					
			Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

Date:08/01/02ISR Number: 3956577-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA00512
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL		32 DAY
Other	Paraesthesia Oral		Flexeril	C				
	Tongue Coated							
	Tongue Oedema							

Date:08/01/02ISR Number: 3956578-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA00099
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cardio-Respiratory Arrest	Vioxx	PS	Merck & Co., Inc	ORAL
58 DAY					
Initial or Prolonged	Cholelithiasis	[Therapy			
	Cold Sweat	Unspecified]	C		
	Coronary Artery Occlusion				
	Dyspnoea				
	Nausea				
	Pulmonary Oedema				
	Weight Increased				

Date:08/01/02ISR Number: 3956581-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02292
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Death	Acidosis
Life-Threatening	Anaphylactic Shock
Hospitalization -	Anuria
Initial or Prolonged	Cardiac Arrest
	Coma
	Diarrhoea
	Fatigue
	Haematemesis
	Heart Rate Decreased
	Hypotension
	Loss Of Consciousness

		Mydriasis Pallor Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
				Sirdalud	C		ORAL
				Coltramyl	C		ORAL
				Mydocalm	C		ORAL
				[Therapy Unspecified]	C		
				[Composition Unspecified]	C		

Date:08/01/02ISR Number: 3956582-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA02341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Irritability Mood Swings		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/02ISR Number: 3956584-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA02385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 46 DAY	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis Haemorrhage					

Date:08/01/02ISR Number: 3956591-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02671
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Stomach Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
			Levoxyl	C		
			Zocor	C		ORAL
			Hydrochlorothiazide			

			And Triamterene	C		
			Ultram	C		
			Avapro	C		
			Singulair	C		ORAL

Date:08/01/02ISR Number: 3956593-1Report Type:Expedited (15-DaCompany Report #WAES 01101993
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	144 DAY	
Hospitalization - Initial or Prolonged	Neoplasm		Atacand	C				
Disability			Lopid	C				
Other			Aspirin	C				
			Osteo-Bi-Flex	C				
			Sudafed	C				
			Benadryl	C				
			Atenolol	C				
			Atenolol	C				
			Hydrodiuril	C				
			Atacand Plus	C				
			Gastrointestinal Preparations					

(Unspecified) C

Date:08/01/02ISR Number: 3956833-9Report Type:Direct Company Report #CTU 173372
Age: Gender:Not SpecifiI/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage		Vioxx 25 Mg	PS		ORAL	50 MG	2 YR
			Tramadol	C				
			Hydrophilic Cream	C				
			Phenytoin	C				
			Labetalol (Trandate)	C				
			Lamotrigine (Lamictal)	C				
			Diphenhydramine	C				
			Multivitamins/Minerals	C				
			Rofecoxib	C				
			Cyclobenzaprine	C				
			Nicotine Patch (Habitrol)	C				
			Bupropion	C				
			Furosemide	C				
			Hydrochlorothiazide	C				
			Potassium Chloride (K-Dur)	C				

Date:08/01/02ISR Number: 3958385-6Report Type:Periodic Company Report #2001COU0977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Flushing	Consumer	Coumadin (Warfarin Sodium)	PS		ORAL		
	Hyperhidrosis							
	Pulmonary Haemorrhage		Vioxx (Rofecoxib)	SS				
			Estrogen	C				

Date:08/01/02ISR Number: 3958760-XReport Type:Expedited (15-DaCompany Report #1660711A
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Cyclobenzaprine					
Required	Arthralgia	Other	Product	PS				
Intervention to	Dialysis		Atorvastatin	SS				
Prevent Permanent	Drug Interaction		Amlodipine	SS				
Impairment/Damage	Haemorrhage		Celecoxib	SS				
	Injury		Clonazepam	SS				
	Myalgia		B Complex Vitamin	SS				
	Psychotic Disorder		Rofecoxib	SS				
	Rash		Paricalcitol	SS				
	Renal Failure		Various Med	SS				
	Skin Graft		Insulin	SS				
			Imuran	SS				
			Prednisone	SS				
			Furosemide	SS				
			Cyclosporine	SS				
			Clonidine	SS				
			Metoprolol	SS				
			Bisoprolol	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/02ISR Number: 3956978-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00029
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		269 DAY
Initial or Prolonged	Cough	Professional	Vioxx	SS		ORAL		166 DAY
	Disorientation		Claritin-D	C		ORAL		
	Dizziness		Tums	C				
	Drug Ineffective		Lorcet 10/650	C				
	Dysphonia		Ultracet	C		ORAL		
	Headache		Ketorolac	C				6 DAY
	Immune System Disorder		Hydrocodone	C				
	Malaise		Bextra	C				
	Meningitis Viral							
	Musculoskeletal Stiffness							
	Nausea							
	Photopsia							
	Thirst							
	Upper Respiratory Tract Infection							
	Vision Blurred							

Date:08/02/02ISR Number: 3956984-9Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00074
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Life-Threatening	Coma	Professional	Aspirin	SS		ORAL		
	Haemodialysis		Molsidomine	SS		ORAL		
	Malaise		Fentanyl	SS				TOPICAL
	Oral Intake Reduced		Furosemide	SS		ORAL		
	Renal Failure		Insulin, Biphasic					
	Somnolence		Isophane [Injection]	C				SUBCUTANEOUS
	Urinary Tract Infection		Digitoxin	C		ORAL		

Date:08/02/02ISR Number: 3956985-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA02309
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Methotrexate Sodium	C				
			Prednisone	C				

Date:08/02/02ISR Number: 3956986-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00160
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cholelithiasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cholestasis	Professional	Hydrochlorothiazide And Valsartan	SS		ORAL		
	Drug Interaction		Melperone	SS		ORAL		
	Renal Disorder		Metoprolol	SS		ORAL		
	Renal Failure Acute		Nitrendipine	SS		ORAL		
			Nitrendipine	SS		ORAL		
			Omeprazole	C		ORAL		
			Prednisolone	C		ORAL		
			Cisapride	C		ORAL		
			Famotidine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/02ISR Number: 3956991-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA02605
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Papillary Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucophage	C				
			Amaryl	C				
			Micardis	C				

Date:08/02/02ISR Number: 3956993-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02731
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			[Therapy Unspecified]	C				

Date:08/02/02ISR Number: 3956994-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA00015
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Digoxin	C				
	Cardiac Failure		Digoxin	C				
Other	Congestive Drug Toxicity							

Date:08/02/02ISR Number: 3956995-3Report Type:Expedited (15-DaCompany Report #WAES 0207KOR00078
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Pain		Dexamethasone	C		ORAL	1	DAY

				Estrogens, Conjugated	C		ORAL
				Medroxyprogesterone Acetate	C		ORAL
				Diclofenac	C		
INTRAMUSCULAR		1	DAY				

Date:08/02/02ISR Number: 3956996-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA01759
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Lithium Citrate	SS				
	Drug Interaction		Allegra	C				
	Gastrointestinal Disorder		Atenolol	C				
	Mania		Klonopin	C				
			Oxycontin	C				
			Paxil	C				
			Trazodone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/02ISR Number: 3957271-5Report Type:Direct Company Report #CTU 173415
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx 25mg Per Tablet Merck	PS	Merck	ORAL	25MG Q DAY	ORAL
			Ferrous Sulfate	C				
			Colace	C				

Date:08/02/02ISR Number: 3957740-8Report Type:Direct Company Report #CTU 173450
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis		Vioxx 25 Mg	PS		ORAL	25 MG PO QD	

Date:08/05/02ISR Number: 3957550-1Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00224
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coxsackie Viral Infection		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
Disability	Erythema Multiforme		Warfarin	C		ORAL		
	Pericardial Effusion		Dihydrocodeine	C		ORAL		
	Pleural Effusion							

Date:08/05/02ISR Number: 3957551-3Report Type:Expedited (15-DaCompany Report #WAES 0207CHE00028
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Increased	Infliximab	SS		
PARENTERAL	1 DAY				
	Deep Vein Thrombosis	Prednisone	C		ORAL
	Pulmonary Embolism	Methotrexate	C		ORAL

Date:08/05/02ISR Number: 3957554-9Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00221
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Vaginal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Estrogens, Conjugated And Norgestrel	C		ORAL
			Cod Liver Oil	C		ORAL
			Calcium (Unspecified)	C		ORAL
			Chondroitin And Glucosamine	C		

Date:08/05/02ISR Number: 3957556-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA02224
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Other	Cerebrovascular Accident
	Difficulty In Walking
	Dyspnoea

		Hypertension					
		Joint Swelling					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity		Atenolol	C		ORAL
				Prevacid	C		ORAL
				Aggrenox	C		ORAL
				Furosemide	C		ORAL

Date:08/05/02ISR Number: 3957558-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA03636
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Duodenal Ulcer		Nicotine	C		
Initial or Prolonged	Upper Gastrointestinal		Combivent	C		
Disability	Haemorrhage		Flovent	C		
Other			Proscar	C		
			Paxil	C		
			Keflex	C		
			Aspirin	C		

Date:08/05/02ISR Number: 3957560-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02713
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive		Torsemide	C		
			Spironolactone	C		

Date:08/05/02ISR Number: 3957563-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage					

Date:08/05/02ISR Number: 3957564-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA02596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/02ISR Number: 3957565-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA02450
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
Initial or Prolonged			Toprol Xl Tablets	C				
			Lipitor	C				
			Nitropaste	C				
			Cardura	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/02ISR Number: 3957849-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA02569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive							
Hospitalization - Initial or Prolonged								

Date:08/05/02ISR Number: 3957857-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02647
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral	Health	Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
		Professional	Ultram	C		ORAL		
			Celexa	C		ORAL		
			Klonopin	C		ORAL		
			Premarin	C		ORAL		
			Zanaflex	C		ORAL		

Date:08/05/02ISR Number: 3957906-7Report Type:Direct Company Report #CTU 173549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Unevaluable Event		Vioxx - Negative Impact .25 -1-Daily	PS			.25	
Disability								
Required Intervention to Prevent Permanent Impairment/Damage			Tylenol	C				

Date:08/05/02ISR Number: 3957910-9Report Type:Direct Company Report #CTU 173551
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Increased	Vioxx 25 (7 Days - Dr Samples)	PS
1 A DAY	Constipation		
Required Intervention to Prevent Permanent Impairment/Damage	Dehydration		
	Eye Pain		
	Fatigue		
	Feeling Cold		
	Gastrointestinal Pain		
	Nephrolithiasis		
	Pneumonia		
	Pruritus		
	Renal Failure Acute		
	Swelling		
	Tremor		
	Vision Blurred		
	Vomiting		

Date:08/05/02ISR Number: 3958975-0Report Type:Expedited (15-DaCompany Report #DSA_21845_2002
Age:82 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain
	Creatinine Renal Clearance Decreased

		Haematocrit Decreased					
		Haemoglobin Decreased					
		Nephritis Interstitial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oliguria	Foreign	Vasotec	PS		ORAL
20 MG DAILY							
		Pyelonephritis	Health				
PO							
		Pyrexia	Professional	Vasotec	SS		ORAL
5 MG DAILY PO							
		Renal Failure Acute	Other	Rofecoxib	SS		
				Acebutolol	C		
				Ofloxacin	C		
				Diclofenac	C		
				Celecoxib	C		

Date:08/05/02ISR Number: 3959118-XReport Type:Expedited (15-DaCompany Report #A0376571A
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthritis	Consumer	Sine-Off (Sine-Off)	PS		
		Bursitis		Guaiphenesin (Guaifenesin)	SS		
		Cerebrovascular Accident		Ibuprofen (Ibuprofen)	SS		
		Coronary Artery Surgery		Dimetapp (Dimetapp)	SS		
		Surgery		Alka-Seltzer Plus Cold Md (Alka-Seltzer Plus Cold Md)	SS		
				Tavist-D (Tavist-D)	SS		
				Triaminic (Triaminic)	SS		
				Phenylpropanolamine Hcl (Phenylpropanolamine)	SS		
				Vicodin (Vicodin)	SS		
				Clonidine (Clonidine)	SS		
				Coricidin (Coricidin)	SS		
				Tylenol Cold Medication (Tylenol			

Cold Medication)	SS
Medrol (Medrol)	SS
Rofecoxib (Rofecoxib)	SS
Ibuprofen (Ibuprofen)	SS
Gabapentin (Gabapentin)	SS
Vicks Dayquil (Vicks Dayquil)	SS
Nyquil (Nyquil)	SS

Date:08/06/02ISR Number: 3958102-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Other	Cardiac Failure Congestive

		Cardiomyopathy					
		Condition Aggravated					
		Dermatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Zemplar	SS		
		Drug Interaction		Insulin	C		
		Haemorrhage		Imuran			
		Hyperkalaemia		(Azathioprine)	C		
		Injury		Prednisone	C		
		Kidney Transplant		Lasix (Furosemide)	C		
		Rejection		Cyclosporine	C		
		Muscular Weakness		Clonidine	C		
		Myalgia		Norvasc	C		
		Myocardial Infarction		Toprol Xl Tablets	C		
		Renal Failure		Zebeta	C		
		Renal Transplant		Cyclobenzaprine			
		Sinus Tachycardia		Hydrochloride	C		
		Weight Decreased		Vitamin B			
				(Unspecified)	C		
				Celebrex	C		
				Lipitor	C		
				Clonazepam	C		

Date:08/06/02ISR Number: 3958391-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01624
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/06/02ISR Number: 3958394-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01820
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Transient	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain	Professional	Corgard	C		
	Electrocardiogram		Hydrodiuril	C		ORAL
	Abnormal		[Therapy			
	Hyperhidrosis		Unspecified]	C		
PARENTERAL						

	Hypoaesthesia	Cozaar	C	ORAL
	Influenza Like Illness	Motrin	C	
	Migraine			
	Pharyngitis Streptococcal			

Date:08/06/02ISR Number: 3958399-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Barrett'S Oesophagus
	Blood Cholesterol Increased
	Cardiomegaly
	Drug Intolerance
	Gastroduodenitis
	Hiatus Hernia
	Hypertension
	Hypotension

		Labyrinthitis					
		Oesophageal Disorder					
		Orthostatic Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prostatic Specific	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Antigen Increased	Professional	Ginseng	SS		ORAL
		Purulence		Cardura	SS		ORAL
		Sinusitis		Flomax (Tamsulosin			
		Vertigo		Hydrochloride)	SS		ORAL
				Citracal Caplets + D	C		ORAL
				Halfprin	C		ORAL
				Vitamin E	C		ORAL

Date:08/06/02ISR Number: 3958405-9Report Type:Expedited (15-DaCompany Report #WAES 0208ISR00001
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Gastric Ulcer	Professional				
	Syncope					

Date:08/07/02ISR Number: 3958990-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA00542
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Disease		Cardizem	C		
	Chest Discomfort		Lanoxin	C		
			Coumadin	C		
			Zocor	C		ORAL

Date:08/07/02ISR Number: 3958991-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA01233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:08/07/02ISR Number: 3958995-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA00992
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged			Metoprolol	C				

Date:08/07/02ISR Number: 3958997-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA01043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:08/07/02ISR Number: 3959160-9Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00008
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Haemorrhage		Dipyrone	C		ORAL		
	Ulcer							

Date:08/07/02ISR Number: 3959161-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02610
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		26 MON
	Haematuria		Ultram	SS				
	Hypertension							
	Proteinuria							

Date:08/07/02ISR Number: 3959165-8Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00063
Age:0 DY Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc			2 YR
	Complications Of Maternal		Levothyroxine Sodium	C				
	Exposure To Therapeutic		Acetaminophen And					
	Drugs		Codeine Phosphate	C				
	Maternal Drugs Affecting		Clomiphene Citrate	C				
	Foetus							
	Pregnancy							

Date:08/07/02ISR Number: 3959166-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Spinal Disorder						

Date:08/07/02ISR Number: 3959167-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA01623
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization -	Dyspnoea		Toprol Xl Tablets	C		ORAL		
Initial or Prolonged			Lipitor	C		ORAL		
Other			Nitropatch	C				
			Enalapril Maleate	C		ORAL		
			Cardura	C		ORAL		

Date:08/07/02ISR Number: 3959172-5Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00021
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc		2	DAY
Initial or Prolonged			Aspirin	C				
			Vasotec	C				
			Furosemide	C				
			Isosorbide Mononitrate	C				

Date:08/07/02ISR Number: 3959173-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02444
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Vioxx	PS	Merck & Co., Inc	ORAL		
	Iritis		Imitrex	C				
	Joint Swelling		Elavil	C		ORAL		
	Optic Neuritis		Inderal	C		ORAL		
	Pupils Unequal		Ambien	C		ORAL		
	Scotoma		Medicon	C				
	Stevens-Johnson Syndrome							
	Uveitis							

Date:08/08/02ISR Number: 3959767-9Report Type:Expedited (15-DaCompany Report #WAES 0205BEL00148
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			Aspirin	SS		ORAL		
			Enalapril Maleate	C		ORAL		
			Diosmin	C		ORAL		

Date:08/08/02ISR Number: 3959769-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA02605
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Renal Papillary Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucophage	C				
			Amaryl	C				
			Micardis	C				

Date:08/08/02ISR Number: 3959770-9Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00166
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/02ISR Number: 3959771-0Report Type:Expedited (15-DaCompany Report #WAES 0208NOR00001
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
3 DAY								
Initial or Prolonged	Nausea							
	Vasculitis							

Date:08/09/02ISR Number: 3960081-6Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00201
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholangitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatitis Cholestatic		Nadroparin Calcium	C				
SUBCUTANEOUS							4	WK
			Estradiol And Norethindrone Acetate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/02ISR Number: 3960083-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA00342
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/02ISR Number: 3960084-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA00020
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/02ISR Number: 3960087-7Report Type:Expedited (15-DaCompany Report #WAES 0207HKG00008
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc			
	Haemorrhagic Stroke		Warfarin	C		ORAL		
	International Normalised Ratio Increased							

Date:08/09/02ISR Number: 3960090-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA01216
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lovenox	C				

Date:08/09/02ISR Number: 3960091-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA01535
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/02ISR Number: 3960092-0Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00173
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY
	Rectal Haemorrhage		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Psyllium Husk	C		ORAL		

Date:08/09/02ISR Number: 3960094-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA01455
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Haematocrit Decreased		Ancef	C				
INTRAVENOUS	2	DAY						
Other	Haemoglobin Decreased		Lovenox	C				
SUBCUTANEOUS	3	DAY						
			Morphine	C				
INTRAVENOUS	6	DAY						

			Darvocet-N	C		ORAL
			Serax	C		ORAL
			Aspirin	C		ORAL
1 DAY						
			Humalog	C		
			Sodium Chloride	C		
INTRAVENOUS						
						DRIP
			Insulin Glargine	C		
			Prinivil	C		ORAL

Date:08/09/02ISR Number: 3960133-0Report Type:Direct Company Report #CTU 173838
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea Exacerbated		Vioxx No Longer Have	PS			2/DAY	2 DAY

Date:08/09/02ISR Number: 3960313-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA00167
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dyspnoea Exertional		Oxycontin	C				
	Ejection Fraction Decreased		Analgesic Or Anesthetic (Unspecified)	C				
	Embolism							
	Heart Rate Increased							
	Hypoxia							
	Myocardial Infarction							
	Vomiting							

Date:08/09/02ISR Number: 3960314-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA01858
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Level Decreased		Dilantin	SS				

Date:08/09/02ISR Number: 3960316-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA02985
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Other	Hypertension							

Date:08/09/02ISR Number: 3960318-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01708
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Headache		Prednisone	C				
	Myocardial Infarction							

Date:08/09/02ISR Number: 3960319-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Flomax (Tamsulosin Hydrochloride)	SS		ORAL		
	Barrett'S Oesophagus		Cardura	SS		ORAL		
	Blood Cholesterol Increased		Ginseng	SS		ORAL		
	Chest Wall Pain		Vitamin E	C		ORAL		
	Dilatation Atrial		Citracal Caplets + D	C		ORAL		
	Dizziness		Halfprin	C		ORAL		
	Drug Intolerance							
	Gastroduodenitis							
	Gastrointestinal Motility Disorder							
	Hiatus Hernia							
	Hypertension							
	Hypotension							
	Labyrinthitis							
	Low Density Lipoprotein Increased							
	Oesophageal Atresia							
	Orthostatic Hypotension							
	Otitis Media							
	Palpitations							
	Prostatic Acid Phosphatase Increased							
	Prostatic Specific Antigen Increased							
	Purulence							
	Sinus Tachycardia							
	Sinusitis							
	Tricuspid Valve Incompetence							
	Troponin I Increased							
	Vertigo							
	Weight Decreased							

Date:08/09/02ISR Number: 3960320-1Report Type:Expedited (15-DaCompany Report #WAES 0207TUR00002
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Bone Marrow Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Necrosis		Fosamax	C		ORAL
Initial or Prolonged	Thrombotic					
	Thrombocytopenic Purpura					

Date:08/09/02ISR Number: 3960321-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA02156
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemoglobin Abnormal		Nonsteroidal			
Other	Upper Gastrointestinal		Anti-Inflammatory			
	Haemorrhage		Drug (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/02ISR Number: 3960323-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01839
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Post Procedural		Vioxx	SS		ORAL		
Initial or Prolonged	Complication		Prempro	SS		ORAL		
Other	Pulmonary Embolism		Vioxx	SS		ORAL		
			Cozaar	C		ORAL		
			Pyridoxine	C				
			Cyanocobalamin	C				
			Covera-Hs	C		ORAL		
			Celebrex	C				
			Folic Acid	C				
			Vitamin E	C				
			Imitrex	C				
			Zestril	C				
			Aspirin	C				
			Chondroitin And Glucosamine	C				

Date:08/09/02ISR Number: 3960325-0Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00017
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		49 DAY
Initial or Prolonged	Haemorrhage		Aspirin	SS		ORAL		4317 DAY
	Haematemesis		Amitriptyline	C		ORAL		
			Acetaminophen	C		ORAL		

Date:08/09/02ISR Number: 3960330-4Report Type:Expedited (15-DaCompany Report #WAES 0208CAN00032
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Encephalitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Meningitis		Zolmitriptan	C				
	Sepsis							

Date:08/09/02ISR Number: 3960338-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA01621
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alveolitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL		331 DAY
Initial or Prolonged	Dizziness		Hydrodiuril	SS		ORAL		
Other	Drug Hypersensitivity		Zoloft	C		ORAL		
	Gait Disturbance		Clonidine	C		ORAL		
	Nausea		Oxycontin	C				
	Normochromic Normocytic		Lipitor	C				
	Anaemia		Coumadin	C		ORAL		
	Pulmonary Oedema		Coumadin	C		ORAL		
	Renal Failure							
	Urinary Tract Infection							

Date:08/09/02ISR Number: 3960794-6Report Type:Expedited (15-DaCompany Report #2002118151US
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Faeces Discoloured Fall Leukopenia Mallory-Weiss Syndrome Prothrombin Time Prolonged Thrombocytopenia Upper Gastrointestinal Haemorrhage	Study Health Professional	Camptosar(Irinotecan) Solution, Sterile	PS		INTRAVENOUS	50 MG/M2, WEEKLY, CYCLE 11, IV	
			Gemzar (Gemcitabine Hydrochloride)	SS		INTRAVENOUS	550 MG/M2, WEEKLY, CYCLE 11, IV	
			Coumadin(Warfarin Sodium)	SS		ORAL	1 MG, QD, ORAL	
			Vioxx()	SS				
			Neurontin (Gabapentin)	C				

Date:08/12/02ISR Number: 3960750-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA00634
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:08/12/02ISR Number: 3960752-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA01597
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		

	Cerebrovascular Accident		Librium	C
	Haematochezia			
	Loss Of Consciousness			
	Syncope			
	Vomiting			

Date:08/12/02ISR Number: 3961463-9Report Type:Direct Company Report #CTU 173932
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis		Vioxx 25mg	PS		ORAL	25MG PO QD	
Initial or Prolonged			Combivent	C				
			Asa	C				
			Premarin	C				
			Zoloft	C				

Date:08/12/02ISR Number: 3961591-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Upper
	Angina Unstable
	Arrhythmia
	Supraventricular
	Atrial Fibrillation
	Atrial Flutter

		Barrett'S Oesophagus					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/PO							
		Coronary Artery Disease	Health				
		Coronary Artery Stenosis	Professional	Flomax (Tamsulosin Hydrochloride) 0.4 Mg	SS		ORAL
		Dizziness					
		Drug Hypersensitivity					
0.4 MG/UNK/PO							
		Drug Intolerance		Ginseng	SS		ORAL
PO							
		Electrocardiogram Pr		Cardura 4 Mg	SS		ORAL
4 MG/DAILY/PO							
		Shortened		Citracal Caplets + D	C		
		Electrocardiogram St		Halfprin	C		
		Segment Depression		Vitamin E	C		
		Electrocardiogram T Wave Abnormal					
		Gastroduodenitis					
		Gastrointestinal Motility Disorder					
		Hiatus Hernia					
		Hyperlipidaemia					
		Hypotension					
		Labyrinthitis					
		Low Density Lipoprotein Increased					
		Myocardial Ischaemia					
		Oesophageal Disorder					
		Orthostatic Hypotension					
		Otitis Media					
		Palpitations					
		Prostatic Acid Phosphatase Increased					
		Prostatic Specific Antigen Increased					
		Purulence					
		Sinus Tachycardia					
		Sinusitis					
		Tricuspid Valve Incompetence					
		Vertigo					

Date:08/12/02ISR Number: 3961716-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA02444
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Other	Drug Hypersensitivity
	Dysphagia
	Erythema Multiforme
	Furuncle
	Herpes Simplex
	Impaired Work Ability
	Influenza Like Illness
	Joint Swelling
	Neuritis
	Oral Candidiasis
	Oral Intake Reduced
	Oral Pain
	Osteoarthritis
	Pain In Extremity
	Pharyngitis
	Sleep Disorder

	Speech Disorder						
	Stevens-Johnson Syndrome						
	Uveitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health					MG/DAILY/PO	
		Professional	Ambien	C				
			Elavil	C				
			Imitrex	C				
			Inderal	C				
			Medicon	C				

Date:08/12/02ISR Number: 3983967-5Report Type:Periodic Company Report #WAES 0205USA03453
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Face Oedema	Health	Tab Vasotec 20 Mg	PS		ORAL	20	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Tab Vioxx Unk	SS		ORAL	PO	
			Hydrodiuril	C				
			Norvasc	C				
			Atenolol	C				
			Clonidine	C				
			Potassium Chloride	C				

Date:08/13/02ISR Number: 3961209-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02309
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	78	DAY
Hospitalization -	Myocardial Infarction		Methotrexate Sodium	C				
Initial or Prolonged			Prednisone	C		ORAL		
Other			Arava	C		ORAL		

Date:08/13/02ISR Number: 3961343-9Report Type:Expedited (15-DaCompany Report #WAES 0206NZL00033
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Herpes Simplex		Vioxx	PS	Merck & Co., Inc			4 DAY
Initial or Prolonged	Oedema Peripheral		Furosemide	C				
	Rheumatoid Arthritis							

Date:08/13/02ISR Number: 3961344-0Report Type:Expedited (15-DaCompany Report #WAES 0206DEU00003
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholestasis		Vioxx	PS	Merck & Co., Inc	ORAL		84 DAY
Initial or Prolonged	Hepatocellular Damage		Atenolol	C		ORAL		
	Hepatomegaly		Potassium Chloride	C		ORAL		
	Jaundice							
	Reflux Oesophagitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/02ISR Number: 3961345-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA01820
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Corgard	C				
	Hyperhidrosis		Hydrodiuril	C		ORAL		
	Hypoaesthesia		[Therapy					
	Influenza Like Illness		Unspecified]	C		PARENTERAL		
	Migraine		Cozaar	C		ORAL		
	Pharyngitis Streptococcal		Motrin	C				

Date:08/13/02ISR Number: 3961503-7Report Type:Direct Company Report #CTU 174008
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS			25MG QD	
Initial or Prolonged	Dizziness		Advil	SS			PRN	
	Faeces Discoloured							
	Haematocrit Decreased							
	Melaena							

Date:08/13/02ISR Number: 3963079-7Report Type:Expedited (15-DaCompany Report #EMADSS2002004712
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Escherichia Urinary Tract	Foreign	Topalgic (Tramadol					
Initial or Prolonged	Infection	Health	Hydrochloride)	PS		ORAL	ORAL	
	Hyponatraemia	Professional	Denoral (Denoral)	SS		ORAL	ORAL	
	Nephritis Interstitial		Ergix (Ibuprofen)	SS		ORAL	ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, DAILY,	
							ORAL	

	Aldacrazine (Spironolactone)	SS	ORAL 0.5 U, 1 IN 2 DAY(S), ORAL
	Prozac (Fluoxetine Hydrochloride)	C	
	Lutenyl (Nomegestrol Acetate)	C	
	Forlax (Macrogol)	C	
	Eductyl (Eductyl)	C	
	Befizal (Bezafibrate)	C	
	Spasfon (Spasfon)	C	
	Ditropan (Oxybutynin)	C	
	Efferalgan (Paracetamol)	C	
	Mopral (Omeprazole)	C	

Date:08/13/02ISR Number: 3963334-0Report Type:Expedited (15-DaCompany Report #001-0981-M0201152
Age: Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
Other	Arthralgia
	Blood Parathyroid Hormone Increased
	Decreased Activity

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dermatitis Exfoliative Drug Interaction Erythema Multiforme Haemorrhage Iatrogenic Injury Injury Kidney Transplant Rejection Myalgia Pain Rash	Consumer Health Professional	Atorvastatin (Atorvastatin)	PS		ORAL
20 MG (DAILY), ORAL				Amlodipine (Amlodipine)	SS		
10 MG (DAILY),				Celecoxib (Celecoxib)	SS		
				Clonazepam (Clonazepam)	SS		
				Cyclobenzaprine (Cyclobenzaprine)	SS		
				B Complex (Becosym Forte)	SS		
				Rofecoxib (Rofecoxib)	SS		
				Paricalcitol (Paricalcitol)	SS		
INTRAVENOUS	INTRAVENOUS			(Humulin N) (Insulin Human Injection, Isophane)	SS		
SUBCUTANEOUS	SUBCUTANEOUS			Imuran (Azathioprine)	SS		
				Prednisone (Prednisone)	SS		
				Furosemide (Furosemide)	SS		
				Cyclosporine (Ciclosporin)	SS		
				Clonidine (Clonidine)	SS		
				Metoprolol Succinate (Metoprolol Succinate)	SS		
				Bisoprolol Fumarate (Bisoprolol Fumarate)	SS		

			Insulin	C
			Erythropoietin	C
			Iron Dextran	C

Date:08/14/02ISR Number: 3961678-XReport Type:Expedited (15-DaCompany Report #WAES 0204DEU00104
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hepatotoxicity		Amoxicillin Trihydrate And Clavulanate Potassium	SS				
	Infection							
	Overdose							
			Corticosteroids (Unspecified)	C				

12 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/02ISR Number: 3961681-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02596
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Intervertebral Disc Protrusion							

Date:08/14/02ISR Number: 3961927-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA01707
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				

Date:08/14/02ISR Number: 3961930-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA01614
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Prilosec	C				
	Oedema Peripheral		Atenolol	C				
			Folic Acid	C				
			Tylenol	C				
			Propulsid	C				
			Hydrochlorothiazide And Triamterene	C				

Date:08/14/02ISR Number: 3961931-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02066
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Plavix	C		ORAL		
	Vascular Graft Occlusion		Synthroid	C		ORAL		
			Zocor	C		ORAL		

			Folic Acid	C		
			Imdur	C		ORAL
			Aspirin	C		ORAL
			Norvasc	C		ORAL

Date:08/14/02ISR Number: 3961936-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA02297
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Hospitalization - Initial or Prolonged			Coumadin	C				

Date:08/14/02ISR Number: 3961939-4Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00013
Age:67 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Confusional State
	Fall
	Logorrhoea

Parkinson'S Disease

			Report Source	Product	Role	Manufacturer	Route	Dose	Duration
				Vioxx	PS	Merck & Co., Inc	ORAL		
				Zopiclone	C		ORAL		
				Benserazide Hydrochloride And Levodopa	C		ORAL		
				Benserazide Hydrochloride And Levodopa	C		ORAL	1	DAY
				Omeprazole	C		ORAL		
				Paroxetine	C		ORAL		
				Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
				Lisinopril	C		ORAL		
				Flecainide Acetate	C		ORAL		
				Aspirin Lysine	C		ORAL		

Date:08/15/02ISR Number: 3962434-9Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00054
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Other			Lithium Carbonate	C		ORAL		
			Risperidone	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:08/15/02ISR Number: 3962444-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA01878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lasix (Furosemide)	C				

Date:08/15/02ISR Number: 3962450-7Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00056
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Hallucination, Visual		Risperidone	SS		ORAL		3 DAY
	Tachyarrhythmia		Atenolol	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Prednisolone	C		ORAL		
			Fosamax	C		ORAL		

Date:08/15/02ISR Number: 3962483-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA02203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/02ISR Number: 3962484-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA02164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/02ISR Number: 3962485-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA02284
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 369 DAY	Gangrene		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Furosemide	C				
	Ulcer		Triazolam	C				
			Alprazolam	C				
			Temazepam	C				
			Zinc (Unspecified)	C				
			Humulin N	C				
			Humulin N	C				

Date:08/15/02ISR Number: 3962510-0Report Type:Direct Company Report #CTU 174185
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx (Rofecoxib)	PS				
Initial or Prolonged	Coagulopathy		Coumadin (Warfarin)	SS				
	International Normalised							
	Ratio Increased							
	Peptic Ulcer							
	Upper Gastrointestinal							
	Haemorrhage							

Date:08/15/02ISR Number: 3962649-XReport Type:Expedited (15-DaCompany Report #WAES 0208NOR00002
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Melaena	Professional	Prednisolone	SS		ORAL
	Nausea		Methotrexate	C		ORAL
			Folic Acid	C		ORAL
			Timolol Maleate	C		
OPHTHALMIC						

Date:08/15/02ISR Number: 3962650-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01902
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Haemorrhage	Professional	Flexeril	C				
	Hypersensitivity							
	Hypertension							

Date:08/15/02ISR Number: 3962654-3Report Type:Expedited (15-DaCompany Report #WAES 0208USA02336
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/02ISR Number: 3963973-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Atrial Fibrillation	Health					MG/DAILY/PO	
	Atrial Flutter	Professional	Flomax (Tamsulosin					
	Atrial Tachycardia		Hydrochloride) 0.4					
	Barrett'S Oesophagus		Mg	SS		ORAL	0.4 MG/PO	
	Benign Prostatic		Ginseng	SS		ORAL	PO	
	Hyperplasia		Cardura 4 Mg	SS		ORAL	4 MG/DAILY/PO	
	Blood Cholesterol		Citracal Caplets + D	C				
	Increased		Halfprin	C				
	Coronary Artery Disease		Vitamin E	C				
	Dilatation Atrial							
	Dizziness							
	Drug Hypersensitivity							
	Electrocardiogram Pr							
	Shortened							
	Electrocardiogram St							
	Segment Depression							
	Electrocardiogram T Wave							
	Biphasic							
	Gastritis							
	Gastroduodenitis							
	Hiatus Hernia							
	Hypertension							
	Intervertebral Disc							
	Disorder							
	Labyrinthitis							
	Low Density Lipoprotein							
	Increased							
	Myocardial Ischaemia							
	Oesophageal Disorder							
	Oesophageal Spasm							
	Oesophagitis							
	Orthostatic Hypotension							
	Otitis Media							
	Prostatic Specific							
	Antigen Increased							
	Sinus Tachycardia							

Sinusitis
Tricuspid Valve
Incompetence
Vertigo

Date:08/15/02ISR Number: 3963976-2Report Type:Expedited (15-DaCompany Report #WAES 01072531
Age:37 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Asthenia
	Back Pain
	Cervical Spinal Stenosis
	Depression
	Electrocardiogram St Segment Depression
	Faecal Incontinence
	Gait Spastic
	Grand Mal Convulsion
	Hypoaesthesia

	Impaired Driving Ability						
	Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Loss Of Consciousness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Loss Of Employment	Health					
	Myelopathy	Professional	Wellbutrin 150 Mg	SS			150 MG/BID
	Pain		Astelin	C			
	Petit Mal Epilepsy		Delestrogen	C			
	Quadriparesis		Flexeril	C			
	Spinal Cord Injury		Lipitor	C			
	Syncope		Nasonex	C			
	Urinary Incontinence		Profen Ii	C			
			Ultram	C			
			Clonazepam	C			

Date:08/16/02ISR Number: 3962913-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA02305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Whole Blood Transfusion		Vioxx	PS	Merck & Co., Inc	ORAL	
			Aspirin	C			

Date:08/16/02ISR Number: 3963009-8Report Type:Direct Company Report #CTU 174366
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Nephrotic Syndrome		Vioxx	PS		ORAL	ORAL
	Renal Failure Acute						

Date:08/16/02ISR Number: 3963027-XReport Type:Expedited (15-DaCompany Report #WAES 0208FRA00022
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - 137 DAY	Eczema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Prurigo		Valsartan	C		ORAL
			Nicardipine	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Furosemide	C		ORAL
			Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL
137 DAY			Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL

Date:08/16/02ISR Number: 3963028-1Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00030
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Left Ventricular Failure		Alfuzosin	C		ORAL
	Lung Infection		Fenofibrate	C		ORAL

Date:08/16/02ISR Number: 3963029-3Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00038
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Escherichia Infection	Professional	Ibuprofen	SS		ORAL	2	DAY
	Nephritis Interstitial		Tramadol					
	Nephrotic Syndrome		Hydrochloride	C		ORAL	20	DAY
	Renal Failure Acute		Nomegestrol	C		ORAL		
			Potassium Bitartrate And Sodium Bicarbonate	C		ORAL		
			Clocinizine	C		ORAL	13	DAY
			Pholcodine	C		ORAL	13	DAY
			Bezafibrate	C		ORAL		
			Polyethylene Glycol 4000	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Althiazide And Spironolactone	C		ORAL	145	DAY

Date:08/16/02ISR Number: 3963031-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA01276
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Grand Mal Convulsion	Professional	Vioxx	SS		ORAL	70	DAY
Initial or Prolonged	Status Epilepticus							

Date:08/16/02ISR Number: 3963032-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01901
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Vioxx	SS		ORAL		
	Fatigue		Methotrexate	C				
			Aspirin	C				
			Paxil	C				
			Hydrochlorothiazide	C				
			Potassium (Unspecified)	C				
			Xanax	C				
			Singulair	C		ORAL		

Date:08/16/02ISR Number: 3963034-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02612
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Chloride Decreased
Hospitalization - Initial or Prolonged	Blood Sodium Decreased
	Blood Urea Increased
Other	Cardiac Murmur
	Coronary Artery Disease
	Coronary Artery Stenosis
	Diabetes Mellitus
	Gastric Ulcer Haemorrhage
	Haematocrit Decreased
	Haemoglobin Abnormal

	Lung Infiltration						
	Lymphocyte Percentage Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	723 DAY
	Myocardial Ischaemia		Prinivil	C		ORAL	
	Neutrophil Percentage Increased		Vicodin Es Tablets	C		ORAL	
			Humibid L.A.	C		ORAL	
	White Blood Cell Count Abnormal		Histussin-Hc Syrup	C		ORAL	
			Glyburide	C		ORAL	

Date:08/16/02ISR Number: 3963035-9Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00159
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Circulatory Collapse	Health	Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY
Initial or Prolonged	Hepatitis Cholestatic	Professional	[Therapy Unspecified]	C		ORAL	

Date:08/16/02ISR Number: 3963037-2Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00027
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9 DAY
Initial or Prolonged	Hypertension	Professional	Vioxx	SS		ORAL	54 DAY
			Zolmitriptan	C		ORAL	
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL	

Date:08/16/02ISR Number: 3963038-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA02193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Coma Hyperkalaemia Pyrexia		Vioxx Vasotec	PS C	Merck & Co., Inc	ORAL

Date:08/16/02ISR Number: 3964858-2Report Type:Expedited (15-DaCompany Report #2002CG01248
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation	Foreign	Mopral	PS		ORAL	20 MG DAILY	
Initial or Prolonged	Confusional State	Health					PO	
	Fall	Professional	Imovane	SS		ORAL	7. 5 MG DAILY	
	Logorrhoea	Other					PO	
	Parkinsonism		Modopar	SS		ORAL	3 DF DAILY PO	
			Vioxx	SS		ORAL	1 DF DAILY PO	
			Deroxat	SS		ORAL	20 MG DAILY	
							PO	

Date:08/17/02ISR Number: 3963390-XReport Type:Direct Company Report #CTU 174390
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL	PO	
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/02ISR Number: 3964614-5Report Type:Expedited (15-DaCompany Report #WAES 0204ESP00010
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Urea Increased	Professional	Vasotec	SS		ORAL		
Initial or Prolonged	Drug Interaction		Furosemide	SS		ORAL		
	Pulmonary Oedema		Tramadol Hydrochloride	C		ORAL		
			Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		
			Clorazepate Dipotassium	C		ORAL		

Date:08/22/02ISR Number: 3964615-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colonic Polyp	Professional	Vitamins (Unspecified)	C				
	Deep Vein Thrombosis		Synthroid	C		ORAL		
	Sinus Bradycardia		Lamisil	C				
			Chondroitin And Glucosamine	C		ORAL		
			Celebrex	C		ORAL		

Date:08/22/02ISR Number: 3964617-0Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00025
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/22/02ISR Number: 3964627-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome PT

Death	Aortic Valve Disease
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Blood Sodium Decreased
	Bronchitis
	Cardiac Failure Congestive
	Cardiomyopathy
	Coronary Artery Disease
	Drug Ineffective
	Hypochromasia
	Hypoxia
	Immobile
	Low Density Lipoprotein Increased
	Mitral Valve Disease
	Myocardial Infarction
	Oedema Peripheral
	Onychomycosis
	Pleural Effusion
	Pneumonia
	Pulmonary Embolism

		Pulmonary Oedema					
		Red Blood Cell Count Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Tachycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles	Professional	Aleve	C		ORAL
		Ventricular Fibrillation		Vicodin Tablets	C		ORAL
		Ventricular Hypokinesia		Oxycontin	C		ORAL
				Ultram	C		ORAL
				Ceftin	C		ORAL
				Mevacor	C		ORAL
				Aspirin	C		ORAL
				Lipitor	C		ORAL
				[Therapy Unspecified]	C		
TOPICAL							

Date:08/22/02ISR Number: 3964628-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA02292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/22/02ISR Number: 3964631-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02610
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
26 MON						
	Asthenia	Professional	Ultram	SS		
	Back Pain					
	Chromaturia					
	Creatinine Renal Clearance Increased					
	Haematuria					
	Hypertension					
	Nausea					
	Proteinuria					
	Renal Disorder					

Date:08/22/02ISR Number: 3964633-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA02883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/22/02ISR Number: 3964635-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA02707
Age:95 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ultram	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/02ISR Number: 3964638-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02066
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Synthroid	C		ORAL		
	Vascular Graft Occlusion		Zocor	C		ORAL		
			Folic Acid	C				
			Plavix	C		ORAL		
			Imdur	C		ORAL		
			Aspirin	C		ORAL		
			Norvasc	C		ORAL		

Date:08/22/02ISR Number: 3964639-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01980
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Perforation		Effexor	C		ORAL		
Initial or Prolonged	Peritonitis		Allopurinol	C		ORAL		
Disability			Xanax	C				
Other			Fosamax	C		ORAL		
			Premarin	C				
			Sinemet	C				
			Aspirin	C		ORAL		
			Prempro	C				

Date:08/22/02ISR Number: 3964643-1Report Type:Expedited (15-DaCompany Report #WAES 0208ISR00009
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Panophthalmitis		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Papilloedema		Etanercept	C			1	YR
	Visual Acuity Reduced		Prednisone	C		ORAL		
			Methotrexate	C		ORAL	6	YR

Date:08/22/02ISR Number: 3964647-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA02625
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/22/02ISR Number: 3964648-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA02817
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Conjunctival Hyperaemia		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Eye Swelling		Neurontin	C				
	Eyelid Margin Crusting		Potassium (Unspecified)	C				
	Systemic Lupus Erythematosus		Synthroid	C				
			Premarin	C				
			Tenex	C				
			Moduretic	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/22/02ISR Number: 3964649-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA02609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/22/02ISR Number: 3964653-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03549
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				
			Quinine Sulfate	C				
			Zyrtec	C				
			Aspirin	C				

Date:08/22/02ISR Number: 3964654-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA00994
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Dizziness Feeling Abnormal	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Neurontin	C				
			[Therapy Unspecified]	C				

Date:08/22/02ISR Number: 3964659-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA03013
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	773 DAY	
Disability	Blood Pressure Increased Musculoskeletal Stiffness Oedema Peripheral Palpitations		Aspirin	C				

Date:08/22/02ISR Number: 3964662-5Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00086
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
			Atenolol	C				
			Felodipine	C				

Date:08/22/02ISR Number: 3964670-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA02784
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Drug Interaction		[Therapy					
	Pyrexia		Unspecified]	SS				
	Renal Failure		Zestril	C				
	Vision Blurred		Indapamide	C				

Date:08/22/02ISR Number: 3964672-8Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00101
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine Increased		Ramipril	SS		ORAL		
	Blood Urea Increased		Furosemide And Spironolactone	SS		ORAL	614 DAY	
	Drug Interaction		Digitoxin	C		ORAL		
	Fatigue		Omeprazole	C		ORAL		
	Hyperkalaemia							
	Muscular Weakness							

Date:08/22/02ISR Number: 3964695-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angiopathy
	Anorexia
Other	Anxiety
	Arthralgia
	Atherosclerosis
	Biliary Neoplasm
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomyopathy
	Chest Pain
	Coronary Artery Disease
	Dermatitis
	Dilatation Atrial
	Drug Interaction
	Drug Withdrawal Syndrome
	Dry Mouth
	Dry Skin
	Dyspnoea
	Erectile Dysfunction
	Erythema Multiforme
	Fatigue
	Graft Dysfunction
	Haematocrit Decreased
	Haemodialysis
	Haemoglobin Decreased

Haemorrhage
Hypertension
Injury
Kidney Transplant
Rejection
Liver Function Test
Abnormal
Lung Infiltration
Muscle Rigidity
Muscular Weakness
Myalgia
Rales
Rash
Red Blood Cell Count
Abnormal
Red Blood Cell Count
Decreased
Renal Disorder

		Renal Failure					
		Rosacea					
		Sinus Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Somnolence	Professional	Lipitor	SS		ORAL
366	DAY						
		Weight Decreased		Zemplar	SS		
				Imuran (Azathioprine)	C		ORAL
				Prednisone	C		ORAL
				Lasix (Furosemide)	C		ORAL
				Sandimmun	C		ORAL
				Clonidine Hydrochloride	C		ORAL
				Calcium (Unspecified) And Vitamin D (Unspecified)	C		
				Zaroxolyn	C		ORAL
				Ultralente Insulin	C		
PARENTERAL							
				Toprol Xl Tablets	C		ORAL
				Viagra	C		ORAL
				Humulin	C		
PARENTERAL							
				Clonazepam	C		
				Norvasc	C		ORAL
				Zebeta	C		ORAL
				Cyclobenzaprine Hydrochloride	C		ORAL
				Vitamin B Complex	C		ORAL
				Celebrex	C		

Date:08/22/02ISR Number: 3964962-9Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11945748
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Haemodialysis		Glucophage Tabs 850 Mg	PS	Bristol-Myers Squibb Company	ORAL
Other		Hypoglycaemia					
		Lactic Acidosis					
		Renal Failure Acute		Spiroctazine	SS		ORAL
				Vioxx	SS		ORAL
				Colchicine	SS		ORAL

			Colchimax	C		

Dose Regimen:

3 tabs/day

during 3

days, then 2

tabs/day

Date:08/22/02ISR Number: 3965062-4Report Type:Expedited (15-DaCompany Report #WAES 0204USA00220
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 4 DAY	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 4 DAY	Coordination Abnormal		Vioxx	SS		ORAL
Disability	Hallucination		Prilosec	C		
			Lasix (Furosemide)	C		
			Humulin 70/30	C		
			Magnesium (Unspecified)	C		
			Fosamax	C		ORAL
			Allopurinol	C		

			Nadolol	C		
			Digoxin	C		
			Miacalcin	C		
			Nitroglycerin	C		
TOPICAL						
			Pravachol	C		
			Pepcid	C		ORAL
			Lotrel	C		
			Plavix	C		
			Levoxyl	C		
			Premarin	C		
5 DAY						
			Cyanocobalamin	C		
PARENTERAL						

Date:08/22/02ISR Number: 3965065-XReport Type:Expedited (15-DaCompany Report #WAES 0208PRI00001
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	
3 DAY						
	Left Ventricular Failure		Propranolol Hydrochloride	C		
	Myocardial Infarction		Glyburide	C		
	Pulmonary Oedema		Metformin Hydrochloride	C		
	Transient Ischaemic Attack		Tramadol Hydrochloride	C		
			Esomeprazole Magnesium	C		

Date:08/22/02ISR Number: 3965076-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA03051
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Gait Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL
	Vertigo		Vioxx	SS		ORAL
			Tenoretic	C		
			Estrogens (Unspecified)	C		
			Aciphex	C		

Date:08/22/02ISR Number: 3965747-XReport Type:Direct Company Report #CTU 174837
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Rofecoxib	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Haemoglobin Decreased						BY MOUTH	2 YR
Other	Upper Gastrointestinal Haemorrhage							

Date:08/23/02ISR Number: 3965431-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA03554
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS		ORAL	4 DAY	
Initial or Prolonged			Paxil	C				
Disability			Ibuprofen	C				
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/02ISR Number: 3965438-5Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00111
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Life-Threatening			Domperidone	C		ORAL		
			Ranitidine	C		ORAL		
			Propranolol	C		ORAL		
			Valsartan	C		ORAL		

Date:08/23/02ISR Number: 3965439-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA02426
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ageusia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anosmia	Professional	Vioxx	SS		ORAL		

Date:08/23/02ISR Number: 3965441-5Report Type:Expedited (15-DaCompany Report #WAES 0208NOR00008
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Bullous	Health	Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
Initial or Prolonged	Rash	Professional	Methotrexate Sodium	C		ORAL		
	Skin Necrosis		Hydrochlorothiazide					
	Vasculitis		And Valsartan	C		ORAL		
	Wound							
	Wound Infection							

Date:08/23/02ISR Number: 3965641-4Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00098
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Hyperhidrosis		[Therapy					

	Palpitations		Unspecified]	C		

Date:08/23/02ISR Number: 3965643-8Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00102
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - MON	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged MON	Reflux Oesophagitis		Fosamax	SS		ORAL
			Fosamax	SS		ORAL

Date:08/23/02ISR Number: 3965646-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA02470
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Upper Gastrointestinal		Vioxx	SS		ORAL
Other	Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/02ISR Number: 3965648-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA03153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/23/02ISR Number: 3965649-9Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00123
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Non-Hodgkin'S Lymphoma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/23/02ISR Number: 3965653-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA02998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Headache		Viramune	C				
	Meningism		Zerit	C				
	Syncope		Epivir	C				
			Viread	C				

Date:08/23/02ISR Number: 3967194-3Report Type:Expedited (15-DaCompany Report #EMADSS2002004934
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression	Foreign	Duragesic (50 Mcg/Hr					
Hospitalization -	Anxiety	Health	Patch) (Fentanyl)	PS				
TRANSDERMAL 50 MCH/H, 1								
Initial or Prolonged	Excitability	Professional						
IN 72								
	Hyperhidrosis							
HOUR(S),								
	Restlessness							
TRANSD								

Oxygesic (Oxycodone) SS ORAL
20 MG, 3 IN 1

DAY(S), ORAL
Vioxx (Rofecoxib) SS ORAL
25 MG, 2 IN 1

DAY(S), ORAL

Date:08/26/02ISR Number: 3965991-1Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Balance Disorder		Vioxx	SS		ORAL		3 DAY
Disability	Bundle Branch Block Left		Vioxx	SS		ORAL		
	Faecal Occult Blood		Vioxx	SS		ORAL		7 DAY
	Positive		Aristocort	C			PARENTERAL	1 DAY
	Fall		Ziac	C		ORAL		
	Haemorrhagic Stroke		Hyzaar	C		ORAL		
	Radius Fracture		Zoloft	C		ORAL		
	Sinus Bradycardia		Toradol	C			INTRAMUSCULAR	
	Thrombocytopenia							

Date:08/26/02ISR Number: 3965997-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA03216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/02ISR Number: 3965999-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA02613
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Congestive		[Therapy					
Other	Diabetes Mellitus		Unspecified]	C				
	Non-Insulin-Dependent							
	Diastolic Dysfunction							
	Tracheobronchitis							

Date:08/26/02ISR Number: 3966000-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA03032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
Initial or Prolonged	Haemorrhage							

Date:08/26/02ISR Number: 3966001-2Report Type:Expedited (15-DaCompany Report #WAES 0208BRA00061
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mesenteric Occlusion		Vioxx	PS	Merck & Co., Inc			

Date:08/26/02ISR Number: 3966002-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA03234
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemoglobin Decreased							
	Ulcer							

Date:08/26/02ISR Number: 3966094-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA02071
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Plendil	C		ORAL		
			Prozac	C				
Other								

Date:08/26/02ISR Number: 3966099-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA03544
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/26/02ISR Number: 3966101-7Report Type:Expedited (15-DaCompany Report #WAES 0208BEL00014
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatotoxicity		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Antineoplastic (Unspecified)	SS				
Disability			Celecoxib	C		ORAL		
			Lorazepam	C		ORAL		
								16 DAY

				Piperacillin Sodium And Tazobactam Sodium	C		
INTRAVENOUS		8	DAY				
				Acyclovir	C		ORAL
				Cisapride	C		ORAL
12	DAY						
				Ranitidine Hydrochloride	C		ORAL
12	DAY						
				Citalopram Hydrobromide	C		ORAL

Date:08/26/02ISR Number: 3966104-2Report Type:Expedited (15-DaCompany Report #WAES 0208FIN00002
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS		ORAL	10	DAY
Initial or Prolonged	Haemoglobin Decreased		Warfarin	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL	4	DAY
			Digitalis	C				
			Isosorbide Mononitrate	C		ORAL		
			Pentoxifylline	C		ORAL		
			Celiprolol Hydrochloride	C		ORAL		
			Lansoprazole	C		ORAL		
			Prednisolone	C		ORAL		

Date:08/26/02ISR Number: 3966106-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA03387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/26/02ISR Number: 3966107-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA03509
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS		ORAL		
			[Therapy Unspecified]	C				

Date:08/26/02ISR Number: 3966108-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA03000
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
292 DAY								
Initial or Prolonged	Back Pain		Axid	C				
	Flatulence		Synthroid	C				
	Gastrointestinal		Hydrodiuril	C		ORAL		
	Haemorrhage		Triamterene	C				
	Myalgia		Diltiazem					
	Myocardial Infarction		Hydrochloride	C				
	Nausea		Miacalcin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/02ISR Number: 3966109-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA03569
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							
	Drug Hypersensitivity							
	Hepatic Neoplasm Malignant							

Date:08/26/02ISR Number: 3966110-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA03551
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oesophageal Disorder		Nexium	C				

Date:08/26/02ISR Number: 3966681-1Report Type:Expedited (15-DaCompany Report #2002118151US
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Study	Camptosar					
	Asthenia	Health	(Irinotecan)					
	Blood Sodium Decreased	Professional	Solution, Sterile	PS			INTRAVENOUS	50 MG/M2, WEEKLY,CYCLE 11, IV
	Chills							
	Faeces Discoloured							
	Fall		Gemzar (Gemcitabine					
	Leukopenia		Hydrochloride)	SS			INTRAVENOUS	550 MG/M2, WEEKLY, CYCLE 11, IV
	Mallory-Weiss Syndrome							
	Prothrombin Time							
	Prolonged		Coumadin (Warfarin					
	Thrombocytopenia		Sodium)	SS		ORAL	1 MG, QD,	

Upper Gastrointestinal
ORAL
Haemorrhage Vioxx SS
White Blood Cell Count Neurontin
Increased (Gabapentin) C

Date:08/26/02ISR Number: 3966770-1Report Type:Direct Company Report #USP 55060
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx (Rofecoxib)	PS	Merck			

Date:08/26/02ISR Number: 3966910-4Report Type:Direct Company Report #CTU 174989
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Hospitalization - Initial or Prolonged	Haemorrhage					ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/02ISR Number: 3967955-0Report Type:Expedited (15-DaCompany Report #2002116411FR
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Health Professional	Aldactazine (Spironolactone, Althiazide)Tablet	PS		ORAL	1 DF, EVERY 2 DAYS, ORAL	
	Body Temperature Increased							
	Culture Urine Positive	Other						
	Dysuria		Topalgic (Tramadol Hydrochloride)	SS		ORAL	ORAL	
	Headache							
	Hyponatraemia		Vioxx (Rofecoxib)	SS		ORAL	25MG, QD, ORAL	
	Nephritis Interstitial							
	Nephrotic Syndrome		Denoral (Clocinizine Hydrochloride, Buxepide Metiodide)	SS		ORAL	ORAL	
	Renal Failure Acute							
			Ergix(Ibuprofen)	SS		ORAL	200 MG , ORAL	
			Befizal	C				

Date:08/27/02ISR Number: 3966359-4Report Type:Expedited (15-DaCompany Report #WAES 0208BRA00068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL	24 DAY	4 MON
	Ventricular Hypertrophy		Omeprazole	C				
			Deflazacort	C				2 YR
			Leflunomide	C				3 MON

Date:08/27/02ISR Number: 3966363-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA01759
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	159 DAY	
	Asthenia		Allegra	C				
	Condition Aggravated		Atenolol	C		ORAL		
	Constipation		Oxycontin	C		ORAL		
	Diarrhoea		Paxil	C		ORAL		
	Difficulty In Walking		Trazodone	C				
	Drug Interaction		Lithium Citrate	C				
	Mania		Klonopin	C		ORAL		
			Insulin	C				

INTRAMUSCULAR

Date:08/27/02ISR Number: 3966365-XReport Type:Expedited (15-DaCompany Report #WAES 0208BRA00062
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
Other								

Date:08/27/02ISR Number: 3966562-3Report Type:Expedited (15-DaCompany Report #WAES 0207ESP00018
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventricular Tachycardia		Bisoprolol Fumarate	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/02ISR Number: 3966566-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02934
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Balsalazide Disodium	C		ORAL		
Other			Bextra	C				

Date:08/27/02ISR Number: 3966567-2Report Type:Expedited (15-DaCompany Report #WAES 0206GBR00160
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Amiloride Hydrochloride And Furosemide	C				
	Cerebrovascular Accident		Lansoprazole	C				
	Transient Ischaemic Attack		Clopidogrel Bisulfate	C				

Date:08/27/02ISR Number: 3966569-6Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00101
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperkalaemia		Ramipril	SS		ORAL		
			Furosemide And Spironolactone	SS		ORAL		
614 DAY			Digitoxin	C		ORAL		
			Omeprazole	C		ORAL		

Date:08/27/02ISR Number: 3966572-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA03645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/27/02ISR Number: 3966574-XReport Type:Expedited (15-DaCompany Report #WAES 0208DEU00164
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/27/02ISR Number: 3966575-1Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00040
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Myocardial Infarction		Celiprolol	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C				976 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/02ISR Number: 3966576-3Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00041
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Hyperkalaemia		Vioxx	SS		ORAL		8 DAY
	Renal Impairment		Potassium Chloride	SS		ORAL		
			Quinapril Hydrochloride	SS		ORAL		
			Quinapril Hydrochloride	SS		ORAL		
			Furosemide	C		ORAL		
			Acetaminophen And Propoxyphene Napsylate	C		ORAL		86 DAY
			Nicardipine	C		ORAL		
			Fenofibrate	C		ORAL		

Date:08/27/02ISR Number: 3966578-7Report Type:Expedited (15-DaCompany Report #WAES 0208NOR00006
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Dyspnoea		Digitoxin	C		ORAL		
			Furosemide	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Nifedipine	C		ORAL		
			Warfarin Sodium	C				
			Lisinopril	C		ORAL		
			Zocor	C		ORAL		

Date:08/27/02ISR Number: 3966579-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA03649
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/28/02ISR Number: 3966993-1Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00147
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemoglobin Decreased		Aspirin	C		ORAL		
Hospitalization -	Shock Haemorrhagic		Prednisolone	C		ORAL		
Initial or Prolonged			Torsemide	C		ORAL		

Date:08/28/02ISR Number: 3966994-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA02630
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bleeding		Celebrex	C				
Initial or Prolonged	Neoplasm Malignant							
Other								

Date:08/28/02ISR Number: 3966996-7Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00158
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	37 DAY	
Hospitalization - Initial or Prolonged	Drug Interaction		Flutamide	SS		ORAL		
	Malaise		Methotrexate	SS		ORAL		
	Pancytopenia		Prednisolone	SS		ORAL		
	Skin Infection		Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL	31 DAY	
	Vomiting		Goserelin Acetate	C		SUBCUTANEOUS	1 DAY	

Date:08/28/02ISR Number: 3967244-4Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00132
Age:12 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Photosensitivity Allergic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/28/02ISR Number: 3967245-6Report Type:Expedited (15-DaCompany Report #WAES 0208NOR00009
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS		ORAL	1 DAY	
	Congestive Dyspnoea							
	Eructation							
	Medication Error							
	Pulmonary Oedema							

Date:08/28/02ISR Number: 3967306-1Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00097
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Primidone	C		ORAL		
			Phenytoin	C		ORAL		
			Potassium Chloride	C		ORAL		
			Doxycycline	C		ORAL		
			Terbutaline Sulfate	C				
RESPIRATORY (INHALATION)								
			Fluticasone Propionate And Salmeterol Xinafoate	C				
			Bendroflumethiazide	C				
			Metoclopramide Hydrochloride	C				
			Quinine Sulfate	C				
			Prednisolone	C				
			Fosamax	C		ORAL		
			Albuterol Sulfate	C				
RESPIRATORY (INHALATION)								
			Ipratropium Bromide	C				
RESPIRATORY (INHALATION)								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/02ISR Number: 3967309-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA01879
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faecal Occult Blood		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Positive		Temazepam	C				
Disability	Gastric Ulcer Haemorrhage		Avandia	C				
Other	Haematocrit Decreased		Epogen	C				
	Haemoglobin Decreased		Iron (Unspecified)	C				
	Hypovolaemia		Tums	C				
	Oedema Peripheral		Nephrocaps	C				
	Pulse Abnormal		Lopid	C				
	Respiratory Rate		Lipitor	C				
	Increased		Neurontin	C				
			Aspirin	C				
			Oxygen	C				

Date:08/29/02ISR Number: 3967751-4Report Type:Expedited (15-DaCompany Report #WAES 0208FIN00002
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS		ORAL		10 DAY
Initial or Prolonged	Haemoglobin Decreased		Warfarin	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		4 DAY
			Warfarin	SS		ORAL		
			Digitalis	C				
			Isosorbide Mononitrate	C		ORAL		
			Pentoxifylline	C		ORAL		
			Celiprolol Hydrochloride	C		ORAL		
			Lansoprazole	C		ORAL		
			Prednisolone	C		ORAL		

Date:08/29/02ISR Number: 3968087-8Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00164
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/29/02ISR Number: 3968090-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA00512
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL
32 DAY						
Other	Tongue Coated		Flexeril	C		

Date:08/29/02ISR Number: 3968091-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA03630
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
23 DAY						
Initial or Prolonged			Monopril	C		ORAL
Disability			Hydrodiuril	C		ORAL
			Humulin Nph	C		
SUBCUTANEOUS						
			Glucotrol Xl	C		
			Glucophage	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/29/02ISR Number: 3968094-5Report Type:Expedited (15-DaCompany Report #WAES 0208ITA00035
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer							
	Melaena							

Date:08/29/02ISR Number: 3968096-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA04005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
Initial or Prolonged			Warfarin	C				

Date:08/29/02ISR Number: 3968099-4Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00151
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
	Haematemesis		Etidronate Disodium	C		ORAL		
	Mallory-Weiss Syndrome		Zocor	C		ORAL		
			Irbesartan	C		ORAL		
			Lorazepam	C		ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C				
			Senna	C				
			Lactulose	C				
			Travoprost	C				
			Perindopril	C				
			Amlodipine	C				
			Doxazosin	C				

Date:08/29/02ISR Number: 3968473-6Report Type:Direct Company Report #CTU 175334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage		Vioxx	PS	Merck			
	Heart Rate Decreased							
	Ill-Defined Disorder							

Date:08/30/02ISR Number: 3970742-0Report Type:Expedited (15-DaCompany Report #DEU-2002-0000137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression	Health	Oxygesic 20					
Hospitalization -	Agitation	Professional	Mg(Oxycodone					
Initial or Prolonged	Anxiety	Other	Hydrochloride) Cr					
	Attention		Tablet	PS		ORAL	20 MG, TID,	
	Deficit/Hyperactivity						ORAL	
	Disorder		Durogesic(Fentanyl)					
	Central Nervous System		Patch	SS		TRANSDERMAL	50 MCG, Q1H,	
	Stimulation						TRANSDERMAL	
	Drug Interaction		Vioxx(Rofecoxib)					
	Hyperhidrosis		Tablet	SS		ORAL	25 MG, BID,	
	Nervousness						ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/03/02ISR Number: 3969242-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthralgia	Professional	Lipitor	SS		ORAL
366 DAY						
Disability	Biliary Neoplasm		Zemplar	SS		
Other	Blood Parathyroid Hormone		[Therapy			
	Increased		Unspecified]	SS		
	Dermatitis		Imuran			
	Drug Hypersensitivity		(Azathioprine)	C		ORAL
	Drug Interaction		Prednisone	C		ORAL
	Drug Withdrawal Syndrome		Lasix (Furosemide)	C		ORAL
	Dry Mouth		Sandimmun	C		ORAL
	Dry Skin		Clonidine			
	Ejection Fraction		Hydrochloride	C		ORAL
	Decreased		Calcium			
	Erectile Dysfunction		(Unspecified) And			
	Erythema Multiforme		Vitamin D			
	Fatigue		(Unspecified)	C		
	Haematocrit Abnormal		Cyclosporine	C		
	Haemodialysis		Paricalcitol	C		
	Haemoglobin Abnormal		Zaroxolyn	C		ORAL
	Haemorrhage		Ultralente Insulin	C		
PARENTERAL						
	Injury		Toprol Xl Tablets	C		ORAL
	Kidney Transplant		Viagra	C		ORAL
	Rejection		Humulin	C		
PARENTERAL						
	Liver Function Test		Clonazepam	C		
	Abnormal		Norvasc	C		ORAL
	Lung Infiltration		Zebeta	C		ORAL
	Mitral Valve Incompetence		Flexeril	C		ORAL
	Myocardial Ischaemia		Vitamin B Complex	C		ORAL
	Myositis		Celebrex	C		
	Nephrocalcinosis					
	Pericardial Effusion					
	Pneumonia					
	Red Blood Cell Count					
	Abnormal					
	Renal Failure					
	Renal Transplant					
	Rib Fracture					
	Rosacea					
	Skin Chapped					

Somnolence
Ventricular Hypertrophy
Ventricular Hypokinesia

Date:09/03/02ISR Number: 3969243-5Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00033
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Stupor		Baclofen	SS		ORAL		
			Deflazacort	SS		ORAL		
			Acetaminophen	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Aspirin	C		ORAL		
			Indapamide	C		ORAL		
			Calcium (Unspecified) And Vitamin D					

(Unspecified)	C		ORAL
Cozaar	C		ORAL
Hydrochlorothiazide And Losartan Potassium	C		ORAL

Date:09/03/02ISR Number: 3969245-9Report Type:Expedited (15-DaCompany Report #WAES 0208BRA00068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pleural Effusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Initial or Prolonged	Ventricular Hypertrophy	Professional	Omeprazole	C			4	MON
			Deflazacort	C			2	YR
			Leflunomide	C			3	MON

Date:09/03/02ISR Number: 3969248-4Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00107
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Central Nervous System	Professional	Fentanyl	SS		TOPICAL	4	DAY
Initial or Prolonged	Stimulation		Oxycodone Hydrochloride	SS		ORAL		
	Drug Interaction							
	Nervousness							

Date:09/03/02ISR Number: 3969252-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA01535
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional	[Therapy Unspecified]	C				

Date:09/03/02ISR Number: 3969253-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA04142
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:09/03/02ISR Number: 3969405-7Report Type:Expedited (15-DaCompany Report #320254
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Leukocytoclastic		Torem	PS	Roche		92	DAY
Initial or Prolonged	Vasculitis		Ranitidine	SS			92	DAY
			Vioxx	SS			366	DAY
			Tiatral	SS			366	DAY
			Stilnox	C				
			Sortis	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/03/02ISR Number: 3969539-7Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00158
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Health	Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
	Proteinuria	Professional	Lansoprazole	C		ORAL		

Date:09/03/02ISR Number: 3969540-3Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00180
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Follicle Stimulating Hormone Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pregnancy Test Negative							

Date:09/03/02ISR Number: 3969550-6Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00157
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		241 DAY
Initial or Prolonged		Professional	Acetaminophen	C		ORAL		
			Furosemide	C		ORAL		
			Ramipril	C		ORAL		
			Floxacillin	C		ORAL		
			Penicillin V	C				

Date:09/03/02ISR Number: 3969556-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA04175
Age:85 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Glucose Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Other		Professional						

Date:09/03/02ISR Number: 3969558-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA04079
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Ulcer Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/04/02ISR Number: 3969902-4Report Type:Expedited (15-DaCompany Report #WAES 0208SGP00005
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
			Irbesartan	C				
			Vitamins (Unspecified)	C				

Date:09/04/02ISR Number: 3969903-6Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00029
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	26 DAY	
	Gastritis		Aspirin	SS		ORAL	27 DAY	

			Clopidogrel Bisulfate	SS		ORAL
27	DAY					
			Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL
6	DAY					
			Nifedipine	C		ORAL
27	DAY					
			Atenolol	C		ORAL
27	DAY					

Date:09/04/02ISR Number: 3970120-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA01783
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dyspnoea					
Initial or Prolonged	Hypoproteinaemia					
Other	Swelling					

Date:09/04/02ISR Number: 3970121-6Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00048
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aphthous Stomatitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Glossitis	Professional	Tolperisone Hydrochloride	SS		ORAL

Date:09/04/02ISR Number: 3970122-8Report Type:Expedited (15-DaCompany Report #WAES 0207AUS00195
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Haemorrhage		Warfarin	C		
	Melaena					

Date:09/04/02ISR Number: 3970123-XReport Type:Expedited (15-DaCompany Report #WAES 0208AUS00185
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Rabeprazole Sodium	C				
			Atenolol	C				
			Aspirin	C				
			Atorvastatin Calcium	C				

Date:09/04/02ISR Number: 3970124-1Report Type:Expedited (15-DaCompany Report #WAES 0208AUS00046
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain In Extremity	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Vasotec	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/04/02ISR Number: 3970125-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01689
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL		24 MON
	Radiculopathy		Cozaar	C		ORAL		
	Stomatitis		Glucophage	C		ORAL		
			Carbidopa And Levodopa	C		ORAL		
			Paxil	C				
			Prempro	C		ORAL		
			Synthroid	C		ORAL		
			Selegiline	C		ORAL		
			Prinivil	C		ORAL		
			Lodosyn	C		ORAL		
			Requip	C		ORAL		

Date:09/04/02ISR Number: 3970130-7Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00129
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/04/02ISR Number: 3970131-9Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00160
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Gastrointestinal Necrosis							
	Maternal Drugs Affecting Foetus							
	Pregnancy							
	Pregnancy Induced Hypertension							
	Volvulus Of Bowel							

Date:09/04/02ISR Number: 3970133-2Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00160
Age: DY Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Essential Hypertension Gastrointestinal Disorder Gastrointestinal Necrosis Maternal Drugs Affecting Foetus Neonatal Disorder Volvulus Of Bowel	Health Professional	Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/04/02ISR Number: 3970137-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA00621
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL	6	WK
	Renal Failure		Lipitor	C				
	Rhabdomyolysis		Glucophage	C				
			Prinivil	C		ORAL		
			Prinivil	C		ORAL		
			Lopressor	C				

Date:09/04/02ISR Number: 3970141-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00025
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Depakote	C				

Date:09/04/02ISR Number: 3970142-3Report Type:Expedited (15-DaCompany Report #WAES 0208USA04263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/04/02ISR Number: 3970145-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA03893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:09/04/02ISR Number: 3970779-1Report Type:Direct Company Report #CTU 175655
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Anaemia		Sotalol	PS				
	Cardio-Respiratory Arrest		Asa	SS				
	Diverticulum		Vioxx	SS				
	Duodenitis		Warfarin	SS				
	Gastrointestinal		Meperidine	SS				
	Haemorrhage		Midazolam	SS				
	Hiatus Hernia							
	Respiratory Arrest							
	Torsade De Pointes							
	Ventricular Extrasystoles							

Date:09/05/02ISR Number: 3970580-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA04229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/02ISR Number: 3970861-9Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glossitis		Vioxx	PS	Merck & Co., Inc	ORAL	90	DAY
	Oedema Peripheral		Vioxx	SS		ORAL	7	DAY
			Pravastatin Sodium	C		ORAL		
			Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		
			Aspirin	C		ORAL		

Date:09/05/02ISR Number: 3970863-2Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00047
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Melilot	C		ORAL		
	Aspartate Aminotransferase Increased		Lorazepam	C				
			Omeprazole	C		ORAL		
			Acetaminophen	C		ORAL		
	Blood Urea Increased		Acetaminophen	C		ORAL		
	Gamma-Glutamyltransferase Increased		Nitroglycerin	C		TOPICAL		

Date:09/05/02ISR Number: 3970864-4Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00049
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glossitis Pharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/05/02ISR Number: 3970875-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA04328
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis Haemorrhage Pneumonia		Vioxx Plendil Aldactone	PS C C	Merck & Co., Inc	ORAL		

Date:09/05/02ISR Number: 3970877-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA04235
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx Aspirin [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL		

Date:09/05/02ISR Number: 3972269-9Report Type:Expedited (15-DaCompany Report #PHBS2002CH10098
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Stupor	Foreign Health Professional Other	Lioresal (Baclofen) Vioxx (Rofecoxib)	PS SS		ORAL ORAL	75 MG/DAY, 25 MG/DAY,ORAL	ORAL

			Calcort (Deflazacort)	SS			ORAL 15 MG/DAY, ORAL
			Dafalgan (Paracetamol)	C			
			Norvasc	C			
			Aspirine	C			
			Fludex (Indapamide)	C			
			Calcimagon-D3	C			
			Cosaar (Losartan Potassium)	C			
			Losartan Potassium W/Hydrochlorothiazide (Losartan Potassium)	C			

Date:09/05/02ISR Number: 3972840-4Report Type:Expedited (15-DaCompany Report #2002-08-2213
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Herpes Zoster	Foreign	Fugerel (Flutamide) (Like Eulexin Capsules)	PS		ORAL	250 MG TID ORAL	
	Pancytopenia	Health Professional Other						
	Pruritus							
	Rash Generalised							
	Rash Pustular							
	Skin Infection		Methotrexat Tablets	SS		ORAL	10 MG QW ORAL	
			Vioxx (Rofecoxib) Tablets	SS		ORAL	25 MG BID ORAL	
			Prednisolon Tablets	SS		ORAL	5 MG BID ORAL	
			Valoron N Tablets	C				
			Zoladex Injectable Solution	C				

Date:09/05/02ISR Number: 3973144-6Report Type:Expedited (15-DaCompany Report #FR9159729AUG2002
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Creatinine Increased Blood Urea Increased Gamma-Glutamyltransferase Increased	Health Professional Other	Temesta (Lorazepam, Tablet, 0) Esberiven (Melilot/Rutoside, , 0) Vioxx (Rofecoxib, Tablet, 0) Mopral (Omeprazole) Nitriderm Tts (Glyceryl Trinitrate) Vastarel (Trimetazidine Hydrochloride) Doliprane (Paracetamol)	PS SS SS C C C C		ORAL ORAL ORAL	1 DOSE 1X PER 1 DAY	1301 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/02ISR Number: 3973345-7Report Type:Expedited (15-DaCompany Report #320254
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukocytoclastic Vasculitis	Foreign Health Professional	Torem (Torsemide Or Torsemide Sodium) 5 Mg	PS		ORAL	5 MG DAILY	
		Other						
			Ranitidine (Ranitidine)	SS		ORAL		
			Vioxx (Rofecoxib)	SS		ORAL		
			Tiatral (Aloxiprin)	SS		ORAL	100 MG DAILY	
			Stilnox (Zolpidem Tartrate)	C				
			Sortis (Atorvastatin Calcium)	C				

Date:09/06/02ISR Number: 3971430-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA02203
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Blood Pressure Increased		Atenolol	C		ORAL		
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage							
Disability	Cerebrovascular Accident							

Date:09/06/02ISR Number: 3971493-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA01475
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Haemorrhage		Prilosec	C				

	Gastrointestinal		Verapamil	C
	Haemorrhage		Warfarin	C
	Medication Error		Furosemide	C
			Potassium Chloride	C
			Digitek	C

Date:09/06/02ISR Number: 3971495-2Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00050
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Diarrhoea							
	Dyspepsia							
	Dyspnoea							

Date:09/06/02ISR Number: 3971505-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Aspirin	C				
	Gastrointestinal Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/06/02ISR Number: 3971510-6Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00014
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Vioxx	SS		ORAL		

Date:09/09/02ISR Number: 3972001-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01936
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Flomax (Tamsulosin Hydrochloride)	SS		ORAL		
	Barrett'S Oesophagus		Cardura	SS		ORAL		
	Blood Cholesterol Increased		Ginseng	SS		ORAL		
	Blood Pressure Increased		Vitamin E	C		ORAL		
	Drug Intolerance		Citracal Caplets + D	C		ORAL		
	Fatigue		Halfprin	C		ORAL		
	Gastroduodenitis							
	Helicobacter Gastritis							
	Hiatus Hernia							
	Hypertension							
	Infection							
	Labyrinthitis							
	Low Density Lipoprotein Increased							
	Oesophageal Disorder							
	Orthostatic Hypotension							
	Otitis Media							
	Prostatic Specific Antigen Increased							
	Sinus Tachycardia							
	Tricuspid Valve Incompetence							

Date:09/09/02ISR Number: 3972002-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA02470
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Gastritis		Vioxx	SS		ORAL		

Date:09/09/02ISR Number: 3972003-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Cardiac Flutter
	Cataract
	Corneal Scar
	Dizziness
	Dyspnoea
	Eye Irritation
	Gastroenteritis
	Headache
	Hypertension
	Maculopathy
	Photopsia

	Retinal Artery Stenosis						
	Retinal Exudates						
	Retinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	193	DAY
	Vitreous Detachment		Vioxx	SS		ORAL	46	DAY
	Vitreous Floaters		Calcium (Unspecified)	C				
			Univasc	C				
			Zoloft	C				
			Baycol	C				
			Ibuprofen	C				
			Celebrex	C				

Date:09/09/02ISR Number: 3972004-4Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00187
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL	28	DAY
Hospitalization - Initial or Prolonged								

Date:09/09/02ISR Number: 3972007-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00011
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Pruritus		Blinded Therapy	C		ORAL	3265	DAY

Date:09/09/02ISR Number: 3972010-XReport Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaphylactic Reaction

Arrhythmia
Atelectasis
Blood Pressure Increased
Body Temperature
Increased
Cardiac Arrest
Chronic Obstructive
Pulmonary Disease
Circulatory Collapse
Contusion
Exsanguination
Gastritis
Gastrointestinal Disorder
Haematemesis
Haematocrit Abnormal
Haemoglobin Abnormal
Heart Rate Increased
Large Intestinal Ulcer
Haemorrhage
Malaise
Mean Cell Volume
Increased
Muscle Tightness
Oedema
Oesophageal Ulcer

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Haemorrhage Pulmonary Fibrosis Regurgitation Of Food Respiratory Arrest					
		Rib Fracture White Blood Cell Count Abnormal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Celebrex	SS		ORAL
				Acetaminophen And Hydrocodone Bitartrate	C		ORAL
				Zydone	C		ORAL
				Pertussin N	C		ORAL
				Accolate	C		ORAL
				Claritin	C		ORAL
				Pravachol	C		ORAL
				Paxil	C		ORAL
				Flonase	C		ORAL
				Toradol	C		ORAL
				Remeron	C		ORAL
				Nystatin	C		ORAL
				Biaxin	C		ORAL
				Depo-Provera	C		
INTRAMUSCULAR							
				Hydrocortisone Acetate	C		
				Skelaxin	C		ORAL
				Tequin	C		ORAL
				Alupent	C		
RESPIRATORY (INHALATION)							
				Serevent	C		
RESPIRATORY (INHALATION)							
				Flovent	C		
RESPIRATORY (INHALATION)							
				Buspar	C		ORAL
				Lipitor	C		ORAL
				Amaryl	C		ORAL
				Percocet	C		ORAL
				Pramoxine Hydrochloride	C		
TOPICAL							
				Premarin	C		ORAL

	Proventil	C	
RESPIRATORY			
(INHALATION)			
	Demerol	C	ORAL
	Alprazolam	C	ORAL
	Carisoprodol	C	ORAL
	Aquaphor	C	
	Promethazine	C	
	Soma	C	ORAL

Date:09/09/02ISR Number: 3972013-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA02426
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anosmia	Professional	Vioxx	SS		ORAL		

Date:09/09/02ISR Number: 3972203-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/02ISR Number: 3972210-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02615
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	164	DAY
Other	Gait Spastic		Decadron					
	Hypoaesthesia		(Dexamethasone)	C		ORAL	10	DAY
	Lethargy		Prilosec	C				
	Muscle Rigidity		Singulair	C		ORAL		
	Muscle Spasticity		Serevent	C				
	Nervous System Disorder		Bromfed	C				
	Paraesthesia							
	Vertigo							

Date:09/09/02ISR Number: 3972212-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA00014
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Diastolic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Decreased		Vioxx	SS		ORAL		
	Blood Pressure Systolic		Sinemet	C				
	Increased		Prevacid	C				
	Cerebrovascular Accident		Singulair	C				
			Norvasc	C				
			Toprol Xl Tablets	C				
			Combivent	C				
			Serevent	C				
			Flovent	C				

Date:09/09/02ISR Number: 3972213-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA00413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain							
	Dyspnoea							
	Oedema Peripheral							

Date:09/09/02ISR Number: 3972214-6Report Type:Expedited (15-DaCompany Report #WAES 0209SWE00002
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization - Initial or Prolonged			Citalopram Hydrobromide	C				
			Levothyroxine Sodium	C				
			Acetaminophen	C				
			Furosemide	C				
			Amiloride Hydrochloride And Hydrochlorothiazide	C				
			Ketobemidone Hydrochloride	C				
			Tramadol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/02ISR Number: 3972215-8Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00016
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Upper Gastrointestinal		Amiloride					
Initial or Prolonged	Haemorrhage		Hydrochloride And					
			Furosemide	C		ORAL		
			Aspirin	C		ORAL		
			Nicorandil	C		ORAL		
			Acetaminophen	C		ORAL		
			Nifedipine	C		ORAL		
			Isosorbide					
			Mononitrate	C				

Date:09/09/02ISR Number: 3972217-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00009
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged			Hyzaar	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Tamsulosin					
			Hydrochloride	C		ORAL		

Date:09/09/02ISR Number: 3972225-0Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00063
Age:0 DY Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc		2	YR
			Levothyroxine Sodium	C				
			Acetaminophen And					
			Codeine Phosphate	C				
			Clomiphene Citrate	C				

Date:09/09/02ISR Number: 3973059-3Report Type:Direct Company Report #CTU 175813
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx 25mg Merck Lot M2362	PS	Merck	ORAL	25MG DAILY	
			Coumadin	C		ORAL		

Date:09/10/02ISR Number: 3972877-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA00040
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Monopril	C		ORAL		
	Haematochezia		Cortisone	C		ORAL		
	Ulcer		Florinef	C		ORAL		
			Zocor	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/02ISR Number: 3972879-9Report Type:Expedited (15-DaCompany Report #WAES 0207USA01597
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Dilantin	C		ORAL		
	Haematochezia		Albuterol	C				
RESPIRATORY								
	Loss Of Consciousness							
(INHALATION)								
	Vomiting		Amitriptyline	C				
			Vistaril	C				
			Librium	C				

Date:09/10/02ISR Number: 3972883-0Report Type:Expedited (15-DaCompany Report #WAES 0208NZL00028
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
11 DAY								
Initial or Prolonged	Congestive		Warfarin	C				
	Dyspnoea		Alendronate Sodium	C				
	Fluid Retention		Albuterol Sulfate					
	Myocardial Infarction		And Ipratropium					
			Bromide	C				
			Fluticasone					
			Propionate	C				
			Formoterol Fumarate	C				
			Furosemide	C		ORAL		
			Digoxin	C				

Date:09/10/02ISR Number: 3972886-6Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00005
Age:74 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Dyspnoea		Fluticasone					
	Respiratory Disorder		Propionate And					
			Salmeterol Xinafoate	C				
2 YR								

				Singulair	C		
2 YR							

Date:09/10/02ISR Number: 3972887-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/10/02ISR Number: 3972888-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00066
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Neutropenia		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
Other			Tramadol	SS		
			Senna	C		ORAL
			Citalopram	C		ORAL
			Acetaminophen	C		
			Fosamax	C		ORAL
			Tolterodine	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/02ISR Number: 3972890-8Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/10/02ISR Number: 3974048-5Report Type:Direct Company Report #CTU 176062
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue Hypersensitivity		Vioxx 25 Mg Tabs Merck	PS	Merck		1 TAB	

Date:09/10/02ISR Number: 3974616-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia	Consumer	Tab Vioxx 10 Mg	PS		ORAL	PO	
	Aortic Valve Incompetence	Health	Lipitor 10 Mg	SS		ORAL	10 MG/DAILY/PO	
Disability	Arthralgia	Professional						
Other	Cardiac Failure		Zemplar	SS				
	Dermatitis		(Therapy Unspecified)	SS				
	Dialysis		Celebrex	C				
	Disease Progression		Flexeril	C				
	Drug Interaction		Humulin	C				
	Dry Skin		Imuran (Azathioprine)	C				
	Dyspnoea		Lasix (Furosemide)	C				
	Erythema Multiforme		Norvasc	C				
	Haemorrhage		Sandimmun	C				
	Hypotension		Toprol Xl Tablets	C				
	Injury		Ultralente Insulin	C				
	Joint Stiffness							
	Kidney Transplant							

Rejection	Viagra	C
Mitral Valve Disease	Zaroxolyn	C
Myalgia	Zebeta	C
Pericardial Effusion	Calcium	
Pulmonary Congestion	(Unspecified) (+)	
Pulmonary Oedema	Vitami	C
Rash	Clonazepam	C
Rash Erythematous	Clonidine	
Renal Failure	Hydrochloride	C
Skin Chapped	Cyclosporine	C
Skin Disorder	Paricalcitol	C
Ventricular Hypokinesia	Prednisone	C
Weight Decreased	Vitamin B Complex	C

Date:09/10/02ISR Number: 4001650-7Report Type:Periodic Company Report #2002118116US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Capillary Disorder	Consumer	Bextra (Valdecoxib)					
	Oedema		Tablet	PS		ORAL	10 MG, ORAL	7 DAY
			Daypro (Oxaprozin)					
			Caplet	SS		ORAL	ORAL	
			Vioxx	SS				

Date:09/11/02ISR Number: 3973238-5Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00147
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haematemesis	Professional	Aspirin	C		ORAL		
Hospitalization -	Haemoglobin Decreased		Prednisolone	C		ORAL		
Initial or Prolonged	Shock Haemorrhagic		Torsemide	C		ORAL		

Date:09/11/02ISR Number: 3973240-3Report Type:Expedited (15-DaCompany Report #WAES 0207USA02357
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	139	DAY
	Hypersensitivity	Professional	Vioxx	SS		ORAL		
	Lacrimation Increased		Estradiol	C				
	Mouth Ulceration		Estradiol	C				
	Tongue Disorder							
	Tongue Oedema							

Date:09/11/02ISR Number: 3973243-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00611
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Congestive		Vioxx	SS		ORAL	1	MON
	Drug Ineffective		Tylenol	C				
			Sulfasalazine	C				
			Furosemide	C				
			Potassium (Unspecified)	C				

Date:09/11/02ISR Number: 3973244-0Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00001
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Gastric Ulcer	Professional	Dipyrone	SS		ORAL	7	DAY
	Gastric Ulcer Perforation		Ibuprofen	SS		ORAL	8	DAY
	Ileus Paralytic		Aspirin	SS		ORAL		
	Shock		Irbesartan	C		ORAL		
			Amiodarone Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Molsidomine	C		ORAL		

Date:09/11/02ISR Number: 3973516-XReport Type:Expedited (15-DaCompany Report #WAES 0209FRA00016
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer Perforation		Ciprofibrate	C		ORAL		
	Gastrointestinal Haemorrhage		Allopurinol	C		ORAL		
			Felodipine	C		ORAL		
			Urapidil	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/02ISR Number: 3973520-1Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00005
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aplastic Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Fluticasone Propionate And Salmeterol Xinafoate	C			2	YR
	Pneumonia		Singulair	C			2	YR

Date:09/11/02ISR Number: 3973524-9Report Type:Expedited (15-DaCompany Report #WAES 0208AUS00185
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Rabeprazole Sodium	C				
			Atenolol	C				
			Aspirin	C				
			Atorvastatin Calcium	C				

Date:09/11/02ISR Number: 3973534-1Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00182
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Haemorrhage		Aspirin	C			4720	DAY
	Dyspepsia		Diclofenac Sodium And Misoprostol	C				

Date:09/11/02ISR Number: 3973541-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00624
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Vaginal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Prevacid	C		

Date:09/11/02ISR Number: 3974700-1Report Type:Direct Company Report #CTU 176231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Hallucination		Vioxx 25mg	PS		

Date:09/11/02ISR Number: 3974907-3Report Type:Direct Company Report #CTU 176210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine		Carboplatin	PS		
INTRAVENOUS 414 MG						
Initial or Prolonged	Increased					
INTRAVENOUS						
	Dialysis		Vioxx	SS		ORAL
50 MG ORAL						
	Fatigue		Gemzar	C		
	Nausea		Darvocet	C		
			Phenergan	C		
			Ativan	C		
			Colace	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/02ISR Number: 3975137-1Report Type:Direct Company Report #CTU 176206
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema Peripheral		Riofecoxib 25mg Msd	PS	Msd	ORAL	25MG QD ORAL	

Date:09/12/02ISR Number: 3974360-XReport Type:Expedited (15-DaCompany Report #WAES 0207GBR00048
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Folic Acid	C		ORAL		
			Morphine Sulfate	C		ORAL		

Date:09/12/02ISR Number: 3974367-2Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00080
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL		49 DAY
			Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Zocor	C		ORAL		

Date:09/12/02ISR Number: 3974406-9Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00180
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Follicle Stimulating Hormone Increased Infertility Female		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/12/02ISR Number: 3974407-0Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00033
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:09/12/02ISR Number: 3974410-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA02624
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Exelon	C		ORAL		
Disability	Gastric Ulcer		Glucotrol Xl	C		ORAL		
Other	Gastritis Erosive Gastrointestinal Haemorrhage		Paxil	C		ORAL		
			Glucophage	C				
			Clorpres	C		ORAL		
			Lorazepam	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/02ISR Number: 3974411-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA00992
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged			Metoprolol	C				

Date:09/12/02ISR Number: 3974422-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00663
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema							

Date:09/12/02ISR Number: 3974424-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA00607
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depressed Level Of Consciousness		Dyazide	C				
			Actonel	C				
	Oedema Peripheral							

Date:09/12/02ISR Number: 3975327-8Report Type:Expedited (15-DaCompany Report #2002055497
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Acuitel (Quinapril					
Initial or Prolonged	Hyperkalaemia	Health	Hydrochloride)	PS		ORAL		
ORAL								
	Renal Failure Acute	Professional	Rofecoxib	SS		ORAL		
ORAL								
			Potassium Chloride	SS		ORAL		
ORAL								
			Furosemide	C				
			Propofan	C				

				Rilmenidine	C		
				Nicardipine Hydrochloride	C		
				Ginkor Procto	C		
				Fenofibrate	C		

Date:09/12/02ISR Number: 3975902-0Report Type:Expedited (15-DaCompany Report #WAES 01082348
Age:98 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Glucose Increased	Consumer	Tab Vioxx 12.5mg	PS		ORAL	12.5MG / PRN	
Hospitalization -	Cerebrovascular Accident	Health					/ PO	
Initial or Prolonged	Haematocrit Decreased	Professional	Cardizem	C				
	Haemoglobin Decreased		Cozaar	C				
	Neoplasm Malignant		K-Dur	C				
	Peptic Ulcer		Lanoxin	C				
	Red Blood Cell Count Decreased		Lasix (Furosemide)	C				
			Zoloft	C				
			Colchilcine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/02ISR Number: 3975969-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Cataract	Health	Baycol	C				
	Dizziness	Professional	Celebrex	C				
	Eye Irritation		Univasc	C				
	Gastroenteritis		Zoloft	C				
	Headache		Calcium					
	Hypertension		(Unspecified)	C				
	Keratoconjunctivitis		Ibuprofen	C				
	Sicca							
	Retinal Artery Stenosis							
	Retinal Haemorrhage							
	Retinal Ischaemia							
	Retinal Vein Thrombosis							
	Rhabdomyolysis							
	Urinary Tract Infection							
	Visual Acuity Reduced							
	Vitreous Detachment							

Date:09/12/02ISR Number: 3976165-2Report Type:Expedited (15-DaCompany Report #WAES 00070501
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Aggression
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
	Aortic Aneurysm
	Atrioventricular Block Complete
	Back Pain
	Blood Cholesterol Increased
	Blood Potassium Increased
	Blood Triglycerides Increased
	Breath Sounds Decreased
	Bundle Branch Block Left
	Cardio-Respiratory Arrest
	Cardiomegaly
	Condition Aggravated

Coronary Artery Disease
Coronary Artery Stenosis
Cough
Crepitations
Decreased Activity
Dilatation Atrial
Dilatation Ventricular
Dizziness
Dyspnoea Paroxysmal
Nocturnal
Electrocardiogram St-T
Segment Abnormal
Fall
Fluid Overload
Headache
Hyperhidrosis
Hypertension
Hypotension

		Ischaemic Cardiomyopathy Mitral Valve Incompetence Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Oedema Peripheral	Health				
MG/DAILY/PO							
		Platelet Disorder	Professional	Lasix 40 Mg	SS		
SEE IMAGE							
		Pulmonary Oedema		Ativan	C		
		Pulse Abnormal		Capoten	C		
		Red Blood Cell		Claritin	C		
		Sedimentation Rate		Deltasone	C		
		Increased		Flonase	C		
		Respiratory Rate		K-Dur	C		
		Increased		Klonopin	C		
		Sputum Abnormal		Motrin	C		
		Ventricular Extrasystoles		Nitropatch	C		
		Ventricular Tachycardia		Nubain	C		
		Weight Increased		Paxil	C		
				Pepcid	C		
				Plavix	C		
				Ritalin	C		
				Snemet	C		
				Tylenol With Codeine #4	C		
				Xanax	C		
				Zantac	C		
				Zocor	C		
				Aspirin	C		
				Atenolol	C		
				Codeine	C		
				Nitroglycerin	C		
				Quinine	C		

Date:09/13/02ISR Number: 3974759-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA02275
Age:75 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test		Vioxx	PS	Merck & Co., Inc	ORAL
42 DAY							
		Abnormal		Accupril	C		
		Oedema Peripheral		Synthroid	C		

Tavor	C
Norvasc	C
Quinine Sulfate	C
Hydrodiuril	C
Vitamins (Unspecified)	C
Pyridoxine	C
Calcium (Unspecified)	C
Ecotrin	C

Date:09/13/02ISR Number: 3974760-8Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dyspnoea Red Blood Cell Sedimentation Rate Increased		Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/02ISR Number: 3974761-XReport Type:Expedited (15-DaCompany Report #WAES 0201USA00365
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Disability	Haemoglobin Decreased		Prevacid	C				
Other	Platelet Disorder		Arthrotec	C				

Date:09/13/02ISR Number: 3974762-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00417
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Lower Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Aspirin	SS				
Initial or Prolonged			Fosamax	C				
Other			Lanoxin	C				
			Prevacid	C				

Date:09/13/02ISR Number: 3974764-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA00394
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholelithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Operative Haemorrhage							

Date:09/13/02ISR Number: 3974765-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA03013
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		773 DAY
Disability	Blood Pressure Increased		Aspirin	C				
	Musculoskeletal Stiffness							
	Oedema Peripheral							
	Palpitations							

Date:09/13/02ISR Number: 3974789-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00998
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/13/02ISR Number: 3974790-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00908
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		6 WK

Date:09/13/02ISR Number: 3974937-1Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00007
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphthous Stomatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/02ISR Number: 3974938-3Report Type:Expedited (15-DaCompany Report #WAES 0209DNK00004
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		363 DAY
Hospitalization -			Acetaminophen	C		ORAL		12 YR
Initial or Prolonged								
Disability								

Date:09/13/02ISR Number: 3974940-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Intentional Misuse		[Therapy					
	Suicidal Ideation		Unspecified]	C				

Date:09/13/02ISR Number: 3974941-3Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00017
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Duodenal Ulcer		Aspirin Lysine	SS		ORAL		
	Haemorrhage							

Date:09/13/02ISR Number: 3974942-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA01583
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Congestive		Vioxx	SS		ORAL		2 WK
Disability			Avandia	SS		ORAL		
Other			Lipitor	C		ORAL		

	Combivent	C	
RESPIRATORY			
(INHALATION)			
	Glucagon	C	
	Flovent	C	
	Depakote	C	
	Glucophage Xr	C	ORAL
	Diovan	C	
	[Therapy Unspecified]	C	
	Serevent Disk	C	
RESPIRATORY			
(INHALATION)			

Date:09/13/02ISR Number: 3974945-0Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00132
Age:12 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Photosensitivity Reaction Pruritus Urticaria White Blood Cell Count Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/02ISR Number: 3974948-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Engorgement		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Mouth		Premarin	C				
	Oedema Peripheral		Ambien	C				
	Superior Vena Caval Occlusion		Cartia (Aspirin)	C				
	Syncope							

Date:09/13/02ISR Number: 3974950-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01001
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/13/02ISR Number: 3975548-4Report Type:Direct Company Report #CTU 176345
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness		Rofecoxib	PS		ORAL	QD ORAL	
	Diarrhoea		Zantac	C				
	Nausea		Zyrtec	C				
	Vomiting		Hydrochodone	C				
			Flonase Nasal Sp	C				

Date:09/13/02ISR Number: 3975698-2Report Type:Direct Company Report #CTU 176340
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx 25mg	PS		ORAL	PO OD	
			Ceften	C				
			Plavix	C				
			Synthroid	C				

				Altace	C		

Date:09/16/02ISR Number: 3975480-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA00500
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Headache		Vioxx	SS		ORAL		
	Malaise		Analgesic Or					
	Nausea		Anesthetic					
	Pain		(Unspecified)	C				
	Treatment Noncompliance		Carbamazepine	C				

Date:09/16/02ISR Number: 3975481-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA02539
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Swelling		Vioxx	SS		ORAL		
			Paxil	C				
			Prilosec	C				
			Advil	C				

				Aleve	C		
				Prednisone	C		

Date:09/16/02ISR Number: 3975482-XReport Type:Expedited (15-DaCompany Report #WAES 0209NOR00009
Age:67 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Melaena		Levothyroxine Sodium	C				
			Irbesartan	C				
			Atorvastatin Calcium	C				
			Doxazosin Mesylate	C				
			Furosemide	C				
			Metoprolol Tartrate	C				

Date:09/16/02ISR Number: 3975483-1Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00107
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Central Nervous System		Fentanyl	SS			TOPICAL	4 DAY
Initial or Prolonged	Stimulation		Oxycodone					
	Drug Interaction		Hydrochloride	SS		ORAL		
	Nervousness							

Date:09/16/02ISR Number: 3975484-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Diovan	C				
	Congestive		Enbrel	C				
	Dyspnoea		Methotrexate	C				
	Fluid Retention							
	Oedema Peripheral							

Date:09/16/02ISR Number: 3975488-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA00662
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/16/02ISR Number: 3975490-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/16/02ISR Number: 3975493-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01059
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Small Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/02ISR Number: 3975494-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00928
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspnoea		Metoprolol Tartrate	C		
	Fluid Retention		Prilosec	C		
			Neurontin	C		
			Neurontin	C		
			Climara	C		
TOPICAL						

Date:09/16/02ISR Number: 3975496-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA01002
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/16/02ISR Number: 3975740-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02194
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Embolism					
	Lacunar Infarction					

Date:09/16/02ISR Number: 3975741-0Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL
Disability						
Other	Antinuclear Antibody Positive					
	Cardiolipin Antibody Positive					

Cerebrovascular Accident
Embolism
Lacunar Infarction

Date:09/16/02ISR Number: 3975743-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA00096
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Hospitalization - Initial or Prolonged	Cardiac Failure		[Therapy Unspecified]	C				
	Congestive							
	Coma		Lasix (Furosemide Sodium)	C		ORAL		
	Disease Recurrence		Lanoxin	C		ORAL		
	Dyspnoea Exertional		Prinivil	C		ORAL		
	Ejection Fraction		Coumadin	C		ORAL		
	Decreased		Glyburide	C				
	Oedema Peripheral		Avandia	C		ORAL		
	Pulse Absent							
	Ventricular Hypokinesia							
	Ventricular Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/02ISR Number: 3975745-8Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia		Vioxx	PS	Merck & Co., Inc			
Hospitalization - Initial or Prolonged								

Date:09/16/02ISR Number: 3975756-2Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00017
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer Haemorrhage		Aspirin Lysine	SS		ORAL		

Date:09/17/02ISR Number: 3976216-5Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neutropenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/17/02ISR Number: 3976219-0Report Type:Expedited (15-DaCompany Report #WAES 0203SGP00002
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			

Date:09/17/02ISR Number: 3976220-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00469
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/17/02ISR Number: 3976222-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA03153
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/17/02ISR Number: 3976223-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA03387
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Axillary Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Ecotrin	C		ORAL		
Initial or Prolonged	Pulmonary Embolism		Catapres	C		ORAL		
Other			Lasix (Furosemide)	C		ORAL		

Date:09/17/02ISR Number: 3976224-4Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00115
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	438 DAY	
	Haemorrhage		Allopurinol	C		ORAL		

			Bendroflumethiazide	C		ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL

Date:09/17/02ISR Number: 3976227-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00468
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/17/02ISR Number: 3976404-8Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00102
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Reflux Oesophagitis	Professional	Fosamax	SS		ORAL		
			Fosamax	SS		ORAL		
			Fosamax	SS		ORAL		

Date:09/17/02ISR Number: 3976407-3Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		122 DAY
Initial or Prolonged								

Date:09/17/02ISR Number: 3976408-5Report Type:Expedited (15-DaCompany Report #WAES 0207NLD00002
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Temazepam	C				

Date:09/17/02ISR Number: 3976413-9Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00060
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse		Verapamil Hydrochloride	C		ORAL		
	Supraventricular Extrasystoles		Sertraline Hydrochloride	C		ORAL		
	Tachycardia		Amitriptyline Hydrochloride	C		ORAL		

Date:09/17/02ISR Number: 3976859-9Report Type:Direct Company Report #CTU 176691
Age:37 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Dizziness
	Dyspepsia
	Halo Vision
	Hypertension
	Muscle Spasms

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS			1 OR 2 X DAILY/MTH	

Date:09/17/02ISR Number: 3977435-4Report Type:Expedited (15-DaCompany Report #B0278639A
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Confusional State Fall Logorrhoea	Foreign	Paxil Tablet (Paroxetine Hydrochloride)	PS		ORAL	20 MG PER DAY/ORAL	
			Zopiclone Tablet (Zopiclone)	SS		ORAL	7.5 MG PER DAY/ORAL	
			Modopar Capsule (Modopar)	SS		ORAL	125 MG THREE TIMES PER DAY/ORAL	
			Rofecoxib Tablet (Rofecoxib)	SS		ORAL	1 TABLET PER DAY/ORAL	
			Omeprazole Capsule (Omeprazole)	SS		ORAL	20 MG PER DAY/ORAL	
			Di-Antalvic	C				
			Flecainide Acetate	C				
			Lisinopril	C				

Lysine Aspirin C

Date:09/17/02ISR Number: 3980210-8Report Type:Expedited (15-DaCompany Report #K200201563
Age:74 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Anaemia
	Angina Unstable
	Anxiety
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiomegaly
	Coronary Artery Disease
	Dilatation Atrial
	Disease Recurrence
	Emphysema
	Hypertension
	Hypertriglyceridaemia
	Mitral Valve Incompetence
	Myocardial Ischaemia
	Nephrolithiasis
	Pericardial Effusion
	Pleural Effusion
	Pulmonary Oedema
	Renal Cyst
	Renal Failure Acute

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Tendonitis Tricuspid Valve Incompetence Ventricular Hypokinesia Ventricular Tachycardia	Study Health Professional Other	Altace Capsules (Ramipril) Capsule, 5/10 Mg	PS		ORAL
5 MG, QD, ORAL							
				H376/95 (Anticoagulant Citrate Dextrose) 2/2/2	SS		ORAL
2 UNK, ORAL							
				Vioxx (Rofecoxib) 50 Mg	SS		ORAL
50 MG, ORAL							
				Motrin (Ibuprofen)	SS		
				Lanoxin (Digoxin)	C		
				Atenolol (Atenolol)	C		
				Glipizide (Glipizide)	C		
				Pacerone (Amiodarone Hydrochloride)	C		
				Tricor (Fenofibrate)	C		
				Zocor (Simvastatin)	C		
				Plavix (Clopidogrel Sulfate)	C		
				Combivent (Salbutamol Sulfate, Ipratropium Bromide)	C		
				Coumadin "Dupont" (Warfarin Sodium)	C		
				Acetaminophen (Paracetamol)	C		
				Norvasc (Amlodipine Besilate)	C		
				Maxzide (Triamterene, Hydrochlorothiazide)	C		
				Ativan (Lorazepam)	C		
				Morphine (Morphine)	C		
				Versed (Midazolam Hydrochloride)	C		
				Lasix (Furosemide)	C		
				Albuterol			

(Salbutamol)	C
Potassium (Potassium)	C
Nitropaste (Glyceryl Trinitrate)	C
Lopressor (Glyceryl Trinitrate)	C
Vitamin K (Phytomenadione)	C
Lidocaine (Lidocaine)	C
Aspirin "Bayer" (Acetylsalicylic Acid)	C
Kefzol (Cefazolin Sodium)	C
Keflex (Cefalexin Monohydrate)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/02ISR Number: 3976900-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00060
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:09/18/02ISR Number: 3977091-5Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00070
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL		519 DAY
	Interstitial Lung Disease		Methotrexate Sodium	SS		ORAL		152 DAY
			Infliximab	SS		INTRAVENOUS	23	DAY

Date:09/18/02ISR Number: 3977093-9Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00043
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tamsulosin Hydrochloride	C		ORAL		425 DAY
			Amlodipine	C		ORAL		2252 DAY
			Aspirin Lysine	C		ORAL		
			Ifenprodil Tartrate	C				
			Glyburide	C				
			Lercanidipine Hydrochloride	C				
			Methylprednisolone	C				
			Alfuzosin Hydrochloride	C				

Date:09/18/02ISR Number: 3977094-0Report Type:Expedited (15-DaCompany Report #WAES 0209BEL00067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lorazepam	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:09/18/02ISR Number: 3977097-6Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00231
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Haemoglobin Decreased		Acetaminophen And Codeine Phosphate	C			550	DAY
	Upper Gastrointestinal Haemorrhage		Codeine Phosphate And Acetaminophen	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/02ISR Number: 3977099-XReport Type:Expedited (15-DaCompany Report #WAES 0204GBR00128
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Renal Impairment		Doxycycline	SS		ORAL		4 DAY

Date:09/18/02ISR Number: 3977101-5Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00055
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Hospitalization -			Torsemide	C		ORAL		
Initial or Prolonged			Furosemide	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Ramipril	C		ORAL		
			Aspirin	C		ORAL		

Date:09/18/02ISR Number: 3977102-7Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00050
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL		132 DAY
Initial or Prolonged	Pulmonary Oedema		Vioxx	SS		ORAL		5 DAY
	Swelling							

Date:09/18/02ISR Number: 3977103-9Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00070
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY

Initial or Prolonged	Hyponatraemia		Bendroflumethiazide	SS	ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C	ORAL
3 DAY					
			Ibuprofen	C	ORAL
9 DAY					
			Budesonide And Formoterol Fumarate	C	
RESPIRATORY					
(INHALATION)	71 DAY				
			Atenolol	C	ORAL
85 DAY					

Date:09/18/02ISR Number: 3977106-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01335
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
	Coronary Artery Disease					

Date:09/18/02ISR Number: 3977107-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01363
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 YR	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fatigue		Bextra	SS		
	Hypertension		Diltiazem Hydrochloride	C		
	Paraesthesia					

			Catapres	C		

Date:09/18/02ISR Number: 3977109-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA01484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aseptic Necrosis Bone		Vioxx	PS	Merck & Co., Inc	ORAL
			Vicodin Tablets	C		
			Prempro	C		
			Neurontin	C		
			Celestone Soluspan	C		
			Kenalog	C		
			Provigil	C		
			[Therapy Unspecified]	C		

Date:09/18/02ISR Number: 3977110-6Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00129
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypoglycaemia		Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY						
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
			Metformin	C		ORAL
			Vasotec	C		ORAL
			Paroxetine	C		ORAL
			Ranitidine	C		ORAL
			Glimepiride	C		ORAL
			Desloratadine	C		ORAL

Date:09/18/02ISR Number: 3977112-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00113
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 485 DAY	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Gastric Ulcer		Vioxx	SS			ORAL
64 DAY							
Other	Melaena		Aspirin	C			ORAL
171 DAY							
			Oxybutynin	C			ORAL
			Chlordiazepoxide	C			ORAL

Date:09/19/02ISR Number: 3977800-5Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00107
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anxiety	Foreign	Tab Vioxx			
Hospitalization -	Central Nervous System	Other	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
Initial or Prolonged	Stimulation		Tds Fentanyl	SS		
TOPICAL 50 MICROGM/HS 4 DAY						
	Drug Interaction		Tab Oxycodone Hcl	SS		ORAL
20 MG/TID						
	Nervousness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/02ISR Number: 3977801-7Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00107
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Foreign	Tab Vioxx					
Hospitalization -	Drug Interaction	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Excitability		Tds Fentanyl	SS			TOPICAL	50 MICROGM/HS 4 DAY
	Nervousness		Tab Oxycodone Hcl	SS		ORAL	20 MG/TID	

Date:09/19/02ISR Number: 3977901-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA03000
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	292 DAY	
Initial or Prolonged	Back Pain		Axid	C				
	Flatulence		Synthroid	C				
	Gastrointestinal		Hydrodiuril	C		ORAL		
	Haemorrhage		Triamterene	C				
	Myalgia		Diltiazem					
	Myocardial Infarction		Hydrochloride	C				
	Nausea		Miacalcin	C				

Date:09/19/02ISR Number: 3977902-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA03436
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Jaundice							
	Liver Disorder							
	Renal Impairment							

Date:09/19/02ISR Number: 3977905-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA00359
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Dizziness Dyspnoea Fatigue							

Date:09/19/02ISR Number: 3977907-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA01376
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/19/02ISR Number: 3977909-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA04079
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Appendicitis
Hospitalization - Initial or Prolonged	Large Intestinal Ulcer Large Intestine
Other	Perforation Leukocytosis Lymphoid Tissue

	Hyperplasia					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/19/02ISR Number: 3977912-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00607
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Dyazide	C		
Other	Cerebrovascular Accident		Actonel	C		
	Coma					
	Hepatic Failure					

Date:09/19/02ISR Number: 3977917-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA01639
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Haemorrhage		Fosamax	C		ORAL

Date:09/19/02ISR Number: 3978255-7Report Type:Expedited (15-DaCompany Report #2002-BP-03751AU(0)
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Melaena	Other	Persantin (Dipyridamole) (Ka) (Dipyridamole)	PS		ORAL
400 & 200 MG,						
2 DAILY) PO						
			Vioxx (Nr)	SS		
12.5 MG						
			Thyroxine Sodium (Levothyroxine			

Sodium) (Nr)	C
Atorvastatin (Nr)	C
Caltrate (Calcium Carbonate) (Nr)	C
Verapamil Hydrochloride (Verapamil Hydrochloride) (Nr)	C

Date:09/20/02ISR Number: 3977943-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA02184
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/20/02ISR Number: 3978006-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00007
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased

		Confusional State Disorientation Drug Level Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hallucination		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
				Digoxin	SS		ORAL
10	DAY						
				[Therapy Unspecified]	SS		ORAL
7	DAY						
				Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL
				Benserazide Hydrochloride And Levodopa	C		ORAL
				Clomipramine Hydrochloride	C		ORAL
				Buflomedil Hydrochloride	C		ORAL
				Paraffin	C		ORAL
				Lansoprazole	C		ORAL
				Fluindione	C		
				Lisuride Maleate	C		ORAL
				Amlodipine	C		ORAL
				Midamor	C		
				Furosemide	C		ORAL

Date:09/20/02ISR Number: 3978007-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Cardiac Failure		Aleve	C		ORAL
		Congestive		Vicodin Tablets	C		ORAL
		Cardiomegaly		Oxycontin	C		ORAL
		Cardiomyopathy		Ultram	C		ORAL
		Coronary Artery Disease		Ceftin	C		ORAL
		Insomnia		Mevacor	C		ORAL
		Joint Swelling		Aspirin	C		ORAL
		Laboratory Test Abnormal		Lipitor	C		ORAL

	Mitral Valve Incompetence	[Therapy	
	Myocardial Infarction	Unspecified]	C
TOPICAL			
	Pain		
	Pericardial Effusion		
	Peripheral Ischaemia		
	Pleural Effusion		
	Pneumonia		
	Pulmonary Embolism		
	Pulmonary Oedema		
	Sinus Tachycardia		
	Total Lung Capacity		
	Decreased		
	Ventricular Extrasystoles		
	Ventricular Fibrillation		
	Ventricular Hypokinesia		

Date:09/20/02ISR Number: 3978010-8Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00211
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Phosphokinase Increased		Tramadol Hydrochloride	C		PARENTERAL		
	Bronchospasm							
	Hepatocellular Damage		Metoclopramide Hydrochloride	C		PARENTERAL		
	Hypersensitivity							
			Fenofibrate	C				YR

Date:09/20/02ISR Number: 3978017-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA02689
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C				
			Casodex	C				
			Vicodin Tablets	C				
			Ultram	C				
			[Therapy Unspecified]	C				

Date:09/20/02ISR Number: 3978023-6Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00061
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Pacemaker		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Malfunction							
	Tachycardia							

Date:09/20/02ISR Number: 3978024-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA01521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/20/02ISR Number: 3978025-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA02883
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biliary Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Bundle Branch Block Right		Vioxx	SS		ORAL	3	DAY
Disability	Inguinal Hernia							
	Pancreatitis Acute							

Date:09/20/02ISR Number: 3978026-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA02998
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cerebrospinal Fluid
Initial or Prolonged	Leakage
Disability	Confusional State
Other	Headache
	Hyperhidrosis
	Loss Of Consciousness
	Pallor

Procedural Complication
Syncope

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Viramune	C				
	Zerit	C				
	Epivir	C				
	Viread	C				
	Aciphex	C				
	Restoril	C				
	Retin-A	C				
	Bactroban	C				
	Carafate	C				
	Ambien	C				
	Prilosec	C				
	Viagra	C				
	Motrin	C				

Date:09/20/02ISR Number: 3978027-3Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00040
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Leflunomide	SS		ORAL		
			Prednisone	SS		ORAL		

Date:09/20/02ISR Number: 3978030-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA01804
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/20/02ISR Number: 3978033-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01756
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Ultram	C		
			Percocet	C		
			Midrin	C		

Date:09/20/02ISR Number: 3978034-0Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00156
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY
	Jaundice		Dothiepin Hydrochloride	SS		ORAL		
	Liver Function Test Abnormal		Ranitidine	C		ORAL		
			Morphine Sulfate	C		ORAL		
			Lansoprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/02ISR Number: 3978036-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01416
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Zanaflex	C				
	Myocardial Infarction		Doxepin Hydrochloride	C				
			Klonopin	C				
			Synthroid	C				

Date:09/23/02ISR Number: 3978037-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01075
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	575	DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Synthroid	C				
			Micardis	C				
			Claritin	C				
			Tylenol	C				
			Aciphex	C				
			Cytotec	C				

Date:09/23/02ISR Number: 3978076-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA03387
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Axillary Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea		Ecotrin	C		ORAL		
	Joint Swelling		Catapres	C		ORAL		
Other	Pulmonary Embolism							

Date:09/23/02ISR Number: 3978077-7Report Type:Expedited (15-DaCompany Report #WAES 0202FRA00007
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 97 DAY	Coronary Artery	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Thrombosis	Professional	Citalopram			
Other	Myocardial Infarction		Hydrobromide	C		ORAL
			Citalopram Hydrobromide	C		ORAL

Date:09/23/02ISR Number: 3978081-9Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident
Initial or Prolonged	Akathisia
Disability	Asthenia
	Balance Disorder
	Bundle Branch Block Left
	Dizziness
	Facial Palsy
	Fall
	Fracture Nonunion
	Haematochezia
	Haemorrhagic Stroke
	Radius Fracture

Sinus Bradycardia

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY					
		Professional	Vioxx	SS		ORAL
3	DAY					
			Vioxx	SS		ORAL
104	DAY					
			Vioxx	SS		ORAL
7	DAY					
			Aristocort	C		
PARENTERAL	1 DAY					
			Ziac	C		ORAL
			Hyzaar	C		ORAL
			Zoloft	C		ORAL
			Toradol	C		
INTRAMUSCULAR						
			Vitamin E	C		
			Ascorbic Acid	C		
			Iron (Unspecified)	C		

Date:09/23/02ISR Number: 3978082-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA02205
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure Congestive					
	Oedema					

Date:09/23/02ISR Number: 3978085-6Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00003
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Arteritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Interaction		Ibuprofen	SS		
	Pain		Ibuprofen	SS		
	Rebound Effect					

Date:09/23/02ISR Number: 3978086-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA01724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haematoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Viagra	SS				

Date:09/23/02ISR Number: 3978087-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00161
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/02ISR Number: 3978093-5Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00042
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Amlodipine	SS		ORAL	6	YR
			Hydrochlorothiazide And Valsartan	SS		ORAL	6	YR
			Acetaminophen And Belladonna And Caffeine And Opium	SS		ORAL		

Date:09/23/02ISR Number: 3978094-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA01598
Age:70 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				

Date:09/23/02ISR Number: 3978095-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:09/23/02ISR Number: 3978096-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01761
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Shock							

Date:09/23/02ISR Number: 3978097-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA01763
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/23/02ISR Number: 3980120-6Report Type:Direct Company Report #177027
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Deep Vein Thrombosis		Rofecoxib	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/02ISR Number: 3980124-3Report Type:Direct Company Report #CTU 177031
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister Chills Rash Swelling		Rofecoxib	PS				

Date:09/24/02ISR Number: 3978108-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02385
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Faeces Discoloured Haematemesis Haemorrhage Platelet Count Decreased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	46	DAY

Date:09/24/02ISR Number: 3978634-8Report Type:Expedited (15-DaCompany Report #WAES 0209BRA00033
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly Pulmonary Oedema Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY

Date:09/24/02ISR Number: 3978636-1Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Sodium Feredetate	C		ORAL	47	DAY

			Opium	C		ORAL
5 DAY						
			Furosemide	C		ORAL
47 DAY						
			Warfarin	C		ORAL
47 DAY						
			Prednisolone	C		ORAL
			Rutin	C		ORAL
			Misoprostol	C		ORAL
			Antimicrobial (Unspecified)	C		ORAL

Date:09/24/02ISR Number: 3978638-5Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00052
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Rash		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Renal Impairment		Spironolactone	SS		ORAL

Date:09/24/02ISR Number: 3978642-7Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00025
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
4 MON						
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS		ORAL
9 DAY						
Other			Atenolol	C		ORAL
			Pravastatin Sodium	C		ORAL
			Hydroxychloroquine			

			Sulfate	C		ORAL
			Methotrexate	C		ORAL

Date:09/24/02ISR Number: 3978646-4Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00126
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	
Hospitalization - Initial or Prolonged	Haematemesis		Ramipril	C		ORAL		
			Trifluoperazine Hydrochloride	C		ORAL		
			Venlafaxine Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Rabeprazole Sodium	C		ORAL		

Date:09/24/02ISR Number: 3980822-1Report Type:Direct Company Report #CTU 177058
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Rofecoxib	PS				
			Aspirin	C				
Required Intervention to Prevent Permanent Impairment/Damage			Rabeprazole	C				

Date:09/25/02ISR Number: 3982542-6Report Type:Expedited (15-DaCompany Report #NSADSS2002032666
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature Health Professional	Ultram (50 Mg Tablet) (Tramadol Hydrochloride)	PS		ORAL	ORAL	
			Gabapentin (Gabapentin)	SS		ORAL	ORAL	

			Rofecoxib	SS	`	ORAL
ORAL						

Date:09/27/02ISR Number: 3984383-2Report Type:Expedited (15-DaCompany Report #WAES 01055160
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign	Vioxx			
	Cardiac Failure	Study	(Rofecoxib)	PS		ORAL
25 MG DAILY						
	Congestive	Health				
PO 115 DAY						
	Fluid Overload	Professional	Becomethasone			
	International Normalised	Other	Dipropionate	C		
	Ratio Increased		Hydrocortisone/Neomy			
	Weight Increased		cin So4/Polymyxin			
			Bso	C		
			Ispaghula Husk	C		
			Nystatin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/02ISR Number: 3984564-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA02998
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrospinal Fluid	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged	Leakage	Professional					MG/DAILY/PO	
Disability	Confusional State		Aciphex	C				
Other	Dizziness		Ambien	C				
	Encephalopathy		Bactroban	C				
	Headache		Carafate	C				
	Hyperhidrosis		Epivir	C				
	Liver Function Test		Motrin	C				
	Abnormal		Prilosec	C				
	Procedural Complication		Restoril	C				
	Syncope		Retin-A	C				
			Viagra	C				
			Viramune	C				
			Viread	C				
			Zerit	C				

Date:09/27/02ISR Number: 3984571-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA02883
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biliary Neoplasm	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged	Bowel Sounds Abnormal	Professional						
Disability	Bradycardia	Company						
	Bundle Branch Block Right	Representative						
	Diarrhoea							
	Hyperhidrosis							
	Inguinal Hernia							
	Pancreatitis Acute							
	Tremor							

Date:09/27/02ISR Number: 3984575-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00735
Age:56 YR Gender:Male I/FU:F

Outcome PT

Death	Acidosis
Hospitalization - Initial or Prolonged	Bronchitis
	Bronchopneumonia
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiomegaly
	Condition Aggravated
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Hamartoma
	Hypoxia
	Mitral Valve Incompetence
	Myocardial Infarction
	Pleural Effusion
	Pneumonia
	Pulmonary Embolism
	Pulmonary Oedema
	Sinus Tachycardia
	Sleep Disorder
	Ventricular Fibrillation

Ventricular Tachycardia

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
25 MG/DAILY/PO		Consumer	Tab Vioxx 25 Mg	PS		ORAL
		Health Professional	Aleve	C		
			Ceftin	C		
			Lipitor	C		
			Mevacor	C		
			Oxycontin	C		
			Ultram	C		
			Vicodin Tablets	C		
			Aspirin	C		

Date:09/27/02ISR Number: 3984585-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Akathisia	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged Disability	Anaemia	Health Professional	Aristocort	C				
	Blood Pressure Diastolic Decreased		Hyzaar	C				
	Bundle Branch Block Left		Toradol	C				
	Convulsion		Ziac	C				
	Electroencephalogram Abnormal		Zoloft	C				
	Faecal Occult Blood Positive		Ascorbic Acid	C				
	Fall		Iron	C				
	Haemorrhagic Stroke		Vitamin E	C				
	Hemiparesis							
	Hypertension							
	Mitral Valve Incompetence							
	Myoglobin Blood Increased							
	Osteoarthritis							
	Radius Fracture							
	Sinus Bradycardia							
	Thrombocytopenia							
	Transient Ischaemic Attack							

Date:09/27/02ISR Number: 3985945-9Report Type:Periodic Company Report #WAES 0204USA01724
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue	Consumer	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Medication Error							
	Somnolence		Prozac	C				
	Vomiting		Zestril	C				

Date:09/27/02ISR Number: 3986047-8Report Type:Periodic Company Report #WAES 0205USA01018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx	PS		ORAL	PO	
	Congestive	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/02ISR Number: 3986797-3Report Type:Periodic Company Report #WAES 0201USA03061
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Somnolence	Health Professional	Mobic	C				
			Prilosec	C				
			Zocor	C				
			Doxazosin	C				
			Verapamil	C				

Date:09/30/02ISR Number: 3983533-1Report Type:Direct Company Report #CTU 177554
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS		ORAL	PO QD	
Hospitalization - Initial or Prolonged	Dysphagia							
	Dyspnoea							
	Speech Disorder							
	Tongue Disorder							

Date:09/30/02ISR Number: 3983767-6Report Type:Direct Company Report #CTU 177596
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Prerenal Failure		Rofecoxib (Msd)	PS	Msd	ORAL	25MG PO	
			Dipyridamole	C				
			Pentoxifylline	C				
			Propranolol	C				
			Simvastatin	C				
			Nitroglycerin	C				
			Colchicine	C				

Date:10/02/02ISR Number: 3983153-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01632
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983158-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01719
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysarthria		Lithium Carbonate	SS				
	Oedema Peripheral		Paxil	SS				
	Paraesthesia		Glucophage	C				
			Glucotrol	C				
			Prilosec	C				
			Lipitor	C				
			Metamucil	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983159-XReport Type:Expedited (15-DaCompany Report #WAES 0209DEU00050
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention	Health	Vioxx	PS	Merck & Co., Inc	ORAL		122 DAY
Initial or Prolonged	Oedema Peripheral	Professional	Vioxx	SS		ORAL		15 DAY
	Pulmonary Oedema		Cholecalciferol	C		ORAL		
	Swelling		Pantoprazole Sodium	C		ORAL		
			Fentanyl	C		TOPICAL		

Date:10/02/02ISR Number: 3983160-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00270
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colitis Ulcerative	Professional	Vioxx	SS		ORAL		
Other	Haemorrhage							
	Nail Disorder							
	Stress							

Date:10/02/02ISR Number: 3983167-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA02625
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage	Professional	[Therapy					
	Peptic Ulcer		Unspecified]	C				

Date:10/02/02ISR Number: 3983168-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA03948
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		46 DAY

	Congestive	Professional	Norvasc	SS

Date:10/02/02ISR Number: 3983170-9Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00063
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged		Professional	Aspirin	SS		ORAL		

Date:10/02/02ISR Number: 3983173-4Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00186
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness	Professional	Vioxx	SS		ORAL		
	Neck Pain		Omeprazole	C		ORAL		
	Pain		Albuterol	C				
	Pain In Jaw		Beclomethasone					
	Palpitations		Dipropionate	C				
			Estropipate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983174-6Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00190
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Haemorrhage		Rabeprazole Sodium	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Cetirizine Hydrochloride	C		ORAL		

Date:10/02/02ISR Number: 3983175-8Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00020
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Visual Acuity Reduced		Prednisolone	C		ORAL		

Date:10/02/02ISR Number: 3983176-XReport Type:Expedited (15-DaCompany Report #WAES 0209TUR00001
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		36 HR
Hospitalization -	Arthralgia	Professional	Diclofenac Sodium	SS		ORAL		36 HR
Initial or Prolonged	Myocardial Infarction							

Date:10/02/02ISR Number: 3983179-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA01864
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemoconcentration	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS		ORAL		
			Celebrex	C				
			Ativan	C				

			Taloxa	C		
			Glucophage	C		
			Avandia	C		
			Zestril	C		
			Norvasc	C		

Date:10/02/02ISR Number: 3983180-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA01898
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemoglobin Decreased		Aspirin	C		

Date:10/02/02ISR Number: 3983181-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA01899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Singulair	C		ORAL
			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983182-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA02009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983185-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA00417
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Lower Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS				
			Fosamax	C				
			Lanoxin	C				
			Prevacid	C				

Date:10/02/02ISR Number: 3983186-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA03153
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983190-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01521
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prinivil	C		ORAL		
			Glyburide	C		ORAL		
			Armour Thyroid Tablets	C		ORAL		
			Bayer Aspirin	C		ORAL		

Date:10/02/02ISR Number: 3983191-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Infarct		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983192-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983199-0Report Type:Expedited (15-DaCompany Report #WAES 0207USA02539
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Inflammation	Professional	Vioxx	SS		ORAL		
	Swelling		Paxil	C				
			Prilosec	C				
			Advil	C				

				Aleve	C		
				Prednisone	C		

Date:10/02/02ISR Number: 3983200-4Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00123
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Non-Hodgkin'S Lymphoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983204-1Report Type:Expedited (15-DaCompany Report #WAES 0209BRA00033
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Pulmonary Oedema							
	Sudden Death							

Date:10/02/02ISR Number: 3983211-9Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00171
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
	Vertigo		Allopurinol	C		ORAL		

Date:10/02/02ISR Number: 3983218-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA02183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:10/02/02ISR Number: 3983219-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA02293
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Lanoxin	C				
			Theophylline	C				
			[Therapy Unspecified]	C				

Date:10/02/02ISR Number: 3983221-1Report Type:Expedited (15-DaCompany Report #WAES 0206NLD00003
Age:102 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Aspirin	C		ORAL		
			Omeprazole	C				
			Furosemide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983222-3Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00014
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vasotec	C		ORAL		12 DAY
			Acetaminophen	C		ORAL		
Other	Intestinal Perforation Post Procedural Complication		Omeprazole Sodium	C				4 DAY
			Doxycycline	C				
			Metronidazole	C				
			Dalteparin Sodium	C				4 DAY

Date:10/02/02ISR Number: 3983223-5Report Type:Expedited (15-DaCompany Report #WAES 0208NLD00021
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Hospitalization - Initial or Prolonged	Organ Failure							

Date:10/02/02ISR Number: 3983227-2Report Type:Expedited (15-DaCompany Report #WAES 0209DNK00015
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		141 DAY
	Gastric Ulcer Helicobacter		Acetaminophen	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Aspirin	C		ORAL		

Date:10/02/02ISR Number: 3983228-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA02500
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Levothyroxine Sodium	C				
	Dizziness		Lotensin	C				
	Nausea		Zoloft	C				
	Vomiting		Aspirin	C				
			Lipitor	C				

Date:10/02/02ISR Number: 3983229-6Report Type:Expedited (15-DaCompany Report #WAES 01113459
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/02ISR Number: 3983230-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia
	Anaemia
Disability	Back Injury
	Blood Pressure Increased

	Brain Oedema						
	Bundle Branch Block Left						
	Cerebral Atrophy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
	Faecal Occult Blood		Vioxx	SS		ORAL	3 DAY
	Positive		Vioxx	SS		ORAL	104 DAY
	Haemorrhagic Stroke		Vioxx	SS		ORAL	7 DAY
	Mitral Valve Incompetence		Aristocort	C			PARENTERAL 1 DAY
	Myoglobin Blood Increased		Ziac	C		ORAL	
	Radius Fracture		Hyzaar	C		ORAL	
	Sinus Bradycardia		Zoloft	C		ORAL	
	Thrombocytopenia		Toradol	C			INTRAMUSCULAR
	Wrist Deformity		Vitamin E	C			
			Ascorbic Acid	C			
			Iron (Unspecified)	C			

Date:10/02/02ISR Number: 3983231-4Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	25 DAY
Initial or Prolonged	Increased	Professional	Lithium Sulfate	SS		ORAL	
	Depressed Level Of		Levothyroxine Sodium	C			
	Consciousness		Dipyridamole	C			
	Drug Level Increased		Lofepramine				
	Extrapyramidal Disorder		Hydrochloride	C			
			Zolpidem Tartrate	C			
			Calcium Carbonate				
			And Cholecalciferol	C			
			Tramadol				
			Hydrochloride	C			

Date:10/02/02ISR Number: 3983236-3Report Type:Expedited (15-DaCompany Report #WAES 0208BRA00068
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pleural Effusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		24 DAY
Initial or Prolonged	Ventricular Hypertrophy	Professional	Omeprazole	C				4 MON
			Deflazacort	C				2 YR
			Leflunomide	C				3 MON
			Aspirin	C		ORAL		

Date:10/02/02ISR Number: 3983238-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA02820
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		35 DAY
Other	Congestive		Atenolol	C				
			Fosamax	C		ORAL		
			Aspirin	C				
			Advair	C				
			Albuterol	C				
			Lipitor	C				
			Imdur	C				
			Coumadin	C				
			Metoprolol	C				
			Nitroglycerin	C				
			Capoten	C				

			Ambien	C		

Date:10/02/02ISR Number: 3983239-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA04229
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 4 DAY	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Motrin	C		
			[Therapy Unspecified]	C		
			[Therapy Unspecified]	C		

Date:10/02/02ISR Number: 3983240-5Report Type:Expedited (15-DaCompany Report #WAES 0209CAN00086
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/02/02ISR Number: 3983244-2Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00016
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer Perforation	Professional	Ciprofibrate	C		ORAL
	Gastrointestinal		Allopurinol	C		ORAL
	Haemorrhage		Felodipine	C		ORAL
			Urapidil	C		ORAL

Date:10/02/02ISR Number: 3983245-4Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00047
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization - 70 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastritis Erosive		Althiazide And Spironolactone	C		ORAL
	Gastritis Haemorrhagic		Benserazide Hydrochloride And Levodopa	C		ORAL
	Melaena		Acetaminophen	C		ORAL
	Renal Failure Acute		Oxazepam	C		

Date:10/02/02ISR Number: 3983246-6Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00048
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 5 DAY	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 89 DAY	Gastritis	Professional	Aspirin Lysine	SS		ORAL
	Haematemesis		Labetalol Hydrochloride	C		
	Melaena		Nitroglycerin	C		
			Acetaminophen	C		
			Atorvastatin Calcium	C		
			Alprazolam	C		
			Paroxetine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983247-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00057
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse	Professional	Clopidogrel Bisulfate	SS		ORAL		
	Gastrointestinal Haemorrhage		Atorvastatin	C		ORAL		
			Nafronyl Oxalate	C		ORAL		
			Doxazosin	C		ORAL		
			Verapamil	C		ORAL		
			Indapamide	C		ORAL		

Date:10/02/02ISR Number: 3983248-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00155
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Palpitations		Prednisolone	C		ORAL		
			Gold Sodium Thiomalate	C		INTRAVENOUS		
			Atorvastatin	C		ORAL		
			Aspirin	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		
			Cholecalciferol And Calcium Carbonate	C		ORAL		
			Acetaminophen	C		ORAL		

Date:10/02/02ISR Number: 3983249-1Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00160
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	39	DAY
	Haemorrhage		Calcium Carbonate	C		ORAL	39	DAY

	Haematemesis		Furosemide	C		ORAL
	Rectal Haemorrhage		Vasotec	C		ORAL
			Fosamax	C		ORAL
18 DAY						
			Acetaminophen And Codeine Phosphate	C		ORAL
39 DAY						
			Etidronate Disodium	C		

Date:10/02/02ISR Number: 3983251-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00175
Age:51 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
36 DAY						
	Orthopnoea		Lansoprazole	C		ORAL
	Weight Increased		Acetaminophen And Codeine Phosphate	C		ORAL
			Amoxicillin	C		ORAL
			Beclomethasone Dipropionate	C		
RESPIRATORY						
(INHALATION) 22 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983253-3Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00022
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Aspirin And Magnesium Oxide	SS		ORAL		
	Helicobacter Infection		Acetaminophen And Codeine Phosphate	C				
	Melaena		Acetaminophen	C				

Date:10/02/02ISR Number: 3983257-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01724
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Subdural Haematoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Viagra	SS			8	DAY

Date:10/02/02ISR Number: 3983260-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA02282
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colon Operation		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Premarin	C				
			Coumadin	C				
			Actonel	C				

Date:10/02/02ISR Number: 3983264-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	193	DAY

	Astigmatism	Professional	Vioxx	SS	ORAL
46 DAY					
	Cardiac Flutter		Calcium		
	Cataract		(Unspecified)	C	
	Corneal Scar		Univasc	C	
	Drug Withdrawal Syndrome		Zoloft	C	
	Dyspnoea		Baycol	C	
	Gastroenteritis		Ibuprofen	C	
	Headache		Celebrex	C	
	Hypertension				
	Keratoconjunctivitis				
	Sicca				
	Presbyopia				
	Retinal Artery Stenosis				
	Retinal Haemorrhage				
	Retinal Ischaemia				
	Retinal Vein Thrombosis				
	Vitreous Detachment				

Date:10/02/02ISR Number: 3983265-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia	Professional	Lipitor	SS		ORAL	366	DAY
	Atherosclerosis		Zemplar	SS				
	Biliary Neoplasm		[Therapy					
	Blood Parathyroid Hormone		Unspecified]	SS				
	Increased		Imuran					
	Coronary Artery Disease		(Azathioprine)	C		ORAL		
	Drug Interaction		Prednisone	C		ORAL		
	Drug Withdrawal Syndrome		Lasix (Furosemide)	C		ORAL		
	Dry Mouth		Sandimmun	C		ORAL		
	Erectile Dysfunction		Clonidine					
	Erythema Multiforme		Hydrochloride	C		ORAL		
	Fatigue		Calcium					
	Haemodialysis		(Unspecified) And					
	Haemorrhage		Vitamin D					
	Hypercholesterolaemia		(Unspecified)	C				
	Injury		Iron Dextran	C				
	Mitral Valve Incompetence		Epoetin	C				
	Muscle Rigidity		Cyclosporine	C				
	Myalgia		Paricalcitol	C			INTRAVENOUS	
	Myocardial Ischaemia		Zaroxolyn	C		ORAL		
	Pericardial Effusion		Ultralente Insulin	C			PARENTERAL	
	Pneumonia		Toprol Xl Tablets	C		ORAL		
	Renal Failure		Viagra	C		ORAL		
	Rib Fracture		Humulin	C			PARENTERAL	
	Somnolence		Clonazepam	C				
	Swelling		Norvasc	C		ORAL		
	Vascular Calcification		Zebeta	C		ORAL		
	Ventricular Hypertrophy		Flexeril	C		ORAL		
	Ventricular Hypokinesia		Vitamin B Complex	C		ORAL		
			Celebrex	C				

Date:10/02/02ISR Number: 3983267-3Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00066
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 45 DAY	Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 45 DAY	Renal Impairment	Professional	Hydrochlorothiazide And Irbesartan	SS		ORAL
			Digoxin	C		ORAL
			Aspirin Lysine	C		ORAL
			Allopurinol	C		ORAL
			Fluoxetine Hydrochloride	C		ORAL
			Ginkgo Biloba Extract	C		ORAL

Date:10/02/02ISR Number: 3983271-5Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00107
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
	Haemoglobin Decreased		Morphine Sulfate	C		ORAL
	Platelet Count Decreased		Morphine Sulfate	C		ORAL
	White Blood Cell Count Decreased					

Date:10/02/02ISR Number: 3983272-7Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00045
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Atrial Fibrillation		Vasotec	C		ORAL		
	Bundle Branch Block Right		Furosemide	C		ORAL		
	Cardiac Failure		Digoxin	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Acenocoumarol	C				

Date:10/02/02ISR Number: 3983275-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA02309
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL		78 DAY
Hospitalization -	Myocardial Infarction	Professional	Methotrexate Sodium	C				
Initial or Prolonged			Prednisone	C		ORAL		
Other			Arava	C		ORAL		

Date:10/02/02ISR Number: 3983276-4Report Type:Expedited (15-DaCompany Report #WAES 0208CAN00032
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Meningitis Aseptic	Professional	Zolmitriptan	C				
	Systemic Lupus Erythematosus							

Date:10/02/02ISR Number: 3983279-XReport Type:Expedited (15-DaCompany Report #WAES 0209BRA00033
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Pulmonary Oedema							

Date:10/02/02ISR Number: 3983280-6Report Type:Expedited (15-DaCompany Report #WAES 0209DNK00013
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization - Initial or Prolonged		Professional	Prednisolone	SS		ORAL		
			Fentanyl	C				

Date:10/02/02ISR Number: 3983283-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3983285-5Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00076
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Prurigo		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Pruritus							

Date:10/02/02ISR Number: 3983286-7Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00091
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jugular Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged			Nicergoline	C		ORAL		

Date:10/02/02ISR Number: 3983288-0Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00216
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Esomeprazole Magnesium	C		ORAL		
			Tramadol	C		ORAL		3 DAY

Date:10/02/02ISR Number: 3983290-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01639
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage	Professional	Fosamax	C		ORAL		
Initial or Prolonged	Renal Failure							

Date:10/02/02ISR Number: 3983292-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02293
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Suicidal Ideation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Lanoxin	C				
			Theophylline	C				
			[Therapy Unspecified]	C				

Date:10/02/02ISR Number: 3983295-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA02702
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mountain Sickness Acute Pulmonary Oedema	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Tylenol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/02ISR Number: 3984368-6Report Type:Direct Company Report #CTU 177793
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gait Disturbance		Vioxx 25mg/D	PS				
	Headache		Synthroid	C				
	Pyrexia		Prednisone	C				
	Speech Disorder		Fosamax	C				
	Tremor							

Date:10/02/02ISR Number: 3984663-0Report Type:Expedited (15-DaCompany Report #200218536GDDC
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Frusemide	PS		ORAL	40 MG BID PO	
	Renal Impairment	Other	Rofecoxib (Vioxx)	SS		ORAL	12.5 MG / DAY	PO 55 DAY
			Perindopril	SS		ORAL	2 MG/DAY PO	
			Digoxin	C				
			Acetylsalicylic Acid (Aspirin)	C				
			Gliclazide	C				
			Cimetidine	C				

Date:10/02/02ISR Number: 3986600-1Report Type:Expedited (15-DaCompany Report #EMADSS2002005698
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Health	Durogesic (Patch) (Fentanyl)	PS		TRANSDERMAL	TRANSD	
	Aspartate Aminotransferase Increased	Professional	Tramadol Hydrochloride (Unspecified)					
	Eosinophilia		(Tramadol					

	Photosensitivity Reaction		Hydrochloride)	SS			ORAL
200 MG,							
	Toxic Skin Eruption						
DAILY, ORAL							
			Bi-Profenid (Ketoprofen)	SS			ORAL
300 MG,							
DAILY, ORAL							
			Vioxx (Rofecoxib)	SS			ORAL
1 CAP, DAILY,							
ORAL							
			Tetrazepam (Tetrazepam)	SS			ORAL
1 TABLE,							
DAILY, ORAL							
			Mopral (Omeprazole)	SS			ORAL
20 MG, DAILY,							
ORAL							

Date:10/02/02ISR Number: 3986839-5Report Type:Expedited (15-DaCompany Report #PERI00202002428
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatinine Abnormal	Foreign	Coversyl			
	Blood Urea Abnormal	Health	(Perindopril)	PS		ORAL
2 MG QD PO						
	Drug Interaction	Professional	Vioxx (Rofecoxib)	SS		ORAL
12.5 MG DAILY						
	Renal Impairment	Other				
PO						
			Frusemide (Frusemide)	SS		ORAL
80 MG DAILY						
PO						
			Digoxin (Digoxin)	C		

Acetylsalicylic Acid (Acetylsalicylic Acid)	C	
Gliclazide (Gliclazide)	C	
Cimetidine (Cimetidine)	C	

Date:10/03/02ISR Number: 3982598-0Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00082
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin Lysine	SS		ORAL		
			Tinzaparin Sodium	SS		SUBCUTANEOUS		9 DAY
	Haemoglobin Decreased Hypovolaemic Shock		Aluminum Hydroxide And Magnesium Hydroxide	C				
			Piribedil	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		
			Calcium Dobesilate	C				
			Ramipril	C		ORAL		
			Insulin	C		SUBCUTANEOUS		

Date:10/03/02ISR Number: 3982600-6Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Muscle Contractions Involuntary Muscular Weakness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/02ISR Number: 3982602-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00227
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Malaise							
	Tachycardia							

Date:10/03/02ISR Number: 3982613-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA01783
Age:20 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactoid Reaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain	Professional	Vioxx	SS		ORAL		
Initial or Prolonged	Dyspnoea							
Other	Hypoproteinaemia							
	Oedema Peripheral							
	Oesophagitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/02ISR Number: 3982618-3Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Duodenal Ulcer		Alclofenac	C		ORAL		
	Perforation		Zopiclone	C		ORAL		
	General Physical Health Deterioration		Hydrochlorothiazide And Losartan Potassium	C		ORAL		
	Peritonitis		Zocor	C		ORAL		
	Syncope		Tamoxifen Citrate	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		

34 DAY

Date:10/03/02ISR Number: 3982620-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00394
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Perirenal Haematoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:10/03/02ISR Number: 3982623-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA02502
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Nortriptyline	SS				
			Sulfamethoxazole And Trimethoprim	SS				

Date:10/03/02ISR Number: 3982624-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA02503
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Gabapentin	SS				
			Tramadol	SS				

Date:10/03/02ISR Number: 3982631-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Zocor	C		ORAL		
	Carotid Artery Stenosis		Zantac	C		ORAL		
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hyperlipidaemia							
	Influenza Like Illness							
	Loss Of Consciousness							
	Vascular Calcification							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/02ISR Number: 3982634-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA03630
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Initial or Prolonged	Haemorrhagic Stroke	Professional	Monopril	C		ORAL		
Disability			Hydrodiuril	C		ORAL		
			Humulin Nph	C			SUBCUTANEOUS	
			Glucotrol Xl	C				
			Glucophage	C				

Date:10/03/02ISR Number: 3982639-0Report Type:Expedited (15-DaCompany Report #WAES 01105003
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL		
	Complications Of Maternal		Acetaminophen And					
	Exposure To Therapeutic		Codeine Phosphate	C				
	Drugs							
	Gastroenteritis							
	Cryptosporidial							
	Lower Respiratory Tract							
	Infection							
	Postpartum Haemorrhage							
	Twin Pregnancy							

Date:10/04/02ISR Number: 3983706-8Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12053179
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Irbesartan	PS	Bristol-Myers Squibb			
Initial or Prolonged	Dyspnoea	Professional			Company	ORAL		1 YR
	Hypotension		Vioxx	SS		ORAL		5 MON
	Infection		Atorvastatin	C		ORAL		
			Indoramin Hcl	C		ORAL		
			Tolterodine	C		ORAL		

Date:10/04/02ISR Number: 3989210-5Report Type:Expedited (15-DaCompany Report #WAES 0201USA02424
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Asthma
	Blood Pressure Abnormal
	Blood Triglycerides Increased
	Cardiomegaly
	Carotid Artery Stenosis
	Choking
	Coronary Artery Disease
	Coronary Artery Occlusion
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hypokinesia
	Influenza Like Illness
	Laryngospasm

	Loss Of Consciousness Pulmonary Congestion Vascular Calcification	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO
		Health Professional	Zantac	C			
			Zocor	C			

Date:10/07/02ISR Number: 3984443-6Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00001
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	
			Aesculus And Metesculetol Sodium	C		ORAL	
			Trimebutine Maleate	C		ORAL	
			Aspirin Lysine	C		ORAL	
			Furosemide And Spironolactone	C		ORAL	
			Ciprofibrate	C		ORAL	
			Nitroglycerin	C			TOPICAL
			Anethole Trithione	C		ORAL	
			Potassium Bicarbonate And Psyllium Husk	C		ORAL	

Date:10/07/02ISR Number: 3984446-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA00130
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Disorientation Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:10/07/02ISR Number: 3984448-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00148
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/02ISR Number: 3984456-4Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00055
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Hospitalization - Initial or Prolonged		Professional	Torsemide	C		ORAL		
			Furosemide	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Ramipril	C		ORAL		
			Aspirin	C		ORAL		

Date:10/07/02ISR Number: 3984461-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00083
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eczema		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Initial or Prolonged	Pruritus		Ketoprofen	C		ORAL		59 DAY
			Tetrazepam	C		ORAL		58 DAY
			Tramadol	C		ORAL		58 DAY
			Omeprazole	C		ORAL		68 DAY
			Fentanyl	C				8 DAY

Date:10/07/02ISR Number: 3984462-XReport Type:Expedited (15-DaCompany Report #WAES 0209GBR00239
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional	Warfarin	SS		ORAL		
			Morphine	C		ORAL		
			Tamoxifen	C		ORAL		

Date:10/07/02ISR Number: 3984463-1Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00241
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Vioxx	PS	Merck & Co., Inc	ORAL		154 DAY
Initial or Prolonged	Hypotension	Professional	Irbesartan	SS		ORAL		366 DAY
			Atorvastatin	C		ORAL		
			Indoramin	C		ORAL		
			Tolterodine	C		ORAL		

Date:10/07/02ISR Number: 3984464-3Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00242
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eczema		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tramadol	C				
			Carbamazepine	C				
			Levothyroxine Sodium	C				
			Prednisolone	C				
			Aspirin	C				
			Prinivil	C				
			Fluoxetine	C				

Date:10/07/02ISR Number: 3984465-5Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00243
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
90 DAY								
Initial or Prolonged	Oesophagitis		Digoxin	C		ORAL		
			Amiloride	C		ORAL		
			Furosemide	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Bumetanide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/02ISR Number: 3984476-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA01521
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blindness Unilateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Retinal Haemorrhage	Professional	Prinivil	C		ORAL
	Visual Acuity Reduced		Glyburide	C		ORAL
			Armour Thyroid Tablets	C		ORAL
			Bayer Aspirin	C		ORAL

Date:10/07/02ISR Number: 3984478-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA02009
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Ankle Operation	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS		ORAL
	Oedema Peripheral					

Date:10/07/02ISR Number: 3984482-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA02724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Zocor	C		ORAL

Date:10/07/02ISR Number: 3984487-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA00013
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspepsia		Plavix	C		
	Feeling Hot		Zonegran	C		
	Medication Error					
	Transient Ischaemic Attack					
	Vomiting					

Date:10/07/02ISR Number: 3984490-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA01841
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		114 DAY
Life-Threatening	Circulatory Collapse	Professional	Vioxx	SS		ORAL		62 DAY
Hospitalization -	Haematemesis		Vitamin E	C		ORAL		170 DAY
Initial or Prolonged	Loss Of Consciousness		Clozaril	C		ORAL		1076 DAY
Disability	Upper Gastrointestinal		Depakote	C		ORAL		334 DAY
Other	Haemorrhage		Klonopin	C		ORAL		1409 DAY
			Levothyroxine Sodium	C		ORAL		598 DAY
			Benztropine Mesylate	C		ORAL		1409 DAY
			Prolixin	C		ORAL		1076 DAY
			Celebrex	C				
			Zantac	C		ORAL		
			[Composition Unspecified]	C				
OPHTHALMIC							532 DAY	
			[Composition Unspecified]	C		ORAL		1409 DAY
			Ddavp	C				141 DAY

Tums	C	ORAL	224 DAY
Peri-Colace	C	ORAL	191 DAY
Detrol	C	ORAL	699 DAY
Atenolol	C	ORAL	257 DAY
Benztropine Mesylate	C	ORAL	1280 DAY
Premarin	C	ORAL	1430 DAY
Klonopin	C	ORAL	1385 DAY
Depakote	C	ORAL	335 DAY
Clozaril	C	ORAL	1076 DAY
Glucosamine	C	ORAL	323 DAY

Date:10/07/02ISR Number: 3984491-6Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00157
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Cardiac Arrest	Professional	Metoprolol	SS				
	Drug Interaction							

Date:10/07/02ISR Number: 3984492-8Report Type:Expedited (15-DaCompany Report #WAES 0209PRT00006
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Gait Disturbance		Spironolactone	C		ORAL		
	Headache		Candesartan Cilexetil	C		ORAL		
			Indapamide	C		ORAL		

Date:10/07/02ISR Number: 3984494-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA01891
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oedema Peripheral Weight Increased	Professional	Vioxx	SS		ORAL		

Date:10/07/02ISR Number: 3984495-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA02389
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive							

Date:10/07/02ISR Number: 3984500-4Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00172
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/02ISR Number: 3984506-5Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00091
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Feeling Drunk	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Jugular Vein Thrombosis	Professional	Nicergoline	C		ORAL		
	Lung Neoplasm Malignant							

Date:10/07/02ISR Number: 3984508-9Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00119
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Neutropenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged		Professional	Acetaminophen	C				
Other								

Date:10/07/02ISR Number: 3984511-9Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00160
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		39 DAY
	Haemorrhage	Professional	Calcium Carbonate	C		ORAL		39 DAY
			Furosemide	C		ORAL		
			Vasotec	C		ORAL		
			Fosamax	C		ORAL		18 DAY
			Acetaminophen And Codeine Phosphate	C		ORAL		39 DAY
			Etidronate Disodium	C				

Date:10/07/02ISR Number: 3984693-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly	Health	Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Professional	Desogen	SS				
	Hypertension		Aleve	C				
	Myositis		Ultram	C				
	Pulmonary Embolism		[Therapy Unspecified]	C				
	Respiratory Failure		Vicodin Tablets	C				
	Supraventricular Tachycardia		Toradol	C		INTRAMUSCULAR		
	Tricuspid Valve Incompetence							

Date:10/07/02ISR Number: 3984695-2Report Type:Expedited (15-DaCompany Report #WAES 01119309
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Tachycardia							

Date:10/08/02ISR Number: 3985367-0Report Type:Expedited (15-DaCompany Report #WAES 0209BRA00033
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiomegaly
	Pulmonary Oedema

	Respiratory Failure Sudden Death						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY

Date:10/08/02ISR Number: 3985370-0Report Type:Expedited (15-DaCompany Report #WAES 0208USA04328
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pneumonia		Vioxx	SS		ORAL		
	Rectal Haemorrhage		Vioxx	SS		ORAL		
			Plendil	C				
			Aldactone	C				
			Vitamins (Unspecified)	C		ORAL		
			Tylenol Extra Strength	C		ORAL		

Date:10/08/02ISR Number: 3985374-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00040
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	SS		ORAL		
			Leflunomide	SS		ORAL		

Date:10/08/02ISR Number: 3985377-3Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00238
Age:75 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Fosamax	SS		ORAL		
	Dyspnoea							
	Vomiting							

Date:10/08/02ISR Number: 3985378-5Report Type:Expedited (15-DaCompany Report #WAES 0209GRC00014
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc		8	DAY

Date:10/08/02ISR Number: 3985424-9Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00048
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Clopidogrel Bisulfate	SS		ORAL		
	Drug Interaction		Phenprocoumon	SS		ORAL		
	Gastrointestinal Ulcer		Acetaminophen	C		ORAL		
	Haemorrhage		Codeine	C		ORAL		
	Melaena		Vitamin B (Unspecified)	C		ORAL		
			Molsidomine	C		ORAL		
			Nitroglycerin	C		TOPICAL		

			Levothyroxine Sodium	C		ORAL

Date:10/08/02ISR Number: 3985594-2Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00048
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness	Professional	Clopidogrel			
	Drug Interaction		Bisulfate	SS		ORAL
	Melaena		Phenprocoumon	SS		ORAL
	Ulcer Haemorrhage		Acetaminophen	C		ORAL
			Codeine	C		ORAL
			Vitamin B			
			(Unspecified)	C		ORAL
			Molsidomine	C		ORAL
			Nitroglycerin	C		
TOPICAL						
			Levothyroxine Sodium	C		ORAL

Date:10/08/02ISR Number: 3985596-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA04196
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Carpal Tunnel Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer	Professional	Vioxx	SS		ORAL
299 DAY						
	Dyspnoea Exertional		Vioxx	SS		ORAL
	Erosive Oesophagitis		Vioxx	SS		ORAL
	Microcytic Anaemia		Celebrex	C		
	Oedema Peripheral		Celebrex	C		
	Perineurial Cyst		Relafen	C		
	Spinal Column Stenosis		Feldene	C		
	Spinal Osteoarthritis		Lasix (Furosemide)	C		

Date:10/08/02ISR Number: 3985597-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA00523
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Life-Threatening	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
16 MON						
Hospitalization -		Professional	Vasotec	C		ORAL
Initial or Prolonged			Estrogens			
Disability			(Unspecified)	C		
Other			Neurontin	C		
			Estrace	C		
			Hydrodiuril	C		ORAL
			Glucosamine	C		

Date:10/08/02ISR Number: 3985599-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02340
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged	Oedema Peripheral	Professional	Diovan Hct	C		
Other			Digoxin	C		
			Metoprolol	C		
			Prinivil	C		ORAL
			Prevacid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/02ISR Number: 3985600-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Vioxx	PS	Merck & Co., Inc			

Date:10/08/02ISR Number: 3985603-0Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00106
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amputation		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged Disability	Gangrene		Dipyrone	C		ORAL		
	Gastric Ulcer Haemorrhage		Enoxaparin Sodium	C		PARENTERAL		

Date:10/08/02ISR Number: 3985884-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA01864
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Vioxx	SS		ORAL	5	DAY
	Attack		Celebrex	C				
			Ativan	C				
			Taloxa	C				
			Glucophage	C				
			Avandia	C				
			Zestril	C				
			Norvasc	C				

Date:10/08/02ISR Number: 3985886-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA02658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive							

Date:10/08/02ISR Number: 3985887-9Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00016
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Initial or Prolonged	Haemorrhage		Ibuprofen	C		ORAL		

Date:10/08/02ISR Number: 3985889-2Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00006
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Bronchitis Bronchospasm		Vioxx	SS		ORAL		

Date:10/08/02ISR Number: 3985892-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02741
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		[Therapy Unspecified]	C				

Date:10/08/02ISR Number: 3985893-4Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00018
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Aspirin	SS		ORAL		
			Prednisolone	C		ORAL	4	DAY
			Terbutaline	C		RESPIRATORY (INHALATION)		
			Oxitropium Bromide	C		RESPIRATORY (INHALATION)		
			Furosemide	C		ORAL		

Date:10/08/02ISR Number: 3985903-4Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00021
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Upper Gastrointestinal Haemorrhage		Acetaminophen And Codeine Phosphate	C		ORAL		

Date:10/08/02ISR Number: 3985909-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/02ISR Number: 3985911-3Report Type:Expedited (15-DaCompany Report #WAES 0207ZAF00011
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage		Zopiclone	C		ORAL		
Hospitalization - Initial or Prolonged			Aspirin	C		ORAL		

Date:10/08/02ISR Number: 3985912-5Report Type:Expedited (15-DaCompany Report #WAES 0209BEL00097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Muscle Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/02ISR Number: 3985913-7Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00111
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	19 DAY	
Life-Threatening		Professional	Domperidone	C		ORAL		

			Ranitidine	C		ORAL
			Propranolol	C		ORAL
			Valsartan	C		ORAL

Date:10/08/02ISR Number: 3985916-2Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00052
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 MON	Eosinophilia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rash	Professional	Spironolactone	SS		ORAL
	Renal Failure Acute					

Date:10/08/02ISR Number: 3985957-5Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00076
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 DAY	Aspiration	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemoptysis	Professional	Fosamax	SS		ORAL
			Dexamethasone	SS		
			Omeprazole Magnesium	C		
			Fentanyl	C		
TOPICAL						
			Butylscopolamine Bromide	C		

Date:10/08/02ISR Number: 3989713-3Report Type:Direct Company Report #CTU 178250
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 MG PO QD	Atrial Fibrillation		Rofecoxib	PS		ORAL
Initial or Prolonged CHRONIC	Hypovolaemia					
	Ulcer		Asa	SS		ORAL
ASA 81 G PO						

	Upper Gastrointestinal					
QD CHRONIC						
	Haemorrhage		Ibuprofen	SS		
			Ketorolac	SS		
			Cozaar	C		
			Zocor	C		
			Nsaids	C		
			Ketorolac	C		

Date:10/08/02ISR Number: 3989715-7Report Type:Direct Company Report #CTU 178249
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ulcer		Rofecoxib	PS		ORAL
25 G PO QD						
Initial or Prolonged	Upper Gastrointestinal					
CHRONIC						
	Haemorrhage		Lasix	C		
			Propoxyphene	C		
			Lasix	C		
			Propoxyphene	C		

Date:10/09/02ISR Number: 3985959-9Report Type:Expedited (15-DaCompany Report #WAES 0208AUS00185
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Pressure Increased
Initial or Prolonged	Transient Ischaemic

	Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	
			Rabeprazole Sodium	C			
			Atenolol	C			
			Aspirin	C		ORAL	
			Atorvastatin Calcium	C			
			Temazepam	C			
			Ubidecarenone	C			

Date:10/09/02ISR Number: 3985960-5Report Type:Expedited (15-DaCompany Report #WAES 0207ITA00003
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Initial or Prolonged	Melaena	Professional	Furosemide Sodium	C		ORAL	

Date:10/09/02ISR Number: 3985962-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL	65 DAY
Initial or Prolonged	Anaemia		Indocin				
Disability	Aneurysm Ruptured		(Indomethacin)	C		ORAL	
Other	Clostridium Colitis		Tylenol Extra				
	Coma		Strength	C			
	Convulsion						
	Enterobacter Pneumonia						
	Hydrocephalus						
	Intraventricular						
	Haemorrhage						
	Malnutrition						
	Pneumonia Aspiration						
	Subarachnoid Haemorrhage						

Date:10/09/02ISR Number: 3985965-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01753
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Ischaemic Stroke	Professional	Vioxx	SS		ORAL	2	WK
			Flovent	C				
RESPIRATORY								
(INHALATION)								
			Serevent	C				
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Herbs (Unspecified)	C				
			Alcohol	C				

Date:10/09/02ISR Number: 3985966-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA04257
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Hypertension		Lanoxin	C				
			A.S.A.	C				

			Synthroid	C		
			Insulin	C		
			Lasix (Furosemide)	C		
			Potassium Chloride	C		
			Diovan	C		
			Dyazide	C		
			Zestril	C		

Date:10/09/02ISR Number: 3985973-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA01756
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Gait Disturbance	Professional	Ultram	C				
Initial or Prolonged	Liver Function Test		Percocet	C				
Disability	Abnormal		Midrin	C				
Other	Nausea		Acupril	C				
			Verapamil	C				
			Clonidine	C				

Date:10/09/02ISR Number: 3985975-7Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00018
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prothrombin Time Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Phenprocoumon	C		ORAL		
Initial or Prolonged								

Date:10/09/02ISR Number: 3985977-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA00519
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C				

Date:10/09/02ISR Number: 3985978-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA00472
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:10/09/02ISR Number: 3986377-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02417
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Fluid Retention		Vioxx	SS		ORAL		
	Pleural Effusion		Dyazide	C				
			Wellbutrin Sr	C				

Date:10/09/02ISR Number: 3986378-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA02384
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Arrhythmia Blood Calcium Abnormal Blood Creatine Phosphokinase Abnormal Blood Triglycerides Increased Heart Rate Increased		Vioxx Glucophage	PS C	Merck & Co., Inc	ORAL		

Date:10/09/02ISR Number: 3986639-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00035
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc		68	DAY

Date:10/09/02ISR Number: 3986643-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00033
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Carcinoma		Vioxx	PS	Merck & Co., Inc		33	DAY

Date:10/09/02ISR Number: 3987318-1Report Type:Direct Company Report #CTU 178436
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tongue Black Hairy		Vioxx 25 Mg	PS		ORAL	ONE DOSE PO	QD

Date:10/09/02ISR Number: 3987555-6Report Type:Direct Company Report #CTU 178320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Effect Decreased		Vioxx 25 Mg /Merck	PS	Merck		ONE DAILY	
	Pharmaceutical Product Complaint							

Date:10/09/02ISR Number: 3991623-2Report Type:Expedited (15-DaCompany Report #2002059560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Consumer	Amlodipine(Amlodipine)	PS				
Other	Blood Pressure Increased							
	Constipation		Nifedipine (Nifedipine)	SS				
	Diarrhoea							
	Dizziness		Bextra (Valdecoxib)	SS		ORAL	10 MG(DAILY), ORAL	
	Face Oedema							
	Headache		Asacol (Mesalazine)	SS				
	Hypersensitivity		Vioxx (Rofecoxib)	SS				
	Myocardial Infarction		Acetylsalicylic Acid	C				
	Nervousness		Alprazolam	C				
	Pain In Extremity		Losartan Potassium	C				
	Renal Mass		Fexofenadine	C				
	Weight Decreased		Rabeprazole Sodium	C				
			Potassium Chloride	C				

			Triobe	C		
			Meclozine	C		
			Spironolactone	C		

Date:10/10/02ISR Number: 3986645-1Report Type:Expedited (15-DaCompany Report #WAES 0210BEL00020
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL
	Depression					

Date:10/10/02ISR Number: 3986646-3Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00009
Age:67 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenitis		Levothyroxine Sodium	C		
	Gastric Ulcer		Hydrochlorothiazide			
	Haemoglobin Decreased		And Irbesartan	C		ORAL
	Helicobacter Infection		Atorvastatin Calcium	C		ORAL
	Melaena		Doxazosin Mesylate	C		ORAL
			Furosemide	C		ORAL
			Metoprolol Tartrate	C		ORAL
			Ebastine	C		ORAL
			Levocabastine			
			Hydrochloride	C		
			Fluticasone			
			Propionate And			
			Salmeterol Xinafoate	C		
RESPIRATORY						
(INHALATION)						
			Albuterol Sulfate	C		
RESPIRATORY						
(INHALATION)						
			Orlistat	C		ORAL

Date:10/10/02ISR Number: 3986648-7Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
			Vioxx	SS		ORAL		

Date:10/10/02ISR Number: 3986650-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00034
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastatic Neoplasm		Vioxx	PS	Merck & Co., Inc		27	DAY

Date:10/10/02ISR Number: 3986651-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00036
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc		108	DAY

Date:10/10/02ISR Number: 3986652-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00041
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastatic Neoplasm		Vioxx	PS	Merck & Co., Inc		270	DAY

Date:10/10/02ISR Number: 3986653-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00039
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc		3	DAY

Date:10/10/02ISR Number: 3986654-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00037
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc		9	DAY

Date:10/10/02ISR Number: 3986655-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00042
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Myeloma		Vioxx	PS	Merck & Co., Inc		2	DAY

Date:10/10/02ISR Number: 3986656-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00541
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		

Haemorrhage

Date:10/10/02ISR Number: 3986658-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00040
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thyroid Gland Cancer		Vioxx	PS	Merck & Co., Inc			18 DAY

Date:10/10/02ISR Number: 3986659-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00038
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc			25 DAY

Date:10/10/02ISR Number: 3986661-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00032
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mediastinum Neoplasm		Vioxx	PS	Merck & Co., Inc			48 DAY

Date:10/10/02ISR Number: 3987247-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00018
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Melanoma		Vioxx	PS	Merck & Co., Inc			21 DAY

Date:10/10/02ISR Number: 3987249-7Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00026
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		5 WK
Initial or Prolonged	Duodenal Stenosis		Diltiazem					
	Duodenal Ulcer		Hydrochloride	C		ORAL		
	Haemorrhage		Ramipril	C		ORAL		
	Fatigue		Trimetazidine					
	Haemoglobin Decreased		Hydrochloride	C		ORAL		
			Molsidomine	C		ORAL		
			Nitroglycerin	C		TOPICAL		

Date:10/10/02ISR Number: 3987252-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00530
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Celebrex	C				
			Avandia	C				

Date:10/10/02ISR Number: 3987256-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00030
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS	Merck & Co., Inc			55 DAY

Date:10/10/02ISR Number: 3987257-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00016
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			5 DAY

Date:10/10/02ISR Number: 3987259-XReport Type:Expedited (15-DaCompany Report #WAES 0210GBR00034
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/02ISR Number: 3987261-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00019
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Melanoma		Vioxx	PS	Merck & Co., Inc			31 DAY

Date:10/10/02ISR Number: 3987262-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00022
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc			110 DAY

Date:10/10/02ISR Number: 3987263-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00020
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Cancer		Vioxx	PS	Merck & Co., Inc			110 DAY

Date:10/10/02ISR Number: 3987265-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00990
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/02ISR Number: 3987266-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00029
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc			151 DAY

Date:10/10/02ISR Number: 3987267-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00531
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Rectal Haemorrhage
Vomiting

Date:10/10/02ISR Number: 3987268-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00023
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc			74 DAY

Date:10/10/02ISR Number: 3987270-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00021
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gallbladder Cancer		Vioxx	PS	Merck & Co., Inc			9 DAY
	Jaundice Cholestatic							

Date:10/11/02ISR Number: 3987611-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00607
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Cardiac Failure
Hospitalization - Initial or Prolonged	Congestive
	Coma
Other	Encephalopathy

	Hepatic Failure Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Dyazide	C				
			Actonel	C				
			Tylenol	C				

Date:10/11/02ISR Number: 3987618-5Report Type:Expedited (15-DaCompany Report #WAES 01119753
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/02ISR Number: 3987620-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00067
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastases To Liver		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY

Date:10/11/02ISR Number: 3987623-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA02829
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	417	DAY
	Throat Tightness		Synthroid	C				
	Urticaria		Alprazolam	C				
			Verapamil	C				
			Maxzide	C				
			Dicyclomine Hydrochloride	C				
			Fluoxetine	C				
			Captopril	C				

				Aciphex	C		
				Estraderm	C		
				Questran	C		

Date:10/11/02ISR Number: 3987625-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00017
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastatic Neoplasm		Vioxx	PS	Merck & Co., Inc		40 DAY	

Date:10/11/02ISR Number: 3987628-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00043
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cellulitis		Vioxx	PS	Merck & Co., Inc		43 DAY	
	Extradural Abscess							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/02ISR Number: 3987629-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00044
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			170 DAY
	Congestive							

Date:10/11/02ISR Number: 3987630-6Report Type:Expedited (15-DaCompany Report #WAES 0210NOR00004
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Pressure Decreased		Warfarin Sodium	SS				
Initial or Prolonged	Duodenal Ulcer		Valsartan	C				
	Haemorrhage		Metoprolol Tartrate	C				
	Tachycardia		Methenamine Hippurate	C				
			Citalopram Hydrobromide	C				
			Risperidone	C				
			Iron (Unspecified)	C		ORAL		
			Vitamins (Unspecified)	C				

Date:10/11/02ISR Number: 3987631-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00049
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc			38 DAY

Date:10/11/02ISR Number: 3987632-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00048
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Pancreatic Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
17 DAY						

Date:10/11/02ISR Number: 3987633-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00046
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	
24 DAY						
	Haemorrhage					
	Myocardial Infarction					

Date:10/11/02ISR Number: 3987634-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00047
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Hyperkalaemia		Vioxx	PS	Merck & Co., Inc	
18 DAY						
	Sepsis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/02ISR Number: 3987635-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00056
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY

Date:10/11/02ISR Number: 3987636-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00052
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Obstruction		Vioxx	PS	Merck & Co., Inc			51 DAY

Date:10/11/02ISR Number: 3987637-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00045
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatic Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		57 DAY

Date:10/11/02ISR Number: 3987638-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00057
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc			78 DAY
	Prostate Cancer							
	Pulmonary Embolism							

Date:10/11/02ISR Number: 3987639-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00053
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death Lung Neoplasm Malignant Vioxx PS Merck & Co., Inc ORAL
84 DAY

Date:10/11/02ISR Number: 3987640-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00058
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Uterine Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	56 DAY	

Date:10/11/02ISR Number: 3987642-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00062
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		147 DAY	

Date:10/11/02ISR Number: 3987643-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00066
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mediastinum Neoplasm		Vioxx	PS	Merck & Co., Inc		29 DAY	
	Pneumonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/02ISR Number: 3987644-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00061
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			117 DAY

Date:10/11/02ISR Number: 3987645-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00064
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc			23 DAY
	Pneumonia							
	Renal Failure Acute							

Date:10/11/02ISR Number: 3987646-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00059
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			61 DAY
	Congestive							
	Pneumonia							
	Sepsis							

Date:10/11/02ISR Number: 3987647-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00063
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc			22 DAY
	Myocardial Infarction							

Date:10/11/02ISR Number: 3987649-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00074
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc			14 DAY

Date:10/11/02ISR Number: 3987650-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00060
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		274 DAY

Date:10/11/02ISR Number: 3987651-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00065
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			61 DAY

Date:10/11/02ISR Number: 3987652-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00068
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc			35 DAY
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/02ISR Number: 3987653-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00072
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			56 DAY

Date:10/11/02ISR Number: 3987654-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00073
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY

Date:10/11/02ISR Number: 3987655-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00077
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc			23 DAY
	Ventricle Rupture							

Date:10/11/02ISR Number: 3987656-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00075
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Life-Threatening								

Date:10/11/02ISR Number: 3987658-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00070
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death Cerebrovascular Accident Vioxx PS Merck & Co., Inc
166 DAY

Date:10/11/02ISR Number: 3987659-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00069
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	49 DAY	

Date:10/11/02ISR Number: 3987660-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00079
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alveolitis Fibrosing		Vioxx	PS	Merck & Co., Inc		43 DAY	

Date:10/11/02ISR Number: 3987662-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00078
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	109 DAY	

Life-Threatening

Date:10/11/02ISR Number: 3987663-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00076
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc		327	DAY
	Congestive Myocardial Ischaemia							

Date:10/11/02ISR Number: 3987664-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00087
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		70	DAY

Date:10/11/02ISR Number: 3987665-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00080
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Laceration		Vioxx	PS	Merck & Co., Inc		87	DAY
	Subdural Haematoma							

Date:10/11/02ISR Number: 3987666-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00089
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Date:10/11/02ISR Number: 3987667-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00084
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia		Vioxx	PS	Merck & Co., Inc			83 DAY

Date:10/11/02ISR Number: 3987668-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00090
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		45 DAY

Date:10/11/02ISR Number: 3987669-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00083
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			22 DAY
	Congestive							

Date:10/11/02ISR Number: 3987670-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00082
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc			26 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/02ISR Number: 3987671-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00088
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Dissection		Vioxx	PS	Merck & Co., Inc			80 DAY

Date:10/11/02ISR Number: 3987673-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00096
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		95 DAY

Date:10/11/02ISR Number: 3987674-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00095
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
	Pneumonia							

Date:10/11/02ISR Number: 3987675-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00094
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY

Date:10/11/02ISR Number: 3987676-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00097
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Oesophageal Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL	
113 DAY							

Date:10/11/02ISR Number: 3987677-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00099
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
122 DAY								

Date:10/11/02ISR Number: 3987678-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA00731
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/02ISR Number: 3988161-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA00648
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Lung Disorder		[Composition					
Hospitalization - Initial or Prolonged	Oxygen Saturation Decreased		Unspecified]	C				

Date:10/11/02ISR Number: 3988166-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA02784
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Drug Interaction	Professional	[Therapy					
	Oedema Peripheral		Unspecified]	SS				
	Pyrexia		Zestril	C				
	Renal Failure		Indapamide	C				
	Vision Blurred							

Date:10/11/02ISR Number: 3988170-0Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00091
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Feeling Drunk	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Jugular Vein Thrombosis	Professional	Nicergoline	C		ORAL		
	Small Cell Lung Cancer							
	Stage Unspecified							

Date:10/11/02ISR Number: 3988187-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00071
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lymphoma		Vioxx	PS	Merck & Co., Inc	ORAL		200 DAY

Date:10/11/02ISR Number: 3992502-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA04196
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG, PO ;	
Initial or Prolonged	Back Pain	Professional					PO; 25 MG,	

	Carpal Tunnel Syndrome	Company		
DAILY, PO ;				
	Condition Aggravated	Representative		
PO				
	Difficulty In Walking		Celebrex	C
	Duodenal Ulcer		Feldene	C
	Dyspnoea		Lasix (Furosemide)	C
	Erosive Oesophagitis		Relafen	C
	Helicobacter Infection			
	Iron Deficiency Anaemia			
	Oedema Peripheral			
	Pain			
	Paraesthesia			
	Perineurial Cyst			
	Tinel'S Sign			

Date:10/11/02ISR Number: 3992506-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Death	Blood Glucose Abnormal
Hospitalization -	Blood Ph Decreased
Initial or Prolonged	Blood Pressure Decreased
	Blood Pressure Increased
	Cardio-Respiratory Arrest
	Cardiomegaly
	Deep Vein Thrombosis
	Haemodynamic Instability

		Myocardial Infarction Pulmonary Embolism Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pupil Fixed	Consumer	Tab Vioxx 25 Mg	PS		ORAL
50							
		Respiratory Failure	Health				
MG/DAILY/PO							
		Sinus Tachycardia	Professional	Desogen Unk	SS		
		Supraventricular	Company	Aleve	C		
		Tachycardia	Representative	Toradol	C		
		Syncope		Ultram	C		
		Tricuspid Valve		Vicodin Tablets	C		
		Incompetence					

Date:10/11/02ISR Number: 3992566-0Report Type:Expedited (15-DaCompany Report #EMADSS2002005994
Age:89 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Bradycardia	Foreign	Risperdal (Tablet)			
Hospitalization -		Cardiac Arrest	Health	(Risperidone)	PS		ORAL
1.5 MG,							
Initial or Prolonged			Professional				
DAILY, ORAL;							
1 MG, DAILY,							
ORAL							
				Beloc-Zok (Metoprolol Succinate)	SS		ORAL
150 MG,							
DAILY, ORAL							
				Vioxx (Rofecoxib)	SS		ORAL
50 MG, DAILY,							
ORAL							
				Coversum Combi (Perindopril)	C		

Date:10/12/02ISR Number: 3988514-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA03649
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988515-1Report Type:Expedited (15-DaCompany Report #WAES 0209BEL00070
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Suicidal Ideation							

Date:10/12/02ISR Number: 3988520-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA01981
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Renal Infarct		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988530-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00091
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	61	DAY

Date:10/12/02ISR Number: 3988532-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00085
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc		337	DAY

Date:10/12/02ISR Number: 3988534-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00086
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Rupture		Vioxx	PS	Merck & Co., Inc		23	DAY

Date:10/12/02ISR Number: 3988535-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00081
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
	Colon Cancer							
	Sudden Cardiac Death							

Date:10/12/02ISR Number: 3988536-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/12/02ISR Number: 3988539-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00093
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:10/12/02ISR Number: 3988540-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00092
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Complete							
	Dyspepsia							
	Hypotension							

Date:10/12/02ISR Number: 3988541-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA00537
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Prozac	C				
Initial or Prolonged			Premarin	C				
Disability			Aricept	C				

				Elavil	C		

Date:10/12/02ISR Number: 3988543-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00728
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged			[Composition Unspecified]	C				

Date:10/12/02ISR Number: 3988549-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00748
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Congestive		Vioxx	SS		ORAL		
	Chronic Obstructive		Verapamil	C				
	Pulmonary Disease		[Therapy Unspecified]	C				
	Myocardial Infarction							
	Oedema Peripheral							
	Respiratory Distress							

Date:10/12/02ISR Number: 3988659-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988660-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Infarct		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988661-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA01521
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eye Haemorrhage		Prinivil	C		ORAL		
			Glyburide	C		ORAL		
			Armour Thyroid Tablets	C		ORAL		
			Bayer Aspirin	C		ORAL		

Date:10/12/02ISR Number: 3988666-1Report Type:Expedited (15-DaCompany Report #WAES 0208USA03153
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988668-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA00417
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Lower Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Aspirin	SS				
Initial or Prolonged			Fosamax	C				
Other			Lanoxin	C				
			Prevacid	C				

Date:10/12/02ISR Number: 3988671-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA01899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Singulair	C		ORAL		
			[Therapy Unspecified]	C				

Date:10/12/02ISR Number: 3988672-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA02009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral							

Date:10/12/02ISR Number: 3988673-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01898
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemoglobin Decreased		Aspirin	C				

Date:10/12/02ISR Number: 3988674-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01864
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Transient Ischaemic Attack		Vioxx	SS		ORAL
			Celebrex	C		
			Ativan	C		
			Taloxa	C		
			Glucophage	C		
			Avandia	C		
			Zestril	C		
			Norvasc	C		

Date:10/12/02ISR Number: 3988681-8Report Type:Expedited (15-DaCompany Report #WAES 0209TUR00001
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
36 HR						
Hospitalization -	Arthralgia		Diclofenac Sodium	SS		ORAL
36 HR						
Initial or Prolonged	Myocardial Infarction					
	Respiratory Rate Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/02ISR Number: 3988683-1Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00020
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Visual Acuity Reduced		Prednisolone	C		ORAL		

Date:10/12/02ISR Number: 3988684-3Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00190
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Rabeprazole Sodium	C		ORAL		6 DAY
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Cetirizine Hydrochloride	C		ORAL		

Date:10/12/02ISR Number: 3988685-5Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00186
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS		ORAL		
	Neck Pain		Omeprazole	C		ORAL		
	Pain		Albuterol	C				
	Pain In Jaw		Beclomethasone Dipropionate	C				
	Palpitations		Estropipate	C		ORAL		

Date:10/12/02ISR Number: 3988688-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01719
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Interaction		Lithium Carbonate	SS				

	Dysarthria	Paxil	SS
	Oedema Peripheral	Glucophage	C
	Paraesthesia	Glucotrol	C
		Prilosec	C
		Lipitor	C
		Metamucil	C
		[Therapy Unspecified]	C

Date:10/12/02ISR Number: 3988689-2Report Type:Expedited (15-DaCompany Report #WAES 0208USA02625
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage Peptic Ulcer		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/02ISR Number: 3988690-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA03948
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	46	DAY
	Congestive		Norvasc	SS				

Date:10/12/02ISR Number: 3988697-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00063
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Aspirin	SS		ORAL		

Date:10/12/02ISR Number: 3988700-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01632
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/02ISR Number: 3988703-4Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00045
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Cardiac Failure		Vasotec	C		ORAL		
			Furosemide	C		ORAL		
			Digoxin	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Acenocoumarol	C				

Date:10/12/02ISR Number: 3988704-6Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00107
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Morphine Sulfate	C		ORAL		
	Platelet Count Decreased		Morphine Sulfate	C		ORAL		
	White Blood Cell Count Decreased							

Date:10/14/02ISR Number: 3989446-3Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00231
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Acetaminophen And Codeine Phosphate	C			550	DAY
			Acetaminophen And Codeine Phosphate	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/02ISR Number: 3989447-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00024
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Cancer		Vioxx	PS	Merck & Co., Inc		73	DAY

Date:10/14/02ISR Number: 3989448-7Report Type:Expedited (15-DaCompany Report #WAES 0210CHE00011
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Oedema Peripheral		Fosamax	C		ORAL		
	Visual Disturbance							

Date:10/14/02ISR Number: 3989449-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00908
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hemiparesis		Vioxx	SS		ORAL		
			Lorcet Plus	C				
			Elavil	C				
			Elavil	C				
			Tarka	C				
			Desyrel	C				
			Zoloft	C				
			Prevacid	C				
			Soma	C				

Date:10/14/02ISR Number: 3989451-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00031
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS	Merck & Co., Inc		140	DAY

Date:10/14/02ISR Number: 3989452-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00025
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc			44 DAY

Date:10/14/02ISR Number: 3989454-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00026
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS	Merck & Co., Inc			10 DAY

Date:10/14/02ISR Number: 3989457-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00027
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Injury		Vioxx	PS	Merck & Co., Inc			31 DAY
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/02ISR Number: 3989458-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00028
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc		22	DAY

Date:10/15/02ISR Number: 3989517-1Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thromboplastin Time		Celebrex	SS		ORAL		
	Prolonged		Acetaminophen And					
	Acute Myocardial		Hydrocodone					
	Infarction		Bitartrate	C		ORAL		
	Alanine Aminotransferase		Zydone	C		ORAL		
	Increased		Pertussin N	C		ORAL		
	Anaphylactic Reaction		Accolate	C		ORAL		
	Arrhythmia		Claritin	C		ORAL		
	Blood Pressure Increased		Pravachol	C		ORAL		
	Cardiac Arrest		Paxil	C		ORAL		
	Chronic Obstructive		Flonase	C		ORAL		
	Pulmonary Disease		Toradol	C		ORAL		
	Contusion		Remeron	C		ORAL		
	Exsanguination		Nystatin	C		ORAL		
	Gastritis		Biaxin	C		ORAL		
	Gastrointestinal		Depo-Provera	C		INTRAMUSCULAR		
	Haemorrhage		Hydrocortisone					
	International Normalised		Acetate	C				
	Ratio Increased		Skelaxin	C		ORAL		
	Large Intestinal Ulcer		Tequin	C		ORAL		
	Haemorrhage		Alupent	C		RESPIRATORY (INHALATION)		
	Oedema							
	Oesophageal Ulcer		Serevent	C		RESPIRATORY (INHALATION)		
	Haemorrhage							
	Platelet Count Decreased		Flovent	C		RESPIRATORY		

	Pleuritic Pain			
(INHALATION)				
	Prothrombin Time	Buspar	C	ORAL
	Prolonged	Lipitor	C	ORAL
	Rib Fracture	Amaryl	C	ORAL
	Sudden Cardiac Death	Percocet	C	ORAL
		Pramoxine Hydrochloride	C	
TOPICAL				
		Premarin	C	ORAL
		Proventil	C	
RESPIRATORY				
(INHALATION)				
		Demerol	C	ORAL
		Alprazolam	C	ORAL
		Carisoprodol	C	ORAL
		Aquaphor	C	
		Promethazine	C	
		Soma	C	ORAL

Date:10/15/02ISR Number: 3989520-1Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00013
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Confusional State
	Fall

		Logorrhoea					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Zopiclone	C		ORAL
				Benserazide Hydrochloride And Levodopa	C		ORAL
				Benserazide Hydrochloride And Levodopa	C		ORAL
1	DAY						
				Omeprazole	C		ORAL
				Paroxetine	C		ORAL
				Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
				Lisinopril	C		ORAL
				Flecainide Acetate	C		ORAL
				Aspirin Lysine	C		ORAL

Date:10/15/02ISR Number: 3989522-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA03551
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cholecystectomy		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Haematemesis		Nexium	C		
		Oesophageal Disorder					

Date:10/15/02ISR Number: 3989523-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00051
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	
22	DAY						
		Myocardial Infarction					

Date:10/15/02ISR Number: 3989524-9Report Type:Expedited (15-DaCompany Report #WAES 01111768
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Intestinal Obstruction Postoperative Wound Complication Postpartum Disorder Postpartum Venous Thrombosis Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989529-8Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00018
Age:64 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer Haemorrhage		Aspirin	SS		ORAL		
			Terbutaline	C				
RESPIRATORY								
(INHALATION)								
			Furosemide	C		ORAL		
			Prednisolone	C		ORAL		
4 DAY								
			Oxitropium Bromide	C				
RESPIRATORY								
(INHALATION)								

Date:10/15/02ISR Number: 3989530-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00050
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
189 DAY								

Date:10/15/02ISR Number: 3989534-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00054
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Head Injury		Vioxx	PS	Merck & Co., Inc			
37 DAY								

Date:10/15/02ISR Number: 3989536-5Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00048
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Decreased Appetite							

Insomnia

Date:10/15/02ISR Number: 3989537-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00055
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY

Date:10/15/02ISR Number: 3989538-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00408
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989539-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA00861
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Composition Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/02ISR Number: 3989541-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Tenderness Burning Sensation Cholecystectomy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989542-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA00929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Stenosis Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989546-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01133
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989547-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/02ISR Number: 3989889-8Report Type:Expedited (15-DaCompany Report #WAES 0210CHE00016
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
	Urticaria		Moduretic	C		ORAL
			Diclofenac Sodium	C		ORAL
			Aspirin	C		ORAL
			Fluvastatin Sodium	C		ORAL

Date:10/15/02ISR Number: 3989891-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA01266
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haematochezia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Nausea		Meclizine	C		
Initial or Prolonged	Stomach Discomfort		Acetaminophen And Propoxyphene Hydrochloride	C		
			Accuretic	C		
			Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/02ISR Number: 3993993-8Report Type:Direct Company Report #CTU 178603
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS		
25 MG QD						
Initial or Prolonged	Haemorrhage		Glipizide Xl	C		
	Melaena		Allegra-D	C		
			Metformin	C		

Date:10/16/02ISR Number: 3990222-6Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00001
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Melaena		Aspirin Lysine	SS		ORAL
3 YR						
			Nitroglycerin	C		
TOPICAL						
			Furosemide And Spironolactone	C		ORAL
			Ciprofibrate	C		ORAL
			Aesculus And Metesculetol Sodium	C		ORAL
			Trimebutine Maleate	C		ORAL
			Anethole Trithione	C		ORAL
			Potassium Bicarbonate And Psyllium Husk	C		ORAL

Date:10/16/02ISR Number: 3990223-8Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	
2 YR						
Initial or Prolonged	Haemorrhage					

Date:10/16/02ISR Number: 3990231-7Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00018
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Iron Deficiency Anaemia		Fosamax	C		ORAL		
			Nifedipine	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		
			Clorazepate Dipotassium	C		ORAL		
			Zopiclone	C		ORAL		

Date:10/16/02ISR Number: 3990232-9Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00055
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Other	Drug Interaction		Sertraline Hydrochloride	SS		ORAL		
	Memory Impairment		Acetaminophen And Codeine Phosphate	C		ORAL		
			Ibuprofen	C		TOPICAL		
			Albuterol	C		RESPIRATORY		

(INHALATION)

Beclomethasone Dipropionate C

RESPIRATORY

(INHALATION)

Date:10/16/02ISR Number: 3990234-2Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00015
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged			Amoxicillin	C		ORAL		9 DAY
			Ambroxol	C		ORAL		9 DAY
			Rabeprazole Sodium	C		ORAL		16 DAY

Date:10/16/02ISR Number: 3990669-8Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00241
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration	Health	Vioxx	PS	Merck & Co., Inc	ORAL		154 DAY
Initial or Prolonged	Dyspnoea	Professional	Irbesartan	SS		ORAL		366 DAY
	Hypotension		Atorvastatin	C		ORAL		
			Indoramin	C		ORAL		
			Tolterodine	C		ORAL		

Date:10/16/02ISR Number: 3990684-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01015
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/16/02ISR Number: 3992597-0Report Type:Direct Company Report #CTU 178844
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 12.5MG PO QD	Bronchospasm		Vioxx 12.5mg	PS		ORAL
Initial or Prolonged	Depression		Zyprexa	C		
	Diabetes Mellitus		Restoril	C		
	Non-Insulin-Dependent		Maxizide	C		
	Hypertension		Colace	C		
	Joint Swelling		Amaryl	C		
	Lobar Pneumonia		Actos	C		
	Mass		Lantus Insulin	C		
	Obesity		Levaquin	C		
	Oedema		Rocephin	C		
			Xopenex	C		
			Neurontin	C		
			Sular	C		
			Ecotrin	C		
			Prevacid	C		
			Detrol	C		
			Zyloprim	C		
			Prinivil	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/02ISR Number: 3990946-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA00928
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Metoprolol Tartrate	C				
	Fluid Retention		Prilosec	C				
			Neurontin	C				
			Neurontin	C				
			Climara	C				
TOPICAL								

Date:10/17/02ISR Number: 3990951-4Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Coumadin	C				
			Allopurinol	C				
			Skelaxin	C				
			Lanoxin	C				
			Lasix (Furosemide)	C				

Date:10/17/02ISR Number: 3990954-XReport Type:Expedited (15-DaCompany Report #WAES 0210BEL00025
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Shock Haemorrhagic						7	DAY

Date:10/17/02ISR Number: 3990955-1Report Type:Expedited (15-DaCompany Report #WAES 0207DEU00013
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -	Gastric Perforation	Vioxx	SS		ORAL
4 DAY					
Initial or Prolonged	Gastric Ulcer	Diclofenac Sodium	SS		
	Intestinal Ischaemia	Etanercept	C		
SUBCUTANEOUS					
		Cortisone	C		
		Prednisolone	C		ORAL
1 DAY					
		Esomeprazole			
		Magnesium	C		
		Omeprazole	C		
		Prednisone	C		
		Cholecalciferol	C		
		Butylscopolamine Bromide	C		
		Calcium (Unspecified)	C		
		Ferrous Glycine Sulfate	C		

Date:10/17/02ISR Number: 3990959-9Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00080
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Clopidogrel			
	Melaena		Bisulfate	SS		ORAL

			Furosemide	C		ORAL

Date:10/17/02ISR Number: 3990961-7Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00006
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Bronchitis		Vioxx	SS		ORAL	1	DAY
	Bronchospasm							

Date:10/17/02ISR Number: 3990962-9Report Type:Expedited (15-DaCompany Report #WAES 0210TUR00001
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Cardiogenic Shock							
Other	Confusional State							
	Crepitations							
	Cyanosis							
	Rales							
	Syncope							

Date:10/17/02ISR Number: 3990964-2Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Perforation							
	Haemorrhage							

Date:10/17/02ISR Number: 3990965-4Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00014
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Duodenal Ulcer Ulcer		Aspirin And Dipyridamole	SS				
			Acebutolol Hydrochloride	C		ORAL		
			Captopril	C		ORAL		
			Venlafaxine Hydrochloride	C		ORAL		
			Polyethylene Glycol 4000	C				
			Prazepam	C		ORAL		
			Inosine Phosphate Disodium	C				
OPHTHALMIC								
			Molsidomine	C		ORAL		
			Adrafinil	C		ORAL		
			Nitroglycerin	C				

Date:10/17/02ISR Number: 3990966-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/17/02ISR Number: 3991245-3Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00160
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Caesarean Section	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Essential Hypertension							
	Gastrointestinal Necrosis							
	Maternal Drugs Affecting Foetus							
	Neonatal Disorder							
	Pregnancy							
	Volvulus Of Bowel							

Date:10/17/02ISR Number: 3991249-0Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00051
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1 YR	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Isosorbide Dinitrate	C				
	Condition Aggravated		Fluoxetine	C				
			Pantoprazole Sodium	C				
			Fosamax	C				
			Metformin Hydrochloride	C				

Date:10/17/02ISR Number: 3991250-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA01347
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Paxil	C				
	Gastrointestinal Perforation		Aspirin	C				
	Haemorrhage		[Therapy Unspecified]	C				
	Oral Intake Reduced							

Date:10/17/02ISR Number: 3991252-0Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00160
Age: DY Gender:Male I/FU:I

Outcome	PT
Death	Caesarean Section
	Complications Of Maternal Exposure To Therapeutic Drugs
	Essential Hypertension
	Gastrointestinal Necrosis
	Maternal Drugs Affecting Foetus
	Neonatal Disorder

	Pregnancy Volvulus Of Bowel						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc			

Date:10/17/02ISR Number: 3991510-XReport Type:Expedited (15-DaCompany Report #WAES 0210AUS00100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc			

Date:10/17/02ISR Number: 3991513-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA02500
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS		ORAL		
Other	Diarrhoea		Lipitor	SS				
	Dizziness		Levothyroxine Sodium	C				
	Nausea		Lotensin	C				
	Vomiting		Zoloft	C				
			Aspirin	C				

Date:10/17/02ISR Number: 3991514-7Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00049
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperkalaemia		Spironolactone	SS		ORAL		
			Torsemide	C		ORAL		
			Lactulose	C		ORAL		
			Insulin, Neutral	C				
			Insulin Human,					

SUBCUTANEOUS

			Isophane	C		
SUBCUTANEOUS						
			Propranolol Hydrochloride	C		ORAL

Date:10/17/02ISR Number: 3991516-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01864
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Transient Ischaemic		Vioxx	SS		ORAL
5 DAY						
	Attack		Celebrex	C		
			Ativan	C		
			Taloxa	C		
			Glucophage	C		
			Avandia	C		
			Zestril	C		
			Norvasc	C		
			Voltaren	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/02ISR Number: 3991523-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01293
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:10/17/02ISR Number: 3991525-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01033
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged	Haemorrhage Feeling Drunk		Celebrex	SS				
			Naprosyn	C			1	YR
	Intestinal Perforation		Oxycontin	C				
			Darvocet-N	C				
			Hytrin	C				
			Synvisc	C				

Date:10/17/02ISR Number: 3991527-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Status Asthmaticus		Vioxx	SS		ORAL		

Date:10/17/02ISR Number: 3995828-6Report Type:Expedited (15-DaCompany Report #NSADSS2002032666
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Enzymes Increased Completed Suicide	Literature Health	Ultram (50 Mg Tablet) (Tramadol					

	Coordination Abnormal	Professional	Hydrochloride)	PS		ORAL
ORAL						
	Cyanosis		Gabapentin			
	Dehydration		(Gabapentin)	SS		ORAL
ORAL						
	Electromechanical		Rofecoxib	SS		ORAL
ORAL						
	Dissociation					
	Heart Rate Decreased					
	Hypotension					
	Mental Status Changes					
	Myoglobin Urine Present					
	Renal Failure					
	Somnolence					
	White Blood Cell Count					
	Increased					

Date:10/17/02ISR Number: 3996107-3Report Type:Expedited (15-DaCompany Report #PHHO2002FR03189
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Renal Failure Acute	Foreign	Esidrex(Hydrochlorot			
Other		Study	hiazide)	PS		ORAL
12.5 MG,						
		Health				
LEVEL 3,						
		Professional				
ORAL; SEE						
		Other				
IMAGE						

			Valsartan +/-Hctz Vs (Code Not Broken) Amlodipine +/-Hctz(Valsartan +/-Hctz Vs	SS		ORAL
LEVEL 1, ORAL; SEE IMAGE						
			Vioxx (Rofecoxib)	SS		
25 MG, QD						
			Hyperium (Rilmenidine)	C		

Date:10/17/02ISR Number: 3997328-6Report Type:Expedited (15-DaCompany Report #A01200202924
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL
	Anaemia		Vioxx (Rofecoxib)	SS		ORAL
	Blood Pressure Decreased		Marcoumar (Phenprocoumon)	SS		ORAL
	Drug Interaction		Co-Dafalgan (Paracematol, Codein)	C		
	Gastrointestinal Ulcer		Eltroxin (Levothyroxine Sodium)	C		
	Haemorrhage		Vitamn B	C		
	Hiatus Hernia		Corvaton Forte (Molsidomine)	C		
	International Normalised Ratio Increased		Nitroderm Tts (Glyceryl Trinitrate)	C		
	Melaena					
	Oesophagitis					
	Syncope					

Date:10/17/02ISR Number: 3997455-3Report Type:Expedited (15-DaCompany Report #001-0906-M0000206
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia	Consumer	Accupril (Quinapril					
	Asthenia		Hydrochloride)	PS		ORAL	40 MG	
	Blood Pressure Decreased						(DAILY), ORAL	
	Difficulty In Walking		Vioxx(Rofecoxib)	SS				
	Drug Interaction		Loratadine	SS				
	Movement Disorder		Ditropan(Oxybutynin)	C				
	Nasopharyngitis		Amoxicillin	C				
	Vertigo							
	Vision Blurred							
	Visual Acuity Reduced							

Date:10/18/02ISR Number: 3992080-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA00748
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease

	Myocardial Infarction Oedema Peripheral Respiratory Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
		Professional	Vioxx	SS		ORAL	
			Verapamil	C			
			[Therapy Unspecified]	C			

Date:10/18/02ISR Number: 3992083-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00018
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Oesophageal Haemorrhage Prothrombin Time Abnormal	Professional	Phenprocoumon	C		ORAL	

Date:10/18/02ISR Number: 3992084-XReport Type:Expedited (15-DaCompany Report #WAES 0207FRA00005
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	
	Coronary Artery Thrombosis		Furosemide	C		ORAL	
	Dyspnoea Exertional Heart Rate Decreased		Tamsulosin Hydrochloride	C		ORAL	

Date:10/18/02ISR Number: 3992085-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA03549
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Aortic Valve Incompetence	Professional	Vioxx	SS		ORAL	
	Benign Prostatic		Vioxx	SS		ORAL	
	Hyperplasia		Vioxx	SS		ORAL	
	Blood Urea Increased		Vioxx	SS		ORAL	

Cerebrovascular Accident	Vioxx	SS	ORAL
Coronary Artery Disease	Vioxx	SS	ORAL
Coronary Artery Stenosis	Prilosec	C	
Diarrhoea	Prilosec	C	
Dilatation Atrial	Quinine Sulfate	C	
Drug Ineffective	Zyrtec	C	
Haemorrhoids	Aspirin	C	
Hypertension	Claritin	C	
Intermittent Claudication	Protonix	C	
Mitral Valve Incompetence	Ultram	C	
Palpitations			
Pulmonary Arterial Wedge Pressure Increased			
Pulmonary Valve Incompetence			
Rectal Haemorrhage			
Sinus Bradycardia			
Tricuspid Valve Incompetence			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/02ISR Number: 3992086-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01521
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		45 DAY
Initial or Prolonged	Gastrointestinal		Celebrex	C				
Other	Haemorrhage		Chondroitin And Glucosamine	C				
			[Therapy Unspecified]	C				

Date:10/18/02ISR Number: 3992239-4Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00157
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Hospitalization -	Cardiac Arrest	Professional	Metoprolol Succinate	SS		ORAL		
Initial or Prolonged	Drug Interaction		Risperidone	SS		ORAL		
			Indapamide And Perindopril Erbumine	C		ORAL		

Date:10/18/02ISR Number: 3992241-2Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00238
Age:75 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia	Professional	Fosamax	C		ORAL		
	Dyspnoea							
	Vomiting							

Date:10/18/02ISR Number: 3992242-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01753
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Asthma	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 WK
	Blood Cholesterol	Professional	Vioxx	SS		ORAL	2 WK
	Increased		Flovent	C			RESPIRATORY
	Cerebral Artery Occlusion						(INHALATION)
	Cerebral Infarction		Serevent	C			
	Cerebrovascular Accident		Albuterol	C			RESPIRATORY
							(INHALATION)
			Herbs (Unspecified)	C			
			Alcohol	C			

Date:10/18/02ISR Number: 3992244-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA02000
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flexeril	C				

Date:10/18/02ISR Number: 3992247-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01285
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/02ISR Number: 3992253-9Report Type:Expedited (15-DaCompany Report #WAES 0210PRT00003
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dry Skin		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Pruritus		Furosemide	C		ORAL		
	Rash Vesicular		Metildigoxin	C		ORAL		

Date:10/18/02ISR Number: 3992257-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Bextra	C				

Date:10/18/02ISR Number: 3997787-9Report Type:Expedited (15-DaCompany Report #EMADSS2002005698
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Health	Durogesic (Patch) (Fentanyl)	PS			TRANSDERMAL	TRANSD
	Aspartate Aminotransferase Increased Eczema Eosinophilia	Professional	Tramadol Hydrochloride (Unspecified) (Tramadol Hydrochloride)	SS		ORAL	200 MG,	DAILY, ORAL
	Gamma-Glutamyltransferase Increased Photosensitivity Reaction Toxic Skin Eruption		Bi-Profenid (Ketoprofen)	SS		ORAL	300 MG ,	DAILY, ORAL
			Vioxx (Rofecoxib)	SS		ORAL	1 CAP , DAILY	ORAL

			Tetrazepam (Tetrazepam)	SS			ORAL
1 TABLET, DAILY, ORAL							
			Mopral (Omeprazole)	SS			ORAL
20 MG, DAILY, ORAL							

Date:10/21/02ISR Number: 3992750-6Report Type:Expedited (15-DaCompany Report #B0282225A
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lymphadenopathy		Clamoxyl	PS	Glaxo Wellcome	ORAL	1G Twice per day	9 DAY
	Productive Cough							
	Rash Maculo-Papular		Surbronc	SS	Glaxo Wellcome	ORAL	1UNIT Three times per day	9 DAY
	Skin Papilloma							
			Vioxx	SS		ORAL	1UNIT per day	16 DAY
			Pariet	SS		ORAL	1UNIT per day	16 DAY

Date:10/21/02ISR Number: 3993319-XReport Type:Expedited (15-DaCompany Report #WAES 0210FRA00028
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	2 MON	
			Acetaminophen	C		ORAL		
			Leuprolide Acetate	C				
			Althiazide And Spironolactone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/02ISR Number: 3993322-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Cerebral Artery		Vioxx	SS		ORAL		33 DAY
Disability	Thrombosis		Vioxx	SS		ORAL		36 DAY
	Cerebral Infarction		Vioxx	SS		ORAL		312 DAY
	Diverticulum		Tricor	C		ORAL		
	Mitral Valve Incompetence		Vicodin Es Tablets	C		ORAL		
	Thrombotic Stroke		Paxil	C		ORAL		
	Tricuspid Valve		Restoril	C		ORAL		
	Incompetence		Aspirin	C		ORAL		
			Estrogens (Unspecified)	C				

Date:10/21/02ISR Number: 3993328-0Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00127
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Sedation		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY

Date:10/21/02ISR Number: 3993335-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00413
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Avandia	SS				
Initial or Prolonged	Congestive		Actos	SS				
	Chest Pain		Zocor	C		ORAL		
			Verapamil	C				
			Accupril	C				
			Humulin N	C				

Date:10/21/02ISR Number: 3993336-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA02203
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cerebral Haemorrhage		Atenolol	C		ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Aspirin	C				
			Ambien	C				
Disability			Paxil	C				

Date:10/21/02ISR Number: 3993337-1Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Blood Blister							

Date:10/21/02ISR Number: 3993344-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Neurontin	C				

				Zanaflex	C		

Date:10/21/02ISR Number: 3998639-0Report Type:Expedited (15-DaCompany Report #2002061392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Foreign	Sertraline(Sertraline)	PS		ORAL	ORAL	
	Drug Interaction	Health						
	Memory Impairment	Professional	Rofecoxib	SS		ORAL	ORAL	
			Panadeine Co	C				
			Ibuprofen	C				
			Salbutamol	C				
			Beclometasone Dipropionate	C				

Date:10/22/02ISR Number: 3994299-3Report Type:Expedited (15-DaCompany Report #WAES 0208USA03598
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Post Thrombotic Syndrome		Zantac	C		ORAL		
Other	Pulmonary Embolism							

Date:10/22/02ISR Number: 3994306-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01891
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged Disability			Nasonex	C				
			Dyazide	C				
			Claritin	C				
			Inderal La	C				
			Prilosec	C				
			Glipizide	C				
			Aspirin And					

			Butalbital And Caffeine	C		

Date:10/22/02ISR Number: 3994310-XReport Type:Expedited (15-DaCompany Report #WAES 0204USA01769
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 21 DAY	Meningitis Aseptic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Meningitis Viral		Vioxx	SS		ORAL
			Allegra-D	C		
			Flonase	C		
			Nexium	C		

Date:10/22/02ISR Number: 3994316-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA01883
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Decreased Activity		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypoaesthesia		[Therapy			
	Thrombosis		Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/02ISR Number: 3994524-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Altace	C		ORAL		
	Blood Pressure Increased		Plavix	C		ORAL		
	Cerebral Ischaemia		Aspirin	C		ORAL		
	Cold Sweat		Nitroglycerin	C		TOPICAL		
	Condition Aggravated		Prevacid	C		ORAL		
	Coronary Artery Atherosclerosis		Zocor	C		ORAL		
	Diarrhoea							
	Dyspepsia							
	Dyspnoea							
	Embolism							
	Facial Palsy							
	Frequent Bowel Movements							
	Gallop Rhythm Present							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hepatic Cyst							
	Hiatus Hernia							
	Hyperhidrosis							
	Hypoaesthesia							
	Ischaemia							
	Low Density Lipoprotein Increased							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nausea							
	Paraesthesia							
	Partial Seizures With Secondary Generalisation							
	Peripheral Coldness							
	Photophobia							
	Pulse Abnormal							
	Syncope Vasovagal							

Date:10/22/02ISR Number: 3996177-2Report Type:Direct Company Report #CTU 179267
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Vioxx 25mg	PS			QD PRN ONE DAILY	
	Abnormal							
	Aspartate Aminotransferase Abnormal							
	Blood Alkaline Phosphatase Abnormal							
	Blood Bilirubin Increased							
	Fatigue							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/02ISR Number: 3996213-3Report Type:Direct Company Report #CTU 179257
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx 25mg (Merck)	PS	Merck	ORAL	25MG PO QD	5 DAY
Initial or Prolonged			Cozaar	C				
			Labetalol	C				
			Digoxin	C				
			Lanoxin	C				
			Sinemet	C				
			Reglan	C				
			Betoptic	C				
			Aspirin	C				
			Nitroglycerin	C				
			Trazodone	C				

Date:10/22/02ISR Number: 3998490-1Report Type:Expedited (15-DaCompany Report #200213805BCC
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoptysis	Study	Rofecoxib	PS				
Initial or Prolonged	Lung Neoplasm	Health	Aricept	C				
		Professional	Aspirin	C				
		Other	Triamterene	C				
			Zocor	C				

Date:10/22/02ISR Number: 3998491-3Report Type:Expedited (15-DaCompany Report #200213810BCC
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Study	Rofecoxib	PS				
Initial or Prolonged		Health	Vitamin E	C				
		Professional	Multivitamin	C				
		Other	Aricept	C				
			Tylenol	C				

Date:10/22/02ISR Number: 4000555-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Respiratory Failure
Initial or Prolonged	Anaemia
Disability	Aneurysm Ruptured
Other	Asthenia
	Brain Damage
	Clostridium Colitis
	Coma
	Convulsion
	Enterobacter Pneumonia
	Fall
	Hydrocephalus
	Intraventricular
	Haemorrhage
	Malnutrition
	Nuclear Magnetic
	Resonance Imaging
	Abnormal
	Pneumonia Aspiration
	Stress

Subarachnoid Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50MG/DAILY	/PO
			Indocin (Indomethacin)	C				
			Tylenol Extra Strength	C				

Date:10/22/02ISR Number: 4000566-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00908
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Back Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged	Blood Alkaline Phosphatase Increased	Health Professional	Desyrel	C				
	Bursitis		Elavil	C				
	Cerebral Ischaemia		Lorcet Plus	C				
	Cerebrovascular Accident		Prevacid	C				
	Condition Aggravated		Soma	C				
	Costovertebral Angle Tenderness		Tarka	C				
	Dysphagia		Zoloft	C				
	Face Oedema							
	Facial Pain							
	Hypertension							
	Neck Pain							
	Neuritis							
	Pain In Extremity							
	Thrombotic Stroke							

Date:10/23/02ISR Number: 3994976-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02731
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Congestive		Zocor	C		ORAL
			[Therapy Unspecified]	C		

Date:10/23/02ISR Number: 3994977-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00070
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 519 DAY	Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 152 DAY	Interstitial Lung Disease		Methotrexate Sodium	SS		ORAL
			Infliximab	SS		
INTRAVENOUS 23 DAY						

Date:10/23/02ISR Number: 3994981-8Report Type:Expedited (15-DaCompany Report #WAES 0210DNK00013
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemoglobin Decreased		Methotrexate Sodium	C		ORAL
			Aspirin	C		ORAL
			Furosemide	C		ORAL

			Potassium Chloride	C		

Date:10/23/02ISR Number: 3994987-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01958
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS		ORAL		
Disability			Lipitor	C				
			[Therapy Unspecified]	C				

Date:10/23/02ISR Number: 3994991-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA01976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Ulcer		Lasix (Furosemide)	C				

Date:10/23/02ISR Number: 3995001-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01133
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/23/02ISR Number: 3997537-6Report Type:Direct Company Report #CTU 179330
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Back Pain		Lisinopril 40mg	PS		ORAL	40 MG QD ORAL	
Intervention to	Blood Creatinine		Rofecoxib 25 Mg	SS		ORAL	25 MG QD ORAL	

Prevent Permanent Impairment/Damage	Increased	Amitriptyline	C
		Bisoprolol/Hctz	C
		Enoxaparin	C
		Glyburide	C
		Hydromorphone	C
		Acetaminophen	C
		Bisacodyl	C
		Vancomycin	C
		Epoetin Alfa	C
		Aluminium Hydroxide/Magnesium Hydroxide/Simethicone	C

Date:10/23/02ISR Number: 3999616-6Report Type:Direct Company Report #CTU 179340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx	PS		ORAL	STANDARD ONCE	
	Dyspnoea						DAILY ORAL	
	Heart Rate Irregular							
	Insomnia							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/23/02ISR Number: 4027648-0Report Type:Periodic Company Report #NSADSS2002015369
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Health	Remicade (5 Mg/Ml					
Hospitalization -	Headache	Professional	Lyophilized Powder)					
Initial or Prolonged	Hypersensitivity		(Infliximab,					
Other	Hypertension		Recombinant)	PS		INTRAVENOUS	500MG , 1 IN	
	Pain							1 TIMES, IV
	Sexual Dysfunction		Wellbutrin					
	Vertigo		(Amfebutamone					
			Hydrochloride)	SS				
			Vioxx (Rofecoxib)	SS				
			Prednisone	C				
			Methotrexate	C				
			Celebrex (Celecoxib)	C				

Date:10/24/02ISR Number: 3996788-4Report Type:Direct Company Report #CTU 179412
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bacterial Infection		Vioxx	PS				
	Blood Culture Positive		Lopressor	C				
	Dermatitis Exfoliative		Pravachol	C				
	Hepatitis		Coumadin	C				
	International Normalised		Darvon	C				
	Ratio Increased		Digoxin	C				
	Rash Morbilliform							

Date:10/24/02ISR Number: 3996825-7Report Type:Direct Company Report #CTU 179422
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Increased		Quinine	PS		ORAL	325 MG PO QHS	
Initial or Prolonged	Blood Urea Increased		Metformin	SS		ORAL	1000 MG PO	

BID

25 MG A DAY

Vioxx	SS
Tricor	SS
Neurontin	C
Glipizide	C
Asa	C
Atenolol	C
Mdur	C
Monopril	C
Ntg	C
Hydrochlorothizide	C
Tylenol #3	C

Date:10/24/02ISR Number: 3997501-7Report Type:Direct Company Report #CTU 179409
Age:52 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome
Disability	Blood Pressure Increased
	Body Temperature Increased
	Cardiac Enzymes Increased

	Disseminated Intravascular Coagulation						
	Drug Tolerance Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gallbladder Disorder		Vioxx 25 Mg One Dose				
	Gastrointestinal		Qd	PS			25 MG OD TOOK
	Haemorrhage						TOTAL OF 6
	Hallucination, Visual						
	Influenza Like Illness						
	Oesophageal Polyp						
	Pulmonary Oedema						
	Respiratory Arrest						
	Vomiting						

Date:10/24/02ISR Number: 4000418-5Report Type:Expedited (15-DaCompany Report #PHBS2002AU12483
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Hyperkalaemia	Foreign	Slow K (Potassium				
	Renal Impairment	Health	Chloride) Tablet	PS		ORAL	1.2G/DAY,
		Professional					ORAL
		Other	Aldactone (Spironolactone)	SS			100 MG/DAY,
			Vioxx (Rofecoxib)	SS			50 MG/DAY,
			Lasix	C			
			Quinate	C			

Date:10/24/02ISR Number: 4000573-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA03549
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Aortic Valve Incompetence
	Benign Prostatic Hyperplasia
	Blood Cholesterol

Increased
Blood Pressure Increased
Blood Urea Increased
Cerebrovascular Accident
Condition Aggravated
Coronary Artery Disease
Diarrhoea
Dilatation Atrial
Drug Ineffective
Gastrooesophageal Reflux
Disease
Haemorrhoids
Intermittent Claudication
Mitral Valve Incompetence
Neck Pain
Osteoarthritis
Palpitations
Pulmonary Valve
Incompetence
Rectal Haemorrhage
Sinus Bradycardia
Transient Ischaemic
Attack
Tricuspid Valve

Incompetence
Ventricular Hypokinesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
Health Professional	Claritin	C				
	Prilosec	C				
	Protonix	C				
	Ultram	C				
	Zyrtec	C				
	Aspirin	C				
	Quinine Sulfate	C				

Date:10/25/02ISR Number: 3996509-5Report Type:Expedited (15-DaCompany Report #WAES 0209BEL00067
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Lorazepam	C		ORAL		
Other			Esomeprazole Magnesium	C		ORAL		
			Fenofibrate	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		

Date:10/25/02ISR Number: 3996510-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00028
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc		22	DAY

Date:10/25/02ISR Number: 3996511-3Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00008
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
86 DAY						
Hospitalization -	Gastrointestinal	Professional	Dipyrone	C		ORAL
Initial or Prolonged	Haemorrhage		Pantoprazole Sodium	C		

Date:10/25/02ISR Number: 3996516-2Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00012
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Upper Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage	Professional				

Date:10/25/02ISR Number: 3996524-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00027
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Chest Injury	Health	Vioxx	PS	Merck & Co., Inc	
31 DAY						
	Road Traffic Accident	Professional				

Date:10/25/02ISR Number: 3996528-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00031
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			140 DAY

Date:10/25/02ISR Number: 3996529-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00025
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			44 DAY

Date:10/25/02ISR Number: 3996534-4Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00024
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			73 DAY

Date:10/25/02ISR Number: 3996537-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00026
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			10 DAY

Date:10/25/02ISR Number: 3996541-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00095
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY
	Pneumonia	Professional						

Date:10/25/02ISR Number: 3996542-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00060
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	274	DAY
		Professional						

Date:10/25/02ISR Number: 3996545-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00096
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	95	DAY
		Professional						

Date:10/25/02ISR Number: 3996549-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00058
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Uterine Cancer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	56	DAY
		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/02ISR Number: 3996553-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA00410
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Congestive	Professional	Pen-Vee K	C				
	Crepitations		Celebrex	C				
	Weight Decreased							

Date:10/25/02ISR Number: 3996554-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00045
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatic Carcinoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL	57	DAY
		Professional						

Date:10/25/02ISR Number: 3996560-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01998
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diaphragmatic Disorder	Professional						

Date:10/25/02ISR Number: 3996561-7Report Type:Expedited (15-DaCompany Report #WAES 0208USA02297
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Hospitalization - Initial or Prolonged	Enterocolitis	Professional	Coumadin	C				
	Haemorrhagic		Ecotrin	C				
	Fatigue							
	Rectal Haemorrhage							

Date:10/25/02ISR Number: 3996567-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00082
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL	24 DAY	
	Duodenal Ulcer	Professional	Pantoprazole Sodium	C		ORAL	14 DAY	
	Haemorrhage		Dipyrone	C		ORAL	10 DAY	
	Helicobacter Infection		Fentanyl	C		TOPICAL		19 DAY
	Shock		Glimepiride	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Molsidomine	C		ORAL		
			Vasotec	C		ORAL		
			Furosemide Sodium	C		ORAL		
			Xipamide	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Carvedilol	C		ORAL		
			Calcium (Unspecified)	C				
			Cholecalciferol	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium					

Bicarbonate And Sodium Chloride	C		ORAL
Diclofenac	C		ORAL
Tramadol	C		

Date:10/25/02ISR Number: 3996568-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01708
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Prednisone	C				
	Myocardial Infarction							

Date:10/25/02ISR Number: 3996575-7Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00060
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Groin Pain		Enoxaparin Sodium	SS				
SUBCUTANEOUS							7	DAY
Initial or Prolonged	Hypoaesthesia		Enoxaparin Sodium	SS				
SUBCUTANEOUS							1	DAY
	Muscle Haemorrhage		Ginkgo Biloba Extract	SS		ORAL		
	Pain In Extremity		Enoxaparin Sodium	SS				
SUBCUTANEOUS								
			Bisoprolol Fumarate	C		ORAL		
			Imipramine Hydrochloride	C		ORAL		
			Medazepam	C		ORAL		
			Trimipramine Maleate	C		ORAL		
			Levothyroxine Sodium And Liothyronine Hydrochloride	C		ORAL		
			Oxerutins	C		ORAL		

Date:10/25/02ISR Number: 3996576-9Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/02ISR Number: 3996579-4Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00103
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Death Hospitalization - Initial or Prolonged	Bradycardia Coagulopathy Convulsion Difficulty In Walking Dyspnoea Intra-Abdominal Haemorrhage Lower Gastrointestinal Haemorrhage Malaise Pallor Shock

	Syncope Urinary Bladder Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Ethinyl Estradiol And Norethindrone Acetate	C				
			Cetirizine Hydrochloride	C				

Date:10/25/02ISR Number: 3996583-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00021
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gallbladder Cancer		Vioxx	PS	Merck & Co., Inc		9	DAY
	Jaundice Cholestatic							

Date:10/25/02ISR Number: 3996584-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00020
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Cancer		Vioxx	PS	Merck & Co., Inc		110	DAY

Date:10/25/02ISR Number: 3996586-1Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00017
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adenocarcinoma		Vioxx	PS	Merck & Co., Inc		40	DAY
	Metastasis							

Date:10/25/02ISR Number: 3996587-3Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00165
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Aspirin	SS		ORAL		
			Bisacodyl	C		ORAL		
			Lactulose	C		ORAL		
			Acetaminophen	C		ORAL		

Date:10/25/02ISR Number: 3996591-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00022
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc		110 DAY	

Date:10/25/02ISR Number: 3996592-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00018
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Melanoma		Vioxx	PS	Merck & Co., Inc		21 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/02ISR Number: 3996595-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00037
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc			9 DAY

Date:10/25/02ISR Number: 3996597-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00032
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Mediastinum Neoplasm		Vioxx	PS	Merck & Co., Inc			48 DAY

Date:10/25/02ISR Number: 3996599-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00035
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc			68 DAY

Date:10/25/02ISR Number: 3996600-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00030
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			55 DAY

Date:10/25/02ISR Number: 3996601-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00034
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Metastatic Neoplasm	Health Professional	Vioxx	PS	Merck & Co., Inc

27 DAY

Date:10/25/02ISR Number: 3996602-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00050
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		189 DAY

Date:10/25/02ISR Number: 3996604-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00033
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Oesophageal Carcinoma	Health Professional	Vioxx	PS	Merck & Co., Inc			33 DAY

Date:10/25/02ISR Number: 3996605-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00040
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thyroid Gland Cancer		Vioxx	PS	Merck & Co., Inc			18 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/02ISR Number: 3996607-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00053
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL	84	DAY

Date:10/25/02ISR Number: 3996608-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00056
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY

Date:10/25/02ISR Number: 3996610-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00055
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY

Date:10/25/02ISR Number: 3996611-8Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00041
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastatic Neoplasm	Health Professional	Vioxx	PS	Merck & Co., Inc		270	DAY

Date:10/25/02ISR Number: 3996615-5Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00097
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Oesophageal Carcinoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	113 DAY

Date:10/25/02ISR Number: 3996617-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00071
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Lymphoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	200 DAY

Date:10/25/02ISR Number: 3996618-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00099
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Prostate Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	122 DAY

Date:10/25/02ISR Number: 3996622-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA01799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hypervolaemia Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	

Date:10/25/02ISR Number: 3996634-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA02107
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/02ISR Number: 3996638-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00036
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc		108 DAY	

Date:10/25/02ISR Number: 3996641-6Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00043
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
	Duodenal Ulcer Haemorrhage		Acetaminophen	C		ORAL		

Date:10/25/02ISR Number: 3996643-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00019
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Melanoma	Health Professional	Vioxx	PS	Merck & Co., Inc		31 DAY	

Date:10/25/02ISR Number: 3996645-3Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00029
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm	Health Professional	Vioxx	PS	Merck & Co., Inc			151 DAY

Date:10/25/02ISR Number: 3996647-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00023
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prostate Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc			74 DAY

Date:10/25/02ISR Number: 3996648-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00069
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Cancer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		49 DAY

Date:10/25/02ISR Number: 3996649-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00038
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant	Health Professional	Vioxx	PS	Merck & Co., Inc			25 DAY

Date:10/25/02ISR Number: 3996650-7Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00048
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatic Carcinoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY

Date:10/25/02ISR Number: 3996651-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00042
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multiple Myeloma	Health Professional	Vioxx	PS	Merck & Co., Inc			2 DAY

Date:10/25/02ISR Number: 3996653-2Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00039
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Neoplasm Malignant	Health Professional	Vioxx	PS	Merck & Co., Inc			3 DAY

Date:10/25/02ISR Number: 3996655-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00067
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastases To Liver		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY

Date:10/25/02ISR Number: 3996657-XReport Type:Expedited (15-DaCompany Report #WAES 0210NZL00073
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY

Date:10/25/02ISR Number: 3996952-4Report Type:Expedited (15-DaCompany Report #WAES 0209GRC00014
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bilirubin Conjugated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Increased	Professional	Paroxetine					
	Blood Bilirubin Increased		Hydrochloride	C				
	Haemolytic Anaemia							
	Renal Failure Acute							

Date:10/25/02ISR Number: 3996954-8Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00048
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Decreased Appetite Insomnia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/02ISR Number: 3996957-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01162
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/02ISR Number: 3996960-3Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00080
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	SS		ORAL		
			Furosemide	C		ORAL		

Date:10/25/02ISR Number: 3996963-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01631
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Cerebral Infarction		Vioxx	SS		ORAL		
	Cerebrovascular Accident		Yasmin	SS			14 DAY	
	Diplopia		Vioxx	SS		ORAL		
	Electrocardiogram St-T Change		Sandimmun	C				
			Sandimmun	C				
	Fall		Prelone Syrup	C				

	Hydrocephalus	Prelone Syrup	C
	International Normalised		
	Ratio Decreased		
	Optic Nerve Disorder		
	Rash		
	Sinus Tachycardia		
	Sneezing		
	Subarachnoid Haemorrhage		
	Superior Sagittal Sinus		
	Thrombosis		
	Tinnitus		
	Tunnel Vision		
	Vaginal Haemorrhage		
	Visual Disturbance		
	Visual Field Defect		

Date:10/25/02ISR Number: 3996964-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA01831
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/02ISR Number: 3996966-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Skin Ulcer	Professional	Lasix (Furosemide)	C				

Date:10/27/02ISR Number: 3979743-XReport Type:Periodic Company Report #WAES 0204USA00389
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lower Respiratory Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Advair	C				
			Singulair	C				
			Zithromax	C				
			....	C				

Date:10/28/02ISR Number: 3997682-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA01452
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Verapamil	C		ORAL		
			Digoxin	C				

Date:10/28/02ISR Number: 3997684-9Report Type:Expedited (15-DaCompany Report #WAES 0210CHE00019
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
	Melaena		Celecoxib	SS		ORAL	6	DAY

			Omeprazole	C		ORAL
			Oxazepam	C		ORAL
8 YR						
			Acetaminophen	C		ORAL
			Tramadol Hydrochloride	C		ORAL
10 DAY						

Date:10/28/02ISR Number: 3997685-0Report Type:Expedited (15-DaCompany Report #WAES 0210PHL00002
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Liver Function Test		Vioxx	PS	Merck & Co., Inc	
	Abnormal		Omeprazole Magnesium	SS		

Date:10/28/02ISR Number: 3997692-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA02097
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal Haemorrhage Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/02ISR Number: 3998063-0Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Level Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
	Epilepsy		Phenytoin	C		
			Venlafaxine Hydrochloride	C		
			Clonazepam	C		

Date:10/28/02ISR Number: 3998064-2Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged 366 DAY	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure		Lipitor	SS		ORAL
Disability	Congestive		Zemplar	SS		
Other	Cardiomyopathy		[Therapy			
	Drug Interaction		Unspecified]	SS		
	Erythema Multiforme		Norvasc	C		ORAL
	Muscular Weakness		Zebeta	C		ORAL
	Myalgia		Flexeril	C		ORAL
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		
			Toprol Xl Tablets	C		ORAL
			Zaroxolyn	C		ORAL
			Cyclosporine	C		
			Clonidine Hydrochloride	C		ORAL
			Sandimmun	C		ORAL
			Lasix (Furosemide)	C		ORAL
			Prednisone	C		ORAL
			Imuran (Azathioprine)	C		ORAL
			Iron Dextran	C		
			Epoetin	C		
			Paricalcitol	C		
INTRAVENOUS						
			Ultralente Insulin	C		
PARENTERAL						

Viagra	C		ORAL
Humulin	C		PARENTERAL
Clonazepam	C		
Vitamin B Complex	C		ORAL
Celebrex	C		

Date:10/28/02ISR Number: 3998065-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01632
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/02ISR Number: 3998069-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA01350
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Pruritus	Professional	Vioxx	SS		ORAL		
	Rash Generalised		Premarin	C		ORAL		
	Urticaria		Zanaflex	C		ORAL		
							3	DAY

Date:10/28/02ISR Number: 3998070-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL	193	DAY
	Cataract		Vioxx	SS		ORAL	46	DAY
	Dizziness		Calcium					
	Dyspnoea		(Unspecified)	C				
	Gastroenteritis		Univasc	C				
	Hypertension		Zoloft	C				
	Maculopathy		Baycol	C				
	Retinal Haemorrhage		Ibuprofen	C				
	Retinal Vein Thrombosis		Celebrex	C				
	Vitreous Detachment							
	Vitreous Floaters							

Date:10/28/02ISR Number: 3998071-XReport Type:Expedited (15-DaCompany Report #WAES 0210FRA00053
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastrointestinal							
Initial or Prolonged	Haemorrhage							
	Haemolysis							
	Pneumonia Aspiration							

Date:10/28/02ISR Number: 3998073-3Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00062
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged			Althiazide And Spironolactone	C		ORAL		

Date:10/28/02ISR Number: 3998082-4Report Type:Expedited (15-DaCompany Report #WAES 0210ZAF00021
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vasculitis		Pravastatin Sodium	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Cilazapril	C		ORAL		
			Fluticasone Propionate	C				
RESPIRATORY (INHALATION)								
			Ipratropium Bromide	C				
RESPIRATORY (INHALATION)								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/02ISR Number: 3999388-5Report Type:Direct Company Report #CTU 179722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain		Vioxx Tabs	PS	Medco Health	ORAL	25 MG 1 DAILY	
	Pain In Extremity							
ORAL								

Date:10/28/02ISR Number: 4001162-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Septal Defect	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Acquired	Health	Paxil	C				
Disability	Blood Potassium Decreased	Professional	Restoril	C				
	Cardiac Aneurysm		Tricor	C				
	Cerebral Artery Embolism		Vicodin Es Tablets	C				
	Cerebral Artery Occlusion		Aspirin	C				
	Cerebral Artery		Estrogens					
	Thrombosis		(Unspecified)	C				
	Embolic Stroke							
	Feeling Cold							
	Haematocrit Abnormal							
	Haemoglobin Abnormal							
	Mitral Valve Incompetence							
	Pain In Extremity							
	Red Blood Cell							
	Sedimentation Rate							
	Abnormal							
	Thrombotic Stroke							
	Tricuspid Valve							
	Incompetence							

Date:10/29/02ISR Number: 3998688-2Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00034
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Retinal Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
3 WK							
Initial or Prolonged	Visual Acuity Reduced	Professional	Bromazepam	C		ORAL	
	Vitreous Detachment						

Date:10/29/02ISR Number: 3999055-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA02450
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/29/02ISR Number: 3999061-3Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
72 DAY								
	Low Density Lipoprotein	Professional	Celecoxib	SS		ORAL		
10 DAY								
	Increased		Atorvastatin	C		ORAL		
573 DAY								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/02ISR Number: 4001124-3Report Type:Direct Company Report #CTU 179846
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Rofecoxib	PS		ORAL	25MG PO QD	3 WK
Hospitalization -	Hyperkalaemia		Seroquel	C				
Initial or Prolonged			Remeron	C				
Required			Prevacid	C				
Intervention to			Docusate	C				
Prevent Permanent			Iron	C				
Impairment/Damage			Gabapentin	C				
			Os-Cal	C				
			Sinemet	C				
			Combivent	C				

Date:10/29/02ISR Number: 4001131-0Report Type:Direct Company Report #CTU 179874
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged	Asthenia		Hydroxyzine	C				
Required	Duodenal Ulcer		Lasix	C				
Intervention to	Dyspnoea		Glyburide	C				
Prevent Permanent	Melaena		Darvocet	C				
Impairment/Damage	Nausea		Diazepam	C				
			Cardene	C				
			Lisinopril	C				

Date:10/29/02ISR Number: 4001159-0Report Type:Direct Company Report #CTU 179866
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Rofecoxib	PS		ORAL	12.5MG PO BID	
Initial or Prolonged	Dyspnoea		Furosemide	C				
Required	Gastric Ulcer		Lactaid	C				
Intervention to	Haematemesis		Glyburide	C				
Prevent Permanent	Melaena		Miacalcin	C				

Impairment/Damage	Rectal Haemorrhage	Calcium Carb	C
		Vit D	C
		Imodium	C
		Hydralazine	C
		Digoxin	C
		Flonase	C
		Claritin	C
		Lorazepam	C
		Vicodin	C
		Celexa	C
		Aldactone	C

Date:10/29/02ISR Number: 4001256-XReport Type:Direct Company Report #CTU 179851
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Hypertension Hypervolaemia Pulmonary Oedema		Vioxx	PS			25 MG QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/02ISR Number: 4001322-9Report Type:Direct Company Report #CTU 179918
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Diverticulum		Warfarin	PS			10MG Q MWF	
Intervention to	Gastrointestinal		Rofexocib	SS			25MG QD	1 DAY
Prevent Permanent	Haemorrhage		Betapace	C				
Impairment/Damage	Haematochezia		Sod Bicarb	C				
			Dialyvite	C				
			Digoxin	C				
			Folic Acid	C				
			Renggel	C				
			Celexa	C				
			Colchicine	C				
			Aricept	C				

Date:10/29/02ISR Number: 4003082-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx	PS		ORAL	25	
Initial or Prolonged	Cardiovascular Disorder	Professional					MG/DAILY/PO	
	Coronary Artery Disease	Other	Altace	C				
	Electrocardiogram St		Plavix	C				
	Segment Depression		Prevacid	C				
	Embolism		Zocor	C				
	Gastritis		Aspirin	C				
	Hepatic Cyst		Nitroglycerin	C				
	Mitral Valve Disease							
	Myocardial Infarction							
	Peripheral Vascular							
	Disorder							
	Syncope							

Date:10/30/02ISR Number: 3999937-7Report Type:Expedited (15-DaCompany Report #WAES 0210SWE00017
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY
Initial or Prolonged			Citalopram Hydrobromide	C				
			Metoprolol Tartrate	C				
			Meprednisone	C				
			Acetylcysteine	C				
			Isosorbide Mononitrate	C				
			Omeprazole Magnesium	C				

Date:10/30/02ISR Number: 3999954-7Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00217
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		42 DAY
Initial or Prolonged	Cerebrovascular Disorder		Omeprazole	C				
			Prednisolone	C				
			Acetaminophen	C				
			Tramadol	C				
			Fosamax	C		ORAL		
			Calcium Carbonate					

			And Cholecalciferol	C		
			Lactulose	C		

Date:10/30/02ISR Number: 3999956-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA02476
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Oedema Mouth		Vioxx	PS	Merck & Co., Inc	ORAL
	Rash		Prozac	C		
			Wellbutrin	C		

Date:10/30/02ISR Number: 4002460-7Report Type:Direct Company Report #CTU 180009
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematemesis		Celebrex 200mg -			
Initial or Prolonged	Mental Status Changes		Pfizer	PS	Pfizer	ORAL
200MG PO QD						
			Vioxx 25mg Merck	SS	Merck	ORAL
25 MG PO QD						
			Aspirin Ec	C		
			Glucosamine			
			Chondroitian	C		

Date:10/30/02ISR Number: 4003581-5Report Type:Expedited (15-DaCompany Report #A0376571A
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthritis	Consumer	Sine-Off (Sine-Off)	PS		
	Bursitis		Guaiphenesin			
	Cerebrovascular Accident		(Guaifenesin)	SS		
	Double Vessel Bypass		Ibuprofen			
	Graft		(Ibuprofen)	SS		
	Surgery		Dimetapp (Dimetapp)	SS		
			Alka-Seltzer Plus			
			Cold Md			
			(Alka-Seltzer Plus			
			Cold Md)	SS		
			Tavist-D (Tavist-D)	SS		

Triaminic (Triaminic)	SS
Phenylpropanolamine Hcl (Phenylpropanolamine)	SS
Vicodin (Vicodin)	SS
Clonidine (Clonidine)	SS
Coricidin (Coricidin)	SS
Tylenol Cold Medication (Tylenol Cold Medication)	SS
Medrol (Medrol)	SS
Rofecoxib (Rofecoxib)	SS
Ibuprofen (Ibuprofen)	SS
Gabapentin (Gabapentin)	SS
Vicks Dayquil (Vicks	

	Dayquil)	SS	
	Nyquil (Nyquil)	SS	

Date:10/31/02ISR Number: 4000892-4Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00201
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Melaena		Levothyroxine Sodium	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Amlodipine	C		ORAL		

Date:10/31/02ISR Number: 4000894-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA02685
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Overdose							

Date:10/31/02ISR Number: 4000897-3Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00020
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Acuity Reduced		Prednisolone	C		ORAL		

Date:10/31/02ISR Number: 4000898-5Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00238
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Fosamax	C		ORAL		

Date:10/31/02ISR Number: 4000899-7Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00013
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Supraventricular		Amitriptyline Hydrochloride	SS				

Date:10/31/02ISR Number: 4000905-XReport Type:Expedited (15-DaCompany Report #WAES 0210BEL00084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema Peripheral							

Date:10/31/02ISR Number: 4003236-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA01631
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Blindness
Initial or Prolonged	Cerebrovascular Accident

		Electrocardiogram Abnormal					
		Electrocardiogram T Wave	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Consumer	Orsu Vioxx 25/5 Mg	PS		ORAL
12.5 MG/							
		Fall	Health				
DIALY; 25 MG/							
		Hypoaesthesia	Professional				
PO							
		Intracranial Venous Sinus		Yasmin	SS		
		Thrombosis		Prelone Syrup	C		
		Papilloedema		Sandimmun	C		
		Photophobia					
		Rash					
		Sinus Tachycardia					
		Sneezing					
		Subarachnoid Haemorrhage					
		Vaginal Haemorrhage					
		Visual Field Defect					

Date:10/31/02ISR Number: 4003644-4Report Type:Expedited (15-DaCompany Report #HQ4770322OCT2002
Age:70 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Ventricular Arrhythmia	Health	Emconcor			
			Professional	(Bisoprolol, Tablet)	PS		
			Other	Vioxx (Rofecoxib,			
				Tablet)	SS		

Date:10/31/02ISR Number: 4005219-XReport Type:Expedited (15-DaCompany Report #2002UW14340
Age:46 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Asthenia	Foreign	Zestoretic "Zeneca"	PS		
		Diarrhoea	Other	Vioxx	SS		ORAL
25 MG DAILY							
		Dizziness					
PO							
		Fall		Acetylsalicylic Acid			
		Hyperkalaemia		Enteric Coated	C		

	Nausea		Clonidine	C			
	Renal Impairment		Famotidine	C			
			Glyburide	C			
			Imipramine	C			
			Metformin	C			
			Warfarin	C			

Date:10/31/02ISR Number: 4006185-3Report Type:Expedited (15-DaCompany Report #KDL021350
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Disease	Health	Il-1ra	PS		SUBCUTANEOUS	100 MG,	
Initial or Prolonged	Cyanosis	Professional					DAILY, SC	
Other	Livedo Reticularis		Rofecoxib	SS		ORAL	25 MG, PO	
	Pain In Extremity		Aspirin	C				
	Peripheral Embolism		Amlodipine Besilate	C				
	Skin Discolouration		Methotrexate	C				
			Folic Acid	C				
			Hydroxychloroquine Phosphate	C				
			Ergocalciferol	C				
			Tums	C				
			Acetaminophen	C				

			Esomeprazole			
			Magnesium	C		
			Folinic Acid	C		
			Hydrochlorothiazide	C		
			Prednisone	C		
			Norethisterone	C		
			Estradiol	C		

Date:11/01/02ISR Number: 4001656-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00076
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer	Professional	Aspirin	SS		ORAL		
Other	Fall		Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		
	Gastric Ulcer Haemorrhage							
	Gastritis Haemorrhagic		Cozaar	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Moxonidine	C		ORAL		
			Furosemide And Spironolactone	C		ORAL		
			Hydrochlorothiazide And Triamterene	C		ORAL		

Date:11/01/02ISR Number: 4001657-XReport Type:Expedited (15-DaCompany Report #WAES 0210FRA00082
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
		Professional	Clopidogrel Bisulfate	SS		ORAL	3	YR
			Trimetazidine Hydrochloride	C		ORAL		
			Hydroxyzine Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

Date:11/01/02ISR Number: 4001658-1Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00087
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depressed Level Of		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Consciousness		Atenolol	C				
Initial or Prolonged	Dyspnoea		Meperidine					
	Paraesthesia		Hydrochloride	C				
			Dimenhydrinate	C				

Date:11/01/02ISR Number: 4001659-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00391
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage							
Initial or Prolonged	Gastrointestinal Pain							
	Haemoglobin Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/02ISR Number: 4001660-XReport Type:Expedited (15-DaCompany Report #WAES 0210CAN00042
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Lower Respiratory Tract	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Infection	Professional	Vioxx	SS		ORAL		
			Acetaminophen	C		ORAL		

Date:11/01/02ISR Number: 4001661-1Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00187
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	28	DAY
Hospitalization - Initial or Prolonged		Professional	Omeprazole	C				
			Furosemide	C				
			Carvedilol	C		ORAL		

Date:11/01/02ISR Number: 4001662-3Report Type:Expedited (15-DaCompany Report #WAES 0210SWE00016
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Fluconazole	C				
			Cilazapril	C				
			Folic Acid	C				
			Acetaminophen	C				
			Cyanocobalamin	C				
			Digoxin	C				
			Picosulfate Sodium	C				
			Prednisolone	C				
			Morphine	C				
			Nitroglycerin	C				
			Metoprolol Tartrate	C				
			Metoclopramide Hydrochloride	C				
			Furosemide	C				
			Nitroglycerin	C				

Dalteparin Sodium	C
Flunitrazepam	C
Morphine	C
Epoetin Alfa	C
Lansoprazole	C
Isosorbide Mononitrate	C
Citalopram Hydrobromide	C
Lactitol	C
Spironolactone	C

Date:11/01/02ISR Number: 4001663-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA02357
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Coronary Artery Occlusion							

Date:11/01/02ISR Number: 4001665-9Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00080
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	C		ORAL		
	Melaena		Vasotec	C		ORAL		

Date:11/01/02ISR Number: 4001668-4Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00022
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Haemoglobin Decreased	Professional	Aspirin And Magnesium Oxide	SS		ORAL		YR
	Melaena		Acetaminophen And Codeine Phosphate	C				
			Acetaminophen	C				

Date:11/01/02ISR Number: 4001674-XReport Type:Expedited (15-DaCompany Report #WAES 0209NOR00023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
Other	Duodenal Ulcer	Professional	Alclofenac	SS		ORAL		
	Perforation		Zopiclone	C		ORAL		
	Peritonitis		Hydrochlorothiazide And Losartan Potassium	C		ORAL		
	Syncope		Zocor	C		ORAL		
	Vomiting		Tamoxifen Citrate	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		34 DAY

Date:11/01/02ISR Number: 4001682-9Report Type:Expedited (15-DaCompany Report #WAES 0209NOR00013
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Supraventricular	Professional	Amitriptyline Hydrochloride	SS				

Date:11/01/02ISR Number: 4001686-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA02707
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Gastrointestinal	Professional	Ultram	C		ORAL		
Hospitalization -	Haemorrhage		Aspirin	C		ORAL		
Initial or Prolonged			Hytrin	C		ORAL		
Disability			Trental	C		ORAL		
Other			Xanax	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/02ISR Number: 4001688-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C		ORAL		
			Vitamins (Unspecified)	C				
			Synthroid	C		ORAL		
			Lamisil	C				
			Chondroitin And Glucosamine	C		ORAL		

Date:11/01/02ISR Number: 4001690-8Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00192
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Peritonitis		Flupentixol Decanoate	C		INTRAMUSCULAR		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL	22	DAY
			Diclofenac Sodium	C		ORAL	17	DAY
			Ranitidine	C		ORAL		

Date:11/01/02ISR Number: 4001691-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA01350
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Pruritus		Vioxx	SS		ORAL		
	Urticaria		Zanaflex	C		ORAL	3	DAY
			Premarin	C		ORAL		

Date:11/01/02ISR Number: 4001693-3Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00114
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Ketoprofen	C		ORAL		
			Tramadol	C				

Date:11/01/02ISR Number: 4001696-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00273
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL	81	DAY
	Joint Swelling		Estraderm	C		TOPICAL		
	Muscle Twitching							
	Neuralgia							
	Pain In Extremity							
	Paraesthesia							
	Parkinsonian Gait							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/02ISR Number: 4001697-0Report Type:Expedited (15-DaCompany Report #WAES 0210DNK00026
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Dipyridamole	C		ORAL		
			Aspirin	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Picosulfate Sodium	C		ORAL		

Date:11/01/02ISR Number: 4001698-2Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00201
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Melaena	Professional	Levothyroxine Sodium	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Amlodipine	C		ORAL		

Date:11/01/02ISR Number: 4001701-XReport Type:Expedited (15-DaCompany Report #WAES 0210SWE00018
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Prothrombin Level Decreased	Professional	Warfarin Sodium	SS		ORAL		
			Allopurinol	C				
			Meprednisone	C				
			Tamoxifen Citrate	C				
			Morphine	C				

Date:11/01/02ISR Number: 4001709-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA02807
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/01/02ISR Number: 4003346-4Report Type:Direct Company Report #CTU 180180
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required Intervention to Prevent Permanent Impairment/Damage	Limb Injury Myalgia Rash		Lipitor 10 Mg Pfizer Us Parke Dav	PS	Pfizer Us Parke Dav	ORAL
1 TABLET DAILY MOUTH 6 YR						
			Vioxx 25 Mg Ms	SS	Ms	ORAL
1 TABLET DAILY MOUTH 6 YR						

Date:11/01/02ISR Number: 4003385-3Report Type:Direct Company Report #CTU 180193
Age:92 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain		Vioxx	PS			NOT	
Asthenia						DOCUMENTED	
Dizziness		Aspirin	SS			325 MG QD	
Duodenal Ulcer		Adalat Cc	C				
Dyspepsia		Atenolol	C				
Faeces Discoloured		Lipitor	C				
Haematemesis							
Muscle Spasms							

Date:11/01/02ISR Number: 4005181-XReport Type:Expedited (15-DaCompany Report #02-10-0943
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Foreign	Enalapril Tablets	PS		ORAL	2.5 MG QD	
	Atherosclerosis	Literature						
	Brain Oedema	Health	Rofecoxib Unknown	SS			ORAL	2 YR
	Cardiac Arrest	Professional	L-Thyroxin	C			25 MG QD	5 DAY
	Cellulitis							
	Cerebrovascular Accident							
	Coma							
	Cystitis Noninfective							
	Fibrosis							
	Hepatic Congestion							
	Hypotension							
	Hypoventilation							
	Marrow Hyperplasia							
	Necrosis							
	Nephrosclerosis							
	Oxygen Saturation Decreased							
	Pain In Extremity							
	Pulmonary Congestion							
	Sepsis							
	Skin Ulcer							

Somnolence
Spleen Congestion
Ventricular Hypertrophy

Date:11/01/02ISR Number: 4007045-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Atherosclerosis
Other	Biliary Neoplasm
	Blood Alkaline Phosphatase Abnormal
	Blood Creatine Abnormal
	Blood Creatinine Abnormal
	Blood Urea Abnormal
	Cardiac Murmur
	Chest Pain
	Diabetes Mellitus
	Dialysis
	Drug Interaction
	Drug Withdrawal Syndrome

	Dry Mouth						
	Dry Skin						
	Ejection Fraction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased	Consumer	Tab Vioxx 10 Mg	PS		ORAL	PO
	Erectile Dysfunction	Health	Lipitor 10 Mg	SS		ORAL	10 MG/ DAILY/
	Erythema Multiforme	Professional					PO
	Haematocrit Abnormal		Zemplar	SS			
	Haemoglobin Abnormal		[Therapy				
	Haemorrhage		Unspecified]	SS			
	Hypokinesia		Celebrex	C			
	Injury		Flexeril	C			
	Intestinal Ischaemia		Humulin	C			
	Joint Stiffness		Imuran				
	Kidney Transplant		(Azathioprine)	C			
	Rejection		Lasix (Furosemide)	C			
	Liver Function Test		Norvasc	C			
	Abnormal		Sandimmun	C			
	Mitral Valve Incompetence		Toprol Xl	C			
	Myalgia		Ultralente Insulin	C			
	Oliguria		Viagra	C			
	Parathyroid Disorder		Zaroxolyn	C			
	Pericardial Effusion		Zebeta	C			
	Rales		Calcium (+) Vitami	C			
	Red Blood Cell Count		Clonazepam	C			
	Abnormal		Clonidine				
	Renal Failure		Hydrochloride	C			
	Renal Transplant		Cyclosporine	C			
	Rosacea		Epoetin	C			
	Somnolence		Iron Dextran	C			
	Ultrasound Kidney		Paricalcitol	C			
	Abnormal		Prednisone	C			
	Vascular Calcification		Vitamin B Complex	C			
	Ventricular Hypertrophy						

Date:11/04/02ISR Number: 4002948-9Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00190
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY

Initial or Prolonged	Haemorrhage	Rabeprazole Sodium	C	ORAL
		Acetaminophen And Codeine Phosphate	C	ORAL
		Acetaminophen And Codeine Phosphate	C	ORAL
		Cetirizine Hydrochloride	C	ORAL

Date:11/04/02ISR Number: 4002953-2Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Activated Partial Thromboplastin Time Prolonged
	Acute Myocardial Infarction
	Alanine Aminotransferase Increased
	Anaphylactic Reaction

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arrhythmia					
		Blood Pressure Increased					
		Cardiac Arrest					
		Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Celebrex	SS		ORAL
		Contusion		Acetaminophen And			
		Exsanguination		Hydrocodone			
		Gastritis		Bitartrate	C		ORAL
		Gastrointestinal		Zydone	C		ORAL
		Haemorrhage		Pertussin N	C		ORAL
		Haematochezia		Accolate	C		ORAL
		International Normalised		Claritin	C		ORAL
		Ratio Increased		Pravachol	C		ORAL
		Large Intestinal Ulcer		Paxil	C		ORAL
		Haemorrhage		Flonase	C		ORAL
		Oedema		Toradol	C		ORAL
		Oesophageal Ulcer		Remeron	C		ORAL
		Haemorrhage		Nystatin	C		ORAL
		Platelet Count Decreased		Biaxin	C		ORAL
		Pleuritic Pain		Depo-Provera	C		
INTRAMUSCULAR							
		Prothrombin Time		Hydrocortisone			
		Prolonged		Acetate	C		
		Rib Fracture		Skelaxin	C		ORAL
		Sudden Cardiac Death		Tequin	C		ORAL
				Alupent	C		
RESPIRATORY							
(INHALATION)							
				Serevent	C		
RESPIRATORY							
(INHALATION)							
				Flovent	C		
RESPIRATORY							
(INHALATION)							
				Buspar	C		ORAL
				Lipitor	C		ORAL
				Amaryl	C		ORAL
				Percocet	C		ORAL
				Pramoxine			
				Hydrochloride	C		
TOPICAL							
				Premarin	C		ORAL

			Proventil	C		
RESPIRATORY						
(INHALATION)						
			Demerol	C		ORAL
			Alprazolam	C		ORAL
			Carisoprodol	C		ORAL
			Aquaphor	C		
			Promethazine	C		
			Soma	C		ORAL
			Ziac	C		

Date:11/04/02ISR Number: 4002960-XReport Type:Expedited (15-DaCompany Report #WAES 01116031
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 136 DAY	Necrotising Fasciitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Diacerein	C		ORAL
			Isradipine	C		ORAL
			Ibuprofen	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/02ISR Number: 4002972-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA02968
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:11/04/02ISR Number: 4002976-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA02450
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
			Tramadol Hydrochloride	C				
			Flexeril	C		ORAL		

Date:11/04/02ISR Number: 4006262-7Report Type:Expedited (15-DaCompany Report #NSADSS2002014331
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoxia Lung Disorder	Foreign Health Professional	Remicade (5 Mg/ Ml Lyophilized Powder) (Infliximab, Recombinant)	PS			INTRAVENOUS	5 MG/KG, 1 IN 1 TIME(S), IV
			Methotrexate (Methotrexate)	SS		ORAL	5 MG, WEEKLY,	ORAL
			Vioxx (Rofecoxib)	SS		ORAL	37.5 MG,	DAILY, ORAL
			Corticosteroid Nos (Corticosteroid Nos)	C				

Date:11/05/02ISR Number: 4003734-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01052
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tofranil	C				
			[Therapy Unspecified]	C				
			Flomax (Tamsulosin Hydrochloride)	C				

Date:11/05/02ISR Number: 4003742-5Report Type:Expedited (15-DaCompany Report #WAES 0210BEL00087
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/06/02ISR Number: 4004741-XReport Type:Expedited (15-DaCompany Report #WAES 0210GBR00274
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombocytopenia		Ibuprofen	C		ORAL		

Date:11/06/02ISR Number: 4004746-9Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00002
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:11/06/02ISR Number: 4004747-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00206
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	WK
	Congestive		[Therapy Unspecified]	C				

Date:11/06/02ISR Number: 4004750-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Lipitor	SS		ORAL	366	DAY
Disability	Congestive		Zemplar	SS				
Other	Coronary Artery Disease		[Therapy Unspecified]	SS				
	Dermatitis		Imuran (Azathioprine)	C		ORAL		
	Drug Hypersensitivity		Prednisone	C		ORAL		
	Drug Interaction							
	Drug Withdrawal Syndrome							

	Erythema Multiforme	Lasix (Furosemide)	C	ORAL
	Haemodialysis	Sandimmun	C	ORAL
	Haemorrhage	Clonidine Hydrochloride	C	ORAL
	Kidney Transplant	Calcium (Unspecified) And Vitamin D (Unspecified)	C	
	Rejection	Iron Dextran	C	
	Lung Infiltration	Epoetin	C	
	Muscular Weakness	Cyclosporine	C	
	Myalgia	Paricalcitol	C	
	Palpitations	Zaroxolyn	C	ORAL
	Skin Disorder	Ultralente Insulin	C	
	Skin Irritation	Toprol Xl Tablets	C	ORAL
		Viagra	C	ORAL
		Humulin	C	
		Clonazepam	C	
		Norvasc	C	ORAL
		Zebeta	C	ORAL
		Flexeril	C	ORAL
		Vitamin B Complex	C	ORAL
		Celebrex	C	

INTRAVENOUS

PARENTERAL

PARENTERAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4004754-8Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00277
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Methotrexate	SS		ORAL		335 DAY
Initial or Prolonged			Folic Acid	C				
Disability			Desloratadine	C				

Date:11/06/02ISR Number: 4004758-5Report Type:Expedited (15-DaCompany Report #WAES 0211AUS00005
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Fall	Professional	Amiodarone	C				
	Nausea		Verapamil	C				
			Indapamide	C				
			Ramipril	C				

Date:11/06/02ISR Number: 4004761-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00731
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage	Professional						

Date:11/06/02ISR Number: 4004763-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA02982
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Rosacea		Synthroid	C				
			Toprol Xl Tablets	C				

Date:11/06/02ISR Number: 4004764-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00183
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Migraine	Professional						
	Rash Erythematous							
	Rash Pruritic							
	Syncope							

Date:11/06/02ISR Number: 4004765-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA00023
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -		Professional	Bupivacaine					
Initial or Prolonged			Hydrochloride	C				
			Lidocaine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/02ISR Number: 4004766-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA00030
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise		Tiazac	C				
	Muscle Spasms							
	Oedema Peripheral							
	Ulcer Haemorrhage							
	Vision Blurred							
	Vomiting							
	Weight Decreased							

Date:11/06/02ISR Number: 4004768-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA00033
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS		ORAL		
	Dyspnoea		Norvasc	C		ORAL		
	Gravitational Oedema		Zoloft	C		ORAL		
			Mysoline	C		ORAL		
			Lipitor	C		ORAL		
			Restoril	C		ORAL		

Date:11/07/02ISR Number: 4005498-9Report Type:Direct Company Report #CTU 180515
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx 25 Mg (Rofecoxib) Po Qd (Merck)	PS	Merck	ORAL	25 MG PO QD	
			Toprol Xl	C				
			Allegra	C				
			Hctz	C				
			Monopril	C				
			Xanax	C				

Date:11/07/02ISR Number: 4005592-2Report Type:Expedited (15-DaCompany Report #WAES 0201GBR00166
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		503 DAY
Hospitalization -	Blood Urea Increased		Aspirin	SS		ORAL		48 DAY
Initial or Prolonged	Haemoglobin Decreased		Furosemide	C		ORAL		
	Melaena		Prochlorperazine Maleate	C		ORAL		
	Ulcer		Ursodiol	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		
			Fenoterol Hydrobromide And Ipratropium Bromide	C		RESPIRATORY (INHALATION)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/02ISR Number: 4005598-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA02450
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Insulin	C				
			Tramadol	C				
			Flexeril	C		ORAL		

Date:11/07/02ISR Number: 4005599-5Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00053
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Gastrointestinal							
Hospitalization -	Haemorrhage							
Initial or Prolonged	Haemolysis							
	Multi-Organ Failure							
	Pneumonia Aspiration							

Date:11/07/02ISR Number: 4005601-0Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00030
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				

Date:11/07/02ISR Number: 4005611-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA02702
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Mountain Sickness Acute		Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Oedema		Vioxx	SS		ORAL
			Tylenol	C		

Date:11/07/02ISR Number: 4005615-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00037
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/07/02ISR Number: 4005617-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA00050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/02ISR Number: 4006340-2Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00010
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Disorientation							
	Hallucination, Visual							
	Memory Impairment							

Date:11/08/02ISR Number: 4006342-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA00381
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		85 DAY
Initial or Prolonged	Gastrointestinal							
Disability	Haemorrhage							
Other	Phlebitis							
	Pneumonia							
	Pulmonary Embolism							

Date:11/08/02ISR Number: 4009315-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chondropathy	Consumer	Tab Vioxx Unk	PS		ORAL		PO
Initial or Prolonged	Colonic Polyp	Health	Celebrex	C				
	Contusion	Professional	Lamisil	C				
	Deep Vein Thrombosis		Synthroid	C				
	Discomfort		Chondroitin (+)					
	Hepatic Steatosis		Glucosamine	C				
	Oedema		Vitamins					
	Pain In Extremity		(Unspecified)	C				
	Plantar Fasciitis							
	Pulmonary Granuloma							
	Renal Cyst							
	Tendon Disorder							

Date:11/08/02ISR Number: 4010633-2Report Type:Expedited (15-DaCompany Report #HQ3002609JUL2001
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ascites	Health Professional	Lodine (Etodolac, Unspec)	PS		ORAL	400 MG DAILY, ORAL	
	Diverticulum Intestinal							
	Gastritis							
	Gastritis Erosive		Vioxx (Rofecoxib, Tablet)	SS				
	Gastrointestinal Haemorrhage		Norvasc (Amlodipine Besilate)	C				
	Haematochezia		Lasix (Furosemide)	C				
	Hypochromic Anaemia		Ecotrin (Acetylsalicylic Acid)	C				
	Ileus Paralytic		Prilosec (Omeprazole)	C				
	Intestinal Ischaemia		Potassium (Potassium)	C				
	Myocardial Infarction		Zocor (Simvastatin)	C				
			Darvocet-N (Dextropropoxyphene/					

			Paracetamol)	C		
			Digoxin (Digoxin)	C		

Date:11/09/02ISR Number: 4006779-5Report Type:Expedited (15-DaCompany Report #WAES 0207USA01176
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Post Procedural Complication							
Other	Pulmonary Embolism							

Date:11/09/02ISR Number: 4006780-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA01075
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	575	DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Synthroid	C				
			Micardis	C				
			Claritin	C				
			Tylenol	C				
			Aciphex	C				
			Cytotec	C				

Date:11/09/02ISR Number: 4006797-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA00228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/02ISR Number: 4006799-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00305
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 4 DAY	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Weight Increased		Vioxx	SS		ORAL
			Synthroid	C		
			Medrol	C		

Date:11/09/02ISR Number: 4006801-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA00359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Renal Failure Acute		[Therapy Unspecified]	C		

Date:11/11/02ISR Number: 4007002-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA00524
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Post Procedural Complication					
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/02ISR Number: 4007005-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA01416
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Zanaflex	C				
			Doxepin Hydrochloride	C				
			Klonopin	C				
			Synthroid	C				

Date:11/11/02ISR Number: 4007007-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00861
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		[Composition Unspecified]	C				
	Cardiomegaly							
	Localised Infection							
	Renal Failure Acute							
	Testicular Disorder							

Date:11/11/02ISR Number: 4007008-9Report Type:Expedited (15-DaCompany Report #WAES 0208USA04263
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Amitriptyline	SS				
Disability			Zomig	SS				
Other			[Therapy Unspecified]	C				

Date:11/11/02ISR Number: 4007010-7Report Type:Expedited (15-DaCompany Report #WAES 0211NOR00004
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Anorexia Blood Alkaline Phosphatase Increased Blood Sodium Decreased Blood Urea Increased Duodenal Ulcer Haematochezia Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	
			Aspirin And Magnesium Oxide	SS		ORAL
			Ramipril	C		
			Metoprolol Tartrate	C		
			Furosemide	C		
			Digitoxin	C		
			Spironolactone	C		
			Nitroglycerin	C		

Date:11/11/02ISR Number: 4007012-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia Asthenia Astigmatism Blood Pressure Increased Cardiac Flutter Dizziness Drug Withdrawal Syndrome

		Gastroenteritis					
		Headache					
		Keratoconjunctivitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sicca	Health	Vioxx	PS	Merck & Co., Inc	ORAL
193	DAY						
		Maculopathy	Professional	Vioxx	SS		ORAL
46	DAY						
		Myalgia		Calcium			
		Presbyopia		(Unspecified)	C		
		Red Blood Cell		Univasc	C		
		Sedimentation Rate		Zoloft	C		
		Increased		Baycol	C		
985	DAY						
		Renal Failure		Ibuprofen	C		
		Retinal Exudates		Celebrex	C		
		Retinal Haemorrhage		Ziac	C		
		Retinal Vein Thrombosis		Ziac	C		
		Rhabdomyolysis		Ziac	C		
		Urinary Tract Infection		Prinivil	C		ORAL
		Visual Disturbance		Aciphex	C		
7	DAY						
		Vitreous Detachment		Plavix	C		
				Aspirin	C		

Date:11/11/02ISR Number: 4007016-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01008
Age:90 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Delirium		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Feeling Abnormal		Vioxx	SS		ORAL
6	DAY						
				Halcion	C		
				Darvocet-N	C		
				Prednisone	C		
				Lasix (Furosemide)	C		
				Probenecid	C		

Date:11/11/02ISR Number: 4007221-0Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00114
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemiparesis		Ketoprofen	C		ORAL		
	Hypertension		Tramadol	C				
			[Therapy Unspecified]	C				

Date:11/11/02ISR Number: 4007223-4Report Type:Expedited (15-DaCompany Report #WAES 01105003
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL		
	Complications Of Maternal Exposure To Therapeutic Drugs		Acetaminophen And Codeine Phosphate	C				
	Diarrhoea							
	Lower Respiratory Tract Infection							
	Parasitic Infection Intestinal							
	Postpartum Haemorrhage							
	Twin Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/02ISR Number: 4007227-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA01733
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease		Synthroid	C				
Other			Glucotrol Xl	C				
			Atenolol	C				
			Zantac	C				
			Hydrodiuril	C		ORAL		
			Lipitor	C				
			Diovan	C				
			Ditropan	C				

Date:11/11/02ISR Number: 4007233-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA00732
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/02ISR Number: 4007237-4Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atropine Sulfate And Diphenoxylate Hydrochloride	C				

Date:11/12/02ISR Number: 4008095-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01598
Age:70 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				

Date:11/12/02ISR Number: 4008096-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01864
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Electrocardiogram Qt Prolonged		Vioxx	SS		ORAL		
	Heart Rate Increased		Celebrex	C				
	Hypertension		Ativan	C				
	Lacunar Infarction		Taloxa	C				
	Low Density Lipoprotein Increased		Glucophage	C				
	Oedema Peripheral		Avandia	C				
	Respiratory Rate Decreased		Zestril	C				
	Ventricular Hypertrophy		Norvasc	C				
			Voltaren	C				
			Diuril	C		ORAL		
			Elavil	C		ORAL		
			Amaryl	C				

Date:11/12/02ISR Number: 4008097-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA01176
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Postoperative Thrombosis	Professional						
	Pulmonary Embolism							
Other								

Date:11/12/02ISR Number: 4008098-XReport Type:Expedited (15-DaCompany Report #WAES 0210CAN00112
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Epilepsy	Professional	Phenytoin	C				
			Venlafaxine Hydrochloride	C				
			Clonazepam	C				

Date:11/12/02ISR Number: 4008099-1Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00022
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Hospitalization - Initial or Prolonged		Professional						

Date:11/12/02ISR Number: 4008100-5Report Type:Expedited (15-DaCompany Report #WAES 0211AUS00022
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/12/02ISR Number: 4008105-4Report Type:Expedited (15-DaCompany Report #WAES 0211NOR00007
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Haemorrhage	Professional	Prednisolone	SS		ORAL		
	Haemoglobin Decreased		Warfarin Sodium	C				
	Helicobacter Infection							
	Hiatus Hernia							
	International Normalised Ratio Abnormal							
	Mean Cell Volume Decreased							
	Nausea							
	Vomiting							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/02ISR Number: 4008106-6Report Type:Expedited (15-DaCompany Report #WAES 0211NOR00008
Age:57 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Arrhythmia	Professional						
	Hepatic Cirrhosis							
	Varices Oesophageal							

Date:11/12/02ISR Number: 4008107-8Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00095
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	[Therapy					
	Gastritis		Unspecified]	C				

Date:11/12/02ISR Number: 4011638-8Report Type:Expedited (15-DaCompany Report #K200201819
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Septra					
	Intentional Misuse	Professional	Tablets/Septra Ds					
		Other	Tablets	PS		ORAL		
ORAL								
			Nortriptyline					
			(Nortriptyline)	SS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:11/13/02ISR Number: 4008473-3Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/13/02ISR Number: 4008476-9Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00091
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:11/13/02ISR Number: 4008481-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA00809
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/13/02ISR Number: 4008746-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA02724
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		

Date:11/13/02ISR Number: 4008752-XReport Type:Expedited (15-DaCompany Report #WAES 0210BRA00055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Dexamethasone Acetate	SS		PARENTERAL		
	Fatigue		Thiamine Hydrochloride	SS		PARENTERAL		
	Hypertension		Pyridoxine Hydrochloride	SS		PARENTERAL		
	Irritability		Cyanocobalamin	SS		PARENTERAL		

Date:11/13/02ISR Number: 4008754-3Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Suicide Attempt		Alcohol	C				

Date:11/13/02ISR Number: 4008756-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA00523
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:11/13/02ISR Number: 4008757-9Report Type:Expedited (15-DaCompany Report #WAES 0211USA00821
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Raynaud'S Phenomenon		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				

Date:11/13/02ISR Number: 4008761-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	12	MON

Date:11/13/02ISR Number: 4011011-2Report Type:Expedited (15-DaCompany Report #WAES 01075034
Age:64 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Foreign	Tab Vioxx					
Hospitalization -	Gastrointestinal	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Haemorrhage							
PO							31	DAY
Disability	Melaena		Acetaminophen/Codein					
Other			e Phosphate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/02ISR Number: 4011099-9Report Type:Expedited (15-DaCompany Report #GB9336005NOV2002
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy	Foreign	Methotrexate					
Hospitalization -		Health	(Methotrexate,					
Initial or Prolonged		Professional	Tablet, 0)	PS		ORAL	12.5MG DAILY	
Disability			Vioxx (Rofecoxib,					
			Tablet, 0)	SS		ORAL	25MG DAILY	
			Folic Acid (Folic					
			Acid)	C				
			Desloratadine					
			(Desloratadine)	C				

Date:11/13/02ISR Number: 4011292-5Report Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Consumer	Tab Vioxx 12.5 Mg	PS				
Initial or Prolonged	Depression	Health					12.5 MG/DAILY/PO	
	Dizziness	Professional	Accupril	C				
	Drug Ineffective		Calan Sr	C				
	Fibromyalgia		Celebrex	C				
	Headache		Dyazide	C				
	Heart Rate Increased		Elavil	C				
	Hypertension		Flexeril	C				
	Lymphadenopathy		Flexeril	C				
	Malaise		Flexeril	C				
	Migraine		Plavix	C				
	Muscle Spasms		Premarin	C				
	Muscle Strain		Ultram	C				
	Muscle Tightness		Vicodin Tablets	C				
	Musculoskeletal Stiffness		Zoloft	C				
	Nausea		Zoloft	C				
	Neck Pain		Atenolol	C				
	Pain							
	Renal Impairment							
	Sleep Disorder							
	Tension Headache							

Date:11/14/02ISR Number: 4009206-7Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00010
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL		
			Trospium Chloride	SS		ORAL		
			Bendroflumethiazide	C		ORAL		
			Aspirin	C		ORAL		
			Nitrofurantoin	C		ORAL		
			Tibolone	C		ORAL		

Date:11/14/02ISR Number: 4009208-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
	Aortic Valve Incompetence
Disability	Arthralgia
Other	Biliary Neoplasm

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure Congestive Complications Of Transplant Surgery Condition Aggravated Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zemplar	SS				
			Lipitor	SS		ORAL	366 DAY	
	Dialysis Diarrhoea Drug Interaction Erythema Multiforme Kidney Small Mitral Valve Incompetence Myositis Nephrolithiasis Palpitations Pulmonary Congestion Raynaud'S Phenomenon Tricuspid Valve Incompetence Ventricular Hypertrophy		[Therapy Unspecified]	SS				
			Humulin	C			PARENTERAL	
			Imuran (Azathioprine)	C		ORAL		
			Prednisone	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Sandimmun	C		ORAL		
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				
			Iron Dextran	C				
			Epoetin	C				
			Cyclosporine	C				
			Paricalcitol	C			INTRAVENOUS	
			Zaroxolyn	C		ORAL		
			Ultralente Insulin	C			PARENTERAL	
			Toprol Xl Tablets	C		ORAL		
			Viagra	C		ORAL		
			Clonazepam	C				
			Clonidine Hydrochloride	C		ORAL		
			Norvasc	C		ORAL		
			Zebeta	C		ORAL		
			Flexeril	C		ORAL		
			Vitamin B Complex	C		ORAL		
			Celebrex	C				

Date:11/14/02ISR Number: 4009211-0Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00100
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
85 DAY						
	Confusional State		Felodipine	C		
	Dizziness		Albuterol	C		
	Gastrooesophageal Reflux		Valsartan	C		
	Disease		Metformin	C		
	Malaise		Acetaminophen And Codeine Phosphate	C		
			Tramadol Hydrochloride	C		
			Doxazosin	C		

Date:11/14/02ISR Number: 4009574-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00982
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL
	Renal Failure					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/02ISR Number: 4009579-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01799
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Convulsion Haemorrhage Intracranial Hypervolaemia Impaired Driving Ability Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/14/02ISR Number: 4009582-5Report Type:Expedited (15-DaCompany Report #WAES 0211BRA00004
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Insomnia Psychotic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY

Date:11/14/02ISR Number: 4009587-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA00524
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Deep Vein Thrombosis Post Procedural Complication		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:11/14/02ISR Number: 4009591-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA00964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Renal Disorder		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Plavix	C
Premarin	C
Protonix	C
Lipitor	C

Date:11/14/02ISR Number: 4009868-4Report Type:Direct Company Report #CTU 180917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoptysis		Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged	Upper Gastrointestinal Haemorrhage							

Date:11/14/02ISR Number: 4010045-1Report Type:Direct Company Report #CTU 180880
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Blood Pressure Systolic Decreased
	Melaena
	Mental Impairment

		Upper Gastrointestinal Haemorrhage					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Aggrenox Once Po Bid	PS		
				Vioxx 25mg Po Qd	SS		
				Glucophage	C		
				K-Dur	C		

Date:11/15/02ISR Number: 4010205-XReport Type:Expedited (15-DaCompany Report #WAES 0211BRA00003
Age:43 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/15/02ISR Number: 4010207-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA00013
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Hot		Plavix	C		
		Medication Error		Zonegran	C		
		Transient Ischaemic Attack					
		Vomiting					

Date:11/15/02ISR Number: 4010460-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02444
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Systolic Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Imitrex	C		
		Drug Hypersensitivity		Elavil	C		ORAL
		Furuncle		Inderal	C		ORAL
		Inflammation		Ambien	C		ORAL
		Influenza Like Illness		Medicon	C		
		Joint Swelling					

Optic Neuritis
Pharyngitis
Pharyngolaryngeal Pain
Scotoma
Stevens-Johnson Syndrome
Uveitis

Date:11/15/02ISR Number: 4010465-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA01138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/02ISR Number: 4010466-7Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 DAY	Depressed Level Of		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Consciousness		Lithium Sulfate	SS		ORAL
	Drug Level Increased		Levothyroxine Sodium	C		
	Extrapyramidal Disorder		Dipyridamole	C		
	Fatigue		Lofepramine Hydrochloride	C		
	Medication Error		Zolpidem Tartrate	C		
	Renal Failure		Calcium Carbonate And Cholecalciferol	C		
			Tramadol Hydrochloride	C		

Date:11/15/02ISR Number: 4010471-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA01347
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening 29 DAY	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Oral Intake Reduced		Paxil	C		
	Ulcer Haemorrhage		Aspirin	C		ORAL
	Upper Gastrointestinal Haemorrhage		Tylenol	C		ORAL
			Vitamins (Unspecified)	C		

Date:11/15/02ISR Number: 4010479-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA00030
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Dizziness		Tiazac	C		
	Gastrointestinal Disorder					
	Muscle Spasms					
	Night Blindness					
	Oedema Peripheral					
	Oral Intake Reduced					

Ulcer Haemorrhage
Vision Blurred
Visual Acuity Reduced
Vomiting
Weight Decreased

Date:11/15/02ISR Number: 4010480-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00121
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	928	DAY
	Vomiting		Nizatidine	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Estradiol	C				
			Amlodipine	C		ORAL		
			Bendroflumethiazide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/02ISR Number: 4010487-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA01217
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema		Coumadin	C				
			Nexium	C				
			Paxil	C				
			Potassium Chloride	C				
			Furosemide	C				
			Tylenol	C				

Date:11/15/02ISR Number: 4010488-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA01036
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL	38	DAY
	Orthopnoea		Retin-A	C		ORAL		
	Weight Increased		Atenolol	C		ORAL		
			Clarinex	C		ORAL		
			Remeron	C		ORAL		
			Ultram	C		ORAL		
			Spironolactone	C		ORAL		
			Spironolactone	C		ORAL		
			Ortho Tri-Cyclen	C		ORAL		

Date:11/15/02ISR Number: 4010489-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA01104
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Oedema							

Date:11/15/02ISR Number: 4010492-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA00961
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Convulsion		Vioxx	SS		ORAL		
	Dizziness		Advil	C				
	Myalgia		Ambien	C				

Date:11/15/02ISR Number: 4014889-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Astigmatism
	Cataract
	Drug Withdrawal Syndrome
	Eye Irritation
	Gastroenteritis
	Hypertension
	Keratoconjunctivitis
	Sicca
	Maculopathy
	Presbyopia
	Renal Failure
	Retinal Exudates

		Retinal Haemorrhage					
		Retinal Vein Thrombosis					
		Rhabdomyolysis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE							
		Vitreous Detachment	Health	...	C		
			Professional	Aciphex	C		
				Baycol	C		
				Celebrex	C		
				Plavix	C		
				Prinivil	C		
				Univasc	C		
				Ziac	C		
				Zoloft	C		
				Aspirin	C		
				Calcium (Unspecified)	C		
				Ibuprofen	C		

Date:11/18/02ISR Number: 4011207-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA00878
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Coronary Artery Disease		Altace	C		
		Pain		Glucophage	C		

Date:11/18/02ISR Number: 4011217-2Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Shock					

Date:11/18/02ISR Number: 4011539-5Report Type:Direct Company Report #CTU 181139
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pseudoporphyria		Rofecoxib	PS			25MG QD	
			Furosemide	SS		ORAL	160 TO 240MG	
							QD PO	
			Nph Insulin	C				
			Metformin	C				
			Gemibrozil	C				
			Diltiazem	C				
			Atorvastatin	C				
			Isosorbide Mono Nitrate	C				
			Aspirin	C				
			Quinine	C				
			Nortriptyline	C				
			Nitroglycerin	C				
			Lansoprazole	C				
			Multivitamin	C				
			Losartan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/02ISR Number: 4014888-XReport Type:Expedited (15-DaCompany Report #PHBS2002AU13153
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute	Foreign Health Professional Other	Slow K(Potassium Chloride) Unknown	PS			1 DF/DAY	
			Vioxx (Rofecoxib)	SS			1 DF/DAY	
			Lasix (Furosemide)	SS			40 MG/DAY	
			Atacand (Candesartan Cilexetil)	SS			1 DF/DAY	
			Adalat Oros	C				

Date:11/19/02ISR Number: 4011605-4Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00047
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Sodium Feredetate	C		ORAL	47	DAY
			Opium	C		ORAL	5	DAY
			Furosemide	C		ORAL	47	DAY
			Warfarin	C		ORAL	47	DAY
			Prednisolone	C		ORAL		
			Rutin	C		ORAL		
			Misoprostol	C		ORAL		
			Antimicrobial (Unspecified)	C		ORAL		

Date:11/19/02ISR Number: 4011608-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA02013
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		[Composition Unspecified]	C		
			Glucophage	C		
			Lipitor	C		
			Aspirin	C		

Date:11/19/02ISR Number: 4011807-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00509
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/02ISR Number: 4011814-4Report Type:Expedited (15-DaCompany Report #WAES 0211ITA00011
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Gastric Ulcer Haemorrhage		Amlodipine Besylate	C				
	Renal Failure Acute		Lorazepam	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/02ISR Number: 4011815-6Report Type:Expedited (15-DaCompany Report #WAES 0211ITA00010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Jaundice Acholuric		Vioxx [Composition Unspecified]	PS SS	Merck & Co., Inc	ORAL	INTRAMUSCULAR	

Date:11/19/02ISR Number: 4011818-1Report Type:Expedited (15-DaCompany Report #WAES 0211USA01123
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/02ISR Number: 4011821-1Report Type:Expedited (15-DaCompany Report #WAES 0211USA01296
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tendon Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/02ISR Number: 4011825-9Report Type:Expedited (15-DaCompany Report #WAES 0211USA01655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Gastrointestinal Disorder		Vioxx [Therapy Unspecified] Quinidine	PS SS C	Merck & Co., Inc	ORAL		

Date:11/19/02ISR Number: 4012872-3Report Type:Direct Company Report #CTU 181301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Neoplasm Malignant		Celebrex 100mg 2x'S Daily	PS			2X'S DAILY	
Other			Vioxx 50mg 1x Daily	SS			1X DAILY	
			Cafergot	C				
			Cefaclor	C				
			Atenolol	C				
			Levoxyl	C				
			Fosamax	C				
			Centrum Silver With Lutein	C				
			Vitamins A,C,E	C				
			Os-Cal	C				
			Glucosomine	C				

Date:11/19/02ISR Number: 4014610-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
Disability	Anxiety
Other	Arthralgia
	Asthenia
	Atherosclerosis

		Biliary Neoplasm					
		Blood Parathyroid Hormone Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complications Of	Consumer	Tab Vioxx 10 Mg	PS		ORAL
PO							
		Transplant Surgery	Health	Lipitor 10 Mg	SS		ORAL
10							
		Dermatitis Exfoliative	Professional				
MG/DAILY/PO							
		Dialysis		Zemplar	SS		
		Drug Interaction		Therapy Unspecified	SS		
		Erythema Multiforme		Celebrex	C		
		Haemorrhage		Flexeril	C		
		Haemorrhage Subcutaneous		Humulin	C		
		Iatrogenic Injury		Imuran			
		Injury		(Azathioprine)	C		
		Kidney Transplant		Lasix (Furosemide)	C		
		Rejection		Norvasc	C		
		Lung Infiltration		Sandimmun	C		
		Movement Disorder		Toprol Xl Tablets	C		
		Myalgia		Ultralente Insulin	C		
		Pain		Viagra	C		
		Paresis		Zaroxolyn	C		
		Rash		Zebeta	C		
		Renal Failure		Calcium (+) Vitami	C		
		Restless Legs Syndrome		Clonazepam	C		
		Skin Disorder		Clonidine			
		Sleep Apnoea Syndrome		Hydrochloride	C		
				Cyclosporine	C		
				Epoetin	C		
				Iron Dextran	C		
				Paricalcitol	C		
				Prednisone	C		
				Vitamin B Complex	C		

Date:11/20/02ISR Number: 4012184-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00018
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Drug Interaction		Rofecoxib	PS	Merck & Co., Inc	ORAL
Hospitalization -		Gastric Haemorrhage		Phenprocoumon	SS		ORAL
Initial or Prolonged		Mucosal Haemorrhage		Aspirin	SS		ORAL
		Oesophageal Haemorrhage		Verapamil	C		

	Prothrombin Time Abnormal		Acetyldigoxin	C		
			Levothyroxine Sodium	C		
			Magnesium Aspartate And Potassium Aspartate	C		
			Hydrochlorothiazide And Irbesartan	C		

Date:11/20/02ISR Number: 4012473-7Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00082
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Duodenal Ulcer		Clopidogrel Bisulfate	C		ORAL		
	Haemorrhage		Carvedilol	C		ORAL		
	Helicobacter Infection		Calcium (Unspecified)	C				
	Shock		Cholecalciferol	C		ORAL		

				Dipyrone	C		ORAL
10 DAY							
				Glimepiride	C		ORAL
				Molsidomine	C		ORAL
				Furosemide Sodium	C		ORAL
				Xipamide	C		ORAL
				Vasotec	C		ORAL
				Isosorbide Mononitrate	C		ORAL
				Fentanyl	C		
TOPICAL		19 DAY					
				Pantoprazole Sodium	C		ORAL
14 DAY							
				Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL
				Diclofenac	C		ORAL
				Tramadol	C		

Date:11/20/02ISR Number: 4012488-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00472
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Neurontin	C		ORAL		
Other			Norflex	C		ORAL		

Date:11/20/02ISR Number: 4012490-7Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dry Mouth		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eczema							
	Erythema							
	Eyelid Oedema							
	Face Oedema							
	Pain In Extremity							
	Rash Scaly							

Skin Fissures

Date:11/20/02ISR Number: 4012496-8Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00044
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hepatitis Fulminant							

Date:11/20/02ISR Number: 4012498-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00160
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/02ISR Number: 4012499-3Report Type:Expedited (15-DaCompany Report #WAES 0211SWE00013
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C				
			Acetaminophen	C				

Date:11/20/02ISR Number: 4012684-0Report Type:Direct Company Report #CTU 181372
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic		Vioxx 25mg Merck And Co	PS	Merck And Co	ORAL	25MG /X1 ORAL	

Date:11/20/02ISR Number: 4016793-1Report Type:Expedited (15-DaCompany Report #HQ3002609JUL2001
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ascites	Health Professional	Lodine (Etodolac, Unspec)	PS		ORAL	400 MG DAILY, ORAL	
	Diverticulum Intestinal							
	Gastritis							
	Gastritis Erosive		Vioxx (Rofecoxib, Tablet)	SS				
	Gastrointestinal Haemorrhage		Norvasc (Amlodipine Besilate)	C				
	Hypochromic Anaemia		Lasix (Furosemide)	C				
	Ileus Paralytic		Ecotrin (Acetylsalicylic Acid)	C				
	Intestinal Ischaemia		Prilosec (Omeprazole)	C				
	Myocardial Infarction		Potassium (Potassium)	C				
			Zocor (Simvastatin)	C				
			Darvocet-N (Dextropropoxyphene/					

			Paracetamol)	C		
			Digoxin (Digoxin)	C		

Date:11/21/02ISR Number: 4012802-4Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00076
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer		Vioxx	SS		ORAL
Other	Fall		Aspirin	SS		ORAL
	Gastric Ulcer Haemorrhage		Insulin, Biphasic			
	Gastritis Haemorrhagic		Isophane [Injection]	C		
SUBCUTANEOUS						
	Weight Decreased		Cozaar	C		ORAL
			Amlodipine Besylate	C		ORAL
			Metoprolol Tartrate	C		ORAL
			Moxonidine	C		ORAL
			Furosemide And Spironolactone	C		ORAL
			Hydrochlorothiazide And Triamterene	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/02ISR Number: 4012810-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01015
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Xanthophyll	C				
	Renal Failure Acute		Detrol	C				
			Synthroid	C				
			Quinine Sulfate	C				
			Os-Cal + D	C				
			Oxycontin	C				
			Desipramine Hydrochloride	C				
			Tylenol	C				
			Allegra	C				
			Prozac	C				
			Prednisone	C				
			Atrovent	C				
			[Therapy Unspecified]	C				

Date:11/21/02ISR Number: 4012812-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01418
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Appendicectomy		Cozaar	C		ORAL		
	Haematoma							

Date:11/21/02ISR Number: 4013063-2Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00064
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Dyspnoea		Acetaminophen	C				
	Fatigue							
	Gastrointestinal Ulcer							
	Melaena							

Date:11/21/02ISR Number: 4013065-6Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00066
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Phlebothrombosis		Pentoxifylline	C				
			Brimonidine Tartrate	C				
			Hyzaar	C		ORAL		

Date:11/21/02ISR Number: 4013066-8Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00183
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
							99	DAY
	Dyspepsia		Bendroflumethiazide	C		ORAL		
	Melaena		Acetaminophen	C		ORAL		
	Nausea							

Date:11/21/02ISR Number: 4013067-XReport Type:Expedited (15-DaCompany Report #WAES 0211GBR00198
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		57 DAY
Other	Diarrhoea		Omeprazole	C		ORAL		
	Dyspepsia		Aspirin	C		ORAL		
	Dyspnoea							
	Joint Swelling							
	Stomatitis							

Date:11/21/02ISR Number: 4013070-XReport Type:Expedited (15-DaCompany Report #WAES 0201GBR00166
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		503 DAY
Hospitalization -	Blood Urea Increased		Aspirin	SS		ORAL		48 DAY
Initial or Prolonged	Haemoglobin Decreased		Ursodiol	C		ORAL		
	Melaena		Furosemide	C		ORAL		
			Prochlorperazine Maleate	C		ORAL		
			Citalopram Hydrobromide	C		ORAL		
			Fenoterol Hydrobromide And Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)								

Date:11/21/02ISR Number: 4013071-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00197
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		78 DAY
Initial or Prolonged	Duodenal Ulcer		Aspirin	SS		ORAL		

	Gastric Ulcer		Acetaminophen	C	ORAL
	Melaena		Aluminum Hydroxide And Simethicone	C	ORAL
			Bendroflumethiazide	C	ORAL
			Nifedipine	C	ORAL
			Cozaar	C	ORAL
			Amitriptyline	C	ORAL
			Lactulose	C	ORAL
			Senna	C	ORAL

Date:11/21/02ISR Number: 4013076-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA01773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/02ISR Number: 4017104-8Report Type:Expedited (15-DaCompany Report #HQ4767322OCT2002
Age:68 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased

	Epistaxis Haemorrhage Petechiae	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Shock	Health Professional Other	Concor Plus (Bisoprolol/Hydrochlorothiazole, Tablet)	PS		ORAL	5 MG 1X PER 1 DAY ORAL
			Acetylsalicylic Acid (Acetylsalicylic Acid)	SS		ORAL	150 MG 1X PER 1 DAY ORAL
			Molsidomine (Molsidomine)	SS			
			Vioxx (Rofecoxib, Tablet)	SS		ORAL	25 MG 1X PER 1 DAY ORAL 2 MON

Date:11/22/02ISR Number: 4013702-6Report Type:Direct Company Report #CTU 181540
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Encephalitis Viral		Vioxx 25mg Merck&Co	PS	Merck And Co	ORAL	ONE/DAY ORAL
Initial or Prolonged	Meningitis Aseptic						ORAL

Date:11/22/02ISR Number: 4013851-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA01696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Somnolence		Vioxx [Composition Unspecified]	PS	Merck & Co., Inc	ORAL	
				SS			
			Zanaflex	SS			

Date:11/22/02ISR Number: 4013872-XReport Type:Expedited (15-DaCompany Report #WAES 0209DEU00141
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hiatus Hernia		Esomeprazole Magnesium	C		ORAL		
	Oesophageal Ulcer		Hydrochlorothiazide And Ramipril	C		ORAL		
	Reflux Oesophagitis		Isosorbide Mononitrate	C		ORAL		
			Candesartan Cilexetil	C		ORAL		

Date:11/22/02ISR Number: 4013878-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA02658
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Aspirin	C		ORAL		
			Lasix (Furosemide Sodium)	C		ORAL		
			Ditropan Xl	C		ORAL		
			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/02ISR Number: 4013882-2Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00121
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		928 DAY
	Vomiting		Nizatidine	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Estradiol	C				
			Amlodipine	C		ORAL		
			Bendroflumethiazide	C		ORAL		

Date:11/22/02ISR Number: 4013886-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA00030
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Disorder		Tiazac	C				
	Malaise							
	Muscle Spasms							
	Oedema Peripheral							
	Oral Intake Reduced							
	Ulcer Haemorrhage							
	Vision Blurred							
	Visual Acuity Reduced							
	Vomiting							
	Weight Decreased							

Date:11/22/02ISR Number: 4020054-4Report Type:Periodic Company Report #PHEH2002US04624
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Increased	Health Professional	Clozaril	PS		ORAL	300 MG, QD, ORAL	
	Grand Mal Convulsion							

Other	Muscle Twitching		Vioxx (Rofecoxib)	SS	ORAL
50 MG, ORAL					
			Guanfacine (Guanfacine)	C	
			Neurontin (Gabapentin)	C	
			Adderall (Dexamfetamine Sulfate, Dexamefetamine Saccharate,	C	
			Cogentin (Benzatropine Mesilate)	C	
			Tetracycline (Tetracycline)	C	

Date:11/25/02ISR Number: 4014440-6Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00072
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hyperthyroidism		Vioxx	PS	Merck & Co., Inc	ORAL
			Interferon Beta-1a	SS		
SUBCUTANEOUS 509 DAY						
			Acenocoumarol	C		ORAL

Hydrocortisone	C		ORAL
Fenofibrate	C		ORAL
Omeprazole	C		ORAL
Etidronate Disodium	C		ORAL
Calcium Carbonate	C		ORAL
Prazepam	C		ORAL
Tramadol Hydrochloride	C		ORAL

Date:11/25/02ISR Number: 4014799-XReport Type:Expedited (15-DaCompany Report #WAES 0211GBR00010
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mouth Ulceration		Vioxx	SS		ORAL		
			Trospium Chloride	SS		ORAL		
			Bendroflumethiazide	C		ORAL		
			Aspirin	C		ORAL		
			Nitrofurantoin	C		ORAL		
			Tibolone	C		ORAL		

Date:11/26/02ISR Number: 4015249-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Anxiety
Other	Arthralgia
	Atherosclerosis
	Biliary Neoplasm
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cardiomyopathy
	Complications Of
	Transplant Surgery
	Congestive Cardiomyopathy
	Dialysis
	Diarrhoea
	Drug Interaction
	Drug Withdrawal Syndrome
	Dry Mouth

Ejection Fraction
Decreased
Erectile Dysfunction
Erythema Multiforme
Fatigue
Haemodialysis
Hypotension
Injury
Kidney Infection
Kidney Transplant
Rejection
Lung Infiltration
Mitral Valve Incompetence
Muscular Weakness
Myalgia
Myocardial Ischaemia
Nephrolithiasis

		Pericardial Effusion Pulmonary Congestion Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Tachycardia	Professional	Lipitor	SS		ORAL
366 DAY							
		Tricuspid Valve Incompetence Ventricular Hypertrophy		Zemplar [Therapy Unspecified]	SS SS		
				Imuran (Azathioprine)	C		ORAL
				Prednisone	C		ORAL
				Lasix (Furosemide)	C		ORAL
				Sandimmun	C		ORAL
				Clonidine Hydrochloride	C		ORAL
				Calcium (Unspecified) And Vitamin D (Unspecified)	C		
				Iron Dextran	C		
				Epoetin	C		
				Cyclosporine	C		
				Paricalcitol	C		
INTRAVENOUS							
				Zaroxolyn	C		ORAL
				Ultralente Insulin	C		
PARENTERAL							
				Toprol Xl Tablets	C		ORAL
				Viagra	C		ORAL
				Humulin	C		
PARENTERAL							
				Clonazepam	C		
				Norvasc	C		ORAL
				Zebeta	C		ORAL
				Flexeril	C		ORAL
				Vitamin B Complex	C		ORAL
				Celebrex	C		

Date:11/26/02ISR Number: 4015253-1Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00066
Age:87 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Hospitalization - Initial or Prolonged	Bronchomalacia		Molsidomine	C		ORAL
	Cardiac Failure		Potassium Chloride	C		ORAL
	Duodenal Ulcer		Furosemide	C		ORAL
	Melaena					
	Renal Impairment					

Date:11/26/02ISR Number: 4015540-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00055
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL
	Therapeutic Response		Chromium Picolinate	C		
	Decreased		Synthroid	C		
			Lipitor	C		

Date:11/26/02ISR Number: 4015543-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02829
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		417 DAY
	Throat Tightness		Synthroid	C				
	Urticaria		Alprazolam	C				
			Verapamil	C				
			Maxzide	C				
			Dicyclomine Hydrochloride	C				
			Fluoxetine	C				
			Captopril	C				
			Aciphex	C				
			Estraderm	C				
			Questran	C				

Date:11/26/02ISR Number: 4015546-8Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00030
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Diltiazem Hydrochloride	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Mirtazapine	C				

Date:11/26/02ISR Number: 4015547-XReport Type:Expedited (15-DaCompany Report #WAES 0211BEL00014
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Ascites		Bisoprolol	C		ORAL		
	Blood Potassium Increased		Althiazide And Spironolactone	C		ORAL		
	Blood Sodium Decreased							

	Cardiac Failure		Aspirin	C			ORAL
	Congestive						
	Cardiomegaly						
	Hypertension						
	Pleural Effusion						
	Renal Impairment						
	Sinus Tachycardia						
	Weight Increased						

Date:11/26/02ISR Number: 4015548-1Report Type:Expedited (15-DaCompany Report #WAES 0211ESP00030
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
	Drug Interaction	Professional	Chlorthalidone	SS		ORAL		
	Hypertension		Zolpidem Tartrate	C		ORAL		
	Oedema Peripheral		Lorazepam	C		ORAL		

Date:11/26/02ISR Number: 4015549-3Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00135
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/26/02ISR Number: 4015556-0Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00075
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Flatulence		Levothyroxine Sodium	C		ORAL		
	Haemoglobin Decreased		Glimepiride	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Ramipril	C		ORAL		
			Ciprofibrate	C		ORAL		
			Promegestone	C		ORAL		
			Estradiol	C		TOPICAL		

Date:11/26/02ISR Number: 4015559-6Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00095
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	[Therapy					
	Gastritis		Unspecified]	C				
	Haematemesis							

Date:11/26/02ISR Number: 4015560-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA01890
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Renal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Ibuprofen	C		
			Glucosamine	C		

Date:11/26/02ISR Number: 4015922-3Report Type:Direct Company Report #CTU 181693
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Face Oedema		Vioxx	PS		ORAL
25 MG PO QD						
	Oedema Peripheral					

Date:11/26/02ISR Number: 4016414-8Report Type:Direct Company Report #CTU 181706
Age:68 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis Infective
	Asthenia
Disability	Cerebrovascular Accident
	Difficulty In Walking
	Epistaxis
	Erythema
	Fall
	Infection

	Laceration						
	Oedema Peripheral						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia		Enbrel	PS				
INTRAMUSCULAR	25MG IM,							
	Weight Decreased							
2X/WEEK	1	YR						
			Vioxx	SS				
UNK DOSE,								
ONCE DAILY	4	WK						
			Diovan	C				
			Norvasc	C				
			Methotrexate	C				
			Folic Acid	C				

Date:11/26/02ISR Number: 4017591-5Report Type:Expedited (15-DaCompany Report #HQ4770322OCT2002
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ventricular Arrhythmia	Foreign	Emconcor					
Hospitalization -		Health	(Bisoprolol, Tablet)	PS		ORAL		
5 MG 1X PER 1								
Initial or Prolonged		Professional						
DAY								
Other		Other	Vioxx (Rofecoxib,					
			Tablet)	SS				

Date:11/26/02ISR Number: 4017832-4Report Type:Expedited (15-DaCompany Report #STA-AE-02-MTX-215
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomyopathy	Foreign	Methotrexate					
Initial or Prolonged		Health	(Methotrexate,					
Disability		Professional	Tablet)	PS		ORAL		
12.5MG DAILY,								
		Other						
ORAL								
			Vioxx (Rofecoxib,					

				Tablet)	SS		ORAL
25 MG DAILY,							
ORAL							
				Folic Acid (Folic Acid)	C		
				Desloratadine (Desloratadine)	C		

Date:11/27/02ISR Number: 4015825-4Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00161
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Initial or Prolonged			Nifedipine	C		ORAL		
			Diazepam	C		ORAL		

Date:11/27/02ISR Number: 4015838-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA02200
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Iron Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Porphyria Non-Acute		Furosemide	SS		ORAL		
			Glucophage	SS				
			Furosemide	SS				
			Insulin Human, Isophane	C				
			Gemfibrozil	C				

Diltiazem Hydrochloride	C	
Atorvastatin	C	
Isosorbide	C	
Aspirin	C	
Quinine	C	
Nortriptyline	C	
Nitroglycerin	C	
Lansoprazole	C	
Vitamins (Unspecified)	C	
Cozaar	C	ORAL

Date:11/27/02ISR Number: 4016008-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01555
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Systolic Increased		Coumadin	C		ORAL		
	Body Temperature Decreased		Tenormin	C		ORAL		
	Cardiac Failure Congestive		Zyloprim	C		ORAL		
	Haematocrit Decreased		Colchicine	C		ORAL		
	Lobar Pneumonia		Oxycontin	C		ORAL		
	Lung Neoplasm							
	Oxygen Saturation Decreased							
	Pleural Effusion							
	Pleuritic Pain							
	Post Procedural Complication							
	Prothrombin Time Prolonged							
	Red Blood Cells Urine Positive							

Date:11/27/02ISR Number: 4016011-4Report Type:Expedited (15-DaCompany Report #WAES 0211NOR00011
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Aspirin And Magnesium Oxide	SS		ORAL		
	International Normalised Ratio Increased		Warfarin Sodium	SS				
	Melaena							

Date:11/27/02ISR Number: 4016012-6Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00126
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	
Hospitalization - Initial or Prolonged	Gastritis Erosive		Ramipril	C		ORAL		
	Haematemesis		Trifluoperazine Hydrochloride	C		ORAL		

			Venlafaxine Hydrochloride	C	ORAL
			Furosemide	C	ORAL
			Rabeprazole Sodium	C	ORAL

Date:11/27/02ISR Number: 4016013-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00004
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Malignant							

Date:11/27/02ISR Number: 4016018-7Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Agitation		Tramadol Hydrochloride	C				
			Dipyrone	C				

Date:11/27/02ISR Number: 4016022-9Report Type:Expedited (15-DaCompany Report #WAES 0211USA02289
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Insulin	C				
	Headache							
	Pain In Extremity							

Date:11/27/02ISR Number: 4016025-4Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00161
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 9 DAY	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc		ORAL
Initial or Prolonged	Congestive	Professional	Nifedipine	C			ORAL
	Myocardial Infarction		Diazepam	C			ORAL

Date:11/27/02ISR Number: 4016030-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA02362
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal Disorder							

Date:12/02/02ISR Number: 4017470-3Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00109
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional						

Date:12/02/02ISR Number: 4017476-4Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00284
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Rash		Prinivil	C		ORAL	15	DAY

Date:12/02/02ISR Number: 4017477-6Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00280
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Inappropriate	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Antidiuretic Hormone	Professional	Paroxetine	SS		ORAL	761	DAY
	Secretion		Acetaminophen	C		ORAL		
			Morphine	C		INTRAVENOUS		

Date:12/02/02ISR Number: 4017481-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA00411
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hiatus Hernia		[Therapy					
Disability	Iron Deficiency Anaemia		Unspecified]	C		ORAL		
Other	Small Intestinal		Robaxin	C		ORAL		
	Haemorrhage		Imodium	C		ORAL		

Date:12/02/02ISR Number: 4017701-XReport Type:Expedited (15-DaCompany Report #WAES 0211DEU00080
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Hospitalization - YR	Duodenal Ulcer		Phenprocoumon	SS		ORAL
Initial or Prolonged	Haemorrhage Haematochezia Haemoglobin Decreased Prothrombin Time Prolonged Renal Impairment					

Date:12/02/02ISR Number: 4017702-1Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00165
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Polyps		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Aspirin	SS		ORAL
	Haemoglobin Decreased		Bisacodyl	C		ORAL
	Melaena		Lactulose	C		ORAL
			Acetaminophen	C		ORAL

Date:12/02/02ISR Number: 4017710-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA02816
Age:49 YR Gender:Male I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Norco	C		ORAL		
	Renal Failure		Celebrex	C				
	Sepsis		Prevacid	C		ORAL		
	Shock		Zoloft	C				
			Zyprexa	C		ORAL		

Date:12/02/02ISR Number: 4017716-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00259
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
			Atenolol	C		ORAL		
			Furosemide	C		ORAL		
			Lansoprazole	C				
			Doxazosin	C				
			Floxacillin	C			9	DAY
			Nitrofurantoin	C			8	DAY
			Enoxaparin Sodium	C			12	DAY

Date:12/02/02ISR Number: 4017717-3Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00293
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Discomfort		Bendroflumethiazide	C		ORAL		
Initial or Prolonged			Diazepam	C		ORAL		
			Vasotec	C		ORAL		

Date:12/02/02ISR Number: 4017718-5Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00291
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Lacidipine	C		ORAL		
	Oesophagitis		Atenolol	C		ORAL		
			Bendroflumethiazide	C		ORAL		

Date:12/02/02ISR Number: 4017720-3Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00276
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Aspirin	SS		ORAL		
			Furosemide	C		ORAL		
	Oesophagitis Ulcerative		Gabapentin	C		ORAL		

Date:12/02/02ISR Number: 4020419-0Report Type:Expedited (15-DaCompany Report #2002CG01722
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Drug Ineffective
	Goitre

Hyperthyroidism

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign	Mopral	PS		ORAL	20 MG QD PO	
Health Professional	Vioxx	SS		ORAL	25 MG DAILY PO	
Other	Sintrom	SS				
	Rebif	SS				
	Hydrocortisone	SS		ORAL	25 MG DAILY PO	
	Lipanthyl "Bristol-Myers Squibb"	SS	Bristol-Myers Squibb	ORAL	200 MG DAILY PO	
	Didronel "Aventis Pharma"	SS	Aventis Pharma			
	Orocal	SS				
	Lysanxia	SS				
	Contramal	SS		ORAL	200 MG DAILY PO	

Date:12/03/02ISR Number: 4018166-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02339
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 MON	
Life-Threatening Hospitalization - Initial or Prolonged	Infarction Cardiac Failure Congestive	Professional	Aspirin	C		ORAL		

Date:12/03/02ISR Number: 4018497-8Report Type:Expedited (15-DaCompany Report #WAES 0211CHE00025
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	28 DAY	
	Liver Disorder							

Date:12/03/02ISR Number: 4018498-XReport Type:Expedited (15-DaCompany Report #WAES 0210GBR00062
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Perforation	Professional						
	Haemorrhage							

Date:12/03/02ISR Number: 4018501-7Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00102
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Naloxone Hydrochloride And Tilidine Hydrochloride	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/02ISR Number: 4018503-0Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00010
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Trospium Chloride	SS		ORAL		
			Bendroflumethiazide	C		ORAL		
			Aspirin	C		ORAL		
			Nitrofurantoin	C		ORAL		
			Tibolone	C		ORAL		

Date:12/03/02ISR Number: 4018504-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA02587
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			[Therapy Unspecified]	C				

Date:12/03/02ISR Number: 4018505-4Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00090
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
20 DAY								
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	SS		ORAL		
	Gastrointestinal		Nifedipine	C		ORAL		
	Haemorrhage		Isosorbide					
	Oesophageal Ulcer		Mononitrate	C		ORAL		
	Rectal Haemorrhage		Acetaminophen	C		ORAL		

Date:12/03/02ISR Number: 4018513-3Report Type:Expedited (15-DaCompany Report #WAES 0211USA02588
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Subclavian Vein
Thrombosis
Superior Vena Caval
Occlusion

Date:12/03/02ISR Number: 4018514-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA02554
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Valproic Acid	C				
	Pulmonary Oedema		Elavil	C				
			Morphine	C				

Date:12/03/02ISR Number: 4018517-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA02586
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/02ISR Number: 4021813-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Tab Vioxx 10 Mg	PS		ORAL	PO	
Initial or Prolonged	Arthralgia	Professional	Lipitor 10 Mg	SS		ORAL	10MG / DAILY	
Disability	Asthenia						/ PO	
Other	Atherosclerosis		Zemplar Unk	SS				
	Biliary Neoplasm		Celebrex	C				
	Blood Parathyroid Hormone		Flexeril	C				
	Increased		Humulin	C				
	Chest X-Ray Abnormal		Imuran					
	Complications Of		(Azathioprine)	C				
	Transplant Surgery		Lasix (Furosemide)	C				
	Decreased Activity		Norvasc	C				
	Dermatitis Exfoliative		Sandimmun	C				
	Dialysis		Toprol Xl Tablets	C				
	Drug Interaction		Ultralente Insulin	C				
	Ejection Fraction		Viagra	C				
	Decreased		Zaroxolyn	C				
	Erythema Multiforme		Zebeta	C				
	Haemorrhage		Calcium					
	Iatrogenic Injury		(Unspecified) (+)					
	Injury		Vitami	C				
	Kidney Transplant		Clonazepam	C				
	Rejection		Clonidine					
	Monoparesis		Hydrochloride	C				
	Movement Disorder		Cyclosporine	C				
	Myalgia		Epoetin	C				
	Orthopnoea		Iron Dextran	C				
	Pain		Paricalcitol	C				
	Paresis		Prednisone	C				
	Rash		Vitamin B Complex	C				
	Renal Failure							
	Restless Legs Syndrome							
	Skin Disorder							
	Sleep Apnoea Syndrome							
	Subcutaneous Haematoma							
	Surgical Procedure							
	Repeated							

Date:12/04/02ISR Number: 4018786-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA00359
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Brain Hypoxia							
	Dyspnoea							
	Fatigue							
	Syncope							
	Transient Ischaemic Attack							

Date:12/04/02ISR Number: 4018789-2Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00308
Age:82 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization - Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Methocarbamol	C		ORAL		
	Melaena		Lactulose	C		ORAL		
	Reflux Oesophagitis		Senna	C		ORAL		
			Acetaminophen	C		ORAL		

Date:12/04/02ISR Number: 4018790-9Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00081
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		114 DAY
Hospitalization -	Haemorrhage		Furosemide	C		ORAL		
Initial or Prolonged	Infection		Bumetanide	C		ORAL		
			Vasotec	C		ORAL		
			Allopurinol	C		ORAL		
			Aspirin	C		ORAL		
			Acetaminophen	C		ORAL		
			Omeprazole	C		ORAL		
			Zolpidem Tartrate	C		ORAL		

Date:12/04/02ISR Number: 4018922-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA00040
Age:72 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive							

Date:12/04/02ISR Number: 4019359-2Report Type:Direct Company Report #CTU 182073
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased		Rofecoxib 50mg					

Initial or Prolonged	Dialysis		Merck	PS	Merck	ORAL
50MG QD PO						
Required	Diarrhoea		Rofecoxib 50mg Merck	SS	Merck	ORAL
DECREASE 25MG						
Intervention to	Pancreatitis					
QD PO						
Prevent Permanent	Renal Failure Acute					
(CONTINUED						
Impairment/Damage						
UNTIL RAN						
OUT)						
			Celexa	C		
			Magnesium	C		
			Zinc	C		
			Augmentin	C		

Date:12/05/02ISR Number: 4019080-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Inderal La	C		
	Mitral Valve Incompetence		Claritin-D	C		
1758 DAY						
	Oedema		Humibid	C		
	Tricuspid Valve		Prevacid	C		
	Incompetence		Nasonex	C		
764 DAY						
	Ventricular Hypokinesia		Darvocet-N	C		

				Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		

Date:12/05/02ISR Number: 4019087-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA00009
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/05/02ISR Number: 4019088-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA00180
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration Erythema Multiforme Renal Failure Acute Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/02ISR Number: 4019658-4Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Retinal Vein Thrombosis		Vioxx	SS		ORAL	9 DAY	
Disability	Visual Acuity Reduced		Morphine Sulfate	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Verapamil	C		ORAL		
			Furosemide Sodium	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium					

			Bicarbonate And Sodium Chloride	C		ORAL

Date:12/06/02ISR Number: 4019659-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00531
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Rectal Haemorrhage Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/06/02ISR Number: 4019661-4Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00292
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Inappropriate Antidiuretic Hormone Secretion		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/02ISR Number: 4019663-8Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00082
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Congestive Myocardial Infarction		Cicletanine Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

Date:12/06/02ISR Number: 4019664-XReport Type:Expedited (15-DaCompany Report #WAES 0211GBR00299
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Diarrhoea Nausea Pyrexia Rash Generalised Rash Macular	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
			Sulfasalazine	SS		ORAL		

Date:12/06/02ISR Number: 4019667-5Report Type:Expedited (15-DaCompany Report #WAES 0211TWN00005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/02ISR Number: 4019668-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01138
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/02ISR Number: 4019669-9Report Type:Expedited (15-DaCompany Report #WAES 0211PRT00004
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Face Oedema		Etofenamate	SS			INTRAMUSCULAR	6 DAY
	Hypertension		Cetirizine Hydrochloride	C				
	Myopathy		Proteoglycans (Unspecified) And Ribosomal Fractions (Unspecified)	C		ORAL		
	Oedema		Omeprazole	C		ORAL	6	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/02ISR Number: 4019671-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01104
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bacterial Infection	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis							
	Pneumonitis							

Date:12/06/02ISR Number: 4019996-5Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00034
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/02ISR Number: 4020001-5Report Type:Expedited (15-DaCompany Report #WAES 0202DEU00016
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Complications Of Maternal		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Exposure To Therapeutic		Folic Acid	C				
	Drugs		Iodine	C				
	Induced Labour		Magnesium					
	Pregnancy Induced		(Unspecified)	C				
	Hypertension							

Date:12/06/02ISR Number: 4020003-9Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00093
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Normochromic Normocytic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia		Aspirin Lysine	SS		ORAL		
	Rectal Haemorrhage							

Date:12/06/02ISR Number: 4020009-XReport Type:Expedited (15-DaCompany Report #WAES 0212USA00225
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/02ISR Number: 4020230-0Report Type:Direct Company Report #CTU 182272
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage Intracranial		Vioxx 50mg	PS		ORAL	50MG ONCE	
Disability							DAILY ORAL	
			Aspirin	C				

Date:12/09/02ISR Number: 4020318-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Colonic Polyp
	Contusion
	Deep Vein Thrombosis
	Joint Sprain
	Oedema

		Plantar Fasciitis					
		Renal Cyst					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vitamins (Unspecified)	C		
				Synthroid	C		ORAL
				Lamisil	C		
				Chondroitin And Glucosamine	C		ORAL
				Celebrex	C		ORAL

Date:12/09/02ISR Number: 4020326-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA02450
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Distension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Hospitalization -	Acute Myocardial		Vioxx	SS		ORAL
1 DAY						
Initial or Prolonged	Infarction		Vioxx	SS		ORAL
Disability	Cardiac Failure		Insulin	C		
Other	Congestive		Insulin	C		
	Constipation		Tramadol	C		
	Drug Eruption		Flexeril	C		ORAL
	Fall		Humulin N	C		
	Flatulence					
	Hypertension					
	Metabolic Acidosis					
	Oedema					
	Pulmonary Oedema					
	Staphylococcal Sepsis					

Date:12/09/02ISR Number: 4020327-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA01754
Age:14 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Diarrhoea		Methotrexate (Methotrexate			
	Dyspepsia					

	Nausea		Sodium)	C			
INTRAMUSCULAR							
			Folic Acid	C			ORAL
			Clarinex	C			ORAL

Date:12/09/02ISR Number: 4020563-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00082
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	24 DAY	
	Duodenal Ulcer		Fentanyl	C				
TOPICAL							19 DAY	
	Haemorrhage		Glimepiride	C		ORAL		
	Helicobacter Infection		Isosorbide Mononitrate	C		ORAL		
	Myocardial Infarction		Molsidomine	C		ORAL		
	Shock		Vasotec	C		ORAL		
			Furosemide Sodium	C		ORAL		
			Xipamide	C		ORAL		
			Pantoprazole Sodium	C		ORAL	14 DAY	
			Dipyrone	C		ORAL	10 DAY	
			Clopidogrel					

Bisulfate	C	ORAL
Carvedilol	C	ORAL
Calcium (Unspecified)	C	
Cholecalciferol	C	ORAL
Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C	ORAL
Diclofenac	C	ORAL
Tramadol	C	

Date:12/09/02ISR Number: 4020565-1Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00088
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Agitation Blood Pressure Increased Condition Aggravated Headache		Vioxx Tramadol Hydrochloride Dipyrone	PS C C	Merck & Co., Inc	ORAL		

Date:12/09/02ISR Number: 4020566-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01831
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/02ISR Number: 4020568-7Report Type:Expedited (15-DaCompany Report #WAES 0211FIN00001
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive Blood Immunoglobulin A Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Hepatic Haematoma
Hepatotoxicity
Laboratory Test Abnormal
Post Procedural
Haemorrhage
Pyrexia

Date:12/09/02ISR Number: 4020570-5Report Type:Expedited (15-DaCompany Report #WAES 0211AUS00005
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Fall		Amiodarone	C				
	Nausea		Verapamil	C				
			Indapamide	C				
			Ramipril	C				

Date:12/09/02ISR Number: 4020571-7Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00014
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		97 DAY

Date:12/09/02ISR Number: 4020572-9Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00003
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
	Oesophagitis Ulcerative							

Date:12/09/02ISR Number: 4020573-0Report Type:Expedited (15-DaCompany Report #WAES 0212AUS00016
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyponatraemia		Allopurinol	C		ORAL		
	Left Ventricular Failure							
	Myocardial Infarction							

Date:12/09/02ISR Number: 4020574-2Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
	Left Ventricular Failure		Aspirin	C		ORAL		
	Pleural Effusion		Temazepam	C		ORAL		
			Cozaar	C		ORAL		
			Bumetanide	C		ORAL		

Date:12/09/02ISR Number: 4020575-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA00230
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/02ISR Number: 4020576-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA00417
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/02ISR Number: 4020578-XReport Type:Expedited (15-DaCompany Report #WAES 0212USA00430
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C				
			Cozaar	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/02ISR Number: 4020847-3Report Type:Direct Company Report #CTU 182362
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 50mg	PS		ORAL	50MG QD ORAL	
Initial or Prolonged	Increased							

Date:12/09/02ISR Number: 4020954-5Report Type:Direct Company Report #CTU 182407
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Muscle Spasms		Vioxx 25 Mg	PS		ORAL	25 MG PO QD/	
Initial or Prolonged	Oedema Peripheral						3-5 DAYS	
	Pruritus							
	Stridor							

Date:12/09/02ISR Number: 4031185-7Report Type:Periodic Company Report #2002122969US
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Bextra(Valdecoxib)					
	Blood Pressure Increased		Tablet	PS		ORAL	10 MG, QD,	
	Face Oedema						ORAL	
	Sinus Headache		Lipitor(Atorvastatin)	SS			10 MG	
			Grapefruit Juice(Citrus Paradisi Fruit Juice)	SS				
			Vioxx (Rofecoxib)	SS				
			Mobic(Meloxicam)	SS		ORAL	ORAL	
			Aspirin Infantil	C				
			Multivitamins					

			(Panthenol, Retinol, Ergocalciferol)	C		

Date:12/10/02ISR Number: 4020940-5Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00083
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		156 DAY
Life-Threatening			Indapamide	C		ORAL		
			Cholecalciferol	C		ORAL		
			Prednisolone	C		ORAL		
			Furosemide And Spironolactone	C		ORAL		
			Aspirin	C		ORAL		
			Tramadol	C		ORAL		

Date:12/10/02ISR Number: 4020945-4Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00038
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		61 DAY
Initial or Prolonged	Haemoglobin Decreased		Aspirin	SS		ORAL		756 DAY
	Rectal Haemorrhage		Furosemide	C		ORAL		
			Amiloride	C		ORAL		
			Diltiazem					

Hydrochloride	C	ORAL
Morphine	C	ORAL
Anastrozole	C	ORAL
Calcium (Unspecified)	C	ORAL
Acetaminophen	C	ORAL

Date:12/10/02ISR Number: 4021221-6Report Type:Expedited (15-DaCompany Report #WAES 0211TWN00005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/02ISR Number: 4021224-1Report Type:Expedited (15-DaCompany Report #WAES 0211USA00821
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Raynaud'S Phenomenon	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				

Date:12/10/02ISR Number: 4021226-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA00732
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/02ISR Number: 4021230-7Report Type:Expedited (15-DaCompany Report #WAES 0212BEL00009
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ileal Stenosis Ileitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/02ISR Number: 4021231-9Report Type:Expedited (15-DaCompany Report #WAES 0212AUS00053
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged								

Date:12/10/02ISR Number: 4021232-0Report Type:Expedited (15-DaCompany Report #WAES 0212AUS00015
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		32 DAY
Initial or Prolonged	Cardiomyopathy Dyspnoea Ejection Fraction Decreased	Professional						

Date:12/10/02ISR Number: 4021235-6Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00016
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Peritonitis	Professional	Aspirin Lysine	C		ORAL		
			Nitroglycerin	C				
			Furosemide	C		ORAL		
			Amlodipine	C		ORAL		
			Ramipril	C		ORAL		
			Moxonidine	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Potassium Chloride	C		ORAL		
			Disopyramide	C		ORAL		

Date:12/10/02ISR Number: 4025233-8Report Type:Expedited (15-DaCompany Report #A01200203794
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Increased	Health	Iscover - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG OD	
	Drug Interaction	Professional						
	Gastric Haemorrhage							
	Gastritis Erosive							
	Gastrointestinal Angiodysplasia		Acetylsalicylic Acid - Tablet - 75 Mg	SS		ORAL	100 MG OD	
	Shock		Vioxx (Rofecoxib)	SS		ORAL	25 MG OD	
	Vertigo		Allopurinol	C				
			Piretanide	C				
			Tilidine + Naloxone (Tilidine, Naloxone)	C				

Date:12/11/02ISR Number: 4021427-6Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00042
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Professional	Amlodipine	SS	ORAL
6 YR				
		Hydrochlorothiazide And Valsartan	SS	ORAL
6 YR				
		Acetaminophen And Belladonna And Caffeine And Opium	SS	ORAL

Date:12/11/02ISR Number: 4021430-6Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
	Activated Partial Thromboplastin Time Prolonged
	Acute Myocardial Infarction
	Alanine Aminotransferase Increased
	Anaphylactic Reaction
	Anion Gap Increased
	Apnoea
	Atelectasis

		Blood Alkaline Phosphatase Increased					
		Blood Bilirubin Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Calcium Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Chloride Increased	Professional	Celebrex	SS		ORAL
		Blood Creatine		Depo-Provera	C		
INTRAMUSCULAR							
		Phosphokinase Increased		Hydrocortisone			
		Blood Creatinine		Acetate	C		
		Increased		Skelaxin	C		ORAL
		Blood Glucose Abnormal		Tequin	C		ORAL
		Blood Potassium Increased		Alupent	C		
RESPIRATORY							
		Blood Sodium Increased					
(INHALATION)							
		Body Temperature		Serevent	C		
RESPIRATORY							
		Increased					
(INHALATION)							
		Cardiac Arrest		Flovent	C		
RESPIRATORY							
		Chronic Obstructive					
(INHALATION)							
		Pulmonary Disease		Buspar	C		ORAL
		Contusion		Lipitor	C		ORAL
		Electromechanical		Amaryl	C		ORAL
		Dissociation		Percocet	C		ORAL
		Exsanguination		Pramoxine			
		Gastritis		Hydrochloride	C		
TOPICAL							
		Haematocrit Decreased		Premarin	C		ORAL
		Haemoglobin Decreased		Proventil	C		
RESPIRATORY							
		Haemorrhoids					
(INHALATION)							
		Heart Rate Increased		Demerol	C		ORAL
		Hypertension		Alprazolam	C		ORAL
		Injury		Carisoprodol	C		ORAL
		International Normalised		Biaxin	C		ORAL
		Ratio Increased		Nystatin	C		ORAL
		Large Intestinal Ulcer		Remeron	C		ORAL
		Haemorrhage		Toradol	C		ORAL
		Mean Cell Volume		Flonase	C		ORAL
		Decreased		Paxil	C		ORAL
		Muscle Tightness		Pravachol	C		ORAL
		Oedema		Claritin	C		ORAL

Oesophageal Ulcer	Accolate	C	ORAL
Haemorrhage	Pertussin N	C	ORAL
Pain	Zydone	C	ORAL
Platelet Count Abnormal	Acetaminophen And Hydrocodone Bitartrate	C	ORAL
Pleural Fibrosis	Aquaphor	C	
Pleuritic Pain	Promethazine	C	
Protein Total Decreased	Soma	C	ORAL
Prothrombin Time Prolonged	Ziac	C	
Pulmonary Fibrosis			
Pulse Absent			
Red Blood Cell Count Decreased			
Respiratory Distress			
Respiratory Rate Increased			
Rib Fracture			
Sinus Arrhythmia			
Sudden Cardiac Death			
White Blood Cell Count Abnormal			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/02ISR Number: 4021436-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01138
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/02ISR Number: 4021715-3Report Type:Direct Company Report #CTU 182558
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fatigue		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	
			Estrace	C				

Date:12/11/02ISR Number: 4022253-4Report Type:Direct Company Report #CTU 182509E
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oesophagitis Ulcerative		Indomethacin	PS				2 WK
	Weight Decreased		Vioxx	SS			12.5MG QD	
Required Intervention to Prevent Permanent Impairment/Damage			Lasix	C				
			Zaroxolyn	C				
			Spironolactone	C				
			Toprol	C				
			Potassium	C				
			Neutontin	C				
			Magnesium	C				
			Tamoxifen	C				
			Aspirin	C				
			Netium	C				
			Vicodin	C				
			Paxil	C				

Date:12/11/02ISR Number: 4027074-4Report Type:Expedited (15-DaCompany Report #EMADSS2002007352
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebral Infarction Cerebral Venous Thrombosis Coagulation Factor Viii Level Abnormal	Foreign Study Health Professional	Remicade (5 Mg/Ml Lyophilized Powder) (Infliximab, Recombinant)	PS		
INTRAVENOUS 200 MG, 1 IN 1 TIME(S), IV						
			Arava (Leflunomide)	SS		
			Methylprednisolone	SS		
THERAPY DATES AND DOSE NOT PROVIDED						
			Marvelon (Desogestrel/Ethinyl estradiol)	SS		
THERAPY DATES AND DOSE NOT PROVIDED						
			Rofecoxib	SS		
THERAPY DATES AND DOSE NOT PROVIDED						
			Omeprazole	C		
THERAPY DATES AND DOSE NOT PROVIDED						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/02ISR Number: 4021779-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02444
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic	Health	Vioxx	PS		ORAL	30	DAY
	Increased	Professional	Imitrex	C	Merck & Co., Inc			
	Drug Eruption		Elavil	C		ORAL		
	Drug Hypersensitivity		Inderal	C		ORAL		
	Erythema Multiforme		Ambien	C		ORAL		
	Herpes Simplex		Medicon	C				
	Influenza Like Illness							
	Iritis							
	Joint Swelling							
	Optic Neuritis							
	Oral Candidiasis							
	Scotoma							
	Stevens-Johnson Syndrome							
	Uveitis							

Date:12/12/02ISR Number: 4022094-8Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00055
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged			Furosemide	C		ORAL		
			Bisoprolol	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		

Date:12/12/02ISR Number: 4022099-7Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00002
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Propranolol Hydrochloride	C				
			Mesalamine	C				
			Omeprazole	C				

				Acetaminophen And Propoxyphene Hydrochloride	C		

Date:12/12/02ISR Number: 4022103-6Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00293
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Discomfort		Bendroflumethiazide	C		ORAL		
Initial or Prolonged	Chest Pain		Diazepam	C		ORAL		
	Myocardial Infarction		Vasotec	C		ORAL		

Date:12/12/02ISR Number: 4022104-8Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00083
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atropine Sulfate And Diphenoxylate					

Hydrochloride C

Date:12/12/02ISR Number: 4022105-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA00183
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Dizziness							
	Headache							
	Oedema Peripheral							
	Rash Maculo-Papular							
	Rash Pruritic							
	Syncope							

Date:12/12/02ISR Number: 4022112-7Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00007
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Extrasystoles		Metoprolol Succinate	SS		ORAL		
	Hallucination, Visual							
	Hypertension							
	Hypertensive Crisis							
	Hyperventilation							
	Transient Ischaemic Attack							
	Visual Acuity Reduced							

Date:12/12/02ISR Number: 4022124-3Report Type:Expedited (15-DaCompany Report #WAES 0212SWE00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
Initial or Prolonged	Loss Of Consciousness		Vioxx	SS		ORAL	1	DAY

	Overdose		Elavil	SS			ORAL
43 DAY							
			Verapamil Hydrochloride	C			
			Acetaminophen	C			
			Aspirin	C			

Date:12/13/02ISR Number: 4022718-5Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00038
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Culture Urine Positive		Vioxx	PS	Merck & Co., Inc	ORAL		
20 DAY								
Initial or Prolonged	Escherichia Infection		Ibuprofen	SS		ORAL		
2 DAY								
	Nephritis Interstitial		Tramadol Hydrochloride	C		ORAL		
	Nephrotic Syndrome							
20 DAY								
	Renal Failure Acute		Nomegestrol	C		ORAL		
			Potassium Bitartrate And Sodium Bicarbonate	C		ORAL		
			Clocinizine	C		ORAL		
13 DAY								
			Pholcodine	C		ORAL		
13 DAY								
			Bezafibrate	C		ORAL		
			Polyethylene Glycol 4000	C		ORAL		
			Fluoxetine					

				Hydrochloride	C		ORAL
				Althiazide And Spironolactone	C		ORAL
145 DAY							

Date:12/13/02ISR Number: 4022724-0Report Type:Expedited (15-DaCompany Report #WAES 0212SWE00004
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Initial or Prolonged	Increased		Aspirin	C				
	Aspartate		Zopiclone	C				
	Aminotransferase							
	Increased							
	Atrial Fibrillation							
	Blood Alkaline							
	Phosphatase Increased							
	Blood Bilirubin Increased							
	Blood Lactate							
	Dehydrogenase Increased							
	C-Reactive Protein							
	Increased							
	Cardiac Enzymes Increased							
	Cardiac Failure							
	Cardiomegaly							
	Gamma-Glutamyltransferase							
	Increased							
	Myocardial Infarction							

Date:12/13/02ISR Number: 4022957-3Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00037
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Leflunomide	C		ORAL		

Date:12/13/02ISR Number: 4022958-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01008
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Vioxx	SS		ORAL		6 DAY
	General Physical Health Deterioration		Halcion	C				
			Darvocet-N	C				
	Gout		Prednisone	C				
			Lasix (Furosemide)	C				
			Probenecid	C				

Date:12/13/02ISR Number: 4022960-3Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00020
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Clopidogrel Bisulfate	SS		ORAL		
	Vitamin K Deficiency		Bumetanide	C		ORAL		
			Nafronyl Oxalate	C		ORAL		
			Bepridil Hydrochloride	C		ORAL		

				Potassium (Unspecified)	C		ORAL

Date:12/13/02ISR Number: 4022961-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA00937
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/02ISR Number: 4022962-7Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00039
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Nausea Renal Failure Acute Vomiting		Sotalol Hydrochloride	SS		ORAL		
			Aspirin	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		

Date:12/13/02ISR Number: 4022964-0Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00197
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	78	DAY
	Gastric Ulcer Hypotension Melaena		Aspirin	SS		ORAL		
			Acetaminophen	C		ORAL		
			Aluminum Hydroxide And Simethicone	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Nifedipine	C		ORAL		
			Cozaar	C		ORAL		
			Amitriptyline	C		ORAL		
			Lactulose	C		ORAL		
			Senna	C		ORAL		

Date:12/13/02ISR Number: 4022966-4Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00024
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged			Hydrochlorothiazide And Valsartan	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Allopurinol	C		ORAL		
			Acetaminophen	C		ORAL		

Date:12/13/02ISR Number: 4022971-8Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00036
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
			Prednisolone	SS		ORAL		
			Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/02ISR Number: 4022972-XReport Type:Expedited (15-DaCompany Report #WAES 0212GBR00070
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Alkaline Phosphatase Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Jaundice		Calcium Carbonate And Calcium Gluconate And Calcium Lactate	C		
	Malaise		Quinine	C		

Date:12/13/02ISR Number: 4022975-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA00191
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Erectile Dysfunction		Vioxx	SS		ORAL
	Migraine		Sonata	C		ORAL
			Ambien	C		ORAL
			Advil	C		ORAL
			Celebrex	C		
			Bextra	C		

Date:12/13/02ISR Number: 4022980-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA00741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Hypertension					

Date:12/13/02ISR Number: 4022981-0Report Type:Expedited (15-DaCompany Report #WAES 0212USA01016
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
			Premarin	C		

Date:12/13/02ISR Number: 4022983-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA00826
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/02ISR Number: 4022984-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA01021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/02ISR Number: 4022985-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA01211
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Laryngitis		Ibuprofen	C				
	Nausea		Darvocet-N	C				
	Vomiting		Prednisone	C				
	Wheezing							

Date:12/16/02ISR Number: 4023930-1Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00037
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Dyspnoea	Professional	Calcium Carbonate	C				
	Ear Pain		Risedronate Sodium	C				
	Hypersensitivity							
	Laryngeal Disorder							
	Tongue Blistering							
	Tongue Oedema							

Date:12/16/02ISR Number: 4023946-5Report Type:Expedited (15-DaCompany Report #WAES 0211BEL00014
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Congestive	Professional	Bisoprolol	SS		ORAL		
	Renal Impairment		Althiazide And Spironolactone	SS		ORAL		
			Aspirin	C		ORAL		

Date:12/16/02ISR Number: 4023947-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Septal Defect	Health	Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Acquired	Professional	Vioxx	SS		ORAL		33 DAY
Disability	Blood Potassium Decreased		Vioxx	SS		ORAL		36 DAY
	Cerebral Artery		Vioxx	SS		ORAL		312 DAY
	Thrombosis		Tricor	C		ORAL		
	Cerebral Infarction		Vicodin Es Tablets	C		ORAL		
	Cerebrovascular Accident		Paxil	C		ORAL		
	Chondromalacia		Restoril	C		ORAL		
	Haematocrit Abnormal		Aspirin	C		ORAL		
	Haemoglobin Abnormal		Estrogens (Unspecified)	C				
	Mitral Valve Incompetence		Premarin	C				
	Osteoarthritis		Vitamins (Unspecified)	C				
	Platelet Count Abnormal		Zantac	C				
	Red Blood Cell Sedimentation Rate Abnormal		Vistaril	C				
	Tricuspid Valve Incompetence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/02ISR Number: 4023948-9Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00113
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatocellular Damage	Health	Vioxx	PS	Merck & Co., Inc			2 DAY
Initial or Prolonged	Neutrophilia	Professional						
	Renal Impairment							

Date:12/16/02ISR Number: 4023951-9Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00081
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Initial or Prolonged	Anorexia	Professional	Factor Viii	C				
	Haemarthrosis		Amitriptyline	C		ORAL		
	Nausea		Antihemophilic					
	Vomiting		Factor (As Drug)	C			INTRAVENOUS	
			Tramadol	C		ORAL		34 DAY
			Pamidronate Disodium	C			INTRAVENOUS	2 DAY

Date:12/16/02ISR Number: 4023952-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA02463
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colon Cancer Stage Iv	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Metastases To Central	Professional	Accupril	C				
Other	Nervous System		Hytrin	C				
			Hydrochlorothiazide	C				
			Triaminic Syrup	C				

Date:12/16/02ISR Number: 4023953-2Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00032
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Crohn'S Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Initial or Prolonged	Haemoglobin Decreased	Professional	Prednisone	C		ORAL		
			Azathioprine	C		ORAL		
			Hydroxychloroquine Sulfate	C		ORAL		

Date:12/16/02ISR Number: 4023995-7Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00088
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Mental Disorder Due To A General Medical Condition		Tramadol Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		

Date:12/16/02ISR Number: 4023996-9Report Type:Expedited (15-DaCompany Report #WAES 0211USA01277
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Other	Balance Disorder
	Cough
	Deafness Unilateral
	Dizziness

	Dysphonia						
	Inflammation						
	Nasal Polyps	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pharyngeal Polyp		Vioxx	PS	Merck & Co., Inc	ORAL	
	Sensation Of Foreign Body		Synthroid	C			
	Throat Irritation		Trazodone	C			
	Tinnitus		Prevacid	C			
			Rhinocort	C			

Date:12/16/02ISR Number: 4023999-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA01773
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Hospitalization -	Chest Discomfort		Vioxx	SS		ORAL	4 DAY
Initial or Prolonged	Coronary Artery Stenosis		Prevacid	C		ORAL	
Other	Dyspepsia						
	Myocardial Infarction						
	Sinus Bradycardia						
	Weight Decreased						

Date:12/16/02ISR Number: 4024009-5Report Type:Expedited (15-DaCompany Report #WAES 0212DNK00004
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Breast Pain		Vioxx	PS	Merck & Co., Inc	ORAL	22 DAY
Hospitalization -	Myocardial Infarction		Aspirin	C		ORAL	
Initial or Prolonged			Plendil	C			
			Vasotec	C		ORAL	

Date:12/16/02ISR Number: 4024013-7Report Type:Expedited (15-DaCompany Report #WAES 0212USA01026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx Toradol	PS C	Merck & Co., Inc	ORAL

Date:12/16/02ISR Number: 4024014-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA01191
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Stomach Discomfort		Vioxx [Therapy Unspecified] Insulin	PS C C	Merck & Co., Inc	ORAL

Date:12/16/02ISR Number: 4024015-0Report Type:Expedited (15-DaCompany Report #WAES 0212USA01203
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease Haematemesis		Vioxx Neurontin	PS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/02ISR Number: 4026642-3Report Type:Expedited (15-DaCompany Report #2002SE06161
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Beloc Zok	PS			50 MG DAILY	
	Diplopia	Health	Vioxx	SS			25 MG DAILY	
	Grimacing	Professional						
	Hallucination, Visual	Other						
	Headache							
	Hypertensive Crisis							
	Hyperventilation							
	Somnolence							

Date:12/16/02ISR Number: 4027098-7Report Type:Expedited (15-DaCompany Report #USA-2002-009362
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dermatitis Bullous	Foreign	Sotalol (Sotalol Hydrochloride)					
	Nausea	Health						
Other	Renal Failure Acute	Professional	Tablet	PS		ORAL	40 MG,	
	Vomiting	Other						
							2X/DAY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG,	
							1X/DAY, ORAL	
			Aspirin Bayer (Acetylsalicylic Acid)	C				
			Co-Amilofruse (Amiloride Hydrochloride)	C				

Date:12/16/02ISR Number: 4027119-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA02450
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Asthenia
	Blood Pressure Fluctuation
	Body Temperature Decreased
	Cardiac Failure Congestive
	Constipation
	Depression
	Diabetes Mellitus
	Dilatation Atrial
	Drug Eruption
	Drug Ineffective
	Flatulence
	Foreign Body Trauma
	High Density Lipoprotein Decreased
	Hyperhidrosis
	Hypertension
	Hypoproteinaemia
	Hypoxia
	Left Ventricular Failure

	Leukocytosis						
	Metabolic Acidosis						
	Movement Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nephropathy	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO;
	Osteoarthritis	Professional					
	Po2 Decreased	Company					25 MG/DAILY/PO;
	Proteinuria	Representative					
	Pulmonary Oedema						PO
	Respiratory Distress		Flexeril	C			
	Respiratory Rate Increased		Humulin N	C			
			Insulin	C			
	Staphylococcal Sepsis		Tramadol	C			
	Stress						
	Tachycardia						
	Thirst						

Date:12/16/02ISR Number: 4027120-8Report Type:Expedited (15-DaCompany Report #WAES 00072278
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO
Initial or Prolonged	Cardiac Disorder	Health	Amaryl	C			
	Myocardial Infarction	Professional					
	Nausea						
	Pain In Extremity						
	Ulcer						
	Vomiting						

Date:12/16/02ISR Number: 4027127-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chondropathy	Consumer	Tab Vioxx Unk	PS		ORAL	PO

Initial or Prolonged	Colonic Polyp	Health	Celebrex	C
	Contusion	Professional	Lamisil	C
	Deep Vein Thrombosis		Synthroid	C
	Fasciitis		Chondroitin (+)	
	Hepatic Steatosis		Glucosamine	C
	Joint Sprain		Vitamins	
	Pulmonary Granuloma		(Unspecified)	C
	Renal Cyst			
	Tendon Disorder			

Date:12/17/02ISR Number: 4024261-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA02587
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other		Professional	[Therapy					
			Unspecified]	C				

Date:12/17/02ISR Number: 4024262-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA02586
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/02ISR Number: 4024264-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		65 DAY
Initial or Prolonged	Anaemia		Indocin					
Disability	Asthenia		(Indomethacin)	C		ORAL		
Other	Clostridium Colitis		Tylenol Extra					
	Coma		Strength	C				
	Convulsion							
	Enterobacter Pneumonia							
	Fall							
	Intraventricular							
	Haemorrhage							
	Joint Stiffness							
	Malnutrition							
	Pneumonia Aspiration							
	Subarachnoid Haemorrhage							

Date:12/17/02ISR Number: 4024265-3Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00105
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Melaena		Venlafaxine					
	Rectal Haemorrhage		Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Tamsulosin					
			Hydrochloride	C		ORAL		

Date:12/17/02ISR Number: 4024372-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA02774
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Increased		[Therapy					
Initial or Prolonged	Palpitations		Unspecified]	C				

Date:12/17/02ISR Number: 4024373-7Report Type:Expedited (15-DaCompany Report #WAES 0209AUS00172
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
	Cardiac Failure Congestive	Professional	Fosamax	C		ORAL		

Date:12/17/02ISR Number: 4024374-9Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00030
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rectal Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Upper Gastrointestinal Haemorrhage	Professional	Aspirin	C		ORAL		
			Diltiazem Hydrochloride	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Mirtazapine	C				

			Furosemide	C		ORAL
			Ramipril	C		ORAL
			Risedronate Sodium	C		ORAL

Date:12/17/02ISR Number: 4024375-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA01191
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Subclavian Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Premarin	C		
Other	Superior Vena Caval Occlusion		Cartia (Aspirin)	C		
			Ambien	C		
			Percocet	C		
			Bumex	C		
			Afrin	C		
			Diltiazem Hydrochloride	C		

Date:12/17/02ISR Number: 4024377-4Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00020
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Rectal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Clopidogrel Bisulfate	SS		ORAL
			Bumetanide	C		ORAL
			Nafronyl Oxalate	C		ORAL
			Bepridil Hydrochloride	C		ORAL
			Potassium (Unspecified)	C		ORAL

Date:12/17/02ISR Number: 4024380-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01521
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening 52 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Celebrex	C		
Other			Chondroitin And Glucosamine	C		
			Aspirin	C		ORAL
78 DAY						
			Seroquel	C		ORAL
78 DAY						
			Acetaminophen	C		ORAL
78 DAY						
			Docusate Sodium	C		ORAL
78 DAY						
			Darvocet-N	C		ORAL
78 DAY						

Date:12/17/02ISR Number: 4024383-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA02588
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Subclavian Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/17/02ISR Number: 4024384-1Report Type:Expedited (15-DaCompany Report #WAES 0212ITA00004
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Health	Vioxx	PS	Merck & Co., Inc	ORAL	32 DAY	
Hospitalization -	Atrial Fibrillation	Professional	Warfarin Sodium	SS		ORAL	3 DAY	
Initial or Prolonged	Bronchitis Acute		Enoxaparin	SS		ORAL	3 DAY	
	Duodenal Ulcer		Prednisone	C		ORAL	6 DAY	
	Haemorrhage		Amoxicillin	C				
	Hypoxia		[Composition					
	Respiratory Failure		Unspecified]	C				
RESPIRATORY								
(INHALATION)								

Date:12/17/02ISR Number: 4024385-3Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00034
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pruritus	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY	
Initial or Prolonged		Professional	Diclofenac Sodium	SS		ORAL	8 DAY	
			Calcitonin	SS				
SUBCUTANEOUS							3 DAY	
			Tramadol	C		ORAL		
			Domperidone	C		ORAL	3 DAY	
			Lorazepam	C		ORAL		

Date:12/17/02ISR Number: 4024389-0Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00038
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematemesis		Atorvastatin Calcium	C		ORAL		

	Rectal Haemorrhage		Acetaminophen	C		ORAL

Date:12/17/02ISR Number: 4024391-9Report Type:Expedited (15-DaCompany Report #WAES 0212NOR00001
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 20 DAY	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis		Aspirin And			
	Melaena		Magnesium Oxide	C		ORAL
			Fosamax	C		ORAL

Date:12/17/02ISR Number: 4024396-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA01189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Heart Rate Increased		[Therapy			
Initial or Prolonged	Palpitations		Unspecified]	C		

Date:12/17/02ISR Number: 4024398-1Report Type:Expedited (15-DaCompany Report #WAES 0212USA01190
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Heart Rate Increased		[Therapy			
Initial or Prolonged	Palpitations		Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/02ISR Number: 4024399-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA01188
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Increased		[Therapy					
Initial or Prolonged	Palpitations		Unspecified]	C				

Date:12/17/02ISR Number: 4026074-8Report Type:Direct Company Report #CTU 182853
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx 25mg /D	PS				
Initial or Prolonged	Renal Failure							

Date:12/17/02ISR Number: 4026075-XReport Type:Direct Company Report #CTU 182854
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25mg /D	PS			25MG /D	4 DAY
Initial or Prolonged	Increased							
	Blood Potassium Increased							
	Cardiac Failure							
	Congestive							

Date:12/17/02ISR Number: 4026076-1Report Type:Direct Company Report #CTU 182855
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx 25mg	PS			25MG /D	5 DAY
Initial or Prolonged	Increased							
	Fatigue							

Date:12/17/02ISR Number: 4028190-3Report Type:Expedited (15-DaCompany Report #HQ3002609JUL2001
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Lodine (Etodolac, Unspec)	PS		ORAL	400MG DAILY, ORAL	
	Ascites							
	Asthenia							
	Diverticulum Intestinal		Vioxx (Rofecoxib, Tablet)	SS				
	Dyspnoea							
	Faecal Incontinence		Norvasc (Amlodipine Besilate)	C				
	Gastritis							
	Gastritis Erosive		Lasix (Furosemide)	C				
	Gastrointestinal Haemorrhage		Ecotrin (Acetylsalicylic Acid)	C				
	Ileus Paralytic							
	Intestinal Ischaemia		Prilosec (Omeprazole)	C				
	Intestinal Ulcer							
	Melaena		Potassium (Potassium)	C				
	Myocardial Infarction		Zocor (Simvastatin)	C				
	Scan Abdomen Abnormal		Darvocet-N (Dextropropoxyphene/ Paracetamol)	C				
			Digoxin (Digoxin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/18/02ISR Number: 4025176-XReport Type:Expedited (15-DaCompany Report #WAES 0212DEU00047
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia	Professional	Aspirin	SS		ORAL		
Initial or Prolonged	Blood Pressure Decreased		Lercanidipine	SS		ORAL		
	Circulatory Collapse		Piretanide	C		ORAL		
	Dizziness		Ramipril	C		ORAL		
	Drug Interaction		Ferrous Glycine Sulfate	C		ORAL		
	Gastritis		Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		
	Gastrointestinal Haemorrhage		Thioctic Acid	C		ORAL		
	Melaena		Glyburide	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Carbomer	C		OPHTHALMIC		
			Clopidogrel Bisulfate	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		

Date:12/18/02ISR Number: 4025178-3Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00083
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Grand Mal Convulsion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Atropine Sulfate And Diphenoxylate Hydrochloride	C				

Date:12/18/02ISR Number: 4025182-5Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00103
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Perforation Upper Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS		ORAL		
			Bisoprolol	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Atorvastatin	C		ORAL		
			Amitriptyline	C		ORAL		

Date:12/18/02ISR Number: 4025184-9Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00099
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Angiodysplasia Haemorrhagic Haemoglobin Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Valsartan	C		ORAL		
			Zocor	C		ORAL		
			Metformin	C		ORAL		
			Desloratadine	C		ORAL		
			Bumetanide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/02ISR Number: 4025639-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	19 DAY	
Hospitalization - Initial or Prolonged	Blood Glucose Abnormal		Desogen	SS				
	Blood Urea Abnormal		Aleve	C				
	Cardio-Respiratory Arrest		Ultram	C				
	Deep Vein Thrombosis		[Therapy Unspecified]	C				
	Dilatation Ventricular		Vicodin Tablets	C				
	Dysfunctional Uterine Bleeding		Toradol	C			INTRAMUSCULAR	
	Haemodynamic Instability		Skelaxin	C				
	Hypertension							
	Hypotension							
	Muscle Spasms							
	Myocardial Infarction							
	Nausea							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Sinus Tachycardia							
	Supraventricular Tachycardia							
	Tricuspid Valve Incompetence							
	White Blood Cell Count Abnormal							

Date:12/19/02ISR Number: 4025932-8Report Type:Expedited (15-DaCompany Report #WAES 0211ITA00010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Jaundice Acholuric		Vioxx	PS	Merck & Co., Inc	ORAL	INTRAMUSCULAR	
			Neridronate Sodium	SS				

Date:12/19/02ISR Number: 4025935-3Report Type:Expedited (15-DaCompany Report #WAES 0211USA01546
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY
Hospitalization - Initial or Prolonged	Congestive Pulmonary Oedema		Tylenol	C		ORAL		
Other								

Date:12/19/02ISR Number: 4025936-5Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00065
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pharyngeal Oedema Tongue Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/19/02ISR Number: 4025937-7Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00063
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/02ISR Number: 4025942-0Report Type:Expedited (15-DaCompany Report #WAES 0212PRT00001
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Oedema		Pirenoxine Sodium	C		OPHTHALMIC		
	Pulmonary Oedema		Delphinidin 3-Glucoside	C		ORAL		
			Piracetam	C		ORAL		
			Betahistine Hydrochloride	C		ORAL		
			Vitamins (Unspecified)	C		ORAL		

Date:12/19/02ISR Number: 4025945-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA01122
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		33 DAY
			Bextra	C				
			Trivora	C		ORAL		

Date:12/19/02ISR Number: 4025946-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA01508
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:12/19/02ISR Number: 4029703-8Report Type:Expedited (15-DaCompany Report #2002UW16674
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine	Study	Vioxx	PS		ORAL	25 MG QD PO	
Intervention to Prevent Permanent Impairment/Damage	Increased Blood Urea Increased Renal Impairment	Health Professional	Prevacid	C				
			Synthroid	C				
			Diclofenac	C				
			Actos "Lilly"	C				
			Glucovance	C				

Date:12/19/02ISR Number: 4037247-2Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-11675733
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nerve Compression	Consumer	Pravachol	PS	Bristol-Myers Squibb Company	ORAL	drug was taken 1 year ago, for 6 to 8 months	8 MON
			Vioxx	SS			2 YR	
			Soma	C			To be used every 8 hours as needed.	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/02ISR Number: 4026318-2Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Immunoglobulin A	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization - Initial or Prolonged	Increased Blood Immunoglobulin G	Professional	Valsartan	SS		ORAL		
			Insulin Human	C		SUBCUTANEOUS		
	Increased Blood Lactate Dehydrogenase Increased		Ibuprofen Lysine	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
	Coombs Direct Test Positive							
	Diabetes Mellitus Inadequate Control							
	Haemolytic Anaemia							
	Jaundice							
	Lymphadenopathy							

Date:12/20/02ISR Number: 4026320-0Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial Thromboplastin Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS		ORAL		
	Acute Myocardial Infarction		Acetaminophen And Hydrocodone Bitartrate	C		ORAL		
	Alanine Aminotransferase Increased		Zydone	C		ORAL		
			Pertussin N	C		ORAL		
	Anaphylactic Reaction		Accolate	C		ORAL		
	Arrhythmia		Claritin	C		ORAL		
	Asthma		Pravachol	C		ORAL		
	Atelectasis		Paxil	C		ORAL		
	Blood Glucose Abnormal		Paxil	C		ORAL		
	Blood Pressure Increased		Paxil	C		ORAL		
	Cardiac Arrest		Flonase	C		ORAL		
	Chronic Obstructive Pulmonary Disease		Toradol	C		ORAL		
			Remeron	C		ORAL		
	Contusion		Nystatin	C		ORAL		
	Exsanguination		Biaxin	C		ORAL		

	Gastritis	Depo-Provera	C	
INTRAMUSCULAR				
	Gastrointestinal	Hydrocortisone		
	Haemorrhage	Acetate	C	
	Haematochezia	Skelaxin	C	ORAL
	Heart Rate Increased	Tequin	C	ORAL
	International Normalised	Alupent	C	
RESPIRATORY				
	Ratio Increased			
(INHALATION)				
	Laboratory Test Abnormal	Serevent	C	
RESPIRATORY				
	Large Intestinal Ulcer			
(INHALATION)				
	Haemorrhage	Flovent	C	
RESPIRATORY				
	Oedema			
(INHALATION)				
	Oesophageal Ulcer	Buspar	C	ORAL
	Haemorrhage	Lipitor	C	ORAL
	Platelet Count Decreased	Amaryl	C	ORAL
	Pleural Infection	Percocet	C	ORAL
	Pleuritic Pain	Pramoxine		
	Prothrombin Time	Hydrochloride	C	
TOPICAL				
	Prolonged	Premarin	C	ORAL
	Pulmonary Fibrosis	Proventil	C	
RESPIRATORY				
	Rib Fracture			
(INHALATION)				
	Sudden Cardiac Death	Demerol	C	ORAL

		Alprazolam	C	ORAL
		Carisoprodol	C	ORAL
		Aquaphor	C	
		Promethazine	C	
		Soma	C	ORAL
		Ziac	C	

Date:12/20/02ISR Number: 4026321-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA00420
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization -	Dialysis		Vioxx	SS		ORAL		4 DAY
Initial or Prolonged	Feeling Abnormal		Augmentin	C				
	Feeling Cold		Celexa	C				
	Pancreatitis							
	Renal Failure Acute							
	Skin Disorder							
	Urticaria							

Date:12/20/02ISR Number: 4026570-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA01646
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Liver Function Test		Percocet	C				
	Abnormal		Levaquin	C				
			Diflucan	C				

Date:12/20/02ISR Number: 4026575-2Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00200
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		36 DAY
Initial or Prolonged	Haemoglobin Decreased		Citalopram	C		ORAL		

			Metformin	C		ORAL
			Gliclazide	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL
			Fosamax	C		ORAL
18 DAY						
			Gliclazide	C		ORAL
			Ibuprofen	C		

Date:12/20/02ISR Number: 4026576-4Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00017
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
			Mesalamine	C		ORAL
			Prednisolone	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/02ISR Number: 4026578-8Report Type:Expedited (15-DaCompany Report #WAES 0210BEL00025
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypotension							
	Melaena							
	Shock Haemorrhagic							
	Sudden Death							

Date:12/20/02ISR Number: 4026580-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA02968
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		[Therapy					
Initial or Prolonged	Cor Pulmonale		Unspecified]	C				
Other	Fluid Retention							
	Hypoproteinaemia							
	Pulmonary Hypertension							
	Rash Maculo-Papular							

Date:12/20/02ISR Number: 4026582-XReport Type:Expedited (15-DaCompany Report #WAES 0212USA01476
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
Initial or Prolonged	Ileus Paralytic		Aspirin	C				
Other			Mobic	C				

Date:12/20/02ISR Number: 4030846-3Report Type:Expedited (15-DaCompany Report #PHFR2002GB04109
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Foreign	Voltaren (Diclofenac					

Other	Duodenal Ulcer	Health	Sodium)	PS	ORAL
ORAL					
	Haemorrhage	Professional	Vioxx (Rofecoxib)	SS	ORAL
12.5 MG, QD,					
	Gastrointestinal	Other			
ORAL					
	Perforation		Warfarin (Warfarin)	C	
	International Normalised		Frusemide	C	
	Ratio Increased		Atenolol	C	
	Myocardial Infarction		Digoxin	C	

Date:12/20/02ISR Number: 4031773-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
Disability	Arterial Thrombosis
	Arthralgia
	Atrial Septal Defect
	Acquired
	Blood Potassium Normal
	Cardiac Aneurysm
	Cartilage Injury
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Chondromalacia

		Condition Aggravated					
		Diverticulum Intestinal					
		Gait Disturbance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Abnormal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE							
		Haemoglobin Abnormal	Health	Paxil	C		
		Joint Effusion	Professional	Premarin	C		
		Joint Swelling		Restoril	C		
		Mitral Valve Incompetence		Tricor	C		
		Muscle Atrophy		Vicodin Es Tablets	C		
		Nasopharyngeal Disorder		Vistaril	C		
		Pain In Extremity		Zantac	C		
		Peripheral Coldness		Aspirin	C		
		Phlebothrombosis		Estrogens	C		
		Platelet Count Abnormal		Vitamins	C		
		Post Procedural					
		Complication					
		Post Procedural Pain					
		Thrombosis					
		Thrombotic Stroke					
		Tricuspid Valve					
		Incompetence					

Date:12/23/02ISR Number: 4027603-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA02200
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Porphyria Non-Acute	Health	Vioxx	PS	Merck & Co., Inc	ORAL
			Professional	Furosemide	SS		ORAL
				Glucophage	SS		
				Furosemide	SS		
				Insulin Human,			
				Isophane	C		
				Gemfibrozil	C		
				Diltiazem			
				Hydrochloride	C		
				Atorvastatin	C		
				Isosorbide			
				Mononitrate	C		
				Aspirin	C		
				Quinine	C		
				Nortriptyline	C		
				Nitroglycerin	C		

Lansoprazole	C		
Vitamins (Unspecified)	C		
Cozaar	C		ORAL

Date:12/23/02ISR Number: 4027604-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA00509
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/02ISR Number: 4027607-8Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00021
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombocytopenic Purpura	Health	Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Initial or Prolonged		Professional	Vioxx	SS		ORAL		

Date:12/23/02ISR Number: 4027612-1Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00086
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Erosive	Health	Vioxx	PS	Merck & Co., Inc	ORAL	86	DAY
Hospitalization -	Haematemesis	Professional						
Initial or Prolonged								

Date:12/23/02ISR Number: 4027613-3Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00161
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	92	DAY
Hospitalization -	Melaena	Professional	Vioxx	SS		ORAL	5	DAY
Initial or Prolonged			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL	87	DAY
			Vasotec	C		ORAL	1704	DAY
			Ascorbic Acid	C		ORAL		
			Ferrous Sulfate	C		ORAL		

Date:12/23/02ISR Number: 4027615-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Altace	C		ORAL		
	Cardiovascular Disorder		Plavix	C		ORAL		
	Chest Pain		Aspirin	C		ORAL		
	Coronary Artery Disease		Nitroglycerin	C		TOPICAL		
	Depression		Prevacid	C		ORAL		
	Dizziness		Zocor	C		ORAL		
	Dyspnoea							
	Facial Palsy							
	Gastritis							
	Headache							
	Hiatus Hernia							
	Hyperlipidaemia							
	Hypoaesthesia							
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Sinus Bradycardia							
	Syncope							
	Thrombosis							
	Thymus Hypertrophy							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/02ISR Number: 4027622-4Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00162
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Sodium Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
Initial or Prolonged	Diarrhoea	Professional	Bendroflumethiazide	SS		ORAL		839 DAY
	Mouth Ulceration		Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY								
(INHALATION)								
			Ramipril	C		ORAL		
			Albuterol Sulfate And Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)								

Date:12/23/02ISR Number: 4028047-8Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00008
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Hepatitis							
	Oesophagitis							

Date:12/23/02ISR Number: 4028053-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00200
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 36 DAY	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 18 DAY	Decubitus Ulcer		Fosamax	C		ORAL
	Gastric Haemorrhage		Calcium Carbonate And Cholecalciferol	C		ORAL
	Haemoglobin Decreased		Citalopram	C		ORAL
	Oedema		Metformin	C		ORAL
			Gliclazide	C		ORAL
			Gliclazide	C		ORAL
			Ibuprofen	C		

Date:12/23/02ISR Number: 4028058-2Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00154
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability 127 DAY	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL
	Rash Maculo-Papular		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL

Date:12/23/02ISR Number: 4028061-2Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00155
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 32 DAY	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Pantoprazole	C		ORAL
			Morphine	C		ORAL

				Ferrous Sulfate	C		ORAL
				Dihydrocodeine	C		ORAL
				Citalopram	C		ORAL

Date:12/23/02ISR Number: 4028062-4Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Haemorrhage Shock							

Date:12/23/02ISR Number: 4028067-3Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00157
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Perforation		Dexamethasone	SS		ORAL	4	DAY
			Lansoprazole	C		ORAL		
			Digoxin	C		ORAL		
			Warfarin	C		ORAL		
			Paroxetine	C		ORAL		
			Propranolol	C		ORAL		
			Oxycodone	C		ORAL		
			Heparinoid And Salicylic Acid	C		TOPICAL	8	DAY
			Gabapentin	C		ORAL	6	DAY

Date:12/23/02ISR Number: 4028068-5Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00158
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 28 DAY	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 2981 DAY	Haemorrhage		Aspirin	SS		ORAL
	Haematemesis		Isosorbide Mononitrate	C		ORAL
			Etidronate Disodium	C		ORAL
			Albuterol Sulfate And Ipratropium Bromide	C		
RESPIRATORY (INHALATION)						
			Levothyroxine Sodium	C		ORAL
			Beclomethasone Dipropionate	C		
RESPIRATORY (INHALATION)						

Date:12/23/02ISR Number: 4028069-7Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00069
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis		Aspirin Lysine	SS		ORAL
			Furosemide	C		ORAL
			Nitroglycerin	C		
			Ramipril	C		ORAL
			Simvastatin	C		ORAL
			Insulin Lispro	C		

				Isosorbide Dinitrate	C		ORAL
				Lacidipine	C		ORAL
				Zolpidem Tartrate	C		ORAL
				Bisoprolol Fumarate	C		ORAL
				Fluticasone Propionate And Salmeterol Xinafoate	C		
RESPIRATORY (INHALATION)							

Date:12/23/02ISR Number: 4028073-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA01776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Disseminated Intravascular Coagulation Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/02ISR Number: 4028509-3Report Type:Direct Company Report #CTU 183224
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased Cardiac Disorder Drug Ineffective Heart Rate Irregular Nasopharyngitis		Vioxx Celebrex	PS SS				

Date:12/23/02ISR Number: 4032428-6Report Type:Expedited (15-DaCompany Report #WAES 0211USA01277
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder	Health	Tab Vioxx Unk	PS		ORAL		

PO

Condition Aggravated	Professional	Prevacid	C
Cough	Other	Rhinocort	C
Dizziness		Synthroid	C
Dysphonia		Trazodone	C
Ear Discomfort			
Fall			
Head Injury			
Hypoacusis			
Nasal Polyps			
Pharyngeal Polyp			
Sensation Of Foreign Body			
Throat Irritation			
Tinnitus			

Date:12/23/02ISR Number: 4032430-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA01773
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Arthralgia
Other	Chest Discomfort

		Coronary Artery Disease Dyspepsia Joint Range Of Motion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased	Health	Tab Vioxx 50 Mg	PS		ORAL
SEE IMAGE PO							
		Microangiopathy Sinus Bradycardia Weight Decreased	Professional Company Representative	Prevacid	C		

Date:12/24/02ISR Number: 4033476-2Report Type:Expedited (15-DaCompany Report #2002-UK-00596UK(0(
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Duodenal Ulcer	Health	Mobic (14598/-)			
Hospitalization -	Haemorrhage	Professional	(Meloxicam) (Nr)			
Initial or Prolonged		Other	(Meloxicam)	PS		ORAL
7.5 MG (ONCE						
DAILY) PO	21 DAY					
			Rofecoxib (Nr)	SS		ORAL
PO, 6.37						
MONTHS	6 MON					
			Magnesium Hydroxide (Nr)	C		

Date:12/24/02ISR Number: 4034232-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Blood Glucose Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL
50 MG/ DAILY/						
Hospitalization -	Blood Urea Abnormal	Health				
PO						
Initial or Prolonged	Cardio-Respiratory Arrest	Professional	Desogen	SS		
	Cardiomegaly	Company	Aleve	C		
	Deep Vein Thrombosis	Representative	Skelaxin	C		
	Dilatation Atrial		Toradol	C		
	Dilatation Ventricular		Ultram	C		
	Dizziness		Vicodin Tablets	C		

Hypertension	Therapy Unspecified	C
Hypotension		
Muscle Rigidity		
Myocardial Infarction		
Myositis		
Pain		
Peripheral Coldness		
Pulmonary Embolism		
Pulmonary Hypertension		
Pupil Fixed		
Respiratory Failure		
Sinus Tachycardia		
Supraventricular		
Tachycardia		
Syncope		
Thirst		
Tricuspid Valve		
Incompetence		
White Blood Cell Count		
Abnormal		

Date:12/26/02ISR Number: 4029635-5Report Type:Expedited (15-DaCompany Report #WAES 0203GBR00066
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Respiratory Disorder		[Therapy					
Initial or Prolonged	Respiratory Distress		Unspecified]	C				

Date:12/26/02ISR Number: 4029988-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA02724
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
22 MON								
Initial or Prolonged	Gastrointestinal Disorder		Vioxx	SS		ORAL		
	Haemorrhage		Zocor	C		ORAL		
	Leukocytosis		Prilosec	C				
	Pyrexia		Chondroitin Sodium					
			Sulfate And					
			Glucosamine					
			Hydrochloride	C				
			Ferrous Sulfate	C		ORAL		
			Toprol Xl Tablets	C				
			Imdur	C				
			Nitroglycerin	C				
SUBLINGUAL								
			Posture-D	C				
			Duragesic	C				
TOPICAL								
			Percocet	C				
			Lanoxin	C				
			Ecotrin	C				
			Motrin	C				
			Naprosyn	C				
			Cyanocobalamin	C				
			[Therapy					
			Unspecified]	C				

Date:12/26/02ISR Number: 4029990-6Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Coumadin	C				
	Diverticulum Intestinal		Allopurinol	C				
	Haemorrhagic		Skelaxin	C				
	Hypovolaemic Shock		Lanoxin	C				
	Iron Deficiency Anaemia		Lasix (Furosemide)	C				
			Celebrex	C				
			Colchicine	C				
			K-Lor	C				

Date:12/26/02ISR Number: 4029992-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Biliary Neoplasm
Disability	Cardiac Failure
Other	Congestive
	Cardiomyopathy
	Complications Of

		Transplant Surgery					
		Drug Hypersensitivity					
		Drug Interaction					
		Erythema Multiforme	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscular Weakness		Lipitor	SS		ORAL
366	DAY						
		Myalgia		Zemplar	SS		
		Pericardial Effusion		[Therapy			
		Renal Failure		Unspecified]	SS		
		Skin Fissures		Imuran			
		Swelling		(Azathioprine)	C		ORAL
		Ventricular Hypertrophy		Prednisone	C		ORAL
				Lasix (Furosemide)	C		ORAL
				Sandimmun	C		ORAL
				Clonidine			
				Hydrochloride	C		ORAL
				Calcium			
				(Unspecified) And			
				Vitamin D			
				(Unspecified)	C		
				Iron Dextran	C		
				Epoetin	C		
				Cyclosporine	C		
				Paricalcitol	C		
INTRAVENOUS							
				Zaroxolyn	C		ORAL
				Ultralente Insulin	C		
PARENTERAL							
				Toprol Xl Tablets	C		ORAL
				Viagra	C		ORAL
				Humulin	C		
PARENTERAL							
				Clonazepam	C		
				Norvasc	C		ORAL
				Zebeta	C		ORAL
				Flexeril	C		ORAL
				Vitamin B Complex	C		ORAL
				Celebrex	C		

Date:12/26/02ISR Number: 4029993-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00017
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Haemorrhage		Vioxx Aspirin Lysine	PS SS	Merck & Co., Inc	ORAL ORAL

Date:12/26/02ISR Number: 4029995-5Report Type:Expedited (15-DaCompany Report #WAES 0212ZAF00018
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/26/02ISR Number: 4029996-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA02357
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Pulmonary Oedema
Hospitalization - Initial or Prolonged	Angina Pectoris Cardiac Failure Congestive

Coronary Artery Occlusion

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
			Vasotec	C		ORAL		
			Premarin	C		ORAL		
			Corgard	C		ORAL		

Date:12/26/02ISR Number: 4030709-3Report Type:Direct Company Report #CTU 183355
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Roficoxib 12.5mg					
	Hypotension		Merck	PS	Merck	ORAL	12.5MG DAILY	
	Upper Gastrointestinal						ORAL	
	Haemorrhage							

Date:12/27/02ISR Number: 4031083-9Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00150
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	579	DAY
Initial or Prolonged	Gastritis	Professional	Vioxx	SS		ORAL		
	Psychotic Disorder		Aspirin	SS		ORAL	862	DAY
			Insulin	C				
			Lofepramine Hydrochloride	C				
			Nitrazepam	C				
			Acetaminophen And Dihydrocodeine Bitartrate	C				
			Olanzapine	C				

Date:12/27/02ISR Number: 4031086-4Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00171
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Malaise		Diclofenac Sodium And Misoprostol	C		ORAL	510	DAY
	Palpitations							

Date:12/27/02ISR Number: 4031087-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA01770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Hypotension	Professional	Vioxx	SS		ORAL		

Date:12/27/02ISR Number: 4031094-3Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00024
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Cholesterol Increased
	Blood Glucose Increased
	Cerebral Ischaemia

	Low Density Lipoprotein Increased					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
72	DAY					
		Professional	Celecoxib	SS		ORAL
10	DAY					
			Atorvastatin	C		ORAL
573	DAY					

Date:12/27/02ISR Number: 4031095-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Altace	C		ORAL
	Arterial Occlusive Disease		Plavix	C		ORAL
			Aspirin	C		ORAL
	Asthenia		Nitroglycerin	C		
TOPICAL						
	Cardiovascular Disorder		Prevacid	C		ORAL
	Coronary Artery Atherosclerosis		Zocor	C		ORAL
	Coronary Artery Disease					
	Coronary Artery Restenosis					
	Depression					
	Facial Palsy					
	Gastritis					
	Headache					
	Hiatus Hernia					
	Hyperlipidaemia					
	Hypoaesthesia					
	Myocardial Infarction					
	Obstructive Airways Disorder					
	Syncope					

Date:12/27/02ISR Number: 4031097-9Report Type:Expedited (15-DaCompany Report #WAES 0212BEL00009
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ileal Stenosis Ileitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:12/27/02ISR Number: 4031101-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00017
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer Haemorrhage		Aspirin Lysine	SS		ORAL		

Date:12/27/02ISR Number: 4031103-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00280
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Inappropriate Antidiuretic Hormone Secretion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Paroxetine	SS		ORAL	761 DAY	
			Acetaminophen	C		ORAL		

Morphine C
INTRAVENOUS

Date:12/27/02ISR Number: 4031105-5Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00182
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Circulatory Collapse	Professional	Aspirin	C			4720	DAY
	Dyspepsia Gallbladder Empyema Gastrointestinal Haemorrhage Ventricular Hypertrophy		Diclofenac Sodium And Misoprostol	C				

Date:12/27/02ISR Number: 4031802-1Report Type:Direct Company Report #CTU 183449
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx 25mg	PS		ORAL	25MG QD ORAL	

Date:12/27/02ISR Number: 4034939-6Report Type:Expedited (15-DaCompany Report #B0284069A
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Interstitial Lung Disease	Foreign Study Health Professional	Flovent Multi Dose Powder Inhaler (Fluticasone Propionate)	PS		RESPIRATORY	(INHALATION) 500 MCG / TWICE PER DAY	

/ INHALED

	Rofecoxib (Rofecoxib)	SS	ORAL
12.5 MG / PER DAY / ORAL			
	Relafen (Nabumetone)	SS	ORAL
1 GRAM(S) / PER DAY / ORAL			

Date:12/27/02ISR Number: 4035025-1Report Type:Expedited (15-DaCompany Report #2002SE06288
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Body Temperature	Foreign	Nexium	PS		ORAL	40 MG DAILY	
Initial or Prolonged	Increased	Health					PO	
	Chills	Professional	Nexium	SS			20 MG DAILY	
	Hepatitis	Other	Vioxx	SS		ORAL	25 MG DAILY	
	Hepatocellular Damage						PO	
	Nerve Root Compression		Progynova	C				
	Oedema		Panadol	C				
			Telfast	C				
			Flixotide "Allen & Hanburys"	C				
			Ventoline	C				
			Zomig	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/02ISR Number: 4035558-8Report Type:Expedited (15-DaCompany Report #WAES01101475
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Anaphylactic Reaction	Health						
	Arrhythmia	Professional	Celebrex 200 Mg	SS		ORAL	200 MG/DAILY/PO	
	Asthma							
	Atelectasis		Accolate	C				
	Chest Wall Pain		Alupent	C				
	Chronic Obstructive		Amaryl	C				
	Pulmonary Disease		Aquaphor	C				
	Colonic Haemorrhage		Biaxin	C				
	Contusion		Buspar	C				
	Exsanguination		Claritin	C				
	Gastrointestinal		Demerol	C				
	Haemorrhage		Depo-Provera	C				
	Haemorrhoids		Flonase	C				
	Heart Rate Increased		Flovent	C				
	Hypertension		Lipitor	C				
	Injury		Paxil	C				
	Large Intestinal Ulcer		Percocet	C				
	Muscle Tightness		Pertussin N	C				
	Myocardial Infarction		Pravachol	C				
	Oedema		Premarin	C				
	Oesophageal Ulcer		Proventil	C				
	Haemorrhage		Remeron	C				
	Pleural Infection		Serevent	C				
	Pulmonary Fibrosis		Skelaxin	C				
	Respiratory Rate		Soma	C				
	Increased		Tequin	C				
	Rib Fracture		Toradol	C				
	Sinus Arrhythmia		Ziac	C				
	Sudden Cardiac Death		Zydone	C				
	White Blood Cell Count		Acetaminophen (+)					
	Increased		Hydrocodone Bi	C				
			Alprazolam	C				
			Carisoprodol	C				
			Hydrocortisone					
			Acetate	C				
			Nystatin	C				
			Pramoxine					

			Hydrochloride	C		
			Promethazine	C		

Date:12/30/02ISR Number: 4032170-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA00711
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hemianopia Homonymous		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged			Lipitor	C		ORAL		

Date:12/30/02ISR Number: 4032237-8Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12144382
Age:77 YR Gender:Male I/FU:I

Outcome	PT
Death	Arthralgia
Life-Threatening	Drug Interaction
Hospitalization -	Fall
Initial or Prolonged	Hypoglycaemia

		Hypovolaemia Lactic Acidosis Metabolic Acidosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute Sepsis Shock	Health Professional	Glucophage Tabs 850 Mg	PS	Bristol-Myers Squibb Company	ORAL
				Physiotens	C		ORAL
				Acetylsalicylic Acid	C		ORAL
				Tavor	C		ORAL
				Isosorbide Mononitrate	C		ORAL
				Adalat Retard	C		ORAL
				Daonil	I		ORAL
				Vioxx	I		ORAL
4	DAY						
				Triatec	I		ORAL

Date:12/30/02ISR Number: 4032396-7Report Type:Direct Company Report #CTU 183484
Age:80 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Renal Failure		Rofecoxib (Merck)	PS	Merck	
25MG DAILY	3 MON						
Initial or Prolonged				Aspirin	C		
Other				Atenolol	C		
				Glucosamine	C		
				Multivits	C		
				Vit E	C		
				Vit C	C		

Date:12/30/02ISR Number: 4032481-XReport Type:Expedited (15-DaCompany Report #WAES 0212USA02066
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/30/02ISR Number: 4032483-3Report Type:Expedited (15-DaCompany Report #WAES 0212ITA00019
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Laryngospasm		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Pharyngitis							

Date:12/30/02ISR Number: 4032484-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA02136
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							

Date:12/30/02ISR Number: 4032715-1Report Type:Direct Company Report #CTU 183517
Age: Gender:Male I/FU:I

Outcome	PT
	Cardiac Disorder
	Cystitis

	Lung Injury Pain Renal Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS				

Date:12/30/02ISR Number: 4032753-9Report Type:Direct Company Report #CTU 183519
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		25 Mg Vioxx	PS		ORAL	25MG DAILY	
	Abnormal Dreams					ORAL		
	Alanine Aminotransferase		20mg Bextra	SS		ORAL	20MG DAILY	
	Increased					ORAL		
	Aspartate		Klonopin	C				
	Aminotransferase							
	Increased							
	Blood Cholesterol							
	Increased							
	Blood Pressure Increased							
	Confusional State							
	Fatigue							
	Headache							
	Influenza Like Illness							
	Insomnia							
	Musculoskeletal Stiffness							
	Vertigo							
	Vision Blurred							

Date:12/30/02ISR Number: 4036058-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Arterial Thrombosis Limb
	Blood Pressure Systolic Increased

Chest Pain
Chronic Obstructive
Pulmonary Disease
Condition Aggravated
Coronary Artery Disease
Coronary Artery
Restenosis
Depression
Drug Ineffective
Dyspnoea
Embolism
Exercise Test Abnormal
Facial Palsy
Gastritis
Gastrooesophageal Reflux
Disease
Gout
Heart Rate Decreased
Heart Rate Increased
Hiatus Hernia
Hyperhidrosis
Hyperlipidaemia

		Hypoaesthesia					
		Myocardial Infarction					
		Peripheral Vascular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder	Consumer	Tab Vioxx	PS		ORAL
25							
		Porphyria Acute	Health				
MG/DAILY/PO							
		Psychosomatic Disease	Professional	Altace	C		
		Sinus Bradycardia		Plavix	C		
		Syncope		Prevacid	C		
		Thymus Hypertrophy		Zocor	C		
		Wheezing		Aspirin	C		
				Nitroglycerin	C		

Date:12/30/02ISR Number: 4036060-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Activities Of Daily	Health	Tab Vioxx	PS		ORAL
25							
Initial or Prolonged		Living Impaired	Professional				
MG/DAILY/PO							
		Atherosclerosis	Other	Altace	C		
		Blood Cholesterol		Plavix	C		
		Increased		Prevacid	C		
		Blood Triglycerides		Zocor	C		
		Increased		Aspirin	C		
		Cardiovascular Disorder		Nitroglycerin	C		
		Coronary Artery					
		Atherosclerosis					
		Coronary Artery Disease					
		Diarrhoea					
		Dizziness					
		Facial Palsy					
		Fatigue					
		Frequent Bowel Movements					
		Gallop Rhythm Present					
		Gastritis					
		Headache					
		Heart Rate Decreased					
		Hepatic Cyst					
		Mitral Valve Disease					
		Myocardial Infarction					

Nuclear Magnetic
Resonance Imaging Brain
Abnormal
Pain
Paraesthesia
Partial Seizures
Peripheral Coldness
Peripheral Vascular
Disorder
Syncope
Syncope Vasovagal
Wheezing

Date:12/30/02ISR Number: 4036611-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA02968
Age:55 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Congestive	Professional					MG/DAILY/PO	
	Drug Effect Decreased	Company	Therapy Unspecified	C				
	Hepatomegaly	Representative						
	Hypoproteinaemia							
	Impaired Gastric Emptying							
	Microcytic Anaemia							
	Post Procedural							
	Complication							
	Pulmonary Hypertension							
	Rash Maculo-Papular							

Date:12/30/02ISR Number: 4036672-3Report Type:Expedited (15-DaCompany Report #PHNU2002DE04159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia Haemolytic	Foreign	Diovan					
Initial or Prolonged	Autoimmune	Study	(Valsartan)Tablet	PS		ORAL	80 MG, QD,	
Other	Asthenia	Health						
ORAL								
	Blood Immunoglobulin A	Professional	Vioxx (Rofecoxib)					
	Increased	Other	Tablet	SS			1 DF, QD	
	Blood Immunoglobulin G		Dolormin (Ibuprofen					
	Increased		Lysinate) Tablet	C				
	Blood Lactate		Insulin Protaphan					
	Dehydrogenase Increased		Hm(Ge) (Insulin					
	Coombs Test Positive		Human) Suspension	C				
	Lymphadenopathy		Actrapid Penfill					
	Platelet Count Increased		(Insulin Human)	C				
	White Blood Cell Count		Magnesium	C				
	Increased							

Date:12/31/02ISR Number: 4033267-2Report Type:Expedited (15-DaCompany Report #WAES 0210BEL00025
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Hypotension	Professional						
	Melaena							
	Shock Haemorrhagic							

Date:12/31/02ISR Number: 4033276-3Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Acenocoumarol	SS		ORAL		
	Blood Ph Decreased		Amiodarone Hydrochloride	SS		ORAL		
	Hepatitis		Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		
			Thiamine Hydrochloride	C		ORAL		

Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL
Potassium Chloride	C		ORAL
Lactulose	C		ORAL
Acetaminophen	C		ORAL

Date:12/31/02ISR Number: 4033282-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA01646
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis Fulminant		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Percocet	C				
Initial or Prolonged			Levaquin	C				
Other			Diflucan	C				
			Altace	C				

Date:12/31/02ISR Number: 4033283-0Report Type:Expedited (15-DaCompany Report #WAES 0212ITA00015
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							

Date:12/31/02ISR Number: 4033284-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA02241
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL	11 MON	
Initial or Prolonged			[Therapy Unspecified]	C				
			Metformin	C				

Date:12/31/02ISR Number: 4033286-6Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00014
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		97 DAY

Date:12/31/02ISR Number: 4033288-XReport Type:Expedited (15-DaCompany Report #WAES 0212USA02140
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Oral Intake Reduced Ulcer Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/31/02ISR Number: 4033290-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA02238
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Other	Abnormal Behaviour Cardiac Disorder

		Myocardial Infarction Night Sweats					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
				Aspirin	C		

Date:12/31/02ISR Number: 4033787-0Report Type:Direct Company Report #CTU 183652
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Dyspepsia		Vioxx	PS		
1 A DAY						

Date:01/02/03ISR Number: 4033889-9Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00083
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Telmisartan	SS		ORAL
			Potassium Chloride	SS		ORAL
			Furosemide	SS		ORAL
			Saw Palmetto	SS		ORAL
			Tamsulosin Hydrochloride	SS		ORAL

Date:01/02/03ISR Number: 4034086-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA02136
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure Congestive Heart Injury					

Date:01/02/03ISR Number: 4034087-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA02377
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
	Weight Increased							

Date:01/02/03ISR Number: 4034088-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA02119
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Local Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash		Vioxx	SS		ORAL		
			Bextra	C				

Date:01/02/03ISR Number: 4034093-0Report Type:Expedited (15-DaCompany Report #WAES 0211USA00521
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Anaemia

		Blood Calcium Decreased					
		Blood Chloride Decreased					
		Blood Glucose Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Phosphorus		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased		Fosamax	SS		ORAL
		Diarrhoea					
		Flatulence					
		Gastric Outlet					
		Obstruction					
		Gastric Ulcer Haemorrhage					
		Oral Intake Reduced					
		Ovarian Cyst					
		Pco2 Increased					
		Rales					
		Upper Gastrointestinal					
		Haemorrhage					
		Wheezing					

Date:01/02/03ISR Number: 4034094-2Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00030
Age:77 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
Hospitalization -		Dyspnoea		Metformin			
Initial or Prolonged		General Physical Health		Hydrochloride	SS		ORAL
		Deterioration		Glyburide	SS		ORAL
		Haemodialysis		Hydrochlorothiazide			
		Hypoglycaemia		And Ramipril	SS		ORAL
		Hypovolaemic Shock		Moxonidine	C		
		Lung Infiltration		Lorazepam	C		
		Metabolic Acidosis		Aspirin	C		
		Mitral Valve Incompetence		Isosorbide			
		Oligodipsia		Mononitrate	C		
		Oral Intake Reduced		Nifedipine	C		
		Renal Failure Acute					
		Septic Shock					
		Tachypnoea					
		Ventricular Hypokinesia					
		White Blood Cell Count					
		Abnormal					

Date:01/02/03ISR Number: 4038489-2Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Activated Partial Thromboplastin Time Prolonged
	Arrhythmia
	Blood Bilirubin Increased
	Body Temperature Decreased
	Cardiac Murmur
	Chromaturia
	Diverticulum Intestinal Haemorrhagic
	Grunting
	Heart Rate Increased

		Hypotension					
		Hypovolaemic Shock					
		International Normalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ratio Increased	Consumer	Tab Vioxx Unk	PS		ORAL
25 MG/BID/PO							
		Iron Deficiency Anaemia		Celebrex	C		
		Mucosal Dryness		Coumadin	C		
		Oxygen Saturation		K-Lor	C		
		Decreased		Lanoxin	C		
		Prothrombin Time		Lasix (Furosemide)	C		
		Shortened		Skelaxin	C		
		Rectal Haemorrhage		Allopurinol	C		
				Colchicine	C		

Date:01/02/03ISR Number: 4038625-8Report Type:Expedited (15-DaCompany Report #M1337-2002
Age:71 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Duodenal Ulcer		Dexamethasone	PS		ORAL
6 MG	4 DAY						
		Perforation		Rofecoxib	SS		ORAL
50 MG	1 WK						
				Lansoprazole	C		
				Digoxin	C		
				Warfarin	C		
				Paroxetine	C		
				Propranolol	C		
				Oxycodone	C		
				Novelat	C		
				Gabapentin	C		

Date:01/03/03ISR Number: 4034791-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA02514
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/03/03ISR Number: 4034797-XReport Type:Expedited (15-DaCompany Report #WAES 0212DNK00033
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Increased							
	Blood Bilirubin Increased							
	Fatigue							
	Jaundice							
	Malaise							

Date:01/03/03ISR Number: 4035219-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA02375
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Consumer	Vioxx	PS		ORAL		
Disability	Dyspnoea		Morphine	C	Merck & Co., Inc			
INTRAVENOUS								
	Somnolence		Wellbutrin Sr	C				
			Neurontin	C				
			Celexa	C				
			Hydrocodone/Apap	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/03ISR Number: 4035226-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA02439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/03ISR Number: 4035227-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA02345
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Lipitor	C				
	Haemorrhage		Metformin	C				
	Mental Impairment		Nexium	C				
	Oxygen Saturation Decreased		Atenolol	C				
	Surgical Procedure Repeated		Lorazepam	C				
	Weight Decreased		Wellbutrin	C				

Date:01/03/03ISR Number: 4035232-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA00036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/03ISR Number: 4039095-6Report Type:Expedited (15-DaCompany Report #K200202066
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Enzymes Increased	Foreign	Altace Capsules					
Hospitalization - Initial or Prolonged	Dialysis	Health	(Ramipril) Capsule,					
	Femur Fracture	Professional	5 Mg	PS		ORAL	5 MG, QD,	

	Hypoglycaemia	Other				ORAL
	Metabolic Acidosis Mitral Valve Incompetence Peritonitis		Hydrochlorothiazide (Hydrochlorothiazide) 25 Mg	SS		ORAL
25 MG, QD,						
	Pneumonia					ORAL
	Renal Failure Acute Septic Shock		Glucophage (Metformin Hydrochloride) 850 Mg	SS		ORAL
850 MG, QD,						
						ORAL
			Daonil (Glibenclamide) 5 Mg	SS		ORAL
5 MG, QD,						
						ORAL
			Vioxx (Rofecoxib) 25 Mg	SS		ORAL
25 MG, ORAL						
			Physiotens (Moxonidine)	C		
			Tavor (Lorazepam)	C		
			Salospir (Acetylsalicylic Acid)	C		
			Isosorbide Mononitrate (Isosorbide			

			Mononitrate)	C
			Adalat (Nifedipine)	C

Date:01/03/03ISR Number: 4039995-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure	Consumer	Tab Vioxx	PS		ORAL	25	
Initial or Prolonged	Fluctuation	Health					MG/DAILY/PO	
	Cardiovascular Disorder	Professional	Altace	C				
	Dyspnoea		Plavix	C				
	Embolism		Prevacid	C				
	Gastritis		Zocor	C				
	Heart Rate Abnormal		Aspirin	C				
	Hyperhidrosis		Nitroglycerin	C				
	Myocardial Infarction							
	Syncope							
	Weight Increased							

Date:01/06/03ISR Number: 4035995-1Report Type:Expedited (15-DaCompany Report #WAES 0208GBR00182
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Cardio-Respiratory Arrest	Professional	Aspirin	C			4720	DAY
	Cholelithiasis		Diclofenac Sodium					
	Circulatory Collapse		And Misoprostol	C				
	Coronary Artery							
	Atherosclerosis							
	Diverticulitis							
	Duodenal Ulcer							
	Haemorrhage							
	Dyspepsia							
	Empyema							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							
	Ventricular Hypertrophy							

Date:01/06/03ISR Number: 4036218-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA00168
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Oedema Peripheral	Professional	Vioxx	SS		ORAL	6	DAY

Date:01/06/03ISR Number: 4036220-8Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00024
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	72	DAY
		Professional	Celecoxib	SS		ORAL	10	DAY
			Atorvastatin	C		ORAL	573	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/03ISR Number: 4036222-1Report Type:Expedited (15-DaCompany Report #WAES 0212DNK00033
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Increased	Professional	Vioxx	SS		ORAL		152 DAY
	Fatigue							
	Jaundice							
	Malaise							

Date:01/06/03ISR Number: 4036229-4Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00060
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal		Vioxx	SS		ORAL		
	Haemorrhage		Carvedilol	C				
			Moxonidine	C				
			Ramipril	C				

Date:01/06/03ISR Number: 4036235-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA00064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/03ISR Number: 4036999-5Report Type:Direct Company Report #CTU 183882
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib Merck	PS	Merck			
Initial or Prolonged	Haemorrhage							

Date:01/07/03ISR Number: 4037100-4Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Acenocoumarol	SS		ORAL		
			Amiodarone Hydrochloride	SS		ORAL		
			Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		
			Thiamine Hydrochloride	C		ORAL		
			Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL		
			Potassium Chloride	C		ORAL		
			Lactulose	C		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/03ISR Number: 4037824-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01597
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Drug Ineffective		Zyrtec	C				
Other	Fatigue							
	Headache							
	Panic Attack							

Date:01/07/03ISR Number: 4037830-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							

Date:01/07/03ISR Number: 4037831-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA00080
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Status Epilepticus		Dilantin	C				
			Lamictal	C				

Date:01/07/03ISR Number: 4037832-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA00153
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Composition Unspecified]	C				

Date:01/08/03ISR Number: 4038405-3Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12144382
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction	Health	Glucophage Tabs 850					
Life-Threatening	Hypoglycaemia	Professional	Mg	PS	Bristol-Myers Squibb			
Hospitalization -	Lactic Acidosis				Company	ORAL		
Initial or Prolonged	Metabolic Acidosis		Physiotens	C		ORAL		
	Renal Failure Acute		Acetylsalicylic Acid	C		ORAL		
	Sepsis		Tavor	C		ORAL		
	Shock		Isosorbide					
			Mononitrate	C		ORAL		
			Adalat Retard	C		ORAL		
			Daonil	I		ORAL		
			Vioxx	I		ORAL	4	DAY
			Triatec	I		ORAL		

Date:01/08/03ISR Number: 4038510-1Report Type:Direct Company Report #CTU 184076
Age: Gender:Female I/FU:I

Outcome	PT
Disability	Adrenal Insufficiency
	Anaemia
	Autonomic Nervous System

		Imbalance					
		Blood Pressure Abnormal					
		Bone Pain					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fat Tissue Increased		Celebrex 200 Mg.			
		Glucose Tolerance		Searle	PS	Searle	ORAL
MAXIMUM ORAL							
		Impaired		Vioxx 25 Mg Merck	SS	Merck	ORAL
MAXIMUM ORAL							
		Hepatocellular Damage		Calcium	C		
		Hypoaesthesia		Multivitamin	C		
		Hypoglycaemia		St John'S Wort	C		
		Loss Of Consciousness		Ultram	C		
		Meningitis Aseptic					
		Muscle Atrophy					
		Neuropathy Peripheral					
		Rash					
		Sensation Of Pressure					
		Sensory Loss					
		Skin Discolouration					
		Spinal Osteoarthritis					
		Syncope					

Date:01/08/03ISR Number: 4038730-6Report Type:Expedited (15-DaCompany Report #WAES 0209CAN00086
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Breast Cancer Female		Vioxx	PS	Merck & Co., Inc	ORAL
		Metastasis					
		Terminal State					

Date:01/08/03ISR Number: 4038736-7Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00020
Age:75 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
				Digoxin	C		ORAL
13 YR							
				Molsidomine	C		ORAL
				Clopidogrel Bisulfate	C		ORAL

Date:01/08/03ISR Number: 4038739-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA00134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/09/03ISR Number: 4039421-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angiopathy
Disability	Anorexia
Other	Arthralgia
	Atherosclerosis
	Biliary Neoplasm
	Blood Pressure Systolic Increased
	Cardiac Failure Congestive

		Cardiac Valve Disease					
		Cardiomegaly					
		Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complications Of		Vioxx	PS	Merck & Co., Inc	ORAL
		Transplant Surgery		Lipitor	SS		ORAL
366	DAY						
		Dialysis		Zemplar	SS		
		Drug Interaction		[Therapy			
		Epistaxis		Unspecified]	SS		
		Erythema Multiforme		Lasix (Furosemide)	C		ORAL
		Kidney Transplant		Sandimmun	C		ORAL
		Rejection		Clonidine			
		Muscular Weakness		Hydrochloride	C		ORAL
		Myalgia		Imuran			
		Nasal Septum Perforation		(Azathioprine)	C		ORAL
		Orthopnoea		Vitamin B Complex	C		ORAL
		Palpitations		Calcium			
		Pericardial Effusion		(Unspecified) And			
		Pleural Effusion		Vitamin D			
		Sinus Tachycardia		(Unspecified)	C		
		Vasodilatation		Iron Dextran	C		
		Weight Decreased		Epoetin	C		
				Cyclosporine	C		
				Paricalcitol	C		
INTRAVENOUS							
				Zaroxolyn	C		ORAL
				Ultralente Insulin	C		
PARENTERAL							
				Toprol Xl Tablets	C		ORAL
				Viagra	C		ORAL
				Humulin	C		
PARENTERAL							
				Clonazepam	C		
				Celebrex	C		
				Prednisone	C		ORAL
				Norvasc	C		ORAL
				Zebeta	C		ORAL
				Flexeril	C		ORAL

Date:01/09/03ISR Number: 4039428-0Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00071B1
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Abortion Missed		Vioxx	PS	Merck & Co., Inc	
5 DAY						
	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus Pregnancy					

Date:01/09/03ISR Number: 4039432-2Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00071M
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abortion Missed		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
	Drug Exposure During Pregnancy Maternal Drugs Affecting Foetus Pregnancy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/03ISR Number: 4039631-XReport Type:Expedited (15-DaCompany Report #WAES 0301GBR00030
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Exfoliative		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
	Oedema Peripheral							
	Red Blood Cell Sedimentation Rate Increased							
	Rheumatoid Factor Positive							

Date:01/09/03ISR Number: 4039637-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	366	DAY
	Anorexia		Lipitor	SS		ORAL		
Disability	Aortic Valve Incompetence		Zemplar	SS				
Other	Arthralgia		[Therapy					
	Biliary Neoplasm		Unspecified]	SS				
	Blood Pressure Systolic Increased		Imuran (Azathioprine)	C		ORAL		
	Cardiac Failure		Prednisone	C		ORAL		
	Congestive		Lasix (Furosemide)	C		ORAL		
	Cardiomegaly		Sandimmun	C		ORAL		
	Congestive Cardiomyopathy		Clonidine Hydrochloride	C		ORAL		
	Dialysis							
	Diarrhoea		Calcium (Unspecified) And Vitamin D (Unspecified)	C				
	Drug Hypersensitivity							
	Drug Interaction							
	Epistaxis							
	Erythema Multiforme		Iron Dextran	C				
	Injury		Epoetin	C				
	Kidney Transplant		Cyclosporine	C				
	Rejection		Paricalcitol	C				
INTRAVENOUS								
	Mitral Valve Incompetence		Zaroxolyn	C		ORAL		
	Myalgia		Ultralente Insulin	C				
PARENTERAL								
	Myocardial Ischaemia		Toprol Xl Tablets	C		ORAL		

	Myositis	Viagra	C	ORAL
	Nasal Septum Deviation	Humulin	C	PARENTERAL
	Nasal Septum Perforation	Clonazepam	C	
	Palpitations	Norvasc	C	ORAL
	Pericardial Effusion	Zebeta	C	ORAL
	Pleural Effusion	Flexeril	C	ORAL
	Pulmonary Congestion	Vitamin B Complex	C	ORAL
	Raynaud'S Phenomenon	Celebrex	C	
	Sinus Tachycardia			
	Skin Chapped			
	Swelling			
	Tricuspid Valve Incompetence			
	Vascular Calcification			
	Ventricular Hypertrophy			
	Ventricular Hypoplasia			
	Weight Decreased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/03ISR Number: 4040109-8Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Initial or Prolonged	Asthenia	Professional	Vioxx	SS		ORAL		1 DAY
	Atrial Fibrillation		Salutensin	C				
	Atrial Flutter		Tenormin	C				
	Atrioventricular Block		Paxil	C				
	First Degree		Xanax	C				
	Bundle Branch Block Right		Lescol	C				
	Cardiac Failure							
	Congestive							
	Chronic Obstructive							
	Pulmonary Disease							
	Decreased Appetite							
	Dyspnoea Exertional							
	Fluid Overload							
	Heart Rate Irregular							
	Hypertension							
	Lung Disorder							
	Lung Neoplasm							
	Mitral Valve Incompetence							
	Myalgia							
	Parkinson'S Disease							
	Pharyngolaryngeal Pain							
	Pleural Effusion							
	Pulmonary Fibrosis							
	Rhinitis Allergic							
	Scar							
	Vision Blurred							
	Weight Decreased							

Date:01/10/03ISR Number: 4040131-1Report Type:Direct Company Report #CTU 184217
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx 25mg Merck	PS	Merck	ORAL		25MG QD ORAL
Hospitalization -	Haematochezia		Coumadin 6mg Bms	SS	Bms	ORAL		65MG QD ORAL

Initial or Prolonged	International Normalised
Required	Ratio Increased
Intervention to	Pain
Prevent Permanent	Pyrexia
Impairment/Damage	

Date:01/10/03ISR Number: 4040360-7Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00011
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Hospitalization -	Drug Interaction		Candesartan					
Initial or Prolonged	Renal Failure Acute		Cilexetil	SS		ORAL		
			Fosamax	C		ORAL		
			Goserelin Acetate	C		SUBCUTANEOUS		
			Cyproterone Acetate	C		ORAL		
			Metoprolol	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/03ISR Number: 4040363-2Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00071
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ear Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tinnitus		Lansoprazole	C				

Date:01/10/03ISR Number: 4040367-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01891
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged Disability			Nasonex	C				
			Dyazide	C				
			Claritin	C				
			Inderal La	C				
			Prilosec	C				
			Glipizide	C				
			Aspirin And Butalbital And Caffeine	C				

Date:01/10/03ISR Number: 4040370-XReport Type:Expedited (15-DaCompany Report #WAES 0210FRA00082
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Cerebral Haemorrhage		Clopidogrel Bisulfate	SS		ORAL	3	YR
	Drug Interaction							
	Hallucination		Trimetazidine Hydrochloride	C		ORAL		
			Hydroxyzine Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

Date:01/10/03ISR Number: 4040371-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00067
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:01/10/03ISR Number: 4040372-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA00053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Death		Vioxx	SS		ORAL		
	Injury							
	Mental Disorder							
	Pain							
	Respiratory Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/03ISR Number: 4040378-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA00529
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive							

Date:01/10/03ISR Number: 4040379-6Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00024
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Dizziness		Vioxx	SS		ORAL	14	DAY
	Fall		Levothyroxine Sodium	C				
	Neurotoxicity		Estrogens, Conjugated	C				
			Amlodipine	C				

Date:01/10/03ISR Number: 4040380-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA00153
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Composition Unspecified]	C				

Date:01/10/03ISR Number: 4040382-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA00391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage							
	Haemorrhage							

Multiple Allergies
Pyrexia
Swelling

Date:01/10/03ISR Number: 4040385-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA00181
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Peptic Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Shock		Zestril	C		ORAL		
Hospitalization - Initial or Prolonged			Ditropan Xl	C		ORAL		
			Sinemet	C		ORAL		
Disability			Plavix	C		ORAL		
Other			Humalog	C		PARENTERAL		

Date:01/10/03ISR Number: 4040386-3Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00044
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/03ISR Number: 4040391-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA00515
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
			Actonel	C				
			Lipitor	C				
			Lotrel	C				
			Zoloft	C				
			Calcium (Unspecified)	C				

Date:01/13/03ISR Number: 4041075-1Report Type:Expedited (15-DaCompany Report #WAES 0212USA02136
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Condition Aggravated		Sectral	C				
	Syncope		Advair	C				
			Atrovent	C				
			Xopenex	C				
			Albuterol	C				
			Tylenol Extra Strength	C				
			Vicodin Tablets	C				
			Hydrodiuril	C		ORAL		
			Captopril	C				
			Myoflex External Analgesic Creme	C				
			Norvasc	C				
			Motrin	C				

Date:01/13/03ISR Number: 4041076-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA01508
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Disability

Date:01/13/03ISR Number: 4041099-4Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00024
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/03ISR Number: 4041106-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA02238
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Cardiac Disorder Myocardial Infarction Night Sweats		Aspirin	C				

Date:01/13/03ISR Number: 4041108-2Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00150
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		579 DAY
Initial or Prolonged	Gastritis		Vioxx	SS		ORAL		
	Psychotic Disorder		Aspirin	SS		ORAL		862 DAY
			Insulin	C				
			Lofepramine Hydrochloride	C				
			Nitrazepam	C				
			Acetaminophen And Dihydrocodeine Bitartrate	C				
			Olanzapine	C				

Date:01/13/03ISR Number: 4041110-0Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00059
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematemesis							

Date:01/13/03ISR Number: 4041111-2Report Type:Expedited (15-DaCompany Report #WAES 0301DNK00002
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Sinemet	C		ORAL		412 DAY
	Blood Alkaline		Tramadol	C		ORAL		16 MON
	Phosphatase Increased		Fluanxol	C		ORAL		
	Blood Lactate		Estradiol	C				
	Dehydrogenase Increased							
	International Normalised							
	Ratio Decreased							

Date:01/13/03ISR Number: 4041112-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA00574
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombotic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/03ISR Number: 4041114-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA00230
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Mouth		Bextra	SS		ORAL		
	Rash Generalised		Allopurinol	SS				
	Rash Maculo-Papular		Cozaar	C		ORAL		
			Cardura	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/03ISR Number: 4041201-4Report Type:Direct Company Report #CTU 184334
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Weight Increased		Rofecoxib 12.5mg Pfizer	PS	Pfizer	ORAL	12.5MG BID	ORAL
			Lisinopril	C				
			Allopurinol	C				
			Sulindac	C				
			Furosemide	C				
			Colchicine	C				

Date:01/14/03ISR Number: 4041385-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	TOPICAL	
	Anxiety		Altace	C		ORAL		
	Cardiovascular Disorder		Plavix	C		ORAL		
	Chest Pain		Aspirin	C		ORAL		
	Coronary Artery Disease		Nitroglycerin	C				
	Coronary Artery		Prevacid	C		ORAL		
	Restenosis		Zocor	C		ORAL		
	Embolism							
	Facial Palsy							
	Gastritis							
	Headache							
	Hiatus Hernia							
	Hyperlipidaemia							
	Myocardial Infarction							
	Obstructive Airways Disorder							
	Sinus Bradycardia							
	Syncope							
	Thymus Hypertrophy							
	Wheezing							

Date:01/14/03ISR Number: 4041543-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA01293
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Gastrointestinal Perforation	Health Professional	Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		

Date:01/14/03ISR Number: 4041546-8Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00016
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Peritonitis	Professional	Aspirin Lysine	SS		ORAL		
			Nitroglycerin	C				
			Furosemide	C		ORAL		
			Amlodipine	C		ORAL		
			Ramipril	C		ORAL		
			Moxonidine	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

				Potassium Chloride	C		ORAL
				Disopyramide	C		ORAL

Date:01/14/03ISR Number: 4041547-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA00707
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Pain In Extremity		Norvasc	SS				
			Captopril	SS				
			Tenormin	SS				
			Lipitor	C				
			Aspirin	C				

Date:01/14/03ISR Number: 4041549-3Report Type:Expedited (15-DaCompany Report #WAES 0211USA01296
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tendon Rupture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/03ISR Number: 4041556-0Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00062
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Left Ventricular Failure		Tramadol	C		ORAL	299	DAY
Initial or Prolonged	Oedema Peripheral		Calcichew D3	C		ORAL		
	Tinnitus		Atenolol	C		ORAL		
			Lansoprazole	C		ORAL		

Date:01/14/03ISR Number: 4041558-4Report Type:Expedited (15-DaCompany Report #WAES 0301DNK00002
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		412 DAY
			Sinemet	C		ORAL		16 MON
	Blood Alkaline Phosphatase Increased		Tramadol	C		ORAL		
			Fluanxol	C		ORAL		
	Blood Lactate Dehydrogenase Increased		Estradiol	C				
	International Normalised Ratio Decreased							

Date:01/14/03ISR Number: 4041559-6Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00039
Age:96 YR Gender:Female I/FU:I

Outcome	PT
Death	Blood Fibrinogen Increased
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased
	Blood Test Abnormal
	Cyanosis
	Depressed Level Of Consciousness

		Erysipelas					
		Hypotension					
		Neutropenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Purpura	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pyrexia	Professional	Cozaar	SS		ORAL
		Renal Impairment		Buflomedil			
		Septic Shock		Hydrochloride	C		ORAL
		Streptococcal Infection		Trimetazidine			
		Thrombocytopenia		Hydrochloride	C		
				Clopidogrel			
				Bisulfate	C		ORAL

Date:01/14/03ISR Number: 4041561-4Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00003
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Haemoglobin Decreased	Professional	Aspirin And			
	Melaena		Magnesium Oxide	SS		ORAL
			Acetaminophen And			
			Codeine Phosphate	C		ORAL

Date:01/14/03ISR Number: 4041562-6Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00004
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Haematemesis	Professional	Aspirin And			
	Haemoglobin Decreased		Magnesium Oxide	SS		ORAL
	Melaena		Dipyridamole	SS		ORAL
	Oesophageal Ulcer		Metoprolol Tartrate	C		ORAL
			Furosemide	C		ORAL
			Acetaminophen And			
			Codeine Phosphate	C		ORAL

Date:01/14/03ISR Number: 4041564-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA00157
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/03ISR Number: 4041567-5Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00024
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Dizziness	Professional	Vioxx	SS		ORAL	14	DAY
	Fall		Levothyroxine Sodium	C				
	Feeling Hot		Estrogens, Conjugated	C				
	Neurotoxicity		Amlodipine	C				
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/03ISR Number: 4042015-1Report Type:Direct Company Report #CTU 184489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 50mg	PS		ORAL	50MG PO QD	
	Blood Sodium Decreased							
	Chest Discomfort							
	Chest X-Ray Abnormal							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Protein Total Decreased							
	Pulmonary Oedema							
	Tinnitus							
	Weight Increased							

Date:01/15/03ISR Number: 4042130-2Report Type:Direct Company Report #CTU 184536
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dialysis		Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Renal Failure Acute							
			Vioxx 50 Mg	SS		ORAL	50 MG DAILY	

ORAL

Date:01/15/03ISR Number: 4042318-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02444
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Health	Vioxx	PS		ORAL	30 DAY	
	Erythema Multiforme	Professional	Imitrex	C	Merck & Co., Inc			
	Influenza Like Illness		Elavil	C		ORAL		
	Iritis		Inderal	C		ORAL		
	Joint Swelling		Ambien	C		ORAL		
	Optic Neuritis		Medicon	C				

	Pharyngitis					
	Scotoma					
	Stevens-Johnson Syndrome					
	Uveitis					

Date:01/15/03ISR Number: 4042320-9Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Decreased Activity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Dermatitis Exfoliative					
	Dry Mouth					
	Eczema					
	Eyelid Oedema					
	Face Oedema					
	Pain In Extremity					

Date:01/15/03ISR Number: 4042322-2Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00038
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Gastric Ulcer
	Haematemesis

Rectal Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Acetaminophen	C		ORAL		

Date:01/15/03ISR Number: 4042324-6Report Type:Expedited (15-DaCompany Report #WAES 0212DEU00086
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
78 DAY								
Initial or Prolonged		Professional	Cinnarizine And Dimenhydrinate	C		ORAL		
			Cowslip And Gentian And Rumex And Sambucus And Vervain	C		ORAL		
152 DAY								
			Ranitidine	C		ORAL		
			Zopiclone	C		ORAL		

Date:01/15/03ISR Number: 4042325-8Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Urea Increased		Acenocoumarol	SS		ORAL		
	Hepatic Necrosis		Amiodarone Hydrochloride	SS		ORAL		
	Hepatitis		Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		
			Thiamine Hydrochloride	C		ORAL		
			Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL		

		Potassium Chloride	C	ORAL
		Lactulose	C	ORAL
		Acetaminophen	C	ORAL

Date:01/15/03ISR Number: 4042327-1Report Type:Expedited (15-DaCompany Report #WAES 0301BEL00006
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Idiopathic Thrombocytopenic Purpura	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Loperamide Hydrochloride	C		ORAL	1	DAY

Date:01/15/03ISR Number: 4043589-7Report Type:Expedited (15-DaCompany Report #2003-DE-00017YA(0)
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemolytic Anaemia	Health Professional Other	Omix (Tamsulosin) (Nr) (Tamsulosin Hydrochloride)	PS		ORAL	0.4	MG

Vioxx (Antiinflammatory/Antirheumatic Products)	SS	ORAL	25 MG
Pritor (Antihypertensives)	SS	ORAL	20 MG
Diffu K (Potassium Chloride)	SS	ORAL	600 MG
Lasilix (Furosemide)	SS	ORAL	20 MG
Permixon (Serenoa Repens)	SS	ORAL	160 MG

Date:01/15/03ISR Number: 4043891-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Tab Vioxx 10 Mg	PS		ORAL	PO	
Initial or Prolonged	Atherosclerosis	Health	Lipitor 10 Mg	SS		ORAL	10	
Disability	Biliary Neoplasm	Professional					MG/DAILY/PO	
Other	Cardiac Failure		Zemplar	SS				
	Congestive		Celebrex	C				
	Chest Pain		Flexeril	C				
	Dialysis		Humulin	C				
	Drug Interaction		Imuran (Azathioprine)	C				
	Ejection Fraction Decreased		Lasix (Furosemide)	C				
	Epistaxis		Norvasc	C				
	Fistula		Sandimmum	C				
	Haemorrhage		Toprol Xl Tablets	C				
	Injury		Ultralente Insulin	C				
	Kidney Transplant		Viagra	C				
	Rejection		Zaroxolyn	C				
	Myalgia		Zebeta	C				
	Nasal Septum Deviation		Calcium + Vitamin	C				
	Orthopnoea		Clonazepam	C				
	Pain		Clonidine					

	Rash	Hydrochloride	C
	Renal Failure	Cyclosporine	C
	Skin Chapped	Epoetin	C
	Skin Disorder	Iron Dextran	C
	Treatment Noncompliance	Paricalcitol	C
	Ventricular Hypokinesia	Prednisone	C
		Vitamin B Complex	C

Date:01/15/03ISR Number: 4043900-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Atrial Fibrillation
	Atrial Flutter
	Atrioventricular Block
	First Degree
	Blood Creatine
	Phosphokinase Increased
	Blood Urea Increased
	Bundle Branch Block Right
	Cardiac Failure
	Congestive

		Cardiac Murmur Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness	Consumer	Vioxx	PS		ORAL
SEE IMAGE							
		Dyspnoea Exertional	Health	Lescol	C		
		Heart Rate Irregular	Professional	Paxil	C		
		Hypertension		Salutensin	C		
		Lung Neoplasm		Tenormin	C		
		Mitral Valve Incompetence		Xanax	C		
		Nausea					
		Parkinson'S Disease					
		Pleural Effusion					
		Pulmonary Fibrosis					
		Rhinitis Allergic					
		Vision Blurred					

Date:01/16/03ISR Number: 4042710-4Report Type:Expedited (15-DaCompany Report #WAES 0209CAN00086
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Breast Cancer Stage Iv	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/16/03ISR Number: 4042715-3Report Type:Expedited (15-DaCompany Report #WAES 0204BEL00022
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
58	DAY						
Hospitalization - Initial or Prolonged		Peritonitis	Professional	Ketotifen	C		ORAL
Other				Hydrochlorothiazide And Lisinopril	C		ORAL
				Fluticasone Propionate And Salmeterol Xinafoate	C		
RESPIRATORY							
(INHALATION)							
				Lorazepam	C		ORAL

Date:01/16/03ISR Number: 4042808-0Report Type:Direct Company Report #CTU 184724
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Hyperkalaemia Oedema Peripheral Renal Failure Acute		Vioxx 25mg Merck	PS	Merck	ORAL	25MG PO QD	

Date:01/16/03ISR Number: 4042865-1Report Type:Direct Company Report #CTU 184683
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Blood Urea Increased Faeces Discoloured Gastrointestinal Haemorrhage Peptic Ulcer Haemorrhage		Vioxx 25mg- Merck	PS	Merck	ORAL	25MG PO QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/03ISR Number: 4042924-3Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00001
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Aspirin Lysine	SS		ORAL		3 YR
			Nitroglycerin	C		TOPICAL		
	Melaena		Furosemide And Spironolactone	C		ORAL		
			Ciprofibrate	C		ORAL		
			Aesculus And Metesculetol Sodium	C		ORAL		
			Trimebutine Maleate	C		ORAL		
			Anethole Trithione	C		ORAL		
			Potassium Bicarbonate And Psyllium Husk	C		ORAL		

Date:01/16/03ISR Number: 4042927-9Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/16/03ISR Number: 4042931-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/16/03ISR Number: 4042932-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/17/03ISR Number: 4043159-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA00441
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Faecal Occult Blood Positive		Albuterol	C		ORAL		
			Ultracet	C		ORAL		
Other	Gastritis							
	Gastrointestinal Haemorrhage							
	Haematemesis							
	Helicobacter Infection							
	Hypotension							
	Nausea							
	Peptic Ulcer							
	Sinus Tachycardia							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/17/03ISR Number: 4043321-7Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00194
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL
			Clarithromycin	C		
			Lansoprazole	C		
			Calcium Carbonate And Cholecalciferol	C		
			Tamsulosin Hydrochloride	C		
			Azithromycin	C		
			Metronidazole	C		
10 DAY						
			Chloramphenicol	C		
7 DAY						
			Doxycycline	C		
1 DAY						
			Doxycycline	C		
13 DAY						

Date:01/17/03ISR Number: 4043322-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA00102
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Bextra	SS		

Date:01/17/03ISR Number: 4043323-0Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL
1 MON						
Hospitalization -	Thromboplastin Time		Coumadin	C		
Initial or Prolonged	Abnormal		Allopurinol	C		
	Aortic Aneurysm		Skelaxin	C		
	Arrhythmia		Lanoxin	C		
	Arthritis		Lasix (Furosemide)	C		

	Atrial Fibrillation	Celebrex	C
2 WK			
	Blood Pressure Diastolic	Colchicine	C
	Abnormal	K-Lor	C
	Cardiac Failure		
	Congestive		
	Discomfort		
	Diverticulum Intestinal		
	Haemorrhagic		
	Heart Rate Increased		
	Hypovolaemic Shock		
	International Normalised		
	Ratio Abnormal		
	Iron Deficiency Anaemia		
	Oxygen Saturation		
	Decreased		
	Prothrombin Time Abnormal		

Date:01/17/03ISR Number: 4043325-4Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00038
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 369 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Atorvastatin Calcium	C		ORAL
	Oesophageal Ulcer		Acetaminophen	C		ORAL
	Rectal Haemorrhage		Metformin			

			Chlorophenoxyacetate	C		ORAL

Date:01/17/03ISR Number: 4043329-1Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Antineutrophil Cytoplasmic Antibody Positive Antinuclear Antibody Positive Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		

Date:01/17/03ISR Number: 4043330-8Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Diarrhoea Pyrexia Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Sertraline Hydrochloride	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Omeprazole	C		ORAL
			Iron (Unspecified)	C		ORAL

Date:01/17/03ISR Number: 4043332-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01034
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Ulcer Oesophageal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		

Date:01/20/03ISR Number: 4043548-4Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00009
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization - 7 DAY	Completed Suicide	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction	Hyzaar	C		ORAL
		Pravastatin Sodium	C		ORAL
		Tamsulosin Hydrochloride	C		ORAL

Date:01/20/03ISR Number: 4043551-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Aphasia
Hospitalization - Initial or Prolonged	Blood Bicarbonate Abnormal
	Blood Creatinine Increased
	Blood Glucose Abnormal
	Blood Potassium Decreased
	Blood Urea Increased
	Body Temperature Decreased
	Bradycardia

		Cold Sweat					
		Depressed Level Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Faecal Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal		Haldol	C		
		Haemorrhage		Nitroglycerin	C		
		Haematocrit Decreased		Trazodone	C		
		Haemoglobin Decreased		Valproic Acid	C		
		Hypotension		Aspirin	C		ORAL
		Injury		Ferrous Sulfate	C		
		Oxygen Saturation		Colace	C		
		Decreased		Sorbitol	C		
		Pallor		[Therapy			
		Pco2 Decreased		Unspecified]	C		
		Red Blood Cell Count					
		Abnormal					
		Respiratory Rate					
		Increased					
		Somnolence					
		Urine Ketone Body Present					
		White Blood Cell Count					
		Abnormal					

Date:01/20/03ISR Number: 4043552-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01282
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blister		Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY						
	Hypertension		Cozaar	C		
	Rash					
	Swelling					
	Thermal Burn					

Date:01/20/03ISR Number: 4043553-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01047
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/20/03ISR Number: 4043588-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043592-7Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00009
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Completed Suicide		Pravastatin Sodium	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Hydrochlorothiazide And Lisinopril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/03ISR Number: 4043594-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01052
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043595-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01090
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043596-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA01088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043597-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01085
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043598-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:01/20/03ISR Number: 4043599-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA01100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/03ISR Number: 4043605-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA01016
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx Premarin	PS C	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043872-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/03ISR Number: 4043874-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043875-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043876-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043878-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043879-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043880-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA01072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043881-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043882-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/03ISR Number: 4043883-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA01092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043885-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043886-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043887-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043888-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043889-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043890-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043892-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/03ISR Number: 4043893-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01229
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043895-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043896-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043897-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA01247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043968-8Report Type:Direct Company Report #CTU 184833
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia Stevens-Johnson Syndrome		Vioxx Erithromiacin	PS SS				

Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:01/21/03ISR Number: 4043984-6Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemodialysis Renal Impairment Urinary Retention		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043986-XReport Type:Expedited (15-DaCompany Report #WAES 0301FRA00052
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Diarrhoea Rectal Haemorrhage	Health Professional	Vioxx Aspirin Lysine Metformin Hydrochloride Atorvastatin Calcium	PS SS C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL	14 DAY	

			Diltiazem Hydrochloride	C		ORAL
			Furosemide	C		ORAL

Date:01/21/03ISR Number: 4043987-1Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00217
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 42 DAY	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Omeprazole	C		
			Prednisolone	C		
			Acetaminophen	C		
			Tramadol	C		
			Fosamax	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		
			Lactulose	C		

Date:01/21/03ISR Number: 4043988-3Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00059
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Delirium		Prednisolone Sodium Metasulfobenzoate	C		ORAL
			Leflunomide	C		ORAL
39 DAY						
			Anakinra	C		
SUBCUTANEOUS 39 DAY						
			Levothyroxine Sodium	C		ORAL

Date:01/21/03ISR Number: 4043994-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Renal Failure					

Date:01/21/03ISR Number: 4043995-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4043996-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01306
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Increased	Professional	[Therapy					
	Blood Pressure Increased		Unspecified]	SS				
	Blood Urea Increased		Imdur	C				
	Cerebrovascular Accident		Aceon	C				
			Lipitor	C				
			Prilosec	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/03ISR Number: 4043998-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/03ISR Number: 4044219-0Report Type:Direct Company Report #CTU 184892
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx 25 Mg Tablet	PS			25 MG ONCE	
Initial or Prolonged	Chest Pain						DAILY	
	Discomfort		Hydrocodone With Apap	C				
	Headache							
	Musculoskeletal Stiffness							
	Neck Pain							
	Pain							

Date:01/21/03ISR Number: 4044335-3Report Type:Direct Company Report #CTU 184924
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS				
Initial or Prolonged	Epistaxis		Motrin	SS				
	Faeces Discoloured							
	Gastrointestinal Haemorrhage							

Date:01/21/03ISR Number: 4044346-8Report Type:Direct Company Report #CTU 184905
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chills		Vioxx	PS			25 MG 1 QD	

Fatigue
Headache
Hepatotoxicity
Hyperhidrosis
Palmar Erythema
Rash

Date:01/21/03ISR Number: 4044581-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Asthenia
	Cardiovascular Disorder
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Dyspnoea
	Facial Palsy
	Gastritis
	Headache
	Hiatus Hernia

		Hyperlipidaemia					
		Hypoaesthesia					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Vascular	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Disorder	Health				
MG/DAILY/PO							
		Sinus Bradycardia	Professional	Altace	C		
		Sleep Apnoea Syndrome		Plavix	C		
		Syncope		Prevacid	C		
		Thrombosis		Zocor	C		
		Thymus Hypertrophy		Aspirin	C		
		Weight Increased		Nitroglycerin	C		
		Wheezing					

Date:01/21/03ISR Number: 4045621-3Report Type:Expedited (15-DaCompany Report #2003000497
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Congenital Anomaly		Cryptorchism	Foreign	Cetirizine (Tablets)			
		Maternal Drugs Affecting	Health	(Cetirizine			
		Foetus	Professional	Hydrochloride)	PS		
				Rofecoxib	SS		ORAL
12.5 MG							
(DAILY) ORAL							
				Cyclizine	SS		
				Panadeine Co	SS		
				Prochlorperazine	C		
				Gaviscon	C		

Date:01/21/03ISR Number: 4045637-7Report Type:Expedited (15-DaCompany Report #2003000498
Age:38 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Complications Of Maternal	Foreign	Cetirizine (Tablets)			
		Exposure To Therapeutic	Health	(Cetirizine			
		Drugs	Professional	Hydrochloride)	PS		
		Cryptorchism		Rofecoxib	SS		ORAL
12.5 MG							

	Hyperemesis Gravidarum					
(DAILY) ORAL						
	Maternal Drugs Affecting		Cyclizine	SS		
	Foetus		Panadeine Co	SS		
	Pregnancy		Prochlorperazine	C		
			Gaviscon	C		

Date:01/21/03ISR Number: 4045697-3Report Type:Expedited (15-DaCompany Report #HQ6077609JAN2003
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Ph Decreased	Health	Cordarone			
Hospitalization -	Coma Hepatic	Professional	(Amiodarone, Tablet)	PS		ORAL
200 MG IX PER						
Initial or Prolonged	Dyspnoea	Other				
1 DAY						
	Hepatitis Fulminant		Sintrom			
	Hypoglycaemia		(Acenocoumarol,)	SS		ORAL
	Renal Failure Chronic		Vioxx (Rofecoxib,			
			Tablet)	SS		ORAL
50 MG 1X PER						
1 DAY						
			Lasix (Furosemide)	C		
			Aldactone			
			(Spironolactone)	C		
			Tramal (Tramadol			
			Hydrochloride)	C		

			Benerva (Thiamine Hydrochloride)	C		
			Becozym (Vitamin B Nos)	C		
			Kalium (Potassium Chloride)	C		
			Duphalac (Lactulose)	C		
			Temesta (Lorazepam)	C		

Date:01/21/03ISR Number: 4045717-6Report Type:Expedited (15-DaCompany Report #2003142056US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Celebrex(Celecoxib)					
		Other	Capsule	PS		ORAL	ORAL	
			Vioxx()	SS				

Date:01/21/03ISR Number: 4045965-5Report Type:Expedited (15-DaCompany Report #2002-08-2213
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Herpes Zoster	Foreign	Fugerel (Flutamide)					
Hospitalization - Initial or Prolonged	Pancytopenia	Health Professional	Tablets Like Eulexin Capsules	PS		ORAL	250 MG TID	ORAL
		Other						
			Methotrexat Tablets	SS		ORAL	10 MG QW	ORAL
			Vioxx (Rofecoxib) Tablets	SS		ORAL	25 MG BID	ORAL
			Prednisolon Tablets	SS		ORAL	5 MG BID	ORAL
			Valoron N	C				
			Zoladex Injectable Solution	C				

Date:01/21/03ISR Number: 4047327-3Report Type:Expedited (15-DaCompany Report #IMM022623
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Foreign	Enbrel	PS			SUBCUTANEOUS	25 MG, TWICE
Initial or Prolonged	Asthenia	Health					WEEKLY, SC	
	Drug Ineffective	Professional	Celecoxib	SS				
	Hypotonia	Company	Rofecoxib	SS		ORAL	25 MG, DAILY,	
	Malaise	Representative					PO	
	Mental Impairment		Topiramate	SS		ORAL	SEE IMAGE	
	Muscle Contractions		Topiramate	SS		ORAL	50 MG, TWICE	
	Involuntary						A DAY, PO	
	Petit Mal Epilepsy		Prednisone	C				
	Sedation		Corticosteroid Nos	C				
	Sleep Disorder		Lynestrenol	C				
	Somnolence							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/03ISR Number: 4044655-2Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00055
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Gastric Ulcer		Acenocoumarol	SS		ORAL		
	Gastritis		Diclofenac Sodium	SS		ORAL		10 DAY
	Melaena		Gliclazide	C		ORAL		
	Prothrombin Time		Captopril	C		ORAL		
	Prolonged		Amlodipine	C		ORAL		
	Varices Oesophageal		Bisoprolol Fumarate	C		ORAL		
			Lorazepam	C		ORAL		
			Nitroglycerin	C		TOPICAL		

Date:01/22/03ISR Number: 4044659-XReport Type:Expedited (15-DaCompany Report #WAES 0212GBR00157
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
	Perforation		Dexamethasone	SS		ORAL		4 DAY
	General Physical Health		Lansoprazole	C		ORAL		
	Deterioration		Digoxin	C		ORAL		
			Warfarin	C		ORAL		
			Paroxetine	C		ORAL		
			Propranolol	C		ORAL		
			Oxycodone	C		ORAL		
			Heparinoid And Salicylic Acid	C		TOPICAL		8 DAY
			Gabapentin	C		ORAL		6 DAY
			[Therapy Unspecified]	C				

Date:01/22/03ISR Number: 4044661-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA00080
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Level Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Epilepsy		Dilantin	SS				
			Lamictal	C				
			Estrogens (Unspecified)	C				

Date:01/22/03ISR Number: 4044665-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:01/22/03ISR Number: 4044666-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01097
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:01/22/03ISR Number: 4044670-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4044671-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4044672-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4044673-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA01096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4044674-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4044675-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/22/03ISR Number: 4045023-XReport Type:Direct Company Report #CTU 185067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx 25mg	PS			ONCE DAILY BY MOUTH	
	Gastrointestinal Haemorrhage		Prednisone 5mg	SS			TWICE DAILY BY MOUTH	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/03ISR Number: 4045061-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Blood Potassium Decreased		Vioxx	SS		ORAL		33 DAY
Disability	Cartilage Injury		Vioxx	SS		ORAL		36 DAY
	Cerebral Artery		Vioxx	SS		ORAL		312 DAY
	Thrombosis		Tricor	C		ORAL		
	Diverticulum Intestinal		Vicodin Es Tablets	C		ORAL		
	Haematocrit Decreased		Paxil	C		ORAL		
	Haemoglobin Decreased		Restoril	C		ORAL		
	Mitral Valve Incompetence		Aspirin	C		ORAL		
	Muscle Atrophy		Estrogens (Unspecified)	C				
	Pain In Extremity		Premarin	C				
	Phlebothrombosis		Vitamins (Unspecified)	C				
	Thrombotic Stroke		Zantac	C				
	Tricuspid Valve Incompetence		Vistaril	C				

Date:01/23/03ISR Number: 4045063-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00515
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Deep Vein Thrombosis	Professional	Vioxx	SS		ORAL		11 MON
	Hepatic Steatosis		Vitamins (Unspecified)	C				
	Joint Sprain		Synthroid	C		ORAL		
	Osteoarthritis		Lamisil	C				
	Plantar Fasciitis		Chondroitin And Glucosamine	C		ORAL		
	Pulmonary Granuloma		Celebrex	C		ORAL		3 DAY
	Renal Cyst							

Date:01/23/03ISR Number: 4045064-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/23/03ISR Number: 4045065-4Report Type:Expedited (15-DaCompany Report #WAES 0211USA01790
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Constipation Heart Rate Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Naprosyn	C				
			Zyrtec	C				
			Wellbutrin	C				
			Toprol Xl Tablets	C				
			Mavik	C				

Date:01/23/03ISR Number: 4045069-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01679
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Plavix	C				
			Flomax (Morniflumate)	C				

Date:01/23/03ISR Number: 4045268-9Report Type:Expedited (15-DaCompany Report #WAES 0211BEL00014
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Ascites		Althiazide And Spironolactone	SS		ORAL		
	Blood Potassium Increased		Bisoprolol	SS		ORAL		
	Blood Pressure Systolic Increased		Aspirin	C		ORAL		
	Cardiac Failure Congestive							
	Cardiomegaly							
	Chest X-Ray Abnormal							
	Drug Interaction							
	Left Ventricular Failure							
	Pleural Effusion							
	Renal Impairment							
	Sinus Tachycardia							

Date:01/23/03ISR Number: 4045271-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01771
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Bladder Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/23/03ISR Number: 4045278-1Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00119
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Warfarin	C				

Date:01/23/03ISR Number: 4045279-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01306
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Increased		[Therapy					
	Blood Urea Increased		Unspecified]	SS				
	Cerebrovascular Accident		Imdur	C				
	Hypertension		Aceon	C				
			Lipitor	C				
			Prilosec	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/03ISR Number: 4045284-7Report Type:Expedited (15-DaCompany Report #WAES 0301FIN00004
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Urticaria		Rofecoxib	PS	Merck & Co., Inc	ORAL		184 DAY
			Proscar	C		ORAL		
			Diclofenac Sodium	C				

Date:01/23/03ISR Number: 4046249-1Report Type:Expedited (15-DaCompany Report #2003-DE-00117GL (0)
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemolytic Anaemia	Foreign Other	Telmisartan (Bibr 277) (Ta) (Telmisartan)	PS		ORAL	20 MG PO	
			Rofecoxib (Antiinflammatory/Antirheumatic Products) (Nr)	SS		ORAL	25 MG PO	
			Potassium Chloride (Potassium Chloride) (Ka)	SS		ORAL	600 MG PO	
			Frusemide (Furosemide) (Ta)	SS		ORAL	20 MG PO	
			Saw Palmetto (Serenoa Repens) (Ka)	SS		ORAL	160 MG PO	
			Tamsulosin (Tamsulosin) (Ka) (Tamsulosin Hydrochloride)	SS		ORAL	40 MCG PO	

Date:01/23/03ISR Number: 4046457-XReport Type:Expedited (15-DaCompany Report #A02200300037
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG OD	
			(Digoxin) - Tablet - 0.25 Mg	SS		ORAL	0.25 MG OD	13 YR
			Corvasal - (Molsidomine) - Tablet - 2 Mg	SS		ORAL	2 MG TID	
			Vioxx - (Rofecoxib) - Tablet - 25 Mg	SS		ORAL	25 MG OD	
			Nitoman - (Tetrabenazine) - Unknown - 25 Mg	SS		ORAL	DAILY DOSE PROGRESSIVELY INCREASED FROM 25 TO 100 MG	17 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/03ISR Number: 4045790-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01673
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Operative Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/03ISR Number: 4045850-9Report Type:Direct Company Report #CTU 185173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD	
							ORAL	

Date:01/24/03ISR Number: 4046048-0Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00158
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatic Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
			Ramipril	C				
			Nifedipine	C				
			Hydrodiuril	C				

Date:01/24/03ISR Number: 4046052-2Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00006
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Liver Function Test Abnormal		Acetaminophen And Codeine Phosphate	C				

Date:01/24/03ISR Number: 4046053-4Report Type:Expedited (15-DaCompany Report #WAES 0301SWE00006
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer		Warfarin Sodium	SS		ORAL
	Haemorrhage		Warfarin Sodium	SS		ORAL
	Prothrombin Level		Carvedilol	C		
	Decreased		Digoxin	C		
			Furosemide	C		
			Insulin, Biphasic			
			Isophane [Injection]	C		

Date:01/24/03ISR Number: 4046054-6Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00057
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Initial or Prolonged	Dyspnoea		Fluindione	SS		ORAL
	Gastric Haemorrhage		Omeprazole	C		ORAL
	Gastritis Erosive		Levothyroxine Sodium	C		ORAL
	International Normalised		Furosemide	C		ORAL
	Ratio Increased		Potassium			
			(Unspecified)	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/03ISR Number: 4046058-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02041
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion Myocardial Infarction		Vioxx Lipitor Atenolol	PS C C	Merck & Co., Inc	ORAL		

Date:01/24/03ISR Number: 4047641-1Report Type:Expedited (15-DaCompany Report #A02200300054
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Blood Fibrinogen Increased Blood Pressure Decreased Cyanosis	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG OD	
	Depressed Level Of Consciousness Erysipelas Febrile Neutropenia		Fonzylane - (Buflomedil Hydrochloride) - Tablet	SS		ORAL	2 UNIT	
	Fibrin Degradation Products Increased Haemoglobin Decreased		Cozaar - (Losartan Potassium) - Tablet - 50 Mg	SS		ORAL	50 MG OD	
	Idiopathic Thrombocytopenic Purpura Livedo Reticularis		Vastarel - (Trimetazidine) - Tablet - 20mg	SS		ORAL	60 MG	
	Renal Failure Streptococcal Bacteraemia		Vioxx - (Rofecoxib) - Tablet	SS		ORAL	2 UNIT	
	White Blood Cell Count Decreased							

Date:01/27/03ISR Number: 4047121-3Report Type:Expedited (15-DaCompany Report #WAES 0211USA02289
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebrovascular Accident Difficulty In Walking Pain In Extremity	Consumer	Vioxx Insulin	PS C	Merck & Co., Inc	ORAL

Date:01/27/03ISR Number: 4047125-0Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00159
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Pulmonary Oedema Upper Respiratory Tract Infection	Health Professional	Vioxx Vioxx	PS SS	Merck & Co., Inc	ORAL ORAL

Date:01/27/03ISR Number: 4047128-6Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00081
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening 4 DAY	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Shock		Aspirin Captopril Atenolol Nitrendipine	C C C C		ORAL ORAL ORAL ORAL

			Levothyroxine Sodium	C		ORAL
			Atorvastatin	C		ORAL

Date:01/27/03ISR Number: 4047129-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01866
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Lotrel	C		
	Hypertension					

Date:01/27/03ISR Number: 4047130-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA01021
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/27/03ISR Number: 4047352-2Report Type:Direct Company Report #CTU-185311
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Discomfort		Vioxx ? Merck	PS	Merck	ORAL
DAILY ORAL						
Initial or Prolonged	Haematochezia					
	Hypotension					

Date:01/27/03ISR Number: 4047422-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01512
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastrointestinal		Aspirin	C		
Initial or Prolonged	Haemorrhage					
Disability	Oesophagitis					

Date:01/27/03ISR Number: 4047425-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/03ISR Number: 4047429-1Report Type:Expedited (15-DaCompany Report #WAES 0301GRC00007
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Palmar Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Plantar Erythema							
	Pruritus							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/03ISR Number: 4047430-8Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00100
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haematemesis Haemoglobin Decreased Melaena		Vioxx Clopidogrel Bisulfate	PS SS	Merck & Co., Inc	ORAL ORAL		

Date:01/27/03ISR Number: 4048566-8Report Type:Expedited (15-DaCompany Report #WAES 0207AUT00013
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Other		Health Professional	Vasotec	C			PO	381 DAY
			Zocor	C				
			Acetaminophen	C				
			Aspirin	C				

Date:01/28/03ISR Number: 4048030-6Report Type:Direct Company Report #CTU 185360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx 25 Mg	PS		ORAL	1 QD PO 25 MG ORAL	

Date:01/28/03ISR Number: 4048035-5Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00153
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	
83 DAY							
	Retinal Haemorrhage						

Date:01/28/03ISR Number: 4048037-9Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00170
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations		Hyzaar	C				
	Photopsia		Atenolol	C				

Date:01/28/03ISR Number: 4048038-0Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00152
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
49 DAY								
Initial or Prolonged	Haemorrhage							

Date:01/28/03ISR Number: 4048042-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA00441
Age:43 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faecal Occult Blood		Ultracet	SS		ORAL		
	Positive		Albuterol	C		ORAL		
	Gastritis							
	Helicobacter Infection							
	Hypotension							
	Peptic Ulcer							
	Sinus Tachycardia							
	Syncope							
	Upper Gastrointestinal Haemorrhage							

Date:01/28/03ISR Number: 4048043-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder							

Date:01/28/03ISR Number: 4048047-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA02252
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Face Oedema		Zoloft	C				
	Rash Pruritic		Ativan	C				
			Inderal La	C				
			Synthroid	C				
			Midrin	C				

Date:01/28/03ISR Number: 4048159-2Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00180
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pregnancy Test Negative	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048161-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA02075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048162-2Report Type:Expedited (15-DaCompany Report #WAES 0301CAN00170
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Other	Blindness Transient Blindness Unilateral Cerebrovascular Accident Heart Rate Increased

	Photopsia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Hyzaar	C				
			Atenolol	C				

Date:01/28/03ISR Number: 4048167-1Report Type:Expedited (15-DaCompany Report #WAES 0211USA00821
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Raynaud'S Phenomenon	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Skin Discolouration	Professional	Lipitor	C				
			Aspirin	C				

Date:01/28/03ISR Number: 4048170-1Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00011
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bicarbonate	Health	Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Hospitalization -	Abnormal	Professional	Candesartan					
Initial or Prolonged	Blood Ph Increased		Cilexetil	SS		ORAL		
	Drug Interaction		Fosamax	C		ORAL		
	Haemodialysis		Goserelin Acetate	C		SUBCUTANEOUS		
	Haemoglobin Abnormal		Cyproterone Acetate	C		ORAL		
	Nausea		Metoprolol	C		ORAL		
	Pco2 Abnormal							
	Pruritus							
	Renal Failure Acute							

Date:01/28/03ISR Number: 4048171-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Decreased Activity
Renal Failure

Date:01/28/03ISR Number: 4048172-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA02076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048173-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA02073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/03ISR Number: 4048175-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA02080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048176-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA02078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048177-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048178-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02079
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/03ISR Number: 4048182-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA02179
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Abnormal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Vioxx	SS		ORAL		
	Myocardial Infarction							
	Renal Disorder							

Date:01/28/03ISR Number: 4049021-1Report Type:Expedited (15-DaCompany Report #WAES 01015246
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis	Foreign	Tab Vioxx					
	Haematemesis	Other	(Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Cap Orlistat	SS		ORAL	360 MG/DAILY	PO 302 DAY
			Aspirin	SS				
			Prinivil	C				
			Zocor	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				

Bisoprolol Fumarate	C
Carisoprodol	C
Chlorpheniramine Maleate	C
Citalopram	C
Furosemide	C
Nicardipine Hcl	C
Nitrazepam	C
Nitroglycerin	C

Date:01/28/03ISR Number: 4049022-3Report Type:Expedited (15-DaCompany Report #WAES 01015246
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Haematemesis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO
			Cap Orlistat	SS		ORAL	360 MG/DAILY	PO 302 DAY
			Aspirin	SS				
			Prinivil	C				
			Zocor	C				
			Aluminum Hydroxide/Magnesium Carbonate	C				
			Bisoprolol Fumarate	C				
			Carisoprodol	C				
			Chlorpheniramine Maleate	C				
			Citalopram	C				
			Furosemide	C				
			Nicardipine Hcl	C				
			Nitrazepam	C				
			Nitroglycerin	C				

Date:01/28/03ISR Number: 4049224-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Agonal Death Struggle
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Abnormal
	Ammonia Abnormal
	Blood Alkaline Phosphatase Abnormal
	Blood Creatinine Increased
	Blood Glucose Abnormal
	Blood Potassium Decreased
	Blood Pressure Decreased
	Blood Urea Increased
	Body Temperature Decreased
	Bradycardia
	Chromaturia
	Cold Sweat
	Crystal Urine Present
	Depressed Level Of Consciousness

		Feeling Cold					
		Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension	Consumer	Tab Vioxx Unk	PS		ORAL
PO							
		Injury	Health	Colace	C		
		Mutism	Professional	Haldol	C		
		Oxygen Saturation		Aspirin	C		
		Decreased		Ferrous Sulfate	C		
		Pallor		Nitroglycerin	C		
		Physical Examination		Sorbitol	C		
		Abnormal		Trazodone	C		
		Pulse Abnormal		Valproic Acid	C		
		Red Blood Cell Count Abnormal					
		Respiration Abnormal					
		Respiratory Rate Increased					
		Somnolence					
		Specific Gravity Urine Abnormal					
		Urine Abnormality					
		Urine Ketone Body Present					
		Urobilin Urine Present					

Date:01/28/03ISR Number: 4049227-1Report Type:Expedited (15-DaCompany Report #WAES 0211BEL00014
Age:80 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Anaemia	Foreign	Tab Vioxx			
		Blood Potassium Increased	Literature	(Rofecoxib)	PS		ORAL
25 MG/DAILY	15 DAY						
		Blood Pressure Systolic	Health	Tab Bisoprolol	SS		ORAL
5 MG/DAILY							
		Increased	Professional	Tab			
		Blood Sodium Decreased		Althiazide/Spironola			
		Cardiac Failure		ctone	SS		ORAL
15+25							
		Congestive					
MG/DAILY							
		Dehydration		Aspirin	C		
		Drug Interaction					
		Hypoventilation					

Renal Impairment
Sinus Tachycardia

Date:01/28/03ISR Number: 4049523-8Report Type:Expedited (15-DaCompany Report #WAES 0211BEL00014
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anaemia
	Ascites
	Blood Creatinine Increased
	Blood Potassium Increased
	Blood Pressure Systolic Increased
	Blood Sodium Decreased
	Blood Urea Decreased
	Cardiac Failure Congestive
	Cardiomegaly
	Creatinine Renal

	Clearance Decreased						
	Dehydration						
	Drug Interaction						
	Ejection Fraction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased	Foreign	Tab Vioxx				
	Fluid Retention	Literature	(Rofecoxib)	PS		ORAL	25 MG/DAILY 15 DAY
	Hypoventilation	Health	Tab Bisoprolol	SS		ORAL	5 MG/DAILY
	Pleural Effusion	Professional	Tab				
	Renal Impairment		Althiazide/Spironola				
	Sinus Tachycardia		ctone	SS		ORAL	15+25 MG/DAILY
			Aspirin	C			

Date:01/28/03ISR Number: 4049633-5Report Type:Expedited (15-DaCompany Report #WAES 01072467
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acute Myocardial	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/ORAL
	Infarction	Health					
	Arrhythmia	Professional	Ibuprofen	C			
	Cardiomegaly						
	Coma						
	Coronary Artery						
	Atherosclerosis						
	Gastritis Haemorrhagic						
	Glomerulosclerosis						
	Hepatic Congestion						
	Hepatic Steatosis						
	Myocardial Fibrosis						
	Palpitations						
	Pulmonary Congestion						
	Pulmonary Oedema						
	Respiratory Arrest						
	Respiratory Tract						
	Congestion						
	Rib Fracture						
	Scar						
	Sudden Death						

Ventricular Fibrillation

Date:01/28/03ISR Number: 4049645-1Report Type:Expedited (15-DaCompany Report #WAES 010600076
Age:53 YR Gender:Male I/FU:F

Outcome PT
Other Antinuclear Antibody
Positive
Anxiety
Auricular Swelling
Burning Sensation
Cardiac Disorder
Dermatitis
Drug Eruption
Drug Hypersensitivity
Eczema
Epidermal Naevus
Epistaxis
Erythema
Excoriation
Hypersensitivity
Lung Disorder

		Nasal Oedema					
		Nervous System Disorder					
		Neurodermatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neutrophil Count	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO							
		Increased	Health	Tab Vioxx 12.5 Mg	SS		ORAL
12.5							
		Otitis Externa	Professional				
MG/DAILY/PO							
		Pain		Celebrex 200 Mg	SS		
200 MG/DAILY							
		Rash		Anafranil	C		
		Rash Erythematous		Lidex	C		
		Rash Macular					
		Rash Pruritic					
		Rash Scaly					
		Scab					
		Scar					
		Skin Necrosis					
		Skin Papilloma					
		Skin Ulcer					
		Sleep Disorder					
		Staphylococcal Infection					
		Urticaria Papular					

Date:01/29/03ISR Number: 4048744-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA01277
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Balance Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cough	Professional	Vioxx	SS		ORAL
		Cyst		Synthroid	C		
		Deafness Unilateral		Trazodone	C		
		Disease Recurrence		Prevacid	C		
		Dizziness		Rhinocort	C		
		Dysphonia					
		Ear Discomfort					
		Fall					
		Head Injury					
		Inflammation					
		Nasal Polyps					
		Pharyngeal Polyp					
		Sensation Of Foreign Body					

Sinus Disorder
Throat Irritation
Tinnitus

Date:01/29/03ISR Number: 4048745-XReport Type:Expedited (15-DaCompany Report #WAES 0211CAN00200
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	International Normalised	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Ratio Decreased	Professional	Vioxx	SS		ORAL	21	DAY
			Warfarin Sodium	C				
			Elavil	C		ORAL		
			Bupivacaine	C				
			Triamcinolone Acetonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/03ISR Number: 4048746-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Altace	C		ORAL		
			Plavix	C		ORAL		
	Blood Homocysteine Increased		Aspirin	C		ORAL		
			Nitroglycerin	C		TOPICAL		
	Coronary Artery Atherosclerosis		Prevacid	C		ORAL		
			Zocor	C		ORAL		
	Gastritis							
	Myocardial Infarction							
	Syncope							

Date:01/29/03ISR Number: 4048747-3Report Type:Expedited (15-DaCompany Report #WAES 0301AUS00094
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc			

Date:01/29/03ISR Number: 4048749-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA02085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Activity							
	Renal Failure							

Date:01/29/03ISR Number: 4048751-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA02077
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Activity							
	Renal Failure							

Date:01/29/03ISR Number: 4048753-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA02084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/03ISR Number: 4048858-2Report Type:Direct Company Report #CTU 185470
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lichen Planus	Foreign	Rofecoxib	PS	Merck & Co	ORAL	25 MG QD PO	
			Methotrexate	C				
			Prednisone	C				
			Vitamin D	C				
			Calcium Carbonate	C				
			Folic Acid	C				
			Omeprazole	C				
			Acetaminophen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/03ISR Number: 4048974-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anoxia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Lipitor	SS		ORAL
366 DAY						
Disability	Arthralgia		Zemplar	SS		
Other	Atherosclerosis		[Therapy			
	Back Pain		Unspecified]	SS		
	Biliary Neoplasm		Imuran			
	Cardiac Failure		(Azathioprine)	C		ORAL
	Congestive		Prednisone	C		ORAL
	Complications Of		Lasix (Furosemide)	C		ORAL
	Transplant Surgery		Sandimmun	C		ORAL
	Congestive Cardiomyopathy		Clonidine			
	Dialysis		Hydrochloride	C		ORAL
	Diarrhoea		Calcium			
	Dilatation Atrial		(Unspecified) And			
	Drug Hypersensitivity		Vitamin D			
	Drug Interaction		(Unspecified)	C		
	Drug Tolerance Decreased		Iron Dextran	C		
	Electrocardiogram Q Wave		Epoetin	C		
	Abnormal		Cyclosporine	C		
	Epistaxis		Paricalcitol	C		
INTRAVENOUS						
	Erythema Multiforme		Zaroxolyn	C		ORAL
	Hyperkalaemia		Ultralente Insulin	C		
PARENTERAL						
	Hypertension		Toprol Xl Tablets	C		ORAL
	Infection		Viagra	C		ORAL
	Inflammation		Humulin	C		
PARENTERAL						
	Injury		Clonazepam	C		
	Kidney Transplant		Norvasc	C		ORAL
	Rejection		Zebeta	C		ORAL
	Mitral Valve Incompetence		Flexeril	C		ORAL
	Muscle Disorder		Vitamin B Complex	C		ORAL
	Myalgia		Celebrex	C		
	Myocardial Infarction					
	Nasal Septum Disorder					
	Pericardial Effusion					
	Pericarditis Uraemic					
	Pleural Effusion					
	Procedural Complication					
	Pulmonary Hypertension					

Pulmonary Oedema
Raynaud'S Phenomenon
Renal Failure
Renal Failure Chronic
Renal Transplant
Sinus Tachycardia
Sinusitis
Swelling
Tricuspid Valve
Incompetence
Vascular Calcification
Weight Decreased

Date:01/29/03ISR Number: 4048976-9Report Type:Expedited (15-DaCompany Report #WAES 0210PHL00002
Age: Gender:Female I/FU:F

Outcome PT
Other Alanine Aminotransferase
Increased

		Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Albumin Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Alkaline Phosphatase Increased		Omeprazole Magnesium	SS		

Date:01/29/03ISR Number: 4048982-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02082
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/29/03ISR Number: 4048983-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02083
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/29/03ISR Number: 4048984-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA02072
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder Decreased Activity Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/29/03ISR Number: 4049862-0Report Type:Expedited (15-DaCompany Report #HQ6077609JAN2003
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Decreased	Health	Cordarone					
Hospitalization -	Coma Hepatic	Professional	(Amiodarone,					
Initial or Prolonged	Drug Toxicity	Other	Tablets)	PS		ORAL	200 MG 1X PER	
	Dyspnoea							
							1 DAY	4 MON
	Haemodialysis		Sintrom					
	Hepatic Cirrhosis		(Acenocoumarol)	SS		ORAL		
							4 MON	
	Hepatitis Fulminant		Vioxx (Rofecoxib,					
	Hypoglycaemia		Tablet)	SS		ORAL	50 MG 1X PER	
	Renal Failure Chronic							
							1 DAY	4 MON
	Weight Increased		Lasix (Furosemide)	C				
			Aldactone (Spironolactone)	C				
			Tramal (Tramadol Hydrochloride)	C				
			Benerva (Thiamine Hydrochloride)	C				
			Becozym (Vitamin B Nos)	C				
			Kalium (Potassium Chloride)	C				
			Duphalac (Lactulose)	C				
			Temesta (Lorazepam)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/03ISR Number: 4049423-3Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00082
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Agitation		Hydroquinidine Hydrochloride	C		ORAL		250 DAY
			Piracetam	C		ORAL		

Date:01/30/03ISR Number: 4049428-2Report Type:Expedited (15-DaCompany Report #WAES 0301ITA00030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged								

Date:01/30/03ISR Number: 4049479-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA01476
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Appendicitis		Vioxx	PS	Merck & Co., Inc	ORAL		30 MON
Initial or Prolonged	Ileus Paralytic		Aspirin	C				
	Intestinal Gangrene		Mobic	C				

Date:01/30/03ISR Number: 4049482-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA00271
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS		ORAL		
Other	Diverticulum		Hydroxyzine	C				
	Duodenal Ulcer		Lasix (Furosemide)	C		ORAL		
	Dyspnoea		Glyburide	C		ORAL		

	Melaena		Darvocet-N	C		
	Nausea		Diazepam	C		
			Cardene	C		
			Zestril	C		ORAL
			Detrol	C		ORAL
			Atarax	C		

Date:01/30/03ISR Number: 4049485-3Report Type:Expedited (15-DaCompany Report #WAES 0211USA02393
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		384 DAY
Hospitalization - Initial or Prolonged	Carotid Artery Stenosis		Seroquel	C		ORAL		
	Coma		Remeron	C		ORAL		
Other	Diarrhoea		Prevacid	C				
	Fall		Docusate Sodium	C				
	Gastrointestinal		Ferro-Sequels	C		ORAL		
	Haemorrhage		Neurontin	C		ORAL		
	Hyperkalaemia		Os-Cal	C				
	Hypertension		Sinemet	C		ORAL		
	Transient Ischaemic		Combivent	C				
RESPIRATORY								
	Attack							
(INHALATION)								
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/03ISR Number: 4049489-0Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00095
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	50MG DAILY X 3D ORAL	3 DAY
			Fenofibrate	C		ORAL		

Date:01/30/03ISR Number: 4049490-7Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00013
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	25MG DAILY ORAL	29 DAY
			Benserazide Hydrochloride And Levodopa	C		ORAL		
			Paraffin	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		
			Sennosides	C		ORAL		
			Acetaminophen	C		ORAL		
			Zopiclone	C		ORAL		

Date:01/30/03ISR Number: 4049571-8Report Type:Direct Company Report #CTU 185591
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Weight Increased		Vioxx 25 Mg	PS		ORAL	50MG DAILY X 3D ORAL	
			Vioxx 25mg	SS		ORAL	25MG DAILY ORAL	
			Vicodin	C				

Date:01/31/03ISR Number: 4049636-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA02688
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/03ISR Number: 4049642-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA00430
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Malaise		Toprol Xl Tablets	C				
			Cozaar	C		ORAL		

Date:01/31/03ISR Number: 4049643-8Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00039
Age:96 YR Gender:Female I/FU:F

Outcome	PT
Death	Depressed Level Of Consciousness
Hospitalization - Initial or Prolonged	Erysipelas
	Neutropenia
	Renal Failure

		Septic Shock Streptococcal Sepsis Thrombocytopenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Cozaar	SS		ORAL
				Clopidogrel Bisulfate	C		ORAL
				Buflomedil Hydrochloride	C		ORAL
				Trimetazidine Hydrochloride	C		

Date:01/31/03ISR Number: 4049974-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Agitation Neonatal Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Gestational Diabetes Maternal Drugs Affecting Foetus Pre-Eclampsia Pregnancy Sinusitis		Vioxx	PS	Merck & Co., Inc	
				Sertraline	SS		

Date:01/31/03ISR Number: 4049975-3Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00044
Age:32 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Hepatitis Fulminant					

Date:01/31/03ISR Number: 4049976-5Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Exposure During Pregnancy		Sertraline	SS				
	Gestational Diabetes							
	Maternal Drugs Affecting Foetus							
	Pre-Eclampsia							
	Pregnancy							
	Sinusitis							
	Streptococcal Infection							

Date:01/31/03ISR Number: 4049988-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA02007
Age:46 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Glomerulonephritis Minimal Lesion

Nephritis Interstitial
Nephrotic Syndrome

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/03ISR Number: 4049992-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02612
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
			Plavix	C				

Date:01/31/03ISR Number: 4049993-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA02793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:01/31/03ISR Number: 4050126-XReport Type:Direct Company Report #CTU 185734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx 25mg Merckk	PS	Merckk	ORAL	25MG QD ORAL	
Hospitalization -	Haematemesis		Aspirin 325mg	SS		ORAL	325MG QD ORAL	
Initial or Prolonged	Haematochezia		Multivitamin	C				
			Hctz	C				
			Vitamin C	C				
			Tylenol	C				
			Zoloft	C				
			Synthroid	C				
			Vasotec	C				
			Ferrous Sulfate	C				
			Alphagan	C				

Risperdal	C
Colace	C
Seroquel	C

Date:01/31/03ISR Number: 4050163-5Report Type:Direct Company Report #CTU 185721
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - ORAL Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Renal Failure Acute		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/03ISR Number: 4051184-9Report Type:Expedited (15-DaCompany Report #N134750
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression Cerebral Atrophy Disorientation Drug Ineffective Gastrointestinal Haemorrhage Leukopenia Myocardial Infarction Pharyngolaryngeal Pain Platelet Count Decreased Sinus Disorder	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	300 MG ONCE THEN 75 MG/D	2 DAY
			Asa (Acetylsalicyclic Acid) Unit Dose	SS		ORAL	325 MG	
			Methylprednisolone	SS			250 MG	2 DAY
			Vioxx (Rofecoxib)	SS		ORAL	25 MG	1 DAY
			Serumlipidereducing Agents Unit Dose	SS				
			Heparin	C				
			Zantac (Ranitidine Hydrochloride)	C				
			Vitamin E	C				
			Levofloxacin	C				
			Haldol (Haloperidol)	C				
			Terazosin	C				
			Diphenhydramine	C				
			Metoprolol	C				

Date:01/31/03ISR Number: 4051659-2Report Type:Expedited (15-DaCompany Report #104279
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Abdomen Anaemia Cardiac Failure Congestive	Foreign Study Other	Herceptin	PS		INTRAVENOUS	4 MG/KG ONCE IV	1 DAY
			Herceptin	SS		INTRAVENOUS	115 MG 1/WK IV	

		Catheter Related	Docetaxel	SS
INTRAVENOUS	120 MG Q3W IV			
		Complication	Carboplatin	SS
INTRAVENOUS	635 MG Q3W IV			
		Dialysis	Rofecoxib	SS
		Escherichia Urinary Tract	Piperacillin Sodium	SS
		Infection	Docetaxel	SS
		Febrile Neutropenia	Dexamethasone	C
		Oesophagitis	Ondansetron	C
		Platelet Count Decreased	Fluoxetine	C
		Renal Failure Acute	Ranitidine	C
		Sepsis	Bisoprolol	C
			Cimetidine	C
			Otilonium	C

Date:02/03/03ISR Number: 4050237-9Report Type:Expedited (15-DaCompany Report #WAES 0301GRC00009
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Potassium Increased	Professional	Perindopril	C		ORAL
	Cardiac Murmur		Hydrodiuril	C		ORAL
	Gallop Rhythm Present		Zocor	C		ORAL
	Haematocrit Decreased		Aspirin	C		ORAL
	Haemoglobin Decreased		Nitroglycerin	C		
	Protein Urine Present		Tamsulosin			
	Renal Failure Acute		Hydrochloride	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/03ISR Number: 4050461-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00193
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arrhythmia		Aspirin	C				
	Arthralgia		Tylenol	C				
	Bradycardia							
	Cardiac Murmur							
	Cardio-Respiratory Arrest							
	Clonic Convulsion							
	Cough							
	Cyanosis							
	Drug Effect Decreased							
	Dyspnoea							
	Hypertension							
	Joint Stiffness							
	Joint Swelling							
	Livedo Reticularis							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Sudden Death							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:02/03/03ISR Number: 4050462-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01181
Age:94 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bleeding Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Platelet Count Decreased		Zantac	SS				
Initial or Prolonged	Rectal Haemorrhage							

Date:02/03/03ISR Number: 4050465-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA02277
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Disorder							

Date:02/03/03ISR Number: 4050467-6Report Type:Expedited (15-DaCompany Report #WAES 0212USA00164
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Irritation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eye Pruritus		Prevacid	C				
	Labyrinthitis		[Therapy Unspecified]	C				
	Lacrimation Increased		Cardizem Cd	C				
	Upper Respiratory Tract Infection		Levoxyl	C				
			Advair	C				
			Ativan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/03ISR Number: 4050844-3Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00167
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL		
	Paraesthesia		Omeprazole Magnesium	C				

Date:02/04/03ISR Number: 4050847-9Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00062
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Oedema Peripheral		Tramadol	C		ORAL	299	DAY
	Pulmonary Oedema		Calcium Carbonate And Cholecalciferol	C		ORAL		
	Tinnitus		Atenolol	C		ORAL		
			Lansoprazole	C		ORAL		

Date:02/04/03ISR Number: 4050853-4Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00191
Age:60 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diuretic (Unspecified)	C				

Date:02/04/03ISR Number: 4051041-8Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00118
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Nausea	Professional	Tramadol Hydrochloride	SS		ORAL	6	DAY
	Vertigo							

			Tetrazepam	SS		ORAL
6 DAY						

Date:02/04/03ISR Number: 4051045-5Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Agitation Neonatal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
80 DAY						
	Apgar Score Low	Professional	Sertraline	SS		
	Caesarean Section					
	Complications Of Maternal					
	Exposure To Therapeutic					
	Drugs					
	Gestational Diabetes					
	Maternal Drugs Affecting					
	Foetus					
	Pre-Eclampsia					
	Pregnancy					
	Sinusitis					
	Streptococcal Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/03ISR Number: 4051048-0Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation Neonatal	Health	Vioxx	PS	Merck & Co., Inc			80 DAY
Initial or Prolonged	Apgar Score Low	Professional	Sertraline	SS				
	Caesarean Section							
	Complications Of Maternal							
	Exposure To Therapeutic Drugs							
	Gestational Diabetes							
	Maternal Drugs Affecting Foetus							
	Pre-Eclampsia							
	Pregnancy							
	Sinusitis							
	Streptococcal Infection							

Date:02/04/03ISR Number: 4051052-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA02998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ulcer	Health Professional	Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
Life-Threatening				C				
Hospitalization - Initial or Prolonged								
Disability								

Date:02/04/03ISR Number: 4051053-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02586
Age:7 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Antineoplastic (Unspecified)	C				
			Carbohydrates (Unspecified) And Electrolytes (Unspecified) And					

			Amino Acids	C		
			Atovaquone	C		

Date:02/04/03ISR Number: 4051056-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA02875
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Breast Mass	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Prednisone	C		

Date:02/04/03ISR Number: 4051057-1Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00206
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Atenolol	C		ORAL
			Irbesartan	C		ORAL
			Furosemide	C		ORAL
			Nifedipine	C		ORAL

				Doxazosin	C		ORAL

Date:02/04/03ISR Number: 4051060-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA02794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/04/03ISR Number: 4052927-0Report Type:Expedited (15-DaCompany Report #M1337-2002F/U
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Dexamethasone	PS		ORAL	6 MG, ORAL	4 DAY
	Perforation		Rofecoxib	SS		ORAL	50 MG, ORAL	1 WK
			Lansoprazole	C				
			Digoxin	C				
			Warfarin	C				
			Paroxetine	C				
			Propranolol	C				
			Oxycodone	C				
			Movelat	C				
			Gabapentin	C				

Date:02/04/03ISR Number: 4054313-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriovenous Fistula	Consumer	Tab Vioxx 10 Mg	PS		ORAL	PO	
Initial or Prolonged	Arthralgia	Health	Lipitor 10 Mg	SS		ORAL	10	
Disability	Biliary Neoplasm	Professional					MG/DAILY/PO	
Other	Calcinosis		Zemplar	C				
	Cardiac Failure		Celebrex	C				

Congestive	Flexeril	C
Chest Pain	Humulin	C
Coronary Artery Disease	Imuran	
Dialysis	(Azathioprine)	C
Drug Interaction	Lasix (Furosemide)	C
Epistaxis	Norvasc	C
Graft Dysfunction	Sandimmun	C
Haemorrhage Subcutaneous	Toprol Xl Tablets	C
Injury	Ultralente Insulin	C
Kidney Transplant	Viagra	C
Rejection	Zaroxolyn	C
Mitral Valve Incompetence	Zebeta	C
Monoparesis	Calcium (+) Vitami	C
Myalgia	Clonazepam	C
Pericarditis Uraemic	Clonidine	
Pulmonary Hypertension	Hydrochloride	C
Rash	Cyclosporine	C
Renal Failure	Epoetin	C
Sinusitis	Iron Dextran	C
Skin Fissures	Paricalcitol	C
Ventricular Hypokinesia	Prednisone	C
	Vitamin B Complex	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/03ISR Number: 4051253-3Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00013
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State		Zopiclone	C		ORAL		
	Fall		Benserazide Hydrochloride And Levodopa	C		ORAL		
	Logorrhoea		Benserazide Hydrochloride And Levodopa	C		ORAL	1	DAY
			Omeprazole	C		ORAL		
			Paroxetine	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Lisinopril	C		ORAL		
			Flecainide Acetate	C		ORAL		
			Aspirin Lysine	C		ORAL		

Date:02/05/03ISR Number: 4051259-4Report Type:Expedited (15-DaCompany Report #WAES 0206AUS00180
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Follicle Stimulating Hormone Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infertility Female							
	Multiple Pregnancy							

Date:02/05/03ISR Number: 4051261-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02502
Age:20 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Nortriptyline	SS				
			Septra	SS		ORAL		

Date:02/05/03ISR Number: 4051262-4Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00038
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Escherichia Urinary Tract		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Infection		Ibuprofen	SS		ORAL		2 DAY
	Nephritis Interstitial		Pholcodine	C		ORAL		13 DAY
	Nephrotic Syndrome		Fluoxetine Hydrochloride	C		ORAL		
	Renal Failure Acute		Polyethylene Glycol 4000	C		ORAL		
			Bezafibrate	C		ORAL		
			Clocinizine	C		ORAL		13 DAY
			Sodium Bicarbonate And Potassium Bitartrate	C		ORAL		
			Nomegestrol	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		20 DAY
			Althiazide And					

			Spironolactone	C			ORAL
145 DAY							

Date:02/05/03ISR Number: 4051263-6Report Type:Expedited (15-DaCompany Report #WAES 0301DNK00017
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peritonitis		Vioxx	PS	Merck & Co., Inc	ORAL	65 DAY	
Hospitalization - Initial or Prolonged			Sulfasalazine	C		ORAL		

Date:02/05/03ISR Number: 4051265-XReport Type:Expedited (15-DaCompany Report #WAES 0207CHE00015
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
	Increased		Aspirin	SS		ORAL	1 YR	
	Aspartate		Atorvastatin Calcium	SS		ORAL	378 DAY	
	Aminotransferase		Bisoprolol Fumarate	C		ORAL	1 YR	
	Increased							
	Drug Interaction							
	Gamma-Glutamyltransferase							
	Increased							
	Gastric Ulcer							
	Liver Disorder							

Date:02/05/03ISR Number: 4051266-1Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00047
Age:92 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Melilot	C		ORAL		
	Aspartate		Lorazepam	C				
	Aminotransferase		Omeprazole	C		ORAL		

	Increased		Acetaminophen	C		ORAL
	Blood Urea Increased		Acetaminophen	C		ORAL
	Gamma-Glutamyltransferase		Nitroglycerin	C		
TOPICAL						
	Increased					

Date:02/05/03ISR Number: 4051268-5Report Type:Expedited (15-DaCompany Report #WAES 0208CHE00033
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Stupor		Baclofen	SS		ORAL
3 DAY						
			Deflazacort	SS		ORAL
			Acetaminophen	C		ORAL
			Amlodipine Besylate	C		ORAL
			Aspirin	C		ORAL
			Indapamide	C		ORAL
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL
			Cozaar	C		ORAL
			Hydrochlorothiazide And Losartan Potassium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/03ISR Number: 4051269-7Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00158
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	37	DAY
Hospitalization - Initial or Prolonged	Drug Interaction		Flutamide	SS		ORAL		
	Malaise		Methotrexate	SS		ORAL		
	Pancytopenia		Prednisolone	SS		ORAL		
	Skin Infection		Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL	31	DAY
	Vomiting		Goserelin Acetate	C		SUBCUTANEOUS	1	DAY

Date:02/05/03ISR Number: 4051271-5Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00076
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Prurigo		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Pruritus							

Date:02/05/03ISR Number: 4051277-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02975
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Life-Threatening	Sudden Death							

Date:02/05/03ISR Number: 4051279-XReport Type:Expedited (15-DaCompany Report #WAES 0301GRC00009
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Anorexia	Vioxx	PS	Merck & Co., Inc	ORAL
	Benign Prostatic Hyperplasia	Perindopril	C		ORAL
		Hydrodiuril	C		ORAL
	Blood Chloride Decreased	Zocor	C		ORAL
	Blood Potassium Increased	Aspirin	C		ORAL
	Blood Pressure Increased	Nitroglycerin	C		
	Cardiac Murmur	Tamsulosin Hydrochloride	C		
	Dyspnoea Exertional				
	Fluid Overload				
	Gallop Rhythm Present				
	Haematocrit Decreased				
	Haemoglobin Decreased				
	Renal Failure Acute				

Date:02/05/03ISR Number: 4051451-9Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00041
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
	Hyperkalaemia	Professional	Vioxx	SS		ORAL	8 DAY	
	Renal Impairment		Potassium Chloride	SS		ORAL		
			Quinapril Hydrochloride	SS		ORAL		
			Quinapril Hydrochloride	SS		ORAL		
			Furosemide	C		ORAL		

				Acetaminophen And Propoxyphene Napsylate	C		ORAL
86	DAY						
				Nicardipine	C		ORAL
				Fenofibrate	C		ORAL

Date:02/05/03ISR Number: 4051453-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA01998
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chills	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Headache		Vioxx	SS		ORAL
	Hepatitis		Pravachol	C		
	Hepatotoxicity		Prempro	C		
	Hyperhidrosis		Zoloft	C		ORAL
	Rash		Calcium (Unspecified)	C		
			Aspirin	C		

Date:02/05/03ISR Number: 4051461-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA03079
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged Disability			Aspirin	C		
			Hydrodiuril	C		
			Ascorbic Acid	C		
			Acetaminophen	C		
			Zoloft	C		
			Synthroid	C		
			Vasotec	C		ORAL
			Ferrous Sulfate	C		
			Alphagan	C		
			Risperdal	C		
			Colace	C		
			Seroquel	C		
			Vitamins (Unspecified)	C		

Date:02/06/03ISR Number: 4051861-XReport Type:Expedited (15-DaCompany Report #WAES 0301DEU00133
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Upper Gastrointestinal Haemorrhage		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:02/06/03ISR Number: 4051865-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA00515
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	23 DAY	
			Actonel	C				
			Lipitor	C				
			Lotrel	C				
			Zoloft	C				
			Calcium					

	(Unspecified)	C
	Ambien	C

Date:02/06/03ISR Number: 4052106-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02375
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:02/06/03ISR Number: 4052107-9Report Type:Expedited (15-DaCompany Report #WAES 01104488
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluctuation							
	Cardiovascular Disorder							
	Oedema							
	Renal Failure							

Date:02/06/03ISR Number: 4052108-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	39	DAY
Hospitalization -	Infarction	Professional	Soma	C				
Initial or Prolonged	Atrial Fibrillation		Elavil	C				
	Brain Death		Esgic-Plus Tablets	C				
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Coma							
	Coronary Artery Disease							
	Hypoxic Encephalopathy							
	Metabolic Acidosis							

Date:02/06/03ISR Number: 4052109-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA01448
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Biliary Tract Disorder
Hospitalization - Initial or Prolonged	Chills
	Cold Sweat
	Dehydration
	Feeling Cold
	Gastric Ulcer
	Gastrointestinal Haemorrhage
	Haematocrit Decreased
	Hiatus Hernia
	Hypoaesthesia
	Intestinal Obstruction
	Leukocytosis
	Mallory-Weiss Syndrome
	Mental Disorder
	Migraine
	Muscle Spasms

		Oesophagitis Oral Intake Reduced Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Platelet Count Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
		Pyrexia Red Blood Cell Count Abnormal Renal Neoplasm Stress Visual Disturbance Weight Decreased	Professional				

Date:02/06/03ISR Number: 4052110-9Report Type:Expedited (15-DaCompany Report #WAES 0212USA00180
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Amylase Increased Blood Immunoglobulin E Decreased Dehydration Dizziness Erythema Multiforme Herpes Simplex Serology Lipase Increased Renal Failure Acute Urticaria	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Cimetidine	C		
			Plavix	C		
			Hydroxyzine	C		

Date:02/06/03ISR Number: 4052111-0Report Type:Expedited (15-DaCompany Report #WAES 0207NOR00011
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
WK						
Hospitalization -			Prednisolone	SS		

Initial or Prolonged	Anaemia	Aspirin And Magnesium Oxide	SS	ORAL
11 DAY				
	Haemorrhage	Dalteparin Sodium	SS	
SUBCUTANEOUS	22 DAY			
	Hyperkalaemia	Dalteparin Sodium	SS	
SUBCUTANEOUS	11 DAY			
	Metabolic Acidosis	Hydrochlorothiazide And Irbesartan	C	ORAL
	Renal Failure Acute			

Date:02/06/03ISR Number: 4052118-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02543
Age:24 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Affective Disorder
	Anorexia
	Asthenia
	Condition Aggravated
	Fatigue
	Insomnia
	Meningitis Viral
	Mental Impairment
	Muscular Weakness

		Paraesthesia					
		Psychomotor Hyperactivity					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS		ORAL
				Lactulose	C		
				Norflex	C		
				Dyazide	C		
				Claritin	C		
				Valtrex	C		
				Flovent	C		

Date:02/06/03ISR Number: 4052119-5Report Type:Expedited (15-DaCompany Report #WAES 0301AUS00094
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Retinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/06/03ISR Number: 4052129-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Injury					

Date:02/06/03ISR Number: 4052131-6Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00010
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS		ORAL
				Methotrexate	C		

Date:02/06/03ISR Number: 4053108-7Report Type:Direct Company Report #CTU 186147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Aspirin	PS		ORAL	325 MG PO QD	
Initial or Prolonged	Haemorrhage		Rofecoxib	SS		ORAL	25 MG PO QD	

Date:02/07/03ISR Number: 4052508-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01662
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Arthralgia
	Back Pain
	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Chest Pain
	Dyspnoea
	Face Oedema
	Fatigue

		Hypokalaemia					
		Musculoskeletal Pain					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema		Zantac	C		
		Oedema Peripheral		Premarin	C		
		Pain In Extremity		Prozac	C		
		Upper Respiratory Tract		Prozac	C		
		Infection		Prozac	C		

Date:02/07/03ISR Number: 4052509-0Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00107
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Central Nervous System		Fentanyl	SS		
TOPICAL			4 DAY				
Initial or Prolonged		Stimulation		Oxycodone			
		Drug Interaction		Hydrochloride	SS		ORAL
		Nervousness					

Date:02/07/03ISR Number: 4052510-7Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00128
Age:18 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Triglycerides					
		Abnormal					
		Fatigue					
		Mouth Ulceration					
		Oral Intake Reduced					
		Speech Disorder					

Date:02/07/03ISR Number: 4052511-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aspiration

Initial or Prolonged	Blood Glucose Increased Blood Potassium Abnormal Blood Pressure Increased Cellulitis Cerebellar Artery Thrombosis Cerebral Hygroma Cerebral Infarction Cerebrovascular Accident Coma Deep Vein Thrombosis Electrocardiogram T Wave Abnormal Gastritis Haemorrhage Intracranial Hyperhidrosis International Normalised Ratio Increased Intracranial Aneurysm Lung Infiltration Pericardial Effusion

	Pericarditis						
	Pneumonia						
	Pulmonary Fibrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Respiratory Distress		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON
	Respiratory Rate		Vioxx	SS		ORAL	6 MON
	Increased		Prednisone	C			
	Subarachnoid Haemorrhage		Hydrocodone	C			
	Syncope						
	Vasospasm						

Date:02/07/03ISR Number: 4052515-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged							

Date:02/07/03ISR Number: 4052517-XReport Type:Expedited (15-DaCompany Report #WAES 0302DEU00023
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	9 DAY
Hospitalization - Initial or Prolonged	Duodenitis						
	Gastritis						
Disability	Upper Gastrointestinal Haemorrhage						

Date:02/07/03ISR Number: 4052780-5Report Type:Expedited (15-DaCompany Report #WAES 0210FRA00053
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
Life-Threatening	Bacterial Infection		Ramipril	C		ORAL	

Hospitalization - Initial or Prolonged	Candidiasis	Furosemide	C	ORAL
	Duodenal Ulcer	Spironolactone	C	ORAL
	Gastrointestinal	Bromazepam	C	ORAL
	Haemorrhage	Acetaminophen	C	ORAL
	Haemolysis			
	Multi-Organ Failure			
	Pneumonia Aspiration			
	Sputum Culture Positive			

Date:02/07/03ISR Number: 4052782-9Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00030
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL	470 DAY	
	Ventricular Extrasystoles							

Date:02/07/03ISR Number: 4052783-0Report Type:Expedited (15-DaCompany Report #WAES 0302AUS00008
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Confusional State
	Decreased Appetite

	Renal Failure Acute						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/03ISR Number: 4052785-4Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00040
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	504 DAY	
	Oesophagitis							

Date:02/07/03ISR Number: 4052789-1Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00042
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	4 WK	
Initial or Prolonged	Haemorrhage							

Date:02/07/03ISR Number: 4052790-8Report Type:Expedited (15-DaCompany Report #WAES 0302AUS00037
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Delirium		Tramadol Hydrochloride	SS		ORAL		
			Amitriptyline Hydrochloride	SS			2 DAY	

Date:02/07/03ISR Number: 4052791-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00017
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Ulcer Haemorrhage		Accupril	C		
	Loss Of Consciousness		Norpace	C		
	Ulcer		Lanoxin	C		
			Aspirin	C		
			Allegra	C		
			Vitamins (Unspecified)	C		

Date:02/07/03ISR Number: 4053930-7Report Type:Expedited (15-DaCompany Report #2002095652US
Age: Gender:Male I/FU:F

Outcome	PT
Other	Arthralgia
	Complications Of Transplant Surgery
	Dermatitis
	Dialysis
	Drug Interaction
	Haemorrhage Subepidermal
	Myalgia
	Rash
	Renal Failure

		Skin Disorder Skin Fissures					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Celebrex(Celecoxib) Capsule	PS		ORAL
ORAL							
				Deltasone (Prednisone) Tablet	SS		ORAL
ORAL							
				Insulin (Insulin)	SS		
				Imuran (Azathioprine)	SS		
				Lasix (Furosemide)	SS		
				Cyclosporine (Ciclosporin)	SS		
				Clonidine (Clonidine)	SS		
				Norvasc (Amlodipine Besilate)	SS		
				Toprol Xl (Metoprolol Succinate)	SS		
				Zebeta (Bisoprolol Fumarate)	SS		
				Cyclobenzaprine (Cyclobenzaprine)	SS		
				B Complex (Pyridoxine Hydrochloride, Thiamine Hydrochloride,	SS		
				Vioxx	SS		
				Lipitor (Atorvastatin)	SS		
				Clonazepam (Clonazepam)	SS		

Date:02/07/03ISR Number: 4054136-8Report Type:Periodic Company Report #2002095652US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Renal Failure	Consumer	Celebrex (Celecoxib)			

	Company	Capsule	PS	ORAL
ORAL				
	Representative	Deltasone(Prednisone) Tablet	SS	ORAL
ORAL				
		Insulin (Insulin)	SS	
		Imuran (Azathioprine)	SS	
		Lasix (Furosemide)	SS	
		Cyclosporine(Ciclosporin)	SS	
		Cvlonidine(Clonidine)	SS	
		Norvasc(Amlodipine Besilate)	SS	
		Toprol	SS	
		Zebeta(Bisoprolol Fumarate)	SS	
		Cyclobenzaprine(Cyclobenzaprine)	SS	
		B Complex (Pyridoxine		

Hydrochloride,	
Thiamine Hydrochloride,	SS
Vioxx	SS
Lipitor (Atorvastatin)	SS
Clonazepam(Clonazepam)	SS

Date:02/07/03ISR Number: 4054543-3Report Type:Periodic Company Report #2002094318US
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)					
	Dermatitis	Health	Capsule	PS			200 MG, QD,	
	Hypersensitivity	Professional	Vioxx (Rofecoxib)	SS			12.5 MG, QD,	
			Lidex (Flucinonide)	C				

Date:02/07/03ISR Number: 4055669-0Report Type:Periodic Company Report #2002106878US
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG, QD,	
Initial or Prolonged	Drug Ineffective	Health					ORAL	
	Gastric Ulcer	Professional	Vioxx (Rofecoxib)	SS				
			Ecotrin	C				

Date:02/07/03ISR Number: 4060644-6Report Type:Periodic Company Report #2002120012US
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Celebrex (Celecoxib)					
	Feeling Abnormal		Capsule	PS		ORAL	ORAL	

	Headache	Vioxx (Rofecoxib)	SS
		Prevacid	C

Date:02/10/03ISR Number: 4053235-4Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00044
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Complications Of		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Transplant Surgery					
Hospitalization -	Dialysis					
Initial or Prolonged	General Physical Health					
	Deterioration					
	Haemangioma Of Liver					
	Hepatic Encephalopathy					
	Hepatic Failure					
	Hepatic Necrosis					
	Hepatitis Fulminant					
	Liver Transplant					
	Neurodermatitis					
	Post Procedural					
	Complication					
	Renal Failure Acute					
	Respiratory Failure					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/03ISR Number: 4053237-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Lipitor	SS		ORAL		366 DAY
Disability	Arthralgia		Zemplar	SS				
Other	Atherosclerosis		[Therapy					
	Biliary Neoplasm		Unspecified]	SS				
	Cardiac Failure		Imuran					
	Congestive		(Azathioprine)	C		ORAL		
	Complications Of		Prednisone	C		ORAL		
	Transplant Surgery		Lasix (Furosemide)	C		ORAL		
	Congestive Cardiomyopathy		Sandimmun	C		ORAL		
	Dermatitis		Clonidine					
	Dialysis		Hydrochloride	C		ORAL		
	Diarrhoea		Calcium					
	Dilatation Atrial		(Unspecified) And					
	Disease Progression		Vitamin D					
	Drug Hypersensitivity		(Unspecified)	C				
	Drug Interaction		Iron Dextran	C				
	Drug Intolerance		Epoetin	C				
	Electrocardiogram Q Wave		Cyclosporine	C				
	Abnormal		Paricalcitol	C			INTRAVENOUS	
	Erythema Multiforme		Zaroxolyn	C		ORAL		
	Haemorrhage Subepidermal		Ultralente Insulin	C			PARENTERAL	
	Hyperkalaemia		Toprol Xl Tablets	C		ORAL		
	Hypertension		Viagra	C		ORAL		
	Hypotension		Humulin	C			PARENTERAL	
	Injury		Clonazepam	C				
	Joint Stiffness		Norvasc	C		ORAL		
	Kidney Transplant		Zebeta	C		ORAL		
	Rejection		Flexeril	C		ORAL		
	Mitral Valve		Vitamin B Complex	C		ORAL		
	Calcification		Celebrex	C				
	Mitral Valve Incompetence							
	Myalgia							
	Myocardial Infarction							
	Nasal Septum Deviation							
	Nasal Septum Perforation							
	Palpitations							
	Pericardial Effusion							

Pericarditis Uraemic
Pleural Effusion
Procedural Complication
Pulmonary Congestion
Pulmonary Oedema
Raynaud'S Phenomenon
Renal Failure
Renal Transplant
Sinus Tachycardia
Sinusitis
Swelling
Tricuspid Valve
Incompetence
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/03ISR Number: 4053240-8Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00057
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Dyspnoea		Fluindione	SS		ORAL		
	Gastric Ulcer Haemorrhage		Omeprazole	C		ORAL		
	Haemoglobin Decreased		Levothyroxine Sodium	C		ORAL		
	International Normalised		Furosemide	C		ORAL		
	Ratio Increased		Potassium					
	Pallor		(Unspecified)	C		ORAL		

Date:02/10/03ISR Number: 4053241-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA02797
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Vioxx	PS	Merck & Co., Inc	ORAL		
			Morphine	C				
			Dihydrocodeine	C				
			Chlorpromazine	C				
			Citalopram	C				

Date:02/10/03ISR Number: 4053242-1Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00043
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastritis		Aspirin	C		ORAL		
Other	Gastrointestinal		Isosorbide					
	Haemorrhage		Mononitrate	C		ORAL		
			Vasotec	C		ORAL		
			Morphine Sulfate	C				

Date:02/10/03ISR Number: 4053451-1Report Type:Expedited (15-DaCompany Report #WAES 0302DNK00005
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Ramipril	SS		ORAL		
			Furosemide	C		ORAL		

Date:02/10/03ISR Number: 4053452-3Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00014
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/03ISR Number: 4053455-9Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00010
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/03ISR Number: 4054774-2Report Type:Direct Company Report #CTU 186327
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Inappropriate		Vioxx 12.5 Merck	PS	Merck	ORAL	12.5MG DAILY	
Initial or Prolonged	Antidiuretic Hormone					ORAL		
	Secretion							

Date:02/10/03ISR Number: 4055087-5Report Type:Expedited (15-DaCompany Report #2003003075
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Gabapentin					
	Intentional Misuse	Health	(Gabapentin)	PS		ORAL	ORAL	
		Professional	Tramadol	SS		ORAL	ORAL	
			Rofecoxib	SS		ORAL	ORAL	

Date:02/10/03ISR Number: 4055214-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA00193
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Other	Agonal Death Struggle	Health	Tylenol	C				
	Aortic Valve Disease	Professional	Aspirin	C				
	Arrhythmia							
	Bradycardia							
	Cardiac Murmur							
	Cardio-Respiratory Arrest							
	Cartilage Injury							
	Cough							
	Drug Effect Decreased							
	Dyspnoea							
	Grand Mal Convulsion							
	Hypertension							

Joint Crepitation
Mitral Valve Incompetence
Myocardial Infarction
Osteoarthritis
Sudden Death
Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Tachycardia

Date:02/10/03ISR Number: 4055434-4Report Type:Expedited (15-DaCompany Report #A02200300054
Age:96 YR Gender:Female I/FU:F

Outcome	PT
Death	Blood Pressure
Hospitalization - Initial or Prolonged	Fluctuation
	Cyanosis
	Depressed Level Of Consciousness
	Erysipelas
	Haemoglobin Decreased
	Idiopathic Thrombocytopenic Purpura
	Leukopenia
	Neutropenia
	Renal Failure

Streptococcal Sepsis

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
75 MG QD		Health Professional	Plavix-(Clopidogrel Sulfate)-Tablet-75 Mg	PS		ORAL
2 UNIT ORAL; A FEW YEARS			Fonzylane-(Buflomedil Hydrochloride)-Tablet-Unit Dose	SS		ORAL
50 MG OD ORAL; A FEW YEARS			Cozaar (Losartan Potassium)-Tablet-50 Mg	SS		ORAL
60 MG ORAL; A FEW YEARS			Vasterel-(Trimetazidine)-Tablet-20 Mg	SS		ORAL
2 UNIT ORAL	1 MON		Vioxx (Rofecoxib)-Tablet-Unit Dose	SS		ORAL

Date:02/11/03ISR Number: 4053973-3Report Type:Expedited (15-DaCompany Report #WAES 0302ESP00006
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Oesophagitis		Gamma-Aminohydroxybutyric Acid	SS		ORAL		
	Upper Gastrointestinal Haemorrhage		Clorazepate Dipotassium	SS		ORAL		
			Pyridoxine Hydrochloride	SS		ORAL		

			Fluoxetine Hydrochloride	SS		ORAL

Date:02/11/03ISR Number: 4053993-9Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00064
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL
			Aspirin	SS		ORAL
			Nifedipine	C		ORAL
			Ranitidine Hydrochloride	C		ORAL
			Bendroflumethiazide	C		ORAL
			Irbesartan	C		ORAL
			Loperamide	C		ORAL

Date:02/11/03ISR Number: 4053995-2Report Type:Expedited (15-DaCompany Report #WAES 0212USA02514
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Death	Arrhythmia
	Arthralgia
	Atelectasis
	Blood Ph Decreased

		Dermatitis Contact					
		Dizziness					
		Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY						
		Hypotension		Vioxx	SS		ORAL
		Incontinence		Vioxx	SS		ORAL
4	DAY						
		Intracranial Aneurysm		Vioxx	SS		ORAL
4	DAY						
		Muscle Tightness					
		Mydriasis					
		Oxygen Saturation					
		Decreased					
		Rash Pruritic					
		Respiratory Arrest					
		Spleen Congestion					
		Sudden Death					
		Syncope					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:02/11/03ISR Number: 4053997-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00181
Age:75 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Haematemesis		Doliprane	SS		
		Hip Fracture					

Date:02/11/03ISR Number: 4053998-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00704
Age:62 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Increased					

Date:02/11/03ISR Number: 4054281-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01123
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/03ISR Number: 4054282-9Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00044
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Complications Of Transplant Surgery Haemangioma Of Liver Hepatic Encephalopathy Hepatic Failure Hepatic Necrosis Hepatitis Fulminant Hepatotoxicity Neurodermatitis Renal Failure Acute Respiratory Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/03ISR Number: 4054283-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01282
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Hypertension		Cozaar	C				
	Rash							
	Swelling							
	Thermal Burn							

Date:02/11/03ISR Number: 4054284-2Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00069
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Gastrointestinal	Professional	Aspirin Lysine	SS		ORAL		
	Haemorrhage		Furosemide	C		ORAL		
			Nitroglycerin	C				
			Ramipril	C		ORAL		
			Zocor	C		ORAL		
			Insulin Lispro	C				
			Isosorbide Dinitrate	C		ORAL		
			Lacidipine	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Fluticasone Propionate And Salmeterol Xinafoate	C				

RESPIRATORY

(INHALATION)

Date:02/11/03ISR Number: 4055282-5Report Type:Direct Company Report #CTU 186402
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS				
			Celebrex	SS				

Date:02/11/03ISR Number: 4055851-2Report Type:Direct Company Report #CTU 186462
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx 50mg	PS		ORAL	1T DAILY PO	10 DAY
Intervention to Prevent Permanent Impairment/Damage								

Date:02/11/03ISR Number: 4055946-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
	Aspiration
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Bunion Operation
	Cardiomegaly
	Cellulitis

		Cerebral Artery Occlusion					
		Cerebral Hygroma					
		Cerebral Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident	Consumer	Tab Vioxx 12.5mg	PS		ORAL
SEE IMAGE							
		Chest X-Ray Abnormal	Health	Hydrocodone	C		
		Coma	Professional	Prednisone	C		
		Deep Vein Thrombosis					
		Diplopia					
		Electrocardiogram T Wave					
		Abnormal					
		Embolism					
		Faecal Occult Blood					
		Positive					
		Gastritis					
		Haemorrhage Intracranial					
		International Normalised					
		Ratio Decreased					
		Laboratory Test Abnormal					
		Muscle Rigidity					
		Pericarditis					
		Peroneal Nerve Palsy					
		Pneumonia					
		Pulmonary Fibrosis					
		Refusal Of Treatment By					
		Patient					
		Respiratory Distress					
		Subarachnoid Haemorrhage					
		Vasospasm					

Date:02/11/03ISR Number: 4055954-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA02543
Age:24 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Affective Disorder	Consumer	Tab Vioxx	PS		ORAL
SEE IMAGE							
Initial or Prolonged		Agitation	Health	Claritin	C		
		Anorexia	Professional	Dyazide	C		
		Asthenia		Flovent	C		
		Chest Pain		Norflex	C		
		Condition Aggravated		Valtrex	C		
		Dyspnoea		Lactulose	C		
		Fatigue					

Headache
Hypersensitivity
Insomnia
Meningitis Viral
Mental Status Changes
Muscular Weakness
Nausea
Panic Attack
Personality Disorder
Restlessness
Sinus Congestion
Sinusitis
Somnolence
Weight Decreased

Date:02/11/03ISR Number: 4055956-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA01662
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PRN/PO	
Initial or Prolonged	Aortic Valve Sclerosis	Health	Premarin	C				
	Arrhythmia	Professional	Prozac	C				
	Arthralgia		Zantac	C				
	Back Pain							
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Chest Pain							
	Condition Aggravated							
	Dyspepsia							
	Fatigue							
	Feeling Abnormal							
	Hypertension							
	Hypokalaemia							
	Mitral Valve Incompetence							
	Musculoskeletal Pain							
	Nausea							
	Neck Pain							
	Oedema Peripheral							
	Pain In Extremity							
	Tricuspid Valve							
	Incompetence							
	Upper Respiratory Tract							
	Infection							

Date:02/12/03ISR Number: 4054790-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00276
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Astigmatism		Vioxx	PS	Merck & Co., Inc	ORAL	193 DAY	
	Blood Pressure Decreased		Vioxx	SS		ORAL	46 DAY	
	Cardiac Flutter		Calcium					
	Cataract		(Unspecified)	C				
	Chest Pain		Univasc	C				
	Dehydration		Zoloft	C				

	Dizziness	Baycol	C	
985 DAY				
	Drug Withdrawal Syndrome	Ibuprofen	C	
	Dyspnoea	Celebrex	C	
	Dyspnoea Exertional	Ziac	C	
	Gastroenteritis	Ziac	C	
	Headache	Ziac	C	
	Hypertension	Prinivil	C	ORAL
	Ischaemia	Aciphex	C	
7 DAY				
	Keratoconjunctivitis	Plavix	C	
	Sicca	Aspirin	C	
	Maculopathy			
	Renal Failure			
	Retinal Exudates			
	Retinal Haemorrhage			
	Retinal Vein Thrombosis			
	Rhabdomyolysis			
	Urinary Tract Infection			
	Visual Acuity Reduced			
	Vitreous Detachment			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/03ISR Number: 4054792-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA00009
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/12/03ISR Number: 4054793-6Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00085
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Malaise		Pantoprazole	SS		ORAL	3	DAY
	Syncope		Heparinoid And Salicylic Acid	C		TOPICAL		

Date:02/12/03ISR Number: 4054795-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA02793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:02/12/03ISR Number: 4054950-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA00574
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombotic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/12/03ISR Number: 4054953-4Report Type:Expedited (15-DaCompany Report #WAES 0208USA00634
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Bradycardia Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:02/12/03ISR Number: 4054954-6Report Type:Expedited (15-DaCompany Report #WAES 0302AUS00039
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:02/12/03ISR Number: 4054955-8Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00014
Age:64 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Duodenal Ulcer Haemorrhage Dyspnoea Helicobacter Infection

	Melaena						
	Pallor						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Valsartan	C		ORAL		
			Allopurinol	C		ORAL		

Date:02/12/03ISR Number: 4054957-1Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00040
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 21 DAY	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Metformin	C				
			Glyburide	C				
			Furosemide	C				

Date:02/12/03ISR Number: 4054958-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01679
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident	Professional	Plavix	C				
			Flomax (Morniflumate)	C				

Date:02/12/03ISR Number: 4054964-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00957
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Lipitor	C				

Date:02/12/03ISR Number: 4054969-8Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00067
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS		ORAL		
			Atenolol	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Simvastatin	C		ORAL		
			Nicorandil	C		ORAL		
			Losartan Potassium	C		ORAL		

Date:02/12/03ISR Number: 4054972-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00965
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/03ISR Number: 4055589-1Report Type:Direct Company Report #CTU 186517
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx -Rofecoxib-	PS		ORAL	25MG DAILY	
Initial or Prolonged	Haematemesis					ORAL		
	Melaena		Synthroid	C				
			Megace	C				
			Colace	C				

Date:02/13/03ISR Number: 4055507-6Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00037
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/13/03ISR Number: 4055510-6Report Type:Expedited (15-DaCompany Report #WAES 0302DNK00005
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased	Professional	Ramipril	SS		ORAL		
			Furosemide	C		ORAL		

Date:02/13/03ISR Number: 4055514-3Report Type:Expedited (15-DaCompany Report #WAES 0301AUS00153
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged	Confusional State		Irbesartan	C				
	Dysarthria		Levothyroxine Sodium	C				
	Hallucination, Visual		Amitriptyline Hydrochloride	C				
	Nightmare		Tryptophan	C				

Temazepam C

Date:02/13/03ISR Number: 4055778-6Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Homocysteine Increased
	Cardiovascular Disorder
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Embolism
	Coronary Artery Restenosis
	Coronary Artery Thrombosis
	Dyspepsia
	Facial Palsy
	Gastritis
	Headache
	Hiatus Hernia
	Hyperlipidaemia
	Myocardial Infarction

		Syncope					
		Thrombosis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Altace	C		ORAL
				Plavix	C		ORAL
				Aspirin	C		ORAL
				Nitroglycerin	C		
TOPICAL							
				Prevacid	C		ORAL
				Zocor	C		ORAL

Date:02/13/03ISR Number: 4055789-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01493
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Laryngitis		Vioxx	SS		ORAL
16 MON						
			Advair	C		
RESPIRATORY						
(INHALATION)						
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Wellbutrin Sr	C		ORAL

Date:02/13/03ISR Number: 4055792-0Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00055
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
28 DAY						
Disability	Blood Pressure		Ramipril	C		
	Inadequately Controlled		Amlodipine Besylate	C		
	Bundle Branch Block Left		Levothyroxine Sodium	C		
	Cardiomyopathy					
	Coronary Artery Stenosis					

Dilatation Ventricular
Dyspnoea
Myocardial Infarction
Pneumonia
Ventricular Fibrillation
Ventricular Hypertrophy

Date:02/13/03ISR Number: 4055793-2Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00081
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Aspirin	SS		ORAL		
	Normochromic Normocytic Anaemia		Captopril	C		ORAL		
			Atenolol	C		ORAL		
	Syncope		Nitrendipine	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Atorvastatin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/03ISR Number: 4055795-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02586
Age:7 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Amylase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lipase Increased		Antineoplastic (Unspecified)	C				
			Amino Acids (Unspecified) And Carbohydrates (Unspecified) And Electrolytes	C				
			Atovaquone	C				

Date:02/13/03ISR Number: 4055796-8Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00020
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL		
	Somnolence		Prazepam	SS		ORAL		
			Spironolactone	SS		ORAL		

Date:02/13/03ISR Number: 4057555-9Report Type:Expedited (15-DaCompany Report #PHRM2003FR00628
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Foreign	Voltarene					
	Gastric Ulcer	Health	(Diclofenac Sodium)					
	Gastritis	Professional	Slow Release Tablet	PS		ORAL	150 MG/DAY,	
	International Normalised	Other						
	Ratio Increased		Sintrom 4					
	Melaena		(Acenocoumarol,					
	Oesophageal Disorder		Acenocoumarol)					
	Prothrombin Level		Tablet	SS		ORAL	4 MG, QD,	
	Abnormal							
			Vioxx (Rofecoxib)					

Tablet	SS		ORAL
1 DF, QD,			
ORAL			
Diamicron	C		
Lopril	C		
Amlor	C		
Detensiel	C		
Temesta	C		
Trinitrine	C		

Date:02/14/03ISR Number: 4056092-5Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00014
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Initial or Prolonged	Choking	Professional						

Date:02/14/03ISR Number: 4056096-2Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00008
Age:90 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased

		Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Potassium Increased		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Cardiac Failure		Carbidopa And Levodopa	C		ORAL
		Electrocardiogram T Wave Abnormal		Perindopril Erbumine	C		ORAL
		Gamma-Glutamyltransferase Increased		Clopidogrel Bisulfate	C		ORAL
		Hypocapnia		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
		Pleural Effusion					
		Renal Failure					
5	DAY						
				Polyethylene Glycol 4000	C		ORAL
				Ferrous Fumarate	C		ORAL

Date:02/14/03ISR Number: 4056101-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA01082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/14/03ISR Number: 4056234-1Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00044
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Gastrointestinal Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged						

Date:02/14/03ISR Number: 4056237-7Report Type:Expedited (15-DaCompany Report #WAES 0209BEL00097
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL

	Muscle Haemorrhage	Professional
	Nerve Compression	

Date:02/14/03ISR Number: 4056238-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA00080
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Level Decreased	Professional	Dilantin	SS		
	Status Epilepticus		Lamictal	C		
			Estrogens (Unspecified)	C		

Date:02/14/03ISR Number: 4056241-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01676
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Asthenia
	Decreased Activity
	Dermatitis

		Diverticulum Intestinal Haemorrhagic					
		Foot Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Glucose Tolerance		Vioxx	PS	Merck & Co., Inc	ORAL
803	DAY						
		Impaired		Percocet	C		
		Goitre		Prednisone	C		
		Injury					
		Kyphosis					
		Lower Gastrointestinal Haemorrhage					
		Oedema					
		Oedema Peripheral					
		Rheumatoid Arthritis					
		Synovitis					
		Urinary Incontinence					

Date:02/14/03ISR Number: 4056242-0Report Type:Expedited (15-DaCompany Report #WAES 0302AUT00008
Age:98 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Food Poisoning		Vioxx	PS	Merck & Co., Inc	ORAL
18	MON						
Hospitalization -		Hepatic Necrosis		Triazolam	C		
Initial or Prolonged				Acetyldigoxin	C		
				Prinivil	C		
				Isosorbide Mononitrate	C		
				Aspirin	C		

Date:02/14/03ISR Number: 4056244-4Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00072
Age:82 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL
16	DAY						
Hospitalization -		Haematocrit Decreased		Certoparin Sodium	SS		
SUBCUTANEOUS		16 DAY					
Initial or Prolonged		Haemoglobin Decreased		Clopidogrel			

	Melaena		Bisulfate	SS		ORAL
16 DAY						
	Upper Gastrointestinal		Metoprolol Succinate	C		ORAL
	Haemorrhage		Isosorbide Dinitrate	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Digitoxin	C		ORAL

Date:02/14/03ISR Number: 4056247-XReport Type:Expedited (15-DaCompany Report #WAES 0302DNK00012
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
	Dizziness		Estradiol Benzoate	C		ORAL
	Mouth Ulceration					
	Oedema					

Date:02/14/03ISR Number: 4056249-3Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00077
Age:83 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	124	DAY
	Gastrointestinal Haemorrhage		Felbinac	C				
			Lanolin Alcohols And Mineral Oil	C				
			Furosemide	C				
			Ramipril	C				
			Warfarin	C				
			Acetaminophen	C				

Date:02/14/03ISR Number: 4056250-XReport Type:Expedited (15-DaCompany Report #WAES 0302GBR00098
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
			Omeprazole	C		ORAL		
			Fosamax	C		ORAL		

Date:02/14/03ISR Number: 4056252-3Report Type:Expedited (15-DaCompany Report #WAES 0302DNK00013
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Decreased		Acetaminophen	C		ORAL		
Initial or Prolonged	Melaena		Mirtazapine	C		ORAL		
Disability	Syncope		Tramadol Hydrochloride	C		ORAL		

Date:02/14/03ISR Number: 4056255-9Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00042
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 4 WK	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage	Professional	Acetaminophen [Therapy Unspecified]	C C		

Date:02/14/03ISR Number: 4056256-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA01076
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Faeces Discoloured Gastritis Erosive Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/14/03ISR Number: 4056677-6Report Type:Direct Company Report #CTU 186684
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Ulcer Upper Gastrointestinal Haemorrhage		Aspirin 325mg Rofecoxib-Vioxx 25mg Merck Metoprolol Isosorbide	PS SS C	Merck	ORAL
325MG QD ORAL						
25MG QD ORAL						

Mononitrate	C
Multivitiamin	C
Levothyroxine	C
Norvasc	C
Sinement	C
Ntg	C
Oscal	C
Digoxin	C
Vasotec	C
Detrol	C
Senokot	C

Date:02/18/03ISR Number: 4056360-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00990
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atelectasis		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Blood Pressure Increased		Nephrocaps	C		ORAL		
Other	Cholelithiasis		Atarax	C				
	Dialysis		Imdur	C		ORAL		
	Gastritis		Restoril	C				
	Gastrointestinal		Renagel	C				
	Haemorrhage		Coumadin	C				
	Pancreatitis Relapsing		Coumadin	C				
	White Blood Cell Count		Ecotrin	C		ORAL		
	Abnormal		Ativan	C		ORAL		
			Protonix	C		ORAL		
			Flexeril	C		ORAL		
			Amino Acids (Unspecified) And Carbohydrates (Unspecified) And Electrolytes	C				

Date:02/18/03ISR Number: 4056361-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arrhythmia
Other	Asthenia
	Atrial Fibrillation

Atrial Flutter
Atrioventricular Block
First Degree
Bradycardia
Bundle Branch Block Right
Calcinosis
Cardiac Failure
Congestive
Cardiomegaly
Chronic Obstructive
Pulmonary Disease
Cough
Decreased Appetite
Dizziness
Dyspnoea
Essential Tremor
Fatigue
Fluid Overload

		Flushing					
		Heart Rate Irregular					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypothyroidism		Vioxx	PS	Merck & Co., Inc	ORAL
12	DAY						
		Lung Disorder		Vioxx	SS		ORAL
1	DAY						
		Mitral Valve Incompetence		Tenormin	C		
		Myalgia		Tenormin	C		
1	DAY						
		Nausea		Salutensin	C		
		Oedema		Paxil	C		
		Pitting Oedema		Xanax	C		
		Pleural Effusion		Lescol	C		
		Pulmonary Fibrosis					
		Rales					
		Rhinitis Allergic					
		Scar					
		Sick Sinus Syndrome					
		Ventricular Extrasystoles					
		Vision Blurred					

Date:02/18/03ISR Number: 4056363-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthroscopy		Vioxx	PS	Merck & Co., Inc	ORAL
308	DAY						
Initial or Prolonged		Asthenia		Vioxx	SS		ORAL
33	DAY						
Disability		Atherosclerosis		Vioxx	SS		ORAL
36	DAY						
		Atrial Septal Defect		Vioxx	SS		ORAL
312	DAY						
		Cerebral Infarction		Tricor	C		ORAL
		Cerebrovascular Accident		Vicodin Es Tablets	C		ORAL
		Chondromalacia		Paxil	C		ORAL
		Diverticulum		Restoril	C		ORAL
		Dysarthria		Aspirin	C		ORAL
		Embolism		Estrogens			
		Haematocrit Decreased		(Unspecified)	C		
		Haemoglobin Decreased		Premarin	C		
		Joint Swelling		Vitamins			

	Mitral Valve Incompetence	(Unspecified)	C
	Muscle Atrophy	Zantac	C
	Osteoarthritis	Vistaril	C
	Pain In Extremity		
	Platelet Count Decreased		
	Tricuspid Valve Incompetence		

Date:02/18/03ISR Number: 4056365-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA01156
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/03ISR Number: 4056368-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA01194
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
Other	Chest Pain Headache							

Date:02/19/03ISR Number: 4056825-8Report Type:Expedited (15-DaCompany Report #WAES 0302BEL00013
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteritis Obliterans		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Leg Amputation		Vioxx	SS		ORAL		3 DAY
Disability	Necrosis		Vioxx	SS		ORAL		9 DAY
	Oedema		Diclofenac Sodium	C		ORAL		
	Skin Ulcer							

Date:02/19/03ISR Number: 4057024-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02179
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastroenteritis Viral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal Haemorrhage							
	Gastrointestinal Ulcer							
	Myocardial Infarction							
	Renal Failure Acute							

Date:02/19/03ISR Number: 4057031-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA01471
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				
			[Therapy Unspecified]	C				

Date:02/19/03ISR Number: 4059571-XReport Type:Expedited (15-DaCompany Report #2003146544FR
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Malaise Sedation Somnolence	Foreign Health Professional	Aldactone (Spironolactone) Tablet, 75mg	PS			ORAL ORAL
		Other	Vioxx (Rofecoxib)	SS			ORAL ORAL
			Lysanxia(Prazepam) 10mg	SS			ORAL ORAL

Date:02/19/03ISR Number: 4060245-XReport Type:Expedited (15-DaCompany Report #2003005583
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability Other	Complications Of Maternal Exposure To Therapeutic Drugs	Foreign Health Professional	Sertraline (Sertraline)	PS		ORAL	100 MG (DAILY), ORAL	
	Gestational Diabetes Pre-Eclampsia Pregnancy Sinusitis Streptococcal Infection		Rofecoxib	SS			25 MG (DAILY)	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/03ISR Number: 4060253-9Report Type:Expedited (15-DaCompany Report #K200201563
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Study	Altace Capsules (Ramipril) Capsule 5/10mg	PS		ORAL	SEE IMAGE	
	Angina Unstable	Health Professional						
	Anxiety	Other	H376/95 (Anticoagulant Citrate Dextrose) 2/2/2/2	SS		ORAL	2, ORAL	
	Atrial Fibrillation							
	Bundle Branch Block Left							
	Cardiac Failure							
	Congestive		Vioxx (Rofecoxib)	SS		ORAL	50 MG, QD, ORAL	
	Cardiomegaly							
	Coronary Artery Disease		Motrin (Ibuprofen)	SS				
	Emphysema		Lanoxin (Digoxin)	C				
	Hypertension		Atenolol (Atenolol)	C				
	Hypertriglyceridaemia		Glipizide (Glipizide)	C				
	Mitral Valve Incompetence		Pacerone (Amiodarone Hydrochloride)	C				
	Nephrolithiasis		Tricor (Fenofibrate)	C				
	Pericardial Effusion		Zocor (Simvastatin)	C				
	Pulmonary Oedema		Plavix (Clopidrogel Sulfate)	C				
	Renal Cyst		Combivent (Salbutamol Sulfate, Ipratropium Bromide)	C				
	Renal Failure Acute		Coumadin "Dupont" (Warfarin Sodium)	C				
	Tendonitis		Acetaminophen (Paracetamol)	C				
	Tricuspid Valve Incompetence		Norvasc (Amdlodipine Besilate)	C				
	Ventricular Tachycardia		Maxzide (Triamterene, Hydrochlorothiazide)	C				
			Ativan (Lorazepam)	C				
			Morphine (Morphine)	C				
			Versed (Midazolam Hydrochloride)	C				
			Lasix (Furosemide)	C				
			Albuterol					

(Salbutamol)	C
Potassium (Potassium)	C
Nitropaste (Glyceryl Trinitrate)	C
Lopressor (Metoprolol Tartrate)	C
Vitamin K (Phytomenadione)	C
Lidocaine (Lidocaine)	C
Aspirin "Bayer" (Acetylsalicylic Acid)	C
Kefzol (Cefazolin Sodium)	C
Keflex (Cefalexin Monohydrate)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/03ISR Number: 4057500-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01673
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Operative Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/20/03ISR Number: 4061283-3Report Type:Expedited (15-DaCompany Report #WAES 99091937
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Blood Cholesterol	Consumer	Tab Vioxx	PS		ORAL		
Initial or Prolonged	Increased Blood Pressure Increased	Health Professional	Methotrexate (Methotrexate Sodiu	C				
	Blood Triglycerides Increased		Cortisone	C				
	Coronary Artery Atherosclerosis		Famotidine	C				
	Coronary Artery Occlusion		Influenza Virus Vaccine	C				
	Eructation		Metoclopramide	C				
	Gastroduodenitis		Omeprazole	C				
	Hepatocellular Damage		Prednisone	C				
	Hiatus Hernia							
	Hyperhidrosis							
	Hyperlipidaemia							
	Low Density Lipoprotein Increased							
	Myocardial Infarction							
	Oesophagitis							
	Psoriatic Arthropathy							
	Thyroid Disorder							

Date:02/20/03ISR Number: 4061394-2Report Type:Expedited (15-DaCompany Report #200310330DE
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Foreign	Docetaxel (Taxotere)	PS				
	Renal Failure Acute	Health	Metamizole Sodium					

		Professional	(Novalgin)	SS		ORAL
30 DROP TID						
		Other				
PO	3 DAY					
			Rofecoxib (Vioxx)	SS		ORAL
25 MG/DAY PO	4 DAY					

Date:02/21/03ISR Number: 4058453-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA00248
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dehydration	Professional	Indocin			
Other	Erosive Oesophagitis		(Indomethacin)	SS		
10 DAY						
	Gastritis Erosive		Lasix (Furosemide)	C		ORAL
			Zaroxolyn	C		ORAL
			Spironolactone	C		
			Toprol Xl Tablets	C		
			Potassium (Unspecified)	C		
			Neurontin	C		ORAL
			Magnesium (Unspecified)	C		
			Tamoxifen	C		

Aspirin	C
Nexium	C
Vicodin Tablets	C
Paxil	C
Ibuprofen	C

Date:02/21/03ISR Number: 4058476-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA01617
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
	Nausea							
	Renal Failure Acute							
	Vomiting							

Date:02/21/03ISR Number: 4058477-XReport Type:Expedited (15-DaCompany Report #WAES 0301BEL00006
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Distress Syndrome	Professional	Loperamide					
Initial or Prolonged	Blood Urine Present		Hydrochloride	C		ORAL	2	DAY
Disability	Cardiac Failure							
	Idiopathic							
	Thrombocytopenic Purpura							
	Pulmonary Haemorrhage							
	Renal Impairment							
	Respiratory Failure							

Date:02/21/03ISR Number: 4058483-5Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Myocardial Infarction							

Date:02/21/03ISR Number: 4058487-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA00855
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Spinal Manipulation							

Date:02/21/03ISR Number: 4058490-2Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00078
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Tubulointerstitial Nephritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/03ISR Number: 4058501-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA01673
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:02/21/03ISR Number: 4058742-6Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 12 DAY	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 1 DAY	Atrial Flutter		Vioxx	SS		ORAL
Other	Bradycardia		Salutensin	C		
	Bundle Branch Block Right		Tenormin	C		
	Cardiac Failure		Tenormin	C		
1 DAY						
	Congestive		Paxil	C		
	Chronic Obstructive		Xanax	C		
	Pulmonary Disease		Lescol	C		
	Condition Aggravated					
	Essential Tremor					
	Hypertension					
	Mitral Valve Incompetence					
	Myalgia					
	Pulmonary Fibrosis					
	Rhinitis Allergic					
	Sick Sinus Syndrome					

Date:02/21/03ISR Number: 4058753-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA01551
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability 3 MON	Granulomatous Liver		Vioxx	PS		ORAL
	Disease		Premarin	C	Merck & Co., Inc	
	Hepatitis		Advil	C		

Date:02/21/03ISR Number: 4059416-8Report Type:Direct Company Report #CTU 187032
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenitis		Vioxx 50mg Q Day	PS		
Initial or Prolonged	Gastritis		Plavix 75mg Q Day	SS		
	Melaena		Asa	C		
			Motrin	C		
			Naproxen	C		

Date:02/21/03ISR Number: 4059445-4Report Type:Direct Company Report #CTU 187027
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx 25mg Qd Merck	PS	Merck	ORAL
25MG PO QD						
Initial or Prolonged			Asa	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/21/03ISR Number: 4060100-5Report Type:Direct Company Report #CTU 187111
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged [WEEKS OR MONTHS]	Faecal Occult Blood Positive		Vioxx 50mg Msd	PS	Msd	ORAL	50MG PO QD	

Date:02/21/03ISR Number: 4060101-7Report Type:Direct Company Report #CTU 187112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged [WEEKS TO MONTHS]	Abdominal Pain Lower International Normalised Ratio Increased		Vioxx Merck Sharpe Dohme	PS	Merck Sharpe Dohme			
			Coumadin	C				
			Bactrim	C				

Date:02/21/03ISR Number: 4062157-4Report Type:Expedited (15-DaCompany Report #EMADSS2003001329
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Nausea Scar Vomiting	Foreign Health Professional	Tramal (Tramadol Hydrochloride)	PS		ORAL	300 MG, DAILY, ORAL	
			Digitoxin	SS			0.1 MG, 1 IN 1 DAY(S)	
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, DAILY, ORAL	

Date:02/21/03ISR Number: 4062232-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA02514
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
	Acid Base Balance
	Abnormal
	Areflexia
	Arrhythmia
	Atelectasis
	Blood Ph Decreased
	Capillary Disorder
	Coma
	Condition Aggravated
	Cyanosis
	Dermatitis Contact
	Dizziness
	Drug Ineffective
	Headache
	Hypotension
	Incontinence
	Intracranial Aneurysm
	Laboratory Test Abnormal
	Loss Of Consciousness
	Muscle Tightness
	Mydriasis
	Pulse Absent
	Pupil Fixed
	Pupils Unequal

		Respiratory Arrest					
		Spinal Disorder					
		Spleen Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sudden Death	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE							
		Syncope	Health				
		Ventricular Fibrillation	Professional				
		Ventricular Tachycardia					

Date:02/21/03ISR Number: 4062236-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY/							
Initial or Prolonged		Anxiety	Health				
PO							
		Arterial Thrombosis Limb	Professional	Altace	C		
		Blood Homocysteine		Plavix	C		
		Increased		Pervacid	C		
		Chronic Obstructive		Zocor	C		
		Pulmonary Disease		Aspirin	C		
		Coronary Artery Disease		Nitroglycerin	C		
		Coronary Artery					
		Restenosis					
		Coronary Artery Stenosis					
		Depression					
		Drug Ineffective					
		Emphysema					
		Facial Palsy					
		Gastritis					
		Gastrooesophageal Reflux					
		Disease					
		Gout					
		Hiatus Hernia					
		Hyperlipidaemia					
		Hypoaesthesia					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Respiratory Rate					
		Increased					
		Sinus Bradycardia					

Syncope
Thymus Hypertrophy

Date:02/24/03ISR Number: 4059404-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Acquired Cardiac Septal Defect
	Aortic Valve Incompetence
	Back Pain
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Condition Aggravated
	Diverticulum
	Duodenitis
	Gastritis

		Gastroenteritis					
		Haemorrhoids					
		Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
412	DAY						
		Hypertension		Vioxx	SS		ORAL
		Mitral Valve Incompetence		Colchicine	C		ORAL
		Pain In Extremity		Ticlid	C		
		Pulmonary Valve		Allopurinol	C		ORAL
		Incompetence		Neurontin	C		ORAL
		Rectal Haemorrhage		Ultram	C		ORAL
		Tricuspid Valve		Lortab	C		
		Incompetence		Elavil	C		ORAL
				Darvocet-N	C		

Date:02/24/03ISR Number: 4059413-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA01449
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY					
Hospitalization -	Cardiac Failure		Vioxx	SS		ORAL
8	DAY					
Initial or Prolonged	Congestive					
Disability	Dyspnoea Paroxysmal					
Other	Nocturnal					
	Hypertension					
	Hypokalaemia					
	Tachycardia					

Date:02/24/03ISR Number: 4059601-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01034
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Dysphagia		[Therapy			
Hospitalization -	Erosive Oesophagitis		Unspecified]	C		
Initial or Prolonged	Gastric Ulcer					
	Oesophageal Ulcer					
	Oesophagitis					

Oral Intake Reduced
Renal Failure

Date:02/24/03ISR Number: 4059602-7Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00031
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Chest Pain							
	Constipation							
	Diarrhoea							
	Flatulence							
	Headache							
	Pollakiuria							
	Somnolence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/03ISR Number: 4059603-9Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatine Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Urea Increased		Acenocoumarol	C		ORAL		
	Hepatic Necrosis		Amiodarone Hydrochloride	C		ORAL		
	Hepatic Neoplasm		Furosemide	C		ORAL		
	Hepatitis B		Spironolactone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		
			Thiamine Hydrochloride	C		ORAL		
			Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL		
			Potassium Chloride	C		ORAL		
			Lactulose	C		ORAL		
			Acetaminophen	C		ORAL		

Date:02/24/03ISR Number: 4059617-9Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	36	DAY
			Methotrexate	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:02/24/03ISR Number: 4059618-0Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00160
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Paroxetine	SS		ORAL		

Hospitalization - 8 DAY	Floxacillin	C
Initial or Prolonged Disability	Acetaminophen And Dihydrocodeine Bitartrate	C
Other	Benserazide Hydrochloride And Levodopa	C
	Dihydrocodeine	C
	Senna	C
	Timoptol-La	C
OPHTHALMIC		
	Hydrargaphen	C
TOPICAL		

Date:02/24/03ISR Number: 4059624-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00965
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/03ISR Number: 4059785-9Report Type:Direct Company Report #CTU 187210
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrasystoles		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY	
	Face Oedema					ORAL		
	Flushing							
	Hypertension							
	Oedema Peripheral							
	Palpitations							
	Urine Odour Abnormal							

Date:02/25/03ISR Number: 4059958-5Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00056
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	
			Insulin	C				
			Irbesartan	C		ORAL		
			Rilmenidene	C		ORAL		

Date:02/25/03ISR Number: 4059959-7Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00057
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum Intestinal Haemorrhagic		Acarbose	C		ORAL		
			Acebutolol	C		ORAL		
	Rectal Haemorrhage							

Date:02/25/03ISR Number: 4059960-3Report Type:Expedited (15-DaCompany Report #WAES 0302SWE00008
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure Pleural Effusion	Health Professional	Vioxx Valsartan Warfarin Sodium Terbutaline Sulfate Potassium Chloride Furosemide Atenolol Glyburide Metformin Hydrochloride	PS C C C C C C C C	Merck & Co., Inc	ORAL

Date:02/25/03ISR Number: 4061953-7Report Type:Direct Company Report #CTU 187409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Transient		Vioxx 50mg	PS			50MG (0) Q	
Hospitalization -	Brain Oedema							DAY
Initial or Prolonged	Pre-Eclampsia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/03ISR Number: 4066094-0Report Type:Expedited (15-DaCompany Report #2003UW01639
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Anaemia	Study	Warfarin	PS		ORAL	2.5 MG QD PO	
Intervention to	Gastrointestinal	Health	Warfarin	SS		ORAL	2.5 MG QD PO	
Prevent Permanent	Haemorrhage	Professional	Vioxx	SS		ORAL	25 MG QD PO	
Impairment/Damage	Post Procedural		Asa	SS		ORAL	81 MG QD PO	
	Haemorrhage		Atenolol	C				
			Calcium With Vitamin D	C				
			Lisinopril	C				
			Multivitamins	C				
			Tylenol	C				
			Clotrimazole	C				
			Melatonin	C				
			Terazosin	C				
			Lovastatin	C				

Date:02/25/03ISR Number: 4075646-3Report Type:Periodic Company Report #WAES 0205USA03453
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Face Oedema	Health	Tab Vasotec 20 Mg	PS		ORAL	20	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Tab Vioxx	SS		ORAL	PO	
			Hydrodiuril	C				
			Norvasc	C				
			Atenolol	C				
			Clonidine	C				
			Potassium Chloride	C				

Date:02/26/03ISR Number: 4060575-1Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00116
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		207 DAY
Hospitalization -	Gastritis Erosive		Dolormin	SS		ORAL		12 DAY
Initial or Prolonged	Gastritis Haemorrhagic		Metoprolol Succinate	C		ORAL		
	Petechiae		Levothyroxine Sodium	C		ORAL		
	Reflux Oesophagitis							
	Varices Oesophageal							

Date:02/26/03ISR Number: 4060591-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Abdominal Pain
	Carpal Tunnel Syndrome
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Diarrhoea
	Diverticulum Intestinal
	Dry Mouth
	Duodenitis
	Dysphagia
	Feeling Cold

	Gastritis						
	Gastroenteritis						
	Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhoids		Vioxx	PS	Merck & Co., Inc	ORAL	412	DAY
	Hyperlipidaemia		Vioxx	SS		ORAL		
	Hypertension		Neurontin	C		ORAL		
	Neck Pain		Colchicine	C		ORAL		
	Pollakiuria		Ticlid	C				
	Rectal Haemorrhage		Allopurinol	C		ORAL		
	Tooth Disorder		Ultram	C		ORAL		
			Lortab	C				
			Elavil	C		ORAL		
			Darvocet-N	C				

Date:02/26/03ISR Number: 4060594-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA01194
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
Other	Chest Pain							
	Headache							
	Hypertension							

Date:02/26/03ISR Number: 4060598-2Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00085
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
			Methotrexate Sodium	C				

Date:02/26/03ISR Number: 4060804-4Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00043
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/26/03ISR Number: 4060808-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA02277
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/03ISR Number: 4060815-9Report Type:Expedited (15-DaCompany Report #WAES 0302AUS00120
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction Dyspnoea Laryngitis Pharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/03ISR Number: 4060820-2Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00154
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS		ORAL		
			Bendroflumethiazide	C				
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Dipyridamole	C		ORAL		

Date:02/26/03ISR Number: 4060821-4Report Type:Expedited (15-DaCompany Report #WAES 0302CHE00026
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
			Nadroparin	C		SUBCUTANEOUS	17	DAY

Date:02/26/03ISR Number: 4060822-6Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00192
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	42	DAY

Date:02/26/03ISR Number: 4060827-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA01846
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/03ISR Number: 4060830-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA02443
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/27/03ISR Number: 4061846-5Report Type:Expedited (15-DaCompany Report #WAES 0212USA02241
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea Haemorrhagic	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
11 MON								
Initial or Prolonged	Headache		[Therapy					
	Musculoskeletal Stiffness		Unspecified]	C				
			Metformin	C				

Date:02/27/03ISR Number: 4062031-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02586
Age:7 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Amylase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
4 DAY								
	Chills		Antineoplastic					
	Lipase Increased		(Unspecified)	C				
	Rash		Amino Acids					
	Weight Increased		(Unspecified) And					

				Carbohydrates (Unspecified) And Electrolytes	C		

Date:02/27/03ISR Number: 4062032-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA02255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				

Date:02/27/03ISR Number: 4062033-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01890
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Activity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Haemorrhage		Ibuprofen	C				
Disability			Glucosamine	C				
Other								

Date:02/27/03ISR Number: 4062036-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA00129
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	186	DAY
	Irritable Bowel Syndrome		Synthroid	C		ORAL		
			Toprol Xl Tablets	C		ORAL		

Date:02/27/03ISR Number: 4062037-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA02224
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Initial or Prolonged Pharmaceutical Product Bextra SS
6 DAY
Other Complaint

Date:02/27/03ISR Number: 4064930-5Report Type:Direct Company Report #CTU 187594
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Creatinine		Vioxx 25 Mg Merck +			
Life-Threatening	Increased		Co	PS	Merck + Co	ORAL
1TBL PER DAY						
Hospitalization -	Blood Pressure Increased					
BY MOUTH 25						
Initial or Prolonged	Diarrhoea					
MG						
Disability	Fatigue		Lisinopril			
	Pulmonary Veno-Occlusive		(Prinivil)	C		
	Disease		Hydrochlorothiazide	C		
	Rash		Isosorbide Dinitrate	C		
	Renal Impairment		Plavix	C		
	Stomach Discomfort		Colchicine	C		
	Stupor		Furosemide	C		
	Transient Ischaemic		Nexium	C		
	Attack		Metoprolol Tartrate	C		
	Weight Decreased		Folic Acid	C		
			Aspirin	C		
			Allopurinal	C		
			Bumex	C		

			Synthroid	C			

Date:02/27/03ISR Number: 4068288-7Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/1X/PO;	
Initial or Prolonged	Arrhythmia	Health					25	
Other	Asthenia	Professional					MG/DAILY/PO	
	Atrial Fibrillation		Lescol	C				
	Atrial Flutter		Paxil	C				
	Atrioventricular Block		Salutensin	C				
	First Degree		Tenormin	C				
	Blood Ph Increased		Xanax	C				
	Blood Urea Increased							
	Bradycardia							
	Bundle Branch Block Right							
	Calcinosis							
	Cardiac Failure							
	Congestive							
	Chronic Obstructive							
	Pulmonary Disease							
	Decreased Appetite							
	Disease Recurrence							
	Dizziness							
	Fluid Overload							
	Flushing							
	Heart Rate Irregular							
	Hypertension							
	Hypertensive Heart							
	Disease							
	Hypothyroidism							
	Lung Neoplasm							
	Lymphadenopathy							
	Mitral Valve Incompetence							
	Myalgia							
	Nausea							
	Palpitations							
	Parkinson'S Disease							
	Pharyngolaryngeal Pain							
	Pleural Effusion							

Pulmonary Fibrosis
Rhinitis Allergic
Sick Sinus Syndrome
Spinal Osteoarthritis
Ventricular Extrasystoles
Vision Blurred
Weight Decreased

Date:02/27/03ISR Number: 4068291-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01676
Age:74 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anorexia
	Diverticulum
	Foot Fracture
	Glucose Tolerance Impaired

		Goitre					
		Hypertension					
		Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Kyphosis	Health	Tab Vioxx 25 Mg	PS		ORAL
25							
		Lower Gastrointestinal	Professional				
MG/DAILY/PO							
		Haemorrhage	Company	Percocet	C		
		Nausea	Representative	Prednisone	C		
		Oedema Peripheral					
		Osteoarthritis					
		Osteoporosis					
		Rheumatoid Arthritis					
		Spinal Osteoarthritis					
		Stasis Dermatitis					
		Urinary Incontinence					

Date:02/28/03ISR Number: 4062485-2Report Type:Expedited (15-DaCompany Report #WAES 0302NOR00006
Age:86 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
		Melaena	Professional	Potassium Chloride	SS		ORAL
				Citalopram Hydrobromide	SS		ORAL
				Furosemide	C		ORAL
				Zopiclone	C		ORAL
				Acetaminophen	C		ORAL

Date:02/28/03ISR Number: 4062488-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA03079
Age:92 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Ulcer Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged			Professional	Aspirin	C		ORAL
				Hydrodiuril	C		
Disability				Ascorbic Acid	C		ORAL
Other				Tylenol	C		ORAL
				Zoloft	C		

Synthroid	C	
Vasotec	C	ORAL
Ferrous Sulfate	C	
Alphagan	C	
Risperdal	C	
Colace	C	
Seroquel	C	
Vitamins (Unspecified)	C	ORAL

Date:02/28/03ISR Number: 4062491-8Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Activated Partial Thromboplastin Time Prolonged
	Acute Myocardial Infarction
	Alanine Aminotransferase Increased

		Anaphylactic Reaction					
		Arrhythmia					
		Asthma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atelectasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Back Injury	Professional	Celebrex	SS		ORAL
		Blood Alkaline		Paxil	C		ORAL
		Phosphatase Increased		Paxil	C		ORAL
		Blood Chloride Increased		Flonase	C		ORAL
		Blood Glucose Decreased		Toradol	C		ORAL
		Blood Potassium Increased		Remeron	C		ORAL
		Blood Sodium Increased		Nystatin	C		ORAL
		Cardiac Arrest		Biaxin	C		ORAL
		Chest Pain		Depo-Provera	C		
INTRAMUSCULAR							
		Chest Wall Pain		Hydrocortisone			
		Chronic Obstructive		Acetate	C		
		Pulmonary Disease		Skelaxin	C		ORAL
		Contusion		Tequin	C		ORAL
		Electromechanical		Alupent	C		
RESPIRATORY							
		Dissociation					
(INHALATION)							
		Exsanguination		Serevent	C		
RESPIRATORY							
		Gastritis					
(INHALATION)							
		Gastrointestinal		Flovent	C		
RESPIRATORY							
		Haemorrhage					
(INHALATION)							
		Haematocrit Decreased		Buspar	C		ORAL
		Haemoglobin Decreased		Lipitor	C		ORAL
		Haemorrhoids		Amaryl	C		ORAL
		Hypertension		Paxil	C		ORAL
		International Normalised		Pravachol	C		ORAL
		Ratio Increased		Claritin	C		ORAL
		Large Intestinal Ulcer		Accolate	C		ORAL
		Haemorrhage		Pertussin N	C		ORAL
		Mean Cell Haemoglobin		Zydone	C		ORAL
		Concentration Decreased		Acetaminophen And			
		Mean Cell Volume		Hydrocodone			
		Decreased		Bitartrate	C		ORAL
		Oedema		Percocet	C		ORAL
		Oesophageal Ulcer		Pramoxine			
		Haemorrhage		Hydrochloride	C		
TOPICAL							

	Platelet Count Decreased	Premarin	C	ORAL
	Pleural Infection	Proventil	C	
RESPIRATORY				
	Pleuritic Pain			
(INHALATION)				
	Prothrombin Time	Demerol	C	ORAL
	Prolonged	Alprazolam	C	ORAL
	Pulse Absent	Carisoprodol	C	ORAL
	Red Blood Cell Count	Aquaphor	C	
	Decreased	Promethazine	C	
	Rib Fracture	Soma	C	ORAL
	Sudden Cardiac Death	Ziac	C	
	Ventricular Arrhythmia			
	White Blood Cell Count			
	Increased			

Date:02/28/03ISR Number: 4062492-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA02688
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Lipitor	C		
Other						

Date:02/28/03ISR Number: 4062494-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA02573
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/28/03ISR Number: 4062497-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA02492
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Urea Increased							

Date:02/28/03ISR Number: 4062549-3Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00102
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Metastases To Liver		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pleural Effusion		Naloxone Hydrochloride And Tilidine Hydrochloride	C				

Date:02/28/03ISR Number: 4062552-3Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/28/03ISR Number: 4062553-5Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00119
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	No Adverse Drug Effect		Vioxx	PS	Merck & Co., Inc	ORAL		
			Warfarin	C				

Date:02/28/03ISR Number: 4062556-0Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00070
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Urticaria							

Date:02/28/03ISR Number: 4062558-4Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00173
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/03ISR Number: 4062563-8Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00190
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Vioxx	PS	Merck & Co., Inc	ORAL		570 DAY
	Abnormal Rash		Acetaminophen And Codeine Phosphate	C		ORAL		
			Bendroflumethiazide	C		ORAL		

Date:02/28/03ISR Number: 4062564-XReport Type:Expedited (15-DaCompany Report #WAES 0302FRA00084
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		4 WK
Initial or Prolonged	Vomiting		Morphine	C		ORAL		
			Hydrochlorothiazide And Valsartan	C		ORAL		

Date:02/28/03ISR Number: 4062567-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA02441
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		2 WK
Initial or Prolonged	Fatigue		Vioxx	SS		ORAL		
	Syncope		Adderall Tablets	C				

Date:02/28/03ISR Number: 4062569-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA02892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL		
	Operation		Vioxx	SS		ORAL		
			Aspirin	C				
			Medrol Dosepak	C				

Date:03/03/03ISR Number: 4064657-XReport Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12142402
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer		Excedrin Migraine Tabs	PS	Bristol-Myers Squibb Company	ORAL	6	MON
			Vioxx	SS				
			Fosamax	C				

Date:03/03/03ISR Number: 4064787-2Report Type:Expedited (15-DaCompany Report #ZA-GLAXOSMITHKLINE-B0284069A
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Fluticasone Propionate	PS	Glaxosmithkline	RESPIRATORY (INHALATION)	500MCG Twice per day	440 DAY
	Alveolitis Allergic							
	Gastritis							
	Gastrointestinal Disorder							
	Interstitial Lung Disease		Vioxx	SS		ORAL	12.5MG Per day	
	Pulmonary Bulla							
	Vomiting		Relifen	SS	Glaxosmithkline	ORAL	1G Per day	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/03ISR Number: 4064848-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA01156
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/03ISR Number: 4064850-6Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00078
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemodialysis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Renal Failure	Professional	Ciprofloxacin	C		ORAL	4	DAY
Initial or Prolonged	Tubulointerstitial Nephritis							

Date:03/03/03ISR Number: 4064851-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00704
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Increased Feeling Abnormal	Professional						

Date:03/03/03ISR Number: 4064852-XReport Type:Expedited (15-DaCompany Report #WAES 0302DNK00029
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Headache		Fenoterol Hydrobromide And Ipratropium Bromide	C				
	Nausea		Budesonide	C				
			Salmeterol Xinafoate	C				

			Tolterodine Tartrate	C		ORAL
			Tolterodine Tartrate	C		ORAL

Date:03/03/03ISR Number: 4064853-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA00957
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Lipitor	C		

Date:03/03/03ISR Number: 4064855-5Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00106
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
Initial or Prolonged	Haematemesis		Aspirin	C		ORAL
	Hiatus Hernia		Albuterol Sulfate	C		
	Oesophagitis		Ramipril	C		ORAL
	Vomiting		Ranitidine	C		ORAL
			Fosamax	C		ORAL

Date:03/03/03ISR Number: 4064972-XReport Type:Expedited (15-DaCompany Report #WAES 0301GBR00191
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Other		Professional	Atenolol	C				

Date:03/03/03ISR Number: 4064985-8Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00216
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Functional Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/03ISR Number: 4064986-XReport Type:Expedited (15-DaCompany Report #WAES 0302DNK00031
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Sick Sinus Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Lercanidipine Hydrochloride	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Aspirin	C		ORAL		

Date:03/03/03ISR Number: 4069157-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Consumer	Tab Vioxx 50mg	PS		ORAL	50 MG/1X/PO ; 25 MG DAILY	
	Atrial Fibrillation	Health						
Other	Atrial Flutter	Professional					PO	
	Cardiac Failure		Lescol	C				
	Congestive		Paxil	C				

	Dyspnoea	Salutensin	C
	Implant Site Reaction	Tenormin	C
	Oedema	Xanax	C
	Sick Sinus Syndrome		
	Swelling		

Date:03/03/03ISR Number: 4069277-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:66 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Aortic Valve Incompetence
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Diverticulum
	Dry Mouth
	Duodenitis
	Feeling Cold
	Food Poisoning
	Gastritis
	Gastroenteritis
	Gingival Bleeding
	Haemorrhoids
	Hiatus Hernia
	Hyperlipidaemia

	Hypertension						
	Mitral Valve Incompetence						
	Neck Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain In Extremity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Pollakiuria	Health					
	Pulmonary Valve Incompetence	Professional	Darvocet-N	C			
			Elavil	C			
	Tooth Loss		Lortab	C			
	Tricuspid Valve Incompetence		Neurontin	C			
			Ticlid	C			
			Ultram	C			
			Allopurinol	C			
			Colchicine	C			

Date:03/04/03ISR Number: 4065553-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02797
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Intentional Misuse	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	
			Morphine	C			
			Dihydrocodeine	C			
			Chlorpromazine	C			
			Citalopram	C			

Date:03/04/03ISR Number: 4065555-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01021
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pulmonary Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/04/03ISR Number: 4065558-3Report Type:Expedited (15-DaCompany Report #WAES 0212USA01211
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Laryngitis	Professional	Ibuprofen	C			
	Nausea		Darvocet-N	C			
	Vomiting		Prednisone	C			
	Wheezing		[Therapy Unspecified]	C			

Date:03/04/03ISR Number: 4065559-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00227
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
Other	Oropharyngeal Swelling		Toprol Xl Tablets	C				
	Tongue Oedema		Lotrel	C				
			Zoloft	C				
			Claritin-D	C				
			Vagifem	C				
			Asacol	C				
			Lodine	C				
			Vicodin Tablets	C				
			Vitamin E	C				
			Minerals					

			(Unspecified) And Vitamins (Unspecified)	C
			Calcium (Unspecified)	C
			Ginseng	C
			Cyanocobalamin	C
			Linseed Oil	C

Date:03/04/03ISR Number: 4065560-1Report Type:Expedited (15-DaCompany Report #WAES 0212USA01919
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Oedema Peripheral	Professional	Vioxx	SS		ORAL	4	DAY
	Periorbital Oedema		Zoloft	C				
			Allegra	C				

Date:03/04/03ISR Number: 4065757-0Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00003
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	37	DAY
Initial or Prolonged	Oesophagitis Ulcerative	Professional						

Date:03/04/03ISR Number: 4065764-8Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00002
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Athetosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Carbidopa And Levodopa	C				
			Acetaminophen And Codeine Phosphate	C				
			Albuterol Sulfate					

				And Ipratropium Bromide	C		
RESPIRATORY (INHALATION)							
				Ferrous Sulfate	C		
				Fosamax	C		ORAL
				Psyllium Husk	C		
				Hydroxocobalamin	C		
INTRAVENOUS							
				Heparinoid And Salicylic Acid	C		
				Pergolide Mesylate	C		
				Perindopril Erbumine	C		
				Quetiapine Fumarate	C		
				Venlafaxine Hydrochloride	C		

Date:03/04/03ISR Number: 4065769-7Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00183
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
Hospitalization - Initial or Prolonged	Oedema		Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Digitoxin	C		ORAL		

		Captopril	C	ORAL
		Allopurinol	C	ORAL
		Metoprolol Succinate	C	ORAL
		Aspirin	C	ORAL

Date:03/04/03ISR Number: 4065770-3Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00215
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Jejunal Perforation		Analgesic Or Anesthetic (Unspecified)	C				
Disability								
PARENTERAL							2	DAY

Date:03/04/03ISR Number: 4065774-0Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00243
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Dizziness							
	Vertigo							
	Vomiting							

Date:03/04/03ISR Number: 4065775-2Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00137
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Gastrointestinal		Methotrexate Sodium	C				
Initial or Prolonged	Haemorrhage		Prednisone	C				
	Pernicious Anaemia		Calcium Carbonate And Etidronate Sodium	C				
			Vitamin D					

			(Unspecified)	C		

Date:03/04/03ISR Number: 4065778-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA02443
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/03ISR Number: 4065780-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA03118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/03ISR Number: 4065781-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA02492
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Urea Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/03ISR Number: 4065784-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA00013
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Mitral Valve Incompetence Oedema Peripheral Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/03ISR Number: 4065786-7Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00005
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		124 DAY
Disability			Sulfasalazine	C		ORAL		

Date:03/05/03ISR Number: 4066272-0Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00177
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
	Fatigue		Naproxen	C				
			Acetaminophen And Codeine Phosphate	C				

Date:03/05/03ISR Number: 4066288-4Report Type:Expedited (15-DaCompany Report #GB-GLAXOSMITHKLINE-B0292824A
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Consumer	Paroxetine	PS	Glaxosmithkline	ORAL	30MG Per day	
Life-Threatening	Haemorrhage		Rofecoxib	SS		ORAL	25MG Per day	

Hospitalization - Flucloxacillin C Glaxosmithkline
UNKNOWN 250MG Four
Initial or Prolonged
times per day 8 DAY
Disability Co-Dydramol C Glaxosmithkline
UNKNOWN 500VA See
Other
dosage text
Madopar C
UNKNOWN 62.5MG Twice

per day
Dihydrocodeine C
UNKNOWN 30MG Twice

per day
Senna C Glaxosmithkline
UNKNOWN 7.5VA At

night
Timolol C
OPHTHALMIC 1DROP Per day
Conotrane C
UNKNOWN

Date:03/05/03ISR Number: 4066509-8Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00209
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL
	Oesophagitis		Meperidine Hydrochloride	C		ORAL
			Tramadol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/03ISR Number: 4066512-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA01217
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Oedema Peripheral	Professional	Coumadin	C		ORAL		
			Nexium	C		ORAL		
			Tylenol	C				
			Xalatan	C		OPHTHALMIC		
			Wellbutrin Sr	C		ORAL	420	DAY
			Augmentin	C		ORAL	33	DAY
			Paxil	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:03/05/03ISR Number: 4066514-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA01471
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional	[Therapy Unspecified]	C				
			Celebrex	C				

Date:03/05/03ISR Number: 4066516-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA00115
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Gastrointestinal Haemorrhage		Neurontin	C				

Date:03/05/03ISR Number: 4066520-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA02920
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Pain Liver Disorder Pancreatic Disorder Swelling White Blood Cell Count Increased		Vioxx Aleve	PS C	Merck & Co., Inc	ORAL		

Date:03/05/03ISR Number: 4066521-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA02904
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged Disability			Darvocet-N	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/03ISR Number: 4067933-XReport Type:Direct Company Report #CTU 188017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Discomfort		Vioxx 50mg	PS		
Q DAY						
	Drug Effect Decreased		Ultram	SS		
Q 6H						

Date:03/06/03ISR Number: 4066905-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA03066
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Loss Of Consciousness		Aspirin	C		
Initial or Prolonged	Myocardial Infarction		[Therapy			
	Thrombosis		Unspecified]	C		
			Tylenol	C		

Date:03/06/03ISR Number: 4067382-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
39 DAY						
Hospitalization -	Infarction	Professional	Soma	C		
Initial or Prolonged	Blood Pressure Decreased		Elavil	C		
	Blood Pressure Increased		Esgic-Plus Tablets	C		
	Brain Death					
	Cardiac Arrest					
	Cardiac Failure					
	Congestive					
	Cardiomegaly					
	Circulatory Collapse					
	Coma					
	Heart Rate Increased					
	Hypoxic Encephalopathy					
	Metabolic Acidosis					
	Pulmonary Congestion					

Date:03/06/03ISR Number: 4067383-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01493
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Allergy To Animal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Laryngitis	Professional	Vioxx	SS		ORAL	16 MON	
			Advair	C			RESPIRATORY (INHALATION)	
			Albuterol	C			RESPIRATORY (INHALATION)	
			Wellbutrin Sr	C		ORAL		

Date:03/06/03ISR Number: 4067385-XReport Type:Expedited (15-DaCompany Report #WAES 0302GBR00244
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL	552 DAY	
	Inadequately Controlled		Irbesartan	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/06/03ISR Number: 4067389-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA02695
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged	Dyspnoea	Professional	Celebrex	SS		ORAL		356 DAY
	Gastrointestinal Disorder		Celebrex	SS		ORAL		246 DAY
	Hypersensitivity		Voltaren	C				126 DAY
	Oesophageal Disorder		Premarin	C				
			Allegra	C				

Date:03/06/03ISR Number: 4067397-6Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00009
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematochezia							

Date:03/06/03ISR Number: 4069274-3Report Type:Direct Company Report #CTU 188059
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema Multiforme		Vioxx	PS		ORAL	12.5M QD	ORAL

Date:03/06/03ISR Number: 4071907-2Report Type:Expedited (15-DaCompany Report #HQ6077609JAN2003
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anti-Hbs Antibody	Health	Cordarone					
Hospitalization -	Positive	Professional	(Amiodarone, Tablet)	PS		ORAL	2000 MG 1X	

Initial or Prolonged	Coma Hepatic	Company				
PER 1 DAY 4 MON						
	Drug Toxicity	Representative	Sintrom			
	Dyspnoea	Other	(Acenocoumarol,)	SS		ORAL
4 MON						
	Hepatic Necrosis		Vioxx (Rofecoxib,			
	Hepatitis Fulminant		Tablet)	SS		ORAL
50 MG 1X PER						
	Hypoglycaemia					
1 DAY 4 MON						
	Oliguria		Lasix (Furosemide)	C		
	Renal Failure Chronic		Aldactone			
	Self-Medication		(Spironolactone)	C		
	Weight Increased		Tramal (Tramadol			
			Hydrochloride)	C		
			Benerva (Thiamine			
			Hydrochloride)	C		
			Becozym (Vitamin B			
			Nos)	C		
			Kalium (Potassium			
			Chloride)	C		
			Duphalac (Lactulose)	C		
			Temesta (Lorazepam)	C		

Date:03/07/03ISR Number: 4068019-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA01052
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/07/03ISR Number: 4068024-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA01449
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Hospitalization -	Cardiac Failure	Professional	Vioxx	SS		ORAL		8 DAY
Initial or Prolonged	Congestive							
Disability	Circulatory Collapse							
Other	Hypertension							
	Hypokalaemia							
	Tachycardia							

Date:03/07/03ISR Number: 4068027-XReport Type:Expedited (15-DaCompany Report #WAES 0210FRA00018
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Iron Deficiency Anaemia	Professional	Fosamax	C		ORAL		
			Nifedipine	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		
			Clorazepate Dipotassium	C		ORAL		
			Zopiclone	C		ORAL		

Date:03/07/03ISR Number: 4068226-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antithrombin Iii		Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Decreased		Vioxx	SS		ORAL		33 DAY
Disability	Aorto-Iliac Arterial		Vioxx	SS		ORAL		312 DAY
	Stenosis		Vioxx	SS		ORAL		36 DAY

Arteriogram Carotid	Premarin	C	
Abnormal	Paxil	C	ORAL
Cardiac Aneurysm	Aspirin	C	ORAL
Cartilage Injury	Vistaril	C	
Cerebral Artery Occlusion	Estrogens		
Cerebral Infarction	(Unspecified)	C	
Cerebrovascular Accident	Restoril	C	ORAL
Chondromalacia	Vicodin Es Tablets	C	ORAL
Diverticulum Intestinal	Vitamins		
Embolism	(Unspecified)	C	
Haematocrit Decreased	Tricor	C	ORAL
Haemoglobin Decreased	Zantac	C	
Joint Effusion			
Mitral Valve Incompetence			
Osteoarthritis			
Pain			
Phlebothrombosis			
Platelet Count Decreased			
Tricuspid Valve Incompetence			

Date:03/07/03ISR Number: 4068230-9Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00147
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
Life-Threatening	Cardio-Respiratory Arrest	Professional	Vioxx	SS		ORAL		
Hospitalization -	Chest Pain							
Initial or Prolonged	Chronic Obstructive							
	Pulmonary Disease							
	Eating Disorder							
	Pneumonia							

Date:03/07/03ISR Number: 4068240-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA03033
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/03ISR Number: 4068241-3Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Gastrointestinal Disorder	Professional	Omeprazole	SS			3	DAY
	Renal Failure							

Date:03/07/03ISR Number: 4068246-2Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00215
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Jejunal Perforation	Professional	Analgesic Or					

Initial or Prolonged			Anesthetic			
Disability			(Unspecified)	C		
PARENTERAL	2	DAY				
			Acetaminophen	C		ORAL

Date:03/07/03ISR Number: 4068254-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA00098
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Behaviour	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebral Ischaemia	Professional	Serevent	C		
	Confusional State		Combivent	C		
	Drug Screen Positive		Azmacort	C		
	Headache		Vivelle	C		
	Hypertension		Celexa	C		
	Incoherent		Valium	C		
	Mental Status Changes		Potassium Chloride	C		
			Calcium Carbonate	C		
			[Composition			
			Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/03ISR Number: 4069586-3Report Type:Direct Company Report #CTU 188132
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Warfarin	PS		ORAL	6 MG PO QD	3 YR
Initial or Prolonged	Drug Interaction		Rofecoxib	SS		ORAL	12.5 MG PO QD	
	Haematoma		Levofloxacin	SS				
	Hyperkalaemia							
	Pancytopenia							
	Pneumonia							
	Renal Impairment							

Date:03/07/03ISR Number: 4069598-XReport Type:Direct Company Report #CTU 188140
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Fluid Overload		Vioxx 25 Mg					
Intervention to	Renal Impairment		(Rofecoxib) Merck	PS	Merck	ORAL	25 MG QD PO X	
Prevent Permanent							2 DAYS	
Impairment/Damage			Vioxx 50 Mg					
			(Rofecoxib) Merck	SS	Merck	ORAL	50 MG QD PO X	
							12D	

Date:03/07/03ISR Number: 4072428-3Report Type:Expedited (15-DaCompany Report #WAES 01101475
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
	Activated Partial
	Thromboplastin Time
	Prolonged
	Acute Myocardial
	Infarction
	Alanine Aminotransferase
	Increased

Albumin Globulin Ratio
Decreased
Anaphylactic Reaction
Anion Gap Increased
Anisocytosis
Arrhythmia
Aspartate
Aminotransferase
Decreased
Asthma
Atelectasis
Band Neutrophil Count
Increased
Blood Albumin Decreased
Blood Bilirubin Increased
Blood Calcium Decreased
Blood Chloride Increased
Blood Creatine
Phosphokinase Increased
Blood Creatinine
Increased
Blood Glucose Decreased
Blood Potassium Increased
Blood Sodium Increased
Blood Urea Increased

		Cardio-Respiratory Arrest					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Contusion	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Cough	Health				
MG/DAILY/PO							
		Eosinophil Count	Professional	Celebrex 200 Mg	SS		ORAL
200							
		Decreased					
MG/DAILY/PO							
		Exsanguination		Accolate	C		
		Gastritis		Alupent	C		
		Gastrointestinal		Amaryl	C		
		Haemorrhage		Aquaphor	C		
		Haematemesis		Biaxin	C		
		Haemorrhoids		Buspar	C		
		Hypertension		Claritin	C		
		Hypogammaglobulinaemia		Demerol	C		
		International Normalised		Depo-Provera	C		
		Ratio Increased		Flonase	C		
		Large Intestinal Ulcer		Flovent	C		
		Haemorrhage		Lipitor	C		
		Limb Injury		Paxil	C		
		Macrocytosis		Percocet	C		
		Mean Cell Haemoglobin		Pertussin N	C		
		Concentration Decreased		Pravachol	C		
		Mean Cell Haemoglobin		Premarin	C		
		Increased		Proventil	C		
		Mean Cell Volume		Remeron	C		
		Increased		Serevent	C		
		Monocyte Count Decreased		Skelaxin	C		
		Muscle Tightness		Soma	C		
		Oedema		Tequin	C		
		Oesophageal Ulcer		Toradol	C		
		Haemorrhage		Ziac	C		
		Pco2 Decreased		Zydone	C		
		Platelet Count Decreased		Acetaminophen (+)			
		Pleural Fibrosis		Hydrocodne Bi	C		
		Pleural Infection		Alprazolam	C		
		Protein Total Decreased		Carisoprodol	C		
		Prothrombin Time		Hydrocortisone			
		Prolonged		Acetate	C		
		Pulmonary Fibrosis		Nystatin	C		
		Rectal Haemorrhage		Pramoxine			
		Red Blood Cell Anisocytes		Hydrochloride	C		

Present Red Blood Cell Count Decreased Red Blood Cell Nucleated Morphology Present Red Cell Distribution Width Increased Regurgitation Of Food Respiratory Distress Rib Fracture Sinus Arrhythmia Sudden Cardiac Death Ventricular Arrhythmia White Blood Cell Count Increased	Promethazine	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/03ISR Number: 4068822-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		425 DAY
Hospitalization - Initial or Prolonged	Infarction		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		
			Lipitor	C				
			Metoprolol	C				
			Prozac	C				
			Combivent	C				
			Daypro	C		ORAL		
			Prednisone	C				

RESPIRATORY

(INHALATION)

Date:03/10/03ISR Number: 4068824-0Report Type:Expedited (15-DaCompany Report #WAES 0212AUS00093
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/03ISR Number: 4068827-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Avandia	C				
	Blood Glucose Abnormal		Blephamide Ointment	C				
	Cardiac Murmur		Viagra	C				
	Erectile Dysfunction		Acetaminophen And Hydrocodone Bitartrate	C				
	Eye Injury		Duratuss	C				
	Injury		Wellbutrin	C				
	Ventricular Hypokinesia							
	Vision Blurred							

Date:03/10/03ISR Number: 4068830-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA03150
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

Date:03/10/03ISR Number: 4069017-3Report Type:Expedited (15-DaCompany Report #WAES 0303BEL00001
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eczema		Telmisartan	C		ORAL		
	Fall		Atorvastatin Calcium	C		ORAL		
	Mood Altered		Omeprazole	C		ORAL		
	Vision Blurred		Tramadol Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/03ISR Number: 4069018-5Report Type:Expedited (15-DaCompany Report #WAES 0212AUS00093
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Disorder Therapeutic Response Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/03ISR Number: 4069022-7Report Type:Expedited (15-DaCompany Report #WAES 0302SWE00018
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Cerebral Infarction		Vioxx Metoprolol Tartrate Glyburide Insulin, Biphasic Isophane [Injection] Warfarin Sodium Aspirin Aspirin	PS C C C C C C	Merck & Co., Inc	ORAL		

Date:03/11/03ISR Number: 4069528-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA02829
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Fluid Retention Insomnia	Health Professional	Vioxx Ziac	PS C	Merck & Co., Inc	ORAL		

Date:03/11/03ISR Number: 4069530-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA00373
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/03ISR Number: 4069738-2Report Type:Expedited (15-DaCompany Report #WAES 0303ESP00008
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Condition Aggravated							
	Diarrhoea							
	Hypertension							
	Nausea							
	Tachycardia							
	Vomiting							

Date:03/11/03ISR Number: 4069739-4Report Type:Expedited (15-DaCompany Report #WAES 0210ESP00012
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/03ISR Number: 4069745-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00041
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Atopic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
	Pruritus	Professional	Lansoprazole	C		ORAL		
	Rash Erythematous		Propranolol	C		ORAL		
			Prochlorperazine Maleate	C				

Date:03/11/03ISR Number: 4069746-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA00092
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage	Professional	Prednisone	C				
			Imuran (Azathioprine)	C				

Date:03/11/03ISR Number: 4069748-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA02904
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged		Professional	Darvocet-N	C				
Disability								

Date:03/11/03ISR Number: 4070389-4Report Type:Direct Company Report #CTU 188403
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dermatitis		Vioxx ?25mg Merck	PS	Merck	ORAL	?25MG	QD PO

Date:03/11/03ISR Number: 4070398-5Report Type:Direct Company Report #CTU 188420
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute		Zometa	PS				
Hospitalization - Initial or Prolonged			Vioxx	SS				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:03/12/03ISR Number: 4070218-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Aortic Atherosclerosis
Hospitalization - Initial or Prolonged	Bundle Branch Block Left
	Cardiac Arrest
	Cerebral Infarction
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Occlusion

	Dilatation Atrial						
	Heart Rate Irregular						
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypothermia		Vioxx	PS	Merck & Co., Inc	ORAL	243	DAY
	Muscle Tightness		Lasix (Furosemide)	C				
	Oedema		Tylenol Extra					
	Platelet Count Abnormal		Strength	C				
			Centrum	C				

Date:03/12/03ISR Number: 4070219-0Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00010
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Skin Exfoliation							

Date:03/12/03ISR Number: 4070236-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA02673
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholecystitis		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Haematochezia		Tylenol	C				
Disability	Hepatitis							
	Hypokalaemia							

Date:03/12/03ISR Number: 4070441-3Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Akathisia		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Anaemia		Vioxx	SS		ORAL	3	DAY

Disability	Asthenia	Vioxx	SS	ORAL
104 DAY				
	Balance Disorder	Vioxx	SS	ORAL
7 DAY				
	Brain Oedema	Aristocort	C	
PARENTERAL	1 DAY			
	Bundle Branch Block Left	Ziac	C	ORAL
	Carpal Tunnel Syndrome	Hyzaar	C	ORAL
	Dizziness	Zoloft	C	ORAL
	Fall	Toradol	C	
INTRAMUSCULAR				
	Haemorrhagic Stroke	Vitamin E	C	
	Hemiparesis	Ascorbic Acid	C	
	Hypertension	Iron (Unspecified)	C	
	Malaise			
	Mitral Valve Incompetence			
	Myoglobin Blood Increased			
	Neuropathy Peripheral			
	Occult Blood Positive			
	Osteoarthritis			
	Radius Fracture			
	Scar			
	Sinus Bradycardia			
	Subcutaneous Nodule			
	Tendonitis			
	Tenosynovitis			
	Thrombocytopenia			
	Upper Limb Deformity			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/03ISR Number: 4070444-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA00193
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aortic Valve		Aspirin	C				
	Calcification		Tylenol	C				
	Aortic Valve Sclerosis							
	Blood Cholesterol Increased							
	Bradycardia							
	Cardiac Murmur							
	Cardio-Respiratory Arrest							
	Cartilage Injury							
	Cyanosis							
	Dermatitis							
	Drug Effect Decreased							
	Drug Ineffective							
	Electromechanical Dissociation							
	Grand Mal Convulsion							
	Hypertension							
	Joint Crepitation							
	Joint Stiffness							
	Joint Swelling							
	Livedo Reticularis							
	Mitral Valve Incompetence							
	Mydriasis							
	Myocardial Infarction							
	Osteoarthritis							
	Pulse Absent							
	Pupil Fixed							
	Sudden Death							
	Ventricular Extrasystoles							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:03/12/03ISR Number: 4070445-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA02224
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
3 DAY								

Initial or Prolonged Bextra SS
6 DAY
Other

Date:03/12/03ISR Number: 4070449-8Report Type:Expedited (15-DaCompany Report #WAES 0303ITA00002
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		32 DAY
Hospitalization -	Haemoglobin Decreased		Clodronate Disodium	C				397 DAY
Initial or Prolonged			Clotiazepam	C				397 DAY
			Lisinopril	C				32 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/03ISR Number: 4070451-6Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00016
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
	Lower Gastrointestinal Haemorrhage		Diclofenac Sodium	C		
			[Therapy Unspecified]	C		

Date:03/12/03ISR Number: 4070452-8Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00072
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 653 DAY	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Haemorrhage		Lansoprazole	C		ORAL
			Amiloride Hydrochloride And Furosemide	C		
			Acetaminophen And Propoxyphene Hydrochloride	C		
			Senna	C		
			Quinine Sulfate	C		
			Amitriptyline Hydrochloride	C		

Date:03/12/03ISR Number: 4070453-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL
	Onychomadesis		Bextra	SS		ORAL
1 DAY						

Date:03/12/03ISR Number: 4070454-1Report Type:Expedited (15-DaCompany Report #WAES 0303ESP00013
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL		
	Phosphokinase Increased		Fluvastatin Sodium	SS		ORAL		
	Blood Pressure Increased							
	Drug Interaction							
	Hypertension							
	Myalgia							
	Oedema Peripheral							
	Pain In Extremity							

Date:03/12/03ISR Number: 4070457-7Report Type:Expedited (15-DaCompany Report #WAES 0303USA00177
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Aspirin	C				
	Chest Pain							
	Mitral Valve Incompetence							

Date:03/12/03ISR Number: 4070459-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA00625
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/12/03ISR Number: 4070461-9Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/12/03ISR Number: 4070464-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA00838
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:03/12/03ISR Number: 4072221-1Report Type:Direct Company Report #USP 55579
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error		Ziox (Urea/Papam/Chlorophyllin Comp.) Vioxx (Rofecoxib) Zyvox (Linezolid)	PS SS SS	Stratus Merck Pharmacia Corp			

Date:03/12/03ISR Number: 4075383-5Report Type:Expedited (15-DaCompany Report #DEU-2002-0000155
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Foreign	Oxygesic (Oxycodone					
Other	Gingival Bleeding	Consumer	Hydrochloride) Cr					
	Osteonecrosis	Health	Tablet	PS		ORAL		
SEE IMAGE								
	Periodontal Destruction	Professional	Vioxx (Rofecoxib)	SS				
		Other						

Date:03/13/03ISR Number: 4071301-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02564
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bacterial Infection		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON
Hospitalization -	Biopsy Stomach Abnormal		Cardura	C		ORAL		
Initial or Prolonged	Fungal Infection		Atenolol	C		ORAL		
Other	Gastritis		Zestril	C		ORAL		
	Iron Deficiency Anaemia		Tylenol	C		ORAL		
	Peptic Ulcer		Actos	C		ORAL		
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/13/03ISR Number: 4071302-6Report Type:Expedited (15-DaCompany Report #WAES 0208USA00634
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Bradycardia							
	Chest Pain							

Date:03/13/03ISR Number: 4071306-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA00793
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Peptic Ulcer Reactivated		Atenolol	C		ORAL		
			Norvasc	C				

Date:03/13/03ISR Number: 4071650-XReport Type:Expedited (15-DaCompany Report #WAES 0303BEL00001
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Eczema		Telmisartan	C		ORAL		
	Elevated Mood		Atorvastatin Calcium	C		ORAL		
	Fall		Omeprazole	C		ORAL		
	Therapeutic Response		Tramadol					
	Unexpected		Hydrochloride	C		ORAL		
	Vision Blurred		Acetaminophen	C		ORAL		

Date:03/13/03ISR Number: 4073634-4Report Type:Direct Company Report #CTU 188674
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Vioxx 25mg Msd	PS	Msd	ORAL	50MG PO ONCE	
	Increased							
THEN 25MG PO								

Blood Urea Increased
QD

Date:03/14/03ISR Number: 4072261-2Report Type:Expedited (15-DaCompany Report #WAES 0209CHE00001
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Gastric Ulcer	Professional	Dipyrone	SS		ORAL	7	DAY
	Gastric Ulcer Perforation		Ibuprofen	SS		ORAL	8	DAY
	Ileus Paralytic		Aspirin	SS		ORAL		
	Shock		Irbesartan	C		ORAL		
			Amiodarone Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Molsidomine	C		ORAL		

Date:03/14/03ISR Number: 4072262-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Aortic Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
		Atherosclerosis	Professional	Lipitor	SS		ORAL
366	DAY						
		Back Pain		Zemplar	SS		
		Biliary Neoplasm		[Therapy			
		Cardiac Disorder		Unspecified]	SS		
		Cardiac Failure		Imuran			
		Congestive		(Azathioprine)	C		ORAL
		Cardiomegaly		Prednisone	C		ORAL
		Complications Of		Lasix (Furosemide)	C		ORAL
		Transplant Surgery		Sandimmun	C		ORAL
		Congestive Cardiomyopathy		Clonidine			
		Dialysis		Hydrochloride	C		ORAL
		Drug Hypersensitivity		Calcium			
		Dry Skin		(Unspecified) And			
		Epistaxis		Vitamin D			
		Erythema Multiforme		(Unspecified)	C		
		Fistula		Iron Dextran	C		
		Haemodialysis		Epoetin	C		
		Haemorrhage Subcutaneous		Cyclosporine	C		
		Influenza Like Illness		Paricalcitol	C		
INTRAVENOUS							
		Injury		Zaroxolyn	C		ORAL
		Kidney Transplant		Ultralente Insulin	C		
PARENTERAL							
		Rejection		Toprol Xl Tablets	C		ORAL
		Mitral Valve Incompetence		Viagra	C		ORAL
		Muscle Rigidity		Humulin	C		
PARENTERAL							
		Myocardial Ischaemia		Clonazepam	C		
		Myositis		Norvasc	C		ORAL
		Nasal Septum Perforation		Zebeta	C		ORAL
		Neck Pain		Flexeril	C		ORAL
		Nephrectomy		Vitamin B Complex	C		ORAL
		Pericardial Effusion		Celebrex	C		
		Pericarditis Uraemic					
		Pleural Effusion					
		Pulmonary Congestion					
		Pulmonary Hypertension					
		Rales					
		Raynaud'S Phenomenon					
		Renal Failure Chronic					

		Rosacea Sinusitis Skin Fissures Tricuspid Valve Incompetence Vascular Calcification Ventricular Hypertrophy Ventricular Hypokinesia					

Date:03/14/03ISR Number: 4072264-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA02289
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Difficulty In Walking Headache Pain In Extremity	Health Professional	Vioxx Insulin	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/03ISR Number: 4072265-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA01679
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Unilateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Carotid Artery Occlusion	Professional	Plavix	C		
			Flomax			
			(Morniflumate)	C		

Date:03/14/03ISR Number: 4072266-1Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00277
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiomyopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Professional	Methotrexate	SS		ORAL
335 DAY						
Initial or Prolonged			Folic Acid	C		
Disability			Desloratadine	C		

Date:03/14/03ISR Number: 4072267-3Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00055
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Other	Drug Interaction	Professional	Sertraline			
	Memory Impairment		Hydrochloride	SS		ORAL
			Acetaminophen And			
			Codeine Phosphate	C		ORAL
			Ibuprofen	C		
TOPICAL						
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Beclomethasone			
			Dipropionate	C		
RESPIRATORY						
(INHALATION)						

Date:03/14/03ISR Number: 4072268-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA01673
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Panic Attack	Health Professional	Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:03/14/03ISR Number: 4072269-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA02277
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Blood Pressure Decreased Dizziness Postural Dyspnoea Exertional Enterococcal Infection Heart Rate Increased Hyperaldosteronism Metabolic Acidosis Metabolic Alkalosis Renal Failure Acute Respiratory Rate Increased

		Rhabdomyolysis Urinary Tract Infection Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	WK						
			Professional	Dyazide	SS		
				Allegra	C		
				Protonix	C		
				Estrace	C		
				Sof-Lax	C		
				Prilosec	C		
				Magnesium (Unspecified)	C		
				Cozaar	C		ORAL
				Synthroid	C		
				Cardizem	C		

Date:03/14/03ISR Number: 4072273-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA01071
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/14/03ISR Number: 4072275-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA01101
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Brain Death		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening Hospitalization - Initial or Prolonged Disability	Haemorrhage Intracranial		Coumadin	C		

Date:03/14/03ISR Number: 4072437-4Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00075
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased		Acetaminophen And Oxycodone Hydrochloride	C				
	Lung Squamous Cell Carcinoma Stage Unspecified		Oxycodone Hydrochloride	C				

Date:03/14/03ISR Number: 4072438-6Report Type:Expedited (15-DaCompany Report #WAES 0204FRA00070
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoxia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		519 DAY
Initial or Prolonged	Lung Disorder	Professional	Methotrexate Sodium	SS		ORAL		152 DAY
			Infliximab	SS		INTRAVENOUS	23	DAY

Date:03/14/03ISR Number: 4072444-1Report Type:Expedited (15-DaCompany Report #WAES 0209DEU00157
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest	Professional	Metoprolol Succinate	SS		ORAL	8	DAY
	Drug Interaction		Risperidone	SS		ORAL		
			Risperidone	SS		ORAL		
			Indapamide And Perindopril Erbumine	C		ORAL	34	DAY

Date:03/14/03ISR Number: 4072446-5Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00176
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Condition Aggravated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
	Drug Interaction	Professional	Perindopril	SS		ORAL		
	Renal Failure Chronic		Furosemide	SS		ORAL		
	Renal Impairment		Digoxin	C		ORAL		
			Aspirin	C		ORAL		
			Gliclazide	C		ORAL		
			Cimetidine	C		ORAL		

Date:03/14/03ISR Number: 4072448-9Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00017
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK

Date:03/14/03ISR Number: 4072455-6Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00053
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Trazodone Hydrochloride	C				
			Sertraline Hydrochloride	C				
			Diazepam	C				
			Flurazepam	C				
			Oxycodone	C				
			[Therapy Unspecified]	C				

Date:03/14/03ISR Number: 4072458-1Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00100
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
	Exercise Test Abnormal		Mirtazapine	C		ORAL		
			Aspirin	C		ORAL		
			Allopurinol	C		ORAL		
			Furosemide	C		ORAL		
			Isosorbide Mononitrate	C				
			Levothyroxine Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/03ISR Number: 4072467-2Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00030
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Overdose		Theophylline	SS		ORAL
15 YR						
	Pulmonary Embolism		Allopurinol	C		ORAL
	Venous Thrombosis Limb		Captopril And Hydrochlorothiazide	C		ORAL
			Acepromazine And Aceprometazine And Clorazepate Dipotassium	C		ORAL
			Terbutaline Sulfate	C		
RESPIRATORY						
(INHALATION)						

Date:03/14/03ISR Number: 4072468-4Report Type:Expedited (15-DaCompany Report #WAES 0303NOR00003
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL
42 DAY						
	Nausea					
	Night Sweats					
	Pyrexia					

Date:03/14/03ISR Number: 4076721-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY;						
Hospitalization -	Infarction	Health				
ORAL						
Initial or Prolonged		Professional	Combivent	C		
			Daypro	C		
			Lipitor	C		

Prozac	C
Metoprolol	C
Nonsterodial Anti-Inflammatory	C
Prednisone	C

Date:03/14/03ISR Number: 4076723-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atherosclerosis
	Blood Potassium Decreased
Disability	Cartilage Injury
	Cerebral Artery Thrombosis
	Cerebrovascular Accident
	Chondromalacia
	Diverticulum Intestinal
	Haematocrit Decreased
	Haemoglobin Decreased
	Infarction
	Joint Effusion
	Mitral Valve Incompetence
	Osteoarthritis
	Platelet Count Decreased

	Post Procedural Pain Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
		Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
UNK, UNK, PO						
		Health	Tab Vioxx 25 Mg	SS		ORAL
UNK, UNK; PO						
		Professional	Tab Vioxx 12.5 Mg	SS		ORAL
UNK, UNK; PO						
			Tab Vioxx 25 Mg	SS		ORAL
UNK, UNK, PO						
			Paxil	C		
			Premarin	C		
			Restoril	C		
			Tricor	C		
			Vicodin Es Tablets	C		
			Vistaril	C		
			Zantac	C		
			Aspirin	C		
			Estrogens (Unspecified)	C		
			Vitamins (Unspecified)	C		

Date:03/14/03ISR Number: 4076733-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25 MG, DAILY;						
Initial or Prolonged	Infarction	Health				
PO						
	Anxiety	Professional	Avandia	C		
	Blood Creatinine Abnormal		Blephamide Ointment	C		
	Blood Urea Abnormal		Duratuss	C		
	Cardiac Failure		Viagra	C		
	Congestive		Wellbutrin	C		
	Cardiac Murmur		Acetaminophen (+)			
	Contusion		Hydrocodone	C		
	Coronary Artery Stenosis					
	Coronary Artery Thrombosis					
	Diabetes Mellitus					

	Feeling Abnormal
	Injury
	Myocardial Infarction
	Scar
	Stress
	Ventricular Hypokinesia
	Vision Blurred

Date:03/17/03ISR Number: 4072922-5Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00135
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Asthenia
	Back Pain
	Cardiomyopathy
	Coronary Artery Stenosis
	Depression
	Dyspnoea
	Eye Swelling
	Fatigue

		Fibromyalgia					
		Heart Rate Increased					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
		Ventricular Hypokinesia	Professional	Atenolol	SS		ORAL

Date:03/17/03ISR Number: 4072923-7Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00015
Age:73 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
3	WK						

Date:03/17/03ISR Number: 4072925-0Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00023
Age:60 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Meningitis Bacterial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Viiith Nerve Lesion		Methotrexate	C		ORAL
				Josamycin Propionate	C		ORAL
15	DAY						

Date:03/17/03ISR Number: 4079333-7Report Type:Expedited (15-DaCompany Report #EMADSS2003001873
Age:51 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cholangitis Acute	Foreign	Remicade (5 Mg/Ml			
Initial or Prolonged		Hepatic Cirrhosis	Health	Lyophilized Powder)			
		Hepatic Fibrosis	Professional	(Infliximab,			
		Hepatic Steatosis		Recombinant)	PS		
INTRAVENOUS	300 MG, 1 IN						
		Muscle Atrophy					
1 TIME(S),							
		Vasculitis					
IV;	300						

MG, IV

Zoloft (Sertraline Hydrochloride)	SS	ORAL

2 MG, 2 IN 1

DAY(S), ORAL

Losec (Omeprazole)	SS	ORAL

20 MG, DAILY,

ORAL

Vioxx (Rofecoxib)	SS	ORAL

25M G, DAILY,

ORAL

Methotrexate (Methotrexate)	SS	ORAL

7.5 MG, 1 IN

1 WEEK(S),

ORAL

Folacin (Folacin)	C
Daonil (Glibenclamide)	C

Date:03/17/03ISR Number: 4093392-7Report Type:Periodic Company Report #2002137644US
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dizziness	Health	Bextra (Valdecoxib)			
	Oedema Mouth	Professional	Tablet	PS		ORAL

10 MG, QD,

Rash Maculo-Papular

ORAL

Vioxx (Rofecoxib)	SS
Allopurinol (Alopurinol)	SS

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/03ISR Number: 4093400-3Report Type:Periodic Company Report #2002138129US
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction	Health Professional	Bextra (Valdecoxib) Tablet	PS		ORAL	3 DF, QD,	
Other							ORAL	6 DAY
			Rofecoxib(Rofecoxib)	SS		ORAL	3 DF, QD,	
							ORAL	3 DAY

Date:03/18/03ISR Number: 4073537-5Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00097
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	44 DAY	
Initial or Prolonged	Congestive Dyspnoea Oedema		Doxazosin Mesylate	C				
			Ramipril	C				
			Digoxin	C				
			Furosemide	C				

Date:03/18/03ISR Number: 4073546-6Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/03ISR Number: 4073552-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA00888
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fibromyalgia		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	

Initial or Prolonged	Meningitis
	Muscle Twitching
	Nausea
	Tremor

Date:03/18/03ISR Number: 4073557-0Report Type:Expedited (15-DaCompany Report #WAES 0211CAN00135
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Asthenia
	Cardiac Disorder
	Chest Pain
	Conjunctival Hyperaemia
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Coronary Artery Stenosis
	Depression
	Dyspnoea Exertional
	Electrocardiogram
	Abnormal
	Eye Swelling
	Fibromyalgia
	Heart Rate Abnormal
	Hypotension

		Musculoskeletal Pain Pleuritic Pain Reaction To Medical Agent	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Preservatives		Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
		Rheumatoid Arthritis Somnolence Ventricular Hypokinesia		Atenolol	SS		ORAL

Date:03/18/03ISR Number: 4073559-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA01211
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
11 DAY						
Initial or Prolonged	Eye Swelling Face Oedema Oedema Peripheral					

Date:03/18/03ISR Number: 4073562-4Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00128
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
333 DAY						
Hospitalization -			Ramipril	C		ORAL
Initial or Prolonged			Oxazepam	C		ORAL
Disability			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL

Date:03/18/03ISR Number: 4073568-5Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00023
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						

Hospitalization - Initial or Prolonged Disability	Duodenitis Gastritis Upper Gastrointestinal Haemorrhage		Nitrendipine	C			ORAL

Date:03/18/03ISR Number: 4073569-7Report Type:Expedited (15-DaCompany Report #WAES 0207ESP00018
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ventricular Tachycardia		Bisoprolol Fumarate	SS		ORAL		
Other								

Date:03/18/03ISR Number: 4073571-5Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00023
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Bacterial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Viiith Nerve Lesion		Methotrexate	C		ORAL		
			Josamycin Propionate	C		ORAL	15	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/03ISR Number: 4073572-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		412 DAY
Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	SS		ORAL		
	Cervical Myelopathy		Neurontin	C		ORAL		
	Cervical Spinal Stenosis		Colchicine	C		ORAL		
	Chest X-Ray Abnormal		Ticlid	C				
	Diverticulum		Allopurinol	C		ORAL		
	Dry Mouth		Ultram	C		ORAL		
	Duodenitis		Lortab	C				
	Dysarthria		Elavil	C		ORAL		
	Feeling Cold		Darvocet-N	C				
	Gastritis							
	Gastroenteritis							
	Haemorrhoids							
	Hiatus Hernia							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Mitral Valve Incompetence							
	Mouth Haemorrhage							
	Neuropathy							
	Non-Small Cell Lung Cancer							
	Pain In Extremity							
	Pollakiuria							
	Post Laminectomy Syndrome							
	Pulmonary Valve Incompetence							
	Tooth Disorder							
	Transient Ischaemic Attack							
	Tricuspid Valve Incompetence							

Date:03/18/03ISR Number: 4073578-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA02503
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Enzymes Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged Other	Completed Suicide Coordination Abnormal Cyanosis Dehydration Electromechanical Dissociation Heart Rate Decreased Hypotension Mental Status Changes Myoglobin Urine Present Renal Failure Somnolence White Blood Cell Count Increased	Gabapentin Ultram	SS SS	 ORAL

Date:03/18/03ISR Number: 4073581-8Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00083
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Initial or Prolonged	Increased		Ketoprofen	C		ORAL	58	DAY
	Aspartate		Tetrazepam	C		ORAL	58	DAY
	Aminotransferase		Tramadol	C		ORAL	58	DAY
	Increased		Omeprazole	C		ORAL	68	DAY
	Drug Ineffective		Fentanyl	C			8	DAY
	Eczema							

Date:03/18/03ISR Number: 4073810-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA01194
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
Other	Chest Pain	Professional						
	Headache							

Date:03/18/03ISR Number: 4073813-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA02739
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
Hospitalization -	Upper Gastrointestinal		[Therapy					
Initial or Prolonged	Haemorrhage		Unspecified]	C				
			Ultram	C				
			Aspirin	C				
			Valium	C				

Date:03/18/03ISR Number: 4073815-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA01494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/03ISR Number: 4073816-1Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00075
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:03/18/03ISR Number: 4073817-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA01435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/03ISR Number: 4073819-7Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00015
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	3	WK

Date:03/18/03ISR Number: 4073820-3Report Type:Expedited (15-DaCompany Report #WAES 0303DNK00006
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged Disability	Hemianopia		Oxycodone Hydrochloride	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Acetaminophen	C		ORAL		
			Acetaminophen	C		ORAL		
			Ferrous Fumarate	C		ORAL		

Date:03/18/03ISR Number: 4073821-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA01434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/03ISR Number: 4073839-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02502
Age:20 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Intentional Misuse		Nortriptyline	SS				
			Septra Ds	SS		ORAL		

Date:03/18/03ISR Number: 4074804-1Report Type:Direct Company Report #CTU 188921
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Impairment		Amphotericin B	PS		
130 MG IV						
Initial or Prolonged	Thrombocytopenia					
THREE TIMES A						
	Venoocclusive Disease					
WEEK						
			Mylotarg 9 Mg Iv	SS		
			Vioxx	SS		
25 MG PO						
THREE TIMES A						
WEEK						
			Tobramycin	SS		
60 MG IV Q 8						
H						

Date:03/18/03ISR Number: 4078111-2Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Auricular Swelling
	Cardiac Disorder
	Culture Positive
	Dermatitis
	Dermatitis Exfoliative

	Drug Hypersensitivity						
	Drug Ineffective						
	Eczema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Enterococcal Infection	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO
	Epidermal Naevus	Health					
	Epistaxis	Professional	Celebrex 200 Mg	SS			200 MG/DAILY/UNK
	Excoriation						
	Lung Disorder		Anafranil	C			
	Neurodermatitis		Lidex	C			
	Oedema Mucosal		Proventil Inhaler	C			
	Otitis Externa						
	Pain						
	Pruritus						
	Scab						
	Skin Discolouration						
	Skin Inflammation						
	Skin Lesion						
	Skin Necrosis						
	Skin Papilloma						
	Skin Ulcer						
	Staphylococcal Infection						

Date:03/18/03ISR Number: 4078114-8Report Type:Expedited (15-DaCompany Report #WAES 0201USA02035
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - SEE IMAGE	Anaemia	Consumer	Tab Vioxx 12.5mg	PS		ORAL	
Initial or Prolonged Disability	Balance Disorder	Health Professional	Aristocort	C			
	Blood Pressure Fluctuation		Hyzaar	C			
	Bundle Branch Block Left		Toradol	C			
	Carotid Artery Stenosis		Ziac	C			
	Carpal Tunnel Syndrome		Zoloft	C			
	Cerebral Atrophy		Ascorbic Acid	C			
	Dizziness		Iron	C			
	Electroencephalogram Abnormal		Vitamin E	C			
	Facial Palsy						

Faecal Occult Blood
Positive
Haemorrhagic Stroke
Scar
Synovitis
Tendon Disorder
Thrombocytopenia

Date:03/18/03ISR Number: 4078121-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Aortic Atherosclerosis
Hospitalization - Initial or Prolonged	Asthenia
	Atherosclerosis
	Bundle Branch Block Left
	Cardiac Murmur
	Cerebrovascular Accident
	Coronary Artery Occlusion
	Dyspnoea
	Fatigue

	Hyperhidrosis						
	Muscle Tightness						
	Supraventricular	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrasystoles	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Ventricular Extrasystoles	Health					MG/DAILY/PO	
		Professional	Centrum	C				
			Lasix (Furosemide)	C				
			Tylenol Extra Strength	C				

Date:03/18/03ISR Number: 4078304-4Report Type:Expedited (15-DaCompany Report #2003GB00586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Omeprazole	PS				
	Dyspepsia	Health	Rofecoxib	SS		ORAL	12.5 MG DAILY	
	Sudden Death	Professional					PO	
		Other						

Date:03/19/03ISR Number: 4074298-6Report Type:Expedited (15-DaCompany Report #WAES 0303ITA00009
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Initial or Prolonged			Risperidone	C				
			Promazine Hydrochloride	C				

Date:03/19/03ISR Number: 4074300-1Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00192
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

41 DAY

Date:03/19/03ISR Number: 4074303-7Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00046
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/19/03ISR Number: 4074304-9Report Type:Expedited (15-DaCompany Report #WAES 0303NZL00022
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged			Methotrexate	C		
			Methylprednisolone Acetate	C		
			Folic Acid	C		
			Acetaminophen	C		
			Cyclizine	C		
			Calcipotriene	C		
			Mometasone Furoate	C		
			Hydrocortisone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/03ISR Number: 4074307-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA01449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/19/03ISR Number: 4074308-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/19/03ISR Number: 4074310-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA01326
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Norvasc	C				
			Synthroid	C				
			Tricor	C				
			Triavil	C				

Date:03/19/03ISR Number: 4074311-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/20/03ISR Number: 4075312-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/20/03ISR Number: 4075313-6Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00042
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 65 DAY	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Sotalol Hydrochloride	C		ORAL
			Trimetazidine Hydrochloride	C		ORAL
			Pantoprazole	C		ORAL
			Bromazepam	C		ORAL

Date:03/20/03ISR Number: 4075340-9Report Type:Expedited (15-DaCompany Report #WAES 0303SWE00009
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Cyclizine	C		
			Acetaminophen	C		
			Ferrous Fumarate	C		
			Ascorbic Acid And Vitamin B			

(Unspecified)	C
Picosulfate Sodium	C
Glipizide	C
Morphine	C
Insulin Human	C
Dihydrocodeine Bitartrate	C
Pantoprazole Sodium	C

Date:03/20/03ISR Number: 4075342-2Report Type:Expedited (15-DaCompany Report #WAES 0302SWE00018
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Metoprolol Tartrate	C				
			Glyburide	C				
			Insulin, Biphasic Isophane [Injection]	C				
			Warfarin Sodium	C				
			Aspirin	C				
			Aspirin	C				

Date:03/20/03ISR Number: 4075346-XReport Type:Expedited (15-DaCompany Report #WAES 0303AUT00011
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		WK
Initial or Prolonged	Gastritis		Corenitec	C		ORAL		
	Haematemesis		Molsidomine	C				
			Pantoprazole Sodium	C		ORAL		
			Aspirin	C		ORAL		

Date:03/20/03ISR Number: 4086218-9Report Type:Expedited (15-DaCompany Report #104279
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Herceptin	PS				
INTRAVENOUS	SEE IMAGE						1	DAY

Initial or Prolonged	Anaemia	Study	Herceptin	SS
	Anuria	Health	Docetaxel	SS
INTRAVENOUS 120 MG, Q3W,				
	Bacteraemia	Professional		
INTRAVENOUS				
	Cardiac Failure	Other	Docetaxel	SS
	Congestive		Carboplatin	SS
INTRAVENOUS 635 MG Q3W,				
	Catheter Related			
INTRAVENOUS				
	Complication		Rofecoxib	SS
	Dialysis		Tazocin	
	Escherichia Urinary Tract		(Piperacillin	
	Infection		Sodium, Tazobactam	
	Nausea		Sodium)	SS
	Neutropenic Sepsis		Dexamethasone	C
	Oesophagitis		Onsansetron	C
	Platelet Count Decreased		Cimetidine	C
	Renal Impairment		Bisoprolol	C
	Vomiting		Otilonium Bromide	C
			Rofecoxib	C
			Fluoxetine	C
			Ranitidine	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/03ISR Number: 4075778-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA00898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/03ISR Number: 4075779-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA02998
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Acute Abdomen		Hydrodiuril	C		ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation		Allegra	C				
			Aricept	C				
Disability	Peritonitis		Lupron	C				
Other	Sepsis		Aciphex	C				
	Upper Gastrointestinal Haemorrhage		Metoprolol	C				

Date:03/21/03ISR Number: 4075931-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA01883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/03ISR Number: 4075933-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA01371
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/03ISR Number: 4079675-5Report Type:Direct Company Report #CTU 189294
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nausea		Vioxx	PS		ORAL	25MG PO QD	
Initial or Prolonged	Upper Gastrointestinal Haemorrhage							
	Vomiting							

Date:03/21/03ISR Number: 4081938-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Aortic Valve Incompetence
	Cerebral Ischaemia
	Cerebrovascular Accident
	Cervical Spinal Stenosis
	Confusional State
	Diarrhoea
	Diverticulum
	Dry Mouth

		Duodenitis					
		Dyspepsia					
		Dysphagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Faeces Discoloured	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Feeling Cold	Health				
MG/DAILY/PO							
		Gastritis	Professional	Darvocet-N	C		
		Gastroenteritis		Elavil	C		
		Haemorrhoids		Lortab	C		
		Headache		Neurontin	C		
		Hiatus Hernia		Ticlid	C		
		Hyperlipidaemia		Ultram	C		
		Hypertension		Allopurinol	C		
		Mitral Valve Incompetence		Colchicine	C		
		Mouth Haemorrhage					
		Myelopathy					
		Neck Pain					
		Neuropathy					
		Non-Small Cell Lung					
		Cancer					
		Pain In Extremity					
		Peptic Ulcer					
		Pollakiuria					
		Post Laminectomy Syndrome					
		Pulmonary Valve					
		Incompetence					
		Radiculopathy					
		Rectal Haemorrhage					
		Scar					
		Tooth Disorder					
		Transient Ischaemic					
		Attack					
		Treatment Noncompliance					
		Tricuspid Valve					
		Incompetence					

Date:03/24/03ISR Number: 4076833-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA01071
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Ineffective	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:03/24/03ISR Number: 4076843-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory Distress Syndrome Hypersensitivity Multi-Organ Failure Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/03ISR Number: 4076848-2Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00169
Age:80 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Haematemesis

Haemoglobin Decreased
Melaena

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	36	DAY
	Gabapentin	C		ORAL		
	Digoxin	C		ORAL		
	Allopurinol	C		ORAL		
	Acetaminophen	C		ORAL		
	Domperidone	C		ORAL		

Date:03/24/03ISR Number: 4076850-0Report Type:Expedited (15-DaCompany Report #WAES 0303MYS00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peptic Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Hospitalization - Initial or Prolonged			Diclofenac Sodium	SS		ORAL		

Date:03/24/03ISR Number: 4076851-2Report Type:Expedited (15-DaCompany Report #WAES 0303SWE00008
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	35	DAY
	Weight Increased		Levothyroxine Sodium	C				
			Ferrous Sulfate	C				
			Potassium Chloride	C				
			Furosemide	C				
			Spironolactone	C				
			Aspirin	C				
			Lansoprazole	C				
			Zopiclone	C				

Date:03/24/03ISR Number: 4076853-6Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00054
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		115 DAY
			Atenolol	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:03/24/03ISR Number: 4076860-3Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00139
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		214 DAY
Initial or Prolonged	Haemorrhage		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
	Haemoglobin Decreased							
	Hiatus Hernia							
	Oesophageal Ulcer							

Date:03/24/03ISR Number: 4076861-5Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00177
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Acetaminophen	C		ORAL		

Date:03/24/03ISR Number: 4076866-4Report Type:Expedited (15-DaCompany Report #WAES 0212USA02140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Other	Cerebrovascular Accident Peptic Ulcer Weight Decreased		Hyzaar	C		ORAL		

Date:03/25/03ISR Number: 4077639-9Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00128
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Fatigue Hypertriglyceridaemia Mouth Ulceration Oedema Mouth Oral Intake Reduced Pain In Jaw Palatal Disorder Procedural Complication Stomatitis Necrotising		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/03ISR Number: 4077642-9Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00130
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated	Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/25/03ISR Number: 4077883-0Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia
	Back Pain
	Drug Eruption
	Dry Mouth
	Eyelid Oedema
	Face Oedema
	Hypersensitivity
	Oedema Peripheral
	Pain In Extremity
	Periorbital Oedema
	Photosensitivity Reaction
	Rash
	Skin Reaction
	Spondylitis

Stasis Dermatitis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx Celecoxib	PS C	Merck & Co., Inc	ORAL		17 DAY

Date:03/25/03ISR Number: 4077888-XReport Type:Expedited (15-DaCompany Report #WAES 0212FRA00003
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 37 DAY Initial or Prolonged	Abdominal Pain Upper Condition Aggravated Haematemesis Helicobacter Infection Hiatus Hernia Oesophagitis Ulcerative	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/03ISR Number: 4077891-XReport Type:Expedited (15-DaCompany Report #WAES 0301AUS00094
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Haemorrhage	Health Professional	Vioxx Irbesartan Estradiol	PS C C	Merck & Co., Inc	ORAL	VAGINAL	

Date:03/25/03ISR Number: 4080164-2Report Type:Direct Company Report #CTU 189404
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Glaucoma		Celebrex 200mg Pfizer	PS	Pfizer		1 TAB QD	
			Vioxx 25mg	SS			1 TAB QD	

			Hyzaar	C		

Date:03/26/03ISR Number: 4078673-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA02180
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Injury					
	Oedema					
	Thrombosis					

Date:03/26/03ISR Number: 4078674-7Report Type:Expedited (15-DaCompany Report #WAES 0212USA02136
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Pleuritic Pain		Sectral	C		
Other	Syncope		Advair	C		
			Atrovent	C		
			Xopenex	C		
			Albuterol	C		
			Tylenol Extra Strength	C		
			Vicodin Tablets	C		

			Hydrodiuril	C		ORAL
			Captopril	C		
			Myoflex External Analgesic Creme	C		
			Norvasc	C		
			Motrin	C		

Date:03/26/03ISR Number: 4078678-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA01522
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	High Density Lipoprotein Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypoglycaemia		Lotensin	C		
	Malaise					

Date:03/26/03ISR Number: 4078679-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01101
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Brain Death		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Drug Interaction		Coumadin	SS		
Hospitalization - Initial or Prolonged	Haemorrhage Intracranial					
Disability						

Date:03/27/03ISR Number: 4079657-3Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00057
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
24 DAY						
Hospitalization - Initial or Prolonged	Circulatory Collapse		Clopidogrel Bisulfate	SS		ORAL
	Gastrointestinal Haemorrhage		Atorvastatin	C		ORAL
			Nafronyl Oxalate	C		ORAL
			Doxazosin	C		ORAL
			Verapamil	C		ORAL

			Indapamide	C		ORAL

Date:03/27/03ISR Number: 4079658-5Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00206
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	13 DAY	
	Dyspnoea		Nitroglycerin	C				
	Feeling Hot		Mebeverine Hydrochloride	C				
	Nausea		Furosemide	C				
	Vision Blurred		Felodipine	C				
			Atenolol	C				
			Aluminum Hydroxide And Magnesium Carbonate	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Fosinopril Sodium	C				

			Ranitidine	C
			Quinine	C
			Temazepam	C

Date:03/27/03ISR Number: 4079867-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA02223
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema		Vioxx	SS		ORAL		
	Rash		Zyrtec	C		ORAL		
	Swelling		Provigil	C		ORAL		
			Celexa	C		ORAL		
			Darvocet-N	C		ORAL		
			Symmetrel	C		ORAL		
			Copaxone	C		SUBCUTANEOUS		

Date:03/27/03ISR Number: 4079868-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA02695
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged	Gastrointestinal Disorder		Celebrex	SS		ORAL		356 DAY
	Hypersensitivity		Celebrex	SS		ORAL		246 DAY
	Oesophageal Disorder		Voltaren	C				126 DAY
	Pain		Premarin	C				
	Rash		Allegra	C				

Date:03/27/03ISR Number: 4079872-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 65 DAY	Anaemia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Aneurysm Ruptured	Indocin (Indomethacin)	C		ORAL
Other	Coma	Tylenol Extra Strength	C		
	Convulsion				
	Headache Postoperative				
	Hydrocephalus				
	Intraventricular Haemorrhage				
	Pneumonia Aspiration				
	Sedation				
	Subarachnoid Haemorrhage				

Date:03/27/03ISR Number: 4079874-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA01805
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/27/03ISR Number: 4079876-6Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00090
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Overdose		Alcohol	SS		ORAL		1 DAY

Date:03/27/03ISR Number: 4079877-8Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00082
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
Initial or Prolonged	Gastrointestinal Haemorrhage		Omeprazole	C		ORAL		
	Rectal Haemorrhage							

Date:03/27/03ISR Number: 4079883-3Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00252
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
	Hyperhidrosis		Valsartan	C				
	Polyuria							

Date:03/27/03ISR Number: 4079885-7Report Type:Expedited (15-DaCompany Report #WAES 0303NOR00007
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
	Increased	Professional	Vioxx	SS				

Date:03/27/03ISR Number: 4086990-8Report Type:Expedited (15-DaCompany Report #2000AH07285
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis Acute	Foreign	Losec	PS		ORAL	20 MG DAILY	
Initial or Prolonged	Condition Aggravated	Health					PO	
	Decreased Appetite	Professional	Methotrexate	SS	Wyeth Lederle	ORAL	7.5 MG WEEK	
	Hepatic Cirrhosis	Other					PO	
	Hepatic Fibrosis		Zoloft	SS		ORAL	2 MG BID PO	
	Hepatic Steatosis		Vioxx	SS		ORAL	25 MG DAILY	
	Muscle Atrophy						PO	
	Muscle Disorder		Remicade	SS			300 MG 4	
	Vasculitis						TIMES	
			Daonil	C				
			Folacin	C				

Date:03/28/03ISR Number: 4080342-2Report Type:Expedited (15-DaCompany Report #WAES 0206FRA00064
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Initial or Prolonged	Dyspnoea		Acetaminophen	C				
	Fatigue							
	Gastrointestinal Ulcer							
	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/03ISR Number: 4080346-XReport Type:Expedited (15-DaCompany Report #WAES 0303DEU00094
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Fentanyl	C		TOPICAL		
	Oedema		Gabapentin	C		ORAL		
	Pulmonary Oedema		Amitriptyline Hydrochloride	C		ORAL		
	Renal Failure Acute							

Date:03/28/03ISR Number: 4080349-5Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Urinary Bladder Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/03ISR Number: 4080352-5Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00141
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bladder Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pravastatin Sodium	C				
			Aspirin	C				

Date:03/28/03ISR Number: 4080489-0Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00130
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amlodipine Maleate	C		ORAL		
	Nasopharyngitis							

Date:03/28/03ISR Number: 4080490-7Report Type:Expedited (15-DaCompany Report #WAES 0303USA02317
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/03ISR Number: 4080496-8Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00207
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Increased		Amitriptyline Hydrochloride	C		ORAL		
	Dysphagia		Aspirin	C		ORAL		
	Dyspnoea		Bisoprolol	C		ORAL		
	Haemoglobin Abnormal		Furosemide	C		ORAL		
	Neutrophil Count Abnormal							
	Platelet Count Abnormal							
	Tongue Oedema							
	White Blood Cell Count Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/03ISR Number: 4080497-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00197
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Dyspnoea Exacerbated		Amitriptyline Hydrochloride	C		ORAL		
	Oedema Mouth		Aspirin	C		ORAL		
			Bisoprolol	C		ORAL		
			Furosemide	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Simvastatin	C		ORAL		
			Zopiclone	C		ORAL		
			Ramipril	C		ORAL		

Date:03/28/03ISR Number: 4080498-1Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00154
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		48 DAY
Life-Threatening			Diltiazem Hydrochloride	C				
Hospitalization -								2211 DAY
Initial or Prolonged			Amoxicillin	C				7 DAY
Disability			Fluticasone Propionate	C				667 DAY

Date:03/28/03ISR Number: 4080505-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA02368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/03ISR Number: 4080507-XReport Type:Expedited (15-DaCompany Report #WAES 0303MYS00006
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pallor		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization -	Peptic Ulcer Haemorrhage		Diclofenac Sodium	C		ORAL		1 DAY
Initial or Prolonged			Cefuroxime Sodium	C			INTRAVENOUS	2 DAY
			Cefuroxime Axetil	C		ORAL		6 DAY
			Acetaminophen	C		ORAL		6 DAY

Date:03/28/03ISR Number: 4083383-4Report Type:Direct Company Report #CTU 189695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Vioxx 25mg (Merck)	PS	Merck	ORAL	1 PO X 1 DOSE	
	Erythema						ONLY	
	Pruritus							
	Swelling							
	Throat Tightness							
	Tongue Oedema							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/03ISR Number: 4083628-0Report Type:Periodic Company Report #2002AP02725
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia	Literature	Lisinopril	PS				
	Renal Failure Acute	Health Professional	Rofecoxib	SS				
			Furosemide	SS				
			Potassium	SS				

Date:03/28/03ISR Number: 4087287-2Report Type:Expedited (15-DaCompany Report #2003AP01331
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Foreign Health Professional Other	Zestril	PS		ORAL	20 MG DAILY PO	
	Chest Pain							
	Nausea		Lopressor	SS		ORAL	50 MG DAILY PO	
	Pulmonary Fibrosis							
	Syncope		Monodur	SS		ORAL	60 MG DAILY PO	
			Colgout	SS		ORAL	0.5 MG DAILY PO	
			Natrilix	SS		ORAL	1.5 MG DAILY PO	
			Aratac	SS		ORAL	200 MG DAILY PO	
			Vioxx	SS		ORAL	12.5 MG DAILY PO	
			Coumadin "Boots"	SS		OPHTHALMIC	3 MG DAILY PO	

Date:03/31/03ISR Number: 4080872-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01771
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Neoplasm	Health	Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY
	Renal Tubular Necrosis	Professional	Vioxx	SS		ORAL		
	Urinary Tract Infection		Radiographic Contrast Medium (Unspecified)	SS				
			Prinivil	C		ORAL		
			Proscar	C		ORAL		
			Ibuprofen	C		ORAL		
			Indapamide	C		ORAL		
			Chondroitin And Glucosamine	C		ORAL		
			Saw Palmetto	C				
			Tylenol	C				

Date:03/31/03ISR Number: 4080874-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation Neonatal
	Apgar Score Low
	Caesarean Section
	Complications Of Maternal Exposure To Therapeutic Drugs
	Gestational Diabetes
	Maternal Drugs Affecting

		Foetus					
		Pre-Eclampsia					
		Pregnancy					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Streptococcal Infection	Health	Vioxx	PS	Merck & Co., Inc	
80	DAY						
			Professional	Sertraline	SS		

Date:03/31/03ISR Number: 4080876-0Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00055
Age:30 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Other		Dizziness	Professional	Sertraline			
		Drug Interaction		Hydrochloride	SS		ORAL
		Memory Impairment		Acetaminophen And			
		Vision Blurred		Codeine Phosphate	C		ORAL
				Ibuprofen	C		
TOPICAL							
				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Beclomethasone			
				Dipropionate	C		
RESPIRATORY							
(INHALATION)							

Date:03/31/03ISR Number: 4080882-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA02263
Age:22 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Alopecia		Hormonal			
		Back Pain		Contraceptives			
		Nausea		(Unspecified)	C		
		Oedema					
		Pain					

Date:03/31/03ISR Number: 4080884-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00254
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		160 DAY
Initial or Prolonged	Chronic Obstructive Airways Disease Exacerbated		Hypromellose	C				
			Etidronate Disodium	C				
			Salmeterol	C				
			Lansoprazole	C				
			Fluticasone Propionate	C				
			Aminophylline	C				
			Quinine	C				
			Bumetanide	C				
			Albuterol	C				

Date:03/31/03ISR Number: 4081840-8Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT
	Agitation Neonatal
	Apgar Score Low
	Drug Exposure During Pregnancy

		Gestational Diabetes					
		Pre-Eclampsia					
		Pregnancy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
80	DAY						
		Streptococcal Infection	Professional	Sertraline	SS		ORAL

Date:03/31/03ISR Number: 4081841-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00213
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
425	DAY						
		Fatigue		Propranolol	C		ORAL
				Paroxetine	C		ORAL
				Lansoprazole	C		ORAL

Date:03/31/03ISR Number: 4081843-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
Initial or Prolonged		Arthralgia		Lipitor	SS		ORAL
366	DAY						
Disability		Asthenia		Zemplar	SS		
Other		Atherosclerosis		[Therapy			
		Back Pain		Unspecified]	SS		
		Cardiac Failure		Imuran			
		Cardiac Failure		(Azathioprine)	C		ORAL
		Congestive		Prednisone	C		ORAL
		Complications Of		Lasix (Furosemide)	C		ORAL
		Transplant Surgery		Sandimmun	C		ORAL
		Congestive Cardiomyopathy		Calcium			
		Diarrhoea		(Unspecified) And			
		Drug Interaction		Vitamin D			
		Dry Skin		(Unspecified)	C		
		Erythema Multiforme		Flexeril	C		ORAL
		Haemodialysis		Iron Dextran	C		
		Hyperkalaemia		Epoetin	C		

	Influenza Like Illness	Cyclosporine	C	
	Kidney Transplant	Paricalcitol	C	
INTRAVENOUS				
	Rejection	Zaroxolyn	C	ORAL
	Mitral Valve Incompetence	Ultralente Insulin	C	
PARENTERAL				
	Muscular Weakness	Toprol Xl Tablets	C	ORAL
	Myalgia	Viagra	C	ORAL
	Neck Pain	Zebeta	C	ORAL
	Pericardial Effusion	Humulin	C	
PARENTERAL				
	Pericarditis Uraemic	Clonazepam	C	
	Renal Transplant	Clonidine		
	Rosacea	Hydrochloride	C	ORAL
	Sinus Tachycardia	Norvasc	C	ORAL
	Tricuspid Valve	Vitamin B Complex	C	ORAL
	Incompetence	Celebrex	C	
	Ventricular Hypertrophy			
	Weight Decreased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/03ISR Number: 4082114-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA03033
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/03ISR Number: 4082119-0Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00030
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Theophylline	SS		ORAL		
15 YR								
	Bundle Branch Block Left		Allopurinol	C		ORAL		
	Deep Vein Thrombosis		Captopril And Hydrochlorothiazide	C		ORAL		
	Drug Interaction		Acepromazine And Aceprometazine And Clorazepate Dipotassium	C		ORAL		
	Overdose		Terbutaline Sulfate	C				
	Pulmonary Embolism							
	Venous Thrombosis Limb							
RESPIRATORY (INHALATION)								

Date:03/31/03ISR Number: 4082124-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA02577
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Neuropathy Peripheral							

Date:04/01/03ISR Number: 4082603-XReport Type:Expedited (15-DaCompany Report #WAES 0303ISR00015M
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	

Date:04/01/03ISR Number: 4082609-0Report Type:Expedited (15-DaCompany Report #WAES 0303ISR00015B1
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Premature Baby		Vioxx	PS	Merck & Co., Inc			

Date:04/01/03ISR Number: 4082819-2Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00084
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Vomiting	Health Professional	Vioxx Globulin, Immune	PS SS	Merck & Co., Inc	ORAL INTRAVENOUS	4 WK 1 DAY	
			Morphine	C		ORAL		
			Hydrochlorothiazide And Valsartan	C		ORAL		

Date:04/01/03ISR Number: 4082821-0Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00216
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Colitis		Vioxx	SS		ORAL		
	Crohn'S Disease		Meloxicam	C				

Date:04/01/03ISR Number: 4082823-4Report Type:Expedited (15-DaCompany Report #WAES 0303FIN00005
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged	Melaena	Professional	Acetaminophen	C		ORAL		
			Allopurinol	C		ORAL		
			Methenamine Hippurate	C		ORAL		
			Nifedipine	C		ORAL		
			Temazepam	C		ORAL		

Date:04/01/03ISR Number: 4082825-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA00809
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Upper Gastrointestinal Haemorrhage							

Date:04/01/03ISR Number: 4082826-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA02728
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
			Estrogens					

			(Unspecified)	C		

Date:04/01/03ISR Number: 4082829-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA02789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adverse Event Rectal Haemorrhage	Consumer	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:04/01/03ISR Number: 4082830-1Report Type:Expedited (15-DaCompany Report #WAES 0303ISR00015B1
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Premature Baby	Health Professional	Vioxx	PS	Merck & Co., Inc	
1 WK						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/03ISR Number: 4082833-7Report Type:Expedited (15-DaCompany Report #WAES 0303ISR00015M
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Caesarean Section	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During Pregnancy Oligohydramnios Premature Baby	Professional						

Date:04/01/03ISR Number: 4082839-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA02790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:04/01/03ISR Number: 4084889-4Report Type:Direct Company Report #CTU 189976
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck And Co , Inc			
Hospitalization -	Diarrhoea							
Initial or Prolonged	Dizziness							
Disability	Gastrointestinal							
Required	Haemorrhage							
Intervention to	Haemorrhage							
Prevent Permanent	Headache							
Impairment/Damage	Lung Disorder							
	Pain							
	Pharyngeal Oedema							
	Purulence							
	Rash							
	Renal Pain							
	Respiratory Disorder							
	Scar							

Skin Ulcer
Tongue Oedema
Urinary Tract Infection

Date:04/01/03ISR Number: 4085016-XReport Type:Direct Company Report #CTU 189950
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Rofecoxib 25mg	PS			1 TAB QD	
Hospitalization -	International Normalised		Warfarin 2.5mg	SS			2 TAB RESTAT	
Initial or Prolonged	Ratio Increased						WEEK	
Required	Melaena		Allopurinol	C				
Intervention to			Aspirin	C				
Prevent Permanent			Atorvastatin	C				
Impairment/Damage			Cervedilol	C				
			Colchicine	C				
			Digoxin	C				
			Furosemide	C				
			Ranitidine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/03ISR Number: 4083514-6Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00293
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		45 DAY
	Congestive	Professional	Lansoprazole	C		ORAL		45 DAY
	Dyspnoea		Lisinopril	C		ORAL		
	Joint Swelling		Furosemide	C		ORAL		
			Doxazosin Mesylate	C		ORAL		
			Aspirin	C		ORAL		

Date:04/02/03ISR Number: 4083515-8Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00235
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL		192 DAY
Initial or Prolonged	Dysphagia	Professional	Acetaminophen	C		ORAL		
	Weight Decreased		Carbamazepine	C		ORAL		90 DAY
			Haloperidol	C		ORAL		5 DAY
			Ramipril	C		ORAL		
			Digoxin	C		ORAL		
			Allopurinol	C		ORAL		
			Furosemide	C		ORAL		

Date:04/02/03ISR Number: 4083518-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA02583
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		125 DAY
	Rash	Professional	Zetia	SS		ORAL		125 DAY
			Acebutolol	C				
			Ogen	C				
			Aspirin	C				

			Vitamins (Unspecified)	C		

Date:04/02/03ISR Number: 4083788-1Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00120
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		374 DAY
Initial or Prolonged	Congestive Coronary Artery Disease		Rosiglitazone Maleate	SS		ORAL		829 DAY
			Atorvastatin Calcium	C				
			Bisoprolol Fumarate	C				
			Folic Acid	C				
			Prinzide	C				

Date:04/02/03ISR Number: 4083795-9Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged	Oedema Peripheral Orthopnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/03ISR Number: 4086336-5Report Type:Direct Company Report #CTU 190030
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Discomfort		Vioxx	PS		ORAL	PO [1ST DOSE]	
	Cough		Vicodin	SS		ORAL	PO [1ST DOSE]	
			Prednisone	C				
			Lipitor	C				
			Lasix	C				
			Enalapril	C				
			Omeprazole	C				
			Foxeril	C				
			Advair	C				
			K-Dur	C				

Date:04/03/03ISR Number: 4084210-1Report Type:Expedited (15-DaCompany Report #WAES 0303ITA00041
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:04/03/03ISR Number: 4084213-7Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00251
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Ulcer		Acetaminophen	C				
			Dihydrocodeine	C				
			Nizatidine	C				
			Nizatidine	C				

Date:04/03/03ISR Number: 4084214-9Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00215
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Jejunal Perforation		Analgesic Or Anesthetic (Unspecified)	C			PARENTERAL	2 DAY
			Acetaminophen	C		ORAL		
			Fentanyl	C			PARENTERAL	2 DAY
			Bupivacaine Hydrochloride	C			PARENTERAL	2 DAY
Disability								

Date:04/03/03ISR Number: 4084560-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA02920
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatomegaly		Vioxx	SS		ORAL		
	Liver Function Test Abnormal		Aleve	C				
	Pancreatic Disorder							
	White Blood Cell Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/03/03ISR Number: 4084563-4Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00095
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatine		Diacerein	C		ORAL		
	Phosphokinase Increased		Levothyroxine Sodium	C		ORAL		
	Oedema		Diosmin	C		ORAL		
	Pain In Extremity							
	Phlebitis							

Date:04/03/03ISR Number: 4084566-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA00092
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia Macrocytic	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Duodenal Ulcer	Professional	Vioxx	SS		ORAL		
Hospitalization - 27 DAY	Haemorrhage		Prednisone	C		ORAL		
Initial or Prolonged Disability	Gastric Ulcer Haemorrhage		Prednisone	C		ORAL		
	Respiratory Failure		Imuran (Azathioprine)	C		ORAL		
Other			Imuran (Azathioprine)	C		ORAL		
			Aldactone	C		ORAL		
			Potassium Chloride	C				
			Lactulose	C				
			[Therapy Unspecified]	C				
			Phytonadione	C				
			Phenergan (Promethazine Hydrochloride)	C				
			Ativan	C				
			Protonix	C				
			Calcium (Unspecified)	C				
			Ascorbic Acid	C				
			Centrum	C				
			Vitamin B (Unspecified)	C				
			Thiamine	C				
			[Therapy					

Unspecified] C

Date:04/03/03ISR Number: 4084569-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00232
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged			Vioxx	SS		ORAL	3	DAY

Date:04/03/03ISR Number: 4084572-5Report Type:Expedited (15-DaCompany Report #WAES 0211USA00030
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Cardiac Disorder
Initial or Prolonged	Dizziness
	Malaise
	Muscle Spasms

		Oedema Peripheral					
		Ulcer Haemorrhage					
		Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Acuity Reduced	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Vomiting		Tiazac	C		
		Weight Decreased					

Date:04/03/03ISR Number: 4087034-4Report Type:Direct Company Report #CTU 190111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastric Ulcer Perforation		Vioxx 25 Mg	PS		ORAL
ONCE Q DAY						
Hospitalization -	Ileus Paralytic					
ORAL						
Initial or Prolonged			Baby Aspirin 81 Mg	SS		ORAL
ONCE A DAY						
Required						
ORAL						
Intervention to			Flexeril	C		
Prevent Permanent			Codeine	C		
Impairment/Damage			Dilitiazem	C		
			Pericolace	C		
			Dyazide	C		
			Calcium	C		

Date:04/04/03ISR Number: 4084860-2Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12219366
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hyperkalaemia		Fosinopril Sodium	PS	Bristol-Myers Squibb	
Initial or Prolonged	Osteoarthritis				Company	ORAL
1 YR						
	Renal Failure		Rofecoxib	SS		ORAL
8 MON						
			Omeprazole	C		
			Thyroxine	C		

Date:04/04/03ISR Number: 4085189-9Report Type:Expedited (15-DaCompany Report #WAES 0303DNK00006
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Neoplasm		Rofecoxib	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Oxycodone Hydrochloride	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Acetaminophen	C		ORAL		
			Acetaminophen	C		ORAL		
			Ferrous Fumarate	C		ORAL		

Date:04/04/03ISR Number: 4085196-6Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00176
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization -	Chest Pain							
Initial or Prolonged	Insomnia							
	Oedema Peripheral							
	Orthopnoea							
	Pulmonary Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/03ISR Number: 4085197-8Report Type:Expedited (15-DaCompany Report #WAES 0303GRC00022
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	25MG QD ORAL	

Date:04/04/03ISR Number: 4085209-1Report Type:Expedited (15-DaCompany Report #WAES 0304FIN00001
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Bradycardia Fatigue Hypotension Thirst		Vioxx Tizanidine Hydrochloride Levothyroxine Sodium Oxybutynin Chloride	PS C C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL		1 DAY

Date:04/04/03ISR Number: 4085422-3Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00267
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tunnel Vision		Vioxx Vioxx	PS SS	Merck & Co., Inc	ORAL ORAL		4 DAY

Date:04/04/03ISR Number: 4087230-6Report Type:Direct Company Report #CTU 190253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash		Rofecoxib 25mg Gabapentin	PS C		ORAL	25MG QD ORAL	

Date:04/04/03ISR Number: 4090306-0Report Type:Expedited (15-DaCompany Report #A-CH2003-02243
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Study	Tracleer(Bosentan) Tablet	PS		ORAL	SEE IMAGE	
Required Intervention to Prevent Permanent Impairment/Damage	Condition Aggravated	Health Professional	Provastatin (Alporstadil)	SS			UNKNOWN	25 MG, UNK
	Drug Tolerance Decreased	Other	Vioxx(Rofecoxib)	SS				
	Extremity Necrosis							
	Oedema Peripheral							
	Pulmonary Congestion		Urbason (Methylprednisolone)	C				
	Sensory Disturbance		Pantozol (Pantoprazole Sodium)	C				
	Supraventricular Tachycardia		Digitoxin "Merck" (Digitoxin)	C				
			Isoptin (Verapamil Hydrochloride)	C				
			Dytide H (Hydrochlorothiazide)	C				
			Marcumar (Pheprocoumon)	C				
			Potassium (Potassium)	C				

			Vigantoletten (Colecalciferol)	C		
			Calcium (Calcium)	C		
			Lasix (Furosemide)	C		
			Uralyt (Solidago Virgaurea, Rubia Tinctorum, Magnesium Phophate, Equisetum Arvense, Echinacea	C		
			Oxygen (Oxygen)	C		

Date:04/04/03ISR Number: 4090383-7Report Type:Expedited (15-DaCompany Report #A-CH2003-02243
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Study	Tracleer (Bosentan) Tablet	PS		ORAL
SEE IMAGE, Required	Condition Aggravated	Health				
ORAL						
Intervention to Prevent Permanent Impairment/Damage	Drug Tolerance Decreased	Professional	Prostavasin (Alprostadil)	SS		
	Extremity Necrosis	Other	Vioxx (Rofecoxib)	SS		
	Oedema Peripheral					
25 MG						
	Pulmonary Congestion		Urbason (Methylprednisolone)	C		
	Sensory Disturbance		Pantozol (Pantoprazole Sodium)	C		
	Supraventricular Tachycardia		Digotoxin "Merck" (Digotoxin)	C		
			Isoptin (Verapamil Hydrochloride)	C		
			Dytide H (Hydrochlorothiazide)	C		
			Marcumar (Phenprocoumon)	C		
			Potassium (Potassium)	C		
			Vigantoletten (Colecalciferol)	C		
			Calcium (Calcium)	C		
			Lasix (Furosemide)	C		

			Uralyt (Solidago Virgaurea, Rubia Tinctorum, Magnesium Phosphate, Equisetum Arvense, Echinacea	C
			Oxygen (Oxygen)	C

Date:04/04/03ISR Number: 4090695-7Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00036
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Oedema Confusional State	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	1 DAY
	Dizziness Epistaxis Hypertensive Crisis Vomiting	Health Professional	Methotrexate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/03ISR Number: 4085797-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA02449
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Blood Pressure		Hydrodiuril	C				
	Inadequately Controlled		Toprol Xl Tablets	C				
	Diarrhoea		Aciphex	C				
	Headache		Lipitor	C				
	Oedema Peripheral		Bextra	C				

Date:04/07/03ISR Number: 4085809-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00299
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Platelet Count Decreased		Lipitor	C				

Date:04/07/03ISR Number: 4085812-9Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00034
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	42	MON
Initial or Prolonged	Drug Interaction	Professional	Aspirin	SS		ORAL		
	Gastrointestinal		Deflazacort	SS		ORAL	42	MON
	Haemorrhage		Alfuzosin Hydrochloride	C		ORAL		
	Haematemesis		Hydrochlorothiazide And Irbesartan	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Calcium Carbonate And Magnesium Carbonate	C		ORAL		

Date:04/07/03ISR Number: 4085880-4Report Type:Expedited (15-DaCompany Report #WAES 0304SWE00001
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Tinnitus		Metoprolol Tartrate	C				
			Ramipril	C				
			Atorvastatin Calcium	C				
			Aspirin	C				

Date:04/07/03ISR Number: 4085883-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA02905
Age:71 YR Gender:Male I/FU:I

Outcome	PT
Death	Blood Pressure Increased
Life-Threatening	Diarrhoea
Hospitalization -	Fatigue
Initial or Prolonged	Pulmonary Hypertension
Disability	Pulmonary Veno-Occlusive
Other	Disease
	Rash
	Renal Impairment
	Stomach Discomfort
	Stupor

		Transient Ischaemic Attack					
		Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS		ORAL

Date:04/07/03ISR Number: 4085884-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Back Pain	Professional	Celecoxib	C		
17	DAY						
		Blood Albumin					
		Burning Sensation					
		Dry Mouth					
		Eyelid Oedema					
		Face Oedema					
		Hypersensitivity					
		Oedema Peripheral					
		Pain In Extremity					
		Periorbital Oedema					
		Photosensitivity Reaction					
		Rash					
		Skin Reaction					
		Spondylitis					
		Stasis Dermatitis					

Date:04/07/03ISR Number: 4085887-7Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00053
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Intraocular Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Cosopt	C		
OPHTHALMIC							
				Prednisolone	C		
				Bendroflumethiazide	C		
				Atorvastatin Calcium	C		
				Mycophenolate Mofetil	C		

Date:04/08/03ISR Number: 4086503-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Aneurysm
	Aspiration
	Blood Glucose
	Blood Potassium
	Blood Pressure
	Fluctuation
	Cardiomegaly
	Cataract
	Cellulitis
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Deep Vein Thrombosis
	Electrocardiogram T Wave

		Abnormal					
		Gastritis					
		Haematochezia					
		Haemoglobin	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
		Hyperhidrosis		Vioxx	SS		ORAL
6	MON						
		International Normalised		Prednisone	C		
		Ratio Decreased		Hydrocodone	C		
		Lung Infiltration					
		Myopathy					
		Neuropathy Peripheral					
		Pericardial Effusion					
		Pericarditis					
		Peroneal Nerve Palsy					
		Pneumonia					
		Post Procedural					
		Complication					
		Post Procedural Pain					
		Prothrombin Time					
		Pulmonary Fibrosis					
		Pyrexia					
		Rales					
		Respiratory Distress					
		Subarachnoid Haemorrhage					
		Syncope					
		Vasospasm					
		White Blood Cell Count					

Date:04/08/03ISR Number: 4089538-7Report Type:Direct Company Report #CTU 190422
Age:41 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required		Anxiety		Rofecoxib	PS		
25MG X 1							
Intervention to		Dyskinesia					
Prevent Permanent		Hypoaesthesia					
Impairment/Damage		Pruritus					
		Urticaria					

Date:04/08/03ISR Number: 4091806-XReport Type:Expedited (15-DaCompany Report #GB-SHR-03-005079
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Health Professional Other	Sotalol (Sotalol Hydrochloride)	PS			300 MG,	
			Asa (Acetylsalicylic Acid)	SS			12.5 MG,	
			Rofecoxib (Rofecoxib)	SS			1X/DAY	
			Frusemide (Furosemide)	SS				
			Enalapril (Enalapril)	SS				
			Alendronic Acid (Alendronic Acid)	SS				
			Fybogel (Isphagula)	SS				
			Felbinac (Felbinac)	C				
			Ranitidine (Ranitidine)	C				
			Co-Dyramol					

			(Dihydrocodeine Bitartrate)	C		

Date:04/09/03ISR Number: 4087815-7Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/09/03ISR Number: 4087816-9Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00027
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea Paroxysmal		Vioxx	PS	Merck & Co., Inc	ORAL	166	DAY
	Nocturnal		Omeprazole	C		ORAL		
	Fluid Retention		Etidronate Disodium	C		ORAL		
			Morphine Sulfate	C		ORAL		
			Diclofenac	C		ORAL		

Date:04/09/03ISR Number: 4087818-2Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00016
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/09/03ISR Number: 4087824-8Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00159
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL	130	MON
	Duodenal Ulcer		Aspirin	SS		ORAL		
	Haemorrhage		Atorvastatin Calcium	C		ORAL		
	Myocardial Infarction		Hydrochlorothiazide					

	Renal Failure		And Ramipril	C		ORAL
			Flunitrazepam	C		ORAL
			Allopurinol	C		ORAL

Date:04/09/03ISR Number: 4087825-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00190
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bone Infection		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gangrene		Vitamins			
Other	Skin Lesion		(Unspecified)	C		
	Toe Amputation		Thyroid	C		
	Tongue Disorder					

Date:04/09/03ISR Number: 4087826-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA02065
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Death	Death
	Dyspnoea
	Fatigue
	Lethargy

	Oedema Peripheral						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/09/03ISR Number: 4087832-7Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00061
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoimmune Hepatitis Urine Abnormality Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/09/03ISR Number: 4087833-9Report Type:Expedited (15-DaCompany Report #WAES 01115015
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL	146 DAY	
	Dyspnoea Headache Palpitations Tremor		Levothyroxine Sodium	C				

Date:04/09/03ISR Number: 4087839-XReport Type:Expedited (15-DaCompany Report #WAES 0303ITA00002
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	32 DAY	
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Clodronate Disodium	C			397 DAY	
			Clotiazepam	C			397 DAY	
			Lisinopril	C			32 DAY	

Date:04/09/03ISR Number: 4087842-XReport Type:Expedited (15-DaCompany Report #WAES 0304ESP00004
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Confusional State		Omeprazole	SS		ORAL	24	DAY
	Hyperhidrosis							
	Insomnia							
	Tachycardia							

Date:04/09/03ISR Number: 4087845-5Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00033
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Peritonitis		Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/03ISR Number: 4087847-9Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00038
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY

Date:04/09/03ISR Number: 4091060-9Report Type:Direct Company Report #CTU 190526
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eosinophil Count		Rofecoxib	PS				
Required Intervention to Prevent Permanent Impairment/Damage	Renal Failure Acute							

Date:04/09/03ISR Number: 4092683-3Report Type:Expedited (15-DaCompany Report #2003GB00586
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Omeprazole	PS				
	Dyspepsia	Health	Rofecoxib	SS		ORAL	12.5 MG DAILY	
	Renal Failure	Professional					PO	
	Sudden Death	Other						

Date:04/10/03ISR Number: 4088500-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA00898
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/10/03ISR Number: 4088501-XReport Type:Expedited (15-DaCompany Report #WAES 0304CHE00005
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Chills	Professional	Vioxx	SS		ORAL		1 DAY
	Dyspnoea		Tizanidine					
	Face Oedema		Hydrochloride	C		ORAL		1 DAY
	Malaise							

Date:04/10/03ISR Number: 4088506-9Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00046
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/10/03ISR Number: 4088507-0Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00042
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive	Health	Vioxx	PS	Merck & Co., Inc	ORAL		65 DAY
Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Professional	Sotalol Hydrochloride	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Bromazepam	C		ORAL		

Date:04/10/03ISR Number: 4088509-4Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00095
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Phosphokinase Increased Oedema Peripheral	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Diacerein	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Diosmin	C		ORAL		

Date:04/10/03ISR Number: 4088516-1Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00022
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Psychotic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged			[Therapy Unspecified]	C				

Date:04/10/03ISR Number: 4088521-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:04/10/03ISR Number: 4093946-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA00092
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Life-Threatening	Abdominal Tenderness
Hospitalization - Initial or Prolonged	Blood Pressure Increased
Disability	Cardio-Respiratory Arrest
Other	Cholecystitis
	Cholelithiasis
	Drug Effect Decreased
	Gastric Ulcer Haemorrhage
	Hiatus Hernia
	Lethargy
	Limb Injury
	Malaise
	Peptic Ulcer
	Respiratory Failure
	Sinus Tachycardia
	Somnolence
	Synovitis
	Traumatic Arthritis

		Upper Gastrointestinal Haemorrhage					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
SEE IMAGE			Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL
				Aldactone	C		
				Ativan	C		
				Centrum	C		
				Imuran (Azathioprine)	C		
				Phenergan (Promethazine Hydrochloride)	C		
				Protonix	C		
				[Therapy Unspecified]	C		
				Ascorbic Acid	C		
				Calcium (Unspecified)	C		
				Lactulose	C		
				Phytonadione	C		
				Potassium Chloride	C		
				Prednisone	C		
				Thiamine	C		
				Vitamin B (Unspecified)	C		

Date:04/11/03ISR Number: 4088916-XReport Type:Expedited (15-DaCompany Report #WAES 0206GBR00160
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Cholesterol	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Urea Increased		Amiloride Hydrochloride And Furosemide	C		
		Cerebrovascular Accident		Lansoprazole	C		
		Confusional State		Clopidogrel Bisulfate	C		
		Mental Impairment					
		Transient Ischaemic Attack					

Date:04/11/03ISR Number: 4088922-5Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00040
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Wheezing		Vioxx	SS		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Acetaminophen And Codeine	C		ORAL		

Date:04/11/03ISR Number: 4088933-XReport Type:Expedited (15-DaCompany Report #WAES 0204FRA00034
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hairy Cell Leukaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C				
			Aspirin Lysine	C				

Date:04/11/03ISR Number: 4088935-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA01101
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Drug Interaction		Coumadin	SS				
Hospitalization - Initial or Prolonged	Haemorrhage Intracranial							
Disability								

Date:04/11/03ISR Number: 4088936-5Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00046
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Toxic Epidermal Necrolysis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				

Date:04/11/03ISR Number: 4089083-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01241
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Vioxx	SS		ORAL		

Date:04/11/03ISR Number: 4089084-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/03ISR Number: 4089087-6Report Type:Expedited (15-DaCompany Report #WAES 01104518
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluctuation							
	Cardiovascular Disorder							
	Death							
	Oedema							
	Renal Failure							

Date:04/11/03ISR Number: 4094059-1Report Type:Expedited (15-DaCompany Report #001-0981-M0201589
Age: Gender:Male I/FU:I

Outcome	PT
Other	Arthralgia
	Asthenia
	Blood Alkaline
	Phosphatase Increased
	Blood Pressure Increased
	Coordination Abnormal
	Dysstasia
	Groin Pain
	Insomnia
	Joint Range Of Motion

	Decreased Myalgia Neck Pain Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash Pruritic Rotator Cuff Syndrome	Consumer	Lipitor (Atorvastatin)	PS		ORAL	10 MG (DAILY), ORAL
			Celecoxib (Celecoxib)	SS			200 MG (DAILY)
			Nicotinic Acid (Nicotinic Acid)	SS			
			Rofecoxib (Rofecoxib)	SS			
			Clidinium	C			
			Sildenafil Citrate	C			
			Penciclovir	C			
			Aciclovir	C			
			Ciclopirox	C			
			Vitamins	C			

Date:04/14/03ISR Number: 4089856-2Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00010
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	285 DAY
Initial or Prolonged	Gastric Ulcer Oesophagitis Ulcerative	Professional	Aspirin Lysine	SS		ORAL	
			Perindopril Erbumine	C		ORAL	
			Nicorandil	C		ORAL	

Date:04/14/03ISR Number: 4089860-4Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00128
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY

	Eating Disorder	Professional
	Hypertriglyceridaemia	
	Mouth Ulceration	
	Odynophagia	
	Stomatitis Necrotising	

Date:04/14/03ISR Number: 4089863-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA02728
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 11 DAY	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Heart Rate Increased	Professional	Prempro	SS		
	Pain In Extremity		Vicodin Es Tablets	C		
			Vitamin E	C		
			Vitamins (Unspecified)	C		
			Aspirin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/03ISR Number: 4089865-3Report Type:Expedited (15-DaCompany Report #WAES 0304GRC00003
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Oedema Peripheral		Acetaminophen And					
	Shock		Orphenadrine Citrate	C				

Date:04/14/03ISR Number: 4089886-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:04/14/03ISR Number: 4090128-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA01551
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Granulomatous Liver	Health	Vioxx	PS		ORAL		
	Disease	Professional	Premarin	C	Merck & Co., Inc			
			Advil	C				

Date:04/14/03ISR Number: 4090134-6Report Type:Expedited (15-DaCompany Report #WAES 0303BEL00001
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		72 DAY
Initial or Prolonged	Cerebral Atrophy		Vioxx	SS		ORAL		30 DAY
	Eczema		Vioxx	SS		ORAL		
	Elevated Mood		Telmisartan	C		ORAL		
	Fall		Atorvastatin Calcium	C		ORAL		
	Therapeutic Response		Omeprazole	C		ORAL		
	Unexpected		Acetaminophen	C		ORAL		

Vision Blurred

Date:04/14/03ISR Number: 4090137-1Report Type:Expedited (15-DaCompany Report #WAES 0304CAN00039
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Helicobacter Infection		Vioxx	PS	Merck & Co., Inc	ORAL	68	DAY
	Oesophagitis							
	Upper Gastrointestinal Haemorrhage							

Date:04/14/03ISR Number: 4090139-5Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00026
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Death	Cardiac Failure
Life-Threatening	Duodenal Ulcer
Hospitalization - Initial or Prolonged	Haemorrhage
	Gastric Ulcer
	Gastrointestinal Haemorrhage
	Hypotension
	Shock Haemorrhagic

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspirin	SS		ORAL		
	Lisinopril	C		ORAL		
	Ciprofloxacin	C		ORAL	15	DAY
	Ferrous Sulfate And Folic Acid	C		ORAL		
	Torsemide	C		ORAL		

Date:04/14/03ISR Number: 4090140-1Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00029
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Eruption		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	SS		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Glimepiride	C		ORAL		
			Lisinopril	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:04/14/03ISR Number: 4095144-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aspiration
	Blood Glucose
	Blood Potassium
	Blood Pressure Increased
	Body Temperature
	Cardiomegaly
	Cataract
	Cellulitis
	Cerebral Atrophy
	Cerebral Hygroma
	Cerebral Infarction
	Cerebrovascular Accident
	Coma

Deep Vein Thrombosis
Electrocardiogram T Wave
Abnormal
Faecal Occult Blood
Positive
Gastritis
Haemoglobin
Hyperkeratosis
International Normalised
Ratio Increased
Myopathy
Neuropathy Peripheral
Pericardial Effusion
Peroneal Nerve Palsy
Pneumonia
Pulmonary Fibrosis
Respiratory Distress
Ruptured Cerebral
Aneurysm

		Sinusitis					
		Subarachnoid Haemorrhage					
		Toxicologic Test Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vasospasm	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE							
		White Blood Cell Count	Health Professional	Hydrocodone	C		
				Prednisone	C		
				..	C		

Date:04/15/03ISR Number: 4090849-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00983
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Oesophageal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/15/03ISR Number: 4090852-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01029
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Death					

Date:04/15/03ISR Number: 4090853-1Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00034
Age:65 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Oedema Peripheral					
		Sinus Tachycardia					
		Supraventricular Extrasystoles					
		Supraventricular Tachycardia					
		Tachycardia					
		Ventricular Extrasystoles					
		Ventricular Tachycardia					

Date:04/15/03ISR Number: 4090951-2Report Type:Expedited (15-DaCompany Report #WAES 01108566
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/03ISR Number: 4090953-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00232
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged			Vioxx	SS		ORAL	3	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/03ISR Number: 4090955-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Distress Syndrome		Vioxx	SS		ORAL		6 MON
	Adrenal Insufficiency		Prednisone	C				
	Aspiration		Hydrocodone	C				
	Blood Glucose							
	Blood Potassium							
	Candidiasis							
	Cardiomegaly							
	Cataract Subcapsular							
	Cerebral Atrophy							
	Cerebral Hygroma							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Coma							
	Deep Vein Thrombosis							
	Drug Screen Positive							
	Electrocardiogram T Wave Abnormal							
	Erythema							
	Faecal Occult Blood Positive							
	Gastritis							
	Headache							
	Herpes Simplex							
	Hypertension							
	International Normalised Ratio Decreased							
	Ivth Nerve Paresis							
	Lung Infiltration							
	Microcytic Anaemia							
	Myopathy							
	Neuropathy Peripheral							
	Pericardial Effusion							
	Pericarditis							
	Peroneal Nerve Palsy							
	Pneumonia							
	Pulmonary Fibrosis							
	Ruptured Cerebral Aneurysm							
	Sinusitis							

Subarachnoid Haemorrhage
Urinary Tract Infection
Fungal
Vasospasm
Vision Blurred
White Blood Cell Count

Date:04/15/03ISR Number: 4091136-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01071
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Ischaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/03ISR Number: 4091144-5Report Type:Expedited (15-DaCompany Report #WAES 0304CAN00039
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Helicobacter Infection		Vioxx	PS	Merck & Co., Inc	ORAL	69	DAY
	Melaena							
	Oesophagitis							

Date:04/15/03ISR Number: 4091146-9Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00051
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Trazodone Hydrochloride	C		ORAL		

Date:04/15/03ISR Number: 4091147-0Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
	Skin Infection		Allopurinol	C		ORAL		
			Gabapentin	C		ORAL		
			Bumetanide	C		ORAL		
			Lansoprazole	C		ORAL		
			Carbomer	C		OPHTHALMIC		
			Doxazosin Mesylate	C		ORAL		
			Senna	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:04/15/03ISR Number: 4092966-7Report Type:Direct Company Report #CTU 190909
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure Acute		Vioxx 25mg	PS		ORAL	BID PO	

Date:04/15/03ISR Number: 4095630-3Report Type:Expedited (15-DaCompany Report #2003005583
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Caesarean Section Complications Of Maternal	Foreign Health	Sertraline (Sertraline)	PS		ORAL	100 MG	
Other	Exposure To Therapeutic Drugs Gestational Diabetes Maternal Drugs Affecting Foetus Pre-Eclampsia Pregnancy Sinusitis Streptococcal Infection	Professional	Rofecoxib (Rofecoxib)	SS			(DAILY), ORAL 25 MG DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/03ISR Number: 4091597-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA01230
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		412 DAY
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS		ORAL		
	Atrial Septal Defect		Neurontin	C		ORAL		
	Blood Cholesterol		Colchicine	C		ORAL		
	Increased		Ticlid	C				
	Cerebrovascular Accident		Allopurinol	C		ORAL		
	Diarrhoea Haemorrhagic		Ultram	C		ORAL		
	Diverticulum		Lortab	C				
	Dry Mouth		Elavil	C		ORAL		
	Duodenitis		Darvocet-N	C				
	Dysphagia							
	Gastritis							
	Gingival Bleeding							
	Gout							
	Haemorrhoids							
	Hiatus Hernia							
	Hyperlipidaemia							
	Hypertension							
	Injury							
	Mitral Valve Incompetence							
	Pulmonary Valve Incompetence							
	Rectal Haemorrhage							
	Tooth Disorder							
	Tricuspid Valve Incompetence							

Date:04/16/03ISR Number: 4091599-6Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00067
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C		ORAL		
			Fluoxetine	C		ORAL		

Date:04/16/03ISR Number: 4091603-5Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00094
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Fentanyl	C		TOPICAL		
	Oedema		Gabapentin	C		ORAL		
	Pulmonary Oedema		Elavil	C		ORAL		
	Renal Failure Acute							

Date:04/16/03ISR Number: 4091605-9Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00071
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Delirium		Bromazepam	C		ORAL		

Date:04/16/03ISR Number: 4091616-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/16/03ISR Number: 4091816-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00838
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:04/16/03ISR Number: 4091817-4Report Type:Expedited (15-DaCompany Report #WAES 0304ITA00012
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Allopurinol	C		ORAL		
	Fall		Lorazepam	C		ORAL		
			Buflomedil Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Vaseretic	C		ORAL		

Date:04/16/03ISR Number: 4091818-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00768
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:04/16/03ISR Number: 4091819-8Report Type:Expedited (15-DaCompany Report #WAES 0304ISR00004
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemiplegia Subdural Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:04/16/03ISR Number: 4091847-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA02449
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Blood Pressure		Hydrodiuril	C				
	Inadequately Controlled		Toprol Xl Tablets	C				
	Diarrhoea		Aciphex	C				
	Headache		Lipitor	C				
	Oedema Peripheral		Bextra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/03ISR Number: 4091848-4Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00072
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	130	DAY
	Condition Aggravated		Aspirin	C		ORAL		
	Oedema Peripheral		Isosorbide Dinitrate	C		ORAL		
			Ramipril	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Albuterol Sulfate [Therapy Unspecified]	C				
RESPIRATORY (INHALATION)								
			Cyanocobalamin	C				
			Furosemide	C		ORAL		
			Furosemide	C		ORAL		

Date:04/16/03ISR Number: 4091852-6Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00040
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Second Degree		Vasotec	SS		ORAL		
	Blood Glucose Increased		Digitoxin	SS		ORAL		
	Blood Potassium Increased		Digitoxin	SS		ORAL	1	DAY
	Drug Interaction		Torsemide	C		ORAL		
	Drug Level Above Therapeutic		Pantoprazole Sodium	C		ORAL		
	Medication Error							
	Overdose							
	Renal Failure							
	White Blood Cell Count							

Date:04/16/03ISR Number: 4094426-6Report Type:Direct Company Report #CTU 191030
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lower Gastrointestinal	Health	Rofecoxib 25mg Qd	PS			SEE ABOVE	
Initial or Prolonged	Haemorrhage	Professional	Aspirin 81mg Qd	SS			SEE ABOVE	
			Clopidogrel 75mg Qd	SS			SEE ABOVE	

Date:04/16/03ISR Number: 4094919-1Report Type:Direct Company Report #CTU 191069
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation		Rofecoxib 25mg Qd	PS			25 MG QD	
Initial or Prolonged			Aspirin 81mg Qd	SS			81MG QD	

Date:04/16/03ISR Number: 4094923-3Report Type:Direct Company Report #CTU 191071
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Rofecoxib 25mg Bid	PS			25MG BID	
Initial or Prolonged	Haemorrhage		Asa Qd	SS			QD	
			Kcl 10meq Qd	SS			10 MEQ QD	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/03ISR Number: 4095156-7Report Type:Direct Company Report #CTU 191023
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - SEE ABOVE	Duodenal Ulcer		Rofecoxib 50mg Po Qd	PS		
Initial or Prolonged SEE ABOVE	Perforation		Prednisone 10mg Po Qd	SS		

Date:04/16/03ISR Number: 4097985-2Report Type:Expedited (15-DaCompany Report #2003014429
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Electrolytes	Foreign	Neurontin			
Hospitalization - 900 MG (TID), ORAL	Abnormal	Health	(Gabapentin)	PS		ORAL
Initial or Prolonged	Diabetes Mellitus	Professional				
	Inadequate Control		Amitriptyline Hydrochloride (Amitriptyline Hydrochloride)	SS		ORAL
	Drug Interaction					
	Renal Failure Acute					
75 MG (TID), ORAL						
			Rofecoxib (Rofecoxib)	SS		ORAL
25 MG (DAILY), ORAL						
			Xipamide (Xipamide)	C		
			Benzbromarone (Benzbromarone)	C		
			Benazepril Hydrochloride (Benazepril Hydrochloride)	C		
			Carvedilol (Carvedilol)	C		
			Furosemide (Furosemide)	C		
			Insulin Lispro			

				(Insulin Lispro)	C		
				Morphine Sulfate (Morphine Sulfate)	C		
				Pantoprazole Sodium (Pantoprazole Sodium)	C		
				Phenytoin (Phenytoin)	C		
				Lorazepam (Lorazepam)	C		

Date:04/16/03ISR Number: 4098522-9Report Type:Expedited (15-DaCompany Report #HQWYE596509APR03
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Eruption Rash Maculo-Papular	Health Professional	Advil (Ibuprofen, Tablet)	PS		ORAL	DOSED WHEN	
Other		Other					PATIENT	
							WISHED	
			Vioxx (Rofecoxib, Tablet)	SS		ORAL		
			Glucophage (Metformin Hydrochloride)	C				
			Amarel (Glimepiride)	C				

				Zestril (Lisinopril)	C		
				Elisor (Pravastatin Sodium)	C		

Date:04/17/03ISR Number: 4092224-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01241
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
		Professional	Vioxx	SS		ORAL		

Date:04/17/03ISR Number: 4092227-6Report Type:Expedited (15-DaCompany Report #WAES 0304CHN00006
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Neurosensory	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
		Professional	Vioxx	SS		ORAL	1	DAY

Date:04/17/03ISR Number: 4092756-5Report Type:Expedited (15-DaCompany Report #WAES 0304DNK00011
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Maculo-Papular	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged		Professional	Methotrimeprazine	C				
			Ceftriaxone Sodium	C				

Date:04/17/03ISR Number: 4092760-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA02892
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - 10 DAY	Gastrointestinal		Vioxx	SS	ORAL
Initial or Prolonged	Haemorrhage		Aspirin	C	
Other			Medrol Dosepak	C	

Date:04/17/03ISR Number: 4092762-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
	Haemorrhage					
	Myocardial Infarction					

Date:04/17/03ISR Number: 4098141-4Report Type:Expedited (15-DaCompany Report #200312261US
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Contusion
Other	Fall
	Haemangioma
	Hepatitis
	Hepatocellular Damage
	Hepatomegaly
	Hepatotoxicity

Dose	Duration							
		Hypertension						
		Lymphocyte Count Decreased	Report Source	Product	Role	Manufacturer	Route	
		Monocyte Count Increased	Consumer	Leflunomide (Arava)	PS			
100 MG QD	3	DAY						
		Neutrophil Count	Health	Leflunomide (Arava)	SS			
20 MG QD	2	MON						
		Decreased	Professional	Rofecoxib (Vioxx)	SS			
50 MG								
		Protein Total Decreased		Methotrexate	C			
		Renal Cyst		Celecoxib (Celebrex)	C			
		Serum Ferritin Increased		Paracetamol (Tylenol)	C			
		Thrombocythaemia		Antibiotics Nos	C			
		White Blood Cell Count Increased		Sulfasalazine	C			
				Clavulanate Potassium	C			
				Amoxicillin Trihydrate (Augmentin)	C			
				Prednisone	C			
				Docusate Sodium (Colace)	C			

Date:04/17/03ISR Number: 4098245-6Report Type:Expedited (15-DaCompany Report #200313998GDDC
Age:64 YR Gender:Female I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged			Gastric Ulcer Perforation	Foreign Other	Frusemide	PS		
					Acetylsalicylic Acid (Aspirin)	SS		ORAL
	300 MG QD PO							
					Rofecoxib	SS		ORAL
	12.5 MG/DAY							
	PO							
					Sotalol	SS		
					Enalapril	SS		
					Alendronic Acid	SS		
					Ispaghula (Fybogel)	SS		
					Felbinac	C		
					Ranitidine	C		
					Co-Dydramol	C		

Date:04/17/03ISR Number: 4098313-9Report Type:Expedited (15-DaCompany Report #PERI00203000940
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Renal Failure Acute	Foreign Health Professional Other	Coversyl (Perindopril)	PS		ORAL	2 MG QD PO	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG DAILY PO	
			Lasix (Furosemide)	SS		ORAL	80 MG DAILY PO	
			Lanoxin (Digoxin)	C				
			Marevan (Wafarin Sodium)	C				
			Lipitor (Atorvastatin)	C				
			Panafcortelone (Prednisolone)	C				
			Losec (Omeprazole)	C				
			Neurontin (Gabapentin)	C				
			Humalog (Insulin					

			Lispro)	C		
			Imdur (Isosorbide Mononitrate)	C		

Date:04/17/03ISR Number: 4098345-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA02728
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Prempro	SS				
			Vicodin Es Tablets	C				
			Aspirin	C				
			Vitamins (Unspecified)	C				

Date:04/17/03ISR Number: 4098430-3Report Type:Expedited (15-DaCompany Report #DSA_22593_2003
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Foreign Other	Vasotec	PS				
			Vioxx	SS		ORAL	12.5 MG PER24HR PO	
			Aspirin	SS				
			Sotalol Hydrochloride	SS				
			Furosemide	SS				
			Alendronic Acid	SS				
			Fybogel	SS				
			Co-Dydramol	C				
			Felbinac	C				
			Ranitidine	C				

Date:04/18/03ISR Number: 4093218-1Report Type:Expedited (15-DaCompany Report #WAES 0303BEL00032
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		

Date:04/18/03ISR Number: 4093230-2Report Type:Expedited (15-DaCompany Report #WAES 0304NOR00013
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Disorientation		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Gastric Ulcer Haemorrhage		Warfarin Sodium	SS				
	Melaena							

Date:04/18/03ISR Number: 4093233-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA00229
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Arthritis
	Blood Pressure Increased

	Cholecystitis Cholecystitis Acute Cholelithiasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	680 DAY
	Fluid Retention Gangrene Gastric Ulcer Liver Function Test Abnormal Malignant Hypertension Surgical Procedure Repeated		Darvocet-N	C			

Date:04/18/03ISR Number: 4093241-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/18/03ISR Number: 4093243-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01516
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/18/03ISR Number: 4093419-2Report Type:Expedited (15-DaCompany Report #WAES 0303DNK00009
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Urticaria	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Initial or Prolonged		Professional	Diazepam	SS		ORAL	1 DAY

Date:04/18/03ISR Number: 4093420-9Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00055
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Other	Dizziness	Professional	Sertraline Hydrochloride	SS		ORAL		
	Drug Interaction		Acetaminophen And Codeine Phosphate	C		ORAL		
	Memory Impairment		Ibuprofen	C		TOPICAL		
	Vision Blurred		Albuterol	C		RESPIRATORY (INHALATION)		
			Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		

Date:04/18/03ISR Number: 4093425-8Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00004
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Fall
	Rotator Cuff Syndrome

Sinus Arrhythmia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
		Professional	Vioxx	SS		ORAL		
			Atenolol	C				
			Aspirin	C				
			Fenofibrate	C				
			Telmisartan	C				
			Allopurinol	C				

Date:04/18/03ISR Number: 4093428-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA01326
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident	Professional	Norvasc	C				
			Synthroid	C				
			Tricor	C				
			Triavil	C				

Date:04/18/03ISR Number: 4093429-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA01772
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Other	Malaise		Toprol Xl Tablets	C		ORAL		
	Ventricular Extrasystoles		Prevacid	C		ORAL		
			Ambien	C		ORAL		

Date:04/18/03ISR Number: 4093430-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain Lower

Disability	Cardiovascular Function
	Test Abnormal
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Discomfort
	Colporrhaphy
	Constipation
	Cyst
	Ear Pain
	Electrocardiogram St-T
	Change
	Flatulence
	Haematochezia
	Hypokalaemia
	Hypotension
	Hysterectomy
	Insomnia
	Liposarcoma
	Oedema Peripheral
	Ovarian Cyst
	Pain

		Pelvic Mass					
		Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectocele		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Cyst		Colace	C		
		Sinus Bradycardia		Paxil	C		
		Sinus Headache		Maxzide	C		
		Stress Incontinence		Potassium Chloride	C		
		Synovial Cyst		Trazodone Hydrochloride	C		
				Coumadin	C		

Date:04/18/03ISR Number: 4093433-7Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00051
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
11 DAY						
Initial or Prolonged	Confusional State		Furosemide And Spironolactone	C		ORAL
	Hallucination					
	Liver Function Test Abnormal					
	Renal Failure					

Date:04/18/03ISR Number: 4093434-9Report Type:Expedited (15-DaCompany Report #WAES 0304SWE00013
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
473 DAY						
Initial or Prolonged	Gastric Ulcer	Professional	Aspirin	SS		ORAL
2162 DAY						
	Oesophagitis		Acetaminophen	C		
			Amitriptyline Hydrochloride	C		
			Clomipramine Hydrochloride	C		
			Zolpidem Tartrate	C		
			Alprazolam	C		
			Sotalol			

			Hydrochloride	C		

Date:04/18/03ISR Number: 4093439-8Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00102
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Neuropathy Peripheral	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Warfarin	SS		ORAL
			Amlodipine Besylate	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL
			Aluminum Hydroxide And Magnesium Trisilicate	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/03ISR Number: 4093440-4Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00076
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 4 DAY	Aortic Valve Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Left Ventricular Failure		Hydrochlorothiazide And Losartan Potassium	C		ORAL
			Alendronate Sodium	C		ORAL
			Acetaminophen And Carbinoxamine Maleate And Phenylephrine Hydrochloride	C		ORAL
			Nitrazepam	C		ORAL
			Quinine	C		ORAL

Date:04/18/03ISR Number: 4093442-8Report Type:Expedited (15-DaCompany Report #WAES 0304SWE00012
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - SUBCUTANEOUS	Intestinal Gangrene 1285 DAY		Etanercept	SS		
Initial or Prolonged	Pulmonary Oedema Sepsis		Estradiol And Norethindrone Acetate	C		
			Cyanocobalamin	C		
			Aspirin	C		
			Lansoprazole	C		
			Pilocarpine Hydrochloride	C		

Date:04/18/03ISR Number: 4093445-3Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/18/03ISR Number: 4093446-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Glomerulonephritis Membranous	Consumer	Vioxx Celebrex	PS SS	Merck & Co., Inc	ORAL		7 DAY

Date:04/18/03ISR Number: 4093448-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00983
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oesophageal Rupture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/03ISR Number: 4093454-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/03ISR Number: 4093457-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01269
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		

Date:04/21/03ISR Number: 4094039-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA02181
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - RESPIRATORY	Dyspnoea		Advair	C				
Initial or Prolonged (INHALATION)	Haematemesis							
Other	Hyperkalaemia		Glucophage	C		ORAL		
	Renal Failure Acute		Avandia	C		ORAL		
			Prednisone	C		ORAL		
			Prednisone	C		ORAL		
			Fosamax	C		ORAL		
			Altace	C		ORAL		
			Zocor	C		ORAL		
			Calcium Citrate	C		ORAL		
			Paxil	C		ORAL		

Date:04/21/03ISR Number: 4094285-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Respiratory Failure
Disability	Anaemia
Other	Blood Alkaline Phosphatase Increased
	Brain Damage
	Cardiac Failure Congestive
	Clostridial Infection
	Coma
	Complex Partial Seizures
	Convulsion
	Fall
	Headache
	Hydrocephalus
	Hypertension
	Hyponatraemia
	Intraventricular Haemorrhage
	Malnutrition
	Mental Status Changes
	Pain
	Pneumonia Aspiration
	Pulmonary Oedema

	Ruptured Cerebral Aneurysm						
	Somnolence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	65 DAY
	Thrombocytopenia		Indocin (Indomethacin)	C		ORAL	
			Tylenol Extra Strength	C			

Date:04/21/03ISR Number: 4094290-5Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00071
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Delirium		Bromazepam	C		ORAL	

Date:04/21/03ISR Number: 4094294-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA02065
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL	
	Dyspnoea						
	Fatigue						
	Lethargy						
	Oedema Peripheral						

Date:04/21/03ISR Number: 4094295-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01753
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	2 WK
	Blood Cholesterol		Vioxx	SS		ORAL	2 WK
	Blood Pressure		Flovent	C			
RESPIRATORY							

	Blood Triglycerides					
(INHALATION)						
	Cerebral Infarction			Serevent	C	
	Cerebrovascular Accident			Albuterol	C	
RESPIRATORY						
(INHALATION)						
				Herbs (Unspecified)	C	
				Alcohol	C	

Date:04/21/03ISR Number: 4096078-8Report Type:Direct Company Report #CTU 191339
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Weight Increased		Rofecoxib 12.5 Mg Merck	PS	Merck	ORAL	12.5 MG DAILY	ORAL
			Digoxin	C				
			Benazepriil	C				
			Furosemide	C				
			Potassium Chloride	C				
			Calcium Carbonate	C				
			Docusate	C				
			Ferrous Sulfate	C				
			Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/03ISR Number: 4099424-4Report Type:Expedited (15-DaCompany Report #2003015276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased	Consumer	Geodon (Ziprasidone)	PS		ORAL	ORAL	
Other	Cerebrovascular Accident		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Coma							
	Electrocardiogram Abnormal		Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	C				
	Electroencephalogram Abnormal		Omeprazole (Omeprazole)	C				
	Tooth Abscess		Diazepam (Diazepam)	C				
	Weight Decreased		Sucralfate (Sucralfate)	C				
			Metoclopramide (Metoclopramide)	C				
			Phentermine (Phentermine)	C				
			Paracetamol (Paracetamol)	C				

Date:04/21/03ISR Number: 4099611-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome
	Adrenal Insufficiency
	Aneurysm
	Aneurysm Ruptured
	Blood Glucose
	Blood Potassium
	Candidiasis
	Cataract Operation
	Cataract Subcapsular
	Cerebellar Artery Thrombosis
	Cerebral Hygroma
	Cerebral Infarction
	Cerebrovascular Accident

Coma
Cranial Nerve Paralysis
Deep Vein Thrombosis
Gastritis
Haemorrhage Intracranial
Herpes Simplex
Hypertension
Microcytic Anaemia
Muscle Rigidity
Myopathy
Neuropathy Peripheral
Opiates Positive
Pericardial Effusion
Pericarditis
Peripheral Coldness
Peroneal Nerve Palsy
Pneumonia
Prothrombin Time
Pulmonary Fibrosis

	Rales						
	Respiratory Distress						
	Subarachnoid Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Subdural Haematoma	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO; 25
	Systemic Lupus	Health					MG/DAILY/PO
	Erythematosus	Professional	Hydrocodone	C			
	Urinary Tract Infection		Prednisone	C			
	Vasospasm						
	White Blood Cell Count						

Date:04/21/03ISR Number: 4099612-7Report Type:Expedited (15-DaCompany Report #WAES 0212USA00229
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthritis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY
Initial or Prolonged	Blood Amylase	Health					PO
	Cartilage Injury	Professional	Darvocet-N	C			
	Cholecystitis Acute						
	Cholelithiasis						
	Dizziness						
	Essential Hypertension						
	Fluid Retention						
	Gangrene						
	Gastric Ulcer						
	Loose Body In Joint						
	Peptic Ulcer						
	Surgical Procedure						
	Repeated						
	White Blood Cell Count						

Date:04/22/03ISR Number: 4094907-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01294
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amputation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 WK

Initial or Prolonged	Skin Discolouration	Professional	Celebrex	C
			Ibuprofen	C

Date:04/22/03ISR Number: 4094910-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dialysis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Glomerulonephritis		Celebrex	SS		
7 DAY						
	Membranous					
	Swelling					

Date:04/22/03ISR Number: 4094912-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA01551
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Glucose	Health	Vioxx	PS		ORAL
	Glycosylated Haemoglobin	Professional	Premarin	C	Merck & Co., Inc	
	Granulomatous Liver		Advil	C		
	Disease					
	Hepatic Steatosis					
	Serum Ferritin Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/03ISR Number: 4094913-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA00793
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atherosclerosis	Professional	Atenolol	C		ORAL		
Initial or Prolonged	Barrett'S Oesophagus		Norvasc	C				
	Faeces Discoloured							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Helicobacter Gastritis							
	Hiatus Hernia							
	Myocardial Infarction							
	Peptic Ulcer Reactivated							

Date:04/22/03ISR Number: 4094914-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01802
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C				
			Metformin	C				
			Prevacid	C				
			Pravachol	C				
			Glucotrol Xl	C				

Date:04/22/03ISR Number: 4095294-9Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00004
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
							7	DAY
	Increased		Vioxx	SS		ORAL		
	Fall		Atenolol	C				
	Rotator Cuff Syndrome		Aspirin	C				
	Sinus Arrhythmia		Fenofibrate	C				
			Telmisartan	C				

				Allopurinol	C		

Date:04/23/03ISR Number: 4095647-9Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12219366
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia Renal Failure	Health Professional	Fosinopril Sodium	PS	Bristol-Myers Squibb Company	ORAL	1	YR
			Rofecoxib	SS		ORAL	8	MON
			Omeprazole	C				
			Thyroxine	C				

Date:04/23/03ISR Number: 4096192-7Report Type:Expedited (15-DaCompany Report #WAES 0304DNK00016
Age:91 YR Gender:Female I/FU:I

Outcome	PT
Death	Duodenal Ulcer
Hospitalization - Initial or Prolonged	Gastric Ulcer
	Gastrointestinal

Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Acetaminophen	C		ORAL		
	Bendroflumethiazide And Potassium Chloride	C		ORAL		

Date:04/23/03ISR Number: 4096197-6Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00027
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Hypertension		Vioxx	SS		ORAL		54 DAY
			[Therapy Unspecified]	SS				
			Zolmitriptan	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		

Date:04/23/03ISR Number: 4096199-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Chloride		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Hospitalization -	Blood Creatinine		Desogen	SS				
Initial or Prolonged	Blood Potassium		Aleve	C				
	Blood Sodium		Ultram	C				
	Blood Urea		[Therapy Unspecified]	C				
	Cardio-Respiratory Arrest		Vicodin Tablets	C				
	Deep Vein Thrombosis		Toradol	C				
	Dilatation Ventricular		Skelaxin	C				
	Haematocrit							
	Hypertension							

INTRAMUSCULAR

Hypotension
Myocardial Infarction
Peripheral Coldness
Platelet Count
Pulmonary Embolism
Pulmonary Hypertension
Pupil Fixed
Respiratory Failure
Sinus Tachycardia
Supraventricular
Tachycardia
Tricuspid Valve
Incompetence

Date:04/24/03ISR Number: 4096808-5Report Type:Expedited (15-DaCompany Report #WAES 0303GRC00022
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis Face Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/03ISR Number: 4097028-0Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00110
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Henoch-Schonlein Purpura							
	Myalgia							

Date:04/24/03ISR Number: 4097030-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA02006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema							

Date:04/24/03ISR Number: 4097033-4Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00216
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Adhesions	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colitis	Professional	Vioxx	SS		ORAL		
	Crohn'S Disease		Meloxicam	C				

Date:04/24/03ISR Number: 4100233-8Report Type:Direct Company Report #CTU 191616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash		Vioxx	PS				

Date:04/24/03ISR Number: 4102661-3Report Type:Expedited (15-DaCompany Report #2003156200US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dialysis	Consumer	Celebrex(Celecoxib)		
	Glomerulonephritis		Capsule	PS	ORAL
ORAL					
	Membranous		Vioxx()	SS	

Date:04/24/03ISR Number: 4102918-6Report Type:Expedited (15-DaCompany Report #WAES 01010328
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Accelerated Hypertension
Initial or Prolonged	Amnesia
Other	Anger
	Anxiety
	Asthenia
	Balance Disorder
	Cardiomegaly
	Convulsion
	Cough
	Dermatitis
	Diastolic Dysfunction
	Drug Hypersensitivity
	Family Stress
	Gait Disturbance
	Headache
	Hyperhidrosis

	Hypertension						
	Hypertensive Crisis						
	Joint Swelling	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Limb Injury	Consumer	Tab Vioxx	PS		ORAL	DAILY/PO
	Loss Of Consciousness	Health	Procrit	SS			UNKNOWN UN, UNK, UNK
	Malaise	Professional	Carbatrol	SS			UNKNOWN UNK, UNK, UNK
	Medication Error	Company	Catapres	C			
	Nausea	Representative	Cozaar	C			
	Oedema Peripheral		Glucotrol	C			
	Pulmonary Hypertension		Hyzaar	C			
	Rash Generalised		Neurontin	C			
	Speech Disorder		Premarin	C			
	Thinking Abnormal		Toprol Xl Tablets	C			
	Tremor		....	C			
	Tricuspid Valve Incompetence						

Date:04/24/03ISR Number: 4102932-0Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 25	Abdominal Distension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	MG/DAILY/PO
Initial or Prolonged	Carotid Artery Stenosis	Health					
Disability	Cerebral Infarction	Professional	Colace	C			
	Cerebrovascular Accident		Coumadin	C			
	Chest Discomfort		Maxzide	C			
	Chest Pain		Paxil	C			
	Constipation		Potassium Chloride	C			
	Drug Ineffective		Trazodone Hyidrochloride	C			
	Ear Pain						
	Electrocardiogram St-T Segment Abnormal						
	Exercise Electrocardiogram Abnormal						
	Gastrointestinal Disorder						
	Haematochezia						
	Heart Rate Increased						

Hypokalaemia
Hypotension
Insomnia
Lipoma
Middle Ear Effusion
Oedema Peripheral
Ovarian Cyst
Oxygen Saturation
Decreased
Pain
Pelvic Mass
Rectocele
Renal Cyst
Sinus Bradycardia
Synovial Cyst
Transient Ischaemic
Attack
Ulcer
Urinary Incontinence

Date:04/25/03ISR Number: 4097733-6Report Type:Expedited (15-DaCompany Report #WAES 0303FRA00095
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pain In Extremity	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Phlebitis	Professional	Diacerein	C		ORAL		
Other			Levothyroxine Sodium	C		ORAL		
			Diosmin	C		ORAL		

Date:04/25/03ISR Number: 4097741-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA00888
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropod Bite	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Back Pain	Professional	Duragesic	C		TOPICAL		122 DAY
Disability	Cellulitis		Methadone Hcl	C		ORAL		42 DAY
	Meningitis Viral		Oxycodone	C		ORAL		
	Muscle Twitching							
	Nausea							
	Tremor							

Date:04/25/03ISR Number: 4097742-7Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00040
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Myocardial Infarction	Professional	Celiprolol	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C				976 DAY

Date:04/25/03ISR Number: 4098092-5Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00197
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea Exacerbated		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Oedema Mouth		Amitriptyline Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Bisoprolol	C		ORAL		
			Furosemide	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Simvastatin	C		ORAL		
			Zopiclone	C		ORAL		
			Ramipril	C		ORAL		

Date:04/25/03ISR Number: 4098096-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01476
Age:57 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Blood Pressure Increased
Other	Contusion
	Fall

		Haemangioma Of Liver					
		Hepatic Cyst					
		Hepatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatocellular Damage		Vioxx	PS		ORAL
		Hepatotoxicity		Arava	SS	Merck & Co., Inc	
3	DAY						
		Lymphocyte Count		Arava	SS		
64	DAY						
		Decreased		Methotrexate	C		
		Monocyte Count Increased		Prednisone	C		
		Neutrophil Count		[Therapy			
		Decreased		Unspecified]	C		
		Platelet Count Increased		Colace	C		
		Renal Cyst		Clavulanate			
		Serum Ferritin		Potassium	C		
		White Blood Cell Count		Sulfasalazine	C		
		Increased		Augmentin	C		
				Celebrex	C		
				Tylenol	C		

Date:04/25/03ISR Number: 4098098-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00190
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Hypersensitivity		Vitamins			
Other	Gangrene		(Unspecified)	C		
	Infection		Thyroid	C		
	Osteomyelitis					
	Skin Lesion					
	Toe Amputation					
	Tongue Disorder					

Date:04/25/03ISR Number: 4098100-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01593
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Bezoar		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastric Outlet		Lasix (Furosemide)	C		
Initial or Prolonged	Obstruction		Procardia	C		

Disability	Gastric Ulcer	Isosorbide Dinitrate	C	
Other	Pneumonia	Prevacid	C	
	Vomiting	Megace	C	
		Restoril	C	
		Darvocet-N	C	
		Tizanidine Hydrochloride	C	
		Histussin-Hc Syrup	C	
		Singulair	C	ORAL
		Nitrostat	C	SUBLINGUAL
		Nitro-Dur	C	
		Flovent	C	
		Albuterol	C	
		Potassium Chloride	C	
		Albuterol	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/03ISR Number: 4098101-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01955
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/03ISR Number: 4102980-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory Failure	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25-50	
Initial or Prolonged	Anaemia	Health					MG/DAILY/PO	
Disability	Asthenia	Professional	Indocin					
Other	Blood Alkaline Phosphatase Increased Body Temperature Increased Cardiac Failure Congestive Cerebral Haemorrhage Cerebrovascular Spasm Clostridium Colitis Cognitive Disorder Coma Communication Disorder Complex Partial Seizures Convulsion Enterobacter Pneumonia Eye Disorder Fall Haemoglobin Decreased Headache Postoperative Hydrocephalus Hypertension Hyponatraemia Hypotension Malnutrition Memory Impairment Mental Status Changes Nervous System Disorder		(Indomethacin) Tylenol Extra Strength	C C				

Pneumonia Aspiration
Post Procedural Pain
Pulmonary Oedema
Ruptured Cerebral
Aneurysm
Sedation
Somnolence
Stress
Subarachnoid Haemorrhage
Thrombocytopenia
White Blood Cell Count

Date:04/28/03ISR Number: 4098692-2Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00006
Age:68 YR Gender:Female I/FU:F

Outcome PT
Disability Arthralgia
Blood Folate
Blood Uric Acid

	Polymyalgia Rheumatica						
	Rash						
	Red Blood Cell	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sedimentation Rate		Vioxx	PS	Merck & Co., Inc	ORAL	182 DAY
	Swelling		Omeprazole Magnesium	C			
	Tendon Disorder		Levothyroxine Sodium	C			
	Vitamin B12		Raloxifene	C			

Date:04/28/03ISR Number: 4098696-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL	65 DAY
Initial or Prolonged	Anaemia		Indocin				
Disability	Aneurysm Ruptured		(Indomethacin)	C		ORAL	
Other	Blood Alkaline		Tylenol Extra				
	Phosphatase Increased		Strength	C			
	Cardiac Failure		Celebrex	C		ORAL	
	Congestive		Celebrex	C		ORAL	
	Cerebral Ventricle						
	Dilatation						
	Clostridial Infection						
	Coma						
	Convulsion						
	Enterobacter Infection						
	Fall						
	Hydrocephalus						
	Hypertension						
	Hyponatraemia						
	Hypotension						
	Intraventricular						
	Haemorrhage						
	Malnutrition						
	Mental Status Changes						
	Myocardial Infarction						
	Osteoarthritis						
	Pneumonia Aspiration						
	Pulmonary Oedema						
	Subarachnoid Haemorrhage						
	Thrombocytopenia						
	White Blood Cell Count						

Date:04/28/03ISR Number: 4098706-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02471
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/03ISR Number: 4099122-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Carotid Artery Stenosis
	Cerebral Infarction
Disability	Cerebrovascular Accident
	Constipation
	Dysarthria

		Ear Pain					
		Electrocardiogram St-T Change	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ganglion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal	Professional	Colace	C		
		Haemorrhage		Paxil	C		
		Hemiparesis		Maxzide	C		
		Hypoaesthesia		Potassium Chloride	C		
		Hypokalaemia		Trazodone			
		Hypotension		Hydrochloride	C		
		Lipoma		Coumadin	C		
		Liposarcoma					
		Musculoskeletal Stiffness					
		Oedema Peripheral					
		Ovarian Cyst					
		Oxygen Saturation Decreased					
		Pelvic Mass					
		Renal Cyst					
		Respiratory Rate Increased					
		Sinus Headache					
		Stress Incontinence					
		Transient Ischaemic Attack					
		Urinary Incontinence					

Date:04/28/03ISR Number: 4099125-2Report Type:Expedited (15-DaCompany Report #WAES 0303NZL00022
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Myelodysplastic Syndrome	Consumer	Vioxx	PS	Merck & Co., Inc	
				Methotrexate	C		
				Methylprednisolone Acetate	C		
				Folic Acid	C		
				Acetaminophen	C		
				Cyclizine	C		
				Calcipotriene	C		
				Mometasone Furoate	C		
				Hydrocortisone	C		

Date:04/28/03ISR Number: 4101619-8Report Type:Direct Company Report #CTU 191731
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS				

Date:04/28/03ISR Number: 4101627-7Report Type:Direct Company Report #CTU 191735
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required 2 PER Intervention to Prevent Permanent Impairment/Damage	Clonic Convulsion		Vioxx 25mg	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/03ISR Number: 4101630-7Report Type:Direct Company Report #CTU 191737
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Rofecoxib	PS		ORAL	ORAL	
Initial or Prolonged	Increased							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:04/28/03ISR Number: 4101726-XReport Type:Direct Company Report #CTU 191678
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck			
Initial or Prolonged	Oesophageal Haemorrhage		Aspirin	SS				

Date:04/28/03ISR Number: 4104478-2Report Type:Expedited (15-DaCompany Report #PHBS2003NL03896
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy	Foreign	Hydrochlorothiazide					
	Capillary Disorder	Literature	(Hydrochlorothiazide					
	Eye Haemorrhage	Other	)	PS				
	Optic Disc Haemorrhage		Infliximab					
	Papilloedema		(Infliximab)	SS				
	Scotoma		Atenolol (Atenolol)	SS				
			Enalapril					
			(Enalapril)	SS				
			Salicylic Acid					
			(Salicylic Acid)	SS				
			Terfenadine					
			(Terfenadine)	SS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:04/29/03ISR Number: 4099734-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Death	Asthenia
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Atrial Flutter
	Bronchitis
	Cardio-Respiratory Arrest
	Chest Pain
	Cholelithiasis
	Chronic Obstructive Airways Disease Exacerbated
	Compression Fracture
	Electrocardiogram St-T Change
	Electromechanical Dissociation
	Emphysema
	Gastritis
	Hepatic Cyst

		Hyperhidrosis					
		Hypertension					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Multiple Myeloma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
425 DAY							
		Myocardial Infarction	Professional	Nonsteroidal			
		Pneumonia Streptococcal		Anti-Inflammatory			
		Streptococcal Sepsis		Drug (Unspecified)	C		ORAL
		Tachycardia		Lipitor	C		
		Tachypnoea		Metoprolol	C		
		Tracheobronchitis		Prozac	C		
		Upper Respiratory Tract		Combivent	C		
RESPIRATORY							
		Infection					
(INHALATION)							
				Daypro	C		ORAL
				Prednisone	C		
				Ventolin (Albuterol			
				Sulfate)	C		
				Cartia (Aspirin)	C		ORAL
				Nicotine	C		
				Xanax	C		ORAL
				Cardizem Cd	C		
				Captopril	C		

Date:04/29/03ISR Number: 4099738-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL
696 DAY							
Initial or Prolonged		Increased	Professional	Reglan	SS		
Other		Carotid Artery Stenosis		Catapres	C		
		Carpal Tunnel Syndrome		Prilosec	C		
		Cerebellar Infarction		Flonase	C		
		Cerebrovascular Accident		Robaxin	C		
		Cerebrovascular Disorder		Celebrex	C		
		Chest Discomfort		Lopid	C		
		Deafness Neurosensory					
		Diabetes Mellitus					
		Fall					
		Fatigue					
		Gallbladder Disorder					

Glossitis
Haematochezia
Low Density Lipoprotein
Increased
Major Depression
Neuropathy Peripheral
Radiculopathy
Subclavian Steal Syndrome
Syncope
Treatment Noncompliance
Tremor

Date:04/29/03ISR Number: 4099743-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00135
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Tunnel Vision Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/03ISR Number: 4099744-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02829
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia	Professional	Ziac	C				
	Fluid Retention							

Date:04/29/03ISR Number: 4099748-0Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00164
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
	Abnormal		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Furosemide	C		ORAL		
			Allopurinol	C		ORAL		
			Omeprazole	C		ORAL		

Date:04/29/03ISR Number: 4100085-6Report Type:Expedited (15-DaCompany Report #WAES 0211ITA00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Lactate Dehydrogenase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Neridronate Sodium	SS		INTRAMUSCULAR		
	Cholelithiasis							
	Jaundice Acholuric							

Date:04/29/03ISR Number: 4100086-8Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Hospitalization - Initial or Prolonged Disability	Ejaculation Disorder Gastrointestinal Haemorrhage Haemorrhage Shock						

Date:04/29/03ISR Number: 4100087-XReport Type:Expedited (15-DaCompany Report #WAES 0208FRA00040
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Initial or Prolonged	Myocardial Infarction		Celiprolol	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL	976 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/03ISR Number: 4100089-3Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00074
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Contusion		Vioxx	SS		ORAL
12 DAY						
Other	Drug Interaction		Fluindione	SS		ORAL
	International Normalised Ratio Increased		Fluindione	SS		ORAL
			Althiazide And Spironolactone	C		ORAL
			Digoxin	C		ORAL
			Quinapril Hydrochloride	C		ORAL

Date:04/29/03ISR Number: 4100093-5Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00082
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
			Bromazepam	C		ORAL
			Acetaminophen	C		ORAL
			Omeprazole	C		ORAL
			Nicardipine Hydrochloride	C		ORAL
			Fluoxetine Hydrochloride	C		ORAL

Date:04/30/03ISR Number: 4100993-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01991
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema Peripheral	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
	Post Procedural Complication		Vioxx	SS		ORAL
			Voltaren	C		
	Rash Pruritic					

Date:04/30/03ISR Number: 4100994-8Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00187
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		

Date:04/30/03ISR Number: 4101091-8Report Type:Expedited (15-DaCompany Report #CH-ROCHE-336869
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Consumer	Torem	PS	Roche	ORAL	4	DAY
			Xenalon	SS		ORAL	14	DAY
			Ciproxin	SS		ORAL	11	DAY
			Primperan	C		ORAL	19	DAY
			Movicol	C		ORAL	15	DAY
			Rimactan	C		ORAL	11	DAY
			Zoloft	C		ORAL	7	DAY
			Zofran Zidis	C		ORAL	12	DAY
			Fraxiparine	C		SUBCUTANEOUS	18	DAY
			Comilorid-Mepha	C		ORAL	4	DAY
			Durogesic	C		ORAL	12	DAY

			Laxoberon	C		ORAL
12 DAY						
			Haldol	C		ORAL
29 DAY						
			Iomeprol	I		
INTRAVENOUS	1 DAY					
			Vioxx	I		ORAL
6 DAY						

Date:04/30/03ISR Number: 4103740-7Report Type:Direct Company Report #CTU 191990
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Meningitis Aseptic		Rofecoxib	PS		ORAL
50 MG PO						
Initial or Prolonged						

Date:04/30/03ISR Number: 4104583-0Report Type:Expedited (15-DaCompany Report #TAP2003Q00944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Anaphylactic Reaction	Health	Prevacid			
Intervention to	Drug Interaction	Professional	(Lansoprazole)	PS		
Prevent Permanent	Urticaria		Advil (Ibuprofen)	SS		
Impairment/Damage			Celebrex (Celecoxib)	SS		
			Vioxx (Rofecoxib)	SS		

Date:04/30/03ISR Number: 4105127-XReport Type:Direct Company Report #CTU 191996
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Blood Creatinine		Vioxx	PS		ORAL
25 MG QD PO						
Intervention to	Increased		Prevacid	C		
Prevent Permanent			Synthroid	C		
Impairment/Damage			Diclofenac	C		
			Actos	C		
			Glucovance	C		

Date:05/01/03ISR Number: 4101852-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA02432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/01/03ISR Number: 4101856-2Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00010
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Initial or Prolonged		Professional	Vioxx	SS		ORAL		54 DAY
			Methotrexate	C				

Date:05/01/03ISR Number: 4102069-0Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00009
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged	Haematochezia	Professional	Tibolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/03ISR Number: 4102070-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dehydration	Professional	Aggrenox	C				
Initial or Prolonged	Duodenal Ulcer		Digoxin	C				
	Haemorrhage		Mag-Ox 400 Tablets	C				
	Gastrointestinal		Reglan	C				
	Haemorrhage		Metoprolol	C				
	Hypovolaemia		Risperdal	C				
	Malnutrition		Vitamins					
	Oesophagitis		(Unspecified)	C				
	Renal Failure		Lasix (Furosemide)	C				
	Urinary Tract Infection		Detrol	C				
			Megace	C				
			Ben-Gay	C				
			Tylenol	C				

Date:05/01/03ISR Number: 4102075-6Report Type:Expedited (15-DaCompany Report #WAES 0304BEL00028
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Peritonitis							
Initial or Prolonged								

Date:05/01/03ISR Number: 4102078-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00198
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage							

Date:05/01/03ISR Number: 4102080-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02371
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				
			Synthroid	C				
			Paxil	C				
			Lasix (Furosemide)	C				
			Protonix	C				

Date:05/01/03ISR Number: 4102084-7Report Type:Expedited (15-DaCompany Report #WAES 0304CHE00024
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Second Degree		Vioxx	SS		ORAL		
11 DAY								
Initial or Prolonged	Bradycardia		Prednisone	C		ORAL		
	Hyperkalaemia		Pravastatin Sodium	C		ORAL		
	Hypertension		Acetaminophen	C		ORAL		
	Medication Error		Moduretic	C		ORAL		
3 DAY								
	Renal Failure Acute							
	Treatment Noncompliance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/03ISR Number: 4102085-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA02565
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Cardiac Arrest Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/01/03ISR Number: 4105237-7Report Type:Direct Company Report #CTU 192087
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Arteriovenous Malformation Blood Pressure Decreased Convulsion Decreased Activity Dizziness Face Oedema Impaired Driving Ability Lethargy Oedema Peripheral Renal Failure Acute Renal Pain Vertigo		Vioxx 25mg Merck	PS	Merck	ORAL	25MG ONE A DAY ORAL	

Date:05/01/03ISR Number: 4105425-XReport Type:Direct Company Report #CTU 192125
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Cardiac Failure Congestive Diverticulum Intestinal Haemorrhagic Fluid Retention Pulmonary Oedema		Vioxx Lasix	PS C	Merck			

Date:05/01/03ISR Number: 4106432-3Report Type:Expedited (15-DaCompany Report #102460ISR
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis Acute	Foreign	Methotrexate	PS		ORAL	ORAL	12 DAY
		Health Professional	Rofecoxib	SS		ORAL	25 MILLIRGAM	
		Other	Budesonide	C				
			Folic Acid	C				

Date:05/01/03ISR Number: 4107304-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Acute Respiratory Failure
Other	Anaemia
	Aneurysm Ruptured

		Blood Alkaline Phosphatase Increased					
		Blood Pressure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inadequately Controlled	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25-50							
		Brain Damage	Health				
MG/DAILY/PO							
		Cardiac Failure	Professional	Celebrex	C		
		Congestive Cardiomyopathy		Indocin (Indomethacin)	C		
		Cerebral Ventricle Dilatation		Tylenol Extra Strength	C		
		Cerebrovascular Spasm					
		Clostridium Colitis					
		Cognitive Disorder					
		Coma					
		Complex Partial Seizures					
		Enterobacter Infection					
		Fall					
		Hydrocephalus					
		Inappropriate Antidiuretic Hormone Secretion					
		Intraventricular Haemorrhage					
		Malnutrition					
		Memory Impairment					
		Mental Status Changes					
		Myocardial Infarction					
		Osteoarthritis					
		Pneumonia Aspiration					
		Pulmonary Oedema					
		Somnolence					
		Subarachnoid Haemorrhage					
		Tenosynovitis Stenosans					
		Thrombocytopenia					
		White Blood Cell Count Increased					

Date:05/02/03ISR Number: 4102368-2Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00224
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Headache		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
	Iiird Nerve Paralysis		Lansoprazole	C		
	Musculoskeletal Stiffness		Bendroflumethiazide	C		
	Vasculitis					

Date:05/02/03ISR Number: 4102372-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01372
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Erythema Multiforme		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
	Pain In Extremity		Levaquin	C		

Date:05/02/03ISR Number: 4102377-3Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00203
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Furosemide	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		
			Aspirin	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Vitamins (Unspecified)	C				

Date:05/02/03ISR Number: 4102378-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA02490
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Kidney Infection		Antineoplastic (Unspecified)	SS				
			Xanax	C				
			Xanax	C				
			Aciphex	C				
			Apap	C				
			Centrum Silver	C				
			Os-Cal	C				

Date:05/02/03ISR Number: 4102744-8Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00292
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Inappropriate Antidiuretic Hormone	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Timoptic OPHTHALMIC	C				

	Secretion		Calcium Lactate	C		
			Psyllium Husk	C		

Date:05/02/03ISR Number: 4102745-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01106
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL
	Nasopharyngitis		Aspirin	C		
	Transient Ischaemic Attack					

Date:05/02/03ISR Number: 4102746-1Report Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatotoxicity		Vioxx	PS	Merck & Co., Inc	ORAL
	Nephropathy Toxic					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/03ISR Number: 4102749-7Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00010
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:05/02/03ISR Number: 4102750-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA02925
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	123	DAY
Initial or Prolonged	Rectal Haemorrhage		Aspirin	C				
			Pilocarpine	C				
OPHTHALMIC								
			Dicyclomine Hydrochloride	C				
			Hydrodiuril	C				
			Vasotec	C				

Date:05/02/03ISR Number: 4102753-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA02506
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Erythematous		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Rash Pruritic		Soma	C				
			Prednisone	C				
			Motrin	C				

Date:05/02/03ISR Number: 4106775-3Report Type:Expedited (15-DaCompany Report #336869
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Torem (Torsemide Or					

	Renal Failure Acute	Other	Torsemide Sodium)	PS		ORAL
10 MG DAILY						
ORAL						
			Iomeprol (Iomeprol)	SS		
INTRAVENOUS	100 ML 1 PER					
ONE DOSE						
INTRAVENOUS						
			Vioxx (Rofecoxib)	SS		ORAL
25 MG DAILY						
ORAL						
			Xenalon (Spironolactone)	SS		ORAL
25 MG DAILY						
ORAL						
			Ciproxin (Ciprofloxacin Hydrochloride Or Ciprofloxacin Lactate)	SS		ORAL
1500 MG DAILY						
ORAL						
			Primperan (Mcp)	C		
			Haldol (Haloperidol)	C		
			Movicol (Polyethylene Glycol/Potassium Chloride/Sodium Bicarbonate/Sodium	C		
			Laxoberon (Sodium Picosulfate)	C		
			Rimactan (Rifampin)	C		

Durogesic (Fentanyl Citrate)	C
Zoloft (Sertraline Hydrochloride)	C
Comilorid-Mepha (Amiloride Hydrochloride/Hydrochlorothiazide)	C
Zofran Zidis (Ondansetron Hydrochloride)	C
Fraxiparine (Nadroparin Calcium)	C

Date:05/02/03ISR Number: 4107020-5Report Type:Expedited (15-DaCompany Report #PHBS2003BR04156
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Syncope	Foreign Health Professional	Cataflam(Diclofenac Potassium)	PS				
		Other	Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:05/05/03ISR Number: 4103083-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00184
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Psychotic Disorder		Amiloride Hydrochloride And Furosemide	C				

Date:05/05/03ISR Number: 4103085-5Report Type:Expedited (15-DaCompany Report #WAES 0304FIN00012
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Alanine Aminotransferase Increased General Physical Health Deterioration Oedema Peripheral Prealbumin Decreased		Dydrogesterone And Estradiol	C		ORAL

Date:05/05/03ISR Number: 4103096-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02882
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/03ISR Number: 4103475-0Report Type:Expedited (15-DaCompany Report #WAES 0303FIN00005
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Hospitalization - Initial or Prolonged	Haemorrhage		Acetaminophen	C		ORAL		
			Allopurinol	C		ORAL		
			Methenamine Hippurate	C		ORAL		
			Nifedipine	C		ORAL		
			Temazepam	C		ORAL		

Date:05/05/03ISR Number: 4103482-8Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00084
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/03ISR Number: 4103488-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00034
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
			Premarin	C				

Date:05/05/03ISR Number: 4103489-0Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00002
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Cortisone	C				

Date:05/05/03ISR Number: 4103490-7Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00184
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression Psychotic Disorder		Vioxx Amiloride Hydrochloride And Furosemide	PS C	Merck & Co., Inc	ORAL		

Date:05/05/03ISR Number: 4103491-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA02896
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Agranulocytosis Febrile Neutropenia Mental Status Changes		Vioxx Elavil [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL		

Date:05/05/03ISR Number: 4103493-2Report Type:Expedited (15-DaCompany Report #WAES 0305USA00132
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/03ISR Number: 4103494-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA02902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/03ISR Number: 4103496-8Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00185
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Condition Aggravated	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Gastric Ulcer Haemorrhage	Professional	Aspirin	SS		ORAL		
Hospitalization - Initial or Prolonged	Myocardial Ischaemia							

Date:05/05/03ISR Number: 4103498-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00216
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	Aspirin	SS		ORAL		
	Gastritis Erosive Oesophagitis		Valsartan	C		ORAL		
	Renal Failure Acute		Isosorbide Mononitrate	C		ORAL		
			Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
			Quinine Sulfate	C		ORAL		
			Zocor	C		ORAL		
			Gabapentin	C		ORAL		

Date:05/05/03ISR Number: 4103499-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA00144
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Rash							

Date:05/05/03ISR Number: 4105793-9Report Type:Direct Company Report #CTU 192253
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx Merck	PS	Merck	ORAL	1 TABLE	QD
Hospitalization -	Haemorrhage							
ORAL								
Initial or Prolonged			Endocet	C				
			Cyclobenzaprene	C				

Date:05/05/03ISR Number: 4107577-4Report Type:Expedited (15-DaCompany Report #2003015276
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthropathy
Initial or Prolonged	Blood Potassium Decreased
Disability	Blood Pressure
Other	Fluctuation
	Body Height Decreased

Condition Aggravated	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cerebrovascular Accident							
Coma							
Dizziness	Consumer	Geodon (Ziprasidone)	PS		ORAL	(BID), ORAL	
Drug Interaction		Erythromycin					
Feeling Abnormal		(Erythromycin)	SS				
Hypertension		Rofecoxib					
Kidney Infection		(Rofecoxib)	SS		ORAL	ORAL	
Laboratory Test Abnormal		Oxycocet					
Migraine		(Paracetamol,					
Nasopharyngitis		Oxycodone					
Tooth Abscess		Hydrochloride)	SS				
Tremor		Temazepam					
Ulcer		(Temazepam)	SS				
Uterine Neoplasm		Cyclobenzaprine					
Weight Decreased		Hydrochloride	SS				
		Fluoxetine					
		Hydrochloride	C				
		Omeprazole	C				
		Diazepam (Diazepam)	C				
		Sucralfate					
		(Sucralfate)	C				
		Metclopramide					
		(Metclopramide)	C				
		Phentermine					
		(Phentermine)	C				
		Paracetamol					
		(Paracetamol)	C				
		Antihistamines	C				
		Benzeftamine					
		Hydrochloride	C				
		Ketorolac					
		Tromethamine	C				
		Estrogens Conjugated	C				
		Lotrel (Amlodipine,					
		Benazepril					
		Hydrochloride)	C				
		Cotylenol					
		(Paracetamol,					
		Chlorphenamine					
		Maleate,					
		Dextromethoprhan	C				
		Medinite (Ethanol,					
		Paracetamol,					

Dextromethorphan Hydrobromide, Ephedrine Sulfate,	C
All Other Non-Therapeutic Products	C
Furosemide (Furosemide)	C

Date:05/05/03ISR Number: 4108262-5Report Type:Expedited (15-DaCompany Report #PHBS2003NL03896
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Other	Capillary Disorder
	Drug Ineffective
	Eye Haemorrhage

		Optic Nerve Disorder Papilloedema Scotoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vision Blurred	Foreign Literature Other	Hydrochlorothiazide(Hydrochlorothiazide)	PS		
				Infliximab(Infliximab)	SS		
				Atenolol(Atenolol)	SS		
				Enalapril(Enalapril)	SS		
				Salicylic Acid(Salicylic Acid)	SS		
				Terfenadine(Terfenadine)	SS		
				Rofecoxib(Rofecoxib)	SS		

Date:05/05/03ISR Number: 4108861-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG,						
Hospitalization -	Asthenia	Health				
DAILY, PO						
Initial or Prolonged	Blood Pressure Decreased	Professional	Aggrenox	C		
	Death		Ben-Gay	C		
	Decreased Appetite		Detrol	C		
	Dehydration		Lasix (Furosemide)	C		
	Duodenal Ulcer		Mag-Ox	C		
	Faeces Discoloured		Megace	C		
	Gastritis Erosive		Reglan	C		
	Gastrointestinal Disorder		Risperdal	C		
	Gastrointestinal		Tylenol	C		
	Haemorrhage		Tylenol	C		
	General Nutrition		Digoxin	C		
	Disorder		Metoprolol	C		
	Haematemesis		Vitamins	C		
	Hypovolaemia					
	Lethargy					
	Oesophagitis					
	Renal Failure					
	Urinary Tract Infection					
	Weight Decreased					

Date:05/05/03ISR Number: 4117047-5Report Type:Periodic Company Report #2002UW15324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Amitriptyline Hydrochloride	PS				
Hospitalization - Initial or Prolonged			Zomig	SS				
Disability			Vioxx	SS		ORAL	25 MG PO	
Required Intervention to Prevent Permanent Impairment/Damage			Multiple Other Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/03ISR Number: 4103928-5Report Type:Expedited (15-DaCompany Report #WAES 0305CAN00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Paraesthesia							

Date:05/06/03ISR Number: 4103931-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA00035
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Vicodin Tablets	C				

Date:05/06/03ISR Number: 4103932-7Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00164
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Function Test	Health	Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
	Abnormal	Professional	Acetaminophen And					
	Malaise		Dihydrocodeine					
			Bitartrate	C		ORAL		
			Isosorbide					
			Mononitrate	C		ORAL		
			Furosemide	C		ORAL		
			Allopurinol	C		ORAL		
			Omeprazole	C		ORAL		

Date:05/06/03ISR Number: 4103933-9Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00016
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY

	Sepsis			Trimethoprim	C		ORAL
2 DAY							
				Gliclazide	C		ORAL
				Metformin	C		ORAL
				Ramipril	C		
				Bumetanide	C		
				Floxacillin	C		
INTRAVENOUS		3	DAY				
				Cefuroxime	C		
INTRAVENOUS		367	DAY				
				Omeprazole	C		
4 DAY							
				Aspirin	C		
				Tolterodine	C		

Date:05/06/03ISR Number: 4104288-6Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00078
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haematuria	Health	Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
Hospitalization -	Haemodialysis	Professional	Ciprofloxacin	C		ORAL
4 DAY						
Initial or Prolonged	Renal Failure Acute Tubulointerstitial Nephritis		Diclofenac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/03ISR Number: 4104294-1Report Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatotoxicity Nephropathy Toxic	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/03ISR Number: 4104302-8Report Type:Expedited (15-DaCompany Report #WAES 0304FIN00012
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Alanine Aminotransferase Increased Malaise Oedema Peripheral Prealbumin Decreased	Health Professional	Vioxx Vioxx Dydrogesterone And Estradiol	PS SS C	Merck & Co., Inc	ORAL ORAL ORAL		

Date:05/06/03ISR Number: 4106539-0Report Type:Direct Company Report #CTU 192346
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fluid Retention Weight Increased		Vioxx 50 Mg	PS		ORAL	25 MG PO QD	

Date:05/06/03ISR Number: 4108622-2Report Type:Expedited (15-DaCompany Report #2003CG00672
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumopathy Respiratory Disorder	Foreign Health Professional	Mopral Lexomil	PS SS		ORAL	20 MG DAILY PO	
		Other	Dafalgan	SS		ORAL	6 DF DAILY PO	

Prozac	SS	ORAL	1 DF DAILY PO
Vioxx	SS	ORAL	1 DF DAILY PO
Loxen	SS	ORAL	20 MG TID PO

Date:05/06/03ISR Number: 4108948-2Report Type:Expedited (15-DaCompany Report #2003015276
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aphasia
Disability	Arthropathy
Other	Blood Potassium Decreased
	Blood Pressure Inadequately Controlled
	Body Height Decreased
	Cerebrovascular Accident
	Condition Aggravated
	Depression
	Hypertension
	Hysterectomy
	Kidney Infection
	Laboratory Test Abnormal
	Malaise
	Migraine
	Post-Traumatic Stress Disorder

		Tooth Abscess Tremor Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased	Consumer	Geodon (Ziprasidone)	PS		ORAL
BID, ORAL							
				Erythromycin	SS		
				Rofecoxib	SS		ORAL
50 MG, BID,							
ORAL							
				Oxycocet (Paracetamol, Oxycodone Hydrochloride)	SS		ORAL
50 MG, BID,							
ORAL							
				Temazepam	SS		
				Cyclobenzaprine Hydrochloride	SS		
				Fluoxetine Hydrochloride	C		
				Omeprazole	C		
				Diazepam	C		
				Sucralfate	C		
				Metoclopramide	C		
				Phentermine	C		
				Paracetamol	C		
				Antihistamines	C		
				Benzfetamine Hydrohcloride	C		
				Ketorolac Tromethamine	C		
				Estrogens Conjugated	C		
				Lotrel (Amlodipine, Benazepril Hydrochloride)	C		
				Cotylenol (Paracetamol, Chropheniramine Maleate, Dextromethorphan	C		
				Medinite (Ethanol, Paracetamol, Dextromethorphan Hydrobromide,			

Ephedrine Sulfate,	C
All Other Non-Therapeutic Products	C
Furosemide	C
Bupropion Hydrochloride	C
Zolpidem Tartrate	C
Topiramate	C
Propacet (Paracetamol, Dextropropoxyphene Napsilate)	C
Oxycodone Hydrochloride	C
All Other Therapeutic Products	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/03ISR Number: 4108949-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Infarction	Health					MG/DAILY/PO	
Initial or Prolonged	Asthenia	Professional	Cardizem Cd	C				
	Atrial Fibrillation		Cartia (Aspirin)	C				
	Atrial Flutter		Combivent	C				
	Atrioventricular Block		Daypro	C				
	Complete		Lipitor	C				
	Back Pain		Prozac	C				
	Bronchitis Acute		Ventolin (Albuterol					
	Cardiac Failure		Sulfate)	C				
	Congestive		Xanax	C				
	Cardio-Respiratory Arrest		Captopril	C				
	Cardiogenic Shock		Metoprolol	C				
	Chest Wall Pain		Nicotine	C				
	Cholelithiasis		Nonsteroidal					
	Chronic Obstructive		Anti-Inflammatory	C				
	Airways Disease		Prednisone	C				
	Exacerbated							
	Compression Fracture							
	Disease Recurrence							
	Electrocardiogram St-T							
	Change							
	Electromechanical							
	Dissociation							
	Emphysema							
	Gastritis							
	Heart Rate Irregular							
	Hepatic Cyst							
	Hyperhidrosis							
	Hypertension							
	Multiple Myeloma							
	Nausea							
	Pain							
	Pallor							
	Pneumonia Streptococcal							
	Streptococcal Sepsis							
	Tachycardia							
	Tachypnoea							
	Tracheobronchitis							
	Upper Respiratory Tract							

Infection
Ventricular Hypokinesia
Wheezing

Date:05/06/03ISR Number: 4108957-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol
Other	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebellar Infarction
	Cerebrovascular Disorder
	Chest Discomfort
	Cognitive Disorder
	Condition Aggravated
	Deafness Neurosensory

		Dementia					
		Depression					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Faecal Occult Blood	Health				
MG/DAILY/PO							
		Positive	Professional	Reglan 10 Mg	SS		
10 MG/QID							
		Fall		Catapres	C		
		High Density Lipoprotein		Celebrex	C		
		Decreased		Flonase	C		
		Hypertension		Lopid	C		
		Hypotension		Prilosec	C		
		Low Density Lipoprotein		Robaxin	C		
		Increased					
		Neuropathy Peripheral					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Subclavian Steal Syndrome					
		Tongue Discolouration					
		Tongue Disorder					
		Tongue Oedema					
		Tremor					

Date:05/06/03ISR Number: 4108965-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Anxiety
Disability	Arterial Disorder
	Cardiac Stress Test
	Abnormal
	Carotid Artery Stenosis
	Cerebral Infarction
	Chest Pain
	Constipation
	Ear Pain
	Electrocardiogram St-T
	Change
	Flatulence
	Haematochezia
	Heart Rate Increased

Hypokalaemia
Hypotension
Insomnia
Lipoma
Liposarcoma
Musculoskeletal Stiffness
Oedema Peripheral
Ovarian Cyst
Pain
Rectocele
Renal Cyst
Sinus Bradycardia
Sinus Headache
Stress Incontinence
Synovial Cyst
Transient Ischaemic
Attack
Tympanic Membrane
Disorder

Ulcer

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Health Professional	Colace	C				
	Coumadin	C				
	Maxzide	C				
	Paxil	C				
	Potassium Chloride	C				
	Trazodone Hydrochloride	C				

Date:05/07/03ISR Number: 4104905-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA00262
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Diovan	C				
			Fosamax	C		ORAL		
			Nexium	C				
			Premarin	C				
			Zocor	C		ORAL		

Date:05/07/03ISR Number: 4105277-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA01805
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysphagia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea							
	Headache							
Disability	Hypersensitivity							

Date:05/07/03ISR Number: 4105284-5Report Type:Expedited (15-DaCompany Report #WAES 0305CAN00020
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/08/03ISR Number: 4106150-1Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00110
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Blood Glucose Increased	Professional	Atenolol	C		ORAL		
	Gamma-Glutamyltransferase Increased							
	Lipase Increased							
	Mean Cell Volume							
	Myalgia							
	Platelet Count							
	Purpura							
	Red Blood Cell Count							
	Systemic Lupus Erythematosus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/03ISR Number: 4106161-6Report Type:Expedited (15-DaCompany Report #WAES 0305CAN00020
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/08/03ISR Number: 4106163-XReport Type:Expedited (15-DaCompany Report #WAES 0305USA00267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/08/03ISR Number: 4106164-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA00370
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Oesophageal Ulcer Rectal Haemorrhage		Prednisone	C				

Date:05/08/03ISR Number: 4106167-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA00575
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/08/03ISR Number: 4106168-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged

Date:05/08/03ISR Number: 4106169-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA00547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:05/08/03ISR Number: 4106170-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA00574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nervousness		[Therapy Unspecified]	C				
			Bextra	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/08/03ISR Number: 4107986-3Report Type:Direct Company Report #CTU 192540
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Headache Lethargy Medication Error Mental Impairment		Vioxx 50 Mg Merck And Co., Inc	PS	Merck And Co., Inc	ORAL	50MG DAILY	ORAL

Date:05/08/03ISR Number: 4117532-6Report Type:Periodic Company Report #PHRM2002FR01131
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Haemodialysis Oliguria Pancreatitis Acute Renal Failure Acute Vomiting	Foreign Health Professional Other	Voltarene Lp (Diclofenac Sodium) Slow Release Tablet	PS		ORAL	ORAL	
			Feldene (Piroxicam) Capsule	SS		ORAL	ORAL	
			Ibuprofen	SS		ORAL	ORAL	
			Vioxx (Rofecoxib) Tablet	SS		ORAL	ORAL	
			Spasfon (Trimethylphloroglucinol, Phloroglucinol)	C				
			Skenan (Morphine Sulphate)	C				

Date:05/08/03ISR Number: 4117560-0Report Type:Periodic Company Report #PHFR2002GB03853
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrectomy	Foreign	Diclofenac Sodium					

Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Health Professional	(Diclofenac Sodium) Unknown	PS		ORAL
75 MG BID						
Other		Other				
ORAL						
			Rofecoxib (Rofecoxib)	SS		ORAL
25 MG/DAY						
ORAL						
			Arthrotec (Misoprostol)	SS		ORAL
75 MG BID						
ORAL						
			Furosemide	C		
			Amlodipine	C		
			Tramadol	C		

Date:05/09/03ISR Number: 4106600-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA02882
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			[Therapy Unspecified]	C				

Date:05/09/03ISR Number: 4106604-8Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00033
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/03ISR Number: 4106607-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA00026
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	300	DAY
			Prevacid	C				
			Levoxyl	C				
			Synthroid	C				

Date:05/09/03ISR Number: 4106854-0Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00093
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epiglottitis		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Exanthem		Carvedilol	C		ORAL		
	Hypersensitivity		Vasotec	C		ORAL		
	Oedema		Pravastatin Sodium	C		ORAL		
			Diclofenac Sodium	C				
INTRAMUSCULAR							1	DAY

Date:05/09/03ISR Number: 4106855-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA02829
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	417	DAY
	Throat Tightness		Synthroid	C				
	Urticaria		Alprazolam	C				

Verapamil	C
Maxzide	C
Dicyclomine Hydrochloride	C
Fluoxetine	C
Captopril	C
Aciphex	C
Estraderm	C
Questran	C

Date:05/09/03ISR Number: 4110556-4Report Type:Expedited (15-DaCompany Report #2003158731US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Blood Pressure Increased Large Intestinal Ulcer Haemorrhage Oedema Oesophageal Ulcer Haemorrhage	Consumer	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/03ISR Number: 4107567-1Report Type:Expedited (15-DaCompany Report #WAES 0304BEL00027
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Haematoma		Warfarin Sodium	SS		ORAL		
	Injection Site		Betamethasone					
	Haemorrhage		Dipropionate And					
	Prothrombin Time		Betamethasone Sodium					
	Shortened		Phosphate	SS				
PARENTERAL								
			Bisoprolol Fumarate	C		ORAL		
			Captopril	C		ORAL		
			Torsemide	C		ORAL		

Date:05/12/03ISR Number: 4107574-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Blood Potassium	Professional	Vioxx	SS		ORAL		33 DAY
Disability	Cardiac Aneurysm		Vioxx	SS		ORAL		36 DAY
Other	Cartilage Injury		Vioxx	SS		ORAL		312 DAY
	Cerebral Artery		Tricor	C		ORAL		
	Thrombosis		Vicodin Es Tablets	C		ORAL		
	Cerebral Infarction		Paxil	C		ORAL		
	Cerebrovascular Accident		Restoril	C		ORAL		
	Chondromalacia		Aspirin	C		ORAL		
	Diverticulum Intestinal		Estrogens					
	Epistaxis		(Unspecified)	C				
	Haematocrit		Premarin	C				
	Haemoglobin		Vitamins					
	Mitral Valve Incompetence		(Unspecified)	C				
	Platelet Count		Zantac	C				
	Red Blood Cell		Vistaril	C				
	Sedimentation Rate							
	Tricuspid Valve							
	Incompetence							

Urticaria

Date:05/12/03ISR Number: 4107899-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA00370
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Oesophageal Ulcer		Prednisone	C				
Initial or Prolonged	Rectal Haemorrhage							

Date:05/12/03ISR Number: 4107900-0Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00022
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Urea		Lansoprazole	C		ORAL		
	Circulatory Collapse		Amlodipine Besylate	C		ORAL		
	Haematemesis		Fluoxetine	C		ORAL		
	Haemoglobin		Dipyridamole	C		ORAL		
	Oesophageal Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/03ISR Number: 4107901-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00023
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/03ISR Number: 4107902-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA02371
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematocrit		Vioxx	SS		ORAL	16 DAY	
	Haemoglobin		Celebrex	SS		ORAL		
	Joint Sprain		Quixin	C				
	Renal Failure Acute		Lasix (Furosemide)	C		ORAL		
	Skin Cancer		Paxil Cr	C		ORAL		
	Vomiting		Tridesilon	C				
			Tylenol	C				
			Chlorophyll	C		ORAL		

Date:05/12/03ISR Number: 4110912-4Report Type:Direct Company Report #CTU 192710
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx 25mg Merck	PS	Merck	ORAL	25MG BID	ORAL

Date:05/12/03ISR Number: 4112700-1Report Type:Direct Company Report #CTU 192776
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS				

Date:05/13/03ISR Number: 4108343-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA02179
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Pravachol	C				
	Coronary Artery Disease		Aspirin	C				
	Heart Rate Decreased		Centrum Silver	C				
	Myocardial Ischaemia		Niaspan	C				
	Nephrolithiasis							
	Nocturnal Dyspnoea							
	Palpitations							

Date:05/13/03ISR Number: 4108350-3Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00012
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Intestinal Perforation		Furosemide	C				
Hospitalization - Initial or Prolonged	Peritonitis		Nitroglycerin	C				
			Potassium Chloride	C				
			Lorazepam	C				
			Betahistine					

				Hydrochloride	C		
				Acetaminophen	C		
				Lansoprazole	C		

Date:05/13/03ISR Number: 4108636-2Report Type:Expedited (15-DaCompany Report #WAES 0305USA00670
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/14/03ISR Number: 4109264-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA00837
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Sonata	C				
			Celexa	C				
			Gabitril	C				
			Fosamax Once Weekly	C		ORAL		
			Keppra	C				

Date:05/14/03ISR Number: 4109599-6Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00216
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Erosive Duodenitis	Professional	Aspirin	SS		ORAL		
	Gastric Ulcer Haemorrhage		Valsartan	C		ORAL		
	Gastritis Erosive		Isosorbide Mononitrate	C		ORAL		
	Oesophagitis		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
	Renal Failure Acute		Quinine Sulfate	C		ORAL		
			Zocor	C		ORAL		
			Gabapentin	C		ORAL		

Date:05/14/03ISR Number: 4109604-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01866
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS		ORAL		
	Hypertension		Vioxx	SS		ORAL		
			Lotrel	C			1 WK	

Date:05/14/03ISR Number: 4109610-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00045
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urea		Aspirin	SS		ORAL		
	Faeces Discoloured		Metformin	C		ORAL		
	Gastric Ulcer		Gliclazide	C		ORAL		
	Haematemesis		Carbimazole	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Ramipril	C		ORAL		

Furosemide	C
Pravastatin Sodium	C
Amoxicillin	C

Date:05/14/03ISR Number: 4109617-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA01043
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia Spinal Laminectomy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/14/03ISR Number: 4109619-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00671
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/14/03ISR Number: 4113559-9Report Type:Direct Company Report #CTU 193010
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Gastric Ulcer Gastrooesophageal Reflux Disease Haematemesis Haematocrit		Rofecoxib Clopidogrel Aspirin	PS SS SS				

Date:05/14/03ISR Number: 4113560-5Report Type:Direct Company Report #CTU 193013
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Rofecoxib	PS		ORAL	25 MG PO QD	

Initial or Prolonged	Gastritis
	Gastrointestinal
	Haemorrhage
	Haematocrit
	Syncope

Date:05/15/03ISR Number: 4109928-3Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00055
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Other	Dizziness		Sertraline Hydrochloride	SS		ORAL	TOPICAL	
	Drug Interaction		Acetaminophen And Codeine Phosphate	C		ORAL	RESPIRATORY	
	Memory Impairment		Ibuprofen	C			(INHALATION)	
	Vision Blurred		Albuterol	C			RESPIRATORY	
			Beclomethasone Dipropionate	C			(INHALATION)	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/15/03ISR Number: 4109934-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS		ORAL		
	Vision Blurred		Ditropan Xl	SS				
			Zoloft	C				
			Xanax	C				
			Temazepam	C				
			Ultram	C				
			Atenolol	C				
			Cyclobenzaprine Hydrochloride	C				
			Detrol La	C				
			Flonase	C				
			Doxazosin Mesylate	C				
			Guaifenesin	C				

Date:05/15/03ISR Number: 4109937-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA00841B1
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc			
Congenital Anomaly	Congenital Musculoskeletal Anomaly							
	Maternal Drugs Affecting Foetus							

Date:05/15/03ISR Number: 4109938-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA00841M
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Growth Retardation							

Date:05/15/03ISR Number: 4109939-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glomerulonephritis Focal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Glomerulonephritis		Celebrex	SS				
	Membranous						7	DAY
	Peritoneal Dialysis							

Date:05/15/03ISR Number: 4109940-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA00913
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident						2	DAY
	Retinal Vein Occlusion							
	Visual Acuity Reduced							

Date:05/15/03ISR Number: 4110301-2Report Type:Expedited (15-DaCompany Report #WAES 0305USA00796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/03ISR Number: 4110304-8Report Type:Expedited (15-DaCompany Report #WAES 0305ESP00007
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephropathy Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/03ISR Number: 4110305-XReport Type:Expedited (15-DaCompany Report #WAES 01108566
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Blood Glucose Blood Triglycerides Cerebellar Syndrome Cerebrovascular Accident Hypoaesthesia Low Density Lipoprotein Paraesthesia Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/15/03ISR Number: 4113361-8Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Antithrombin Iii Decreased Aortic Atherosclerosis	Consumer Health Professional	Tab Vioxx 12.5/25 Mg	PS C C		ORAL PO		

Other	Arterial Thrombosis	...	C
	Arthralgia	Paxil	C
	Blood Potassium	Premarin	C
	Cardiac Aneurysm	Restoril	C
	Cartilage Injury	Tricor	C
	Cerebral Artery	Vicodin Es Tablets	C
	Thrombosis	Vistaril	C
	Cerebral Infarction	Zantac	C
	Cerebral Thrombosis	Aspirin	C
	Cerebrovascular Accident	Estrogens	C
	Chondromalacia	Vitamins	C
	Epistaxis		
	Haematocrit		
	Haemoglobin		
	Joint Contracture		
	Joint Swelling		
	Mitral Valve Incompetence		
	Pain In Extremity		
	Phlebothrombosis		
	Platelet Count		
	Tricuspid Valve Incompetence		
	Urticaria		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/03ISR Number: 4110594-1Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00020
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Malaise	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Somnolence	Professional	Prazepam	SS		ORAL		
			Spironolactone	SS		ORAL		

Date:05/16/03ISR Number: 4110598-9Report Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain	Professional	Altace	C		ORAL		
	Coronary Artery		Plavix	C		ORAL		
	Atherosclerosis		Aspirin	C		ORAL		
	Coronary Artery		Nitroglycerin	C		TOPICAL		
	Reocclusion		Prevacid	C		ORAL		
	Gastritis		Zocor	C		ORAL		
	Headache							
	Hiatus Hernia							
	Hyperlipidaemia							
	Myocardial Infarction							
	Obstructive Airways							
	Disorder							
	Sinus Bradycardia							
	Sleep Apnoea Syndrome							
	Syncope							
	Thymus Disorder							

Date:05/16/03ISR Number: 4110618-1Report Type:Expedited (15-DaCompany Report #WAES 0305CHE00010
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Condition Aggravated	Professional	Acenocoumarol	SS		ORAL		
	Drug Interaction		Iron (Unspecified)	C		ORAL		
	International Normalised							

Ratio
Melaena
Prothrombin Time
Prolonged

Date:05/16/03ISR Number: 4110622-3Report Type:Expedited (15-DaCompany Report #WAES 0303CHE00017
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Left Ventricular Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	33 DAY	
Hospitalization - Initial or Prolonged	Myocardial Infarction	Professional						

Date:05/16/03ISR Number: 4110625-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01228
Age: Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Discomfort
	Arrhythmia
	Blood Pressure Increased

		Large Intestinal Ulcer Haemorrhage Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophageal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage		Celebrex	SS		ORAL

Date:05/16/03ISR Number: 4110626-0Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00044
Age:76 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure Acute	Professional	Perindopril Erbumine	SS		ORAL
				Furosemide	SS		ORAL
				Digoxin	C		
				Warfarin Sodium	C		
				Atorvastatin Calcium	C		
				Prednisolone	C		
				Omeprazole Magnesium	C		
				Gabapentin	C		
				Insulin Lispro	C		
				Isosorbide Mononitrate	C		

Date:05/16/03ISR Number: 4110627-2Report Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 25 DAY		Activated Partial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Thromboplastin Time	Professional	Dexchlorpheniramine			
Other		Prolonged		Maleate	C		
		Gallbladder Disorder		Desloratadine	C		
		Haematocrit Decreased					
		Hepatotoxicity					
		Jaundice					
		Nephropathy Toxic					
		Renal Failure					
		Tooth Disorder					
		Urticaria					

Date:05/16/03ISR Number: 4110630-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00073
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage Melaena		Prednisolone	SS		ORAL		
			Chloroquine	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Alendronate Sodium	C		ORAL		
			Acetaminophen	C		ORAL		

Date:05/16/03ISR Number: 4112640-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA02371
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
	Arthralgia

		Condition Aggravated Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypothyroidism	Health	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE, PO							
		Joint Sprain	Professional	Celebrex 200 Mg	SS		ORAL
200							
		Renal Failure Acute	Company				
MG/DAILY/PO							
		Skin Cancer	Representative	Lasix (Furosemide)	C		
		Vomiting		Paxil Cr	C		
				Quixin	C		
				Tridesilon	C		
				Tylenol	C		
				Chlorophyll	C		

Date:05/16/03ISR Number: 4112650-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA02179
Age:63 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Coronary Artery	Health				
MG/DAILY/PO							
		Atherosclerosis	Professional	Centrum Silver	C		
		Coronary Artery Disease		Niaspan	C		
		Dyspnoea		Pravachol	C		
		Heart Rate Decreased		Aspirin	C		
		Hyperlipidaemia					
		Myocardial Ischaemia					
		Nephrolithiasis					
		Palpitations					
		Vascular Calcification					

Date:05/16/03ISR Number: 4113707-0Report Type:Expedited (15-DaCompany Report #K200202066
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anuria	Foreign	Altace Capsules			
Hospitalization -		Arthralgia	Health	(Ramipril) Capsule,			

Initial or Prolonged	Cardiac Enzymes Increased	Professional	5mg	PS	ORAL
5 MG QD ORAL					
	Confusional State	Other	Hydrochlorothiazide		
	Dialysis		(Hydrochlorothiazide		
	Dyspnoea		) 25 Mg	SS	ORAL
25 MG QD ORAL					
	Fall		Glucophag (Metformin		
	Femur Fracture		Hydrochloride) 850mg	SS	ORAL
850 MG QD					
	General Physical Health				
ORAL					
	Deterioration		Daonil		
	Hypoglycaemia		(Glibenclamide) 5 Mg	SS	ORAL
5 MG QD ORAL					
	Hypotension		Vioxx (Rofecoxib) 25		
	Metabolic Acidosis		Mg	SS	ORAL
25 MG ORAL					
	Mitral Valve Incompetence		Physiotens		
	Peritonitis		(Moxonidine)	C	
	Pneumonia		Tavor (Lorazepam)	C	
	Renal Failure Acute		Salospir		
	Septic Shock		(Acetylsalicylic		
	Tachypnoea		Acid)	C	
			Isosorbide		
			Mononitrate	C	
			Adalat (Nifedipine)	C	

Date:05/19/03ISR Number: 4111088-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02432
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:05/19/03ISR Number: 4111096-9Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00002
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Haemorrhage		Vioxx	SS		ORAL	26	DAY
			Prednisolone	C			37	DAY
			Budesonide	C		ORAL		
			Cholestyramine Resin	C			YR	
			Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C		ORAL	184	DAY
			Azathioprine	C				

Date:05/19/03ISR Number: 4111457-8Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00079
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Haemorrhage		Digoxin	C		ORAL		
	Pneumonia Aspiration		Allopurinol	C		ORAL		
			Omeprazole	C		ORAL		
			Albuterol Sulfate	C				

RESPIRATORY

(INHALATION)

Date:05/19/03ISR Number: 4111458-XReport Type:Expedited (15-DaCompany Report #WAES 0305USA00370
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thromboplastin Time		Prednisone	C				
Initial or Prolonged	Blood Glucose							
Other	Blood Sodium							
	Blood Urea							
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Lymphocyte Count							
	Oesophageal Ulcer							
	Haemorrhage							
	Prothrombin Time							

Date:05/19/03ISR Number: 4111460-8Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00064
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Cardiac Disorder
Initial or Prolonged	Joint Swelling
	Movement Disorder
	Oedema

	Oedema Peripheral Paraesthesia Skin Discolouration	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Diazepam	C				
			Budesonide	C				

Date:05/19/03ISR Number: 4111462-1Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00037
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL		
12 DAY								
Initial or Prolonged			Tetrazepam	SS		ORAL		
12 DAY								

Date:05/19/03ISR Number: 4111463-3Report Type:Expedited (15-DaCompany Report #WAES 0302CAN00085
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
1 YR								
Hospitalization -			Methotrexate Sodium	C				
Initial or Prolonged								
Disability								

Date:05/19/03ISR Number: 4111466-9Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00012
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Tramadol Hydrochloride	C		ORAL		
			Zocor	C		ORAL		

Date:05/19/03ISR Number: 4111467-0Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00038
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	SS		ORAL		
	Melaena		Aspirin Lysine	SS		ORAL		

Date:05/19/03ISR Number: 4114763-6Report Type:Direct Company Report #CTU 193360
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx 12.5 Mg	PS		ORAL	12.5 MG QD	
Initial or Prolonged	Faeces Discoloured						ORAL	
	Haematocrit Decreased		Heparin	C				
	Haemoglobin Decreased							

Date:05/20/03ISR Number: 4112216-2Report Type:Expedited (15-DaCompany Report #WAES 0304NOR00013
Age:84 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Disorientation		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Gastric Ulcer Haemorrhage Melaena		Warfarin Sodium	SS				

Date:05/20/03ISR Number: 4112224-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA01720
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine		Vioxx	SS		ORAL		
	Increased		Nexium	C				
	Blood Urea Increased		Atenolol	C				
	Vomiting		Ranitidine	C				
			Ogen	C				
			Duragesic	C				
			Valium	C				
			Celebrex	C				
			Prozac	C				

Date:05/20/03ISR Number: 4112472-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	425	DAY
Hospitalization - Initial or Prolonged	Supraventricular		Nonsteroidal					
	Bronchitis		Anti-Inflammatory					
	Cardio-Respiratory Arrest		Drug (Unspecified)	C		ORAL		
	Cholelithiasis		Lipitor	C				
	Chronic Obstructive		Metoprolol	C				
	Pulmonary Disease		Prozac	C				
	Electromechanical		Combivent	C				
RESPIRATORY								
	Dissociation							
(INHALATION)								
	Gastritis		Daypro	C		ORAL		

	Hypertension		Prednisone	C			
	Multiple Myeloma		Ventolin (Albuterol Sulfate)	C			
	Myocardial Infarction		Cartia (Aspirin)	C			ORAL
	Pneumonia Pneumococcal		Nicotine	C			
	Streptococcal Sepsis		Xanax	C			ORAL
	Tracheobronchitis		Cardizem Cd	C			
	Upper Respiratory Tract Infection		Captopril	C			

Date:05/20/03ISR Number: 4112474-4Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00045
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
			Estrogens, Conjugated And Medroxyprogesterone Acetate	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C				
			Vitamin E	C				

Date:05/20/03ISR Number: 4112475-6Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Circulatory Collapse							
Disability	Diverticulitis							
	Diverticulum Intestinal Haemorrhagic							
	Ejaculation Disorder							
	Haemoglobin Decreased							
	Lower Gastrointestinal Haemorrhage							
	Rectal Haemorrhage							

Date:05/20/03ISR Number: 4112476-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA03066
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Aspirin	C				
	Loss Of Consciousness		[Therapy					
	Myocardial Infarction		Unspecified]	C				
	Thrombosis		Tylenol	C				

Date:05/20/03ISR Number: 4112477-XReport Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Sodium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY
Other	Hepatotoxicity		Dexchlorpheniramine					
	Nephropathy Toxic		Maleate	C				
	Skin Depigmentation		Desloratadine	C				
	Tooth Disorder							

Date:05/20/03ISR Number: 4112482-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA01814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:05/20/03ISR Number: 4112485-9Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00060
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
2 DAY								
Initial or Prolonged	Hypersensitivity							
	Psychosomatic Disease							

Date:05/20/03ISR Number: 4112486-0Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00077
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Diclofenac	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/03ISR Number: 4114256-6Report Type:Expedited (15-DaCompany Report #200314885GDDC
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Furosemide (Lasix)	PS		ORAL	80 MG/DAY PO	
Initial or Prolonged	Renal Failure Acute	Health Professional	Perindopril (Coversyl)	SS		ORAL	2 MG QD PO	
Other		Other	Rofecoxib (Vioxx)	SS		ORAL	12.5 MG QD PO	10 MON
			Digoxin (Lanoxin)	C				
			Warfarin Sodium	C				
			Atorvastatin (Lipitor)	C				
			Prednisolone (Panafcortelone)	C				
			Omeprazole (Losec)	C				
			Gabapentin (Neurontin)	C				
			Insulin Lispro (Humalog)	C				
			Isosorbide Mononitrate (Imdur)	C				

Date:05/20/03ISR Number: 4115705-XReport Type:Expedited (15-DaCompany Report #2003-05-1145
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Pain Renal Failure	Health Professional Company Representative	Peg-Intron (Peginterferon Alfa-2b) Injectable Powder	PS		SUBCUTANEOUS	SUBCUTANEOUS	22 WK
			Rebetol (Ribavirin) Capsules	SS		ORAL	ORAL	22 WK
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	

Date:05/21/03ISR Number: 4113035-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01593
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Bezoar		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Chronic Obstructive		Lasix (Furosemide)	C		
Hospitalization -	Pulmonary Disease		Procardia	C		
Initial or Prolonged	Gastric Outlet		Isosorbide Dinitrate	C		
Other	Obstruction		Prevacid	C		
	Gastric Ulcer		Megace	C		
	Myocardial Infarction		Restoril	C		
	Pneumonia		Darvocet-N	C		
			Tizanidine Hydrochloride	C		
			Histussin-Hc Syrup	C		
			Singulair	C		ORAL
			Nitrostat	C		
SUBLINGUAL						
			Nitro-Dur	C		
			Flovent	C		
			Albuterol	C		
			Potassium Chloride	C		
			Albuterol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/03ISR Number: 4113036-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA02902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Renal Failure					

Date:05/21/03ISR Number: 4113040-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA01603
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Lithium Carbonate	C		
Disability	Retinal Disorder		Prozac	C		
			Lorazepam	C		

Date:05/21/03ISR Number: 4113041-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA02471
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Headache		Aspirin	C		
Initial or Prolonged			Minocin	C		
			Fosamax	C		ORAL
			Singulair	C		ORAL

Date:05/21/03ISR Number: 4113416-8Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00049
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastroduodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY						
Initial or Prolonged	Haematemesis	Professional	Clopidogrel Bisulfate	SS		
			Pravastatin Sodium	C		ORAL
			Acebutolol	C		ORAL
			Tamoxifen Citrate	C		

			Acetaminophen And Belladonna And Caffeine And Opium	C		

Date:05/21/03ISR Number: 4113422-3Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00111
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haematemesis	Health Professional	Rofecoxib	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged			Simvastatin	C		ORAL
			Diltiazem Hydrochloride	C		ORAL
			Aspirin	C		ORAL
			Isosorbide Mononitrate	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/03ISR Number: 4113427-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00016
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
	Sepsis	Professional	Trimethoprim	C		ORAL		2 DAY
			Gliclazide	C		ORAL		
			Metformin	C		ORAL		
			Ramipril	C				
			Bumetanide	C				
			Floxacillin	C			INTRAVENOUS	3 DAY
			Cefuroxime	C			INTRAVENOUS	367 DAY
			Omeprazole	C				4 DAY
			Aspirin	C				
			Tolterodine	C				

Date:05/21/03ISR Number: 4115797-8Report Type:Expedited (15-DaCompany Report #PHNU2002DE04159
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haemolytic Autoimmune	Foreign Study	Diovan (Valsartan) Tablet	PS		ORAL	80 MG, QD,	
	Asthenia	Health Professional					ORAL	
	Blood Immunoglobulin A Increased	Other	Vioxx(Rofecoxib) Tablet	SS			1 DF, QD	
	Blood Immunoglobulin G Increased		Dolormin (Ibupofen Lysinate)	C				
	Blood Immunoglobulin M Decreased		Insulin Protaphan Hm (Ge) (Insulin Human)	C				
	Complement Factor C3 Decreased		Actrapid Penfill (Insulin Human)	C				
	Lymphadenopathy		Magnesium	C				
	Platelet Count Reticulocyte Count White Blood Cell Count							

Date:05/21/03ISR Number: 4115984-9Report Type:Direct Company Report #CTU 193625
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 WK	Haematemesis		Vioxx	PS		
Initial or Prolonged	Melaena		Simvastatin	C		
			Lisinopril	C		
			Docusate	C		
			Dig	C		
			Carvedilol	C		

Date:05/21/03ISR Number: 4117204-8Report Type:Direct Company Report #CTU 193592
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Creatinine		Vioxx	PS		
Initial or Prolonged	Increased					
	Nervous System Disorder					
	Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/03ISR Number: 4117533-8Report Type:Direct Company Report #CTU 193564
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS				
	Gastrointestinal Haemorrhage		Potassium Chloride	SS				
			Ferrous Gluconate	SS				

Date:05/22/03ISR Number: 4113887-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA02152
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lupus Nephritis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C				

Date:05/22/03ISR Number: 4114165-2Report Type:Expedited (15-DaCompany Report #WAES 0205GBR00194
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient Visual Acuity Reduced	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Azithromycin	C			10	DAY
			Clarithromycin	C			7	DAY
			Lansoprazole	C			1	DAY
			Calcium Carbonate And Cholecalciferol	C			13	DAY
			Tamsulosin Hydrochloride	C				
			Metronidazole	C				
			Chloramphenicol	C				
			Doxycycline	C				
			Doxycycline	C				

Date:05/22/03ISR Number: 4114167-6Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00002
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Athetosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Carbidopa And Levodopa	C				
			Acetaminophen And Codeine Phosphate	C				
			Albuterol Sulfate And Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)								
			Ferrous Sulfate	C				
			Fosamax	C		ORAL		
			Psyllium Husk	C				
			Hydroxocobalamin	C				
INTRAVENOUS								
			Heparinoid And Salicylic Acid	C				
			Pergolide Mesylate	C				
			Perindopril Erbumine	C				
			Quetiapine Fumarate	C				
			Venlafaxine Hydrochloride	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/03ISR Number: 4114170-6Report Type:Expedited (15-DaCompany Report #WAES 0302NOR00006
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Melaena		Potassium Chloride	SS		ORAL		
			Citalopram Hydrobromide	SS		ORAL		
			Furosemide	C		ORAL		
			Zopiclone	C		ORAL		
			Acetaminophen	C		ORAL		

Date:05/22/03ISR Number: 4116671-3Report Type:Expedited (15-DaCompany Report #PERI00203000940
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Foreign	Coversyl					
	Renal Failure Acute	Health	(Perindopril)	PS		ORAL	2 MG QD PO	
		Professional	Vioxx (Rofecoxib)	SS		ORAL	12.5 MG DAILY PO	
		Other						
			Lasix (Furosemide)	SS		ORAL	80 MG DAILY PO	
			Lanoxin (Digoxin)	C				
			Marevan (Warfarin Sodium)	C				
			Lipitor (Atorvastatin)	C				
			Panafcortelone (Prednisolone)	C				
			Losec (Omeprazole)	C				
			Neurontin (Gabapentin)	C				
			Humalog (Insulin Lispro)	C				
			Imdur (Isosorbide Mononitrate)	C				

Date:05/23/03ISR Number: 4114765-XReport Type:Expedited (15-DaCompany Report #WAES 0304DEU00064
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Demyelination	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Factor V Leiden Mutation		Hormonal Contraceptives (Unspecified)	C		ORAL		
	Thrombocythaemia		Levothyroxine Sodium [Therapy Unspecified]	C		ORAL		
	Vith Nerve Paralysis			C		ORAL		

Date:05/23/03ISR Number: 4114767-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA01503
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Foot Fracture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Impaired Healing		Premarin	C		ORAL		
	Postoperative Infection		Maxzide	C		ORAL		
			Ranitidine	C		ORAL		
			Cyclobenzaprine Hydrochloride	C		ORAL		

			Zyrtec	C		ORAL

Date:05/23/03ISR Number: 4114770-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	39	DAY
Hospitalization - Initial or Prolonged	Infarction	Professional	Soma	C				
	Apnoea		Elavil	C				
	Atrial Fibrillation		Esgic-Plus Tablets	C				
	Blood Pressure Increased							
	Brain Death							
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Coma							
	Coronary Artery Disease							
	Heart Rate Increased							
	Heart Rate Irregular							
	Hypoxic Encephalopathy							
	Metabolic Acidosis							
	Myocardial Ischaemia							
	Pulmonary Vascular Disorder							
	Pulse Abnormal							
	Pupil Fixed							
	Ventricular Hypertrophy							

Date:05/23/03ISR Number: 4114773-9Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00110
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Blood Alkaline Phosphatase Increased	Professional	Atenolol	C		ORAL		
	Blood Glucose Increased							
	Gamma-Glutamyltransferase Increased							

Lipase Decreased
Myalgia
Purpura
Red Blood Cell Count
Systemic Lupus
Erythematosus

Date:05/23/03ISR Number: 4114777-6Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00013
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY	
Hospitalization - Initial or Prolonged	Gastric Ulcer	Professional	Benserazide Hydrochloride And Levodopa	C		ORAL		
	Melaena		Paraffin	C		ORAL		
	Peptic Ulcer Haemorrhage		Paroxetine Hydrochloride	C		ORAL		
	Rectal Haemorrhage		Dipyrone	C		ORAL		

			Sennosides	C	ORAL
			Acetaminophen	C	ORAL
			Zopiclone	C	ORAL

Date:05/23/03ISR Number: 4114779-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
			Omeprazole	SS			3	DAY

Date:05/23/03ISR Number: 4114780-6Report Type:Expedited (15-DaCompany Report #WAES 0305NLD00009
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Oesophagitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Faeces Discoloured	Professional	Zocor	C		ORAL		
Initial or Prolonged	Gastritis Erosive		Gliclazide	C		ORAL		
	Haematemesis		Metformin	C		ORAL		
	Mallory-Weiss Syndrome							

Date:05/23/03ISR Number: 4114781-8Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00130
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Reflux Oesophagitis	Professional						

Date:05/23/03ISR Number: 4114791-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA01365
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort Dizziness Dyspnoea Hyperhidrosis Hyperventilation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/23/03ISR Number: 4114956-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01866
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS		ORAL		
	Cerebrovascular Accident		Vioxx	SS		ORAL	1	WK
	Headache		Lotrel	C				
	Hypertension		Aspirin	C				

Date:05/23/03ISR Number: 4114958-1Report Type:Expedited (15-DaCompany Report #WAES 0303NOR00007
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Increased		Vioxx	SS				
Other								

Date:05/23/03ISR Number: 4114959-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA02263
Age:22 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL	58	DAY
Hospitalization -	Thromboplastin Time		Hormonal					
Initial or Prolonged	Alopecia		Contraceptives					
Other	Arthralgia		(Unspecified)	C				
	Asthenia							
	Blood Potassium							
	Chest Pain							
	Dehydration							
	Diarrhoea							
	Dyspnoea							
	Epistaxis							
	Gastritis							
	Haematocrit							
	Haemoglobin							
	Infected Insect Bite							
	Influenza Like Illness							
	Joint Swelling							
	Lymphocyte Count							
	Oedema							
	Paraesthesia							
	Petechiae							
	Platelet Count							
	Prothrombin Level							
	Red Blood Cell Count							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Viral Infection							

Date:05/23/03ISR Number: 4114968-4Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00198
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	195	DAY
Hospitalization -	Gastritis		Acetaminophen	C				
Initial or Prolonged	Gastritis Erosive		Atenolol	C				
Other	Haemorrhage		Zocor	C		ORAL		

	Oesophageal Ulcer		Isosorbide Mononitrate	C		
			Amlodipine Maleate	C		
			Nicorandil	C		

Date:05/23/03ISR Number: 4114970-2Report Type:Expedited (15-DaCompany Report #WAES 0304AUS00114
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Celecoxib	SS				
	Confusional State		Aspirin	C				
	Disorientation		Perindopril Erbumine	C				
	Hallucination, Visual		Isosorbide Mononitrate	C				
	Psychiatric Symptom		Ranitidine Hydrochloride	C				
	Road Traffic Accident		Atorvastatin Calcium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/03ISR Number: 4114976-3Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00044
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
	Renal Failure Acute		Perindopril Erbumine	SS		ORAL
			Furosemide	SS		ORAL
			Digoxin	C		
			Warfarin Sodium	C		
			Atorvastatin Calcium	C		
			Prednisolone	C		
			Omeprazole Magnesium	C		
			Gabapentin	C		
			Insulin Lispro	C		
			Isosorbide Mononitrate	C		

Date:05/23/03ISR Number: 4114979-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00796
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/27/03ISR Number: 4116020-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Arthralgia		Celebrex	SS		
Disability	Contusion					
Other	Deep Vein Thrombosis					
	Dehydration					
	Dialysis					
	Glomerulonephritis Focal					
	Glomerulonephritis					
	Membranous					
	Impaired Healing					
	Limb Injury					
	Loss Of Consciousness					

Pulmonary Embolism
Renal Failure
Vomiting

Date:05/27/03ISR Number: 4117357-1Report Type:Direct Company Report #CTU 194050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS		ORAL	50 MG QD PO	
	Oedema Peripheral		Percocet	C				
	Weight Increased		Ecotrin	C				
			Synthroid	C				
			Lipitor	C				
			Metoprolol	C				
			Trental	C				
			Xanax	C				
			Imdur	C				
			Nitrostat	C				
			Zoloft	C				

			Niaspan	C		

Date:05/28/03ISR Number: 4117293-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA02212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/28/03ISR Number: 4117304-2Report Type:Expedited (15-DaCompany Report #WAES 0203BRA00016
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc			

Date:05/28/03ISR Number: 4117305-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Jejunal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Avapro	C				
			Lipitor	C				

Date:05/28/03ISR Number: 4117674-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA01993
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Basal Cell Carcinoma Pancreatitis Renal Cell Carcinoma Stage Unspecified		Vioxx	PS	Merck & Co., Inc	ORAL		
			Estrogens (Unspecified)	C				
			Prometrium	C				
			Prilosec	C				
			Vitamins (Unspecified)	C				

Date:05/28/03ISR Number: 4117696-4Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00143
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
	Diarrhoea		Medroxyprogesterone Acetate And Estrogens, Conjugated	C				
			Diclofenac Sodium	C		ORAL		

Date:05/28/03ISR Number: 4117702-7Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00151
Age:45 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Levothyroxine Sodium	C		ORAL		
			Zolmitriptan	C		ORAL		
			Homeopathic Medications					

(Unspecified) C

Date:05/28/03ISR Number: 4117733-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA01976
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Alanine Aminotransferase Increased		Wellbutrin	C				
	Aspartate Aminotransferase Increased							

Date:05/29/03ISR Number: 4118366-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA02322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Imitrex	C				
	Nausea		[Therapy Unspecified]	C				
	Oedema Peripheral							
	Pain							
	Urinary Incontinence							

Date:05/29/03ISR Number: 4118369-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02324
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Neurontin	C				
			Estradiol	C				
			Flovent	C				
			Diltiazem Hydrochloride	C				
			Synthroid	C				

Date:05/29/03ISR Number: 4118383-9Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00022
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemolytic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		47 DAY

Date:05/29/03ISR Number: 4118387-6Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00059
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY
Initial or Prolonged			Flecainide Acetate	C		ORAL		
			Ethinyl Estradiol And Levonorgestrel	C		TOPICAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/03ISR Number: 4119292-1Report Type:Direct Company Report #CTU 194163
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Liver Function Test Abnormal		Lamisil	PS				
			Vioxx	SS				

Date:05/29/03ISR Number: 4119877-2Report Type:Expedited (15-DaCompany Report #200312261US
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Leflunomide (Arava)	PS			100 MG QD	3 DAY
Initial or Prolonged	Bilirubin Conjugated	Health	Leflunomide (Arava)	SS			20 MG QD	2 MON
Other	Blood Albumin Decreased	Professional	Rofecoxib (Vioxx)	SS			50 MG	
	Blood Bilirubin		Methotrexate	C				
	Blood Bilirubin Unconjugated		Celecoxib (Celebrex)	C				
	Condition Aggravated		Paracetamol (Tylenol)	C				
	Contusion		Antibiotics Nos	C				
	Fall		Sulfasalazine	C				
	Fatigue		Clavulanate Potassium, Amoxicillin Trihydrate (Augmentin)	C				
	Haemangioma							
	Hepatic Cyst							
	Hepatitis							
	Hepatomegaly							
	Hepatotoxicity		Prednisone	C				
	Hypertension		Docusate Sodium (Colace)	C				
	Lymphocyte Count Decreased		Gabapentin (Neurontin)	C				
	Monocyte Count Increased		Guaifenesin	C				
	Neutrophil Count Decreased		Hydrocodone	C				
	Platelet Count Increased		Ranitidine	C				
	Protein Total Decreased							
	Red Blood Cell Count Decreased							
	Renal Cyst							
	White Blood Cell Count							

Increased

Date:05/29/03ISR Number: 4120174-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA01785
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cough		Aspirin	C				
	Eye Swelling							
	Rash							
	Swelling Face							
	Throat Tightness							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/03ISR Number: 4120195-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01476
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Vioxx	PS		ORAL		
	Contusion		Arava	SS	Merck & Co., Inc			3 DAY
Other	Fall		Arava	SS				64 DAY
	Haemangioma		Methotrexate	C				
	Hepatitis		Prednisone	C				
	Hepatotoxicity		[Therapy Unspecified]	C				
	Hypertension		Clavulanate Potassium	C				
	Lymphocyte Count Decreased		Colace	C				
	Monocyte Count Increased		Sulfasalazine	C				
	Neutrophil Count Decreased		Augmentin	C				
	Renal Cyst		Celebrex	C				
	Serum Ferritin Increased		Tylenol	C				
	Thrombocythaemia							
	White Blood Cell Count Increased							

Date:05/29/03ISR Number: 4120205-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		425 DAY
Hospitalization - Initial or Prolonged	Supraventricular Asthenia		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		
	Atrial Fibrillation		Lipitor	C				
	Atrial Flutter		Metoprolol	C				
	Atrial Tachycardia		Prozac	C				
	Back Pain		Combivent	C				
	Blood Ph Increased							
RESPIRATORY (INHALATION)	Bone Pain							
	Bronchitis		Daypro	C		ORAL		
	Cardio-Respiratory Arrest		Prednisone	C				
	Cholelithiasis		Ventolin (Albuterol					

Chronic Obstructive	Sulfate)	C	
Airways Disease	Cartia (Aspirin)	C	ORAL
Exacerbated	Nicotine	C	
Compression Fracture	Xanax	C	ORAL
Coronary Artery Disease	Cardizem Cd	C	
Electromechanical	Captopril	C	
Dissociation			
Emphysema			
Gastritis			
Haemoptysis			
Hepatic Cyst			
Hypotension			
Malaise			
Multiple Myeloma			
Myocardial Infarction			
Pneumonia Pneumococcal			
Rib Fracture			
Sinus Tachycardia			
Streptococcal Sepsis			
Tachypnoea			
Tracheobronchitis			
Upper Respiratory Tract Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/03ISR Number: 4120207-0Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00171
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
			Tranexamic Acid	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Gliclazide	C				
			Metformin	C				

Date:05/29/03ISR Number: 4120208-2Report Type:Expedited (15-DaCompany Report #WAES 0305CHE00028
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Urticaria		Diclofenac Epolamine	C				
TOPICAL							5	DAY

Date:05/29/03ISR Number: 4120231-8Report Type:Expedited (15-DaCompany Report #WAES 0305PRT00005
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Normochromic Normocytic Anaemia		Captopril And Hydrochlorothiazide	C		ORAL		
			Bromazepam	C		ORAL		

Date:05/29/03ISR Number: 4120233-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA02277
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Synthroid	C				
Disability	Condition Aggravated							
	Confusional State							

Dementia
Hallucination
Insomnia
Upper Respiratory Tract
Infection

Date:05/29/03ISR Number: 4120234-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA02385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness							
	Gastric Infection							
	Gastric Ulcer							
	Haemoptysis							
	Pain							

Date:05/29/03ISR Number: 4120247-1Report Type:Expedited (15-DaCompany Report #WAES 0305CAN00090
Age:85 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Rectal Haemorrhage		Spironolactone	C		ORAL		
Renal Failure Acute		Furosemide	C				
		Furosemide	C				
		Digoxin	C				
		Amiodarone Hydrochloride	C				
		Nitroglycerin	C		TOPICAL		
		Nitroglycerin	C				
		Acetaminophen	C				
		Potassium Chloride	C				
		Aspirin	C				
		Pantoprazole Sodium	C				
		Oxazepam	C				
		Ipratropium Bromide	C		RESPIRATORY (INHALATION)		
		Albuterol	C		RESPIRATORY (INHALATION)		
		Fluticasone Propionate	C				
		Docusate Sodium	C				
		Insulin Human	C				
		Influenza Virus Vaccine	C				
		Influenza Virus Vaccine	C				
		Pneumococcal Vaccine 23 Polyvalent	C				

Date:05/29/03ISR Number: 4120248-3Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00071
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 6 DAY	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rectal Haemorrhage	Professional	Aspirin Lysine	SS		ORAL

Date:05/29/03ISR Number: 4120249-5Report Type:Expedited (15-DaCompany Report #WAES 0305DNK00022
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blood Creatinine	Professional	Ramipril	SS		ORAL
Initial or Prolonged	Increased		Potassium Chloride	C		ORAL
	Blood Potassium Increased		Furosemide	C		ORAL
	Drug Interaction		Metoprolol Tartrate	C		ORAL
			Aspirin	C		ORAL
			Isosorbide Mononitrate	C		ORAL

Date:05/29/03ISR Number: 4120434-2Report Type:Expedited (15-DaCompany Report #PHBS2003NO05251
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Life-Threatening	Haemolytic Anaemia	Foreign
		Health

Professional
Other

Product	Role	Manufacturer	Route	Dose	Duration
Aredia (Disodium Pamidronate) Vial	PS			INTRAVENOUS	60 MG , ONCE/SINGLE, INTRAVENOUS
Vioxx (Rofecoxib)	SS		ORAL	25 MG/D, ORAL	
Sinemet (Carbidopa, Levodopa)	SS		ORAL	1 DF/D, ORAL	
Eldepryl (Selegiline Hydrochloride)	SS		ORAL	5 MG/D, ORAL	
Paracetamol	C				
Alkeran (Melphalan)	C				
Prednisolone	C				

Date:05/29/03ISR Number: 4120518-9Report Type:Expedited (15-DaCompany Report #WAES 00068620
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Foreign Health Professional	Tab Vioxx (Rofecoxib)	PS				

Date:05/29/03ISR Number: 4140059-2Report Type:Periodic Company Report #200217787US
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis Haematocrit Decreased Haemoglobin Decreased	Health Professional	Heparin -Fraction, Sodium Salt (Lovenox)	PS			SUBCUTANEOUS	30 MG BID SC 3 DAY
			Rofecoxib (Vioxx)	SS		ORAL	25 MG QD PO	4 DAY

Cefazolin Sodium (Ancef)	C
Morphine	C
Paracetamol, Dextropropoxyphene Napsilate (Darvocet-N)	C
Oxazepam (Serax)	C
Acetylsalicylic Acid (Asa)	C
Normal Saline	C
Insulin Lispro (Humalog)	C
Insulin Glargine	C
Lisinopril (Prinivil)	C
Olanzapine (Zyprexa)	C

Date:05/30/03ISR Number: 4119462-2Report Type:Expedited (15-DaCompany Report #FR-ROCHE-338433
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Respiratory Disorder		Loxen	PS	Roche	ORAL		
			Lexomil	SS	Roche	ORAL		
			Mopral	SS		ORAL		
			Vioxx	SS		ORAL		

			Prozac	SS		ORAL
			Dafalgan	SS		ORAL

Date:05/30/03ISR Number: 4119571-8Report Type:Expedited (15-DaCompany Report #WAES 0305USA02554
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 305 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Toprol Xl Tablets	C		
			Digitek	C		
			Isosorbide Mononitrate	C		
			Centrum Silver	C		
			Tylenol Arthritis Extended Relief	C		

Date:05/30/03ISR Number: 4119575-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA02905
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Fatigue		Vioxx	SS		ORAL
Hospitalization -	Hypertension		Prinivil	C		ORAL
Initial or Prolonged	Pulmonary Hypertension		Hydrodiuril	C		
Disability	Pulmonary Veno-Occlusive		Isosorbide Dinitrate	C		
Other	Disease		Plavix	C		
	Rash		Colchicine	C		
	Renal Impairment		Furosemide	C		
	Stomach Discomfort		Nexium	C		
	Stupor		Metoprolol Tartrate	C		
	Transient Ischaemic		Folic Acid	C		
	Attack		Aspirin	C		
	Weight Decreased		Allopurinol	C		
			Bumex	C		
			Synthroid	C		

Date:05/30/03ISR Number: 4119581-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA02325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/30/03ISR Number: 4119650-5Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00161
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Oedema Peripheral Swelling		Triamcinolone Acetonide	C		INTRAMUSCULAR		
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/03ISR Number: 4119785-7Report Type:Expedited (15-DaCompany Report #WAES 0305CAN00020
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
	Asthenia		Paroxetine Hydrochloride	C		ORAL		
	Bundle Branch Block Left		Estrogens, Conjugated	C				
	Cardiac Failure Congestive		Levothyroxine Sodium	C		ORAL		
	Chills		Bisoprolol Fumarate	C				
	Condition Aggravated		Zocor	C				
	Electrocardiogram St-T Change		Pantoprazole Sodium	C				
	Haemoglobin		Quinine	C				
	Hyperaemia		Oxazepam	C				
	Movement Disorder		Calcium (Unspecified)	C		ORAL		
	Nasal Congestion							
	Otitis Media							
	Qrs Axis Abnormal							
	Refusal Of Treatment By Patient							
	Sinus Bradycardia							
	White Blood Cell Count							

Date:05/30/03ISR Number: 4119788-2Report Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY
Initial or Prolonged	Alanine Aminotransferase Increased		Dexchlorpheniramine Maleate	C				
Other	Aspartate Aminotransferase Increased		Desloratadine	C				
	Blood Albumin Decreased							
	Blood Alkaline Phosphatase Increased							
	Blood Lactate Dehydrogenase Increased							
	Blood Potassium Increased							
	Blood Sodium Decreased							

Eosinophil Count
Faeces Discoloured
Gamma-Glutamyltransferase
Increased
Haematocrit Decreased
Hepatotoxicity
Jaundice
Nephropathy Toxic
Platelet Count
Protein Total Decreased
Rash Erythematous
Rash Macular
Renal Failure
Sensory Disturbance
Tooth Disorder
Ultrasound Abdomen
Abnormal
White Blood Cell Count

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/03ISR Number: 4119790-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		308 DAY
Initial or Prolonged	Radius Fracture		Vioxx	SS		ORAL		33 DAY
Disability	Thromboembolic Stroke		Vioxx	SS		ORAL		36 DAY
Other	Urticaria		Vioxx	SS		ORAL		312 DAY
			Tricor	C		ORAL		
			Vicodin Es Tablets	C		ORAL		
			Paxil	C		ORAL		
			Restoril	C		ORAL		
			Aspirin	C		ORAL		
			Estrogens (Unspecified)	C				
			Premarin	C				
			Vitamins (Unspecified)	C				
			Zantac	C				
			Vistaril	C				

Date:05/30/03ISR Number: 4119791-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA00092
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Tenderness		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Anaemia		Vioxx	SS		ORAL		
Hospitalization -	Arthritis		Prednisone	C		ORAL		27 DAY
Initial or Prolonged	Blood Pressure Increased		Prednisone	C		ORAL		
Disability	Cardiac Arrest		Imuran (Azathioprine)	C		ORAL		
Other	Cardio-Respiratory Arrest		Imuran (Azathioprine)	C		ORAL		
	Cholecystitis Chronic		Aldactone	C		ORAL		
	Cholelithiasis		Potassium Chloride	C				
	Duodenal Ulcer		Lactulose [Therapy Unspecified]	C				
	Haemorrhage							
	Gastric Ulcer Haemorrhage							
	Hepatic Cirrhosis							
	Hepatic Failure							

	Hiatus Hernia	Phytonadione	C
	Limb Injury	Phenergan (Promethazine Hydrochloride)	C
	Peptic Ulcer	Ativan	C
	Respiratory Failure	Protonix	C
	Shock Haemorrhagic	Calcium (Unspecified)	C
	Sinus Tachycardia	Ascorbic Acid	C
	Synovitis	Centrum	C
		Vitamin B (Unspecified)	C
		Thiamine	C
		[Therapy Unspecified]	C

Date:05/30/03ISR Number: 4119793-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction

		Myocardial Ischaemia Refusal Of Treatment By Patient	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
1	WK						

Date:05/30/03ISR Number: 4119797-3Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00017
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS		ORAL
		Congestive		Insulin	C		
		Medication Error		Propoxyphene Hydrochloride And Acetaminophen	C		
				Metformin	C		
				Vasotec	C		
				Fluoxetine	C		

Date:05/30/03ISR Number: 4119798-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA00228
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
3	WK						
		Blood Pressure Increased		Bextra	SS		
3	WK						
		Cardiac Failure		Bextra	SS		
		Congestive		Vasotec	C		ORAL
		Cardiomyopathy		Aspirin	C		
		Coronary Artery Disease		Gemfibrozil	C		
		Hypertensive Heart		Demadex	C		
		Disease		Glucosamine	C		
				Folic Acid	C		
				Pyridoxine	C		
				Chondroitin	C		
				Pantoloc	C		
				Norvasc	C		
				Zocor	C		ORAL

Glucophage	C
Spironolactone	C
Vitamins (Unspecified)	C

Date:05/30/03ISR Number: 4119800-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA00370
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Duodenitis		Prednisone	C		ORAL		
Initial or Prolonged	Gastric Ulcer Haemorrhage		Prozac	C				
Other	Gastritis		Tylenol	C				
	Gastritis Erosive							
	Gastrointestinal Haemorrhage							
	Gastrointestinal Pain							
	Oesophageal Ulcer Haemorrhage							
	Oesophagitis							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/30/03ISR Number: 4119802-4Report Type:Expedited (15-DaCompany Report #WAES 0305POL00006
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diplegia		Vioxx	SS		ORAL		
	Loss Of Consciousness		Vioxx	SS		ORAL	1	DAY
	Overdose		Indapamide	C		ORAL		
	Vertigo		Gliclazide	C		ORAL		
			Trandolapril	C		ORAL		
			Potassium Chloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL	1	DAY

Date:05/30/03ISR Number: 4119803-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA02657
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/30/03ISR Number: 4119806-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA02562
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/30/03ISR Number: 4121226-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA02263
Age:22 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Alopecia
Other	Arthralgia
	Asthenia
	Blood Creatine
	Phosphokinase

Blood Creatinine
Blood Glucose
Blood Lactate
Dehydrogenase
Blood Potassium
Blood Urea
Chest Pain
Dehydration
Diarrhoea
Dyspepsia
Dyspnoea
Epistaxis
Haematocrit
Haemoglobin
Infected Insect Bite
Influenza Like Illness
Lymphocyte Count
Nausea
Oedema
Oedema Peripheral
Pain
Paraesthesia
Pco2

	Petechiae						
	Platelet Count						
	Prothrombin Time	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Red Blood Cell Count	Health	Vioxx	PS		ORAL	25
	Red Blood Cell	Professional					MG/DAILY/PO
	Sedimentation Rate	Company	Hormonal				
	Sinus Tachycardia	Representative	Contraceptives	C			
	Upper Respiratory Tract Infection						
	Urinary Tract Infection						
	Vomiting						

Date:05/30/03ISR Number: 4121228-4Report Type:Expedited (15-DaCompany Report #WAES 0303USA02263
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper	Health	Tab Vioxx 25 Mg	PS		ORAL	25
Initial or Prolonged	Alopecia	Professional					MG/DAILY/PO
	Back Pain	Company	Hormonal				
	Generalised Oedema	Representative	Contraceptives	C			
	Nausea						
	Pain						

Date:05/30/03ISR Number: 4121231-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03057
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acute Myocardial	Consumer	Vioxx	PS		ORAL	50
Hospitalization -	Infarction	Health					MG/DAILY/PO
Initial or Prolonged	Apnoea	Professional	Elavil	C			
	Atrial Fibrillation		Esgic-Plus Tablets	C			
	Blood Creatinine Increased		Soma	C			
	Brain Death						

Cardiac Arrest
Cardiac Failure
Congestive
Cardiomegaly
Circulatory Collapse
Coma
Coronary Artery Disease
Goitre
Headache
Hypoxic Encephalopathy
Metabolic Acidosis
Myocardial Ischaemia
Odynophagia
Pharyngolaryngeal Pain
Pulmonary Congestion
Sensation Of Foreign Body
Ventricular Hypertrophy

Date:06/02/03ISR Number: 4120461-5Report Type:Expedited (15-DaCompany Report #WAES 0305ITA00005
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased

	Hypertension Myalgia Thrombocytopenia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	64 DAY
			Moduretic	SS		ORAL	2 DAY

Date:06/02/03ISR Number: 4120466-4Report Type:Expedited (15-DaCompany Report #WAES 0305MEX00014
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Pleural Effusion		Ketorolac				
	Tachycardia		Tromethamine	C			2 DAY
			Enoxaparin Sodium	C			
			Acenocoumarol	C		ORAL	3 MON

Date:06/02/03ISR Number: 4120498-6Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00224
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Iiird Nerve Paralysis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Initial or Prolonged	Vasculitis	Professional	Lansoprazole	C			
Other			Bendroflumethiazide	C			

Date:06/02/03ISR Number: 4120504-9Report Type:Expedited (15-DaCompany Report #WAES 0303NOR00007
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
Initial or Prolonged	Increased		Vioxx	SS			
Other							

Date:06/02/03ISR Number: 4120687-0Report Type:Direct Company Report #CTU 194446
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chills Crying Muscle Spasms Pain Respiratory Disorder		Vioxx 12.5 Mg Merck & Co., Inc Lo-Ogesterol	PS C	Merck & Co., Inc	ORAL	2 TABLE DAY	ORAL

Date:06/02/03ISR Number: 4120728-0Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00177
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cognitive Disorder Disorientation Disturbance In Attention Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:06/02/03ISR Number: 4120735-8Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Diverticulitis		Naloxone Hydrochloride And Tilidine Hydrochloride	C				
Disability	Ejaculation Disorder							
	Lower Gastrointestinal Haemorrhage							

Date:06/02/03ISR Number: 4120738-3Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00096
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Blood Pressure Decreased							
	Pruritus							

Date:06/03/03ISR Number: 4122098-0Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00062
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Flushing		[Therapy Unspecified]	C		ORAL		
	Rectal Haemorrhage							

Date:06/03/03ISR Number: 4122099-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00191
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
	Haematemesis		Tramadol					

	Nausea		Hydrochloride	SS		ORAL
6 DAY						
			Atenolol	C		ORAL
			Mebeverine Hydrochloride	C		ORAL

Date:06/03/03ISR Number: 4122105-5Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00208
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
	Haematemesis		Timolol	C		ORAL
			Nifedipine	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL
			Aluminum Hydroxide And Magnesium Carbonate	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/03ISR Number: 4122110-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA02888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/03ISR Number: 4122111-0Report Type:Expedited (15-DaCompany Report #WAES 0305USA02749
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	
Hospitalization - Initial or Prolonged			Zoloft	C				
			Pravachol	C				
			Pepcid	C				
			Atenolol	C				
			Levothyroxine Sodium	C				
			Caltrate	C				

Date:06/03/03ISR Number: 4122113-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:06/03/03ISR Number: 4122121-3Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00115
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vomiting		Valproate Sodium	SS				
	Wrist Fracture		Ranitidine Hydrochloride	C				
			Calcitriol	C				
			Norethindrone	C				
			Estradiol	C				

			Oxycodone Hydrochloride	C		
			Oxycodone Hydrochloride	C		

Date:06/03/03ISR Number: 4122130-4Report Type:Expedited (15-DaCompany Report #WAES 0305CRI00005
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cutaneous Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			Propylthiouracil	C		ORAL		DAY

Date:06/03/03ISR Number: 4122131-6Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00132
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/03ISR Number: 4122144-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02946
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypotension		Diltiazem					
Initial or Prolonged	Musculoskeletal Stiffness		Hydrochloride	C				
	Sepsis		Accupril	C				
	Vomiting		Synthroid	C				
			Prevacid	C				
			Neurontin	C				
			Premarin	C				
			Hydrodiuril	C		ORAL		

Date:06/04/03ISR Number: 4122435-7Report Type:Expedited (15-DaCompany Report #WAES 0305POL00006
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS		ORAL		
	Diplegia		Vioxx	SS		ORAL	1	DAY
	Loss Of Consciousness		Gliclazide	C		ORAL		
	Monoplegia		Indapamide	C		ORAL		
	Overdose		Trandolapril	C		ORAL		
	Vertigo		Potassium Chloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL	1	DAY

Date:06/04/03ISR Number: 4122457-6Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00017
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS		ORAL		
	Congestive		Insulin	C				
			Acetaminophen And Propoxyphene Hydrochloride	C				
			Metformin	C				

			Vasotec	C		
			Fluoxetine	C		

Date:06/04/03ISR Number: 4122462-XReport Type:Expedited (15-DaCompany Report #WAES 0305NOR00054
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		
			Estradiol And Norethindrone Acetate	C				

Date:06/04/03ISR Number: 4122567-3Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041113A
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acidosis		Seroxat	PS	Glaxosmithkline	ORAL	50TAB	Single dose
	Flushing							
	Suicide Attempt		Ibuprofen	SS	Glaxosmithkline	ORAL	20TAB	Single dose
	Tachycardia							

Ibutad	SS	Glaxosmithkline	ORAL	20TAB Single dose
Vioxx	SS		ORAL	10TAB Single dose
Diclofenac	SS		ORAL	20TAB Single dose
Ass	SS	Glaxosmithkline	ORAL	20TAB Single dose
Promethazine	SS		ORAL	20TAB Single dose
Paracetamol	SS	Glaxosmithkline	ORAL	20TAB Single dose
Talvosilen	SS		ORAL	20TAB Single dose

Date:06/04/03ISR Number: 4123546-2Report Type:Direct Company Report #CTU 195011
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Aldactone	PS		ORAL	25MG PO BID	
Initial or Prolonged	Blood Potassium Increased		Altace	SS		ORAL	2.5 PO QD	
Required			Vioxx	SS		ORAL	25 PO QD	
Intervention to Prevent Permanent Impairment/Damage			Lasix	C				
			Ecotrin	C				
			Isosorbide Din	C				
			Theo-Dur	C				
			Accolate	C				

			Lipitor	C		
			Plavix	C		
			Norvasc	C		
			Atenolol	C		
			Protonix	C		
			Caltrate	C		
			Duoneb	C		
			Vicodin	C		

Date:06/04/03ISR Number: 4123551-6Report Type:Direct Company Report #CTU 195014
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer		Vioxx	PS		ORAL	25MG PO QD	3 MON
	Gastric Ulcer		Vicodin	C				
	Nausea							
	Peptic Ulcer							
	Vomiting							

Date:06/04/03ISR Number: 4124287-8Report Type:Expedited (15-DaCompany Report #PHBS2003NO05251
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Bilirubin	Foreign	Aredia (Disodium					
	Blood Lactate	Health	Pamidronate) Vial	PS			INTRAVENOUS	60 MG,
	Dehydrogenase	Professional					ONCE/SINGLE,	
	Haemolytic Anaemia	Other					INTRAVENOUS;	
SEE IMAGE								
			Vioxx (Rofecoxib)	SS		ORAL	25 MG/D, ORAL	
			Sinemet	C				
			Eldepryl	C				

Paracet	C
Alkeran (Melphalan) Tablet	C
Prednisolon Tablet	C

Date:06/04/03ISR Number: 4124527-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
Hospitalization - Initial or Prolonged	Arrhythmia
	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Atrial Tachycardia
	Back Pain
	Blood Creatinine
	Blood Ph Increased
	Blood Thyroid Stimulating Hormone
	Blood Urea
	Bone Lesion
	Bone Pain
	Bronchitis Acute
	Cardio-Respiratory Arrest
	Cholelithiasis
	Chronic Obstructive Airways Disease Exacerbated
	Compression Fracture
	Condition Aggravated
	Coronary Artery Disease
	Dyspnoea
	Electromechanical Dissociation
	Emphysema
	Feeling Abnormal
	Gastritis
	Haematocrit
	Haemoglobin
	Haemoptysis
	Hepatic Cyst
	Hypotension
	Injury

Lobar Pneumonia
Multiple Myeloma
Nausea
Oxygen Saturation
Decreased
Pallor
Platelet Count
Post Procedural
Complication
Respiratory Rate
Increased
Rib Fracture
Streptococcal Sepsis
Tachypnoea
Thyroxine Free

	Vomiting White Blood Cell Count					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
		Health				
MG/DAILY/PO						
		Professional	Cardizem Cd	C		
			Cartia (Aspirin)	C		
			Combivent	C		
			Daypro	C		
			Lipitor	C		
			Prozac	C		
			Ventolin (Albuterol Sulfate)	C		
			Xanax	C		
			Captopril	C		
			Metoprolol	C		
			Nicotine	C		
			Nonsteroidal Anti-Inflammatory	C		
			Prednisone	C		

Date:06/04/03ISR Number: 4124582-2Report Type:Expedited (15-DaCompany Report #2003022882
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation	Consumer	Tikosyn (Dofetilide)	PS		ORAL
1000 MCG						
Initial or Prolonged	Blood Pressure Increased					
(BID), ORAL						
	Economic Problem		Rofecoxib (Rofecoxib)	SS		
	Hyperthyroidism		Citalopram Hydrobromide (Citalopram Hydrobromide)	C		
	Pancreatitis		Valdecoxib (Valdecoxib)	C		
	Parathyroidectomy		Atorvastatin (Atorvastatin)	C		
	Treatment Noncompliance		Ezetimibe (Ezetimibe)	C		

			Alprazolam (Alprazolam)	C		
			Warfarin Sodium (Warfarin Sodium)	C		
			Panadeine Co (Codeine Phosphate, Paracetamol)	C		

Date:06/05/03ISR Number: 4123129-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02853
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Hallucination		Lortab	C				
	Hyperhidrosis		Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/03ISR Number: 4123139-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA00026
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		302 DAY
Initial or Prolonged	Pharyngeal Mass		Vioxx	SS		ORAL		
Other			Prevacid	C		ORAL		
			Levoxyl	C				
			Synthroid	C		ORAL		
			Actonel	C		ORAL		

Date:06/05/03ISR Number: 4123140-3Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00018
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastritis Haemorrhagic		Prednisolone	SS		ORAL		
	Gastrointestinal		Aspirin And					
	Haemorrhage		Magnesium Oxide	SS		ORAL		

Date:06/05/03ISR Number: 4123143-9Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00012
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carotid Artery Stenosis		Tramadol					
Disability	Cerebral Infarction		Hydrochloride	C		ORAL		
			Zocor	C		ORAL		

Date:06/05/03ISR Number: 4123148-8Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00059
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Large Intestine		Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY
Initial or Prolonged	Perforation		Flecainide Acetate	SS		ORAL		

			Ethinyl Estradiol And Levonorgestrel	C		
TOPICAL						

Date:06/05/03ISR Number: 4123409-2Report Type:Expedited (15-DaCompany Report #WAES 0306BRA00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:06/05/03ISR Number: 4123417-1Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00017
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Nephropathy Toxic		Morphine Sulfate	C		ORAL		

Date:06/05/03ISR Number: 4123418-3Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00002
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Collagenous		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Initial or Prolonged	Colitis Ischaemic		Acetaminophen	C				
	Diarrhoea		Lansoprazole	C				
	Diverticulitis		Perindopril Erbumine	C				
	Haematemesis		Aspirin Lysine	C				
	Large Intestinal Ulcer		Althiazide And Spironolactone	C				
	Scar							

Date:06/05/03ISR Number: 4123420-1Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00010
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
	Face Oedema		Budesonide And Formoterol Fumarate	C				
	Hypersensitivity							
	Localised Oedema							

RESPIRATORY (INHALATION)

Date:06/05/03ISR Number: 4123421-3Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00008
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemodynamic Instability		Betamethasone	C				15 YR
Initial or Prolonged	Localised Infection		Prednisone	C		ORAL		
	Quadriplegia		Terbutaline Sulfate	C				
	Respiratory Distress		Ipratropium Bromide	C				
	Spinal Disorder		Fluticasone Propionate And Salmeterol Xinafoate	C				
	Staphylococcal Sepsis		Rilmenidene	C				
			Glimepiride	C				

Date:06/05/03ISR Number: 4126431-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA00228
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	3 WK
	Cardiac Failure	Health						
	Congestive	Professional	Bextra 20 Mg	SS			SEE IMAGE	
	Chest Wall Pain		Demadex	C				
	Coronary Artery Disease		Glucophage	C				
	Fluid Retention		Norvasc	C				
	Hypertensive		Pantoloc	C				
	Cardiomyopathy		Vasotec	C				
	Hypertensive Heart		Zocor	C				
	Disease		Aspirin	C				
	Weight Increased		Chondroitin	C				
			Folic Acid	C				
			Gemfibrozil	C				
			Glucosamine	C				
			Pyridoxine	C				
			Spironolactone	C				
			Vitamins (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/05/03ISR Number: 4126440-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Consumer Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:06/05/03ISR Number: 4126442-XReport Type:Expedited (15-DaCompany Report #WAES 0303USA00092
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Abdominal Tenderness Activated Partial Thromboplastin Time Anaemia Blood Albumin Decreased Blood Creatinine Blood Potassium Blood Pressure Increased Blood Sodium Blood Urea Cardio-Respiratory Arrest Cholecystitis Cholelithiasis Cushingoid Duodenal Ulcer Duodenal Ulcer Haemorrhage Gastrointestinal Ulcer Haemorrhage Haemorrhage Hepatic Cirrhosis Hepatic Failure Hiatus Hernia Lethargy Limb Injury Malaise Oedema Peripheral Peptic Ulcer Platelet Count Decreased	Health Professional Company Representative	Tab Vioxx 25 Mg Aldactone Ativan Centrum Imuran (Azathioprine) Imuran (Azathioprine) Phenergan (Promethazine Hydrochloride) Protonix Ascorbic Acid Calcium Lactulose Phytonadione Potassium Chloride Prednisone Prednisone Thiamine Vitamin B (Unspecified)	PS C C C C C C C C C C C C C C C C		ORAL	SEE IMAGE	

Prothrombin Time
Pulse Absent
Respiratory Failure
Shock Haemorrhagic
Sinus Tachycardia
Somnolence
Synovitis
Traumatic Arthritis
Upper Gastrointestinal
Haemorrhage

Date:06/06/03ISR Number: 4123804-1Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00016
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		299 DAY
Initial or Prolonged	Skin Ulcer		Amlodipine Maleate	C		ORAL		
			Vaseretic	C		ORAL		
			Chondroitin Sulfate					

			Sodium	C		ORAL

Date:06/06/03ISR Number: 4123806-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aortic Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthenia	Professional	Vioxx	SS		ORAL
Other	Bundle Branch Block Left		Vioxx	SS		ORAL
	Cardiac Failure		Lasix (Furosemide)	SS		
	Congestive		Lasix (Furosemide)	SS		
INTRAVENOUS						
	Cardiomegaly		Zocor	C		ORAL
	Change Of Bowel Habit		Zocor	C		ORAL
	Condition Aggravated		Lopressor	C		
	Constipation		Salagen Tablets	C		
	Contusion		Plaquenil	C		
	Coronary Artery Disease		Femhrt	C		
	Coronary Artery Stenosis		Lotemax	C		
OPHTHALMIC						
	Depression		Timolol	C		
OPHTHALMIC						
	Diarrhoea		Advil	C		
	Dizziness					
	Fall					
	Glaucoma					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Haemorrhage					
	Hypercholesterolaemia					
	Hypertension					
	Ischaemic Cardiomyopathy					
	Joint Sprain					
	Mitral Valve Incompetence					
	Myocardial Infarction					
	Nephropathy Toxic					
	Orthostatic Hypotension					
	Pallor					
	Pneumonitis					
	Pulmonary Oedema					
	Pulmonary Valve					
	Incompetence					
	Renal Failure					
	Respiratory Distress					
	Respiratory Rate					

Increased
Rosacea
Sjogren'S Syndrome
Systemic Lupus
Erythematosus
Thrombocytopenia
Tooth Disorder
Tricuspid Valve
Incompetence
Ventricular Dysfunction
Visual Disturbance

Date:06/06/03ISR Number: 4123816-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00142
Age:86 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/03ISR Number: 4123834-XReport Type:Expedited (15-DaCompany Report #WAES 0302BEL00013
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteritis Obliterans	Health	Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Foot Amputation	Professional	Vioxx	SS		ORAL	3	DAY
Disability	Ischaemic Ulcer		Vioxx	SS		ORAL	10	DAY
Other	Necrosis		Diclofenac Sodium	C		ORAL		
	Oedema							
	Skin Ulcer							
	Toe Amputation							

Date:06/06/03ISR Number: 4123835-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01866
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS		ORAL		
	Hypertension		Vioxx	SS		ORAL	1	WK
			Lotrel	C				
			Aspirin	C				

Date:06/06/03ISR Number: 4124019-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Arrhythmia

Supraventricular
Atrial Fibrillation
Atrial Flutter
Atrioventricular Block
Complete
Back Pain
Bone Pain
Bronchitis Acute
Cardiac Failure
Congestive
Cardio-Respiratory Arrest
Cardiogenic Shock
Cholelithiasis
Chronic Obstructive
Airways Disease
Exacerbated
Compression Fracture
Electromechanical
Dissociation
Gastritis
Haemoptysis
Heart Rate Irregular
Hepatic Cyst
Hypertension

		Hypotension					
		Multiple Myeloma					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia Streptococcal		Vioxx	PS	Merck & Co., Inc	ORAL
425	DAY						
		Rib Fracture		Nonsteroidal			
		Streptococcal Sepsis		Anti-Inflammatory			
		Tachycardia		Drug (Unspecified)	C		ORAL
		Tachypnoea		Lipitor	C		
		Tracheobronchitis		Metoprolol	C		
		Upper Respiratory Tract		Prozac	C		
		Infection		Combivent	C		
RESPIRATORY							
		Vomiting					
(INHALATION)							
				Daypro	C		ORAL
				Prednisone	C		
				Ventolin (Albuterol			
				Sulfate)	C		
				Cartia (Aspirin)	C		ORAL
				Nicotine	C		
				Xanax	C		ORAL
				Cardizem Cd	C		
				Captopril	C		

Date:06/06/03ISR Number: 4124021-1Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Acute Respiratory Failure
Other	Anaemia
	Asthenia
	Body Temperature Increased
	Cardiac Failure Congestive
	Clostridium Colitis
	Coma
	Complex Partial Seizures
	Convulsion
	Enterobacter Pneumonia
	Fall

Headache Postoperative
Hydrocephalus
Hypertension
Hyponatraemia
Hypotension
Inappropriate
Antidiuretic Hormone
Secretion
Intraventricular
Haemorrhage
Joint Stiffness
Malnutrition
Mental Status Changes
Postoperative
Myocardial Infarction
Non-Cardiogenic Pulmonary
Oedema
Osteoarthritis
Pneumonia Aspiration

		Post Procedural Pain Ruptured Cerebral Aneurysm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL
65	DAY						
		Subarachnoid Haemorrhage		Indocin			
		Tenosynovitis Stenosans		(Indomethacin)	C		ORAL
		Thrombocytopenia		Tylenol Extra			
				Strength	C		
				Celebrex	C		ORAL
				Celebrex	C		ORAL

Date:06/06/03ISR Number: 4124027-2Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00013
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
29	DAY						
Hospitalization -		Melaena		Benserazide			
Initial or Prolonged		Peptic Ulcer Haemorrhage		Hydrochloride And			
		Rectal Haemorrhage		Levodopa	C		ORAL
				Paraffin	C		ORAL
				Paroxetine			
				Hydrochloride	C		ORAL
				Dipyrone	C		ORAL
				Sennosides	C		ORAL
				Acetaminophen	C		ORAL
				Zopiclone	C		ORAL

Date:06/06/03ISR Number: 4124033-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00190
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aphthous Stomatitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Autoimmune Disorder		Vitamins			
		Behcet'S Syndrome		(Unspecified)	C		
		Cellulitis Staphylococcal		Synthroid	C		
		Coagulopathy		Inderal	C		
		Drug Hypersensitivity		Zantac	C		
		Dry Mouth		Cenestin	C		

	Enterococcal Infection	Valium	C
	Erythema	Valtrex	C
	Gangrene	Imitrex	C
	Haemorrhage	Vicodin Tablets	C
	Hypertension	Prozac	C
	Ischaemic Ulcer	[Therapy	
	Keratoconjunctivitis	Unspecified]	C
	Sicca	Levbid	C
	Klebsiella Infection		
	Oedema Peripheral		
	Oral Intake Reduced		
	Osteomyelitis		
	Pain In Extremity		
	Papilloma Viral Infection		
	Pseudomonas Infection		
	Scab		
	Scar		
	Skin Discolouration		
	Superinfection		
	Toe Amputation		
	Vasculitis		

Date:06/06/03ISR Number: 4124034-XReport Type:Expedited (15-DaCompany Report #WAES 0303DEU00090
Age:17 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Blood Ethanol Increased		Alcohol	SS		ORAL		1 DAY
	Overdose							

Date:06/06/03ISR Number: 4125455-1Report Type:Expedited (15-DaCompany Report #2003GB00586
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea	Foreign	Omeprazole	PS				
	Dyspepsia	Health	Rofecoxib	SS		ORAL	12.5 MG DAILY	
	Neoplasm Malignant	Professional					PO	
		Other						

Date:06/06/03ISR Number: 4126437-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA00370
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Thromboplastin Time	Professional					MG/DAILY/PO	
Initial or Prolonged	Blood Glucose	Company	Prozac	C				
Other	Blood Sodium	Representative	Tylenol	C				
	Blood Urea		Prednisone	C				
	Duodenitis							
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Gastritis Erosive							
	Haematocrit							
	Haemoglobin							
	Lymphocyte Count							
	Oesophageal Ulcer							

Haemorrhage
Oesophagitis
Red Blood Cell Count

Date:06/09/03ISR Number: 4124665-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA02797
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Death	Brain Oedema
	Cardiomegaly
	Coma
	Contusion
	Convulsion
	Drug Toxicity
	Faecal Incontinence
	Hepatic Siderosis
	Intentional Misuse
	Lip Disorder
	Mouth Haemorrhage
	Pulmonary Congestion
	Pulmonary Oedema
	Pyelonephritis Chronic
	Sudden Death
	Swelling Face
	Tongue Disorder

Urinary Incontinence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dihydrocodeine	SS				
	Citalopram	SS				
	Morphine	C				
	Chlorpromazine	C				

Date:06/09/03ISR Number: 4124667-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Hospitalization - Initial or Prolonged	Basilar Artery Occlusion		Celebrex	C			252	DAY
	Basilar Artery Stenosis		Glucophage	C			79	DAY
	Brain Stem Infarction		Glucophage	C				
	Cerebellar Infarction		Glucophage	C				
	Cerebral Infarction		Diovan Hct	C				
	Cerebral Ischaemia		Darvocet-N	C				
	Cerebrovascular Accident		Aspirin	C				
	Coma							
	Coordination Abnormal							
	Culture Wound Positive							
	Diabetes Mellitus Non-Insulin-Dependent							
	Ecg Signs Of Myocardial Ischaemia							
	Electrocardiogram St Segment Depression							
	Electroencephalogram Abnormal							
	Enterobacter Infection							
	Fall							
	Haemorrhage							
	Hydrocephalus							
	Hyperaesthesia							
	Hypertension							
	Injury							
	Necrosis							

Nystagmus
Ophthalmoplegia
Pupillary Disorder
Vertebral Artery Stenosis
Vertigo
White Blood Cell Count

Date:06/09/03ISR Number: 4124668-2Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00010
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Extremity Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/03ISR Number: 4124682-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Hospitalization - Initial or Prolonged	Ammonia	Professional	Haldol	C				
	Blood Creatinine Increased		Nitroglycerin	C				
	Blood Glucose Increased		Trazodone	C		ORAL		
	Blood Potassium Decreased		Valproic Acid	C		ORAL		
	Blood Urea Increased		Aspirin	C		ORAL		
	Bradycardia		Ferrous Sulfate	C				
	Cold Sweat		Colace	C				
	Death		Sorbitol	C		ORAL		
	Depressed Level Of Consciousness		[Therapy Unspecified]	C				
	Drug Ineffective		Celebrex	C		ORAL		
	Faecal Incontinence		Celebrex	C		ORAL		29 DAY
	Faeces Discoloured		Celebrex	C		ORAL		
	Feeling Cold		Vitamins (Unspecified)	C				
	Gastrointestinal Haemorrhage		Isosorbide Dinitrate	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypotension							
	Injury							
	Ketonuria							
	Pallor							
	Respiratory Rate Increased							
	Somnolence							

Date:06/09/03ISR Number: 4124683-9Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00008
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Peripheral Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Vasculitis							

Date:06/09/03ISR Number: 4124687-6Report Type:Expedited (15-DaCompany Report #WAES 0212NLD00003
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS		ORAL		
	Pancreatitis Acute		Prednisone	C		ORAL		
	Pancreatitis Relapsing		Methotrexate	C		ORAL		
			Folic Acid	C		ORAL		
			Omeprazole Magnesium	C		ORAL		
			Calcium Carbonate And Calcium Glubionate	C		ORAL		
			Ferrous Sulfate	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Metoprolol Tartrate	C		SUBCUTANEOUS		
			Isosorbide Mononitrate	C		ORAL		
			Valsartan	C		ORAL		
			Naproxen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/03ISR Number: 4124691-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00259
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/03ISR Number: 4124967-4Report Type:Expedited (15-DaCompany Report #WAES 0305FRA00059
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticular Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY
Initial or Prolonged		Professional	Flecainide Acetate	C		ORAL		
			Ethinyl Estradiol And Levonorgestrel	C		TOPICAL		

Date:06/09/03ISR Number: 4124969-8Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		25 DAY
Initial or Prolonged	Increased Depressed Level Of Consciousness Drug Level Increased Extrapyramidal Disorder General Physical Health Deterioration Renal Failure	Professional	Lithium Sulfate	SS		ORAL		
			Levothyroxine Sodium	C				
			Dipyridamole	C				
			Lofepramine Hydrochloride	C				
			Zolpidem Tartrate	C				
			Calcium Carbonate And Cholecalciferol	C				
			Tramadol Hydrochloride	C				

Date:06/09/03ISR Number: 4124981-9Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00054
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Respiratory Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		280 DAY
Initial or Prolonged	Urticaria	Professional	Estradiol And Norethindrone Acetate	C				

Date:06/09/03ISR Number: 4124984-4Report Type:Expedited (15-DaCompany Report #WAES 0306BRA00004
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Infarction	Professional						

Date:06/09/03ISR Number: 4124986-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/03ISR Number: 4124988-1Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00007
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Suicide Attempt	Professional	Acetaminophen	SS		ORAL	1	DAY
	Vomiting		Ibuprofen	SS		ORAL	1	DAY
			Phloroglucinol And Trimethylphloroglucinol	SS		ORAL	1	DAY

Date:06/09/03ISR Number: 4124990-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/03ISR Number: 4124993-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/03ISR Number: 4126654-5Report Type:Expedited (15-DaCompany Report #200312261US
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 100 MG QD 3 DAY	Arthralgia	Consumer	Leflunomide (Arava)	PS
Initial or Prolonged 20 MG QD 2 MON	Blood Albumin Decreased	Health	Leflunomide (Arava)	SS
Other 50 MG	Bone Disorder	Professional	Rofecoxib (Vioxx)	SS
	Condition Aggravated		Methotrexate	C
	Contusion		Celecoxib (Celebrex)	C
	Fall		Paracetamol (Tylenol)	C
	Haemangioma		Antibiotics Nos	C
	Hepatic Cyst		Sulfasalazine	C
	Hepatitis		Clavulanate Potassium, Amoxicillin Trihydrate (Augmentin)	C
	Hepatocellular Damage		Prednisone	C
	Hepatotoxicity		Docusate Sodium (Colace)	C
	Hypertension		Gabapentin (Neurontin)	C
	Monocyte Count Increased		Guaifenesin	C
	Neutrophil Count Decreased		Hydrocodone	C
	Platelet Count Increased		Ranitidine	C
	Protein Total Decreased			
	Renal Cyst			
	Serum Ferritin Increased			
	White Blood Cell Count Increased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/03ISR Number: 4125696-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01294
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cyanosis		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
			Celebrex	C				
			Ibuprofen	C				

Date:06/10/03ISR Number: 4125706-3Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00207
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS		ORAL		
	Asthenia		Vitamins (Unspecified) [Therapy Unspecified]	C				
	Back Pain							
	Confusional State							
	Dyspnoea			C				
	Hyponatraemia							
	Immobile							
	Loss Of Consciousness							
	Malaise							
	Neck Pain							
	Pain							
	Pain In Extremity							
	Pneumonia Aspiration							
	Rhabdomyolysis							
	Stress							
	Thirst							
	Venous Occlusion							
	Vomiting							

Date:06/10/03ISR Number: 4125753-1Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00048
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Face Oedema		Calcium Carbonate					

				And Cholecalciferol	C		
				Dexketoprofen	C		
				Atorvastatin Calcium	C		
				Telmisartan	C		
				Aspirin	C		

Date:06/10/03ISR Number: 4125765-8Report Type:Expedited (15-DaCompany Report #WAES 0306ITA00008
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Peritonitis		Gliclazide	C		ORAL	2	YR

Date:06/10/03ISR Number: 4125775-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00708
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Amylase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Premarin	C				
			Detrol	C				

Claritin C

Date:06/10/03ISR Number: 4125930-XReport Type:Expedited (15-DaCompany Report #WAES 0306CAN00028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Movement Disorder							
	Syncope							

Date:06/10/03ISR Number: 4125937-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/10/03ISR Number: 4125938-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/10/03ISR Number: 4125941-4Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00014
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Abdomen		Fosamax	PS	Merck & Co., Inc	ORAL	43	DAY

Hospitalization - Initial or Prolonged	Asthenia	Rofecoxib	SS	ORAL
	Back Pain	Azathioprine	C	ORAL
	Duodenal Ulcer	Atenolol	C	ORAL
	Perforation	Amiloride		
	Dyspepsia	Hydrochloride And		
	Metastatic Neoplasm	Furosemide	C	ORAL
	Renal Failure	Oxybutynin Chloride	C	ORAL
	Sepsis	Ferrous Sulfate	C	ORAL

Date:06/10/03ISR Number: 4125942-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/03ISR Number: 4125944-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00692
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Hospitalization - Initial or Prolonged Disability	Renal Cell Carcinoma Stage Iv							

Date:06/10/03ISR Number: 4125945-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125946-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125947-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125948-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125951-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/03ISR Number: 4125957-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125959-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125961-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125966-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4125975-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							

Date:06/10/03ISR Number: 4125981-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/03ISR Number: 4125982-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/03ISR Number: 4126160-8Report Type:Direct Company Report #CTU 195419
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Hypertension		Vioxx 12.5mg Merck	PS	Merck	ORAL	12.5 Q12 ORAL	

Date:06/10/03ISR Number: 4127124-0Report Type:Direct Company Report #CTU 195499
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Loss Of Consciousness Melaena		Ibuprofen Rofecoxib 25mg Tab	PS SS				

Date:06/11/03ISR Number: 4126613-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Convulsion

Date:06/11/03ISR Number: 4126616-8Report Type:Expedited (15-DaCompany Report #WAES 0306NOR00005
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Gastric Ulcer							
	Haematemesis							

Date:06/11/03ISR Number: 4126623-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/03ISR Number: 4126624-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							
	Pain							

Date:06/11/03ISR Number: 4126626-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							
	Pain							

Date:06/11/03ISR Number: 4126628-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							
	Pain							

Date:06/11/03ISR Number: 4126898-2Report Type:Expedited (15-DaCompany Report #WAES 0305BEL00011
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Warfarin	SS		ORAL		
	Melaena		Theophylline	C		ORAL		
			Methylprednisolone	C		ORAL		

Date:06/11/03ISR Number: 4126902-1Report Type:Expedited (15-DaCompany Report #WAES 0306AUT00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/11/03ISR Number: 4126903-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00623
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/03ISR Number: 4126904-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00964
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/11/03ISR Number: 4126906-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00625
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/11/03ISR Number: 4126907-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00683
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Upper Gastrointestinal Haemorrhage		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:06/11/03ISR Number: 4126908-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00673
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/11/03ISR Number: 4127982-XReport Type:Expedited (15-DaCompany Report #HQWYE450203JUN03
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Intentional Misuse	Health Professional	Advil (Ibuprofen, Tablet)	PS		ORAL	6 TABLETS	
Other	Suicide Attempt	Other					ORAL	
	Vomiting		Doliprane (Paracetamol,)	SS			13 TABLETS	
			Spasfon (Phloroglucinol/Trimethylphloroglucinol,)	SS			7 TABLETS	
			Vioxx (Rofecoxib, Tablet)	SS			14 TABLETS	

Date:06/11/03ISR Number: 4128565-8Report Type:Expedited (15-DaCompany Report #2002SE06288
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Coagulation Time	Foreign Health	Nexium	PS		ORAL	40 MG DAILY PO	
	Prolonged	Professional	Nexium	SS		ORAL	20 MG DAILY PO	
	Hepatitis Toxic	Other						
			Vioxx	SS		ORAL	25 MG DAILY PO	

	Vioxx	SS	ORAL
25 MG DAILY			
PO			
	Progynova	C	
	Panadol	C	
	Telfast	C	
	Flixotide "Allen & Hanburys"	C	
	Ventoline	C	
	Zomig	C	

Date:06/11/03ISR Number: 4129353-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00026
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Carotid Artery Stenosis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Cerebral Atrophy	Health				
MG/DAILY/PO						
Other	Cerebrovascular Accident	Professional	Actonel	C		
	Pharyngeal Cyst		Levoxyl	C		
			Prevacid	C		
			Synthroid	C		

Date:06/11/03ISR Number: 4129354-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Prerenal Failure
Initial or Prolonged	Aortic Valve Incompetence
Other	Asthenia
	Back Pain
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiomegaly
	Change Of Bowel Habit
	Constipation
	Contusion
	Coronary Artery Stenosis
	Crepitations

Depression
Diarrhoea
Dizziness
Ejection Fraction
Decreased
Eye Disorder
Eye Pain
Fall
Glaucoma
Haematocrit Decreased
Haemoglobin Decreased
Haemorrhage
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Ischaemic Cardiomyopathy
Joint Sprain
Myocardial Infarction
Nephritis Interstitial
Orthostatic Hypotension
Pitting Oedema

	Pleural Effusion						
	Pneumonitis						
	Post Procedural	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Complication	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5
	Pulmonary Oedema	Health					MG/DAILY/PO;
	Pulmonary Valve	Professional					25
	Incompetence						MG/DAILY/PO;
	Respiratory Distress						12.5
	Respiratory Rate		Lasix (Furosemide)	SS		INTRAVENOUS	IV; 80
	Increased						MG/DAILY
	Retinal Toxicity		Advil	C			
	Rosacea		Femhrt	C			
	Sjogren'S Syndrome		Lopressor	C			
	Synovitis		Lotemax	C			
	Systemic Lupus		Plaquenil	C			
	Erythematosus		Salagen Tablets	C			
	Thrombocytopenia		Zocor	C			
	Tooth Disorder		Timolol	C			
	Tricuspid Valve						
	Incompetence						
	Visual Acuity Reduced						

Date:06/11/03ISR Number: 4164741-6Report Type:Periodic Company Report #02/02158-USE
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Health	Yasmin				
Initial or Prolonged	Blindness	Professional	(Ethinylestradiol,				
Other	Depressed Level Of	Company	Drospirenone) Film				
	Consciousness	Representative	Tablet	PS		ORAL	1 TAB/DAY,
	Dyskinesia	Other					ORAL
	Headache		Vioxx (Rofecoxib)	SS			
	Nausea		Cyclosporin	C			
	Optic Nerve Disorder		Prednisone	C			

Thrombotic Stroke
Tunnel Vision
Vomiting

Date:06/12/03ISR Number: 4127361-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127362-7Report Type:Expedited (15-DaCompany Report #FR-ROCHE-338433
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumopathy	Consumer	Loxen	PS	Roche	ORAL		
			Lexomil	SS	Roche	ORAL		
			Mopral	SS		ORAL		
			Vioxx	SS		ORAL		
			Prozac	SS		ORAL		
			Dafalgan	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127363-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127364-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127365-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00749
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127366-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127367-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127368-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127369-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127370-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00750
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127371-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127373-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127375-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127376-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00657
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127377-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00721
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127378-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127380-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00763
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127381-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127382-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127383-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127384-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127385-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00176
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthropathy		[Therapy					
Initial or Prolonged	Difficulty In Walking		Unspecified]	C				
	Fall							
	Hip Fracture							
	Pancreatitis							

Date:06/12/03ISR Number: 4127388-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/12/03ISR Number: 4127389-5Report Type:Expedited (15-DaCompany Report #WAES 0303CAN00130
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chronic Obstructive	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Airways Disease	Professional	Amlodipine Besylate	C		ORAL		
	Exacerbated							
	Nasopharyngitis							

Date:06/12/03ISR Number: 4127390-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00726
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127392-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00759
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127393-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127395-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127396-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00728
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127397-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127398-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00739
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127400-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00737
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127401-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127402-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127403-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127560-2Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00018
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Helicobacter Infection							

Date:06/12/03ISR Number: 4127562-6Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00028
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Hepatocellular Damage		Fluvastatin Sodium	C		ORAL		
	Pain		Analgesic Or Anesthetic (Unspecified)	C		ORAL		

Date:06/12/03ISR Number: 4127565-1Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00045
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Aspirin	SS		ORAL		
	Haematemesis		Metformin	C		ORAL		
			Gliclazide	C		ORAL		
			Carbimazole	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Ramipril	C		ORAL		
			Furosemide	C				
			Pravastatin Sodium	C				

			Amoxicillin	C		

Date:06/12/03ISR Number: 4127567-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127569-9Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00057
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rectal Prolapse		Furosemide	C		ORAL		
			Zopiclone	C		ORAL		
			Acetaminophen	C		ORAL		

Date:06/12/03ISR Number: 4127570-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127571-7Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00207
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brachial Plexus Lesion		Vioxx	SS		ORAL		

Circulatory Collapse	Vitamins	
Compartment Syndrome	(Unspecified)	SS
Confusional State	[Therapy	
Dyspnoea	Unspecified]	SS
Fibromyalgia		
Hyponatraemia		
Loss Of Consciousness		
Malaise		
Muscle Atrophy		
Pain		
Pneumonia Aspiration		
Polydipsia		
Rhabdomyolysis		
Venous Occlusion		
Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127572-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00770
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127573-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127574-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127575-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00780
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127576-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00772
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127578-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00773
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127579-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127581-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00785
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127582-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127583-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127584-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127585-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4127586-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127587-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127588-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127589-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/12/03ISR Number: 4127590-0Report Type:Expedited (15-DaCompany Report #WAES 0212USA02317
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Gastrooesophageal Reflux		Evista	C				
	Disease		Synthroid	C				
	Haemorrhoids		Serevent	C				
	Hiatus Hernia		Atrovent	C				
	Lower Gastrointestinal		Vancenase	C				
	Haemorrhage		Zocor	C				
	Polyp Colorectal							

Date:06/12/03ISR Number: 4127591-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/12/03ISR Number: 4129316-3Report Type:Expedited (15-DaCompany Report #WAES0301USA02797
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema	Foreign	Tab Vioxx					
	Cardiomegaly	Health	(Rofecoxib)	PS		ORAL	PO	
	Coma	Professional	Dihydrocodeine	SS				
	Completed Suicide		Chlorpromazine	C				
	Contusion		Morphine	C				
	Convulsion							
	Drug Toxicity							
	Faecal Incontinence							
	Haemosiderosis							
	Hepatic Siderosis							
	Intentional Misuse							
	Lip Haemorrhage							
	Mouth Haemorrhage							
	Pulmonary Oedema							
	Pyelonephritis Chronic							
	Sickle Cell Anaemia							
	Sudden Death							
	Swelling Face							
	Tongue Biting							
	Toxicologic Test Abnormal							
	Urinary Incontinence							

Date:06/12/03ISR Number: 4129349-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA02235
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Alanine Aminotransferase
Hospitalization - Initial or Prolonged	Ammonia
	Aphasia
	Blood Alkaline Phosphatase
	Blood Bicarbonate
	Blood Creatinine Increased
	Blood Glucose
	Blood Potassium Decreased
	Blood Pressure Decreased
	Blood Urea Increased
	Body Temperature

Decreased
Bradycardia
Chromaturia
Cold Sweat
Crystal Urine Present
Death
Depressed Level Of
Consciousness
Drug Ineffective
Faecal Incontinence
Feeling Cold
Gastrointestinal
Haemorrhage
Haematocrit Decreased
Haemoglobin Decreased
Hypotension
Injury
Oxygen Saturation

		Decreased Pallor Pco2 Po2	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Red Blood Cell Count	Consumer	Tab Vioxx 25 Mg	PS		
		Respiratory Disorder	Health	Celebrex	C		
		Respiratory Rate	Professional	Celebrex	C		
		Increased Somnolence Urine Bilirubin Increased Urine Ketone Body Present White Blood Cell Count					

Date:06/12/03ISR Number: 4129350-3Report Type:Expedited (15-DaCompany Report #WAES 0206USA01278
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Acute Respiratory Failure
Other	Anaemia Asthenia Blood Alkaline Phosphatase Increased Blood Pressure Increased Body Temperature Increased Brain Damage Cardiac Failure Congestive Cardiomyopathy Clostridium Colitis Cognitive Disorder Coma Communication Disorder Complex Partial Seizures Convulsion Difficulty In Walking Discomfort Electroencephalogram Abnormal Enterobacter Pneumonia Eye Movement Disorder Fall Feeling Abnormal

Headache
Hydrocephalus
Hyponatraemia
Hypotension
Inappropriate
Antidiuretic Hormone
Secretion
Intraventricular
Haemorrhage
Joint Stiffness
Malnutrition
Memory Impairment
Mental Status Changes
Mobility Decreased
Myocardial Infarction
Nervous System Disorder

		Pain					
		Pneumonia Aspiration					
		Post Procedural	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complication	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25-50							
		Post Procedural Pain	Health				
MG/DAILY/PO							
		Pulmonary Oedema	Professional	Celebrex	C		
		Sedation		Indocin			
		Somnolence		(Indomethacin)	C		
		Stress		Tylenol Extra			
		Subarachnoid Haemorrhage		Strength	C		
		Thrombocytopenia					
		Vasospasm					
		White Blood Cell Count					

Date:06/12/03ISR Number: 4129351-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00190
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aphthous Stomatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
Initial or Prolonged		Autoimmune Disorder	Health				
MG/DAILY/PO							
		Back Disorder	Professional	Cenestin	C		
		Cellulitis Staphylococcal		Imitrex	C		
		Cervicitis Human		Inderal	C		
		Papilloma Virus		Levbid	C		
		Colposcopy		Prozac	C		
		Culture Wound Positive		Synthroid	C		
		Dry Mouth		Valium	C		
		Eating Disorder		Valtrex	C		
		Enterococcal Infection		Vicodin Tablets	C		
		Eschar		Zantac	C		
		Gangrene		Vitamins	C		
		Haemorrhage					
		Hypertension					
		Ischaemic Ulcer					
		Joint Dislocation					
		Keratoconjunctivitis					
		Sicca					
		Klebsiella Infection					
		Osteomyelitis					

Pain
Pathogen Resistance
Pseudomonas Infection
Skin Lesion
Skin Ulcer
Toe Amputation
Vasculitis

Date:06/12/03ISR Number: 4129352-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Death	Abasia
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Arterial Disorder
	Asthenia
	Balance Disorder
	Basilar Artery Occlusion
	Basilar Artery Stenosis
	Blood Glucose Increased

Dose	Duration						
		Cerebellar Infarction					
		Cerebral Ischaemia					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
25 MG/DAILY/PO		Coma	Consumer	Tab Vioxx 25 Mg	PS		ORAL
		Coordination Abnormal	Health				
		Csf Pressure Increased	Professional	Celebrex	C		
		Culture Wound Positive		Darvocet-N	C		
		Depressed Level Of		Diovan Hct	C		
		Consciousness		Glucophage	C		
		Discomfort		Glucophage	C		
		Dizziness		Glucophage	C		
		Dysarthria		Aspirin	C		
		Dyskinesia					
		Dysstasia					
		Electrocardiogram St					
		Segment Depression					
		Electroencephalogram					
		Abnormal					
		Enterobacter Infection					
		Facial Paresis					
		Fall					
		Haemorrhage					
		Headache					
		Hydrocephalus					
		Hyperaesthesia					
		Hyperreflexia					
		Hypoaesthesia					
		Injury					
		Ischaemia					
		Nausea					
		Necrosis					
		Nervous System Disorder					
		Nystagmus					
		Ophthalmoplegia					
		Pupillary Reflex Impaired					
		Pupils Unequal					
		Qrs Axis Abnormal					
		Respiratory Disorder					
		Thrombosis					
		Vertebral Artery Stenosis					
		Vertigo					
		White Blood Cell Count					

Date:06/13/03ISR Number: 4127961-2Report Type:Expedited (15-DaCompany Report #WAES 0304AUS00114
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Activities Of Daily Living Impaired	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Celecoxib	SS				
	Chest Pain		Aspirin	C				
	Confusional State		Perindopril Erbumine	C				
	Disorientation		Isosorbide Mononitrate	C				
	Disturbance In Attention		Ranitidine Hydrochloride	C				
	Fear		Atorvastatin Calcium	C				
	Hallucination, Visual							
	Mental Disorder							
	Obsessive Thoughts							
	Psychiatric Symptom							
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4127968-5Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00185
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure	Professional	Aspirin	SS				
Hospitalization -	Congestive		Metformin	C				
Initial or Prolonged	Gastric Ulcer Haemorrhage		Gliclazide	C				
			Ranitidine	C				

Date:06/13/03ISR Number: 4127974-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/13/03ISR Number: 4127975-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:06/13/03ISR Number: 4127983-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA00779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							

Date:06/13/03ISR Number: 4127984-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4127988-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA00777
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4127989-2Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00021
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Bundle Branch Block Right Hypertension Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4127994-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4127996-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128310-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA00925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128311-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA00920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128312-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Convulsion Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4128314-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128315-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128316-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA00932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128317-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00927
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128319-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA01227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128320-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128323-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA01402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4128325-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA01231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:06/13/03ISR Number: 4128326-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antithrombin Iii	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
308 DAY								
Initial or Prolonged	Decreased	Professional	Vioxx	SS		ORAL		
33 DAY								
Disability	Asthenia		Vioxx	SS		ORAL		
36 DAY								
Other	Atherosclerosis		Vioxx	SS		ORAL		
312 DAY								
	Blood Potassium		Tricor	C		ORAL		
	Cardiac Aneurysm		Vicodin Es Tablets	C		ORAL		
	Cerebral Artery		Paxil	C		ORAL		
	Thrombosis		Restoril	C		ORAL		
	Cerebral Infarction		Aspirin	C		ORAL		
	Chondromalacia		Estrogens					
	Diverticulum Intestinal		(Unspecified)	C				
	Epistaxis		Premarin	C				
	Feeling Cold		Vitamins					
	Flushing		(Unspecified)	C				
	Haematocrit		Zantac	C				
	Haemoglobin		Vistaril	C				
	Pain In Extremity		Cenestin	C				
	Phlebothrombosis							
	Platelet Count							
	Post Procedural Pain							
	Radius Fracture							
	Thromboembolic Stroke							
	Urticaria							

Date:06/13/03ISR Number: 4128328-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA01394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128329-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA01397
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128330-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/03ISR Number: 4128336-2Report Type:Expedited (15-DaCompany Report #WAES 0306CAN00056
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Rupture		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY

Date:06/13/03ISR Number: 4128338-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA02325
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coronary Arterial Stent Insertion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/03ISR Number: 4128339-8Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00044
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Renal Failure Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Perindopril Erbumine	SS		ORAL		
			Furosemide	SS		ORAL		
			Digoxin	C				
			Warfarin Sodium	C				
			Atorvastatin Calcium	C				
			Prednisolone	C				
			Omeprazole Magnesium	C				
			Gabapentin	C				
			Insulin Lispro	C				
			Isosorbide Mononitrate	C				

Date:06/13/03ISR Number: 4128452-5Report Type:Direct Company Report #CTU 195695
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myositis		Vioxx 25 Mg		Merck			

Hospitalization -	Nephritis	& Co.	PS	Merck & Co.	ORAL
25 MG PER					
Initial or Prolonged	Oedema				
DAY ORAL					
Disability	Oedema Peripheral				
Required					
Intervention to					
Prevent Permanent					
Impairment/Damage					

Date:06/13/03ISR Number: 4129529-0Report Type:Expedited (15-DaCompany Report #2003-06-0256
Age:65 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Allergic Granulomatous
Hospitalization -	Angiitis
Initial or Prolonged	Antinuclear Antibody
Other	Positive
	Back Pain
	Blood Culture Positive
	Confusional State
	Eosinophilia
	Haemodynamic Instability
	Intervertebral Disc

		Disorder Quadriplegia Respiratory Distress Sciatica	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Staphylococcal Infection Systemic Inflammatory Response Syndrome Tenosynovitis	Foreign Health Professional Other	Celestene (Betametasone) Tablets "Like Celestone Syrup"	PS		ORAL
1.5-0.5MG QD*							
ORAL							
				Cortancyl	SS		ORAL
60 MG QD ORAL							
				Solu-Medrol Injectable Solution	SS		
INTRAVENOUS							
							BOLUS
1 BOLUS							
INTRAVENOUS							
				Vioxx (Rofecoxib) Tablets	SS		ORAL
1 QD ORAL							
				Bricanyl	C		
				Atrovent	C		
				Seretide (Salmeterol Xinafoate/Fluticason e Propionate)	C		
				Hyperium (Rilmenidine)	C		
				Glimepiride	C		

Date:06/13/03ISR Number: 4129692-1Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Renal Failure Acute Renal Tubular Necrosis	Other	Zometa (Zoledronate) Solution For Injection	PS		
INTRAVENOUS	UNK, UNK,						
INTRAVENOUS							
				Vioxx (Rofecoxib)	SS		
UNKNOWN	25 MG, UNK,						

UNK

E7070 (Goal)
(Paraffin Soft) SS

INTRAVENOUS 1449 MG, OT,

INTRAVENOUS

Date:06/13/03ISR Number: 4130018-8Report Type:Expedited (15-DaCompany Report #001-0981-M0201152
Age: Gender:Male I/FU:F

Outcome	PT
Disability	Accident
Other	Anxiety
	Arthralgia
	Dialysis
	Drug Interaction
	Erythema Multiforme
	Haemorrhage
	Iatrogenic Injury
	Injury
	Kidney Transplant
	Rejection
	Myalgia
	Organ Failure
	Pain
	Rash
	Renal Failure
	Restless Legs Syndrome

Skin Chapped

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
OPHTHALMIC	20 MG DAILY,	Consumer Health	Lipitor (Atorvastatin)	PS		
ORAL		Professional				
10 MG DAILY			Norvasc (Amlodipine)	SS		
			Celecoxib (Celecoxib)	SS		
			Clonazepam (Clonazepam)	SS		
			Cyclobenzaprine (Cyclobenzaprine)	SS		
			Becosym Forte (Pyridoxine Hydrochloride, Thaimine Hydrochloride,	SS		
			Rofecoxib (Rofecoxib)	SS		
			Paricalcitol (Paricalcitol)	SS		
INTRAVENOUS	INTRAVENOUS		All Other Therapeutic Products	SS		
			Insulin Human Injectin, Isophane (Insulin Human Injection, Isophane)	SS		
SUBCUTANEOUS	SUBCUTANEOUS		Azathioprine (Azathioprine)	SS		
			Prednisone (Prednisone)	SS		
			Furosemide (Furosemide)	SS		
			Ciclosporin (Ciclosporin)	SS		
			Clonidine (Clonidine)	SS		
			Metoprolol Succinate (Metoprolol Succinate)	SS		

Bisoprolol Fumarate (Bisoprolol Fumarate)	SS
Insulin (Insulin)	C
Erythropoietin (Erythropoietin)	C
Iron Dextran (Iron Dextran)	C

Date:06/16/03ISR Number: 4128909-7Report Type:Expedited (15-DaCompany Report #WAES 0211USA01277
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Other	Balance Disorder
	Cough
	Deafness Unilateral
	Dizziness
	Dysphonia
	Sensation Of Foreign Body

	Throat Irritation Tinnitus					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Professional	Vioxx	SS		ORAL
			Synthroid	C		
			Trazodone	C		
			Prevacid	C		
			Rhinocort	C		

Date:06/16/03ISR Number: 4128913-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/16/03ISR Number: 4128915-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA01133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/16/03ISR Number: 4128919-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00451
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Renal Cyst	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Renal Tubular Necrosis	Professional	Zometa	SS		
			[Therapy Unspecified]	SS		
INTRAVENOUS	177 DAY					

Date:06/16/03ISR Number: 4128920-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA01064
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lower Gastrointestinal Haemorrhage		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:06/16/03ISR Number: 4129189-9Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00081
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Urea		Diclofenac	C		ORAL		
	Circulatory Collapse							
	Dizziness							
	Duodenal Ulcer							
	Dyspnoea							
	Faeces Discoloured							
	Haemoglobin							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/03ISR Number: 4129194-2Report Type:Expedited (15-DaCompany Report #WAES 0306CAN00056
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Rupture	Health	Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
		Professional	Hyzaar	C		ORAL	1201	DAY
			Oxycodone Hydrochloride	C			147	DAY
			Acetaminophen	C			147	DAY

Date:06/16/03ISR Number: 4129391-6Report Type:Direct Company Report #CTU 195801
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Feeling Abnormal		Vioxx	PS			25MG	

Date:06/16/03ISR Number: 4130853-6Report Type:Expedited (15-DaCompany Report #PHEH2003US03458
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioplasty	Health	Gleevec (Imatinib)					
	Anorexia	Professional	Capsule	PS		ORAL	400 MG, QD,	
	Asthenia						ORAL	
	Chest Pain		Vioxx (Rofecoxib)	SS				
	Dyspepsia		Glucotrol (Glipizide)	C				
	Gastrooesophageal Reflux Disease		Verapamil	C				
	Insomnia		Atacand (Candesartan Cilexetil)	C				
	Kidney Infection		Premarin (Estrogens Conjugated)	C				
	Muscle Spasms		Toprol Xl (Metoprolol					
	Nausea							
	Oedema							
	Renal Pain							

	Vomiting	Succinate)	C
	Weight Increased	Moexipril	C
		Atenolol	C

Date:06/17/03ISR Number: 4129779-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Death	Anxiety
Hospitalization -	Blood Chloride
Initial or Prolonged	Blood Glucose
	Blood Potassium
	Blood Sodium
	Blood Urea
	Cardio-Respiratory Arrest
	Deep Vein Thrombosis
	Dilatation Atrial
	Dilatation Ventricular
	Haematocrit
	Haemoglobin
	Heart Rate Increased
	Hypertension
	Hypotension
	Muscle Spasms
	Myalgia
	Myocardial Infarction

		Nausea Pain Pco2	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Platelet Count	Health	Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Pulmonary Embolism	Professional	Desogen	SS		
		Pulmonary Hypertension		Aleve	C		
		Respiratory Failure		Ultram	C		
		Sensation Of Heaviness		[Therapy			
		Supraventricular		Unspecified]	C		
		Tachycardia		Vicodin Tablets	C		
		Tachycardia		Toradol	C		
INTRAMUSCULAR							
		Tricuspid Valve		Skelaxin	C		
		Incompetence					
		Troponin I					
		Vomiting					
		White Blood Cell Count					

Date:06/17/03ISR Number: 4129795-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01077
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged		Professional	Clexane (Enoxaparin			
Other			Sodium)	C		ORAL
5 DAY						
			Clexane (Enoxaparin			
			Sodium)	C		ORAL
			Cataflam (Diclofenac			
			Sodium)	C		
PARENTERAL	5 DAY					

Date:06/17/03ISR Number: 4129832-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA01538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction	Professional				

Other

Date:06/17/03ISR Number: 4129835-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA01833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/03ISR Number: 4130211-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA00708
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Amylase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Premarin	C				
			Detrol	C				
			Claritin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/03ISR Number: 4130632-XReport Type:Direct Company Report #CTU 196032
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombocytopenia		Vioxx (Rofecoxib)	PS				

Date:06/17/03ISR Number: 4130655-0Report Type:Direct Company Report #CTU 196047
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Escherichia Infection		Vioxx	PS		ORAL	50 MG QD ORAL	
Initial or Prolonged	Renal Failure							
	Urosepsis							

Date:06/17/03ISR Number: 4134026-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Septal Defect	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Blood Potassium	Health	Cenestin	C				
Disability	Carotid Artery Stenosis	Professional	Paxil	C				
Other	Cerebral Artery		Premarin	C				
	Thrombosis		Restoril	C				
	Cerebrovascular Accident		Tricor	C				
	Epistaxis		Vicodin Es Tablets	C				
	Fatigue		Vistaril	C				
	Flushing		Zantac	C				
	Haematocrit		Aspirin	C				
	Haemoglobin		Estrogens (Unspecified)	C				
	Joint Contracture		Vitamins (Unspecified)	C				
	Mitral Valve Incompetence							
	Muscle Atrophy							
	Pain In Extremity							
	Phlebothrombosis							
	Platelet Count							
	Radius Fracture							
	Swelling							
	Tricuspid Valve							

Incompetence
Urticaria

Date:06/18/03ISR Number: 4131107-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA01432
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/18/03ISR Number: 4131113-XReport Type:Expedited (15-DaCompany Report #WAES 0305USA00796
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/03ISR Number: 4131114-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA01080
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C				
Other								

Date:06/18/03ISR Number: 4131115-3Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00147
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Shock Haemorrhagic	Professional	Aspirin	C		ORAL		
Hospitalization -			Prednisolone	C		ORAL		
Initial or Prolonged			Torsemide	C		ORAL		

Date:06/18/03ISR Number: 4131131-1Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00017
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Delirium	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Renal Failure Acute	Professional	Morphine Sulfate	C		ORAL	8	DAY
			Dipyrone	C		ORAL	8	DAY
			Sertraline Hydrochloride	C		ORAL	8	DAY
			Hydrochlorothiazide And Triamterene	C		ORAL	8	DAY
			Bisoprolol Fumarate	C		ORAL	8	DAY

Date:06/18/03ISR Number: 4131135-9Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00044
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/18/03ISR Number: 4131136-0Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00067
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	795 DAY	
	Cellulitis		Aspirin	C		ORAL		
	Cerebrovascular Disorder		Rabeprazole Sodium	C		ORAL		
	Haematoma		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		

Date:06/18/03ISR Number: 4131137-2Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00071
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonitis		Vioxx	PS	Merck & Co., Inc	ORAL	23 DAY	
	Surgery		Vioxx	SS		ORAL		
			Vioxx	SS		ORAL	3 DAY	
			Acetaminophen And					

			Codeine Phosphate	C		ORAL
			Enoxaparin Sodium	C		ORAL
			Ferrous Sulfate	C		ORAL
			Folic Acid	C		ORAL
			Furosemide	C		ORAL

Date:06/18/03ISR Number: 4131138-4Report Type:Expedited (15-DaCompany Report #WAES 0208FRA00023
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 13 DAY	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Acetaminophen And Belladonna And Caffeine And Opium	C		ORAL

Date:06/18/03ISR Number: 4131144-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA01263
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Renal Failure		Vioxx	SS		ORAL
	Weight Decreased		[Composition Unspecified]	C		
			Lipitor	C		
			Aspirin	C		
			Diazide	C		
			Magnesia [Milk Of]	C		

Date:06/18/03ISR Number: 4131145-1Report Type:Expedited (15-DaCompany Report #WAES 0306NOR00008
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 18 MON	International Normalised		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Ratio		Digitoxin	C		ORAL
	Transient Ischaemic		Warfarin Sodium	C		ORAL
	Attack		Verapamil Hydrochloride	C		ORAL

			Lisinopril	C		ORAL
			Insulin	C		
SUBCUTANEOUS						

Date:06/18/03ISR Number: 4131151-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA01692
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Calcium Metabolism		Vioxx	SS		ORAL
	Disorder		Vioxx	SS		ORAL
	Impaired Healing		Vioxx	SS		ORAL
			Coumadin	C		
			Prinivil	C		ORAL
			Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/03ISR Number: 4131154-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA01502
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Glomerulonephritis Nephrolithiasis Urinary Tract Infection		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:06/18/03ISR Number: 4132174-4Report Type:Expedited (15-DaCompany Report #200315803GDDC
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haemoglobin Decreased Oesophagitis	Foreign Other	Heparin-Fraction, Sodium Salt (Clexane)	PS		
SUBCUTANEOUS 75 MG	SC 2 DAY					
			Rofecoxib (Vioxx)	SS		ORAL
25 MG PO 4 MON						
			Acetylsalicylic Acid (Aspirin)	SS		ORAL
75 MG PO						
			Prednisolone	C		
			Methotrexate	C		
			Folic Acid	C		
			Isosorbide	C		
			Nicorandil	C		
			Amlodipine	C		
			Atenolol	C		
			Nizatidine	C		

Date:06/19/03ISR Number: 4131473-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02563
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable Blood Pressure Increased Cardiac Stress Test Abnormal Chest Discomfort Chest Pain Coronary Artery

Atherosclerosis
Coronary Artery
Reocclusion
Duodenitis
Eczema
Embolism
Emphysema
Facial Palsy
Folliculitis
Gastritis
Headache
Hiatus Hernia
Loss Of Consciousness
Myocardial Infarction
Palpitations
Rash Erythematous
Respiratory Rate
Increased
Sleep Apnoea Syndrome
Syncope
Total Lung Capacity
Decreased

		Ulcer Ventilation/Perfusion Scan Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Altace	C		ORAL
				Plavix	C		ORAL
				Aspirin	C		ORAL
				Nitroglycerin	C		
TOPICAL							
				Prevacid	C		ORAL
				Zocor	C		ORAL

Date:06/19/03ISR Number: 4131476-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
243 DAY							
Hospitalization - Initial or Prolonged		Aortic Atherosclerosis		Lasix (Furosemide)	C		
		Arrhythmia		Tylenol Extra Strength	C		
		Arthritis		Centrum	C		
		Atherosclerosis					
		Blood Pressure Increased					
		Bundle Branch Block Left					
		Cardiac Murmur					
		Cerebrovascular Accident					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Depressed Level Of Consciousness					
		Dilatation Atrial					
		Heart Rate Irregular					
		Hyperhidrosis					
		Myocardial Ischaemia					
		Platelet Count					

Date:06/19/03ISR Number: 4131861-1Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00033
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Life-Threatening	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
123 DAY						
Hospitalization -	Peritonitis	Professional	Aspirin	SS		ORAL
Initial or Prolonged			Omeprazole	C		ORAL
			Amlodipine Besylate	C		ORAL
			Ramipril	C		ORAL

Date:06/19/03ISR Number: 4131874-XReport Type:Expedited (15-DaCompany Report #WAES 0305DEU00141
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Autoimmune		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Initial or Prolonged	Thrombocytopenia		Cyproterone Acetate			
	Haematoma		And Ethinyl			
	Petechiae		Estradiol	C		ORAL
			Dipyrone	C		ORAL
1 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/03ISR Number: 4131876-3Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00010
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Congestive		Torsemide	C		ORAL	2	WK
Initial or Prolonged	Gamma-Glutamyltransferase		Aspirin	C		ORAL	7	YR
	Increased		Atorvastatin Calcium	C		ORAL	2	YR
			Latanoprost	C				
OPHTHALMIC							7	YR

Date:06/19/03ISR Number: 4131880-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00111
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Other	Swollen Tongue		Prinivil	C		ORAL		
	Throat Tightness		Atenolol	C		ORAL		
			Welchol	C				
			Lasix (Furosemide)	C		ORAL		

Date:06/19/03ISR Number: 4131881-7Report Type:Expedited (15-DaCompany Report #WAES 0306AUS00063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Psychotic Disorder		Probenecid	C				
			Warfarin	C				

Date:06/19/03ISR Number: 4131892-1Report Type:Expedited (15-DaCompany Report #WAES 0306NZL00010
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy Diarrhoea Glossodynia Lung Consolidation Palpitations Pharyngitis Streptococcal Renal Failure Acute Respiratory Disorder Septic Shock Thrombocytopenia Toxic Epidermal Necrolysis Vomiting	Health Professional	Vioxx Aspirin	PS SS	Merck & Co., Inc	ORAL		

Date:06/19/03ISR Number: 4131895-7Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00087
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	First Degree Bundle Branch Block Right Insomnia Loss Of Consciousness		Ibuprofen Acetaminophen And Codeine Phosphate	C C		ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/19/03ISR Number: 4132467-0Report Type:Direct Company Report #CTU 196217
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue		Vioxx	PS		ORAL	25MG PO	4 DAY
	Muscular Weakness							
	Oedema Peripheral							
	Weight Increased							

Date:06/19/03ISR Number: 4133051-5Report Type:Expedited (15-DaCompany Report #A0402402A
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Health	Remifemin Tablet					
	Eye Swelling	Professional	(Cimicifuga)	PS		ORAL	TWICE PER	
	Face Oedema						DAY/ ORAL	
	Feeling Abnormal		Sertraline					
	Food Allergy		Hydrochloride					
	Glossodynia		(Sertraline					
	Oedema Mouth		Hydrochloride)	SS				
	Oral Pain		Ascorbic Acid					
	Oropharyngeal Swelling		(Ascorbic Acid)	SS		ORAL	ORAL	
	Tongue Oedema		Multivitamin					
			(Multivitamin)	SS		ORAL	ORAL	
			Rofecoxib					
			(Rofecoxib)	SS		ORAL	ORAL	

Date:06/19/03ISR Number: 4188922-0Report Type:Periodic Company Report #325146
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Literature	Klonopin					
		Health	(Clonazepam)	PS		ORAL	ORAL	

	Professional	Elavil (Amitriptyline Hydrochloride)	SS	ORAL
ORAL				
		Adderall (Amphetamine Aspartate/Amphetamine Sulfated/Dextroamphe	SS	ORAL
ORAL				
		Vioxx (Rofecoxib)	SS	ORAL
ORAL				
		Topamax(Topiramate)	SS	ORAL
ORAL				
		Geodon (Ziprasidone Hydrochloride)	SS	ORAL
ORAL				
		Remeron (Mirtazapine)	SS	ORAL
ORAL				
		Methadone (Methadone Hydrochloride)	SS	ORAL
ORAL				
		Neurontin (Gabapentin)	SS	ORAL
ORAL				

Date:06/20/03ISR Number: 4132338-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time
	Acute Respiratory

Distress Syndrome
Adrenal Insufficiency
Aneurysm Ruptured
Angiopathy
Aspiration
Asthenia
Binocular Eye Movement
Disorder
Blood Glucose
Blood Potassium
Candidiasis
Cardiomegaly
Cataract
Cerebral Atrophy
Cerebral Hygroma
Cerebral Infarction
Cerebrovascular Accident
Coma
Deep Vein Thrombosis
Diplopia
Dizziness
Erythema
Eye Pain
Faecal Occult Blood
Positive
Fatigue
Foot Deformity
Gastritis
Gaze Palsy
Glaucoma
Haemoglobin
Haemorrhage Intracranial
Head Injury
Headache
Herpes Simplex
Hyperhidrosis
Hypertension
Hypoventilation
International Normalised
Ratio Increased
Labile Blood Pressure
Laboratory Test Abnormal
Loss Of Consciousness
Lung Disorder
Lung Infiltration
Memory Impairment
Microcytic Anaemia
Muscle Rigidity

Myoglobin Blood
Myopathy
Neck Pain
Neuropathy Peripheral
Pain
Pain In Extremity
Pericardial Effusion
Pericarditis
Peripheral Coldness
Peroneal Nerve Palsy
Pneumonia
Prothrombin Time
Pulmonary Fibrosis
Pupillary Disorder

		Pupils Unequal					
		Pyrexia					
		Rales	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
		Respiratory Distress	Professional	Vioxx	SS		ORAL
6	MON						
		Respiratory Rate		Prednisone	C		
		Increased		Hydrocodone	C		
		Sinus Disorder					
		Sinusitis					
		Subarachnoid Haemorrhage					
		Urinary Tract Infection					
		Varicose Vein					
		Vasospasm					
		Vision Blurred					
		Visual Acuity Reduced					
		White Blood Cell Count					

Date:06/20/03ISR Number: 4132340-8Report Type:Expedited (15-DaCompany Report #WAES 0306BEL00006
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Melaena		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/20/03ISR Number: 4132343-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Atrial Fibrillation	Professional	Aggrenox	C		
Initial or Prolonged		Coronary Artery Disease		Digoxin	C		
		Dehydration		Mag-Ox 400 Tablets	C		
		Dementia		Reglan	C		
		Duodenal Ulcer		Metoprolol	C		
		Haemorrhage		Risperdal	C		
		Erosive Oesophagitis		Vitamins			
		Gastrointestinal		(Unspecified)	C		
		Haemorrhage		Lasix (Furosemide)	C		
		Hypovolaemia		Detrol	C		

	Malnutrition	Megace	C
	Oesophagitis	Ben-Gay	C
	Renal Failure	Tylenol	C
	Urinary Tract Infection		

Date:06/20/03ISR Number: 4132356-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Back Disorder
	Cardiac Failure
	Congestive
	Colonic Polyp
	Conjunctival Haemorrhage
	Coronary Artery Atherosclerosis
	Coronary Artery Disease

		Coronary Artery Stenosis					
		Coronary Artery Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dermatitis Contact	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum Intestinal	Professional	Avandia	C		
		Ecchymosis		Blephamide Ointment	C		
		Erectile Dysfunction		Viagra	C		
		Eye Infection		Acetaminophen And			
		Eye Injury		Hydrocodone			
		Eye Pruritus		Bitartrate	C		
		Haemorrhoids		Duratuss	C		
		Rectal Haemorrhage		Wellbutrin	C		
		Ventricular Dysfunction					
		Vision Blurred					
		Vitreous Floaters					

Date:06/20/03ISR Number: 4132358-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA02256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Renal Failure Acute		Accupril	C		

Date:06/20/03ISR Number: 4132406-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA02219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged	Nausea					
	Renal Failure Acute					
	Vomiting					

Date:06/20/03ISR Number: 4132678-4Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00207
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Anxiety

Initial or Prolonged	Arthralgia
	Asthenia
	Back Pain
	Brachial Plexus Lesion
	Compartment Syndrome
	Confusional State
	Dyspnoea
	Feeling Abnormal
	Fibromyalgia
	Hyponatraemia
	Intervertebral Disc
	Protrusion
	Loss Of Consciousness
	Mobility Decreased
	Muscle Atrophy
	Neck Pain
	Pain
	Pain In Extremity
	Pneumonia Aspiration
	Renal Disorder
	Rhabdomyolysis

	Thirst Vasodilatation Vomiting	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Vitamins (Unspecified)	SS				
			[Therapy Unspecified]	SS				

Date:06/20/03ISR Number: 4132683-8Report Type:Expedited (15-DaCompany Report #WAES 0306NOR00010
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 17 DAY Initial or Prolonged	Urticaria		Vioxx	PS	Merck & Co., Inc			
			Estradiol And Norethindrone Acetate	C				

Date:06/20/03ISR Number: 4132690-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA02103
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/03ISR Number: 4132691-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA02099
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/03ISR Number: 4132694-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/03ISR Number: 4132695-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA02101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pulmonary Oedema Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/03ISR Number: 4132979-XReport Type:Direct Company Report #CTU 196239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute		Vioxx 25 Mg	PS		ORAL	25 MG QD	Initial or Prolonged
			Asprin	C				
			Lipitor	C				

				Ambien	C		

Date:06/20/03ISR Number: 4136539-6Report Type:Expedited (15-DaCompany Report #2003-05-1145
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health Professional Company Representative	Peg-Intron (Peginterferon Alfa-2b) Injectable Powder	PS		SUBCUTANEOUS	SUBCUTANEOUS	
Other	Dehydration							
	Haemoglobin Decreased							
	Headache							
	Migraine		Rebetol (Ribavirin)	SS		ORAL	ORAL	
	Nausea		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Neutrophil Count		Depakote	C				
	Oedema		Advil	C				
	Pain		Premarin	C				
	Renal Failure Acute							
	Viral Infection							
	Vomiting							
	White Blood Cell Count Decreased							

Date:06/23/03ISR Number: 4133077-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA00958
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Tachycardia		Synthroid	C				
			Aspirin	C				

Date:06/23/03ISR Number: 4133079-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA01987
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Disability	Renal Disorder		Norvasc	C		
	Renal Impairment					
	Urinary Retention					

Date:06/23/03ISR Number: 4133080-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02245
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blood Pressure Increased		Prinzide	C		ORAL
Initial or Prolonged	Diarrhoea		Nitrostat	C		
	Dyspepsia		Toprol Xl Tablets	C		
			Zocor	C		ORAL
			Metformin	C		

Date:06/23/03ISR Number: 4133081-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA00061
Age:88 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
	Gastrointestinal		Aspirin	C				
	Haemorrhage		Norvasc	C		ORAL		
	Haematemesis		Exelon	C		ORAL		
	Melaena		Ambien	C		ORAL		
			Paxil	C		ORAL		

Date:06/23/03ISR Number: 4133377-5Report Type:Expedited (15-DaCompany Report #WAES 0302AUS00039
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	C-Reactive Protein							
	Coronary Artery Occlusion							
	Coronary Artery							
	Thrombosis							
	Ejection Fraction							
	Decreased							
	Myocardial Infarction							

Date:06/23/03ISR Number: 4134560-5Report Type:Expedited (15-DaCompany Report #200312261US
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Leflunomide (Arava)	PS				
							100 MG QD	3 DAY
Initial or Prolonged	Chemical Injury	Health	Leflunomide (Arava)	SS				
							20 MG QD	2 MON
Other	Fall	Professional	Rofecoxib (Vioxx)	SS				
							50MG	
	Hepatic Cyst		Methotrexate	C				
	Hepatitis		Celecoxib (Celebrex)	C				
	Hepatocellular Damage		Paracetamol					
	Hypertension		(Tylenol)	C				
	Lymphocyte Count		Antibiotics Nos	C				
	Decreased		Sulfasalazine	C				

	Monocyte Count Increased	Clavulanate Potassium, Amoxicillin Trihydrate (Augmentin)	C
	Neutrophil Count Decreased	Prednisone	C
	Platelet Count Increased	Docusate Sodium (Colace)	C
	Renal Cyst	Gabapentin (Neurontin)	C
	Serum Ferritin Increased	Guaifenesin	C
	White Blood Cell Count Increased	Hydrocodone	C
		Ranitidine	C

Date:06/23/03ISR Number: 4134566-6Report Type:Expedited (15-DaCompany Report #2003164730AT
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Nausea Syncope	Foreign Health Professional	Celebrex(Celecoxib) Capsule	PS		ORAL	200 MG, SINGLE, ORAL	
		Other	Vioxx (Rofecoxib)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/03ISR Number: 4134161-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00564
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		163 DAY
Hospitalization - Initial or Prolonged	Bundle Branch Block Left	Professional	Lasix (Furosemide)	C				
	Candidiasis		K-Dur	C				
	Cardiac Failure		Glucophage	C		ORAL		
	Congestive		Lanoxin	C				
	Cardio-Respiratory Arrest		Maxzide	C				
	Cardiomegaly		Darvocet-N	C				
	Depression		Capoten	C				
	Dyspepsia		Reglan	C				
	Headache		Zoloft	C				
	Hypokalaemia		Zantac	C				
	Hypotension		Xanax	C				
	Hypoxic Encephalopathy		Diabeta	C				
	Pneumonia							
	Pruritus							
	Rash Erythematous							
	Respiratory Distress							
	Sinusitis							
	Weight Increased							
	Wheelchair User							

Date:06/24/03ISR Number: 4134166-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02274
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram Qt Prolonged	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/03ISR Number: 4134167-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA02299
Age:10 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Accidental Exposure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Hospitalization -	Gastrointestinal Disorder	Professional						

Initial or Prolonged	Metabolic Acidosis Overdose						

Date:06/24/03ISR Number: 4134397-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA02198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Disability	Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/03ISR Number: 4134403-XReport Type:Expedited (15-DaCompany Report #WAES 0302FRA00070
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1 DAY Initial or Prolonged	Angioneurotic Oedema Drug Hypersensitivity Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/03ISR Number: 4134407-7Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00091
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Dysaesthesia		Morphine	C		ORAL	4	DAY
	Hypertension		Morphine Sulfate	C		ORAL	4	DAY
	Palpitations		Dipyrone	C		ORAL	4	DAY

Date:06/24/03ISR Number: 4134661-1Report Type:Direct Company Report #CTU 196515
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg	PS		ORAL	ONE DAILY PO	[MONTHS]
			Flexeril	C				

Date:06/24/03ISR Number: 4134766-5Report Type:Direct Company Report #CTU 196540
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS			1 A DAY	3 WK
Initial or Prolonged	Diarrhoea							
	Faeces Discoloured							
	Gastrointestinal Ulcer Haemorrhage							
	Gastrointestinal Ulcer Perforation							

Date:06/24/03ISR Number: 4135290-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Rigidity
	Activated Partial Thromboplastin Time
	Acute Respiratory Distress Syndrome
	Adrenal Insufficiency
	Aneurysm Ruptured
	Aspiration
	Blood Glucose
	Blood Potassium
	Blood Pressure Increased
	Bunion
	Cardiomegaly
	Cataract
	Cerebral Atrophy
	Cerebral Infarction
	Coma
	Deep Vein Thrombosis
	Electrocardiogram Abnormal
	Erythema
	Gastritis
	Haemoglobin
	Herpes Simplex
	Hyperhidrosis
	Hyperkeratosis

		Hypertension International Normalised Ratio Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ivth Nerve Paresis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE							
		Microcytic Anaemia	Health	Hydrocodone	C		
		Myoglobin Blood	Professional	Prednisone	C		
		Myopathy					
		Neuropathy Peripheral					
		Pericardial Effusion					
		Pericarditis					
		Peroneal Nerve Palsy					
		Pneumonia					
		Prothrombin Time					
		Pupils Unequal					
		Sinusitis					
		Subarachnoid Haemorrhage					
		Subdural Hygroma					
		Toxicologic Test Abnormal					
		Urinary Tract Infection					
		Vasospasm					
		White Blood Cell Count					

Date:06/24/03ISR Number: 4135818-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia	Consumer	Tab Vioxx 12.5mg	PS		ORAL
12.MG/DAILY/P							
Hospitalization - O		Asthenia	Health				
Initial or Prolonged		Atrial Fibrillation	Professional	Aggrenox	C		
		Coronary Artery Disease		Ben-Gay	C		
		Decreased Appetite		Detrol	C		
		Dehydration		Lasix (Furosemide)	C		
		Dementia		Mag-Ox 400 Tablets	C		
		Duodenal Ulcer		Magace	C		
		Faeces Discoloured		Reglan	C		
		Gastrointestinal		Risperdal	C		
		Haemorrhage		Tylenol	C		
		General Nutrition		Digoxin	C		
		Disorder		Metoprolol	C		
		Hypovolaemia		Vitamins			

	Oesophagitis		(Unspecified)	C		
	Renal Failure					
	Urinary Tract Infection					

Date:06/25/03ISR Number: 4135316-XReport Type:Expedited (15-DaCompany Report #WAES 0304FRA00051
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 11 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Confusional State		Furosemide And			
	Hallucination		Spironolactone	C		ORAL
	Liver Function Test Abnormal					
	Renal Failure					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/03ISR Number: 4135320-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02290
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS		ORAL		
	Wheezing		Vioxx	SS		ORAL		
			Albuterol	C				
			Synthroid	C				
			Premarin	C				
			Flovent	C				
			Serevent	C				
			Verapamil	C				
			Prilosec	C				
			Colestid	C				

Date:06/25/03ISR Number: 4135699-0Report Type:Direct Company Report #CTU 196640
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Rofecoxib	PS			25MG QD	
Initial or Prolonged	Ascites							
Required	Right Ventricular Failure							
Intervention to	Weight Increased							
Prevent Permanent								
Impairment/Damage								

Date:06/25/03ISR Number: 4135780-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Atherosclerosis	Health					MG/DAILY/PO	
Disability	Back Pain	Professional	Avandia	C				
	Cardiac Failure		Blephamide Ointment	C				
	Congestive		Duratuss	C				
	Cardiac Murmur		Viagra	C				

	Chest X-Ray Abnormal	Wellbutrin	C
	Colonic Polyp	Acetaminophen (+)	
	Conjunctival Haemorrhage	Hydrocodone Bi	C
	Coronary Artery Atherosclerosis		
	Coronary Artery Stenosis		
	Dilatation Ventricular		
	Diverticulum		
	Ecchymosis		
	Ejection Fraction Decreased		
	Eye Infection		
	Eye Injury		
	Feeling Abnormal		
	Haemorrhoids		
	Heart Sounds Abnormal		
	Hypersensitivity		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Stress		
	Ventricular Dysfunction		
	Ventricular Hypokinesia		
	Vitreous Floaters		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/03ISR Number: 4135952-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01320
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Consumer	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/	
Hospitalization -	Arthritis	Health					PO	
Initial or Prolonged	Asthenia	Professional	Desogen	SS				
	Atrial Hypertrophy	Company	Aleve	C				
	Blood Bicarbonate	Representative	Skelaxin	C				
	Blood Chloride		Toradol	C				
	Blood Creatinine		Ultram	C				
	Blood Glucose		Vicodin	C				
	Blood Ph Decreased							
	Blood Potassium							
	Blood Sodium							
	Blood Urea							
	Cardio-Respiratory Arrest							
	Deep Vein Thrombosis							
	Drug Ineffective							
	Ejection Fraction Decreased							
	Haematocrit							
	Haemoglobin							
	Heart Rate Decreased							
	Hypertension							
	Hypotension							
	Loss Of Consciousness							
	Muscle Rigidity							
	Muscle Tightness							
	Myocardial Infarction							
	Myositis							
	Nausea							
	Oxygen Saturation Decreased							
	Pco2							
	Peripheral Coldness							
	Platelet Count							
	Po2							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Pupil Fixed							
	Respiratory Failure							
	Shock							
	Sinus Tachycardia							

Supraventricular
Tachycardia
Tricuspid Valve
Incompetence
Troponin I
Ventricular Hypertrophy
Vomiting
White Blood Cell Count

Date:06/25/03ISR Number: 4175328-3Report Type:Periodic Company Report #SU-2003-000725
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder	Consumer	Welchol	PS		ORAL	1875 MG BID	
	Rash						PO	
			Vioxx	SS		ORAL	MG PO	
			Avandia	C				

Glucophage "Merck"	C
Aciphex	C
Adavir	C
Albuterol	C
Asa	C

Date:06/26/03ISR Number: 4135777-6Report Type:Expedited (15-DaCompany Report #WAES 0208DEU00158
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	37 DAY	
Hospitalization - Initial or Prolonged	Drug Interaction	Professional	Flutamide	SS		ORAL		
	Feeling Abnormal		Methotrexate	SS		ORAL		
	Herpes Zoster		Prednisolone	SS		ORAL		
	Pancytopenia		Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL	31 DAY	
	Rash Pruritic							
	Rash Pustular							
	Skin Infection							
	Vomiting		Goserelin Acetate	C		SUBCUTANEOUS	1 DAY	

Date:06/26/03ISR Number: 4135811-3Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00084
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Autoimmune		Tetrazepam	C		ORAL		

Date:06/26/03ISR Number: 4135956-8Report Type:Direct Company Report #CTU 196662
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematochezia		Toradol	PS			TWICE DAILY	
	Malaise		Vioxx	SS			TWICE DAILY	

Medication Error
Memory Impairment
Pain
Protein Urine

Date:06/26/03ISR Number: 4136019-8Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00020
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
			Tramadol Hydrochloride	SS		ORAL		6 DAY
			Tizanidine Hydrochloride	SS		ORAL		6 DAY

Date:06/26/03ISR Number: 4136029-0Report Type:Expedited (15-DaCompany Report #WAES 0306CAN00073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/03ISR Number: 4136038-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02605
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Paxil	C				
	Gastroenteritis							
	Haematochezia							
	Hypertension							
	Weight Increased							

Date:06/26/03ISR Number: 4136039-3Report Type:Expedited (15-DaCompany Report #WAES 0306NOR00008
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
			Digitoxin	C		ORAL		
			Warfarin Sodium	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		
			Lisinopril	C		ORAL		
			Insulin	C		SUBCUTANEOUS		

Date:06/26/03ISR Number: 4136041-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01232
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Cardiac Failure		Lipitor	C		ORAL		
	Congestive Gastrointestinal Haemorrhage		Altace	C		ORAL		
			Labetalol Hydrochloride	C		ORAL		
	Oedema		Dyazide	C				
	Pulmonary Oedema		Plavix	C		ORAL		

Date:06/27/03ISR Number: 4136537-2Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00084
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Autoimmune		Tetrazepam	C		ORAL		
	General Physical Health Deterioration							

Date:06/27/03ISR Number: 4136540-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA02286
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Synthroid	C				
	Drug Ineffective							
	Hair Colour Changes							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/03ISR Number: 4136541-4Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00180
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Ranitidine	C		ORAL		
			Albuterol	C				
RESPIRATORY								
(INHALATION)								

Date:06/27/03ISR Number: 4136542-6Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00178
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Haemorrhage		Levothyroxine Sodium	C		ORAL		
	Gastrooesophageal Reflux		Metoprolol Tartrate	C		ORAL		
	Disease		Ranitidine	C		ORAL		

Date:06/27/03ISR Number: 4136544-XReport Type:Expedited (15-DaCompany Report #WAES 0211FIN00001
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Autoimmune Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Blood Immunoglobulin A	Professional						
	Increased							
	Hepatic Haematoma							
	Hepatitis Toxic							

Date:06/27/03ISR Number: 4136554-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA01875
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1 MON
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Carafate	C			
			Protonix	C			
			Calcium (Unspecified)	C			
			Vitamins (Unspecified)	C			

Date:06/27/03ISR Number: 4136565-7Report Type:Expedited (15-DaCompany Report #WAES 0302NOR00006
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1 MON	
	Melaena		Potassium Chloride	SS		ORAL		YR
	Ulcer Haemorrhage		Citalopram Hydrobromide	SS		ORAL		YR
			Furosemide	C		ORAL		YR
			Zopiclone	C		ORAL		
			Acetaminophen	C		ORAL		YR

Date:06/27/03ISR Number: 4136593-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02586
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Urea Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Creatinine Renal Clearance Decreased		Flomax (Tamsulosin Hydrochloride)	C		
			Prevacid	C		
			Nitrostat	C		
			Effexor Xr	C		
			Ascorbic Acid	C		
			Cosopt	C		
OPHTHALMIC						
			Guiatuss	C		
			Tylenol	C		
			Methocarbamol	C		

Date:06/27/03ISR Number: 4136741-3Report Type:Expedited (15-DaCompany Report #WAES 0302BEL00013
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 20 DAY	Arteritis Obliterans		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 3 DAY	Extremity Necrosis		Vioxx	SS		ORAL
Disability 10 DAY	Foot Amputation		Vioxx	SS		ORAL
Other	Ischaemic Ulcer		Diclofenac Sodium	C		ORAL
	Leg Amputation					
	Oedema					
	Toe Amputation					

Date:06/27/03ISR Number: 4136742-5Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00072
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hyperthyroidism		Vioxx	PS	Merck & Co., Inc	ORAL
			Interferon Beta-1a	SS		
SUBCUTANEOUS 509 DAY						
			Acenocoumarol	C		ORAL

			Hydrocortisone	C		ORAL
			Fenofibrate	C		ORAL
			Omeprazole	C		ORAL
			Etidronate Disodium	C		ORAL
			Calcium Carbonate	C		ORAL
			Prazepam	C		ORAL
			Tramadol Hydrochloride	C		ORAL

Date:06/27/03ISR Number: 4136743-7Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00030
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Drug Interaction		Metformin Hydrochloride	SS		ORAL		
	Haemodialysis		Glyburide	SS		ORAL		
	Hypoglycaemia		Hydrochlorothiazide And Ramipril	SS		ORAL		
	Hypokinesia		Moxonidine	C				
	Hypovolaemic Shock		Lorazepam	C				
	Metabolic Acidosis		Aspirin	C				
	Renal Failure Acute		Isosorbide Mononitrate	C				
	Septic Shock							

			Nifedipine	C		

Date:06/27/03ISR Number: 4136744-9Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00007
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 7 DAY	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cataract		Metoprolol Succinate	SS		ORAL
	Extrasystoles					
	Hallucination, Visual					
	Hypertensive Crisis					
	Hyperventilation					
	Visual Acuity Reduced					

Date:06/27/03ISR Number: 4136745-0Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening 10 DAY	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Autoimmune		Valsartan	SS		ORAL
Initial or Prolonged SUBCUTANEOUS	Diabetes Mellitus		Insulin Human	C		
	Inadequate Control		Ibuprofen Lysine	C		ORAL
			Magnesium (Unspecified)	C		ORAL

Date:06/27/03ISR Number: 4136746-2Report Type:Expedited (15-DaCompany Report #WAES 0212GBR00039
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis Bullous		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Nausea		Sotalol Hydrochloride	SS		ORAL
Other	Renal Failure Acute		Aspirin	C		ORAL
	Vomiting		Amiloride Hydrochloride And			

			Furosemide	C		ORAL

Date:06/27/03ISR Number: 4136759-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA02502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/27/03ISR Number: 4136765-6Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00138
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rectal Haemorrhage		Sotalol			
	Rectal Ulcer		Hydrochloride	C		ORAL
			Calcitriol	C		ORAL
			Lactulose	C		ORAL
			Vitamins			
			(Unspecified)	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/03ISR Number: 4136767-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA02815
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Lung Disorder							
	Pulmonary Embolism							
Disability								

Date:06/27/03ISR Number: 4138820-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA00564
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis	Consumer	Vioxx	PS		ORAL	25	MG/DAILY/PO
Hospitalization - Initial or Prolonged	Asthenia	Health						
	Blood Creatine	Professional	Capoten	C				
	Phosphokinase Increased		Darvocet-N	C				
	Bundle Branch Block Left		Diabeta	C				
	Candidiasis		Glucophage	C				
	Cardiac Failure		K-Dur	C				
	Congestive		Lanoxin	C				
	Cardiac Fibrillation		Lasix (Furosemide)	C				
	Cardio-Respiratory Arrest		Maxzide	C				
	Cardiomegaly		Reglan	C				
	Cerebral Infarction		Xanax	C				
	Cerebrovascular Accident		Zantac	C				
	Coma		Zoloft	C				
	Depression							
	Diabetic Eye Disease							
	Diabetic Retinopathy							
	Dizziness							
	Dyspepsia							
	Dyspnoea							
	Encephalopathy							
	Erythema							
	Fluid Overload							
	Fungal Infection							
	Gastric Disorder							
	Haemorrhage Intracranial							
	Headache							

Hypokalaemia
Hypotension
Metabolic Acidosis
Myocardial Infarction
Pleural Effusion
Pneumonia
Pruritus
Respiratory Distress
Respiratory Rate
Increased
Sinus Tachycardia
Sinusitis
Spondylolisthesis
Acquired
Supraventricular
Tachycardia
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/03ISR Number: 4139340-2Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Other	Zometa(Zoledronate)					
	Blood Pressure Abnormal		Solution For					
	Femoral Bruit		Injection	PS			INTRAVENOUS	INTRAVENOUS
	Herpes Zoster		Vioxx(Rofecoxib)	SS			25 MG,	
	Hypertension		E7070					
	Nocturia		(Goal)(Paraffin					
	Oedema Peripheral		Soft)	SS			INTRAVENOUS	1449 MG, OT,
	Renal Cyst						INTRAVENOUS	
	Renal Failure Acute		Co-Diovan	C				
	Renal Tubular Necrosis		Verapamil					
	Urine Analysis Abnormal		(Verapamil)	C				
			Duragesic (Fentanyl)	C				
			Lipitor	C				
			Zoloft (Sertraline					
			Hydrochloride)	C				
			Percocet (Oxycodone					
			Hydrochloride)	C				
			Prevacid					
			(Lansoprazole)	C				
			Lasix	C				

Date:06/30/03ISR Number: 4137269-7Report Type:Expedited (15-DaCompany Report #WAES 0212FRA00083
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemolytic Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional	Telmisartan	SS		ORAL		
			Potassium Chloride	SS		ORAL		
			Furosemide	SS		ORAL		
			Saw Palmetto	SS		ORAL		
			Tamsulosin					
			Hydrochloride	SS		ORAL		

Date:06/30/03ISR Number: 4137271-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
	Atherosclerosis
	Back Disorder
	Blood Calcium Increased
	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Chest Pain
	Colonic Polyp
	Conjunctival Haemorrhage
	Contusion
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Stenosis
	Dermatitis Contact

		Dilatation Ventricular					
		Diverticulum Intestinal					
		Ecchymosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erectile Dysfunction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Eye Infection	Professional	Avandia	C		
		Eye Injury		Blephamide Ointment	C		
		Eye Irritation		Viagra	C		
		Eye Pruritus		Acetaminophen And			
		Gallop Rhythm Present		Hydrocodone			
		Glycosylated Haemoglobin		Bitartrate	C		
		Increased		Duratuss	C		
		Haemorrhoids		Wellbutrin	C		
		Hyperhidrosis					
		Injury					
		Musculoskeletal Pain					
		Nausea					
		Rectal Haemorrhage					
		Scar					
		Stress					
		Ventricular Dysfunction					
		Vision Blurred					

Date:06/30/03ISR Number: 4137279-XReport Type:Expedited (15-DaCompany Report #WAES 0305USA02861
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Haemorrhoidal Haemorrhage					
	Medication Error					

Date:06/30/03ISR Number: 4137280-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA02960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/30/03ISR Number: 4137283-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/03ISR Number: 4137285-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA02082
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased Blood Urea Increased		Vioxx Prinivil Demadex	PS C C	Merck & Co., Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/03ISR Number: 4137889-XReport Type:Expedited (15-DaCompany Report #WAES 0303NOR00007
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Increased		Vioxx	SS				

Date:06/30/03ISR Number: 4137892-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00952
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Disability	Tachycardia							
	Tremor							

Date:06/30/03ISR Number: 4137893-1Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00022
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Immunoglobulin A		Vioxx	PS	Merck & Co., Inc	ORAL		47 DAY
	Decreased							
	Haemolytic Anaemia							
	White Blood Cell Count							
	Decreased							

Date:06/30/03ISR Number: 4137894-3Report Type:Expedited (15-DaCompany Report #WAES 0303DEU00046
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural							
	Complication							

Date:06/30/03ISR Number: 4137907-9Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00085
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Enzyme Increased		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Hepatitis Cholestatic		Acetaminophen	SS		ORAL		8 DAY
	Pyrexia		Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C		ORAL		4 DAY

Date:06/30/03ISR Number: 4137910-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA02958
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Enterocolitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhagic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/03ISR Number: 4137911-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA03102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Difficulty In Walking Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/03ISR Number: 4139308-6Report Type:Expedited (15-DaCompany Report #2003165789DE
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Foreign Health Professional Other	Bextra (Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	

Date:06/30/03ISR Number: 4139386-4Report Type:Expedited (15-DaCompany Report #GB-JNJFOC-20030602208
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neutropenia	Foreign Health Professional	Zydol (Tramadol Hydrochloride)	PS				
Other			Vioxx (Rofecoxib)	SS			25 MG, 1 IN 1 DAY	
			Senna (Senna)	C				
			Citalopram (Citalopram)	C				
			Alendronate Sodium (Alendronate Sodium)	C				
			Tolterodine (Tolterodine)	C				

Date:06/30/03ISR Number: 4139626-1Report Type:Expedited (15-DaCompany Report #2003165787DE
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Foreign Health Professional Other	Bextra(Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	ORAL	

Date:07/01/03ISR Number: 4138605-8Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00084
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haemolytic Autoimmune Asthenia General Physical Health Deterioration	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Tetrazepam	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/03ISR Number: 4138928-2Report Type:Direct Company Report #CTU 196967
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DAY	Diverticulum		Vioxx 12.5mg Merck	PS	Merck	
Initial or Prolonged 1 DAY	Drug Effect Decreased		Celebrex 200mg	SS		

Date:07/01/03ISR Number: 4139098-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blood Pressure		Aggrenox	C		
Initial or Prolonged	Dehydration		Digoxin	C		
	Duodenal Ulcer		Mag-Ox 400 Tablets	C		
	Haemorrhage		Reglan	C		
	Erosive Oesophagitis		Metoprolol	C		
	Hypovolaemia		Risperdal	C		
	Malnutrition		Vitamins			
	Oesophagitis		(Unspecified)	C		
	Renal Failure		Lasix (Furosemide)	C		
	Urinary Tract Infection		Detrol	C		
	Weight Decreased		Megace	C		
			Ben-Gay	C		
			Tylenol	C		

Date:07/01/03ISR Number: 4139102-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA02888
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypotension		Vioxx	SS		ORAL
2 WK						
	Therapeutic Response		Vioxx	SS		ORAL
	Decreased		Bextra	C		
	Vertigo		Arava	C		ORAL
			Prilosec	C		
			Plaquenil	C		

			Plaquenil	C		
			Plaquenil	C		

Date:07/01/03ISR Number: 4139104-XReport Type:Expedited (15-DaCompany Report #WAES 0305NOR00054
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Urticaria		Vioxx	PS	Merck & Co., Inc	ORAL
			Estradiol And Norethindrone Acetate	C		

Date:07/01/03ISR Number: 4139105-1Report Type:Expedited (15-DaCompany Report #WAES 0305PRT00005
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Normochromic Normocytic Anaemia		Captopril And Hydrochlorothiazide	C		ORAL
			Bromazepam	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/03ISR Number: 4139107-5Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00030
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Aspirin	SS		ORAL		
	Bradycardia		Atenolol	C		ORAL		
	Drug Interaction		Magnesium (Unspecified)	C		ORAL		
	Dyspnoea		Omeprazole	C		ORAL		
			Acetaminophen	C		ORAL		
			Furosemide	C		ORAL		

Date:07/01/03ISR Number: 4139108-7Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00026
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/03ISR Number: 4139110-5Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00089
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis Necrotising		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C			12	DAY

Date:07/01/03ISR Number: 4139116-6Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00155
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/03ISR Number: 4139117-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02626
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Protonix	C				
Initial or Prolonged	Gastrointestinal		Zantac	C				
	Haemorrhage		Nexium	C				
	Ulcer		[Therapy					
	Vomiting		Unspecified]	C				
			Advil	C				

Date:07/01/03ISR Number: 4139121-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA03067
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash						2	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/03ISR Number: 4140666-7Report Type:Expedited (15-DaCompany Report #2003165902DE
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Foreign Health Professional Other	Bextra(Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS				

Date:07/01/03ISR Number: 4140670-9Report Type:Expedited (15-DaCompany Report #2003165699DE
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Foreign Health Professional Other	Bextra (Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS				

Date:07/02/03ISR Number: 4139790-4Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00071
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged	Delirium Drug Withdrawal Syndrome Refusal Of Treatment By Patient	Professional	Bromazepam	C		ORAL		

Date:07/02/03ISR Number: 4139791-6Report Type:Expedited (15-DaCompany Report #WAES 0306NOR00010
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	General Symptom	Health	Vioxx	PS	Merck & Co., Inc		17	DAY

Initial or Prolonged	Respiratory Disorder Urticaria	Professional	Estradiol And Norethindrone Acetate	C

Date:07/02/03ISR Number: 4139793-XReport Type:Expedited (15-DaCompany Report #WAES 0206DEU00050
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction Coronary Artery Atherosclerosis Coronary Artery Stenosis Upper Gastrointestinal Haemorrhage Vomiting	Professional	Pepcid	C				

Date:07/02/03ISR Number: 4139794-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA03249
Age:80 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lithium Carbonate	C				

Date:07/02/03ISR Number: 4139795-3Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00008
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Confusional State	Professional	Betamethasone	C				
15 YR								
Initial or Prolonged	Csf Test Abnormal		Prednisone	C		ORAL		
	Haemodynamic Instability		Terbutaline Sulfate	C				
	Intervertebral Disc		Ipratropium Bromide	C				
	Disorder		Fluticasone					
	Localised Infection		Propionate And					
	Quadriplegia		Salmeterol Xinafoate	C				
	Respiratory Distress		Rilmenidene	C				
	Sciatica		Glimepiride	C				
	Spinal Osteoarthritis							
	Staphylococcal Infection							

Date:07/02/03ISR Number: 4139800-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA03174
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:07/02/03ISR Number: 4140083-XReport Type:Direct Company Report #CTU 197125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Rofecoxib 25mg	PS		ORAL		
25MG QD ORAL								

Initial or Prolonged

Date:07/02/03ISR Number: 4140087-7Report Type:Direct Company Report #CTU 197088
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bilirubin Conjugated Increased		Rofecoxib	PS		ORAL	12.5 MG BID PO	
	Dizziness		Rabeprazole	SS		ORAL	20 MG BID PO	
	Fatigue							
	Haemolytic Anaemia							
	Low Density Lipoprotein Increased							
	Reticulocyte Count Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/03ISR Number: 4140194-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Infarction							
	Cardiomegaly							
	Contusion							
	Coronary Artery Occlusion							
	Eosinophilia							
	Excoriation							
	Pulmonary Congestion							
	Pulmonary Oedema							

Date:07/02/03ISR Number: 4140198-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA02502
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemic Stroke		Advil	C				

Date:07/02/03ISR Number: 4140199-8Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00078
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Terbinafine	C				

Date:07/02/03ISR Number: 4140202-5Report Type:Expedited (15-DaCompany Report #WAES 0302NOR00006
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Melaena		Potassium Chloride	SS		ORAL		YR

	Ulcer Haemorrhage		Citalopram Hydrobromide	SS			ORAL
YR							
			Furosemide	C			ORAL
YR							
			Zopiclone	C			ORAL
			Acetaminophen	C			ORAL
YR							

Date:07/02/03ISR Number: 4140203-7Report Type:Expedited (15-DaCompany Report #WAES 0306GBR00191
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Chest Pain		Tibolone	C		ORAL		
	Conjunctival Haemorrhage		Escitalopram Oxalate	C		ORAL		
	Diarrhoea		Irbesartan	C		ORAL		
	Dyspnoea		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
	Dysuria							
	Headache							
	Neck Pain		Albuterol	C		RESPIRATORY (INHALATION)		
	Rash							
	Somnolence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/03ISR Number: 4140212-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA03272
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:07/02/03ISR Number: 4140215-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA03352
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/02/03ISR Number: 4140664-3Report Type:Expedited (15-DaCompany Report #2003165905DE
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Foreign	Bextra(Valdecoxib)Ta					
	Procedural Complication	Health	blet	PS		ORAL	ORAL	
		Professional	Vioxx (Rofecoxib)	SS		ORAL	ORAL	
		Other						

Date:07/02/03ISR Number: 4141483-4Report Type:Expedited (15-DaCompany Report #A-US2003-02718
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Health	Tracleer (Bosentan)					
Hospitalization -	Coma	Professional	Tablet	PS		ORAL	62.5 MG, BID,	
Initial or Prolonged	Confusional State	Distributor					ORAL; 125 MG,	
	Dysphagia						BID	
	Haematocrit		Flolan (Epoprostenol					

		Hyperhidrosis	Sodium)	SS
INTRAVENOUS	UNK, UNK,			
		Hypoglycaemia		
INTRAVENOUS				
		Hyponatraemia	Vioxx (Rofecoxib)	SS
		Pneumonia Aspiration	Cardizem (Diltiazem	
		Pyrexia	Hydrochloride)	SS
		Rash Erythematous	Neurontin	
		Rash Generalised	(Gabapentin)	SS
		Respiratory Arrest	Prevacid	
		Thrombocytopenia	(Lansoprazole)	C
		Weight Decreased	Aldactone	
			(Spironolactone)	C
			Elavil	
			(Amitriptyline	
			Hydrochloride)	C
			Celexa (Citalopram	
			Hydrobromide)	C
			Oxycontin (Oxycodone	
			Hydrochloride)	C
			Allegra	
			(Fexofenadine	
			Hydrochloride)	C
			Lasix (Furosemide)	C
			Coumadin (Warfarin	
			Sodium)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/02/03ISR Number: 4141711-5Report Type:Expedited (15-DaCompany Report #2003016308
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Food Allergy	Health Professional	Zoloft (Sertraline)	PS				
			Cimicifuga Racemosa Root (Cimicifuga Racemosa Root)	SS		ORAL	(BID) ORAL	
			Ascorbic Acid (Ascorbic Acid)	SS		ORAL	ORAL	
			Multivitamins (Ergocalciferol, Ascorbic Acid, Folic Acid, Thiamine Hydrochloride,	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:07/02/03ISR Number: 4181708-2Report Type:Periodic Company Report #EMADSS2002005698
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Function Abnormal Pruritus	Foreign Health	Durogesic (Patch) (Fentanyl)	PS				
	Rash	Professional	Tramadol Hydrochloride (Tramadol Hydrochloride)	SS		ORAL	200 MG DAILY	ORAL
			Bi-Profenid (Ketoprofen)	SS		ORAL	300 MG DAILY	ORAL
			Vioxx (Rofecoxib)	SS		ORAL	1 CAP, DAILY,	

TRANSDERMAL TRANSD

ORAL

Tetrazepam (Tetrazepam)	SS	ORAL	1 TABLET, DAILY, ORAL
Mopral (Omeprazole)	SS	ORAL	20 MG DAILY ORAL

Date:07/03/03ISR Number: 4140745-4Report Type:Expedited (15-DaCompany Report #WAES 0304BEL00028
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Peritonitis	Professional	Bumetanide	C		ORAL		
			Spironolactone	C		ORAL		
			Oxybutynin Chloride	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Aspirin	C		ORAL		

Date:07/03/03ISR Number: 4140750-8Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00160
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Generalised Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/03/03ISR Number: 4140757-0Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00107
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema Atrioventricular Block Cardiac Failure Congestive Heart Valve Calcification	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/03ISR Number: 4141053-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA01080
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C				
Other								

Date:07/03/03ISR Number: 4141054-XReport Type:Expedited (15-DaCompany Report #WAES 0306CAN00107
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/03ISR Number: 4141055-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00187
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Campylobacter Infection	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Aspirin	C		ORAL		
	Erosive Oesophagitis		Zocor	C		ORAL		
	Gastritis Erosive		Isosorbide					
	Gastrointestinal		Mononitrate	C				
	Haemorrhage		Amlodipine Besylate	C				
			Nicorandil	C				

			Nitroglycerin	C		
			Lansoprazole	C		
32 DAY						
			Atenolol	C		

Date:07/03/03ISR Number: 4141060-5Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 DAY	Coronary Artery	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Thrombosis	Professional	Ethinyl Estradiol			
	Hypokinesia		And Levonorgestrel	SS		ORAL
	Myocardial Infarction					

Date:07/03/03ISR Number: 4141068-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA02299
Age:10 MON Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accidental Exposure
Hospitalization -	Gastrointestinal Disorder
Initial or Prolonged	Metabolic Acidosis

	Overdose						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:07/03/03ISR Number: 4141071-XReport Type:Expedited (15-DaCompany Report #WAES 0306FRA00093
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Increased	Professional	Aspirin	SS		ORAL		
	Enterocolitis							
	Haemorrhagic							
	Erythema							
	Mucous Membrane Disorder							
	Neutrophil Count							
	Increased							
	White Blood Cell Count							
	Increased							

Date:07/03/03ISR Number: 4141074-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA00070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/03/03ISR Number: 4141075-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA00074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Duodenal Ulcer							
Hospitalization -	Procedural Complication							
Initial or Prolonged								

Date:07/03/03ISR Number: 4142235-1Report Type:Expedited (15-DaCompany Report #2003-06-0256
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Albumin Csf Increased
Hospitalization - Initial or Prolonged	Allergic Granulomatous Angiitis
Other	Antinuclear Antibody Positive
	Asthma
	Back Pain
	Blood Culture Positive
	Condition Aggravated
	Haemodynamic Instability
	Hypereosinophilic Syndrome
	Hypotonia
	Quadriplegia
	Respiratory Distress
	Sciatica
	Spinal Osteoarthritis
	Staphylococcal Infection

		Systemic Inflammatory Response Syndrome					
		Tenosynovitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional Other	Celestene (Betamethasone) Tablets "Like Celestone Syrup"	PS		ORAL
SEE IMAGE							
				Cortancyl	SS		ORAL
60 MG QD ORAL							
				Solu-Medrol Injectable Solution	SS		
INTRAVENOUS	1 BOLUS						
INTRAVENOUS							
				Vioxx (Rofecoxib) Tablets	SS		ORAL
1 QD ORAL							
				Bricanyl 2 Qd For Asthma	C		
				Atrovent Qd For Asthma	C		
				Seretide (Salmeterol Xinafoate/Fluticasone Propionate) 2 Qd Inhalation	C		
				Hyperium (Rilmenidine) Oral	C		
				Glimepiride 2 Qd Oral	C		

Date:07/03/03ISR Number: 4190237-1Report Type:Periodic Company Report #US030755
Age:46 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Required		Pharyngolaryngeal Pain	Consumer	Enbrel	PS		
SUBCUTANEOUS	3 TIMES/WK,						
Intervention to		Recurring Skin Boils					
SC							
Prevent Permanent				Prednisone	SS		
Impairment/Damage				Rofecoxib	SS		
25 MG							

Date:07/07/03ISR Number: 4142069-8Report Type:Expedited (15-DaCompany Report #WAES 0301NOR00013
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY	
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Professional	Benserazide Hydrochloride And Levodopa	C		ORAL		
	Melaena		Paraffin	C		ORAL		
	Peptic Ulcer Haemorrhage		Paroxetine Hydrochloride	C		ORAL		
	Rectal Haemorrhage		Dipyrone	C		ORAL		
			Sennosides	C		ORAL		
			Acetaminophen	C		ORAL		
			Zopiclone	C		ORAL		

Date:07/07/03ISR Number: 4142485-4Report Type:Expedited (15-DaCompany Report #WAES 0306MYS00004M
Age: Gender:Female I/FU:I

Outcome	PT
	Caesarean Section
	Drug Exposure During Pregnancy

		Elbow Deformity					
		Foetal Growth Retardation					
		Maternal Drugs Affecting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Foetus		Vioxx	PS	Merck & Co., Inc	ORAL
9	MON						
		Oligohydramnios		Prednisolone	C		ORAL
		Pulmonary Hypoplasia		Acetaminophen	C		ORAL
		Renal Failure					
		Talipes					

Date:07/07/03ISR Number: 4142495-7Report Type:Expedited (15-DaCompany Report #WAES 0306MYS00004B1
Age:0 DY Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Caesarean Section		Vioxx	PS	Merck & Co., Inc	
9 MON						
Hospitalization -	Elbow Deformity		Prednisolone	C		
Initial or Prolonged	Foetal Growth Retardation		Acetaminophen	C		
Congenital Anomaly	Maternal Drugs Affecting					
	Foetus					
	Oligohydramnios					
	Pulmonary Hypoplasia					
	Renal Failure					
	Talipes					

Date:07/07/03ISR Number: 4142499-4Report Type:Expedited (15-DaCompany Report #WAES 0307DNK00001
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						
Hospitalization -	Haemoglobin Decreased		Bendroflumethiazide	C		
Initial or Prolonged	Nausea		Potassium Chloride	C		
	Vomiting		Amlodipine Besylate	C		
			Acetaminophen	C		
			Pantoprazole Sodium	C		
16 DAY						
			Iron (Unspecified)	C		
14 DAY						

		Lactulose	C
59	DAY		
		Codeine	C
17	DAY		
		Vitamins (Unspecified)	C
		Fluconazole	C
12	DAY		
		Esomeprazole Magnesium	C
		Iron (Unspecified)	C

Date:07/07/03ISR Number: 4143177-8Report Type:Direct Company Report #CTU 197409
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Distension		Vioxx 25mg (Merck)	PS	Merck	
1 DAILY						
	Back Pain					
	Chest Pain					
	Heart Rate Irregular					
	Intestinal Dilatation					
	Respiratory Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/03ISR Number: 4143182-1Report Type:Direct Company Report #CTU 197407
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Vioxx 50	PS		ORAL	ONCE , PO	
	Blood Pressure Diastolic Increased		Celebrex	C			[ONLY ONCE]	
	Chest Pain							
	Heart Rate Increased							
	Hypoaesthesia							
	Palpitations							
	Self-Medication							

Date:07/07/03ISR Number: 4143221-8Report Type:Direct Company Report #CTU 197398
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx , Merck	PS	Merck			
	Renal Disorder							

Date:07/07/03ISR Number: 4144386-4Report Type:Expedited (15-DaCompany Report #NLWYE193328JUN03
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health Professional	Ledertrexate (Methotrexate, Tablet, 0)	PS		ORAL	SEE IMAGE	14 DAY
Hospitalization - Initial or Prolonged	Drug Interaction	Other						
	Hypertension							
	Syncope		Vioxx (Rofecoxib, Tablet, 0)	SS		ORAL	25 MG 1X PER 1 DAY	333 DAY
			Folic Acid (Folic Acid)	C				

Date:07/08/03ISR Number: 4143094-3Report Type:Expedited (15-DaCompany Report #WAES 0306NLD00024
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	
333 DAY						
Hospitalization -	Hypertension	Professional	Methotrexate	SS		
15 DAY						
Initial or Prolonged	Syncope		Methotrexate	SS		
15 DAY						
			Methotrexate	SS		
15 DAY						
			Folic Acid	C		
			Folic Acid	C		

Date:07/08/03ISR Number: 4143096-7Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00054
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Urticaria	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Estradiol And Norethindrone Acetate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/03ISR Number: 4143346-7Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00009
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dehydration Haematemesis Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/03ISR Number: 4143350-9Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C				
			Acetaminophen	C				

Date:07/08/03ISR Number: 4143353-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA00366
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Demadex	C				

Date:07/08/03ISR Number: 4143355-8Report Type:Expedited (15-DaCompany Report #WAES 0305USA02861
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Fatigue Haemorrhoidal Haemorrhage Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/03ISR Number: 4143357-1Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00034
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	93 DAY	
Hospitalization - Initial or Prolonged			Furosemide	C		ORAL		
Other			Perindopril	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Aspirin	C		ORAL		

Date:07/08/03ISR Number: 4145096-XReport Type:Expedited (15-DaCompany Report #2003165902DE
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign Health Professional Other	Bextra(Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/03ISR Number: 4145098-3Report Type:Expedited (15-DaCompany Report #2003165905DE
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign Health Professional Other	Bextra(Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	ORAL	

Date:07/08/03ISR Number: 4145103-4Report Type:Expedited (15-DaCompany Report #2003165789DE
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign Health Professional Other	Bextra(Valdecoxib) Tablet	PS		ORAL	ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	ORAL	

Date:07/09/03ISR Number: 4143863-XReport Type:Expedited (15-DaCompany Report #WAES 0306NLD00024
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Health	Vioxx	PS	Merck & Co., Inc		333	DAY
Hospitalization -	Hypertension	Professional	Methotrexate	SS			15	DAY
Initial or Prolonged	Syncope		Methotrexate	SS			15	DAY
			Folic Acid	C				
			Folic Acid	C				

Date:07/09/03ISR Number: 4143872-0Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/03ISR Number: 4144127-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA00235
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Vein Occlusion							

Date:07/09/03ISR Number: 4144129-4Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00079
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
	Haemorrhage		Digoxin	C		ORAL		
	Pneumonia Aspiration		Allopurinol	C		ORAL		
			Omeprazole	C		ORAL		
			Albuterol Sulfate	C				

RESPIRATORY

(INHALATION)

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/03ISR Number: 4144133-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01976
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Other	Skin Ulcer		Lasix (Furosemide)	C		ORAL		
			Metoprolol	C		ORAL		
			Lotensin	C				
			Coumadin	C				
			Lanoxin	C				

Date:07/09/03ISR Number: 4144148-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA00219
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Dizziness		Celebrex	SS		ORAL		
	Nausea		Synthroid	C				
	Oedema Peripheral		Accupril	C				
	Pollakiuria		Glynase Prestab Tablets	C				
			Actos	C				

Date:07/09/03ISR Number: 4146370-3Report Type:Expedited (15-DaCompany Report #2001USA01458
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anti-Platelet Antibody Negative
	Antinuclear Antibody Positive
	Antiphospholipid Syndrome
	Arthralgia
	Atherosclerosis
	Chest Pain
	Confusional State
	Coombs Test Positive
	Cryofibrinogenaemia
	Cytomegalovirus Antibody

Positive
Dehydration
Diarrhoea
Disorientation
Embolism
Epstein-Barr Virus
Antibody Positive
Extravascular Haemolysis
Hypotension
Lethargy
Lyme Disease
Nausea
Pain
Pericarditis
Petechiae
Post Procedural
Complication
Renal Failure Acute
Renal Tubular Necrosis
Splinter Haemorrhages
Thrombocytopenia

		Thrombotic Thrombocytopenic Purpura Vasculitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Plavix - Clopidogrel Sulfate - Tablet - 75 Mg	PS		ORAL
75 MG OD - ORAL							
				Statin - Form : Unknown - 40 Mg	SS		ORAL
40 MG - ORAL							
				Vioxx - Rofecoxib - Form : Unknown - 50mg	SS		ORAL
50 MG - ORAL							
				Warfarin Sodium	C		
				Fluticasone Propionate	C		
				Prednisone	C		
				Digoxin	C		
				Thyroid	C		
				Heparin	C		

Date:07/09/03ISR Number: 4146803-2Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased	Consumer	Tab Vioxx 12.5mg	PS		ORAL
12.5 MG/DAILY/PO							
		Cardiac Disorder	Health Professional				
		Cataract		Celebrex 200 Mg	SS		
200 MG/DAILY							
		Drug Eruption		Anafranil	C		
		Drug Hypersensitivity		Lidex	C		
		Excoriation		Proventil Inhaler	C		
		Fatigue					
		Lung Disorder					
		Nervous System Disorder					
		Nervousness					
		Neurodermatitis					
		Peripheral Coldness					

Pruritus
Rash Macular
Scar
Skin Discolouration
Skin Disorder
Skin Reaction
Skin Ulcer
Sleep Disorder

Date:07/09/03ISR Number: 4146812-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anorexia
	Asthenia
	Atrial Fibrillation
	Coronary Artery Disease
	Decreased Appetite
	Dehydration
	Dementia
	Depressed Level Of Consciousness

		Diverticulum					
		Duodenal Ulcer					
		Erosive Oesophagitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fluid Intake Reduced	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Gastrointestinal	Health				
MG/DAILY/PO							
		Haemorrhage	Professional	Aggrenox	C		
		Hypotension		Ben-Gay	C		
		Hypovolaemia		Detrol	C		
		Malnutrition		Lasix (Furosemide)	C		
		Oesophagitis		Mag-Ox 400 Tablets	C		
		Oral Intake Reduced		Megace	C		
		Refusal Of Treatment By		Reglan	C		
		Patient		Risperdal	C		
		Renal Failure		Tylenol	C		
		Urinary Tract Infection		Digoxin	C		
		Vomiting		Metoprolol	C		
		Weight Decreased		Vitamins	C		

Date:07/09/03ISR Number: 4146873-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial	Consumer	Tab Vioxx Unk	PS		ORAL
PO							
		Infarction	Health				
		Arcus Lipoides	Professional				
		Arthralgia					
		Asthenia					
		Atherosclerosis					
		Cardiomegaly					
		Cervicobrachial Syndrome					
		Conjunctival Hyperaemia					
		Contusion					
		Coronary Artery					
		Thrombosis					
		Eosinophilia					
		Excoriation					
		Eye Swelling					
		Hypertrophy					
		Periorbital Haematoma					
		Pulmonary Congestion					

Pulmonary Oedema
Swelling Face
Transient Ischaemic
Attack

Date:07/09/03ISR Number: 4146892-5Report Type:Expedited (15-DaCompany Report #2003165787DE
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS		ORAL	ORAL	
	Neurolysis	Health Professional Other	Bextra (Valdecoxib) Tablet	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/03ISR Number: 4146895-0Report Type:Expedited (15-DaCompany Report #2003165699DE
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haemorrhage	Foreign	Vioxx (Rofecoxib)	PS				
	Neurolysis Chemical	Health	Bextra (Valdecoxib)					
		Professional	Tablet	SS		ORAL	ORAL	
		Other						

Date:07/10/03ISR Number: 4144536-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA03064
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depressed Level Of		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Consciousness							
Initial or Prolonged	Renal Failure							

Date:07/10/03ISR Number: 4144544-9Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Eyelid Ptosis							

Date:07/10/03ISR Number: 4144546-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Bradycardia
Disability	Calcinosis
	Cardiac Stress Test
	Abnormal
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Discomfort

Chest Pain
Constipation
Cyst
Cystocele
Ear Pain
Electrocardiogram St-T
Change
Enterocele
Flatulence
Ganglion
Haematochezia
Heart Rate Increased
Hypokalaemia
Hypotension
Liposarcoma
Oedema Peripheral
Ovarian Cyst
Pain
Pelvic Mass
Post Procedural
Complication
Pyrexia

		Rectocele					
		Renal Cyst					
		Sinus Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Stress Incontinence	Professional	Colace	C		
		Tenderness		Paxil	C		
		Tympanic Membrane		Maxzide	C		
		Disorder		Potassium Chloride	C		
		Ulcer		Trazodone			
		Uterine Prolapse		Hydrochloride	C		
				Coumadin	C		

Date:07/10/03ISR Number: 4144866-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01476
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia	Health	Vioxx	PS		ORAL
Initial or Prolonged		Contusion	Professional	Arava	SS	Merck & Co., Inc	
3	DAY						
Other		Fall		Arava	SS		
64	DAY						
		Haemangioma Of Liver		Methotrexate	C		
		Hepatic Cyst		Prednisone	C		
		Hepatitis		[Therapy			
		Hepatocellular Damage		Unspecified]	C		
		Hepatomegaly		Clavulanate			
		Hypertension		Potassium	C		
		Lymphocyte Count		Guaifenesin	C		
		Decreased		Ranitidine	C		
		Monocyte Count Increased		Hydrocodone			
		Neutrophil Count		Bitartrate	C		
		Decreased		Neurontin	C		
		Red Blood Cell Count		Colace	C		
		Decreased		Sulfasalazine	C		
		Renal Cyst		Augmentin	C		
		Serum Ferritin Increased		Celebrex	C		
		Thrombocythaemia		Tylenol	C		
		White Blood Cell Count					
		Increased					

Date:07/10/03ISR Number: 4144868-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA00402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/10/03ISR Number: 4144879-XReport Type:Expedited (15-DaCompany Report #WAES 0305BEL00026
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
	Oedema Peripheral		Piracetam	C		ORAL		
			Terazosin Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/03ISR Number: 4144880-6Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Metastatic Neoplasm		Antineoplastic (Unspecified)	C				

Date:07/10/03ISR Number: 4144883-1Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00046
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization - Initial or Prolonged			Gabapentin	C				
			Elavil	C				
			Atropine	C		INTRAVENOUS		
			Enoxaparin Sodium	C		SUBCUTANEOUS		

Date:07/10/03ISR Number: 4144884-3Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00009
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dehydration		Acetaminophen	C		ORAL		

Date:07/10/03ISR Number: 4144885-5Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00006
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Living Impaired		Furosemide	C		ORAL		
	Diabetes Mellitus		Furosemide	C		ORAL		
	Insulin-Dependent		Levothyroxine Sodium	C		ORAL		
	Ischaemic Cardiomyopathy		Lormetazepam	C		ORAL		

	Parkinson'S Disease		Benserazide Hydrochloride And Levodopa	C		ORAL
			Aspirin	C		ORAL
			Lisinopril	C		ORAL
			Molsidomine	C		ORAL
			Amlodipine Besylate	C		ORAL
INTRAMUSCULAR			Insulin, Biphasic Isophane [Injection]	C		
INTRAMUSCULAR			Insulin, Biphasic Isophane [Injection]	C		

Date:07/10/03ISR Number: 4144888-0Report Type:Expedited (15-DaCompany Report #WAES 0307AUT00005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Vomiting		Metoprolol Tartrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/03ISR Number: 4144889-2Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/10/03ISR Number: 4144890-9Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00007
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/10/03ISR Number: 4145032-6Report Type:Direct Company Report #CTU 197685
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased Eye Haemorrhage Retinal Vein Occlusion		Vioxx 25-50mg Daily	PS				

Date:07/11/03ISR Number: 4145272-6Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-D0041113A
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acidosis Flushing		Seroxat	PS	Glaxosmithkline	ORAL	50TAB Single dose	
	Suicide Attempt Tachycardia		Ibuprofen	SS	Glaxosmithkline	ORAL	20TAB Single dose	
			Ibutad	SS	Glaxosmithkline	ORAL	20TAB Single	

dose				
	Vioxx	SS		ORAL
10TAB Single				
dose				
	Diclofenac	SS		ORAL
20TAB Single				
dose				
	Ass	SS	Glaxosmithkline	ORAL
20TAB Single				
dose				
	Promethazine	SS		ORAL
20TAB Single				
dose				
	Paracetamol	SS	Glaxosmithkline	ORAL
20TAB Single				
dose				
	Talvosilen	SS		ORAL
20TAB Single				
dose				

Date:07/11/03ISR Number: 4145461-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01228
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
	Arrhythmia		Celebrex	SS		ORAL
	Blood Pressure Increased					
	Large Intestinal Ulcer					
	Haemorrhage					
	Oedema					
	Oesophageal Ulcer					
	Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/03ISR Number: 4145462-2Report Type:Expedited (15-DaCompany Report #WAES 0305USA02325
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/03ISR Number: 4145464-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA00483
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nipple Pain		Vioxx	SS		ORAL		
	Syncope		Toprol Xl Tablets	C				
			Altace	C				
			L-Thyroxin	C				
			Diuril	C		ORAL		
			Nexium	C				
			Atarax	C				
			Aspirin	C				
			Pravachol	C				
			Bextra	C				

Date:07/11/03ISR Number: 4145465-8Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00068
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Potassium Increased		Fluticasone Propionate And Salmeterol Xinafoate	C				
	Blood Urea Increased		Fluticasone Propionate And Salmeterol Xinafoate	C				
			Perindopril Erbumine	C				
			[Therapy Unspecified]	C				

Date:07/11/03ISR Number: 4145471-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA00851
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Pulmonary Oedema		Avapro	C				
	Respiratory Distress		Estrogens					
	Swelling Face		(Unspecified)	C				

Date:07/11/03ISR Number: 4145476-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA00237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Fluctuation							
	Cardiovascular Disorder							
	Cerebrovascular Disorder							
	Injury							
	Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/03ISR Number: 4145477-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA00498
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Dysphagia		[Therapy					
	Feeling Abnormal		Unspecified]	C				
	Headache							
	Swelling Face							
	Tinnitus							

Date:07/11/03ISR Number: 4145480-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA00914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:07/11/03ISR Number: 4145481-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA00873
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:07/11/03ISR Number: 4148054-4Report Type:Expedited (15-DaCompany Report #STA-AE-03-MTX-056
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Lactate	Literature	Methotrexate					
Initial or Prolonged	Dehydrogenase Increased	Distributor	(Methotrexate					
	Cerebral Haemorrhage		Unspec)	PS				
	Drug Ineffective		Rofecoxib				11	YR
	Drug Interaction		(Rofecoxib, Unspec)	SS				
	Epistaxis							

Haematocrit Decreased
Haemoglobin Decreased
Petechiae
Purpura
Renal Failure Acute
Reticulocyte Count
Increased
Sepsis
Thrombocytopenia
White Blood Cell Count

Date:07/14/03ISR Number: 4146230-8Report Type:Expedited (15-DaCompany Report #WAES 0210CAN00105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/03ISR Number: 4146232-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA00366
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Demadex	C				

Date:07/14/03ISR Number: 4146622-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA00035
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ligament Repair	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Meningitis Viral	Professional	Vioxx	SS		ORAL		
Disability			Vicodin Tablets	C				
Other								

Date:07/14/03ISR Number: 4146628-8Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00028
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatocellular Damage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
							10	DAY
Hospitalization -	Pain	Professional	Fluvastatin Sodium	C		ORAL		
Initial or Prolonged			Cholecalciferol	C		ORAL		
			Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		
			Levothyroxine Sodium And Liothyronine Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Magnesium Aspartate And Potassium Aspartate	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL		

Date:07/14/03ISR Number: 4146637-9Report Type:Expedited (15-DaCompany Report #WAES 0307ITA00008
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	International Normalised	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Ratio Increased	Professional	Acenocoumarol	SS		ORAL		32 DAY
	Peritoneal Haemorrhage		Digoxin	C				
			Verapamil Hydrochloride	C				
			Glyburide	C				
			Nitroglycerin	C				

Date:07/14/03ISR Number: 4146638-0Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00006
Age:88 YR Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activities Of Daily Living Impaired	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Insulin, Biphasic Isophane [Injection]	C			INTRAMUSCULAR	
	Insulin-Dependent		Lisinopril	C		ORAL		
	Ischaemic Cardiomyopathy		Aspirin	C		ORAL		
	Parkinson'S Disease		Furosemide	C		ORAL		
			Furosemide	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Lormetazepam	C		ORAL		
			Benserazide Hydrochloride And Levodopa	C		ORAL		
			Molsidomine	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Insulin, Biphasic Isophane [Injection]	C			INTRAMUSCULAR	

Date:07/14/03ISR Number: 4146639-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA00960
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/03ISR Number: 4146759-2Report Type:Direct Company Report #CTU 197886
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Cutaneous Vasculitis		Vioxx 25 Mg Po Qd	PS		ORAL	25 MG PO QD	

Date:07/15/03ISR Number: 4147538-2Report Type:Expedited (15-DaCompany Report #WAES 0307NZL00013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vasotec	C				
			Cilazapril	C				

Date:07/15/03ISR Number: 4147544-8Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Skin Disorder							
	Skin Reaction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/03ISR Number: 4147554-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA01431
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/03ISR Number: 4147559-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA01459
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/03ISR Number: 4149503-8Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Other	Zometa (Zoledronate) Solution For Injection	PS		INTRAVENOUS	INTRAVENOUS	
	Blood Pressure Abnormal							
	Femoral Bruit							
	Herpes Zoster		Vioxx (Rofecoxib)	SS			25 MG	
	Oedema Peripheral		E7070 (Goal) (Paraffin Soft)	SS		INTRAVENOUS	1449 MG, OT,	
	Renal Cyst							
	Renal Failure Acute					INTRAVENOUS		
	Renal Tubular Necrosis		Co-Diovan	C				
	Urine Analysis Abnormal		Verapamil (Verapamil)	C				
			Duragesic (Fentanyl)	C				
			Lipitor	C				
			Zoloft (Sertraline Hydrochloride)	C				
			Percocet (Oxycodone Hydrochloride)	C				
			Prevacid (Lansoprazole)	C				
			Lasix	C				

Date:07/16/03ISR Number: 4147698-3Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-11945748
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Level Increased		Glucophage Tabs 850			
Other	Haemodialysis		Mg	PS	Bristol-Myers Squibb	
	Hypoglycaemia				Company	ORAL
	Hypovolaemia		Spiroctazine	SS		ORAL
	Lactic Acidosis		Vioxx	SS		ORAL
	Renal Failure Acute		Colchicine	SS		ORAL
	Renal Tubular Necrosis		Colchimax	SS		
Dose Regimen:						
3 tabs/day						
during 3						
days, then 2						
tabs/day						
			Diamicron	SS		
			Diastabol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/03ISR Number: 4148341-XReport Type:Expedited (15-DaCompany Report #WAES 0307AUT00005
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Vomiting		Metoprolol Tartrate	C				

Date:07/16/03ISR Number: 4148345-7Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00072
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Dialysis		Enalapril Maleate	SS		ORAL		
Hospitalization -	Drug Interaction		Risperidone	SS		ORAL		
Initial or Prolonged	Duodenal Ulcer		Olanzapine	SS		ORAL		
	Haemorrhage		Esomeprazole					
	Renal Failure		Magnesium	SS		ORAL		
			Furosemide Sodium	SS		ORAL		

Date:07/16/03ISR Number: 4148347-0Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Diclofenac	C		ORAL		
			Piroxicam	C		ORAL		

Date:07/16/03ISR Number: 4148350-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA01513
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:07/16/03ISR Number: 4148351-2Report Type:Expedited (15-DaCompany Report #WAES 0307NOR00012
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Scotoma							

Date:07/16/03ISR Number: 4148490-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Lower
Disability	Blood Pressure Systolic Decreased
	Cardiac Stress Test Abnormal
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident

		Chest Pain					
		Constipation					
		Cystocele	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ear Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Electrocardiogram St-T	Health				
MG/DAILY/PO							
		Change	Professional	Colace	C		
		Enterocele		Coumadin	C		
		Flatulence		Maxzide	C		
		Haematochezia		Paxil	C		
		Heart Rate Increased		Potassium Chloride	C		
		Hypokalaemia		Trazodone			
		Hypotension		Hydrochloride	C		
		International Normalised					
		Ratio Increased					
		Lipoma					
		Oedema Peripheral					
		Ovarian Cyst					
		Pain					
		Pain In Jaw					
		Post Procedural					
		Complication					
		Rectocele					
		Renal Cyst					
		Sinus Bradycardia					
		Sinus Disorder					
		Sleep Disorder					
		Stress Incontinence					
		Synovial Cyst					
		Transient Ischaemic					
		Attack					
		Uterine Prolapse					

Date:07/16/03ISR Number: 4150486-5Report Type:Expedited (15-DaCompany Report #CH-JNJFOC-20030701841
Age:29 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Bradycardia	Foreign	Tramal (Tramadol			
Initial or Prolonged		Drug Interaction	Health	Hydrochloride)	PS		ORAL
20 GTT, ORAL							
			Professional	Vioxx (Rofecoxib)	SS		ORAL
50 MG, ORAL							

			Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
6 MG, 1 IN 1 DAY, ORAL						

Date:07/17/03ISR Number: 4148639-5Report Type:Direct Company Report #CTU 198104
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Hypersensitivity		Vioxx	PS		ORAL
25 MG PO Q						
Hospitalization -	Encephalitis					
DAILY						
Initial or Prolonged	Oropharyngeal Swelling					
Disability	Pneumonia Herpes Viral					
	Pruritus					
	Urticaria					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/17/03ISR Number: 4148723-6Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00078
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activated Partial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization -	Thromboplastin Time	Professional	Phenprocoumon	SS		ORAL		
Initial or Prolonged	Prolonged		Metoprolol	C		ORAL		
	Drug Interaction							
	Haematocrit							
	International Normalised							
	Ratio Increased							
	Oedema Peripheral							
	Pain In Extremity							
	Prothrombin Time							
	Prolonged							
	Soft Tissue Haemorrhage							

Date:07/17/03ISR Number: 4148731-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA01420
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged	Dyspnoea							
Disability	Eye Swelling							
	Fatigue							
	Gallbladder Disorder							
	Gastric Infection							
	Thyroid Disorder							

Date:07/17/03ISR Number: 4148880-1Report Type:Direct Company Report #CTU 198153
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx Merck	PS	Merck	ORAL		RECOMMENDE 1X
Hospitalization -								DAY ORAL
Initial or Prolonged								

Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:07/17/03ISR Number: 4148915-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA00774
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fluid Retention		Prilosec	C		ORAL		
Initial or Prolonged	Weight Increased		Effexor	C				
Other			Reglan	C				
			Compazine	C				
			Seroquel	C				

Date:07/17/03ISR Number: 4148918-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA00810
Age:51 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Heart Rate Decreased		Glucosamine	C		ORAL	5	DAY
	Hypertension							

Date:07/17/03ISR Number: 4148920-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA01256
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged			[Composition Unspecified]	C				

Date:07/17/03ISR Number: 4148923-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA01590
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Test Abnormal		Plavix	C				
	Faeces Discoloured		Isosorbide Mononitrate	C				
			Atenolol	C				
			Lipitor	C				

Date:07/17/03ISR Number: 4148924-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA01449
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Lacrimation Increased							
	Rhinitis							

Sneezing

Date:07/17/03ISR Number: 4148925-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA01431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/17/03ISR Number: 4150936-4Report Type:Expedited (15-DaCompany Report #HQWYE964414JUL03
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Hypertension	Health Professional	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release	PS		ORAL	SEE IMAGE	
			Vioxx (Rofecoxib, Tablet)	SS			25 MG 1X PER 1 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/03ISR Number: 4149310-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA01376
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	203	DAY
	Anaemia		Vioxx	SS		ORAL		
	Azotaemia		Lortab	C				
	Bilirubinuria		Amitriptyline					
	Chondropathy		Hydrochloride	C				
	Constipation		Amitriptyline					
	Diabetes Mellitus		Hydrochloride	C				
	Goitre		Premarin	C				
	Heart Rate Increased		Premarin	C				
	Hyperlipidaemia		Provera	C			81	DAY
	Hypertension		Provera	C				
	Macular Degeneration		Spironolactone	C				
	Nausea		Spironolactone	C				
	Osteoarthritis		Vitamins					
	Post Procedural		(Unspecified)	C				
	Complication		Vitamins					
	Renal Failure		(Unspecified)	C				
	Unevaluable Event		Chondroitin	C				
	Weight Increased		Chondroitin	C				
			Glucosamine	C				
			Glucosamine	C				
			Toprol Xl Tablets	C				
			Toprol Xl Tablets	C				
			Maxzide	C				
			Maxzide	C				
			Synthroid	C				
			Synthroid	C				
			Lasix (Furosemide)	C				
			Lasix (Furosemide)	C				
			Pneumovax 23	C				

Date:07/18/03ISR Number: 4149312-XReport Type:Expedited (15-DaCompany Report #WAES 0306MYS00004B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Caesarean Section	Health	Vioxx	PS	Merck & Co., Inc		9	MON

Hospitalization -	Elbow Deformity	Professional	Prednisolone	C
Initial or Prolonged	Foetal Growth Retardation		Acetaminophen	C
Congenital Anomaly	Maternal Drugs Affecting			
	Foetus			
	Neonatal Disorder			
	Oligohydramnios			
	Premature Baby			
	Pulmonary Hypoplasia			
	Renal Failure			
	Small For Dates Baby			
	Talipes			

Date:07/18/03ISR Number: 4149316-7Report Type:Expedited (15-DaCompany Report #WAES 0305USA02749
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arteriovenous
Initial or Prolonged	Malformation
Other	Dysphagia
	Erosive Oesophagitis

		Gastrointestinal Haemorrhage Oesophageal Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Zoloft	C		
				Pravachol	C		
				Pepcid	C		
				Atenolol	C		
				Levothyroxine Sodium	C		
				Caltrate	C		
				Aspirin	C		

Date:07/18/03ISR Number: 4149320-9Report Type:Expedited (15-DaCompany Report #WAES 0306MYS00004M
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Arthropathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
9 MON						
	Caesarean Section		Prednisolone	C		ORAL
	Drug Exposure During Pregnancy		Acetaminophen	C		ORAL
	Foetal Growth Retardation					
	Oligohydramnios					
	Pulmonary Hypoplasia					
	Renal Failure Neonatal					
	Small For Dates Baby					
	Talipes					

Date:07/18/03ISR Number: 4149323-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA00366
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Demadex	C		

Date:07/18/03ISR Number: 4149324-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA01806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Disorder Fracture Delayed Union		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/03ISR Number: 4149328-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA01809
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/03ISR Number: 4149713-XReport Type:Expedited (15-DaCompany Report #WAES 0206USA02558
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Antithrombin Iii Decreased
Disability	Asthenia
Other	Atrial Septal Defect

		Blood Potassium					
		Cerebral Artery Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chondromalacia		Vioxx	PS	Merck & Co., Inc	ORAL
308	DAY						
		Epistaxis		Vioxx	SS		ORAL
33	DAY						
		Flushing		Vioxx	SS		ORAL
36	DAY						
		Haematocrit		Vioxx	SS		ORAL
312	DAY						
		Haemoglobin		Tricor	C		ORAL
		Mitral Valve Incompetence		Vicodin Es Tablets	C		ORAL
		Osteoarthritis		Paxil	C		ORAL
		Phlebothrombosis		Restoril	C		ORAL
		Platelet Count		Aspirin	C		ORAL
		Radius Fracture		Estrogens			
		Red Blood Cell		(Unspecified)	C		
		Sedimentation Rate		Premarin	C		
		Thromboembolic Stroke		Vitamins			
		Tricuspid Valve		(Unspecified)	C		
		Incompetence		Zantac	C		
		Urticaria		Vistaril	C		
				Cenestin	C		
				Lovenox	C		
				Xenical	C		
				Parafon Forte	C		

Date:07/18/03ISR Number: 4149719-0Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00028
Age:81 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
Hospitalization -		Cholestasis		Fluvastatin Sodium	C		ORAL
Initial or Prolonged		Hepatic Necrosis		Fluvastatin Sodium	C		ORAL
		Hepatocellular Damage		Cholecalciferol	C		ORAL
		Hepatotoxicity		Candesartan			
		Pain		Cilexetil And			
		Pancreas Lipomatosis		Hydrochlorothiazide	C		ORAL
		Renal Cyst		Levothyroxine Sodium			
		Retching		And Liothyronine			
				Hydrochloride	C		ORAL

			Aspirin	C		ORAL
			Magnesium Aspartate And Potassium Aspartate	C		ORAL
			Magnesium (Unspecified)	C		ORAL
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL

Date:07/18/03ISR Number: 4149723-2Report Type:Expedited (15-DaCompany Report #WAES 0307CAN00034
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Schizophrenia		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Zafirlukast	C				
			Fluticasone Propionate And Salmeterol Xinafoate	C				
			Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/03ISR Number: 4149725-6Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Dermatitis Allergic		[Therapy Unspecified]					
	Dermatitis Exfoliative			C		ORAL		

Date:07/18/03ISR Number: 4149727-XReport Type:Expedited (15-DaCompany Report #WAES 0307DEU00084
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Interaction		Aspirin	SS		ORAL		
	Enterocolitis		Pentoxifylline	C		ORAL		
	Haemorrhagic		Furosemide	C		ORAL		
	Haematocrit		Trimipramine Maleate	C		ORAL		
	Haemoglobin Decreased		Theophylline	C		ORAL		
	Nausea							

Date:07/18/03ISR Number: 4149731-1Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
	Disease		Diclofenac	C			29	DAY
			Omeprazole	C			29	DAY

Date:07/18/03ISR Number: 4149732-3Report Type:Expedited (15-DaCompany Report #WAES 0307PHL00013
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged	Myocardial Infarction		Dipyridamole	C		ORAL 1 YR

Date:07/18/03ISR Number: 4152626-0Report Type:Expedited (15-DaCompany Report #2003029575
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Tube Insertion	Consumer	Neurontin (Gabapentin)	PS				
Hospitalization - Initial or Prolonged	Haematocrit Decreased		Diltiazem Hydrochloride (Diltiazem Hydrochloride)	SS				
Other	Pneumonia Aspiration		Rofecoxib (Rofecoxib)	SS				
	Pulmonary Hypertension		Lansoprazole (Lansoprazole)	C				
	Thrombocytopenia		Spironolactone (Spironolactone)	C				
			Amitripryline (Amitriptyline)	C				
			Citalopram Hydrobromide (Citalopram Hydrobromide)	C				

Oxycodone Hydrochloride (Oxycodone Hydrochloride)	C
Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C
Furosemide (Furosemide)	C
Warfarin (Warfarin)	C

Date:07/18/03ISR Number: 4181842-7Report Type:Periodic Company Report #WAES 0208USA03525
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4150552-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/03ISR Number: 4150555-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA01895
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/03ISR Number: 4150964-9Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY

Date:07/21/03ISR Number: 4150969-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02502
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Advil	C				
	Hypertension							
	Ischaemic Stroke							
	Radicular Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4150970-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA01625
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Confusional State		Tracleer	SS		ORAL		53 DAY
Initial or Prolonged	Dyskinesia Oesophageal		Tracleer	SS		ORAL		
Other	Hypoglycaemia		Flolan	SS			INTRAVENOUS	
	Idiopathic		Cardizem	SS				
	Thrombocytopenic Purpura		Neurontin	SS				
	Myocardial Infarction		Prevacid	C				
	Pneumonia Aspiration		Aldactone	C				
	Respiratory Arrest		Elavil	C		ORAL		
	Sepsis		Celexa	C				
			Oxycontin	C				
			Allegra	C				
			Lasix (Furosemide)	C				
			Coumadin	C				

Date:07/21/03ISR Number: 4150972-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA00634
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bradycardia		Zanaflex	SS				1 DAY
Initial or Prolonged	Chest Pain		Premarin	C				
	Difficulty In Walking		Lidocaine	C				
	Dyspnoea		Alprazolam	C				
	Myocardial Infarction							

Date:07/21/03ISR Number: 4152913-6Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Other	Zometa (Zoledronate)					
	Blood Pressure Increased		Solution For					

		Femoral Bruit	Injection	PS
INTRAVENOUS	4 MG,			
		Herpes Zoster		
INTRAVENOUS				
		Nocturia	Vioxx (Rofecoxib)	SS
25 MG				
		Oedema Peripheral	E7070 (Goal)	
		Renal Failure Acute	(Paraffin Soft)	SS
INTRAVENOUS	1449 MG, OT,			
		Renal Tubular Necrosis		
INTRAVENOUS				
			Co-Diovan	C
			Verapamil (Verapamil)	C
			Duragesic (Fentanyl)	C
			Lipitor	C
			Zoloft (Sertraline Hydrochloride)	C
			Percocet (Oxycodone Hydrochloride)	C
			Prevacid (Lansoprazole)	C
			Lasix	C

Date:07/21/03ISR Number: 4181829-4Report Type:Periodic Company Report #WAES 0208USA04003
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25/MG/QOD/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative	Lortab	C				
			Xanax	C				
Other			Prednisone	C				

Date:07/21/03ISR Number: 4181833-6Report Type:Periodic Company Report #WAES 0208USA03938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:07/21/03ISR Number: 4181834-8Report Type:Periodic Company Report #WAES 0208USA03924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative						

Date:07/21/03ISR Number: 4181837-3Report Type:Periodic Company Report #WAES 0208USA03913
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Hospitalization - MG/DAILY/PO		Professional		
Initial or Prolonged		Company	Bactrim	C
Other		Representative	Atenolol	C
			Prednisone	C
			Verapamil Hydrochloride	C

Date:07/21/03ISR Number: 4181844-0Report Type:Periodic Company Report #WAES 0208USA03380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25/MG/DAILY/P	
Initial or Prolonged	Haemorrhage						O	
			Levoxyl	C				

Date:07/21/03ISR Number: 4181850-6Report Type:Periodic Company Report #WAES 0208USA03298
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4181853-1Report Type:Periodic Company Report #WAES 0208USA03027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Avandia	C				
Disability		Representative	Xanax	C				
Other			Aspirin	C				
			Glyburide	C				
			Theophylline	C				

Date:07/21/03ISR Number: 4181858-0Report Type:Periodic Company Report #WAES 0208USA02916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181861-0Report Type:Periodic Company Report #WAES 0208USA02605
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company	Accolate	C				
		Representative	Celebrex	C				
			Nexium	C				
			Premarin	C				
			Albuterol	C				
			Atenolol	C				

Date:07/21/03ISR Number: 4181862-2Report Type:Periodic Company Report #WAES 0208USA02473
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Alkaline	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/DAILY ;						
Initial or Prolonged	Phosphatase Increased	Professional				
PRN :PO						
Other	Clostridium Colitis	Company	Citracal	C		
	Gastric Ulcer Haemorrhage	Representative	Demadex	C		
			Keflex	C		
			Plavix	C		
			Toprol Xl Tablets	C		
			Albuterol	C		
			Aspirin	C		
			Hydrochlorothiazide (+) Triamter	C		
			Thyroid	C		
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4181863-4Report Type:Periodic Company Report #WAES 0208USA02428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Aspirin	C				

Date:07/21/03ISR Number: 4181865-8Report Type:Periodic Company Report #WAES 0208USA02412
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Perforation	Professional					MG/DAILY/PO	
Initial or Prolonged			Bextra	C				
Disability			Synthroid	C				
Other			Zoloft	C				

Date:07/21/03ISR Number: 4181867-1Report Type:Periodic Company Report #WAES 0208USA02386
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Other	Vicodin Tablets	C				
Other			Zocor	C				
			Gabapentin	C				
			Imipramine	C				
			Levothyroxine Sodium	C				

Date:07/21/03ISR Number: 4181868-3Report Type:Periodic Company Report #WAES 0208USA02177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4181870-1Report Type:Periodic Company Report #WAES 0208USA02163
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Lipitor	C				
			Vasotec	C				
			Vicodin Es Tablets	C				
			Prednisone	C				

Date:07/21/03ISR Number: 4181871-3Report Type:Periodic Company Report #WAES 0208USA02154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization -	Oedema Peripheral	Health
Initial or Prolonged		Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 25 Mg	PS		ORAL
PO						

Date:07/21/03ISR Number: 4181872-5Report Type:Periodic Company Report #WAES 0208USA01727
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
		Company Representative				

Date:07/21/03ISR Number: 4181874-9Report Type:Periodic Company Report #WAES 0208USA01087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		
PO						
Initial or Prolonged		Professional				
		Company Representative				

Date:07/21/03ISR Number: 4181876-2Report Type:Periodic Company Report #WAES 0208USA01052
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastric Ulcer	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Haemorrhage					
MG/DAILY/PO						
	Nausea		Evista	C		
			Pravachol	C		

Date:07/21/03ISR Number: 4181882-8Report Type:Periodic Company Report #WAES 0208USA00036
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4181883-XReport Type:Periodic Company Report #WAES 0208USA00041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Aspirin	C				

Date:07/21/03ISR Number: 4181889-0Report Type:Periodic Company Report #WAES 0207USA02733
Age:70 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Perforation	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Diazide	C				
			Zithromax	C				
			Atenolol	C				

Date:07/21/03ISR Number: 4181891-9Report Type:Periodic Company Report #WAES 0207USA02695
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4181894-4Report Type:Periodic Company Report #WAES 0207USA02526
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY;	
Initial or Prolonged	Erythema Multiforme	Health					25 MG : PO	
		Professional	Avapro	C				
			Levoxyl	C				
			Singulair	C				
			Ultram	C				
			Hydrochlorothiazide (+) Triamter	C				

Date:07/21/03ISR Number: 4181897-XReport Type:Periodic Company Report #WAES 0207USA02419
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Erosive Oesophagitis	Professional					MG/DAILY/PO	
Other	Gastrointestinal Haemorrhage		Celebrex	C				
			Folic Acid	C				
			Glucosamine	C				
			Methotrexate	C				

Date:07/21/03ISR Number: 4181898-1Report Type:Periodic Company Report #WAES 0207USA02210
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertensive Crisis	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181899-3Report Type:Periodic Company Report #WAES 0207USA01698
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE	Renal Failure	Health	Tab Vioxx 50 Mg	PS		ORAL		
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4181900-7Report Type:Periodic Company Report #WAES 0207USA01578
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Aspirin	C				
Other								

Date:07/21/03ISR Number: 4181901-9Report Type:Periodic Company Report #WAES 0207USA01575
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Actonel	C				
			Coenzyme	C				
			Ester-C	C				
			Borage Oil	C				
			Silibinin	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:07/21/03ISR Number: 4181902-0Report Type:Periodic Company Report #WAES 0207USA00934
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
Other		Company	Celebrex	C				
		Representative	Dyazide	C				
			Parlodel	C				
			Sinemet Cr	C				

Date:07/21/03ISR Number: 4181903-2Report Type:Periodic Company Report #WAES 0207USA00823
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged			Fosamax	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4181904-4Report Type:Periodic Company Report #WAES 0207USA00619
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4181905-6Report Type:Periodic Company Report #WAES 0207USA00498
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Renal Failure Acute	Professional					MG/DAILY/PO	
Disability		Company Representative	Advair	C				
Other			Combivent	C				
			Fosamax	C				
			Lasix (Furosemide)	C				
			Protonix	C				
			Calcitonin	C				
			Folic Acid	C				
			Lactulose	C				
			Spironolactone	C				
			Thiamine	C				
			Vitamins (Unspecified)	C				

Date:07/21/03ISR Number: 4181906-8Report Type:Periodic Company Report #WAES 0207USA00305
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other		Professional					MG/DAILY/PO	

Date:07/21/03ISR Number: 4181907-XReport Type:Periodic Company Report #WAES 0207USA00179
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
Other			Norvasc	C				
			Aspirin	C				
			Tamoxifen	C				

Date:07/21/03ISR Number: 4181908-1Report Type:Periodic Company Report #WAES 0207USA00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Blood Pressure Increased	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181909-3Report Type:Periodic Company Report #WAES 0206USA02762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4181910-XReport Type:Periodic Company Report #WAES 0206USA02764
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4181911-1Report Type:Periodic Company Report #WAES 0206USA02624
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -		Professional						
Initial or Prolonged		Company	Advair	C				
Other		Representative	Lotensin	C				
			Tequin	C				
			Albuterol	C				
			Aspirin	C				

Date:07/21/03ISR Number: 4181912-3Report Type:Periodic Company Report #WAES 0206USA02450
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other		Company Representative						

Date:07/21/03ISR Number: 4181913-5Report Type:Periodic Company Report #WAES 0206USA02275
Age:81 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181914-7Report Type:Periodic Company Report #WAES 0206USA02037
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged			Glucophage	C				

Date:07/21/03ISR Number: 4181915-9Report Type:Periodic Company Report #WAES 0206USA01979
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181916-0Report Type:Periodic Company Report #WAES 0206USA01873
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4181917-2Report Type:Periodic Company Report #WAES 0206USA01653
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peptic Ulcer	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Disability		Company Representative						

Date:07/21/03ISR Number: 4181918-4Report Type:Periodic Company Report #WAES 0206USA01430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO

Date:07/21/03ISR Number: 4181919-6Report Type:Periodic Company Report #WAES 0206USA01317
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/03ISR Number: 4181920-2Report Type:Periodic Company Report #WAES 0206USA01310
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4181921-4Report Type:Periodic Company Report #WAES 0206USA01298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accidental Overdose	Health	Tab Vioxx 25 Mg	PS		ORAL	75	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company	Tab Vioxx	SS		ORAL	PO	
		Representative						

Date:07/21/03ISR Number: 4182790-9Report Type:Periodic Company Report #WAES 0206USA01191
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	[Therapy Unspecified]	C				

Date:07/21/03ISR Number: 4182792-2Report Type:Periodic Company Report #WAES 0206USA01015
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4182793-4Report Type:Periodic Company Report #WAES 0206USA00748
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO;	
		Company					12.5	
		Representative					MG/DAILY/PO	
			Lasix (Furosemide)	C				
			Aspirin	C				

Date:07/21/03ISR Number: 4182794-6Report Type:Periodic Company Report #WAES 0206USA00590
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4182795-8Report Type:Periodic Company Report #WAES 0206USA00582
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged	Dyspepsia							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4182796-XReport Type:Periodic Company Report #WAES 0206USA00355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/03ISR Number: 4182797-1Report Type:Periodic Company Report #WAES 0205USA02725
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Accolate	C				
			Atrovent	C				
			Azmacort	C				
			Claritin	C				
			Creon	C				
			Flovent	C				
			Fosamax	C				
			Serevent	C				
			Ultracet	C				
			Albuterol	C				
			Prednisone	C				
			Theophylline	C				

Date:07/21/03ISR Number: 4182799-5Report Type:Periodic Company Report #WAES 0205USA02577
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Professional Company	Pentasa	C				

Disability		Representative	Prempro	C
Other			Triamcinolone	C

Date:07/21/03ISR Number: 4185203-6Report Type:Periodic Company Report #WAES 0305USA00368
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 MG/DAIL/PO	Adverse Event	Consumer	Tab Vioxx 25mg	PS		ORAL
Initial or Prolonged Disability	Renal Failure Acute		Atacand	C		
			Diazide	C		
			Lipitor	C		
			Clozapine	C		

Date:07/21/03ISR Number: 4185227-9Report Type:Periodic Company Report #WAES 0305USA00068
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - PO	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
Initial or Prolonged	Haemorrhage	Professional Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4185229-2Report Type:Periodic Company Report #WAES 0304USA02951
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/03ISR Number: 4185232-2Report Type:Periodic Company Report #WAES 0304USA02870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaphylactic Reaction	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/03ISR Number: 4185233-4Report Type:Periodic Company Report #WAES 0304USA02573
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Respiratory Tract Infection	Consumer	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/03ISR Number: 4185236-XReport Type:Periodic Company Report #WAES 0304USA02148
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Nexium	C				
			Singulair	C				

			Aspirin	C		
			Diltiazem Hydrochloride	C		

Date:07/21/03ISR Number: 4185239-5Report Type:Periodic Company Report #WAES 0304USA02111
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Coumadin	C				
			Aspirin	C				

Date:07/21/03ISR Number: 4185241-3Report Type:Periodic Company Report #WAES 0304USA02096
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4185243-7Report Type:Periodic Company Report #WAES 0304USA01491
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Tablet	PS		ORAL	3	
Other	Haemorrhage	Professional					TABLET/WKY/PO	
	Gastric Ulcer	Company	Aspirin	C				
	Gastritis	Representative						

Date:07/21/03ISR Number: 4185246-2Report Type:Periodic Company Report #WAES 0304USA01481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4186262-7Report Type:Periodic Company Report #WAES 0304USA01305
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage		Coumadin	C				
			Aspirin	C				

Date:07/21/03ISR Number: 4186266-4Report Type:Periodic Company Report #WAES 0304USA00765
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Swelling	Consumer	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Urinary Tract Infection	Health			
MG/DAILY/PO					
		Professional	Coumadin	C	
		Company	Elavil	C	
		Representative	Fosamax	C	
			Lanoxin	C	
			Lasix (Furosemide)	C	
			Lotrel	C	
			Premarin	C	
			Clonidine	C	
			Isosorbide	C	
			Metoprolol	C	

Date:07/21/03ISR Number: 4186267-6Report Type:Periodic Company Report #WAES 0304USA00339
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Ulcer	Consumer	Tab Vioxx 50 Mg	PS		ORAL
SEE IMAGE						
Hospitalization -	Gastric Ulcer Haemorrhage		Ambien	C		
Initial or Prolonged			Oxycontin	C		
			Oxyir	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4186270-6Report Type:Periodic Company Report #WAES 0303USA02493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - SEE IMAGE Initial or Prolonged Disability	Stevens-Johnson Syndrome	Consumer	Tab Vioxx 50 Mg	PS		ORAL		

Date:07/21/03ISR Number: 4186271-8Report Type:Periodic Company Report #WAES 0303USA01898
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Health Professional						

Date:07/21/03ISR Number: 4186272-XReport Type:Periodic Company Report #WAES 0303USA01874
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged								

Date:07/21/03ISR Number: 4186274-3Report Type:Periodic Company Report #WAES 0303USA01423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	
Initial or Prolonged		Company Representative	Aspirin	C				

Date:07/21/03ISR Number: 4186275-5Report Type:Periodic Company Report #WAES 0303USA00324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative						
Disability								

Date:07/21/03ISR Number: 4186276-7Report Type:Periodic Company Report #WAES 0302USA03069
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG ; PRN/PO :	
	Haemorrhage	Professional Company Representative						
			Lipitor	C			BID/PO	
			Synthroid	C				

Date:07/21/03ISR Number: 4186277-9Report Type:Periodic Company Report #WAES 0302USA02692
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged			Allegra	C				
			Atenolol (+) Chlorothalidone	C				

Date:07/21/03ISR Number: 4186279-2Report Type:Periodic Company Report #WAES 0302USA02623
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:07/21/03ISR Number: 4186280-9Report Type:Periodic Company Report #WAES 0302USA02326
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged Other								

Date:07/21/03ISR Number: 4186286-XReport Type:Periodic Company Report #WAES 0302USA01771
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx	PS		ORAL	12.5-25 MG/DAILY/PO	
Other			Aspirin 81 Mg	SS		ORAL	81 MG/DAILY/PO	
			Fosamax	C				
			Maxzide	C				
			Micardis	C				

Date:07/21/03ISR Number: 4186288-3Report Type:Periodic Company Report #WAES 0302USA01773
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
Other			Aspirin	SS		ORAL	325 MG/DAILY/PO	
			Accuretic	C				
			Humulin R	C				
			Humulin U	C				
			Levothroid	C				
			Tiazac	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4186290-1Report Type:Periodic Company Report #WAES 0302USA01680
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Asacol	C				
Other		Representative						

Date:07/21/03ISR Number: 4186292-5Report Type:Periodic Company Report #WAES 0302USA01499
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4186295-0Report Type:Periodic Company Report #WAES 0302USA01272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						
		Company Representative						

Date:07/21/03ISR Number: 4186297-4Report Type:Periodic Company Report #WAES 0302USA01116
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx	PS		ORAL PO
			Effexor	C		
			Lipitor	C		
			Lortab	C		
			Zonegran	C		
			Warfarin	C		

Date:07/21/03ISR Number: 4186300-1Report Type:Periodic Company Report #WAES 0302USA00510
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4186302-5Report Type:Periodic Company Report #WAES 0302USA00316
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4186306-2Report Type:Periodic Company Report #WAES0301USA03052
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Haemorrhage	Professional					MG/DAILY/PO	
Initial or Prolonged	Duodenal Ulcer Perforation	Company Representative	Therapy Unspecifed	C				

Date:07/21/03ISR Number: 4186308-6Report Type:Periodic Company Report #WAES0301USA02872
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nausea	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional						

Date:07/21/03ISR Number: 4186311-6Report Type:Periodic Company Report #WAES0301USA02709
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Haemorrhage	Health Professional	Casodex	C				

Date:07/21/03ISR Number: 4186313-XReport Type:Periodic Company Report #WAES0301US02271
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company						

Date:07/21/03ISR Number: 4186314-1Report Type:Periodic Company Report #WAES0301USA01389
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Triglycerides	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Increased	Health						
Initial or Prolonged	Chest Pain	Professional	Lasix (Furosemide)					
Disability	Nephritis Interstitial		40 Mg	SS			40 MG/DAILY	
Other	Rash		Norvasc	C				
	Renal Failure Acute		Plavix	C				
			Zestril	C				
			Atenolol	C				
			Prednisone	C				

Date:07/21/03ISR Number: 4186315-3Report Type:Periodic Company Report #WAES0301USA01203
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Tab Vioxx 25 Mg	PS		ORAL	24 MG/DAILY/PO	
Hospitalization -	Fluid Retention	Health						
Initial or Prolonged	Hyponatraemia	Professional	Enalapril Maleate					
Other	Pain In Extremity		5mg	SS			5 MG/DAILY	
			Spironolactone 25 Mg	SS			50 MG/DAILY	
			Levoxyl	C				

				Norvasc	C		
				Premarin	C		

Date:07/21/03ISR Number: 4186317-7Report Type:Periodic Company Report #WAES0301USA01198
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Other		Professional	Hydrodiuril	C				
		Company	Lamisil	C				
		Representative						

Date:07/21/03ISR Number: 4186318-9Report Type:Periodic Company Report #WAES 0301USA01119
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional						
		Company						
		Representative						

Date:07/21/03ISR Number: 4186319-0Report Type:Periodic Company Report #WAES0301USA00847
Age:14 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company						
		Representative						

Date:07/21/03ISR Number: 4186320-7Report Type:Periodic Company Report #WAES0301USA00620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	3 DAY
			Cozaar	C				
			Zetia	C				
			Aspirin	C				
			Atenolol	C				
			Hormones (Unspecified)	C				

Date:07/21/03ISR Number: 4191538-3Report Type:Periodic Company Report #WAES 0210USA01562
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis	Health Professional	Tab Vioxx	PS		ORAL	PO	

Date:07/21/03ISR Number: 4191541-3Report Type:Periodic Company Report #WAES 0210USA01399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional

		Company Representative	Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY/PO; SEE IMAGE						

Date:07/21/03ISR Number: 4191542-5Report Type:Periodic Company Report #WAES 0210USA01402
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO						
		Company Representative	Coreg	C		
			Coumadin	C		
			Cozaar	C		
			Darvocet-N	C		
			Lanoxin	C		
			Lasix (Furosemide)	C		
			Slow-Mag	C		
			Uniphyl	C		

Date:07/21/03ISR Number: 4191543-7Report Type:Periodic Company Report #WAES 0210USA01296
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 MG/PO; Initial or Prolonged	Haemorrhage	Professional				
SEE IMAGE	1 MON					
Other		Company Representative	Celebrex	C		
			Nonsteroidal Anti-Inflammatory	C		

Date:07/21/03ISR Number: 4191545-0Report Type:Periodic Company Report #WAES 0210USA01299
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4191547-4Report Type:Periodic Company Report #WAES 0210USA01020
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Disability								
Other								

Date:07/21/03ISR Number: 4191549-8Report Type:Periodic Company Report #WAES 0210USA01001
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Renal Failure	Health
Initial or Prolonged		Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
PO						

Date:07/21/03ISR Number: 4191551-6Report Type:Periodic Company Report #WAES 0210USA00896
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL
PO						
Initial or Prolonged			Plavix	C		

Date:07/21/03ISR Number: 4191553-XReport Type:Periodic Company Report #WAES 0210USA00897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional				
Disability		Company Representative				

Date:07/21/03ISR Number: 4191555-3Report Type:Periodic Company Report #WAES 0210USA00735
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Oedema Peripheral	Professional				
MG/DAILY/PO						
		Company Representative				

Date:07/21/03ISR Number: 4191557-7Report Type:Periodic Company Report #WAES 0210USA00474
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Vomiting	Professional Company Representative						

Date:07/21/03ISR Number: 4191559-0Report Type:Periodic Company Report #WAES 0210USA00131
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Impairment	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged		Professional						

Date:07/21/03ISR Number: 4191561-9Report Type:Periodic Company Report #WAES 0210USA00138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased	Health	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	
Other		Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4191562-0Report Type:Periodic Company Report #WAES 0209USA02811
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	

Date:07/21/03ISR Number: 4191564-4Report Type:Periodic Company Report #WAES 0209USA02390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Oedema Peripheral	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/03ISR Number: 4191565-6Report Type:Periodic Company Report #WAES 0209USA01988
Age:54 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg Prevacid	PS C		ORAL	25 MG/DAILY/PO	3 WK

Date:07/21/03ISR Number: 4191566-8Report Type:Periodic Company Report #WAES 0209USA01960
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema	Consumer	Tab Vioxx 25mg	PS		ORAL	25MG/DAILY/PO	

Hospitalization - Initial or Prolonged				Cozaar	C		

Date:07/21/03ISR Number: 4191567-XReport Type:Periodic Company Report #WAES 0209USA01712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Consumer	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Urinary Tract Infection		Cortisone	C				

Date:07/21/03ISR Number: 4191568-1Report Type:Periodic Company Report #WAES 0209USA01670
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Ulcer	Health	Tab Vioxx 50 Mg	PS		ORAL	50MG/DAILY/PO	
Other		Professional	Remicade	C				
			Methotrexate	C				
			Prednisone	C				

Date:07/21/03ISR Number: 4191569-3Report Type:Periodic Company Report #WAES 0209USA01366
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Peptic Ulcer	Company	Accupril	C				
		Representative	Arava	C				
			Hyzaar	C				
			Senokot-S	C				

Date:07/21/03ISR Number: 4191570-XReport Type:Periodic Company Report #WAES 0212USA00600
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -		Professional					MG/DAILY/PO	
Initial or Prolonged		Company	Atenolol 50 Mg	SS			50 MG/BID	
Other		Representative	Ativan	C				
			Dolobid	C				
			Norflex	C				
			Prozac	C				
			Tylenol	C				
			Ultracet	C				
			Albuterol	C				

Date:07/21/03ISR Number: 4191571-1Report Type:Periodic Company Report #WAES 0211USA02564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hepatitis Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Other		Professional					MG/DAILY/PO	
		Company	Avonex	C				

	Representative	Celexa	C
		Imitrex	C
		Neurontin	C
		Baclofen	C

Date:07/21/03ISR Number: 4191572-3Report Type:Periodic Company Report #WAES 0211USA02420
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4191573-5Report Type:Periodic Company Report #WAES 0211USA02002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx Unk	PS		ORAL	25-50	
Initial or Prolonged		Professional Company Representative					MG/DAILY/PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4191574-7Report Type:Periodic Company Report #WAES 0211USA01877
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO; SEE IMAGE	
			Axid	C				
			Baycol	C				
			K-Dur	C				
			Lotesin	C				
			Furosemide	C				

Date:07/21/03ISR Number: 4191575-9Report Type:Periodic Company Report #WAES 0211USA01801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Advil	C				
			Aleve	C				
			Prevpac	C				

Date:07/21/03ISR Number: 4191576-0Report Type:Periodic Company Report #WAES 0211USA01693
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	6 DAY
Hospitalization - Initial or Prolonged		Company Representative	Antineoplastic	C				

Date:07/21/03ISR Number: 4191577-2Report Type:Periodic Company Report #WAES 0211USA01562
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative	Amaryl	C				
Disability			Flomax (Tamsulosin Hydrochloride)	C				
Other			Lasix (Furosemide)	C				
			Pravachol	C				
			Tylenol With Codeine #3	C				
			Vasotec	C				
			[Composition Unspecified]	C				
			Aspirin	C				
			Potassium Chloride	C				
			Vitamins	C				

Date:07/21/03ISR Number: 4191578-4Report Type:Periodic Company Report #WAES 0211USA01365
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/1X/PO	
	Nausea	Professional Company Representative						
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4191579-6Report Type:Periodic Company Report #WAES 0211USA01190
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Nausea						MG/DAILY/PO	
	Vomiting		Hyzaar	C				
			Pepcid	C				

Date:07/21/03ISR Number: 4191580-2Report Type:Periodic Company Report #WAES 0211USA01095
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged								

Date:07/21/03ISR Number: 4191581-4Report Type:Periodic Company Report #WAES 0211USA00520
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Haemorrhage	Professional	Celebrex	C				

Date:07/21/03ISR Number: 4191582-6Report Type:Periodic Company Report #WAES 0210USA02973
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Vioxx	PS		ORAL	25	
Hospitalization -	Gastrointestinal	Professional					MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Company	Celebrex	C				
Other		Representative	Effexor Xr	C				

Fosamax	C
Isordil	C
Synthroid	C
Ibuprofen	C
Verapamil	C

Date:07/21/03ISR Number: 4191583-8Report Type:Periodic Company Report #WAES 0210USA02696
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pancreatitis	Health Professional Company Representative	Vioxx	PS		ORAL	25 MG/PRN/PO	

Date:07/21/03ISR Number: 4191584-XReport Type:Periodic Company Report #WAES 0210USA02566
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Health	Vioxx	PS		ORAL	50 MG/DAILY/PO	
Hospitalization - Initial or Prolonged Disability	Dizziness	Professional						
	Rash	Company Representative	[Therapy Unspecified]	C				
Other								

Date:07/21/03ISR Number: 4191585-1Report Type:Periodic Company Report #WAES 0210USA02327
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Renal Failure Acute	Company Representative	Ms Contin	C				

Date:07/21/03ISR Number: 4191586-3Report Type:Periodic Company Report #WAES 0210USA02306
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Stevens-Johnson Syndrome	Health	Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Glucotrol Xl	C				

Date:07/21/03ISR Number: 4191587-5Report Type:Periodic Company Report #WAES 0210USA02076
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	UNK/UNK/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4191588-7Report Type:Periodic Company Report #WAES 0210USA01771
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastric Haemorrhage	Consumer	Vioxx	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
			Claritin-D	C		
			Plavix	C		
			Tiazac	C		
			Furosemide	C		
			Potassium Chloride	C		

Date:07/21/03ISR Number: 4191589-9Report Type:Periodic Company Report #WAES 0210USA01659
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Health	Vioxx	PS		ORAL
25						
Hospitalization -	Perforation	Professional				
MG/DAILY/PO						
Initial or Prolonged	Renal Failure		Diovan	C		
Other			Lipitor	C		
			Tarka	C		

Date:07/21/03ISR Number: 4191590-5Report Type:Periodic Company Report #WAES 0209USA01313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure	Health	Tab Vioxx 25 Mg	PS		
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4191591-7Report Type:Periodic Company Report #WAES 0209USA01213
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Vioxx	PS			25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/03ISR Number: 4191592-9Report Type:Periodic Company Report #WAES 0209USA01200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Health	Vioxx	PS			UNK	
Initial or Prolonged		Professional						
		Company Representative						

Date:07/21/03ISR Number: 4191593-0Report Type:Periodic Company Report #WAES 0209USA01175
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx 12.5 Mg	PS			12.5	
	Nausea	Health					MG/DAILY/PO	
		Professional	Premarin	C				
			Toprol Xl Tablets	C				
			Ibuprofen	C				
			Theophylline	C				

Date:07/21/03ISR Number: 4191594-2Report Type:Periodic Company Report #WAES 0209USA00612
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastroduodenal Ulcer	Health	Vioxx	PS			UNK	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company Representative	Detrol La	C				
			Vicodin Tablets	C				
Other	Oesophageal Ulcer							

Date:07/21/03ISR Number: 4191595-4Report Type:Periodic Company Report #WAES 0209USA00346
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Consumer	Vioxx Unk	PS		ORAL	PO	

Date:07/21/03ISR Number: 4191596-6Report Type:Periodic Company Report #WAES 0209USA00041
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4191597-8Report Type:Periodic Company Report #WAES 0208USA04261
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4191598-XReport Type:Periodic Company Report #WAES 0208USA04017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4191599-1Report Type:Periodic Company Report #WAES 0208USA04018
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Oedema	Health	Vioxx	PS		OPHTHALMIC	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4193346-6Report Type:Periodic Company Report #WAES 0204USA02084
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Hospitalization - MG/DAILY/PO	Haemorrhage	Professional
Initial or Prolonged Other	Gastric Ulcer Haemorrhage	Company Representative

Date:07/21/03ISR Number: 4193349-1Report Type:Periodic Company Report #WAES 0204USA01728
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective	Health	Tab Vioxx 25 Mg	PS		ORAL	MG	
Other	Gastric Ulcer Pain	Professional	Claritin-D	C				
			Tamoxifen	C				
			Vitamins (Unspecified)	C				

Date:07/21/03ISR Number: 4193354-5Report Type:Periodic Company Report #WAES 0203USA03029
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other		Company Representative	Tab Flexeril 10 Mg	SS			OPHTHALMIC	10 MG/TID/PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4193359-4Report Type:Periodic Company Report #WAES 0201USA01376
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
		Professional Company Representative	Tylenol	C				
			Herbs (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:07/21/03ISR Number: 4193361-2Report Type:Periodic Company Report #WAES 99110750
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Therapeutic Response	Professional						
	Unexpected	Company Representative	Aspirin	C				

Date:07/21/03ISR Number: 4193363-6Report Type:Periodic Company Report #WAES 0305USA02127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative	Glucophage	C				
Disability								
Other								

Date:07/21/03ISR Number: 4193365-XReport Type:Periodic Company Report #WAES 0305USA01992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
PO						
Hospitalization - Initial or Prolonged	Haemorrhage	Professional	Prevacid	C		

Date:07/21/03ISR Number: 4193366-1Report Type:Periodic Company Report #WAES 0305USA01732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional Company Representative	Aspirin	C		

Date:07/21/03ISR Number: 4193368-5Report Type:Periodic Company Report #WAES 0305USA01604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hepatic Failure	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative				

Date:07/21/03ISR Number: 4193369-7Report Type:Periodic Company Report #WAES 0305USA01400
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4193370-3Report Type:Periodic Company Report #WAES 0205USA01788
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -	Perforation	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Mobic	C				
Other								

Date:07/21/03ISR Number: 4193372-7Report Type:Periodic Company Report #WAES 0205USA01285
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
Initial or Prolonged	Haemorrhage		Coumadin	C				

Date:07/21/03ISR Number: 4193374-0Report Type:Periodic Company Report #WAES 0205USA01178
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	3 DAY

		Company Representative	Therapy Unspecified	C		

Date:07/21/03ISR Number: 4193376-4Report Type:Periodic Company Report #WAES 0205USA00725
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -		Health						
Initial or Prolonged		Professional	Atacand	C				
			Dyazide	C				
			Lipitor	C				
			Clorazepate Dipotassium	C				

Date:07/21/03ISR Number: 4193378-8Report Type:Periodic Company Report #WAES 0205USA00584
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	
		Professional	Aleve	C				
		Company	Zoloft	C				
		Representative	Ibuprofen	C				
			Vitamins	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4193381-8Report Type:Periodic Company Report #WAES 0205USA00545
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis Aseptic	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/03ISR Number: 4193383-1Report Type:Periodic Company Report #WAES 0205USA00290
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hyperkalaemia		Tab Vioxx 25 Mg	PS		ORAL	PO	
			Prempro	C				
			Prednisone	C				

Date:07/21/03ISR Number: 4193386-7Report Type:Periodic Company Report #WAES 0205USA00143
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional Company	Coumadin 2.5 Mg	SS			SEE IMAGE	
Other	International Normalised Ratio Increased	Representative	Celebrex	C				
	Prothrombin Time Prolonged		Cosopt	C				
	Thrombocytopenia		Hyzaar	C				
			Lipitor	C				
			Synthroid	C				
			Tiazac	C				
			Xalatan	C				
			Aspirin	C				
			Pilocarpine	C				

Date:07/21/03ISR Number: 4193390-9Report Type:Periodic Company Report #WAES 0204USA02988
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage							
Other								

Date:07/21/03ISR Number: 4193391-0Report Type:Periodic Company Report #WAES 0204USA02378
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic		Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged			Aspirin	C				
			Cyanocobalamin	C				
			Nonsteroidal Anti-Inflammatory	C				

Date:07/21/03ISR Number: 4194649-1Report Type:Periodic Company Report #WAES 0301USA00586
Age: Gender:Male I/FU:I

Outcome	PT	Report Source
Hospitalization -	Gastrointestinal	Health
Initial or Prolonged	Haemorrhage	Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Vioxx Unk	PS		ORAL	PO	

Date:07/21/03ISR Number: 4194651-XReport Type:Periodic Company Report #WAES 0301USA00347
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/03ISR Number: 4194654-5Report Type:Periodic Company Report #WAES 0301USA00194
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Tab Vioxx Unk	PS		ORAL	50 MG/DAILY/PO	
	Chills	Professional						
	Feeling Abnormal	Company Representative	Miacalcin	C				
			Synthroid	C				
			Zyrtec	C				
			Ibuprofen	C				

Date:07/21/03ISR Number: 4194656-9Report Type:Periodic Company Report #WAES 0301USA00041
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Renal Failure	Consumer	Vioxx	PS		ORAL	25 MG/DAILY/PO	

Initial or Prolonged			Prinivil 20 Mg	SS		ORAL
20						
MG/DAILY/PO						
			Celexa	C		
			Lipitor	C		
			Neurontin	C		
			Norvasc	C		
			Prilosec	C		
			Toprol Xl	C		
			Tricor	C		
			Warfarin	C		

Date:07/21/03ISR Number: 4194658-2Report Type:Periodic Company Report #WAES 0212USA01811
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS		ORAL
25						
MG/DAILY/PO						
			Alphagan	C		
			Atacand	C		
			Flomax (Tamsulosin Hydrochloride)	C		
			Xalatan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/03ISR Number: 4194660-0Report Type:Periodic Company Report #WAES 0212USA01682
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Renal Failure							

Date:07/21/03ISR Number: 4194662-4Report Type:Periodic Company Report #WAES 0212USA01367
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema	Health	Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/03ISR Number: 4194664-8Report Type:Periodic Company Report #WAES 0212USA01227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/03ISR Number: 4194665-XReport Type:Periodic Company Report #WAES 0212USA00982
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged	Haemorrhage	Professional Company						

Representative

Date:07/21/03ISR Number: 4194667-3Report Type:Periodic Company Report #WAES 0212USA00876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Vioxx	PS		ORAL	DAILY/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Aspirin	C				
			Ibuprofen	C				

Date:07/22/03ISR Number: 4151507-6Report Type:Expedited (15-DaCompany Report #WAES 0307CAN00034
Age:16 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY	
	Anxiety		Zafirlukast	C				
	Hallucination		Fluticasone Propionate And Salmeterol Xinafoate	C				
	Insomnia							
	Paranoia							
	Schizophrenia		Albuterol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/03ISR Number: 4151516-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA01256
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Myocardial Infarction		Vioxx	SS		ORAL		
			[Composition Unspecified]	C				
			[Therapy Unspecified]	C				

Date:07/22/03ISR Number: 4151752-XReport Type:Expedited (15-DaCompany Report #WAES 0307DNK00007
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Helicobacter Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema Peripheral		Furosemide	C		ORAL		
			Spironolactone	C		ORAL		

Date:07/22/03ISR Number: 4151755-5Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00026
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		138 DAY
	Attack		Vioxx	SS		ORAL		
			Testosterone Undecanoate	C		ORAL		
			Desmopressin	C				
			Valproate Sodium	C		ORAL		

Date:07/22/03ISR Number: 4151757-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01538
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged		Cardiac Disorder					
Disability		Myocardial Infarction					

Date:07/22/03ISR Number: 4151763-4Report Type:Expedited (15-DaCompany Report #WAES 0307HUN00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cytolytic Hepatitis Hepatotoxicity		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/03ISR Number: 4151767-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA02087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/03ISR Number: 4152224-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01504
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Asthenia		Klonopin	C				
Initial or Prolonged	Blood Creatine		Xanax	C				
Disability	Phosphokinase Increased							
Other	Blood Urine Present							
	Bone Pain							
	Dehydration							
	Fatigue							
	Generalised Oedema							
	Hypoaesthesia							
	Muscle Spasms							
	Myositis							
	Oedema Peripheral							
	Polyuria							
	Weight Decreased							
	Weight Increased							

Date:07/23/03ISR Number: 4152225-0Report Type:Expedited (15-DaCompany Report #WAES 0307ZAF00019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Peptic Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/23/03ISR Number: 4152226-2Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00009
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dehydration							
	Gastrointestinal							
	Haemorrhage							
	Haematemesis							

Date:07/23/03ISR Number: 4152236-5Report Type:Direct Company Report #CTU 198504
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arterial Occlusive		Vioxx Merck	PS	Merck	ORAL	2/DAY ORAL	
	Disease							
	Headache							
	Hypertension							
	Renal Disorder							

Date:07/23/03ISR Number: 4152681-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA00074
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage							
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/03ISR Number: 4152684-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA01513
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Diverticulum Duodenal							
	Duodenal Perforation							
	Respiratory Disorder							

Date:07/23/03ISR Number: 4152686-7Report Type:Expedited (15-DaCompany Report #WAES 0302ZAF00013
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Hallucination, Auditory		Vioxx	SS		ORAL	11	DAY

Date:07/23/03ISR Number: 4152688-0Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Arrhythmia
	Supraventricular
	Atrial Flutter
	Atrial Tachycardia
	Back Pain
	Blood Urea
	Bronchitis
	Bronchitis Acute
	Cardio-Respiratory Arrest
	Chest Pain
	Cholelithiasis
	Chronic Obstructive
	Airways Disease
	Exacerbated
	Compression Fracture
	Coronary Artery Disease
	Electrocardiogram St-T

Segment Abnormal
Electromechanical
Dissociation
Gastritis
General Physical Health
Deterioration
Haematocrit
Haemoglobin
Haemoptysis
Hepatic Cyst
Hyperhidrosis
Hypertension
Hypotension
Multiple Myeloma
Oxygen Saturation
Decreased
Pallor
Platelet Count
Pneumonia Pneumococcal
Pneumonia Streptococcal
Rib Fracture

	Streptococcal Sepsis						
	Tachypnoea						
	Tobacco User	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tracheobronchitis		Vioxx	PS	Merck & Co., Inc	ORAL	425	DAY
	Upper Respiratory Tract Infection		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL		
	White Blood Cell Count		Lipitor	C				
			Metoprolol	C				
			Prozac	C				
			Combivent	C				
							RESPIRATORY (INHALATION)	
			Daypro	C		ORAL		
			Prednisone	C				
			Ventolin (Albuterol Sulfate)	C				
			Cartia (Aspirin)	C		ORAL		
			Nicotine	C				
			Xanax	C		ORAL		
			Cardizem Cd	C				
			Captopril	C				

Date:07/23/03ISR Number: 4152689-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA02261
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
			Inderal	C				
			Isordil	C				
			Aspirin	C				
			Zocor	C		ORAL		

Date:07/23/03ISR Number: 4152693-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02254
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Haemoglobin Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Synthroid	C		
			Lipitor	C		
			Nexium	C		
			Vicodin Tablets	C		

Date:07/23/03ISR Number: 4152694-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA02343
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Ultracet	C		
			Cozaar	C		ORAL

Date:07/23/03ISR Number: 4153464-5Report Type:Direct Company Report #CTU 198601
Age:53 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Eye Swelling
	Rash

Swelling Face
Urticaria

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 25 Mg	PS		ORAL	25 MG ORAL	DAILY

Date:07/23/03ISR Number: 4154344-1Report Type:Expedited (15-DaCompany Report #WAES0306USA01376
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Lower	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	
	Anaemia	Professional	Lasix (Furosemide)	C				
	Arthralgia	Company	Maxzide	C				
	Blood Cholesterol	Representative	Pneumovax 23	C				
	Increased		Premarin	C				
	Blood Thyroid Stimulating		Provera	C				
	Hormone Decreased		Synthroid	C				
	Constipation		Toprol Xl	C				
	Creatinine Renal		Amitriptyline					
	Clearance Decreased		Hydrochloride)	C				
	Diabetes Mellitus		Chondroitin	C				
	Goitre		Glucosamine	C				
	Gravitational Oedema		Spironolactone	C				
	Heart Rate Increased		Vitamins					
	Hyperglycaemia		(Unspecified)	C				
	Hyperlipidaemia		Lortab	C				
	Hypertension							
	Low Density Lipoprotein							
	Increased							
	Macular Degeneration							
	Nausea							
	Oedema							
	Osteoarthritis							
	Red Blood Cell Count							
	Decreased							
	Renal Failure							
	Renal Impairment							
	Thyroid Cyst							
	Urine Bilirubin Increased							
	Weight Increased							

White Blood Cell Count
Increased

Date:07/24/03ISR Number: 4153198-7Report Type:Expedited (15-DaCompany Report #WAES 0307CHN00014
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Leflunomide	C		ORAL		
	Hypoaesthesia		Methotrexate	C				
	Lacunar Infarction		Fosinopril Sodium	C		ORAL		
			Thymopentin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/24/03ISR Number: 4153541-9Report Type:Expedited (15-DaCompany Report #WAES 0305DEU00033
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer Haemorrhage		Tramadol Hydrochloride	C		ORAL		
	Hiatus Hernia		Oxazepam	C		ORAL		
	Reflux Oesophagitis		Phenprocoumon	C		ORAL		

Date:07/24/03ISR Number: 4153542-0Report Type:Expedited (15-DaCompany Report #WAES 0307CAN00068
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Oedema							

Date:07/24/03ISR Number: 4153543-2Report Type:Expedited (15-DaCompany Report #WAES 0304BEL00028
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer		Bumetanide	C		ORAL		
	Peritonitis		Spironolactone	C		ORAL		
Other			Oxybutynin Chloride	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Aspirin	C		ORAL		
			Citalopram Hydrobromide	C				
			Betahistine Hydrochloride	C				

Date:07/24/03ISR Number: 4153546-8Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00160
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Generalised Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:07/24/03ISR Number: 4153548-1Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
			Methotrexate	C				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				

Date:07/24/03ISR Number: 4153549-3Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age:83 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening

Hospitalization - Initial or Prolonged	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Cardiac Failure Dermatitis Exfoliative Skin Lesion Skin Reaction		[Therapy Unspecified]	C		ORAL		

Date:07/24/03ISR Number: 4153551-1Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00173
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Dyspepsia Melaena		Aluminum Hydroxide And Magnesium Carbonate	C				
			Alginic Acid And Aluminum Hydroxide And Magnesium Trisilicate And Sodium Bicarbonate	C		ORAL		

Date:07/24/03ISR Number: 4153552-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA01431
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Toprol Xl Tablets	C				

Date:07/24/03ISR Number: 4153554-7Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00049
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 179 DAY	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 366 DAY	Drug Level Increased		Spironolactone	C		ORAL
	International Normalised Ratio Increased		Digoxin	C		ORAL
			Fluindione	C		ORAL
	Kidney Enlargement		Fluindione	C		ORAL
	Lung Disorder		Furosemide	C		ORAL
	Renal Failure		Cozaar	C		ORAL
			Melilot And Rutin	C		
			Adrafinil	C		
			Buflomedil Hydrochloride	C		ORAL
			Buflomedil Hydrochloride	C		ORAL

Date:07/24/03ISR Number: 4153557-2Report Type:Expedited (15-DaCompany Report #WAES 0307PHL00017
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death 6 DAY	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Haemorrhage		Aluminum Hydroxide And Magnesium Hydroxide	C		ORAL
Hospitalization - Initial or Prolonged 2 DAY			Sulfamethoxazole And			

			Trimethoprim	C		ORAL
2 DAY						

Date:07/24/03ISR Number: 4156101-9Report Type:Expedited (15-DaCompany Report #2003020437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression	Health	Zoloft (Sertraline)	PS		
	Disease Recurrence	Professional	Rofecoxib			
	Drug Interaction	Company	(Rofecoxib)	SS		
	Grand Mal Convulsion	Representative	Olanzapine			
			(Olanzapine)	SS		

Date:07/24/03ISR Number: 4156354-7Report Type:Expedited (15-DaCompany Report #DSA_22996_2003
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dialysis	Foreign	Enalapril Maleate	PS		ORAL
5 MG QD PO						
Life-Threatening	Drug Interaction	Health	Rofecoxib	SS		ORAL
25 MG UNK PO						
Hospitalization -	Duodenal Ulcer	Professional	Risperdal	SS		ORAL
1.5 MG QD PO						
Initial or Prolonged	Haemorrhage	Other	Zyprexa	SS		ORAL
10 MG QD PO						
	Renal Failure		Nexium	SS		
20 MG BID						
			Lasix	SS		ORAL
40 MG QD PO						

Date:07/24/03ISR Number: 4156514-5Report Type:Expedited (15-DaCompany Report #DSA_23002_2003
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Coma	Health	Cardizem	PS		
Hospitalization -	Confusional State	Professional	Tracleer	SS		
125 MG BID						
Initial or Prolonged	Haematocrit Decreased		Tracleer	SS		ORAL
62.5 MG BID						

	Hypoglycaemia		
PO			
	Pneumonia	Flolan	SS
	Pneumonia Aspiration	Vioxx	SS
	Respiratory Arrest	Neurontin	SS
	Thrombocytopenia	Prevacid	C
	White Blood Cell Count	Aldactone	C
	Decreased	Elavil	C
		Celexa	C
		Oxycontin	C
		Allegra	C
		Lasix	C
		Warfarin Sodium	C

Date:07/25/03ISR Number: 4153847-3Report Type:Expedited (15-DaCompany Report #PHNU2003DE02717
Age:78 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Aspartate
Hospitalization -	Aminotransferase
Initial or Prolonged	Increased
	Blood Creatine
	Phosphokinase Increased
	Blood Creatinine
	Increased
	Blood Lactate
	Dehydrogenase Increased
	Blood Potassium Increased
	Blood Urea Increased

		Blood Urine C-Reactive Protein Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Disorder		Voltaren Plus	PS	Novartis Sector: Pharma	ORAL
1 DF, BID	1440 MIN	Fluid Overload					
		Fluid Retention		Vioxx	SS		ORAL
25 mg, QD	2880 MIN						
		Haematocrit Decreased		Cefotaxime	C		
		Haemodialysis		Novamin	C		
		Haemoglobin Decreased		Rapifen	C		
		Hydrocholecystis		Dynasteit	C		
		Mean Cell Haemoglobin		Furosemide	C		
		Concentration		Clexane	C		
		Mean Cell Haemoglobin		Mcp "Aliud Pharma"	C		
		Decreased		Vomex A "Endopharm"	C		
		Nausea		Adalat	C		
		Pallor		Valoron "Goedecke"	C		
		Perihepatic Discomfort					
		Platelet Count Decreased					
		Pleural Effusion					
		Postoperative Renal Failure					
		Red Blood Cell Count Decreased					
		Renal Disorder					
		Urine Output Decreased					

Date:07/25/03ISR Number: 4153944-2Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0417428A
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Asthenia		Flolan	PS	Glaxosmithkline	INTRAVENOUS
Hospitalization -		Coma		Tracleer	SS		ORAL
62.5MG Twice Initial or Prolonged		Confusional State					
per day	53 DAY						
Other		Dysphagia		Vioxx	SS		
		Gastrointestinal Motility		Cardizem	SS	Glaxosmithkline	
		Disorder		Neurontin	SS		
		Haematocrit Decreased		Prevacid	C		
		Hyperhidrosis		Aldactone	C		

Hypoglycaemia	Elavil	C	Glaxosmithkline
Lung Infiltration	Celexa	C	
Pneumonia Aspiration	Oxycontin	C	
Pyrexia	Allegra	C	
Rash Erythematous	Lasix	C	Glaxosmithkline
Rash Generalised	Coumadin	C	Glaxosmithkline
Respiratory Arrest			
Sepsis			
Thrombocytopenia			
Weight Decreased			
White Blood Cell Count Decreased			

Date:07/25/03ISR Number: 4155094-8Report Type:Direct Company Report #CTU 198685
Age:90 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Distension		Vioxx	PS		ORAL	PO	
	Duodenal Ulcer		Aspirin	SS				
	Perforation							
	Malnutrition							
	Peritonitis							
	Pneumothorax							
	Renal Failure Acute							
	Respiratory Failure							
	Sepsis							
	Septic Shock							

Date:07/25/03ISR Number: 4156831-9Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Health Professional	Zometa (Zoledronate) Solution For Injection	PS		INTRAVENOUS	4 MG, UNK,	
	Blood Pressure Increased							
	Femoral Bruit							
	Glucose Urine					INTRAVENOUS		
	Herpes Zoster		Vioxx (Rofecoxib)	SS			25 MG	
	Oedema Peripheral		E7070 (Goal) (Paraffin Soft)	SS		INTRAVENOUS	1449 MG, OT,	
	Renal Failure Acute							
	Renal Tubular Necrosis					INTRAVENOUS		
			Co-Diovan	C				
			Verapamil (Verapamil)	C				
			Duragesic (Fentanyl)	C				
			Lipitor	C				
			Zoloft (Sertraline Hydrochloride)	C				
			Percocet (Oxycodone Hydrochloride)	C				
			Prevacid (Lansoprazole)	C				

Lasix C

Date:07/25/03ISR Number: 4157506-2Report Type:Expedited (15-DaCompany Report #WAES 01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Antinuclear Antibody
	Positive
	Anxiety
	Auricular Swelling
	Biopsy Skin Abnormal
	Blood Lactate
	Dehydrogenase Increased
	Blood Pressure Increased
	Burning Sensation
	Cataract
	Dermatitis
	Diabetes Mellitus
	Non-Insulin-Dependent
	Drug Hypersensitivity
	Eczema
	Enterococcal Infection

		Epidermal Naevus					
		Epidermal Necrosis					
		Erectile Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erythema	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Excoriation	Health				
MG/DAILY/PO							
		Fatigue	Professional	Celebrex 200 Mg	SS		
200 MG/DAILY							
		Feeling Cold		Anafranil	C		
		Heart Injury		Lidex	C		
		Hypercholesterolaemia		Lipitor	C		
		Inflammation		Proventil Inhaler	C		
		Insomnia					
		Lung Injury					
		Lymphocytic Infiltration					
		Nasal Oedema					
		Nervousness					
		Neurodermatitis					
		Neutrophil Count					
		Increased					
		Pain					
		Pruritus					
		Pulse Abnormal					
		Rash Macular					
		Rash Pruritic					
		Rash Scaly					
		Rhinorrhoea					
		Scab					
		Scar					
		Seborrhoeic Keratosis					
		Secretion Discharge					
		Skin Discolouration					
		Skin Oedema					
		Skin Ulcer					
		Sleep Disorder					
		Staphylococcal Infection					
		Upper Respiratory Tract					
		Infection					
		Urticaria					
		Urticaria Papular					
		Vascular Insufficiency					
		White Blood Cell Count					

Date:07/25/03ISR Number: 4157514-1Report Type:Expedited (15-DaCompany Report #WAES 99091937
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort Atherosclerosis Blood Cholesterol Increased Blood Pressure Increased Blood Thyroid Stimulating Hormone Increased Blood Triglycerides Increased Chest Pain Coronary Artery Disease Coronary Artery Occlusion Dyspepsia Electrocardiogram St-T Segment Abnormal

		Epigastric Discomfort					
		Eructation					
		Gastroduodenitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Disorder	Consumer	Vioxx Unk	PS		ORAL
1-2TABLET/DAI							
		Hepatic Steatosis	Health				
LY/PO							
		Hepatocellular Damage	Professional	Methotrexate			
		Hiatus Hernia		(Methotrexate			
		Hyperlipidaemia		Sodium)	C		
		Hypothyroidism		Cortisone	C		
		Inflammation		Famotidine	C		
		Low Density Lipoprotein		Influenza Virus			
		Increased		Vaccine	C		
		Myocardial Infarction		Metoclopramide	C		
		Oedema Peripheral		Omeprazole	C		
		Psoriatic Arthropathy		Prednisone	C		
		Respiratory Rate					
		Increased					

Date:07/25/03ISR Number: 4157531-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02502
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia	Health	Tab Vioxx Unk	PS		ORAL
PO							
		Blood Glucose Increased	Professional	Advil	C		
		Brain Stem Infarction	Company				
		Buttock Pain	Representative				
		Cerebral Infarction					
		Hypertension					
		Radicular Syndrome					

Date:07/29/03ISR Number: 4156746-6Report Type:Expedited (15-DaCompany Report #WAES 0307NZL00013
Age:69 YR Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Dyspnoea		Vasotec	C		
		Myocardial Infarction		Cilazapril	C		

Allopurinol	C
Cabergoline	C

Date:07/29/03ISR Number: 4156747-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01597
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Other	Anaemia
	Blood Potassium Decreased
	Cardiac Murmur
	Drug Abuser
	Dysfunctional Uterine
	Bleeding
	Dysmenorrhoea
	Endometriosis
	Hypertension
	Muscle Spasms
	Myalgia
	Nephrotic Syndrome
	Pain In Extremity
	Pharyngitis

		Renal Failure Chronic Sinus Headache Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Uterine Leiomyoma		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS		ORAL
				Vioxx	SS		ORAL
310	DAY						
				Celebrex	SS		ORAL
				Cephalexin	C		
10	DAY						
				Cephalexin	C		
				Ferrous Sulfate	C		
				Ultram	C		
				Vicoprofen	C		
				Acetaminophen And Hydrocodone Bitartrate	C		
				Terazol 3 Vaginal Cream	C		
VAGINAL		7 DAY					
				Zyrtec	C		
				Biaxin Xl	C		
				Acetaminophen And Codeine	C		
				Cenestin	C		
				Premarin	C		
				Motrin	C		
				[Therapy Unspecified]	C		

Date:07/30/03ISR Number: 4157375-0Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12275871
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fluid Retention Weight Increased		Metaglip Tabs 5 Mg/500 Mg	PS	Bristol-Myers Squibb Company	ORAL
				Vioxx	SS		
				Allopurinol	C		
				Actos	C		
				Lipitor	C		
				Accupril	C		

Date:07/30/03ISR Number: 4158867-0Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12275871
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Fluid Retention		Metaglip Tabs 5			
	Weight Increased		Mg/500 Mg	PS	Bristol-Myers Squibb	
					Company	ORAL
			Vioxx	SS		
			Allopurinol	C		
			Actos	C		
			Lipitor	C		
			Accupril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/03ISR Number: 4158894-3Report Type:Expedited (15-DaCompany Report #WAES 0211ITA00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	INTRAMUSCULAR	
	Cholelithiasis		Neridronate Sodium	SS				
	Haemolysis							
	Jaundice							

Date:07/30/03ISR Number: 4158912-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA00774
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Anaemia		Prilosec	C		ORAL		
Other	Cardiac Failure High Output		Effexor	C				
	Cardiomegaly		Reglan	C				
	Diarrhoea		Compazine	C				
	Diastolic Dysfunction		Seroquel	C				
	Gastritis		Lortab	C				
	Hydronephrosis		Coumadin	C				
	Hypertension		Coumadin	C				
	Loss Of Consciousness		Lasix (Furosemide)	C				
	Mitral Valve Incompetence		Welchol	C				
	Nausea							
	Nephrolithiasis							
	Pelvi-Ureteric Obstruction							
	Pulmonary Congestion							
	Pulmonary Hypertension							
	Renal Cyst							
	Ventricular Hypertrophy							
	Vomiting							
	Weight Increased							

Date:07/30/03ISR Number: 4158979-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA00042
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Premarin	C				
			Verapamil	C				
			Klor-Con	C				
			[Therapy Unspecified]	C				
			Chlorhexidine Gluconate	C		ORAL		

Date:07/30/03ISR Number: 4158980-8Report Type:Expedited (15-DaCompany Report #WAES 0307DNK00014
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Discomfort		Acetaminophen	SS		ORAL	6	DAY
	Drug Interaction		Diclofenac Sodium	C		ORAL	2	DAY
	Headache							
	Renal Failure Acute							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/03ISR Number: 4158984-5Report Type:Expedited (15-DaCompany Report #WAES 0307ITA00023
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Duodenal Ulcer		Hydrochlorothiazide And Lisinopril	C				
	Haemorrhage							
	Melaena							

Date:07/30/03ISR Number: 4158987-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA02698
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vasotec	SS		ORAL		
			[Therapy Unspecified]	SS				

Date:07/30/03ISR Number: 4158990-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA02876
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS		ORAL		8 DAY
	Blood Pressure Increased		Ultracet	C				
	Chest Discomfort		Hydrocodone Bitartrate	C				
	Confusional State		Percocet	C				
	Diarrhoea							
	Disorientation							
	Dizziness							
	Drug Ineffective							
	Dyspnoea							
	Headache							
	Hyperhidrosis							
	Nausea							
	Oedema Peripheral							
	Oropharyngeal Swelling							
	Palpitations							

Swelling Face
Urinary Tract Infection
Vertigo
Vision Blurred

Date:07/30/03ISR Number: 4160289-3Report Type:Expedited (15-DaCompany Report #2003GB01985
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine	Foreign	Atenolol	PS		ORAL	50 MG QAM PO	
Intervention to	Increased	Health	Atenolol	SS		ORAL	25 MG QAM PO	
Prevent Permanent	Blood Urea Increased	Professional	Trimethoprim	SS		ORAL	200 MG PO	
Impairment/Damage	Circulatory Collapse	Other	Trimethoprim	SS		ORAL	960 MG DAILY	
	Feeling Abnormal						PO	
	Heart Rate Decreased		Rofecoxib	SS			25 MG DAIILY	
	Hyperkalaemia		Aspirin	C				
	Hypotension		Nitrazepam	C				
			Gabapentin	C				
			Lansoprazole	C				
			Alendronate Sodium	C				
			Senna	C				

Co-Codamol	C
Lactulose	C
Vitamin B Complex	C
Ranitidine	C
Folic Acid	C
Viscotears	C
Simvastatin	C

Date:07/30/03ISR Number: 4160932-9Report Type:Expedited (15-DaCompany Report #HQWYE133422JUL03
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaemia	Study	Leucovorin Calcium			
	Drug Toxicity	Literature	(Leucovorin Calcium,			
	Gastrointestinal		Injection, Unspec)	PS		
20 MG/M^2						
	Haemorrhage					
DAILY FOR 5						
DAYS						
			Fluorouracil			
			(Fluorouracil,)	SS		
425 MG/M^2						
DAILY FOR 5						
DAYS						
			Rofecoxib			
			(Rofecoxib,)	SS		
50 MG/DAY ON						
DAY 1 OF						
CHEMOTHERAPY						

Date:07/30/03ISR Number: 4160933-0Report Type:Expedited (15-DaCompany Report #HQWYE211128JUL03
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaemia	Study	Leucovorin Calcium			
	Drug Toxicity	Literature	(Leucovorin Calcium,			

		Gastrointestinal		Injection, Unspec)	PS		
20 MG/M^2							
		Haemorrhage					
DAILY FOR 5							
DAYS							
				Fluorouracil (Fluorouracil,)	SS		
425 MG/M^2							
DAILY FOR 5							
DAYS							
				Rofecoxib (Rofecoxib,)	SS		
50 MG/DAY ON							
DAY 1 OF							
CHEMOTHERAPY							
				Atorvastatin (Atorvastatin)	C		
				Premarin (Conjugated Estrogens)	C		

Date:07/30/03ISR Number: 4160945-7Report Type:Expedited (15-DaCompany Report #HQWYE211228JUL03
Age:47 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia	Study	Leucovorin Calcium	PS		
20 MG/M^2							
		Drug Ineffective	Literature				
DAILY FOR 5							
		Drug Toxicity					
DAYS							
		Gastrointestinal Haemorrhage		Fluorouracil (Fluorouracil,)	SS		
425 MG/M^2							
DAILY FOR 5							

DAYS

	Rofecoxib (Rofecoxib,)	SS

50 MG/DAY ON

DAY 1 OF

CHEMOTHERAPY

	Glyburide (Glibenclamide)	C
	Olanzapine (Olanzapine)	C

Date:07/31/03ISR Number: 4158532-XReport Type:Expedited (15-DaCompany Report #WAES 0307CHN00025
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Lymphocytic		Vioxx	PS		ORAL	2	DAY
	Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Haemodialysis		Nimodipine	C		ORAL	44	DAY
	Metastatic Neoplasm		Hydrotalcite	C		ORAL		
	Nuclear Magnetic		Captopril	C		ORAL	46	DAY
	Resonance Imaging		Amlodipine Besylate	C		ORAL		
	Abnormal		Pyridoxine	C		ORAL		
	Renal Failure Acute							

Date:07/31/03ISR Number: 4158535-5Report Type:Expedited (15-DaCompany Report #WAES 0301FRA00055
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Gastric Ulcer		Acenocoumarol	SS		ORAL		
	Gastritis		Diclofenac Sodium	SS		ORAL	10	DAY
	Melaena		Gliclazide	C		ORAL		
	Varices Oesophageal		Captopril	C		ORAL		

			Amlodipine	C		ORAL
			Bisoprolol Fumarate	C		ORAL
			Lorazepam	C		ORAL
			Nitroglycerin	C		
TOPICAL						

Date:07/31/03ISR Number: 4158639-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Inderal La	C		
Disability 1758 DAY	Arteriospasm Coronary		Claritin-D	C		
	Dyspepsia		Humibid	C		
	Mitral Valve Incompetence		Prevacid	C		
764 DAY	Tachyarrhythmia		Nasonex	C		
	Tricuspid Valve Incompetence		Darvocet-N	C		
			Bactrim	C		
	Weight Increased		Pseudoephedrine	C		
			Maxzide	C		
			Naprosyn	C		
			Entex La	C		
			Voltaren	C		
			Evening Primrose Oil	C		
			Glucosamine	C		
			Chondroitin	C		
			Zantac	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/03ISR Number: 4158663-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/31/03ISR Number: 4158664-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA02355
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/31/03ISR Number: 4158670-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	340 DAY	
Life-Threatening	Cardiac Arrest		Vioxx	SS		ORAL	340 DAY	
Hospitalization -	Chronic Hepatitis		Vioxx	SS		ORAL	340 DAY	
Initial or Prolonged	Coronary Artery		Proventil Repetabs					
	Atherosclerosis		And Tablets	C				
	Cystocele		Prevacid	C				
	Electrocardiogram St		Lorabid	C				
	Segment Abnormal		Prilosec	C				
	Hepatic Steatosis		Zyrtec	C				
	Hepatomegaly		Vicodin Tablets	C				
	Myocardial Infarction		Claritin-D	C				
	Myocardial Ischaemia		Zithromax	C				
	Oxygen Saturation		Promethazine	C				
	Decreased		Cipro	C				
	Pleural Adhesion		Soma	C				
	Procedural Complication		Voltaren	C				
	Pulmonary Oedema		Triamcinolone	C				
	Rhonchi		Hydroxyzine					
	Sinus Tachycardia		Hydrochloride	C				
	Stress Incontinence		Tequin	C				

	Sudden Cardiac Death	Tussi-12	C
	Vaginal Prolapse	Ditropan	C
	Wheezing	Lorazepam	C
		Prempro	C
41 DAY			
		Remeron	C
		Benzonatate	C

Date:07/31/03ISR Number: 4158675-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA02413
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/03ISR Number: 4158677-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anoxic Encephalopathy		Tylenol With Codeine					
	Areflexia		#4	C				
	Cardiac Arrest		Premarin	C				
	Cardio-Respiratory Arrest		Provera	C				
	Coma							
	Convulsion							
	Coronary Artery Disease							
	Deep Vein Thrombosis							
	Dyspepsia							
	Gastric Disorder							
	Haematocrit							
	Haemoglobin							
	Myocardial Infarction							
	Myoclonus							
	Operative Haemorrhage							
	Pulmonary Oedema							
	Sinus Tachycardia							
	Spinal Column Stenosis							
	Spondylitis							
	Syphilis							
	Tricuspid Valve Incompetence							
	Ventricular Hypokinesia							

Date:07/31/03ISR Number: 4158689-0Report Type:Direct Company Report #CTU 198971
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS		ORAL	50 MG PO QD	

Date:07/31/03ISR Number: 4158743-3Report Type:Direct Company Report #CTU 198987
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Meningitis Aseptic		Vioxx 25mg Tab 25MG QD	PS

Date:07/31/03ISR Number: 4159008-6Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00063
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Diclofenac	C		ORAL		
			Piroxicam	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/03ISR Number: 4159010-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00115
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/31/03ISR Number: 4159012-8Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation Neonatal		Vioxx	PS	Merck & Co., Inc		80	DAY
Initial or Prolonged	Apgar Score Low		Sertraline	SS				

Date:07/31/03ISR Number: 4159013-XReport Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL	80	DAY
	Complications Of Maternal		Sertraline	SS		ORAL		
	Exposure To Therapeutic							
	Drugs							
	Gestational Diabetes							
	Labour Complication							
	Pre-Eclampsia							
	Pregnancy							
	Sinusitis							
	Streptococcal Infection							

Date:07/31/03ISR Number: 4159016-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Cancer Pain		Zestril	C				

Depression	Lasix (Furosemide)	C		
Diabetes Mellitus	Lithium Carbonate	C		
Emotional Distress	Pepcid	C		ORAL
Fatigue	Ibuprofen	C		
Hyperhidrosis				
Insomnia				
Nausea				
Non-Hodgkin'S Lymphoma				
Oedema Peripheral				
Stomatitis				

Date:07/31/03ISR Number: 4159018-9Report Type:Expedited (15-DaCompany Report #WAES 0307NLD00010
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aplasia Pure Red Cell		Vioxx	PS	Merck & Co., Inc	ORAL		926 DAY
Initial or Prolonged			Atenolol	C		ORAL		799 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/03ISR Number: 4159022-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA01504
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Disability	Asthenia		Klonopin	C				
Other	Back Pain		Xanax	C				
	Blood Creatine Phosphokinase Increased							
	Bone Pain							
	Dehydration							
	Fatigue							
	Generalised Oedema							
	Hypersensitivity							
	Hypoaesthesia							
	Muscle Spasms							
	Muscular Weakness							
	Myositis							
	Neck Pain							
	Nephritis							
	Oedema Peripheral							
	Pain In Extremity							
	Polyuria							
	Sinus Headache							
	Weight Fluctuation							

Date:07/31/03ISR Number: 4159023-2Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Life-Threatening	Cardiac Failure		Dipyrone	SS		ORAL		6 DAY
Hospitalization -	Dermatitis Allergic		Dipyrone	SS		ORAL		2 DAY
Initial or Prolonged	Dermatitis Exfoliative		Dipyrone	SS		ORAL		2 DAY
	Eyelid Oedema		Vioxx	SS		ORAL		2 DAY
	Face Oedema		Dipyrone	SS		ORAL		9 DAY

	Mucosal Erosion	Furosemide Sodium	C	ORAL
		Tramadol Hydrochloride	C	ORAL
11 DAY				
		Amlodipine Besylate	C	ORAL
		Moxonidine	C	ORAL
		Isosorbide Mononitrate	C	ORAL
		Potassium Bicarbonate And Potassium Citrate	C	ORAL
6 DAY				
		Potassium Bicarbonate And Potassium Citrate	C	ORAL
1 DAY				
		Tramadol Hydrochloride	C	ORAL
4 DAY				
		Pantoprazole Sodium	C	ORAL
		Pantoprazole Sodium	C	ORAL
		Lisinopril	C	ORAL
		Aspirin	C	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/03ISR Number: 4159026-8Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00073
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Hospitalization - Initial or Prolonged	Oedema		Allopurinol	C		ORAL		
			Avocado Oil And Soybean Oil	C		ORAL		
			Furosemide	C		ORAL		
			Grape Seeds	C		ORAL		

Date:07/31/03ISR Number: 4159027-XReport Type:Expedited (15-DaCompany Report #WAES 0307ZAF00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diabetic Hyperglycaemic Coma		Vioxx	SS		ORAL		
			Insulin, Neutral	C			PARENTERAL	
Other	Myocardial Infarction		Clopidogrel Bisulfate	C				
	Pain		Felodipine And Ramipril	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Insulin Human, Isophane	C			PARENTERAL	

Date:07/31/03ISR Number: 4159030-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03098
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Walking Aid User							

Date:07/31/03ISR Number: 4159032-3Report Type:Expedited (15-DaCompany Report #WAES 0307NLD00012
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		333 DAY
Hospitalization -	Drug Interaction		Methotrexate	SS		ORAL		15 DAY
Initial or Prolonged	Hypertension		Methotrexate	SS		ORAL		
	Syncope		Folic Acid	C		ORAL		

Date:08/01/03ISR Number: 4159143-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA02639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vitamins (Unspecified)	C				

Date:08/01/03ISR Number: 4159145-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Benign Prostatic		Prevacid	C				
Hyperplasia		Allopurinol	C				
Blood Pressure Increased							
Bronchitis Acute							
Cerebellar Infarction							
Cerebrovascular Accident							
Coma							
Coordination Abnormal							
Diplopia							
Dizziness							
Dysstasia							
Dysuria							
Ejaculation Disorder							
Epidermal Naevus							
Fall							
Haematospermia							
Haemoptysis							
Haemorrhoidal Haemorrhage							
Labyrinthitis							
Micturition Urgency							
Nasal Congestion							
Nephrolithiasis							
Nystagmus							
Penile Haemorrhage							
Prostatism							
Purulent Discharge							
Renal Cyst							
Renal Failure							
Respiratory Rate Increased							
Shock							
Sinusitis							
Testicular Pain							
Vertigo							

Date:08/01/03ISR Number: 4159146-8Report Type:Expedited (15-DaCompany Report #WAES 0212USA00230
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 222 DAY	Angina Pectoris	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Coronary Artery Disease	Humulin	C		
	Myocardial Infarction	Humulin	C		
	Sinus Arrhythmia	Clotrimazole	C		
	Stomach Discomfort	Neurotonin Capsules	C		
		Vicoprofen	C		

Date:08/01/03ISR Number: 4159147-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01516
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Cardiac Arrest
	Coma
	Seborrhoeic Keratosis

Ventricular Fibrillation

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Beclomethasone Dipropionate	C				
RESPIRATORY (INHALATION)						
	Allegra	C				
	Adalat	C				
	Zocor	C		ORAL		
	Zantac	C				

Date:08/01/03ISR Number: 4159149-3Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00183
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis		Lansoprazole	C		ORAL		
	Helicobacter Infection		Nifedipine	C				
	Melaena		Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY (INHALATION)								

Date:08/01/03ISR Number: 4159150-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00476
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash Vesicular							

Date:08/01/03ISR Number: 4159151-1Report Type:Expedited (15-DaCompany Report #WAES 0307PHL00017
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Life-Threatening	Haemorrhage		Aluminum Hydroxide And Magnesium Hydroxide	C		ORAL	2	DAY
Hospitalization - Initial or Prolonged			Sulfamethoxazole And Trimethoprim	C		ORAL	2	DAY

Date:08/01/03ISR Number: 4159155-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA02421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gangrene		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS		ORAL		
	Poor Peripheral Circulation		[Therapy Unspecified]	C				
	Vasospasm							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/03ISR Number: 4159160-2Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00168
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Sulfamethoxazole And Trimethoprim	SS		ORAL		
Other	Circulatory Collapse							
	Feeling Abnormal		Atenolol	SS				
	Heart Rate Decreased		Atenolol	SS				
	Hyperkalaemia		Aspirin	C				
	Hypotension		Nitrazepam	C				
	Nausea		Gabapentin	C				
			Lansoprazole	C				
			Fosamax	C		ORAL		
			Senna	C				
			Acetaminophen And Codeine Phosphate	C				
			Lactulose	C				
			Vitamin B Complex	C				
			Ranitidine	C				
			Folic Acid	C				
			Carbomer	C		OPHTHALMIC		
			Zocor	C				

Date:08/01/03ISR Number: 4159163-8Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00171
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C		ORAL		
			Diltiazem Malate	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:08/01/03ISR Number: 4159166-3Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00093
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Enterocolitis		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Haemorrhagic		Aspirin	SS		ORAL		

Date:08/01/03ISR Number: 4159170-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Bundle Branch Block Left
	Cholelithiasis
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Diverticulum
	Gastritis Haemorrhagic
	Myocardial Infarction
	Myocardial Ischaemia
	Nausea
	Pruritus Generalised
	Pulmonary Mass
	Pulmonary Tuberculosis

		Upper Respiratory Tract Infection					
		Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS		ORAL
				Infed	C		
INTRAMUSCULAR							
				Cyanocobalamin	C		
INTRAMUSCULAR							
				Soma	C		ORAL
				Soma	C		ORAL
				Elavil	C		ORAL
				Robaxin	C		ORAL
				Premarin	C		
				Prilosec	C		

Date:08/01/03ISR Number: 4159171-7Report Type:Expedited (15-DaCompany Report #WAES 0207USA00042
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
				Klor-Con	C		
				[Therapy Unspecified]	C		
				Verapamil	C		
				Premarin	C		
				Chlorhexidine Gluconate	C		ORAL

Date:08/01/03ISR Number: 4159174-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Amnesia		Atenolol	C		
		Atherosclerosis		Prozac	C		
		Blood Cholesterol Increased		Tylenol	C		
				Buspar	C		
				Atrovent	C		

Cardiac Failure	Magnesium Sulfate	C	
Congestive	Claforan	C	
Cardio-Respiratory Arrest	Cordarone	C	
Cardiogenic Shock	Pepcid	C	
Chest Pain	Reopro	C	
Convulsion	Dopamine		
Coronary Artery Occlusion	Hydrochloride	C	
Haematuria	Restoril	C	
Hypertension	Aspirin	C	ORAL
Lung Infiltration	Celexa	C	
Myalgia	Neurontin	C	
Orthostatic Hypotension	Dalmane	C	
Ventricular Fibrillation	Vasotec	C	
Ventricular Hypokinesia			
Ventricular Tachycardia			

Date:08/01/03ISR Number: 4159177-8Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00179
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Liver Function Test		Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Initial or Prolonged	Abnormal		Acetaminophen	C				

Date:08/01/03ISR Number: 4159182-1Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00180
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Other	Pruritus		Tiotropium Bromide	C		ORAL		
	Urticaria		Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY (INHALATION)								

Date:08/01/03ISR Number: 4159184-5Report Type:Expedited (15-DaCompany Report #WAES 0203FRA00021
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged			Ethinyl Estradiol And Levonorgestrel	SS		ORAL		

Date:08/01/03ISR Number: 4159185-7Report Type:Expedited (15-DaCompany Report #WAES 0307CAN00079
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage							

Initial or Prolonged

Date:08/01/03ISR Number: 4159186-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA02594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C				

Date:08/01/03ISR Number: 4159192-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01002
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrioventricular Block Second Degree
Disability	Blindness Cortical
Other	Carotid Artery Stenosis
	Cerebrovascular Accident
	Circulatory Collapse
	Electrocardiogram Abnormal
	Extrasystoles
	Hypertension
	Retinal Haemorrhage

		Supraventricular Extrasystoles					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Buspar	C		ORAL
				Cozaar	C		ORAL
				Zyloprim	C		ORAL
				Indocin (Indomethacin)	C		ORAL
				Tenormin	C		ORAL
				Tenormin	C		ORAL
				Pravachol	C		
				Hydrochlorothiazide	C		ORAL
				Slow-K	C		ORAL
				Plavix	C		ORAL
				Aspirin	C		ORAL
				Ambien	C		
				Celebrex	C		ORAL

Date:08/01/03ISR Number: 4159193-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 2 DAY		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction					
Other		Atherosclerosis					
		Bundle Branch Block Right					
		Cardiac Murmur					
		Cardiomyopathy					
		Chest Wall Pain					
		Chronic Obstructive Pulmonary Disease					
		Conduction Disorder					
		Cough					
		Drug Hypersensitivity					
		Ejection Fraction Decreased					
		Electrocardiogram Q Wave Abnormal					
		Electrocardiogram St Segment Elevation					
		Haemoglobin					

Injury
Myocardial Ischaemia
Platelet Count

Date:08/01/03ISR Number: 4159194-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Arthropathy
	Encephalitis Viral
	Hyperlipidaemia
	Hypertension
	Hypoaesthesia Oral
	Hyponatraemia
	Joint Sprain
	Labyrinthitis

		Mental Disorder Mental Disorder Due To A General Medical Condition	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neuropathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Otitis Media		Skelaxin	C		
		Transient Ischaemic		Vicodin Tablets	C		
		Attack		Effexor Xr	C		
		Vertigo		Univasc	C		
				Benadryl	C		
				Wellbutrin	C		
				Celexa	C		
				Ibuprofen	C		
				Temazepam	C		
				Ambien	C		
				Trazodone Hydrochloride	C		
				Naproxen	C		
				Tylenol	C		
				Tenormin	C		
				Ativan	C		
				Ranitidine	C		
				Premarin	C		
				Meclizine	C		
				Aspirin	C		
				Plavix	C		
				Neurontin	C		
				Zithromax	C		
				Claritin	C		
				Amoxicillin	C		
				Glucosamine	C		
				Hypericin	C		

Date:08/01/03ISR Number: 4159198-5Report Type:Expedited (15-DaCompany Report #WAES 0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adenomyosis
Other	Arthralgia
	Asthenia
	Back Pain
	Blood Potassium
	Bronchitis
	Cardiac Valve Disease
	Cardiomegaly

Cardiomyopathy
Cellulitis
Chest Pain
Duodenal Ulcer
Dyspnoea Exertional
Fatigue
Gastritis
Haematoma Infection
Hypertension
Hypokalaemia
Irritable Bowel Syndrome
Malignant Hypertension
Micturition Urgency
Myocardial Infarction
Nausea
Nicotine Dependence

		Oesophagitis					
		Orthopnoea					
		Ovarian Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Salpingitis		Vioxx	SS		ORAL
		Supraventricular		Normodyne	C		
		Tachycardia		Prevacid	C		
		Uterine Leiomyoma		Flagyl	C		
				Minoxidil	C		
				Procardia Xl	C		
				Cardura	C		

Date:08/01/03ISR Number: 4159202-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Asthenia
	Atrophy
	Blood Pressure Systolic Increased
	Bundle Branch Block Right
	Cardiac Failure Congestive
	Cardiomyopathy
	Cataract
	Chest Pain
	Chronic Sinusitis
	Confusional State
	Culture Urine Positive
	Dehydration
	Delirium
	Depression
	Dizziness
	Fall
	Fatigue
	Gangrene
	Gastric Ulcer
	Gastritis
	Helicobacter Infection
	Herpes Zoster
	Hypersensitivity
	Hypokalaemia
	Hypovolaemia

Leg Amputation
Mastitis
Muscle Spasms
Myocardial Infarction
Myopathy
Oesophagitis
Orthostatic Hypotension
Paraesthesia
Peripheral Occlusive
Disease
Pneumonia
Renal Cyst
Renal Failure Acute
Sinus Tachycardia
Skin Ulcer
Syncope

		Tachycardia					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS		ORAL
		Vasculitis		Misoprostol	C		ORAL
		Weight Decreased		Beclomethasone Dipropionate	C		
RESPIRATORY (INHALATION)							
				Albuterol Sulfate	C		
RESPIRATORY (INHALATION)							
				Folic Acid	C		ORAL
				Prednisone	C		ORAL
				Fosamax	C		ORAL
				Estrogens (Unspecified)	C		ORAL
				Isosorbide Mononitrate	C		ORAL
				Ipratropium Bromide	C		
				Hydroxychloroquine Sulfate	C		ORAL
				Lotensin	C		
				Indocin (Indomethacin)	C		
				Calcium Carbonate	C		ORAL
				Naproxen	C		ORAL
				Diphenhydramine Hydrochloride	C		ORAL
				Amlodipine Besylate	C		ORAL
				Hydrodiuril	C		ORAL
				Aspirin	C		ORAL
				Baycol	C		
				Atorvastatin Calcium	C		

Date:08/01/03ISR Number: 4159359-5Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00020
Age:81 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Malaise		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Somnolence	Prazepam	SS	ORAL
		Spironolactone	SS	ORAL

Date:08/01/03ISR Number: 4159361-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome
	Adrenal Insufficiency
	Blood Glucose
	Blood Potassium
	Blood Pressure
	Fluctuation
	Candidiasis
	Cardiomegaly
	Cataract
	Cerebral Artery Occlusion
	Cerebral Infarction
	Cerebrovascular Accident

		Coma					
		Deep Vein Thrombosis					
		Diplopia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Screen Positive		Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
		Faecal Occult Blood		Vioxx	SS		ORAL
6	MON						
		Positive		Prednisone	C		
		Gastritis		Hydrocodone	C		
		Gaze Palsy					
		Haemoglobin					
		Herpes Simplex					
		Hyperhidrosis					
		Intracranial Aneurysm					
		Ivth Nerve Paresis					
		Loss Of Consciousness					
		Lower Extremity Mass					
		Microcytic Anaemia					
		Oxygen Saturation					
		Decreased					
		Pain					
		Pericardial Effusion					
		Peroneal Nerve Palsy					
		Pneumonia					
		Pulmonary Fibrosis					
		Rales					
		Respiration Abnormal					
		Respiratory Distress					
		Subarachnoid Haemorrhage					
		Vision Blurred					
		White Blood Cell Count					

Date:08/01/03ISR Number: 4159367-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA02503
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Enzymes Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Completed Suicide		Gabapentin	SS		
Initial or Prolonged		Coordination Abnormal		Ultram	SS		ORAL
Other		Cyanosis					
		Dehydration					
		Electromechanical					
		Dissociation					

Heart Rate Decreased
Hypotension
Mental Status Changes
Myoglobin Urine Present
Renal Failure
Somnolence
White Blood Cell Count
Increased

Date:08/01/03ISR Number: 4159368-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01596
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Other	Abdominal Hernia
	Accident At Home
	Adverse Event
	Anaemia

		Angina Pectoris					
		Appendicitis Perforated					
		Asthma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Vioxx	SS		ORAL
		Chest Pain		Vioxx	SS		ORAL
		Depression		Vioxx	SS		ORAL
		Dermatitis Contact		Vioxx	SS		ORAL
		Dizziness		Vioxx	SS		ORAL
		Dyspepsia		Proventil Inhaler	C		
		Dyspnoea Exertional		Prednisone	C		
		Dysuria		Maxzide	C		
		Fatigue		Maxzide	C		
		Fungal Infection		Prilosec	C		
		Hypertension		Hydrocodone/Apap	C		
		Hypokalaemia		Norvasc	C		
		Medication Error		Norvasc	C		
		Meniscus Lesion		Trazodone			
		Nasopharyngitis		Hydrochloride	C		
		Nephrolithiasis		Lasix (Furosemide)	C		
		Oedema		Nitroglycerin	C		
		Pharyngitis		Atrovent	C		
		Pneumonia		Albuterol	C		
		Rash		Hyzaar	C		ORAL
		Rheumatoid Arthritis		Folic Acid	C		
		Rhinitis Allergic					
		Trigger Finger					
		Upper Respiratory Tract					
		Infection					
		Weight Increased					

Date:08/01/03ISR Number: 4159497-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Aortic Valve Incompetence
Disability	Arthralgia
Other	Asthenia
	Atherosclerosis
	Back Pain
	Biliary Neoplasm
	Blood Pressure Systolic
	Increased

Cardiac Failure
Cardiac Failure
Congestive
Chest Discomfort
Chest Pain
Congestive Cardiomyopathy
Coronary Artery Disease
Dermatitis Contact
Dialysis
Diarrhoea
Dilatation Atrial
Drug Hypersensitivity
Drug Interaction
Dyspnoea
Electrocardiogram Q Waves
Epistaxis

		Erythema Multiforme					
		Hyperkalaemia					
		Influenza Like Illness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Jugular Vein Distension		Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
		Kidney Infection		[Therapy			
		Kidney Transplant		Unspecified]	SS		
		Rejection		Lipitor	SS		ORAL
366	DAY						
		Mitral Valve		Zemplar	SS		
		Calcification		Zaroxolyn	C		ORAL
		Mitral Valve Incompetence		Paricalcitol	C		
INTRAVENOUS							
		Muscle Rigidity		Imuran			
		Muscular Weakness		(Azathioprine)	C		ORAL
		Myalgia		Lasix (Furosemide)	C		ORAL
		Nasal Septum Perforation		Clonidine			
		Neck Pain		Hydrochloride	C		ORAL
		Pain		Zebeta	C		ORAL
		Pericardial Effusion		Vitamin B Complex	C		ORAL
		Pericarditis Uraemic		Ultralente Insulin	C		
PARENTERAL							
		Pleural Effusion		Toprol Xl Tablets	C		ORAL
		Polytraumatism		Viagra	C		ORAL
		Pulmonary Congestion		Calcium			
		Pulmonary Hypertension		(Unspecified) And			
		Pulmonary Vascular		Vitamin D			
		Disorder		(Unspecified)	C		
		Rosacea		Humulin	C		
PARENTERAL							
		Sinus Tachycardia		Clonazepam	C		
		Sinusitis		Celebrex	C		
		Skin Haemorrhage		Flexeril	C		ORAL
		Swelling		Norvasc	C		ORAL
		Tricuspid Valve		Sandimmun	C		ORAL
		Incompetence		Prednisone	C		ORAL
		Vascular Calcification		Iron Dextran	C		
		Ventricular Dysfunction		Epoetin	C		
		Ventricular Hypertrophy		Cyclosporine	C		
		Weight Decreased					

Date:08/01/03ISR Number: 4159498-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02117
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Indocin					
	Diarrhoea		(Indomethacin)	C		ORAL		
	Dyspnoea		Allopurinol	C				
	Emotional Distress		Advil	C				
	Fatigue							
	Hypotension							
	Mental Disorder							
	Nausea							
	Pain In Extremity							
	Paraesthesia							
	Rosacea							
	Silent Myocardial Infarction							

Date:08/01/03ISR Number: 4159502-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01866
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS		ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS		ORAL		
							1	WK
Disability			Aspirin	C				
Other								

Date:08/01/03ISR Number: 4159503-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery		Vioxx	SS		ORAL		
Other	Atherosclerosis		Vioxx	SS		ORAL		
	Coronary Artery Stenosis		Lipitor	C				
	Dyspepsia		Betagan	C				
	Hernia		Lumigan	C				
	Intestinal Obstruction		Relafen	C				
	Mental Disorder		Paxil	C				
	Myocardial Infarction		Tylenol	C				
			Saw Palmetto	C				

Date:08/01/03ISR Number: 4159505-3Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00058
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
							25	MON
Initial or Prolonged	Colonic Polyp		Tramadol					
	Rectal Haemorrhage		Hydrochloride	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Acetaminophen	C		ORAL		

Date:08/01/03ISR Number: 4159512-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA03088
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cyst Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Ibuprofen	SS				
	Dysstasia		Coumadin	C				
	Hypersensitivity		Os-Cal	C				
	Oedema Peripheral							
	Oropharyngeal Swelling							
	Prothrombin Time							
	Prolonged							
	Swelling Face							
	Therapeutic Response							
	Decreased							

Date:08/01/03ISR Number: 4159743-XReport Type:Direct Company Report #CTU 199073
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	ORAL
			Nitro	C				

			Nipride	C		
			Amlodipine	C		
			Fosinopril	C		
			Dopamine	C		

Date:08/01/03ISR Number: 4159747-7Report Type:Direct Company Report #CTU 199075
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
			Furosemide	C				
			Tolterodine La	C				
			Labetalol	C				

Date:08/01/03ISR Number: 4159806-9Report Type:Direct Company Report #CTU 199070
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
			Carvedilol	C				
			Clonidine	C				
			Diltiazem	C				
			Dopamine	C				
			Furosemide	C				

Date:08/01/03ISR Number: 4159820-3Report Type:Direct Company Report #CTU 199071
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema		Rofecoxib 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	

ORAL

Metformin	C	
Hyzaar	C	
Ketorolac	C	
D5w	C	
Nacl	C	
Kcl	C	

Date:08/01/03ISR Number: 4162623-7Report Type:Expedited (15-DaCompany Report #K200301248
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Circulatory Collapse Feeling Abnormal Heart Rate Decreased Hyperkalaemia Hypotension	Foreign Health Professional Other	Septra Tablets/Septra Ds Tablets (Trimethoprim, Sulfamethoxazole)	PS		ORAL	960 MG, QD,	
			Atenolol (Atenolol) 50mg	SS			50 MG	
			Rofecoxib (Rofecoxib) 25 Mg	SS			25 MG	
			Trimethoprim (Trimethoprim) 200mg	SS		ORAL	200 MG, UNK,	

ORAL

Aspirin "Bayer" (Acetylsalicylic Acid)	C
Nitrazepam (Nitrazepam)	C
Gabapentin	C
Lansoprazole (Lansoprazole)	C
Alendronate Sodium (Alendronate Sodium)	C
Sennosides	C
Lactulose (Lactulose)	C
Vitamin B Complex (Calcium Pantothenate, Nicotinamide, Pyridoxine	C
Ranitidine Hydrochloride (Ranitidine Hydrochloride)	C
Folic Acid (Folic Acid)	C
Carbomer (Carbomer)	C
Simvastatin (Simvastatin)	C
Co-Codamol (Codeine Phosphate, Paracetamol)	C

Date:08/01/03ISR Number: 4204660-XReport Type:Periodic Company Report #2002UW15324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Amitriptyline Hydrochloride	PS				
Hospitalization - Initial or Prolonged			Zomig	SS				
Disability			Vioxx	SS		ORAL	25 MG PO	
Required Intervention to Prevent Permanent			Multiple Other Medications	C				

Impairment/Damage

Date:08/01/03ISR Number: 4205366-3Report Type:Periodic Company Report #2002UW15324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Amitriptyline Hydrochloride	PS				
Hospitalization - Initial or Prolonged			Zomig	SS				
Disability			Vioxx	SS		ORAL	25 MG PO	
Required Intervention to Prevent Permanent Impairment/Damage			Multiple Other Medications	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/03ISR Number: 4160413-2Report Type:Expedited (15-DaCompany Report #WAES 0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vitamins (Unspecified)	C				
	Eczema							
	Hypertension							
	Macular Degeneration							
	Rhinitis Allergic							
	Sciatica							
	Transient Ischaemic Attack							

Date:08/04/03ISR Number: 4160417-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Celebrex	C				
	Anxiety		Celebrex	C				
	Hypertension		Fosamax	C		ORAL		
	Myocardial Infarction		Duragesic	C				
	Nervousness							

Date:08/04/03ISR Number: 4160423-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Cardizem	C				
	Congestive		Glipizide	C				
	Impaired Driving Ability		Prozac	C				
	Impaired Self-Care		Spironolactone	C				
	Renal Disorder		Calcium (Unspecified)	C				
			Temazepam	C				
			Nitro	C				
			Prinivil	C				

		Zestril	C	
		Motrin	C	
		Naproxen	C	
		Tylenol	C	

Date:08/04/03ISR Number: 4160425-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA00026
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		301 DAY
Initial or Prolonged	Cerebral Atrophy		Prevacid	C		ORAL		
Other	Cerebrovascular Accident		Levoxyl	C				
	Osteoarthritis		Synthroid	C		ORAL		
	Pharyngeal Mass		Actonel	C		ORAL		
	Vertebral Artery Occlusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/03ISR Number: 4160583-6Report Type:Direct Company Report #CTU 199217
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Angina Pectoris		Vioxx 12mg Merc	PS	Merc	ORAL	12MG DAY	
	Dyspnoea		Vioxx 50mg Merc	SS	Merc	ORAL	50MG DAY	
	Palpitations							

Date:08/04/03ISR Number: 4160609-XReport Type:Direct Company Report #CTU 199187
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Light Chain Disease		Vioxx 25mg	PS		ORAL	2 DAY	
	Renal Disorder							
	Renal Impairment							

Date:08/04/03ISR Number: 4160841-5Report Type:Expedited (15-DaCompany Report #WAES 0307CAN00034
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Schizophrenia		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
			Zafirlukast	C				
			Fluticasone Propionate And Salmeterol Xinafoate	C				
			Albuterol	C				
			Bromazepam	C			5	DAY
			Terbutaline Sulfate	C				

Date:08/04/03ISR Number: 4160844-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02043
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Cerebrovascular Accident		Micronase	C				
	Depression		Cardizem	C				
	Disturbance In Attention		Metformin	C				
	Dizziness		Pravachol	C				
	Insomnia		Flexeril	C				
	Mania		Ibuprofen	C				
			Cimetidine	C				
			Prinivil	C				

Date:08/04/03ISR Number: 4160846-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Back Injury
	Blood Cholesterol Increased
	Cardiac Failure
	Cardiomyopathy
	Coronary Artery Thrombosis

		Dyspepsia					
		High Density Lipoprotein Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein Increased		Lopressor	C		

Date:08/04/03ISR Number: 4160849-XReport Type:Expedited (15-DaCompany Report #WAES 0210GBR00217
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
42 DAY						
Initial or Prolonged			Omeprazole	C		
			Prednisolone	C		
			Acetaminophen	C		
			Tramadol	C		
			Fosamax	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		
			Lactulose	C		

Date:08/04/03ISR Number: 4160851-8Report Type:Expedited (15-DaCompany Report #WAES 0307PHL00027
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	International Normalised		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Initial or Prolonged	Ratio Increased		Vioxx	SS		ORAL
1 DAY						
	Overdose		Ranitidine Hydrochloride	C		ORAL
	Pericardial Haemorrhage					
3 DAY						
			Ranitidine Hydrochloride	C		
INTRAVENOUS						DRIP
1 DAY						
			Bromhexine			

Hydrochloride	C		ORAL
5 DAY			
Guaifenesin	C		ORAL
4 DAY			
Warfarin Sodium	C		ORAL
Warfarin Sodium	C		ORAL
Ciprofloxacin	C		ORAL
7 DAY			
Ketorolac	C		
INTRAVENOUS			
			DRIP
2 DAY			
Mefenamic Acid	C		ORAL
Ceftriaxone Sodium	C		
INTRAVENOUS			
			DRIP
2 DAY			

Date:08/04/03ISR Number: 4163793-7Report Type:Expedited (15-DaCompany Report #2003029575
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Asthenia
Hospitalization - Initial or Prolonged	Blood Glucose Decreased
	Coma
Other	Confusional State
	Dysphagia
	Gastrointestinal Motility Disorder
	Haematocrit Decreased
	Myocardial Infarction
	Pneumonia Aspiration

		Pulmonary Hypertension Pyrexia Rash Erythematous	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Arrest Sepsis Thrombocytopenia Weight Decreased White Blood Cell Count Decreased	Consumer	Neurontin (Gabapentin)	PS		
				Diltiazem Hydrochloride (Diltiazem Hydrochloride)	SS		
				Rofecoxib (Rofecoxib)	SS		
(BID), ORAL				Bosentan (Bosentan)	SS		ORAL
INTRAVENOUS	INTRAVENOUS			Epoprostenol Sodium (Epoprostenol Sodium)	SS		
				Lansoprazole (Lansoprazole)	C		
				Spironolactone (Spironolactone)	C		
				Amitriptyline Hydrochloride (Amitriptyline Hydrochloride)	C		
				Citalopram Hydrobromide (Citalopram Hydrobromide)	C		
				Oxycodone Hydrochloride (Oxycodone Hydrochloride)	C		
				Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C		
				Furosemide (Furosemide)	C		
				Warfarin (Warfarin)	C		

Date:08/05/03ISR Number: 4161713-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged Disability	Arthralgia							
	Back Pain							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Deep Vein Thrombosis							
	Dizziness							
	Dyspnoea							
	Hodgkin'S Disease							
	Hyperhidrosis							
	Hypertension							
	Joint Swelling							
	Non-Hodgkin'S Lymphoma							
	Oedema Peripheral							
	Skin Cancer							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/03ISR Number: 4161720-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		55 DAY
Initial or Prolonged	Blood Triglycerides		Zocor	C		ORAL		
Disability	Increased		Estrace	C				
	Cerebrovascular Accident		Prilosec	C				
	Drug Hypersensitivity							
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Gout							
	Hypercholesterolaemia							
	Pain In Extremity							
	Peptic Ulcer							
	Vulvovaginal Dryness							

Date:08/05/03ISR Number: 4161721-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01982
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY

Date:08/05/03ISR Number: 4161724-7Report Type:Expedited (15-DaCompany Report #WAES 0203USA00073
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Arthralgia
Disability	Asthenia
Other	Atherosclerosis
	Back Pain
	Biliary Neoplasm
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomegaly
	Cardiomyopathy

Complications Of
Transplant Surgery
Coronary Artery Disease
Dialysis
Diarrhoea
Dilatation Atrial
Drug Hypersensitivity
Drug Interaction
Epistaxis
Erythema Multiforme
Haemorrhage
Hyperkalaemia
Iatrogenic Injury
Infection
Influenza Like Illness
Injury
Kidney Transplant
Rejection
Mitral Valve Incompetence
Muscle Rigidity
Muscular Weakness

		Myalgia					
		Myocardial Ischaemia					
		Nasal Septum Perforation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
		Organ Failure		Lipitor	SS		ORAL
366	DAY						
		Pericardial Effusion		Zemplar	SS		
		Pericarditis		[Therapy			
		Pulmonary Congestion		Unspecified]	SS		
		Pulmonary Hypertension		Flexeril	C		ORAL
		Rales		Imuran			
		Rash		(Azathioprine)	C		ORAL
		Renal Failure		Lasix (Furosemide)	C		ORAL
		Sinus Tachycardia		Clonidine			
		Sinusitis		Hydrochloride	C		ORAL
		Skin Chapped		Zebeta	C		ORAL
		Tricuspid Valve		Calcium			
		Incompetence		(Unspecified) And			
		Ventricular Hypertrophy		Vitamin D			
		Weight Decreased		(Unspecified)	C		
				Iron Dextran	C		
				Epoetin	C		
				Cyclosporine	C		
				Paricalcitol	C		
INTRAVENOUS							
				Zaroxolyn	C		ORAL
				Ultralente Insulin	C		
PARENTERAL							
				Toprol Xl Tablets	C		ORAL
				Viagra	C		ORAL
				Humulin	C		
PARENTERAL							
				Clonazepam	C		
				Norvasc	C		ORAL
				Sandimmun	C		ORAL
				Prednisone	C		ORAL
				Vitamin B Complex	C		ORAL
				Celebrex	C		

Date:08/05/03ISR Number: 4161728-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02983
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pancreatitis		Norvasc	C				
	Panniculitis		Prevacid	C				
			Fosamax	C				
			Nasacort Aq	C				
			Zyrtec	C				
			Atarax	C				
			Feosol	C				
			Vitamin D (Unspecified)	C				
			Tums	C				

Date:08/05/03ISR Number: 4161729-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA03231
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Temperature		Vioxx	PS		ORAL		
	Increased		Tylenol	SS	Merck & Co., Inc	ORAL		
	Drug Interaction							
	Feeling Abnormal							

Date:08/05/03ISR Number: 4161736-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/03ISR Number: 4161828-9Report Type:Expedited (15-DaCompany Report #WAES 0308ZAF00003
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged			Vioxx	SS		ORAL		2 DAY
			Lansoprazole	C		ORAL		9 DAY

Date:08/05/03ISR Number: 4161846-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA03159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/03ISR Number: 4161847-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA01513
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Duodenal Perforation							
Other	Respiratory Disorder							

Date:08/05/03ISR Number: 4161851-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA03510
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		1669 DAY
Initial or Prolonged	Retinal Haemorrhage		Amiodarone	C				
Other			Diovan	C				
			Corgard	C				
			Plendil	C		ORAL		
			Paxil	C				
			Pravachol	C				
			Plavix	C				
			Aspirin	C				

Date:08/05/03ISR Number: 4161857-5Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00010
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Colitis Ulcerative							
	Diarrhoea							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/03ISR Number: 4161858-7Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haematemesis		Aspirin	SS				
Initial or Prolonged	Rectal Haemorrhage		Atenolol	C				
			Omeprazole Magnesium	C				
			Zocor	C		ORAL		
			Acetaminophen And Aspirin And Caffeine And Hydrocodone Bitartrate	C				

Date:08/05/03ISR Number: 4161859-9Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00012
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged	Melaena		Celecoxib	SS		ORAL	62	DAY
	Pulmonary Oedema		Aspirin	SS				

Date:08/05/03ISR Number: 4165419-5Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction	Foreign	Tab Vioxx					
Hospitalization -	Angioneurotic Oedema	Health	(Rofecoxib)	PS		ORAL	12.5 MG/BID	2 DAY
Initial or Prolonged	Blood Glucose	Professional	Prinivil	C				
	Blood Pressure Increased	Other	Acetaminophen	C				
	Chronic Obstructive		Cyclosporin A	C				
	Airways Disease		Docusate Na	C				
	Exacerbated		Folic Acid	C				
	Complement Factor C3		Furosemide	C				
	Decreased		Insulin, Biphasic					
	Complement Factor C4		Isophane [Injection]	C				
	Decreased		Methotrexate	C				

	Ecchymosis	Paroxetine	C
	Haemoglobin Decreased	Prednisolone	C
	Mouth Haemorrhage	Senna	C
	Mouth Ulceration	Thioridazine	C
	Nausea		
	Paraesthesia Oral		
	Petechiae		
	Pulmonary Alveolar Haemorrhage		
	Pulmonary Fibrosis		
	Pulmonary Haemorrhage		

Date:08/05/03ISR Number: 4165593-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA00774
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Cardiac Failure High Output
Hospitalization - Initial or Prolonged	Cardiomegaly
Other	Diarrhoea
	Gastritis
	Hydronephrosis

		Hypertension					
		International Normalised Ratio Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Iron Deficiency Anaemia	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Loss Of Consciousness	Professional				
MG/DAILY/PO							
		Mitral Valve Incompetence	Company	Compazine	C		
		Nausea	Representative	Coumadin	C		
		Nephrolithiasis		Effexor	C		
		Pulmonary Hypertension		Lasix (Furosemide)	C		
		Refusal Of Treatment By		Lortab	C		
		Patient		Prilosec	C		
		Renal Cyst		Reglan	C		
		Urinary Tract Obstruction		Seroquel	C		
		Ventricular Hypertrophy		Welchol	C		
		Vomiting					

Date:08/05/03ISR Number: 4165594-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01597
Age:36 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5							
		Blood Albumin	Health				
MG/PRN/PO;							
		Blood Potassium	Professional				
SEE IMAGE							
		Body Temperature		Celebrex 100mg	SS		ORAL
100 MG/PRN/PO							
		Cardiac Murmur		Biaxin Xl	C		
		Drug Abuser		Cenestin	C		
		Dysfunctional Uterine		Motrin	C		
		Bleeding		Premarin	C		
		Dysmenorrhoea		Terazol 3 Vaginal			
		Endometriosis		Cream	C		
		Headache		Ultram	C		
		Hypertension		Vicoprofen	C		
		Muscle Spasms		Zyrtec	C		
		Myalgia		Acetaminophen (+)			
		Nephrotic Syndrome		Codeine	C		
		Oedema		Acetaminophen (+)			
		Oedema Peripheral		Hydrocodone	C		

Pain In Extremity	Cephalexin	C
Pharyngitis	Ferrous Sulfate	C
Pharyngolaryngeal Pain		
Proteinuria		
Purulence		
Renal Disorder		
Renal Failure Chronic		
Respiratory Rate		
Rhinitis		
Sinus Headache		
Sinusitis		
Tympanic Membrane Disorder		
Tympanic Membrane Hyperaemia		
Uterine Leiomyoma		
Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/03ISR Number: 4162573-6Report Type:Expedited (15-DaCompany Report #WAES 01104477
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cellulitis		Darvocet-N	C				
	Chloracne		Klor-Con	C				
	Dyspnoea		[Therapy Unspecified]	C				
	Erythema		Celebrex	C				
	Hypoaesthesia		Oxygen	C				
	Hypoxia							
	Sleep Apnoea Syndrome							
	Testicular Swelling							

Date:08/06/03ISR Number: 4162577-3Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00010
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	285	DAY
Initial or Prolonged	Oesophagitis Ulcerative		Aspirin Lysine	SS		ORAL		
			Perindopril Erbumine	C		ORAL		
			Nicorandil	C		ORAL		

Date:08/06/03ISR Number: 4162578-5Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00234
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Nightmare		Fenbufen	C		ORAL		
			Atenolol	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		

Date:08/06/03ISR Number: 4162579-7Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00233
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
	Melaena		Aspirin	C				
			Alcohol	C				

Date:08/06/03ISR Number: 4162580-3Report Type:Expedited (15-DaCompany Report #WAES 0307CHN00025
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Lymphocytic		Vioxx	PS		ORAL	2	DAY
	Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Dialysis		Nimodipine	C		ORAL	44	DAY
	Metastases To Spine		Pyridoxine	C		ORAL		
	Renal Failure Acute		Amlodipine Besylate	C		ORAL		
			Hydrotalcite	C		ORAL		
			Captopril	C		ORAL	46	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/03ISR Number: 4162585-2Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00029
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL		6 MON
Initial or Prolonged	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		3 MON
	Haemorrhage		Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		
	Renal Failure		Budesonide And Formoterol Fumarate	C		RESPIRATORY (INHALATION)		
			Torsemide	C		ORAL		

Date:08/06/03ISR Number: 4162586-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/06/03ISR Number: 4162588-8Report Type:Expedited (15-DaCompany Report #WAES 0307NOR00026
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY

Date:08/06/03ISR Number: 4162592-XReport Type:Expedited (15-DaCompany Report #WAES 0308GBR00006
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY

	Suicidal Ideation		Lansoprazole	C		ORAL
30 DAY						

Date:08/06/03ISR Number: 4162593-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA03484
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Headache		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Lethargy		Norvasc	C		
	Meningitis Aseptic		Hydrodiuril	C		
	Photosensitivity Reaction					

Date:08/06/03ISR Number: 4162940-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA02959
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Asthenia
Other	Atrial Fibrillation
	Atrial Flutter
	Atrioventricular Block
	First Degree
	Blood Pressure
	Blood Pressure Increased
	Bradycardia
	Bundle Branch Block Right
	Cardiac Failure

		Congestive Cardiac Pacemaker Insertion					
		Cardiomegaly	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL
12	DAY						
		Dyspnoea		Vioxx	SS		ORAL
1	DAY						
		Dyspnoea Exertional		Salutensin	C		
		Fatigue		Tenormin	C		
		Fluid Overload		Tenormin	C		
1	DAY						
		Myalgia		Paxil	C		
		Nausea		Xanax	C		
		Oedema		Lescol	C		
		Pharyngolaryngeal Pain					
		Pulmonary Fibrosis					
		Rales					
		Sick Sinus Syndrome					
		Sneezing					
		Tremor					
		Vision Blurred					

Date:08/06/03ISR Number: 4162941-2Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00087M
Age:33 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bradycardia Foetal		Vioxx	PS	Merck & Co., Inc	ORAL
		Breech Presentation		Thiocolchicoside	C		ORAL
31	DAY						
		Caesarean Section		Acetaminophen And			
		Complications Of Maternal		Belladonna And			
		Exposure To Therapeutic		Caffeine And Opium	C		ORAL
31	DAY						
		Drugs		Tetrazepam	C		ORAL
31	DAY						
		Foetal Growth Retardation					
		Maternal Drugs Affecting					
		Foetus					
		Pregnancy					

Date:08/06/03ISR Number: 4162945-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02144
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		98 DAY
Initial or Prolonged	Cerebrovascular Accident		Amitriptyline					
Other			Hydrochloride	C				
			Hydrodiuril	C				
			Levoxyl	C				
			Premarin	C				

Date:08/06/03ISR Number: 4162946-1Report Type:Expedited (15-DaCompany Report #WAES 0209FRA00087B1
Age:0 DY Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Vioxx	PS	Merck & Co., Inc			
	Breech Presentation		Thiocolchicoside	C				31 DAY
	Foetal Disorder		Acetaminophen And					
	Foetal Growth Retardation		Belladonna And					
	Maternal Drugs Affecting		Caffeine And Opium	C				31 DAY
	Foetus		Tetrazepam	C				31 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/03ISR Number: 4162949-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anxiety		Atenolol	C				
	Asthenia		Coumadin	C				
	Back Pain		Bayer Aspirin	C				
	Blood Triglycerides		Vicodin Tablets	C				
	Increased		Nitrostat	C				
	Cardiomegaly		Albuterol	C				
	Cerebrovascular Accident		Aspirin	C				
	Chest Pain		Naproxen	C				
	Chronic Obstructive							
	Pulmonary Disease							
	Coagulopathy							
	Contusion							
	Deafness Bilateral							
	Dyspnoea							
	Dysuria							
	Epistaxis							
	Gastrointestinal Disorder							
	Gingival Bleeding							
	Haematochezia							
	Haemorrhage							
	Heart Rate Irregular							
	Hypertension							
	Insomnia							
	Menstrual Disorder							
	Oedema							
	Oedema Peripheral							
	Osteoarthritis							
	Silent Myocardial							
	Infarction							
	Transient Ischaemic							
	Attack							

Date:08/06/03ISR Number: 4162951-5Report Type:Expedited (15-DaCompany Report #WAES 0304DEU00046
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Skin Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Toxic Epidermal		Acetyldigoxin	C		ORAL		

Initial or Prolonged	Necrolysis	Phenytoin	C	ORAL
		Isosorbide Dinitrate	C	ORAL
		Tilidine Hydrochloride	C	ORAL
		Dipyrone	C	ORAL

Date:08/06/03ISR Number: 4162955-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01476
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Contusion
Other	Fall
	Haemangioma
	Hepatic Cyst
	Hepatitis
	Hepatocellular Damage

		Hepatomegaly					
		Hepatotoxicity					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphocyte Count		Vioxx	PS		ORAL
		Decreased		Arava	SS	Merck & Co., Inc	
3	DAY						
		Monocyte Count Increased		Arava	SS		
64	DAY						
		Neutrophil Count		Methotrexate	C		
		Decreased		Prednisone	C		
		Red Blood Cell Count		[Therapy			
		Decreased		Unspecified]	C		
		Renal Cyst		Clavulanate			
		Serum Ferritin Increased		Potassium	C		
		Thrombocythaemia		Guaifenesin	C		
		White Blood Cell Count		Ranitidine	C		
		Increased		Hydrocodone			
				Bitartrate	C		
				Neurontin	C		
				Colace	C		
				Sulfasalazine	C		
				Augmentin	C		
				Celebrex	C		
				Tylenol	C		

Date:08/06/03ISR Number: 4162956-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA02124
Age:91 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Disorder		Aricept	C		
		Melaena		Meclizine	C		

Date:08/06/03ISR Number: 4162957-6Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00043
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aseptic Necrosis Bone		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Meloxicam	C		

Date:08/06/03ISR Number: 4162961-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA01625
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Asthenia
Hospitalization -	Coma
Initial or Prolonged	Confusional State
Other	Dyskinesia Oesophageal
	Dysphagia
	Haematocrit Decreased
	Hyperhidrosis
	Hypoglycaemia
	Hyponatraemia
	Pneumonia Aspiration
	Pyrexia
	Rash Erythematous
	Respiratory Arrest
	Thrombocytopenia
	Weight Decreased
	White Blood Cell Count

	Decreased					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Tracleer	SS		ORAL
53	DAY					
			Tracleer	SS		ORAL
			Flolan	SS		
INTRAVENOUS						
			Cardizem	SS		
			Neurontin	SS		
			Prevacid	C		
			Aldactone	C		
			Elavil	C		ORAL
			Celexa	C		
			Oxycontin	C		
			Allegra	C		
			Lasix (Furosemide)	C		
			Coumadin	C		

Date:08/06/03ISR Number: 4162967-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA03625
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY					
	Increased		Potassium			
	Gastrointestinal		(Unspecified)	SS		
	Haemorrhage		Famotidine	C		
	Hyperkalaemia					

Date:08/06/03ISR Number: 4162970-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA03634
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY					
Initial or Prolonged	Increased		Furosemide	SS		
	Drug Interaction		Aspirin	SS		
	Hyperkalaemia		Prinivil	SS		ORAL

Date:08/06/03ISR Number: 4162971-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA03627
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Aspirin	SS				

Date:08/06/03ISR Number: 4162972-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA03624
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Warfarin	SS				
	International Normalised		Cozaar	SS		ORAL		
	Ratio Increased		Furosemide	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/03ISR Number: 4162976-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03622
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Increased		Valsartan	SS				
	Gastrointestinal		Furosemide	SS				
	Haemorrhage		Metolazone	SS				

Date:08/06/03ISR Number: 4162978-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03626
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		45 DAY
Initial or Prolonged	Increased		Warfarin	SS				
	International Normalised		Valsartan	SS				
	Ratio Increased		Furosemide	SS				

Date:08/06/03ISR Number: 4162981-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03619
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
	Hypersensitivity							
	Urticaria							

Date:08/06/03ISR Number: 4162982-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA03635
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Increased		Vasotec	SS		ORAL		
	Duodenal Ulcer		Furosemide	SS				

	Hyperkalaemia		Potassium (Unspecified)	C

Date:08/06/03ISR Number: 4162983-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA03621
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Increased		Bumetanide	SS				
	Cardiac Failure							
	Congestive							
	Drug Interaction							
	Hyperkalaemia							

Date:08/06/03ISR Number: 4162985-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA03636
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Haemorrhage		Furosemide	SS				
	Haemodialysis							
	Hyperkalaemia							
	Renal Tubular Necrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/03ISR Number: 4162986-2Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00001
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Haematemesis							
	Muscle Spasms							

Date:08/06/03ISR Number: 4162987-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00053M
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL		
	Complications Of Maternal							
	Exposure To Therapeutic							
	Drugs							
	Drug Exposure During							
	Pregnancy							

Date:08/06/03ISR Number: 4162989-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA00016
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Blood Pressure Increased		Lipitor	C				
	Diarrhoea		Azopt Drops	C				
			Altace	C				
			Glyburide	C				
			Digitek	C				
			Dipyridamole	C				

Date:08/06/03ISR Number: 4162995-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA00053B1
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abortion Spontaneous Maternal Drugs Affecting Foetus		Vioxx	PS	Merck & Co., Inc

Date:08/06/03ISR Number: 4163453-2Report Type:Direct Company Report #CTU 199434
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
	Increased							
			Hydrochlorothiazide	C				

Date:08/06/03ISR Number: 4163491-XReport Type:Direct Company Report #CTU 199523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx 12.5 Mg	PS		ORAL	12.5 MG PO QD	
Initial or Prolonged	Diarrhoea							
	Haematochezia							
	Paraesthesia Oral							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/03ISR Number: 4163267-3Report Type:Expedited (15-DaCompany Report #WAES 01104488
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Fluctuation		Lasix (Furosemide Sodium)	C				
Other	Cardiac Failure		Herbs (Unspecified)	C				
	Congestive Cardiovascular Disorder		Aspirin	C				
	Oedema							
	Renal Failure							

Date:08/07/03ISR Number: 4163268-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Hot		Cardizem	C				
	Hyperhidrosis		Lasix (Furosemide)	C				
	Malaise		Tylenol	C				
			[Therapy Unspecified]	C				

Date:08/07/03ISR Number: 4163269-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00435
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Vitamins (Unspecified)	C				
Other	Congestive Cardiomyopathy		Vicodin Tablets	C				
	Ejection Fraction Decreased		Prilosec	C				
	Gastric Disorder							
	Major Depression							

Date:08/07/03ISR Number: 4163270-3Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation Neonatal		Vioxx	PS	Merck & Co., Inc			80 DAY
Initial or Prolonged	Apgar Score Low Caesarean Section Complications Of Maternal Exposure To Therapeutic Drugs Gestational Diabetes Maternal Drugs Affecting Foetus Pre-Eclampsia Pregnancy Sinusitis Streptococcal Infection		Sertraline	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/03ISR Number: 4163271-5Report Type:Expedited (15-DaCompany Report #WAES 0211FIN00001
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Positive		Vioxx	SS		ORAL		46 DAY
	Chills		Esomeprazole					
	Coagulation Time		Magnesium	SS		ORAL		
	Prolonged		Progesterone	SS				
	Fatigue		Progesterone	SS				
	Hepatic Haematoma		Esomeprazole					
	Hepatitis Toxic		Magnesium	SS				
	Oedema Due To Hepatic		Acetaminophen	C		ORAL		
	Disease		Estradiol Valerate	C		ORAL		
	Post Procedural		Fluticasone					
	Complication		Propionate	C				
			Albuterol Sulfate	C				
			Fexofenadine					
			Hydrochloride	C				
			Zolmitriptan	C				

Date:08/07/03ISR Number: 4163272-7Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Agitation Neonatal		Vioxx	PS	Merck & Co., Inc	ORAL		80 DAY
	Apgar Score Low		Sertraline	SS		ORAL		
	Caesarean Section							
	Complications Of Maternal							
	Exposure To Therapeutic							
	Drugs							
	Drug Exposure During							
	Pregnancy							
	Gestational Diabetes							
	Maternal Drugs Affecting							
	Foetus							
	Pre-Eclampsia							
	Pregnancy							
	Sinusitis							
	Streptococcal Infection							

Date:08/07/03ISR Number: 4163273-9Report Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure		Vioxx	SS		ORAL		
	Fluctuation							
	Cardiovascular Disorder							
	Hip Arthroplasty							
	Myocardial Infarction							
	Oedema							
	Oedema Peripheral							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/03ISR Number: 4163274-0Report Type:Expedited (15-DaCompany Report #WAES 01113468
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Aspirin	SS		ORAL		
	Rectal Haemorrhage		Fish Oil (Unspecified)	SS		ORAL		
	Syncope							

Date:08/07/03ISR Number: 4163275-2Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00029
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Dipyridamole	SS				
			Levothyroxine Sodium	C				
			Atorvastatin Calcium	C		ORAL		
			Calcium Carbonate	C				
			Verapamil Hydrochloride	C				

Date:08/07/03ISR Number: 4163276-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00104
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:08/07/03ISR Number: 4163279-XReport Type:Expedited (15-DaCompany Report #WAES 0308AUS00025
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Gastric Ulcer		Aspirin	SS		ORAL		
	Haematemesis		Diltiazem					

Melaena	Hydrochloride	C	ORAL
Oesophagitis	Zocor	C	ORAL
Syncope	Levothyroxine Sodium	C	ORAL
	Calcium Carbonate	C	ORAL
	Nitroglycerin	C	
	Acetaminophen	C	

Date:08/07/03ISR Number: 4163358-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Death	Asthenia
Hospitalization - Initial or Prolonged	Blood Pressure Decreased
	Decreased Appetite
	Dehydration
	Diverticulum Gastric
	Duodenal Ulcer
	Haemorrhage
	Erosive Oesophagitis
	Gastrointestinal
	Haemorrhage
	Hypovolaemia

		Lethargy					
		Malnutrition					
		Oesophagitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Intake Reduced		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure		Aggrenox	C		
				Digoxin	C		
				Mag-Ox 400 Tablets	C		
				Reglan	C		
				Metoprolol	C		
				Risperdal	C		
				Vitamins (Unspecified)	C		
				Lasix (Furosemide)	C		
				Detrol	C		
				Megace	C		
				Ben-Gay	C		
				Tylenol	C		

Date:08/07/03ISR Number: 4163360-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA03194
Age:86 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure Congestive					
		Cerebrovascular Accident					
		Coronary Artery Disease					
		Hernia					

Date:08/07/03ISR Number: 4163512-4Report Type:Expedited (15-DaCompany Report #WAES 0206USA02554
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Atrial Flutter
	Atrial Tachycardia
	Back Pain
	Bronchitis
	Cardio-Respiratory Arrest

Cholelithiasis
Chronic Obstructive
Airways Disease
Exacerbated
Coronary Artery Disease
Electrocardiogram St-T
Change
Electromechanical
Dissociation
Gastritis
Haemoptysis
Hepatic Cyst
Hypertension
Hypotension
Multiple Myeloma
Myocardial Infarction
Pneumonia Pneumococcal
Pneumonia Streptococcal

	Respiratory Rate Increased						
	Rib Fracture	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Streptococcal Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL	425 DAY
	Tracheobronchitis		Nonsteroidal				
	Upper Respiratory Tract		Anti-Inflammatory				
	Infection		Drug (Unspecified)	C		ORAL	
			Lipitor	C			
			Metoprolol	C			
			Prozac	C			
			Combivent	C			RESPIRATORY
							(INHALATION)
			Daypro	C		ORAL	
			Prednisone	C			
			Ventolin (Albuterol Sulfate)	C			
			Cartia (Aspirin)	C		ORAL	
			Nicotine	C			
			Xanax	C		ORAL	
			Cardizem Cd	C			
			Captopril	C			

Date:08/07/03ISR Number: 4163513-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	
	Congestive		Zestril	C			
	Hypertension		Procardia	C			
	Injury		Trental	C			
	Myocardial Infarction		Potassium (Unspecified)	C			
	Overdose		Lasix (Furosemide)	C			
			Ranitidine	C			
			Aspirin	C			
			Atenolol	C			
			Cyclobenzaprine Hydrochloride	C		ORAL	
			Novolin	C			SUBCUTANEOUS

Date:08/07/03ISR Number: 4163514-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA02433
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Aortic Calcification
	Atherosclerosis
	Cardiomegaly
	Contusion
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Hepatic Congestion
	Hepatic Steatosis
	Hepatomegaly
	Myocardial Rupture
	Nephrosclerosis
	Pericardial Haemorrhage

		Polycystic Ovaries					
		Pulmonary Congestion					
		Renal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Spleen Congestion		Armour Thyroid Tablets	C		
				Acetaminophen And Codeine	C		
				Norvasc	C		
				Vasotec	C		ORAL
				Glucophage	C		
				Hytrin	C		
				Trimox	C		
				Metronidazole	C		
				Aspirin	C		

Date:08/07/03ISR Number: 4163521-5Report Type:Expedited (15-DaCompany Report #WAES 0307PRT00006
Age:78 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
Initial or Prolonged		Gastric Ulcer Haemorrhage		Nimesulide	SS		ORAL
7	DAY						
		Gastrointestinal		Acetaminophen	C		ORAL
7	DAY						
		Haemorrhage		Clomipramine Hydrochloride	C		ORAL
366	DAY						
				Rilmenidine	C		ORAL
366	DAY						
				Enalapril Maleate	C		ORAL
366	DAY						

Date:08/07/03ISR Number: 4163528-8Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00020
Age:83 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Iron Decreased		Ketoprofen	SS		ORAL

	Gastric Ulcer Haemorrhage		Aspirin	SS		ORAL
			Prednisolone	C		
			Acetaminophen	C		
			Amiodarone Hydrochloride	C		
			Felodipine	C		
			Furosemide	C		

Date:08/07/03ISR Number: 4163530-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/07/03ISR Number: 4163531-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/07/03ISR Number: 4163536-7Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00019
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise		Aspirin	SS				
	Melaena		Morphine Sulfate	C				
			Lactulose	C				
			Morphine Sulfate	C				
			Docusate Sodium And Senna	C				

Date:08/07/03ISR Number: 4163541-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA00051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural							
Other	Haemorrhage							

Date:08/07/03ISR Number: 4163542-2Report Type:Expedited (15-DaCompany Report #WAES 0308CHE00005
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Second Degree		Ibuprofen	SS		ORAL		
	Bradycardia		Digoxin	SS		ORAL		
	Loss Of Consciousness		Clomipramine Hydrochloride	C		ORAL		
	Myocardial Infarction		Estradiol	C				
			Mebeverine Hydrochloride	C		ORAL		
			Zopiclone	C		ORAL		
			Metronidazole	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		
			Veralipride	C		ORAL		
			Dydrogesterone	C		ORAL		

Date:08/07/03ISR Number: 4163543-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00064
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx Inderal	PS C	Merck & Co., Inc	ORAL		

Date:08/07/03ISR Number: 4166733-XReport Type:Expedited (15-DaCompany Report #HQWYE904505AUG03
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Enzyme Increased Hepatic Function Abnormal	Health Professional Other	Premarin (Conjugated Estrogens, Tablet, Unspec)	PS		ORAL	ONE TABLET ONCE DAILY	
			Lipitor (Atorvastatin)	SS		ORAL	ONE TABLET DAILY	262 DAY
			Vioxx (Rofecoxib,					

	Tablet)	SS	ORAL
	Aspirin (Acetylsalicylic Acid), 100 Mg 1x Per 1 Day, Unknown	C	

Date:08/07/03ISR Number: 4167337-5Report Type:Expedited (15-DaCompany Report #WAES 01010328
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Anger	Health	Procrit Unk	SS				
Other	Asthenia	Professional	Carafate Unk	SS				
	Balance Disorder	Company	Carbatrol	C				
	Convulsion	Representative	Catapres	C				
	Dermatitis		Cozaar	C				
	Diastolic Dysfunction		Glucotrol	C				
	Drooling		Hyzaar	C				
	Drug Hypersensitivity		Neurontin	C				
	Gait Disturbance		Premarin	C				
	Headache		Toprol Xl Tablets	C				
	Hyperhidrosis							
	Hypertension							
	Hypertensive Crisis							
	Limb Injury							
	Loss Of Consciousness							
	Malaise							
	Medication Error							
	Nausea							
	Oedema Peripheral							
	Posturing							
	Road Traffic Accident							
	Speech Disorder							
	Thinking Abnormal							
	Tremor							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							

Date:08/08/03ISR Number: 4164056-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
Disability	Blood Cholesterol Increased
Other	Blood Pressure
	Cerebrovascular Accident
	Cognitive Disorder
	Confusional State
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Gait Disturbance
	Impaired Driving Ability
	Impaired Work Ability
	Insomnia
	Loss Of Libido
	Sexual Dysfunction
	Speech Disorder

	Transient Ischaemic Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Fosamax	C		ORAL		

Date:08/08/03ISR Number: 4164057-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA00074
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Phoslo	C				
Initial or Prolonged	Anaemia		Procardia Xl	C				
	Atrial Fibrillation		Pravachol	C				
	Blood Creatinine		Cardura	C				
	Blood Glucose		Timoptic	C				
OPHTHALMIC								
	Blood Pressure Increased		Tenormin	C				
	Blood Sodium		Aspirin	C				
	Blood Urea		Tylenol	C				
	Bradycardia		Advil	C				
	Cardiogenic Shock		Calcium (Unspecified)	C				
	Cardiomegaly		Vitamins (Unspecified)	C				
	Circulatory Collapse							
	Dehydration							
	Dizziness							
	Hypokalaemia							
	Hypoxic Encephalopathy							
	Insomnia							
	Metabolic Acidosis							
	Muscle Strain							
	Renal Failure							
	Respiratory Rate Increased							
	Ventricular Extrasystoles							
	Ventricular Hypertrophy							
	Ventricular Tachycardia							

Date:08/08/03ISR Number: 4164058-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00802
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hypertension Transient Ischaemic Attack		Vioxx Synthroid Estrace Accupril	PS C C C	Merck & Co., Inc	ORAL

Date:08/08/03ISR Number: 4164059-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01999
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death 54 DAY	Coma		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - 568 DAY	Haemorrhagic Stroke		Lipitor	C		
Initial or Prolonged 3778 DAY	Hypertension Respiratory Failure		Celexa Allopurinol Estratest	C C C		
51 DAY			Study Drug (Unspecified)	C		

Date:08/08/03ISR Number: 4164060-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Lorcet Plus	C				
	Cerebral Cyst							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Depression							
	Dyspnoea							
	Emotional Distress							
	Heart Rate Irregular							
	Hypertension							
	Spleen Disorder							

Date:08/08/03ISR Number: 4164061-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		[Therapy Unspecified]	C				
	Erectile Dysfunction							
	Hypersensitivity							
	Muscle Tightness							
	Myocardial Infarction							

Date:08/08/03ISR Number: 4164062-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01983
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc			
Other	Benign Prostatic Hyperplasia		Aspirin	C				
	Cardiac Valve Disease		Lasix (Furosemide)	C				
	Coronary Artery Disease		[Therapy Unspecified]	C				
	Dyspnoea		Coumadin	C				
	Glaucoma							
	Haemorrhage							
	Heart Rate Irregular							

	Hypertension Myocardial Infarction Peripheral Vascular Disorder Polytraumatism

Date:08/08/03ISR Number: 4164063-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome Hospitalization - Initial or Prolonged	PT Blood Cholesterol Increased Blood Triglycerides Increased Chest Pain Cold Sweat Depression Dizziness Dyspepsia

		Dyspnoea					
		Generalised Anxiety Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Injury		Aspirin	C		
		Myocardial Infarction		Lipitor	C		
		Nausea		Prometrium	C		
				Vivelle	C		
				Zyrtec	C		
				Fioricet Tablets	C		
				Ambien	C		
				Motrin	C		

Date:08/08/03ISR Number: 4164064-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Aspirin	C		
		Basal Cell Carcinoma		Lipitor	C		
		Buttock Pain		Premarin	C		
		Chest Pain		Calcium (Unspecified)	C		
		Cough		Vitamins (Unspecified)	C		
		Ecchymosis		[Therapy Unspecified]	C		
		Hepatitis		Acyclovir	C		
		Hypertension					
		Myalgia					
		Pain In Extremity					
		Respiratory Tract Infection					
		Ventricular Extrasystoles					

Date:08/08/03ISR Number: 4164065-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Bilirubin		Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						

Initial or Prolonged Disability	Unconjugated Increased	Vioxx	SS	ORAL 15 DAY
	Cerebellar Haemorrhage	Vioxx	SS	ORAL
	Constipation	Avapro	C	
	Dehydration	Valium	C	
	Diverticulum	Neurontin	C	
	Fall	Neurontin	C	
	Femur Fracture	Macrodantin	C	
	Haemorrhagic Stroke	Nortriptyline	C	
	Hyperglycaemia	Nortriptyline	C	
	Hyponatraemia	Misoprostol	C	
	Lung Neoplasm			
	Pyelonephritis			
	Rectal Cramps			
	Sleep Apnoea Syndrome			
	Urinary Tract Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/03ISR Number: 4164068-2Report Type:Expedited (15-DaCompany Report #WAES 0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Hospitalization -	Aortic Valve Incompetence		Vioxx	SS		ORAL		
Initial or Prolonged	Asthenia		Premarin	C				
Disability	Cardiac Failure		Prinivil	C				
	Congestive		Diazepam	C				
	Chest Pain		Calcium					
	Diabetes Mellitus		(Unspecified)	C				
	Headache							
	Heart Rate Irregular							
	Heart Valve Stenosis							
	Hypotonia							
	Neoplasm Malignant							
	Palpitations							
	Paraesthesia							
	Paraesthesia Oral							
	Visual Acuity Reduced							

Date:08/08/03ISR Number: 4164070-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Arthralgia		Klonopin	C				
Disability	Cerebrovascular Accident		Albuterol	C				
RESPIRATORY								
	Chronic Obstructive							
(INHALATION)								
	Pulmonary Disease		Prempro	C				
	Electrocardiogram Qt		Cyclobenzaprine					
	Prolonged		Hydrochloride	C		ORAL		
	Heart Rate Irregular		Relafen	C		ORAL		
	Hypertensive Crisis		Clonidine	C				
	Hypokalaemia		Triamterene	C				
	Pain In Extremity		Trinalin	C				
	Sinusitis							
	Stress							

Date:08/08/03ISR Number: 4164071-2Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00185
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure		Aspirin	SS				
Hospitalization - Initial or Prolonged	Congestive		Metformin	C				
	Fall		Gliclazide	C				
	Gastric Ulcer Haemorrhage		Ranitidine	C				
	Melaena							

Date:08/08/03ISR Number: 4164072-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00004
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Back Disorder
Other	Back Injury
	Back Pain
	Blood Cholesterol Increased

	Blood Pressure Increased						
	Breast Operation						
	Cardiac Murmur	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS		ORAL		
	Gastrooesophageal Reflux		Celebrex	C				
	Disease		Vicodin Tablets	C				
	Heart Rate Irregular		Percocet	C				
	Osteoarthritis		Darvocet-N	C				
	Post Procedural		Soma	C				
	Complication		Oxycontin	C				
	Sensory Loss		Ibuprofen	C				
	Sleep Apnoea Syndrome		Aleve	C				

Date:08/08/03ISR Number: 4164073-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00764
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Visual Acuity Reduced		Hytrin	C				

Date:08/08/03ISR Number: 4164074-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00074
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anorexia		Azopt Drops	C				
	Asthenia		Levoxyl	C				
	Dizziness		Ocupress	C				
	Injury		Prempro	C				
	Urinary Retention		Maxzide	C				

Date:08/08/03ISR Number: 4164076-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA00116
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Pulmonary Embolism					

Date:08/08/03ISR Number: 4164085-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA02229
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DAY	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Pelvic Pain		Vioxx	SS		ORAL
			Vasotec	C		ORAL
			Neurontin	C		ORAL
			Prevacid	C		ORAL
			Remeron	C		ORAL
			Carafate	C		ORAL
			Donnatal	C		ORAL
			Reglan	C		ORAL
			Tylenol Extra Strength	C		
			Urecholine	C		ORAL
5 DAY						
			Levaquin	C		
			Levaquin	C		
7 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/03ISR Number: 4164092-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03440
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Warfarin	C				
Initial or Prolonged	Blood Glucose Increased		Triamterene	C				
	Blood Urea Increased		Hydrodiuril	C		ORAL		
	Diabetes Mellitus		Omeprazole	C				
	Necrotising Fasciitis		Prednisone	C				
	Streptococcal		Methotrexate	C				
			Propoxyphene Hydrochloride	C				

Date:08/08/03ISR Number: 4164099-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA00185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Postoperative Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Augmentin	C				

Date:08/08/03ISR Number: 4164331-5Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00026
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL	332 MON	
Hospitalization -	Haemorrhagic		Candesartan Cilexetil	C		ORAL		
Initial or Prolonged	Haemoglobin Decreased		Harpagophytum Procumbens	C		ORAL	92 DAY	
	Melaena		Levothyroxine Sodium	C		ORAL		
			Acetyldigoxin	C		ORAL		

Date:08/08/03ISR Number: 4164332-7Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00014
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Lethargy		Naproxen	SS				
	Melaena		Aspirin	SS				
			Amlodipine Besylate	C				
			Atorvastatin Calcium	C				
			Heparin Sodium	C				
			Levothyroxine Sodium	C				
			Acetaminophen	C				
			Calcitriol	C				

Date:08/08/03ISR Number: 4164334-0Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00005
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Melaena							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/03ISR Number: 4164336-4Report Type:Expedited (15-DaCompany Report #WAES 01104485
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine		Lozol	C		ORAL		
	Blood Urea		Norvasc	C		ORAL		
	Cardiac Murmur		Zantac	C		ORAL		
	Defaecation Urgency		Aspirin	C		ORAL		
	Diverticulum Intestinal		Lorazepam	C				
	Emotional Distress		Tylenol	C		ORAL		
	Gastritis							
	Gastroenteritis							
	Helicobacter							
	Haemoglobin							
	Helicobacter Infection							
	Hypertension							
	International Normalised							
	Ratio Decreased							
	Lower Gastrointestinal							
	Haemorrhage							
	Pain							
	Prothrombin Time							
	Red Blood Cell Count							
	Scoliosis							
	Spinal Osteoarthritis							
	Weight Decreased							
	White Blood Cell Count							

Date:08/08/03ISR Number: 4164337-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02086
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vasotec	C		ORAL		
	Depression		Ultram	C				
	Dyspepsia		Prilosec	C				
	Dyspnoea		Miacalcin	C				
	Gastrooesophageal Reflux		Ferrous Sulfate	C				
	Disease		Deltasone	C				
	Haematochezia		Valium	C				
	Injury		Timoptic	C				
	Nausea		Hydrodiuril	C		ORAL		

	Spinal Compression	Morphine	C
	Fracture		
	Syncope		
	Weight Decreased		

Date:08/08/03ISR Number: 4164338-8Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal
	Cardiovascular Disorder
Disability	Cerebrovascular Accident
	Disturbance In Attention
	Fatigue
	Headache
	Hypoaesthesia
	Oedema

Renal Failure

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Tavist-D	C				
			Tylenol	C				

Date:08/08/03ISR Number: 4164340-6Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00030
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Aspirin	SS		ORAL		
	Gastric Ulcer Haemorrhage		Atenolol	C		ORAL		
	Melaena		Diltiazem Hydrochloride	C		ORAL		
			Albuterol	C				
RESPIRATORY (INHALATION)			Ipratropium Bromide	C		ORAL		

Date:08/08/03ISR Number: 4164342-XReport Type:Expedited (15-DaCompany Report #WAES 0308NZL00005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/03ISR Number: 4164343-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA00123
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Probenecid	C				
Disability			Dilantin	C				
			Nexium	C				

Date:08/08/03ISR Number: 4164347-9Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00022
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Spironolactone	SS		ORAL		
	Melaena		Azathioprine	C		ORAL		
	Myocardial Infarction		Furosemide	C		ORAL		
	Oedema Peripheral		Testosterone Enanthate	C		ORAL		
	Pitting Oedema		Calcitriol	C		ORAL		
			Ranitidine	C		ORAL		
			Pyridostigmine Bromide	C		ORAL		
			Valproate Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/03ISR Number: 4164348-0Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00037
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Melaena		Aspirin	SS		ORAL		17 DAY
			Diclofenac Sodium	SS		ORAL		1379 DAY
			Atorvastatin Calcium	C				
			Ranitidine Hydrochloride	C				
			Amlodipine Besylate	C				

Date:08/08/03ISR Number: 4164349-2Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00017
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Aspirin	SS		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Furosemide	C				
			Acetaminophen	C				
			Omeprazole Magnesium	C		ORAL		
			Verapamil Hydrochloride	C				
			Prednisone	C		ORAL		
			Potassium Chloride	C				

Date:08/08/03ISR Number: 4164350-9Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00038
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Amylase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Lipase Increased		Mesalamine	SS				
	Pancreatitis		Acetaminophen	C				
	Rectal Haemorrhage		Acetaminophen And Codeine Phosphate	C				

			Pseudoephedrine Hydrochloride	C		

Date:08/08/03ISR Number: 4166149-6Report Type:Direct Company Report #CTU 199626
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25 Mg	PS		ORAL	1 PER	ORAL

Date:08/08/03ISR Number: 4166301-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Back Injury
	Blood Cholesterol Increased
	Cardiac Failure
	Cardiomyopathy
	Coronary Artery

	Thrombosis						
	Dyspepsia						
	High Density Lipoprotein Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
	Low Density Lipoprotein Increased		Lopressor	C			

Date:08/09/03ISR Number: 4167353-3Report Type:Expedited (15-DaCompany Report #DSA_23048_2003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Unstable	Consumer	Vasotec	PS			
			Vioxx	SS			
			Invest Study Medications	SS			

Date:08/11/03ISR Number: 4164977-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02079
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	276 DAY
Initial or Prolonged	Arterial Disorder		Vioxx	SS		ORAL	
Other	Back Disorder		Fosamax	C		ORAL	328 DAY
	Blood Cholesterol Increased		Baycol	C			
			Folic Acid	C			
	Blood Triglycerides Increased		Betimol	C			OPHTHALMIC
			Vicodin Tablets	C			
	Cardiac Failure Congestive						
	Coronary Artery Disease						
	Haematoma						
	Hypertension						
	Low Density Lipoprotein Increased						
	Myocardial Infarction						

Stress

Date:08/11/03ISR Number: 4164978-6Report Type:Expedited (15-DaCompany Report #WAES 01113465
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Colchicine	C				
			Acetaminophen	C				
			Aspirin	C				

Date:08/11/03ISR Number: 4164980-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00004
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Back Disorder
Other	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Cardiac Murmur
	Cardiac Valve Disease

		Dyspnoea					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS		ORAL
		Osteoarthritis		Percocet	C		
		Sensory Loss		Vicodin Tablets	C		
		Sleep Apnoea Syndrome		Oxycontin	C		
				Aleve	C		
				Ibuprofen	C		
				Soma	C		
				Celebrex	C		
				Darvocet-N	C		

Date:08/11/03ISR Number: 4164981-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01024
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Atelectasis					
		Chronic Obstructive Pulmonary Disease					
		Cough					
		Dermatitis					
		Hypokalaemia					
		Lobar Pneumonia					
		Nausea					
		Pleuritic Pain					
		Pulmonary Congestion					
		Respiratory Failure					
		Rheumatoid Arthritis					
		Sinusitis					
		Viral Infection					
		Vomiting					

Date:08/11/03ISR Number: 4164983-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA01976
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 106 DAY	Anxiety	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain	Tylenol	C		
	Diabetes Mellitus	Bayer Aspirin	C		
	Drug Hypersensitivity				
	Dyspnoea				
	Glaucoma				
	Heart Rate Increased				
	Hypertension				
	Pain In Extremity				
	Thyroid Disorder				
	Tooth Extraction				

Date:08/11/03ISR Number: 4164987-7Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00125
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Allopurinol	SS		ORAL
	Renal Failure Acute		Furosemide	SS		

Ramipril	SS
Docusate Sodium And Senna	C
Olanzapine	C
Pantoprazole	C
Shark Cartilage (As Drug)	C
Tramadol Hydrochloride	C
Cranberry Extract	C

Date:08/11/03ISR Number: 4164989-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertension							
	Myocardial Infarction							
	Sleep Apnoea Syndrome							

Date:08/11/03ISR Number: 4164990-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Hypertension		Actos	C				
	Injury		Amaryl	C				
	Libido Decreased		Glucophage	C				
	Personality Change		Aspirin	C				
			Lipitor	C				
			Persantine	C				

Date:08/11/03ISR Number: 4164992-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA00323
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
22 DAY						
	Dyspnoea		Effexor	C		
	Generalised Oedema		Prilosec	C		

Date:08/11/03ISR Number: 4164994-4Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00126
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
165 MON						
Initial or Prolonged	Left Ventricular Failure		Furosemide	SS		ORAL
	Pulmonary Oedema		Quinapril			
	Renal Failure Acute		Hydrochloride	SS		ORAL
			Carvedilol	C		ORAL
			Pravastatin Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/03ISR Number: 4164996-8Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00026
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Zocor	C		ORAL
	Melaena		Candesartan			
			Cilexetil	C		

Date:08/11/03ISR Number: 4164998-1Report Type:Expedited (15-DaCompany Report #WAES 0307ZAF00025
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coronary Artery Occlusion		Folic Acid	C		ORAL
Initial or Prolonged	Electrocardiogram St-T		Prednisone	C		ORAL
Other	Segment Depression		Prednisone	C		ORAL
	Myocardial Infarction		Methotrexate	C		ORAL

Date:08/11/03ISR Number: 4165382-7Report Type:Expedited (15-DaCompany Report #WAES 0207AUS00195
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Haemorrhage		Warfarin	C		
	Melaena					

Date:08/11/03ISR Number: 4165386-4Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00031
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Unstable		Enoxaparin Sodium	SS		
INTRAVENOUS	3 DAY					
	Blood Potassium		Aspirin	SS		ORAL
	Blood Sodium		Gliclazide	C		ORAL
	Haematemesis		Ramipril	C		ORAL

Date:08/11/03ISR Number: 4165387-6Report Type:Expedited (15-DaCompany Report #WAES 0308ZAF00003
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Claustrophobia		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Dyspepsia		Vioxx	SS		ORAL		2 DAY
	Dyspnoea		Vioxx	SS		ORAL		
			Lansoprazole	C		ORAL		9 DAY

Date:08/11/03ISR Number: 4165390-6Report Type:Expedited (15-DaCompany Report #WAES 0306ZAF00017
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Vesicular		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Amlodipine Besylate	SS		ORAL		
Disability			Atorvastatin Calcium	SS		ORAL		
			Glimepiride	C		ORAL		
			Hyzaar	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/03ISR Number: 4165392-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA00706
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/03ISR Number: 4165395-5Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00013
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Appetite		Aspirin	SS		ORAL		
	Haematemesis		Oxazepam	C				
	Nausea		Mineral Oil And Petrolatum, White	C			OPHTHALMIC	
	Peptic Ulcer		Nitroglycerin	C				
			Prednisolone Sodium Phosphate	C			OPHTHALMIC	
			Bendroflumethiazide	C				
			Loratadine	C				
			Isosorbide Mononitrate	C				
			Mebeverine Hydrochloride	C				
			Oil Of Peppermint	C				

Date:08/11/03ISR Number: 4165396-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA00688
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/03ISR Number: 4165998-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Aspirin	C				
	Back Pain		Lipitor	C				
	Basal Cell Carcinoma		Premarin	C				
	Blood Potassium Decreased		Calcium (Unspecified)	C				
	Chest Pain		Vitamins (Unspecified)	C				
	Cough		[Therapy Unspecified]	C				
	Dyspnoea		Acyclovir	C				
	Ecchymosis							
	Heart Rate Increased							
	Hypertension							
	Intervertebral Disc Protrusion							
	Pain In Extremity							
	Respiratory Tract Infection							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/03ISR Number: 4165999-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03199
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Isosorbide	C		
	Chest Pain		Potassium			
	Myalgia		(Unspecified)	C		
			Zocor	C		ORAL
			Docusate Calcium	C		
			Plavix	C		
			Lasix (Furosemide)	C		
1680 DAY						
			Psyllium Husk	C		
			Folic Acid	C		
			Vitamin E	C		
			Psyllium Husk	C		
			Dorzolamide Hydrochloride	C		
			Betaxolol Hydrochloride	C		
			Digoxin	C		
			Warfarin	C		
			Atrovent	C		
			Nitroglycerin	C		
			Diltiazem Hydrochloride	C		
			Atenolol	C		
			Cerivastatin Sodium	C		
			Meclizine	C		
			Celebrex	C		
			Prednisone	C		
			Percocet	C		
			Rabeprazole Sodium	C		
			Atropine Sulfate	C		
			Xalatan	C		

Date:08/12/03ISR Number: 4166000-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Angina Pectoris
Hospitalization - Initial or Prolonged	Anxiety
	Aortic Aneurysm

Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Failure Congestive
	Cardiac Valve Disease
	Cerebrovascular Accident
	Coronary Artery Disease
	Depression
	Dyspnoea
	Haemorrhage
	Heart Rate Irregular
	Hernia
	High Density Lipoprotein Decreased
	Low Density Lipoprotein Increased

	Myocardial Infarction						
	Prostate Cancer						
	Stress	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	786	DAY
	Attack		Aspirin	C				
			Plavix	C				
			Atenolol	C				
			[Therapy Unspecified]	C				
			Prinivil	C		ORAL		
			Zocor	C				

Date:08/12/03ISR Number: 4166003-XReport Type:Expedited (15-DaCompany Report #WAES 0304GBR00045
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
			Estrogens, Conjugated And Medroxyprogesterone Acetate	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C				
			Vitamin E	C				

Date:08/12/03ISR Number: 4166004-1Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00049
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	182	DAY
Initial or Prolonged	Cardioactive Drug Level		Spironolactone	C		ORAL		
	Increased		Digoxin	C		ORAL		
	International Normalised		Fluindione	C		ORAL	366	DAY
	Ratio Increased		Fluindione	C		ORAL		
	Kidney Small		Furosemide	C		ORAL		
	Renal Failure		Cozaar	C		ORAL		

			Melilot And Rutin	C			
			Adrafinil	C			
			Buflomedil Hydrochloride	C			ORAL
			Buflomedil Hydrochloride	C			ORAL

Date:08/12/03ISR Number: 4166050-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA02343
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		62 DAY
Initial or Prolonged	Haemorrhagic		Ultracet	C				
			Cozaar	C		ORAL		
			Calan Sr	C		ORAL		
			Pepcid	C		ORAL		
			Detrol La	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/03ISR Number: 4166055-7Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00005
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Headache		Hydrochlorothiazide					
	Nausea		And Ramipril	C		ORAL		
	Vertigo							

Date:08/13/03ISR Number: 4166067-3Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00026
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	332	MON
Hospitalization -	Diverticulum Intestinal		Candesartan					
Initial or Prolonged	Haemorrhagic		Cilexetil	C		ORAL		
	Melaena		Harpagophytum					
			Procumbens	C		ORAL	92	DAY
			Levothyroxine Sodium	C		ORAL		
			Acetyldigoxin	C		ORAL		

Date:08/13/03ISR Number: 4166098-3Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00022
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive		Diclofenac	C				
	Oedema							

Date:08/13/03ISR Number: 4166102-2Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction

Disability	Asthenia
	Back Disorder
	Blood Cholesterol Increased
	Blood Glucose Increased
	Cardiac Failure Congestive
	Colonic Polyp
	Conjunctival Haemorrhage
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Thrombosis
	Dermatitis Contact
	Dilatation Ventricular
	Diverticulum Intestinal
	Ecchymosis
	Erectile Dysfunction
	Eye Infection
	Eye Injury
	Eye Oedema
	Feeling Abnormal

		Glycosylated Haemoglobin Increased					
		Haemorrhoids	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Avandia	C		
		Rectal Haemorrhage		Blephamide Ointment	C		
		Ventricular Dysfunction		Viagra	C		
		Vision Blurred		Acetaminophen And Hydrocodone Bitartrate	C		
				Duratuss	C		
				Wellbutrin	C		

Date:08/13/03ISR Number: 4166659-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA00448
Age:58 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Mouth Ulceration		Vioxx	SS		ORAL
		Throat Tightness		Estrogens (Unspecified)	C		

Date:08/13/03ISR Number: 4166661-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA00839
Age:86 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Activated Partial Thromboplastin Time		Vioxx	PS	Merck & Co., Inc	ORAL
		Prolonged		Coumadin	C		
		Contusion		Aspirin	C		

Date:08/13/03ISR Number: 4167039-5Report Type:Direct Company Report #CTU 199924
Age:65 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chest Pain		Vioxx 25 Mg Merck	PS	Merck	
QD							

Initial or Prolonged			Aspirin	C		
			Lescol	C		

Date:08/13/03ISR Number: 4167124-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Hypertension		Actos	C				
	Loss Of Libido		Amaryl	C				
			Glucophage	C				
			Aspirin	C				
			Lipitor	C				
			Persantine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/03ISR Number: 4167127-3Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00173
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cytomegalovirus Infection		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Life-Threatening	Eosinophil Count		Prednisolone	C				
Hospitalization -	Multi-Organ Failure		Formoterol Fumarate	C				
RESPIRATORY								
Initial or Prolonged	Myocardial Infarction							
(INHALATION)								
	Sepsis		Theophylline	C				
RESPIRATORY								
	White Blood Cell Count							
(INHALATION)								

Date:08/13/03ISR Number: 4167398-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA00735
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Aspirin	C				
	Weight Decreased							

Date:08/13/03ISR Number: 4167399-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA00751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/13/03ISR Number: 4167400-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA00868
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive							

Date:08/13/03ISR Number: 4167403-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00051
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematocrit Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
	Haemoglobin Decreased		Aspirin	C				
	Post Procedural Haematoma							
	Post Procedural Haemorrhage							

Date:08/13/03ISR Number: 4167405-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA03505
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/14/03ISR Number: 4167409-5Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00126
Age:79 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Potassium
	Chest Pain
	Left Ventricular Failure

	Pulmonary Oedema Renal Failure Acute						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	165	MON
			Furosemide	SS		ORAL		
			Quinapril Hydrochloride	SS		ORAL		
			Carvedilol	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:08/14/03ISR Number: 4167410-1Report Type:Expedited (15-DaCompany Report #WAES 0308DEU00030
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:08/14/03ISR Number: 4167870-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA02946
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diarrhoea		Diltiazem Hydrochloride	C				
	Sepsis		Accupril	C				
	Spondylitis		Synthroid	C				
	Vomiting		Prevacid	C				
			Neurontin	C				
			Premarin	C				
			Hydrodiuril	C		ORAL		

Date:08/14/03ISR Number: 4167871-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01000
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
	Oedema Peripheral					
	Tenderness					
	Weight Increased					

Date:08/14/03ISR Number: 4167875-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00362
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Generalised Oedema		Aspirin	C		ORAL		
	Sensation Of Heaviness		Lopressor	C		ORAL		
	Weight Increased		Zestoretic	C		ORAL		
			Lanoxin	C		ORAL		
			Advil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/14/03ISR Number: 4169070-2Report Type:Expedited (15-DaCompany Report #DSA_23101_2003
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Literature Health	Vasotec	PS				
			Vioxx	SS				30 DAY
	Drug Interaction	Professional	Furosemide	SS				
	Duodenal Ulcer		Potassium	C				
	Hyperkalaemia							

Date:08/14/03ISR Number: 4169073-8Report Type:Expedited (15-DaCompany Report #STA-AE-03-MTX-069
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy	Consumer Distributor	Methotrexate (Methotrexate, Unspec)	PS				
	Fibromyalgia		Remicade (Infliximab)	SS				
			Unspecified Non-Steroidal Anti-Inflammatory Agent	SS				
			Vioxx (Rofecoxib, Tablet)	SS				

Date:08/15/03ISR Number: 4168328-0Report Type:Expedited (15-DaCompany Report #WAES 01113471
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
							647 DAY	
	Pancytopenia		Aspirin	SS		ORAL		
	Rectal Haemorrhage		Methotrexate Sodium	SS				
							43 DAY	
			Prednisolone	SS		ORAL		
			Omeprazole	C		ORAL		
			Levothyroxine Sodium	C				
			Furosemide Sodium	C				

			Calcitriol	C
			Pravastatin Sodium	C
			Mianserin Hydrochloride	C
			Acetaminophen	C

Date:08/15/03ISR Number: 4168334-6Report Type:Expedited (15-DaCompany Report #WAES 0306CAN00056
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Rupture		Vioxx	PS	Merck & Co., Inc	ORAL	22 DAY	
	Sudden Death		Hyzaar	C		ORAL	1201 DAY	
			Oxycodone Hydrochloride	C			147 DAY	
			Acetaminophen	C			147 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/03ISR Number: 4168336-XReport Type:Expedited (15-DaCompany Report #WAES 0307DEU00064
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:08/15/03ISR Number: 4168338-3Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00054
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS		ORAL		
	Feeling Abnormal		Fexofenadine Hydrochloride	SS				

Date:08/15/03ISR Number: 4168339-5Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00014
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
	Pruritus		Aspirin Lysine	C		ORAL		
	Rash Papular		Acebutolol Hydrochloride	C		ORAL		
			Nitroglycerin	C				
			Amiloride And Furosemide	C		ORAL		

Date:08/15/03ISR Number: 4168343-7Report Type:Expedited (15-DaCompany Report #WAES 0308NOR00001
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Alkaline Phosphatase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure							
	Gamma-Glutamyltransferase							

Increased

Date:08/15/03ISR Number: 4168344-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA00781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/03ISR Number: 4168346-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/03ISR Number: 4168347-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00832
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paraesthesia Oral		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Pruritus							
	Rash							

Date:08/15/03ISR Number: 4168349-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01224
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoaesthesia							
	Paraesthesia							

Date:08/15/03ISR Number: 4168350-4Report Type:Expedited (15-DaCompany Report #WAES 0305USA02453
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:08/15/03ISR Number: 4168679-XReport Type:Expedited (15-DaCompany Report #WAES 0207USA00100
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulitis		Celebrex	SS				
	Gastric Disorder							
	Haematochezia							

Date:08/15/03ISR Number: 4168684-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA00547
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:08/15/03ISR Number: 4168687-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
Disability	Angina Unstable
Other	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Discomfort
	Constipation
	Cystocele
	Depression
	Diabetes Mellitus
	Ear Pain
	Enterocele
	Fibromyalgia
	Ganglion
	Haematochezia

		Haemorrhagic Ovarian Cyst					
		Hypertension					
		Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
		Ovarian Cyst		Vioxx	SS		ORAL
		Phlebitis Superficial		Vioxx	SS		ORAL
		Rectocele		Colace	C		
		Renal Cyst		Paxil	C		
		Sinus Headache		Maxzide	C		
		Stress Incontinence		Potassium Chloride	C		
		Thrombophlebitis		Trazodone			
		Superficial		Hydrochloride	C		
		Uterine Prolapse		Coumadin	C		
				Flexeril	C		ORAL

Date:08/15/03ISR Number: 4168690-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA00985
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastrointestinal					
Initial or Prolonged	Haemorrhage					

Date:08/15/03ISR Number: 4168694-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA01048
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Disability	Chills		Vicodin Tablets	C		
	Confusional State		Neurontin	C		
	Dysarthria					
	Hallucination					
	Headache					
	Musculoskeletal Stiffness					
	Nausea					
	Skin Disorder					

Date:08/15/03ISR Number: 4168697-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA01151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/03ISR Number: 4168904-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	
Hospitalization - Initial or Prolonged	Basilar Artery Occlusion		Celebrex	C				
	Basilar Artery Stenosis		Glucophage	C			252 DAY	
	Brain Stem Infarction		Glucophage	C			79 DAY	
	Cerebral Infarction		Glucophage	C				
	Coma		Diovan Hct	C				
	Coordination Abnormal		Darvocet-N	C				
	Fall		Aspirin	C				
	Ophthalmoplegia		Feldene	C				
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/03ISR Number: 4168907-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA01806
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Foot Fracture Fracture Nonunion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/03ISR Number: 4168908-2Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00068
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatinine Increased Blood Potassium Increased Blood Urea Increased		Vioxx Fluticasone Propionate And Salmeterol Xinafoate Fluticasone Propionate And Salmeterol Xinafoate Perindopril Erbumine [Therapy Unspecified] Spironolactone	PS C C C C C	Merck & Co., Inc	ORAL		

Date:08/15/03ISR Number: 4168909-4Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00071
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gynaecomastia		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY

Date:08/15/03ISR Number: 4168911-2Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00029
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Initial or Prolonged	Gastrointestinal		Vioxx	SS		ORAL
6 MON						
	Haemorrhage		Candesartan			
	Pancreatic Carcinoma		Cilexetil And			
	Metastatic		Hydrochlorothiazide	C		ORAL
	Renal Failure		Budesonide And			
			Formoterol Fumarate	C		
RESPIRATORY						
(INHALATION)						
			Torsemide	C		ORAL

Date:08/15/03ISR Number: 4168913-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA00807
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Glibenclamid	C		
			Amlodipine Besylate	C		
			Atenolol	C		
			L-Thyroxin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/03ISR Number: 4168914-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA00185
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthritis Infective		Vioxx	PS	Merck & Co., Inc	ORAL		161 DAY
Life-Threatening	Peptic Ulcer Haemorrhage		Augmentin	C				
Hospitalization - Initial or Prolonged			Hydrodiuril	C		ORAL		

Date:08/15/03ISR Number: 4168923-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA01138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Physical Assault		Vioxx	PS	Merck & Co., Inc	ORAL		
			Oxycontin	C				

Date:08/15/03ISR Number: 4168924-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00053
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization - Initial or Prolonged	Dystonia		Celecoxib	C				8 DAY
	Gastrointestinal Haemorrhage		Fluoxetine	C		ORAL		
	Melaena		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
	Pectus Excavatum		Lorazepam	C		ORAL		
	Peptic Ulcer		Zopiclone	C		ORAL		
	Pneumonia		Diclofenac Sodium And Misoprostol	C		ORAL		
	Spinal Osteoarthritis		Ibuprofen	C		ORAL		
			Psyllium Husk	C				
			Bismuth Subgallate And Pramoxine Hydrochloride	C		RECTAL		

Date:08/15/03ISR Number: 4172048-6Report Type:Expedited (15-DaCompany Report #200303111
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dizziness Intentional Misuse Suicide Attempt Vomiting	Foreign Health Professional Other	Tylenol Analgesic Unknown(Acetaminophen)	PS		ORAL	PO	
			Ketoprofen	SS		ORAL	PO	
			Naphazoline	SS		ORAL	PO	
			Metamizole	SS		ORAL	PO	
			Rofecoxib	SS		ORAL	PO	
			Cefadroxila	SS				
			Metamizole/Orphenadrine/Caffeine	SS		ORAL	PO	

Date:08/18/03ISR Number: 4169322-6Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00010
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis Exfoliative		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY
Initial or Prolonged	Generalised Erythema		Hydroxychloroquine Sulfate	SS		ORAL	62	DAY

			Plendil	C		
			Omeprazole	C		
			Meprednisone	C		

Date:08/18/03ISR Number: 4169326-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA00839
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	International Normalised		Coumadin	SS				
	Ratio Increased		Aspirin	C				
	Rash Generalised							

Date:08/18/03ISR Number: 4169328-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA00227
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Zetia	PS	Merck & Co., Inc	ORAL		1 DAY
	Blood Pressure Decreased		Vioxx	SS		ORAL		
	Chest Pain		Diovan	SS		ORAL		
	Dyspepsia		Spironolactone	SS		ORAL		
	Dysphagia		Aspirin	SS		ORAL		
	Eructation		Lasix (Furosemide)	SS		ORAL		
	Fatigue		Nitroglycerin	C				
	Feeling Abnormal							
	Heart Rate Increased							
	Neck Pain							
	Tenderness							

Date:08/18/03ISR Number: 4169331-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA01432
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Urinary Tract Infection		Lasix (Furosemide)	C				

Prinivil	C			ORAL
Toprol Xl Tablets	C			
Advair	C			
Axid	C			

Date:08/18/03ISR Number: 4169615-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA01484
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS		ORAL		
	Aseptic Necrosis Bone		Vioxx	SS		ORAL		
	Liver Function Test		Vicodin Es Tablets	C				
	Abnormal		Prempro	C				
	Pain		Neurontin	C				
	Platelet Count Decreased		Celestone Soluspan	C				
	Red Blood Cell Count		Kenalog	C				
	Decreased		Provigil	C				
			[Therapy Unspecified]	C				
			Prevacid	C				
			Aciphex	C				

			Nortriptyline	C		

Date:08/18/03ISR Number: 4169619-XReport Type:Expedited (15-DaCompany Report #WAES 0307CAN00048
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Lactic Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Metabolic Acidosis		Metformin	SS		ORAL		
	Renal Disorder							

Date:08/18/03ISR Number: 4169620-6Report Type:Expedited (15-DaCompany Report #WAES 0307NOR00026
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Inflammatory Bowel Disease							

Date:08/18/03ISR Number: 4169631-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00059
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amlodipine Maleate	C		ORAL		
			Aspirin	C		ORAL		
			Lactulose	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		

Date:08/18/03ISR Number: 4169640-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA01261
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Increased Blood Pressure Increased Chest Pain	Lasix (Furosemide Sodium) [Therapy Unspecified]	C C

Date:08/19/03ISR Number: 4170059-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01260
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS		ORAL
	Depression		Vioxx	SS		ORAL
	Fatigue		Vioxx	SS		ORAL
	Hypoaesthesia					
	Insomnia					
	Paraesthesia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/03ISR Number: 4170249-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA01335
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4170727-8Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00010
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Initial or Prolonged			Vioxx	SS		ORAL	54	DAY
			Methotrexate	C				

Date:08/20/03ISR Number: 4170731-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA01654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4170733-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA01987
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Disability	Urinary Retention		Norvasc	C				

Date:08/20/03ISR Number: 4170734-5Report Type:Expedited (15-DaCompany Report #WAES 0210GBR00217
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		42 DAY
Initial or Prolonged	Thrombosis		Omeprazole	C				
			Prednisolone	C				
			Acetaminophen	C				
			Tramadol	C				
			Fosamax	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C				
			Lactulose	C				

Date:08/20/03ISR Number: 4170742-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA01489
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
	Blood Pressure Increased		[Therapy Unspecified]	C				19 DAY
	Ventricular Extrasystoles		[Therapy Unspecified]	C				19 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/03ISR Number: 4170743-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA01526
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4170745-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA01519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4171033-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA01590
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C				
			Isosorbide Mononitrate	C				
			Atenolol	C				
			Lipitor	C				

Date:08/20/03ISR Number: 4171044-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA01320
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Rash		Percocet	C				
			Norvasc	C				
			Metoprolol	C				
			Albuterol	C				
			Atrovent	C				
			Combivent	C				

RESPIRATORY

(INHALATION)

			Advair	C		

Date:08/20/03ISR Number: 4171045-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA01466
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Operation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4171051-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA01614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/03ISR Number: 4171053-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA01782
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:08/20/03ISR Number: 4171054-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA01705
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
			Allopurinol	C				
			Tricor	C				
			Vicodin Tablets	C				

Date:08/20/03ISR Number: 4171056-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA01618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis Atrial Fibrillation Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/20/03ISR Number: 4171068-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA00358
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Second Degree Liver Function Test Abnormal Platelet Count Decreased Viral Infection White Blood Cell Count Decreased		Vioxx	SS		ORAL		

Date:08/20/03ISR Number: 4172198-4Report Type:Direct Company Report #CTU 200272
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx 25 Mg	PS		ORAL	50 MG DAILY	
Hospitalization -	Anuria							
Initial or Prolonged	Haemodialysis		Lisinopril 20 Mg	SS		ORAL	20 MG DAILY	
Required	Metabolic Acidosis							
Intervention to Prevent Permanent Impairment/Damage	Renal Failure Acute							

Date:08/20/03ISR Number: 4172199-6Report Type:Direct Company Report #CTU 200273
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Frequent Bowel Movements		Plavix 75 Mg	PS		ORAL	75 MG DAILY	
Hospitalization -	Hypotension							
Initial or Prolonged	Rectal Haemorrhage		Vioxx 25 Mg	SS		ORAL	50 MG DAILY	

ORAL

	Digoxin	C
	Lopressor	C
	Nitroglycerin	C
	Insulin	C

Date:08/20/03ISR Number: 4172773-7Report Type:Direct Company Report #CTU 200370
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Aspirin	PS			81 MG QD	
Initial or Prolonged	Duodenal Ulcer		Rofecoxib	SS			25 MG QD	
	Faeces Discoloured							

Date:08/20/03ISR Number: 4172910-4Report Type:Direct Company Report #CTU 200344
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Warfarin	PS				
Hospitalization -	Melaena		Rofecoxib	SS			25 MG PO BID	
Initial or Prolonged								
(PRIOR TO								
ADMIT)							3	WK

Date:08/21/03ISR Number: 4171529-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiomegaly		Zoloft	C				
Other	Coronary Artery Disease		Tenormin	C				
	Difficulty In Walking		Temazepam	C				
	Emotional Distress		Cimetidine					
	Gastrointestinal Disorder		Hydrochloride	C				

	Haematocrit		Aspirin	C		
	Haemoglobin		Augmentin	C		
	Mediastinitis		Zocor	C		ORAL
	Oedema Peripheral		Motrin	C		
	Pleural Effusion		Plavix	C		
	Postpericardiotomy Syndrome					
	Wound Secretion					

Date:08/21/03ISR Number: 4171799-7Report Type:Direct Company Report #CTU 200425
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspepsia		Vioxx 50 Mg	PS		ORAL	1/2 TAB 1 X DAY ORAL	
	Dyspnoea							
	Fluid Retention							
	Weight Increased							

Date:08/21/03ISR Number: 4171858-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA03088
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Disability	Blood Sodium Increased
	Bursitis

		Dehydration					
		Difficulty In Walking					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysstasia		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS		ORAL
		Oropharyngeal Swelling		Coumadin	C		
		Pitting Oedema		Os-Cal	C		
		Prothrombin Time		Ibuprofen	C		
		Prolonged		[Therapy			
		Swelling Face		Unspecified]	C		

Date:08/21/03ISR Number: 4171875-9Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 DAY	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 1 DAY	Oropharyngeal Swelling		Vioxx	SS		ORAL

Date:08/21/03ISR Number: 4171878-4Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00184
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL
	Aggression		Amiloride			
	Psychotic Disorder		Hydrochloride And			
			Furosemide	C		
1 YR						

Date:08/21/03ISR Number: 4171880-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intracardiac Thrombus		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS		ORAL

Date:08/21/03ISR Number: 4171881-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA01534
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Ulcer Haemorrhage							

Date:08/21/03ISR Number: 4171882-6Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00007
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Intentional Misuse		Acetaminophen	SS		ORAL	1	DAY
	Suicide Attempt		Ibuprofen	SS		ORAL	1	DAY
	Vomiting		Phloroglucinol And Trimethylphloroglucinol	SS		ORAL	1	DAY

Date:08/21/03ISR Number: 4171883-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01552
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
	Nausea		Amaryl	C				
	Pain		Actos	C				
	Stomach Discomfort		Aspirin	C				
	Vomiting		Avacor	C				
			Avalide	C				
			Furosemide	C				
			[Therapy Unspecified]	C				
			Ambien	C				
			Avandia	C				

Date:08/23/03ISR Number: 4172552-0Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00084
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Autoimmune		Tetrazepam	C		ORAL		
	Asthenia							
	Fatigue							
	General Physical Health Deterioration							

Date:08/23/03ISR Number: 4172553-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agoraphobia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anxiety Disorder							
	Chronic Fatigue Syndrome							
	Depression							
	Disturbance In Attention							
	Gout							
	High Density Lipoprotein Decreased							

Hypertension
Injury
Insomnia
Myocardial Infarction
Panic Disorder
Personality Disorder
Social Phobia

Date:08/23/03ISR Number: 4172554-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory Failure
Hospitalization - Initial or Prolonged	Angiogram Cerebral Abnormal
	Basilar Artery Occlusion
	Blood Homocysteine Increased
	Brain Stem Ischaemia
	Cerebral Artery

		Thrombosis					
		Cerebral Infarction					
		Cerebrovascular Accident					
		Coma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Csf Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Enterobacter Infection		Celebrex	C		
		Fall		Glucophage	C		
252	DAY						
		Hydrocephalus		Glucophage	C		
79	DAY						
		Injury		Glucophage	C		
		Myocardial Ischaemia		Diovan Hct	C		
		Necrosis		Darvocet-N	C		
		Nervous System Disorder		Aspirin	C		
		White Blood Cell Count		Feldene	C		

Date:08/23/03ISR Number: 4172561-1Report Type:Expedited (15-DaCompany Report #WAES 0308DEU00097
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Interaction		Phenprocoumon	SS		ORAL
	International Normalised					
	Ratio Increased					

Date:08/23/03ISR Number: 4172566-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA01723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive					

Date:08/23/03ISR Number: 4172575-1Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00096
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Life-Threatening	Asthenia	Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY					
Hospitalization -	Circulatory Collapse	Aspirin	SS		ORAL
1512 DAY					
Initial or Prolonged	Melaena	Acetaminophen	C		ORAL
		Senna	C		ORAL
		Amitriptyline Hydrochloride	C		ORAL
		Morphine Sulfate	C		ORAL
5 DAY					

Date:08/23/03ISR Number: 4172576-3Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00107
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
	Incontinence					
	Micturition Urgency					

Date:08/26/03ISR Number: 4173196-7Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:67 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Apathy		Aspirin	C				
Asthenia		Restoril	C				
Atelectasis							
Circulatory Collapse							
Cognitive Disorder							
Depersonalisation							
Duodenitis							
Gastrooesophageal Reflux Disease							
Hypertension							
Lethargy							
Libido Decreased							
Mental Impairment							
Mitral Valve Incompetence							
Oesophageal Rupture							
Oesophagitis							
Self Esteem Decreased							
Supraventricular Extrasystoles							
Thromboembolic Stroke							
Transient Ischaemic Attack							
Weight Below Normal							

Date:08/26/03ISR Number: 4173198-0Report Type:Expedited (15-DaCompany Report #WAES 01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Anaprox	C				
	Blood Pressure Fluctuation		Femhrt	C				
	Cardiac Disorder		Herbs (Unspecified)	C				
	Cardiovascular Disorder		Celebrex	C				
	Dizziness							
	Emotional Distress							
	Grand Mal Convulsion							
	Memory Impairment							
	Mitral Valve Prolapse							

Oedema
Renal Failure

Date:08/26/03ISR Number: 4173200-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Asthenia
Disability	Blood Creatine Phosphokinase Increased
Other	Blood Pressure Systolic Increased
	Contusion
	Decreased Appetite
	Deep Vein Thrombosis

		Dehydration					
		Dialysis					
		Flushing	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS		ORAL
		Glomerulonephritis Focal		Vioxx	SS		ORAL
		Glomerulonephritis		Celebrex	SS		
2	WK						
		Membranous		Advil	C		
		Haematemesis		[Therapy			
		Injury		Unspecified]	C		
		Joint Sprain		Creatine	C		
		Laceration		Solu-Medrol	C		
		Malaise					
		Myalgia					
		Nasopharyngitis					
		Nausea					
		Nephritis Allergic					
		Oesophagitis					
		Periorbital Oedema					
		Pulmonary Embolism					
		Renal Failure					
		Renal Failure Chronic					
		Swelling Face					
		Tendon Injury					
		Tendonitis					
		Vomiting					

Date:08/26/03ISR Number: 4173212-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA01993
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Inappropriate					
Initial or Prolonged	Antidiuretic Hormone					
	Secretion					

Date:08/26/03ISR Number: 4173213-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01024
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS		ORAL		
	Adverse Event		Pepcid	C	Merck & Co., Inc	ORAL		
	Chronic Obstructive Pulmonary Disease		Meclizine Hydrochloride	C				
	Cough							
	Dermatitis							
	Heart Rate Increased							
	Hypokalaemia							
	Lobar Pneumonia							
	Nausea							
	Pleuritic Pain							
	Pulmonary Congestion							
	Respiratory Failure							
	Rheumatoid Arthritis							
	Sinusitis							
	Viral Infection							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/03ISR Number: 4173214-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA01705
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Congestive		Allopurinol	C				
			Tricor	C				
			Vicodin Tablets	C				

Date:08/26/03ISR Number: 4173223-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA03380
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS		ORAL	23	DAY
Initial or Prolonged	Dizziness		Lipitor	C	Merck & Co., Inc	ORAL		
Other	Gastrointestinal Haemorrhage		Enalapril Maleate	C		ORAL		
	Rectal Haemorrhage							

Date:08/26/03ISR Number: 4173431-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA02286
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS		ORAL		
	Arthropathy		Synthroid	C	Merck & Co., Inc			
	Drug Ineffective							
	Hair Colour Changes							

Date:08/26/03ISR Number: 4173434-0Report Type:Expedited (15-DaCompany Report #WAES 0302DEU00078
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cholelithiasis		Vioxx	PS		ORAL	8	DAY

Hospitalization - 4 DAY	Haemodialysis		Ciprofloxacin	C	Merck & Co., Inc	ORAL
Initial or Prolonged 1 DAY	Hepatic Cyst		Diclofenac	C		
	Hypertension					
	Nephritis Interstitial					
	Renal Failure Acute					

Date:08/26/03ISR Number: 4173618-1Report Type:Expedited (15-DaCompany Report #WAES 0307BEL00043
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 36 DAY	Aseptic Necrosis Bone		Vioxx	PS		ORAL		
Initial or Prolonged 34 DAY			Meloxicam	C	Merck & Co., Inc	ORAL		
Other								

Date:08/26/03ISR Number: 4173619-3Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00107
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Incontinence							
	Micturition Urgency							

Date:08/26/03ISR Number: 4178831-5Report Type:Expedited (15-DaCompany Report #WAES 01010328
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accelerated Hypertension
Other	Actinic Keratosis
	Alopecia
	Amnesia
	Anaemia
	Asthenia
	Atrophy
	Back Pain
	Balance Disorder
	Cataract
	Cerebrovascular Accident
	Condition Aggravated
	Convulsion
	Cough
	Depression
	Dermatitis
	Diastolic Dysfunction
	Diverticulum Intestinal
	Drooling
	Drug Eruption
	Drug Hypersensitivity
	Drug Toxicity
	Dysphonia
	Eye Pain
	Gait Disturbance
	Gastritis
	Haemorrhage
	Headache
	Hiatus Hernia
	Hyperhidrosis
	Hypertension
	Hypertensive Crisis
	Joint Swelling
	Laryngitis
	Limb Injury
	Loss Of Consciousness
	Malaise
	Medication Error
	Muscle Spasms
	Nausea
	Neck Pain
	Neuropathy
	Oedema Peripheral

Pallor
Posturing
Psoriasis
Pulmonary Hypertension
Rash Erythematous
Rash Macular
Rash Morbilliform
Reflux Oesophagitis
Renovascular Hypertension
Somnolence
Stasis Dermatitis
Surgical Procedure
Repeated
Thinking Abnormal
Tremor

		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection	Report Source: Consumer	Product: Tab Vioxx Unk	Role: PS	Manufacturer:	Route: ORAL
Dose: PO	Duration:						
		Ventricular Dysfunction	Report Source: Health Professional Company Representative	Product: Procrit Unk	Role: SS		
		Ventricular Hypertrophy		Product: Carafate Unk	Role: SS		
				Product: Carbatrol	Role: C		
				Product: Catapres	Role: C		
				Product: Cozaar	Role: C		
				Product: Glucotrol	Role: C		
				Product: Hyzaar	Role: C		
				Product: Neurontin	Role: C		
				Product: Premarin	Role: C		
				Product: Toprol Xl Tablets	Role: C		

Date:08/26/03ISR Number: 4216528-3Report Type:Periodic Company Report #WAES 0307USA01432
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose: PO Duration:						
	Blood Creatine	Report Source: Consumer	Product: Tab Zetia 10 Mg	Role: PS		Route: ORAL
	Phosphokinase Increased		Product: Tab Vioxx Unk	Role: SS		Route: ORAL
	Myalgia		Product: Altace	Role: C		
			Product: Coreg	Role: C		
			Product: Nexium	Role: C		
			Product: Aspirin	Role: C		

Date:08/27/03ISR Number: 4174278-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA01988
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose: Duration:						
Other	Blood Urea Increased		Product: Vioxx	Role: PS		Route: ORAL
	Knee Arthroplasty		Product: Vicodin Tablets	Role: C	Manufacturer: Merck & Co., Inc	
			Product: Flurazepam	Role: C		
			Product: Prevacid	Role: C		
			Product: Cytotec	Role: C		

Date:08/27/03ISR Number: 4174282-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Disorder Embolism Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/27/03ISR Number: 4174286-5Report Type:Expedited (15-DaCompany Report #WAES 01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anhedonia
Other	Aortic Valve Incompetence Apathy Aphasia Asthenia Atelectasis Blood Pressure Cerebral Infarction Chest Pain

	Choking					
	Circulatory Collapse					
	Cognitive Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cranial Nerve Disorder		Vioxx	PS		ORAL
	Dementia		Aspirin	C	Merck & Co., Inc	
	Depersonalisation		Restoril	C		
	Depressed Level Of Consciousness					
	Difficulty In Walking					
	Disorientation					
	Duodenitis					
	Dysarthria					
	Dyskinesia					
	Gait Disturbance					
	Gastrooesophageal Reflux Disease					
	Haematemesis					
	Heart Rate Increased					
	Heart Rate Irregular					
	Hemiparesis					
	Hypertension					
	Hypoacusis					
	Lethargy					
	Libido Decreased					
	Malaise					
	Memory Impairment					
	Mental Impairment					
	Mitral Valve Incompetence					
	Oesophageal Rupture					
	Oesophagitis					
	Self Esteem Decreased					
	Speech Disorder					
	Supraventricular Extrasystoles					
	Thromboembolic Stroke					
	Transient Ischaemic Attack					
	Weight Below Normal					

Date:08/27/03ISR Number: 4175377-5Report Type:Direct Company Report #CTU 200785
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - ORAL	Haematochezia	Warfarin	PS	ORAL
Initial or Prolonged ORAL	Haematuria	Rofecoxib	SS	ORAL
Required Intervention to Prevent Permanent Impairment/Damage	Orthostatic Hypotension	Meclizine	C	
	Rectal Haemorrhage	Digoxin	C	
		Lisinopril	C	
		Rabeprazole	C	
		Sodium Chloride	C	
		Insulin	C	
		Atenolol	C	
		Sinemet	C	
		Amitriptyline	C	
		Prednisone	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/03ISR Number: 4177196-2Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00216
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS		ORAL		
	Colitis		Vioxx	SS		ORAL		
	Crohn'S Disease		Meloxicam	C	Merck & Co., Inc			

Date:08/27/03ISR Number: 4177198-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA02143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage Subcutaneous		Vioxx	PS	Merck & Co., Inc	ORAL		
	Subdural Haematoma		Thyroid	C				
Other								

Date:08/27/03ISR Number: 4180849-3Report Type:Expedited (15-DaCompany Report #200310321BNE
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain	Foreign	Aspirin					
Hospitalization - Initial or Prolonged	Circulatory Collapse	Health Professional	(Acetylsalicylic Acid)	PS		ORAL	75 MG, TOTAL	
	Constipation							
	Melaena	Other					DAILY, ORAL	
			Rofecoxib	SS		ORAL	ORAL	
			Paracetamol	C				
			Senna	C				
			Amitriptyline	C				
			Morphine	C				

Date:08/27/03ISR Number: 4180853-5Report Type:Expedited (15-DaCompany Report #DSA_23148_2003
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Alanine Aminotransferase	Foreign	Vasotec	PS		ORAL
10 MG BID PO						
Hospitalization -	Increased	Other	Vasotec	SS		ORAL
5 MG BID PO						
Initial or Prolonged	Aspartate		Gentamicin	SS		
INTRAVENOUS 80 MG QID IV						
	Aminotransferase		Vioxx	SS		
	Increased		Sobelin	C		
	Dialysis		Disalunil	C		
	Gastric Ulcer Haemorrhage		Pantozol	C		
	Renal Failure Acute		Novonorm	C		

Date:08/28/03ISR Number: 4175477-XReport Type:Expedited (15-DaCompany Report #WAES 0308CHE00033
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Fungal Infection		Vioxx	PS		ORAL
2 DAY						
Initial or Prolonged	Urticaria Generalised		Diclofenac Sodium	SS	Merck & Co., Inc	ORAL
13 DAY						
			Omeprazole	SS		ORAL
13 DAY						
			Tramadol Hydrochloride	SS		ORAL
13 DAY						
			Tizanidine Hydrochloride	C		ORAL
13 DAY						

Date:08/28/03ISR Number: 4175487-2Report Type:Expedited (15-DaCompany Report #WAES 0308BEL00028
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS		ORAL		
	Cardiac Failure		Atorvastatin Calcium	C	Merck & Co., Inc	ORAL		
	Tricuspid Valve Incompetence		Bumetanide	C		ORAL		
			Captopril	C		ORAL		
			Digoxin	C		ORAL		
			Warfarin Sodium	C		ORAL		
			Spironolactone	C		ORAL		
			Gliquidone	C		ORAL		
			Hydrochlorothiazide And Metoprolol Succinate	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:08/28/03ISR Number: 4175494-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA02426
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/28/03ISR Number: 4176016-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA01970
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural Discharge							

Date:08/28/03ISR Number: 4176017-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA02116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Altered Visual Depth		Vioxx	PS	Merck & Co., Inc	ORAL		

	Perception		Vioxx	SS		ORAL
	Retinal Vein Thrombosis					
	Retinopathy Hypertensive					
	Visual Acuity Reduced					

Date:08/28/03ISR Number: 4176021-3Report Type:Expedited (15-DaCompany Report #WAES 0308SWE00010
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Subarachnoid Haemorrhage		Vioxx	PS		ORAL
Life-Threatening			Aspirin	SS		ORAL
Hospitalization - Initial or Prolonged			Citalopram Hydrobromide	SS		ORAL
			[Therapy Unspecified]	C	Merck & Co., Inc	
			Bezafibrate	C		
			Estriol	C		
			Lisinopril	C		
			Furosemide	C		
			Estradiol	C		
			Carvedilol	C		

			Acetaminophen	C		

Date:08/28/03ISR Number: 4176022-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA00192
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS		ORAL
	Haemoglobin Decreased		[Therapy Unspecified]	C	Merck & Co., Inc	
Disability	Upper Gastrointestinal Haemorrhage		Aspirin	C		
Other	Varices Oesophageal		Evoxac	C		
			Premarin	C		
			Metformin	C		
			Methotrexate	C		

Date:08/28/03ISR Number: 4176028-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA02123
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/29/03ISR Number: 4182429-2Report Type:Expedited (15-DaCompany Report #2003173718AU
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Foreign Health Professional Other	Celebrex (Celecoxib) Capsule	PS		
200 MG, QD						
	Anaemia		Rofecoxib (Rofecoxib)	SS		
	Melaena					
25 MG, QD,						
			Aspirin "Bayer" (Acetylsalicylic Acid)	SS		
100 MG, QD						

Date:09/02/03ISR Number: 4177045-2Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00161
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Oedema Peripheral		Triamcinolone					
	Vomiting		Acetonide	C				
INTRAMUSCULAR								

Date:09/02/03ISR Number: 4177050-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00601
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS		ORAL		
Initial or Prolonged	Right Ventricular Failure		Vioxx	SS		ORAL		
			Aspirin	C	Merck & Co., Inc			
			Lipitor	C				
			Dyazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/02/03ISR Number: 4177051-8Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00170
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspepsia		Vioxx	PS		ORAL	21	DAY
Hospitalization - Initial or Prolonged	Dyspnoea		Acetaminophen	C	Merck & Co., Inc			
Disability	Haematemesis		Amlodipine Besylate	C				
Other	Loss Of Consciousness		Aspirin	C				
	Malaise		Atenolol	C				
	Melaena		Simvastatin	C				
			Furosemide	C				
			Lisinopril	C				
			Metformin	C				

Date:09/02/03ISR Number: 4177056-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA00661
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS		ORAL		
	Transient Ischaemic Attack		Aspirin	C	Merck & Co., Inc	ORAL		
			Premarin	C		ORAL		
			Triamterene	C		ORAL		
			Ibuprofen	C				
			Toprol Xl Tablets	C		ORAL		

Date:09/02/03ISR Number: 4177061-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS		ORAL		
			Aspirin	SS	Merck & Co., Inc			

Date:09/02/03ISR Number: 4177400-0Report Type:Expedited (15-DaCompany Report #WAES 0308SWE00010
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Subarachnoid Haemorrhage	Vioxx	PS		ORAL
Life-Threatening		Citalopram			
Hospitalization -		Hydrobromide	SS		ORAL
Initial or Prolonged		Aspirin	SS		ORAL
		Bezafibrate	C		
		[Therapy			
		Unspecified]	C	Merck & Co., Inc	
		Estriol	C		
		Lisinopril	C		
		Furosemide	C		
		Estradiol	C		
		Acetaminophen	C		
		Carvedilol	C		

Date:09/02/03ISR Number: 4177401-2Report Type:Expedited (15-DaCompany Report #WAES 0305NOR00018
Age:79 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Drug Interaction
Initial or Prolonged	Gastric Ulcer Haemorrhage
	Gastritis Erosive
	Gastritis Haemorrhagic

	Ulcer Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS		ORAL		
			Aspirin And Magnesium Oxide	SS	Merck & Co., Inc	ORAL		
			Prednisolone	SS		ORAL		

Date:09/02/03ISR Number: 4177404-8Report Type:Expedited (15-DaCompany Report #WAES 0306BEL00006
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:09/02/03ISR Number: 4177407-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA02247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/02/03ISR Number: 4177408-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA02540
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Fluid Retention							

Date:09/02/03ISR Number: 4183378-6Report Type:Expedited (15-DaCompany Report #2003174265US
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Consumer	Celebrex (Celecoxib)					

Other	Orthopnoea	Capsule	PS
	Peripheral Vascular Disorder	Rofecoxib (Rofecoxib)	SS
	Reflux Oesophagitis	Risedronic Acid (Risedronic Acid)	SS
		Calcium	C
		Gaviscon (Sodium Alginate)	C
		Neurontin (Gabapentin)	C
		Norvasc (Amlodipine Besilate)	C
		Propoxyphene (Dextropropoxyphene)	C
		Soligen	C

Date:09/03/03ISR Number: 4178058-7Report Type:Expedited (15-DaCompany Report #WAES 0306AUS00137
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Disability	Back Pain
	Impaired Healing
	Injury
	Skin Ulcer

	Wound						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS		ORAL		
			Vioxx	SS		ORAL		
			Acetaminophen	C	Merck & Co., Inc	ORAL		

Date:09/03/03ISR Number: 4178060-5Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00188
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Swelling Face							
	Type I Hypersensitivity							

Date:09/03/03ISR Number: 4178256-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00144
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS		ORAL		
Hospitalization -	Dehydration		Tylenol	C	Merck & Co., Inc			
Initial or Prolonged	Duodenal Ulcer		Aggrenox	C				
	Haemorrhage		Ben-Gay	C				
	Erosive Oesophagitis		Digoxin	C				
	Haematemesis		Lasix (Furosemide)	C				
	Hypovolaemia		Detrol	C				
	Malnutrition		Vitamins					
	Oesophagitis		(Unspecified)	C				
	Renal Failure		Mag-Ox 400 Tablets	C				
	Urinary Tract Infection		Megace	C				
	Weight Decreased		Reglan	C				
			Metoprolol	C				
			Risperdal	C				

Date:09/03/03ISR Number: 4178261-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA00839
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis		Vioxx	PS		ORAL		5 DAY
Initial or Prolonged	International Normalised Ratio Increased		Coumadin	SS				
	Rash		Aspirin	C	Merck & Co., Inc			

Date:09/03/03ISR Number: 4178262-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA00922
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS		ORAL		3 DAY
Hospitalization -	Laryngeal Oedema		Albuterol	C	Merck & Co., Inc			
Initial or Prolonged	Stevens-Johnson Syndrome		Vitamins					
Other	Urticaria		(Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/03/03ISR Number: 4178265-3Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00178
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS		ORAL		7 DAY
Initial or Prolonged	Blood Albumin		Acetaminophen	C	Merck & Co., Inc			8 DAY
	Blood Alkaline Phosphatase		Acetaminophen And Propoxyphene Hydrochloride	C				
	Blood Bilirubin		Aspirin	C				
	Gamma-Glutamyltransferase		Calcium Carbonate And Cholecalciferol	C				
	Liver Function Test Abnormal		Cyclizine	C				6 DAY
			Docusate Calcium	C				
			Domperidone	C				
			Senna	C				
			Trimethoprim	C				
			Tramadol Hydrochloride	C				
			Tolterodine	C				
			Enoxaparin Sodium	C				9 DAY
			Furosemide	C				
			Lactulose	C				
			Lansoprazole	C				
			Levothyroxine Sodium	C				
			Levothyroxine Sodium	C				
			Nitroglycerin	C				
SUBLINGUAL								

Date:09/03/03ISR Number: 4178267-7Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00017
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS		ORAL		
Hospitalization -	Jaundice Cholestatic		Esomeprazole Magnesium	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Hydrochlorothiazide And Ramipril	SS		ORAL		

Date:09/03/03ISR Number: 4178270-7Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00175
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS		ORAL		
	Melaena		Aspirin	SS	Merck & Co., Inc	ORAL		
	Syncope		Digoxin	C		ORAL		
			Simvastatin	C		ORAL		
			Carvedilol	C		ORAL		
			Calcitriol	C		ORAL		
			Sodium Bicarbonate	C				
			Warfarin	C		ORAL		

Date:09/03/03ISR Number: 4178272-0Report Type:Expedited (15-DaCompany Report #WAES 0308NLD00008
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS		ORAL	21 DAY	
Hospitalization - Initial or Prolonged	Haematemesis		Aspirin	SS	Merck & Co., Inc	ORAL		
			Furosemide	C		ORAL		
			Latanoprost	C				

OPHTHALMIC

				Oxazepam	C		ORAL

Date:09/03/03ISR Number: 4178273-2Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00002
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tamsulosin Hydrochloride	C		ORAL		

Date:09/03/03ISR Number: 4178274-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA02666
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
	Oedema Peripheral							
	Weight Increased							

Date:09/03/03ISR Number: 4178275-6Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00001
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Erythema							
	Rash Vesicular							
	Sepsis							
	Wheezing							

Date:09/04/03ISR Number: 4179051-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00190
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS		ORAL		

Hospitalization - Initial or Prolonged	Barrett'S Oesophagus		Fluoxetine	C	Merck & Co., Inc	ORAL
	Gastritis		Gabapentin	C		ORAL
	Gastrointestinal		Temazepam	C		ORAL
	Haemorrhage		Omeprazole	C		ORAL
			Prochlorperazine	C		ORAL

Date:09/04/03ISR Number: 4179055-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA02717
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Haematochezia		Vioxx	PS		ORAL
	Ulcer		Ziac	C	Merck & Co., Inc	
			Bentyl	C		
			Allegra	C		
			Zocor	C		ORAL
			Prevacid	C		
			Synthroid	C		
			Ativan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/04/03ISR Number: 4179058-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA02773
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS		ORAL		
Life-Threatening			Prevacid	C	Merck & Co., Inc			
Disability								

Date:09/04/03ISR Number: 4179060-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA02507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematochezia							

Date:09/04/03ISR Number: 4179064-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA02598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/04/03ISR Number: 4179065-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA02143
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Balance Disorder		Vioxx	SS		ORAL		
	Haemorrhage Subcutaneous		Thyroid	C				
	Muscle Spasms							
	Pain							
	Somnolence							

Date:09/04/03ISR Number: 4179067-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA01048
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS		ORAL	10	DAY
Disability	Chills		Vicodin Tablets	C	Merck & Co., Inc			
	Confusional State		Neurontin	C				
	Dysarthria							
	Hallucination							
	Headache							
	Musculoskeletal Stiffness							
	Nausea							
	Skin Disorder							

Date:09/04/03ISR Number: 4179197-7Report Type:Expedited (15-DaCompany Report #WAES 0308DNK00029M
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abortion Spontaneous		Vioxx	PS		ORAL	82	DAY
	Complications Of Maternal		Codeine	C	Merck & Co., Inc			
	Exposure To Therapeutic		Nortriptyline	C				
	Drugs							
	Drug Exposure During							
	Pregnancy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/04/03ISR Number: 4179199-0Report Type:Expedited (15-DaCompany Report #WAES 0308DNK00029B1
Age:0 DY Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abortion Spontaneous		Vioxx	PS		
82 DAY						
Hospitalization - Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs Maternal Drugs Affecting Foetus		Codeine	C	Merck & Co., Inc	
			Nortriptyline	C		

Date:09/04/03ISR Number: 4179201-6Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00033
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Colitis Ulcerative		Vioxx	PS		ORAL
	Vomiting		Chondroitin Sulfate Sodium	C	Merck & Co., Inc	ORAL
			Fluvastatin Sodium	C		ORAL
			Irbesartan	C		ORAL
			Omeprazole	C		ORAL

Date:09/04/03ISR Number: 4180802-XReport Type:Direct Company Report #CTU 201244
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression		Vioxx	PS		ORAL
25 MG PO QD						
	Thinking Abnormal					

Date:09/04/03ISR Number: 4183800-5Report Type:Expedited (15-DaCompany Report #K200301407
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Hepatic Failure	Foreign Health	Altace Capsules (Ramipril)	PS		

Professional Other	Esomeprazole (Esomeprazole)	SS
	Rofecoxib(Refecoxib)	SS

Date:09/05/03ISR Number: 4180272-1Report Type:Expedited (15-DaCompany Report #WAES 0309AUS00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS		ORAL
			Isosorbide Mononitrate	SS		
			Atorvastatin Calcium	C	Merck & Co., Inc	
			Carbamazepine	C		
			Telmisartan	C		
			Metoprolol Tartrate	C		
			Clonazepam	C		
			Clopidogrel Bisulfate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/03ISR Number: 4180281-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA02565
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL
	Congestive		[Therapy Unspecified]	C	Merck & Co., Inc	
			[Therapy Unspecified]	C		
			Neurontin	C		

Date:09/05/03ISR Number: 4180282-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA02595
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/05/03ISR Number: 4180283-6Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00168
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Urea Increased		Vioxx	PS		ORAL
110 DAY	Circulatory Collapse		Atenolol	SS		
Other	Feeling Abnormal		Sulfamethoxazole And Trimethoprim	SS		ORAL
6 DAY	Heart Rate Decreased					
	Hyperkalaemia		Atenolol	SS		
	Hypotension		Acetaminophen And Codeine Phosphate	C	Merck & Co., Inc	
			Carbomer	C		
OPHTHALMIC						
			Gabapentin	C		
			Lansoprazole	C		
			Senna	C		
			Vitamin B Complex	C		
			Zocor	C		
			Ranitidine	C		
			Nitrazepam	C		
			Lactulose	C		

			Folic Acid	C		
			Fosamax	C		ORAL
			Aspirin	C		

Date:09/05/03ISR Number: 4180325-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00601
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure		Vioxx	PS		ORAL	1	WK
	Congestive		Vioxx	SS		ORAL	3	WK
	Fluid Overload		Vioxx	SS		ORAL		
	Oedema Peripheral		Aspirin	C	Merck & Co., Inc			
			Lipitor	C				
			Lipitor	C				
			Prempro	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/03ISR Number: 4180329-5Report Type:Expedited (15-DaCompany Report #WAES 0302GBR00215
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS		ORAL	2	DAY
Hospitalization - Initial or Prolonged Disability	Jejunal Perforation		Acetaminophen	C	Merck & Co., Inc	ORAL		
			Analgesic Or Anesthetic (Unspecified)	C		PARENTERAL	2	DAY
			Bupivacaine Hydrochloride	C		PARENTERAL	2	DAY
			Fentanyl	C		PARENTERAL	2	DAY

Date:09/05/03ISR Number: 4180333-7Report Type:Expedited (15-DaCompany Report #WAES 0307AUS00015
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Gastrointestinal Disorder							

Date:09/05/03ISR Number: 4180335-0Report Type:Expedited (15-DaCompany Report #WAES 0308NLD00007
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation		Vioxx	PS		ORAL	297	DAY
Hospitalization - Initial or Prolonged	Peritonitis		Glimepiride	C	Merck & Co., Inc	ORAL		
			Metformin	C		ORAL		

Date:09/05/03ISR Number: 4180341-6Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00017
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Hepatic Necrosis		Esomeprazole Magnesium	SS	Merck & Co., Inc	ORAL		
	Jaundice Cholestatic		Hydrochlorothiazide And Ramipril	SS		ORAL		

Date:09/05/03ISR Number: 4180346-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA00448
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphthous Stomatitis		Vioxx	PS		ORAL	35 DAY	
	Dyspnoea		Albuterol	C	Merck & Co., Inc			
	Mouth Ulceration		Climara	C		TOPICAL		
	Throat Tightness		Nasonex	C				

Date:09/05/03ISR Number: 4180347-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA02720
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS		ORAL		
	Joint Swelling		Premarin	C	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/05/03ISR Number: 4180348-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA00024
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/05/03ISR Number: 4180354-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00026
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Upper Gastrointestinal		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		Aspirin	C	Merck & Co., Inc	ORAL		
			Calcium Carbonate	C		ORAL		
			Dihydrocodeine	C		ORAL		
			Felodipine	C		ORAL		

Date:09/05/03ISR Number: 4180357-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/05/03ISR Number: 4180358-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA00104
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Operative Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/05/03ISR Number: 4186100-2Report Type:Expedited (15-DaCompany Report #200310333BNE
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Melaena Syncope	Foreign Health Professional Other	Aspirin (Acetylsalicylic Acid)	PS		ORAL	75 MG, TOTAL DAILY,ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG, TOTAL DAILY, ORAL	
			Warfarin	C				
			Digoxin	C				
			Carvedilol	C				
			Simvastatin	C				
			Calcitriol	C				
			Sodium Bicarbonate	C				

Date:09/08/03ISR Number: 4180941-3Report Type:Expedited (15-DaCompany Report #WAES 0306DEU00084
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Autoimmune		Tetrazepam	C		ORAL		

Date:09/08/03ISR Number: 4180944-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00142
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive							
Hospitalization - Initial or Prolonged								

Date:09/08/03ISR Number: 4180961-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA00296
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Joint Swelling		Vioxx	PS		ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C	Merck & Co., Inc			
			[Therapy Unspecified]	C				
			Lopressor	C				

Date:09/08/03ISR Number: 4180966-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01654
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS		ORAL	18 DAY	
Hospitalization - Initial or Prolonged	Nephritis Interstitial		Lipitor	C	Merck & Co., Inc			
Other	Vomiting		Glipizide	C				
			Humulin	C				
			Isordil	C				
			Lopressor	C				

Date:09/08/03ISR Number: 4180967-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA00415
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		

Drug Ineffective
Duodenal Ulcer
Gastric Ulcer
Oesophageal Ulcer

Date:09/08/03ISR Number: 4180969-3Report Type:Expedited (15-DaCompany Report #WAES 0308DEU00097
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS		ORAL		5 DAY
Initial or Prolonged	International Normalised Ratio Increased		Phenprocoumon	SS		ORAL		
	Muscle Haemorrhage		Doxepin Hydrochloride	C	Merck & Co., Inc			
			Spironolactone	C				
			Tramadol Hydrochloride	C				
			Furosemide	C				
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/03ISR Number: 4181103-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS		ORAL		6 MON
Initial or Prolonged	Blood Cholesterol		Yasmin	SS				14 DAY
Disability	Increased		Vioxx	SS		ORAL		
Other	Blood Triglycerides		Vioxx	SS		ORAL		
	Increased		Sandimmun	C	Merck & Co., Inc			
	Body Temperature		Sandimmun	C				
	Breath Sounds Decreased		Prelone Syrup	C				
	Cerebral Infarction		Prednisone	C				
	Cerebrovascular Accident		Prelone Syrup	C				
	Deep Vein Thrombosis		Hormonal Contraceptives (Unspecified)	C		INTRAMUSCULAR		
	Depressed Level Of Consciousness		Sandimmun	C				
	Depression							
	Diabetes Mellitus Non-Insulin-Dependent							
	Dyspepsia							
	Electrocardiogram St Segment Abnormal							
	Electrocardiogram T Wave Abnormal							
	Fall							
	Fibromyalgia							
	Heart Rate Irregular							
	Hydrocephalus							
	International Normalised Ratio Decreased							
	Intracranial Venous Sinus Thrombosis							
	Joint Effusion							
	Lung Disorder							
	Memory Impairment							
	Muscle Disorder							
	Nausea							
	Optic Nerve Disorder							
	Polycystic Ovaries							
	Rash							
	Sex Hormone Binding Globulin Decreased							
	Sinus Tachycardia							

Subarachnoid Haemorrhage
Tinnitus
Uterine Enlargement
Uterine Leiomyoma
Vaginal Haemorrhage
Vision Blurred
Visual Field Defect
Vomiting

Date:09/08/03ISR Number: 4181106-1Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00018
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Anuria
	Blood Potassium Increased
	Dehydration
	Diarrhoea

		Gouty Arthritis					
		Haemodialysis					
		Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoglycaemia		Vioxx	PS		ORAL
		Lactic Acidosis		Althiazide And Spironolactone	SS	Merck & Co., Inc	ORAL
		Nausea		Colchicine	SS		ORAL
		Overdose		Metformin Hydrochloride	SS		ORAL
		Renal Failure Acute		Colchicine And Opium, Powdered And Tiemonium Methylsulfate	SS		ORAL
		Vomiting		Cyanocobalamin	C		
				Ferrous Sulfate	C		
				Miglitol	C		
				Gliclazide	C		

Date:09/08/03ISR Number: 4181107-3Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS		ORAL
9	DAY					
Life-Threatening	Haematemesis		Aspirin	SS		ORAL
Hospitalization -	Toxic Epidermal		Dipyrone	SS		ORAL
6	DAY					
Initial or Prolonged	Necrolysis		Dipyrone	SS		ORAL
2	DAY					
			Dipyrone	SS		ORAL
2	DAY					
			Vioxx	SS		ORAL
			Tramadol Hydrochloride	SS		ORAL
11	DAY					
			Tramadol Hydrochloride	SS		ORAL
4	DAY					
			Vioxx	SS		ORAL
2	DAY					
			Furosemide Sodium	SS		ORAL
			Furosemide Sodium	SS		ORAL
			Moxonidine	SS		ORAL

		Dipyrone	SS		ORAL
9	DAY				
		Amlodipine Besylate	C	Merck & Co., Inc	ORAL
		Tolperisone Hydrochloride	C		ORAL
2	DAY				
		Tolperisone Hydrochloride	C		ORAL
		Sucralfate	C		ORAL
		Potassium Bicarbonate And Potassium Citrate	C		ORAL
1	DAY				
		Potassium Bicarbonate And Potassium Citrate	C		ORAL
6	DAY				
		Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL
		Isosorbide Mononitrate	C		ORAL
		Moxonidine	C		ORAL
		Nadroparin Calcium	C		
SUBCUTANEOUS					
		Pantoprazole Sodium	C		ORAL
		Pantoprazole Sodium	C		ORAL

			Lisinopril	C		ORAL
			Dexamethasone	C		ORAL

Date:09/09/03ISR Number: 4181321-7Report Type:Expedited (15-DaCompany Report #WAES 0309ITA00001
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Scintillating Scotoma		Vioxx	PS		ORAL	2	DAY
			Glyburide	C	Merck & Co., Inc			
			Lacidipine	C				

Date:09/09/03ISR Number: 4181322-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA02958
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Enterocolitis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/09/03ISR Number: 4181922-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
	Arteriosclerosis
Disability	Asthenia
Other	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Blood Pressure Increased
	Chest Pain
	Constipation
	Contusion
	Decreased Appetite
	Deep Vein Thrombosis
	Dehydration
	Drug Hypersensitivity

Flushing
Gastritis
Gastroenteritis
Glomerulonephritis Focal
Glomerulonephritis
Membranous
Glomerulosclerosis
Haematemesis
Injury
Joint Sprain
Laceration
Lobar Pneumonia
Malaise
Muscle Strain
Myalgia
Nasopharyngitis
Nausea
Nephritis Allergic
Nephritis Interstitial
Oesophagitis

		Pain					
		Penile Swelling					
		Periorbital Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peritoneal Dialysis		Vioxx	PS		ORAL
		Plantar Fasciitis		Celebrex	SS		
2	WK						
		Pulmonary Embolism		Vioxx	SS		ORAL
		Renal Failure		Vioxx	SS		ORAL
		Renal Failure Chronic		[Therapy			
		Renal Transplant		Unspecified]	C	Merck & Co., Inc	
		Scrotal Swelling		Creatine	C		
		Swelling		Advil	C		
		Swelling Face		Solu-Medrol	C		
		Tendon Injury					
		Tendonitis					
		Treatment Noncompliance					
		Upper Respiratory Tract					
		Infection					
		Vomiting					
		Weight Increased					

Date:09/09/03ISR Number: 4181923-8Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS		ORAL
1	DAY						
		Sudden Death		Estradiol Valerate			
				And Norethindrone	C	Merck & Co., Inc	ORAL
				Omeprazole	C		ORAL
1	DAY						

Date:09/09/03ISR Number: 4181925-1Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00043
Age:68 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
Initial or Prolonged		Urticaria					

Date:09/09/03ISR Number: 4181926-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA00524
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Function Test Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/09/03ISR Number: 4181928-7Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00024
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Malignant Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/09/03ISR Number: 4187545-7Report Type:Expedited (15-DaCompany Report #2003SE03866
Age:61 YR Gender:Male I/FU:I

Outcome	PT
Death	Hepatic Failure Hepatic Necrosis

Jaundice Cholestatic

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign	Esomeprazole	PS		ORAL	20 MG DAILY	
Health Professional	Triatec	SS		ORAL	2.5 MG DAILY	
Other	Arofexx	SS		ORAL	25 MG DAILY	

PO

Date:09/10/03ISR Number: 4183067-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02901
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/10/03ISR Number: 4183120-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA00739
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Bilirubin Excretion Disorder Jaundice		Vioxx	PS		ORAL		
			Celebrex	C	Merck & Co., Inc			

Date:09/10/03ISR Number: 4183121-0Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00016
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS		ORAL		
	Anaemia		Acetaminophen	C	Merck & Co., Inc			
	Asthenia		Acetaminophen And Belladonna And Caffeine And Opium	C				
	Dyspnoea		Fosamax	C		ORAL		

Date:09/10/03ISR Number: 4183126-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00728
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
Initial or Prolonged	Attack							

Date:09/11/03ISR Number: 4183420-2Report Type:Expedited (15-DaCompany Report #WAES 0309ITA00005
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysarthria		Vioxx	PS		ORAL		
5 DAY								
Initial or Prolonged	Hypertensive Crisis		Glyburide And Phenformin	C	Merck & Co., Inc			
	Transient Ischaemic Attack		Perindopril Erbumine	C		ORAL		
			Pravastatin Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/11/03ISR Number: 4183906-0Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00025
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS		ORAL		5 DAY
Initial or Prolonged	Alanine Aminotransferase		Citalopram					
	Increased		Hydrobromide	C	Merck & Co., Inc	ORAL		
	Aspartate		Spironolactone	C		ORAL		
	Aminotransferase		Hyzaar	C		ORAL		
	Increased							
	Asthenia							
	Breast Cancer Metastatic							
	Cholestasis							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal							
	Haemorrhage							

Date:09/11/03ISR Number: 4183908-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA01431
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS		ORAL		
	Myocardial Infarction		Toprol Xl Tablets	C	Merck & Co., Inc			

Date:09/11/03ISR Number: 4183920-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA00838
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/11/03ISR Number: 4183922-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA00837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/11/03ISR Number: 4183923-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA00840
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/11/03ISR Number: 4183924-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA00839
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/11/03ISR Number: 4183926-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/12/03ISR Number: 4184808-6Report Type:Expedited (15-DaCompany Report #WAES 0309CHE00015
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Headache		Vioxx	PS		ORAL	4	YR
			Celecoxib	SS	Merck & Co., Inc	ORAL	119	DAY
			Vioxx	SS		ORAL		

Date:09/12/03ISR Number: 4185440-0Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00216
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis	Health	Vioxx	PS		ORAL	7	DAY
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Professional	Aspirin	SS	Merck & Co., Inc	ORAL		
	Gastritis Erosive		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
	Oesophagitis							
	Renal Failure Acute							
			Gabapentin	C		ORAL		
			Valsartan	C		ORAL		
			Zocor	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Quinine Sulfate	C		ORAL		

Date:09/12/03ISR Number: 4185446-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02274
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Electrocardiogram Qt Prolonged	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/12/03ISR Number: 4187812-7Report Type:Expedited (15-DaCompany Report #200312676EU
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amyloidosis		Arava	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Blood Creatinine Increased		Vioxx	SS		ORAL		
	Drug Interaction		Pamol	C		ORAL		
	Proteinuria							
	Renal Disorder							

Date:09/12/03ISR Number: 4190050-5Report Type:Expedited (15-DaCompany Report #2003036888
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Consumer	Lipitor (Atorvastatin)	PS			40 MG	
	Arthropathy							
	Asthenia		Rofecoxib (Rofecoxib)	SS				
	Constipation							
	Difficulty In Walking		Prednisone (Prednisone)	SS				
	Gait Disturbance							
	Hypothyroidism		Potassium (Potassium)	C				
	Muscle Atrophy							
	Muscular Weakness		Amlodipine Besilate (Amlodipine Besilate)	C				
	Myopathy							
			Dyazide					

(Hydrochlorothiazide , Triamterene)	C	
Narine Repetabs (Psudoephedrine Sulfate, Loratadine)	C	
Esomeprazole (Esomeprazole)	C	
Levothyroxine Sodium (Levothyroxine Sodium)	C	

Date:09/12/03ISR Number: 4190198-5Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00018
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria	Foreign	Tab Vioxx					
Hospitalization -	Blood Potassium Increased	Other	(Rofecoxib)	PS		ORAL	PO	
Initial or Prolonged	Diarrhoea		Althiazide/Spironola					
	Haemodialysis		ctone	SS		ORAL	PO	
	Haemoglobin Decreased		Metformin Hcl	SS		ORAL	850MG/TID, PO	
	Hypoglycaemia		Colchicine	SS		ORAL	PO	
	Lactic Acidosis		Colchicine (+)					
	Nausea		Opium, Powdered (+)					
	Overdose		Tiemonium Me	SS		ORAL	PO	
	Renal Failure Acute		Cyanocobalamin	C				
	Vomiting		Ferrouss04	C				
			Gliclazide	C				
			Miglitol	C				

Date:09/15/03ISR Number: 4185830-6Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00089
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea	Health	Vioxx	PS		ORAL		
Initial or Prolonged	Gastric Ulcer	Professional	Aspirin	SS	Merck & Co., Inc	ORAL		
	Haemoglobin		Atenolol	C		ORAL		
	Helicobacter Infection		Furosemide	C		ORAL		

	Melaena		Gliclazide	C		ORAL
			Ramipril	C		ORAL

Date:09/15/03ISR Number: 4185847-1Report Type:Expedited (15-DaCompany Report #WAES 0309CAN00045
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Wheezing	Health	Vioxx	PS	Merck & Co., Inc	ORAL	36	DAY
Hospitalization - Initial or Prolonged		Professional						

Date:09/15/03ISR Number: 4185855-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA00901
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS		ORAL	5	WK
Initial or Prolonged	Fall		Aspirin	C	Merck & Co., Inc			
	Gastrointestinal Ulcer		Cardizem Cd	C				
	Haemorrhage		Prozac	C				
	Helicobacter Infection		Lopid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/03ISR Number: 4185857-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00086
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 435 DAY	Gastric Ulcer		Vioxx	PS		ORAL
Initial or Prolonged	Hypotension		Doxazosin Mesylate	C	Merck & Co., Inc	ORAL
	Melaena		Flecainide Acetate	C		ORAL
			Mebeverine Hydrochloride	C		ORAL

Date:09/15/03ISR Number: 4185861-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00910
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS		ORAL
			Aspirin	C	Merck & Co., Inc	

Date:09/15/03ISR Number: 4185865-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA01194
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Pulmonary Artery Thrombosis Pulmonary Embolism Pulmonary Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/15/03ISR Number: 4185868-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA01221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/15/03ISR Number: 4185885-9Report Type:Expedited (15-DaCompany Report #WAES 0309ZAF00014
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pleural Effusion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/15/03ISR Number: 4186468-7Report Type:Expedited (15-DaCompany Report #WAES 0211DEU00035
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS		ORAL	5	DAY
Hospitalization - Initial or Prolonged Disability	Circulatory Collapse Diverticulitis Ejaculation Disorder Haemoglobin Decreased Lower Gastrointestinal Haemorrhage Red Blood Cell Count Decreased		Naloxone Hydrochloride And Tilidine Hydrochloride	C	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/03ISR Number: 4186477-8Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00018
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS		ORAL		305 DAY
Life-Threatening	Aortic Valve Incompetence		Aspirin Lysine	C	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure Acute		Zocor	C		ORAL		
Initial or Prolonged	Cardiac Failure		Clopidogrel					
Disability	Congestive		Bisulfate	C		ORAL		169 DAY
	Coronary Artery Stenosis							
	Ejection Fraction							
	Decreased							
	Mitral Valve Disease							
	Multi-Organ Failure							
	Myocardial Infarction							

Date:09/15/03ISR Number: 4186480-8Report Type:Expedited (15-DaCompany Report #WAES 0309ZAF00011
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination		Vioxx	PS		ORAL		2 DAY
Initial or Prolonged	Headache		Ethinyl Estradiol					
	Hypertension		And Norgestrel	C	Merck & Co., Inc	ORAL		
	Visual Disturbance							

Date:09/15/03ISR Number: 4190276-0Report Type:Expedited (15-DaCompany Report #03-09-1096
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Perforation	Foreign	Enalapril Maleate					
Initial or Prolonged	Splenectomy	Other	Tablets - Ipi	PS	Ipi	ORAL		
ORAL								
			Aspirin	SS				
300MG QD								
			Rofecoxib	SS				
12.5 MG OD								
			Sotalol	SS				

			Frusemide	SS		
			Alendronic Acid	SS		
			Fybogel	SS		
			Felbinac Gel	C		
			Ranitidine	C		
			Dydramol	C		

Date:09/15/03ISR Number: 4190278-4Report Type:Expedited (15-DaCompany Report #03-09-1099
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mobility Decreased	Foreign	Tramadol Tablets -					
Other	Neutropenia	Other	Ipi	PS	Ipi	ORAL	ORAL	
	Skin Ulcer		Vioxx	SS			25MG OD	
			Senna	C				
			Citalopram	C				
			Paracetamol	C				
			Alendronate	C				
			Tolterodine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/03ISR Number: 4190634-4Report Type:Expedited (15-DaCompany Report #200310354BNE
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Foreign Health Professional Other	Aspirin (Acetylsalicylic Acid)	PS				
			Rofecoxib	SS		ORAL	ORAL	

Date:09/15/03ISR Number: 4190860-4Report Type:Expedited (15-DaCompany Report #S03-SWE-03794-01
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	General Physical Health Deterioration	Foreign Health	Cipramil (Citalopram Hydrobromide)	PS		ORAL	20 MG QD PO	
	Headache Subarachnoid Haemorrhage	Professional Other	Vioxx (Rofecoxib)	SS				
			Trombyl (Acetylsalicylic Acid)	SS		ORAL	75 MG QD PO	
			Zestril (Lisinopril)	C				
			Vagifem (Estradiol)	C				
			Kredex (Carvedilol)	C				
			Furix (Furosemide)	C				
			Alvedon (Paracetamol)	C				
			Oestriol (Estriol)	C				
			Bezaplip Retard (Bezafibrate)	C				

Date:09/16/03ISR Number: 4186988-5Report Type:Expedited (15-DaCompany Report #WAES 0309DNK00004
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS		ORAL		
	Hyperkalaemia		Acetaminophen	C	Merck & Co., Inc	ORAL		
	Microcytic Anaemia		Aspirin	C		ORAL		
	Nephropathy		Digoxin	C		ORAL		

	Therapeutic Agent		Furosemide	C	ORAL
	Toxicity		Spironolactone	I	ORAL

Date:09/16/03ISR Number: 4187528-7Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Macular Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/16/03ISR Number: 4187529-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA00964
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/03ISR Number: 4187530-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA03272
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort		Vioxx	PS		ORAL	2	DAY
Hospitalization -	Acute Respiratory		Vioxx	SS		ORAL	3	MON
Initial or Prolonged	Distress Syndrome		[Therapy					
	Arthralgia		Unspecified]	C	Merck & Co., Inc			
	Blood Chloride		Toradol	C				
INTRAMUSCULAR								
	Blood Creatinine		Prevacid	C				
	Blood Culture Positive							
	Blood Glucose							
	Blood Potassium							
	Blood Pressure							
	Blood Sodium							
	Blood Urea							
	Chills							
	Coma							
	Confusional State							
	Culture Urine Positive							
	Dry Mouth							
	Duodenal Perforation							
	Erythema							
	Faecal Occult Blood							
	Positive							
	Fluid Overload							
	Haemoglobin Decreased							
	Hypotension							
	Hypoxia							
	Infection							
	Jaundice							
	Klebsiella Infection							
	Multi-Organ Failure							
	Nausea							
	Pain							
	Pancreatitis							
	Peritonitis							
	Pitting Oedema							
	Platelet Count							
	Pleural Effusion							
	Post Procedural							
	Complication							
	Pseudomonas Infection							

Pupil Fixed
Pyrexia
Renal Failure
Sepsis
Shock
Sputum Culture Positive
Tachycardia
Tachypnoea
White Blood Cell Count
Decreased
Wound Drainage

Date:09/16/03ISR Number: 4187532-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA00498
Age:55 YR Gender:Female I/FU:F

Outcome PT
Disability Dysphagia
Feeling Abnormal

	Headache						
	Hypoaesthesia						
	Memory Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain		Vioxx	PS		ORAL	1 MON
	Swelling Face		Vioxx	SS			
	Tinnitus		[Therapy				
	Trigeminal Nerve Disorder		Unspecified]	C	Merck & Co., Inc		

Date:09/16/03ISR Number: 4187535-4Report Type:Expedited (15-DaCompany Report #WAES 0309ITA00012
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Face Oedema		Vioxx	PS		ORAL	4 DAY
	Tongue Oedema		Cozaar	C	Merck & Co., Inc	ORAL	363 DAY
	Urticaria						

Date:09/16/03ISR Number: 4187536-6Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00111
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal		Vioxx	PS		ORAL	
Initial or Prolonged	Haemorrhage		Aspirin	C	Merck & Co., Inc	ORAL	
	Haemoglobin Decreased		Tramadol				
	Oesophageal Ulcer		Hydrochloride	C		ORAL	
			Trazodone				
			Hydrochloride	C		ORAL	

Date:09/16/03ISR Number: 4187538-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA01304
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Cerebrovascular Accident		Vioxx	PS		ORAL	1 WK
	Gastric Disorder		[Therapy				

	Insomnia		Unspecified]	C	Merck & Co., Inc
	Nervousness		[Therapy		
	Panic Disorder		Unspecified]	C	
			[Therapy		
			Unspecified]	C	
			Ibuprofen	C	
			Insulin	C	

Date:09/16/03ISR Number: 4187539-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA01226
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Ischaemia		Vioxx	PS		ORAL	4	DAY
Hospitalization -	Prescribed Overdose		[Therapy					
Initial or Prolonged			Unspecified]	C	Merck & Co., Inc			
			[Therapy					
			Unspecified]	C				
			Percocet	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/03ISR Number: 4187541-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA01174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/16/03ISR Number: 4191034-3Report Type:Expedited (15-DaCompany Report #2003176387CH
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Headache	Foreign	Celebrex (Celecoxib)					
	Headache	Health	Capsule	PS		ORAL	400 MG, QD,	
		Professional					ORAL	
		Other	Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, QD,	
							ORAL	

Date:09/17/03ISR Number: 4188693-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01705
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS		ORAL	5 DAY	
Initial or Prolonged	Congestive		Vicodin Tablets	C	Merck & Co., Inc			
			Allopurinol	C				
			Tricor	C				

Date:09/17/03ISR Number: 4188705-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA01024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:09/17/03ISR Number: 4188707-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01135
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia		Vioxx	PS		ORAL		
Other	Gastrooesophageal Reflux Disease		Celebrex	SS				
	Oedema Peripheral		Gaviscon Antacid Tablets	C				
	Oesophageal Discomfort		Norvasc	C				
	Orthopnoea		[Therapy Unspecified]	C	Merck & Co., Inc			
	Peripheral Vascular Disorder		Neurontin	C				
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				
			Calcium (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/03ISR Number: 4188779-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA00895
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Damage		Vioxx	PS		ORAL		
Hospitalization -	Pneumonia Herpes Viral		Lortab	C	Merck & Co., Inc			
Initial or Prolonged	Pruritus Generalised		Dulcolax	C				
RECTAL								
Disability	Swollen Tongue		Lovenox	C				
	Tongue Disorder		Adalat	C				
	Urticaria Generalised		Phenergan Tablets/Suppositories	C				

Date:09/17/03ISR Number: 4191303-7Report Type:Expedited (15-DaCompany Report #2003GB02479
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Omeprazole	PS		ORAL	20 MG PO	
	Sudden Death	Health	Rofecoxib	SS		ORAL	50 MG PO	
		Professional Other	Climagest	C				

Date:09/17/03ISR Number: 4192197-6Report Type:Expedited (15-DaCompany Report #A02200302177
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis Cholestatic	Health	Arixtra - (Fondaparinux					
	Jaundice	Professional	Sodium) - Solution - 2.5 Mg	PS		SUBCUTANEOUS	2.5 MG, OD,	
						SUBCUTANEOUS		
			Vioxx - (Rofecoxib) - Tablet	SS		ORAL	5	DAY
			Vancomycine					

			(Vancomycin)	C		

Date:09/17/03ISR Number: 4192453-1Report Type:Expedited (15-DaCompany Report #200310358BNE
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis	Foreign	Aspirin					
Hospitalization -	Gastric Ulcer Haemorrhage	Health	(Acetylsalicylic					
Initial or Prolonged	Gastritis Erosive	Professional	Acid)	PS		ORAL	75 MG TOTAL	
	Oesophagitis	Other					DAILY, ORAL	
	Renal Failure Acute		Rofecoxib	SS		ORAL	25 MG, TOTAL	
							DAILY, ORAL	
			Warfarin	C				
			Valsartan	C				
			Isosorbide					
			Mononitrate	C				
			Beclomethasone	C				
			Quinine Sulphate	C				
			Simvastatin	C				
			Gabapentin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/18/03ISR Number: 4189174-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA00249
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS		ORAL	1	YR
Other	Diarrhoea		Zyrtec	C	Merck & Co., Inc			
	Fluid Retention		Digoxin	C				
	Muscle Spasms		Coumadin	C				
			Zocor	C		ORAL		
			Xalatan	C				
OPHTHALMIC								

Date:09/18/03ISR Number: 4189175-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00524
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Liver Function Test		Vioxx	PS		ORAL	3	DAY
	Abnormal		Rocephin	C	Merck & Co., Inc			

Date:09/18/03ISR Number: 4193232-1Report Type:Direct Company Report #CTU 202044
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Ulcer		Aspirin	PS				
			Rofecoxib	SS				
			Diclofenac Ophth	SS				

Date:09/19/03ISR Number: 4189182-7Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00016
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS		ORAL		
	Anaemia		Acetaminophen	C	Merck & Co., Inc	ORAL		
			Acetaminophen And Belladonna And					

Caffeine And Opium	C		ORAL
Fosamax	C		ORAL
Calcium Carbonate	C		ORAL
Diltiazem Hydrochloride	C		ORAL
Isosorbide Mononitrate	C		ORAL

Date:09/19/03ISR Number: 4189186-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00128
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS		ORAL		
	Gastrointestinal Haemorrhage		Aspirin	SS	Merck & Co., Inc	ORAL		

Date:09/19/03ISR Number: 4189192-XReport Type:Expedited (15-DaCompany Report #WAES 0307PHL00027
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Cardiac Tamponade
Other	Cardiomegaly

		International Normalised Ratio Increased					
		Overdose	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pericardial Effusion		Vioxx	PS		ORAL
10	DAY						
		Pericardial Haemorrhage		Vioxx	SS		ORAL
1	DAY						
				Bromhexine Hydrochloride	C	Merck & Co., Inc	ORAL
5	DAY						
				Ceftriaxone Sodium	C		
INTRAVENOUS							
							DRIP
2	DAY						
				Ciprofloxacin	C		ORAL
7	DAY						
				Guaifenesin	C		ORAL
4	DAY						
				Warfarin Sodium	C		ORAL
				Warfarin Sodium	C		ORAL
				Ketorolac	C		
INTRAVENOUS							
							DRIP
2	DAY						
				Mefenamic Acid	C		ORAL
				Ranitidine Hydrochloride	C		ORAL
3	DAY						
				Ranitidine Hydrochloride	C		
INTRAVENOUS							
							DRIP
1	DAY						

Date:09/19/03ISR Number: 4189212-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Anaemia Of Chronic Disease
Other	Anorexia
	Arteriosclerosis

Asthenia
Blood Creatine
Phosphokinase Increased
Blood Pressure Ambulatory
Increased
Chills
Constipation
Contusion
Decreased Appetite
Deep Vein Thrombosis
Dehydration
Dialysis
Drug Ineffective
Dyspnoea
Fatigue
Flushing
Gastritis
Gastroenteritis
Gastrointestinal Oedema
Generalised Oedema
Glomerulonephritis Focal
Glomerulonephritis
Membranous
Haematemesis
Haemodialysis
Heart Rate Increased
Hypertension
Injury

		Joint Sprain					
		Kidney Enlargement					
		Laceration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lobar Pneumonia		Vioxx	PS		ORAL
		Malaise		Celebrex	SS		
2	WK						
		Muscle Strain		Vioxx	SS		ORAL
		Myalgia		Vioxx	SS		ORAL
		Nasopharyngitis		[Therapy			
		Nausea		Unspecified]	C	Merck & Co., Inc	
		Nephritis Allergic		Creatine	C		
		Nephrotic Syndrome		Advil	C		
		Night Sweats		Solu-Medrol	C		
		Oesophagitis					
		Pain					
		Painful Respiration					
		Periorbital Oedema					
		Peritoneal Dialysis					
		Plantar Fasciitis					
		Pulmonary Embolism					
		Renal Failure					
		Renal Failure Chronic					
		Renal Interstitial					
		Fibrosis					
		Renal Transplant					
		Respiratory Rate					
		Increased					
		Swelling Face					
		Tendon Injury					
		Tendonitis					
		Thrombosis					
		Treatment Noncompliance					
		Upper Respiratory Tract					
		Infection					
		Vomiting					
		Weight Increased					

Date:09/19/03ISR Number: 4189217-1Report Type:Expedited (15-DaCompany Report #WAES 0209USA00350
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Discomfort		Vioxx	PS		ORAL
		Abdominal Pain Upper		Darvocet-N	C	Merck & Co., Inc	

Atherosclerosis	Aspirin	C
Blood Cholesterol	Lipitor	C
Increased	Metformin	C
Cerebrovascular Accident	Zantac	C
Drug Hypersensitivity		
Hernia		
Hodgkin'S Disease		
Liver Disorder		
Myocardial Infarction		
Non-Hodgkin'S Lymphoma		
Transient Ischaemic		
Attack		
Tuberculosis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/03ISR Number: 4189219-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01515
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/19/03ISR Number: 4189224-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/19/03ISR Number: 4189230-4Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00010
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Psoriasis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Skin Exfoliation							

Date:09/19/03ISR Number: 4189317-6Report Type:Expedited (15-DaCompany Report #WAES 0209USA00434
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS		ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Hyperhidrosis							
	Injury							
	Intervertebral Disc Disorder							
	Myocardial Infarction							
	Pallor							
	Palpitations							

Date:09/19/03ISR Number: 4189318-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS		ORAL	1	MON
	Extraocular Muscle		Amiodarone	C	Merck & Co., Inc			
	Paresis		Digoxin	C				
	Headache		Premarin	C				
	Hypertension		Estratab	C				
	Hypertensive Crisis		Menest	C				
	Injury		Trazodone Hydrochloride	C				
	Migraine		Armour Thyroid Tablets	C				
	Musculoskeletal Disorder		Garlic Extract	C				
	Transient Ischaemic Attack		Synthroid	C				
			Methotrexate	C				
			Rythmol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/03ISR Number: 4189319-XReport Type:Expedited (15-DaCompany Report #WAES 0209USA00437
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS		ORAL		
Initial or Prolonged	Convulsion		Tylenol	C	Merck & Co., Inc			
Disability	Gastrointestinal Ulcer		Atenolol	C				
Other	Haemorrhage		Captopril	C				
	Nausea		Prempro	C				
	Vomiting		Salsalate	C				
			Sulfasalazine	C				
			Hydrodiuril	C		ORAL		
			Hydroxychloroquine Sulfate	C				
			Claritin	C				
			Potassium (Unspecified)	C				

Date:09/19/03ISR Number: 4189324-3Report Type:Expedited (15-DaCompany Report #WAES 0307HUN00007
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis Viral		Vioxx	PS		ORAL		
Initial or Prolonged	Hepatotoxicity		Acetaminophen	C	Merck & Co., Inc			
2 DAY								
	Prescribed Overdose		Enalapril Maleate And Hydrochlorothiazide	C				

Date:09/19/03ISR Number: 4189327-9Report Type:Expedited (15-DaCompany Report #WAES 0307HUN00007
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis Viral		Vioxx	PS		ORAL		
Initial or Prolonged	Hepatotoxicity		Acetaminophen	C	Merck & Co., Inc			
2 DAY								
			Enalapril Maleate And Hydrochlorothiazide	C				

Date:09/19/03ISR Number: 4189330-9Report Type:Expedited (15-DaCompany Report #WAES 0309ZAF00011
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination		Vioxx	PS		ORAL		1 DAY
Initial or Prolonged	Headache		Vioxx	SS		ORAL		1 DAY
	Hypertension		Ethinyl Estradiol					
	Prescribed Overdose		And Norgestrel	C	Merck & Co., Inc	ORAL		
	Visual Disturbance							

Date:09/19/03ISR Number: 4189334-6Report Type:Expedited (15-DaCompany Report #WAES 0309HUN00004
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic		Vioxx	PS		ORAL		2 DAY
Initial or Prolonged			Doxycycline	C	Merck & Co., Inc	ORAL		2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/19/03ISR Number: 4189335-8Report Type:Expedited (15-DaCompany Report #WAES 0309ZAF00013
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Circulatory Collapse	Health	Vioxx	PS		ORAL
Hospitalization -	Fall	Professional	Perindopril Erbumine	SS		ORAL
Initial or Prolonged	Head Injury		Allopurinol	C	Merck & Co., Inc	ORAL
Disability	Renal Failure		Aspirin Calcium	C		ORAL
	Skin Laceration		Spironolactone	C		ORAL
			Colchicine	C		ORAL
			Furosemide	C		ORAL

Date:09/22/03ISR Number: 4190430-8Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00025
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS		ORAL
5 DAY						
Initial or Prolonged	Alanine Aminotransferase		Citalopram			
	Increased		Hydrobromide	C	Merck & Co., Inc	ORAL
	Aspartate		Spironolactone	C		ORAL
	Aminotransferase		Hyzaar	C		ORAL
	Increased					
	Asthenia					
	Breast Cancer Metastatic					
	Cholestasis					
	Gastric Ulcer Haemorrhage					
	Gastrointestinal					
	Haemorrhage					

Date:09/22/03ISR Number: 4190437-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA01594
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematochezia		Vioxx	PS		ORAL
2 WK						
Initial or Prolonged	Hypotension		Proscar	C	Merck & Co., Inc	ORAL
			Vitamins (Unspecified)	C		
			Flomax			

			(Morniflumate)	C		

Date:09/22/03ISR Number: 4190467-9Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00049
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 182 DAY	Cardiac Failure		Vioxx	PS		ORAL
Initial or Prolonged	Cardioactive Drug Level Increased		Spironolactone	SS		ORAL
	International Normalised Ratio Increased		Buflomedil Hydrochloride	C		ORAL
	Lung Disorder		Buflomedil Hydrochloride	C		ORAL
	Renal Failure		Digoxin	C		ORAL
			Fluindione	C		ORAL
366 DAY						
			Fluindione	C		ORAL
			Furosemide	C		ORAL
			Adrafinil	C	Merck & Co., Inc	
			Cozaar	C		ORAL
			Melilot And Rutin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/03ISR Number: 4190470-9Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00119
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated		Vioxx	PS		ORAL		3 DAY
Life-Threatening	Intravascular Coagulation		Vioxx	SS		ORAL		2 DAY
	Hepatitis Toxic		Amiodarone					
	Renal Failure		Hydrochloride	C	Merck & Co., Inc	ORAL		
	Rhabdomyolysis							

Date:09/22/03ISR Number: 4190475-8Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00185
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL		
Hospitalization -			Aspirin	C	Merck & Co., Inc			
Initial or Prolonged			Atenolol	C				
			Pravastatin Sodium	C				
			Ramipril	C				

Date:09/23/03ISR Number: 4191661-3Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00115
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	General Physical Health		Vioxx	PS		ORAL		4 DAY
Hospitalization -	Deterioration		Candesartan					
Initial or Prolonged	Haemodialysis		Cilexetil	C	Merck & Co., Inc			
	Incision Site Abscess		Felodipine	C		ORAL		
	Multi-Organ Failure		Insulin	C				
	Post Procedural		Moxonidine	C		ORAL		
	Complication		Piretanide	C		ORAL		
	Renal Failure Acute							
	Respiratory Failure							
	Sepsis							
	Staphylococcal Infection							

Date:09/23/03ISR Number: 4191670-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00128
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS		ORAL		
	Gastrointestinal Haemorrhage		Aspirin	SS	Merck & Co., Inc	ORAL		
	Oesophageal Ulcer		Tramadol Hydrochloride	C		ORAL		
			Trazodone Hydrochloride	C		ORAL		

Date:09/23/03ISR Number: 4191674-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA01416
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/03ISR Number: 4191675-3Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00166
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS		ORAL		
	Peptic Ulcer Perforation		Fosamax	SS	Merck & Co., Inc			
			Amitriptyline Hydrochloride	C		ORAL		
			Zocor	C				
			Nitrazepam	C				

Date:09/23/03ISR Number: 4195355-XReport Type:Direct Company Report #CTU 202289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatinine		Vioxx	PS		ORAL	25 MG	BID
Intervention to Prevent Permanent Impairment/Damage	Increased							
			Phenergan	C				
			Sinequan	C				
			Coreg	C				
			Cardizem	C				
			Carafate	C				
			Papaverine	C				
			Darvon	C				
			Mvi	C				
			Atacand	C				

Date:09/23/03ISR Number: 4195534-1Report Type:Direct Company Report #CTU 202366
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Gastric Ulcer		Lovenox	PS			30 MG	Q 12
Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Haemorrhage		Vioxx	SS				
	Haematocrit Decreased							
	Hiatus Hernia							
	Post Procedural							

Haemorrhage

Date:09/23/03ISR Number: 4196921-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA03272
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Abscess
Hospitalization - Initial or Prolonged	Abdominal Adhesions
	Acute Respiratory Distress Syndrome
	Alanine Aminotransferase
	Anuria
	Aspartate Aminotransferase
	Biliary Tract Disorder
	Blood Bilirubin
	Blood Culture Positive
	Blood Glucose
	Blood Urea Increased
	Cardiac Arrest
	Coma
	Confusional State

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Culture Urine Positive Dry Mouth Duodenal Ulcer					
50 MG/DAILY/PO		Perforation	Health	Tab Vioxx	PS		ORAL
		Emotional Distress	Professional				
		Facial Paresis	Company	Prevacid	C		
		Faecal Occult Blood Positive	Representative	Toradol	C		
		Generalised Oedema					
		Haemoglobin Decreased					
		Hypotension					
		Hypoxia					
		Jaundice					
		Klebsiella Infection					
		Leukopenia					
		Liver Function Test Abnormal					
		Lung Infiltration					
		Multi-Organ Failure					
		Mydriasis					
		Pain					
		Pancreatitis					
		Peritonitis					
		Pitting Oedema					
		Pleural Effusion					
		Post Procedural Complication					
		Pseudomonas Infection					
		Pupil Fixed					
		Rash Maculo-Papular					
		Renal Failure					
		Respiratory Failure					
		Sepsis					
		Shock					
		Sputum Culture Positive					
		Stupor					
		Tachycardia					
		White Blood Cell Count Increased					
		Wound Secretion					

Date:09/23/03ISR Number: 4198285-2Report Type:Expedited (15-DaCompany Report #2003169396FR
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health Professional	Aldactone(Spironolactone) Tablet, 25mg	PS		ORAL	25 MG, DAILY	
	Bronchial Infection	Other					, ORAL	
	Cardiac Failure		Digoxin "Nativelle" (Digoxin)	SS		ORAL	ORAL	
	Cardioactive Drug Level Increased		Previscan (Fluindione) 20mg	SS			10 MG DAILY	
	Coagulopathy		Furosemide(Furosemide) 40mg	SS			60 MG DAILY	
	International Normalised Ratio Increased		Rofecoxib(Rofecoxib)	SS		ORAL	25 MG DAILY	
	Left Ventricular Failure		Cozaar(Losartan Potassium)	SS		ORAL	100 MG DAILY	
	Renal Atrophy		Esberiven				ORAL	
	Renal Failure Acute							

	Forte(Melilot) 50mg	SS	ORAL
ORAL			
	Olmifon(Adrafinil)	SS	
	Fonzylane(Buflomedil Hydrochloride) 300mg	SS	ORAL
600 MG DAILY			
ORAL			

Date:09/24/03ISR Number: 4192956-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA01513
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fracture Delayed Union		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/24/03ISR Number: 4192961-3Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00192
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Vulval Ulceration		Vioxx	PS		ORAL	1	DAY
Initial or Prolonged			Cefaclor	SS	Merck & Co., Inc	ORAL	1	DAY
Disability								

Date:09/24/03ISR Number: 4192962-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01230
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Drug Reaction		Vioxx	PS		ORAL		
	Dermatitis Allergic		[Therapy					
	Ecchymosis		Unspecified]	C	Merck & Co., Inc			
	Hypersensitivity		Furosemide	C				
	Stomatitis							

Date:09/24/03ISR Number: 4192963-7Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00041
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS		ORAL	14	DAY
Initial or Prolonged			Celecoxib	SS		ORAL	11	DAY
			Betamethasone Dipropionate And Salicylic Acid	C	Merck & Co., Inc			

Date:09/24/03ISR Number: 4192965-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02077
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
	Haemorrhage							
	Haematochezia							

Date:09/24/03ISR Number: 4193312-0Report Type:Expedited (15-DaCompany Report #WAES 0309CAN00088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/03ISR Number: 4193317-XReport Type:Expedited (15-DaCompany Report #WAES 0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema	Health	Vioxx	PS		ORAL		
Other	Cardio-Respiratory Arrest	Professional	Vicoprofen	C	Merck & Co., Inc			
	Cardiomegaly		Methocarbamol	C				
	Coma							
	Coronary Artery Atherosclerosis							
	Coronary Artery Thrombosis							
	Myocardial Infarction							
	Pulmonary Oedema							
	Splenomegaly							
	Sudden Death							
	Ventricular Fibrillation							

Date:09/24/03ISR Number: 4193318-1Report Type:Expedited (15-DaCompany Report #WAES 0207GBR00165
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS		ORAL		
			[Therapy Unspecified]	C	Merck & Co., Inc			
			Gliclazide	C				
			Metformin	C				

Date:09/24/03ISR Number: 4193321-1Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Health	Vioxx	PS		ORAL	3	DAY
	Diabetes Mellitus	Professional	Omeprazole	SS	Merck & Co., Inc		3	DAY
	Diarrhoea							
	Dyspepsia							
	Gastric Disorder							
	Renal Failure Chronic							

Date:09/24/03ISR Number: 4193326-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00113
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Increased		Analgesic Or Anesthetic (Unspecified)	C	Merck & Co., Inc			
	Blood Triglycerides Increased							
	Dyspepsia							
	Heart Rate Irregular							
	Myocardial Infarction							

Date:09/24/03ISR Number: 4193327-2Report Type:Expedited (15-DaCompany Report #WAES 0309ITA00012
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema	Health	Vioxx	PS		ORAL	4	DAY
	Tongue Oedema	Professional	Tizanidine Hydrochloride	SS		ORAL	2	DAY
	Urticaria							

			Cozaar	C	Merck & Co., Inc	ORAL
363 DAY						

Date:09/24/03ISR Number: 4193328-4Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS		ORAL
Initial or Prolonged	Chest Discomfort	Professional	Amlodipine Besylate	SS	Merck & Co., Inc	ORAL
	Collagen Disorder		Prednisolone	SS		
	Drug Interaction					
	General Physical Health					
	Deterioration					
	Polyserositis					
	Tachyarrhythmia					
	Vasculitis					

Date:09/24/03ISR Number: 4193331-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00170
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Gastritis		Vioxx	PS		ORAL
	Gastrointestinal		Aspirin	C	Merck & Co., Inc	ORAL
	Haemorrhage		Calcium Carbonate			
	Melaena		And Cholecalciferol	C		ORAL
			Lactulose	C		ORAL

Date:09/25/03ISR Number: 4193989-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Acute Myocardial		Vioxx	PS		ORAL
	Infarction		Lotensin	C	Merck & Co., Inc	
	Coronary Artery Disease		Vasotec	C		ORAL
	Depression		Prozac	C		
			Ginseng	C		
			Naproxen	C		
			Accupril	C		

Date:09/25/03ISR Number: 4194494-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02052
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Aneurysm	Consumer	Vioxx	PS		ORAL
	Blood Cholesterol		Lotrel	C	Merck & Co., Inc	ORAL
	Increased		Clonidine	C		ORAL
249 DAY						
	Haemorrhagic Stroke		Clonidine	C		ORAL
	Hemiparesis		Zoloft	C		ORAL
	Hypertension		Labetalol			
	Memory Impairment		Hydrochloride	C		ORAL
	Sensory Loss		Labetalol			
			Hydrochloride	C		ORAL
			Ranitidine	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/03ISR Number: 4194495-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01029
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/25/03ISR Number: 4194497-2Report Type:Expedited (15-DaCompany Report #WAES 0309NOR00010
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS		ORAL		4 DAY
			Chlorprothixene Hydrochloride	C	Merck & Co., Inc	ORAL		
			Omeprazole	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:09/25/03ISR Number: 4194499-6Report Type:Expedited (15-DaCompany Report #WAES 0304DNK00016
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Disorder	Health Professional	Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastrointestinal Haemorrhage		Acetaminophen	C	Merck & Co., Inc	ORAL		
			Bendroflumethiazide And Potassium Chloride	C		ORAL		

Date:09/25/03ISR Number: 4194504-7Report Type:Expedited (15-DaCompany Report #WAES 0309SWE00010
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy Compartment Syndrome Haemorrhage Haemorrhagic Diathesis	Health Professional	Vioxx	PS		ORAL		
			Aspirin	SS	Merck & Co., Inc	ORAL		
			Lansoprazole	C				

Movement Disorder
Pain In Extremity
Sensory Disturbance
Skin Discolouration
Swelling

Date:09/25/03ISR Number: 4194506-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA01875
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS		ORAL	2	DAY
	Generalised Oedema		Xanax	C	Merck & Co., Inc			
	Oedema		Amitriptyline Hydrochloride	C				
			Celexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/25/03ISR Number: 4194508-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Pulmonary Oedema							

Date:09/25/03ISR Number: 4194509-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA02021
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/25/03ISR Number: 4194510-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02345
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS		ORAL		
	Adverse Event		Darvocet-N	C	Merck & Co., Inc			
Disability	Dysarthria		Bisacodyl	C				
	Dysphonia		Colace	C				
	Memory Impairment		Furosemide	C				
			Torsemide	C				
			Ambien	C				
			Spironolactone	C				
			Neurontin	C				
			Paxil	C				
			Dilantin	C				

Date:09/25/03ISR Number: 4200919-0Report Type:Expedited (15-DaCompany Report #200310372BNE
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal	Foreign Health	Aspirin (Acetylsalicylic					

	Haemorrhage	Professional	Acid)	PS		ORAL
75 MG, TOTAL						
	Oesophageal Ulcer	Other				
DAILY ORAL						
			Vioxx (Rofecoxib)	SS		ORAL
25 MG, TOTAL						
DAILY, ORAL						
			Trazodone	C		
			Tramadol	C		

Date:09/26/03ISR Number: 4197146-2Report Type:Direct Company Report #CTU 202707
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Pioglitazone	PS		ORAL
30 MG PO QD						
Initial or Prolonged	Congestive		Rofecoxib	SS		ORAL
25MG PO BID						
	Condition Aggravated		Norvasc	C		
	Hypertension		Clonidine	C		
			Vasotec	C		
			Lasix	C		
			Kcl	C		
			Lopressor	C		
			Vioxx	C		
			Coumadin	C		

Lipitor	C
Seroquel	C
Actos	C
Lantus	C
Celexa	C

Date:09/26/03ISR Number: 4199349-XReport Type:Expedited (15-DaCompany Report #2003SE03866
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated	Foreign	Esomeprazole	PS		ORAL	20 MG DAILY	
	Intravascular Coagulation	Health					PO	
	Hepatic Failure	Professional	Triatec	SS		ORAL	2.5 MG DAILY	
	Hepatic Necrosis	Other					PO	
	Hepatomegaly		Arofexx	SS		ORAL	25 MG DAILY	
	Hepatorenal Syndrome						PO	
	Hepatotoxicity							
	Jaundice Cholestatic							
	Oliguria							

Date:09/26/03ISR Number: 4200281-3Report Type:Expedited (15-DaCompany Report #2003-09-2044
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis	Foreign	Diprosalic					
	Cystic Lymphangioma	Health	(Betamethasone					
	Infection	Professional	Dipropionate/Salicyl					
		Other	ic Aci Topicals	PS			1 DOSE BID	
			Vioxx (Rofecoxib)					
			Tablets	SS		ORAL	12.5 MG BID	
						ORAL		

Date:09/29/03ISR Number: 4196511-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA02979
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased Blood Triglycerides Increased Cerebrovascular Accident Heart Rate Irregular Hypertension Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4196512-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02027
Age: Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
Other	Blindness Emotional Distress Medication Error Spondylitis Urinary Tract Infection Vision Blurred

	Visual Field Defect						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS		ORAL		
			Premarin	C	Merck & Co., Inc			
			Motrin	C				
			Progesterone	C				

Date:09/29/03ISR Number: 4196514-2Report Type:Expedited (15-DaCompany Report #WAES 0204USA02612
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS		ORAL		
781 DAY								
Hospitalization -	Blood Chloride		Vicodin Es Tablets	C	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Potassium		Histussin-Hc Syrup	C		ORAL		
Disability	Blood Sodium		Glyburide	C		ORAL		
Other	Cardiac Murmur		Humibid L.A.	C		ORAL		
	Coronary Artery Disease		Prinivil	C		ORAL		
	Gastric Ulcer Haemorrhage							
	Hyperglycaemia							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Pneumonia							
	White Blood Cell Count							

Date:09/29/03ISR Number: 4196515-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Hypertension							
	Oedema Peripheral							

Date:09/29/03ISR Number: 4196516-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA02190
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder Gangrene Hypertension Myocardial Infarction Peripheral Vascular Disorder Pneumonia Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4196820-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Blood Creatine Phosphokinase Increased Blood Pressure Increased Contusion Deep Vein Thrombosis Dehydration

		Dialysis					
		Drug Hypersensitivity					
		Gastritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS		ORAL
		Glomerulonephritis Focal		Celebrex	SS		
2	WK						
		Glomerulonephritis		Vioxx	SS		ORAL
		Membranous		Vioxx	SS		ORAL
		Haematemesis		[Therapy			
		Injury		Unspecified]	C	Merck & Co., Inc	
		Joint Sprain		Creatine	C		
		Laceration		Advil	C		
		Nasopharyngitis		Solu-Medrol	C		
		Nephrosclerosis					
		Oesophagitis					
		Pulmonary Embolism					
		Renal Failure Chronic					
		Tendon Injury					
		Tendonitis					

Date:09/29/03ISR Number: 4196821-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03191
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Injury		Vioxx	PS		ORAL
5	MON						
Initial or Prolonged		Transient Ischaemic		Aspirin	C	Merck & Co., Inc	
Disability		Attack		Plaquenil	C		

Date:09/29/03ISR Number: 4196823-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01025
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:09/29/03ISR Number: 4196824-9Report Type:Expedited (15-DaCompany Report #WAES 0203USA02029
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS		ORAL
Disability	Cardiac Disorder		Tylenol	C	Merck & Co., Inc	
Other	Cardiac Failure		Aspirin	C		
	Congestive		Aspirin	C		
	Cardiac Valve Disease		Coumadin	C		
	Coronary Artery Disease		Atenolol	C		
	Hypertension		Indocin			
	Injury		(Indomethacin)	C		
	Myocardial Infarction					
	Respiratory Disorder					

Date:09/29/03ISR Number: 4196829-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA02271
Age:22 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drug Abuser		Vioxx	PS		ORAL
Other	Intentional Misuse		Methadone Hydrochloride	SS	Merck & Co., Inc	
			Warfarin	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/03ISR Number: 4196835-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA02405
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cystitis Disease Recurrence Swelling Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4196880-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA02507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4196882-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA02509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4197277-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Dyspepsia Gastrooesophageal Reflux Disease		Vioxx Aspirin	PS C	 Merck & Co., Inc	ORAL		

Date:09/29/03ISR Number: 4197284-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cerebrovascular Accident		Coumadin	C		
	Death					
	Injury					
	Oedema					

Date:09/29/03ISR Number: 4197285-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS		ORAL
Initial or Prolonged	Increased		Vioxx	SS		ORAL
	Hypertension		Tylenol	C	Merck & Co., Inc	
	Injury		Norvasc	C		
	Insomnia		Dicyclomine			
	Myocardial Infarction		Hydrochloride	C		
			Prevacid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/03ISR Number: 4197286-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01988
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Injury							

Date:09/29/03ISR Number: 4197291-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS		ORAL	27	DAY
			Aspirin	C	Merck & Co., Inc			
			Lipitor	C				
			Plavix	C				
			Zestril	C				

Date:09/29/03ISR Number: 4197292-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00741
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL	23	DAY
Initial or Prolonged	Blood Iron Decreased		Tylenol	C	Merck & Co., Inc		790	DAY
Disability	Cardiac Murmur		Lipitor	C			790	DAY
	Coronary Artery Disease		Celebrex	C			96	DAY
	Fall							
	Haemorrhage							
	High Density Lipoprotein Decreased							
	Hypertension							
	Low Density Lipoprotein Increased							
	Myocardial Infarction							
	Pain							

Ulcer

Date:09/29/03ISR Number: 4197297-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00866
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS		ORAL		10 MON
Initial or Prolonged	Blood Pressure Increased		Ziagen	C	Merck & Co., Inc			
Disability	Cardiac Failure		Esavir	C				
	Congestive		Extendryl	C				
	Coronary Artery Disease		Zerit	C				
	Dyspnoea		Estratest	C				
	Emotional Distress		Glucophage	C				
	Fatigue		Viramune	C				
	Gastrointestinal							
	Haemorrhage							
	Haemorrhage							
	Heart Rate Irregular							
	Myocardial Infarction							
	Pancreatitis							
	Thrombosis							
	Thyroid Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/03ISR Number: 4197298-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA02507
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL	30 DAY	
Initial or Prolonged	Asthenia		Vicodin Tablets	C	Merck & Co., Inc			
	Drug Ineffective							
	Duodenal Ulcer							
	Haemorrhage							

Date:09/29/03ISR Number: 4201991-4Report Type:Expedited (15-DaCompany Report #1427
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Foreign	Targretin Capsules	PS		ORAL	600 MG DAILY	
Initial or Prolonged		Health					PO	
		Professional	Rofecoxib	SS		ORAL	MG DAILY PO	
		Other	Rofecoxib	SS		ORAL	25 MG DAILY	
							PO	
			Lanzoprazole	C				
			Penicillin V	C				
			Rofecoxib	C				

Date:09/30/03ISR Number: 4197821-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02383
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS		ORAL		
	Arthropathy		Vioxx	SS		ORAL		
	Asthenia		Vioxx	SS		ORAL		
	Cardiac Disorder		Aspirin	C	Merck & Co., Inc			
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							

Cardiac Valve Disease
Cardiomegaly
Carotid Artery Stenosis
Chest Discomfort
Chest Pain
Coronary Artery Disease
Emotional Distress
Injury
Myocardial Infarction
Overdose

Date:09/30/03ISR Number: 4197822-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA02381
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Cardiac Murmur
	Chills
	Depression
	Dyspepsia
	Dysphagia
	Emotional Distress
	Feeling Abnormal
	Gastric Disorder
	Gastrooesophageal Reflux

	Disease						
	Haematemesis						
	Haematochezia						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS		ORAL		
	Overdose		Cannabis	C	Merck & Co., Inc			
	Pyrexia		Oramorph	C				
	Renal Pain		Protonix	C				
	Sleep Disorder							
	Swelling							
	Vomiting							

Date:09/30/03ISR Number: 4197823-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA02315
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 220 DAY	Aortic Stenosis		Vioxx	PS		ORAL		
Initial or Prolonged Disability	Aortic Valve Incompetence		Zocor	C		ORAL		
	Atrial Fibrillation		Tylenol	C	Merck & Co., Inc			
	Chest Pain		Vasotec	C		ORAL		
	Depressed Level Of Consciousness		Hydrocodone Hydrochloride	C				
	Dizziness		Synthroid	C		ORAL		
	Dyspnoea Exertional		Prilosec	C		ORAL		
	Hyperhidrosis							
	Medical Device Complication							
	Sternal Injury							
	Syncope							
	Ventricular Hypertrophy							

Date:09/30/03ISR Number: 4197825-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/30/03ISR Number: 4197827-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS		ORAL		
Disability	Angioplasty		Tylenol	C	Merck & Co., Inc			
Other	Arrhythmia		Aspirin	C				
	Blood Cholesterol Increased		Aspirin	C				
	Blood Triglycerides Increased		Coumadin	C				
	Cardiac Disorder		Atenolol	C				
	Cardiac Failure Congestive		Indocin (Indomethacin)	C				
	Cardiac Valve Disease							
	Coronary Artery Disease							
	Dyspnoea							
	Emotional Distress							
	Hypertension							
	Low Density Lipoprotein Increased							
	Myocardial Infarction							

Date:09/30/03ISR Number: 4197828-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02435
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Medication Error		Vioxx	SS		ORAL		
	Tinnitus							

Date:09/30/03ISR Number: 4197829-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02263
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		Vioxx	SS		ORAL		

Date:09/30/03ISR Number: 4197831-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02583
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Fosamax	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		

Date:09/30/03ISR Number: 4197832-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/30/03ISR Number: 4197833-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02008
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper Chest Pain Drug Hypersensitivity Dyspnoea Myocardial Infarction Pain		Vioxx Vicodin Tablets	PS C	Merck & Co., Inc	ORAL

Date:09/30/03ISR Number: 4197834-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS		ORAL
Hospitalization - Initial or Prolonged	Death Dyspnoea		[Therapy Unspecified]	C	Merck & Co., Inc	
Other	Upper Gastrointestinal Haemorrhage		Vicodin Es Tablets	C		
			Coumadin	C		ORAL
			Restoril	C		
			Zestril	C		

Date:09/30/03ISR Number: 4197835-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA02142
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Atrial Fibrillation Cardiac Failure Congestive Hypertension Hypothyroidism Injury Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/30/03ISR Number: 4197836-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA02688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/30/03ISR Number: 4197837-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris Anxiety Back Pain Blood Cholesterol Increased Cardiac Disorder Cardiac Valve Disease Crying Depression Extrasystoles Gastric Disorder Gastrointestinal Haemorrhage Headache Movement Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

		Photopsia					
		Vision Blurred					

Date:09/30/03ISR Number: 4197838-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA01996
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Hypertension					
		Sudden Death					

Date:09/30/03ISR Number: 4197839-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01985
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper		Vioxx	PS		ORAL
Other		Dyspepsia		Vioxx	SS		ORAL
		Myocardial Infarction		Tylenol	C		

Mylanta & Mylanta Ds	C	
Celebrex	C	
Catapres	C	
Dyazide	C	
Motrin	C	
Orudis	C	
[Therapy Unspecified]	C	Merck & Co., Inc
Zestril	C	
Cytotec	C	
Naproxen	C	
Procardia	C	
Actifed	C	

Date:09/30/03ISR Number: 4197840-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02083
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Calculus Bladder		Vioxx	PS		ORAL		
	Gastrooesophageal Reflux Disease		Antimicrobial (Unspecified)	C	Merck & Co., Inc			
	Injury							
	Myocardial Infarction							
	Prostatic Disorder							
	Testicular Disorder							

Date:09/30/03ISR Number: 4197841-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS		ORAL		
4 MON								
Initial or Prolonged	Gastrooesophageal Reflux		Claritin	C	Merck & Co., Inc			
8 MON								
	Disease							
	Injury							
	Oesophageal Stenosis							
	Pain							
	Palpitations							
	Stress							
	Tachycardia							

Date:09/30/03ISR Number: 4197842-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Abnormal Behaviour
	Blood Cholesterol Increased
	Blood Pressure Increased
	Bradycardia
	Contusion
	Drug Hypersensitivity
	Feeling Abnormal
	Hypersensitivity
	Hypertension
	Injury
	Myocardial Infarction
	Nervousness

		Paralysis					
		Road Traffic Accident					
		Spinal Cord Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cervical		Vioxx	PS	Merck & Co., Inc	ORAL
		Tremor					

Date:09/30/03ISR Number: 4197843-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03167
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthma		Vioxx	PS		ORAL
		Coagulopathy		Catapres	C	Merck & Co., Inc	
347 DAY							
		Dyspepsia		Lasix (Furosemide)	C		
		Dyspnoea		Micardis	C		
		Gastrooesophageal Reflux		Cozaar	C		
		Disease					
		Glaucoma					
		Infection					
		Injury					
		Obesity					
		Osteoarthritis					
		Pulmonary Embolism					
		Rheumatoid Arthritis					
		Sleep Apnoea Syndrome					
		Thrombosis					

Date:09/30/03ISR Number: 4197844-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
		Breast Cancer Female					
		Cerebrovascular Accident					
		Hypertension					
		Injury					
		Oedema Peripheral					

Date:09/30/03ISR Number: 4197845-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Chest Pain							
	Chest Wall Pain							
	Dizziness							
	Dyspnoea							
	Heart Rate Increased							
	Injury							
	Myocardial Infarction							

Date:09/30/03ISR Number: 4197846-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02052
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aneurysm
	Blood Cholesterol Increased

		Haemorrhagic Stroke					
		Hemiparesis					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Impaired Work Ability		Vioxx	PS		ORAL
		Injury		Lotrel	C	Merck & Co., Inc	ORAL
		Memory Impairment		Clonidine	C		ORAL
249 DAY							
		Sensory Loss		Clonidine	C		ORAL
				Zoloft	C		ORAL
				Labetalol Hydrochloride	C		ORAL
				Labetalol Hydrochloride	C		ORAL
				Ranitidine	C		ORAL

Date:09/30/03ISR Number: 4197847-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02055
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS		ORAL
33 DAY							
Initial or Prolonged		Blood Pressure		Acyclovir	C	Merck & Co., Inc	
		Inadequately Controlled		Ascorbic Acid	C		
		Chronic Obstructive		Hydrochlorothiazide			
		Pulmonary Disease		And Triamterene	C		
		Coronary Artery		Vitamin B Complex	C		
		Atherosclerosis		Vitamin E	C		
		Emotional Distress		Vitamin D			
		Headache		(Unspecified)	C		
		Heart Rate Increased		Vitamin A	C		
		Heart Rate Irregular		Adalat	C		
		Hypertension		Phenazopyridine			
		Lacunar Infarction		Hydrochloride	C		
		Transient Ischaemic					
		Attack					

Date:09/30/03ISR Number: 4197848-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Back Disorder Blood Disorder Gastric Disorder Gastrointestinal Disorder Glaucoma Hypertension Injury Osteoarthritis Skin Infection Sleep Disorder	Vioxx Coumadin	PS C	Merck & Co., Inc	ORAL

Date:09/30/03ISR Number: 4197849-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01482
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event Atrioventricular Block
Disability	Cardiac Disorder
Other	Cardiac Murmur Cataract

		Chest Pain					
		Chronic Fatigue Syndrome					
		Chronic Obstructive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Disease		Vioxx	PS		ORAL
		Depression		Vioxx	SS		ORAL
		Diplopia		Tylenol	C	Merck & Co., Inc	
		Dyspnoea		Aspirin	C		
		Emotional Distress		Lipitor	C		
1304 DAY							
		Endocarditis		Premarin	C		
		Eye Disorder		Micronase	C		
		Fatigue		Motrin	C		
		Feeling Abnormal		Levothyroxine Sodium	C		
		Fibromyalgia		Glucophage	C		
		Gastric Disorder		Naproxen	C		
		Heart Rate Irregular					
		Injury					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Nervous System Disorder					
		Pain					
		Somnolence					
		Stress					

Date:09/30/03ISR Number: 4197850-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:09/30/03ISR Number: 4197851-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Disorder					
		Chest Pain					
		Dyspnoea					
		Emotional Distress					

Heart Injury
Injury
Lung Disorder
Myocardial Infarction
Vascular Injury

Date:09/30/03ISR Number: 4197852-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time
Disability	Ageusia
Other	Anosmia
	Aortic Valve Calcification
	Arthralgia
	Arthropathy
	Atelectasis

		Bronchitis					
		Cardiomegaly					
		Coagulation Factor Viii	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Level Increased		Vioxx	PS		ORAL
161	DAY						
		Colon Adenoma		Zoloft	C		
		Condition Aggravated		Lipitor	C		
		Cough		Aspirin	C	Merck & Co., Inc	
		Deep Vein Thrombosis		Atenolol	C		
		Depression		Iron (Unspecified)	C		
		Diverticulum		Niaspan	C		
		Dyspnoea					
		Fatigue					
		Haemoglobin					
		Hypercholesterolaemia					
		Hypertension					
		Injury					
		Osteopenia					
		Osteoporosis					
		Protein S Decreased					
		Pulmonary Embolism					
		Pyrexia					
		Rectal Haemorrhage					
		Renal Disorder					
		Rhinitis					
		Skeletal Injury					
		Thrombosis					
		Weight Increased					
		White Blood Cell Count					

Date:09/30/03ISR Number: 4197853-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA00071
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Injury					
		Malaise					
		Neoplasm Malignant					
		Prescribed Overdose					

Date:09/30/03ISR Number: 4197855-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysgraphia		Vioxx	PS		ORAL		8 DAY
	Hypertension		Vioxx	SS		ORAL		
	Memory Impairment		[Therapy Unspecified]	C	Merck & Co., Inc			
	Pulmonary Oedema		Tylenol	C				
	Respiratory Disorder		Aspirin	C				
	Suicidal Ideation		Buspirone Hydrochloride	C				
			Valium	C				
			Aricept	C				
			Premarin	C				
			Fluoxetine	C				
			Prozac	C				
			Lorazepam	C				
			Metoclopramide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/03ISR Number: 4197856-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Acute Myocardial		Vioxx	PS		ORAL
	Infarction		Lotensin	C	Merck & Co., Inc	
	Coronary Artery Disease		Vasotec	C		ORAL
	Depression		Prozac	C		
	Fatigue		Ginseng	C		
			Naproxen	C		
			Accupril	C		

Date:09/30/03ISR Number: 4197862-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deep Vein Thrombosis		Vioxx	PS		ORAL
20 MON						
	Diabetes Mellitus		Premarin	C	Merck & Co., Inc	
	Dyspnoea		Lasix (Furosemide)	C		
366 DAY						
	Gout		Ultram	C		
	Hypertension		Accupril	C		
535 DAY						
	Injury					
	Oedema Peripheral					
	Phlebitis					

Date:09/30/03ISR Number: 4197863-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS		ORAL
4 MON						
	Haemorrhage		Lanoxin	C	Merck & Co., Inc	
	Palpitations		Lasix (Furosemide)	C		
			K-Dur	C		
			Propoxyphene Hydrochloride	C		

Date:09/30/03ISR Number: 4197864-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03190
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS		ORAL		37 DAY
Initial or Prolonged Disability	Dialysis Emotional Distress		[Therapy Unspecified]	C	Merck & Co., Inc	PARENTERAL		
	Myocardial Infarction Renal Failure Sleep Apnoea Syndrome							

Date:09/30/03ISR Number: 4197866-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Vioxx	PS		ORAL		6 DAY
	Gastrooesophageal Reflux Disease		[Therapy Unspecified]	C	Merck & Co., Inc			144 DAY
	Hemiparesis		Tylenol	C				
	Hypoaesthesia		Darvocet-N	C				
	Injury		Soma	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/03ISR Number: 4197867-1Report Type:Expedited (15-DaCompany Report #WAES 0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Angina Pectoris		Vioxx	PS		ORAL
	Condition Aggravated		Vicodin Tablets	C	Merck & Co., Inc	
	Depression		Xanax	C		
	Diabetes Mellitus		Elavil	C		ORAL
	Dizziness		Aspirin	C		
	Dyspepsia		Lotensin	C		
	Fibromyalgia		Captopril	C		
	Generalised Anxiety		Heparin	C		
	Disorder		Hydro-Chlor	C		
	Haematochezia		Insulin	C		
	Hypertension		Ms Contin	C		
	Injury					
	Intestinal Obstruction					
	Lupus-Like Syndrome					
	Malaise					
	Nervousness					
	Sjogren'S Syndrome					
	Thrombocytopenia					
	Tremor					
	Vomiting					

Date:09/30/03ISR Number: 4197868-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Asthenia		Vioxx	PS		ORAL
	Blood Cholesterol		[Therapy			
	Increased		Unspecified]	C	Merck & Co., Inc	
	Diabetes Mellitus		Tylenol Arthritis			
	Dialysis		Extended Relief	C		
	Duodenal Ulcer					
	Dyspnoea					
	Emotional Distress					
	Fatigue					
	Fluid Retention					
	Hypertension					
	Hypotonia					
	Impaired Work Ability					
	Monarthritis					

Myocardial Infarction
Renal Failure
Swelling

Date:09/30/03ISR Number: 4197871-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Anaemia
Other	Asthenia
	Atherosclerosis
	Blood Creatinine
	Blood Glucose
	Blood Potassium
	Blood Pressure

	Fluctuation						
	Blood Sodium						
	Blood Urea						
	Bronchitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colon Cancer							
	Deafness							
	Difficulty In Walking							
	Dyspnoea							
	Eye Haemorrhage							
	Fibromyalgia							
	Gastric Ulcer							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal							
	Haemorrhage							
	Haemodynamic Instability							
	Hypertension							
	Myocardial Infarction							
	Oedema							
	Oesophageal Disorder							
	Platelet Count							
	White Blood Cell Count							

Date:09/30/03ISR Number: 4197872-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00113
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Analgesic Or Anesthetic (Unspecified)	C	Merck & Co., Inc			
Disability	Blood Triglycerides Increased							
	Dyspepsia							
	Heart Rate Irregular							
	Injury							
	Myocardial Infarction							

Date:09/30/03ISR Number: 4197873-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00111
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cerebral Infarction	Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY					
Hospitalization -	Coma	Vioxx	SS		ORAL
1 DAY					
Initial or Prolonged	Confusional State				
Disability	Disorientation				
	Dizziness				
	Gastrooesophageal Reflux				
	Disease				
	Thyroid Disorder				

Date:09/30/03ISR Number: 4197874-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arrhythmia
Disability	Arthritis
	Cardiac Disorder
	Cardiac Murmur

		Chronic Lymphocytic Leukaemia					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal		Vioxx	PS		ORAL
		Haemorrhage		Vioxx	SS		ORAL
		Heart Injury		Vioxx	SS		ORAL
		Heart Rate Irregular		Vioxx	SS		ORAL
		Hypertension		Prempro	C	Merck & Co., Inc	
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Overdose					
		Silent Myocardial Infarction					
		Ventricular Dyskinesia					

Date:09/30/03ISR Number: 4197875-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00123
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 2 YR		Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia		Diovan	C		
Other		Asthenia					
		Cardiac Failure					
		Congestive					
		Chest Pain					
		Dysstasia					
		Emotional Distress					
		Fatigue					
		Insomnia					
		Irritable Bowel Syndrome					
		Pain					
		Pain In Extremity					
		Rheumatoid Arthritis					
		Stress					
		Thrombosis					

Date:09/30/03ISR Number: 4197876-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activities Of Daily		Vioxx	PS		ORAL	80	DAY
	Living Impaired		Prinivil	C		ORAL		
	Anxiety		Magnesium (Unspecified)	C				
	Blood Cholesterol Increased		Vitamin E [Therapy Unspecified]	C	Merck & Co., Inc			
	Breast Disorder		Calcium (Unspecified)	C				
	Cardiac Failure Congestive		Premarin	C				
	Congestive Cardiomyopathy		Ginkgo Biloba Extract	C				
	Dizziness		Levocarnitine	C				
	Gastric Ulcer		Lasix (Furosemide)	C				
	Hypertension		Lanoxin	C				
			Ascorbic Acid	C				
			Coumadin	C				
			Vitamin B (Unspecified)	C				

			Pamelor	C		

Date:09/30/03ISR Number: 4197877-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS		ORAL	401	DAY
	Anxiety		Aspirin	C	Merck & Co., Inc			
	Asthenopia		Estratab	C				
	Binocular Eye Movement		L-Thyroxin	C				
	Disorder		Hytrin	C				
	Cerebrovascular Accident		Prinivil	C		ORAL		
	Chest Pain		Ranitidine	C				
	Chronic Fatigue Syndrome							
	Depression							
	Diplopia							
	Dyspnoea							
	Endocarditis							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							
	Haematochezia							
	Heterophoria							
	Hypoacusis							
	Impaired Work Ability							
	Injury							
	Migraine With Aura							
	Panic Disorder							
	Sleep Apnoea Syndrome							
	Strabismus							
	Transient Ischaemic Attack							
	Vision Blurred							

Date:09/30/03ISR Number: 4197878-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anxiety

Disability	Barrett'S Oesophagus
	Blindness Transient
	Blindness Unilateral
	Blood Cholesterol Increased
	Blood Test Abnormal
	Cerebrovascular Accident
	Disturbance In Attention
	Drug Hypersensitivity
	Dyspepsia
	Dysphagia
	Dyspnoea
	Emotional Distress
	Eye Pain
	Fibromyalgia
	Gastrooesophageal Reflux Disease
	Haematochezia

		High Density Lipoprotein Decreased					
		Impaired Driving Ability	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Low Density Lipoprotein		Vioxx	PS		ORAL
1	YR						
		Increased		Amitriptyline			
		Memory Impairment		Hydrochloride	C	Merck & Co., Inc	
		Oesophageal Achalasia		Rocaltrol	C		
		Oesophageal Disorder		Os-Cal	C		
		Oesophageal Stenosis		Valium	C		
		Renal Failure		Synthroid	C		
		Visual Acuity Reduced		Slow-Mag	C		
		Weight Decreased		Ambien	C		
				Reglan	C		
				Reglan	C		
				Prilosec	C		
				Ditropan Xl	C		
				Potassium Chloride	C		

Date:09/30/03ISR Number: 4197879-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Disorder					
Other		Cerebrovascular Accident					
		Chest Pain					
		Fibromyalgia					
		Heart Valve Insufficiency					
		Hypertension					
		Liver Disorder					
		Nephrectomy					
		Renal Disorder					

Date:09/30/03ISR Number: 4197880-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Cholesterol		Vioxx	PS		ORAL
		Increased		Lasix (Furosemide)	C	Merck & Co., Inc	

	Blood Triglycerides	Hydrodiuril	C
	Increased		
	Cardiac Disorder		
	High Density Lipoprotein		
	Decreased		
	Hypertension		
	Myocardial Infarction		
	Oedema Peripheral		

Date:09/30/03ISR Number: 4197881-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Arrhythmia
Disability	Arthralgia
	Blood Cholesterol
	Increased
	Cardiac Discomfort
	Cardiac Failure

		Congestive					
		Cardiac Murmur					
		Cardiac Valve Disease					
		Death	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorientation		Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Hypersensitivity					
		Dyspepsia					
		Emotional Distress					
		Eye Haemorrhage					
		Glaucoma					
		Heart Rate Irregular					
		Herpes Virus Infection					
		Hypersensitivity					
		Low Density Lipoprotein					
		Increased					
		Oedema					
		Rheumatic Fever					
		Swelling					

Date:09/30/03ISR Number: 4197882-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00826
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abasia		Vioxx	PS		ORAL
15	DAY						
		Anxiety		Vioxx	SS		ORAL
7	DAY						
		Asthenia		Vioxx	SS		ORAL
		Blood Chloride Increased		Zocor	C		ORAL
		Blood Glucose Increased		Vicodin Tablets	C	Merck & Co., Inc	
		Blood Ph Increased		Beta Carotene	C		
		Chronic Fatigue Syndrome		Zyrtec	C		
		Confusional State		Flonase	C		
		Crying		Neurontin	C		
		Depression		Garlic Extract	C		
		Disturbance In Attention		Ginkgo Biloba			
		Drug Ineffective		Extract	C		
		Dyspnoea		Glyburide	C		
		Headache		Maxzide	C		
		Herpes Zoster		Atrovent	C		
		Hypertension		Lorazepam	C		
		Hyperventilation		Ocuvite	C		
		Hypoaesthesia		Naprosyn	C		
		Injury		Naprosyn	C		

	Insomnia	Temazepam C
	International Normalised	Pyridoxine C
	Ratio Decreased	Altace C
	Loss Of Libido	Verapamil C
	Nausea	Calan C
	Oedema Peripheral	Vitamin E C
	Palpitations	Vitamins
	Panic Attack	(Unspecified) C
	Personality Disorder	
	Post-Traumatic Stress	
	Disorder	
	Sinus Bradycardia	
	Sleep Apnoea Syndrome	
	Suicidal Ideation	
	Syncope	
	Treatment Noncompliance	
	Tremor	
	Vision Blurred	

Date:09/30/03ISR Number: 4197883-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03183
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:09/30/03ISR Number: 4197884-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS		ORAL	2	MON
	Angina Pectoris		Insulin	C				
	Cardiac Disorder		[Therapy					
	Cerebrovascular Accident		Unspecified]	C	Merck & Co., Inc			
	Coronary Artery Disease							
	Dyspnoea							
	Eye Swelling							
	Hepatocellular Damage							
	Liver Disorder							
	Muscle Tightness							
	Myocardial Infarction							
	Renal Disorder							
	Renal Injury							
	Thyroid Disorder							

Date:09/30/03ISR Number: 4198313-4Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00152
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chills		Vioxx	SS		ORAL		
	Dyspnoea							
	Hallucination							
	Headache							
	Oesophageal Spasm							
	Oropharyngeal Swelling							
	Sneezing							
	Swelling Face							

Swollen Tongue
Toothache

Date:09/30/03ISR Number: 4198320-1Report Type:Expedited (15-DaCompany Report #WAES 01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Other	Vioxx	PS		ORAL		
	Chest Pain		Vioxx	SS		ORAL		
	Coronary Artery Stenosis		Diovan	C				
	Gastrooesophageal Reflux Disease		Trazodone Hydrochloride	C				
	Hypertension		Azulfidine	C				
	Myocardial Infarction		Enbrel	C	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/03ISR Number: 4198323-7Report Type:Expedited (15-DaCompany Report #WAES 0307NOR00026
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Rofecoxib	PS	Merck & Co., Inc	ORAL	4	DAY
	Diarrhoea	Professional						
	Faeces Discoloured							
	Inflammatory Bowel Disease							
	Odynophagia							
	Reflux Oesophagitis							

Date:09/30/03ISR Number: 4198327-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02382
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction							
	Ventricular Fibrillation							

Date:09/30/03ISR Number: 4198330-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00009
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Bypass Operation		Vioxx [Therapy Unspecified]	PS		ORAL		
	Atherosclerosis			C	Merck & Co., Inc			
	Blood Triglycerides Increased							
	Cardiac Operation							
	Condition Aggravated							
	Gastric Disorder							
	Gastric Haemorrhage							
	Injury							

Date:09/30/03ISR Number: 4200615-XReport Type:Direct Company Report #CTU 202858
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased		Rofecoxib (Vioxx) 25 Mg Tablets	PS		ORAL	25 MG PO QD	
	Blood Urea Increased		Avapro	C				
			Allegra	C				
			Soma	C				
			Alendronate	C				
			Aciphex	C				
			Zestril	C				

Date:09/30/03ISR Number: 4202921-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Arteriosclerosis
Other	Brain Oedema
	Calcinosis
	Cardio-Respiratory Arrest
	Cardiomegaly
	Coma
	Coronary Artery

		Atherosclerosis Coronary Artery Occlusion Coronary Artery Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25							
		Feeling Hot	Health				
MG/DAILY/PO							
		Lung Disorder	Professional	Vicoprofen	C		
		Myocardial Infarction		Methocarbamol	C		
		Pulmonary Congestion					
		Pulmonary Oedema					
		Splenomegaly					
		Sudden Death					
		Ventricular Fibrillation					

Date:10/01/03ISR Number: 4199075-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA00054
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Benign Prostatic		Vioxx	PS		ORAL
Initial or Prolonged	Hyperplasia		Vioxx	SS		ORAL
Disability	Difficulty In Walking		[Therapy			
Other	Fluid Retention		Unspecified]	C	Merck & Co., Inc	
	Gout					
	Liver Function Test					
	Abnormal					
	Prescribed Overdose					
	Renal Failure					
	Therapeutic Response					
	Decreased					

Date:10/01/03ISR Number: 4199078-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00108
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Arterial Thrombosis
Other	Arthropathy
	Asthma
	Atherosclerosis

Blood Cholesterol
Increased
Blood Triglycerides
Increased
Cardiac Failure
Congestive
Cardiac Valve Disease
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Colon Cancer
Drug Hypersensitivity
Emotional Distress
Glaucoma
Gout
Hypertension
Injury
Kidney Infection
Leg Amputation
Pulmonary Hypertension

	Rectal Haemorrhage						
	Sleep Apnoea Syndrome						
	Thrombosis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic		Vioxx	PS		ORAL		
	Attack		Ibuprofen	C	Merck & Co., Inc			
	Vertigo		Insulin	C				

Date:10/01/03ISR Number: 4199084-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA02381
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS		ORAL		
Initial or Prolonged	Chills		Cannabis	C	Merck & Co., Inc			
	Depression		Oramorph	C				
	Dyspepsia		Protonix	C				
	Dysphagia							
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	Haematemesis							
	Haematochezia							
	Injury							
	Oedema Peripheral							
	Overdose							
	Pyrexia							
	Renal Pain							
	Sleep Disorder							
	Swelling							
	Vomiting							

Date:10/01/03ISR Number: 4199310-5Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00266
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	DAY
Hospitalization -	Haemorrhage							
Initial or Prolonged	Melaena							
Other								

Date:10/01/03ISR Number: 4199312-9Report Type:Expedited (15-DaCompany Report #WAES 0207FRA00018
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anuria		Rofecoxib	PS		ORAL		
Hospitalization - Initial or Prolonged	Blood Potassium Increased		Althiazide And Spironolactone	SS	Merck & Co., Inc	ORAL		
	Haemodialysis		Colchicine	SS		ORAL		
	Haemoglobin Decreased		Metformin Hydrochloride	SS		ORAL		
	Hypoglycaemia		Colchicine And Opium, Powdered And Tiemonium Methylsulfate	SS		ORAL		
	Lactic Acidosis		Cyanocobalamin	C				
	Renal Failure Acute		Ferrous Sulfate	C				
	Weight Decreased		Miglitol	C				
			Gliclazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/03ISR Number: 4199315-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA00287
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory		Vioxx	PS		ORAL		7 MON
Initial or Prolonged	Distress Syndrome		Vioxx	SS		ORAL		6 MON
Disability	Adrenal Insufficiency		Hydrocodone	C	Merck & Co., Inc			
	Blood Glucose		Prednisone	C				
	Blood Potassium							
	Blood Pressure Increased							
	Breath Sounds Decreased							
	Candidiasis							
	Cataract							
	Cerebellar Artery Thrombosis							
	Cerebral Hygroma							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Coma							
	Deep Vein Thrombosis							
	Faecal Occult Blood Positive							
	Gastritis							
	Haemorrhage Intracranial							
	Headache							
	Herpes Simplex							
	Hyperhidrosis							
	Hyperkeratosis							
	Loss Of Consciousness							
	Lung Infiltration							
	Microcytic Anaemia							
	Neck Pain							
	Neuropathy Peripheral							
	Oxygen Saturation Decreased							
	Pain In Extremity							
	Pneumonia							
	Rales							
	Respiratory Distress							
	Respiratory Rate Increased							
	Ruptured Cerebral Aneurysm							
	Sinusitis							

Subarachnoid Haemorrhage
Urinary Tract Infection

Date:10/01/03ISR Number: 4199319-1Report Type:Expedited (15-DaCompany Report #WAES 0309PRT00002
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Generalised Oedema		Vioxx	PS		ORAL	4	DAY
			Amlodipine Besylate	C	Merck & Co., Inc			

Date:10/01/03ISR Number: 4199325-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA03139
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/03ISR Number: 4199964-3Report Type:Direct Company Report #CTU 202884
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Creatinine Increased		Rofecoxib 25mg Merck	PS	Merck	ORAL	25MG DAILY ORAL	
	Blood Urea Increased							
			Irbesartan	C				
			Fexofenadine	C				
			Carisoprodol	C				
			Alendronate	C				
			Rabeprazole	C				
			Lisinopril	C				

Date:10/01/03ISR Number: 4203557-9Report Type:Expedited (15-DaCompany Report #163-20785-03040335
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Glioblastoma Multiforme Malignant Neoplasm Progression	Health Professional	Thalomid (Thalidomide) (50 Milligram, Capsules)	PS		ORAL	100 MG, GHS, ORAL	
			Vp-16 (Etoposide)	SS		ORAL	ORAL	
			Cytoxan (Cyclophosphamide)	SS		ORAL	ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	

Date:10/02/03ISR Number: 4199933-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA02594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/03ISR Number: 4199936-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA02588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Gastrointestinal Haemorrhage		Vioxx [Therapy Unspecified]	PS C	 Merck & Co., Inc	ORAL		

Date:10/02/03ISR Number: 4200244-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00844
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Colon Cancer Emotional Distress Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/03ISR Number: 4200246-1Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00170
Age:83 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization - Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Dyspepsia		Vioxx	PS		ORAL	21	DAY
Dyspnoea		Acetaminophen	C	Merck & Co., Inc			
Haematemesis		Amlodipine Besylate	C				
Loss Of Consciousness		Aspirin	C				
Malaise		Atenolol	C				
Melaena		Zocor	C				
		Furosemide	C				
		Lisinopril	C				
		Metformin	C				

Date:10/02/03ISR Number: 4200249-7Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS		ORAL		
Disability	Disturbance In Attention		Tylenol	C	Merck & Co., Inc			
	Fatigue		Tavist-D	C				
	Headache							
	Hypoaesthesia							

Date:10/02/03ISR Number: 4200257-6Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00317
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS		ORAL		
	Multi-Organ Failure		Enalapril Maleate	C	Merck & Co., Inc	ORAL		
			Folic Acid	C				
			Glyburide	C		ORAL		
			Metformin	C		ORAL		
			Methotrexate	C				

Date:10/02/03ISR Number: 4200259-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02569
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/02/03ISR Number: 4200276-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA03028
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/02/03ISR Number: 4200718-XReport Type:Direct Company Report #CTU 203031
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Abdominal Injury		Warfarin	PS		ORAL	QD ORAL	
Intervention to	Fall		Vioxx 25 Mg Merck	SS	Merck	ORAL	25 MG QD ORAL	
Prevent Permanent Impairment/Damage	Peritoneal Haematoma		Ferrous Sulfate	C				
			Clonazepam	C				
			Cefazolin	C				
			Atenolol	C				
			Paroxetine	C				
			Lisinopril	C				
			Zolpidem	C				
			Multivitamin	C				
			Calcium	C				

Date:10/02/03ISR Number: 4203900-0Report Type:Expedited (15-DaCompany Report #2003-DE-04283GD
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intervertebral Disc Degeneration	Foreign Literature	Methotrexate (Methotrexate)	PS			15 MG Q8D	
			Rofecoxib	SS			25 MG	

Date:10/03/03ISR Number: 4200820-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02014
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS		ORAL	604 DAY	
	Cardiac Disorder		Bayer Aspirin	C	Merck & Co., Inc			
	Carotid Artery Stenosis		Cyanocobalamin	C				
	Cerebrovascular Accident		Neurontin	C				
	Chest Pain		Glucotrol	C				
	Contusion		Zestril	C				
	Joint Swelling		Ultram	C				

	Pain	Zocor	C
		Mobic	C
		Niacin	C
		Actos	C
		Evista	C

Date:10/03/03ISR Number: 4200821-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00009
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Atherosclerosis		Vioxx	PS		ORAL
	Blood Triglycerides		[Therapy			
	Increased		Unspecified]	C	Merck & Co., Inc	
	Cardiac Operation					
	Gastric Disorder					
	Gastric Haemorrhage					
	Injury					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/03ISR Number: 4200825-1Report Type:Expedited (15-DaCompany Report #WAES 0305USA01532
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS			4	DAY
	Drug Exposure During		Vioxx	SS			4	DAY
	Pregnancy		Tylenol	C	Merck & Co., Inc			

Date:10/03/03ISR Number: 4200835-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA03067
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased		Vioxx	PS		ORAL		
			Glucophage	C	Merck & Co., Inc			
			Glucophage	C				

Date:10/03/03ISR Number: 4201096-2Report Type:Expedited (15-DaCompany Report #WAES 01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Prerenal Failure		Vioxx	PS		ORAL		
	Anaemia		[Therapy Unspecified]	C	Merck & Co., Inc			
	Blood Pressure Abnormal							
	Diarrhoea		[Therapy Unspecified]	C				
	Gastritis							
	Myocardial Infarction		Aspirin	C				
	Oedema		Lipitor	C				
	Oesophagitis		Pepto-Bismol	C				
	Peptic Ulcer		Vitamins (Unspecified)	C				
	Rash							
	Sinus Tachycardia		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				
	Stress							
	Torsade De Pointes							
	Upper Gastrointestinal Haemorrhage		Vasoretic	C		ORAL		
	Ventricular Arrhythmia		Neurontin	C				
			Prevacid	C				
			Inderal	C				

Date:10/03/03ISR Number: 4201099-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthroscopy		Vioxx	PS		ORAL		
	Blood Pressure Increased		Fosamax	C	Merck & Co., Inc	ORAL		
	Eye Haemorrhage		Prempro	C				
	Hypertension		Advil	C				
	Hypothyroidism		Synthroid	C				
	Injury		Claritin	C				
	Loose Body In Joint							
	Optic Nerve Injury							
	Thyroid Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/03ISR Number: 4201101-3Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00003
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS		ORAL	18 DAY	
Other	Hypocoagulable State		Acenocoumarol	SS	Merck & Co., Inc	ORAL	6 YR	
			Acenocoumarol	SS		ORAL		
			Desogestrel	C		ORAL	2 YR	
			Fluticasone Propionate And Salmeterol Xinafoate	C		RESPIRATORY (INHALATION)	16 MON	
			Homeopathic Medications (Unspecified)	C		ORAL		

Date:10/03/03ISR Number: 4201103-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA03247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction Thrombocytopenia		Vioxx	PS		ORAL		
			Celebrex	SS	Merck & Co., Inc			

Date:10/03/03ISR Number: 4201108-6Report Type:Expedited (15-DaCompany Report #WAES 0309NOR00021
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation		Vioxx	PS		ORAL	2 WK	
			Aspirin And Magnesium Oxide	SS	Merck & Co., Inc			
			Furosemide Sodium	C				
			Isosorbide Mononitrate	C				

			Nifedipine	C		

Date:10/03/03ISR Number: 4201111-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 55 DAY	Arthralgia		Vioxx	PS		ORAL
Initial or Prolonged Disability	Blood Triglycerides Increased		Estrace	C	Merck & Co., Inc	
			Zocor	C		ORAL
	Cerebrovascular Accident		Prilosec	C		
	Drug Hypersensitivity					
	Dyspepsia					
	Dyspnoea					
	Emotional Distress					
	Gout					
	Hypercholesterolaemia					
	Low Density Lipoprotein Increased					
	Pain In Extremity					
	Peptic Ulcer					
	Transient Ischaemic Attack					
	Vulvovaginal Dryness					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/03ISR Number: 4201114-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA00072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Blood Pressure Increased Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201115-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA01221
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS		ORAL		
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Haemorrhage Gastric Mucosal Lesion		Aspirin	SS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201122-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA00123
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201123-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA00128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201124-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA00108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201125-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA00073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201127-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA00105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/03/03ISR Number: 4201128-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA00074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201129-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA00124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Dyspnoea Epistaxis Oropharyngeal Swelling Swelling Face Swollen Tongue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201130-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA00174
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colonic Haemorrhage Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/03/03ISR Number: 4201134-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA00135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201819-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02090
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Murmur		Vioxx	PS		ORAL
Hospitalization -	Cardiac Valve Disease		[Therapy			
Initial or Prolonged	Cerebrovascular Accident		Unspecified]	C	Merck & Co., Inc	
	Death		Aspirin	C		
	Gastrointestinal		Digoxin	C		
	Haemorrhage		Lasix (Furosemide)	C		
	Injury		Lopressor	C		

Date:10/06/03ISR Number: 4201825-8Report Type:Expedited (15-DaCompany Report #WAES 01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Distension
	Arthralgia
	Back Disorder
	Balance Disorder
	Blood Pressure Abnormal
	Cardiovascular Disorder
	Decreased Appetite
	Dizziness

		Dyspepsia					
		Injury					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mood Altered		Vioxx	PS		ORAL
		Oedema		Tylenol	C	Merck & Co., Inc	
		Pain		Ascorbic Acid	C		
		Renal Failure		Aspirin	C		
				Atenolol	C		
				Lotensin	C		
				Colchicine	C		
				Coenzyme Q10	C		
				Vitamin E	C		
				Zocor	C		
				Glucosamine	C		
				Aleve	C		
				Nonsteroidal			
				Anti-Inflammatory			
				Drug (Unspecified)	C		
				Omega-3	C		
				Zantac	C		

Date:10/06/03ISR Number: 4201826-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00881
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain					
		Injury					
		Nausea					

Date:10/06/03ISR Number: 4201828-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS		ORAL
161 DAY							
Other		Condition Aggravated		Herbs (Unspecified)	C	Merck & Co., Inc	
840 DAY							
		Dizziness		Prilosec	C		
		Dyspepsia					

Emotional Distress
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Injury
Oesophageal Disorder
Osteoarthritis
Pain In Extremity
Personality Disorder
Transient Ischaemic
Attack

Date:10/06/03ISR Number: 4201830-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00811
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/03ISR Number: 4201832-5Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00078
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Terbinafine	C				

Date:10/06/03ISR Number: 4201835-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA00126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201836-2Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00033
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ulcerative		Vioxx	PS		ORAL		
	Vomiting		Chondroitin Sulfate Sodium	C	Merck & Co., Inc	ORAL		
			Fluvastatin Sodium	C		ORAL		
			Irbesartan	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/06/03ISR Number: 4201837-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA01277
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/06/03ISR Number: 4201843-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA00099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201846-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA00089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201848-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA00050
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/03ISR Number: 4201850-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA00086
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Convulsion							
	Renal Failure							

Date:10/06/03ISR Number: 4201854-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA00147
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201857-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02422
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Chloride		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Vioxx	SS		ORAL		
Other	Diabetes Mellitus		Vitamins					
	Insulin-Dependent		(Unspecified)	C				
	Haematocrit							
	Haemoglobin							

Date:10/06/03ISR Number: 4201860-XReport Type:Expedited (15-DaCompany Report #WAES 01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS		ORAL	178 DAY	
	Cough		[Therapy					
	Dizziness		Unspecified]	C	Merck & Co., Inc			
	Dysuria		Albuterol	C				
RESPIRATORY								

	Encephalomalacia		
(INHALATION)			
	Epistaxis	Albuterol	C	ORAL
	Erectile Dysfunction	Aspirin	C	
	Gastrointestinal	Atenolol	C	
	Haemorrhage	Mavik	C	ORAL
	Haemorrhoids	Mavik	C	ORAL
	Headache	Palgic D	C	ORAL
	Ileus	Celebrex	C	
	Nausea	Hydrodiuril	C	ORAL
	Proctalgia	Atrovent	C	
	Prostate Cancer			
	Rectal Haemorrhage			
	Rectal Polyp			
	Sinusitis			
	Vomiting			
	Wheezing			

Date:10/06/03ISR Number: 4201862-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA01513
Age:88 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum							
	Duodenal Perforation							
	Respiratory Disorder							

Date:10/06/03ISR Number: 4201918-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA02996
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Back Injury							
	Chest Injury							
	Depression							
	Heart Rate Irregular							
	Hypertension							
	Limb Injury							

Date:10/06/03ISR Number: 4201921-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA03317
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4201923-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA02995
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS		ORAL		
	Bipolar Disorder		Tylenol	C	Merck & Co., Inc			
	Chest Pain		Ultracet	C				
	Delusional Disorder,		Lipitor	C			55	DAY
	Persecutory Type		Celebrex	C				
	Depression		Welchol	C				

		Disturbance In Attention			Cyclobenzaprine		
		Impaired Driving Ability			Hydrochloride	C	
		Injury			Tricor	C	
		Insomnia			Hydrocodone		
		Nervous System Disorder			Hydrochloride	C	
		Panic Attack			Motrin	C	
19	DAY						
		Personality Disorder			Naproxen	C	
19	DAY						
		Prescribed Overdose					
		Stomach Discomfort					

Date:10/06/03ISR Number: 4202246-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA01047
Age:44 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Gastrointestinal Disorder		Vioxx	PS		ORAL
		Rectal Haemorrhage		Celebrex	C	Merck & Co., Inc	

Date:10/06/03ISR Number: 4202247-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatine		Vioxx	PS		ORAL
Hospitalization -	Phosphokinase Increased		Celebrex	SS		
2 WK						
Initial or Prolonged	Contusion		Vioxx	SS		ORAL
Disability	Deep Vein Thrombosis		Vioxx	SS		ORAL
Other	Dehydration		[Therapy			
	Drug Hypersensitivity		Unspecified]	C	Merck & Co., Inc	
	Fasciitis		Creatine	C		
	Gastritis		Advil	C		
	Gastroenteritis		Solu-Medrol	C		
	Glomerulonephritis Focal					
	Glomerulonephritis					
	Membranous					
	Haematemesis					
	Hepatomegaly					
	Hypertension					
	Impaired Healing					
	Injury					
	Joint Sprain					
	Laceration					
	Lobar Pneumonia					
	Nasopharyngitis					
	Nephritis Allergic					
	Nephritis Interstitial					
	Nephrosclerosis					
	Nephrotic Syndrome					
	Oesophagitis					
	Peritoneal Dialysis					
	Pulmonary Embolism					
	Renal Failure Chronic					
	Renal Interstitial					
	Fibrosis					
	Renal Transplant					
	Swelling					
	Tendon Injury					
	Tendonitis					
	Treatment Noncompliance					

Date:10/06/03ISR Number: 4202250-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00901
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS		ORAL		5 WK
Initial or Prolonged	Haemorrhage		Aspirin	C	Merck & Co., Inc			
	Fall		Cardizem Cd	C				
	Helicobacter Infection		Prozac	C				
			Lopid	C				

Date:10/06/03ISR Number: 4202251-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA00144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Cold							
	Flushing							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/03ISR Number: 4202255-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA00227
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4202256-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA00338
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/03ISR Number: 4205184-6Report Type:Expedited (15-DaCompany Report #2003-09-2044
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis Infected Cyst	Foreign Health Professional Other	Diprosalic (Betamethasone Dipropionate/Salicylic Aci Topicals	PS			1 DOSE BID	
			Vioxx (Rofecoxib) Tablets	SS		ORAL	12.5 MG BID	ORAL
			Celebrex (Celecoxib) Capsules	SS		ORAL	200 MG BID	ORAL

Date:10/07/03ISR Number: 4202491-8Report Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Neoplasm		Vioxx	PS		ORAL		

Initial or Prolonged	Bacteria Urine Identified	Aspirin	C	Merck & Co., Inc
	Deep Vein Thrombosis	Lipitor	C	
	Gastroenteritis	Motrin	C	
	Haematemesis			
	Headache			
	Iliac Vein Occlusion			
	Lipoma			
	Productive Cough			
	Urinary Tract Infection			
	Venous Stenosis			
	Wheezing			

Date:10/07/03ISR Number: 4202492-XReport Type:Expedited (15-DaCompany Report #WAES 0309DEU00024
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Malignant Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/03ISR Number: 4202493-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA02450
Age:90 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Unstable		Vioxx	PS		ORAL	5	DAY
	Dyspnoea		Aspirin	C	Merck & Co., Inc			
			Lipitor	C		ORAL		
			Cardura	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Toprol Xl Tablets	C		ORAL		
			Nitropatch	C				

Date:10/07/03ISR Number: 4202494-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA00201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal Ulcer							
	Haemorrhage							
	Intestinal Perforation							
	Joint Swelling							

Date:10/07/03ISR Number: 4202495-5Report Type:Expedited (15-DaCompany Report #WAES 0208USA01623
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS		ORAL	5	DAY
Hospitalization -			Lipitor	C	Merck & Co., Inc	ORAL		
Initial or Prolonged			Cardura	C		ORAL		
Other			Enalapril Maleate	C		ORAL		
			Toprol Xl Tablets	C		ORAL		
			Nitropatch	C				

Date:10/07/03ISR Number: 4202809-6Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00003
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS		ORAL	27	DAY
			Hydroflumethiazide And Spironolactone	C	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Perindopril	C		ORAL		

Date:10/07/03ISR Number: 4202812-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA00080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/03ISR Number: 4203898-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA03341
Age: Gender:Female I/FU:I

Outcome	PT
Death	Injury Pulmonary Embolism

Thrombosis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/03ISR Number: 4203899-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA00104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion							
	Cystitis							

Date:10/08/03ISR Number: 4203901-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA03342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Atrioventricular Block							
	Blood Creatinine Decreased							
	Cerebral Haemorrhage							
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Ejection Fraction Decreased							
	Haemodialysis							
	Haemodynamic Instability							
	Heart Injury							
	Hypertension							
	Mitral Valve Incompetence							
	Oedema							
	Post Procedural Complication							
	Renal Failure							
	Respiratory Failure							
	Sleep Apnoea Syndrome							
	Transient Ischaemic Attack							
	Tricuspid Valve							

Incompetence
Ventricle Rupture

Date:10/08/03ISR Number: 4203904-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA00506
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/03ISR Number: 4203905-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA00369
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/03ISR Number: 4204383-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA00070
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/03ISR Number: 4204384-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA01526
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS		ORAL		
Initial or Prolonged	Congestive		Allopurinol	C	Merck & Co., Inc	ORAL		
Other	Renal Failure Acute		Aspirin	C		ORAL		
			Coreg	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Cozaar	C		ORAL		

Date:10/08/03ISR Number: 4204385-0Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00321
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cutaneous Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema Peripheral		Vioxx	SS		ORAL		
	Renal Impairment							

Date:10/08/03ISR Number: 4204388-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA01221
Age:92 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS		ORAL		
Life-Threatening	Gastric Haemorrhage		Aspirin	SS		ORAL		
Hospitalization -	Gastric Mucosal Lesion		Tylenol With Codeine					
Initial or Prolonged	Pain		#3	C	Merck & Co., Inc			
			Celebrex	C				

Date:10/08/03ISR Number: 4204394-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA00351
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged								
Other								

Date:10/08/03ISR Number: 4204396-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA03327
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Escherichia Urinary Tract		Vioxx	PS		ORAL	1040	DAY
Initial or Prolonged	Infection		Ultracet	C	Merck & Co., Inc	ORAL		
Other	Hypertension		Nortriptyline	C		ORAL		
	Hyponatraemia		Omeprazole	C		ORAL		
	Renal Failure Acute							
	Renal Tubular Necrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/03ISR Number: 4208085-2Report Type:Direct Company Report #CTU 203432
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dehydration Dyspnoea Oedema Peripheral Swelling		Vioxx 25 Mg Tab Merck Effexor Xr Omeprazole	PS C C	Merck	25MG BID		

Date:10/08/03ISR Number: 4208116-XReport Type:Direct Company Report #CTU 203423
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Scotoma Visual Disturbance		Rofecoxib Tablets (Vioxx, Merck) Acetaminophen Baclofen Levothyroxine Multiple Vitamin Interferon Beta Omeprazole Atenolol	PS C C C C C C C	Merck	ORAL	25 MG PO BID	

Date:10/09/03ISR Number: 4205329-8Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00041
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Intestinal Haemorrhage Mallory-Weiss Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/09/03ISR Number: 4205331-6Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00013
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased Fibrin D Dimer Increased Haematoma Haemoglobin Decreased Leg Amputation Peripheral Artery Aneurysm Peripheral Ischaemia Platelet Count Decreased Prothrombin Time Prolonged		Vioxx Aspirin Lysine Nitroglycerin	PS C C	Merck & Co., Inc	ORAL ORAL TOPICAL

Date:10/09/03ISR Number: 4205336-5Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00069
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Hypoglycaemic Coma		Vioxx Gliclazide Acebutolol Hydrochloride Acetaminophen Althiazide And	PS SS C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL	12	DAY

			Spironolactone	C		ORAL
			Timoptic	C		
OPHTHALMIC						
			Trimetazidine Hydrochloride	C		ORAL
			Zopiclone	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Perindopril	C		ORAL
			Paroxetine Hydrochloride	C		ORAL
			Clonazepam	C		ORAL
			Fenofibrate	C		ORAL

Date:10/09/03ISR Number: 4208117-1Report Type:Expedited (15-DaCompany Report #WAES 0205CHE00003
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Foreign	Tab Vioxx					
Other	Hypocoagulable State	Other	(Rofecoxib)	PS		ORAL	75 MG/DAILY	18 DAY
	International Normalised		Tab Acenocoumarol	SS		ORAL	SEE IMAGE	6 YR
	Ratio Increased		Desogestrel	C				
			Fluticasone Propionate (+) Salmetrol Xi	C				
			Homeopathic Medications (Unspecified)	C				

Date:10/10/03ISR Number: 4205931-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA00884
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL	59 DAY	
Hospitalization - Initial or Prolonged Disability			Hyzaar	C	Merck & Co., Inc	ORAL		

Date:10/10/03ISR Number: 4205935-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02338
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx [Therapy	PS		ORAL		
Other	Gastrointestinal Ulcer		Unspecified]	C	Merck & Co., Inc			

Date:10/10/03ISR Number: 4205939-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA00936
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/03ISR Number: 4206280-XReport Type:Expedited (15-DaCompany Report #WAES 0308ZAF00024
Age:87 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Haemorrhage		Vioxx	PS		ORAL		
	Haematemesis		Captopril	C	Merck & Co., Inc	ORAL		
	Haematochezia		Furosemide	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Potassium (Unspecified)	C		ORAL		

Date:10/10/03ISR Number: 4206291-4Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00184
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS		ORAL		
			Aspirin	SS				
			Acetaminophen And Codeine Phosphate	C	Merck & Co., Inc			
			Bendroflumethiazide	C				
			Fluoxetine	C				
			Prochlorperazine Maleate	C				
			Nicorandil	C				
			Doxazosin Mesylate	C				
			Fosamax	C		ORAL		

Date:10/10/03ISR Number: 4206294-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01073
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/10/03ISR Number: 4208993-2Report Type:Direct Company Report #CTU 203615
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Arterial Thrombosis Limb		Vioxx 25 Mg	PS		ORAL
25 MG DAILY						
	Disseminated					
ORAL						
	Intravascular Coagulation					
	Gastric Ulcer Perforation					
	Peritonitis					
	Upper Gastrointestinal					
	Haemorrhage					

Date:10/10/03ISR Number: 4208997-XReport Type:Direct Company Report #CTU 203602
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia		Vioxx	PS		ORAL
25MG EVERY						
Initial or Prolonged	Chest Pain					
NIGHT ORAL						
	Cold Sweat		Lipitor	C		
	Nausea		Aspirin	C		
			Vitamin E	C		
			Diltiazem Er	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/03ISR Number: 4207376-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01043
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/03ISR Number: 4207385-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA02143
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Balance Disorder		Vioxx	SS		ORAL		
	Haemorrhage Subcutaneous		Thyroid	C				
	Muscle Spasms							
	Pain							
	Somnolence							

Date:10/13/03ISR Number: 4207386-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA01705
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS		ORAL	5	DAY
	Congestive		Vicodin Tablets	C	Merck & Co., Inc			
			Allopurinol	C				
			Tricor	C				

Date:10/13/03ISR Number: 4207391-5Report Type:Expedited (15-DaCompany Report #WAES 0310NOR00005
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS		ORAL	2	YR
	Haematemesis		Citalopram					
	Melaena		Hydrobromide	SS	Merck & Co., Inc	ORAL		

Date:10/13/03ISR Number: 4207392-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02159
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL		
Hospitalization -	Congestive		Vioxx	SS		ORAL		
5 DAY								
Initial or Prolonged	Pulmonary Oedema		Tylenol	C	Merck & Co., Inc			
Other			Ultracet	C				
			Flexeril	C		ORAL		

Date:10/13/03ISR Number: 4207483-0Report Type:Expedited (15-DaCompany Report #PHHO2003FI12424
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Esidrex	PS	Novartis Sector:			
Initial or Prolonged	Increased				Pharma	ORAL		
25 mg, QD,								
	Dizziness							
Level 4								
	Drug Interaction		Valsartan +/-Hctz Vs					
	Knee Operation		Amlodipine +/-Hctz	SS				
Level 1								
	Post Procedural Pain		Valsartan +/-Hctz Vs					
	Vertigo		Amlodipine +/-Hctz	SS				
Level 4								
	Vomiting		Vioxx	SS		ORAL		
50 mg								

				Ibuprofen	SS		ORAL 1000mg

Date:10/13/03ISR Number: 4207542-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA00323
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dehydration		Vioxx	PS		ORAL	22 DAY	
Other	Dyspnoea		Prilosec	C	Merck & Co., Inc	ORAL		
	Generalised Oedema		Effexor Xr	C		ORAL		
	Hypertension							
	Orthopnoea							
	Paraesthesia							

Date:10/14/03ISR Number: 4207893-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA01230
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Vioxx	PS		ORAL		
			[Therapy Unspecified]	C	Merck & Co., Inc			
			Furosemide	C				

Date:10/14/03ISR Number: 4207896-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:10/14/03ISR Number: 4208281-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02583
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Fosamax Vioxx	PS SS	Merck & Co., Inc	ORAL ORAL

Date:10/14/03ISR Number: 4208288-7Report Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Neoplasm Deep Vein Thrombosis Gastroenteritis Haematemesis Headache Iliac Vein Occlusion Productive Cough Venous Stenosis		Vioxx Aspirin Lipitor Motrin	PS C C C	Merck & Co., Inc	ORAL

Date:10/14/03ISR Number: 4208295-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA00950
Age:61 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Gallbladder Pain Headache

	Hypersensitivity						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Singulair	PS		ORAL		
			Vioxx	SS		ORAL		
			Synthroid	C	Merck & Co., Inc	ORAL		

Date:10/14/03ISR Number: 4209873-9Report Type:Direct Company Report #CTU 203823
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Rofecoxib	PS				

Date:10/14/03ISR Number: 4211652-3Report Type:Periodic Company Report #2002068672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block	Health Professional Company Representative	Neurontin (Gabapentin)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:10/15/03ISR Number: 4208781-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/03ISR Number: 4208784-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Pain

Date:10/15/03ISR Number: 4209186-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/03ISR Number: 4211223-9Report Type:Expedited (15-DaCompany Report #2003181190US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction Thrombocytopenia	Consumer	Celebrex (Celecoxib) Capsule Rofecoxib (Rofecoxib)	PS SS				

Date:10/16/03ISR Number: 4209898-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01083
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Operative Haemorrhage							
Other								

Date:10/16/03ISR Number: 4209899-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:10/16/03ISR Number: 4209905-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01242
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/03ISR Number: 4209906-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA01431
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Abuser		Vioxx	PS	Merck	ORAL		
			Cocaine	SS				
			Toprol Xl Tablets	C				

Date:10/16/03ISR Number: 4209910-1Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00038
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lichen Planus		Vioxx	PS		ORAL		44 DAY
Initial or Prolonged			Dihydroergocristine Mesylate And Raubasine	C	Merck & Co., Inc	ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Tetrazepam	C		ORAL		
			Melilot	C		ORAL		

Date:10/16/03ISR Number: 4209913-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA00936
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombotic Stroke		Vioxx	PS		ORAL		
			Albuterol	C	Merck & Co., Inc			
RESPIRATORY								
(INHALATION)								
			Elavil	C		ORAL		
			Atenolol	C				
			Tricor	C				
			Synthroid	C				
			Nitro-Bid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/03ISR Number: 4209917-4Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00138
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY

Date:10/16/03ISR Number: 4209918-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/03ISR Number: 4209928-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01299
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/03ISR Number: 4209931-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/03ISR Number: 4209932-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01353
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Chest Pain
Decreased Appetite
Diarrhoea
Dizziness
Dyspnoea
Lymphadenopathy
Nausea
Oropharyngeal Swelling
Rash
Renal Pain
Urinary Retention

Date:10/16/03ISR Number: 4209940-XReport Type:Expedited (15-DaCompany Report #WAES 0212GBR00157
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS		ORAL	7 DAY	
	Perforation		Dexamethasone	SS		ORAL	4 DAY	
			[Therapy Unspecified]	C	Merck & Co., Inc			
			Digoxin	C		ORAL		
			Gabapentin	C		ORAL	6 DAY	
			Heparinoid And Salicylic Acid	C		TOPICAL		8 DAY

Warfarin	C		ORAL
Lansoprazole	C		ORAL
Oxycodone	C		ORAL
Paroxetine	C		ORAL
Propranolol	C		ORAL

Date:10/16/03ISR Number: 4210647-3Report Type:Direct Company Report #CTU 203967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Haemorrhage		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG QD ORAL	
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							

Date:10/16/03ISR Number: 4211746-2Report Type:Expedited (15-DaCompany Report #PERI00203002910
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Renal Failure Acute	Foreign Health Professional Other	Coversyl (Perindopril)	PS		ORAL	2 MG QD PO	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
			Lasix (Furosemide)	SS		ORAL	80 MG DAILY	
			Humalog (Insulin Lispro)	C			PO	
			Imdur (Isosorbide Mononitrate)	C				
			Lanoxin (Digoxin)	C				
			Lipitor (Atorvastatin)	C				
			Losec (Omeprazole)	C				
			Marevan (Warfarin Sodium)	C				
			Neurontin (Gabapentin)	C				
			Panafcortelone					

			(Prednisolone)	C		

Date:10/16/03ISR Number: 4213077-3Report Type:Expedited (15-DaCompany Report #01040103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 MON	Anorexia	Literature	Enbrel	PS		
Initial or Prolonged INTRAVENOUS IV	Cellulitis	Health	Infliximab	SS		
Other 40 MG	Citrobacter Infection	Professional	Prednisone	SS		
	Culture Positive		Leflunomide	SS		
	Hypoaesthesia		Methotrexate	SS		
	Necrosis		Prednisone	SS		
	Paraesthesia		Oxycodone	C		
	Psoriatic Arthropathy		Rofecoxib	C		
	Renal Failure Acute		Amoxicillin			
	Skin Ulcer		W/Potassium			
	Sporotrichosis		Clavulanate	C		
	Weight Decreased		Ibuprofen	C		
			Sulfasalazine	C		

Date:10/16/03ISR Number: 4213126-2Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00321
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein Cutaneous Vasculitis Oedema Peripheral Pain Petechiae Red Blood Cell Sedimentation Rate Increased Renal Impairment	Foreign Literature Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	12.5 MG/DAILY	

Date:10/16/03ISR Number: 4213305-4Report Type:Expedited (15-DaCompany Report #2003-10-0325
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Suicide Attempt Vomiting	Foreign Health Professional	Lisino (Loratadine) Tablets	PS		ORAL	30 MG QD ORAL	
			Paracetamol Tablets	SS		ORAL	10 G QD ORAL	
			Ambroxoxy(Ambroxol Hcl/Doxycycline)	SS		ORAL	10 CAPS, QD	ORAL
			Vioxx (Rofecoxib) Tablets	SS		ORAL	250 MG QD	ORAL
			Acetylsalicylic Acid Tablets	SS		ORAL	3 G QD ORAL	

Date:10/16/03ISR Number: 4213369-8Report Type:Expedited (15-DaCompany Report #WAES 01010328
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Actinic Keratosis
	Alopecia
	Amnesia
	Anaemia
	Anxiety
	Asthenia
	Back Pain
	Cataract
	Cerebrovascular Accident
	Convulsion
	Cough
	Depression
	Dermatitis
	Disease Progression
	Diverticulitis
	Diverticulum Intestinal
	Drug Eruption
	Drug Hypersensitivity
	Drug Toxicity
	Gait Disturbance
	Gastritis
	Gastrooesophageal Reflux Disease
	Gastrooesophagitis
	Headache

		Hiatus Hernia					
		Hyperhidrosis					
		Hypertensive Crisis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Swelling	Consumer	Tab Vioxx	PS		ORAL
DAILY/PO							
		Laryngeal Infiltration	Health	Procrit	SS		
		Laryngitis	Professional	Carafate	SS		
		Malaise	Company	Carbatrol	C		
		Medication Error	Representative	Catapres	C		
		Muscle Spasms		Cozaar	C		
		Nausea		Glucotrol	C		
		Neck Pain		Hyzaar	C		
		Neuropathy		Neurontin	C		
		Oedema Peripheral		Premarin	C		
		Post Procedural		Toprol Xl T	C		
		Haemorrhage					
		Psoriasis					
		Pulmonary Hypertension					
		Rash Macular					
		Rash Morbilliform					
		Renovascular Hypertension					
		Sciatica					
		Somnolence					
		Thinking Abnormal					
		Tremor					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					

Date:10/17/03ISR Number: 4210713-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01378M
Age:31 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Lactation Disorder		Vioxx	PS		ORAL
		Suppressed Lactation		Vicodin Tablets	C	Merck & Co., Inc	

Date:10/17/03ISR Number: 4210714-4Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS		ORAL	3	DAY
	Diabetes Mellitus		Omeprazole	SS	Merck & Co., Inc		3	DAY
	Diarrhoea							
	Dyspepsia							
	Gastric Disorder							
	Renal Failure Chronic							

Date:10/17/03ISR Number: 4210717-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01378B1
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure Via Breast		Vioxx	PS				
	Milk		Vicodin Tablets	C	Merck & Co., Inc			
	Suppressed Lactation							

Date:10/17/03ISR Number: 4210723-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01574
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Convulsion Nasal Oedema Oedema Peripheral Pain In Extremity Pruritus Renal Pain Visual Disturbance Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/17/03ISR Number: 4210955-6Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Eruption		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Skin Ulcer		Vioxx	SS		ORAL	12	DAY
			Tramadol Hydrochloride	C		ORAL		

Date:10/17/03ISR Number: 4210956-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01534
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastritis Erosive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	134	DAY
	Iron Deficiency Anaemia Upper Gastrointestinal Haemorrhage							

Date:10/17/03ISR Number: 4210957-XReport Type:Expedited (15-DaCompany Report #WAES 0310DEU00101
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/17/03ISR Number: 4210959-3Report Type:Expedited (15-DaCompany Report #WAES 0310CHE00016
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine	Health Professional	Vioxx	PS		ORAL	8	DAY
	Increased Blood Pressure Decreased		Carbamazepine	SS	Merck & Co., Inc	ORAL		
	Drug Interaction		Lithium Carbonate	SS		ORAL		
	Drug Level Increased		Mirtazapine	C		ORAL		
	Electrocardiogram Abnormal		Pipamperone Hydrochloride	C		ORAL		
	Headache		Zopiclone	C		ORAL		
	Malaise							
	Sinus Bradycardia							
	Tremor							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/17/03ISR Number: 4210965-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01483
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea							
	Loss Of Consciousness							
	Myocardial Infarction							

Date:10/17/03ISR Number: 4211200-8Report Type:Direct Company Report #CTU 204048
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Discomfort		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG QD ORAL	
	Dyspepsia							
	Oedema Peripheral							

Date:10/20/03ISR Number: 4212044-3Report Type:Expedited (15-DaCompany Report #PHBS2003CH11264
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Tegretol Cr	PS	Novartis Sector: Pharma	ORAL	400 mg/day	
	Drug Interaction		Priadel	SS			UNKNOWN	400 mg/day
	Drug Level Increased		Vioxx	SS			UNKNOWN	50 mg/day 11520MIN
	Electrocardiogram T Wave Inversion		Dipiperon	SS			UNKNOWN	60 mg/day
			Mirtazapine	C			UNKNOWN	
	Headache		Imovane	C			UNKNOWN	
	Hypotension							
	Malaise							
	Sinus Bradycardia							
	Tremor							

Vomiting

Date:10/20/03ISR Number: 4212855-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA00950
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gallbladder Pain		Singulair	PS		ORAL		
	Headache		Vioxx	SS		ORAL		
	Hypersensitivity		Synthroid	C	Merck & Co., Inc	ORAL		

Date:10/20/03ISR Number: 4212864-5Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00122
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS		ORAL		
2 DAY								
Initial or Prolonged	Arrhythmia		Eucalyptol	C	Merck & Co., Inc	ORAL		

Date:10/20/03ISR Number: 4215036-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01486
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/03ISR Number: 4215046-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/03ISR Number: 4215048-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/03ISR Number: 4215049-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA01012
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS		ORAL		
Hospitalization -	Blood Creatinine		Vioxx	SS		ORAL		
4 YR								
Initial or Prolonged	Blood Glucose		Aspirin	C	Merck & Co., Inc			
	Blood Urea		Lanoxin	C		ORAL		
	Cardiomegaly		Premarin	C		ORAL		
	Cold Sweat		Lasix (Furosemide					
	Constipation		Sodium)	C		ORAL		
	Decubitus Ulcer		Iron (Unspecified)	C				
	Diarrhoea		Lisinopril	C		ORAL		
	Dizziness							
	Ecchymosis							
	Fall							
	Gastric Ulcer							
	Gastritis Atrophic							
	Gastritis Erosive							
	Gastrointestinal							
	Haemorrhage							
	Gravitational Oedema							
	Haematemesis							
	Heart Rate Irregular							
	Hypotension							
	Hypothermia							

Iron Deficiency Anaemia
Melaena
Pleural Effusion
Respiratory Rate
Increased
Rotator Cuff Syndrome
Urinary Tract Infection
Vomiting

Date:10/20/03ISR Number: 4215077-6Report Type:Expedited (15-DaCompany Report #PHRM2003FR02708
Age:92 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cyanosis
	Haematoma
	Leg Amputation
	Oedema
	Pain In Extremity
	Peripheral Artery Aneurysm

Peripheral Coldness
Pulse Absent

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nitriderm Tts	PS	Novartis Sector: Pharma	TRANSDERMAL		
	Kardegic	SS		ORAL		
	Vioxx	SS		ORAL		

Date:10/21/03ISR Number: 4213409-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/03ISR Number: 4213412-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/03ISR Number: 4213414-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/03ISR Number: 4213415-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/21/03ISR Number: 4215080-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01673
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Halo Vision		Vioxx	PS		ORAL
	Scotoma		Acetaminophen	C	Merck & Co., Inc	ORAL
			Atenolol	C		ORAL
			Baclofen	C		ORAL
			Vitamins (Unspecified)	C		ORAL
			Interferon Beta	C		
INTRAMUSCULAR						
			Levothyroxine Sodium	C		ORAL
			Omeprazole	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/03ISR Number: 4215081-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01225
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS		ORAL		
	Rectal Haemorrhage		Lipitor	C	Merck & Co., Inc	ORAL		
			Bumex	C		ORAL		
			Glucotrol Xl	C		ORAL		
			Diovan Hct	C		ORAL		
			Isordil	C				
			Ativan	C		ORAL		
			Nitroglycerin	C				

Date:10/21/03ISR Number: 4215083-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01834
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/03ISR Number: 4215165-4Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00028
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:10/21/03ISR Number: 4215172-1Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00030
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Renal Impairment							

Date:10/21/03ISR Number: 4215174-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01764
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Limb Discomfort		Vitamins (Unspecified)	C				

Date:10/21/03ISR Number: 4215175-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:10/21/03ISR Number: 4215177-0Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00041
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 14 DAY	Cellulitis		Vioxx	PS		ORAL		
Initial or Prolonged	Infection		Betamethasone Dipropionate And Salicylic Acid	SS	Merck & Co., Inc			

			Celecoxib	SS		ORAL	11 DAY

Date:10/21/03ISR Number: 4215181-2Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma Hepatic		Vioxx	PS		ORAL		
Hospitalization -	Drug Toxicity		Acenocoumarol	C	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Acetaminophen	C		ORAL		
	Haemodialysis		Amiodarone					
	Hepatic Cirrhosis		Hydrochloride	C		ORAL		
	Hepatic Necrosis		Ascorbic Acid And					
	Hepatitis		Vitamin B					
	Hepatitis B		(Unspecified)	C		ORAL		
	Hepatitis Fulminant		Spironolactone	C		ORAL		
	Hypoglycaemia		Tramadol					
	Psychomotor Retardation		Hydrochloride	C		ORAL		
	Renal Impairment		Thiamine					
	Somnolence		Hydrochloride	C		ORAL		
	Weight Increased		Furosemide	C		ORAL		
			Lactulose	C		ORAL		
			Lorazepam	C		ORAL		
			Potassium Chloride	C		ORAL		

Date:10/21/03ISR Number: 4215186-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01749
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS		ORAL		
Initial or Prolonged	Adverse Event		Celebrex	SS	Merck & Co., Inc			
Disability	Arrhythmia		Vioxx	SS		ORAL		
	Blood Potassium Decreased		Clonidine	C				
	Blood Pressure Increased		Plavix	C				
	Bursitis		Neurontin	C				
	Cerebrovascular Accident		Miacalcin	C				
	Electrocardiogram T Wave		Neurontin	C				
	Inversion		Neurontin	C				
	Fall		Motrin	C				
	Large Intestinal Ulcer		Skelaxin	C				
	Haemorrhage		Skelaxin	C				

Myocardial Ischaemia
Oedema
Oesophageal Ulcer
Haemorrhage
Rotator Cuff Syndrome
Skeletal Injury
Supraventricular
Extrasystoles

Date:10/21/03ISR Number: 4215870-XReport Type:Expedited (15-DaCompany Report #2002061392
Age:31 YR Gender:Female I/FU:F

Outcome PT
Other Arthralgia
Confusional State
Dizziness
Drug Interaction
Memory Impairment

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Lustral (Sertraline)	PS		ORAL	50 MG (DAILY), ORAL	
	Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (DAILY), ORAL	
	Panadeine Co (Codeine Phosphate, Paracetamol)	C				
	Ibuprofen (Ibuprofen)	C				
	Salbutamol (Salbutamol)	C				
	Beclometasone Dipropionate	C				

Date:10/22/03ISR Number: 4213948-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA02261
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage Faecaloma Large Intestinal Ulcer		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Insulin	C				
			Zocor	C		ORAL		
			Isordil	C				
			Inderal	C				

Date:10/22/03ISR Number: 4213955-5Report Type:Expedited (15-DaCompany Report #WAES 0301DEU00128
Age:18 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL	
5 DAY							
	Odynophagia						
	Stomatitis Necrotising						

Date:10/22/03ISR Number: 4213957-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA02565
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS		ORAL		
8 DAY								
	Congestive		[Therapy Unspecified]	C	Merck & Co., Inc			
			Vicodin Tablets	C		ORAL		
			Atenolol	C		ORAL		
			Effexor	C		ORAL		
			Clonidine Hydrochloride	C		ORAL		
			Neurontin	C				
			Hydrochlorothiazide And Triamterene	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/03ISR Number: 4213963-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02343
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis Intestinal		Vioxx	PS		ORAL		62 DAY
Initial or Prolonged	Haemorrhagic		Vioxx	SS		ORAL		
			Ultracet	C	Merck & Co., Inc			
			Detrol La	C		ORAL		
			Calan Sr	C		ORAL		
			Pepcid	C		ORAL		
			Cozaar	C		ORAL		

Date:10/22/03ISR Number: 4213975-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:10/22/03ISR Number: 4214917-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02588
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urea Increased		Vioxx	PS		ORAL		
Hospitalization -	Colonic Polyp		Coumadin	SS				
Initial or Prolonged	Diverticulitis Intestinal		Digoxin	C	Merck & Co., Inc			
Other	Haemorrhagic		Lasix (Furosemide)	C				
	Fall		Megace	C				
	Haemorrhoids		Oxycontin	C				
	Heart Rate Irregular							
	Immobile							
	International Normalised							
	Ratio Increased							
	Lower Gastrointestinal							
	Haemorrhage							
	Neoplasm Prostate							

Date:10/22/03ISR Number: 4214918-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01477
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose		Vioxx	PS		ORAL		
	Cerebrovascular Accident		Globulin, Immune	SS	Merck & Co., Inc	INTRAVENOUS		
	Hypertension		Vioxx	SS		ORAL		

Date:10/22/03ISR Number: 4214920-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/03ISR Number: 4215474-9Report Type:Direct Company Report #CTU 204314
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS			1 TAB PER DA	
Initial or Prolonged	Congestive							
Required	Cough							
Intervention to	Dyspnoea							
Prevent Permanent	Fluid Retention							
Impairment/Damage	Pneumonia							
	Weight Increased							

Date:10/23/03ISR Number: 4215837-1Report Type:Direct Company Report #CTU 204462
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Warfarin	PS		ORAL	4 MG PO QD	
	Gastrointestinal		Rofecoxib	SS		ORAL	25MG PO QD	
	Haemorrhage						PRN	
	International Normalised		Coumadin	C				
	Ratio Increased		Vioxx	C				
	Oesophageal Spasm		Atenolol	C				
			Lotrel	C				
			Triamterene/Hctz	C				
			Isosorbide Mononitrate	C				
			Ntg Sl	C				

Date:10/24/03ISR Number: 4217134-7Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00024
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	374 DAY	
	Multi-Organ Failure							

Date:10/24/03ISR Number: 4217136-0Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00026
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		35 DAY
	Neoplasm Malignant							
	Pulmonary Oedema							

Date:10/24/03ISR Number: 4217140-2Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00132
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive		Vioxx	PS		ORAL		
Initial or Prolonged	Gastritis Haemorrhagic		Aspirin	SS	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	SS		ORAL		90 DAY
			Atorvastatin Calcium	C		ORAL		
			Gabapentin	C		ORAL		
			Nebivolol Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/24/03ISR Number: 4217154-2Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00024
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		374 DAY
	Multi-Organ Failure							

Date:10/24/03ISR Number: 4217157-8Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00025
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		39 DAY
	Renal Failure Acute							

Date:10/24/03ISR Number: 4217162-1Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00169
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS		ORAL		
			Amitriptyline Hydrochloride	C	Merck & Co., Inc			
			Fluoxetine	C				
			Gold Sodium Thiomalate	C				
INTRAMUSCULAR								
			Tolterodine	C				
			Lansoprazole	C				
			Prochlorperazine	C				

Date:10/24/03ISR Number: 4217191-8Report Type:Expedited (15-DaCompany Report #WAES 0308NZL00017
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc			

Date:10/24/03ISR Number: 4217195-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01764
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		128 DAY
	Limb Discomfort		Vitamins (Unspecified)	C				

Date:10/24/03ISR Number: 4218588-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA01012
Age:95 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Arthralgia
	Atrial Fibrillation
	Blood Potassium Decreased
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cold Sweat
	Constipation
	Coronary Artery Disease

Dose	Duration						
		Decubitus Ulcer					
		Diarrhoea					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
		Dyspnoea	Health	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE							
		Ecchymosis	Professional	Lanoxin	C		
		Electrocardiogram T Wave	Company	Lasix (Furosemide			
		Inversion	Representative	Sodium)	C		
		Emotional Distress		Premarin	C		
		Faecal Occult Blood		Aspirin	C		
		Positive		Iron	C		
		Fall		Lisinopril	C		
		Gastric Ulcer					
		Gastritis Atrophic					
		Gastritis Erosive					
		Gastrointestinal Disorder					
		Gastrointestinal					
		Haemorrhage					
		Gravitational Oedema					
		Haematemesis					
		Haemoglobin					
		Heart Rate Irregular					
		Hypertension					
		Hypotension					
		Hypothermia					
		Hypoxia					
		Infusion Site Erythema					
		Melaena					
		Metaplasia					
		Oedema Peripheral					
		Osteoarthritis					
		Pallor					
		Pitting Oedema					
		Platelet Disorder					
		Pleural Effusion					
		Rotator Cuff Syndrome					
		Upper Gastrointestinal					
		Haemorrhage					
		Urinary Tract Infection					
		White Blood Cell Count					

Date:10/24/03ISR Number: 4218902-8Report Type:Expedited (15-DaCompany Report #2003181807DE
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancytopenia	Foreign Health Professional	Aromasin(Exemastane) Tablet	PS		ORAL	25 MG, QD, ORAL	
		Other	Rofecoxib(Rofecoxib)	SS				
			Jatrosom(Tranylcypromine Sulfate,Trifluoperazine Hydrochloride)	SS		ORAL		

SEE IMAGE

Date:10/24/03ISR Number: 4220401-4Report Type:Expedited (15-DaCompany Report #2003156200US
Age:20 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Cholesterol Increased	Consumer	Celebrex (Celecoxib)Capsule	PS		ORAL	ORAL	
	Blood Pressure Increased		Vioxx	SS				
	Chromaturia							
	Cough							
	Dialysis							
	Dyspnoea							
	Gastroenteritis							
	Glomerulonephritis Focal							
	Glomerulonephritis							
	Membranous							
	Hypertriglyceridaemia							
	Kidney Enlargement							
	Nasal Sinus Drainage							
	Nasopharyngitis							
	Nausea							
	Nephrotic Syndrome							
	Nerve Compression							
	Pain In Extremity							
	Penile Swelling							
	Pulmonary Embolism							
	Renal Failure Chronic							
	Renal Transplant							
	Scrotal Swelling							
	Shock							
	Sports Injury							
	Tooth Injury							

Date:10/26/03ISR Number: 4218009-XReport Type:Expedited (15-DaCompany Report #WAES 0310GBR00163
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/26/03ISR Number: 4218013-1Report Type:Expedited (15-DaCompany Report #WAES 0308NZL00005
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage		Vioxx	PS		ORAL
			Amitriptyline Hydrochloride	C	Merck & Co., Inc	ORAL
			Bendroflumethiazide	C		
			Calcium (Unspecified)	C		
			Furosemide	C		
			Hydroxocobalamin	C		
			Quinapril Hydrochloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/03ISR Number: 4218016-7Report Type:Expedited (15-DaCompany Report #WAES 0310CHE00016
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS		ORAL		8 DAY
Initial or Prolonged	Increased		Carbamazepine	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased		Lithium Carbonate	SS		ORAL		
	Creatinine Renal		Mirtazapine	C		ORAL		
	Clearance Decreased		Pipamperone					
	Drug Interaction		Hydrochloride	C		ORAL		
	Drug Level Increased		Zopiclone	C		ORAL		
	Electrocardiogram							
	Abnormal							
	Headache							
	Sinus Bradycardia							
	Tremor							
	Vomiting							

Date:10/26/03ISR Number: 4218019-2Report Type:Expedited (15-DaCompany Report #WAES 0310AUS00053
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS		ORAL		349 DAY
Hospitalization -	Fall		Hydrochlorothiazide					
Initial or Prolonged	Hyponatraemia		And Irbesartan	SS	Merck & Co., Inc	ORAL		
Disability	Joint Arthroplasty		Prednisone	C				
Other	Nausea							
	Vomiting							

Date:10/26/03ISR Number: 4218022-2Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00146
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS		ORAL		
	Amnesia		Rabeprazole Sodium	C	Merck & Co., Inc			
	Asthenia							
	Circulatory Collapse							
	Confusional State							

Flushing
Hyperhidrosis
Mental Impairment
Mouth Ulceration
Nausea
Palpitations
Tremor
Vision Blurred

Date:10/26/03ISR Number: 4218024-6Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00021
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL	63 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/03ISR Number: 4218025-8Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00156
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative		Vioxx	PS		ORAL	4	DAY
	Oesophagitis Ulcerative		Vioxx	SS		ORAL	3	MON
			Acetaminophen And Codeine	C	Merck & Co., Inc			
			Albuterol	C				
			Fosamax	C		ORAL		
			Beclomethasone Dipropionate	C				
			Bisacodyl	C				
			Calcium Carbonate And Cholecalciferol	C				
			Chloramphenicol	C				
			Docusate Sodium	C				
			Hypromellose	C				
			Lansoprazole	C				
			Plantago Seed	C				
			Ranitidine	C				

Date:10/26/03ISR Number: 4218026-XReport Type:Expedited (15-DaCompany Report #WAES 0310NZL00022
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	46	DAY

Date:10/26/03ISR Number: 4218027-1Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00023
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	74	DAY
	Skin Infection							

Date:10/26/03ISR Number: 4218028-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/03ISR Number: 4218029-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/03ISR Number: 4218031-3Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00029
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	63 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/03ISR Number: 4218032-5Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00020
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY
	Haemorrhage							
	Myocardial Infarction							

Date:10/26/03ISR Number: 4218034-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA02407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS		ORAL		
			Axert	C	Merck & Co., Inc			

Date:10/27/03ISR Number: 4218166-5Report Type:Expedited (15-DaCompany Report #PHHO2003FI12424
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Esidrex	PS	Novartis Sector: Pharma	ORAL	25 mg, QD,	
	Dizziness							
	Knee Operation		Valsartan +/-Hctz Vs Amlodipine +/-Hctz	SS				
	Osteoarthritis							
	Vertigo		Valsartan +/-Hctz Vs Amlodipine +/-Hctz	SS				
	Vomiting							
			Vioxx	SS		ORAL	50 mg	
			Burana	SS		ORAL	1000mg	

Date:10/27/03ISR Number: 4218341-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA00323
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dehydration		Vioxx	PS		ORAL	22	DAY
Other	Dyspnoea		Prilosec	C	Merck & Co., Inc	ORAL		
	Generalised Oedema		Effexor Xr	C		ORAL		
	Hypertension							
	Orthopnoea							
	Paraesthesia							
	Pitting Oedema							

Date:10/27/03ISR Number: 4218347-0Report Type:Expedited (15-DaCompany Report #WAES 0309BEL00022
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Melaena							

Date:10/27/03ISR Number: 4218348-2Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00027
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	201	DAY
	Myocardial Infarction		Tolcapone	C		ORAL	1210	DAY
	Pulmonary Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/03ISR Number: 4218351-2Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Eruption		Vioxx	PS		ORAL	7	DAY
	Skin Ulcer		Vioxx	SS		ORAL	12	DAY
			Atorvastatin Calcium	C	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Diclofenac	C			3	DAY

Date:10/27/03ISR Number: 4218352-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01486
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4218355-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01580
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS		ORAL		
			Aspirin	C	Merck & Co., Inc			

Date:10/27/03ISR Number: 4218356-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS		ORAL	1	DAY
	Haemorrhage		Toradol	C	Merck & Co., Inc			

Date:10/27/03ISR Number: 4218673-5Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnestic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Antinuclear Antibody Positive							
Other	Cerebrovascular Accident							
	Coordination Abnormal							
	Drug Hypersensitivity							
	Extensor Plantar Response							
	Extrasystoles							
	Flank Pain							
	Haematuria							
	Hyperreflexia							
	Hypersensitivity							
	Hypertension							
	Hypokalaemia							
	Insomnia							
	Lacunar Infarction							
	Nephrolithiasis							
	Palpitations							
	Sensation Of Heaviness							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/03ISR Number: 4218690-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA03159
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4218695-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA02152
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4218954-5Report Type:Expedited (15-DaCompany Report #WAES 0310AUS00053
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS		ORAL	349 DAY	
Hospitalization - Initial or Prolonged Disability	Blood Chloride Decreased Fall Hyponatraemia		Hydrochlorothiazide And Irbesartan Prednisone	SS C	Merck & Co., Inc	ORAL		
Other	Knee Arthroplasty Nausea Vomiting							

Date:10/27/03ISR Number: 4218963-6Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Uterine Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4218964-8Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00224
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged			Elavil	C	Merck & Co., Inc			
Other								

Date:10/27/03ISR Number: 4218965-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA02523
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4218967-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA00369
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/03ISR Number: 4218970-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA00506
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/03ISR Number: 4219828-6Report Type:Direct Company Report #CTU 204622
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx 25 Mg	PS		ORAL	25 MG QD PO	
Initial or Prolonged	Dyspnoea		Prinzide	C				
Required	Oesophagitis		Atenolol	C				
Intervention to			Aldomet	C				
Prevent Permanent			Furosemide	C				
Impairment/Damage			Cardura	C				
			Alopurinol	C				
			Levoxyl	C				
			Actos	C				
			Cozaar	C				
			Prilosec	C				
			Lantus Insulin	C				
			Pravachol	C				
			Xenical	C				
			Imdur	C				
			Baby Asa	C				
			Multivit	C				
			Fish Oil	C				
			Condroitin/Glucosamine	C				
			Msm	C				

Date:10/27/03ISR Number: 4220909-1Report Type:Expedited (15-DaCompany Report #2003-DE-04863GD
Age:22 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Literature	Prednisone					
Initial or Prolonged	Drug Toxicity	Health	(Prednisone)	PS				
	Gastrointestinal	Professional	Rofecoxib					

	Haemorrhage		(Antiinflammatory/Antirheumatic Products)	SS		

Date:10/28/03ISR Number: 4219670-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02065
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 228 DAY	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diarrhoea					
Other	Disturbance In Attention					
	Encephalopathy					
	Headache					
	Meningitis Aseptic					
	Nausea					
	Neck Pain					
	Upper Respiratory Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/03ISR Number: 4219678-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Unstable		Vioxx	PS		ORAL		
	Anxiety		Allegra	C	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Zoloft	C		ORAL		
	Asthenia							
	Blood Cholesterol Increased							
	Blood Pressure Increased							
	Bundle Branch Block Left							
	Cardiac Failure Congestive							
	Cardiomyopathy							
	Depression							
	Dyspnoea							
	Headache							
	Heart Rate Increased							
	Hypertension							
	Hypokinesia							
	Mitral Valve Incompetence							
	Palpitations							
	Sinus Disorder							
	Tricuspid Valve Incompetence							
	Weight Fluctuation							

Date:10/28/03ISR Number: 4219679-2Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00166
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS		ORAL		
Hospitalization -	Duodenal Ulcer		Aspirin	SS	Merck & Co., Inc	ORAL		
4 YR								
Initial or Prolonged	Haemorrhage		Insulin, Neutral	C				
SUBCUTANEOUS								
			Molsidomine	C		ORAL		
			Ramipril	C		ORAL		

Date:10/28/03ISR Number: 4219688-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA02505
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Lung Neoplasm Malignant		Vioxx	PS		ORAL
	Pneumonitis		[Therapy			
	Radiation Injury		Unspecified]	C	Merck & Co., Inc	
			Tylenol	C		
			Vicodin Tablets	C		
			Diovan	C		
			Lipitor	C		
			Aleve	C		

Date:10/28/03ISR Number: 4220218-0Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00115
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Multi-Organ Failure
Hospitalization -	Renal Failure Acute
Initial or Prolonged	Respiratory Failure
	Sepsis

Staphylococcal Infection

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS		ORAL	4	DAY
			Candesartan Cilexetil	C	Merck & Co., Inc			
			Felodipine	C		ORAL		
			Insulin	C				
			Moxonidine	C		ORAL		
			Piretanide	C		ORAL		

Date:10/28/03ISR Number: 4220219-2Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00045
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vision Blurred		Vioxx	PS		ORAL	4	DAY
			Calcium Carbonate And Cholecalciferol	C	Merck & Co., Inc			
			Vitamin E	C				
			Estrogens, Conjugated And Medroxyprogesterone Acetate	C		ORAL		

Date:10/28/03ISR Number: 4220224-6Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged			Esomeprazole Magnesium	SS		ORAL		
			Fluoxetine Hydrochloride	SS		ORAL		
			Acetaminophen	C	Merck & Co., Inc	ORAL		
			Piroxicam	C		ORAL		
			Diclofenac	C		ORAL		

Date:10/28/03ISR Number: 4220228-3Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00031
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc			

Date:10/28/03ISR Number: 4220231-3Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00019
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gangrene		Vioxx	PS		ORAL		
	Pain		Buflomedil Hydrochloride	C	Merck & Co., Inc	ORAL		
Disability	Vasculitis						5	DAY
			Ciprofloxacin Hydrochloride	C				
			Pentoxifylline	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/03ISR Number: 4221284-9Report Type:Direct Company Report #CTU 204779
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Rofecoxib	PS			25 MG Q DAY	
Initial or Prolonged	Rectal Haemorrhage		Aspirin	SS			2	WK
	Transient Ischaemic Attack		Propranolol	C				
			Hydrochlorothiazide	C				
			Levothyroxine	C				
			Potassium	C				

Date:10/30/03ISR Number: 4221744-0Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00156
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oesophagitis Ulcerative		Vioxx	PS		ORAL	4	DAY
			Vioxx	SS		ORAL	3	MON
			Acetaminophen And Codeine	C	Merck & Co., Inc			
			Albuterol	C				
			Fosamax	C		ORAL		
			Beclomethasone Dipropionate	C				
			Bisacodyl	C				
			Calcium Carbonate And Cholecalciferol	C				
			Chloramphenicol	C				
			Docusate Sodium	C				
			Hypromellose	C				
			Lansoprazole	C				
			Plantago Seed	C				
			Ranitidine	C				

Date:10/30/03ISR Number: 4221747-6Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00064
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Bullous		Vioxx	PS		ORAL		
			Vioxx	SS		ORAL		
			Allopurinol	C	Merck & Co., Inc	ORAL		

Date:10/30/03ISR Number: 4221749-XReport Type:Expedited (15-DaCompany Report #WAES 0310GBR00199
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hallucination, Auditory		Vioxx	PS		ORAL		
55 DAY								
Initial or Prolonged	Head Injury		Chlorpheniramine					
	Loss Of Consciousness		Maleate	C	Merck & Co., Inc	ORAL		
22 DAY								

Date:10/30/03ISR Number: 4221750-6Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00041
Age:91 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS		ORAL		
Hospitalization -	Gastrointestinal		Glyburide	C		ORAL		
Initial or Prolonged	Haemorrhage		Insulin, Biphasic					
	Mallory-Weiss Syndrome		Isophane [Injection]	C				
SUBCUTANEOUS								
			Aspirin	C	Merck & Co., Inc	ORAL		

			Ramipril	C		ORAL

Date:10/30/03ISR Number: 4222312-7Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cataract Keratoconjunctivitis Sicca		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/30/03ISR Number: 4222323-1Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00099
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Haemorrhage Microcytic Anaemia Renal Impairment		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
RESPIRATORY (INHALATION)			Acetaminophen And Propoxyphene Hydrochloride	C		

Date:10/30/03ISR Number: 4222325-5Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00179
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction Overdose		Vioxx Vioxx	PS SS	Merck & Co., Inc	ORAL ORAL
1 DAY						

Date:10/30/03ISR Number: 4222337-1Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00239
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS		ORAL		10 DAY
Initial or Prolonged	Haemorrhage		Vioxx	SS		ORAL		7 DAY
	Melaena		Aspirin	C	Merck & Co., Inc	ORAL		

Date:10/30/03ISR Number: 4222338-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA02730
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Congestive							

Date:10/30/03ISR Number: 4222339-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA02386
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Macular Degeneration		Vioxx	PS		ORAL		
			[Therapy Unspecified]	C	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/03ISR Number: 4222482-0Report Type:Direct Company Report #CTU 204895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Complications Of Maternal Exposure To Therapeutic Drugs		Clarinex 5 Mg Schering-Plough	PS	Schering-Plough	ORAL	5 MG 1 DAILY	
	Dysmenorrhoea		Vioxx 50 Mg Merck	SS	Merck	ORAL	50 MG 1 DAILY	
	Intra-Uterine Death							
	Maternal Drugs Affecting Foetus Pregnancy							

Date:10/30/03ISR Number: 4222880-5Report Type:Expedited (15-DaCompany Report #WAES 01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Atrophy		Vioxx	PS		ORAL		
	Cough		[Therapy Unspecified]	C	Merck & Co., Inc			
	Dizziness							
	Encephalomalacia		Albuterol	C			RESPIRATORY (INHALATION)	
	Epistaxis							
	Erectile Dysfunction		Albuterol	C		ORAL		
	Gastrointestinal		Allopurinol	C				
	Haemorrhage		Ecotrin	C				
	Haemorrhoids		Atenolol	C				
	Headache		Mavik	C		ORAL		
	Hypertension		Mavik	C		ORAL		
	Ileus Paralytic		Palgic D	C		ORAL		
	Nausea		Celebrex	C				
	Proctalgia		Guaifenex La	C				
	Prostate Cancer		Hydrodiuril	C		ORAL		
	Rectal Haemorrhage		Ibuprofen	C				
	Rectal Polyp		Atrovent	C				
	Red Blood Cell Count							
	Sinusitis							
	Vomiting							

Wheezing
White Blood Cell Count

Date:10/30/03ISR Number: 4222887-8Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00069
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS		ORAL	12 DAY	
Hospitalization - Initial or Prolonged	Hemiparesis		Gliclazide	SS		ORAL		
	Hypoglycaemic Coma		Gliclazide	SS		ORAL		
	Iatrogenic Injury		Acebutolol Hydrochloride	C	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Zopiclone	C		ORAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Timoptic OPHTHALMIC	C				
			Perindopril Althiazide And	C		ORAL		

Spironolactone	C		ORAL
Clonazepam	C		ORAL
Fenofibrate	C		ORAL

Date:10/30/03ISR Number: 4222890-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA01135
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dyspepsia		Vioxx	PS		ORAL
Other	Oedema Peripheral		[Therapy			
	Oesophageal Discomfort		Unspecified]	SS		
	Orthopnoea		Celebrex	SS		
	Peripheral Vascular		[Therapy			
	Disorder		Unspecified]	C	Merck & Co., Inc	
	Reflux Oesophagitis		Gaviscon Antacid			
			Tablets	C		
			Propoxyphene			
			Hydrochloride	C		
			Neurontin	C		
			Norvasc	C		
			Calcium			
			(Unspecified)	C		

Date:10/30/03ISR Number: 4222896-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA00054
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Benign Prostatic		Vioxx	PS		ORAL
Initial or Prolonged	Hyperplasia		Vioxx	SS		ORAL
Disability	Drug Effect Decreased		[Therapy			
Other	Fluid Retention		Unspecified]	C	Merck & Co., Inc	
	Gout					
	Liver Function Test					
	Abnormal					
	Prescribed Overdose					
	Renal Failure					
	Therapeutic Response					
	Decreased					
	Weight Decreased					

Date:10/30/03ISR Number: 4222897-0Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00119
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated		Vioxx	PS		ORAL	3	DAY
Life-Threatening	Intravascular Coagulation		Vioxx	SS		ORAL	2	DAY
	Hepatitis Toxic Renal Failure Rhabdomyolysis		Amiodarone Hydrochloride	C	Merck & Co., Inc	ORAL	2	DAY

Date:10/30/03ISR Number: 4222902-1Report Type:Expedited (15-DaCompany Report #WAES 0310AUS00064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/03ISR Number: 4222904-5Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00078
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS		ORAL		34 DAY
Initial or Prolonged	Rectal Haemorrhage		Acenocoumarol	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Beclomethasone Dipropionate	C		ORAL		
			Troxerutin	C		ORAL		
			Spironolactone	C		ORAL		
			Clonazepam	C		ORAL		
			Furosemide	C		ORAL		

Date:10/30/03ISR Number: 4222918-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA02501
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Retinal Vein Occlusion Tunnel Vision		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/30/03ISR Number: 4223149-5Report Type:Direct Company Report #CTU 204932
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Alanine Aminotransferase		Vioxx 25 Mg	PS		ORAL	25MG PO QD	
Intervention to Prevent Permanent Impairment/Damage	Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased		Zocor 10 Mg	SS		ORAL	ZOCOR 10 MG PO QD	

Blood Lactate
Dehydrogenase Increased
Gamma-Glutamyltransferase
Increased
Myalgia

Date:10/30/03ISR Number: 4223216-6Report Type:Direct Company Report #CTU 204951
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Uniretic					
	Pancreatitis		(Hctz/Moexipril)	PS		ORAL	? MG PO QAM	
			Vioxx	SS		ORAL	2 MG PO QD	2 WK
			Centrum Silver	C				
			Amaryl	C				

Date:10/30/03ISR Number: 4223997-1Report Type:Expedited (15-DaCompany Report #S03-SWI-04412-01
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia
	Exanthem

		Gamma-Glutamyltransferase Increased Monocyte Count Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neutrophil Count Increased	Foreign Health	Cipralex (Escitalopram)	PS		ORAL
5 MG QD PO							
			Professional Other	Cipralex (Escitalopram)	SS		ORAL
10 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Vioxx (Rofecoxib)	SS		ORAL
12.5 MG QD PO							
				Zyprexa (Olanzapine)	C		
				Temesta (Lorazepam)	C		
				Duphalac (Lactulose)	C		
				Paragol	C		
				Fig Syrup	C		

Date:10/30/03ISR Number: 4224367-2Report Type:Expedited (15-DaCompany Report #2003113128
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia	Foreign	Norvasc (Amlodipine)	PS		ORAL
5 MG (DAILY),						
Hospitalization -	Drug Interaction	Health				
ORAL						
Initial or Prolonged	Gastrointestinal Ulcer	Professional	Diclofenac Sodium			

	Haemorrhage	(Diclofenac Sodium)	SS	ORAL
75 MG				
	Melaena			
(DAILY), ORAL				
	Pain In Extremity	Ginkgo Biloba Extract (Ginkgo Biloba Extract)	SS	ORAL
120 MG				
(DAILY), ORAL				
		Harpagophytum Procumbens (Harpogophytm Procumbens)	SS	ORAL
(TID), ORAL				
		Rofecoxib (Rofecoxib)	SS	ORAL
25 MG				
(DAILY), ORAL				
		Blopress Plus (Hydrochlorothiazide , Candesartan Cilexetil)	C	
		Digitoxin (Digitoxin)	C	
		Ferro "Sanol" / Old Form/ (Aminoacetic Acid, Ferrous Sulfate)	C	
		Sedariston (Valerian Tincture, Hypericum Extract, Melissa Extract)	C	
		Sotalol Hydrochloride (Sotalol Hydrochloride)	C	

			Torasemide (Torasemide)	C		

Date:10/31/03ISR Number: 4223500-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS		ORAL		
Other	Anxiety		Vioxx	SS		ORAL		
	Arthritis		Vioxx	SS		ORAL		
	Asthenia		Folic Acid	C	Merck & Co., Inc			
	Cardiomegaly		Arava	C				
	Diarrhoea		Methotrexate	C				441 DAY
	Dyspnoea Paroxysmal		Inderal	C				
	Nocturnal		Inderal	C				
	Hypertension							
	Insomnia							
	Melaena							
	Myocardial Infarction							
	Nightmare							
	Palpitations							
	Panic Attack							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Stress							
	Weight Increased							

Date:10/31/03ISR Number: 4223510-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA02613
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Gastric Haemorrhage							
Disability								

Date:10/31/03ISR Number: 4224133-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Blood Cholesterol Increased Cardiomyopathy Coronary Artery Thrombosis High Density Lipoprotein Decreased Hypertension Low Density Lipoprotein Increased		Vioxx Lopressor	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/31/03ISR Number: 4224137-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA02787
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Drug Hypersensitivity		Vioxx	SS		ORAL	10	WK
	Multiple Allergies							
	Pain							
	Surgery							
	Urticaria							

Date:10/31/03ISR Number: 4224140-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA02887
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS		ORAL		
Other	Congestive		Vasodilan	C	Merck & Co., Inc	ORAL		
			Prevacid	C		ORAL		
			Coumadin	C		ORAL		
			Zocor	C		ORAL		
			Trental	C		ORAL		

Date:10/31/03ISR Number: 4224146-6Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00024
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/31/03ISR Number: 4224148-XReport Type:Expedited (15-DaCompany Report #WAES 0310DEU00190
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Wegener'S Granulomatosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/03ISR Number: 4224641-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA00347
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Basilar Artery Occlusion		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Cerebral Infarction Cerebral Ischaemia Polytraumatism		Zestril	C	Merck & Co., Inc			

Date:11/03/03ISR Number: 4224647-0Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00065
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation Peritonitis		Vioxx	PS		ORAL	5	DAY
			Bisoprolol Fumarate	C	Merck & Co., Inc	ORAL		
			Pravastatin Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/03ISR Number: 4224949-8Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00024
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/03ISR Number: 4224953-XReport Type:Expedited (15-DaCompany Report #WAES 0310GBR00310
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS		ORAL	278 DAY	
			Cimetidine	C	Merck & Co., Inc	ORAL		

Date:11/03/03ISR Number: 4224954-1Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00030B1
Age:0 DY Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Caesarean Section		Vioxx	PS	Merck & Co., Inc		16 DAY	
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Pregnancy							
	Pregnancy Induced Hypertension							
	Premature Baby							
	Small For Dates Baby							

Date:11/03/03ISR Number: 4224955-3Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00122
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS		ORAL	2 DAY	
Initial or Prolonged	Nausea		Eucalyptol	C	Merck & Co., Inc	ORAL	2 DAY	

Panic Reaction
Tachycardia

Date:11/03/03ISR Number: 4224958-9Report Type:Expedited (15-DaCompany Report #WAES 0302FRA00030M
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Caesarean Section		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
Initial or Prolonged	Complications Of Maternal Exposure To Therapeutic Drugs Drug Exposure During Pregnancy Maternal Drugs Affecting Foetus Pregnancy Pregnancy Induced Hypertension Premature Baby Small For Dates Baby							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/03ISR Number: 4226311-0Report Type:Expedited (15-DaCompany Report #DEU-2003-0000629
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Foreign	Mst(Morphine					
Hospitalization -	Convulsion	Health	Sulfate)Unknown	PS		ORAL	20 MG, BID,	
Initial or Prolonged	Drug Interaction	Professional					ORAL	
Disability	Hypoglycaemia	Other	Amaryl(Glimepiride)	SS			3 MG, Q24H	
	Hypoxic Encephalopathy		Enalapril Maleate					
	Respiratory Failure		(Enalapril Maleate)	SS		ORAL	10 MG, BID,ORAL	
			Norvasc (Amlodipine Besilate)	SS		ORAL	5 MG, BID, ORAL	
			Vioxx(Rofecoxib)	SS		ORAL	25 MG, Q24H, ORAL	
			Novalgin(Metamizole Sodium)	SS			2 ML, DAILY	
			Durogesic(Fentanyl)	SS			TRANSDERMAL 75 MCG/HR, Q1H, TRANSDERMAL	
			Madopar (Benserazide Hydrochloride, Levodopa)	C				
			Pk-Merz (Amantadine Sulfate)	C				
			Neurontin (Gabapentin)	C				
			Pantozol (Pantoprazole Sodium)	C				
			Calcium Effervescent Tablet (Calcium					

Carbonate, Calcium Lactogluconate)	C
Ospur D3 (Colecalciferol)	C
Remergil (Mirtazapine)	C
Movicol (Macrogol, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride)	C
Fosamax (Alendronate Sodium)	C
Clexane (Heparin-Fraction, Sodium Salt)	C
Atosil (Isopromethazine Hydrochloride)	C
Sevredol 20 Mg (Morphine Sulfate) Ir Tablet	C
Dipidolor (Piritramide)	C
Catapressan (Clonidine)	C
Triflupromazine (Triflupromazine)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/03ISR Number: 4225388-6Report Type:Expedited (15-DaCompany Report #PHBS2003CH11829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Voltaren	PS	Novartis Sector: Pharma		150 mg/day	20160MIN
	Anxiety							
	Chills		Quilonorm	SS			12.5 mmol/day	
	Confusional State		Vioxx	SS			150 mg/day	
	Coordination Abnormal		Cozaar Plus	SS			50 losa /12.5 hctz mg/day	
	Cystitis							
	Dehydration		Anafranil	SS			75 mg/day	
	Delirium		Ludiomil	SS			75 mg/day	
	Drug Interaction		Akineton	SS				
	Drug Level Increased		Concor	C				
	Drug Resistance		Amlodipine Besilate	C				
	Hallucination		Marcoumar	C				
	Renal Failure		Fraxiparin	C				
	Speech Disorder		Nexium					
	Therapeutic Agent Toxicity		/Unk/	C				
	Urinary Tract Infection							

Date:11/04/03ISR Number: 4225656-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS		ORAL	260 DAY	
	Increased		Fosamax	C	Merck & Co., Inc	ORAL		
	Chest Pain		Nitrostat	C				
	Depression		Valtrex	C				
	Dyspepsia		Evista	C				
	Fractured Sacrum							
	Generalised Anxiety Disorder							
	Hernia							

Hip Fracture
Hyperkeratosis
Impaired Healing
Metastatic Neoplasm
Oedema Peripheral
Pelvic Fracture
Rib Fracture
Spinal Fracture

Date:11/04/03ISR Number: 4225661-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Blood Disorder
	Cardiac Failure
	Congestive
	Crying
	Epistaxis
	Irritable Bowel Syndrome
	Meniscus Lesion
	Menorrhagia
	Mood Swings
	Neuropathic Pain
	Ovarian Mass

		Pneumonia					
		Pulmonary Oedema					
		Respiratory Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Failure		Vioxx	PS		ORAL
518	DAY						
				Ventolin (Albuterol Sulfate)	C	Merck & Co., Inc	
				Tenormin	C		
				Vasotec	C		ORAL
				Lodine Xl	C		
				Ultram	C		
				Lasix (Furosemide Sodium)	C		
				Ditropan	C		
				K-Dur	C		
				Quinine Sulfate	C		

Date:11/04/03ISR Number: 4225662-3Report Type:Expedited (15-DaCompany Report #WAES 0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Agitation		Vioxx	PS		ORAL
Initial or Prolonged		Alcohol Interaction		Vioxx	SS		ORAL
Disability		Anxiety		Proventil	C	Merck & Co., Inc	
		Arrhythmia		Aspirin	C		
		Arthralgia		Coreg	C		
		Diarrhoea		Foltx	C		
		Diverticular Perforation		Zestril	C		
		Diverticulitis		Niaspan	C		
		Drug Hypersensitivity		Pravachol	C		ORAL
		Electrocardiogram Q Waves		Metamucil	C		
		Electrocardiogram St Segment Depression					
		Emotional Distress					
		Hypokalaemia					
		Impaired Work Ability					
		Injury					
		Nausea					
		Oxygen Saturation Decreased					
		White Blood Cell Count					

Date:11/04/03ISR Number: 4225664-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Prerenal Failure
Initial or Prolonged	Affect Lability
Other	Anxiety Disorder
	Arthropathy
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Calcinosis
	Cardiac Murmur
	Chronic Obstructive
	Pulmonary Disease
	Diverticulum
	Dyspepsia

		Encephalitis					
		Encephalopathy					
		Gastric Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS		ORAL
		Disease		Vioxx	SS		ORAL
		Hiatus Hernia		Bextra	SS		
		Hypertensive Heart		[Therapy			
		Disease		Unspecified]	C	Merck & Co., Inc	
		Memory Impairment		Albuterol	C		
		Meningitis		Lanoxin	C		
		Mitral Valve Incompetence		Effexor	C		
		Myocardial Infarction		Flovent	C		
		Normochromic Normocytic		Hydrochlorothiazide			
		Anaemia		And Triamterene	C		ORAL
		Oesophageal Spasm		Atrovent	C		
		Pancreatitis		Singulair	C		ORAL
		Tension		Daypro	C		
		Therapeutic Agent					
		Toxicity					
		Tricuspid Valve					
		Incompetence					
		Urosepsis					
		Ventricular Hypertrophy					

Date:11/04/03ISR Number: 4225671-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA02395
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Rash		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY					
			Vioxx	SS		ORAL

Date:11/04/03ISR Number: 4225681-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA02407
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS		ORAL
Initial or Prolonged	Myocardial Infarction		Axert	C	Merck & Co., Inc	

Date:11/04/03ISR Number: 4225685-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA03199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive							
Disability								

Date:11/04/03ISR Number: 4226254-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA00964
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/03ISR Number: 4226256-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis		Vioxx	PS		ORAL		
	Arrhythmia		Aspirin	C	Merck & Co., Inc			
Other	Cerebrovascular Accident		Lipitor	C				
	Cervical Vertebral Fracture		Calcium (Unspecified)	C				
	Chest Pain		Monopril	C		ORAL		
	Mitral Valve Incompetence		Hydrochlorothiazide	C				
	Road Traffic Accident		Adalat	C				

Date:11/04/03ISR Number: 4226257-8Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00031
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS		ORAL		
			Acetaminophen	C	Merck & Co., Inc			
			Omeprazole	C				

Date:11/04/03ISR Number: 4226262-1Report Type:Expedited (15-DaCompany Report #WAES 0310CHE00033
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS		ORAL		
	Bacteria Urine Identified		Diclofenac Sodium	SS		ORAL	14	DAY
	Confusional State		Hyzaar	SS		ORAL		
	Disturbance In Attention		Lithium Carbonate	SS		ORAL		
	Drug Interaction		Lithium Carbonate	SS		ORAL	15	YR
	Drug Level Increased		Amlodipine Besylate	C	Merck & Co., Inc	ORAL		
	Fear		Maprotiline Hydrochloride	C		ORAL		
	Hallucination		Phenprocoumon	C		ORAL		
	Speech Disorder		Nadroparin	C		SUBCUTANEOUS		
	Tremor		Cozaar	C		ORAL		
	Urinary Tract Infection							

		Bisoprolol Fumarate	C	ORAL
		Esomeprazole Magnesium	C	ORAL
		Clomipramine Hydrochloride	C	ORAL

Date:11/04/03ISR Number: 4226263-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA03464
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/03ISR Number: 4226823-XReport Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Gastrointestinal Disorder							
	Hypertension							

Date:11/05/03ISR Number: 4226827-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA00019
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gallbladder Disorder		Vioxx	PS		ORAL		
	Hepatic Cirrhosis		Vasotec	C	Merck & Co., Inc			
	Liver Disorder		Vitamins (Unspecified)	C				
			Furosemide	C				

Date:11/05/03ISR Number: 4226830-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA03355
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Aspirin	C	Merck & Co., Inc			

Date:11/05/03ISR Number: 4227016-2Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12420261
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lichen Planus		Coaprovel	PS	Bristol-Myers Squibb Company	ORAL		
			Esberiven Fort	SS		ORAL		
			Iskedyl	SS		ORAL		
			Panos	SS		ORAL		
			Vioxx	SS		ORAL	44	DAY

Date:11/05/03ISR Number: 4227409-3Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00170
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Menometrorrhagia		Vioxx	PS		ORAL	5	WK
			Ferrous Glycine					

			Sulfate	C	Merck & Co., Inc	ORAL
			Omeprazole	C		ORAL

Date:11/05/03ISR Number: 4227416-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02021
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS		ORAL
316 DAY						
Initial or Prolonged	Gastric Ulcer Haemorrhage		Diltiazem			
Other			Hydrochloride	C	Merck & Co., Inc	ORAL
			Uroqid-Acid No. 2	C		ORAL
			Macrodantin	C		ORAL
			Exelon	C		ORAL

Date:11/05/03ISR Number: 4227418-4Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS		ORAL
90 DAY						
Hospitalization -	Infarction		Aspirin	C	Merck & Co., Inc	
Initial or Prolonged			Tenormin	C		
Other			Lipitor	C		

				Clonidine	C		
				Monopril	C		

Date:11/05/03ISR Number: 4227429-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01242
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/03ISR Number: 4227439-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA03395
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS		ORAL	1	DAY
Hospitalization -	Gastrointestinal		Vioxx	SS		ORAL	4	DAY
Initial or Prolonged Disability	Haemorrhage		Tylenol	C	Merck & Co., Inc			

Date:11/05/03ISR Number: 4227440-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA00026
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS		ORAL		
			Norvasc	C	Merck & Co., Inc			
			Imitrex	C				

Date:11/05/03ISR Number: 4227641-9Report Type:Direct Company Report #CTU 205278
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure Acute		Vioxx 50 Mg	PS		ORAL	50 MG	PO QD

Date:11/05/03ISR Number: 4227747-4Report Type:Direct Company Report #CTU 205334
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pancreatitis		Declomycin 300 Mg	PS		
4 TIMES / DAY						
Initial or Prolonged	Renal Impairment		Vioxx 25 Mg	SS		
DAILY						

Date:11/05/03ISR Number: 4228815-3Report Type:Expedited (15-DaCompany Report #03P-122-0238372-00
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction	Foreign	Klacid (Biaxin)			
Initial or Prolonged	Epistaxis	Health	(Clarithromycin)			
	International Normalised	Professional	(Clarithromycin)	PS		
250 MG, 2 IN						
	Ratio Increased	Other				
1 D						
			Warfarin Sodium	SS		
40 MG, 1 IN 1						
WK						
			Rofecoxib	SS		
25 MG, 1 IN 1						
D						
			Metronidazole	SS		
400 MG, 2 IN						
1 D						
			Metoprolol Succinate	C		

			Pantoprazole Sodium	C		
			Levothyroxine Sodium	C		

Date:11/06/03ISR Number: 4227947-3Report Type:Expedited (15-DaCompany Report #WAES 0310BEL00009
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 197 DAY	Diverticulum Intestinal		Vioxx	PS		ORAL
Initial or Prolonged 501 DAY	Haemorrhagic		Aspirin	SS	Merck & Co., Inc	ORAL
			Carvedilol	C		ORAL
			Hydrochlorothiazide And Triamterene	C		ORAL

Date:11/06/03ISR Number: 4227951-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA02143
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Balance Disorder		Vioxx	SS		ORAL
	Contusion		Thyroid	C		
	Drug Intolerance					
	Fear Of Disease					
	Haemorrhage					
	Haemorrhage Subcutaneous					
	Muscle Spasms					
	Pain					
	Somnolence					

Date:11/06/03ISR Number: 4227956-4Report Type:Expedited (15-DaCompany Report #WAES 0310FIN00017
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability 8 DAY	Blood Creatinine		Vioxx	PS		ORAL
	Increased		Lithium Carbonate	SS		ORAL

	General Physical Health	Vioxx	SS		ORAL
28 DAY					
	Deterioration	Acetaminophen	C	Merck & Co., Inc	ORAL
	Therapeutic Agent	Cefuroxime	C		ORAL
19 DAY					
	Toxicity	Cefuroxime Sodium	C		
INTRAVENOUS	4 DAY				
		Chlorpromazine Hydrochloride	C		ORAL
		Tolterodine Tartrate	C		
		Tramadol Hydrochloride	C		ORAL
		Zuclopenthixol Hydrochloride	C		
INTRAMUSCULAR					
		Vitamins (Unspecified)	C		ORAL
		Valproate Sodium	C		ORAL
		Valproate Sodium	C		ORAL
		Tolterodine Tartrate	C		ORAL
216 DAY					
		Olanzapine	C		ORAL
		Picosulfate Sodium	C		ORAL
		Lorazepam	C		ORAL
		Etilefrine Hydrochloride	C		ORAL
		Levothyroxine Sodium	C		ORAL
		Levothyroxine Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/03ISR Number: 4228504-5Report Type:Expedited (15-DaCompany Report #WAES 0310FIN00018
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatinine		Vioxx	PS		ORAL	29 DAY	
	Increased		Lithium Carbonate	SS		ORAL		
	General Physical Health		Lithium Carbonate	SS		ORAL		
	Deterioration		Moduretic	C	Merck & Co., Inc	ORAL		
	Therapeutic Agent		Ascorbic Acid And					
	Toxicity		Nitrofurantoin	C		ORAL	10 DAY	
			Picosulfate Sodium	C		ORAL		
			Trimethoprim	C		ORAL		
			Risperidone	C			OPHTHALMIC	
			Propoxyphene					
			Hydrochloride	C			27 DAY	
			Methotrimeprazine	C		ORAL		
			Fluoxetine					
			Hydrochloride	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:11/06/03ISR Number: 4228509-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA00901
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS		ORAL		
Hospitalization -	Haemorrhage		Aspirin	C	Merck & Co., Inc			
Initial or Prolonged	Fall		Cardizem Cd	C				
	Helicobacter Infection		Prozac	C				
	Peptic Ulcer		Lopid	C				

Date:11/06/03ISR Number: 4228515-XReport Type:Expedited (15-DaCompany Report #WAES 0310CHE00032
Age:0 DY Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced		Vioxx	PS			20 DAY	

Other	Complications Of Maternal	Celecoxib	SS	
17 DAY				
	Exposure To Therapeutic	Aspirin Lysine	C	Merck & Co., Inc
4 DAY				
	Drugs	Cinnarizine	C	
1 DAY				
	Maternal Drugs Affecting	Mefenamic Acid	C	
8 DAY				
	Foetus	Morphine	C	
1 DAY				

Date:11/06/03ISR Number: 4228518-5Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00329
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cellulitis		Vioxx	PS		ORAL
8 DAY						
Initial or Prolonged	Pitting Oedema		Bumetanide	C	Merck & Co., Inc	
			Buprenorphine Hydrochloride	C		
			Warfarin	C		
			Verapamil	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/06/03ISR Number: 4228522-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA00034
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS		ORAL		7 DAY
Initial or Prolonged			Lortab	C	Merck & Co., Inc	ORAL		
			Norvasc	C				
			Premarin	C				
			Bextra	C				17 DAY
			Hyzaar	C		ORAL		
			Prevacid	C				

Date:11/06/03ISR Number: 4228540-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA03293
Age:95 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Ineffective		Vioxx	PS		ORAL		3 DAY
Life-Threatening	Myocardial Infarction		[Therapy					
Disability			Unspecified]	C	Merck & Co., Inc			
			Aspirin	C				

Date:11/06/03ISR Number: 4230479-XReport Type:Expedited (15-DaCompany Report #200310354BNE
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Foreign	Aspirin(Acetylsalicy					
	Haemorrhage	Health	lic Acid)	PS				
		Professional	Rofecoxib	SS		ORAL		
		Other	Fosamax	C				
			Co-Codamol	C				
			Bendroflumethiazide	C				
			Nicorandil	C				
			Doxazosin Mesylate	C				
			Fluoxetine	C				
			Prochlorperazine					
			Maleate	C				

Date:11/07/03ISR Number: 4230486-7Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00209
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intentional Misuse		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	No Adverse Drug Effect							
	Suicide Attempt							

Date:11/07/03ISR Number: 4230488-0Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00347
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrapyramidal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
			Valproate Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4230493-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01083
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Operative Haemorrhage							
Other								

Date:11/07/03ISR Number: 4230499-5Report Type:Expedited (15-DaCompany Report #WAES 0310AUS00066
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Febrile		Vioxx	PS		ORAL		
	Neutrophilic Dermatosis		Perindopril Erbumine	C	Merck & Co., Inc			

Date:11/07/03ISR Number: 4230503-4Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00007
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS		ORAL	108	DAY
	Gastritis		Albuterol	C	Merck & Co., Inc	RESPIRATORY		
	Haematemesis					(INHALATION)		
	Oesophagitis		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
			Salmeterol	C		RESPIRATORY (INHALATION)		
			Bendroflumethiazide	C		ORAL		

Date:11/07/03ISR Number: 4230510-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA00083
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Collapse Of Lung		Vioxx	PS		ORAL		
	Lung Disorder		[Therapy Unspecified]	C	Merck & Co., Inc			
	Medication Error		Combivent	C				
	Myocardial Infarction		Alprazolam	C				
	Respiratory Tract Infection		Salmeterol	C				
			Loratadine	C				
			Metoprolol Tartrate	C				
			Rabeprazole Sodium	C				

Date:11/07/03ISR Number: 4230520-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA00267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/07/03ISR Number: 4230521-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA00124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Pulmonary Haemorrhage							
	Pulmonary Mass							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/07/03ISR Number: 4232130-1Report Type:Expedited (15-DaCompany Report #2003CG01523
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia	Foreign	Mopral	PS		
Initial or Prolonged	Biopsy Liver Abnormal	Health	Topalgic	SS	Hoechst	
	Cytolytic Hepatitis	Professional	Profenid	SS	Rhone-Poulenc	
	Pyrexia	Other	Vioxx	SS		

Date:11/07/03ISR Number: 4232233-1Report Type:Expedited (15-DaCompany Report #2003UW14274
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Myocardial Infarction	Foreign	Atenolol	PS		ORAL
12.5 MG DAILY						
Intervention to		Health				
PO 12 DAY						
Prevent Permanent		Professional	Vioxx	SS		ORAL
25 MG DAILY						
Impairment/Damage		Other				
PO 6 DAY						

Date:11/10/03ISR Number: 4231035-XReport Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Neoplasm
Initial or Prolonged	Abdominal Pain Upper
	Arthralgia
	Back Pain
	Blood Pressure Systolic
	Increased
	Body Temperature
	Increased
	Chest Pain
	Coagulation Factor Vii
	Level Increased
	Constipation
	Deep Vein Thrombosis
	Ear Pain
	Face Oedema

Flank Pain
Gastroenteritis
Haematemesis
Headache
Hyperlipidaemia
Iliac Vein Occlusion
Lipoma
Menometrorrhagia
Nasopharyngitis
Nausea
Neoplasm
Oedema Peripheral
Osteoarthritis
Postnasal Drip
Productive Cough
Protein C Increased
Pulmonary Calcification
Pulmonary Granuloma
Sneezing
Urinary Tract Infection
Uterine Leiomyoma
Uterine Neoplasm
Venous Insufficiency

		Venous Stenosis					
		Vomiting					
		Wheezing	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Wound Dehiscence	Health Professional	Vioxx	PS		ORAL
				[Therapy Unspecified]	C	Merck & Co., Inc	
				Aspirin	C		
				Lipitor	C		ORAL
				Tiazac	C		
				Detrol	C		
				Meridia	C		
				Cardura	C		
				Motrin	C		
				Zestril	C		

Date:11/10/03ISR Number: 4231039-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia		Vioxx	PS		ORAL
Hospitalization -	Blood Creatine		Celebrex	SS		
7 DAY						
Initial or Prolonged	Phosphokinase Increased		Vioxx	SS		ORAL
Disability	Contusion		Vioxx	SS		ORAL
Other	Deep Vein Thrombosis		[Therapy Unspecified]	C	Merck & Co., Inc	
	Dehydration		Creatine	C		
	Dialysis		Advil	C		
	Drug Ineffective		Solu-Medrol	C		
	Gastritis					
	Gastroenteritis					
	Glomerulonephritis Focal					
	Glomerulonephritis					
	Membranous					
	Haematemesis					
	Hypersensitivity					
	Hypertension					
	Impaired Healing					
	Injury					
	Joint Sprain					
	Laceration					
	Lobar Pneumonia					
	Lymphadenopathy					
	Nasopharyngitis					

Nephritis Interstitial
Oesophagitis
Plantar Fasciitis
Pulmonary Embolism
Renal Failure Chronic
Renal Transplant
Renal Vessel Disorder
Swelling
Tendon Injury
Tendonitis
Tooth Injury
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/03ISR Number: 4231042-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA03302
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder		Vioxx	PS		ORAL		
	Prescribed Overdose		Vioxx	SS		ORAL		
	Pruritus		Vioxx	SS		ORAL	10	DAY
	Rash Erythematous		Minocycline	C	Merck & Co., Inc			
	Urticaria Papular							

Date:11/10/03ISR Number: 4233161-8Report Type:Expedited (15-DaCompany Report #DSA_23550_2003
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apallic Syndrome	Foreign	Enalapril Maleate	PS		ORAL	10 MG BID PO	
Hospitalization -	Convulsion	Health	Amaryl	SS		ORAL	3 MG Q DAY PO	
Initial or Prolonged	Drug Interaction	Professional	Norvasc	SS		ORAL	5 MG BID PO	
	Hypoglycaemia	Other	Vioxx	SS		ORAL	25 MG QD PO	
	Hypoxic Encephalopathy		Dipyrone	SS			1 U BID	
	Respiratory Failure		Mst	SS		ORAL	20 MG BID PO	
	Simple Partial Seizures		Duragesic	SS			75 MCG Q 3RD	DAY TP
			Fosamax	C				
			Pk-Merz	C				
			Madopar	C				
			Calcium	C				
			Cholecalciferol	C				
			Catapressan	C				
			Enoxaparin	C				
			Neurontin	C				
			Remergil	C				
			Sevredol	C				
			Pantozol	C				

			Dipidolor	C		
			Movicol	C		
			Atosil	C		
			Psyquil	C		

Date:11/10/03ISR Number: 4234482-5Report Type:Expedited (15-DaCompany Report #2003114749
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apallic Syndrome	Foreign	Norvasc (Amlodipine)	PS		ORAL	10 MG (BID),	
	Drug Interaction	Health						
	Hypoglycaemic Seizure	Professional	Glimepiride				ORAL	
	Hypoxic Encephalopathy		(Glimepiride)	SS		ORAL	3 MG (DAILY),	
	Respiratory Failure							
			Enalapril Maleate				ORAL	
			(Enalapril Maleate)	SS		ORAL	20 MG (BID),	
			Rofecoxib					
			(Rofecoxib)	SS		ORAL	25 MG	
			Metamizole Sodium				(DAILY), ORAL	
			(Metamizole Sodium)	SS				
			Morphine Sulfate					
			(Morphine Sulfate)	SS		ORAL	(BID), ORAL	
			Fentanyl (Fentanyl)	C				
			Elomel B (Sodium					
			Acetate, Potassium					

Chloride, Sodium Phosphate Monobasic (Anhydrate), Sodium	C
Madopar (Levodopa, Benserazide Hydrochloride)	C
Amantadine Sulfate (Amantadine Sulfate)	C
Gabapentin (Gabapentin)	C
Pantoprazole Sodium (Pantoprazole Sodium)	C
Calcium-Sandoz Forte (Calcium Carbonate, Calcium Lactogluconate)	C
Colecalciferol (Colecalciferol)	C
Mirtazapine (Mirtazapine)	C
Nulytely (Sodium Bicarbonate, Potassium Chloride, Sodium Chloride, Macrogol)	C
Alendronate Sodium (Alendronate Sodium)	C
Heparin-Fraction, Sodium Salt (Heparin-Fraction, Sodium Salt)	C
Isopromethazine Hydrochloride (Isopromethazine Hydrochloride)	C
Piritramide (Piritramide)	C
Clonidine (Clonidine)	C
Triflupromazine (Triflupromazine)	C

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Back Pain Dyspnoea Loss Of Consciousness Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/03ISR Number: 4233735-4Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00051
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	36 DAY	

Date:11/12/03ISR Number: 4233737-8Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00044
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS		ORAL		
	Renal Failure Acute		Furosemide	SS		ORAL		
			Perindopril Erbumine	SS		ORAL		
			Atorvastatin Calcium	C	Merck & Co., Inc			
			Gabapentin	C				
			Isosorbide Mononitrate	C				
			Warfarin Sodium	C				
			Prednisolone	C				
			Omeprazole Magnesium	C				
			Insulin Lispro	C				
			Digoxin	C				

Date:11/12/03ISR Number: 4233739-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA00570
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS		ORAL	6	DAY
	Oedema Peripheral		Protonix	C	Merck & Co., Inc			
	Pain In Extremity		Penicillin (Unspecified)	C				
	Renal Pain							

Date:11/12/03ISR Number: 4233770-6Report Type:Expedited (15-DaCompany Report #WAES 0310NZL00031
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	SS		ORAL		
			Acetaminophen	C	Merck & Co., Inc			
Disability			Omeprazole	C				

Date:11/12/03ISR Number: 4233772-XReport Type:Expedited (15-DaCompany Report #WAES 0310DEU00101
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged			Benzthiazide And Triamterene	C	Merck & Co., Inc	ORAL		
			Fosinopril Sodium	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Hypericin	C		ORAL		

Date:11/12/03ISR Number: 4233775-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS		ORAL		
Life-Threatening	Death		[Therapy Unspecified]	C	Merck & Co., Inc			
Hospitalization - Initial or Prolonged								

Date:11/12/03ISR Number: 4233776-7Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00015
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL	7	DAY
Hospitalization - Initial or Prolonged			Acetaminophen	C	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Gamolenic Acid	C		ORAL		
			Indapamide	C		ORAL		
			Prinivil	C		ORAL		

Date:11/12/03ISR Number: 4233777-9Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00008
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Erysipelas							

Date:11/12/03ISR Number: 4233787-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA00187
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Discomfort		Vioxx	PS		ORAL	1	DAY
	Dizziness		Vicodin Tablets	C	Merck & Co., Inc			
	Nausea							
	Oedema Peripheral							

Date:11/12/03ISR Number: 4233789-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00532
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS		ORAL	3	WK
Hospitalization -	Confusional State		Prempro	C	Merck & Co., Inc			

Initial or Prolonged		Dizziness		Ambien	C		
Disability		Headache					
		Hypoaesthesia					
		Influenza Like Illness					
		Muscle Twitching					
		Oedema Peripheral					
		Paraesthesia					
		Vision Blurred					

Date:11/12/03ISR Number: 4233791-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA00497
Age:79 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal					
		Haemorrhage					

Date:11/12/03ISR Number: 4233792-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00468
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Coumadin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/03ISR Number: 4233796-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA00115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/03ISR Number: 4233798-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA00529
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Fluid Overload		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/03ISR Number: 4234877-XReport Type:Direct Company Report #CTU 205951
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Oedema Right Ventricular Failure Weight Increased		Vioxx 25 Mg Enalapril L-Thyroxin Aspirin Glyburide Atenolol Kcl Lasix Lipitor Actos Ciproflox Oxycontin Colace Mult Vit Xalatan Levobunolol Opth	PS C C C C C C C C C C C C C C C			1-2 DAILY	2 WK

Date:11/12/03ISR Number: 4235096-3Report Type:Expedited (15-DaCompany Report #2003UW14202
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Bradycardia	Foreign	Atacand	PS		ORAL	8 MG DAILY PO	
Intervention to	Drug Interaction	Health	Vioxx	SS		ORAL	25 MG DAILY	
Prevent Permanent	Hyperkalaemia	Professional					PO	4 DAY
Impairment/Damage	Renal Failure Acute	Other	Lipitor	C				
	Syncope		Metoprolol	C				
			Norvasc	C				
			Bromazepam	C				
			Rivasa	C				

Date:11/12/03ISR Number: 4236072-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01043
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/03ISR Number: 4234019-0Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00026
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS		ORAL		
	Back Pain		Aspirin	SS		ORAL		
	Blood Urea		Ibuprofen	SS		TOPICAL		
	Fatigue		Acetaminophen	C	Merck & Co., Inc			
	Haematemesis		Fosamax	C		ORAL		
	Haemoglobin		Calcium Carbonate And Cholecalciferol	C		ORAL		
	Melaena		Simvastatin	C		ORAL		
	Myocardial Infarction		Levothyroxine Sodium	C		ORAL		
			Dihydrocodeine	C				
			Betahistine Hydrochloride	C				
			Alfacalcidol	C		ORAL		

Date:11/13/03ISR Number: 4234020-7Report Type:Expedited (15-DaCompany Report #WAES 0310CHE00016
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS		ORAL	8	DAY
Hospitalization - Initial or Prolonged	Increased		Carbamazepine	SS	Merck & Co., Inc	ORAL		
	Bradycardia		Lithium Carbonate	SS		ORAL		
	Drug Interaction		Propranolol Hydrochloride	SS		ORAL	1	DAY
	Drug Level Increased		Mirtazapine	C		ORAL		
	Electrocardiogram Abnormal		Pipamperone Hydrochloride	C		ORAL		
	Headache		Zopiclone	C		ORAL		
	Hypotension							
	Malaise							
	Tremor							
	Vomiting							

Date:11/13/03ISR Number: 4234023-2Report Type:Expedited (15-DaCompany Report #WAES 0311NZL00003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Vasculitis Wegener'S Granulomatosis		Vioxx	PS	Merck & Co., Inc			

Date:11/13/03ISR Number: 4234032-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA02501
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/13/03ISR Number: 4234044-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA00295
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Back Disorder Hepatic Failure		Vioxx Metformin	PS C	 Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/03ISR Number: 4234045-1Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Arthralgia		Zocor	PS		ORAL		
	Asthenia		Vioxx	SS		ORAL		
	Bone Pain		Amitriptyline Hydrochloride	C	Merck & Co., Inc			
	Cerebrovascular Accident		Aspirin	C		ORAL		
	Circulatory Collapse		Diclofenac Sodium	C				
	Difficulty In Walking		Dihydrocodeine	C				
	Fall		Gabapentin	C				
	Fatigue		Senna	C				
	Fluid Retention		Morphine Sulfate	C				
	Headache		Nicardipine Hydrochloride	C				
	Loss Of Consciousness		Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C				
	Myalgia		Ranitidine	C				
	Oedema							
	Pain In Extremity							
	Speech Disorder							

Date:11/13/03ISR Number: 4234066-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA00238
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Inappropriate Antidiuretic Hormone Secretion		Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY

Date:11/13/03ISR Number: 4234067-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA01005
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS		ORAL	5	DAY
	Congestive Hypertension		Digoxin	C	Merck & Co., Inc			
			Monopril	C				

	Oedema Peripheral		Glipizide	C		
	Orthopnoea		Avandia	C		
			Coumadin	C		
			Synthroid	C		
			Cytomel	C		
			Toprol Xl Tablets	C		ORAL

Date:11/13/03ISR Number: 4234079-7Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00030
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Extrasystoles							

Date:11/13/03ISR Number: 4234081-5Report Type:Expedited (15-DaCompany Report #WAES 0311NZL00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/13/03ISR Number: 4234459-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA00402
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/13/03ISR Number: 4234903-8Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00030
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Systolic		Vioxx	PS		ORAL	5	DAY
Hospitalization - Initial or Prolonged	Decreased		Glyburide	SS		ORAL		
	Femur Fracture		Hydrochlorothiazide And Ramipril	SS		ORAL		
	General Physical Health Deterioration		Metformin Hydrochloride	SS		ORAL		
	Haemodialysis		Aspirin	C	Merck & Co., Inc			
	Hypoglycaemia		Nifedipine	C				
	Hypokinesia		Moxonidine	C				
	Hypotension		Isosorbide Mononitrate	C				
	Hypovolaemic Shock		Lorazepam	C				
	Metabolic Acidosis							
	Mitral Valve Incompetence							
	Oral Intake Reduced							
	Peritonitis							
	Pneumonia							
	Renal Failure Acute							
	Septic Shock							
	Tachypnoea							

Date:11/13/03ISR Number: 4234904-XReport Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma Hepatic		Vioxx	PS		ORAL		
Hospitalization - Initial or Prolonged	Drug Toxicity		Acenocoumarol	C	Merck & Co., Inc	ORAL		
	Dyspnoea		Acetaminophen	C		ORAL		
	Haemodialysis		Amiodarone Hydrochloride	C		ORAL		
	Hepatic Necrosis		Ascorbic Acid And					
	Hepatitis							

	Hepatitis Fulminant		Vitamin B			
	Hypoglycaemia		(Unspecified)	C		ORAL
	Psychomotor Retardation		Spironolactone	C		ORAL
	Renal Impairment		Tramadol			
	Somnolence		Hydrochloride	C		ORAL
	Weight Increased		Thiamine			
			Hydrochloride	C		ORAL
			Furosemide	C		ORAL
			Lactulose	C		ORAL
			Lorazepam	C		ORAL
			Potassium Chloride	C		ORAL

Date:11/13/03ISR Number: 4234906-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03635
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS		ORAL		30 DAY
Initial or Prolonged	Increased		Vasotec	SS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Furosemide	SS				
	Hyperkalaemia		Potassium					

(Unspecified) C

Date:11/13/03ISR Number: 4234910-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA03315
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS		ORAL		3 DAY
Initial or Prolonged	Cholelithiasis		Norvasc	C	Merck & Co., Inc			
	Cold Sweat		Glucovance	C				
	Dizziness		Hydrodiuril	C		ORAL		
	Feeling Abnormal							
	Feeling Hot							
	Hyperhidrosis							
	Nausea							
	Pain							

Date:11/13/03ISR Number: 4234919-1Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation Neonatal		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Caesarean Section		Sertraline	SS				80 DAY
	Complications Of Maternal							
	Exposure To Therapeutic							
	Drugs							
	Gestational Diabetes							
	Maternal Drugs Affecting							
	Foetus							
	Pre-Eclampsia							
	Pregnancy							
	Sinusitis							
	Streptococcal Infection							

Date:11/13/03ISR Number: 4234929-4Report Type:Expedited (15-DaCompany Report #WAES 0202GBR00116M
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Complications Of Maternal	Vioxx	PS	Merck & Co., Inc	ORAL 80 DAY
Exposure To Therapeutic Drugs Drug Exposure During Pregnancy Gestational Diabetes Pre-Eclampsia Sinusitis Streptococcal Infection	Sertraline	SS		ORAL

Date:11/13/03ISR Number: 4235549-8Report Type:Expedited (15-DaCompany Report #S03-SWI-04412-01
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Akathisia Exanthem Gamma-Glutamyltransferase Increased Monocyte Percentage Increased Neutrophil Count

Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Cipralex (Escitalopram)	PS		ORAL	5 MG QD PO	
Other	Cipralex (Escitalopram)	SS		ORAL	10 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Vioxx (Refecoxibid)	SS		ORAL	12.5 MG QD PO	
	Zyprexa (Olanzapine)	C				
	Temesta (Lorazepam)	C				
	Duphalac (Lactulose)	C				
	Paragol	C				
	Fig Syrup	C				

Date:11/13/03ISR Number: 4235993-9Report Type:Expedited (15-DaCompany Report #2003-10-0325
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Suicide Attempt	Foreign Health Professional	Lisino (Loratadine) Tablets Like Claritin	PS		ORAL	30 MG QD ORAL	
Other	Vomiting		Paracetamol Tablets	SS		ORAL	10 G QD ORAL	

			Ambrodoxy (Ambroxol Hcl/Doxycycline) Capsules	SS		ORAL
10 CAPS. QD ORAL						
			Vioxx (Rofecoxib) Tablets	SS		ORAL
250 MG QD ORAL						
			Acetysalicylic Acid Tablets	SS		ORAL
3 G QD ORAL						

Date:11/13/03ISR Number: 4236006-5Report Type:Expedited (15-DaCompany Report #2003184487GB
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia Blood Urea Decreased Haematemesis Haemoglobin Decreased Melaena	Foreign Health Professional Other	Ibuprofen(Ibuprofen) Tablet, Effervescent	PS		
			Aspirin "Bayer" (Acetylsalicylic Acid)	SS	Bayer	ORAL
15 MG QD, ORAL	Myocardial Infarction					
			Rofecoxib(Rofecoxib)	SS		ORAL
12.5 MG QD, ORAL						
			Alendronic Acid	C		
			Alfacalcidol	C		
			Calcium With Vitamin D (Ergocalciferol, Calcium Phosphate, Calcium Sodium Lactate)	C		

Thyroxine Sodium (Levothyroxine Sodium)	C	
Simvastatin	C	
Betahistine	C	
Paracetamol	C	
Dihydrocodeine	C	

Date:11/14/03ISR Number: 4235398-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA02728
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS		ORAL		
Disability	Asthenia		Norvasc	C	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased		Cardizem	C		ORAL		
			Premarin	C		ORAL		
	Diarrhoea		Claritin	C		ORAL		
	Diverticulum Intestinal		Singulair	C		ORAL		
	Fungal Infection		Mysoline	C		ORAL		
	Helicobacter Infection							
	Hepatomegaly							
	Irritable Bowel Syndrome							
	Liver Function Test Abnormal							
	Nausea							
	Pyrexia							
	Tongue Discolouration							
	Very Low Density Lipoprotein Increased							
	Weight Decreased							
	White Blood Cell Count Decreased							

Date:11/14/03ISR Number: 4235399-2Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS		ORAL	3	DAY
	Diabetes Mellitus		Omeprazole	SS	Merck & Co., Inc		3	DAY

Diarrhoea
Dyspepsia
Gastric Disorder
Renal Failure Chronic

Date:11/14/03ISR Number: 4235409-2Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00082
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumopathy		Vioxx	PS		ORAL		
			Acetaminophen	C	Merck & Co., Inc	ORAL		
			Bromazepam	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Nicardipine Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/03ISR Number: 4235411-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01574
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization - Initial or Prolonged	Arteriovenous Malformation							
Disability	Balance Disorder							
Other	Blood Pressure Decreased							
	Cerebral Haemorrhage							
	Convulsion							
	Decreased Activity							
	Dizziness							
	Face Oedema							
	Impaired Driving Ability							
	Lethargy							
	Nasal Oedema							
	Oedema Peripheral							
	Pain In Extremity							
	Pruritus							
	Renal Failure Acute							
	Renal Pain							
	Vertigo							
	Visual Disturbance							
	Weight Increased							

Date:11/14/03ISR Number: 4235423-7Report Type:Direct Company Report #CTU 206109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Acute		Vioxx Merck	PS	Merck			
	Pollakiuria							

Date:11/14/03ISR Number: 4235426-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA00895
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/14/03ISR Number: 4235753-9Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00052
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY
	Diarrhoea		Vioxx	SS		ORAL		
	Dyspepsia							
	Nausea							

Date:11/14/03ISR Number: 4235787-4Report Type:Expedited (15-DaCompany Report #WAES 0311CHE00010
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema		Vioxx	PS		ORAL		
			Vioxx	SS		ORAL	3	DAY
			Buthiazide And Spironolactone	C	Merck & Co., Inc	ORAL	500	DAY
			Carvedilol	C		ORAL	76	DAY
			Diclofenac	C		ORAL		

				Diosmin And Hesperidin	C		ORAL
371 DAY							
				Lisinopril	C		ORAL
296 DAY							

Date:11/14/03ISR Number: 4235793-XReport Type:Expedited (15-DaCompany Report #WAES 0311DNK00002
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drug Interaction	Health	Vioxx	PS		ORAL
203 DAY						
Life-Threatening	Haematemesis	Professional	Prednisolone	SS		ORAL
2054 DAY						
	Melaena		Risperidone	C		ORAL
325 DAY						
			Digitalis	C	Merck & Co., Inc	ORAL
2166 DAY						
			Furosemide	C		ORAL
2444 DAY						
			Isosorbide Dinitrate	C		ORAL
2166 DAY						
			Mirtazapine	C		ORAL
325 DAY						

Date:11/14/03ISR Number: 4236286-6Report Type:Expedited (15-DaCompany Report #A-US2003-03650
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Alanine Aminotransferase	Health	Tracleer (Bosentan)			
Other	Increased	Professional	Tablet	PS		ORAL
62.5 MG, BID,						
	Aspartate					
ORAL						
	Aminotransferase		Lipitor			
	Increased		(Atorvastatin)	SS		
10 MG, QD						
	Blood Bilirubin Increased		Vioxx (Rofecoxib)	SS		
100 MG						
			Cytoxan (Cyclophosphamide)	C		

			Coumadin (Warfarin Sodium)	C		
			Imdur (Isosorbide Mononitrate)	C		
			Spironolactone (Spironolactone)	C		

Date:11/14/03ISR Number: 4236615-3Report Type:Expedited (15-DaCompany Report #HQWYE704603NOV03
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated Intravascular Coagulation	Health Professional	Cordarex (Amiodarone, Tablet)	PS		ORAL	200 MG 3X PER	1 DAY ORAL 2 DAY
	Electrocardiogram	Other						
	Abnormal Hepatitis Toxic		Vioxx (Rofecoxib, Tablet)	SS		ORAL	SEE IMAGE	2 DAY
	Renal Failure Acute							
	Rhabdomyolysis							
	Ventricular Extrasystoles							

Date:11/17/03ISR Number: 4236300-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA00034
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS		ORAL	4 DAY	
Initial or Prolonged			Lortab	C	Merck & Co., Inc	ORAL	5 DAY	
			Norvasc	C				
			Premarin	C				
			Bextra	C			17 DAY	

				Hyzaar	C		ORAL
				Prevacid	C		

Date:11/17/03ISR Number: 4236316-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01764
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	128	DAY
	Limb Discomfort		Vitamins (Unspecified)	C				

Date:11/17/03ISR Number: 4236318-5Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00019
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL	11	DAY
Initial or Prolonged	Diverticulum Intestinal Haemorrhagic		Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Amlodipine Besylate	C		ORAL		
			Buflomedil Hydrochloride	C		ORAL		
			Diltiazem Malate	C		ORAL		
			Gliclazide	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Omeprazole	C		ORAL		

Date:11/17/03ISR Number: 4236655-4Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00091
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS		ORAL	8	DAY
Initial or Prolonged	Melaena		Acetaminophen	C	Merck & Co., Inc	ORAL		

Aspirin	C		ORAL
Lactulose	C		ORAL
Morphine Sulfate	C		ORAL
Nitroglycerin	C		

Date:11/17/03ISR Number: 4236661-XReport Type:Expedited (15-DaCompany Report #WAES 0304ESP00020
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS		ORAL		19 DAY
Initial or Prolonged	Hepatitis Toxic	Professional	Desloratadine	C	Merck & Co., Inc			
Other	Nephropathy Toxic		Dexchlorpheniramine					
	Renal Failure		Maleate	C				
	Tooth Disorder							

Date:11/17/03ISR Number: 4237014-0Report Type:Expedited (15-DaCompany Report #MK200311-0062-1
Age:74 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Anxiety

		Chills					
		Confusional State					
		Coordination Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis	Foreign	Anafranil 25mg			
		Dehydration		Capsules 100	PS		
		Delirium		Voltaren	SS		
		Disorientation		Ludiomil	SS		
		Disturbance In Attention		Akineton	SS		
		Drug Interaction		Quilnorm	SS		
		Drug Level Increased		Vioxx	SS		
		Drug Toxicity		Cozaar Plus	SS		
		Electroencephalogram		Amlodipine Besilate	C		
		Abnormal		Nexium	C		
		Fluid Intake Reduced		Marcoumar	C		
		Hallucination		Concor	C		
		Pathogen Resistance		Fraxiparin	C		
		Renal Failure					
		Speech Disorder					
		Urinary Tract Infection					

Date:11/18/03ISR Number: 4236836-XReport Type:Expedited (15-DaCompany Report #WAES 0311GBR00113
Age:91 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Duodenal Ulcer		Vioxx	PS		ORAL
		Perforation		Mometasone Furoate	C	Merck & Co., Inc	

Date:11/18/03ISR Number: 4236837-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Atherosclerosis	Health	Vioxx	PS		ORAL
Initial or Prolonged		Arrhythmia	Professional	Aspirin	C	Merck & Co., Inc	
Other		Cerebrovascular Accident		Lipitor	C		
		Cervical Vertebral		Calcium			
		Fracture		(Unspecified)	C		
		Chest Pain		Monopril	C		ORAL
		Laryngitis		Hydrochlorothiazide	C		
		Mitral Valve Incompetence		Adalat	C		
		Road Traffic Accident					

Date:11/18/03ISR Number: 4236843-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA01335
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Accidental Overdose
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Arrhythmia Supraventricular
	Blood Pressure Increased
	Bradycardia
	Cardiac Failure Congestive
	Cardiogenic Shock
	Carotid Artery Stenosis
	Chest Discomfort

		Chest Pain					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease	Health	Vioxx	PS		ORAL
		Electrocardiogram St	Professional	Vioxx	SS		ORAL
		Segment Elevation		Darvocet-N	C	Merck & Co., Inc	
		Electrocardiogram St-T		Aspirin	C		
		Change		Plavix	C		
		Heart Rate Irregular		Vasotec	C		ORAL
		Hypotension		Imdur	C		
		Hypoxia		Synthroid	C		
		Palpitations		Zocor	C		ORAL
		Postoperative Infection		Mylicon	C		ORAL
		Qrs Axis Abnormal		Synthroid	C		
		Staphylococcal Infection		Synthroid	C		
		Ventricular Extrasystoles		Synthroid	C		
				Levothroid	C		
				Zestril	C		
				Nitroglycerin	C		

Date:11/18/03ISR Number: 4236846-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA01420
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/18/03ISR Number: 4236849-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01427
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aphasia		Vioxx	PS		ORAL
Initial or Prolonged	Cerebrovascular Accident		Synthroid	C	Merck & Co., Inc	
			Evista	C		

Date:11/18/03ISR Number: 4237108-XReport Type:Expedited (15-DaCompany Report #WAES 0306FRA00089
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis Necrotising		Vioxx	PS		ORAL	12 DAY	
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C	Merck & Co., Inc		12 DAY	

Date:11/18/03ISR Number: 4237115-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA01475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/03ISR Number: 4237490-3Report Type:Expedited (15-DaCompany Report #WAES 0311AUS00024
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS		ORAL		
	Flatulence		Calcium Ascorbate	C	Merck & Co., Inc			
			Doxepin Hydrochloride	C				

				Garlic Extract	C		
				Hydrochlorothiazide And Irbesartan	C		ORAL
				Indapamide	C		
				Insulin	C		
				Metformin Hydrochloride	C		ORAL

Date:11/19/03ISR Number: 4237491-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01562
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Disorder		Vioxx	PS		ORAL		
	Renal Disorder		Nexium	C	Merck & Co., Inc			
			Lasix (Furosemide)	C				
			Hydrochlorothiazide And Lisinopril	C				
			Nolvadex	C				
			Potassium (Unspecified)	C				
			Pravachol	C				

Date:11/19/03ISR Number: 4237777-4Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bacterial Infection		Vioxx	PS		ORAL	9	DAY
	Dermatitis		Vioxx	SS		ORAL	21	DAY
	Drug Eruption		Atorvastatin Calcium	C	Merck & Co., Inc	ORAL		
	Graft Versus Host Disease		Diclofenac	C			3	DAY
	Mycosis Fungoides		Tramadol Hydrochloride	C		ORAL		
	Non-Hodgkin'S Lymphoma		Dipyrone	C		ORAL		
	Pain		Metoprolol Succinate	C		ORAL		
	Skin Exfoliation							

Date:11/19/03ISR Number: 4237781-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA02975
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Vioxx	PS		ORAL	4	DAY
	Inflammation		Norvasc	C	Merck & Co., Inc			
	Pruritus		Premarin	C				
	Rash		Allegra	C				
			Micardis	C				
			Lasix (Furosemide)	C				
			Pravachol	C				
			Zantac	C				

Date:11/19/03ISR Number: 4237788-9Report Type:Expedited (15-DaCompany Report #WAES 0311NOR00008
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Interstitial Lung Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/03ISR Number: 4237791-9Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00030
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS		ORAL		1 YR
Initial or Prolonged	Diverticulum Intestinal		Clopidogrel Bisulfate	SS		ORAL		1 YR
	Drug Interaction							
	Gastric Ulcer		Acetaminophen	C	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Tiapride	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		

Date:11/19/03ISR Number: 4239252-XReport Type:Expedited (15-DaCompany Report #US048583
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Foreign	Enbrel	PS			SUBCUTANEOUS	25 MG, TWICE WEEKLY, SC
	Haemorrhage Subcutaneous	Health Professional	Rofecoxib	SS		ORAL	25 MG, DAILY, PO	
			Morphine Sulfate	C				
			Prednisone	C				
			Calcium Carbonate	C				
			Spironolactone & Furosemide	C				

Date:11/20/03ISR Number: 4238310-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA01036
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive							

Date:11/20/03ISR Number: 4238312-7Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00003
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS		ORAL	27	DAY
			Hydroflumethiazide And Spironolactone	C	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Perindopril	C		ORAL		

Date:11/20/03ISR Number: 4238316-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA02107
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS		ORAL		
	Fall		Pepcid	C	Merck & Co., Inc	ORAL		
Disability			Hemocyte	C		ORAL		
Other			Dyazide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238322-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA01318
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged								
Disability								

Date:11/20/03ISR Number: 4238642-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01516
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS		ORAL		
	Cardio-Respiratory Arrest		Beclomethasone Dipropionate	C	Merck & Co., Inc	RESPIRATORY (INHALATION)		
	Coma							
	Seborrhoeic Keratosis		Allegra	C				
	Ventricular Fibrillation		Zocor	C		ORAL		
			Adalat	C				
			Zantac	C				

Date:11/20/03ISR Number: 4238643-0Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00051
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis		Vioxx	PS		ORAL		
	Haemoglobin Decreased		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	SS	Merck & Co., Inc	ORAL		
	Intestinal Haemorrhage							

Date:11/20/03ISR Number: 4238647-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01006
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemiparesis		Vioxx	PS		ORAL		
			Pepcid	C	Merck & Co., Inc	ORAL		
			Hemocyte	C				

Date:11/20/03ISR Number: 4238648-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA01208
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/20/03ISR Number: 4238651-XReport Type:Expedited (15-DaCompany Report #WAES 0311DEU00062
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/20/03ISR Number: 4238653-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA01171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS		ORAL		
			Motrin	C	Merck & Co., Inc			

Date:11/20/03ISR Number: 4238654-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01206
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/20/03ISR Number: 4238655-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA01019
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer Renal Infarct		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/03ISR Number: 4239144-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01242
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/03ISR Number: 4239145-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged

Date:11/21/03ISR Number: 4239146-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA01798
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Paraesthesia Paraesthesia Oral Stomatitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/03ISR Number: 4239148-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA01197
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/21/03ISR Number: 4239149-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01065
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anosmia		Vioxx	PS		ORAL	4	DAY
	Dermatitis Allergic		[Therapy Unspecified]	C	Merck & Co., Inc	ORAL	4	DAY

Date:11/21/03ISR Number: 4239150-1Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00006
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS		ORAL	9	DAY
	Suicidal Ideation		Lansoprazole	C	Merck & Co., Inc	ORAL	30	DAY

Date:11/21/03ISR Number: 4239155-0Report Type:Expedited (15-DaCompany Report #WAES 0311USA01998
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Surgery		Vioxx	PS		ORAL		
Disability			[Therapy Unspecified]	C	Merck & Co., Inc			
PARENTERAL								
			Aspirin	C				
			Lipitor	C				
			Plavix	C				
			Enalapril Maleate	C		ORAL		
			Lithium Carbonate	C				
			Glucophage	C				

Date:11/21/03ISR Number: 4239158-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA01978
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		167 DAY
Initial or Prolonged	Nephritis Interstitial							

Date:11/21/03ISR Number: 4239159-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eye Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Rash							
	Swelling Face							
	Urticaria							

Date:11/21/03ISR Number: 4239436-0Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00179
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL		
Hospitalization -	Overdose		Vioxx	SS		ORAL		
Initial or Prolonged			Betaxolol Hydrochloride	C	Merck & Co., Inc	ORAL		
			Felodipine And Ramipril	C		ORAL		
			Insulin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/03ISR Number: 4239437-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS		ORAL		
	Bundle Branch Block Left		Lasix (Furosemide)	SS				
	Cardiac Failure		Lasix (Furosemide)	SS			INTRAVENOUS	
	Congestive		Vioxx	SS		ORAL		
	Cardiomegaly		Vioxx	SS		ORAL		
	Change Of Bowel Habit		Femhrt	C	Merck & Co., Inc			
	Constipation		Plaquenil	C				
	Contusion		Timoptic	C			OPHTHALMIC	
	Coronary Artery Disease		Advil	C				
	Coronary Artery Stenosis		Lotemax	C			OPHTHALMIC	
	Crackles Lung		Lopressor	C				
	Depression		Centrum	C				
	Difficulty In Walking		Salagen Tablets	C				
	Dizziness							
	Drug Hypersensitivity							
	Fall							
	Glaucoma							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypercholesterolaemia							
	Hypertension							
	Ischaemic Cardiomyopathy							
	Joint Sprain							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nephropathy Toxic							
	Orthostatic Hypotension							
	Pleural Effusion							
	Pneumonitis							
	Pulmonary Oedema							
	Pulmonary Valve Incompetence							
	Renal Failure							
	Respiratory Distress							
	Respiratory Rate Increased							
	Rosacea							
	Thrombocytopenia							
	Tooth Injury							

Tricuspid Valve
Incompetence
Ventricular Dysfunction
Visual Acuity Reduced

Date:11/21/03ISR Number: 4239442-6Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00047
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - DAY	Haemoglobin Decreased		Vioxx	PS		ORAL		
Initial or Prolonged	Rectal Haemorrhage		Aspirin Lysine	C	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/21/03ISR Number: 4239449-9Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00166
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS		ORAL		3 DAY
Initial or Prolonged	Nausea		Acetaminophen	C	Merck & Co., Inc	ORAL		
	Renal Colic		Aspirin	C		ORAL		
	Urinary Tract Infection		Tramadol Hydrochloride	C		ORAL		
			Zocor	C		ORAL		
			Aspirin	C		ORAL		

Date:11/21/03ISR Number: 4239451-7Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00026
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased		Vioxx	PS		ORAL		32 DAY
Initial or Prolonged	Drug Interaction		Amiloride Hydrochloride And Hydrochlorothiazide	SS		ORAL		32 DAY
	Renal Failure Acute							
	Urinary Tract Infection							
	Enterococcal		Acetaminophen	C	Merck & Co., Inc	ORAL		
			Anthocyanins (Unspecified)	C		ORAL		
			Aspirin	C		ORAL		
			Mianserin Hydrochloride	C		ORAL		
			Nifuroxazide	C		ORAL		

Date:11/21/03ISR Number: 4239452-9Report Type:Expedited (15-DaCompany Report #WAES 0311NLD00013
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Haemorrhage		Vioxx	PS				
Life-Threatening			Aspirin	C	Merck & Co., Inc			
Hospitalization -			Chlorthalidone	C				
Initial or Prolonged			Domperidone	C				

Date:11/21/03ISR Number: 4239453-0Report Type:Expedited (15-DaCompany Report #WAES 0311NOR00010
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hemiparesis		Vioxx	PS		ORAL		11 DAY
Initial or Prolonged	Transient Ischaemic Attack		Carisoprodol	C	Merck & Co., Inc	ORAL		
			Dipyrone	C		ORAL		

Date:11/24/03ISR Number: 4240189-0Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00159
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Anxiety Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/03ISR Number: 4240198-1Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00160
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS		ORAL
Initial or Prolonged	Gastric Ulcer		Aspirin	SS		ORAL
	Haematemesis		Acetaminophen And			
	Melaena		Codeine	C	Merck & Co., Inc	ORAL
			Atenolol	C		ORAL
			Bumetanide	C		ORAL
			Venlafaxine			
			Hydrochloride	C		
			Cyclizine	C		ORAL
			Folic Acid	C		ORAL
			Polyethylene Glycol			
			3350 And Potassium			
			Chloride And Sodium			
			Bicarbonate And			
			Sodium Chloride	C		

Date:11/24/03ISR Number: 4240564-4Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00076
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amaurosis		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Initial or Prolonged			Vioxx	SS		ORAL
1 DAY						

Date:11/24/03ISR Number: 4240570-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA01866
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chronic Obstructive		Vioxx	PS		ORAL
Hospitalization -	Airways Disease		Lotensin	C	Merck & Co., Inc	
Initial or Prolonged	Exacerbated		Colace	C		
Disability	Chronic Obstructive		Nexium	C		
	Pulmonary Disease		Tricor	C		
	Diabetic Ketoacidosis		Insulin	C		
	Hyperchloraemia					

Myocardial Infarction
Renal Failure
Therapeutic Agent
Toxicity

Date:11/24/03ISR Number: 4240572-3Report Type:Expedited (15-DaCompany Report #WAES 0311ZAF00015
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/03ISR Number: 4240574-7Report Type:Expedited (15-DaCompany Report #WAES 0311ZAF00014
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/03ISR Number: 4240606-6Report Type:Direct Company Report #CTU 206712
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial		Vioxx 25mg	PS			25MG DAILY	2 WK
	Infarction		Bextra 20 Mg	SS			20 MG DAILY	2 WK
	Cardiac Failure		Furosemide	C				
	Congestive		Cardizem Cd	C				
	Condition Aggravated		Digoxin	C				
	Renal Failure		Kcl	C				
			Zantac	C				
			Spironolactone	C				

Date:11/24/03ISR Number: 4240651-0Report Type:Direct Company Report #CTU 206774
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Photopsia		Vioxx (Very Mild) ?	PS			1 PER DAY	1 MON
Intervention to Prevent Permanent Impairment/Damage	Visual Disturbance		Atenolol	C				
			Levoxyl	C				

Date:11/24/03ISR Number: 4241241-6Report Type:Expedited (15-DaCompany Report #2003GB00586
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Foreign	Omeprazole	PS				
	Diabetes Mellitus	Health	Rofecoxib	SS		ORAL	12.5 MG DAILY	
	Diarrhoea	Professional					PO	
	Dyspepsia	Other						
	Renal Failure Chronic							

Date:11/24/03ISR Number: 4241411-7Report Type:Expedited (15-DaCompany Report #2003-10-0325
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Multiple Drug Overdose Suicide Attempt Vomiting	Foreign Health Professional	Lisino (Loratadine) Tablets Like Claritin	PS		ORAL	30 MG QD ORAL	
Other			Paracetamol Tablets	SS		ORAL	10 G QD ORAL	
			Ambrodoxy (Ambroxol Hcl/Doxycycline) Capsules	SS		ORAL	10 CAPS QD ORAL	
			Vioxx (Rofecoxib) Tablets	SS		ORAL	250 MG QD ORAL	
			Acetylsalicylic Acid Tablets	SS		ORAL	3 G QD ORAL	

Date:11/25/03ISR Number: 4240770-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0314623A
Age:90 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Cardiac Murmur
Other	Diverticulum Intestinal
	Drug Interaction

	Pallor						
	Rectal Haemorrhage						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Deroxat	PS	Glaxosmithkline	ORAL		
			Vioxx	SS		ORAL		
			Plavix	SS		ORAL		
			Efferalgan	C	Glaxosmithkline	ORAL		
			Tiapridal	C		ORAL		
			Detensiel	C		ORAL		

Date:11/25/03ISR Number: 4241051-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA02165
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Face Oedema		[Therapy					
	Haematemesis		Unspecified]	C				
			Prilosec	C				

Date:11/25/03ISR Number: 4241055-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA01065
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anosmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Dermatitis Allergic	Professional	Flexofen	SS		ORAL	4	DAY

Date:11/25/03ISR Number: 4241056-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA01782
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Palpitations		[Therapy					

	Trigger Finger		Unspecified]	C		

Date:11/25/03ISR Number: 4241122-8Report Type:Expedited (15-DaCompany Report #WAES 0311CAN00077
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR

Date:11/25/03ISR Number: 4241124-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA02161
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Hypertension Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/25/03ISR Number: 4241125-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA02143
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Impaired Healing		Vioxx	SS	Merck & Co., Inc	ORAL		
	Incision Site Haemorrhage		Enoxaparin Sodium	C				
	Post Procedural Complication							

Date:11/25/03ISR Number: 4241126-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA02289
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/25/03ISR Number: 4241127-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02374
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1 WK	
	Generalised Oedema							

Date:11/25/03ISR Number: 4241821-8Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00026
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	32 DAY	
	Enterococcal Infection		Amiloride Hydrochloride And Hydrochlorothiazide	SS		ORAL	32 DAY	
	Renal Failure Acute							
	Urine Analysis Abnormal							
			Acetaminophen	C		ORAL		
			Anthocyanins (Unspecified)	C		ORAL		

			Aspirin	C		ORAL
			Mianserin Hydrochloride	C		ORAL
			Nifuroxazide	C		ORAL

Date:11/25/03ISR Number: 4241822-XReport Type:Expedited (15-DaCompany Report #WAES 0311NOR00008
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased Interstitial Lung Disease	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/25/03ISR Number: 4241828-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02422
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Chloride Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Diabetes Mellitus Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vitamins (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/25/03ISR Number: 4241830-9Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00173
Age:87 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Atenolol	C		ORAL		
	Haematemesis		Bendroflumethiazide	C		ORAL		

Date:11/25/03ISR Number: 4241833-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA01006
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemiparesis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Pepcid	C		ORAL		
			Hemocyte	C				

Date:11/25/03ISR Number: 4241837-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA02372
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		[Therapy					
	Transient Ischaemic		Unspecified]	C				
	Attack		Tylenol	C				
			Guaifenex	C				
			Hydrochlorothiazide	C				
			Singulair	C		ORAL		

Date:11/25/03ISR Number: 4241838-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA00529
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Fluid Overload							

Date:11/25/03ISR Number: 4241839-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01514
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	19	DAY
	Congestive		Ecotrin	C		ORAL		
	Ventricular Hypertrophy		Celebrex	C		ORAL		
			Glucotrol Xl	C		ORAL		
			Lisinopril	C		ORAL		
			Lisinopril	C		ORAL		
			Aciphex	C		ORAL		

Date:11/25/03ISR Number: 4241841-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA00083
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Collapse Of Lung
	Medication Error
	Myocardial Infarction
	Procedural Complication

		Respiratory Tract Infection					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
				Albuterol	C		
				Combivent	C		
				Salmeterol	C		
				Alprazolam	C		
				Loratadine	C		
				Metoprolol Tartrate	C		
				Rabeprazole Sodium	C		

Date:11/25/03ISR Number: 4241843-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02107
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL
Other			Pepcid	C		ORAL
			Hemocyte	C		ORAL
			Dyazide	C		ORAL

Date:11/25/03ISR Number: 4241844-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02088
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged Disability						

Date:11/25/03ISR Number: 4241845-0Report Type:Expedited (15-DaCompany Report #WAES 0311USA02120
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Rectal Haemorrhage		Vioxx Flomax (Morniflumate)	PS C	Merck & Co., Inc	ORAL		

Date:11/25/03ISR Number: 4241846-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02253
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dialysis Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/25/03ISR Number: 4241848-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA02387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cystitis Hydronephrosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/25/03ISR Number: 4243019-6Report Type:Periodic Company Report #2003032751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Arteriogram Coronary Abnormal Cardiac Stress Test Abnormal Coronary Artery Disease Hypertension	Health Professional	Lipitor (Atorvastatin)	PS				
			Enalapril Maleate (Enalapril Maleate)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Oxygen (Oxygen)	SS				
			Clopidogrel Sulfate (Clopidogrel Sulfate)	SS				
			Hydrochlorothiazide (Hydrochlorothiazide)	C				
			Udramil (Verapamil Hydrochloride, Trandolapril)	C				
			Verapamil Hydrochloride (Verapamil Hydrochloride)	C				
			Trandolapril (Trandolapril)	C				

Date:11/26/03ISR Number: 4242352-1Report Type:Direct Company Report #CTU 206904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Perforation		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD ORAL	

Date:11/28/03ISR Number: 4243184-0Report Type:Direct Company Report #CTU 207006
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Renal Impairment		Vioxx	PS		ORAL
12.5 MG BID PO						

Date:12/01/03ISR Number: 4243224-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02236
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Hospitalization - Initial or Prolonged	Blood Pressure Increased Feeling Abnormal Heart Rate Decreased Loss Of Consciousness Memory Impairment Speech Disorder		Accupril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/03ISR Number: 4243228-6Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Desloratadine	C		ORAL		
	Haemorrhage		Indapamide	C		ORAL		
	Haematemesis		Pravastatin Sodium	C		ORAL		

Date:12/01/03ISR Number: 4243229-8Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00204
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Amlodipine Maleate	C		ORAL		
	Dyspnoea		Antimicrobial (Unspecified)	C				
			Clopidogrel Bisulfate	C		ORAL		
			Zopiclone	C		ORAL		
			Mirtazapine	C		ORAL		
			Omeprazole	C		ORAL		

Date:12/01/03ISR Number: 4243231-6Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00200
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis Erosive		Aspirin	C		ORAL		
	Haematemesis		Atenolol And Chlorthalidone	C		ORAL		
	Melaena							

Date:12/01/03ISR Number: 4243232-8Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00212
Age:41 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination		Vioxx	PS	Merck & Co., Inc	ORAL		

Headache
Irritability
Tremor
Visual Disturbance

Date:12/01/03ISR Number: 4243233-XReport Type:Expedited (15-DaCompany Report #WAES 0311GBR00211
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
	Condition Aggravated							
	Wheezing							

Date:12/01/03ISR Number: 4243318-8Report Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	MIN
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	1	MIN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/03ISR Number: 4243324-3Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00065
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Bullous		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Multiple Myeloma		Captopril	C		ORAL		
			Digoxin	C		ORAL		
			Furosemide	C		ORAL		

Date:12/01/03ISR Number: 4243326-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02216
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Blood Pressure Increased		Fosamax	C		ORAL		
	Myocardial Infarction		Synthroid	C				
	Sinus Tachycardia		Zocor	C		ORAL		
			Prilosec	C				

Date:12/01/03ISR Number: 4243330-9Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00033
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Phlebitis		Chondroitin Sulfate					
	Vomiting		Sodium	C		ORAL		
			Fluvastatin Sodium	C		ORAL		
			Irbesartan	C		ORAL		
			Omeprazole	C		ORAL		

Date:12/01/03ISR Number: 4243331-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		

	Dermatitis Contact		Vioxx	SS	Merck & Co., Inc	ORAL
	Intracardiac Thrombus		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Colchicine	C		
			Kenalog	C		
PARENTERAL						
			Indocin (Indomethacin)	C		
			Ultram	C		
			Bactroban	C		

Date:12/01/03ISR Number: 4243336-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00901
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fall		Aspirin	C		
	Gastric Ulcer Haemorrhage		Cardizem Cd	C		
	Helicobacter Infection		Prozac	C		
			Lopid	C		

Date:12/01/03ISR Number: 4243341-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01477
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
	Antiphospholipid		Globulin, Immune	SS		INTRAVENOUS		
Other	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pyruvic Acid Decreased		Tegretol	C				
	Cerebrovascular Accident							
	Convulsion							
	Electroencephalogram Abnormal							
	Hypertension							
	Medication Error							
	Transient Ischaemic Attack							

Date:12/01/03ISR Number: 4243344-9Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00046
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage Subcutaneous		Etanercept	SS		SUBCUTANEOUS		
			Calcium Carbonate	C		ORAL		
			Furosemide And Spironolactone	C		ORAL		
			Morphine Sulfate	C				
			Prednisone	C				

Date:12/01/03ISR Number: 4243347-4Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Initial or Prolonged	Haemoglobin Decreased		Aspirin	SS		ORAL		
	Melaena		Aspirin	SS		ORAL		

		Amiloride Hydrochloride And Furosemide	C	ORAL
		Atenolol	C	ORAL
		Atorvastatin Calcium	C	ORAL
		Isosorbide Mononitrate	C	ORAL
		Nicorandil	C	ORAL

Date:12/01/03ISR Number: 4243348-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA02435
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
	Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL		
			Calcium Citrate	C		ORAL		
			Vitamins (Unspecified)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/03ISR Number: 4243353-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA02115
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Flexeril	C				
			Monopril	C				
	Carpal Tunnel Syndrome		Pravachol	C				
	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							
	Dermoid Cyst							
	Diabetes Mellitus Non-Insulin-Dependent							
	Emotional Distress							
	Low Density Lipoprotein Increased							
	Lyme Disease							
	Nerve Compression							
	Polytraumatism							
	Sinus Bradycardia							
	Tendonitis							
	Trigger Finger							
	Weight Decreased							
	White Blood Cell Count Increased							

Date:12/01/03ISR Number: 4243357-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		[Therapy Unspecified]	SS				

Date:12/01/03ISR Number: 4243358-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02577
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/01/03ISR Number: 4243361-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02575
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Failure							

Date:12/01/03ISR Number: 4243708-3Report Type:Expedited (15-DaCompany Report #WAES 0311CHE00037
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Metastases To Lung		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
			Acetaminophen	C		ORAL	2	MON

				Diclofenac Sodium	C		ORAL
1 DAY							
				Tramadol Hydrochloride	C		ORAL
2 DAY							
				Misoprostol And Diclofenac Sodium	C		ORAL
3 DAY							
				Fentanyl	C		
SUBCUTANEOUS	5	DAY					
				Morphine	C		
SUBCUTANEOUS	2	DAY					

Date:12/01/03ISR Number: 4243711-3Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00075
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Diarrhoea Haemorrhagic							

Date:12/01/03ISR Number: 4243712-5Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00031
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	366	DAY
	Pulmonary Congestion		Allopurinol	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Magnesium Chloride	C				

Date:12/01/03ISR Number: 4243729-0Report Type:Direct Company Report #CTU 207068
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Required	Aspartate		Vioxx 25 Mg	PS		ORAL
50 MG QD ORAL						
Intervention to	Aminotransferase		Guaifenesin Sa	C		
Prevent Permanent	Increased		Cyclobenzaprine	C		
Impairment/Damage	Liver Function Test		Ranitidine	C		
	Abnormal		Coumadin	C		

Date:12/02/03ISR Number: 4243966-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00479
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Life-Threatening	Death		Vioxx	SS	Merck & Co., Inc	ORAL
3 DAY						
Hospitalization -	Dyspnoea		[Therapy			
Initial or Prolonged	Weight Increased		Unspecified]	C		

Date:12/02/03ISR Number: 4243973-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA03098
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
	Muscle Rigidity		Vioxx	SS	Merck & Co., Inc	ORAL
	Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Cortisone	C		

			Ibuprofen	C		

Date:12/02/03ISR Number: 4243974-4Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00151
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Urinary Retention		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/02/03ISR Number: 4243975-6Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00083
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Creatinine		Aspirin	SS		ORAL		
	Increased		Amlodipine Maleate	C		ORAL		
	Blood Potassium Increased		Vasotec	C		ORAL		
	Blood Urea Increased		Ketoprofen	C		TOPICAL		
	Gastritis Atrophic		Pravastatin Sodium	C		ORAL		
	Oesophageal Haemorrhage							
	Oesophageal Ulcer							
	Haemorrhage							
	Oesophagitis							

Date:12/02/03ISR Number: 4243977-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA00873
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Renal Disorder							
	Renal Failure							

Date:12/02/03ISR Number: 4244407-4Report Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Arthralgia
	Back Pain
	Blood Cholesterol Increased
	Chest Pain
	Coagulation Factor Vii Level Increased
	Constipation
	Cough
	Deep Vein Thrombosis
	Face Oedema
	Flank Pain
	Haematemesis
	Haemoptysis
	Headache
	Hypertension
	Iliac Vein Occlusion
	Low Density Lipoprotein Increased

		Menometrorrhagia					
		Nausea					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Postnasal Drip		Vioxx	PS	Merck & Co., Inc	ORAL
		Productive Cough		[Therapy			
		Urinary Tract Infection		Unspecified]	C		
		Uterine Enlargement		Aspirin	C		
		Uterine Neoplasm		Lipitor	C		ORAL
		Venous Insufficiency		Tiazac	C		
		Venous Stenosis		Detrol	C		
		Vomiting		Meridia	C		
		Wheezing		Cardura	C		
		Wound Dehiscence		Motrin	C		
				Zestril	C		

Date:12/02/03ISR Number: 4244420-7Report Type:Expedited (15-DaCompany Report #WAES 0311ESP00036
Age:63 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
34 DAY							
		Asthenia		Carvedilol	C		ORAL
		Blood Pressure Increased		Citalopram			
		Chest Pain		Hydrobromide	C		ORAL
		Dyspnoea		Zopiclone	C		ORAL
		Genital Burning Sensation		Indapamide	C		ORAL
				Quinapril			
				Hydrochloride	C		ORAL

Date:12/02/03ISR Number: 4244421-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02750
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -							
Initial or Prolonged							

Date:12/02/03ISR Number: 4244661-9Report Type:Direct Company Report #CTU 207177
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Gastritis		Vioxx 25 Mg	PS				
DAILY								
Intervention to			Hyosyamine	C				
Prevent Permanent			Colchicine	C				
Impairment/Damage			Nasonex	C				
			Clariton	C				
			Fibercon	C				
			Calcium	C				
			Fish Oil	C				
			Ambien	C				
			Amytriptoline	C				
			Estrodil	C				
			Prometrium	C				
			Aberteral	C				
			Multi Vitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/03ISR Number: 4245534-8Report Type:Direct Company Report #CTU 207277
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecchymosis		Vioxx 50 Mg	PS		ORAL	25 MG PO ORAL	
Initial or Prolonged	Haemorrhage							
	Pruritus							
	Rash Erythematous							

Date:12/03/03ISR Number: 4245412-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA00020
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc			
Life-Threatening								
Hospitalization -								
Initial or Prolonged								

Date:12/03/03ISR Number: 4245424-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA00884
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	59 DAY	
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	59 DAY	
Initial or Prolonged	Dyspnoea		Hyzaar	C		ORAL		
Disability	Myocardial Infarction							
Other								

Date:12/03/03ISR Number: 4245429-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA02120
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Flomax					

	Rectal Haemorrhage		(Morniflumate)	C		
	White Blood Cell Count Decreased					

Date:12/03/03ISR Number: 4245430-6Report Type:Expedited (15-DaCompany Report #WAES 0312AUS00005
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL

Date:12/03/03ISR Number: 4245433-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA02372
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Dizziness		[Therapy			
	Transient Ischaemic		Unspecified]	C		
	Attack		Tylenol	C		
			Guaifenex	C		
			Hydrochlorothiazide	C		
			Singulair	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/03ISR Number: 4245755-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA01034
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	82	DAY
	Joint Effusion		Vioxx	SS	Merck & Co., Inc	ORAL	82	DAY
			[Therapy Unspecified]	C				
			Tylenol	C				

Date:12/04/03ISR Number: 4245756-6Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00211
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Cataract		Aspirin	C		ORAL		
	Disorientation		Atorvastatin Calcium	C		ORAL		
	Retinal Degeneration		Diltiazem Hydrochloride	C		ORAL		
	Visual Acuity Reduced							

Date:12/04/03ISR Number: 4245760-8Report Type:Expedited (15-DaCompany Report #WAES 0311ITA00017
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Renal Failure Acute							

Date:12/04/03ISR Number: 4245764-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00034
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Initial or Prolonged	Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY				
	Lortab	C		ORAL
5 DAY				
	Lortab	C		ORAL
5 DAY				
	Norvasc	C		ORAL
	Bextra	C		ORAL
17 DAY				
	Bextra	C		ORAL
17 DAY				
	Premarin	C		ORAL
	Hyzaar	C		ORAL
	Prevacid	C		
	Prilosec	C		ORAL

Date:12/04/03ISR Number: 4245837-7Report Type:Expedited (15-DaCompany Report #WAES 0303USA02180
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Blood Pressure Decreased
Initial or Prolonged	Body Temperature
Disability	Increased
	Cardiomyopathy
	Cerebral Artery Occlusion
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Dehydration
	Diabetes Mellitus

	Inadequate Control						
	Diabetic Neuropathy						
	Dizziness						
	Dysarthria	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Essential Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Face Injury		Cipro	C			7	DAY
	Fall		Glucophage	C				
	Heart Rate Increased							
	Hypoglycaemia							
	Iron Deficiency Anaemia							
	Lymphadenopathy							
	Melaena							
	Oedema							
	Pleural Effusion							
	Pleuritic Pain							
	Pneumonia							
	Pseudobulbar Palsy							
	Pulmonary Hypertension							
	Renal Failure							
	Respiratory Rate Increased							
	Retinal Ischaemia							
	Road Traffic Accident							
	Sinusitis							
	Skin Ulcer							
	Thrombosis							
	Urinary Tract Infection							
	Weight Increased							

Date:12/04/03ISR Number: 4245838-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01099
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	91	DAY

Date:12/04/03ISR Number: 4245839-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome PT

Disability	Abdominal Pain Upper
Other	Anxiety
	Asthenia
	Back Pain
	Blood Triglycerides
	Increased
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coagulopathy
	Contusion
	Deafness Bilateral
	Drug Ineffective
	Dyspnoea
	Dysuria
	Epistaxis
	Gastrointestinal Disorder
	Gingival Bleeding

		Haematochezia					
		Haemorrhage					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		[Therapy			
		Lung Disorder		Unspecified]	C		
		Menstrual Disorder		Tylenol	C		
		Oedema Peripheral		Vicodin Tablets	C		
		Osteoarthritis		Albuterol	C		
		Silent Myocardial		Bayer Aspirin	C		
		Infarction		Bayer Aspirin	C		
		Stress Incontinence		Aspirin	C		
		Transient Ischaemic		Coumadin	C		
		Attack		Coumadin	C		
		Upper Gastrointestinal		Ticlid	C		
		Haemorrhage		Atenolol	C		
				Atenolol	C		
				Digoxin	C		
				Vasotec	C		ORAL
				Lopressor	C		
				Naproxen	C		
				Nitrostat	C		

Date:12/04/03ISR Number: 4245844-4Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Lower
Disability	Adnexa Uteri Mass
Other	Angina Unstable
	Anxiety
	Arthralgia
	Asthenia
	Atherosclerosis
	Back Pain
	Balance Disorder
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Discomfort
	Chills
	Constipation

Cystocele
Depression
Difficulty In Walking
Dysarthria
Ear Pain
Enterocele
Facial Palsy
Fibromyalgia
Flatulence
Ganglion
Haematochezia
Headache
Hearing Impaired
Hyperlipidaemia
Hypoaesthesia Oral
Hypokalaemia

		Incontinence					
		Insomnia					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Stiffness		Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Ovarian Cyst		Flexeril	C		ORAL
		Pain		Colace	C		
		Paraesthesia		Coumadin	C		
		Pelvic Pain		Trazodone			
		Phlebitis Superficial		Hydrochloride	C		
		Pollakiuria		Maxzide	C		
		Rectocele		Paxil	C		
		Sinus Headache		Potassium Chloride	C		
		Stress Incontinence					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Tympanic Membrane					
		Disorder					
		Uterine Prolapse					

Date:12/04/03ISR Number: 4245853-5Report Type:Expedited (15-DaCompany Report #WAES 0312AUS00004
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Fall		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Renal Failure		[Therapy			
Other			Unspecified]	C		
			Furosemide	C		

Date:12/04/03ISR Number: 4245856-0Report Type:Expedited (15-DaCompany Report #WAES 0311CAN00108
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Aphonia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cough		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY					

	Feeling Abnormal	Diphenhydramine		
	Oral Discomfort	Hydrochloride	C	ORAL
	Paraesthesia Oral	Fexofenadine		
	Pruritus	Hydrochloride	C	ORAL
	Rash Pruritic	Prednisone	C	ORAL
	Urticaria			

Date:12/05/03ISR Number: 4246113-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA00274
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	183 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/05/03ISR Number: 4246424-7Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00329
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Pitting Oedema		Bumetanide	C				
			Buprenorphine Hydrochloride	C				
			Warfarin	C				
			Verapamil	C				
			Omeprazole	C				

Date:12/05/03ISR Number: 4246428-4Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Amnestic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Antinuclear Antibody Positive							
Other	Arthralgia							
	Arthritis							
	Asthenia							
	Blood Pressure Diastolic Increased							
	Blood Pressure Systolic Increased							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Chest Pain							
	Clumsiness							
	Difficulty In Walking							
	Disease Progression							
	Disturbance In Attention							
	Extensor Plantar Response							
	Extrasystoles							
	Fatigue							
	Heart Rate Increased							
	Hemiparesis							
	Hyperreflexia							
	Hypersensitivity							
	Hypokalaemia							

Initial Insomnia
Insomnia
Lacunar Infarction
Memory Impairment
Nephrolithiasis
Palpitations
Paraesthesia
Social Avoidant Behaviour
Vertigo
Vertigo Labyrinthine

Date:12/05/03ISR Number: 4246434-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02435
Age:60 YR Gender:Female I/FU:F

Outcome PT
Deafness
Medication Error
Osteoarthritis

Tinnitus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Calcium Citrate	C		ORAL		
	Vitamins (Unspecified)	C		ORAL		

Date:12/05/03ISR Number: 4246442-9Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00051
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Erosive Enterocolitis Haemorrhagic Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diclofenac	SS		ORAL		

Date:12/05/03ISR Number: 4246445-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA01171
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	36	DAY
			Aspirin	C				
			Celebrex	C				
			Plavix	C				
			Zocor	C		ORAL		
			Lasix (Furosemide)	C				
			Motrin	C				

Date:12/05/03ISR Number: 4246448-XReport Type:Expedited (15-DaCompany Report #WAES 0312USA00076
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Oedema		Vicodin Tablets	C				
	Respiratory Distress		Albuterol	C				
			Bumex	C				
			Nexium	C				
			Flonase	C				
			Maxzide	C				

Date:12/05/03ISR Number: 4246451-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA02861
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Lortab	C				
	Haematochezia		Aspirin	C				
			Baclofen	C				
			Valium	C				
			Vasotec	C		ORAL		
			Glucotrol Xl	C				

Date:12/05/03ISR Number: 4246455-7Report Type:Expedited (15-DaCompany Report #WAES 0312DEU00023
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Condition Aggravated							
	Duodenal Ulcer Perforation							
	Nausea							
	Vomiting							

Date:12/05/03ISR Number: 4246456-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA01866
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Disease		Lotensin	C				
Initial or Prolonged	Diabetic Ketoacidosis		Colace	C				
Disability	Hyperchloraemia		Nexium	C				
	Myocardial Infarction		Tricor	C				
	Renal Failure		Insulin	C				
	Therapeutic Agent Toxicity							

Date:12/08/03ISR Number: 4247134-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01083
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Operative Haemorrhage							
Other								

Date:12/08/03ISR Number: 4247139-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dermatitis Contact		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eye Swelling		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hepatic Cyst		Allopurinol	C				
	Hypertensive		Ultram	C				
	Cardiomyopathy		Kenalog	C				
PARENTERAL								
			Trazodone Hydrochloride	C				
			Celexa	C				
			Colchicine	C				
			Indocin (Indomethacin)	C		ORAL		
			Bactroban	C				
			Serzone	C				
			Prednisone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/03ISR Number: 4247142-1Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00031
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		366 DAY
	Pulmonary Congestion		Allopurinol	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Magnesium Chloride	C				

Date:12/08/03ISR Number: 4247144-5Report Type:Expedited (15-DaCompany Report #WAES 0305GBR00207
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brachial Plexus Lesion		[Therapy Unspecified]	SS				
	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL		
	Compartment Syndrome		Vitamins (Unspecified)	SS				
	Emotional Distress							
	Fibromyalgia							
	Hyponatraemia							
	Loss Of Consciousness							
	Pneumonia Aspiration							
	Rhabdomyolysis							
	Thirst							
	Venous Occlusion							
	Vomiting							

Date:12/08/03ISR Number: 4247485-1Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00076
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
			Aspirin	C		ORAL		

			Levothyroxine Sodium	C		ORAL

Date:12/09/03ISR Number: 4248702-4Report Type:Expedited (15-DaCompany Report #WAES 0312AUT00003
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL
			Fosamax	C		
			Methylprednisolone	C		ORAL

Date:12/09/03ISR Number: 4248704-8Report Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Pressure Fluctuation
	Cardiovascular Disorder
	Fall
	Joint Swelling
	Myocardial Infarction
	Oedema

	Oedema Peripheral Renal Failure						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/10/03ISR Number: 4249117-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA02161
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Postural	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/03ISR Number: 4249120-5Report Type:Expedited (15-DaCompany Report #WAES 01104477
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Right		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		[Therapy Unspecified]	C				
	Cardiomegaly		Darvocet-N	C				
	Cardiovascular Disorder		Celebrex	C				
	Cellulitis		Furosemide	C				
	Chloracne		Oxygen	C				
	Cor Pulmonale		Klor-Con	C				
	Drug Toxicity							
	Dyspnoea							
	Erythema							
	Glaucoma							
	Hypoaesthesia							
	Hypoxia							
	Oedema							
	Renal Failure							
	Sinus Tachycardia							
	Sleep Apnoea Syndrome							
	Testicular Swelling							

Date:12/10/03ISR Number: 4249125-4Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Abnormal Cardiac Murmur Cardiovascular Disorder Cerebrovascular Accident Disturbance In Attention Fatigue Headache High Density Lipoprotein Decreased Hypoaesthesia Oedema Renal Failure	Health Professional	Vioxx Tylenol Tavist-D	PS C C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/03ISR Number: 4249126-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA02372
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Dizziness	Professional	[Therapy			
	Transient Ischaemic		Unspecified]	C		
	Attack		Tylenol	C		
			Guaifenex	C		
			Hydrochlorothiazide	C		
			Singulair	C		ORAL

Date:12/10/03ISR Number: 4249381-2Report Type:Expedited (15-DaCompany Report #WAES 0312BEL00012
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/10/03ISR Number: 4249384-8Report Type:Expedited (15-DaCompany Report #WAES 0312NLD00003
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastritis					
	Pancreatitis Chronic					

Date:12/10/03ISR Number: 4249386-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA00778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
	Transient Ischaemic		[Therapy			
	Attack		Unspecified]	C		

Date:12/10/03ISR Number: 4249387-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA00780
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/03ISR Number: 4249390-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA00895
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/03ISR Number: 4249712-3Report Type:Expedited (15-DaCompany Report #WAES 0305USA00564
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Bundle Branch Block Left
	Candidiasis
	Cardiac Failure
	Congestive

		Cardiac Fibrillation					
		Cardio-Respiratory Arrest					
		Cardiomegaly	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
163	DAY						
		Depression	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
163	DAY						
		Diabetic Microangiopathy		Maxzide	C		
		Dyspepsia		Glucophage	C		ORAL
		Gastric Disorder		Zoloft	C		
		Hypokalaemia		Xanax	C		
		Hypoxic Encephalopathy		Lanoxin	C		
		Pleural Effusion		Diabeta	C		
		Pneumonia		Lasix (Furosemide)	C		
		Sinus Tachycardia		Capoten	C		
		Sinusitis		Darvocet-N	C		
		Spondylolisthesis		Reglan	C		
		Acquired		K-Dur	C		
		Sputum Culture Positive		Zantac	C		

Date:12/11/03ISR Number: 4249714-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02144
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Haemorrhagic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
Initial or Prolonged		Hip Arthroplasty	Professional	Elavil	C		
		Hypotension		Premarin	C		
		Oxygen Saturation		Glucosamine	C		
		Decreased		Hydrodiuril	C		
				Vitamins (Unspecified)	C		
				Levoxyl	C		
				Levoxyl	C		
				Imodium	C		

Date:12/11/03ISR Number: 4249715-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA02730
Age:30 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY						
Initial or Prolonged	Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY						

Date:12/11/03ISR Number: 4249720-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA00808
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
	Cerebrovascular Accident		Propranolol			
	Fibromyalgia		Hydrochloride	C		
	Headache		Diovan	C		
	Nail Discolouration					
	Osteoporosis					
	Paraesthesia					
	Peripheral Coldness					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/03ISR Number: 4249722-6Report Type:Expedited (15-DaCompany Report #WAES 0312USA00899
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lasix (Furosemide)	C		ORAL		
			Effexor Xr	C		ORAL		
			Actos	C		ORAL		
			Potassium (Unspecified)	C		ORAL		
			Altace	C		ORAL		

Date:12/11/03ISR Number: 4250129-6Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00146
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia	Professional	Rabeprazole Sodium	C				
	Asthenia							
	Confusional State							
	Flushing							
	Mental Impairment							
	Mouth Ulceration							
	Nausea							
	Palpitations							
	Tremor							
	Vision Blurred							

Date:12/11/03ISR Number: 4250131-4Report Type:Expedited (15-DaCompany Report #WAES 0312NOR00013
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Colitis Ulcerative							
	Diarrhoea							
	Haemorrhage							

Date:12/11/03ISR Number: 4250136-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA00020
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation Gastrointestinal Ulcer Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/03ISR Number: 4250139-9Report Type:Expedited (15-DaCompany Report #WAES 0312FIN00002
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Diarrhoea Face Oedema Hyperaesthesia Localised Oedema Muscle Tightness

	Paraesthesia Vertigo						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Cortisone	C				
			Prednisolone	C		ORAL		

Date:12/11/03ISR Number: 4250143-0Report Type:Expedited (15-DaCompany Report #WAES 0312USA00989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	577	DAY

Date:12/12/03ISR Number: 4250961-9Report Type:Expedited (15-DaCompany Report #WAES 0312FRA00032
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Generalised Erythema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged	Pruritus Rash Vesicular	Professional	Acetaminophen And Tramadol Hydrochloride	SS		ORAL	1	MON
			Diltiazem Hydrochloride	C		ORAL		
			Diosmin	C		ORAL		
			Furosemide	C		ORAL		
			Nitroglycerin	C				
			Piribedil	C		ORAL		

Date:12/12/03ISR Number: 4250962-0Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00094
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Aspirin C

Date:12/12/03ISR Number: 4250966-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atherosclerosis
Initial or Prolonged	Atrioventricular Block
Disability	First Degree
Other	Bundle Branch Block Right
	Cerebellar Infarction
	Cerebral Atrophy
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Pain
	Dizziness
	Dyslipidaemia
	Hyperhidrosis
	Hypertension
	Nystagmus
	Polytraumatism
	Sinus Arrhythmia
	Sinus Bradycardia
	Sinus Tachycardia

	Supraventricular Tachycardia						
	Vertigo	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C				

Date:12/12/03ISR Number: 4250968-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA00993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:12/12/03ISR Number: 4250970-XReport Type:Expedited (15-DaCompany Report #WAES 0310FRA00084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Esomeprazole Magnesium	SS		ORAL	2	MON
			Fluoxetine Hydrochloride	SS		ORAL		
			Acetaminophen	C		ORAL		
			Piroxicam	C		ORAL		
			Diclofenac	C		ORAL		

Date:12/12/03ISR Number: 4251059-6Report Type:Expedited (15-DaCompany Report #WAES 0312DEU00076
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Increased Erysipelas		Digoxin	C				
	Oedema Peripheral		Methotrexate	C				
			Xipamide	C				

	Pain In Extremity		Spironolactone	C		
	Thrombosis		Prednisolone	C		

Date:12/12/03ISR Number: 4251064-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA00026
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Norvasc	C		
Initial or Prolonged			Imitrex	C		
Disability						

Date:12/12/03ISR Number: 4251065-1Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00053
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Intraocular Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
	Increased		Atorvastatin Calcium	C		
			Bendroflumethiazide	C		
			Mycophenolate			
			Mofetil	C		
			Prednisolone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/03ISR Number: 4251067-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA02750
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hospitalisation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				

Date:12/12/03ISR Number: 4251069-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		[Therapy Unspecified]	C				
Other	Blood Triglycerides Increased		Tylenol	C				
	Cardiac Murmur		Vicodin Tablets	C				
	Cardiomegaly		Albuterol	C				
	Cerebrovascular Accident		Bayer Aspirin	C				
	Chest Pain		Bayer Aspirin	C				
	Chills		Aspirin	C				
	Chronic Obstructive Pulmonary Disease		Tenormin	C				
			Tenormin	C				
	Coagulopathy		Coumadin	C				
	Contusion		Coumadin	C				
	Convulsion		Ticlid	C				
	Deafness Bilateral		Restoril	C				
	Dyspnoea		Digoxin	C				
	Dysuria		Anzemet	C				
	Epistaxis		Vasotec	C		ORAL		
	Fall		Isordil	C				
	Gastrointestinal Disorder		Lopressor	C				
	Gingival Bleeding		Naproxen	C				
	Haematochezia		Nitrostat	C				
	Heart Rate Irregular							
	Hypertension							
	Insomnia							
	International Normalised Ratio Decreased							
	Oedema							
	Oedema Peripheral							
	Pollakiuria							

	Polytraumatism Pulmonary Haemorrhage Silent Myocardial Infarction Transient Ischaemic Attack Vision Blurred

Date:12/12/03ISR Number: 4251070-5Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00070
Age:84 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Blood Alkaline Phosphatase Increased Gamma-Glutamyltransferase

Increased
Liver Function Test
Abnormal

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Acetaminophen	C				
	Aspirin	C		ORAL		
	Bumetanide	C		ORAL		
	Calcium Carbonate And Cholecalciferol	C		ORAL		
	Spironolactone	C		ORAL		
	Tramadol Hydrochloride	C				
	Docusate Sodium	C				
	Lactulose	C				
	Nicorandil	C		ORAL		
	Ramipril	C				
	Ranitidine	C		ORAL		

Date:12/12/03ISR Number: 4251074-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA00954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/12/03ISR Number: 4251075-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA00991
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	244	DAY

Date:12/12/03ISR Number: 4252356-0Report Type:Expedited (15-DaCompany Report #S03-SWI-04412-01
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation	Foreign	Cipralex					
	Akathisia	Health	(Escitalopram)	PS		ORAL	5 MG QD PO	
	Disturbance In Attention	Professional	Cipralex					
	Drug Eruption	Other	(Escitalopram)	SS		ORAL	10 MG QD PO	
	Gamma-Glutamyltransferase		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Mean Cell Haemoglobin		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Concentration Decreased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Monocyte Count Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Neutrophil Count		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Parkinsonism		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Reading Disorder		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Sleep Disorder		Zyprexa (Olanzapine)	C				
			Temesta (Lorazepam)	C				
			Duphalac (Lactulose)	C				
			Paragol	C				
			Fig Syrup	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/03ISR Number: 4271651-2Report Type:Periodic Company Report #2003178546US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Withdrawal Headache	Health Professional	Bextra (Valdecoxib) Tablet	PS		ORAL	ORAL	
			Celebrex (Celecoxib) Capsule	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:12/15/03ISR Number: 4251507-1Report Type:Expedited (15-DaCompany Report #WAES 00085092
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaphylactic Reaction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Angioneurotic Oedema		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Arterial Disorder		Acetaminophen	C		ORAL		
	Blood Glucose Increased		Cyclosporin A	C				
	Cardiac Disorder		Docusate Sodium	C		ORAL		
	Complement Factor C3 Decreased		Folic Acid	C				
			Furosemide	C		ORAL		
	Complement Factor C4 Decreased		Senna	C				
			Thioridazine	C				
	Conjunctival Haemorrhage		Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		
	Drug Ineffective							
	Ecchymosis		Insulin, Biphasic Isophane [Injection]	C		SUBCUTANEOUS		
	Haemorrhage							
	Mouth Ulceration		Lisinopril	C				
	Mucosal Haemorrhage		Methotrexate	C		SUBCUTANEOUS		
	Nausea		Paroxetine	C		ORAL		
	Necrosis		Prednisolone	C		ORAL		
	Petechiae							
	Pleural Adhesion							
	Pulmonary Fibrosis							

Pulmonary Haemorrhage
Pulmonary Oedema
Spleen Congestion
Urine Output Decreased
Vasoconstriction

Date:12/15/03ISR Number: 4251508-3Report Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/15/03ISR Number: 4251512-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA01723
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Congestive	Professional	Aspirin	C		ORAL		
Other			Cardura	C		ORAL		
			Mevacor	C		ORAL		
			Lopressor	C		ORAL		
			Naprosyn	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/03ISR Number: 4251527-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02575
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction Anaemia Blood Sodium Decreased Cardiac Failure Congestive Cardio-Respiratory Arrest Cerebral Artery Occlusion Cerebral Haemorrhage Convulsion Decerebration Endocarditis Haemorrhage Intracranial International Normalised Ratio Decreased Ischaemic Stroke Mental Status Changes Mitral Valve Disease Mitral Valve Incompetence Mycotic Aneurysm Pulmonary Hypertension Pulmonary Valve Incompetence Pupil Fixed Pupillary Reflex Impaired Renal Failure Acute Streptococcal Bacteraemia Ventricular Dysfunction Ventricular Hypertrophy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/15/03ISR Number: 4251535-6Report Type:Expedited (15-DaCompany Report #WAES 0312USA00992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		246 DAY

Date:12/15/03ISR Number: 4251538-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA00990
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY

Date:12/15/03ISR Number: 4251801-4Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00030
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Myocarditis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Supraventricular Extrasystoles							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/03ISR Number: 4251802-6Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00015
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
Hospitalization - Initial or Prolonged Disability			Amlodipine Besylate	C				
			Zocor	C				

Date:12/15/03ISR Number: 4251806-3Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00011
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hepatitis Toxic		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Perforated Ulcer		Lorazepam	C				

Date:12/15/03ISR Number: 4251809-9Report Type:Expedited (15-DaCompany Report #WAES 0312CAN00070
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hearing Disability		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
	Tinnitus		Acetaminophen And Tramadol Hydrochloride	C			3	DAY

Date:12/15/03ISR Number: 4251811-7Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Celecoxib	C			17	DAY

Dry Mouth
Eczema
Eye Swelling
Eyelid Oedema
Oedema Peripheral
Pain In Extremity
Skin Reaction
Stasis Dermatitis
Swelling Face

Date:12/15/03ISR Number: 4251813-0Report Type:Expedited (15-DaCompany Report #WAES 0312FRA00040
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis Bacterial		Infliximab	SS			INTRAVENOUS	465 DAY
	Cardiac Operation		Prednisone	SS				
	Erysipelas		Acetaminophen	C				
	Stent Placement		Tramadol Hydrochloride	C		ORAL		
	Streptococcal Infection		Isradipine	C		ORAL		
			Leflunomide	C		ORAL		
			Omeprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/03ISR Number: 4252013-0Report Type:Direct Company Report #CTU 208064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Impairment		Vioxx 25 Mg (Merck)	PS	Merck	ORAL	25 MG QD PO	
Initial or Prolonged			Atenolol	C				
			Aspirin	C				
			Tamulosin	C				
			Simvastatin	C				
			Vicodin	C				
			Diazepam	C				

Date:12/16/03ISR Number: 4252257-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA02996
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Accident At Work	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Back Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased Activity							
	Depression							
	Difficulty In Walking							
	Headache							
	Heart Rate Irregular							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Musculoskeletal Stiffness							
	Pyrexia							
	Sciatica							
	Spinal Compression							
	Fracture							

Date:12/16/03ISR Number: 4252262-1Report Type:Expedited (15-DaCompany Report #WAES 0311USA01562
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder		Nexium	C				
			Lasix (Furosemide)	C				

		Hydrochlorothiazide And Lisinopril	C
		Nolvadex	C
		Potassium (Unspecified)	C
		Pravachol	C

Date:12/16/03ISR Number: 4252322-5Report Type:Direct Company Report #CTU 208175
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Medication Error		Vioxx 25 Mg Merck And Co Inc	PS	Merck And Co Inc			

Date:12/16/03ISR Number: 4252505-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Asthenia	Professional	Pepcid	C		ORAL		
	Cancer Pain		Lasix (Furosemide)	C				
	Colonic Polyp		Ibuprofen	C				
	Depression		Zestril	C				
	Diabetes Mellitus		Lithium Carbonate	C				
	Emotional Distress							
	Fatigue							
	Haemorrhoids							
	Hyperhidrosis							
	Inflammation							
	Insomnia							
	Lymphocytic Lymphoma							
	Marrow Hyperplasia							
	Myelodysplastic Syndrome							
	Nausea							
	Oedema Peripheral							
	Rectal Polyp							
	Stomatitis							

Date:12/16/03ISR Number: 4252511-XReport Type:Expedited (15-DaCompany Report #WAES 0312CHE00023
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colitis	Professional	Aspirin	SS		ORAL		
	Diverticulum Intestinal		Diclofenac Sodium	SS		ORAL		
	Gastritis Erosive		Calcium Dobesilate	C		ORAL		
	Helicobacter Infection		Nadolol	C		ORAL		
	Melaena		Pravastatin Sodium	C		ORAL		

Date:12/16/03ISR Number: 4252512-1Report Type:Expedited (15-DaCompany Report #WAES 0303GBR00053
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Intraocular Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Atorvastatin Calcium	C		
			Bendroflumethiazide	C		
			Mycophenolate Mofetil	C		
			Prednisolone	C		

Date:12/16/03ISR Number: 4252982-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA00614
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Gastroenteritis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL

Dose Duration
25 MG/DAILY

PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/03ISR Number: 4254109-6Report Type:Expedited (15-DaCompany Report #2003GB00586
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer	Foreign	Omeprazole	PS				
	Diabetes Mellitus	Health	Rofecoxib	SS			12.5 MG DAILY	
	Diarrhoea	Professional					PO	
	Dyspepsia	Other						
	Renal Failure							

Date:12/17/03ISR Number: 4253406-8Report Type:Expedited (15-DaCompany Report #WAES 0312AUT00003
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Purpura		Fosamax	C				
	Rash		Benserazide Hydrochloride And Levodopa	C				
			Methylprednisolone	C		ORAL		

Date:12/17/03ISR Number: 4253410-XReport Type:Expedited (15-DaCompany Report #WAES 0312GBR00114
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Duodenitis		Warfarin	SS				
Other	Gastrointestinal Haemorrhage		Goserelin Acetate	C				
	International Normalised Ratio Increased							

Date:12/17/03ISR Number: 4253676-6Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00062
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhagic		Amitriptyline					
	Duodenitis Haemorrhagic		Hydrochloride	C		ORAL		
	Gastritis Haemorrhagic		Aspirin	C		ORAL		
	Haemoglobin Decreased		Verapamil	C		ORAL		
			Prinivil	C		ORAL		
			Pantoprazole	C		ORAL		

Date:12/17/03ISR Number: 4253679-1Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00103
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Chest Discomfort
Hospitalization -	Drug Interaction
Initial or Prolonged	Dyspnoea
	General Physical Health
	Deterioration
	Hypertension
	Oedema
	Polyserositis
	Tachyarrhythmia

Tachycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Amlodipine Besylate	SS		ORAL	18	DAY
	Prednisolone	SS				

Date:12/17/03ISR Number: 4253680-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA02975
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Pruritus		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Rash Erythematous		Norvasc	C				
			Premarin	C				
			Allegra	C				
			Micardis	C				
			Lasix (Furosemide)	C				
			Pravachol	C				
			Zantac	C				

Date:12/17/03ISR Number: 4253682-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00764
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Increased		Hytrin	C				
	Blood Glucose Decreased							
	Blood Lactate							
	Dehydrogenase Increased							
	Blood Triglycerides							
	Increased							
	Cerebrovascular Accident							
	Macular Oedema							
	Retinal Haemorrhage							
	Retinal Oedema							

Retinal Vein Occlusion
Vision Blurred
Visual Acuity Reduced

Date:12/17/03ISR Number: 4253683-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA02216
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Disability	Injury		Fosamax	C		ORAL		
	Myocardial Infarction		Zocor	C		ORAL		
	Nausea		Synthroid	C				
	Sinus Tachycardia		Prilosec	C				

Date:12/17/03ISR Number: 4253691-2Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00090
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/03ISR Number: 4253692-4Report Type:Expedited (15-DaCompany Report #WAES 0312NOR00014
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenitis Haemorrhagic Erosive Duodenitis Gastritis Erosive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
			Aspirin And Magnesium Oxide	SS		ORAL		YR
			Enalapril Maleate	C		ORAL		YR
			Furosemide	C				YR
			Metoprolol Tartrate	C		ORAL		YR
			Paroxetine Hydrochloride	C		ORAL		YR

Date:12/17/03ISR Number: 4254279-XReport Type:Expedited (15-DaCompany Report #2003SE03866
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated	Foreign	Esomeprazole	PS		ORAL	20 MG DAILY	
Hospitalization - Initial or Prolonged	Intravascular Coagulation General Physical Health	Health Professional	Triatec	SS		ORAL	PO 2.5 MG DAILY	
Required Intervention to Prevent Permanent Impairment/Damage	Deterioration Hepatic Failure Hepatic Necrosis Hepatorenal Syndrome Hepatotoxicity Jaundice Cholestatic	Other	Arofexx	SS		ORAL	PO 25 MG DAILY PO	

Date:12/17/03ISR Number: 4269230-6Report Type:Periodic Company Report #USA-2003-0005478
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Oxycontin Tablets					
Other	Drug Abuser	Professional	(Oxycodone					
	Multiple Drug Overdose	Company	Hydrochloride)	PS			20 MG, BID,	
		Representative					OTHER	
		Other	Hydrocodone Bitartrate (Similar To Ind 59,175) (Hydrocodone Bitartrate,	SS				
			Morphine Sulfate (Similar To Nda 19-516) (Morphine Sulfate)	SS				
			Ativan (Lorazepam)	SS			1 MG	
			Paxil (Paroxetine Hydrochloride)	SS			40 MG, DAILY	
			Vioxx (Rofecoxib)	SS			50 MG, DAILY	
			Flexeril (Cyclobenzaprine Hydrochloride)	SS			10 MG, TID	
			Cocaine (Cocaine)	SS				
			Propoxyphene (Dextropropoxyphene)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/18/03ISR Number: 4254060-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00741
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Initial or Prolonged	Infarction	Professional	Aspirin	SS				
Disability	Blood Pressure Increased		Celebrex	SS				96 DAY
	Coronary Artery		Dyazide	SS				
	Restenosis		Iron (Unspecified)	SS				
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Nitroglycerin	SS				
	Haematocrit Decreased		Tylenol	C				790 DAY
	Haemoglobin Decreased		Lipitor	C				790 DAY
	Insomnia							
	Iron Deficiency Anaemia							
	Myocardial Infarction							
	Rash							
	Rheumatoid Arthritis							
	Stress							

Date:12/18/03ISR Number: 4254682-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction	Professional	Advil	C				
Disability	Arthritis							
Other	Blood Triglycerides							
	Increased							
	Cardiac Failure							
	Chest Pain							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Stenosis							
	Diabetes Mellitus							
	Gastrooesophageal Reflux							
	Disease							
	Hypercholesterolaemia							
	Hyperhidrosis							

Nausea
Osteoarthritis
Sensation Of Pressure
Spinal Compression
Fracture
Stent Occlusion
Vomiting

Date:12/18/03ISR Number: 4254689-0Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthenia
	Blood Pressure Fluctuation
	Cardiac Murmur
	Cerebrovascular Accident
	Disturbance In Attention
	Fatigue

		Headache					
		Hypercalcaemia					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ischaemic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Tylenol	C		
		Nuclear Magnetic		Tavist-D	C		
		Resonance Imaging Brain		Afrin Nasal Spray	C		
		Abnormal					
		Oedema					
		Platelet Count Abnormal					
		Pyrexia					
		Renal Failure					
		Respiratory Rate					
		Increased					
		Sinus Congestion					
		Subarachnoid Haemorrhage					
		Vomiting					

Date:12/18/03ISR Number: 4254693-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00844
Age:86 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Activities Of Daily	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Living Impaired	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Amyloidosis					
		Arthralgia					
		Blood Pressure Systolic					
		Increased					
		Cerebral Ischaemia					
		Cerebrovascular Accident					
		Colon Cancer					
		Dysuria					
		Emotional Distress					
		Facial Pain					
		Impaired Work Ability					
		Injury					
		Insomnia					
		Paraesthesia					
		Subarachnoid Haemorrhage					

Date:12/18/03ISR Number: 4254700-7Report Type:Expedited (15-DaCompany Report #WAES 0312USA00808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Diarrhoea		Propranolol Hydrochloride	C				
	Dizziness		Diovan	C				
	Feeling Abnormal							
	Fibromyalgia							
	Gait Disturbance							
	Headache							
	Hypoaesthesia							
	Loss Of Consciousness							
	Nail Discolouration							
	Osteoporosis							
	Paraesthesia							
	Peripheral Coldness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/18/03ISR Number: 4254702-0Report Type:Expedited (15-DaCompany Report #WAES 0309FRA00041
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Infected Cyst Superinfection	Professional	Betamethasone Dipropionate And Salicylic Acid	SS				
			Celecoxib	SS		ORAL		11 DAY

Date:12/18/03ISR Number: 4254706-8Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00146
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		30 DAY
	Blood Alkaline Phosphatase Increased		Oxerutins	C		ORAL		30 DAY
	Gamma-Glutamyltransferase Increased							
	Jaundice							
	Liver Function Test Abnormal							

Date:12/18/03ISR Number: 4254708-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA01725
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/18/03ISR Number: 4254709-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA01359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/18/03ISR Number: 4254712-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA01210
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Actonel	SS		ORAL		
			Actonel	SS		ORAL		
			Aricept	C				
			Prozac	C				
			Zyprexa	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/18/03ISR Number: 4256299-8Report Type:Expedited (15-DaCompany Report #12454641
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Tenderness	Foreign	Metformin Hcl	PS		ORAL	500	
Initial or Prolonged	Agitation	Literature					MILLIGRAM,	
	Blood Glucose Increased	Other					2/1 DAY ORAL	
	Depressed Level Of		Rofecoxib	SS		ORAL	ORAL	
	Consciousness							
	Haemodialysis							
	Heart Rate Increased							
	Lactic Acidosis							
	Renal Failure Acute							

Date:12/19/03ISR Number: 4255181-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01168
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Phosphokinase Increased	Professional	Celebrex	SS				
7 DAY								
Initial or Prolonged	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dehydration		Celebrex	SS				
7 DAY								
	Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glomerulonephritis Focal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glomerulonephritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Membranous		[Therapy					
	Haematemesis		Unspecified]	C				
	Haemodialysis		Creatine	C				
	Hypersensitivity		Advil	C				
	Injury		Solu-Medrol	C				
	Joint Sprain							
	Laceration							
	Nasopharyngitis							
	Pulmonary Embolism							
	Pyrexia							
	Renal Failure Chronic							

Tendon Injury
Tendonitis
Tooth Injury
Vomiting

Date:12/19/03ISR Number: 4255182-1Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00011
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis Toxic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged Disability	Perforated Ulcer	Professional	Lorazepam	C				

Date:12/19/03ISR Number: 4255555-7Report Type:Expedited (15-DaCompany Report #WAES 0312BRA00027
Age:14 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Dyspnoea
	Oedema Peripheral
	Prescribed Overdose
	Serum Sickness

	Shock						
	Urticaria						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Date:12/19/03ISR Number: 4255558-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA00936
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombotic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Percocet	C				
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Elavil	C		ORAL		
			Atenolol	C				
			Soma	C				
			Restoril	C				
			Effexor Xr	C				
			Plavix	C				
			Plavix	C				
			Tricor	C				
			Hydrodiuril	C		ORAL		
			Synthroid	C				
			Nitro-Bid	C				

Date:12/19/03ISR Number: 4255561-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bundle Branch Block Right		Vicodin Tablets	C				
	Cardiac Murmur		Zyloprim	C				
	Carotid Bruit		Xanax	C				
	Gastric Ulcer Haemorrhage		Ecotrin	C				
	Gastritis Erosive		Aspirin	C				
	Hiatus Hernia		Lipitor	C				

	Incisional Hernia	Ultram	C
	Myocardial Infarction	Carisoprodol	C
	Myocardial Ischaemia	Vasotec	C
	Small Intestinal	Micronase	C
	Obstruction	Prevacid	C
		Glucophage	C
		Centrum	C

Date:12/19/03ISR Number: 4255564-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adnexa Uteri Mass
Initial or Prolonged	Angina Unstable
Disability	Back Pain
Other	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Discomfort
	Chills
	Constipation
	Cystocele

		Ear Pain					
		Enterocele					
		Fibromyalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ganglion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematochezia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hearing Impaired		Colace	C		
		Hypokalaemia		Maxzide	C		
		Neck Pain		Coumadin	C		
		Oedema Peripheral		Trazodone			
		Ovarian Cyst		Hydrochloride	C		
		Paraesthesia		Flexeril	C		ORAL
		Phlebitis Superficial		Paxil	C		
		Rectocele		Potassium Chloride	C		
		Sinus Headache					
		Stress Incontinence					
		Thrombophlebitis					
		Superficial					
		Uterine Prolapse					

Date:12/19/03ISR Number: 4255565-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2 MON						
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
2 MON						
Disability	Arthritis		Tylenol Pm	C		
	Blood Chloride Increased		Aspirin	C		
	Blood Creatinine		Zocor	C		ORAL
	Decreased		Tagamet	C		
	Blood Glucose Increased		Tagamet	C		
	Cardiac Failure		Cardura	C		ORAL
	Congestive					
	Cardiomyopathy					
	Chronic Fatigue Syndrome					
	Coronary Artery Occlusion					
	Depression					
	Dizziness					
	Fatigue					
	Gastrooesophageal Reflux					
	Disease					

Hypercholesterolaemia
Hyperhidrosis
Hypertension
Pco2 Decreased
Sinus Tachycardia
Supraventricular
Extrasystoles
Ulcer
Ventricular Extrasystoles
Weight Decreased

Date:12/19/03ISR Number: 4255567-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA01301
Age:67 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Balance Disorder
Initial or Prolonged	Cerebrovascular Accident
Other	Deep Vein Thrombosis

	Hip Arthroplasty Inner Ear Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Ascorbic Acid	C				
			Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				
			Tricor	C				
			Allegra	C				
			Proscar	C		ORAL		
			Folic Acid	C				
			Vitamin E	C				
			Zinc (Unspecified)	C				
			Thiamine	C				
			Hydrochlorothiazide And Triamterene	C				
			Prevacid	C				
			Lisinopril	C				
			Flomax (Morniflumate)	C				
			Pyridoxine	C				

Date:12/19/03ISR Number: 4255568-5Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00128
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation Haemodialysis Heart Rate Increased Intestinal Ischaemia Lactic Acidosis Renal Failure Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Metformin	SS				

Date:12/22/03ISR Number: 4255701-5Report Type:Expedited (15-DaCompany Report #PHBS2003CH14005
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Caecitis		Voltaren	PS	Novartis Sector:			

Initial or Prolonged	Diverticulum Intestinal			Pharma
UNKNOWN				
	Drug Abuser	Vioxx	SS	
UNKNOWN				
	Gastritis Erosive	Aspirin Cardio	SS	
100 mg/d				
	Haemoglobin Decreased	Corgard	C	
30 mg/d				
	Helicobacter Gastritis	Selipran	C	
20 mg/d				
	Melaena	Doxium	C	
500 mg/d				
	Syncope			

Date:12/22/03ISR Number: 4256043-4Report Type:Direct Company Report #CTU 208530
Age:51 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blood Pressure Increased		Vioxx 25 Mg Merck	PS	Merck	ORAL	DAILY BY MOUTH	
Coronary Artery Occlusion							
Myocardial Infarction		Nexium	C				
Post Procedural Haemorrhage		Prevacid	C				
		Plavix	C				
		Altace	C				
		Aspirin	C				
		Lipitor	C				

Date:12/22/03ISR Number: 4256142-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Balance Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		[Therapy Unspecified]	C				
	Congestive		Avandia	C				
	Carotid Artery Stenosis		Vicoprofen	C				
	Cerebrovascular Accident		Glucophage	C				
	Contusion							
	Coordination Abnormal							
	Difficulty In Walking							
	Diplopia							
	Exostosis							
	Head Injury							
	Lacunar Infarction							
	Nasopharyngitis							
	Osteoarthritis							
	Pain In Extremity							
	Road Traffic Accident							
	Spinal Osteoarthritis							
	Strabismus							
	Ventricular Hypertrophy							
	Vision Blurred							
	Whiplash Injury							

Date:12/22/03ISR Number: 4256147-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA00235
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		379 DAY
Other	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		379 DAY
	Blindness Unilateral		Vicodin Tablets	C				
	Emotional Distress		Celebrex	C				
	Hypercoagulation							
	Injury							
	Joint Dislocation							
	Migraine With Aura							
	Platelet Count Increased							
	Retinal Vein Occlusion							
	Retinal Vein Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/03ISR Number: 4256148-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		272 DAY
Initial or Prolonged	Diabetes Mellitus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Insulin-Dependent		[Therapy					
	Gout		Unspecified]	C				
	Lacunar Infarction		Aspirin	C				
	Neuropathy		Lipitor	C				
	Pupils Unequal		Calcium					
	Weight Decreased		(Unspecified)	C				
			Vitamins					
			(Unspecified)	C				
			Monopril	C		ORAL		
			Hydrochlorothiazide	C				
			Hydrocodone					
			Hydrochloride	C				
			Insulin	C				
SUBCUTANEOUS								
			Adalat	C				

Date:12/22/03ISR Number: 4256150-6Report Type:Expedited (15-DaCompany Report #WAES 0312ITA00007
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
	Asthenia		Doxazosin Mesylate	C				2 YR
	Gastric Ulcer Haemorrhage							
	Melaena							
	Syncope							
	Tachycardia							

Date:12/22/03ISR Number: 4256206-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia

Initial or Prolonged	Acute Prerenal Failure
	Asthenia
	Back Pain
	Blood Creatine Increased
	Bundle Branch Block
	Cardiac Failure
	Congestive
	Cardiomegaly
	Change Of Bowel Habit
	Chest Pain
	Constipation
	Contusion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Diarrhoea
	Eye Pain
	Fall
	Fatigue
	Gingival Bleeding
	Glaucoma
	Haematocrit Decreased
	Haemoglobin Decreased

		Haemorrhage					
		Hyperlipidaemia					
		Ischaemic Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Sprain		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Lasix (Furosemide)	SS		
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Nephropathy Toxic		Lasix (Furosemide)	SS		
INTRAVENOUS							
		Orthostatic Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Pleural Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Plavix	C		
		Respiratory Distress		Advil	C		
		Respiratory Rate		Lopressor	C		
		Increased		Timoptic	C		
OPHTHALMIC							
		Rosacea		Zocor	C		ORAL
		Skin Discolouration		Pilocarpine	C		
		Thrombocytopenia		Salagen Tablets	C		
		Tooth Fracture		Salagen Tablets	C		
		Troponin I Increased		Centrum	C		
		Ventricular Dysfunction		Lotemax	C		
OPHTHALMIC							
		Visual Acuity Reduced		Plaquenil	C		
				Femhrt	C		

Date:12/22/03ISR Number: 4256209-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA00004
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arrhythmia
Other	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Increased
	Breast Hyperplasia
	Cardiac Murmur
	Cardiac Valve Disease
	Cervicobrachial Syndrome
	Depression
	Dizziness

Drug Hypersensitivity
Drug Ineffective
Dyspnoea
Erythema
Gastrooesophageal Reflux
Disease
General Physical Health
Deterioration
Haematocrit Decreased
Heart Rate Irregular
Hypoaesthesia
Hypovolaemia
Injury
Intervertebral Disc
Disorder
Muscle Strain
Osteoarthritis
Pain In Extremity
Paraesthesia

	Paraesthesia Oral						
	Sensory Loss						
	Sleep Apnoea Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope Vasovagal		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				
			Percocet	C				
			Darvocet-N	C				
			Soma	C				
			Celebrex	C				
			Ibuprofen	C				
			Aleve	C				
			Oxycontin	C				

Date:12/22/03ISR Number: 4256210-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA01019
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Antibodies Positive							
Initial or Prolonged	Duodenal Ulcer							
Other	Haemorrhage							
	Renal Infarct							

Date:12/22/03ISR Number: 4256212-3Report Type:Expedited (15-DaCompany Report #WAES 0312CHE00033
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged			Domperidone	C		ORAL		

Date:12/22/03ISR Number: 4256214-7Report Type:Expedited (15-DaCompany Report #WAES 0312ITA00017
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 6 DAY	Exanthem		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Purpura Urticaria Generalised		Simvastatin	C		ORAL

Date:12/22/03ISR Number: 4256217-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA02101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		91 DAY

Date:12/22/03ISR Number: 4256218-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA02103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Ejection Fraction Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		194 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/03ISR Number: 4256219-6Report Type:Expedited (15-DaCompany Report #WAES 0312USA01852
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glyburide	C				
			Glucophage	C				

Date:12/22/03ISR Number: 4256231-7Report Type:Expedited (15-DaCompany Report #WAES 0205CAN00073
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Fosamax	SS		ORAL		
			Estrogens, Conjugated	SS		ORAL		
			Codeine Phosphate And Acetaminophen	C				

Date:12/22/03ISR Number: 4256233-0Report Type:Expedited (15-DaCompany Report #WAES 0311USA00325
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL		
	Peritonitis Bacterial							

Date:12/22/03ISR Number: 4256234-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA02730
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Pulmonary Oedema		Aspirin	C		ORAL		
	Weight Increased		Atenolol	C		ORAL		
			Lescol	C				

Date:12/22/03ISR Number: 4256235-4Report Type:Expedited (15-DaCompany Report #WAES 0311AUS00133
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							
	Reflux Oesophagitis							

Date:12/22/03ISR Number: 4256245-7Report Type:Expedited (15-DaCompany Report #WAES 0312USA02102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	574	DAY
	Hepatitis C							

Date:12/22/03ISR Number: 4256246-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Hospitalization - Initial or Prolonged	Basilar Artery Occlusion		Darvocet-N	C				
	Basilar Artery Stenosis		Aspirin	C				
	Brain Stem Infarction		Celebrex	C				
	Cerebellar Infarction		Diovan Hct	C				
	Cerebral Infarction		Glucophage	C				252 DAY
	Coma		Glucophage	C				79 DAY
	Electroencephalogram		Glucophage	C				
	Abnormal		Feldene	C				
	Hydrocephalus							
	Injury							
	Myocardial Ischaemia							
	Necrosis							
	Vertebral Artery Stenosis							

Date:12/22/03ISR Number: 4256247-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Aspirin	C				
Disability	Myocardial Infarction		Atenolol	C				
			Cyclobenzaprine Hydrochloride	C		ORAL		
			Lasix (Furosemide)	C				
			Novolin	C				SUBCUTANEOUS
			Zestril	C				
			Procardia	C				
			Trental	C				
			Potassium (Unspecified)	C				
			Ranitidine	C				

Date:12/22/03ISR Number: 4256251-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA02042
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged			Aspirin	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				
			Folic Acid	C				
			Neurontin	C				

Date:12/23/03ISR Number: 4256985-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02050
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
	Aortic Valve Incompetence
Other	Body Tinea
	Bronchitis Viral
	Bronchospasm

		Carotid Artery Stenosis					
		Dizziness					
		Foot Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Injury	Professional				
		Lymphadenopathy					
		Mediastinal					
		Nausea					
		Skin Papilloma					
		Therapy Non-Responder					
		Vertigo					

Date:12/23/03ISR Number: 4256986-1Report Type:Expedited (15-DaCompany Report #WAES 0211GBR00143
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Back Pain	Professional	Celecoxib	C		
17	DAY						
		Burning Sensation					
		Dry Mouth					
		Eczema					
		Eye Swelling					
		Eyelid Oedema					
		Hypersensitivity					
		Oedema Peripheral					
		Pain In Extremity					
		Scratch					
		Skin Reaction					
		Spondylitis					
		Stasis Dermatitis					
		Swelling Face					

Date:12/23/03ISR Number: 4256993-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00113
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Triglycerides		Analgesic Or			

Disability	Increased	Anesthetic	
	Dyspepsia	(Unspecified)	C
	Heart Rate Irregular	Celebrex	C
	Injury		
	Myocardial Infarction		

Date:12/23/03ISR Number: 4256995-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Chest Pain
Disability	Coronary Artery Disease
Other	Depression
	Heart Rate Irregular
	Hypertension
	Injury
	Intervertebral Disc
	Protrusion

		Obesity					
		Pyrexia					
		Respiratory Rate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL

Date:12/23/03ISR Number: 4257011-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA00615
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
32 DAY						
Initial or Prolonged	Cor Pulmonale		[Therapy			
	Heart Rate Irregular		Unspecified]	C		
	International Normalised		Lorcet Plus	C		
	Ratio Increased		Xanax	C		
	Limb Discomfort		Hytrin	C		
	Mitral Valve Incompetence		Coumadin	C		
	Osteoarthritis		Lipitor	C		
	Pulmonary Hypertension		Flexeril	C		
	Respiratory Rate		Flomax			
	Increased		(Morniflumate)	C		
	Tricuspid Valve					
	Incompetence					
	Venous Pressure Jugular					
	Increased					

Date:12/23/03ISR Number: 4257015-6Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00128
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Agitation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Depressed Level Of	Professional	Metformin	SS		
	Consciousness					
	Haemodialysis					
	Heart Rate Increased					
	Lactic Acidosis					
	Renal Failure Acute					

Date:12/23/03ISR Number: 4257019-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Disability	Anxiety
	Arthralgia
	Blindness Transient
	Blindness Unilateral
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased
	Cellulitis
	Cerebrovascular Accident
	Disturbance In Attention
	Drug Hypersensitivity
	Dyspnoea
	Emotional Distress

		Eye Pain					
		Fibromyalgia					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Haematochezia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Hypersensitivity		Amitriptyline			
		Injury		Hydrochloride	C		
		Musculoskeletal Stiffness		Rocaltrol	C		
		Renal Failure		Os-Cal	C		
		Respiratory Disorder		Valium	C		
		Transient Ischaemic		Synthroid	C		
		Attack		Ambien	C		
		Viral Infection		Slow-Mag	C		
		Weight Decreased		Reglan	C		
				Reglan	C		
				Prilosec	C		
				Ditropan Xl	C		
				Potassium Chloride	C		

Date:12/23/03ISR Number: 4257022-3Report Type:Expedited (15-DaCompany Report #WAES 01104477
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Fluctuation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Bundle Branch Block Right		[Therapy			
		Cardiac Failure		Unspecified]	C		
		Congestive		Darvocet-N	C		
		Cardiovascular Disorder		Celebrex	C		
		Cellulitis		Furosemide	C		
		Chloracne		Oxygen	C		
		Dilatation Ventricular		Klor-Con	C		
		Drug Toxicity					
		Dyspnoea					
		Glaucoma					
		Hypoaesthesia					
		Hypoxia					
		Oedema					
		Pulmonary Hypertension					
		Renal Failure					
		Sinus Tachycardia					

Sleep Apnoea Syndrome
Testicular Disorder
Ventricular Hypertrophy
Weight Decreased

Date:12/23/03ISR Number: 4257256-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Blood Cholesterol
Other	Increased
	Chest Pain
	Deep Vein Thrombosis
	Drug Hypersensitivity
	Myocardial Infarction
	Nephropathy Toxic
	Oedema Peripheral

		Pleuritic Pain					
		Pulmonary Embolism					
		Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombophlebitis		Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol	C		
				Diuretic (Unspecified)	C		
				Dyazide	C		
				Advil	C		
				Prevacid	C		
				Triamterene	C		
				Asacol	C		
				Naproxen	C		
				Ditropan	C		
				Quinidine	C		
				Quinine Sulfate	C		

Date:12/23/03ISR Number: 4257258-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cancer Pain		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR							
Disability		Cardio-Respiratory Arrest		Pepcid	C		ORAL
		Colonic Polyp		Lasix (Furosemide)	C		
		Depression		Ibuprofen	C		
		Diabetes Mellitus		Zestril	C		
		Emotional Distress		Lithium Carbonate	C		
		Fall					
		Fatigue					
		Femur Fracture					
		Haemorrhoids					
		Hemiparesis					
		Hip Fracture					
		Insomnia					
		Lymphadenopathy					
		Marrow Hyperplasia					
		Myelodysplastic Syndrome					
		Nausea					
		Non-Hodgkin'S Lymphoma					
		Oedema Peripheral					
		Pleural Effusion					

Pneumonia Aspiration
Rectal Polyp
Septic Shock
Splenomegaly
Stomatitis

Date:12/23/03ISR Number: 4257261-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Anxiety
	Asthma
	Blood Cholesterol Increased
	Bundle Branch Block Left
	Cardiac Failure

	Congestive						
	Cardiomyopathy						
	Depression						
	Dizziness	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ganglion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Allegra	C		ORAL		
	Hypertension		Zoloft	C		ORAL		
	Hypokinesia							
	Insomnia							
	Mitral Valve Incompetence							
	Tendonitis							

Date:12/23/03ISR Number: 4257264-7Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00025
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Pain		Vioxx	PS	Merck & Co., Inc			
OPHTHALMIC							6	DAY
Initial or Prolonged	Diarrhoea		Vioxx	SS	Merck & Co., Inc			
OPHTHALMIC							6	DAY
	Dizziness							
	Fatigue							
	Nausea							
	Tinnitus							

Date:12/23/03ISR Number: 4257284-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess
Initial or Prolonged	Abdominal Distension
	Abdominal Pain
	Abdominal Sepsis
	Blood Pressure Increased
	Bowel Sounds Abnormal
	Breath Sounds Decreased
	Bundle Branch Block Right
	Colitis
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Emotional Distress

Gastrooesophageal Reflux
Disease
Hiatus Hernia
Ileal Ulcer
Ileitis
Large Intestinal
Obstruction
Large Intestinal Ulcer
Large Intestine
Perforation
Metabolic Acidosis
Miosis
Multi-Organ Failure
Nausea
Necrosis
Necrotising Colitis
Osteoarthritis
Peripheral Ischaemia
Pleural Effusion
Qrs Axis Abnormal

		Renal Cortical Necrosis					
		Renal Failure Acute					
		Renal Mass	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Tubular Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Septic Shock		Ecotrin	C		
		Sinus Tachycardia		Lipitor	C		
		Skin Discolouration		Vasotec	C		ORAL
		Small Intestine Ulcer		Vasotec	C		ORAL
		Spinal Osteoarthritis		Hydrochlorothiazide	C		
		Spleen Disorder		Prevacid	C		
		Urine Output Decreased		Relafen	C		
		Vasospasm					
		Vomiting					
		Wound Infection					

Date:12/23/03ISR Number: 4257285-4Report Type:Expedited (15-DaCompany Report #WAES 0312ESP00025
Age:70 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Agranulocytosis		Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
Hospitalization -		Asthenia		Allopurinol	SS		ORAL
2	MON						
Initial or Prolonged		Blood Culture Positive					
Other		Dialysis					
		Duodenal Ulcer					
		Haemorrhage					
		Faeces Discoloured					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Jaundice					
		Joint Injury					
		Klebsiella Infection					
		Nocturia					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Staphylococcal Infection					
		Thrombocytopenia					

Date:12/23/03ISR Number: 4257286-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA01224
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	798 DAY	
	Myocardial Infarction							
	Renal Disorder							
	Renal Failure							

Date:12/23/03ISR Number: 4257288-XReport Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthropathy
	Blood Pressure Fluctuation
Other	Cardiovascular Disorder
	Constipation
	Fall
	Gastric Disorder

		Intervertebral Disc Disorder					
		Joint Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure					

Date:12/23/03ISR Number: 4257291-XReport Type:Expedited (15-DaCompany Report #WAES 01061634
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anxiety		Fosamax	SS		ORAL
Initial or Prolonged	Blood Pressure Increased		Plavix	SS		
Disability	Bloody Discharge		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Procedure		Lortab	C		ORAL
	Complication		Septra	C		ORAL
	Cerebrovascular Accident		Zanaflex	C		
	Chills		Septra	C		ORAL
	Cholelithiasis		Robaxin	C		
	Obstructive		Synthroid	C		ORAL
	Contusion		Insulin	C		
	Coronary Artery		Norvasc	C		ORAL
	Atherosclerosis					
	Diabetes Mellitus					
	Inadequate Control					
	Dyspepsia					
	Dyspnoea Exertional					
	Gastric Haemorrhage					
	Hypertensive Heart					
	Disease					
	Insomnia					
	Myocardial Infarction					
	Nausea					
	Ocular Hyperaemia					
	Oedema Peripheral					
	Osteopenia					
	Pain In Extremity					
	Postinfarction Angina					
	Retroperitoneal Haematoma					
	Rheumatoid Arthritis					
	Supraventricular					
	Tachycardia					

Thrombosis
Tremor
Venous Insufficiency

Date:12/23/03ISR Number: 4257294-5Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angiopathy
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arteritis
	Blood Pressure Fluctuation
	Brain Mass
	Breast Mass
	Cardiac Murmur

	Cardiovascular Disorder					
	Difficulty In Walking					
	Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL
	High Density Lipoprotein		Tylenol	C		
	Decreased		Tavist-D	C		
	Hypercalcaemia		Afrin Nasal Spray	C		
	Hypertension					
	Hypoaesthesia					
	Hypovolaemia					
	Impaired Driving Ability					
	Impaired Work Ability					
	Infarction					
	Ischaemia					
	Ischaemic Stroke					
	Multiple Myeloma					
	Muscle Twitching					
	Nausea					
	Oedema					
	Paranasal Sinus					
	Hypersecretion					
	Protein Total Increased					
	Pyrexia					
	Renal Failure					
	Subarachnoid Haemorrhage					
	Subdural Haemorrhage					
	Tension Headache					
	Urticaria					
	Vasculitis					

Date:12/23/03ISR Number: 4258691-4Report Type:Direct Company Report #CTU 208673
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Cardiac Failure		Vioxx	PS		
25 MG Q D	2 WK					
Intervention to	Congestive					
Prevent Permanent	Condition Aggravated					
Impairment/Damage						

Date:12/24/03ISR Number: 4279770-1Report Type:Periodic Company Report #03P-163-0238169-00
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Blood Potassium Decreased Hypertension	Consumer Health Professional	Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab)	PS		
40 MG, 1 IN 2 WK, SUBCUTANEOUS						
			Rofecoxib	SS		
			Prednisone	C		
			Folic Acid	C		
			Cyanocobalamin	C		
			Acetylsalicylic Acid	C		
			Alendronate Sodium	C		
			Rofecoxib	C		
			Allopurinol	C		
			Pyridoxine			

Hydrochloride	C
Sertraline Hydrochloride	C
Leflunomide	C
Pantoprazole	C

Date:12/26/03ISR Number: 4258438-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Injury	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Noroxin	SS		ORAL		
	Bronchial Carcinoma							
	Cardiac Failure							
	Congestive							
	Cough							
	Dermatitis							
	Dizziness							
	Dyspnoea							
	Fatigue							
	Headache							
	Hyperlipidaemia							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Polytraumatism							
	Pulmonary Mass							
	Rash							
	Respiratory Tract Congestion							
	Sleep Apnoea Syndrome							
	Urinary Tract Infection							

Date:12/26/03ISR Number: 4258440-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA02073
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Decreased Activity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	319 DAY	
	Myocardial Infarction							
	Renal Disorder							
	Renal Failure							

Date:12/26/03ISR Number: 4258443-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA02081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Activity							
	Myocardial Infarction							
	Renal Disorder							
	Renal Failure							

Date:12/26/03ISR Number: 4258445-9Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardio-Respiratory Arrest
Other	Difficulty In Walking

		Multiple Allergies					
		Muscle Strain					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Patellofemoral Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Sudden Cardiac Death		Vioxx	SS	Merck & Co., Inc	ORAL
		Tendon Injury		Vioxx	SS	Merck & Co., Inc	ORAL
				Atenolol	C		
				Hydrodiuril	C		
				Prevacid	C		
				Claritin	C		

Date:12/26/03ISR Number: 4258446-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00741
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY						
Initial or Prolonged		Infarction	Professional	Aspirin	SS		
Disability		Catheter Related		Celebrex	SS		
96	DAY						
		Complication		Dyazide	SS		
		Constipation		Iron (Unspecified)	SS		
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Fall		Nitroglycerin	SS		
		Gastrointestinal		Tylenol	C		
790	DAY						
		Haemorrhage		Lipitor	C		
790	DAY						
		Haemorrhage					
		Heart Rate Increased					
		High Density Lipoprotein Decreased					
		Hyperlipidaemia					
		Hypertension					
		Iron Deficiency Anaemia					
		Muscle Contracture					
		Myocardial Infarction					
		Rash					
		Rectal Haemorrhage					

Stress
Ulcer

Date:12/26/03ISR Number: 4258452-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adjustment Disorder
	Angina Pectoris
	Anxiety
	Aspiration
	Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Arrest
	Coma
	Coronary Artery Stenosis
	Depression

		Emotional Distress					
		Gastritis					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Lethargy	Professional	Aspirin	SS		
		Myocardial Infarction		Plavix	SS		
1	YR						
		Procedural Complication		Vioxx	SS	Merck & Co., Inc	ORAL
		Prothrombin Time		Heparin	SS		
INTRAVENOUS							
		Shortened		Vicodin Tablets	C		
339	DAY						
		Upper Gastrointestinal		Lipitor	C		
		Haemorrhage		Zoloft	C		
		Ventricular Fibrillation		Niacin	C		
				Metoprolol	C		
				Monopril	C		
				Celebrex	C		
				Analgesic Or Anesthetic (Unspecified)	C		

Date:12/26/03ISR Number: 4258453-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abscess Jaw	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		[Therapy			
		Blood Cholesterol		Unspecified]	C		
		Increased		Vicodin Tablets	C		
		Blood Creatine		Trimox	C		
		Phosphokinase Increased		Covera	C		
		Blood Pressure Increased		Atenolol	C		
		Carotid Artery Stenosis		Soma	C		
		Depression		Relafen	C		
		Duodenal Ulcer					
		Haemorrhage					
		Food Poisoning					
		Gastritis					
		Gastroenteritis					
		Gastrointestinal					
		Haemorrhage					

Gout
Head Injury
Hypovolaemia
Loss Of Consciousness
Myocardial Infarction
Sinus Tachycardia
Skin Nodule
Tooth Infection
Toothache

Date:12/26/03ISR Number: 4258454-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02686
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/03ISR Number: 4258468-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Aortic Valve Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	First Degree		Vioxx	SS	Merck & Co., Inc	ORAL	13	DAY
	Bladder Spasm		Vioxx	SS	Merck & Co., Inc	ORAL	13	DAY
	Bronchial Infection		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
	Bursitis		Tylenol	C				
	Cardiomyopathy		Parafon Forte	C				
	Carotid Artery Disease		Serevent	C				
	Cerebral Infarction							
	Cerebral Ischaemia		Proventil	C				
	Conduction Disorder							
	Dysuria		Aspirin	C				
	Ejection Fraction		Lioresal	C				
	Decreased		Valium	C				
	Electrocardiogram St-T		Demerol	C				
	Change		Ditropan	C				
	Embolic Stroke		Inderal	C				
	Emotional Distress							
	Escherichia Infection							
	Fall							
	Hypertension							
	Joint Effusion							
	Migraine							
	Mitral Valve Incompetence							
	Movement Disorder							
	Oedema Peripheral							
	Pneumonia							
	Pollakiuria							
	Rotator Cuff Syndrome							
	Scar							
	Tricuspid Valve							

Incompetence
Ultrasound Doppler
Abnormal
Urinary Tract Infection
Ventricular Hypertrophy

Date:12/26/03ISR Number: 4258472-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA02227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/26/03ISR Number: 4258474-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Catheter Site Infection Chest Wall Abscess Drug Effect Decreased Emotional Distress Encephalitis Brain Stem Herpes Zoster

	Hodgkin'S Disease Nodular Sclerosis Stage Unspecified	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Intervertebral Disc Displacement Meningitis Aseptic Pruritus Staphylococcal Sepsis	Professional					

Date:12/26/03ISR Number: 4258480-0Report Type:Expedited (15-DaCompany Report #WAES 0311BEL00027
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Electrocardiogram	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Hospitalization -	Repolarisation	Professional	Warfarin Sodium	SS		ORAL	251 DAY
Initial or Prolonged	Abnormality		Warfarin Sodium	SS		ORAL	
Disability	Gastric Haemorrhage		Acebutolol Hydrochloride	C		ORAL	
	Haematemesis		Furosemide	C		ORAL	
	Haemoglobin Decreased		Cozaar	C		ORAL	
	Mean Cell Volume Abnormal		Prazosin Hydrochloride	C		ORAL	
	Melaena						
	Myocardial Infarction						
	Prothrombin Time Prolonged						
	White Blood Cell Count Increased						

Date:12/26/03ISR Number: 4258481-2Report Type:Expedited (15-DaCompany Report #WAES 0312CHE00036
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	38 DAY
Hospitalization -	Cerebrovascular Accident		Dipyrone	C		ORAL	
Initial or Prolonged	Monoplegia		Irbesartan	C		ORAL	
Other							

Date:12/26/03ISR Number: 4258490-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA00780
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction No Adverse Effect	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/26/03ISR Number: 4258492-7Report Type:Expedited (15-DaCompany Report #WAES 0312USA02112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/03ISR Number: 4258879-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01081
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	67	DAY

Date:12/26/03ISR Number: 4258885-8Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00209
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Alcohol Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Drug Level Increased							
	Intentional Misuse							
	No Adverse Drug Effect							
	Suicide Attempt							

Date:12/26/03ISR Number: 4258888-3Report Type:Expedited (15-DaCompany Report #WAES 0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Aspirin	C				
	Congestive		Atenolol	C				
	Coronary Artery		Cyclobenzaprine					
	Atherosclerosis		Hydrochloride	C		ORAL		
	Dry Skin		Lasix (Furosemide)	C				
	Injury		Novolin	C				
SUBCUTANEOUS								
	Lumbar Radiculopathy		Ultram	C				
	Musculoskeletal Stiffness		Zestril	C				
	Myocardial Infarction		Procardia	C				
	Pain		Trental	C				
			Potassium (Unspecified)	C				
			Ranitidine	C				

Date:12/26/03ISR Number: 4260867-7Report Type:Expedited (15-DaCompany Report #S03-SWI-04412-01
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Behaviour	Foreign	Cipralex					
	Agitation	Health	(Escitalopram)	PS		ORAL	5 MG QD PO	
	Akathisia	Professional	Cipralex					
	Anxiety	Other	(Escitalopram)	SS		ORAL	10 MG QD PO	
	Disturbance In Attention		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Drug Eruption		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Gamma-Glutamyltransferase		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Mean Cell Haemoglobin		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Concentration Decreased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Monocyte Count Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Neutrophil Count		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Parkinsonism		Zyprexa (Olanzapine)	C				
	Sleep Disorder		Temesta (Lorazepam)	C				
			Duphalac (Lactulose)	C				
			Paragol	C				
			Fig Syrup	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/03ISR Number: 4259387-5Report Type:Expedited (15-DaCompany Report #WAES 0312AUS00054
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Circulatory Collapse		[Therapy Unspecified]	C				
	Dizziness							
	Fall							
	Insomnia							
	Loss Of Consciousness							
	Neck Pain							
	Pruritus							
	Syncope							
	Urticaria							
	Vertigo							

Date:12/29/03ISR Number: 4259554-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02509
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Infarction	Professional	Methotrexate	C				
	Angina Pectoris		Berplex Plus	C				
	Blood Triglycerides		Prednisone	C				
	Increased							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Occlusion							
	Hypercholesterolaemia							
	Hypotension							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:12/29/03ISR Number: 4259555-2Report Type:Expedited (15-DaCompany Report #WAES 0312FRA00057
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 11 DAY	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased Polymyalgia Rheumatica Renal Failure					

Date:12/29/03ISR Number: 4259557-6Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00202
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Aluminum Hydroxide			
Initial or Prolonged	Self-Medication		And Magnesium			
			Trisilicate	C		ORAL
			Diclofenac Sodium			
			And Misoprostol	C		ORAL
			Rabeprazole Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/03ISR Number: 4259558-8Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vein Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Visual Acuity Reduced	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
Disability			Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
			Furosemide Sodium	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Verapamil	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Morphine Sulfate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		
			Enalapril Maleate	C		ORAL		

Date:12/29/03ISR Number: 4259570-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA02042
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged		Professional	Ecotrin	C				
Disability			Calcium (Unspecified)	C		ORAL		
			Vitamins (Unspecified)	C		ORAL		
			Folic Acid	C		ORAL		
			Neurontin	C		ORAL		

Date:12/29/03ISR Number: 4259571-0Report Type:Expedited (15-DaCompany Report #WAES 0312USA01987
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/03ISR Number: 4259831-3Report Type:Expedited (15-DaCompany Report #WAES 0312NLD00016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemarthrosis		Vioxx	PS	Merck & Co., Inc		4	DAY
Initial or Prolonged			Acenocoumarol	C				

Date:12/29/03ISR Number: 4259834-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02216
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Coronary Artery
	Atherosclerosis
	Dizziness
	Dizziness Postural
	Emotional Disorder

	Injury						
	Myocardial Infarction						
	Sinus Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY
			Fosamax	C		ORAL	
			Zocor	C		ORAL	
			Synthroid	C			
			Prilosec	C			

Date:12/29/03ISR Number: 4259839-8Report Type:Expedited (15-DaCompany Report #WAES 0312USA02234
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
	Pruritus Generalised		Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY
	Rash						
	Tunnel Vision						

Date:12/29/03ISR Number: 4259840-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA02301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/29/03ISR Number: 4261491-2Report Type:Expedited (15-DaCompany Report #2003116907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Chronic Sinusitis	Consumer	Neurontin				
	Cough		(Gabapentin)	PS			900 MG (TID)
	Difficulty In Walking		Lipitor				

	Nasopharyngitis	(Atorvastatin)	SS
	Pain In Extremity	Rofecoxib (Rofecoxib)	SS

25 MG (DAILY)

Date:12/29/03ISR Number: 4263091-7Report Type:Periodic Company Report #2003-05984
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure Acute	Health	Viread	PS		ORAL
300 MG QD PO						
Initial or Prolonged	Renal Failure Chronic	Professional	Vioxx	SS		
50 MG QD						
Other			Acyclovir	SS		
			Ziagen	C		
			Viramune	C		
			Ambien	C		
			Pravachol	C		
			Doxazosin	C		
			Paxil	C		
			Amitriptyline	C		
			Protegra	C		
			Tricor	C		
			Neurontin	C		
			Vitamin C	C		
			Vitamin E	C		
			Lotensin	C		
			Norvasc	C		

				Oxycontin	C		

Date:12/30/03ISR Number: 4260730-1Report Type:Expedited (15-DaCompany Report #WAES 0304GBR00216
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Erosive Duodenitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Gastric Ulcer Haemorrhage	Professional	Aspirin	SS		ORAL		
Initial or Prolonged	Gastritis Erosive		Aspirin	SS		ORAL		
	Oesophagitis		Beclomethasone					
	Renal Failure Acute		Dipropionate	C				
RESPIRATORY								
(INHALATION)								
			Gabapentin	C		ORAL		
			Valsartan	C		ORAL		
			Valsartan	C		ORAL		
			Zocor	C		ORAL		
			Isosorbide					
			Mononitrate	C		ORAL		
			Isosorbide					
			Mononitrate	C		ORAL		
			Quinine Sulfate	C		ORAL		

Date:12/30/03ISR Number: 4260731-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		[Therapy					
	Contusion		Unspecified]	C				
	Depression		Antimicrobial					
	Fall		(Unspecified)	C				
	Gastric Haemorrhage		Soma	C				
	Haematochezia		Estrogens					
	Haemorrhoids		(Unspecified)	C				
1036 DAY								
	Heart Rate Irregular		Herbs (Unspecified)	C				
	Hiatus Hernia		Imdur	C				

Injury	Nitro	C	
Pain In Extremity			
Upper Gastrointestinal Haemorrhage			
Urinary Tract Infection			

Date:12/30/03ISR Number: 4260735-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00184
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS				
	Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C				
			Bendroflumethiazide	C				
			Fluoxetine	C				
			Prochlorperazine Maleate	C				
			Nicorandil	C				
			Doxazosin Mesylate	C				

Fosamax C ORAL

Date:12/30/03ISR Number: 4260738-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Activated Partial Thromboplastin Time Prolonged
Other	Acute Coronary Syndrome
	Alopecia
	Angina Pectoris
	Anxiety
	Anxiety Disorder
	Asthenia
	Atelectasis
	Back Pain
	Blood Triglycerides Increased
	Bronchitis
	Bronchospasm
	Cardiac Failure Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chills
	Chronic Obstructive Pulmonary Disease
	Coagulopathy
	Contusion
	Deafness Bilateral
	Deep Vein Thrombosis
	Diarrhoea
	Difficulty In Walking
	Diplopia
	Drug Level Below Therapeutic
	Dysphagia
	Dyspnoea
	Dysuria
	Epistaxis
	Fall
	Gastrointestinal Disorder

Gingival Bleeding
Haematochezia
Haemorrhage
Heart Rate Irregular
Hypertension
International Normalised
Ratio Decreased
Intervertebral Disc
Protrusion
Iron Deficiency Anaemia
Limb Discomfort
Lung Disorder
Menstrual Disorder
Microcytic Anaemia
Mouth Haemorrhage

		Muscle Spasms					
		Musculoskeletal Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Stiffness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nerve Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Obstructive Airways		Coumadin	SS		
		Disorder		Coumadin	SS		
		Odynophagia		[Therapy			
		Oedema Peripheral		Unspecified]	C		
		Osteoarthritis		Tylenol	C		
		Pain In Extremity		Vicodin Tablets	C		
		Pollakiuria		Albuterol	C		
		Prothrombin Time		Bayer Aspirin	C		
		Prolonged		Bayer Aspirin	C		
		Radiculitis		Aspirin	C		
		Renal Disorder		Tenormin	C		
		Silent Myocardial		Tenormin	C		
		Infarction		Ticlid	C		
		Sleep Disorder		Restoril	C		
		Stress Incontinence		Digoxin	C		
		Swelling		Anzemet	C		
		Transient Ischaemic		Vasotec	C		ORAL
		Attack		Isordil	C		
		Urinary Tract Infection		Lopressor	C		
		Vision Blurred		Naproxen	C		
		Wheezing		Nitrostat	C		

Date:12/30/03ISR Number: 4260739-8Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00204
Age:80 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
59 DAY							
Initial or Prolonged		Upper Gastrointestinal	Professional	Aspirin	SS		ORAL
292 DAY							
		Haemorrhage		Carbimazole	C		ORAL
				Ferrous Sulfate	C		ORAL
				Folic Acid	C		ORAL
				Isosorbide Mononitrate	C		ORAL
				Nicorandil	C		ORAL
				Propranolol Hydrochloride	C		ORAL

Date:12/30/03ISR Number: 4261009-4Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00210
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		217 DAY
Initial or Prolonged	Haemorrhage		Warfarin	SS		ORAL		
	Gastritis Erosive		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
	Haemoglobin Decreased		Amitriptyline Hydrochloride	C		ORAL		
	International Normalised Ratio Increased		Torsemide	C		ORAL		
	Melaena		Fluoxetine	C		ORAL		
			Nitrazepam	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/03ISR Number: 4261012-4Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00213
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Prothrombin Level		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Decreased		Warfarin	SS		ORAL		
			Aspirin	C				
			Rosuvastatin Calcium	C				
			Zopiclone	C				
			Tramadol Hydrochloride	C				
			Ramipril	C				

Date:12/30/03ISR Number: 4261013-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01084
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization -	Upper Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Haemorrhage		Vitamins (Unspecified)	C				

Date:12/30/03ISR Number: 4261014-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA00083
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Collapse Of Lung		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
	Post Procedural Complication		Albuterol	C				
	Respiratory Tract Infection		Combivent	C				
			Salmeterol	C				
			Alprazolam	C				
			Loratadine	C				
			Metoprolol Tartrate	C				
			Rabeprazole Sodium	C				

Date:12/30/03ISR Number: 4261836-3Report Type:Direct Company Report #CTU 208968
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL	ORAL	
Initial or Prolonged	Haemorrhage		Warfarin	SS		ORAL	ORAL	

Date:12/30/03ISR Number: 4262579-2Report Type:Expedited (15-DaCompany Report #PERI00203003611
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Coversyl					
Initial or Prolonged	Renal Failure Acute	Health	(Perindopril)	PS		ORAL	2 MG QD; PO	
		Professional	Lasix (Furosemide)	SS		ORAL	80 MG DAILY; PO	
		Other						
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD; PO	
			Lanoxin (Digoxin)	C				
			Marevan (Warfarin Sodium)	C				

	Lipitor (Atorvastatin)	C
	Losec (Omeprazole)	C
	Neurontin (Gabapentin)	C
	Humalog (Insulin Lispro)	C
	Imdur (Isosorbide Mononitrate)	C

Date:12/31/03ISR Number: 4261379-7Report Type:Expedited (15-DaCompany Report #WAES 0312USA02379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/31/03ISR Number: 4261382-7Report Type:Expedited (15-DaCompany Report #WAES 0203DEU00179
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization - Initial or Prolonged	Blood Bilirubin Increased Blood Immunoglobulin A Increased Blood Immunoglobulin G Increased Blood Lactate Dehydrogenase Increased Coombs Direct Test Positive Diabetes Mellitus Inadequate Control Fatigue Haemolysis Haemolytic Anaemia Jaundice Lymphadenopathy Platelet Count Abnormal	Professional	Valsartan Ibuprofen Lysine Insulin Human Magnesium (Unspecified)	SS C C C		ORAL ORAL SUBCUTANEOUS ORAL		

Reticulocyte Count
Abnormal
Stress
White Blood Cell Count
Abnormal

Date:12/31/03ISR Number: 4261383-9Report Type:Expedited (15-DaCompany Report #WAES 0304FRA00082
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumopathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Bromazepam	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		
			Nicardipine Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/03ISR Number: 4261385-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA03635
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Increased	Professional	Vasotec	SS		ORAL		
	Drug Interaction		Furosemide	SS				
	Duodenal Ulcer		Potassium					
	Hyperkalaemia		(Unspecified)	C				

Date:12/31/03ISR Number: 4261390-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01110
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:12/31/03ISR Number: 4261637-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA02789
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum Intestinal		Lortab	C				
	Haemorrhagic		Ascorbic Acid	C				
	Gastric Disorder		Vitamin B Complex	C		ORAL		
	Gastrointestinal Tract		Vitamins					
	Adenoma		(Unspecified)	C				
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypertension							
	Lower Gastrointestinal							
	Haemorrhage							
	Muscle Spasms							
	Pain In Extremity							
	Radiculopathy							
	Rectal Haemorrhage							

Road Traffic Accident
Syncope

Date:12/31/03ISR Number: 4261639-XReport Type:Expedited (15-DaCompany Report #WAES 0312ESP00025
Age:70 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Agranulocytosis
Hospitalization -	Asthenia
Initial or Prolonged	Biopsy Bone Marrow
Other	Abnormal
	Dialysis
	Duodenal Ulcer
	Duodenal Ulcer
	Haemorrhage
	Dupuytren'S Contracture
	Faeces Discoloured
	Haematocrit Decreased
	Haemoglobin Decreased
	Jaundice

		Joint Injury					
		Klebsiella Bacteraemia					
		Nocturia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post Procedural		Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
		Complication		Allopurinol	SS		ORAL
2	MON						
		Red Blood Cell					
		Schistocytes Present					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Staphylococcal					
		Bacteraemia					
		Staphylococcal Infection					
		Thrombocytopenia					

Date:12/31/03ISR Number: 4261641-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthropod Bite		Vioxx	SS	Merck & Co., Inc	ORAL
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatitis Contact		Allopurinol	C		
		Epicondylitis		Ultram	C		
		Eye Swelling		Kenalog	C		
PARENTERAL							
		Hepatic Cyst		Trazodone			
		Hypertensive		Hydrochloride	C		
		Cardiomyopathy		Celexa	C		
		Muscle Strain		Colchicine	C		
		Muscular Weakness		Indocin			
		Nerve Injury		(Indomethacin)	C		ORAL
		Neuropathy Peripheral		Bactroban	C		
		Radiculopathy		Serzone	C		
		Sciatica		Prednisone	C		ORAL
		Skin Burning Sensation					

Date:12/31/03ISR Number: 4261642-XReport Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Other	Arthralgia
	Arthropathy
	Asthenia
	Blood Pressure
	Fluctuation
	Cardiovascular Disorder
	Constipation
	Difficulty In Walking
	Fall
	Gait Disturbance
	Gastric Disorder
	Joint Sprain
	Lumbar Spinal Stenosis
	Myocardial Infarction
	Nocturia

	Oedema						
	Oedema Peripheral						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C				
			Aspirin	C				

Date:12/31/03ISR Number: 4261647-9Report Type:Expedited (15-DaCompany Report #WAES 0309CHE00015
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Withdrawal Headache		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Celecoxib	SS		ORAL	119	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/31/03ISR Number: 4261650-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA03118
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Chest Pain		Ultracet	C				
	Myocardial Infarction		Synthroid	C				
	Nervousness							

Date:12/31/03ISR Number: 4261652-2Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00066
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neutropenia		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Other			Tramadol	SS				

Acetaminophen	C	
Fosamax	C	ORAL
Tolterodine	C	ORAL
Senna	C	ORAL
Citalopram	C	ORAL

Date:12/31/03ISR Number: 4261653-4Report Type:Expedited (15-DaCompany Report #WAES 01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Arthritis
	Asthenia
	Blood Pressure Fluctuation
	Cardiovascular Disorder
	Dizziness
	Eczema Asteatotic
	Emotional Distress
	Encephalitis
	Fatigue
	Fibromyalgia
	Grand Mal Convulsion
	Hot Flush

		Joint Swelling					
		Lacrimation Increased					
		Meningitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Prolapse		Vioxx	PS	Merck & Co., Inc	ORAL
		Myalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema		Celebrex	C		
		Renal Failure		Femhrt	C		
		Sleep Disorder		Herbs (Unspecified)	C		
		Upper Respiratory Tract Infection		Anaprox	C		

Date:12/31/03ISR Number: 4261655-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anxiety		Coumadin	SS		
Other	Blood Triglycerides Increased		Coumadin [Therapy Unspecified]	SS		
	Bronchitis		Tylenol	C		
	Cardiomegaly		Vicodin Tablets	C		
	Cerebrovascular Accident		Albuterol	C		
	Chest Pain		Bayer Aspirin	C		
	Chills		Bayer Aspirin	C		
	Chronic Obstructive Pulmonary Disease		Aspirin	C		
	Coagulopathy		Tenormin	C		
	Contusion		Tenormin	C		
	Deafness Bilateral		Ticlid	C		
	Diplopia		Restoril	C		
	Dysphagia		Digoxin	C		
	Dyspnoea		Anzemet	C		
	Dysuria		Vasotec	C		ORAL
	Epistaxis		Isordil	C		
	Fall		Lopressor	C		
	Gastrointestinal Disorder		Naproxen	C		
	Gingival Bleeding		Nitrostat	C		
	Haematochezia					
	Haemorrhage					
	Heart Rate Irregular					
	Hypertension					
	Injury					

International Normalised
Ratio Decreased
Intervertebral Disc
Protrusion
Limb Discomfort
Lung Disorder
Mouth Haemorrhage
Odynophagia
Oedema
Oedema Peripheral
Silent Myocardial
Infarction
Sleep Disorder
Stress Incontinence
Transient Ischaemic
Attack
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/31/03ISR Number: 4261665-0Report Type:Expedited (15-DaCompany Report #WAES 0311USA01998
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
Initial or Prolonged			Lipitor	C				
Disability			Plavix	C				
Other			Corticosteroids (Unspecified)	C		PARENTERAL		
			Vasotec	C		ORAL		
			Lithium Carbonate	C				
			Glucophage	C				

Date:12/31/03ISR Number: 4262396-3Report Type:Expedited (15-DaCompany Report #DSA_23750_2003
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Osmolarity	Foreign	Teveten	PS		ORAL	600 MG Q DAY	
Initial or Prolonged	Decreased	Other					PO	
	Duodenitis		Vioxx	SS		ORAL	25 MG Q DAY	
	Gastrointestinal						PO	
	Haemorrhage		Ovesterin	C				
	General Physical Health Deterioration		Timosan	C				
	Hyponatraemia							

Date:12/31/03ISR Number: 4262492-0Report Type:Direct Company Report #CTU 209080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Libido Decreased		Vioxx 25 Mg Merc	PS	Merc	ORAL	1 DAY ORAL	

Date:01/02/04ISR Number: 4262189-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia Haemolytic
Disability	Autoimmune
	Anxiety
	Arthralgia
	Arthritis Infective
	Barrett'S Oesophagus
	Blindness Unilateral
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased
	Blood Iron Decreased
	Blood Test Abnormal
	Blood Urine
	C-Reactive Protein
	Increased
	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Chest Wall Pain
	Coagulation Factor Viii

		Level Increased					
		Cough					
		Decreased Appetite					
		Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Emotional Distress		Amitriptyline			
		Erythema		Hydrochloride	C		
		Eye Pain		Rocaltrol	C		
		Face Oedema		Os-Cal	C		
		Fibromyalgia		Valium	C		
		Gastrooesophageal Reflux		Synthroid	C		
		Disease		Ambien	C		
		Granuloma		Slow-Mag	C		
		Haematochezia		Reglan	C		
		High Density Lipoprotein		Reglan	C		
		Decreased		Prilosec	C		
		Hypercalcaemia		Ditropan Xl	C		
		Hyperglycaemia		Potassium Chloride	C		
		Hypocalcaemia					
		Hypomagnesaemia					
		Hypoparathyroidism					
		Hypothyroidism					
		Hypotonia					
		Impaired Driving Ability					
		Increased Appetite					
		Injury					
		Joint Swelling					
		Leukocytosis					
		Low Density Lipoprotein					
		Increased					
		Lung Neoplasm					
		Malaise					
		Mental Status Changes					
		Mucosal Dryness					
		Muscle Twitching					
		Musculoskeletal Stiffness					
		Oedema Peripheral					
		Oesophageal Achalasia					
		Oesophageal Stenosis					
		Overdose					
		Pain In Extremity					
		Pollakiuria					
		Pyrexia					
		Renal Failure					

Tachycardia
Transient Ischaemic
Attack
Urine Ketone Body Present
Viral Infection
Von Willebrand'S Factor
Multimers Abnormal
Weight Decreased
Weight Increased
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/02/04ISR Number: 4262191-5Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00017
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hepatic Necrosis		Esomeprazole Magnesium	SS		ORAL		
	Jaundice Cholestatic		Hydrochlorothiazide And Ramipril	SS		ORAL		

Date:01/02/04ISR Number: 4262193-9Report Type:Expedited (15-DaCompany Report #WAES 0312NLD00016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemarthrosis		Vioxx	PS	Merck & Co., Inc		4	DAY
			Acenocoumarol	C				

Date:01/02/04ISR Number: 4262194-0Report Type:Expedited (15-DaCompany Report #WAES 0308SWE00010
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Aspirin	SS		ORAL		
Hospitalization - Initial or Prolonged			Citalopram Hydrobromide	SS		ORAL		
			[Therapy Unspecified]	C				
			Bezafibrate	C				
			Estriol	C				
			Lisinopril	C				
			Furosemide	C				
			Estradiol	C				
			Carvedilol	C				
			Acetaminophen	C				

Date:01/02/04ISR Number: 4262195-2Report Type:Expedited (15-DaCompany Report #WAES 0311BEL00027
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization -	Myocardial Infarction		Warfarin Sodium	SS		ORAL	251	DAY
Initial or Prolonged Disability			Warfarin Sodium	SS		ORAL		
			Acebutolol Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Cozaar	C		ORAL		
			Prazosin Hydrochloride	C		ORAL		

Date:01/02/04ISR Number: 4262565-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01087
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	94	DAY
	Renal Failure Acute							
	Shock							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/02/04ISR Number: 4262568-8Report Type:Expedited (15-DaCompany Report #WAES 0312USA02504
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization - Initial or Prolonged	Dyspnoea							
Other	Fatigue							
	Gastrointestinal Haemorrhage							

Date:01/02/04ISR Number: 4262569-XReport Type:Expedited (15-DaCompany Report #WAES 0310DEU00194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dry Mouth		Vioxx	SS	Merck & Co., Inc	ORAL		
	Keratoconjunctivitis Sicca							

Date:01/02/04ISR Number: 4262573-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01106
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
	Cardiovascular Disorder							
	Renal Failure							

Date:01/02/04ISR Number: 4278723-7Report Type:Periodic Company Report #BLOC000338
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dizziness	Consumer	Myobloc (Botulinum Toxin Type B)	PS		INTRAMUSCULAR	INTRAMUSCULAR	
	Hypertension							
	Influenza Like Illness		Vioxx (Rofecoxib)	SS				

Micronor (Norethisterone)	C
Zovirax (Aciclovir)	C
Prozac (Fluoxetine)	C
Phrenilin Forte (Paracetamol/Butalbital)	C
Amerge	C

Date:01/04/04ISR Number: 4263251-5Report Type:Direct Company Report #CTU 209261
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx 25mg	PS		ORAL	25 MG 1/DAY	
Required Intervention to Prevent Permanent Impairment/Damage	Orthostatic Hypotension					ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/04ISR Number: 4263351-XReport Type:Expedited (15-DaCompany Report #WAES 0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Stenosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bundle Branch Block Left		Captopril	C				
Other	Cardiac Failure		Celebrex	C				
	Congestive		Plavix	C				
	Cardio-Respiratory Arrest		Pepcid Ac	C		ORAL		
	Cardiomegaly		Lasix (Furosemide)	C				
	Chronic Obstructive		Ambien	C				
	Pulmonary Disease		Zoloft	C				
	Coma		Glyburide	C				
	Coronary Artery Disease		Synthroid	C				
	Diabetes Mellitus		Lorazepam	C				
	Inadequate Control		Meclizine	C				
	Dizziness		Phenergan Tablets/Suppositories	C				
	Dyspepsia							
	Faecal Occult Blood Positive							
	Gastritis							
	Gastrointestinal Disorder							
	Hyperhidrosis							
	Hyperkalaemia							
	Hypertension							
	Microcytic Anaemia							
	Myocardial Infarction							
	Peptic Ulcer							
	Renal Failure							
	Respiratory Distress							

Date:01/05/04ISR Number: 4263359-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA03199
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident	Professional	Lasix (Furosemide)	C				
1680 DAY								
	Chest Pain		Warfarin	C				
1284 DAY								
	Injury							
	Myalgia							

Date:01/05/04ISR Number: 4263363-6Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00114
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Duodenitis	Professional	Warfarin	SS				
Initial or Prolonged	Gastrointestinal		Goserelin Acetate	C				
Other	Haemorrhage							
	International Normalised							
	Ratio Increased							

Date:01/05/04ISR Number: 4263365-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Benign Prostatic
Initial or Prolonged	Hyperplasia

		Blood Cholesterol Increased					
		Coronary Artery Surgery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Libido Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Tylenol	C		
		Pollakiuria		Saw Palmetto	C		
		Urine Flow Decreased		Ambien	C		
				Norvasc	C		
				Aspirin	C		
				Dicyclomine Hydrochloride	C		
				Prevacid	C		

Date:01/05/04ISR Number: 4263366-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
697 DAY							
Initial or Prolonged		Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
697 DAY							
Disability		Blood Cholesterol Increased		Acetaminophen And Hydrocodone Bitartrate	C		
		Blood Glucose Increased		Wellbutrin	C		
		Cardiac Failure		Viagra	C		
		Congestive		Avandia	C		
		Colonic Polyp		Duratuss	C		
		Conjunctival Haemorrhage		Blephamide Ointment	C		
		Coronary Artery Atherosclerosis					
		Dermatitis Contact					
		Dilatation Ventricular					
		Diverticulum Intestinal					
		Ecchymosis					
		Excoriation					
		Eye Injury					
		Eye Oedema					
		Haemorrhoids					
		Rectal Haemorrhage					
		Ventricular Dysfunction					

Ventricular Extrasystoles
Vision Blurred

Date:01/05/04ISR Number: 4263367-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA01809
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hallucination		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hepatic Failure		Tylenol	SS				
Disability	Hepatotoxicity							
Other	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/04ISR Number: 4263368-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA02730
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Pulmonary Oedema		Aspirin	C		ORAL		
	Weight Increased		Atenolol	C		ORAL		
			Lescol	C				

Date:01/05/04ISR Number: 4263369-7Report Type:Expedited (15-DaCompany Report #WAES 01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arteritis		Tylenol	C				
Disability	Blood Pressure		Tavist-D	C				
	Fluctuation		Afrin Nasal Spray	C				
	Cardiac Murmur							
	Cardiovascular Disorder							
	Disturbance In Attention							
	Dyspepsia							
	Fatigue							
	Flatulence							
	Fungal Infection							
	Headache							
	High Density Lipoprotein Decreased							
	Hypercalcaemia							
	Hypoaesthesia							
	Ischaemic Stroke							
	Nausea							
	Oedema							
	Pyrexia							
	Renal Failure							
	Subarachnoid Haemorrhage							
	Vascular Rupture							
	Vasculitis							

Date:01/05/04ISR Number: 4263370-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Disability	Asthenia
	Cancer Pain
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Colonic Polyp
	Depression
	Dyspnoea
	Emotional Distress
	Fall
	Fatigue
	Haemorrhoids
	Hemiparesis
	Hip Fracture
	Hyperhidrosis

		Injury					
		Insomnia					
		Lymphadenopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphadenopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
		Mediastinal	Professional	Pepcid	C		ORAL
		Lymphoma		Lasix (Furosemide)	C		
		Malaise		Neurontin	C		
		Marrow Hyperplasia		Ibuprofen	C		
		Myelodysplastic Syndrome		Zestril	C		
		Myeloproliferative		Lithium Carbonate	C		
		Disorder					
		Nausea					
		Night Sweats					
		Non-Hodgkin'S Lymphoma					
		Oedema Peripheral					
		Pleural Effusion					
		Pneumonia Aspiration					
		Rectal Polyp					
		Septic Shock					
		Splenomegaly					
		Stomatitis					

Date:01/05/04ISR Number: 4263373-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA02635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/05/04ISR Number: 4263376-4Report Type:Expedited (15-DaCompany Report #WAES 0312FRA00088
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypotension	Professional	Candesartan			
	Renal Failure Acute		Cilexetil	SS		ORAL
	Somnolence					

Date:01/05/04ISR Number: 4263378-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01214
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amitriptyline Hydrochloride	C				
			Antimicrobial (Unspecified)	C				

Date:01/05/04ISR Number: 4265025-8Report Type:Expedited (15-DaCompany Report #03-12-1619
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anorexia
	Haemodialysis
	Lactic Acidosis
	Lethargy
	Nausea

	Renal Failure Acute						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Foreign	Metformin Hcl - Ipi				
		Other	Tablets	PS			1000MG	
			Rofecoxib	SS		ORAL	ORAL	1 MON

Date:01/05/04ISR Number: 4265027-1Report Type:Expedited (15-DaCompany Report #03-12-1618
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Metformin Hcl - Ipi					
Initial or Prolonged	Anorexia	Other	Tablets	PS		ORAL	500MG BD ORAL	
	Depressed Level Of		Rofecoxib	SS		ORAL	ORAL	
	Consciousness							
	Haemodialysis							
	Intestinal Ischaemia							
	Lactic Acidosis							
	Lethargy							
	Nausea							
	Renal Failure Acute							

Date:01/05/04ISR Number: 4265028-3Report Type:Expedited (15-DaCompany Report #03-12-1640
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Metformin Hcl - Ipi					
Initial or Prolonged	Anorexia	Other	Tablets	PS		ORAL	500MG BD ORAL	
	Depressed Level Of		Rofecoxib	SS				
	Consciousness							
	Haemodialysis							
	Lactic Acidosis							
	Lethargy							
	Nausea							
	Renal Failure Acute							

Date:01/05/04ISR Number: 4265029-5Report Type:Expedited (15-DaCompany Report #03-12-1620
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Agitation Anorexia Depressed Level Of Consciousness Haemodialysis Lactic Acidosis Lethargy Nausea Renal Failure	Foreign Other	Metformin Hcl - Ipi Tablets Rofecoxib	PS SS		ORAL	1000MG ORAL	

Date:01/06/04ISR Number: 4264551-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT
Amnesia
Anaemia Haemolytic
Autoimmune
Anxiety
Arthralgia
Arthritis Infective
Barrett'S Oesophagus
Blindness Unilateral
Blood Cholesterol
Increased
Blood Creatine
Phosphokinase Increased
Blood Iron Decreased
C-Reactive Protein
Increased
Calcium Metabolism
Disorder
Cellulitis
Cerebrovascular Accident
Chest Pain
Chest Wall Pain
Coagulation Factor Viii
Level Increased
Cough
Decreased Appetite
Diplopia
Disturbance In Attention
Drug Hypersensitivity
Dyspnoea
Emotional Distress
Eye Pain
Face Oedema
Fibromyalgia
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Granuloma
Haematochezia
Headache
Hiatus Hernia
High Density Lipoprotein
Decreased
Hypercalcaemia
Hypocalcaemia

Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism
Increased Appetite
Joint Swelling
Leukocytosis
Low Density Lipoprotein
Increased
Lung Neoplasm
Mucosal Dryness
Muscle Spasms
Muscle Twitching
Musculoskeletal Stiffness
Oedema Peripheral

		Oesophageal Achalasia					
		Oesophageal Stenosis					
		Pain In Extremity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pollakiuria	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Pyrexia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Renal Failure		Amitriptyline			
		Tachycardia		Hydrochloride	C		
		Tinnitus		Rocaltrol	C		ORAL
		Transient Ischaemic		Os-Cal + D	C		
		Attack		Valium	C		
		Upper Respiratory Tract		Synthroid	C		
		Infection		Synthroid	C		ORAL
		Vision Blurred		Ambien	C		
		Von Willebrand'S Factor		Slow-Mag	C		
		Multimers Abnormal		Reglan	C		
		Weight Decreased		Reglan	C		
		Weight Increased		Prilosec	C		
				Ditropan Xl	C		
				Potassium Chloride	C		

Date:01/06/04ISR Number: 4264562-XReport Type:Expedited (15-DaCompany Report #WAES 0312USA02736
Age:60 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Wound Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						

Date:01/06/04ISR Number: 4264981-1Report Type:Expedited (15-DaCompany Report #WAES 0212CHE00032
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anuria		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Cardiomyopathy		Acenocoumarol	C		ORAL
Initial or Prolonged		Coma Hepatic		Acetaminophen	C		ORAL
		Drug Toxicity		Amiodarone			
		Dyspnoea		Hydrochloride	C		ORAL
		Hepatic Cirrhosis		Ascorbic Acid And			
		Hepatic Necrosis		Vitamin B			

	Hepatic Neoplasm		(Unspecified)	C		ORAL
	Hepatic Steatosis		Spironolactone	C		ORAL
	Hepatitis B		Tramadol			
	Hepatitis Fulminant		Hydrochloride	C		ORAL
	Hypoglycaemia		Thiamine			
	Pco2 Decreased		Hydrochloride	C		ORAL
	Psychomotor Retardation		Furosemide	C		ORAL
	Renal Impairment		Lactulose	C		ORAL
	Somnolence		Lorazepam	C		ORAL
	Weight Increased		Potassium Chloride	C		ORAL

Date:01/06/04ISR Number: 4264982-3Report Type:Expedited (15-DaCompany Report #WAES 0308FRA00033
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Phlebitis		Chondroitin Sulfate			
			Sodium	C		ORAL
			Fluvastatin Sodium	C		ORAL
			Irbesartan	C		ORAL
			Omeprazole	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/04ISR Number: 4264983-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Tenormin	C				
			Lipitor	C				
			Lovenox	C			8	DAY
			Monopril	C				

Date:01/06/04ISR Number: 4265922-3Report Type:Expedited (15-DaCompany Report #2003-DE-06467GD
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depressed Level Of	Literature	Lithium Carbonate					
Initial or Prolonged	Consciousness	Health	(Lithium Carbonate)	PS			42 MG	
	Muscle Rigidity	Professional	Rofecoxib					
	Renal Failure		(Rofecoxib)	SS			25 MG	
	Tremor							

Date:01/06/04ISR Number: 4265924-7Report Type:Expedited (15-DaCompany Report #2003-DE-06466GD
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy	Literature	Lithium Carbnoate					
Initial or Prolonged	Drug Interaction	Health	(Lithium Carbonate)	PS			600 MG	
	Drug Level Increased	Professional	Rofecoxib					
	Gait Disturbance		(Rofecoxib)	SS			25 MG	
	Hypertonia							

Mood Altered
Myoclonus

Date:01/06/04ISR Number: 4265926-0Report Type:Expedited (15-DaCompany Report #2003-DE-06460GD
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Drug Level Increased Neurotoxicity	Literature Health Professional	Lithium Carbonate(Lithium Carbonate)	PS			600 MG	
			Rofecoxib (Rofecoxib)	SS				9 DAY

Date:01/06/04ISR Number: 4265927-2Report Type:Expedited (15-DaCompany Report #2003-DE-06459GD
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium Drug Interaction Drug Level Increased	Literature Health Professional	Lithium Carbonate(Lithium Carbonate)	PS			450 MG	
	Dysarthria Sedation		Rofecoxib (Rofecoxib)	SS				LESS THAN 1 MONTH

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/04ISR Number: 4265929-6Report Type:Expedited (15-DaCompany Report #2003-DE-06453GD
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Literature	Lithium Carbonate					
	Coordination Abnormal	Health	(Lithium Carbonate)	PS			900 MG	
	Disorientation	Professional	Rofecoxib					
	Drug Interaction		(Rofecoxib)	SS			25 MG	
	Drug Level Increased							

Date:01/06/04ISR Number: 4265930-2Report Type:Expedited (15-DaCompany Report #2003-DE-06455GD
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Literature	Lithium Carbonate					
	Disorientation	Health	(Lithium Carbonate)	PS			ALTERNATING	
	Drug Interaction	Professional						
	Drug Level Increased						1200 MG/D AND 900 MG/D	
	Gait Disturbance		Rofecoxib					
	Tremor		(Rofecoxib)	SS				

Date:01/06/04ISR Number: 4265931-4Report Type:Expedited (15-DaCompany Report #2003-DE-06456GD
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asterixis	Literature	Lithium Carbonate					
	Coordination Abnormal	Health	(Lithium Carbonate)	PS			900 MG	
	Dialysis	Professional	Rofecoxib	SS			25 MG	
	Drug Interaction							
	Drug Level Increased							
	Nystagmus							

Date:01/06/04ISR Number: 4265932-6Report Type:Expedited (15-DaCompany Report #2003-DE-06457GD
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State	Literature	Lithium Carbonate					
	Drug Interaction	Health	(Lithium Carbonate)	PS			900 MG	
	Drug Level Increased	Professional	Rofecoxib					
	Urinary Tract Infection		(Rofecoxib)	SS			25 MG	

Date:01/06/04ISR Number: 4265935-1Report Type:Expedited (15-DaCompany Report #2003-DE-06448GD
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Calcium Increased	Literature	Lithium Carbonate					
	Blood Lactic Acid	Health	(Lithium Carbonate)	PS			600 MG	
	Drug Interaction	Professional	Rofecoxib					
	Dysarthria		(Rofecoxib)	SS			40 MG	
	Hemiparesis							
	Renal Failure							
	Renal Neoplasm							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/04ISR Number: 4265588-2Report Type:Direct Company Report #CTU 209475
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alopecia		Vioxx 25 Mg Merck	PS	Merck		25 MG ONCE	
	Anxiety						DAILY	
	Chest Pain							
	Dyspnoea							
	Gingival Bleeding							
	Heart Rate Increased							
	Pain							

Date:01/07/04ISR Number: 4265716-9Report Type:Expedited (15-DaCompany Report #WAES 0312FRA00057
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Initial or Prolonged	Increased	Professional						
	Condition Aggravated							
	General Physical							
	Condition Abnormal							
	Inflammation							
	Renal Failure							

Date:01/07/04ISR Number: 4266298-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis	Professional	Xanax	C				
	Electrocardiogram St-T		Aspirin	C				
	Segment Abnormal		Celebrex	C				
	Emotional Distress		Zyrtec	C				
	Myocardial Infarction		Prozac	C				
	Oedema Peripheral		Zestril	C				
	Sinus Bradycardia		Naproxen	C				
	Ventricular Hypokinesia		Prilosec	C				

Date:01/07/04ISR Number: 4266301-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA00051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Medication Error	Professional						

Date:01/08/04ISR Number: 4266846-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Disability	Angina Unstable
	Asthma
	Blood Pressure Decreased
	Breath Sounds Decreased
	Bundle Branch Block Left
	Cardiac Failure
	Congestive

		Cardiac Murmur					
		Cardiomyopathy					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional	Allegra	C		ORAL
		Dyspnoea		Zoloft	C		ORAL
		Electrocardiogram					
		Abnormal					
		Fatigue					
		Fluid Retention					
		Ganglion					
		Headache					
		Hypertension					
		Insomnia					
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Pain					
		Respiratory Rate					
		Increased					
		Tendonitis					
		Ventricular Hypokinesia					

Date:01/08/04ISR Number: 4266848-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02050
Age:69 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Atherosclerosis	Professional				
Other		Aortic Valve Incompetence					
		Asthma					
		Body Tinea					
		Bronchitis					
		Cardiac Failure					
		Congestive					
		Cardiomegaly					
		Carotid Artery Stenosis					
		Cellulitis					
		Chronic Obstructive					
		Airways Disease					
		Exacerbated					
		Foot Fracture					
		Gastroenteritis					
		Hypertension					

Lymphadenopathy
Mediastinal
Nausea
Pain In Extremity
Sinus Bradycardia
Skin Papilloma
Vascular Calcification
Vertigo
Vital Capacity Decreased
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/08/04ISR Number: 4266850-XReport Type:Expedited (15-DaCompany Report #WAES 0311USA02216
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
Disability	Akinesia		Fosamax	C		ORAL		
	Cardiac Disorder		Zocor	C		ORAL		
	Coronary Artery		Synthroid	C				
	Atherosclerosis		Prilosec	C				
	Coronary Artery Disease							
	Diverticulum							
	Diverticulum Intestinal							
	Dizziness							
	Emotional Disorder							
	Hypercholesterolaemia							
	Hypothyroidism							
	Injury							
	Irritable Bowel Syndrome							
	Myocardial Infarction							
	Osteoporosis							

Date:01/08/04ISR Number: 4266863-8Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
		Professional	Estradiol Valerate And Norethindrone	C		ORAL		
			Omeprazole	C		ORAL	1	DAY

Date:01/08/04ISR Number: 4267276-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization -	Arthralgia

Initial or Prolonged Disability	Asthenia B-Cell Small Lymphocytic Lymphoma Blood Pressure Increased Cancer Pain Cardiac Failure Congestive Cardio-Respiratory Arrest Chromosome Abnormality Colonic Polyp Depressed Level Of Consciousness Depression Diabetes Mellitus Non-Insulin-Dependent Disease Progression Facial Palsy Fall Fatigue Femoral Neck Fracture Fluid Retention Gastrointestinal Haemorrhage

	Haematuria					
	Haemorrhage Intracranial					
	Haemorrhoids	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL
	Hip Fracture		Pepcid	C		ORAL
	Hyperhidrosis		Lasix (Furosemide)	C		
	Injury		Neurontin	C		
	Insomnia		Ibuprofen	C		
	Intestinal Polyp		Zestril	C		
	Lymphadenopathy		Lithium Carbonate	C		
	Lymphadenopathy					
	Mediastinal					
	Marrow Hyperplasia					
	Nausea					
	Non-Hodgkin'S Lymphoma					
	Oedema Peripheral					
	Oesophagitis Haemorrhagic					
	Pathological Fracture					
	Platelet Disorder					
	Pleural Effusion					
	Pneumonia Aspiration					
	Pulse Absent					
	Rectal Polyp					
	Respiratory Distress					
	Septic Shock					
	Sinus Tachycardia					
	Sinusitis					
	Stomatitis					
	Vomiting					

Date:01/08/04ISR Number: 4267277-7Report Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Other	Angina Pectoris
	Arthralgia
	Asthenia
	Blood Pressure Increased
	Bone Pain
	Bunion
	Calcinosis
	Constipation

Difficulty In Walking
Dizziness
Fall
Gait Disturbance
Gastric Disorder
Globulins Increased
Intervertebral Disc
Disorder
Joint Sprain
Laceration
Lumbar Radiculopathy
Lumbar Spinal Stenosis
Muscle Spasms
Myalgia
Myocardial Infarction
Nasal Congestion

	Nausea						
	Nocturia						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Onychomycosis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL	
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL	
	Respiratory Rate		Tylenol	C			
	Increased		Aspirin	C			
	Rotator Cuff Syndrome						
	Scoliosis						
	Sinusitis						
	Spinal Osteoarthritis						
	Wound Infection						

Date:01/08/04ISR Number: 4267279-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA03118
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 7 DAY	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged Disability	Asthenia		Ultracet	C			
	Back Pain		Zoloft	C			
	Blood Cholesterol Increased		Synthroid	C			
	Blood Glucose Increased						
	Blood Magnesium Decreased						
	Blood Pressure Increased						
	Chest Pain						
	Coronary Artery Occlusion						
	Difficulty In Walking						
	Dizziness						
	Dyspnoea						
	Electrocardiogram St Segment Depression						
	Fatigue						
	Heart Rate Increased						
	Hyperhidrosis						
	Insomnia						
	Leukocytosis						
	Liver Disorder						
	Myocardial Infarction						
	Nausea						

	Nervousness
	Pain In Extremity
	Pollakiuria
	Productive Cough
	Pruritus
	Pyrexia

Date:01/08/04ISR Number: 4267280-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Azotaemia
	Back Pain
	Bundle Branch Block Left
	Cardiac Failure
	Congestive

		Cardiomegaly					
		Change Of Bowel Habit					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Constipation		Vioxx	PS	Merck & Co., Inc	ORAL
		Contusion		Lasix (Furosemide)	SS		
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Lasix (Furosemide)	SS		
INTRAVENOUS							
		Crackles Lung		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Eye Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Plavix	C		
		Haematocrit Decreased		Advil	C		
		Haemoglobin Decreased		Lopressor	C		
		Hypercholesterolaemia		Timoptic	C		
OPHTHALMIC							
		Hypertension		Zocor	C		ORAL
2	MON						
		Hypotension		Zocor	C		ORAL
		Ischaemic Cardiomyopathy		Pilocarpine	C		
		Joint Sprain		Salagen Tablets	C		
		Jugular Vein Distension		Salagen Tablets	C		
		Mitral Valve Incompetence		Centrum	C		
		Myocardial Infarction		Lotemax	C		
OPHTHALMIC							
		Nephropathy Toxic		Plaquenil	C		
		Oral Candidiasis		Femhrt	C		
		Oxygen Saturation					
		Decreased					
		Pitting Oedema					
		Pleural Effusion					
		Pneumonitis					
		Pulmonary Oedema					
		Pulmonary Valve					
		Incompetence					
		Renal Failure					
		Respiratory Distress					
		Rosacea					
		Rotator Cuff Syndrome					
		Tendonitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Visual Disturbance					

Date:01/08/04ISR Number: 4267281-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Blood Immunoglobulin G Increased
	Breast Pain
	Chest Pain
	Chills
	Chondromalacia
	Contusion
	Coronary Artery Atherosclerosis
	Dizziness
	Dyspepsia
	Dyspnoea

		Emotional Distress					
		Eructation					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
157	DAY						
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
157	DAY						
		Keratoacanthoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vicodin Tablets	C		
		Pain In Extremity		Hydrocodone			
		Pericarditis		Bitartrate	C		
		Pigmented Naevus		Relafen	C		
		Skin Lesion					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypokinesia					

Date:01/08/04ISR Number: 4267283-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01596
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Hospitalization -		Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Cardiac Arrest		Percocet	C		
5	DAY						
Disability		Cardio-Respiratory Arrest		Amiodarone	C		
		Chest Wall Pain		Bicarbonate	C		
		General Physical Health		Calcium			
		Deterioration		(Unspecified)	C		
		Hyperkalaemia		Fentanyl	C		
3	DAY						
		Lactic Acidosis		Fentanyl	C		
		Myocardial Infarction		Neurontin	C		ORAL
		Nausea		Toradol	C		
INTRAVENOUS		1	DAY				
		Peripheral Embolism		Toradol	C		
INTRAVENOUS		3	DAY				
		Pneumonia		Metformin	C		
7	DAY						
		Prescribed Overdose		Morphine Sulfate	C		

Pulse Absent
Renal Embolism
Renal Failure Acute
Respiratory Failure
Ventricular Tachycardia

Date:01/08/04ISR Number: 4267284-4Report Type:Expedited (15-DaCompany Report #WAES 0312SWE00018
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Cardiac Failure		[Therapy					
	Weight Increased		Unspecified]	C				
			Acetaminophen	C				
			Fosamax	C				
			Benserazide Hydrochloride And					
			Levodopa	C				
			Budesonide	C				
			Cyanocobalamin	C				
			Enoxaparin Sodium	C				
			Ferrous Sulfate	C				
			Folic Acid	C				
			Furosemide	C				
			Gabapentin	C				

Insulin Aspart	C
Insulin Glargine	C
Lactulose	C
Levofloxacin	C
Omeprazole Magnesium	C
Pancreatin	C
Warfarin Sodium	C
Tramadol Hydrochloride	C
Terbutaline Sulfate	C
Spironolactone	C
Ramipril	C

Date:01/08/04ISR Number: 4267285-6Report Type:Expedited (15-DaCompany Report #WAES 0312NOR00023
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Aspirin And Magnesium Oxide	SS		ORAL		
	Faecal Occult Blood Positive		Citalopram Hydrobromide	SS		ORAL		
	Gastric Ulcer		Acetaminophen	C		ORAL		
	General Physical Health Deterioration		Renitec Comp.	C		ORAL		
	Haematemesis		Sotalol Hydrochloride	C		ORAL		
	Haemoglobin Decreased		Sotalol Hydrochloride	C		ORAL		
	Melaena							
	Oesophageal Ulcer							

Date:01/08/04ISR Number: 4267288-1Report Type:Expedited (15-DaCompany Report #WAES 0401USA00096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:01/08/04ISR Number: 4267289-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
Disability	Acute Myocardial Infarction
Other	Arthralgia
	Arthropod Sting
	Aspartate Aminotransferase Increased
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Blood Triglycerides Increased
	Chest Pain
	Compression Fracture
	Coronary Artery Atherosclerosis
	Depression

		Diabetes Mellitus					
		Dyspepsia					
		Ejection Fraction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Percocet	SS		
		Disease		Alcohol	SS		
		Hypercholesterolaemia		Xanax	SS		
		Hyperhidrosis		Ambien	SS		
		Incoherent		Soma	C		
		Intentional Misuse		Advil	C		
		Intervertebral Disc Space					
		Narrowing					
		Myocardial Infarction					
		Nausea					
		Neural Tube Defect					
		Osteoarthritis					
		Somnolence					
		Stent Occlusion					
		Suicide Attempt					
		Swelling Face					
		Vomiting					

Date:01/08/04ISR Number: 4267290-XReport Type:Expedited (15-DaCompany Report #WAES 0312NOR00019
Age:77 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
197	DAY						
Initial or Prolonged		Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Haemoglobin Decreased		Aspirin And			
		Helicobacter Infection		Magnesium Oxide	C		ORAL
		Melaena					

Date:01/09/04ISR Number: 4267962-7Report Type:Expedited (15-DaCompany Report #WAES 01104477
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Blood Pressure
	Fluctuation

Blood Pressure Increased
Bundle Branch Block Right
Cardiovascular Disorder
Cellulitis
Chloracne
Cor Pulmonale
Drug Toxicity
Dyspnoea
Generalised Oedema
Glaucoma
Hypoaesthesia
Hypoxia
Oedema
Oedema Peripheral
Pickwickian Syndrome
Renal Failure
Respiratory Failure
Respiratory Rate
Increased
Restrictive Pulmonary

		Disease					
		Right Ventricular Failure					
		Sinus Tachycardia					
		Sleep Apnoea Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Testicular Swelling		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Decreased		[Therapy			
				Unspecified]	C		
				Darvocet-N	C		
				Celebrex	C		
				Furosemide	C		
				Oxygen	C		
				Klor-Con	C		

Date:01/09/04ISR Number: 4267963-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiomegaly		Allopurinol	C		
		Coronary Artery		Ultram	C		
		Atherosclerosis		Kenalog	C		
PARENTERAL							
		Coronary Artery		Trazodone			
		Thrombosis		Hydrochloride	C		
111 DAY							
		Demyelinating		Celexa	C		
		Polyneuropathy		Colchicine	C		
		Depression		Indocin			
		Dermatitis Contact		(Indomethacin)	C		ORAL
		Eye Swelling		Bactroban	C		
		Hepatic Cyst		Serzone	C		
		Hepatic Steatosis		Prednisone	C		ORAL
		Hypertensive					
		Cardiomyopathy					
		Nephrosclerosis					
		Peroneal Nerve Palsy					
		Pigmentation Disorder					
		Scar					

Sciatica

Date:01/09/04ISR Number: 4267965-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		58 DAY
Disability	Coronary Artery Occlusion		Vicodin Tablets	C				
	Injury		Aspirin	C				
	Myocardial Infarction		Advil	C				
	Nervousness		Advil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4267966-4Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00020
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage		Aspirin	C		ORAL		
Hospitalization -			Nafronyl Oxalate	C		ORAL		
Initial or Prolonged			Oxybutynin Chloride	C		ORAL		

Date:01/09/04ISR Number: 4267968-8Report Type:Expedited (15-DaCompany Report #WAES 0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Aspirin	C				
Other	Blood Pressure Systolic		Atenolol	C				
	Increased		Cyclobenzaprine					
	Cardiac Failure		Hydrochloride	C		ORAL		
	Congestive		Lasix (Furosemide)	C				
	Cardiac Murmur		Novolin	C				
SUBCUTANEOUS								
	Constipation		Ultram	C				
	Coronary Artery		Novolin	C				
SUBCUTANEOUS								
	Atherosclerosis		Zestril	C				
	Coronary Artery Surgery		Procardia	C				
	Diabetes Mellitus		Trental	C				
	Non-Insulin-Dependent		Potassium					
	Dry Skin		(Unspecified)	C				
	Dyspnoea		Ranitidine	C				
	Gallop Rhythm Present							
	Gastrooesophageal Reflux							
	Disease							
	Herpes Zoster							
	Hyperlipidaemia							
	Hypoaesthesia							
	Injury							
	Joint Range Of Motion							
	Decreased							
	Lumbar Radiculopathy							
	Lung Neoplasm							
	Musculoskeletal Stiffness							

Myocardial Infarction
Pallor
Pneumonia
Pneumonitis
Rales
Renal Artery Stenosis
Rhonchi
Silent Myocardial
Infarction
Urinary Tract Infection
Urine Analysis Abnormal

Date:01/09/04ISR Number: 4268174-3Report Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL		
	Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Diastolic Increased							
	Cerebrovascular Accident							
	Extensor Plantar Response							
	Fatigue							
	Feeling Abnormal							
	Flank Pain							
	Haematuria							
	Hyperreflexia							
	Hypokalaemia							
	Lacunar Infarction							
	Muscular Weakness							
	Nephrolithiasis							
	Palpitations							
	Sensation Of Heaviness							
	Vertigo							

Date:01/09/04ISR Number: 4268175-5Report Type:Expedited (15-DaCompany Report #WAES 0303USA00625
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	37	DAY
Hospitalization -	Alanine Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL	37	DAY
Initial or Prolonged	Increased		Tylenol	C				
Disability	Arthralgia		Lomotil	C				
	Blood Alkaline		Prednisone	C			3	DAY
	Phosphatase Increased		Prednisone	C		ORAL	3	DAY
	Cardiovascular Disorder		Prednisone	C				
	Cholelithiasis							
	Dehydration							
	Diarrhoea							
	Early Satiety							
	Emotional Distress							
	Gastritis							

Haematemesis
Joint Crepitation
Joint Effusion
Joint Range Of Motion
Decreased
Mucosal Haemorrhage
Nausea
Oesophagitis
Renal Failure
Respiratory Arrest
Synovitis
Upper Gastrointestinal
Haemorrhage
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4268176-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		272 DAY
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C				
	Chest Wall Pain		Lipitor	C				
	Dysphagia		Os-Cal	C				
	Fall		Casanthranol And					
	Gastrooesophageal Reflux		Docusate Sodium	C				
	Disease		Monopril	C		ORAL		
	Gout		Vitamins					
	Joint Swelling		(Unspecified)	C				
	Lacunar Infarction		Hydrodiuril	C		ORAL		
	Mononeuritis		Hydrocodone					
	Muscle Spasms		Hydrochloride	C				
	Neuropathy		Humulin R	C			SUBCUTANEOUS	
	Oesophagitis		Humulin Nph	C			SUBCUTANEOUS	
	Oropharyngeal Spasm		Humulin Nph	C			SUBCUTANEOUS	
	Osteoarthritis		Adalat	C				
	Regurgitation Of Food							
	Speech Disorder							
	Tendonitis							
	Vocal Cord Disorder							

Date:01/09/04ISR Number: 4268177-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Surgery		Tylenol	C				
	Cutis Laxa		Saw Palmetto	C				
	Erectile Dysfunction		Ambien	C				
	Hypoaesthesia		Norvasc	C				
	Insomnia		Aspirin	C				

	Libido Decreased	Dicyclomine	
	Myocardial Infarction	Hydrochloride	C
	Nocturia	Prevacid	C
	Ocular Hypertension		
	Pollakiuria		
	Post Procedural Complication		
	Prostatitis		
	Vision Blurred		

Date:01/09/04ISR Number: 4268178-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Blood Bilirubin Increased
	Blood Glucose Increased

		Blood Pressure Increased					
		Carpal Tunnel Syndrome					
		Electrocardiogram St	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Segment Depression		Vioxx	PS	Merck & Co., Inc	ORAL
105	DAY						
		Electrocardiogram St		Claritin-D	SS		ORAL
		Segment Elevation		Vicodin Es Tablets	C		ORAL
		Emotional Distress		Zoloft	C		ORAL
		Fatigue		Ambien	C		ORAL
		Hypertension		Zoloft	C		ORAL
		Hypertensive Heart		Percocet	C		ORAL
		Disease		Ceftin	C		ORAL
		Incision Site					
		Complication					
		Insomnia					
		Ischaemia					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Sleep Apnoea Syndrome					
		Thrombosis					
		Trigger Finger					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					

Date:01/09/04ISR Number: 4268180-9Report Type:Expedited (15-DaCompany Report #WAES 0310DEU00190
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Respiratory Failure					
Initial or Prolonged	Wegener'S Granulomatosis					
Disability						

Date:01/09/04ISR Number: 4268181-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abscess		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY					

Disability	Anaemia	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Anastomotic Complication	Vioxx	SS	Merck & Co., Inc	ORAL
	Angiodysplasia	Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Discomfort	Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY					
	Colitis	Lipitor	C		
	Depression	Celebrex	C		
	Diverticulitis	Zoloft	C		
	Dyspnoea Exertional	Triamterene	C		
	Headache	Voltaren	C		
	Osteoarthritis	Duragesic	C		
TOPICAL					
	Palpitations	Dyazide	C		
	Polyp Colorectal	Metoprolol	C		
	Post Procedural Pain	Lopressor	C		
	Rheumatoid Arthritis	Prilosec	C		
	Small Intestinal Haemorrhage	Denavir	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4268182-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Aortic Valve Incompetence		Aspirin	SS				
Disability	Blood Pressure Systolic		Celebrex	SS				95 DAY
	Increased		Dyazide	SS				
	Constipation		Iron (Unspecified)	SS				
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		13 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Restenosis		Nitroglycerin	SS				
	Fall		Tylenol	C				790 DAY
	Hyperlipidaemia		Lipitor	C				790 DAY
	Hypertension							
	Insomnia							
	Iron Deficiency Anaemia							
	Malabsorption							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Rash							
	Rectal Haemorrhage							
	Stress							
	Ulcer							

Date:01/09/04ISR Number: 4268183-4Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Repair		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Hospitalization -	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Arthropathy		Allopurinol	C				
	Cardiac Murmur		Celebrex	C				2 WK

	Diverticulum Intestinal	Colchicine	C
	Haemorrhagic	Coumadin	C
	Hypovolaemic Shock	Lanoxin	C
		Lasix (Furosemide)	C
		Skelaxin	C
		K-Lor	C

Date:01/09/04ISR Number: 4268189-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA00520
Age:73 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/09/04ISR Number: 4268190-1Report Type:Expedited (15-DaCompany Report #WAES 0401USA00213
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/04ISR Number: 4268191-3Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00065
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Bullous		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Multiple Myeloma		Captopril	C		ORAL		
			Digoxin	C		ORAL		
			Furosemide	C		ORAL		

Date:01/09/04ISR Number: 4268193-7Report Type:Expedited (15-DaCompany Report #WAES 0312USA00808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Fall		Propranolol Hydrochloride	C				
	Fibromyalgia		Diovan	C				
	Headache							
	Nail Discolouration							
	Osteoporosis							
	Paraesthesia							
	Peripheral Coldness							
	Transient Ischaemic Attack							

Date:01/09/04ISR Number: 4269310-5Report Type:Expedited (15-DaCompany Report #M2004.6711
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse	Foreign	Atenolol 50mg	PS			50 MG AM	
Initial or Prolonged	Feeling Abnormal	Health						
Other	Heart Rate Decreased	Professional					25MG THEN	
	Hyperkalaemia	Other					STOPPED)	

Hypotension

960MG

25 MG AM

200MG

Co-Trimoxazole (Sulphamethoxazole/Trimethoprim)	SS
Rofecoxib	SS
Trimethoprim	SS
Aspirin	C
Nitrazepam	C
Gabapentin	C
Lansoprazole	C
Alendronate Sodium	C
Senna	C
Co-Codamol (Paracetamol/Codeine)	C
Lactulose	C
Vitamin B Complex (Thiamine/Nicotinamide/Riboflavine)	C
Ranitidine	C
Folic Acid	C
Viscotears	C
Simvastatin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/04ISR Number: 4268630-8Report Type:Expedited (15-DaCompany Report #WAES 01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acoustic Stimulation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Tests Abnormal	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Amnesia		Celebrex	C		
	Asthenia		Femhrt	C		
	Chronic Fatigue Syndrome		Herbs (Unspecified)	C		
	Clavicle Fracture		Anaprox	C		
	Coccidioidomycosis					
	Drug Ineffective					
	Eczema Asteatotic					
	Emotional Distress					
	Fall					
	Fibromyalgia					
	Gastrooesophageal Reflux Disease					
	Grand Mal Convulsion					
	Insomnia					
	Iritis					
	Joint Dislocation					
	Keratoconjunctivitis Sicca					
	Lacrimation Increased					
	Meningitis					
	Mitral Valve Prolapse					
	Nausea					
	Stomatitis					
	Vertigo					

Date:01/12/04ISR Number: 4268636-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Atrophy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebral Ischaemia	Professional	Lanoxin	C		
	Cerebrovascular Accident		Zocor	C		
	Coronary Artery Disease		Zestril	C		
	Diabetes Mellitus					
	Dilatation Atrial Ejection Fraction Decreased					

Heart Rate Irregular
Hyperlipidaemia
Hypertension
Myocardial Ischaemia
Transient Ischaemic
Attack

Date:01/12/04ISR Number: 4268637-0Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Arthralgia
	Asthenia

		Back Pain					
		Blood Pressure Decreased					
		Blood Triglycerides	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea Exertional		Aspirin	C		
		Fatigue		Tenormin	C		
		Fear		Tenormin	C		
		Gastritis		Lipitor	C		
		Gastrooesophageal Reflux		Clonidine	C		
TOPICAL							
		Disease		Clonidine	C		ORAL
		Groin Pain		Monopril	C		
		Haemorrhoids		Ibuprofen	C		
		Heart Rate Decreased		Anaprox	C		
		Hyperhidrosis					
		Hyperkinesia					
		Lower Respiratory Tract					
		Infection					
		Mitral Valve Incompetence					
		Musculoskeletal Stiffness					
		Nasopharyngitis					
		Nausea					
		Osteoarthritis					
		Pleural Effusion					
		Rectal Haemorrhage					
		Skin Irritation					
		Sleep Apnoea Syndrome					
		Tension Headache					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Weight Increased					

Date:01/12/04ISR Number: 4268638-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome PT

Death	Angiopathy
Hospitalization - Initial or Prolonged	Anxiety
Disability	Back Pain
	Blood Pressure Increased
	Cerebrovascular Accident
	Computerised Tomogram Abnormal
	Difficulty In Walking
	Dizziness
	Dyspnoea
	Dysuria
	Emotional Distress
	Facial Pain
	Fall
	Gait Disturbance
	Headache
	Injury

		Insomnia					
		Neck Pain					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paraesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pruritus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Cyst					
		Subarachnoid Haemorrhage					
		Vertigo					

Date:01/12/04ISR Number: 4268641-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA03191
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
Initial or Prolonged		Autoimmune Disorder	Professional	Aspirin	C		
Disability		Carotid Artery Aneurysm		Plaquenil	C		
		Cataract					
		Cerebral Ischaemia					
		Cerebrovascular Accident					
		Lung Neoplasm					
		Transient Ischaemic					
		Attack					
		Vasculitis					

Date:01/12/04ISR Number: 4268642-4Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Agitation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
Initial or Prolonged		Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Blood Triglycerides		Xanax	C		
		Increased		Aspirin	C		
		Coronary Artery		Lipitor	C		
		Atherosclerosis		Wellbutrin	C		
		Coronary Artery Occlusion		Celebrex	C		
		Coronary Artery		Plavix	C		
		Thrombosis		Folic Acid	C		

	Depression	Toprol Xl Tablets	C
	Ecchymosis	Pyridoxine	C
	Groin Pain		
	Haematoma		
	Myocardial Infarction		

Date:01/12/04ISR Number: 4268648-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA00013
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		[Therapy					
Initial or Prolonged	Speech Disorder		Unspecified]	SS				
Disability								

Date:01/12/04ISR Number: 4268649-7Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00030
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Melaena	Health	Vioxx	PS	Merck & Co., Inc	ORAL	33	DAY
	Rectal Haemorrhage	Professional	Bumetanide	C		ORAL		
			Citalopram	C		ORAL		
			Ferrous Sulfate	C		ORAL		
			Spironolactone	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Perindopril	C				

Date:01/12/04ISR Number: 4268650-3Report Type:Expedited (15-DaCompany Report #WAES 0401FIN00002
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dermatitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Initial or Prolonged		Professional	Allopurinol	C		ORAL		
			Amiloride Hydrochloride And Hydrochlorothiazide	C				
			Estradiol And Norethindrone Acetate	C				
			Theophylline	C		ORAL		
			Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY (INHALATION)								
			Singulair	C		ORAL		

Date:01/12/04ISR Number: 4268657-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability Other	Acute Myocardial Infarction Bradycardia Carpal Tunnel Syndrome Coronary Artery Atherosclerosis Dermoid Cyst Diabetes Mellitus Non-Insulin-Dependent Emotional Distress Injury Low Density Lipoprotein Increased Sinus Bradycardia Tendonitis Trigger Finger Weight Decreased White Blood Cell Count Increased	Health Professional	Vioxx Vioxx Flexeril Monopril Pravachol	PS SS C C C	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/04ISR Number: 4268809-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01998
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Aspirin	C				
			Lipitor	C				
Disability			Plavix	C				
Other			Corticosteroids (Unspecified)	C				
PARENTERAL			Vasotec	C		ORAL		
			Lithium Carbonate	C				
			Glucophage	C				

Date:01/12/04ISR Number: 4268811-3Report Type:Expedited (15-DaCompany Report #WAES 0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Macular Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Retinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
Disability	Retinal Oedema		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	Retinal Vascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
	Retinal Vein Occlusion		Enalapril Maleate	C		ORAL		
	Visual Acuity Reduced		Tamoxifen Citrate	C		ORAL		
			Verapamil	C		ORAL		
			Furosemide Sodium	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Morphine Sulfate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		

Date:01/12/04ISR Number: 4268843-5Report Type:Direct Company Report #CTU 209693
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS				
Initial or Prolonged	Hepatic Enzyme Increased		Bextra	SS				
	Rash							

Date:01/12/04ISR Number: 4269590-6Report Type:Direct Company Report #CTU 209820
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperkalaemia		Lisinopril	PS			20MG QD	
Initial or Prolonged	Renal Failure Acute		Leflunomide	SS			50MG QD	
			Rofecoxib	SS			250MG QD	
			Insulin	C				
			Asa	C				
			Metformin	C				
			Zocor	C				
			Methocarbamol	C				
			Kcl	C				
			Prazosin	C				
			Hydroxyzine	C				
			Calcium Carbonate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/04ISR Number: 4269867-4Report Type:Direct Company Report #CTU 209817
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia		Rofecoxib	PS				

Date:01/13/04ISR Number: 4269381-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02050
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchitis Chronic		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Calcinosis		Vioxx	SS	Merck & Co., Inc	ORAL	14	MON
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	14	MON
	Cellulitis							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Condition Aggravated							
	Cyst							
	Erythema							
	Gastroenteritis							
	Hypertension							
	Lymphadenopathy Mediastinal							
	Musculoskeletal Discomfort							
	Nausea							
	Oedema							
	Sinus Bradycardia							
	Skin Papilloma							
	Sputum Discoloured							
	Vertigo							
	White Blood Cell Count Increased							

Date:01/13/04ISR Number: 4269388-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00764
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Other	Blood Cholesterol Increased
	Blood Glucose Decreased
	Blood Triglycerides Increased
	Decreased Activity
	High Density Lipoprotein Decreased
	Injury
	Joint Swelling
	Low Density Lipoprotein Increased
	Peripheral Vascular Disorder
	Retinal Haemorrhage
	Retinal Oedema
	Retinal Vascular Disorder
	Retinal Vein Occlusion
	Tendon Rupture
	Total Cholesterol/Hdl

	Ratio Decreased						
	Visual Acuity Reduced						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Hytrin	C				

Date:01/13/04ISR Number: 4269395-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Disability	Blood Pressure Decreased		Tylenol Pm	C				
	Blood Pressure Increased		Aspirin	C				
	Cardiac Failure		Zocor	C		ORAL		
	Congestive		Tagamet	C				
	Cardiomyopathy		Tagamet	C				
	Chest Pain		Cardura	C		ORAL		
	Chronic Fatigue Syndrome							
	Coronary Artery Occlusion							
	Depression							
	Dilatation Ventricular							
	Gastrooesophageal Reflux							
	Disease							
	Haemoglobin Decreased							
	Mitral Valve Incompetence							
	Sinus Tachycardia							
	Supraventricular							
	Extrasystoles							
	Ulcer							
	Ventricular Extrasystoles							
	Ventricular Hypokinesia							
	Ventricular Septal Defect							
	Acquired							
	Weight Decreased							

Date:01/13/04ISR Number: 4269765-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA01883
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening	Congestive							
Hospitalization -	Hypertensive Crisis							
Initial or Prolonged	Oedema Peripheral							
	Renal Failure Acute							

Date:01/13/04ISR Number: 4270521-3Report Type:Direct Company Report #CTU 209939
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx 40 Mg	PS				
	Hypersensitivity		Synthroid 88 Mg	SS				
	Nasal Congestion							
	Oropharyngeal Swelling							
	Urticaria							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/04ISR Number: 4270549-3Report Type:Direct Company Report #CTU 209945
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction		Vioxx	PS			25 MG	
Hospitalization - Initial or Prolonged	Renal Pain							
Disability								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/14/04ISR Number: 4270663-2Report Type:Expedited (15-DaCompany Report #WAES 0401USA00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased Renal Impairment	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/04ISR Number: 4270665-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA00613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Subdural Haematoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/04ISR Number: 4270668-1Report Type:Expedited (15-DaCompany Report #WAES 0401USA00759
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage							

Date:01/14/04ISR Number: 4270669-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA00619
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/04ISR Number: 4270670-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00051
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea Exertional	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Haemorrhage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
Other	Gastritis Erosive							
	Iron Deficiency Anaemia							
	Medication Error							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/04ISR Number: 4270876-XReport Type:Expedited (15-DaCompany Report #AU-BRISTOL-MYERS SQUIBB COMPANY-11813706
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Pravastatin Sodium	PS	Bristol-Myers Squibb Company	ORAL	Drug was	
Other	Electrocardiogram T Wave						permanently	
	Peaked						discontinued.	
	Hyperkalaemia							
	Myopathy		Gatifloxacin	SS	Bristol-Myers Squibb Company	ORAL	discontinued	
	Renal Failure Acute						due to	
	Ventricular Hypertrophy						non-serious	
							event	
			Perindopril	SS		ORAL		
			Sertraline	SS		ORAL	dose reduced	
							to 50 mg	
							daily due to	
							events	
			Vioxx	SS		ORAL		
			Clopidogrel Bisulfate	C	Regulatory Health Authority South Africa	ORAL		
			Gliclazide	C		ORAL		
			Quinine	C		ORAL		
			Nicorandil	C		ORAL		
			Vitamin A	C		ORAL	Dose was one	
							tablet per	
							day	
			Lasix	C		ORAL		
			Pantoprazole	C				

Date:01/14/04ISR Number: 4270973-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03191
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Angiogram Cerebral		Aspirin	C				
Disability	Abnormal		Aspirin	C				
Other	Antinuclear Antibody		Plaquenil	C				
	Positive		Prednisone	C				
	Autoimmune Disorder							
	Carotid Artery Aneurysm							
	Cataract							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Fatigue							
	Headache							
	Injury							
	Pruritus							
	Transient Ischaemic							
	Attack							
	Vasculitis							

Date:01/14/04ISR Number: 4270980-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Valve Incompetence

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Atrioventricular Block First Degree					
		Bladder Spasm					
		Bronchial Infection		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Conduction Disorder		Tylenol	C		
		Dysuria		Parafon Forte	C		
		Electrocardiogram St-T		Serevent	C		
RESPIRATORY							
		Segment Abnormal					
(INHALATION)							
		Embolic Stroke		Proventil	C		
RESPIRATORY							
		Emotional Distress					
(INHALATION)							
		Escherichia Urinary Tract		Aspirin	C		
		Infection		Lioresal	C		
		Fall		Valium	C		
		Hypertension		Demerol	C		
		Intervertebral Disc		Ditropan	C		
		Degeneration		Inderal	C		
		Joint Effusion					
		Lumbar Radiculopathy					
		Mitral Valve Incompetence					
		Neck Pain					
		Nerve Compression					
		Oedema Peripheral					
		Pneumonia					
		Pollakiuria					
		Rotator Cuff Syndrome					
		Spondylolisthesis					
		Acquired					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					

Date:01/14/04ISR Number: 4271264-2Report Type:Direct Company Report #CTU 210057
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx 25 Mg	PS			1 DAILY	
Hospitalization - Initial or Prolonged								

Date:01/14/04ISR Number: 4272936-6Report Type:Expedited (15-DaCompany Report #UK062321
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis Bacterial	Foreign	Kineret	PS			SUBCUTANEOUS	DAILY, SC
Initial or Prolonged	Biopsy Bone Marrow	Health	Ofloxacin	SS		ORAL	200 MG,	DAILY, PO
	Abnormal	Professional						
	Pancytopenia		Omeprazole	SS		ORAL	DAILY, PO	
			Rofecoxib	SS				
			Paroxetine	SS				
			Chlorpromazine Hydrochloride	SS			INTRAVENOUS	25 MG, DAILY,
							IV	
			Cloxacillin Sodium	SS		ORAL	2 MG, DAILY,	

PO

Date:01/14/04ISR Number: 4273566-2Report Type:Expedited (15-DaCompany Report #WAES 01072106
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Duodenal Ulcer	Health					PO	
Other	Duodenitis	Professional	Tab Placebo	SS		ORAL	PO	
	Erosive Duodenitis		Fosamax	C				
	Gastric Ulcer		Tylenol	C				
	Haematemesis		Zocor	C				
	Helicobacter Infection		Aspirin	C				
	Melaena							
	Oesophagitis Ulcerative							
	Upper Gastrointestinal							
	Haemorrhage							

Date:01/15/04ISR Number: 4271851-1Report Type:Expedited (15-DaCompany Report #WAES 0401USA00086M
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
	Living Impaired		[Therapy					
	Complications Of Maternal		Unspecified]	C				
	Exposure To Therapeutic		Enbrel	C				
	Drugs							
	Drug Exposure During							
	Pregnancy							
	Feeling Abnormal							
	Infertility							
	Joint Swelling							
	Oligohydramnios							
	Pregnancy							
	Premature Baby							
	Stress							

Date:01/15/04ISR Number: 4271852-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA00086B1
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc			
	Complications Of Maternal Exposure To Therapeutic Drugs		[Therapy Unspecified]	C				
	Feeling Abnormal		Enbrel	C				
	Infertility							
	Joint Swelling							
	Oligohydramnios							
	Pregnancy							
	Premature Baby							
	Small For Dates Baby							
	Stress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/15/04ISR Number: 4271855-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA00179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Paralysis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -		Professional						
Initial or Prolonged								

Date:01/15/04ISR Number: 4271857-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA03118
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Arthralgia	Professional	Ultracet	C				
Disability	Back Pain		Zoloft	C				
	Blood Magnesium Decreased		Synthroid	C				
	Blood Pressure Increased							
	Bronchitis							
	Chest Pain							
	Coronary Artery Occlusion							
	Dizziness							
	Dyspnoea							
	Heart Rate Increased							
	Influenza							
	Insomnia							
	Leukocytosis							
	Lobar Pneumonia							
	Myocardial Infarction							
	Nervousness							
	Pain In Extremity							
	Periarthritis							
	Polyuria							
	Productive Cough							
	Pruritus							
	Pruritus Generalised							
	Pyrexia							
	Tachyarrhythmia							
	Tendonitis							

Date:01/15/04ISR Number: 4271860-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA02420
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Nervous System Disorder Paralysis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/15/04ISR Number: 4272456-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA01335
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death Hospitalization - Initial or Prolonged	Accidental Overdose Acute Myocardial Infarction Angina Pectoris Cardiac Failure Congestive Cardiogenic Shock Carotid Artery Stenosis

		Chronic Obstructive Pulmonary Disease					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Postoperative Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
				Aspirin	C		
				Plavix	C		
				Vasotec	C		ORAL
				Imdur	C		
				Zocor	C		ORAL
				Mylicon	C		ORAL
				Synthroid	C		
				Synthroid	C		
				Synthroid	C		
				Synthroid	C		
				Levothroid	C		
				Zestril	C		
				Nitroglycerin	C		

Date:01/15/04ISR Number: 4272463-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	B-Cell Lymphoma Stage Ii
Disability	Cancer Pain
	Cardiac Failure Congestive
	Cardio-Respiratory Arrest
	Colonic Polyp
	Depressed Level Of Consciousness
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Diverticulum
	Emotional Distress
	Facial Palsy
	Fall
	Femur Fracture
	Flank Pain

Fluid Retention
Haematuria
Haemorrhage Intracranial
Haemorrhoids
Hemiparesis
Hip Fracture
Hypertension
Influenza
Injury
Insomnia
Marrow Hyperplasia
Myelodysplastic Syndrome
Nausea
Neoplasm Progression
Non-Hodgkin'S Lymphoma
Oesophagitis Haemorrhagic

		Pathological Fracture					
		Pitting Oedema					
		Platelet Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia Aspiration	Professional	Pepcid	C		ORAL
		Pulse Absent		Lasix (Furosemide)	C		
		Rectal Haemorrhage		Neurontin	C		
		Rectal Polyp		Ibuprofen	C		
		Respiratory Distress		Zestril	C		
		Respiratory Failure		Lithium Carbonate	C		
		Septic Shock					
		Sinus Tachycardia					
		Sinusitis					
		Splenomegaly					
		Stomatitis					
		Vomiting					

Date:01/15/04ISR Number: 4272465-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
92 DAY						
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY						
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain		Duragesic	C		
	Cerebral Artery Occlusion		Prevacid	C		
	Cognitive Disorder		Effexor	C		
	Depression					
	Disturbance In Attention					
	Drug Ineffective					
	Dyskinesia					
	Dyspepsia					
	Gait Disturbance					
	Hemiparesis					
	Hypoaesthesia					
	Impaired Work Ability					
	Ischaemic Stroke					
	Memory Impairment					
	Mental Impairment					
	Nephrolithiasis					
	Oesophageal Disorder					

Performance Status
Decreased
Rheumatoid Arthritis
Sensory Disturbance
Visual Disturbance

Date:01/15/04ISR Number: 4272468-5Report Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Other

PT
Activities Of Daily Living Impaired
Blood Cholesterol Increased
Blood Pressure Increased
Bunion
Cardiac Failure Congestive

		Cardiovascular Disorder					
		Constipation					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Headache	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Tylenol	C		
		Hypertensive Heart		Aspirin	C		
		Disease					
		Joint Sprain					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Myalgia					
		Nocturia					
		Oedema Peripheral					
		Osteoarthritis					
		Renal Failure					
		Rotator Cuff Syndrome					
		Sinusitis					
		Spinal Osteoarthritis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Wound Infection					

Date:01/15/04ISR Number: 4272474-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Disability	Anaemia Haemolytic
Other	Autoimmune
	Anxiety
	Arthralgia
	Arthritis Infective
	Barrett'S Oesophagus
	Blindness Unilateral
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased

Calcium Metabolism
Disorder
Cellulitis
Cerebrovascular Accident
Chest Pain
Cholecystitis
Cholelithiasis
Coagulation Factor Viii
Level Increased
Cystocele
Diplopia
Disturbance In Attention
Drug Hypersensitivity
Dysphagia
Dyspnoea
Emotional Distress

		Erythema					
		Eye Pain					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Haematochezia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Haemorrhage		Amitriptyline			
		Headache		Hydrochloride	C		
		Hiatus Hernia		Rocaltrol	C		ORAL
		High Density Lipoprotein		Os-Cal + D	C		
		Decreased		Valium	C		
		Hypercalcaemia		Synthroid	C		
		Hyperglycaemia		Synthroid	C		ORAL
		Hypocalcaemia		Ambien	C		
		Hypomagnesaemia		Slow-Mag	C		
		Hypoparathyroidism		Reglan	C		
		Hypothyroidism		Reglan	C		
		Leukocytosis		Prilosec	C		
		Low Density Lipoprotein		Ditropan Xl	C		
		Increased		Potassium Chloride	C		
		Menopause					
		Mental Status Changes					
		Musculoskeletal Stiffness					
		Neurogenic Bladder					
		Oesophageal Achalasia					
		Oesophageal Stenosis					
		Overdose					
		Pulmonary Granuloma					
		Pyrexia					
		Rectocele					
		Renal Failure					
		Sputum Discoloured					
		Stress Incontinence					
		Tachycardia					
		Tinnitus					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urge Incontinence					
		Viral Infection					
		Vision Blurred					
		Von Willebrand'S Factor					
		Multimers Abnormal					
		Weight Decreased					

Date:01/15/04ISR Number: 4272478-8Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00025
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Diarrhoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Dizziness							
	Fatigue							
	Hypertension							
	Nausea							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/15/04ISR Number: 4272479-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Increased		Tylenol	C				
	Deep Vein Thrombosis		Z-Pak	C				
	Hypersensitivity		Diuretic					
	Myocardial Infarction		(Unspecified)	C				
	Nephropathy		Dyazide	C				
	Pulmonary Embolism		Advil	C				
	Renal Failure Acute		Triamterene	C				
	Renal Failure Chronic		Prevacid	C				
	Skin Cancer		Asacol	C				
	Thrombophlebitis		Naproxen	C				
			Ditropan	C				
			Quinidine	C				
			Quinine Sulfate	C				

Date:01/15/04ISR Number: 4272480-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA01978
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
167 DAY								
Initial or Prolonged	Nephritis Interstitial	Professional						

Date:01/15/04ISR Number: 4272492-2Report Type:Expedited (15-DaCompany Report #WAES 0401NOR00004
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
6 DAY								
Initial or Prolonged	Haemorrhage	Professional	Aspirin And					
	Haematemesis		Magnesium Oxide	SS		ORAL		
			Enoxaparin Sodium	C				
PARENTERAL							11	DAY

Date:01/16/04ISR Number: 4273173-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA01087
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ecchymosis		Fosamax	C		ORAL		
	Meniscus Lesion		Norvasc	C		ORAL		
			Centrum Silver	C		ORAL		

Date:01/16/04ISR Number: 4273265-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA01410
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cognitive Disorder							
	Confusional State							
	Dysarthria							
	Motor Dysfunction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/04ISR Number: 4273267-0Report Type:Expedited (15-DaCompany Report #WAES 0312USA01301
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deep Vein Thrombosis		Ascorbic Acid	C				
Other	Labyrinthitis		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				
			Cardura	C				
			Doxycycline	C				
			Tricor	C				
			Allegra	C				
			Thiamine	C				
			Zinc (Unspecified)	C				
			Vitamin E	C				
			Proscar	C		ORAL		
			Folic Acid	C				
			Maxzide	C				
			Prevacid	C				
			Lisinopril	C				
			Flomax (Morniflumate)	C				
			Pyridoxine	C				

Date:01/16/04ISR Number: 4273268-2Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Coronary Artery Disease		Estradiol Valerate And Norethindrone	C		ORAL		
	Myocardial Infarction							
	Sudden Death		Omeprazole	C		ORAL	1	DAY

Date:01/16/04ISR Number: 4273270-0Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00015
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -	Bacterial Infection		Leuprolide Acetate	SS		SUBCUTANEOUS		
Initial or Prolonged	Cough		Acebutolol Hydrochloride	C		ORAL		
	Dermatitis		Acetaminophen	C		ORAL		
	Injection Site Infection		Tramadol Hydrochloride	C		ORAL		
	Rash Vesicular		Nicardipine Hydrochloride	C		ORAL		
	Staphylococcal Infection		Allopurinol	C		ORAL		

Date:01/16/04ISR Number: 4273271-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA02112
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/04ISR Number: 4273272-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01949
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		41 DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blister		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		41 DAY
	Cerebral Ischaemia		Lasix (Furosemide)	C				
	Cerebrovascular Accident		Humulin	C				
	Ecchymosis		Trental	C				
	Emotional Distress							
	Erythema							
	Excoriation							
	Femoral Arterial Stenosis							
	Fungal Skin Infection							
	Gangrene							
	Hemiparesis							
	Hypertension							
	Ischaemic Stroke							
	Lacunar Infarction							
	Necrosis							
	Oedema							
	Pain							
	Popliteal Stenosis							
	Rectal Haemorrhage							
	Skin Candida							
	Skin Discolouration							
	Skin Ulcer							
	Stasis Dermatitis							
	Transient Ischaemic							
	Attack							
	Vaginal Haemorrhage							

Date:01/16/04ISR Number: 4273275-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		760 DAY

Date:01/16/04ISR Number: 4273280-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA00911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Aspirin	C				

Date:01/16/04ISR Number: 4273281-5Report Type:Expedited (15-DaCompany Report #WAES 0401NZL00009
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Acetaminophen	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/16/04ISR Number: 4273283-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA00957
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Ultracet	C				

Date:01/19/04ISR Number: 4273323-7Report Type:Expedited (15-DaCompany Report #200313333EU
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia	Health Professional	Arava	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Atrophy							
	Crohn'S Disease		Vioxx	SS		ORAL		
	Defaecation Urgency		Aspirin	SS		ORAL		
	Duodenal Ulcer		Coversum	C		ORAL		
	Gastrointestinal Disorder		Torem	C		ORAL		
	Gastrointestinal Ulcer		Mevalotin	C		ORAL		
	Large Intestinal Ulcer							
	Oesophageal Ulcer							
	Pyrexia							
	Reflux Oesophagitis							

Date:01/19/04ISR Number: 4273625-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA00809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion							
	Pulmonary Oedema							
Disability								

Date:01/19/04ISR Number: 4273626-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthralgia

Initial or Prolonged Disability	Back Pain
Other	Blood Calcium Decreased
	Blood Pressure Abnormal
	Blood Pressure Diastolic Abnormal
	Bone Pain
	Carpal Tunnel Syndrome
	Cervicobrachial Syndrome
	Constipation
	Drug Ineffective
	Fibromyalgia
	Gastrooesophageal Reflux Disease
	Hyperaesthesia
	Hypercalcaemia
	Hyperkalaemia
	Hypertension
	Hypothyroidism
	Infection
	Intervertebral Disc Degeneration

		Intervertebral Disc Displacement					
		Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
5	DAY			Vioxx	PS	Merck & Co., Inc	ORAL
		Jaw Disorder		Microzide	SS		
		Kidney Small		Microzide	SS		
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	
28	DAY						
		Nephritis Interstitial		Vioxx	SS	Merck & Co., Inc	ORAL
231	DAY						
		Nervous System Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Neuropathy Peripheral		Feldene	SS		
60	DAY						
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
12	DAY						
		Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Sleep Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
231	DAY						
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	
28	DAY						
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						

						Vioxx	SS	Merck & Co., Inc	ORAL
12 DAY									
						Vicodin Es Tablets	C		ORAL
						Vicodin Es Tablets	C		
						Norco	C		
156 DAY									
						Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1	DAY						
						Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1	DAY						
						Beconase	C		
						Prevacid	C		
						Effexor	C		
						Trazodone Hydrochloride	C		
						Claritin	C		
						Zestoretic	C		
						Celebrex	C		
						Flexeril	C		
						Valium	C		
						Estratest	C		
						Neurotonin Capsules	C		
						Neurotonin Capsules	C		

Date:01/19/04ISR Number: 4273627-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00116
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Injury					
	Pulmonary Embolism					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/04ISR Number: 4273631-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00844
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/04ISR Number: 4273635-7Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00056
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Calcium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypokalaemia		Fosamax	C		ORAL		
	Vomiting		Calcium Carbonate And Cholecalciferol	C		ORAL		
			Insulin Human, Isophane	C		SUBCUTANEOUS		
			Insulin, Neutral	C		SUBCUTANEOUS		

Date:01/19/04ISR Number: 4273639-4Report Type:Expedited (15-DaCompany Report #WAES 0311USA02861
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Convulsion		Lortab	C				
	Haematochezia		Aspirin	C				
			Baclofen	C				
			Valium	C				
			Vasotec	C		ORAL		
			Glucotrol Xl	C				

Date:01/19/04ISR Number: 4273641-2Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1 MON						
Hospitalization -	Aortic Valve Sclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1 MON						
Initial or Prolonged	Arthritis		Coumadin	SS		
	Atrial Fibrillation		Allopurinol	C		
	Back Pain		Celebrex	C		
2 WK						
	Cardiac Failure		Colchicine	C		
	Congestive		Lanoxin	C		
	Cardiac Murmur		Lasix (Furosemide)	C		
	Carotid Artery Disease		Skelaxin	C		
	Carotid Artery Occlusion		K-Lor	C		
	Dilatation Atrial					
	Diverticulum Intestinal					
	Haemorrhagic					
	Heart Rate Irregular					
	Hepatic Rupture					
	Hypovolaemic Shock					
	Iron Deficiency Anaemia					
	Mitral Valve Sclerosis					
	Myocardial Infarction					
	Spinal Osteoarthritis					
	Ventricular Hypertrophy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/04ISR Number: 4273642-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA00076
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoxia		Vicodin Tablets	C				
	Pulmonary Oedema		Albuterol	C				
	Respiratory Distress		Bumex	C				
			Nexium	C				
			Flonase	C				
			Maxzide	C				

Date:01/19/04ISR Number: 4273643-6Report Type:Expedited (15-DaCompany Report #WAES 0311USA01397
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Decreased							
Other	Diverticulum							
	Erosive Oesophagitis							
	Fluid Overload							
	Heart Rate Increased							
	Hiatus Hernia							
	Intervertebral Disc Protrusion							
	Lower Gastrointestinal Haemorrhage							
	Malnutrition							
	Rectal Haemorrhage							
	Urinary Tract Infection							

Date:01/19/04ISR Number: 4273645-XReport Type:Expedited (15-DaCompany Report #WAES 0311ZAF00015
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 WK	
Other	Circulatory Collapse	Professional	Estrogens, Conjugated	C		ORAL	10 YR	
	Pain In Extremity							

Pulmonary Embolism

Date:01/19/04ISR Number: 4273788-0Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bacterial Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Drug Eruption	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY
	Skin Exfoliation		Atorvastatin Calcium	C		ORAL		
	Skin Test Positive		Diclofenac	C			3	DAY
			Tramadol Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Pantoprazole Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/04ISR Number: 4273789-2Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophageal Varices		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
Hospitalization - Initial or Prolonged	Haemorrhage							

Date:01/20/04ISR Number: 4274128-3Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-10889319
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Health Professional	Gatifloxacin	PS	Bristol-Myers Squibb Company	ORAL	most recent dose prior to event 18 June 2001	
	Aspartate Aminotransferase Increased							
	Blood Alkaline Phosphatase Increased		Atorvastatin	SS		ORAL	most recent dose prior to event 18 June 2001	
	Blood Sodium Decreased							
	Diabetes Mellitus							
	Fatigue		Vioxx	SS		ORAL		
	Gamma-Glutamyltransferase Increased		Lopressor	C		ORAL		
			Aspirin	C		ORAL		
	Liver Function Test Abnormal		Plavix	C	Regulatory Health Authority South Africa			
	Respiratory Rate Increased							
	Weight Decreased							

Date:01/20/04ISR Number: 4274357-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02050
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Other	Bronchitis Chronic
	Calcinosis
	Cardiomegaly
	Carotid Artery Stenosis
	Cellulitis
	Chronic Obstructive
	Pulmonary Disease
	Dermal Cyst
	Dizziness
	Erythema
	Gastroenteritis
	Hypertension
	Injury
	Joint Dislocation
	Lymphadenopathy
	Mediastinal
	Musculoskeletal
	Discomfort
	Nausea
	Oedema
	Pain
	Pleuritic Pain
	Productive Cough
	Sinus Bradycardia
	Skin Papilloma
	Sputum Discoloured

	Vertigo						
	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL	14 MON
			Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	14 MON

Date:01/20/04ISR Number: 4274364-6Report Type:Expedited (15-DaCompany Report #WAES 0202USA00854
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastrointestinal Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	

Date:01/20/04ISR Number: 4274367-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Acute Coronary Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Anxiety		Coumadin	SS			
Other	Blood Triglycerides		Coumadin	SS			
	Increased		[Therapy				
	Cardiomegaly		Unspecified]	C			
	Cerebrovascular Accident		Tylenol	C			
	Chest Pain		Vicodin Tablets	C			
	Chills		Albuterol	C			
	Chronic Obstructive		Bayer Aspirin	C			
	Pulmonary Disease		Bayer Aspirin	C			
	Contusion		Aspirin	C			
	Deafness Bilateral		Tenormin	C			
	Dyspnoea		Tenormin	C			
	Dysuria		Ticlid	C			
	Epistaxis		Restoril	C			
	Fall		Digoxin	C			

Gingival Bleeding	Anzemet	C	
Haematochezia	Vasotec	C	ORAL
Heart Rate Irregular	Isordil	C	
Hypertension	Lopressor	C	
International Normalised	Naproxen	C	
Ratio Decreased	Nitrostat	C	
Intervertebral Disc			
Protrusion			
Limb Discomfort			
Menstrual Disorder			
Oedema Peripheral			
Osteoarthritis			
Radiculitis			
Silent Myocardial			
Infarction			
Sleep Disorder			
Stress Incontinence			
Transient Ischaemic			
Attack			
Urinary Tract Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/04ISR Number: 4274387-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Atelectasis		Tylenol	C		
	Benign Prostatic		Saw Palmetto	C		
	Hyperplasia		Ambien	C		
	Blood Cholesterol		Norvasc	C		ORAL
	Increased		Aspirin	C		ORAL
	Bradycardia		Dicyclomine			
	Coronary Artery		Hydrochloride	C		
	Atherosclerosis		Prevacid	C		
	Coronary Artery Disease					
	Coronary Artery Stenosis					
	Dyspnoea					
	Electrocardiogram Poor					
	R-Wave Progression					
	Electrocardiogram T Wave					
	Abnormal					
	Epididymal Tenderness					
	Erectile Dysfunction					
	Groin Pain					
	Haematuria					
	Hyperglycaemia					
	Hypertension					
	Hypokalaemia					
	Libido Decreased					
	Ocular Hypertension					
	Osteoarthritis					
	Pericarditis					
	Pleural Effusion					
	Prostatitis					
	Testicular Pain					

Date:01/20/04ISR Number: 4274398-1Report Type:Expedited (15-DaCompany Report #WAES 0312DNK00011
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization - 2 MON	Eosinophil Count	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Increased Hepatitis Toxic Perforated Ulcer	Professional	Lorazepam	C		

Date:01/20/04ISR Number: 4274399-3Report Type:Expedited (15-DaCompany Report #WAES 0401DNK00009
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Tramadol			
Initial or Prolonged	Angina Pectoris		Hydrochloride	C		ORAL
	Coronary Artery Occlusion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/04ISR Number: 4274406-8Report Type:Expedited (15-DaCompany Report #WAES 0401DNK00006
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		317 DAY
Initial or Prolonged			Acetaminophen	C				
			Amlodipine Besylate	C				
			Aspirin	C				
			Citalopram Hydrobromide	C				
			Dextromethorphan	C				
			Esomeprazole Magnesium	C				
			Furosemide	C				
			Zocor	C				
			Zopiclone	C				
			Tolbutamide	C				
			Glimepiride	C				
			Heparinoid	C				
			Metoclopramide Hydrochloride	C				
			Metoprolol Tartrate	C				
			Mianserin Hydrochloride	C				
			Potassium Chloride	C				
			Ramipril	C				

Date:01/20/04ISR Number: 4274918-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02236
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization -	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bradycardia		Atenolol	C		ORAL		
	Confusional State		Lipitor	C		ORAL		
	Dilatation Atrial		Lipitor	C				
	Encephalopathy		Saw Palmetto	C				
	Feeling Abnormal		Flonase	C				
	Headache		Glucosamine	C				
	Heart Rate Decreased		Accupril	C				
OPHTHALMIC								

Hypertensive Crisis
Hypertensive
Encephalopathy
Hypoaesthesia
Hyporeflexia
Loss Of Consciousness
Muscle Spasms
Myositis
Nausea
Speech Disorder
Tremor
Vomiting

Date:01/20/04ISR Number: 4274926-6Report Type:Expedited (15-DaCompany Report #WAES 01104522
Age: Gender:Female I/FU:F

Outcome	PT
Death	Blood Pressure
Other	Fluctuation
	Cardiovascular Disorder

	Convulsion						
	Death						
	Oedema	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:01/20/04ISR Number: 4274928-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Cardiac Failure		Imuran				
	Congestive		(Azathioprine)	C			
	Cerebrovascular Accident		Tagamet	C			
	Emotional Distress		Digoxin	C			
			Tiazac	C			
			Flomax (Tamsulosin				
			Hydrochloride)	C			
			Lasix (Furosemide)	C			
			Glipizide	C			
			Motrin	C			
			Prednisone	C			

Date:01/20/04ISR Number: 4274929-1Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00080
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
	Gastrointestinal		Bendroflumethiazide	C		ORAL	
	Haemorrhage		Lisinopril	C		ORAL	
	Haemoglobin Decreased						
	Melaena						

Date:01/20/04ISR Number: 4274930-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA00613
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Fall Haemorrhage Subdural Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/04ISR Number: 4274931-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00619
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/04ISR Number: 4276188-2Report Type:Direct Company Report #CTU 210462
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Alanine Aminotransferase		Vioxx	PS	Merck	ORAL	25MG PO QD	
	Increased Aspartate Aminotransferase Increased		Zocor 40 Mg Po Qd Merck	SS	Merck			
			Levoxyl	C				
			Coumadin	C				
			Sinemet	C				
			Multivitamin	C				

Date:01/21/04ISR Number: 4275788-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	136 DAY	
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	136 DAY	
	Injury							

Date:01/21/04ISR Number: 4275792-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02094
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY	
	Cardiac Murmur		Cosopt	C				
	Feeling Cold		Xalatan	C				
	Gastric Haemorrhage		Synthroid	C				
	Headache		Cozaar	C				
	Hot Flush		Naprosyn	C				
	Hypertension		Nitro-Dur	C				
			Prilosec	C				
			Aspirin	C				

Date:01/21/04ISR Number: 4276576-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02027
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vasotec	C				
	Heart Rate Increased		Glipizide	C				
	Heart Rate Irregular		Terbutaline Sulfate	C				
	Myocardial Infarction		Actos	C				
	Respiratory Disorder							

Date:01/21/04ISR Number: 4276578-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00109
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Flutter	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		11 MON
	Chest Pain							
	Emotional Distress							
	Hypertension							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/04ISR Number: 4276583-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02070
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure		Lanoxin	C		
	Congestive		Premarin	C		
VAGINAL						
	Cardiomyopathy		Lasix (Furosemide)	C		
	Chest Pain					
	Dizziness					
	Drug Intolerance					
	Dyspnoea					
	Nausea					
	Stress					

Date:01/21/04ISR Number: 4276588-0Report Type:Expedited (15-DaCompany Report #WAES 0210USA00193
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acidosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Acute Myocardial	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Infarction		Tylenol	C		
	Aortic Valve		Aspirin	C		
	Calcification					
	Aortic Valve Sclerosis					
	Arrhythmia					
	Blood Pressure Decreased					
	Bradycardia					
	Cardio-Respiratory Arrest					
	Cartilage Injury					
	Cough					
	Crepitations					
	Cyanosis					
	Drug Ineffective					
	Dyspnoea					
	Electromechanical					
	Dissociation					
	Grand Mal Convulsion					
	Hypertension					
	Hypotonia					
	Joint Lock					

Joint Stiffness
Joint Swelling
Livedo Reticularis
Mitral Valve Incompetence
Osteoarthritis
Pulse Absent
Pupil Fixed
Respiratory Arrest
Sudden Death
Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/04ISR Number: 4276589-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02165
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Drug Hypersensitivity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Face Oedema		[Therapy			
	Haematemesis		Unspecified]	C		
	Swelling		Prilosec	C		
	Vomiting					

Date:01/21/04ISR Number: 4276590-9Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00100
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrointestinal		[Therapy			
	Perforation		Unspecified]	C		
			Iron (Unspecified)	C		

Date:01/21/04ISR Number: 4276591-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Intestinal Obstruction					
	Meningitis Viral					
	Oesophageal Disorder					

Date:01/21/04ISR Number: 4277756-4Report Type:Expedited (15-DaCompany Report #2004CG00076
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DF DAILY PO	Asthenia	Foreign	Atacand	PS		ORAL
Initial or Prolonged	Dizziness	Health	Vioxx	SS		
	General Physical Health	Professional				

	Deterioration	Other
	Hypotension	
	Renal Failure Acute	
	Self-Medication	
	Somnolence	

Date:01/21/04ISR Number: 4277783-7Report Type:Expedited (15-DaCompany Report #200310354BNE
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage Haematemesis	Foreign Health Professional	Aspirin (Acetylsalicylic Acid)	PS			75 MG, TOTAL	
		Other					DAILY	
			Rofecoxib	SS		ORAL	25 MG, TOTAL	
							DAILY, ORAL	
			Fosamax	C				
			Co-Codamol	C				
			Bendroflumethiazide	C				
			Micorandil	C				
			Doxazosin Mesylate	C				
			Fluoxetine	C				

				Prochlorperazine Maleate	C		

Date:01/22/04ISR Number: 4277470-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00034
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged		Professional	Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Lortab	C		ORAL	5	DAY
			Lortab	C		ORAL	5	DAY
			Norvasc	C		ORAL		
			Bextra	C		ORAL	17	DAY
			Bextra	C		ORAL	17	DAY
			Premarin	C		ORAL		
			Hyzaar	C		ORAL		
			Prevacid	C				
			Prilosec	C		ORAL		

Date:01/22/04ISR Number: 4277472-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C				
			Estradiol	C				
			Synthroid	C				

Date:01/22/04ISR Number: 4277473-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA02594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C				

Date:01/22/04ISR Number: 4277474-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA02639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C				

Date:01/22/04ISR Number: 4277476-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01980
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anorexia
Disability	Anxiety
	Asthenia
	Back Injury
	Back Pain
	Balance Disorder

		Blood Pressure Decreased					
		Cardiac Disorder					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coordination Abnormal	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
52	DAY						
		Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Depression		[Therapy			
		Dialysis		Unspecified]	C		
		Diarrhoea		Atenolol	C		
		Dysphagia		Lonox	C		
		Feeling Jittery		Trazodone			
		Haemorrhage		Hydrochloride	C		
		Hypertension		Hydrocortisone	C		
		Hypoaesthesia		Zestril	C		
		Hypoaesthesia Oral		Paxil	C		
		Injury					
		Joint Stiffness					
		Muscle Twitching					
		Myalgia					
		Renal Failure					
		Salivary Hypersecretion					
		Septic Shock					
		Sleep Apnoea Syndrome					
		Tachycardia					
		Tinnitus					
		Tremor					
		Vision Blurred					
		Vomiting					

Date:01/22/04ISR Number: 4277477-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01986
Age:79 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy			
				Unspecified]	C		
				Lasix (Furosemide)	C		
				Plaquenil	C		
				Claritin	C		
				Singulair	C		ORAL
				Prednisone	C		

Date:01/22/04ISR Number: 4277480-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Anaemia
	Arthritis
	Back Pain
	Dizziness
	Dyspepsia
	Fatigue
	Gastrooesophageal Reflux
	Disease
	Hiatus Hernia
	Hypersensitivity
	Hypertension
	Inflammation
	Joint Injury

		Ligament Injury					
		Oedema Peripheral					
		Peptic Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
				Atenolol	C		
				Feosol	C		
				Ibuprofen	C		
				Prevacid	C		
				Relafen	C		

Date:01/22/04ISR Number: 4277485-7Report Type:Expedited (15-DaCompany Report #WAES 0401USA01000
Age:61 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Collapse Of Lung	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
		Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
		Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy		Tylenol	C		
		Pneumonia		Elavil	C		ORAL
		Pneumothorax		Premarin	C		
		Urinary Incontinence		Detrol La	C		
				Lasix (Furosemide)	C		
				Prinzide	C		ORAL
				Singulair	C		ORAL
				Potassium (Unspecified)	C		
				Prednisone	C		
				Aciphex	C		

Date:01/22/04ISR Number: 4277486-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA01157
Age:49 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:01/22/04ISR Number: 4277487-0Report Type:Expedited (15-DaCompany Report #WAES 0401USA00957
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		85 DAY
Hospitalization -		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		85 DAY
Initial or Prolonged			Ultracet	C				
Other			Soma Compound With Codeine	C		ORAL		

Date:01/22/04ISR Number: 4277576-0Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Exfoliative		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Drug Eruption		Vioxx	SS	Merck & Co., Inc	ORAL		22 DAY
	Pain		Atorvastatin Calcium	C		ORAL		
	Skin Exfoliation		Diclofenac	C				3 DAY
	Skin Test Positive		Tramadol Hydrochloride	C		ORAL		

Dipyrone	C			ORAL
Metoprolol Succinate	C			ORAL
Pantoprazole Sodium	C			

Date:01/22/04ISR Number: 4277582-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL	532	DAY
Initial or Prolonged	Thromboplastin Time		[Therapy					
Disability	Prolonged		Unspecified]	C				
Other	Angina Pectoris		Tylenol	C				
	Anxiety		Proventil	C				
	Asthenia		Buspar	C				
	Blood Cholesterol		Cipro	C				
	Increased		Tranxene	C				
	Blood Pressure Decreased		Diphenhydramine					
	Chronic Obstructive		Citrate	C				
	Pulmonary Disease		Epi-Pen	C				
	Coronary Artery Occlusion		Allegra	C				
	Diverticulum Intestinal		Duratuss	C				
	Gastritis		Hydroxyzine Pamoate	C				
	Gastrointestinal		Motrin	C				
	Haemorrhage		Loperamide					
	Haematocrit Decreased		Hydrochloride	C				
	Haemoglobin Decreased		Methylprednisolone	C				
	Haemorrhoids		Nasonex	C				
	Hypertension		Elocon	C				
	Intestinal Ischaemia		Actonel	C				
	Myocardial Infarction		Ultram	C				
	Palpitations							
	Proctitis							
	Stress							
	Thrombosis							
	Upper Gastrointestinal							
	Haemorrhage							
	Weight Decreased							

Date:01/22/04ISR Number: 4277583-8Report Type:Expedited (15-DaCompany Report #WAES 0308AUS00012
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Anaemia		Aspirin	SS				
	Melaena		Celecoxib	SS		ORAL		62 DAY
	Pulmonary Oedema							

Date:01/22/04ISR Number: 4277595-4Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00042
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorectal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Diarrhoea Haemorrhagic		Calcium Dobesilate	C		ORAL		
	Diverticulum		Insulin Human, Isophane	C				
	Proctalgia		Insulin, Biphasic Isophane [Injection]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/22/04ISR Number: 4277601-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02088
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coronary Artery Disease		Aspirin	C		ORAL
Initial or Prolonged	Gastrooesophageal Reflux		Atenolol	C		ORAL
Disability	Disease		Plavix	C		ORAL
	Hypercholesterolaemia		Nitro-Spray	C		
	Myocardial Infarction		Zocor	C		ORAL
			Vitamins			
			(Unspecified)	C		
			Imdur	C		ORAL
			Prinivil	C		ORAL
			Nitrolingual	C		
SUBLINGUAL						
			Oxazepam	C		ORAL

Date:01/22/04ISR Number: 4278922-4Report Type:Expedited (15-DaCompany Report #WAES 00020306
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Burns Second Degree	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Drug Eruption	Professional				
MG/DAILY/PO						
Initial or Prolonged	Nodular Vasculitis	Company	Flovent	C		
Disability	Stevens-Johnson Syndrome	Representative	Lipitor	C		
Other	Toxic Epidermal		Proscar	C		
	Necrolysis		Serevent	C		
			Symmetrel	C		
			Prednisone	C		

Date:01/23/04ISR Number: 4278118-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03186
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL

	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Disorder					
	Gallbladder Disorder					
	Gastric Disorder					
	Injury					
	Nervousness					
	Ulcer Haemorrhage					
	Weight Gain Poor					

Date:01/23/04ISR Number: 4278120-4Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00146
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Large Intestine Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/04ISR Number: 4278121-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA02101
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure		Diuretic (Unspecified)	SS		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
	Drug Hypersensitivity		Acetaminophen	C		
	Drug Ineffective		Vitamins (Unspecified)	C		
	Emotional Distress		Allopurinol	C		
	Exostosis		Atenolol	C		
	Hypernatraemia		Atenolol	C		
	Hypertensive Crisis					
	Musculoskeletal Pain					
	Myocardial Infarction					
	Pollakiuria					
	Postnasal Drip					
	Pulmonary Embolism					
	Renal Failure					
	Sinusitis					
	Skin Lesion					
	Urinary Tract Infection					

Date:01/23/04ISR Number: 4278122-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 482 DAY	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 482 DAY	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Reocclusion		Celebrex	C		
	Myocardial Infarction					
	Vascular Bypass Dysfunction					

Date:01/23/04ISR Number: 4278123-XReport Type:Expedited (15-DaCompany Report #WAES 0205GBR00194
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Blindness Transient Visual Acuity Reduced	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Azithromycin	C		
			Calcium Carbonate And Cholecalciferol	C		
			Chloramphenicol	C		
7 DAY						
			Clarithromycin	C		
			Tamsulosin Hydrochloride	C		
			Doxycycline	C		
1 DAY						
			Doxycycline	C		
13 DAY						
			Lansoprazole	C		
			Metronidazole	C		
10 DAY						

Date:01/23/04ISR Number: 4278125-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA01339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/04ISR Number: 4278127-7Report Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Dreams	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
27 DAY						
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
27 DAY						
	Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness		Vicodin Tablets	C		
	Drug Ineffective		Elavil	C		
	Fall		Atenolol	C		
	Fear		Celebrex	C		
	Fibromyalgia		Plavix	C		
	Headache		Calan Sr	C		
	Muscle Strain		Ultram	C		
	Neck Pain		Zoloft	C		
	Pain		Zoloft	C		
	Renal Failure		Flexeril	C		
21 DAY						
	Respiratory Disorder		Flexeril	C		
13 DAY						
	Sleep Disorder		Flexeril	C		
	Stress		Premarin	C		
	Therapeutic Response		Pepcid	C		ORAL
	Decreased		Dyazide	C		
			Accupril	C		

Date:01/23/04ISR Number: 4278128-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01432
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction	Professional	Albuterol	C		
RESPIRATORY						
Disability	Angina Pectoris					
(INHALATION)						
Other	Angina Unstable		Tricor	C		ORAL
	Blood Disorder		Ibuprofen	C		
	Cardiac Valve Disease		Detrol	C		
	Convulsion		Ibuprofen	C		
	Coronary Artery Disease		Dilantin	C		ORAL

Depression
Dizziness
Dyspnoea
Gastrooesophageal Reflux
Disease
Haemorrhage
Hyperhidrosis
Hypertension
Nausea
Orthopnoea
Osteoarthritis
Palpitations
Syncope

Date:01/23/04ISR Number: 4278134-4Report Type:Expedited (15-DaCompany Report #WAES 0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome PT
Disability Accident At Work
Arthritis
Bursitis
Chondromalacia
Contusion

		Emotional Distress					
		Fall					
		Gastric Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY							
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY							
		Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Tylenol	C		
		Osteoarthritis		Combivent	C		
RESPIRATORY							
		Patellofemoral Pain					
(INHALATION)							
		Syndrome		Allopurinol	C		
		Polytraumatism		Celebrex	C		
		Therapeutic Response		Estradiol	C		
		Decreased		Vitamin E	C		
				Diovan	C		
				Ultram	C		
				Bactrim Ds Tablets	C		
				Glucosamine	C		
				Avalide	C		
				Atrovent	C		
				Claritin	C		
				Niferex	C		
				Potassium (Unspecified)	C		
				Pyridoxine	C		

Date:01/23/04ISR Number: 4278465-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain					
		Chronic Fatigue Syndrome					
		Deep Vein Thrombosis					
		Dyspepsia					
		Gastric Disorder					
		Gout					
		Haematochezia					
		Haemorrhage					

Hepatitis
Hypertension
Injury
Renal Disorder
Stomach Discomfort

Date:01/23/04ISR Number: 4278471-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01305
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Brain Mass
Other	Cerebral Artery
	Thrombosis
	Cerebral Infarction
	Cerebrovascular Accident
	Convulsion
	Gastric Ulcer
	Hypertension
	Hypertensive Heart

		Disease Intracranial Aneurysm Osteoarthritis Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Clotrimazole	C		
				Diuretic (Unspecified)	C		
				Triamterene	C		
				Broncholate	C		
				Tri-Norinyl	C		

Date:01/23/04ISR Number: 4278472-5Report Type:Expedited (15-DaCompany Report #WAES 0401DNK00009
Age:74 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged		Acute Myocardial Infarction Angina Pectoris Low Density Lipoprotein Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Tramadol Hydrochloride	C		ORAL

Date:01/23/04ISR Number: 4278473-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Discomfort Abdominal Pain Cardiac Murmur Chest Pain Chest Wall Pain Emotional Distress Erythema Fear Heart Injury Injury Intervertebral Disc Protrusion Rectal Haemorrhage Skin Discolouration		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Analgesic Or Anesthetic (Unspecified)	C		
				Antimicrobial (Unspecified)	C		
				Butalbital	C		

	Stress
	Thrombosis

Date:01/23/04ISR Number: 4278474-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00117
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Death	Abasia
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Arterial Thrombosis
	Basilar Artery Occlusion
	Basilar Artery Stenosis
	Blood Chloride Decreased
	Blood Glucose Increased
	Blood Triglycerides Increased
	Brain Stem Infarction
	Cerebral Infarction

		Coma					
		Coordination Abnormal					
		Electrocardiogram St	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Segment Depression		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Electroencephalogram		Darvocet-N	C		
		Abnormal		Aspirin	C		
		Hydrocephalus		Celebrex	C		
		Injury		Diovan Hct	C		
		Low Density Lipoprotein		Glucophage	C		
252	DAY						
		Increased		Glucophage	C		
79	DAY						
		Necrosis		Glucophage	C		
		Qrs Axis Abnormal		Feldene	C		
		White Blood Cell Count					
		Increased					

Date:01/23/04ISR Number: 4278475-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia Haemolytic
Disability	Autoimmune
Other	Anxiety
	Arthralgia
	Atelectasis
	Blindness Unilateral
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased
	Cellulitis
	Cerebrovascular Accident
	Cholelithiasis
	Coagulation Factor Viii
	Level Increased
	Cystocele
	Decreased Appetite
	Disturbance In Attention
	Drug Hypersensitivity
	Dyspnoea
	Eye Pain

Haematochezia
Haemorrhage
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism
Neurogenic Bladder
Oesophageal Disorder
Pulmonary Granuloma
Pyrexia
Rectocele
Renal Failure
Tinnitus
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection

		Von Willebrand'S Factor Multimers Abnormal Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
8	MON						
				Amitriptyline Hydrochloride	C		
				Rocaltrol	C		ORAL
				Os-Cal + D	C		
				Valium	C		
				Synthroid	C		
				Synthroid	C		ORAL
				Ambien	C		
				Claritin	C		
				Slow-Mag	C		
				Reglan	C		
				Reglan	C		
				Prilosec	C		
				Ditropan Xl	C		
				Potassium Chloride	C		

Date:01/23/04ISR Number: 4278476-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Body Temperature Decreased		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL
		Bone Graft			C		
		Depression		Analgesic Or Anesthetic (Unspecified)			
		Fall			C		
		Gait Disturbance		Calcium Carbonate	C		
		Memory Impairment		Vitamin E	C		
		Musculoskeletal Disorder		Premarin	C		
		Neck Injury		Lasix (Furosemide)	C		
		Osteoporosis		Neurontin	C		
		Radius Fracture		Actonel	C		
		Transient Ischaemic Attack					

Date:01/23/04ISR Number: 4278477-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA03302
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Pruritus		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Rash Erythematous		Minocycline	C				
	Urticaria Papular							

Date:01/23/04ISR Number: 4278478-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Impairment							

Date:01/23/04ISR Number: 4278479-8Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00015
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -	Cough		Leuprolide Acetate	SS		SUBCUTANEOUS		
Initial or Prolonged	Dermatitis		Acebutolol					
	Injection Site Infection		Hydrochloride	C		ORAL		
	Injection Site Rash		Acetaminophen	C		ORAL		
	Rash Vesicular		Tramadol					
	Staphylococcal Abscess		Hydrochloride	C		ORAL		
			Nicardipine					
			Hydrochloride	C		ORAL		
			Allopurinol	C		ORAL		

Date:01/23/04ISR Number: 4278480-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Injury		Tylenol	C				
	Blood Cholesterol		Z-Pak	C				
	Increased		Diuretic					
	Deep Vein Thrombosis		(Unspecified)	C				
	Drug Hypersensitivity		Dyazide	C				
	Fall		Advil	C				
	Myocardial Infarction		Triamterene	C				
	Osteoarthritis		Prevacid	C				
	Pleural Effusion		Asacol	C				
	Pleuritic Pain		Naproxen	C				
	Pulmonary Embolism		Ditropan	C				
	Radius Fracture		Quinidine	C				
	Renal Failure		Quinine Sulfate	C				
	Rotator Cuff Syndrome							
	Skin Cancer							

Date:01/23/04ISR Number: 4278481-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arthropod Sting		Percocet	SS				
Other	Cardiac Failure		Alcohol	SS				
	Coronary Artery Disease		Xanax	SS				
	Diabetes Mellitus		Ambien	SS				
	Gastrooesophageal Reflux Disease		Soma	C				
	Hypercholesterolaemia		Advil	C				
	Hyperlipidaemia		Imdur	C				
	Hypertension							
	Intentional Misuse							
	Major Depression							
	Myocardial Infarction							
	Stent Occlusion							
	Suicide Attempt							
	Tooth Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/04ISR Number: 4278490-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol Increased		Aspirin	C		
			Celebrex	C		
	Chest Pain		Sudal	C		
	Coronary Artery Stenosis		Ultram	C		
	Costochondritis		Levaquin	C		
	Diastolic Dysfunction		Synthroid	C		
	Dyspnoea		Zantac	C		
	Gastrooesophageal Reflux Disease					
	Haemarthrosis					
	Libido Decreased					
	Musculoskeletal Chest Pain					
	Myocardial Infarction					
	Oedema					
	Pain					
	Panic Attack					
	Spinal Osteoarthritis					

Date:01/23/04ISR Number: 4278492-0Report Type:Expedited (15-DaCompany Report #WAES 0312USA01987
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/23/04ISR Number: 4278494-4Report Type:Expedited (15-DaCompany Report #WAES 0401ESP00016
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Lower Gastrointestinal Haemorrhage		Aspirin	SS		ORAL
			Telmisartan	C		ORAL

Date:01/23/04ISR Number: 4278496-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01090
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blister Nausea Oedema Peripheral Thrombosis		Vioxx Arimidex	PS C	Merck & Co., Inc	ORAL		

Date:01/23/04ISR Number: 4278497-XReport Type:Expedited (15-DaCompany Report #WAES 0312NLD00016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemarthrosis International Normalised Ratio Increased		Vioxx Acenocoumarol	PS C	Merck & Co., Inc			4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/23/04ISR Number: 4278498-1Report Type:Expedited (15-DaCompany Report #WAES 0401USA01505
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/23/04ISR Number: 4278499-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA01228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/23/04ISR Number: 4278500-7Report Type:Expedited (15-DaCompany Report #WAES 0401USA00981
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Vicodin Tablets	C				
			Neurontin	C				

Date:01/23/04ISR Number: 4278501-9Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00096
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
			Amiloride Hydrochloride And Furosemide	C				
			Bendroflumethiazide	C		ORAL		

Date:01/23/04ISR Number: 4278502-0Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00091
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/23/04ISR Number: 4278503-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 21 DAY	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diverticulum Intestinal		Tylenol	C				
	Haemorrhagic		Ecotrin	C				
	Emotional Distress		Calan Sr	C				
	Gastritis Atrophic		Celebrex	C				
	Helicobacter Infection		Advil	C				
	Neck Pain							

Date:01/23/04ISR Number: 4279216-3Report Type:Expedited (15-DaCompany Report #2004003686
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy	Literature	Lithium (Lithium)	PS			600 MG	
Initial or Prolonged	Drug Interaction	Health					(DAILY)	
	Drug Level Increased	Professional	Rofecoxib					
	Gait Disturbance		(Rofecoxib)	SS			25 MG (DAILY)	
	Hypertonia							
	Mood Altered							
	Myoclonus							

Date:01/23/04ISR Number: 4279274-6Report Type:Expedited (15-DaCompany Report #2004003675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Literature	Lithium (Lithium)	PS			900 MG	
Initial or Prolonged	Coordination Abnormal	Health					(DAILY),	
Other	Dialysis	Professional	Rofecoxib					
	Disorientation		(Rofecoxib)	SS			25 MG (DAILY)	
	Drug Interaction							
	Drug Level Increased							

Date:01/23/04ISR Number: 4279276-XReport Type:Expedited (15-DaCompany Report #2004003671
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Literature	Lithium (Lithium)	PS			600 MG	
Initial or Prolonged	Drug Level Increased	Health					(DAILY)	
Other	Dysarthria	Professional	Rofecoxib					
	Hemiparesis		(Rofecoxib)	SS			40 MG (DAILY)	

Renal Failure
Renal Neoplasm

Date:01/23/04ISR Number: 4279604-5Report Type:Expedited (15-DaCompany Report #2004003677
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction	Literature	Lithium	PS			600 MG, DAILY	
	Drug Level Increased	Health Professional	Rofecoxib	SS				
	Neurotoxicity							

Date:01/23/04ISR Number: 4279606-9Report Type:Expedited (15-DaCompany Report #2004003674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Level Increased	Literature	Lithium	PS			25 MG, DAILY	
		Health Professional	Rofecoxib	SS				

Date:01/23/04ISR Number: 4279615-XReport Type:Expedited (15-DaCompany Report #2004004014
Age:81 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness
	Drug Interaction

	Drug Level Increased Muscle Rigidity Renal Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tremor	Literature	Lithium (Lithium)	PS			42 MG, DAILY
		Health	Rofecoxib	SS			25 MG, DAILY
		Professional					

Date:01/23/04ISR Number: 4279675-6Report Type:Expedited (15-DaCompany Report #2004003672
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asterixis	Literature	Lithium (Lithium)	PS			900 MG
Initial or Prolonged	Coordination Abnormal	Health					(DAILY),
Other	Drug Interaction	Professional					UNKNOWN
	Nystagmus		Rofecoxib (Rofecoxib)	SS			25 MG
							(DAILY),
							UNKNOWN

Date:01/23/04ISR Number: 4279676-8Report Type:Expedited (15-DaCompany Report #2004003681
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Delirium	Literature	Lithium (Lithium)	PS			450 MG
Initial or Prolonged	Drug Interaction	Health					(DAILY),
	Drug Level Increased	Professional					UNKNOWN
	Dysarthria Sedation		Rofecoxib (Rofecoxib)	SS			

Date:01/23/04ISR Number: 4279677-XReport Type:Expedited (15-DaCompany Report #2004003683
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Aphasia	Literature	Lithium (Lithium)	PS				
Initial or Prolonged (DAILY),	Disorientation	Health						
	Drug Interaction	Professional	Rofecoxib (Rofecoxib)	SS				
	Gait Disturbance							
	Tremor							

Date:01/23/04ISR Number: 4280129-1Report Type:Expedited (15-DaCompany Report #2004194784US
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Celebrex (Celecoxib) Capsule	PS				
	Convulsion		Vioxx (Rofecoxib)	SS				
			Aleve (Naproxen Sodium)	SS				

Date:01/23/04ISR Number: 4280655-5Report Type:Expedited (15-DaCompany Report #2004003685
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Confusional State
	Drug Interaction
	Drug Level Increased

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Literature	Lithium (Lithium)	PS			900 MG (DAILY),	
Health Professional	Rofecoxib (Rofecoxib)	SS			25 MG (DAILY),	

Date:01/26/04ISR Number: 4278968-6Report Type:Expedited (15-DaCompany Report #WAES 0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Calcium (Unspecified)	C				
	Cardiac Disorder		Diazepam	C				
	Chest Pain		Premarin	C				
	Fall							
	Heart Rate Irregular							
	Hypertension							
	Mitral Valve Incompetence							
	Palpitations							
	Tendonitis							
	Transient Ischaemic Attack							
	Tricuspid Valve Incompetence							

Date:01/26/04ISR Number: 4278976-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00070
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Arrhythmia							

Arthralgia
Asthma
Blood Cholesterol
Increased
Bronchitis Chronic
Cardiac Valve Disease
Death
Gallbladder Disorder
Glucose Tolerance
Impaired
Headache
Heart Rate Irregular
Hypertension
Pulmonary Embolism

Date:01/26/04ISR Number: 4278980-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01432
Age:54 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Pressure Increased		Vicodin Tablets	C				
Bone Cyst		Carisoprodol	C				
Cardio-Respiratory Arrest							
Electromechanical Dissociation							
Osteoarthritis							
Respiratory Rate Increased							
Sciatica							
Spinal Column Stenosis							
Ventricular Fibrillation							

Date:01/26/04ISR Number: 4278981-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiomegaly		[Therapy Unspecified]	C				
	Dry Mouth						10	YR
	Fatigue		Tenormin	C				
	Fluid Retention		Premarin	C				
	Gastrooesophageal Reflux		Prinivil	C		ORAL	9872	DAY
	Disease						1501	DAY
	Haemorrhoids							
	Hypertension							
	Lung Disorder							
	Migraine							

Date:01/26/04ISR Number: 4278982-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability	Adjustment Disorder Adrenal Adenoma Aneurysm Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Colonic Polyp Depression Diverticulum Dizziness Emotional Distress Hyperlipidaemia Hypoaesthesia Joint Dislocation Large Cell Carcinoma Of The Respiratory Tract Stage Unspecified Pneumothorax Stress Incontinence Ventricular Extrasystoles	Health Professional	Vioxx Vioxx Darvocet-N Amitriptyline Hydrochloride Meclizine	PS SS C C C	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/04ISR Number: 4278984-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Disability	Arthritis		Tylenol Pm	C				
	Blood Glucose Increased		Aspirin	C				
	Blood Pressure Increased		Zocor	C		ORAL		
	Blood Triglycerides		Tagamet	C				
	Increased		Tagamet	C				
	Cardiac Failure		Cardura	C		ORAL		
	Congestive							
	Cardiomyopathy							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Dilatation Ventricular							
	Drug Intolerance							
	Electrocardiogram Poor							
	R-Wave Progression							
	Gastrooesophageal Reflux							
	Disease							
	Haemoglobin Decreased							
	Headache							
	Hypercholesterolaemia							
	Hypogonadism							
	Mitral Valve Incompetence							
	Respiratory Rate							
	Increased							
	Sinus Tachycardia							
	Supraventricular							
	Extrasystoles							
	Ulcer							
	Ventricular Extrasystoles							
	Ventricular Hypokinesia							
	Weight Increased							

Date:01/26/04ISR Number: 4278985-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01097
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/04ISR Number: 4278986-8Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00019
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Duodenal Ulcer Escherichia Urinary Tract Infection Gastrointestinal Haemorrhage Haematemesis Hallucination, Visual Melaena	Professional	Aspirin Lysine	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/04ISR Number: 4278987-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
Other	Aortic Valve Incompetence		Amitriptyline Hydrochloride	C				
	Cardiac Disorder		Analgesic Or Anesthetic (Unspecified)	C				
	Carpal Tunnel Syndrome		Atenolol	C				
	Cerebral Ischaemia		Lipitor	C				
	Crying		Zoloft	C				
	Decreased Appetite		Premarin	C				
	Depression		Hydrodiuril	C				
	Headache		Altace	C				
	Insomnia							
	Lacunar Infarction							
	Mitral Valve Incompetence							
	Muscle Spasms							
	Obesity							
	Osteoarthritis							
	Peripheral Vascular Disorder							
	Treatment Noncompliance							
	Tricuspid Valve Incompetence							
	Weight Increased							

Date:01/26/04ISR Number: 4278988-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Anaemia Macrocytic
	Angiopathy
	Arthralgia
	Arthritis
	Asthenia
	Back Pain
	Balance Disorder
	Blood Pressure Systolic Increased
	Blood Triglycerides Increased

Bone Scan Abnormal
Bronchitis
Carotid Artery Disease
Carotid Artery Stenosis
Cerebrovascular Accident
Chest Pain
Chest Wall Pain
Chest X-Ray Abnormal
Chronic Obstructive
Pulmonary Disease
Compression Fracture
Depression
Difficulty In Walking
Dyspnoea
Electrocardiogram Qt
Prolonged
Electrocardiogram St-T
Change
Gait Disturbance

		Haematochezia					
		Hypercholesterolaemia					
		Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Ldl/Hdl Ratio Increased		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Low Density Lipoprotein		Zovirax	C		
		Increased		Trimox	C		
		Migraine		Celebrex	C		
		Movement Disorder		Zyrtec	C		
		Muscular Weakness		Nexium	C		
		Nausea		Paxil	C		
533	DAY						
		Neck Pain		Prednisone	C		
		Neoplasm Malignant					
		Nuclear Magnetic					
		Resonance Imaging Brain					
		Abnormal					
		Osteopenia					
		Osteoporosis					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Pharyngolaryngeal Pain					
		Red Blood Cell					
		Sedimentation Rate					
		Increased					
		Respiratory Rate					
		Increased					
		Rhinitis Allergic					
		Sinusitis					
		Spinal Disorder					
		Tendonitis					
		Thoracic Outlet Syndrome					
		Thrombocytopenia					
		Transient Ischaemic					
		Attack					
		Very Low Density					
		Lipoprotein Increased					

Date:01/26/04ISR Number: 4278989-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anxiety
	Arterial Restenosis
	Blood Cholesterol Increased
	Bradycardia
	Bundle Branch Block Left
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Dilatation Atrial
	Ejection Fraction Abnormal
	Electrocardiogram St Segment Elevation
	Fatigue

		Gastric Disorder					
		Heart Rate Irregular					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		International Normalised	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ratio Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Valve		Acetaminophen And			
		Incompetence		Oxycodone			
		Thrombosis		Hydrochloride	C		
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:01/26/04ISR Number: 4278991-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
220 DAY						
Initial or Prolonged	Acute Myocardial	Professional	Propacet	C		
Disability	Infarction		Wellbutrin	C		
	Angina Pectoris		Prevacid	C		
	Anxiety					
	Back Injury					
	Cardiac Arrest					
	Cardiac Disorder					
	Cardiac Failure					
	Congestive					
	Chest Pain					
	Coronary Artery Disease					
	Coronary Artery					
	Restenosis					
	Haematemesis					
	Hyperlipidaemia					
	Hypersensitivity					
	Hypertension					
	Muscle Contractions					
	Involuntary					

Non-Cardiac Chest Pain
Oesophagitis
Osteoarthritis
Pulmonary Oedema
Tendonitis
Urticaria
Ventricular Fibrillation
Visual Acuity Reduced

Date:01/26/04ISR Number: 4278992-3Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00020
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged		Professional	Tizanidine Hydrochloride	SS		ORAL	6	DAY
			Tramadol					

			Hydrochloride	SS	ORAL
6 DAY					

Date:01/26/04ISR Number: 4278993-5Report Type:Expedited (15-DaCompany Report #WAES 0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease	Professional	Mobic	C		
	Coronary Artery Stenosis		Skelaxin	C		
	Diaphragmatic Disorder		Zantac	C		
	Dyspnoea					
	Ecchymosis					
	Emotional Distress					
	Fatigue					
	Groin Pain					
	Myocardial Infarction					

Date:01/26/04ISR Number: 4278995-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Atrioventricular Block		Tylenol	C		
Other	First Degree					
	Benign Prostatic					
	Hyperplasia					
	Bundle Branch Block Right					
	Cerebellar Infarction					
	Cerebrovascular Accident					
	Chest Pain					
	Coronary Artery Disease					
	Dyslipidaemia					
	Hyperhidrosis					
	Hypertension					
	Nystagmus					
	Polytraumatism					
	Sinus Arrhythmia					
	Sinus Bradycardia					
	Sinus Tachycardia					
	Vestibular Disorder					

Date:01/26/04ISR Number: 4278997-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01296
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
Initial or Prolonged	Blood Cholesterol	Professional	Lipitor	C				
Disability	Increased		Premarin	C		ORAL		
	Bunion Operation		Allegra	C				
	Bursitis		Covera	C				
	Carotid Artery Atheroma		Claritin-D 12 Hour	C		ORAL		
	Carotid Artery Stenosis		Adalat	C		ORAL		
	Cerebrovascular Accident		Zantac	C				
	Chest Pain							
	Diabetes Mellitus							
	Fall							
	Infection							
	Pain							

Date:01/26/04ISR Number: 4278998-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		16 DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		3 DAY
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		16 DAY
	Increased							
	Cardiac Aneurysm							
	Cardiac Failure							
	Congestive							
	Myocardial Infarction							

Date:01/26/04ISR Number: 4279087-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA01421
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ruptured Cerebral Aneurysm	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Effexor	C				

Date:01/26/04ISR Number: 4279088-7Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00175
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Genital Pruritus Female	Health	Vioxx	PS	Merck & Co., Inc	ORAL		907 DAY
		Professional	Acetaminophen	C		ORAL		

Date:01/26/04ISR Number: 4279089-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA02790
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia

Initial or Prolonged	Asthenia
	Atelectasis
	Back Pain
	Bursitis
	Contusion
	Diverticulum Intestinal
	Dysplasia
	Endometrial Hyperplasia
	Faecal Occult Blood
	Positive
	Gastric Ulcer
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haemorrhoids
	Headache
	Hiatus Hernia
	Hot Flush
	Joint Effusion
	Lung Neoplasm
	Melaena
	Muscle Strain
	Osteoarthritis
	Periodontal Disease
	Rash
	Rectal Haemorrhage

		Reflux Oesophagitis					
		Road Traffic Accident					
		Tenderness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Uterine Leiomyoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Vaginal Haemorrhage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Betamethasone And Bupivacaine Hydrochloride	C		
PARENTERAL							
				Arthrotec	C		
				Naprelan	C		

Date:01/26/04ISR Number: 4279090-5Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00158
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenitis	Professional	Aspirin	SS		ORAL
	Dyspepsia		Acetaminophen And Codeine Phosphate	C		ORAL
	Faeces Discoloured		Atorvastatin Calcium	C		ORAL
	Haemoglobin Decreased		Lisinopril	C		ORAL
			Gliclazide	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL

Date:01/26/04ISR Number: 4279911-6Report Type:Expedited (15-DaCompany Report #RS004142-CDN
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Required	Blood Glucose Increased	Foreign	Pariet (Rabeprazole)			
Intervention to	Confusional State	Health	(Rabeprazole Sodium)	PS		ORAL
20 MG, 1 IN 1						
Prevent Permanent	Disturbance In Attention	Professional				
D, ORAL						
Impairment/Damage	Dysgeusia		Vioxx (Rofecoxib)	SS		
50 MG, 2 IN 1						
	Hyperchlorhydria					
D,						
	Insomnia		Allopurinol			

Muscle Rigidity	(Allopurinol)	C
Myalgia	Codeine Contin (Codeine Contin)	C
Paraesthesia	Divalproex Sodium (Valproate Semisodium)	C
Pruritus	Effexor Xr (Venlafaxine Hydrochloride)	C
Somnolence	Humalog (Insulin Lispro)	C
	Ibuprofen (Ibuprofen)	C
	Levothyroxine (Levothyroxine)	C
	Insulin Ph (Insulin)	C
	Salmon Oil (Fish Oil)	C
	Tylenol With Codeine No. 3 (Panadeine Co)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/04ISR Number: 4279962-1Report Type:Expedited (15-DaCompany Report #S03-SWI-04412-01
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Akathisia	Foreign	Cipralex					
	Exanthem	Health	(Escitalopram)	PS		ORAL	5 MG QD PO	
	Gamma-Glutamyltransferase Increased	Professional	Cipralex (Escitalopram)	SS		ORAL	10 MG QD PO	
	Monocyte Count Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Neutrophil Count		Vioxx (Rofecoxib)	SS		ORAL	25 MG QD PO	
	Increased		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Parkinsonism		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
	Rash		Zyprexa (Olanzapine)	C				
	Sleep Disorder		Temesta (Lorazepam)	C				
			Duphalac (Lactulose)	C				
			Paragol	C				
			Fig Syrup	C				

Date:01/26/04ISR Number: 4280249-1Report Type:Expedited (15-DaCompany Report #2003GB02479
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute	Foreign	Omeprazole	PS		ORAL	20 MG PO	
Required	Coronary Artery	Health	Rofecoxib	SS		ORAL	50 MG PO	
Intervention to Prevent Permanent Impairment/Damage	Atherosclerosis	Professional	Climagest	C				
	Myocardial Ischaemia	Other						

Date:01/27/04ISR Number: 4279375-2Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00072
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Dialysis	Professional	Vasotec	SS		ORAL
Hospitalization -	Drug Interaction		Esomeprazole			
Initial or Prolonged	Duodenal Ulcer		Magnesium	SS		ORAL
	Haemorrhage		Furosemide Sodium	SS		ORAL
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
			Olanzapine	SS		ORAL
			Risperidone	SS		ORAL

Date:01/27/04ISR Number: 4279383-1Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00096
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Hospitalization -	Haemoglobin Decreased	Professional	Aspirin	SS		ORAL
1512 DAY						
Initial or Prolonged	Melaena		Acetaminophen	C		ORAL
			Senna	C		ORAL
			Morphine Sulfate	C		ORAL
5 DAY						
			Amitriptyline Hydrochloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279386-7Report Type:Expedited (15-DaCompany Report #WAES 0401NOR00016
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Ulcer		Fosamax	SS		ORAL		
			Aspirin And Magnesium Oxide	SS		ORAL		
			Zestoretic	C		ORAL		
			Verapamil	C		ORAL		

Date:01/27/04ISR Number: 4279387-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Lymphocytic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Prempro	C				
	Haemorrhage							
	Heart Injury							
	Heart Rate Irregular							
	Hypertension							
	Injury							
	Mitral Valve Incompetence							
	Oedema Peripheral							
	Overdose							
	Pneumonia							
	Silent Myocardial Infarction							

Date:01/27/04ISR Number: 4279388-0Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00049
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 182 DAY	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 366 DAY	Cardioactive Drug Level Increased	Professional	Spironolactone	SS		ORAL
			Fluindione	C		ORAL
	International Normalised Ratio Increased		Fluindione	C		ORAL
			Adrafinil	C		
	Lung Disorder		Buflomedil Hydrochloride	C		ORAL
	Renal Disorder		Digoxin	C		ORAL
	Renal Failure		Buflomedil Hydrochloride	C		ORAL
			Furosemide	C		ORAL
			Losartan Potassium	C		ORAL
			Melilot And Rutin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279389-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA02152
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization -		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Lasix (Furosemide Sodium)	C		ORAL		
			Lasix (Furosemide Sodium)	C		ORAL		
			Toprol Xl Tablets	C		ORAL		

Date:01/27/04ISR Number: 4279391-0Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00188
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Haemorrhage	Professional	Aspirin	C		ORAL		
	Gastrointestinal Ulcer		Lisinopril	C		ORAL		5 DAY
	Renal Impairment							

Date:01/27/04ISR Number: 4279392-2Report Type:Expedited (15-DaCompany Report #WAES 0401ITA00012
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rash Maculo-Papular	Health	Vioxx	PS	Merck & Co., Inc	ORAL		25 DAY
Initial or Prolonged		Professional						

Date:01/27/04ISR Number: 4279393-4Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00186
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hypoglycaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						
		Professional	Insulin	C		

Date:01/27/04ISR Number: 4279394-6Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00098
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Decreased Appetite	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Drug Interaction	Professional	Enalapril Maleate	SS		ORAL
	Nausea		Theophylline	SS		ORAL
	Vomiting		Torsemide	SS		ORAL
			Leflunomide	SS		ORAL
12 DAY						

Date:01/27/04ISR Number: 4279395-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01288
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Vioxx	SS	Merck & Co., Inc	ORAL
			Vicodin Tablets	C		
			Norco	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279396-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA01697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/27/04ISR Number: 4279433-2Report Type:Expedited (15-DaCompany Report #WAES 0307GBR00168
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine		Atenolol	SS				
							110	DAY
Other	Increased Blood Urea Increased		Sulfamethoxazole And Trimethoprim	SS		ORAL		
							6	DAY
	Circulatory Collapse		Trimethoprim	SS				
							11	DAY
	Feeling Abnormal		Atenolol	SS				
	Heart Rate Decreased		Acetaminophen And Codeine Phosphate	C				
	Hyperkalaemia							
	Hypotension		Carbomer	C				
							OPHTHALMIC	
	Nausea		Gabapentin	C				
			Lansoprazole	C				
			Senna	C				
			Vitamin B Complex	C				
			Simvastatin	C				
			Ranitidine	C				
			Nitrazepam	C				
			Lactulose	C				
			Folic Acid	C				
			Fosamax	C		ORAL		
			Aspirin	C				

Date:01/27/04ISR Number: 4279434-4Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00175
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Aspirin	SS		ORAL		
	Melaena		Calcitriol	C		ORAL		
	Syncope		Zocor	C		ORAL		
			Warfarin	C		ORAL		
			Sodium Bicarbonate	C				
			Carvedilol	C		ORAL		
			Digoxin	C		ORAL		

Date:01/27/04ISR Number: 4279435-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Bundle Branch Block Right
	Colonic Polyp
	Constipation
	Gastric Ulcer Haemorrhage
	Gastritis
	Gastritis Erosive
	Gastrointestinal Disorder

		Haemorrhoids					
		Hiatus Hernia					
		Ileus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incisional Hernia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure	Professional	Vicodin Tablets	C		
		Small Intestinal		Zyloprim	C		
		Obstruction		Xanax	C		
				Ecotrin	C		
				Aspirin	C		
				Lipitor	C		
				Ultram	C		
				Carisoprodol	C		
				Vasotec	C		
				Micronase	C		
				Prevacid	C		
				Glucophage	C		
				Centrum	C		

Date:01/27/04ISR Number: 4279722-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00845
Age:26 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
437 DAY							
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
437 DAY							
		Emotional Distress					
		Hypertension					
		Injury					
		Joint Swelling					
		Migraine					
		Oedema Peripheral					
		Osteoarthritis					
		Syncope					
		Thyroid Disorder					

Date:01/27/04ISR Number: 4279723-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Lipitor	C		
2371 DAY						
			Accupril	C		
2373 DAY						

Date:01/27/04ISR Number: 4279730-0Report Type:Expedited (15-DaCompany Report #WAES 0311ZAF00015
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
10 WK						
Initial or Prolonged	Circulatory Collapse		Estrogens,			
	Pulmonary Embolism		Conjugated	C		ORAL
10 YR						

Date:01/27/04ISR Number: 4279731-2Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00111
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Hospitalization -	Face Oedema		Amlodipine Besylate	C		ORAL
Initial or Prolonged	Pulmonary Congestion		Isosorbide			

Mononitrate	C		ORAL
Valsartan	C		ORAL
Metoprolol Succinate	C		ORAL
Moxonidine	C		ORAL

Date:01/27/04ISR Number: 4279733-6Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00192
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Other			Acetaminophen	C				
			Albuterol Sulfate	C				
			Beclomethasone Dipropionate	C				

Date:01/27/04ISR Number: 4279734-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA03537
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abnormal Faeces		Vioxx	SS	Merck & Co., Inc	ORAL		
	Constipation		[Therapy Unspecified]	C				
	Deafness		Premarin	C				
	Depression		Flonase	C				
	Diarrhoea		Ambien	C				
	Dyspepsia		Zoloft	C				
	Gastric Disorder		Hydroxychloroquine Sulfate	C				
	Haematuria		Claritin	C				
	Haemorrhoids		Daypro	C				
	Headache							
	Labyrinthitis							
	Nasal Congestion							
	Nephrocalcinosis							
	Nystagmus							
	Oesophageal Disorder							
	Ovarian Cyst							
	Panic Disorder							
	Peptic Ulcer							
	Proctalgia							
	Rectal Haemorrhage							
	Rheumatoid Arthritis							

Rhinitis Allergic
Systemic Lupus
Erythematosus
Urethral Stricture
Vertigo

Date:01/27/04ISR Number: 4279739-7Report Type:Expedited (15-DaCompany Report #WAES 0401DNK00020
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
			Aspirin	C		ORAL		
			Pravastatin Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/04ISR Number: 4279745-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02385
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Vicodin Tablets	C				
Initial or Prolonged	Helicobacter Pylori		Coumadin	C				
Other	Identification Test		Digoxin	C				
	Positive							

Date:01/28/04ISR Number: 4280545-8Report Type:Expedited (15-DaCompany Report #WAES 0307FRA00049
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Rofecoxib	PS	Merck & Co., Inc	ORAL		
								182 DAY
Initial or Prolonged	Cardioactive Drug Level		Spironolactone	SS		ORAL		
	Increased		Adrafinil	C				
	International Normalised		Buflomedil					
	Ratio Increased		Hydrochloride	C		ORAL		
	Lung Disorder		Buflomedil					
	Renal Atrophy		Hydrochloride	C		ORAL		
	Renal Failure		Digoxin	C		ORAL		
			Fluindione	C		ORAL		
								366 DAY
			Fluindione	C		ORAL		
			Furosemide	C		ORAL		
			Losartan Potassium	C		ORAL		
			Melilot And Rutin	C				

Date:01/28/04ISR Number: 4280548-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA01421
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ruptured Cerebral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aneurysm		Lortab	C				
			Effexor	C				

Date:01/28/04ISR Number: 4280551-3Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00058
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Thrombosis Hypokinesia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/04ISR Number: 4281181-XReport Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris Bladder Spasm Bronchial Infection Carotid Artery Stenosis Cerebral Infarction Cerebral Ischaemia Cervicobrachial Syndrome Chest Pain

		Cholelithiasis					
		Dysuria					
		Embolic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Escherichia Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Microangiopathy		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Mitral Valve Incompetence		Tylenol	C		
		Myofascial Pain Syndrome		Parafon Forte	C		
		Nerve Compression		Serevent	C		
RESPIRATORY							
		Oedema Peripheral					
(INHALATION)							
		Pollakiuria		Proventil	C		
RESPIRATORY							
		Rotator Cuff Syndrome					
(INHALATION)							
		Tricuspid Valve		Aspirin	C		
		Incompetence		Lioresal	C		
		Urinary Tract Infection		Valium	C		
		Ventricular Hypertrophy		Demerol	C		
				Ditropan	C		
				Inderal	C		

Date:01/29/04ISR Number: 4281228-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00753
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Acute Myocardial	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Infarction		Indocin			
		Injury		(Indomethacin)	C		ORAL
				Naproxen	C		
				Oxycontin	C		

Date:01/29/04ISR Number: 4281230-9Report Type:Expedited (15-DaCompany Report #WAES 0204USA02294
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Photosensitivity Reaction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/04ISR Number: 4281233-4Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00183
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	768	DAY
	Photosensitivity Reaction		Dermatologic (Unspecified)	C				
			Estradiol And Estriol And Estrone	C				
			Fexofenadine Hydrochloride	C				
			Levothyroxine Sodium	C				
			Prednisolone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/04ISR Number: 4281236-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Chest Wall Pain	Professional						
	Dizziness							
	Dyspnoea							
	Heart Rate Increased							
	Myocardial Infarction							

Date:01/29/04ISR Number: 4281244-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA02861
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	138	DAY
Hospitalization -	Anorexia	Professional	[Therapy					
Initial or Prolonged	Arthritis		Unspecified]	C				
Disability	Back Injury		Lortab	C		ORAL		
Other	Blood Creatinine		Vicodin Tablets	C				
	Increased		Lorcet 10/650	C				
	Blood Urea Increased		Darvocet-N	C				
	Brain Neoplasm		Aspirin	C		ORAL		
	Brain Stem Infarction		Baclofen	C		ORAL		
	Bundle Branch Block Left		Valium	C		ORAL		
	Cold Sweat		Vasotec	C		ORAL		
	Dehydration		Glucotrol Xl	C		ORAL		
	Diabetes Mellitus							
	Inadequate Control							
	Dilatation Atrial							
	Duodenal Ulcer							
	Haemorrhage							
	Dysphagia							
	Facial Palsy							
	Grand Mal Convulsion							
	Hemiparesis							
	Hypokalaemia							
	Hyponatraemia							
	Nausea							
	Positive Rombergism							
	Rectal Haemorrhage							

Sinus Tachycardia
Speech Disorder
Syncope
Thought Blocking
Urinary Tract Infection
Ventricular Hypertrophy

Date:01/29/04ISR Number: 4281838-0Report Type:Expedited (15-DaCompany Report #WAES 0401DNK00030
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc			4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/04ISR Number: 4281841-0Report Type:Expedited (15-DaCompany Report #WAES 0401USA01975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:01/29/04ISR Number: 4281846-XReport Type:Expedited (15-DaCompany Report #WAES 0401DNK00026
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	59	DAY
Initial or Prolonged			Aspirin	SS		ORAL		

Date:01/29/04ISR Number: 4281847-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cancer Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Pepcid	C		ORAL		
Initial or Prolonged	Congestive		Lasix (Furosemide)	C				
Disability	Cardiac Valve Disease		Neurontin	C				
	Cardio-Respiratory Arrest		Ibuprofen	C				
	Colonic Polyp		Zestril	C				
	Depression		Lithium Carbonate	C				
	Diabetes Mellitus							
	Diverticulum							
	Facial Palsy							
	Fall							
	Fatigue							
	Flank Pain							
	Fluid Retention							
	Haemorrhoids							
	Hemiparesis							
	Influenza							
	Insomnia							
	Lymphadenopathy							
	Lymphadenopathy							
	Mediastinal							

Marrow Hyperplasia
Myeloproliferative
Disorder
Nasopharyngitis
Nausea
Non-Hodgkin'S Lymphoma
Oedema Peripheral
Oesophagitis Haemorrhagic
Pathological Fracture
Pleural Effusion
Pneumonia Aspiration
Polyp Colorectal
Pulmonary Hypertension
Rectal Haemorrhage
Rectal Polyp
Sepsis
Septic Shock
Sinusitis
Stomatitis
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/04ISR Number: 4281851-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA01000
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dysstasia		Vioxx	SS	Merck & Co., Inc	ORAL
	Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
	Mixed Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
	Neuropathy		Tylenol	C		
	Pneumonia		Elavil	C		ORAL
	Pneumothorax		Premarin	C		
			Detrol La	C		
			Lasix (Furosemide)	C		
			Prinzide	C		ORAL
			Singulair	C		ORAL
			Potassium (Unspecified)	C		
			Prednisone	C		
			Aciphex	C		

Date:01/29/04ISR Number: 4281852-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA00532
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL
3 WK						
Hospitalization -	Blood Pressure Increased		Prempro	C		
Initial or Prolonged	Cerebral Artery Embolism		Ambien	C		
Disability	Confusional State					
Other	Dizziness					
	Feeling Abnormal					
	Headache					
	Hypoaesthesia					
	Influenza Like Illness					
	Muscle Twitching					
	Oedema Peripheral					
	Paraesthesia					
	Rash					
	Vision Blurred					

Date:01/29/04ISR Number: 4281853-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA00402
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/29/04ISR Number: 4281858-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA02180
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Anaemia
	Aphasia
Disability	Cardiomyopathy
	Cerebrovascular Accident
	Deep Vein Thrombosis
	Dehydration
	Diabetes Mellitus
	Diabetes Mellitus
	Inadequate Control

		Diabetic Neuropathy					
		Difficulty In Walking					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysgraphia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphonia		Cipro	C		
7	DAY						
		Ear Disorder		Glucophage	C		
		Facial Palsy					
		Fall					
		Hearing Impaired					
		Iron Deficiency Anaemia					
		Melaena					
		Micturition Urgency					
		Nocturia					
		Oedema					
		Oestrogen Deficiency					
		Pain					
		Pelvic Organ Injury					
		Pneumonia					
		Pollakiuria					
		Positive Rombergism					
		Pulmonary Hypertension					
		Renal Failure					
		Retinal Ischaemia					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinusitis					
		Skin Ulcer					
		Trigger Finger					
		Urge Incontinence					
		Urinary Tract Infection					
		Weight Increased					

Date:01/30/04ISR Number: 4282373-6Report Type:Expedited (15-DaCompany Report #WAES 0401NZL00009
Age:90 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Gastric Ulcer	Professional	Acetaminophen	C		

Date:01/30/04ISR Number: 4282377-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA01410
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Cognitive Disorder Confusional State Dysarthria Motor Dysfunction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/30/04ISR Number: 4282378-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA01968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/04ISR Number: 4282379-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Injury		Tylenol	C				
	Blood Potassium Increased		Z-Pak	C				
	Bronchitis		Diuretic (Unspecified)	C				
	Carcinoma In Situ Of Skin		Dyazide	C				
	Coronary Artery Disease		Advil	C				
	Deep Vein Thrombosis		Triamterene	C				
	Diarrhoea		Prevacid	C				
	Drug Hypersensitivity		Asacol	C				
	Enterocele		Naproxen	C				
	Fall		Ditropan	C				
	Gastrointestinal Infection		Quinidine	C				
	Gastrooesophageal Reflux Disease		Quinine Sulfate	C				
	Hiatus Hernia							
	Hyperlipidaemia							
	Osteoarthritis							
	Pulmonary Embolism							
	Radius Fracture							
	Renal Failure Acute							
	Rotator Cuff Syndrome							
	Thrombophlebitis							
	Ulna Fracture							
	Urinary Tract Infection							

Date:01/30/04ISR Number: 4282382-7Report Type:Expedited (15-DaCompany Report #WAES 0401USA01976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/30/04ISR Number: 4282384-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA03167
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Catapres	C				
347 DAY								
	Dyspnoea		Lasix (Furosemide)	C				
	Gastrooesophageal Reflux		Micardis	C				
	Disease		Lasix (Furosemide)	C				
	Glaucoma		Cozaar	C				
	Hypertension							
	Infection							
	Injury							
	Obesity							
	Pulmonary Embolism							
	Rheumatoid Arthritis							
	Sleep Apnoea Syndrome							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/04ISR Number: 4282390-6Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Disability	Barrett'S Oesophagus		Aspirin	C				
	Blood Chloride Increased		Tagamet	C				
	Blood Glucose Increased		Tylenol Pm	C				
	Blood Pressure Increased		Zocor	C		ORAL		
	Blood Triglycerides		Tagamet	C				
	Increased		Cardura	C		ORAL		
	Cardiac Failure							
	Congestive							
	Cardiomyopathy							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Dizziness							
	Duodenal Ulcer							
	Duodenitis							
	Dyspepsia							
	Dyspnoea							
	Ejection Fraction							
	Decreased							
	Gastritis Erosive							
	Gastrooesophageal Reflux							
	Disease							
	Haemoglobin Decreased							
	Headache							
	Helicobacter Infection							
	Hyperhidrosis							
	Hypogonadism							
	Mitral Valve Incompetence							
	Pco2 Decreased							
	Peptic Ulcer							
	Reflux Oesophagitis							
	Respiratory Rate							
	Increased							
	Sinus Tachycardia							
	Ventricular Dysfunction							
	Ventricular Extrasystoles							

Weight Increased

Date:01/30/04ISR Number: 4282391-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/30/04ISR Number: 4282392-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Arterial Bruit
Other	Aspartate

		Aminotransferase Increased					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Occlusion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Lipitor	C		
		Diastolic Dysfunction					
		Dizziness					
		Dysarthria					
		Fall					
		Fatigue					
		Hemiplegia					
		Joint Injury					
		Left Ventricular Failure					
		Nausea					
		Pain					
		Restlessness					
		Wheezing					

Date:01/30/04ISR Number: 4282393-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Distension	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Plendil	C		
		Constipation		Dyazide	C		
		Dyspepsia					
		Emotional Distress					
		Haematochezia					
		Hypersensitivity					
		Simple Partial Seizures					
		Urine Flow Decreased					
		Vision Blurred					
		Weight Increased					

Date:01/30/04ISR Number: 4282989-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Atelectasis
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Bradycardia
	Cellulitis
	Chest Wall Pain
	Coronary Artery Disease
	Dyspnoea
	Electrocardiogram Q Waves
	Erectile Dysfunction
	Hyperglycaemia
	Hyperlipidaemia
	Hypokalaemia
	Libido Decreased

		Myocardial Infarction					
		Ocular Hypertension					
		Pericarditis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Postoperative Wound		Vioxx	SS	Merck & Co., Inc	ORAL
		Complication		Vioxx	SS	Merck & Co., Inc	ORAL
		Prostatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Tylenol	C		
				Saw Palmetto	C		
				Ambien	C		
				Norvasc	C		ORAL
				Aspirin	C		ORAL
				Dicyclomine Hydrochloride	C		
				Prevacid	C		

Date:01/30/04ISR Number: 4282997-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Balance Disorder		Soma	C		
		Blood Chloride Increased		Motrin	C		
		Blood Cholesterol Increased		Lamisil	C		
		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Chondromalacia					
		Cough					
		Dizziness					
		Dysarthria					
		Fall					
		Hemiparesis					
		Hypertension					
		Mastoiditis					
		Muscle Strain					
		Nausea					
		Oedema Peripheral					
		Paraesthesia					
		Visual Acuity Reduced					

Date:01/30/04ISR Number: 4282999-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00809
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Fluid Retention Pulmonary Oedema Stent Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/04ISR Number: 4283000-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Percocet	SS		
Disability	Arthropod Sting		Alcohol	SS		
Other	Cardiac Failure		Xanax	SS		
	Coronary Artery Disease		Ambien	SS		
	Diabetes Mellitus		Soma	C		
	Ejection Fraction		Advil	C		
	Decreased		Imdur	C		
	Gastrooesophageal Reflux					
	Disease					
	Hypercholesterolaemia					
	Hyperhidrosis					
	Hyperlipidaemia					
	Hypertension					
	Intentional Misuse					
	Joint Swelling					
	Major Depression					
	Myocardial Infarction					
	Polyarthritis					
	Spondylitis					
	Stent Occlusion					
	Suicide Attempt					
	Tooth Disorder					

Date:01/30/04ISR Number: 4283004-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
	Drug Ineffective		Lidocaine And			
	Dysarthria		Triamcinolone			
	Emotional Distress		Acetonide	C		
PARENTERAL	1 DAY					
	Gastric Disorder		Glucophage Xr	C		ORAL
	Headache		Glucophage Xr	C		
	Hypertension		Glucophage Xr	C		ORAL

Hypoaesthesia
Joint Dislocation
Labyrinthitis
Lower Limb Fracture
Overdose
Pain
Photophobia
Sinus Disorder
Sinusitis

Date:01/30/04ISR Number: 4283006-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA01716
Age:38 YR Gender:Female I/FU:I

Outcome PT
Other Atherosclerosis
Blood Cholesterol
Increased
Cardiac Valve Disease

		Chronic Fatigue Syndrome					
		Coronary Artery Disease					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Glaucoma		[Therapy			
		Hypertension		Unspecified]	C		
		Myocardial Infarction		Albuterol	C		
		Oedema Peripheral		Proventil	C		
RESPIRATORY							
		Thrombosis					
(INHALATION)							
				Antimicrobial			
				(Unspecified)	C		
				Amaryl	C		
				Glipizide	C		
				Glucophage	C		

Date:01/30/04ISR Number: 4283009-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
586 DAY							
Hospitalization -		Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
586 DAY							
Initial or Prolonged		Blood Triglycerides		Tylenol	C		
Disability		Increased		Albuterol	C		
Other		Cerebral Haemorrhage		Amoxicillin	C		
		Chest Wall Pain		Aspirin	C		
		Death		Lotensin	C		
119 DAY							
		Deep Vein Thrombosis		Correctol			
		Depression		(Bisacodyl)	C		
		Drug Hypersensitivity		Cerivastatin Sodium	C		
		Dyspepsia		Baycol	C		
		Dyspnoea		Doxepin			
		Emotional Distress		Hydrochloride	C		
		Gastrointestinal Disorder		Calan	C		
		High Density Lipoprotein		Hydrochlorothiazide	C		
		Increased		Maxzide	C		
		Hyperlipidaemia		Dyazide	C		
		Hypertension		Dyazide	C		

	Transient Ischaemic Attack	Medrol	C
		Singulair	C
		Pravachol	C

1210 DAY

Date:01/30/04ISR Number: 4283011-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Unstable
	Anxiety
	Aortic Valve Incompetence
	Asthenia
	Asthma
	Breath Sounds Decreased
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomyopathy
	Compartment Syndrome

		Depression					
		Dizziness					
		Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ejection Fraction		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased		Allegra	C		ORAL
		Fatigue		Zoloft	C		ORAL
		Fluid Retention					
		Ganglion					
		Headache					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypertension					
		Hypokinesia					
		Insomnia					
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Sinus Disorder					
		Tendonitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					

Date:01/30/04ISR Number: 4283012-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Blood Pressure Increased		[Therapy			
		Bronchitis		Unspecified]	C		
		Cataract		Acetaminophen	C		
		Cerebrovascular Accident		Percocet	C		
		Dehydration		Soma	C		
		Diarrhoea		Zyrtec	C		
		Diverticulitis		Ultram	C		
		Eye Disorder		Premarin	C		
		Gastrointestinal Disorder		Motrin	C		
		Pain		Ocuflox	C		
				Oxycodone	C		
				Prednisone	C		

OPHTHALMIC

Date:01/30/04ISR Number: 4283013-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02378
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anorexia
	Anxiety
	Blood Cholesterol
	Increased
	Bradycardia
	Cardiac Failure
	Congestive
	Dehydration
	Diarrhoea
	Dyspepsia
	Dyspnoea
	Emotional Distress
	Erosive Oesophagitis

		Faeces Discoloured					
		Frequent Bowel Movements					
		Gastrointestinal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		[Therapy			
		Haemorrhoids		Unspecified]	C		
		Heart Rate Irregular		Valium	C		
		Hypertension		Nexium	C		
		Nasopharyngitis		Paxil	C		
		Nausea					
		Oedema Peripheral					
		Otitis Media					
		Pain					
		Peptic Ulcer					
		Urinary Tract Infection					
		Vomiting					
		Weight Increased					

Date:01/30/04ISR Number: 4283014-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebral Infarction		Norvasc	C		
395	DAY						
		Cerebrovascular Accident		Lotrel	C		
		Chest Pain		Aspirin	C		
		Depression		Lipitor	C		
831	DAY						
		Diabetes Mellitus		Lipitor	C		
831	DAY						
		Non-Insulin-Dependent		Plavix	C		
		Dyslipidaemia		Nexium	C		
		Dysphagia		Zetia	C		ORAL
		Dyspnoea		Zocor	C		ORAL
		Fatigue		Tricor	C		
		Gastrooesophageal Reflux		Neurontin	C		
		Disease		Ibuprofen	C		
		Hypercholesterolaemia		Methocarbamol	C		
		Hypertension		Toprol Xl Tablets	C		

Hypertriglyceridaemia	Prilosec	C
Irritability	Paxil	C
Lacunar Infarction		
Oedema Peripheral		
Pain		
Sleep Apnoea Syndrome		
Sputum Discoloured		
Tremor		
Upper Respiratory Tract Infection		
Vascular Dementia		
Weight Increased		
Wheezing		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/30/04ISR Number: 4283015-6Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00200
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis		Aspirin	C		ORAL		
	Gastritis Erosive		Atenolol And Chlorthalidone	C		ORAL		
	Haematemesis							
	Melaena							

Date:01/30/04ISR Number: 4283016-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dry Mouth		Zanaflex	SS				1 DAY
	Hyperhidrosis		Ultracet	C				
	Hypotension							
	Somnolence							
	Speech Disorder							
	Vision Blurred							

Date:01/30/04ISR Number: 4284537-4Report Type:Expedited (15-DaCompany Report #N134750
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aggression	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	300 MG ONCE	
	Angina Unstable							
	Cerebral Atrophy							
	Computerised Tomogram							
	Abnormal							
	Disorientation		Asa (Acetylsalicylic Acid)	SS		ORAL	325 MG	
	Drug Ineffective							
	Gastrointestinal		Methylprednisolone	SS			250 MG	2 DAY

		Haemorrhage		Vioxx (Rofecoxib)	SS		ORAL
25 MG	1 DAY						
		Haematocrit Decreased		Atorvastatin Calcium	C		
		Leukopenia		Heparin	C		
		Myocardial Infarction		Zantac (Ranitidine Hydrochloride)	C		
		Pharyngolaryngeal Pain		Vitamin E	C		
		Platelet Count Decreased		Levofloxacin	C		
		Sinus Disorder		Haldol (Haloperidol)	C		
				Terazosin	C		
				Diphenhydramine	C		
				Metoprolol	C		

Date:02/02/04ISR Number: 4283703-1Report Type:Expedited (15-DaCompany Report #WAES 0401SWE00017
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer	Professional	Aspirin	SS		ORAL
	Faeces Discoloured					
	Fatigue					
	Helicobacter Pylori Identification Test Positive					

Date:02/02/04ISR Number: 4283712-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02575
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Infarction	Professional				
Hospitalization -	Alpha Haemolytic					
Initial or Prolonged	Streptococcal Infection					
Disability	Anaemia					
	Aphasia					
	Cardiac Failure					
	Congestive					
	Cardiac Murmur					
	Cerebral Artery Occlusion					
	Cerebral Haemorrhage					
	Cerebrovascular Accident					
	Confusional State					
	Dyspnoea					
	Embolic Stroke					
	Endocarditis					
	Haemorrhage Intracranial					
	Headache					
	Mental Status Changes					
	Mitral Valve Incompetence					
	Movement Disorder					
	Mycotic Aneurysm					
	Pulmonary Hypertension					
	Pulmonary Valve					
	Incompetence					
	Renal Failure Acute					
	Ventricular Hypertrophy					

Date:02/02/04ISR Number: 4283715-8Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00211
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis	Professional	Acetaminophen And			
Other	Mobility Decreased		Dihydrocodeine			
	Oesophagitis		Bitartrate	C		
			Acetaminophen And			
			Propoxyphene			
			Hydrochloride	C		ORAL

			Amitriptyline Hydrochloride	C		ORAL
			Furosemide	C		ORAL
			Prinivil	C		ORAL
			Morphine Sulfate	C		ORAL

Date:02/02/04ISR Number: 4283716-XReport Type:Expedited (15-DaCompany Report #WAES 0401GBR00227
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 303 DAY	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer	Professional	Benzalkonium Chloride And Mineral Oil And Triclosan	C		
	Gastrointestinal Haemorrhage		Dermatologic (Unspecified)	C		
	Myocardial Infarction					

Date:02/02/04ISR Number: 4283726-2Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00226
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	49	DAY
Hospitalization - Initial or Prolonged	Infarction	Professional	Aspirin	C				
Other								

Date:02/02/04ISR Number: 4283727-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Increased		Amoxicillin	C				
	Depression		Hydrocodone					
	Dermatitis Papillaris		Bitartrate	C				
	Capillitii		Lorazepam	C				
	Disturbance In Attention							
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	General Physical							
	Condition Abnormal							
	Hypertension							
	Impaired Healing							
	Irritability							
	Keloid Scar							
	Pain							
	Self Esteem Decreased							
	Sexual Dysfunction							
	Vascular Injury							

Date:02/02/04ISR Number: 4283735-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		552 DAY
Initial or Prolonged	Anxiety		Aleve	SS				
Disability	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		552 DAY
	Blood Pressure Increased		Tylenol	C				
	Cognitive Disorder		Paxil	C				2 MON
	Dizziness							
	Emotional Distress							
	Haematochezia							
	Injury							
	Lethargy							
	Transient Ischaemic Attack							

Date:02/02/04ISR Number: 4283737-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Disability	Agitation
	Anaemia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arthralgia					
		Arthropod Bite					
		Arthropod Sting					
15	DAY	Blister	Health	Vioxx	PS	Merck & Co., Inc	ORAL
245	DAY	Blood Calcium Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Parathyroid Hormone		Fosamax	C		ORAL
		Decreased		Valium	C		
		Blood Pressure Increased		Neurontin	C		
		Bursitis		Neurontin	C		
		Chest Pain		Valtrex	C		
		Chest X-Ray Abnormal		Neurontin	C		
		Chronic Sinusitis		Glucosamine	C		
		Compression Fracture		Nitrostat	C		
		Conjunctivitis		Evista	C		
		Constipation					
		Cough					
		Crying					
		Depression					
		Difficulty In Walking					
		Drug Intolerance					
		Dyspepsia					
		Fungal Infection					
		Generalised Anxiety					
		Disorder					
		Groin Pain					
		Head Injury					
		Headache					
		Heart Rate Increased					
		Hypoaesthesia					
		Impaired Healing					
		Influenza					
		Injury					
		Insomnia					
		Joint Sprain					
		Libido Decreased					
		Metastasis					
		Multiple Fractures					
		Myofascitis					
		Nuclear Magnetic					
		Resonance Imaging					
		Abnormal					
		Oedema Peripheral					
		Osteoporosis					
		Pain In Jaw					

Panic Attack
Panic Disorder
Pelvic Fracture
Productive Cough
Radiculopathy
Rhinorrhoea
Road Traffic Accident
Sacroiliitis
Scoliosis
Sebaceous Hyperplasia
Sputum Discoloured
Thoracic Outlet Syndrome
Vertebral Column Mass
Viral Pharyngitis
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/04ISR Number: 4283738-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA03118
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Angina Pectoris	Professional	Ultracet	C				
Disability	Arthralgia		Zoloft	C				
	Back Pain		Synthroid	C				
	Blood Cholesterol Increased							
	Blood Magnesium Decreased							
	Bronchitis							
	Chest Pain							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Diabetes Mellitus Non-Insulin-Dependent							
	Dyspnoea							
	Electrocardiogram St-T Segment Abnormal							
	Electrocardiogram T Wave Abnormal							
	Heart Rate Irregular							
	Hyperhidrosis							
	Hypertension							
	Hypothyroidism							
	Influenza							
	Insomnia							
	Leukocytosis							
	Lobar Pneumonia							
	Myocardial Infarction							
	Nausea							
	Nervousness							
	Pain In Extremity							
	Periarthritis							
	Productive Cough							
	Pruritus							
	Pruritus Generalised							
	Pyrexia							
	Tachycardia							
	Tendonitis							
	Treatment Noncompliance							

Date:02/02/04ISR Number: 4283741-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Asthenia
Other	Atherosclerosis
	Blood Iron Decreased
	Blood Pressure
	Fluctuation
	Bronchitis
	Chest Pain
	Colon Cancer
	Cystitis
	Deafness
	Decreased Activity
	Dyspnoea
	Emotional Distress

		Fatigue					
		Fibromyalgia					
		Fluid Retention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gallbladder Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Ulcer Haemorrhage					
		Haemodynamic Instability					
		Haemoglobin Decreased					
		Heart Rate Increased					
		Hypertension					
		Hypotension					
		Myocardial Infarction					
		Oedema					
		Oesophageal Disorder					
		Platelet Count Decreased					
		Rheumatic Fever					
		Sinus Disorder					

Date:02/02/04ISR Number: 4283742-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	MON						
Initial or Prolonged		Anoxic Encephalopathy	Professional	[Therapy			
Other		Atrioventricular Block		Unspecified]	C		
		Blindness		Insulin	C		
		Cardiogenic Shock					
		Cerebrovascular Accident					
		Colitis Ischaemic					
		Constipation					
		Coronary Artery Disease					
		Cough					
		Diarrhoea					
		Gastritis					
		Haemorrhoids					
		Hepatic Failure					
		Ischaemia					
		Ischaemic Cardiomyopathy					
		Mitral Valve Incompetence					
		Muscle Tightness					
		Myocardial Infarction					
		Renal Cyst					

Thyroid Disorder

Date:02/02/04ISR Number: 4283743-2Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Arteriosclerosis
	Arthralgia
	Atherosclerosis
	Bursitis
	Cardiomegaly
	Coronary Artery
	Thrombosis
	Depression
	Dermatitis Contact
	Epicondylitis
	Eye Swelling

		Hepatic Cyst					
		Hepatic Steatosis					
		Hypertensive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiomyopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Lumbar Radiculopathy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscular Weakness		Vioxx	SS	Merck & Co., Inc	ORAL
		Nephrosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Disorder		Allopurinol	C		
		Spinal Disorder		Kenalog	C		
PARENTERAL							
				Trazodone Hydrochloride	C		
111	DAY						
				Celexa	C		
				Colchicine	C		
				Indocin (Indomethacin)	C		ORAL
				Ultram	C		
				Bactroban	C		
				Serzone	C		
				Prednisone	C		ORAL

Date:02/02/04ISR Number: 4283746-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
424	DAY						
Initial or Prolonged		Coronary Artery Disease	Professional	Respaire	C		
Other		Electrocardiogram T Wave		Minocycline	C		
		Inversion		Piroxicam	C		
		Hypoxia		Prednisone	C		
		Ischaemia		Zantac	C		
		Myocardial Infarction					
		Pulmonary Oedema					
		Rotator Cuff Syndrome					
		Skin Disorder					
		Syncope					

Date:02/02/04ISR Number: 4283950-9Report Type:Expedited (15-DaCompany Report #WAES 00121877
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease Recurrence		Vioxx	SS	Merck & Co., Inc	ORAL		
			Glynase Prestab Tablets	C				
			Synthroid	C				

Date:02/02/04ISR Number: 4283955-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acidosis
Disability	Arthritis
	Asthenia
	Blood Cholesterol

		Increased Blood Creatine Phosphokinase Increased Blood Magnesium Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Breath Sounds Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiomegaly		Zocor	SS		ORAL
		Depressed Level Of Consciousness		[Therapy Unspecified]	C		
		Diabetes Mellitus		Tylenol Arthritis Extended Relief	C		
		Dialysis		Lasix (Furosemide)	C		
		Duodenal Ulcer		Glyburide	C		
		Dyspnoea		Glucophage	C		
		Electrocardiogram Qt Prolonged		Accupril	C		
		Emotional Distress					
		Fatigue					
		Fluid Retention					
		Hypocalcaemia					
		Hypotension					
		Hypotonia					
		Injury					
		Mental Impairment					
		Monarthritis					
		Muscle Spasms					
		Myocardial Infarction					
		Oedema Peripheral					
		Pain					
		Renal Failure					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Rhabdomyolysis					
		Stupor					
		Swelling					
		White Blood Cell Count Increased					

Date:02/02/04ISR Number: 4283960-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA00338
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Cardiac Arrest Cardiomegaly					
Disability		Cholelithiasis					

Coronary Artery
Atherosclerosis
Coronary Artery Stenosis
Dilatation Ventricular
Emphysema
Hepatomegaly
Hyperlipidaemia
Pulmonary Congestion
Ventricular Hypertrophy
Vomiting

Date:02/02/04ISR Number: 4283961-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Benign Prostatic		Tylenol	C		
Other	Hyperplasia					
	Bundle Branch Block Right					
	Carotid Artery Disease					
	Cerebellar Infarction					
	Cerebrovascular Accident					
	Chest Pain					
	Coronary Artery Disease					
	Dyslipidaemia					
	Embolism					
	Gastric Disorder					
	Hyperhidrosis					
	Hypertension					
	Lacunar Infarction					
	Nystagmus					
	Polytraumatism					
	Refusal Of Treatment By Patient					
	Supraventricular Tachycardia					
	Urinary Retention					
	Vertigo					
	Vestibular Disorder					

Date:02/02/04ISR Number: 4283962-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01283
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Infarction		Aspirin	C		
	Anaemia		Klonopin	C		
	Back Pain		Premarin	C		
	Blood Pressure Increased		Flonase	C		
	Cardiac Arrest		Lopid	C		
	Coronary Artery Atherosclerosis		Prevacid	C		

Coronary Artery Disease
Depression
Dizziness
Dyspepsia
Emotional Distress
Gastrooesophageal Reflux
Disease
Hypercholesterolaemia
Hypertension
Hypotension
Injury
Lumbar Spinal Stenosis
Oral Intake Reduced
Pain In Extremity
Spinal Osteoarthritis
Thyroid Disorder
Ventricular Fibrillation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/04ISR Number: 4283963-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01385
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Disease		Premarin	C				
Other	Cardiac Failure		Synthroid	C				
	Congestive							
	Cardiac Murmur							
	Chest Pain							
	Coronary Artery Occlusion							
	Dyspnoea Exertional							
	Fluid Retention							
	Gastric Disorder							
	Gastritis							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Ischaemia							
	Lung Neoplasm							
	Myocardial Infarction							
	Oedema Peripheral							
	Oesophageal Spasm							
	Pain In Extremity							

Date:02/02/04ISR Number: 4284285-0Report Type:Direct Company Report #CTU 211302
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Plavix 75 Mg	PS		ORAL	75 MG PO QDAY	
Initial or Prolonged	Haemorrhage		Vioxx 25 Mg	SS		ORAL	VIOXX 25 MG PO QDAY	

Date:02/02/04ISR Number: 4284292-8Report Type:Direct Company Report #CTU 211305
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Blister		Vioxx Samples	PS				
Hospitalization -	Contusion		Verapamil	C				
Initial or Prolonged	Epistaxis		Potassium	C				
	Thrombocytopenia		Glucotrol	C				
			Hctz	C				

Date:02/02/04ISR Number: 4285160-8Report Type:Expedited (15-DaCompany Report #TPA2004A00090
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Actos (Pioglitazone					
Initial or Prolonged	Cardiac Failure		Hydrochloride) (30					
	Congestive		Milligram, Tablets)	PS		ORAL	30 MG,	1 IN
	Haemorrhage						1 D, PER ORAL	
	Laceration		Vioxx (Rofecoxib)	SS				
	Pneumonia		Metoprolol					
	Renal Impairment		(Metoprolol)	C				
			Amiodarone					
			(Amiodarone)	C				
			Zaroxolyn					
			(Metolazone)	C				

Glyburide (Glibenclamide)	C
Isosorbide Dn (Isosorbide Dinitrate)	C
Norvasc (Amlodipine Besilate)	C
Furosemide (Furosemide)	C
Hydralazine (Hydralazine)	C
Claritin-D (Narine Repetabs)	C
Aspirin (Acetylsalicylic Acid)	C

Date:02/03/04ISR Number: 4284263-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01363
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Other	Aneurysm
	Anxiety
	Asthenia
	Blood Cholesterol Increased
	Carpal Tunnel Syndrome
	Chronic Fatigue Syndrome
	Contusion
	Crying
	Depression
	Dizziness
	Dry Mouth
	Dyspepsia
	Ear Pruritus
	Emotional Distress
	Fibromyalgia
	Food Craving
	Food Intolerance
	Gait Disturbance
	Gastrooesophageal Reflux Disease
	Increased Tendency To Bruise
	Injury

Insomnia
Irritable Bowel Syndrome
Keratoconjunctivitis
Sicca
Mitral Valve Incompetence
Muscle Atrophy
Musculoskeletal Stiffness
Myalgia
Myocardial Infarction
Nasal Disorder
Nausea
Night Cramps
Osteoarthritis
Pain
Paraesthesia

		Pruritus					
		Restless Legs Syndrome					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Apnoea Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
634	DAY						
		Stress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
		Thirst		Vioxx	SS	Merck & Co., Inc	ORAL
634	DAY						
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
		Incompetence		Synthroid	C		ORAL
		Varicose Vein		Claritin-D	C		ORAL
		Ventricular Dysfunction		Ultram	C		
		Visual Disturbance		Sonata	C		
		Weight Increased		Panlor Ss	C		
				Lansoprazole	C		ORAL
				Humibid	C		
				Glucosamine	C		
				Docusate Sodium	C		ORAL
				Tessalon	C		
				Zovirax	C		ORAL
				Ambien	C		
				Effexor Xr	C		
				Nasonex	C		
				Prilosec	C		
				Prilosec	C		
				Oxybutynin Chloride	C		
				Paxil	C		ORAL

Date:02/03/04ISR Number: 4284297-7Report Type:Expedited (15-DaCompany Report #WAES 0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Back Disorder
	Blepharitis
	Cardiac Failure
	Congestive
	Colonic Polyp
	Conjunctival Haemorrhage
	Coronary Artery

Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Artery
Thrombosis
Dermatitis Contact
Diabetes Mellitus
Non-Insulin-Dependent
Diverticulum Intestinal
Ecchymosis
Ejection Fraction
Decreased
Electrocardiogram St
Segment Elevation
Electrocardiogram T Wave
Peaked
Erectile Dysfunction
Eye Infection
Eye Injury
Haemorrhoids

		Hyperlipidaemia					
		Injury					
		Myocardial Ischaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Pain		Vioxx	PS	Merck & Co., Inc	ORAL
697	DAY						
		Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
697	DAY						
		Treatment Noncompliance		Acetaminophen And			
		Ventricular Dysfunction		Hydrocodone			
		Ventricular Extrasystoles		Bitartrate	C		
		Vision Blurred		Wellbutrin	C		
		Vitreous Floaters		Viagra	C		
				Avandia	C		
				Duratuss	C		
				Blephamide Ointment	C		

Date:02/03/04ISR Number: 4284300-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01392
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		[Therapy			
		Drug Ineffective		Unspecified]	C		
		Emotional Distress		Premarin	C		
		Fatigue					
		Fibromyalgia					
		Fluid Retention					
		Foot Fracture					
		Headache					
		Herpes Zoster					
		Hypertension					
		Hypoacusis					
		Hypoaesthesia					
		Injury					
		Intervertebral Disc Space					
		Narrowing					
		Intestinal Functional					
		Disorder					
		Ischaemic Stroke					
		Muscular Weakness					
		Musculoskeletal					
		Discomfort					

Musculoskeletal Stiffness
Nausea
Neuralgia
Night Sweats
Pain In Extremity
Radiculitis
Sleep Disorder
Tremor
Vision Blurred
Weight Decreased

Date:02/03/04ISR Number: 4284301-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01384
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Cardiac Failure

		Congestive					
		Chest Pain					
		Diastolic Dysfunction					
		Dilatation Atrial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea Paroxysmal		Vioxx	PS	Merck & Co., Inc	ORAL
430	DAY						
		Nocturnal		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematuria		Vioxx	SS	Merck & Co., Inc	ORAL
430	DAY						
		Injury		Avandia	SS		
		Jugular Vein Distension		Atenolol	C		
		Mitral Valve		Lanoxin	C		
		Calcification		Vasotec	C		ORAL
		Mitral Valve Incompetence		Ultram	C		
		Myocardial Infarction		Premarin	C		
		Pain In Extremity		Lasix (Furosemide)	C		
		Sleep Apnoea Syndrome		Lasix (Furosemide)	C		
		Tricuspid Valve		Glipizide	C		
		Incompetence		Levothyroxine Sodium	C		
		Urinary Tract Infection		Glucophage	C		
		Varicose Vein		Nifedipine	C		
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					

Date:02/03/04ISR Number: 4284304-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01262
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
521	DAY						
Initial or Prolonged		Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
521	DAY						
Disability		Atrioventricular Block		Aspirin	C		
Other		First Degree		Lipitor	C		
		Cardiac Disorder		Synthroid	C		
		Cardiac Murmur					
		Carotid Bruit					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Coronary Artery					
		Thrombosis					
		Dilatation Atrial					
		Dyspnoea					

Electrocardiogram St-T
Change
Graft Thrombosis
Hypertension
Injury
Inner Ear Disorder
Mitral Valve
Calcification
Oedema Peripheral
Rotator Cuff Syndrome
Ventricular Hypertrophy

Date:02/03/04ISR Number: 4284305-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01368
Age:47 YR Gender:Female I/FU:F

Outcome PT
Disability Blood Pressure Increased
Cardiac Murmur
Chronic Obstructive
Pulmonary Disease

		Depression					
		Diabetes Mellitus					
		Dyspnoea Exacerbated	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emphysema		Vioxx	PS	Merck & Co., Inc	ORAL
586	DAY						
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
586	DAY						
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Lung Infection		Darvocet-N	C		
		Muscle Spasms		Albuterol	C		
		Oedema Peripheral		Proventil	C		
		Osteoarthritis		Zithromax	C		
		Wheezing		Atacand	C		
				Biaxin	C		
				Flovent	C		
				Advair	C		
				Foradil	C		
				Furosemide	C		
				Guaifenesin	C		
				Meclizine	C		
				Methylprednisolone	C		
				Oxycontin	C		

Date:02/03/04ISR Number: 4284306-5Report Type:Expedited (15-DaCompany Report #WAES 0311USA01214
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
				Amitriptyline Hydrochloride	C		
				Antimicrobial (Unspecified)	C		

Date:02/03/04ISR Number: 4284307-7Report Type:Expedited (15-DaCompany Report #WAES 0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anaemia Macrocytic
Disability	Angiodysplasia

Other	Anxiety
	Asthenia
	Cardiac Murmur
	Chest Discomfort
	Depression
	Diverticular Perforation
	Dizziness
	Dyspnoea Exertional
	Faecal Occult Blood Positive
	Faeces Discoloured
	Gastritis
	Gastrointestinal Haemorrhage
	Hyperlipidaemia
	Hypertension
	Melaena
	Muscle Spasms
	Osteoarthritis
	Pallor

		Palpitations					
		Polyp Colorectal					
		Post Procedural	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complication	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Small Intestinal	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Lipitor	C		
				Celebrex	C		
				Zoloft	C		
				Triamterene	C		
				Voltaren	C		
				Duragesic	C		
TOPICAL							
				Dyazide	C		
				Metoprolol	C		
				Lopressor	C		
				Prilosec	C		
				Denavir	C		

Date:02/03/04ISR Number: 4284324-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA01433
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
157	DAY						
Initial or Prolonged		Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL
157	DAY						
Disability		Arthropathy		Hyzaar	C		ORAL
		Atrial Fibrillation					
		Blood Cholesterol					
		Increased					
		Cardioactive Drug Level					
		Increased					
		Cholelithiasis					
		Colitis					
		Gastric Disorder					
		Glaucoma					
		Hepatic Steatosis					

Hepatomegaly
Hormone Level Abnormal
Myocardial Infarction
Nephrolithiasis
Oedema Peripheral
Oesophageal Spasm
Overdose
Palpitations
Prinzmetal Angina
Road Traffic Accident
Stress
Venous Insufficiency

Date:02/03/04ISR Number: 4284325-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA01988
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluid Retention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/04ISR Number: 4284327-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02216
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Coronary Artery	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
Disability	Atherosclerosis		Fosamax	C		ORAL		
	Coronary Artery Disease		Zocor	C		ORAL		
	Coronary Artery Occlusion		Synthroid	C				
	Diverticulum Intestinal		Prilosec	C				
	Dizziness							
	Dyspepsia							
	Ejection Fraction							
	Decreased							
	Hypothyroidism							
	Muscle Strain							
	Myocardial Infarction							
	Osteoporosis							
	Polytraumatism							
	Sinus Tachycardia							

Date:02/03/04ISR Number: 4284328-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA01980
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Barrett'S Oesophagus		Aspirin	C				
Other	Blood Pressure Systolic		Atenolol	C				
	Increased		Tums	C				
	Cardiac Failure		Adalat	C		ORAL		
	Congestive		Prilosec	C				
	Dehydration							
	Depression							
	Diabetes Mellitus							
	Dizziness							
	Faecal Occult Blood							
	Positive							
	Fatigue							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Lipids Abnormal							

Myocardial Infarction
Oedema Peripheral
Oesophageal Ulcer
Prostate Cancer
Upper Gastrointestinal
Haemorrhage

Date:02/03/04ISR Number: 4284329-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01364
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tuberculosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				
			Theo-Dur	C		ORAL		

				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Soma	C		ORAL
				Hydrochlorothiazide	C		ORAL
				Hydrochlorothiazide	C		ORAL
				Atrovent	C		
RESPIRATORY							
(INHALATION)							

Date:02/03/04ISR Number: 4284331-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01289
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1 MON
	Cough		Tylenol	C				
	Gastric Disorder		Amitriptyline					
	Hypertension		Hydrochloride	C				
	Injury		Lotrel	C				
	Overdose		Premarin	C				
	Stress		Lopressor	C				
	Tricuspid Valve		Prilosec	C				
	Incompetence		Rabeprazole Sodium	C				

Date:02/03/04ISR Number: 4284656-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Decreased	Professional	Xanax	C				
	Coronary Artery Disease		Aspirin	C				
	Coronary Artery Stenosis		Celebrex	C				
	Depression		Zyrtec	C				
	Emotional Distress		Prozac	C				
	Heart Rate Decreased		Zestril	C				
	Hyperhidrosis		Naproxen	C				

	Myocardial Infarction	Prilosec	C
	Myocardial Ischaemia		
	Nausea		
	Oedema Peripheral		
	Sinus Bradycardia		
	Tremor		
	Ventricular Hypokinesia		
	Vomiting		

Date:02/03/04ISR Number: 4284660-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Disorder
	Asthenopia
Disability	Back Pain
	Binocular Eye Movement Disorder
	Blood Sodium Decreased
	Cerebral Haemorrhage
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome

		Depression					
		Diplopia					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Endocarditis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Gastrooesophageal Reflux	Professional	Aspirin	C		
		Disease		Tagamet	C		
		Generalised Anxiety		Premarin	C		
		Disorder		Estratab	C		
		Haematochezia		Hytrin	C		
		Heterophoria		L-Thyroxin	C		
		Hypertension		Prinivil	C		ORAL
		Hypoacusis		Ranitidine	C		
		Injury					
		Migraine With Aura					
		Nasal Congestion					
		Non-Cardiac Chest Pain					
		Pain In Extremity					
		Pain In Jaw					
		Panic Disorder					
		Paraesthesia					
		Sleep Apnoea Syndrome					
		Strabismus					
		Thalamus Haemorrhage					
		Transient Ischaemic					
		Attack					
		Ventricular Hypertrophy					

Date:02/03/04ISR Number: 4284669-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Activities Of Daily	Health	Vioxx	PS	Merck & Co., Inc	ORAL
80	DAY						
		Living Impaired	Professional	[Therapy			
		Anxiety		Unspecified]	C		
		Breast Disorder		Ascorbic Acid	C		
		Cardiac Failure		Calcium			
		Congestive		(Unspecified)	C		
		Congestive Cardiomyopathy		Lanoxin	C		
		Difficulty In Walking		Premarin	C		
		Dizziness		Lasix (Furosemide)	C		
		Hypertension		Vitamin E	C		

Impaired Work Ability	Coumadin	C	
	Vitamin B (Unspecified)	C	
	Ginkgo Biloba Extract	C	
	Levocarnitine	C	
	Prinivil	C	ORAL
	Magnesium (Unspecified)	C	
	Pamelor	C	

Date:02/03/04ISR Number: 4284675-6Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00240
Age:85 YR Gender:Female I/FU:I

Outcome	PT
Other	Aspartate Aminotransferase Increased

	Blood Alkaline Phosphatase Increased Liver Function Test	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY

Date:02/03/04ISR Number: 4284679-3Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00175
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Genital Pruritus Female	Health	Vioxx	PS	Merck & Co., Inc	ORAL	907 DAY
		Professional	Acetaminophen	C		ORAL	

Date:02/03/04ISR Number: 4284680-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA02168
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL	
	Coronary Artery Occlusion						
	Injury						
	Myocardial Infarction						

Date:02/03/04ISR Number: 4285343-7Report Type:Direct Company Report #CTU 211415
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Post Procedural		Aspirin	PS		ORAL	81 MG PO
Initial or Prolonged	Haemorrhage		Rofecoxib	SS			
	Rectal Haemorrhage		Donepezil	C			
	Syncope		Furosemide Te	C			
			Terazosin	C			
			Insulin	C			
			Carbidopa/Levodopa	C			

Date:02/03/04ISR Number: 4285712-5Report Type:Expedited (15-DaCompany Report #2004CG00167
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hallucination, Visual	Foreign	Atacand	PS				
		Health	Colopriv	SS				
		Professional	Di-Antalvic	SS				
		Other	Lexomil	SS				
			Lanzor	SS				
			Vioxx	SS				
			Temesta	C				

Date:02/04/04ISR Number: 4285038-XReport Type:Expedited (15-DaCompany Report #WAES 0306FRA00016
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura	Health	Vioxx	PS	Merck & Co., Inc	ORAL		299 DAY
	Skin Ulcer	Professional	Amlodipine Maleate	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		
			Vaseretic	C		ORAL		

Date:02/04/04ISR Number: 4285040-8Report Type:Expedited (15-DaCompany Report #WAES 0310ZAF00031
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		366 DAY
	Oedema Peripheral	Professional	Allopurinol	C		ORAL		
	Pulmonary Congestion		Aspirin Calcium	C		ORAL		
	Wheezing		Aspirin Calcium	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Magnesium Chloride	C				

Date:02/04/04ISR Number: 4285042-1Report Type:Expedited (15-DaCompany Report #WAES 0401ZAF00007
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc			
	Air Embolism	Professional	Albuterol	C				
RESPIRATORY								
	Bradycardia							
(INHALATION)								
	Cerebrovascular Accident		Aspirin	C				
	Chest Discomfort		Clopidogrel					
	Hypoaesthesia Oral		Bisulfate	C		ORAL		
	Lethargy		Estradiol	C		ORAL		
	Loss Of Consciousness		Fluticasone					
	Pruritus		Propionate	C				
RESPIRATORY								
	Rash							
(INHALATION)								
	Rectal Cancer		Formoterol Fumarate	C				
	Transient Ischaemic		Irbesartan	C		ORAL		
	Attack		Piroxicam	C		ORAL		

Date:02/04/04ISR Number: 4285044-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA02199
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Injury		Aspirin	C
	Intestinal Obstruction			
	Ulcer			

Date:02/04/04ISR Number: 4285047-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Chloride Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL
	Carotid Artery Stenosis		Soma	C		
	Cerebrovascular Accident		Motrin	C		
	Cough		Lamisil	C		
	Eye Disorder					
	Fall					
	Hypertension					
	Injury					
	Mastoiditis					
	Mucous Membrane Disorder					
	Muscle Strain					
	Nausea					
	Oedema Peripheral					

Date:02/04/04ISR Number: 4285050-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Atherosclerosis		Betaxolol Ophthalmic Solution	C		
	Blood Pressure Decreased		Calcitonin	C		
	Cardiac Murmur		Digoxin	C		
	Cerebrovascular Accident		Docusate Sodium	C		
	Coronary Artery Stenosis		Trusopt	C		
	Epistaxis		Zocor	C		
OPHTHALMIC	Heart Rate Decreased		Warfarin	C		
	Hypertension		Vitamin E	C		
1284 DAY	Lacunar Infarction		Folic Acid	C		
	Muscle Spasms		Lasix (Furosemide)	C		
	Myalgia		Isosorbide	C		
1680 DAY	Nuclear Magnetic Resonance Imaging Abnormal		Potassium (Unspecified)	C		
	Pleural Fibrosis		Psyllium Husk	C		
	Productive Cough					
	Transient Ischaemic Attack					

Date:02/05/04ISR Number: 4285978-1Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00044
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Rash		Vioxx	PS	Merck & Co., Inc	ORAL
106 DAY			Coal Tar And Allantoin	C		
			Fentanyl	C		
89 DAY			Tramadol Hydrochloride	C		
			Morphine Sulfate	C		
			Psyllium Husk And Senna	C		

Date:02/05/04ISR Number: 4285989-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01853
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fall		[Therapy					
Initial or Prolonged	Fracture		Unspecified]	C				
Disability	Gastrointestinal		Actos	C				
Other	Haemorrhage							

Date:02/05/04ISR Number: 4285992-6Report Type:Expedited (15-DaCompany Report #WAES 0402USA00065
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		432 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/05/04ISR Number: 4285993-8Report Type:Expedited (15-DaCompany Report #WAES 0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 15 DAY	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Atherosclerosis		Fosamax	C		ORAL
	Bradycardia		Celebrex	C		
	Coronary Artery Disease		Celebrex	C		
	Electrocardiogram St		Celebrex	C		
	Segment Elevation		Celebrex	C		
	Electrocardiogram T Wave		Duragesic	C		
	Abnormal					
	Hypertension					
	Injury					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Nervousness					
	Radiculitis Cervical					
	Ventricular Hypertrophy					

Date:02/05/04ISR Number: 4285995-1Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Application Site		Vioxx	SS	Merck & Co., Inc	ORAL
	Irritation		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Bronchitis		Aspirin	C		
	Chest Pain		Tenormin	C		
	Coronary Artery Disease		Tenormin	C		
	Cough		Lipitor	C		
	Diverticulum		Clonidine	C		
TOPICAL						
	Gastritis		Clonidine	C		ORAL
	Gastrooesophageal Reflux		Monopril	C		
	Disease		Ibuprofen	C		
	Groin Pain		Anaprox	C		

Haemorrhoids
Hypertension
Joint Crepitation
Lower Respiratory Tract
Infection
Mitral Valve Incompetence
Musculoskeletal Stiffness
Nasopharyngitis
Pleural Effusion
Rectal Haemorrhage
Skin Irritation
Sleep Apnoea Syndrome
Tension Headache
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Weight Increased

Date:02/05/04ISR Number: 4285999-9Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00036
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		26 DAY
Initial or Prolonged	Haemoglobin Decreased		Fosamax	SS		ORAL		32 DAY
	Melaena		Aspirin	SS		ORAL		5 DAY
	Rectal Haemorrhage		Donepezil Hydrochloride	SS				26 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C				
			Lactulose	C				
			Senna	C				
			Simvastatin	C				
			Nutritional Supplements	C		ORAL		
			Nutritional Supplements	C		ORAL		
			Magnesium Hydroxide	C				
			Indapamide	C				
			Benserazide Hydrochloride And Levodopa	C				
			Calcium Carbonate And Cholecalciferol	C				

Date:02/05/04ISR Number: 4286001-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Aspirin	C				
	Blood Cholesterol		Celebrex	C				
	Increased		Sudal	C				
	Catheter Site Haemorrhage		Ultram	C				
	Coronary Artery Disease		Levaquin	C				
	Coronary Artery Stenosis		Synthroid	C				

Costochondritis	Zantac	C
Diarrhoea		
Diastolic Dysfunction		
Drug Withdrawal Syndrome		
Dyspnoea		
Gastrooesophageal Reflux Disease		
Haemarthrosis		
Libido Decreased		
Musculoskeletal Chest Pain		
Myocardial Infarction		
Neuralgia		
Oedema		
Pain		
Panic Attack		
Pneumonia		
Spinal Osteoarthritis		
Stress Incontinence		

Date:02/05/04ISR Number: 4286006-4Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00049
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/05/04ISR Number: 4286007-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA01616
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropod Bite	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dermatitis Contact		Allopurinol	C				
	Hepatic Cyst		Kenalog	C			PARENTERAL	
	Hepatic Steatosis		Trazodone					
	Hypertensive		Hydrochloride	C			111 DAY	
	Cardiomyopathy		Celexa	C				
	Intracardiac Thrombus		Colchicine	C				
	Nephrosclerosis		Indocin					
	Nerve Injury		(Indomethacin)	C		ORAL		
	Neuropathy		Ultram	C				
	Radiculopathy		Bactroban	C				
	Skin Burning Sensation		Serzone	C				
	Sleep Disorder		Prednisone	C		ORAL		
	Treatment Noncompliance							

Date:02/05/04ISR Number: 4286008-8Report Type:Expedited (15-DaCompany Report #WAES 0312USA02504
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	

Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional
Other	Haematocrit Decreased	
	Melaena	

Date:02/05/04ISR Number: 4286009-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA00066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:02/05/04ISR Number: 4286010-6Report Type:Expedited (15-DaCompany Report #WAES 0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anxiety
Disability	Bacteria Urine
Other	Blood Cholesterol Increased
	Cardiac Failure

		Congestive					
		Cardiac Murmur					
		Constipation					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Surgery		Aspirin	C		
		Crepitations		Atenolol	C		
		Diabetes Mellitus		Cyclobenzaprine			
		Non-Insulin-Dependent		Hydrochloride	C		ORAL
		Dyspnoea		Lasix (Furosemide)	C		
		Exostosis		Novolin	C		
SUBCUTANEOUS							
		Gallop Rhythm Present		Ultram	C		
		Gastrooesophageal Reflux		Novolin	C		
SUBCUTANEOUS							
		Disease		Zestril	C		
		Herpes Zoster		Procardia	C		
		Hypertension		Trental	C		
		Injury		Potassium			
		Intervertebral Disc		(Unspecified)	C		
		Degeneration		Ranitidine	C		
		Joint Range Of Motion					
		Decreased					
		Lumbar Radiculopathy					
		Lung Neoplasm					
		Muscle Spasms					
		Myocardial Infarction					
		Oedema Peripheral					
		Peripheral Vascular					
		Disorder					
		Pneumonitis					
		Renal Artery Stenosis					
		Silent Myocardial					
		Infarction					
		Spinal Column Stenosis					
		Urinary Tract Infection					

Date:02/05/04ISR Number: 4286018-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
18 MON							

Initial or Prolonged Disability	Arthralgia Back Pain Cardiac Failure Congestive Chest Pain Deep Vein Thrombosis Dizziness Dyspnoea Hodgkin'S Disease Hyperhidrosis Hypertension Intervertebral Disc Degeneration Joint Swelling Non-Hodgkin'S Lymphoma Oedema Peripheral Skin Cancer Weight Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL 18 MON

Date:02/05/04ISR Number: 4286024-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Coronary Artery		Xanax	C				
	Atherosclerosis		Aspirin	C				
	Coronary Artery		Lipitor	C				
	Thrombosis		Wellbutrin	C				
	Dyslipidaemia		Celebrex	C				
	Ecchymosis		Plavix	C				
	Haematoma		Folic Acid	C				
	Major Depression		Toprol Xl Tablets	C				
	Myocardial Infarction		Pyridoxine	C				
	Panic Disorder							
	Patellofemoral Pain Syndrome							

Date:02/05/04ISR Number: 4286354-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00023
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Other			Etodolac	C		ORAL		
			Nebivolol	C		ORAL		
			Ramipril	C		ORAL		
			Ranitidine	C		ORAL		
							3	DAY

Date:02/05/04ISR Number: 4286356-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA01359
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization -	Pain							

Initial or Prolonged	Renal Failure Acute
Disability	Renal Tubular Necrosis
Other	

Date:02/05/04ISR Number: 4286358-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA01228
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive					
	Fall					
	Hip Fracture					
	Sepsis					
	Upper Limb Fracture					

Date:02/05/04ISR Number: 4286359-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Other	Amnesia
	Blood Cholesterol Increased

Ischaemic Stroke

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	56	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	156	DAY
			Celebrex	C				

Date:02/05/04ISR Number: 4286360-3Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Coronary Artery Disease		Estradiol Valerate					
	Coronary Artery Stenosis		And Norethindrone	C		ORAL		
	Myocardial Ischaemia		Omeprazole	C		ORAL	1	DAY

Date:02/05/04ISR Number: 4286361-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY

Date:02/05/04ISR Number: 4289124-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02145
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Study	Tab Vioxx Unk	PS			25 MG DAILY	
Initial or Prolonged	Abdominal Pain Upper	Health	Benicar	C				
Other	Biliary Colic	Professional	Celexa	C				
	Blood Sodium Decreased		Lipitor	C				
	Chest Pain		Percocet	C				

	Cholelithiasis	Prilosec	C
	Diverticulum	Provera	C
	Dyspnoea	Remicade	C
	Gastritis	Valtrex	C
	Haematocrit Decreased	Vicodin Tablets	C
	Haemoglobin Decreased	Aspirin	C
	Ileus	Folic Acid	C
	Rectal Haemorrhage	Methotrexate	C
		Pre-Therapy	C
		Prednisone	C

Date:02/06/04ISR Number: 4286637-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01296
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Disability	Back Pain
	Blood Cholesterol Increased
	Bunion
	Bursitis
	Carotid Artery Atheroma
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Pain
	Diabetes Mellitus

	Dizziness					
	Fall					
	Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	MON					
		Professional	Lipitor	C		
			Premarin	C		ORAL
			Allegra	C		
			Covera	C		
			Claritin-D 12 Hour	C		ORAL
			Adalat	C		ORAL
			Zantac	C		

Date:02/06/04ISR Number: 4286645-0Report Type:Expedited (15-DaCompany Report #WAES 00091403
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Abnormal Faeces
	Adverse Event
	Alopecia
	Antiphospholipid Antibodies Positive
	Aphasia
	Aphthous Stomatitis
	Arthralgia
	Arthritis
	Asthenia
	Back Pain
	Balance Disorder
	Burning Sensation
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Cervical Cyst
	Coagulopathy
	Constipation
	Convulsion
	Depression
	Difficulty In Walking
	Drug Hypersensitivity
	Emotional Distress
	Fall

Fatigue
Feeling Abnormal
Feeling Cold
Fluid Retention
Gingival Infection
Head Injury
Headache
Herpes Virus Infection
Hot Flush
Hypersensitivity
Hypoaesthesia
Injury
Insomnia
Intervertebral Disc
Degeneration
Memory Impairment
Muscle Spasms

		Myalgia					
		Nail Ridging					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
392	DAY						
		Neuropathy Peripheral	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Oedema Peripheral		Tylenol	C		
		Pain		Fioricet Tablets	C		
		Pain In Extremity		Fioricet Tablets	C		
		Paraesthesia		Aspirin	C		
		Rash		Zithromax	C		
		Sciatica		Cimicifuga	C		
		Sinusitis		Ambien	C		
		Speech Disorder		Celexa	C		
		Transient Ischaemic		Dipyridamole	C		
		Attack		Prempro	C		
		Vision Blurred		Lasix (Furosemide)	C		
927	DAY						
		Vomiting		Advil	C		
		Weight Increased		Motrin	C		

Date:02/06/04ISR Number: 4286650-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Abdominal Adhesions	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Asthma	Professional	Catapres	C		
347	DAY						
Initial or Prolonged		Bacterial Infection		Lasix (Furosemide)	C		
Other		Blood Disorder		Micardis	C		
		Cardiac Failure		Lasix (Furosemide)	C		
		Congestive		Cozaar	C		
		Cholecystitis Chronic					
		Cholesterosis					
		Chronic Obstructive					
		Pulmonary Disease					
		Dyspepsia					
		Dyspnoea					
		Gastrooesophageal Reflux					
		Disease					
		Glaucoma					
		Gynaecomastia					

Hepatic Steatosis
Hypercapnia
Hyperglycaemia
Hypoxia
Incisional Hernia
Low Density Lipoprotein
Increased
Malnutrition
Obesity
Pickwickian Syndrome
Postoperative Fever
Pulmonary Embolism
Pulmonary Hypertension
Refractory Anaemia
Rheumatoid Arthritis
Sleep Apnoea Syndrome
Staphylococcal Infection
Thrombosis
Umbilical Hernia
Umbilical Hernia Repair

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/04ISR Number: 4286657-7Report Type:Expedited (15-DaCompany Report #WAES 0401NOR00020
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiogenic Shock	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Aspirin And Magnesium Oxide	SS		ORAL		
	Haematemesis		Allopurinol	C		ORAL		
	Melaena		Ranitidine Hydrochloride	C		ORAL		

Date:02/06/04ISR Number: 4286658-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA02152
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Infarction		[Therapy Unspecified]	C				
			Bufferin	C				
			Plavix	C				
			Isoket	C				

Date:02/06/04ISR Number: 4286952-1Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00100
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation		Aspirin	C				
			Ferrous Sulfate	C				
			Pantoprazole	C				

Date:02/06/04ISR Number: 4286953-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Aortic Valve Incompetence

Initial or Prolonged	Benign Prostatic
Disability	Hyperplasia
Other	Blood Glucose Increased
	Blood Pressure Diastolic
	Increased
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Colon Adenoma
	Constipation
	Cranial Nerve Palsies
	Multiple
	Depression
	Dizziness
	Dry Mouth
	Dysgeusia
	Dyspepsia
	Ejection Fraction
	Decreased
	Epicondylitis
	Facial Palsy
	Fatigue
	Headache

		Hemiparesis					
		Hypercholesterolaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Low Density Lipoprotein		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Micturition Urgency		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Neurogenic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash Erythematous		Vioxx	SS	Merck & Co., Inc	ORAL
		Trigger Finger		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Urinary Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
		Zinc Deficiency		Monopril	C		
1183	DAY						
				Monopril	C		
				Ambien	C		
				Effexor	C		
				Zocor	C		ORAL
2099	DAY						
				Prevacid	C		
				Prevacid	C		
				Levaquin	C		
				Levaquin	C		
				Naprosyn	C		
				Naprosyn	C		
				Zantac	C		

Date:02/06/04ISR Number: 4286954-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA00067
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
109	DAY						

Date:02/06/04ISR Number: 4286955-7Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00008
Age:90 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Drug Eruption Dysphagia Facial Palsy Hemiplegia Multi-Organ Failure Pneumonia Aspiration Skin Ulcer

Date:02/06/04ISR Number: 4286958-2Report Type:Expedited (15-DaCompany Report #WAES 0402USA00068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	133	DAY

Date:02/06/04ISR Number: 4286959-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA02136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/06/04ISR Number: 4286960-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA00840
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Infarction		Vicodin Tablets	C				
	Feeling Abnormal		Flonase	C				
	Loss Of Consciousness		Vitamins					
	Pain In Extremity		(Unspecified)	C				
			Motrin	C				
			Serzone	C				

Date:02/06/04ISR Number: 4286961-2Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00075
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coagulopathy		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Cytolytic Hepatitis		Acetaminophen	C		ORAL	3	DAY
	Hepatic Necrosis							
	Hepatitis Cholestatic							
	Influenza Like Illness							

Date:02/06/04ISR Number: 4286963-6Report Type:Expedited (15-DaCompany Report #WAES 0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Infarction		Vicodin Tablets	C				
Other	Coronary Artery Occlusion		Aspirin	C				
	Fatigue		Ultram	C				
	Influenza		Ultram	C				
	Injury		Advil	C				
	Mitral Valve Incompetence		Advil	C				
	Nervousness							
	Pneumonia							

Pneumonia Influenzal
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Date:02/06/04ISR Number: 4290207-9Report Type:Expedited (15-DaCompany Report #200410413BCC
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Convulsion	Consumer Other	Aleve (Naproxen Sodium)	PS		ORAL	ORAL	
			Celebrex (Celecoxib)	SS		ORAL	ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	

Date:02/06/04ISR Number: 4290391-7Report Type:Direct Company Report #CTU 211785
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Dermatitis Exfoliative Oedema Peripheral Skin Tightness Swelling Face		Vioxx 25 Mg Tablets Merk	PS	Merk	ORAL	2 TABLET ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4288682-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Lipitor	C		
	Coronary Artery Disease		Lotensin	C		
	Depression		Lotensin	C		
	Ischaemia		Vasotec	C		ORAL
	Osteoarthritis		Vasotec	C		ORAL
	Sinus Tachycardia		Prozac	C		
	Stress		Prozac	C		
			Prozac	C		
			Ginseng	C		
			Naproxen	C		
			Accupril	C		
			Accupril	C		

Date:02/09/04ISR Number: 4288686-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Anxiety
	Arteriosclerosis
	Back Pain
	Blood Cholesterol Increased
	Cardiac Valve Replacement Complication
	Carotid Artery Atheroma
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dilatation Atrial
	Disturbance In Attention
	Drug Ineffective
	Duodenitis
	Gastritis
	Gastrointestinal Haemorrhage
	Haematochezia
	Hypertension
	Hypokalaemia
	Laryngitis

Migraine
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Orthostatic Hypotension
Palpitations
Pelvic Peritoneal
Adhesions
Phlebothrombosis
Photophobia
Stent Occlusion
Supraventricular
Extrasystoles
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Ventricular Hypokinesia

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/09/04ISR Number: 4288702-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Azotaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Tylenol	C				
	Colonic Polyp		Acetaminophen And Propoxyphene					
	Coronary Artery Disease		Napsylate	C				
	Coronary Artery Stenosis		Xanax	C				
	Epidermal Naevus		Aspirin	C				
	Fall		Librax Capsules	C				
	Generalised Anxiety Disorder		Cyclobenzaprine Hydrochloride	C				
	Haematoma		Allegra	C				
	Hypercholesterolaemia		Prilosec	C				
	Hypertension		Zantac	C				
	Intervertebral Disc Degeneration							
	Irritable Bowel Syndrome							
	Myocardial Infarction							
	Sleep Disorder							
	Tendonitis							
	Urinary Tract Infection							

Date:02/09/04ISR Number: 4288703-3Report Type:Expedited (15-DaCompany Report #WAES 0312USA00076
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Drug Reaction
Hospitalization - Initial or Prolonged	Asthma
	Blood Albumin Decreased
Other	Blood Alkaline Phosphatase Increased
	Cardiac Failure

Congestive
Cardiomegaly
Chest X-Ray Abnormal
Chronic Obstructive
Airways Disease
Exacerbated
Chronic Obstructive
Pulmonary Disease
Confusional State
Dyspnoea
Fluid Retention
Fungal Rash
Hypersensitivity
Hypoxia
Pickwickian Syndrome
Pulmonary Oedema
Respiratory Distress
Sinus Congestion

Sleep Apnoea Syndrome
Somnolence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	14	DAY
	Vicodin Tablets	C		ORAL		
	Albuterol	C		ORAL		
	Bumex	C		ORAL		
	Nexium	C		ORAL		
	Pepcid	C		ORAL		
	Flonase	C				
	Maxzide	C		ORAL		
	Reglan	C				
	Nystatin	C				

Date:02/09/04ISR Number: 4288708-2Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00013
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea Haemorrhagic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Other	Malaise	Professional	Acetaminophen And Codeine Phosphate	C				
			Mometasone Furoate	C				

RESPIRATORY

(INHALATION)

Date:02/09/04ISR Number: 4288709-4Report Type:Expedited (15-DaCompany Report #WAES 0306USA02099
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Acute Respiratory Distress Syndrome
	Acute Respiratory Failure
	Adverse Event
	Angina Pectoris

Atrial Tachycardia
Brain Hypoxia
Cardiac Failure
Congestive
Cardiogenic Shock
Coronary Artery Disease
Depression
Ejection Fraction
Decreased
Emotional Distress
Encephalopathy
Hypercholesterolaemia
Hyperphosphataemia
Hypokalaemia
Hyponatraemia
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Lung Infiltration
Mental Status Changes
Multi-Organ Failure
Muscle Haemorrhage
Oedema Peripheral
Panic Disorder

		Pleural Effusion					
		Proteus Infection					
		Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombocytopenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Tract Infection	Professional	Oxycodone	C		
		Ventricular Fibrillation		Ultram	C		
		Ventricular Tachycardia		Diovan	C		
				Zantac	C		

Date:02/09/04ISR Number: 4288711-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
560 DAY							
Initial or Prolonged		Back Pain		Nexium	C		
Disability		Blood Cholesterol		Lasix (Furosemide)	C		
		Increased		Lasix (Furosemide)	C		
		Blood Triglycerides		Diovan	C		
		Increased		Torsemide	C		
		Cerebrovascular Accident		Zaroxolyn	C		
		Chest Pain		Oxycontin	C		
		Chronic Fatigue Syndrome					
		Depression					
		Fluid Retention					
		Haematochezia					
		Hypoxia					
		Lobar Pneumonia					
		Low Density Lipoprotein					
		Increased					
		Myocardial Infarction					
		Pneumonia					
		Rash					
		Renal Failure Acute					

Date:02/09/04ISR Number: 4288714-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA00838
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Blood Potassium Decreased	Professional	Aspirin	C
Disability	Burns Second Degree		Glucosamine	C
Other	Cardiomegaly		Hytrin	C
	Cerebral Infarction		Levothyroxine Sodium	C
	Cerebrovascular Accident			
	Deafness Neurosensory			
	Depression			
	Emotional Distress			
	Myocardial Infarction			
	Myofascial Pain Syndrome			
	Neurogenic Bladder			
	Osteoarthritis			
	Platelet Count Decreased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4288724-0Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00005
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Biopsy Oesophagus	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Abnormal Gastrointestinal Stenosis		Lisinopril	C		ORAL		
	Oesophagitis		Oxazepam	C		ORAL		

Date:02/09/04ISR Number: 4288941-XReport Type:Expedited (15-DaCompany Report #PHNR2004AU00524
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia	Health Professional	Lopressor	PS	Novartis Sector: Pharma	ORAL	50 mg, QD	
	Chest Pain							
	Dyspnoea		Zestril	SS		ORAL	20 mg, QD	
	Nausea		Colgout	SS		ORAL	500 ug, QD	
	Pulmonary Fibrosis		Natrilix - Slow Release	SS		ORAL	1.5 mg, QD	
	Syncope							
			Aratac	SS		ORAL	200 mg, QD	
			Vioxx	SS		ORAL	12.5 mg, QD	
			Monodur	SS		ORAL	60 mg, QD	
			Coumadin "Boots"	SS		ORAL	3 mg, QD	

Date:02/09/04ISR Number: 4289055-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02027
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blindness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Premarin	C				
	Medication Error		Motrin	C				

	Spondylitis		Progesterone	C
	Urinary Tract Infection			
	Vision Blurred			
	Visual Field Defect			

Date:02/09/04ISR Number: 4289057-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 319 DAY	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 319 DAY	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Decreased Activity		Xanax	C		
Other	Diabetes Mellitus		Diovan	C		
	Drug Ineffective		Ibuprofen	C		
	Dyspnoea		Humulin N	C		
	Fluid Retention					
	Hypertension					
	Lung Disorder					
	Myocardial Infarction					
	Oedema					
	Osteoarthritis					
	Thyroid Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4289058-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
Other	Depression							
	Erectile Dysfunction							
	Heart Rate Irregular							
	Hypertension							
	Hypoaesthesia							
	Orchitis							
	Osteoarthritis							
	Pain							
	Paraesthesia							
	Peripheral Coldness							
	Pyrexia							
	Respiratory Rate Increased							
	Tachycardia							
	Urinary Incontinence							

Date:02/09/04ISR Number: 4289059-2Report Type:Expedited (15-DaCompany Report #WAES 0402USA00262
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:02/09/04ISR Number: 4289060-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Chest Wall Pain							
	Dizziness							
	Dyspnoea							
	Heart Rate Increased							

Myocardial Infarction

Date:02/09/04ISR Number: 4289061-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA02789
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Adjustment Disorder With
Hospitalization -	Depressed Mood
Initial or Prolonged	Asthenia
	Depression
	Dermatitis Allergic
	Diverticulum Intestinal
	Haemorrhagic
	Eye Pain
	Gastrointestinal Tract
	Adenoma
	Hypertension
	Lower Gastrointestinal
	Haemorrhage
	Muscle Spasms
	Post Procedural

Complication						
Rectal Haemorrhage						
Road Traffic Accident						
Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Lortab	C				
		Ascorbic Acid	C				
		Vitamin B Complex	C		ORAL		
		Vitamins (Unspecified)	C				

Date:02/09/04ISR Number: 4289062-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
Disability	Amnesia
	Anaemia
	Anxiety
	Atelectasis
	Blood Cholesterol Increased
	Blood Sodium Decreased
	Bundle Branch Block Right
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Confusional State
	Coronary Artery Disease
	Diabetes Mellitus Inadequate Control
	Emotional Distress
	Fall
	Gait Disturbance
	Heart Rate Increased
	Hypertension
	Hypokalaemia
	Influenza Like Illness
	Mitral Valve Incompetence
	Myocardial Infarction
	Myocardial Ischaemia

Nasopharyngitis
Oedema Peripheral
Palpitations
Post Procedural
Complication
Pulmonary Congestion
Rotator Cuff Syndrome
Sinus Tachycardia
Supraventricular
Tachycardia
Syncope
Transient Ischaemic
Attack
Treatment Noncompliance
Ventricular Hypertrophy
Ventricular Hypokinesia

Vision Blurred

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	5	MON
			Aspirin	C				
			Lasix (Furosemide)	C				
			Glucotrol Xl	C				
			Glyburide	C				
			Ativan	C				
			Lopressor	C				
			Orphenadrine	C				

Date:02/09/04ISR Number: 4289063-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA01135
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL	433	DAY
Initial or Prolonged	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	433	DAY
Disability	Cerebrovascular Accident		Acetaminophen And Hydrocodone Bitartrate	C				
	Depression		Celebrex	C				
	Diabetes Mellitus							
	Emotional Distress							
	Eye Disorder							
	Glaucoma							
	Hypertension							
	Prostatic Disorder							
	Sleep Disorder							
	Surgery							

Date:02/09/04ISR Number: 4289065-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Clonidine	C				

Back Pain
Cerebrovascular Accident
Chest Pain
Chronic Fatigue Syndrome
Dizziness
Emotional Disorder
Gastrooesophageal Reflux
Disease
Headache
Hernia
Hypertension
Insomnia
Neck Pain
Peripheral Vascular
Disorder
Renal Failure
Road Traffic Accident
Stress
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4289066-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		92 DAY
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bladder Disorder		Duragesic	C				
	Cerebral Artery Occlusion		Prevacid	C				
	Depression		Effexor	C				
	Disturbance In Attention							
	Drug Ineffective							
	Drug Withdrawal Syndrome							
	Dyskinesia							
	Dyspepsia							
	Dysuria							
	Feeling Abnormal							
	Gait Disturbance							
	Hemiparesis							
	Hyperreflexia							
	Hypoaesthesia							
	Intermittent Claudication							
	Ischaemic Cerebral							
	Infarction							
	Ischaemic Stroke							
	Memory Impairment							
	Mental Impairment							
	Motor Dysfunction							
	Neck Pain							
	Nephrolithiasis							
	Oesophageal Disorder							
	Pain							
	Reflexes Abnormal							
	Spinal Column Stenosis							
	Spinal Disorder							
	Visual Acuity Reduced							

Date:02/09/04ISR Number: 4289067-1Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00075
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Coagulopathy		Vioxx	PS	Merck & Co., Inc	ORAL	
3 DAY							
Initial or Prolonged	Cytolytic Hepatitis		Acetaminophen	SS		ORAL	
3 DAY							
	Hepatitis Cholestatic						
	Influenza Like Illness						

Date:02/09/04ISR Number: 4289068-3Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00008
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
6 WK							
Initial or Prolonged	Drug Eruption		Digoxin	C		ORAL	
	Dysphagia		Furosemide	C		ORAL	
	Multi-Organ Failure		Glimepiride	C		ORAL	
	Pneumonia Aspiration		Cozaar	C		ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4289069-5Report Type:Expedited (15-DaCompany Report #WAES 0401NOR00020
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiogenic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Aspirin And Magnesium Oxide	SS		ORAL		
	Haematemesis		Allopurinol	C		ORAL		
	Haemoglobin Decreased		Ranitidine Hydrochloride	C		ORAL		
	Helicobacter Infection							
	Melaena							

Date:02/09/04ISR Number: 4289070-1Report Type:Expedited (15-DaCompany Report #WAES 0402COL00005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc			
			Warfarin	C				

Date:02/09/04ISR Number: 4289071-3Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00090
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/09/04ISR Number: 4289072-5Report Type:Expedited (15-DaCompany Report #WAES 0401USA02152
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Infarction		[Therapy Unspecified]	C				
			Bufferin	C				
			Plavix	C				
			Isoket	C				

Date:02/09/04ISR Number: 4289819-8Report Type:Expedited (15-DaCompany Report #WAES 0211USA01885
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adenocarcinoma	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Aphagia	Health						
Initial or Prolonged	Asthenia	Professional	Tab Acetaminophen					
Disability	Cerebrovascular Accident		325 Mg	SS		ORAL	325 MG/PRN/PO	
Other	Chest Pain		Zocor	C				
	Face Oedema		Atenolol	C				
	Hemiparesis		Lansoprazole	C				
	Laryngeal Oedema		Losartan Potassium	C				
	Local Swelling		Meclizine	C				
	Myocardial Infarction		Terazosin Hydrochloride	C				
	Neoplasm Malignant							
	Oropharyngeal Swelling							
	Pneumonia							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/04ISR Number: 4289893-9Report Type:Expedited (15-DaCompany Report #WAES 0401USA01540
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Murmur Chest Pain	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	14 DAY
			Fosamax	C				
			Alfacalcidol	C				
			Aprindine Hydrochloride	C				
			Calcium	C				
			Nitrazepam	C				
			Pravastatin Na	C				
			Spironolactone	C				

Date:02/10/04ISR Number: 4289998-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cataract		Fosamax	C		ORAL		
	Contusion		Prempro	C				
	Dyspepsia		Advil	C				
	Dyspnoea		Synthroid	C				
	Dysuria		Claritin	C				
	Ear Pain							
	Eye Haemorrhage							
	Eye Pain							
	Fall							
	Glaucoma							
	Headache							
	Hearing Impaired							
	Hypertension							
	Hypokalaemia							
	Hypothyroidism							
	Keratoconjunctivitis							
	Sicca							
	Loose Body In Joint							
	Migraine							

Mitral Valve Incompetence
Nasal Septum Ulceration
Neurodermatitis
Optic Nerve Injury
Palpitations
Polymyalgia Rheumatica
Sinusitis
Skin Laceration
Syncope
Syncope Vasovagal
Vision Blurred

Date:02/10/04ISR Number: 4290008-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
		Percocet	SS				
Alcohol Poisoning		Alcohol	SS				
Arthropod Sting		Xanax	SS				
Blood Calcium Decreased		Ambien	SS				
Cardiac Failure		Soma	C				
Coronary Artery Atherosclerosis		Advil	C				
		Imdur	C				
Coronary Artery Disease							
Depression							
Diabetes Mellitus							
Dyspnoea Exertional							
Ejection Fraction Decreased							
Gastrooesophageal Reflux Disease							
Haematocrit Decreased							
Haemoglobin Decreased							
Hypercholesterolaemia							
Hyperlipidaemia							
Hypertension							
Hypokalaemia							
Intentional Misuse							
Major Depression							
Myocardial Infarction							
Red Blood Cell Count Decreased							
Spondylitis							
Stent Occlusion							
Suicide Attempt							
Swelling Face							
Tooth Disorder							
Treatment Noncompliance							

Date:02/10/04ISR Number: 4290023-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Balance Disorder

Other	Cerebrovascular Accident
	Circulatory Collapse
	Cognitive Disorder
	Confusional State
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Gait Disturbance
	Impaired Driving Ability
	Impaired Work Ability
	Injury
	Loss Of Libido
	Sexual Dysfunction
	Sleep Disorder
	Speech Disorder
	Thrombosis

	Transient Ischaemic Attack					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/10/04ISR Number: 4290024-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Balance Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Barrett'S Oesophagus		Herbs (Unspecified)	C		
840 DAY						
Other	Blood Glucose Increased		Prilosec	C		
	Blood Pressure Increased					
	Burning Sensation					
	Cerebrovascular Accident					
	Coordination Abnormal					
	Dizziness Postural					
	Dyspepsia					
	Dyspnoea					
	Emotional Distress					
	Gait Disturbance					
	Gallbladder Disorder					
	Hypertension					
	Injury					
	Joint Sprain					
	Joint Swelling					
	Lacunar Infarction					
	Ligament Injury					
	Memory Impairment					
	Nausea					
	Osteoarthritis					
	Pain In Extremity					
	Tachycardia					
	Transient Ischaemic Attack					
	Tremor					
	Vomiting					
	Wernicke'S Encephalopathy					

Date:02/10/04ISR Number: 4290027-5Report Type:Expedited (15-DaCompany Report #WAES 0202USA02142
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
Disability	Cardiac Failure
	Congestive
	Chest Pain
	Deep Vein Thrombosis
	Dilatation Atrial
	Dyspnoea Exertional
	Fluid Retention
	Gastrooesophageal Reflux Disease
	Homans' Sign
	Hypercholesterolaemia

		Hypertension					
		Hyperthyroidism					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Polytraumatism		Vioxx	SS	Merck & Co., Inc	ORAL
		Rales		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Allopurinol	C		
		Weight Increased		Keflex	C		
				Hydrochlorothiazide	C		
				Indocin (Indomethacin)	C		ORAL
				Synthroid	C		

Date:02/10/04ISR Number: 4290029-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
48 DAY						
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
48 DAY						
Disability	Dizziness		Deconamine	C		
Other	Haemorrhoidal Haemorrhage		Lisinopril	C		
	Impaired Work Ability		Meclizine	C		
	Palpitations		Aciphex	C		
	Renal Failure					
	Rheumatoid Arthritis					
	Urinary Tract Obstruction					

Date:02/10/04ISR Number: 4290030-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01432
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
159 DAY						
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
159 DAY						
Initial or Prolonged	Blood Pressure Increased		Vicodin Tablets	C		
Disability	Bone Cyst		Carisoprodol	C		

Other	Cardio-Respiratory Arrest Electromechanical Dissociation Osteoarthritis Respiratory Rate Increased Sciatica Spinal Column Stenosis Ventricular Fibrillation

Date:02/10/04ISR Number: 4290031-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris Aortic Valve Incompetence
Disability	Arthritis Asthma Atherosclerosis Cardiac Disorder Cardiac Murmur Chronic Lymphocytic

		Leukaemia					
		Coronary Artery Disease					
		Diarrhoea					
		Gastritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Voltaren	C		
		Hypertension		Prempro	C		
		Hypokinesia					
		Mitral Valve Incompetence					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Overdose					
		Pneumonia					
		Stress					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypertrophy					

Date:02/10/04ISR Number: 4290033-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02052
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Aneurysm		Lotrel	C		ORAL
		Anger		Wellbutrin	C		
		Asthenia		Celebrex	C		
		Blood Cholesterol		Klonopin	C		
		Increased		Clonidine	C		ORAL
249	DAY						
		Blood Pressure Increased		Clonidine	C		ORAL
		Carotid Artery Stenosis		Zoloft	C		ORAL
		Carpal Tunnel Syndrome		Labetalol			
		Cerebral Infarction		Hydrochloride	C		ORAL
		Depression		Labetalol			
		Dizziness		Hydrochloride	C		ORAL
		Facial Paresis		Claritin	C		
		Haemorrhagic Stroke		Paxil	C		ORAL

Hemiparesis	Dilantin	C	ORAL
Hyperhidrosis	Ranitidine	C	ORAL
Hypertension			
Injury			
Intracranial Aneurysm			
Irritability			
Memory Impairment			
Peptic Ulcer			
Tearfulness			
Vascular Calcification			

Date:02/10/04ISR Number: 4290035-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other								
	Catheter Site Infection		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Cerebral Atrophy							
	Chest Wall Abscess							
	Coordination Abnormal							
	Emotional Distress							
	Encephalitis Brain Stem							
	Fall							
	Gram Stain Negative							
	Herpes Ophthalmic							
	Herpes Zoster							
	Hodgkin'S Disease Nodular							
	Sclerosis Stage							
	Unspecified							
	Intervertebral Disc							
	Displacement							
	Lacunar Infarction							
	Meningitis Aseptic							
	Pathogen Resistance							
	Pruritus							
	Staphylococcal Sepsis							
	Vestibulitis							
	Vision Blurred							

Date:02/10/04ISR Number: 4290042-1Report Type:Expedited (15-DaCompany Report #WAES 0401ZAF00007
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Air Embolism		Albuterol	C				
RESPIRATORY								
Disability	Bradycardia							
(INHALATION)								
Other	Cerebrovascular Accident		Aspirin	C				
	Chest Discomfort		Clopidogrel					
	Disturbance In Attention		Bisulfate	C		ORAL		
	Ejection Fraction		Estradiol	C		ORAL		
	Decreased		Fluticasone					
	Fatigue		Propionate	C				
RESPIRATORY								

	Lethargy					
(INHALATION)						
	Loss Of Consciousness		Formoterol Fumarate	C		
	Pruritus		Irbesartan	C		ORAL
	Rash		Piroxicam	C		ORAL
	Rectal Cancer					
	Sudden Onset Of Sleep					
	Transient Ischaemic					
	Attack					

Date:02/10/04ISR Number: 4290043-3Report Type:Expedited (15-DaCompany Report #WAES 0402USA00570
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Urinary Incontinence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
			Lortab	C		
			Wellbutrin	C		
			Premarin	C		
			Prednisone	C		

Date:02/10/04ISR Number: 4290435-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	18 MON	
Disability	Back Pain							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Deep Vein Thrombosis							
	Dizziness							
	Dyspnoea							
	Headache							
	Hodgkin'S Disease							
	Hyperhidrosis							
	Hypertension							
	Intervertebral Disc Degeneration							
	Joint Swelling							
	Myocardial Infarction							
	Non-Hodgkin'S Lymphoma							
	Oedema Peripheral							
	Skin Cancer							
	Vertigo							
	Weight Increased							

Date:02/10/04ISR Number: 4290452-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA00235
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	379 DAY	
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	379 DAY	
	Balance Disorder		Vicodin Tablets	C				
	Blood Pressure Systolic Increased		Celebrex	C				
	Cardiolipin Antibody Positive							
	Emotional Distress							

Eye Irritation
Headache
Joint Dislocation
Keratoconjunctivitis
Sicca
Myeloproliferative
Disorder
Pain
Platelet Count Increased
Polytraumatism
Retinal Vein Occlusion
Retinal Vein Thrombosis

Date:02/10/04ISR Number: 4290453-4Report Type:Expedited (15-DaCompany Report #WAES 0402THA00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:02/10/04ISR Number: 4290454-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 272 DAY	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cataract		Aspirin	C				
	Cataract Cortical		Lipitor	C				
	Cerebrovascular Accident		Os-Cal	C				
	Chest Wall Pain		Casanthranol And Docusate Sodium	C				
	Condition Aggravated		Monopril	C		ORAL		
	Diabetic Retinopathy		Vitamins (Unspecified)	C				
	Dysphagia		Hydrodiuril	C		ORAL		
	Exostosis		Hydrocodone Hydrochloride	C				
	Fall		Humulin R	C			SUBCUTANEOUS	
	Gastrooesophageal Reflux Disease		Humulin Nph	C			SUBCUTANEOUS	
	Glaucoma		Humulin Nph	C			SUBCUTANEOUS	
	Gout		Adalat	C				
	Haemoglobin Decreased							
	Hypertension							
	Lacunar Infarction							
	Laryngitis							
	Macular Degeneration							
	Mononeuritis							
	Neuropathy							
	Ocular Hypertension							
	Oesophagitis							
	Onychomycosis							
	Oropharyngeal Spasm							
	Osteoarthritis							
	Peripheral Vascular Disorder							
	Tendonitis							

Date:02/10/04ISR Number: 4290455-8Report Type:Expedited (15-DaCompany Report #WAES 0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability	Balance Disorder Blindness Unilateral Cerebral Haemorrhage Cerebral Infarction Cerebrovascular Accident Disorientation Dyspepsia Excoriation Gastrooesophageal Reflux Disease Haemorrhagic Stroke Laceration Monoparesis Skin Laceration	Health Professional	Vioxx Vioxx Aspirin	PS SS C	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL

Date:02/10/04ISR Number: 4290456-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5	MON
Blood Cholesterol Increased		Aspirin	C				
		Lasix (Furosemide)	C				
Chest Discomfort		Glucotrol Xl	C				
Chronic Obstructive Pulmonary Disease		Glyburide	C				
		Ativan	C				
Cognitive Disorder		Lopressor	C				
Coronary Artery Disease		Orphenadrine	C				
Depression							
Diabetes Mellitus Inadequate Control							
Emotional Distress							
Hypertension							
Hypokalaemia							
Myocardial Infarction							
Palpitations							
Rotator Cuff Syndrome							
Supraventricular Tachycardia							
Transient Ischaemic Attack							
Vision Blurred							

Date:02/11/04ISR Number: 4292050-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Carotid Artery Disease							
	Coronary Artery Disease							
	Depression							
	Diarrhoea							

	Dyspepsia Emotional Distress Gastrointestinal Disorder Hypertension Injury Myocardial Infarction

Date:02/11/04ISR Number: 4292052-7Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00005
Age:87 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Ulcer Haemoglobin Decreased Helicobacter Infection Helicobacter Pylori Identification Test Positive

	Melaena						
	Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	17	DAY
			Aspirin And Magnesium Oxide	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:02/11/04ISR Number: 4292054-0Report Type:Expedited (15-DaCompany Report #WAES 0401USA01853
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fall		Glipizide	C				
Initial or Prolonged	Fracture		Actos	C				
Disability	Gastrointestinal							
Other	Haemorrhage							

Date:02/11/04ISR Number: 4292057-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01697
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL		
	Unexpected		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/11/04ISR Number: 4292061-8Report Type:Expedited (15-DaCompany Report #WAES 0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction Adverse Event Angina Pectoris Atrial Tachycardia Brain Hypoxia Cardiac Failure Congestive Cardiogenic Shock Coronary Artery Disease Depression Ejection Fraction Decreased Electrocardiogram Qrs Complex Prolonged Emotional Distress Encephalopathy Hypercholesterolaemia Ischaemic Cardiomyopathy Ischaemic Hepatitis Lung Infiltration

		Mental Status Changes					
		Multi-Organ Failure					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Oxycodone	C		
		Renal Failure		Ultram	C		
		Urinary Tract Infection		Diovan	C		
		Ventricular Fibrillation		Zantac	C		
		Ventricular Tachycardia					

Date:02/11/04ISR Number: 4292066-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01305
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Asthma		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cerebral Artery		Clotrimazole	C		
		Thrombosis		Diuretic			
		Cerebrovascular Accident		(Unspecified)	C		
		Convulsion		Triamterene	C		
		Diabetes Mellitus		Broncholate	C		
		Hypertension		Tri-Norinyl	C		
		Hypertensive Heart					
		Disease					
		Intracranial Aneurysm					
		Osteoarthritis					
		Pain					
		Peptic Ulcer					

Date:02/11/04ISR Number: 4292069-2Report Type:Expedited (15-DaCompany Report #WAES 00091403
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Other	Abnormal Faeces
	Adverse Event
	Alopecia
	Aphthous Stomatitis
	Bronchitis Acute
	Cerebrovascular Accident

Cervical Cyst
Constipation
Contusion
Depression
Emotional Distress
Feeling Abnormal
Feeling Cold
Gingival Infection
Head Injury
Hot Flush
Hypercoagulation
Hyperkeratosis
Hypersensitivity
Insomnia
Migraine
Nail Ridging
Nausea
Neuropathy Peripheral

		Oedema					
		Tooth Abscess					
		Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack		Vioxx	PS	Merck & Co., Inc	ORAL
392	DAY						
		Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Weight Increased		Tylenol	C		
				Fioricet Tablets	C		
				Fioricet Tablets	C		
				Aspirin	C		
				Zithromax	C		
				Ambien	C		
				Cimicifuga	C		
				Prempro	C		
				Advil	C		
				Motrin	C		
				Naproxen	C		
84	DAY						

Date:02/11/04ISR Number: 4292081-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
Initial or Prolonged		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Bladder Spasm		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Bronchial Infection		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Cervicobrachial Syndrome		Tylenol	C		
		Cholelithiasis		Parafon Forte	C		
		Confusional State		Serevent	C		
RESPIRATORY							
		Dysuria					
(INHALATION)							

	Embolic Stroke	Proventil	C
RESPIRATORY			
	Emotional Distress		
(INHALATION)			
	Fall	Aspirin	C
	Hypertension	Lioresal	C
	Hypoaesthesia	Valium	C
	Intervertebral Disc	Demerol	C
	Degeneration	Ditropan	C
	Lumbar Radiculopathy	Inderal	C
	Migraine		
	Myofascial Pain Syndrome		
	Nerve Compression		
	Oedema Peripheral		
	Pollakiuria		
	Rotator Cuff Syndrome		
	Speech Disorder		
	Spondylolisthesis		
	Acquired		
	Treatment Noncompliance		
	Urinary Tract Infection		
	Ventricular Hypertrophy		

Date:02/11/04ISR Number: 4292093-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01476
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Blood Pressure Increased
Other	Contusion

		Fall					
		Fatigue					
		Haemangioma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatitis		Arava	SS		
3	DAY						
		Hepatocellular Damage		Arava	SS		
64	DAY						
		Hepatotoxicity		Tylenol	C		
		Hypertension		Augmentin	C		
		Lymphocyte Count Decreased		Antimicrobial (Unspecified)	C		
		Monocyte Count Increased		Celebrex	C		
		Neutrophil Count Decreased		Methotrexate	C		
		Pain		Sulfasalazine	C		
		Platelet Count Increased		Ranitidine	C		
		Red Blood Cell Count Decreased		Prednisone	C		
		Renal Cyst		Clavulanate Potassium	C		
		Serum Ferritin Increased		Colace	C		
		Skeletal Injury		Neurontin	C		
		Thrombocythaemia		Guaifenesin	C		
		White Blood Cell Count Increased		Hydrocodone Bitartrate	C		

Date:02/11/04ISR Number: 4292715-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Coumadin	C		
	Speech Disorder					
	Tremor					

Date:02/11/04ISR Number: 4292727-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blindness Unilateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged Disability	Carotid Artery Stenosis Cerebral Haemorrhage Cerebral Infarction Cerebrovascular Accident Dysarthria Dyspepsia Gastrooesophageal Reflux Disease Hemianopia Skin Laceration	Professional	Vioxx Aspirin	SS C	Merck & Co., Inc	ORAL

Date:02/11/04ISR Number: 4292728-1Report Type:Expedited (15-DaCompany Report #WAES 0312CAN00056
Age:75 YR Gender:Male I/FU:F

Outcome Dose Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/04ISR Number: 4292729-3Report Type:Expedited (15-DaCompany Report #WAES 01104522
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure	Other	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluctuation							
	Cardiovascular Disorder							
	Convulsion							
	Death							
	Oedema							
	Renal Failure							

Date:02/11/04ISR Number: 4292730-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA00397
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fall		Aspirin	C				
	Fluid Retention		Monopril	C				
	Head Injury							
	Weight Increased							

Date:02/11/04ISR Number: 4292731-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA02378
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anorexia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Arrhythmia		[Therapy					
	Blood Cholesterol		Unspecified]	C				
	Increased		Valium	C				
	Bradycardia		Nexium	C				
	Cardiac Failure		Paxil	C				
	Congestive							
	Cardiovascular Disorder							
	Dehydration							
	Diarrhoea							
	Dyspepsia							
	Dysuria							
	Ear Pain							

Emotional Distress
Erosive Oesophagitis
Faeces Discoloured
Frequent Bowel Movements
Gastrointestinal Ulcer
Heart Rate Irregular
Hypertension
Nasopharyngitis
Nausea
Oedema Peripheral
Otitis Media
Peptic Ulcer
Pharyngitis
Pyrexia
Tinnitus
Urinary Tract Infection
Vomiting
Weight Increased

Date:02/11/04ISR Number: 4292732-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Disability	Agitation
	Anaemia
	Arthralgia
	Arthropod Bite
	Arthropod Sting
	Back Pain
	Blister
	Blood Calcium Decreased
	Blood Cholesterol Increased
	Blood Parathyroid Hormone Decreased
	Blood Pressure Increased
	Bone Lesion
	Bursitis
	Buttock Pain
	Cervicobrachial Syndrome
	Chest Pain
	Chest X-Ray Abnormal
	Chronic Sinusitis
	Compression Fracture
	Conjunctivitis
	Constipation
	Coronary Artery Disease
	Cough
	Crying
	Depression
	Drug Intolerance
	Dyspepsia
	Fractured Sacrum
	Fungal Infection
	Generalised Anxiety Disorder
	Groin Pain
	Head Injury
	Headache
	Heart Rate Increased
	Hip Fracture
	Hypercalcaemia
	Impaired Healing
	Infection
	Influenza
	Insomnia

Joint Sprain
Libido Decreased
Metabolic Disorder
Metastatic Neoplasm
Multiple Fractures
Myocardial Ischaemia
Myofascitis
Neck Pain
Nuclear Magnetic
Resonance Imaging
Abnormal
Oedema Peripheral
Osteopenia
Osteoporosis
Osteoporotic Fracture

		Pain In Jaw					
		Panic Disorder					
		Pubic Rami Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radiculopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Rib Fracture	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
245	DAY						
		Road Traffic Accident		Fosamax	C		ORAL
		Sacroiliitis		Valium	C		
		Scoliosis		Neurontin	C		
		Sebaceous Hyperplasia		Neurontin	C		
		Spinal Fracture		Valtrex	C		
		Sputum Discoloured		Neurontin	C		
		Thoracic Outlet Syndrome		Glucosamine	C		
		Viral Pharyngitis		Nitrostat	C		
		Weight Increased		Evista	C		

Date:02/11/04ISR Number: 4292733-5Report Type:Expedited (15-DaCompany Report #WAES 01104504
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Contusion					
	Emotional Distress					
	Gastrooesophageal Reflux					
	Disease					
	Hypertension					
	Oedema					
	Renal Failure					
	Rheumatoid Arthritis					

Date:02/11/04ISR Number: 4292734-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anxiety
Disability	Arterial Restenosis
	Barrett'S Oesophagus
	Blood Cholesterol
	Increased

Bradycardia
Bundle Branch Block Left
Coronary Artery Disease
Depression
Dyspnoea Exertional
Ejection Fraction
Decreased
Electrocardiogram St
Segment Elevation
Fatigue
Gastric Disorder
Gastrooesophageal Reflux
Disease
Heart Rate Irregular
Hiatus Hernia
Hypotension
Myocardial Infarction
Pain
Palpitations
Thrombosis

		Ventricular Dysfunction Ventricular Fibrillation Ventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Acetaminophen And Oxycodone Hydrochloride	C		

Date:02/11/04ISR Number: 4292735-9Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00094
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
	Haemoglobin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
	Rectal Haemorrhage		Aspirin	C		

Date:02/11/04ISR Number: 4292736-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA00191
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
175 DAY						
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
50 DAY						
Hospitalization - Initial or Prolonged	Bradycardia		Aspirin	C		
	Chest Pain					
Disability	Duodenal Ulcer Haemorrhage					

Date:02/11/04ISR Number: 4292737-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL		
	Paranoia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Suicidal Ideation		Lithium Carbonate	C				

Date:02/11/04ISR Number: 4292739-6Report Type:Expedited (15-DaCompany Report #WAES 0211FRA00072
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Goitre	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperthyroidism		Interferon Beta-1a	SS		SUBCUTANEOUS	509	DAY
			Acenocoumarol	C		ORAL		
			Calcium Carbonate	C		ORAL		
			Etidronate Disodium	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Prazepam	C		ORAL		
			Omeprazole	C		ORAL		

			Fenofibrate	C		ORAL
			Hydrocortisone	C		ORAL

Date:02/11/04ISR Number: 4292740-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cellulitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Xanax	C		
	Coronary Artery Thrombosis		Aspirin	C		
	Electrocardiogram St Segment Elevation		Celebrex	C		
	Electrocardiogram T Wave Inversion		Zyrtec	C		
	Emotional Distress		Prozac	C		
	Haemangioma		Zestril	C		
	Hyperlipidaemia		Naproxen	C		
	Hypertension		Prilosec	C		
	Myocardial Infarction					
	Myocardial Ischaemia					
	Nervousness					
	Oedema Peripheral					
	Radiculopathy					
	Sinus Bradycardia					
	Spinal Osteoarthritis					
	Urethritis					

Date:02/11/04ISR Number: 4294204-9Report Type:Expedited (15-DaCompany Report #US-SHR-03-015153
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arrhythmia	Consumer	Yasmin(Ethinylestrad			
	Drug Interaction	Health	iol, Drospirenone)			
	Dyspnoea	Professional	Film Tablet	PS		ORAL
SEE IMAGE						
	Pharmaceutical Product		Vioxx			
	Complaint		/Ysa/(Rofecoxib)	SS		ORAL
ORAL						
	Tachycardia		Wellbutrin			
	Thyroid Disorder		(Bupropion			

	Thyroid Function Test Abnormal Ventricular Extrasystoles		Hydrochloride)	C		

Date:02/11/04ISR Number: 4294524-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01540
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Aortic Valve Stenosis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	94 DAY
	Cardiac Failure Chronic Dehydration Renal Impairment	Health Professional	Fosamax	C				
			Alfacalcidol	C				
			Aprindine Hydrochloride	C				
			Calcium	C				
			Nitrazepam	C				
			Pravastatin Na	C				
			Spironolactone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/04ISR Number: 4293793-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA01866
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chronic Obstructive	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Airways Disease	Professional	Lotensin	C		
Initial or Prolonged	Exacerbated		Colace	C		
Disability	Chronic Obstructive		Nexium	C		
	Pulmonary Disease		Tricor	C		
	Diabetic Ketoacidosis		Insulin	C		
	Hyperchloraemia					
	Myocardial Infarction					
	Renal Failure					
	Sputum Discoloured					
	Therapeutic Agent					
	Toxicity					

Date:02/12/04ISR Number: 4293794-XReport Type:Expedited (15-DaCompany Report #WAES 0402FRA00007
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hyperkalaemia		Ferrous Sulfate	C		ORAL
	Renal Failure Acute		Levothyroxine Sodium	C		ORAL
			Spironolactone	C		ORAL
			Spironolactone	C		ORAL
			Nicorandil	C		ORAL

Date:02/12/04ISR Number: 4293798-7Report Type:Expedited (15-DaCompany Report #WAES 0311USA02107
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fall	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Pepcid	C		ORAL
Other			Hemocyte	C		ORAL
			Dyazide	C		ORAL

Date:02/12/04ISR Number: 4293799-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Asthenia
	Blood Cholesterol Increased
	Bronchitis
	Catheter Site Haemorrhage
	Cellulitis
	Cognitive Disorder
	Contusion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Costochondritis
	Depression
	Diarrhoea
	Diastolic Dysfunction
	Drug Ineffective

		Drug Withdrawal Syndrome					
		Dyspnoea					
		Gastritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haemarthrosis		Aspirin	C		
		Haematoma		Celebrex	C		
		Headache		Sudal	C		
		Hypertonic Bladder		Ultram	C		
		Hypothyroidism		Levaquin	C		
		Increased Tendency To		Synthroid	C		
		Bruise		Zantac	C		
		Libido Decreased					
		Musculoskeletal Chest					
		Pain					
		Myocardial Infarction					
		Neuralgia					
		Oedema					
		Pain					
		Panic Attack					
		Pneumonia					
		Respiratory Rate					
		Increased					
		Spinal Osteoarthritis					
		Stress Incontinence					
		Weight Increased					

Date:02/12/04ISR Number: 4293992-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA00342
Age:55 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Atenolol	C		
				Celebrex	C		
				Adalat	C		

Date:02/12/04ISR Number: 4293995-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Arrhythmia
	Arthropathy
	Azotaemia
	Blood Pressure Diastolic Decreased
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure
	Congestive
	Cellulitis
	Crying
	Epistaxis
	Eye Disorder
	Haematocrit Decreased
	Hypertension

		Hypoxia					
		Induration					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Irritable Bowel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Meniscus Lesion		Vioxx	SS	Merck & Co., Inc	ORAL
		Menorrhagia		Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Mood Swings		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Ventolin (Albuterol			
		Neuropathic Pain		Sulfate)	C		
		Nocturia		Tenormin	C		
		Non-Cardiac Chest Pain		Vasotec	C		ORAL
		Ovarian Mass		Ultram	C		
		Palpitations		Lodine Xl	C		
		Pickwickian Syndrome		Lasix (Furosemide			
		Pitting Oedema		Sodium)	C		
		Pneumonia		Ditropan	C		
		Respiratory Failure		K-Dur	C		
		Retching		Quinine Sulfate	C		
		Skin Odour Abnormal					
		Weight Increased					

Date:02/12/04ISR Number: 4293996-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA01211
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arteriovenous		Vioxx	PS	Merck & Co., Inc	ORAL
9	DAY					
Initial or Prolonged	Malformation		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY					
Disability	Balance Disorder					
Congenital Anomaly	Blood Pressure Decreased					
	Cardiac Failure					
	Congestive					
	Cerebral Haemorrhage					
	Cerebrovascular Accident					
	Convulsion					
	Cough					
	Drug Hypersensitivity					
	Eye Swelling					
	Face Oedema					
	Inflammation					

Lacrimation Increased
Oedema Peripheral
Panic Reaction
Pruritus
Renal Cyst
Renal Injury
Renal Pain
Sneezing
Vertigo
Vitreous Floaters
Weight Increased

Date:02/12/04ISR Number: 4293997-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Coronary Syndrome
Disability	Anxiety
Other	Blood Triglycerides

		Increased					
		Bronchitis					
		Bronchospasm					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Congestive		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Coumadin	SS		
		Chest Pain		Coumadin	SS		
		Chills		[Therapy			
		Chronic Obstructive		Unspecified]	C		
		Pulmonary Disease		Tylenol	C		
		Coagulopathy		Vicodin Tablets	C		
		Contusion		Albuterol	C		
		Deafness Bilateral		Bayer Aspirin	C		
		Drug Level Decreased		Bayer Aspirin	C		
		Dyspnoea		Aspirin	C		
		Dysuria		Tenormin	C		
		Epistaxis		Tenormin	C		
		Fall		Ticlid	C		
		Gastrointestinal Disorder		Restoril	C		
		Gingival Bleeding		Digoxin	C		
		Haematochezia		Anzemet	C		
		Haemorrhage		Vasotec	C		ORAL
		Heart Rate Irregular		Isordil	C		
		Hypertension		Lopressor	C		
		International Normalised		Naproxen	C		
		Ratio Decreased		Nitrostat	C		
		Intervertebral Disc					
		Protrusion					
		Iron Deficiency Anaemia					
		Limb Discomfort					
		Lung Disorder					
		Menstrual Disorder					
		Nerve Compression					
		Oedema Peripheral					
		Osteoarthritis					
		Pollakiuria					
		Radiculitis					
		Silent Myocardial					
		Infarction					
		Sleep Disorder					
		Stress Incontinence					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vision Blurred					

Date:02/12/04ISR Number: 4293998-6Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00105
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		162 DAY
Other			Meloxicam	C				

Date:02/12/04ISR Number: 4293999-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01799
Age:42 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arteriovenous		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Malformation		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
	Blood Pressure Decreased							
	Cerebrovascular Accident							
	Convulsion							
	Drug Hypersensitivity							
	Haemorrhage Intracranial							
	Hypervolaemia							
	Memory Impairment							
	Oedema Peripheral							
	Renal Cyst							
	Weight Increased							

Date:02/12/04ISR Number: 4294000-2Report Type:Expedited (15-DaCompany Report #WAES 0402SWE00001
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase		Acetaminophen And Codeine Phosphate	SS		ORAL		
			Acyclovir	SS		ORAL	7	DAY
	Increased		Carbamazepine	SS		ORAL	25	DAY
	Blood Alkaline Phosphatase Increased		Norfloxacin	C				
	Blood Bilirubin Increased							
	Chromaturia							
	Faeces Discoloured							
	Infection							
	Liver Disorder							

Date:02/12/04ISR Number: 4294001-4Report Type:Expedited (15-DaCompany Report #WAES 0402USA00626
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/12/04ISR Number: 4294002-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01421
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ruptured Cerebral		Lortab	C				
	Aneurysm		Effexor	C				

Date:02/12/04ISR Number: 4294003-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00099
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia Alzheimer'S Type		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/12/04ISR Number: 4294004-XReport Type:Expedited (15-DaCompany Report #WAES 0402GBR00106
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Bendroflumethiazide	C		ORAL		
			Citalopram	C		ORAL		
			Lercanidipine	C		ORAL		

Date:02/12/04ISR Number: 4294005-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01978
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Blood Cholesterol Increased		[Therapy Unspecified]	C				
	Chest Pain		Xanax	C				
	Chronic Fatigue Syndrome		Prilosec	C				
	Depression							
	Emotional Distress							
	Feeling Abnormal							
	Hypertension							
	Intervertebral Disc Protrusion							
	Malaise							
	Panic Disorder							
	Peptic Ulcer							

Date:02/12/04ISR Number: 4294007-5Report Type:Expedited (15-DaCompany Report #WAES 01065105
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Aspirin	SS		ORAL		
	Oesophagitis		Suriclone	SS				
SUBCUTANEOUS							2	DAY
			Amlodipine	C		ORAL		
			Atenolol	C		ORAL		
			Folic Acid	C		ORAL		

				Isosorbide Mononitrate	C		ORAL
				Methotrexate	C		ORAL
				Nicorandil	C		ORAL
				Nizatidine	C		ORAL
				Prednisolone	C		ORAL

Date:02/12/04ISR Number: 4295941-2Report Type:Expedited (15-DaCompany Report #PERI00203000940
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Renal Failure Acute	Foreign Health Professional Other	Coversyl (Perindopril)	PS		ORAL	2 MG QD PO	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG DAILY PO	
			Lasix (Furosemide)	SS		ORAL	80 MG DAILY PO	
			Lanoxin (Digoxin)	C				
			Marevan (Warfarin Sodium)	C				
			Lipitor					

(Atorvastatin)	C
Panafcortelone (Prednisolone)	C
Losec (Omeprazole)	C
Neurontin (Gabapentin)	C
Humalog (Insulin Lispro)	C
Imdur (Isosorbide Mononitrate)	C

Date:02/13/04ISR Number: 4294559-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety							
	Back Pain							
	Blood Cholesterol Increased							
	Cardiac Failure							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Depression							
	Duodenitis							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Generalised Oedema							
	Haematochezia							
	Hypertension							
	Hypokalaemia							
	Laryngitis							
	Migraine							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Orthostatic Hypotension							
	Palpitations							
	Pelvic Peritoneal Adhesions							
	Phlebothrombosis							
	Stent Occlusion							
	Supraventricular Extrasystoles							

Syncope
Thrombophlebitis
Superficial
Tricuspid Valve
Incompetence
Ventricular Extrasystoles

Date:02/13/04ISR Number: 4294589-3Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00024
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Haematemesis		Folic Acid	C		ORAL		
			Vitamin D (Unspecified)	C		ORAL		

			Reboxetine	C		ORAL

Date:02/13/04ISR Number: 4294616-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 10 DAY	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 10 DAY	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Congestive					
Other	Carpal Tunnel Syndrome					
	Complex Regional Pain Syndrome					
	Gastrooesophageal Reflux Disease					
	Hypersensitivity					
	Impaired Healing					
	Injury					
	Intervertebral Disc Disorder					
	Prescribed Overdose					
	Sleep Apnoea Syndrome					
	Sleep Terror					

Date:02/13/04ISR Number: 4294617-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other 1 MON	Aortic Valve Sclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Atrial Fibrillation	Professional	Premarin	C		
	Corneal Deposits		Estratab	C		
	Dilatation Atrial		Menest	C		
	Hypertensive Crisis		Armour Thyroid			
	Injury		Tablets	C		
	Migraine		Trazodone			
	Mitral Valve		Hydrochloride	C		
	Calcification		Garlic Extract	C		
	Mitral Valve Disease		Synthroid	C		
	Musculoskeletal Disorder		Methotrexate	C		

Plastic Surgery To The
Face
Renal Cyst
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence

Date:02/13/04ISR Number: 4294620-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anaemia Macrocytic
Other	Arthralgia
	Arthritis Infective
	Asthenia
	Atrioventricular Block
	First Degree
	Back Pain

Dose	Duration						
		Benign Prostatic Hyperplasia					
		Bundle Branch Block Left	Report Source	Product	Role	Manufacturer	Route
		Bursitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Bursitis Infective		Vioxx	SS	Merck & Co., Inc	ORAL
		Staphylococcal		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Tylenol	C		
		Restenosis		Saw Palmetto	C		
		Depression		Ultram	C		
		Dermatitis Allergic		Lipitor	C		
		Diarrhoea		Lumigan	C		
		Drug Hypersensitivity		Corticosteroids (Unspecified)	C		
		Ejection Fraction					
PARENTERAL							
		Decreased		Betagan	C		
		Gait Disturbance		Relafen	C		
		Headache		Paxil	C		
		Hyperlipidaemia					
		Hypertension					
		Hypoaesthesia					
		Inguinal Hernia					
		Intestinal Obstruction					
		Joint Abscess					
		Mental Disorder					
		Musculoskeletal Stiffness					
		Myocardial Infarction					
		Osteoarthritis					
		Osteoporosis					
		Pain In Extremity					
		Paraesthesia					
		Pneumonia					
		Post Procedural Cellulitis					
		Post Procedural Complication					
		Radiculopathy					
		Spinal Disorder					
		Spinal Osteoarthritis					
		Staphylococcal Sepsis					
		Weight Decreased					

Date:02/13/04ISR Number: 4294629-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Anxiety
	Blood Potassium Decreased
	Blood Pressure Systolic Increased
	Coronary Artery Disease
	Crepitations
	Electrocardiogram St Segment Abnormal
	Emotional Distress
	Fear
	Haemoglobin Decreased
	Myocardial Infarction

		Pain					
		Rhonchi					
		Tendonitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						

Date:02/13/04ISR Number: 4294631-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Sexual Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
	Sleep Apnoea Syndrome					

Date:02/13/04ISR Number: 4294633-3Report Type:Expedited (15-DaCompany Report #WAES 0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiac Failure		Imuran			
	Congestive		(Azathioprine)	C		
	Cerebrovascular Accident		Tagamet	C		
	Emotional Distress		Digoxin	C		
			Tiazac	C		
			Flomax (Tamsulosin			
			Hydrochloride)	C		
			Lasix (Furosemide)	C		
			Glipizide	C		
			Motrin	C		
			Prednisone	C		

Date:02/13/04ISR Number: 4294634-5Report Type:Expedited (15-DaCompany Report #WAES 0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	194 DAY	
Other	Congestive		Adderall Tablets	C				
	Cerebrovascular Accident		Ibuprofen	C				
	Depression							
	Ejection Fraction Decreased							
	Mitral Valve Incompetence							
	Stress							

Date:02/13/04ISR Number: 4294636-9Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00008
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Allergic Granulomatous
Hospitalization -	Angiitis
Initial or Prolonged	Antinuclear Antibody
	Positive
	Back Pain
	Condition Aggravated

		Confusional State					
		Eosinophilia					
		Haemodynamic Instability	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inflammation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Localised Infection	Professional	Betamethasone	SS		
15	YR						
		Quadriplegia		Methylprednisolone			
		Respiratory Distress		Sodium Succinate	SS		
1	DAY						
		Sciatica		Prednisone	SS		ORAL
		Tenosynovitis		Fluticasone			
		Wound Infection		Propionate And			
		Staphylococcal		Salmeterol Xinafoate	C		
				Terbutaline Sulfate	C		
				Rilmenidene	C		
				Glimepiride	C		
				Ipratropium Bromide	C		

Date:02/13/04ISR Number: 4294637-0Report Type:Expedited (15-DaCompany Report #WAES 0306USA02101
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia	Professional	Diuretic			
		Blood Cholesterol		(Unspecified)	SS		
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Acetaminophen	C		
		Congestive		Vitamins			
		Drug Hypersensitivity		(Unspecified)	C		
		Drug Ineffective		Allopurinol	C		
		Dysphoria		Atenolol	C		
		Dysuria		Atenolol	C		
		Emotional Distress					
		Exostosis					
		Fall					
		Hypernatraemia					
		Hypertensive Crisis					
		Musculoskeletal Pain					
		Myocardial Infarction					
		Nausea					
		Pollakiuria					
		Postnasal Drip					
		Pulmonary Embolism					

Pyuria
Renal Failure
Sinusitis
Skin Lesion
Urinary Tract Infection

Date:02/13/04ISR Number: 4294638-2Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00014
Age:28 YR Gender:Female I/FU:I

Outcome PT
Disability Abdominal Discomfort
Depression
Fatigue
Headache
Memory Impairment
Muscle Spasms
Upper Respiratory Tract
Inflammation

Vaginal Mycosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	799	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	799	DAY
	Acetaminophen	C		ORAL		
	Omeprazole	C		ORAL		

Date:02/13/04ISR Number: 4294759-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02052
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Lotrel	C		ORAL		
	Increased		Wellbutrin	C				
	Carotid Artery Stenosis		Celebrex	C				
	Carpal Tunnel Syndrome		Klonopin	C				
	Cerebral Infarction		Clonidine	C		ORAL	249	DAY
	Depression		Clonidine	C		ORAL		
	Dizziness		Zoloft	C		ORAL		
	Hypertension		Labetalol Hydrochloride	C		ORAL		
	Intracranial Aneurysm		Labetalol Hydrochloride	C		ORAL		
	Peptic Ulcer		Claritin	C				
			Paxil	C		ORAL		
			Dilantin	C		ORAL		
			Ranitidine	C		ORAL		

Date:02/13/04ISR Number: 4294764-8Report Type:Expedited (15-DaCompany Report #WAES 01104492
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder							
	Carotid Artery Stenosis							
	Cerebrovascular Accident							

Hypertension
Injury
Oedema
Renal Failure

Date:02/13/04ISR Number: 4294769-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Cerebrovascular Accident							
	Convulsion							
	Migraine							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/04ISR Number: 4294770-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00435
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Congestive		Antineoplastic					
Other	Cardiomyopathy		(Unspecified)	SS				
	Diffuse Large B-Cell		Vicodin Tablets	C				
	Lymphoma Recurrent		Vitamins					
	Disturbance In Attention		(Unspecified)	C				
	Ejection Fraction		Prilosec	C				
	Decreased							
	Gastric Disorder							
	Major Depression							
	Seborrhoeic Keratosis							
	Sleep Disorder							
	Upper Respiratory Tract							
	Infection							

Date:02/13/04ISR Number: 4294772-7Report Type:Expedited (15-DaCompany Report #WAES 0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diplopia		Vitamins					
	Diverticulitis		(Unspecified)	C				
	Eczema							
	Gastrointestinal Disorder							
	Hypertension							
	Kyphosis							
	Lacunar Infarction							
	Lung Adenocarcinoma							
	Macular Degeneration							
	Nephrolithiasis							
	Nocturia							
	Non-Small Cell Lung							
	Cancer							
	Rhinitis Allergic							
	Sciatica							
	Transient Ischaemic							
	Attack							

Date:02/13/04ISR Number: 4294773-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02043
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
	Arrhythmia
	Back Pain
	Cerebrovascular Accident
	Coronary Artery Disease
	Depression
	Disturbance In Attention
	Dizziness
	Hypertension
	Injury
	Intervertebral Disc
	Disorder
	Mania

	Radiculopathy Sleep Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2 WK
			Cimetidine	C			
			Flexeril	C			
			Cardizem	C			
			Micronase	C			
			Ibuprofen	C			
			Prinivil	C			
			Metformin	C			
			Pravachol	C			

Date:02/13/04ISR Number: 4294774-0Report Type:Expedited (15-DaCompany Report #WAES 0211FIN00001
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chills		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY
Initial or Prolonged	Coagulation Time		Esomeprazole				
	Prolonged		Magnesium	SS		ORAL	
	Hepatic Haematoma		Esomeprazole				
	Hepatitis Toxic		Magnesium	SS			
			Vioxx	SS	Merck & Co., Inc	ORAL	46 DAY
			Progesterone	SS			
			Progesterone	SS			
			Acetaminophen	C		ORAL	
			Fexofenadine Hydrochloride	C			
			Fluticasone Propionate	C			
			Zolmitriptan	C			
			Estradiol Valerate	C		ORAL	
			Albuterol Sulfate	C			

Date:02/13/04ISR Number: 4294777-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	80	DAY
Initial or Prolonged	Aortic Calcification		[Therapy					
Disability	Breast Disorder		Unspecified]	C				
	Bundle Branch Block Left		Ascorbic Acid	C				
	Cardiac Failure		Calcium					
	Congestive		(Unspecified)	C				
	Cardiomegaly		Lanoxin	C				
	Congestive Cardiomyopathy		Premarin	C				
	Depression		Lasix (Furosemide)	C				
	Drug Ineffective		Vitamin E	C				
	Dyspepsia		Coumadin	C				
	Ejection Fraction		Vitamin B					
	Decreased		(Unspecified)	C				
	Hypertension		Ginkgo Biloba					
	Injury		Extract	C				
	Mood Swings		Levocarnitine	C				
	Nightmare		Prinivil	C		ORAL		
	Orthopnoea		Magnesium					
	Palpitations		(Unspecified)	C				
	Ventricular Extrasystoles		Pamelor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/13/04ISR Number: 4294778-8Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00053
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
	Haemorrhage		Bismuth Subgallate And Pramoxine Hydrochloride	C		RECTAL		
	Dystonia							
	Gastrointestinal Haemorrhage							
	Melaena							
	Pectus Excavatum		Celecoxib	C				8 DAY
	Peptic Ulcer		Diclofenac Sodium And Misoprostol	C		ORAL		
	Pneumonia		Zopiclone	C		ORAL		
	Spinal Osteoarthritis		Fluoxetine	C		ORAL		
	Upper Gastrointestinal Haemorrhage		Ibuprofen	C		ORAL		
			Lorazepam	C		ORAL		
			Psyllium Husk	C				

Date:02/13/04ISR Number: 4294779-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA00344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

Date:02/13/04ISR Number: 4294780-6Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00084
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Esomeprazole Magnesium	SS		ORAL		
			Fluoxetine Hydrochloride	SS		ORAL		74 MON

Acetaminophen	C	ORAL
Tramadol Hydrochloride	C	ORAL
Piroxicam	C	ORAL
Diclofenac	C	ORAL

Date:02/13/04ISR Number: 4294781-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Jaw
	Angina Pectoris
Disability	Anxiety
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Cardiac Murmur
	Carotid Artery Stenosis
	Coronary Artery Disease
	Depression
	Duodenal Ulcer Haemorrhage

		Duodenitis					
		Dyspnoea					
		Food Poisoning	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gout		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemoglobin Decreased		[Therapy			
		Hypertension		Unspecified]	C		
		Loss Of Consciousness		Vicodin Tablets	C		
		Medication Error		Xanax	C		
		Myocardial Infarction		Covera	C		
		Oesophageal Disorder		Trimox	C		
		Otitis Media		Atenolol	C		
		Overdose		Soma	C		
		Peptic Ulcer Haemorrhage		Relafen	C		

Date:02/13/04ISR Number: 4294782-XReport Type:Expedited (15-DaCompany Report #WAES 0307BEL00063
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
				Acetaminophen	C		ORAL
				Diclofenac	C		ORAL
				Esomeprazole			
				Magnesium	C		ORAL
				Tramadol			
				Hydrochloride	C		ORAL
				Fluoxetine			
				Hydrochloride	C		ORAL
				Piroxicam	C		ORAL

Date:02/13/04ISR Number: 4297555-7Report Type:Expedited (15-DaCompany Report #TPA2004A00090
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia	Consumer	Actos (Pioglitazone			
Initial or Prolonged		Cardiac Failure	Health	Hydrochloride) (30			
		Congestive	Professional	Milligram, Tablets)	PS		ORAL
30 MG, 1 IN 1							
		Condition Aggravated					
D, PER ORAL							

	Haemorrhage	Vioxx (Rofcoxib)	SS
	Oedema Peripheral	Metoprolol (Metoprolol)	C
	Open Wound	Amiodarone (Amiodarone)	C
	Pneumonia	Zaroxolyn (Metolazone)	C
	Renal Impairment	Glyburide (Glibenclamide)	C
	Treatment Noncompliance	Isosorbide Dn (Isosorbide Dinitrate)	C
		Norvasc (Amlodipine Besilate)	C
		Furosemide (Furosemide)	C
		Hydralazine (Hydralazine)	C
		Claritin-D (Narine Repetabs)	C
		Aspirin	

(Acetylsalicyclic
Aicd) C

Date:02/16/04ISR Number: 4294927-1Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0398711A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rash Generalised		Lamictal	PS	Glaxosmithkline	ORAL	6	MON
			Vioxx	SS			UNKNOWN	

Date:02/16/04ISR Number: 4295001-0Report Type:Expedited (15-DaCompany Report #200214587FR
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperthyroidism		Hydrocortisone	PS	Aventis Pharmaceuticals Inc.	ORAL		
			Vioxx	SS		ORAL		
			Sintrom	SS				
			Mopral	SS		ORAL		
			Rebif	SS			SUBCUTANEOUS	
			Lipanthyl "Thissen"	SS		ORAL		
			Didronel	C				
			Calcium With Vitamin D	C				
			Lysanxia 10 Mg	C				
			Contramal	C				

Date:02/17/04ISR Number: 4296669-5Report Type:Expedited (15-DaCompany Report #WAES 01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Other	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON

	Injury	Ma Huang Extract	C
1523 DAY			
	Insomnia	Ambien	C
	Nervous System Disorder		
	Pain		
	Pulmonary Embolism		
	Shock		
	Suicidal Ideation		

Date:02/17/04ISR Number: 4296683-XReport Type:Expedited (15-DaCompany Report #WAES 01100374
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnestic Disorder
	Antinuclear Antibody Positive
Disability	Arthritis
Other	Blood Pressure Increased
	Cerebrovascular Accident
	Disease Progression
	Heart Rate Increased
	Hypersensitivity
	Hypertension
	Hypokalaemia
	Insomnia
	Lacunar Infarction

		Nephrolithiasis					
		Palpitations					
		Periarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL
		Swelling Face		Vioxx	SS	Merck & Co., Inc	ORAL
		Vertigo					

Date:02/17/04ISR Number: 4296693-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Antiphospholipid Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
Other		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Increased		[Therapy			
		Cerebrovascular Accident		Unspecified]	C		
		Chronic Fatigue Syndrome					
		Colonic Polyp					
		Dyspepsia					
		Emotional Distress					
		Gallbladder Disorder					
		Injury					
		Ovarian Cyst					
		Transient Ischaemic					
		Attack					
		Uterine Disorder					

Date:02/17/04ISR Number: 4296698-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Bronchitis					
		Chest Pain					
		Dizziness					
		Dyspnoea					
		Epididymitis					
		Foot Fracture					

Foreign Body Trauma
Heart Rate Increased
Infertility Male
Injury
Myocardial Infarction
Sinusitis
Tinea Cruris
Tinea Infection
Viral Rash

Date:02/17/04ISR Number: 4296700-7Report Type:Expedited (15-DaCompany Report #WAES 0209GBR00066
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neutropenia		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Other			Tramadol	SS				
			Acetaminophen	C				
			Fosamax	C		ORAL		
			Tolterodine	C		ORAL		
			Senna	C		ORAL		
			Citalopram	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/04ISR Number: 4296701-9Report Type:Expedited (15-DaCompany Report #WAES 0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
44 DAY						
Disability	Adjustment Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Adjustment Disorder With		Vioxx	SS	Merck & Co., Inc	ORAL
113 DAY						
	Mixed Anxiety And		Vioxx	SS	Merck & Co., Inc	ORAL
44 DAY						
	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL
113 DAY						
	Anxiety		Vicodin Tablets	C		
	Arthralgia		Hydrocodone			
	Back Pain		Bitartrate	C		
	Blood Pressure Increased		Relafen	C		
	Blood Triglycerides					
	Increased					
	Breast Pain					
	Chest Pain					
	Chondromalacia					
	Contusion					
	Coronary Artery					
	Atherosclerosis					
	Depression					
	Dizziness					
	Dyspepsia					
	Dyspnoea					
	Electrocardiogram St					
	Segment Elevation					
	Extrasystoles					
	Fatigue					
	Hypertension					
	Hypotension					
	Joint Sprain					
	Keratoacanthoma					
	Mitral Valve Incompetence					
	Pericarditis					
	Pigmented Naevus					
	Pneumonia Chlamydial					
	Tricuspid Valve					
	Incompetence					
	Upper Respiratory Tract					
	Infection					

Date:02/17/04ISR Number: 4296703-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Disorder Blood Cholesterol Increased Blood Triglycerides Increased Chest Pain Cystocele Deep Vein Thrombosis Depression Dizziness Dyspepsia Dyspnoea Generalised Anxiety Disorder

		Hot Flush					
		Injury					
		Metrorrhagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Nausea		Fioricet Tablets	C		
		Rectocele		Fioricet Tablets	C		
		Stress Incontinence		Aspirin	C		
		Urinary Incontinence		Aspirin	C		
				Lipitor	C		
				Ambien	C		
				Zyrtec	C		
				Vivelle	C		
TOPICAL							
				Motrin	C		
				Prometrium	C		

Date:02/17/04ISR Number: 4296704-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bacteriuria		Lasix (Furosemide)	C		
Disability		Cardiac Disorder		Hydrodiuril	C		
		Cataract					
		Culture Urine Positive					
		Deafness Neurosensory					
		Diabetic Complication					
		Diabetic Retinopathy					
		Electrocardiogram T Wave					
		Inversion					
		Escherichia Infection					
		Feeling Abnormal					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hyperlipidaemia					
		Hypertension					
		Hypoaesthesia					
		Hypoglycaemia					
		Injury					
		Joint Swelling					
		Lacunar Infarction					

Myocardial Infarction
Nocturia
Oedema Peripheral
Refusal Of Treatment By
Patient
Skin Lesion
Spinal Column Stenosis
Weight Increased

Date:02/17/04ISR Number: 4296706-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Disability	Cardiac Valve Disease
Other	Chondrocalcinosis
	Pyrophosphate
	Coronary Artery Disease
	Myocardial Infarction

Thrombosis

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/04ISR Number: 4296707-XReport Type:Expedited (15-DaCompany Report #WAES 0303GBR00006
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Diabetes Mellitus		Omeprazole	SS			3	DAY
	Diarrhoea							
	Dyspepsia							
	Gastric Disorder							
	Renal Failure Chronic							

Date:02/17/04ISR Number: 4296709-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	540	DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	540	DAY
Disability	Cardiac Valve Disease		[Therapy					
	Cardiomegaly		Unspecified]	C				
	Coronary Artery Disease		Norco	C				
	Coronary Artery Stenosis		Atenolol	C				
	Diabetes Mellitus		Tenormin	C				
	Diabetes Mellitus		Celebrex	C				
	Non-Insulin-Dependent		Chlorthalidone	C				
	Electrocardiogram St		Ultram	C				
	Segment Depression		Diovan	C				
	Emotional Distress		Avandia	C				
	Essential Hypertension		Hygroton	C				
	Gastrooesophageal Reflux		Cyclobenzaprine					
	Disease		Hydrochloride	C				
	Hypercholesterolaemia		Cardizem	C				

	Hypoxia	Propecia	C
	Injury	Glucovance	C
	Insomnia	Hydrocodone	
	Muscle Strain	Hydrochloride	C
	Nervousness		
	Platelet Count Decreased		
	Pleural Effusion		
	Quadruple Vessel Bypass		
	Graft		
	Respiratory Failure		
	Thrombosis		

Date:02/17/04ISR Number: 4296710-XReport Type:Expedited (15-DaCompany Report #WAES 0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Anxiety
	Atherosclerosis
	Back Disorder

		Back Injury					
		Back Pain					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Lortab	C		
		Depression		Amitriptyline			
		Ejection Fraction		Hydrochloride	C		
874	DAY						
		Decreased		Amitriptyline			
		Emotional Distress		Hydrochloride	C		
874	DAY						
		High Density Lipoprotein		Celebrex	C		
362	DAY						
		Decreased		Trazodone			
		Hyperlipidaemia		Hydrochloride	C		
1291	DAY						
		Hypertension		Trazodone			
		Hypotension		Hydrochloride	C		
1291	DAY						
		Impaired Work Ability		Cipro	C		
		Insomnia		Neurontin	C		
		Loss Of Consciousness		Hydrocodone			
		Mitral Valve Incompetence		Bitartrate	C		
		Myocardial Infarction		Lorazepam	C		
2	DAY						
		Neck Injury		Methocarbamol	C		
957	DAY						
		Neck Pain					
		Osteoarthritis					
		Pain					
		Panic Attack					

Date:02/17/04ISR Number: 4296716-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest

Cardiac Disorder
Cardiac Failure
Congestive
Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Diverticulitis
Haematemesis
Haematoma
Hyperlipidaemia
Hypersensitivity
Hypertension
Muscle Contractions
Involuntary
Non-Cardiac Chest Pain
Oesophagitis
Osteoarthritis
Pulmonary Oedema
Retroperitoneal
Haemorrhage
Stent Occlusion
Tendonitis

	Urticaria Ventricular Fibrillation Visual Acuity Reduced	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	220 DAY
			Propacet	C			
			Wellbutrin	C			
			Prevacid	C			

Date:02/17/04ISR Number: 4296721-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased Cardiac Disorder Coronary Artery Disease Myocardial Infarction Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Atenolol	C			

Date:02/17/04ISR Number: 4296722-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA00613
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Death Dizziness Fall Haemorrhage Subdural Haematoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/17/04ISR Number: 4296725-1Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY

	Coronary Artery	Professional	Estradiol Valerate				
	Atherosclerosis		And Norethindrone	C			ORAL
	Coronary Artery Disease		Omeprazole	C			ORAL
1 DAY							
	Myocardial Ischaemia						

Date:02/17/04ISR Number: 4296726-3Report Type:Expedited (15-DaCompany Report #WAES 0402USA00709
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cervix Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
4 MON						
Other	Depression					
	Dyspnoea					
	Joint Injury					
	Mental Disorder					
	Panic Disorder					
	Road Traffic Accident					
	Swelling Face					
	Tuberculosis					

Date:02/17/04ISR Number: 4296727-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Glucose Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Potassium Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Sodium Decreased		Vioxx	SS	Merck & Co., Inc			
	Cerebral Infarction		[Therapy					
	Cerebrovascular Accident		Unspecified]	C				
	Chest Pain		Tylenol	C				
	Chest X-Ray Abnormal		Proventil	C				
	Chronic Sinusitis		Allopurinol	C				
	Colonic Polyp		Elavil	C		ORAL		
	Depression		Fiorinal With					
	Felty'S Syndrome		Codeine	C				
	Herpes Zoster		Azathioprine	C				
	Hiatus Hernia		Tegretol	C				
	Inflammation		Tegretol	C				
	Nephrolithiasis		Tegretol	C				
	Nocturia		Zyrtec	C				
	Pain		Advil	C				
	Pancytopenia		Remicade	C				
INTRAVENOUS								
	Platelet Disorder		Purinethol	C				
	Pyrexia		Methotrexate	C				
	Rheumatoid Arthritis		Prilosec	C				
	Sepsis		K-Dur	C				
	Tinnitus		Triamterene	C				
	Urine Ketone Body Present		Prednisone	C				
	Urobilin Urine Present							
	Viral Infection							

Date:02/17/04ISR Number: 4296729-9Report Type:Expedited (15-DaCompany Report #WAES 0311ZAF00015
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
							10	WK
Initial or Prolonged	Circulatory Collapse	Professional	Estrogens,					
	Pulmonary Embolism		Conjugated	C		ORAL		
							10	YR

Date:02/17/04ISR Number: 4296731-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Blister
Other	Catheter Site Infection
	Cerebral Atrophy
	Chest Wall Abscess
	Cyst
	Emotional Distress
	Encephalitis Brain Stem
	Haematocrit Decreased
	Herpes Ophthalmic
	Herpes Zoster
	Hodgkin'S Disease Nodular Sclerosis Stage
	Unspecified Intervertebral Disc

		Displacement					
		Lacunar Infarction					
		Meningitis Herpes					
		Meningitis Viral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nephrotic Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Pruritus	Professional				
		Staphylococcal Sepsis					
		Vestibulitis					

Date:02/17/04ISR Number: 4296734-2Report Type:Expedited (15-DaCompany Report #WAES 0402USA00678
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Myocardial Infarction					

Date:02/17/04ISR Number: 4297100-6Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00112
Age:82 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Melaena	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Rectal Haemorrhage	Professional	Aspirin	SS		ORAL
				Atenolol	C		ORAL
				Isosorbide Mononitrate	C		ORAL
				Levothyroxine Sodium	C		ORAL
				Pyridoxine	C		ORAL

Date:02/17/04ISR Number: 4297103-1Report Type:Expedited (15-DaCompany Report #WAES 0402ZAF00014
Age:69 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged							

Date:02/17/04ISR Number: 4300757-4Report Type:Expedited (15-DaCompany Report #2002CG01722
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective	Foreign	Mopral	PS		ORAL	20 MG QD PO	
Initial or Prolonged	Hyperthyroidism	Health	Vioxx	SS		ORAL	25 MG DAILY	
		Professional					PO	
		Other	Sintrom	SS				
			Rebif	SS				
			Hydrocortisone	SS		ORAL	25 MG DAILY	
							PO	
			Lipanthyl "Bristol-Myers Squibb"	SS		ORAL	200 MG DAILY	
							PO	
			Didronel "Aventis Pharma"	SS				
			Orocal	SS				
			Lysanxia	SS				
			Contramal	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/04ISR Number: 4298520-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA02199
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Small Intestine Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirin	C		
			Lipitor	C		
			Vitamins (Unspecified)	C		
			Calcium (Unspecified)	C		
			Atacand	C		
			Aciphex	C		

Date:02/18/04ISR Number: 4298521-8Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00227
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 303 DAY	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Benzalkonium Chloride And Mineral Oil And Triclosan	C		
	Gastrointestinal Haemorrhage					
	Myocardial Infarction		Dermatologic (Unspecified)	C		

Date:02/18/04ISR Number: 4298523-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA02112
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Myocardial Infarction					

Date:02/18/04ISR Number: 4298525-5Report Type:Expedited (15-DaCompany Report #WAES 0402DEU00057
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Asthenia		Bisoprolol Fumarate	SS		ORAL		
	Cardiac Failure		Diazepam	SS		ORAL	6	DAY
	Drug Interaction		Paroxetine	SS		ORAL	10	DAY
	Pain		Glyburide	SS		ORAL		
	Somnolence		Allopurinol	C		ORAL		
	Urinary Tract Infection		Aspirin	C		ORAL		
	Vomiting		Metformin	C		ORAL		

Date:02/18/04ISR Number: 4298528-0Report Type:Expedited (15-DaCompany Report #WAES 0210NZL00211
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Cataract		Aspirin	C		ORAL		
	Disorientation		Atorvastatin Calcium	C		ORAL		
	Retinal Degeneration		Diltiazem Hydrochloride	C		ORAL		
	Road Traffic Accident							
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/04ISR Number: 4298530-9Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00139
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C				
			Fentanyl	C				
TOPICAL								
			Fluoxetine	C				

Date:02/18/04ISR Number: 4298800-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased		Xanax	C				
	Cellulitis		Aspirin	C				
	Coronary Artery Disease		Celebrex	C				
	Coronary Artery Stenosis		Zyrtec	C				
	Coronary Artery Thrombosis		Prozac	C				
	Electrocardiogram T Wave Abnormal		Zestril	C				
	Emotional Distress		Naproxen	C				
	Haemangioma		Prilosec	C				
	Heart Rate Decreased							
	Lumbar Spinal Stenosis							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nervousness							
	Oedema Peripheral							
	Radiculopathy							
	Sinus Bradycardia							
	Spinal Osteoarthritis							
	Urethritis							
	Ventricular Hypokinesia							

Date:02/18/04ISR Number: 4298801-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT

Hospitalization - Initial or Prolonged	Arteriospasm Coronary Blood Pressure Decreased Blood Triglycerides Increased Coronary Artery Disease Cystocele Diverticulitis Dyspepsia Dyspnoea Electrocardiogram T Wave Inversion Gastrooesophageal Reflux Disease Generalised Anxiety Disorder Hot Flush Hypercholesterolaemia Myocardial Infarction Nausea Prinzmetal Angina

	Stress Incontinence						
	Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Varicose Vein	Health	Vioxx	PS	Merck & Co., Inc	ORAL	84 DAY
	Venous Insufficiency	Professional	Fioricet Tablets	C			
	Weight Increased		Fioricet Tablets	C			
			Alprazolam	C			
			Gnc Womens Ultra Mega	C			
			Aspirin	C			
			Aspirin	C			
			Lipitor	C			
			Vitamin E	C			
			Ambien	C			
			Zyrtec	C			
			Vivelle	C			TOPICAL
			Motrin	C			
			Lecithin	C			
			Prilosec	C			
			Paxil	C			
			Prometrium	C			

Date:02/18/04ISR Number: 4298802-8Report Type:Expedited (15-DaCompany Report #WAES 0401CAN00052
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/18/04ISR Number: 4298805-3Report Type:Expedited (15-DaCompany Report #WAES 0402USA00978
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	
	Haematemesis		Fosamax	SS		ORAL	1090 DAY
	Rectal Haemorrhage		Enbrel	SS		SUBCUTANEOUS	

Albuterol Sulfate	C	
Fexofenadine Hydrochloride	C	ORAL
Cozaar	C	ORAL
Paroxetine Hydrochloride	C	ORAL
Isosorbide	C	ORAL
Atorvastatin Calcium	C	ORAL
Diltiazem Hydrochloride	C	ORAL

Date:02/18/04ISR Number: 4298809-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Bursitis
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Crying
	Decreased Appetite

		Depression					
		Fatigue					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
9	MON						
		Lacunar Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Meniscus Lesion		Vioxx	SS	Merck & Co., Inc	ORAL
9	MON						
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Amitriptyline			
		Disorder		Hydrochloride	C		
		Rebound Hypertension		Analgesic Or			
		Treatment Noncompliance		Anesthetic			
		Vision Blurred		(Unspecified)	C		
		Weight Decreased		Zoloft	C		
526	DAY						
		Weight Increased		Atenolol	C		
				Lipitor	C		
				Premarin	C		
				Hydrodiuril	C		ORAL
				Altace	C		

Date:02/18/04ISR Number: 4300122-XReport Type:Expedited (15-DaCompany Report #200214587FR
Age:45 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Goitre	Foreign	Hydrocortisone			
Initial or Prolonged		Hyperthyroidism	Other	Tablets	PS		ORAL
25 MG/DAY PO							
				Rofecoxib (Vioxx)			
				Tablets	SS		ORAL
25 MG/DAY PO							
				Acenocoumarol			
				(Sintrom)	SS		
				Omeprazole (Mopral)			
				Capsules	SS		ORAL
PO							
				Interferon Beta			
				(Rebif)	SS		
SUBCUTANEOUS	SC						
				Fenofibrate			
				(Lipanthyl			

	"Thissen") Capsules	SS	ORAL
200 MG/DAY PO			
	Etidronate Disodium (Didronel)	C	
	Ergocalciferol, Calcium Phosphate, Calcium Sodium Lactate (Calcium With Vitamin D)	C	
	Prazepam (Lysanxia 10 Mg)	C	
	Tramadol Hydrochloride (Contramal)	C	

Date:02/18/04ISR Number: 4300458-2Report Type:Expedited (15-DaCompany Report #WAES 0401USA01540
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Valve Stenosis
	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Cardiac Murmur

	Chest Pain Dehydration Dyspnoea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Impairment	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG DAILY PO; 25 MG/DAILY PO	14 DAY
			Fosamax	C				
			Alfacalcidol	C				
			Aprindine Hydrochloride	C				
			Calcium (Unspecified)	C				
			Nitrazepam	C				
			Pravastatin Na	C				
			Spironolactone	C				

Date:02/18/04ISR Number: 4301118-4Report Type:Expedited (15-DaCompany Report #A02200302177
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis Cholestatic Prothrombin Time Prolonged	Foreign Health Professional Other	Arixtra - (Fondaparinux Sodium) - Solution - 2.5 Mg	PS		SUBCUTANEOUS	2.5 MG OD SUBCUTANEOUS	5 DAY
			Vioxx - (Rofecoxib)	SS		ORAL	ORAL	
			Vancomycine (Vancomycin)	C				

Date:02/19/04ISR Number: 4299424-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 31 DAY	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 31 DAY	Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Pressure Decreased		Albuterol	C		
RESPIRATORY						
	Cerebrovascular Accident					
(INHALATION)						
	Chest Pain		Trinalin	C		
	Chronic Obstructive		Klonopin	C		
	Pulmonary Disease		Clonidine	C		
	Dysarthria		Triamterene	C		
	Electrocardiogram Qt		Cyclobenzaprine			
	Prolonged		Hydrochloride	C		ORAL
	Headache		Cyclobenzaprine			
	Heart Rate Irregular		Hydrochloride	C		ORAL
	Hemiparesis		Prempro	C		
	Hypertensive Crisis		Relafen	C		ORAL
	Hypokalaemia					
	Injury					
	Lacunar Infarction					
	Respiratory Rate					
	Increased					
	Sinusitis					
	Stress					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/04ISR Number: 4299433-6Report Type:Expedited (15-DaCompany Report #WAES 0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Anxiety	Professional	Fosamax	C		ORAL		
	Aortic Atherosclerosis		Celebrex	C				
	Bradycardia		Celebrex	C				
	Coronary Artery Disease		Celebrex	C				
	Coronary Artery Stenosis		Celebrex	C				
	Coronary Ostial Stenosis		Duragesic	C				
	Hypertension							
	Injury							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nervousness							
	Ventricular Hypertrophy							

Date:02/19/04ISR Number: 4299436-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Actinic Keratosis
Other	Anaemia
	Aortic Valve Incompetence
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Cataract
	Closed Head Injury
	Contusion
	Dermographism
	Drug Ineffective
	Dry Skin
	Dyspepsia
	Dyspnoea
	Dyspnoea Exertional
	Dysuria
	Ear Pain
	Eye Haemorrhage
	Eye Pain
	Fall

Glaucoma
Headache
Hearing Impaired
Heart Sounds Abnormal
Hypertension
Hypoacusis
Hypokalaemia
Injury
Intervertebral Disc
Degeneration
Keratoconjunctivitis
Sicca
Laceration
Loose Body In Joint
Migraine
Mitral Valve Incompetence
Nasal Septum Deviation
Nasal Septum Ulceration

		Neck Pain					
		Neurodermatitis					
		Optic Nerve Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Papilloedema	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Photopsia		Fosamax	C		ORAL
		Polymyalgia Rheumatica		Prempro	C		
		Pruritus Generalised		Advil	C		
		Pulmonary Valve		Synthroid	C		
		Incompetence		Claritin	C		
		Rash					
		Refusal Of Treatment By					
		Patient					
		Rhinitis					
		Sinusitis					
		Skeletal Injury					
		Skin Laceration					
		Stress					
		Syncope					
		Vision Blurred					
		Visual Acuity Reduced					
		Visual Disturbance					

Date:02/19/04ISR Number: 4299804-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram St		Vicodin Tablets	C		
		Segment Elevation		Aspirin	C		ORAL
		Electrocardiogram T Wave		Lipitor	C		ORAL
		Inversion		Plavix	C		ORAL
41	DAY						
		Heart Rate Decreased		Plavix	C		ORAL
		Hypertension		Plavix	C		ORAL
41	DAY						
		Hypothyroidism		Flomax (Tamsulosin			
		Injury		Hydrochloride)	C		
		Musculoskeletal		Plavix	C		ORAL
		Discomfort		Colace	C		
		Myocardial Infarction		Prevacid	C		
		Post Procedural		Synthroid	C		

	Complication	Prinivil	C	ORAL
		Zestril	C	

Date:02/19/04ISR Number: 4299817-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Benign Prostatic Hyperplasia
	Bundle Branch Block Left
	Cardiac Arrest
	Cardiac Failure
	Congestive Cellulitis
	Chronic Obstructive Pulmonary Disease

		Coronary Artery Disease					
		Delirium					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Inguinal Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Tylenol	C		
		Ischaemia		Saw Palmetto	C		
		Liver Function Test		Ultram	C		
		Abnormal		Lipitor	C		
		Myocardial Infarction		Lumigan	C		
		Osteoarthritis		Corticosteroids			
		Osteoporosis		(Unspecified)	C		
PARENTERAL							
		Rash		Betagan	C		
		Spinal Column Stenosis		Relafen	C		
		Staphylococcal Sepsis		Paxil	C		

Date:02/19/04ISR Number: 4299819-XReport Type:Expedited (15-DaCompany Report #WAES 0402NOR00011
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
	Sudden Death					
	Vomiting					

Date:02/19/04ISR Number: 4299820-6Report Type:Expedited (15-DaCompany Report #WAES 0402USA00725
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Feeling Abnormal					
	Gastric Ulcer					
	Rectal Haemorrhage					
	Weight Decreased					

Date:02/19/04ISR Number: 4299826-7Report Type:Expedited (15-DaCompany Report #WAES 0402DEU00066
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Toxicity		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hepatocellular Damage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Herpes Simplex		Hyzaar	C		ORAL		
			Metoprolol Succinate	C		ORAL		

Date:02/19/04ISR Number: 4299827-9Report Type:Expedited (15-DaCompany Report #WAES 0402USA00262
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
							4	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/04ISR Number: 4299828-0Report Type:Expedited (15-DaCompany Report #WAES 0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Eye Haemorrhage		Norvasc	C				
Disability	Eye Injury		Lipitor	C				
Other	Gallbladder Disorder							
	Ischaemic Stroke							

Date:02/19/04ISR Number: 4299829-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00108
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Ibuprofen	C				
Disability	Arthropathy		Insulin	C				
Other	Asthma							
	Atherosclerosis							
	Cardiac Failure							
	Congestive							
	Cardiac Valve Disease							
	Cerebrovascular Accident							
	Chronic Obstructive							
	Pulmonary Disease							
	Emotional Distress							
	Glaucoma							
	Kidney Infection							
	Pulmonary Hypertension							
	Rectal Haemorrhage							
	Sleep Apnoea Syndrome							
	Thrombosis							
	Vertigo							

Date:02/19/04ISR Number: 4299830-9Report Type:Expedited (15-DaCompany Report #WAES 0401CAN00089
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anorexia	Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY					
Hospitalization -	Decreased Appetite	Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY					
Initial or Prolonged	Localised Infection	Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY					
	Peripheral Coldness	Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY					
	Thirst	Acetaminophen And			
	Urine Output Decreased	Codeine Phosphate	C		ORAL
		Zopiclone	C		
		Cyclobenzaprine Hydrochloride	C		
		Cyclobenzaprine Hydrochloride	C		
		Cyclobenzaprine Hydrochloride	C		
		Lorazepam	C		

Date:02/19/04ISR Number: 4299831-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Arthralgia

		Chest X-Ray Abnormal					
		Coronary Artery Disease					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ecchymosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Ejection Fraction		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased		Percocet	C		
		Emotional Distress		Mobic	C		
		Fatigue		Skelaxin	C		
		Groin Pain		Zantac	C		
		Heart Rate Increased					
		Inflammation					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Palpitations					
		Respiratory Rate					
		Increased					

Date:02/20/04ISR Number: 4300267-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arterial Occlusive	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Arterial Stenosis Limb		Herbs (Unspecified)	C		
840 DAY							
Other		Barrett'S Oesophagus		Prilosec	C		
		Burning Sensation					
		Cerebrovascular Accident					
		Dizziness					
		Dizziness Postural					
		Dyspepsia					
		Dysphagia					
		Emotional Distress					
		Emphysema					
		Exostosis					
		Gait Disturbance					
		Gallbladder Disorder					
		Gastrooesophageal Reflux					
		Disease					
		Hiatus Hernia					
		Hypertension					
		Injury					

Joint Sprain
Joint Swelling
Lacunar Infarction
Ligament Injury
Memory Impairment
Oesophageal Achalasia
Oesophageal Stenosis
Osteoarthritis
Pain In Extremity
Peripheral Vascular
Disorder
Transient Ischaemic
Attack
Tremor

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300276-5Report Type:Expedited (15-DaCompany Report #WAES 01080883
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Fatigue	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Macular Oedema		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vision Blurred		Lipitor	C				
	Visual Acuity Reduced		Celebrex	C		ORAL		
			Zocor	C				
			Celebrex	C		ORAL		
			Prevacid	C				
			Singulair	C		ORAL		
			Singulair	C		ORAL		

Date:02/20/04ISR Number: 4300281-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01429
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Calcinosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	146	DAY
	Chondrocalcinosis	Professional	Norvasc	C			1549	DAY
	Dermal Cyst		Premarin	C			201	DAY
	Headache		Dyazide	C				
	Insomnia		Sular	C				
	Myalgia							
	Pulmonary Embolism							

Date:02/20/04ISR Number: 4300284-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		

Disability	Back Pain	Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY					
Other	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Depression	Vioxx	SS	Merck & Co., Inc	ORAL
	Duodenitis	Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY					
	Gastritis				
	Gastrointestinal				
	Haemorrhage				
	Haematochezia				
	Hypertension				
	Hypokalaemia				
	Laryngitis				
	Migraine				
	Mitral Valve Incompetence				
	Mitral Valve Prolapse				
	Myocardial Infarction				
	Palpitations				
	Pelvic Peritoneal				
	Adhesions				
	Phlebothrombosis				
	Stent Occlusion				
	Syncope				
	Tricuspid Valve				
	Incompetence				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300303-5Report Type:Expedited (15-DaCompany Report #WAES 0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Folic Acid	C				
	Cardiac Failure		Arava	C				
	Congestive		Methotrexate	C				
	Diarrhoea		Aredia	C				
	Dyspnoea Paroxysmal		Prednisone	C				
	Nocturnal		Inderal	C				
	Hypertension		Inderal	C				
	Insomnia							
	Melaena							
	Myocardial Infarction							
	Nightmare							
	Palpitations							
	Panic Attack							
	Phlebitis Superficial							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Stress							
	Thrombophlebitis Superficial							
	Thrombosis							
	Tricuspid Valve Incompetence							
	Upper Respiratory Tract Infection							
	Weight Increased							

441 DAY

Date:02/20/04ISR Number: 4300304-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Arteriospasm Coronary
	Arthralgia
	Asthma
	Blood Triglycerides Increased

Cystocele
Deep Vein Thrombosis
Diverticulitis
Dyspnoea
Dysuria
Flank Pain
Gastroenteritis
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder
Haematuria
Haemorrhoids
Hot Flush
Hypercholesterolaemia
Menopausal Symptoms
Myocardial Infarction
Nausea

	Neck Pain						
	Postoperative Ileus						
	Prinzmetal Angina	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rhinitis Allergic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	84 DAY
	Sinusitis	Professional	Fioricet Tablets	C			
	Stress Incontinence		Fioricet Tablets	C			
	Urinary Tract Infection		Alprazolam	C			
	Venous Insufficiency		Gnc Womens Ultra				
	Vertigo		Mega	C			
	Weight Increased		Aspirin	C			
			Aspirin	C			
			Lipitor	C			
			Vitamin E	C			
			Ambien	C			
			Zyrtec	C			
			Vivelle	C			TOPICAL
			Motrin	C			
			Lecithin	C			
			Prilosec	C			
			Paxil	C			
			Prometrium	C			

Date:02/20/04ISR Number: 4300305-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01382
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY
	Acute Respiratory						
	Distress Syndrome						
	Agitation						
	Bundle Branch Block Right						
	Cardiac Failure						
	Congestive						
	Cardiogenic Shock						
	Chronic Obstructive						
	Pulmonary Disease						
	Confusional State						
	Constipation						

Contusion
Cough
Disorientation
Dyspnoea
Gastritis
Gastrointestinal
Haemorrhage
Helicobacter Infection
Ischaemic Cardiomyopathy
Pneumonia Aspiration
Pulmonary Haemorrhage
Pulmonary Hypertension
Urine Output Decreased
Ventricular Arrhythmia
Ventricular Fibrillation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300307-2Report Type:Expedited (15-DaCompany Report #WAES 0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc		1	DAY
Other	Coronary Artery Atherosclerosis		Flexeril	C				
			Monopril	C				
	Dermoid Cyst		Pravachol	C				
	Diabetes Mellitus Non-Insulin-Dependent							
	Emotional Distress							
	Eructation							
	Hypersensitivity							
	Muscle Spasms							
	Overdose							
	Polytraumatism							
	Sciatica							
	Tendonitis							
	Trigger Finger							
	Weight Decreased							
	White Blood Cell Count Increased							

Date:02/20/04ISR Number: 4300313-8Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00008
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Aspirin And Magnesium Oxide	SS		ORAL		
	Helicobacter Infection		Atenolol Msd	C		ORAL		
	Melaena		Bendroflumethiazide	C		ORAL		

Date:02/20/04ISR Number: 4300754-9Report Type:Direct Company Report #CTU 212715
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Abdominal Adhesions	Fosamax 70 Mg Po Q Week	PS	ORAL 70 MG PO Q WEEK
	Abdominal Pain			
	Mucosal Ulceration			
	Occult Blood Positive	Vioxx 25 Mg Po Q Day	SS	ORAL 25 MG PO Q DAY
	Sepsis			
	Small Intestinal Perforation	Prednisone	C	
		Atenolol	C	
		Levoxyl	C	
		Diazepam	C	

Date:02/20/04ISR Number: 4300844-0Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Alopecia
Other	Asthenia
	Back Pain
	Blindness
	Blood Pressure Increased

	Carotid Artery Stenosis					
	Cataract					
	Cerebral Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Confusional State		Heparin	SS		
	Depression		Provera	SS		
	Epistaxis		[Therapy			
	Flushing		Unspecified]	C		
	Gastrooesophageal Reflux		Tylenol With Codeine			
	Disease		#3	C		
	Gout		Captopril	C		
	Haemorrhage Intracranial		Capozide	C		
	Headache		Cisapride	C		
	Hemianopia Homonymous		Glyburide	C		
	Herpes Zoster					
	Hyperhidrosis					
	Hypertension					
	Injury					
	Nasal Congestion					
	Nausea					
	Pain					
	Pallor					
	Pneumonia					
	Rash					
	Rift Valley Fever					
	Sciatica					
	Tachycardia					
	Thyroid Mass					

Date:02/20/04ISR Number: 4300851-8Report Type:Expedited (15-DaCompany Report #WAES 01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Other	Blood Cholesterol
	Increased
	Blood Pressure
	Fluctuation
	Blood Pressure Increased
	Bunion
	Cardiac Failure
	Congestive
	Cardiovascular Disorder

Chest Pain
Constipation
Drug Intolerance
Dyspnoea
Electrocardiogram
Abnormal
Fall
Gait Disturbance
Gastric Disorder
Globulins Increased
Headache
Hyperhidrosis
Hypertensive Heart
Disease
Intervertebral Disc
Disorder

		Joint Sprain					
		Limb Discomfort					
		Lumbar Spinal Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Myalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Tylenol	C		
		Oedema		Aspirin	C		
		Oedema Peripheral					
		Onychomycosis					
		Osteoarthritis					
		Osteoporosis					
		Pulmonary Granuloma					
		Renal Failure					
		Respiratory Rate					
		Increased					
		Rotator Cuff Syndrome					
		Sinusitis					
		Spinal Osteoarthritis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		Wound Infection					

Date:02/20/04ISR Number: 4300853-1Report Type:Expedited (15-DaCompany Report #WAES 0207USA01010
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
Initial or Prolonged		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Blood Cholesterol		Vicodin Tablets	C		
		Increased		Celebrex	C		
		Cardiac Disorder		Baycol	C		
		Cold Sweat		Motrin	C		
		Contusion					
		Drug Hypersensitivity					
		Dyspnoea					
		Emotional Distress					
		Fall					
		Heart Rate Increased					

Hyperhidrosis
Hypertension
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Myocardial Infarction
Palpitations
Respiratory Disorder
Respiratory Rate
Increased
Rib Fracture
Rotator Cuff Syndrome

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300857-9Report Type:Expedited (15-DaCompany Report #WAES 0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Atrial Fibrillation		Premarin	C				
Other	Corneal Deposits		Estratab	C				
	Dizziness		Menest	C				
	Dyspnoea		Armour Thyroid					
	Haematoma		Tablets	C				
	Haematuria		Trazodone					
	Hypertension		Hydrochloride	C				
	Hypertensive Crisis		Garlic Extract	C				
	Injury		Synthroid	C				
	Musculoskeletal Disorder		Methotrexate	C				
	Oedema Peripheral							
	Renal Cyst							
	Transient Ischaemic Attack							

Date:02/20/04ISR Number: 4300858-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Nitroglycerin	C				
	Coronary Artery Disease		Tolinase	C				
	Drug Ineffective		Verapamil	C				
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Hyperhidrosis							
	Injury							
	Intervertebral Disc Displacement							
	Muscle Spasms							
	Musculoskeletal Chest Pain							
	Myalgia							
	Myocardial Infarction							
	Pain In Extremity							

Palpitations
Productive Cough
Pyrexia
Sciatica
Swelling
Treatment Noncompliance
Varicose Vein

Date:02/20/04ISR Number: 4300859-2Report Type:Expedited (15-DaCompany Report #WAES 0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accident
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Anxiety
	Application Site Irritation

		Arthralgia					
		Back Pain					
		Blood Pressure Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Crepitations		Vioxx	SS	Merck & Co., Inc	ORAL
		Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Aspirin	C		
		Gastrooesophageal Reflux		Tenormin	C		
		Disease		Tenormin	C		
		Groin Pain		Lipitor	C		
		Haemorrhoids		Clonidine	C		
TOPICAL							
		Heart Rate Decreased		Clonidine	C		ORAL
		Hypertension		Monopril	C		
		Joint Crepitation		Ibuprofen	C		
		Mitral Valve Incompetence		Anaprox	C		
		Muscular Weakness					
		Musculoskeletal Stiffness					
		Nasopharyngitis					
		Platelet Count Increased					
		Pleural Effusion					
		Productive Cough					
		Rectal Haemorrhage					
		Red Blood Cell Count					
		Decreased					
		Skin Irritation					
		Sleep Apnoea Syndrome					
		Tension Headache					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Weight Increased					

Date:02/20/04ISR Number: 4300864-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower

Initial or Prolonged Disability	Adenomyosis Anaemia Cervicitis Chest Pain Dysstasia Gastrooesophageal Reflux Disease Haemorrhagic Ovarian Cyst Impaired Work Ability Injury Leiomyoma Metaplasia Oesophageal Stenosis Pain Palpitations Pelvic Pain Tachycardia

		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
				Claritin	C		
8	MON						

Date:02/20/04ISR Number: 4300866-XReport Type:Expedited (15-DaCompany Report #WAES 0208USA02294
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Aspirin	C		
	Depression		Celebrex	C		
	Emotional Distress		Glyburide	C		
	Injury		Prinivil	C		
	Irritability					

Date:02/20/04ISR Number: 4300867-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Cataract		Fosamax	C		ORAL
	Closed Head Injury		Prempro	C		
	Contusion		Advil	C		
	Dyspepsia		Synthroid	C		
	Dyspnoea		Claritin	C		
	Dysuria					
	Ear Pain					
	Eye Haemorrhage					
	Eye Pain					
	Fall					
	Glaucoma					
	Headache					
	Hearing Impaired					

Hypertension
Hypokalaemia
Keratoconjunctivitis
Sicca
Loose Body In Joint
Migraine
Mitral Valve Incompetence
Nausea
Neurodermatitis
Optic Nerve Injury
Palpitations
Paraesthesia Oral
Peripheral Vascular
Disorder
Polymyalgia Rheumatica
Retinal Vein Occlusion
Sinusitis
Skin Laceration
Syncope
Vision Blurred

Date:02/20/04ISR Number: 4300869-5Report Type:Expedited (15-DaCompany Report #WAES 0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Blood Cholesterol							
Disability	Increased							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Depressive Symptom							
	Emotional Distress							
	Heart Rate Irregular							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Low Density Lipoprotein							
	Increased							
	Mitral Valve Disease							
	Sleep Apnoea Syndrome							

Date:02/20/04ISR Number: 4300870-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthma		Catapres	C				
347 DAY								
Initial or Prolonged	Bacterial Infection		Lasix (Furosemide)	C				
Other	Cholecystitis Chronic		Micardis	C				
	Cholesterosis		Lasix (Furosemide)	C				
	Dyspepsia		Cozaar	C				
	Dyspnoea							
	Gastrooesophageal Reflux							
	Disease							
	Glaucoma							
	Gynaecomastia							
	Hepatic Steatosis							
	Hypercapnia							
	Hyperglycaemia							
	Hypoxia							
	Incisional Hernia							

Malnutrition
Obesity
Pickwickian Syndrome
Pulmonary Embolism
Pulmonary Hypertension
Refractory Anaemia
Rheumatoid Arthritis
Sleep Apnoea Syndrome
Thrombosis
Umbilical Hernia

Date:02/20/04ISR Number: 4300871-3Report Type:Expedited (15-DaCompany Report #WAES 0210USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Blood Glucose Increased

		Blood Pressure Decreased					
		Bronchitis					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Contusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		[Therapy			
		Fall		Unspecified]	C		
		Gastric Haemorrhage		Antimicrobial			
		Gastritis		(Unspecified)	C		
		Haematochezia		Soma	C		
		Haemorrhoids		Estrogens			
		Heart Rate Irregular		(Unspecified)	C		
1036	DAY						
		Hiatus Hernia		Herbs (Unspecified)	C		
		Hyperhidrosis		Imdur	C		
		Injury		Nitro	C		
		Loss Of Consciousness					
		Middle Insomnia					
		Nausea					
		Pain In Extremity					
		Palpitations					
		Syncope					
		Tremor					
		Upper Gastrointestinal					
		Haemorrhage					
		Urinary Tract Infection					
		Viral Infection					

Date:02/20/04ISR Number: 4300873-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Valve Incompetence
Disability	Arthritis
Other	Arthropathy
	Asthenia
	Asthma
	Cardiac Disorder
	Chronic Lymphocytic
	Leukaemia
	Coronary Artery Disease
	Diarrhoea
	Dyspnoea

Electrocardiogram
Abnormal
Gastritis
Gastroenteritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Heart Injury
Heart Rate Irregular
Hiatus Hernia
Hyperlipidaemia
Hypertension
Hypokinesia
Mitral Valve Incompetence
Movement Disorder
Myocardial Ischaemia

		Oedema Peripheral					
		Oesophagitis					
		Overdose	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Silent Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Wound Infection		Voltaren	C		
		Staphylococcal		Prempro	C		

Date:02/20/04ISR Number: 4300877-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01361
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
Initial or Prolonged		Arthropathy		[Therapy			
		Back Injury		Unspecified]	C		
		Back Pain		Diuretic			
		Depression		(Unspecified)	C		
		Dyslipidaemia					
		Fall					
		Fibroadenoma Of Breast					
		Galactorrhoea					
		Injury					
		Intervertebral Disc					
		Degeneration					
		Joint Sprain					
		Liver Function Test					
		Abnormal					
		Lumbar Radiculopathy					
		Nephrolithiasis					
		Oedema Peripheral					
		Overdose					
		Pain					
		Spinal Osteoarthritis					

Date:02/20/04ISR Number: 4300879-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA01388
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Atelectasis
	Blood Pressure Increased
	Cardiac Failure Congestive
	Hypercholesterolaemia
	Injury
	Leukocytosis
	Lung Infiltration
	Nephrolithiasis
	Oedema Peripheral
	Pleural Effusion
	Pneumonia
	Post Procedural

	Complication						
	Productive Cough						
	Pyrexia						
	Silent Myocardial	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Triple Vessel Bypass							
	Graft							
	Urticaria							
	Ventricular Arrhythmia							

Date:02/20/04ISR Number: 4300880-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
2 MON								
Initial or Prolonged	Angina Pectoris		[Therapy					
Other	Anoxic Encephalopathy		Unspecified]	C				
	Ascites		Insulin	C				
	Atrioventricular Block							
	Blindness							
	Blood Glucose Increased							
	Cardiac Failure							
	Congestive							
	Cardiogenic Shock							
	Cerebrovascular Accident							
	Chest Discomfort							
	Colitis Ischaemic							
	Constipation							
	Coronary Artery Disease							
	Cough							
	Diarrhoea							
	Encephalopathy							
	Gastritis							
	Haemorrhoids							
	Hepatic Cirrhosis							
	Hepatic Failure							
	Injury							
	Ischaemia							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Muscle Tightness							
	Myocardial Infarction							
	Oedema Peripheral							

Renal Cyst
Thyroid Disorder
Weight Decreased

Date:02/20/04ISR Number: 4300884-1Report Type:Expedited (15-DaCompany Report #WAES 0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anxiety
	Bronchitis
	Bursitis
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Chronic Obstructive Pulmonary Disease
	Contusion

		Depression					
		Fall					
		Fibromyalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lower Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		[Therapy			
		Pain In Extremity		Unspecified]	C		
		Radius Fracture		Vicodin Tablets	C		ORAL
		Renal Disorder		Elavil	C		ORAL
		Renal Pain		Analgesic Or			
		Sinusitis		Anesthetic			
		Sleep Disorder		(Unspecified)	C		
		Tendonitis		Vitamin E	C		
		Transient Ischaemic		Aspirin	C		ORAL
		Attack		Calcium Carbonate	C		
		Urinary Tract Infection		Premarin	C		
				Lasix (Furosemide)	C		
				Neurontin	C		
				Paxil	C		ORAL
				Actonel	C		

Date:02/20/04ISR Number: 4300885-3Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00075
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cytolytic Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Hepatic Necrosis		Acetaminophen	SS		ORAL
11	DAY						
		Hepatitis Acute					
		Hepatitis Cholestatic					
		Influenza Like Illness					

Date:02/20/04ISR Number: 4300886-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anxiety

Disability	Arterial Restenosis Barrett'S Oesophagus Blood Cholesterol Increased Bradycardia Bundle Branch Block Left Coagulopathy Coronary Artery Disease Depression Dilatation Atrial Dyspnoea Exertional Fatigue Gastric Disorder Gastrooesophageal Reflux Disease Heart Rate Irregular Hiatus Hernia Hypotension International Normalised Ratio Increased

		Mitral Valve Incompetence					
		Myocardial Infarction					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tongue Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Acetaminophen And Oxycodone Hydrochloride	C		

Date:02/20/04ISR Number: 4300887-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 220 DAY	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Aortic Valve Incompetence		Tylenol	C		
	Asthenia		Vasotec	C		ORAL
	Atelectasis		Hydrocodone Hydrochloride	C		
	Atrial Fibrillation		Zocor	C		ORAL
	Chest Pain		Synthroid	C		ORAL
	Constipation		Prilosec	C		ORAL
	Depressed Level Of Consciousness					
	Dizziness					
	Dyspnoea					
	Dyspnoea Exertional					
	Hyperhidrosis					
	Medical Device Complication					
	Postoperative Infection					
	Sternal Injury					
	Syncope					
	Ventricular Hypertrophy					

Date:02/20/04ISR Number: 4300888-9Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00040
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
			[Therapy Unspecified]	C				

Date:02/20/04ISR Number: 4300889-0Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00024
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	YR	
Life-Threatening	Haemorrhage		Acetaminophen	C				
			Flunitrazepam	C				
			Metoprolol Tartrate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300890-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		80 DAY
Initial or Prolonged	Anxiety		[Therapy					
Disability	Asthenia		Unspecified]	C				
	Blood Cholesterol		Ascorbic Acid	C				
	Increased		Calcium					
	Bundle Branch Block Left		(Unspecified)	C				
	Cardiac Failure		Lanoxin	C				
	Congestive		Premarin	C				
	Chest Pain		Lasix (Furosemide)	C				
	Congestive Cardiomyopathy		Vitamin E	C				
	Depression		Coumadin	C				
	Dizziness		Vitamin B					
	Dyspepsia		(Unspecified)	C				
	Dyspnoea		Ginkgo Biloba					
	Fibroadenoma Of Breast		Extract	C				
	Hypertension		Levocarnitine	C				
	Mood Swings		Prinivil	C		ORAL		
	Nightmare		Magnesium					
	Palpitations		(Unspecified)	C				
	Ventricular Extrasystoles		Pamelor	C				

Date:02/20/04ISR Number: 4300891-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA01416
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vicodin Tablets	C				
	Blood Glucose Increased		Zocor	C		ORAL		
	Blood Pressure Increased		Vicodin Tablets	C				
	Brain Damage		Novolin 70/30	C			SUBCUTANEOUS	
	Constipation		Prilosec	C				
	Depression							
	Emotional Distress							
	Epistaxis							

Flank Pain
Headache
Heart Rate Increased
Injury
Joint Injury
Laryngospasm
Nausea
Palpitations
Rotator Cuff Syndrome
Sinus Congestion
Sinusitis
Transient Ischaemic
Attack
Vomiting
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/04ISR Number: 4300892-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Unstable		Lasix (Furosemide)	C				
Other	Aortic Valve Incompetence		Hydrodiuril	C				
	Bacteriuria							
	Cardiac Disorder							
	Cataract							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Deafness							
	Diabetic Complication							
	Diabetic Nephropathy							
	Diabetic Neuropathy							
	Diabetic Retinopathy							
	Electrocardiogram Poor R-Wave Progression							
	Electrocardiogram T Wave Inversion							
	Escherichia Infection							
	Fatigue							
	Feeling Abnormal							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hyperlipidaemia							
	Hypertension							
	Hypoglycaemia							
	Ischaemia							
	Joint Swelling							
	Lacunar Infarction							
	Maculopathy							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nocturia							
	Oedema Peripheral							
	Pulmonary Hypertension							
	Skin Lesion							
	Spinal Column Stenosis							
	Tricuspid Valve Incompetence							
	Upper Limb Fracture							
	Ventricular Hypertrophy							
	Weight Increased							

Date:02/20/04ISR Number: 4300893-2Report Type:Expedited (15-DaCompany Report #WAES 0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Bundle Branch Block
	Cardiac Failure
	Congestive
	Carotid Bruit
	Colonic Polyp
	Constipation
	Gastric Ulcer Haemorrhage
	Gastritis
	Gastritis Erosive

		Gastrointestinal Disorder					
		Haemorrhoids					
		Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incisional Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Metaplasia		Vicodin Tablets	C		
		Renal Failure		Zyloprim	C		
		Small Intestinal		Xanax	C		
		Obstruction		Ecotrin	C		
		Ventricular Hypertrophy		Aspirin	C		
				Lipitor	C		
				Ultram	C		
				Carisoprodol	C		
				Vasotec	C		
				Micronase	C		
				Prevacid	C		
				Glucophage	C		
				Centrum	C		

Date:02/20/04ISR Number: 4300894-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA01386
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Atrial Fibrillation		Premarin	C		
		Back Injury		Lodine	C		
		Cardiomegaly		Synthroid	C		
		Cystocele					
		Depression					
		Emotional Distress					
		Fatigue					
		Injury					
		Intermittent Claudication					
		Intervertebral Disc					
		Degeneration					
		Medication Error					
		Myocardial Infarction					
		Myofascial Pain Syndrome					
		Oedema Peripheral					
		Piriformis Syndrome					
		Pleural Effusion					
		Pulmonary Hypertension					
		Pulmonary Oedema					

Rectocele
Sciatica
Spinal Osteoarthritis
Supraventricular
Tachycardia
Therapeutic Response
Decreased

Date:02/20/04ISR Number: 4300896-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA01288
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Blood Cholesterol Increased
Disability	Bundle Branch Block Right
Other	

		Chest X-Ray Abnormal					
		Coronary Artery Disease					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein		Ecotrin	C		
		Increased		Plavix	C		
		Mediastinal Haematoma		Dyazide	C		
		Mitral Valve Incompetence		Avapro	C		
		Pneumothorax		Miacalcin	C		
		Post Procedural		Ativan	C		
		Complication		Meclizine	C		
		Qrs Axis Abnormal		Lopressor	C		
		Ventricular Hypokinesia		Midazolam	C		
		Ventricular Tachycardia					

Date:02/20/04ISR Number: 4300897-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety		Aspirin	C		
Disability		Back Disorder		Plavix	C		
Other		Blood Triglycerides		Coumadin	C		
		Increased		Cardizem	C		
		Cardiac Failure		Maxair	C		
RESPIRATORY							
		Congestive					
(INHALATION)							
		Coronary Artery Disease					
		Coronary Artery					
		Restenosis					
		Depression					
		Dyspepsia					
		Hiatus Hernia					
		Myocardial Infarction					

Date:02/20/04ISR Number: 4300899-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Adjustment Disorder Angina Pectoris Anxiety Aspiration Asthenia Atherosclerosis Atrial Fibrillation Blood Cholesterol Increased Blood Triglycerides Increased Cardiac Arrest Cardio-Respiratory Arrest Chest Discomfort Coma Coronary Artery Disease Coronary Artery Stenosis Crying Depression Dyspnoea

		Ejection Fraction Decreased					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
297	DAY						
		Haematemesis		Aspirin	SS		
		Headache		Plavix	SS		
1	YR						
		Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL
297	DAY						
		Hypertension		Heparin	SS		
INTRAVENOUS							
		Lethargy		Vicodin Tablets	C		
339	DAY						
		Myocardial Infarction		Lipitor	C		
		Stress		Zoloft	C		
		Upper Gastrointestinal		Niacin	C		
		Haemorrhage		Metoprolol	C		
		Ventricular Fibrillation		Monopril	C		
				Celebrex	C		
				Analgesic Or Anesthetic (Unspecified)	C		

Date:02/20/04ISR Number: 4300900-7Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
Initial or Prolonged		Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Anxiety		Xanax	C		
		Blood Triglycerides		Aspirin	C		
		Increased		Lipitor	C		
		Coronary Artery Aneurysm		Wellbutrin	C		
		Coronary Artery		Celebrex	C		
		Atherosclerosis		Plavix	C		
		Coronary Artery Occlusion		Folic Acid	C		
		Dyslipidaemia		Toprol Xl Tablets	C		
		Ecchymosis		Pyridoxine	C		
		Haematoma					
		Major Depression					

Myocardial Infarction
Panic Disorder
Ventricular Hypokinesia

Date:02/20/04ISR Number: 4300901-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Asthenia
	Bronchitis
	Catheter Site Haemorrhage
	Cellulitis
	Coronary Artery Disease
	Coronary Artery Stenosis
	Costochondritis
	Cough
	Diarrhoea
	Diastolic Dysfunction
	Drug Withdrawal Syndrome
	Dyspnoea
	Gastrooesophageal Reflux

		Disease					
		Haemarthrosis					
		Hypothyroidism					
		Increased Tendency To	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bruise		Vioxx	PS	Merck & Co., Inc	ORAL
		Libido Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Chest		Aspirin	C		
		Pain		Celebrex	C		
		Myocardial Infarction		Sudal	C		
		Neuralgia		Ultram	C		
		Oedema		Levaquin	C		
		Overdose		Synthroid	C		
		Pain		Zantac	C		
		Palpitations					
		Panic Attack					
		Pneumonia					
		Spinal Osteoarthritis					
		Weight Increased					

Date:02/20/04ISR Number: 4300907-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA00735
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Choking		Vioxx	PS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Epistaxis					

Date:02/20/04ISR Number: 4300908-1Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00012
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Pulmonary Embolism					

Date:02/20/04ISR Number: 4300909-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01434
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial

Initial or Prolonged Disability	Infarction Acute Respiratory Distress Syndrome Anaemia Cardiac Arrest Cardiogenic Shock Catheter Related Infection Coagulopathy Coronary Artery Atherosclerosis Coronary Artery Occlusion Deep Vein Thrombosis Depression Diarrhoea Hepatic Failure Injury Intervertebral Disc Disorder Ischaemia

		Osteoarthritis					
		Pneumonia Aspiration					
		Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Infarct		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
		Splenic Infarction		Prozac	C		
		Therapy Non-Responder		Interferon			
		Thrombosis		(Unspecified)	C		
		Vomiting					

Date:02/20/04ISR Number: 4300911-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia Macrocytic		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
Disability		Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Diverticulum		Lipitor	C		
		Dyspepsia		Celebrex	C		
		Dyspnoea		Zoloft	C		
		Epigastric Discomfort		Triamterene	C		
		Faecal Occult Blood		Voltaren	C		
		Positive		Duragesic	C		
TOPICAL							
		Faeces Discoloured		Dyazide	C		
		Gastritis		Metoprolol	C		
		Gastrointestinal		Lopressor	C		
		Haemorrhage		Prilosec	C		
		Headache		Denavir	C		
		Hypertension					
		Melaena					
		Muscle Spasms					
		Osteoarthritis					
		Pallor					
		Polyp Colorectal					
		Rectal Polyp					
		Rheumatoid Arthritis					
		Small Intestinal					

Haemorrhage

Date:02/20/04ISR Number: 4300917-2Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00178
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness Neurosensory		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
			Acetaminophen	C		ORAL	20	DAY
			Ibuprofen	C		ORAL	20	DAY

Date:02/20/04ISR Number: 4300920-2Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00025
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
Disability			Telmisartan	C		ORAL		

Date:02/20/04ISR Number: 4302166-0Report Type:Expedited (15-DaCompany Report #2004008916
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Replacement	Foreign	Lithium (Lithium)	PS			168 MG (BID)	
Initial or Prolonged	Confusional State	Literature	Rofecoxib					
	Coronary Artery Surgery	Health	(Rofecoxib)	SS			12.5 MG	
	Gait Disturbance	Professional					(DAILY)	
	Irritability							
	Osteitis							
	Pain							
	Somnolence							
	Therapeutic Agent							
	Toxicity							
	Tremor							

Date:02/23/04ISR Number: 4301833-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		401 DAY
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adnexa Uteri Mass		Vioxx	SS	Merck & Co., Inc	ORAL		401 DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Azotaemia		Ventolin (Albuterol					
	Burning Sensation		Sulfate)	C				
	Candidiasis		Tenormin	C				
	Cardiac Failure		Vasotec	C		ORAL		
	Congestive		Ultram	C				
	Cellulitis		Lodine Xl	C				
	Endometrial Disorder		Lasix (Furosemide					
	Epistaxis		Sodium)	C				
	Eye Disorder		Ditropan	C				
	Fistula		K-Dur	C				
	Hypertension		Quinine Sulfate	C				
	Irritable Bowel Syndrome							
	Limb Discomfort							
	Meniscus Lesion							

Menorrhagia
Mood Swings
Neuropathic Pain
Non-Cardiac Chest Pain
Oedema Peripheral
Palpitations
Paraesthesia
Peau D'Orange
Pickwickian Syndrome
Pneumonia
Postmenopausal
Haemorrhage
Pulmonary Oedema
Retching
Weight Increased

Date:02/23/04ISR Number: 4301875-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	18	MON
Back Pain							
Blood Glucose Increased							
Blood Pressure Increased							
Cardiac Failure							
Congestive							
Chest Pain							
Deep Vein Thrombosis							
Diabetes Mellitus							
Dizziness							
Dyspnoea							
Fatigue							
Gait Disturbance							
Headache							
Hodgkin'S Disease							
Hyperhidrosis							
Hypertension							
Injury							
Intervertebral Disc Degeneration							
Joint Swelling							
Labile Hypertension							
Myocardial Infarction							
Neoplasm Malignant							
Non-Hodgkin'S Lymphoma							
Oedema Peripheral							
Orthopnoea							
Skin Cancer							
Vertigo							
Weight Increased							

Date:02/23/04ISR Number: 4301878-2Report Type:Expedited (15-DaCompany Report #WAES 00091403
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Abnormal Faeces

Adverse Event
Alopecia
Aphthous Stomatitis
Bronchitis Acute
Cerebrovascular Accident
Cervical Cyst
Constipation
Contusion
Depression
Emotional Distress
Feeling Abnormal
Feeling Cold
Gingival Infection
Head Injury
Hot Flush
Hypercoagulation
Hyperkeratosis
Hypersensitivity

		Insomnia					
		Migraine					
		Nail Ridging	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
392	DAY						
		Neuropathy Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Oedema		Tylenol	C		
		Tooth Abscess		Fioricet Tablets	C		
		Transient Ischaemic		Fioricet Tablets	C		
		Attack		Aspirin	C		
		Urticaria		Zithromax	C		
		Weight Increased		Ambien	C		
				Cimicifuga	C		
				Prempro	C		
				Advil	C		
				Motrin	C		
				Naproxen	C		
84	DAY						

Date:02/23/04ISR Number: 4301882-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aspiration		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Brain Stem Infarction		[Therapy			
Other		Cardiac Failure		Unspecified]	C		
		Congestive		Avandia	C		
		Cardiomegaly		Vicoprofen	C		
		Carotid Artery Occlusion		Glucophage	C		
		Carotid Artery Stenosis					
		Cataract					
		Contusion					
		Coronary Artery Disease					
		Dyspnoea					
		Nasopharyngitis					
		Neoplasm Malignant					
		Osteoarthritis					
		Pain In Extremity					
		Road Traffic Accident					
		Snoring					
		Spinal Osteoarthritis					

Toe Deformity
Vascular Occlusion
Ventricular Hypertrophy
Whiplash Injury

Date:02/23/04ISR Number: 4301883-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01287
Age:66 YR Gender:Male I/FU:F

Outcome PT
Other Arthralgia
Blindness
Cataract
Ejection Fraction
Decreased
Headache
Hypokinesia
Joint Range Of Motion
Decreased
Myocardial Infarction

		Optic Atrophy					
		Optic Ischaemic Neuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Papilloedema		Vioxx	PS	Merck & Co., Inc	ORAL
		Polytraumatism		Vioxx	SS	Merck & Co., Inc	ORAL
		Retinal Vascular		Aspirin	C		
		Occlusion		Aciphex	C		
		Tension Headache					

Date:02/23/04ISR Number: 4301884-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA02292
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
217 DAY						
Hospitalization - Initial or Prolonged	Acute Myocardial		Vicodin Tablets	C		
	Infarction		Fosamax	C		
	Arteriosclerosis		Aspirin	C		
	Aspiration		Buspar	C		
	Blood Pressure Increased		Vitamin E	C		
	Cardiac Failure		Vitamins			
	Congestive		(Unspecified)	C		
	Cardiogenic Shock		Calcium			
	Cardiomegaly		(Unspecified) And			
	Cerebrovascular Accident		Vitamin D			
	Coronary Artery Disease		(Unspecified)	C		
	Coronary Artery Stenosis		Docusate Sodium	C		
	Dementia Alzheimer'S Type		Prevacid	C		
	Electrocardiogram St		Zyprexa	C		
	Segment Elevation					
	Fall					
	Heart Rate Increased					
	Lacunar Infarction					
	Pneumonia					
	Pneumonia Aspiration					
	Respiratory Rate					
	Increased					
	Sepsis					
	Tachycardia					
	Ventricular Hypertrophy					
	White Blood Cell Count					
	Increased					

Date:02/23/04ISR Number: 4301886-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Anuria
	Aortic Valve Sclerosis
	Aspiration
	Atelectasis
	Atrial Fibrillation
	Back Pain
	Breast Tenderness
	Cardio-Respiratory Arrest
	Cholelithiasis
	Coagulopathy
	Coronary Artery Disease

		Depression					
		General Physical Health Deterioration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY						
		Hypokalaemia		Tylenol With Codeine			
		Hypotension		#3	C		
		Inflammation		Percocet	C		
		Influenza Like Illness		Ascorbic Acid	C		
		Injury		Vitamin E	C		
		Multi-Organ Failure		Zocor	C		
		Myocardial Infarction		Beta Carotene	C		
		Nausea		Centrum	C		
		Pancreatitis					
		Pericardial Effusion					
		Radiculitis					
		Rash					
		Renal Failure					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Sepsis					
		Tachycardia					
		Toxic Shock Syndrome					
		Vaginal Haemorrhage					
		Ventricular Fibrillation					
		Ventricular Tachycardia					
		Viral Infection					
		Vomiting					
		White Blood Cell Count Increased					

Date:02/23/04ISR Number: 4301887-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA01945
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Congestive Dialysis		Vioxx [Therapy	SS	Merck & Co., Inc	ORAL
Disability	Renal Failure Renal Injury		Unspecified]	C		

Date:02/23/04ISR Number: 4301888-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ischaemia		Lipitor	C				3142 DAY
	Stress		Lotensin	C				
			Lotensin	C				
			Vasotec	C		ORAL		3507 DAY
			Vasotec	C		ORAL		3507 DAY
			Prozac	C				
			Prozac	C				
			Prozac	C				
			Ginseng	C				

			Naproxen	C		
			Accupril	C		
			Accupril	C		

Date:02/23/04ISR Number: 4301890-3Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00016
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 299 DAY	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 46 DAY	Skin Ulcer		Amlodipine Maleate	SS		ORAL
			Vaseretic	SS		ORAL
			Chondroitin Sulfate Sodium	C		ORAL

Date:02/23/04ISR Number: 4301891-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01260
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Unstable		Methotrexate			
Disability	Asthenia		(Methotrexate			
	Cardiac Murmur		Sodium)	C		
	Chest Pain		Fosamax	C		
	Chest X-Ray Abnormal		Atacand	C		
	Dizziness		Estratest	C		
	Dyspnoea		Allegra	C		
	Headache		Motrin	C		
	Hypertension		Motrin	C		
	Mitral Valve Incompetence		Synthroid	C		
	Osteoarthritis					
	Paraesthesia					
	Tinnitus					
	Tricuspid Valve Incompetence					
	Ventricular Hypertrophy					
	Vision Blurred					

Date:02/23/04ISR Number: 4301893-9Report Type:Expedited (15-DaCompany Report #WAES 01051746
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		548 DAY
Initial or Prolonged	Diverticulum		Mylanta & Mylanta Ds	C				
	Gastric Ulcer		Os-Cal	C				
	Irritable Bowel Syndrome		Neurotonin Capsules	C				
	Pancreatitis		Hydrochlorothiazide And Triamterene	C				
	Tremor		Lorazepam	C				
	Urinary Tract Infection		Vitamins (Unspecified)	C				
			Placebo (Unspecified)	C		ORAL		949 DAY
			Placebo (Unspecified)	C		ORAL		46 DAY
			Pravastatin Sodium	C				
			Propoxyphene Napsylate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/04ISR Number: 4301896-4Report Type:Expedited (15-DaCompany Report #WAES 0402COL00022
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Hospitalization - Initial or Prolonged	Infarction							

Date:02/23/04ISR Number: 4301897-6Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00046
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Blister		Etanercept	SS				
SUBCUTANEOUS								
	Haemorrhage Subcutaneous		Calcium Carbonate	C		ORAL		
			Furosemide And Spironolactone	C		ORAL		
			Morphine Sulfate	C				
			Prednisone	C				

Date:02/23/04ISR Number: 4301900-3Report Type:Expedited (15-DaCompany Report #WAES 0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		710 DAY
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		710 DAY
	Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Aspirin	C				
	Cerebral Haemorrhage							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Disorientation							
	Drug Hypersensitivity							
	Dyspepsia							
	Embolism							

Excoriation
Gastrooesophageal Reflux
Disease
Hyperlipidaemia
Localised Infection
Myasthenic Syndrome
Nasal Congestion
Rash Erythematous
Rhinitis Allergic
Skin Laceration
Temperature Intolerance
Visual Field Defect

Date:02/23/04ISR Number: 4301901-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia
	Anaemia Macrocytic
	Arthralgia
	Asthenia
	Back Injury

		Back Pain						
		Balance Disorder						
		Blood Triglycerides	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Carotid Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	78	DAY
		Carotid Artery Stenosis		Zovirax	C				
		Cerebrovascular Accident		Trimox	C				
		Cervicobrachial Syndrome		Celebrex	C				
		Chest Pain		Zyrtec	C				
		Chest Wall Pain		Nexium	C				
		Chronic Obstructive		Paxil	C				
		Pulmonary Disease		Prednisone	C			533	DAY
		Compression Fracture							
		Depression							
		Drug Ineffective							
		Dyspnoea							
		Electrocardiogram Qt							
		Prolonged							
		Electrocardiogram St							
		Segment Abnormal							
		Fall							
		Folate Deficiency							
		Haematochezia							
		Headache							
		Hypercholesterolaemia							
		Hyperhidrosis							
		Hypoaesthesia							
		Insomnia							
		Nausea							
		Neck Pain							
		Neoplasm Malignant							
		Osteoporosis							
		Pain							
		Pain In Extremity							
		Pharyngolaryngeal Pain							
		Pleural Fibrosis							
		Rash							
		Red Blood Cell							
		Sedimentation Rate							
		Increased							
		Rhinitis Allergic							
		Sinusitis							
		Thrombocytopenia							

Transient Ischaemic
Attack
Vitamin B12 Deficiency

Date:02/23/04ISR Number: 4302284-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome PT
Other Angina Pectoris
Anxiety
Arrhythmia
Arthralgia
Asthenia
Back Pain
Chest Pain
Dermatitis

		Diarrhoea					
		Drug Ineffective					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Eye Pain		Allopurinol	C		
		Fatigue		Advil	C		
		Headache		Indocin			
		Hypotension		(Indomethacin)	C		ORAL
		Mental Disorder		Noritate	C		
		Nausea					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Rosacea					
		Silent Myocardial					
		Infarction					
		Sinusitis					
		Skin Lesion					

Date:02/23/04ISR Number: 4302299-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Arthropathy		[Therapy			
		Atrial Fibrillation		Unspecified]	C		
		Basal Cell Carcinoma		Acyclovir	C		
		Blood Cholesterol		Aspirin	C		
		Increased		Vitamins			
		Buttock Pain		(Unspecified)	C		
		Chest Pain		Lipitor	C		
		Condition Aggravated		Calcium			
		Cough		(Unspecified)	C		
		Disease Recurrence		Premarin	C		
		Dyspnoea					
		Ecchymosis					
		Hepatitis					
		Hypertension					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Disorder					

Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Muscle Spasms
Myalgia
Pain In Extremity
Respiratory Tract
Infection

Date:02/23/04ISR Number: 4302303-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01949
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
	Adverse Event
	Anxiety

		Blister					
		Blood Glucose Fluctuation					
		Bursitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
41	DAY						
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatitis Bullous		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						
		Ecchymosis		Lasix (Furosemide)	C		
		Emotional Distress		Humulin	C		
		Erythema		Trental	C		
		Excoriation					
		Feeling Abnormal					
		Femoral Arterial Stenosis					
		Foot Amputation					
		Gangrene					
		Halitosis					
		Hypertension					
		Intertrigo Candida					
		Ischaemic Stroke					
		Lacunar Infarction					
		Localised Infection					
		Medical Device					
		Complication					
		Mental Disorder					
		Musculoskeletal Stiffness					
		Neuropathy					
		Oedema					
		Pain					
		Pain In Extremity					
		Popliteal Stenosis					
		Pulse Absent					
		Rectal Haemorrhage					
		Skin Candida					
		Skin Necrosis					
		Skin Ulcer					
		Stasis Dermatitis					
		Swelling Face					
		Transient Ischaemic					
		Attack					
		Vaginal Haemorrhage					

Date:02/23/04ISR Number: 4302306-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Akinesia
	Angina Pectoris
	Anxiety
	Back Injury
	Bone Pain
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive Cardiomegaly
	Chest Pain
	Coronary Artery Disease

		Coronary Artery Restenosis					
		Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY						
		Ejection Fraction		Propacet	C		
		Decreased		Wellbutrin	C		
		Epicondylitis		Prevacid	C		
		Feeling Cold					
		Gastrooesophageal Reflux					
		Disease					
		Haematemesis					
		Haematoma					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypertension					
		Hypotension					
		Mitral Valve					
		Calcification					
		Mitral Valve Stenosis					
		Muscle Contractions					
		Involuntary					
		Myocardial Ischaemia					
		Neck Pain					
		Non-Cardiac Chest Pain					
		Oesophagitis					
		Osteoarthritis					
		Pulmonary Oedema					
		Refusal Of Treatment By					
		Patient					
		Retroperitoneal					
		Haemorrhage					
		Sinus Tachycardia					
		Sleep Disorder					
		Stent Occlusion					
		Syncope					
		Tendonitis					
		Treatment Noncompliance					
		Urticaria					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Ventricular Hypokinesia					

Visual Acuity Reduced

Date:02/23/04ISR Number: 4302311-7Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00011
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Sudden Death Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/04ISR Number: 4302312-9Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00008
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Aspirin And Magnesium Oxide	SS		ORAL		
	Helicobacter Infection		Atenolol	C		ORAL		
	Melaena		Bendroflumethiazide	C		ORAL		

Date:02/23/04ISR Number: 4302314-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Other	Arthralgia		Premarin	C				
	Atrial Fibrillation		Estratab	C				
	Corneal Deposits		Menest	C				
	Dilatation Atrial		Armour Thyroid Tablets	C				
	Dizziness		Trazodone Hydrochloride	C				
	Dyspnoea		Garlic Extract	C				
	Extraocular Muscle Disorder		Synthroid	C				
	Fibrosis		Methotrexate	C				
	Haematoma							
	Haematuria							
	Haemorrhage							
	Headache							
	Hypertension							
	Hypertensive Crisis							
	Joint Contracture							
	Mitral Valve Calcification							
	Mitral Valve Disease							
	Musculoskeletal Disorder							
	Neuroma							
	Oedema Peripheral							
	Pain							
	Prothrombin Time Shortened							
	Pulse Abnormal							
	Refusal Of Treatment By							

	Patient Renal Cyst Toe Deformity Transient Ischaemic Attack Ventricular Dysfunction

Date:02/23/04ISR Number: 4302315-4Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable Anxiety Back Pain Cellulitis Coronary Artery Disease Coronary Artery Stenosis Emotional Distress

		Eyelid Ptosis					
		Haemangioma					
		Macular Degeneration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Xanax	C		
		Pain		Aspirin	C		
		Radiculopathy		Celebrex	C		
		Sinus Bradycardia		Zyrtec	C		
		Spinal Osteoarthritis		Prozac	C		
		Urethritis		Zestril	C		
		Visual Disturbance		Naproxen	C		
				Prilosec	C		

Date:02/23/04ISR Number: 4302316-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
9 MON							
Initial or Prolonged		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
9 MON							
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Amitriptyline			
		Cerebrovascular Accident		Hydrochloride	C		
		Choking Sensation		Analgesic Or			
		Decreased Appetite		Anesthetic			
		Depression		(Unspecified)	C		
		Dysarthria		Zoloft	C		
526 DAY							
		Facial Palsy		Atenolol	C		
		Fatigue		Lipitor	C		
		Headache		Premarin	C		
		Hypertension		Hydrodiuril	C		ORAL
		Insomnia		Altace	C		
		Lacunar Infarction					
		Meniscus Lesion					
		Muscle Spasms					
		Peripheral Vascular					
		Disorder					
		Treatment Noncompliance					
		Vision Blurred					
		Weight Increased					

Date:02/23/04ISR Number: 4302317-8Report Type:Expedited (15-DaCompany Report #WAES 0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bacterial Infection		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY
	Dermatitis Contact		Atorvastatin Calcium	C		ORAL		
	Dermatitis Exfoliative		Diclofenac	C			3	DAY
	Disease Recurrence		Tramadol Hydrochloride	C		ORAL		
	Drug Hypersensitivity		Dipyrone	C		ORAL		
	Ichthyosis Acquired		Metoprolol Succinate	C		ORAL		
	Nosocomial Infection		Pantoprazole Sodium	C				
	Pain Of Skin							
	Rash Generalised							
	Rash Papular							
	Rash Vesicular							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/04ISR Number: 4302318-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome							
	Deep Vein Thrombosis							
	Dyspepsia							
	Gastric Disorder							
	Gout							
	Haematochezia							
	Haemorrhage							
	Hepatitis							
	Hypertension							
	Renal Disorder							
	Rib Fracture							
	Spinal Osteoarthritis							
	Stomach Discomfort							
	Thrombosis							

Date:02/23/04ISR Number: 4302319-1Report Type:Expedited (15-DaCompany Report #WAES 0310USA01296
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
	Asthenia		Lipitor	C				
	Back Pain		Premarin	C		ORAL		
	Blood Cholesterol Increased		Allegra	C				
			Covera	C				
	Bunion		Claritin-D 12 Hour	C		ORAL		
	Bursitis		Adalat	C		ORAL		
	Carotid Artery Atheroma		Zantac	C				
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Chest Pain							
	Diabetes Mellitus							
	Dizziness							
	Fall							
	Hypoaesthesia							
	Infection							
	Pain							
	Rhinitis Allergic							

Date:02/23/04ISR Number: 4302322-1Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00026
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY

Date:02/23/04ISR Number: 4302323-3Report Type:Expedited (15-DaCompany Report #WAES 0402NLD00008
Age:96 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Creatinine Increased
Hospitalization - Initial or Prolonged	Blood Pressure Diastolic Decreased

	Blood Urea Increased						
	Duodenitis						
	Gastritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL	421 DAY
	Melaena		Acetaminophen	C			RECTAL
	White Blood Cell Count		Acetaminophen	C		ORAL	
	Increased		Aspirin Calcium	C		ORAL	1237 DAY
			Bumetanide	C		ORAL	

Date:02/23/04ISR Number: 4303224-7Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Consumer	Neurontin				
Initial or Prolonged	Back Disorder		(Gabapentin)	PS		ORAL	1800 MG
Other	Back Pain						(TID), ORAL
	Blood Cholesterol		Lipitor				
	Increased		(Atorvastatin)	SS		ORAL	20 MG
	Chest Pain						(DAILY), ORAL
	Drug Effect Decreased		Lithium (Lithium)				
	Drug Intolerance		(Lithium)	SS			
	Erectile Dysfunction		Naproxen (Naproxen)	SS			
	Facial Pain		Rofecoxib				
	Feeling Cold		(Rofecoxib)	SS			
	Gastrooesophageal Reflux		Amoxicillin				
	Disease		(Amoxicillin)	SS		ORAL	1000 MG
	Hypersomnia						(BID), ORAL
	Medication Error		All Other				
	Neck Pain		Therapeutic Products	C			
	Pain In Jaw		Levothyroxine Sodium				
	Sleep Disorder		(Levothyroxine				
	Somnolence		Sodium)	C			
	Tremor		Vitamins	C			
			Diltiazem				

				Hydrochloride (Diltiazem Hydrochloride)	C		

Date:02/23/04ISR Number: 4303424-6Report Type:Expedited (15-DaCompany Report #23064M02FRA
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Goitre Hyperthyroidism	Foreign	Rebif (Interferon Beta)	PS		SUBCUTANEOUS	3 IN 1 WEEKS,	
			Rofecoxib	SS		ORAL	25 MG, 1 IN 1 DAYS, PER ORAL	
			Acenocoumarol	SS		ORAL	PER ORAL	
			Omeprazole	SS		ORAL	2O MG, 1 IN1 DAYS, PER ORAL	
			Hydrocortisone Hydrogen Succinate	SS		ORAL	25 MG, 1 IN 1 DAYS, PER ORAL	
			Fenofibrate	SS		ORAL	1 IN 1 DAYS, PER ORAL	
			Etidronate Disodium	C				

Calcium Carbonate	C
Prazepam	C
Tramadol Hydrochloride	C

Date:02/24/04ISR Number: 4303024-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Disability	Anaemia
Other	Angina Unstable
	Anxiety
	Back Pain
	Blood Cholesterol Increased
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis
	Crying
	Depression
	Dilatation Atrial
	Dizziness
	Duodenitis
	Dyspepsia
	Dyspnoea
	Extrasystoles
	Fatigue
	Gastric Disorder
	Gastritis
	Gastrointestinal Haemorrhage
	Haematochezia
	Headache
	Hypertension
	Hypokalaemia
	Injury
	Laryngitis
	Loss Of Employment
	Migraine
	Mitral Valve Incompetence
	Myocardial Infarction
	Myocardial Ischaemia
	Nausea
	Oedema Peripheral

Orthostatic Hypotension
Pain
Palpitations
Pelvic Peritoneal
Adhesions
Phlebothrombosis
Photophobia
Photopsia
Stent Occlusion
Supraventricular
Extrasystoles
Syncope
Tricuspid Valve
Incompetence
Ventricular Extrasystoles

Ventricular Hypokinesia
Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY

Date:02/24/04ISR Number: 4303038-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vicodin Tablets	C				
	Antinuclear Antibody Positive		Zyloprim	C				
	Bundle Branch Block Right		Xanax	C				
	Cardiac Failure Congestive		Ecotrin	C				
	Cardiac Murmur		Aspirin	C				
	Carotid Bruit		Lipitor	C				
	Cerebral Infarction		Ultram	C				
	Cerumen Impaction		Carisoprodol	C				
	Change Of Bowel Habit		Vasotec	C				
	Colonic Polyp		Micronase	C				
	Constipation		Prevacid	C				
	Deafness Neurosensory		Glucophage	C				
	Eustachian Tube Dysfunction		Centrum	C				
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Gastritis Erosive							
	Haemorrhoids							
	Hiatus Hernia							
	Incisional Hernia							
	Melaena							
	Metaplasia							
	Nausea							

Pulse Absent
Red Blood Cell Count
Decreased
Renal Failure
Scar
Small Intestinal
Obstruction
Upper Gastrointestinal
Haemorrhage
Ventricular Hypertrophy
Vomiting

Date:02/24/04ISR Number: 4303039-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA01432
Age:51 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Lorcet 10/650	C				
			Albuterol	C				
RESPIRATORY	Arterial Stenosis							
(INHALATION)	Blood Disorder		Prempro	C				
	Cardiac Valve Disease		Tricor	C		ORAL		
	Convulsion		Detrol	C				
	Coronary Artery Disease		Ibuprofen	C				
	Depression		Ibuprofen	C				
	Dyspepsia		Dilantin	C		ORAL		
	Gastrooesophageal Reflux Disease							
	Haemorrhage							
	Hypertension							
	Intracardiac Thrombus							
	Osteoarthritis							
	Pain In Extremity							
	Sleep Disorder							

Date:02/24/04ISR Number: 4303040-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Autonomic Nervous System Imbalance
Disability	Blood Bilirubin Unconjugated Increased
	Bradycardia
	Cerebral Atrophy
	Cerebral Infarction
	Chronic Obstructive Pulmonary Disease
	Constipation
	Dehydration
	Depression
	Diverticulum
	Fall
	Femur Fracture

Gastritis
Haemorrhagic Stroke
Hiatus Hernia
Hip Fracture
Hyperglycaemia
Hyponatraemia
Inappropriate
Antidiuretic Hormone
Secretion
Lung Disorder
Lung Neoplasm
Prostatitis
Pyelonephritis
Rectal Cramps
Sleep Apnoea Syndrome
Urinary Tract Infection
Urinary Tract Infection
Bacterial

Urinary Tract Infection
Pseudomonal

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY					
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY					
			Vioxx	SS	Merck & Co., Inc	ORAL
			Valium	C		
			Neurontin	C		
			Neurontin	C		
			Neurontin	C		
			Neurontin	C		
			Avapro	C		
			Misoprostol	C		
			Macrodantin	C		
			Nortriptyline	C		
			Nortriptyline	C		

Date:02/24/04ISR Number: 4303042-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arterial Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiomegaly		Soma	C		
	Carotid Artery Stenosis		Motrin	C		
	Cerebral Infarction		Lamisil	C		
	Cerebrovascular Accident					
	Chest Pain					
	Chest X-Ray Abnormal					
	Chondromalacia					
	Cough					
	Depression					
	Dizziness					
	Eye Irritation					
	Fall					
	Hypertension					
	Mastoiditis					
	Muscle Strain					
	Nausea					
	Oedema Peripheral					

Transient Ischaemic
Attack
Visual Acuity Reduced

Date:02/24/04ISR Number: 4303043-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Brain Stem Infarction
Disability	Cardiac Failure
Other	Congestive
	Cardiomegaly
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cataract
	Contusion
	Coronary Artery Disease
	Dyspnoea

		Hypoacusis					
		Hypoaesthesia					
		Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lumbar Spinal Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		[Therapy			
		Pain In Extremity		Unspecified]	C		
		Road Traffic Accident		[Therapy			
		Spinal Osteoarthritis		Unspecified]	C		
		Toe Deformity		Avandia	C		ORAL
		Whiplash Injury		Avandia	C		ORAL
				Vicoprofen	C		ORAL
				Glucophage	C		ORAL
				Glucophage	C		ORAL

Date:02/24/04ISR Number: 4303044-3Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00114
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastrointestinal	Professional	Clopidogrel			
Initial or Prolonged	Haemorrhage		Bisulfate	SS		ORAL
	Haematemesis		Furosemide	C		ORAL
			Medicinalproduct Not			
			Specified By Sender	C		
INTRAMUSCULAR						
			Omeprazole	C		ORAL
			Ramipril	C		ORAL

Date:02/24/04ISR Number: 4303045-5Report Type:Expedited (15-DaCompany Report #WAES 0401GBR00211
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis	Professional	Acetaminophen And			
Other	Mobility Decreased		Dihydrocodeine			
	Oesophagitis		Bitartrate	C		
			Acetaminophen And			
			Propoxyphene			
			Hydrochloride	C		ORAL

Amitriptyline Hydrochloride	C	ORAL
Furosemide	C	ORAL
Prinivil	C	ORAL
Morphine Sulfate	C	ORAL

Date:02/24/04ISR Number: 4303046-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Sclerosis
Disability	Atherosclerosis
Other	Blood Cholesterol Increased
	Bundle Branch Block Right
	Cardiac Murmur
	Cerebrovascular Accident
	Chest Discomfort
	Circulatory Collapse

		Coronary Artery Disease					
		Cough					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Electrocardiogram St	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Segment Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Embolic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL
		Gallop Rhythm Present					
		Injury					
		Mitral Valve Sclerosis					
		Sexual Dysfunction					
		Sleep Apnoea Syndrome					
		Somnolence					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					
		Weight Increased					

Date:02/24/04ISR Number: 4303047-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 26 DAY		Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Azotaemia	Professional	[Therapy			
Other		Cerebrovascular Accident		Unspecified]	C		
		Hypertension		Aspirin	C		
		Hypoglycaemia		Aspirin	C		
		Loss Of Libido		Lipitor	C		
		Mental Status Changes		Persantine	C		
				Coenzyme Q10	C		
				Amaryl	C		
				Glucophage	C		
				Actos	C		
				Zantac	C		

Date:02/24/04ISR Number: 4303048-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA01452
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		1219 DAY

Date:02/24/04ISR Number: 4303772-XReport Type:Direct Company Report #CTU 212957
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx 25 Mg	PS		ORAL	25 MG PO	
Initial or Prolonged	Gastrointestinal						DAILY	
Required	Haemorrhage							
Intervention to	Hiatus Hernia							
Prevent Permanent								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/04ISR Number: 4304564-8Report Type:Expedited (15-DaCompany Report #EMADSS2003001873
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholangitis Acute Decreased Appetite Gamma-Glutamyltransferase Increased Hepatic Cirrhosis Hepatic Fibrosis Hepatic Steatosis Muscle Atrophy Vasculitis	Foreign Health Professional	Remicade (Infliximab, Recombinant)Lyophilized Powder	PS		INTRAVENOUS DRIP	300 MG, 1 IN 1 AS NECESSARY, INTRAVENOUS DRIP; 300 MG,	
			Zoloft(Sertraline Hydrochloride) Tablets	SS		ORAL	2 MG, 2 IN 1 DAY, ORAL	
			Losec(Omeprazole)	SS		ORAL	20 MG, ORAL	
			Vioxx (Rofecoxib) Tablets	SS		ORAL	25 MG, ORAL	
			Methotrexate (Methotrexate) Tablets	SS		ORAL	7.5 MG, 1 IN 1 WEEK, ORAL	
			Folacin (Folacin)	C				
			Daonil(Glibenclamide)	C				

Date:02/25/04ISR Number: 4303902-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthritis
	Arthropathy
	Asthma
	Cardiac Disorder
	Cardiac Murmur
	Chronic Lymphocytic Leukaemia
	Coronary Artery Disease
	Diarrhoea
	Dyspnoea
	Ejection Fraction Decreased
	Electrocardiogram Abnormal
	Electrocardiogram T Wave Inversion
	Gastritis
	Gastroenteritis
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux Disease
	Heart Injury
	Heart Rate Irregular
	Hyperlipidaemia
	Hypersensitivity

		Hypertension					
		Hypokinesia					
		Mitral Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Calcification		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Peptic Ulcer		Voltaren	C		
		Pneumonia		Prempro	C		
		Stress					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Wound Infection					
		Staphylococcal					

Date:02/25/04ISR Number: 4303905-5Report Type:Expedited (15-DaCompany Report #WAES 0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL
		Bursitis		Tylenol	C		
		Cardiac Arrest		Saw Palmetto	C		
		Cardiac Failure		Ultram	C		
		Congestive		Lipitor	C		
		Cellulitis		Lumigan	C		
		Cerebral Ischaemia		Corticosteroids			
		Chronic Obstructive		(Unspecified)	C		
PARENTERAL							
		Pulmonary Disease		Betagan	C		
		Congestive Cardiomyopathy		Relafen	C		

Coronary Artery Disease	Paxil	C
Delirium		
Depression		
Diarrhoea		
Drug Hypersensitivity		
Gastroenteritis		
Headache		
Hypertension		
Inguinal Hernia		
Liver Function Test Abnormal		
Myocardial Infarction		
Osteoarthritis		
Osteoporosis		
Pulmonary Oedema		
Rash		
Spinal Column Stenosis		
Staphylococcal Sepsis		

Date:02/25/04ISR Number: 4303909-2Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00198
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		55 DAY
Hospitalization - Initial or Prolonged	Haematemesis		Acetaminophen And Codeine Phosphate	C		ORAL		15 DAY
			Atenolol	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Risedronate Sodium	C		ORAL		

Date:02/25/04ISR Number: 4303910-9Report Type:Expedited (15-DaCompany Report #WAES 0402USA01484
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				
			Prempro	C				

Date:02/25/04ISR Number: 4303915-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01115
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/04ISR Number: 4303916-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY
Initial or Prolonged	Blood Pressure Systolic		Vioxx	SS	Merck & Co., Inc	ORAL		31 DAY
Disability	Increased		Albuterol	C				
RESPIRATORY								

	Cerebrovascular Accident			
(INHALATION)				
	Dysarthria	Trinalin	C	
	Electrocardiogram Qt	Klonopin	C	
	Prolonged	Clonidine	C	
	Electrocardiogram St-T	Triamterene	C	
	Change	Cyclobenzaprine		
	Facial Palsy	Hydrochloride	C	ORAL
	Headache	Cyclobenzaprine		
	Heart Rate Irregular	Hydrochloride	C	ORAL
	Hemiparesis	Prempro	C	
	Hypertensive Crisis	Relafen	C	ORAL
	Hypokalaemia			
	Lacunar Infarction			
	Sinusitis			
	Stress			

Date:02/25/04ISR Number: 4303920-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA02789
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization -	Colonic Polyp
Initial or Prolonged	Depression
	Dermatitis Allergic
	Diverticulum
	Diverticulum Intestinal

		Haemorrhagic					
		Dyspepsia					
		Flatulence					
		Gastrointestinal Tract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Adenoma		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Large Intestinal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Employment		Lortab	C		
		Lower Gastrointestinal		Vitamins			
		Haemorrhage		(Unspecified)	C		
		Muscle Spasms		Vitamin B Complex	C		ORAL
		Paraesthesia		Ascorbic Acid	C		
		Post Procedural		Aspirin	C		
		Haemorrhage		Uniretic	C		
		Rectal Haemorrhage					
		Road Traffic Accident					
		Syncope					

Date:02/25/04ISR Number: 4303921-3Report Type:Expedited (15-DaCompany Report #WAES 00091403
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Abdominal Pain Upper
	Abnormal Faeces
	Adverse Event
	Affect Lability
	Alopecia
	Amnesia
	Antiphospholipid Antibodies
	Aphthous Stomatitis
	Appetite Disorder
	Asthenia
	Back Pain
	Blood Pressure Decreased
	Bone Cyst
	Bronchitis Acute
	Cardiolipin Antibody Positive
	Cerebral Atrophy
	Cerebrovascular Accident
	Coagulopathy

Constipation
Contusion
Convulsion
Depression
Difficulty In Walking
Dizziness
Emotional Disorder
Emotional Distress
Fatigue
Feeling Abnormal
Feeling Cold
Fluid Retention
Generalised Oedema
Gingival Infection
Haemodynamic Instability
Head Injury

		Headache					
		Herpes Virus Infection					
		Hot Flush	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypercoagulation		Vioxx	PS	Merck & Co., Inc	ORAL
392	DAY						
		Hyperkeratosis		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Hypersensitivity		Tylenol	C		
		Hypoaesthesia		Fioricet Tablets	C		
		Injury		Fioricet Tablets	C		
		Insomnia		Aspirin	C		
		Intervertebral Disc		Zithromax	C		
		Degeneration		Ambien	C		
		Migraine		Cimicifuga	C		
		Myalgia		Prempro	C		
		Nail Ridging		Advil	C		
		Nausea		Motrin	C		
		Neck Pain		Naproxen	C		
84	DAY						
		Neuropathy Peripheral					
		Oedema					
		Oedema Peripheral					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Rash					
		Rash Pruritic					
		Sciatica					
		Sensory Disturbance					
		Sinusitis					
		Skin Lesion					
		Sleep Disorder					
		Speech Disorder					
		Systolic Hypertension					
		Tooth Abscess					
		Transient Ischaemic					
		Attack					
		Urticaria					
		Vomiting					
		Weight Increased					

Date:02/25/04ISR Number: 4303923-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00753
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zyrtec	C				
	Coronary Artery Disease		Indocin (Indomethacin)	C		ORAL		
	Injury		Naproxen	C				
	Road Traffic Accident		Prilosec	C				
	Skin Laceration		Oxycontin	C				

Date:02/25/04ISR Number: 4303924-9Report Type:Expedited (15-DaCompany Report #WAES 0402USA01500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Epi-Pen	SS				
							1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/04ISR Number: 4303925-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Diastolic Increased		Percocet	C				
			Mobic	C				
	Coronary Artery Disease		Skelaxin	C				
	Coronary Artery Occlusion		Zantac	C				
	Ecchymosis							
	Ejection Fraction Decreased							
	Emotional Distress							
	Groin Pain							
	Heart Rate Increased							
	Movement Disorder							
	Myocardial Infarction							

Date:02/25/04ISR Number: 4303926-2Report Type:Expedited (15-DaCompany Report #WAES 0402USA01451
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:02/25/04ISR Number: 4303927-4Report Type:Expedited (15-DaCompany Report #WAES 0402USA01460
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/25/04ISR Number: 4304247-4Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00056
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Hospitalization - Initial or Prolonged			Atenolol	C		ORAL

Date:02/25/04ISR Number: 4304261-9Report Type:Expedited (15-DaCompany Report #WAES 0402USA00570
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Treatment Noncompliance		Vioxx	PS	Merck & Co., Inc	ORAL
	Urinary Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
			Lortab	C		
			Premarin	C		
			Prednisone	C		

Date:02/25/04ISR Number: 4304265-6Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00114
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Gastritis
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage

	Haematemesis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	SS		ORAL		
			Furosemide	C		ORAL		
			Medicinalproduct Not Specified By Sender	C			INTRAMUSCULAR	
			Omeprazole	C		ORAL		
			Ramipril	C		ORAL		

Date:02/25/04ISR Number: 4306027-2Report Type:Periodic Company Report #US-BRISTOL-MYERS SQUIBB COMPANY-12142402
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Ulcer		Excedrin Migraine Tabs	PS	Bristol-Myers Squibb Company	ORAL	6 MON	
			Vioxx	SS				
			Fosamax	C				

Date:02/25/04ISR Number: 4306961-3Report Type:Expedited (15-DaCompany Report #2004UW02967
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatine	Foreign	Crestor	PS		ORAL	40 MG QD PO	
Intervention to	Phosphokinase Increased	Consumer	Crestor	SS		ORAL	20 MG QD PO	
Prevent Permanent	Drug Interaction	Other	Ezetrol	SS			10 MG DAILY	
Impairment/Damage	Hepatic Enzyme Increased		Vioxx	SS			25 MG DAILY	
			Niacin	C				
			Ec Asa	C				
			Plavix	C				
			Atenolol	C				

Accupril	C
Allopurinol	C
Folic Acid	C
Vitamin C	C
Glucosamine	C

Date:02/26/04ISR Number: 4305211-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vicodin Tablets	C				
Other	Calculus Ureteric		Aspirin	C				
	Calculus Urinary		Ultram	C				
	Coronary Artery Occlusion		Ultram	C				
	Diverticulitis		Advil	C				
	Epigastric Discomfort		Advil	C				
	Hepatic Cyst							
	Injury							
	Mitral Valve Incompetence							
	Pneumonia Influenzal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4305213-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA01104
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/26/04ISR Number: 4305215-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arterial Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Erectile Dysfunction		[Therapy			
	Hypersensitivity		Unspecified]	C		
	Injury					
	Muscle Tightness					
	Myocardial Infarction					

Date:02/26/04ISR Number: 4305218-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00004
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased		Vicodin Tablets	C		
Other	Breast Disorder		Percocet	C		
	Cardiac Murmur		Darvocet-N	C		
	Cardiac Valve Disease		Soma	C		
	Cervicobrachial Syndrome		Celebrex	C		
	Depression		Ibuprofen	C		
	Dizziness		Aleve	C		
	Drug Hypersensitivity		Oxycontin	C		
	Dyspnoea					
	Erythema					
	Gastrooesophageal Reflux					
	Disease					
	Haematocrit Decreased					
	Heart Rate Irregular					
	Hypertension					
	Hypoaesthesia					

Injury
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Muscle Strain
Osteoarthritis
Osteopenia
Paraesthesia
Sleep Apnoea Syndrome
Sleep Disorder
Spinal Cord Compression
Spinal Osteoarthritis
Syncope Vasovagal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4305220-2Report Type:Expedited (15-DaCompany Report #WAES 0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
	Asthenia		Folic Acid	C		
	Cardiac Failure		Arava	C		
	Congestive		Methotrexate	C		
441 DAY						
	Diarrhoea		Aredia	C		
	Dyspnoea Paroxysmal		Prednisone	C		
	Nocturnal		Inderal	C		
	Hypertension		Inderal	C		
	Infection		Inderal La	C		
	Injury					
	Insomnia					
	Melaena					
	Myocardial Infarction					
	Nightmare					
	Orthopnoea					
	Palpitations					
	Panic Attack					
	Phlebitis Superficial					
	Pulmonary Embolism					
	Pulmonary Hypertension					
	Stress					
	Tachycardia					
	Thrombosis					
	Tricuspid Valve					
	Incompetence					
	Upper Respiratory Tract					
	Infection					
	Weight Increased					

Date:02/26/04ISR Number: 4305221-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA02077
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Decreased Activity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
335 DAY						
	Myocardial Infarction					

Renal Failure

Date:02/26/04ISR Number: 4305222-6Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00031
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mycosis Fungoides		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Hospitalization - Initial or Prolonged								

Date:02/26/04ISR Number: 4305223-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01094
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		618 DAY

Date:02/26/04ISR Number: 4305224-XReport Type:Expedited (15-DaCompany Report #WAES 0402DEU00146
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Ineffective	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening	Hepatic Failure	Professional	Dipyrone	SS		ORAL	4	DAY
Hospitalization -	Pericardial Effusion		Dipyrone	SS		ORAL	4	DAY
Initial or Prolonged	Pleural Effusion		Ibuprofen	SS			3	DAY
Other	Pleurisy		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Renal Failure		Ibuprofen	SS			3	DAY
			Mephenesin	SS		ORAL	3	DAY
			Mephenesin	SS		ORAL	3	DAY

Date:02/26/04ISR Number: 4305225-1Report Type:Expedited (15-DaCompany Report #WAES 00052935
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient	Health	Vioxx	PS	Merck & Co., Inc	ORAL	168	DAY
	Cardiovascular Disorder	Professional	Fosamax	C				
	Essential		Aspirin	C				
	Thrombocythaemia		Lanoxin	C				
	Myeloproliferative		Zocor	C				
	Disorder		Levoxyl	C				
	Retinal Artery Embolism		Lopressor	C				
			Relafen	C				

Date:02/26/04ISR Number: 4305226-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01112
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Professional

Date:02/26/04ISR Number: 4305227-5Report Type:Expedited (15-DaCompany Report #WAES 0402DNK00024
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Upper Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL		YR
Life-Threatening	Haemorrhage	Professional	Acetaminophen	C				
			Flunitrazepam	C				
			Metoprolol Tartrate	C				

Date:02/26/04ISR Number: 4305228-7Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00071
Age:38 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Biliary Cirrhosis
	Blood Alkaline Phosphatase Increased
	Cytolytic Hepatitis
	Gamma-Glutamyltransferase Increased
	Jaundice

Weight Decreased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
			Ethinyl Estradiol And Levonorgestrel	C		ORAL		

Date:02/26/04ISR Number: 4305229-9Report Type:Expedited (15-DaCompany Report #WAES 0311DEU00151
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Urinary Retention		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
			Bisoprolol Fumarate	C		ORAL		

Date:02/26/04ISR Number: 4305230-5Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00197
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer		Aspirin	SS		ORAL		
	Haematemesis		Aspirin	SS		ORAL		
	Oesophageal Ulcer		Allopurinol	C		ORAL		
			Furosemide	C		ORAL		
			Indoramin	C		ORAL		
			Lisinopril	C		ORAL		

Date:02/26/04ISR Number: 4305231-7Report Type:Expedited (15-DaCompany Report #WAES 0402NZL00031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			

Date:02/26/04ISR Number: 4305232-9Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00067
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure Acute	Professional	Furosemide	SS		ORAL		
			Furosemide	SS		ORAL		
			Perindopril	SS		ORAL		
			Omeprazole	C		ORAL		

Date:02/26/04ISR Number: 4305884-3Report Type:Expedited (15-DaCompany Report #WAES 0303USA00625
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Blood Alkaline
Disability	Phosphatase Increased
	Cardiovascular Disorder
	Cholelithiasis
	Dehydration
	Diarrhoea

	Gastritis						
	Joint Effusion						
	Liver Function Test	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	37 DAY
	Metastatic Neoplasm	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	37 DAY
	Mucosal Haemorrhage		Tylenol	C			
	Oedema Peripheral		Lomotil	C			
	Oesophagitis		Prednisone	C			3 DAY
	Renal Failure		Prednisone	C		ORAL	3 DAY
	Respiratory Arrest		Prednisone	C			
	Upper Gastrointestinal Haemorrhage						

Date:02/26/04ISR Number: 4305886-7Report Type:Expedited (15-DaCompany Report #WAES 0303USA02790
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Back Pain		Betamethasone And				
	Bursitis		Bupivacaine				
	Contusion		Hydrochloride	C			PARENTERAL
	Diverticulum Intestinal		Arthrotec	C			
	Dyspnoea		Naprelan	C			
	Endometrial Hyperplasia						
	Faecal Occult Blood Positive						
	Gastric Ulcer						
	Gastritis						
	Gastrointestinal Haemorrhage						
	Haemorrhoids						
	Headache						
	Hiatus Hernia						
	Hot Flush						
	Lung Neoplasm						
	Melaena						
	Muscle Strain						

	Osteoarthritis
	Periodontal Disease
	Rash
	Rectal Haemorrhage
	Reflux Oesophagitis
	Road Traffic Accident
	Uterine Leiomyoma
	Vaginal Haemorrhage

Date:02/26/04ISR Number: 4305887-9Report Type:Expedited (15-DaCompany Report #WAES 00062833
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Aspartate
	Aminotransferase
	Increased
	Cardiac Failure
	Congestive
	Chest Pain

		Costochondritis					
		Cough					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphadenopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
21	DAY						
		Nail Avulsion	Professional	Aspirin	C		ORAL
		Pharyngolaryngeal Pain		Lipitor	C		ORAL
		Renal Failure		Flomax (Niflumic			
		Seborrhoeic Keratosis		Acid			
		Skin Laceration		(Beta)-Morpholinoeth			
				yl Ester)	C		ORAL

Date:02/26/04ISR Number: 4305898-3Report Type:Expedited (15-DaCompany Report #WAES 0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	
1	DAY						
Other		Blood Glucose Increased		Flexeril	C		
		Blood Pressure Systolic		Monopril	C		
		Increased		Pravachol	C		
		Carpal Tunnel Syndrome					
		Coronary Artery					
		Atherosclerosis					
		Coronary Artery Occlusion					
		Dermoid Cyst					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Emotional Distress					
		Eructation					
		Hypersensitivity					
		Lyme Disease					
		Nerve Compression					
		Overdose					
		Pain In Extremity					
		Polytraumatism					
		Sinus Bradycardia					
		Tendonitis					
		Trigger Finger					
		Weight Decreased					
		White Blood Cell Count					

Increased

Date:02/26/04ISR Number: 4305900-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01090
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	135 DAY	
	Myocardial Infarction							
	Renal Failure							

Date:02/26/04ISR Number: 4305901-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abscess Jaw
Disability	Angina Pectoris

		Anxiety Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL
		Phosphokinase Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		[Therapy			
		Cardiac Murmur		Unspecified]	C		
		Carotid Artery Stenosis		Vicodin Tablets	C		
		Coronary Artery Disease		Xanax	C		
		Depression		Covera	C		
		Drug Hypersensitivity		Trimox	C		
		Duodenal Ulcer		Atenolol	C		
		Duodenal Ulcer		Soma	C		
		Haemorrhage		Relafen	C		
		Duodenitis					
		Food Poisoning					
		Gastritis					
		Gastroenteritis					
		Gastrointestinal Disorder					
		Gastrointestinal Haemorrhage					
		Gout					
		Gouty Arthritis					
		Haemoglobin Decreased					
		Hypertension					
		Myocardial Infarction					
		Oedema Peripheral					
		Oesophageal Disorder					
		Osteoarthritis					
		Otitis Media					
		Overdose					
		Pain In Extremity					

Date:02/26/04ISR Number: 4305902-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Cerebrovascular Accident
Other	Chest Pain
	Chronic Fatigue Syndrome
	Cognitive Disorder
	Confusional State

Depression
Diplopia
Disturbance In Attention
Duodenitis
Dyspnoea
Endocarditis
Fatigue
Gallbladder Disorder
Gastritis
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder
Haematochezia
Herpes Zoster
Heterophoria

	Hypertension						
	Hypoacusis						
	Irritable Bowel Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	401 DAY
	Migraine With Aura		Aspirin	C			
	Non-Cardiac Chest Pain		Tagamet	C			
	Pain In Jaw		Premarin	C			
	Panic Disorder		Estratab	C			
	Sleep Apnoea Syndrome		Hytrin	C			
	Thalamus Haemorrhage		L-Thyroxin	C			
	Transient Ischaemic		Prinivil	C		ORAL	
	Attack		Ranitidine	C			
	Ventricular Hypertrophy						
	Visual Disturbance						

Date:02/26/04ISR Number: 4305903-4Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00056
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Atenolol	C		ORAL	

Date:02/26/04ISR Number: 4305904-6Report Type:Expedited (15-DaCompany Report #WAES 0312USA02429
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anuria		Vioxx	PS	Merck & Co., Inc	ORAL	
Disability	Cystitis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Urinary Retention						
	Urine Output Decreased						

Date:02/26/04ISR Number: 4305905-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00202
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Haematemesis Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		
			Amiloride Hydrochloride And Furosemide	C		ORAL		
			Aspirin	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Tolterodine	C		ORAL		
			Tolterodine	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/04ISR Number: 4305907-1Report Type:Expedited (15-DaCompany Report #WAES 0402USA01646
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/04ISR Number: 4305908-3Report Type:Expedited (15-DaCompany Report #WAES 0401USA00609
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Creatinine Increased							
	Feeling Abnormal							
	Nausea							
	Nephritis Interstitial							
	Renal Impairment							

Date:02/26/04ISR Number: 4305909-5Report Type:Expedited (15-DaCompany Report #WAES 0307DEU00059
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Life-Threatening	Haematemesis		Aspirin	SS		ORAL		
Hospitalization -	Stevens-Johnson Syndrome		Dipyrone	SS		ORAL		6 DAY
Initial or Prolonged	Toxic Epidermal		Dipyrone	SS		ORAL		2 DAY
	Necrolysis		Dipyrone	SS		ORAL		2 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tramadol Hydrochloride	SS		ORAL		11 DAY
			Tramadol Hydrochloride	SS		ORAL		4 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY

	Furosemide Sodium	SS	ORAL
	Furosemide Sodium	SS	ORAL
	Moxonidine	SS	ORAL
	Dipyrone	SS	ORAL
9 DAY			
	Amlodipine Besylate	C	ORAL
	Tolperisone Hydrochloride	C	ORAL
2 DAY			
	Tolperisone Hydrochloride	C	ORAL
	Sucralfate	C	ORAL
	Potassium Bicarbonate And Potassium Citrate	C	ORAL
1 DAY			
	Potassium Bicarbonate And Potassium Citrate	C	ORAL
6 DAY			
	Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C	ORAL
	Isosorbide Mononitrate	C	ORAL
	Moxonidine	C	ORAL
	Nadroparin Calcium	C	
SUBCUTANEOUS			
	Pantoprazole Sodium	C	ORAL
	Pantoprazole Sodium	C	ORAL

Lisinopril	C	ORAL
Dexamethasone	C	ORAL

Date:02/26/04ISR Number: 4305911-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Angina Unstable
Disability	Aortic Valve Incompetence
Other	Bacteriuria
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cataract
	Coronary Artery Disease
	Depression
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Ejection Fraction
	Abnormal
	Electrocardiogram T Wave
	Inversion
	Escherichia Infection
	Fatigue
	Feeling Abnormal
	Fluid Retention
	Gastrooesophageal Reflux
	Disease
	Headache
	Hyperlipidaemia
	Hypertension
	Hypoglycaemia
	Hypoxia
	Joint Swelling
	Lacunar Infarction
	Maculopathy
	Metabolic Alkalosis
	Metastases To Lung
	Mitral Valve Incompetence
	Myocardial Infarction
	Nocturia
	Oedema Peripheral

Pleural Effusion
Proteinuria
Pulmonary Embolism
Pulmonary Granuloma
Pulmonary Hypertension
Pulmonary Oedema
Rash Pruritic
Renal Failure Chronic
Scoliosis
Seasonal Allergy
Skin Lesion
Spinal Column Stenosis
Tricuspid Valve
Incompetence
Upper Limb Fracture

		Ventricular Hypertrophy Weight Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Percocet	C		
				Pepcid	C		
				Lasix (Furosemide)	C		
				Hydrodiuril	C		
				Insulin, Biphasic Isophane [Injection]	C		
				Synthroid	C		

Date:02/26/04ISR Number: 4307298-9Report Type:Expedited (15-DaCompany Report #2004200020US
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Interaction	Study	Celebrex (Celecoxib)			
	Fall	Consumer	Capsule	PS		
	Fungal Infection		Vioxx (Rofecoxib)	SS		
	Genital Pruritus Female		Aspirine	C		
	Rotator Cuff Syndrome		Allopurinol	C		
			Propranolol (Propranolol)	C		
			Lipitor (Atorvastatin)	C		
			Glipizide	C		
			Furosemide	C		
			Vitamins	C		
			Librium (Chlordiazepoxide Hydrochloride)	C		
			Tricor	C		
			Lortab	C		

Date:02/26/04ISR Number: 4307319-3Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Back Disorder
Other	Back Pain

Blood Cholesterol
Increased
Chest Pain
Drug Ineffective
Drug Intolerance
Erectile Dysfunction
Facial Pain
Feeling Cold
Gastrooesophageal Reflux
Disease
Glossodynia
Hypersomnia
Medication Error
Neck Pain
Oesophageal Spasm
Pain In Jaw
Sleep Disorder
Tooth Abscess

Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Neurontin (Gabapentin)	PS		ORAL	1800 MG	(TID), ORAL
	Lipitor (Atorvastatin)	SS		ORAL	20 MG	(DAILY), ORAL
	Lithium (Lithium) (Lithium)	SS				
	Naproxen (Naproxen)	SS				
	Rofecoxib (Rofecoxib)	SS				
	Amoxicillin (Amoxicillin)	SS		ORAL	1000 MG	(BID), ORAL
	All Other Therapeutic Products	C				
	Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Vitamins	C				
	Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C				

Date:02/26/04ISR Number: 4307884-6Report Type:Periodic Company Report #2002094318
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)					
	Dermatitis	Health	Capsule	PS			200 MG, QD,	
	Drug Ineffective	Professional					UNK	

	Hypersensitivity		Vioxx (Rofecoxib)	SS		
12.5 MG, QD,						
UNK						
			Lidex (Flucinonide)	C		

Date:02/26/04ISR Number: 4307885-8Report Type:Periodic Company Report #2002095652US
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia	Consumer	Celebrex (Celecoxib)			
	Drug Interaction		Capsule	PS		ORAL
UNK, ORAL						
	Myalgia		Deltasone			
	Rash		(Prednisone) Tablet	SS		ORAL
UNK, ORAL						
	Renal Failure		Insulin (Insulin)	SS		
	Skin Disorder		Imuran			
	Skin Fissures		(Azathioprine)	SS		
			Lasix (Furosemide)	SS		
			Cyclosporine			
			(Ciclosporin)	SS		
			Clonidine			
			(Clonidine)	SS		
			Norvasc (Amlodipine			
			Besilate)	SS		
			Toprol Xl			
			(Metoprolol			

Succinate)	SS
Zebet A (Bisoprolol Fumarate)	SS
Cyclobenzaprine (Cyclobenzaprine)	SS
B Complex (Pyridoxine Hyrochloride, Thiamine Hyrochloride,	SS
Vioxx ()	SS
Lipitor (Atorvastatin)	SS
Clonazepam (Clonazepam)	SS

Date:02/26/04ISR Number: 4308477-7Report Type:Periodic Company Report #2003182887US
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Celebrex (Celecoxib) Capsule	PS				
			Vioxx(Rofecoxib)	SS				

Date:02/26/04ISR Number: 4308533-3Report Type:Periodic Company Report #2003172978US
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer	Health Professional Other	Celebrex (Celecoxib) Capsule	PS				
			Vioxx ()	SS				

Date:02/27/04ISR Number: 4306934-0Report Type:Expedited (15-DaCompany Report #WAES 0308USA01526
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Embolic Cerebral Infarction Headache	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Hypertension
Ventricular Hypertrophy

Date:02/27/04ISR Number: 4306935-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adenomyosis
Disability	Anaemia
	Cervicitis
	Chest Pain
	Dizziness
	Dyspnoea
	Dysstasia
	Haemorrhagic Ovarian Cyst
	Hyperhidrosis
	Impaired Work Ability
	Injury
	Leiomyoma

		Metaplasia					
		Muscular Weakness					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain		Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
		Palpitations		Claritin	C		
8	MON						
		Pelvic Pain					
		Tachycardia					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					

Date:02/27/04ISR Number: 4306938-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Arrhythmia		Allopurinol	C		
		Arthralgia		Advil	C		
		Back Pain		Indocin			
		Chest Pain		(Indomethacin)	C		ORAL
		Dermatitis		Noritate	C		
		Diarrhoea					
		Disturbance In Attention					
		Drug Ineffective					
		Dyspnoea					
		Emotional Distress					
		Eye Pain					
		Fatigue					
		Headache					
		Hypoaesthesia					
		Hypotension					
		Intercostal Neuralgia					
		Mental Disorder					
		Nausea					
		Pain In Extremity					
		Paraesthesia					
		Rosacea					
		Silent Myocardial					
		Infarction					
		Sinusitis					

Date:02/27/04ISR Number: 4306939-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged Angina Unstable Aortic Atherosclerosis Congestive Cardiomyopathy Coronary Artery Disease Coronary Artery Restenosis Dilatation Atrial Dilatation Ventricular Dizziness Electrocardiogram St Segment Elevation

		Hypertension					
		Hypotension					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal		Vioxx	PS	Merck & Co., Inc	ORAL
		Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vicodin Tablets	C		
		Pulmonary Embolism		Aspirin	C		ORAL
		Sick Sinus Syndrome		Lipitor	C		ORAL
				Plavix	C		ORAL
41	DAY						
				Plavix	C		ORAL
				Plavix	C		ORAL
41	DAY						
				Flomax (Tamsulosin Hydrochloride)	C		
				Plavix	C		ORAL
				Colace	C		
				Prevacid	C		
				Synthroid	C		
				Prinivil	C		ORAL
				Zestril	C		

Date:02/27/04ISR Number: 4306940-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alcohol Poisoning
	Alcohol Withdrawal
Disability	Syndrome
Other	Atelectasis
	Blood Pressure Increased
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Chest Pain
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Coma
	Contusion
	Deep Vein Thrombosis
	Dermatitis

Disorientation
Diverticulum
Dysarthria
Dyspepsia
Fall
Gastric Disorder
Gastrointestinal
Haemorrhage
Gastrointestinal Pain
Gout
Haematochezia
Haemorrhage
Haemorrhoids
Hepatic Encephalopathy
Hepatic Steatosis
Hepatitis
Hypernatraemia
Hypertension

		Indifference International Normalised Ratio Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Peritoneal Haemorrhage					
		Peritonitis Bacterial					
		Pleural Effusion					
		Pneumonia					
		Pneumonia Aspiration					
		Polyp Colorectal					
		Prothrombin Time Prolonged					
		Pruritus					
		Rectal Haemorrhage					
		Renal Disorder					
		Renal Failure Acute					
		Respiratory Failure					
		Rhonchi					
		Social Avoidant Behaviour					
		Staring					
		Syncope					
		Varices Oesophageal					

Date:02/27/04ISR Number: 4306942-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA01381
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged Disability	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
			Vicodin Tablets	C		
			Lasix (Furosemide Sodium)	C		
			Neurontin	C		
			Glucosamine	C		
			Klor-Con	C		

Date:02/27/04ISR Number: 4306944-3Report Type:Expedited (15-DaCompany Report #WAES 0402AUT00011
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Memory Impairment Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc			

Date:02/27/04ISR Number: 4306946-7Report Type:Expedited (15-DaCompany Report #WAES 0402SWE00014
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx Trimethoprim	PS C	Merck & Co., Inc	ORAL		

Date:02/27/04ISR Number: 4306948-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia
	Anaemia Macrocytic
	Anxiety
	Asthenia
	Back Injury
	Back Pain
	Blindness
	Blood Triglycerides Increased
	Bronchitis
	Carotid Artery Disease
	Carotid Artery Stenosis
	Carotid Bruit
	Cerebral Infarction
	Cerebral Thrombosis
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Compression Fracture
	Contusion
	Depression
	Drug Ineffective
	Dysarthria
	Dyspepsia
	Dysphagia
	Dyspnoea
	Electrocardiogram Qt Prolonged
	Electrocardiogram St-T Change
	Fall
	Fatigue
	Gait Disturbance
	Haematochezia
	Headache
	Hypercholesterolaemia
	Hyperhidrosis
	Hyperreflexia
	Hypertriglyceridaemia
	Hypoaesthesia

Insomnia
Migraine
Myalgia
Myofascial Pain Syndrome
Nasal Congestion
Nausea
Neck Pain
Neoplasm Malignant
Osteopenia
Osteoporosis
Oxygen Saturation
Decreased
Pain
Pain In Extremity
Paraesthesia

		Pharyngolaryngeal Pain					
		Phonophobia					
		Photophobia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radiculopathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash Generalised		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Red Blood Cell		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Sedimentation Rate		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Zyrtec	C		
		Sinusitis		Celebrex	C		
		Sleep Disorder		Trimox	C		
		Spinal Fracture		Plavix	C		ORAL
		Stress		Nexium	C		
		Tendonitis		Zovirax	C		
		Thrombocytopenia		Paxil	C		
533	DAY						
		Transient Ischaemic		Prednisone	C		
		Attack					
		Tremor					
		Visual Disturbance					
		Vitamin B12 Deficiency					
		Vomiting					

Date:02/27/04ISR Number: 4306952-2Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00203
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Pneumonitis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/27/04ISR Number: 4306953-4Report Type:Expedited (15-DaCompany Report #WAES 0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Upper
Other	Acute Pulmonary Oedema
	Agitation
	Amnesia

Anaemia
Anxiety
Asthenia
Atherosclerosis
Back Injury
Balance Disorder
Cardiac Failure
Congestive
Cataract
Cerebral Atrophy
Cerebral Ventricle
Dilatation
Cholelithiasis
Contusion
Coronary Artery Disease
Dehydration
Diplopia
Disorientation
Dysarthria
Dysgraphia
Dyspnoea Paroxysmal

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Nocturnal Electrocardiogram Qt Prolonged					
		Eructation		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Feeling Of Despair		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		[Therapy			
		Gastrooesophageal Reflux		Unspecified]	C		
		Disease		Tylenol	C		
		Hallucination		Vicodin Tablets	C		
		Head Injury		Darvocet-N	C		
		Hiatus Hernia		Amitriptyline			
		Hypertension		Hydrochloride	C		ORAL
		Hypoaesthesia		Aspirin	C		
		Hypoxia		Aspirin	C		
		Insomnia		Buspirone			
		Laceration		Hydrochloride	C		
		Lacunar Infarction		Valium	C		
		Mental Status Changes		Aricept	C		ORAL
		Mitral Valve Incompetence		Premarin	C		ORAL
		Nocturia		Fluoxetine	C		
		Pain		Prozac	C		
		Paraesthesia		Lorazepam	C		
		Pollakiuria		Metoclopramide	C		
		Psychotic Disorder					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Refusal Of Treatment By Patient					
		Renal Failure					
		Respiratory Failure					
		Rotator Cuff Syndrome					
		Skin Ulcer					
		Spinal Compression Fracture					
		Suicidal Ideation					
		Toe Deformity					
		Tricuspid Valve Incompetence					
		Urinary Tract Infection					
		Venous Pressure Jugular Increased					
		Visual Acuity Reduced					

Date:02/27/04ISR Number: 4307262-XReport Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Back Pain
Disability	Blindness
Other	Blood Glucose Increased
	Carotid Artery Stenosis
	Cataract
	Cerebral Artery Embolism
	Cerebral Infarction
	Cerebrovascular Accident
	Convulsion
	Depression
	Dry Skin

	Dyspnoea					
	Embolism					
	Epistaxis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Flushing		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrooesophageal Reflux		Heparin	SS		
	Disease		Provera	SS		
	Gout		[Therapy			
	Haemorrhage Intracranial		Unspecified]	C		
	Headache		Tylenol With Codeine			
	Hemianopia Homonymous		#3	C		
	Hemiparesis		Captopril	C		
	Herpes Zoster		Capozide	C		
	Hyperhidrosis		Cisapride	C		
	Hypertension		Glyburide	C		
	Impaired Driving Ability					
	Impaired Work Ability					
	Injury					
	Intervertebral Disc					
	Degeneration					
	Joint Injury					
	Loss Of Consciousness					
	Meningioma					
	Nasal Congestion					
	Nausea					
	Neurological Symptom					
	Pain					
	Pallor					
	Pneumonia					
	Radiculopathy					
	Rash					
	Rift Valley Fever					
	Sciatica					
	Tachycardia					
	Thyroid Mass					
	Treatment Noncompliance					
	Vaginal Haemorrhage					
	Visual Field Defect					
	Weight Decreased					
	Weight Increased					

Date:02/27/04ISR Number: 4307270-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01432
Age:51 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Blood Disorder
	Cardiac Valve Disease
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Thrombosis
	Depression
	Dizziness
	Dyspepsia
	Dyspnoea Paroxysmal Nocturnal
	Gastrooesophageal Reflux

		Disease					
		Haemorrhagic Disorder					
		Hypertension					
		Intermittent Claudication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Lorcet 10/650	C		
		Palpitations		Albuterol	C		
RESPIRATORY							
		Restlessness					
(INHALATION)							
		Sleep Disorder		Prempro	C		
		Syncope		Detrol	C		
		Ventricular Hypokinesia		Tricor	C		ORAL
				Ibuprofen	C		
				Ibuprofen	C		
				Dilantin	C		ORAL

Date:02/27/04ISR Number: 4307272-2Report Type:Expedited (15-DaCompany Report #WAES 0209USA01976
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 106 DAY	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Tylenol	C		
	Chest Pain		Bayer Aspirin	C		
	Drug Hypersensitivity					
	Dyspnoea					
	Glaucoma					
	Headache					
	Heart Rate Increased					
	Injury					
	Insomnia					
	Non-Cardiac Chest Pain					
	Palpitations					
	Sleep Disorder					
	Thyroid Disorder					
	Tooth Extraction					

Date:02/27/04ISR Number: 4307273-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Amnesia
Other	Asthenia
	Autonomic Nervous System Imbalance
	Blood Bilirubin Unconjugated Increased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Blood Pressure Systolic Increased
	Bradycardia
	Calcinosis
	Cerebellar Haemorrhage
	Chronic Obstructive Pulmonary Disease
	Constipation
	Coordination Abnormal
	Culture Urine Positive

		Decreased Appetite					
		Dehydration					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Valium	C		
		Dysphagia		Neurontin	C		
		Fall		Neurontin	C		
		Fatigue		Neurontin	C		
		Femur Fracture		Neurontin	C		
		Gastritis		Avapro	C		
		Haemorrhagic Stroke		Misoprostol	C		
		Head Injury		Macrodantin	C		
		Hiatus Hernia		Nortriptyline	C		
		Hip Fracture		Nortriptyline	C		
		Hyperglycaemia					
		Hypertension					
		Hyponatraemia					
		Inappropriate					
		Antidiuretic Hormone					
		Secretion					
		Injury					
		Lung Neoplasm					
		Mental Status Changes					
		Nausea					
		Nystagmus					
		Obstructive Airways					
		Disorder					
		Oesophageal Disorder					
		Proctalgia					
		Proctitis					
		Prostatitis					
		Pyelonephritis					
		Rectal Cramps					
		Sleep Apnoea Syndrome					
		Staphylococcal Infection					
		Urethral Stricture					
		Urinary Tract Infection					
		Bacterial					
		Urinary Tract Infection					
		Pseudomonal					
		Urinary Tract Obstruction					
		Vomiting					

White Blood Cell Count
Increased

Date:02/27/04ISR Number: 4307274-6Report Type:Expedited (15-DaCompany Report #WAES 0301USA01083
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/04ISR Number: 4307275-8Report Type:Expedited (15-DaCompany Report #WAES 0301USA01084
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/27/04ISR Number: 4307276-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Abscess Limb
	Adnexa Uteri Mass
	Anxiety
	Azotaemia
	Back Pain
	Bronchitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cardiac Flutter
	Cellulitis
	Cervicitis
	Chest Pain
	Cough
	Crying
	Cystitis
	Dyspnoea
	Epistaxis
	Eye Disorder
	Fallopian Tube Cyst
	Feeling Hot
	Fistula
	Fluid Retention
	Haematocrit Decreased
	Hypertension
	Hypoventilation
	Injury
	Irritable Bowel Syndrome
	Limb Discomfort
	Meniscus Lesion
	Menorrhagia
	Mood Swings

Nasal Dryness
Neuropathic Pain
Nocturia
Non-Cardiac Chest Pain
Oedema Peripheral
Ovarian Fibrosis
Palpitations
Paraesthesia
Peau D'Orange
Pelvic Pain
Pickwickian Syndrome
Pneumonia
Pulmonary Congestion
Pulmonary Oedema
Pyrexia
Respiratory Failure
Retching

		Sputum Discoloured					
		Sweat Gland Infection					
		Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Ventolin (Albuterol Sulfate)	C		
				Tenormin	C		
				Vasotec	C		ORAL
				Ultram	C		
				Lodine Xl	C		
				Lasix (Furosemide Sodium)	C		
				Ditropan	C		
				K-Dur	C		
				Quinine Sulfate	C		

Date:02/27/04ISR Number: 4307278-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Akinesia		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Anxiety					
		Arthralgia					
		Arthropathy					
		Blood Pressure Decreased					
		Cardiac Failure					
		Congestive					
		Chest Discomfort					
		Chondrocalcinosis					
		Pyrophosphate					
		Clostridium Colitis					
		Coronary Artery Disease					
		Dehydration					
		Diarrhoea					
		Dizziness					
		Drug Ineffective					
		Dyspnoea Exertional					
		Feeling Abnormal					

Haemoglobin Decreased
Injury
Meniscus Lesion
Mitral Valve Repair
Myocardial Infarction
Osteoarthritis
Pco2 Decreased
Photosensitivity Reaction
Pleuritic Pain
Renal Failure
Thrombosis
Tooth Disorder
Tooth Infection
Tremor
Urinary Tract Infection
Vision Blurred

Date:02/27/04ISR Number: 4307279-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01400
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Antibody Test Positive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Central Nervous System Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coccidioidomycosis							
	Emotional Disorder							
	Glioma							
	Heart Rate Increased							
	Hereditary Haemorrhagic Telangiectasia							
	Hyperhidrosis							
	Infection							
	Joint Effusion							
	Large Intestinal Ulcer							
	Melanosis Coli							
	Mental Status Changes							
	Musculoskeletal Chest Pain							
	Osteopenia							
	Platelet Count Increased							
	Pneumonia							
	Polyarthritis							
	Prothrombin Time Shortened							
	Pulmonary Haemorrhage							
	Pulmonary Mass							
	Pyelonephritis							
	Red Blood Cell Sedimentation Rate Increased							
	Renal Failure							
	Renal Failure Acute							
	Spleen Disorder							
	Transfusion Reaction							
	Urinary Tract Infection							
	Wegener'S Granulomatosis							

Date:02/27/04ISR Number: 4307280-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA01356
Age:41 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis B		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hiv Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Tylenol	C				
	Panic Attack		Cough, Cold, And Flu Therapies (Unspecified)	C				
			Claritin	C				

Date:02/27/04ISR Number: 4307281-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01102
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Peripheral Embolism							
	Renal Failure Acute							
	Sudden Death							

Date:02/27/04ISR Number: 4307282-5Report Type:Expedited (15-DaCompany Report #WAES 0402NLD00016
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hallucination		Diclofenac Sodium	C		RECTAL		
	Migraine		Zopiclone	C		ORAL		

Date:02/27/04ISR Number: 4307283-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	16	DAY
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL	19	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	16	DAY
	Body Temperature Decreased							
	Cardiac Aneurysm							
	Cardiac Failure							
	Congestive Cholelithiasis							
	Colonic Pseudo-Obstruction							
	Congestive Cardiomyopathy							
	Coronary Artery Disease							
	Ileus							
	Intestinal Dilatation							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Ventricular Dysfunction							
	Ventricular Tachycardia							

Date:02/27/04ISR Number: 4307284-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01305
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cerebral Artery		Clotrimazole	C		
	Thrombosis		Diuretic			
	Cerebral Infarction		(Unspecified)	C		
	Cerebrovascular Accident		Triamterene	C		
	Coagulation Factor Viii		Broncholate	C		
	Level Increased		Tri-Norinyl	C		
	Convulsion					
	Diabetes Mellitus					
	Hemiparesis					
	Hypertensive Heart					
	Disease					
	Pain					
	Peptic Ulcer					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/27/04ISR Number: 4307285-0Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00231
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	1044 DAY	
	Dermatitis Exfoliative							

Date:02/27/04ISR Number: 4307286-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01285
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	51 DAY	
	Cardiac Arrest		Aspirin	C				
	Coronary Artery Disease							
	Emotional Distress							
	Myocardial Infarction							
	Sleep Apnoea Syndrome							
	Weight Increased							

Date:02/27/04ISR Number: 4307287-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY	
	Cardiac Failure		Estradiol Valerate					
	Coronary Artery Disease		And Norethindrone	C		ORAL		
	Coronary Artery Occlusion		Omeprazole	C		ORAL	1 DAY	
	Coronary Artery Stenosis							
	Myocardial Ischaemia							
	Pulmonary Congestion							

Date:02/27/04ISR Number: 4307289-8Report Type:Expedited (15-DaCompany Report #WAES 0402USA01829
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	466	DAY

Date:02/27/04ISR Number: 4307290-4Report Type:Expedited (15-DaCompany Report #WAES 0402USA01835
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure Congestive Impaired Work Ability		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/04ISR Number: 4308404-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Blood Urine Present
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Constipation
	Dyspepsia
	Emotional Distress

		Epilepsy					
		Haematochezia					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Plendil	C		
		Pulmonary Valve		Dyazide	C		
		Incompetence					
		Simple Partial Seizures					
		Tricuspid Valve					
		Incompetence					
		Urine Flow Decreased					
		Vision Blurred					
		Weight Increased					

Date:03/01/04ISR Number: 4308406-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA01397
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY						
Initial or Prolonged	Back Pain		[Therapy			
	Brain Scan Abnormal		Unspecified]	C		
	Cardiac Failure		Captopril	C		
	Congestive		Klonopin	C		
	Cerebral Infarction		Lasix (Furosemide)	C		
	Chest X-Ray Abnormal		Potassium			
	Deep Vein Thrombosis		(Unspecified)	C		
	Dyspepsia					
	Dyspnoea					
	Headache					
	Hypersensitivity					
	Ileus Paralytic					
	Injury					
	Lower Limb Fracture					
	Oedema Peripheral					
	Open Wound					
	Pruritus					
	Rash					
	Stevens-Johnson Syndrome					
	Ventricular Hypertrophy					
	Weight Increased					

Date:03/01/04ISR Number: 4308409-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Arterial Thrombosis Limb
	Atherosclerosis
	Balance Disorder
	Blood Glucose Increased
	Blood Pressure Increased
	Burning Sensation
	Bursitis
	Coordination Abnormal
	Cough
	Dizziness
	Dyspepsia
	Dysphagia

		Dyspnoea					
		Emotional Distress					
		Emphysema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Exostosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Herbs (Unspecified)	C		
840	DAY						
		Femoral Arterial Stenosis		Prilosec	C		
		Gait Disturbance					
		Gastritis					
		Haemorrhoids					
		Hypertension					
		Impaired Work Ability					
		Injury					
		Intermittent Claudication					
		Joint Sprain					
		Joint Swelling					
		Lacunar Infarction					
		Ligament Injury					
		Memory Impairment					
		Meniscus Lesion					
		Nausea					
		Oesophageal Disorder					
		Oesophagitis					
		Osteoarthritis					
		Pain In Extremity					
		Peripheral Vascular					
		Disorder					
		Qrs Axis Abnormal					
		Rectal Polyp					
		Spinal Osteoarthritis					
		Synovitis					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Vascular Calcification					
		Wheezing					

Date:03/01/04ISR Number: 4308410-8Report Type:Expedited (15-DaCompany Report #WAES 0210USA01482
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower Adverse Event

Disability	Angina Unstable
Other	Anxiety
	Atrioventricular Block
	Back Pain
	Blood Glucose Increased
	Bundle Branch Block Left
	Cataract
	Chest Pain
	Chorioretinal Disorder
	Constipation
	Diabetes Mellitus
	Diarrhoea
	Diplopia
	Dysphonia
	Dyspnoea
	Emotional Distress
	Eructation

		Eye Disorder					
		Faeces Discoloured					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Cold		Vioxx	PS	Merck & Co., Inc	ORAL
		Flatulence		[Therapy			
		Hot Flush		Unspecified]	C		
OPHTHALMIC							
		Impaired Work Ability		Tylenol	C		
		Inflammatory Bowel		Aspirin	C		
		Disease		Aspirin	C		
		Nausea		Lipitor	C		
1304 DAY							
		Pain		Premarin	C		
		Palpitations		Micronase	C		
		Pinguecula		Motrin	C		
		Refusal Of Treatment By		Synthroid	C		
		Patient		Synthroid	C		
		Sinus Bradycardia		Glucophage	C		
		Somnolence		Naproxen	C		
		Stress		Nitroglycerin	C		
		Upper Respiratory Tract		Refresh	C		
OPHTHALMIC							
		Infection					
		Visual Disturbance					

Date:03/01/04ISR Number: 4308411-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA01355
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Amnesia		Prempro	C		ORAL
		Anxiety		Diovan	C		ORAL
		Blood Cholesterol					
		Increased					
		Cerebrovascular Accident					
		Confusional State					
		Cough					
		Depression					
		Drug Hypersensitivity					
		Drug Interaction					
		Essential Hypertension					
		Eye Haemorrhage					
		Fatigue					

Headache
Hyperlipidaemia
Hypertension
Hypoaesthesia
Hypothyroidism
Injury
Nausea

Date:03/01/04ISR Number: 4308413-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA02188
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/04ISR Number: 4308414-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sinus Tachycardia		Lipitor	C			3142 DAY	
	Ventricular Dysfunction		Lotensin	C				
			Lotensin	C				
			Vasotec	C		ORAL	3507 DAY	
			Vasotec	C		ORAL	3507 DAY	
			Prozac	C				
			Prozac	C				
			Prozac	C				
			Ginseng	C				
			Naproxen	C				
			Accupril	C				
			Accupril	C				

Date:03/01/04ISR Number: 4308415-7Report Type:Expedited (15-DaCompany Report #WAES 0202USA02142
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Allopurinol	C				
	Dilatation Atrial		Keflex	C				
	Drug Ineffective		Hydrochlorothiazide	C				
	Electrocardiogram St-T		Indocin					
	Change		(Indomethacin)	C		ORAL		
	Fluid Retention		Synthroid	C				
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							

Homans' Sign
Hypercholesterolaemia
Injury
Nausea
Pulmonary Oedema
Restrictive Pulmonary
Disease
Sinusitis
Supraventricular
Extrasystoles
Vomiting
Weight Increased

Date:03/01/04ISR Number: 4308417-0Report Type:Expedited (15-DaCompany Report #WAES 0304USA01284
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Abdominal Pain Upper
	Abdominal Strangulated

		Hernia					
		Aerophagia					
		Anaemia Macrocytic					
		Asthma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Candidiasis		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Colonic Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Albuterol	C		
RESPIRATORY							
		Drug Hypersensitivity					
(INHALATION)							
		Dyspepsia		Beconase Aq	C		
		Dysphagia		Synthroid	C		
		Fatigue		Singulair	C		ORAL
		Fibromyalgia		Singulair	C		ORAL
		Gastric Haemorrhage		Norflex	C		
		Gastric Perforation					
		Gastric Ulcer					
		Gastritis					
		Headache					
		Heart Injury					
		Hepatic Steatosis					
		Hepatomegaly					
		Impaired Gastric Emptying					
		Influenza Like Illness					
		Injury					
		Muscle Spasms					
		Nephrolithiasis					
		Oesophagitis					
		Osteoarthritis					
		Paraesthesia					
		Rectal Haemorrhage					
		Renal Disorder					
		Skin Discolouration					
		Umbilical Hernia					
		Vision Blurred					
		Weight Decreased					

Date:03/01/04ISR Number: 4308420-0Report Type:Expedited (15-DaCompany Report #WAES 0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Arrhythmia
	Blood Creatinine Increased
	Cardiac Failure Congestive
	Cardiac Valve Disease
	Chest Discomfort
	Coronary Artery Disease
	Coronary Artery Stenosis
	Decreased Activity
	Ejection Fraction Decreased
	Emotional Distress
	Gout
	Hypertension
	Injury
	Ischaemic Cardiomyopathy

		Myocardial Infarction Platelet Count Decreased Renal Failure Chronic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Tylenol	C		
				Aspirin	C		
				Aspirin	C		
				Coumadin	C		
				Atenolol	C		
				Indocin (Indomethacin)	C		

Date:03/01/04ISR Number: 4308424-8Report Type:Expedited (15-DaCompany Report #WAES 0402USA01565
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Life-Threatening	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
Hospitalization - Initial or Prolonged Disability	Congestive Thrombosis					

Date:03/01/04ISR Number: 4308428-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA01445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Life-Threatening	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
Hospitalization - Initial or Prolonged Disability	Congestive Thrombosis					

Date:03/01/04ISR Number: 4308429-7Report Type:Expedited (15-DaCompany Report #WAES 0401USA02199
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Abdominal Pain Lower		Aspirin	C				
	Clostridium Colitis		Lipitor	C				
	Dehydration		Vitamins (Unspecified)	C				
	Diarrhoea		Calcium (Unspecified)	C				
	Diverticular Hernia		Atacand	C				
	Diverticulitis		Aciphex	C				
	Iron Deficiency Anaemia							
	Lymphadenopathy							
	Nausea							
	Small Intestinal Obstruction							
	Small Intestine Ulcer							
	Tendonitis							
	Thirst							
	Vomiting							

Date:03/01/04ISR Number: 4308431-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01412
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Aspirin	C				
	Blindness Transient		Plavix	C				
	Cardiac Failure		Lanoxin	C				
	Congestive		Coumadin	C		ORAL		
	Cerebellar Infarction		Coumadin	C		ORAL		
	Cerebrovascular Accident		Coumadin	C		ORAL		
	Chronic Obstructive		Calan	C				
	Pulmonary Disease		Hyzaar	C				
	Coronary Artery Disease		Hyzaar	C		ORAL		
	Coronary Artery Occlusion							
	Dilatation Atrial							
	Hypertension							
	Injury							
	Ischaemic Stroke							
	Mitral Valve Incompetence							
	Osteoarthritis							
	Sick Sinus Syndrome							
	Sleep Apnoea Syndrome							
	Tricuspid Valve Incompetence							
	Urinary Tract Infection							
	Ventricular Hypertrophy							

Date:03/01/04ISR Number: 4308433-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA01091
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	419 DAY	
	Ischaemic Stroke							
	Renal Failure							

Date:03/01/04ISR Number: 4308434-0Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Aortic Valve Sclerosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Circulatory Collapse							
	Coronary Artery Disease							
	Cough							
	Depression							
	Embolic Stroke							
	Injury							
	Mitral Valve Incompetence							
	Mitral Valve Sclerosis							
	Quadruple Vessel Bypass Graft							
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							
	Thrombosis							
	Transient Ischaemic Attack							

Date:03/01/04ISR Number: 4308568-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability Other	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Arthropod Sting		Percocet	SS		
	Bradycardia		Alcohol	SS		
	Cardiac Failure		Xanax	SS		
	Coronary Artery Disease		Ambien	SS		
	Coronary Artery Stenosis		Soma	C		
	Diabetes Mellitus		Advil	C		
	Gastrooesophageal Reflux Disease		Imdur	C		
	Hypercholesterolaemia					
	Hyperlipidaemia					
	Hypertension					
	Intentional Misuse					
	Major Depression					
	Myocardial Infarction					
	Pain In Jaw					
	Snoring					
	Spondylitis					
	Stent Occlusion					
	Suicide Attempt					
	Swelling Face					
	Tooth Disorder					
	Ventricular Dysfunction					

Date:03/01/04ISR Number: 4308573-4Report Type:Expedited (15-DaCompany Report #WAES 0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability Other	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure		Tylenol	C		
	Congestive		Aspirin	C		
	Cardiac Valve Disease		Coumadin	C		
	Coronary Artery Disease		Aspirin	C		
	Deep Vein Thrombosis		Atenolol	C		
	Dyspnoea		Indocin (Indomethacin)	C		
	Ejection Fraction Decreased					

Emotional Distress
Gout
Hypertension
Injury
Ischaemic Cardiomyopathy
Myocardial Infarction
Osteoarthritis
Pain In Extremity
Platelet Count Decreased
Renal Failure Chronic
Sinusitis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/04ISR Number: 4308578-3Report Type:Expedited (15-DaCompany Report #WAES 0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Arthralgia	Professional	Premarin	C				
Other	Atrial Fibrillation		Estratab	C				
	Cerebral Artery Embolism		Menest	C				
	Corneal Deposits		Armour Thyroid Tablets	C				
	Dizziness		Trazodone Hydrochloride	C				
	Drug Ineffective		Garlic Extract	C				
	Dyspnoea		Synthroid	C				
	Haematoma		Methotrexate	C				
	Haematuria							
	Haemorrhage							
	Hypertension							
	Hypertensive Crisis							
	Injury							
	Morton'S Neuroma							
	Musculoskeletal Disorder							
	Oedema Peripheral							
	Refusal Of Treatment By Patient							
	Renal Cyst							
	Toe Deformity							
	Transient Ischaemic Attack							
	Ventricular Dysfunction							

Date:03/01/04ISR Number: 4308581-3Report Type:Expedited (15-DaCompany Report #WAES 0402USA01893
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				
			Crestor	C				
			Toprol Xl Tablets	C				
			Altace	C				

Date:03/01/04ISR Number: 4308582-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Pulmonary Oedema
Initial or Prolonged	Amnesia
Disability	Anaemia
	Anxiety
	Atelectasis
	Blood Cholesterol
	Increased
	Bundle Branch Block Right
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Diabetes Mellitus

		Inadequate Control					
		Emotional Distress					
		Hypertension					
		Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
5	MON						
		Nasopharyngitis		Glucotrol Xl	C		
		Pain In Extremity		Glyburide	C		
		Palpitations		Aspirin	C		
		Pulmonary Congestion		Lasix (Furosemide)	C		
		Respiratory Rate		Ativan	C		
		Increased		Lopressor	C		
		Rotator Cuff Syndrome		Orphenadrine	C		
		Self-Medication					
		Supraventricular					
		Tachycardia					
		Syncope					
		Transient Ischaemic					
		Attack					
		Urinary Incontinence					
		Urinary Tract Infection					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Vision Blurred					
		White Blood Cell Count					
		Increased					

Date:03/01/04ISR Number: 4308588-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aphasia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
710	DAY						
Initial or Prolonged		Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
710	DAY						
		Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL
		Brain Stem Infarction		Aspirin	C		
		Carotid Artery Stenosis					
		Cerebral Haemorrhage					
		Cerebral Infarction					
		Disorientation					

Dysarthria
Dyspepsia
Excoriation
Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Haemorrhagic Stroke
Hyperlipidaemia
Localised Infection
Nasal Congestion
Rash Erythematous
Sinus Congestion
Skin Laceration
Visual Field Defect

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/04ISR Number: 4309440-2Report Type:Expedited (15-DaCompany Report #2004011155
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pain In Extremity	Foreign	Amlodipine					
	Purpura	Health	(Amlodipine)	PS				
	Rash Pruritic	Professional	Vaseretic					
	Skin Ulcer		(Hydrochlorothiazide , Enalapril Maleate)	SS				
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Chondroitin Sulfate Sodium (Chondroitin Sulfate Sodium)	SS				

Date:03/01/04ISR Number: 4309711-XReport Type:Expedited (15-DaCompany Report #200410131BNE
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Foreign	Aspirin					
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health	(Acetylsalicylic					
	Haematemesis	Professional	Acid)	PS		ORAL	SEE IMAGE	
	Oesophageal Ulcer	Other	Vioxx (Rofecoxib)	SS		ORAL	25 MG, TOTAL	DAILY; ORAL
			Allopurinol	C				
			Indoramin	C				
			Frusemide	C				
			Lisinopril	C				

Date:03/01/04ISR Number: 4309820-5Report Type:Periodic Company Report #1427
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Foreign	Targretin Capsules	PS		ORAL	600 MG DAILY	

Initial or Prolonged Health
PO

Professional Rofecoxib SS
MG DAILY PO

Other Rofecoxib SS ORAL
25 MG DAILY

PO

Lanzoprazole C
Penicillin V C

Date:03/01/04ISR Number: 4310249-4Report Type:Direct Company Report #CTU 213504
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Increased		Vioxx 12.5 Mg Merc	PS	Merc	ORAL	12.5 MG 1-2 TIMES ORAL	
			Diamox	C				

Date:03/02/04ISR Number: 4309338-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00252
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
Other	Blood Pressure Systolic Increased
	Bunion
	Burning Sensation

		Bursitis					
		Carotid Artery Atheroma					
		Cataract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cataract Cortical	Health	Vioxx	PS	Merck & Co., Inc	ORAL
272	DAY						
		Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Wall Pain		Aspirin	C		
		Corneal Disorder		Lipitor	C		
		Diabetic Neuropathy		Os-Cal	C		
		Dysphagia		Casanthranol And			
		Dysphonia		Docusate Sodium	C		
		Epistaxis		Monopril	C		ORAL
		Exostosis		Vitamins			
		Fall		(Unspecified)	C		
		Gastrooesophageal Reflux		Hydrodiuril	C		ORAL
		Disease		Hydrocodone			
		Glaucoma		Hydrochloride	C		
		Gout		Humulin R	C		
SUBCUTANEOUS							
		Haemoglobin Decreased		Humulin Nph	C		
SUBCUTANEOUS							
		Hyperlipidaemia		Humulin Nph	C		
SUBCUTANEOUS							
		Hypertension		Adalat	C		
		Hypoaesthesia					
		Lacunar Infarction					
		Laryngitis					
		Macular Degeneration					
		Medication Error					
		Neuropathy					
		Ocular Hypertension					
		Oedema Peripheral					
		Oesophagitis					
		Oropharyngeal Spasm					
		Osteoarthritis					
		Palatal Disorder					
		Peripheral Vascular					
		Disorder					
		Pupils Unequal					
		Regurgitation Of Food					
		Tendonitis					
		Vibration Test Abnormal					
		Vision Blurred					
		Weight Decreased					

Date:03/02/04ISR Number: 4309344-5Report Type:Expedited (15-DaCompany Report #WAES 0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Adhesions
Initial or Prolonged	Abscess Intestinal
Disability	Anaemia
Other	Anaemia Macrocytic
	Angiodysplasia
	Aortic Stenosis
	Asthenia
	Back Pain
	Blood Pressure Systolic
	Increased
	Cardiac Murmur
	Chest Discomfort
	Colitis
	Colonic Polyp
	Coronary Artery Disease

		Depression					
		Diarrhoea					
		Diverticular Perforation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram St-T		Vioxx	SS	Merck & Co., Inc	ORAL
		Change		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Lipitor	C		
		Haemorrhage		Celebrex	C		
		Impaired Work Ability		Zoloft	C		
		Injury		Triamterene	C		
		Metaplasia		Voltaren	C		
		Muscle Spasms		Duragesic	C		
TOPICAL							
		Night Cramps		Dyazide	C		
		Osteoarthritis		Metoprolol	C		
		Palpitations		Lopressor	C		
		Polyp Colorectal		Prilosec	C		
		Rectal Haemorrhage		Denavir	C		
		Small Intestinal					
		Haemorrhage					
		Thrombosis					

Date:03/02/04ISR Number: 4309347-0Report Type:Expedited (15-DaCompany Report #WAES 0308ITA00017
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Ascites	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Disseminated	Professional	Esomeprazole			
Initial or Prolonged	Intravascular Coagulation		Magnesium	SS		ORAL
	Hepatic Failure		Hydrochlorothiazide			
	Hepatic Necrosis		And Ramipril	SS		ORAL
	Hepatorenal Syndrome					
	Jaundice Cholestatic					
	Oliguria					

Date:03/02/04ISR Number: 4309352-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence Arterial Disorder Benign Prostatic Hyperplasia Blood Pressure Increased Blood Triglycerides Increased Bundle Branch Block Right Coronary Artery Disease Coronary Artery Occlusion Dermal Cyst Erectile Dysfunction Fatigue Hypersensitivity Inguinal Hernia Injury Mitral Valve Incompetence Muscle Tightness

		Myocardial Infarction					
		Pneumonitis					
		Prostatic Specific	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Antigen Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy			
				Unspecified]	C		
				Vicodin Tablets	C		
				Ultram	C		
				Soma	C		
				Celebrex	C		

Date:03/02/04ISR Number: 4309355-XReport Type:Expedited (15-DaCompany Report #WAES 01104477
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure Systolic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Bundle Branch Block Right		[Therapy			
		Cardiac Failure		Unspecified]	C		
		Congestive		Darvocet-N	C		
		Cardiomegaly		Celebrex	C		
		Cardiovascular Disorder		Furosemide	C		
		Cellulitis		Oxygen	C		
		Chloracne		Klor-Con	C		
		Cor Pulmonale					
		Drug Toxicity					
		Dyspnoea					
		Erythema					
		Generalised Oedema					
		Glaucoma					
		Heart Rate Increased					
		Hypoaesthesia					
		Hypoxia					
		Infection					
		Pickwickian Syndrome					
		Polycythaemia					
		Pulmonary Hypertension					
		Respiratory Failure					
		Respiratory Rate					
		Increased					
		Restrictive Pulmonary					
		Disease					

Rhinitis
Scrotal Oedema
Sinus Tachycardia
Sleep Apnoea Syndrome
Thermal Burn
Venous Stasis
Weight Decreased
Wound

Date:03/02/04ISR Number: 4309361-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01432
Age:54 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	159	DAY
	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	159	DAY
	Asthenia		Vicodin Tablets	C				
	Bone Cyst		Carisoprodol	C				
	Cardio-Respiratory Arrest							
	Electromechanical							
	Dissociation							
	Intervertebral Disc							
	Protrusion							
	Osteoarthritis							
	Pain In Extremity							
	Pupil Fixed							
	Sciatica							
	Spinal Column Stenosis							
	Ventricular Fibrillation							

Date:03/02/04ISR Number: 4309599-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	18	MON
Disability	Arthropod Bite		Acetaminophen And Hydrocodone Bitartrate	C				
	Back Pain							
	Blood Glucose Increased							
	Cardiac Failure							
	Congestive							
	Cerumen Impaction							
	Chest Pain							
	Deep Vein Thrombosis							
	Diabetes Mellitus							
	Dizziness							
	Dyspnoea							
	Gait Disturbance							
	Headache							
	Hodgkin'S Disease							

Hyperhidrosis
Hypertension
Injury
Intervertebral Disc
Degeneration
Joint Swelling
Labile Hypertension
Labyrinthitis
Myocardial Infarction
Non-Hodgkin'S Lymphoma
Oedema Peripheral
Skin Cancer
Thrombophlebitis
Vertigo
Vestibular Disorder
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/04ISR Number: 4309604-8Report Type:Expedited (15-DaCompany Report #WAES 01051542
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Chest Discomfort	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Disability	Emotional Distress		Ibuprofen	C				
	Hyperhidrosis							
	Hypersensitivity							
	Injury							
	Muscular Weakness							
	Myocardial Infarction							

Date:03/02/04ISR Number: 4309610-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adenomyosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Anaemia	Professional	Claritin	C				8 MON
Disability	Blood Cholesterol Increased							
	Cervicitis							
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Haemorrhagic Ovarian Cyst							
	Hyperhidrosis							
	Leiomyoma							
	Low Density Lipoprotein Increased							
	Metaplasia							
	Nausea							
	Palpitations							
	Pelvic Pain							
	Tachycardia							
	Uterine Haemorrhage							
	Uterine Leiomyoma							
	Vaginal Haemorrhage							

Date:03/02/04ISR Number: 4309611-5Report Type:Expedited (15-DaCompany Report #WAES 0402AUT00019
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:03/02/04ISR Number: 4309614-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA02038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	73	DAY

Date:03/02/04ISR Number: 4309615-2Report Type:Expedited (15-DaCompany Report #WAES 0402USA01950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/04ISR Number: 4309616-4Report Type:Expedited (15-DaCompany Report #WAES 0402USA00725
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastric Ulcer Helicobacter Gastritis Rectal Haemorrhage Weight Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/04ISR Number: 4309618-8Report Type:Expedited (15-DaCompany Report #WAES 0402USA02049
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/04ISR Number: 4309619-XReport Type:Expedited (15-DaCompany Report #WAES 0402NOR00019
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemoglobin Decreased Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/04ISR Number: 4309620-6Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00070
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Alkaline	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Phosphatase Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY	
	Gamma-Glutamyltransferase Increased		Acetaminophen	C				
	Liver Function Test Abnormal		Aspirin	C		ORAL		
			Bumetanide	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		

Spironolactone	C		ORAL
Tramadol Hydrochloride	C		
Docusate Sodium	C		
Lactulose	C		
Nicorandil	C		ORAL
Ramipril	C		
Ranitidine	C		ORAL

Date:03/02/04ISR Number: 4309625-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA01954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	614	DAY

Date:03/02/04ISR Number: 4309626-7Report Type:Expedited (15-DaCompany Report #WAES 0402DEU00173
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Macular Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Visual Disturbance		Vioxx	SS	Merck & Co., Inc	ORAL		
			Tibolone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/04ISR Number: 4309627-9Report Type:Expedited (15-DaCompany Report #WAES 0402USA01953
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/04ISR Number: 4310295-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01574
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriovenous	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization -	Malformation		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Balance Disorder							
Disability	Blood Pressure Decreased							
Other	Cerebral Haemorrhage							
	Convulsion							
	Decreased Activity							
	Dizziness							
	Face Oedema							
	Impaired Driving Ability							
	Impaired Work Ability							
	Lethargy							
	Nasal Oedema							
	Oedema Peripheral							
	Pain In Extremity							
	Pruritus							
	Renal Failure Acute							
	Renal Pain							
	Vertigo							
	Visual Disturbance							
	Weight Increased							

Date:03/03/04ISR Number: 4310298-6Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00090
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	

Hospitalization - Initial or Prolonged	Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased Drug Toxicity Hepatocellular Damage	[Therapy Unspecified]	C
		Atropine	C
		Dobutamine Hydrochloride	C
		Dopamine Hydrochloride	C
		Sodium Bicarbonate	C
		Sufentanil Citrate	C
		Tinzaparin Sodium	C
		Sodium Chloride	C
		Epinephrine Hydrochloride	C
		Heparin	C
		Metaproterenol Sulfate	C
		Propofol	C

Date:03/03/04ISR Number: 4310299-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Disability	Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Blood Cholesterol Increased		Amoxicillin Hydrocodone Bitartrate	C				
	Depression		Lorazepam	C				
	Dermatitis Papillaris Capillitii							
	Difficulty In Walking							
	Disturbance In Attention							
	Dysstasia							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	General Physical Condition Abnormal							
	Hypertension							
	Impaired Healing							
	Irritability							
	Keloid Scar							
	Malaise							
	Pain							
	Self Esteem Decreased							
	Sexual Dysfunction							
	Vascular Injury							

Date:03/03/04ISR Number: 4310302-5Report Type:Expedited (15-DaCompany Report #WAES 0402USA01870
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				

Date:03/03/04ISR Number: 4310303-7Report Type:Expedited (15-DaCompany Report #WAES 0402USA02013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/04ISR Number: 4310305-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA00678
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive Oedema	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/03/04ISR Number: 4310308-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01799
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Hospitalization -	Abdominal Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
Initial or Prolonged Disability	Amnesia							
	Arteriovenous Malformation							
	Balance Disorder							
	Blood Pressure Decreased							
	Convulsion							
	Decreased Activity							
	Dizziness							
	Drug Hypersensitivity							
	Face Oedema							
	Feeling Abnormal							
	Haemorrhage Intracranial							
	Heart Rate Increased							
	Hypervolaemia							
	Impaired Driving Ability							
	Lethargy							
	Nasal Oedema							
	Oedema							
	Oedema Peripheral							
	Panic Reaction							
	Pruritus							
	Renal Cyst							
	Renal Failure Acute							
	Renal Pain							
	Transient Ischaemic Attack							
	Vertigo							
	Visual Disturbance							
	Weight Increased							

Date:03/03/04ISR Number: 4310566-8Report Type:Expedited (15-DaCompany Report #DE-GLAXOSMITHKLINE-B0324072A
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death			Cardiac Failure	Paroxetine	PS	Glaxosmithkline	ORAL
10MG per day	10	DAY					
Hospitalization -			Confusional State	Diazepam	SS		ORAL
45MG per day	6	DAY					
Initial or Prolonged			Drug Interaction	Rofecoxib	SS		ORAL
25MG per day	3	YR					
			Foreign Body Aspiration	Glibenclamide	SS		ORAL
10.5MG per day		YR					
				Bisoprolol + Hydrochlorothiazide	SS		ORAL
7.5MG per day		YR					
				Allopurinol	C	Glaxosmithkline	ORAL
300MG per day		YR					
				Acetyl Salicylic Acid	C	Glaxosmithkline	ORAL
200MG per day		YR					
				Metformin Hydrochloride	C		ORAL
2550MG per day		YR					
				Fentanyl	C		
50MG per day	4	DAY					
				Fentanyl	C		
75MG per day							
				Amlodipine	C		
10MG per day							
				Chloral Hydrate	C		
1SP per day	2	DAY					
				Chlormethiazole Edisylate	C		
2CAP per day							
				Dipyrone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/04ISR Number: 4310753-9Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00079
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Valproate Sodium	C				

Date:03/03/04ISR Number: 4310773-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA00759
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Injury
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Arteriosclerosis
Other	Ascites
	Aspartate Aminotransferase Increased
	Asthenia
	Blood Alkaline Phosphatase Increased
	Blood Bilirubin Increased
	Blood Calcium Decreased
	Blood Glucose Increased
	Blood Ph Decreased
	Blood Potassium Decreased
	Blood Pressure Systolic Increased
	Blood Urea Increased
	Bloody Discharge
	Body Temperature Increased
	Bowel Sounds Abnormal
	Calcinosis
	Cholecystitis
	Cholelithiasis
	Diverticulum
	Duodenal Ulcer Perforation
	Fall

Gastric Perforation
Gastrointestinal
Haemorrhage
Haemoglobin Decreased
Heart Rate Increased
Intestinal Functional
Disorder
Intestinal Perforation
Leukocytosis
Pancreatitis
Pelvic Abscess
Pneumonia
Po2 Increased
Post Procedural Bile Leak
Post Procedural
Complication
Procedural Hypotension

		Pseudomonas Infection					
		Respiratory Failure					
		Respiratory Rate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Sinus Tachycardia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Staphylococcal Infection		Synthroid	C		
		Syncope		Tamiflu	C		
		Vascular Insufficiency		Propranolol			
		Ventricular Arrhythmia		Hydrochloride	C		ORAL

Date:03/03/04ISR Number: 4310775-8Report Type:Expedited (15-DaCompany Report #WAES 0402USA01838
Age:73 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
424	DAY						
		Fluctuation					
		Cardiac Arrest					
		Erythema					
		Essential Hypertension					
		Hypothyroidism					
		Myocardial Infarction					
		Oedema Peripheral					
		Swelling Face					
		Ventricular Fibrillation					

Date:03/03/04ISR Number: 4310778-3Report Type:Expedited (15-DaCompany Report #WAES 0402SGP00004
Age:91 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Dialysis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Oxygen Saturation		[Therapy			
		Decreased		Unspecified]	C		
		Pneumonia Staphylococcal					
		Renal Failure Acute					

Date:03/03/04ISR Number: 4310787-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
Disability	Adjustment Disorder With Depressed Mood
Other	Blood Cholesterol Increased
	Bradycardia
	Cardiomyopathy
	Catheter Related Complication
	Cellulitis
	Coronary Artery Disease
	Epicondylitis
	Fall
	Feeling Abnormal
	Hypersensitivity
	Hypotension
	Injury
	Myocardial Infarction
	Nervousness

		Quadriplegia					
		Road Traffic Accident					
		Skin Laceration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Spinal Cord Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Treatment Noncompliance	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Tremor					
		Ulcer					
		Urinary Tract Infection					
		Wound Infection					

Date:03/03/04ISR Number: 4311959-5Report Type:Expedited (15-DaCompany Report #2003GB02479
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure	Foreign	Omeprazole	PS		ORAL
20 MG PO						
Required	Cardiac Output Decreased	Health	Rofecoxib	SS		ORAL
50 MG PO						
Intervention to	Coronary Artery	Professional	Climagest	C		
Prevent Permanent	Atherosclerosis	Other				
Impairment/Damage	Coronary Artery Disease					
	Myocardial Ischaemia					
	Pulmonary Oedema					
	Stroke Volume Decreased					
	Sudden Death					

Date:03/04/04ISR Number: 4311255-6Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00014
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bronchitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Discomfort	Professional	Clopidogrel			
	Dyspnoea		Bisulfate	C		ORAL
	Fibrinous Bronchitis		Esomeprazole			
	Purulence		Magnesium	C		ORAL

Date:03/04/04ISR Number: 4311257-XReport Type:Expedited (15-DaCompany Report #WAES 0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis Infective
Disability	Back Injury
Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Chest Pain
	Diabetes Mellitus Inadequate Control
	Diabetes Mellitus Non-Insulin-Dependent
	Dizziness
	Drooling
	Dysaesthesia
	Dysarthria
	Dyslipidaemia
	Dyspnoea
	Ejaculation Disorder
	Erectile Dysfunction

		Glaucoma					
		Glycosylated Haemoglobin Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache	Health	Vioxx	PS	Merck & Co., Inc	ORAL
149	DAY						
		Hemiparesis	Professional	Tylenol	C		
		Hypertension		Augmentin	C		
		Hypoaesthesia		Aspirin	C		
		Lacunar Infarction		Lipitor	C		
		Nasal Sinus Drainage		Betoptic	C		
		Nausea		Cipro	C		
		Pain		Cardura	C		
255	DAY						
		Pain In Extremity		Allegra	C		
		Paraesthesia		Amaryl	C		
		Road Traffic Accident		Hydrochlorothiazide	C		
1106	DAY						
		Sexual Dysfunction		Ibuprofen	C		
		Sinus Disorder		Avapro	C		
60	DAY						
		Transient Ischaemic		Xalatan	C		
		Attack		Metoprolol	C		
		Treatment Noncompliance		Naproxen	C		
82	DAY						
		Visual Field Defect		Niacin	C		
		Whiplash Injury		Accupril	C		
				Verapamil	C		

Date:03/04/04ISR Number: 4311260-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA01724
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthritis	Health	Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged	Arthropathy	Professional	Vicodin Tablets	C		
Other	Blood Pressure Increased		Soma	C		
	Coronary Artery Disease		Soma	C		
	Coronary Artery Stenosis		Premarin	C		
	Drug Dependence		Allegra	C		
	Dyspnoea		Levoxyl	C		
	Fatigue		Claritin	C		
	Headache					
	Myocardial Infarction					
	Post Procedural					

Haemorrhage

Date:03/04/04ISR Number: 4311748-1Report Type:Direct Company Report #CTU 213814
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Amnesia
Hospitalization - Initial or Prolonged	Asthenia
Required Intervention to Prevent Permanent Impairment/Damage	Body Temperature Decreased
	Confusional State
	Dehydration
	Dementia
	Depression
	Diarrhoea
	Dizziness
	Dysarthria
	Dyspepsia
	Erythema Of Eyelid
	Eyelid Pain
	Feeling Abnormal

	Headache						
	Oral Intake Reduced						
	Photophobia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Vioxx	PS		ORAL	ORAL	

Date:03/04/04ISR Number: 4311818-8Report Type:Expedited (15-DaCompany Report #WAES 0303USA02180
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Artery Occlusion		Aspirin	C				
Disability	Cerebral Atrophy		Cipro	C				
7 DAY								
	Cerebral Infarction		Heparin	C				
	Cerebrovascular Accident		Insulin	C				
	Cough		Glucophage	C				
	Deep Vein Thrombosis							
	Dehydration							
	Diabetes Mellitus							
	Dizziness							
	Dysphonia							
	Ear Disorder							
	Epistaxis							
	Fall							
	Glycosylated Haemoglobin							
	Increased							
	Hearing Impaired							
	Heart Rate Increased							
	Hypercoagulation							
	Hypertension							
	Hypochromic Anaemia							
	Iron Deficiency Anaemia							
	Lymphadenopathy							
	Melaena							
	Micturition Urgency							
	Nocturia							
	Oedema							
	Oestrogen Deficiency							
	Pain							
	Pelvic Organ Injury							
	Pleural Effusion							

Pneumonia
Pollakiuria
Pulmonary Hypertension
Renal Failure
Road Traffic Accident
Rotator Cuff Syndrome
Skin Ulcer
Transient Ischaemic
Attack
Trigger Finger
Urge Incontinence
Urinary Tract Infection
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/04ISR Number: 4311824-3Report Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Initial or Prolonged	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		5 MON
Disability	Anaemia		Aspirin	C				
Other	Anxiety		Lasix (Furosemide)	C				
	Atelectasis		Glucotrol Xl	C				
	Balance Disorder		Glyburide	C				
	Blood Cholesterol		Ativan	C				
	Increased		Lopressor	C				
	Blood Sodium Decreased		Orphenadrine	C				
	Bundle Branch Block Right							
	Chest Discomfort							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Cognitive Disorder							
	Confusional State							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Depression							
	Diabetes Mellitus							
	Inadequate Control							
	Dilatation Atrial							
	Drug Ineffective							
	Dysaesthesia							
	Emotional Distress							
	Fall							
	Hypertension							
	Hypokalaemia							
	Influenza Like Illness							
	Medication Error							
	Memory Impairment							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nasopharyngitis							
	Oedema Peripheral							
	Pain In Extremity							
	Palpitations							
	Pulmonary Congestion							

Rotator Cuff Syndrome
Stress Incontinence
Supraventricular
Tachycardia
Syncope
Tetany
Transient Ischaemic
Attack
Treatment Noncompliance
Urinary Tract Infection
Urine Odour Abnormal
Ventricular Hypertrophy
Ventricular Hypokinesia
Vision Blurred

Date:03/04/04ISR Number: 4311826-7Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00090
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Hepatocellular Damage		[Therapy Unspecified]	C				
Other	Hepatotoxicity		Atropine	C				
	Post Procedural Complication		Dobutamine Hydrochloride	C				
	Pulmonary Embolism		Dopamine Hydrochloride	C				
			Epinephrine Hydrochloride	C				
			Sodium Chloride	C				
			Tinzaparin Sodium	C				
			Sufentanil Citrate	C				
			Sodium Bicarbonate	C				
			Heparin	C				
			Metaproterenol Sulfate	C				
			Propofol	C				
			Propofol	C				

Date:03/04/04ISR Number: 4311827-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA02509
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Acute Myocardial Infarction		Methotrexate	C				
	Angina Pectoris		Berplex Plus	C				
	Blood Triglycerides Increased		Prednisone	C				
	Calculus Ureteric							
	Cardio-Respiratory Arrest							
	Colonic Obstruction							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							

Drug Ineffective
Electrocardiogram St
Segment Elevation
Electrocardiogram St-T
Change
Feeling Abnormal
Hypercholesterolaemia
Hyperhidrosis
Hypotension
Nephrolithiasis
Oesophagitis
Oral Pain
Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Hypokinesia
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/04ISR Number: 4311828-0Report Type:Expedited (15-DaCompany Report #WAES 0302USA00116
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Moenckeberg-Type		Lomotil	C		
Initial or Prolonged	Aspiration		Plavix	C		
Other	Atrioventricular Block		Zocor	C		ORAL
	First Degree		Ultram	C		
	Blood Glucose Increased		Hydrochlorothiazide	C		
	Blood Potassium Increased		Evista	C		
	Blood Pressure Decreased					
	Cerebrosclerosis					
	Deep Vein Thrombosis					
	Electroencephalogram					
	Abnormal					
	Grand Mal Convulsion					
	Inflammation					
	Injury					
	Mastoid Disorder					
	Nervous System Disorder					
	Pulmonary Embolism					
	Respiration Abnormal					
	Respiratory Failure					
	Rhinitis					
	Status Epilepticus					
	White Blood Cell Count					
	Increased					

Date:03/04/04ISR Number: 4311830-9Report Type:Expedited (15-DaCompany Report #WAES 0311USA00083
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Collapse Of Lung		Vioxx	SS	Merck & Co., Inc	ORAL
	Lung Disorder		[Therapy			
	Medication Error		Unspecified]	C		
	Myocardial Infarction		Albuterol	C		
	Respiratory Tract		Combivent	C		
	Infection		Salmeterol	C		
			Alprazolam	C		
			Loratadine	C		
			Metoprolol Tartrate	C		

			Rabeprazole Sodium	C		

Date:03/04/04ISR Number: 4311831-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA01500
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Hypersensitivity		Epi-Pen	C		
1 DAY						
	Myocardial Ischaemia					
	Tachycardia					
	Troponin Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/04ISR Number: 4311832-2Report Type:Expedited (15-DaCompany Report #WAES 0402NOR00012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/04ISR Number: 4311834-6Report Type:Expedited (15-DaCompany Report #WAES 0403USA00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/04ISR Number: 4312233-3Report Type:Direct Company Report #CTU 213862
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oedema Peripheral		Vioxx 12.5 Mg <Msd>	PS			ONE DOSE QD	

Date:03/04/04ISR Number: 4313344-9Report Type:Expedited (15-DaCompany Report #DSA_24023_2004
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pain Pain In Extremity Purpura	Foreign Health Professional	Enalapril Maleate W/Hydrochlorothiazide	PS		ORAL	1 TAB Q DAY	
	Skin Ulcer	Other					PO	
			Rofecoxib	SS		ORAL	25 MG Q DAY	
							PO	
			Amlodipine Maleate	SS				
			Chondroitin Sulfate Sodium	C				

Date:03/05/04ISR Number: 4312210-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
Disability	Benign Prostatic Hyperplasia
Other	Beta Haemolytic Streptococcal Infection
	Bladder Neck Sclerosis
	Cardiovascular Disorder
	Cerebrovascular Accident
	Dizziness Postural
	Haemorrhoidal Haemorrhage
	Head Discomfort
	Hypotension
	Hypovolaemia
	Muscle Spasms
	Nausea
	Palpitations
	Prostatic Disorder
	Renal Failure
	Renal Failure Acute
	Rheumatoid Arthritis
	Staphylococcal Infection

Urethral Stricture
Vomiting
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Deconamine	C				
	Lisinopril	C				
	Meclizine	C				
	Aciphex	C				

Date:03/05/04ISR Number: 4312218-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Adrenal Insufficiency
	Anaemia
	Asthma
	Bacterial Infection
	Candidiasis
	Cardiac Failure
	Congestive
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Chronic Obstructive
	Pulmonary Disease
	Coagulopathy
	Colitis
	Decubitus Ulcer
	Deep Vein Thrombosis
	Diverticulum
	Duodenitis
	Dyspepsia
	Escherichia Infection
	Fungaemia
	Gastric Bypass
	Gastritis
	Gastrointestinal
	Haemorrhage
	Gastrooesophageal Reflux

Disease
Glaucoma
Gynaecomastia
Haemorrhoids
Headache
Hepatic Steatosis
Hiatus Hernia
Hypercoagulation
Hyperglycaemia
Hypertension
Incisional Hernia
Inguinal Hernia
Injury
Malnutrition
Obesity
Oesophagitis
Optic Neuropathy
Otitis Media

		Pickwickian Syndrome					
		Pneumonia					
		Pulmonary Embolism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Refractory Anaemia	Professional	Catapres	C		
347	DAY						
		Renal Failure Acute		Lasix (Furosemide)	C		
		Rheumatoid Arthritis		Micardis	C		
		Sepsis		Lasix (Furosemide)	C		
		Sputum Culture Positive		Cozaar	C		
		Syncope Vasovagal					
		Thrombocytopenia					
		Thrombosis					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vertigo					

Date:03/05/04ISR Number: 4312219-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Triglycerides		[Therapy			
		Increased		Unspecified]	C		
		Blood Urine		Celebrex	C		
		Blood Urine Present		Depo-Medrol With			
		Cardiac Operation		Lidocaine	C		
1	DAY						
		Gastric Disorder		Depo-Medrol With			
		Gastric Haemorrhage		Lidocaine	C		
1	DAY						
		Injury					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Stiffness					
		Melaena					
		Neck Pain					
		Rotator Cuff Syndrome					
		Scoliosis					
		Spinal Column Stenosis					

Date:03/05/04ISR Number: 4312223-0Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00018
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Gastrointestinal	Professional	Enoxaparin Sodium	SS		SUBCUTANEOUS		
	Haemorrhage		Albuterol Sulfate	C		RESPIRATORY		
	Heart Rate Increased					(INHALATION)		
	Hiatus Hernia		Theophylline	C		ORAL		
	Hypotension		Levomepromazine	C		ORAL		
	Oesophagitis Haemorrhagic		Ofloxacin	C		ORAL		8 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/04ISR Number: 4312225-4Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00022
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Potassium Decreased		Dipyrone	SS		ORAL		
	Drug Interaction		Glimepiride	SS		ORAL		
	Hypertension		Quinapril Hydrochloride	SS		ORAL		
	Hyponatraemia		Piretanide	SS		ORAL		
	Oedema Peripheral		Acyclovir	C		ORAL		
	Oesophageal Candidiasis		Tolperisone Hydrochloride	C		ORAL		
	Vomiting		Procaine Hydrochloride	C		INTRAVENOUS DRIP		
			Hydroxyzine Hydrochloride	C		ORAL		
			Thioctic Acid	C		ORAL		
			Bisoprolol	C		ORAL		

Date:03/05/04ISR Number: 4312226-6Report Type:Expedited (15-DaCompany Report #WAES 0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Anaemia
Disability	Ankylosing Spondylitis
Other	Arrhythmia
	Arthralgia
	Blood Pressure Increased
	Bone Pain
	Cardiac Flutter
	Carpal Tunnel Syndrome
	Chest Pain
	Constipation
	Coronary Artery Stenosis
	Drug Effect Decreased
	Drug Ineffective
	Dysphagia
	Dysphoria
	Electrocardiogram St-T Change

Facet Joint Syndrome
Facial Bones Fracture
Fall
Fibromyalgia
Gastrooesophageal Reflux
Disease
Hyperaesthesia
Hypercalcaemia
Hyperkalaemia
Hypertension
Hypoaesthesia
Hypothyroidism
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Jaw Disorder
Muscle Spasms

		Nausea						
		Neck Pain						
		Nephritis Interstitial	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Nephropathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
		Oedema Peripheral	Professional	Microzide	SS				
		Osteoporosis		Microzide	SS				
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL	26	HR
		Palpitations		Prinzide	SS				
		Paraesthesia		Feldene	SS			60	DAY
		Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	24	DAY
		Psoriasis		Vioxx	SS	Merck & Co., Inc	ORAL	97	DAY
		Psoriatic Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
		Raynaud'S Phenomenon		Vioxx	SS	Merck & Co., Inc	ORAL	97	DAY
		Reiter'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	179	DAY
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL	24	DAY
		Sacroiliitis		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
		Scoliosis		Vioxx	SS	Merck & Co., Inc	ORAL	179	DAY
		Sleep Disorder		Vicodin Es Tablets	C		ORAL		
		Spinal Cord Compression		Vicodin Es Tablets	C				
		Spinal Osteoarthritis		Norco	C			156	DAY
		Weight Increased		Analgesic Or Anesthetic (Unspecified)	C			PARENTERAL	1 DAY
				Analgesic Or Anesthetic (Unspecified)	C			PARENTERAL	1 DAY
				Beconase	C				
				Effexor	C				
				Trazodone Hydrochloride	C				
				Imitrex	C				
				Claritin	C				
				Prevacid	C				

			Zestoretic	C		
			Celebrex	C		
			Flexeril	C		
			Valium	C		
			Estratest	C		
			Neurotonin Capsules	C		
			Neurotonin Capsules	C		

Date:03/05/04ISR Number: 4312229-1Report Type:Expedited (15-DaCompany Report #WAES 0403NOR00002
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	32 DAY	

Date:03/05/04ISR Number: 4312230-8Report Type:Expedited (15-DaCompany Report #WAES 0312GBR00213
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Prothrombin Level		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	
	Decreased		Warfarin	SS		ORAL		
			Aspirin	C				
			Rosuvastatin Calcium	C				
			Zopiclone	C				
			Tramadol Hydrochloride	C				

			Ramipril	C		

Date:03/05/04ISR Number: 4312608-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arterial Injury		Lipitor	C		
2371 DAY						
Other	Carotid Artery Stenosis		Accupril	C		
2373 DAY						
	Cerebrovascular Accident					
	Embolism					
	Haematoma					
	Heart Rate Decreased					
	Hypertension					
	Injury					
	Osteoarthritis					
	Plantar Fasciitis					
	Retinal Artery Embolism					
	Transient Ischaemic					
	Attack					

Date:03/05/04ISR Number: 4312624-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
	Arterial Disorder		[Therapy			
	Benign Prostatic		Unspecified]	C		
	Hyperplasia		Vicodin Tablets	C		
	Blood Pressure Increased		Ultram	C		
	Blood Triglycerides		Soma	C		
	Increased		Celebrex	C		
	Bundle Branch Block Right					
	Cardiac Enzymes Increased					
	Chest Pain					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Dermal Cyst					

Emotional Distress
Erectile Dysfunction
Hypersensitivity
Inguinal Hernia
Injury
Mitral Valve Incompetence
Muscle Tightness
Myocardial Infarction
Neck Pain
Palpitations
Pneumonitis
Prostatic Specific
Antigen Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/04ISR Number: 4312628-8Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Disability	Angina Unstable		Tylenol Pm	C				
	Aortic Aneurysm		Aspirin	C				
	Arthritis		Zocor	C		ORAL		
	Barrett'S Oesophagus		Tagamet	C				
	Blood Chloride Increased		Tagamet	C				
	Blood Creatine Decreased		Cardura	C		ORAL		
	Blood Glucose Increased							
	Blood Pressure Decreased							
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Cardiomyopathy							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Dizziness							
	Duodenal Ulcer							
	Duodenitis							
	Dyspnoea							
	Ejection Fraction							
	Decreased							
	Electrocardiogram St							
	Segment Elevation							
	Emotional Distress							
	Fatigue							
	Gastritis							
	Gastritis Erosive							
	Gastrooesophageal Reflux							
	Disease							
	Haemoglobin Decreased							
	Headache							
	Heart Rate Increased							
	Helicobacter Infection							
	Hypercholesterolaemia							
	Hyperhidrosis							
	Hyperkinesia							

Hypertension
Hypogonadism
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Oesophageal Ulcer
Pco2 Decreased
Peptic Ulcer
Reflux Oesophagitis
Sinus Tachycardia
Supraventricular
Extrasystoles
Troponin Increased
Ventricular Extrasystoles
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/04ISR Number: 4312629-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00845
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		437 DAY
Initial or Prolonged	Increased		Atenolol	SS				
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		437 DAY
	Aspartate							
	Aminotransferase							
	Increased							
	Back Pain							
	Blood Creatine							
	Phosphokinase Increased							
	Blood Lactate							
	Dehydrogenase Increased							
	Blood Pressure Increased							
	Blood Thyroid Stimulating							
	Hormone Increased							
	Confusional State							
	Contusion							
	Convulsion							
	Coordination Abnormal							
	Dehydration							
	Difficulty In Walking							
	Dizziness							
	Dysarthria							
	Dyspepsia							
	Emotional Distress							
	Fall							
	Gait Disturbance							
	Head Injury							
	Hyperhidrosis							
	Hypertension							
	Hypothyroidism							
	Injury							
	Joint Swelling							
	Loss Of Consciousness							
	Migraine							
	Nausea							
	Neuroma							
	Oedema Peripheral							
	Osteoarthritis							
	Palpitations							
	Photophobia							

Respiratory Rate
Increased
Sinus Congestion
Spinal Osteoarthritis
Syncope
Tremor
Vomiting

Date:03/05/04ISR Number: 4312630-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Angiogram Cerebral
Disability	Abnormal
	Carpal Tunnel Syndrome
	Cerebrovascular Accident

Cervicobrachial Syndrome
Constipation
Convulsion
Demyelination
Dyspepsia
Emotional Distress
Haematochezia
Hyperlipidaemia
Hypersensitivity
Hypertension
Injury
Lyme Disease
Mitral Valve Incompetence
Myalgia
Pulmonary Valve
Incompetence
Sarcoidosis
Simple Partial Seizures
Tricuspid Valve
Incompetence
Urine Flow Decreased
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Plendil	C				
	Dyazide	C				

Date:03/05/04ISR Number: 4312631-8Report Type:Expedited (15-DaCompany Report #WAES 0302USA00108
Age: Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Acute Myocardial Infarction
Apnoea
Asthma
Atherosclerosis
Cardiac Failure Congestive
Cardiac Valve Disease
Cardiomegaly
Cerebrovascular Accident
Chest Pain
Chronic Obstructive Pulmonary Disease
Confusional State
Congestive Cardiomyopathy
Depression
Dizziness

Dyspnoea
Dysuria
Emotional Distress
Feeling Abnormal
Gastrointestinal
Haemorrhage
Glaucoma
Headache
Hypoacusis
Injury
Kidney Infection
Myalgia
Nausea
Pollakiuria
Pulmonary Hypertension
Pyrexia

		Renal Failure Chronic					
		Sleep Apnoea Syndrome					
		Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Ibuprofen	C		
		Treatment Noncompliance		Insulin	C		
		Urge Incontinence					
		Ventricular Hypokinesia					
		Vertigo					
		Weight Increased					

Date:03/05/04ISR Number: 4312632-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00867
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
107 DAY							
Initial or Prolonged		Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL
107 DAY							
		Blood Bilirubin Increased		Vicodin Tablets	C		
127 DAY							
		Blood Cholesterol		Vicodin Tablets	C		
127 DAY							
		Increased		Darvocet-N	C		
		Blood Triglycerides					
		Increased					
		Cardiac Aneurysm					
		Cardiac Failure					
		Congestive					
		Colonic					
		Pseudo-Obstruction					
		Congestive Cardiomyopathy					
		Coronary Artery Disease					
		Coronary Artery Surgery					
		Dyspnoea					
		Ear Haemorrhage					
		Ear Pain					
		Ejection Fraction					
		Decreased					
		Ileus					
		Injury					
		Ischaemic Cardiomyopathy					
		Myocardial Infarction					

Myocardial Ischaemia
Oedema Peripheral
Pharyngitis
Seborrhoeic Keratosis
Skin Papilloma
Ventricular Dysfunction
Ventricular Tachycardia
White Blood Cell Count
Increased

Date:03/05/04ISR Number: 4312633-1Report Type:Expedited (15-DaCompany Report #WAES 0307USA01945
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Cardiac Failure
	Congestive
Disability	Dialysis
	Hypertension
	Iron Deficiency Anaemia

Renal Failure Chronic
Renal Injury

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	[Therapy Unspecified]	C				
	Atenolol	C				
	Prevacid	C				
	Accupril	C				

Date:03/05/04ISR Number: 4312634-3Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Acute Myocardial Infarction		Tylenol	C				
			Z-Pak	C				
	Asthenia		Cipro	C				
	Back Injury		Diuretic (Unspecified)	C				
	Benign Breast Neoplasm		Dyazide	C				
	Blood Potassium Increased		Advil	C				
	Bronchitis		Triamterene	C				
	Carcinoma In Situ Of Skin		Prevacid	C				
	Chest Pain		Asacol	C				
	Coronary Artery Disease		Naproxen	C				
	Deep Vein Thrombosis		Ditropan	C				
	Diarrhoea		Quinidine	C				
	Dizziness		Quinine Sulfate	C				
	Drug Hypersensitivity							
	Enterocele							
	Fall							
	Gastrointestinal Infection							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hiatus Hernia							
	Hyperlipidaemia							
	Hypoaesthesia							
	Osteoarthritis							
	Pulmonary Embolism							

Radius Fracture
Renal Failure Acute
Rotator Cuff Syndrome
Ulna Fracture
Urinary Tract Infection
Visual Disturbance

Date:03/05/04ISR Number: 4312635-5Report Type:Expedited (15-DaCompany Report #WAES 0403ITA00001
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Melaena		Allopurinol	C		ORAL		
	Red Blood Cell Count Decreased		Amlodipine Besylate	C		ORAL		
			Digoxin	C		ORAL		
			Vasotec	C		ORAL		

			Ferrous Sulfate	C
			Furosemide	C

Date:03/05/04ISR Number: 4312636-7Report Type:Expedited (15-DaCompany Report #WAES 0402ISR00003
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Drug Exposure During Pregnancy							

Date:03/05/04ISR Number: 4312637-9Report Type:Expedited (15-DaCompany Report #WAES 0309USA01194
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Buspar	C				
	Coronary Artery Atherosclerosis		Zoloft	C				
			Claritin	C				
	Deep Vein Thrombosis							
	Haematoma							
	Haemoptysis							
	Haemothorax							
	Heart Rate Increased							
	Platelet Count Increased							
	Pleural Effusion							
	Pulmonary Artery Thrombosis							
	Pulmonary Infarction							
	Sarcoma							
	Weight Decreased							

Date:03/05/04ISR Number: 4312638-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA01991
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/05/04ISR Number: 4312639-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Back Pain
	Blood Creatine Phosphokinase Increased
	Cardiac Disorder
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Dyslipidaemia

		Echocardiogram Abnormal					
		Fatigue					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinus Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Lipitor	C		
3142 DAY							
				Lotensin	C		
				Lotensin	C		
				Vasotec	C		ORAL
3507 DAY							
				Vasotec	C		ORAL
3507 DAY							
				Prozac	C		
				Prozac	C		
				Prozac	C		
				Ginseng	C		
				Naproxen	C		
				Accupril	C		
				Accupril	C		

Date:03/05/04ISR Number: 4312640-9Report Type:Expedited (15-DaCompany Report #WAES 0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
105 DAY							
Initial or Prolonged		Infarction		Claritin-D	SS		ORAL
Disability		Angina Pectoris		Vicodin Es Tablets	C		ORAL
Other		Aortic Atherosclerosis		Zoloft	C		ORAL
		Aortic Valve Incompetence		Ambien	C		ORAL
		Aortic Valve Sclerosis		Zoloft	C		ORAL
		Blood Bilirubin Increased		Percocet	C		ORAL
		Blood Cholesterol		Ceftin	C		ORAL
		Increased					
		Blood Glucose Increased					
		Cardiac Flutter					
		Carpal Tunnel Syndrome					
		Chest Discomfort					

Coronary Artery Disease
Emotional Distress
Hypertension
Hypertensive Heart
Disease
Incision Site
Complication
Mitral Valve Disease
Mitral Valve Incompetence
Mitral Valve Prolapse
Sleep Apnoea Syndrome
Thrombosis
Trigger Finger
Ventricular Extrasystoles
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/05/04ISR Number: 4313924-0Report Type:Expedited (15-DaCompany Report #2004UW02967
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatine	Foreign	Crestor	PS		ORAL	40 MG QD PO	
Intervention to	Phosphokinase Increased	Health	Crestor	SS		ORAL	20 MG QD PO	
Prevent Permanent	Drug Interaction	Professional	Ezetrol	SS			10 MG DAILY	
Impairment/Damage	Hepatic Enzyme Increased	Other	Vioxx	SS			25 MG DAILY	
			Niacin	C				
			Ec Asa	C				
			Plavix	C				
			Atenolol	C				
			Accupril	C				
			Allopurinol	C				
			Folic Acid	C				
			Vitamin C	C				
			Glucosamine	C				

Date:03/08/04ISR Number: 4313407-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event	Professional	Vioxx	SS	Merck & Co., Inc			
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc			
	Atrial Fibrillation		[Therapy					
	Back Pain		Unspecified]	C				
	Basal Cell Carcinoma		Acyclovir	C				
	Blood Cholesterol		Vitamins					
	Increased		(Unspecified)	C				
	Blood Potassium Decreased		Aspirin	C				
	Blood Pressure Increased		Lipitor	C				
	Bursitis		Calcium					
	Chest Pain		(Unspecified)	C				
	Cough		Premarin	C				
	Drug Ineffective							
	Ecchymosis							
	Hepatitis							

Hypertension
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Ligament Sprain
Lumbar Spinal Stenosis
Neck Pain
Pain In Extremity
Radiculitis Cervical
Respiratory Tract
Infection
Rotator Cuff Syndrome
Spinal Osteoarthritis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/04ISR Number: 4313411-XReport Type:Expedited (15-DaCompany Report #WAES 0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vein Occlusion	Health	Rofecoxib	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Visual Acuity Reduced	Professional	Rofecoxib	SS	Merck & Co., Inc	ORAL		9 DAY
Disability			Rofecoxib	SS	Merck & Co., Inc	ORAL		6 MON
			Rofecoxib	SS	Merck & Co., Inc	ORAL		9 DAY
			Enalapril Maleate	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Verapamil	C		ORAL		
			Furosemide Sodium	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Morphine Sulfate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		

Date:03/08/04ISR Number: 4313444-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		84 DAY
Initial or Prolonged	Arteriospasm Coronary	Professional	Fioricet Tablets	C				
	Arthralgia		Fioricet Tablets	C				
	Asthma		Alprazolam	C				
	Blood Triglycerides Increased		Gnc Womens Ultra Mega	C				
	Coronary Artery Disease		Aspirin	C				
	Cystocele		Aspirin	C				
	Deep Vein Thrombosis		Lipitor	C				
	Diverticulitis		Vitamin E	C				
	Diverticulum		Ambien	C				
	Dyspnoea		Zyrtec	C				

	Dysuria	Vivelle	C
TOPICAL			
	Flank Pain	Motrin	C
	Gastroenteritis	Lecithin	C
	Gastrooesophageal Reflux	Prilosec	C
	Disease	Paxil	C
	Generalised Anxiety	Prometrium	C
	Disorder		
	Haematuria		
	Haemorrhoids		
	Hot Flush		
	Hypercholesterolaemia		
	Menopausal Symptoms		
	Myocardial Infarction		
	Nausea		
	Neck Pain		
	Postoperative Ileus		
	Prinzmetal Angina		
	Rhinitis Allergic		
	Sinusitis		
	Stress Incontinence		
	Urinary Tract Infection		
	Venous Insufficiency		
	Vertigo		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/04ISR Number: 4313448-0Report Type:Expedited (15-DaCompany Report #WAES 0204USA00243
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Acute Respiratory Distress Syndrome Pneumonitis Respiratory Failure	Health Professional	Vioxx Herbs (Unspecified)	PS C	Merck & Co., Inc	ORAL		

Date:03/08/04ISR Number: 4313451-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Acute Myocardial Infarction Arrhythmia Cardiac Disorder Change Of Bowel Habit Coronary Artery Atherosclerosis Coronary Artery Occlusion Diverticulum Ejection Fraction Decreased Haemorrhoids Heart Rate Decreased Myocardial Infarction Myocardial Ischaemia Polyp Rectal Haemorrhage Renal Failure Thrombosis Visual Disturbance	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	66	DAY

Date:03/08/04ISR Number: 4313454-6Report Type:Expedited (15-DaCompany Report #WAES 0302USA00104
Age:66 YR Gender:Female I/FU:F

Outcome	PT

Other	Angina Pectoris
	Arthralgia
	Asthenia
	Carotid Artery Disease
	Carotid Artery Occlusion
	Dizziness
	Drug Ineffective
	Dyspnoea Exertional
	Epistaxis
	Gingival Bleeding
	Headache
	Hypertension
	Increased Tendency To Bruise
	Lymphadenopathy
	Muscle Fatigue
	Muscle Spasms
	Musculoskeletal Stiffness
	Myalgia
	Myocardial Ischaemia

		Nausea					
		Night Cramps					
		Nocturia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations	Professional	Aspirin	C		
		Rheumatoid Arthritis		Aspirin	C		
		Sinus Disorder		Lomotil	C		
		Synovitis		Insulin	C		
		Tachycardia		Avandia	C		
		Transient Ischaemic		Zocor	C		ORAL
		Attack		Kenalog	C		
INTRAMUSCULAR							
		Weight Increased		Zocor	C		ORAL
635 DAY							
		Wheezing		Zocor	C		ORAL
				Synthroid	C		
				Melatonin	C		
				Pamelor	C		
				Prilosec	C		

Date:03/08/04ISR Number: 4313458-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA00076
Age:83 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Pulmonary Arterial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pressure Increased	Professional				
		Pulmonary Toxicity					
		Viral Infection					

Date:03/08/04ISR Number: 4313459-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aortic Valve Incompetence
Initial or Prolonged	Aortic Valve Sclerosis
Disability	Arthralgia
Other	Blood Pressure Systolic
	Increased
	Chest Pain
	Chronic Fatigue Syndrome
	Cognitive Disorder

Depression
Dilatation Atrial
Disturbance In Attention
Duodenitis
Dyspnoea
Electrocardiogram Poor
R-Wave Progression
Endocarditis
Gallbladder Disorder
Gastritis
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder
Herpes Zoster
Hyperhidrosis
Hypertension
Hypoacusis
Injury
Irritable Bowel Syndrome

		Lacunar Infarction					
		Migraine With Aura					
		Mitral Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Calcification	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Mitral Valve Incompetence	Professional	Aspirin	C		
		Nausea		Tagamet	C		
		Non-Cardiac Chest Pain		Premarin	C		
		Pain In Extremity		Estratab	C		
		Pain In Jaw		Hytrin	C		
		Panic Disorder		L-Thyroxin	C		
		Sleep Apnoea Syndrome		Prinivil	C		ORAL
		Thalamus Haemorrhage		Ranitidine	C		
		Transient Ischaemic					
		Attack					
		Ventricular Hypertrophy					

Date:03/08/04ISR Number: 4313463-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Angina Unstable
	Antinuclear Antibody Positive
	Aortic Valve Incompetence
	Bacteriuria
	Cardiac Disorder
	Cardiac Failure Congestive
	Carotid Artery Disease
	Cataract
	Cerebral Ischaemia
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Drug Tolerance Decreased

Electrocardiogram T Wave
Inversion
Escherichia Urinary Tract
Infection
Fall
Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Headache
Hyperhidrosis
Hyperlipidaemia
Hypertension
Hypoaesthesia
Hypoglycaemia
Injury
Joint Swelling

		Lacunar Infarction					
		Lipids Increased					
		Lung Neoplasm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Maculopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Metabolic Alkalosis	Professional	Darvocet-N	C		
		Mitral Valve Incompetence		Amitriptyline			
		Myocardial Infarction		Hydrochloride	C		
		Nausea		Aspirin	C		
		Nocturia		Pepcid	C		
		Oedema Peripheral		Lasix (Furosemide)	C		
		Pain		Hydrodiuril	C		
		Pleural Effusion		Dyrenium	C		
		Pulmonary Hypertension		Vitamins			
		Pulmonary Oedema		(Unspecified)	C		
		Radius Fracture		Insulin, Biphasic			
		Renal Failure Chronic		Isophane [Injection]	C		
		Scoliosis		Synthroid	C		
		Seasonal Allergy		Alupent	C		
		Skin Lesion		Zaroxolyn	C		
		Skull Fracture		Niacin	C		
		Spinal Column Stenosis		Potassium			
		Stasis Dermatitis		(Unspecified)	C		
		Tremor					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Vomiting					
		Weight Increased					
		Wrist Fracture					

Date:03/08/04ISR Number: 4313844-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
216 DAY							
		Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
216 DAY							
		Cough					
		Dizziness					
		Dyspnoea					
		Fatigue					
		Gout					

Headache
Lung Neoplasm Malignant
Myocardial Infarction
Oedema
Rales

Date:03/08/04ISR Number: 4313847-7Report Type:Expedited (15-DaCompany Report #WAES 0402NZL00031
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		148 DAY
Initial or Prolonged	Pulmonary Oedema	Professional	Folic Acid	C		ORAL		
	Ventricular Hypertrophy		Sulfasalazine	C		ORAL		
			Vitamins (Unspecified)	C				
			Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/04ISR Number: 4313848-9Report Type:Expedited (15-DaCompany Report #WAES 0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Mass	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Adjustment Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aneurysm		Darvocet-N	C				
	Arthralgia		Amitriptyline Hydrochloride	C				
	Blood Cholesterol Increased		Meclizine	C				
	Cerebrovascular Accident							
	Chronic Obstructive Pulmonary Disease							
	Colon Adenoma							
	Colonic Polyp							
	Complex Regional Pain Syndrome							
	Depression							
	Diverticulum							
	Dizziness							
	Emotional Distress							
	Hearing Impaired							
	Hyperlipidaemia							
	Hypoaesthesia							
	Joint Dislocation							
	Large Cell Carcinoma Of The Respiratory Tract Stage Unspecified							
	Lung Infiltration							
	Mitral Valve Incompetence							
	Oedema Peripheral							
	Pneumonia							
	Pneumothorax							
	Post Procedural Complication							
	Refusal Of Treatment By Patient							
	Stress Incontinence							
	Ventricular Extrasystoles							

Date:03/08/04ISR Number: 4313849-0Report Type:Expedited (15-DaCompany Report #WAES 0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Angina Pectoris Aortic Stenosis Aortic Valve Incompetence Atelectasis Atrial Fibrillation Cardiac Murmur Cellulitis Chest Pain Constipation Cough Depressed Level Of Consciousness Depression Dizziness Dyspnoea Exertional Hyperhidrosis Medical Device

		Complication					
		Muscle Spasms					
		Postoperative Infection					
		Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sternal Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Syncope	Professional	Tylenol	C		
		Ventricular Hypertrophy		Codeine	C		
		Wound Dehiscence		Vasotec	C		ORAL
				Premarin	C		
				Premarin	C		
				Zocor	C		ORAL
				Hydrocodone Hydrochloride	C		
				Levsin	C		
				Synthroid	C		ORAL
				Prilosec	C		ORAL

Date:03/08/04ISR Number: 4313850-7Report Type:Expedited (15-DaCompany Report #WAES 0311FRA00019
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Diverticulum Intestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY					
Initial or Prolonged	Rectal Haemorrhage	Professional	Methylprednisolone			
	Shock Haemorrhagic		Sodium Succinate	SS		
INTRAMUSCULAR	8	DAY				
			Hydrochlorothiazide And Irbesartan	C		ORAL
			Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C		ORAL
			Amlodipine Besylate	C		ORAL
			Buflomedil Hydrochloride	C		ORAL
			Diltiazem Malate	C		ORAL
			Gliclazide	C		ORAL

Date:03/08/04ISR Number: 4313851-9Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00014
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL	2085 DAY	
	Gastric Ulcer							
	Gastritis							

Date:03/08/04ISR Number: 4313852-0Report Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Neoplasm
	Arthralgia
	Blood Chloride Increased
	Blood Cholesterol Increased
	Blood Sodium Increased
	Chest Pain
	Coagulation Factor Vii Level Increased
	Constipation
	Deep Vein Thrombosis

		Face Oedema					
		Gastroenteritis					
		Haematemesis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperlipidaemia	Professional	[Therapy			
		Iliac Vein Occlusion		Unspecified]	C		
		Menometrorrhagia		Aspirin	C		
		Postnasal Drip		Lipitor	C		ORAL
		Productive Cough		Tiazac	C		
		Pulmonary Granuloma		Detrol	C		
		Sneezing		Meridia	C		
		Uterine Leiomyoma		Cardura	C		
		Venous Insufficiency		Motrin	C		
		Venous Stenosis		Zestril	C		
		Wheezing					
		Wound Dehiscence					

Date:03/08/04ISR Number: 4313853-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
52 DAY						
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
33 DAY						
Disability	Asthenia		[Therapy			
	Back Injury		Unspecified]	C		
	Back Pain		Atenolol	C		
	Balance Disorder		Lonox	C		
	Cardiac Disorder		Trazodone			
	Chest Pain		Hydrochloride	C		
	Coordination Abnormal		Hydrocortisone	C		
	Decreased Appetite		Zestril	C		
	Depression		Paxil	C		
	Diabetes Mellitus					
	Diarrhoea					
	Difficulty In Walking					
	Dizziness Postural					
	Ear Pain					
	Eye Movement Disorder					
	Fatigue					
	Feeling Jittery					
	Haemorrhage					

Hyperlipidaemia
Hypertension
Irritable Bowel Syndrome
Myalgia
Renal Failure
Septic Shock
Sleep Apnoea Syndrome
Tremor
Vision Blurred
Vomiting

Date:03/08/04ISR Number: 4313855-6Report Type:Expedited (15-DaCompany Report #WAES 0306FRA00008
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Allergic Granulomatous
Hospitalization -	Angiitis
Initial or Prolonged	Antinuclear Antibody

		Positive					
		Back Pain					
		Confusional State					
		Csf Protein Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Csf Test Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypereosinophilic		Betamethasone	SS		
15	YR						
		Syndrome		Methylprednisolone			
		Intervertebral Discitis		Sodium Succinate	SS		
1	DAY						
		Localised Infection		Prednisone	SS		ORAL
		Quadriplegia		Fluticasone			
		Respiratory Distress		Propionate And			
		Sciatica		Salmeterol Xinafoate	C		
		Sepsis		Terbutaline Sulfate	C		
		Spondylitis		Rilmenidene	C		
		Staphylococcal Sepsis		Glimepiride	C		
		Systemic Inflammatory		Ipratropium Bromide	C		
		Response Syndrome					
		Tenosynovitis					

Date:03/08/04ISR Number: 4314121-5Report Type:Direct Company Report #CTU 214001
Age:47 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Extrasystoles		Vioxx 25 Mg Merck	PS	Merck	ORAL
1 1 PER DAY							
ORAL							
				Alesse	C		

Date:03/08/04ISR Number: 4314359-7Report Type:Expedited (15-DaCompany Report #2004012237
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Ineffective	Consumer	Sinequan (Doxepin)	PS		ORAL
50 MG, ORAL							
		Facial Palsy		Navane (Capsules)			
		Insomnia		(Tiotixene)			
		Tinnitus		(Thiothixene)	SS		ORAL
ORAL							

	Neurontin (Gabapentin) (Gabapentin)	SS	ORAL 300 MG (DAILY), ORAL
	Rofecoxib (Rofexcoxib)	SS	

Date:03/08/04ISR Number: 4314423-2Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Back Disorder
	Back Pain
	Blood Cholesterol Increased
	Chest Pain
	Condition Aggravated
	Erectile Dysfunction
	Facial Pain
	Feeling Cold
	Gastrooesophageal Reflux Disease
	Glossodynia

	Hypersomnia Medication Error Movement Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Pain Oesophageal Spasm	Consumer	Neurontin (Gabapentn)	PS		ORAL	1800 MG (TID), ORAL
	Oral Mucosal Disorder Pain In Jaw Sleep Disorder		Lipitor (Atorvsatatin)	SS		ORAL	20 MG (DAILY), ORAL
	Tooth Abscess Tremor		Lithium (Lithium)	SS			
			Naproxen (Naproxen)	SS			
			Rofecoxib (Rofecoxib)	SS			
			Amoxicillin (Amoxicillin)	SS		ORAL	1000 MG (BID), ORAL
			Levothyroxine Sodium (Levothyroxine Sodium)	C			
			Vitamins	C			
			Diltiazem Hydrocloride (Diltiazem Hydrochloride)	C			

Date:03/08/04ISR Number: 4314837-0Report Type:Expedited (15-DaCompany Report #K200301407
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death Hospitalization - Initial or Prolonged	Abdominal Pain Cholestasis Disseminated Intravascular Coagulation	Foreign Health Professional Other	Altace Capsules (Ramipril) Altace Capsules(Ramipril) Capsule, 1.25mg	PS			UNKNOWN 1 TABLET, QD,
	Hepatic Failure						UNK
	Hepatic Necrosis		Hydrochlorothiazide				

		Hepatomegaly Hepatorenal Syndrome	(Hydrochlorothiazide) Tablet, 1 Tablet	SS
UNKNOWN	1 TABLET, QD,	Jaundice		
UNK				
			Esomeprazole (Esomeprazole) 20mg	SS
UNKNOWN	20 MG, QD,			
UNK				
			Rofecoxib (Rofecoxib) 25mg	SS
UNKNOWN	25 MG, QD,			
UNK				

Date:03/09/04ISR Number: 4314304-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
	Aortic Dissection
Disability	Asthenia
	Depression
	Dermatitis Papillaris Capillitii
	Disturbance In Attention
	Emotional Distress
	Gastrooesophageal Reflux Disease

		General Physical Condition Abnormal					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Impaired Healing	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Irritability		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Keloid Scar		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Loss Of Employment		Amoxicillin	C		
		Pain		Hydrocodone			
		Procedural Complication		Bitartrate	C		
		Self Esteem Decreased		Lorazepam	C		
		Sexual Dysfunction					
		Vascular Injury					

Date:03/09/04ISR Number: 4314306-8Report Type:Expedited (15-DaCompany Report #WAES 0209USA00432
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Abdominal Pain Lower
	Adnexa Uteri Mass
	Angina Unstable
	Anxiety
	Arthralgia
	Arthritis
	Back Pain
	Balance Disorder
	Cardiac Stress Test Abnormal
	Carotid Artery Stenosis
	Carotid Bruit
	Cerebrovascular Accident
	Chest Discomfort
	Chills
	Constipation
	Cystocele
	Diabetes Mellitus
	Dysarthria
	Ear Pain
	Electrocardiogram St-T

Change
Enterocele
Facial Palsy
Fibromyalgia
Flatulence
Ganglion
Haematochezia
Haemorrhagic Ovarian Cyst
Headache
Hearing Impaired
Hemiparesis
Hyperlipidaemia
Hypertension
Hypoaesthesia
Hypokalaemia
Hypotension
Liposarcoma
Major Depression
Memory Impairment
Musculoskeletal Stiffness

		Neck Pain					
		Oedema Peripheral					
		Ovarian Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paraesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Phlebitis Superficial	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Rectocele		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Cyst		Flexeril	C		ORAL
		Sinus Headache		Colace	C		
		Sleep Disorder		Coumadin	C		
		Stress Incontinence		Trazodone			
		Thrombophlebitis		Hydrochloride	C		
		Superficial		Maxzide	C		
		Uterine Prolapse		Paxil	C		
				Potassium Chloride	C		

Date:03/09/04ISR Number: 4314308-1Report Type:Expedited (15-DaCompany Report #WAES 0305AUS00044
Age:76 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Renal Failure Acute	Professional	Furosemide	SS		ORAL
				Perindopril Erbumine	SS		ORAL
				Atorvastatin Calcium	C		
				Gabapentin	C		
				Isosorbide			
				Mononitrate	C		
				Warfarin Sodium	C		
				Prednisolone	C		
				Omeprazole Magnesium	C		
				Insulin Lispro	C		
				Digoxin	C		

Date:03/09/04ISR Number: 4314310-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02055
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable
	Atrial Fibrillation
	Blood Pressure
	Inadequately Controlled

Cardiac Murmur
Cerebrovascular Accident
Chest Discomfort
Chronic Obstructive
Pulmonary Disease
Coronary Artery
Atherosclerosis
Dysarthria
Emotional Distress
Headache
Heart Rate Increased
Heart Rate Irregular
Hemiparesis
Hypercholesterolaemia
Hypertension
Hypoaesthesia
Lacunar Infarction
Paraesthesia

	Transient Ischaemic Attack					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY					
		Professional	Acyclovir	C		
			Ascorbic Acid	C		
			Hydrochlorothiazide And Triamterene	C		
			Vitamin B Complex	C		
			Vitamin E	C		
			Vitamin D (Unspecified)	C		
			Vitamin A	C		
			Adalat	C		
			Phenazopyridine Hydrochloride	C		

Date:03/09/04ISR Number: 4314314-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Arthralgia		Zyrtec	C		
	Asthenia		Celexa	C		
	Cardiac Disorder		Indocin (Indomethacin)	C		ORAL
	Coronary Artery Disease		Naproxen	C		
	Dilatation Ventricular		Prilosec	C		
	Ejection Fraction Decreased		Aciphex	C		
	Fall					
	Injury					
	Laceration					
	Muscular Weakness					
	Pain					
	Road Traffic Accident					
	Rotator Cuff Syndrome					
	Scapula Fracture					
	Skin Laceration					
	Sleep Disorder Due To General Medical Condition, Insomnia Type					

Date:03/09/04ISR Number: 4314321-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Bursitis
Disability	Cardiac Disorder
Other	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Pain
	Cough
	Decreased Appetite
	Depression
	Dyspepsia
	Emphysema
	Fatigue

		Fibromyalgia					
		Headache					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
9	MON						
		Impaired Work Ability	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
9	MON						
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Meniscus Lesion		Amitriptyline			
		Mitral Valve Incompetence		Hydrochloride	C		
		Obesity		Amitriptyline			
		Osteoarthritis		Hydrochloride	C		
		Pain		Amitriptyline			
		Peripheral Vascular		Hydrochloride	C		
17	DAY						
		Disorder		Amitriptyline			
		Productive Cough		Hydrochloride	C		
		Rebound Hypertension		Amitriptyline			
		Rhinorrhoea		Hydrochloride	C		
		Sinusitis		Amitriptyline			
		Spondylolisthesis		Hydrochloride	C		
17	DAY						
		Acquired		Zoloft	C		
582	DAY						
		Spondylolysis		Analgesic Or			
		Treatment Noncompliance		Anesthetic			
		Tricuspid Valve		(Unspecified)	C		
		Incompetence		Atenolol	C		
		Weight Decreased		Lipitor	C		
		Wheezing		Celebrex	C		
				Premarin	C		
				Hydrodiuril	C		ORAL
				Altace	C		

Date:03/09/04ISR Number: 4314322-6Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00007
Age:96 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
16	DAY						
Initial or Prolonged		Abdominal Tenderness	Professional				
		Anorexia					

Depressed Level Of
Consciousness
Duodenal Ulcer
Haemorrhage
Flatulence
Haematemesis
Haemoglobin Decreased
Intestinal Functional
Disorder
Malaise
Melaena

Date:03/09/04ISR Number: 4314323-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01310
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Congestive	Professional	Tylenol	C		ORAL		
	Pleural Effusion		Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Lipitor	C				
			Coumadin	C				

Digoxin	C		ORAL
Imdur	C		ORAL
Ranitidine	C		ORAL

Date:03/09/04ISR Number: 4314325-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	91	DAY
Other	Infarction		Glipizide	C				
	Arrhythmia							
	Blood Pressure Increased							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Cardiomyopathy							
	Coronary Artery Disease							
	Heart Rate Irregular							
	Hypertension							
	Influenza							
	Oedema							
	Pulmonary Oedema							

Date:03/09/04ISR Number: 4314538-9Report Type:Expedited (15-DaCompany Report #WAES 0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Arteriospasm Coronary
	Arthralgia
	Asthma
	Back Pain
	Blood Pressure Systolic Increased
	Blood Triglycerides Increased
	Cardiac Flutter
	Chest Pain
	Cold Sweat
	Constipation
	Coronary Artery Disease

Cystocele
Deep Vein Thrombosis
Dehydration
Depression
Diverticulitis
Diverticulum
Dizziness
Dysfunctional Uterine
Bleeding
Dyspepsia
Dyspnoea
Dysuria
Flank Pain
Gastroenteritis
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder

		Haematuria					
		Haemorrhoids					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hot Flush		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Hypercholesterolaemia		Fioricet Tablets	C		
		Menopausal Symptoms		Fioricet Tablets	C		
		Musculoskeletal Pain		Alprazolam	C		
		Myocardial Infarction		Gnc Womens Ultra			
		Nausea		Mega	C		
		Neck Pain		Aspirin	C		
		Postoperative Ileus		Aspirin	C		
		Prinzmetal Angina		Lipitor	C		
		Rectocele		Vitamin E	C		
		Rhinitis Allergic		Ambien	C		
		Sinusitis		Zyrtec	C		
		Stress Incontinence		Vivelle	C		
TOPICAL							
		Urinary Tract Infection		Motrin	C		
		Varicose Vein		Lecithin	C		
		Vein Pain		Prilosec	C		
		Venous Insufficiency		Paxil	C		
		Vertigo		Prometrium	C		
		Weight Increased					

Date:03/09/04ISR Number: 4314551-1Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Aortic Valve Incompetence
Other	Aortic Valve Sclerosis
	Arthralgia
	Asthenopia
	Back Pain
	Binocular Eye Movement Disorder
	Blood Cholesterol Increased
	Blood Pressure Inadequately Controlled
	Blood Triglycerides Increased

Brain Oedema
Cerebral Ischaemia
Cerebrovascular Accident
Cerebrovascular Disorder
Chronic Fatigue Syndrome
Cognitive Disorder
Depression
Dilatation Atrial
Diplopia
Disturbance In Attention
Duodenitis
Dyspnoea
Electrocardiogram Poor
R-Wave Progression
Electrocardiogram St-T
Change
Endocarditis
Fatigue

		Gallbladder Disorder					
		Gastritis					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Generalised Anxiety		Aspirin	C		
		Disorder		Tagamet	C		
		Herpes Zoster		Premarin	C		
		Heterophoria		Estratab	C		
		Hypertension		Hytrin	C		
		Hypoacusis		L-Thyroxin	C		
		Irritable Bowel Syndrome		Prinivil	C		ORAL
		Lacunar Infarction		Ranitidine	C		
		Low Density Lipoprotein					
		Increased					
		Memory Impairment					
		Mental Impairment					
		Migraine With Aura					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Motor Dysfunction					
		Non-Cardiac Chest Pain					
		Pain In Extremity					
		Pain In Jaw					
		Panic Disorder					
		Reading Disorder					
		Sleep Apnoea Syndrome					
		Thalamus Haemorrhage					
		Transient Ischaemic					
		Attack					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:03/09/04ISR Number: 4314556-0Report Type:Expedited (15-DaCompany Report #WAES 0401FRA00027
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
Initial or Prolonged		Oesophageal Varices		Furosemide	C		ORAL
		Haemorrhage		Gliclazide	C		ORAL
				Nitroglycerin	C		ORAL

Propranolol Hydrochloride	C	ORAL

Date:03/09/04ISR Number: 4314557-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma
Other	Blood Pressure Increased
	Coronary Artery Disease
	Dizziness Postural
	Electrocardiogram Abnormal
	Hypoxia
	Ischaemia
	Myocardial Infarction
	Pulmonary Oedema
	Rotator Cuff Syndrome

Syncope

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		424 DAY
	Respaire	C				
	Minocycline	C				
	Piroxicam	C				
	Prednisone	C				
	Zantac	C				

Date:03/09/04ISR Number: 4314558-4Report Type:Expedited (15-DaCompany Report #WAES 0312USA02102
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		573 DAY
Initial or Prolonged	Depression		Celebrex	C				
Disability	Emotional Distress		Lasix (Furosemide)	C				615 DAY
	Haemorrhagic Stroke		Hydrocodone Hydrochloride	C				
	Hepatitis C		Spironolactone	C				
			Demadex	C				615 DAY
			Ibuprofen	C				
			Lozol	C				615 DAY
			Synthroid	C				

Date:03/09/04ISR Number: 4314560-2Report Type:Expedited (15-DaCompany Report #WAES 0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Coronary Artery Disease		Fosamax	C		ORAL		
	Coronary Artery Occlusion		Celebrex	C				
	Coronary Artery Stenosis		Celebrex	C				
	Hypertension		Diovan	C				

Injury	Verapamil Msd Lp	C		ORAL
Myocardial Infarction	Diovan	C		
Myocardial Ischaemia	Celebrex	C		
Nervousness	Celebrex	C		
Radiculitis Cervical	Duragesic	C		
Ventricular Hypertrophy				

Date:03/09/04ISR Number: 4314566-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA00459
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/04ISR Number: 4314873-4Report Type:Expedited (15-DaCompany Report #PHBS2004SE02933
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia		Zometa	PS	Novartis Sector: Pharma	UNKNOWN		
			Vioxx	SS		UNKNOWN		
			Aranesp	C		UNKNOWN	30 ug	
			Oxynorm	C		UNKNOWN	5 mg	

				Zoladex	C		
3.6 mg							
				Primperan	C		ORAL
10 mg							
				Lomir	C		ORAL
2.5 mg							
				Oxycontin	C		ORAL
10 mg							

Date:03/10/04ISR Number: 4314883-7Report Type:Direct Company Report #CTU 214209
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Diarrhoea		Vioxx 25 Mg Merck &			
	Dyspepsia		Co.	PS	Merck & Co	ORAL
1 PILL ONES A						
	Eye Swelling					
DAY ORAL						
	Fatigue					

Date:03/10/04ISR Number: 4314915-6Report Type:Expedited (15-DaCompany Report #WAES 0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery		Vicodin Tablets	C		
	Restenosis		Aspirin	C		ORAL
	Hypertension		Lipitor	C		ORAL
	Hypotension		Plavix	C		ORAL
41 DAY						
	Ischaemic Cardiomyopathy		Plavix	C		ORAL
	Musculoskeletal		Plavix	C		ORAL
41 DAY						
	Discomfort		Flomax (Tamsulosin			
	Myocardial Infarction		Hydrochloride)	C		
	Sick Sinus Syndrome		Plavix	C		ORAL
	Treatment Noncompliance		Colace	C		
			Prevacid	C		
			Synthroid	C		
			Prinivil	C		ORAL

			Zestril	C		

Date:03/10/04ISR Number: 4314919-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02043
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Arrhythmia	Professional	Cimetidine	C				
	Cerebrovascular Accident		Flexeril	C				
	Coronary Artery Disease		Cardizem	C				
	Depression		Micronase	C				
	Disturbance In Attention		Ibuprofen	C				
	Dizziness		Prinivil	C				
	Mania		Metformin	C				
	Sleep Disorder		Pravachol	C				

Date:03/10/04ISR Number: 4314921-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Atelectasis
	Cardiac Valve Disease

		Cardiomegaly					
		Coronary Artery Stenosis					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypokinesia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		[Therapy			
		Muscle Strain		Unspecified]	C		
		Nervousness		Norco	C		
		Pleural Effusion		Atenolol	C		
		Respiratory Failure		Tenormin	C		
		Thrombosis		Celebrex	C		
				Chlorthalidone	C		
				Ultram	C		
				Diovan	C		
				Avandia	C		
				Hygroton	C		
				Cyclobenzaprine			
				Hydrochloride	C		
				Cardizem	C		
				Propecia	C		
				Glucovance	C		
				Hydrocodone			
				Hydrochloride	C		

Date:03/10/04ISR Number: 4314924-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Cervicobrachial Syndrome		Plendil	C		
		Constipation		Dyazide	C		
		Dyspepsia					
		Emotional Distress					
		Epilepsy					
		Haematochezia					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypertension					
		Mitral Valve Incompetence					
		Oliguria					
		Pulmonary Valve					
		Incompetence					

Simple Partial Seizures
Tricuspid Valve
Incompetence
Urine Flow Decreased
Weight Increased

Date:03/10/04ISR Number: 4314927-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA00338
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Cardiac Arrest
	Cardio-Respiratory Arrest
Disability	Cardiomegaly
	Cholelithiasis
	Circulatory Collapse

		Coma					
		Emphysema					
		Hepatomegaly	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Pulmonary Congestion	Professional				

Date:03/10/04ISR Number: 4314928-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA00838
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bronchopneumonia	Professional	Aspirin	C		
Disability		Burns Second Degree		Glucosamine	C		
Other		Cardiac Failure		Hytrin	C		
		Congestive		Levothyroxine Sodium	C		
		Coronary Artery Disease					
		Deafness Neurosensory					
		Depression					
		Emotional Distress					
		Haemorrhagic Stroke					
		Intentional Self-Injury					
		Lobar Pneumonia					
		Myocardial Infarction					
		Myofascial Pain Syndrome					
		Neurogenic Bladder					

Date:03/10/04ISR Number: 4314929-6Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Angina Pectoris
	Angina Unstable
	Anxiety
	Back Injury
	Blood Creatine
	Phosphokinase Increased
	Cardiac Arrest

Cardiac Disorder
Cardiac Failure
Congestive
Cardiomegaly
Chest Pain
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Restenosis
Coronary Artery Stenosis
Diverticulitis
Ejection Fraction
Decreased
Electrocardiogram St
Segment Elevation
Haematemesis
Haematoma
Haemoptysis
Hyperhidrosis

		Hyperkinesia					
		Hyperlipidaemia					
		Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Muscle Contractions	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY						
		Involuntary		Propacet	C		
		Nausea		Wellbutrin	C		
		Non-Cardiac Chest Pain		Prevacid	C		
		Oesophagitis					
		Osteoarthritis					
		Pulmonary Oedema					
		Retroperitoneal					
		Haemorrhage					
		Shock					
		Sinus Tachycardia					
		Stent Occlusion					
		Stress					
		Syncope					
		Tendonitis					
		Tongue Biting					
		Urticaria					
		Ventricular Fibrillation					
		Visual Acuity Reduced					
		Vomiting					

Date:03/10/04ISR Number: 4314931-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Other	Arthralgia
	Atherosclerosis
	Back Pain
	Blood Triglycerides
	Increased
	Blood Urine
	Blood Urine Present
	Decreased Activity
	Drug Ineffective
	Exostosis
	Gastric Disorder
	Gastric Haemorrhage
	Gastrointestinal Disorder

Hypoaesthesia
Injury
Intervertebral Disc
Degeneration
Joint Range Of Motion
Decreased
Joint Stiffness
Melaena
Musculoskeletal Stiffness
Neck Pain
Pain
Pain In Extremity
Paraesthesia
Post Procedural
Complication
Rotator Cuff Syndrome
Sciatica
Scoliosis

Spinal Column Stenosis

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
			Celebrex	C		
			Depo-Medrol With Lidocaine	C		
1	DAY					
			Depo-Medrol With Lidocaine	C		
1	DAY					

Date:03/10/04ISR Number: 4314933-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02052
Age:59 YR Gender:Male I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability			Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Other			Blood Cholesterol Increased		Lotrel	C		ORAL
					Wellbutrin	C		
			Carotid Artery Stenosis		Wellbutrin	C		
	5	DAY						
			Carpal Tunnel Syndrome		Celebrex	C		
			Cerebral Infarction		Klonopin	C		
			Dizziness		Clonidine	C		ORAL
	249	DAY						
			Haemorrhagic Stroke		Clonidine	C		ORAL
			Hyperhidrosis		Zoloft	C		ORAL
			Hypertension		Labetalol Hydrochloride	C		ORAL
			Injury					
			Intracranial Aneurysm		Labetalol Hydrochloride	C		ORAL
			Intraventricular Haemorrhage					
					Claritin	C		
			Peptic Ulcer		Paxil	C		ORAL
			Transient Ischaemic Attack		Dilantin	C		ORAL
					Ranitidine	C		ORAL
			Vascular Calcification					

Date:03/10/04ISR Number: 4314934-XReport Type:Expedited (15-DaCompany Report #WAES 0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Cerebrovascular Accident
Disability	Delusion
Other	Depression
	Emotional Distress
	Glucose Tolerance
	Impaired
	Hernia
	Hyperlipidaemia
	Hypertension
	Injury
	Insomnia
	Low Density Lipoprotein
	Increased
	Male Sexual Dysfunction
	Oedema Peripheral
	Panic Attack

		Somnolence					
		Tendonitis					
		Varicose Vein	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health	Vioxx	PS	Merck & Co., Inc	ORAL
577	DAY						
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Lorcet 10/650	C		
283	DAY						
				Hydrocodone Bitartrate	C		
201	DAY						
				Ambien	C		
				Ibuprofen	C		
				Cozaar	C		

Date:03/10/04ISR Number: 4315184-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA01102
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Deep Vein Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Hand Fracture		Femhrt	C		
		Peripheral Embolism					
Other		Renal Failure Acute					
		Sudden Death					

Date:03/10/04ISR Number: 4315189-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Blood Pressure Increased	Professional				
		Bronchitis					
		Chest Discomfort					
		Chest Pain					
		Dizziness					
		Dyspnoea					
		Epididymitis					
		Foot Fracture					
		Foreign Body Trauma					

Head Injury
Heart Rate Increased
Infertility Male
Injury
Muscle Spasms
Myocardial Infarction
Orchitis
Sinusitis
Tinea Cruris
Treatment Noncompliance
Viral Rash

Date:03/10/04ISR Number: 4315190-9Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00009
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cutaneous Vasculitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Oedema Peripheral	Professional	Ketoprofen	SS		ORAL		4 DAY
	Proteinuria		Prednisolone	C		PARENTERAL		1 DAY
	Purpura							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/04ISR Number: 4315192-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Tenderness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adrenal Insufficiency		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Aspirin	C				
	Anxiety		Celebrex	C				
	Asthenia		Sudal	C				
	Blood Creatine		Ultram	C				
	Phosphokinase Mb		Levaquin	C				
	Increased		Synthroid	C				
	Bronchitis		Zantac	C				
	Cardiomegaly							
	Catheter Site Haemorrhage							
	Cellulitis							
	Chest Pain							
	Chest Wall Pain							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Costochondritis							
	Diarrhoea							
	Diastolic Dysfunction							
	Drug Withdrawal Syndrome							
	Dysphagia							
	Dyspnoea							
	Electrocardiogram T Wave Inversion							
	Facial Pain							
	Fibromyalgia							
	Gastrooesophageal Reflux Disease							
	Haemarthrosis							
	Hyperparathyroidism							
	Hypothyroidism							
	Increased Tendency To Bruise							
	Intestinal Functional Disorder							
	Joint Injury							
	Libido Decreased							
	Musculoskeletal Chest Pain							
	Myocardial Infarction							
	Neuralgia							
	Oedema							

Pain
Panic Attack
Pneumonia
Raynaud'S Phenomenon
Spinal Osteoarthritis
Tension Headache
Troponin Increased
Weight Increased

Date:03/11/04ISR Number: 4315513-0Report Type:Expedited (15-DaCompany Report #WAES 0402USA01838
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Death	Anxiety
	Asthenia

		Blood Pressure Fluctuation					
		Bundle Branch Block Right	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
424	DAY						
		Chest Discomfort		Codeine And			
		Cold Sweat		Acetaminophen	C		
		Cyanosis		Lotrel	C		
		Dyspnoea		Clorpres	C		ORAL
		Electrocardiogram Qrs		Colchicine	C		ORAL
		Complex Abnormal		Premarin	C		ORAL
		Erythema		Allegra	C		
		Essential Hypertension		Synthroid	C		ORAL
		Hypothyroidism		Slow-Mag	C		ORAL
		Myocardial Infarction		Aldomet (Methyldopa)	C		ORAL
		Nausea		Potassium Chloride	C		ORAL
		Oedema Peripheral					
		Oxygen Saturation Decreased					
		Pallor					
		Restlessness					
		Sinus Tachycardia					
		Swelling Face					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Wheezing					

Date:03/11/04ISR Number: 4315515-4Report Type:Expedited (15-DaCompany Report #WAES 0310USA03464
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Darvocet-N	C		
		Coronary Artery Disease		Fosamax	C		ORAL
		Faecal Incontinence		Cleocin	C		
		Malabsorption		Cyanocobalamin	C		
		Stress		Vitamin D			
		Transient Ischaemic		(Unspecified)	C		
		Attack		Premarin	C		
		Urinary Tract Infection		Cytomel	C		
		Vertigo		Creon	C		
				Potassium (Unspecified)	C		

Date:03/11/04ISR Number: 4315516-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Anal Fissure
	Angina Pectoris
	Anxiety
	Asthenia
	Back Injury
	Back Pain
	Balance Disorder
	Binge Eating
	Blood Arsenic Increased
	Blood Pressure Decreased
	Bronchitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Bursitis					
		Cardiomegaly					
		Chest Pain					
		Chest Wall Pain		Vioxx	PS	Merck & Co., Inc	ORAL
71	DAY						
		Choking		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
71	DAY						
		Coordination Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Cough		[Therapy			
		Diabetes Mellitus		Unspecified]	C		
		Diarrhoea		Atenolol	C		
		Diastolic Dysfunction		Trazodone			
		Disturbance In Attention		Hydrochloride	C		
		Dizziness Postural		Atenolol	C		
		Dry Throat		Lonox	C		
		Dyspepsia		Hydrocortisone	C		
		Dysphagia		Zestril	C		
		Ear Pain		Paxil	C		
		Feeling Abnormal					
		Feeling Jittery					
		Gastrooesophageal Reflux					
		Disease					
		Haemodialysis					
		Haemorrhage					
		Hepatic Steatosis					
		Hunger					
		Hypercholesterolaemia					
		Hypoaesthesia Oral					
		Initial Insomnia					
		Insomnia					
		Irritable Bowel Syndrome					
		Metabolic Syndrome					
		Migraine					
		Muscle Rigidity					
		Muscle Twitching					
		Myalgia					
		Nausea					
		Nephritis Interstitial					
		Night Sweats					
		Nocturia					
		Palpitations					
		Panic Attack					
		Proctalgia					

Renal Failure Acute
Septic Shock
Sinusitis
Speech Disorder
Tendonitis
Therapeutic Agent
Toxicity
Tinnitus
Tremor
Ventricular Hypertrophy
Vision Blurred
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/04ISR Number: 4315525-7Report Type:Expedited (15-DaCompany Report #WAES 0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc			
	Anxiety		Allegra	C		ORAL		
	Aortic Valve Incompetence		Zoloft	C		ORAL		
	Bundle Branch Block Left							
	Cardiac Failure							
	Cardiac Failure							
	Congestive							
	Cardiomyopathy							
	Compartment Syndrome							
	Depression							
	Dermatitis Contact							
	Dizziness							
	Dyspnoea Exertional							
	Ejection Fraction							
	Decreased							
	Ganglion							
	Headache							
	Hyperlipidaemia							
	Hypertension							
	Hypokinesia							
	Insomnia							
	Mitral Valve Incompetence							
	Oedema Peripheral							
	Tendonitis							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							

Date:03/11/04ISR Number: 4315533-6Report Type:Expedited (15-DaCompany Report #WAES 0309USA00840
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Infarction		Tylenol With Codeine					
	Blood Pressure		#3	C		ORAL	3	DAY
	Immeasurable		Vicodin Tablets	C				

	Circulatory Collapse	Flonase	C
	Feeling Abnormal	Vitamins	
	Loss Of Consciousness	(Unspecified)	C
	Pulse Absent	Motrin	C
	Pupil Fixed	Serzone	C
	Respiratory Arrest		
	Sleep Apnoea Syndrome		

Date:03/11/04ISR Number: 4316024-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Aortic Valve Incompetence
	Atrioventricular Block Complete
	Blood Pressure Increased
	Cardiac Arrest

		Cervical Dysplasia					
		Coronary Artery Disease					
		Coronary Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Culture Urine Positive		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematuria		Tylenol	C		
		International Normalised		Estradiol	C		
		Ratio Decreased		Synthroid	C		
		Klebsiella Infection					
		Micturition Urgency					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Sinus Bradycardia					
		Urinary Tract Infection					
		Uterine Leiomyoma					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		White Blood Cells Urine					
		Positive					

Date:03/11/04ISR Number: 4316026-2Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00026
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY						
Initial or Prolonged	Face Oedema		Diacerein	C		ORAL
			Fluvastatin Sodium	C		ORAL
			Heptaminol Adenylate	C		ORAL
			Indapamide	C		ORAL

Date:03/12/04ISR Number: 4316219-4Report Type:Expedited (15-DaCompany Report #WAES 0204SWE00002
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
25 DAY						
Initial or Prolonged	Increased		Lithium Sulfate	SS		ORAL
	Depressed Level Of		Calcium Carbonate			
	Consciousness		And Cholecalciferol	C		

	Drug Interaction	Dipyridamole	C
	Drug Level Increased	Zolpidem Tartrate	C
	Extrapyramidal Disorder	Tramadol Hydrochloride	C
	Fatigue	Lofepramine Hydrochloride	C
	Renal Failure	Levothyroxine Sodium	C

Date:03/12/04ISR Number: 4316220-0Report Type:Expedited (15-DaCompany Report #WAES 0303USA02789
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Depression
	Dermatitis Allergic
	Diverticulum Intestinal Haemorrhagic
	Gastrointestinal Tract Adenoma

	Large Intestinal Ulcer Haemorrhage						
	Lower Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	
	Refusal Of Treatment By Patient		Vioxx	SS	Merck & Co., Inc	ORAL	
	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
			Lortab	SS	Merck & Co., Inc	ORAL	
			Vitamins (Unspecified)	C			
			Vitamin B Complex	C		ORAL	
			Ascorbic Acid	C			
			Aspirin	C			
			Uniretic	C			

Date:03/12/04ISR Number: 4316221-2Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00082
Age:90 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 27 DAY	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Hepatitis		Acetazolamide	C		ORAL	
	Jaundice		Amlodipine Besylate	C		ORAL	
	Weight Decreased		Zocor	C		ORAL	
			Aspirin	C		ORAL	
			Proscar	C		ORAL	

Date:03/12/04ISR Number: 4316222-4Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00047
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/12/04ISR Number: 4316224-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Anxiety
	Arthralgia
	Atrial Fibrillation
	Cardiac Failure
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chondrocalcinosis Pyrophosphate
	Chondrocalcinosis Pyrophosphate
	Colon Cancer Recurrent
	Coronary Artery Disease
	Dehydration
	Diarrhoea
	Dizziness
	Gastritis
	Gastrointestinal Haemorrhage

		Gastrooesophageal Reflux Disease					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intracardiac Thrombus		Vioxx	PS	Merck & Co., Inc	ORAL
		Meniscus Lesion		Premarin	C		
		Mitral Valve Incompetence		Glipizide	C		
		Orthostatic Hypotension					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Renal Failure					
		Thrombophlebitis					
		Tooth Infection					
		Urinary Tract Infection					
		Vertigo					

Date:03/12/04ISR Number: 4316226-1Report Type:Expedited (15-DaCompany Report #WAES 01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acoustic Stimulation Tests Abnormal
Disability	Amnesia
	Asthenia
	Blindness
	Blood Pressure Fluctuation
	Cardiac Disorder
	Cardiovascular Disorder
	Chronic Fatigue Syndrome
	Clavicle Fracture
	Coccidioidomycosis
	Cognitive Disorder
	Csf Test Abnormal
	Dementia
	Dizziness
	Drug Ineffective
	Dysstasia
	Eczema Asteatotic
	Electroencephalogram Abnormal
	Emotional Distress
	Encephalitis
	Endocarditis

Fall
Fatigue
Feeling Jittery
Fibromyalgia
Fracture
Gastrooesophageal Reflux
Disease
Grand Mal Convulsion
Headache
Injury
Insomnia
Iritis
Joint Dislocation
Joint Injury
Keratoconjunctivitis
Sicca

		Lacrimation Increased					
		Limb Injury					
		Malaise	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Prolapse		Celebrex	C		
		Motor Dysfunction		Femhrt	C		
		Myocarditis		Herbs (Unspecified)	C		
		Nausea		Anaprox	C		
		Night Sweats					
		Oedema					
		Paraesthesia					
		Photosensitivity Reaction					
		Pulmonary Calcification					
		Renal Failure					
		Stomatitis					
		Tunnel Vision					
		Upper Respiratory Tract					
		Infection					
		Vertigo					
		Viral Infection					
		Vomiting					

Date:03/12/04ISR Number: 4316228-5Report Type:Expedited (15-DaCompany Report #WAES 0310USA01949
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL
41	DAY						
Initial or Prolonged		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Glucose Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						
		Carotid Artery Stenosis		Lasix (Furosemide)	C		
		Cerebrovascular Accident		Humulin	C		
		Diarrhoea		Trental	C		
		Ecchymosis					
		Emotional Distress					
		Excoriation					
		Femoral Arterial Stenosis					
		Foot Amputation					
		Gangrene					
		Halitosis					

Hypertension
Ischaemic Stroke
Lacunar Infarction
Localised Infection
Oedema
Pain
Pain In Extremity
Popliteal Stenosis
Rectal Haemorrhage
Skin Candida
Transient Ischaemic
Attack
Vaginal Haemorrhage

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/04ISR Number: 4316229-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		560 DAY
Initial or Prolonged	Cardiomegaly		Amitriptyline					
Disability	Cardiovascular Disorder		Hydrochloride	C				
	Cerebrovascular Accident		Celexa	C				
	Chest Pain		Nexium	C				
	Chronic Fatigue Syndrome		Lasix (Furosemide)	C				
	Fluid Retention		Lasix (Furosemide)	C				
	Haematochezia		Zanaflex	C				
	Hypercholesterolaemia		Ultram	C				
	Ileus		Ambien	C				
	Methicillin-Resistant		Diovan	C				
	Staphylococcal Aureus		Torsemide	C				
	Test Positive		Neurontin	C				
	Mitral Valve Incompetence		Zaroxolyn	C				
	Mitral Valve Prolapse		Aleve	C				
	Myocardial Infarction		Oxycontin	C				
	Pneumonia		Potassium Chloride	C				
	Rash							
	Renal Failure Acute							
	Respiratory Failure							
	Rhabdomyolysis							
	Sinusitis							
	Staphylococcal Infection							

Date:03/12/04ISR Number: 4316230-3Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Perforation							

Date:03/12/04ISR Number: 4316231-5Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00086
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Lung Infiltration	Vioxx	PS	Merck & Co., Inc	ORAL
71 DAY					
Disability	Pneumonitis	Acetaminophen	C		
	Pulmonary Fibrosis	Omeprazole	C		

Date:03/12/04ISR Number: 4316500-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA00993
Age:33 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Bradycardia
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Emotional Distress
	Fatigue
	Gastrooesophageal Reflux Disease
	Hypotension
	Urinary Retention

	Ventricular Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Tylenol	C				
			Tylenol	C				
			Imitrex	C				
			Advil	C				
			Advil	C				

Date:03/12/04ISR Number: 4316503-4Report Type:Expedited (15-DaCompany Report #WAES 00101917
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Drug Level Increased		Lithobid	SS		ORAL	9	YR
Other	Dysarthria		Lithobid	SS		ORAL		
	Hemiparesis							
	Mental Status Changes							
	Renal Failure							
	Renal Neoplasm							
	Therapeutic Agent							
	Toxicity							

Date:03/12/04ISR Number: 4316504-6Report Type:Expedited (15-DaCompany Report #WAES 00091582
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Drug Level Increased		Lithium Carbonate	SS				

Date:03/12/04ISR Number: 4316506-XReport Type:Expedited (15-DaCompany Report #WAES 00030893
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Disorientation Drug Interaction Drug Level Increased Therapeutic Agent Toxicity		Vioxx Lithium Carbonate [Therapy Unspecified] [Therapy Unspecified] Estrogenic Preparations (Composition Unspecified)	PS SS C C C	Merck & Co., Inc	ORAL ORAL		

Date:03/12/04ISR Number: 4316507-1Report Type:Expedited (15-DaCompany Report #WAES 00110445
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State Disorientation Drug Interaction Therapeutic Agent Toxicity Urinary Tract Infection		Vioxx Lithium Carbonate (Roxane)	PS SS	Merck & Co., Inc	ORAL ORAL	5 DAY 10 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/04ISR Number: 4316508-3Report Type:Expedited (15-DaCompany Report #WAES 01060813
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Drug Interaction		Lithium Carbonate	SS		ORAL		
	Drug Level Increased		Clonazepam	C				
	Gait Disturbance		Zyprexa	C				
	Hypersomnia							
	Hypertonia							
	Mood Altered							
	Myoclonus							
	Oedema Peripheral							
	Speech Disorder							

Date:03/12/04ISR Number: 4316509-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abnormal Behaviour
Initial or Prolonged	Adjustment Disorder With
Disability	Depressed Mood
Other	Anxiety
	Arthralgia
	Asthenia
	Atrioventricular Block
	Complete
	Bacteria Urine
	Blood Alcohol Increased
	Bradycardia
	Bundle Branch Block
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Catheter Related
	Complication
	Cellulitis
	Cervicobrachial Syndrome
	Congestive Cardiomyopathy
	Coronary Artery Disease
	Dilatation Ventricular
	Drug Hypersensitivity

Epicondylitis
Fall
Feeling Abnormal
Gait Disturbance
Gastrooesophageal Reflux
Disease
Hyperlipidaemia
Hypersensitivity
Hypotension
Hypoxic Encephalopathy
Laceration
Mitral Valve Incompetence
Myocardial Infarction
Neck Pain
Neurogenic Bladder
Neurogenic Bowel
Paraplegia
Quadriplegia

		Red Blood Cells Urine					
		Road Traffic Accident					
		Spinal Cord Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Treatment Noncompliance		Vioxx	PS	Merck & Co., Inc	ORAL
		Tremor		Vioxx	SS	Merck & Co., Inc	ORAL
		Ulcer					
		Urinary Tract Infection					
		Ventricular Hypokinesia					
		White Blood Cells Urine					
		Positive					
		Wound Infection					

Date:03/12/04ISR Number: 4316510-1Report Type:Expedited (15-DaCompany Report #WAES 0204USA02770
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Asterixis		Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
Initial or Prolonged		Coordination Abnormal		Lithium Carbonate	SS		ORAL
20	YR						
		Dehydration					
		Dizziness					
		Drug Interaction					
		Drug Level Increased					
		Nystagmus					

Date:03/12/04ISR Number: 4316511-3Report Type:Expedited (15-DaCompany Report #WAES 01031627
Age:69 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blindness		Lithium Carbonate	SS		ORAL
		Confusional State		Lithium Carbonate	SS		ORAL
		Disorientation		Lortab	C		
		Drug Interaction		Fosamax	C		
		Gait Disturbance		Prempro	C		
		Goitre		Prevacid	C		
		Haematocrit Decreased		Zestril	C		
		Haemoglobin Decreased					
		Hallucination					

Headache
Incoherent
Kyphosis
Medication Error
Mental Status Changes
Neuropathy
Peripheral Sensory
Neuropathy
Pollakiuria
Supraventricular
Extrasystoles
Therapeutic Agent
Toxicity
Tremor
Visual Disturbance
Weight Decreased

Date:03/12/04ISR Number: 4316512-5Report Type:Expedited (15-DaCompany Report #WAES 0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiac Failure		Tylenol	C		
Other	Congestive		Aspirin	C		
	Cardiac Valve Disease		Coumadin	C		
	Coronary Artery Disease		Aspirin	C		
	Deep Vein Thrombosis		Atenolol	C		
	Dyspnoea		Indocin			
	Ejection Fraction		(Indomethacin)	C		
	Decreased					
	Emotional Distress					
	Exostosis					
	Gout					
	Hypertension					
	Injury					
	Ischaemic Cardiomyopathy					
	Myocardial Infarction					
	Osteoarthritis					
	Platelet Count Decreased					
	Renal Failure Chronic					
	Sinusitis					

Date:03/12/04ISR Number: 4316513-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aortic Valve Prolapse		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
	Carotid Artery Stenosis		Fosamax	C		ORAL
	Cerebrovascular Accident		Hydrochlorothiazide	C		
	Chest Discomfort					
	Circulatory Collapse					
	Conduction Disorder					
	Coronary Artery Disease					
	Coronary Artery Stenosis					
	Cough					
	Depression					

Dilatation Atrial
Embolic Stroke
Impaired Driving Ability
Libido Decreased
Mitral Valve Incompetence
Mitral Valve Prolapse
Mitral Valve Sclerosis
Scan Myocardial Perfusion
Abnormal
Sexual Dysfunction
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Ventricular Hypokinesia
Weight Increased
White Blood Cell Count
Increased

Date:03/12/04ISR Number: 4316514-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amaurosis Fugax
Disability	Amnesia
Other	Anaemia Haemolytic
	Autoimmune
	Anxiety
	Aortic Valve Incompetence
	Arthralgia
	Atelectasis
	Blindness Transient
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Blood Pressure Decreased
	Cellulitis
	Cerebral Atrophy
	Cerebrovascular Accident
	Chest Pain
	Cholecystitis
	Cholelithiasis
	Coagulation Factor Viii Level Increased
	Cough
	Cystocele
	Decreased Appetite
	Diplopia
	Disease Recurrence
	Disturbance In Attention
	Drug Hypersensitivity
	Drug Ineffective
	Dyspepsia
	Dysphagia
	Dyspnoea
	Emotional Distress
	Endocrine Disorder
	Eye Pain
	Face Oedema
	Haematochezia
	Haemorrhage
	High Density Lipoprotein Decreased
	Hypercalcaemia
	Hyperglycaemia

Hypocalcaemia
Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism
Increased Appetite
Injury
Iron Deficiency
Joint Swelling
Leukocytosis
Low Density Lipoprotein
Increased
Lung Neoplasm
Menopause
Mental Status Changes
Mitral Valve Incompetence

		Mucosal Dryness					
		Muscle Spasms					
		Muscle Twitching	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Stiffness		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Neurogenic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
8	MON						
		Oesophageal Disorder		Amitriptyline			
		Pollakiuria		Hydrochloride	C		
		Pruritus		Rocaltrol	C		ORAL
		Pulmonary Granuloma		Os-Cal + D	C		
		Pyrexia		Valium	C		
		Rectal Prolapse Repair		Synthroid	C		
		Rectocele		Synthroid	C		ORAL
		Red Blood Cell		Ambien	C		
		Spherocytes Present		Claritin	C		
		Renal Failure		Slow-Mag	C		
		Sputum Discoloured		Reglan	C		
		Tachycardia		Reglan	C		
		Tinnitus		Prilosec	C		
		Transient Ischaemic		Ditropan Xl	C		
		Attack		Potassium Chloride	C		
		Upper Respiratory Tract					
		Infection					
		Urinary Incontinence					
		Viral Infection					
		Vision Blurred					
		Visual Disturbance					
		Von Willebrand'S Factor					
		Multimers Abnormal					
		Weight Decreased					
		Weight Increased					

Date:03/12/04ISR Number: 4316515-0Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00184
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage		Aspirin	SS		
		Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL
				Acetaminophen And Codeine Phosphate	C		
				Bendroflumethiazide	C		

Fluoxetine	C	
Prochlorperazine Maleate	C	
Nicorandil	C	
Doxazosin Mesylate	C	
Fosamax	C	ORAL

Date:03/12/04ISR Number: 4316516-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Blood Urine Present
	Cerebrovascular Accident
	Constipation
	Dyspepsia
	Electroencephalogram Abnormal

		Emotional Distress					
		Haematochezia					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Plendil	C		
		Simple Partial Seizures		Dyazide	C		
		Tricuspid Valve					
		Incompetence					
		Urine Flow Decreased					
		Weight Increased					

Date:03/12/04ISR Number: 4316517-4Report Type:Expedited (15-DaCompany Report #WAES 0403CAN00038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Groin Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Necrotising Fasciitis		Acetaminophen	C		
			Acetaminophen	C		

Date:03/12/04ISR Number: 4316518-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01084
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Hospitalization -	Upper Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
3 DAY						
Initial or Prolonged	Haemorrhage		Vitamins			
Other			(Unspecified)	C		

Date:03/12/04ISR Number: 4316519-8Report Type:Expedited (15-DaCompany Report #WAES 0311ESP00036
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Anxiety	Vioxx	PS	Merck & Co., Inc	ORAL
34 DAY					
	Asthenia	Medicinalproduct Not			
	Depressed Level Of	Specified By Sender	SS		ORAL
	Consciousness	Medicinalproduct Not			
	Dyskinesia	Specified By Sender	C		
	Genital Burning Sensation	Medicinalproduct Not			
	Hypertension	Specified By Sender	C		ORAL
	Nausea	Medicinalproduct Not			
	Paraesthesia	Specified By Sender	C		ORAL
1 DAY					
		Medicinalproduct Not			
		Specified By Sender	C		ORAL
		Medicinalproduct Not			
		Specified By Sender	C		
		Medicinalproduct Not			
		Specified By Sender	C		ORAL
		Medicinalproduct Not			
		Specified By Sender	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/04ISR Number: 4316520-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA01556
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Neurotoxicity		Lithium Carbonate	SS				
	Therapeutic Agent Toxicity							

Date:03/12/04ISR Number: 4316521-6Report Type:Expedited (15-DaCompany Report #WAES 0401USA01557
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Delirium		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Drug Interaction		Lithium Carbonate	SS		ORAL		
	Drug Level Increased							
	Dysarthria							
	Sedation							

Date:03/12/04ISR Number: 4316522-8Report Type:Expedited (15-DaCompany Report #WAES 0403AUS00318
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Sepsis		Aspirin And Dipyridamole	C				
Initial or Prolonged	Urinary Tract Infection		Atorvastatin Calcium	C				
			Venlafaxine Hydrochloride	C				
			Pantoprazole Sodium	C				

Date:03/12/04ISR Number: 4316523-XReport Type:Expedited (15-DaCompany Report #WAES 0402USA00254
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Arthralgia	Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure	Actos	SS		ORAL
	Congestive	Amiodarone	C		
	Haemorrhage	Norvasc	C		
	Laceration	Aspirin	C		
	Oedema Peripheral	Furosemide	C		
	Pneumonia	Glyburide	C		
	Renal Impairment	Hydralazine	C		
		Isosorbide	C		
		Claritin-D	C		
		Zaroxolyn	C		
		Metoprolol	C		

Date:03/12/04ISR Number: 4316524-1Report Type:Expedited (15-DaCompany Report #WAES 0403USA00846
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Refusal Of Treatment By Patient							
	Renal Failure Acute							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/04ISR Number: 4316525-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA00756
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Rigidity		Zocor	C		ORAL		
	Chest Discomfort							
	Flatulence							
	Hypertension							
	Muscle Spasms							

Date:03/12/04ISR Number: 4316527-7Report Type:Expedited (15-DaCompany Report #WAES 0403USA00704
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:03/12/04ISR Number: 4316528-9Report Type:Expedited (15-DaCompany Report #WAES 0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	450	DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	450	DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Lorcet Plus	C				
	Blood Ph Decreased		Combivent	C				
	Cardiac Failure		Aspirin	C				
	Congestive		Lipitor	C				
	Chronic Obstructive		Rhinocort	C				
	Pulmonary Disease		Wellbutrin	C				
	Coronary Artery Disease		Coreg	C				
	Hepatic Enzyme Increased		Tagamet	C				
	Hypertension		Biaxin	C				
	Hypertensive Heart		Plavix	C				
	Disease		Cyclobenzaprine					
	Hypokalaemia		Hydrochloride	C				

Hypoxia	
Myocardial Infarction	
Pulmonary Oedema	
Respiratory Failure	
Syncope	
Ventricular Hypertrophy	
Ventricular Hypokinesia	

Valium	C
Valium	C
Benadryl	C
Prempro	C
Advair	C
Prolex Dh	C
Mavik	C
Detrol	C
Micardis	C
Hydrocodone Hydrochloride	C
Motrin	C
Motrin	C
Toprol Xl Tablets	C
Daypro	C

Date:03/12/04ISR Number: 4317086-5Report Type:Expedited (15-DaCompany Report #2003-06-0256
Age:65 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Albumin Csf Increased	Foreign	Celestene					
Allergic Granulomatous	Health	(Betamethasone)					
Angiitis	Professional	Tablets "Like					
Antinuclear Antibody	Other	Celestone Syrup"	PS		ORAL	1.5MG QD	
Positive						ORAL; 0.5MG	
Back Pain						QD ORAL	
Condition Aggravated		Cortancyl	SS		ORAL	60 MG QD ORAL	
Confusional State		Solu-Medrol					
Csf Neutrophil Count		Injectable Solution	SS			INTRAVENOUS	
Positive					BOLUS	1 BOLUS	
Eosinophilia						INTRAVENOUS	
Haemodynamic Instability		Vioxx (Rofecoxib)					
Intervertebral Discitis		Tablets	SS		ORAL	1 QD ORAL	
Paralysis Flaccid		Bricanyl	C				
Postoperative Infection		Seretide (Salmeterol					
Quadriplegia		Xinafoate/Fluticason					
Respiratory Distress		e Propionate)	C				
Sciatica		Hyperium					
Staphylococcal Sepsis		(Rilmenidine)	C				
Systemic Inflammatory		Glimepiride	C				
Response Syndrome		Atrovent	C				
Tenosynovitis							
Wound Infection							

Date:03/15/04ISR Number: 4317666-7Report Type:Expedited (15-DaCompany Report #WAES 0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anal Fissure
Disability	Angina Pectoris
	Anorexia
	Anxiety

Arthralgia
Asthenia
Atrial Fibrillation
Atrial Tachycardia
Azotaemia
Back Injury
Back Pain
Balance Disorder
Binge Eating
Blood Arsenic Increased
Blood Creatine
Phosphokinase Increased
Blood Pressure Decreased
Bronchitis
Bursitis
C-Reactive Protein
Increased
Cardiac Stress Test
Abnormal
Cardiomegaly
Chest Pain
Chest Wall Pain
Choking
Constipation

Coordination Abnormal
Coronary Artery Disease
Cough
Cyst
Depression
Diabetes Mellitus
Diarrhoea
Diastolic Dysfunction
Difficulty In Walking
Disturbance In Attention
Dizziness
Dizziness Postural
Dry Throat
Dyspepsia
Dysphagia
Dyspnoea
Ear Pain
Eye Disorder
Fatigue
Feeling Jittery
Fibromyalgia
Gastric Disorder
Gastrooesophageal Reflux
Disease
Haemodialysis
Haemorrhage
Hepatic Steatosis
Hunger
Hydronephrosis
Hypercholesterolaemia
Hyperventilation
Hypoaesthesia
Hypoaesthesia Oral
Hypoperfusion
Impaired Driving Ability
Initial Insomnia
Insomnia
Irritable Bowel Syndrome
Metabolic Syndrome
Migraine
Muscle Disorder
Muscle Rigidity
Muscle Spasms
Muscle Twitching
Muscular Weakness
Musculoskeletal Pain
Myalgia

Myasthenia Gravis
Nausea
Neck Pain
Night Sweats
Nocturia
Palpitations
Panic Attack
Pericardial Effusion
Proctalgia
Red Blood Cell
Sedimentation Rate
Increased
Renal Failure Acute
Respiratory Rate

		Increased					
		Rhonchi					
		Salivary Hypersecretion					
		Septic Shock	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Shock		Vioxx	PS	Merck & Co., Inc	ORAL
71	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Speech Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
71	DAY						
		Supraventricular		[Therapy			
		Extrasystoles		Unspecified]	C		
		Tachycardia		Elavil	C		
		Tendonitis		Atenolol	C		
		Therapeutic Agent		Trazodone			
		Toxicity		Hydrochloride	C		
		Tinnitus		Atenolol	C		
		Tremor		Lonox	C		
		Tubulointerstitial		Dyazide	C		
		Nephritis		Hydrocortisone	C		
		Ventricular Extrasystoles		Zestril	C		
		Ventricular Hypertrophy		Paxil	C		
		Vision Blurred					
		Vomiting					
		Weight Decreased					

Date:03/15/04ISR Number: 4317669-2Report Type:Expedited (15-DaCompany Report #WAES 0312USA00992
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
227	DAY						
Initial or Prolonged		Blood Pressure Systolic		Aspirin	C		
Disability		Increased		Vasotec	C		ORAL
		Carotid Artery Stenosis		Prempro	C		
299	DAY						
		Cerebral Artery Occlusion		Allegra-D	C		
		Cerebral Infarction		Amaryl	C		
		Cerebrovascular Accident		Levoxyl	C		
		Circulatory Collapse		Toprol Xl Tablets	C		
		Depression		Univasc	C		
		Diabetes Mellitus		Nitrostat	C		

Non-Insulin-Dependent
Dilatation Atrial
Dyskinesia
Dysstasia
Extensor Plantar Response
Fall
Headache
Heart Rate Increased
Hypertension
Hyporeflexia
Hypothyroidism
Intracranial Aneurysm
Mitral Valve Incompetence
Mitral Valve Sclerosis
Movement Disorder
Muscle Disorder
Muscle Spasms
Pain In Extremity
Pco2 Decreased
Platelet Count Decreased
Respiratory Rate
Increased
Troponin Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/04ISR Number: 4317670-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Infarction		Atenolol	C				
	Angina Pectoris		Zyrtec	C				
	Arthralgia		Celexa	C				
	Asthenia		Indocin					
	Back Pain		(Indomethacin)	C		ORAL		
	Coronary Artery Disease		Naproxen	C				
	Dilatation Ventricular		Prilosec	C				
	Ejection Fraction		Oxycontin	C				
	Decreased		Aciphex	C				
	Fall							
	Hypokinesia							
	Ischaemia							
	Muscle Injury							
	Muscular Weakness							
	Neck Pain							
	Pain							
	Peripheral Coldness							
	Road Traffic Accident							
	Rotator Cuff Syndrome							
	Scapula Fracture							
	Skin Laceration							

Date:03/15/04ISR Number: 4317673-4Report Type:Expedited (15-DaCompany Report #WAES 0309GBR00024
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Cardiac Failure Acute		Estradiol Valerate					
	Coronary Artery Disease		And Norethindrone	C		ORAL		
	Coronary Artery Occlusion		Omeprazole	C		ORAL	1	DAY
	Myocardial Ischaemia							
	Pulmonary Congestion							
	Pulmonary Oedema							
	Sudden Death							

Date:03/15/04ISR Number: 4317675-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Balance Disorder
Initial or Prolonged	Cellulitis
Other	Cerebrovascular Accident
	Chest Pain
	Fibromyalgia
	Headache
	Hypertension
	Labyrinthitis
	Liver Disorder
	Lumbar Spinal Stenosis
	Pneumonia
	Red Blood Cell
	Sedimentation Rate
	Increased
	Spondylolisthesis
	Acquired

		Transient Ischaemic Attack					
		Urinary Retention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL
		Wound Infection		Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol With Codeine	C		

Date:03/15/04ISR Number: 4317677-1Report Type:Expedited (15-DaCompany Report #WAES 0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 8 DAY	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Angina Pectoris					
Other	Anxiety Disorder					
	Arrhythmia					
	Bradycardia					
	Cardiac Failure					
	Congestive					
	Chronic Fatigue Syndrome					
	Convulsion					
	Coronary Artery Disease					
	Dizziness					
	Drug Hypersensitivity					
	Electrocardiogram St					
	Segment Elevation					
	Headache					
	Hypertension					
	Hypotension					
	Intervertebral Disc					
	Protrusion					
	Irritability					
	Ischaemia					
	Lung Neoplasm					
	Major Depression					
	Meniere'S Disease					
	Myocardial Infarction					
	Nightmare					
	Osteoarthritis					
	Pain					
	Sleep Disorder					

Syncope

Date:03/15/04ISR Number: 4317764-8Report Type:Expedited (15-DaCompany Report #WAES 01051542
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Increased		Ibuprofen	C				
	Emotional Distress							
	Hyperhidrosis							
	Hypersensitivity							
	Injury							
	Muscular Weakness							
	Nausea							
	Non-Cardiac Chest Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/04ISR Number: 4317765-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Tylenol	C				
	Arthralgia		Estradiol	C				
	Atrioventricular Block Complete		Synthroid	C				
			Provera	C				
	Cervical Dysplasia							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Haematuria							
	Injury							
	Klebsiella Infection							
	Micturition Urgency							
	Mitral Valve Incompetence							
	Osteoarthritis							
	Rectal Haemorrhage							
	Spinal Column Stenosis							
	Spinal Osteoarthritis							
	Urinary Tract Infection							
	Uterine Leiomyoma							
	Ventricular Dysfunction							
	Ventricular Fibrillation							

Date:03/15/04ISR Number: 4317766-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Arthritis
	Atelectasis
	Back Pain
	Cardiac Valve Disease
	Cardiomegaly
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Diabetes Mellitus
	Diabetes Mellitus Non-Insulin-Dependent

Disease Recurrence
Emotional Distress
Facet Joint Syndrome
Hand Fracture
Hypercholesterolaemia
Insomnia
Intervertebral Disc
Protrusion
Joint Ligament Rupture
Limb Injury
Lumbar Spinal Stenosis
Muscle Strain
Nervousness
Osteoarthritis
Pain In Extremity
Platelet Count Decreased
Pleural Effusion

		Respiratory Failure Sciatica Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
				Norco	C		
				Atenolol	C		
				Tenormin	C		
				Celebrex	C		
				Diovan	C		
				Ultram	C		
				Avandia	C		
				Chlorthalidone	C		
				Hygroton	C		
				Cyclobenzaprine Hydrochloride	C		
				Cardizem	C		
				Propecia	C		
				Glucovance	C		
				Hydrocodone Hydrochloride	C		

Date:03/15/04ISR Number: 4317767-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Blood Pressure Decreased
	Cellulitis
	Coronary Artery Disease
	Coronary Artery Thrombosis
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Drug Hypersensitivity
	Emotional Distress
	Eyelid Ptosis
	Glucose Tolerance

Impaired
Haemangioma
Hyperhidrosis
Hypertension
Ischaemia
Macular Degeneration
Myocardial Infarction
Nausea
Oedema Peripheral
Radiculopathy
Sensory Disturbance
Sinus Bradycardia
Spinal Osteoarthritis
Troponin Increased
Urethritis
Visual Disturbance

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Xanax	C				
	Aspirin	C				
	Celebrex	C				
	Zyrtec	C				
	Prozac	C				
	Zestril	C				
	Naproxen	C				
	Prilosec	C				

Date:03/15/04ISR Number: 4317769-7Report Type:Expedited (15-DaCompany Report #WAES 0311ESP00036
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	
	Asthenia		Medicinalproduct Not					
	Chest Pain		Specified By Sender	C				
	Dyskinesia		Medicinalproduct Not					
	Dyspnoea		Specified By Sender	C		ORAL		
	Genital Burning Sensation		Medicinalproduct Not					
	Hypertension		Specified By Sender	C		ORAL	1 DAY	
	Loss Of Consciousness		Medicinalproduct Not					
	Nausea		Specified By Sender	C		ORAL		
	Paraesthesia		Medicinalproduct Not					
			Specified By Sender	C		ORAL		
			Medicinalproduct Not					
			Specified By Sender	C				
			Medicinalproduct Not					
			Specified By Sender	C		ORAL		
			Medicinalproduct Not					
			Specified By Sender	C		ORAL		

Date:03/15/04ISR Number: 4317770-3Report Type:Expedited (15-DaCompany Report #WAES 0403ZAF00002
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Hospitalization -	Shock		Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged			Aspirin	C		ORAL	11	MON
			Warfarin	C		ORAL		
			Warfarin	C		ORAL		

Date:03/15/04ISR Number: 4317771-5Report Type:Expedited (15-DaCompany Report #WAES 0403SWE00012
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL	642	DAY
Initial or Prolonged	Vision Blurred		Acetaminophen	C				
			Aspirin	C				
			Enalapril Maleate	C				
			Glucosamine	C				
			Metoprolol Tartrate	C				
			Nitroglycerin	C				
			Nitroglycerin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4317838-1Report Type:Expedited (15-DaCompany Report #200413034GDDC
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Renal Failure Acute		Indapamide	PS	Aventis Pharmaceuticals Inc.	ORAL
			Rofecoxib	SS		
			Raloxifene	C		
			Omeprazole	C		
			Atrovent Forte	C		
			Ventolin	C		
			Flixotide	C		

Date:03/16/04ISR Number: 4317868-XReport Type:Expedited (15-DaCompany Report #WAES 0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Acute Pulmonary Oedema
Other	Agitation
	Anaemia
	Anxiety
	Atherosclerosis
	Back Injury
	Blood Lactate Dehydrogenase Increased
	Cardiac Failure Congestive
	Cataract
	Cerebral Atrophy
	Cervical Myelopathy
	Cholelithiasis
	Contusion
	Coronary Artery Disease
	Dehydration
	Depression
	Dilatation Atrial
	Diplopia
	Drug Intolerance
	Electrocardiogram Qt Prolonged
	Fall
	Gastroenteritis
	Gastrooesophageal Reflux

Disease
Hallucination
Heart Rate Increased
Hiatus Hernia
Hypertension
Insomnia
Intervertebral Disc
Degeneration
Kyphosis
Laceration
Lacunar Infarction
Mitral Valve Incompetence
Nausea
Nuclear Magnetic
Resonance Imaging
Abnormal
Oedema Peripheral

		Pain					
		Pollakiuria					
		Psychotic Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Rales		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Respiratory Failure		[Therapy			
		Rotator Cuff Syndrome		Unspecified]	C		
		Spinal Compression		Tylenol	C		
		Fracture		Vicodin Tablets	C		
		Suicidal Ideation		Darvocet-N	C		
		Treatment Noncompliance		Amitriptyline			
		Tricuspid Valve		Hydrochloride	C		ORAL
		Incompetence		Aspirin	C		
		Urinary Tract Infection		Aspirin	C		
		Venous Pressure Jugular		Buspirone			
		Increased		Hydrochloride	C		
		Ventricular Hypertrophy		Ambien	C		
		Vomiting		Valium	C		
				Aricept	C		ORAL
				Premarin	C		ORAL
				Fluoxetine	C		
				Prozac	C		
				Lorazepam	C		
				Metoclopramide	C		

Date:03/16/04ISR Number: 4317871-XReport Type:Expedited (15-DaCompany Report #WAES 0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Murmur		Betaxolol Ophthalmic			
Other	Cerebrovascular Accident		Solution	C		
	Embolism		Calcitonin	C		
	Epistaxis		Digoxin	C		
	Haematemesis		Docusate Sodium	C		
	Heart Rate Decreased		Trusopt	C		
OPHTHALMIC						
	Hypercholesterolaemia		Zocor	C		
	Hypertension		Warfarin	C		
1284 DAY						
	Lacunar Infarction		Vitamin E	C		

	Muscle Spasms	Folic Acid	C
	Myalgia	Lasix (Furosemide)	C
1680 DAY			
	Nuclear Magnetic	Isosorbide	C
	Resonance Imaging	Potassium	
	Abnormal	(Unspecified)	C
	Pleural Fibrosis	Psyllium Husk	C
	Productive Cough		
	Vomiting		

Date:03/16/04ISR Number: 4317873-3Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Drug Reaction
Initial or Prolonged	Agitation
	Angina Unstable
	Anxiety
	Asthenia
	Coronary Artery Aneurysm

		Coronary Artery Atherosclerosis					
		Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ecchymosis		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Major Depression		Xanax	C		
		Myocardial Infarction		Aspirin	C		
		Panic Disorder		Lipitor	C		
				Wellbutrin	C		
				Celebrex	C		
				Plavix	C		
				Folic Acid	C		
				Toprol Xl Tablets	C		
				Lopressor	C		
				Pyridoxine	C		

Date:03/16/04ISR Number: 4317875-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Aneurysm
	Aortic Atherosclerosis
	Aortic Dissection
	Aortic Embolus
	Artery Dissection
	Asthenia
	Atelectasis
	Cholelithiasis
	Cognitive Disorder
	Depression
	Disturbance In Attention
	Emotional Distress
	Enterobacter Pneumonia
	Gastrooesophageal Reflux Disease
	General Physical Condition Abnormal
	Haematocrit Decreased
	Haemoglobin Decreased

Hypertension
Iliac Artery Thrombosis
Impaired Healing
Incision Site
Complication
Irritability
Keloid Scar
Loss Of Employment
Pain
Pharyngolaryngeal Pain
Platelet Count Increased
Pneumonia
Post Procedural
Complication
Prothrombin Time
Prolonged
Renal Cyst
Self Esteem Decreased

		Sexual Dysfunction Soft Tissue Haemorrhage Troponin I Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vascular Injury		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Amoxicillin	C		
				Hydrocodone Bitartrate	C		
				Lorazepam	C		

Date:03/16/04ISR Number: 4317878-2Report Type:Expedited (15-DaCompany Report #WAES 0309USA02402
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/16/04ISR Number: 4317879-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Cholesterol Increased		Darvocet-N	C		
				Wellbutrin	C		
		Blood Pressure Systolic Increased		Carisoprodol	C		
				Diflunisal	C		
		Carotid Artery Occlusion		Premarin	C		
		Cerebrovascular Accident		Estratest	C		
		Chest Pain		Ultram	C		
		Constipation		Allegra	C		
		Depression		Rebetron	C		
3	DAY						
		Faecal Occult Blood		Nortriptyline	C		
		Positive		Accupril	C		
		Fall		Rebetol	C		

Gait Disturbance
Grip Strength Decreased
Hemiplegia
Hyperlipidaemia
Ischaemic Stroke
Low Density Lipoprotein
Increased
Lumbar Vertebral Fracture
Melaena
Microcytic Anaemia
Myalgia
Orthostatic Hypotension
Pain In Extremity
Pulmonary Congestion
Somnolence
Spinal Compression
Fracture
Urinary Incontinence
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4317880-0Report Type:Expedited (15-DaCompany Report #WAES 0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adrenal Insufficiency		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Aspirin	C				
	Animal Bite		Celebrex	C				
	Anxiety		Sudal	C				
	Asthenia		Ultram	C				
	Bronchitis		Levaquin	C				
	Cardiomegaly		Synthroid	C				
	Catheter Site Haemorrhage		Zantac	C				
	Cellulitis							
	Constipation							
	Contusion							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Costochondritis							
	Depression							
	Diarrhoea							
	Diastolic Dysfunction							
	Drug Withdrawal Syndrome							
	Dysphagia							
	Dysphonia							
	Dyspnoea							
	Gastrooesophageal Reflux Disease							
	Gravitational Oedema							
	Haemarthrosis							
	Haematoma							
	Heart Sounds Abnormal							
	Hyperparathyroidism							
	Hypothyroidism							
	Increased Tendency To Bruise							
	Intestinal Functional Disorder							
	Joint Injury							
	Libido Decreased							
	Multiple Allergies							
	Musculoskeletal Chest Pain							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Neuralgia							

Oedema
Pain
Panic Attack
Pharyngolaryngeal Pain
Pneumonia
Raynaud'S Phenomenon
Refusal Of Treatment By
Patient
Sensation Of Foreign Body
Spinal Osteoarthritis
Tachycardia
Tension Headache
Ventricular Hypokinesia
Weight Increased
Wound Secretion

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4317884-8Report Type:Expedited (15-DaCompany Report #WAES 0311USA02165
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Generalised Oedema		[Therapy			
	Gravitational Oedema		Unspecified]	C		
	Haematemesis		Prilosec	C		
	Swelling					
	Vomiting					

Date:03/16/04ISR Number: 4317885-XReport Type:Expedited (15-DaCompany Report #WAES 0311GBR00223
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL
31 DAY						
Initial or Prolonged	Haemoglobin Decreased		Aspirin	SS		ORAL
	Melaena		Aspirin	SS		ORAL
			Amiloride Hydrochloride And Furosemide	C		ORAL
			Atenolol	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Isosorbide Mononitrate	C		ORAL
			Nicorandil	C		ORAL

Date:03/16/04ISR Number: 4317886-1Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00103
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL
	Rash Generalised		Vioxx	SS	Merck & Co., Inc	ORAL
			Acetaminophen	C		
			Aspirin	C		
			Butylscopolamine Bromide	C		
			Danthron And Poloxamer 188	C		

Enalapril Maleate	C
Exemestane	C
Gabapentin	C
Verapamil	C
Tramadol Hydrochloride	C
Senna	C
Insulin, Biphasic Isophane [Injection]	C
Isosorbide Mononitrate	C
Lansoprazole	C
Morphine Sulfate	C
Oxycodone	C
Oxycodone Hydrochloride	C
Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4317888-5Report Type:Expedited (15-DaCompany Report #WAES 0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Bursitis		[Therapy			
	Cervicobrachial Syndrome		Unspecified]	C		
	Chronic Obstructive		Vicodin Tablets	C		
	Pulmonary Disease		Elavil	C		ORAL
	Contusion		Analgesic Or			
	Cough		Anesthetic			
	Depression		(Unspecified)	C		
	Emotional Disorder		Aspirin	C		ORAL
	Exostosis		Vitamins			
	Fall		(Unspecified)	C		
	Fatigue		Vitamin E	C		
	Feeling Abnormal		Calcium Carbonate	C		
	Fibromyalgia		Premarin	C		
	Gait Disturbance		Lasix (Furosemide)	C		
	Intervertebral Disc		Neurontin	C		
	Protrusion		Oxycontin	C		
	Lower Respiratory Tract		Paxil	C		ORAL
	Infection		Actonel	C		
	Memory Impairment					
	Migraine					
	Oedema Peripheral					
	Osteoporosis					
	Pain In Extremity					
	Radius Fracture					
	Renal Disorder					
	Renal Pain					
	Sinusitis					
	Sleep Disorder					
	Somnolence					
	Spinal Osteoarthritis					
	Tendonitis					
	Transient Ischaemic					
	Attack					
	Urinary Tract Infection					
	Visual Disturbance					
	Weight Increased					

Date:03/16/04ISR Number: 4318008-3Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Aortic Atherosclerosis
Initial or Prolonged	Aortic Valve Sclerosis
Disability	Aphasia
	Asthenia
	Basal Cell Carcinoma
	Blood Calcium Increased
	Bundle Branch Block Right
	Cardiac Murmur
	Cerebrovascular Accident
	Circulatory Collapse
	Conduction Disorder
	Coronary Artery Disease

		Cough					
		Depression					
		Embolic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sexual Dysfunction		Fosamax	C		ORAL
		Skin Graft		Hydrochlorothiazide	C		
		Sleep Apnoea Syndrome					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		White Blood Cell Count					
		Increased					

Date:03/16/04ISR Number: 4318014-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
Initial or Prolonged		Anaemia		Microzide	SS		
Disability		Ankylosing Spondylitis		Microzide	SS		
Other		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Prinzide	SS		ORAL
26	HR						
		Constipation		Feldene	SS		
60	DAY						
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
24	DAY						
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphoria		Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Facet Joint Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY						
		Facial Bones Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
24	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						

	Fibromyalgia	Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY					
	Gastrooesophageal Reflux	Vicodin Es Tablets	C		ORAL
	Disease	Vicodin Es Tablets	C		
	Hypothyroidism	Norco	C		
156 DAY					
	Intervertebral Disc Degeneration	Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL	Intervertebral Disc 1 DAY				
	Displacement Intervertebral Disc Protrusion	Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL	1 DAY				
	Jaw Disorder	Beconase	C		
	Nephritis Interstitial	Effexor	C		
	Osteoporosis	Trazodone Hydrochloride	C		
	Polyarthritis	Imitrex	C		
	Psoriatic Arthropathy	Claritin	C		
	Raynaud'S Phenomenon	Prevacid	C		
	Reiter'S Syndrome	Zestoretic	C		
	Renal Failure	Celebrex	C		
	Sacroiliitis	Flexeril	C		
	Weight Increased	Valium	C		
		Estratest	C		
		Neurotonin Capsules	C		
		Neurotonin Capsules	C		

Date:03/16/04ISR Number: 4318015-0Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00059
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Adverse Event Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amlodipine Besylate	C				
			Certoparin Sodium	C				
			Digoxin	C				
			Dipyrone	C				
			Tramadol Hydrochloride	C				
			Hydrochlorothiazide	C				
			Metoprolol Succinate	C				
			Ramipril	C				

Date:03/16/04ISR Number: 4318016-2Report Type:Expedited (15-DaCompany Report #WAES 0403DNK00011
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY

Date:03/16/04ISR Number: 4318018-6Report Type:Expedited (15-DaCompany Report #WAES 0403CHE00022
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
	Dyspnoea		Acenocoumarol	SS		ORAL		
	Gastritis Erosive		Methylprednisolone Acetate	SS		PARENTERAL		61 DAY
	Melaena							
	Pallor		Methylprednisolone Acetate	SS		PARENTERAL		61 DAY
			Clonazepam	C		ORAL		
			Digoxin	C		ORAL		
			Spironolactone	C		ORAL		

	Torsemide	C		ORAL
52 DAY				
	Nitroglycerin	C		ORAL
12 MON				
	Molsidomine	C		ORAL
12 MON				
	Vasotec	C		ORAL
	Glimepiride	C		ORAL
	Levothyroxine Sodium	C		ORAL

Date:03/16/04ISR Number: 4318019-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA00096
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/04ISR Number: 4318020-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA03417
Age:52 YR Gender:Female I/FU:I

Outcome	PT
Death	Arrhythmia
	Cardio-Respiratory Arrest
	Coma
	Gastric Haemorrhage

Weight Decreased

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
			Vioxx	PS	Merck & Co., Inc	ORAL
			Chlorpromazine	SS		
			Clozapine	SS		
			Naproxen	SS		
2	DAY					
			Naproxen	SS		
4	DAY					
			Naproxen	SS		
4	DAY					
			Naproxen	SS		
			Naproxen	SS		
1	DAY					
			Naproxen	SS		
2	DAY					
			Naproxen	SS		
			Naproxen	SS		
1	DAY					
			Ascorbic Acid	C		
2	DAY					
			Vitamins (Unspecified)	C		
			Oxycodone	C		
			Oxycodone	C		
			Nefazodone Hydrochloride	C		ORAL
			Chlorzoxazone	C		
			Gabapentin	C		ORAL
			Levothyroxine Sodium	C		
			Gabapentin	C		ORAL
			Folic Acid	C		
			Clonazepam	C		
			Ascorbic Acid	C		ORAL

Date:03/16/04ISR Number: 4318023-XReport Type:Expedited (15-DaCompany Report #WAES 0203USA02027
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypoaesthesia		Premarin	C		

	Medication Error	Motrin	C
	Optic Ischaemic	Progesterone	C
	Neuropathy		
	Spondylitis		
	Urinary Tract Infection		

Date:03/16/04ISR Number: 4319078-9Report Type:Expedited (15-DaCompany Report #2004CG00167
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall	Foreign Health Professional	Atacand	PS				
	Hallucination, Visual		Colopriv	SS				
			Di-Antalvic	SS		ORAL	4 DF DAILY	PO
		Other	Lexomil	SS		ORAL	1 DF DAILY	PO
			Lanzor	SS		ORAL	1 DF DAILY	PO
			Vioxx	SS		ORAL	1 DF DAILY	PO
			Temesta	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/04ISR Number: 4319708-1Report Type:Expedited (15-DaCompany Report #US067234
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse	Study	Enbrel	PS		SUBCUTANEOUS	25 MG, 2 IN 1	
Other	Heart Rate Increased	Health						WEEK, SC
Required	Pain	Professional	Rofecoxib	SS		ORAL	25 MG, 2 IN 1	
Intervention to	Sudden Death							DAY, PO
Prevent Permanent			Vicodin	SS			5 MG, AS	
Impairment/Damage							NECESSARY	
			Hydromoprhone Hydrochloride	SS				
			Folate Sodiuim	C				
			Prednisone	C				
			Leflunomide	C				
			Lansoprazole	C				
			Furosemide	C				
			Potassium Chloride	C				

Date:03/17/04ISR Number: 4318038-1Report Type:Expedited (15-DaCompany Report #200410474DE
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Amaryl	PS	Aventis			
Initial or Prolonged	Blood Sodium Decreased				Pharmaceuticals Inc.	ORAL		
	Electrolyte Imbalance		Arelix	SS		ORAL		
	Haemoglobin Decreased		Accupro	SS		ORAL		
	Hypertension		Vioxx	SS		ORAL		
	Oedema Peripheral		Novalgin	C		ORAL		
	Oesophageal Candidiasis						frequency:	
							irregular	
			Aciclostad	C		ORAL		
			Alpha-Liponsaure	C		ORAL		
			Atarax	C		ORAL		
			Bisoprolol	C		ORAL		
			Mydocalm	C		ORAL		

			Procain	C		
INTRAVENOUS						

Date:03/17/04ISR Number: 4318094-0Report Type:Expedited (15-DaCompany Report #WAES 0403USA01238
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Fear	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Tylenol	C		
	Stress		Norvasc	C		
			Aspirin	C		
			Indapamide	C		

Date:03/17/04ISR Number: 4318095-2Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00046
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastritis Erosive	Professional	Azathioprine	SS		ORAL
	Helicobacter Infection		Buprenorphine			
	Nausea		Hydrochloride	SS		
TOPICAL	6 DAY					
	Upper Gastrointestinal		Phenprocoumon	SS		ORAL
	Haemorrhage		Prednisolone	SS		ORAL
			Phenprocoumon	SS		ORAL
			Amlodipine Besylate	C		ORAL

			Torsemide	C		ORAL
			Xipamide	C		ORAL

Date:03/17/04ISR Number: 4318096-4Report Type:Expedited (15-DaCompany Report #WAES 0403USA01235
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY

Date:03/17/04ISR Number: 4318099-XReport Type:Expedited (15-DaCompany Report #WAES 0403USA01341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	237	DAY

Date:03/17/04ISR Number: 4318100-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA01342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/04ISR Number: 4318102-7Report Type:Expedited (15-DaCompany Report #WAES 0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
Initial or Prolonged	Blood Triglycerides		Estrace	C				
Disability	Increased		Estrace	C				
	Cerebrovascular Accident		Zocor	C		ORAL		
	Drug Hypersensitivity		Prilosec	C				

Dyspepsia
Dyspnoea
Emotional Distress
Gout
High Density Lipoprotein
Decreased
Hypercholesterolaemia
Hypoaesthesia
Injury
Low Density Lipoprotein
Increased
Pain In Extremity
Peptic Ulcer
Transient Ischaemic
Attack
Vulvovaginal Dryness

Date:03/17/04ISR Number: 4318311-7Report Type:Expedited (15-DaCompany Report #WAES 00072225
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Depression		Alcohol	SS				
Disability	Gastric Ulcer Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
	Hypertension		Tylenol	C				

			Tylenol With Codeine	C		
			Ambien	C		

Date:03/17/04ISR Number: 4318324-5Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00037
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	13 DAY	
Hospitalization - Initial or Prolonged	Thrombocytopenia		Acetaminophen	C		ORAL	27 DAY	
			Alfuzosin Hydrochloride	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Fenspiride Hydrochloride	C		ORAL		
			Furosemide	C		ORAL		

Date:03/17/04ISR Number: 4318328-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA01258
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atrial Flutter		Tylenol	C				
Other	Blood Pressure Increased		Proventil	C				
	Cardiac Failure		Aspirin	C				
	Congestive		Serevent	C				
	Chronic Obstructive		Cardura	C				
	Pulmonary Disease		Flovent	C				
	Congestive Cardiomyopathy		Prilosec	C				
	Coronary Artery Disease		Zantac	C				
	Diabetes Mellitus Non-Insulin-Dependent							
	Dilatation Ventricular							
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Hypoaesthesia							
	Hypoglycaemia							

Mitral Valve Incompetence
Myocardial Infarction
Orthostatic Hypotension
Pain In Extremity
Pulmonary Hypertension
Tachycardia
Tricuspid Valve
Incompetence

Date:03/17/04ISR Number: 4318329-4Report Type:Expedited (15-DaCompany Report #WAES 0403USA00911
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Microalbuminuria		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	92 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Allegra	C		ORAL		
			Glucotrol	C		ORAL		
			Lisinopril	C		ORAL		

			Mobic	C		ORAL
15 DAY						
			Glucophage	C		ORAL

Date:03/17/04ISR Number: 4318330-0Report Type:Expedited (15-DaCompany Report #WAES 01061634
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Adverse Event		Fosamax	SS		ORAL
Initial or Prolonged	Anorexia		Plavix	SS		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthropathy		Lortab	C		ORAL
	Blood Pressure Increased		Septra	C		ORAL
	Bloody Discharge		Zanaflex	C		
	Cardiac Procedure		Septra	C		ORAL
	Complication		Synthroid	C		ORAL
	Cerebrovascular Accident		Robaxin	C		
	Chills		Insulin	C		
	Cholelithiasis		Norvasc	C		ORAL
	Obstructive					
	Contusion					
	Coronary Artery					
	Atherosclerosis					
	Diabetes Mellitus					
	Inadequate Control					
	Dyspepsia					
	Dyspnoea Exertional					
	Gastric Haemorrhage					
	Gingival Disorder					
	Hypercholesterolaemia					
	Hypertensive Heart					
	Disease					
	Insomnia					
	Intervertebral Disc					
	Protrusion					
	Intestinal Functional					
	Disorder					
	Myocardial Infarction					
	Nausea					
	Night Sweats					
	Ocular Hyperaemia					
	Oedema Peripheral					
	Osteopenia					

Pain
Peripheral Vascular
Disorder
Postinfarction Angina
Retinopathy
Retroperitoneal Haematoma
Rheumatoid Arthritis
Supraventricular
Tachycardia
Thrombosis
Tremor
Vaginal Erythema
Vertigo
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/04ISR Number: 4318332-4Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00007
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		16 DAY
	Anorexia							
	Depressed Level Of Consciousness							
	Duodenal Ulcer Haemorrhage							
	Flatulence							
	Gastrointestinal Disorder							
	Haematemesis							
	Malaise							
	Melaena							
	Thrombosis							

Date:03/17/04ISR Number: 4318927-8Report Type:Direct Company Report #CTU 214541
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Rofecoxib (Vioxx) 50 Mg -Merck	PS	Merck	ORAL	50 MG PO Q	DAY
	Congestive Condition Aggravated							
			Asa	C				
			Omeprazole	C				
			Amiodarone	C				
			Pseudophedrine	C				
			Furosemide	C				
			Citaloprim	C				
			Naproxen	C				
			Folic Acid	C				
			Fe-Tinic	C				
			Humulin 70/30 Insulin	C				

Date:03/17/04ISR Number: 4320281-2Report Type:Expedited (15-DaCompany Report #2004014889
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Drug Interaction Electrolyte Imbalance Hypertension Hyponatraemia Oedema Peripheral Oesophageal Candidiasis Vomiting	Foreign Health Professional	Accupro (Quinapril Hydrochloride)	PS		ORAL	20 MG (BID),	
			Piertande (Piretanide)	SS		ORAL	3 MG (DAILY),	
			Metamizole Sodium (Metamizole Sodium)	SS		ORAL	20 DROP	(PRN),
			Glimepiride (Glimepirdie)	SS		ORAL	2 MG (DAILY),	
			Rofecoxib (Rofecoxib)	SS		ORAL	100 MG (BID),	
			Aciclovir (Aciclovir)	C				
			Thioctic Acid (Thioctic Acid)	C				
			Hydroxyzine					

		Hydrochloride (Hydroxyzine Hydrochloride)	C
		Bisoprolol (Bisoprolol)	C
		Tolperisone (Tolperisone)	C
		Procaine (Procaine)	C

Date:03/18/04ISR Number: 4318817-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02122
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Suicidal Ideation		Acetaminophen	C				
Other			Vicodin Tablets	C				

Date:03/18/04ISR Number: 4318819-4Report Type:Expedited (15-DaCompany Report #WAES 0311ESP00036
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY
	Asthenia	Professional	Zopiclone	SS		ORAL		
	Chest Pain		[Therapy					
	Depressed Level Of		Unspecified]	C				
	Consciousness		Acetaminophen	C				
	Dyskinesia		Brompheniramine					
	Dyspnoea		Maleate	C				
	Genital Burning Sensation		Caffeine	C				
	Hypertension		Carvedilol	C		ORAL		
	Nausea		Carvedilol	C		ORAL	1	DAY
	Paraesthesia		Citalopram Hydrobromide	C		ORAL		
			Diacerein	C				
			Indapamide	C		ORAL		
			Quinapril Hydrochloride	C		ORAL		

Date:03/18/04ISR Number: 4318826-1Report Type:Expedited (15-DaCompany Report #WAES 0403USA01230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/04ISR Number: 4319089-3Report Type:Direct Company Report #CTU 214670
Age: Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abasia
Other	Asthenia
Required	Cardiac Murmur
Intervention to	Cardiomegaly
Prevent Permanent	Feeling Abnormal
Impairment/Damage	Fluid Retention
	Hypertension
	Lung Disorder
	Oedema Peripheral

	Pain Scar Thyroid Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx 25 Mg Merck	PS	Merck		.25 MG /DAY	

Date:03/18/04ISR Number: 4319117-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00867
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL	107 DAY	
Initial or Prolonged	Atrial Fibrillation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	107 DAY	
	Blood Albumin Decreased		Vicodin Tablets	C			127 DAY	
	Blood Bilirubin Increased		Vicodin Tablets	C			127 DAY	
	Blood Cholesterol Increased		Darvocet-N	C				
	Blood Triglycerides Increased							
	Cardiac Aneurysm							
	Cardiac Failure							
	Congestive Colonic Pseudo-Obstruction							
	Congestive Cardiomyopathy							
	Coronary Artery Surgery							
	Dyspnoea							
	Ear Haemorrhage							
	Ear Injury							
	Ear Pain							
	Ileus							
	Injury							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Pharyngitis							
	Seborrhoeic Keratosis							
	Skin Lesion							
	Skin Papilloma							

Ventricular Tachycardia

Date:03/18/04ISR Number: 4319132-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome PT
Other Acute Sinusitis
Blood Pressure Increased
Bronchitis
Chest Pain
Dizziness
Dyspnoea
Epididymitis
Exposure To Communicable
Disease
Foot Fracture
Foreign Body Trauma
Head Injury
Heart Rate Increased
Infertility
Injury

		Limb Injury					
		Muscle Spasms					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Tinea Cruris					
		Treatment Noncompliance					
		Viral Rash					

Date:03/18/04ISR Number: 4319134-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
Initial or Prolonged		Adenomyosis	Professional	[Therapy			
Disability		Anaemia		Unspecified]	C		
		Asthenia		Claritin	C		
8	MON						
		Blood Cholesterol					
		Increased					
		Cervicitis					
		Chest Pain					
		Dizziness					
		Dyspnoea					
		Electrocardiogram Qrs					
		Complex Abnormal					
		Haemorrhagic Ovarian Cyst					
		Hyperhidrosis					
		Leiomyoma					
		Loss Of Employment					
		Low Density Lipoprotein					
		Increased					
		Metaplasia					
		Nausea					
		Pain					
		Palpitations					
		Pelvic Pain					
		Tachycardia					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Ventricular Tachycardia					

Date:03/18/04ISR Number: 4319136-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease							
	Carotid Artery Disease							
	Dementia							
	Dizziness							
	Drug Hypersensitivity							
	Eye Disorder							
	Gallbladder Disorder							
	Unevaluable Event							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/04ISR Number: 4319137-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02070
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL		155 DAY
Initial or Prolonged	Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		155 DAY
	Cardiac Failure		Chondroitin Sulfate					
	Congestive		Sodium And					
	Cardiomyopathy		Glucosamine					
	Dizziness		Hydrochloride	C				
	Dyspnoea		Lanoxin	C				
	Ejection Fraction		Premarin	C				VAGINAL
	Decreased		Lasix (Furosemide)	C				
	Electrocardiogram T Wave							
	Abnormal							
	Mitral Valve Incompetence							
	Myocardial Ischaemia							
	Nausea							
	Stress							
	Ventricular Dysfunction							

Date:03/18/04ISR Number: 4319138-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02069
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		[Therapy					
	Congestive		Unspecified]	C				
	Cholelithiasis							
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	Injury							
	Mental Disorder							
	Renal Impairment							
	Swelling							
	Urinary Tract Infection							

Date:03/18/04ISR Number: 4319139-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Agitation
Initial or Prolonged	Alcohol Poisoning
Disability	Alcohol Withdrawal
Other	Syndrome
	Alcoholic Liver Disease
	Atelectasis
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Cardiomegaly
	Chest Pain
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Coma
	Contusion

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Deep Vein Thrombosis Dermatitis Disorientation Diverticulum Dysarthria Dyspepsia Fall Gastric Disorder Gastrointestinal Haemorrhage Gastrointestinal Pain Gout Haematochezia Haemorrhage Haemorrhoids Hallucination, Visual Hepatic Cirrhosis Hepatic Encephalopathy Hepatitis Hypernatraemia Hypertension Hypotension Injury International Normalised Ratio Decreased Liver Disorder Loss Of Consciousness Mental Disorder Myocardial Infarction Oedema Peripheral Pain In Extremity Palpitations Peritonitis Peritonitis Bacterial Pleural Effusion Pneumonia Pneumonia Aspiration Polyp Prothrombin Time Prolonged Pruritus Pulmonary Oedema Rash Pruritic Rectal Haemorrhage Renal Failure Acute Respiratory Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Rhonchi
Syncope
Thrombosis
Toxicologic Test Abnormal
Varices Oesophageal

Date:03/18/04ISR Number: 4319141-2Report Type:Expedited (15-DaCompany Report #WAES 0403NZL00020
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/04ISR Number: 4319143-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		424 DAY
Initial or Prolonged	Basal Cell Carcinoma	Professional	Respaire	C				
Other	Bronchitis		Minocycline	C				
	Chest Pain		Piroxicam	C				
	Coronary Artery Disease		Prednisone	C				
	Diabetes Mellitus		Zantac	C				
	Insulin-Dependent							
	Diastolic Dysfunction							
	Dizziness							
	Drug Hypersensitivity							
	Fluid Overload							
	Haemorrhage							
	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							
	Neck Pain							
	Pulmonary Oedema							
	Rash Generalised							
	Rotator Cuff Syndrome							
	Skin Necrosis							
	Skin Ulcer							
	Syncope							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							

Date:03/18/04ISR Number: 4319144-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Abnormal Behaviour		Aspirin	C				668 DAY
	Anxiety		Warfarin	C				96 DAY
	Anxiety Disorder							
	Arterial Disorder							
	Arterial Occlusive							

Disease
Bipolar Disorder
Bipolar I Disorder
Cardiac Disorder
Cerebrovascular Accident
Chest Pain
Depression
Dyspnoea
Emotional Distress
Hypertension
Injury
Myocardial Infarction
Pain
Post-Traumatic Stress
Disorder
Spinal Osteoarthritis
Sudden Death

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/04ISR Number: 4319145-XReport Type:Expedited (15-DaCompany Report #WAES 0403USA00851
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/04ISR Number: 4319146-1Report Type:Expedited (15-DaCompany Report #WAES 0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vicodin Tablets	C				
	Antinuclear Antibody		Zyloprim	C				
	Positive		Xanax	C				
	Bundle Branch Block Right		Ecotrin	C				
	Cardiac Failure		Aspirin	C				
	Congestive		Lipitor	C				
	Carotid Bruit		Ultram	C				
	Cerebral Infarction		Carisoprodol	C				
	Colonic Polyp		Vasotec	C				
	Constipation		Micronase	C				
	Deafness Neurosensory		Prevacid	C				
	Gastric Ulcer Haemorrhage		Glucophage	C				
	Gastritis		Centrum	C				
	Gastritis Erosive							
	Haemorrhoids							
	Hiatus Hernia							
	Hypoacusis							
	Incisional Hernia							
	Metaplasia							
	Myocardial Infarction							
	Renal Failure							
	Small Intestinal Obstruction							

Date:03/18/04ISR Number: 4319148-5Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00156
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Aspiration	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Cardiac Arrest	Amlodipine Besylate	C		ORAL
	Decubitus Ulcer	Betahistine Maleate	C		ORAL
	Duodenal Ulcer	Citalopram	C		ORAL
	Haemorrhage				
	Pneumonia				
	Post Procedural Complication				
	Staphylococcal Infection				

Date:03/18/04ISR Number: 4319149-7Report Type:Expedited (15-DaCompany Report #WAES 0309USA02509
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Angina Pectoris
	Blood Triglycerides

		Increased					
		Calculus Ureteric					
		Cardiac Arrest					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Coronary Artery Stenosis	Professional	Methotrexate	C		
		Feeling Abnormal		Berplex Plus	C		
		Hypercholesterolaemia		Prednisone	C		
		Hyperhidrosis					
		Hypotension					
		Oesophagitis					
		Oral Pain					
		Ventricular Fibrillation					
		Ventricular Hypokinesia					
		Ventricular Tachycardia					

Date:03/18/04ISR Number: 4319150-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Arterial Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Aspirin	C		
		Depression					
		Emotional Distress					
		Injury					
		Mental Disorder					
		Muscle Spasms					
		Myocardial Infarction					
		Pain In Extremity					
		Sleep Disorder					

Date:03/18/04ISR Number: 4319151-5Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00097
Age:51 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
17	DAY						
Hospitalization -		Gastric Ulcer		Propoxyphene			
Initial or Prolonged		Gastric Ulcer Haemorrhage		Hydrochloride And			

	Gastrointestinal		Acetaminophen	C	ORAL
	Haemorrhage		Amlodipine Besylate	C	ORAL
			Tramadol Hydrochloride	C	ORAL
			Aspirin	C	
			Ranitidine	C	ORAL

Date:03/19/04ISR Number: 4319628-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02063
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Cholesterol	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Increased		[Therapy			
	Dyspepsia		Unspecified]	C		
	Emotional Distress		Aspirin	C		
	Fibromyalgia		Wellbutrin	C		
	Gallbladder Disorder		Codeine	C		
	Heart Rate Irregular		Lovastatin	C		
	Myocardial Infarction		Naproxen	C		
	Nausea					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4319649-XReport Type:Expedited (15-DaCompany Report #WAES 0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Distension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Plendil	C				
	Blood Pressure Inadequately Controlled		Dyazide	C				
	Carpal Tunnel Syndrome							
	Cerebrovascular Accident							
	Constipation							
	Dyspepsia							
	Emotional Distress							
	Fatigue							
	Haematochezia							
	Hyperlipidaemia							
	Hypersensitivity							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Myalgia							
	Myoclonus							
	Osteopenia							
	Peptic Ulcer							
	Simple Partial Seizures							
	Urine Flow Decreased							
	Weight Increased							

Date:03/19/04ISR Number: 4319652-XReport Type:Expedited (15-DaCompany Report #WAES 01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY
	Blood Pressure Fluctuation							
	Cardiovascular Disorder							
	Convulsion							
	Haematemesis							
	Motor Dysfunction							

	Oedema Renal Failure Tremor

Date:03/19/04ISR Number: 4319654-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Acute Prerenal Failure Acute Respiratory Failure Asthma Blood Glucose Increased Cardiac Failure Congestive Chronic Obstructive Pulmonary Disease

		Depression					
		Dilatation Atrial					
		Heart Rate Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypothyroidism	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Flexeril	C		
		Osteoarthritis		Vasotec	C		
		Pericardial Effusion		Lasix (Furosemide)	C		
		Pneumonia		Brethine	C		
		Pulmonary Oedema		Glipizide	C		
		Respiratory Disorder		Actos	C		
		Sinus Tachycardia		K-Dur	C		
		Sleep Apnoea Syndrome		Altace	C		
		Tachycardia					

Date:03/19/04ISR Number: 4319655-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
Disability	Aortic Valve Sclerosis
Other	Arthralgia
	Cerebral Haemorrhage
	Cerebral Infarction
	Chest Pain
	Chronic Fatigue Syndrome
	Deafness
	Depression
	Dilatation Atrial
	Diplopia
	Duodenitis
	Dysarthria
	Dyspnoea
	Endocarditis
	Gallbladder Disorder
	Gastritis
	Gastrooesophageal Reflux
	Disease
	Generalised Anxiety
	Disorder
	Haemorrhagic Stroke
	Herpes Zoster
	Hypertension
	Hypertensive Crisis

Hypoacusis
Hypoaesthesia
Irritable Bowel Syndrome
Lacunar Infarction
Low Density Lipoprotein
Increased
Migraine
Migraine With Aura
Mitral Valve
Calcification
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Nuclear Magnetic
Resonance Imaging Brain
Abnormal
Pain In Jaw

		Panic Disorder					
		Sleep Apnoea Syndrome					
		Thalamus Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Attack	Professional	Aspirin	C		
		Ventricular Hypertrophy		Aspirin	C		
				Tagamet	C		
				Premarin	C		
				Hytrin	C		
				Estratab	C		
				L-Thyroxin	C		
				Ranitidine	C		

Date:03/19/04ISR Number: 4319657-9Report Type:Expedited (15-DaCompany Report #WAES 01104508
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Asthma		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Zocor	C		
		Blood Pressure					
		Fluctuation					
		Cardiovascular Disorder					
		Chronic Obstructive					
		Pulmonary Disease					
		Emotional Distress					
		Headache					
		Injury					
		Muscle Atrophy					
		Oedema					
		Pain					
		Renal Failure					
		Somnolence					

Date:03/19/04ISR Number: 4319660-9Report Type:Expedited (15-DaCompany Report #WAES 0302USA00108
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

Disability	Arterial Thrombosis
Other	Asthma
	Atherosclerosis
	Cardiac Failure
	Congestive
	Cardiomegaly
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Confusional State
	Congestive Cardiomyopathy
	Depression
	Dizziness
	Emotional Distress
	Gastrointestinal
	Haemorrhage
	Glaucoma
	Headache
	Hypoacusis

		Kidney Infection					
		Myalgia					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure Chronic	Professional	Ibuprofen	C		
		Sleep Apnoea Syndrome		Insulin	C		
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Vertigo					
		Weight Increased					

Date:03/19/04ISR Number: 4319661-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02146
Age:78 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
		Adverse Event					
		Arrhythmia					
		Arthropathy					
		Atrial Fibrillation					
		Diverticulitis					
		Gastrointestinal Disorder					
		Heart Rate Irregular					
		Injury					
		Knee Arthroplasty					
		Muscle Spasms					
		Prostate Cancer					

Date:03/19/04ISR Number: 4319663-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acidosis
Disability	Arthritis
Other	Asthenia
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased

Breath Sounds Decreased
Cardiomegaly
Cartilage Injury
Chondromalacia
Depressed Level Of
Consciousness
Diabetes Mellitus
Dialysis
Duodenal Ulcer
Dyspnoea
Emotional Distress
Fatigue
Fluid Retention
Hypocalcaemia
Hypotension
Hypotonia
Injury
Localised Infection
Meniscus Lesion

		Mental Status Changes					
		Monarthritis					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral	Professional	Zocor	SS		ORAL
		Renal Failure		[Therapy			
		Renal Tubular Necrosis		Unspecified]	C		
		Rhabdomyolysis		Tylenol Arthritis			
		Rotator Cuff Syndrome		Extended Relief	C		
		Stupor		Lasix (Furosemide)	C		
		Swelling		Glyburide	C		
		X-Ray Limb Abnormal		Glucophage	C		
				Accupril	C		

Date:03/19/04ISR Number: 4319666-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acute Myocardial	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Chills		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Lipitor	C		
3142 DAY							
		Reocclusion		Lotensin	C		
		Coronary Artery Stenosis		Lotensin	C		
		Depression		Vasotec	C		ORAL
3507 DAY							
		Dyslipidaemia		Vasotec	C		ORAL
3507 DAY							
		Flank Pain		Prozac	C		
		Hyperhidrosis		Prozac	C		
		Hyperlipidaemia		Prozac	C		
		Hypertension		Ginseng	C		
		Ischaemia		Naproxen	C		
		Osteoarthritis		Accupril	C		
		Stress		Accupril	C		
		Ventricular Hypokinesia					

Date:03/19/04ISR Number: 4319667-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Arterial Occlusive Disease
	Barrett'S Oesophagus
	Burning Sensation
	Bursitis
	Cerebrovascular Accident
	Dizziness
	Dyspnoea
	Emotional Distress
	Exostosis
	Gastritis
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Hypertension
	Injury

		Joint Sprain					
		Lacunar Infarction					
		Meniscus Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophageal Achalasia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophagitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Herbs (Unspecified)	C		
840	DAY						
		Pain In Extremity		Prilosec	C		
		Peripheral Vascular Disorder					
		Rectal Polyp					
		Synovitis					
		Tachycardia					
		Transient Ischaemic Attack					
		Tremor					
		Vertebral Artery Occlusion					

Date:03/19/04ISR Number: 4319668-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Ankle Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Tylenol With Codeine	C		
		Fibromyalgia					
		Headache					
		Hypertension					
		Injury					
		Intervertebral Disc Degeneration					
		Labyrinthitis					
		Liver Disorder					
		Localised Infection					
		Lumbar Spinal Stenosis					
		Lung Disorder					
		Pneumonia					
		Tooth Infection					
		Urinary Retention					
		Wound Infection					

Date:03/19/04ISR Number: 4319669-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02055
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable
Other	Anxiety
	Aortic Valve Incompetence
	Atrial Fibrillation
	Atrioventricular Block
	First Degree
	Blood Pressure
	Inadequately Controlled
	Cardiomyopathy
	Cardiovascular Disorder
	Chronic Obstructive

	Pulmonary Disease Coronary Artery Atherosclerosis Emotional Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache	Health	Vioxx	PS	Merck & Co., Inc	ORAL	33 DAY
	Heart Rate Increased Heart Rate Irregular Hypercholesterolaemia Hypertension Hypertensive Crisis Injury Lacunar Infarction Mitral Valve Incompetence Sinus Bradycardia Transient Ischaemic Attack Tricuspid Valve Incompetence	Professional	Acyclovir Ascorbic Acid Hydrochlorothiazide And Triamterene Vitamin B Complex Vitamin E Vitamin D (Unspecified) Vitamin A Adalat Phenazopyridine Hydrochloride	C C C C C C C C C			

Date:03/19/04ISR Number: 4319676-2Report Type:Expedited (15-DaCompany Report #WAES 0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Cardiac Valve Disease Chronic Obstructive Pulmonary Disease Coronary Arterial Stent Insertion Coronary Artery Occlusion Emotional Distress Myocardial Infarction Oedema Peripheral Overdose Renal Failure Renal Injury Sleep Disorder	Consumer	Vioxx Aspirin Coreg Insulin	PS C C C	Merck & Co., Inc	ORAL	

Date:03/19/04ISR Number: 4319677-4Report Type:Expedited (15-DaCompany Report #WAES 0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Abdominal Distension Angina Pectoris Aspartate Aminotransferase Increased Atelectasis Blood Bilirubin Increased Blood Ph Decreased Blood Pressure Decreased Blood Pressure Systolic Decreased Blood Pressure Systolic Increased Body Temperature Decreased Body Temperature Increased Bronchopneumonia Cardiac Failure

	Congestive						
	Cardiomegaly						
	Cerebrovascular Accident						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chronic Fatigue Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL	560	DAY
	Dyspnoea	Professional	Amitriptyline					
	False Positive Laboratory		Hydrochloride	C				
	Result		Celexa	C				
	Fatigue		Nexium	C				
	Fluid Retention		Lasix (Furosemide)	C				
	Haematochezia		Lasix (Furosemide)	C				
	Haematocrit Decreased		Zanaflex	C				
	Haemoglobin Decreased		Ultram	C				
	Heart Rate Increased		Ambien	C				
	Hypercholesterolaemia		Diovan	C				
	Hyperlipidaemia		Torsemide	C				
	Hypertension		Neurontin	C				
	Hypoxia		Zaroxolyn	C				
	Ileus		Aleve	C				
	Kidney Small		Oxycontin	C				
	Lobar Pneumonia		Potassium Chloride	C				
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Myocardial Infarction							
	Pco2 Increased							
	Pleural Effusion							
	Pneumonia Staphylococcal							
	Rash							
	Renal Failure							
	Renal Failure Acute							
	Respiratory Failure							
	Respiratory Rate Increased							
	Rhabdomyolysis							
	Sinusitis							
	Staphylococcal Infection							
	Swelling							
	Ventricular Hypokinesia							

Date:03/19/04ISR Number: 4319679-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial

Initial or Prolonged	Infarction
Other	Aortic Valve Incompetence
	Atrioventricular Block
	Complete
	Bacteria Urine Identified
	Blood Pressure Increased
	Bunion
	Cardiac Arrest
	Cervical Dysplasia
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Drug Hypersensitivity
	Haematuria
	Hypothyroidism
	Injury
	Klebsiella Infection

		Micturition Urgency					
		Mitral Valve Incompetence					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Rash	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage		Tylenol	C		
		Sinus Bradycardia		Estradiol	C		ORAL
		Spinal Column Stenosis		Synthroid	C		ORAL
		Spinal Osteoarthritis		Provera	C		ORAL
		Toe Deformity					
		Urinary Tract Infection					
		Uterine Leiomyoma					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		White Blood Cells Urine					
		Positive					

Date:03/19/04ISR Number: 4319680-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00766
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
				Advil	C		

Date:03/19/04ISR Number: 4319681-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
14 DAY							
		Depression					
		Emotional Distress					
		Injury					
		Oedema Peripheral					

Date:03/19/04ISR Number: 4319682-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Anorexia
	Antiphospholipid Antibodies Positive
	Atrial Fibrillation
	Blood Cholesterol Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Blood Pyruvic Acid Decreased
	Blood Sodium Decreased
	Blood Thyroid Stimulating Hormone Decreased
	Bone Marrow Depression
	Breast Cyst
	Cerebral Infarction
	Cerebrovascular Accident
	Chest X-Ray Abnormal
	Chronic Sinusitis

		Colonic Polyp					
		Contusion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Enuresis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Epilepsy		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	
		Fatigue		[Therapy			
		Feeling Abnormal		Unspecified]	C		
		Felty'S Syndrome		Tylenol	C		
		Gastrointestinal Disorder		Proventil	C		
		Herpes Zoster		Allopurinol	C		
		Herpes Zoster Ophthalmic		Elavil	C		ORAL
		Hiatus Hernia		Fiorinal With			
		Hypercoagulation		Codeine	C		
		Infection In An		Azathioprine	C		
		Immunocompromised Host		Tegretol	C		
		Infrequent Bowel		Tegretol	C		
		Movements		Tegretol	C		
		Keratitis Herpetic		Zyrtec	C		
		Mitral Valve Incompetence		Advil	C		
		Neutrophil Toxic		Remicade	C		
INTRAVENOUS							
		Granulation Present		Purinethol	C		
		Nocturia		Methotrexate	C		
		Pain		Prilosec	C		
		Pancytopenia		K-Dur	C		
		Pleuritic Pain		Triamterene	C		
		Polyp		Prednisone	C		
		Purulence					
		Pyrexia					
		Reflux Oesophagitis					
		Renal Pain					
		Rheumatoid Arthritis					
		Rib Fracture					
		Shift To The Left					
		Sinus Polyp					
		Sinusitis					
		Urine Ketone Body Present					
		Urobilin Urine					
		Viral Infection					
		Weight Decreased					

Date:03/19/04ISR Number: 4319684-1Report Type:Expedited (15-DaCompany Report #WAES 0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
	Arthritis
	Atelectasis
	Blood Cholesterol Increased
	Cardiac Valve Disease
	Cardiomegaly
	Coronary Artery Disease
	Coronary Artery Stenosis
	Diabetes Mellitus
	Emotional Distress
	Facet Joint Syndrome

		Graft Thrombosis					
		Hand Fracture					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Lumbar Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL
		Nervousness		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		[Therapy			
		Platelet Count Decreased		Unspecified]	C		
		Pleural Effusion		Norco	C		
		Raynaud'S Phenomenon		Atenolol	C		
		Renal Artery Stenosis		Tenormin	C		
		Respiratory Failure		Celebrex	C		
		Sciatica		Celebrex	C		
		Spinal Column Stenosis		Diovan	C		
		Thrombosis		Ultram	C		
				Avandia	C		
				Chlorthalidone	C		
				Hygroton	C		
				Cyclobenzaprine			
				Hydrochloride	C		
				Cardizem	C		
				Propecia	C		
				Glucovance	C		
				Hydrocodone			
				Hydrochloride	C		

Date:03/19/04ISR Number: 4319685-3Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
	Aortic Aneurysm
	Barrett'S Oesophagus
	Blood Chloride Increased
	Blood Glucose Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Cardiac Failure
	Congestive

Cardiomyopathy
Chest Pain
Chronic Fatigue Syndrome
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Dizziness
Duodenal Ulcer
Duodenitis
Dyspepsia
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Headache
Helicobacter Infection

		Hypercholesterolaemia					
		Hyperhidrosis					
		Hypertriglyceridaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypogonadism	Health	Vioxx	PS	Merck & Co., Inc	ORAL
39	DAY						
		Mitral Valve Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
39	DAY						
		Peptic Ulcer		Tylenol Pm	C		
		Reflux Oesophagitis		Tagamet	C		
		Sinus Tachycardia		Zocor	C		ORAL
		Supraventricular		Tagamet	C		
		Extrasystoles		Plavix	C		
		Tendonitis		Cardura	C		ORAL
		Ventricular Extrasystoles					
		Weight Decreased					

Date:03/19/04ISR Number: 4319686-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00818
Age:34 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Cyclobenzaprine			
		Depression		Hydrochloride	C		
		Disturbance In Attention		Skelaxin	C		
		Emotional Distress		Naproxen	C		
		Hypertension					
		Impaired Work Ability					
		Stress					

Date:03/19/04ISR Number: 4319688-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Anxiety
Other	Arthralgia
	Atherosclerosis
	Back Disorder
	Back Pain

Cardiac Failure
Congestive
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Coronary Artery Disease
Depression
Drug Effect Decreased
Dyspnoea
Ejection Fraction
Decreased
Emotional Distress
Fatigue
Fear
Headache
High Density Lipoprotein
Decreased
Hyperlipidaemia
Hypertension
Hypotension

		Insomnia					
		Loss Of Consciousness					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Spasms	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Lortab	C		
		Neck Pain		Amitriptyline			
		Osteoarthritis		Hydrochloride	C		
874	DAY						
		Pain		Amitriptyline			
		Panic Attack		Hydrochloride	C		
874	DAY						
		Paraesthesia		Celebrex	C		
362	DAY						
		Pyrexia		Trazodone			
		Sinus Bradycardia		Hydrochloride	C		
1291	DAY						
		Vision Blurred		Trazodone			
				Hydrochloride	C		
1291	DAY						
				Cipro	C		
				Neurontin	C		
				Hydrocodone			
				Bitartrate	C		
				Lorazepam	C		
2	DAY						
				Methocarbamol	C		
957	DAY						

Date:03/19/04ISR Number: 4319691-9Report Type:Expedited (15-DaCompany Report #WAES 0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Glucose Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased Appetite		Lidocaine And			
		Drug Ineffective		Triamcinolone			
		Gastric Disorder		Acetonide	C		
PARENTERAL		1	DAY				
		Haemoglobin Decreased		Glucophage Xr	C		ORAL
		Hypertension		Glucophage Xr	C		

Joint Dislocation Labyrinthitis Lower Limb Fracture Mitral Valve Incompetence Overdose Pain Pharyngolaryngeal Pain Rhinorrhoea Sinus Disorder Sinusitis Treatment Noncompliance Tricuspid Valve Incompetence Ventricular Hypertrophy White Blood Cell Count Increased	Glucophage Xr	C	ORAL

Date:03/19/04ISR Number: 4319693-2Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00090
Age:43 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Blood Creatine	Professional	[Therapy					
	Phosphokinase Mb		Unspecified]	C				
	Increased		Atropine	C				
	Coma Hepatic		Dobutamine					
	Confusional State		Hydrochloride	C				
	Depression		Dopamine					
	General Physical Health		Hydrochloride	C				
	Deterioration		Epinephrine					
	Haemoglobin Decreased		Hydrochloride	C				
	Hallucination		Sodium Chloride	C				
	Post Procedural		Tinzaparin Sodium	C				
	Complication		Sufentanil Citrate	C				
	Pulmonary Embolism		Sodium Bicarbonate	C				
			Heparin	C				
			Metaproterenol					
			Sulfate	C				
			Propofol	C				
			Propofol	C				

Date:03/19/04ISR Number: 4319694-4Report Type:Expedited (15-DaCompany Report #WAES 0401USA01615
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
Other	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive							
	Coronary Artery Disease							
	Disease Progression							
	Venous Pressure Jugular							
	Increased							
	Weight Increased							

Date:03/19/04ISR Number: 4319695-6Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00164
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Disturbance		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/19/04ISR Number: 4319697-XReport Type:Expedited (15-DaCompany Report #WAES 0401USA00981
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				
			Neurontin	C				

Date:03/19/04ISR Number: 4319698-1Report Type:Expedited (15-DaCompany Report #WAES 0403USA01519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4319699-3Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00166
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Nausea		Flurazepam Hydrochloride	C				
	Rash		Lansoprazole	C				
	Tremor							

Date:03/19/04ISR Number: 4319996-1Report Type:Expedited (15-DaCompany Report #WAES 01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Heparin	SS				
	Blindness		Provera	SS				
	Cataract		[Therapy Unspecified]	C				
	Cerebral Haemorrhage		Tylenol With Codeine #3	C				
	Cerebrovascular Accident		Captopril	C				
	Depressed Level Of Consciousness		Capozide	C				
	Depression		Cisapride	C				
	Embolism		Glyburide	C				
	Epistaxis							
	Flushing							
	Gastrooesophageal Reflux Disease							
	Gout							
	Haemorrhage Intracranial							
	Headache							
	Hemianopia Homonymous							
	Herpes Zoster							
	Hyperhidrosis							
	Hypertension							
	Joint Injury							
	Meningioma							
	Nasal Congestion							
	Nausea							
	Osteoarthritis							
	Pain							
	Pallor							
	Pneumonia							

Radiculopathy
Rash
Rift Valley Fever
Sciatica
Tachycardia
Thyroid Mass
Vaginal Haemorrhage
Visual Disturbance

Date:03/19/04ISR Number: 4320003-5Report Type:Expedited (15-DaCompany Report #WAES 01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Bladder Obstruction
	Cough
	Dysuria
	Encephalomalacia

		Epistaxis					
		Erectile Dysfunction					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematochezia		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		[Therapy			
		Hypertension		Unspecified]	C		
		Ileus Paralytic		Albuterol	C		
RESPIRATORY							
		Nausea					
(INHALATION)							
		Prostate Cancer		Albuterol	C		ORAL
		Rectal Haemorrhage		Allopurinol	C		
		Rectal Polyp		Ecotrin	C		
		Sinusitis		Atenolol	C		
		Spinal Column Stenosis		Mavik	C		ORAL
		Wheezing		Mavik	C		ORAL
				Palgic D	C		ORAL
				Celebrex	C		
				Guaifenex La	C		
				Hydrodiuril	C		ORAL
				Ibuprofen	C		
				Atrovent	C		

Date:03/19/04ISR Number: 4320007-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Cardiac Failure		[Therapy			
Other		Congestive		Unspecified]	C		
		Cardiomegaly		[Therapy			
		Carotid Artery Occlusion		Unspecified]	C		
		Carotid Artery Stenosis		Avandia	C		ORAL
		Cataract		Avandia	C		ORAL
		Cerebrovascular Accident		Vicoprofen	C		ORAL
		Choking Sensation		Glucophage	C		ORAL
		Contusion		Glucophage	C		ORAL
		Coordination Abnormal					
		Coronary Artery Disease					
		Difficulty In Walking					
		Diplopia					

Dyspnoea
Hallucination, Visual
Head Injury
Hypoaesthesia
Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Nasopharyngitis
Osteoarthritis
Pain In Extremity
Road Traffic Accident
Spinal Osteoarthritis
Strabismus
Toe Deformity
Vision Blurred
Whiplash Injury

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4320009-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Norvasc	C				
	Chromaturia		Aspirin	C				
	Decreased Appetite		Lipitor	C				
	Diarrhoea		Monopril	C				
	Fatigue		Indocin					
	Gout		(Indomethacin)	C				
	Heart Rate Increased		Toprol Xl Tablets	C				
	Hypertension		Lopressor	C				
	Injury		Naproxen	C				
	Insomnia							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Rectal Haemorrhage							
	Rheumatoid Arthritis							

Date:03/19/04ISR Number: 4320012-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02044
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysuria		Coumadin	C				
	Emotional Distress							
	Injury							
	Oedema Peripheral							
	Prostatitis							
	Rheumatoid Arthritis							
	Thrombosis							

Date:03/19/04ISR Number: 4320013-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Cholesterol Increased	Vioxx	PS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Bronchitis	[Therapy Unspecified]	C		
	Cataract	Acetaminophen	C		
	Cerebrovascular Accident	Percocet	C		
	Dehydration	Soma	C		
	Diarrhoea	Zyrtec	C		
	Diverticulitis	Ultram	C		
	Eye Disorder	Premarin	C		
	Fibromyalgia	Motrin	C		
	Gastroenteritis Viral	Ocuflox	C		
	Gastrointestinal Disorder	Oxycodone	C		
	Hypertension	Prednisone	C		
	Nausea				
OPHTHALMIC					
	Normochromic Normocytic Anaemia				
	Pain				
	Renal Failure Acute				
	Vomiting				

Date:03/19/04ISR Number: 4320014-XReport Type:Expedited (15-DaCompany Report #WAES 0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 80 DAY	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Aortic Calcification		[Therapy			
	Bundle Branch Block Left		Unspecified]	C		
	Cardiac Failure		Ascorbic Acid	C		
	Congestive		Calcium			
	Cardiomegaly		(Unspecified)	C		
	Congestive Cardiomyopathy		Lanoxin	C		
	Depression		Premarin	C		
	Dyspepsia		Lasix (Furosemide)	C		
	Ejection Fraction		Vitamin E	C		
	Decreased		Coumadin	C		
	Fibroadenoma Of Breast		Vitamin B			
	Gastrointestinal Tract		(Unspecified)	C		
	Adenoma		Ginkgo Biloba			
	Haemorrhoids		Extract	C		
	Hyperlipidaemia		Levocarnitine	C		
	Hypertension		Prinivil	C		ORAL
	Injury		Magnesium			
	Mood Swings		(Unspecified)	C		
	Nightmare		Pamelor	C		
	Orthopnoea					
	Pain In Extremity					
	Palpitations					
	Spinal Osteoarthritis					
	Ventricular Extrasystoles					

Date:03/19/04ISR Number: 4320015-1Report Type:Expedited (15-DaCompany Report #WAES 0301USA01135
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 433 DAY	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 433 DAY	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiovascular Disorder		Acetaminophen And			
Other	Cataract		Hydrocodone			
	Cerebrovascular Accident		Bitartrate	C		
	Depression		Celebrex	C		

Diabetes Mellitus
Emotional Distress
Eye Disorder
Glaucoma
Hypertension
Injury
Major Depression
Prostatic Disorder
Sleep Disorder
Transient Ischaemic
Attack

Date:03/19/04ISR Number: 4320017-5Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
Disability	Aortic Valve Sclerosis
	Basal Cell Carcinoma
	Blood Calcium Increased

		Blood Pressure Increased					
		Cardiac Murmur					
		Carotid Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Conduction Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Fosamax	C		ORAL
		Hyperlipidaemia		Hydrochlorothiazide	C		
		Injury					
		Loss Of Libido					
		Mitral Valve Sclerosis					
		Sexual Dysfunction					
		Sleep Apnoea Syndrome					
		Supraventricular					
		Extrasystoles					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		White Blood Cell Count					
		Increased					

Date:03/19/04ISR Number: 4320018-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Cholesterol		Premarin	C		
Other		Increased					
		Blood Pressure Increased					
		Cardiac Disorder					
		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Chronic Obstructive					
		Pulmonary Disease					
		Corneal Disorder					
		Drug Hypersensitivity					
		Fall					
		Injury					
		Lung Infection					
		Nosocomial Infection					
		Oedema Peripheral					
		Transient Ischaemic					

Attack

Date:03/19/04ISR Number: 4320019-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02132
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Injury							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4320020-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA00759
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Ineffective		Pepcid	C		ORAL		
	Headache		Iron (Unspecified)	C				
	Hip Fracture							
	Injury							
	Oedema Peripheral							
	Skin Cancer							
	Skin Graft							

Date:03/19/04ISR Number: 4320021-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00839
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Heart Rate Irregular							
	Injury							

Date:03/19/04ISR Number: 4320022-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Balance Disorder		Aspirin	C				
Other	Basal Cell Carcinoma		Celexa	C				
	Disturbance In Attention		Lexapro	C				
	Emotional Distress		Synthroid	C				
	Generalised Anxiety		Niacin	C				
14671DAY								
	Disorder							
	Headache							
	Impaired Work Ability							
	Lacunar Infarction							
	Mobility Decreased							
	Oesophageal Spasm							
	Pain In Extremity							

Reading Disorder
Refusal Of Treatment By
Patient
Thrombosis
Vision Blurred

Date:03/19/04ISR Number: 4320023-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02043
Age:59 YR Gender:Male I/FU:F

Outcome PT
Disability Anxiety
Arrhythmia
Back Pain
Blood Pressure Diastolic
Decreased
Blood Pressure Systolic
Increased
Cerebral Ischaemia
Cerebrovascular Accident
Coronary Artery Disease

		Depression					
		Disturbance In Attention					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL
2	WK						
		Hemiparesis		Cimetidine	C		
		Mania		Flexeril	C		
		Respiratory Rate		Cardizem	C		
		Increased		Micronase	C		
		Sleep Disorder		Ibuprofen	C		
		Spinal Column Stenosis		Prinivil	C		
		Vocal Cord Atrophy		Metformin	C		
				Pravachol	C		

Date:03/19/04ISR Number: 4320024-2Report Type:Expedited (15-DaCompany Report #WAES 0401DEU00111
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Accelerated		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
Hospitalization -		Idioventricular Rhythm		Amlodipine Besylate	C		ORAL
Initial or Prolonged		Angioneurotic Oedema		Aspirin	C		ORAL
		Blood Pressure Increased		Doxepin			
		Blood Sodium Decreased		Hydrochloride	C		
		Bronchitis		Isosorbide			
		Cardiac Failure		Mononitrate	C		ORAL
		Cardiomegaly		Zocor	C		ORAL
		Dilatation Ventricular		Valsartan	C		ORAL
		Electrocardiogram		Magnesium Aspartate			
		Repolarisation		And Potassium			
		Abnormality		Aspartate	C		ORAL
		Lung Infiltration		Metoprolol Succinate	C		ORAL
		Mitral Valve Incompetence		Moxonidine	C		ORAL
		Pleural Effusion		Nafronyl Oxalate	C		ORAL
		Pulmonary Congestion					
		Rales					
		Respiratory Depression					
		Respiratory Failure					
		Tricuspid Valve					
		Incompetence					
		Ventricular Failure					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					

Weight Decreased

Date:03/19/04ISR Number: 4320025-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 125 DAY	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrooesophageal Reflux		Coricidin	C		
Other	Disease		Allegra-D	C		
	Injury		Flonase	C		
	Pain		Westcort	C		
	Pulmonary Embolism		Singulair	C		
	Skin Ulcer		Elidel	C		
	Sleep Apnoea Syndrome					
	Venous Stasis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4320027-8Report Type:Expedited (15-DaCompany Report #WAES 0403AUT00008
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Feeling Abnormal Flushing		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/19/04ISR Number: 4320028-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Distension Acute Myocardial Infarction Acute Respiratory Failure Agitation Angina Pectoris Arthralgia Atrial Tachycardia Back Pain Bacteria Urine Identified Blood Sodium Increased Brain Hypoxia Breath Sounds Decreased Cardiac Arrest Cardiac Failure Congestive Cardiac Murmur Cardiogenic Shock Chest Pain Coronary Artery Atherosclerosis Coronary Artery Disease Coronary Artery Occlusion Coronary Artery Stenosis Dilatation Ventricular Dyspnoea At Rest Electrocardiogram Qrs Complex Prolonged Emotional Distress Encephalopathy Gallop Rhythm Present Haematocrit Decreased

Haematoma
Haemoglobin Decreased
Heart Rate Abnormal
Heart Sounds Abnormal
Hepatic Failure
Hypercholesterolaemia
Hyperphosphataemia
Hypokalaemia
Hyponatraemia
Hypoperfusion
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Loss Of Consciousness
Lung Infiltration
Mental Status Changes

		Multi-Organ Failure					
		Oedema Peripheral					
		Orthopnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pacemaker Generated		Vioxx	PS	Merck & Co., Inc	ORAL
		Rhythm		Oxycodone	C		
		Pain		Ultram	C		
		Panic Attack		Diovan	C		
		Panic Disorder		Zantac	C		
		Pleural Effusion					
		Proteus Infection					
		Pulmonary Oedema					
		Pupil Fixed					
		Pyrexia					
		Rales					
		Renal Failure					
		Renal Failure Acute					
		Screaming					
		Thrombocytopenia					
		Urinary Tract Infection					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		Ventricular Tachycardia					
		Visual Disturbance					

Date:03/19/04ISR Number: 4320031-XReport Type:Expedited (15-DaCompany Report #WAES 0403USA01237
Age:40 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Aspirin	C		
		Cardiac Failure		Celebrex	C		
		Congestive		Ambien	C		
		Depression		Meridia	C		
		Emotional Distress		Antivert	C		
		Gastric Disorder		Relafen	C		
		Gastric Ulcer		Naproxen	C		
		Hypertension					
		Injury					
		Prescribed Overdose					

Date:03/22/04ISR Number: 4320791-8Report Type:Expedited (15-DaCompany Report #WAES 0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased
Disability	Aspartate
Other	Aminotransferase
	Increased
	Blood Creatine
	Phosphokinase Increased
	Blood Pressure
	Inadequately Controlled
	Blood Thyroid Stimulating
	Hormone Increased
	Blood Uric Acid Increased
	Carotid Artery Occlusion

		Cerebral Infarction					
		Cerebrovascular Accident					
		Comminuted Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cough		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Lipitor	C		
		Dizziness		Lipitor	C		
		Dysphoria					
		Eye Injury					
		Fall					
		Fatigue					
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Hypertriglyceridaemia					
		Joint Sprain					
		Left Ventricular Failure					
		Loss Of Consciousness					
		Nausea					
		Pain					
		Pain In Extremity					
		Radius Fracture					
		Restlessness					
		Rib Fracture					
		Syncope					
		Syncope Vasovagal					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Weight Increased					
		Wheezing					

Date:03/22/04ISR Number: 4320793-1Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00202
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Gastric Ulcer Haemorrhage		Amiloride			
Initial or Prolonged		Haematemesis		Hydrochloride And			
		Melaena		Furosemide	C		ORAL
				Amiloride			

Hydrochloride And Furosemide	C	ORAL
Aspirin	C	ORAL
Calcium Carbonate And Cholecalciferol	C	ORAL
Tolterodine	C	ORAL
Tolterodine	C	ORAL
Cholecalciferol And Calcium Carbonate	C	ORAL
Levothyroxine Sodium	C	ORAL
Levothyroxine Sodium	C	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4320797-9Report Type:Expedited (15-DaCompany Report #WAES 0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Chromaturia		[Composition					
	Chronic Fatigue Syndrome		Unspecified]	C				
	Convulsion		Baycol	C				
	Depression		Actos	C				
	Difficulty In Walking							
	Disturbance In Attention							
	Dizziness							
	Drug Hypersensitivity							
	Emotional Distress							
	Fatigue							
	General Physical Health							
	Deterioration							
	Hypertension							
	Injury							
	Mental Status Changes							
	Mood Altered							
	Musculoskeletal Stiffness							
	Oedema							
	Oedema Peripheral							
	Pain In Extremity							
	Syncope							

Date:03/22/04ISR Number: 4320807-9Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00068
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombophlebitis		Diacerein	C		ORAL		

Date:03/22/04ISR Number: 4320812-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Cardiomegaly
	Coronary Artery Atherosclerosis
	Coronary Artery Stenosis
	Dilatation Ventricular
	Dyslipidaemia
	Electrocardiogram St Segment Elevation
	Fall
	Loose Body In Joint
	Mitral Valve Incompetence
	Muscular Weakness
	Myalgia

		Peripheral Coldness					
		Road Traffic Accident					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scapula Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Skin Laceration		Atenolol	C		
		Spinal Osteoarthritis		Zyrtec	C		
		Supraventricular		Celexa	C		
		Extrasystoles		Flonase	C		
		Tendonitis		Hydrocodone			
		Ventricular Dysfunction		Bitartrate	C		
				Levsin	C		
				Indocin			
				(Indomethacin)	C		ORAL
				Naproxen	C		
				Prilosec	C		
				Oxycontin	C		
				Aciphex	C		

Date:03/22/04ISR Number: 4320819-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Disorder		Tylenol	C		
		Gastric Disorder		Augmentin	C		
		Gastrointestinal Disorder		Clonazepam	C		
		Hypertension		Diabeta	C		
		Osteoarthritis		Coumadin	C		
		Skin Infection		Zestril	C		
		Sleep Disorder		Reglan	C		
				Aciphex	C		
				Ranitidine	C		

Date:03/22/04ISR Number: 4321170-XReport Type:Expedited (15-DaCompany Report #WAES 01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abnormal Dreams
Initial or Prolonged	Back Pain
	Blood Pressure Increased

Condition Aggravated
Confusional State
Depression
Disturbance In Attention
Dizziness
Drug Ineffective
Emotional Distress
Fall
Fear
Headache
Heart Rate Increased
Malaise
Muscle Spasms
Muscle Strain
Musculoskeletal Stiffness
Nausea
Neck Pain
Pain

		Renal Failure					
		Respiratory Disorder					
		Sciatica	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
27	DAY						
		Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL
27	DAY						
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vicodin Tablets	C		
				Elavil	C		
				Atenolol	C		
				Celebrex	C		
				Plavix	C		
				Calan Sr	C		
				Ultram	C		
				Zoloft	C		
				Zoloft	C		
				Flexeril	C		
21	DAY						
				Flexeril	C		
13	DAY						
				Flexeril	C		
				Premarin	C		
				Pepcid	C		ORAL
				Dyazide	C		
				Accupril	C		

Date:03/22/04ISR Number: 4321172-3Report Type:Expedited (15-DaCompany Report #WAES 01101051
Age:74 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
Hospitalization -		Aortic Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
1	MON						
Initial or Prolonged		Aortic Valve Disease		Coumadin	SS		
		Arthropathy		Allopurinol	C		
		Atrial Fibrillation		Celebrex	C		
2	WK						
		Blood Bilirubin Increased		Colchicine	C		
		Blood Pressure Decreased		Lanoxin	C		
		Cardiac Failure		Lasix (Furosemide)	C		

Congestive	Skelaxin	C
Cardiomegaly	K-Lor	C
Carotid Artery Disease		
Chronic Obstructive		
Pulmonary Disease		
Congestive Cardiomyopathy		
Diverticulum Intestinal		
Haemorrhagic		
Gastrooesophageal Reflux		
Disease		
Grunting		
Heart Rate Increased		
Hypovolaemic Shock		
Iron Deficiency Anaemia		
Lower Gastrointestinal		
Haemorrhage		
Mitral Valve Disease		
Myocardial Infarction		
Oxygen Saturation		
Decreased		
Rectal Haemorrhage		
Renal Cyst		
Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321174-7Report Type:Expedited (15-DaCompany Report #WAES 0209USA01335
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anorexia		Darvocet-N	C				
	Arrhythmia		Aspirin	C				
	Supraventricular		Plavix	C				
	Bradycardia		Vasotec	C		ORAL		
	Cardiac Failure		Imdur	C				
	Congestive		Zocor	C		ORAL		
	Cardiogenic Shock		Mylicon	C		ORAL		
	Carotid Artery Stenosis		Synthroid	C				
	Chronic Obstructive		Synthroid	C				
	Pulmonary Disease		Synthroid	C				
	Coronary Artery Disease		Synthroid	C				
	Fatigue		Levothroid	C				
	Haemodynamic Instability		Zestril	C				
	Heart Rate Irregular		Nitroglycerin	C				
	Hypertension							
	Muscle Spasms							
	Palpitations							
	Post Procedural							
	Complication							
	Postoperative Infection							
	Pulmonary Oedema							
	Rales							
	Renal Failure							
	Ventricular Arrhythmia							
	Ventricular Extrasystoles							
	Weight Decreased							
	Wound Infection							
	Staphylococcal							

Date:03/22/04ISR Number: 4321177-2Report Type:Expedited (15-DaCompany Report #WAES 0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Other	Acute Myocardial

Infarction
Asthenia
Atelectasis
Back Injury
Benign Breast Neoplasm
Blood Potassium Increased
Bronchitis
Carcinoma In Situ Of Skin
Chest Injury
Chest Pain
Coronary Artery Disease
Deep Vein Thrombosis
Diarrhoea
Dizziness
Drug Hypersensitivity
Dyspepsia
Enterocele

		Fall					
		Gastrointestinal Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Tylenol	C		
		Hiatus Hernia		Z-Pak	C		
		Hypoaesthesia		Cipro	C		
		Intervertebral Disc Degeneration		Diuretic (Unspecified)	C		
		Migraine		Dyazide	C		
		Osteoarthritis		Advil	C		
		Pulmonary Embolism		Triamterene	C		
		Radius Fracture		Prevacid	C		
		Renal Failure Acute		Asacol	C		
		Renal Failure Chronic		Naproxen	C		
		Rotator Cuff Syndrome		Ditropan	C		
		Squamous Cell Carcinoma Of Skin		Quinidine	C		
		Thrombosis		Quinine Sulfate	C		
		Transient Ischaemic Attack					
		Ulna Fracture					
		Urinary Tract Infection					
		Visual Disturbance					

Date:03/22/04ISR Number: 4321178-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
		Anxiety		Allopurinol	C		
		Arrhythmia		Advil	C		
		Arthralgia		Indocin (Indomethacin)	C		ORAL
		Asthenia		Noritate	C		
		Back Pain					
		Chest Pain					
		Dermatitis					
		Diarrhoea					
		Drug Ineffective					
		Dyspnoea					
		Emotional Distress					
		Eye Pain					

Fatigue
Headache
Hypoaesthesia
Hypotension
Injury
Intercostal Neuralgia
Mental Disorder
Nausea
Pain In Extremity
Paraesthesia
Rosacea
Silent Myocardial
Infarction
Sinusitis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321179-6Report Type:Expedited (15-DaCompany Report #WAES 0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Thromboplastin Time		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
Disability	Prolonged		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Aortic Dissection		Amoxicillin	C				
	Asthenia		Viagra	C				
	Atelectasis		Chlorhexidine Hydrochloride	C				
	Depression		Hydrocodone Bitartrate	C				
	Disturbance In Attention		Lorazepam	C				
	Dizziness							
	Emotional Distress							
	Enterobacter Pneumonia							
	Gastrooesophageal Reflux Disease							
	General Physical Condition Abnormal							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hyperhidrosis							
	Hypertension							
	Iliac Artery Thrombosis							
	Impaired Healing							
	Injury							
	Irritability							
	Keloid Scar							
	Lung Infiltration							
	Pain							
	Pharyngolaryngeal Pain							
	Platelet Count Decreased							
	Pneumonia							
	Prothrombin Time Prolonged							
	Self Esteem Decreased							
	Sexual Dysfunction							
	Vascular Injury							

Date:03/22/04ISR Number: 4321180-2Report Type:Expedited (15-DaCompany Report #WAES 0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Pulmonary Oedema
Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Anxiety
	Arrhythmia
	Atelectasis
	Blood Cholesterol
	Increased
	Blood Pressure Increased
	Bundle Branch Block Right
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Coronary Artery Disease
	Depression
	Diabetes Mellitus

		Inadequate Control					
		Diabetic Ketoacidosis					
		Emotional Distress					
		Hyperkinesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
5	MON						
		Influenza		Aspirin	C		
		Mitral Valve Incompetence		Lasix (Furosemide)	C		
		Myocardial Infarction		Glucotrol Xl	C		
		Nasopharyngitis		Glyburide	C		
		Palpitations		Ativan	C		
		Respiratory Rate		Lopressor	C		
		Increased		Orphenadrine	C		
		Rotator Cuff Syndrome					
		Sinus Tachycardia					
		Supraventricular					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Ventricular Hypertrophy					
		Vision Blurred					
		White Blood Cell Count					
		Increased					

Date:03/22/04ISR Number: 4321183-8Report Type:Expedited (15-DaCompany Report #WAES 0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Arthralgia
Disability	Arthropathy
	Atrial Fibrillation
	Back Pain
	Basal Cell Carcinoma
	Blood Potassium Decreased
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Chest Discomfort
	Chest Pain
	Cough
	Drug Ineffective

Drug Intolerance
Ecchymosis
Electrocardiogram T Wave
Amplitude Decreased
Exercise Tolerance
Decreased
Hepatitis
Hypercholesterolaemia
Hypertension
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Muscle Spasms

		Myalgia					
		Non-Cardiac Chest Pain					
		Pain In Extremity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radiculitis Cervical		Vioxx	PS	Merck & Co., Inc	ORAL
		Recurrent Cancer		Vioxx	SS	Merck & Co., Inc	
		Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	
		Rotator Cuff Syndrome		[Therapy			
		Spinal Osteoarthritis		Unspecified]	C		
		Ventricular Extrasystoles		Acyclovir	C		
		Viral Upper Respiratory		Vitamins			
		Tract Infection		(Unspecified)	C		
				Aspirin	C		
				Lipitor	C		
				Calcium			
				(Unspecified)	C		
				Premarin	C		

Date:03/22/04ISR Number: 4321184-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Arthralgia		Tylenol	C		
		Atrioventricular Block		Estradiol	C		ORAL
		Complete		Synthroid	C		ORAL
		Cervical Dysplasia		Provera	C		ORAL
		Compression Fracture					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Electrocardiogram St					
		Segment Elevation					
		Fall					
		Haematuria					
		Hypertension					
		Hypothyroidism					
		Intervertebral Disc					
		Degeneration					
		Nausea					
		Osteoarthritis					
		Rash					
		Rectal Haemorrhage					

Road Traffic Accident
Scoliosis
Sinus Bradycardia
Spinal Column Stenosis
Spinal Compression
Fracture
Spinal Osteoarthritis
Toe Deformity
Urinary Tract Infection
Uterine Leiomyoma
Vaginitis Atrophic
Ventricular Asystole
Ventricular Fibrillation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321185-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Claritin-D	SS		ORAL
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Aortic Valve Incompetence		Vicodin Es Tablets	C		ORAL
	Aortic Valve Sclerosis		Zoloft	C		ORAL
	Blood Bilirubin Increased		Ambien	C		ORAL
	Blood Cholesterol		Zoloft	C		ORAL
	Increased		Percocet	C		ORAL
	Blood Glucose Increased		Ceftin	C		ORAL
	Cardiac Flutter					
	Carpal Tunnel Syndrome					
	Coronary Artery Disease					
	Electrocardiogram St					
	Segment Elevation					
	Emotional Distress					
	Hypertension					
	Hypertensive Heart					
	Disease					
	Insomnia					
	Mitral Valve Incompetence					
	Mitral Valve Prolapse					
	Sleep Apnoea Syndrome					
	Thrombosis					
	Trigger Finger					
	Ventricular Hypokinesia					

Date:03/22/04ISR Number: 4321186-3Report Type:Expedited (15-DaCompany Report #WAES 0304USA01364
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vicodin Tablets	C		
	Tuberculosis		Theo-Dur	C		ORAL

Albuterol	C		
RESPIRATORY			
(INHALATION)			
Soma	C		ORAL
Hydrochlorothiazide	C		ORAL
Hydrochlorothiazide	C		ORAL
Atrovent	C		
RESPIRATORY			
(INHALATION)			

Date:03/22/04ISR Number: 4321187-5Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00189
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Other	Myocardial Ischaemia		Ibuprofen	C		ORAL	323	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321188-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
Initial or Prolonged	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Amitriptyline					
	Bursitis		Hydrochloride	C				
	Cardiac Disorder		Amitriptyline					
	Carpal Tunnel Syndrome		Hydrochloride	C				
	Cerebrovascular Accident		Amitriptyline					
	Chest Pain		Hydrochloride	C				17 DAY
	Crying		Amitriptyline					
	Deafness Unilateral		Hydrochloride	C				
	Decreased Appetite		Amitriptyline					
	Depression		Hydrochloride	C				
	Dizziness		Amitriptyline					
	Drooling		Hydrochloride	C				17 DAY
	Emphysema		Zoloft	C				582 DAY
	Fatigue		Analgesic Or					
	Feeding Disorder		Anesthetic					
	Fibromyalgia		(Unspecified)	C				
	Headache		Atenolol	C				
	Hyperhidrosis		Lipitor	C				
	Hyperlipidaemia		Celebrex	C				
	Hypertension		Premarin	C				
	Hypoaesthesia		Hydrodiuril	C		ORAL		
	Impaired Work Ability		Altace	C				
	Insomnia							
	Lacunar Infarction							
	Memory Impairment							
	Meniscus Lesion							
	Mitral Valve Incompetence							
	Nausea							
	Osteoarthritis							
	Pain							
	Peripheral Vascular Disorder							
	Productive Cough							

Rebound Hypertension
Rhinorrhoea
Sinusitis
Speech Disorder
Spondylolisthesis
Acquired
Spondylolysis
Treatment Noncompliance
Tricuspid Valve
Incompetence
Vision Blurred
Visual Disturbance
Weight Increased

Date:03/22/04ISR Number: 4321189-9Report Type:Expedited (15-DaCompany Report #WAES 0403USA01571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321190-5Report Type:Expedited (15-DaCompany Report #WAES 0403NOR00011
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Urticaria							

Date:03/22/04ISR Number: 4321191-7Report Type:Expedited (15-DaCompany Report #WAES 0302USA00104
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Aspirin	C				
	Asthenia		Aspirin	C				
	Blood Cholesterol		Lomotil	C				
	Increased		Insulin	C				
	Blood Pressure Systolic		Avandia	C				
	Increased		Zocor	C		ORAL		
	Cardiac Stress Test		Kenalog	C			INTRAMUSCULAR	
	Abnormal		Zocor	C		ORAL	635	DAY
	Carotid Artery Atheroma		Zocor	C		ORAL		
	Carotid Artery Disease		Synthroid	C				
	Disorientation		Melatonin	C				
	Dizziness		Pamelor	C				
	Drug Ineffective		Prilosec	C				
	Dyspnoea							
	Dyspnoea Exertional							
	Epistaxis							
	Fatigue							
	Gingival Bleeding							
	Headache							
	Heart Rate Increased							
	Hypertension							
	Hypoglycaemia							
	Increased Tendency To Bruise							
	Influenza							
	Injury							
	Lymphadenopathy							
	Muscle Fatigue							

Muscle Spasms
Musculoskeletal Stiffness
Myalgia
Myocardial Ischaemia
Nausea
Night Cramps
Nocturia
Oedema
Oedema Peripheral
Palpitations
Rheumatoid Arthritis
Sinus Disorder
Tachycardia
Transient Ischaemic
Attack
Vascular Calcification
Weight Increased
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/04ISR Number: 4321855-5Report Type:Direct Company Report #CTU 214954
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bipolar Disorder		Vioxx 25 Mg	PS		ORAL	ONE PO QD	
			Zyprexa 10 Mg	SS		ORAL	ONE PO QD	

Date:03/22/04ISR Number: 4322850-2Report Type:Expedited (15-DaCompany Report #THQ2004A00150
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall Hallucination, Visual	Health Professional Other	Lanzor (Lansoprazole) (Tablets)	PS		ORAL	1 DF (1 DF, 1 IN 1 D)	
			Atacand (Candesartan Cilexetil) (Tablets)	SS		ORAL		
			Colopriv (Mebeverine Hydrochloride) Preparation For Oral Use (Nos))	SS		ORAL		
			Di-Antalvic (Aporex) (Capsules)	SS		ORAL	4 DF (4 DF, 1 IN 1 D)	
			Lexomil (Bromazepam) (Preparation For Oral Use (Nos))	SS		ORAL	1 DF (1 DF, 1 IN 1 D)	
			Vioxx (Rofecoxib) Tablets	SS		ORAL	1 DF (1 DF, 1 IN 1 D)	
			Temesta (Lorazepam)	C				

Date:03/22/04ISR Number: 4323218-5Report Type:Expedited (15-DaCompany Report #2004UW04843
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Nexium	PS		ORAL	"40" QD PO	
Initial or Prolonged		Professional	Vioxx	SS			"25" QD	

Date:03/23/04ISR Number: 4321947-0Report Type:Expedited (15-DaCompany Report #WAES 0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
Other	Aortic Valve Incompetence
	Bladder Disorder
	Cataract
	Closed Head Injury
	Contusion
	Dyspepsia
	Dyspnoea
	Dysuria
	Ear Pain
	Eye Haemorrhage
	Eye Pain
	Fall
	Glaucoma

		Headache					
		Hearing Impaired					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Keratoconjunctivitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sicca		Vioxx	SS	Merck & Co., Inc	ORAL
		Loose Body In Joint		Vioxx	SS	Merck & Co., Inc	ORAL
		Migraine		Fosamax	C		ORAL
		Mitral Valve Incompetence		Prempro	C		
		Nausea		Advil	C		
		Neurodermatitis		Synthroid	C		
		Optic Nerve Injury		Claritin	C		
		Palpitations					
		Paraesthesia Oral					
		Peripheral Vascular					
		Disorder					
		Polymyalgia Rheumatica					
		Retinal Vein Occlusion					
		Sinusitis					
		Skin Laceration					
		Syncope					
		Vision Blurred					

Date:03/23/04ISR Number: 4321951-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Tylenol	C		
		Increased		Saw Palmetto	C		
		Bradycardia		Ambien	C		
		Cellulitis		Norvasc	C		ORAL
		Chest Wall Pain		Aspirin	C		ORAL
		Coronary Artery		Dicyclomine			
		Atherosclerosis		Hydrochloride	C		
		Coronary Artery Disease		Prevacid	C		
		Coronary Artery Stenosis					
		Cutis Laxa					
		Dressler'S Syndrome					
		Dyspnoea					

Electrocardiogram T Wave
Abnormal
Erectile Dysfunction
Glaucoma
Haematuria
Hyperglycaemia
Hyperlipidaemia
Hypokalaemia
Insomnia
Libido Decreased
Myocardial Infarction
Ocular Hypertension
Pericarditis
Prostatitis
Sleep Apnoea Syndrome

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/04ISR Number: 4321952-4Report Type:Expedited (15-DaCompany Report #WAES 0402FRA00007
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
	Hyperkalaemia		Ferrous Sulfate	C		ORAL
	Renal Failure Acute		Levothyroxine Sodium	C		ORAL
			Spironolactone	C		ORAL
			Spironolactone	C		ORAL
			Nicorandil	C		ORAL

Date:03/23/04ISR Number: 4321963-9Report Type:Expedited (15-DaCompany Report #WAES 0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial
Disability	Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Diplopia
	Diverticulitis
	Dizziness
	Dyspepsia
	Dyspnoea
	Gastrooesophageal Reflux
	Disease
	Haematemesis
	Haematoma
	Hiatus Hernia
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Lactose Intolerance
	Muscle Contractions

Involuntary
Myalgia
Non-Cardiac Chest Pain
Osteoarthritis
Pulmonary Oedema
Retroperitoneal
Haemorrhage
Shock
Sinus Tachycardia
Sleep Disorder
Stent Occlusion
Syncope
Tendonitis
Tinnitus
Urticaria
Ventricular Extrasystoles
Ventricular Fibrillation

	Vision Blurred						
	Visual Acuity Reduced						
	Wheezing	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	220	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	220	DAY
			Propacet	C				
			Wellbutrin	C				
			Prevacid	C				

Date:03/23/04ISR Number: 4322247-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02187
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Obstructive							
	Pulmonary Disease							
	Drug Hypersensitivity							
	Emotional Distress							
	Glaucoma							
	Haemorrhagic Disorder							
	Hypoacusis							
	Oedema Peripheral							
	Sleep Apnoea Syndrome							

Date:03/23/04ISR Number: 4322254-2Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00124
Age:6 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Proteinuria		Sulfasalazine	C				

Date:03/23/04ISR Number: 4323970-9Report Type:Expedited (15-DaCompany Report #2004-01027
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Pleurisy	Consumer	Allopurinol (Watson Laboratories) (Allopurinol) Tablet, 300 Mg	PS	Watson Laboratories	ORAL 300 MG, DAILY, ORAL
			Vioxx (Rofecoxib)	SS		ORAL 25 MG, DAILY, ORAL
			Neurontin (Gabapentin)	C		
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C		
			Multivitamins (Ergocalciferol/Ascorbic Acid, Folic Acid, Thiamine Hydrochloride,	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/04ISR Number: 4324616-6Report Type:Expedited (15-DaCompany Report #22985(1)
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Appetite Drug Interaction Nausea Polymyalgia Rheumatica Vomiting	Health Professional Other	Theolair (Theophylline) (Theophylline)	PS		ORAL	400 MG (200 MG, 2 IN 1 DAY(S); ORAL	3 YR
			Arava (Leflunomide)	SS			(1 IN 1 DAY(S);	11 DAY
			Corvo (Enalapril Maleate)	SS			(1 IN 1 DAY(S)	3 YR
			Torem (Torasemide)	SS			(1 IN 1 DAY(S)	3 YR
			Vioxx (Rofecoxib)	SS			(2 IN 1 DAY(S)	

Date:03/24/04ISR Number: 4322618-7Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00137
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Mallory-Weiss Syndrome	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Doxylamine Succinate	C		ORAL		
			Propiverine Hydrochloride	C		ORAL		

Date:03/24/04ISR Number: 4322621-7Report Type:Expedited (15-DaCompany Report #WAES 0303USA02790
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Asthenia
	Atelectasis
	Back Pain
	Bursitis
	Cervical Dysplasia
	Change Of Bowel Habit
	Chest Discomfort
	Contusion
	Cough
	Diverticulum Intestinal
	Dysphagia
	Dyspnoea
	Endometrial Hyperplasia
	Gastric Ulcer
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haemorrhoids
	Headache
	Hiatus Hernia
	Hot Flush
	Lung Neoplasm
	Muscle Strain
	Neck Pain
	Odynophagia
	Oesophagitis

		Periodontal Disease					
		Proctalgia					
		Rash	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectal Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Reflux Oesophagitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Betamethasone And			
		Sinus Disorder		Bupivacaine			
		Uterine Leiomyoma		Hydrochloride	C		
PARENTERAL							
		Vaginal Haemorrhage		Arthrotec	C		
				Naprelan	C		

Date:03/24/04ISR Number: 4322622-9Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00139
Age:89 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrioventricular Block	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Complete	Professional	Hydrochlorothiazide			
		Blood Urea Increased		And Irbesartan	SS		ORAL
		Bundle Branch Block Left		Nebivolol			
		Electrocardiogram Qt		Hydrochloride	SS		ORAL
		Prolonged		Albuterol Sulfate	C		ORAL
		Hyperkalaemia		Amitriptyline			
		Syncope		Hydrochloride	C		ORAL
				Budesonide And			
				Formoterol Fumarate	C		
RESPIRATORY							
(INHALATION)							
				Ginkgo Biloba			
				Extract	C		ORAL
				Glimepiride	C		ORAL

Date:03/24/04ISR Number: 4322625-4Report Type:Expedited (15-DaCompany Report #WAES 0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain
	Anxiety
	Arthralgia

Asthenia
Bone Graft
Bronchitis
Bursitis
Cerebrovascular Accident
Cervicobrachial Syndrome
Chronic Obstructive
Pulmonary Disease
Condition Aggravated
Contusion
Depression
Exostosis
Fall
Fatigue
Fibromyalgia
Insomnia
Intervertebral Disc
Protrusion
Lower Respiratory Tract
Infection
Migraine

		Oedema Peripheral					
		Osteoarthritis					
		Osteoporosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Radius Fracture	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		[Therapy			
		Somnolence		Unspecified]	C		
		Spinal Osteoarthritis		Vicodin Tablets	C		
		Sputum Discoloured		Elavil	C		ORAL
		Tendonitis		Analgesic Or			
		Transient Ischaemic		Anesthetic			
		Attack		(Unspecified)	C		
		Urinary Tract Infection		Aspirin	C		ORAL
		Weight Increased		Vitamins			
				(Unspecified)	C		
				Vitamin E	C		
				Calcium Carbonate	C		
				Premarin	C		
				Lasix (Furosemide)	C		
				Neurontin	C		
				Oxycontin	C		
				Paxil	C		ORAL
				Actonel	C		

Date:03/24/04ISR Number: 4322630-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00099
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dementia Alzheimer'S Type	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/04ISR Number: 4322632-1Report Type:Expedited (15-DaCompany Report #WAES 0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						

Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY						
Disability	Adverse Drug Reaction		Xanax	C		
	Agitation		Aspirin	C		
	Anxiety		Lipitor	C		
	Blood Triglycerides		Wellbutrin	C		
	Increased		Celebrex	C		
4 DAY						
	Coronary Artery Aneurysm		Plavix	C		
	Coronary Artery		Folic Acid	C		
	Atherosclerosis		Toprol Xl Tablets	C		
	Coronary Artery Occlusion		Lopressor	C		
	Coronary Artery Stenosis		Pyridoxine	C		
	Depression					
	Ecchymosis					
	Haematoma					
	Major Depression					
	Myocardial Infarction					
	Panic Disorder					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/04ISR Number: 4322633-3Report Type:Expedited (15-DaCompany Report #WAES 0403DEU00138
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Aspirin	SS		ORAL		
	Rectal Adenoma		Garlic Extract	SS		ORAL		
	Rectal Haemorrhage		Buprenorphine Hydrochloride	C		TOPICAL		
	Rectal Polyp		Ruscogenin	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Caffeine	C		ORAL		

Date:03/24/04ISR Number: 4322634-5Report Type:Expedited (15-DaCompany Report #WAES 0403USA01904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/04ISR Number: 4322635-7Report Type:Expedited (15-DaCompany Report #WAES 0403USA01650
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticular Perforation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Protonix	C				
			Effexor	C				

Date:03/24/04ISR Number: 4322891-5Report Type:Expedited (15-DaCompany Report #WAES 01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Neoplasm
	Arthralgia
	Bacteria Urine Identified
	Blood Chloride Increased

Blood Cholesterol
Increased
Blood Glucose Increased
Blood Sodium Increased
Cervicitis
Chest Pain
Constipation
Deep Vein Thrombosis
Face Oedema
Gastroenteritis
Haematemesis
Headache
Hyperlipidaemia
Iliac Vein Occlusion
Lipoma
Menometrorrhagia
Postnasal Drip
Productive Cough
Pulmonary Granuloma
Urinary Tract Infection
Uterine Leiomyoma
Venous Stenosis

		Wheezing					
		Wound Dehiscence					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
				Aspirin	C		
				Lipitor	C		ORAL
				Tiazac	C		
				Detrol	C		
				Meridia	C		
				Cardura	C		
				Motrin	C		
				Zestril	C		

Date:03/24/04ISR Number: 4322897-6Report Type:Expedited (15-DaCompany Report #WAES 0205USA02074
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Myocardial Infarction		Wellbutrin	C		
		Overdose		Enbrel	C		
				Glucosamine	C		
				Methotrexate	C		

Date:03/24/04ISR Number: 4322899-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -	10 DAY	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	95 DAY	Arthritis	Professional	Celebrex	SS		
Disability	7 DAY	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Iron (Unspecified)	SS		
	12 DAY	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL

	Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Fall		Tylenol	C			790 DAY
	Gastrointestinal Haemorrhage		Tylenol	C			
			Triamcinolone	C			TOPICAL 366 DAY
	Hyperlipidaemia		Lipitor	C			790 DAY
	Hypertension						
	Iron Deficiency Anaemia						
	Joint Injury						
	Myocardial Infarction						
	Myocardial Ischaemia						
	Osteoarthritis						
	Rash						
	Rectal Haemorrhage						
	Stress						
	Ulcer						

Date:03/24/04ISR Number: 4322900-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA01343
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/04ISR Number: 4322901-5Report Type:Expedited (15-DaCompany Report #WAES 0403NLD00021
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Maculopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
	Retinal Pigment Epitheliopathy	Professional	Acetaminophen And Codeine	C		ORAL	6	DAY
	Visual Acuity Reduced		Clemastine Fumarate	C		ORAL	16	DAY
			Fexofenadine Hydrochloride	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

Date:03/24/04ISR Number: 4322902-7Report Type:Expedited (15-DaCompany Report #WAES 0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Acute Myocardial Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adhesion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Lortab	C				
	Back Disorder		Amitriptyline Hydrochloride	C			874	DAY
	Cerebrovascular Accident							
	Chest Pain		Trazodone Hydrochloride	C			1291	DAY
	Coronary Artery Disease							
	Coronary Artery Stenosis		Trazodone Hydrochloride	C			1291	DAY
	Decreased Activity							
	Depression		Amitriptyline Hydrochloride	C			874	DAY
	Drug Dependence							
	Drug Ineffective		Celebrex	C			362	DAY
	Emotional Distress		Cipro	C				
	Fatigue		Neurontin	C				
	Headache		Hydrocodone					

	Hyperlipidaemia	Bitartrate	C
	Hypertension	Lorazepam	C
2 DAY			
	Hypotension	Methocarbamol	C
957 DAY			
	Insomnia		
	Irritability		
	Loss Of Consciousness		
	Muscle Spasms		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Myofascial Pain Syndrome		
	Neck Pain		
	Osteoarthritis		
	Panic Attack		
	Paraesthesia		
	Pneumonia		
	Pyrexia		
	Sinus Bradycardia		
	Syncope		
	Vision Blurred		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/04ISR Number: 4322904-0Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00077
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Other	Septic Shock	Professional	Omeprazole	SS		ORAL	8	DAY
			Perindopril	C		ORAL	8	DAY
			Pravastatin Sodium	C		ORAL	8	DAY

Date:03/24/04ISR Number: 4323504-9Report Type:Direct Company Report #CTU 215203
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anuria		Rofecoxib	PS		ORAL	12.5 MG BID	
Initial or Prolonged	Blood Creatinine						ORAL	
	Increased		Mycophenolate	C				
			Nifedipine	C				
			Prednisone	C				
			Cyclosporin	C				
			Tramadol	C				

Date:03/24/04ISR Number: 4325433-3Report Type:Expedited (15-DaCompany Report #WAES 0403USA01230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:03/24/04ISR Number: 4325945-2Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Back Disorder	Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (TID), ORAL	
Other	Back Pain	Professional						
	Blood Cholesterol Increased		Lipitor (Atorvastatin)	SS		ORAL	20 MG (DAILY), ORAL	
	Cardiac Disorder							
	Chest Pain Drug Ineffective Drug Intolerance Drug Level Increased Erectile Dysfunction Facial Pain Feeling Cold		Lithium (Lithium) (Lithium) Naproxen (Naproxen) Rofecoxib (Rofecoxib) Amoxicillin (Amoxicillin)	SS SS SS SS		ORAL	1000 MG (BID), ORAL	
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux Disease Glossodynia Hypersomnia Neck Pain Oesophageal Spasm Pain In Jaw Paralysis Post Procedural Pain Sleep Disorder Tooth Abscess Treatment Noncompliance Tremor		All Other Therapeutic Products Levothyroxine Sodium (Levothyroxine Sodium) Vitamins Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/04ISR Number: 4323420-2Report Type:Expedited (15-DaCompany Report #WAES 0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activities Of Daily	Health	Vioxx	PS	Merck & Co., Inc	ORAL		401 DAY
Initial or Prolonged	Living Impaired	Professional	Aspirin	C				
Disability	Anxiety		Aspirin	C				
Other	Aortic Atherosclerosis		Tagamet	C				
	Aortic Valve Incompetence		Premarin	C				
	Aortic Valve Sclerosis		Hytrin	C				
	Blood Cholesterol		Estratab	C				
	Increased		L-Thyroxin	C				
	Blood Pressure		Ranitidine	C				
	Inadequately Controlled							
	Cerebral Atrophy							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Condition Aggravated							
	Depression							
	Dilatation Atrial							
	Dizziness							
	Duodenitis							
	Dyspnoea							
	Endocarditis							
	Fatigue							
	Gallbladder Disorder							
	Gastritis							
	Gastrooesophageal Reflux							
	Disease							
	Generalised Anxiety							
	Disorder							
	Haematuria							
	Haemorrhagic Cerebral							
	Infarction							
	Herpes Zoster							
	Hypertension							
	Hypertensive Crisis							
	Hypertriglyceridaemia							
	Hypoacusis							
	Hypokalaemia							
	Injury							
	International Normalised							
	Ratio Decreased							
	Irritable Bowel Syndrome							
	Lacunar Infarction							

Low Density Lipoprotein
Increased
Migraine With Aura
Mitral Valve
Calcification
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Panic Disorder
Prothrombin Time
Shortened
Sleep Apnoea Syndrome
Tension Headache
Thalamus Haemorrhage
Transient Ischaemic
Attack
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/04ISR Number: 4323425-1Report Type:Expedited (15-DaCompany Report #WAES 01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Enbrel	C		
	Cerebrovascular Accident		Trazodone			
	Chest Pain		Hydrochloride	C		
	Coronary Artery Stenosis		Azulfidine	C		
	Gastrooesophageal Reflux		Enbrel	C		
	Disease					
	Hypertension					
	Myocardial Infarction					

Date:03/25/04ISR Number: 4323430-5Report Type:Expedited (15-DaCompany Report #WAES 0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Unstable
Disability	Anxiety
Other	Back Pain
	Blood Cholesterol
	Increased
	Blood Pressure
	Inadequately Controlled
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Coronary Artery Stenosis
	Depression
	Dilatation Atrial
	Dizziness
	Duodenitis
	Extrasystoles
	Fatigue
	Gastritis
	Gastrointestinal
	Haemorrhage
	Haematochezia
	Hypertension
	Hypokalaemia
	Injury

Laryngitis
Loss Of Consciousness
Loss Of Employment
Migraine
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Nausea
Orthostatic Hypotension
Palpitations
Pelvic Peritoneal
Adhesions
Pericardial Effusion
Phlebothrombosis
Phonophobia
Photophobia
Photopsia

		Postoperative Adhesion					
		Stent Occlusion					
		Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						

Date:03/25/04ISR Number: 4323434-2Report Type:Expedited (15-DaCompany Report #WAES 0302USA00108
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Arterial Thrombosis
	Arthralgia
	Atherosclerosis
	Bursitis
	Cardiac Failure Congestive
	Cardiac Valve Disease
	Cellulitis
	Chest Pain
	Chronic Obstructive Airways Disease Exacerbated
	Chronic Obstructive Pulmonary Disease
	Confusional State
	Congestive Cardiomyopathy
	Depression
	Dizziness
	Drug Level Above Therapeutic
	Emotional Distress
	Fall
	Feeling Abnormal
	Gastrointestinal Haemorrhage

Glaucoma
Gout
Headache
Hypoacusis
Injury
Intervertebral Disc
Protrusion
Intervertebral Disc Space
Narrowing
Ischaemic Cardiomyopathy
Kidney Infection
Lacunar Infarction
Leg Amputation
Major Depression
Medication Error
Myalgia
Myocardial Infarction
Nausea

		Neck Pain					
		Oedema Peripheral					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Personality Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia	Professional	Ibuprofen	C		
		Post-Traumatic Stress		Insulin	C		
		Disorder					
		Protein Urine					
		Proteinuria					
		Pulmonary Hypertension					
		Pulse Abnormal					
		Renal Failure Chronic					
		Rotator Cuff Syndrome					
		Sciatica					
		Sleep Apnoea Syndrome					
		Spondylitis					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Treatment Noncompliance					
		Urine Flow Decreased					
		Ventricular Hypokinesia					
		Vertigo					
		Viral Infection					
		Visual Disturbance					
		Visual Field Defect					
		Weight Decreased					
		Weight Increased					

Date:03/25/04ISR Number: 4323435-4Report Type:Expedited (15-DaCompany Report #WAES 0302USA00065
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Triglycerides	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Coagulopathy		Vicodin Tablets	C		
		Coronary Artery		Aspirin	C		
		Thrombosis		Plavix	C		
		Fluid Retention		Premarin	C		
		Injury		Insulin	C		
		Myocardial Infarction		Synthroid	C		
		Stress		Glucophage	C		
				Metoprolol Tartrate	C		

			Accupril	C		

Date:03/25/04ISR Number: 4323436-6Report Type:Expedited (15-DaCompany Report #WAES 0310FRA00078
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 34 DAY	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Angiodysplasia Hypoprothrombinaemia Rectal Haemorrhage	Professional	Acenocoumarol	SS		ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
			Beclomethasone Dipropionate	C		ORAL
			Troxerutin	C		ORAL
			Spironolactone	C		ORAL
			Clonazepam	C		ORAL

			Furosemide	C		ORAL

Date:03/25/04ISR Number: 4323439-1Report Type:Expedited (15-DaCompany Report #WAES 0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Burning Sensation		[Therapy Unspecified]	C		
	Bursitis					
1478 DAY						
	Cerebrovascular Accident		Herbs (Unspecified)	C		
840 DAY						
	Condition Aggravated		Prilosec	C		
	Coordination Abnormal					
	Cough					
	Dizziness					
	Dyspnoea					
	Emotional Distress					
	Exostosis					
	Fall					
	Femoral Arterial Stenosis					
	Gait Disturbance					
	Ganglion					
	Gastritis					
	Haemorrhoids					
	Hypertension					
	Injury					
	Joint Sprain					
	Lacunar Infarction					
	Meniscus Lesion					
	Oesophagitis					
	Osteoarthritis					
	Pain In Extremity					
	Peripheral Occlusive Disease					
	Peripheral Vascular Disorder					
	Personality Disorder					
	Qrs Axis Abnormal					
	Rectal Polyp					
	Synovitis					
	Tachycardia					
	Transient Ischaemic					

Attack
Vascular Calcification
Wernicke'S Encephalopathy
Wheezing

Date:03/25/04ISR Number: 4323539-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
Disability	Blood Potassium Decreased
	Blood Sodium Decreased
	Breast Cyst
	Cerebrovascular Accident
	Chronic Sinusitis
	Colonic Polyp
	Contusion

		Depression					
		Diverticulum Intestinal					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Felty'S Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoidal Haemorrhage		Vioxx	SS	Merck & Co., Inc	
		Herpes Zoster		[Therapy			
		Hiatus Hernia		Unspecified]	C		
		Hypertension		Tylenol	C		
		Hypertonic Bladder		Proventil	C		
		Keratitis Herpetic		Allopurinol	C		
		Mitral Valve Incompetence		Elavil	C		ORAL
		Pain		Fiorinal With			
		Pancytopenia		Codeine	C		
		Pyrexia		Azathioprine	C		
		Renal Pain		Tegretol	C		
		Rheumatoid Arthritis		Tegretol	C		
		Rib Fracture		Tegretol	C		
		Viral Infection		Zyrtec	C		
				Advil	C		
				Remicade	C		
INTRAVENOUS							
				Purinethol	C		
				Methotrexate	C		
				Prilosec	C		
				K-Dur	C		
				Triamterene	C		
				Prednisone	C		

Date:03/25/04ISR Number: 4323545-1Report Type:Expedited (15-DaCompany Report #WAES 0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthralgia		Lipitor	C		
2371 DAY						
Other	Carotid Artery Stenosis		Accupril	C		
2373 DAY						
	Embolism					
	Haematoma					
	Haemorrhage					
	Heart Rate Decreased					

Hypertension
Limb Injury
Retinal Artery Embolism
Road Traffic Accident
Transient Ischaemic
Attack
Ulcer

Date:03/25/04ISR Number: 4323547-5Report Type:Expedited (15-DaCompany Report #WAES 01072444
Age:57 YR Gender:Female I/FU:F

Outcome PT
Disability Amnesia
Other Cerebrovascular Accident
Depression
Disturbance In Attention
Emotional Distress
Fatigue
Hypertension

		Impaired Work Ability					
		Insomnia					
		Low Density Lipoprotein	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Hydrocodin	SS		
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Speech Disorder					
		Thinking Abnormal					

Date:03/25/04ISR Number: 4323550-5Report Type:Expedited (15-DaCompany Report #WAES 0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Emotional Distress		Glimepiride	C		
				Metformin	C		

Date:03/25/04ISR Number: 4323551-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00764
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Blood Cholesterol		Hytrin	C		
		Increased					
		Blood Triglycerides					
		Increased					
		Cerebrovascular Accident					
		High Density Lipoprotein					
		Decreased					
		Injury					
		Joint Swelling					
		Low Density Lipoprotein					
		Increased					
		Peripheral Vascular					
		Disorder					
		Retinal Haemorrhage					

Retinal Oedema
Retinal Vein Occlusion
Tendon Rupture
Vision Blurred

Date:03/25/04ISR Number: 4323552-9Report Type:Expedited (15-DaCompany Report #WAES 0304USA00747
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Tylenol	C				
Other	Deafness							
	Dyspepsia							
	Emotional Distress							
	Gastrointestinal Disorder							
	Injury							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/04ISR Number: 4323553-0Report Type:Expedited (15-DaCompany Report #WAES 0403AUT00008
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
	Dilatation Atrial					
	Fatigue					
	Flushing					
	Tachycardia					

Date:03/25/04ISR Number: 4323554-2Report Type:Expedited (15-DaCompany Report #WAES 0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 39 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 39 DAY	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Angina Unstable		Tylenol Pm	C		
	Aortic Aneurysm		Tagamet	C		
	Arthritis		Zocor	C		ORAL
	Barrett'S Oesophagus		Tagamet	C		
	Blood Pressure Increased		Plavix	C		
	Cardiac Failure		Cardura	C		ORAL
	Congestive					
	Chest Pain					
	Chronic Fatigue Syndrome					
	Contusion					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Cyst					
	Depression					
	Duodenitis					
	Dyspepsia					
	Ejection Fraction					
	Decreased					
	Gastritis Erosive					
	Gastrooesophageal Reflux					
	Disease					
	Haemoglobin Decreased					
	Headache					
	Hypercholesterolaemia					
	Hyperhidrosis					

Hypertension
Hypogonadism
Injury
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Mood Altered
Peptic Ulcer
Reflux Oesophagitis
Sinus Tachycardia
Sleep Apnoea Syndrome
Tendonitis
Ventricular Extrasystoles
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/04ISR Number: 4323555-4Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00049
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/04ISR Number: 4323556-6Report Type:Expedited (15-DaCompany Report #WAES 0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Alanine Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Folic Acid	C				
	Congestive		Arava	C				
	Diarrhoea		Methotrexate	C			441	DAY
	Dizziness		Aredia	C				
	Dyspnoea Paroxysmal		Prednisone	C			10	MON
	Nocturnal		Inderal	C				
	Faeces Discoloured		Inderal	C				
	Hypertension		Inderal La	C				
	Injury							
	Insomnia							
	Malaise							
	Melaena							
	Myocardial Infarction							
	Myocarditis							
	Nightmare							
	Orthopnoea							
	Palpitations							
	Panic Attack							
	Phlebitis							
	Phlebitis Superficial							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Sensation Of Foreign Body							
	Stress							
	Tachycardia							

	Thrombosis
	Treatment Noncompliance
	Tricuspid Valve
	Incompetence
	Upper Respiratory Tract
	Infection
	Weight Increased

Date:03/25/04ISR Number: 4323557-8Report Type:Expedited (15-DaCompany Report #WAES 0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Pulmonary Oedema
Hospitalization -	Anaemia
Initial or Prolonged	Aortic Stenosis
Other	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest

		Cardiomegaly					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Depressed Level Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
				Captopril	C		
		Diabetes Mellitus		Celebrex	C		
		Inadequate Control		Plavix	C		
		Dizziness		Pepcid Ac	C		ORAL
		Dyspepsia		Lasix (Furosemide)	C		
		Gastritis		Ambien	C		
		Gastrointestinal		Zoloft	C		
		Haemorrhage		Glyburide	C		
		Hyperkalaemia		Synthroid	C		
		Microcytic Anaemia		Lorazepam	C		
		Myocardial Infarction		Meclizine	C		
		Occult Blood Positive		Phenergan			
		Peptic Ulcer		Tablets/Suppositories			
		Renal Failure			C		

Date:03/25/04ISR Number: 4323558-XReport Type:Expedited (15-DaCompany Report #WAES 0403DNK00019
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL
93 DAY						
Hospitalization -			Atorvastatin Calcium	C		ORAL
Initial or Prolonged			Levothyroxine Sodium	C		ORAL
			Ramipril	C		ORAL

Date:03/25/04ISR Number: 4323560-8Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00075
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Alveolitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Initial or Prolonged			Metformin Hydrochloride	C		ORAL

Date:03/25/04ISR Number: 4327869-3Report Type:Expedited (15-DaCompany Report #AU-JNJFOC-20040304307
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia Confusional State Drug Interaction Drug Level Increased Drug Toxicity Psychotic Disorder Restlessness Speech Disorder	Foreign Health Professional	Tramal (Tramadol Hydrochloride) Unspecified	PS		ORAL	50 MG, 3 IN 1	DAY, ORAL
			Vioxx (Rofecoxib) Unknown	SS		ORAL	12.5 MG, 1 IN	1 DAY, ORAL
			Lithium Carbonate (Lithium Carbonate) Unknown	SS		ORAL	250 MG, 4 IN	1 DAY, ORAL
			Zoloft (Sertraline Hydrochloride) Unknown	SS		ORAL	100 MG, 1 IN	1 DAY, ORAL

Date:03/26/04ISR Number: 4324724-XReport Type:Expedited (15-DaCompany Report #WAES 0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
Initial or Prolonged	Arteriovenous Fistula	Professional	Tylenol	C				
Other	Blood Pressure Increased		Ecotrin	C				
	Blood Urea Increased		Calan Sr	C				
	Bundle Branch Block Left		Celebrex	C				
	Chest Discomfort		Advil	C				
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Dehydration							
	Diverticulum Intestinal Haemorrhagic							
	Electrocardiogram Poor R-Wave Progression							
	Electrocardiogram T Wave Abnormal							
	Emotional Distress							
	Gastritis							
	Gastritis Atrophic							
	Gastrointestinal Haemorrhage							
	Haematochezia							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Helicobacter Infection							
	Hypertension							
	Iron Deficiency Anaemia							
	Musculoskeletal Pain							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Neck Pain							
	Polytraumatism							
	Stent Occlusion							
	Treatment Noncompliance							
	Weight Increased							

Date:03/26/04ISR Number: 4324725-1Report Type:Expedited (15-DaCompany Report #WAES 01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Other	Hypersensitivity	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
	Nausea		Atenolol	C				
	Patellofemoral Pain		Hydrodiuril	C				
	Syndrome		Prevacid	C				
	Sudden Death		Claritin	C				
	Tendon Injury							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/04ISR Number: 4324726-3Report Type:Expedited (15-DaCompany Report #WAES 0205USA02003
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cardiac Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardio-Respiratory Arrest		[Therapy			
	Cerebrovascular Disorder		Unspecified]	C		
	Depression		Insulin	C		
	Diabetes Mellitus		Pentasa	C		
	Insomnia		Nitroglycerin	C		
	Pneumonia					
	Polytraumatism					
	Renal Failure Acute					
	Sepsis					
	Vascular Bypass Graft					

Date:03/26/04ISR Number: 4324727-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 92 DAY	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 5 DAY	Arterial Occlusive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Aseptic Necrosis Bone		Duragesic	C		
	Asthenia		Prevacid	C		
	Bladder Disorder		Effexor	C		
	Carotid Artery Stenosis					
	Cerebral Artery Occlusion					
	Cerebrovascular Accident					
	Depression					
	Disturbance In Attention					
	Drug Ineffective					
	Drug Withdrawal Syndrome					
	Dyspepsia					
	Dysuria					
	Feeling Abnormal					
	Gait Disturbance					
	Headache					
	Hypoaesthesia					
	Ischaemic Stroke					

Memory Impairment
Neck Pain
Nephrolithiasis
Oesophageal Disorder
Sensory Disturbance
Spinal Disorder

Date:03/26/04ISR Number: 4324728-7Report Type:Expedited (15-DaCompany Report #WAES 0304USA00834
Age:62 YR Gender:Male I/FU:F

Outcome PT
Disability Blood Cholesterol
Other Increased
Cardiac Failure
Coronary Artery Disease
Depression
Drug Hypersensitivity
Hypoaesthesia
Impaired Work Ability

Injury Myocardial Infarction Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
		[Therapy Unspecified]	C				
		Tenormin	C				
		Tenormin	C				
		Lanoxin	C			1051 DAY	
		Glyburide	C				
		Zestril	C			2170 DAY	
		Zestril	C			2170 DAY	
		Metformin	C				

Date:03/26/04ISR Number: 4324730-5Report Type:Expedited (15-DaCompany Report #WAES 0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Anxiety
Other	Back Disorder
	Blood Cholesterol Increased
	Blood Homocysteine Increased
	Blood Triglycerides Increased
	Cardiac Failure Congestive
	Cardiac Murmur
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Disturbance In Attention
	Dyspepsia
	Electrocardiogram St-T

Change
Gastrooesophageal Reflux
Disease
Hiatus Hernia
High Density Lipoprotein
Decreased
Insomnia
Intervertebral Disc
Degeneration
Left Ventricular
End-Diastolic Pressure
Increased
Low Density Lipoprotein
Increased
Myocardial Infarction
Nephrolithiasis
Post Laminectomy Syndrome
Radiculopathy
Stress

		Suicidal Ideation					
		Total Cholesterol/Hdl Ratio Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Umbilical Hernia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
380	DAY						
		Very Low Density Lipoprotein Increased	Professional	Aspirin	C		
				Plavix	C		
				Coumadin	C		
				Cardizem	C		
				Maxair	C		

RESPIRATORY

(INHALATION)

Date:03/26/04ISR Number: 4324732-9Report Type:Expedited (15-DaCompany Report #WAES 0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Aortic Calcification	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Arthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Systolic		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Soma	C		
		Cardiomegaly		Lamisil	C		
		Carotid Artery Stenosis		Motrin	C		
		Cerebrovascular Accident					
		Chest Pain					
		Chondromalacia					
		Coordination Abnormal					
		Cough					
		Depression					
		Dysphagia					
		Fall					
		Hemiparesis					
		Hypertension					
		Impaired Work Ability					
		Lymphoedema					
		Mastoiditis					
		Mucosal Membrane					
		Hyperplasia					
		Nausea					

Oedema Peripheral
Speech Disorder
Treatment Noncompliance

Date:03/26/04ISR Number: 4324733-0Report Type:Expedited (15-DaCompany Report #WAES 0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Angina Pectoris
	Atrioventricular Block
	First Degree
	Bladder Spasm
	Bronchial Infection
	Bursitis
	Cerebral Infarction
	Cerebral Ischaemia
	Cervicobrachial Syndrome
	Chest Pain

		Cholelithiasis					
		Contusion					
		Dysuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Embolic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Escherichia Infection		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Head Injury		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Intervertebral Disc		Tylenol	C		
		Degeneration		Parafon Forte	C		
		Joint Effusion		Serevent	C		
RESPIRATORY							
		Joint Injury					
(INHALATION)							
		Lumbar Radiculopathy		Proventil	C		
RESPIRATORY							
		Migraine					
(INHALATION)							
		Mitral Valve Incompetence		Aspirin	C		
		Myofascial Pain Syndrome		Lioresal	C		
		Nerve Compression		Valium	C		
		Oedema Peripheral		Demerol	C		
		Pollakiuria		Ditropan	C		
		Rotator Cuff Syndrome		Inderal	C		
		Spondylolisthesis					
		Acquired					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					
		Ventricular Hypertrophy					

Date:03/26/04ISR Number: 4324734-2Report Type:Expedited (15-DaCompany Report #WAES 0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged Disability	Basal Cell Carcinoma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
	Carotid Artery Stenosis		Fosamax	C		ORAL
	Cerebrovascular Accident		Hydrochlorothiazide	C		
	Conduction Disorder					
	Coronary Artery Disease					
	Coronary Artery Stenosis					
	Cough					
	Depression					
	Dilatation Atrial					
	Dizziness					
	Gallop Rhythm Present					
	Injury					
	Sexual Dysfunction					
	Sleep Apnoea Syndrome					
	Somnolence					
	Supraventricular Extrasystoles					
	Transient Ischaemic Attack					
	Ventricular Hypokinesia					
	Weight Increased					
	White Blood Cell Count Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/04ISR Number: 4324735-4Report Type:Expedited (15-DaCompany Report #WAES 0205USA02043
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Aortic Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	2	WK
	Aortic Stenosis		Cimetidine	C				
	Arrhythmia		Flexeril	C				
	Atherosclerosis		Cardizem	C				
	Blood Pressure Increased		Micronase	C				
	Cardiac Murmur		Ibuprofen	C				
	Cerebral Ischaemia		Prinivil	C				
	Cerebrovascular Accident		Metformin	C				
	Coronary Artery Disease		Pravachol	C				
	Depression							
	Diastolic Dysfunction							
	Dilatation Atrial							
	Disturbance In Attention							
	Dizziness							
	Feeling Abnormal							
	Hemiparesis							
	Hypertensive Heart Disease							
	Injury							
	Mania							
	Mitral Valve Calcification							
	Mitral Valve Incompetence							
	Osteoarthritis							
	Radiculopathy							
	Refusal Of Treatment By Patient							
	Respiratory Rate Increased							
	Sleep Disorder							
	Treatment Noncompliance							
	Ventricular Extrasystoles							
	Ventricular Hypertrophy							
	Ventricular Tachycardia							

Date:03/26/04ISR Number: 4324736-6Report Type:Expedited (15-DaCompany Report #WAES 0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Other	Bronchitis
	Cataract
	Cerebrovascular Accident
	Dehydration
	Diarrhoea
	Diverticulitis
	Fibromyalgia
	Gastroenteritis Viral
	Gastrointestinal Disorder
	Hypertension
	Nausea
	Normochromic Normocytic Anaemia
	Pain
	Platelet Count Increased

		Renal Failure Acute White Blood Cell Count Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
				Acetaminophen	C		
				Percocet	C		
				Soma	C		
				Zyrtec	C		
				Ultram	C		
				Premarin	C		
				Motrin	C		
				Ocuflox	C		
				Oxycodone	C		
				Prednisone	C		
OPHTHALMIC							

Date:03/26/04ISR Number: 4324737-8Report Type:Expedited (15-DaCompany Report #WAES 0403GBR00220
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
75 DAY						
Other						

Date:03/26/04ISR Number: 4324738-XReport Type:Expedited (15-DaCompany Report #WAES 0306USA01224
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
798 DAY						
Initial or Prolonged	Anger		Vioxx	SS	Merck & Co., Inc	ORAL
798 DAY						
Disability	Blood Cholesterol Increased		Tetracycline	C		
			Ambien	C		
	Chronic Obstructive Pulmonary Disease		[Therapy Unspecified]	C		
	Coronary Artery Disease		Tylenol	C		

	Depression	Acetaminophen And		
	Diabetes Mellitus	Hydrocodone		
	Non-Insulin-Dependent	Bitartrate	C	
	Ear Disorder	Acetic Acid	C	
AURICULAR				
	Emotional Distress			
(OTIC)				
	Eye Infection	Albuterol	C	
	Fear	Amlodipine Maleate	C	
	Hypertension	Aspirin	C	
	Muscle Spasms	Baclofen	C	
	Myalgia	Beconase	C	
	Myocardial Infarction	Artificial Tears	C	
	Nasopharyngitis	Bupropion		
	Neuralgia	Hydrochloride	C	
	Oedema Peripheral	Carbamide Peroxide	C	
	Pain	Clopidogrel		
	Peptic Ulcer	Bisulfate	C	
	Rash	Clotrimazole	C	
	Sleep Disorder	Prozac	C	
		Zocor	C	ORAL
		Neurontin	C	
		Advil	C	
		Lansoprazole	C	
		Lovastatin	C	

	Methocarbamol	C
	Metoprolol	C
	Mirtazapine	C
	Nitroglycerin	C
	Nystatin	C
OPHTHALMIC	Olopatadine Hydrochloride	C
	Phenylpropanolamine	C
	Pseudoephedrine	C
	Rabeprazole Sodium	C

Date:03/26/04ISR Number: 4324740-8Report Type:Expedited (15-DaCompany Report #WAES 0403USA01954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Myocardial Infarction	Professional						

Date:03/26/04ISR Number: 4324746-9Report Type:Expedited (15-DaCompany Report #WAES 0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Anaemia
Disability	Ankylosing Spondylitis
Other	Cardiac Flutter
	Carpal Tunnel Syndrome
	Chest Pain
	Constipation
	Coronary Artery Stenosis
	Drug Ineffective
	Dysphagia
	Dysphoria
	Ejection Fraction Decreased
	Electrocardiogram St-T Change
	Facet Joint Syndrome
	Facial Bones Fracture
	Fall

Fatigue
Fibromyalgia
Gastrooesophageal Reflux
Disease
Hyperaesthesia
Hypothyroidism
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Jaw Disorder
Nausea
Nephritis Interstitial
Osteoporosis
Polyarthritis
Psoriatic Arthropathy
Raynaud'S Phenomenon

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Reiter'S Syndrome Renal Failure Sacroiliitis					
		Spinal Cord Compression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY							
		Weight Increased	Professional	Microzide	SS		
				Microzide	SS		
				Vioxx	SS	Merck & Co., Inc	ORAL
				Prinzide	SS		ORAL
26 HR							
				Feldene	SS		
60 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
97 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
97 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
				Vicodin Es Tablets	C		ORAL
				Vicodin Es Tablets	C		
				Norco	C		
156 DAY							
				Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1 DAY					
				Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1 DAY					
				Beconase	C		
				Effexor	C		
				Trazodone Hydrochloride	C		
				Imitrex	C		
				Claritin	C		
				Prevacid	C		

			Zestoretic	C
			Celebrex	C
			Flexeril	C
			Valium	C
			Estratest	C
			Neurotonin Capsules	C
			Neurotonin Capsules	C

Date:03/26/04ISR Number: 4324749-4Report Type:Expedited (15-DaCompany Report #WAES 0403USA01985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C				

Date:03/26/04ISR Number: 4324751-2Report Type:Expedited (15-DaCompany Report #WAES 0403USA00252
Age:31 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Arthralgia
Hospitalization -	Aspiration Bone Marrow
Initial or Prolonged	Abnormal
	Chills
	Drug Hypersensitivity

		Epistaxis					
		Fatigue					
		Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Idiopathic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
12	DAY						
		Thrombocytopenic Purpura	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
12	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						

Date:03/26/04ISR Number: 4324752-4Report Type:Expedited (15-DaCompany Report #WAES 0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Angina Pectoris
	Anoxic Encephalopathy
	Anxiety
	Ascites
	Atrioventricular Block Complete
	Blindness
	Cardiac Aneurysm
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiogenic Shock
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Colitis Ischaemic
	Coma
	Constipation
	Contusion
	Coronary Artery Disease
	Cough
	Dehydration
	Depressed Level Of Consciousness
	Diabetes Mellitus Insulin-Dependent
	Diarrhoea

Encephalopathy
Escherichia Infection
Fall
Gastritis
Haematoma
Haemorrhoidal Haemorrhage
Hepatic Cirrhosis
Hepatic Failure
Hyperglycaemia
Hypothyroidism
Injury
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Muscle Tightness
Myocardial Infarction
Nervousness
Pain In Extremity
Post Procedural
Haemorrhage
Productive Cough

		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	MON						
		Sedation	Professional	[Therapy			
		Sick Sinus Syndrome		Unspecified]	C		
		Silent Myocardial		Insulin	C		
		Infarction					
		Spinal Osteoarthritis					
		Tendonitis					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					
		Weight Decreased					

Date:03/26/04ISR Number: 4324753-6Report Type:Expedited (15-DaCompany Report #WAES 0403USA01877
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/26/04ISR Number: 4324754-8Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00071
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Adhesions	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastric Ulcer Perforation	Professional	Ketoprofen	SS		
2	DAY					
Initial or Prolonged	Intestinal Obstruction		Acetaminophen	C		
INTRAVENOUS						
	Peritonitis		Morphine	C		
	Pneumonia		Omeprazole	C		ORAL
	Post Procedural					
	Complication					
	Sciatica					
	Septic Shock					

Date:03/26/04ISR Number: 4324755-XReport Type:Expedited (15-DaCompany Report #WAES 0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Azotaemia
	Benign Neoplasm
	Blood Cholesterol Increased
	Blood Pressure Increased
	Bundle Branch Block Right
	Chest Pain
	Colonic Polyp
	Coronary Artery Disease
	Coronary Artery Stenosis
	Fall
	Generalised Anxiety Disorder
	Haematoma
	High Density Lipoprotein Increased
	Hypercholesterolaemia
	Hypertension

		Intervertebral Disc Degeneration					
		Lipoprotein (A) Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Low Density Lipoprotein	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Tylenol	C		
		Polyp		Acetaminophen And			
		Sleep Disorder		Propoxyphene			
		Tendonitis		Napsylate	C		
		Urinary Tract Infection		Xanax	C		
				Aspirin	C		
				Librax Capsules	C		
				Cyclobenzaprine			
				Hydrochloride	C		
				Allegra	C		
				Prilosec	C		
				Zantac	C		

Date:03/26/04ISR Number: 4325166-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Cardiac Arrest		[Therapy			
Initial or Prolonged		Dyspnoea		Unspecified]	C		
Other		Upper Gastrointestinal		Vicodin Es Tablets	C		
		Haemorrhage		Coumadin	C		ORAL
				Restoril	C		
				Zestril	C		

Date:03/26/04ISR Number: 4325167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bladder Obstruction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cerebral Atrophy		[Therapy			
		Dizziness		Unspecified]	C		
		Encephalomalacia		Albuterol	C		
RESPIRATORY							

	Epistaxis			
(INHALATION)				
	Erectile Dysfunction	Albuterol	C	ORAL
	Gastrointestinal	Allopurinol	C	
	Haemorrhage	Ecotrin	C	
	Haemorrhoids	Atenolol	C	
	Headache	Mavik	C	ORAL
	Ileus Paralytic	Mavik	C	ORAL
	International Normalised	Palgic D	C	ORAL
	Ratio Decreased	Celebrex	C	
	Lymphadenopathy	Guaifenex La	C	
	Prostate Cancer	Hydrodiuril	C	ORAL
	Rectal Haemorrhage	Ibuprofen	C	
	Rectal Polyp	Atrovent	C	
	Sinusitis			
	Spinal Column Stenosis			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/04ISR Number: 4325169-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00435
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Congestive		Antineoplastic					
Other	Cardiomyopathy		(Unspecified)	SS				
	Diffuse Large B-Cell		Vicodin Tablets	C				
	Lymphoma Recurrent		Vitamins					
	Disturbance In Attention		(Unspecified)	C				
	Ejection Fraction		Prilosec	C				
	Decreased							
	Gastric Disorder							
	Major Depression							
	Seborrhoeic Keratosis							
	Sleep Disorder							
	Upper Respiratory Tract							
	Infection							

Date:03/26/04ISR Number: 4325170-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthritis Bacterial		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Tylenol	C				
Other	Congestive		Aspirin	C				
	Cardiac Valve Disease		Coumadin	C				
	Coronary Artery Disease		Aspirin	C				
	Deep Vein Thrombosis		Atenolol	C				
	Emotional Distress		Indocin					
	Exostosis		(Indomethacin)	C				
	Gout							
	Ischaemic Cardiomyopathy							
	Mobility Decreased							
	Myocardial Infarction							
	Platelet Count Decreased							
	Renal Failure Chronic							
	Sinusitis							

Date:03/26/04ISR Number: 4325172-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02101
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
	Arthralgia
	Blood Pressure Increased
	Breast Microcalcification
	Cardiac Failure
	Congestive
	Drug Hypersensitivity
	Drug Ineffective
	Dysphoria
	Dysuria
	Emotional Distress
	Exostosis
	Fall
	Hypernatraemia
	Hypertensive Crisis
	Hypertensive Heart

		Disease					
		Iliac Artery Stenosis					
		Mitral Valve Incompetence					
		Musculoskeletal Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Diuretic			
		Nephritis Interstitial		(Unspecified)	SS		
		Pollakiuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Postnasal Drip		Acetaminophen	C		
		Pulmonary Embolism		Vitamins			
		Pulmonary Oedema		(Unspecified)	C		
		Pyuria		Allopurinol	C		
		Renal Artery Stenosis		Atenolol	C		
		Renal Cyst		Atenolol	C		
		Renal Failure					
		Renal Impairment					
		Renal Tubular Necrosis					
		Sinusitis					
		Skin Lesion					
		Urinary Tract Infection					
		Vascular Calcification					
		Ventricular Hypertrophy					

Date:03/26/04ISR Number: 4325173-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arterial Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Benign Prostatic		[Therapy			
		Hyperplasia		Unspecified]	C		
		Blood Pressure Increased		Vicodin Tablets	C		
		Blood Triglycerides		Ultram	C		
		Increased		Soma	C		
		Bundle Branch Block Right		Celebrex	C		
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Dermal Cyst					
		Erectile Dysfunction					
		Fatigue					
		Hypersensitivity					
		Inguinal Hernia					
		Injury					
		Mitral Valve Incompetence					

Muscle Tightness
Myocardial Infarction
Pneumonitis
Prostatic Specific
Antigen Increased
Ventricular Extrasystoles

Date:03/26/04ISR Number: 4325174-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		62 DAY
Initial or Prolonged	Depression		Aspirin	C				
Other	Heart Injury		Atenolol	C				
	Injury		Glyburide	C				
			Zocor	C		ORAL		

			Motrin	C		
			Prinivil	C		ORAL

Date:03/26/04ISR Number: 4325175-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
	Cardiac Disorder		Aspirin	C		ORAL		
	Cerebrovascular Accident		Bumex	C				
	Depression		Premarin	C				
	Dyspnoea		Prinivil	C		ORAL		
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Hepatitis C							
	Hypertension							
	Injury							
	Oedema							
	Oropharyngeal Spasm							
	Parkinson'S Disease							
	Vertigo							

Date:03/26/04ISR Number: 4325176-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01363
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety
	Chest Pain
	Cyst
	Depression
	Diabetes Mellitus
	Dizziness
	Dry Mouth
	Ear Pruritus
	Emotional Distress
	Food Intolerance
	Fungal Infection
	Gastrooesophageal Reflux Disease

Increased Tendency To
Bruise
Injury
Irritable Bowel Syndrome
Keratoconjunctivitis
Sicca
Major Depression
Mitral Valve Incompetence
Myocardial Infarction
Nasal Disorder
Night Cramps
Ovarian Cyst
Paraesthesia
Post-Traumatic Stress
Disorder
Scar
Sleep Disorder
Stress

		Tricuspid Valve Incompetence Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
634	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
634	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
				Panlor Ss	C		
				Zovirax	C		ORAL
				Tessalon	C		
				Docusate Sodium	C		ORAL
				Erythromycin	C		
TOPICAL							
				Ethinyl Estradiol And Norgestimate	C		
				Glucosamine	C		
				Humibid	C		
				Hydroquinone	C		
TOPICAL							
				Ketoconazole	C		
TOPICAL							
				Lansoprazole	C		ORAL
				Synthroid	C		ORAL
				Claritin-D	C		ORAL
				Nasonex	C		
				Prilosec	C		
				Prilosec	C		
				Oxybutynin Chloride	C		
				Ambien	C		
				Sonata	C		
				Effexor Xr	C		
				Urea	C		
TOPICAL							
				Triamcinolone	C		
TOPICAL							
				Tretinoin	C		
TOPICAL							
				Ultram	C		
				Paxil	C		ORAL

Date:03/26/04ISR Number: 4325177-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Acute Myocardial Infarction
	Asthenia
	Back Injury
	Benign Breast Neoplasm
	Blood Potassium Increased
	Bronchitis
	Carcinoma In Situ Of Skin
	Chest Pain
	Coronary Artery Disease
	Deep Vein Thrombosis
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Enterocele
	Fall
	Gastrointestinal Infection
	Gastrooesophageal Reflux Disease

	Headache					
	Hiatus Hernia					
	Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
	Radius Fracture		Tylenol	C		
	Renal Failure Acute		Z-Pak	C		
	Rotator Cuff Syndrome		Cipro	C		
	Ulna Fracture		Diuretic			
	Urinary Tract Infection		(Unspecified)	C		
	Visual Disturbance		Dyazide	C		
			Advil	C		
			Triamterene	C		
			Prevacid	C		
			Asacol	C		
			Naproxen	C		
			Ditropan	C		
			Quinidine	C		
			Quinine Sulfate	C		

Date:03/26/04ISR Number: 4325178-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Adverse Event
	Angina Unstable
	Asthenia
	Asthma
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Bowel Sounds Abnormal
	Bundle Branch Block Left
	Cardiac Failure
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiac Valve Disease
	Cardiomyopathy
	Compartment Syndrome
	Depression
	Dermatitis Contact

Discomfort
Dizziness
Fatigue
Fluid Retention
Ganglion
Headache
Hyperlipidaemia
Hypertension
Hypokinesia
Insomnia
Major Depression
Mitral Valve Incompetence
Oedema Peripheral
Pain
Palpitations
Respiratory Rate

Increased
Sinus Disorder
Stress
Synovial Cyst

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendonitis					
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Tricuspid Valve					
	Vioxx	SS	Merck & Co., Inc			
	Incompetence					
	Allegra	C		ORAL		
	Ventricular Extrasystoles					
	Zoloft	C		ORAL		
	Ventricular Hypertrophy					

Date:03/26/04ISR Number: 4325179-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
	Anxiety
	Back Pain
	Blood Pressure Decreased
	Cellulitis
	Coronary Artery Disease
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Cystitis Glandularis
	Depression
	Diabetes Mellitus
	Diabetes Mellitus Non-Insulin-Dependent
	Electrocardiogram St Segment Elevation
	Electrocardiogram T Wave Abnormal
	Electrocardiogram T Wave Inversion
	Emotional Distress
	Eyelid Ptosis
	Haemangioma
	Hypercholesterolaemia
	Hyperhidrosis
	Hyperlipidaemia
	Hypertension
	Intervertebral Disc Protrusion
	Lumbar Spinal Stenosis
	Macular Degeneration

Myocardial Infarction
Myocardial Ischaemia
Nausea
Nervousness
Oedema Peripheral
Osteoarthritis
Qrs Axis Abnormal
Radiculopathy
Renal Disorder
Renal Failure
Sinus Bradycardia
Sinusitis
Spinal Column Stenosis
Spinal Osteoarthritis
Urethritis
Vision Blurred

		Visual Disturbance					
		Vomiting					
		Wound Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Xanax	C		
				Aspirin	C		
				Celebrex	C		
				Zyrtec	C		
				Prozac	C		
				Zestril	C		
				Naproxen	C		
				Prilosec	C		

Date:03/26/04ISR Number: 4325180-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Arterial Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Bradycardia		Acetaminophen And			
	Coagulopathy		Oxycodone			
	Coronary Artery Disease		Hydrochloride	C		
	Depression		Avapro	C		
	Gastric Disorder		Protonix	C		
	Heart Rate Irregular					
	Hypotension					
	International Normalised					
	Ratio Increased					
	Myocardial Infarction					
	Pain					
	Palpitations					
	Thrombosis					
	Tongue Haemorrhage					
	Ventricular Fibrillation					
	Ventricular Tachycardia					

Date:03/29/04ISR Number: 4325864-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01999
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma	Health	Vioxx	PS	Merck & Co., Inc	ORAL	54 DAY	
Hospitalization -	Haemorrhagic Stroke	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	54 DAY	
Initial or Prolonged	Hypertension		Allopurinol	C			UNKNOWN	
	Respiratory Failure		Lipitor	C			UNKNOWN	568 DAY
			Study Drug (Unspecified)	C			UNKNOWN	51 DAY
			Celexa	C			UNKNOWN	
			Estratest	C			UNKNOWN	3778 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/04ISR Number: 4325878-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01061634
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
Other	Angina Unstable
	Anorexia
	Anxiety
	Arrhythmia
	Arthralgia
	Arthropathy
	Asthenia
	Blood Glucose Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Bloody Discharge
	Cardiac Procedure
	Complication
	Cerebrovascular Accident
	Chills
	Cholecystitis Chronic
	Cholelithiasis
	Cholelithiasis
	Obstructive
	Colonic Polyp
	Contusion
	Coronary Artery
	Atherosclerosis
	Coronary Artery Stenosis
	Depressed Mood
	Diabetes Mellitus
	Inadequate Control
	Diarrhoea
	Dyspepsia
	Dyspnoea Exertional
	Exostosis
	Eye Disorder
	Fungal Infection
	Gastric Haemorrhage
	Gastritis
	Gastrooesophageal Reflux
	Disease
	Gingival Disorder
	Haematoma

Hypertensive Heart
Disease
Insomnia
Intervertebral Disc
Protrusion
Intestinal Functional
Disorder
Joint Swelling
Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Nausea
Night Sweats
Ocular Hyperaemia
Oedema Peripheral

		Osteopenia					
		Pain					
		Pain In Extremity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Fosamax	SS		ORAL
		Disorder		Plavix	SS		
UNKNOWN							
		Pneumonia		Lortab	C		ORAL
		Postinfarction Angina		Synthroid	C		ORAL
		Procedural Complication		Septra	C		ORAL
		Renal Disorder		Zanaflex	C		
UNKNOWN							
		Retroperitoneal Haematoma		Septra	C		ORAL
		Rheumatoid Arthritis		Robaxin	C		
UNKNOWN							
		Supraventricular		Insulin	C		
UNKNOWN							
		Tachycardia		Norvasc	C		ORAL
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urinary Tract Infection					
		Vaginal Erythema					
		Ventricular Tachycardia					
		Vertigo					
		Vomiting					
		Weight Decreased					

Date:03/29/04ISR Number: 4325880-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abnormal Dreams
Initial or Prolonged	Anaemia
Other	Arthralgia
	Asthma
	Back Pain
	Blood Pressure Increased
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Confusional State
	Depression
	Diarrhoea

Disturbance In Attention
Dizziness
Drug Ineffective
Emotional Distress
Exostosis
Fall
Fear
Fibromyalgia
Gait Disturbance
Headache
Heart Rate Increased
Hypertension
Injury
Intervertebral Disc
Disorder
Lymphadenopathy
Malaise
Middle Insomnia
Migraine Without Aura
Muscle Spasms

		Muscle Strain					
		Musculoskeletal Stiffness					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
65 DAY							
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
65 DAY							
		Renal Failure Acute		Vicodin Tablets	C		
UNKNOWN							
		Renal Impairment		Elavil	C		
UNKNOWN							
		Respiratory Disorder		Atenolol	C		
UNKNOWN							
		Rotator Cuff Syndrome		Lipitor	C		
UNKNOWN							
		Sciatica		Celebrex	C		
UNKNOWN							
		Sleep Disorder		Plavix	C		
UNKNOWN							
		Spinal Column Stenosis		Calan Sr	C		
UNKNOWN							
		Spinal Osteoarthritis		Ultram	C		
UNKNOWN							
		Stress		Zoloft	C		
UNKNOWN							
		Tension Headache		Zoloft	C		
UNKNOWN							
		Therapeutic Response		Flexeril	C		
UNKNOWN		21 DAY					
		Decreased		Flexeril	C		
UNKNOWN		13 DAY					
		Transient Ischaemic		Flexeril	C		
UNKNOWN							
		Attack		Premarin	C		
UNKNOWN							
				Pepcid	C		ORAL
				Dyazide	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Anaemia
Other	Angina Unstable
	Anxiety
	Asthenia
	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Blood Potassium Decreased
	Blood Pressure Decreased
	Bronchitis
	Bronchitis Acute
	Cardiac Disorder
	Cardiac Failure
	Cardiac Valve Disease
	Conjunctival Haemorrhage
	Contusion
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Depression
	Dilatation Atrial
	Dizziness
	Drug Ineffective
	Duodenitis
	Dyspepsia
	Fall

		Fatigue					
		Fear					
		Feeling Hot And Cold	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Generalised Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Headache					
		Heart Rate Irregular					
		Hyperplasia					
		Hypertension					
		Hypokalaemia					
		Injury					
		Joint Sprain					
		Laryngitis					
		Loss Of Consciousness					
		Menopausal Symptoms					
		Migraine					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Orthostatic Hypotension					
		Pain					
		Palpitations					
		Pelvic Peritoneal					
		Adhesions					
		Pericardial Effusion					
		Phaeochromocytoma					
		Phlebothrombosis					
		Phonophobia					
		Photophobia					
		Photopsia					
		Rhinitis Allergic					
		Sinus Bradycardia					
		Stent Occlusion					
		Supraventricular					
		Extrasystoles					
		Syncope					
		Temperature Intolerance					
		Tension Headache					

Thrombophlebitis
Superficial
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Vision Blurred

Date:03/29/04ISR Number: 4325889-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome PT
Other Arterial Disorder
Carotid Artery Disease
Circulatory Collapse
Coronary Artery Disease
Emotional Distress

		Gastrointestinal Disorder					
		Hypertension					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Migraine		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Tylenol	C		
UNKNOWN							
		Neovascularisation		Vicodin Tablets	C		
UNKNOWN							
		Stress		Celexa	C		
UNKNOWN		1839 DAY					
				Plavix	C		
UNKNOWN		366 DAY					
				Flexeril	C		ORAL
				Avapro	C		
UNKNOWN		1681 DAY					
				Ativan	C		
UNKNOWN		1344 DAY					
				Niacin	C		
UNKNOWN		1830 DAY					

Date:03/29/04ISR Number: 4325890-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Calcium			
		Blindness Unilateral		(Unspecified)	C		
UNKNOWN							
		Cardiac Failure		Diazepam	C		
UNKNOWN							
		Congestive		Premarin	C		
UNKNOWN							
		Chest Pain					
		Difficulty In Walking					
		Dizziness					
		Dyspnoea					
		Fall					
		Feeling Abnormal					
		Heart Rate Irregular					
		Hypertension					
		Mitral Valve Incompetence					
		Palpitations					

Paraesthesia
Sensation Of Blood Flow
Skin Discolouration
Tendonitis
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Vision Blurred

Date:03/29/04ISR Number: 4325893-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Acute Respiratory Failure
	Angina Pectoris
	Aspartate Aminotransferase Increased
	Atelectasis
	Back Pain
	Blood Bilirubin Increased
	Blood Ph Decreased
	Blood Pressure Decreased
	Blood Pressure Systolic

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Increased Body Temperature Decreased Bronchopneumonia					
560	DAY	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Congestive Cardiomegaly	Professional	Amitriptyline Hydrochloride	C		
UNKNOWN		Cerebrovascular Accident		Celexa	C		
UNKNOWN		Chest Pain		Nexium	C		
UNKNOWN		Chronic Fatigue Syndrome		Lasix (Furosemide)	C		
UNKNOWN		Depression		Lasix (Furosemide)	C		
UNKNOWN		Dilatation Atrial		Zanaflex	C		
UNKNOWN		Dizziness		Ultram	C		
UNKNOWN		False Positive Laboratory		Ambien	C		
UNKNOWN		Result		Diovan	C		
UNKNOWN		Fatigue		Torsemide	C		
UNKNOWN		Fluid Retention		Neurontin	C		
UNKNOWN		Haematochezia		Zaroxolyn	C		
UNKNOWN		Headache		Aleve	C		
UNKNOWN		Heart Rate Increased		Oxycontin	C		
UNKNOWN		Hypercholesterolaemia		Potassium Chloride	C		
UNKNOWN		Hyperlipidaemia Hypoxia Ileus Kidney Small Lobar Pneumonia Mitral Valve Prolapse Myocardial Infarction Nephrolithiasis Oedema Peripheral Pathogen Resistance					

Pco2 Increased
Pleural Effusion
Pneumonia Aspiration
Pneumonia Pneumococcal
Pneumonia Staphylococcal
Pulmonary Arterial
Pressure Increased
Pulmonary Fibrosis
Rash
Renal Failure
Renal Failure Acute
Respiratory Rate
Increased
Rhabdomyolysis
Rhinorrhoea
Sinus Disorder
Sinusitis
Staphylococcal Infection
Swelling

Date:03/29/04ISR Number: 4325894-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Abdominal Tenderness
Other	Adverse Event
	Angina Unstable
	Anxiety
	Atrioventricular Block

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Back Pain Blood Glucose Increased Bundle Branch Block Left					
		Cataract Chest Pain Constipation		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
OPHTHALMIC							
		Cough		Tylenol	C		
UNKNOWN							
		Diarrhoea		Aspirin	C		
UNKNOWN							
		Diplopia		Aspirin	C		
UNKNOWN							
		Dysphonia		Lipitor	C		
UNKNOWN	1304 DAY						
		Dyspnoea		Premarin	C		
UNKNOWN							
		Emotional Distress		Micronase	C		
UNKNOWN							
		Eructation		Motrin	C		
UNKNOWN							
		Eye Disorder		Synthroid	C		
UNKNOWN							
		Faeces Discoloured		Synthroid	C		
UNKNOWN							
		Fatigue		Glucophage	C		
UNKNOWN							
		Feeling Cold		Naproxen	C		
UNKNOWN							
		Flatulence		Nitroglycerin	C		
UNKNOWN							
		Hot Flush		Refresh	C		
OPHTHALMIC							
		Inflammatory Bowel Disease Injury Nausea Pain Palpitations Pinguecula Sinus Bradycardia Somnolence Stress Upper Respiratory Tract Infection					

Date:03/29/04ISR Number: 4325896-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Other	Anal Haemorrhage
	Arrhythmia
	Arthropathy
	Breast Haemorrhage
	Concussion
	Contusion
	Depression
	Dizziness
	Emotional Disorder
	Emotional Distress
	Extrasystoles
	Fall
	Fatigue
	Female Reproductive
	Neoplasm
	Gingival Disorder
	Haematochezia
	Haemorrhage
	Headache
	Heart Rate Irregular
	Hypercholesterolaemia
	Injury
	Post-Traumatic Stress
	Disorder

		Sleep Disorder					
		Syncope					
		Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Uterine Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
		Uterine Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL
		Vaginal Haemorrhage		Vioxx	SS		ORAL
		Vasodilatation		Vioxx	SS		ORAL
		Vein Disorder		Bayer Aspirin	C		ORAL
		Vomiting		Bayer Aspirin	C		ORAL
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:03/29/04ISR Number: 4325900-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Acute Coronary Syndrome
	Acute Myocardial Infarction
	Acute Respiratory Distress Syndrome
	Acute Respiratory Failure
	Agitation
	Angina Pectoris
	Angina Unstable
	Aortic Valve Disease
	Atrial Tachycardia
	Brain Hypoxia
	Cardiac Arrest
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cardiomegaly
	Cerebrovascular Accident
	Chest X-Ray Abnormal
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Electroencephalogram Abnormal
	Emotional Distress

Encephalopathy
Gallop Rhythm Present
Headache
Hepatic Failure
Hypercholesterolaemia
Hyperphosphataemia
Hypokalaemia
Hyponatraemia
Insomnia
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Loss Of Consciousness
Lung Infiltration
Mental Status Changes
Mitral Valve Disease

		Multi-Organ Failure					
		Myocardial Infarction					
		Myocardial Ischaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteopenia		Oxycodone	C		
UNKNOWN							
		Panic Attack		Ultram	C		
UNKNOWN							
		Panic Disorder		Diovan	C		
UNKNOWN							
		Proteus Infection		Zantac	C		
UNKNOWN							
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Failure					
		Renal Failure Acute					
		Respiratory Failure					
		Thrombocytopenia					
		Thyroid Neoplasm					
		Tricuspid Valve Incompetence					
		Urinary Tract Infection					
		Ventricular Fibrillation					
		Ventricular Hypokinesia					
		Ventricular Tachycardia					
		Visual Disturbance					

Date:03/29/04ISR Number: 4325901-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Aortic Stenosis
	Aortic Valve Incompetence
	Asthenia
	Atelectasis
	Atrial Fibrillation
	Blood Pressure Increased
	Cardiac Murmur
	Carotid Bruit
	Cellulitis
	Constipation
	Depression
	Disturbance In Attention

Diverticulum
Dizziness
Dyspepsia
Dysphagia
Dyspnoea Exertional
Dyspnoea Paroxysmal
Nocturnal
Exercise Tolerance
Decreased
Fatigue
Impaired Healing
Injury
Lung Neoplasm
Medical Device
Complication
Mitral Valve Incompetence
Muscle Spasms
Nausea
Palpitations
Postoperative Infection

Sternal Injury
Syncope
Ventricular Hypertrophy

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	220	DAY
	Tylenol	C			UNKNOWN	
	Codeine	C			UNKNOWN	
	Vasotec	C		ORAL		
	Premarin	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Zocor	C		ORAL		
	Hydrocodone Hydrochloride	C			UNKNOWN	
	Levsin	C			UNKNOWN	
	Synthroid	C		ORAL		
	Prilosec	C		ORAL		

Date:03/29/04ISR Number: 4325902-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome
Disability

PT
Agitation
Anaemia
Anxiety
Arthropod Bite
Arthropod Sting
Back Pain
Blister
Blood Cholesterol Increased
Blood Parathyroid Hormone Decreased
Blood Pressure Increased
Bone Disorder
Bursitis
Chest Pain
Chronic Sinusitis
Compression Fracture

Conjunctivitis
Constipation
Coronary Artery Disease
Crying
Depression
Difficulty In Walking
Drug Intolerance
Dyspepsia
Fungal Infection
Generalised Anxiety
Disorder
Groin Pain
Heart Rate Increased
Hypoaesthesia
Impaired Healing
Infection
Influenza
Insomnia
Joint Sprain
Libido Decreased
Mass
Metastasis
Multiple Fractures

		Oedema Peripheral					
		Osteopenia					
		Osteoporosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
245	DAY						
		Productive Cough		Fosamax	C		ORAL
		Radiculopathy		Valium	C		
UNKNOWN							
		Road Traffic Accident		Neurontin	C		
UNKNOWN							
		Sacroiliitis		Neurontin	C		
UNKNOWN							
		Scoliosis		Valtrex	C		
UNKNOWN							
		Sebaceous Gland Disorder		Neurontin	C		
UNKNOWN							
		Sebaceous Hyperplasia		Glucosamine	C		
UNKNOWN							
		Stress		Nitrostat	C		
UNKNOWN							
		Thoracic Outlet Syndrome		Evista	C		
UNKNOWN							
		Viral Pharyngitis					
		Weight Decreased					
		Weight Increased					

Date:03/29/04ISR Number: 4325903-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03341
Age:32 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
Hospitalization -		Blood Albumin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Alkaline		Vioxx	SS	Merck & Co., Inc	ORAL
		Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Blood Lactate		Darvocet-N	C		
UNKNOWN							
		Dehydrogenase Increased		Ortho-Cyclen	C		
UNKNOWN							

Blood Ph Increased Iron (Unspecified) C
UNKNOWN

Chest Pain
Convulsion
Deep Vein Thrombosis
Dizziness
Dyspnoea
Dyspnoea Exertional
Fall
Fatigue
Gastrooesophageal Reflux
Disease
Headache
Hyperhidrosis
Mydriasis
Nausea
Pallor
Paraesthesia
Po2 Decreased
Pulmonary Embolism
Sinus Tachycardia
Vomiting

Date:03/29/04ISR Number: 4325904-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability

PT
Adjustment Disorder
Adrenal Adenoma
Aneurysm
Arthralgia
Asthenia

		Balance Disorder					
		Blood Aldosterone Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Breast Microcalcification		Darvocet-N	C		
UNKNOWN							
		Carotid Artery Disease		Amitriptyline			
		Cerebrovascular Accident		Hydrochloride	C		
UNKNOWN							
		Chronic Obstructive		Meclizine	C		
UNKNOWN							
		Pulmonary Disease					
		Colon Adenoma					
		Colonic Polyp					
		Complex Regional Pain					
		Syndrome					
		Depression					
		Diverticulum					
		Dizziness					
		Emotional Distress					
		Hearing Impaired					
		Hyperlipidaemia					
		Hypoaesthesia					
		Joint Dislocation					
		Lacunar Infarction					
		Large Cell Carcinoma Of					
		The Respiratory Tract					
		Stage Unspecified					
		Lymphadenopathy					
		Lymphadenopathy					
		Mediastinal					
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Pneumonia					
		Pneumothorax					
		Post Procedural					
		Complication					
		Refusal Of Treatment By					
		Patient					
		Stress Incontinence					
		Ventricular Extrasystoles					

Date:03/29/04ISR Number: 4325905-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Myocardial Infarction		Griseofulvin	C				UNKNOWN

Date:03/29/04ISR Number: 4325906-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01101
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		323 DAY
Other	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		323 DAY
	Congestive Gastric Ulcer		Albuterol And Ipratropium Bromide	C				RESPIRATORY (INHALATION)
	Myocardial Infarction							
	Renal Failure		Aspirin	C				UNKNOWN
	Sudden Death		Lipitor	C				UNKNOWN
			Beconase	C				UNKNOWN

	Pulmicort	C
RESPIRATORY (INHALATION)		
	Wellbutrin	C
UNKNOWN		
	Wellbutrin	C
UNKNOWN		
	Klonopin	C
UNKNOWN		
	Klonopin	C
UNKNOWN		
	Plavix	C
UNKNOWN		
	Allegra	C
UNKNOWN		
	Prozac	C
UNKNOWN		
	Lasix (Furosemide)	C
UNKNOWN		
	Aldactazide	C
UNKNOWN		
	Advil	C
UNKNOWN		
	Toprol Xl Tablets	C
UNKNOWN		
	Toprol Xl Tablets	C
UNKNOWN		
	Demadex	C
UNKNOWN		
	Theophylline	C
UNKNOWN		
	Hytrin	C
UNKNOWN		
	Zocor	C
UNKNOWN		
	Serevent	C
RESPIRATORY (INHALATION)		
	Lopressor	C
UNKNOWN		
	Lopressor	C
UNKNOWN		
	Singulair	C
UNKNOWN		

	Naproxen	C
UNKNOWN		
	Nitroglycerin	C
TOPICAL		
	Prilosec	C
UNKNOWN		
	Potassium Chloride	C
UNKNOWN		
	Inderal	C
UNKNOWN		
	Inderal	C
UNKNOWN		
	Altace	C
UNKNOWN		
	Altace	C
UNKNOWN		

Date:03/29/04ISR Number: 4325908-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01412
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
Disability	Arteriosclerosis
Other	Arthralgia
	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Blindness Transient
	Blood Pressure Decreased
	Cardiac Failure Congestive
	Cardiac Murmur
	Carotid Artery Stenosis
	Cerebellar Infarction
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Diverticulitis
	Diverticulum
	Dizziness
	Insomnia

		Ischaemic Stroke					
		Mitral Valve Incompetence					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Congestion		Aspirin	C		
UNKNOWN							
		Pulmonary Fibrosis		Plavix	C		
UNKNOWN							
		Rotator Cuff Syndrome		Lanoxin	C		
UNKNOWN							
		Sick Sinus Syndrome		Coumadin	C		ORAL
		Sleep Apnoea Syndrome		Coumadin	C		ORAL
		Syncope		Coumadin	C		ORAL
		Tricuspid Valve		Calan	C		
UNKNOWN							
		Incompetence		Hyzaar	C		
UNKNOWN							
		Urinary Tract Infection		Hyzaar	C		ORAL
		Ventricular Hypokinesia					
		Vertigo					

Date:03/29/04ISR Number: 4325909-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00724
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Haemorrhage		Ibuprofen	C		
UNKNOWN						
Initial or Prolonged						

Date:03/29/04ISR Number: 4325910-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
194 DAY						
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
194 DAY						
Disability	Cardiac Failure		Adderall Tablets	C		
UNKNOWN						

	Congestive	Ibuprofen	C
UNKNOWN			
	Cardiomegaly		
	Cardiomyopathy		
	Cerebrovascular Accident		
	Congestive Cardiomyopathy		
	Depression		
	Dilatation Atrial		
	Fatigue		
	Intracardiac Thrombus		
	Mitral Valve Incompetence		
	Sinus Tachycardia		
	Stress		
	Treatment Noncompliance		
	Tricuspid Valve		
	Incompetence		
	Ventricular Dysfunction		

Date:03/29/04ISR Number: 4325911-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Aortic Valve Sclerosis
Initial or Prolonged	Basal Cell Carcinoma
Other	Coronary Artery Disease
	Diabetes Mellitus
	Insulin-Dependent
	Diastolic Dysfunction

		Dizziness					
		Haemorrhage					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
424	DAY						
		Hypoxia		Respaire	C		
UNKNOWN							
		Myocardial Infarction		Minocycline	C		
UNKNOWN							
		Myocardial Ischaemia		Piroxicam	C		
UNKNOWN							
		Post Procedural		Prednisone	C		
UNKNOWN							
		Complication		Zantac	C		
UNKNOWN							
		Pulmonary Oedema					
		Rotator Cuff Syndrome					
		Skin Ulcer					
		Syncope					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					

Date:03/29/04ISR Number: 4326246-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Acute Prerenal Failure		Flexeril	C		
UNKNOWN							
		Acute Respiratory Failure		Vasotec	C		
UNKNOWN							
		Asthma		Lasix (Furosemide)	C		
UNKNOWN							
		Chronic Obstructive		Brethine	C		
UNKNOWN							
		Pulmonary Disease		Glipizide	C		
UNKNOWN							
		Depression		Actos	C		
UNKNOWN							
		Dilatation Atrial		K-Dur	C		
UNKNOWN							

	Fatigue		Altace	C		
UNKNOWN						
	Heart Rate Increased					
	Heart Rate Irregular					
	Hypothyroidism					
	Mitral Valve Incompetence					
	Osteoarthritis					
	Pericardial Effusion					
	Pneumonia					
	Pulmonary Oedema					
	Respiratory Disorder					
	Sinus Tachycardia					
	Sleep Apnoea Syndrome					
	Tachycardia					
	Tricuspid Valve					
	Incompetence					

Date:03/29/04ISR Number: 4326247-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL	20 MON	
	Dyspnoea		Ultram	C			UNKNOWN	
	Hypertension		Premarin	C			UNKNOWN	
	Oedema Peripheral		Lasix (Furosemide)	C			UNKNOWN	366 DAY
	Phlebitis		Plaquenil	C			UNKNOWN	
			Plaquenil	C			UNKNOWN	
			Accupril	C			UNKNOWN	535 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/04ISR Number: 4326259-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bladder Obstruction		[Therapy Unspecified]	C			UNKNOWN	
	Cerebral Atrophy							
	Cerebral Infarction		Albuterol	C			RESPIRATORY (INHALATION)	
	Cerebrovascular Accident							
	Coronary Artery Atherosclerosis		Albuterol	C		ORAL		
			Allopurinol	C			UNKNOWN	
	Cough		Ecotrin	C			UNKNOWN	
	Dizziness		Atenolol	C			UNKNOWN	
	Encephalomalacia		Palgic D	C		ORAL		
	Epistaxis		Mavik	C		ORAL		
	Erectile Dysfunction		Mavik	C		ORAL		
	Haematochezia		Celebrex	C			UNKNOWN	
	Haemorrhoids		Docusate Calcium	C			UNKNOWN	
	Headache		Guaifenex La	C			UNKNOWN	
	Hypertension		Hydrodiuril	C		ORAL		
	Ileus Paralytic		Ibuprofen	C			UNKNOWN	
	Infection		Atrovent	C			UNKNOWN	
	Inflammation		Nitroglycerin	C			UNKNOWN	
	International Normalised Ratio Decreased							
	Lymphadenopathy							
	Nausea							
	Prostate Cancer							
	Rectal Haemorrhage							
	Rectal Polyp							
	Sinusitis							
	Spinal Column Stenosis							
	Tic							

Urinary Retention
Vertigo
Vomiting
Wheezing

Date:03/29/04ISR Number: 4326260-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02070
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Angina Unstable
	Arthralgia
	Asthenia
	Cardiac Failure
	Congestive
	Chest Pain
	Cholelithiasis
	Congestive Cardiomyopathy
	Diarrhoea
	Difficulty In Walking
	Dilatation Ventricular
	Dizziness
	Drug Tolerance Decreased
	Drug Toxicity
	Dyspnoea
	Ejection Fraction Decreased

	Haemangioma						
	Haemorrhage						
	Hepatic Lesion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypokinesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	155 DAY
	Injury	Professional	Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C			UNKNOWN
	Mitral Valve Incompetence						
	Myocardial Ischaemia						
	Renal Failure						
	Speech Disorder		Lanoxin	C			UNKNOWN
	Stress		Premarin	C			VAGINAL
	Ventricular Dysfunction		Lasix (Furosemide)	C			UNKNOWN
	Vision Blurred						
	Vulval Disorder						

Date:03/29/04ISR Number: 4326261-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Other	Apathy
	Balance Disorder
	Blood Cholesterol Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebellar Infarction
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Discomfort
	Cholecystectomy
	Cognitive Disorder
	Cogwheel Rigidity
	Coordination Abnormal
	Deafness Neurosensory
	Dementia
	Diabetes Mellitus

Non-Insulin-Dependent
Difficulty In Walking
Dizziness
Fall
Fatigue
Gallbladder Disorder
Glossitis
Haematochezia
Hiatus Hernia
High Density Lipoprotein
Decreased
Loss Of Consciousness
Low Density Lipoprotein
Increased
Lumbar Radiculopathy
Major Depression
Neuropathy Peripheral
Orthostatic Hypotension
Pain In Extremity
Pseudodementia
Radiculopathy

		Sinusitis					
		Sleep Apnoea Syndrome					
		Somnolence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Swollen Tongue		Vioxx	PS	Merck & Co., Inc	ORAL
696	DAY						
		Tongue Disorder		Reglan	SS		
UNKNOWN							
		Treatment Noncompliance		Celebrex	C		
UNKNOWN							
		Tremor		Catapres	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Lopid	C		
UNKNOWN							
				Robaxin	C		
UNKNOWN							

Date:03/29/04ISR Number: 4326263-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Valve Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthralgia	Professional	Lipitor	C		
UNKNOWN	2371 DAY					
Other	Carotid Artery Stenosis		Accupril	C		
UNKNOWN	2373 DAY					
	Embolism					
	Eye Disorder					
	Haematoma					
	Hypertension					
	Injury					
	Myocardial Ischaemia					
	Road Traffic Accident					
	Transient Ischaemic					
	Attack					
	Ulcer					
	Vascular Pseudoaneurysm					

Date:03/29/04ISR Number: 4326264-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Bradycardia
	Cellulitis
	Chest Wall Pain
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Stenosis
	Cutis Laxa
	Dressler'S Syndrome
	Dyspnoea
	Electrocardiogram T Wave Abnormal
	Erectile Dysfunction
	Gastrooesophageal Reflux Disease
	Glaucoma
	Hyperglycaemia

		Hyperhidrosis					
		Hyperlipidaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Libido Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Saw Palmetto	C		
UNKNOWN							
		Ocular Hypertension		Ambien	C		
UNKNOWN							
		Osteoarthritis		Tylenol	C		
UNKNOWN							
		Pericarditis		Norvasc	C		ORAL
		Pleural Effusion		Aspirin	C		ORAL
		Prostatitis		Dicyclomine			
		Sleep Apnoea Syndrome		Hydrochloride	C		
UNKNOWN							
		Snoring		Prevacid	C		
UNKNOWN							
		Testicular Pain					

Date:03/29/04ISR Number: 4326265-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Asthenia	Professional	Clonidine	C		
UNKNOWN							
		Back Injury					
		Cerebrovascular Accident					
		Chest Pain					
		Chronic Fatigue Syndrome					
		Dizziness					
		Emotional Disorder					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hernia					
		Hypertension					
		Insomnia					
		Intervertebral Disc					
		Protrusion					

	Neck Pain Peripheral Vascular Disorder Renal Failure Road Traffic Accident Spinal Osteoarthritis Stress Vomiting

Date:03/29/04ISR Number: 4326268-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adjustment Disorder Angina Pectoris Anxiety Aspiration Atherosclerosis Blood Cholesterol Increased

	Blood Triglycerides Increased					
	Cardiac Arrest	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
297 DAY						
	Coma	Professional	Aspirin	SS		
UNKNOWN						
	Coronary Artery Disease		Plavix	SS		
UNKNOWN	1 YR					
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
297 DAY						
	Emotional Distress		Heparin	SS		
INTRAVENOUS						
	Gastritis		Vicodin Tablets	C		
UNKNOWN	339 DAY					
	Haematemesis		Lipitor	C		
UNKNOWN						
	Hypertension		Zoloft	C		
UNKNOWN						
	Lethargy		Niacin	C		
UNKNOWN						
	Myocardial Infarction		Metoprolol	C		
UNKNOWN						
	Tension Headache		Monopril	C		
UNKNOWN						
	Upper Gastrointestinal		Celebrex	C		
UNKNOWN						
	Haemorrhage		Analgesic Or			
	Ventricular Fibrillation		Anesthetic (Unspecified)	C		
UNKNOWN						

Date:03/29/04ISR Number: 4326270-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abnormal Behaviour	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial	Professional	Percocet	SS		
UNKNOWN						
Disability	Infarction		Alcohol	SS		
UNKNOWN						
Other	Arthropod Sting		Xanax	SS		
UNKNOWN						

	Blood Calcium Decreased	Ambien	SS
UNKNOWN			
	Blood Ethanol Increased	Soma	C
UNKNOWN			
	Cardiac Failure	Advil	C
UNKNOWN			
	Coronary Artery Disease	Imdur	C
UNKNOWN			
	Coronary Artery Restenosis Diabetes Mellitus Gastrooesophageal Reflux Disease Hypercholesterolaemia Hyperlipidaemia Hypertension Hypokalaemia Intentional Misuse Major Depression Myocardial Infarction Spondylitis Stent Occlusion Suicide Attempt Swelling Face Tooth Disorder Treatment Noncompliance Ventricular Dysfunction		

Date:03/29/04ISR Number: 4326274-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01430
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		205 DAY
	Injury		Vioxx	SS		ORAL		205 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/04ISR Number: 4326275-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cellulitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Tylenol With Codeine	C			UNKNOWN	
	Hypertension							
	Labyrinthitis							
	Liver Disorder							
	Lumbar Spinal Stenosis							
	Pneumonia							
	Urinary Retention							

Date:03/29/04ISR Number: 4326277-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		44 DAY
Disability	Adjustment Disorder With Mixed Anxiety And		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		44 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
	Back Pain		Vicodin Tablets	C			UNKNOWN	
	Blood Pressure Increased		Hydrocodone Bitartrate	C			UNKNOWN	
	Blood Triglycerides Increased		Relafen	C			UNKNOWN	
	Bone Pain							
	Breast Pain							
	Chest Pain							
	Chondromalacia							
	Contusion							

Coronary Artery
Atherosclerosis
Dizziness
Dyspepsia
Extrasystoles
Fatigue
Joint Sprain
Keratoacanthoma
Kyphosis
Musculoskeletal Stiffness
Pericarditis
Tension Headache
Upper Respiratory Tract
Infection

Date:03/29/04ISR Number: 4326278-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Anaemia Macrocytic
Other	Angiodysplasia
	Depression
	Diverticular Perforation
	Gastritis

		Gastrointestinal Haemorrhage Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Polyp Colorectal		Vioxx	SS	Merck & Co., Inc	ORAL
		Small Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
				Lipitor	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Voltaren	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Duragesic	C		
TOPICAL							
				Triamterene	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Denavir	C		
UNKNOWN							

Date:03/29/04ISR Number: 4326280-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL

	Cardiac Failure	Aredia	C
UNKNOWN			
	Congestive	Methotrexate	C
UNKNOWN	441 DAY		
	Diarrhoea	Arava	C
UNKNOWN			
	Dilatation Atrial	Prednisone	C
UNKNOWN	10 MON		
	Dilatation Ventricular	Inderal	C
UNKNOWN			
	Dizziness	Folic Acid	C
UNKNOWN			
	Dyspnoea Paroxysmal	Inderal	C
UNKNOWN			
	Nocturnal	Inderal La	C
UNKNOWN			
	Hypertension		
	Insomnia		
	Melaena		
	Myocardial Infarction		
	Nightmare		
	Orthopnoea		
	Palpitations		
	Panic Attack		
	Phlebitis Superficial		
	Pulmonary Embolism		
	Pulmonary Hypertension		
	Stress		
	Thrombosis		
	Tricuspid Valve Incompetence		
	Upper Respiratory Tract Infection		
	Venous Thrombosis Limb		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/04ISR Number: 4326281-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01917
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Maternal Drugs Affecting Foetus Pulmonary Artery Atresia		Vioxx	PS	Merck & Co., Inc			

Date:03/29/04ISR Number: 4326283-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01935
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Increased Musculoskeletal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Vasotec	C				
Other	Renal Failure		Lasix (Furosemide)	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Lantus	C				UNKNOWN
			Zocor	C		ORAL		UNKNOWN
			Zoloft	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Flomax (Morniflumate)	C				UNKNOWN
			Quinine Sulfate	C				UNKNOWN

Date:03/29/04ISR Number: 4329776-9Report Type:Expedited (15-DaCompany Report #RS004142-CDN
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to	Blood Glucose Increased Confusional State	Foreign Health	Pariet (Rabeprazole) (Rabeprazole Sodium)	PS		ORAL	20 MG, 1 IN 1	

Prevent Permanent Disturbance In Attention Professional
D, ORAL
Impairment/Damage Dysgeusia Vioxx (Rofecoxib) SS
UNKNOWN 50 MG, 2 IN 1
Hyperchlorhydria
D; UNKNOWN
Insomnia Allopurinol C
Muscle Rigidity Codeine Contin C
Myalgia Divalproex Sodium
Paraesthesia (Valproate
Pruritus Semisodium) C
Somnolence Effexor Xr
(Venlafaxine
Hydrochloride) C
Humalog (Insulin
Lispro) C
Ibuprofen C
Levothyroxine C
Insulin Ph (Insulin) C
Salmon Oil (Fish
Oil) C
Tylenol With Codeine
No. 3 (Panadeine Co) C
..... C

Date:03/29/04ISR Number: 4330503-XReport Type:Expedited (15-DaCompany Report #2004204695CH
Age: Gender:Male I/FU:I

Outcome PT
Hospitalization - Anaemia
Initial or Prolonged Arthralgia
Dyspnoea

		Gastric Haemorrhage Gastritis Erosive Oesophagitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional	Depo-Medrol (Methylprednisolone) Suspension, Sterile	PS		
LUMBAR INFILTRATION			Other				
				Rofecoxib(Rofecoxib) Tablet, 50mg	SS		ORAL
50 MG, QD, ORAL							
				Sintrom(Acenocoumarol) Tablet	SS		ORAL
ORAL							
				Ferro-Gradumet Tablet	C		
				Digoxine Tablet	C		
				Reniten Tablet	C		
				Aldactone Tablet	C		
				Torem Tablet	C		
				Eltroxin (Levothyroxine Sodium) Tablet	C		
				Amaryl (Glimepiride) Tablet	C		
				Nitroderm Ts Patch	C		
				Molsidomine Tablet	C		
				Rivotril	C		

Date:03/30/04ISR Number: 4326888-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01288
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased		Ecotrin	C		
UNKNOWN						
Other	Bundle Branch Block Right		Plavix	C		
UNKNOWN						

	Coronary Artery Disease	Dyazide	C
UNKNOWN			
	Ejection Fraction	Avapro	C
UNKNOWN			
	Decreased	Miacalcin	C
UNKNOWN			
	Intracardiac Thrombus	Ativan	C
UNKNOWN			
	Low Density Lipoprotein	Meclizine	C
UNKNOWN			
	Increased	Lopressor	C
UNKNOWN			
	Mediastinal Haematoma	Midazolam	C
UNKNOWN			
	Mitral Valve Incompetence		
	Myocardial Ischaemia		
	Pneumothorax		
	Silent Myocardial		
	Infarction		
	Supraventricular		
	Tachycardia		
	Ventricular Hypokinesia		
	Ventricular Tachycardia		

Date:03/30/04ISR Number: 4326890-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	380	DAY
Anxiety		Aspirin	C			UNKNOWN	
Breath Sounds Decreased		Plavix	C			UNKNOWN	
Cardiac Failure		Coumadin	C			UNKNOWN	
Congestive		Cardizem	C			UNKNOWN	
Chest Pain		Maxair	C			RESPIRATORY (INHALATION)	
Coronary Artery Disease							
Coronary Artery Restenosis							
Deep Vein Thrombosis							
Depression							
Diabetes Mellitus Non-Insulin-Dependent							
Dilatation Atrial							
Dizziness							
Dyspepsia							
Dyspnoea Exertional							
Gastrooesophageal Reflux Disease							
Haematoma							
Hepatic Cyst							
Hiatus Hernia							
Hypersensitivity							
Insomnia							
Intervertebral Disc Degeneration							
Intervertebral Disc Displacement							
Lung Neoplasm							
Myocardial Infarction							
Nephrolithiasis							
Pain In Extremity							
Post Laminectomy Syndrome							
Post Procedural Pain							
Post Thrombotic Syndrome							
Pulmonary Vascular							

Disorder
Radiculopathy
Sleep Apnoea Syndrome
Stress
Suicidal Ideation
Tricuspid Valve
Incompetence
Umbilical Hernia
Weight Decreased

Date:03/30/04ISR Number: 4326893-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
Other	Cerebral Atrophy
	Cerebral Ischaemia
	Diverticulitis
	Eczema
	Gastrointestinal Disorder

		Hypertension					
		Kyphosis					
		Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Macular Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL
		Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy		Vitamins			
		Non-Small Cell Lung		(Unspecified)	C		
UNKNOWN							
		Cancer Metastatic					
		Rhinitis Allergic					
		Sciatica					
		Spinal Disorder					
		Transient Ischaemic					
		Attack					

Date:03/30/04ISR Number: 4326898-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01949
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
41 DAY							
Initial or Prolonged		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Glucose Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL
41 DAY							
		Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Lasix (Furosemide)	C		
UNKNOWN							
		Diarrhoea		Humulin	C		
UNKNOWN							
		Dyskinesia					
		Dysphagia					
		Emotional Distress					
		Excoriation					
		Femoral Arterial Stenosis					
		Halitosis					
		Hypertension					
		Lacunar Infarction					
		Localised Infection					
		Oedema					
		Pain					
		Pain In Extremity					
		Peripheral Vascular					
		Disorder					

Popliteal Stenosis
Rectal Haemorrhage
Skin Candida
Skin Ulcer
Transient Ischaemic
Attack
Vaginal Haemorrhage

Date:03/30/04ISR Number: 4326900-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01432
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Angina Unstable
	Anhedonia
	Blood Disorder
	Cardiac Valve Disease
	Convulsion
	Coronary Artery Disease

		Coronary Artery Occlusion					
		Crying					
		Depressed Mood	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspepsia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Ejection Fraction		Lorcet 10/650	C		
UNKNOWN							
		Decreased		Albuterol	C		
RESPIRATORY							
		Feeling Abnormal					
(INHALATION)							
		Gastrooesophageal Reflux		Prempro	C		
UNKNOWN							
		Disease		Detrol	C		
UNKNOWN							
		Haemorrhage		Tricor	C		ORAL
		Hallucination, Auditory		Ibuprofen	C		
UNKNOWN							
		Hyperhidrosis		Dilantin	C		ORAL
		Hypertension					
		Injury					
		Intermittent Claudication					
		Major Depression					
		Myocardial Infarction					
		Nausea					
		Night Sweats					
		Oedema Peripheral					
		Osteoarthritis					
		Pain In Extremity					
		Palpitations					
		Restlessness					
		Self Esteem Decreased					
		Sleep Disorder					
		Suicidal Ideation					
		Syncope					
		Vasodilatation					
		Vomiting					

Date:03/30/04ISR Number: 4326901-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01382
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

Acute Respiratory
Distress Syndrome
Agitation
Aspiration
Breath Sounds Decreased
Bundle Branch Block Right
Cardiac Arrest
Cardiac Failure
Congestive
Cardiac Murmur
Cardiogenic Shock
Chronic Obstructive
Pulmonary Disease
Confusional State
Constipation
Contusion
Coronary Artery Disease
Cough
Disorientation
Dyspnoea
Dyspnoea Exertional
Ecchymosis

		Ejection Fraction Decreased					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY						
		Haemorrhage					
		Helicobacter Infection					
		Hyperhidrosis					
		Hypoxia					
		Injury					
		Irritability					
		Ischaemic Cardiomyopathy					
		Loss Of Consciousness					
		Miosis					
		Mitral Valve Incompetence					
		Pneumonia Aspiration					
		Pulmonary Haemorrhage					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Respiratory Failure					
		Somnolence					
		Urine Output Decreased					
		Ventricular Arrhythmia					
		Ventricular Fibrillation					
		Ventricular Hypertrophy					
		Vomiting					

Date:03/30/04ISR Number: 4326903-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01381
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL
Disability		Angina Pectoris			C		
UNKNOWN							
		Blood Cholesterol		Aspirin	C		
UNKNOWN							
		Increased		Isosorbide	C		
UNKNOWN							
		Chest Pain					
		Emphysema					

Headache
Hyperlipidaemia
Hypertension
Injury
Myocardial Infarction

Date:03/30/04ISR Number: 4326904-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01426
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Initial or Prolonged	Blood Cholesterol		Aspirin	C				UNKNOWN
	Increased		Plavix	C				UNKNOWN
	Chest Pain		Proscar	C		ORAL		
	Emotional Disorder		Gemfibrozil	C				UNKNOWN
	Emotional Distress		Accupril	C				UNKNOWN
	Heart Rate Increased							
	Hypertension							
	Injury							
	Stress							

Date:03/30/04ISR Number: 4326905-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Abdominal Pain Upper
Other	Anorexia
	Arthralgia
	Asthenia
	Atrial Fibrillation
	Basal Cell Carcinoma
	Blister
	Blood Creatinine Increased
	Blood Potassium Decreased
	Bone Marrow Depression
	Breast Cyst
	Breast Mass
	Bronchitis
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Sinusitis
	Colonic Polyp
	Contusion
	Depression
	Dysarthria
	Dyspepsia
	Dyspnoea
	Ecchymosis
	Episcleritis
	Epistaxis
	Facial Palsy
	Faeces Discoloured
	Fall
	Fatigue
	Felty'S Syndrome
	Fluid Overload
	Gastrooesophageal Reflux Disease
	Haematoma
	Haemorrhoidal Haemorrhage
	Haemorrhoids
	Head Injury
	Herpes Simplex
	Herpes Zoster

Hiatus Hernia
Hypertension
Hypertonic Bladder
Hypoaesthesia
Hypogammaglobulinaemia
Immunoglobulins Decreased
Immunosuppression
Influenza Like Illness
Injury
Insomnia
International Normalised
Ratio Decreased
Irritability
Keratitis Herpetic
Laryngitis

		Laryngitis Viral					
		Leukopenia					
		Libido Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Mental Impairment	Professional	Remicade	SS		
INTRAVENOUS							
		Migraine		Remicade	SS		
INTRAVENOUS							
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Mouth Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Methotrexate	SS		
UNKNOWN							
		Myocardial Infarction		Methotrexate	SS		
UNKNOWN							
		Nausea		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Neuropathic Pain		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Neutropenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Vioxx	SS	Merck & Co., Inc	ORAL
		Orthostatic Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Pancytopenia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Platelet Disorder		[Therapy			
		Platelet Morphology		Unspecified]	C		
UNKNOWN							
		Abnormal		Tylenol	C		
UNKNOWN							
		Prostatitis		Acyclovir	C		
INTRAVENOUS							
		Pyrexia		Proventil	C		ORAL
		Rash		Allopurinol	C		
UNKNOWN							
		Renal Disorder		Elavil	C		ORAL
		Renal Pain		Fiorinal With			
		Respiratory Tract		Codeine	C		
UNKNOWN							
		Congestion		Triamterene	C		
UNKNOWN							
		Rheumatoid Arthritis		Prednisone	C		
UNKNOWN							

	Rib Fracture	K-Dur	C
UNKNOWN			
	Scotoma	Prilosec	C
UNKNOWN			
	Sepsis	Purinethol	C
UNKNOWN			
	Sinus Polyp	Azathioprine	C
UNKNOWN			
	Sinusitis	Tegretol	C
UNKNOWN			
	Skin Lesion	Tegretol	C
UNKNOWN			
	Swelling	Tegretol	C
UNKNOWN			
	Tenosynovitis Stenosans	Zyrtec	C
UNKNOWN			
	Thrombocytopenia	Hydroxychloroquine	
	Transient Ischaemic	Sulfate	C
UNKNOWN			
	Attack	Advil	C
UNKNOWN			
	Trigger Finger		
	Vasculitis		
	Viral Pharyngitis		
	Vomiting		
	Weight Decreased		

Date:03/30/04ISR Number: 4326909-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA02044
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Feeling Abnormal							
	Renal Failure							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/04ISR Number: 4327407-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY	
Disability	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Epicondylitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Monopril	C			UNKNOWN	1183 DAY
	Insomnia		Monopril	C			UNKNOWN	
	Low Density Lipoprotein		Ambien	C			UNKNOWN	
	Increased		Effexor	C			UNKNOWN	
	Mitral Valve Incompetence		Zocor	C		ORAL	2099 DAY	
	Rash Erythematous		Prevacid	C			UNKNOWN	
	Treatment Noncompliance		Prevacid	C			UNKNOWN	
	Trigger Finger		Levaquin	C			UNKNOWN	
	Urinary Incontinence		Levaquin	C			UNKNOWN	
	Ventricular Hypertrophy		Naprosyn	C			UNKNOWN	4268 DAY
			Naprosyn	C			UNKNOWN	4268 DAY
			Zantac	C			UNKNOWN	

Date:03/30/04ISR Number: 4327409-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0403CAN00151
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/04ISR Number: 4327417-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01895
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Acute Myocardial Infarction Cardiomegaly Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/04ISR Number: 4327419-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00174
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	11 DAY	UNKNOWN
			Acetyldigoxin	C				UNKNOWN
			Candesartan Cilexetil	C				UNKNOWN
			Molsidomine	C				UNKNOWN
			Piretanide	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/04ISR Number: 4327420-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		424 DAY
Initial or Prolonged	Coronary Artery Disease		Respaire	C				UNKNOWN
Other	Diabetes Mellitus		Flonase	C				UNKNOWN
	Insulin-Dependent		Minocycline	C				UNKNOWN
	Diastolic Dysfunction		Piroxicam	C				UNKNOWN
	Hyperlipidaemia		Prednisone	C				UNKNOWN
	Hypertension		Zantac	C				UNKNOWN
	Myocardial Infarction							
	Pulmonary Oedema							
	Rotator Cuff Syndrome							
	Skin Ulcer							
	Syncope							

Date:03/30/04ISR Number: 4327536-6Report Type:Direct Company Report #CTU 215517
Age:89 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx 12.5 Mg	PS		ORAL	12.5 MG DAILY	
Hospitalization -	Cardio-Respiratory Arrest					ORAL		
Initial or Prolonged	Gastrointestinal Haemorrhage		Aspirin	SS				

Date:03/31/04ISR Number: 4328053-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -	Anxiety	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Breast Mass	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiac Murmur	Tylenol	C		
UNKNOWN					
	Disturbance In Attention	Tavist-D	C		
UNKNOWN					
	Fatigue	Afrin Nasal Spray	C		
UNKNOWN					
	Flatulence				
	Fungal Infection				
	Headache				
	Hypercalcaemia				
	Hypertension				
	Hypoaesthesia				
	Nausea				
	Respiratory Disorder				
	Subarachnoid Haemorrhage				
	Urticaria				
	Vomiting				

Date:03/31/04ISR Number: 4328054-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Anxiety
Other	Atrial Fibrillation
	Cardiac Failure Acute
	Cardiac Failure
	Congestive

		Chest Pain Chondrocalcinosis Pyrophosphate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Colon Cancer Recurrent		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Premarin	C		
UNKNOWN							
		Diarrhoea		Glipizide	C		
UNKNOWN							
		Dizziness Gastritis Gastrooesophageal Reflux Disease Mitral Valve Incompetence Osteoarthritis Photosensitivity Reaction Pleuritic Pain Renal Failure Thrombophlebitis Tooth Infection Urinary Tract Infection Vein Pain Vertigo					

Date:03/31/04ISR Number: 4328059-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Abdominal Pain Upper
Disability	Abscess Limb
Other	Adnexa Uteri Mass Anxiety Azotaemia Bronchitis Candidiasis Cardiac Failure Congestive Cellulitis Cervicitis Crying Cystitis Epistaxis Eye Disorder Fallopian Tube Cyst

Fistula
Fluid Retention
Hypertension
Hypoventilation
Irritable Bowel Syndrome
Meniscus Lesion
Menorrhagia
Mood Swings
Neuropathic Pain
Non-Cardiac Chest Pain
Ovarian Fibrosis
Palpitations
Peau D'Orange
Pickwickian Syndrome
Pneumonia
Pulmonary Oedema
Respiratory Failure
Retching

Urinary Tract Infection
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	401	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	3	MON
	Ventolin (Albuterol Sulfate)	C			UNKNOWN	
	Tenormin	C			UNKNOWN	
	Vasotec	C		ORAL		
	Cenestin	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Lodine Xl	C			UNKNOWN	
	Lasix (Furosemide Sodium)	C			UNKNOWN	
	Ditropan	C			UNKNOWN	
	K-Dur	C			UNKNOWN	
	Quinine Sulfate	C			UNKNOWN	

Date:03/31/04ISR Number: 4328063-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Dreams	Health	Vioxx	PS	Merck & Co., Inc	ORAL	65	DAY
	Asthma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	65	DAY
	Cerebrovascular Accident		Vicodin Tablets	C			UNKNOWN	
	Depression		Elavil	C			UNKNOWN	

	Disturbance In Attention	Atenolol	C	
UNKNOWN				
	Dizziness	Lipitor	C	
UNKNOWN				
	Fall	Celebrex	C	
UNKNOWN				
	Fear	Plavix	C	
UNKNOWN				
	Headache	Calan Sr	C	
UNKNOWN				
	Hypertension	Ultram	C	
UNKNOWN				
	Muscle Strain	Zoloft	C	
UNKNOWN				
	Pain	Zoloft	C	
UNKNOWN				
	Renal Failure	Flexeril	C	
UNKNOWN	21 DAY			
	Renal Failure Acute	Flexeril	C	
UNKNOWN	13 DAY			
	Respiratory Disorder	Flexeril	C	
UNKNOWN				
	Rotator Cuff Syndrome	Premarin	C	
UNKNOWN				
	Sciatica	Pepcid	C	ORAL
	Spinal Column Stenosis	Dyazide	C	
UNKNOWN				
	Stress	Accupril	C	
UNKNOWN				
	Therapeutic Response Decreased			

Date:03/31/04ISR Number: 4328067-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Acute Myocardial Infarction
	Anaemia
	Angina Pectoris
	Anxiety
	Asthenia

		Blood Cholesterol Increased					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY						
		Coronary Artery Occlusion		[Therapy Unspecified]	C		
		Coronary Artery Thrombosis		Tylenol	C		
		Diverticulum		Proventil	C		
		Diverticulum Intestinal		Buspar	C		
		Dressler'S Syndrome		Cipro	C		
		Emotional Distress		Tranxene	C		
		Feeling Abnormal		Diphenhydramine Citrate	C		
		Gastritis					
		Gastrointestinal Disorder		Epi-Pen	C		
		Gastrointestinal		Allegra	C		
		Haemorrhage		Duratuss	C		
		Haematochezia		Hydroxyzine Pamoate	C		
		Haematocrit Decreased		Motrin	C		
		Haemoglobin Decreased		Loperamide Hydrochloride	C		
		Haemorrhoids					
		Hypertension		Methylprednisolone	C		
		Myocardial Infarction		Nasonex	C		
		Platelet Count Increased		Elocon	C		
		Proctitis		Actonel	C		
		Prothrombin Time		Ultram	C		
		Prolonged Stress					
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							

Thrombosis
Upper Gastrointestinal
Haemorrhage
Weight Decreased

Date:03/31/04ISR Number: 4328509-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Coronary Artery Disease		Percocet	C			UNKNOWN	
	Coronary Artery		Mobic	C			UNKNOWN	
	Restenosis		Skelaxin	C			UNKNOWN	
	Ecchymosis		Zantac	C			UNKNOWN	
	Emotional Distress							
	Groin Pain							
	Mitral Valve Prolapse							
	Myocardial Infarction							
	Tachycardia							

Date:03/31/04ISR Number: 4328510-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01516
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Other	Infarction
	Cardiac Arrest
	Dizziness
	Medication Error
	Nasal Disorder
	Nasal Septum Deviation

	Seborrhoeic Keratosis Ventricular Fibrillation Vertigo Positional	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)
			Allegra	C			UNKNOWN
			Zocor	C		ORAL	
			Adalat	C			UNKNOWN
			Zantac	C			UNKNOWN

Date:03/31/04ISR Number: 4328511-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 84 DAY	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arteriospasm Coronary		Fioricet Tablets	C			UNKNOWN
	Arthralgia		Fioricet Tablets	C			UNKNOWN
	Chest Pain		Alprazolam	C			UNKNOWN
	Coronary Artery Disease Cystocele		Gnc Womens Ultra Mega	C			UNKNOWN
	Deep Vein Thrombosis		Aspirin	C			UNKNOWN
	Dehydration		Aspirin	C			UNKNOWN
	Diverticulitis		Lipitor	C			UNKNOWN
	Diverticulum		Vitamin E	C			UNKNOWN
	Dysfunctional Uterine		Ambien	C			UNKNOWN

	Bleeding	Zyrtec	C
UNKNOWN			
	Dyspepsia	Vivelle	C
TOPICAL			
	Dyspnoea	Motrin	C
UNKNOWN			
	Dysuria	Lecithin	C
UNKNOWN			
	Flank Pain	Prilosec	C
UNKNOWN			
	Gastroenteritis	Paxil	C
UNKNOWN			
	Generalised Anxiety	Prometrium	C
UNKNOWN			
	Disorder		
	Haematuria		
	Haemorrhoids		
	Hot Flush		
	Menopausal Symptoms		
	Myocardial Infarction		
	Nausea		
	Neck Pain		
	Non-Cardiac Chest Pain		
	Phlebitis Superficial		
	Postoperative Ileus		
	Prinzmetal Angina		
	Rectal Polyp		
	Rhinitis Allergic		
	Sinusitis		
	Stress Incontinence		
	Urinary Tract Infection		
	Venous Insufficiency		
	Vertigo		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/04ISR Number: 4328513-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02180
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Atrophy		Aspirin	C				
UNKNOWN								
Disability	Cerebral Infarction		Cipro	C				
UNKNOWN							7	DAY
	Cerebral Ischaemia		Heparin	C				
UNKNOWN								
	Cerebrovascular Accident		Insulin	C				
UNKNOWN								
	Deep Vein Thrombosis		Glucophage	C				
UNKNOWN								
	Dehydration							
	Diabetes Mellitus							
	Diabetes Mellitus							
	Inadequate Control							
	Dysphonia							
	Ear Disorder							
	Epistaxis							
	Fall							
	Hearing Impaired							
	Heart Rate Increased							
	Hypercoagulation							
	Hypochromic Anaemia							
	Iron Deficiency Anaemia							
	Lymphadenopathy							
	Melaena							
	Micturition Urgency							
	Nocturia							
	Oedema							
	Oestrogen Deficiency							
	Pain							
	Pelvic Organ Injury							
	Pleural Effusion							
	Pneumonia							
	Pollakiuria							
	Pulmonary Hypertension							
	Renal Failure							
	Respiratory Rate Increased							
	Road Traffic Accident							
	Rotator Cuff Syndrome							

Skin Ulcer
Trigger Finger
Urge Incontinence
Urinary Tract Infection
Ventricular Hypokinesia

Date:03/31/04ISR Number: 4328514-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	
Other	Amaurosis Fugax
	Amnesia
	Anaemia
	Anaemia Haemolytic
	Autoimmune
	Anxiety
	Aortic Valve Incompetence

Arthralgia
Atelectasis
Blindness Transient
Blood Cholesterol
Increased
Blood Creatine
Phosphokinase Increased
Cardiac Flutter
Cellulitis
Cerebrovascular Accident
Cholecystitis
Cholelithiasis
Coagulopathy
Condition Aggravated
Cystocele
Decreased Appetite
Disturbance In Attention
Drug Hypersensitivity
Dyspepsia
Dyspnoea
Emotional Distress
Eye Pain
Gastrooesophageal Reflux
Disease
Granuloma
Haematochezia
Haemolysis
Haemophilus Infection
Haemorrhage
Headache
Hiatus Hernia
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism
Hypothyroidism
Postoperative
Increased Appetite
Injury
Iron Deficiency
Leukocytosis
Loss Of Consciousness
Lung Neoplasm
Mental Status Changes
Migraine With Aura

Mitral Valve Incompetence
Muscle Spasms
Muscle Twitching
Musculoskeletal Stiffness
Neurogenic Bladder
Oesophageal Disorder
Platelet Count Increased
Pulmonary Granuloma
Pyrexia
Rectocele
Red Blood Cell
Spherocytes Present
Renal Failure
Sinusitis

		Tachycardia					
		Tinnitus					
		Tracheobronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
8	MON						
		Upper Respiratory Tract		Amitriptyline			
		Infection		Hydrochloride	C		
UNKNOWN							
		Urinary Incontinence		Rocaltrol	C		ORAL
		Viral Infection		Os-Cal + D	C		
UNKNOWN							
		Visual Disturbance		Valium	C		
UNKNOWN							
		Weight Decreased		Synthroid	C		
UNKNOWN							
		Weight Increased		Synthroid	C		ORAL
				Ambien	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Slow-Mag	C		
UNKNOWN							
				Reglan	C		
UNKNOWN							
				Reglan	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:03/31/04ISR Number: 4328516-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
710 DAY						
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
710 DAY						
	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Drug Hypersensitivity		Aspirin	C		
UNKNOWN						
	Dyspepsia					
	Gastrooesophageal Reflux Disease					
	Haemorrhagic Stroke					
	Headache					
	Hyperlipidaemia					
	Localised Infection					
	Myasthenic Syndrome					
	Nasal Congestion					
	Rash Erythematous					
	Rhinitis Allergic					
	Sinus Congestion					
	Skin Laceration					

Date:03/31/04ISR Number: 4328517-9Report Type:Expedited (15-DaCompany Report #PR-MERCK-0402USA01695
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Initial or Prolonged	Renal Tubular Necrosis		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY						
Other			Ultracet	C		ORAL
4 DAY						
			Keflex	C		ORAL
5 DAY						

Date:03/31/04ISR Number: 4328518-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Activities Of Daily Living Impaired
Other	Acute Myocardial Infarction
	Adhesion
	Akinesia
	Anaemia
	Anxiety
	Arthralgia
	Atherosclerosis
	Back Pain
	Biliary Neoplasm
	Bronchitis
	Bronchopneumonia
	Buttock Pain
	Cardiac Disorder
	Cardiac Failure Congestive
	Cardiac Flutter
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Drug Dependence
	Drug Ineffective
	Emotional Distress
	Faecal Occult Blood Positive
	Fatigue
	Fear
	Headache
	Hepatitis C
	Hyperlipidaemia
	Hypertension
	Hypotension
	Insomnia
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Irritability
	Lobar Pneumonia

Loss Of Consciousness
Meralgia Paraesthetica
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Myofascial Pain Syndrome
Neck Pain
Occult Blood Positive
Osteoarthritis
Osteoarthropathy
Pain
Pain In Extremity
Panic Attack
Pneumonia

		Pneumonia Viral						
		Pyrexia						
		Radiculitis Lumbosacral		Report Source	Product	Role	Manufacturer	Route
Dose	Duration							
		Sinus Bradycardia			Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis			Vioxx	SS	Merck & Co., Inc	ORAL
		Syncope			Vioxx	SS	Merck & Co., Inc	ORAL
		Vision Blurred			Vioxx	SS	Merck & Co., Inc	ORAL
					Vioxx	SS	Merck & Co., Inc	ORAL
					Vioxx	SS	Merck & Co., Inc	ORAL
					Lortab	C		
UNKNOWN								
					Amitriptyline Hydrochloride	C		
UNKNOWN			874	DAY				
					Trazodone Hydrochloride	C		
UNKNOWN			1291	DAY				
					Trazodone Hydrochloride	C		
UNKNOWN			1291	DAY				
					Amitriptyline Hydrochloride	C		
UNKNOWN			874	DAY				
					Celebrex	C		
UNKNOWN			362	DAY				
					Cipro	C		
UNKNOWN								
					Neurontin	C		
UNKNOWN								
					Hydrocodone Bitartrate	C		
UNKNOWN								
					Lorazepam	C		
UNKNOWN			2	DAY				
					Methocarbamol	C		
UNKNOWN			957	DAY				

Date:03/31/04ISR Number: 4328519-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02445
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - UNKNOWN	Anorexia	Lanoxin	C
Initial or Prolonged UNKNOWN	Asthenia	Coumadin	C
Disability	Chest Pain		
	Coronary Artery Occlusion		
	Dyspnoea		
	Haemorrhage		
	Weight Decreased		

Date:03/31/04ISR Number: 4328520-9Report Type:Expedited (15-DaCompany Report #NL-MERCK-0403NLD00022
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Death		Acetaminophen	C				
	Delirium		Aspirin	C		ORAL		
	Mental Impairment		Dalteparin Sodium	C		PARENTERAL		
	Refusal Of Treatment By		Dexamethasone	C				
	Patient		Fentanyl	C				
	Renal Failure		Sennosides	C				
			Metoclopramide Hydrochloride	C				
			Metoprolol Tartrate	C				
			Morphine	C				
			Morphine Sulfate	C				
			Pantoprazole Sodium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/04ISR Number: 4328521-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01917
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Maternal Drugs Affecting Foetus Pulmonary Artery Atresia		Vioxx	PS	Merck & Co., Inc			

Date:03/31/04ISR Number: 4328522-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY

Date:03/31/04ISR Number: 4328523-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	38	DAY

Date:03/31/04ISR Number: 4329472-8Report Type:Direct Company Report #CTU 215619
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Vioxx 25 Mg	PS		ORAL	25 MG PO Q	
Hospitalization -	Decreased Appetite							DAY PTA
Initial or Prolonged	Duodenal Ulcer		Mobic 15 Mg	SS		ORAL	15 MG PO Q	
Disability	Perforation							DAY PTA
Required			Aspirin	SS			1	DAY
Intervention to								

Prevent Permanent
Impairment/Damage

Date:04/01/04ISR Number: 4329467-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Acute Prerenal Failure
	Acute Pulmonary Oedema
	Acute Respiratory Failure
	Asthenia
	Asthma
	Atelectasis
	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Depression
	Dilatation Atrial
	Dyspnoea
	Fatigue
	Heart Rate Increased
	Heart Rate Irregular
	Hypothyroidism
	Hypoxia
	Increased Bronchial Secretion

Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Mitral Valve Incompetence							
Myocardial Infarction							
Myocardial Ischaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
Pericardial Effusion		Flexeril	C			UNKNOWN	
Pneumonia		Vasotec	C			UNKNOWN	
Pulmonary Oedema		Lasix (Furosemide)	C			UNKNOWN	
Respiratory Disorder		Brethine	C			UNKNOWN	
Respiratory Failure		Glipizide	C			UNKNOWN	
Sinus Tachycardia		Actos	C			UNKNOWN	
Sleep Apnoea Syndrome		K-Dur	C			UNKNOWN	
Tachycardia		Altace	C			UNKNOWN	
Tricuspid Valve Incompetence							

Date:04/01/04ISR Number: 4329470-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00625
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Anastomotic Stenosis
	Arthralgia
	Blood Alkaline Phosphatase Increased
	Blood Pressure Increased
	Cardiovascular Disorder
	Catheter Related Complication
	Catheter Site Discharge
	Chest Pain
	Cholelithiasis
	Colon Cancer Metastatic
	Constipation

Dehydration
Diarrhoea
Dyspepsia
Early Satiety
Gastritis
Haematocrit Decreased
Haemoglobin Decreased
Hydronephrosis
Hypernatraemia
Impaired Work Ability
Joint Crepitation
Joint Effusion
Joint Range Of Motion
Decreased
Metastatic Neoplasm
Mucosal Inflammation
Nausea
Neutrophil Count
Increased
Oesophageal Stenosis
Oesophagitis
Platelet Count Increased
Pneumonia
Pneumoperitoneum

		Procedural Site Reaction					
		Prothrombin Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pyrexia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Refusal Of Treatment By	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
19	DAY						
		Patient		Tylenol	C		
UNKNOWN							
		Renal Failure		Lomotil	C		
UNKNOWN							
		Renal Failure Acute		Prednisone	C		
UNKNOWN		3 DAY					
		Respiratory Arrest		Prednisone	C		ORAL
3	DAY						
		Septic Shock		Prednisone	C		
UNKNOWN							
		Shock					
		Small Intestinal Obstruction					
		Tachycardia					
		Upper Gastrointestinal Haemorrhage					
		Urinary Retention					
		Urinary Tract Infection					
		Urinary Tract Obstruction					
		Vomiting					
		Weight Decreased					

Date:04/01/04ISR Number: 4329471-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0403CAN00189
Age:50 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Epilepsy	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN		2 DAY					
Initial or Prolonged		Hypoaesthesia	Professional				
		Paraesthesia					

Date:04/01/04ISR Number: 4329475-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Arthralgia
	Aspartate Aminotransferase Increased
	Atrial Fibrillation
	Blood Pressure Diastolic Increased
	Cardiac Failure Congestive
	Cardiomyopathy
	Cerebrovascular Accident
	Congestive Cardiomyopathy
	Depression
	Dilatation Atrial
	Dyspnoea Exertional
	Dyspnoea Paroxysmal Nocturnal
	Fatigue
	Haematocrit Decreased
	Haemoglobin Decreased
	Insomnia
	Intracardiac Thrombus
	Lobar Pneumonia

		Mitral Valve Incompetence Orthopnoea Pleural Effusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
194	DAY						
		Po2 Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
194	DAY						
		Qrs Axis Abnormal		Adderall Tablets	C		
UNKNOWN							
		Sinus Tachycardia		Ibuprofen	C		
UNKNOWN							
		Stress Supraventricular Extrasystoles Tricuspid Valve Incompetence Ventricular Hypertrophy Ventricular Hypokinesia Ventricular Tachycardia					

Date:04/01/04ISR Number: 4329476-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0401FRA00025
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Diverticulum Intestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
61	DAY					
Initial or Prolonged	Haemorrhagic	Professional	Aspirin Lysine	SS		ORAL
			Allopurinol	C		ORAL
			Diclofenac Sodium	C		
TOPICAL						
			Nifuroxazide	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Quinapril Hydrochloride	C		ORAL
			Lansoprazole	C		ORAL
			Amlodipine Besylate	C		ORAL

Date:04/01/04ISR Number: 4329479-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
Other	Supraventricular
	Arthralgia
	Atherosclerosis
	Back Pain
	Blood Urine Present
	Bundle Branch Block
	Cold Sweat
	Coronary Artery Disease
	Dizziness
	Electrocardiogram St
	Segment Depression
	Gastric Disorder
	Gastric Haemorrhage
	Hyperhidrosis
	Intervertebral Disc
	Degeneration
	Joint Stiffness
	Muscle Strain
	Nausea
	Neck Pain
	Pain In Extremity
	Pallor

		Palpitations					
		Paraesthesia					
		Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rotator Cuff Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Depo-Medrol With Lidocaine	C		
UNKNOWN		1 DAY					
				Depo-Medrol With Lidocaine	C		
UNKNOWN		1 DAY					

Date:04/01/04ISR Number: 4329481-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02609
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Generalised Oedema					
		Liver Disorder					
		Lung Disorder					
		Pain					

Date:04/01/04ISR Number: 4329959-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00007
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL
372 DAY							
		Arthritis		Norvasc	SS		
UNKNOWN							
		Bronchiolitis		Cartia Xt	SS		
UNKNOWN							
		Bronchospasm		Cartia (Diltiazem			

Drug Hypersensitivity Hydrochloride) C
UNKNOWN

Erythema
Eustachian Tube
Dysfunction
Faecal Occult Blood
Positive
Gastrooesophageal Reflux
Disease
Haematochezia
Headache
Hypertension
Rash
Sinus Headache
Upper Respiratory Tract
Infection
Uterine Leiomyoma
Weight Increased

Date:04/01/04ISR Number: 4329962-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anaemia
	Angina Unstable

		Asthenia					
		Atrophy					
		Azotaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Brain Mass		Vioxx	SS	Merck & Co., Inc	ORAL
		Bundle Branch Block Right		Albuterol Sulfate	C		
RESPIRATORY							
		Cardiac Failure					
(INHALATION)							
		Congestive		Fosamax	C		ORAL
		Cardiomyopathy		Amlodipine Besylate	C		ORAL
		Cataract		Aspirin	C		ORAL
		Chronic Sinusitis		Atorvastatin Calcium	C		
UNKNOWN							
		Confusional State		Beclomethasone			
		Dehydration		Dipropionate	C		
RESPIRATORY							
		Delirium					
(INHALATION)							
		Depression		Lotensin	C		
UNKNOWN							
		Dizziness		Calcium Carbonate	C		ORAL
		Drug Hypersensitivity		Baycol	C		
UNKNOWN							
		Essential Hypertension		Diphenhydramine			
		Fall		Hydrochloride	C		ORAL
		Fatigue		Estrogens			
		Gangrene		(Unspecified)	C		ORAL
		Gastric Ulcer		Folic Acid	C		ORAL
		Gastritis		Hydrodiuril	C		ORAL
		Helicobacter Infection		Hydroxychloroquine			
		Herpes Zoster		Sulfate	C		ORAL
		Hypoaesthesia		Indocin			
		Hypokalaemia		(Indomethacin)	C		
UNKNOWN							
		Hypovolaemia		Ipratropium Bromide	C		
UNKNOWN							
		Interstitial Lung Disease		Isosorbide			
		Leg Amputation		Mononitrate	C		ORAL
		Lung Infiltration		Misoprostol	C		ORAL
		Mastitis		Naproxen	C		ORAL
		Meningioma		Prednisone	C		ORAL
		Muscle Spasms					
		Myocardial Infarction					
		Myopathy					
		Nausea					

Oesophagitis
Oral Intake Reduced
Orthostatic Hypotension
Paraesthesia
Peripheral Occlusive
Disease
Pneumonia
Pruritus
Pulmonary Embolism
Renal Cyst
Renal Failure Acute
Respiratory Distress
Sinus Tachycardia
Syncope
Transient Ischaemic
Attack
Upper Gastrointestinal
Haemorrhage
Vasculitis
Ventilation/Perfusion
Scan Abnormal
Visual Acuity Reduced
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/04ISR Number: 4329964-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		696 DAY
Initial or Prolonged	Apathy		Reglan	SS				UNKNOWN
Disability	Balance Disorder		Celebrex	C				UNKNOWN
	Carotid Artery Stenosis		Catapres	C				UNKNOWN
	Carpal Tunnel Syndrome		Flonase	C				UNKNOWN
	Cerebellar Infarction		Prilosec	C				UNKNOWN
	Cerebrovascular Accident		Lopid	C				UNKNOWN
	Cerebrovascular Disorder		Robaxin	C				UNKNOWN
	Chest Discomfort							
	Cognitive Disorder							
	Cogwheel Rigidity							
	Coordination Abnormal							
	Deafness Neurosensory							
	Decreased Interest							
	Dementia							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Diabetic Neuropathy							
	Difficulty In Walking							
	Dizziness							
	Fall							
	Fatigue							
	Gait Disturbance							
	Gallbladder Disorder							
	Glossitis							
	Haematochezia							
	Headache							
	Hiatus Hernia							
	Loss Of Consciousness							
	Major Depression							
	Memory Impairment							
	Neuropathy Peripheral							
	Orthostatic Hypotension							
	Pseudodementia							

Radiculopathy
Sensory Disturbance
Sinusitis
Sleep Apnoea Syndrome
Somnolence
Subclavian Steal Syndrome
Treatment Noncompliance
Tremor

Date:04/01/04ISR Number: 4329965-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Activities Of Daily Living Impaired
	Arthralgia
	Arthropathy
	Asthenia
	Blood Cholesterol Increased
	Blood Pressure Increased
	Body Temperature

		Increased					
		Bunion					
		Cardiac Failure					
		Congestive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Intolerance		Tylenol	C		
UNKNOWN							
		Electrocardiogram T Wave		Aspirin	C		
UNKNOWN							
		Inversion					
		Fall					
		Gait Disturbance					
		Gastric Disorder					
		Globulins Increased					
		Headache					
		Hypertensive Heart					
		Disease					
		Intervertebral Disc					
		Disorder					
		Joint Sprain					
		Joint Swelling					
		Laceration					
		Limb Discomfort					
		Lumbar Spinal Stenosis					
		Mitral Valve Incompetence					
		Mobility Decreased					
		Muscle Spasms					
		Myalgia					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasal Congestion					
		Nausea					
		Nocturia					
		Oedema Peripheral					
		Onychomycosis					
		Osteoarthritis					
		Pericarditis					
		Postnasal Drip					
		Pulmonary Granuloma					
		Radiculopathy					
		Renal Failure					
		Respiratory Rate					
		Increased					
		Rotator Cuff Syndrome					

Scoliosis
Seborrhoeic Keratosis
Sinusitis
Skin Lesion
Spinal Osteoarthritis
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Ventricular Hypertrophy
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/04ISR Number: 4329969-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		80 DAY
Initial or Prolonged	Living Impaired		Ascorbic Acid	C				UNKNOWN
Disability	Anxiety		Wellbutrin	C				UNKNOWN
	Aortic Calcification		Calcium (Unspecified)	C				UNKNOWN
	Blood Cholesterol Increased		Lanoxin	C				UNKNOWN
	Blood Triglycerides Increased		Premarin	C				UNKNOWN
	Bundle Branch Block Left		Lasix (Furosemide)	C				UNKNOWN
	Burning Sensation		Coenzyme Q10	C				UNKNOWN
	Cardiac Failure		Vitamin E	C				UNKNOWN
	Congestive Cardiomegaly		Coumadin	C				UNKNOWN
	Carotid Artery Disease		Vitamin B (Unspecified)	C				UNKNOWN
	Chest Discomfort		Ginkgo Biloba Extract	C				UNKNOWN
	Chest Pain		Levocarnitine	C				UNKNOWN
	Congestive Cardiomyopathy		Prinivil	C		ORAL		
	Cough		Magnesium (Unspecified)	C				UNKNOWN
	Depression		Nicotine	C				UNKNOWN
	Difficulty In Walking		Pamelor	C				UNKNOWN
	Dizziness							
	Dyspepsia							
	Dyspnoea							
	Fatigue							
	Feeling Abnormal							
	Fibroadenoma Of Breast							

Gastrointestinal Tract
Adenoma
Haemorrhoids
Hyperlipidaemia
Hypertension
Impaired Work Ability
Insomnia
Mood Swings
Nightmare
Orthopnoea
Pain In Extremity
Palpitations
Proctalgia
Prothrombin Time
Shortened
Pulmonary Vascular
Disorder
Sinus Tachycardia
Spinal Osteoarthritis
Ventricular Extrasystoles

Date:04/01/04ISR Number: 4329971-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome PT
Death Acute Myocardial
Infarction
Angina Pectoris
Cardiomegaly
Cervicobrachial Syndrome
Coronary Artery Occlusion

	Excoriation						
	Pulmonary Oedema						
	Swelling Face	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Attack							

Date:04/01/04ISR Number: 4329974-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01388
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Naprosyn	C				
UNKNOWN								
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Eye Disorder							
	Hypercholesterolaemia							
	Injury							
	Leukocytosis							
	Lung Infiltration							
	Nephrolithiasis							
	Oedema Peripheral							
	Pleural Effusion							
	Productive Cough							
	Pyrexia							
	Silent Myocardial							
	Infarction							
	Sleep Apnoea Syndrome							
	Urticaria							
	Ventricular Arrhythmia							

Date:04/01/04ISR Number: 4329975-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris

Initial or Prolonged Disability	Aortic Stenosis Aortic Valve Incompetence Asthenia Atelectasis Atrial Fibrillation Cardiac Murmur Cellulitis Constipation Cough Depressed Level Of Consciousness Depression Dizziness Dyspnoea Dyspnoea Exertional Gastrointestinal Motility Disorder Gastrooesophageal Reflux Disease Hyperhidrosis

		Injury					
		Insomnia					
		Lung Neoplasm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Medical Device		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Complication		Tylenol	C		
UNKNOWN							
		Nausea		Codeine	C		
UNKNOWN							
		Oesophageal Spasm		Vasotec	C		ORAL
		Postoperative Infection		Premarin	C		
UNKNOWN							
		Pyrexia		Premarin	C		
UNKNOWN							
		Sternal Injury		Zocor	C		ORAL
		Syncope		Hydrocodone			
		Ventricular Hypertrophy		Hydrochloride	C		
UNKNOWN							
				Levsin	C		
UNKNOWN							
				Synthroid	C		ORAL
				Prilosec	C		ORAL

Date:04/01/04ISR Number: 4329976-8Report Type:Expedited (15-DaCompany Report #US-MERCK-99091937
Age:48 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Aspartate		Vioxx	SS	Merck & Co., Inc	ORAL
		Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL
19	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Thyroid Stimulating		Vioxx	SS	Merck & Co., Inc	ORAL
		Hormone Increased		[Therapy			
		Chest Pain		Unspecified]	C		
UNKNOWN							
		Coronary Artery		Cortisone	C		
UNKNOWN							
		Atherosclerosis		Famotidine	C		
UNKNOWN							
		Coronary Artery Disease		Influenza Virus			

	Coronary Artery Occlusion	Vaccine	C
UNKNOWN			
	Dermatitis Contact Disease Progression Dyspepsia	Methotrexate (Methotrexate Sodium)	C
UNKNOWN			
	Gastroduodenitis	Metoclopramide	C
UNKNOWN			
	Gastrointestinal Disorder	Omeprazole	C
UNKNOWN			
	Gout	Prednisone	C
UNKNOWN			
	Hepatic Enzyme Increased Hepatic Steatosis Hepatitis Hepatocellular Damage Hyperlipidaemia Hypertension Hypothyroidism Liver Disorder Myocardial Infarction Oesophagitis Palindromic Rheumatism Polyarthritis Psoriatic Arthropathy Rash Erythematous Squamous Cell Carcinoma		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/04ISR Number: 4329979-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA02044
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Renal Failure Acute							
	Vomiting							

Date:04/01/04ISR Number: 4329980-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01870
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	12	DAY
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:04/01/04ISR Number: 4329981-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01985
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:04/01/04ISR Number: 4330295-4Report Type:Direct Company Report #CTU 215772
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Csf Glucose Decreased		Vioxx	PS		ORAL		
ORAL								

Initial or Prolonged	Csf Protein Increased Csf White Blood Cell Count Increased Headache Lethargy Meningitis Aseptic Musculoskeletal Stiffness Neck Pain Night Sweats

Date:04/02/04ISR Number: 4331538-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accident
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Anxiety Arthralgia Blood Pressure Decreased Blood Triglycerides Increased Bronchitis Coronary Artery Disease Coronary Artery Stenosis Diverticulum Drug Ineffective

		Fatigue					
		Gastritis					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Groin Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematocrit Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemoglobin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Aspirin	C		
UNKNOWN							
		Mitral Valve Incompetence		Tenormin	C		
UNKNOWN							
		Muscle Disorder		Tenormin	C		
UNKNOWN							
		Musculoskeletal Stiffness		Lipitor	C		
UNKNOWN							
		Osteoarthritis		Clonidine	C		
TOPICAL							
		Pleural Effusion		Clonidine	C		ORAL
		Rectal Haemorrhage		Monopril	C		
UNKNOWN							
		Red Blood Cell Count		Ibuprofen	C		
UNKNOWN							
		Decreased		Anaprox	C		
UNKNOWN							
		Respiratory Rate					
		Increased					
		Skin Irritation					
		Sleep Apnoea Syndrome					
		Subendocardial Ischaemia					
		Tension Headache					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Weight Increased					

Date:04/02/04ISR Number: 4331546-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02052
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Disability	Amnesia	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Anger	Lotrel	C		ORAL
	Blood Cholesterol	Wellbutrin	C		
UNKNOWN					
	Increased	Wellbutrin	C		
UNKNOWN	5 DAY				
	Carotid Artery Stenosis	Celebrex	C		
UNKNOWN					
	Carpal Tunnel Syndrome	Klonopin	C		
UNKNOWN					
	Cerebral Haemorrhage	Clonidine	C		ORAL
249 DAY					
	Cerebral Infarction	Clonidine	C		ORAL
	Depression	Zoloft	C		ORAL
	Dizziness	Labetalol			
	Drug Ineffective	Hydrochloride	C		ORAL
	Haemorrhagic Stroke	Labetalol			
	Hyperhidrosis	Hydrochloride	C		ORAL
	Hypertension	Claritin	C		
UNKNOWN					
	Injury	Paxil	C		ORAL
	Intracranial Aneurysm	Dilantin	C		ORAL
	Intraventricular	Ranitidine	C		ORAL
	Haemorrhage				
	Irritability				
	Peptic Ulcer				
	Tearfulness				
	Transient Ischaemic				
	Attack				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/04ISR Number: 4331551-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0401FRA00075
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cytolytic Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Hepatic Necrosis		Acetaminophen	SS		ORAL		11 DAY
	Hepatitis Acute							
	Hepatitis Cholestatic							
	Prothrombin Time Ratio Decreased							

Date:04/02/04ISR Number: 4331552-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00295
Age:38 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Morphine	C		ORAL		18 DAY
Initial or Prolonged			Senna	C		ORAL		11 DAY

Date:04/02/04ISR Number: 4331553-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Urine Present		[Therapy					
	Bundle Branch Block Right		Unspecified]	C				UNKNOWN
	Cold Sweat		Celebrex	C				UNKNOWN
	Coronary Artery Disease		Depo-Medrol With					
	Coronary Artery Occlusion		Lidocaine	C			1 DAY	UNKNOWN
	Dizziness		Depo-Medrol With					

	Electrocardiogram St Segment Depression 1 DAY Gastric Disorder Gastric Haemorrhage Hyperhidrosis Hyperlipidaemia Intervertebral Disc Degeneration Ischaemia Joint Stiffness Muscle Strain Nausea Pain In Extremity Pallor Post Procedural Complication Road Traffic Accident Rotator Cuff Syndrome Spinal Column Stenosis Syncope Vasovagal Ventricular Dysfunction	Lidocaine	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/04ISR Number: 4331556-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01289
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		1 MON
	Gastric Disorder		Tylenol	C				UNKNOWN
	Hypertension		Amitriptyline Hydrochloride	C				UNKNOWN
	Overdose							
	Sensory Loss		Lotrel	C				UNKNOWN
	Stress		Premarin	C				UNKNOWN
	Tricuspid Valve		Lopressor	C				UNKNOWN
	Incompetence		Prilosec	C				UNKNOWN
			Rabeprazole Sodium	C				UNKNOWN

Date:04/02/04ISR Number: 4331562-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0403CHE00047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Varicella		Tizanidine Hydrochloride	C		ORAL		

Date:04/02/04ISR Number: 4331581-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Alopecia
	Anaemia Macrocytic
	Anxiety

Arthralgia
Asthenia
Back Injury
Back Pain
Balance Disorder
Blindness
Blood Pressure Diastolic
Increased
Blood Triglycerides
Increased
Bone Scan Abnormal
Bronchitis
Carotid Artery Disease
Carotid Artery Stenosis
Carotid Bruit
Cerebral Infarction
Cerebral Thrombosis
Cerebrovascular Accident
Chest Pain
Chest Wall Pain
Chronic Obstructive
Pulmonary Disease
Compression Fracture
Coronary Artery Disease
Depression
Difficulty In Walking
Drug Ineffective
Dysphagia
Dyspnoea

		Electrocardiogram Qt Prolonged					
		Electrocardiogram St-T Change	Report Source	Product	Role	Manufacturer	Route
Dose	Duration			Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Folate Deficiency		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Formication		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		Zovirax	C		
UNKNOWN							
		Headache		Trimox	C		
UNKNOWN							
		Hypercholesterolaemia		Celebrex	C		
UNKNOWN							
		Hyperhidrosis		Zyrtec	C		
UNKNOWN							
		Hyperreflexia		Plavix	C		ORAL
		Hypoaesthesia		Nexium	C		
UNKNOWN							
		Hyporeflexia		Paxil	C		
UNKNOWN			533 DAY				
		Increased Tendency To		Prednisone	C		
UNKNOWN							
		Bruise					
		Insomnia					
		Joint Range Of Motion					
		Decreased					
		Migraine					
		Muscular Weakness					
		Myalgia					
		Myofascial Pain Syndrome					
		Nausea					
		Neck Pain					
		Neoplasm Malignant					
		Nuclear Magnetic					
		Resonance Imaging Brain					
		Abnormal					
		Osteopenia					
		Osteoporosis					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Rash					
		Red Blood Cell					

Sedimentation Rate
Increased
Rhinitis Allergic
Sinus Headache
Sinusitis
Stress
Tendonitis
Thoracic Outlet Syndrome
Thrombocytopenia
Transient Ischaemic
Attack
Visual Disturbance
Vitamin B12 Deficiency

Date:04/02/04ISR Number: 4331594-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Aortic Valve Incompetence
	Arrhythmia
	Bladder Disorder

		Blood Glucose Increased					
		Bradycardia					
		Cataract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Closed Head Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermographism		Vioxx	SS	Merck & Co., Inc	ORAL
		Dry Skin		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Fosamax	C		ORAL
		Dyspnoea		Celebrex	C		
UNKNOWN							
		Dyspnoea Exertional		Prempro	C		
UNKNOWN							
		Dysuria		Hyaluronate Sodium	C		
PARENTERAL							
		Ear Pain		Advil	C		
UNKNOWN							
		Eye Haemorrhage		Synthroid	C		
UNKNOWN							
		Eye Pain		Claritin	C		
UNKNOWN							
		Fall					
		Gallop Rhythm Present					
		Gastrointestinal Disorder					
		Glaucoma					
		Haematocrit Decreased					
		Headache					
		Hearing Impaired					
		Hypertension					
		Hypokalaemia					
		Hypothyroidism					
		Insomnia					
		Keratoconjunctivitis					
		Sicca					
		Loose Body In Joint					
		Migraine					
		Mitral Valve Incompetence					
		Nasal Septum Ulceration					
		Nausea					
		Neck Pain					
		Nervous System Disorder					
		Neurodermatitis					
		Optic Nerve Injury					
		Osteoporosis					
		Palpitations					
		Papilloedema					
		Paraesthesia Oral					

Paralysis
Peripheral Vascular
Disorder
Photopsia
Platelet Count Decreased
Polymyalgia Rheumatica
Pruritus
Pulmonary Valve
Incompetence
Rash
Renal Disorder
Retinal Vein Occlusion
Sinusitis
Skin Laceration
Stress
Syncope Vasovagal
Tachycardia
Treatment Noncompliance
Vision Blurred
Visual Acuity Reduced

Date:04/02/04ISR Number: 4331599-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
	Acute Respiratory Failure
	Agitation
	Angina Pectoris
	Aortic Valve Calcification
	Arterial Disorder
	Arthralgia
	Asthenia
	Atelectasis
	Atrial Tachycardia
	Back Pain
	Blood Pressure Decreased
	Brain Hypoxia
	Cardiac Arrest
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cerebrovascular Accident
	Coronary Artery Disease
	Dilatation Atrial
	Dilatation Ventricular
	Electrocardiogram Qrs Complex Prolonged
	Emotional Distress
	Encephalopathy
	Fatigue
	Folliculitis
	Gastrooesophageal Reflux Disease
	Headache
	Hypercholesterolaemia
	Hypokinesia
	Intervertebral Disc Protrusion
	Ischaemic Cardiomyopathy
	Ischaemic Hepatitis
	Loss Of Consciousness
	Lung Infiltration
	Mental Status Changes
	Migraine

Mitral Valve Disease
Multi-Organ Failure
Multiple Sclerosis
Muscle Spasms
Oedema Peripheral
Panic Disorder
Pulmonary Oedema
Pulse Abnormal
Renal Failure Acute
Tendonitis
Thyroid Neoplasm
Ulcer Haemorrhage
Urinary Tract Infection
Ventricular Dysfunction
Ventricular Fibrillation

Ventricular Tachycardia
Visual Disturbance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	14	MON
	Zoloft	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Diovan	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Oxycodone	C			UNKNOWN	
	Zantac	C			UNKNOWN	
	Maxalt (Rizatriptan Benzoate)	C		ORAL		

Date:04/02/04ISR Number: 4331654-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0403CHE00047
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Varicella		Tizanidine Hydrochloride	C		ORAL	1	DAY

Date:04/02/04ISR Number: 4332304-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
Other	Aortic Valve Incompetence
	Bladder Disorder
	Cataract
	Closed Head Injury
	Contusion

Dyspepsia
Dyspnoea
Dysuria
Ear Pain
Eye Haemorrhage
Eye Pain
Fall
Glaucoma
Headache
Hearing Impaired
Hypertension
Hypokalaemia
Keratoconjunctivitis
Sicca
Loose Body In Joint
Migraine
Mitral Valve Incompetence
Nasal Turbinate
Hypertrophy
Nausea
Neurodermatitis
Optic Nerve Injury
Palpitations
Paraesthesia Oral
Peripheral Vascular
Disorder
Polymyalgia Rheumatica

		Retinal Vein Occlusion					
		Reversible Airways Obstruction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Skin Laceration	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Syncope		Vioxx	SS	Merck & Co., Inc	ORAL
		Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL
				Fosamax	C		ORAL
				Celebrex	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Hyaluronate Sodium	C		
PARENTERAL							
				Advil	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							

Date:04/02/04ISR Number: 4333615-XReport Type:Expedited (15-DaCompany Report #2004004824
Age:97 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gastrointestinal	Consumer	Zoloft (Sertraline)	PS		
2 YR							
Hospitalization -		Haemorrhage		Celecoxib			
Initial or Prolonged		Haematemesis		(Celecoxib)	SS		
200 MG							
		Malaise					
(DAILY)							
				Rofecoxib (Fofecoxib)	SS		

Date:04/02/04ISR Number: 4333841-XReport Type:Expedited (15-DaCompany Report #2003036888
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arthralgia	Consumer	Lipitor			

	Asthenia	Health	(Atorvastatin)	PS
40 MG				
	Blood Potassium Decreased	Professional	Rofecoxib	
	Blood Sodium Decreased		(Rofecoxib)	SS
	Constipation		Prednisone	
	Difficulty In Walking		(Prednisone)	SS
	Gait Disturbance		Potassium	
	Hypothyroidism		(Potassium)	C
	Muscle Atrophy		Amlodipine Besilate	
	Muscular Weakness		(Amlodipine	
	Myopathy		Besilate)	C
	Pain		Dyazide	
			(Hydrochlorothiazide	
			, Triamterene)	C
			Narine Repetabs	
			(Pseudoephedrine	
			Sulfate, Loratadine)	C
			Esomeprazole	
			(Esomeprazole)	C
			Levothyroxine Sodium	
			(Levothyroxine	
			Sodium)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/02/04ISR Number: 4334089-5Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00044
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
	Helicobacter Infection	Health Professional					PO	9 DAY
	Peritonitis		Tab Placebo	SS		ORAL	PO	9 DAY
			Acetaminophen	C				
			Cortisone	C				

Date:04/02/04ISR Number: 4334238-9Report Type:Expedited (15-DaCompany Report #2004PK00564
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Spasm	Foreign	Asco Top	PS		ORAL	2.5 MG PRN PO	
Required	Arteriosclerosis	Health	Asco Top	SS		ORAL	2.5 MG PO	
Intervention to	Gastrointestinal Disorder	Professional	Vioxxdolor	SS		ORAL	50 MG PRN PO	
Prevent Permanent	Gastrointestinal Erosion	Other	Imigran Nasal	SS		NASAL	20 MG IN	
Impairment/Damage	Intestinal Hypermotility		Propanolol	C				
	Mesenteric Artery Stenosis		Glucocorticoids	C				
	Migraine							
	Peritoneal Adhesions							
	Retroperitoneal Fibrosis							

Date:04/05/04ISR Number: 4331557-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis		Vioxx	PS	Merck & Co., Inc	ORAL	153 DAY	

Initial or Prolonged	Fatigue	Infliximab	SS	
INTRAVENOUS	122 DAY			
	Hepatic Cirrhosis	Methotrexate	SS	ORAL
YR				
	Hepatic Fibrosis	Omeprazole Magnesium	SS	ORAL
153 DAY				
	Hepatic Steatosis	Sertraline		
	Jaundice	Hydrochloride	SS	ORAL
	Liver Disorder	Sertraline		
	Muscle Atrophy	Hydrochloride	SS	ORAL
	Nausea	Omeprazole Magnesium	SS	ORAL
153 DAY				
	Pruritus	Folic Acid	C	
UNKNOWN				
	Vasculitis	Glyburide	C	
UNKNOWN				

Date:04/05/04ISR Number: 4331565-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Disability	Abscess Limb
Other	Adnexa Uteri Mass
	Anxiety
	Azotaemia
	Bronchitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cardiac Flutter
	Cellulitis
	Cervicitis

		Crying					
		Cystitis					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Eye Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Fallopian Tube Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Fistula		Vioxx	SS	Merck & Co., Inc	ORAL
		Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercapnia		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Hypertension		Ventolin (Albuterol			
		Hypoventilation		Sulfate)	C		
UNKNOWN							
		Injury		Tenormin	C		
UNKNOWN							
		Irritable Bowel Syndrome		Ultram	C		
UNKNOWN							
		Joint Dislocation		Vasotec	C		ORAL
		Joint Effusion		Cenestin	C		
UNKNOWN							
		Joint Injury		Lodine Xl	C		
UNKNOWN							
		Limb Discomfort		Lasix (Furosemide			
		Lower Extremity Mass		Sodium)	C		
UNKNOWN							
		Mass		Ditropan	C		
UNKNOWN							
		Meniscus Lesion		K-Dur	C		
UNKNOWN							
		Menorrhagia		Quinine Sulfate	C		
UNKNOWN							
		Mood Swings					
		Nasal Dryness					
		Neuropathic Pain					
		Nocturia					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Ovarian Fibrosis					
		Palpitations					
		Paraesthesia					
		Peau D'Orange					
		Pelvic Pain					
		Pickwickian Syndrome					

Pneumonia
Pulmonary Oedema
Respiratory Failure
Retching
Sweat Gland Infection
Urinary Tract Infection
Weight Increased

Date:04/05/04ISR Number: 4331570-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
Disability	Adverse Event
Other	Angina Unstable
	Anxiety
	Atrioventricular Block
	Blood Glucose Increased
	Bundle Branch Block Left
	Cataract
	Chest Pain
	Conjunctivitis Infective
	Contusion
	Cough
	Diarrhoea
	Diplopia
	Dizziness

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dysphonia Dyspnoea Emotional Distress					
		Eye Disorder Fatigue Feeling Cold		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
OPHTHALMIC							
		Head Injury		Tylenol	C		
UNKNOWN							
		Hot Flush		Aspirin	C		
UNKNOWN							
		Inflammatory Bowel		Aspirin	C		
UNKNOWN							
		Disease		Lipitor	C		
UNKNOWN		1304 DAY					
		Irritable Bowel Syndrome		Premarin	C		
UNKNOWN							
		Mitral Valve Prolapse		Micronase	C		
UNKNOWN							
		Nasopharyngitis		Motrin	C		
UNKNOWN							
		Nausea		Synthroid	C		
UNKNOWN							
		Pain		Synthroid	C		
UNKNOWN							
		Palpitations		Glucophage	C		
UNKNOWN							
		Pinguecula		Naproxen	C		
UNKNOWN							
		Refusal Of Treatment By		Nitroglycerin	C		
UNKNOWN							
		Patient		Refresh	C		
OPHTHALMIC							
		Sinus Bradycardia Somnolence Stress Tenderness Upper Respiratory Tract Infection					

Date:04/05/04ISR Number: 4331574-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Arthritis Blood Cholesterol Increased Cardiac Valve Disease Dementia Alzheimer'S Type Diabetes Mellitus Hepatocellular Damage Hypertension Insomnia Low Density Lipoprotein Increased Parkinson'S Disease Rheumatoid Arthritis Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/04ISR Number: 4331575-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abscess Jaw Angina Pectoris Anxiety Blood Cholesterol Increased Blood Creatine Phosphokinase Increased Cardiac Murmur Carotid Artery Stenosis

	Chest Pain Coronary Artery Disease Dental Caries	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Depression		Vioxx	PS	Merck & Co., Inc	ORAL
846	DAY					
	Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
846	DAY					
	Duodenal Ulcer Duodenal Ulcer		[Therapy Unspecified]	C		
UNKNOWN						
	Haemorrhage		Vicodin Tablets	C		
UNKNOWN						
	Duodenitis		Xanax	C		
UNKNOWN						
	Electrocardiogram St		Covera	C		
UNKNOWN						
	Segment Abnormal		Trimox	C		
UNKNOWN						
	Food Poisoning		Atenolol	C		
UNKNOWN						
	Gastroenteritis		Soma	C		
UNKNOWN						
	Gastrointestinal		Relafen	C		
UNKNOWN						
	Haemorrhage Gout Hypertension Hypovolaemia Medication Error Myocardial Infarction Oesophageal Disorder Osteoarthritis Otitis Media Overdose Peptic Ulcer Haemorrhage Sinus Tachycardia Tooth Infection					

Date:04/05/04ISR Number: 4331577-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01392
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthropathy Asthenia

Depression
Drug Effect Decreased
Drug Ineffective
Dysstasia
Emotional Distress
Fibromyalgia
Fluid Retention
Foot Fracture
Herpes Zoster
Hypertension
Hypertonic Bladder
Hypoacusis
Hypoaesthesia
Influenza
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Intervertebral Disc Space
Narrowing
Intestinal Functional
Disorder
Ischaemic Stroke
Multiple Sclerosis
Nephrolithiasis
Neuralgia

		Radiculitis					
		Tension Headache					
		Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:04/05/04ISR Number: 4331578-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00230
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
16	DAY						
		Dyspnoea		Lansoprazole	C		ORAL
		Swelling Face		Morphine Sulfate	C		ORAL
				Psyllium Husk And Senna	C		ORAL

Date:04/05/04ISR Number: 4331579-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02521
Age:14 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
6	WK						
		Erosive Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
6	WK						
		Gastritis					
		Prescribed Overdose					
		Weight Decreased					

Date:04/05/04ISR Number: 4331585-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Anxiety
Other	Atelectasis
	Cardiac Failure
	Congestive
	Chest Pain
	Coagulopathy
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Dilatation Atrial
	Dizziness
	Dyspepsia
	Gastrooesophageal Reflux Disease
	Haematoma
	Hepatic Cyst
	Hepatic Steatosis
	Hiatus Hernia

		Injury Insomnia Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL
380	DAY						
		Intervertebral Disc		Aspirin	C		
UNKNOWN							
		Displacement		Plavix	C		
UNKNOWN							
		Intervertebral Disc		Coumadin	C		
UNKNOWN							
		Protrusion		Cardizem	C		
UNKNOWN							
		Lung Neoplasm		Maxair	C		
RESPIRATORY							
		Myocardial Infarction					
(INHALATION)							
		Nephrolithiasis Pain In Extremity Post Laminectomy Syndrome Post Procedural Haemorrhage Post Thrombotic Syndrome Prothrombin Time Prolonged Pulmonary Hypertension Radiculopathy Refusal Of Treatment By Patient Scar Sleep Apnoea Syndrome Suicidal Ideation Tricuspid Valve Incompetence Umbilical Hernia Vascular Calcification Ventricular Hypokinesia Weight Decreased					

Date:04/05/04ISR Number: 4331587-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Arthropathy	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Gastric Disorder	Albuterol	C		
Other	Gastrointestinal	Combivent	C		
UNKNOWN	Haemorrhage	Atenolol	C		
UNKNOWN	Gout	Wellbutrin	C		
UNKNOWN	Intestinal Haemorrhage	Celebrex	C		
UNKNOWN	Intestinal Obstruction	Advair	C		
UNKNOWN	Knee Operation	Furosemide	C		
UNKNOWN	Lung Disorder	Diazide	C		
UNKNOWN	Lung Operation	Lithium Sulfate	C		
UNKNOWN	Pulmonary Embolism	Sandostatin	C		
UNKNOWN	Rectal Haemorrhage	Protonix	C		
UNKNOWN	Rheumatoid Arthritis	Prednisone	C		
UNKNOWN	Sleep Apnoea Syndrome	Prochlorperazine	C		
UNKNOWN	Swelling	Aciphex	C		
UNKNOWN	Systemic Lupus Erythematosus				
	Thrombosis				
	Ulcer				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/04ISR Number: 4331589-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00725
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Fosamax	C				UNKNOWN
Disability	Gastric Ulcer		Aspirin	C		ORAL		
Other	Helicobacter Gastritis		Atenolol	C				UNKNOWN
	Nausea		Buspar	C				UNKNOWN
	Rectal Haemorrhage		Synthroid	C				UNKNOWN
	Vomiting		Accupril	C				UNKNOWN
	Weight Decreased							

Date:04/05/04ISR Number: 4331598-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Disability	Cardiac Failure		Tylenol	C				UNKNOWN
Other	Congestive		Aspirin	C				UNKNOWN
	Cardiac Valve Disease		Aspirin	C				UNKNOWN
	Carotid Artery Disease		Atenolol	C				UNKNOWN
	Carotid Artery Stenosis		Coumadin	C				UNKNOWN
	Coronary Artery Stenosis		Coumadin	C				UNKNOWN
	Deep Vein Thrombosis		Indocin					
	Emotional Distress		(Indomethacin)	C				UNKNOWN
	Exostosis		Isosorbide	C				UNKNOWN

	Gout	Isosorbide	C
UNKNOWN			
	Impaired Work Ability	Nitroglycerin	C
UNKNOWN			
	Injury	Nitroglycerin	C
UNKNOWN			
	International Normalised Ratio Decreased		
	Ischaemic Cardiomyopathy		
	Mobility Decreased		
	Myocardial Infarction		
	Platelet Count Decreased		
	Renal Failure Chronic		
	Respiratory Disorder		
	Sinusitis		
	Sleep Apnoea Syndrome		
	Thrombosis		
	Ventricular Hypokinesia		

Date:04/05/04ISR Number: 4331610-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0211FRA00072
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperthyroidism		Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	509 DAY
			Interferon Beta-1a	SS				
			Acenocoumarol	C		ORAL		
			Calcium Carbonate	C		ORAL		
			Etidronate Disodium	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Prazepam	C		ORAL		
			Omeprazole	C		ORAL		
			Fenofibrate	C		ORAL		
			Hydrocortisone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/04ISR Number: 4331611-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthralgia		Vioxx	SS	Merck & Co., Inc			
Disability	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc			
	Back Pain		[Therapy Unspecified]	C			UNKNOWN	
	Basal Cell Carcinoma							
	Blood Potassium Decreased		Acyclovir	C			UNKNOWN	
	Blood Urea Increased		Vitamins (Unspecified)	C			UNKNOWN	
	Bronchitis							
	Bursitis		Aspirin	C			UNKNOWN	
	Cardiac Murmur		Lipitor	C			UNKNOWN	
	Chest Pain		Calcium (Unspecified)	C			UNKNOWN	
	Cough							
	Drug Ineffective		Premarin	C			UNKNOWN	
	Drug Intolerance							
	Dyspepsia							
	Ecchymosis							
	Electrocardiogram St Segment Depression							
	Electrocardiogram T Wave Amplitude Decreased							
	Headache							
	Hepatitis							
	Hypertension							
	Hypokalaemia							
	Injury							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Displacement							
	Intervertebral Disc Protrusion							
	Joint Dislocation							

Lumbar Spinal Stenosis
Myalgia
Non-Cardiac Chest Pain
Pneumonia
Pollakiuria
Radiculitis Cervical
Respiratory Tract
Infection
Rotator Cuff Syndrome
Stress Incontinence
Viral Upper Respiratory
Tract Infection

Date:04/05/04ISR Number: 4331617-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00254
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Cardiac Failure
	Congestive
	Haemorrhage
	Laceration
	Oedema Peripheral
	Open Wound

		Pneumonia Renal Impairment Treatment Noncompliance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Actos	SS		ORAL
				Amiodarone	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Hydralazine	C		
UNKNOWN							
				Isosorbide	C		
UNKNOWN							
				Claritin-D	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							

Date:04/05/04ISR Number: 4331620-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00840
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Infarction Circulatory Collapse		Tylenol With Codeine #3	C		ORAL
3	DAY						
		Feeling Abnormal		Vicodin Tablets	C		
UNKNOWN							
		Loss Of Consciousness		Flonase	C		
UNKNOWN							
		Osteoarthritis Pupil Fixed		Vitamins (Unspecified)	C		
UNKNOWN							

	Sleep Apnoea Syndrome		Motrin	C		
UNKNOWN						
	Ventricular Extrasystoles		Serzone	C		
UNKNOWN						

Date:04/05/04ISR Number: 4331624-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01287
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Disease		Aspirin	C		
UNKNOWN						
	Joint Range Of Motion		Aciphex	C		ORAL
	Decreased		Restoril	C		
UNKNOWN						
	Miosis					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Optic Atrophy					
	Optic Ischaemic					
	Neuropathy					
	Osteoarthritis					
	Papilloedema					
	Sexual Dysfunction					
	Tension Headache					

Date:04/05/04ISR Number: 4331632-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01061634
Age:69 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT
Abdominal Distension
Abdominal Pain Upper
Angina Unstable
Anorexia
Anxiety
Arthropathy
Ascites
Asthenia
Atelectasis
Blood Pressure Decreased
Blood Pressure Increased
Bloody Discharge
Cardiac Procedure
Complication
Cerebrovascular Accident
Chills
Cholecystitis Chronic
Cholelithiasis
Cholelithiasis
Obstructive
Colonic Polyp
Contusion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Depressed Mood
Diabetes Mellitus
Inadequate Control
Diarrhoea
Dyspepsia
Dyspnoea Exertional
Electrocardiogram St
Segment Depression
Exostosis
Extravasation
Eye Haemorrhage
Fatigue
Fungal Infection
Gastric Haemorrhage
Gastritis
Gingival Disorder
Haematoma
Haemoglobin Decreased

Hypertensive Heart
Disease
Insomnia
Intervertebral Disc
Protrusion
Intestinal Functional
Disorder
Muscle Spasms
Myocardial Infarction
Nausea
Night Sweats
Ocular Hyperaemia
Oedema Peripheral
Osteopenia

		Pain					
		Palpitations					
		Peripheral Vascular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Pleural Effusion		Fosamax	SS		ORAL
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
		Postinfarction Angina		Lortab	C		ORAL
		Retroperitoneal Haematoma		Norvasc	C		ORAL
		Rheumatoid Arthritis		Humulin N	C		
UNKNOWN							
		Supraventricular		Septra	C		ORAL
		Tachycardia		Zanaflex	C		
UNKNOWN							
		Therapy Non-Responder		Septra	C		ORAL
		Thrombosis		Synthroid	C		ORAL
		Transient Ischaemic		Robaxin	C		
UNKNOWN							
		Attack		Synthroid	C		ORAL
		Tremor		Plavix	C		
UNKNOWN							
		Urinary Tract Infection		Lortab	C		ORAL
		Vaginal Erythema					
		Ventricular Hypokinesia					
		Ventricular Tachycardia					
		Vertigo					
		Vomiting					
		Weight Decreased					

Date:04/05/04ISR Number: 4331640-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Arthralgia
Other	Brain Stem Infarction
	Cardiac Failure
	Congestive
	Cardiomegaly
	Carotid Artery Stenosis
	Cataract
	Cerebrovascular Accident
	Choking
	Contusion

Coronary Artery Disease
Diplopia
Dysphagia
Exostosis
Fall
Glaucoma
Head Injury
Hypoaesthesia
Illusion
Intervertebral Disc
Protrusion
Joint Swelling
Lumbar Spinal Stenosis
Nasopharyngitis
Osteoarthritis
Pain In Extremity
Positive Rombergism
Road Traffic Accident
Snoring
Spinal Osteoarthritis

		Toe Deformity					
		Ventricular Hypertrophy					
		Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Whiplash Injury		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Avandia	C		ORAL
				Avandia	C		ORAL
				Vicoprofen	C		ORAL
				Glucophage	C		ORAL
				Glucophage	C		ORAL

Date:04/05/04ISR Number: 4331641-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02080
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Bronchopneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorientation		Synthroid	C		
UNKNOWN							
		Feeling Abnormal					
		Hypertension					
		Impaired Work Ability					
		Injury					
		Sleep Disorder					

Date:04/05/04ISR Number: 4331643-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Bronchitis					
		Chest Pain					
		Dizziness					
		Dyspnoea					

Epididymitis
Foot Fracture
Foreign Body Trauma
Heart Rate Increased
Hypersensitivity
Injury
Occupational Exposure To
Toxic Agent
Rash
Tinea Cruris
Viral Rash

Date:04/05/04ISR Number: 4331644-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Azotaemia
	Benign Neoplasm
	Bundle Branch Block Right
	Chest Pain
	Colonic Polyp

		Condition Aggravated Coronary Artery Disease Coronary Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
		Generalised Anxiety Disorder		Vioxx Tylenol	SS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Haematoma Hypercholesterolaemia Hypertension		Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN							
		Intervertebral Disc		Xanax	C		
UNKNOWN							
		Degeneration		Aspirin	C		
UNKNOWN							
		Intervertebral Disc		Librax Capsules	C		
UNKNOWN							
		Protrusion Low Density Lipoprotein		Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
		Increased		Allegra	C		
UNKNOWN							
		Myocardial Infarction		Prilosec	C		
UNKNOWN							
		Osteochondrosis		Zantac	C		
UNKNOWN							
		Sleep Disorder Spinal Column Stenosis Tendonitis Urinary Tract Infection					

Date:04/05/04ISR Number: 4331645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 10 DAY		Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 10 DAY		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Pressure Diastolic Increased Coronary Artery Disease Economic Problem					

Emotional Distress
Fear Of Disease
Haemoglobin Decreased
Injury
Lipids Abnormal
Myocardial Infarction
Pain
Tendonitis

Date:04/05/04ISR Number: 4331648-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03537
Age:49 YR Gender:Female I/FU:F

Outcome PT
Other Abdominal Pain
Abnormal Faeces
Constipation
Deafness
Depression
Diarrhoea
Disease Recurrence
Dyspepsia
Flank Pain
Gastric Disorder
Haematochezia
Haematuria
Haemorrhoids
Headache

		Labyrinthitis					
		Nasal Congestion					
		Nephrocalcinosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nystagmus		Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophageal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Ovarian Cyst		[Therapy			
		Panic Disorder		Unspecified]	C		
UNKNOWN							
		Peptic Ulcer		Premarin	C		
UNKNOWN							
		Phlebolith		Flonase	C		
UNKNOWN							
		Proctalgia		Ambien	C		
UNKNOWN							
		Rectal Haemorrhage		Zoloft	C		
UNKNOWN							
		Rheumatoid Arthritis		Hydroxychloroquine			
		Rhinitis Allergic		Sulfate	C		
UNKNOWN							
		Systemic Lupus		Claritin	C		
UNKNOWN							
		Erythematosus		Daypro	C		
UNKNOWN							
		Tinnitus					
		Urethral Stricture					
		Vertigo					

Date:04/05/04ISR Number: 4331649-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Affective Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged	Alopecia		Microzide	SS		
UNKNOWN						
Disability	Anaemia		Microzide	SS		
UNKNOWN						
Other	Ankylosing Spondylitis		Prinzide	SS		ORAL
26 HR						
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY						

	Constipation	Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY
	Coronary Artery Stenosis	Vioxx	SS	Merck & Co., Inc	ORAL	24 DAY
	Depression	Vioxx	SS	Merck & Co., Inc	ORAL	97 DAY
	Drug Ineffective	Vioxx	SS	Merck & Co., Inc	ORAL	179 DAY
	Dysphagia	Vioxx	SS	Merck & Co., Inc	ORAL	
	Dysphoria	Vioxx	SS	Merck & Co., Inc	ORAL	97 DAY
	Facet Joint Syndrome	Vioxx	SS	Merck & Co., Inc	ORAL	24 DAY
	Facial Bones Fracture	Vicodin Es Tablets	C			UNKNOWN
	Fall	Analgesic Or Anesthetic (Unspecified)	C		PARENTERAL	1 DAY
	Fibromyalgia					
	Gastrooesophageal Reflux Disease	Beconase	C			UNKNOWN
	Hypothyroidism	Prevacid	C			UNKNOWN
	Intervertebral Disc Degeneration	Effexor	C			UNKNOWN
	Intervertebral Disc Displacement	Trazodone Hydrochloride	C			UNKNOWN
	Intervertebral Disc Protrusion	Trazodone Hydrochloride	C			UNKNOWN
	Jaw Disorder	Imitrex	C			UNKNOWN
	Nephritis Interstitial	Claritin	C			UNKNOWN
	Osteoporosis	Claritin	C			UNKNOWN
	Polyarthritis	Prevacid	C			UNKNOWN
	Psoriatic Arthropathy	Zestoretic	C			UNKNOWN
	Raynaud'S Phenomenon	Celebrex	C			UNKNOWN
	Reiter'S Syndrome	Valium	C			UNKNOWN
	Renal Failure	Estratest	C			UNKNOWN
	Sacroiliitis					
	Urinary Tract Pain					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/04ISR Number: 4331651-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	216	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	216	DAY
	Anxiety							
	Back Pain							
	Cardiac Failure							
	Congestive							
	Cardio-Respiratory Arrest							
	Dizziness							
	Fatigue							
	Headache							
	Hypertensive Heart							
	Disease							
	Injury							
	Myocardial Infarction							

Date:04/05/04ISR Number: 4331655-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02432
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Liver Function Test		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Abnormal							

Date:04/05/04ISR Number: 4331657-1Report Type:Expedited (15-DaCompany Report #PT-MERCK-0403PRT00001
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Hypersensitivity		Trazodone					
	Oedema		Hydrochloride	C		ORAL		
	Rash							

Date:04/05/04ISR Number: 4332292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01999
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Death	Brain Death
Hospitalization - Initial or Prolonged	Brain Herniation
	Brain Oedema
	Coma
	Cough
	Decerebration
	Dry Mouth
	Electrocardiogram St-T Change
	Haemorrhage Intracranial
	Headache
	Hypertension
	Injury
	Mydriasis
	Pco2 Decreased
	Po2 Decreased
	Pupil Fixed
	Respiratory Arrest
	Respiratory Failure

		Respiratory Rate Decreased					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Snoring	Health	Vioxx	PS	Merck & Co., Inc	ORAL
54	DAY						
		Subarachnoid Haemorrhage	Professional	Blinded Therapy	SS		
UNKNOWN		70 DAY					
		Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
54	DAY						
				Allopurinol	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Estratest	C		
UNKNOWN		3778 DAY					
				Celexa	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN		568 DAY					

Date:04/05/04ISR Number: 4332294-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY					
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY					
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY					
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY					
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY					
	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY					
	First Degree		Tylenol	C		
UNKNOWN						
	Back Pain		Parafon Forte	C		
UNKNOWN						

	Bladder Spasm	Serevent	C
RESPIRATORY			
	Blood Pressure Increased		
(INHALATION)			
	Bronchial Infection	Proventil	C
RESPIRATORY			
	Cerebral Infarction		
(INHALATION)			
	Cerebral Ischaemia	Aspirin	C
UNKNOWN			
	Cervicobrachial Syndrome	Lioresal	C
UNKNOWN			
	Cholelithiasis	Valium	C
UNKNOWN			
	Contusion	Demerol	C
UNKNOWN			
	Dyspepsia	Ditropan	C
UNKNOWN			
	Dysuria	Inderal	C
UNKNOWN			
	Embolic Stroke		
	Emotional Distress		
	Escherichia Infection		
	Fall		
	Flatulence		
	Head Injury		
	Hypertension		
	Joint Injury		
	Migraine		
	Mitral Valve Incompetence		
	Myofascial Pain Syndrome		
	Nail Disorder		
	Nerve Compression		
	Oedema Peripheral		
	Osteoarthritis		
	Pollakiuria		
	Radiculopathy		
	Rotator Cuff Syndrome		
	Tricuspid Valve Incompetence		
	Urinary Tract Infection		
	Ventricular Hypertrophy		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/04ISR Number: 4332297-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL		560 DAY
Initial or Prolonged	Anxiety	Professional	Amitriptyline					
Disability	Atelectasis		Hydrochloride	C				UNKNOWN
	Back Pain		Celexa	C				UNKNOWN
	Blood Ph Decreased		Nexium	C				UNKNOWN
	Blood Pressure Decreased		Lasix (Furosemide)	C				UNKNOWN
	Bronchopneumonia		Lasix (Furosemide)	C				UNKNOWN
	Cardiomegaly		Zanaflex	C				UNKNOWN
	Cardiovascular Disorder		Ultram	C				UNKNOWN
	Cerebrovascular Accident		Ambien	C				UNKNOWN
	Chest Pain		Diovan	C				UNKNOWN
	Chronic Fatigue Syndrome		Torsemide	C				UNKNOWN
	Dizziness		Neurontin	C				UNKNOWN
	Fluid Retention		Zaroxolyn	C				UNKNOWN
	Gastrooesophageal Reflux		Aleve	C				UNKNOWN
	Disease		Oxycontin	C				UNKNOWN
	Haematochezia		Potassium Chloride	C				UNKNOWN
	Headache							
	Hyperlipidaemia							
	Hypokalaemia							
	Ileus							
	Lobar Pneumonia							
	Lung Infiltration							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Myocardial Infarction							

Nephrolithiasis
Pleural Effusion
Pneumonia
Pneumonia Aspiration
Pneumonia Pneumococcal
Pulmonary Fibrosis
Pyrexia
Rash
Renal Failure
Renal Failure Acute
Respiratory Failure
Rhabdomyolysis
Sinusitis
Staphylococcal Infection
Streptococcal Infection

Date:04/05/04ISR Number: 4332298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:04/05/04ISR Number: 4332299-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0402GBR00203
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pneumonitis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/04ISR Number: 4332306-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		80 DAY
Initial or Prolonged	Aortic Calcification	Professional	Ascorbic Acid	C				UNKNOWN
Disability	Blood Cholesterol		Wellbutrin	C				UNKNOWN
	Increased Blood Triglycerides		Calcium (Unspecified)	C				UNKNOWN
	Increased		Lanoxin	C				UNKNOWN
	Bundle Branch Block Left		Premarin	C				UNKNOWN
	Cardiac Failure		Lasix (Furosemide)	C				UNKNOWN
	Congestive		Coenzyme Q10	C				UNKNOWN
	Chest Pain		Vitamin E	C				UNKNOWN
	Congestive Cardiomyopathy		Coumadin	C				UNKNOWN
	Cough		Vitamin B (Unspecified)	C				UNKNOWN
	Depression							
	Dyspepsia		Ginkgo Biloba Extract	C				UNKNOWN
	Fibroadenoma Of Breast							
	Gastrointestinal Tract		Levocarnitine	C				UNKNOWN
	Adenoma		Prinivil	C		ORAL		
	Haemorrhoids		Magnesium (Unspecified)	C				UNKNOWN
	Hypertension							
	Injury		Nicotine	C				UNKNOWN
	Insomnia		Pamelor	C				UNKNOWN
	Mood Swings							
	Nightmare							
	Pain In Extremity							
	Palpitations							
	Proctalgia							

Sinus Tachycardia
Snoring
Somnolence
Spinal Osteoarthritis
Ventricular Extrasystoles
Viral Infection

Date:04/05/04ISR Number: 4332307-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00027
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/04ISR Number: 4332309-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
	Angina Unstable
	Back Pain
	Cellulitis
	Coronary Artery Disease
	Coronary Ostial Stenosis
	Depression
	Emotional Distress
	Eyelid Ptosis
	Haemangioma
	Intervertebral Disc Protrusion
	Macular Degeneration

		Myocardial Infarction					
		Nervousness					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radiculopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Disorder	Professional	Xanax	C		
UNKNOWN							
		Renal Failure		Aspirin	C		
UNKNOWN							
		Sinus Bradycardia		Celebrex	C		
UNKNOWN							
		Sinusitis		Zyrtec	C		
UNKNOWN							
		Spinal Column Stenosis		Prozac	C		
UNKNOWN							
		Spinal Osteoarthritis		Zestril	C		
UNKNOWN							
		Urethritis		Naproxen	C		
UNKNOWN							
		Ventricular Hypokinesia		Prilosec	C		
UNKNOWN							
		Visual Disturbance					

Date:04/05/04ISR Number: 4332310-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01382
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Acute Respiratory Distress Syndrome
	Agitation
	Akinesia
	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Blood Creatine Phosphokinase Increased
	Blood Glucose Increased
	Blood Pressure Systolic Increased
	Bundle Branch Block Right
	Cardiac Arrest

Cardiac Disorder
Cardiac Failure
Congestive
Cardiac Murmur
Cardiogenic Shock
Chronic Obstructive
Pulmonary Disease
Confusional State
Constipation
Contusion
Cough
Disorientation
Dyspnoea
Ecchymosis
Gastritis
Gastrointestinal
Haemorrhage
Haemoptysis
Heart Rate Decreased
Heart Sounds Abnormal
Helicobacter Infection
Hypoxia
Injury
Ischaemic Cardiomyopathy

		Joint Crepitation					
		Joint Dislocation					
		Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Infiltration	Health	Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Mitral Valve Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY						
		Pneumonia Aspiration		[Therapy			
		Pulmonary Haemorrhage		Unspecified]	C		
UNKNOWN							
		Pulmonary Hypertension		Vitamins			
		Pulmonary Oedema		(Unspecified)	C		
UNKNOWN							
		Respiratory Arrest					
		Respiratory Failure					
		Somnolence					
		Urine Output Decreased					
		Ventricular Arrhythmia					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Vomiting					
		White Blood Cell Count Increased					

Date:04/05/04ISR Number: 4332311-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
790 DAY						

Date:04/05/04ISR Number: 4333232-1Report Type:Direct Company Report #CTU 215929
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Idiopathic		Vioxx Merck	PS	Merck	ORAL
DAILY ORAL						
Initial or Prolonged	Thrombocytopenic Purpura		Cytomel	C		
			Avapro	C		
			Lipiotr	C		

Aspirin	C
Lasix	C
Potassium Chloride	C
Celexa	C
Synthroid	C

Date:04/06/04ISR Number: 4332970-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01135
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		433 DAY
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		433 DAY
Disability	Cataract		Acetaminophen And					
Other	Cerebrovascular Accident		Hydrocodone					
	Depression		Bitartrate	C				UNKNOWN
	Eye Disorder		Celebrex	C				UNKNOWN
	Glaucoma							
	Major Depression							
	Prostatic Disorder							
	Psychomotor Skills Impaired							
	Sleep Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4332972-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vicodin Tablets	C				
UNKNOWN								
Other	Calculus Ureteric		Aspirin	C				
UNKNOWN								
	Calculus Urinary		Ultram	C				
UNKNOWN								
	Coronary Artery Occlusion		Ultram	C				
UNKNOWN								
	Cough		Advil	C				
UNKNOWN								
	Dilatation Ventricular		Advil	C				
UNKNOWN								
	Diverticulitis							
	Haematuria							
	Influenza							
	Mitral Valve Incompetence							
	Myalgia							
	Nausea							
	Pharyngolaryngeal Pain							
	Pneumonia							
	Pneumonia Influenzal							
	Tricuspid Valve							
	Incompetence							
	Vomiting							

Date:04/06/04ISR Number: 4332974-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Anxiety		Synthroid	C				
UNKNOWN								
Other	Arthralgia		Armour Thyroid					
	Arthropathy		Tablets	C				
UNKNOWN								

	Atrial Fibrillation	Premarin	C
UNKNOWN			
	Cardiac Aneurysm	Menest	C
UNKNOWN			
	Corneal Deposits	Garlic Extract	C
UNKNOWN			
	Dizziness	Estratab	C
UNKNOWN			
	Dyspnoea	Trazodone	
	Embolism	Hydrochloride	C
UNKNOWN			
	Fibrosis	Methotrexate	C
UNKNOWN			
	Haematoma		
	Haematuria		
	Hypertension		
	Hypertensive Crisis		
	Meniscus Lesion		
	Musculoskeletal Disorder		
	Neuroma		
	Nuclear Magnetic		
	Resonance Imaging		
	Abnormal		
	Oedema Peripheral		
	Pulse Waveform Abnormal		
	Refusal Of Treatment By		
	Patient		
	Renal Cyst		
	Residual Urine Volume		
	Transient Ischaemic		
	Attack		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4332975-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01434
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Infarction		Prozac	C				UNKNOWN
Disability	Acute Respiratory Distress Syndrome		Interferon (Unspecified)	C				UNKNOWN
	Anaemia							
	Aspiration							
	Cardiac Arrest							
	Cardiogenic Shock							
	Catheter Sepsis							
	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							
	Deep Vein Thrombosis							
	Depression							
	Diarrhoea							
	Hepatic Failure							
	Hypertension							
	Intervertebral Disc Disorder							
	Intracardiac Thrombus							
	Lactic Acidosis							
	Mitral Valve Incompetence							
	Myocardial Ischaemia							
	Osteoarthritis							
	Pneumonia Aspiration							
	Pyrexia							
	Renal Infarct							
	Respiratory Failure							
	Splenic Infarction							
	Therapy Non-Responder							
	Thrombosis							
	Ventricular Hypokinesia							
	Vomiting							

Date:04/06/04ISR Number: 4332977-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00307
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL	125	DAY

Date:04/06/04ISR Number: 4332981-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00028
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Estrogens (Unspecified)	C				

UNKNOWN

Date:04/06/04ISR Number: 4332982-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4332984-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00094
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	232	DAY

Date:04/06/04ISR Number: 4332985-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/04ISR Number: 4332987-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bone Graft		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		[Therapy					
	Bursitis		Unspecified]	C				
UNKNOWN								
	Cerebrovascular Accident		Vicodin Tablets	C				
UNKNOWN								
	Cervicobrachial Syndrome		Elavil	C		ORAL		
	Chronic Obstructive		Analgesic Or					
	Pulmonary Disease		Anesthetic					
	Condition Aggravated		(Unspecified)	C				
UNKNOWN								
	Contusion		Aspirin	C		ORAL		
	Depression		Vitamins					
	Exostosis		(Unspecified)	C				
UNKNOWN								
	Fall		Vitamin E	C				
UNKNOWN								
	Fatigue		Calcium Carbonate	C				
UNKNOWN								

	Fibromyalgia	Premarin	C	
UNKNOWN				
	Increased Tendency To	Lasix (Furosemide)	C	
UNKNOWN				
	Bruise	Neurontin	C	
UNKNOWN				
	Insomnia	Oxycontin	C	
UNKNOWN				
	Intervertebral Disc	Paxil	C	ORAL
	Protrusion	Actonel	C	
UNKNOWN				
	Lower Respiratory Tract Infection			
	Migraine			
	Oedema Peripheral			
	Osteoarthritis			
	Osteoporosis			
	Pain In Extremity			
	Radius Fracture			
	Renal Disorder			
	Rotator Cuff Syndrome			
	Sinusitis			
	Somnolence			
	Spinal Osteoarthritis			
	Tendonitis			
	Transient Ischaemic Attack			
	Urinary Tract Infection			
	Weight Increased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4333329-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bladder Obstruction		[Therapy Unspecified]	C			UNKNOWN	
	Blood Pressure Increased							
	Cerebral Atherosclerosis		Albuterol	C			RESPIRATORY (INHALATION)	
	Cerebral Atrophy							
	Cerebral Infarction		Albuterol	C		ORAL		
	Dizziness		Allopurinol	C			UNKNOWN	
	Dysuria		Ecotrin	C			UNKNOWN	
	Encephalomalacia		Atenolol	C			UNKNOWN	
	Epistaxis		Palgic D	C		ORAL		
	Erectile Dysfunction		Mavik	C		ORAL		
	Gastrointestinal		Mavik	C		ORAL		
	Haemorrhage		Celebrex	C			UNKNOWN	
	Haematochezia		Docusate Calcium	C			UNKNOWN	
	Haemorrhoids		Guaifenex La	C			UNKNOWN	
	Headache		Hydrodiuril	C		ORAL		
	Ileus Paralytic		Ibuprofen	C			UNKNOWN	
	Nasal Sinus Drainage		Atrovent	C			UNKNOWN	
	Nausea		Nitroglycerin	C			UNKNOWN	
	Prostate Cancer							
	Prostatic Specific Antigen Increased							
	Rectal Haemorrhage							
	Rectal Polyp							
	Vertigo							
	Vomiting							

Date:04/06/04ISR Number: 4333340-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02050
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Bronchitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		14 MON
Other	Cardiac Failure High		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Output		Vioxx	SS	Merck & Co., Inc	ORAL		14 MON
	Cardiomegaly							
	Carotid Artery Stenosis							
	Cellulitis							
	Dermal Cyst							
	Dizziness							
	Gastroenteritis							
	Hypertension							
	Injury							
	Lymphadenopathy							
	Mediastinal							
	Musculoskeletal							
	Discomfort							
	Nausea							
	Oedema							
	Pain							
	Pulmonary Hypertension							
	Renal Artery Stenosis							
	Sinus Bradycardia							
	Skin Papilloma							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4333343-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Bronchitis Acute							
	Carpal Tunnel Syndrome							
	Conjunctival Haemorrhage							
	Contusion							
	Coronary Artery Disease							
	Coronary Artery Restenosis							
	Depression							
	Duodenitis							
	Fall							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Haematochezia							
	Hypertension							
	Hypokalaemia							
	Joint Sprain							
	Laryngitis							
	Menopausal Symptoms							
	Migraine							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Palpitations							
	Pelvic Peritoneal Adhesions							
	Phlebothrombosis							
	Rhinitis Allergic							
	Stent Occlusion							
	Syncope							
	Tricuspid Valve Incompetence							
	Ventricular Extrasystoles							

Date:04/06/04ISR Number: 4333348-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arteriosclerosis
Other	Blood Pressure Systolic
	Increased
	Cardiac Murmur
	Cerebrovascular Accident
	Dizziness
	Epistaxis
	Haematemesis
	Hypertension
	Injury
	Lacunar Infarction
	Muscle Spasms

		Myalgia Productive Cough Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Betaxolol Ophthalmic Solution	C		
UNKNOWN				Calcitonin	C		
UNKNOWN				Digoxin	C		
UNKNOWN				Docusate Sodium	C		
OPHTHALMIC				Trusopt	C		
UNKNOWN				Zocor	C		
UNKNOWN		1284 DAY		Warfarin	C		
UNKNOWN				Vitamin E	C		
UNKNOWN				Folic Acid	C		
UNKNOWN		1680 DAY		Lasix (Furosemide)	C		
UNKNOWN				Isosorbide	C		
UNKNOWN				Potassium (Unspecified)	C		
UNKNOWN				Psyllium Husk	C		

Date:04/06/04ISR Number: 4333349-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL

	Cardiac Failure	Tylenol	C
UNKNOWN			
	Congestive	Saw Palmetto	C
UNKNOWN			
	Cellulitis	Ultram	C
UNKNOWN			
	Cerebral Ischaemia	Lipitor	C
UNKNOWN			
	Chronic Obstructive	Lumigan	C
UNKNOWN			
	Pulmonary Disease	Corticosteroids	
	Colitis Ischaemic	(Unspecified)	C
PARENTERAL			
	Coronary Artery Disease	Betagan	C
UNKNOWN			
	Delirium	Relafen	C
UNKNOWN			
	Depression	Paxil	C
UNKNOWN			
	Diarrhoea		
	Drug Hypersensitivity		
	Gastroenteritis		
	Headache		
	Hypertension		
	Inguinal Hernia		
	Liver Function Test		
	Abnormal		
	Myocardial Infarction		
	Osteoarthritis		
	Osteoporosis		
	Periorbital Haematoma		
	Rash		
	Spinal Column Stenosis		
	Staphylococcal Sepsis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4333351-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
	Adenomyosis		[Therapy Unspecified]	C				
	Anaemia							
	Blood Cholesterol Increased		Claritin	C				
	Cervicitis							
	Chest Pain							
	Electrocardiogram Qrs Complex Prolonged							
	Haemorrhagic Ovarian Cyst							
	Hyperhidrosis							
	Injury							
	Leiomyoma							
	Low Density Lipoprotein Increased							
	Metaplasia							
	Nausea							
	Pain							
	Palpitations							
	Pelvic Pain							
	Tachycardia							
	Uterine Haemorrhage							
	Uterine Leiomyoma							
	Vaginal Haemorrhage							
	Ventricular Tachycardia							

Date:04/06/04ISR Number: 4333352-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01288
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Accident At Work
	Angina Pectoris
	Aortic Valve Incompetence
	Blister
	Blood Cholesterol Increased
	Blood Pressure Increased

Bundle Branch Block Right
Cardiomegaly
Cellulitis
Chest Pain
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery Stenosis
Electrocardiogram Qrs
Complex Prolonged
Electrocardiogram T Wave
Abnormal
Injury
Low Density Lipoprotein
Increased
Mediastinal Disorder
Mediastinal Haematoma
Mitral Valve Incompetence
Pleural Effusion
Pneumothorax
Postoperative Infection

		Silent Myocardial Infarction					
		Staphylococcal Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Supraventricular		Vioxx	PS	Merck & Co., Inc	ORAL
		Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Ecotrin	C		
UNKNOWN							
		Incompetence		Plavix	C		
UNKNOWN							
		Ventricular Dysfunction		Dyazide	C		
UNKNOWN							
		Ventricular Hypokinesia		Avapro	C		
UNKNOWN							
		Ventricular Tachycardia		Miacalcin	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Midazolam	C		
UNKNOWN							

Date:04/06/04ISR Number: 4333353-3Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0402ZAF00014
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/06/04ISR Number: 4333354-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Affective Disorder
	Alopecia
Disability	Anaemia
Congenital Anomaly	Ankylosing Spondylitis
Other	Carpal Tunnel Syndrome
	Chest Pain

Chronic Obstructive
Pulmonary Disease
Constipation
Coronary Artery Stenosis
Depression
Drug Ineffective
Dysphagia
Dysphoria
Facet Joint Syndrome
Facial Bones Fracture
Fall
Fibromyalgia
Gastrooesophageal Reflux
Disease
Hypothyroidism
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Jaw Disorder
Nephritis Interstitial
Oesophageal Stenosis
Osteoporosis
Polyarthritis
Psoriatic Arthropathy

Dose	Duration	Raynaud'S Phenomenon Reflux Oesophagitis Reiter'S Syndrome	Report Source	Product	Role	Manufacturer	Route
5 DAY		Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Sacroiliitis		Microzide	SS		
UNKNOWN		Urinary Tract Pain		Microzide	SS		
26 HR		Weight Increased		Prinzide	SS		ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
97 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
97 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN				Vicodin Es Tablets	C		
PARENTERAL	1 DAY			Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN				Beconase	C		
UNKNOWN				Prevacid	C		
UNKNOWN				Effexor	C		
UNKNOWN				Trazodone Hydrochloride	C		
UNKNOWN				Trazodone Hydrochloride	C		

UNKNOWN	Imitrex	C
UNKNOWN	Claritin	C
UNKNOWN	Claritin	C
UNKNOWN	Prevacid	C
UNKNOWN	Zestoretic	C
UNKNOWN	Celebrex	C
UNKNOWN	Valium	C
UNKNOWN	Estratest	C
UNKNOWN		

Date:04/06/04ISR Number: 4333355-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01392
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Disability	Asthenia
	Choking
	Coordination Abnormal
	Depression
	Diarrhoea
	Diplopia
	Disturbance In Attention
	Drug Effect Decreased
	Drug Ineffective
	Electrocardiogram St
	Segment Depression
	Emotional Distress
	Fatigue
	Fibromyalgia
	Fluid Retention
	Foot Fracture
	Headache
	Herpes Zoster
	Hypertension
	Hypertonic Bladder

		Hypoacusis					
		Influenza					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		[Therapy			
		Protrusion		Unspecified]	C		
UNKNOWN							
		Intervertebral Disc Space		Premarin	C		
UNKNOWN							
		Narrowing					
		Intestinal Functional					
		Disorder					
		Ischaemic Stroke					
		Loss Of Employment					
		Muscle Spasms					
		Nausea					
		Nephrolithiasis					
		Nervousness					
		Neuralgia					
		Night Sweats					
		Pain					
		Pain In Extremity					
		Peroneal Nerve Palsy					
		Radiculitis					
		Sleep Disorder					
		Spinal Column Stenosis					
		Thinking Abnormal					
		Vision Blurred					
		Weight Decreased					

Date:04/06/04ISR Number: 4333356-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00099
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						

Date:04/06/04ISR Number: 4333357-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00230
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Dyspnoea		Lansoprazole	C		ORAL		
	Dyspnoea Exertional		Morphine Sulfate	C		ORAL		
	Swelling Face		Psyllium Husk And Senna	C		ORAL		

Date:04/06/04ISR Number: 4333358-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00120
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Initial or Prolonged	Gastroenteritis		Ginkgo Biloba Extract	C		ORAL		
	Melaena							
	Nausea							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/04ISR Number: 4336002-3Report Type:Expedited (15-DaCompany Report #2004UW02967
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Creatine	Foreign	Crestor	PS		ORAL	40 MG QD PO	
Intervention to	Phosphokinase Increased	Health	Crestor	SS		ORAL	20 MG QD PO	
Prevent Permanent	Drug Interaction	Professional	Ezetrol	SS			10 MG QD	
Impairment/Damage	Hepatic Enzyme Increased	Other	Vioxx	SS			25 MG PRN	
			Niacin	C				
			Ec Asa	C				
			Plavix	C				
			Atenolol	C				
			Accupril	C				
			Allopurinol	C				
			Folic Acid	C				
			Vitamin C	C				
			Glucosamine	C				

Date:04/06/04ISR Number: 4336023-0Report Type:Expedited (15-DaCompany Report #2003163125FR
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State	Foreign	Solu-Medrol					
	Haemodynamic Instability	Health	(Methylprednisolone)					
	Localised Infection	Professional	Powder, Sterile	PS			INTRAVENOUS	UNK, UNK, IV
	Quadriplegia	Other	Celestene					
	Respiratory Distress		(Betamethasone)	SS		ORAL	0.5 MG, QD,	
	Sciatica						ORAL	
	Spondylitis		Cortancyl					
	Staphylococcal Sepsis		(Prednisone)	SS		ORAL	60 MG, QD,	
							ORAL	
			Rofecoxib					
			(Rofecoxib)	SS		ORAL	1 DF, QD,	

ORAL

Bricanyl	C	
Atrovent	C	
Seretide Mite (Fluticasone Propionate)	C	
Hyperium (Rilmenidine)	C	
Amarel (Glimepiride)	C	

Date:04/07/04ISR Number: 4333981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02080
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Disorientation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Synthroid	C				
UNKNOWN								
	Hypertension							
	Sleep Disorder							

Date:04/07/04ISR Number: 4334456-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Artery Dissection
	Back Pain
	Basilar Artery Stenosis

		Cardiac Disorder					
		Cerebrovascular Accident					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL
93	MON						
		Haemoglobin Abnormal					
		Prothrombin Time					
		Prolonged					
		Ventricular Hypertrophy					
		Vertebral Artery Stenosis					
		Vertebrobasilar					
		Insufficiency					

Date:04/07/04ISR Number: 4334457-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Blood Pressure Increased	Professional				
		Bronchitis					
		Cervical Spine Flattening					
		Chest Pain					
		Dizziness					
		Dyspnoea					
		Epididymitis					
		Foot Fracture					
		Foreign Body Trauma					
		Head Injury					
		Heart Rate Increased					
		Hypersensitivity					
		Injury					
		Intervertebral Disc					
		Protrusion					
		Muscle Spasms					
		Myocardial Infarction					
		Occupational Exposure To					
		Toxic Agent					
		Radiculopathy					
		Rash					
		Spinal Cord Compression					
		Tinea Cruris					
		Viral Rash					

Date:04/07/04ISR Number: 4334463-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0404AUS00006
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Sudden Death							

Date:04/07/04ISR Number: 4334464-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Abdominal Pain Upper
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia

		Arthritis					
		Arthropathy					
		Asthma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
		Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Lymphocytic		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Voltaren	C		
UNKNOWN							
		Electrocardiogram		Prempro	C		
UNKNOWN							
		Abnormal					
		Electrocardiogram St					
		Segment Abnormal					
		Electrocardiogram T Wave					
		Inversion					
		Fatigue					
		Gastritis					
		Gastroenteritis					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Heart Injury					
		Heart Rate Irregular					
		Hiatus Hernia					
		Hyperlipidaemia					
		Hypertension					
		Mallory-Weiss Syndrome					
		Meniscus Lesion					
		Mitral Valve					
		Calcification					
		Mitral Valve Prolapse					
		Mitral Valve Stenosis					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Oesophagitis					
		Osteoarthritis					
		Overdose					
		Peptic Ulcer					
		Pneumonia					

Stress
Tricuspid Valve
Incompetence
Ulcer Haemorrhage
Upper Respiratory Tract
Infection
Urinary Tract Infection
Ventricular Hypertrophy
Ventricular Hypokinesia
Weight Decreased
Wound Infection
Staphylococcal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/04ISR Number: 4334471-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Ageusia		Prevacid	SS				
UNKNOWN								
Disability	Aortic Valve Incompetence		Prevacid	SS				
UNKNOWN								
Other	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Creatine		Vioxx	SS	Merck & Co., Inc	ORAL		
46 DAY								
	Phosphokinase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
5 DAY								
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
5 DAY								
	Carpal Tunnel Syndrome		Zocor	SS		ORAL		
2099 DAY								
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
46 DAY								
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholecystitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Monopril	C				
UNKNOWN							1183 DAY	
	Colon Adenoma		Levaquin	C				
UNKNOWN								
	Constipation		Effexor	C				
UNKNOWN								
	Depression		Ambien	C				
UNKNOWN								
	Dizziness		Effexor	C				
UNKNOWN								
	Dizziness Postural		Naprosyn	C				
UNKNOWN							4268 DAY	
	Dry Mouth		Zantac	C				
UNKNOWN								
	Dyspepsia		Naprosyn	C				
UNKNOWN							4268 DAY	
	Dysplasia		Levaquin	C				
UNKNOWN								
	Emotional Disorder		Monopril	C				
UNKNOWN								
	Epicondylitis							
	Fatigue							

Gastrointestinal Disorder
Haemorrhage
Headache
Hypertension
Insomnia
Ischaemic Stroke
Laceration
Lichen Planus
Micturition Urgency
Mitral Valve Incompetence
Prostate Cancer
Prostatic Intraepithelial
Neoplasia
Psoriasis
Rash Erythematous
Respiratory Rate
Increased
Thrombotic Stroke
Tongue Discolouration
Trigger Finger
Urinary Incontinence
Ventricular Hypertrophy
Zinc Deficiency

Date:04/07/04ISR Number: 4334474-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01384
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Akinesia Angina Pectoris

		Blood Pressure Systolic Increased					
		Cardiac Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
430	DAY						
		Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL
430	DAY						
		Disease Recurrence		Avandia	SS		
UNKNOWN							
		Emotional Distress		Atenolol	C		
UNKNOWN							
		Haematuria		Lanoxin	C		
UNKNOWN							
		Mitral Valve		Vasotec	C		ORAL
		Calcification		Ultram	C		
UNKNOWN							
		Mitral Valve Incompetence		Premarin	C		
UNKNOWN							
		Mitral Valve Stenosis		Lasix (Furosemide)	C		
UNKNOWN							
		Oedema Peripheral		Lasix (Furosemide)	C		
UNKNOWN							
		Pain In Extremity		Glipizide	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Levothyroxine Sodium	C		
UNKNOWN							
		Treatment Noncompliance		Glucophage	C		
UNKNOWN							
		Tricuspid Valve		Nifedipine	C		
UNKNOWN							
		Incompetence					
		Urinary Tract Infection					
		Varicose Vein					
		Vasodilatation					
		Ventricular Hypertrophy					
		Weight Decreased					

Date:04/07/04ISR Number: 4334475-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01262
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable

Initial or Prolonged	Aortic Valve Sclerosis
Disability	Arterial Bruit
Other	Atrioventricular Block
	First Degree
	Axillary Pain
	Balance Disorder
	Bursitis
	Cardiac Murmur
	Chest Pain
	Colonic Polyp
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Coronary Artery
	Thrombosis
	Dilatation Atrial
	Diverticulum
	Dizziness
	Dyspnoea
	Ecchymosis
	Electrocardiogram St-T
	Change
	Gastric Ulcer
	Gastritis Erosive
	Graft Thrombosis
	Haemorrhoids
	Hypertension
	Inner Ear Disorder
	Irritable Bowel Syndrome
	Malaise

		Myocardial Ischaemia					
		Oedema Peripheral					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Mass		Vioxx	PS	Merck & Co., Inc	ORAL
521	DAY						
		Presbyoesophagus		Vioxx	SS	Merck & Co., Inc	ORAL
521	DAY						
		Rotator Cuff Syndrome		Aspirin	C		
UNKNOWN							
		Supraventricular		Aspirin	C		
UNKNOWN							
		Extrasystoles		Lipitor	C		
UNKNOWN							
		Upper Gastrointestinal		Allegra	C		
UNKNOWN							
		Haemorrhage		Synthroid	C		
UNKNOWN							
		Vascular Calcification					
		Ventricular Hypertrophy					

Date:04/07/04ISR Number: 4334594-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01101051
Age:74 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
Hospitalization -		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
1	MON						
Initial or Prolonged		Congestive		Coumadin	SS		
UNKNOWN							
		Carotid Artery Disease		Allopurinol	C		
UNKNOWN							
		Congestive Cardiomyopathy		Celebrex	C		
UNKNOWN		2 WK					
		Diverticulum Intestinal		Colchicine	C		
UNKNOWN							
		Haemorrhagic		Lanoxin	C		
UNKNOWN							
		Hypovolaemic Shock		Lasix (Furosemide)	C		
UNKNOWN							
		Myocardial Infarction		Skelaxin	C		
UNKNOWN							

	Renal Cyst		K-Lor	C			
UNKNOWN							

Date:04/07/04ISR Number: 4334598-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bladder Obstruction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebral Atherosclerosis		[Therapy					
	Cerebral Atrophy		Unspecified]	C				
UNKNOWN								
	Cerebral Infarction		Albuterol	C				
RESPIRATORY								
	Dizziness							
(INHALATION)								
	Encephalomalacia		Albuterol	C		ORAL		
	Epistaxis		Allopurinol	C				
UNKNOWN								
	Erectile Dysfunction		Ecotrin	C				
UNKNOWN								
	Haematochezia		Atenolol	C				
UNKNOWN								
	Haemorrhoids		Palgic D	C		ORAL		
	Headache		Mavik	C		ORAL		
	Ileus Paralytic		Mavik	C		ORAL		
	Nausea		Celebrex	C				
UNKNOWN								
	Pneumonia		Docusate Calcium	C				
UNKNOWN								
	Prostate Cancer		Guaifenex La	C				
UNKNOWN								
	Rectal Haemorrhage		Hydrodiuril	C		ORAL		
	Rectal Polyp		Ibuprofen	C				
UNKNOWN								
	Sinusitis		Atrovent	C				
UNKNOWN								
	Spinal Column Stenosis		Nitroglycerin	C				
UNKNOWN								
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/04ISR Number: 4334600-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Benign Lung Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Tylenol With Codeine	C				
UNKNOWN								
	Chest Pain							
	Dizziness Postural							
	Empty Sella Syndrome							
	Fibromyalgia							
	Headache							
	Hepatic Cyst							
	Hypertension							
	Hypoaesthesia							
	Incision Site Complication							
	Injury							
	Labyrinthitis							
	Liver Disorder							
	Lumbar Spinal Stenosis							
	Nausea							
	Paraesthesia							
	Pneumonia							
	Red Blood Cell Sedimentation Rate Increased							
	Residual Urine Volume							
	Scar							
	Urinary Retention							
	Vertebrobasilar Insufficiency							
	Vertigo							
	Wound Infection							

Date:04/07/04ISR Number: 4334601-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01287
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Arthralgia

Blindness
Blood Pressure Systolic
Decreased
Blood Urea Increased
Cataract
Coronary Artery Disease
Coronary Artery Stenosis
Electrocardiogram St
Segment Depression
Electrocardiogram T Wave
Inversion
Heart Rate Decreased
Injury
Myocardial Ischaemia
Optic Atrophy
Optic Ischaemic
Neuropathy
Osteoarthritis

	Papilloedema						
	Rotator Cuff Syndrome						
	Sinus Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tension Headache		Vioxx	PS	Merck & Co., Inc	ORAL	
	Visual Field Defect		Vioxx	SS	Merck & Co., Inc		UNKNOWN
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN
			Aspirin	C			UNKNOWN
			Aciphex	C		ORAL	
			Restoril	C			UNKNOWN

Date:04/07/04ISR Number: 4334603-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Lower Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Haemorrhage		Acetaminophen	C		ORAL	
			Fluoxetine	C		ORAL	
			Irbesartan	C		ORAL	
			Molsidomine	C		ORAL	

Date:04/07/04ISR Number: 4334604-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cholangitis		Vioxx	PS	Merck & Co., Inc	ORAL	153 DAY
Initial or Prolonged	Fatigue		Infliximab	SS			INTRAVENOUS 122 DAY
	Hepatic Cirrhosis		Omeprazole Magnesium	SS		ORAL	153 DAY
	Hepatic Fibrosis		Omeprazole Magnesium	SS		ORAL	153 DAY
	Hepatic Steatosis		Sertraline				
	Hepatitis		Hydrochloride	SS		ORAL	
	Jaundice		Sertraline				

	Liver Disorder		Hydrochloride	SS		ORAL
	Muscle Atrophy		Folic Acid	C		
UNKNOWN						
	Nausea		Methotrexate	C		ORAL
YR						
	Pruritus		Glyburide	C		
UNKNOWN						
	Vasculitis					

Date:04/07/04ISR Number: 4334606-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0304ESP00020
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Sodium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
25 DAY						
Initial or Prolonged	Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL
25 DAY						
Other	Faeces Discoloured		Desloratadine	C		
UNKNOWN						
	Haematocrit Decreased		Dexchlorpheniramine			
	Haemoglobin Decreased		Maleate	C		
UNKNOWN						
	Hepatitis Toxic					
	Muscle Rupture					
	Nephropathy Toxic					
	Nerve Compression					
	Personality Disorder					
	Renal Impairment					
	Tooth Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/07/04ISR Number: 4334611-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01292
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Injury							
	Myocardial Infarction							

Date:04/07/04ISR Number: 4334613-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01283
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia		Aspirin	C				
UNKNOWN								
	Back Pain		Klonopin	C				
UNKNOWN								
	Chest Wall Pain		Premarin	C				
UNKNOWN								
	Contusion		Flonase	C				
UNKNOWN								
	Coronary Artery		Lopid	C				
UNKNOWN								
	Atherosclerosis		Prevacid	C				
UNKNOWN								
	Depression							
	Dizziness							
	Dyspnoea							
	Eating Disorder							
	Emotional Distress							
	Fall							
	Gastrooesophageal Reflux							
	Disease							
	Hypercholesterolaemia							
	Hypertension							
	Hypotension							
	Injury							
	Lumbar Spinal Stenosis							
	Pain In Extremity							
	Palpitations							
	Thyroid Disorder							

Ventricular Fibrillation

Date:04/07/04ISR Number: 4334614-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anaemia
	Atrophy
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cataract
	Chronic Sinusitis
	Confusional State
	Dehydration
	Depression
	Fatigue
	Gangrene
	Gastric Ulcer
	Gastritis
	Herpes Zoster
	Hypokalaemia

		Hypovolaemia					
		Muscle Spasms					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myopathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Orthostatic Hypotension		Albuterol Sulfate	C		
RESPIRATORY							
		Paraesthesia					
(INHALATION)							
		Peripheral Occlusive		Fosamax	C		ORAL
		Disease		Amlodipine Besylate	C		ORAL
		Pneumonia		Aspirin	C		ORAL
		Renal Cyst		Atorvastatin Calcium	C		
UNKNOWN							
		Renal Failure Acute		Beclomethasone			
		Syncope		Dipropionate	C		
RESPIRATORY							
		Transient Ischaemic					
(INHALATION)							
		Attack		Lotensin	C		
UNKNOWN							
		Upper Gastrointestinal		Calcium Carbonate	C		ORAL
		Haemorrhage		Baycol	C		
UNKNOWN							
		Vasculitis		Diphenhydramine			
		Weight Decreased		Hydrochloride	C		ORAL
				Estrogens			
				(Unspecified)	C		ORAL
				Folic Acid	C		ORAL
				Hydrodiuril	C		ORAL
				Hydroxychloroquine			
				Sulfate	C		ORAL
				Indocin			
				(Indomethacin)	C		
UNKNOWN							
				Ipratropium Bromide	C		
UNKNOWN							
				Isosorbide			
				Mononitrate	C		ORAL
				Misoprostol	C		ORAL
				Naproxen	C		ORAL
				Prednisone	C		ORAL

Date:04/07/04ISR Number: 4334617-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00235
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	379 DAY	
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	379 DAY	
	Blindness Unilateral		Vicodin Tablets	C			UNKNOWN	
	Emotional Distress		Celebrex	C			UNKNOWN	
	Eye Irritation							
	Hypercoagulation							
	Injury							
	Joint Dislocation							
	Keratoconjunctivitis							
	Sicca							
	Migraine With Aura							
	Myeloproliferative							
	Disorder							
	Pain							
	Platelet Count Increased							
	Retinal Vein Occlusion							

Date:04/07/04ISR Number: 4334618-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01386
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atrial Fibrillation		Premarin	C			UNKNOWN	
	Back Injury		Lodine	C			UNKNOWN	
	Cardiac Disorder		Synthroid	C			UNKNOWN	
	Cardiomegaly							
	Cystocele							
	Depression							
	Emotional Distress							
	Fatigue							
	Intermittent Claudication							
	Intervertebral Disc Degeneration							
	Medication Error							
	Myocardial Infarction							
	Myofascial Pain Syndrome							
	Oedema Peripheral							
	Piriformis Syndrome							
	Pleural Effusion							
	Pulmonary Hypertension							
	Pulmonary Oedema							
	Rectocele							
	Sciatica							
	Spinal Osteoarthritis							
	Supraventricular Tachycardia							
	Therapeutic Response Decreased							

Date:04/07/04ISR Number: 4334620-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Anxiety

Cardiac Failure
Congestive
Chest Pain
Coagulopathy
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Restenosis
Deep Vein Thrombosis
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Dizziness
Drug Hypersensitivity
Dyspepsia
Fall
Gastrooesophageal Reflux
Disease
Haematoma
Hepatic Cyst

		Hepatic Steatosis					
		Hiatus Hernia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
380	DAY						
		Intervertebral Disc		Aspirin	C		
UNKNOWN							
		Degeneration		Plavix	C		
UNKNOWN							
		Intervertebral Disc		Coumadin	C		
UNKNOWN							
		Displacement		Cardizem	C		
UNKNOWN							
		Joint Dislocation		Maxair	C		
RESPIRATORY							
		Myocardial Infarction					
(INHALATION)							
		Nephrolithiasis					
		Pain In Extremity					
		Post Laminectomy Syndrome					
		Post Procedural					
		Haemorrhage					
		Post Thrombotic Syndrome					
		Radiculopathy					
		Refusal Of Treatment By					
		Patient					
		Sleep Apnoea Syndrome					
		Suicidal Ideation					
		Umbilical Hernia					

Date:04/07/04ISR Number: 4334626-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00028
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Estrogens			
				(Unspecified)	C		
UNKNOWN							

Date:04/07/04ISR Number: 4334627-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01650
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticular Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Protonix	C		ORAL		
			Effexor Xr	C		ORAL		

Date:04/07/04ISR Number: 4334629-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00196
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Erosive Oesophagitis		Sumatriptan	SS				
Initial or Prolonged	Mesenteric Artery		Zolmitriptan	SS		ORAL		
Other	Stenosis		Zolmitriptan	SS		ORAL		
	Migraine		Corticosteroids (Unspecified)	C		ORAL		
	Peritoneal Adhesions		Drofenine Hydrochloride And Propyphenazone	C		RECTAL		
			Propranolol Hydrochloride	C		ORAL		

Date:04/08/04ISR Number: 4334927-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
Disability	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Emotional Distress							
	Fear							
	Haemoglobin Decreased							
	Heart Rate Decreased							
	Injury							
	Lipids Abnormal							
	Myocardial Infarction							
	Pain							
	Tendonitis							

Date:04/08/04ISR Number: 4334928-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Creatine		Vioxx	SS	Merck & Co., Inc	ORAL		
	Phosphokinase Mb		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Folic Acid	C				UNKNOWN
	Congestive		Arava	C				UNKNOWN
	Diarrhoea		Methotrexate	C				UNKNOWN
	Dilatation Atrial		Aredia	C			441 DAY	UNKNOWN
	Dilatation Ventricular		Prednisone	C				UNKNOWN
	Dyspnoea Paroxysmal		Inderal	C			10 MON	UNKNOWN

	Nocturnal	Inderal	C
UNKNOWN			
	Faeces Discoloured	Inderal La	C
UNKNOWN			
	Hypertension		
	Injury		
	Insomnia		
	Melaena		
	Myocardial Infarction		
	Myocarditis		
	Nightmare		
	Palpitations		
	Panic Attack		
	Phlebitis		
	Phlebitis Superficial		
	Pulmonary Embolism		
	Pulmonary Hypertension		
	Sleep Disorder		
	Stress		
	Tachycardia		
	Thrombosis		
	Tricuspid Valve Incompetence		
	Upper Respiratory Tract Infection		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/04ISR Number: 4334930-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0404AUS00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Haemorrhage	Professional						

Date:04/08/04ISR Number: 4334933-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Asthenia	Professional	Clonidine	C				
	Back Injury							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Dizziness							
	Emotional Disorder							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hernia							
	Hypertension							
	Insomnia							
	Intervertebral Disc Protrusion							
	Joint Sprain							
	Neck Pain							
	Peripheral Vascular Disorder							
	Renal Disorder							
	Renal Failure							
	Road Traffic Accident							
	Spinal Osteoarthritis							
	Vomiting							

Date:04/08/04ISR Number: 4335064-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0329087A
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activated Partial		Clamoxyl	PS	Glaxosmithkline	ORAL	2G Per day	15 DAY
	Thromboplastin Time Prolonged		Vioxx	SS		ORAL		
	Neutropenia							

Date:04/08/04ISR Number: 4335247-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00037
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
	Aggression							
	Amnesia							
	Cognitive Disorder							
	Fear							
	Mood Swings							
	Sneezing							
	Thinking Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/04ISR Number: 4335248-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Other	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Amitriptyline Hydrochloride	C			UNKNOWN	
	Emphysema							
	Fibromyalgia		Amitriptyline Hydrochloride	C			UNKNOWN	
	Headache							
	Hyperlipidaemia		Amitriptyline Hydrochloride	C			UNKNOWN	
	Hypertension							17 DAY
	Lacunar Infarction		Amitriptyline Hydrochloride	C			UNKNOWN	
	Meniscus Lesion							
	Peripheral Vascular Disorder		Amitriptyline Hydrochloride	C			UNKNOWN	
	Sinusitis		Amitriptyline Hydrochloride	C			UNKNOWN	
	Spondylolisthesis							17 DAY
	Acquired		Zoloft	C			UNKNOWN	
								582 DAY
	Spondylolysis		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Hydrodiuril	C		ORAL		
			Altace	C			UNKNOWN	

Date:04/08/04ISR Number: 4335250-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01433
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Anxiety
	Arthropathy
	Atrial Fibrillation
	Back Pain
	Blood Cholesterol Increased
	Bronchial Irritation
	Cardioactive Drug Level Increased
	Cholelithiasis
	Colitis
	Gastric Disorder
	Gastroenteritis Viral
	Glaucoma
	Hepatic Steatosis
	Hepatomegaly
	Hormone Level Abnormal
	Myocardial Infarction
	Nephrolithiasis
	Oedema Peripheral
	Oesophageal Spasm
	Otitis Media Acute
	Overdose
	Pain In Extremity
	Palpitations
	Pharyngitis

		Prinzmetal Angina					
		Road Traffic Accident					
		Seasonal Allergy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Stress		Vioxx	PS	Merck & Co., Inc	ORAL
157	DAY						
		Venous Insufficiency		Vioxx	SS	Merck & Co., Inc	ORAL
157	DAY						
				Hyzaar	C		ORAL
				Vitamins (Unspecified)	C		
UNKNOWN							
				Klor-Con	C		
UNKNOWN							

Date:04/08/04ISR Number: 4335251-8Report Type:Expedited (15-DaCompany Report #DK-MERCK-0404DNK00002
Age:71 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
Initial or Prolonged		Atrioventricular Block		Aspirin	C		
UNKNOWN							
		First Degree		Ramipril	C		
UNKNOWN							
		Chest Discomfort					
		Heart Rate Increased					
		Heart Rate Irregular					
		Malaise					

Date:04/08/04ISR Number: 4335260-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
Initial or Prolonged		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
1	MON						
		Cardiac Flutter		Percocet	C		
UNKNOWN							

	Coronary Artery Disease		Mobic	C
UNKNOWN				
	Coronary Artery Stenosis		Skelaxin	C
UNKNOWN				
	Ecchymosis		Zantac	C
UNKNOWN				
	Emotional Distress			
	Fall			
	Fatigue			
	Groin Pain			
	Joint Range Of Motion			
	Decreased			
	Myocardial Infarction			
	Pain In Extremity			
	Sinus Tachycardia			
	Urticaria			

Date:04/08/04ISR Number: 4335261-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00014
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL
32 DAY						
Initial or Prolonged			Aspirin Lysine	SS		ORAL

Date:04/08/04ISR Number: 4335262-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anger
Initial or Prolonged	Angina Unstable
Disability	Anxiety

		Blood Cholesterol Increased					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
195	DAY						
		Atherosclerosis					
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Depression					
		Dilatation Atrial					
		Fatigue					
		Headache					
		Hypertension					
		Hypoaesthesia					
		Insomnia					
		Low Density Lipoprotein Increased					
		Malaise					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Non-Cardiac Chest Pain					
		Pain In Extremity					
		Sinus Bradycardia					
		Ventricular Hypertrophy					
		Vision Blurred					
		Visual Disturbance					

Date:04/08/04ISR Number: 4335263-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01935
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Potassium Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Musculoskeletal Disorder		Vasotec	C		
UNKNOWN							
Other		Renal Failure		Lasix (Furosemide)	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Lantus	C		
UNKNOWN							
				Zocor	C		ORAL
				Zoloft	C		
UNKNOWN							

			Toprol Xl Tablets	C		
UNKNOWN						
			Flomax (Morniflumate)	C		
UNKNOWN						
			Quinine Sulfate	C		
UNKNOWN						

Date:04/08/04ISR Number: 4335264-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00009
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Life-Threatening Hospitalization - Initial or Prolonged	Bronchopulmonary Aspergillosis Cheilitis Facial Palsy Oedema Pancytopenia		Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/04ISR Number: 4335265-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:04/08/04ISR Number: 4335266-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0404SWE00002
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
Initial or Prolonged								

Date:04/08/04ISR Number: 4335293-2Report Type:Direct Company Report #CTU 216266
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Rofecoxib	PS		ORAL		
25 MG , 25 MG								
Initial or Prolonged	Haemorrhage							
QD , ORAL								
			Colchicine	C				

Date:04/08/04ISR Number: 4336734-7Report Type:Expedited (15-DaCompany Report #2003036888
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Consumer	Lipitor					
Initial or Prolonged	Aseptic Necrosis Bone	Health	(Atorvastatin)	PS				
40 MG								
Disability	Bacteria Urine	Professional	Rofecoxib					
	Blood Chloride Decreased		(Rofecoxib)	SS				
	Blood Potassium Decreased		Prednisone					
	Blood Sodium Decreased		(Prednisone)	SS				
	Bundle Branch Block Right		Potassium					

Constipation	(Potassium)	C
Dilatation Atrial	Amlodipine Besilate	
Electrocardiogram P Wave	(Amlodipine	
Abnormal	Besilate)	C
Gait Disturbance	Dyazide	
Haematocrit Decreased	(Hydrochlorothiazide	
Haemoglobin Decreased	, Triamterene)	C
Hypothyroidism	Narine Repetabs	
Mean Cell Volume	(Pseudoephedrine	
Increased	Sulfate, Loratadine)	C
Muscle Atrophy	Esomeprazole	
Muscular Weakness	(Esomeprazole)	C
Myopathy	Levothyroxine Sodium	
Nausea	(Levothyroxine	
Osteoarthritis	Sodium)	C
Pain	Centrum Silver	
Polymyositis	(Ascorbic Acid,	
Red Blood Cell Count	Calcium, Mineral	
Decreased	Nos, Retinol,	
Red Blood Cells Urine	Tocopheryl Acetate,	C
Positive	Acetylsalicylic Acid	
Scoliosis	(Acetylsalicylic	
Synovitis	Acid)	C
Urinary Tract Infection	Calcium Citrate	
Urine Ketone Body Present	(Calcium Citrate)	C
Ventricular Extrasystoles	Chondroitin/Glucosam	
	ine (Chondroitin,	

Glucosamine)	C
Vitamin B (Vitamin B)	C
Ascorbic Acid (Ascorbic Acid)	C
Tocopherol (Tocopherol)	C
Methylcellulose (Methylcellulose)	C
Piroxicam (Piroxicam)	C
Hydroxyzine Hydrochloride (Hydroxyzine Hydrochloride)	C
Ferrous Sulfate (Ferrous Sulfate)	C

Date:04/09/04ISR Number: 4335357-3Report Type:Expedited (15-DaCompany Report #200410474DE
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Amaryl	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Drug Interaction							
	Electrolyte Imbalance		Arelix	SS		ORAL		
	Hypertension		Accupro	SS		ORAL		
	Inappropriate		Vioxx	SS		ORAL		
	Antidiuretic Hormone		Novalgin	C		ORAL	frequency:	
	Secretion						irregular	
	Oedema Peripheral		Aciclostad	C		ORAL		
	Oesophageal Candidiasis		Alpha-Liponsaure	C		ORAL		
	Vomiting		Atarax	C		ORAL		
			Bisoprolol	C		ORAL		
			Mydocalm	C		ORAL		
			Procain	C			INTRAVENOUS	

Date:04/09/04ISR Number: 4335589-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01385
Age:75 YR Gender:Female I/FU:F

Outcome	PT

Hospitalization - Initial or Prolonged Other	Breast Cyst Cardiac Failure Congestive Cardiac Murmur Coronary Artery Disease Coronary Artery Occlusion Dysphagia Dyspnoea Electrocardiogram Abnormal Gastric Disorder Gastritis Hyperlipidaemia Hypertension Hypoaesthesia Ischaemia Lower Gastrointestinal Haemorrhage Lung Neoplasm Myocardial Infarction

		Non-Cardiac Chest Pain Oesophageal Spasm Oxygen Saturation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
				Premarin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Prevacid	C		ORAL
				Synthroid	C		ORAL
				Potassium (Unspecified)	C		
UNKNOWN							

Date:04/09/04ISR Number: 4335590-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01357
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Deafness		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		[Therapy			
		Gastric Ulcer		Unspecified]	C		
UNKNOWN							
		Influenza Like Illness		Percocet	C		
UNKNOWN							
		Musculoskeletal Disorder		Norvasc	C		
UNKNOWN							
		Nasal Polyps		Valium	C		
UNKNOWN							
		Nausea		Calan	C		
UNKNOWN							
		Panic Disorder		Premarin	C		
UNKNOWN							
		Tinnitus		Avalide	C		
UNKNOWN							
		Transient Ischaemic		Maxzide	C		
UNKNOWN							

	Attack	Claritin	C
UNKNOWN			
		Ativan	C
UNKNOWN			
		Toprol Xl Tablets	C
UNKNOWN			
		Lopressor	C
UNKNOWN			

Date:04/09/04ISR Number: 4335600-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Pulmonary Oedema
Other	Amnesia
	Anaemia
	Anxiety
	Back Injury
	Blood Lactate Dehydrogenase Increased
	Cardiac Failure Congestive
	Cataract
	Cholelithiasis
	Contusion
	Coronary Artery Disease
	Dehydration
	Dilatation Atrial
	Diplopia
	Drug Ineffective

		Electrocardiogram Qt Prolonged					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacunar Infarction		[Therapy			
		Mitral Valve Incompetence		Unspecified]	C		
UNKNOWN							
		Nausea		Tylenol	C		
UNKNOWN							
		Pain		Vicodin Tablets	C		
UNKNOWN							
		Pollakiuria		Darvocet-N	C		
UNKNOWN							
		Rotator Cuff Syndrome		Amitriptyline			
		Skin Ulcer		Hydrochloride	C		ORAL
		Spinal Compression		Aspirin	C		
UNKNOWN							
		Fracture		Aspirin	C		
UNKNOWN							
		Suicidal Ideation		Buspirone			
		Urinary Tract Infection		Hydrochloride	C		
UNKNOWN							
		Vomiting		Ambien	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Aricept	C		ORAL
				Premarin	C		ORAL
				Fluoxetine	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Metoclopramide	C		
UNKNOWN							

Date:04/09/04ISR Number: 4335605-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Agitation
	Angina Pectoris
	Angina Unstable
	Anoxic Encephalopathy
	Anxiety
	Ascites
	Atrioventricular Block Complete
	Blindness
	Blood Albumin Increased
	Blood Pressure Increased
	Cardiac Aneurysm
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiogenic Shock
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Colitis Ischaemic
	Coma
	Constipation
	Contusion
	Coronary Artery Disease
	Cough

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dehydration Depressed Level Of Consciousness					
2	MON	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Insulin-Dependent Diabetic Retinopathy		[Therapy Unspecified]	C		
UNKNOWN		Diarrhoea		Insulin	C		
		Escherichia Infection Fall Gastritis Haematoma Haemorrhoidal Haemorrhage Haemorrhoids Heart Sounds Abnormal Hepatic Cirrhosis Hepatic Failure Hyperglycaemia Injury Ischaemic Cardiomyopathy Mitral Valve Incompetence Muscle Tightness Myocardial Infarction Pain In Extremity Productive Cough Pruritus Pulmonary Hypertension Pulmonary Oedema Rash Renal Cyst Renal Failure Acute Sick Sinus Syndrome Silent Myocardial Infarction Spinal Osteoarthritis Tendonitis Tricuspid Valve Incompetence Urinary Tract Infection Weight Decreased					

Date:04/09/04ISR Number: 4335609-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01999
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Death		Vioxx	PS	Merck & Co., Inc	ORAL		54 DAY
Hospitalization -	Brain Oedema		Vioxx	SS	Merck & Co., Inc	ORAL		54 DAY
Initial or Prolonged	Coma		Allopurinol	C				UNKNOWN
	Cough		Lipitor	C				UNKNOWN 568 DAY
	Dry Mouth		Blinded Therapy	C				UNKNOWN 70 DAY
	Haemorrhage Intracranial		Ultram	C				UNKNOWN
	Headache		Wellbutrin	C				UNKNOWN
	Hypertension		Celexa	C				UNKNOWN
	Respiratory Arrest		Estratest	C				UNKNOWN 3778 DAY
	Tachycardia							

Date:04/09/04ISR Number: 4335615-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0404DEU00015
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
Hospitalization -	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Myocardial Infarction		Candesartan Cilexetil	C				UNKNOWN
			Torsemide	C				UNKNOWN
			Miglitol	C				UNKNOWN

Date:04/09/04ISR Number: 4335619-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/09/04ISR Number: 4335620-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		220 DAY
Initial or Prolonged	Aortic Stenosis	Professional	Tylenol	C				UNKNOWN
Disability	Aortic Valve Incompetence		Codeine	C				UNKNOWN
	Atelectasis		Vasotec	C		ORAL		
	Atrial Fibrillation		Premarin	C				UNKNOWN
	Constipation		Premarin	C				UNKNOWN
	Depression		Zocor	C		ORAL		

	Dyspnoea Exertional	Hydrocodone		
	Lung Neoplasm	Hydrochloride	C	
UNKNOWN				
	Medical Device	Levsin	C	
UNKNOWN				
	Complication	Synthroid	C	ORAL
	Postoperative Infection	Prilosec	C	ORAL
	Sternal Injury			
	Syncope			
	Ventricular Hypertrophy			

Date:04/09/04ISR Number: 4335622-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01412
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Sclerosis
Disability	Arthralgia
Other	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Cardiac Failure Congestive
	Cardiac Murmur
	Carotid Artery Disease
	Carotid Artery Stenosis
	Cerebellar Infarction
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Stenosis

		Crackles Lung					
		Diastolic Dysfunction					
		Dilatation Atrial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum	Professional	Aspirin	C		
UNKNOWN							
		Dizziness		Plavix	C		
UNKNOWN							
		Injury		Lanoxin	C		
UNKNOWN							
		Ischaemic Stroke		Calan	C		
UNKNOWN							
		Mitral Valve Incompetence		Coumadin	C		ORAL
		Myocardial Infarction		Coumadin	C		ORAL
		Osteoarthritis		Coumadin	C		ORAL
		Palpitations		Digoxin	C		
UNKNOWN							
		Pleural Effusion		Hyzaar	C		
UNKNOWN							
		Pulmonary Congestion		Hyzaar	C		ORAL
		Pulmonary Fibrosis					
		Rotator Cuff Syndrome					
		Sick Sinus Syndrome					
		Sleep Apnoea Syndrome					
		Syncope					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Vertigo					
		Wheezing					

Date:04/09/04ISR Number: 4335623-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0404SWE00001
Age:77 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY							
		Atherosclerosis		Lansoprazole	C		
UNKNOWN							
		Myocardial Infarction		Sotalol			

Sudden Death Hydrochloride C
UNKNOWN

Date:04/09/04ISR Number: 4335624-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Benign Neoplasm
	Chest Pain
	Colonic Polyp
	Coronary Artery Disease
	Depression
	Fall
	Gastroenteritis Viral
	Generalised Anxiety Disorder
	Haematoma
	Hypercholesterolaemia
	Hypertension
	Insomnia
	Intervertebral Disc Degeneration
	Myocardial Infarction
	Myositis
	Osteochondrosis

	Pain In Extremity Sleep Disorder Tendonitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Tylenol	C			UNKNOWN	
			Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Librax Capsules	C			UNKNOWN	
			Cyclobenzaprine Hydrochloride	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Zantac	C			UNKNOWN	

Date:04/09/04ISR Number: 4335625-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00145
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Paraesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Codeine	C			UNKNOWN	
			Codeine	C			UNKNOWN	

Date:04/09/04ISR Number: 4335626-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00024
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL	143 DAY	
	Rash		Clobetasone Butyrate	C		TOPICAL		
			Hydrocortisone Butyrate	C		TOPICAL		
			Omeprazole	C		ORAL		

Date:04/09/04ISR Number: 4335628-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Emotional Distress		Amitriptyline Hydrochloride	C			UNKNOWN	
	Hyperlipidaemia		Aspirin	C			UNKNOWN	
	Therapeutic Response		Pravachol	C			UNKNOWN	
	Decreased		Altace	C			UNKNOWN	
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/04ISR Number: 4335629-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Mouth Ulceration							
	Swollen Tongue							

Date:04/09/04ISR Number: 4336119-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Activities Of Daily	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Tylenol	C				
UNKNOWN								
	Blood Pressure Increased		Aspirin	C				
UNKNOWN								
	Bunion							
	Cardiac Failure							
	Congestive							
	Constipation							
	Drug Intolerance							
	Fall							
	Gastric Disorder							
	Headache							
	Hypertensive Heart							
	Disease							
	Intervertebral Disc							
	Disorder							
	Joint Sprain							
	Limb Discomfort							
	Muscle Spasms							
	Myalgia							
	Nocturia							
	Onychomycosis							
	Osteoarthritis							
	Pain							
	Pulmonary Granuloma							
	Renal Failure							

Rotator Cuff Syndrome
Seborrhoeic Keratosis
Sinusitis
Wound Infection

Date:04/09/04ISR Number: 4336122-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-01113727
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		241 DAY
Initial or Prolonged			Aspirin	C		ORAL		
			Budesonide	C				
RESPIRATORY								
(INHALATION)								
			Prednisolone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/09/04ISR Number: 4336123-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
Initial or Prolonged Disability	Ischaemic Cerebral Infarction	Professional	[Therapy Unspecified]	SS				UNKNOWN
	Migraine		Yasmin	SS				UNKNOWN
			Tylenol	C				UNKNOWN
			Skelaxin	C				UNKNOWN
			Paxil	C				UNKNOWN
			Advil	C				UNKNOWN
			Fioricet Tablets	C				UNKNOWN

Date:04/09/04ISR Number: 4336124-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01432
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		159 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		159 DAY
Initial or Prolonged	Bone Cyst		Vicodin Tablets	C				UNKNOWN
Disability	Cardio-Respiratory Arrest		Carisoprodol	C				UNKNOWN
Other	Osteoarthritis							
	Sciatica							
	Spinal Column Stenosis							

Date:04/09/04ISR Number: 4336126-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C			UNKNOWN	
Other	Bundle Branch Block Left		Ecotrin	C			UNKNOWN	
	Chest Discomfort		Viagra	C			UNKNOWN	
	Coronary Artery Disease		Calan Sr	C			UNKNOWN	
	Dehydration		Zocor	C			UNKNOWN	
	Diverticulum Intestinal		Celebrex	C			UNKNOWN	
	Haemorrhagic		Advil	C			UNKNOWN	
	Emotional Distress							
	Gastritis Atrophic							
	Helicobacter Infection							
	Neck Pain							
	Stent Occlusion							

Date:04/09/04ISR Number: 4336129-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Depression
	Drug Hypersensitivity
	Fall
	Generalised Anxiety
	Disorder
	Haemorrhage Intracranial
	Hypertension
	Memory Impairment

		Meniscus Lesion Retinal Ischaemia Sleep Apnoea Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Acuity Reduced		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL
UNKNOWN					C		
				Doxepin Hydrochloride	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							

Date:04/09/04ISR Number: 4336130-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0404CAN00033
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/09/04ISR Number: 4336365-9Report Type:Direct Company Report #CTU 216312
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Heart Rate Increased		Gammagard 10 Gram Baxter Bioscience	PS	Baxter Bioscience	
INTRAVENOUS 20 GRAMS						
EVERY 2 WE						
INTRAVENOUS						

				Vioxx	SS		ORAL
50MG Q24H							
ORAL							
				Moduretic	C		
				Albuterol	C		
				Maxair	C		
				Skelaxin	C		
				Ultracet	C		

Date:04/09/04ISR Number: 4337673-8Report Type:Expedited (15-DaCompany Report #PHEH2004US03626
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatic Cirrhosis	Consumer	Lamisil At Cream			
	Hepatocellular Damage		Unknown Af Or Ji			
	Psoriasis		(Nch) (Terbinafine			
			Hydrochloride) Cream	PS		
TOPICAL BIW, TOPICAL						
			Vioxx (Rofecoxib)	SS		ORAL
ORAL 29 DAY						
			Thiamine	C		
			Fibercon			
			(Polycarbophil			
			Calcium)	C		
			Vitamins	C		
			Lactulose	C		
			Lasix (Furosemide			
			Sodium)	C		
			Spironolactone	C		
			Propranolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/04ISR Number: 4336630-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Systolic Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lidocaine And Triamcinolone Acetonide	C				
	Chest Pain							
PARENTERAL							1	DAY
	Decreased Appetite		Glucophage Xr	C		ORAL		
	Diabetes Mellitus		Glucophage Xr	C				
UNKNOWN								
	Inadequate Control		Glucophage Xr	C		ORAL		
	Drug Ineffective							
	Dyspepsia							
	Dyspnoea							
	Electrocardiogram T Wave Inversion							
	Emotional Distress							
	Gastric Disorder							
	Haemoglobin Decreased							
	Headache							
	Hemiparesis							
	Hypertension							
	Joint Dislocation							
	Labyrinthitis							
	Lower Limb Fracture							
	Mitral Valve Incompetence							
	Monoplegia							
	Overdose							
	Pain							
	Pharyngolaryngeal Pain							
	Platelet Count Increased							
	Rhinorrhoea							
	Self-Medication							
	Sinusitis							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							
	White Blood Cell Count Increased							

Date:04/12/04ISR Number: 4336643-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00004
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Dyspnoea							
	Dysuria							
	Enterobacter Infection							
	Gastrointestinal Disorder							
	Heart Sounds Abnormal							
	Lung Crepitation							
	Nausea							
	Oedema Peripheral							
	Renal Failure							

Date:04/12/04ISR Number: 4336645-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		44 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder With Mixed Anxiety And		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		44 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
	Back Pain		Vicodin Tablets	C				UNKNOWN
	Blood Pressure Increased		Hydrocodone Bitartrate	C				UNKNOWN
	Blood Triglycerides Increased		Relafen	C				UNKNOWN
	Bone Pain							
	Breast Pain							
	Chest Pain							
	Chondromalacia							
	Contusion							
	Coronary Artery Atherosclerosis							
	Dizziness							
	Dyspepsia							
	Extrasystoles							
	Fatigue							
	Joint Sprain							
	Keratoacanthoma							
	Kyphosis							
	Musculoskeletal Stiffness							
	Pericarditis							
	Pneumonia							
	Tension Headache							
	Upper Respiratory Tract Infection							

Date:04/12/04ISR Number: 4336646-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00478
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	1	YR

Date:04/12/04ISR Number: 4336648-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Acute Myocardial Infarction
Other	Adhesion
	Alcohol Withdrawal Syndrome
	Alcoholism
	Anaemia
	Anxiety
	Arthralgia
	Atherosclerosis
	Back Disorder
	Biliary Neoplasm
	Cerebrovascular Accident

		Coronary Artery Disease					
		Depression					
		Drug Dependence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Faecal Occult Blood		Vioxx	SS	Merck & Co., Inc	ORAL
		Positive		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hepatitis		Trazodone			
		Hepatitis C		Hydrochloride	C		
UNKNOWN	1291 DAY						
		Hyperlipidaemia		Trazodone			
		Hypertension		Hydrochloride	C		
UNKNOWN							
		Insomnia		Trazodone			
		Intervertebral Disc		Hydrochloride	C		
UNKNOWN	1291 DAY						
		Protrusion		Lortab	C		
UNKNOWN							
		Loss Of Consciousness		Amitriptyline			
		Muscle Spasms		Hydrochloride	C		
UNKNOWN	874 DAY						
		Myocardial Infarction		Celebrex	C		
UNKNOWN	362 DAY						
		Myofascial Pain Syndrome		Neurontin	C		
UNKNOWN							
		Osteoarthritis		Hydrocodone			
		Panic Attack		Bitartrate	C		
UNKNOWN							
		Pneumonia		Lorazepam	C		
UNKNOWN	2 DAY						
		Prostatitis		Robaxin	C		
UNKNOWN	957 DAY						
		Pyrexia					
		Sinus Bradycardia					
		Urinary Tract Infection					
		Vision Blurred					

Date:04/12/04ISR Number: 4336650-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01429
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Arthropathy	Vioxx	PS	Merck & Co., Inc	ORAL	146 DAY
Other	Dermal Cyst	[Therapy Unspecified]	C			UNKNOWN
	Headache	Norvasc	C			UNKNOWN 1549 DAY
	Injury	Premarin	C			UNKNOWN 201 DAY
	Insomnia	Dyazide	C			UNKNOWN
	Myalgia	Sular	C			UNKNOWN
	Pain In Extremity					
	Pulmonary Embolism					
	Sudden Death					

Date:04/12/04ISR Number: 4336903-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0402FRA00040
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
			[Therapy Unspecified]	C			UNKNOWN	

Date:04/12/04ISR Number: 4336906-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01980
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus
	Cardiac Failure
Other	Congestive

		Cholelithiasis					
		Colon Adenoma					
		Colonic Polyp	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Aspirin	C		
UNKNOWN							
		Diabetes Mellitus		Atenolol	C		
UNKNOWN							
		Diverticulum		Tums	C		
UNKNOWN							
		Diverticulum Intestinal		Adalat	C		ORAL
		Haemorrhoids		Prilosec	C		
UNKNOWN							
		Hepatic Steatosis					
		Hiatus Hernia					
		Hyperthyroidism					
		Lipids Abnormal					
		Myocardial Infarction					
		Oedema Peripheral					
		Oesophageal Ulcer					
		Prostate Cancer					
		Upper Gastrointestinal					
		Haemorrhage					

Date:04/12/04ISR Number: 4337735-5Report Type:Expedited (15-DaCompany Report #WAES 0403FRA00044
Age:49 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Abdomen	Foreign	Tab Vioxx			
Initial or Prolonged		Duodenal Ulcer	Study	(Rofecoxib)	PS		
50 MG/DAILY,							
		Perforation	Health				
PO	8 DAY						
		Helicobacter Infection	Professional	Tab Placebo	SS		ORAL
PO	8 DAY						
		Peritonitis	Other	Ibuprofen	SS		ORAL
				Acetaminophen	C		
				Cortisone	C		

Date:04/13/04ISR Number: 4337689-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Aortic Valve Incompetence
	Bladder Disorder
	Cataract
	Closed Head Injury
	Contusion
	Dyspepsia
	Dyspnoea
	Dysuria
	Ear Pain
	Eye Haemorrhage
	Eye Pain
	Fall
	Glaucoma
	Headache
	Hearing Impaired
	Hypertension
	Hypokalaemia
	Injury
	Keratoconjunctivitis
	Sicca
	Loose Body In Joint

		Migraine					
		Mitral Valve Incompetence					
		Nasal Turbinate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertrophy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Neurodermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Optic Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Fosamax	C		ORAL
		Paraesthesia Oral		Celebrex	C		
UNKNOWN							
		Peripheral Vascular		Prempro	C		
UNKNOWN							
		Disorder		Hyaluronate Sodium	C		
PARENTERAL							
		Polymyalgia Rheumatica		Advil	C		
UNKNOWN							
		Retinal Vein Occlusion		Synthroid	C		
UNKNOWN							
		Reversible Airways		Claritin	C		
UNKNOWN							
		Obstruction					
		Sinusitis					
		Skin Laceration					
		Syncope					
		Vision Blurred					

Date:04/13/04ISR Number: 4337691-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0404ESP00007
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Cerebrovascular Accident		[Therapy Unspecified]	C		
UNKNOWN							

Date:04/13/04ISR Number: 4337692-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02432
Age:21 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Liver Function Test	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
3 DAY							
	Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	

Date:04/13/04ISR Number: 4337693-3Report Type:Expedited (15-DaCompany Report #IT-MERCK-0404ITA00012
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
6 DAY								
Initial or Prolonged	Perforation		Gabapentin	C		ORAL		
	Peritonitis							

Date:04/13/04ISR Number: 4337697-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01904
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiomyopathy		Coreg	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Altace	C				
UNKNOWN								

Date:04/13/04ISR Number: 4337699-4Report Type:Expedited (15-DaCompany Report #NL-MERCK-01113727
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		241 DAY
Initial or Prolonged	Gastric Ulcer	Professional	Aspirin	C		ORAL		
			Budesonide	C				
RESPIRATORY								
(INHALATION)								
			Prednisolone	C		ORAL		

Date:04/13/04ISR Number: 4337701-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00022
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization -			Acetaminophen	C		ORAL		
Initial or Prolonged			Amitriptyline Hydrochloride	C		ORAL		
			Bromazepam	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Oxazepam	C		ORAL		

Date:04/13/04ISR Number: 4337702-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00397
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Interaction		Monopril	SS		ORAL		
Initial or Prolonged	Embolic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Fall		Aspirin	C				
UNKNOWN								
	Head Injury							
	Oedema							
	Weight Increased							

Date:04/13/04ISR Number: 4337704-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00767
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/04ISR Number: 4337956-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Skin Reaction Stevens-Johnson Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/04ISR Number: 4337961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Congenital Anomaly
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Adjustment Disorder With		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY	
Depressed Mood		Microzide	SS			UNKNOWN	
Affective Disorder		Microzide	SS			UNKNOWN	
Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
Anaemia		Prinzide	SS		ORAL	26 HR	
Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	24 DAY	
Ankylosing Spondylitis		Vioxx	SS	Merck & Co., Inc	ORAL	97 DAY	
Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL	179 DAY	
Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	97 DAY	
Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL	24 DAY	
Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY	
Concussion		Vioxx	SS	Merck & Co., Inc	ORAL	179 DAY	
Constipation		Vicodin Es Tablets	C			UNKNOWN	
Depression		Analgesic Or					
Drug Ineffective		Anesthetic					
Dysphagia		(Unspecified)	C			PARENTERAL	1 DAY
Dysphoria		Beconase	C			UNKNOWN	
Facet Joint Syndrome		Prevacid	C			UNKNOWN	
Facial Bones Fracture		Claritin	C			UNKNOWN	
Fall		Effexor	C			UNKNOWN	
Fibromyalgia		Trazodone					
Gastrooesophageal Reflux		Hydrochloride	C			UNKNOWN	
Disease		Trazodone					

	Hypothyroidism	Hydrochloride	C
UNKNOWN			
	Intervertebral Disc	Imitrex	C
UNKNOWN			
	Degeneration	Claritin	C
UNKNOWN			
	Intervertebral Disc	Prevacid	C
UNKNOWN			
	Displacement	Zestoretic	C
UNKNOWN			
	Intervertebral Disc	Celebrex	C
UNKNOWN			
	Protrusion	Valium	C
UNKNOWN			
	Jaw Disorder	Estratest	C
UNKNOWN			
	Myofascial Pain Syndrome	Estratest	C
UNKNOWN			
	Neck Pain		
	Nephritis Interstitial		
	Oesophageal Stenosis		
	Osteoporosis		
	Palpitations		
	Polyarthritis		
	Psoriatic Arthropathy		
	Raynaud'S Phenomenon		
	Reflux Oesophagitis		
	Reiter'S Syndrome		
	Renal Failure		
	Sacroiliitis		
	Spondyloarthropathy		
	Urinary Tract Pain		
	Weight Increased		

Date:04/13/04ISR Number: 4337965-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01092
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Darvocet-N	C				
UNKNOWN								
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/04ISR Number: 4337967-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0404SWE00005
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Acetaminophen	C				
	Bradycardia		Acetaminophen And Codeine	C			UNKNOWN	
	C-Reactive Protein Increased		Vasotec	C			UNKNOWN	
	Hyperkalaemia		Isradipine	C			UNKNOWN	
	Kyphosis		Lactulose	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	

Date:04/13/04ISR Number: 4337968-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Other	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cold Sweat		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Electromechanical		Atenolol	C			UNKNOWN	
	Dissociation		Hydrodiuril	C			UNKNOWN	
	Hypersensitivity		Prevacid	C			UNKNOWN	
	Multiple Allergies		Claritin	C			UNKNOWN	
	Muscle Strain							
	Myocardial Infarction							
	Nausea							
	Patellofemoral Pain							

Syndrome
Sudden Death
Tendon Injury
Vomiting

Date:04/13/04ISR Number: 4340880-1Report Type:Expedited (15-DaCompany Report #2004200020US
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Fall	Study	Celebrex			
	Fungal Infection	Consumer	(Celecoxib)Capsule	PS		
	Genital Pruritus Female		Vioxx (Rofecoxib)	SS		
	Rotator Cuff Syndrome		Aspirine	C		
	Triple Vessel Bypass		Allopurinol	C		
	Graft		Propranolol			
			(Propranolol)	C		
			Lipitor			
			(Atorvastatin)	C		
			Glucotrol	C		
			Furosemide	C		
			Vitamins	C		
			Librium			
			(Chlordiazepoxide			
			Hydrochloride)	C		
			Tricor	C		
			Lortab	C		

Date:04/13/04ISR Number: 4341009-6Report Type:Expedited (15-DaCompany Report #ZANA001161
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Foreign	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL	2 DF/DAY	ORAL
	Body Temperature	Consumer						
	Increased	Other	Vioxx (Rofecoxib)	SS		ORAL	25 MG/DAY	ORAL
	Dermatitis Bullous							
	Exanthem							
	Rash Macular							

Date:04/14/04ISR Number: 4338602-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01101051
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 MON	
Hospitalization -	Cardiac Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	1 MON	
Initial or Prolonged	Cardiac Failure		Coumadin	SS			UNKNOWN	
	Congestive		Allopurinol	C			UNKNOWN	
	Cardio-Respiratory Arrest		Celebrex	C			UNKNOWN	2 WK
	Carotid Artery Disease		Colchicine	C			UNKNOWN	
	Congestive Cardiomyopathy		Lanoxin	C			UNKNOWN	
	Diverticulum Intestinal		Lasix (Furosemide)	C			UNKNOWN	
	Haemorrhagic		Skelaxin	C			UNKNOWN	
	Hypertension		K-Lor	C			UNKNOWN	
	Hypovolaemic Shock							
	Myocardial Infarction							
	Renal Cyst							

Date:04/14/04ISR Number: 4338603-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oesophageal Haemorrhage		Fosamax	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS		ORAL		
			Aspirin	C				

UNKNOWN

Date:04/14/04ISR Number: 4338609-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01368
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Cardiac Murmur
Disability	Chronic Obstructive Pulmonary Disease
	Depression
	Diabetes Mellitus
	Emphysema
	Fatigue
	Hyperhidrosis
	Hypertension
	Joint Swelling
	Lung Infection
	Muscle Spasms
	Nausea
	Oedema Peripheral
	Osteoarthritis
	Tracheobronchitis
	Ventricular Hypertrophy

Wheezing

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	586 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	586 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Darvocet-N	C			UNKNOWN	
	Albuterol	C			UNKNOWN	
	Proventil	C			UNKNOWN	
	Zithromax	C			UNKNOWN	
	Atacand	C			UNKNOWN	
	Biaxin	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Flovent	C			UNKNOWN	
	Advair	C			UNKNOWN	
	Foradil	C			UNKNOWN	
	Furosemide	C			UNKNOWN	
	Guaifenesin	C			UNKNOWN	
	Meclizine	C			UNKNOWN	
	Methylprednisolone	C			UNKNOWN	
	Oxycontin	C			UNKNOWN	

Date:04/14/04ISR Number: 4338612-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	226	DAY

Date:04/14/04ISR Number: 4338844-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01988
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluid Retention							
	Post Procedural Complication							

Date:04/14/04ISR Number: 4338845-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01000
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Other	Congestive Post Procedural Complication		Lipitor	C		ORAL		
			Lovenox	C		SUBCUTANEOUS	4	DAY
			Coumadin	C		ORAL	39	DAY
			Toprol Xl Tablets	C		ORAL		
			Prilosec	C		ORAL		

Date:04/14/04ISR Number: 4338847-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00176
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/04ISR Number: 4339226-4Report Type:Direct Company Report #CTU 216627
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Rofecoxib	PS				

Date:04/15/04ISR Number: 4339389-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON	
Initial or Prolonged	Anaemia Haemolytic		Vioxx	SS	Merck & Co., Inc	ORAL	8 MON	
Disability	Autoimmune		Amitriptyline					
Other	Anxiety		Hydrochloride	C			UNKNOWN	
	Arthralgia		Rocaltrol	C		ORAL		
	Atelectasis		Os-Cal + D	C			UNKNOWN	
	Blood Cholesterol		Valium	C			UNKNOWN	
	Increased		Synthroid	C			UNKNOWN	
	Blood Creatine		Synthroid	C		ORAL		
	Phosphokinase Increased		Ambien	C			UNKNOWN	
	Cellulitis		Claritin	C			UNKNOWN	
	Cerebrovascular Accident		Slow-Mag	C			UNKNOWN	
	Cholelithiasis		Reglan	C			UNKNOWN	
	Coagulopathy		Reglan	C			UNKNOWN	
	Cystocele		Prilosec	C			UNKNOWN	
	Decreased Appetite		Ditropan Xl	C			UNKNOWN	
	Disturbance In Attention		Potassium Chloride	C			UNKNOWN	
	Drug Hypersensitivity							

Dyspnoea
Eye Pain
Haematochezia
Haemorrhage
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism
Injury
Neurogenic Bladder
Oesophageal Disorder
Pulmonary Granuloma
Pyrexia
Rectocele
Renal Failure
Sinusitis
Tinnitus
Tracheobronchitis
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Visual Disturbance
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/04ISR Number: 4339392-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01101
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Retention		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK

Date:04/15/04ISR Number: 4339393-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00918
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	32	DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/15/04ISR Number: 4339394-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery
	Restenosis
	Dental Caries
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspepsia

Fall
Gastrooesophageal Reflux
Disease
Haematoma
Hepatic Cyst
Hiatus Hernia
Injury
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Joint Dislocation
Myocardial Infarction
Nephrolithiasis
Pain In Extremity
Periodontal Disease
Post Laminectomy Syndrome
Post Procedural
Haemorrhage
Post Thrombotic Syndrome
Radiculopathy

	Sleep Apnoea Syndrome Suicidal Ideation Umbilical Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
380	DAY					
			Aspirin	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Coumadin	C		
UNKNOWN						
			Cardizem	C		
UNKNOWN						
			Maxair	C		
RESPIRATORY						
(INHALATION)						

Date:04/15/04ISR Number: 4339608-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
Disability	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Basal Cell Carcinoma		[Therapy			
	Brain Scan Abnormal		Unspecified]	C		
UNKNOWN						
	Bronchitis		Acyclovir	C		
UNKNOWN						
	Bursitis		Vitamins			
	Chest Pain		(Unspecified)	C		
UNKNOWN						
	Cough		Aspirin	C		
UNKNOWN						
	Drug Ineffective		Lipitor	C		
UNKNOWN						
	Dyspepsia		Calcium			
	Ecchymosis		(Unspecified)	C		
UNKNOWN						

Hepatitis Premarin C
UNKNOWN

Hypertension
Hypokalaemia
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Myalgia
Non-Cardiac Chest Pain
Pain
Pneumonia
Pollakiuria
Radiculitis Cervical
Respiratory Tract
Infection
Rotator Cuff Syndrome
Stress Incontinence
Temporal Arteritis
Tooth Disorder
Viral Upper Respiratory
Tract Infection

Date:04/15/04ISR Number: 4339623-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01262
Age:78 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	521	DAY
Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL	521	DAY
Cholelithiasis		Aspirin	C			UNKNOWN	
Colonic Polyp		Aspirin	C			UNKNOWN	
Diverticulum		Lipitor	C			UNKNOWN	
Gastric Ulcer		Allegra	C			UNKNOWN	
Gastritis Erosive		Synthroid	C			UNKNOWN	
Graft Thrombosis							
Haemorrhoids							
Hypertension							
Inner Ear Disorder							
Oedema Peripheral							
Osteoarthritis							
Pelvic Mass							
Presbyoesophagus							
Rotator Cuff Syndrome							
Synovitis							
Upper Gastrointestinal Haemorrhage							

Date:04/15/04ISR Number: 4339625-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Benign Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Tylenol	C			UNKNOWN	
	Colonic Polyp		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN	
	Coronary Artery Disease							
	Depression							

	Fall	Xanax	C
UNKNOWN			
	Gastroenteritis Viral	Aspirin	C
UNKNOWN			
	Generalised Anxiety	Librax Capsules	C
UNKNOWN			
	Disorder	Cyclobenzaprine	
	Haematoma	Hydrochloride	C
UNKNOWN			
	Hypercholesterolaemia	Allegra	C
UNKNOWN			
	Hypertension	Prilosec	C
UNKNOWN			
	Insomnia	Zantac	C
UNKNOWN			
	Intervertebral Disc Degeneration		
	Myocardial Infarction		
	Myositis		
	Osteochondrosis		
	Pain In Extremity		
	Sleep Disorder		
	Tendonitis		
	Urinary Tract Infection		

Date:04/15/04ISR Number: 4339626-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Angiopathy
Other	Arterial Disorder
	Atherosclerosis

Dose	Duration						
		Cardiac Murmur					
		Cardioactive Drug Level Increased	Report Source	Product	Role	Manufacturer	Route
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Betaxolol Ophthalmic Solution	C		
UNKNOWN		Chest X-Ray Abnormal					
UNKNOWN		Epistaxis		Calcitonin	C		
UNKNOWN		Faeces Discoloured		Digoxin	C		
UNKNOWN		Haematemesis		Docusate Sodium	C		
OPHTHALMIC		Haematocrit Decreased		Trusopt	C		
UNKNOWN		Haemoglobin Decreased		Zocor	C		
UNKNOWN		Heart Rate Decreased		Warfarin	C		
UNKNOWN	1284 DAY	Hypertension		Vitamin E	C		
UNKNOWN		Lacunar Infarction		Folic Acid	C		
UNKNOWN		Muscle Spasms		Lasix (Furosemide)	C		
UNKNOWN	1680 DAY	Myalgia		Isosorbide	C		
UNKNOWN		Productive Cough		Potassium (Unspecified)	C		
UNKNOWN		Prothrombin Time Prolonged		Psyllium Husk	C		
UNKNOWN		Rhonchi					
		Tracheal Deviation					
		Transient Ischaemic Attack					
		Vascular Graft Occlusion					
		Vascular Stenosis					

Date:04/15/04ISR Number: 4339627-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01260
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Abdominal Tenderness	Fosamax	C		
Disability	Angina Unstable	Atacand	C		
UNKNOWN	Aortic Valve Incompetence	Estratest	C		
UNKNOWN	Aortic Valve Sclerosis	Allegra	C		
UNKNOWN	Asthenia	Motrin	C		
UNKNOWN	Blood Pressure Increased	Motrin	C		
UNKNOWN	Cardiac Murmur	Synthroid	C		
UNKNOWN	Chest Pain Chest Wall Pain Dizziness	Methotrexate (Methotrexate Sodium)	C		
UNKNOWN	Dyspnoea Emotional Distress Headache Hypertension Mitral Valve Incompetence Osteoarthritis Pain Paraesthesia Tinnitus Tricuspid Valve Incompetence Ventricular Hypertrophy Vision Blurred				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/04ISR Number: 4339631-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01351
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Blood Pressure Increased		Norvasc	C			UNKNOWN	
	Cold Sweat		Zocor	C		ORAL		
	Contusion		Zyrtec	C			UNKNOWN	
	Coronary Artery Disease		Plavix	C			UNKNOWN	
	Dyspepsia							
	Hypertension							
	Loss Of Consciousness							
	Oesophageal Disorder							
	Pain							
	Peptic Ulcer							

Date:04/15/04ISR Number: 4339632-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01283
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Anaemia
	Asthenia
	Atrial Fibrillation
	Back Pain
	Blood Creatine
	Phosphokinase Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Body Temperature
	Decreased
	Bronchitis
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Chest Pain

Chest Wall Pain
Chronic Obstructive
Pulmonary Disease
Contusion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Depression
Dizziness
Dyspepsia
Dyspnoea
Eating Disorder
Electrocardiogram St
Segment Abnormal
Electrocardiogram St
Segment Elevation
Emotional Distress
Fall
Gastrooesophageal Reflux
Disease
Haemothorax
Hypercholesterolaemia

		Hypertension					
		Hypotension					
		Hypothyroidism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Prevacid	C		
UNKNOWN							
		Intestinal Dilatation		Aspirin	C		
UNKNOWN							
		Iron Deficiency Anaemia		Klonopin	C		
UNKNOWN							
		Lumbar Spinal Stenosis		Premarin	C		
UNKNOWN							
		Mitral Valve Incompetence		Flonase	C		
UNKNOWN							
		Oxygen Saturation		Lopid	C		
UNKNOWN							
		Decreased					
		Platelet Count Increased					
		Pleural Effusion					
		Post Procedural					
		Complication					
		Spinal Osteoarthritis					
		Spondylitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Fibrillation					

Date:04/15/04ISR Number: 4339634-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Cervicobrachial Syndrome		[Therapy			
		Chronic Obstructive		Unspecified]	C		
UNKNOWN							
		Pulmonary Disease		Vicodin Tablets	C		
UNKNOWN							
		Contusion		Elavil	C		ORAL
		Depression		Analgesic Or			

	Dysthymic Disorder	Anesthetic		
	Fall	(Unspecified)	C	
UNKNOWN				
	Fibromyalgia	Aspirin	C	ORAL
	Hypertension	Vitamins		
	Increased Tendency To	(Unspecified)	C	
UNKNOWN				
	Bruise	Vitamin E	C	
UNKNOWN				
	Lacunar Infarction	Calcium Carbonate	C	
UNKNOWN				
	Lower Respiratory Tract	Premarin	C	
UNKNOWN				
	Infection	Lasix (Furosemide)	C	
UNKNOWN				
	Migraine	Neurontin	C	
UNKNOWN				
	Oedema Peripheral	Oxycontin	C	
UNKNOWN				
	Osteoporosis	Paxil	C	ORAL
	Pain In Extremity	Actonel	C	
UNKNOWN				
	Radius Fracture			
	Renal Disorder			
	Rotator Cuff Syndrome			
	Sinusitis			
	Spinal Osteoarthritis			
	Tendonitis			
	Transient Ischaemic Attack			
	Urinary Tract Infection			

Date:04/15/04ISR Number: 4339641-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0404DNK00002
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	First Degree		Vioxx	SS	Merck & Co., Inc	ORAL		3 DAY
	Syncope		Aspirin	C				
UNKNOWN								
			Ramipril	C				
UNKNOWN								

Date:04/15/04ISR Number: 4339642-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01096
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		[Therapy Unspecified]	C				
UNKNOWN								

Date:04/15/04ISR Number: 4339645-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01039
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		[Therapy Unspecified]	C				
UNKNOWN								

Date:04/16/04ISR Number: 4340003-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		216 DAY

Cardiac Failure	Vioxx	SS	Merck & Co., Inc	ORAL
216 DAY				
Congestive				
Cardio-Respiratory Arrest				
Dizziness				
Emotional Distress				
Fatigue				
Feeling Abnormal				
Headache				
Injury				
Myocardial Infarction				

Date:04/16/04ISR Number: 4340004-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01980
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Barrett'S Oesophagus
Initial or Prolonged	Blood Cholesterol
Other	Abnormal
	Cardiac Failure
	Congestive
	Cholecystitis
	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease
	Colon Adenoma
	Colonic Polyp
	Coronary Artery Disease
	Depression

		Diabetes Mellitus Non-Insulin-Dependent					
		Diverticulum	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
51	DAY						
		Dysplasia		Tylenol With Codeine	C		
UNKNOWN							
		Gastritis		Aspirin	C		
UNKNOWN							
		Haemorrhoidal Haemorrhage		Atenolol	C		
UNKNOWN							
		Haemorrhoids		Tums	C		
UNKNOWN							
		Hepatic Steatosis		Cardura	C		ORAL
		Hiatus Hernia		Prevacid	C		
UNKNOWN							
		Hypokalaemia		Zestril	C		ORAL
		Lipids Abnormal		Adalat	C		ORAL
		Lobar Pneumonia		Prilosec	C		
UNKNOWN							
		Myocardial Infarction		Aciphex	C		ORAL
		Oedema Peripheral					
		Oesophageal Ulcer					
		Prostate Cancer					
		Pulmonary Mass					
		Ulcer Haemorrhage					
		Upper Gastrointestinal Haemorrhage					

Date:04/16/04ISR Number: 4340005-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY					
Initial or Prolonged	Angina Pectoris		Elocon	C		
UNKNOWN						
Disability	Anxiety		[Therapy			
	Blood Cholesterol		Unspecified]	C		
UNKNOWN						
	Increased		Proventil	C		
UNKNOWN						

	Chronic Obstructive	Cipro	C
UNKNOWN			
	Pulmonary Disease	Diphenhydramine	
	Coronary Artery Occlusion	Citrate	C
UNKNOWN			
	Diverticulum Intestinal	Allegra	C
UNKNOWN			
	Gastritis	Hydroxyzine Pamoate	C
UNKNOWN			
	Gastrointestinal	Loperamide	
	Haemorrhage	Hydrochloride	C
UNKNOWN			
	Haematuria	Ultram	C
UNKNOWN			
	Haemorrhoids	Nasonex	C
UNKNOWN			
	Hypertension	Methylprednisolone	C
UNKNOWN			
	Myocardial Infarction	Motrin	C
UNKNOWN			
	Pain	Duratuss	C
UNKNOWN			
	Pain In Extremity	Epi-Pen	C
UNKNOWN			
	Proctitis	Tranxene	C
UNKNOWN			
	Stress	Buspar	C
UNKNOWN			
	Thrombosis	Tylenol	C
UNKNOWN			
	Upper Gastrointestinal	Actonel	C
UNKNOWN			
	Haemorrhage		
	Upper Respiratory Tract		
	Infection		
	Urinary Tract Infection		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/04ISR Number: 4340006-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Increased Chest Pain		[Composition Unspecified]	C			UNKNOWN	
	Chromaturia		Baycol	C			UNKNOWN	
	Chronic Fatigue Syndrome		Actos	C			UNKNOWN	
	Convulsion							
	Depression							
	Difficulty In Walking							
	Disturbance In Attention							
	Dizziness							
	Drug Hypersensitivity							
	Emotional Distress							
	General Physical Health Deterioration							
	Hypertension							
	Injury							
	Insomnia							
	Mental Status Changes							
	Mood Altered							
	Muscle Atrophy							
	Musculoskeletal Stiffness							
	Oedema							
	Oedema Peripheral							
	Pain In Extremity							
	Syncope							
	Weight Decreased							

Date:04/16/04ISR Number: 4340008-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01392
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Disability	Activities Of Daily

Living Impaired
Arthropathy
Depression
Diabetes Mellitus
Inadequate Control
Dizziness
Drug Ineffective
Emotional Distress
Fibromyalgia
Fluid Retention
Foot Fracture
Hypertension
Hypertonic Bladder
Hypokalaemia
Incontinence
Influenza
Insomnia
Intestinal Functional
Disorder
Ischaemic Stroke
Musculoskeletal Stiffness
Nephrolithiasis

Neuralgia
Tremor
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	[Therapy Unspecified]	C			UNKNOWN	
	Premarin	C			UNKNOWN	

Date:04/16/04ISR Number: 4340011-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Other

PT
Abdominal Pain
Agitation
Alcohol Withdrawal Syndrome
Anaemia
Aortic Valve Incompetence
Apnoea
Benign Prostatic Hyperplasia
Blood Pressure Immeasurable
Blood Sodium Increased
Bundle Branch Block Left
Cardiac Arrest
Cardiac Failure Congestive
Cardiac Murmur
Cellulitis
Cerebral Ischaemia
Chronic Obstructive Pulmonary Disease
Colitis Ischaemic
Confusional State
Congestive Cardiomyopathy
Coronary Artery Disease
Delirium
Depression
Diarrhoea
Drug Hypersensitivity

Ejection Fraction
Decreased
Gastroenteritis
Headache
Hypertension
Inguinal Hernia
Injury
Liver Function Test
Abnormal
Mitral Valve Incompetence
Myocardial Infarction
Osteoarthritis
Osteoporosis
Periorbital Haematoma
Rash
Spinal Column Stenosis
Staphylococcal Sepsis
Tricuspid Valve

Incompetence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Tylenol	C			UNKNOWN	
	Saw Palmetto	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Lumigan	C			UNKNOWN	
	Corticosteroids (Unspecified)	C			PARENTERAL	
	Betagan	C			UNKNOWN	
	Relafen	C			UNKNOWN	
	Paxil	C			UNKNOWN	

Date:04/16/04ISR Number: 4340012-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Barrett'S Oesophagus
	Burning Sensation
	Bursitis
	Cartilage Injury
	Cerebrovascular Accident
	Dizziness
	Dysphagia
	Emotional Distress
	Exostosis
	Fall

Femoral Artery Occlusion
Gait Disturbance
Gastritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hiatus Hernia
Hypertension
Injury
Joint Sprain
Lacunar Infarction
Meniscus Lesion
Oesophageal Achalasia
Oesophageal Stenosis
Oesophagitis
Osteoarthritis
Pain In Extremity
Peripheral Vascular
Disorder
Personality Disorder
Rectal Polyp
Synovitis
Tachycardia
Transient Ischaemic
Attack

	Tremor						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	1478 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	840 DAY
			[Therapy Unspecified]	C			UNKNOWN	
			Herbs (Unspecified)	C			UNKNOWN	
			Prilosec	C			UNKNOWN	

Date:04/16/04ISR Number: 4340013-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01209
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 5 DAY	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Initial or Prolonged	Swollen Tongue		Tums	C			UNKNOWN	
			Imodium	C			UNKNOWN	
			Tigan	C			UNKNOWN	
			Nystatin Usp (Paddock)	C			UNKNOWN	

Date:04/16/04ISR Number: 4340014-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01835
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Prescribed Overdose							
	Ulcer Haemorrhage							

Date:04/16/04ISR Number: 4340195-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01285
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	51 DAY	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Dyspepsia							
	Emotional Distress							
	Erectile Dysfunction							
	Hypersensitivity							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Tricuspid Valve Incompetence							
	Ventricular Fibrillation							
	Ventricular Hypokinesia							
	Weight Increased							

Date:04/16/04ISR Number: 4340196-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulitis		Vitamins (Unspecified)	C				
	Eczema							
	Gastrointestinal Disorder							
	Hypertension							
	Kyphosis							
	Macular Degeneration							
	Nephrolithiasis							
	Nocturia							
	Non-Small Cell Lung Cancer Metastatic							
	Rhinitis Allergic							
	Sciatica							
	Transient Ischaemic Attack							

Date:04/16/04ISR Number: 4340197-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Percocet	SS				
Disability	Alcohol Poisoning		Alcohol	SS				
Other	Arthropod Sting		Xanax	SS				
	Cardiac Failure		Ambien	SS				
	Coronary Artery Disease		Soma	C				
	Diabetes Mellitus		Advil	C				
	Gastrooesophageal Reflux Disease		Imdur	C				
	Hypercholesterolaemia							

Hyperlipidaemia
Hypertension
Hypokalaemia
Intentional Misuse
Joint Swelling
Major Depression
Myocardial Infarction
Overdose
Spondylitis
Stent Occlusion
Suicide Attempt
Swelling Face
Tooth Disorder

Date:04/16/04ISR Number: 4340198-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Arthritis
	Cardiac Failure
	Congestive
	Constipation
	Coronary Artery Disease

		Coronary Artery Restenosis					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Haemoglobin Decreased		Celebrex	SS		
UNKNOWN			95 DAY				
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Hypertension		Iron (Unspecified)	SS		
UNKNOWN							
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
12	DAY						
		Iron Deficiency Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Joint Injury		Tylenol	C		
UNKNOWN			790 DAY				
		Myocardial Infarction		Tylenol	C		
UNKNOWN							
		Myocardial Ischaemia		Triamcinolone	C		
TOPICAL			366 DAY				
		Psoriatic Arthropathy		Lipitor	C		
UNKNOWN			790 DAY				
		Pulmonary Oedema					
		Rash					
		Rectal Haemorrhage					
		Stress					
		Ulcer					

Date:04/16/04ISR Number: 4340199-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00993
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY					
Initial or Prolonged	Infarction		Tylenol	C		
UNKNOWN						
Disability	Blood Pressure Increased		Tylenol	C		
UNKNOWN						
	Chest Pain		Imitrex	C		
UNKNOWN						
	Coronary Artery Stenosis		Advil	C		
UNKNOWN						

Depression Advil C
UNKNOWN

Electrocardiogram St
Segment Elevation
Emotional Distress
Fatigue
Gastritis
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Hypercholesterolaemia
Urinary Retention
Ventricular Hypokinesia
Ventricular Tachycardia

Date:04/16/04ISR Number: 4340200-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome PT
Life-Threatening Anxiety
Disability Aortic Valve Incompetence
Back Pain
Cardiac Failure
Congestive
Cardiac Murmur
Cardiac Valve Disease
Cerebrovascular Accident
Coronary Artery Disease
Drug Hypersensitivity
Fall
Heart Rate Irregular
Hypertension

	Mitral Valve Incompetence					
	Monoparesis					
	Pain In Extremity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Function Test		Prinivil	SS		ORAL
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Subacute Endocarditis		Prinivil	SS		ORAL
198 DAY						
	Supraventricular		Calcium			
	Tachycardia		(Unspecified)	C		
UNKNOWN						
	Tendonitis		Diazepam	C		
UNKNOWN						
	Transient Ischaemic		Premarin	C		
UNKNOWN						
	Attack					
	Tricuspid Valve					
	Incompetence					
	Ventricular Extrasystoles					
	Ventricular Hypertrophy					
	Vision Blurred					

Date:04/16/04ISR Number: 4340201-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Diplopia
	Diverticulitis
	Dizziness
	Dyspnoea

Gastrooesophageal Reflux
Disease
Haematemesis
Haematoma
Hyperlipidaemia
Hypersensitivity
Hypertension
Lactose Intolerance
Muscle Contractions
Involuntary
Myalgia
Non-Cardiac Chest Pain
Osteoarthritis
Pulmonary Oedema
Retroperitoneal
Haemorrhage
Stent Occlusion
Syncope
Tendonitis
Tinnitus

		Urticaria					
		Ventricular Fibrillation					
		Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Acuity Reduced		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Wheezing		Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY						
				Propacet	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:04/16/04ISR Number: 4340206-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Stress Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vicodin Tablets	C		
UNKNOWN							
		Back Injury		Desyrel	C		
UNKNOWN							
		Cerebrovascular Accident		Clonidine	C		
UNKNOWN							
		Chest Pain		Skelaxin	C		
UNKNOWN							
		Chronic Fatigue Syndrome					
		Dizziness					
		Emotional Disorder					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hernia					
		Hypertension					
		Hyperthyroidism					
		Insomnia					
		Intervertebral Disc					
		Protrusion					
		Muscle Contracture					
		Neck Pain					
		Peripheral Vascular					

Disorder
Radiculopathy
Renal Disorder
Renal Failure
Road Traffic Accident
Spinal Osteoarthritis
Transient Ischaemic
Attack
Treatment Noncompliance
Vomiting

Date:04/16/04ISR Number: 4340207-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0404CAN00055
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Lactate Dehydrogenase Increased Creatinine Renal Clearance Decreased Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/16/04ISR Number: 4340208-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Creatine Phosphokinase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Lipitor	C			UNKNOWN	3142 DAY
	Chills		Lotensin	C			UNKNOWN	
	Coronary Artery Disease		Lotensin	C			UNKNOWN	
	Coronary Artery Surgery		Vasotec	C		ORAL	3507 DAY	
	Depression		Vasotec	C		ORAL	3507 DAY	
	Diverticulum		Prozac	C			UNKNOWN	
	Fatigue		Prozac	C			UNKNOWN	
	Flank Pain		Prozac	C			UNKNOWN	
	Gastritis		Ginseng	C			UNKNOWN	
	Haemorrhoids		Naproxen	C			UNKNOWN	
	Hiatus Hernia		Accupril	C			UNKNOWN	
	Hyperhidrosis		Accupril	C			UNKNOWN	
	Osteoarthritis							
	Sinus Tachycardia							

Date:04/19/04ISR Number: 4341052-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	394 DAY	

Initial or Prolonged	Atrial Fibrillation	Vioxx	SS	Merck & Co., Inc	ORAL
394 DAY					
Disability	Cardiac Failure	Adderall Tablets	C		
UNKNOWN					
	Congestive	Cefzil	C		
UNKNOWN					
	Cerebrovascular Accident	Biaxin Xl	C		
UNKNOWN					
	Congestive Cardiomyopathy	Entex La	C		ORAL
	Depression	Ibuprofen	C		
UNKNOWN					
	Hypertension				
	Insomnia				
	Intracardiac Thrombus				
	Mitral Valve Incompetence				
	Pneumonia				
	Sinus Tachycardia				
	Stress				
	Tricuspid Valve				
	Incompetence				

Date:04/19/04ISR Number: 4341057-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Abdominal Pain Upper
Disability	Anaemia
Other	Angina Pectoris
	Aortic Valve Incompetence
	Arthritis
	Arthropathy
	Asthenia
	Asthma
	Candidiasis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chronic Lymphocytic Leukaemia					
		Coronary Artery Disease					
		Electrocardiogram T Wave Inversion		Vioxx	PS	Merck & Co., Inc	ORAL
				Voltaren	SS		
UNKNOWN							
		Emotional Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Prempro	C		
UNKNOWN							
		Hypertension					
		Impaired Work Ability					
		Mallory-Weiss Syndrome					
		Meniscus Lesion					
		Mitral Valve Calcification					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Movement Disorder					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Osteoarthritis					
		Overdose					
		Pain					
		Peptic Ulcer					
		Pneumonia					
		Reflux Oesophagitis					
		Stress					
		Tricuspid Valve Incompetence					
		Ulcer Haemorrhage					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Weight Decreased					
		Wound Infection Staphylococcal					

Date:04/19/04ISR Number: 4341058-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Prerenal Failure
Initial or Prolonged	Anaemia
Disability	Arthritis
	Eczema
	Gastritis
	Hypertension
	Myocardial Infarction
	Oesophagitis
	Peptic Ulcer
	Sinus Tachycardia
	Stress
	Tachycardia
	Torsade De Pointes

	Upper Gastrointestinal Haemorrhage Ventricular Arrhythmia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	168 DAY
			[Therapy Unspecified]	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Lipitor	C			UNKNOWN
			Pepto-Bismol	C			UNKNOWN
			Vitamins (Unspecified)	C			UNKNOWN
			Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C			UNKNOWN
			Vasoretic	C		ORAL	
			Neurontin	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Inderal	C			UNKNOWN

Date:04/19/04ISR Number: 4341059-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01509
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Hepatotoxicity		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/19/04ISR Number: 4341230-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 26 DAY	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Azotaemia		[Therapy Unspecified]	C				
Other	Blood Pressure Systolic Increased		Aspirin	C				
UNKNOWN	Carotid Artery Disease		Aspirin	C				
UNKNOWN	Cerebral Ischaemia		Lipitor	C				
UNKNOWN	Cerebrovascular Accident		Persantine	C				
UNKNOWN	Confusional State		Coenzyme Q10	C				
UNKNOWN	Demyelination		Amaryl	C				
UNKNOWN	Diastolic Dysfunction		Glucophage	C				
UNKNOWN	Disorientation		Actos	C				
UNKNOWN	Gliosis		Zantac	C				
UNKNOWN	Hypertrophic Cardiomyopathy							
	Hypoglycaemia							
	Incoherent							
	Injury							
	Libido Decreased							
	Mental Status Changes							
	Oedema Mucosal							
	Personality Change							
	Respiratory Rate Increased							
	Sinus Polyp							
	Sinusitis							
	Thinking Abnormal							

Date:04/19/04ISR Number: 4341231-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01412
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Stenosis
Disability	Arthralgia
Other	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Blindness Transient
	Blood Pressure Decreased
	Bradyarrhythmia
	Bradycardia
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiac Valve Disease
	Carotid Artery Atheroma
	Carotid Artery Disease
	Carotid Artery Stenosis
	Carotid Bruit
	Cerebellar Infarction
	Cerebral Atrophy
	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Clumsiness
	Coordination Abnormal
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Crepitations
	Deafness
	Dilatation Atrial
	Diverticulum
	Dizziness
	Ejection Fraction Decreased
	Electrocardiogram St-T Change
	Fall
	Hemiparesis
	Hypertension
	Insomnia
	International Normalised

Ratio Increased
Ischaemic Stroke
Mitral Valve
Calcification
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Osteoarthritis
Oxygen Saturation
Decreased
Pco2 Decreased
Pleural Effusion
Po2 Decreased
Poor Peripheral
Circulation

		Pulmonary Congestion					
		Pulmonary Fibrosis					
		Respiratory Rate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Aspirin	C		
UNKNOWN							
		Sick Sinus Syndrome		Plavix	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Lanoxin	C		
UNKNOWN							
		Syncope		Calan	C		
UNKNOWN							
		Tachycardia		Coumadin	C		ORAL
		Tricuspid Valve		Coumadin	C		ORAL
		Incompetence		Coumadin	C		ORAL
		Ulcer		Digoxin	C		
UNKNOWN							
		Urinary Tract Infection		Hyzaar	C		
UNKNOWN							
		Ventricular Hypertrophy		Hyzaar	C		ORAL
		Ventricular Hypokinesia					
		Vertigo					
		Wheezing					

Date:04/19/04ISR Number: 4341233-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01388
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Naprosyn	C		
UNKNOWN							
		Congestive					
		Coronary Artery Disease					
		Hypercholesterolaemia					
		Leukocytosis					
		Lung Infiltration					
		Nephrolithiasis					
		Oedema Peripheral					
		Productive Cough					
		Pyrexia					

Silent Myocardial
Infarction
Sleep Apnoea Syndrome
Urticaria
Ventricular Arrhythmia

Date:04/19/04ISR Number: 4341235-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00106
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Hospitalization -	Faeces Discoloured		Aspirin	SS		ORAL		841 DAY
Initial or Prolonged	Gastrointestinal		Furosemide	C		ORAL		
	Haemorrhage		Gliclazide	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Lisinopril	C		ORAL		
			Metformin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/04ISR Number: 4341236-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lanoxin	C				UNKNOWN
	Dilatation Atrial		Zocor	C				UNKNOWN
	Heart Rate Irregular		Zestril	C				UNKNOWN
	Transient Ischaemic Attack							
	Visual Acuity Reduced							

Date:04/20/04ISR Number: 4341735-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		216 DAY
	Cardiac Failure	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		216 DAY
	Congestive Cardio-Respiratory Arrest							
	Dizziness							
	Gout							
	Headache							
	Myocardial Infarction							

Date:04/20/04ISR Number: 4341745-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Arrhythmia
Other	Supraventricular Arthralgia
	Atherosclerosis
	Blood Pressure Increased
	Blood Urine Present

Bundle Branch Block Right
Chest Wall Pain
Coronary Artery Disease
Depression
Dizziness
Eye Disorder
Faecal Incontinence
Flank Pain
Gastric Disorder
Gastric Haemorrhage
Haemorrhoids
Headache
Herpes Virus Infection
Hypoaesthesia
Intervertebral Disc
Degeneration
Joint Stiffness
Muscle Strain
Rectal Haemorrhage
Road Traffic Accident
Rotator Cuff Syndrome
Spinal Column Stenosis
Tendonitis
Ulcer

Ventricular Dysfunction
Viral Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vicodin Tablets	C				
	Effexor Xr	C				
	Ecotrin	C				
	Wellbutrin Sr	C				
	Prevacid	C				
	Pravachol	C				
	Accupril	C				

Date:04/20/04ISR Number: 4341746-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Anxiety
Bronchitis
Bursitis
Carpal Tunnel Syndrome
Cerebrovascular Accident
Cervicobrachial Syndrome
Chronic Obstructive Pulmonary Disease
Contusion
Cough
Depression
Drug Ineffective
Dyspepsia
Dysthymic Disorder
Fall
Fatigue

Fibromyalgia
Gravitational Oedema
Hypertension
Increased Tendency To
Bruise
Lacunar Infarction
Lower Respiratory Tract
Infection
Migraine
Oedema Peripheral
Osteopenia
Osteoporosis
Pain In Extremity
Radius Fracture
Renal Disorder
Rotator Cuff Syndrome
Self-Medication
Sinusitis
Somnolence
Spinal Osteoarthritis
Stress
Tendonitis
Transient Ischaemic

		Attack Urinary Tract Infection Weight Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Elavil	C		ORAL
				Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							
				Aspirin	C		ORAL
				Vitamins (Unspecified)	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Calcium Carbonate	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Paxil	C		ORAL
				Actonel	C		
UNKNOWN							

Date:04/20/04ISR Number: 4342080-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01617
Age:65 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL

				Xanax	C		
UNKNOWN							
				Topamax	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN							
				Methadone Hcl	C		
UNKNOWN							

Date:04/20/04ISR Number: 4342081-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01286
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Digoxin	C				
UNKNOWN								
Other	Rash Maculo-Papular		Lasix (Furosemide)	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Potassium (Unspecified)	C				
UNKNOWN								

Date:04/20/04ISR Number: 4342082-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01851
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Contusion		Zyrtec	C		ORAL		
	Plastic Surgery		Zocor	C		ORAL		
	Post Procedural Complication							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/04ISR Number: 4345988-2Report Type:Expedited (15-DaCompany Report #HQWYE704603NOV03
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anal Discomfort	Health	Cordarex					
	Disseminated	Professional	(Amiodarone, Tablet)	PS		ORAL	200 MG 3X PER	
	Intravascular Coagulation	Other						
1 DAY	2 DAY							
	Hepatitis Toxic		Vioxx (Rofecoxib,					
	Renal Failure Acute		Tablet)	SS		ORAL	SEE IMAGE	2 DAY
	Rhabdomyolysis							
	Tachycardia							
	Ventricular Extrasystoles							

Date:04/21/04ISR Number: 4343230-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00108
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Atherosclerosis
Other	Bursitis
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Confusional State
	Congestive Cardiomyopathy
	Depression
	Diverticulum
	Dizziness
	Drug Toxicity
	Emotional Distress
	Erectile Dysfunction
	Gastrointestinal
	Haemorrhage
	Glaucoma
	Haemorrhoids
	Headache
	Hypoacusis

Intervertebral Disc
Protrusion
Intervertebral Disc Space
Narrowing
Kidney Infection
Lacunar Infarction
Myalgia
Nausea
Prostatic Disorder
Prostatic Specific
Antigen Increased
Proteinuria
Pulmonary Hypertension
Pulmonary Oedema
Pyrexia
Radiculitis
Renal Failure Chronic
Rotator Cuff Syndrome
Sleep Apnoea Syndrome
Thrombosis

	Vertigo						
	Viral Infection						
	Visual Field Defect	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C			UNKNOWN	
			Insulin	C			UNKNOWN	

Date:04/21/04ISR Number: 4343233-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
2 MON								
Initial or Prolonged	Anoxic Encephalopathy		[Therapy					
Other	Atrioventricular Block		Unspecified]	C				
UNKNOWN								
	Complete		Insulin	C				
UNKNOWN								
	Cardiogenic Shock							
	Carotid Artery Occlusion							
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Colitis Ischaemic							
	Constipation							
	Coronary Artery Disease							
	Cough							
	Diabetes Mellitus							
	Insulin-Dependent							
	Diabetic Retinopathy							
	Fall							
	Gastritis							
	Haematoma							
	Haemorrhoidal Haemorrhage							
	Hepatic Failure							
	Hyperglycaemia							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Muscle Tightness							
	Myocardial Infarction							
	Pain In Extremity							
	Pulmonary Hypertension							

Rash
Renal Cyst
Renal Failure Acute
Silent Myocardial
Infarction
Tendonitis
Tricuspid Valve
Incompetence
Urinary Tract Infection

Date:04/21/04ISR Number: 4343238-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Angina Unstable
	Anxiety
	Atrial Fibrillation
	Cardiac Failure Acute

		Cardiac Failure					
		Congestive					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chondrocalcinosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pyrophosphate		Premarin	C		
UNKNOWN							
		Colon Cancer		Glipizide	C		
UNKNOWN							
		Colon Cancer Recurrent					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Diabetes Mellitus					
		Diarrhoea					
		Dizziness					
		Emotional Distress					
		Faecal Occult Blood					
		Positive					
		Gastritis					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Injury					
		Inner Ear Disorder					
		Mitral Valve Incompetence					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Renal Failure					
		Thrombophlebitis					
		Tooth Infection					
		Urinary Tract Infection					
		Vein Pain					
		Vertigo					

Date:04/21/04ISR Number: 4343245-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL

	Cardiomegaly	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetes Mellitus	[Therapy			
	Diverticulitis	Unspecified]	C		
UNKNOWN					
	Emotional Distress	Norco	C		
UNKNOWN					
	Facet Joint Syndrome	Atenolol	C		
UNKNOWN					
	Graft Thrombosis	Tenormin	C		
UNKNOWN					
	Hand Fracture	Celebrex	C		
UNKNOWN					
	Hypertension	Celebrex	C		
UNKNOWN					
	Insomnia	Diovan	C		
UNKNOWN					
	Intervertebral Disc	Ultram	C		
UNKNOWN					
	Protrusion	Avandia	C		
UNKNOWN					
	Lumbar Spinal Stenosis	Chlorthalidone	C		
UNKNOWN					
	Muscle Strain	Hygroton	C		
UNKNOWN					
	Nervousness	Cyclobenzaprine			
	Pleural Effusion	Hydrochloride	C		
UNKNOWN					
	Raynaud'S Phenomenon	Cardizem	C		
UNKNOWN					
	Respiratory Failure	Propecia	C		
UNKNOWN					
	Thrombosis	Glucovance	C		
UNKNOWN					

				Hydrocodone Hydrochloride	C		
UNKNOWN							

Date:04/21/04ISR Number: 4343246-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00111
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	285	DAY
Life-Threatening	Perforation		Albuterol	C				
RESPIRATORY Hospitalization - (INHALATION)								
Initial or Prolonged			Amlodipine Besylate	C				
UNKNOWN								
Other			Bisoprolol Fumarate	C				
UNKNOWN								
			Fosinopril Sodium	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								

Date:04/21/04ISR Number: 4343248-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01945
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bacterial Test Positive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		[Therapy					
Disability	Dialysis		Unspecified]	C				
UNKNOWN								
	Haemodialysis		Atenolol	C				
UNKNOWN								
	Hypertension		Prevacid	C				
UNKNOWN								
	Iron Deficiency Anaemia		Accupril	C				
UNKNOWN								
	Renal Failure Chronic							
	Renal Injury							

Date:04/21/04ISR Number: 4345593-8Report Type:Expedited (15-DaCompany Report #NSADSS2003016538
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Demyelination	Consumer	Remicade			
	Depressed Level Of Consciousness	Health Professional	(Infliximab, Recombinant)			
	Dyspnoea		Lyophilized Powder	PS		
INTRAVENOUS						
	Ear Discomfort					DRIP
SEE IMAGE						
	Fall		Vioxx (Rofecoxib)	SS		
25 MG PER DAY						
	Glioma		Mtx (Methotrexate Sodium)	C		
	Head Injury		Levoxyl (Levothyroxine Sodium)	C		
	Hoffmann'S Sign		Dicyclomine (Dicycloverine Hydrochloride)	C		
	Hypoaesthesia		Zoloft (Sertraline Hydrochloride)	C		
	Loss Of Consciousness		Premarin (Estrogens Conjugated)	C		
	Medication Error		Folic Acid (Folic Acid)	C		
	Neuropathy Peripheral		Mvi (Multivitamins)	C		
	Paraesthesia		Vitamin C (Ascorbic Acid)	C		
	Self-Medication		Vitamin B6 (Pyridoxine			
	Tinnitus					
	Vision Blurred					

Hydrochloride)	C
Vitamin E (Tocopherol)	C
Calcium With D (Calcium With Vitamin D)	C
Glucosamine/Chondroitin (Glucosamine W/Chondroitin Sulfates)	C
Bentyl (Dicycloverine Hydrochloride)	C
Medrol (Methylprednisolone)	C

Date:04/21/04ISR Number: 4347501-2Report Type:Periodic Company Report #2004016472
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Relpax (Eletriptan)	PS			40 MG	
	Amnesia		Sumatriptan Succinate (Sumatriptan Succinate)	SS				
	Arthritis		Rofecoxib (Rofecoxib)	SS				
	Back Pain		Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Drug Ineffective		Propranolol Hydrochloride (Propranolol Hydrochloride)	C				
	Feeling Abnormal		Raloxifene Hydrochloride (Raloxifene Hydrochloride)	C				
	Hypoaesthesia		Calcitonin, Salmon (Calcitonin, Salmon)	C				
	Migraine		Atorvastatin (Atorvastatin)	C				
	Muscle Tightness		Propacet (Paracetamol,					
	Neck Pain							
	Somnolence							

Dextropropoxyphene Napsilate)	C
Diazepam (Diazepam)	C
Valdecoxib (Valdecoxib)	C
Temazepam (Temazepam)	C

Date:04/22/04ISR Number: 4344003-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Arrhythmia
Other	Supraventricular
	Arthralgia

		Atherosclerosis					
		Blood Pressure Increased					
		Blood Urine Present	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cataract Operation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Wall Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Eye Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
		Flank Pain		Vicodin Tablets	C		
UNKNOWN							
		Gastric Disorder		Effexor Xr	C		
UNKNOWN							
		Gastric Haemorrhage		Ecotrin	C		
UNKNOWN							
		Haemorrhoids		Wellbutrin Sr	C		
UNKNOWN							
		Herpes Virus Infection		Prevacid	C		
UNKNOWN							
		Influenza		Pravachol	C		
UNKNOWN							
		Intervertebral Disc		Accupril	C		
UNKNOWN							
		Degeneration					
		Ischaemia					
		Joint Stiffness					
		Muscle Strain					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Spinal Column Stenosis					
		Syncope Vasovagal					
		Tendonitis					
		Ulcer					
		Viral Infection					

Date:04/22/04ISR Number: 4344539-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Lower
Disability	Arthralgia
	Balance Disorder
	Blood Glucose Increased

Burning Sensation
Bursitis
Cerebrovascular Accident
Computerised Tomogram
Abnormal
Dizziness
Dysphagia
Dyspnoea
Emotional Distress
Exostosis
Fall
Fatigue
Femoral Artery Occlusion
Gait Disturbance
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hypertension
Hypoaesthesia
Impaired Work Ability
Injury
Joint Sprain
Joint Swelling

		Lacunar Infarction					
		Ligament Injury					
		Memory Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Meniscus Lesion		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		[Therapy			
		Paraesthesia		Unspecified]	C		
UNKNOWN		1478 DAY					
		Peripheral Vascular		Herbs (Unspecified)	C		
UNKNOWN		840 DAY					
		Disorder		Prilosec	C		
UNKNOWN							
		Personality Disorder					
		Qrs Axis Abnormal					
		Rectal Polyp					
		Synovitis					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Tremor					
		Vascular Calcification					
		Wheezing					

Date:04/22/04ISR Number: 4344544-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Aortic Atherosclerosis
Disability	Arthralgia
Other	Arthropathy
	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine
	Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Bone Marrow Depression
	Breast Cyst
	Breast Mass
	Bronchitis
	Cachexia

Cardiolipin Antibody
Positive
Carotid Artery Disease
Carotidynia
Carpal Tunnel Syndrome
Cerebral Infarction
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Chest X-Ray Abnormal
Colonic Polyp
Coronary Artery Disease
Depression
Disease Recurrence
Dyspepsia
Dyspnoea
Ecchymosis
Epilepsy
Episcleritis

Epistaxis
Faeces Discoloured
Fall
Fatigue
Feeling Abnormal
Felty'S Syndrome
Fluid Overload
Gait Disturbance
Gastrooesophageal Reflux
Disease
Haemorrhoidal Haemorrhage
Head Injury
Headache
Herpes Simplex
Herpes Zoster
Herpes Zoster Ophthalmic
Hiatus Hernia
Hypertension
Hypertonic Bladder
Immunoglobulins Decreased
Immunosuppression
Influenza Like Illness
Insomnia
International Normalised
Ratio Decreased
International Normalised
Ratio Increased
Keratitis Herpetic
Laryngitis Viral
Leukopenia
Local Swelling
Lymphoma
Mental Impairment
Migraine
Mitral Valve Incompetence
Mouth Injury
Musculoskeletal Pain
Musculoskeletal Stiffness
Nausea
Neck Pain
Neutropenia
Nocturia
Orthostatic Hypotension
Overdose
Pain
Pancytopenia
Platelet Disorder

Productive Cough
Prostatitis
Pyrexia
Rash
Red Blood Cells Semen
Renal Disorder
Renal Pain
Rheumatoid Arthritis
Rib Fracture
Sinusitis
Skin Ulcer
Tenosynovitis Stenosans
Therapy Non-Responder
Thrombocytopenia

		Tinnitus					
		Tongue Injury					
		Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack		Vioxx	PS	Merck & Co., Inc	ORAL
		Trigger Finger		Remicade	SS		
INTRAVENOUS							
		Vasculitis		Remicade	SS		
INTRAVENOUS							
		Viral Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Viral Pharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Methotrexate	SS		
UNKNOWN							
		Weight Decreased		Methotrexate	SS		
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Acyclovir	C		
INTRAVENOUS							
				Proventil	C		ORAL
				Allopurinol	C		
UNKNOWN							
				Elavil	C		ORAL
				Fiorinal With Codeine	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

UNKNOWN	K-Dur	C
UNKNOWN	Prilosec	C
UNKNOWN	Purinethol	C
UNKNOWN	Azathioprine	C
UNKNOWN	Tegretol	C
UNKNOWN	Tegretol	C
UNKNOWN	Tegretol	C
UNKNOWN	Zyrtec	C
UNKNOWN	Hydroxychloroquine Sulfate	C
UNKNOWN	Advil	C
UNKNOWN		

Date:04/22/04ISR Number: 4344549-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02100
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Unstable
	Anion Gap Decreased
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Asthenia
	Asthma
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Blood Pressure Diastolic Increased
	Blood Pressure Orthostatic
	Breath Sounds Decreased

		Bundle Branch Block Left					
		Cardiac Failure					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Congestive		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Chest Pain		Allegra	C		ORAL
		Compartment Syndrome		Zoloft	C		ORAL
		Depression					
		Dermatitis Contact					
		Discomfort					
		Dizziness					
		Ear Infection					
		Electrocardiogram					
		Ambulatory Abnormal					
		Extrasystoles					
		Fluid Retention					
		Ganglion					
		Headache					
		Hyperlipidaemia					
		Hypertension					
		Impaired Work Ability					
		Insomnia					
		Major Depression					
		Mitral Valve Incompetence					
		Mitral Valve Sclerosis					
		Oedema Peripheral					
		Pain					
		Palpitations					
		Pulmonary Valve					
		Incompetence					
		Respiratory Rate					
		Increased					
		Sinusitis					
		Sleep Disorder Due To					
		General Medical					
		Condition, Insomnia Type					
		Tendonitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Weight Fluctuation					

Date:04/22/04ISR Number: 4344554-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
	Angina Unstable
	Anxiety
	Back Pain
	Cellulitis
	Coronary Artery Disease
	Coronary Artery Thrombosis
	Depression
	Drug Ineffective
	Emotional Distress
	Eyelid Ptosis

		Family Stress					
		Glucose Tolerance Impaired	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemangioma		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemodynamic Test		Xanax	C		
UNKNOWN							
		Abnormal		Aspirin	C		
UNKNOWN							
		Hypertension		Celebrex	C		
UNKNOWN							
		Intervertebral Disc		Zyrtec	C		
UNKNOWN							
		Protrusion		Prozac	C		
UNKNOWN							
		Macular Degeneration		Zestril	C		
UNKNOWN							
		Myocardial Infarction		Naproxen	C		
UNKNOWN							
		Nervousness		Prilosec	C		
UNKNOWN							
		Oedema Peripheral					
		Osteoporosis					
		Pain					
		Paraesthesia					
		Qrs Axis Abnormal					
		Radiculopathy					
		Renal Disorder					
		Renal Failure					
		Sinus Bradycardia					
		Sinusitis					
		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Urethritis					
		Ventricular Hypokinesia					
		Visual Disturbance					
		Wound					

Date:04/22/04ISR Number: 4344555-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0402FRA00071
Age:38 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 29 DAY		Biliary Cirrhosis		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Biliary Cirrhosis Primary Cholangiolitis Cytolytic Hepatitis Hepatitis Cholestatic Jaundice Weight Decreased		Ethinyl Estradiol And Levonorgestrel	C	ORAL

Date:04/22/04ISR Number: 4344556-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00044
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Haemorrhage		Fluindione	C		ORAL
			Fluindione	C		ORAL

Date:04/22/04ISR Number: 4348095-8Report Type:Expedited (15-DaCompany Report #WAES 0404ESP00007
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haematoma	Foreign	Tab Vioxx			
Hospitalization -	Haemorrhagic Stroke	Study	(Rofecoxib)	PS		
25 MG/DAILY 30 DAY						
Initial or Prolonged		Other	Escin	C		
			Nimodipine	C		
			Omeprazole	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/04ISR Number: 4348299-4Report Type:Expedited (15-DaCompany Report #200410255BNE
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness	Foreign	Aspirin					
Hospitalization -	Gastrointestinal	Health	(Acetylsalicylic					
Initial or Prolonged	Haemorrhage	Professional	Acid)	PS		ORAL	300 MG, TOTAL	
	Gout	Other					DAILY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, TOTAL	
							DAILY, ORAL	
			Frusemide	C				
			Thyroxin	C				
			Lisinopril	C				
			Isosorbide					
			Mononitrate	C				
			Gliclazide	C				
			Metformin	C				

Date:04/23/04ISR Number: 4345130-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00137
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Irritability		Vioxx	PS	Merck & Co., Inc	ORAL	51 DAY	
	Vision Blurred							

Date:04/23/04ISR Number: 4345137-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia Haemolytic
Disability	Autoimmune
Other	Anxiety
	Arthralgia
	Atelectasis
	Blood Cholesterol

Increased
Blood Creatine
Phosphokinase Increased
Cellulitis
Cerebrovascular Accident
Cholecystitis
Cholelithiasis
Coagulation Factor Viii
Level Increased
Coagulopathy
Cystocele
Decreased Appetite
Disturbance In Attention
Drug Hypersensitivity
Dyspnoea
Eye Pain
Haematochezia
Haemorrhage
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Hypoparathyroidism
Hypothyroidism

		Injury					
		Neurogenic Bladder					
		Oesophageal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Granuloma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Pyrexia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
8	MON						
		Rectocele		Amitriptyline			
		Renal Failure		Hydrochloride	C		
UNKNOWN							
		Renal Failure Acute		Rocaltrol	C		ORAL
		Sinusitis		Os-Cal + D	C		
UNKNOWN							
		Tinnitus		Valium	C		
UNKNOWN							
		Tracheobronchitis		Synthroid	C		
UNKNOWN							
		Transient Ischaemic		Synthroid	C		ORAL
		Attack		Ambien	C		
UNKNOWN							
		Upper Respiratory Tract		Claritin	C		
UNKNOWN							
		Infection		Slow-Mag	C		
UNKNOWN							
		Visual Disturbance		Reglan	C		
UNKNOWN							
		Weight Decreased		Reglan	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:04/23/04ISR Number: 4345138-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01621
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY					
Hospitalization -	Hypertension	Professional	Lisinopril	C		
UNKNOWN						

Initial or Prolonged	Left Ventricular Failure		Toprol Xl Tablets	C		
UNKNOWN						
	Ventricular Dysfunction		Zocor	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						
			Exelon	C		
UNKNOWN						

Date:04/23/04ISR Number: 4345141-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02144
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aseptic Necrosis Bone		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Initial or Prolonged	Bacteria Urine Identified		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Elavil	C		
UNKNOWN						
	Haemorrhagic Stroke		Premarin	C		
UNKNOWN						
	Hypertension		Glucosamine	C		
UNKNOWN						
	Osteoarthritis		Vitamins (Unspecified)	C		
UNKNOWN						
			Hydrodiuril	C		
UNKNOWN						
			Levoxyl	C		
UNKNOWN						
			Levoxyl	C		
UNKNOWN						
			Imodium	C		
UNKNOWN						

Date:04/24/04ISR Number: 4345819-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
56 DAY						
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
156 DAY						
	Increased		Celebrex	C		
UNKNOWN						
	Ischaemic Stroke					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/24/04ISR Number: 4345820-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiomegaly		Darvocet-N	C				
UNKNOWN								
Other	Carotid Artery Occlusion		Wellbutrin	C				
UNKNOWN								
	Cerebrovascular Accident		Carisoprodol	C				
UNKNOWN								
	Chest Pain		Diflunisal	C				
UNKNOWN								
	Constipation		Premarin	C				
UNKNOWN								
	Depression		Ultram	C				
UNKNOWN								
	Drug Abuser		Estratest	C				
UNKNOWN								
	Excoriation		Allegra	C				
UNKNOWN								
	Hyperlipidaemia		Rebetron	C				
UNKNOWN							3	DAY
	Ischaemic Stroke		Nortriptyline	C				
UNKNOWN								
	Melaena		Accupril	C				
UNKNOWN								
	Microcytic Anaemia		Rebetol	C				
UNKNOWN								
	Orthostatic Hypotension							
	Pain In Extremity							
	Pulmonary Congestion							
	Skin Ulcer							
	Spinal Compression							
	Fracture							
	Suicidal Ideation							
	Tibia Fracture							
	Urinary Tract Infection							
	Vasculitis							
	Weight Increased							

Date:04/24/04ISR Number: 4345821-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01659
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Weight Increased		Lipitor	C			UNKNOWN	
			Detrol La	C			UNKNOWN	

Date:04/24/04ISR Number: 4345822-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01991
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/24/04ISR Number: 4345824-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Anal Fissure
	Angina Pectoris
	Anxiety
	Asthenia
	Atrial Fibrillation
	Back Injury
	Back Pain
	Balance Disorder
	Blood Pressure Decreased

Bronchitis
Bursitis
C-Reactive Protein
Increased
Cardiomegaly
Carpal Tunnel Syndrome
Chest Pain
Chest Wall Pain
Choking
Clumsiness
Condition Aggravated
Constipation
Coordination Abnormal
Coronary Artery Disease
Cough
Cyst
Depression
Diabetes Mellitus
Diarrhoea
Diastolic Dysfunction
Difficulty In Walking
Diplopia
Disturbance In Attention
Dizziness Postural
Dry Throat
Dyspepsia
Dysphagia
Ear Pain
Eye Disorder
Fatigue
Feeling Jittery
Fibromyalgia
Gastrooesophageal Reflux
Disease
Haemodialysis
Haemorrhage
Hepatic Steatosis
Hunger
Hydronephrosis
Hypercholesterolaemia
Hypoaesthesia
Hypoaesthesia Oral
Hypotension
Impaired Driving Ability
Injury
Insomnia
Metabolic Syndrome

Metal Poisoning
Middle Insomnia
Migraine
Muscle Rigidity
Muscle Spasms
Muscle Twitching
Myalgia
Nephritis
Nephritis Interstitial
Night Sweats
Nocturia
Palpitations
Panic Attack
Pericardial Effusion

		Proctalgia Pulmonary Hypertension Red Blood Cell	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sedimentation Rate		Vioxx	PS	Merck & Co., Inc	ORAL
71	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Renal Failure Acute		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Salivary Hypersecretion		Vioxx	SS	Merck & Co., Inc	ORAL
71	DAY						
		Septic Shock Sinusitis		[Therapy Unspecified]	C		
UNKNOWN							
		Somnolence		Elavil	C		
UNKNOWN							
		Speech Disorder		Atenolol	C		
UNKNOWN							
		Tendonitis Therapeutic Agent		Trazodone Hydrochloride	C		
UNKNOWN							
		Toxicity		Atenolol	C		
UNKNOWN							
		Tinnitus		Lonox	C		
UNKNOWN							
		Tremor		Dyazide	C		
UNKNOWN							
		Ventricular Hypertrophy		Hydrocortisone	C		
UNKNOWN							
		Vision Blurred		Zestril	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:04/24/04ISR Number: 4345828-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01432
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Anhedonia
	Arthritis
	Blood Disorder

Bronchitis Acute
Bronchitis Acute Viral
Cardiac Valve Disease
Cholecystitis
Cholelithiasis
Convulsion
Coronary Artery Disease
Coronary Artery Occlusion
Drug Level Below
Therapeutic
Ear Infection
Ejection Fraction
Decreased
Epigastric Discomfort
Fibula Fracture
Gastrooesophageal Reflux
Disease
Hallucination, Auditory
Major Depression
Osteoarthritis
Pain In Extremity
Polytraumatism
Road Traffic Accident
Sinus Bradycardia
Sleep Disorder
Suicidal Ideation
Treatment Noncompliance
Upper Respiratory Tract
Infection
Urge Incontinence

	Urinary Incontinence						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Vioxx	SS	Merck & Co., Inc	ORAL	RESPIRATORY (INHALATION)
			Lorcet 10/650	C			UNKNOWN
			Albuterol	C			UNKNOWN
			Lipitor	C			UNKNOWN
			Prempro	C			UNKNOWN
			Detrol	C			UNKNOWN
			Tricor	C		ORAL	
			Ibuprofen	C			UNKNOWN
			Ibuprofen	C			UNKNOWN
			Dilantin	C		ORAL	

Date:04/24/04ISR Number: 4345829-3Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0404ZAF00017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/24/04ISR Number: 4345830-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00130
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Dyspnoea	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
	Mouth Ulceration		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY

Swollen Tongue
Tongue Ulceration

Date:04/26/04ISR Number: 4346806-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Anaemia
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiac Failure Congestive
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Dizziness
	Hepatic Enzyme Increased
	Hypertensive Cardiomyopathy
	Hypertensive Heart Disease
	Hypokalaemia
	Hypoxia
	Insomnia
	Myocardial Infarction

		Palpitations Pulmonary Oedema Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
450	DAY						
		Syncope Vasovagal		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
450	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Plavix	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Benadryl	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Rhinocort	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Lorcet Plus	C		
UNKNOWN							
				Mavik	C		
UNKNOWN							
				Detrol	C		
UNKNOWN							
				Micardis	C		
UNKNOWN							
				Biaxin	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Coreg	C		
UNKNOWN							

UNKNOWN	Advair	C
UNKNOWN	Prolex Dh	C
UNKNOWN	Hydrocodone Hydrochloride	C
UNKNOWN	Motrin	C
UNKNOWN	Motrin	C
UNKNOWN	Toprol Xl Tablets	C
UNKNOWN	Daypro	C

Date:04/26/04ISR Number: 4346810-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01412
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Aortic Atherosclerosis
	Atrial Fibrillation
	Atrioventricular Block
	Benign Prostatic Hyperplasia
	Blindness Transient
	Cardiac Failure Congestive
	Cardiac Murmur
	Carotid Bruit
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Stenosis
	Deafness
	Dilatation Atrial
	Diverticulum
	Ischaemic Stroke
	Mitral Valve Incompetence

		Osteoarthritis					
		Pleural Effusion					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sick Sinus Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Aspirin	C		
UNKNOWN							
		Syncope		Plavix	C		
UNKNOWN							
		Tricuspid Valve		Lanoxin	C		
UNKNOWN							
		Incompetence		Calan	C		
UNKNOWN							
		Urinary Tract Infection		Coumadin	C		ORAL
		Ventricular Hypertrophy		Coumadin	C		ORAL
				Coumadin	C		ORAL
				Digoxin	C		
UNKNOWN							
				Hyzaar	C		
UNKNOWN							
				Hyzaar	C		ORAL

Date:04/26/04ISR Number: 4346813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01061634
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Angina Unstable
Disability	Anorexia
Other	Anxiety
	Arthropathy
	Atelectasis
	Blood Glucose Decreased
	Blood Pressure Increased
	Bloody Discharge
	Cardiac Procedure
	Complication
	Cerebrovascular Accident
	Chills
	Cholelithiasis
	Obstructive
	Colonic Polyp
	Contusion
	Coronary Artery

Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Depressed Mood
Diabetes Mellitus
Inadequate Control
Diarrhoea
Dyspepsia
Dyspnoea Exertional
Extravasation
Fungal Infection
Gastric Haemorrhage
Gastritis
Gingival Disorder
Haematoma
Hypertensive Heart
Disease
Insomnia
Intervertebral Disc
Protrusion
Intestinal Functional
Disorder

		Muscle Spasms					
		Myocardial Infarction					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Night Sweats		Vioxx	PS	Merck & Co., Inc	ORAL
		Ocular Hyperaemia		Fosamax	SS		ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Optic Ischaemic		Lortab	C		ORAL
		Neuropathy		Norvasc	C		ORAL
		Osteopenia		Humulin N	C		
UNKNOWN							
		Pain		Septra	C		ORAL
		Peripheral Vascular		Zanaflex	C		
UNKNOWN							
		Disorder		Septra	C		ORAL
		Pneumonia		Synthroid	C		ORAL
		Postinfarction Angina		Robaxin	C		
UNKNOWN							
		Retroperitoneal Haematoma		Synthroid	C		ORAL
		Rheumatoid Arthritis		Plavix	C		
UNKNOWN							
		Supraventricular		Lortab	C		ORAL
		Tachycardia					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urinary Tract Infection					
		Vaginal Erythema					
		Ventricular Tachycardia					
		Vertigo					
		Vomiting					
		Weight Decreased					

Date:04/26/04ISR Number: 4346820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial Infarction
Disability	Acute Respiratory Failure
	Agitation
	Angina Unstable
	Arthralgia

Asthenia
Atrial Tachycardia
Back Pain
Cardiac Arrest
Cardiac Failure
Congestive
Cardiac Murmur
Cardiogenic Shock
Cerebrovascular Accident
Chest X-Ray Abnormal
Coronary Artery Disease
Coronary Artery Stenosis
Culture Urine Positive
Ejection Fraction
Decreased
Electrocardiogram Qrs
Complex Prolonged
Emotional Distress
Encephalopathy
Fatigue

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Folliculitis					
		Gallop Rhythm Present					
		Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL
14 MON							
		Headache		Prozac	C		
UNKNOWN							
		Hepatitis		Oxycodone	C		
UNKNOWN							
		Hypercholesterolaemia		Zoloft	C		
UNKNOWN							
		Hyperhidrosis		Diovan	C		
UNKNOWN							
		Intervertebral Disc		Ultram	C		
UNKNOWN							
		Protrusion		Zantac	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Maxalt (Rizatriptan Benzoate)	C		ORAL
		Ischaemic Hepatitis					
		Lung Infiltration					
		Mental Status Changes					
		Migraine					
		Multi-Organ Failure					
		Muscle Spasms					
		Oedema Peripheral					
		Panic Attack					
		Panic Disorder					
		Proteus Infection					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Failure Acute					
		Respiratory Failure					
		Tendonitis					
		Thrombocytopenia					
		Thyroid Neoplasm					
		Tricuspid Valve Incompetence					
		Ulcer Haemorrhage					
		Urinary Tract Infection					
		Ventricular Fibrillation					
		Ventricular Tachycardia					
		Visual Disturbance					

Date:04/26/04ISR Number: 4346826-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Amnesia
	Anxiety
	Asthenia
	Atherosclerosis
	Back Pain
	Blood Pressure Increased
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Convulsion
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dysphagia
	Dyspnoea
	Eructation
	Fatigue
	Hypercholesterolaemia

		Hypertriglyceridaemia					
		Lacunar Infarction					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Twitching		Vioxx	PS	Merck & Co., Inc	ORAL
		Myalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Darvocet-N	C		
UNKNOWN							
		Tremor		Norvasc	C		
UNKNOWN		395 DAY					
		Upper Respiratory Tract		Lotrel	C		
UNKNOWN							
		Infection		Aspirin	C		
UNKNOWN							
		Wheezing		Lipitor	C		
UNKNOWN		831 DAY					
				Lipitor	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN		831 DAY					
				Lipitor	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Clorazepate Dipotassium	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Zetia	C		ORAL
				Zetia	C		ORAL
				Tricor	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Glucovance	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Zocor	C		ORAL
				Zocor	C		ORAL
				Hydrodiuril	C		ORAL
				Ibuprofen	C		
UNKNOWN							

			Robaxin	C		ORAL
			Toprol Xl Tablets	C		ORAL
			Toprol Xl Tablets	C		ORAL
			Prilosec	C		
UNKNOWN						
			Paxil	C		
UNKNOWN						

Date:04/26/04ISR Number: 4346827-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00133
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oral Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Rash Erythematous		Etanercept	SS		
SUBCUTANEOUS						
			Acetaminophen	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL
			Omeprazole	C		ORAL
			Prednisolone	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL
			Calcium (Unspecified)	C		ORAL

Date:04/26/04ISR Number: 4346828-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization - Initial or Prolonged	Back Disorder
	Blood Cholesterol
Other	Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Triglycerides Increased					
		Cerebral Haemorrhage					
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased Activity		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		[Therapy			
		Gastric Ulcer		Unspecified]	C		
UNKNOWN							
		Gastrooesophageal Reflux		Tylenol	C		
UNKNOWN							
		Disease		Roxicet	C		
UNKNOWN							
		Joint Injury		Norvasc	C		
UNKNOWN							
		Myocardial Infarction		Lotrel	C		
UNKNOWN							
		Pain		Aspirin	C		
UNKNOWN							
		Renal Failure		Zithromax	C		
UNKNOWN							
		Stomach Discomfort		Butalbital	C		
UNKNOWN		2869 DAY					
				Butalbital	C		
UNKNOWN		2869 DAY					
				Celebrex	C		
UNKNOWN		73 DAY					
				Cipro	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN		1023 DAY					
				Mycelex	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN		2673 DAY					
				Diazepam	C		
UNKNOWN							
				Depakote	C		
UNKNOWN		26 DAY					
				Vasotec	C		ORAL
2112 DAY							
				Zanaflex	C		
UNKNOWN							
				Estrace	C		
UNKNOWN							

UNKNOWN	Estrace	C
UNKNOWN	Diflucan	C
UNKNOWN	Amibid La	C
UNKNOWN	Hydrocodone Bitartrate	C
UNKNOWN	Lactulose	C
UNKNOWN	Toprol Xl Tablets	C
UNKNOWN	Metrogel	C
UNKNOWN	Ultram	C
UNKNOWN	Nasonex	C
UNKNOWN	Avelox	C
UNKNOWN	Macrobid	C
UNKNOWN	Nitrostat	C
UNKNOWN	Prilosec	C
UNKNOWN	Miralax	C
UNKNOWN	Accupril	C
UNKNOWN	Quinine Sulfate	C
UNKNOWN		

Date:04/26/04ISR Number: 4347223-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aphasia
Other	Arthralgia
	Blood Glucose Increased
	Blood Urine
	Bronchitis
	Bursitis
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Chronic Obstructive

		Pulmonary Disease					
		Constipation					
		Contusion					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Crying		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
		Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysthymic Disorder		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Dysuria		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Exostosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Fatigue		Vicodin Tablets	C		
UNKNOWN							
		Fibromyalgia		Elavil	C		ORAL
		Gait Disturbance		Analgesic Or			
		Gravitational Oedema		Anesthetic			
		Headache		(Unspecified)	C		
UNKNOWN							
		Hypertension		Aspirin	C		ORAL
		Increased Tendency To		[Therapy			
		Bruise		Unspecified]	C		
UNKNOWN							
		Insomnia		Vitamins			
		Intervertebral Disc		(Unspecified)	C		
UNKNOWN							
		Protrusion		Vitamin E	C		
UNKNOWN							
		Irritable Bowel Syndrome		Calcium Carbonate	C		
UNKNOWN							
		Lacunar Infarction		Premarin	C		
UNKNOWN							
		Lower Respiratory Tract		Lasix (Furosemide)	C		
UNKNOWN							
		Infection		Neurontin	C		
UNKNOWN							
		Medication Error		Oxycontin	C		
UNKNOWN							
		Memory Impairment		Paxil	C		ORAL

	Migraine	Actonel	C
UNKNOWN			
	Neck Pain		
	Neuralgia		
	Oedema Peripheral		
	Osteoarthritis		
	Osteopenia		
	Osteoporosis		
	Ovarian Failure		
	Pain		
	Pain In Extremity		
	Postmenopause		
	Radicular Pain		
	Radius Fracture		
	Renal Disorder		
	Renal Pain		
	Rotator Cuff Syndrome		
	Self-Medication		
	Sinusitis		
	Somnolence		
	Spinal Column Stenosis		
	Spinal Osteoarthritis		
	Stress		
	Tenderness		
	Tendonitis		
	Transient Ischaemic		
	Attack		
	Urinary Tract Infection		
	Visual Disturbance		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/04ISR Number: 4347231-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01904
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	24 DAY	
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	24 DAY	
Other	Cardiomyopathy		Coreg	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Altace	C			UNKNOWN	

Date:04/26/04ISR Number: 4347235-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Atherosclerosis
Disability	Atrioventricular Block
Other	First Degree
	Benign Prostatic
	Hyperplasia
	Bundle Branch Block Right
	Carotid Artery Atheroma
	Cerebellar Infarction
	Cerebral Atherosclerosis
	Cerebral Atrophy
	Cerebral Infarction
	Cerebral Ventricle
	Dilatation
	Cerebrovascular Disorder
	Chest Pain
	Coordination Abnormal
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Dizziness
	Dyslipidaemia
	Gait Disturbance
	Gastric Disorder
	Gastrooesophageal Reflux

Disease
Headache
Hemiparesis
Hyperhidrosis
Hypertension
Hypertensive Heart
Disease
Lacunar Infarction
Nystagmus
Polytraumatism
Prostatic Specific
Antigen Increased
Refusal Of Treatment By
Patient
Sinus Bradycardia
Sinus Tachycardia
Supraventricular
Tachycardia
Thromboembolic Stroke
Transient Ischaemic
Attack
Urinary Retention

Ventricular Tachycardia
Vertigo
Vestibular Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Tylenol	C			UNKNOWN	

Date:04/26/04ISR Number: 4347236-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0302CHE00026
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
	Hepatocellular Damage		Acetaminophen	C			UNKNOWN	
			Tizanidine Hydrochloride	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Nadroparin	C			SUBCUTANEOUS	17 DAY

Date:04/26/04ISR Number: 4347237-8Report Type:Expedited (15-DaCompany Report #IT-MERCK-0404ITA00019
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL	37 DAY	
	Rhabdomyolysis		Sulfasalazine	C		ORAL	3 YR	

Date:04/26/04ISR Number: 4347238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01744
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Behcet'S Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							
Other	Hypochromic Anaemia							

Date:04/26/04ISR Number: 4347239-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01681
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Life-Threatening	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
Hospitalization - Initial or Prolonged	Respiratory Distress							
Disability								

Date:04/26/04ISR Number: 4349825-1Report Type:Expedited (15-DaCompany Report #2004-03-2204
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx (Rofecoxib)	PS		ORAL	25 MG QD ORAL	
Hospitalization -	Coordination Abnormal	Professional	Altace	SS		ORAL	10 MG QD ORAL	
Initial or Prolonged	Jaundice	Company	Aspirin Tablets	SS		ORAL	81 MG QD ORAL	
	Mental Status Changes	Representative	Peg-Intron					
	Therapeutic Agent		(Peginterferon					
	Toxicity		Alfa-2b) Injectable					
			Powder	SS				
SUBCUTANEOUS	96 MCG QWK							

SUBCUTANEOUS

Rebetol (Ribavirin) Capsules	SS	ORAL

800 MG QD

ORAL

Lithium	SS

300 BID

Geodon (Ziprasidone)	C
Zyprexa (Olanzapine)	C
Lexapro (Escitalopram)	C
Protonix (Pantoprazole Sodium)	C
Neurontin	C
Clonazepam	C
Hydrocodone	C
Phenergan	C

Date:04/27/04ISR Number: 4348263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Angina Unstable
	Anxiety
	Atrial Fibrillation
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chest Pain
	Chondrocalcinosis Pyrophosphate
	Colon Cancer Recurrent
	Colonic Polyp
	Coronary Artery Disease
	Diarrhoea
	Dizziness
	Dysphagia
	Ejection Fraction Decreased
	Emotional Distress

Faecal Occult Blood
Positive
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Injury
Inner Ear Disorder
Mitral Valve Incompetence
Osteoarthritis
Photosensitivity Reaction
Pleuritic Pain
Renal Cyst
Renal Failure
Thrombophlebitis
Tooth Infection
Umbilical Hernia
Urinary Tract Infection

	Vein Pain						
	Vertigo						
	Weight Decreased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				UNKNOWN
			Glipizide	C				UNKNOWN

Date:04/27/04ISR Number: 4348265-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Prinivil	SS		ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Balance Disorder		Prinivil	SS		ORAL		
198 DAY								
	Cardiac Disorder		Calcium					
	Cerebrovascular Accident		(Unspecified)	C				UNKNOWN
	Chest Pain		Diazepam	C				UNKNOWN
	Coronary Artery Disease		Premarin	C				UNKNOWN
	Drug Hypersensitivity							
	Fall							
	Heart Rate Irregular							
	Hypertension							
	Hypoaesthesia							
	Mitral Valve Incompetence							
	Palpitations							
	Paraesthesia							
	Pharyngolaryngeal Pain							
	Supraventricular							
	Tachycardia							
	Tendonitis							
	Transient Ischaemic							
	Attack							
	Tricuspid Valve							
	Incompetence							
	Vision Blurred							
	Visual Acuity Reduced							

Date:04/27/04ISR Number: 4348269-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01964
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY	
	Membranous		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY	
	Prescribed Overdose		Percocet	C			UNKNOWN	
			Senna	C			UNKNOWN	
			Toradol	C			INTRAVENOUS	
			Zofran	C			UNKNOWN	

Date:04/27/04ISR Number: 4348273-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02577
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/04ISR Number: 4348699-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Captopril	C				
UNKNOWN								
Other	Congestive		Celebrex	C				
UNKNOWN								
	Cardio-Respiratory Arrest		Plavix	C				
UNKNOWN								
	Cardiomegaly		Pepcid Ac	C		ORAL		
	Cholecystitis		Lasix (Furosemide)	C				
UNKNOWN								
	Cholelithiasis		Ambien	C				
UNKNOWN								
	Chronic Obstructive		Zoloft	C				
UNKNOWN								
	Airways Disease		Glyburide	C				
UNKNOWN								
	Exacerbated		Synthroid	C				
UNKNOWN								
	Chronic Obstructive		Lorazepam	C				
UNKNOWN								
	Pulmonary Disease		Meclizine	C				
UNKNOWN								
	Coma		Phenergan					
	Coronary Artery Disease		Tablets/Suppositorie					
	Diabetes Mellitus		s	C				
UNKNOWN								
	Inadequate Control							
	Dizziness							
	Dyspepsia							
	Faecal Occult Blood							
	Positive							
	Gastritis							
	Hyperhidrosis							
	Hyperkalaemia							
	Hypoglycaemia							
	Microcytic Anaemia							
	Myocardial Infarction							
	Nausea							
	Pulmonary Oedema							
	Rales							
	Renal Failure							

Respiratory Depression

Date:04/27/04ISR Number: 4348708-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00091403
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Abnormal Faeces
	Adverse Event
	Alopecia
	Aphthous Stomatitis
	Bone Cyst
	Bronchitis Acute
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Constipation
	Contusion
	Depression
	Diverticulitis
	Emotional Distress
	Feeling Abnormal
	Feeling Cold
	Fibrocystic Breast Disease

Gingival Infection
Head Injury
Hot Flush

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypercoagulation					
	Vioxx	PS	Merck & Co., Inc	ORAL	392	DAY
	Hyperkeratosis					
	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Hypersensitivity					
	Tylenol	C			UNKNOWN	
	Insomnia					
	Fioricet Tablets	C			UNKNOWN	
	Migraine					
	Fioricet Tablets	C			UNKNOWN	
	Nail Ridging					
	Aspirin	C			UNKNOWN	
	Nausea					
	Zithromax	C			UNKNOWN	
	Neuropathy Peripheral					
	Ambien	C			UNKNOWN	
	Non-Cardiac Chest Pain					
	Cimicifuga	C			UNKNOWN	
	Oedema					
	Prempro	C			UNKNOWN	
	Pain					
	Advil	C			UNKNOWN	
	Rash					
	Motrin	C			UNKNOWN	
	Rhinitis Allergic					
	Naproxen	C			UNKNOWN	84 DAY

Systolic Hypertension
Tooth Abscess
Transient Ischaemic
Attack
Urticaria
Weight Increased

Date:04/27/04ISR Number: 4348716-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01288
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident At Work
	Angina Pectoris
Disability	Aortic Valve Incompetence
	Blister

Blood Cholesterol
Increased
Blood Creatine
Phosphokinase Increased
Blood Pressure Increased
Bronchospasm
Bundle Branch Block Right
Cardiomegaly
Cellulitis
Chest Pain
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Thrombosis
Dizziness
Headache
Injury
Low Density Lipoprotein
Increased
Malaise
Mediastinal Haematoma
Mitral Valve Incompetence
Myocardial Ischaemia
Nausea
Osteomyelitis
Pleural Effusion
Pneumothorax
Postoperative Infection
Silent Myocardial

		Infarction					
		Tricuspid Valve Incompetence					
		Ventricular Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Hypokinesia		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Vertigo		Ecotrin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Avapro	C		
UNKNOWN							
				Miacalcin	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Midazolam	C		
UNKNOWN							

Date:04/27/04ISR Number: 4348720-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain		Heparin	SS		
UNKNOWN						
Disability	Balance Disorder		Provera	SS		
UNKNOWN						
Other	Blindness		[Therapy			
	Blood Glucose Increased		Unspecified]	C		
UNKNOWN						
	Carotid Artery Stenosis		Tylenol With Codeine			
	Cataract		#3	C		
UNKNOWN						
	Cerebral Infarction		Captopril	C		
UNKNOWN						
	Cerebrovascular Accident		Capozide	C		
UNKNOWN						

	Depression	Cisapride	C
UNKNOWN			
	Dry Skin	Glyburide	C
UNKNOWN			
	Epistaxis		
	Flushing		
	Gastrooesophageal Reflux		
	Disease		
	Gout		
	Haemorrhage Intracranial		
	Headache		
	Hemianopia Homonymous		
	Herpes Zoster		
	Hyperhidrosis		
	Hypertension		
	Injury		
	Intervertebral Disc		
	Degeneration		
	Joint Injury		
	Loss Of Consciousness		
	Meningioma		
	Nasal Congestion		
	Nausea		
	Pain		
	Pallor		
	Pneumonia		
	Radiculopathy		
	Rash		
	Rift Valley Fever		
	Sciatica		
	Tachycardia		
	Thyroid Mass		
	Vaginal Haemorrhage		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/04ISR Number: 4348723-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01901
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Circulatory Collapse		[Therapy					
	Haemorrhage		Unspecified]	C				
UNKNOWN								

Date:04/27/04ISR Number: 4348724-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01724
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adjustment Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vicodin Tablets	C				
UNKNOWN								
	Arthritis		Soma	C				
UNKNOWN								
	Balance Disorder		Soma	C				
UNKNOWN								
	Blood Pressure Increased		Premarin	C				
UNKNOWN								
	Bursitis		Allegra	C				
UNKNOWN								
	Coronary Artery Disease		Levoxyl	C				
UNKNOWN								
	Coronary Artery Stenosis		Claritin	C				
UNKNOWN								
	Decreased Appetite							
	Drug Dependence							
	Drug Effect Decreased							
	Fall							
	Gait Disturbance							
	Headache							
	Heart Rate Decreased							
	Hip Fracture							
	Insomnia							
	Irritability							
	Myocardial Infarction							
	Nervousness							

Post Procedural
Haemorrhage
Restlessness

Date:04/27/04ISR Number: 4348725-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder With Depressed Mood
Disability	Affective Disorder
Congenital Anomaly	Alopecia
Other	Anaemia
	Angina Unstable
	Ankylosing Spondylitis
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Concussion
	Constipation
	Depression
	Drug Ineffective
	Dysphagia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dysphoria Facet Joint Syndrome Facial Bones Fracture					
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY							
		Fibromyalgia		Microzide	SS		
UNKNOWN							
		Gastrooesophageal Reflux		Microzide	SS		
UNKNOWN							
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercalcaemia		Prinzide	SS		ORAL
26 HR							
		Hyperkalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
99 DAY							
		Hypothyroidism		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
		Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
99 DAY							
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
		Displacement		Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY							
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
		Protrusion		Vicodin Es Tablets	C		
UNKNOWN							
		Jaw Disorder Myofascial Pain Syndrome Neck Pain		Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1 DAY					
		Nephritis Interstitial		Beconase	C		
UNKNOWN							
		Oesophageal Stenosis		Prevacid	C		
UNKNOWN							
		Osteoarthritis		Claritin	C		
UNKNOWN							
		Osteoporosis		Effexor	C		
UNKNOWN							
		Palpitations Peripheral Sensory		Trazodone Hydrochloride	C		
UNKNOWN							
		Neuropathy		Trazodone			

	Polyarthritis	Hydrochloride	C
UNKNOWN			
	Psoriatic Arthropathy	Imitrex	C
UNKNOWN			
	Raynaud'S Phenomenon	Claritin	C
UNKNOWN			
	Reflux Oesophagitis	Prevacid	C
UNKNOWN			
	Reiter'S Syndrome	Zestoretic	C
UNKNOWN			
	Renal Failure	Celebrex	C
UNKNOWN			
	Sacroiliitis	Valium	C
UNKNOWN			
	Spinal Cord Compression	Estratest	C
UNKNOWN			
	Spondyloarthropathy	Estratest	C
UNKNOWN			
	Urinary Tract Pain		
	Weight Increased		

Date:04/27/04ISR Number: 4348728-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
Other	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cellulitis
	Cerebral Ischaemia
	Chronic Obstructive
	Pulmonary Disease
	Colitis Ischaemic
	Coronary Artery Disease
	Delirium
	Depression
	Diarrhoea
	Drug Hypersensitivity
	Gastroenteritis
	Headache

		Inguinal Hernia					
		Liver Function Test Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Periorbital Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Staphylococcal Sepsis		Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol	C		
UNKNOWN							
				Saw Palmetto	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Lumigan	C		
UNKNOWN							
				Corticosteroids (Unspecified)	C		
PARENTERAL							
				Betagan	C		
UNKNOWN							
				Relafen	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:04/27/04ISR Number: 4348729-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01950
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/27/04ISR Number: 4348735-3Report Type:Expedited (15-DaCompany Report #US-MERCK-00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Hospitalization -	Basal Cell Carcinoma	Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY					
Initial or Prolonged	Blood Creatine	Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY					
Disability	Phosphokinase Increased	Zocor	SS		ORAL
83 DAY					
	Cerebrovascular Accident	Acetaminophen	C		
UNKNOWN					
	Dermatitis	Vitamins			
	Dermatomyositis	(Unspecified)	C		
UNKNOWN					
	Fatigue	Calcium			
	Haematuria	(Unspecified)	C		
UNKNOWN					
	Headache	Hydrodiuril	C		ORAL
	Hyperhidrosis	Claritin	C		
UNKNOWN					
	Injury				
	Insomnia				
	Myalgia				
	Myopathy				
	Pain In Extremity				
	Paraesthesia				
	Pharyngitis				
	Restless Legs Syndrome				
	Skin Lesion				
	Tendonitis				

Date:04/27/04ISR Number: 4348736-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Congestive							
	Chronic Fatigue Syndrome							
	Chronic Obstructive							
	Pulmonary Disease							
	Convulsion							
	Coronary Artery Disease							
	Dizziness							
	Headache							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Lung Neoplasm							
	Major Depression							
	Myocardial Infarction							
	Osteoarthritis							
	Syncope							

Date:04/27/04ISR Number: 4348738-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02003
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ruptured Cerebral Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/04ISR Number: 4348739-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Other	Cold Sweat		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		

	Hypersensitivity	Vioxx	SS	Merck & Co., Inc	ORAL 4 DAY
	Muscle Strain	Atenolol	C		UNKNOWN
	Myocardial Infarction	Hydrodiuril	C		UNKNOWN
	Nausea	Prevacid	C		UNKNOWN
	Patellofemoral Pain	Claritin	C		UNKNOWN
	Syndrome Pulse Absent Sudden Death Vomiting				

Date:04/28/04ISR Number: 4349233-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Arthralgia
	Asthenia
	Cardiomegaly
	Coronary Artery Atherosclerosis

		Drug Ineffective					
		Dyslipidaemia					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscular Weakness		Vioxx	PS	Merck & Co., Inc	ORAL
		Peripheral Coldness		Vioxx	SS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Atenolol	C		
UNKNOWN							
		Rotator Cuff Syndrome		Zyrtec	C		
UNKNOWN							
		Scapula Fracture		Celexa	C		
UNKNOWN							
		Sinus Bradycardia		Flonase	C		
UNKNOWN							
		Skin Laceration		Hydrocodone			
		Ventricular Hypertrophy		Bitartrate	C		
UNKNOWN							
				Levsin	C		
UNKNOWN							
				Indocin			
				(Indomethacin)	C		ORAL
				Naproxen	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:04/28/04ISR Number: 4349234-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Body Tinea		Vioxx	SS	Merck & Co., Inc	
UNKNOWN		1 DAY					
Other		Carpal Tunnel Syndrome		Flexeril	C		
UNKNOWN							
		Coronary Artery		Monopril	C		
UNKNOWN							
		Atherosclerosis		Pravachol	C		
UNKNOWN							

Dermoid Cyst
Diabetes Mellitus
Non-Insulin-Dependent
Emotional Distress
Fatigue
Hypersensitivity
Overdose
Pain In Extremity
Tendonitis
Tenosynovitis
Trigger Finger
Weight Increased

Date:04/28/04ISR Number: 4349237-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Anaemia Of Chronic Disease
Other	Angiodysplasia
	Bronchitis
	Contusion
	Depression
	Diverticular Perforation
	Gastritis
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux Disease

		Intestinal Polyp					
		Muscle Spasms					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polyp Colorectal		Vioxx	PS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Small Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Lipitor	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Voltaren	C		
UNKNOWN							
				Duragesic	C		
TOPICAL							
				Dyazide	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Denavir	C		
UNKNOWN							

Date:04/28/04ISR Number: 4349243-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Initial or Prolonged	Cholecystitis Chronic		Norvasc	C		
UNKNOWN						
Disability	Cholelithiasis		Lipitor	C		
UNKNOWN						
Other	Eye Haemorrhage					

Eye Injury
Ischaemic Stroke
Syncope Vasovagal

Date:04/28/04ISR Number: 4349536-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00184
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL	67	DAY
			Atenolol	C		ORAL		
			Fluoxetine	C		ORAL		
			Sulfasalazine	C		ORAL		
			Nifedipine	C		ORAL		

Date:04/28/04ISR Number: 4349537-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00059
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Osteoarthritis		Amlodipine Besylate	C				
UNKNOWN								
Hospitalization -	Sepsis		Certoparin Sodium	C				
UNKNOWN								
Initial or Prolonged			Digoxin	C				
UNKNOWN								
			Dipyrone	C				
UNKNOWN								
			Tramadol Hydrochloride	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								
			Metoprolol Succinate	C				
UNKNOWN								
			Pantoprazole Sodium	C				
UNKNOWN								
			Ramipril	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/04ISR Number: 4349539-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adhesion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Alcohol Withdrawal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Lortab	C				
UNKNOWN								
	Anxiety		Trazodone					
	Arthralgia		Hydrochloride	C				
UNKNOWN								
	Back Disorder		Amitriptyline					
	Biliary Neoplasm		Hydrochloride	C				
UNKNOWN							874	DAY
	Bronchitis		Celebrex	C				
UNKNOWN							362	DAY
	Cardiac Failure		Neurontin	C				
UNKNOWN								
	Congestive		Hydrocodone					
	Cerebrovascular Accident		Bitartrate	C				
UNKNOWN								
	Coronary Artery Disease		Lorazepam	C				
UNKNOWN							2	DAY
	Depression		Robaxin	C				
UNKNOWN							957	DAY
	Drug Dependence							
	Drug Ineffective							
	Emotional Distress							
	Faecal Occult Blood							
	Positive							
	Fatigue							
	Headache							
	Hepatitis C							
	Hyperlipidaemia							
	Hypertension							
	Insomnia							
	Intervertebral Disc							
	Degeneration							
	Intervertebral Disc							
	Protrusion							
	Lobar Pneumonia							
	Loss Of Consciousness							

Lumbar Spinal Stenosis
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Myofascial Pain Syndrome
Osteoarthritis
Panic Attack
Pneumonia
Prostatitis
Pyrexia
Sciatica
Sinus Bradycardia
Spinal Osteoarthritis
Syncope
Urinary Tract Infection
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/04ISR Number: 4349542-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02196
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anaemia		Aspirin	SS		ORAL		
Initial or Prolonged	Coordination Abnormal		Lithium Carbonate	SS				
UNKNOWN								
	Depression		Lithium Carbonate	SS				
UNKNOWN								
	Haematocrit Decreased		Altace	SS		ORAL		
	Jaundice		Rebetol	SS		ORAL		
40 DAY								
	Therapeutic Agent		Peg-Intron	SS				
SUBCUTANEOUS							40	DAY
	Toxicity		Hydrocodone/Apap	C		ORAL		
			Geodon	C		ORAL		
			Zyprexa	C		ORAL		
			Phenergan Tablets/Suppositories	C		ORAL		
			Protonix	C		ORAL		
			Clonazepam	C		ORAL		
			Lexapro	C		ORAL		
			Neurontin	C		ORAL		

Date:04/28/04ISR Number: 4349913-XReport Type:Expedited (15-DaCompany Report #WAES 0404ESP00007
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematoma	Foreign	Tab Vioxx					
Hospitalization -	Haemorrhagic Stroke	Study	(Rofecoxib)	PS				
25 MG/DAILY								
Initial or Prolonged		Other	Escin	C				
			Nimodipine	C				
			Omeprazole	C				

Date:04/28/04ISR Number: 4349920-7Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Dyspnoea	Study					MG/DAILY/PO	
Initial or Prolonged	Myocardial Infarction	Health	Digoxin	C				
	Ventricular Dysfunction	Professional	Warfarin	C				

Date:04/29/04ISR Number: 4350076-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01392
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia
	Arthropathy
	Contusion
	Depression
	Diabetes Mellitus
	Inadequate Control
	Diarrhoea
	Disturbance In Attention
	Dizziness
	Drug Ineffective
	Embolism
	Emotional Distress
	Fibromyalgia
	Fluid Retention

	Foot Fracture						
	Headache						
	Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypoaesthesia		[Therapy				
	Hypokalaemia		Unspecified]	C			UNKNOWN
	Injury		Premarin	C			UNKNOWN
	Insomnia						
	Intestinal Functional						
	Disorder						
	Ischaemic Stroke						
	Multiple Sclerosis						
	Muscle Spasms						
	Nausea						
	Nephrolithiasis						
	Neuralgia						
	Night Sweats						
	Oedema Peripheral						
	Pain In Extremity						
	Radiculitis						
	Spinal Osteoarthritis						
	Viral Infection						
	Vision Blurred						
	Weight Decreased						

Date:04/29/04ISR Number: 4350077-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00190
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Diclofenac	SS			UNKNOWN

Date:04/29/04ISR Number: 4350079-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort

Initial or Prolonged Disability	Abdominal Pain Anaemia Blood Calcium Increased Blood Glucose Increased Blood Potassium Increased Blood Pressure Abnormal Cardiovascular Disorder Colitis Eczema Faeces Discoloured Gastritis Hypochloraemia Hyponatraemia International Normalised Ratio Decreased Myocardial Infarction Nausea Oedema Oesophagitis Peptic Ulcer Rash Generalised

		Rash Pruritic Rectal Haemorrhage Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
168	DAY						
		Stress Tachycardia		[Therapy Unspecified]	C		
UNKNOWN							
		Torsade De Pointes Upper Gastrointestinal		[Therapy Unspecified]	C		
UNKNOWN							
		Haemorrhage		Aspirin	C		
UNKNOWN							
		Ventricular Arrhythmia		Lipitor	C		
UNKNOWN							
				Pepto-Bismol	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C		
UNKNOWN							
				Vasoretic	C		ORAL
				Neurontin	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Inderal	C		
UNKNOWN							

Date:04/29/04ISR Number: 4350087-XReport Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0508560A
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Agitation		Lithium	PS	Glaxosmithkline	
UNKNOWN	300MG Twice					
Hospitalization -	Anaemia					
per day						
Initial or Prolonged	Coordination Abnormal		Aspirin	SS	Glaxosmithkline	ORAL
81MG Per day						

	Depression	Peg-Intron	SS			
SUBCUTANEOUS	96MCG Weekly 40 DAY					
	Drug Toxicity	Rebetol	SS			ORAL
800MG Per day 40 DAY						
	Haematocrit Decreased	Vioxx	SS			ORAL
25MG Per day						
	Jaundice	Altace	SS			ORAL
10MG Per day						
	Mental Status Changes	Escitalopram	C			ORAL
10MG Per day						
	Therapeutic Agent	Protonix	C			ORAL
40MG Per day						
	Toxicity	Neurontin	C			ORAL
100MG Three						
times per day						
		Clonazepam	C			ORAL
1MG Twice per						
day						
		Hydrocodone	C			ORAL
		Phenergan	C	Glaxosmithkline		ORAL
25MG As						
required						
		Geodon	C			ORAL
40MG Per day						
		Zyprexa	C			ORAL
15MG Per day						

Date:04/29/04ISR Number: 4350289-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Blood Bilirubin Increased
	Blood Cholesterol Increased
	Carpal Tunnel Syndrome
	Coronary Artery Disease

		Emotional Distress					
		Gallop Rhythm Present					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertensive Heart		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Claritin-D	SS		ORAL
		Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vicodin Es Tablets	C		ORAL
		Trigger Finger		Ambien	C		ORAL
				Percocet	C		ORAL
				Zoloft	C		ORAL
				Zoloft	C		ORAL
				Ceftin	C		ORAL

Date:04/29/04ISR Number: 4350293-4Report Type:Expedited (15-DaCompany Report #NL-MERCK-0307NLD00012
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
333 DAY						
Hospitalization -	Drug Interaction		Methotrexate	SS		ORAL
15 DAY						
Initial or Prolonged	Hypertension		Methotrexate	SS		ORAL
	Syncope		Folic Acid	C		ORAL

Date:04/29/04ISR Number: 4350297-1Report Type:Expedited (15-DaCompany Report #NL-MERCK-0306NLD00024
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
333 DAY						
Hospitalization -	Drug Interaction		Methotrexate	SS		
UNKNOWN	15 DAY					
Initial or Prolonged	Hypertension		Methotrexate	SS		
UNKNOWN	15 DAY					
	Syncope		Folic Acid	C		
UNKNOWN						
			Folic Acid	C		
UNKNOWN						

Date:04/29/04ISR Number: 4350299-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01385
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Premarin	C				
UNKNOWN								
Other	Congestive		Lasix (Furosemide)	C				
UNKNOWN								
	Cardiac Murmur		Prevacid	C		ORAL		
	Coronary Artery Disease		Synthroid	C		ORAL		
	Faeces Discoloured		Potassium (Unspecified)	C				
	Gastric Disorder							
UNKNOWN								
	Gastritis							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Lung Neoplasm							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Non-Cardiac Chest Pain							
	Oesophageal Spasm							
	Pain							

Date:04/29/04ISR Number: 4350301-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
Disability	Amnesia
Other	Anaemia
	Angina Pectoris
	Anxiety
	Arrhythmia
	Atelectasis
	Blood Cholesterol Increased
	Blood Sodium Decreased
	Bundle Branch Block Right
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Confusional State
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Crackles Lung
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Ketoacidosis
	Dilatation Atrial
	Dysaesthesia
	Electrocardiogram T Wave Abnormal
	Emotional Distress
	Erythema
	Fall
	Gait Disturbance
	Graft Dysfunction
	Hypertension
	Hypoaesthesia
	Hypokalaemia
	Hypokinesia
	Influenza Like Illness
	Intervertebral Disc Degeneration
	Ischaemia
	Mitral Valve Incompetence
	Myocardial Infarction

Myocardial Ischaemia
Nasopharyngitis
Palpitations
Pulmonary Embolism
Rotator Cuff Syndrome
Spinal Osteoarthritis
Supraventricular
Tachycardia
Syncope
Tetany
Transient Ischaemic
Attack
Treatment Noncompliance
Tremor
Urinary Tract Infection

	Ventricular Dysfunction Ventricular Extrasystoles Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirin	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Glucotrol Xl	C		
UNKNOWN						
			Glyburide	C		
UNKNOWN						
			Ativan	C		
UNKNOWN						
			Lopressor	C		
UNKNOWN						
			Orphenadrine	C		
UNKNOWN						

Date:04/29/04ISR Number: 4350304-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Bronchitis		[Therapy			
	Cataract		Unspecified]	C		
UNKNOWN						
	Cerebrovascular Accident		Acetaminophen	C		
UNKNOWN						
	Dehydration		Percocet	C		
UNKNOWN						
	Depression		Soma	C		
UNKNOWN						
	Diarrhoea		Zyrtec	C		
UNKNOWN						
	Diverticulitis		Cyanocobalamin	C		
UNKNOWN						
	Gastroenteritis Viral		Ultram	C		
UNKNOWN						
	Gastrointestinal Disorder		Lamisil	C		
UNKNOWN						

	Hypertension	Estrace	C
UNKNOWN			
	Migraine	Premarin	C
UNKNOWN			
	Normochromic Normocytic	Motrin	C
UNKNOWN			
	Anaemia	Ocuflox	C
UNKNOWN			
	Pain	Oxycodone	C
UNKNOWN			
	Pneumonia	Prednisone	C
OPHTHALMIC			
	Renal Failure Acute		

Date:04/29/04ISR Number: 4350306-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00124
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL	133	DAY
	Proteinuria		Sulfasalazine	C		ORAL		

Date:04/29/04ISR Number: 4350307-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0404NOR00006
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Peptic Ulcer Perforation		Aspirin And Magnesium Oxide	SS		ORAL		
			Acetaminophen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/04ISR Number: 4350308-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00174
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Hospitalization -	Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Upper Gastrointestinal		Acetyldigoxin	C				UNKNOWN
	Haemorrhage		Candesartan Cilexetil	C				UNKNOWN
			Molsidomine	C				UNKNOWN
			Piretanide	C				UNKNOWN

Date:04/29/04ISR Number: 4350495-7Report Type:Direct Company Report #CTU 217683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased		Vioxx 25 Mg Merck	PS	Merck	ORAL		TWICE DAILY
	Blood Pressure							PO
	Fluctuation							
	Hypertension							
	Hyponatraemia							

Date:04/30/04ISR Number: 4350707-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atelectasis		Zocor	SS		ORAL		
Disability	Atrial Fibrillation		Percocet	C				UNKNOWN
Other	Back Pain		Atenolol	C				UNKNOWN

	Blood Cholesterol	Folic Acid	C	
UNKNOWN				
	Increased	Ambien	C	
UNKNOWN				
	Bradycardia	Ismo	C	
UNKNOWN				
	Coronary Artery	Methotrexate	C	
UNKNOWN				
	Atherosclerosis	Oxycodone		
	Coronary Artery Disease	Hydrochloride	C	
UNKNOWN				
	Coronary Artery	Prednisone	C	ORAL
	Reocclusion			
	Diarrhoea Haemorrhagic			
	Diverticulitis Intestinal			
	Haemorrhagic			
	Diverticulum			
	Hyperlipidaemia			
	Hypertension			
	Intervertebral Disc			
	Degeneration			
	Lower Gastrointestinal			
	Haemorrhage			
	Lung Disorder			
	Myocardial Infarction			
	Myocardial Ischaemia			
	Palpitations			
	Pleural Effusion			
	Pulmonary Oedema			
	Renal Failure Chronic			
	Respiratory Distress			
	Tachyarrhythmia			
	Thrombosis			
	Ventricular Hypertrophy			

Date:04/30/04ISR Number: 4350708-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02577
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/30/04ISR Number: 4350709-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00065
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glycosylated Haemoglobin		Zyrtec	C				
	Increased		Flonase	C				
	Headache		Glyburide	C				
	Intervertebral Disc Disorder							
	Intervertebral Disc Protrusion							
	Lacunar Infarction							
	Nerve Injury							
	Pain In Extremity							
	Rhinitis Allergic							
	Somnolence							
	Stomach Discomfort							

Date:04/30/04ISR Number: 4350710-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01976
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	106 DAY	
Initial or Prolonged	Arthralgia		Tylenol	C				
UNKNOWN								

	Back Pain		Bayer Aspirin	C		
UNKNOWN						
	Decreased Appetite					
	Diabetes Mellitus					
	Drug Hypersensitivity					
	Dyspnoea					
	Glaucoma					
	Headache					
	Heart Rate Increased					
	Hypertension					
	Injury					
	Insomnia					
	Non-Cardiac Chest Pain					
	Palpitations					
	Stress					
	Thyroid Disorder					
	Tooth Extraction					

Date:04/30/04ISR Number: 4350711-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01115
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Injury		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL		

Vioxx SS Merck & Co., Inc
UNKNOWN

Date:04/30/04ISR Number: 4350714-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01357
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deafness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness Postural		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		[Therapy					
	Dyspnoea		Unspecified]	C				
	Electrocardiogram		Percocet	C				
	Abnormal		Norvasc	C				
	Emotional Distress		Valium	C				
	Enophthalmos		Calan	C				
	Gastric Ulcer		Premarin	C				
	Gastrointestinal Disorder		Avalide	C				
	Headache		Maxzide	C				
	Heart Rate Irregular		Claritin	C				
	Influenza Like Illness		Ativan	C				
	Injury		Toprol Xl Tablets	C				
	Lacrimation Increased		Lopressor	C				
	Medication Error							
	Mood Swings							
	Musculoskeletal Disorder							
	Nasal Polyps							

Nausea
Panic Disorder
Tinnitus
Tooth Disorder
Transient Ischaemic
Attack
Vertigo
Vision Blurred
Weight Increased

Date:04/30/04ISR Number: 4350719-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		156 DAY
Initial or Prolonged	Blood Pressure Systolic		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Disability	Increased		[Therapy					
Other	Cerebral Artery Occlusion		Unspecified]	C				
UNKNOWN								585 DAY
	Cerebral Infarction		Tylenol	C				
UNKNOWN								585 DAY
	Cerebrovascular Accident		Ortho-Novum	C				
UNKNOWN								
	Cerebrovascular Stenosis		Necon	C				
UNKNOWN								
	Hypercholesterolaemia		Zoloft	C				
UNKNOWN								
	Low Density Lipoprotein		Advil	C				
UNKNOWN								585 DAY
	Increased		Motrin	C				
UNKNOWN								585 DAY
			Methylphenidate	C				
UNKNOWN								
			Naproxen	C				
UNKNOWN								585 DAY
			Aleve	C				
UNKNOWN								585 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/30/04ISR Number: 4351108-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01388
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Naprosyn	C				
UNKNOWN	Congestive Cholelithiasis							
	Eye Disorder							
	Hypercholesterolaemia							
	Leukocytosis							
	Lung Infiltration							
	Nephrolithiasis							
	Oedema Peripheral							
	Productive Cough							
	Pyrexia							
	Renal Colic							
	Silent Myocardial Infarction							
	Sleep Apnoea Syndrome							
	Urticaria							
	Ventricular Arrhythmia							

Date:04/30/04ISR Number: 4351125-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Neoplasm
	Anxiety
	Arthralgia
	Back Pain
	Blood Chloride Increased
	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Homocysteine Increased
	Blood Sodium Increased
	Bloody Discharge
	Body Temperature

Increased
Breath Holding
Calcinosis
Cervicitis
Cervicitis Cystic
Chest Pain
Coagulation Factor Vii
Level Increased
Constipation
Cough
Deep Vein Thrombosis
Face Oedema
Fatigue
Gastric Neoplasm
Gastroenteritis
Haematemesis
Haematocrit Decreased
Headache

		Hyperhidrosis					
		Hyperlipidaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Iliac Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Lipoma		[Therapy			
		Low Density Lipoprotein		Unspecified]	C		
UNKNOWN							
		Increased		Aspirin	C		
UNKNOWN							
		Middle Insomnia		Lipitor	C		ORAL
		Neovascularisation		Tiazac	C		
UNKNOWN							
		Oedema Peripheral		Detrol	C		
UNKNOWN							
		Ovarian Atrophy		Meridia	C		
UNKNOWN							
		Postnasal Drip		Cardura	C		
UNKNOWN							
		Productive Cough		Motrin	C		
UNKNOWN							
		Protein C Increased		Zestril	C		
UNKNOWN							
		Pulmonary Granuloma					
		Sleep Apnoea Syndrome					
		Sneezing					
		Snoring					
		Urinary Tract Infection					
		Uterine Enlargement					
		Uterine Leiomyoma					
		Venous Insufficiency					
		Venous Stenosis					
		Wheezing					
		Wound Dehiscence					

Date:04/30/04ISR Number: 4351132-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00846
Age:85 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
12 DAY							
Life-Threatening		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
12 DAY							

Hospitalization - UNKNOWN	Congestive	Alprazolam	C	
Initial or Prolonged OPHTHALMIC	Conduction Disorder	Artificial Tears	C	
Disability	Electrocardiogram Qt Prolonged	Tessalon Perles	C	ORAL
		Dulcolax	C	ORAL
	Electrocardiogram St-T Segment Abnormal	Calcitriol	C	ORAL
		Aranesp	C	
SUBCUTANEOUS	Hepatic Congestion	Digoxin	C	ORAL
	Hyperkalaemia	Colace	C	ORAL
	Renal Failure Acute	Insulin	C	
UNKNOWN	Therapy Non-Responder	Xalatan	C	
OPHTHALMIC		Levothyroxine Sodium	C	ORAL
		Claritin	C	ORAL
		Metoprolol	C	ORAL
		Remeron	C	ORAL
		Nitroglycerin	C	
SUBLINGUAL		Protonix	C	ORAL
		Darvon	C	
UNKNOWN		Vitamins (Unspecified)	C	ORAL

Date:04/30/04ISR Number: 4351136-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Acute Coronary Syndrome
	Acute Myocardial Infarction

		Arthritis					
		Cardiac Valve Disease					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Surgery		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		[Therapy			
		Diverticulitis		Unspecified]	C		
UNKNOWN							
		Emotional Distress		Norco	C		
UNKNOWN							
		Facet Joint Syndrome		Atenolol	C		
UNKNOWN							
		Hand Fracture		Tenormin	C		
UNKNOWN							
		Hypertension		Celebrex	C		
UNKNOWN							
		Hypoxia		Celebrex	C		
UNKNOWN							
		Insomnia		Diovan	C		
UNKNOWN							
		Intervertebral Disc		Ultram	C		
UNKNOWN							
		Protrusion		Avandia	C		
UNKNOWN							
		Joint Ligament Rupture		Chlorthalidone	C		
UNKNOWN							
		Lumbar Spinal Stenosis		Hygroton	C		
UNKNOWN							
		Muscle Strain		Cyclobenzaprine			
		Nervousness		Hydrochloride	C		
UNKNOWN							
		Osteoarthritis		Cardizem	C		
UNKNOWN							
		Rales		Propecia	C		
UNKNOWN							
		Raynaud'S Phenomenon		Glucovance	C		
UNKNOWN							
		Respiratory Failure		Hydrocodone			
				Hydrochloride	C		
UNKNOWN							

Date:05/03/04ISR Number: 4351590-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Distension
	Anxiety
	Arthritis
	Asthenia
	Blood Cholesterol Increased
	Blood Pressure Increased
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Clonic Convulsion
	Constipation
	Dyspepsia
	Emotional Distress
	Epilepsy
	Fatigue
	Haematochezia
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Hypoaesthesia
	Hypoaesthesia Oral
	Impaired Work Ability
	Labile Blood Pressure
	Mitral Valve Incompetence
	Myalgia
	Nervous System Disorder

		Osteopenia					
		Paraesthesia					
		Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Valve		Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Simple Partial Seizures		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Plendil	C		
UNKNOWN							
		Incompetence		Dyazide	C		
UNKNOWN							
		Urine Flow Decreased					
		Vision Blurred					
		Weight Increased					

Date:05/03/04ISR Number: 4351608-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
Other	Adrenal Mass
	Angina Unstable
	Antinuclear Antibody Positive
	Aortic Valve Incompetence
	Bacteria Urine Identified
	Cardiac Failure Congestive
	Cataract
	Coronary Artery Disease
	Depression
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Escherichia Urinary Tract Infection
	Fall
	Fatigue
	Feeling Abnormal
	Gastrooesophageal Reflux Disease

Headache
Heart Rate Increased
Hypertension
Hypoglycaemia
Lacunar Infarction
Lipids Increased
Lung Neoplasm
Maculopathy
Mass
Metabolic Alkalosis
Metastasis
Mitral Valve Incompetence
Nocturia
Pleural Effusion
Pulmonary Hypertension
Radius Fracture
Renal Cyst
Renal Failure Chronic

		Respiratory Failure					
		Scoliosis					
		Seasonal Allergy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Lesion		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Darvocet-N	C		
UNKNOWN							
		Stasis Dermatitis		Amitriptyline			
		Tricuspid Valve		Hydrochloride	C		
UNKNOWN							
		Incompetence		Aspirin	C		
UNKNOWN							
		Ventricular Hypertrophy		Pepcid	C		
UNKNOWN							
		Weight Increased		Lasix (Furosemide)	C		
UNKNOWN							
		Wrist Fracture		Hydrodiuril	C		
UNKNOWN							
				Dyrenium	C		
UNKNOWN							
				Vitamins			
				(Unspecified)	C		
UNKNOWN							
				Insulin, Biphasic			
				Isophane [Injection]	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Alupent	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Potassium			
				(Unspecified)	C		
UNKNOWN							

Date:05/03/04ISR Number: 4351613-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-00115157
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 15 DAY	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
36 DAY						
			Acetaminophen And Codeine Phosphate	C		ORAL
			Atenolol	C		ORAL
			Danthron And Poloxamer 188	C		ORAL
			Etidronate Disodium	C		ORAL
			Ranitidine	C		ORAL

Date:05/03/04ISR Number: 4352032-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0404NOR00012
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hyperkalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	International Normalised		Carvedilol	C		ORAL
YR						
	Ratio Abnormal		Digitoxin	C		ORAL
YR						
	Renal Failure		Spironolactone	C		ORAL
YR						
			Warfarin Sodium	C		ORAL
			Vasotec	C		ORAL
			Furosemide	C		ORAL
YR						

Date:05/03/04ISR Number: 4352034-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Cardiac Failure
Disability	Congestive
Other	Chronic Fatigue Syndrome
	Chronic Obstructive

		Pulmonary Disease					
		Convulsion					
		Coronary Artery Disease					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Hyperlipidaemia					
		Hypertension					
		Intervertebral Disc					
		Protrusion					
		Lung Neoplasm					
		Major Depression					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Osteoarthritis					
		Syncope					

Date:05/03/04ISR Number: 4352037-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01516
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Arrest		Beclomethasone			
		Electromechanical		Dipropionate	C		
RESPIRATORY							
		Dissociation					
(INHALATION)							
		Hypertension		Allegra	C		ORAL
		Medication Error		Zocor	C		ORAL
		Nasal Disorder		Adalat	C		ORAL
		Seborrhoeic Keratosis		Zantac	C		ORAL
		Ventricular Fibrillation					
		Vertigo Positional					

Date:05/03/04ISR Number: 4352039-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01901
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Adverse Event Asthenia Circulatory Collapse Haemorrhage Unevaluable Event		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:05/03/04ISR Number: 4352044-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01112
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged Disability	Cerebrovascular Accident Emotional Distress Generalised Anxiety Disorder Heart Rate Irregular Upper Limb Fracture		Vioxx Synthroid	PS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/04ISR Number: 4353213-1Report Type:Direct Company Report #CTU 217862
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperkalaemia		Refecoxib	PS			12.5 MG QD	
			Lisinopril	SS			20 MG QD	
			Lovastatin	C				
			Metoprolol	C				
			Aspirin	C				
			Misoprostol	C				
			Hydrochlorothiazide	C				
			Methocarbamol	C				
			Oxybutynin	C				
			Ranitidine	C				

Date:05/04/04ISR Number: 4352639-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0309DEU00119
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Life-Threatening	Intravascular Coagulation		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY	
	Hepatitis Toxic		Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY	
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY	
	Rhabdomyolysis		Amiodarone Hydrochloride	C		ORAL	2 DAY	
			Sultamicillin Tosylate	C			UNKNOWN	
			Theophylline	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Magnesium (Unspecified)	C			UNKNOWN	

			Pantoprazole Sodium	C			
UNKNOWN							
			Prednisolone	C			
UNKNOWN							

Date:05/04/04ISR Number: 4352641-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02113
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Atherosclerosis		Atenolol	C				
UNKNOWN								
Other	Back Pain		Premarin	C				
UNKNOWN								
	Blood Cholesterol		Premarin	C				
UNKNOWN								
	Increased		Plendil	C		ORAL		
	Blood Creatinine		Levoxyl	C		ORAL		
	Increased		Levoxyl	C		ORAL		
	Blood Triglycerides		Zoloft	C		ORAL		
	Increased		Zoloft	C		ORAL		
	Breath Sounds Decreased		Levoxyl	C		ORAL		
	Cholelithiasis		Zestril	C		ORAL		
	Dizziness		Zestril	C		ORAL		
	Gastrooesophageal Reflux		Zestril	C		ORAL		90 DAY
	Disease		Zestril	C		ORAL		
	Haemorrhoids							
	Headache							
	Hypertension							
	Hypokalaemia							
	Injury							
	Pleuritic Pain							
	Pneumonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/04ISR Number: 4352645-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00089
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Distress Syndrome		Carbamazepine	C		ORAL		
	White Blood Cell Count Increased		Topiramate	C		ORAL		
			Valproate Sodium	C		ORAL		
			Phenobarbital	C		ORAL		

Date:05/04/04ISR Number: 4352649-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01964
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Membranous		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Prescribed Overdose		Percocet	C			UNKNOWN	
			Senna	C			UNKNOWN	
			Toradol	C			INTRAVENOUS	
			Zofran	C			UNKNOWN	

Date:05/04/04ISR Number: 4352650-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00204
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
Other	Diarrhoea		Levothyroxine Sodium	C			UNKNOWN	
			Meloxicam	C			UNKNOWN	
			Potassium Bicarbonate And					

Sodium Alginate C
UNKNOWN

Date:05/04/04ISR Number: 4352962-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acidosis
Other	Adrenal Insufficiency
	Arteriosclerosis
	Asthma
	Bacteraemia
	Bacterial Infection
	Candidiasis
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Colitis
	Decubitus Ulcer
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Duodenitis
	Dyspepsia
	Escherichia Infection
	Fatigue
	Fungaemia
	Gastritis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Gastrointestinal Haemorrhage					
		Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Glaucoma		Catapres	C		
UNKNOWN	347 DAY						
		Gynaecomastia		Lasix (Furosemide)	C		
UNKNOWN							
		Haemorrhoids		Micardis	C		
UNKNOWN							
		Headache		Lasix (Furosemide)	C		
UNKNOWN							
		Hepatic Steatosis		Cozaar	C		
UNKNOWN							
		Hiatus Hernia					
		Hypercoagulation					
		Hyperglycaemia					
		Hypertension					
		Incisional Hernia					
		Inguinal Hernia					
		Injury					
		Malnutrition					
		Normochromic Normocytic Anaemia					
		Obesity					
		Oesophagitis					
		Optic Neuropathy					
		Otitis Media					
		Pickwickian Syndrome					
		Pneumonia					
		Postoperative Fever					
		Pseudomonas Infection					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Refractory Anaemia					
		Renal Failure Acute					
		Rheumatoid Arthritis					
		Sepsis					
		Sputum Culture Positive					
		Staphylococcal Infection					
		Syncope Vasovagal					
		Thrombocytopenia					
		Thrombosis					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vertigo					

Date:05/04/04ISR Number: 4353173-3Report Type:Direct Company Report #CTU 217949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Vioxx	PS			25 MG ONE QD	

Date:05/04/04ISR Number: 4355125-6Report Type:Expedited (15-DaCompany Report #GBR-2004-0001028
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Oxycontin					
Other	Delusional Disorder, Persecutory Type	Health Professional	Tablets(Oxycodone Hydrochloride) Cr					
	Disorientation	Other	Tablet	PS		ORAL	40 MG ,	
	Hallucination						DAILY, ORAL	
	Mental Disorder		Laroxyl(Amitriptylin e Hydrochloride)	SS		ORAL	5 DROP ,	

DAILY, ORAL

			Vioxx(Rofecoxib)	SS		ORAL
ORAL						

Date:05/04/04ISR Number: 4355399-1Report Type:Expedited (15-DaCompany Report #200303111
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Dizziness	Foreign	Tylenol Analgesic			
Intervention to	Intentional Misuse	Health	Unknown			
Prevent Permanent	Suicide Attempt	Professional	(Acetaminophen)	PS		ORAL
PO						
Impairment/Damage	Vomiting	Other	Ketoprofen	SS		ORAL
PO						
			Naphazoline	SS		ORAL
PO						
			Metamizole	SS		ORAL
PO						
			Rofecoxib	SS		ORAL
PO						
			Cefadroxila	SS		
			Metamizole/Orphenadr			
			ine/Caffeine	SS		ORAL
PO						

Date:05/05/04ISR Number: 4353495-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Pulmonary Oedema		Amitriptyline			
Other	Anaemia		Hydrochloride	SS		ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
	Cataract		[Therapy			

	Cholelithiasis	Unspecified]	C	
UNKNOWN				
	Contusion	Tylenol	C	
UNKNOWN				
	Coronary Artery Disease	Aspirin	C	
UNKNOWN				
	Dehydration	Buspirone		
	Drug Ineffective	Hydrochloride	C	
UNKNOWN				
	Electrocardiogram Qt	Aricept	C	ORAL
	Prolonged	Fluoxetine	C	
UNKNOWN				
	Fall	Lorazepam	C	
UNKNOWN				
	Fat Embolism	Ambien	C	
UNKNOWN				
	Femur Fracture	Metoclopramide	C	
UNKNOWN				
	Gastroenteritis	Prozac	C	
UNKNOWN				
	Gastrooesophageal Reflux	Premarin	C	ORAL
	Disease	Valium	C	
UNKNOWN				
	Hypertension	Aspirin	C	
UNKNOWN				
	Laceration	Vicodin Tablets	C	
UNKNOWN				
	Lacunar Infarction	Darvocet-N	C	
UNKNOWN				
	Nausea			
	Pain			
	Pollakiuria			
	Rotator Cuff Syndrome			
	Skin Ulcer			
	Spinal Compression			
	Fracture			
	Suicidal Ideation			
	Urinary Tract Infection			
	Vomiting			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/04ISR Number: 4353501-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		257 DAY

Date:05/05/04ISR Number: 4353743-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Alcohol Withdrawal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		Tylenol	C			UNKNOWN	
	Cardiac Failure		Saw Palmetto	C			UNKNOWN	
	Congestive		Ultram	C			UNKNOWN	
	Cellulitis		Lipitor	C			UNKNOWN	
	Cerebral Ischaemia		Lumigan	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Corticosteroids (Unspecified)	C			PARENTERAL	
	Colitis Ischaemic		Betagan	C			UNKNOWN	
	Confusional State		Relafen	C			UNKNOWN	
	Congestive Cardiomyopathy		Paxil	C			UNKNOWN	
	Coronary Artery Disease							
	Delirium							
	Depression							
	Diarrhoea							
	Drug Hypersensitivity							
	Dysphagia							
	Gastroenteritis							

Headache
Hypertension
Hypoaesthesia
Ileus
Inguinal Hernia
Liver Function Test
Abnormal
Myocardial Infarction
Nodal Arrhythmia
Osteoarthritis
Osteoporosis
Paraesthesia
Periorbital Haematoma
Spinal Column Stenosis
Staphylococcal Sepsis
Tachycardia

Date:05/05/04ISR Number: 4353745-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-00065503
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Hospitalization - Initial or Prolonged	Positive		Diclofenac Sodium	SS		ORAL		
	Cholestasis		Equilin Sodium Sulfate And Estrone Sodium Sulfate Hydrochlorothiazide	SS		ORAL		
	Dialysis							
	Hepatic Failure							
	Pruritus							

			And Quinapril	SS	ORAL
			Isosorbide-5-Mononit rate	SS	ORAL
			Vioxx	SS	Merck & Co., Inc ORAL
3 MON					
			Medrogestone	SS	ORAL
			Metoprolol Succinate	SS	ORAL
			Phenprocoumon	SS	ORAL

Date:05/05/04ISR Number: 4353746-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0404AUS00074
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 32 DAY	Eosinophilic Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:05/05/04ISR Number: 4353750-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder		Darvocet-N	C				
UNKNOWN								
	Adrenal Adenoma		Amitriptyline					
	Aneurysm		Hydrochloride	C				
UNKNOWN								
	Blood Cholesterol		Meclizine	C				
UNKNOWN								
	Increased Breast Microcalcification							
	Cerebrovascular Accident							
	Chronic Obstructive Pulmonary Disease							
	Colon Adenoma							
	Colonic Polyp							
	Complex Regional Pain Syndrome							
	Depression							
	Diverticulum							
	Diverticulum Intestinal							

Dizziness
Emotional Distress
Facial Palsy
Hyperlipidaemia
Hypoaesthesia
Impaired Driving Ability
Joint Dislocation
Lacunar Infarction
Large Cell Carcinoma Of
The Respiratory Tract
Stage Unspecified
Mitral Valve Incompetence
Pneumonia
Pneumothorax
Post Procedural
Complication
Stress Incontinence
Ventricular Extrasystoles

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/04ISR Number: 4353753-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0404SWE00015
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Acetylcysteine	C			UNKNOWN	
			Amiloride Hydrochloride And Hydrochlorothiazide	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	

Date:05/05/04ISR Number: 4353755-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02296
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON	
	Weight Decreased		Calcium (Unspecified)	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

Date:05/05/04ISR Number: 4356012-XReport Type:Expedited (15-DaCompany Report #WAES 0211USA01496
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Study	Tab Vioxx Unk	PS		ORAL	50	

Initial or Prolonged	Congestive	Health				
MG/DAILY/PO						
	Cardiomyopathy	Professional	Tab Acetaminophen			
	Dementia Alzheimer'S Type		325 Tablet	SS		ORAL
PRN/PO						
	Electrocardiogram Change		Centrum Silver	C		
	Renal Failure		Di-Gel	C		
	Ventricular Dysfunction		Reminyl	C		
			Tylenol Sinus	C		
			Vasotec	C		
			Zantac	C		
			Malathion	C		

Date:05/05/04ISR Number: 4356018-0Report Type:Expedited (15-DaCompany Report #WAES 0403USA00135
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Activities Of Daily	Study	Tab Vioxx Unk	PS		
Initial or Prolonged	Living Impaired	Health	Blinded Therapy Unk	SS		
	Arthralgia	Professional	Celebrex	SS		
	Depression		Levaquin Unk	SS		
	Drug Hypersensitivity		Lipitor	C		
	Duodenitis		Vicodin Es Tablets	C		
	Dyspnoea					
	Gastritis					
	Joint Swelling					
	Pyrexia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/04ISR Number: 4354191-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00007
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:05/06/04ISR Number: 4354192-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:05/06/04ISR Number: 4354193-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01621
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Hospitalization - Initial or Prolonged	Hypertension		Lisinopril	C				
	Left Ventricular Failure		Toprol Xl Tablets	C				
	Ventricular Dysfunction		Zocor	C				
			Protonix	C				
			Exelon	C				

Date:05/06/04ISR Number: 4354195-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00009
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Hospitalization - Initial or Prolonged	Tachyarrhythmia						

Date:05/06/04ISR Number: 4354198-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased		Coumadin	C				
	Chest Pain							

Date:05/06/04ISR Number: 4354366-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104504
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Contusion							
	Emotional Distress							
	Foot Fracture							
	Fracture Nonunion							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Oedema							
	Renal Failure							
	Rheumatoid Arthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/04ISR Number: 4354368-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		532 DAY
Initial or Prolonged Disability	Angina Pectoris		[Therapy Unspecified]	C				UNKNOWN
	Anxiety		Tylenol	C				UNKNOWN
	Blood Cholesterol Increased		Proventil	C				UNKNOWN
	Blood Pressure Decreased		Buspar	C				UNKNOWN
	Calcinosis		Cipro	C				UNKNOWN
	Chronic Obstructive Pulmonary Disease		Tranxene	C				UNKNOWN
	Coronary Artery Occlusion		Diphenhydramine Citrate	C				UNKNOWN
	Diverticulum Intestinal		Epi-Pen	C				UNKNOWN
	Drug Ineffective		Allegra	C				UNKNOWN
	Ejection Fraction Decreased		Duratuss	C				UNKNOWN
	Emotional Distress		Hydroxyzine Pamoate	C				UNKNOWN
	Gastritis		Motrin	C				UNKNOWN
	Gastritis Erosive		Loperamide Hydrochloride	C				UNKNOWN
	Gastritis Haemorrhagic		Methylprednisolone	C				UNKNOWN
	Gastrointestinal		Nasonex	C				UNKNOWN
	Haemorrhage		Elocon	C				UNKNOWN
	Haematuria		Actonel	C				UNKNOWN
	Haemorrhoids		Ultram	C				UNKNOWN
	Hypertension							

Myocardial Infarction
Pain
Pain In Extremity
Proctitis
Stress
Thrombosis
Upper Gastrointestinal
Haemorrhage
Upper Respiratory Tract
Infection
Urinary Tract Infection
Weight Decreased

Date:05/06/04ISR Number: 4354369-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00114
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:05/06/04ISR Number: 4354370-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00091
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Initial or Prolonged	Increased		Acetaminophen	C		ORAL		
	Aspartate		Lorazepam	C		ORAL		
	Aminotransferase		Minocycline	C		ORAL		
	Increased							
	Drug Eruption							
	Hepatitis Cholestatic							
	Pain							
	Skin Exfoliation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/04ISR Number: 4354373-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01629
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		[Therapy Unspecified]	C		UNKNOWN		
	Myocardial Infarction		Methadone Hydrochloride	C		UNKNOWN		

Date:05/06/04ISR Number: 4354374-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00558
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Caesarean Section		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Complications Of Maternal Exposure To Therapeutic Drugs							
	Drug Exposure During Pregnancy							
	Impetigo							
	Oligohydramnios							
	Ovarian Epithelial Cancer							
	Pregnancy							
	Prescribed Overdose							

Date:05/06/04ISR Number: 4354375-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01472
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	32	HR
	Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	96	DAY

Date:05/06/04ISR Number: 4354376-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01949
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Blood Glucose Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Femoral Arterial Stenosis		Lasix (Furosemide)	C				
	Halitosis		Humulin	C				
	Hypertension							
	Lacunar Infarction							
	Localised Infection							
	Oedema							
	Pain							
	Pain In Extremity							
	Popliteal Stenosis							
	Rectal Haemorrhage							
	Skin Candida							
	Transient Ischaemic Attack							
	Vaginal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/04ISR Number: 4354377-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vicodin Tablets	C				UNKNOWN
	Restenosis		Aspirin	C		ORAL		
	Hypertension		Lipitor	C		ORAL		
	Hypotension		Plavix	C		ORAL		41 DAY
	Ischaemic Cardiomyopathy		Plavix	C		ORAL		
	Musculoskeletal		Plavix	C		ORAL		41 DAY
	Discomfort		Flomax (Tamsulosin Hydrochloride)	C				UNKNOWN
	Myocardial Infarction							
	Sick Sinus Syndrome		Plavix	C		ORAL		
			Colace	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Prinivil	C		ORAL		
			Zestril	C				UNKNOWN

Date:05/06/04ISR Number: 4356368-8Report Type:Expedited (15-DaCompany Report #K200400654
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation	Health Professional Other	Altace Capsules (Ramipril) Capsule, 10 Mg	PS		ORAL	10 MG, QD,	ORAL
Hospitalization - Initial or Prolonged	Anaemia							
	Coordination Abnormal							
	Depression							
	Drug Level Increased		Vioxx (Rofecoxib) 25 Mg	SS		ORAL	25 MG, QD,	
	Drug Toxicity							

		Jaundice				
ORAL						
		Mental Status Changes	Aspirin "Bayer" (Acetylsalicylic Acid) Tablet 81 Mg	SS	Bayer	
			Pegintron "Schering-Plough (Peginterferon Alfa-2b) Injection, 96mcg	SS		
SUBCUTANEOUS	96 MCG, QWK,					
SUBCUTANEOUS						
			Rebetol (Ribavirin) Capsule, 800 Mcg	SS		ORAL
800 MG, QD,						
ORAL						
			Lithium (Lithium) 300 Mg	SS		
300 MG, BID						
			Geodon (Ziprasidone Hydrochloride)	C		
			Zyprexa (Olanzapine)	C		
			Lexapro (Escitalopram Oxalate)	C		
			Protonix (Pantoprazole)	C		
			Neurontin	C		
			Clonazepam (Clonazepam)	C		
			Hydrocodone	C		
			Phenergan (Promethazine Hydrochloride)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4354778-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01260
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Fosamax	C			UNKNOWN	
	Cardiac Murmur		Atacand	C			UNKNOWN	
	Carpal Tunnel Syndrome		Celebrex	C		ORAL		
	Chest Pain		Estratest	C			UNKNOWN	
	Dizziness		Allegra	C			UNKNOWN	
	Dyspnoea		Motrin	C			UNKNOWN	
	Electrocardiogram T Wave		Motrin	C			UNKNOWN	
	Abnormal		Indomethacin	C		ORAL		
	Genital Rash		Synthroid	C		ORAL		
	Headache		Methotrexate (Methotrexate Sodium)	C			UNKNOWN	
	Hypertension							
	Injury							
	Mitral Valve Incompetence							
	Osteoarthritis							
	Pain							
	Pain In Extremity							
	Paraesthesia							
	Tinnitus							
	Tricuspid Valve Incompetence							
	Urinary Tract Infection							
	Ventricular Hypertrophy							
	Vision Blurred							

Date:05/07/04ISR Number: 4354780-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01102173
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardio-Respiratory Arrest	Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY					
Other	Cold Sweat	Vioxx	SS	Merck & Co., Inc	ORAL
	Hypersensitivity	Vioxx	SS	Merck & Co., Inc	ORAL
	Muscle Strain	Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY					
	Myocardial Infarction	Hydrodiuril	C		
UNKNOWN					
	Nasopharyngitis	Atenolol	C		
UNKNOWN					
	Nausea	Prevacid	C		
UNKNOWN					
	Patellofemoral Pain	Claritin	C		
UNKNOWN					
	Syndrome				
	Sudden Death				
	Vomiting				

Date:05/07/04ISR Number: 4354781-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Back Injury
Disability	Blood Pressure Increased
Other	Blood Triglycerides
	Increased
	Cellulitis
	Cerebrovascular Accident
	Chest Pain

Dose	Duration	Coagulopathy Diabetes Mellitus Inadequate Control	Report Source	Product	Role	Manufacturer	Route
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Ejaculation Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Erectile Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Tylenol	C		
UNKNOWN							
		Hypoaesthesia		Augmentin	C		
UNKNOWN							
		Joint Effusion		Aspirin	C		
UNKNOWN							
		Nausea		Lipitor	C		
UNKNOWN							
		Pain In Extremity		Betoptic	C		
UNKNOWN							
		Road Traffic Accident		Cipro	C		
UNKNOWN							
		Sinus Disorder		Cardura	C		
UNKNOWN	255 DAY						
		Treatment Noncompliance		Allegra	C		
UNKNOWN							
		Whiplash Injury		Amaryl	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN	1106 DAY						
				Ibuprofen	C		
UNKNOWN							
				Avapro	C		
UNKNOWN	60 DAY						
				Xalatan	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN	82 DAY						
				Niacin	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							

Date:05/07/04ISR Number: 4354782-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00024
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL	143 DAY	
			Clobetasone Butyrate	C		TOPICAL		
			Hydrocortisone Butyrate	C		TOPICAL		
			Omeprazole	C		ORAL		

Date:05/07/04ISR Number: 4354784-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	26 DAY	
Initial or Prolonged	Azotaemia		[Therapy Unspecified]	C		UNKNOWN		
	Bursitis							
	Cerebrovascular Accident		Aspirin	C		UNKNOWN		
	Confusional State		Aspirin	C		UNKNOWN		
	Disorientation		Lipitor	C		UNKNOWN		
	Fall		Persantine	C		UNKNOWN		
	Head Injury		Coenzyme Q10	C		UNKNOWN		
	Hypoglycaemia		Amaryl	C		UNKNOWN		
	Injury		Glucophage	C		UNKNOWN		
	Mental Status Changes		Actos	C		UNKNOWN		
	Sinus Polyp		Zantac	C		UNKNOWN		
	Sinusitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4354789-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Blindness		Yasmin	SS				
UNKNOWN							14 DAY	
Disability	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Sandimmun	C				UNKNOWN
	Coordination Abnormal		Sandimmun	C				UNKNOWN
	Deep Vein Thrombosis		Prelone Syrup	C				UNKNOWN
	Depressed Level Of		Prednisone	C				UNKNOWN
	Consciousness		Prelone Syrup	C				UNKNOWN
	Depression		Hormonal					
	Diabetes Mellitus		Contraceptives					
	Non-Insulin-Dependent		(Unspecified)	C				INTRAMUSCULAR
	Dyspepsia		Sandimmun	C				UNKNOWN
	Electrocardiogram St-T							
	Change							
	Electrocardiogram T Wave							
	Abnormal							
	Fall							
	Gastritis							
	Hair Disorder							
	Heart Rate Irregular							
	Hydrocephalus							
	Hypochromic Anaemia							
	International Normalised							
	Ratio Decreased							
	Intracranial Venous Sinus							
	Thrombosis							
	Joint Effusion							
	Male Pattern Baldness							

Muscle Disorder
Nausea
Optic Nerve Injury
Papilloedema
Paraesthesia
Photophobia
Rash
Sinus Tachycardia
Sneezing
Subarachnoid Haemorrhage
Tinnitus
Uterine Leiomyoma
Vomiting
Weight Loss Poor

Date:05/07/04ISR Number: 4354791-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01209
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Swollen Tongue		[Therapy Unspecified]	C				UNKNOWN
			Tums	C				UNKNOWN
			Tigan	C				UNKNOWN
			Imodium	C				UNKNOWN

				Nystatin Usp (Paddock)	C		
UNKNOWN							

Date:05/07/04ISR Number: 4354792-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02003
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ruptured Cerebral Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:05/07/04ISR Number: 4354890-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02433
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Calcification		Acetaminophen And Codeine	C				
UNKNOWN								
	Atherosclerosis		Norvasc	C				
UNKNOWN								
	Cardiomegaly		Trimox	C				
UNKNOWN								
	Contusion		Aspirin	C				
UNKNOWN								
	Coronary Artery Stenosis		Armour Thyroid Tablets	C				
	Coronary Artery							
UNKNOWN								
	Thrombosis		Hytrin	C				
UNKNOWN								
	Hepatic Congestion		Vasotec	C		ORAL		
	Hepatic Steatosis		Glucophage	C				
UNKNOWN								
	Hepatomegaly		Metronidazole	C				
UNKNOWN								
	Myocardial Rupture							
	Nephrosclerosis							
	Pericardial Haemorrhage							
	Polycystic Ovaries							
	Pulmonary Congestion							

Pulmonary Oedema
Renal Disorder
Road Traffic Accident
Spleen Congestion
Vascular Calcification

Date:05/07/04ISR Number: 4354893-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Back Pain
Disability	Blindness
Other	Cataract
	Cerebrovascular Accident
	Depression
	Endometrial Hyperplasia
	Epistaxis
	Flushing
	Gastrooesophageal Reflux
	Disease
	Gout
	Haemorrhage Intracranial
	Headache
	Hemianopia Homonymous
	Herpes Zoster
	Hyperhidrosis

		Hypertension					
		Joint Injury					
		Nasal Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Heparin	SS		
UNKNOWN							
		Pallor		Provera	SS		
UNKNOWN							
		Pneumonia		[Therapy			
		Rash		Unspecified]	C		
UNKNOWN							
		Rift Valley Fever		Tylenol With Codeine			
		Sciatica		#3	C		
UNKNOWN							
		Tachycardia		Captopril	C		
UNKNOWN							
		Thyroid Mass		Capozide	C		
UNKNOWN							
		Uterine Polyp		Cisapride	C		
UNKNOWN							
		Vaginal Haemorrhage		Glyburide	C		
UNKNOWN							

Date:05/07/04ISR Number: 4354894-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Arrhythmia		Allopurinol	C		
UNKNOWN							
		Chest Pain		Advil	C		
UNKNOWN							
		Dermatitis		Indocin			
		Diarrhoea		(Indomethacin)	C		ORAL
		Drug Ineffective		Noritate	C		
UNKNOWN							
		Dyspnoea					
		Emotional Distress					
		Fatigue					
		Gouty Arthritis					
		Headache					
		Hypoaesthesia					
		Hypotension					

Intercostal Neuralgia
Mental Disorder
Nausea
Paraesthesia
Rosacea
Silent Myocardial
Infarction
Sinusitis
Spinal Osteoarthritis

Date:05/07/04ISR Number: 4354897-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		243 DAY
Hospitalization - Initial or Prolonged	Angina Pectoris		Tylenol Extra Strength	C				UNKNOWN
	Aortic Atherosclerosis		Lasix (Furosemide)	C				UNKNOWN
	Cerebral Infarction		Centrum	C				UNKNOWN
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Disease							
	Heparin-Induced Thrombocytopenia							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4354899-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02438
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatine Phosphokinase Increased							
	Cerebrovascular Accident							
	Coagulopathy							

Date:05/07/04ISR Number: 4354900-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
19 DAY								
Initial or Prolonged	Apathy		Vioxx	SS	Merck & Co., Inc	ORAL		
15 DAY								
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Autonomic Nervous System		Valium	C				
UNKNOWN								
	Imbalance		Neurontin	C				
UNKNOWN								
	Blood Bilirubin		Neurontin	C				
UNKNOWN								
	Unconjugated Increased		Neurontin	C				
UNKNOWN								
	Blood Pressure Increased		Neurontin	C				
UNKNOWN								
	Bradycardia		Avapro	C				
UNKNOWN								
	Chronic Obstructive		Misoprostol	C				
UNKNOWN								
	Pulmonary Disease		Macrodantin	C				
UNKNOWN								
	Constipation		Nortriptyline	C				
UNKNOWN								
	Dehydration		Nortriptyline	C				
UNKNOWN								
	Dementia							
	Depression							
	Diverticulum							
	Fall							

Feeling Cold
Femur Fracture
Gastritis
Haemorrhagic Stroke
Hiatus Hernia
Hyperglycaemia
Hyponatraemia
Inappropriate
Antidiuretic Hormone
Secretion
Lung Neoplasm
Pain
Pelvic Pain
Pollakiuria
Proctitis
Prostatitis
Pyelonephritis
Rectal Cramps
Sinusitis
Sleep Apnoea Syndrome
Urethral Stricture
Urinary Tract Infection
Bacterial
Urinary Tract Infection
Pseudomonal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4354901-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02596
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage							

Date:05/07/04ISR Number: 4354902-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Occlusion		Aspirin	C			UNKNOWN	
	Dysphagia		Soma	C			UNKNOWN	
	Emotional Distress		Cardizem	C			UNKNOWN	
	Gastrooesophageal Reflux		Lasix (Furosemide)	C			UNKNOWN	
	Disease		Aleve	C			UNKNOWN	
	Haematoma		Nitroglycerin	C			UNKNOWN	
	Hypercholesterolaemia		Paxil	C			UNKNOWN	
	Hypertension		K-Dur	C			UNKNOWN	
	Myocardial Infarction		Accupril	C			UNKNOWN	
	Pain							

Date:05/07/04ISR Number: 4354903-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	450	DAY

Initial or Prolonged	Infarction	Vioxx	SS	Merck & Co., Inc	ORAL	450 DAY
	Anaemia	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN
	Asthenia	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN
	Atelectasis	Lorcet Plus	C			UNKNOWN
	Blood Pressure Increased	Combivent	C			UNKNOWN
	Cardiac Failure	Aspirin	C			UNKNOWN
	Congestive	Lipitor	C			UNKNOWN
	Chronic Obstructive	Rhinocort	C			UNKNOWN
	Pulmonary Disease	Wellbutrin	C			UNKNOWN
	Coronary Artery Disease	Coreg	C			UNKNOWN
	Dizziness	Tagamet	C			UNKNOWN
	Gout	Biaxin	C			UNKNOWN
	Hepatic Enzyme Increased	Plavix	C			UNKNOWN
	Hypercholesterolaemia	Cyclobenzaprine				
	Hypertensive	Hydrochloride	C			UNKNOWN
	Cardiomyopathy	Valium	C			UNKNOWN
	Hypertensive Heart	Valium	C			UNKNOWN
	Disease	Benadryl	C			UNKNOWN
	Hypokalaemia	Prempro	C			UNKNOWN
	Hypoxia	Advair	C			UNKNOWN
	Ischaemia	Prolex Dh	C			UNKNOWN
	Lung Disorder	Mavik	C			UNKNOWN
	Mitral Valve Incompetence	Detrol	C			UNKNOWN
	Myocardial Infarction	Micardis	C			UNKNOWN
	Palpitations	Hydrocodone				
	Pulmonary Oedema	Hydrochloride	C			UNKNOWN
	Respiratory Failure	Motrin	C			UNKNOWN
	Syncope	Motrin	C			UNKNOWN

	Syncope Vasovagal	Toprol Xl Tablets	C
UNKNOWN			
	Ventricular Arrhythmia	Daypro	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/04ISR Number: 4354904-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00115
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Exposure During Pregnancy							
	Pregnancy							

Date:05/07/04ISR Number: 4354905-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0404DEU00015
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		18 DAY
Hospitalization -	Coronary Artery Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Coronary Artery Disease		Candesartan					
	Coronary Artery Occlusion		Cilexetil	C			UNKNOWN	
	Myocardial Infarction		Torsemide	C			UNKNOWN	
			Miglitol	C			UNKNOWN	

Date:05/07/04ISR Number: 4354906-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0404DEU00171
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Sensation Of Foreign Body							

Date:05/07/04ISR Number: 4354910-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension

Initial or Prolonged Disability	Anxiety
	Atelectasis
	Back Pain
	Blood Ph Decreased
	Blood Pressure Decreased
	Bronchitis
	Bronchopneumonia
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Clostridium Colitis
	Dizziness
	Fatigue
	Fluid Retention
	Gastrooesophageal Reflux
	Disease
	Haematochezia
	Headache
	Hyperlipidaemia
	Hypokalaemia
	Hypoxia
	Ileus
	Lobar Pneumonia
	Mitral Valve Incompetence

		Mitral Valve Prolapse Myocardial Infarction Nephrolithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL
560	DAY						
		Pneumonia Pneumonia Aspiration		Amitriptyline Hydrochloride	C		
UNKNOWN							
		Pneumonia Pneumococcal		Celexa	C		
UNKNOWN							
		Pulmonary Fibrosis		Nexium	C		
UNKNOWN							
		Pyrexia		Lasix (Furosemide)	C		
UNKNOWN							
		Rash		Lasix (Furosemide)	C		
UNKNOWN							
		Renal Failure Acute		Zanaflex	C		
UNKNOWN							
		Respiratory Failure		Ultram	C		
UNKNOWN							
		Rhabdomyolysis		Ambien	C		
UNKNOWN							
		Scar		Diovan	C		
UNKNOWN							
		Sinus Tachycardia		Torsemide	C		
UNKNOWN							
		Sinusitis		Neurontin	C		
UNKNOWN							
		Staphylococcal Infection		Zaroxolyn	C		
UNKNOWN							
		Streptococcal Infection		Aleve	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:05/07/04ISR Number: 4354911-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02516
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL

Attack

Date:05/07/04ISR Number: 4355877-5Report Type:Direct Company Report #CTU 218127
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Rofecoxib 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Heart Rate Decreased						ORAL	
Required	Helicobacter Infection		Alendronate	C				
Intervention to	Mental Status Changes		Asprin	C				
Prevent Permanent	Upper Gastrointestinal		Lisinopril	C				
Impairment/Damage	Haemorrhage		Atenolol	C				
			Ferrous Sulfate	C				
			Megace	C				
			Mvi	C				
			Tramadol	C				
			Gabapentin	C				
			Caco3/Vitamin D	C				
			Vitamin C	C				
			Amitriptyline	C				

Date:05/07/04ISR Number: 4356774-1Report Type:Expedited (15-DaCompany Report #2004023410
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Compression Fracture
Initial or Prolonged	Convulsion
Other	Hyponatraemia
	Muscle Spasms
	Nausea
	Neuralgia

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health	Neurontin (Gabapentin)	PS		ORAL	600 MG (BID), ORAL	
Professional						
	Rofecoxib (Rofecoxib)	SS				
	Ibuprofen (Ibuprofen)	C				
	Lotrel (Amlodipine, Benazepril Hydrochloride)	C				
	Alendronate Sodium (Alendronate Sodium)	C				
	Provella-14 (Estrogens Conjugated, Medroxyprogesterone Acetate)	C				

Date:05/07/04ISR Number: 4356962-4Report Type:Expedited (15-DaCompany Report #200403667
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrotic Syndrome Renal Failure Chronic	Consumer Health	Unspecified Motrin Product (Ibuprofen)	PS			UP TO 4 DAILY	
	Weight Decreased	Professional	Celebrex (Celecoxib)	SS		ORAL	100 MG BID PRN, PO	
		Other						
			Vioxx (Rofecoxib)	SS		ORAL	12.5-50 MG DAILY, PRN, PO	
			Ultram (Tramadol Hydrochloride)	SS		ORAL	50-100MG,	

Q6H, PRN, PO			
	Ketorolac	SS	ORAL
10MG Q6H, PRN, PO			
	Vicoprofen (Hydrocodone Bitartrate; Ibuprofen)	SS	ORAL
1 TAB Q8H, PRN, PO			
	Hydrocodone With Acetaminophen	SS	ORAL
5/500 Q4-6H, PRN, PO			
	Acetaminophen With Codeine	SS	ORAL
1-2 TABS Q6H, PRN, PO			
	Excedrin (Salicylamide)	SS	

Date:05/10/04ISR Number: 4355456-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abdominal Pain Upper
Other	Atherosclerosis
	Blood Cholesterol

Increased
Cerebrovascular Accident
Drug Hypersensitivity
Hernia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Darvocet-N	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Metformin	C			UNKNOWN	
	Zantac	C			UNKNOWN	

Hypertension
Liver Disorder
Myocardial Infarction
Non-Hodgkin'S Lymphoma
Simple Partial Seizures
Transient Ischaemic
Attack
Tuberculosis

Date:05/10/04ISR Number: 4355460-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01061634
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Anorexia
Other	Anxiety
	Arthropathy
	Blood Pressure Increased
	Bloody Discharge
	Cardiac Procedure
	Complication
	Cerebrovascular Accident
	Chills
	Cholelithiasis
	Obstructive
	Colonic Polyp
	Contusion
	Coronary Artery
	Atherosclerosis
	Depressed Mood
	Diabetes Mellitus
	Inadequate Control
	Diarrhoea
	Dyspepsia
	Dyspnoea Exertional

Fungal Infection
Gastric Haemorrhage
Gastritis
Gingival Disorder
Hypertensive Heart
Disease
Insomnia
Intervertebral Disc
Protrusion
Intestinal Functional
Disorder
Myocardial Infarction
Nausea
Night Sweats
Ocular Hyperaemia
Oedema Peripheral
Osteopenia
Pain
Peripheral Vascular
Disorder
Pneumonia

		Postinfarction Angina					
		Retroperitoneal Haematoma					
		Rheumatoid Arthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Supraventricular		Vioxx	PS	Merck & Co., Inc	ORAL
		Tachycardia		Fosamax	SS		ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tremor		Lortab	C		ORAL
		Urinary Tract Infection		Norvasc	C		ORAL
		Vaginal Erythema		Humulin N	C		
UNKNOWN							
		Ventricular Tachycardia		Septra	C		ORAL
		Vertigo		Zanaflex	C		
UNKNOWN							
		Vomiting		Septra	C		ORAL
		Weight Decreased		Synthroid	C		ORAL
				Robaxin	C		
UNKNOWN							
				Synthroid	C		ORAL
				Plavix	C		
UNKNOWN							
				Lortab	C		ORAL

Date:05/10/04ISR Number: 4355466-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Anxiety
	Aortic Valve Incompetence
	Atrial Fibrillation
	Blood Pressure Inadequately Controlled
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chest Pain
	Chondrocalcinosis Pyrophosphate
	Colon Cancer Recurrent
	Colonic Polyp
	Coronary Artery Disease
	Diarrhoea

Dizziness
Dysphagia
Emotional Distress
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Inner Ear Disorder
Mitral Valve Incompetence
Osteoarthritis
Photosensitivity Reaction
Pleuritic Pain
Renal Cyst
Renal Failure
Thrombophlebitis
Tooth Infection
Tricuspid Valve
Incompetence
Umbilical Hernia

	Urinary Tract Infection						
	Vein Pain						
	Vertigo	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C			UNKNOWN	
			Glipizide	C			UNKNOWN	

Date:05/10/04ISR Number: 4355467-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Clonidine	C			UNKNOWN	
	Depression		Metabolife 356	C			UNKNOWN	
	Emotional Distress		Hydrochlorothiazide	C			UNKNOWN	
	Oedema Peripheral		Adalat	C			UNKNOWN	
	Pain		Potassium Chloride	C			UNKNOWN	
	Renal Disorder		Zantac	C			UNKNOWN	
	Renal Failure							
	Thrombosis							
	Weight Increased							

Date:05/10/04ISR Number: 4355470-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Adhesions
Initial or Prolonged	Abdominal Pain Upper
Disability	Acute Coronary Syndrome
Other	Anaemia
	Angina Unstable
	Anxiety

Arrhythmia
Back Injury
Blood Pressure
Inadequately Controlled
Bronchitis Acute
Conjunctival Haemorrhage
Contusion
Coronary Arterial Stent
Insertion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery
Restenosis
Coronary Artery Stenosis
Depression
Dilatation Atrial
Duodenitis
Dyspepsia
Extrasystoles
Fall
Gastritis
Gastrointestinal
Haemorrhage
Haematochezia
Headache

		Hypertension					
		Hypoaesthesia					
		Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Melaena		Vioxx	SS	Merck & Co., Inc	ORAL
		Menopausal Symptoms		Vioxx	SS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Nausea					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Palpitations					
		Pelvic Peritoneal					
		Adhesions					
		Pericardial Effusion					
		Phaeochromocytoma					
		Phlebothrombosis					
		Photopsia					
		Rhinitis Allergic					
		Scan Myocardial Perfusion					
		Abnormal					
		Stent Occlusion					
		Supraventricular					
		Extrasystoles					
		Syncope					
		Temperature Intolerance					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		Vision Blurred					

Date:05/10/04ISR Number: 4355475-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01285
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
51 DAY						

Initial or Prolonged	Coronary Artery Disease	Aspirin	C
UNKNOWN			
Disability	Coronary Artery Occlusion	Ziac	C
UNKNOWN			
	Coronary Artery Restenosis		
	Deafness		
	Dyspepsia		
	Emotional Distress		
	Erectile Dysfunction		
	Injury		
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Sinusitis		
	Sleep Apnoea Syndrome		
	Sleep Disorder		
	Tricuspid Valve Incompetence		
	Ventricular Fibrillation		
	Ventricular Tachycardia		
	Weight Increased		

Date:05/10/04ISR Number: 4355476-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vicodin Tablets	C				
	Anaemia		Zyloprim	C			UNKNOWN	
	Antinuclear Antibody		Xanax	C			UNKNOWN	
	Positive		Ecotrin	C			UNKNOWN	
	Atherosclerosis		Aspirin	C			UNKNOWN	
	Cardiac Failure		Lipitor	C			UNKNOWN	
	Congestive		Ultram	C			UNKNOWN	
	Carotid Bruit		Carisoprodol	C			UNKNOWN	
	Colonic Polyp		Vasotec	C			UNKNOWN	
	Deafness Neurosensory		Micronase	C			UNKNOWN	
	Diastolic Dysfunction		Prevacid	C			UNKNOWN	
	Gastric Ulcer Haemorrhage		Glucophage	C			UNKNOWN	
	Gastritis		Centrum	C			UNKNOWN	
	Gastritis Erosive							
	Haemorrhoids							
	Hiatus Hernia							
	Ileus							
	Renal Failure							
	Small Intestinal Obstruction							
	Ventricular Hypertrophy							

Date:05/10/04ISR Number: 4355478-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0403CAN00189
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								1 DAY

Date:05/10/04ISR Number: 4355479-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Bronchitis Chronic		Norvasc	C				
UNKNOWN								
Disability	Cardiac Arrest		Lipitor	C				
UNKNOWN								
Other	Cholecystitis Chronic							
	Cholelithiasis							
	Eye Haemorrhage							
	Eye Injury							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Ingrowing Nail							
	Ischaemic Stroke							
	Syncope Vasovagal							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/04ISR Number: 4355481-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Azotaemia		Tylenol	C				
UNKNOWN								
	Benign Neoplasm		Acetaminophen And Propoxyphene Napsylate	C				
	Bundle Branch Block Right							
	Chest Pain							
UNKNOWN								
	Colonic Polyp		Xanax	C				
UNKNOWN								
	Coronary Artery Disease		Aspirin	C				
UNKNOWN								
	Coronary Artery		Librax Capsules	C				
UNKNOWN								
	Restenosis		Cyclobenzaprine Hydrochloride	C				
	Depression							
UNKNOWN								
	Fall		Allegra	C				
UNKNOWN								
	Gastroenteritis Viral		Prilosec	C				
UNKNOWN								
	Generalised Anxiety		Zantac	C				
UNKNOWN								
	Disorder							
	Haematoma							
	Hypercholesterolaemia							
	Hypertension							
	Insomnia							
	Intervertebral Disc Degeneration							
	Irritable Bowel Syndrome							
	Low Density Lipoprotein Increased							
	Myocardial Infarction							
	Myositis							
	Oesophageal Spasm							
	Osteochondrosis							
	Pain In Extremity							
	Polyp							
	Sleep Disorder							
	Stress							
	Tendonitis							

Urinary Tract Infection

Date:05/10/04ISR Number: 4355482-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0405NOR00002
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Risperidone	SS		ORAL		
			Atenolol	C		ORAL		
			Warfarin Sodium	C				

YR

UNKNOWN YR

Date:05/10/04ISR Number: 4355484-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
Disability	Aortic Atherosclerosis
	Aortic Valve Incompetence
	Arthritis
	Atherosclerosis
	Cardiac Failure
	Congestive

		Cardiac Murmur					
		Constipation					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Coronary Artery		Celebrex	SS		
UNKNOWN		95	DAY				
		Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Coronary Artery Stenosis		Iron (Unspecified)	SS		
UNKNOWN							
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
12	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Gastrointestinal		Tylenol	C		
UNKNOWN		790	DAY				
		Haemorrhage		Tylenol	C		
UNKNOWN							
		Hyperlipidaemia		Triamcinolone	C		
TOPICAL		366	DAY				
		Hypertension		Lipitor	C		
UNKNOWN		790	DAY				
		Iron Deficiency Anaemia					
		Joint Injury					
		Joint Stiffness					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Psoriatic Arthropathy					
		Pulmonary Oedema					
		Rash					
		Rectal Haemorrhage					
		Stress					
		Ulcer					

Date:05/10/04ISR Number: 4355659-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01135
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
433	DAY						

Initial or Prolonged	Arthropathy	Vioxx	SS	Merck & Co., Inc	ORAL
433 DAY					
Disability	Back Injury	Acetaminophen And			
Other	Blood Pressure Increased	Hydrocodone			
	Cataract	Bitartrate	C		
UNKNOWN					
	Cerebrovascular Accident	Celebrex	C		
UNKNOWN					
	Emotional Distress				
	Eye Disorder				
	Fatigue				
	Gait Disturbance				
	Glaucoma				
	Hemiparesis				
	Impaired Work Ability				
	Intervertebral Disc Protrusion				
	Joint Range Of Motion Decreased				
	Lumbar Radiculopathy				
	Major Depression				
	Post Procedural Complication				
	Posture Abnormal				
	Prostatic Disorder				
	Psychomotor Retardation				
	Sleep Disorder				
	Transient Ischaemic Attack				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/04ISR Number: 4355662-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00204
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
			[Therapy Unspecified]	C				
UNKNOWN								

Date:05/10/04ISR Number: 4355664-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Emotional Distress		Tagamet	C				
UNKNOWN								
	Femur Fracture		Estropipate	C				
UNKNOWN		3956 DAY						
	Gastrointestinal Disorder		Lasix (Furosemide)	C				
UNKNOWN		1218 DAY						

Date:05/10/04ISR Number: 4355667-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01101
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	323	DAY
Hospitalization -	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	323	DAY
Initial or Prolonged	Cardiac Failure		Albuterol And					
Other	Congestive		Ipratropium Bromide	C				
RESPIRATORY								
	Chest Pain							
(INHALATION)								
	Chronic Obstructive		Aspirin	C				
UNKNOWN								
	Pulmonary Disease		Lipitor	C				
UNKNOWN								

UNKNOWN	Circulatory Collapse	Beconase	C
RESPIRATORY (INHALATION)	Coronary Artery Disease	Pulmicort	C
UNKNOWN	Diarrhoea		
UNKNOWN	Ear Infection	Wellbutrin	C
UNKNOWN	Gastric Ulcer	Wellbutrin	C
UNKNOWN	Headache	Klonopin	C
UNKNOWN	Myocardial Infarction	Klonopin	C
UNKNOWN	Nausea	Plavix	C
UNKNOWN	Oedema Peripheral	Allegra	C
UNKNOWN	Pulse Absent	Prozac	C
UNKNOWN	Renal Failure	Lasix (Furosemide)	C
UNKNOWN	Sudden Death	Aldactazide	C
UNKNOWN	Vomiting	Advil	C
UNKNOWN		Toprol Xl Tablets	C
UNKNOWN		Toprol Xl Tablets	C
UNKNOWN		Demadex	C
UNKNOWN		Theophylline	C
UNKNOWN		Hytrin	C
UNKNOWN		Zocor	C
UNKNOWN		Serevent	C
RESPIRATORY (INHALATION)			
UNKNOWN		Lopressor	C
UNKNOWN		Lopressor	C
UNKNOWN		Singulair	C
UNKNOWN		Naproxen	C
UNKNOWN		Nitroglycerin	C
TOPICAL			

UNKNOWN	Prilosec	C
UNKNOWN	Potassium Chloride	C
UNKNOWN	Inderal	C
UNKNOWN	Inderal	C
UNKNOWN	Altace	C
UNKNOWN	Altace	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4356046-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01010
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Other	Blood Cholesterol		Vicodin Tablets	C				UNKNOWN
	Increased		Celebrex	C				UNKNOWN
	Cold Sweat		Baycol	C				UNKNOWN
	Contusion		Motrin	C				UNKNOWN
	Drug Hypersensitivity							
	Emotional Distress							
	Fall							
	Heart Rate Increased							
	Hypertension							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Myocardial Infarction							
	Pain In Extremity							
	Palpitations							
	Respiratory Disorder							
	Respiratory Rate Increased							
	Rib Fracture							
	Rotator Cuff Syndrome							

Date:05/11/04ISR Number: 4356055-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adrenal Insufficiency
Other	Arteriosclerosis
	Asthma
	Bacterial Infection

Blood Erythropoietin
Decreased
Candidiasis
Cellulitis
Cholecystitis Chronic
Cholesterosis
Coagulopathy
Colitis
Condition Aggravated
Decubitus Ulcer
Deep Vein Thrombosis
Diarrhoea
Diverticulum
Duodenitis
Dyspepsia
Escherichia Infection
Fungaemia
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma

		Gynaecomastia					
		Haemorrhoids					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Steatosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Catapres	C		
UNKNOWN		347 DAY					
		Hypercoagulation		Lasix (Furosemide)	C		
UNKNOWN							
		Hyperglycaemia		Micardis	C		
UNKNOWN							
		Hypertension		Lasix (Furosemide)	C		
UNKNOWN							
		Hypotension		Cozaar	C		
UNKNOWN							
		Incisional Hernia					
		Inguinal Hernia					
		Injury					
		International Normalised					
		Ratio Increased					
		Malnutrition					
		Normochromic Normocytic					
		Anaemia					
		Obesity					
		Oesophagitis					
		Optic Neuropathy					
		Otitis Media					
		Pickwickian Syndrome					
		Pneumonia					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Refractory Anaemia					
		Renal Failure Acute					
		Rheumatoid Arthritis					
		Sepsis					
		Sputum Culture Positive					
		Syncope Vasovagal					
		Thrombocytopenia					
		Thrombosis					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vertigo					

Date:05/11/04ISR Number: 4356056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Calcification
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Carotid Artery Disease
	Chest Pain
	Colon Adenoma
	Congestive Cardiomyopathy
	Cough
	Depression
	Difficulty In Walking
	Dizziness
	Drug Hypersensitivity
	Dyspepsia
	Ejection Fraction Decreased

	Fatigue Fibroadenoma Of Breast Fluid Retention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Gastrointestinal Tract		Vioxx	PS	Merck & Co., Inc	ORAL
80	DAY					
	Adenoma		Ascorbic Acid	C		
UNKNOWN						
	Haemorrhoids		Wellbutrin	C		
UNKNOWN						
	Hyperlipidaemia Hypertension		Calcium (Unspecified)	C		
UNKNOWN						
	Injury		Lanoxin	C		
UNKNOWN						
	Insomnia		Premarin	C		
UNKNOWN						
	Mitral Valve Incompetence		Lasix (Furosemide)	C		
UNKNOWN						
	Mood Swings		Coenzyme Q10	C		
UNKNOWN						
	Multiple Allergies		Vitamin E	C		
UNKNOWN						
	Nightmare		Coumadin	C		
UNKNOWN						
	Pain In Extremity Proctalgia		Vitamin B (Unspecified)	C		
UNKNOWN						
	Sinus Tachycardia Snoring		Ginkgo Biloba Extract	C		
UNKNOWN						
	Somnolence		Levocarnitine	C		
UNKNOWN						
	Spinal Osteoarthritis		Prinivil	C		ORAL
	Tricuspid Valve Incompetence		Magnesium (Unspecified)	C		
UNKNOWN						
	Ventricular Extrasystoles		Nicotine	C		
UNKNOWN						
	Viral Infection		Pamelor	C		
UNKNOWN						
	Weight Increased					

Date:05/11/04ISR Number: 4356057-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00437
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Convulsion		Hydrodiuril	C		ORAL	UNKNOWN	
Other	Drug Level Fluctuating		Hydroxychloroquine Sulfate	C			UNKNOWN	
	Gastrointestinal Ulcer		Salsalate	C			UNKNOWN	
	Haemorrhage		Tylenol	C			UNKNOWN	
	Grand Mal Convulsion		Captopril	C			UNKNOWN	
	Injury		Prempro	C			UNKNOWN	
	Mental Impairment		Atenolol	C			UNKNOWN	
	Mental Status Changes		Sulfasalazine	C			UNKNOWN	
	Muscle Contracture		Claritin	C			UNKNOWN	
	Nausea		Potassium (Unspecified)	C			UNKNOWN	
	Pallor							
	Sinus Arrhythmia							
	Sinus Tachycardia							
	Vomiting							

Date:05/11/04ISR Number: 4356058-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Arthropathy
Other	Atrial Fibrillation
	Cardiac Aneurysm
	Corneal Deposits
	Haematoma
	Haematuria
	Headache
	Hypertension

		Hypertensive Crisis					
		Injury					
		Meniscus Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
		Paraesthesia		Premarin	C		
UNKNOWN							
		Refusal Of Treatment By		Estratab	C		
UNKNOWN							
		Patient		Menest	C		
UNKNOWN							
		Renal Cyst		Armour Thyroid			
		Transient Ischaemic		Tablets	C		
UNKNOWN							
		Attack		Trazodone			
		Tricuspid Valve		Hydrochloride	C		
UNKNOWN							
		Incompetence		Garlic Extract	C		
UNKNOWN							
		Urinary Retention		Synthroid	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							

Date:05/11/04ISR Number: 4356059-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Congestive		[Therapy			
Other		Cardiomegaly		Unspecified]	C		
UNKNOWN							
		Carotid Artery Stenosis		[Therapy			
		Cataract		Unspecified]	C		
UNKNOWN							
		Contusion		Avandia	C		ORAL
		Coronary Artery Disease		Avandia	C		ORAL
		Glaucoma		Vicoprofen	C		ORAL
		Hypoaesthesia		Glucophage	C		ORAL
		Lumbar Spinal Stenosis		Glucophage	C		ORAL
		Nasopharyngitis					
		Neuropathy Peripheral					

Osteoarthritis
Pain In Extremity
Road Traffic Accident
Spinal Osteoarthritis
Toe Deformity
Whiplash Injury

Date:05/11/04ISR Number: 4356060-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0404CHE00038
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Confusional State		Bisoprolol Fumarate	C		ORAL		
	Dialysis							
	Disseminated Intravascular Coagulation							
	Electroencephalogram Abnormal							
	Renal Failure							
	Sepsis							
	Skin Necrosis							
	Somnolence							
	Streptococcal Sepsis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4356061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	350 DAY	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	350 DAY	
	Coronary Artery		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Diverticulitis		[Therapy Unspecified]	C			UNKNOWN	
	Emotional Distress							
	Facet Joint Syndrome		Norco	C			UNKNOWN	
	Hand Fracture		Atenolol	C			UNKNOWN	
	Hypertension		Tenormin	C			UNKNOWN	
	Insomnia		Celebrex	C			UNKNOWN	
	Intervertebral Disc		Celebrex	C			UNKNOWN	
	Protrusion		Diovan	C			UNKNOWN	
	Lumbar Spinal Stenosis		Ultram	C			UNKNOWN	
	Muscle Strain		Avandia	C			UNKNOWN	
	Nervousness		Chlorthalidone	C			UNKNOWN	
	Raynaud'S Phenomenon		Hygroton	C			UNKNOWN	
	Respiratory Failure		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
			Cardizem	C			UNKNOWN	
			Propecia	C			UNKNOWN	

	Glucovance	C
UNKNOWN		
	Hydrocodone Hydrochloride	C
UNKNOWN		

Date:05/11/04ISR Number: 4356062-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Aortic Valve Incompetence
Other	Aortic Valve Sclerosis
	Blood Pressure Inadequately Controlled
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Cognitive Disorder
	Condition Aggravated
	Depression
	Dilatation Atrial
	Diplopia
	Dizziness
	Duodenitis
	Electrocardiogram Poor R-Wave Progression
	Endocarditis
	Fatigue
	Gallbladder Disorder
	Gastritis
	Gastrooesophageal Reflux Disease
	Generalised Anxiety

		Disorder Haematuria Herpes Zoster Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Hypoacusis		Aspirin	C		
UNKNOWN							
		Hypokalaemia		Aspirin	C		
UNKNOWN							
		Injury		Tagamet	C		
UNKNOWN							
		International Normalised		Premarin	C		
UNKNOWN							
		Ratio Decreased		Hytrin	C		
UNKNOWN							
		Irritable Bowel Syndrome		Estratab	C		
UNKNOWN							
		Lacunar Infarction		L-Thyroxin	C		
UNKNOWN							
		Migraine With Aura		Ranitidine	C		
UNKNOWN							
		Mitral Valve Calcification Mitral Valve Incompetence Non-Cardiac Chest Pain Pain In Jaw Panic Disorder Prothrombin Time Shortened Sleep Apnoea Syndrome Tension Headache Thalamus Haemorrhage Transient Ischaemic Attack Ventricular Hypertrophy					

Date:05/11/04ISR Number: 4356064-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0405AUS00047
Age:53 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angiogram Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Myocardial Infarction		Moduretic	C		ORAL
				Beclomethasone			

			Dipropionate	C		
UNKNOWN						
			Fluticasone Propionate And Salmeterol Xinafoate	C		
UNKNOWN						
			Zocor	C		ORAL
			Sildenafil Citrate	C		
UNKNOWN						
			Quinine Bisulfate	C		
UNKNOWN						
			Rabeprazole Sodium	C		
UNKNOWN						

Date:05/11/04ISR Number: 4356065-9Report Type:Expedited (15-DaCompany Report #NL-MERCK-0405NLD00003
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Hydrochlorothiazide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4356067-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00734
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged	Accident At Work		Sectral	SS				UNKNOWN
	Anorexia		Zestril	SS				UNKNOWN
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zestril	SS				UNKNOWN
	Blood Magnesium Increased		Zestril	SS				UNKNOWN
	Chills		Vioxx	SS	Merck & Co., Inc	ORAL		13 DAY
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Costochondritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dehydration		Tylenol	C				UNKNOWN
	Dizziness		Tylenol With Codeine	C				UNKNOWN
	Dry Mouth		Xanax	C				UNKNOWN
	Emotional Disorder		Vitamin B Complex	C				UNKNOWN
	Emotional Distress		Aspirin	C				UNKNOWN
	Erosive Duodenitis		Keflex	C				UNKNOWN
	Fatigue		Cipro	C				UNKNOWN
	Fibula Fracture							
	Flatulence							
	Gastritis							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Headache							
	Helicobacter Gastritis							
	Hypertension							
	Intervertebral Disc Degeneration							
	Intervertebral Disc							

Protrusion
Muscle Spasms
Nausea
Nephrosclerosis
Neuritis
Neuropathy
Night Cramps
Oedema Peripheral
Osteoarthritis
Proteinuria
Renal Cyst
Renal Failure
Renal Failure Acute
Renal Injury
Tendonitis
Wound

Date:05/11/04ISR Number: 4356225-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Disability	Arthralgia
	Arthropod Bite
	Back Pain
	Blood Glucose Increased
	Cardiac Failure
	Congestive

Cardiac Murmur
Cerumen Impaction
Chest Pain
Chest Wall Pain
Condition Aggravated
Deep Vein Thrombosis
Dizziness
Drug Dependence
Dyspnoea
Dysuria
Fatigue
Gait Disturbance
Headache
Heart Rate Increased
Hodgkin'S Disease
Hyperhidrosis
Hypertension
Injury
Intervertebral Disc
Degeneration
Joint Swelling
Labile Hypertension
Labyrinthitis
Myocardial Infarction
Neck Pain
Non-Hodgkin'S Lymphoma
Oedema Peripheral
Orthopnoea
Skin Cancer
Thrombophlebitis
Vertigo
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
	Vioxx	SS	Merck & Co., Inc	ORAL	18	MON
	Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

Date:05/11/04ISR Number: 4356226-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Shortened
Other	Arthralgia

Back Pain
Blood Pressure Systolic
Increased
Cerebrovascular Accident
Chest Pain
Chronic Obstructive
Pulmonary Disease
Coronary Artery Disease
Drug Effect Decreased
Dyspepsia
Dyspnoea
Gait Disturbance
Hyperhidrosis
Injury
International Normalised
Ratio Decreased
Intervertebral Disc
Displacement
Intervertebral Disc

		Protrusion					
		Lymphadenitis					
		Musculoskeletal Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Nitroglycerin	C		
UNKNOWN							
		Pain In Extremity		Tolinase	C		
UNKNOWN							
		Palpitations		Verapamil	C		
UNKNOWN							
		Paronychia					
		Peripheral Vascular Disorder					
		Productive Cough					
		Prothrombin Time Shortened					
		Pyrexia					
		Sciatica					
		Treatment Noncompliance					
		Varicose Vein					

Date:05/11/04ISR Number: 4356228-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Atenolol	C		
UNKNOWN							
		Coronary Artery		Zyrtec	C		
UNKNOWN							
		Atherosclerosis		Celexa	C		
UNKNOWN							
		Drug Ineffective		Flonase	C		
UNKNOWN							
		Dyslipidaemia		Hydrocodone Bitartrate			
		Fall			C		
UNKNOWN							
		Muscular Weakness		Levsin	C		
UNKNOWN							

	Peripheral Coldness		Indocin			
	Road Traffic Accident		(Indomethacin)	C		ORAL
	Rotator Cuff Syndrome		Naproxen	C		
UNKNOWN						
	Scapula Fracture		Prilosec	C		
UNKNOWN						
	Skin Laceration		Oxycontin	C		
UNKNOWN						
	Trigger Finger		Aciphex	C		
UNKNOWN						

Date:05/11/04ISR Number: 4356229-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01895
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Infarction		Vicoprofen	C		
UNKNOWN						
	Aortic Atherosclerosis					
	Cardiomegaly					
	Coronary Artery					
	Atherosclerosis					
	Hypertension					
	Pulmonary Calcification					
	Pulmonary Congestion					
	Spleen Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4356230-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL		71 DAY
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		33 DAY
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		33 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		71 DAY
	Asthenopia		[Therapy Unspecified]	C				UNKNOWN
	Atrial Fibrillation							
	Back Injury		Elavil	C				UNKNOWN
	Back Pain		Atenolol	C				UNKNOWN
	Balance Disorder		Trazodone Hydrochloride	C				UNKNOWN
	Blood Pressure Decreased							
	Bronchitis		Atenolol	C				UNKNOWN
	Bursitis		Lonox	C				UNKNOWN
	Cardiomegaly		Dyazide	C				UNKNOWN
	Chest Pain		Hydrocortisone	C				UNKNOWN
	Chest Wall Pain		Zestril	C				UNKNOWN
	Constipation		Paxil	C				UNKNOWN
	Coordination Abnormal							
	Coronary Artery Disease							
	Diabetes Mellitus							
	Diastolic Dysfunction							
	Diplopia							
	Gastrooesophageal Reflux Disease							
	Haemorrhage							
	Hypoaesthesia							
	Hypoaesthesia Oral							
	Insomnia							
	Metabolic Syndrome							

Migraine
Muscle Twitching
Muscular Weakness
Musculoskeletal Stiffness
Myasthenia Gravis
Nephritis
Night Sweats
Panic Attack
Pericardial Effusion
Renal Failure Acute
Septic Shock
Sinusitis
Tendonitis
Therapeutic Agent
Toxicity
Tinnitus
Tubulointerstitial
Nephritis
Ventricular Extrasystoles
Ventricular Hypertrophy
Vision Blurred

Date:05/11/04ISR Number: 4356231-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01472
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cystocele		Vioxx	PS	Merck & Co., Inc	ORAL	32 HR	
	Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	96 DAY	
			Atenolol	C				

UNKNOWN

			Lipitor	C		
UNKNOWN						

Date:05/11/04ISR Number: 4356232-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0311FRA00030
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Diverticulum Intestinal		Clopidogrel					
	Drug Interaction		Bisulfate	SS		ORAL		1 YR
	Rectal Haemorrhage		Paroxetine					
	Tachycardia		Hydrochloride	SS		ORAL		
			Acetaminophen	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Tiapride	C		ORAL		

Date:05/11/04ISR Number: 4356233-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00025
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged								

Date:05/11/04ISR Number: 4357463-XReport Type:Direct Company Report #CTU 218386
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS				2 MON
Initial or Prolonged	Endoscopy Abnormal		Prednisone	SS				
A TAPER							6	WK
Required	Gastric Ulcer		5 Fu	C				
Intervention to	Haemoglobin Decreased		Cisplatin	C				
Prevent Permanent	Melaena		Cozaar	C				
Impairment/Damage	Syncope		Zantac	C				

	Ulcer Haemorrhage		Percocet	C		
			Triamterene	C		
			Compazine	C		

Date:05/11/04ISR Number: 4357468-9Report Type:Direct Company Report #CTU 218390
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS		ORAL
50 MG PO QD <						
Initial or Prolonged	Haemorrhage					
1 YR						
Required	Mental Status Changes		Ms Contin	C		
Intervention to			Orphenadrine	C		
Prevent Permanent			Zyprexa	C		
Impairment/Damage			Neurontin	C		
			Prevacid	C		
			Tamoxifen	C		
			Tizanidine	C		
			Hydroxyzine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/04ISR Number: 4357998-XReport Type:Expedited (15-DaCompany Report #WAES 0404USA02606
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Study	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Increased Nephropathy	Health Professional	Cap Blinded Therapy Unk	SS		ORAL	SEE IMAGE	
			Alene	SS				
			,	C				
			,	C				
			Ativan	C				
			Dyazide	C				
			Neurontin	C				
			Ibuprofen	C				
			Prednisone	C				
			Spironolactone	C				

Date:05/11/04ISR Number: 4358709-4Report Type:Expedited (15-DaCompany Report #2004212032US
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Health Professional	Celebrex(Celecoxib) Capsule	PS		ORAL	ORAL	
Initial or Prolonged			Vioxx (Rofecoxib)	SS				

Date:05/12/04ISR Number: 4356438-4Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0429585A
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Relafen	PS	Glaxosmithkline			
	Stomach Discomfort		Vioxx	SS				

Date:05/12/04ISR Number: 4356443-8Report Type:Periodic Company Report #USA030946165
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness	Health	Relafen	PS	Glaxosmithkline	ORAL	1000MG Twice	
Initial or Prolonged	Fall	Professional					per day	
	Feeling Abnormal		Vioxx	SS		ORAL	25MG Per day	
	Medication Error		Plaquenil	C			200MG Twice	
	Retching						per day	
	Vertigo		Vicodin	C				
			Aspirin	C	Glaxosmithkline		81MG Per day	
			Diovan Hct	C				
			Neurontin	C			300MG Four	
							times per day	
			Ultram	C				
			Synthroid	C	Glaxosmithkline		.2MG Per day	
			Lasix	C	Glaxosmithkline			
			Norvasc	C			5MG Per day	
			Premarin	C				
			Allegra	C				
			Calcium	C				

Date:05/12/04ISR Number: 4356860-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		577 DAY
Initial or Prolonged	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Lorcet 10/650	C				
UNKNOWN								283 DAY
Other	Delusion		Hydrocodone					
	Depression		Bitartrate	C				
UNKNOWN								201 DAY
	Glucose Tolerance		Ambien	C				
UNKNOWN								
	Impaired		Ibuprofen	C				
UNKNOWN								
	Hernia		Cozaar	C				
UNKNOWN								
	Hyperlipidaemia							
	Hypertension							
	Insomnia							
	Male Sexual Dysfunction							
	Mitral Valve Incompetence							
	Nocturia							
	Oedema Peripheral							
	Panic Attack							
	Periarthritis							
	Somnolence							
	Varicose Vein							
	Ventricular Hypertrophy							

Date:05/12/04ISR Number: 4356863-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Disability	Abscess Limb
Other	Adnexa Uteri Mass
	Anxiety
	Azotaemia
	Blepharitis
	Candidiasis
	Cardiac Failure

Congestive
Cellulitis
Cervicitis
Cough
Cystitis
Diarrhoea
Endometrial Hyperplasia
Epistaxis
Fallopian Tube Cyst
Feeling Of Despair
Fistula
Fluid Retention
Hypertension
Injury
Irritable Bowel Syndrome
Lower Extremity Mass
Meniscus Lesion
Mood Swings
Nervousness
Neuropathic Pain
Non-Cardiac Chest Pain
Ovarian Fibrosis
Palpitations

		Peau D'Orange					
		Pharynx Discomfort					
		Pickwickian Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Post Procedural	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Retching		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Infection		Ventolin (Albuterol			
		Urinary Tract Infection		Sulfate)	C		
UNKNOWN							
		Weight Increased		Tenormin	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Vasotec	C		ORAL
				Cenestin	C		
UNKNOWN							
				Lodine Xl	C		
UNKNOWN							
				Lasix (Furosemide			
				Sodium)	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							

Date:05/12/04ISR Number: 4356877-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104477
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Cellulitis		[Therapy			

	Chloracne		Unspecified]	C
UNKNOWN				
	Cor Pulmonale		Darvocet-N	C
UNKNOWN				
	Depression		Celebrex	C
UNKNOWN				
	Erythema		Furosemide	C
UNKNOWN				
	Extremity Necrosis		Oxygen	C
UNKNOWN				
	Generalised Oedema		Klor-Con	C
UNKNOWN				
	Glaucoma			
	Glucose Tolerance			
	Impaired			
	Hypoaesthesia			
	Pickwickian Syndrome			
	Polycythaemia			
	Respiratory Failure			
	Rhinitis			
	Sleep Apnoea Syndrome			

Date:05/12/04ISR Number: 4356883-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00206
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diaphragmalgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Musculoskeletal Stiffness		Premarin	C				
UNKNOWN								
	Myalgia							
	Respiration Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/04ISR Number: 4356884-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/04ISR Number: 4356886-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00006
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia							
	Gastrointestinal Haemorrhage							

Date:05/12/04ISR Number: 4357119-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00052
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Leflunomide	SS		ORAL		
	Aspartate Aminotransferase Increased		Leflunomide	SS		ORAL		
			Fosamax	C		ORAL	2227 DAY	
	Blood Alkaline Phosphatase Increased		Tramadol Hydrochloride	C		ORAL		
			Prednisolone	C		ORAL		
	C-Reactive Protein Increased		Calcium Carbonate And Cholecalciferol	C		ORAL		
	Gamma-Glutamyltransferase Increased							
	Glutamate Dehydrogenase Increased							
	Laboratory Test Abnormal							

Date:05/12/04ISR Number: 4357123-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Increased Dyspepsia		[Therapy Unspecified]	C				
UNKNOWN								
	Emotional Distress		Aspirin	C				
UNKNOWN								
	Fibromyalgia		Wellbutrin	C				
UNKNOWN								
	Gallbladder Disorder		Codeine	C				
UNKNOWN								
	Myocardial Infarction		Lovastatin	C				
UNKNOWN								
	Nausea		Naproxen	C				
UNKNOWN								

Date:05/12/04ISR Number: 4357124-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Arterial Occlusive Disease
	Arterial Stenosis
	Arteriosclerosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arthralgia					
		Barrett'S Oesophagus					
		Blood Glucose Increased					
		Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coordination Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphagia		[Therapy			
		Dyspnoea		Unspecified]	C		
UNKNOWN	1478 DAY						
		Emotional Distress		Herbs (Unspecified)	C		
UNKNOWN	840 DAY						
		Exostosis		Prilosec	C		
UNKNOWN							
		Fall					
		Fatigue					
		Femoral Artery Occlusion					
		Gastrooesophageal Reflux					
		Disease					
		Haemorrhoids					
		Hiatus Hernia					
		Hypertension					
		Injury					
		Joint Sprain					
		Lacunar Infarction					
		Meniscus Lesion					
		Nausea					
		Oesophageal Achalasia					
		Oesophagitis					
		Osteoarthritis					
		Pain In Extremity					
		Peripheral Vascular					
		Disorder					
		Personality Disorder					
		Rectal Polyp					
		Synovitis					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Vascular Calcification					
		Vomiting					
		Wernicke'S Encephalopathy					
		Wheezing					

Date:05/12/04ISR Number: 4357126-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Blood Bilirubin Increased
	Blood Cholesterol Increased
	Blood Glucose Increased
	Carpal Tunnel Syndrome
	Coronary Artery Disease
	Emotional Distress
	Heart Sounds Abnormal
	Hypertension
	Mitral Valve Incompetence

	Mitral Valve Prolapse						
	Myocardial Ischaemia						
	Nasal Turbinate	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL	
	Sleep Apnoea Syndrome		Claritin-D	SS		ORAL	
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Trigger Finger		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ventricular Hypokinesia		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vicodin Es Tablets	C		ORAL	
			Ambien	C		ORAL	
			Percocet	C		ORAL	
			Zoloft	C		ORAL	
			Zoloft	C		ORAL	
			Ceftin	C		ORAL	

Date:05/12/04ISR Number: 4357127-2Report Type:Expedited (15-DaCompany Report #MA-MERCK-0405USA00381
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
Initial or Prolonged	Fluid Retention		Fludex	C			UNKNOWN

Date:05/12/04ISR Number: 4358385-0Report Type:Direct Company Report #CTU 218538
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Foot Fracture		Vioxx-No-Heart Risk	PS			
			Tylenol-Ok	SS			

Date:05/12/04ISR Number: 4359734-XReport Type:Expedited (15-DaCompany Report #DSA_24313_2004
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aggression	Foreign	Temesta	PS		ORAL	1 MG Q DAY PO

Initial or Prolonged	Amnesia	Health	Mst	SS		
	Cholestasis	Professional	Morphine	SS		
SUBCUTANEOUS 45 MG SC						
	Confusional State	Other	Vioxx	SS		ORAL
25 MG Q DAY						
	Disorientation					
PO						
	Drug Interaction		Lexotanil	SS		ORAL
1.5 MG Q DAY						
	Insomnia					
PO						
	Overdose		Aspirin Cardio	C		
	Parotitis		Zestril	C		
			Lasix	C		
			Deponit	C		
			Dafalgan	C		

Date:05/13/04ISR Number: 4357360-XReport Type:Expedited (15-DaCompany Report #200413034GDDC
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure Acute		Indapamide	PS	Aventis	
Initial or Prolonged					Pharmaceuticals Inc.	ORAL
			Rofecoxib	SS		
			Raloxifene	C		
			Omeprazole	C		
			Atrovent Forte	C		
			Ventolin	C		

			Flixotide	C			

Date:05/13/04ISR Number: 4357380-5Report Type:Expedited (15-DaCompany Report #200411019DE
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cataract		Arava	PS		ORAL		
Initial or Prolonged	Hepatic Enzyme Increased		Vioxx	SS		ORAL		
			Os-Cal D	C		ORAL		
			Fosamax	C		ORAL		
			Prednisolon	C		ORAL		
			Tramadolor	C		ORAL		

Date:05/13/04ISR Number: 4357650-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral	Health	Vioxx	PS	Merck & Co., Inc	ORAL	573	DAY
Initial or Prolonged	Depression	Professional	Celebrex	C			UNKNOWN	
Disability	Emotional Distress		Lasix (Furosemide)	C			UNKNOWN	615 DAY
	Haemorrhagic Stroke		Hydrocodone Hydrochloride	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	
			Demadex	C			UNKNOWN	615 DAY
			Ibuprofen	C			UNKNOWN	
			Lozol	C			UNKNOWN	615 DAY
			Synthroid	C			UNKNOWN	

Date:05/13/04ISR Number: 4357656-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00173
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cataract	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Macular Oedema		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
Disability	Visual Disturbance		Tibolone	C		ORAL		

Date:05/13/04ISR Number: 4357659-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01104485
Age:87 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Glucose Increased
	Blood Pressure Fluctuation
	Blood Urea Increased
	Cardiovascular Disorder
	Chest X-Ray Abnormal
	Diverticulum
	Diverticulum Intestinal
	Emotional Distress
	Faecal Occult Blood Positive
	Faeces Discoloured
	Gastritis
	Gastroenteritis
	Helicobacter
	Lower Gastrointestinal Haemorrhage

	Oedema						
	Pain						
	Polytraumatism	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rectal Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Renal Failure	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Scoliosis		Tylenol	C		ORAL	
	Spinal Osteoarthritis		Norvasc	C		ORAL	
	Weight Decreased		Aspirin	C		ORAL	
			Lozol	C		ORAL	
			Lorazepam	C			UNKNOWN
			Zantac	C		ORAL	

Date:05/13/04ISR Number: 4357660-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01238
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Fear	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Haemorrhage		Tylenol	C			UNKNOWN
	Stress		Norvasc	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Indapamide	C			UNKNOWN

Date:05/13/04ISR Number: 4357662-7Report Type:Expedited (15-DaCompany Report #PT-MERCK-0405PRT00003
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Eyelid Oedema	Professional					
	Rash						

Date:05/13/04ISR Number: 4357663-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
Other	Aortic Atherosclerosis
	Aortic Dilatation
	Back Pain
	Cardiac Disorder
	Confusional State
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Drug Hypersensitivity
	Fall
	Generalised Anxiety Disorder
	Haemorrhage Intracranial
	Hypertension
	Hypoaesthesia
	International Normalised Ratio Decreased
	Mitral Valve Prolapse
	Pain
	Panic Attack
	Pulmonary Congestion

		Retinal Ischaemia Rhinitis Scar	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Apnoea Syndrome Ventricular Hypokinesia Visual Acuity Reduced	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
				Doxepin Hydrochloride	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							

Date:05/13/04ISR Number: 4357664-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0311FRA00046
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angioneurotic Oedema Haemorrhage Subcutaneous	Health Professional	Vioxx Etanercept	PS SS	Merck & Co., Inc	ORAL
SUBCUTANEOUS							
				Calcium Carbonate	C		ORAL
				Furosemide And Spironolactone	C		ORAL
				Morphine Sulfate	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

Date:05/13/04ISR Number: 4357665-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00113
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Death	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides Increased		Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN						
	Body Temperature		Celebrex	C		
UNKNOWN						
	Decreased					
	Cardiac Arrest					
	Dyspepsia					
	Electromechanical Dissociation					
	Heart Rate Irregular					
	Injury					
	Lung Disorder					
	Mydriasis					
	Myocardial Infarction					
	Periorbital Haematoma					

Date:05/13/04ISR Number: 4357668-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Alopecia
	Back Pain
	Blindness
Other	Cataract
	Cerebrovascular Accident
	Depression

		Endometrial Hyperplasia					
		Epistaxis					
		Flushing	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Disease	Professional	Heparin	SS		
UNKNOWN							
		Gout		Provera	SS		
UNKNOWN							
		Haemorrhage Intracranial		[Therapy			
		Headache		Unspecified]	C		
UNKNOWN							
		Hemianopia Homonymous		Tylenol With Codeine			
		Herpes Zoster		#3	C		
UNKNOWN							
		Hyperhidrosis		Captopril	C		
UNKNOWN							
		Hypertension		Capozide	C		
UNKNOWN							
		Joint Injury		Cisapride	C		
UNKNOWN							
		Nasal Congestion		Glyburide	C		
UNKNOWN							
		Nausea					
		Pain					
		Pallor					
		Pneumonia					
		Postmenopausal					
		Haemorrhage					
		Rash					
		Rift Valley Fever					
		Sciatica					
		Tachycardia					
		Thyroid Mass					
		Uterine Polyp					
		Vaginal Haemorrhage					

Date:05/13/04ISR Number: 4357670-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Hyperlipidaemia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Hypotension	Norvasc	C
UNKNOWN			
	Myocardial Infarction	Atenolol	C
UNKNOWN			
	Peripheral Vascular Disorder		
	Shock		
	Upper Respiratory Tract Infection		
	Ventricular Tachycardia		

Date:05/13/04ISR Number: 4357671-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Cardiomegaly
	Coronary Artery Atherosclerosis
	Coronary Artery Stenosis
	Drug Ineffective
	Dyslipidaemia

		Extravasation					
		Fall					
		High Density Lipoprotein	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoaesthesia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve		Atenolol	C		
UNKNOWN							
		Calcification		Zyrtec	C		
UNKNOWN							
		Mitral Valve Incompetence		Celexa	C		
UNKNOWN							
		Muscular Weakness		Flonase	C		
UNKNOWN							
		Myalgia		Hydrocodone			
		Osteoarthritis		Bitartrate	C		
UNKNOWN							
		Peripheral Coldness		Levsin	C		
UNKNOWN							
		Procedural Site Reaction		Indocin			
		Road Traffic Accident		(Indomethacin)	C		ORAL
		Rotator Cuff Syndrome		Naproxen	C		
UNKNOWN							
		Scapula Fracture		Prilosec	C		
UNKNOWN							
		Sinus Bradycardia		Oxycontin	C		
UNKNOWN							
		Skin Laceration		Aciphex	C		
UNKNOWN							
		Spinal Osteoarthritis					
		Supraventricular					
		Extrasystoles					
		Tendonitis					
		Trigger Finger					
		Ventricular Hypokinesia					

Date:05/13/04ISR Number: 4357673-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00867
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Atrial Fibrillation
	Back Pain

Blood Albumin Decreased
Blood Bilirubin Increased
Blood Cholesterol
Increased
Blood Pressure Increased
Blood Triglycerides
Increased
Cardiac Aneurysm
Cardiac Failure
Congestive
Cardiomegaly
Cholelithiasis
Colonic
Pseudo-Obstruction
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery Stenosis
Drug Ineffective
Ear Haemorrhage
Ear Pain
Fatigue
Ileus
International Normalised
Ratio Abnormal
Intestinal Ischaemia
Ischaemic Cardiomyopathy

	Myocardial Infarction						
	Myocardial Ischaemia						
	Pharyngitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pitting Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	107 DAY
	Post Procedural	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	107 DAY
	Complication		Vicodin Tablets	C			UNKNOWN 127 DAY
	Prothrombin Time Abnormal		Vicodin Tablets	C			UNKNOWN 127 DAY
	Seborrhoeic Keratosis		Darvocet-N	C			UNKNOWN
	Sinus Tachycardia						
	Skin Lesion						
	Skin Papilloma						
	Ventricular Dysfunction						
	Ventricular Tachycardia						

Date:05/13/04ISR Number: 4357794-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY
Initial or Prolonged	Aortic Atherosclerosis		Celebrex	SS			UNKNOWN 95 DAY
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Arthritis		Iron (Unspecified)	SS			UNKNOWN
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	12 DAY
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Constipation		Tylenol	C			UNKNOWN 790 DAY
	Coronary Artery		Tylenol	C			UNKNOWN
	Atherosclerosis		Triamcinolone	C			TOPICAL 366 DAY
	Coronary Artery		Lipitor	C			UNKNOWN 790 DAY

Restenosis
Fall
Gastrointestinal
Haemorrhage
Hyperlipidaemia
Hypertension
Insomnia
Iron Deficiency Anaemia
Joint Injury
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Pulmonary Oedema
Rales
Rash
Rectal Haemorrhage
Stress
Ulcer

Date:05/13/04ISR Number: 4357795-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Accident
Disability	Adverse Event
Other	Angina Unstable
	Anxiety
	Atrioventricular Block
	Back Pain
	Blood Glucose Increased

		Cataract					
		Chest Pain					
		Congenital Eye Naevus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Conjunctivitis Infective		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		[Therapy			
		Contusion		Unspecified]	C		
OPHTHALMIC							
		Cough		Tylenol	C		
UNKNOWN							
		Diarrhoea		Aspirin	C		
UNKNOWN							
		Diplopia		Aspirin	C		
UNKNOWN							
		Dysphonia		Lipitor	C		
UNKNOWN	1304 DAY						
		Dyspnoea		Premarin	C		
UNKNOWN							
		Emotional Distress		Micronase	C		
UNKNOWN							
		Eructation		Motrin	C		
UNKNOWN							
		Eye Disorder		Synthroid	C		
UNKNOWN							
		Eye Injury		Synthroid	C		
UNKNOWN							
		Family Stress		Glucophage	C		
UNKNOWN							
		Feeling Cold		Naproxen	C		
UNKNOWN							
		Flatulence		Nitroglycerin	C		
UNKNOWN							
		Head Injury		Refresh	C		
OPHTHALMIC							
		Hot Flush					
		Irritable Bowel Syndrome					
		Mitral Valve Prolapse					
		Nasopharyngitis					
		Nausea					
		Pain					
		Palpitations					
		Pinguecula					
		Sinus Bradycardia					
		Somnolence					
		Stress					
		Upper Respiratory Tract Infection					

Date:05/13/04ISR Number: 4357797-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104504
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Other	Blood Pressure
	Fluctuation
	Bronchitis
	Cardiovascular Disorder
	Chest Pain
	Comminuted Fracture
	Contusion
	Dizziness
	Electrocardiogram
	Abnormal
	Electrocardiogram St-T
	Change
	Emotional Distress
	Fall
	Foot Fracture
	Fracture Nonunion
	Gastrooesophageal Reflux
	Disease
	Hypertension
	Insomnia
	Oedema
	Osteoarthritis

		Panic Reaction Patellofemoral Pain Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia Refusal Of Treatment By Patient Renal Failure Rheumatoid Arthritis Stress Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/13/04ISR Number: 4357798-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
		Abdominal Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Abdominal Pain Upper		Darvocet-N	C		
UNKNOWN							
		Abscess Intestinal		Aspirin	C		
UNKNOWN							
		Angina Unstable		Lipitor	C		
UNKNOWN							
		Asthenia		Metformin	C		
UNKNOWN							
		Atherosclerosis		Zantac	C		
UNKNOWN							
		Blood Pressure Increased Blood Triglycerides Increased Cerebrovascular Accident Cerebrovascular Disorder Chest Pain Diverticular Perforation Dizziness Drug Hypersensitivity Dysarthria Fall Hiatus Hernia High Density Lipoprotein Decreased Hypercholesterolaemia					

Hyperhidrosis
Hypertension
Joint Injury
Liver Disorder
Myocardial Infarction
Non-Cardiac Chest Pain
Non-Hodgkin'S Lymphoma
Sensation Of Heaviness
Simple Partial Seizures
Transient Ischaemic
Attack
Tuberculosis

Date:05/13/04ISR Number: 4357799-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00437
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
Disability	Blood Glucose Increased
Other	Blood Pressure Increased
	Cerebrovascular Accident

		Convulsion					
		Drug Level Fluctuating					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Femoral Neck Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal Ulcer		Tylenol	C		
UNKNOWN							
		Haemorrhage		Atenolol	C		
UNKNOWN							
		Grand Mal Convulsion		Captopril	C		
UNKNOWN							
		Injury		Prempro	C		
UNKNOWN							
		Mental Impairment		Salsalate	C		
UNKNOWN							
		Nausea		Sulfasalazine	C		
UNKNOWN							
		Osteopenia		Hydrodiuril	C		ORAL
		Sinus Arrhythmia		Hydroxychloroquine			
		Vascular Calcification		Sulfate	C		
UNKNOWN							
		Vomiting		Claritin	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							

Date:05/13/04ISR Number: 4357800-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Affect Lability
Disability	Anaesthetic Complication
Other	Anger
	Angina Pectoris
	Anhedonia
	Asthenia
	Autonomic Nervous System Imbalance
	Back Disorder
	Back Pain
	Blood Pressure Increased
	Bradycardia
	Burning Sensation
	Cardiac Failure

Congestive
Chest Pain
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Convulsion
Coronary Artery Disease
Coronary Artery Stenosis
Cough
Crackles Lung
Crying
Decreased Appetite
Depressed Mood
Dermatitis
Diarrhoea
Dissociation
Disturbance In Attention
Dizziness
Dyspnoea
Emotional Disorder
Erectile Dysfunction
Fatigue
Fear
Feelings Of Worthlessness
Flat Affect

		Haemorrhoids					
		Headache					
		Hypercholesterolaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Impaired Work Ability					
		Intervertebral Disc					
		Protrusion					
		Irritability					
		Lung Neoplasm					
		Lymphadenopathy					
		Lymphadenopathy					
		Mediastinal					
		Major Depression					
		Mental Disorder					
		Migraine					
		Muscle Spasms					
		Muscle Tightness					
		Musculoskeletal					
		Discomfort					
		Myocardial Infarction					
		Nausea					
		Neck Pain					
		Nervousness					
		Osteoarthritis					
		Oxygen Saturation					
		Decreased					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Peripheral Coldness					
		Postnasal Drip					
		Self Esteem Decreased					
		Sleep Disorder					
		Social Avoidant Behaviour					
		Spinal Osteoarthritis					
		Suicidal Ideation					
		Syncope					
		Tooth Loss					
		Ulnar Nerve Palsy					
		Ventricular Hypokinesia					

Date:05/13/04ISR Number: 4357802-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00483
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
	Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
	Mental Impairment							

Date:05/13/04ISR Number: 4357804-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00061
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		34 DAY
Initial or Prolonged	Oedema Peripheral		Acetaminophen	C		ORAL		
	Pain In Extremity		Atenolol	C		ORAL		
			Simvastatin	C		ORAL		

Dihydrocodeine C ORAL

Date:05/13/04ISR Number: 4357805-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Respiratory Failure
	Adrenal Insufficiency
	Anaemia Of Chronic Disease
	Arteriosclerosis
	Asthma
	Bacterial Infection
	Blood Erythropoietin Decreased
	Candidiasis
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Colitis
	Decubitus Ulcer
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Duodenitis
	Fungaemia
	Gastritis
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux Disease
	Glaucoma
	Gynaecomastia
	Haemorrhoids
	Headache
	Hepatic Steatosis
	Hiatus Hernia
	Hypercoagulation
	Hyperglycaemia
	Hypertension
	Hypotension
	Incisional Hernia
	Inguinal Hernia

Malnutrition
Metabolic Acidosis
Obesity
Oesophagitis
Optic Neuropathy
Otitis Media
Pickwickian Syndrome
Pneumonia
Pulmonary Embolism
Pulmonary Hypertension
Renal Failure
Renal Failure Acute
Rheumatoid Arthritis
Sepsis
Staphylococcal Infection

	Syncope Vasovagal						
	Thrombocytopenia						
	Umbilical Hernia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vertigo		Catapres	C			UNKNOWN	347 DAY
			Lasix (Furosemide)	C			UNKNOWN	
			Micardis	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Cozaar	C			UNKNOWN	

Date:05/13/04ISR Number: 4357806-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00429
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C			UNKNOWN	

Date:05/13/04ISR Number: 4358087-0Report Type:Expedited (15-DaCompany Report #A-US2004-05972
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis	Study	Tracleer (Bosentan)					
Initial or Prolonged	Cholelithiasis	Health	Tablet	PS		ORAL	SEE IMAGE	
Other	Chromaturia	Professional	Vioxx (Rofecoxib)	SS			25 MG, QD	
	Diarrhoea	Distributor	Coumadin (Warfarin					
	Gastric Ulcer		Sodium)	C				
	Nasopharyngitis		Cardizem (Diltiazem					
	Pharyngolaryngeal Pain		Hydrochloride)	C				
	Pruritus		Fosamax (Alendronate					
	Pyrexia		Sodium)	C				
			Zantac (Ranitidine					
			Hydrochloride)	C				

Synthroid (Levothyroxine Sodium)	C
Diovan "Ciba-Geigy" (Valsartan)	C
Norvasc (Amlodipine Besilate)	C
Prednisone (Prednisone)	C
Aspirin (Acetylsalicylic Acid)	C
Lopressor (Metoprolol Tartrate)	C
Digoxin (Digoxin)	C
Premarin (Estrogens Conjugated)	C
Reglan (Metoclopramide)	C
Lasix (Furosemide)	C
Nitroglycerin Transdermal System (Glyceryl Trinitrate)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/04ISR Number: 4358188-7Report Type:Direct Company Report #CTU 218584
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Rofecoxib 25 Mg					
Initial or Prolonged	Bronchitis		Merck	PS	Merck	ORAL	25 MG EVERY	
	Dyspnoea Exertional						OTHER ORAL	
	Faeces Discoloured		Ibuprofen	SS			EVERY OTHE	
	Gastrointestinal		Naproxen	SS				
	Haemorrhage		Biaxin	C				
	Melaena		Vioxx	C				
	Thrombosis		Vitamin E 400 Iu	C				
			Mvi	C				

Date:05/14/04ISR Number: 4358311-4Report Type:Expedited (15-DaCompany Report #US-MERCK-00101917
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Calcium Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 WK	
Initial or Prolonged	Drug Interaction	Professional	Lithobid	SS		ORAL	9 YR	
Other	Drug Level Increased		Lithobid	SS		ORAL		
	Dysarthria							
	Hemiparesis							
	Mental Status Changes							
	Renal Failure							
	Renal Neoplasm							
	Therapeutic Agent							
	Toxicity							

Date:05/14/04ISR Number: 4358316-3Report Type:Expedited (15-DaCompany Report #US-MERCK-00030893
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Coordination Abnormal	Lithium Carbonate	SS	
UNKNOWN				
	Dialysis	[Therapy		
	Disorientation	Unspecified]	C	
UNKNOWN				
	Drug Interaction	[Therapy		
	Drug Level Increased	Unspecified]	C	ORAL
	Therapeutic Agent	Estrogenic		
	Toxicity	Preparations		
		(Composition		
		Unspecified)	C	
UNKNOWN				

Date:05/14/04ISR Number: 4358324-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104488
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Creatine
Hospitalization -	Phosphokinase Increased
Initial or Prolonged	Blood Pressure Decreased
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomyopathy
	Confusional State
	Cough
	Death
	Dehydration

		Diarrhoea					
		Encephalopathy					
		Flank Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperkalaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoglycaemia	Professional	[Therapy			
		Influenza		Unspecified]	C		
UNKNOWN							
		Injury		Acetaminophen	C		
UNKNOWN		1 DAY					
		Lymphadenopathy		Acetaminophen And			
		Metabolic Acidosis		Codeine	C		
UNKNOWN							
		Nausea		Diamox	C		
UNKNOWN							
		Oedema Peripheral		Vitamins			
		Oral Intake Reduced		(Unspecified)	C		
UNKNOWN							
		Overdose		Aspirin	C		
UNKNOWN							
		Renal Failure		Capoten	C		
UNKNOWN							
		Sepsis		Lasix (Furosemide			
		Troponin Increased		Sodium)	C		
UNKNOWN							
		Visual Acuity Reduced		Herbs (Unspecified)	C		
UNKNOWN							
		Visual Disturbance					
		Vomiting					
		Weight Decreased					

Date:05/14/04ISR Number: 4358326-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0204SWE00002
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL
25 DAY						
Initial or Prolonged	Increased	Professional	Lithium Sulfate	SS		ORAL
	Depressed Level Of		Calcium Carbonate			
	Consciousness		And Cholecalciferol	C		
UNKNOWN						
	Drug Effect Decreased		Dipyridamole	C		
UNKNOWN						

	Drug Interaction	Zolpidem Tartrate	C
UNKNOWN			
	Drug Level Increased	Tramadol Hydrochloride	C
	Extrapyramidal Disorder		
UNKNOWN			
	Renal Failure	Lofepramine Hydrochloride	C
UNKNOWN			
		Levothyroxine Sodium	C
UNKNOWN			

Date:05/14/04ISR Number: 4358327-8Report Type:Expedited (15-DaCompany Report #US-MERCK-00110445
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Disorientation	Professional	Lithium Carbonate (Roxane)	SS		ORAL	10	YR
	Drug Interaction							
	Therapeutic Agent Toxicity							

Date:05/14/04ISR Number: 4358328-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Tenderness
Initial or Prolonged	Acute Prerenal Failure
Other	Affect Lability
	Amnesia
	Anxiety Disorder
	Aortic Valve Calcification

Aortic Valve Sclerosis
Arthralgia
Arthritis
Arthropathy
Ascites
Aspartate
Aminotransferase
Increased
Asthma
Av Dissociation
Back Pain
Bacteriuria
Blood Cholesterol
Increased
Blood Glucose Increased
Blood Pressure Increased
Blood Triglycerides
Increased
Bundle Branch Block Right
Cardiac Murmur
Cholelithiasis
Chronic Obstructive
Pulmonary Disease
Confusional State
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Depressed Level Of
Consciousness
Depression
Diverticulum
Dyspepsia
Electrocardiogram St-T
Change
Emotional Distress
Encephalitis
Encephalopathy
Fall
Fatigue
Gastric Disorder
Gastrooesophageal Reflux
Disease
Head Injury
Headache
Heart Rate Decreased
Hiatus Hernia
Hyperlipidaemia

Hypertensive Heart
Disease
Hypertrophic
Cardiomyopathy
Hypotension
Injury
Klebsiella Infection
Laceration
Leukocytosis
Limb Discomfort
Memory Impairment
Meningitis Aseptic
Mitral Valve Incompetence
Myocardial Infarction

		Nausea					
		Nodal Arrhythmia					
		Normochromic Normocytic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophageal Spasm	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Bextra	SS		
UNKNOWN							
		Pancreatitis		[Therapy			
		Pulmonary Arterial		Unspecified]	C		
UNKNOWN							
		Pressure Increased		Albuterol	C		
UNKNOWN							
		Pyuria		Lanoxin	C		
UNKNOWN							
		Skin Laceration		Effexor	C		
UNKNOWN							
		Spinal Column Stenosis		Flovent	C		
UNKNOWN							
		Stress		Hydrochlorothiazide			
		Tension		And Triamterene	C		ORAL
		Therapeutic Agent		Atrovent	C		
UNKNOWN							
		Toxicity		Singulair	C		ORAL
		Tricuspid Valve		Daypro	C		
UNKNOWN							
		Incompetence					
		Urinary Tract Infection					
		Urosepsis					
		Ventricular Hypertrophy					
		Vomiting					

Date:05/14/04ISR Number: 4358575-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02770
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asterixis		Vioxx	PS	Merck & Co., Inc	ORAL
3 MON						
Initial or Prolonged	Asthenia		Lithium Carbonate			
	Coordination Abnormal		(Roxane)	SS		ORAL
20 YR						
	Dehydration					
	Dizziness					
	Drug Interaction					

Drug Level Increased
Nausea
Nystagmus

Date:05/14/04ISR Number: 4358578-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Anxiety
	Blood Cholesterol Increased
	Coronary Artery Disease
	Depression
	Dislocation Of Vertebra
	Headache
	Hypertension
	Hypoaesthesia
	Injury
	Joint Dislocation
	Low Density Lipoprotein Increased
	Malaise
	Mitral Valve Incompetence
	Myocardial Infarction
	Non-Cardiac Chest Pain

	Pain In Extremity Road Traffic Accident Scrotal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Hypertrophy Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	195 DAY

Date:05/14/04ISR Number: 4358580-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0312GBR00128
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged UNKNOWN	Agitation Depressed Level Of Consciousness Haemodialysis Heart Rate Increased Lactic Acidosis Renal Failure Acute Respiratory Rate Increased		Vioxx Metformin	PS SS	Merck & Co., Inc	ORAL	

Date:05/14/04ISR Number: 4358581-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability Other	Alcohol Poisoning Alcohol Withdrawal Syndrome Alcoholic Liver Disease Cardiac Failure Congestive Cardio-Respiratory Arrest Chest Pain Chronic Fatigue Syndrome Chronic Obstructive Pulmonary Disease Colonic Polyp Deep Vein Thrombosis Dermatitis		Vioxx	PS	Merck & Co., Inc	ORAL	

Diverticulum
Fall
Gastrointestinal
Haemorrhage
Gout
Haemorrhoids
Hepatic Encephalopathy
Hypernatraemia
Hypertension
Injury
Myocardial Infarction
Palpitations
Peritonitis Bacterial
Pneumonia Aspiration
Renal Failure Acute
Respiratory Failure
Syncope
Varices Oesophageal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/14/04ISR Number: 4358583-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00075
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Diclofenac	SS		ORAL		
	Haematemesis		Diclofenac	SS		ORAL		
	Melaena		Acetaminophen And Dihydrocodeine Bitartrate	C			UNKNOWN	
	Nausea		Esomeprazole Sodium	C		ORAL		
	Vomiting		Lactulose	C			UNKNOWN	
			Senna	C			UNKNOWN	
			Metoclopramide	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Aspirin	C		ORAL		
			Codeine	C		ORAL		

Date:05/17/04ISR Number: 4358958-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Atrophy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Decreased Appetite		Vitamins (Unspecified)	C			UNKNOWN	
	Eczema							
	Gastrointestinal Disorder							
	Hypertension							
	Injury							
	Kyphosis							
	Lacunar Infarction							
	Macular Degeneration							
	Nocturia							
	Non-Small Cell Lung Cancer Metastatic							
	Pleural Effusion							
	Rhinitis Allergic							

Sciatica
Transient Ischaemic
Attack

Date:05/17/04ISR Number: 4358960-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01060813
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Apathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Drug Interaction	Professional	Lithium Carbonate	SS		ORAL		
	Drug Level Increased		Clonazepam	C				UNKNOWN
	Gait Disturbance		Zyprexa	C				UNKNOWN
	Hypersomnia							
	Hypertonia							
	Mood Altered							
	Myoclonus							
	Oedema Peripheral							
	Speech Disorder							

Date:05/17/04ISR Number: 4358961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Plavix	SS				
UNKNOWN								
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		
	Conjunctival Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression							
	Duodenitis							
	Fall							
	Gastritis							
	Haematochezia							
	Hypertension							
	Hypokalaemia							
	Joint Sprain							
	Laryngitis							
	Menopausal Symptoms							
	Migraine							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Palpitations							
	Pelvic Peritoneal Adhesions							
	Phlebothrombosis							
	Rhinitis Allergic							
	Sinus Polyp							
	Stent Occlusion							
	Syncope							
	Tricuspid Valve Incompetence							
	Upper Gastrointestinal Haemorrhage							
	Ventricular Extrasystoles							

Date:05/17/04ISR Number: 4358962-7Report Type:Expedited (15-DaCompany Report #US-MERCK-00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
Disability	Blood Creatine Phosphokinase Increased
	Cerebrovascular Accident
	Coordination Abnormal
	Dermatitis
	Dizziness
	Fatigue
	Feeling Abnormal
	Headache
	Hyperhidrosis
	Hypertension
	Insomnia
	Myalgia
	Myopathy
	Pain In Extremity
	Paraesthesia

		Pharyngitis					
		Pupillary Disorder					
		Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Lesion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Tendonitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Vertigo		Zocor	SS		ORAL
83	DAY						
		Vomiting		Acetaminophen	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Claritin	C		
UNKNOWN							

Date:05/17/04ISR Number: 4358963-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01031627
Age:69 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blindness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Confusional State	Professional	Lithium Carbonate	SS		ORAL
		Drug Interaction		Lithium Carbonate	SS		ORAL
		Haematocrit Decreased		Lortab	C		
UNKNOWN							
		Haemoglobin Decreased		Fosamax	C		
UNKNOWN							
		Hallucination		Prempro	C		
UNKNOWN							
		Headache		Prevacid	C		
UNKNOWN							
		Incoherent		Zestril	C		
UNKNOWN							
		Mental Status Changes					
		Neuropathy					
		Oedema Peripheral					
		Therapeutic Agent					
		Toxicity					

Treatment Noncompliance
Tremor

Date:05/17/04ISR Number: 4358964-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anaemia
	Atrophy
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cataract
	Chronic Sinusitis
	Confusional State
	Dehydration
	Depression
	Fatigue
	Gangrene
	Gastric Ulcer
	Gastritis
	Herpes Zoster
	Hypokalaemia
	Hypovolaemia
	Muscle Spasms
	Myocardial Infarction
	Myopathy

		Oesophagitis					
		Orthostatic Hypotension					
		Paraesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Occlusive	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		Albuterol Sulfate	C		
RESPIRATORY							
		Renal Cyst					
(INHALATION)							
		Renal Failure Acute		Fosamax	C		ORAL
		Soft Tissue Injury		Amlodipine Besylate	C		ORAL
		Syncope		Aspirin	C		ORAL
		Transient Ischaemic		Atorvastatin Calcium	C		
UNKNOWN							
		Attack		Beclomethasone			
		Upper Gastrointestinal		Dipropionate	C		
RESPIRATORY							
		Haemorrhage					
(INHALATION)							
		Vasculitis		Lotensin	C		
UNKNOWN							
		Weight Decreased		Calcium Carbonate	C		ORAL
				Baycol	C		
UNKNOWN							
				Diphenhydramine			
				Hydrochloride	C		ORAL
				Estrogens			
				(Unspecified)	C		ORAL
				Folic Acid	C		ORAL
				Hydrodiuril	C		ORAL
				Hydroxychloroquine			
				Sulfate	C		ORAL
				Indocin			
				(Indomethacin)	C		
UNKNOWN							
				Ipratropium Bromide	C		
UNKNOWN							
				Isosorbide			
				Mononitrate	C		ORAL
				Misoprostol	C		ORAL
				Naproxen	C		ORAL
				Prednisone	C		ORAL

Date:05/17/04ISR Number: 4358965-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Coronary Syndrome
Other	Anxiety
	Blood Triglycerides Increased
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chills
	Chronic Obstructive Pulmonary Disease
	Contusion
	Deafness Bilateral
	Dyspnoea
	Dysuria
	Epistaxis
	Fall
	Gingival Bleeding
	Haematochezia
	Heart Rate Irregular
	Hypertension
	Injury

		International Normalised Ratio Decreased					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Limb Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Menstrual Disorder		Coumadin	SS		
UNKNOWN							
		Oedema Peripheral		Coumadin	SS		
UNKNOWN							
		Osteoarthritis		[Therapy			
		Radiculitis		Unspecified]	C		
UNKNOWN							
		Silent Myocardial		Tylenol	C		
UNKNOWN							
		Infarction		Vicodin Tablets	C		
UNKNOWN							
		Sleep Disorder		Albuterol	C		
UNKNOWN							
		Stress Incontinence		Bayer Aspirin	C		
UNKNOWN							
		Transient Ischaemic		Bayer Aspirin	C		
UNKNOWN							
		Attack		Aspirin	C		
UNKNOWN							
		Urinary Tract Infection		Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Ticlid	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Anzemet	C		
UNKNOWN							
				Vasotec	C		ORAL
				Isordil	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:05/17/04ISR Number: 4358966-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0210FRA00080
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	C		ORAL		
	Melaena		Vasotec	C		ORAL		

Date:05/17/04ISR Number: 4358967-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0309DEU00119
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Disseminated	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Life-Threatening	Intravascular Coagulation	Professional	Amiodarone Hydrochloride	SS		ORAL		2 DAY
	Hepatitis Toxic							
	Renal Failure Acute		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
	Rhabdomyolysis		Vioxx	SS	Merck & Co., Inc	ORAL		3 DAY
			Amiodarone Hydrochloride	SS		ORAL		2 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
			Furosemide	C				UNKNOWN
			Magnesium (Unspecified)	C				UNKNOWN
			Pantoprazole Sodium	C				UNKNOWN
			Theophylline	C				UNKNOWN
			Sultamicillin Tosylate	C				UNKNOWN
			Prednisolone	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/04ISR Number: 4358968-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		220 DAY
Initial or Prolonged	Aortic Stenosis	Professional	Tylenol	C				UNKNOWN
Disability	Aortic Valve		Codeine	C				UNKNOWN
	Calcification		Vasotec	C		ORAL		
	Aortic Valve Incompetence		Premarin	C				UNKNOWN
	Atelectasis		Premarin	C				UNKNOWN
	Atrial Fibrillation		Zocor	C		ORAL		
	Carotid Bruit		Hydrocodone					
	Constipation		Hydrochloride	C				UNKNOWN
	Contusion		Levsin	C				UNKNOWN
	Cough		Synthroid	C		ORAL		
	Depressed Level Of Consciousness		Prilosec	C		ORAL		
	Depression							
	Diastolic Dysfunction							
	Disturbance In Attention							
	Dizziness							
	Dyspepsia							
	Dysphagia							
	Dysphonia							
	Dyspnoea							
	Dyspnoea Exertional							
	Exercise Tolerance Decreased							
	Fatigue							
	Fracture Nonunion							
	Hyperhidrosis							
	Injury							
	Insomnia							
	Intervertebral Disc Degeneration							
	Lung Neoplasm							
	Medical Device Complication							
	Mitral Valve Incompetence							

Nocturia
Oesophageal Spasm
Osteopenia
Palpitations
Post Procedural
Cellulitis
Postoperative Infection
Pyrexia
Rib Fracture
Spinal Osteoarthritis
Sternal Injury
Syncope
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Wound Dehiscence

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/04ISR Number: 4358969-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01434
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Infarction	Professional	Prozac	C				UNKNOWN
Disability	Acute Respiratory Distress Syndrome		Interferon (Unspecified)	C				UNKNOWN
	Anaemia							
	Bradycardia							
	Cardiac Arrest							
	Cardiogenic Shock							
	Catheter Sepsis							
	Coagulopathy							
	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Deep Vein Thrombosis							
	Depression							
	Diarrhoea							
	Drug Ineffective							
	Hepatic Failure							
	Injury							
	Intervertebral Disc Disorder							
	Lactic Acidosis							
	Mitral Valve Incompetence							
	Myocardial Ischaemia							
	Osteoarthritis							
	Pneumonia Aspiration							
	Pyrexia							
	Renal Infarct							
	Spinal Osteoarthritis							
	Splenic Infarction							
	Therapy Non-Responder							
	Thrombosis							
	Ventricular Hypokinesia							
	Vomiting							
	White Blood Cell Count Increased							

Date:05/17/04ISR Number: 4358970-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Arthritis
	Cardiac Valve Disease
	Coronary Artery Disease
	Coronary Artery Restenosis
	Diabetes Mellitus
	Diverticulitis
	Emotional Distress
	Facet Joint Syndrome
	Hand Fracture
	Hypertension
	Insomnia
	Intervertebral Disc

		Protrusion Lumbar Spinal Stenosis Muscle Strain Nervousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Raynaud'S Phenomenon	Health	Vioxx	PS	Merck & Co., Inc	ORAL
350 DAY							
		Respiratory Failure	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
350 DAY							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN		27 DAY					
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN		27 DAY					
				[Therapy Unspecified]	C		
UNKNOWN							
				Norco	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Avandia	C		
UNKNOWN							
				Chlorthalidone	C		
UNKNOWN							
				Hygroton	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Propecia	C		
UNKNOWN							

			Glucovance	C			
UNKNOWN							
			Hydrocodone Hydrochloride	C			
UNKNOWN							

Date:05/17/04ISR Number: 4358971-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
Initial or Prolonged	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	9 MON	
Other	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Depression		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Dizziness		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Emphysema		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Fibromyalgia		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Headache		Amitriptyline Hydrochloride	C			17	DAY
UNKNOWN								
	Hyperhidrosis		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Hyperlipidaemia		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Hypertension		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Lacunar Infarction		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Meniscus Lesion		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Nausea		Amitriptyline Hydrochloride	C			17	DAY
UNKNOWN								
	Peripheral Vascular Disorder		Zoloft	C			582	DAY
UNKNOWN								
	Sinusitis		Analgesic Or Anesthetic (Unspecified)	C				
UNKNOWN								
	Spondylolisthesis		Atenolol	C				
UNKNOWN								
	Acquired		Lipitor	C				
UNKNOWN								
	Spondylolysis		Celebrex	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		

			Altace	C			
UNKNOWN							

Date:05/17/04ISR Number: 4358972-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	45	DAY
Hospitalization - Initial or Prolonged	Distress Syndrome		Tylenol With Codeine #3	C				
UNKNOWN	Aortic Valve Sclerosis							
	Aspiration		Percocet	C				
UNKNOWN								
	Atelectasis		Ascorbic Acid	C				
UNKNOWN								
	Atrial Fibrillation		Vitamin E	C				
UNKNOWN								
	Blood Pressure		Zocor	C				
UNKNOWN								
	Fluctuation		Beta Carotene	C				
UNKNOWN								
	Breast Tenderness		Centrum	C				
UNKNOWN								
	Cardio-Respiratory Arrest							
	Cholelithiasis							
	Coagulopathy							
	Coronary Artery Disease							
	Depression							
	Extradural Abscess							
	Hepatic Function Abnormal							
	Hypersensitivity							
	Hypokalaemia							
	Hypotension							
	Influenza							
	Injury							
	Intervertebral Disc Disorder							
	Intervertebral Discitis							
	Multi-Organ Failure							
	Myocardial Infarction							
	Pancreatitis							
	Rash Generalised							
	Renal Tubular Necrosis							

Sepsis
Tachycardia
Toxic Shock Syndrome
Vaginal Haemorrhage
Ventricular Fibrillation
Ventricular Tachycardia

Date:05/17/04ISR Number: 4358973-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0307GBR00168
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Creatinine Increased		Atenolol	SS				110 DAY
Other	Blood Urea Increased		Sulfamethoxazole And Trimethoprim	SS		ORAL	6 DAY	
	Feeling Abnormal		Trimethoprim	SS			UNKNOWN	
	Heart Rate Decreased		Atenolol	SS			UNKNOWN	
	Hyperkalaemia		Acetaminophen And Codeine Phosphate	C			UNKNOWN	
	Hypotension							
	Infection		Carbomer	C			OPHTHALMIC	
	Loss Of Consciousness		Gabapentin	C			UNKNOWN	
	Nausea		Lansoprazole	C			UNKNOWN	
			Senna	C			UNKNOWN	
			Vitamin B Complex	C			UNKNOWN	

			Simvastatin	C			
UNKNOWN							
			Ranitidine	C			
UNKNOWN							
			Nitrazepam	C			
UNKNOWN							
			Lactulose	C			
UNKNOWN							
			Folic Acid	C			
UNKNOWN							
			Fosamax	C			ORAL
			Aspirin	C			
UNKNOWN							

Date:05/17/04ISR Number: 4358974-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01557
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Delirium	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Drug Interaction	Professional	Lithium Carbonate	SS		ORAL		
	Drug Level Increased							
	Dysarthria							
	Sedation							

Date:05/17/04ISR Number: 4358976-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Inadequately Controlled		Tylenol	C				
UNKNOWN								
	Cellulitis		Augmentin	C				
UNKNOWN								
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Chest Pain		Lipitor	C				
UNKNOWN								

	Coagulopathy	Betoptic	C
UNKNOWN			
	Diabetes Mellitus	Cipro	C
UNKNOWN			
	Inadequate Control	Cardura	C
UNKNOWN	255 DAY		
	Dyspnoea	Allegra	C
UNKNOWN			
	Erectile Dysfunction	Amaryl	C
UNKNOWN			
	Hypertension	Hydrochlorothiazide	C
UNKNOWN	1106 DAY		
	Hypoaesthesia	Ibuprofen	C
UNKNOWN			
	Joint Effusion	Avapro	C
UNKNOWN	60 DAY		
	Lacunar Infarction	Xalatan	C
UNKNOWN			
	Nausea	Metoprolol	C
UNKNOWN			
	Pain In Extremity	Naproxen	C
UNKNOWN	82 DAY		
	Road Traffic Accident	Niacin	C
UNKNOWN			
	Sinus Disorder	Accupril	C
UNKNOWN			
	Treatment Noncompliance	Verapamil	C
UNKNOWN			
	Whiplash Injury		

Date:05/17/04ISR Number: 4358977-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01556
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Neurotoxicity	Professional	Lithium Carbonate	SS				
UNKNOWN								
	Therapeutic Agent Toxicity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/04ISR Number: 4358978-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00524
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Wegener'S Granulomatosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/17/04ISR Number: 4358979-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Glucose Increased		[Therapy					
	Bronchitis		Unspecified]	C				
UNKNOWN								
	Cataract		Acetaminophen	C				
UNKNOWN								
	Cerebral Infarction		Percocet	C				
UNKNOWN								
	Cerebrovascular Accident		Soma	C				
UNKNOWN								
	Constipation		Zyrtec	C				
UNKNOWN								
	Dehydration		Cyanocobalamin	C				
UNKNOWN								
	Depression		Ultram	C				
UNKNOWN								
	Diarrhoea		Lamisil	C				
UNKNOWN								
	Diverticulitis		Estrace	C				
UNKNOWN								
	Drooling		Premarin	C				
UNKNOWN								
	Facial Palsy		Motrin	C				
UNKNOWN								
	Fatigue		Ocuflox	C				
UNKNOWN								
	Gastroenteritis Viral		Oxycodone	C				
UNKNOWN								
	Gastrointestinal Disorder		Prednisone	C				
OPHTHALMIC								
	Hypertension							
	Migraine							

Muscle Spasms
Nausea
Normochromic Normocytic
Anaemia
Pain
Pneumonia
Renal Failure Acute
Vomiting
Wheezing
White Blood Cell Count
Decreased

Date:05/17/04ISR Number: 4358980-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00077
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Septic Shock	Professional	Omeprazole	SS		ORAL	8	DAY
Initial or Prolonged	White Blood Cell Count		Perindopril	C		ORAL	8	DAY
	Decreased		Pravastatin Sodium	C		ORAL	8	DAY

Date:05/17/04ISR Number: 4359083-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Dyspnoea
Disability	Emotional Distress
	Gastrooesophageal Reflux Disease

		Mitral Valve Prolapse Small Intestinal Ulcer Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
30 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY							
				Aspirin	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Dicyclomine Hydrochloride	C		
UNKNOWN							
				Echinacea	C		
UNKNOWN		1483 DAY					
				Nexium	C		
UNKNOWN							

Date:05/17/04ISR Number: 4359085-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
Disability	Congestive					
Other	Carpal Tunnel Syndrome					
	Complex Regional Pain Syndrome					
	Emotional Distress					
	Fear					
	Gastrooesophageal Reflux Disease					
	Hypersensitivity					
	Impaired Healing					
	Injury					

	Intervertebral Disc Disorder
	Oedema Peripheral
	Orthopnoea
	Prescribed Overdose
	Skin Discolouration
	Sleep Apnoea Syndrome
	Weight Increased

Date:05/17/04ISR Number: 4359088-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Calcification
	Blood Chloride Increased
Disability	Blood Pressure Increased
	Cardiomegaly
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Cough
	Depression
	Fall
	Hypertension
	Impaired Work Ability
	Ischaemia

	Joint Swelling						
	Lymphoedema						
	Mastoiditis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	
	Nervous System Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Sinus Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL	
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL	
	Visual Acuity Reduced		Lamisil	C			UNKNOWN
			Soma	C			UNKNOWN
			Motrin	C			UNKNOWN

Date:05/17/04ISR Number: 4359089-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
Initial or Prolonged	Deep Vein Thrombosis		Yasmin	SS			UNKNOWN 14 DAY
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL	6 MON
	Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL	
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Heart Rate Irregular		Sandimmun	C			UNKNOWN
	Hypochromic Anaemia		Sandimmun	C			UNKNOWN
	Insomnia		Prelone Syrup	C			UNKNOWN
	Intracranial Venous Sinus		Prednisone	C			UNKNOWN
	Thrombosis		Prelone Syrup	C			UNKNOWN
	Joint Effusion		Hormonal				
	Nausea		Contraceptives				

	Pharyngolaryngeal Pain		(Unspecified)	C		
INTRAMUSCULAR						
	Rash		Sandimmun	C		
UNKNOWN						
	Sinus Tachycardia					
	Subarachnoid Haemorrhage					
	Uterine Leiomyoma					
	Vomiting					

Date:05/17/04ISR Number: 4359098-1Report Type:Direct Company Report #CTU 218754
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Petechiae		Vioxx 12.5 Mg	PS		ORAL
ONE -TWO /DAY						
	Platelet Count Decreased					
PO						

Date:05/17/04ISR Number: 4359642-4Report Type:Direct Company Report #CTU 218796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Renal Failure Acute		Vioxx 25 Mg Merck &			
Life-Threatening			Co., Inc	PS	Merck & Co., Inc	ORAL
25 MG PILL						
Hospitalization -						
ONCE DAILY						
Initial or Prolonged						
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/04ISR Number: 4359738-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00425
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Closed Head Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State	Professional	Remicade	SS			INTRAVENOUS	
	Demyelination					DRIP	871 DAY	
	Depressed Level Of		Remicade	SS			INTRAVENOUS	
	Consciousness					DRIP		
	Difficulty In Walking		Ascorbic Acid	C			UNKNOWN	
	Dizziness		Calcium (Unspecified) And Vitamin D (Unspecified)	C			UNKNOWN	
	Dyspnoea							
	Ear Discomfort							
	Fall							
	Glioma		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C			UNKNOWN	
	Hoffmann'S Sign							
	Hypoaesthesia							
	Loss Of Consciousness							
	Medication Error		Levoxyl	C			UNKNOWN	
	Paraesthesia		Medrol	C			UNKNOWN	
	Rheumatoid Arthritis		Vitamin E	C			UNKNOWN	
	Self-Medication		Vitamins (Unspecified)	C			UNKNOWN	
	Tinnitus							
			Zoloft	C			UNKNOWN	
			Pyridoxine	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Dicyclomine Hydrochloride	C			UNKNOWN	
			Bentyl	C			UNKNOWN	
			Premarin	C			UNKNOWN	

				Folic Acid	C		
UNKNOWN							

Date:05/18/04ISR Number: 4359742-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA00034
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
			Lortab	SS		ORAL		7 DAY
			Lortab	SS		ORAL		7 DAY
			Bextra	C		ORAL		17 DAY
			Bextra	C		ORAL		17 DAY
			Norvasc	C		ORAL		
			Premarin	C		ORAL		
			Hyzaar	C		ORAL		
			Prevacid	C				UNKNOWN
			Prilosec	C		ORAL		

Date:05/18/04ISR Number: 4359745-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Burning Sensation
Disability	Cardiac Disorder
	Chest Pain
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Emotional Distress
	Intervertebral Disc

	Degeneration						
	Kyphoscoliosis						
	Lung Disorder						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Spinal Osteoarthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	

Date:05/18/04ISR Number: 4359746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8 MON
Initial or Prolonged	Anaemia Haemolytic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	8 MON
Disability	Autoimmune		Amitriptyline				
Other	Anxiety		Hydrochloride	C			UNKNOWN
	Arthralgia		Rocaltrol	C		ORAL	
	Atelectasis		Os-Cal + D	C			UNKNOWN
	Blood Cholesterol		Valium	C			UNKNOWN
	Increased		Synthroid	C			UNKNOWN
	Blood Creatine		Synthroid	C		ORAL	
	Phosphokinase Increased		Ambien	C			UNKNOWN
	Cellulitis		Claritin	C			UNKNOWN
	Cerebrovascular Accident		Slow-Mag	C			UNKNOWN
	Cholelithiasis		Reglan	C			UNKNOWN
	Coagulopathy		Reglan	C			UNKNOWN
	Cystocele		Prilosec	C			UNKNOWN
	Decreased Appetite		Ditropan Xl	C			UNKNOWN
	Disturbance In Attention		Potassium Chloride	C			UNKNOWN
	Drug Hypersensitivity						
	Dyspnoea						

Eye Pain
Haematochezia
Haemorrhage
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Insomnia
Neurogenic Bladder
Oesophageal Disorder
Pulmonary Granuloma
Pyrexia
Rectocele
Renal Failure
Sinusitis
Tinnitus
Tooth Disorder
Toothache
Tracheobronchitis
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Viral Infection
Visual Disturbance
Weight Decreased

Date:05/18/04ISR Number: 4359937-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bladder Obstruction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebral Atherosclerosis		[Therapy					
	Cerebral Infarction		Unspecified]	C				
UNKNOWN								
	Encephalomalacia		Albuterol	C				
RESPIRATORY								
	Epistaxis							
(INHALATION)								
	Haemorrhoids		Albuterol	C		ORAL		
	Headache		Allopurinol	C				
UNKNOWN								
	Pneumonia		Ecotrin	C				
UNKNOWN								
	Prostate Cancer		Atenolol	C				
UNKNOWN								
	Rectal Haemorrhage		Palgic D	C		ORAL		
	Rectal Polyp		Mavik	C		ORAL		
			Mavik	C		ORAL		
			Celebrex	C				
UNKNOWN								
			Docusate Calcium	C				
UNKNOWN								
			Guaifenex La	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		
			Ibuprofen	C				
UNKNOWN								
			Atrovent	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								

Date:05/18/04ISR Number: 4359939-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
1 MON								

Initial or Prolonged	Arthropathy	Premarin	C
UNKNOWN			
Other	Atrial Fibrillation	Estratab	C
UNKNOWN			
	Cardiac Aneurysm	Menest	C
UNKNOWN			
	Corneal Deposits	Armour Thyroid	
	Haematuria	Tablets	C
UNKNOWN			
	Haemorrhage	Trazodone	
	Hypertension	Hydrochloride	C
UNKNOWN			
	Hypertensive Crisis	Garlic Extract	C
UNKNOWN			
	Musculoskeletal Disorder	Synthroid	C
UNKNOWN			
	Renal Cyst	Methotrexate	C
UNKNOWN			
	Transient Ischaemic Attack		

Date:05/18/04ISR Number: 4359941-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0404DEU00083
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Sulpiride	C				
UNKNOWN								
			Pentoxifylline	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/04ISR Number: 4359942-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bradycardia		Norvasc	C				UNKNOWN
	Conjunctival Haemorrhage		Atenolol	C				UNKNOWN
	Coronary Artery Disease							
	Hyperlipidaemia							
	Intermittent Claudication							
	Memory Impairment							
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Pharyngitis							
	Polydipsia							
	Upper Respiratory Tract Infection							
	Ventricular Tachycardia							

Date:05/18/04ISR Number: 4359943-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01518
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Dialysis		Norvasc	C		ORAL		
	Renal Failure Chronic		Levothroid	C		ORAL		
Other			Trazodone Hydrochloride	C		ORAL		
			Methocarbamol	C		ORAL		
			Prilosec	C		ORAL		

Date:05/18/04ISR Number: 4362439-2Report Type:Expedited (15-DaCompany Report #WAES 0405USA00128
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cholangitis	Study	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Cholelithiasis	Health			
MG/DAILY/PO					
Other	Diarrhoea	Professional	Tab Tracleer 62.5 Mg	SS	ORAL
62.5/BID/PO					
	Gastric Ulcer		Tab Tracleer	SS	ORAL
125					
	Gastrointestinal Disorder				
MG/BID/PO; PO					
	Nasopharyngitis		Cardizem	C	
	Pharyngolaryngeal Pain		Coumadin	C	
			Diovan	C	
			Fosamax	C	
			Lasix (Furosemide)	C	
			Lopressor	C	
			Norvasc	C	
			Premarin	C	
			Reglan	C	
			Synthroid	C	
			Zantac	C	
			Aspirin	C	
			Digoxin	C	
			Nitroglycerin	C	
			Prednisone	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/04ISR Number: 4362731-1Report Type:Expedited (15-DaCompany Report #WAES 0404ESP00007
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhagic Stroke	Foreign	Tab Vioxx					
Hospitalization -	Subdural Haematoma	Study	(Rofecoxib)	PS			25 MG/DAILY	
Initial or Prolonged		Health	Escin	C				
		Professional	Nimodipine	C				
			Omeprazole	C				

Date:05/18/04ISR Number: 4363009-2Report Type:Expedited (15-DaCompany Report #ZANA001306
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Sirdalud (Tizanidine					
Initial or Prolonged	Bacteria Urine Identified	Health	Hydrochloride)	PS		ORAL	2 MG/D ORAL	
	Diarrhoea	Professional	Trasicor (Oxprenolol					
	Drug Interaction	Other	Hydrochloride)	SS		ORAL	20 MG/D ORAL	
	Pyelocaliectasis		Alzodone (Butizide)	SS		ORAL	27.5 MG, QW3	
	Renal Failure Acute						ORAL	
			Celebrex (Celecoxib)	SS		ORAL	200 MG/D ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Becozyme Forte (Pyridoxine)	C				
			Bioflorin (Lactobacillus Acidophilus)	C				

Date:05/19/04ISR Number: 4360385-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accident
Hospitalization -	Acute Myocardial

Initial or Prolonged	Infarction
Other	Anxiety
	Arthralgia
	Bronchitis
	Condition Aggravated
	Coronary Artery Disease
	Coronary Artery Stenosis
	Dilatation Ventricular
	Diverticulum
	Diverticulum Intestinal
	Fatigue
	Gastritis
	Gastrooesophageal Reflux Disease
	Groin Pain
	Haemorrhoids
	Hypertension
	Mitral Valve Incompetence
	Musculoskeletal Stiffness
	Nasopharyngitis
	Pleural Effusion
	Post Procedural Pain
	Rectal Haemorrhage
	Red Blood Cell Count Decreased
	Skin Irritation

		Sleep Apnoea Syndrome					
		Tension Headache					
		Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Hypokinesia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Clonidine	C		
TOPICAL							
				Clonidine	C		ORAL
				Monopril	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Anaprox	C		
UNKNOWN							

Date:05/19/04ISR Number: 4360508-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02020
Age:81 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bladder Cancer Recurrent					
		Blood Pressure Abnormal					
		Cataract					
		Chronic Obstructive					
		Pulmonary Disease					
		Gastric Disorder					
		Heart Rate Irregular					
		Injury					
		Palpitations					

Date:05/19/04ISR Number: 4360509-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
Disability	Angina Pectoris
Other	Anxiety
	Breath Sounds Decreased
	Cardiomegaly
	Carpal Tunnel Syndrome
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Coronary Artery Disease
	Crackles Lung
	Cystitis
	Dizziness
	Electrocardiogram St Segment Elevation
	Emotional Distress
	Erectile Dysfunction
	Gastritis
	Gastrointestinal Disorder

	Haematemesis						
	Injury						
	Joint Range Of Motion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	
	Mediastinitis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oedema Peripheral		Augmentin	C			UNKNOWN
	Pleural Effusion		Aspirin	C			UNKNOWN
	Pleuritic Pain		Zoloft	C			UNKNOWN
	Postpericardiotomy		Temazepam	C			UNKNOWN
	Syndrome		Zocor	C		ORAL	
	Purulent Discharge		Tenormin	C			UNKNOWN
	Sinus Bradycardia		Tenormin	C			UNKNOWN
	Spinal Column Stenosis		Tagamet	C			UNKNOWN
	Spinal Osteoarthritis		Plavix	C			UNKNOWN
	Stress		Motrin	C			UNKNOWN
	Ulnar Nerve Injury						
	Wound Secretion						

Date:05/19/04ISR Number: 4360510-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Acute Prerenal Failure		Lasix (Furosemide)	C			UNKNOWN
	Acute Respiratory Failure		Glipizide	C			UNKNOWN
	Anxiety		Actos	C			UNKNOWN
	Asthenia		Brethine	C			UNKNOWN

	Asthma	Flexeril	C
UNKNOWN			
	Atelectasis	Vasotec	C
UNKNOWN			
	Cardiac Failure	K-Dur	C
UNKNOWN			
	Congestive	Altace	C
UNKNOWN			
	Cardiac Murmur Depression Dilatation Atrial Fatigue Gastrooesophageal Reflux Disease Heart Rate Increased Heart Rate Irregular Hypothyroidism Injury Mitral Valve Incompetence Osteoarthritis Pericardial Effusion Pneumonia Pulmonary Oedema Respiratory Disorder Sinus Tachycardia Sleep Apnoea Syndrome Tachycardia Tricuspid Valve Incompetence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/04ISR Number: 4360511-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00007
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL	372	DAY
	Arthritis		Norvasc	SS			UNKNOWN	
	Bronchiolitis		Cartia Xt	SS			UNKNOWN	
	Bronchospasm		Cartia (Diltiazem Hydrochloride)	C			UNKNOWN	
	Cervicitis							
	Drug Hypersensitivity							
	Drug Intolerance							
	Ear Pain							
	Erythema							
	Eustachian Tube Dysfunction							
	Faecal Occult Blood Positive							
	Headache							
	Hirsutism							
	Hypertension							
	Injury							
	Rash							
	Refusal Of Treatment By Patient							
	Sinus Headache							
	Skin Disorder							
	Upper Respiratory Tract Infection							
	Uterine Cervical Squamous Metaplasia							
	Uterine Leiomyoma							
	Weight Increased							

Date:05/19/04ISR Number: 4360513-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00114
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Infarction

Date:05/19/04ISR Number: 4360514-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Anaemia
	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Gout
	Hepatic Enzyme Increased
	Hypercholesterolaemia
	Hypokalaemia
	Myocardial Infarction
	Palpitations
	Pulmonary Oedema

Respiratory Failure
Syncope
Syncope Vasovagal

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	450	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	450	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lorcet Plus	C			UNKNOWN	
	Combivent	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Rhinocort	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Coreg	C			UNKNOWN	
	Tagamet	C			UNKNOWN	
	Biaxin	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Valium	C			UNKNOWN	
	Valium	C			UNKNOWN	
	Benadryl	C			UNKNOWN	
	Prempro	C			UNKNOWN	
	Advair	C			UNKNOWN	
	Prolex Dh	C			UNKNOWN	
	Mavik	C			UNKNOWN	

			Detrol	C		
UNKNOWN						
			Micardis	C		
UNKNOWN						
			Hydrocodone Hydrochloride	C		
UNKNOWN						
			Motrin	C		
UNKNOWN						
			Motrin	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Daypro	C		
UNKNOWN						

Date:05/19/04ISR Number: 4360515-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		85 DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C				
UNKNOWN								
Other	Bacterial Infection		Ecotrin	C				
UNKNOWN								
	Bundle Branch Block Left		Viagra	C				
UNKNOWN								
	Chest Discomfort		Calan Sr	C				
UNKNOWN								
	Coronary Artery Disease		Zocor	C				
UNKNOWN								
	Dehydration		Celebrex	C				
UNKNOWN								
	Diverticulum Intestinal		Advil	C				
UNKNOWN								
	Haemorrhagic							
	Emotional Distress							
	Gastritis Atrophic							
	Helicobacter Infection							
	Neck Pain							
	Neuropathy Peripheral							
	Stent Occlusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/04ISR Number: 4360516-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Chest Pain		Cardizem	C				UNKNOWN
Other	Depression		Ismo	C				UNKNOWN
	Emotional Distress							
	Joint Injury							
	Oedema Peripheral							
	Palpitations							
	Pneumonia							
	Skin Discolouration							
	Synovitis							

Date:05/19/04ISR Number: 4360518-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00687
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oesophageal Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/04ISR Number: 4360520-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Oedema Peripheral							
	Swelling							

Date:05/19/04ISR Number: 4360608-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia

Initial or Prolonged	Apathy
Disability	Asthenia
Other	Autonomic Nervous System
	Imbalance
	Blood Bilirubin
	Unconjugated Increased
	Blood Pressure Increased
	Bradycardia
	Chronic Obstructive
	Pulmonary Disease
	Citrobacter Infection
	Constipation
	Dehydration
	Dementia
	Depression
	Diverticulum
	Enterobacter Infection
	Fall
	Feeling Cold
	Femur Fracture
	Gastritis
	Haemorrhagic Stroke
	Hiatus Hernia
	Hyperglycaemia

		Hyponatraemia Inappropriate Antidiuretic Hormone	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Secretion		Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Interstitial Lung Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Lung Neoplasm		Valium	C		
UNKNOWN							
		Otitis Media		Neurontin	C		
UNKNOWN							
		Pain		Neurontin	C		
UNKNOWN							
		Pelvic Pain		Neurontin	C		
UNKNOWN							
		Pollakiuria		Neurontin	C		
UNKNOWN							
		Proctitis		Avapro	C		
UNKNOWN							
		Prostatitis		Misoprostol	C		
UNKNOWN							
		Pyelonephritis		Macrodantin	C		
UNKNOWN							
		Rectal Cramps		Nortriptyline	C		
UNKNOWN							
		Sinusitis		Nortriptyline	C		
UNKNOWN							
		Sleep Apnoea Syndrome					
		Urethral Stricture					
		Urinary Tract Infection Bacterial					
		Urinary Tract Infection Pseudomonal					

Date:05/19/04ISR Number: 4360610-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arteriosclerosis		Vicodin Tablets	C		
UNKNOWN							
Disability		Atherosclerosis					

Blood Cholesterol
Increased
Cardiac Failure
Congestive
Cardiac Murmur
Connective Tissue
Inflammation
Depressive Symptom
Dyspnoea Exertional
Emotional Distress
Heart Rate Irregular
Hypertension
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Low Density Lipoprotein
Increased
Mitral Valve Disease
Pulmonary Valve Stenosis
Sleep Apnoea Syndrome

Date:05/19/04ISR Number: 4360611-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Balance Disorder
Disability	Blood Pressure Increased

		Carpal Tunnel Syndrome					
		Cerebellar Infarction					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
696	DAY						
		Cognitive Disorder		Reglan	SS		
UNKNOWN							
		Cogwheel Rigidity		Celebrex	C		
UNKNOWN							
		Deafness Neurosensory		Catapres	C		
UNKNOWN							
		Diabetes Mellitus		Flonase	C		
UNKNOWN							
		Diabetes Mellitus		Prilosec	C		
UNKNOWN							
		Non-Insulin-Dependent		Lopid	C		
UNKNOWN							
		Diabetic Neuropathy		Robaxin	C		
UNKNOWN							
		Dystonia					
		Fall					
		Fatigue					
		Gallbladder Disorder					
		Glossitis					
		Haematochezia					
		Hiatus Hernia					
		Loss Of Consciousness					
		Low Density Lipoprotein					
		Increased					
		Major Depression					
		Neuropathy Peripheral					
		Orthostatic Hypotension					
		Pseudodementia					
		Radiculopathy					
		Sinusitis					
		Treatment Noncompliance					
		Tremor					

Date:05/19/04ISR Number: 4360618-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01237
Age:40 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL

	Anxiety	Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia	Vioxx	SS	Merck & Co., Inc	ORAL
	Back Injury	Meridia	C		
UNKNOWN					
	Back Pain	Ambien	C		
UNKNOWN					
	Bronchitis Chronic	Aspirin	C		
UNKNOWN					
	Cardiac Failure	Celebrex	C		
UNKNOWN					
	Congestive	Antivert	C		
UNKNOWN					
	Emotional Distress	Relafen	C		
UNKNOWN					
	Gastric Disorder	Naproxen	C		
UNKNOWN					
	Gastric Ulcer				
	Hypertension				
	Intervertebral Disc Degeneration				
	Intervertebral Disc Protrusion				
	Joint Effusion				
	Joint Injury				
	Ligament Injury				
	Major Depression				
	Meniscus Lesion				
	Osteoarthritis				
	Prescribed Overdose				
	Radiculopathy				
	Rotator Cuff Syndrome				
	Spinal Osteoarthritis				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/04ISR Number: 4360621-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01102
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder		Femhrt	C				
UNKNOWN								
	Coma							
	Deep Vein Thrombosis							
	Diverticulum							
	Finger Deformity							
	Hand Fracture							
	Hepatic Cyst							
	Livedo Reticularis							
	Peripheral Embolism							
	Pulmonary Embolism							
	Pupil Fixed							
	Renal Failure Acute							
	Uterine Leiomyoma							
	Varicose Vein							

Date:05/19/04ISR Number: 4360622-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease		Amitriptyline					
	Coronary Artery Stenosis		Hydrochloride	C				
UNKNOWN								
	Dizziness		Aspirin	C				
UNKNOWN								
	Drug Dependence		Pravachol	C				
UNKNOWN								
	Emotional Distress		Altace	C				
UNKNOWN								
	Fatigue							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hypercholesterolaemia							
	Hypertension							
	Therapeutic Response							

Decreased
Upper Respiratory Tract
Infection

Date:05/19/04ISR Number: 4360624-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Bipolar I Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Lipitor	C			UNKNOWN	
	Renal Failure Acute		Lipitor	C			UNKNOWN	
			Avapro	C			UNKNOWN	
			Geodon	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Paxil	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/04ISR Number: 4360626-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Claritin-D	SS		ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Bilirubin Increased		Vicodin Es Tablets	C		ORAL		
	Blood Glucose Increased		Ambien	C		ORAL		
	Blood Pressure Increased		Percocet	C		ORAL		
	Carpal Tunnel Syndrome		Zoloft	C		ORAL		
	Coronary Artery Disease		Zoloft	C		ORAL		
	Emotional Distress		Ceftin	C		ORAL		
	Hypertension							
	Hypertensive Heart Disease							
	Incision Site Complication							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Sleep Apnoea Syndrome							
	Thrombosis							
	Trigger Finger							

Date:05/19/04ISR Number: 4360627-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	297 DAY	
Initial or Prolonged	Infarction		Aspirin	SS			UNKNOWN	
Disability	Adjustment Disorder		Plavix	SS			UNKNOWN	1 YR
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	297 DAY	
	Anxiety		Heparin	SS			INTRAVENOUS	
	Aspiration		Vicodin Tablets	C			UNKNOWN	339 DAY

	Atherosclerosis	Lipitor	C
UNKNOWN			
	Blood Cholesterol	Zoloft	C
UNKNOWN			
	Increased	Niacin	C
UNKNOWN			
	Blood Triglycerides	Metoprolol	C
UNKNOWN			
	Increased	Monopril	C
UNKNOWN			
	Cardiac Arrest	Celebrex	C
UNKNOWN			
	Chest Pain	Analgesic Or	
	Coronary Artery Disease	Anesthetic	
	Depression	(Unspecified)	C
UNKNOWN			
	Emotional Distress		
	Gastritis		
	Hypertension		
	Lethargy		
	Myocardial Infarction		
	Upper Gastrointestinal		
	Haemorrhage		
	Ventricular Fibrillation		

Date:05/19/04ISR Number: 4360628-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00257
Age: Gender:Female I/FU:F

Outcome	PT
Death	Asthenia
	Death

	Pain						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/19/04ISR Number: 4360863-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Aura		Vioxx	PS	Merck & Co., Inc	ORAL	138 DAY
Other	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL	138 DAY
	Encephalomalacia						
	Feeling Abnormal						
	Headache						
	Intervertebral Disc Displacement						
	Lumbar Vertebral Fracture						
	Nasal Septum Deviation						
	Nasal Turbinate Hypertrophy						
	Nose Deformity						
	Otitis Media						
	Road Traffic Accident						
	Tremor						

Date:05/20/04ISR Number: 4361096-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Aspartate Aminotransferase Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
Other			Vioxx	SS	Merck & Co., Inc	ORAL	
			Lipitor	C			UNKNOWN
	Blood Pressure Inadequately Controlled		Lipitor	C			UNKNOWN

Carotid Artery Occlusion
Cerebral Infarction
Comminuted Fracture
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diastolic Dysfunction
Dysphoria
Eye Injury
Fall
Fatigue
Hyperlipidaemia
Joint Sprain
Pain
Rib Fracture
Syncope
Upper Respiratory Tract
Infection
Weight Increased

Date:05/20/04ISR Number: 4361099-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0307GBR00168
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Creatinine		Atenolol	SS				
UNKNOWN							110	DAY
Other	Increased Blood Urea Increased		Sulfamethoxazole And Trimethoprim	SS		ORAL	6	DAY
	Circulatory Collapse		Trimethoprim	SS				
UNKNOWN							11	DAY
	Heart Rate Decreased		Atenolol	SS				
UNKNOWN								
	Hyperkalaemia Hypotension		Acetaminophen And Codeine Phosphate	C				
UNKNOWN								
	Nausea		Carbomer	C				
OPHTHALMIC								
			Gabapentin	C				
UNKNOWN								
			Lansoprazole	C				
UNKNOWN								
			Senna	C				
UNKNOWN								
			Vitamin B Complex	C				
UNKNOWN								
			Simvastatin	C				
UNKNOWN								
			Ranitidine	C				
UNKNOWN								
			Nitrazepam	C				
UNKNOWN								
			Lactulose	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Fosamax	C		ORAL		
			Aspirin	C				
UNKNOWN								

Date:05/20/04ISR Number: 4361100-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	125	DAY
Initial or Prolonged	Gastrooesophageal Reflux		Coricidin	C			UNKNOWN	
Other	Disease		Allegra-D	C			UNKNOWN	
	Injury		Flonase	C			UNKNOWN	
	Pain In Extremity		Westcort	C			UNKNOWN	
	Pulmonary Embolism		Singulair	C			UNKNOWN	
	Skin Ulcer		Elidel	C			UNKNOWN	
	Sleep Apnoea Syndrome							
	Venous Stasis							

Date:05/20/04ISR Number: 4361102-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Glucose Increased
Disability	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Coronary Artery Disease
	Gastrointestinal
	Infection
	Insomnia
	Ischaemic Cardiomyopathy
	Mitral Valve Incompetence
	Nerve Compression
	Osteoporosis
	Pharyngitis
	Renal Disorder
	Renal Failure Chronic
	Seasonal Allergy

		Silent Myocardial Infarction					
		Skin Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
				Zestril	SS		
UNKNOWN							
		Ventricular Dysfunction		Zestril	SS		
UNKNOWN	406 DAY						
				Tylenol	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Nitro	C		
UNKNOWN							
				Zocor	C		ORAL
				Temazepam	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Miacalcin	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Prinivil	C		
UNKNOWN							

Date:05/20/04ISR Number: 4361103-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00089
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Hospitalization -	Distress Syndrome		Carbamazepine	C		ORAL
Initial or Prolonged	Dyspnoea Exertional		Topiramate	C		ORAL
	Hypoxia		Valproate Sodium	C		ORAL
	Viral Infection		Phenobarbital	C		ORAL
	White Blood Cell Count Increased					

Date:05/20/04ISR Number: 4361104-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Death					
	Injury					

Date:05/20/04ISR Number: 4361105-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00095
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Initial or Prolonged	Haematemesis					
	Nausea					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/04ISR Number: 4361106-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00113
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Iiird Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:05/20/04ISR Number: 4361322-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	220	DAY
Initial or Prolonged	Aortic Stenosis		Tylenol	C			UNKNOWN	
Disability	Aortic Valve		Codeine	C			UNKNOWN	
	Calcification		Vasotec	C		ORAL		
	Aortic Valve Incompetence		Premarin	C			UNKNOWN	
	Atelectasis		Premarin	C			UNKNOWN	
	Atrial Fibrillation		Zocor	C		ORAL		
	Blood Pressure Increased		Hydrocodone Hydrochloride	C			UNKNOWN	
	Cardiac Murmur							
	Cellulitis		Levsin	C			UNKNOWN	
	Chest Wall Pain		Synthroid	C		ORAL		
	Constipation		Prilosec	C		ORAL		
	Cough							
	Decreased Appetite							
	Depressed Level Of Consciousness							
	Depression							
	Disturbance In Attention							
	Dyspepsia							
	Dysphagia							
	Dysphonia							
	Dyspnoea Exertional							
	Dyspnoea Paroxysmal Nocturnal							
	Exercise Tolerance							

Decreased
Fatigue
Injury
Insomnia
Intervertebral Disc
Degeneration
Lung Neoplasm
Medical Device
Complication
Mitral Valve Incompetence
Nocturia
Oesophageal Disorder
Oesophageal Spasm
Osteopenia
Palpitations
Panic Attack
Postoperative Infection
Postoperative Thoracic
Procedure Complication
Pyrexia
Regurgitation Of Food
Rib Fracture
Spinal Osteoarthritis
Syncope
Ventricular Hypertrophy
Wound Dehiscence

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/04ISR Number: 4361328-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cancer Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Pepcid	C		ORAL		
	Congestive		Lasix (Furosemide)	C				
Disability	Cardiac Valve Disease		Neurontin	C				
	Cardio-Respiratory Arrest		Ibuprofen	C				
	Colonic Polyp		Zestril	C				
	Depression		Lithium Carbonate	C				
	Diabetes Mellitus							
	Diverticulum							
	Dyspnoea Exertional							
	Dyspnoea Paroxysmal							
	Nocturnal							
	Emotional Distress							
	Emphysema							
	Facial Palsy							
	Fall							
	Fatigue							
	Flank Pain							
	Fluid Retention							
	Haemorrhoids							
	Hemiparesis							
	Influenza							
	Insomnia							
	Myelodysplastic Syndrome							
	Myeloproliferative							
	Disorder							
	Nasopharyngitis							
	Nausea							
	Non-Hodgkin'S Lymphoma							
	Oedema Peripheral							
	Oesophagitis Haemorrhagic							
	Pathological Fracture							
	Pleural Effusion							
	Pneumonia Aspiration							
	Productive Cough							
	Pulmonary Hypertension							
	Rectal Haemorrhage							

Rectal Polyp
Sepsis
Septic Shock
Sinusitis
Splenomegaly
Sputum Discoloured
Stomatitis
Ventricular Hypertrophy

Date:05/20/04ISR Number: 4361329-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Aneurysm
	Angiopathy
	Anxiety
	Aortic Dissection

		Asthenia Atelectasis Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bacteria Sputum		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Identified		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Cognitive Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Difficulty In Walking		Amoxicillin	C		
UNKNOWN							
		Disturbance In Attention		Viagra	C		
UNKNOWN							
		Dizziness Dysstasia		Chlorhexidine Hydrochloride	C		
UNKNOWN							
		Emotional Distress Enterobacter Infection		Hydrocodone Bitartrate	C		
UNKNOWN							
		Fatigue		Lorazepam	C		
UNKNOWN							
		Gastrooesophageal Reflux Disease General Physical Condition Abnormal Haematocrit Decreased Haemoglobin Decreased Hypertension Hypoaesthesia Iliac Artery Thrombosis Impaired Healing Incision Site Complication Irritability Keloid Scar Loss Of Employment Malaise Pain Platelet Count Decreased Pneumonia Post Procedural Complication Prothrombin Time Prolonged					

Rash Pruritic
Self Esteem Decreased
Sexual Dysfunction
Soft Tissue Haemorrhage
Thrombosis
Troponin I Increased
Vascular Injury

Date:05/20/04ISR Number: 4365967-9Report Type:Expedited (15-DaCompany Report #2004212582DE
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Foreign	Bextra (Valdecoxib)					
	Drug Interaction	Health	Tablet	PS		ORAL	ORAL	
		Professional	Rofecoxib					
		Other	(Rofecoxib)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4361347-0Report Type:Expedited (15-DaCompany Report #PHRM2004FR01809
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Voltarene	PS	Novartis Sector: Pharma			
	First Degree							
RECTAL								36000MIN
	Bradycardia		Vioxx	SS		ORAL	70560MIN	
	Cardiomegaly		Stilnox	C		ORAL		
	Chest Pain		Zocor	C		ORAL	20 mg/day	
	Dyspnoea		Levothyrox	C		ORAL	100 ug/day	
	Malaise		Sectral	C		ORAL	200 mg/day	

Date:05/21/04ISR Number: 4362364-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Lorcet Plus	C				
UNKNOWN								
Disability	Brain Mass							
	Cardiac Murmur							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Depression							
	Dyspnoea							
	Emotional Distress							
	Erythema							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Hypertension							
	Mixed Hyperlipidaemia							
	Oedema							
	Osteoarthritis							
	Rhinitis Allergic							
	Spherocytic Anaemia							

Date:05/21/04ISR Number: 4362366-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticular Perforation		Proventil	C			UNKNOWN	
	Diverticulitis		Aspirin	C			UNKNOWN	
	Drug Hypersensitivity		Aspirin	C			UNKNOWN	
	Electrocardiogram		Coreg	C			UNKNOWN	
	Abnormal		Foltx	C			UNKNOWN	
	Electrocardiogram St		Zestril	C			UNKNOWN	
	Segment Depression		Niaspan	C			UNKNOWN	
	Emotional Distress		Pravachol	C		ORAL		
	Erectile Dysfunction		Metamucil	C			UNKNOWN	
	Hypokalaemia							
	Pyrexia							
	Umbilical Hernia							
	Ventricular Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362367-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrophy		Albuterol Sulfate	C			RESPIRATORY (INHALATION)	
	Cardiac Failure							
	Congestive		Fosamax	C		ORAL		
	Cardiomyopathy		Amlodipine Besylate	C		ORAL		
	Cataract		Aspirin	C		ORAL		
	Chronic Sinusitis		Atorvastatin Calcium	C			UNKNOWN	
	Confusional State		Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)	
	Dehydration							
	Depression							
	Fatigue		Lotensin	C			UNKNOWN	
	Gangrene		Calcium Carbonate	C		ORAL		
	Gastric Ulcer		Baycol	C			UNKNOWN	
	Gastritis		Diphenhydramine Hydrochloride	C		ORAL		
	Herpes Zoster		Estrogens (Unspecified)	C		ORAL		
	Hypokalaemia		Folic Acid	C		ORAL		
	Hypovolaemia		Hydrodiuril	C		ORAL		
	Muscle Spasms		Hydroxychloroquine Sulfate	C		ORAL		
	Myocardial Infarction		Indocin (Indomethacin)	C			UNKNOWN	
	Myopathy		Ipratropium Bromide	C			UNKNOWN	
	Oesophagitis		Isosorbide Mononitrate	C		ORAL		
	Orthostatic Hypotension		Misoprostol	C		ORAL		
	Paraesthesia		Naproxen	C		ORAL		
	Peripheral Occlusive Disease		Prednisone	C		ORAL		
	Pneumonia							
	Renal Cyst							
	Renal Failure Acute							
	Soft Tissue Injury							
	Syncope							
	Transient Ischaemic Attack							

Upper Gastrointestinal
Haemorrhage
Vasculitis
Weight Decreased

Date:05/21/04ISR Number: 4362368-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome PT
Disability Antiphospholipid Syndrome
Other Blood Cholesterol
Increased
Cerebrovascular Accident
Chronic Fatigue Syndrome
Colonic Polyp
Contusion
Dyspepsia
Emotional Distress
Gallbladder Disorder
Gastroenteritis Viral
Nervousness
Ovarian Cyst
Transient Ischaemic
Attack

Urinary Tract Infection
Uterine Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY

Date:05/21/04ISR Number: 4362372-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	401	DAY
Initial or Prolonged	Abdominal Pain Upper	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	3	MON
Disability	Adnexa Uteri Mass		Vioxx	SS	Merck & Co., Inc	ORAL	401	DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Azotaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blepharitis		Vioxx	SS	Merck & Co., Inc	ORAL	3	MON
	Candidiasis		Ventolin (Albuterol Sulfate)	C			UNKNOWN	
	Cardiac Failure							
	Congestive		Tenormin	C			UNKNOWN	
	Cellulitis		Ultram	C			UNKNOWN	
	Cervicitis		Vasotec	C		ORAL		
	Cough		Cenestin	C			UNKNOWN	
	Cystitis		Lodine Xl	C			UNKNOWN	
	Diarrhoea		Lasix (Furosemide Sodium)	C			UNKNOWN	
	Emotional Distress							
	Endometrial Hyperplasia		Ditropan	C			UNKNOWN	
	Epistaxis		K-Dur	C			UNKNOWN	
	Fallopian Tube Cyst		Quinine Sulfate	C			UNKNOWN	

Fistula
Fluid Retention
Hypertension
Infection
Irritable Bowel Syndrome
Lower Extremity Mass
Meniscus Lesion
Mobility Decreased
Mood Swings
Nervousness
Neuropathic Pain
Non-Cardiac Chest Pain
Osteoarthritis
Ovarian Fibrosis
Pain In Extremity
Palpitations
Peau D'Orange
Pharynx Discomfort
Pickwickian Syndrome
Pneumonia
Post Procedural
Haemorrhage
Pulmonary Oedema
Retching
Upper Respiratory Tract
Infection
Urinary Tract Infection
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362373-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastric Disorder		Tylenol With Codeine	C			AURICULAR (OTIC)	
	Gastrointestinal Disorder		Domeboro	C				
	Hypertension							
	Lumbar Spinal Stenosis		Amoxicillin	C			UNKNOWN	
	Skin Infection		Augmentin	C			UNKNOWN	
	Sleep Disorder		Lotrisone	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	
			Diabeta	C		ORAL		
			Triamcinolone	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Triamterene	C			UNKNOWN	
			Lactulose	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Levobunolol Hydrochloride	C			OPHTHALMIC	
			Zestril	C			UNKNOWN	
			Reglan	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Ranitidine	C		ORAL		

Date:05/21/04ISR Number: 4362374-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Abscess Intestinal		Darvocet-N	C			UNKNOWN	
	Atherosclerosis		Aspirin	C			UNKNOWN	
	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Chest Discomfort		Metformin	C			UNKNOWN	
	Diverticulitis		Zantac	C			UNKNOWN	
	Drug Hypersensitivity							
	Fall							
	Gastritis							
	Hiatus Hernia							
	Hypercholesterolaemia							
	Hypertension							
	Injury							
	Joint Injury							
	Liver Disorder							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Non-Hodgkin'S Lymphoma							
	Simple Partial Seizures							
	Tuberculosis							

Date:05/21/04ISR Number: 4362375-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02074
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Bone Cyst
	Bronchitis

	Chondropathy						
	Coronary Artery Stenosis						
	Dilatation Atrial	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Initial Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Wellbutrin	C			UNKNOWN
	Nocturia		Enbrel	C			UNKNOWN
	Overdose		Glucosamine	C			UNKNOWN
	Pericarditis		Methotrexate	C			UNKNOWN
	Pleurisy						
	Pleuritic Pain						
	Rheumatoid Arthritis						
	Rotator Cuff Syndrome						
	Sinus Tachycardia						
	Upper Respiratory Tract Infection						

Date:05/21/04ISR Number: 4362376-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02292
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	217 DAY
Hospitalization -	Acute Myocardial		Vicodin Tablets	C			UNKNOWN
Initial or Prolonged	Infarction		Fosamax	C			UNKNOWN
	Arteriosclerosis		Aspirin	C			UNKNOWN
	Aspiration		Buspar	C			UNKNOWN
	Bronchopneumonia		Vitamin E	C			UNKNOWN
	Cardiac Failure		Vitamins				
	Congestive		(Unspecified)	C			UNKNOWN
	Cardiogenic Shock		Calcium				

	Cardiomegaly	(Unspecified) And	
	Cerebrovascular Accident	Vitamin D	
	Dementia Alzheimer'S Type	(Unspecified)	C
UNKNOWN			
	Fall	Docusate Sodium	C
UNKNOWN			
	Heart Rate Increased	Prevacid	C
UNKNOWN			
	Infection	Zyprexa	C
UNKNOWN			
	Pneumonia Aspiration		
	Sepsis		
	Tachycardia		
	White Blood Cell Count Increased		

Date:05/21/04ISR Number: 4362379-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Other	Aphasia
	Arthralgia
	Arthropathy
	Atrial Fibrillation
	Cardiac Aneurysm
	Corneal Deposits
	Embolism
	Haematuria
	Haemorrhage
	Hypertension

		Hypertensive Crisis					
		Hypoaesthesia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
		Neuroma	Professional	Premarin	C		
UNKNOWN							
		Oedema		Estratab	C		
UNKNOWN							
		Oedema Peripheral		Menest	C		
UNKNOWN							
		Pain In Extremity		Armour Thyroid			
		Paraesthesia		Tablets	C		
UNKNOWN							
		Renal Cyst		Trazodone			
		Toe Deformity		Hydrochloride	C		
UNKNOWN							
		Transient Ischaemic		Garlic Extract	C		
UNKNOWN							
		Attack		Synthroid	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							

Date:05/21/04ISR Number: 4362380-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Respiratory Failure
Other	Adrenal Insufficiency
	Anaemia Of Chronic
	Disease
	Arteriosclerosis
	Asthma
	Bacterial Infection
	Blood Erythropoietin
	Decreased
	Candidiasis
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Colitis

Decubitus Ulcer
Deep Vein Thrombosis
Diarrhoea
Diverticulum
Duodenitis
Fungaemia
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Gynaecomastia
Haemorrhoids
Headache
Hepatic Steatosis
Hiatus Hernia
Hypercoagulation
Hyperglycaemia
Hypertension
Incisional Hernia
Inguinal Hernia
Injury
Malnutrition
Metabolic Acidosis

		Obesity					
		Oesophagitis					
		Optic Neuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Otitis Media	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pickwickian Syndrome	Professional	Catapres	C		
UNKNOWN	347 DAY						
		Pneumonia		Lasix (Furosemide)	C		
UNKNOWN							
		Pulmonary Embolism		Micardis	C		
UNKNOWN							
		Pulmonary Hypertension		Lasix (Furosemide)	C		
UNKNOWN							
		Renal Failure		Cozaar	C		
UNKNOWN							
		Renal Failure Acute					
		Rheumatoid Arthritis					
		Sepsis					
		Syncope Vasovagal					
		Thrombocytopenia					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vertigo					

Date:05/21/04ISR Number: 4362382-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
Disability	Affect Lability
Other	Anxiety Disorder
	Aortic Valve Sclerosis
	Arthralgia
	Arthropathy
	Asthma
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bundle Branch Block Right
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diverticulum

Dyspepsia
Encephalitis
Encephalopathy
Fall
Fatigue
Gastric Disorder
Gastrooesophageal Reflux
Disease
Hiatus Hernia
Hyperlipidaemia
Hypertensive Heart
Disease
Hypertrophic
Cardiomyopathy
Hypotension
Injury
Memory Impairment
Meningitis
Migraine
Myocardial Infarction
Neuritis

		Nodal Arrhythmia					
		Normochromic Normocytic Anaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophageal Spasm	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Pancreatitis		Bextra	SS		
UNKNOWN							
		Skin Laceration		[Therapy			
		Spinal Column Stenosis		Unspecified]	C		
UNKNOWN							
		Stress		Albuterol	C		
UNKNOWN							
		Tension		Lanoxin	C		
UNKNOWN							
		Therapeutic Agent		Effexor	C		
UNKNOWN							
		Toxicity		Flovent	C		
UNKNOWN							
		Urosepsis		Hydrochlorothiazide And Triamterene	C		ORAL
				Atrovent	C		
UNKNOWN							
				Singulair	C		ORAL
				Daypro	C		
UNKNOWN							

Date:05/21/04ISR Number: 4362385-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00434
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Chills		Vioxx	SS	Merck & Co., Inc	ORAL
	Cold Sweat		Vicodin Tablets	C		
UNKNOWN						
	Dizziness Postural					
	Dyspnoea					
	Electrocardiogram Abnormal					
	Gastrooesophageal Reflux Disease					
	Hyperhidrosis					

Injury
Intervertebral Disc
Protrusion
Myocardial Infarction
Nausea
Sleep Disorder

Date:05/21/04ISR Number: 4362386-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01102
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Breast Mass	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardio-Respiratory Arrest	Professional	Femhrt	C				
UNKNOWN								
	Deep Vein Thrombosis							
	Diverticulum							
	Fall							
	Finger Deformity							
	Hepatic Cyst							
	Peripheral Embolism							
	Renal Failure Acute							
	Uterine Leiomyoma							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362387-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aortic Atherosclerosis		[Therapy					
	Arthralgia		Unspecified]	C				
UNKNOWN							10 YR	
	Asthenia		Endocet	C				
UNKNOWN								
	Back Pain		Elavil	C				
UNKNOWN								
	Cardiomegaly		Tenormin	C				
UNKNOWN								
	Chromaturia		Vancenase	C				
UNKNOWN								
	Condition Aggravated		Premarin	C				
UNKNOWN							9872 DAY	
	Constipation		Prevacid	C				
UNKNOWN								
	Diarrhoea		Synthroid	C				
UNKNOWN								
	Dry Mouth		Prinivil	C		ORAL		
1501 DAY								
	Dyspnoea		Methocarbamol	C				
UNKNOWN								
	Fatigue		Prilosec	C				
UNKNOWN								
	Fluid Retention							
	Gastrooesophageal Reflux							
	Disease							
	Haemorrhoidal Haemorrhage							
	Hypersensitivity							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Lung Disorder							
	Malaise							
	Migraine							
	Myalgia							
	Nausea							
	Neuritis							
	Oedema Peripheral							
	Rash							
	Spinal Osteoarthritis							
	Splenic Cyst							

Urine Odour Abnormal
Wound Dehiscence

Date:05/21/04ISR Number: 4362388-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Angina Pectoris
	Atherosclerosis
	Bradycardia
	Conjunctival Haemorrhage
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Difficulty In Walking
	Ejection Fraction Decreased
	Fatigue
	Hyperlipidaemia
	Hypotension
	Iliac Artery Stenosis
	Intermittent Claudication
	Memory Impairment
	Mitral Valve Incompetence

		Myocardial Infarction					
		Neuropathy					
		Peripheral Vascular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pharyngitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Polydipsia		Norvasc	C		
UNKNOWN							
		Rhythm Idioventricular		Atenolol	C		
UNKNOWN							
		Upper Respiratory Tract					
		Infection					
		Ventricular Tachycardia					
		Weight Increased					

Date:05/21/04ISR Number: 4362389-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cataract		Darvocet-N	C		
UNKNOWN							
		Gastritis		Lanoxin	C		
UNKNOWN							
		Gastrointestinal		Lasix (Furosemide)	C		
UNKNOWN							
		Haemorrhage		K-Dur	C		
UNKNOWN							
		Heart Rate Irregular		Propoxyphene			
		Supraventricular		Hydrochloride	C		
UNKNOWN							
		Tachycardia					
		Weight Decreased					

Date:05/21/04ISR Number: 4362390-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Adjustment Disorder With

Mixed Anxiety And
Depressed Mood
Anger
Arthralgia
Back Pain
Blood Pressure Increased
Blood Triglycerides
Increased
Bone Pain
Breast Pain
Chest Discomfort
Chest Pain
Chills
Chondromalacia
Contusion
Coronary Artery
Atherosclerosis
Dizziness
Dressler'S Syndrome
Dyslipidaemia
Dyspepsia
Dyspnoea
Electrocardiogram T Wave
Abnormal
Emotional Distress

		Eructation					
		Extrasystoles					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gout	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
44	DAY						
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL
113	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
44	DAY						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
113	DAY						
		Joint Sprain		Vicodin Tablets	C		
UNKNOWN							
		Keratoacanthoma		Hydrocodone			
		Kyphosis		Bitartrate	C		
UNKNOWN							
		Mitral Valve Incompetence		Relafen	C		
UNKNOWN							
		Musculoskeletal Stiffness					
		Nausea					
		Pain In Extremity					
		Paraesthesia					
		Pericarditis					
		Pneumonia					
		Tension Headache					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypokinesia					

Date:05/21/04ISR Number: 4362392-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00840
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Infarction	Professional	Tylenol With Codeine			
		Circulatory Collapse		#3	C		ORAL
3	DAY						

		Feeling Abnormal		Vicodin Tablets	C		
UNKNOWN							
		Loss Of Consciousness		Flonase	C		
UNKNOWN							
		Pain In Extremity		Vitamins			
		Pulse Absent		(Unspecified)	C		
UNKNOWN							
		Pupil Fixed		Motrin	C		
UNKNOWN							
		Respiratory Arrest		Serzone	C		
UNKNOWN							
		Sleep Apnoea Syndrome					

Date:05/21/04ISR Number: 4362397-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00116
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer Haemorrhage		Aspirin	SS		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL
			Enalapril Maleate	C		ORAL

Date:05/21/04ISR Number: 4362401-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00181
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY						
Other	Myalgia		Ranitidine	C		
UNKNOWN	15 DAY					
	Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362403-3Report Type:Expedited (15-DaCompany Report #LB-MERCK-0405USA01185
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Paracetamol Tablets Bp	C			UNKNOWN	
			Vitamin B (Unspecified)	C			UNKNOWN	

Date:05/21/04ISR Number: 4362406-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00128
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiodysplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Endoscopy Upper Gastrointestinal Tract Abnormal		Acetaminophen And Codeine Phosphate	C		ORAL		
	Melaena		Atenolol	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Betahistine Hydrochloride	C		ORAL		
			Calcium Carbonate	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Nitroglycerin	C			SUBLINGUAL	
			Peanut Oil	C			UNKNOWN	
			Ranitidine	C		ORAL		

Date:05/21/04ISR Number: 4362407-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01231
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged

Date:05/21/04ISR Number: 4362408-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
Initial or Prolonged	Balance Disorder	Professional	[Therapy					
Disability	Cerebellar Infarction		Unspecified]	SS				
UNKNOWN								
	Diarrhoea		Yasmin	SS				
UNKNOWN								
	Dizziness		Tylenol	C				
UNKNOWN								
	Emotional Distress		Skelaxin	C				
UNKNOWN								
	Headache		Paxil	C				
UNKNOWN								
	Ischaemic Cerebral		Advil	C				
UNKNOWN								
	Infarction		Fioricet Tablets	C				
UNKNOWN								
	Migraine							
	Protein S Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest			C			UNKNOWN	
	Confusion Postoperative		Restoril	C			UNKNOWN	
	Dilatation Atrial		Coumadin	C		ORAL		
	Dilatation Ventricular		Vicodin Es Tablets	C			UNKNOWN	
	Duodenal Ulcer		Zestril	C			UNKNOWN	
	Haemorrhage							
	Dyspnoea							
	Faeces Discoloured							
	Gastric Ulcer							
	Helicobacter Pylori Identification Test Positive							
	Melaena							
	Oesophagitis							
	Osteoarthritis							
	Polytraumatism							
	Rectal Haemorrhage							
	Restrictive Pulmonary Disease							
	Ventricular Extrasystoles							
	Vitreous Floaters							

Date:05/21/04ISR Number: 4362591-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Antithrombin Iii Decreased
Disability	Atrial Fibrillation
Other	Bronchitis
	Cardiomyopathy
	Chest Pain
	Chronic Obstructive

Pulmonary Disease
Coagulation Factor Viii
Level Increased
Depression
Electrocardiogram T Wave
Inversion
Emotional Distress
Fatigue
Feeling Abnormal
Haemoptysis
Hypercoagulation
Influenza
Insomnia
International Normalised
Ratio Increased
Pain
Palpitations
Productive Cough
Pulmonary Embolism
Pulmonary Hypertension
Pyrexia

		Renal Cyst Sputum Discoloured Suicidal Ideation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
				Ma Huang Extract	C		
UNKNOWN		1523 DAY					
				Ambien	C		
UNKNOWN							

Date:05/21/04ISR Number: 4362593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthropathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
Disability		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Basal Cell Carcinoma		[Therapy			
		Bronchitis		Unspecified]	C		
UNKNOWN							
		Bursitis		Acyclovir	C		
UNKNOWN							
		Chest Pain		Vitamins			
		Cough		(Unspecified)	C		
UNKNOWN							
		Drug Ineffective		Aspirin	C		
UNKNOWN							
		Dyspepsia		Lipitor	C		
UNKNOWN							
		Ecchymosis		Calcium			
		Hypertension		(Unspecified)	C		
UNKNOWN							
		Hypokalaemia		Premarin	C		
UNKNOWN							
		Intervertebral Disc Degeneration Intervertebral Disc Displacement					

Migraine
Non-Cardiac Chest Pain
Pneumonia
Radiculitis Cervical
Rectocele
Respiratory Tract
Infection
Rotator Cuff Syndrome
Tooth Disorder
Viral Upper Respiratory
Tract Infection

Date:05/21/04ISR Number: 4362594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Back Injury
Initial or Prolonged	Benign Prostatic
Disability	Hyperplasia
Other	Bladder Neck Sclerosis
	Cardiovascular Disorder
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Haemolysis
	Haemorrhoidal Haemorrhage
	Hyperkalaemia
	Hyperlipidaemia
	Hypertension

		Liver Function Test Abnormal					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL
48	DAY						
		Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Rhinitis Allergic		Deconamine	C		
UNKNOWN							
		Tooth Abscess		Lisinopril	C		
UNKNOWN							
		Urethral Stricture		Meclizine	C		
UNKNOWN							
		Vertigo		Aciphex	C		
UNKNOWN							

Date:05/21/04ISR Number: 4362595-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
138	DAY						
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
138	DAY						
		Arrhythmia		Digoxin	C		
UNKNOWN		48 DAY					
		Cardiac Failure		Digoxin	C		
UNKNOWN							
		Congestive		Digoxin	C		
UNKNOWN							
		Chest Pain		Cardizem	C		
UNKNOWN							
		Dizziness		Terazosin			
		Feeling Hot		Hydrochloride	C		
UNKNOWN							
		Hyperhidrosis		Tylenol	C		
UNKNOWN							
		Ingrowing Nail		Phoslo	C		
UNKNOWN							
		Injury		[Therapy			
		Malaise		Unspecified]	C		
UNKNOWN							

	Onychomycosis	Epogen	C
UNKNOWN			
	Palpitations	Lasix (Furosemide)	C
UNKNOWN			
	Renal Failure Chronic	Apresoline	C
UNKNOWN			
	Skin Lesion	Infed	C
UNKNOWN			
	Urinary Tract Infection	Zemplar	C
UNKNOWN			

Date:05/21/04ISR Number: 4362596-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02381
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Chills		Vioxx	SS	Merck & Co., Inc	ORAL
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Cannabis	C		
UNKNOWN						
	Dysphagia		Ambien	C		
UNKNOWN						
	Emotional Distress		Lorazepam	C		
UNKNOWN						
	Feeling Hot And Cold		Oramorph	C		
UNKNOWN						
	Gastrooesophageal Reflux		Protonix	C		
UNKNOWN						
	Disease					
	Haematemesis					
	Haematochezia					
	Joint Effusion					
	Leukocytosis					
	Ligament Injury					
	Lumbar Radiculopathy					
	Nausea					
	Oedema Peripheral					
	Overdose					
	Pyrexia					
	Renal Pain					
	Sleep Disorder					
	Vomiting					

Date:05/21/04ISR Number: 4362597-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01901
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		[Therapy					
Initial or Prolonged	Circulatory Collapse		Unspecified]	C				
UNKNOWN								
	Gastrointestinal		Coumadin	C				
UNKNOWN								
	Haemorrhage		Aspirin	C				
UNKNOWN								

Date:05/21/04ISR Number: 4362598-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01945
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arteriovenous Fistula		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Site Complication		[Therapy					
Disability	Blood Amylase Increased		Unspecified]	C				
UNKNOWN								
	Cardiac Failure		Atenolol	C				
UNKNOWN								
	Congestive		Prevacid	C				
UNKNOWN								
	Cardiomegaly		Accupril	C				
UNKNOWN								
	Dialysis							
	Haematuria							
	Hypertension							
	Iron Deficiency Anaemia							
	Knee Arthroplasty							
	Lipase Increased							
	Nausea							
	Pulmonary Vascular							
	Disorder							
	Renal Failure Chronic							
	Renal Injury							
	Scoliosis							
	Staphylococcal Infection							
	Vomiting							

Date:05/21/04ISR Number: 4362599-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chloasma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Sinusitis		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease							
	Depression							
	Difficulty In Walking							
	Eustachian Tube Disorder							
	Hypercholesterolaemia							
	Injury							
	Intermittent Claudication							
	Limb Discomfort							
	Muscle Spasms							
	Myocardial Infarction							
	Peripheral Vascular							
	Disorder							
	Rash							

Date:05/21/04ISR Number: 4362600-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety							
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Bronchitis							
	Carotid Artery Stenosis							
	Cervicobrachial Syndrome							
	Coronary Artery Disease							
	Depression							
	Dermatitis Allergic							
	Diarrhoea							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Injury							
	Irritable Bowel Syndrome							
	Lung Neoplasm							
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Staphylococcal Infection							
	Ventricular Fibrillation							

Date:05/21/04ISR Number: 4362601-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		424 DAY
Initial or Prolonged	Coronary Artery Disease		Respaire	C				UNKNOWN
Other	Diabetes Mellitus		Flonase	C				UNKNOWN
	Insulin-Dependent		Minocycline	C				UNKNOWN

	Diastolic Dysfunction	Piroxicam	C
UNKNOWN			
	Fluid Overload	Prednisone	C
UNKNOWN			
	Hyperlipidaemia	Zantac	C
UNKNOWN			
	Hypertension		
	Hypoxia		
	Myocardial Infarction		
	Pain		
	Pulmonary Oedema		
	Rotator Cuff Syndrome		
	Seborrhoeic Keratosis		
	Skin Necrosis		
	Skin Ulcer		
	Syncope		
	Tricuspid Valve Incompetence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/21/04ISR Number: 4362602-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		[Therapy Unspecified]	C				
UNKNOWN	Bronchitis		Acetaminophen	C				
UNKNOWN	Cataract		Percocet	C				
UNKNOWN	Cerebral Infarction		Soma	C				
UNKNOWN	Cerebrovascular Accident		Zyrtec	C				
UNKNOWN	Dehydration		Cyanocobalamin	C				
UNKNOWN	Depression		Ultram	C				
UNKNOWN	Diarrhoea		Lamisil	C				
UNKNOWN	Diverticulitis		Estrace	C				
UNKNOWN	Gastroenteritis Viral		Premarin	C				
UNKNOWN	Gastrointestinal Disorder		Motrin	C				
UNKNOWN	Hypertension		Ocuflox	C				
UNKNOWN	Joint Range Of Motion		Oxycodone	C				
UNKNOWN	Decreased		Prednisone	C				
OPHTHALMIC	Migraine							
	Normochromic Normocytic Anaemia							
	Pain							
	Platelet Count Increased							
	Pneumonia							
	Renal Failure Acute							

Date:05/21/04ISR Number: 4362603-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00036
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		26 DAY
Initial or Prolonged			Diclofenac Sodium	SS				
			Acebutolol Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Zocor	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:05/21/04ISR Number: 4362604-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess
Initial or Prolonged	Bundle Branch Block Right
	Cyst
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Emotional Distress
	Extravasation
	Gastrooesophageal Reflux
	Disease
	Hiatus Hernia
	Ileal Ulcer
	Ileitis
	Intervertebral Disc
	Degeneration

	Ischaemia						
	Large Intestinal Obstruction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Large Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Large Intestine		Vioxx	SS	Merck & Co., Inc	ORAL	15 DAY
	Perforation		Ecotrin	C		ORAL	
	Metabolic Acidosis		Lipitor	C			UNKNOWN
	Multi-Organ Failure		Zebeta	C			UNKNOWN
	Necrotising Colitis		Ziac	C			UNKNOWN
	Osteoarthritis		Vasotec	C		ORAL	
	Pleural Effusion		Vasotec	C		ORAL	
	Renal Cortical Necrosis		Hydrochlorothiazide	C			UNKNOWN
	Renal Cyst		Prevacid	C			UNKNOWN
	Renal Failure Acute		Relafen	C			UNKNOWN
	Renal Tubular Necrosis						
	Respiratory Failure						
	Septic Shock						
	Small Intestine Ulcer						
	Vasospasm						
	Wound Infection						

Date:05/21/04ISR Number: 4362605-6Report Type:Expedited (15-DaCompany Report #FI-MERCK-0405FIN00005
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	
Life-Threatening	Haemorrhage						

Date:05/21/04ISR Number: 4362606-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00030
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - 17 DAY	Asthma	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Nicardipine Hydrochloride	C		ORAL
		Risedronate Sodium	C		ORAL
17 DAY					

Date:05/21/04ISR Number: 4364597-2Report Type:Expedited (15-DaCompany Report #2004031829
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Body Height Decreased	Consumer	Lipitor			
	Cardiac Operation		(Atorvastatin)	PS		ORAL
10 MG (10 MG,						
	Carpal Tunnel Syndrome					
1 IN 1 D),						
	Depression					
ORAL						
	Drug Ineffective		Rofecoxib			
	Fall		(Rofecoxib)	SS		
	Intervertebral Disc		Fexofenadine			
	Disorder		Hydrochloride			
	Ligament Disorder		(Fexofenadine			
	Oedema Peripheral		Hydrochloride)	SS		
	Prostatic Disorder		Loratadine			
	Sinus Disorder		(Loratadine)	SS		
	Stent Placement		Esomeprazole			
			(Esomeprazole)	C		
			General			
			Nutrients/Minerals/V			
			itamins (General			

Nutrients, Minerals Nos, Vitamins Nos)	C
Dyazide (Hydrochlorothiazide , Triamterene)	C
Tocopherol (Tocopherol)	C
Lecithin (Lecithin)	C
Cod-Liver Oil (Cod-Liver Oil)	C
Propanolol (Propanolol)	C

Date:05/24/04ISR Number: 4363356-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Pulmonary Oedema		Amitriptyline Hydrochloride	SS		ORAL		
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cataract		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis			C			UNKNOWN	
	Contusion		Tylenol	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Cystitis		Buspirone Hydrochloride	C			UNKNOWN	
	Dehydration							
	Drug Ineffective		Aricept	C		ORAL		
	Electrocardiogram Qt Prolonged		Fluoxetine	C			UNKNOWN	
			Lorazepam	C			UNKNOWN	
	Fall		Ambien	C			UNKNOWN	

	Fat Embolism	Metoclopramide	C	
UNKNOWN				
	Femur Fracture	Prozac	C	
UNKNOWN				
	Gastroenteritis	Premarin	C	ORAL
	Gastrooesophageal Reflux	Valium	C	
UNKNOWN				
	Disease	Aspirin	C	
UNKNOWN				
	Hypertension	Vicodin Tablets	C	
UNKNOWN				
	Laceration	Darvocet-N	C	
UNKNOWN				
	Lacunar Infarction			
	Nausea			
	Pain			
	Pollakiuria			
	Renal Failure			
	Rotator Cuff Syndrome			
	Skin Ulcer			
	Spinal Compression			
	Fracture			
	Suicidal Ideation			
	Urinary Tract Infection			
	Vomiting			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/04ISR Number: 4363359-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		34 DAY
Initial or Prolonged	Alcoholic Seizure							
Other	Blood Pressure							
	Fluctuation							
	Cardiovascular Disorder							
	Change Of Bowel Habit							
	Encephalopathy							
	Gastrointestinal Disorder							
	Grand Mal Convulsion							
	Haematemesis							
	Headache							
	Influenza							
	Nasopharyngitis							
	Oedema							
	Pruritus							
	Renal Failure							
	Vision Blurred							
	Weight Decreased							

Date:05/24/04ISR Number: 4363360-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Norvasc	C				
UNKNOWN								
	Restenosis		Aspirin	C				
UNKNOWN								
	Cough		Lipitor	C				
UNKNOWN								
	Decreased Appetite		Monopril	C				
UNKNOWN								
	Diarrhoea		Indocin					
	Drug Ineffective		(Indomethacin)	C				
UNKNOWN								

	Dyspnoea	Toprol Xl Tablets	C
UNKNOWN			
	Fatigue	Lopressor	C
UNKNOWN			
	Fluid Retention	Naproxen	C
UNKNOWN			
	Hypertension		
	Hypoaesthesia		
	Injury		
	Insomnia		
	Myocardial Infarction		
	Nausea		
	Non-Cardiac Chest Pain		
	Oedema Peripheral		
	Paraesthesia		
	Prostatic Specific		
	Antigen Increased		
	Rectal Haemorrhage		
	Rheumatoid Arthritis		
	Umbilical Hernia		
	Ventricular Extrasystoles		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/04ISR Number: 4363361-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis							
	Emotional Distress							
	Hyperlipidaemia							
	Injury							
	Intervertebral Disc Degeneration							
	Irritable Bowel Syndrome							
	Myocardial Infarction							

Date:05/24/04ISR Number: 4363363-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Balance Disorder		Tylenol	C				
UNKNOWN								
	Cellulitis		Ascorbic Acid	C				
UNKNOWN								
	Decreased Appetite		Aspirin	C				
UNKNOWN								
	Dizziness		Atenolol	C				
UNKNOWN								
	Drug Ineffective		Lotensin	C				
UNKNOWN								
	Dyspepsia		Zocor	C				
UNKNOWN								
	Feeling Jittery		Vitamin E	C				
UNKNOWN								
	Gout		Coenzyme Q10	C				
UNKNOWN								
	Injury		Colchicine	C				
UNKNOWN								
	Insomnia		Glucosamine	C				
UNKNOWN								
	Intervertebral Disc		Aleve	C				
UNKNOWN								

	Degeneration	Nonsteroidal	
	Mood Altered	Anti-Inflammatory	
	Osteoarthritis	Drug (Unspecified)	C
UNKNOWN			
	Pain	Omega-3	C
UNKNOWN			
	Scoliosis	Zantac	C
UNKNOWN			
	Spondylolisthesis		
	Acquired		

Date:05/24/04ISR Number: 4363365-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Arthralgia
Disability	Blood Pressure Decreased
	Cerebrovascular Accident
	Chest Pain
	Dysarthria
	Electrocardiogram Qt Prolonged
	Electrocardiogram St-T Change
	Facial Palsy
	Headache
	Heart Rate Irregular
	Hemiparesis
	Hypertensive Crisis
	Hypertonia

		Hypokalaemia					
		Hypotonia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
31	DAY						
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
31	DAY						
		Respiratory Rate		Albuterol	C		
RESPIRATORY							
		Increased					
(INHALATION)							
		Rhinitis		Trinalin	C		
UNKNOWN							
		Sinusitis		Klonopin	C		
UNKNOWN							
				Clonidine	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		ORAL
				Cyclobenzaprine Hydrochloride	C		ORAL
				Prempro	C		
UNKNOWN							
				Relafen	C		ORAL

Date:05/24/04ISR Number: 4363366-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Disorder	Professional	Tylenol With Codeine	C		
UNKNOWN						
	Gastric Disorder		Domeboro	C		
AURICULAR						
	Gastrointestinal Disorder					
(OTIC)						
	Hypertension		Amoxicillin	C		
UNKNOWN						
	Lumbar Spinal Stenosis		Augmentin	C		
UNKNOWN						

	Sciatica	Lotrisone	C	
UNKNOWN				
	Skin Infection	Clonazepam	C	
UNKNOWN				
	Sleep Disorder	Diabeta	C	ORAL
		Triamcinolone	C	
UNKNOWN				
		Coumadin	C	
UNKNOWN				
		Coumadin	C	
UNKNOWN				
		Vitamin E	C	
UNKNOWN				
		Triamterene	C	
UNKNOWN				
		Lactulose	C	
UNKNOWN				
		Prevacid	C	
UNKNOWN				
		Levobunolol Hydrochloride	C	
OPHTHALMIC				
		Zestril	C	
UNKNOWN				
		Reglan	C	
UNKNOWN				
		Aciphex	C	
UNKNOWN				
		Ranitidine	C	ORAL

Date:05/24/04ISR Number: 4363367-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Strangulated Hernia
	Activities Of Daily Living Impaired
	Acute Prerenal Failure
	Anaemia
	Atherosclerosis
	Blood Creatinine Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Glucose Increased Blood Sodium Decreased Blood Urea Increased					
		Bundle Branch Block Right Cardiac Failure	Health Professional	Vioxx Vicodin Tablets	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Congestive		Zyloprim	C		
UNKNOWN							
		Cardiac Murmur		Xanax	C		
UNKNOWN							
		Carotid Bruit		Ecotrin	C		
UNKNOWN							
		Carpal Tunnel Syndrome		Aspirin	C		
UNKNOWN							
		Cerumen Impaction		Lipitor	C		
UNKNOWN							
		Colonic Polyp		Ultram	C		
UNKNOWN							
		Constipation		Carisoprodol	C		
UNKNOWN							
		Contusion		Vasotec	C		
UNKNOWN							
		Deafness		Micronase	C		
UNKNOWN							
		Deafness Neurosensory		Prevacid	C		
UNKNOWN							
		Dehydration		Glucophage	C		
UNKNOWN							
		Diarrhoea		Centrum	C		
UNKNOWN							
		Diastolic Dysfunction Eustachian Tube Dysfunction Faecal Occult Blood Positive Gastric Ulcer Haemorrhage Gastritis Gastritis Erosive Gastroenteritis Gastrointestinal Disorder Haemoglobin Decreased Haemorrhoids Hearing Impaired Hiatus Hernia Ileus Melaena					

Metaplasia
Musculoskeletal Stiffness
Nausea
Pyrexia
Renal Failure
Small Intestinal
Obstruction
Thrombocytopenia
Upper Gastrointestinal
Haemorrhage
Ventricular Hypertrophy
Vomiting

Date:05/24/04ISR Number: 4363368-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization -	Acute Respiratory
Initial or Prolonged	Distress Syndrome
	Arthralgia
	Aspiration
	Atelectasis
	Atrial Fibrillation
	Bacterial Infection
	Blood Pressure Decreased
	Blood Pressure

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Inadequately Controlled Breast Tenderness Cardio-Respiratory Arrest Chills					
		Coagulopathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY	Coronary Artery Disease Depression		Tylenol With Codeine #3	C		
UNKNOWN		Dyspnoea Exertional		Percocet	C		
UNKNOWN		Extradural Abscess		Ascorbic Acid	C		
UNKNOWN		Fatigue		Vitamin E	C		
UNKNOWN		Groin Pain		Zocor	C		
UNKNOWN		Hypersensitivity		Beta Carotene	C		
UNKNOWN		Hypokalaemia		Centrum	C		
UNKNOWN		Influenza Injury Intervertebral Disc Disorder Intervertebral Discitis Multi-Organ Failure Myalgia Myocardial Infarction Nausea Pancreatic Atrophy Pancreatitis Pyrexia Radiculitis Rash Renal Failure Acute Renal Tubular Necrosis Sepsis Throat Irritation Upper Respiratory Tract Infection Ureteric Obstruction Ventricular Fibrillation Ventricular Tachycardia Viral Infection Vomiting					

Date:05/24/04ISR Number: 4363369-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00002
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Renal Failure							

Date:05/24/04ISR Number: 4363370-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Death	Angiopathy
Hospitalization -	Anxiety
Initial or Prolonged	Back Injury
Disability	Back Pain
	Cerebrovascular Accident
	Dehydration
	Dementia Alzheimer'S Type
	Dysuria
	Emotional Distress
	Facial Pain

		Fall					
		Hypertension					
		Renal Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL

Date:05/24/04ISR Number: 4363373-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Asthenia		Atenolol	C		
UNKNOWN						
	Back Pain		Zyrtec	C		
UNKNOWN						
	Carpal Tunnel Syndrome		Celexa	C		
UNKNOWN						
	Coronary Artery		Flonase	C		
UNKNOWN						
	Atherosclerosis		Hydrocodone			
	Drug Ineffective		Bitartrate	C		
UNKNOWN						
	Dyslipidaemia		Levsin	C		
UNKNOWN						
	Extravasation		Indocin			
	Fall		(Indomethacin)	C		ORAL
	High Density Lipoprotein		Naproxen	C		
UNKNOWN						
	Decreased		Prilosec	C		
UNKNOWN						
	Injury		Oxycontin	C		
UNKNOWN						
	Intervertebral Disc		Aciphex	C		
UNKNOWN						
	Disorder					
	Loose Body In Joint					
	Muscle Injury					
	Muscular Weakness					
	Myalgia					
	Osteoarthritis					

Peripheral Coldness
Road Traffic Accident
Rotator Cuff Syndrome
Scapula Fracture
Sinus Bradycardia
Skin Laceration
Tendonitis
Trigger Finger

Date:05/24/04ISR Number: 4363377-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00022
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Balance Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Hospitalization - Initial or Prolonged	Brain Neoplasm Malignant	Professional	Amitriptyline Hydrochloride	C		ORAL		
			Bromazepam	C		ORAL		
			Acetaminophen	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Oxazepam	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/04ISR Number: 4363378-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Abdominal Discomfort	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Accident At Work		Vioxx	SS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adhesion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Alcohol Withdrawal Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
			Lortab	C			UNKNOWN	
	Alcoholism		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Anaemia							
	Anxiety							
	Arthralgia		Trazodone Hydrochloride	C			UNKNOWN	
	Arthropathy							
	Biliary Neoplasm		Amitriptyline Hydrochloride	C			UNKNOWN	874 DAY
	Bronchitis							
	Cardiac Failure		Celebrex	C			UNKNOWN	362 DAY
	Congestive		Neurontin	C			UNKNOWN	
	Cerebrovascular Accident		Hydrocodone Bitartrate	C			UNKNOWN	
	Coronary Artery Disease							
	Depression		Ibuprofen	C			UNKNOWN	
	Drug Dependence		Lorazepam	C			UNKNOWN	2 DAY
	Drug Ineffective		Robaxin	C			UNKNOWN	957 DAY
	Dysuria							
	Emotional Distress							
	Facet Joint Syndrome							
	Faecal Occult Blood Positive							
	Fatigue							
	Headache							
	Hepatitis C							
	Hyperlipidaemia							
	Hypertension							
	Insomnia							

Intervertebral Disc
Protrusion
Loss Of Consciousness
Lumbar Spinal Stenosis
Micturition Urgency
Mouth Ulceration
Muscle Spasms
Myocardial Infarction
Myofascial Pain Syndrome
Osteoarthritis
Panic Attack
Pneumonia
Pollakiuria
Prostatitis
Pyrexia
Rash Pruritic
Spinal Osteoarthritis
Syncope
Urinary Tract Infection
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/04ISR Number: 4363449-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01681
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Ineffective	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Life-Threatening	Fatigue	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Hospitalization -	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	5	MON
Disability	Respiratory Failure		Tylenol	C		ORAL		
Other	Spinal Column Stenosis		Norvasc	C		ORAL		
			Hyzaar	C		ORAL		
			Darvon	C		ORAL		

Date:05/24/04ISR Number: 4363450-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00124
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Skin Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	746	DAY
	Vasculitic Rash		Dihydrocodeine	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:05/24/04ISR Number: 4363452-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Anaemia
Other	Arthritis
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Cardiomyopathy
	Colonic Polyp
	Convulsion

Coronary Artery Disease
Decubitus Ulcer
Dysphagia
Electrolyte Imbalance
Faecaloma
Gastrointestinal
Haemorrhage
Heart Rate Irregular
Herpes Zoster
Hypertension
Influenza
Ischaemic Cardiomyopathy
Liver Function Test
Abnormal
Malnutrition
Myocardial Infarction
Oedema
Pericarditis
Pneumonia
Pneumonia Aspiration
Post Herpetic Neuralgia
Pulmonary Oedema
Pyrexia
Radiculitis Brachial

		Respiratory Failure Rotator Cuff Syndrome Staphylococcal Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Stent Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
91	DAY						
		Thrombocytopenia		Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Capoten	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Glipizide	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Nitrol (Nitroglycerin)	C		
UNKNOWN							
				Altace	C		
UNKNOWN							

Date:05/24/04ISR Number: 4363454-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Unstable
Other	Atelectasis
	Azotaemia
	Beta Haemolytic Streptococcal Infection
	Bronchitis
	Cardiac Failure

Congestive
Carotid Artery Disease
Carotid Artery Stenosis
Central Line Infection
Cerebral Artery Occlusion
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Coronary Artery Disease
Coronary Artery
Restenosis
Depressed Level Of
Consciousness
Diabetes Mellitus
Dressler'S Syndrome
Gastrointestinal
Haemorrhage
Hyperbilirubinaemia
Hyperlipidaemia
Leukocytosis
Myocardial Infarction
Peripheral Vascular
Disorder
Pneumonia
Post Procedural
Complication
Pyrexia
Rash
Respiratory Failure

		Skin Candida Staphylococcal Infection Stent Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Subclavian Artery		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Stenosis					

Date:05/24/04ISR Number: 4363795-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00007
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL
372 DAY							
		Arthritis		Norvasc	SS		
UNKNOWN							
		Bronchiolitis		Cartia Xt	SS		
UNKNOWN							
		Bronchospasm Cervicitis		Cartia (Diltiazem Hydrochloride)	C		
UNKNOWN							
		Drug Hypersensitivity Erythema Eustachian Tube Dysfunction Faecal Occult Blood Positive Hirsutism Hypertension Injury Rash Skin Disorder Upper Respiratory Tract Infection Uterine Cervical Squamous Metaplasia Uterine Leiomyoma Weight Increased					

Date:05/24/04ISR Number: 4363796-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		552 DAY
Initial or Prolonged	Abdominal Distension		Aleve	SS				UNKNOWN
Disability	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		552 DAY
	Anxiety		Tylenol	C				UNKNOWN
	Back Pain		Paxil	C				
UNKNOWN	Cognitive Disorder						2 MON	
	Confusional State							
	Constipation							
	Dizziness							
	Emotional Distress							
	Global Amnesia							
	Haematochezia							
	Hypertension							
	Influenza Like Illness							
	Injury							
	Lethargy							
	Transient Ischaemic Attack							

Date:05/24/04ISR Number: 4363797-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
	Diabetes Mellitus		[Therapy					
	Gastrooesophageal Reflux		Unspecified]	C				
UNKNOWN							144 DAY	
	Disease		Tylenol	C				
UNKNOWN								
	Hemiparesis		Darvocet-N	C				
UNKNOWN								
	Hypoaesthesia		Soma	C				
UNKNOWN								
	Injury							
	Intervertebral Disc							
	Degeneration							
	Lipoma							
	Spinal Osteoarthritis							

Date:05/24/04ISR Number: 4363798-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/04ISR Number: 4363800-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00060
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	SS		ORAL		
			Amlodipine Besylate	C		ORAL		
			Atenolol	C		ORAL		
			Fenofibrate	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		

Date:05/24/04ISR Number: 4363801-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01287
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Arthralgia
	Blindness Unilateral
	Blood Pressure Systolic Decreased
	Blood Urea Increased
	Cataract
	Coronary Artery Disease
	Coronary Artery Stenosis
	Gastrooesophageal Reflux Disease
	Myocardial Infarction
	Myocardial Ischaemia
	Nuclear Magnetic Resonance Imaging Brain Abnormal
	Ocular Vascular Disorder
	Optic Atrophy
	Optic Ischaemic Neuropathy
	Osteoarthritis

		Papilloedema					
		Rotator Cuff Syndrome					
		Sinus Bradycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Tension Headache		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Vascular Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypokinesia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Visual Field Defect		Aspirin	C		
UNKNOWN							
				Aciphex	C		ORAL
				Restoril	C		
UNKNOWN							

Date:05/24/04ISR Number: 4363802-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03194
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acquired Diaphragmatic
Initial or Prolonged	Eventration
Other	Angina Pectoris
	Angina Unstable
	Arthritis
	Asthenia
	Atelectasis
	Atrial Fibrillation
	Atrioventricular Block
	First Degree
	Back Pain
	Bereavement Reaction
	Blood Pressure Systolic
	Increased
	Body Temperature
	Increased
	Bradycardia
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Decreased Appetite

Depression
Dilatation Atrial
Dilatation Ventricular
Drug Ineffective
Dyspnoea Exertional
Electrocardiogram
Repolarisation
Abnormality
Exercise Lack Of
Fall
Fluid Retention
Hyperlipidaemia
Hypertension
Inguinal Hernia
Intracardiac Thrombus
Mitral Valve Disease
Mitral Valve Incompetence
Musculoskeletal
Discomfort
Myocardial Infarction

		Myocardial Ischaemia					
		Neovascularisation					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oxygen Saturation		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity					
		Pitting Oedema					
		Pleural Effusion					
		Post Procedural					
		Complication					
		Pulmonary Fibrosis					
		Pulmonary Hilum Mass					
		Pulmonary Hypertension					
		Rales					
		Respiratory Rate					
		Increased					
		Stress					
		Supraventricular					
		Extrasystoles					
		Thrombosis					
		Urinary Retention					
		Vascular Bypass					
		Dysfunction					
		Ventricular Dyskinesia					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					

Date:05/25/04ISR Number: 4364250-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Anaemia
Disability	Angina Unstable
Other	Anxiety
	Arthralgia
	Back Injury
	Back Pain
	Blood Pressure
	Inadequately Controlled
	Bronchitis Acute
	Condition Aggravated
	Conjunctival Haemorrhage

Contusion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Restenosis
Coronary Artery Stenosis
Coronary Ostial Stenosis
Depression
Diarrhoea
Diastolic Dysfunction
Dizziness
Duodenitis
Dyspnoea
Fall

		Fatigue					
		Feeling Hot And Cold					
		Fibroma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematochezia	Professional	Plavix	SS		
UNKNOWN							
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Consciousness		Fioricet Tablets	C		
UNKNOWN							
		Menopausal Symptoms		Vicodin Tablets	C		
UNKNOWN							
		Migraine		Vasotec	C		ORAL
		Mitral Valve Incompetence		Calan Sr	C		
UNKNOWN							
		Myocardial Infarction		Hydrochlorothiazide	C		
UNKNOWN							
		Myocardial Ischaemia		Cardizem	C		
UNKNOWN							
		Nausea		Ecotrin	C		
UNKNOWN							
		Orthostatic Hypotension					
		Palpitations					
		Paraesthesia					
		Pelvic Peritoneal					
		Adhesions					
		Phaeochromocytoma					
		Phlebothrombosis					
		Photopsia					
		Respiratory Failure					
		Rhinitis Seasonal					
		Scar					
		Sinus Polyp					
		Stent Occlusion					
		Supraventricular					
		Extrasystoles					
		Syncope					
		Temperature Intolerance					
		Thrombophlebitis					
		Superficial					
		Tricuspid Valve					

Incompetence
Upper Gastrointestinal
Haemorrhage
Ventricular Extrasystoles
Vision Blurred

Date:05/25/04ISR Number: 4364255-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02187
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Blood Pressure Increased
	Bronchitis Acute
	Chest Pain
	Constipation
	Drug Hypersensitivity
	Dyspnoea Exertional
	Emotional Distress
	Fatigue
	Gastrointestinal Disorder
	Gastrooesophageal Reflux

		Disease Haemorrhagic Disorder Ischaemia Limb Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Laceration		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Compression Fracture Transient Ischaemic Attack Upper Respiratory Tract Infection					

Date:05/25/04ISR Number: 4364257-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Antiphospholipid Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Other	Blood Cholesterol	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
7 DAY						
	Increased Cerebrovascular Accident Cholecystitis Chronic Fatigue Syndrome Colonic Polyp Contusion Diverticulum Dyspepsia Emotional Distress Gastroenteritis Viral Haemorrhoids Nervousness Ovarian Cyst Transient Ischaemic Attack Urinary Tract Infection Uterine Disorder					

Date:05/25/04ISR Number: 4364258-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acoustic Neuritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Darvocet-N	C				
UNKNOWN								
	Cardiac Ventricular		Coumadin	C				
UNKNOWN								
	Disorder		Darvocet-N	C				
UNKNOWN								
	Cerebellar Infarction							
	Dilatation Atrial							
	Labyrinthitis							
	Osteoarthritis							
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							

Date:05/25/04ISR Number: 4364260-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anaemia
	Arthropod Bite
	Arthropod Sting

		Bursitis					
		Chest Pain					
		Chronic Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Conjunctivitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Constipation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
245	DAY						
		Coronary Artery Disease		Fosamax	C		ORAL
		Dyspepsia		Valium	C		
UNKNOWN							
		Fracture Nonunion		Neurontin	C		
UNKNOWN							
		Generalised Anxiety		Neurontin	C		
UNKNOWN							
		Disorder		Valtrex	C		
UNKNOWN							
		Influenza		Neurontin	C		
UNKNOWN							
		Injury		Glucosamine	C		
UNKNOWN							
		Joint Sprain		Nitrostat	C		
UNKNOWN							
		Libido Decreased		Evista	C		
UNKNOWN							
		Multiple Fractures					
		Oedema Peripheral					
		Osteoporosis					
		Panic Disorder					
		Road Traffic Accident					
		Sebaceous Hyperplasia					
		Thoracic Outlet Syndrome					
		Viral Pharyngitis					
		Weight Increased					

Date:05/25/04ISR Number: 4364261-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01724
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Adjustment Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Vicodin Tablets	C		ORAL

	Arthritis	Soma	C	ORAL
	Asthenia	Soma	C	ORAL
	Bursitis	Cyanocobalamin	C	INTRAMUSCULAR
	Coronary Artery Disease	Estradiol	C	INTRAMUSCULAR
	Coronary Artery Stenosis	Premarin	C	UNKNOWN
	Decreased Appetite	Allegra	C	UNKNOWN
	Drug Effect Decreased	Levoxyl	C	UNKNOWN
	Fall	Claritin	C	UNKNOWN
	Fatigue			
	Headache			
	Hip Fracture			
	Hypertension			
	Insomnia			
	Irritability			
	Myocardial Infarction			
	Nervousness			
	Post Procedural Haemorrhage			

Date:05/25/04ISR Number: 4364263-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	586 DAY	
		Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL	586 DAY	
		Blood Triglycerides		Tylenol	C			UNKNOWN	
		Increased		Albuterol	C			UNKNOWN	
		Cerebral Haemorrhage		Amoxicillin	C			UNKNOWN	
		Chest Wall Pain		Aspirin	C			UNKNOWN	
		Death		Lotensin	C			UNKNOWN	119 DAY
		Deep Vein Thrombosis		Correctol (Bisacodyl)	C			UNKNOWN	
		Depression		Cerivastatin Sodium	C			UNKNOWN	
		Dizziness		Baycol	C			UNKNOWN	
		Drug Hypersensitivity		Doxepin Hydrochloride	C			UNKNOWN	
		Dyspepsia		Calan	C			UNKNOWN	
		Dyspnoea		Hydrochlorothiazide	C			UNKNOWN	
		Emotional Distress		Maxzide	C			UNKNOWN	
		Fatigue		Dyazide	C			UNKNOWN	
		Gastrointestinal Disorder		Dyazide	C			UNKNOWN	
		High Density Lipoprotein		Medrol	C			UNKNOWN	
		Increased		Singulair	C			UNKNOWN	
		Hyperlipidaemia		Pravachol	C			UNKNOWN	
		Hypertension						UNKNOWN	
		Injury						UNKNOWN	1210 DAY
		Transient Ischaemic Attack							

Date:05/25/04ISR Number: 4364266-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome	Health Professional	Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
Disability	Acute Myocardial Infarction			C				
Other	Aortic Dilatation		Doxepin Hydrochloride	C				
	Back Pain							
	Convulsion		Neurontin	C				
	Drug Hypersensitivity		Ultram	C				
	Fall		Zanaflex	C				
	Generalised Anxiety		Serzone	C				
	Disorder		Oxycodone	C				
	Haemorrhage Intracranial							
	Hypertension							
	Hypoaesthesia							
	Pain							
	Panic Attack							
	Pulmonary Congestion							
	Retinal Ischaemia							
	Rhinitis							
	Sleep Apnoea Syndrome							
	Visual Acuity Reduced							

Date:05/25/04ISR Number: 4364267-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Benign Neoplasm
Other	Chest Pain

		Colonic Polyp					
		Coronary Artery Disease					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Restenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Depression	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Epicondylitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Exostosis		Tylenol	C		
UNKNOWN							
		Gastroenteritis Viral		Acetaminophen And			
		Generalised Anxiety		Propoxyphene			
		Disorder		Napsylate	C		
UNKNOWN							
		Gout		Xanax	C		
UNKNOWN							
		Haematoma		Aspirin	C		
UNKNOWN							
		Hypercholesterolaemia		Librax Capsules	C		
UNKNOWN							
		Hypertension		Cyclobenzaprine			
		Insomnia		Hydrochloride	C		
UNKNOWN							
		Intervertebral Disc		Allegra	C		
UNKNOWN							
		Degeneration		Prilosec	C		
UNKNOWN							
		Lung Neoplasm		Zantac	C		
UNKNOWN							
		Myocardial Infarction					
		Myositis					
		Osteochondrosis					
		Pain In Extremity					
		Rotator Cuff Syndrome					
		Sleep Disorder					
		Tendonitis					
		Tinnitus					
		Urinary Tract Infection					

Date:05/25/04ISR Number: 4364269-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01516
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Other	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Arrest		Beclomethasone			
	Dizziness		Dipropionate	C		
RESPIRATORY						
	Electromechanical					
(INHALATION)						
	Dissociation		Allegra	C		ORAL
	Hypertension		Zocor	C		ORAL
	Medication Error		Adalat	C		ORAL
	Nasal Disorder		Zantac	C		ORAL
	Seborrhoeic Keratosis					
	Ventricular Fibrillation					
	Vertigo Positional					

Date:05/25/04ISR Number: 4364270-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
	Anaemia
	Anxiety
	Asthenia
	Atelectasis
	Blood Pressure Increased
	Cardiac Failure
	Congestive

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chronic Obstructive Pulmonary Disease					
		Coronary Artery Disease					
450	DAY	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gout	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
450	DAY	Hepatic Enzyme Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Hypokalaemia		Lorcet Plus	C		
UNKNOWN		Insomnia		Combivent	C		
UNKNOWN		Ischaemia		Aspirin	C		
UNKNOWN		Mitral Valve Disease		Lipitor	C		
UNKNOWN		Myocardial Infarction		Rhinocort	C		
UNKNOWN		Palpitations		Wellbutrin	C		
UNKNOWN		Pulmonary Oedema		Coreg	C		
UNKNOWN		Respiratory Failure		Tagamet	C		
UNKNOWN		Syncope		Biaxin	C		
UNKNOWN		Syncope Vasovagal		Plavix	C		
UNKNOWN		Tricuspid Valve Incompetence		Cyclobenzaprine Hydrochloride	C		
UNKNOWN		Ventricular Arrhythmia		Valium	C		
UNKNOWN				Valium	C		
UNKNOWN				Benadryl	C		
UNKNOWN				Prempro	C		
UNKNOWN				Advair	C		
UNKNOWN				Prolex Dh	C		
UNKNOWN				Mavik	C		
UNKNOWN							

			Detrol	C			
UNKNOWN							
			Micardis	C			
UNKNOWN							
			Hydrocodone Hydrochloride	C			
UNKNOWN							
			Motrin	C			
UNKNOWN							
			Motrin	C			
UNKNOWN							
			Toprol Xl Tablets	C			
UNKNOWN							
			Daypro	C			
UNKNOWN							

Date:05/25/04ISR Number: 4364271-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00992
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 227 DAY	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN	Depression		Aspirin	C				
	Haemorrhagic Stroke		Cortisone (Cortisone Acetate)	C				
UNKNOWN	Headache							
	Hypersensitivity		Vasotec	C		ORAL		
	Hypothyroidism		Prempro	C				
UNKNOWN	299 DAY							
	Muscle Spasms		Allegra-D	C				
UNKNOWN								
	Nausea		Amaryl	C				
UNKNOWN								
	Pain In Extremity		Levoxyl	C				
UNKNOWN								
	Proteinuria		Claritin-D	C				
UNKNOWN								
	Troponin Increased		Toprol Xl Tablets	C				
UNKNOWN								
			Univasc	C				
UNKNOWN								
			Nitrostat	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/04ISR Number: 4364272-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Glucose Increased		Lasix (Furosemide)	SS				
Disability	Cardiac Failure		Zestril	SS			UNKNOWN	
Other	Congestive		Zestril	SS			UNKNOWN	406 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Tylenol	C			UNKNOWN	
	Gastrointestinal Infection		Calcium (Unspecified)	C			UNKNOWN	
	Hyperparathyroidism		Plavix	C			UNKNOWN	
	Secondary		Naproxen	C			UNKNOWN	
	Injury		Temazepam	C			UNKNOWN	
	Insomnia		Spironolactone	C			UNKNOWN	
	Ischaemic Cardiomyopathy		Zocor	C		ORAL		
	Meniere'S Disease		Miacalcin	C			UNKNOWN	
	Mitral Valve Incompetence		Zantac	C			UNKNOWN	
	Myalgia		Nitro	C			UNKNOWN	
	Nerve Compression		Motrin	C			UNKNOWN	
	Osteoporosis		Prinivil	C			UNKNOWN	
	Pharyngitis		Glucotrol	C			UNKNOWN	
	Renal Failure Acute		Cardizem	C			UNKNOWN	
	Renal Failure Chronic		Prozac	C			UNKNOWN	
	Seasonal Allergy							
	Silent Myocardial Infarction							
	Sinusitis							

	Skin Ulcer
	Tricuspid Valve
	Incompetence
	Ventricular Dysfunction

Date:05/25/04ISR Number: 4364276-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02596
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN								

Date:05/25/04ISR Number: 4364277-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Arrest
Hospitalization - Initial or Prolonged	Cardiac Failure
	Congestive
Other	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Diabetes Mellitus
	Inadequate Control
	Dizziness
	Dyspepsia
	Gastritis
	Hyperkalaemia
	Microcytic Anaemia

Myocardial Infarction
Renal Failure

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Captopril	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Pepcid Ac	C		ORAL	UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	Zoloft	C			UNKNOWN	
	Glyburide	C			UNKNOWN	
	Synthroid	C			UNKNOWN	
	Lorazepam	C			UNKNOWN	
	Meclizine	C			UNKNOWN	
	Phenergan Tablets/Suppositories	C			UNKNOWN	

Date:05/25/04ISR Number: 4364284-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00105
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bile Duct Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	

Date:05/25/04ISR Number: 4364285-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00646
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash							
	Swelling							

Date:05/25/04ISR Number: 4364286-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01109
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oropharyngeal Swelling		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Rash Macular		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Swelling Face		Vioxx	SS	Merck & Co., Inc	ORAL		
	Swollen Tongue		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
			Zyrtec	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Benicar Hct	C			UNKNOWN	

Date:05/25/04ISR Number: 4364569-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Blood Pressure Immeasurable
	Cardiac Arrest
	Coma

		Confusion Postoperative					
		Decreased Activity					
		Dilatation Atrial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dilatation Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Duodenal Ulcer		[Therapy			
		Haemorrhage		Unspecified]	C		
UNKNOWN							
		Dyspnoea		Restoril	C		
UNKNOWN							
		Gastric Ulcer		Coumadin	C		ORAL
		Helicobacter Infection		Vicodin Es Tablets	C		
UNKNOWN							
		Injury		Zestril	C		
UNKNOWN							
		Oesophagitis					
		Osteoarthritis					
		Rectal Haemorrhage					
		Restrictive Pulmonary					
		Disease					
		Upper Gastrointestinal					
		Haemorrhage					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Vitreous Floaters					

Date:05/25/04ISR Number: 4364571-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00132
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Duodenal Ulcer					
Hospitalization -						
Initial or Prolonged						

Date:05/25/04ISR Number: 4364572-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/25/04ISR Number: 4364573-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Stenosis
Other	Atrial Fibrillation
	Cardiac Failure Congestive
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Occlusion
	Cough
	Dehydration
	Emotional Distress
	Erectile Dysfunction
	Gouty Arthritis
	Ischaemic Cardiomyopathy
	Mitral Valve Incompetence
	Mitral Valve Prolapse
	Myocardial Infarction

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Oedema Peripheral					
		Overdose					
		Peripheral Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Allopurinol	C		
UNKNOWN							
		Renal Failure		Allopurinol	C		
UNKNOWN							
		Sleep Disorder		Aspirin	C		
UNKNOWN							
		Syncope		Lipitor	C		
UNKNOWN							
		Vascular Graft Occlusion		Lotensin	C		
UNKNOWN							
		Vascular Occlusion		Coreg	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Clopidogrel Bisulfate	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Fluvastatin Sodium	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Glipizide	C		
UNKNOWN							
				Glycine	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							

			Nitroglycerin	C		
UNKNOWN						
			Actos	C		
UNKNOWN						
			Actos	C		
UNKNOWN						

Date:05/25/04ISR Number: 4364574-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01471
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure Acute							

Date:05/25/04ISR Number: 4365435-4Report Type:Direct Company Report #CTU 219431
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS		ORAL	12.5 MG PO	
Initial or Prolonged	Diarrhoea						DAILY	
	Gastritis Erosive		Prednisone	SS		ORAL	5 MG PO	
	Haematemesis						DAILY/	
	Hiatus Hernia						RESTARTED	
	Melaena		Paxil	C				
	Vomiting		Xanax	C				
			Synthroid	C				
			Maxzide	C				
			Tamoxifen	C				

Date:05/25/04ISR Number: 4368272-XReport Type:Expedited (15-DaCompany Report #KII-2002-0010294
Age:80 YR Gender:Male I/FU:I

Outcome	PT
Death	Bile Duct Stone
	Biliary Abscess

		Blood Creatinine Increased					
		Blood Glucose Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Potassium Increased	Health	Oxycontin			
		Blood Urea Increased	Professional	Tablets(Oxycodone			
		Cholangitis Acute	Company	Hydrochloride) Cr			
		Haematocrit Decreased	Representative	Tablet	PS		ORAL
10 MG, BID,							
		Haemoglobin Decreased					
ORAL							
		Intra-Abdominal		Altace(Ramipril)	SS		ORAL
5 MG, DAILY,							
		Haemorrhage					
ORAL							
		Liver Abscess		Bumex(Bumetanide)	SS		
1 MG, AM							
		Medication Error		Flomax(Morniflumate)	SS		
0.4 MG, DAILY							
				Coumadine(Warfarin Sodium)	SS		
5 MG , HS, :							
2.5							
				Tylenol W/Codeine No.3 (Codeine Phosphate, Paracetamol)	SS		ORAL
2 TABLET,							
PRN, ORAL							
				Cardizem Cd(Diltiazem Hydrochloride)	SS		ORAL
240 MG, AM,							
ORAL							
				Vioxx(Rofecoxib)	SS		

Date:05/26/04ISR Number: 4365495-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amenorrhoea
	Anxiety

Disability	Arthralgia
Other	Cardiac Failure
	Congestive
	Carpal Tunnel Syndrome
	Complex Regional Pain
	Syndrome
	Dehydration
	Depression
	Diverticulum
	Emotional Distress
	Fear
	Gastritis
	Gastrooesophageal Reflux
	Disease
	Haemorrhoids
	Hiatus Hernia
	Hypersensitivity
	Intervertebral Disc
	Disorder
	Intervertebral Disc
	Protrusion
	Joint Swelling
	Menorrhagia
	Ovarian Cyst
	Prescribed Overdose
	Skin Laceration
	Sleep Apnoea Syndrome
	Tachycardia

Uterine Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	10	DAY
	Albuterol	C			RESPIRATORY (INHALATION)	
	Augmentin	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Allegra	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Toradol	C			UNKNOWN	

Date:05/26/04ISR Number: 4365498-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	585	DAY
Initial or Prolonged	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	585	DAY
Disability	Cerebrovascular Accident		Lorcet 10/650	C			UNKNOWN	283 DAY
Other	Delusion		Hydrocodone Bitartrate	C			UNKNOWN	201 DAY
	Depression		Ambien	C			UNKNOWN	
	Glucose Tolerance		Ibuprofen	C			UNKNOWN	
	Impaired		Cozaar	C			UNKNOWN	
	Hernia							
	Hyperlipidaemia							

Hypertension
Insomnia
Male Sexual Dysfunction
Mitral Valve Incompetence
Nocturia
Oedema Peripheral
Panic Attack
Periarthritis
Somnolence
Varicose Vein
Ventricular Hypertrophy

Date:05/26/04ISR Number: 4365499-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00294
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/26/04ISR Number: 4365500-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anxiety
Other	Aortic Aneurysm
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased

	Cardiac Failure Congestive						
	Cardiac Valve Disease	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	786 DAY
	Coronary Artery Disease		[Therapy				
	Death		Unspecified]	C			UNKNOWN
	Depression		Aspirin	C			UNKNOWN
	Dyspnoea		Atenolol	C			UNKNOWN
	Haemorrhage		Zocor	C			UNKNOWN
	Heart Rate Irregular		Plavix	C			UNKNOWN
	Hernia		Prinivil	C		ORAL	
	High Density Lipoprotein Decreased						
	Low Density Lipoprotein Increased						
	Myocardial Infarction						
	Prostate Cancer						
	Stress						
	Transient Ischaemic Attack						

Date:05/26/04ISR Number: 4365501-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR
Other	Asthenia		Diovan	C			UNKNOWN
	Cardiac Failure Congestive						
	Cerebrovascular Accident						
	Chest Pain						
	Congestive Cardiomyopathy						
	Diabetes Mellitus						

Non-Insulin-Dependent
Drug Hypersensitivity
Dyslipidaemia
Dysstasia
Emotional Distress
Fatigue
Insomnia
Irritable Bowel Syndrome
Lactose Intolerance
Macular Degeneration
Pain
Renal Failure Chronic
Rheumatoid Arthritis
Skin Cancer
Thrombosis

Date:05/26/04ISR Number: 4365502-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00157
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			General Anesthesia (Unspecified)	C				
			Oxycodone Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/04ISR Number: 4365596-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00122
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastritis Erosive		Phenprocoumon	SS		ORAL
Initial or Prolonged	Gastrointestinal		Phenprocoumon	SS		ORAL
Other	Haemorrhage		Tramadol			
	Prothrombin Time		Hydrochloride	SS		ORAL
	Prolonged		Digitoxin	C		ORAL
			Metoprolol Succinate	C		ORAL
			Xipamide	C		ORAL

Date:05/26/04ISR Number: 4365598-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA00347
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory Failure
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased
	Areflexia
	Aspartate
	Aminotransferase
	Increased
	Basilar Artery Occlusion
	Blood Albumin Decreased
	Blood Amylase Increased
	Blood Pressure Systolic
	Decreased
	Bradycardia
	Brain Herniation
	Brain Stem Infarction
	Cardiac Murmur
	Cardio-Respiratory Arrest
	Cerebellar Infarction
	Cerebral Haemorrhage
	Cerebral Infarction
	Cerebral Ischaemia
	Coma
	Dehydration
	Embolic Stroke
	Gastrointestinal
	Haemorrhage
	Haematemesis

Haematocrit Decreased
Hepatic Function Abnormal
Idiopathic
Thrombocytopenic Purpura
Influenza Like Illness
Leukocytosis
Lipoma
Loss Of Consciousness
Malnutrition
Miosis
Mitral Valve Incompetence
Mitral Valve Prolapse
Mydriasis
Myocardial Infarction
Nephropathy
Nervous System Disorder
Pericardial Effusion

		Posturing					
		Pyrexia					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL
		Rhonchi		Zestril	C		
UNKNOWN							
		Transfusion Reaction					
		Troponin Increased					
		Viral Infection					

Date:05/26/04ISR Number: 4365599-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Chloasma		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Sinusitis		Aspirin	C		
UNKNOWN							
		Coronary Artery Disease					
		Depression					
		Difficulty In Walking					
		Drug Dependence					
		Emotional Distress					
		Eustachian Tube Disorder					
		Hypercholesterolaemia					
		Injury					
		Intermittent Claudication					
		Limb Discomfort					
		Muscle Spasms					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Sinusitis					

Date:05/26/04ISR Number: 4365600-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01237
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Disability	Acrochordon
	Acute Sinusitis
	Angina Pectoris

Anhedonia
Anxiety
Apathy
Appetite Disorder
Arthralgia
Asthenia
Back Injury
Back Pain
Bronchitis Chronic
Cardiac Disorder
Cardiac Failure
Congestive
Chest Pain
Contusion
Depression
Disturbance In Attention
Drug Effect Decreased
Electrocardiogram T Wave
Inversion
Emotional Distress

		Exostosis					
		Fatigue					
		Feeling Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Aspirin	C		
UNKNOWN							
		Hypoaesthesia		Celebrex	C		
UNKNOWN							
		Influenza		Ambien	C		
UNKNOWN							
		Intervertebral Disc		Meridia	C		
UNKNOWN							
		Degeneration		Antivert	C		
UNKNOWN							
		Intervertebral Disc		Relafen	C		
UNKNOWN							
		Protrusion		Naproxen	C		
UNKNOWN							
		Joint Effusion					
		Joint Swelling					
		Ligament Injury					
		Major Depression					
		Meniscus Lesion					
		Muscle Strain					
		Myalgia					
		Osteoarthritis					
		Pain					
		Paraesthesia					
		Post Procedural					
		Complication					
		Prescribed Overdose					
		Radiculopathy					
		Respiratory Syncytial					
		Virus Infection					
		Rotator Cuff Syndrome					
		Scar					
		Sleep Disorder					
		Social Avoidant Behaviour					
		Spinal Osteoarthritis					
		Tenderness					

Date:05/26/04ISR Number: 4365601-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
Disability	Affect Lability
Other	Anxiety Disorder
	Aortic Valve Sclerosis
	Arthralgia
	Arthropathy
	Asthma
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bundle Branch Block Right
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diverticulum
	Dyspepsia
	Encephalitis
	Encephalopathy

		Fall					
		Fatigue					
		Gastric Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Bextra	SS		
UNKNOWN							
		Hyperlipidaemia		[Therapy			
		Hypertensive Heart		Unspecified]	C		
UNKNOWN							
		Disease		Albuterol	C		
UNKNOWN							
		Hypertrophic		Lanoxin	C		
UNKNOWN							
		Cardiomyopathy		Effexor	C		
UNKNOWN							
		Hypotension		Flovent	C		
UNKNOWN							
		Injury		Hydrochlorothiazide			
		Memory Impairment		And Triamterene	C		ORAL
		Meningitis		Atrovent	C		
UNKNOWN							
		Migraine		Singulair	C		ORAL
		Myocardial Infarction		Daypro	C		
UNKNOWN							
		Neuritis					
		Nodal Arrhythmia					
		Normochromic Normocytic					
		Anaemia					
		Oesophageal Spasm					
		Pain In Extremity					
		Pancreatitis					
		Skin Laceration					
		Spinal Column Stenosis					
		Stress					
		Tension					
		Therapeutic Agent					
		Toxicity					
		Urosepsis					

Date:05/26/04ISR Number: 4365602-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00148
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypocalcaemia		Vioxx	PS	Merck & Co., Inc	ORAL	152 DAY	
Hospitalization - Initial or Prolonged	Hyponatraemia		Hypericin	SS		ORAL	UNKNOWN	
			Aloe	C				
			Trimethoprim	C		ORAL	1 DAY	

Date:05/26/04ISR Number: 4365603-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Arthritis
	Bronchitis Acute
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cardiomyopathy
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Convulsion
	Coronary Artery Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Decubitus Ulcer Dysphagia Electrolyte Imbalance					
		Faecaloma		Vioxx	PS	Merck & Co., Inc	ORAL
91	DAY						
		Gastrointestinal		Aspirin	C		
UNKNOWN							
		Haemorrhage		Lipitor	C		
UNKNOWN							
		Heart Rate Irregular		Capoten	C		
UNKNOWN							
		Herpes Zoster		Plavix	C		
UNKNOWN							
		Hypertension Influenza		Lasix (Furosemide Sodium)	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Amaryl	C		
UNKNOWN							
		Liver Function Test		Glipizide	C		
UNKNOWN							
		Abnormal		Prevacid	C		
UNKNOWN							
		Malnutrition		Glucophage	C		
UNKNOWN							
		Myocardial Infarction		Lopressor	C		
UNKNOWN							
		Oedema Pericarditis		Nitrol (Nitroglycerin)	C		
UNKNOWN							
		Pneumonia		Altace	C		
UNKNOWN							
		Pneumonia Aspiration Post Herpetic Neuralgia Pulmonary Oedema Pyrexia Radiculitis Brachial Respiratory Failure Rotator Cuff Syndrome Staphylococcal Infection Stent Occlusion Thrombocytopenia					

Date:05/26/04ISR Number: 4365604-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0405CAN00127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hepatic Necrosis Jaundice		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/04ISR Number: 4365605-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00062
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Amiodarone	C			UNKNOWN	
	Coagulopathy		Coumadin	C			UNKNOWN	
	Dyspnoea		Prinzide	C		ORAL		
	Gastrointestinal Haemorrhage							

Date:05/26/04ISR Number: 4365607-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00524
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Wegener'S Granulomatosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/04ISR Number: 4366288-0Report Type:Direct Company Report #CTU 219484
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required Intervention to Prevent Permanent Impairment/Damage	Oedema		Vioxx 12.5 Mg Tab	PS		
	Weight Increased		Bumetanide	C		
			Metoclopramide Hcl	C		
			Fosinopril Na	C		
			Cetrizine Hcl	C		
			Gg 600/Pseudoephedrine	C		
			Sertraline Hcl	C		
			Warfarin (Sodium)	C		
			Omeprazole	C		
			Simvastatin	C		
			Isosorbide Mononitrate	C		
			Terazosin Hcl	C		
			Calcium 500 Mg/Sennosides	C		
			Finasteride	C		
			Docusate Na 50 Mg/Semnosides	C		
			Hydrocortisone	C		
			Lidocaine	C		
			Potassium Chloride	C		
			Menthol 10%/Methyl Salic	C		

Date:05/26/04ISR Number: 4372874-4Report Type:Expedited (15-DaCompany Report #2004214592US
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Incoherent	Consumer	Azulfidine-En (Sulfasalazine) Tablet	PS		
Other	Renal Failure Acute		Rofecoxib (Rofecoxib)	SS		
	Vertigo		Detrol La (Tolterodine L-Tartrate)	C		

Date:05/27/04ISR Number: 4365689-4Report Type:Expedited (15-DaCompany Report #PHEH2003US04530
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Zometa	PS	Novartis Sector: Pharma			
	Blood Creatinine							
INTRAVENOUS							4 mg, UNK	31680MIN
	Increased		Vioxx	SS				
25 mg, UNK								177 DAY
	Blood Pressure Abnormal		E7070 (Goal)	SS				
INTRAVENOUS							1449 mg, OT	199 DAY
	Femoral Bruit		Co-Diovan	C				
	Herpes Zoster		Verapamil	C				
	Nocturia		Duragesic	C				
	Oedema Peripheral		Lipitor	C				
	Renal Failure Acute		Zoloft	C				
	Renal Tubular Necrosis		Percocet	C				
	Urine Analysis Abnormal		Prevacid	C				
			Lasix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/04ISR Number: 4366547-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00206
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diaphragmalgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Musculoskeletal Stiffness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Myalgia		Premarin	C				
UNKNOWN								

Date:05/27/04ISR Number: 4366554-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial Infarction
Disability	Adrenal Mass
Other	Angina Unstable
	Asthenia
	Bacteriuria
	Bronchitis Acute
	Cardiac Failure Congestive
	Cataract
	Conjunctivitis
	Coronary Artery Disease
	Cystitis
	Depression
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Escherichia Urinary Tract Infection
	Fall
	Fatigue
	Gastrooesophageal Reflux Disease
	Headache
	Hearing Impaired
	Hypertension
	Hypoglycaemia
	Lacunar Infarction
	Lipids Increased

Lung Neoplasm
Maculopathy
Mass
Metabolic Alkalosis
Nocturia
Pleural Effusion
Proteinuria
Pulmonary Hypertension
Radius Fracture
Rectal Haemorrhage
Renal Cyst
Renal Failure Chronic
Scoliosis
Seasonal Allergy
Sinusitis
Skin Lesion
Spinal Column Stenosis
Stasis Dermatitis

		Vaginal Infection Ventricular Hypertrophy Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Wrist Fracture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Hydrodiuril	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Dyrenium	C		
UNKNOWN							
				Insulin, Biphasic Isophane [Injection]	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Alupent	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							

Date:05/27/04ISR Number: 4366556-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Cardiac Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
62 DAY						
Initial or Prolonged	Depression	Professional	Aspirin	C		
UNKNOWN						
Other	Heart Injury		Atenolol	C		
UNKNOWN						
			Glyburide	C		
UNKNOWN						
			Zocor	C		ORAL
			Motrin	C		
UNKNOWN						
			Prinivil	C		ORAL

Date:05/27/04ISR Number: 4366557-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Emotional Distress		Aspirin	C		
UNKNOWN						
Disability	Generalised Anxiety		Celexa	C		
UNKNOWN						
Other	Disorder		Lexapro	C		
UNKNOWN						
	Lacunar Infarction		Synthroid	C		
UNKNOWN						
	Oesophageal Spasm		Niacin	C		
UNKNOWN	14671DAY					
	Thrombosis					

Date:05/27/04ISR Number: 4366558-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01976
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthropathy
	Asthenia
	Back Pain
	Decreased Appetite
	Diabetes Mellitus

		Drug Hypersensitivity					
		Dyspnoea					
		Electrocardiogram	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
106	DAY						
		Glaucoma	Professional	Tylenol	C		
UNKNOWN							
		Headache		Bayer Aspirin	C		
UNKNOWN							
		Heart Rate Increased					
		Hypertension					
		Injury					
		Insomnia					
		Non-Cardiac Chest Pain					
		Palpitations					
		Thyroid Disorder					
		Tooth Extraction					

Date:05/27/04ISR Number: 4366559-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Congestive	Professional	Vicodin Tablets	C		
UNKNOWN							
Disability		Connective Tissue					
		Inflammation					
		Coronary Artery Disease					
		Depression					
		Dilatation Atrial					
		Dyspnoea					
		Emotional Distress					
		Heart Rate Irregular					
		Injury					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Normochromic Normocytic					
		Anaemia					
		Sleep Apnoea Syndrome					

Treatment Noncompliance
Ventricular Extrasystoles
Weight Increased

Date:05/27/04ISR Number: 4366561-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01436
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Other			Lortab	C				
UNKNOWN								
			Aspirin	C		ORAL		
			Lopid	C		ORAL		
			Glucophage	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/04ISR Number: 4366562-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Body Tinea		Vioxx	SS	Merck & Co., Inc	
UNKNOWN	1 DAY					
Other	Carpal Tunnel Syndrome		Flexeril	C		
UNKNOWN						
	Coronary Artery		Monopril	C		
UNKNOWN						
	Atherosclerosis		Pravachol	C		
UNKNOWN						
	Coronary Artery Occlusion					
	Diabetes Mellitus					
	Non-Insulin-Dependent					
	Emotional Distress					
	Fatigue					
	Hypersensitivity					
	Injury					
	Overdose					
	Pain In Extremity					
	Pilonidal Cyst					
	Sinus Bradycardia					
	Tendonitis					
	Tenosynovitis					
	Trigger Finger					
	Weight Increased					

Date:05/27/04ISR Number: 4366721-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104504
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Chest Pain					
	Contusion					
	Dizziness					
	Electrocardiogram					
	Abnormal					
	Emotional Distress					
	Foot Fracture					
	Fracture Nonunion					

Gastrooesophageal Reflux
Disease
Hypertension
Insomnia
Osteoarthritis
Patellofemoral Pain
Syndrome
Pneumonia
Rheumatoid Arthritis
Upper Respiratory Tract
Infection

Date:05/27/04ISR Number: 4366724-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Colonic Polyp
Initial or Prolonged	Deep Vein Thrombosis
Disability	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent

	Dyspepsia						
	Gastritis						
	Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hot Flush		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
	Hypochromic Anaemia		Yasmin	SS			UNKNOWN 14 DAY
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Intracranial Venous Sinus		Vioxx	SS	Merck & Co., Inc	ORAL	6 MON
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Joint Effusion		Vioxx	SS	Merck & Co., Inc	ORAL	
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pharyngolaryngeal Pain		Sandimmun	C			UNKNOWN
	Rash		Sandimmun	C			UNKNOWN
	Sinus Tachycardia		Prelone Syrup	C			UNKNOWN
	Subarachnoid Haemorrhage		Prednisone	C			UNKNOWN
	Uterine Leiomyoma		Prelone Syrup	C			UNKNOWN
	Vomiting		Hormonal Contraceptives (Unspecified)	C			INTRAMUSCULAR
			Sandimmun	C			UNKNOWN

Date:05/27/04ISR Number: 4366725-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Activities Of Daily		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	
	Increased		Tylenol	C			UNKNOWN
	Blood Pressure Increased		Aspirin	C			UNKNOWN
	Bunion						

Cardiac Failure
Congestive
Constipation
Drug Intolerance
Fall
Gastric Disorder
Headache
Hypertensive Heart
Disease
Intervertebral Disc
Disorder
Joint Sprain
Limb Discomfort
Muscle Spasms
Myalgia
Nocturia
Onychomycosis
Osteoarthritis
Pain
Pulmonary Granuloma
Renal Failure
Rotator Cuff Syndrome
Seborrhoeic Keratosis
Sinusitis
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/04ISR Number: 4366727-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other RESPIRATORY (INHALATION) UNKNOWN	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Aspirin	SS		ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Fluctuation		Albuterol	C				
	Bronchitis		Ciprofloxacin	C				
	Chest Pain		Ciprofloxacin	C				
	Colon Cancer		Hyzaar	C		ORAL		
	Deafness		Dyazide	C				
	Dyspnoea		Isosorbide	C				
	Emotional Distress		Ativan	C		ORAL		
	Fibromyalgia		Nitroglycerin	C				
	Fluid Retention		Oxybutynin	C		ORAL		
	Gallbladder Disorder		Propranolol Hydrochloride	C				
	Gastric Ulcer Haemorrhage							
	Haemodynamic Instability		Quinine	C				
	Hypertension							
	Injury							
	Myocardial Infarction							
	Oedema							
	Oesophageal Disorder							
	Rheumatic Fever							
	Sinus Disorder							
	Weight Decreased							

Date:05/27/04ISR Number: 4366731-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Diabetes Mellitus	Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY					
	Gastritis	[Therapy			
	Gastrooesophageal Reflux	Unspecified]	C		
UNKNOWN	144 DAY				
	Disease	Tylenol	C		
UNKNOWN					
	Hemiparesis	Darvocet-N	C		
UNKNOWN					
	Hypoaesthesia	Soma	C		
UNKNOWN					
	Lipoma				
	Spinal Osteoarthritis				

Date:05/27/04ISR Number: 4366732-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Asthma
Disability	Blood Cholesterol
Other	Increased
	Blood Creatine
	Phosphokinase Increased
	Cardiomegaly
	Cellulitis
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Constipation
	Coronary Artery Disease
	Cough

		Diabetes Mellitus					
		Duodenal Ulcer					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Zocor	SS		ORAL
		Fluid Retention		[Therapy			
		Gastrooesophageal Reflux		Unspecified]	C		
UNKNOWN							
		Disease		Tylenol Arthritis			
		Hyperhidrosis		Extended Relief	C		
UNKNOWN							
		Hypotension		Lasix (Furosemide)	C		
UNKNOWN							
		Hypotonia		Glyburide	C		
UNKNOWN							
		Interstitial Lung Disease		Glucophage	C		
UNKNOWN							
		Meniscus Lesion		Accupril	C		
UNKNOWN							
		Monarthritis					
		Muscle Spasms					
		Myocardial Infarction					
		Renal Failure					
		Renal Tubular Necrosis					
		Rotator Cuff Syndrome					
		Swelling					

Date:05/27/04ISR Number: 4366736-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
573 DAY							
Initial or Prolonged		Haemorrhagic Stroke		Celebrex	C		
UNKNOWN							
Disability				Lasix (Furosemide)	C		
UNKNOWN	615 DAY						
				Hydrocodone			
				Hydrochloride	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							

				Demadex	C		
UNKNOWN		615	DAY				
				Ibuprofen	C		
UNKNOWN							
				Lozol	C		
UNKNOWN		615	DAY				
				Synthroid	C		
UNKNOWN							

Date:05/27/04ISR Number: 4366737-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diverticulum Intestinal		Acetaminophen	C		ORAL		
Initial or Prolonged	Lower Gastrointestinal		Fluoxetine	C		ORAL		
	Haemorrhage		Irbesartan	C		ORAL		
			Molsidomine	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:05/27/04ISR Number: 4366945-6Report Type:Direct Company Report #CTU 219636
Age:97 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Aspirin 81mg	PS		ORAL	81MG DAILY	
Initial or Prolonged	Haematochezia					ORAL		
	Syncope		Rofecoxib 25mg Merck	SS	Merck	ORAL	25MG DAILY	
						ORAL		
			Cardizem	C				
			Amiodarone	C				

Date:05/28/04ISR Number: 4367077-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
Other	Complicated Migraine							
	Convulsion							
	Hypercholesterolaemia							
	Migraine							
	Tremor							

Date:05/28/04ISR Number: 4367079-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02294
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Aspirin	C				UNKNOWN
Disability	Blood Pressure Increased		Celebrex	C				UNKNOWN
Other	Cerebrovascular Accident		Glyburide	C				UNKNOWN
	Confusional State		Prinivil	C				UNKNOWN
	Dementia							
	Depression							
	Diabetes Mellitus							
	Disorientation							
	Emotional Distress							
	Fall							
	Flatulence							
	Gastroenteritis							
	Hyperhidrosis							
	Hypoglycaemia							
	Hypomagnesaemia							
	Injury							
	Irritability							
	Lacunar Infarction							
	Osteopenia							
	Pallor							
	Proteinuria							
	Retching							

	Somnolence
	Troponin Increased
	Urinary Incontinence
	Urticaria
	Vomiting

Date:05/28/04ISR Number: 4367080-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02142
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Atrial Tachycardia
Disability	Atrioventricular Block
	First Degree
	Cardiac Failure
	Congestive
	Deep Vein Thrombosis
	Dyspnoea Exertional
	Fluid Retention
	Gastrooesophageal Reflux
	Disease

		Gout					
		Hypercholesterolaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypothyroidism	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Polytraumatism		Vioxx	SS	Merck & Co., Inc	ORAL
		Rales		Allopurinol	C		
UNKNOWN							
		Sinusitis		Keflex	C		
UNKNOWN							
		Vomiting		Hydrochlorothiazide	C		
UNKNOWN							
		Weight Increased		Indocin			
				(Indomethacin)	C		ORAL
				Synthroid	C		
UNKNOWN							

Date:05/28/04ISR Number: 4367081-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA03168
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
2	WK						
Other		Hyperkalaemia		Furosemide	C		
UNKNOWN							
		Renal Failure Acute					

Date:05/28/04ISR Number: 4367082-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Atrial Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Abnormal		Amaryl	C		
UNKNOWN							
		Cardiac Arrest		Metformin	C		
UNKNOWN							

Cardiac Failure
Congestive
Cardiomyopathy
Cataract
Constipation
Convulsion
Coronary Artery Disease
Dizziness
Emotional Distress
Hepatitis B
Hypertension
Hypoaesthesia
Mitral Valve Incompetence
Nausea
Paraesthesia
Sinus Bradycardia
Tricuspid Valve
Incompetence

Date:05/28/04ISR Number: 4367084-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Disability	Arrhythmia
Other	Arthritis
	Blindness
	Blood Testosterone
	Decreased

		Bronchitis Cholecystitis Chronic Cholelithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Duodenal Scarring	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		[Therapy			
		Gastrooesophageal Reflux		Unspecified]	C		
UNKNOWN							
		Disease		Aspirin	C		
UNKNOWN							
		Hiatus Hernia		Wellbutrin	C		
UNKNOWN							
		Hypercholesterolaemia		Codeine	C		
UNKNOWN							
		Impaired Healing		Lovastatin	C		
UNKNOWN							
		Mental Disorder		Naproxen	C		
UNKNOWN							
		Muscle Spasms Myocardial Infarction Nausea Neck Pain Overdose Road Traffic Accident Skin Laceration Spondyloarthropathy Tympanic Membrane Perforation Vertigo Positional Vision Blurred Vitreous Floaters					

Date:05/28/04ISR Number: 4367085-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Adverse Event
Disability	Anaemia
Other	Angina Unstable Anxiety Back Injury

Back Pain
Bronchitis Acute
Conjunctival Haemorrhage
Contusion
Coronary Artery Disease
Cyst
Depression
Duodenitis
Dyspnoea
Fall
Fatigue
Fibroma
Gastritis
Haematochezia
Hypertension
Hypokalaemia
Hypotension
Joint Sprain
Laryngitis
Menopausal Symptoms
Migraine
Mitral Valve Incompetence
Myocardial Infarction

		Nightmare					
		Palpitations					
		Paraesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Peritoneal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Adhesions	Professional	Plavix	SS		
UNKNOWN							
		Phlebothrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Rhinitis Seasonal		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
		Stent Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Syncope		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Gastrointestinal		Fioricet Tablets	C		
UNKNOWN							
		Haemorrhage		Vicodin Tablets	C		
UNKNOWN							
		Ventricular Extrasystoles		Vasotec	C		ORAL
				Calan Sr	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Ecotrin	C		
UNKNOWN							

Date:05/28/04ISR Number: 4367087-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
Disability	Coagulation Factor Viii		Ma Huang Extract	C		
UNKNOWN	1523 DAY					
Other	Level Increased		Ambien	C		
UNKNOWN						
	Depression					
	Emotional Distress					
	Haemoptysis					
	Influenza					

Insomnia
International Normalised
Ratio Increased
Pain
Pulmonary Embolism
Pulmonary Hypertension
Renal Cyst
Suicidal Ideation
Upper Respiratory Tract
Infection

Date:05/28/04ISR Number: 4367088-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebellar Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Hypertension		Darvocet-N	C			UNKNOWN	
	Osteoarthritis		Coumadin	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:05/28/04ISR Number: 4367089-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Amitriptyline Hydrochloride	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Coronary Artery Stenosis		Pravachol	C			UNKNOWN	
	Dizziness		Altace	C			UNKNOWN	
	Drug Ineffective							
	Emotional Distress							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Headache							
	Therapeutic Response Decreased							
	Upper Respiratory Tract Infection							

Date:05/28/04ISR Number: 4367090-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00646
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash							
	Swelling							

Date:05/28/04ISR Number: 4367091-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough	Health	Vioxx	PS	Merck & Co., Inc	ORAL	125	DAY

Initial or Prolonged	Deep Vein Thrombosis	Professional	Coricidin	C
UNKNOWN				
	Dyspnoea Exertional		Allegra-D	C
UNKNOWN				
	Epistaxis		Flonase	C
UNKNOWN				
	Gastrooesophageal Reflux		Westcort	C
UNKNOWN				
	Disease		Singulair	C
UNKNOWN				
	Gynaecomastia		Elidel	C
UNKNOWN				
	Injury			
	International Normalised			
	Ratio Increased			
	Pulmonary Embolism			
	Skin Ulcer			
	Sleep Apnoea Syndrome			
	Somnolence			
	Venous Insufficiency			
	Venous Stasis			

Date:05/28/04ISR Number: 4367092-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
Other	Anaemia
	Anal Skin Tags
	Aortic Atherosclerosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Asthenia Back Pain Blister					
		Bursa Disorder Cardiomegaly Cholelithiasis	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN	10 YR						
		Chromaturia		Endocet	C		
UNKNOWN							
		Condition Aggravated		Elavil	C		
UNKNOWN							
		Constipation		Tenormin	C		
UNKNOWN							
		Cough		Vancenase	C		
UNKNOWN							
		Diarrhoea		Premarin	C		
UNKNOWN	9872 DAY						
		Disease Recurrence		Prevacid	C		
UNKNOWN							
		Dizziness		Synthroid	C		
UNKNOWN							
		Dry Mouth		Prinivil	C		ORAL
1501 DAY							
		Fatigue		Methocarbamol	C		
UNKNOWN							
		Fluid Retention		Prilosec	C		
UNKNOWN							
		Gastrooesophageal Reflux Disease Haematoma Haemorrhoidal Haemorrhage Herpes Zoster Hypersensitivity Hypertension Hypoaesthesia Hypothyroidism Impaired Work Ability Injury Intervertebral Disc Degeneration Joint Effusion Lung Disorder Malaise Migraine Mononeuritis Myalgia					

Nausea
Nephrolithiasis
Oedema Peripheral
Rectal Haemorrhage
Road Traffic Accident
Spinal Osteoarthritis
Splenic Cyst
Syncope
Tenderness
Tricuspid Valve
Incompetence
Urinary Tract Infection
Urine Odour Abnormal
Vomiting
Wound Dehiscence

Date:05/28/04ISR Number: 4367093-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01519
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/04ISR Number: 4367094-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00168
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Dry Throat		Cod Liver Oil	C		ORAL		
	Headache		Evening Primrose Oil	C		ORAL		
	Nausea		Levothyroxine Sodium	C		ORAL		

Date:05/28/04ISR Number: 4367095-5Report Type:Expedited (15-DaCompany Report #LB-MERCK-0405USA01185
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pruritus	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Paracetamol Tablets Bp	C			UNKNOWN	
			Vitamin B (Unspecified)	C			UNKNOWN	

Date:05/28/04ISR Number: 4367096-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		[Therapy Unspecified]	C			UNKNOWN	
	Cardiac Valve Disease		Albuterol	C			UNKNOWN	
	Chest Discomfort		Proventil	C			RESPIRATORY	
	Chest Pain						(INHALATION)	

	Chronic Fatigue Syndrome	Antimicrobial	
	Coronary Artery Disease	(Unspecified)	C
UNKNOWN			
	Depression	Amaryl	C
UNKNOWN			
	Dyspepsia	Glipizide	C
UNKNOWN			
	Dyspnoea	Glucophage	C
UNKNOWN			
	Emotional Distress		
	Gastric Disorder		
	Gastrooesophageal Reflux		
	Disease		
	Glaucoma		
	Headache		
	Hypercholesterolaemia		
	Hyperhidrosis		
	Hypertension		
	Hypoaesthesia		
	Myocardial Infarction		
	Oedema Peripheral		
	Thrombosis		

Date:05/28/04ISR Number: 4367099-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anaemia
Other	Angina Unstable
	Atelectasis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Azotaemia Bronchitis Cardiac Failure Congestive	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Carotid Artery Stenosis	Professional	Allopurinol	C		
UNKNOWN							
		Carotid Bruit		Aspirin	C		
UNKNOWN							
		Central Line Infection		Aricept	C		
UNKNOWN							
		Cerebral Artery Occlusion		Glucotrol	C		
UNKNOWN							
		Cholelithiasis Chronic Obstructive Pulmonary Disease Coronary Artery Restenosis Coronary Artery Stenosis Depressed Level Of Consciousness Dressler'S Syndrome Faecal Occult Blood Positive Faeces Discoloured Fungal Rash Gastrointestinal Haemorrhage Hyperbilirubinaemia Hyperlipidaemia Injury Leukocytosis Mitral Valve Incompetence Myocardial Infarction Myocardial Ischaemia Peripheral Vascular Disorder Post Procedural Complication Pyrexia Respiratory Failure Skin Candida Sputum Culture Positive Staphylococcal Infection Stent Occlusion Subclavian Artery					

Stenosis
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Ventricular Hypokinesia

Date:05/28/04ISR Number: 4367101-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00114
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/28/04ISR Number: 4367453-9Report Type:Periodic Company Report #CIP03003040
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Haematemesis	Consumer	Actonel (Risedronate Sodium) Tablet, 35 Mg	PS		ORAL	35 MG ONCE WEEKLY FOR 2-4 DOSES, ORAL	
			Vioxx (Rofecoxib)	SS			AS NEEDED	
			Zyprexa (Olanzapine)	C				
			Aricept (Donepezil Hydrochloride)	C				
			Prozac (Fluoxetine Hydrochloride)	C				

Date:05/28/04ISR Number: 4369733-XReport Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Back Disorder	Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (TID), ORAL	
Other	Blood Cholesterol Increased Chest Pain Drug Ineffective	Professional	Lipitor (Atorvastatin)	SS		ORAL	20 MG (DAILY), ORAL	
	Drug Intolerance Erectile Dysfunction Facial Pain Feeling Cold Gastrooesophageal Reflux Disease		Lithium (Lithium) (Lithium)	SS				
			Naproxen (Naproxen)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Amoxicillin					

	General Physical Health	(Amoxicillin)	SS	ORAL 1000 MG (BID), ORAL
	Deterioration			
	Gingival Disorder	All Other Therapeutic Products (All Other Therapeutic Products)	C	
	Glossodynia			
	Medication Error			
	Mobility Decreased			
	Neck Pain			
	Oesophageal Spasm	Levothyroxine Sodium (Levothyroxine Sodium)	C	
	Pain In Jaw			
	Sleep Disorder			
	Somnolence	Vitamins (Vitamins)	C	
	Tooth Abscess	Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C	
	Tremor			

Date:06/01/04ISR Number: 4367555-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Alcoholic Seizure
	Anaemia
	Aura
	Blood Pressure Abnormal
	Blood Pressure Fluctuation

		Cardiovascular Disorder Cerebral Atrophy Change Of Bowel Habit	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
34	DAY	Drug Hypersensitivity	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Duodenitis Encephalopathy Grand Mal Convulsion Haematemesis Headache Hordeolum Influenza Limb Injury Liver Function Test Abnormal Mean Cell Volume Increased Oedema Pruritus Renal Failure Tachycardia Tenosynovitis Stenosans Vision Blurred Weight Decreased	Professional				

Date:06/01/04ISR Number: 4367557-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Neoplasm Abdominal Pain Upper Abscess Angiopathy Arthralgia Back Pain Blood Chloride Increased Blood Cholesterol Increased Blood Glucose Increased Blood Sodium Increased Bloody Discharge Body Temperature Increased Breath Holding

Cellulitis
Cervicitis
Chest Pain
Coagulation Factor Vii
Level Increased
Constipation
Cough
Deep Vein Thrombosis
Ear Pain
Endometrial Hyperplasia
Face Oedema
Fatigue
Flank Pain
Gastroenteritis
Haematemesis
Haematocrit Decreased
Headache

		Hyperhidrosis					
		Hyperlipidaemia					
		Iliac Vein Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lipoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein	Professional	[Therapy			
		Increased		Unspecified]	C		
UNKNOWN							
		Menometrorrhagia		Aspirin	C		
UNKNOWN							
		Nasopharyngitis		Lipitor	C		ORAL
		Nausea		Tiazac	C		
UNKNOWN							
		Oedema Peripheral		Detrol	C		
UNKNOWN							
		Ovarian Atrophy		Meridia	C		
UNKNOWN							
		Post Procedural		Cardura	C		
UNKNOWN							
		Complication		Motrin	C		
UNKNOWN							
		Postoperative Infection		Zestril	C		
UNKNOWN							
		Productive Cough					
		Pulmonary Granuloma					
		Sleep Apnoea Syndrome					
		Snoring					
		Urinary Tract Infection					
		Uterine Disorder					
		Uterine Enlargement					
		Uterine Leiomyoma					
		Venous Insufficiency					
		Venous Stenosis					
		Vomiting					
		Wheezing					
		Wound Dehiscence					
		Wound Secretion					

Date:06/01/04ISR Number: 4367568-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02074
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Unstable	Professional	Vioxx	SS	Merck & Co., Inc	ORAL

	Aortic Valve Incompetence	Vioxx	SS	Merck & Co., Inc	ORAL
	Bone Cyst	Vioxx	SS	Merck & Co., Inc	ORAL
	Bronchitis	Wellbutrin	C		
UNKNOWN					
	Coronary Artery Stenosis	Flexeril	C		ORAL
	Depression	Enbrel	C		
SUBCUTANEOUS					
	Emotional Distress	Ambien	C		
UNKNOWN					
	Hyperlipidaemia	Pepcid	C		ORAL
	Initial Insomnia	Folic Acid	C		
UNKNOWN					
	Myocardial Infarction	Glucosamine	C		
UNKNOWN					
	Nocturia	Plaquenil	C		
UNKNOWN					
	Overdose	Methotrexate	C		
UNKNOWN					
	Pleurisy				
	Rheumatoid Arthritis				
	Rotator Cuff Syndrome				
	Upper Respiratory Tract Infection				

Date:06/01/04ISR Number: 4367569-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Anaemia
Other	Angle Closure Glaucoma

	Cholelithiasis						
	Dehydration						
	Faeces Discoloured	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Pain In Extremity		Tiazac	C			UNKNOWN	
	Renal Failure Chronic		Advil	C			UNKNOWN	

Date:06/01/04ISR Number: 4367570-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Allopurinol	C			UNKNOWN	
Other	Aortic Stenosis		Allopurinol	C			UNKNOWN	
	Arrhythmia		Aspirin	C			UNKNOWN	
	Atrial Fibrillation		Lipitor	C			UNKNOWN	
	Cardiac Failure		Lotensin	C			UNKNOWN	
	Congestive		Coreg	C			UNKNOWN	
	Chest Pain		Celebrex	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Clopidogrel Bisulfate	C			UNKNOWN	
	Condition Aggravated		Cardizem	C			UNKNOWN	
	Coronary Artery Disease		Pepcid	C			UNKNOWN	

	Coronary Artery Occlusion	Fluvastatin Sodium	C
UNKNOWN			
	Coronary Artery Stenosis	Furosemide	C
UNKNOWN			
	Diverticulum	Neurontin	C
UNKNOWN			
	Diverticulum Intestinal	Glipizide	C
UNKNOWN			
	Emotional Distress	Glycine	C
UNKNOWN			
	Erectile Dysfunction	Insulin	C
UNKNOWN			
	Eye Haemorrhage	Glucophage	C
UNKNOWN			
	Glaucoma	Coumadin	C
UNKNOWN			
	Gouty Arthritis	Trazodone	
	Hypotension	Hydrochloride	C
UNKNOWN			
	Injury	Spironolactone	C
UNKNOWN			
	Ischaemic Cardiomyopathy	Nitroglycerin	C
UNKNOWN			
	Mitral Valve Incompetence	Actos	C
UNKNOWN			
	Mitral Valve Prolapse	Actos	C
UNKNOWN			
	Myocardial Infarction		
	Myocardial Ischaemia		
	Oedema Peripheral		
	Osteomyelitis		
	Overdose		
	Peripheral Occlusive		
	Disease		
	Pulmonary Hypertension		
	Pulmonary Oedema		
	Rectal Haemorrhage		
	Renal Failure		
	Respiratory Arrest		
	Respiratory Failure		
	Sleep Apnoea Syndrome		
	Sleep Disorder		
	Syncope		
	Vascular Graft Occlusion		
	Vascular Occlusion		

Date:06/01/04ISR Number: 4367571-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Anorexia
	Anxiety Disorder
	Arterial Stenosis
	Back Injury
	Bronchitis
	Cardiomegaly
	Chest Discomfort
	Chromaturia
	Contusion
	Coronary Artery Restenosis
	Cough
	Decreased Appetite
	Depressed Mood
	Diarrhoea
	Disturbance In Attention
	Diverticulum Intestinal Haemorrhagic
	Drug Ineffective
	Dyspepsia
	Dyspnoea
	Fatigue
	Fear
	Fluid Retention
	Generalised Anxiety Disorder
	Gout
	Heart Rate Increased
	Hypertension
	Hypoaesthesia
	Injury
	Insomnia
	Iron Deficiency
	Libido Decreased
	Lung Neoplasm
	Mediastinal Disorder
	Muscle Tightness
	Myocardial Infarction
	Nausea
	Non-Cardiac Chest Pain
	Oedema Peripheral

Paraesthesia
Pneumonia
Postinfarction Angina
Prostatic Specific
Antigen Increased
Proteinuria
Rectal Haemorrhage
Renal Cyst
Rheumatoid Arthritis
Rhinitis Allergic
Sneezing
Stress
Tendon Rupture
Umbilical Hernia
Ventricular Extrasystoles

Ventricular Hypertrophy
Ventricular Hypokinesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Norvasc	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Monopril	C			UNKNOWN	
	Indocin (Indomethacin)	C			UNKNOWN	
	Toprol Xl Tablets	C			UNKNOWN	
	Lopressor	C			UNKNOWN	
	Naproxen	C			UNKNOWN	

Date:06/01/04ISR Number: 4367573-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Other	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiac Failure
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Decreased Appetite
	Dizziness
	Drug Ineffective
	Dyspepsia

Dyspnoea
Feeling Abnormal
Hyperhidrosis
Injury
International Normalised
Ratio Decreased
Intervertebral Disc
Displacement
Limb Discomfort
Lymphadenitis
Muscle Spasms
Musculoskeletal Chest
Pain
Myalgia
Myocardial Infarction
Oedema Peripheral
Pain In Extremity
Palpitations
Paronychia
Peripheral Vascular
Disorder
Productive Cough
Prothrombin Time
Shortened

	Pyrexia						
	Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL	
	Infection Viral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Sciatica		Nitroglycerin	C			UNKNOWN
	Treatment Noncompliance		Tolinase	C			UNKNOWN
	Varicose Vein		Verapamil	C			UNKNOWN

Date:06/01/04ISR Number: 4367575-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02122
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Chlamydial Infection		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Depression		Acetaminophen	C			UNKNOWN
Other	Diarrhoea		Vicodin Tablets	C			UNKNOWN
	Musculoskeletal Stiffness						
	Pain						
	Scrotal Pain						
	Sleep Disorder						
	Suicidal Ideation						
	Syncope						
	Tachycardia						

Date:06/01/04ISR Number: 4367576-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02079
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	276 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Anaemia		[Therapy				
	Angina Pectoris		Unspecified]	C			UNKNOWN

	Arterial Disorder	Vicodin Tablets	C	
UNKNOWN				
	Back Disorder	Fosamax	C	ORAL
328 DAY				
	Blood Glucose Fluctuation	Norvasc	C	
UNKNOWN				
	Cardiac Failure	Baycol	C	
UNKNOWN				
	Congestive	Betimol	C	
OPHTHALMIC				
	Chest Pain	Benadryl	C	
UNKNOWN				
	Coronary Artery Disease	Folic Acid	C	
UNKNOWN				
	Diabetes Mellitus	Prinivil	C	ORAL
	Non-Insulin-Dependent	Pravachol	C	
UNKNOWN				
	Glaucoma	Evista	C	
UNKNOWN				
	Haematoma			
	Hypertension			
	Myocardial Infarction			
	Osteoporosis			
	Spondylolisthesis			
	Acquired			
	Stress			

Date:06/01/04ISR Number: 4367580-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Adjustment Disorder With		Vioxx	PS	Merck & Co., Inc	ORAL		
Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		
Anxiety							
Bundle Branch Block							
Cardiac Failure							
Congestive							
Cardiomyopathy							
Cellulitis							
Coronary Artery Disease							
Epicondylitis							
Gastrooesophageal Reflux							
Disease							
Hyperlipidaemia							
Hypersensitivity							
Hypotension							
Hypoxic Encephalopathy							
Myocardial Infarction							
Pulmonary Oedema							
Quadriplegia							
Respiratory Failure							
Road Traffic Accident							
Rotator Cuff Syndrome							
Spinal Cord Injury							
Ulcer							
Urinary Tract Infection							

Date:06/01/04ISR Number: 4367582-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01978
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
3 MON								
Initial or Prolonged	Cervicobrachial Syndrome		[Therapy					
Other	Chest Pain		Unspecified]	C				
UNKNOWN								
	Chronic Fatigue Syndrome		Xanax	C				
UNKNOWN								
	Colitis		Prilosec	C				
UNKNOWN								
	Drug Dependence							

Emotional Distress
Fall
Feeling Abnormal
Gastritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Head Injury
Hypercholesterolaemia
Hypertension
Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Malaise
Myofascial Pain Syndrome
Oesophagitis
Osteoarthritis
Panic Disorder
Radiculitis Cervical

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/04ISR Number: 4367583-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Initial or Prolonged	Apathy		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Autonomic Nervous System		Valium	C				UNKNOWN
	Imbalance		Neurontin	C				UNKNOWN
	Blood Bilirubin		Neurontin	C				UNKNOWN
	Unconjugated Increased		Neurontin	C				UNKNOWN
	Blood Pressure Increased		Neurontin	C				UNKNOWN
	Bradycardia		Avapro	C				UNKNOWN
	Chronic Obstructive		Misoprostol	C				UNKNOWN
	Pulmonary Disease		Macrodantin	C				UNKNOWN
	Citrobacter Infection		Nortriptyline	C				UNKNOWN
	Constipation		Nortriptyline	C				UNKNOWN
	Dehydration							
	Dementia							
	Depression							
	Diverticulum							
	Enterobacter Infection							
	Fall							
	Feeling Cold							
	Femur Fracture							
	Gastritis							
	Haemorrhagic Stroke							
	Hiatus Hernia							
	Hyperglycaemia							
	Hyponatraemia							
	Inappropriate Antidiuretic Hormone Secretion							
	Interstitial Lung Disease							

Lipoma
Lung Neoplasm
Otitis Media
Pain
Pelvic Pain
Pollakiuria
Proctitis
Prostatitis
Pyelonephritis
Rectal Cramps
Sinusitis
Sleep Apnoea Syndrome
Urethral Stricture
Urinary Tract Infection
Bacterial
Urinary Tract Infection
Pseudomonal

Date:06/01/04ISR Number: 4367587-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Aspiration
	Atrial Fibrillation
	Breast Tenderness

		Cardio-Respiratory Arrest					
		Coagulopathy					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY						
		Diarrhoea		Tylenol With Codeine			
		Dyspnoea Exertional		#3	C		
UNKNOWN							
		Extradural Abscess		Percocet	C		
UNKNOWN							
		Fatigue		Ascorbic Acid	C		
UNKNOWN							
		Haematochezia		Vitamin E	C		
UNKNOWN							
		Hypersensitivity		Zocor	C		
UNKNOWN							
		Hypokalaemia		Beta Carotene	C		
UNKNOWN							
		Intervertebral Disc		Centrum	C		
UNKNOWN							
		Disorder					
		Intervertebral Discitis					
		Multi-Organ Failure					
		Myocardial Infarction					
		Pancreatitis					
		Renal Tubular Necrosis					
		Sepsis					
		Upper Respiratory Tract					
		Infection					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:06/01/04ISR Number: 4367588-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Anxiety		Celebrex	C		
UNKNOWN							
		Blood Cholesterol					
		Increased					
		Blood Triglycerides					

Increased
Bronchitis
Cardiomyopathy
Carotid Artery Stenosis
Cervicobrachial Syndrome
Coronary Artery Disease
Depression
Dermatitis Allergic
Diarrhoea
Gastritis
Gastrooesophageal Reflux
Disease
Hypertension
Irritable Bowel Syndrome
Lung Neoplasm
Metabolic Encephalopathy
Myocardial Infarction
Peripheral Vascular
Disorder
Pulmonary Hypertension
Sexual Dysfunction
Sleep Disorder
Staphylococcal Infection
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/04ISR Number: 4367589-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Condition Aggravated		Vicodin Tablets	C				
Disability	Contusion		Xanax	C			UNKNOWN	
	Depression		Elavil	C		ORAL		
	Diabetes Mellitus		Aspirin	C			UNKNOWN	
	Diabetic Neuropathy		Aspirin	C			UNKNOWN	
	Dizziness		Lotensin	C			UNKNOWN	
	Fall		Captopril	C			UNKNOWN	
	Fibromyalgia		Heparin	C			UNKNOWN	
	Generalised Anxiety		Hydro-Chlor	C			UNKNOWN	
	Disorder		Insulin	C			UNKNOWN	
	Haematochezia		Ms Contin	C			UNKNOWN	
	Haemorrhage							
	Hypertension							
	Injury							
	Intestinal Obstruction							
	Joint Lock							
	Lupus-Like Syndrome							
	Malaise							
	Nervousness							
	Osteoarthritis							
	Pain							
	Sjogren'S Syndrome							
	Stomach Discomfort							
	Thrombocytopenia							
	Tremor							
	Vomiting							
	Weight Increased							

Date:06/01/04ISR Number: 4367591-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00074
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Azopt Drops	C			UNKNOWN	
	Asthenia		Ocupress	C			UNKNOWN	
	Atrial Bigeminy		Prempro	C			UNKNOWN	
	Blood Creatinine		Maxzide	C			UNKNOWN	
	Increased		Levoxyl	C			UNKNOWN	
	Blood Urea Increased							
	Bundle Branch Block Left							
	Death							
	Decreased Appetite							
	Dizziness Postural							
	Fall							
	Head Injury							
	Injury							
	Laceration							
	Limb Injury							
	Skin Laceration							
	Urinary Retention							

Date:06/01/04ISR Number: 4367592-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00802
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		109 DAY
Initial or Prolonged	First Degree		Estrace	C				UNKNOWN
Other	Chills		Lasix (Furosemide)	C				UNKNOWN
	Global Amnesia		Synthroid	C				UNKNOWN
	Hypertension		Potassium (Unspecified)	C				UNKNOWN
	Injury							
	Ischaemic Stroke		Accupril	C				UNKNOWN
	Lacunar Infarction							
	Transient Ischaemic Attack							
	Urinary Tract Infection							

Date:06/01/04ISR Number: 4367594-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Imuran (Azathioprine)	C				UNKNOWN
Other	Atrial Fibrillation							
	Back Pain		Chloracon	C				UNKNOWN
	Cardiac Failure		Celebrex	C				UNKNOWN
	Congestive		Tagamet	C				UNKNOWN
	Cerebrovascular Accident		Cyanocobalamin	C				UNKNOWN
	Chest Pain		Lanoxin	C				UNKNOWN
	Condition Aggravated		Tiazac	C				UNKNOWN

	Coronary Artery Disease	Cartia (Diltiazem	
	Dizziness	Hydrochloride)	C
UNKNOWN			
	Drug Toxicity	Folic Acid	C
UNKNOWN			
	Emotional Distress	Lasix (Furosemide)	C
UNKNOWN			
	Extrasystoles	Glipizide	C
UNKNOWN			
	Injury	Motrin	C
UNKNOWN			
	Myocardial Infarction	Insulin	C
UNKNOWN			
	Myocardial Ischaemia	Insulin Human,	
	Neck Pain	Isophane	C
UNKNOWN			
	Oral Candidiasis	Imdur	C
UNKNOWN			
	Pain	Methotrexate	C
UNKNOWN			
	Polymyalgia Rheumatica	Niacin	C
UNKNOWN			
	Refusal Of Treatment By	Vitamin E	C
UNKNOWN			
	Patient	Flomax (Tamsulosin	
	Skin Ulcer	Hydrochloride)	C
UNKNOWN			
	Temporal Arteritis	Potassium	
	Thrombosis	(Unspecified)	C
UNKNOWN			
	Transient Ischaemic	Prednisone	C
UNKNOWN			
	Attack		
	Wandering Pacemaker		

Date:06/01/04ISR Number: 4367599-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Disability	Angina Pectoris
Other	Back Pain
	Blood Iron Decreased
	Blood Triglycerides
	Increased

	Breast Pain						
	Chromaturia						
	Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		[Composition					
	Drug Hypersensitivity		Unspecified]	C				UNKNOWN
	Drug Ineffective		Baycol	C				UNKNOWN
	Emotional Distress		Actos	C				UNKNOWN
	General Physical Health							
	Deterioration							
	Hypertension							
	Insomnia							
	Mood Altered							
	Muscle Atrophy							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain In Extremity							
	Road Traffic Accident							
	Tachycardia							
	Weight Decreased							

Date:06/01/04ISR Number: 4367603-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00839
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		[Therapy					
Disability	Embolic Stroke		Unspecified]	C				UNKNOWN
	Gout		Allopurinol	C				UNKNOWN
	Hypertension		Adalat	C				UNKNOWN
	Hypertrophic		Accupril	C				UNKNOWN
	Cardiomyopathy							
	Joint Effusion							

Sleep Apnoea Syndrome
Urinary Tract Infection
Vitamin B12 Deficiency

Date:06/01/04ISR Number: 4367607-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00235
Age:31 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
Other	Arthralgia
	Balance Disorder
	Blindness Unilateral
	Emotional Distress
	Hypoaesthesia
	Injury
	Joint Dislocation
	Keratoconjunctivitis
	Sicca
	Migraine With Aura
	Pain In Extremity
	Paraesthesia
	Platelet Count Increased
	Retinal Haemorrhage

Retinal Vein Occlusion

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	379	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	379	DAY
	Vicodin Tablets	C			UNKNOWN	
	Celebrex	C			UNKNOWN	

Date:06/01/04ISR Number: 4367608-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased		[Therapy Unspecified]	C			UNKNOWN	
	Blood Pressure		Acetaminophen	C			UNKNOWN	
	Inadequately Controlled		Percocet	C			UNKNOWN	
	Bronchitis		Soma	C			UNKNOWN	
	Cachexia		Zyrtec	C			UNKNOWN	
	Cataract		Cyanocobalamin	C			UNKNOWN	
	Cerebrovascular Accident		Ultram	C			UNKNOWN	
	Constipation		Lamisil	C			UNKNOWN	
	Cough		Estrace	C			UNKNOWN	
	Dehydration		Premarin	C			UNKNOWN	
	Depression		Motrin	C			UNKNOWN	
	Diarrhoea		Ocuflox	C			UNKNOWN	

	Diverticulitis	Oxycodone	C
UNKNOWN			
	Fatigue	Prednisone	C
OPHTHALMIC			
	Gastroenteritis Viral		
	Gastrointestinal Disorder		
	Increased Tendency To Bruise		
	Irritable Bowel Syndrome		
	Migraine		
	Neurodermatitis		
	Normochromic Normocytic Anaemia		
	Oedema Peripheral		
	Osteopenia		
	Pain		
	Pneumonia		
	Renal Failure Acute		

Date:06/01/04ISR Number: 4367612-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01954
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
Hospitalization - Initial or Prolonged	Angiopathy
	Blood Pressure Systolic Increased
	Cardiac Arrest
	Cardiomegaly
	Cellulitis
	Hypoaesthesia
	Joint Sprain
	Myocardial Infarction

	Oedema Peripheral Skin Ulcer Venous Stasis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL	614	DAY
			Allopurinol	C			UNKNOWN	
			Benzonatate	C			UNKNOWN	
			Colchicine	C			UNKNOWN	
			Vasotec	C			UNKNOWN	725 DAY
			Enalapril Maleate	C			UNKNOWN	323 DAY
			Verapamil	C			UNKNOWN	418 DAY
			Glucotrol Xl	C			UNKNOWN	
			Glucovance	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Accupril	C			UNKNOWN	418 DAY

Date:06/01/04ISR Number: 4367613-7Report Type:Expedited (15-DaCompany Report #FI-MERCK-0405FIN00005
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage							

Date:06/01/04ISR Number: 4367614-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

	Chills	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Diverticulum	Vioxx	SS	Merck & Co., Inc	ORAL
	Flank Pain	Lipitor	C		
UNKNOWN	3142 DAY				
	Gastritis	Lotensin	C		
UNKNOWN					
	Haemorrhoids	Lotensin	C		
UNKNOWN					
	Hiatus Hernia	Vasotec	C		ORAL
3507 DAY					
	Hyperhidrosis	Vasotec	C		ORAL
3507 DAY					
		Prozac	C		
UNKNOWN					
		Prozac	C		
UNKNOWN					
		Prozac	C		
UNKNOWN					
		Ginseng	C		
UNKNOWN					
		Naproxen	C		
UNKNOWN					
		Accupril	C		
UNKNOWN					
		Accupril	C		
UNKNOWN					

Date:06/01/04ISR Number: 4367616-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01953
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Chest Pain Coronary Artery Disease Epicondylitis Gastrooesophageal Reflux Disease Hypercholesterolaemia Hypertension

		Intervertebral Disc Degeneration					
		Muscle Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Periarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Seborrhoeic Keratosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Telangiectasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Tenosynovitis					
		Ventricular Tachycardia					

Date:06/01/04ISR Number: 4367617-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0403GBR00294
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL

Date:06/01/04ISR Number: 4367618-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease					
	Emotional Distress					
	Hyperlipidaemia					
	Myocardial Infarction					
	Sinus Arrhythmia					

Date:06/01/04ISR Number: 4367619-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Atrioventricular Block
Hospitalization -	Benign Prostatic
Initial or Prolonged	Hyperplasia
Other	Cardiac Failure
	Congestive
	Cerebrovascular Accident

Coronary Artery Disease
Dehydration
Dizziness
Ejection Fraction
Decreased
Hiatus Hernia
Hypertension
Mitral Valve Incompetence
Myocardial Infarction
Oedema
Pneumonia Escherichia
Post Procedural
Complication
Renal Failure
Respiratory Failure
Sepsis
Subarachnoid Haemorrhage
Syncope
Transient Ischaemic
Attack

		Tricuspid Valve Incompetence					
		Varicose Vein	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricle Rupture		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Neurontin	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:06/01/04ISR Number: 4367622-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL
138 DAY							
Other		Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
138 DAY							
		Amnesia					
		Aura					
		Back Pain					
		Blood Glucose Increased					
		Bradyphrenia					
		Cognitive Disorder					
		Compression Fracture					
		Condition Aggravated					
		Convulsion					
		Depression					
		Encephalomalacia					
		Feeling Abnormal					
		Headache					
		Injury					
		Intervertebral Disc Displacement					
		Loss Of Consciousness					
		Lumbar Vertebral Fracture					
		Nasal Septum Deviation					
		Nasal Turbinate Hypertrophy					
		Nose Deformity					
		Otitis Media					
		Palpitations					

Photopsia
Road Traffic Accident
Sexual Dysfunction
Somnolence
Stress
Tremor
White Blood Cell Count
Increased

Date:06/01/04ISR Number: 4367624-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Cerebrovascular Accident
	Electrocardiogram Qt Prolonged
	Heart Rate Irregular
	Hypertensive Crisis
	Hypokalaemia
	Sinusitis

Stress

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health	Vioxx	PS	Merck & Co., Inc	ORAL
31	DAY	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Trinalin	C		
UNKNOWN						
			Klonopin	C		
UNKNOWN						
			Clonidine	C		
UNKNOWN						
			Triamterene	C		
UNKNOWN						
			Cyclobenzaprine Hydrochloride	C		ORAL
			Cyclobenzaprine Hydrochloride	C		ORAL
			Prempro	C		
UNKNOWN						
			Relafen	C		ORAL

Date:06/01/04ISR Number: 4367625-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Alcoholism	Professional	Ms Contin	SS		
UNKNOWN						
	Balance Disorder		Aspirin	C		
UNKNOWN						
	Complex Partial Seizures		Vitamins (Unspecified)	C		
	Constipation					
UNKNOWN						
	Depressed Mood		Tegretol	C		
UNKNOWN						
	Diarrhoea		Depakote	C		
UNKNOWN						

Dizziness
Drug Hypersensitivity
Drug Ineffective
Emotional Distress
Fall
Fatigue
Gingival Hyperplasia
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypertension
Hypoacusis
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Periarthritis
Psoriasis
Spinal Osteoarthritis
Synovitis
Tinnitus
Vaginal Infection
Weight Increased
Wrist Fracture

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/04ISR Number: 4367627-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02790
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diverticulum Intestinal		Betamethasone And Bupivacaine Hydrochloride	C		PARENTERAL		
	Dyspnoea							
	Endometrial Hyperplasia							
	Gastric Ulcer		Arthrotec	C		UNKNOWN		
	Gastritis		Naprelan	C		UNKNOWN		
	Gastrointestinal Haemorrhage							
	Haemorrhoids							
	Headache							
	Hiatus Hernia							
	Lung Neoplasm							
	Muscle Strain							
	Periodontal Disease							
	Rash							
	Rectal Haemorrhage							
	Reflux Oesophagitis							
	Road Traffic Accident							
	Sinus Disorder							
	Uterine Leiomyoma							

Date:06/01/04ISR Number: 4367629-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00111
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Coma		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Disability	Gastrooesophageal Reflux Disease							
	Thyroid Disorder							

Date:06/01/04ISR Number: 4367630-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL		85 DAY
Initial or Prolonged	Arteriovenous Fistula	Professional	Tylenol	C				
UNKNOWN								
Other	Bundle Branch Block Left		Ecotrin	C				
UNKNOWN								
	Chest Discomfort		Viagra	C				
UNKNOWN								
	Coronary Artery Disease		Calan Sr	C				
UNKNOWN								
	Dehydration		Zocor	C				
UNKNOWN								
	Diverticulum Intestinal		Celebrex	C				
UNKNOWN								
	Haemorrhagic		Advil	C				
UNKNOWN								
	Emotional Distress							
	Gastritis Atrophic							
	Helicobacter Infection							
	Neck Pain							
	Neuropathy Peripheral							
	Stent Occlusion							

Date:06/01/04ISR Number: 4367631-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
Disability	Ageusia
Other	Aortic Valve Incompetence
	Arthralgia
	Benign Prostatic Hyperplasia
	Blood Creatine Phosphokinase Increased
	Blood Glucose Increased
	Blood Pressure Increased
	Carotid Artery Atheroma
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Cholecystitis Chronic
	Cholelithiasis
	Colon Adenoma
	Colonic Polyp
	Constipation
	Depression
	Dizziness
	Drug Ineffective
	Dry Mouth
	Dysgeusia
	Dyspepsia
	Dysplasia
	Dysthymic Disorder
	Electrocardiogram Abnormal
	Epicondylitis
	Exercise Electrocardiogram Abnormal
	Fatigue
	Headache
	Hemiparesis
	Hypertension
	Impaired Driving Ability
	Insomnia
	Laceration
	Lacunar Infarction
	Limb Injury
	Low Density Lipoprotein Increased

Micturition Urgency
Mitral Valve Incompetence
Neurogenic Bladder
Osteoarthritis
Pain In Extremity
Paraesthesia
Prostate Cancer
Prostatic Intraepithelial
Neoplasia
Psoriasis
Radiculopathy
Rash Erythematous
Respiratory Rate
Increased
Sleep Disorder

		Stress Tendonitis Thrombotic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tongue Coated	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Trigger Finger	Professional	Prevacid	SS		
UNKNOWN							
		Ventricular Hypertrophy		Prevacid	SS		
UNKNOWN							
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
46	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Zocor	SS		ORAL
2099	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
46	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Monopril	C		
UNKNOWN		1183 DAY					
				Levaquin	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN		4268 DAY					
				Zantac	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN		4268 DAY					
				Levaquin	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							

Date:06/01/04ISR Number: 4367633-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Premarin	C				
UNKNOWN								
Other	Increased							
	Blood Pressure Increased							
	Cardiac Disorder							
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Chronic Obstructive							
	Pulmonary Disease							
	Corneal Disorder							
	Drug Hypersensitivity							
	Nosocomial Infection							
	Oedema Peripheral							
	Pneumonia							
	Pulmonary Hypertension							
	Transient Ischaemic							
	Attack							

Date:06/01/04ISR Number: 4367634-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adenosquamous Cell Lung
	Cancer
Other	Asthenia
	Atherosclerosis
	Band Neutrophil
	Percentage Increased

		Blood Pressure Systolic Increased					
		Cerebral Atrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Vitamins			
		Pulmonary Disease		(Unspecified)	C		
UNKNOWN							
		Confabulation					
		Confusional State					
		Coordination Abnormal					
		Decreased Appetite					
		Diplopia					
		Dizziness					
		Dysarthria					
		Dyspnoea Exertional					
		Eczema					
		Feeling Abnormal					
		Gastrointestinal Disorder					
		Hypertension					
		Kyphosis					
		Lymphadenopathy					
		Memory Impairment					
		Mental Status Changes					
		Monocyte Percentage Increased					
		Nocturia					
		Non-Small Cell Lung Cancer Metastatic					
		Nuclear Magnetic Resonance Imaging Brain Abnormal					
		Pharmaceutical Product Complaint					
		Pleural Effusion					
		Refusal Of Treatment By Patient					
		Respiratory Rate Increased					
		Restrictive Pulmonary Disease					
		Rhinitis Allergic					
		Scar					
		Sciatica					
		Scotoma					
		Spinal Osteoarthritis					

Transient Ischaemic
Attack
Vascular Calcification
Vision Blurred

Date:06/01/04ISR Number: 4367635-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Atherosclerosis
	Blood Cholesterol Increased
	Cardiac Failure

		Congestive Cardio-Respiratory Arrest Cardiogenic Shock Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematuria	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Reopro	C		
UNKNOWN							
		Lung Infiltration		Tylenol	C		
UNKNOWN							
		Myalgia		Cordarone	C		
UNKNOWN							
		Orthostatic Hypotension		Aspirin	C		ORAL
		Ventricular Tachycardia		Atenolol	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				Claforan	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Dopamine Hydrochloride	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Dalmane	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Magnesium Sulfate	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							

Date:06/01/04ISR Number: 4367636-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00075
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Prescribed Overdose	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Rhabdomyolysis	Professional	Pravastatin Sodium	SS		ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Benzthiazide And Triamterene	C				
UNKNOWN								
			Isosorbide Mononitrate	C				
UNKNOWN								
			Pantoprazole Sodium	C				
UNKNOWN							4	DAY
			Phenprocoumon	C				
UNKNOWN								

Date:06/01/04ISR Number: 4367641-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00007
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Aortic Aneurysm
	Arthralgia
	Atrial Septal Defect
	Blood Cholesterol Increased
	Bronchitis
	Bursitis
	Cellulitis
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Condition Aggravated
	Depression

		Dilatation Atrial Drug Ineffective Electrocardiogram Poor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		R-Wave Progression		Vioxx	PS	Merck & Co., Inc	ORAL
93	DAY						
		Electrocardiogram St		Vioxx	SS	Merck & Co., Inc	ORAL
93	DAY						
		Segment Depression		Tylenol	C		
UNKNOWN							
		Fear		Darvocet-N	C		
UNKNOWN							
		Hypertension		Xanax	C		
UNKNOWN							
		Intervertebral Disc		Zoloft	C		
UNKNOWN		764 DAY					
		Protrusion		Zoloft	C		
UNKNOWN							
		Joint Swelling		Zoloft	C		
UNKNOWN		2 WK					
		Low Density Lipoprotein		Xanax	C		
UNKNOWN							
		Increased		Xalatan	C		
UNKNOWN							
		Mean Cell Volume		Synthroid	C		
UNKNOWN							
		Increased Nervousness Oedema Peripheral Panic Disorder With Agoraphobia Radiculitis Lumbosacral Rhonchi Skin Laceration Skin Ulcer Spinal Column Stenosis Spinal Osteoarthritis Spondylolisthesis Acquired Wheezing					

Date:06/01/04ISR Number: 4367643-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01704
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/01/04ISR Number: 4367645-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 73 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Roxicet	C				
UNKNOWN							799	DAY
Disability	Anxiety		Proscar	C				
UNKNOWN								
	Bundle Branch Block Right		Zantac	C				
UNKNOWN								
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hernia							
	Hypertension							
	Hypokinesia							
	Myocardial Infarction							
	Panic Disorder							

Date:06/01/04ISR Number: 4367648-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01883
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Atherosclerosis

		Cardiomegaly					
		Contusion					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	WK						
		Coronary Artery Disease	Professional				
		Coronary Artery Occlusion					
		Eosinophilia					
		Excoriation					
		Eye Swelling					
		Myocardial Ischaemia					
		Pulmonary Congestion					
		Pulmonary Oedema					
		Scar					
		Swelling Face					
		Vascular Graft Occlusion					

Date:06/01/04ISR Number: 4367649-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cellulitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
14	DAY						
Initial or Prolonged		Chest Pain	Professional	Cardizem	C		
UNKNOWN							
Other		Depression		Ismo	C		
UNKNOWN							
		Joint Injury					
		Oedema Peripheral					
		Palpitations					
		Pneumonia					
		Skin Discolouration					
		Synovitis					

Date:06/01/04ISR Number: 4367786-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
138	DAY						

	Infarction	Vioxx	SS	Merck & Co., Inc	ORAL
138 DAY					
	Arrhythmia	[Therapy			
	Cardiac Failure	Unspecified]	C		
UNKNOWN					
	Congestive	Tylenol	C		
UNKNOWN					
	Chest Pain	Phoslo	C		
UNKNOWN					
	Dizziness	Digoxin	C		
UNKNOWN	48 DAY				
	Feeling Hot	Digoxin	C		
UNKNOWN					
	Hyperhidrosis	Digoxin	C		
UNKNOWN					
	Ingrowing Nail	Terazosin			
	Malaise	Hydrochloride	C		
UNKNOWN					
	Onychomycosis	Cardizem	C		
UNKNOWN					
	Palpitations	Epogen	C		
UNKNOWN					
	Renal Failure Chronic	Lasix (Furosemide)	C		
UNKNOWN					
	Skin Lesion	Apresoline	C		
UNKNOWN					
	Urinary Tract Infection	Infed	C		
UNKNOWN					
		Zemplar	C		
UNKNOWN					

Date:06/01/04ISR Number: 4367787-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
Asthenia		Amitriptyline Hydrochloride	C			UNKNOWN	
Back Pain		Aspirin	C			UNKNOWN	
Contusion		Pravachol	C			UNKNOWN	
Coronary Artery Disease		Altace	C			UNKNOWN	
Coronary Artery Stenosis							
Dizziness							
Emotional Distress							
Fall							
Fatigue							
Gastrooesophageal Reflux Disease							
Hypercoagulation							
Therapeutic Response Decreased							
Upper Respiratory Tract Infection							

Date:06/01/04ISR Number: 4367789-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00190
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Aspirin	SS		ORAL		
	Tremor		Bendroflumethiazide	SS		ORAL		
			Donepezil Hydrochloride	SS		ORAL		
			Omeprazole	SS		ORAL		
			Atorvastatin Calcium	C			UNKNOWN	
			Dothiepin Hydrochloride	C			UNKNOWN	

Date:06/01/04ISR Number: 4367791-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00194
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
	Palpitations							

Date:06/01/04ISR Number: 4367869-0Report Type:Direct Company Report #CTU 219803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective		Vioxx 25 Mg Merck	PS	Merck	ORAL	1 1 ORAL	
Initial or Prolonged	Fungal Infection		Wellbutrin 300 Mg					
	Stevens-Johnson Syndrome		Glaxo	SS	Glaxo	ORAL	1 1 ORAL	

Date:06/01/04ISR Number: 4370842-XReport Type:Expedited (15-DaCompany Report #04P-062-0261391-00
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Asthma
Initial or Prolonged	Drug Ineffective

	Pain Poisoning Suicide Attempt	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
		Foreign Health Professional	Humira 40 Mg/0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab)	PS		
SUBCUTANEOUS	80 MG, 1 IN 2 WK, SUBCUTANEOUS					
			Clomipramine	SS		ORAL
250 MG, ONCE, PER ORAL						
			Rofecoxib	SS		ORAL
PER ORAL						
			Methotrexate Sodium	C		

Date:06/01/04ISR Number: 4371017-0Report Type:Expedited (15-DaCompany Report #200410349BNE
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Convulsion Dizziness Tremor	Foreign Health Professional Other	Aspirin (Acetylsalicylic Acid)	PS		ORAL
75 MG, TOTAL DAILY, ORAL						
			Aricept (Donepezil Hydrochloride)	SS		ORAL
10 MG, TOTAL DAILY, ORAL						
			Bendrofluazide	SS		ORAL
2.5 MG, TOTAL DAILY, ORAL						
			Omeprazole	SS		ORAL
20 MG, TOTAL DAILY, ORAL						

Rofecoxib	SS	ORAL

12.5 MG,

TOTAL DAILY,

ORAL

Dothiepin	C
Atorvastatin	C

Date:06/02/04ISR Number: 4368124-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Apathy
Other	Asthenia
	Atelectasis
	Cerebral Infarction
	Cerebral Thrombosis
	Cerebrovascular Accident
	Choking
	Circulatory Collapse
	Cognitive Disorder
	Depersonalisation
	Disorientation
	Duodenitis
	Gastrooesophageal Reflux Disease
	Heart Rate Increased
	Heart Rate Irregular
	Hypertension
	Hypoacusis
	Injury
	Libido Decreased

		Mental Impairment					
		Mental Status Changes					
		Oesophageal Rupture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oesophagitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Self Esteem Decreased		Aspirin	C		
UNKNOWN							
		Supraventricular		Restoril	C		
UNKNOWN							
		Extrasystoles					
		Thromboembolic Stroke					
		Transient Ischaemic					
		Attack					
		Weight Below Normal					

Date:06/02/04ISR Number: 4368129-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01789
Age:59 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
				Vicodin Tablets	C		
UNKNOWN							
				Arava	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

Date:06/02/04ISR Number: 4368130-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Disturbance In Attention		Aspirin	C		
UNKNOWN							
Disability		Emotional Distress		Celexa	C		
UNKNOWN							
Other		Generalised Anxiety		Lexapro	C		
UNKNOWN							

Disorder Synthroid C
UNKNOWN
Headache Niacin C
UNKNOWN 14671DAY
Impaired Work Ability
Injury
Lacunar Infarction
Oesophageal Spasm
Pain In Extremity
Reading Disorder
Thrombosis
Tremor
Vision Blurred

Date:06/02/04ISR Number: 4368131-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01237
Age:40 YR Gender:Female I/FU:F

Outcome PT
Disability Acrochordon
Acute Sinusitis
Angina Pectoris
Anxiety
Arthralgia
Back Injury
Bronchitis Chronic
Cardiac Failure
Congestive
Chest Pain

		Contusion					
		Emotional Distress					
		Exostosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Ulcer		Aspirin	C		
UNKNOWN							
		Headache		Celebrex	C		
UNKNOWN							
		Hypertension		Ambien	C		
UNKNOWN							
		Hypoaesthesia		Meridia	C		
UNKNOWN							
		Influenza		Antivert	C		
UNKNOWN							
		Intervertebral Disc		Relafen	C		
UNKNOWN							
		Degeneration		Naproxen	C		
UNKNOWN							
		Intervertebral Disc					
		Protrusion					
		Joint Effusion					
		Ligament Injury					
		Major Depression					
		Meniscus Lesion					
		Muscle Strain					
		Osteoarthritis					
		Prescribed Overdose					
		Radiculopathy					
		Rotator Cuff Syndrome					
		Spinal Osteoarthritis					
		Tenderness					

Date:06/02/04ISR Number: 4368632-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00132
Age:93 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
55 DAY							
Life-Threatening		Duodenal Ulcer		Amlodipine Besylate	C		ORAL
Hospitalization -		Haemorrhage		Dipyrone	C		ORAL
135 DAY							

Initial or Prolonged	Gastric Ulcer Haemorrhage	Furosemide	C	ORAL

475 DAY

Date:06/02/04ISR Number: 4368634-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Disability	Aortic Valve Incompetence
Other	Arthritis
	Arthropathy
	Candidiasis
	Chronic Lymphocytic
	Leukaemia
	Coronary Artery Disease
	Gastritis
	Gastrointestinal
	Haemorrhage
	Heart Injury
	Heart Rate Irregular
	Hyperlipidaemia
	Hypertension
	Meniscus Lesion
	Mitral Valve Prolapse
	Oedema Peripheral

	Osteoarthritis						
	Overdose						
	Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Reflux Oesophagitis		Voltaren	SS			UNKNOWN
	Stress		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL	
	Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ulcer Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	
	Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL	
	Wound Infection		Prempro	C			UNKNOWN
	Staphylococcal						

Date:06/02/04ISR Number: 4368636-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00111
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	285 DAY
Life-Threatening	Perforation		Albuterol	C			RESPIRATORY (INHALATION)
Hospitalization - Initial or Prolonged			Amlodipine Besylate	C			UNKNOWN
Other			Bisoprolol Fumarate	C			UNKNOWN
			Fosinopril Sodium	C			UNKNOWN
			Ibuprofen	C			UNKNOWN

Date:06/02/04ISR Number: 4368637-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adjustment Disorder With

Initial or Prolonged Disability	Depressed Mood
Other	Affective Disorder
	Alopecia
	Anaemia
	Angina Unstable
	Ankylosing Spondylitis
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Concussion
	Constipation
	Depression
	Drug Ineffective
	Dysphagia
	Dysphoria
	Facet Joint Syndrome
	Facial Bones Fracture
	Fall
	Gastrooesophageal Reflux Disease
	Hypothyroidism
	Intervertebral Disc Degeneration
	Intervertebral Disc Displacement

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Intervertebral Disc Protrusion					
		Jaw Disorder					
		Myofascial Pain Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY							
		Neck Pain		Microzide	SS		
UNKNOWN							
		Nephritis Interstitial		Microzide	SS		
UNKNOWN							
		Oesophageal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Prinzide	SS		ORAL
26 HR							
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
		Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
99 DAY							
		Psoriatic Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Raynaud'S Phenomenon		Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
		Reflux Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
99 DAY							
		Reiter'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
24 DAY							
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY							
		Sacroiliitis		Vioxx	SS	Merck & Co., Inc	ORAL
179 DAY							
		Spondyloarthropathy		Celebrex	C		
UNKNOWN							
		Urinary Tract Pain		Valium	C		
UNKNOWN							
		Weight Increased		Analgesic Or Anesthetic (Unspecified)	C		
PARENTERAL		1 DAY					
				Prevacid	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Trazodone			

Hydrochloride	C	UNKNOWN
Imitrex	C	UNKNOWN
Claritin	C	UNKNOWN
Prevacid	C	UNKNOWN
Beconase	C	UNKNOWN
Vicodin Es Tablets	C	UNKNOWN
Zestoretic	C	UNKNOWN
Estratest	C	UNKNOWN
Estratest	C	UNKNOWN

Date:06/02/04ISR Number: 4368639-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00195
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY	
Hospitalization - Initial or Prolonged	Increased Nausea Oedema Peripheral							

Date:06/02/04ISR Number: 4368640-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00483
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
	Disorientation		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Mental Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/04ISR Number: 4372261-9Report Type:Direct Company Report #CTU 219989
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetic Nephropathy		Vioxx 50 Mg	PS				PRN
	Dialysis		Cozaar	SS				
	Drug Toxicity		Spironolactone	SS				
	Electrocardiogram Change							
	Hypovolaemia							
	Renal Failure Acute							

Date:06/03/04ISR Number: 4369832-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02086
Age:91 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Balance Disorder	Professional	Valium	C				UNKNOWN
Hospitalization -	Cardiac Failure		Vasotec	C		ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vasotec	C		ORAL		
Disability	Constipation		Ferrous Sulfate	C				UNKNOWN
Other	Death		Timoptic	C				OPHTHALMIC
	Decubitus Ulcer		Ultram	C				UNKNOWN
	Depression		Miacalcin	C				UNKNOWN
	Dry Skin		Hydrodiuril	C		ORAL		
	Dyspnoea		Morphine	C				UNKNOWN
	Fall		Deltasone	C				UNKNOWN
	Gastrooesophageal Reflux Disease							
	Haematochezia							
	Haemorrhage							
	Hyperkeratosis							
	Hypoacusis							
	Inflammation							
	Muscle Spasms							
	Nausea							

Pain
Pelvic Fracture
Pulmonary Mass
Respiratory Tract
Infection
Senile Dementia
Spinal Compression
Fracture
Syncope
Tinea Pedis
Transient Ischaemic
Attack
Weight Decreased

Date:06/03/04ISR Number: 4369834-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Affective Disorder
	Colonic Polyp
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent

	Dyspepsia						
	Gastritis						
	Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hot Flush	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
	Hypochromic Anaemia	Professional	Yasmin	SS			UNKNOWN 14 DAY
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Intracranial Venous Sinus		Vioxx	SS	Merck & Co., Inc	ORAL	6 MON
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Joint Effusion		Vioxx	SS	Merck & Co., Inc	ORAL	
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pharyngolaryngeal Pain		Sandimmun	C			UNKNOWN
	Rash		Sandimmun	C			UNKNOWN
	Sinus Tachycardia		Prelone Syrup	C			UNKNOWN
	Subarachnoid Haemorrhage		Prednisone	C			UNKNOWN
	Uterine Leiomyoma		Prelone Syrup	C			UNKNOWN
	Vomiting		Hormonal Contraceptives (Unspecified)	C			INTRAMUSCULAR
			Sandimmun	C			UNKNOWN

Date:06/03/04ISR Number: 4369835-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Balance Disorder		Tylenol	C			UNKNOWN
	Cellulitis		Ascorbic Acid	C			UNKNOWN
	Clostridium Colitis		Aspirin	C			UNKNOWN

	Decreased Appetite	Atenolol	C
UNKNOWN			
	Dizziness	Lotensin	C
UNKNOWN			
	Drug Ineffective	Zocor	C
UNKNOWN			
	Dyspepsia	Vitamin E	C
UNKNOWN			
	Feeling Jittery	Coenzyme Q10	C
UNKNOWN			
	Gout	Colchicine	C
UNKNOWN			
	Insomnia	Glucosamine	C
UNKNOWN			
	Intervertebral Disc	Aleve	C
UNKNOWN			
	Degeneration	Nonsteroidal	
	Mood Altered	Anti-Inflammatory	
	Osteoarthritis	Drug (Unspecified)	C
UNKNOWN			
	Pain	Omega-3	C
UNKNOWN			
	Scoliosis	Zantac	C
UNKNOWN			
	Spondylolisthesis		
	Acquired		

Date:06/03/04ISR Number: 4369841-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Angina Pectoris
Hospitalization -	Anxiety
Initial or Prolonged	Aortic Aneurysm
Other	Blood Triglycerides
	Increased
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cerebrovascular Accident
	Cholelithiasis

		Death Depressed Level Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
786	DAY						
		Dyspnoea Haemorrhage	Professional	[Therapy Unspecified]	C		
UNKNOWN							
		Heart Rate Irregular		Aspirin	C		
UNKNOWN							
		High Density Lipoprotein		Atenolol	C		
UNKNOWN							
		Decreased		Zocor	C		
UNKNOWN							
		Low Density Lipoprotein		Celebrex	C		
UNKNOWN							
		Increased		Plavix	C		
UNKNOWN							
		Myocardial Infarction Stress Transient Ischaemic Attack		Prinivil	C		ORAL

Date:06/03/04ISR Number: 4369844-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0404DEU00083
Age:79 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Rhabdomyolysis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				[Therapy Unspecified]	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Doxazosin Mesylate	C		
UNKNOWN							
				Sulpiride	C		
UNKNOWN							
				Hetastarch And Sodium Chloride	C		
INTRAVENOUS							

DRIP

Lisinopril C

UNKNOWN

Pentoxifylline C

UNKNOWN

Date:06/03/04ISR Number: 4369845-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Apnoea
	Arthritis
	Cardiac Valve Disease
	Coronary Artery Disease
	Coronary Artery Restenosis
	Diabetes Mellitus
	Diverticulitis
	Dysphonia
	Dyspnoea
	Emotional Distress
	Facet Joint Syndrome
	Hand Fracture
	Hyperlipidaemia
	Hypertension
	Insomnia
	Intervertebral Disc Protrusion
	Lumbar Spinal Stenosis
	Muscle Strain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Nervousness Pneumothorax Raynaud'S Phenomenon					
350 DAY		Respiratory Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Somnolence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
350 DAY							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN	27 DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN	27 DAY						
				[Therapy Unspecified]	C		
UNKNOWN							
				Norco	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Avandia	C		
UNKNOWN							
				Chlorthalidone	C		
UNKNOWN							
				Hygroton	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Propecia	C		
UNKNOWN							

		Glucovance	C	
UNKNOWN				
		Hydrocodone Hydrochloride	C	
UNKNOWN				

Date:06/03/04ISR Number: 4369846-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspiration Gastrooesophageal Reflux Disease Lung Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/04ISR Number: 4370563-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01996
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/03/04ISR Number: 4370568-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Angina Unstable
Other	Aortic Stenosis Arrhythmia Arterial Stenosis Atrial Fibrillation Cardiac Failure

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Congestive Chest Pain Chronic Obstructive Pulmonary Disease					
		Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Coronary Artery Occlusion		Allopurinol	C		
UNKNOWN		Diabetes Mellitus		Allopurinol	C		
UNKNOWN		Diverticulum		Aspirin	C		
UNKNOWN		Dizziness		Lipitor	C		
UNKNOWN		Emotional Distress		Lotensin	C		
UNKNOWN		Erectile Dysfunction		Coreg	C		
UNKNOWN		Eye Haemorrhage		Celebrex	C		
UNKNOWN		Glaucoma Gouty Arthritis		Clopidogrel Bisulfate	C		
UNKNOWN		Hypotension		Cardizem	C		
UNKNOWN		Injury		Pepcid	C		
UNKNOWN		Ischaemic Cardiomyopathy		Fluvastatin Sodium	C		
UNKNOWN		Localised Infection		Furosemide	C		
UNKNOWN		Mental Disorder		Neurontin	C		
UNKNOWN		Mitral Valve Incompetence		Glipizide	C		
UNKNOWN		Mitral Valve Prolapse		Glycine	C		
UNKNOWN		Myocardial Infarction		Insulin	C		
UNKNOWN		Non-Cardiac Chest Pain		Glucophage	C		
UNKNOWN		Oedema Peripheral		Coumadin	C		
UNKNOWN		Osteomyelitis Overdose		Trazodone Hydrochloride	C		
UNKNOWN		Peripheral Coldness		Spironolactone	C		
UNKNOWN							

	Peripheral Occlusive	Nitroglycerin	C
UNKNOWN			
	Disease	Actos	C
UNKNOWN			
	Post Procedural Complication Pulmonary Hypertension Pulmonary Oedema Rectal Haemorrhage Renal Failure Respiratory Arrest Respiratory Failure Sleep Apnoea Syndrome Sleep Disorder Syncope Treatment Noncompliance Vascular Graft Occlusion Vascular Occlusion Ventricular Dysfunction		

Date:06/03/04ISR Number: 4370570-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Arterial Occlusive Disease Arthralgia Aseptic Necrosis Bone Asthenia Bladder Disorder Bursitis Carotid Artery Stenosis Cerebral Artery Occlusion Colonic Polyp Dementia
Disability	

		Depression					
		Disturbance In Attention					
		Diverticulum	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
92	DAY						
		Drug Withdrawal Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Duragesic	C		
UNKNOWN							
		Dysuria		Prevacid	C		
UNKNOWN							
		Feeling Abnormal		Effexor	C		
UNKNOWN							
		Gait Disturbance					
		Haematochezia					
		Headache					
		Hemiparesis					
		Hiatus Hernia					
		Hypoaesthesia					
		Intervertebral Disc					
		Degeneration					
		Ischaemic Cerebral					
		Infarction					
		Ischaemic Stroke					
		Joint Swelling					
		Memory Impairment					
		Mental Impairment					
		Musculoskeletal					
		Discomfort					
		Neck Pain					
		Nephrolithiasis					
		Oesophageal Disorder					
		Pain					
		Radiculopathy					
		Seborrhoeic Keratosis					
		Sensory Disturbance					
		Spinal Column Stenosis					
		Spinal Disorder					

Date:06/03/04ISR Number: 4370571-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00145
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Calcinosis		Codeine	C				UNKNOWN
Other	Cerebrovascular Disorder		Vitamins (Unspecified)	C				UNKNOWN
	Haemangioma							
	Hypoaesthesia		Codeine	C				UNKNOWN
	Migraine							
	Nuclear Magnetic Resonance Imaging Brain Abnormal							
	Paraesthesia							
	Sensory Level Abnormal							
	Simple Partial Seizures							
	Stress							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/04ISR Number: 4370573-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aortic Atherosclerosis		[Therapy					
	Arterial Disorder		Unspecified]	C				
UNKNOWN							10	YR
	Arthralgia		Endocet	C				
UNKNOWN								
	Asthenia		Elavil	C				
UNKNOWN								
	Back Injury		Tenormin	C				
UNKNOWN								
	Back Pain		Vancenase	C				
UNKNOWN								
	Bursa Disorder		Premarin	C				
UNKNOWN							9872	DAY
	Bursitis		Prevacid	C				
UNKNOWN								
	Cardiomegaly		Synthroid	C				
UNKNOWN								
	Cholelithiasis		Prinivil	C		ORAL		
1501 DAY								
	Chromaturia		Methocarbamol	C				
UNKNOWN								
	Constipation		Prilosec	C				
UNKNOWN								
	Deep Vein Thrombosis							
	Diarrhoea							
	Dry Mouth							
	Dyspnoea							
	Fatigue							
	Fluid Retention							
	Gastrooesophageal Reflux							
	Disease							
	Haematoma							
	Haemorrhoidal Haemorrhage							
	Herpes Zoster							
	Hypersensitivity							
	Hypertension							
	Hypoaesthesia							
	Impaired Work Ability							
	Injury							
	Intervertebral Disc							
	Degeneration							

Joint Effusion
Lung Disorder
Micturition Disorder
Migraine
Mononeuritis
Myalgia
Nausea
Nephrolithiasis
Oedema Peripheral
Pain In Extremity
Rectal Haemorrhage
Rectocele
Road Traffic Accident
Spinal Osteoarthritis
Splenic Cyst
Tricuspid Valve
Incompetence
Urinary Tract Infection
Urine Odour Abnormal
Wheezing
Wound Dehiscence

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/04ISR Number: 4370577-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Triglycerides		Ibuprofen	C				
UNKNOWN								
	Increased		Methotrexate	C				
UNKNOWN								
	Coronary Artery Disease							
	Emotional Distress							
	Hypertension							
	Myocardial Infarction							

Date:06/03/04ISR Number: 4370579-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02381
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chills		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Cannabis	C				
UNKNOWN								
	Dysphagia		Ambien	C				
UNKNOWN								
	Emotional Distress		Lorazepam	C				
UNKNOWN								
	Feeling Hot And Cold		Oramorph	C				
UNKNOWN								
	Gastrooesophageal Reflux		Protonix	C				
UNKNOWN								
	Disease							
	Haematemesis							
	Haematochezia							
	Joint Effusion							
	Leukocytosis							
	Ligament Injury							
	Lumbar Radiculopathy							
	Nausea							
	Oedema Peripheral							
	Overdose							

Pyrexia
Renal Pain
Sleep Disorder
Vomiting

Date:06/04/04ISR Number: 4370805-4Report Type:Expedited (15-DaCompany Report #DE-JNJFOC-20040506261
Age: Gender:Female I/FU:I

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
	Blood Calcium Decreased
	Blood Creatine Increased
	Blood Urea Increased
	Cardioactive Drug Level
	Increased
	Drug Interaction
	Gastritis Erosive
	Gastrointestinal
	Haemorrhage
	Haematemesis
	Haematocrit Decreased
	Haemoglobin Decreased

		International Normalised Ratio Increased					
		Melaena	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mucosal Haemorrhage	Health	Tramal	PS		
OROPHARINGEAL							
		Petechiae	Professional	Aquaphor	C		
OROPHARINGEAL							
				Aquaphor	C		
OROPHARINGEAL							
				Aquaphor	C		
OROPHARINGEAL							
				Aquaphor	C		
OROPHARINGEAL							
				Beloc-Zok	C		
OROPHARINGEAL							
				Digitoxin	C		
OROPHARINGEAL							
				Beloc-Zok	C		
OROPHARINGEAL							
				Vioxx	I		
OROPHARINGEAL							
				Falithrom	I		
OROPHARINGEAL							
				Falithrom	I		
OROPHARINGEAL							

Date:06/04/04ISR Number: 4371044-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
Other	Apathy
	Asthenia
	Atelectasis
	Blood Creatine Phosphokinase Mb Increased
	Cerebrovascular Accident
	Chest Pain
	Choking
	Circulatory Collapse
	Cognitive Disorder
	Dehydration
	Depersonalisation

Duodenitis
Dyskinesia
Erosive Oesophagitis
Gastrooesophageal Reflux
Disease
Haematemesis
Heart Rate Increased
Heart Rate Irregular
Heat Stroke
Hypertension
Hypoacusis
Injury
Lacunar Infarction
Libido Decreased
Mental Impairment
Mitral Valve Incompetence
Myoglobin Blood Present
Oesophageal Rupture
Oesophagitis Ulcerative
Self Esteem Decreased
Sensation Of Foreign Body
Supraventricular
Extrasystoles
Thromboembolic Stroke
Transient Ischaemic
Attack
Vomiting

Weight Below Normal

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspirin	C			UNKNOWN	
	Restoril	C			UNKNOWN	

Date:06/04/04ISR Number: 4371065-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bunion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		[Therapy					
Other	Congestive		Unspecified]	C			UNKNOWN	
	Cardiomegaly		[Therapy					
	Carotid Artery Stenosis		Unspecified]	C			UNKNOWN	
	Cataract		Avandia	C		ORAL		
	Contusion		Avandia	C		ORAL		
	Coronary Artery Disease		Vicoprofen	C		ORAL		
	Glaucoma		Glucophage	C		ORAL		
	Hypoaesthesia		Glucophage	C		ORAL		
	Lumbar Spinal Stenosis							
	Nasopharyngitis							
	Neuropathy Peripheral							
	Osteoarthritis							
	Road Traffic Accident							
	Spinal Osteoarthritis							
	Toe Deformity							
	Whiplash Injury							

Date:06/04/04ISR Number: 4371068-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 552 DAY	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Abdominal Distension	Professional	Aleve	SS		
Disability 552 DAY	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN	Anxiety		Tylenol	C		
UNKNOWN	Back Pain 2 MON		Paxil	C		
	Calculus Ureteric					
	Cognitive Disorder					
	Confusional State					
	Constipation					
	Dizziness					
	Emotional Distress					
	Haematochezia					
	Hypertension					
	Influenza Like Illness					
	Lethargy					
	Renal Cyst					
	Transient Ischaemic Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371070-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Aneurysm		Aspirin	SS		ORAL		
Other	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
RESPIRATORY (INHALATION)	Blood Pressure		Albuterol	C				
	Fluctuation							
UNKNOWN	Bronchitis		Ciprofloxacin	C				
UNKNOWN	Cardiomegaly		Ciprofloxacin	C				
	Cataract		Hyzaar	C		ORAL		
UNKNOWN	Chest Pain		Dyazide	C				
UNKNOWN	Chronic Obstructive		Isosorbide	C				
	Pulmonary Disease		Ativan	C		ORAL		
UNKNOWN	Chronic Sinusitis		Nitroglycerin	C				
	Colon Cancer		Oxybutynin	C		ORAL		
	Coronary Artery Disease		Propranolol Hydrochloride	C				
UNKNOWN	Deep Vein Thrombosis							
UNKNOWN	Dyspepsia		Quinine	C				
	Dysphagia							
	Dyspnoea							
	Ecchymosis							
	Emotional Distress							
	Essential Tremor							
	Faeces Discoloured							
	Fibromyalgia							
	Fluid Overload							
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Gastroenteritis Viral							
	Gastrointestinal Haemorrhage							
	Hypertension							
	Iron Deficiency Anaemia							
	Myocardial Infarction							
	Oesophageal Pain							

Osteoarthritis
Osteoporosis
Pyrexia
Renal Cyst
Rheumatic Fever
Rhinitis Allergic
Stress Incontinence
Venous Stasis
Vertigo
Weight Decreased

Date:06/04/04ISR Number: 4371071-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00178
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:06/04/04ISR Number: 4371073-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aggression
Other	Anxiety

	Bursitis						
	Carpal Tunnel Syndrome						
	Depression	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	
	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL	
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Joint Dislocation		Vioxx	SS	Merck & Co., Inc	ORAL	
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Paranoia		Lithium Carbonate	C			UNKNOWN
	Sacroiliitis						
	Stomach Discomfort						
	Suicidal Ideation						

Date:06/04/04ISR Number: 4371074-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Bipolar Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	135 DAY
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	135 DAY
	Myocardial Infarction		Depakote	C			UNKNOWN
			Lisinopril	C			UNKNOWN
			Lithium Sulfate	C			UNKNOWN

Date:06/04/04ISR Number: 4371076-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00060
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	
	Blood Folate Decreased		Aspirin Lysine	SS		ORAL	
	Blood Iron Decreased		Amlodipine Besylate	C		ORAL	
	Serum Ferritin Decreased		Atenolol	C		ORAL	
	Transferrin Increased		Fenofibrate	C		ORAL	
	Transferrin Saturation		Hydrochlorothiazide				

Decreased And Irbesartan C ORAL
Vitamin B12 Decreased

Date:06/04/04ISR Number: 4371079-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome	PT
Death	Agitation
Hospitalization - Initial or Prolonged	Angiopathy
Disability	Anxiety
	Arthralgia
	Back Injury
	Back Pain
	Blood Glucose Increased
	Blood Urea Increased
	Cerebrovascular Accident
	Crying
	Dehydration
	Dementia Alzheimer'S Type
	Depression
	Dizziness
	Drug Intolerance
	Dysuria
	Emotional Distress

		Facial Pain					
		Faecal Occult Blood Positive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Flank Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis					
		Hypertension					
		Hyporeflexia					
		Hypoventilation					
		Injury					
		Insomnia					
		Intervertebral Disc Degeneration					
		Nausea					
		Neck Pain					
		Neutrophil Percentage Increased					
		Oedema Peripheral					
		Renal Cyst					
		Spinal Osteoarthritis					
		Subarachnoid Haemorrhage					
		Vertigo					
		White Blood Cell Count Increased					

Date:06/04/04ISR Number: 4371084-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 14 DAY	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Arteriospasm Coronary	Professional	Cardizem	C		
Other UNKNOWN	Back Pain		Ismo	C		
	Cellulitis					
	Chest Pain					
	Depression					
	Emotional Distress					
	Hyperhidrosis					
	Injury					
	Joint Injury					
	Oedema Peripheral					

Palpitations
Pneumonia
Skin Discolouration
Synovitis
White Blood Cell Count
Increased

Date:06/04/04ISR Number: 4371088-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00089
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening	Distress Syndrome	Professional	Carbamazepine	C		ORAL		
Hospitalization -	Viral Infection		Topiramate	C		ORAL		
Initial or Prolonged	White Blood Cell Count		Valproate Sodium	C		ORAL		
	Increased		Phenobarbital	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371089-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02165
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gravitational Oedema		[Therapy Unspecified]	C				
	Haematemesis							
	Oedema Peripheral		Estrogens (Unspecified)	C				
	Swelling							
	Vomiting		Prilosec	C				

Date:06/04/04ISR Number: 4371090-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholism	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Aspirin	C				
Other	Back Pain							
	Blood Pressure Increased							
	Chest Discomfort							
	Chloasma							
	Chronic Sinusitis							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Cough							
	Depression							
	Diverticulum Oesophageal							
	Drug Dependence							
	Emotional Distress							
	Eustachian Tube Disorder							
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Iliac Artery Stenosis							
	Injury							

Intermittent Claudication
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Nervousness
Poor Peripheral
Circulation
Ventricular Hypokinesia

Date:06/04/04ISR Number: 4371118-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Adverse Event
Disability	Back Pain
Other	Blood Iron Decreased
	Blood Triglycerides Increased
	Breast Pain

		Chest Pain					
		Chest Wall Pain					
		Chromaturia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Fatigue Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Costochondritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		[Composition			
		Diabetic Retinopathy		Unspecified]	C		
UNKNOWN							
		Difficulty In Walking		Baycol	C		
UNKNOWN							
		Disturbance In Attention		Actos	C		
UNKNOWN							
		Dizziness					
		Drug Hypersensitivity					
		Drug Ineffective					
		Emotional Distress					
		General Physical Health					
		Deterioration					
		Hypertension					
		Insomnia					
		Mood Altered					
		Muscle Atrophy					
		Myalgia					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Pain					
		Pain In Extremity					
		Restless Legs Syndrome					
		Road Traffic Accident					
		Tachycardia					
		Weight Decreased					

Date:06/04/04ISR Number: 4371119-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104477
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiomegaly	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiovascular Disorder		[Therapy			
		Cellulitis		Unspecified]	C		
UNKNOWN							

	Chloracne	Darvocet-N	C
UNKNOWN			
	Cor Pulmonale	Celebrex	C
UNKNOWN			
	Depression	Furosemide	C
UNKNOWN			
	Erythema	Oxygen	C
UNKNOWN			
	Extremity Necrosis	Klor-Con	C
UNKNOWN			
	Generalised Oedema		
	Glaucoma		
	Glucose Tolerance		
	Impaired		
	Hypoaesthesia		
	Pickwickian Syndrome		
	Polycythaemia		
	Respiratory Failure		
	Rhinitis		
	Sleep Apnoea Syndrome		

Date:06/04/04ISR Number: 4371120-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Coagulation Factor Viii		Ma Huang Extract	C				
UNKNOWN								1523 DAY
Other	Level Increased		Ambien	C				
UNKNOWN								
	Depression							
	Emotional Distress							
	Haemoptysis							
	Influenza							
	Insomnia							
	International Normalised							
	Ratio Increased							
	Pain							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Renal Cyst							
	Suicidal Ideation							
	Upper Respiratory Tract							
	Infection							

Date:06/04/04ISR Number: 4371122-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02079
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		276 DAY
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia		[Therapy					
	Angina Pectoris		Unspecified]	C				
UNKNOWN								
	Arterial Disorder		Vicodin Tablets	C				
UNKNOWN								
	Arthralgia		Fosamax	C		ORAL		328 DAY
	Back Disorder		Norvasc	C				
UNKNOWN								

	Cardiac Failure	Baycol	C	
UNKNOWN				
	Congestive	Betimol	C	
OPHTHALMIC				
	Chest Pain	Benadryl	C	
UNKNOWN				
	Coronary Artery Disease	Folic Acid	C	
UNKNOWN				
	Dehydration	Prinivil	C	ORAL
	Dermatitis Allergic	Pravachol	C	
UNKNOWN				
	Diabetes Mellitus	Evista	C	
UNKNOWN				
	Non-Insulin-Dependent			
	Dyspnoea			
	Ear Infection			
	Gastroenteritis			
	Glaucoma			
	Haematoma			
	Hiatus Hernia			
	Hypertension			
	Myocardial Infarction			
	Osteoporosis			
	Renal Failure			
	Sciatica			
	Spondylolisthesis			
	Acquired			
	Stress			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371127-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebellar Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Darvocet-N	C				
	Osteoarthritis		Coumadin	C				
			Darvocet-N	C				

Date:06/04/04ISR Number: 4371128-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00434
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chills		Vicodin Tablets	C				
	Cold Sweat							
	Dizziness Postural							
	Dyspnoea							
	Extrasystoles							
	Feeling Hot And Cold							
	Gastrooesophageal Reflux Disease							
	Hyperhidrosis							
	Injury							
	Intervertebral Disc Disorder							
	Intervertebral Disc Protrusion							
	Musculoskeletal Stiffness							
	Myocardial Infarction							
	Nausea							
	Pallor							
	Palpitations							
	Sleep Disorder							

Date:06/04/04ISR Number: 4371129-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Activities Of Daily
Disability	Living Impaired
	Anxiety
	Aphagia
	Arthralgia
	Aspergillosis
	Bradyphrenia
	Bronchitis
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Complicated Migraine
	Condition Aggravated
	Conversion Disorder
	Convulsion
	Depression
	Drug Dependence

Dose	Duration						
		Drug Ineffective Dysphagia Dysphemia Emotional Disorder Gait Disturbance Hemianopia Hypercholesterolaemia Hyperhidrosis Hypertriglyceridaemia Hyperventilation Hypotension Injury Iris Disorder Irritability Lethargy Loss Of Consciousness Major Depression Melas Syndrome Memory Impairment Migraine Migraine With Aura Muscle Spasms Muscle Strain Nausea Neuritis Night Sweats Nystagmus Oesophageal Spasm Pain Paraesthesia Photophobia Photopsia Pigmented Naevus Road Traffic Accident Sensory Disturbance Skeletal Injury Skin Hypopigmentation Skin Laceration Somatisation Disorder Somnolence Speech Disorder Staring Syncope Tremor Tunnel Vision Vasculitis	Report Source Health Professional	Product Vioxx	Role PS	Manufacturer Merck & Co., Inc	Route ORAL

Visual Field Defect
Vomiting

Date:06/04/04ISR Number: 4371131-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
Disability	Bursitis
Other	Contusion
	Emotional Distress
	Gastric Ulcer
	Gastritis
	Gastrointestinal

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Haemorrhage Osteoarthritis Patellofemoral Pain Syndrome					
		Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL
		Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY							
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol	C		
UNKNOWN							
				Combivent	C		
RESPIRATORY							
(INHALATION)							
				Allopurinol	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Estradiol	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Bactrim Ds Tablets	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Avalide	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Niferex	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							
				Pyridoxine	C		
UNKNOWN							

Date:06/04/04ISR Number: 4371132-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vicodin Tablets	C			UNKNOWN	
	Condition Aggravated		Aspirin	C		ORAL		
	Coronary Artery Disease		Lipitor	C		ORAL		
	Coronary Artery Occlusion		Plavix	C		ORAL	41 DAY	
	Coronary Artery		Plavix	C		ORAL		
	Restenosis		Plavix	C		ORAL	41 DAY	
	Dilatation Atrial		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Dilatation Ventricular							
	Dizziness		Plavix	C		ORAL		
	Drug Ineffective		Colace	C			UNKNOWN	
	Dyspepsia		Prevacid	C			UNKNOWN	
	Gastrooesophageal Reflux		Synthroid	C			UNKNOWN	
	Disease		Prinivil	C		ORAL		
	Hypertension		Zestril	C			UNKNOWN	
	Hypotension							
	Injury							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Musculoskeletal Discomfort							
	Myocardial Infarction							
	Scar							
	Sick Sinus Syndrome							
	Supraventricular Extrasystoles							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371134-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cholelithiasis		Elavil	C		ORAL		
	Coronary Artery Disease		Soma	C		ORAL		
	Diverticulum		Soma	C		ORAL		
	Gastritis Haemorrhagic		Cyanocobalamin	C			INTRAMUSCULAR	
	Hepatitis		Premarin	C			UNKNOWN	
	Mycobacterium Avium		Infed	C			INTRAMUSCULAR	
	Complex Infection		Robaxin	C		ORAL		
	Myocardial Infarction		Prilosec	C			UNKNOWN	
	Nausea							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							

Date:06/04/04ISR Number: 4371268-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Atrial Tachycardia		Metformin	C				UNKNOWN
	Blood Cholesterol		Amaryl	C				UNKNOWN
	Abnormal							
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiac Valve Disease							
	Cardiomyopathy							
	Cataract							
	Constipation							

Convulsion
Coronary Artery Disease
Dizziness
Emotional Distress
Grand Mal Convulsion
Hepatitis B
Hypertension
Hypoaesthesia
Myocardial Infarction
Nausea
Paraesthesia
Sarcoidosis
Sick Sinus Syndrome
Sinus Bradycardia
Syncope

Date:06/04/04ISR Number: 4371269-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arterial Disorder
	Blood Pressure Increased
	Coronary Artery Occlusion
	Dermal Cyst
	Emotional Distress

		Erectile Dysfunction					
		Hypersensitivity					
		Inguinal Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Tightness		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonitis		[Therapy			
		Prostatic Specific		Unspecified]	C		
UNKNOWN							
		Antigen Increased		Vicodin Tablets	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:06/04/04ISR Number: 4371270-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
84 DAY							
Initial or Prolonged		Angina Unstable		Fioricet Tablets	C		
UNKNOWN							
		Arteriospasm Coronary		Fioricet Tablets	C		
UNKNOWN							
		Arthralgia		Alprazolam	C		
UNKNOWN							
		Back Pain		Gnc Womens Ultra			
		Chest Pain		Mega	C		
UNKNOWN							
		Coronary Artery Disease		Aspirin	C		
UNKNOWN							
		Cystocele		Aspirin	C		
UNKNOWN							
		Deep Vein Thrombosis		Lipitor	C		
UNKNOWN							
		Dehydration		Vitamin E	C		
UNKNOWN							
		Diverticulitis		Ambien	C		
UNKNOWN							

	Diverticulum	Zyrtec	C
UNKNOWN			
	Dysfunctional Uterine	Vivelle	C
TOPICAL			
	Bleeding	Motrin	C
UNKNOWN			
	Dyspepsia	Lecithin	C
UNKNOWN			
	Dyspnoea	Prilosec	C
UNKNOWN			
	Dysuria	Paxil	C
UNKNOWN			
	Flank Pain	Prometrium	C
UNKNOWN			
	Gastroenteritis		
	Generalised Anxiety Disorder		
	Haematuria		
	Haemorrhoids		
	Hot Flush		
	Menopausal Symptoms		
	Myocardial Infarction		
	Nausea		
	Neck Pain		
	Non-Cardiac Chest Pain		
	Phlebitis Superficial		
	Postoperative Ileus		
	Rectal Polyp		
	Rhinitis Allergic		
	Sinusitis		
	Stress Incontinence		
	Urinary Tract Infection		
	Venous Insufficiency		
	Vertigo		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371271-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02022
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Dysgeusia		Aspirin	C			UNKNOWN	
	Gingival Recession		Lotensin	C			UNKNOWN	
	Hypoaesthesia		Norvasc	C			UNKNOWN	
	Hypoaesthesia Oral		Zocor	C		ORAL		
	Injury		Avandia	C			UNKNOWN	
	Scab		Glyburide	C			UNKNOWN	
			Advil	C			UNKNOWN	

Date:06/04/04ISR Number: 4371272-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01981
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	216	DAY
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	216	DAY
	Congestive Cardio-Respiratory Arrest							
	Dizziness							
	Headache							
	Hypertensive Heart Disease							
	Myocardial Infarction							

Date:06/04/04ISR Number: 4371274-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess

Initial or Prolonged	Cyst
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Emotional Distress
	Gastrooesophageal Reflux
	Disease
	Hiatus Hernia
	Ileal Ulcer
	Ileitis
	Intervertebral Disc
	Degeneration
	Large Intestinal
	Obstruction
	Large Intestinal Ulcer
	Large Intestine
	Perforation
	Metabolic Acidosis
	Multi-Organ Failure
	Necrotising Colitis
	Osteoarthritis
	Pleural Effusion
	Renal Cortical Necrosis
	Renal Cyst
	Renal Failure Acute
	Renal Tubular Necrosis
	Respiratory Failure
	Septic Shock

		Small Intestine Ulcer					
		Vasospasm					
		Wound Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
				Ecotrin	C		ORAL
				Lipitor	C		
UNKNOWN							
				Zebeta	C		
UNKNOWN							
				Ziac	C		
UNKNOWN							
				Vasotec	C		ORAL
				Vasotec	C		ORAL
				Hydrochlorothiazide	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Relafen	C		
UNKNOWN							

Date:06/04/04ISR Number: 4371275-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Degeneration		Premarin	C		
UNKNOWN							
		Meniscus Lesion		Lasix (Furosemide)	C		
UNKNOWN		366 DAY					
		Oedema Peripheral		Plaquenil	C		
UNKNOWN							
		Phlebitis		Ultram	C		
UNKNOWN							
				Plaquenil	C		
UNKNOWN							

Accupril C
UNKNOWN 535 DAY

Date:06/04/04ISR Number: 4371276-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 195 DAY	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Anxiety							
	Coronary Artery Disease							
	Depression							
	Dislocation Of Vertebra							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Joint Dislocation							
	Malaise							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Road Traffic Accident							
	Visual Disturbance							

Date:06/04/04ISR Number: 4371278-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Jaw		Vioxx	PS	Merck & Co., Inc	ORAL		846 DAY
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		846 DAY
Disability	Anxiety		Covera	C				UNKNOWN
	Blood Cholesterol Increased		[Therapy Unspecified]	C				UNKNOWN
	Blood Creatine		Vicodin Tablets	C				UNKNOWN
	Phosphokinase Increased		Xanax	C				UNKNOWN
	Cardiac Murmur		Trimox	C				UNKNOWN
	Carotid Artery Stenosis		Atenolol	C				UNKNOWN
	Coronary Artery Disease		Soma	C				UNKNOWN
	Depression		Relafen	C				UNKNOWN
	Dizziness							
	Drug Hypersensitivity							
	Duodenal Ulcer							
	Haemorrhage							
	Duodenitis							
	Food Poisoning							
	Gastroenteritis							
	Gout							
	Hypertension							
	Loss Of Consciousness							
	Myocardial Infarction							
	Oesophageal Disorder							
	Osteoarthritis							
	Otitis Media							
	Overdose							
	Somnolence							

Date:06/04/04ISR Number: 4371279-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01978
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
Other	Cervicobrachial Syndrome
	Chest Pain
	Chronic Fatigue Syndrome
	Colitis
	Drug Dependence
	Emotional Distress
	Fall
	Feeling Abnormal
	Gastritis
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Head Injury
	Hypercholesterolaemia
	Hypertension
	Intervertebral Disc Protrusion
	Loss Of Consciousness
	Lumbar Spinal Stenosis
	Malaise
	Muscle Spasms
	Myofascial Pain Syndrome
	Oesophagitis
	Osteoarthritis

	Panic Disorder Radiculitis Cervical Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	3 MON
			[Therapy Unspecified]	C			UNKNOWN
			Xanax	C			UNKNOWN
			Prilosec	C			UNKNOWN

Date:06/04/04ISR Number: 4371280-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery Disease						
	Emotional Distress						
	Hyperlipidaemia						
	Myocardial Infarction						
	Sinus Arrhythmia						

Date:06/04/04ISR Number: 4371281-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY
Disability	Ischaemic Cerebral Infarction		[Therapy Unspecified]	SS			UNKNOWN
	Migraine		Yasmin	SS			UNKNOWN
			Tylenol	C			UNKNOWN
			Skelaxin	C			UNKNOWN

			Paxil	C		
UNKNOWN						
			Advil	C		
UNKNOWN						
			Fioricet Tablets	C		
UNKNOWN						

Date:06/04/04ISR Number: 4371282-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00189
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Clozapine	SS		ORAL		
	Drug Interaction		Clozapine	SS		ORAL		
			Clozapine	SS		ORAL	77 DAY	
			Clozapine	SS		ORAL		
			Lithium Acetate	SS			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	

Date:06/04/04ISR Number: 4371283-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Valve Sclerosis
Other	Cerebrovascular Accident
	Delusion
	Depression

	Dizziness						
	Fatigue						
	Feeling Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Glucose Tolerance		Vioxx	PS	Merck & Co., Inc	ORAL	585 DAY
	Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	585 DAY
	Hallucination		Lorcet 10/650	C			UNKNOWN 283 DAY
	Hernia		Hydrocodone				
	Hyperlipidaemia		Bitartrate	C			UNKNOWN 201 DAY
	Hypertension		Ambien	C			UNKNOWN
	Insomnia		Ibuprofen	C			UNKNOWN
	Male Sexual Dysfunction		Cozaar	C			UNKNOWN
	Mitral Valve Incompetence						
	Nocturia						
	Oedema Peripheral						
	Panic Attack						
	Periarthritis						
	Somnolence						
	Varicose Vein						
	Ventricular Hypertrophy						

Date:06/04/04ISR Number: 4371284-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01988
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/04/04ISR Number: 4371285-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Blood Albumin Decreased		Premarin	C			
UNKNOWN							

Other	Blood Cholesterol Increased
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure Congestive
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Conjunctivitis
	Corneal Disorder
	Drug Hypersensitivity
	Dyspepsia
	Fall
	Hypertension
	Oedema Peripheral
	Pain
	Pneumonia
	Transient Ischaemic Attack

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/04/04ISR Number: 4371286-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01436
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Lortab	C			UNKNOWN	
			Aspirin	C		ORAL		
			Lopid	C		ORAL		
			Glucophage	C		ORAL		

Date:06/04/04ISR Number: 4371287-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	85	DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C			UNKNOWN	
Other	Bundle Branch Block Left		Ecotrin	C			UNKNOWN	
	Chest Discomfort		Viagra	C			UNKNOWN	
	Coronary Artery Disease		Calan Sr	C			UNKNOWN	
	Dehydration		Zocor	C			UNKNOWN	
	Diverticulum Intestinal		Celebrex	C			UNKNOWN	
	Haemorrhagic		Advil	C			UNKNOWN	
	Emotional Distress							
	Gastritis Atrophic							
	Helicobacter Infection							
	Neck Pain							
	Neuropathy Peripheral							
	Stent Occlusion							

Date:06/04/04ISR Number: 4371288-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02043
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Hydralazine	SS				
	Pulmonary Oedema		Nicotine Polacrilex	SS				
	Weight Increased		Albuterol Sulfate	C				
			Advair	C				
			Verapamil	C				
			Coumadin	C				

Date:06/04/04ISR Number: 4371289-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00012
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/04/04ISR Number: 4371706-8Report Type:Direct Company Report #CTU 220159
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute		Valtrex 1 Gram Bid	PS				
1 GRAM BID								
Initial or Prolonged			Vioxx 25 Mg Daily	SS				
25 MG DAILY								
Other			Asa	C				
			Plavix	C				
			Vioxx	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/04ISR Number: 4372095-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthritis		Vioxx	SS	Merck & Co., Inc			
Disability	Blindness		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholecystitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Duodenal Scarring		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis		[Therapy					
	Gastrooesophageal Reflux		Unspecified]	C			UNKNOWN	
	Disease		Aspirin	C			UNKNOWN	
	Haematuria		Wellbutrin	C			UNKNOWN	
	Herpes Simplex		Zoloft	C			UNKNOWN	
	Hiatus Hernia		Trazodone					
	Hypermetropia		Hydrochloride	C			UNKNOWN	
	Hyperreflexia		Sulfasalazine	C			UNKNOWN	
	Hypersensitivity		Codeine	C			UNKNOWN	
	Inguinal Hernia		Flexeril	C			UNKNOWN	
	Irritable Bowel Syndrome		Lovastatin	C			UNKNOWN	
	Joint Contracture		Naproxen	C			UNKNOWN	
	Mental Disorder							
	Morton'S Neuroma							
	Muscle Contractions Involuntary							
	Myocardial Infarction							
	Nasopharyngitis							
	Nausea							
	Neck Pain							

Nephrolithiasis
Overdose
Polycythaemia
Presbyopia
Road Traffic Accident
Skin Discolouration
Skin Laceration
Tympanic Membrane
Perforation
Upper Respiratory Tract
Infection
Vertigo Positional
Vision Blurred
Vitreous Floaters
Vomiting
Whiplash Injury
Wound Infection

Date:06/07/04ISR Number: 4372097-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00437
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Atrial Fibrillation
	Azotaemia
	Cellulitis
	Cerebrovascular Accident

		Cholelithiasis					
		Chronic Sinusitis					
		Complex Partial Seizures	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Contusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
		Dehydration	Professional	Tylenol	C		
UNKNOWN							
		Drug Level Fluctuating		Atenolol	C		
UNKNOWN							
		Epistaxis		Captopril	C		
UNKNOWN							
		Exostosis		Prempro	C		
UNKNOWN							
		Fall		Salsalate	C		
UNKNOWN							
		Femoral Neck Fracture		Sulfasalazine	C		
UNKNOWN							
		Gastritis Atrophic		Hydrodiuril	C		ORAL
		Gastrooesophageal Reflux Disease		Hydroxychloroquine Sulfate	C		
UNKNOWN							
		Goitre		Claritin	C		
UNKNOWN							
		Grand Mal Convulsion		Potassium (Unspecified)	C		
		Haemorrhoids					
UNKNOWN							
		Hypokalaemia					
		Hyponatraemia					
		Malnutrition					
		Oesophagitis					
		Pleural Effusion					
		Pneumonia Aspiration					
		Pyelonephritis					
		Rectal Ulcer					
		Reflux Gastritis					
		Staphylococcal Infection					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:06/07/04ISR Number: 4372103-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Respiratory Failure

Initial or Prolonged	Anaemia
	Atrophy
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cataract
	Cholelithiasis
	Chronic Sinusitis
	Confusional State
	Dehydration
	Depression
	Fatigue
	Gangrene
	Gastric Ulcer
	Gastritis
	Glaucoma
	Herpes Zoster
	Hypokalaemia
	Hypovolaemia
	Muscle Spasms
	Myocardial Infarction
	Myopathy
	Oesophagitis
	Orthostatic Hypotension
	Paraesthesia
	Peripheral Occlusive

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Pneumonia							
Renal Cyst							
Renal Failure Acute							
Soft Tissue Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Syncope	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Transient Ischaemic		Albuterol Sulfate	C			RESPIRATORY	
Attack						(INHALATION)	
Upper Gastrointestinal		Fosamax	C		ORAL		
Haemorrhage		Amlodipine Besylate	C		ORAL		
Vasculitis		Aspirin	C		ORAL		
Weight Decreased		Atorvastatin Calcium	C			UNKNOWN	
		Beclomethasone Dipropionate	C			RESPIRATORY	
						(INHALATION)	
		Lotensin	C			UNKNOWN	
		Calcium Carbonate	C		ORAL		
		Baycol	C			UNKNOWN	
		Diphenhydramine Hydrochloride	C		ORAL		
		Estrogens (Unspecified)	C		ORAL		
		Folic Acid	C		ORAL		
		Hydrodiuril	C		ORAL		
		Hydroxychloroquine Sulfate	C		ORAL		
		Indocin (Indomethacin)	C			UNKNOWN	
		Ipratropium Bromide	C			UNKNOWN	
		Isosorbide Mononitrate	C		ORAL		
		Misoprostol	C		ORAL		
		Naproxen	C		ORAL		
		Prednisone	C		ORAL		

Date:06/07/04ISR Number: 4372107-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Arthritis
	Condition Aggravated
	Connective Tissue Disorder
	Depression
	Diabetes Mellitus
	Diabetic Neuropathy
	Dizziness
	Drug Ineffective
	Fall
	Fibromyalgia
	Generalised Anxiety Disorder
	Haematochezia
	Hypertension
	Injury
	Intestinal Obstruction
	Joint Lock
	Malaise
	Nervousness
	Osteoarthritis

		Pain Stomach Discomfort Thrombocytopenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tremor Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Heparin	C		
UNKNOWN							
				Hydro-Chlor	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Elavil	C		ORAL
				Aspirin	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Ms Contin	C		
UNKNOWN							

Date:06/07/04ISR Number: 4372108-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthenia					
Disability	Blood Cholesterol					
Other	Increased					
	Blood Pressure Decreased					
	Bradycardia					
	Cardiac Discomfort					
	Cardiac Failure					
	Congestive					
	Cardiac Murmur					
	Cardiac Valve Disease					
	Cardiomyopathy					

Crepitations
Death
Disorientation
Dizziness
Dyspepsia
Emotional Distress
Eye Haemorrhage
Foreign Body Trauma
Glaucoma
Heart Rate Irregular
Herpes Simplex
Herpes Virus Infection
Hypersensitivity
Hypertension
Hypotension
Injury
Low Density Lipoprotein
Increased
Oedema
Pulmonary Hypertension
Rheumatic Fever
Swelling
Tracheal Obstruction
Treatment Noncompliance

Date:06/07/04ISR Number: 4372109-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Aortic Valve Sclerosis
	Arrhythmia
	Arthralgia
	Asthenia
	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Blindness
	Blindness Transient
	Cardiac Failure Congestive
	Cardiac Valve Vegetation
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Chest X-Ray Abnormal
	Chills
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Dehydration
	Diastolic Dysfunction
	Dilatation Atrial
	Dizziness
	Drug Toxicity
	Dyspnoea
	Embolism
	Emotional Distress
	Extrasystoles
	Eye Inflammation
	Gait Disturbance
	Headache
	Heart Rate Decreased
	Injury
	Medication Error
	Mitral Valve Calcification
	Mitral Valve Incompetence
	Mitral Valve Stenosis
	Motor Dysfunction

Myalgia
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema
Optic Neuritis
Oral Candidiasis
Oral Pain
Pain
Pharyngolaryngeal Pain
Pneumonia
Polymyalgia Rheumatica
Pyrexia
Reading Disorder
Skin Ulcer

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Sleep Apnoea Syndrome					
		Temporal Arteritis					
		Thrombosis					
		Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve Incompetence		Imuran (Azathioprine)	C		
UNKNOWN							
		Vascular Pseudoaneurysm		Chloracon	C		
UNKNOWN							
		Vasculitis		Celebrex	C		
UNKNOWN							
		Ventricular Dysfunction		Tagamet	C		
UNKNOWN							
		Ventricular Hypertrophy		Cyanocobalamin	C		
UNKNOWN							
		Vision Blurred		Lanoxin	C		
UNKNOWN							
		Visual Acuity Reduced		Tiazac	C		
UNKNOWN							
		Visual Disturbance		Cartia (Diltiazem Hydrochloride)	C		
		Vomiting					
UNKNOWN							
		Wandering Pacemaker		Folic Acid	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Glipizide	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Insulin Human, Isophane	C		
UNKNOWN							
				Imdur	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Flomax (Tamsulosin			

	Hydrochloride)	C
UNKNOWN		
	Potassium (Unspecified)	C
UNKNOWN		
	Prednisone	C
UNKNOWN		

Date:06/07/04ISR Number: 4372118-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02090
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Aortic Stenosis
	Aphasia
Other	Atrial Fibrillation
	Blood Glucose Increased
	Calcinosis
	Cardiac Failure
	Cardiac Murmur
	Cardiac Valve Disease
	Cardiomegaly
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Condition Aggravated
	Convulsion
	Death
	Decreased Appetite
	Dehydration
	Dementia
	Depressed Level Of Consciousness
	Diarrhoea
	Erosive Duodenitis
	Facial Palsy
	Gastrointestinal

		Haemorrhage					
		Hemiparesis					
		Hemiplegia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Mental Status Changes		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		[Therapy			
		Pneumonia		Unspecified]	C		
UNKNOWN							
		Pulmonary Congestion		Aspirin	C		
UNKNOWN							
		Pupils Unequal		Digoxin	C		
UNKNOWN							
		Weight Decreased		Lasix (Furosemide)	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							

Date:06/07/04ISR Number: 4372122-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY							
		Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY							
		Diabetes Mellitus		[Therapy			
		Dysuria		Unspecified]	C		
UNKNOWN		144 DAY					
		Gastritis		Tylenol	C		
UNKNOWN							
		Gastrooesophageal Reflux		Darvocet-N	C		
UNKNOWN							
		Disease		Soma	C		
UNKNOWN							
		Haemangioma					
		Hemiparesis					
		Hypoaesthesia					
		Injury					
		Irritable Bowel Syndrome					
		Joint Dislocation					
		Joint Effusion					
		Joint Range Of Motion					

Decreased
Joint Sprain
Lipoma
Nuclear Magnetic
Resonance Imaging
Abnormal
Post Procedural
Complication
Spinal Osteoarthritis
Synovial Disorder

Date:06/07/04ISR Number: 4372123-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00108
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Atherosclerosis
Other	Bursitis
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Depression
	Diverticulum

		Dizziness					
		Emotional Distress					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Glaucoma	Professional	Ibuprofen	C		
UNKNOWN							
		Haemorrhoids		Insulin	C		
UNKNOWN							
		Hyperglycaemia					
		Hypoacusis					
		Intervertebral Disc					
		Protrusion					
		Intervertebral Disc Space					
		Narrowing					
		Kidney Infection					
		Lacunar Infarction					
		Lobar Pneumonia					
		Prostatic Disorder					
		Prostatic Specific					
		Antigen Increased					
		Proteinuria					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Failure Chronic					
		Thrombosis					
		Vertigo					
		Viral Infection					

Date:06/07/04ISR Number: 4372126-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Amnesia
Hospitalization -	Atrioventricular Block
Initial or Prolonged	Benign Prostatic
Other	Hyperplasia
	Cardiac Failure
	Congestive
	Cerebral Haemorrhage
	Confusional State
	Coronary Artery Disease
	Deafness Neurosensory
	Dehydration
	Dysphagia

Dyspnoea
Ejection Fraction
Decreased
Headache
Hiatus Hernia
Hypertension
Mitral Valve Incompetence
Myocardial Infarction
Oedema
Pneumonia Escherichia
Post Procedural
Complication
Renal Failure
Respiratory Failure
Sepsis
Subarachnoid Haemorrhage
Syncope
Transient Ischaemic

	Attack						
	Tricuspid Valve Incompetence						
	Varicose Vein	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricle Rupture	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Ventricular Tachycardia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Vertigo Positional		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Neurontin	C			UNKNOWN
			Glucosamine	C			UNKNOWN
			Prilosec	C			UNKNOWN

Date:06/07/04ISR Number: 4372130-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00148
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	152 DAY
Hospitalization -	Hypocalcaemia	Professional	Hypericin	SS		ORAL	
Initial or Prolonged	Hyponatraemia		Aloe	C			UNKNOWN

Date:06/07/04ISR Number: 4372131-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bronchitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY
Disability	Emotional Distress						
	Haemoglobin Decreased						
	Myocardial Infarction						
	Rotator Cuff Syndrome						
	Sinusitis						
	Tendonitis						
	Upper Respiratory Tract Infection						

Date:06/07/04ISR Number: 4372132-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02086
Age:91 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
Life-Threatening	Anaemia
Hospitalization -	Balance Disorder
Initial or Prolonged	Cardiac Failure
Disability	Cerebral Atherosclerosis
Other	Chronic Obstructive
	Pulmonary Disease
	Constipation
	Death
	Decubitus Ulcer
	Depression
	Dry Skin
	Dyspnoea
	Fall
	Gastrooesophageal Reflux
	Disease
	Haematochezia
	Haematoma
	Haemorrhage
	Hyperkeratosis

		Hypoacusis					
		Inflammation					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pain	Professional	Valium	C		
UNKNOWN							
		Pelvic Fracture		Vasotec	C		ORAL
		Peripheral Vascular		Vasotec	C		ORAL
		Disorder		Ferrous Sulfate	C		
UNKNOWN							
		Pulmonary Mass		Timoptic	C		
OPHTHALMIC							
		Respiratory Tract		Ultram	C		
UNKNOWN							
		Infection		Miacalcin	C		
UNKNOWN							
		Senile Dementia		Hydrodiuril	C		ORAL
		Spinal Compression		Morphine	C		
UNKNOWN							
		Fracture		Deltasone	C		
UNKNOWN							
		Syncope					
		Tinea Pedis					
		Vulval Erythema					
		Vulval Oedema					
		Weight Decreased					

Date:06/07/04ISR Number: 4372138-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Arrhythmia
	Arthritis
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Cardiomyopathy
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp

Convulsion
Coronary Artery Disease
Decubitus Ulcer
Dysphagia
Electrolyte Imbalance
Faecaloma
Gastrointestinal
Haemorrhage
Herpes Zoster
Hypertension
Influenza
Ischaemic Cardiomyopathy
Liver Function Test
Abnormal
Malnutrition
Myocardial Infarction
Oedema
Pericarditis
Pneumonia
Pneumonia Aspiration
Post Herpetic Neuralgia
Pulmonary Oedema
Pyrexia

		Radiculitis Brachial Respiratory Failure Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Staphylococcal Infection		Vioxx	PS	Merck & Co., Inc	ORAL
91	DAY						
		Stent Occlusion		Aspirin	C		
UNKNOWN							
		Thrombocytopenia		Lipitor	C		
UNKNOWN							
				Capoten	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Glipizide	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Nitrol (Nitroglycerin)	C		
UNKNOWN							
				Altace	C		
UNKNOWN							

Date:06/07/04ISR Number: 4372140-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00223
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Lung Neoplasm Malignant Pulmonary Fibrosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Amoxicillin And Clavulanate Potassium	C		
UNKNOWN						
			Clarithromycin	C		
UNKNOWN						

				Warfarin	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							

Date:06/07/04ISR Number: 4372141-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00007
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Increased	Professional	Allopurinol	C				
UNKNOWN								
	Hyperkalaemia		Clopidogrel Bisulfate	C				
UNKNOWN								
			Fludrocortisone	C				
UNKNOWN								
			Fusidate Sodium	C		ORAL	3	DAY
			Fusidate Sodium	C		ORAL	3	DAY
			Vancomycin	C				
UNKNOWN							6	DAY
			Trimethoprim	C				
UNKNOWN								
			Mirtazapine	C				
UNKNOWN								
			Morphine Sulfate	C				
UNKNOWN								
			Omeprazole	C				
UNKNOWN								
			Prednisolone	C				
UNKNOWN								

Date:06/07/04ISR Number: 4372144-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02099
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Cardiac Failure	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Congestive Pulmonary Oedema		Aspirin	C		ORAL		
			Lipitor	C				
UNKNOWN								
			Diovan	C		ORAL		

			Coreg	C		ORAL
			Plavix	C		ORAL

Date:06/07/04ISR Number: 4372146-8Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0405ZAF00025
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eczema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise	Professional						
	Rash Vesicular							

Date:06/07/04ISR Number: 4372147-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00004
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Increased	Professional	Acetaminophen	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	
			Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)	
			Carbomer	C			UNKNOWN	
			Senna	C			UNKNOWN	
			Temazepam	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	
			Cimetidine	C			UNKNOWN	

	Furosemide	C
UNKNOWN		
	Hydrargaphen	C
TOPICAL		
	Isosorbide Mononitrate	C
UNKNOWN		
	Lactulose	C
UNKNOWN		
	Nitroglycerin	C
UNKNOWN		

Date:06/07/04ISR Number: 4372209-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Anxiety
	Aortic Valve Incompetence
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Depression
	Dizziness
	Dyspnoea
	Emotional Distress
	Fall
	Gastrooesophageal Reflux
	Disease
	Headache
	Heart Rate Irregular
	Hyperglycaemia
	Oedema
	Onychomycosis

		Oropharyngeal Spasm					
		Parkinson'S Disease					
		Peripheral Vascular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
15	MON						
		Renal Failure		Aspirin	C		ORAL
		Seborrhoeic Keratosis		Bumex	C		ORAL
		Sleep Apnoea Syndrome		Lamisil	C		ORAL
		Stomach Discomfort		Premarin	C		ORAL
		Swelling Face		Prinivil	C		ORAL
		Transient Ischaemic					
		Attack					
		Tremor					
		Vascular Stenosis					
		Vertigo					

Date:06/07/04ISR Number: 4372210-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
48	DAY						
Initial or Prolonged		Benign Prostatic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
Disability		Hyperplasia		Deconamine	C		
UNKNOWN							
Other		Bladder Neck Sclerosis		Lisinopril	C		
UNKNOWN							
		Cerebrovascular Accident		Meclizine	C		
UNKNOWN							
		Chest Pain		Aciphex	C		
UNKNOWN							
		Dizziness					
		Haemolysis					
		Haemorrhoidal Haemorrhage					
		Hyperkalaemia					
		Hyperlipidaemia					
		Hypertension					
		Liver Function Test					
		Abnormal					
		Palpitations					
		Renal Failure Acute					
		Rheumatoid Arthritis					

Rhinitis Allergic
Tooth Abscess
Urethral Stricture
Vertigo

Date:06/07/04ISR Number: 4372212-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01757
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Mouth Swollen Tongue	Consumer	Vioxx Fosamax	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:06/07/04ISR Number: 4374164-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
	Bundle Branch Block Left
	Cardiac Arrest
	Cardiac Failure

		Congestive Cellulitis Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Confusion Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Cor Pulmonale		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Ventricular		[Therapy			
		Duodenal Ulcer		Unspecified]	C		
UNKNOWN							
		Haemorrhage		Coumadin	C		ORAL
		Duodenitis		Vicodin Es Tablets	C		
UNKNOWN							
		Gastric Ulcer		Restoril	C		
UNKNOWN							
		Oesophagitis		Zestril	C		
UNKNOWN							
		Onychomycosis Osteoarthritis Pericardial Effusion Pleural Effusion Polytraumatism Rash Restrictive Pulmonary Disease Rib Fracture Vitreous Floaters					

Date:06/07/04ISR Number: 4374166-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01988
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Bone Neoplasm Malignant Carotid Artery Disease Cerebral Artery Occlusion Chronic Obstructive Pulmonary Disease Death Injury Corneal Pneumonia Bacterial Polytraumatism					

Date:06/07/04ISR Number: 4374168-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Proventil	C			UNKNOWN	
	Hypokalaemia		Aspirin	C			UNKNOWN	
	Memory Impairment		Aspirin	C			UNKNOWN	
	Muscle Spasms		Coreg	C			UNKNOWN	
	Pyrexia		Foltx	C			UNKNOWN	
	Umbilical Hernia		Zestril	C			UNKNOWN	
	Ventricular Tachycardia		Niaspan	C			UNKNOWN	
			Pravachol	C		ORAL	141 DAY	
			Pravachol	C		ORAL		
			Metamucil	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/04ISR Number: 4374173-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Other	Angle Closure Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Dehydration		Tiazac	C			UNKNOWN	
	Faeces Discoloured		Advil	C			UNKNOWN	
	Headache							
	Myocardial Infarction							
	Nephrolithiasis							
	Oedema Peripheral							
	Pain In Extremity							
	Renal Failure Chronic							
	Wound Infection							
	Staphylococcal							

Date:06/07/04ISR Number: 4374174-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02107
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain Upper		Tylenol	C			UNKNOWN	
	Adverse Event		Lasix (Furosemide)	C			UNKNOWN	
	Angioneurotic Oedema		Lasix (Furosemide)	C			UNKNOWN	
	Anxiety		Ginkgo Biloba Extract	C			UNKNOWN	
	Atrioventricular Block Second Degree		Coumadin	C			UNKNOWN	
	Blood Creatine		Ginseng	C			UNKNOWN	

	Phosphokinase Increased	Naproxen	C
UNKNOWN			
	Chest Pain	Klor-Con	C
UNKNOWN			
	Depression	Slow-K	C
UNKNOWN			
	Dizziness		
	Fatigue		
	Hypertension		
	Intervertebral Disc		
	Degeneration		
	Lipids Abnormal		
	Nausea		
	Neck Pain		
	Osteoarthritis		
	Osteochondrosis		
	Palpitations		
	Paraesthesia		
	Pleurisy		
	Pulmonary Valve		
	Incompetence		
	Spinal Column Stenosis		
	Tricuspid Valve		
	Incompetence		
	Vomiting		

Date:06/07/04ISR Number: 4374176-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02020
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthropathy

		Asthma					
		Atrial Fibrillation					
		Bladder Cancer Recurrent	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cataract		Vioxx	PS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Aspirin	C		
UNKNOWN							
		Pulmonary Disease					
		Duodenitis					
		Gastric Disorder					
		Gastritis Erosive					
		Gastrointestinal					
		Haemorrhage					
		Hyperglycaemia					
		Oesophagitis					
		Presbyoesophagus					

Date:06/07/04ISR Number: 4374179-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Lorcet Plus	C		
UNKNOWN							
Disability		Anxiety					
		Arthralgia					
		Back Pain					
		Cardiac Murmur					
		Chest Pain					
		Cholesterol Granuloma					
		Chronic Fatigue Syndrome					
		Depression					
		Dyspnoea					
		Erythema					
		Heart Rate Irregular					
		Hyperlipidaemia					
		Hypoacusis					
		Hypoaesthesia					
		Insomnia					
		Labile Hypertension					
		Muscle Spasms					
		Nail Disorder					
		Nausea					
		Oedema					

Osteoarthritis
Rhinitis Allergic
Rhinorrhoea
Spherocytic Anaemia
Tachycardia

Date:06/07/04ISR Number: 4375744-0Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign Health Professional	Premarin (Conjugated Estrogens, Unspec, 0)	PS				
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection, 0)	SS				

Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, ,0)	SS
Fluoxetine (Fluoxetine, ,0)	SS
Humira (Adalimumab, ,0)	SS
Methotrexate (Methotrexate, ,0)	SS
Rofecoxib (Rofecoxib, ,0)	SS

Date:06/07/04ISR Number: 4375857-3Report Type:Expedited (15-DaCompany Report #DE-JNJFOC-20040506261
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Abnormal Blood Creatinine Increased Blood Urea Increased Drug Interaction Gastritis Erosive Gastrointestinal Haemorrhage Haematocrit Decreased Haemoglobin Decreased International Normalised Ratio Increased White Blood Cell Count Increased	Foreign Health Professional	Tramal (Tramadol Hydrochloride) Unspecified	PS		ORAL	100 MG, 2 IN	1 DAY, ORAL
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, 1 IN 1	DAY, ORAL
			Falithrom (Phenprocoumon)	SS		ORAL	3 MG, 1 IN 1	DAY, ORAL
			Aquaphor (Aquaphor)	C				
			Beloc-Zok (Beloc-Zok Comp)	C				
			Digitoxin (Digitoxin)	C				

Date:06/07/04ISR Number: 4375913-XReport Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage	Health Professional	Premarin (Conjugated Estrogens, Unspec, 0)	PS		
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection, 0)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, , O)	SS		
			Fluoxetine (Fluoxetine, , 0)	SS		
			Humira (Adalimumab, , 0)	SS		

			Methotrexate (Methotrexate, Unspec, 0)	SS		
			Rofecoxib (Rofecoxib, , 0)	SS		

Date:06/07/04ISR Number: 4375940-2Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage Retinal Haemorrhage	Health Professional	Premarin (Conjugated Estrogens, Unspec, 0)	PS				
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection, 0)	SS				
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, , 0)	SS				
			Fluoxetine (Fluoxetine, , 0)	SS				
			Methotrexate (Methotrexate, Unspec, 0)	SS				
			Rofecoxib (Rofecoxib, , 0)	SS				

Date:06/08/04ISR Number: 4372992-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Blood Pressure Increased		Aspirin	C			UNKNOWN	
	Cystocele		Diovan	C			UNKNOWN	

Headache Premarin C
UNKNOWN

Lung Neoplasm
Lymphadenopathy
Ovarian Mass
Pneumatosis
Rectocele
Skin Lesion
Stress Incontinence
Vaginal Prolapse

Date:06/08/04ISR Number: 4372995-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Other

PT
Adjustment Disorder
Anxiety
Arrhythmia
Supraventricular
Arthralgia
Atherosclerosis
Blood Pressure Increased

	Blood Urine Present						
	Cataract						
	Chest Wall Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	
	Eye Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL	
	Flank Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Gastric Haemorrhage		Vicodin Tablets	C			UNKNOWN
	Haemorrhoids		Effexor Xr	C			UNKNOWN
	Herpes Virus Infection		Ecotrin	C			UNKNOWN
	Influenza		Wellbutrin Sr	C			UNKNOWN
	Injury		Prevacid	C			UNKNOWN
	Intervertebral Disc		Pravachol	C			UNKNOWN
	Degeneration		Accupril	C			UNKNOWN
	Joint Stiffness						
	Muscle Strain						
	Road Traffic Accident						
	Rotator Cuff Syndrome						
	Spinal Column Stenosis						
	Tendonitis						
	Ulcer						
	Viral Infection						

Date:06/08/04ISR Number: 4372998-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 62 DAY	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Angina Unstable		Pepcid	C			UNKNOWN
Other	Cardiomegaly		Glyburide	C			UNKNOWN
	Coronary Artery Disease		Zocor	C		ORAL	

	Depression	Atenolol	C	
UNKNOWN				
	Gastrooesophageal Reflux	Aspirin	C	
UNKNOWN				
	Disease	Motrin	C	
UNKNOWN				
	Injury	Prinivil	C	ORAL
	Migraine			
	Rash Pruritic			
	Scrotal Abscess			
	Syncope Vasovagal			

Date:06/08/04ISR Number: 4373003-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthma
Initial or Prolonged	Benign Prostatic
Disability	Hyperplasia
Other	Cardiac Failure
	Congestive
	Cellulitis
	Chronic Obstructive
	Pulmonary Disease
	Constipation
	Coronary Artery Disease
	Cough
	Duodenal Ulcer
	Emotional Distress

		Gastrooesophageal Reflux Disease					
		Interstitial Lung Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Leukocytosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Meniscus Lesion		Zocor	SS		ORAL
		Monarthritis		[Therapy			
		Myocardial Infarction		Unspecified]	C		
UNKNOWN							
		Pain In Extremity		Tylenol Arthritis			
		Renal Failure		Extended Relief	C		
UNKNOWN							
		Renal Tubular Necrosis		Aspirin	C		
UNKNOWN							
		Rhabdomyolysis		Diltiazem Msd	C		
UNKNOWN							
		Rotator Cuff Syndrome		Glyburide	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Date:06/08/04ISR Number: 4373004-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 2 MON	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anoxic Encephalopathy		[Therapy			
Other	Atrioventricular Block		Unspecified]	C		
UNKNOWN						
	Complete		Insulin	C		
UNKNOWN						
	Cardiogenic Shock					
	Carotid Artery Occlusion					
	Carotid Artery Stenosis					
	Cerebrovascular Accident					
	Colitis Ischaemic					
	Constipation					
	Coronary Artery Disease					

Cough
Diabetes Mellitus
Insulin-Dependent
Diabetic Retinopathy
Fall
Gastritis
Haematoma
Haemorrhoidal Haemorrhage
Hepatic Failure
Hyperglycaemia
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Muscle Tightness
Myocardial Infarction
Pain In Extremity
Pulmonary Hypertension
Rash
Renal Cyst
Renal Failure Acute
Silent Myocardial
Infarction
Tendonitis
Tricuspid Valve
Incompetence
Urinary Tract Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/04ISR Number: 4373005-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01625
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hyponatraemia		Tracleer	SS		ORAL		
53 DAY								
Initial or Prolonged	Oesophageal Disorder		Tracleer	SS		ORAL		
Other	Pneumonia Aspiration		Cardizem	SS				
UNKNOWN								
	Respiratory Arrest		Neurontin	SS				
UNKNOWN								
	Sepsis		Flolan	SS				
INTRAVENOUS								
	Thrombocytopenia		Elavil	C		ORAL		
			Coumadin	C				
UNKNOWN								
			Aldactone	C				
UNKNOWN								
			Oxycontin	C				
UNKNOWN								
			Celexa	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								

Date:06/08/04ISR Number: 4373425-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00709
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cervix Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
4 MON								
Other	Depression							
	Dyspnoea							
	Joint Injury							
	Mental Disorder							
	Panic Disorder							
	Road Traffic Accident							
	Swelling Face							

Tuberculosis

Date:06/08/04ISR Number: 4373429-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Clostridium Colitis		Tylenol	C				UNKNOWN
	Decreased Appetite		Ascorbic Acid	C				UNKNOWN
	Dizziness		Aspirin	C				UNKNOWN
	Drug Ineffective		Atenolol	C				UNKNOWN
	Dyspepsia		Zocor	C				UNKNOWN
	Feeling Jittery		Vitamin E	C				UNKNOWN
	Gout		Coenzyme Q10	C				UNKNOWN
	Insomnia		Lotensin	C				UNKNOWN
	Intervertebral Disc		Colchicine	C				UNKNOWN
	Degeneration		Glucosamine	C				UNKNOWN
	Mood Altered		Aleve	C				UNKNOWN
	Osteoarthritis		Nonsteroidal					
	Pain		Anti-Inflammatory					
	Scoliosis		Drug (Unspecified)	C				UNKNOWN
	Spondylolisthesis		Omega-3	C				UNKNOWN
	Acquired		Zantac	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/04ISR Number: 4373439-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00043
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Initial or Prolonged	Glossodynia		Vioxx	SS	Merck & Co., Inc	ORAL		19 DAY
	Herpes Virus Infection		Diclofenac	C				UNKNOWN
	Insomnia		Ibuprofen	C				UNKNOWN
	Oedema Peripheral							13 DAY
	Oropharyngeal Swelling							
	Paraesthesia Oral							
	Pruritus							

Date:06/08/04ISR Number: 4373441-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00028
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
			Atorvastatin Calcium	C		ORAL		
			Digoxin	C		ORAL		
			Furosemide	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Senna	C		ORAL		
			Acetaminophen	C		ORAL		5 DAY
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Aspirin	C				UNKNOWN
			Nitrazepam	C		ORAL		

Date:06/08/04ISR Number: 4373443-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00195
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged			Levofloxacin	SS		ORAL	18 DAY	
			Levofloxacin	SS		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Dalteparin Sodium	C			UNKNOWN	
			Hydrochlorothiazide And Triamterene	C		ORAL		

Date:06/08/04ISR Number: 4374305-7Report Type:Direct Company Report #CTU 220338
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Zocor 20 Mg	PS		ORAL	20 MG A DAY	
	Nausea					ORAL		
			Vioxx 50 Mg	SS		ORAL	ONCE A DAY	
						ORAL		
			Hctz	C				
			Allegra	C				
			Aciphex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/04ISR Number: 4376385-1Report Type:Expedited (15-DaCompany Report #WAES 0405USA02046
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Study	Fosamax	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer	Health	Vioxx	SS		ORAL	PO	
	Syncope	Professional	Enbrel	SS			SUBCUTANEOUS	25 MG/2XW/SC
	Upper Gastrointestinal Haemorrhage		Hydrodiuril	C				
			Azathioprine	C				
			Calcium	C				
			Hydroxychloroquine Sulfate	C				
			Prednisone	C				
			Ranitidine Hydrochloride	C				
			Tramadol Hydrochloride	C				

Date:06/08/04ISR Number: 4376471-6Report Type:Expedited (15-DaCompany Report #0104-1655
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acquired Diaphragmatic	Health	Advicor	PS		ORAL	1 TABLET (S)	
Hospitalization -	Eventration	Professional					QD PO	
Initial or Prolonged	Hepatic Congestion	Company	Vioxx	SS		ORAL		
Disability	Oedema	Representative	Toprol Xl	C				
	Right Ventricular Failure		Altace	C				
			Coumadin	C				

Date:06/09/04ISR Number: 4374571-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Aortic Stenosis
Initial or Prolonged	Atrial Fibrillation
Other	Cardiac Failure

Congestive
Chest Pain
Chronic Obstructive
Pulmonary Disease
Coronary Artery Occlusion
Diabetic Foot
Diverticulum
Emotional Distress
Erectile Dysfunction
Gouty Arthritis
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Mitral Valve Prolapse
Myocardial Infarction
Oedema Peripheral
Open Angle Glaucoma
Overdose
Peptic Ulcer
Peripheral Occlusive
Disease
Pulmonary Hypertension
Pulmonary Oedema
Renal Failure
Respiratory Failure

		Sleep Apnoea Syndrome Sleep Disorder Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vascular Graft Occlusion Vascular Occlusion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Allopurinol	C		
UNKNOWN				Allopurinol	C		
UNKNOWN				Aspirin	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Lotensin	C		
UNKNOWN				Coreg	C		
UNKNOWN				Celebrex	C		
UNKNOWN				Clopidogrel Bisulfate	C		
UNKNOWN				Cardizem	C		
UNKNOWN				Pepcid	C		
UNKNOWN				Fluvastatin Sodium	C		
UNKNOWN				Furosemide	C		
UNKNOWN				Neurontin	C		
UNKNOWN				Glipizide	C		
UNKNOWN				Glycine	C		
UNKNOWN				Insulin	C		
UNKNOWN				Glucophage	C		
UNKNOWN				Coumadin	C		
UNKNOWN				Trazodone Hydrochloride	C		
UNKNOWN				Spironolactone	C		
UNKNOWN							

				Nitroglycerin	C		
UNKNOWN							
				Actos	C		
UNKNOWN							

Date:06/09/04ISR Number: 4374574-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Acute Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								
Other	Aortic Dilatation		Doxepin Hydrochloride	C				
UNKNOWN								
	Back Pain		Neurontin	C				
UNKNOWN								
	Convulsion		Ultram	C				
UNKNOWN								
	Drug Hypersensitivity		Zanaflex	C				
UNKNOWN								
	Fall		Serzone	C				
UNKNOWN								
	Generalised Anxiety		Oxycodone	C				
UNKNOWN								
	Disorder							
	Haemorrhage Intracranial							
	Hypertension							
	Hypoaesthesia							
	Pain							
	Panic Attack							
	Pulmonary Congestion							
	Retinal Ischaemia							
	Rhinitis							
	Sleep Apnoea Syndrome							
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/04ISR Number: 4374591-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Sclerosis		Allopurinol	C				
UNKNOWN	Balance Disorder		Prevacid	C				
	Benign Prostatic Hyperplasia							
	Blood Pressure Increased							
	Bronchitis Acute							
	Calculus Ureteric							
	Cerebellar Infarction							
	Cerebrovascular Accident							
	Constipation							
	Defaecation Urgency							
	Diplopia							
	Dizziness							
	Drug Ineffective							
	Dysuria							
	Epidermal Naevus							
	Fall							
	Gait Disturbance							
	Haematochezia							
	Haematospermia							
	Haemorrhoidal Haemorrhage							
	Labyrinthitis							
	Micturition Urgency							
	Nausea							
	Nephrolithiasis							
	Nystagmus							
	Osteoarthritis							
	Phlebolith							
	Prostatism							
	Renal Cyst							
	Renal Failure							
	Sinusitis							
	Testicular Pain							
	Tricuspid Valve Incompetence							
	Tympanic Membrane Disorder							
	Vascular Calcification							

Vertigo
Vomiting

Date:06/09/04ISR Number: 4374593-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Anaemia
	Anxiety
	Arteriospasm Coronary
	Biliary Neoplasm
	Blood Albumin Decreased
	Bronchiectasis
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease

		Collapse Of Lung					
		Constipation					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum Intestinal	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Elavil	C		ORAL
		Dysuria		Soma	C		ORAL
		Emphysema		Soma	C		ORAL
		Fear Of Disease		Cyanocobalamin	C		
INTRAMUSCULAR							
		Gastritis Haemorrhagic		Premarin	C		
UNKNOWN							
		Hepatitis		Infed	C		
INTRAMUSCULAR							
		Lung Neoplasm		Robaxin	C		ORAL
		Mycobacterium Avium		Prilosec	C		
UNKNOWN							
		Complex Infection					
		Myocardial Infarction					
		Nausea					
		Oedema Peripheral					
		Pain In Extremity					
		Pruritus Generalised					
		Pulmonary Calcification					
		Rash					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		White Blood Cell Count					
		Decreased					

Date:06/09/04ISR Number: 4374600-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00028
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebrovascular Accident	Professional	Lotrel	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:06/09/04ISR Number: 4374604-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00016
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Melaena		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
			Caffeine And Phenobarbital	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:06/09/04ISR Number: 4374605-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00265
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/04ISR Number: 4374610-4Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0405ZAF00025
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eczema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise	Professional						
	Rash Vesicular							

Date:06/09/04ISR Number: 4374611-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00309
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Trismus		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Aspirin	C			UNKNOWN	
			Atacand	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Prilosec	C			UNKNOWN	

Date:06/09/04ISR Number: 4375110-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02012
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Coronary Syndrome
Disability	Adverse Event
Other	Anaemia
	Angina Pectoris
	Angina Unstable
	Angiopathy
	Anxiety
	Asthenia
	Back Injury
	Back Pain
	Bronchitis Acute
	Calcinosis
	Chest Discomfort

Conjunctival Haemorrhage
Contusion
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Ostial Stenosis
Cyst
Depression
Diarrhoea
Diastolic Dysfunction
Dizziness
Duodenitis
Dyspepsia
Dyspnoea
Dyspnoea Exertional
Electrocardiogram Q Waves
Fall
Fatigue
Fear
Feeling Hot And Cold
Fibroma
Gastric Disorder
Gastritis
Haematochezia
Headache

		Heart Rate Increased					
		Hypertension					
		Hyperventilation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypotension		Plavix	SS		
UNKNOWN							
		Impaired Work Ability		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
		Melaena		Vioxx	SS	Merck & Co., Inc	ORAL
		Menopausal Symptoms		Vioxx	SS	Merck & Co., Inc	ORAL
		Menopause		Fioricet Tablets	C		
UNKNOWN							
		Migraine		Vicodin Tablets	C		
UNKNOWN							
		Mitral Valve Incompetence		Vasotec	C		ORAL
		Myocardial Infarction		Calan Sr	C		
UNKNOWN							
		Myocardial Ischaemia		Hydrochlorothiazide	C		
UNKNOWN							
		Nausea		Cardizem	C		
UNKNOWN							
		Nightmare		Ecotrin	C		
UNKNOWN							
		Oedema Peripheral					
		Orthostatic Hypotension					
		Pain					
		Pain In Extremity					
		Palpitations					
		Paraesthesia					
		Pelvic Peritoneal					
		Adhesions					
		Phaeochromocytoma					
		Phlebothrombosis					
		Photopsia					
		Pulmonary Valve					
		Incompetence					
		Rhinitis Seasonal					
		Road Traffic Accident					
		Sinus Disorder					
		Sinus Polyp					
		Stent Occlusion					
		Supraventricular					
		Extrasystoles					

Syncope
Tearfulness
Temperature Intolerance
Tension Headache
Thrombophlebitis
Superficial
Tricuspid Valve
Incompetence
Upper Gastrointestinal
Haemorrhage
Ventricular Extrasystoles
Vision Blurred

Date:06/09/04ISR Number: 4375123-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anaemia Of Chronic
Disability	Disease
Other	Angiodysplasia

		Bronchitis					
		Depression					
		Diverticular Perforation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Lipitor	C		
UNKNOWN							
		Polyp Colorectal		Celebrex	C		
UNKNOWN							
		Rectal Haemorrhage		Zoloft	C		
UNKNOWN							
		Small Intestinal		Triamterene	C		
UNKNOWN							
		Haemorrhage		Voltaren	C		
UNKNOWN							
				Duragesic	C		
TOPICAL							
				Dyazide	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Denavir	C		
UNKNOWN							

Date:06/09/04ISR Number: 4375130-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02540
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased		Aspirin	C		
UNKNOWN						
	Cerebrovascular Accident		Lipitor	C		
UNKNOWN						
	Coma					

Depression
Hypertension
Hypoaesthesia
Muscle Spasms
Stomach Discomfort
Stress
Transient Ischaemic
Attack

Date:06/09/04ISR Number: 4375131-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00625
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Blood Alkaline
Disability	Phosphatase Increased
	Catheter Site Discharge
	Cholelithiasis
	Dehydration
	Gastritis
	Hydronephrosis
	Joint Effusion
	Metastatic Neoplasm
	Oesophageal Stenosis
	Oesophagitis
	Pneumonia
	Renal Failure Acute
	Respiratory Arrest

Septic Shock						
Small Intestinal Obstruction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Upper Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	19	DAY
Urinary Tract Infection		Tylenol	C			UNKNOWN	
		Lomotil	C			UNKNOWN	
		Prednisone	C			UNKNOWN	3 DAY
		Prednisone	C		ORAL	3	DAY
		Prednisone	C			UNKNOWN	

Date:06/09/04ISR Number: 4375133-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
Disability	Affect Lability
Other	Anxiety Disorder
	Aortic Valve Sclerosis
	Arthralgia
	Arthropathy
	Asthma
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bundle Branch Block Right
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diverticulum
	Dyspepsia
	Encephalitis
	Encephalopathy
	Fall
	Fatigue

Gastric Disorder
Gastrooesophageal Reflux
Disease
Hiatus Hernia
Hyperlipidaemia
Hypertensive Heart
Disease
Hyperthyroidism
Hypertrophic
Cardiomyopathy
Hypotension
Memory Impairment
Meningitis
Migraine
Myocardial Infarction
Neuritis
Nodal Arrhythmia
Normochromic Normocytic
Anaemia
Oesophageal Spasm
Pain In Extremity
Pancreatitis
Skin Laceration

	Spinal Column Stenosis						
	Stress						
	Tension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Therapeutic Agent		Vioxx	PS	Merck & Co., Inc	ORAL	
	Toxicity		Vioxx	SS	Merck & Co., Inc	ORAL	
	Upper Respiratory Tract		Bextra	SS			UNKNOWN
	Infection		[Therapy				
	Urosepsis		Unspecified]	C			UNKNOWN
			Albuterol	C			UNKNOWN
			Lanoxin	C			UNKNOWN
			Effexor	C			UNKNOWN
			Flovent	C			UNKNOWN
			Hydrochlorothiazide And Triamterene	C		ORAL	
			Atrovent	C			UNKNOWN
			Singulair	C		ORAL	
			Daypro	C			UNKNOWN

Date:06/09/04ISR Number: 4375137-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01091
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 419 DAY	Anorectal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged Disability	Depression						
	Ischaemic Stroke						

Date:06/09/04ISR Number: 4375138-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Acute Myocardial	Vioxx	PS	Merck & Co., Inc	ORAL
450 DAY					
Initial or Prolonged	Infarction	Vioxx	SS	Merck & Co., Inc	ORAL
	Anaemia	Vioxx	SS	Merck & Co., Inc	ORAL
450 DAY					
	Blood Pressure Increased	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure	Lorcet Plus	C		
UNKNOWN					
	Congestive	Combivent	C		
UNKNOWN					
	Cardiomyopathy	Aspirin	C		
UNKNOWN					
	Chronic Obstructive	Lipitor	C		
UNKNOWN					
	Pulmonary Disease	Rhinocort	C		
UNKNOWN					
	Coronary Artery Disease	Wellbutrin	C		
UNKNOWN					
	Gout	Coreg	C		
UNKNOWN					
	Hepatic Enzyme Increased	Tagamet	C		
UNKNOWN					
	Hypercholesterolaemia	Biaxin	C		
UNKNOWN					
	Hypokalaemia	Plavix	C		
UNKNOWN					
	Myocardial Infarction	Cyclobenzaprine			
	Pulmonary Oedema	Hydrochloride	C		
UNKNOWN					
	Respiratory Failure	Valium	C		
UNKNOWN					
	Syncope Vasovagal	Valium	C		
UNKNOWN					
		Benadryl	C		
UNKNOWN					
		Prempro	C		
UNKNOWN					
		Advair	C		
UNKNOWN					
		Prolex Dh	C		
UNKNOWN					
		Mavik	C		
UNKNOWN					
		Detrol	C		
UNKNOWN					
		Micardis	C		
UNKNOWN					
		Hydrocodone			
		Hydrochloride	C		
UNKNOWN					
		Motrin	C		
UNKNOWN					

Motrin C

UNKNOWN

22-Aug-2005 10:31 AM
Page: 7985

			Toprol Xl Tablets	C		
UNKNOWN						
			Daypro	C		
UNKNOWN						

Date:06/09/04ISR Number: 4375139-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
	Congestive		Tylenol	C		
UNKNOWN						
	Cardiomyopathy		Saw Palmetto	C		
UNKNOWN						
	Cellulitis		Ultram	C		
UNKNOWN						
	Cerebral Ischaemia		Lipitor	C		
UNKNOWN						
	Chronic Obstructive		Lumigan	C		
UNKNOWN						
	Pulmonary Disease		Corticosteroids			
	Colitis Ischaemic		(Unspecified)	C		
PARENTERAL						
	Coronary Artery Disease		Betagan	C		
UNKNOWN						
	Delirium		Relafen	C		
UNKNOWN						
	Depression		Paxil	C		
UNKNOWN						
	Diarrhoea					
	Drug Hypersensitivity					
	Gastroenteritis					
	Headache					
	Hypercholesterolaemia					
	Inguinal Hernia					
	Iron Deficiency Anaemia					
	Liver Function Test Abnormal					
	Myocardial Infarction					

Osteoarthritis
Osteoporosis
Periorbital Haematoma
Spinal Column Stenosis
Staphylococcal Sepsis

Date:06/09/04ISR Number: 4375143-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00504
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Small Intestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/04ISR Number: 4375144-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Arterial Occlusive Disease
	Atherosclerosis
	Blood Pressure Decreased
	Bronchitis
	Cardiac Valve Disease
	Chest Pain

		Chronic Fatigue Syndrome Coronary Artery Disease Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
		Inadequate Control		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia Emotional Distress		[Therapy Unspecified]	C		
UNKNOWN							
		Gastric Disorder		Albuterol	C		
UNKNOWN							
		Gastrooesophageal Reflux		Proventil	C		
RESPIRATORY							
		Disease					
(INHALATION)							
		Glaucoma Headache		Antimicrobial (Unspecified)	C		
UNKNOWN							
		Hypercholesterolaemia		Amaryl	C		
UNKNOWN							
		Hypertension		Glipizide	C		
UNKNOWN							
		Myocardial Infarction		Glucophage	C		
UNKNOWN							
		Oedema Peripheral Thrombosis Vision Blurred					

Date:06/09/04ISR Number: 4377870-9Report Type:Expedited (15-DaCompany Report #04P-062-0261391-00
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Asthma	Foreign	Humira 40 Mg/ 0.8 Ml			
Initial or Prolonged		Drug Ineffective	Health	Pre-Filled Syringe			
		Drug Toxicity	Professional	(Humira)			
		Suicide Attempt		(Adalimumab)	PS		
SUBCUTANEOUS	80 MG,	1 IN 2					
WK,							
SUBCUTANEOUS							
				Clomipramine	SS		ORAL
250 MG, ONCE,							

PER ORAL

Rofecoxib	SS	ORAL
Methotrexate Sodium	C	

PER ORAL

Date:06/10/04ISR Number: 4375579-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Adnexa Uteri Mass
	Anxiety
	Azotaemia
	Blepharitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cellulitis
	Cervicitis
	Cough
	Cystitis
	Diarrhoea
	Emotional Distress
	Endometrial Hyperplasia
	Epistaxis
	Fallopian Tube Cyst
	Fistula
	Fluid Retention
	Hypertension

		Infection					
		Irritable Bowel Syndrome					
		Lower Extremity Mass	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Meniscus Lesion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Mobility Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Mood Swings		Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Nervousness		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathic Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Osteoarthritis		Ventolin (Albuterol			
		Ovarian Fibrosis		Sulfate)	C		
UNKNOWN							
		Pain In Extremity		Tenormin	C		
UNKNOWN							
		Palpitations		Ultram	C		
UNKNOWN							
		Peau D'Orange		Vasotec	C		ORAL
		Pharynx Discomfort		Cenestin	C		
UNKNOWN							
		Pickwickian Syndrome		Lodine Xl	C		
UNKNOWN							
		Pneumonia		Lasix (Furosemide			
		Post Procedural		Sodium)	C		
UNKNOWN							
		Haemorrhage		Ditropan	C		
UNKNOWN							
		Pulmonary Oedema		K-Dur	C		
UNKNOWN							
		Retching		Quinine Sulfate	C		
UNKNOWN							
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Weight Increased					

Date:06/10/04ISR Number: 4375580-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Abdominal Discomfort	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Abscess Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Atherosclerosis		Darvocet-N	C		
UNKNOWN						
	Chest Discomfort		Aspirin	C		
UNKNOWN						
	Cold Sweat		Lipitor	C		
UNKNOWN						
	Diverticulitis		Metformin	C		
UNKNOWN						
	Drug Hypersensitivity		Zantac	C		
UNKNOWN						
	Dyspnoea					
	Fall					
	Gastritis					
	Hiatus Hernia					
	Hypercholesterolaemia					
	Hypertension					
	Joint Injury					
	Liver Disorder					
	Myocardial Infarction					
	Non-Cardiac Chest Pain					
	Non-Hodgkin'S Lymphoma					
	Pharyngolaryngeal Pain					
	Pyrexia					
	Simple Partial Seizures					
	Tuberculosis					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375583-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Blood Testosterone Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
			Tylenol	C				UNKNOWN
	Encephalitis Viral		Vicodin Tablets	C				UNKNOWN
	Hypertension		Amoxicillin	C				UNKNOWN
	Hyponatraemia		Aspirin	C				UNKNOWN
	Joint Sprain		Tenormin	C				UNKNOWN
	Mental Disorder		Zithromax	C				UNKNOWN
	Otitis Media		Wellbutrin	C				UNKNOWN
	Temporomandibular Joint		Celexa	C				UNKNOWN
	Syndrome		Plavix	C				UNKNOWN
	Transient Ischaemic		Benadryl	C				UNKNOWN
	Attack		Premarin	C				UNKNOWN
	Tri-Iodothyronine Free		Neurontin	C				UNKNOWN
	Increased		Glucosamine	C				UNKNOWN
	Vertigo		Hypericin	C				UNKNOWN
			Ibuprofen	C				UNKNOWN
			Claritin	C				UNKNOWN
			Ativan	C				UNKNOWN
			Ambien	C				UNKNOWN
			Effexor Xr	C				UNKNOWN
			Trazodone					

	Hydrochloride	C
UNKNOWN		
	Temazepam	C
UNKNOWN		
	Meclizine	C
UNKNOWN		
	Skelaxin	C
UNKNOWN		
	Univasc	C
UNKNOWN		
	Naproxen	C
UNKNOWN		
	Ranitidine	C
UNKNOWN		

Date:06/10/04ISR Number: 4375586-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Arthropathy
	Atrial Fibrillation
	Back Pain
	Basal Cell Carcinoma
	Bronchitis
	Bursitis
	Chest Pain
	Cough
	Drug Ineffective
	Dyspepsia
	Ecchymosis
	Hypertension
	Hypokalaemia
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Migraine
	Non-Cardiac Chest Pain
	Pneumonia
	Radiculitis Cervical
	Rectocele

		Respiratory Tract Infection					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tooth Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Viral Upper Respiratory	Professional	Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Acyclovir	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:06/10/04ISR Number: 4375594-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Abdominal Pain Upper	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Acute Myocardial		Tylenol	C		
UNKNOWN							
		Infarction		Z-Pak	C		
UNKNOWN							
		Asthenia		Cipro	C		
UNKNOWN							
		Back Injury		Diuretic (Unspecified)	C		
		Benign Breast Neoplasm					
UNKNOWN							

	Blood Potassium Increased	Dyazide	C
UNKNOWN			
	Bronchitis	Advil	C
UNKNOWN			
	Carcinoma In Situ Of Skin	Triamterene	C
UNKNOWN			
	Chest Pain	Prevacid	C
UNKNOWN			
	Coronary Artery Disease	Asacol	C
UNKNOWN			
	Deep Vein Thrombosis	Naproxen	C
UNKNOWN			
	Diarrhoea	Ditropan	C
UNKNOWN			
	Dizziness	Quinidine	C
UNKNOWN			
	Drug Hypersensitivity	Quinine Sulfate	C
UNKNOWN			
	Enterocele		
	Fall		
	Gastrointestinal		
	Infection		
	Gastrooesophageal Reflux		
	Disease		
	Headache		
	Hiatus Hernia		
	Hypoaesthesia		
	Osteoarthritis		
	Pulmonary Embolism		
	Radius Fracture		
	Renal Failure Acute		
	Rotator Cuff Syndrome		
	Ulna Fracture		
	Urinary Tract Infection		
	Visual Disturbance		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375599-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anorexia		Aspirin	C				
Other	Chest Discomfort							
	Chloasma							
	Chronic Sinusitis							
	Coronary Artery Disease							
	Cough							
	Depression							
	Drug Dependence							
	Eustachian Tube Disorder							
	Feeling Abnormal							
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Iliac Artery Stenosis							
	Intermittent Claudication							
	Muscle Spasms							
	Myocardial Infarction							

Date:06/10/04ISR Number: 4375603-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02533
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
	Cerebrovascular Accident							
	Emotional Distress							
	Hypertension							
	Stress							

Date:06/10/04ISR Number: 4375604-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		195 DAY
Initial or Prolonged Disability	Anxiety Coronary Artery Disease Depression Dislocation Of Vertebra Dysarthria Headache Hypertension Hypoaesthesia Injury Joint Dislocation Malaise Myocardial Infarction Non-Cardiac Chest Pain Pain In Extremity Road Traffic Accident Visual Disturbance	Professional						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375608-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00178
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rhabdomyolysis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:06/10/04ISR Number: 4375609-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00015
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Acetaminophen	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Cyclophosphamide	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

Date:06/10/04ISR Number: 4375610-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Voltaren	SS			UNKNOWN	
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Candidiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Lymphocytic Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis		Prempro	C			UNKNOWN	
	Gastrointestinal Haemorrhage							

Heart Rate Irregular
Hyperlipidaemia
Hypertension
Meniscus Lesion
Mitral Valve Prolapse
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Overdose
Peptic Ulcer
Pneumonia
Reflux Oesophagitis
Stress
Tricuspid Valve
Incompetence
Ulcer Haemorrhage
Urinary Tract Infection
Ventricular Dysfunction
Vomiting
Wound Infection
Staphylococcal

Date:06/10/04ISR Number: 4375756-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Respiratory Failure
Other	Adrenal Insufficiency
	Anaemia Of Chronic
	Disease
	Arteriosclerosis
	Asthenia
	Asthma
	Bacterial Infection
	Blood Erythropoietin
	Decreased
	Candidiasis
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Colitis
	Decubitus Ulcer
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Duodenitis
	Faecal Incontinence
	Fungaemia
	Gastritis
	Gastrointestinal
	Haemorrhage
	Gastrooesophageal Reflux
	Disease
	Glaucoma
	Gynaecomastia
	Haemorrhoids
	Headache
	Hepatic Steatosis
	Hiatus Hernia
	Hypercoagulation
	Hyperglycaemia
	Hypertension
	Incisional Hernia
	Inguinal Hernia
	Malnutrition
	Metabolic Acidosis
	Obesity

Oesophagitis
Optic Neuropathy
Otitis Media
Pickwickian Syndrome
Pneumonia
Pulmonary Embolism
Pulmonary Hypertension
Renal Failure
Renal Failure Acute
Rheumatoid Arthritis
Sepsis
Syncope Vasovagal
Thrombocytopenia
Umbilical Hernia
Urinary Incontinence

Urinary Tract Infection
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	347 DAY
	Catapres	C			UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Micardis	C			UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Cozaar	C			UNKNOWN	

Date:06/10/04ISR Number: 4375757-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atelectasis							
	Cardiac Disorder							
	Cardiac Valve Disease							
	Carotid Artery Disease							
	Delirium							
	Dementia							
	Difficulty In Walking							
	Dizziness							
	Drug Hypersensitivity							
	Eye Disorder							
	Fall							
	Gallbladder Disorder							
	Insomnia							
	Laceration							
	Myocardial Ischaemia							
	Pain In Extremity							
	Renal Cyst							
	Seasonal Allergy							

Date:06/10/04ISR Number: 4375763-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety Disorder
	Connective Tissue Disorder
	Depression
	Diabetes Mellitus
	Diabetic Neuropathy
	Dizziness
	Fall
	Fibromyalgia
	Generalised Anxiety Disorder
	Haematochezia
	Haemorrhage
	Hypertension
	Intestinal Obstruction
	Joint Lock
	Malaise
	Nervousness
	Pain
	Stomach Discomfort

		Thrombocytopenia Tremor Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vicodin Tablets	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Elavil	C		ORAL
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Heparin	C		
UNKNOWN							
				Hydro-Chlor	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Ms Contin	C		
UNKNOWN							

Date:06/10/04ISR Number: 4375764-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
401 DAY						
Initial or Prolonged	Aortic Valve Sclerosis		Aspirin	C		
UNKNOWN						
Disability	Chest Pain		Aspirin	C		
UNKNOWN						
Other	Chronic Fatigue Syndrome		Tagamet	C		
UNKNOWN						
	Depression		Premarin	C		
UNKNOWN						
	Dizziness		Hytrin	C		
UNKNOWN						

	Duodenitis	Estratab	C
UNKNOWN			
	Endocarditis	L-Thyroxin	C
UNKNOWN			
	Gallbladder Disorder	Ranitidine	C
UNKNOWN			
	Gastritis Gastrooesophageal Reflux Disease Generalised Anxiety Disorder Haematuria Herpes Zoster Hypertension Hypertensive Crisis Hypoacusis Hypokalaemia Irritable Bowel Syndrome Lacunar Infarction Migraine With Aura Mitral Valve Calcification Mitral Valve Incompetence Non-Cardiac Chest Pain Panic Disorder Sleep Apnoea Syndrome Tension Headache Thalamus Haemorrhage Transient Ischaemic Attack		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375765-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Concussion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS		ORAL		
	Depression		Vioxx	SS		ORAL		
	Dizziness		Bayer Aspirin	C		ORAL		
	Emotional Distress		Bayer Aspirin	C		ORAL		
	Extrasystoles		Vitamins					
	Fall		(Unspecified)	C				
UNKNOWN								
	Fatigue							
	Female Reproductive							
	Neoplasm							
	Gingival Disorder							
	Haematochezia							
	Haemorrhage							
	Headache							
	Heart Rate Irregular							
	Hypercholesterolaemia							
	Post-Traumatic Stress Disorder							
	Sleep Disorder							
	Vaginal Haemorrhage							
	Vasodilatation							
	Vomiting							

Date:06/10/04ISR Number: 4375766-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00873
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
255 DAY								
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
255 DAY								
Disability	Anxiety		Tylenol	C				
UNKNOWN								
	Arterial Injury		Aspirin	C				
UNKNOWN								
	Arthritis							
	Blood Cholesterol							

Increased
Coronary Artery Occlusion
Depression
Device Failure
Diarrhoea
Dyspepsia
Gastric Disorder
Hypertension
Hypotension
Joint Swelling
Liver Disorder
Post Procedural
Complication
Pyelonephritis
Vision Blurred

Date:06/10/04ISR Number: 4375767-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00012
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375768-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00048
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vasculitis Necrotising		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/04ISR Number: 4375769-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	147 DAY	

Date:06/10/04ISR Number: 4375770-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	91 DAY	UNKNOWN
Disability	Anaemia		Lipitor	C				UNKNOWN
Other	Arrhythmia		Capoten	C				UNKNOWN
	Arthritis		Plavix	C				UNKNOWN
	Bronchitis Acute		Lasix (Furosemide Sodium)	C				UNKNOWN
	Cardiac Failure							
	Congestive		Amaryl	C				UNKNOWN
	Cardiogenic Shock		Glipizide	C				UNKNOWN
	Cardiomyopathy		Prevacid	C				UNKNOWN
	Chronic Obstructive		Glucophage	C				UNKNOWN

	Pulmonary Disease	Lopressor	C
UNKNOWN			
	Colonic Polyp	Nitrol	
	Convulsion	(Nitroglycerin)	C
UNKNOWN			
	Coronary Artery Disease	Altace	C
UNKNOWN			
	Decubitus Ulcer		
	Diabetic Neuropathy		
	Dysphagia		
	Electrolyte Imbalance		
	Faecaloma		
	Gastrointestinal		
	Haemorrhage		
	Herpes Zoster		
	Hypertension		
	Influenza		
	Ischaemic Cardiomyopathy		
	Liver Function Test		
	Abnormal		
	Malnutrition		
	Myocardial Infarction		
	Oedema		
	Pericarditis		
	Pneumonia		
	Pneumonia Aspiration		
	Post Herpetic Neuralgia		
	Pulmonary Oedema		
	Pyrexia		
	Radiculitis Brachial		
	Respiratory Failure		
	Rotator Cuff Syndrome		
	Staphylococcal Infection		
	Stent Occlusion		
	Thrombocytopenia		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/04ISR Number: 4375771-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Increased		Moduretic	C		ORAL		
	Bradycardia		Bisoprolol	C		ORAL		113 DAY
	Dizziness		Flecainide Acetate	C		ORAL		82 DAY
	Hypertension							

Date:06/10/04ISR Number: 4375772-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02532
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		1074 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1074 DAY
Disability	Blood Cholesterol		Darvocet-N	C				UNKNOWN
	Increased		Zyrtec	C				UNKNOWN
	Cerebrovascular Accident		Prozac	C				UNKNOWN
	Depression		Motrin	C				UNKNOWN
	Intracranial Aneurysm		Synthroid	C				UNKNOWN
	Mental Disability		Nasonex	C				UNKNOWN
	Stress		Serzone	C				UNKNOWN
		62 DAY						

Date:06/10/04ISR Number: 4375773-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Distress Syndrome					
Initial or Prolonged						

Date:06/10/04ISR Number: 4375774-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00547
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive		Lipitor	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Cozaar	C		ORAL

Date:06/11/04ISR Number: 4376039-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
27 DAY						
Initial or Prolonged	Eczema	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Gastritis		[Therapy			
	Myocardial Infarction		Unspecified]	C		
UNKNOWN						
	Oesophagitis		[Therapy			
	Peptic Ulcer		Unspecified]	C		
UNKNOWN						
	Stress		Aspirin	C		
UNKNOWN						
	Tachycardia		Lipitor	C		
UNKNOWN						
	Upper Gastrointestinal		Pepto-Bismol	C		
UNKNOWN						
	Haemorrhage		Chondroitin Sulfate			
	Ventricular Arrhythmia		Sodium And			
			Glucosamine			
			Hydrochloride	C		
UNKNOWN						

Vitamin E	C			
UNKNOWN				
Vitamin B (Unspecified)	C			
UNKNOWN				
Vasoretic	C			ORAL
Vasoretic	C			ORAL
Neurontin	C			
UNKNOWN				
Prevacid	C			
UNKNOWN				
Centrum	C			
UNKNOWN				
Inderal	C			
UNKNOWN				

Date:06/11/04ISR Number: 4376041-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02014
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		604 DAY
Initial or Prolonged	Cardiac Disorder	Professional	Bayer Aspirin	C				
UNKNOWN								
Other	Carotid Artery Stenosis		Cyanocobalamin	C				
UNKNOWN								
	Cerebrovascular Accident		Neurontin	C				
UNKNOWN								
	Chest Pain		Glucotrol	C				
UNKNOWN								
	Contusion		Zestril	C				
UNKNOWN								
	Fall		Zestril	C				
UNKNOWN								
	Joint Swelling		Zocor	C				
UNKNOWN								
	Liver Disorder		Ultram	C				
UNKNOWN								
	Lung Neoplasm		Zocor	C				
UNKNOWN								
	Pain		Mobic	C				
UNKNOWN								
	Renal Arteriosclerosis		Niacin	C				
UNKNOWN								

	Renal Atrophy	Actos	C
UNKNOWN			
	Renal Cyst	Actos	C
UNKNOWN			
	Renal Failure	Evista	C
UNKNOWN			

Date:06/11/04ISR Number: 4376048-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01988
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Aphasia
	Arteriosclerosis
	Aspergillosis
	Back Pain
	Blood Glucose Increased
	Bronchial Obstruction
	Bronchitis Acute
	Candidiasis
	Carotid Artery Disease
	Cerebral Artery Occlusion
	Cerebral Atrophy
	Cerebrovascular Accident
	Chronic Obstructive
	Airways Disease
	Exacerbated
	Chronic Obstructive
	Pulmonary Disease
	Confusional State
	Death
	Febrile Neutropenia
	Incoherent
	Injury
	Injury Corneal
	Mental Impairment

		Mental Status Changes					
		Metastases To Bone					
		Metastases To Liver	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Metastases To Lymph Nodes	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain	Professional				
		Pneumonia					
		Pneumonia Bacterial					
		Productive Cough					
		Septic Shock					
		Spinal Compression					
		Fracture					
		Staphylococcal Infection					

Date:06/11/04ISR Number: 4376049-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02433
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
63 DAY							
		Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
63 DAY							
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiomegaly		Acetaminophen And			
		Contusion		Codeine	C		
UNKNOWN							
		Coronary Artery Stenosis		Norvasc	C		
UNKNOWN							
		Coronary Artery		Hytrin	C		
UNKNOWN							
		Thrombosis		Armour Thyroid			
		Diabetes Mellitus		Tablets	C		
UNKNOWN							
		Inadequate Control		Trimox	C		
UNKNOWN							
		Hepatic Congestion		Aspirin	C		
UNKNOWN							
		Hepatic Steatosis		Vasotec	C		ORAL
		Hepatomegaly		Glucophage	C		
UNKNOWN							
		Myocardial Rupture		Metronidazole	C		
UNKNOWN							
		Nephrosclerosis					

Osteoporosis
Pericardial Haemorrhage
Polycystic Ovaries
Pulmonary Congestion
Renal Disorder
Road Traffic Accident
Skin Depigmentation
Spleen Congestion

Date:06/11/04ISR Number: 4376050-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Anxiety
	Aortic Valve Incompetence
	Atrial Fibrillation
	Blood Pressure Inadequately Controlled
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chest Pain
	Chondrocalcinosis

		Pyrophosphate					
		Colon Cancer Recurrent					
		Colonic Polyp					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Premarin	C		
UNKNOWN							
		Dysphagia		Glipizide	C		
UNKNOWN							
		Emotional Distress					
		Gastritis					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Inner Ear Disorder					
		Mitral Valve Incompetence					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Renal Cyst					
		Renal Failure					
		Syncope					
		Thrombophlebitis					
		Tooth Infection					
		Tricuspid Valve					
		Incompetence					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vein Pain					
		Vertigo					

Date:06/11/04ISR Number: 4376051-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02790
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Contusion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Diverticulum Intestinal		Betamethasone And			
		Dyspnoea		Bupivacaine			
		Endometrial Hyperplasia		Hydrochloride	C		
PARENTERAL							
		Eustachian Tube		Arthrotec	C		
UNKNOWN							

	Dysfunction	Naprelan	C
UNKNOWN			
	Gastric Ulcer		
	Gastritis		
	Gastrointestinal		
	Haemorrhage		
	Haemorrhoids		
	Headache		
	Hiatus Hernia		
	Lung Neoplasm		
	Migraine		
	Muscle Strain		
	Periodontal Disease		
	Rash		
	Rectal Haemorrhage		
	Reflux Oesophagitis		
	Road Traffic Accident		
	Sinus Disorder		
	Uterine Leiomyoma		

Date:06/11/04ISR Number: 4376053-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00040
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Decreased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Oedema		Amlodipine Besylate	C				
	Weight Increased		Aspirin	C				
			Propafenone Hydrochloride	C				

Date:06/11/04ISR Number: 4376054-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0402GBR00013
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea Haemorrhagic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Other	Malaise	Professional	Acetaminophen And Codeine Phosphate	C				
			Mometasone Furoate	C				

RESPIRATORY

(INHALATION)

Date:06/11/04ISR Number: 4376055-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	74	DAY
	Varicose Vein	Professional	[Therapy Unspecified]	C				
			Furosemide	C		ORAL		
			Ibuprofen	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

			Ibuprofen	C		ORAL
			Methotrexate	C		ORAL

Date:06/11/04ISR Number: 4376056-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0406BRA00007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Skin Inflammation	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Initial or Prolonged		Professional				

Date:06/11/04ISR Number: 4376057-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00067
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Haemorrhage	Professional	Aspirin	C		
UNKNOWN						
Initial or Prolonged	Haematemesis		Digoxin	C		
UNKNOWN						
	Hypotension		Furosemide	C		
UNKNOWN						
	Melaena		Levothyroxine Sodium	C		
UNKNOWN						

Date:06/11/04ISR Number: 4376247-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Glucose Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Iron Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
Increased		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
Chromaturia		[Composition					
Chronic Fatigue Syndrome		Unspecified]	C				UNKNOWN
Constipation		Baycol	C				UNKNOWN
Convulsion		Actos	C				UNKNOWN
Costochondritis							
Depression							
Dizziness							
Drug Hypersensitivity							
Drug Ineffective							
Emotional Distress							
Fatigue							
General Physical Health Deterioration							
Hypertension							
Macular Oedema							
Myalgia							
Neuritis							
Neuropathy Peripheral							
Oedema Peripheral							
Pain							
Peripheral Vascular Disorder							
Restless Legs Syndrome							
Road Traffic Accident							
Tachycardia							

Date:06/11/04ISR Number: 4376248-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Choking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Aspirin	C				
UNKNOWN								
Disability	Diverticulum		Restoril	C				
UNKNOWN								
	Erosive Duodenitis							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Hiatus Hernia							
	Hypertension							
	Hypoacusis							
	Oesophageal Rupture							
	Renal Cyst							
	Supraventricular Extrasystoles							
	Thromboembolic Stroke							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/04ISR Number: 4376249-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104492
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cellulitis							
	Cerebrovascular Accident							
	Hypertension							
	Injury							
	Joint Swelling							
	Oedema							
	Osteoarthritis							
	Osteoporosis							
	Renal Failure							
	Tendon Injury							
	Tendonitis							
	Ventricular Hypertrophy							

Date:06/11/04ISR Number: 4376250-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bunion		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Avandia	C		ORAL		
Other	Congestive		Avandia	C		ORAL		
	Cardiomegaly		[Therapy					
	Carotid Artery Stenosis		Unspecified]	C				
UNKNOWN								
	Cataract		[Therapy					
	Cerebrovascular Accident		Unspecified]	C				
UNKNOWN								
	Contusion		Vicoprofen	C		ORAL		
	Coronary Artery Disease		Glucophage	C		ORAL		
	Glaucoma		Glucophage	C		ORAL		
	Head Injury							
	Hemianopia Homonymous							
	Hypoaesthesia							
	Lumbar Spinal Stenosis							
	Nasopharyngitis							
	Neuropathy Peripheral							
	Osteoarthritis							

Road Traffic Accident
Spinal Osteoarthritis
Toe Deformity
Ventricular Hypertrophy
Whiplash Injury

Date:06/11/04ISR Number: 4376251-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00433
Age:39 YR Gender:Male I/FU:F

Outcome PT
Disability Arthralgia
Back Injury
Drug Ineffective
Dyspnoea
Ear Pain
Fall
Heart Rate Irregular
Hyperventilation
Hypoaesthesia

		Hypocalcaemia					
		Injury					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Lumbar Spinal Stenosis		Soma	C		
UNKNOWN							
		Movement Disorder		Naprosyn	C		
UNKNOWN							
		Musculoskeletal Stiffness					
		Myofascial Pain Syndrome					
		Non-Cardiac Chest Pain					
		Ocular Icterus					
		Onychomycosis					
		Rotator Cuff Syndrome					
		Sinus Congestion					
		Viral Infection					

Date:06/11/04ISR Number: 4376252-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02022
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
24 DAY							
		Blood Glucose Increased		Glyburide	C		
UNKNOWN							
		Cataract		Avandia	C		
UNKNOWN							
		Cerebral Infarction		Norvasc	C		
UNKNOWN							
		Cerebrovascular Accident		Lotensin	C		
UNKNOWN							
		Dysgeusia		Aspirin	C		
UNKNOWN							
		Facial Palsy		Zocor	C		ORAL
		Gingival Recession		Advil	C		
UNKNOWN							
		Glycosylated Haemoglobin					
		Increased					
		Hypoaesthesia					
		Injury					
		Osteoarthritis					
		Paraesthesia					
		Rotator Cuff Syndrome					

Scab
Seborrhoeic Keratosis
Sinusitis
Spinal Osteoarthritis

Date:06/11/04ISR Number: 4376253-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Amnesia
Other	Apathy
	Asthenia
	Autonomic Nervous System Imbalance
	Blood Bilirubin Increased
	Blood Bilirubin Unconjugated Increased
	Blood Pressure Fluctuation
	Blood Pressure Increased
	Blood Pressure Systolic Increased
	Bradycardia
	Calcinosis

Cerebellar Haemorrhage
Chronic Obstructive
Pulmonary Disease
Citrobacter Infection
Cognitive Disorder
Constipation
Dehydration
Dementia
Depression
Diverticulum
Diverticulum Intestinal
Dizziness
Dysphagia
Enterobacter Infection
Facet Joint Syndrome
Fall
Fatigue
Feeling Cold
Femur Fracture
Gastritis
Gastrointestinal Disorder
Haemorrhagic Stroke
Hiatus Hernia
Hip Fracture
Hyperglycaemia
Hyponatraemia
Inappropriate
Antidiuretic Hormone
Secretion
Inflammation
Injury
Interstitial Lung Disease
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Lipoma
Lumbar Spinal Stenosis
Lung Infiltration
Lung Neoplasm
Nausea
Nuclear Magnetic
Resonance Imaging
Abnormal
Nystagmus
Obstructive Airways
Disorder

Oesophageal Disorder
Otitis Media
Pain
Pelvic Pain
Personality Disorder
Pneumonia
Pollakiuria
Proctalgia
Proctitis
Prostatitis
Pyelonephritis
Radicular Pain
Rectal Cramps
Scoliosis

		Sinusitis					
		Sleep Apnoea Syndrome					
		Spinal Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Staphylococcal Infection		Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Urethral Stricture		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Bacterial		Valium	C		
UNKNOWN							
		Urinary Tract Infection		Neurontin	C		
UNKNOWN							
		Pseudomonal		Neurontin	C		
UNKNOWN							
		White Blood Cell Count		Neurontin	C		
UNKNOWN							
		Increased		Neurontin	C		
UNKNOWN							
				Avapro	C		
UNKNOWN							
				Misoprostol	C		
UNKNOWN							
				Macrodantin	C		
UNKNOWN							
				Nortriptyline	C		
UNKNOWN							
				Nortriptyline	C		
UNKNOWN							

Date:06/11/04ISR Number: 4376254-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02107
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain Upper
	Adverse Event
	Angioneurotic Oedema
	Anxiety
	Atrioventricular Block Second Degree
	Blood Creatine Phosphokinase Increased
	Chest Pain
	Depression

Dizziness
Drug Hypersensitivity
Dyspnoea
Fatigue
Gallbladder Disorder
Gastric Disorder
Gastritis
Hypertension
Injury
Insomnia
Intervertebral Disc
Degeneration
Lipids Abnormal
Memory Impairment
Myalgia
Nausea
Neck Pain
Osteoarthritis
Osteochondrosis
Palpitations
Paraesthesia
Pleurisy
Pulmonary Valve
Incompetence
Radiculopathy
Rhabdomyolysis
Spinal Column Stenosis
Treatment Noncompliance

		Tricuspid Valve Incompetence					
		Vascular Resistance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Systemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Vomiting		Tylenol	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Ginkgo Biloba Extract	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Ginseng	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Klor-Con	C		
UNKNOWN							
				Slow-K	C		
UNKNOWN							

Date:06/11/04ISR Number: 4376255-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01985
Age:35 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Death		[Therapy Unspecified]	C		
Other		Dyspnoea					
UNKNOWN							
		Epigastric Discomfort		Tylenol	C		
UNKNOWN							
		Injury		Mylanta & Mylanta Ds	C		
UNKNOWN							
		Myocardial Infarction		Celebrex	C		
UNKNOWN							
		Pco2 Decreased		Catapres	C		
UNKNOWN							
		Stomach Discomfort		Dyazide	C		
UNKNOWN							

	Ventricular Hypertrophy	Motrin	C
UNKNOWN			
	Vomiting	Orudis	C
UNKNOWN			
		Zestril	C
UNKNOWN			
		Cytotec	C
UNKNOWN			
		Naproxen	C
UNKNOWN			
		Procardia	C
UNKNOWN			
		Actifed	C
UNKNOWN			

Date:06/11/04ISR Number: 4376256-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	56 DAY	
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	156 DAY	
	Increased		Aspirin	C				
UNKNOWN								
	Cellulitis		Celebrex	C				
UNKNOWN								
	Ischaemic Stroke							
	Paraesthesia							
	Spondylitis							
	Transient Ischaemic							
	Attack							

Date:06/11/04ISR Number: 4376257-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Back Injury
Disability	Benign Prostatic
Other	Hyperplasia

Bladder Neck Sclerosis
Cerebrovascular Accident
Chest Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Deconamine	C			UNKNOWN	
	Lisinopril	C			UNKNOWN	
	Meclizine	C			UNKNOWN	
	Aciphex	C			UNKNOWN	

Dizziness
Haemolysis
Haemorrhoidal Haemorrhage
Hyperkalaemia
Hyperlipidaemia
Hypertension
Liver Function Test
Abnormal
Palpitations
Renal Failure Acute
Rheumatoid Arthritis
Rhinitis Allergic
Stress
Tooth Abscess
Urethral Stricture
Vertigo

Date:06/11/04ISR Number: 4376258-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Amnesia
Other	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic Hyperplasia
	Cardiac Failure Congestive
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Confusional State
	Coronary Artery Disease
	Deafness Neurosensory

Dehydration
Depression
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fibrous Histiocytoma
Headache
Hiatus Hernia
Hypertension
Mitral Valve Incompetence
Myocardial Infarction
Oedema
Pneumonia Escherichia
Post Procedural
Complication
Pupillary Disorder
Renal Failure
Respiratory Failure
Sepsis

	Subarachnoid Haemorrhage					
	Syncope					
	Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Attack		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY					
	Tremor		Vioxx	SS	Merck & Co., Inc	ORAL
	Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
	Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY					
	Varicose Vein		Neurontin	C		
UNKNOWN						
	Ventricle Rupture		Glucosamine	C		
UNKNOWN						
	Ventricular Tachycardia		Prilosec	C		
UNKNOWN						
	Vertigo Positional					
	Vision Blurred					

Date:06/11/04ISR Number: 4376259-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia Haemolytic
Disability	Autoimmune
Other	Arthralgia
	Atelectasis
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased
	Cellulitis
	Cerebrovascular Accident
	Cholelithiasis
	Coagulopathy
	Cystocele
	Decreased Appetite
	Disturbance In Attention
	Drug Hypersensitivity
	Dyspnoea
	Eye Pain
	Haematochezia
	Haemorrhage
	Hypercalcaemia

Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Insomnia
Neurogenic Bladder
Oesophageal Disorder
Pulmonary Granuloma
Pyrexia
Rectocele
Renal Failure
Sinusitis
Tinnitus
Tooth Disorder
Toothache
Tracheobronchitis
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Viral Infection
Visual Disturbance

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
	Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
	Amitriptyline Hydrochloride	C			UNKNOWN	
	Rocaltrol	C		ORAL		
	Os-Cal + D	C			UNKNOWN	
	Valium	C			UNKNOWN	
	Synthroid	C			UNKNOWN	
	Synthroid	C		ORAL		
	Ambien	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Slow-Mag	C			UNKNOWN	
	Reglan	C			UNKNOWN	
	Reglan	C			UNKNOWN	
	Prilosec	C			UNKNOWN	
	Ditropan Xl	C			UNKNOWN	
	Potassium Chloride	C			UNKNOWN	

Date:06/11/04ISR Number: 4376260-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01363
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	634	DAY
	Cyst		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON

		Diabetes Mellitus	Vioxx	SS	Merck & Co., Inc	ORAL
634	DAY					
		Dizziness	Vioxx	SS	Merck & Co., Inc	ORAL
2	MON					
		Dry Mouth	Panlor Ss	C		
UNKNOWN						
		Ear Pruritus	Vicodin Tablets	C		ORAL
		Emotional Distress	Zovirax	C		ORAL
		Food Intolerance	Tessalon	C		
UNKNOWN						
		Fungal Infection	Docusate Sodium	C		ORAL
		Gastrooesophageal Reflux	Erythromycin	C		
TOPICAL						
		Disease	Ethinyl Estradiol			
		Increased Tendency To	And Norgestimate	C		
UNKNOWN						
		Bruise	Glucosamine	C		
UNKNOWN						
		Keratoconjunctivitis	Humibid	C		
UNKNOWN						
		Sicca	Hydroquinone	C		
TOPICAL						
		Major Depression	Ketoconazole	C		
TOPICAL						
		Mitral Valve Incompetence	Lansoprazole	C		ORAL
		Myocardial Infarction	Synthroid	C		ORAL
		Nasal Disorder	Claritin-D	C		ORAL
		Night Cramps	Nasonex	C		
UNKNOWN						
		Ovarian Cyst	Prilosec	C		
UNKNOWN						
		Post-Traumatic Stress	Prilosec	C		
UNKNOWN						
		Disorder	Ambien	C		
UNKNOWN						
		Tricuspid Valve	Sonata	C		
UNKNOWN						
		Incompetence	Effexor Xr	C		ORAL
			Urea	C		
TOPICAL						
			Triamcinolone	C		
TOPICAL						
			Tretinoin	C		
TOPICAL						
			Ultram	C		
UNKNOWN						
			Oxybutynin Chloride	C		
UNKNOWN						
			Paxil	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/11/04ISR Number: 4376261-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acne		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Chest Pain		[Therapy Unspecified]	C			UNKNOWN	144 DAY
	Diabetes Mellitus							
	Dysuria		Tylenol	C			UNKNOWN	
	Gastritis		Darvocet-N	C			UNKNOWN	
	Gastrooesophageal Reflux		Soma	C			UNKNOWN	
	Disease							
	Haemangioma							
	Hemiparesis							
	Hypoaesthesia							
	Injury							
	Intervertebral Disc							
	Degeneration							
	Irritable Bowel Syndrome							
	Joint Dislocation							
	Joint Effusion							
	Joint Range Of Motion							
	Decreased							
	Joint Sprain							
	Ligament Sprain							
	Lipoma							
	Spinal Osteoarthritis							
	Synovial Disorder							

Date:06/11/04ISR Number: 4376262-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Aneurysm
	Aneurysm Ruptured

Aortic Atherosclerosis
Aortic Dissection
Asthenia
Atelectasis
Blood Pressure
Inadequately Controlled
Depression
Disturbance In Attention
Diverticulitis
Dizziness
Emotional Distress
Enterobacter Infection
Gastrooesophageal Reflux
Disease
General Physical
Condition Abnormal
Haematocrit Decreased
Haemoglobin Decreased
Hyperhidrosis
Hypertension
Iliac Artery Thrombosis
Impaired Healing
Injury

	Irritability						
	Keloid Scar						
	Lung Infiltration	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
	Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Platelet Count Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Prothrombin Time		Amoxicillin	C			UNKNOWN
	Prolonged		Viagra	C			UNKNOWN
	Rash Pruritic		Chlorhexidine				
	Self Esteem Decreased		Hydrochloride	C			UNKNOWN
	Sexual Dysfunction		Hydrocodone				
	Sputum Culture Positive		Bitartrate	C			UNKNOWN
	Stress		Lorazepam	C			UNKNOWN
	Troponin I Increased						
	Vascular Injury						

Date:06/11/04ISR Number: 4376263-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	93 DAY
Initial or Prolonged	Aortic Thrombosis		Tylenol	C			UNKNOWN
Other	Aortic Valve Sclerosis		Ecotrin	C			UNKNOWN
	Arteriovenous Fistula		Viagra	C			UNKNOWN
	Blood Albumin Increased		Calan Sr	C			UNKNOWN
	Blood Pressure Increased		Zocor	C			UNKNOWN

	Bundle Branch Block Left	Celebrex	C
UNKNOWN			
	Chest Discomfort	Advil	C
UNKNOWN			
	Coronary Artery Disease		
	Coronary Artery Occlusion		
	Dehydration		
	Dilatation Atrial		
	Diverticulum Intestinal		
	Haemorrhagic		
	Electrocardiogram Poor		
	R-Wave Progression		
	Emotional Distress		
	Gastritis Atrophic		
	Helicobacter Infection		
	Injury		
	Iron Deficiency Anaemia		
	Low Density Lipoprotein		
	Increased		
	Mitral Valve Incompetence		
	Myocardial Ischaemia		
	Neck Pain		
	Neuropathy Peripheral		
	Peripheral Coldness		
	Stent Occlusion		
	Ventricular Hypokinesia		
	Weight Increased		

Date:06/11/04ISR Number: 4376264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01526
Age:50 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	14	DAY
Arthralgia							
Blood Pressure							
Fluctuation							
Blood Pressure							
Inadequately Controlled							
Bradycardia							
Cardiac Failure							
Congestive							
Carotid Artery Stenosis							
Carpal Tunnel Syndrome							
Circadian Rhythm Sleep							
Disorder							
Coronary Artery Disease							
Depression							
Dermatitis							
Disease Recurrence							
Dizziness							
Embolic Cerebral							
Infarction							
Epicondylitis							
Erectile Dysfunction							
Fatigue							
Gastritis							
Gout							
Headache							
Hypotension							
Memory Impairment							
Multiple Sclerosis							
Muscular Weakness							
Myocardial Ischaemia							
Oesophagitis							
Osteoarthritis							
Palpitations							
Peripheral Vascular							
Disorder							
Rheumatoid Factor							
Positive							
Sinusitis							
Sleep Apnoea Syndrome							
Somnolence							

Syncope Vasovagal
Tenosynovitis
Transient Ischaemic
Attack
Vascular Graft Occlusion
Ventricular Hypertrophy
Weight Increased

Date:06/11/04ISR Number: 4376265-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02524
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blindness Unilateral
Disability	Blood Cholesterol Increased

	Hypertension Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/11/04ISR Number: 4376266-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02527
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Strangulated		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Hernia		Vioxx	SS	Merck & Co., Inc	ORAL	
1452 DAY							
Disability	Anxiety		Tylenol With Codeine				
	Atrial Fibrillation		#3	C			
UNKNOWN							
	Blood Cholesterol		Atenolol	C			
UNKNOWN							
	Increased		Vasotec	C			
UNKNOWN							
	Carotid Artery Stenosis		Allegra	C			
UNKNOWN							
	Cerebral Infarction Depression Eye Disorder Gallbladder Disorder Gastrooesophageal Reflux Disease Hypertension Oedema Peripheral Osteoarthritis Sleep Apnoea Syndrome Stomach Discomfort						

Date:06/11/04ISR Number: 4376268-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00021
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
7 DAY							
Life-Threatening	Cardiac Arrest		Alprazolam	C		ORAL	

Hospitalization - Initial or Prolonged	Duodenal Ulcer Gastric Perforation Hypotension		Modamide	C	ORAL
			Tamsulosin Hydrochloride	C	ORAL
			Citalopram Hydrobromide	C	ORAL
			Hydrochlorothiazide	C	ORAL

Date:06/11/04ISR Number: 4376269-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02534
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Cerebrovascular Accident		Vioxx Lipitor	PS C	Merck & Co., Inc	ORAL		UNKNOWN
Disability	Emotional Distress		Remicade	C				UNKNOWN
	Injury		Methotrexate	C				UNKNOWN
	Myocardial Infarction		Methotrexate	C				UNKNOWN
	Stress Transient Ischaemic Attack							

Date:06/11/04ISR Number: 4376270-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0406AUS00021
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged			Trandolapril	C				
UNKNOWN								

Date:06/11/04ISR Number: 4376272-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01829
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		466 DAY
Other	Increased		Aspirin	C				
UNKNOWN								
	Cerebrovascular Accident							
	Emotional Distress							
	Gout							
	Oedema Peripheral							
	Renal Injury							

Date:06/14/04ISR Number: 4376968-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01978
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Back Injury
Initial or Prolonged	Carpal Tunnel Syndrome
Other	Cellulitis
	Cervicobrachial Syndrome
	Chest Pain
	Chronic Fatigue Syndrome
	Colitis
	Contusion
	Drug Dependence
	Emotional Distress
	Exostosis
	Fall
	Feeling Abnormal
	Gastritis

Gastrooesophageal Reflux
Disease
Haemorrhoids
Head Injury
Helicobacter Infection
Hypercholesterolaemia
Hypertension
Injury
Intervertebral Disc
Protrusion
Ligament Sprain
Loss Of Consciousness
Lumbar Spinal Stenosis
Malaise
Migraine
Muscle Spasms
Myofascial Pain Syndrome
Oesophagitis
Osteoarthritis
Panic Disorder
Pelvic Pain
Radiculitis Cervical
Road Traffic Accident

		Therapeutic Response Decreased					
		Trigger Finger	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Acuity Reduced	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
			Professional	[Therapy Unspecified]	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:06/14/04ISR Number: 4376970-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Angiopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Arterial Disorder	Professional	Tylenol	C		
UNKNOWN							
Other		Circulatory Collapse		Vicodin Tablets	C		
UNKNOWN							
		Coronary Artery Disease		Celexa	C		
UNKNOWN		1839 DAY					
		Dyspnoea Exertional		Plavix	C		
UNKNOWN		366 DAY					
		Emotional Distress		Flexeril	C		ORAL
		Femur Fracture		Avapro	C		
UNKNOWN		1681 DAY					
		Gastrointestinal Disorder		Ativan	C		
UNKNOWN		1344 DAY					
		Hypertension		Niacin	C		
UNKNOWN		1830 DAY					
		Migraine					
		Myocardial Infarction					
		Stress					

Date:06/14/04ISR Number: 4376972-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Anaemia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Other	Angle Closure Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Headache		Tiazac	C				UNKNOWN
	Muscle Spasms		Advil	C				UNKNOWN
	Myocardial Infarction							
	Nephrolithiasis							
	Osteoarthritis							
	Pharyngolaryngeal Pain							
	Renal Artery Atherosclerosis							
	Renal Failure Chronic							
	Wound Infection Staphylococcal							

Date:06/14/04ISR Number: 4376975-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01102
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardio-Respiratory Arrest
Other	Deep Vein Thrombosis
	Diverticulum
	Finger Deformity
	Hepatic Cyst
	Peripheral Embolism

Renal Failure Acute
Uterine Leiomyoma

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	378 DAY	
	Femhrt	C			UNKNOWN	

Date:06/14/04ISR Number: 4376977-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Angiopathy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety							
	Back Injury							
	Back Pain							
	Cerebrovascular Accident							
	Confusional State							
	Dementia Alzheimer'S Type							
	Diarrhoea							
	Dysuria							
	Emotional Distress							
	Facial Pain							
	Faecal Occult Blood							
	Positive							
	Faeces Discoloured							
	Fall							
	Gastroenteritis							
	Hypertension							
	Injury							
	Renal Cyst							
	Subarachnoid Haemorrhage							
	Vertigo							

Date:06/14/04ISR Number: 4376979-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial

Disability	Infarction
Other	Adrenal Mass
	Angina Unstable
	Antinuclear Antibody Positive
	Aortic Valve Incompetence
	Asthenia
	Back Pain
	Bacteriuria
	Blood Pressure Increased
	Bronchitis Acute
	Cardiac Failure Congestive
	Cataract
	Cerebral Ischaemia
	Chest X-Ray Abnormal
	Conjunctivitis
	Coronary Artery Atherosclerosis
	Coronary Artery Disease

Coronary Artery Stenosis
Culture Urine Positive
Cystitis
Depression
Dermatitis
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinal Oedema
Diabetic Retinopathy
Drug Intolerance
Dyspnoea
Electrocardiogram Poor
R-Wave Progression
Escherichia Infection
Escherichia Urinary Tract
Infection
Exercise Tolerance
Decreased
Fall
Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Headache
Hearing Impaired
Hypertension
Hypoglycaemia
Injury
Joint Swelling
Lacunar Infarction
Lipids Increased
Lung Neoplasm
Maculopathy
Mass
Metabolic Alkalosis
Metastases To Lung
Mitral Valve Incompetence
Nervousness
Nocturia
Pleural Effusion
Proteinuria
Pulmonary Hypertension
Radius Fracture
Rash Pruritic
Rectal Haemorrhage
Renal Cyst
Renal Failure Chronic

Respiratory Failure
Road Traffic Accident
Scoliosis
Seasonal Allergy
Sinusitis
Skin Lesion
Spinal Column Stenosis
Spinal Osteoarthritis
Stasis Dermatitis
Stress
Tension
Tricuspid Valve
Incompetence
Vaginal Infection

		Ventricular Extrasystoles Ventricular Hypertrophy Ventricular Hypokinesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased Wrist Fracture	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Hydrodiuril	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Dyrenium	C		
UNKNOWN							
				Insulin, Biphasic Isophane [Injection]	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Alupent	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							

Date:06/14/04ISR Number: 4376981-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Agoraphobia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Angina Pectoris		Atenolol	C		
Disability	Anxiety		Soma	C		
UNKNOWN						
	Anxiety Disorder					
	Arthralgia					
	Catheter Site Pain					
	Chronic Fatigue Syndrome					
	Depression					
	Diastolic Dysfunction					
	Disturbance In Attention					
	Dyspnoea					
	Gout					
	High Density Lipoprotein Decreased					
	Hypertension					
	Hypoaesthesia					
	Hypokinesia					
	Injury					
	Insomnia					
	Joint Swelling					
	Lymphadenopathy					
	Myocardial Infarction					
	Pain In Extremity					
	Panic Disorder					
	Personality Disorder					
	Puncture Site Reaction					
	Rectal Haemorrhage					
	Skin Nodule					
	Social Phobia					
	Ventricular Dysfunction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/04ISR Number: 4376984-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00839
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cellulitis		[Therapy Unspecified]	C				
Disability	Depression							
UNKNOWN								
Other	Embolic Stroke		Allopurinol	C				
UNKNOWN								
	Erythema		Adalat	C				
UNKNOWN								
	Feeling Hot		Accupril	C				
UNKNOWN								
	Gout							
	Hypertension							
	Hypertrophic Cardiomyopathy							
	Insomnia							
	Joint Effusion							
	Localised Infection							
	Low Density Lipoprotein Increased							
	Nasal Polyps							
	Nasal Septum Deviation							
	Neurodermatitis							
	Oedema Peripheral							
	Pain In Extremity							
	Proteinuria							
	Rhinitis Allergic							
	Sleep Apnoea Syndrome							
	Thermal Burn							
	Urinary Tract Infection							
	Ventricular Hypertrophy							
	Vitamin B12 Deficiency							

Date:06/14/04ISR Number: 4376985-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
261 DAY								

Disability	Contusion	Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY					
Other	Emotional Distress	Vioxx	SS	Merck & Co., Inc	ORAL
	Gastric Ulcer	Tylenol	C		
UNKNOWN					
	Gastritis	Combivent	C		
RESPIRATORY					
	Gastrointestinal				
(INHALATION)					
	Haemorrhage	Allopurinol	C		
UNKNOWN					
	Osteoarthritis	Celebrex	C		
UNKNOWN					
	Patella Fracture	Estradiol	C		
UNKNOWN					
	Patellofemoral Pain	Vitamin E	C		
UNKNOWN					
	Syndrome	Diovan	C		
UNKNOWN					
	Pyrexia	Ultram	C		
UNKNOWN					
	Therapeutic Response	Bactrim Ds Tablets	C		
UNKNOWN					
	Decreased	Glucosamine	C		
UNKNOWN					
	Wound Infection	Avalide	C		
UNKNOWN					
		Atrovent	C		
UNKNOWN					
		Claritin	C		
UNKNOWN					
		Niferex	C		
UNKNOWN					
		Potassium (Unspecified)	C		
UNKNOWN					
		Pyridoxine	C		
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/04ISR Number: 4376987-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02525
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS		ORAL		
	Arthritis		Tylenol	C				
	Bone Neoplasm Malignant		Ambien	C				
	Breast Cancer		Tamoxifen Citrate	C				
	Cervix Carcinoma		Phenergan (Promethazine Hydrochloride)	C				
	Constipation							
	Coronary Artery Disease							
	Dizziness							
	Hypercholesterolaemia							
	Hypertension							
	Lymphoedema							
	Myocardial Infarction							
	Oedema Peripheral							
	Panic Attack							

Date:06/14/04ISR Number: 4376988-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02523
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Disease		Toprol Xl Tablets	C				
	Depression							
	Fear							
	Myocardial Infarction							

Date:06/14/04ISR Number: 4376989-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02383
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Disorder		Vioxx	SS		ORAL
	Cardiac Failure		Aspirin	C		
UNKNOWN						
	Congestive					
	Cardiac Murmur					
	Cardiac Valve Disease					
	Cardiomegaly					
	Carotid Artery Stenosis					
	Chest Discomfort					
	Convulsion					
	Coronary Artery Disease					
	Emotional Distress					
	Myocardial Infarction					
	Overdose					

Date:06/14/04ISR Number: 4376990-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aphasia
	Arthralgia
Disability	Asthenia
	Balance Disorder

		Blindness Unilateral					
		Blood Pressure Diastolic Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Systolic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
710	DAY						
		Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
710	DAY						
		Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebral Artery Occlusion		Aspirin	C		
UNKNOWN							
		Cerebral Haemorrhage					
		Cerebral Infarction					
		Disorientation					
		Dysarthria					
		Dysgraphia					
		Dyspepsia					
		Eating Disorder					
		Embolism					
		Excoriation					
		Feeling Abnormal					
		Gastrooesophageal Reflux Disease					
		Haemorrhage					
		Haemorrhagic Stroke					
		Headache					
		Hemianopia					
		Hyperlipidaemia					
		Localised Infection					
		Musculoskeletal Stiffness					
		Myalgia					
		Nasal Congestion					
		Petechiae					
		Pruritus					
		Rash Erythematous					
		Rhinitis Allergic					
		Sinus Congestion					
		Skin Laceration					
		Speech Disorder					
		Temperature Intolerance					
		Visual Field Defect					

Date:06/14/04ISR Number: 4376991-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Pain
	Abdominal Pain Upper
	Arrhythmia
	Cardiac Failure
	Cardiac Failure
	Congestive
	Chest Pain
	Congestive Cardiomyopathy
	Depression
	Diastolic Dysfunction
	Extrasystoles
	Fatigue
	Generalised Anxiety
	Disorder
	Haematochezia
	Hypertension
	Injury

		Mitral Valve Incompetence					
		Nocturia					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Papillary Muscle Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Stress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Tachycardia					
		Tricuspid Valve					
		Incompetence					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					

Date:06/14/04ISR Number: 4376992-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00646
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Eyelid Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Oedema Peripheral	Professional				
		Pruritus					
		Rash					
		Weight Increased					

Date:06/14/04ISR Number: 4376994-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Unstable
Other	Azotaemia
	Beta Haemolytic
	Streptococcal Infection
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure
	Congestive
	Carotid Artery Stenosis
	Catheter Sepsis
	Central Line Infection
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Chest Pain

Cholecystitis Acute
Cholelithiasis
Chronic Obstructive
Pulmonary Disease
Coronary Artery
Restenosis
Depressed Level Of
Consciousness
Dilatation Atrial
Dilatation Ventricular
Dressler'S Syndrome
Dysphagia
Faecal Occult Blood
Positive
Fungal Rash
Gastritis
Gastrointestinal
Haemorrhage
Hyperbilirubinaemia

		Hyperlipidaemia Hypertension Leukocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lipase Increased	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Mitral Valve Incompetence	Professional	Allopurinol	C		
UNKNOWN							
		Myocardial Infarction		Aspirin	C		
UNKNOWN							
		Myocardial Ischaemia		Aricept	C		
UNKNOWN							
		Oral Intake Reduced		Glucotrol	C		
UNKNOWN							
		Peptic Ulcer Peripheral Vascular Disorder Pleural Fibrosis Postoperative Fever Pyrexia Respiratory Failure Skin Candida Staphylococcal Infection Subclavian Artery Stenosis Tricuspid Valve Incompetence Ventricular Hypokinesia					

Date:06/14/04ISR Number: 4376996-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02158
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Aspiration	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Foreign Body Aspiration Gastrooesophageal Reflux Disease Lung Injury Medication Error Vomiting	Professional				

Date:06/14/04ISR Number: 4376997-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	284 DAY	
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	284 DAY	
	Depression		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Gastrooesophageal Reflux Disease		Albuterol	C			UNKNOWN	
	Myocardial Infarction		Augmentin	C			UNKNOWN	
	Pain		Vantin	C			UNKNOWN	
	Panic Attack		Cephalexin	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	
			Cyanocobalamin	C			UNKNOWN	
			Estradiol	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Flonase	C			UNKNOWN	
			Tequin	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Meclizine	C			UNKNOWN	
			Methylprednisolone	C			UNKNOWN	
			Remeron	C			UNKNOWN	

			Serzone	C		
UNKNOWN						
			Verapamil Msd Lp	C		
UNKNOWN						
			Sulfamethoxazole And Trimethoprim	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						
			Prometrium	C		
UNKNOWN						
			Promethazine	C		
UNKNOWN						
			Aciphex	C		
UNKNOWN						

Date:06/14/04ISR Number: 4376998-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02535
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 67 DAY	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage	Professional	Excedrin			
	Nausea		(Acetaminophen (+)			
	Stress		Aspirin (+)			
	Vomiting		Caffeine)	C		
UNKNOWN						
			Midrin	C		
UNKNOWN						
			Ascorbic Acid	C		
UNKNOWN						
			Grape Seeds	C		
UNKNOWN						
			Linseed Oil	C		
UNKNOWN						

Date:06/14/04ISR Number: 4376999-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02531
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amaurosis Fugax
Initial or Prolonged	Anxiety

Disability	Atrial Fibrillation
	Back Pain
	Bone Pain
	Burning Sensation
	Cerebrovascular Accident
	Chest Pain
	Coagulopathy
	Contusion
	Coronary Artery Disease
	Diarrhoea
	Diverticulum
	Dyspnoea
	Epistaxis
	Haemoptysis
	Haemorrhage
	Headache
	Hypercholesterolaemia
	Hyperchromic Anaemia
	Hyperlipidaemia
	Hypertension
	Irritable Bowel Syndrome
	Joint Sprain
	Mitral Valve Incompetence
	Mitral Valve Prolapse
	Myofascitis
	Nausea
	Occult Blood Positive
	Pain
	Palpitations
	Phlebitis

		Polyp Colorectal					
		Radicular Pain					
		Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Stress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Supraventricular	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Tachycardia		Prempro	C		
UNKNOWN							
		Thalassaemia		Synthroid	C		
UNKNOWN							
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Ventricular Tachycardia					
		Vomiting					

Date:06/14/04ISR Number: 4377003-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02536
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Darvocet-N	C		
UNKNOWN							
		Depression		Avalide	C		
UNKNOWN							
		Drug Hypersensitivity		Zestril	C		
UNKNOWN							
		Gastrooesophageal Reflux					
		Disease					
		Gout					
		High Density Lipoprotein					
		Decreased					
		Hypertension					
		Low Density Lipoprotein					
		Increased					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Nephrolithiasis					
		Renal Function Test					
		Abnormal					

Date:06/14/04ISR Number: 4377077-5Report Type:Expedited (15-DaCompany Report #US-MERCK-00091403
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Abnormal Faeces
	Adverse Event
	Alopecia
	Aphthous Stomatitis
	Bone Cyst
	Bronchitis Acute
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Constipation
	Contusion
	Depression
	Diverticulitis
	Emotional Distress
	Feeling Abnormal

		Feeling Cold					
		Fibrocystic Breast Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gingival Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL
392	DAY						
		Head Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Hot Flush		Tylenol	C		
UNKNOWN							
		Hypercoagulation		Fioricet Tablets	C		
UNKNOWN							
		Hyperkeratosis		Fioricet Tablets	C		
UNKNOWN							
		Hypersensitivity		Aspirin	C		
UNKNOWN							
		Insomnia		Zithromax	C		
UNKNOWN							
		Migraine		Ambien	C		
UNKNOWN							
		Nail Ridging		Cimicifuga	C		
UNKNOWN							
		Nausea		Prempro	C		
UNKNOWN							
		Neuropathy Peripheral		Advil	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Motrin	C		
UNKNOWN							
		Oedema		Naproxen	C		
UNKNOWN							
	84	DAY					
		Pain					
		Rash					
		Rhinitis Allergic					
		Systolic Hypertension					
		Tooth Abscess					
		Transient Ischaemic Attack					
		Urticaria					
		Weight Increased					

Date:06/14/04ISR Number: 4377080-5Report Type:Expedited (15-DaCompany Report #GR-MERCK-0404GRC00010
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Abortion Induced	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
	Drug Exposure During		Omeprazole	C		ORAL	7 DAY
	Pregnancy		Roxithromycin	C		ORAL	7 DAY
	No Adverse Effect						

Date:06/14/04ISR Number: 4377081-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
Initial or Prolonged	Coronary Artery	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY	
Disability	Atherosclerosis		Xanax	C			UNKNOWN	
	Haematoma		Aspirin	C			UNKNOWN	
	Major Depression		Lipitor	C			UNKNOWN	
	Myocardial Infarction		Wellbutrin	C			UNKNOWN	
	Panic Disorder		Celebrex	C			UNKNOWN	4 DAY
			Plavix	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Pyridoxine	C			UNKNOWN	

Date:06/14/04ISR Number: 4377082-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00033
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Duodenitis

Gastritis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL		DAY
Professional	Aspirin Lysine	SS		ORAL		
	Fluindione	SS		ORAL		2108 DAY
	Amoxicillin	C		ORAL	6 DAY	
	Glyburide	C		ORAL		
	Enoxaparin Sodium	C		SUBCUTANEOUS	30 DAY	

Date:06/14/04ISR Number: 4377083-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Balance Disorder
Other	Band Neutrophil Percentage Increased
	Catheter Related Infection
	Catheter Site Infection
	Cerebellar Ataxia
	Cerebral Atrophy
	Chest Wall Abscess
	Csf Lymphocyte Count Increased
	Csf White Blood Cell Count Increased
	Difficulty In Walking
	Diplopia
	Dysarthria
	Emotional Distress
	Encephalitis Brain Stem
	Excoriation
	Fall
	Gait Disturbance
	Haematocrit Decreased
	Herpes Ophthalmic
	Herpes Zoster

Hodgkin'S Disease Nodular
Sclerosis Stage
Unspecified
Hodgkin'S Disease Stage I
Hypoaesthesia
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Lacunar Infarction
Loss Of Employment
Lymphocyte Percentage
Decreased
Meningitis
Meningitis Aseptic
Meningitis Herpes
Meningitis Viral
Nasal Cyst
Non-Hodgkin'S Lymphoma
Paraesthesia

	Polytraumatism						
	Pruritus						
	Pyrexia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Staphylococcal Abscess	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Staphylococcal Sepsis	Professional					
	Vertigo						
	Vestibulitis						
	Vision Blurred						
	Vomiting						

Date:06/14/04ISR Number: 4377329-9Report Type:Direct Company Report #CTU 220667
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastrointestinal		Vioxx	PS		ORAL	ORAL
Hospitalization -	Haemorrhage		Advil	SS		ORAL	ORAL
Initial or Prolonged			Vicodin	C			

Date:06/14/04ISR Number: 4377797-2Report Type:Direct Company Report #CTU 220687
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dysgeusia		Vioxx	PS		ORAL	25 MG PO
Initial or Prolonged	Fatigue						DAILY SEVERAL
Other	Malaise						YEARS
	Metabolic Acidosis		Aciphex	C			
	Renal Failure Acute		Actonel	C			
			Ditopan Xl	C			

Date:06/14/04ISR Number: 4377798-4Report Type:Direct Company Report #CTU 220684
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS		ORAL	25 MG PO DAILY OUTPT	
Other			Asa	SS		ORAL	81 MG PO DAILY OUTPT	

Date:06/14/04ISR Number: 4377799-6Report Type:Direct Company Report #CTU 220682
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS			2 TABS DAILY OUTPATIENT	
Other			Excedrin Pm	C				
			Suboxone	C				
			Medrol Dosepack	C				

Date:06/14/04ISR Number: 4379403-XReport Type:Expedited (15-DaCompany Report #8157
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign Health Professional Other	Methotrexate	PS				
			Premarin	SS				
			Augmentin	SS				
			Co-Dydramol	SS				

			Fluoxetine	SS
			Humira	SS
			Rofecoxib	SS

Date:06/14/04ISR Number: 4380995-5Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Haematemesis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/BID	
	Haemoglobin Decreased		Aspirin	SS		ORAL	75 MG/UNK	
	Myocardial Infarction		Blinded Therapy	C				
			Diltiazem Hydrochloride	C				

Date:06/15/04ISR Number: 4377517-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		71 DAY
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		33 DAY
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		33 DAY
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		71 DAY
	Back Pain		[Therapy Unspecified]	C				UNKNOWN
	Balance Disorder							
	Blood Pressure Decreased		Elavil	C				UNKNOWN
	Bronchitis		Atenolol	C				UNKNOWN
	Bursitis		Trazodone Hydrochloride	C				UNKNOWN
	Cardiomegaly							
	Chest Pain		Atenolol	C				UNKNOWN

	Chest Wall Pain	Lonox	C
UNKNOWN			
	Constipation	Dyazide	C
UNKNOWN			
	Coordination Abnormal	Hydrocortisone	C
UNKNOWN			
	Diabetes Mellitus	Zestril	C
UNKNOWN			
	Diastolic Dysfunction	Paxil	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	Haemodialysis		
	Haemorrhage		
	Insomnia		
	Metabolic Syndrome		
	Nephritis		
	Panic Attack		
	Pericardial Effusion		
	Septic Shock		
	Sinusitis		
	Tendonitis		
	Therapeutic Agent		
	Toxicity		
	Ventricular Hypertrophy		

Date:06/15/04ISR Number: 4377533-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Back Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Iron Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
Increased		Vioxx	SS	Merck & Co., Inc	ORAL	DAY	
Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL	DAY	
Chronic Fatigue Syndrome		[Composition					
Constipation		Unspecified]	C			UNKNOWN	
Convulsion		Baycol	C			UNKNOWN	
Costochondritis		Actos	C			UNKNOWN	
Depression							
Diabetes Mellitus							
Inadequate Control							
Dizziness							
Drug Hypersensitivity							
Drug Ineffective							
Emotional Distress							
Fatigue							
General Physical Health							
Deterioration							
Hypertension							
Macular Oedema							
Myalgia							
Neuritis							
Neuropathy Peripheral							
Oedema Peripheral							
Pain							
Peripheral Vascular							
Disorder							
Restless Legs Syndrome							
Retinopathy							
Road Traffic Accident							
Tachycardia							

Date:06/15/04ISR Number: 4377535-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		319 DAY
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		319 DAY
Disability	Cyst		Xanax	C				UNKNOWN
Other	Diabetes Mellitus		Valium	C				UNKNOWN
	Drug Ineffective		Diovan	C				UNKNOWN
	Hypertension		Ibuprofen	C				UNKNOWN
	Lung Disorder		Humulin N	C				UNKNOWN
	Myocardial Infarction		Synthroid	C				UNKNOWN
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Osteoarthritis							

Date:06/15/04ISR Number: 4377538-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:54 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Blindness		Vioxx	SS	Merck & Co., Inc	ORAL		
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Catheter Site Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
		Cholecystitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Duodenal Scarring		Vioxx	SS	Merck & Co., Inc	ORAL		
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Gastritis		Zoloft	C			UNKNOWN	
		Gastrooesophageal Reflux		Sulfasalazine	C			UNKNOWN	
		Disease		Trazodone Hydrochloride	C			UNKNOWN	
		Haematuria							
		Herpes Simplex		[Therapy Unspecified]	C			UNKNOWN	
		Hiatus Hernia							
		Hypermetropia		Aspirin	C			UNKNOWN	
		Hyperreflexia		Wellbutrin	C			UNKNOWN	
		Hypersensitivity		Codeine	C			UNKNOWN	
		Inguinal Hernia		Flexeril	C			UNKNOWN	
		Irritable Bowel Syndrome		Lovastatin	C			UNKNOWN	
		Joint Contracture		Naproxen	C			UNKNOWN	
		Mental Disorder							
		Morton'S Neuroma							
		Muscle Contractions Involuntary							
		Myocardial Infarction							
		Nasopharyngitis							
		Nausea							

Neck Pain
Nephrolithiasis
Overdose
Polycythaemia
Presbyopia
Road Traffic Accident
Skin Discolouration
Skin Laceration
Tympanic Membrane
Perforation
Upper Respiratory Tract
Infection
Vertigo Positional
Vision Blurred
Vitreous Floaters
Vomiting
Whiplash Injury
Wound Infection

Date:06/15/04ISR Number: 4377549-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Epistaxis							
	Fear							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/04ISR Number: 4377551-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:06/15/04ISR Number: 4377557-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01433
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		157 DAY
Initial or Prolonged	Arteriospasm Coronary	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		157 DAY
Disability	Atrial Fibrillation		Tamoxifen Citrate	C				UNKNOWN
	Back Pain		Vitamins					
	Bronchial Irritation		(Unspecified)	C				UNKNOWN
	Cardiac Failure		Hyzaar	C		ORAL		
	Congestive		Klor-Con	C				UNKNOWN
	Cardioactive Drug Level Increased							
	Cholelithiasis							
	Colitis							
	Gastric Disorder							
	Gastroenteritis Viral							
	Glaucoma							
	Hepatic Steatosis							
	Hepatomegaly							
	Hormone Level Abnormal							
	Myocardial Infarction							
	Nephrolithiasis							
	Oedema Peripheral							
	Oesophageal Spasm							
	Otitis Media Acute							
	Overdose							
	Pain In Extremity							
	Palpitations							
	Pharyngitis							

Prinzmetal Angina
Road Traffic Accident
Seasonal Allergy
Stress
Temporomandibular Joint
Syndrome
Venous Insufficiency

Date:06/15/04ISR Number: 4377676-0Report Type:Expedited (15-DaCompany Report #AU-ROCHE-370523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Behaviour	Consumer	Rivotril	PS	Roche		UNKNOWN	
	Delirium		Aspirin	SS	Roche		UNKNOWN	
	Hyponatraemia		Vioxx	SS		ORAL	32 DAY	
	Melaena		Moduretic	SS		ORAL		
	Peptic Ulcer		Epilim	C				
			Flucloxacillin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/04ISR Number: 4377756-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02292
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		217 DAY
Hospitalization -	Acute Myocardial		Vicodin Tablets	C				UNKNOWN
Initial or Prolonged	Infarction		Fosamax	C				UNKNOWN
	Arteriosclerosis		Aspirin	C				UNKNOWN
	Aspiration		Buspar	C				UNKNOWN
	Bronchopneumonia		Vitamin E	C				UNKNOWN
	Cardiac Failure Congestive		Vitamins (Unspecified)	C				UNKNOWN
	Cardiogenic Shock		Calcium (Unspecified) And Vitamin D (Unspecified)	C				UNKNOWN
	Cardiomegaly							
	Cerebrovascular Accident							
	Dementia Alzheimer'S Type							
	Electrocardiogram St		Docusate Sodium	C				UNKNOWN
	Segment Elevation		Prevacid	C				UNKNOWN
	Fall		Zyprexa	C				UNKNOWN
	Heart Rate Increased							
	Hypotension							
	Lacunar Infarction							
	Pneumonia Aspiration							
	Respiratory Rate Increased							
	Sepsis							
	Tachycardia							

Date:06/15/04ISR Number: 4377759-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0406BRA00007
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Skin Inflammation		Vioxx	PS	Merck & Co., Inc
UNKNOWN					
Initial or Prolonged					

Date:06/15/04ISR Number: 4377760-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00862
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Pulmonary Oedema		Lanoxin	C		ORAL
	Ventricular Dysfunction		Neurontin	C		
UNKNOWN						
			Coumadin	C		
UNKNOWN						
			Metoprolol	C		ORAL
			Prednisone	C		ORAL

Date:06/15/04ISR Number: 4378026-6Report Type:Direct Company Report #CTU 22074
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Aggression
Initial or Prolonged	Confusional State
	Deep Vein Thrombosis
	Dehydration
	Delirium
	Hypernatraemia
	Hypotension
	Hypoxia

Mental Status Changes
Neutropenia
Psychotic Disorder
Pyrexia
Renal Failure Acute

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cisplatin	PS		INTRAVENOUS	38 MG	96 HRS
	5 Fu	SS		INTRAVENOUS	1920 MG	96 HRS IV
	Iressa	SS		ORAL	250 MG DAILY	PO
	Vioxx	SS		ORAL	25 MG DAILY	PO
	Hctz	SS		ORAL	25 MG DAILY	PO
	Norvasc	SS		ORAL	10 MG DAILY	PO
	Toprol Xl	SS		ORAL	50 MG DAILY	PO

Date:06/15/04ISR Number: 4382013-1Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Health Professional	Premarin (Conjugated Estrogens, Unspec,0)	PS				
			Augmentin (Amoxicillin Sodium/ Clavulante Potassium, Injectio, 0)	SS				

			Co-Dydramol (Dihydrocodeine Bitartrate/ Paracetamol, , 0)	SS		
			Fluoxetine (Fluoxetine, , 0)	SS		
			Humira (Adalimumab, , 0)	SS		
			Methotrexate (Methotrexate, Unspec, 0)	SS		
			Rofecoxib (Rofecoxib, , 0)	SS		

Date:06/15/04ISR Number: 4382052-0Report Type:Expedited (15-DaCompany Report #A0508127A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective Oedema Peripheral Pulmonary Oedema Weight Increased	Consumer	Commit Nicotine Polacrilex Lozenge, 4mg Lozenge 4 Mg (Nicotine Polacrilex)	PS		
4 MG AS REQUIRED TRANSBUCCAL						
			Rofecoxib (Formulation Unknown) (Rofecoxib)	SS		ORAL
ORAL						
			Hydralazine (Formulation			

Unknown)		
(Hydralazine)	SS	ORAL
ORAL		
Verapamil	C	
Fluticasone-Salmeter ol	C	
Salbutamol Sulphate	C	
Warfarin Sodium	C	

Date:06/16/04ISR Number: 4378397-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Amnesia
Other	Apathy
	Asthenia
	Autonomic Nervous System Imbalance
	Balance Disorder
	Blood Bilirubin Increased
	Blood Bilirubin Unconjugated Increased
	Blood Pressure Fluctuation
	Blood Pressure Increased
	Blood Pressure Systolic Increased
	Bradycardia
	Buttock Pain
	Calcinosis
	Cerebellar Haemorrhage
	Cerebellar Infarction
	Cerebellar Syndrome
	Chronic Obstructive Pulmonary Disease
	Citrobacter Infection
	Constipation
	Decreased Appetite
	Dehydration
	Dementia
	Depressed Level Of Consciousness
	Depression
	Diverticulum
	Diverticulum Intestinal

Dizziness
Dysphagia
Dyspnoea
Early Satiety
Enterobacter Infection
Facet Joint Syndrome
Fall
Fatigue
Feeling Cold
Femur Fracture
Gastritis
Haemorrhagic Stroke
Hiatus Hernia
Hip Fracture
Hyperglycaemia
Hyponatraemia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Inappropriate Antidiuretic Hormone Secretion					
19	DAY	Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY	Interstitial Lung Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Lipoma		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Lumbar Spinal Stenosis		Valium	C		
UNKNOWN		Lung Infiltration		Neurontin	C		
UNKNOWN		Lung Neoplasm		Neurontin	C		
UNKNOWN		Malaise		Neurontin	C		
UNKNOWN		Muscle Strain		Neurontin	C		
UNKNOWN		Nausea		Avapro	C		
UNKNOWN		Neuropathy		Misoprostol	C		
UNKNOWN		Otitis Media		Macrodantin	C		
UNKNOWN		Pain		Nortriptyline	C		
UNKNOWN		Pelvic Pain		Nortriptyline	C		
UNKNOWN		Pneumonia					
		Pollakiuria					
		Proctitis					
		Prostatitis					
		Pseudomonas Infection					
		Pyelonephritis					
		Pyrexia					
		Rectal Cramps					
		Scoliosis					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Spinal Osteoarthritis					
		Staphylococcal Infection					
		Urethral Stricture					
		Urinary Tract Infection					
		Urinary Tract Infection Bacterial					
		Urinary Tract Infection					

Pseudomonal
Urinary Tract Obstruction
White Blood Cell Count
Increased

Date:06/16/04ISR Number: 4378398-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01845
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	22	MON
	Gastritis							

Date:06/16/04ISR Number: 4378399-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02043
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Hydralazine	SS			UNKNOWN	
	Pulmonary Oedema		Nicotine Polacrilex	SS				
	Weight Increased		Albuterol Sulfate	C			UNKNOWN	
			Advair	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Coumadin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/04ISR Number: 4378400-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Dilatation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Murmur		Betaxolol Ophthalmic Solution	C			UNKNOWN	
	Cerebral Atherosclerosis		Calcitonin	C			UNKNOWN	
	Cerebrovascular Accident		Digoxin	C			UNKNOWN	
	Dilatation Atrial		Docusate Sodium	C			UNKNOWN	
	Dilatation Ventricular		Trusopt	C			OPHTHALMIC	
	Epistaxis		Vitamin E	C			UNKNOWN	
	Haematemesis		Warfarin	C			UNKNOWN	1284 DAY
	Hypertension		Zocor	C			UNKNOWN	
	Injury		Folic Acid	C			UNKNOWN	
	Lacunar Infarction		Lasix (Furosemide)	C			UNKNOWN	1680 DAY
	Muscle Spasms		Isosorbide	C			UNKNOWN	
	Myalgia		Potassium (Unspecified)	C			UNKNOWN	
	Pleural Fibrosis		Psyllium Husk	C			UNKNOWN	
	Productive Cough							
	Prothrombin Time							
	Prolonged Tracheal Deviation							
	Transient Ischaemic Attack							

Date:06/16/04ISR Number: 4378887-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspnoea		Albuterol	C		
UNKNOWN						
Other	Gastric Disorder		Combivent	C		
UNKNOWN						
	Gout		Atenolol	C		
UNKNOWN						
	Haematochezia		Wellbutrin	C		
UNKNOWN						
	Intestinal Haemorrhage		Celebrex	C		
UNKNOWN						
	Intestinal Obstruction		Advair	C		
UNKNOWN						
	Lung Disorder		Furosemide	C		
UNKNOWN						
	Pulmonary Embolism		Diazide	C		
UNKNOWN						
	Rectal Haemorrhage		Lithium Sulfate	C		
UNKNOWN						
	Rheumatoid Arthritis		Sandostatin	C		
UNKNOWN						
	Sleep Apnoea Syndrome		Protonix	C		
UNKNOWN						
	Swelling		Prednisone	C		
UNKNOWN						
	Systemic Lupus		Prochlorperazine	C		
UNKNOWN						
	Erythematosus		Aciphex	C		
UNKNOWN						
	Ulcer					

Date:06/16/04ISR Number: 4378888-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00038
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Erysipelas		Furosemide	SS		ORAL
	Hyperphosphataemia		Gentamicin	SS		
INTRAVENOUS						
	Hyponatraemia		Lisinopril	SS		ORAL
	Renal Failure Acute		Amiodarone	C		ORAL
	Sepsis		Lansoprazole	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/04ISR Number: 4378892-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Chest Pain		[Therapy Unspecified]	C				UNKNOWN
	Congestive Cardiomyopathy		Tenormin	C				UNKNOWN
	Coronary Artery Disease		Tenormin	C				UNKNOWN
	Coronary Artery		Lanoxin	C				UNKNOWN 1051 DAY
	Restenosis		Glyburide	C				UNKNOWN
	Depression		Zestril	C				UNKNOWN 2170 DAY
	Drug Ineffective		Zestril	C				UNKNOWN 2170 DAY
	Hepatitis		Metformin	C				UNKNOWN
	Herpes Zoster							
	Intervertebral Disc Disorder							
	Lipids Increased							
	Sepsis							
	Sexual Dysfunction							

Date:06/16/04ISR Number: 4378899-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - UNKNOWN	Anaemia	Vioxx	PS	Merck & Co., Inc
Initial or Prolonged UNKNOWN	Angina Unstable	Allopurinol	C	
Other UNKNOWN	Azotaemia	Aspirin	C	
	Bronchitis	Aricept	C	
UNKNOWN	Cardiac Failure	Glucotrol	C	
UNKNOWN	Congestive			
	Carotid Artery Stenosis			
	Central Line Infection			
	Cerebral Artery Occlusion			
	Chest Pain			
	Chronic Obstructive			
	Pulmonary Disease			
	Coronary Artery			
	Restenosis			
	Dressler'S Syndrome			
	Faecal Occult Blood			
	Positive			
	Gastrointestinal			
	Haemorrhage			
	Hyperbilirubinaemia			
	Hyperlipidaemia			
	Hypertension			
	Myocardial Infarction			
	Peripheral Vascular			
	Disorder			
	Respiratory Failure			
	Skin Candida			
	Subclavian Artery			
	Stenosis			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/04ISR Number: 4379311-4Report Type:Expedited (15-DaCompany Report #200412265FR
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Ph Decreased		Lasilix Faible	PS	Aventis Pharmaceuticals Inc.	ORAL	INTRAVENOUS	
	Dehydration							
	Erysipelas		Gentamicin "Panpharma"	SS				
	Hyperkalaemia							
	Hyperphosphataemia		Vioxx	SS		ORAL		
	Hyponatraemia		Zestril	SS		ORAL		
	Renal Failure Acute		Cordarone	C		ORAL		
	Staphylococcal Sepsis		Ogast	C		ORAL		

Date:06/17/04ISR Number: 4379623-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Balance Disorder		Ms Contin	SS				
Other	Complex Partial Seizures		Aspirin	C			UNKNOWN	
	Constipation		Vitamins (Unspecified)	C			UNKNOWN	
	Depressed Level Of Consciousness		Tegretol	C			UNKNOWN	
	Depressed Mood		Depakote	C			UNKNOWN	
	Diarrhoea							
	Dizziness							
	Drug Hypersensitivity							
	Drug Ineffective							
	Drug Level Decreased							
	Emotional Distress							
	Fall							
	Fatigue							
	Gingival Hyperplasia							
	Hepatic Enzyme Increased							
	Hepatic Steatosis							
	Hyperlipidaemia							
	Hypernatraemia							

Hypertension
Hypoacusis
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Periarthritis
Psoriasis
Rash
Sepsis
Spinal Osteoarthritis
Synovitis
Tinnitus
Vaginal Infection
Weight Increased
Wrist Fracture

Date:06/17/04ISR Number: 4379626-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03191
Age:51 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Homocysteine		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
	Cataract		Aspirin	C				
	Cerebral Infarction		Aspirin	C				
	Posterior Capsule		Plaquenil	C				
	Opacification		Prednisone	C				
	Pruritus							

Date:06/17/04ISR Number: 4379632-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	733	DAY
Hospitalization - Initial or Prolonged	Infarction	Professional	[Therapy					
	Adverse Event		Unspecified]	C				
	Angina Unstable		Aspirin	C				
	Anxiety		Atenolol	C				
	Aortic Aneurysm		Zocor	C				
	Blood Triglycerides		Celebrex	C				
	Increased		Plavix	C				
	Cardiac Failure		Prinivil	C		ORAL		
	Congestive							
	Cardiac Valve Disease							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Cholelithiasis							
	Depression							
	Diverticulum							

Ejection Fraction
Decreased
Haematuria
Haemorrhage
Hepatic Cyst
High Density Lipoprotein
Decreased
Injury
Low Density Lipoprotein
Increased
Mental Status Changes
Myocardial Infarction
Nephrosclerosis
Renal Mass
Stress
Ventricular Tachycardia

Date:06/17/04ISR Number: 4379646-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Atrial Fibrillation
Other	Blood Cholesterol Increased
	Bradycardia
	Coronary Artery Disease
	Coronary Artery

		Reocclusion					
		Diverticulitis Intestinal Haemorrhagic					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc Degeneration	Professional	Zocor	SS		ORAL
				Percocet	C		
UNKNOWN							
		Myocardial Infarction		Atenolol	C		
UNKNOWN							
		Renal Failure Chronic		Folic Acid	C		
UNKNOWN							
		Respiratory Distress		Ambien	C		
UNKNOWN							
		Thrombosis		Ismo	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Oxycodone Hydrochloride	C		
UNKNOWN							
				Prednisone	C		ORAL

Date:06/17/04ISR Number: 4379648-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00058
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 15 DAY	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased Body Temperature	Professional	Clopidogrel Bisulfate	SS		ORAL
	Increased Diarrhoea		Ginkgo Biloba Extract	SS		ORAL
			Trimetazidine Hydrochloride	SS		ORAL
			Sotalol Hydrochloride	SS		ORAL
			Pravastatin Sodium	SS		ORAL

Date:06/17/04ISR Number: 4379649-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Asthma
	Atrial Fibrillation
	Blood Cholesterol Increased
	Bradycardia
	Bronchospasm
	Cardiac Discomfort
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiac Valve Disease
	Cardiomyopathy
	Death
	Disorientation
	Emotional Distress
	Eye Haemorrhage
	Glaucoma
	Heart Rate Irregular
	Herpes Zoster
	Hypersensitivity
	Hypertension
	Hypoaesthesia

		Hypotension					
		Interstitial Lung Disease					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoporosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Rheumatic Heart Disease					
		Spinal Compression					
		Fracture					
		Tracheal Obstruction					

Date:06/17/04ISR Number: 4380057-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA00267
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
117 DAY							
		Coronary Artery Disease		Pravachol	C		
UNKNOWN							
		Feeling Abnormal		Pravachol	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:06/17/04ISR Number: 4380058-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01988
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aspergillosis					
Initial or Prolonged		Blood Glucose Increased					
Other		Carotid Artery Disease					
		Cerebral Artery Occlusion					
		Chronic Obstructive					
		Pulmonary Disease					
		Death					
		Dyspnoea					
		Hypotension					
		Hypoxia					
		Injury Corneal					
		Mental Status Changes					

Metastases To Liver
Metastases To Lymph Nodes
Pneumonia
Pneumonia Bacterial
Pneumonia Staphylococcal
Polytraumatism
Spinal Compression
Fracture
Weight Decreased

Date:06/17/04ISR Number: 4380059-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adrenal Insufficiency
	Angina Unstable
	Anxiety
	Asthenia
	Bronchitis
	Cardiomegaly
	Catheter Site Haemorrhage
	Cellulitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Contusion					
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Costochondritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Aspirin	C		
UNKNOWN							
		Drug Ineffective		Celebrex	C		
UNKNOWN							
		Drug Withdrawal Syndrome		Sudal	C		
UNKNOWN							
		Dysphagia		Ultram	C		
UNKNOWN							
		Dyspnoea		Levaquin	C		
UNKNOWN							
		Electrocardiogram T Wave		Synthroid	C		
UNKNOWN							
		Inversion		Zantac	C		
UNKNOWN							
		Gastrooesophageal Reflux Disease					
		Haemarthrosis					
		Haematoma					
		Hyperparathyroidism					
		Hypothyroidism					
		Increased Tendency To Bruise					
		Intestinal Functional Disorder					
		Joint Swelling					
		Libido Decreased					
		Muscle Spasms					
		Musculoskeletal Chest Pain					
		Myocardial Infarction					
		Neuralgia					
		Oedema					
		Pain					
		Panic Attack					
		Pneumonia					
		Raynaud'S Phenomenon					
		Spinal Osteoarthritis					
		Weight Increased					

Date:06/17/04ISR Number: 4380067-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Aortic Calcification
	Apathy
	Asthenia
	Balance Disorder
	Blood Cholesterol Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebellar Infarction
	Cerebrovascular Disorder
	Chest Discomfort
	Cholecystitis
	Cognitive Disorder
	Cogwheel Rigidity
	Coordination Abnormal

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Deafness Neurosensory					
		Decreased Interest					
		Dementia					
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
696	DAY						
		Non-Insulin-Dependent		Reglan	SS		
UNKNOWN							
		Diabetic Neuropathy		Celebrex	C		
UNKNOWN							
		Difficulty In Walking		Catapres	C		
UNKNOWN							
		Dizziness		Flonase	C		
UNKNOWN							
		Dystonia		Prilosec	C		
UNKNOWN							
		Fall		Lopid	C		
UNKNOWN							
		Fatigue		Robaxin	C		
UNKNOWN							
		Gait Disturbance					
		Glossitis					
		Haematochezia					
		Headache					
		Hiatus Hernia					
		High Density Lipoprotein Decreased					
		Hyporeflexia					
		Loss Of Consciousness					
		Low Density Lipoprotein Increased					
		Major Depression					
		Memory Impairment					
		Neuropathy Peripheral					
		Orthostatic Hypotension					
		Pseudodementia					
		Radiculopathy					
		Sensory Disturbance					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Tongue Discolouration					
		Treatment Noncompliance					
		Tremor					

Date:06/17/04ISR Number: 4380070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02020
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arrhythmia
Other	Supraventricular
	Asthma
	Atrial Fibrillation
	Bladder Cancer Recurrent
	Breast Cancer Male
	Cataract
	Chronic Obstructive
	Pulmonary Disease
	Dehydration
	Diverticulum
	Duodenitis
	Gastric Disorder
	Gastritis Erosive
	Gastrointestinal
	Haemorrhage
	Haemorrhoids
	Hyperglycaemia
	Ileus
	Injury

	Myocardial Infarction						
	Oesophagitis						
	Presbyoesophagus	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infection		Aspirin	C				UNKNOWN
	Small Intestinal							
	Obstruction							

Date:06/17/04ISR Number: 4380075-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cholelithiasis		Elavil	C		ORAL		
	Coronary Artery Disease		Soma	C		ORAL		
	Diverticulum		Soma	C		ORAL		
	Drug Ineffective		Cyanocobalamin	C				INTRAMUSCULAR
	Gastritis Haemorrhagic		Diphenhydramine					
	Hepatitis		Hydrochloride	C		ORAL		
	Mycobacterium Avium		Premarin	C				UNKNOWN
	Complex Infection		Infed	C				INTRAMUSCULAR
	Myocardial Infarction		Robaxin	C		ORAL		
	Nausea		Prilosec	C				UNKNOWN
	Otitis Externa							
	Pruritus							
	Rash Morbilliform							
	Upper Respiratory Tract							
	Infection							
	Urinary Tract Infection							

Date:06/17/04ISR Number: 4380078-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Cerebrovascular Accident		Ceftin	C		
Disability	Cough		Guaifenesin	C		
UNKNOWN						
Other	Dilatation Atrial					
	Emotional Distress					
	Meningioma					
	Myocardial Infarction					
	Retinal Artery Occlusion					

Date:06/17/04ISR Number: 4380080-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02158
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease							
Disability	Lung Injury							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/04ISR Number: 4380081-4Report Type:Expedited (15-DaCompany Report #NL-MERCK-0406NLD00006
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Perforation		Acetaminophen	C		ORAL		
	Vomiting		Furosemide	C		ORAL		
			Hypromellose	C		OPHTHALMIC		
			Nortriptyline Hydrochloride	C		ORAL		

Date:06/17/04ISR Number: 4380082-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00547
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Lipitor	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Cozaar	C		ORAL		

Date:06/17/04ISR Number: 4380083-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01389
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/04ISR Number: 4380085-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00114
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY

Hospitalization - Initial or Prolonged Disability			Aspirin	C		ORAL
			Lipitor	C		ORAL
			Hydrochlorothiazide	C		ORAL
			Avapro	C		ORAL
			Leucovorin Calcium	C		
UNKNOWN						
			Methotrexate	C		
UNKNOWN						
			Toprol Xl Tablets	C		ORAL
			Zantac	C		
UNKNOWN						

Date:06/17/04ISR Number: 4382466-9Report Type:Expedited (15-DaCompany Report #2004GB01333
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Foreign	Omeprazole	PS		ORAL	20 MG DAILY PO	
	Dizziness	Health Professional						
	Tremor		Aricept	SS		ORAL	10 MG DAILY PO	
		Other						
			Aspirin	SS		ORAL	75 MG DAILY PO	
			Bendrofluazide	SS		ORAL	2.5 MG DAILY PO	
			Rofecoxib	SS		ORAL	12.5 MG DAILY PO	
			Dothiepin	C				
			Atorvastatin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/04ISR Number: 4382672-3Report Type:Expedited (15-DaCompany Report #200410399BNE
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive Haematemesis Myocardial Infarction	Foreign Health Professional Other	Aspirin (Acetylsalicylic Acid)	PS		ORAL	75 MG, TOTAL DAILY, ORAL	
			Rofecoxib	SS		ORAL	50 MG, TOTAL DAILY, ORAL	
			Diltiazem	C				

Date:06/17/04ISR Number: 4382704-2Report Type:Expedited (15-DaCompany Report #2003004038
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Adenoma Benign Anxiety Candidiasis Cervical Myelopathy Chromaturia Cough Diplopia Diverticulitis Dry Skin Dysphagia Dysuria Economic Problem Emotional Distress Fall Fibromyalgia Fungal Cystitis Genital Ulceration Herpes Simplex Hydronephrosis Hypertension Hypoglycaemia Hypokalaemia Increased Appetite Inflammation

Insomnia
Irritable Bowel Syndrome
Myositis
Neuralgia
Neuropathy
Oedema
Osteopetrosis
Palpitations
Pruritus
Psychomotor Hyperactivity
Rash
Respiratory Disorder
Rhabdomyolysis
Rhinitis Allergic
Spinal Cord Disorder
Stress Incontinence
Temperature Intolerance
Thirst
Urinary Tract Infection
Weight Increased
White Blood Cell Count

Increased
Xerosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Lipitor (Atorvastatin)	PS			20 MG	
	Quetiapine Fumarate (Quetiapine Fumarate)	SS				
	Rofecoxib (Rofecoxib)	SS				
	Azithromycin (Azithromycin)	C				
	Vicodin (Paracetamol, Hydrocodone Bitartrate)	C				
	Sertraline Hydrochloride (Sertraline Hydrochloride)	C				
	Torasemide (Torasemide)	C				
	Potassium Chloride (Potassium Chloride)	C				
	Salbutamol (Salbutamol)	C				
	Chromagen (Ascorbic Acid, Cyanocobalamin, Ferrous Fumarate, Stomach Desiccated)	C				
	Omeprazole (Omeprazole)	C				
	Estrogens Conjugated (Estrogens Conjugated)	C				
	Buspirone Hydrochloride (Buspirone Hydrochloride)	C				
	Citalopram Hydrobromide (Citalopram Hydrobromide)	C				
	Bupropion					

Hydrochloride (Bupropion Hydrochloride)	C
Clonazepam (Clonazepam)	C
Prednisone (Prednisone)	C
Estratest Hs (Methyltestosterone, Estrogens Esterified)	C
Ranitidine (Ranitidine)	C
Furosemide (Furosemide)	C
Gabapentin	

(Gabapentin)	C
Metaxalone (Metaxalone)	C
Valaciclovir Hydrochloride (Valaciclovir Hydrochloride)	C
Diazepam (Diazepam)	C
Librax (Chlordiazepoxide Hydrochloride, Clidinium Bromide)	C
Pseudoephedrine Hydrochloride (Pseudoephedrine Hydrochloride)	C
Metronidazole (Metronidazole)	C
Dicycloverine (Dicycloverine)	C
Clarithromycin (Clarithromycin)	C
Estrates Hs (Methyltestosterone, Estrogens Esterified)	C
Alprazolam (Alprazolam)	C
Theophylline (Theophylline)	C
Ketoconazole (Ketoconazole)	C
Histex Hc (Pseudoephedrine Hydrochloride, Hydrocodone Bitartrate,	C
Guaifenesin (Guaifenesin)	C
Combivent (Ipratropium Bromide, Salbutamol Sulfate)	C
Lansoprazole (Lansoprazole)	C
Fexofenadine Hydrochloride (Fexofenadine	

Hydrochloride)	C
Orlistat (Orlistat)	C
Arthrotec (Diclofenac Sodium, Misoprostol)	C
Aerobid-M (Flunisolide, Menthol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/04ISR Number: 4380550-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthma		[Therapy Unspecified]	C			UNKNOWN	
	Bronchitis							
	Cardiac Valve Disease		Albuterol	C			UNKNOWN	
	Chest Pain		Proventil	C			RESPIRATORY (INHALATION)	
	Chronic Fatigue Syndrome							
	Chronic Obstructive Pulmonary Disease		Antimicrobial (Unspecified)	C			UNKNOWN	
	Coronary Artery		Amaryl	C			UNKNOWN	
	Atherosclerosis		Glipizide	C			UNKNOWN	
	Coronary Artery Disease		Glucophage	C			UNKNOWN	
	Depression							
	Diarrhoea							
	Dyspnoea							
	Gastrooesophageal Reflux Disease							
	Haematoma							
	Hypercholesterolaemia							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Viral Infection							

Date:06/18/04ISR Number: 4380555-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02055
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	33	DAY

Initial or Prolonged	Angina Unstable	Professional	Acyclovir	C
UNKNOWN				
Other	Aortic Valve Incompetence		Ascorbic Acid	C
UNKNOWN				
	Atrial Fibrillation		Hydrochlorothiazide	
	Chronic Obstructive		And Triamterene	C
UNKNOWN				
	Pulmonary Disease		Vitamin B Complex	C
UNKNOWN				
	Emotional Distress		Vitamin E	C
UNKNOWN				
	Headache		Vitamin D	
	Heart Rate Increased		(Unspecified)	C
UNKNOWN				
	Heart Rate Irregular		Vitamin A	C
UNKNOWN				
	Hypercholesterolaemia		Adalat	C
UNKNOWN				
	Hypertension		Phenazopyridine	
	Hypertensive Crisis		Hydrochloride	C
UNKNOWN				
	Lacunar Infarction			
	Mitral Valve Incompetence			
	Transient Ischaemic			
	Attack			
	Tricuspid Valve			
	Incompetence			

Date:06/18/04ISR Number: 4380558-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia
Disability	Aspergillosis
	Bronchitis

		Cerebrovascular Accident Complicated Migraine Drug Dependence Drug Ineffective Hypercholesterolaemia Hypertriglyceridaemia Hypotension Iris Disorder Major Depression Migraine Migraine With Aura Muscle Spasms Neuritis Night Sweats Nystagmus Oesophageal Spasm Pigmented Naevus Road Traffic Accident Skeletal Injury Skin Hypopigmentation Skin Laceration Syncope Tremor	Report Source Health Professional	Product Vioxx	Role PS	Manufacturer Merck & Co., Inc	Route ORAL
Dose	Duration						

Date:06/18/04ISR Number: 4380559-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:U

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Aneurysm
Other	Angina Unstable
	Anxiety
	Arthropathy
	Benign Prostatic Hyperplasia
	Chest Pain
	Congestive Cardiomyopathy
	Coronary Artery Aneurysm
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Restenosis
	Coronary Artery Stenosis

Depression
Diabetic Nephropathy
Diabetic Neuropathy
Drug Effect Decreased
Drug Ineffective
Faecal Occult Blood
Positive
Hepatitis
Herpes Zoster
Hypotension
Injury
Insomnia
Intervertebral Disc
Disorder
Lipids Increased
Muscle Atrophy

	Myocardial Ischaemia						
	Renal Cyst						
	Renal Mass	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sepsis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Sexual Dysfunction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
			[Therapy Unspecified]	C			UNKNOWN	
			Tenormin	C			UNKNOWN	
			Tenormin	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	1051 DAY
			Glyburide	C			UNKNOWN	
			Zestril	C			UNKNOWN	2170 DAY
			Zestril	C			UNKNOWN	2170 DAY
			Metformin	C			UNKNOWN	

Date:06/18/04ISR Number: 4380562-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01380
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY	
Hospitalization -	Right Ventricular Failure	Professional	Advicor	SS		ORAL	15 DAY	
Initial or Prolonged			Toprol Xl Tablets	C			UNKNOWN	
Disability			Coumadin	C			UNKNOWN	

			Altace	C		
UNKNOWN						

Date:06/18/04ISR Number: 4380564-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1127 DAY						
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1127 DAY						
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
1127 DAY						
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
1127 DAY						
	Arthropathy		Amoxicillin	C		
UNKNOWN						
	Coronary Artery Disease		Plavix	C		
UNKNOWN						
	Coronary Artery Stenosis		Zanaflex	C		
UNKNOWN						
	Depression		Ambien	C		
UNKNOWN						
	Erectile Dysfunction		Trazodone			
	Head Injury		Hydrochloride	C		
UNKNOWN						
	Hypercholesterolaemia		Viagra	C		
UNKNOWN						
	Hypertension		Diazepam	C		
UNKNOWN						
	Laceration		Hydrocodone			
	Peroneal Nerve Palsy		Bitartrate	C		
UNKNOWN						
	Pleuritic Pain		Ibuprofen	C		
UNKNOWN						
			Altace	C		
UNKNOWN						

Date:06/18/04ISR Number: 4380565-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
	Anxiety
	Back Disorder

	Blood Cholesterol Increased						
	Blood Triglycerides Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	237 DAY
	Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	237 DAY
	Coronary Artery		Soma	C			UNKNOWN
	Thrombosis		Flexeril	C		ORAL	
	Hallucination		Doxepin Hydrochloride	C			UNKNOWN
	Hypertension						
	Panic Disorder		Premarin	C			UNKNOWN
	Rheumatoid Arthritis		Ambien	C			UNKNOWN
	Skin Cancer		Prozac	C			UNKNOWN
	Sleep Apnoea Syndrome		Hydrochlorothiazide	C			UNKNOWN
			Hydrocodone Hydrochloride	C			UNKNOWN
			Seroquel	C			UNKNOWN

Date:06/18/04ISR Number: 4380566-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0306FRA00089
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Pancreatitis Necrotising	Health	Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY
Hospitalization - Initial or Prolonged		Professional	[Therapy Unspecified]	C			UNKNOWN 12 DAY

Date:06/18/04ISR Number: 4380568-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00108
Age:69 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
Other	Atherosclerosis
	Bursitis
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Depression
	Diverticulum
	Dizziness
	Drug Intolerance
	Emotional Distress
	Gastrointestinal Haemorrhage
	Glaucoma
	Haemorrhoids
	Hyperglycaemia
	Hypoacusis
	Intervertebral Disc Protrusion
	Intervertebral Disc Space Narrowing
	Kidney Infection
	Lacunar Infarction
	Lobar Pneumonia
	Prostatic Disorder

		Prostatic Specific Antigen Increased					
		Proteinuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Oedema	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Vertigo		Ibuprofen	C		
UNKNOWN							
		Viral Infection		Insulin	C		
UNKNOWN							

Date:06/18/04ISR Number: 4380569-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01109
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Oropharyngeal Swelling	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Other	Rash Macular	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY						
	Swelling Face		Vioxx	SS	Merck & Co., Inc	ORAL
	Swollen Tongue		Vioxx	SS	Merck & Co., Inc	ORAL
			Zyrtec	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						
			Benicar Hct	C		
UNKNOWN						

Date:06/18/04ISR Number: 4380574-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02086
Age:91 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Balance Disorder
	Cardiac Failure
Disability	Cerebral Atherosclerosis
Other	Chronic Obstructive

Pulmonary Disease
Constipation
Death
Decubitus Ulcer
Depression
Dry Skin
Dyspnoea
Fall
Fracture Displacement
Gastrooesophageal Reflux
Disease
Haematochezia
Haematoma
Haemorrhage
Hyperkeratosis
Hypoacusis
Ilium Fracture
Inflammation
Muscle Spasms
Nausea
Pain
Pelvic Fracture
Pulmonary Mass
Respiratory Tract
Infection
Senile Dementia

		Skin Cancer					
		Spinal Compression Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Tinea Pedis	Professional	Morphine	C		
UNKNOWN							
		Vulval Erythema		Miacalcin	C		
UNKNOWN							
		Vulval Oedema		Ultram	C		
UNKNOWN							
		Weight Decreased		Vasotec	C		ORAL
				Ferrous Sulfate	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Vasotec	C		ORAL
				Valium	C		
UNKNOWN							
				Timoptic	C		
OPHTHALMIC							
				Deltasone	C		
UNKNOWN							

Date:06/18/04ISR Number: 4380576-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation	Professional	Premarin	C		
UNKNOWN						
Other	Blood Albumin Decreased		Azmacort	C		
RESPIRATORY						
	Blood Cholesterol					
(INHALATION)						
	Increased		Singulair	C		
UNKNOWN						
	Bronchitis					
	Cardiac Failure					
	Congestive					
	Carotid Artery Stenosis					
	Cerebrovascular Accident					
	Chronic Obstructive					
	Pulmonary Disease					
	Conjunctivitis					

Corneal Disorder
Drug Hypersensitivity
Dyspepsia
Fall
Hiatus Hernia
Mitral Valve Incompetence
Nausea
Oedema Peripheral
Pain
Pneumonia
Skin Laceration
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence

Date:06/18/04ISR Number: 4380577-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
Disability	Angina Pectoris
Other	Carpal Tunnel Syndrome
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Coronary Artery Disease

		Coronary Artery Stenosis					
		Cystitis					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Erectile Dysfunction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Injection Site Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Mediastinitis		Augmentin	C		
UNKNOWN							
		Nausea		Aspirin	C		
UNKNOWN							
		Oedema Peripheral		Zoloft	C		
UNKNOWN							
		Pleural Effusion		Temazepam	C		
UNKNOWN							
		Postoperative Infection		Zocor	C		ORAL
		Postpericardiotomy		Tenormin	C		
UNKNOWN							
		Syndrome		Tenormin	C		
UNKNOWN							
		Spinal Osteoarthritis		Tagamet	C		
UNKNOWN							
		Ulnar Nerve Injury		Plavix	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Relafen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:06/18/04ISR Number: 4380578-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Confusional State
Disability	Connective Tissue Disorder
	Contusion
	Depression
	Diabetes Mellitus

Dizziness
Drug Ineffective
Dysphoria
Faeces Discoloured
Fall
Gastritis
Generalised Anxiety
Disorder
Haemorrhoids
Hypertension
Idiopathic
Thrombocytopenic Purpura
Inflammation
Intestinal Obstruction
Joint Lock
Malaise
Melaena
Nervousness
Pain
Scar
Sjogren'S Syndrome
Stomach Discomfort
Systemic Lupus
Erythematosus
Thrombocytopenia
Tremor
Upper Gastrointestinal

Haemorrhage
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Captopril	C			UNKNOWN	
	Neurontin	C			UNKNOWN	
	Heparin	C			UNKNOWN	
	Zoloft	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Lotensin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Elavil	C		ORAL		
	Vicodin Tablets	C			UNKNOWN	
	Hydro-Chlor	C			UNKNOWN	
	Insulin	C			UNKNOWN	
	Ms Contin	C			UNKNOWN	
	Zantac	C			UNKNOWN	

Date:06/18/04ISR Number: 4380579-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02077
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Depression		Aspirin	C			UNKNOWN	
Disability	Emotional Distress		Valium	C			UNKNOWN	

Other	Guillain-Barre Syndrome	Paxil	C
UNKNOWN			
	Heart Rate Irregular		
	Myocardial Infarction		
	Paralysis		
	Renal Failure		
	Sleep Apnoea Syndrome		

Date:06/18/04ISR Number: 4380580-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Disability	Aortic Valve Incompetence
Other	Arthritis
	Arthropathy
	Candidiasis
	Chronic Lymphocytic
	Leukaemia
	Coronary Artery Disease
	Gastritis
	Gastrointestinal
	Haemorrhage
	Heart Rate Irregular
	Hyperlipidaemia
	Hypertension
	Knee Arthroplasty
	Meniscus Lesion
	Mitral Valve Incompetence
	Mitral Valve Prolapse
	Myocardial Infarction
	Oedema Peripheral

		Osteoarthritis					
		Overdose					
		Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Reflux Oesophagitis	Professional	Voltaren	SS		
UNKNOWN							
		Silent Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Ulcer Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Prempro	C		
UNKNOWN							
		Ventricular Hypertrophy					
		Vomiting					
		Wound Infection					
		Staphylococcal					

Date:06/18/04ISR Number: 4380583-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Burning Sensation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Distress		[Therapy			
	Exostosis		Unspecified]	C		
UNKNOWN	1478 DAY					
	Femoral Arterial Stenosis		Herbs (Unspecified)	C		
UNKNOWN	840 DAY					
	Femoral Artery Occlusion		Prilosec	C		
UNKNOWN						
	Gastrooesophageal Reflux					
	Disease					
	Haemorrhoids					
	Hypertension					
	Joint Sprain					
	Lacunar Infarction					
	Meniscus Lesion					
	Oesophagitis					

Osteoarthritis
Pain In Extremity
Peripheral Vascular
Disorder
Pulse Absent
Rectal Polyp
Synovitis
Transient Ischaemic
Attack
Wernicke'S Encephalopathy

Date:06/18/04ISR Number: 4380584-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma
Disability	Cerebrovascular Accident
Other	Emotional Distress
	Generalised Anxiety Disorder
	Lacunar Infarction

		Loss Of Consciousness Oesophageal Spasm Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post Procedural Complication	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Ventolin (Albuterol)	C		
RESPIRATORY (INHALATION)		Thrombosis					
				Aspirin	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Lexapro	C		
UNKNOWN							
				Aerobid	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Niacin	C		
UNKNOWN		14671DAY					

Date:06/18/04ISR Number: 4380585-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Arthropathy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Bursitis		Vioxx	SS		ORAL
33	DAY						
		Closed Head Injury		Vioxx	SS		ORAL
33	DAY						
		Complex Regional Pain		Bayer Aspirin	C		ORAL
		Syndrome		Bayer Aspirin	C		ORAL
		Concussion		Vitamins			
		Contusion		(Unspecified)	C		
UNKNOWN							
		Depression					
		Dizziness					
		Emotional Distress					

Extrasystoles
Fall
Fatigue
Female Reproductive
Neoplasm
Gingival Disorder
Haematochezia
Haemorrhage
Headache
Heart Rate Irregular
Hypercholesterolaemia
Mitral Valve Prolapse
Nausea
Nerve Injury
Post-Traumatic Stress
Disorder
Sleep Disorder
Vaginal Haemorrhage
Vasodilatation
Vomiting

Date:06/18/04ISR Number: 4380950-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angiopathy
Initial or Prolonged	Arterial Disorder
Other	Circulatory Collapse
	Coronary Artery Disease
	Dyspnoea Exertional

		Emotional Distress					
		Femur Fracture					
		Gastrointestinal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Tylenol	C		
UNKNOWN							
		Ischaemia		Vicodin Tablets	C		
UNKNOWN							
		Migraine		Celexa	C		
UNKNOWN	1839 DAY						
		Myocardial Infarction		Plavix	C		
UNKNOWN	366 DAY						
		Stress		Flexeril	C		ORAL
				Avapro	C		
UNKNOWN	1681 DAY						
				Ativan	C		
UNKNOWN	1344 DAY						
				Niacin	C		
UNKNOWN	1830 DAY						

Date:06/18/04ISR Number: 4380956-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Haemorrhagic Cerebral		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Darvocet-N	C		
UNKNOWN						
	Hypertension		Coumadin	C		
UNKNOWN						
	Osteoarthritis		Darvocet-N	C		
UNKNOWN						

Date:06/18/04ISR Number: 4380961-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02090
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL

	Cerebral Artery Occlusion	Aspirin	C
UNKNOWN			
	Death	Digoxin	C
UNKNOWN			
	Dehydration	Coumadin	C
UNKNOWN			
	Depression	Diltiazem Hydrochloride	C
	Diarrhoea		
UNKNOWN			
	Erosive Duodenitis	Lasix (Furosemide)	C
UNKNOWN			
	Fall	Hydrochlorothiazide And Triamterene	C
	Fatigue		
UNKNOWN			
	Grand Mal Convulsion	Lopressor	C
UNKNOWN			
	Haematoma	Potassium (Unspecified)	C
	Hypernatraemia		
UNKNOWN			
	International Normalised Ratio Increased		
	Lower Gastrointestinal Haemorrhage		
	Muscle Necrosis		
	Peptic Ulcer Haemorrhage		
	Pneumonia		
	Skin Laceration		
	Skin Necrosis		
	Urinary Tract Infection		
	Weight Decreased		
	Wound Dehiscence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/18/04ISR Number: 4380962-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN	Anorexia		Aspirin	C				
Other	Chest Discomfort							
	Chloasma							
	Chronic Sinusitis							
	Coronary Artery Disease							
	Cough							
	Depression							
	Drug Dependence							
	Eustachian Tube Disorder							
	Feeling Abnormal							
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Iliac Artery Stenosis							
	Intermittent Claudication							
	Muscle Spasms							
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Pleurisy							
	Stomatitis							

Date:06/18/04ISR Number: 4380966-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01230
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Tenormin	C				
UNKNOWN								
	Dermatitis		Lotensin	C				
UNKNOWN								
	Oesophageal Varices		Cardizem	C				
UNKNOWN								

	Haemorrhage	Hytrin	C	
UNKNOWN				
	Osteoarthritis	Vasotec	C	ORAL
	Upper Gastrointestinal	Toprol Xl Tablets	C	
UNKNOWN				
	Haemorrhage	Procardia	C	
UNKNOWN				
	Vertigo Positional			

Date:06/18/04ISR Number: 4380967-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Acute Coronary Syndrome
	Acute Myocardial Infarction
	Acute Respiratory Distress Syndrome
	Acute Respiratory Failure
	Agitation
	Angina Unstable
	Arthralgia
	Arthritis
	Asthenia

Atrial Tachycardia
Back Pain
Blood Pressure Decreased
Brain Hypoxia
Cardiac Arrest
Cardiac Failure
Congestive
Cardiac Murmur
Cardiogenic Shock
Cardiomegaly
Cardiomyopathy
Cerebrovascular Accident
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Culture Urine Positive
Dilatation Atrial
Electrocardiogram Qrs
Complex Prolonged
Electroencephalogram
Abnormal
Emotional Distress
Encephalopathy
Fatigue
Folliculitis
Gallop Rhythm Present
Gastrooesophageal Reflux
Disease
Headache
Hepatic Failure
Hypercholesterolaemia
Hyperphosphataemia
Hypokalaemia
Hyponatraemia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Lung Infiltration
Metabolic Disorder
Migraine
Multi-Organ Failure
Muscle Spasms
Oedema Peripheral

Panic Attack
Panic Disorder
Proteus Infection
Pulmonary Hypertension
Pulmonary Oedema
Pupil Fixed
Renal Failure Acute
Sudden Death
Tendonitis
Thrombocytopenia
Thyroid Neoplasm
Tricuspid Valve
Incompetence
Ulcer Haemorrhage

		Urinary Tract Infection Ventricular Fibrillation Ventricular Hypokinesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
14	MON						
		Visual Disturbance		Prozac	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Maxalt (Rizatriptan Benzoate)	C		ORAL

Date:06/18/04ISR Number: 4380971-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00075
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/18/04ISR Number: 4380972-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01470
Age:95 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatinine Abnormal Blood Creatinine Increased Blood Urea Abnormal Blood Urea Increased Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/18/04ISR Number: 4380973-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		38 DAY
Initial or Prolonged	Bipolar I Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		38 DAY
Disability	Cerebral Artery Occlusion		Duradrin	C				UNKNOWN
Other	Cerebrovascular Accident		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
	Chest Pain							
	Chronic Fatigue Syndrome							840 DAY
	Depression		Alprazolam	C				UNKNOWN
	Dyspnoea		Klonopin	C				UNKNOWN
	Fall		Benadryl	C				UNKNOWN
	Hypotension		Estraderm	C				409 DAY
	Loss Of Consciousness		Prozac	C				UNKNOWN
	Migraine		Lasix (Furosemide)	C				976 DAY
	Myocardial Infarction		Hydrocodone Bitartrate	C				UNKNOWN
	Neuropathic Pain							663 DAY
	Renal Failure Acute		Indomethacin	C				UNKNOWN
	Temperature Intolerance		Avonex	C				INTRAMUSCULAR
			Methotrexate	C				UNKNOWN
			Nizatidine	C				UNKNOWN
			Zyprexa	C		ORAL		
			Klor-Con	C				UNKNOWN
			Prochlorperazine	C				UNKNOWN

				Propranolol Hydrochloride	C		
UNKNOWN							
				Vitamin E	C		ORAL
				Trazodone Hydrochloride	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN	473	DAY					
				Zocor	C		
UNKNOWN							
				Zocor	C		ORAL
809	DAY						
				Seroquel	C		
UNKNOWN							

Date:06/18/04ISR Number: 4380975-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00071
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gallbladder Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Gastrointestinal Disorder							

Date:06/18/04ISR Number: 4380977-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization -	Amnesia
Initial or Prolonged	Apnoea
Other	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Cardiac Failure
	Congestive
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Confusional State
	Coronary Artery Disease
	Deafness Neurosensory

Dehydration
Depression
Diabetes Mellitus
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fibrous Histiocytoma
Gastritis Haemorrhagic
Headache
Hiatus Hernia
Hypertension
Leukocytosis
Mitral Valve Incompetence
Myocardial Infarction
Oedema
Pneumonia Escherichia
Post Procedural
Complication
Pupillary Disorder
Renal Failure
Respiratory Failure

	Sepsis						
	Subarachnoid Haemorrhage						
	Syncope	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	100 DAY
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tremor		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL	100 DAY
	Incompetence		Neurontin	C			UNKNOWN
	Varicose Vein		Glucosamine	C			UNKNOWN
	Ventricle Rupture		Prilosec	C			UNKNOWN
	Ventricular Tachycardia						
	Vertigo Positional						
	Vision Blurred						

Date:06/21/04ISR Number: 4381539-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
Initial or Prolonged	Antiphospholipid Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
Disability	Blood Cholesterol						
Other	Increased						
	Cerebrovascular Accident						
	Cholecystitis						
	Chronic Fatigue Syndrome						
	Colonic Polyp						
	Contusion						
	Diverticulum						
	Dyspepsia						
	Emotional Distress						
	Gastroenteritis Viral						
	Haemorrhoids						
	Menorrhagia						
	Nervousness						
	Ovarian Cyst						
	Transient Ischaemic						

Attack
Urinary Tract Infection

Date:06/21/04ISR Number: 4381545-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Immunodeficiency Syndrome
Disability	Anticonvulsant Drug Level Decreased
Other	Aortic Dilatation
	Aortic Valve Incompetence
	Cardiovascular Disorder
	Cerebrovascular Accident
	Convulsion
	Depression
	Dizziness
	Facial Palsy
	Gait Disturbance
	Headache
	Hemiparesis
	Hiv Infection

Hypertension
Hypoaesthesia
Impaired Work Ability
Sinus Disorder
Spinal Osteoarthritis
Visual Field Defect

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dilantin	C			UNKNOWN	

Date:06/21/04ISR Number: 4381548-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Abdominal Tenderness
Acute Prerenal Failure
Affect Lability
Agitation
Alopecia
Anxiety Disorder
Aortic Valve Calcification
Aortic Valve Sclerosis
Arteriosclerosis
Arthralgia
Arthropathy
Ascites
Aspiration
Asthma
Atrial Fibrillation
Av Dissociation
Back Pain
Blood Amylase Decreased
Blood Bicarbonate Decreased
Blood Calcium Increased
Blood Cholesterol Increased
Blood Glucose Increased
Blood Pressure Diastolic Decreased
Blood Pressure Systolic Increased
Blood Triglycerides Increased
Bundle Branch Block Right

Cardiac Murmur
Chronic Obstructive
Airways Disease
Exacerbated
Chronic Obstructive
Pulmonary Disease
Confusional State
Contusion
Coronary Artery Disease
Delirium
Depressed Level Of
Consciousness
Depression
Diverticulum
Drug Toxicity
Dyspepsia
Emotional Disorder

Emotional Distress
Encephalitis Viral
Encephalopathy
Fall
Fatigue
Gastric Disorder
Gastrooesophageal Reflux
Disease
Goitre
Haemoglobin Increased
Hallucination
Head Injury
Hiatus Hernia
Hyperlipidaemia
Hypertensive Heart
Disease
Hyperthyroidism
Hypertrophic
Cardiomyopathy
Hypotension
Hypoventilation
Injury
Klebsiella Infection
Memory Impairment
Meningitis Aseptic
Meningitis Viral
Mental Status Changes
Migraine
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Neuritis
Nodal Arrhythmia
Normochromic Normocytic
Anaemia
Oesophageal Spasm
Osteoarthritis
Pain In Extremity
Pancreatitis
Pneumonia
Radiculopathy
Rebound Effect
Respiratory Distress
Restlessness
Sedation
Sepsis
Skin Laceration

Spinal Column Stenosis
Spondylolisthesis
Acquired
Stress
Tension
Therapeutic Agent
Toxicity
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Urinary Incontinence
Urinary Tract Infection
Urosepsis

		Ventricular Hypertrophy					
		Viral Infection					
		Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Bextra	SS		
UNKNOWN							
				Albuterol	C		ORAL
				Lanoxin	C		
UNKNOWN							
				Tiazac	C		
UNKNOWN							
				Flovent	C		ORAL
				Effexor	C		
UNKNOWN							
				Thyroid	C		
UNKNOWN							
				Hydrochlorothiazide And Triamterene	C		ORAL
				Atrovent	C		ORAL
				Singulair	C		ORAL
				Daypro	C		
UNKNOWN							

Date:06/21/04ISR Number: 4381551-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Bursitis					
	Chest Pain					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Dyspnoea					
	Emotional Distress					
	Hyperlipidaemia					
	Injury					
	Ischaemia					
	Musculoskeletal Disorder					
	Myocardial Infarction					
	Sinus Arrhythmia					
	Stress					

Date:06/21/04ISR Number: 4381552-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00116
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Moenckeberg-Type		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased		Zocor	C		ORAL		
Other	Chest Pain		Ultram	C			UNKNOWN	
	Cognitive Disorder		Lomotil	C			UNKNOWN	
	Cough		Plavix	C			UNKNOWN	
	Deep Vein Thrombosis		Hydrochlorothiazide	C			UNKNOWN	
	Pulmonary Embolism		Evista	C			UNKNOWN	
	Pyrexia							
	Respiratory Failure							
	Rhinitis							
	Status Epilepticus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/04ISR Number: 4381553-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01526
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Amaurosis Fugax	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
14 DAY								
Disability	Anxiety							
Other	Arthralgia							
	Bradycardia							
	Cardiac Failure							
	Congestive							
	Carotid Artery Stenosis							
	Carpal Tunnel Syndrome							
	Cerebrovascular Disorder							
	Circadian Rhythm Sleep							
	Disorder							
	Coronary Artery Disease							
	Depression							
	Dermatitis							
	Embolic Cerebral							
	Infarction							
	Epicondylitis							
	Erectile Dysfunction							
	Headache							
	Hypotension							
	Memory Impairment							
	Multiple Sclerosis							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Osteoarthritis							
	Peripheral Vascular							
	Disorder							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Syncope							
	Tenosynovitis							
	Vascular Graft Occlusion							
	Ventricular Hypertrophy							

Date:06/21/04ISR Number: 4381555-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		611 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		611 DAY
Initial or Prolonged	Bipolar Disorder		Midrin	C				UNKNOWN
Disability	Blood Cholesterol		Tricor	C				UNKNOWN
	Increased		Neurontin	C				UNKNOWN
	Blood Triglycerides		Hydrochlorothiazide	C				UNKNOWN
	Increased		Trazodone Hydrochloride	C				UNKNOWN
	Emotional Distress		Zanaflex	C				UNKNOWN
	Hypertension		Maxzide	C				UNKNOWN
	Oedema Peripheral		Hydrocodone Hydrochloride	C				UNKNOWN
	Renal Failure		Ativan	C				UNKNOWN
	Tibia Fracture		Remeron	C				UNKNOWN
	Uterine Disorder							

Date:06/21/04ISR Number: 4382061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C				UNKNOWN
Other	Bundle Branch Block Left		Ecotrin	C				UNKNOWN
	Chest Discomfort		Viagra	C				UNKNOWN
	Coronary Artery Disease		Calan Sr	C				UNKNOWN
	Dehydration		Zocor	C				UNKNOWN
	Diverticulum		Celebrex	C				UNKNOWN
	Diverticulum Intestinal		Advil	C				UNKNOWN
	Haemorrhagic							
	Emotional Distress							
	Gastritis							
	Gastritis Atrophic							
	Gastrointestinal							
	Haemorrhage							
	Haematochezia							
	Helicobacter Infection							
	Hypertension							
	Iron Deficiency Anaemia							
	Neck Pain							
	Neuropathy Peripheral							
	Polytraumatism							
	Rotator Cuff Syndrome							
	Stent Occlusion							

Date:06/22/04ISR Number: 4382584-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Dreams	Health	Vioxx	PS	Merck & Co., Inc	ORAL		252 DAY

Initial or Prolonged	Asthma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	65 DAY
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	252 DAY
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	65 DAY
	Cerebrovascular Accident		Vicodin Tablets	C			UNKNOWN
	Depression		Elavil	C			UNKNOWN
	Disturbance In Attention		Atenolol	C			UNKNOWN
	Dizziness		Lipitor	C			UNKNOWN
	Fall		Celebrex	C			UNKNOWN
	Fear		Plavix	C			UNKNOWN
	Headache		Calan Sr	C			UNKNOWN
	Injury		Ultram	C			UNKNOWN
	Insomnia		Zoloft	C			UNKNOWN
	Muscle Strain		Zoloft	C			UNKNOWN
	Nephrosclerosis		Flexeril	C			UNKNOWN 21 DAY
	Nocturia		Flexeril	C			UNKNOWN 13 DAY
	Pain		Flexeril	C			UNKNOWN
	Renal Failure Acute		Premarin	C			UNKNOWN
	Respiratory Disorder		Pepcid	C		ORAL	
	Rotator Cuff Syndrome		Dyazide	C			UNKNOWN
	Spinal Column Stenosis		Accupril	C			UNKNOWN
	Stress						
	Therapeutic Response Decreased						
	Transient Ischaemic Attack						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/04ISR Number: 4382586-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Asthma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Atrial Tachycardia		Amaryl	C				UNKNOWN
	Blood Cholesterol		Metformin	C				UNKNOWN
	Abnormal							
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiac Valve Disease							
	Cardiomyopathy							
	Cataract							
	Constipation							
	Convulsion							
	Coronary Artery Disease							
	Dizziness							
	Emotional Distress							
	Excoriation							
	Grand Mal Convulsion							
	Hepatitis B							
	Hypertension							
	Hypoaesthesia							
	Myocardial Infarction							
	Nausea							
	Paraesthesia							
	Sarcoidosis							
	Sick Sinus Syndrome							
	Sinus Bradycardia							
	Syncope							

Date:06/22/04ISR Number: 4382594-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0406NOR00013
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON

Initial or Prolonged	Haemoglobin Decreased		Bendroflumethiazide	C	ORAL
	Melaena		Zocor	C	ORAL
			Metoprolol Tartrate	C	ORAL

Date:06/22/04ISR Number: 4382595-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 YR	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Bronchitis Chronic	Professional	Norvasc	C		
Disability UNKNOWN	Cholecystitis Chronic		Lipitor	C		
Other	Cholelithiasis					
	Eye Haemorrhage					
	Eye Injury					
	Gastrooesophageal Reflux Disease					
	Hypertension					
	Ingrowing Nail					
	Ischaemic Stroke					
	Syncope Vasovagal					
	Vertigo					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/04ISR Number: 4382596-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01408
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged Disability	Thrombosis							

Date:06/22/04ISR Number: 4382598-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Brunner'S Gland	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Hyperplasia		Darvocet-N	C				
UNKNOWN								
	Cardiac Disorder		Lanoxin	C				
UNKNOWN								
	Cardiac Pacemaker		Lasix (Furosemide)	C				
UNKNOWN								
	Insertion		K-Dur	C				
UNKNOWN								
	Cataract		Propoxyphene Hydrochloride	C				
	Diarrhoea							
UNKNOWN								
	Duodenitis							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Haemorrhoids							
	Heart Rate Irregular							
	Hiatus Hernia							
	Injury							
	Supraventricular							
	Tachycardia							
	Weight Decreased							

Date:06/22/04ISR Number: 4382653-XReport Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage		Augmentin	PS	Glaxosmithkline		UNKNOWN	
			Fluoxetine	SS			UNKNOWN	
			Unspecified Drug	SS			UNKNOWN	40MG Unknown
			Methotrexate	SS			UNKNOWN	
			Rofecoxib	SS			UNKNOWN	
			Co-Dydramol	SS	Glaxosmithkline		UNKNOWN	
			Premarin	SS			UNKNOWN	

Date:06/22/04ISR Number: 4382953-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02381
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anxiety
	Chills
	Depression
	Dyspepsia
	Dysphagia
	Emotional Distress
	Feeling Hot And Cold
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux

		Disease					
		Haematemesis					
		Joint Effusion					
		Leukocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ligament Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Lumbar Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Overdose		Cannabis	C		
UNKNOWN							
		Pyrexia		Ambien	C		
UNKNOWN							
		Renal Pain		Lorazepam	C		
UNKNOWN							
		Sleep Disorder		Oramorph	C		
UNKNOWN							
		Vomiting		Protonix	C		
UNKNOWN							

Date:06/22/04ISR Number: 4382958-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00984
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Meningitis Aseptic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Flexeril	C		
UNKNOWN						

Date:06/22/04ISR Number: 4382961-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00077
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Agranulocytosis		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Hospitalization -	Cervical Root Pain		Omeprazole	SS		ORAL
8 DAY						
Initial or Prolonged	Septic Shock		Perindopril	C		ORAL
8 DAY						
	Urinary Tract Infection		Pravastatin Sodium	C		ORAL
8 DAY						
	White Blood Cell Count					

Decreased

Date:06/23/04ISR Number: 4383520-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
	Cough		Fosamax	C		ORAL		
	Depression		Hydrochlorothiazide	C				UNKNOWN
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							

Date:06/23/04ISR Number: 4383521-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		482 DAY
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		482 DAY
Other	Reocclusion		Celebrex	C				UNKNOWN
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/04ISR Number: 4383524-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		340 DAY
Life-Threatening	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
Hospitalization -	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Cystocele		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Hepatomegaly		Vicodin Tablets	C				UNKNOWN
	Myocardial Infarction		Proventil Repetabs And Tablets	C				UNKNOWN
	Oxygen Saturation Decreased		Zithromax	C				UNKNOWN
	Pleural Adhesion		Benzonatate	C				UNKNOWN
	Procedural Complication		Tussi-12	C				UNKNOWN
	Pulmonary Oedema		Soma	C				UNKNOWN
	Rhonchi		Zyrtec	C				UNKNOWN
	Sinus Tachycardia		Cipro	C				UNKNOWN
	Stress Incontinence		Voltaren	C				UNKNOWN
	Sudden Cardiac Death		Prempro	C			41 DAY	UNKNOWN
	Vaginal Prolapse		Tequin	C				UNKNOWN
	Wheezing		Hydroxyzine Hydrochloride	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Lorabid	C				UNKNOWN

			Claritin-D	C		
UNKNOWN						
			Lorazepam	C		
UNKNOWN						
			Remeron	C		
UNKNOWN						
			Triamcinolone	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Ditropan	C		
UNKNOWN						
			Ditropan	C		
UNKNOWN						
			Promethazine	C		
UNKNOWN						

Date:06/23/04ISR Number: 4383525-7Report Type:Expedited (15-DaCompany Report #IE-MERCK-0403GBR00166
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Nausea		Flurazepam Hydrochloride	C				
	Rash							
UNKNOWN								
	Tremor		Lansoprazole	C				
UNKNOWN								

Date:06/23/04ISR Number: 4383526-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Metabolic Disorder							
	Renal Failure							

Date:06/23/04ISR Number: 4383527-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Dreams
	Asthma
Other	Blood Pressure Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Confusional State					
252 DAY		Constipation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
65 DAY		Depression	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
252 DAY		Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL
65 DAY		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Drug Ineffective		Vicodin Tablets	C		
UNKNOWN		Fall		Elavil	C		
UNKNOWN		Fear		Atenolol	C		
UNKNOWN		Headache		Lipitor	C		
UNKNOWN		Injury		Celebrex	C		
UNKNOWN		Insomnia		Plavix	C		
UNKNOWN		Muscle Strain		Calan Sr	C		
UNKNOWN		Neck Pain		Ultram	C		
UNKNOWN		Nephrosclerosis		Zoloft	C		
UNKNOWN		Nocturia		Zoloft	C		
UNKNOWN		Pain		Flexeril	C		
UNKNOWN	21 DAY	Renal Failure Acute		Flexeril	C		
UNKNOWN	13 DAY	Respiratory Disorder		Flexeril	C		
UNKNOWN		Rotator Cuff Syndrome		Premarin	C		
UNKNOWN		Sciatica		Pepcid	C		ORAL
		Spinal Column Stenosis		Dyazide	C		
UNKNOWN		Stress		Accupril	C		
UNKNOWN		Therapeutic Response Decreased					

Transient Ischaemic
Attack

Date:06/23/04ISR Number: 4383529-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01724
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adjustment Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vicodin Tablets	C		ORAL		
	Coronary Artery Disease		Soma	C		ORAL		
	Drug Abuser		Soma	C		ORAL		
	Fall		Cyanocobalamin	C		INTRAMUSCULAR		
	Hip Fracture		Estradiol	C		INTRAMUSCULAR		
	Hypertension		Premarin	C		UNKNOWN		
	Myocardial Infarction		Allegra	C		UNKNOWN		
			Levoxyl	C		UNKNOWN		
			Claritin	C		UNKNOWN		

Date:06/23/04ISR Number: 4383530-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Other	Anal Haemorrhage
	Angina Pectoris
	Arrhythmia
	Arthralgia
	Arthropathy
	Breast Cyst
	Breast Haemorrhage
	Bursitis

		Chest Discomfort					
		Closed Head Injury					
		Complex Regional Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Concussion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Contusion		Vioxx	SS		ORAL
33	DAY						
		Depression		Vioxx	SS		ORAL
33	DAY						
		Dizziness		Bayer Aspirin	C		ORAL
		Dyspnoea Exertional		Bayer Aspirin	C		ORAL
		Dyspnoea Paroxysmal		Vitamins			
		Nocturnal		(Unspecified)	C		
UNKNOWN							
		Emotional Disorder					
		Emotional Distress					
		Extrasystoles					
		Fall					
		Fatigue					
		Gingival Disorder					
		Haematochezia					
		Haemorrhage					
		Headache					
		Heart Rate Irregular					
		Hypercholesterolaemia					
		Hysterectomy					
		Injury					
		Lumbar Spinal Stenosis					
		Mitral Valve Prolapse					
		Nausea					
		Nerve Compression					
		Nerve Injury					
		Palpitations					
		Post-Traumatic Stress					
		Disorder					
		Salpingo-Oophorectomy					
		Sleep Disorder					
		Stress					
		Syncope					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Vasodilatation					
		Vomiting					

Date:06/23/04ISR Number: 4383533-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01761
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Disability	Perforation		[Therapy Unspecified]	C				
	Overdose							
UNKNOWN			Prozac	C				
UNKNOWN								

Date:06/23/04ISR Number: 4383621-4Report Type:Expedited (15-DaCompany Report #PHNR2004AU01056
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoglycaemia		Lamisil	PS	Novartis Sector: Pharma	ORAL		
			Vioxx	SS		ORAL		
			Diamicron	C				

Efexor	C
Folic Acid	C
Fosamax	C
Lanoxin Pg	C
Lasix	C

Date:06/23/04ISR Number: 4383768-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Calcification	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Artery Embolism		Darvocet-N	C			UNKNOWN	
	Deep Vein Thrombosis		Coumadin	C			UNKNOWN	
	Dilatation Atrial		Darvocet-N	C			UNKNOWN	
	Dizziness							
	Encephalopathy							
	Haemorrhagic Cerebral Infarction							
	Heart Valve Calcification							
	Hydrocephalus							
	Hypertension							
	Injury							
	Lipids Increased							
	Nausea							
	Osteoarthritis							
	Pericardial Effusion							
	Rheumatoid Arthritis							
	Tricuspid Valve Incompetence							
	Vertigo Positional							
	Vestibular Disorder							

Date:06/23/04ISR Number: 4383772-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
	Abdominal Pain
Other	Adenomyosis

Anorexia
Anxiety
Aortic Valve Incompetence
Arthralgia
Asthenia
Back Pain
Bronchitis
Bundle Branch Block Left
Cardiac Valve Disease
Cardiomyopathy
Cellulitis
Chest Pain
Complex Regional Pain
Syndrome
Constipation
Convulsion
Cough
Depressed Level Of
Consciousness
Depression

		Dilatation Atrial					
		Dilatation Ventricular					
		Diverticulitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Duodenal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Duodenitis		Cardura	C		
UNKNOWN							
		Dysphagia		Normodyne	C		
UNKNOWN							
		Dyspnoea		Prevacid	C		
UNKNOWN							
		Dyspnoea Exertional		Flagyl	C		
UNKNOWN							
		Dysuria		Minoxidil	C		
UNKNOWN							
		Fatigue		Procardia Xl	C		
UNKNOWN							
		Feeling Abnormal					
		Gallop Rhythm Present					
		Gastritis					
		Haematoma					
		Haematoma Infection					
		Haemorrhoids					
		Heart Sounds Abnormal					
		Helicobacter Gastritis					
		Hyperhidrosis					
		Hypertension					
		Hypertensive Crisis					
		Hypokalaemia					
		Hysterectomy					
		Irritable Bowel Syndrome					
		Laceration					
		Malignant Hypertension					
		Memory Impairment					
		Mental Disorder					
		Micturition Urgency					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Nicotine Dependence					
		Night Sweats					
		Oedema Peripheral					
		Oesophagitis					
		Orthopnoea					
		Ovarian Cyst					

Pain In Extremity
Palpitations
Paranoia
Pelvic Inflammatory
Disease
Pharyngolaryngeal Pain
Salpingitis
Salpingo-Oophorectomy
Sinus Congestion
Supraventricular
Tachycardia
Swelling Face
Tricuspid Valve
Incompetence
Uterine Leiomyoma
Vision Blurred
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/04ISR Number: 4383775-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Atrial Fibrillation		Zocor	SS		ORAL		
	Blood Cholesterol		Percocet	C				UNKNOWN
Other	Increased		Atenolol	C				UNKNOWN
	Bradycardia		Folic Acid	C				UNKNOWN
	Coronary Artery Disease		Ambien	C				UNKNOWN
	Coronary Artery		Ismo	C				UNKNOWN
	Reocclusion		Methotrexate	C				UNKNOWN
	Deep Vein Thrombosis		Oxycodone Hydrochloride	C				UNKNOWN
	Diverticulitis Intestinal		Prednisone	C		ORAL		
	Haemorrhagic							
	Hyperlipidaemia							
	Hypertension							
	Intervertebral Disc Degeneration							
	Myocardial Infarction							
	Renal Failure Chronic							
	Respiratory Distress							

Date:06/23/04ISR Number: 4383776-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Cellulitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
Other	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY

	Emotional Distress		Zithromax	C		
UNKNOWN	7 DAY					
	Gout		Cardizem	C		
UNKNOWN						
	Injury		Ismo	C		
UNKNOWN						
	Insomnia		Morphine Sulfate	C		ORAL
	Intervertebral Disc		Ms Contin	C		ORAL
	Disorder		Ms Contin	C		
UNKNOWN						
	Joint Injury		Ms Contin	C		
UNKNOWN						
	Livedo Reticularis					
	Oedema Peripheral					
	Palpitations					
	Pneumonia					
	Skin Discolouration					
	Synovitis					

Date:06/23/04ISR Number: 4383777-3Report Type:Expedited (15-DaCompany Report #PR-MERCK-0406USA01801
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Toxicity		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Prescribed Overdose		[Therapy			
	Renal Failure		Unspecified]	C		
UNKNOWN						
			Parafon Forte	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/04ISR Number: 4383779-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01335
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Darvocet-N	C				UNKNOWN
	Congestive		Aspirin	C				UNKNOWN
	Cardiogenic Shock		Plavix	C				UNKNOWN
	Carotid Artery Stenosis		Vasotec	C		ORAL		
	Chronic Obstructive		Imdur	C				UNKNOWN
	Pulmonary Disease		Zocor	C		ORAL		
	Coronary Artery Disease		Mylicon	C		ORAL		
	Heart Rate Irregular		Synthroid	C				UNKNOWN
	Palpitations		Synthroid	C				UNKNOWN
	Postoperative Infection		Synthroid	C				UNKNOWN
	Renal Failure		Synthroid	C				UNKNOWN
			Levothroid	C				UNKNOWN
			Zestril	C				UNKNOWN
			Nitroglycerin	C				UNKNOWN

Date:06/23/04ISR Number: 4383780-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/23/04ISR Number: 4383781-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01861
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Gastrointestinal Haemorrhage		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:06/23/04ISR Number: 4383782-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/23/04ISR Number: 4383783-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Pressure Increased
	Convulsion
	Cystitis
	Depression
	Emotional Distress
	Herpes Zoster
	Intervertebral Disc Displacement
	Nervousness

	Stomach Discomfort						
	Thyroid Disorder						
	Uterine Cancer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Propulsid	C				UNKNOWN
			Estrogens (Unspecified)	C				UNKNOWN

Date:06/23/04ISR Number: 4384166-8Report Type:Direct Company Report #CTU 221332
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Systolic		Rofecoxib 25 Mg					
Hospitalization -	Decreased		Merck	PS	Merck	ORAL	25 MG DAILY	
Initial or Prolonged	Catheter Site Haemorrhage							
	Contusion		Warfarin 2.5 Mg	SS		ORAL	2.5 MG DAILY	
	Dizziness							
	Duodenal Ulcer							
	Faeces Discoloured							
	Gastric Ulcer							
	Gastrointestinal Haemorrhage							
	Haematemesis							
	Haemoglobin Decreased							
	Jugular Vein Thrombosis							
	Nausea							
	Subclavian Vein Thrombosis							
	Swelling							
	Syncope							

Date:06/24/04ISR Number: 4384253-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0310CHE00016
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Increased Bradycardia	Professional	Carbamazepine	SS		ORAL		
	Drug Interaction		Lithium Carbonate	SS		ORAL		
	Electrocardiogram		Propranolol Hydrochloride	SS		ORAL	1	DAY
	Abnormal		Mirtazapine	C		ORAL		
	Headache		Pipamperone Hydrochloride	C		ORAL		
	Hypotension		Zopiclone	C		ORAL		
	Malaise							
	Therapeutic Agent Toxicity							
	Tremor							
	Vomiting							

Date:06/24/04ISR Number: 4384264-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial
Other	Infarction
	Blood Cholesterol

		Increased Cardiac Failure Congestive Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease Diarrhoea Myocardial Infarction Renal Failure Transient Ischaemic Attack Urinary Tract Infection	Other	Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/04ISR Number: 4384268-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01909
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/04ISR Number: 4384479-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Angiopathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Back Injury Back Pain Cerebrovascular Accident Dementia Alzheimer'S Type Dysuria Emotional Distress Facial Pain Fall Gastroenteritis Hypertension Injury Intervertebral Disc Protrusion Renal Cyst Subarachnoid Haemorrhage Vertigo					

Date:06/24/04ISR Number: 4384483-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00140
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Pressure Increased		[Therapy Unspecified]	C				
	Emotional Distress							
	Headache		Percocet	C				
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/04ISR Number: 4384486-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Allopurinol	C				
UNKNOWN								
	Aortic Valve Sclerosis		Prevacid	C				
UNKNOWN								
	Blood Pressure Increased							
	Bronchitis Acute							
	Cerebellar Infarction							
	Cerebrovascular Accident							
	Dysuria							
	Epidermal Naevus							
	Haematospermia							
	Haemorrhoidal Haemorrhage							
	Micturition Urgency							
	Nephrolithiasis							
	Phlebolith							
	Prostatism							
	Renal Cyst							
	Sinusitis							
	Tricuspid Valve Incompetence							
	Vascular Calcification							
	Vertigo							
	Vomiting							

Date:06/24/04ISR Number: 4384487-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Hypersensitivity		[Therapy					
	Emotional Distress		Unspecified]	C				
UNKNOWN								
	Faeces Discoloured							
	Gastric Disorder							
	Hypertension							
	Oedema Peripheral							

Polytraumatism
Sleep Apnoea Syndrome

Date:06/24/04ISR Number: 4384488-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00143
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Cardiac Disorder							
	Chest Pain							
	Cyst							
	Dyspepsia							
	Emotional Distress							
	Heart Rate Irregular							
	Hypertension							
	Intraspinal Abscess							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/04ISR Number: 4384489-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02383
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anaemia Macrocytic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS		ORAL
	Bronchitis					
	Convulsion					
	Cough					
	Dyspepsia					
	Emotional Distress					
	Exostosis					
	Headache					
	Hyperkeratosis					
	Keratoconjunctivitis					
	Sicca					
	Neutropenia					
	Onychomycosis					
	Overdose					
	Pharyngolaryngeal Pain					
	Priapism					
	Toothache					
	Urinary Incontinence					

Date:06/24/04ISR Number: 4384492-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atelectasis					
Disability	Cardiac Failure					
	Congestive					
	Cardiomegaly					
	Cerebrovascular Accident					
	Chronic Obstructive					
	Pulmonary Disease					
	Headache					
	Insomnia					
	Muscle Spasms					
	Orthopnoea					
	Pneumonia					
	Pulmonary Embolism					

Tremor

Date:06/24/04ISR Number: 4384493-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome PT
Disability Abdominal Discomfort
Abdominal Pain Upper
Adverse Event
Blood Pressure Increased
Chest Pain
Diabetes Mellitus
Dyspepsia
Emotional Distress
Gastric Disorder
Gastrooesophageal Reflux
Disease

	Liver Disorder						
	Nausea						
	Pancreatitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	

Date:06/24/04ISR Number: 4384497-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthma		[Therapy					
	Bronchitis		Unspecified]	C			UNKNOWN	
	Cardiac Valve Disease		Albuterol	C			UNKNOWN	
	Chest Pain		Proventil	C			RESPIRATORY	
	Chronic Fatigue Syndrome						(INHALATION)	
	Chronic Obstructive		Zocor	C			UNKNOWN	
	Pulmonary Disease		Antimicrobial					
	Coronary Artery		(Unspecified)	C			UNKNOWN	
	Atherosclerosis		Amaryl	C			UNKNOWN	
	Coronary Artery Disease		Glipizide	C			UNKNOWN	
	Depression		Glucophage	C			UNKNOWN	
	Diarrhoea							
	Dyspepsia							
	Dyspnoea							
	Gastric Disorder							
	Gastrooesophageal Reflux							

Disease
Haematoma
Myocardial Infarction
Nausea
Oedema Peripheral
Viral Infection

Date:06/24/04ISR Number: 4384501-0Report Type:Expedited (15-DaCompany Report #GR-MERCK-0406GRC00011
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Renal Impairment		Antimicrobial (Unspecified)	C		ORAL	2	DAY

Date:06/24/04ISR Number: 4384502-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Aortic Valve Sclerosis
Disability	Blood Glucose Increased
Other	Cerebrovascular Accident
	Delusion
	Depression
	Dizziness
	Emotional Distress

	Fatigue					
	Feeling Abnormal					
	Glucose Tolerance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Impaired		Vioxx	PS	Merck & Co., Inc	ORAL
585 DAY						
	Hallucination		Vioxx	SS	Merck & Co., Inc	ORAL
585 DAY						
	Hernia		Lorcet 10/650	C		
UNKNOWN	283 DAY					
	Hyperlipidaemia		Hydrocodone			
	Hypertension		Bitartrate	C		
UNKNOWN	201 DAY					
	Insomnia		Ambien	C		
UNKNOWN						
	Low Density Lipoprotein		Ibuprofen	C		
UNKNOWN						
	Increased		Cozaar	C		
UNKNOWN						
	Male Sexual Dysfunction					
	Mitral Valve Incompetence					
	Neuropathy					
	Nocturia					
	Oedema Peripheral					
	Panic Attack					
	Periarthritis					
	Sedation					
	Somnolence					
	Stress					
	Varicose Vein					
	Ventricular Hypertrophy					

Date:06/24/04ISR Number: 4388859-8Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00102
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Colitis	Foreign	Tab Vioxx			
Initial or Prolonged	Haemoglobin Decreased	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Sepsis					
PO	144 DAY					
	Tachycardia		Aspirin	C		

Date:06/24/04ISR Number: 4389094-XReport Type:Expedited (15-DaCompany Report #2004039285
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased	Health	Norvasc (Amlodipine)	PS		ORAL	1 IN 1 D,	
	Blood Pressure	Professional						
	Inadequately Controlled Drug Interaction		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D),	
	Heart Rate Decreased							
	Oedema							
	Rash Erythematous		Atenolol (Atenolol)	SS		ORAL	ORAL	
			Hydrochlorothiazide (Hydrochlorothiazide)	C				

Date:06/25/04ISR Number: 4384882-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anoxic Encephalopathy
	Cardio-Respiratory Arrest
Other	Convulsion
	Coronary Artery Disease
	Deep Vein Thrombosis

	Gastric Disorder Hypertension Hypokalaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lumbar Spinal Stenosis Myocardial Infarction Pneumonia Aspiration		Vioxx Tylenol With Codeine #4	PS C	Merck & Co., Inc	ORAL	UNKNOWN
	Postoperative Ileus Pulmonary Oedema		Tylenol With Codeine #4	C			UNKNOWN
	Shock		Premarin	C			UNKNOWN
	Syphilis		Provera	C			UNKNOWN

Date:06/25/04ISR Number: 4384892-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia Arthropathy	Health Professional	Vioxx Premarin	PS C	Merck & Co., Inc	ORAL	UNKNOWN
Other	Atrial Fibrillation		Estratab	C			UNKNOWN
	Blood Urine		Menest	C			UNKNOWN
	Cardiac Aneurysm Cerebral Artery Embolism		Armour Thyroid Tablets	C			UNKNOWN
	Contusion Corneal Deposits		Trazodone Hydrochloride	C			UNKNOWN
	Dizziness		Garlic Extract	C			UNKNOWN
	Exostosis		Synthroid	C			UNKNOWN
	Haematuria		Methotrexate	C			UNKNOWN
	Haemorrhage Heart Rate Increased High Density Lipoprotein Increased Hypertension						

Hypertensive Crisis
Injury
Joint Effusion
Meniscus Lesion
Musculoskeletal Disorder
Oedema Peripheral
Osteoarthritis
Pain In Extremity
Paraesthesia
Renal Cyst
Toe Deformity
Transient Ischaemic
Attack
Urinary Retention
Ventricular Dysfunction

Date:06/25/04ISR Number: 4384893-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01799
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Duodenal Ulcer Perforation Hypertension Neoplasm Malignant		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:06/25/04ISR Number: 4385210-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Allopurinol	C			UNKNOWN	
	Cerebellar Infarction		Prevacid	C			UNKNOWN	
	Cerebrovascular Accident							
	Dysuria							
	Epidermal Naevus							
	Haematospermia							
	Haemorrhoidal Haemorrhage							
	Impaired Work Ability							
	Micturition Urgency							
	Nephrolithiasis							
	Prostatism							
	Sinusitis							
	Vascular Calcification							
	Vomiting							

Date:06/25/04ISR Number: 4385213-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Lipitor	C			UNKNOWN	2371 DAY
	Embolism		Accupril	C			UNKNOWN	2373 DAY
	Haematoma							
	Hypertension							
	Injury							
	Laceration							
	Myocardial Ischaemia							
	Post Procedural Complication							
	Road Traffic Accident							
	Rotator Cuff Syndrome							

Transient Ischaemic
Attack

Date:06/25/04ISR Number: 4385214-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01810
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Atherosclerosis
	Arrhythmia
	Blood Pressure Systolic Increased
	Bradyarrhythmia
	Bundle Branch Block Left
	Cardiac Murmur
	Cerebral Infarction
	Cerebrovascular Accident
	Coronary Artery Atherosclerosis
	Coronary Artery Disease

		Dilatation Atrial Heparin-Induced Thrombocytopenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incisional Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
243	DAY						
		Muscle Tightness Oedema		Tylenol Extra Strength	C		
UNKNOWN							
		Palpitations		Lasix (Furosemide)	C		
UNKNOWN							
		Supraventricular		Centrum	C		
UNKNOWN							
		Extrasystoles Ventricular Extrasystoles					

Date:06/25/04ISR Number: 4385215-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104488
Age:84 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Blood Pressure Decreased		[Therapy			
Initial or Prolonged		Cardiac Failure		Unspecified]	C		
UNKNOWN							
		Congestive		Acetaminophen	C		
UNKNOWN		1	DAY				
		Cardiomyopathy Cardiovascular Disorder		Acetaminophen And Codeine	C		
UNKNOWN							
		Chronic Obstructive		Diamox	C		
UNKNOWN							
		Pulmonary Disease Cough		Vitamins (Unspecified)	C		
UNKNOWN							
		Dehydration		Aspirin	C		
UNKNOWN							
		Diarrhoea		Capoten	C		
UNKNOWN							
		Encephalopathy Hypoglycaemia		Lasix (Furosemide Sodium)	C		
UNKNOWN							
		Influenza		Herbs (Unspecified)	C		
UNKNOWN							
		Injury					

Lymphadenopathy
Metabolic Acidosis
Nausea
Oedema
Oedema Peripheral
Renal Failure Acute
Sepsis
Visual Acuity Reduced
Vomiting
Weight Decreased

Date:06/25/04ISR Number: 4385216-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Carotid Artery Stenosis
Other	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Dyspnoea
	Faeces Discoloured
	Hypercholesterolaemia
	Hypertension
	Injury
	Intervertebral Disc
	Degeneration
	Meniscus Lesion
	Mitral Valve Incompetence

		Mixed Incontinence					
		Myalgia					
		Myositis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Post Thrombotic Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Syncope		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Premarin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN	366 DAY						
				Plaquenil	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Plaquenil	C		
UNKNOWN							
				Accupril	C		
UNKNOWN	535 DAY						

Date:06/25/04ISR Number: 4385217-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
80 DAY						
Initial or Prolonged	Cardiac Failure		Magnesium			
Disability	Congestive		(Unspecified)	C		
UNKNOWN						
	Cardioactive Drug Level		Nicotine	C		
UNKNOWN						
	Increased		Coenzyme Q10	C		
UNKNOWN						
	Congestive Cardiomyopathy		Vitamin E	C		
UNKNOWN						
	Depression		Wellbutrin	C		
UNKNOWN						
	Dyspepsia		Lanoxin	C		
UNKNOWN						
	Fibroadenoma Of Breast		Lasix (Furosemide)	C		
UNKNOWN						

	Gastrointestinal Tract	Levocarnitine	C	UNKNOWN
	Adenoma	Prinivil	C	ORAL
	Haemorrhoids	Ginkgo Biloba		
	Hypertension	Extract	C	UNKNOWN
	Mood Swings	Premarin	C	UNKNOWN
	Musculoskeletal Chest	Calcium		
	Pain	(Unspecified)	C	UNKNOWN
	Nightmare	Coumadin	C	UNKNOWN
	Pain In Extremity	Vitamin B		
	Pleurisy	(Unspecified)	C	UNKNOWN
	Snoring	Ascorbic Acid	C	UNKNOWN
	Somnolence	Pamelor	C	UNKNOWN
	Spinal Osteoarthritis			

Date:06/25/04ISR Number: 4385218-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anal Fissure
	Angina Pectoris
Disability	Anxiety
	Back Injury
	Back Pain
	Balance Disorder
	Blood Pressure Decreased
	Bronchitis
	Bursitis
	Cardiomegaly
	Chest Pain
	Chest Wall Pain

		Constipation					
		Coordination Abnormal					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diastolic Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
71	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
71	DAY						
		Insomnia		[Therapy			
		Metabolic Syndrome		Unspecified]	C		
UNKNOWN							
		Nephritis		Elavil	C		
UNKNOWN							
		Panic Attack		Atenolol	C		
UNKNOWN							
		Pericardial Effusion		Trazodone			
		Septic Shock		Hydrochloride	C		
UNKNOWN							
		Sinusitis		Atenolol	C		
UNKNOWN							
		Tendonitis		Lonox	C		
UNKNOWN							
		Therapeutic Agent		Dyazide	C		
UNKNOWN							
		Toxicity		Hydrocortisone	C		
UNKNOWN							
		Ventricular Hypertrophy		Zestril	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:06/25/04ISR Number: 4385219-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00111
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
Hospitalization -		Thyroid Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						

Initial or Prolonged			Tylenol	C		
UNKNOWN						
			Norvasc	C		ORAL
			Aspirin	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			Univasc	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						

Date:06/25/04ISR Number: 4385220-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00065
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anaemia		Vicodin Tablets	C		
UNKNOWN						
	Chest Pain		Aspirin	C		
UNKNOWN						
	Coagulopathy		Lipitor	C		
UNKNOWN						
	Coronary Artery Occlusion		Celebrex	C		
UNKNOWN						
	Dilatation Atrial		Plavix	C		
UNKNOWN						
	Dyspnoea		Premarin	C		
UNKNOWN						
	Fluid Retention		Insulin, Biphasic			
	Haematoma		Isophane [Injection]	C		
UNKNOWN						
	Injury		Insulin, Biphasic			
	Mitral Valve Incompetence		Isophane [Injection]	C		
UNKNOWN						
	Myalgia		Synthroid	C		
UNKNOWN						
	Oedema Peripheral		Glucophage	C		
UNKNOWN						
	Stress		Lopressor	C		
UNKNOWN						
	Tricuspid Valve		Accupril	C		
UNKNOWN						
	Incompetence		Prandin	C		
UNKNOWN						
	Vascular Graft Occlusion					
	Ventricular Hypertrophy					
	Ventricular Hypokinesia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/04ISR Number: 4385221-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03191
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Homocysteine		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
Disability	Cataract		Aspirin	C				UNKNOWN
Other	Ischaemic Cerebral		Aspirin	C				UNKNOWN
	Infarction		Plaquenil	C				UNKNOWN
	Posterior Capsule		Prednisone	C				UNKNOWN
	Opacification							
	Pruritus							

Date:06/25/04ISR Number: 4385222-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease							
	Hypertension							
	Injury							
	Intestinal Obstruction							
	Meningitis Viral							
	Oesophageal Disorder							

Date:06/25/04ISR Number: 4385223-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0210GBR00055
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	DAY
Other	Dizziness		Sertraline					
	Drug Interaction		Hydrochloride	SS		ORAL		
	Memory Impairment		Acetaminophen And					

	Vision Blurred		Codeine Phosphate	C		ORAL
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Beclomethasone Dipropionate	C		
RESPIRATORY						
(INHALATION)						
			Ibuprofen	C		
TOPICAL						

Date:06/25/04ISR Number: 4385224-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Wall Pain		Analgesic Or Anesthetic (Unspecified)	C		
	Emotional Distress					
	Injury					
UNKNOWN						
	Intervertebral Disc Protrusion		Antimicrobial (Unspecified)	C		
UNKNOWN						
	Rectal Haemorrhage		Butalbital	C		
UNKNOWN						
	Skin Discolouration					

Date:06/25/04ISR Number: 4385225-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00144
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Convulsion							
	Feeling Cold							
	Hot Flush							
	Hypertension							
	Injury							
	Myocardial Infarction							

Date:06/25/04ISR Number: 4385226-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	350 DAY	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL	350 DAY	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Restenosis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Diabetes Mellitus		[Therapy					
	Diverticulitis		Unspecified]	C			UNKNOWN	
	Dysphonia		Norco	C			UNKNOWN	
	Dyspnoea		Atenolol	C			UNKNOWN	
	Emotional Distress		Tenormin	C			UNKNOWN	
	Facet Joint Syndrome		Celebrex	C			UNKNOWN	
	Hand Fracture		Celebrex	C			UNKNOWN	

	Hyperlipidaemia	Diovan	C
UNKNOWN			
	Hypertension	Ultram	C
UNKNOWN			
	Insomnia	Avandia	C
UNKNOWN			
	Intervertebral Disc	Chlorthalidone	C
UNKNOWN			
	Protrusion	Hygroton	C
UNKNOWN			
	Lumbar Spinal Stenosis	Cyclobenzaprine	
	Muscle Strain	Hydrochloride	C
UNKNOWN			
	Nervousness	Cardizem	C
UNKNOWN			
	Pain	Propecia	C
UNKNOWN			
	Pneumothorax	Glucovance	C
UNKNOWN			
	Raynaud'S Phenomenon	Hydrocodone	
	Respiratory Failure	Hydrochloride	C
UNKNOWN			
	Somnolence		

Date:06/25/04ISR Number: 4385227-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00069
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Arthropathy
	Blood Cholesterol
	Increased
	Blood Pressure Increased
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Dyspnoea
	Gastric Disorder
	Haematochezia

		Headache Hypertension Knee Arthroplasty	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea Optic Ischaemic Neuropathy		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
				Tylenol Extra Strength	C		
UNKNOWN							

Date:06/25/04ISR Number: 4385228-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Atrioventricular Block		Tylenol	C		
UNKNOWN						
Other	First Degree Benign Prostatic Hyperplasia Bundle Branch Block Right Cerebellar Infarction Cerebrovascular Accident Chest Pain Coronary Artery Disease Dizziness Dyslipidaemia Gastric Disorder Gastrooesophageal Reflux Disease Hypertension Injury Lacunar Infarction Supraventricular Tachycardia Vertigo Vestibular Disorder					

Date:06/25/04ISR Number: 4385231-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Adverse Event
	Anxiety
	Blood Cholesterol Increased
	Chest Pain
	Convulsion
	Dyspepsia
	Dysuria
	Eye Disorder
	Gastrooesophageal Reflux Disease
	Haemorrhage
	Hypertension
	Kidney Infection
	Oedema Peripheral
	Oesophageal Disorder
	Palpitations

	Renal Disorder Ulcer						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				UNKNOWN
			Zocor	C		ORAL		

Date:06/25/04ISR Number: 4385232-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Chest Pain Emotional Distress Gastrooesophageal Reflux Disease Myocardial Infarction Oesophagitis							

Date:06/25/04ISR Number: 4385233-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00235
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Emotional Distress Irritable Bowel Syndrome		[Therapy Unspecified]	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Darvocet-N	C				UNKNOWN
			Emergen C	C				UNKNOWN
			Astelin	C				UNKNOWN

	Meridia	C	UNKNOWN
	Valtrex	C	UNKNOWN
	Zomig	C	UNKNOWN
	Imitrex	C	UNKNOWN
	Stadol	C	UNKNOWN
	Zyrtec	C	UNKNOWN
	Allegra	C	UNKNOWN
	Claritin	C	UNKNOWN
	Anaprox	C	UNKNOWN

Date:06/25/04ISR Number: 4385234-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00147
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Jaundice Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL	373	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	373	DAY

Date:06/25/04ISR Number: 4385235-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02099
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Congestive		Aspirin	C		ORAL		
Other	Pulmonary Oedema		Lipitor	C		ORAL		
			Diovan	C		ORAL		

			Coreg	C		ORAL
			Plavix	C		ORAL

Date:06/25/04ISR Number: 4385237-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Sular	C				
UNKNOWN								
	Blood Pressure Increased		Micardis	C				
UNKNOWN								
	Bone Disorder							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Emotional Distress							
	Large Intestinal Ulcer							
	Haemorrhage							
	Nausea							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Rotator Cuff Syndrome							
	Spinal Disorder							
	Stomach Discomfort							

Date:06/25/04ISR Number: 4385238-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00094
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
223 DAY								
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Apnoea		Tylenol	C				
UNKNOWN								
	Back Pain		Albuterol	C				
UNKNOWN								
	Cardio-Respiratory Arrest		Norvasc	C				
UNKNOWN								
	Chronic Obstructive		Norvasc	C				
UNKNOWN								

	Pulmonary Disease		Wellbutrin Sr	C		
UNKNOWN						
	Convulsion		Claritin-D	C		ORAL
	Coronary Artery Disease		Toprol Xl Tablets	C		
UNKNOWN						
	Cough		Toprol Xl Tablets	C		
UNKNOWN						
	Dyslipidaemia					
	Emotional Distress					
	Malaise					
	Myocardial Infarction					
	Obesity					
	Pneumonia					
	Pyrexia					
	Respiratory Failure					
	Upper Respiratory Tract Infection					
	Ventricular Fibrillation					

Date:06/25/04ISR Number: 4385240-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01369
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Generalised Oedema		Vioxx	SS	Merck & Co., Inc	ORAL		
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/25/04ISR Number: 4385241-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		[Therapy					
	Alopecia		Unspecified]	C				
UNKNOWN								
	Arrhythmia		Insulin	C				
UNKNOWN								
	Blood Pressure Increased							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Drug Hypersensitivity							
	Dyspnoea							
	Emotional Distress							
	Gallbladder Disorder							
	Glaucoma							
	Gout							
	Hernia							
	Large Intestinal Ulcer							
	Haemorrhage							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Osteoarthritis							
	Rheumatoid Arthritis							
	Weight Decreased							

Date:06/25/04ISR Number: 4385243-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
195 DAY								
Initial or Prolonged	Anxiety							
Disability	Coronary Artery Disease							
	Depression							
	Dislocation Of Vertebra							
	Dysarthria							
	Headache							
	Hypertension							
	Hypoaesthesia							

	Injury Joint Dislocation Malaise Myocardial Infarction Non-Cardiac Chest Pain Pain In Extremity Road Traffic Accident Visual Disturbance

Date:06/25/04ISR Number: 4385244-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00095
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Disability	Coronary Artery Disease Generalised Anxiety Disorder Myocardial Infarction Post Polio Syndrome

	Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Estrace	C			UNKNOWN	

Date:06/25/04ISR Number: 4385250-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01914
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Aspirin	C			UNKNOWN	
	Oesophagitis		Zocor	C		ORAL		
			Cozaar	C		ORAL		
			Singulair	C		ORAL		

Date:06/25/04ISR Number: 4386297-5Report Type:Direct Company Report #CTU 221569
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Warfarin	PS				
Initial or Prolonged	Hemiparesis		Rofecoxib	SS		ORAL	25 MG DAILY	
	International Normalised						PO	
	Ratio Decreased							
	International Normalised							
	Ratio Increased							
	Rectal Haemorrhage							

Date:06/25/04ISR Number: 4388220-6Report Type:Expedited (15-DaCompany Report #2004033139
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Bedridden	Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (600 MG, 3 IN 1 D), ORAL	
Other	Blood Test Abnormal Hypotension Interstitial Lung Disease Mobility Decreased Paralysis Pneumonitis Respiratory Disorder	Professional	Rofecoxib (Rofecoxib) Simvastatin (Simvastatin) Seretide Mite (Fluticasone Propionate, Salmeterol Xinafoate) Pantoprazole (Pantoprazole) Montelukast Sodium (Montelukast Sodium) Salbutamol (Salbutamol) Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	SS C C C C C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/26/04ISR Number: 4388148-1Report Type:Expedited (15-DaCompany Report #2004CG01193
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Mopral	PS		ORAL	20 MG QD PO	
Life-Threatening	Septic Shock	Health	Coversyl	SS		ORAL	2 MG QD PO	
		Professional	Elisor	SS		ORAL	10 MG QD PO	
		Other	Vioxx	SS		ORAL	25 MG QD PO	

Date:06/28/04ISR Number: 4385735-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00436
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
Disability	Affect Lability
Other	Anxiety Disorder
	Aortic Valve Sclerosis
	Arthralgia
	Asthma
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bundle Branch Block Right
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diverticulum
	Dyspepsia
	Emotional Distress
	Encephalitis
	Encephalopathy
	Fall
	Fatigue
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hyperlipidaemia

Hypertensive Heart
Disease
Hyperthyroidism
Hypertrophic
Cardiomyopathy
Hypotension
Injury
Memory Impairment
Meningitis
Migraine
Myocardial Infarction
Neuritis
Nodal Arrhythmia
Normochromic Normocytic
Anaemia
Oesophageal Spasm
Pain In Extremity
Pancreatitis
Pneumonia
Sepsis
Skin Laceration

		Spinal Column Stenosis					
		Stress					
		Tension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Therapeutic Agent	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Toxicity	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Bextra	SS		
UNKNOWN							
		Infection		Albuterol	C		ORAL
		Urosepsis		Lanoxin	C		
UNKNOWN							
				Tiazac	C		
UNKNOWN							
				Flovent	C		ORAL
				Effexor	C		
UNKNOWN							
				Thyroid	C		
UNKNOWN							
				Hydrochlorothiazide And Triamterene	C		ORAL
				Atrovent	C		ORAL
				Singulair	C		ORAL
				Daypro	C		
UNKNOWN							

Date:06/28/04ISR Number: 4385738-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02060
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Deep Vein Thrombosis	Professional	Darvocet-N	C		
UNKNOWN							
		Dilatation Atrial		Coumadin	C		
UNKNOWN							
		Encephalopathy		Darvocet-N	C		
UNKNOWN							
		Haemorrhagic Cerebral Infarction					
		Headache					
		Hydrocephalus					
		Hypertension					
		Injury					
		Labyrinthitis					
		Lipids Increased					

Mitral Valve
Calcification
Osteoarthritis
Tricuspid Valve
Incompetence
Vertigo Positional
Vestibular Neuronitis

Date:06/28/04ISR Number: 4385741-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02083
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess
Other	Angiopathy
	Blood Creatinine Increased
	Blood Pressure Decreased
	Calculus Bladder
	Cardiac Failure Congestive
	Cardiomegaly
	Cholelithiasis
	Crackles Lung
	Dizziness
	Epididymal Disorder

		Gastrooesophageal Reflux Disease					
		Haematuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction	Professional	Antimicrobial			
		Orchitis		(Unspecified)	C		
UNKNOWN							
		Pleural Effusion		Prinivil	C		
UNKNOWN							
		Pulmonary Fibrosis		Hytrin	C		
UNKNOWN							
		Renal Cyst		Tolazamide	C		
UNKNOWN							
		Scar		Mevacor	C		
UNKNOWN							
		Spinal Osteoarthritis		Glucophage	C		
UNKNOWN							
		Syncope					
		Urinary Tract Infection					

Date:06/28/04ISR Number: 4385742-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Activities Of Daily	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Tylenol	C		
UNKNOWN							
		Blood Pressure		Aspirin	C		
UNKNOWN							
		Fluctuation					
		Blood Pressure Increased					
		Bunion					
		Cardiac Failure					
		Congestive					
		Cardiovascular Disorder					
		Constipation					
		Drug Intolerance					
		Fall					
		Gastric Disorder					
		Headache					

Hypertensive Heart
Disease
Intervertebral Disc
Disorder
Joint Sprain
Limb Discomfort
Muscle Spasms
Myalgia
Nocturia
Oedema
Onychomycosis
Osteoarthritis
Pain
Pulmonary Granuloma
Renal Failure
Rotator Cuff Syndrome
Seborrhoeic Keratosis
Sinusitis
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/04ISR Number: 4385746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02008
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				
UNKNOWN								
	Arthralgia							
	Blood Cholesterol Increased							
	Bronchitis							
	Chest Pain							
	Coronary Artery Disease							
	Dermatitis Contact							
	Diabetes Mellitus							
	Drug Hypersensitivity							
	Dyspnoea							
	Eye Pain							
	Fall							
	Gastroenteritis Viral							
	Prostatic Specific Antigen Abnormal							

Date:06/28/04ISR Number: 4385747-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02187
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Acute Coronary Syndrome							
	Angina Unstable							
	Bronchitis							
	Cardiac Failure Congestive							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Constipation							
	Diverticulitis							
	Drug Hypersensitivity							
	Emotional Distress							
	Fatigue							
	Gastrointestinal Disorder							

Gastrooesophageal Reflux
Disease
Haemorrhagic Disorder
Ileus Paralytic
Limb Injury
Lumbar Radiculopathy
Lumbar Vertebral Fracture
Paraesthesia
Pulmonary Hypertension
Restless Legs Syndrome
Skin Laceration
Spinal Compression
Fracture
Thrombocytopenia
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Urinary Incontinence

Date:06/28/04ISR Number: 4385748-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cholelithiasis		Fosamax	C				UNKNOWN
	Constipation		Premarin	C				UNKNOWN
	Coronary Artery Disease		Robaxin	C		ORAL		
	Diverticulum		Prilosec	C				UNKNOWN
	Drug Ineffective							
	Duodenitis							
	Ear Pain							
	Erosive Oesophagitis							
	Gastritis Haemorrhagic							
	Hepatitis							
	Lung Neoplasm							
	Mycobacterium Avium Complex Infection							
	Myocardial Infarction							
	Nausea							
	Otitis Externa							
	Pruritus							
	Rash Morbilliform							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							

Date:06/28/04ISR Number: 4385749-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Flutter	Health	Vioxx	PS	Merck & Co., Inc	ORAL		11 MON
Initial or Prolonged	Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Diazide	C				UNKNOWN
	Transient Ischaemic Attack		Metoprolol	C				UNKNOWN

Date:06/28/04ISR Number: 4385750-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00108
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
Other	Arterial Thrombosis
	Asthma
	Atherosclerosis
	Blood Pressure Fluctuation
	Bronchitis Acute
	Bursitis
	Cardiac Failure Congestive
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Depression
	Diverticulum
	Dizziness

		Drug Intolerance					
		Emotional Distress					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Glaucoma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperglycaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoacusis		Ibuprofen	C		
UNKNOWN							
		Hypoglycaemia		Insulin	C		
UNKNOWN							
		Impaired Work Ability					
		Injury					
		Insomnia					
		Intervertebral Disc					
		Protrusion					
		Intervertebral Disc Space					
		Narrowing					
		Ischaemic Cardiomyopathy					
		Kidney Infection					
		Lacunar Infarction					
		Lobar Pneumonia					
		Nasal Congestion					
		Prostatic Disorder					
		Prostatic Specific					
		Antigen Increased					
		Proteinuria					
		Pulmonary Oedema					
		Renal Failure Chronic					
		Rhinitis Allergic					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Ventricular Arrhythmia					
		Vertigo					
		Viral Infection					
		Visual Acuity Reduced					

Date:06/28/04ISR Number: 4385752-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Accidental Overdose
Hospitalization -	Anxiety

Initial or Prolonged	Aortic Aneurysm
Other	Aortic Valve Sclerosis
	Arteriosclerosis
	Arthralgia
	Asthma
	Atrial Fibrillation
	Blindness
	Bradycardia
	Bronchitis
	Bronchospasm
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Death
	Disorientation
	Dizziness
	Emotional Distress
	Hypotension

		Injury					
		Interstitial Lung Disease					
		Labile Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Laryngitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Calcification		Percocet	C		
UNKNOWN							
		Mitral Valve Incompetence		Fosamax	C		
UNKNOWN							
		Myocardial Infarction		Diltiazem			
		Neuropathy		Hydrochloride	C		
UNKNOWN							
		Pain		Zestril	C		
UNKNOWN							
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Syncope					
		Tracheal Obstruction					
		Tricuspid Valve					
		Incompetence					
		Urinary Retention					
		Ventricular Hypertrophy					

Date:06/28/04ISR Number: 4385753-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00440
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Discomfort	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
6	WK						
Initial or Prolonged		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
6	WK						
Disability		Alopecia					
		Arthropathy					
		Kidney Infection					

Date:06/28/04ISR Number: 4385754-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia

Other	Arthropathy
	Breast Cyst
	Bursitis
	Chest Discomfort
	Closed Head Injury
	Complex Regional Pain
	Syndrome
	Concussion
	Contusion
	Depression
	Dizziness
	Emotional Distress
	Extrasystoles
	Fall
	Fatigue
	Gingival Disorder
	Haematochezia
	Haemorrhage
	Headache
	Heart Rate Irregular
	Hypercholesterolaemia
	Lumbar Spinal Stenosis
	Nausea
	Nerve Injury

		Palpitations					
		Post-Traumatic Stress Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Syncope	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Uterine Haemorrhage		Vioxx	SS		ORAL
33	DAY						
		Uterine Leiomyoma		Vioxx	SS		ORAL
33	DAY						
		Vaginal Haemorrhage		Bayer Aspirin	C		ORAL
		Vasodilatation		Bayer Aspirin	C		ORAL
		Vomiting		Vitamins (Unspecified)	C		
UNKNOWN							

Date:06/28/04ISR Number: 4385758-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6	MON					
Initial or Prolonged	Apnoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6	MON					
Disability	Asthma		Amaryl	C		
UNKNOWN						
	Atrial Tachycardia		Metformin	C		
UNKNOWN						
	Blood Cholesterol Abnormal					
	Brain Hypoxia					
	Cardiac Arrest					
	Cardiac Failure					
	Congestive					
	Cardiac Valve Disease					
	Cardio-Respiratory Arrest					
	Cardiomegaly					
	Cardiomyopathy					
	Cataract					
	Coma					
	Constipation					
	Convulsion					

Coronary Artery Disease
Diabetes Mellitus
Dizziness
Emotional Distress
Excoriation
Grand Mal Convulsion
Hepatitis B
Hypertension
Hypoaesthesia
Injury
Lacunar Infarction
Lung Disorder
Myocardial Infarction
Nausea
Nervous System Disorder
Paraesthesia
Sarcoidosis
Sick Sinus Syndrome
Sinus Bradycardia
Sleep Apnoea Syndrome
Syncope
Thrombosis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/04ISR Number: 4385760-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Back Pain		[Therapy Unspecified]	C				UNKNOWN
	Benign Prostatic Hyperplasia		Tenormin	C				UNKNOWN
	Cardiac Failure		Tenormin	C				UNKNOWN
	Congestive		Lanoxin	C				UNKNOWN 1051 DAY
	Chest Pain		Micronase	C				UNKNOWN
	Coronary Artery Disease		Zestril	C				UNKNOWN 2170 DAY
	Coronary Artery		Zestril	C				UNKNOWN 2170 DAY
	Restenosis		Glucophage	C				UNKNOWN
	Depression		Aciphex	C				UNKNOWN
	Diabetes Mellitus Non-Insulin-Dependent							
	Diabetic Nephropathy							
	Diabetic Neuropathy							
	Diabetic Retinopathy							
	Drug Effect Decreased							
	Drug Ineffective							
	Fall							
	Hepatitis							
	Herpes Zoster							
	Hypercholesterolaemia							
	Infection							
	Injury							

Insomnia
Intervertebral Disc
Disorder
Ischaemic Cardiomyopathy
Pneumonia
Sepsis
Sexual Dysfunction

Date:06/28/04ISR Number: 4385763-6Report Type:Expedited (15-DaCompany Report #IT-MERCK-0308ITA00017
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ascites	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disseminated	Professional	Esomeprazole					
Initial or Prolonged	Intravascular Coagulation		Magnesium	SS		ORAL		
	Hepatic Failure		Hydrochlorothiazide					
	Hepatorenal Syndrome		And Ramipril	SS		ORAL		
	Jaundice Cholestatic							
	Oliguria							

Date:06/28/04ISR Number: 4385764-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00068
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Cholesterol
	Increased
	Breast Disorder

	Chest Pain						
	Emotional Distress						
	Gastric Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL	4 MON
	Hypertension						
	Nervousness						
	Peptic Ulcer						

Date:06/28/04ISR Number: 4385765-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0311GBR00026
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Haematemesis	Professional	Aspirin	SS		ORAL	
	Melaena		Ibuprofen	SS			TOPICAL
	Myocardial Infarction		Acetaminophen	C			UNKNOWN
			Fosamax	C		ORAL	
			Calcium Carbonate And Cholecalciferol	C		ORAL	
			Simvastatin	C		ORAL	
			Levothyroxine Sodium	C		ORAL	
			Dihydrocodeine	C			UNKNOWN
			Betahistine Hydrochloride	C			UNKNOWN
			Alfacalcidol	C		ORAL	

Date:06/28/04ISR Number: 4385767-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01470
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Blood Urea Abnormal	Professional					
	Gastrointestinal Haemorrhage						

Date:06/28/04ISR Number: 4385768-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01718
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Intervertebral Disc Disorder							

Date:06/28/04ISR Number: 4385769-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0312FRA00088
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypotension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure Acute		Candesartan Cilexetil	SS		ORAL		
	Somnolence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/04ISR Number: 4385770-3Report Type:Expedited (15-DaCompany Report #IT-MERCK-0406ITA00034
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged			Carbamazepine	C		ORAL		

Date:06/28/04ISR Number: 4385771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01681
Age:89 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Life-Threatening	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		2 MON
Hospitalization -	Duodenal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		5 MON
Initial or Prolonged	Perforation		Vioxx	SS	Merck & Co., Inc	ORAL		2 MON
Disability	Gastrointestinal		Tylenol	C		ORAL		
Other	Haemorrhage		Fosamax	C		ORAL		
	Post Procedural		Norvasc	C		ORAL		
	Complication		Aspirin	C				UNKNOWN
	Respiratory Failure		Lipitor	C				UNKNOWN
	Spinal Column Stenosis		Hyzaar	C		ORAL		
			Toprol Xl Tablets	C				UNKNOWN
			Darvon	C		ORAL		

Date:06/28/04ISR Number: 4385772-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00130
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Morphine Sulfate	C				UNKNOWN

Date:06/28/04ISR Number: 4385999-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization - Initial or Prolonged	Aneurysm
Disability	Angina Pectoris
Other	Anxiety
	Blood Triglycerides Increased
	Cerebral Haemorrhage
	Chest Wall Pain
	Death
	Deep Vein Thrombosis
	Depression
	Dizziness
	Drug Hypersensitivity
	Dyspepsia
	Dyspnoea
	Emotional Distress
	Gastrointestinal Disorder
	High Density Lipoprotein Increased
	Hyperlipidaemia
	Hypertension
	Injury
	Oedema Peripheral
	Transient Ischaemic

Attack						
Dose	Duration	Report Source	Product	Role	Manufacturer	Route
586 DAY			Vioxx	PS	Merck & Co., Inc	ORAL
586 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN			Tylenol	C		
UNKNOWN			Albuterol	C		
UNKNOWN			Amoxicillin	C		
UNKNOWN			Aspirin	C		
UNKNOWN	119 DAY		Lotensin	C		
UNKNOWN			Correctol (Bisacodyl)	C		
UNKNOWN			Cerivastatin Sodium	C		
UNKNOWN			Baycol	C		
UNKNOWN			Doxepin Hydrochloride	C		
UNKNOWN			Calan	C		
UNKNOWN			Hydrochlorothiazide	C		
UNKNOWN			Maxzide	C		
UNKNOWN			Dyazide	C		
UNKNOWN			Dyazide	C		
UNKNOWN			Medrol	C		
UNKNOWN			Singulair	C		
UNKNOWN			Pravachol	C		
UNKNOWN	1210 DAY					

Date:06/28/04ISR Number: 4386003-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02122
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chlamydial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Depression		Acetaminophen	C				
UNKNOWN								
Other	Diarrhoea		Vicodin Tablets	C				
UNKNOWN								
	Musculoskeletal Stiffness							
	Pain							
	Scrotal Pain							
	Sleep Disorder							
	Suicidal Ideation							
	Syncope							
	Tachycardia							

Date:06/28/04ISR Number: 4386005-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0309GBR00128
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Aspirin	SS		ORAL		
	Oesophageal Ulcer		Tramadol Hydrochloride	C		ORAL		
			Trazodone Hydrochloride	C		ORAL		

Date:06/28/04ISR Number: 4386006-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	422 DAY	
		Blood Glucose Increased		Lasix (Furosemide)	SS			UNKNOWN	
		Cardiac Failure		Zestril	SS			UNKNOWN	
		Congestive		Zestril	SS			UNKNOWN	
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	406 DAY	
		Coronary Artery Disease		Tylenol	C			UNKNOWN	
		Gastrointestinal Infection		Calcium (Unspecified)	C			UNKNOWN	
		Hyperparathyroidism		Plavix	C			UNKNOWN	
		Secondary		Naproxen	C			UNKNOWN	
		Injury		Temazepam	C			UNKNOWN	
		Insomnia		Spironolactone	C			UNKNOWN	
		Ischaemic Cardiomyopathy		Zocor	C		ORAL		
		Meniere'S Disease		Miacalcin	C			UNKNOWN	
		Mitral Valve Incompetence		Zantac	C			UNKNOWN	
		Myalgia		Nitro	C			UNKNOWN	
		Nerve Compression		Motrin	C			UNKNOWN	
		Osteoporosis		Prinivil	C			UNKNOWN	
		Pharyngitis		Glucotrol	C			UNKNOWN	
		Renal Failure Acute		Cardizem	C			UNKNOWN	
		Renal Failure Chronic		Prozac	C			UNKNOWN	
		Seasonal Allergy							
		Silent Myocardial Infarction							
		Sinusitis							

Skin Ulcer
Tricuspid Valve
Incompetence
Ventricular Dysfunction

Date:06/28/04ISR Number: 4386011-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01617
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Urinary Tract Infection		Xanax	C			UNKNOWN	
			Methadone Hcl	C			UNKNOWN	
			Zanaflex	C			UNKNOWN	
			Topamax	C			UNKNOWN	

Date:06/28/04ISR Number: 4386012-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01731
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:06/28/04ISR Number: 4386014-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety Disorder
	Arthritis

		Arthropathy					
		Cardiac Murmur					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Contusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea					
		Emotional Distress					
		Fatigue					
		Gastric Disorder					
		Haemorrhage					
		Neoplasm Malignant					
		Palpitations					
		Panic Disorder					
		Peptic Ulcer					
		Swelling					
		Urine Odour Abnormal					

Date:06/28/04ISR Number: 4386016-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Aspirin	C		
UNKNOWN							
		Cardiac Disorder		Captopril	C		
UNKNOWN							
		Emotional Distress		Baycol	C		
UNKNOWN							
		Gastrointestinal Disorder		Estrogens			
		Myalgia		(Unspecified)	C		
UNKNOWN							
		Myocardial Infarction		Hydrodiuril	C		
UNKNOWN							
		Pain In Extremity		Motrin	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Nitroquick	C		
UNKNOWN							

Date:06/28/04ISR Number: 4386017-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chills		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum		Lipitor	C			UNKNOWN	3142 DAY
	Flank Pain		Lotensin	C			UNKNOWN	
	Gastritis		Lotensin	C			UNKNOWN	
	Haemorrhoids		Vasotec	C		ORAL	3507 DAY	
	Helicobacter Infection		Vasotec	C		ORAL	3507 DAY	
	Hiatus Hernia		Prozac	C			UNKNOWN	
	Hyperhidrosis		Prozac	C			UNKNOWN	
	Hyperlipidaemia		Prozac	C			UNKNOWN	
	Hypertension		Ginseng	C			UNKNOWN	
	Sinus Tachycardia		Naproxen	C			UNKNOWN	
			Accupril	C			UNKNOWN	
			Accupril	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/04ISR Number: 4386019-8Report Type:Expedited (15-DaCompany Report #IE-MERCK-0406GBR00184
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS		ORAL		
			Bumetanide	SS		ORAL		

Date:06/28/04ISR Number: 4386020-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02027
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	International Normalised							
	Ratio Increased							

Date:06/28/04ISR Number: 4386021-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0406NOR00016
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
10 DAY								
Initial or Prolonged	Perforation		Dalteparin Sodium	C				
SUBCUTANEOUS							4	DAY
	Haematemesis		Vasotec	C		ORAL		
	Peritonitis		Escitalopram Oxalate	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

Date:06/28/04ISR Number: 4386022-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
12 DAY								

Date:06/28/04ISR Number: 4386040-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00099
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
Disability	Bladder Spasm
Other	Cellulitis
	Cerebrovascular Accident
	Convulsion
	Depression
	Emotional Distress
	Facial Pain
	Fracture Malunion
	Generalised Anxiety Disorder
	Haemorrhage
	Hypertension
	Hypertriglyceridaemia
	Hypotension
	Nasal Congestion
	Post-Traumatic Stress Disorder
	Skin Laceration
	Sleep Disorder
	Transient Ischaemic Attack

	Vaginal Mycosis Ventricular Hypertrophy White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
			[Therapy Unspecified]	C			UNKNOWN	
			Adenosine	C			UNKNOWN	
			Keflex	C			UNKNOWN	

Date:06/28/04ISR Number: 4386870-4Report Type:Direct Company Report #CTU 221699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation		Vioxx (Rofecoxib -Merck)	PS	Merck	ORAL	25 MG PO	DAILY PRN

Date:06/28/04ISR Number: 4389533-4Report Type:Expedited (15-DaCompany Report #04P-167-0263855-00
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Retinal Haemorrhage	Foreign Health Professional	Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab)	PS		SUBCUTANEOUS	40 MG,	SUBCUTANEOUS
			Estrogens Conjugated	SS				
			Fluoxetine	SS				
			Methotrexate	SS				
			Rofecoxib	SS				
			Paramol-118	SS				
			Clavulin	SS				

Date:06/29/04ISR Number: 4386128-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00108
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Feprazone	C			UNKNOWN	
	Dizziness		Injectable Gold (Unspecified)	C			UNKNOWN	
	Emotional Distress							
	Headache							

Date:06/29/04ISR Number: 4386129-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amenorrhoea
Disability	Anxiety
Other	Arthralgia
	Cardiac Failure
	Congestive
	Carpal Tunnel Syndrome
	Complex Regional Pain Syndrome
	Dehydration
	Depression

		Diverticulum					
		Emotional Distress					
		Fear	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Gastrooesophageal Reflux	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Disease		Albuterol	C		
RESPIRATORY							
		Haemorrhoids					
(INHALATION)							
		Headache		Augmentin	C		
UNKNOWN							
		Hiatus Hernia		Vitamins			
		Hypersensitivity		(Unspecified)	C		
UNKNOWN							
		Intervertebral Disc		Allegra	C		
UNKNOWN							
		Disorder		Flonase	C		
UNKNOWN							
		Intervertebral Disc		Toradol	C		
UNKNOWN							
		Protrusion					
		Joint Swelling					
		Menorrhagia					
		Orthopnoea					
		Ovarian Cyst					
		Prescribed Overdose					
		Skin Laceration					
		Sleep Apnoea Syndrome					
		Tachycardia					
		Uterine Haemorrhage					
		Weight Increased					

Date:06/29/04ISR Number: 4386504-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acrochordon	Health	Vioxx	PS	Merck & Co., Inc	ORAL
34	DAY						
Initial or Prolonged		Alcoholic Seizure	Professional				
Other		Anaemia					
		Blood Pressure					

Fluctuation
Cardiovascular Disorder
Change Of Bowel Habit
Duodenitis
Encephalopathy
Grand Mal Convulsion
Haematemesis
Headache
Hordeolum
Influenza
Limb Injury
Oedema
Pruritus
Renal Failure
Tenosynovitis Stenosans
Vision Blurred
Weight Decreased

Date:06/29/04ISR Number: 4386510-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Artery Dissection
Disability	Blood Cholesterol Increased
	Blood Pressure

		Fluctuation					
		Cardiac Disorder					
		Carotid Artery Stenosis					
		Cerebral Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
93	MON						
		Drug Ineffective	Professional	Baclofen	C		
UNKNOWN							
		Embolic Stroke		Flonase	C		
UNKNOWN							
		Peroneal Nerve Palsy		Prilosec	C		
UNKNOWN							
		Respiratory Failure					
		Ventricular Hypertrophy					
		Vertebral Artery Stenosis					
		Vertebrobasilar					
		Insufficiency					

Date:06/29/04ISR Number: 4386511-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Aortic Valve Stenosis	Professional				
		Arthralgia					
		Carotid Artery Disease					
		Coronary Artery Disease					
		Dementia					
		Difficulty In Walking					
		Dizziness					
		Drug Hypersensitivity					
		Fall					
		Insomnia					
		Joint Swelling					
		Laceration					
		Myocardial Ischaemia					
		Pain In Extremity					
		Renal Cyst					
		Seasonal Allergy					
		Urinary Tract Infection					

Date:06/29/04ISR Number: 4386513-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		156 DAY
Initial or Prolonged	Cerebral Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Disability	Gliosis		Zoloft	C				UNKNOWN
Other	Hydrocephalus		[Therapy Unspecified]	C				UNKNOWN
	Hypercholesterolaemia		Tylenol	C				UNKNOWN
	Temporomandibular Joint		Ortho-Novum	C				UNKNOWN
	Syndrome		Necon	C				UNKNOWN
			Advil	C				UNKNOWN
			Motrin	C				UNKNOWN
			Methylphenidate	C				UNKNOWN
			Naproxen	C				UNKNOWN
			Aleve	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/04ISR Number: 4386514-1Report Type:Expedited (15-DaCompany Report #PT-MERCK-0406PRT00013
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/04ISR Number: 4386515-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	RESPIRATORY (INHALATION)	
	Cerebrovascular Accident		Ventolin (Albuterol)	C				
Disability	Conversion Disorder							
Other	Dizziness		Aspirin	C			UNKNOWN	
	Emotional Distress		Celexa	C			UNKNOWN	
	Generalised Anxiety		Lexapro	C			UNKNOWN	
	Disorder		Aerobid	C			UNKNOWN	
	Hypertension		Synthroid	C			UNKNOWN	
	Injury		Claritin	C			UNKNOWN	
	Lacunar Infarction		Niacin	C			UNKNOWN	
	Loss Of Consciousness							
	Oesophageal Spasm							
	Palpitations							
	Post Procedural Complication							
	Thrombosis							

14671DAY

Date:06/29/04ISR Number: 4386516-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Atherosclerosis		Reopro	C		
UNKNOWN						
	Blood Cholesterol		Tylenol	C		
UNKNOWN						
	Increased		Cordarone	C		
UNKNOWN						
	Cardiac Failure		Aspirin	C		ORAL
	Congestive		Atenolol	C		
UNKNOWN						
	Cardio-Respiratory Arrest		Buspar	C		
UNKNOWN						
	Cardiogenic Shock		Claforan	C		
UNKNOWN						
	Chest Pain		Celexa	C		
UNKNOWN						
	Convulsion		Dopamine			
	Haematuria		Hydrochloride	C		
UNKNOWN						
	Hypertension		Vasotec	C		
UNKNOWN						
	Lung Infiltration		Pepcid	C		
UNKNOWN						
	Myalgia		Prozac	C		
UNKNOWN						
	Orthostatic Hypotension		Prozac	C		
UNKNOWN						
	Ventricular Tachycardia		Dalmane	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Atrovent	C		
UNKNOWN						
			Magnesium Sulfate	C		
UNKNOWN						
			Restoril	C		
UNKNOWN						

Date:06/29/04ISR Number: 4386755-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Coronary Syndrome Acute Myocardial Infarction Adverse Event Blood Cholesterol Increased Blood Potassium Decreased Cardiac Failure Congestive Cardiomegaly Cerebrovascular Accident Coronary Artery Disease Depression Diabetes Mellitus Inadequate Control Diabetic Neuropathy Diarrhoea Escherichia Sepsis Fall Hypertension Intermittent Claudication Mitral Valve Incompetence Myocardial Infarction Oedema Peripheral Peripheral Occlusive Disease Renal Failure Respiratory Distress Transient Ischaemic Attack Urinary Tract Infection Urosepsis Uterine Infection		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/04ISR Number: 4386761-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00064
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Other	Depressed Level Of	Enoxaparin Sodium	C
SUBCUTANEOUS			
	Consciousness	Furosemide	C
UNKNOWN			
	Gammopathy	Thioctic Acid	C
UNKNOWN			
	Hepatic Failure	Torsemide	C
UNKNOWN			
		Spironolactone	C
UNKNOWN			
		Ramipril	C
UNKNOWN			

Date:06/29/04ISR Number: 4386762-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02221
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/04ISR Number: 4386764-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00152
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/04ISR Number: 4386765-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0312CHE00023
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis Erosive		Aspirin	SS		ORAL		
	Melaena		Diclofenac Sodium	SS		ORAL		
			Calcium Dobesilate	C		ORAL		
			Nadolol	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:06/29/04ISR Number: 4386767-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00007
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY

Date:06/29/04ISR Number: 4386792-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Cardiac Failure
	Congestive
	Chest Pain

Cholecystitis
Diabetes Mellitus
Inadequate Control
Drug Hypersensitivity
Duodenitis
Dyslipidaemia
Dysstasia
Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Gastritis
Hypertensive Crisis
Hypertrophic
Cardiomyopathy
Injury
Insomnia
Irritable Bowel Syndrome
Lactose Intolerance
Macular Degeneration
Myocardial Infarction
Pain

	Pain In Extremity						
	Pharyngolaryngeal Pain						
	Renal Failure Chronic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
	Salivary Gland Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR
	Skin Cancer		Diovan	C			UNKNOWN
	Spinal Osteoarthritis						
	Thrombosis						
	Urinary Tract Infection						

Date:06/30/04ISR Number: 4387706-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Ankle Fracture	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Cellulitis		Tylenol With Codeine	C			UNKNOWN
	Cerebrovascular Accident						
	Chest Pain						
	Condition Aggravated						
	Diverticulum Intestinal						
	Dizziness						
	Empty Sella Syndrome						
	Fibromyalgia						
	Gait Disturbance						
	Headache						
	Hepatic Cyst						
	Hepatic Lesion						
	Hypertension						
	Injury						
	Intervertebral Disc						
	Degeneration						
	Labyrinthitis						
	Liver Disorder						
	Lumbar Radiculopathy						
	Lumbar Spinal Stenosis						
	Lung Disorder						

Lung Neoplasm
Nausea
Pain In Extremity
Pneumonia
Post Procedural Pain
Scar
Syncope
Urinary Retention
Vertigo Positional
Vision Blurred
Wound Infection

Date:06/30/04ISR Number: 4387708-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Disability	Arthralgia
	Arthropod Bite
	Back Pain

		Blood Glucose Increased Cardiac Failure Congestive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerumen Impaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
18	MON						
		Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
18	MON						
		Condition Aggravated Crying Deep Vein Thrombosis		Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
		Diabetes Mellitus Dizziness Drug Dependence Dyspnoea Dysuria Fall Fatigue Gait Disturbance Headache Hodgkin'S Disease Hyperhidrosis Hypertension Injury Intervertebral Disc Degeneration Intervertebral Disc Protrusion Joint Swelling Labile Hypertension Labyrinthitis Myocardial Infarction Non-Hodgkin'S Lymphoma Oedema Peripheral Orthopnoea Pain Skin Cancer Thrombophlebitis Vertigo Vertigo Positional Weight Increased					

Date:06/30/04ISR Number: 4387711-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Dermatitis		Fosamax	C		ORAL		
	Hypertension		Celebrex	C				
UNKNOWN								
	Myocardial Infarction		Celebrex	C				
UNKNOWN								
	Myocardial Ischaemia		Diovan	C				
UNKNOWN								
	Nervousness		Verapamil Msd Lp	C		ORAL		
	Streptococcal Infection		Diovan	C				
UNKNOWN								
	Urinary Tract Infection		Celebrex	C				
UNKNOWN								
	Enterococcal		Celebrex	C				
UNKNOWN								
			Duragesic	C				
UNKNOWN								

Date:06/30/04ISR Number: 4387713-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0301NOR00013
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Hospitalization - Initial or Prolonged	Melaena	Professional	Acetaminophen	C		ORAL		
	Rectal Haemorrhage		Benserazide Hydrochloride And Levodopa	C		ORAL		
			Dipyrone	C		ORAL		
			Zopiclone	C		ORAL		
			Sennosides	C		ORAL		
			Paraffin	C		ORAL		
			Paroxetine Hydrochloride	C		ORAL		

Date:06/30/04ISR Number: 4387714-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aura	Health	Vioxx	PS	Merck & Co., Inc	ORAL		138 DAY
Other	Convulsion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		138 DAY
	Emotional Distress		Dilantin	C				UNKNOWN
	Encephalomalacia		Zoloft	C				UNKNOWN
	Feeling Abnormal							
	Headache							
	Intervertebral Disc Displacement							
	Lumbar Vertebral Fracture							
	Nasal Septum Deviation							
	Nasal Turbinate Hypertrophy							
	Nose Deformity							
	Otitis Media							
	Road Traffic Accident							
	Tremor							

Date:06/30/04ISR Number: 4387717-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adjustment Disorder With Mixed Anxiety And Depressed Mood
	Arthralgia
	Back Pain
	Blood Pressure Increased
	Blood Triglycerides Increased
	Bone Pain
	Breast Pain
	Chest Pain
	Chondromalacia
	Contusion
	Coronary Artery Atherosclerosis
	Dizziness
	Drug Hypersensitivity

		Dyspepsia					
		Extrasystoles					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Sprain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Keratoacanthoma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
44	DAY						
		Kyphosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL
113	DAY						
		Pericarditis		Vioxx	SS	Merck & Co., Inc	ORAL
44	DAY						
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
113	DAY						
		Tension Headache		Vicodin Tablets	C		
UNKNOWN							
		Upper Respiratory Tract		Hydrocodone			
		Infection		Bitartrate	C		
UNKNOWN							
		Wound		Relafen	C		
UNKNOWN							

Date:06/30/04ISR Number: 4387718-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acidosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Chills		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Lipitor	C		
UNKNOWN		3142 DAY					
		Diverticulum		Lotensin	C		
UNKNOWN							
		Flank Pain		Lotensin	C		
UNKNOWN							
		Gastritis		Vasotec	C		ORAL
3507 DAY							
		Haemorrhoids		Vasotec	C		ORAL
3507 DAY							
		Hiatus Hernia		Prozac	C		
UNKNOWN							

	Hyperhidrosis	Prozac	C
UNKNOWN			
	Rhinorrhoea	Prozac	C
UNKNOWN			
		Ginseng	C
UNKNOWN			
		Naproxen	C
UNKNOWN			
		Accupril	C
UNKNOWN			
		Accupril	C
UNKNOWN			

Date:06/30/04ISR Number: 4387720-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Aspartate Aminotransferase Increased
Other	Blood Cholesterol Increased
	Blood Pressure Inadequately Controlled
	Blood Triglycerides Increased
	Blood Uric Acid Increased
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Carotid Bruit
	Cerebral Infarction
	Cerebrovascular Accident
	Comminuted Fracture

		Contusion					
		Depression					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Insulin-Dependent	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphoria		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysthymic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Eye Injury		Lipitor	C		
UNKNOWN							
		Fall		Lipitor	C		
UNKNOWN							
		Fatigue					
		High Density Lipoprotein					
		Increased					
		Hyperlipidaemia					
		Joint Injury					
		Joint Sprain					
		Loss Of Consciousness					
		Pain					
		Pain In Extremity					
		Pallor					
		Radius Fracture					
		Rib Fracture					
		Somnolence					
		Syncope					
		Syncope Vasovagal					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Weight Increased					

Date:06/30/04ISR Number: 4387722-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Accident At Work
Disability	Acute Myocardial
Other	Infarction
	Adhesion
	Alcohol Withdrawal
	Syndrome
	Alcoholism

Anaemia
Anxiety
Arthralgia
Arthropathy
Atherosclerosis
Biliary Neoplasm
Bronchitis
Bronchopneumonia
Cardiac Failure
Congestive
Cerebrovascular Accident
Condition Aggravated
Convulsion
Coronary Artery Disease
Coronary Ostial Stenosis
Depression
Drug Dependence
Drug Ineffective

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dysuria					
		Ejection Fraction Decreased					
		Emotional Distress	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Facet Joint Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Faecal Occult Blood		Vioxx	SS	Merck & Co., Inc	ORAL
		Positive		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Hepatitis C		Lortab	C		
		Hyperlipidaemia		Acetaminophen And Hydrocodone Bitartrate	C		
		Hypertension					
UNKNOWN		Iliac Artery Stenosis					
		Insomnia		Trazodone Hydrochloride	C		
		Intervertebral Disc					
UNKNOWN		Protrusion		Amitriptyline Hydrochloride	C		
		Loss Of Consciousness					
UNKNOWN	874 DAY	Lumbar Spinal Stenosis		Celebrex	C		
UNKNOWN	362 DAY	Meralgia Paraesthetica		Neurontin	C		
UNKNOWN		Micturition Urgency		Hydrocodone Bitartrate	C		
		Mitral Valve Incompetence					
UNKNOWN		Mouth Ulceration		Ibuprofen	C		
		Muscle Spasms		Lorazepam	C		
UNKNOWN	2 DAY	Myocardial Infarction		Robaxin	C		
UNKNOWN	957 DAY	Myofascial Pain Syndrome					
		Osteoarthritis					
		Panic Attack					
		Peripheral Vascular Disorder					
		Pneumonia					
		Pneumonia Viral					
		Pollakiuria					
		Postoperative Adhesion					
		Procedural Hypertension					
		Prostatitis					
		Pyrexia					

Radiculitis
Rash Erythematous
Rash Pruritic
Sciatica
Spinal Osteoarthritis
Stress
Syncope
Urinary Tract Infection
Vision Blurred

Date:06/30/04ISR Number: 4387725-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00021
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY	
Hospitalization -	Insufficiency		Aspirin	C			UNKNOWN	
Initial or Prolonged	Leukopenia		Ferrous Glycine Sulfate	C			UNKNOWN	
	Renal Failure		Glimepiride	C			UNKNOWN	
	Urinary Retention		Torsemide	C			UNKNOWN	
	Urinary Tract Infection		Levothyroxine Sodium	C			UNKNOWN	
			Metoprolol Succinate	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/04ISR Number: 4387726-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0406SWE00016
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Alprazolam	C			UNKNOWN	
			Flunitrazepam	C			UNKNOWN	
			Hydroxyzine Hydrochloride	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Mirtazapine	C			UNKNOWN	
			Propiomazine Maleate	C			UNKNOWN	

Date:06/30/04ISR Number: 4387729-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abdominal Pain Upper
Disability	Arthralgia
Other	Atherosclerosis
	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine Increased
	Bone Marrow Depression
	Breast Cyst
	Bronchitis
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Colonic Polyp
	Coronary Artery Disease
	Depression
	Disease Recurrence
	Dyspepsia
	Ecchymosis

Episcleritis
Faeces Discoloured
Fall
Felty'S Syndrome
Fluid Overload
Gastrooesophageal Reflux
Disease
Haemorrhoidal Haemorrhage
Herpes Zoster
Herpes Zoster Ophthalmic
Hiatus Hernia
Hypertension
Hypertonic Bladder
Immunoglobulins Decreased
Immunosuppression
Influenza Like Illness
Insomnia
Keratitis Herpetic
Laryngitis Viral
Leukopenia
Lymphoma
Mental Impairment
Migraine

		Mitral Valve Incompetence					
		Mouth Injury					
		Musculoskeletal Stiffness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nocturia	Professional	Remicade	SS		
INTRAVENOUS							
		Orthostatic Hypotension		Remicade	SS		
INTRAVENOUS							
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pancytopenia		Methotrexate	SS		
UNKNOWN							
		Platelet Disorder		Methotrexate	SS		
UNKNOWN							
		Prostatitis		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Rib Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Therapy Non-Responder		[Therapy			
		Thrombocytopenia		Unspecified]	C		
UNKNOWN							
		Transient Ischaemic		Tylenol	C		
UNKNOWN							
		Attack		Acyclovir	C		
INTRAVENOUS							
		Trigger Finger		Proventil	C		ORAL
		Viral Pharyngitis		Allopurinol	C		
UNKNOWN							
		Weight Decreased		Elavil	C		ORAL
				Fiorinal With			
				Codeine	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

	K-Dur	C
UNKNOWN		
	Prilosec	C
UNKNOWN		
	Purinethol	C
UNKNOWN		
	Azathioprine	C
UNKNOWN		
	Tegretol	C
UNKNOWN		
	Tegretol	C
UNKNOWN		
	Tegretol	C
UNKNOWN		
	Zyrtec	C
UNKNOWN		
	Hydroxychloroquine Sulfate	C
UNKNOWN		
	Advil	C
UNKNOWN		

Date:06/30/04ISR Number: 4387942-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Arthritis
Other	Bursitis
	Chondromalacia
	Contusion
	Dyspnoea
	Ecchymosis
	Emotional Distress
	Eschar
	Fall
	Flank Pain
	Gastric Ulcer
	Gastritis
	Gastrointestinal Haemorrhage

Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Meniscus Lesion							
Osteoarthritis							
Patella Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Patellofemoral Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
Postoperative Fever		Vioxx	SS	Merck & Co., Inc	ORAL		
Pyrexia		Tylenol	C			UNKNOWN	
Therapeutic Response		Combivent	C			RESPIRATORY	
Decreased						(INHALATION)	
Wheezing		Allopurinol	C			UNKNOWN	
Wound Infection		Celebrex	C			UNKNOWN	
		Estradiol	C			UNKNOWN	
		Vitamin E	C			UNKNOWN	
		Diovan	C			UNKNOWN	
		Ultram	C			UNKNOWN	
		Bactrim Ds Tablets	C			UNKNOWN	
		Glucosamine	C			UNKNOWN	
		Avalide	C			UNKNOWN	
		Atrovent	C			UNKNOWN	
		Claritin	C			UNKNOWN	
		Niferex	C			UNKNOWN	
		Potassium (Unspecified)	C			UNKNOWN	
		Pyridoxine	C			UNKNOWN	

Date:06/30/04ISR Number: 4387948-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Lithium Carbonate	C				
UNKNOWN								
	Groin Pain							
	Heart Injury							
	Heart Rate Irregular							
	Hip Arthroplasty							
	Injury							
	Joint Dislocation							
	Osteoarthritis							
	Paranoia							
	Sacroiliitis							
	Stomach Discomfort							
	Suicidal Ideation							

Date:06/30/04ISR Number: 4387950-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Celebrex	C				
UNKNOWN								
	Headache							
	Intracranial Aneurysm							

Date:06/30/04ISR Number: 4387952-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0211CAN00135
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Infarction	Professional	Atenolol	SS		ORAL	12	DAY
Other	Back Pain							
	Chest Pain							
	Coronary Artery Disease							
	Coronary Artery Restenosis							
	Coronary Artery Stenosis							
	Depression							
	Fatigue							
	Hypersensitivity							
	Somnolence							

Date:06/30/04ISR Number: 4387953-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Anxiety
Other	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Inadequately Controlled
	Blood Pressure Increased
	Bronchitis
	Cachexia
	Cataract
	Cerebral Infarction
	Cerebrovascular Accident
	Constipation
	Contusion
	Cough
	Dehydration
	Depression
	Diarrhoea
	Diverticulitis
	Dizziness

Fatigue
Gastroenteritis Viral
Gastrointestinal Disorder
Increased Tendency To
Bruise
Irritable Bowel Syndrome
Keratoconjunctivitis
Sicca
Migraine
Myocardial Ischaemia
Nausea
Neurodermatitis
Normochromic Normocytic
Anaemia
Oedema Peripheral
Osteopenia
Pain
Platelet Count Increased
Pneumonia

		Renal Failure Acute Vision Blurred Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL
UNKNOWN					C		
				Acetaminophen	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Lamisil	C		
UNKNOWN							
				Estrace	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Ocuflox	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							
				Prednisone	C		
OPHTHALMIC							

Date:06/30/04ISR Number: 4387956-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01744
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Behcet'S Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
9 DAY						
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Professional				

Other	Hypochromic Anaemia

Date:06/30/04ISR Number: 4387957-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0305AUS00044
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Renal Failure Acute		Furosemide	SS		ORAL	UNKNOWN	
			Perindopril Erbumine	SS		ORAL	UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Gabapentin	C			UNKNOWN	
			Isosorbide Mononitrate	C			UNKNOWN	
			Warfarin Sodium	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	
			Omeprazole Magnesium	C			UNKNOWN	
			Insulin Lispro	C			UNKNOWN	
			Digoxin	C			UNKNOWN	

Date:06/30/04ISR Number: 4387958-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00977
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/04ISR Number: 4390064-6Report Type:Expedited (15-DaCompany Report #PERI00204002039
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Foreign	Coversyl					
Life-Threatening	Septic Shock	Health	(Perindopril)	PS		ORAL	2 MG QD PO	
Hospitalization -		Professional	Vioxx					
Initial or Prolonged		Other	(Rofecoxib)	SS		ORAL	25 MG QD PO	
			Mopral (Omeprazole)	SS		ORAL	20 MG DAILYPO	
			Elisor (Pravastatin Sodium)	SS		ORAL	10 MG DAILYPO	

Date:06/30/04ISR Number: 4415347-2Report Type:Periodic Company Report #2003021805
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Zoloft (Sertraline)	PS		ORAL	25 MG	
Initial or Prolonged	Abdominal Pain Upper						(DAILY), ORAL	
	Adverse Event		Celecoxib					
	Anorexia		(Celecoxib)	SS				
	Anxiety		Rofecoxib					
	Arthritis		(Rofecoxib)	SS				
	Asthenia		Vicodin					
	Chest Pain		(Paracetamol,					
	Confusional State		Hydrocodone					
	Cough		Bitartrate)	C				
	Delusion		Diazepam (Diazepam)	C				
	Dizziness		Vitamins (Vitamins)	C				
	Dysgeusia							
	Dyspnoea							
	Feeling Cold							
	Haematochezia							
	Hallucination							
	Hyperhidrosis							
	Hypoaesthesia							
	Influenza Like Illness							
	Insomnia							

Pruritus
Stomach Discomfort
Tremor

Date:07/01/04ISR Number: 4388346-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
Other	Adenomyosis
	Arthralgia
	Asthenia
	Bronchitis
	Cardiac Valve Disease
	Cardiomyopathy
	Cellulitis
	Chest Pain
	Complex Regional Pain Syndrome
	Constipation
	Convulsion
	Costochondritis
	Diverticulitis

		Duodenal Ulcer					
		Duodenitis					
		Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Grand Mal Convulsion		Cardura	C		
UNKNOWN							
		Haematoma Infection		Normodyne	C		
UNKNOWN							
		Haemorrhoids		Prevacid	C		
UNKNOWN							
		Helicobacter Gastritis		Flagyl	C		
UNKNOWN							
		Hypertension		Minoxidil	C		
UNKNOWN							
		Hypertensive Crisis		Procardia Xl	C		
UNKNOWN							
		Hypokalaemia					
		Irritable Bowel Syndrome					
		Laceration					
		Loss Of Consciousness					
		Memory Impairment					
		Mental Status Changes					
		Micturition Urgency					
		Myocardial Infarction					
		Nausea					
		Oedema Peripheral					
		Oesophagitis					
		Orthopnoea					
		Pain In Extremity					
		Palpitations					
		Salpingitis					
		Sensory Loss					
		Supraventricular					
		Tachycardia					
		Upper Respiratory Tract					
		Infection					

Date:07/01/04ISR Number: 4388351-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Bladder Obstruction	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cerebral Atherosclerosis	[Therapy			
	Cerebral Infarction	Unspecified]	C		
UNKNOWN					
	Epistaxis	Albuterol	C		
RESPIRATORY					
	Haemorrhoids				
(INHALATION)					
	Headache	Albuterol	C		ORAL
	Pneumonia	Allopurinol	C		
UNKNOWN					
	Prostate Cancer	Ecotrin	C		
UNKNOWN					
	Rectal Haemorrhage	Atenolol	C		
UNKNOWN					
	Rectal Polyp	Palgic D	C		ORAL
	Scleral Haemorrhage	Mavik	C		ORAL
	Sinusitis	Mavik	C		ORAL
		Celebrex	C		
UNKNOWN					
		Docusate Calcium	C		
UNKNOWN					
		Guaifenex La	C		
UNKNOWN					
		Hydrodiuril	C		ORAL
		Ibuprofen	C		
UNKNOWN					
		Atrovent	C		
UNKNOWN					
		Nitroglycerin	C		
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/04ISR Number: 4388352-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anoxic Encephalopathy		Tylenol With Codeine					
Initial or Prolonged	Anxiety		#4	C				
UNKNOWN								
Other	Cardio-Respiratory Arrest		Tylenol With Codeine					
	Convulsion		#4	C				
UNKNOWN								
	Coronary Artery Disease		Celebrex	C				
UNKNOWN								
	Deep Vein Thrombosis		Arthrotec	C		ORAL		
	Gastric Disorder		Arthrotec	C		ORAL		
	Hypertension		Arthrotec	C		ORAL		
	Hypokalaemia		Premarin	C				
UNKNOWN								
	Lumbar Spinal Stenosis		Provera	C				
UNKNOWN								
	Myocardial Infarction		Daypro	C				
UNKNOWN								
	Palpitations							
	Pneumonia Aspiration							
	Postoperative Ileus							
	Pulmonary Oedema							
	Shock							
	Syphilis							

Date:07/01/04ISR Number: 4388354-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vicodin Tablets	C				
UNKNOWN								
Disability	Connective Tissue							
	Inflammation							
	Coronary Artery Disease							
	Depression							
	Dyspnoea							
	Emotional Distress							
	Heart Rate Irregular							

Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Mitral Valve Prolapse
Normochromic Normocytic
Anaemia
Sleep Apnoea Syndrome
Weight Increased

Date:07/01/04ISR Number: 4388355-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02180
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Cardiomyopathy
Disability	Cerebrovascular Accident
	Deep Vein Thrombosis
	Dehydration
	Diabetes Mellitus
	Diabetic Gangrene
	Dysphonia
	Ear Disorder
	Fall

		Hearing Impaired					
		Hypercoagulation					
		Hypochromic Anaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Iron Deficiency Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Micturition Urgency		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Aspirin	C		
UNKNOWN							
		Oedema		Cipro	C		
UNKNOWN		7 DAY					
		Oestrogen Deficiency		Heparin	C		
UNKNOWN							
		Pain		Insulin	C		
UNKNOWN							
		Pelvic Organ Injury		Glucophage	C		
UNKNOWN							
		Pneumonia					
		Pollakiuria					
		Pulmonary Hypertension					
		Renal Failure					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Skin Ulcer					
		Trigger Finger					
		Urge Incontinence					
		Urinary Tract Infection					

Date:07/01/04ISR Number: 4388356-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
	Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vicodin Tablets	C		
UNKNOWN						
	Blood Urine Present		Effexor Xr	C		
UNKNOWN						
	Cataract		Ecotrin	C		
UNKNOWN						

	Chest Wall Pain	Wellbutrin Sr	C
UNKNOWN			
	Depression	Prevacid	C
UNKNOWN			
	Dizziness	Pravachol	C
UNKNOWN			
	Eye Disorder	Accupril	C
UNKNOWN			
	Faecal Incontinence		
	Flank Pain		
	Gastric Disorder		
	Gastric Haemorrhage		
	Haemorrhoids		
	Herpes Virus Infection		
	Influenza		
	Intervertebral Disc Degeneration		
	Joint Stiffness		
	Muscle Strain		
	Road Traffic Accident		
	Rotator Cuff Syndrome		
	Spinal Column Stenosis		
	Tendonitis		
	Ulcer		
	Viral Infection		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/04ISR Number: 4388359-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Disorder		Tylenol	C				
UNKNOWN								
Other	Blood Pressure Increased		Vicodin Tablets	C				
UNKNOWN								
	Carotid Artery Occlusion		Celexa	C				
UNKNOWN							1839 DAY	
	Carotid Artery Stenosis		Plavix	C				
UNKNOWN							366 DAY	
	Cerebral Ischaemia		Flexeril	C		ORAL		
	Circulatory Collapse		Avapro	C				
UNKNOWN							1681 DAY	
	Coronary Artery Disease		Ativan	C				
UNKNOWN							1344 DAY	
	Coronary Artery Occlusion		Niacin	C				
UNKNOWN							1830 DAY	
	Coronary Artery Stenosis							
	Deafness							
	Dizziness							
	Dyspnoea Exertional							
	Emotional Distress							
	Femur Fracture							
	Gastrointestinal Disorder							
	Injury							
	Migraine							
	Muscle Spasms							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Neovascularisation							
	Post Procedural Complication							
	Sinusitis							
	Stress							
	Ventricular Hypokinesia							

Date:07/01/04ISR Number: 4388362-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0304FRA00005
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/01/04ISR Number: 4388363-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Stenosis
Disability	Aortic Valve Incompetence
	Atelectasis
	Atrial Fibrillation
	Blood Pressure Increased
	Carotid Bruit
	Constipation
	Depressed Level Of Consciousness
	Depression
	Dizziness
	Dyspnoea Exertional
	Dystrophic Calcification
	Injury
	Intervertebral Disc Degeneration

		Lung Neoplasm					
		Medical Device Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Nocturia		Tylenol	C		
UNKNOWN							
		Osteopenia		Codeine	C		
UNKNOWN							
		Palpitations		Vasotec	C		ORAL
		Postoperative Infection		Premarin	C		
UNKNOWN							
		Postoperative Thoracic		Premarin	C		
UNKNOWN							
		Procedure Complication		Zocor	C		ORAL
		Syncope		Hydrocodone			
		Ventricular Dysfunction		Hydrochloride	C		
UNKNOWN							
		Ventricular Hypertrophy		Levsin	C		
UNKNOWN							
				Synthroid	C		ORAL
				Prilosec	C		ORAL

Date:07/01/04ISR Number: 4388364-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01717
Age:58 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Pressure Increased					
		Diabetes Mellitus					
		Gout					
		Inner Ear Disorder					
		Pollakiuria					
		Ulcer					

Date:07/01/04ISR Number: 4388365-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02064
Age:88 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 7 DAY	Cardiac Failure	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive	[Therapy			
Other		Unspecified]	C		
UNKNOWN					

Date:07/01/04ISR Number: 4388366-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Body Tinea
Other	Carpal Tunnel Syndrome
	Coronary Artery
	Atherosclerosis
	Diabetes Mellitus
	Non-Insulin-Dependent
	Emotional Distress
	Fatigue
	Hypersensitivity
	Overdose
	Pain In Extremity
	Pilonidal Cyst
	Tendonitis
	Tenosynovitis
	Trigger Finger

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc		UNKNOWN	1 DAY
	Flexeril	C			UNKNOWN	
	Monopril	C			UNKNOWN	
	Pravachol	C			UNKNOWN	

Date:07/01/04ISR Number: 4388368-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		[Therapy					
	Cardiac Disorder		Unspecified]	C			UNKNOWN	
	Cardiac Flutter		Remicade	C			UNKNOWN	
	Gastric Disorder		Injectable Gold					
	Headache		(Unspecified)	C			UNKNOWN	
	Nausea		Methotrexate	C			UNKNOWN	
	Swelling							
	Uterine Disorder							

Date:07/01/04ISR Number: 4388369-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00178
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis C		Vioxx	PS	Merck & Co., Inc	ORAL	61	DAY
Initial or Prolonged								

Date:07/01/04ISR Number: 4388370-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01232
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Unstable
	Anxiety Disorder
	Arthralgia
	Asthenia
	Cardiac Disorder
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Deafness
	Dementia
	Dyskinesia
	Gastrooesophageal Reflux
	Disease
	Hepatitis B
	Hypertension
	Joint Sprain
	Myocardial Ischaemia
	Neuropathy Peripheral
	Osteoporosis

		Otitis Media					
		Palpitations					
		Panic Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Pain		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Peripheral Vascular		Norvasc	C		
UNKNOWN							
		Disorder		Lotrel	C		
UNKNOWN							
		Prescribed Overdose		Venlafaxine			
		Rheumatoid Arthritis		Hydrochloride	C		
UNKNOWN							
		Schizophrenia, Paranoid		Celebrex	C		
UNKNOWN							
		Type		Lorazepam	C		
UNKNOWN							
		Toe Deformity					

Date:07/01/04ISR Number: 4388371-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
611 DAY							
Initial or Prolonged		Infarction		Tylenol	C		
UNKNOWN							
		Angina Unstable		Lipitor	C		ORAL
		Anxiety		Lipitor	C		
UNKNOWN							
		Cardiac Failure		Zithromax	C		
UNKNOWN							
		Congestive		Nitrostat	C		
SUBLINGUAL							
		Coronary Artery Disease		Prilosec	C		ORAL
		Ischaemic Cardiomyopathy		Inderal	C		
UNKNOWN							
		Mixed Hyperlipidaemia		Zantac	C		ORAL

Date:07/01/04ISR Number: 4388372-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		413 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		413 DAY
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		413 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		413 DAY
	Chronic Obstructive		Aspirin	C				UNKNOWN
	Pulmonary Disease		Aspirin	C				UNKNOWN
	Deep Vein Thrombosis		Lotensin	C				UNKNOWN
	Drug Hypersensitivity		Zyrtec	C				UNKNOWN
	Emotional Distress		Hydro-Chlor	C				UNKNOWN
	Epistaxis		Prednisone	C				UNKNOWN
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Lung Disorder							
	Oedema Peripheral							
	Oropharyngeal Swelling							
	Swelling Face							
	Swollen Tongue							

Date:07/01/04ISR Number: 4388380-7Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12624763
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Elisor Tabs 20 Mg	PS	Bristol-Myers Squibb			
Initial or Prolonged	Haemodynamic Instability				Company	ORAL		
Duration of								
	Pyrexia							
Therapy:								
	Vomiting							
"few years"								
			Sotalex Tabs 80 Mg	SS	Comptoir Medical Du			

	Plavix	SS	Cambodge Regulatory Health Authority South Africa	ORAL
Duration of Therapy: "few years"				
	Vastarel	SS		ORAL
Dose Value: 3 Unit; Duration of Therapy: "few years"				
	Vioxx	SS		ORAL
	Tanakan	SS		ORAL

Date:07/01/04ISR Number: 4388780-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Affect Lability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Enbrel	C			UNKNOWN	
	Arterial Stenosis		Enbrel	C			UNKNOWN	
	Atherosclerosis		Prozac	C			UNKNOWN	
	Back Pain		Azulfidine	C			UNKNOWN	
	Blood Cholesterol Increased		Trazodone Hydrochloride	C			UNKNOWN	
	Cellulitis		Prozac	C			UNKNOWN	
	Cerebrovascular Accident		Prozac	C			UNKNOWN	
	Chest Pain		Prilosec	C			UNKNOWN	

	Coagulopathy	Prednisone	C
UNKNOWN			
	Coronary Artery Restenosis Coronary Artery Stenosis Dizziness Postural Electrocardiogram Poor R-Wave Progression Electrocardiogram T Wave Inversion Erectile Dysfunction Feeling Abnormal Fluid Retention Gastrointestinal Pain Gastrooesophageal Reflux Disease Groin Pain Gynaecomastia Hiatus Hernia Hypertension Liver Disorder Myocardial Infarction Nephrolithiasis Post Procedural Complication Psoriatic Arthropathy Rhinitis Seasonal Sinus Bradycardia Therapeutic Response Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/04ISR Number: 4388787-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		696 DAY
Initial or Prolonged	Aortic Calcification	Professional	Reglan	SS				UNKNOWN
Disability	Blood Cholesterol		Celebrex	C				UNKNOWN
	Increased		Catapres	C				UNKNOWN
	Blood Pressure Increased		Flonase	C				UNKNOWN
	Blood Triglycerides		Prilosec	C				UNKNOWN
	Increased		Lopid	C				UNKNOWN
	Carotid Artery Stenosis		Robaxin	C				UNKNOWN
	Cerebellar Infarction							
	Cerebrovascular Disorder							
	Cholecystitis							
	Cognitive Disorder							
	Deafness Neurosensory							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Diabetic Neuropathy							
	Dystonia							
	Fall							
	Glossitis							
	Haematochezia							
	Hiatus Hernia							
	High Density Lipoprotein							
	Decreased							
	Low Density Lipoprotein							
	Increased							
	Major Depression							
	Neuropathy Peripheral							
	Orthostatic Hypotension							
	Pseudodementia							
	Radiculopathy							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Treatment Noncompliance							
	Tremor							

Date:07/01/04ISR Number: 4388790-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00114
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Celecoxib	SS		ORAL		
	Generalised Oedema		Cefpodoxime Proxetil	C		ORAL		

Date:07/01/04ISR Number: 4388792-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0310CHE00016
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Creatinine
Hospitalization -	Increased
Initial or Prolonged	Bradycardia
	Drug Interaction
	Electrocardiogram
	Abnormal
	Headache
	Hypotension
	Malaise

		Therapeutic Agent Toxicity					
		Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Health	Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
			Professional	Carbamazepine	SS		ORAL
12	YR						
				Carbamazepine	SS		ORAL
				Lithium Carbonate	SS		ORAL
12	YR						
				Lithium Carbonate	SS		ORAL
				Mirtazapine	C		ORAL
3	MON						
				Zopiclone	C		ORAL
				Pipamperone Hydrochloride	C		ORAL
6	YR						

Date:07/01/04ISR Number: 4388795-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0312GBR00128
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Lactic Acidosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Renal Failure Acute	Professional	Metformin	SS		
UNKNOWN							

Date:07/01/04ISR Number: 4388797-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Deep Vein Thrombosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Depression	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Premarin	C		
UNKNOWN							
		Degeneration		Vitamins			

	Meniscus Lesion	(Unspecified)	C
UNKNOWN			
	Mixed Incontinence	Ultram	C
UNKNOWN			
	Myalgia	Allegra	C
UNKNOWN			
	Myositis	Lasix (Furosemide)	C
UNKNOWN	366 DAY		
	Post Thrombotic Syndrome	Plaquenil	C
UNKNOWN			
		Plaquenil	C
UNKNOWN			
		Accupril	C
UNKNOWN	535 DAY		

Date:07/01/04ISR Number: 4388803-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
	Cellulitis
	Coronary Artery Disease
	Emotional Distress
	Eyelid Ptosis
	Haemangioma
	Macular Degeneration
	Myocardial Infarction
	Oedema Peripheral
	Osteoporosis
	Postnasal Drip
	Radiculopathy
	Renal Failure
	Sinusitis

		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Urethritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Disturbance	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Increased	Professional	Xanax	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:07/01/04ISR Number: 4388807-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Effexor	C		
UNKNOWN							
		Cardiac Murmur					
		Cardiomegaly					
		Chest Pain					
		Convulsion					
		Deep Vein Thrombosis					
		Depression					
		Eye Haemorrhage					
		Gallbladder Disorder					
		Gastrointestinal Disorder					
		Hypercholesterolaemia					
		Hypertension					
		Immune System Disorder					
		Kidney Infection					
		Lung Disorder					
		Migraine					

Parathyroid Disorder
Pericardial Effusion
Thyroid Disorder
Urinary Incontinence
Uterine Disorder

Date:07/01/04ISR Number: 4388810-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Colitis Ulcerative Headache Insomnia Iron Deficiency Anaemia Muscle Spasms Pneumonia Pulmonary Embolism Rectal Ulcer Thrombosis Tremor	Health Professional	Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/04ISR Number: 4388813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Candidiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Lymphocytic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Leukaemia		Voltaren	SS				
UNKNOWN								
	Coronary Artery Disease		Prempro	C				
UNKNOWN								
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Hypertension							
	Injury							
	Meniscus Lesion							
	Mitral Valve Prolapse							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Overdose							
	Peptic Ulcer							
	Pneumonia							
	Reflux Oesophagitis							
	Stress							
	Tricuspid Valve Incompetence							
	Ulcer Haemorrhage							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Ventricular Dysfunction							
	Vomiting							
	Wound Infection							
	Staphylococcal							

Date:07/01/04ISR Number: 4389017-3Report Type:Direct Company Report #CTU 221970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute		Rofecoxib	PS			25 MG QD	
Initial or Prolonged			Lisinopril	C				
			Cyclosporine	C				

Date:07/02/04ISR Number: 4389416-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Coronary Syndrome
Disability	Anxiety
Other	Blood Triglycerides
	Increased
	Cardiomegaly

		Cerebrovascular Accident					
		Chest Pain					
		Chills	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Contusion		Coumadin	SS		
UNKNOWN							
		Deafness Bilateral		Coumadin	SS		
UNKNOWN							
		Dyspnoea		[Therapy			
		Dysuria		Unspecified]	C		
UNKNOWN							
		Epistaxis		Tylenol	C		
UNKNOWN							
		Fall		Vicodin Tablets	C		
UNKNOWN							
		Gingival Bleeding		Albuterol	C		
UNKNOWN							
		Haematochezia		Bayer Aspirin	C		
UNKNOWN							
		Heart Rate Irregular		Bayer Aspirin	C		
UNKNOWN							
		Hypertension		Aspirin	C		
UNKNOWN							
		International Normalised		Tenormin	C		
UNKNOWN							
		Ratio Decreased		Tenormin	C		
UNKNOWN							
		Intervertebral Disc		Ticlid	C		
UNKNOWN							
		Protrusion		Restoril	C		
UNKNOWN							
		Limb Discomfort		Digoxin	C		
UNKNOWN							
		Menstrual Disorder		Anzemet	C		
UNKNOWN							
		Neck Pain		Vasotec	C		ORAL
		Oedema Peripheral		Isordil	C		
UNKNOWN							
		Osteoarthritis		Lopressor	C		
UNKNOWN							
		Radiculitis		Naproxen	C		
UNKNOWN							
		Silent Myocardial		Nitrostat	C		
UNKNOWN							
		Infarction					

Sleep Disorder
Stress Incontinence
Transient Ischaemic
Attack
Urinary Tract Infection
Wheezing

Date:07/02/04ISR Number: 4389419-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Other	Abscess Intestinal
	Atherosclerosis
	Chest Discomfort
	Cold Sweat
	Diverticulitis
	Drug Hypersensitivity
	Dyspnoea
	Fall
	Gastritis
	Hiatus Hernia
	Hypercholesterolaemia
	Hypertension
	Joint Injury
	Liver Disorder
	Myocardial Infarction
	Non-Cardiac Chest Pain
	Non-Hodgkin'S Lymphoma
	Pharyngolaryngeal Pain
	Post Laminectomy Syndrome
	Pyrexia
	Simple Partial Seizures

Tuberculosis
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Darvocet-N	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Metformin	C			UNKNOWN	
	Zantac	C			UNKNOWN	

Date:07/02/04ISR Number: 4389422-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00115
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiopulmonary Failure		Amitriptyline Hydrochloride	C			UNKNOWN	
	Death		Diethylpropion Hydrochloride	C			UNKNOWN	
			Prinzide	C			UNKNOWN	
			Arava	C			UNKNOWN	
			Meridia	C			UNKNOWN	
			Phendimetrazine Hydrochloride	C			UNKNOWN	
			Phentermine	C			UNKNOWN	
			Phenylpropanolamine	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

Date:07/02/04ISR Number: 4389423-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Back Disorder
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Blood Triglycerides Increased
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Clostridium Colitis
	Convulsion
	Dizziness
	Emotional Distress
	Fibrosis
	Fluid Retention
	Gastrooesophageal Reflux Disease
	Haematochezia
	Headache
	Hyperlipidaemia
	Hypoxia
	Ileus

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Lumbar Radiculopathy					
		Myocardial Infarction					
		Nephrolithiasis					
560	DAY	Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Pneumonia	Professional	Alprazolam	C		
		Pneumonia Aspiration		Amitriptyline			
UNKNOWN		Pneumonia Pneumococcal		Hydrochloride	C		
		Rash		Amitriptyline			
UNKNOWN		Renal Failure Acute		Hydrochloride	C		
UNKNOWN		Rhabdomyolysis		Celexa	C		
UNKNOWN		Sinusitis		Lexapro	C		
UNKNOWN		Staphylococcal Infection		Nexium	C		
UNKNOWN				Lasix (Furosemide)	C		
UNKNOWN				Zanaflex	C		
UNKNOWN				Ambien	C		
UNKNOWN				Diovan	C		
UNKNOWN				Ultram	C		
UNKNOWN				Torsemide	C		
UNKNOWN				Lasix (Furosemide)	C		
UNKNOWN				Neurontin	C		
UNKNOWN				Zaroxolyn	C		
UNKNOWN				Aleve	C		
UNKNOWN				Nortriptyline	C		
UNKNOWN				Oxycontin	C		
UNKNOWN				Potassium Chloride	C		

Date:07/02/04ISR Number: 4389431-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Acute Myocardial							
Other	Infarction							
	Atherosclerosis							
	Bundle Branch Block Right							
	Cardiomyopathy							
	Chronic Obstructive							
	Pulmonary Disease							
	Diverticulitis							
	Drug Hypersensitivity							
	Ejection Fraction							
	Decreased							
	Injury							
	Myocardial Ischaemia							
	Polycythaemia Vera							

Date:07/02/04ISR Number: 4389432-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00065
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Anaemia
	Chest Pain
	Coagulopathy
	Dyspnoea
	Fluid Retention
	Haematoma
	Mitral Valve Incompetence

		Myalgia					
		Oedema Peripheral					
		Stress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Vascular Graft Occlusion		Vicodin Tablets	C		
UNKNOWN							
		Ventricular Hypertrophy		Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Insulin, Biphasic Isophane [Injection]	C		
UNKNOWN							
				Insulin, Biphasic Isophane [Injection]	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Axid	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Prandin	C		
UNKNOWN							

Date:07/02/04ISR Number: 4389433-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Other	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Bacterial Infection		Lipitor	C		
UNKNOWN						
	Bipolar I Disorder		Lipitor	C		
UNKNOWN						
	Chest Pain		Avapro	C		
UNKNOWN						
	Hydronephrosis		Geodon	C		
UNKNOWN						
	Nephrolithiasis		Levoxyl	C		
UNKNOWN						
	Pyuria		Prilosec	C		
UNKNOWN						
	Renal Failure		Paxil	C		
UNKNOWN						
	Renal Failure Acute					
	Sepsis					
	Urinary Retention					
	Urinary Tract Infection					

Date:07/02/04ISR Number: 4389436-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01135
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
Disability	Cataract
Other	Cerebrovascular Accident
	Diabetes Mellitus
	Dyspepsia
	Eye Disorder
	Glaucoma
	Intervertebral Disc Protrusion
	Lumbar Radiculopathy
	Major Depression
	Oedema Peripheral
	Post Procedural Complication

Prostatic Disorder
Sleep Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	433	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	433	DAY
	Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Celebrex	C			UNKNOWN	

Date:07/02/04ISR Number: 4389442-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aortic Atherosclerosis	Professional	[Therapy Unspecified]	C				
	Arthralgia						UNKNOWN	10 YR
	Back Pain		Endocet	C			UNKNOWN	
	Bursa Removal		Elavil	C			UNKNOWN	
	Bursitis		Tenormin	C			UNKNOWN	
	Cardiomegaly		Vancenase	C			UNKNOWN	
	Chromaturia		Premarin	C			UNKNOWN	9872 DAY
	Deep Vein Thrombosis		Prevacid	C			UNKNOWN	
	Drug Hypersensitivity		Synthroid	C			UNKNOWN	
	Dry Mouth		Prinivil	C		ORAL	1501	DAY
	Fatigue		Methocarbamol	C			UNKNOWN	
	Fluid Retention		Prilosec	C			UNKNOWN	
	Gastrooesophageal Reflux							

Disease
Haematoma
Haemorrhoidal Haemorrhage
Hypersensitivity
Hypertension
Hypoaesthesia
Intervertebral Disc
Degeneration
Joint Effusion
Lung Disorder
Medication Error
Migraine
Mononeuritis
Myalgia
Nausea
Oedema Peripheral
Pain In Extremity
Rectocele
Road Traffic Accident
Spinal Osteoarthritis
Splenic Cyst
Treatment Noncompliance
Urine Odour Abnormal

Date:07/02/04ISR Number: 4389443-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00446
Age:32 YR Gender:Male I/FU:F

Outcome PT
Other Abdominal Discomfort
Abdominal Pain Upper
Adverse Event

		Blood Pressure Increased					
		Headache					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Large Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage					
		Limb Operation					
		Oedema					
		Oesophageal Ulcer					
		Haemorrhage					

Date:07/02/04ISR Number: 4389444-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0309NOR00021
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2 WK						
	Gastric Ulcer Perforation	Professional	Aspirin And Magnesium Oxide	SS		
UNKNOWN						
			Furosemide Sodium	C		
UNKNOWN						
			Isosorbide Mononitrate	C		
UNKNOWN						
			Nifedipine	C		
UNKNOWN						

Date:07/02/04ISR Number: 4389445-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00713
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain		Ranitidine	C		
UNKNOWN						
	Dyspnoea					
	Hyperhidrosis					
	Neuroma					
	Treatment Noncompliance					

Date:07/02/04ISR Number: 4389446-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01861
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		428 DAY
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Gastric Ulcer Haemorrhage		Lopid	C				UNKNOWN
	Intestinal Obstruction		Diovan	C				UNKNOWN
			Skelaxin	C				UNKNOWN
			Aciphex	C				UNKNOWN

Date:07/02/04ISR Number: 4389447-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0406SWE00019
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/02/04ISR Number: 4389449-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00097
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Infarction	Professional	Tyrosine	C				UNKNOWN
Disability	Angina Unstable		Vitamin B (Unspecified)	C		PARENTERAL		
	Anxiety							
	Arrhythmia		Vitamins (Unspecified)	C		UNKNOWN		
	Arteriospasm Coronary							
	Coronary Artery		Arginine Glutamate	C		UNKNOWN		
	Thrombosis		Garlic Extract	C		ORAL		
	Dyslipidaemia							
	Emotional Distress							
	Ischaemic Cardiomyopathy							
	Joint Sprain							
	Mitral Valve Incompetence							
	Transaminases Increased							

Date:07/02/04ISR Number: 4389453-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		156 DAY
Initial or Prolonged	Cerebral Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Disability	Hypercholesterolaemia		Advil	C				UNKNOWN
							585 DAY	
Other	Hypersensitivity		Motrin	C				UNKNOWN
							585 DAY	
	Sinusitis		Zoloft	C				UNKNOWN
	Temporomandibular Joint		Tylenol	C				UNKNOWN
							585 DAY	
	Syndrome		Necon	C				UNKNOWN

			Ortho-Novum	C
UNKNOWN				
			[Therapy Unspecified]	C
UNKNOWN	585	DAY		
			Methylphenidate	C
UNKNOWN				
			Naproxen	C
UNKNOWN	585	DAY		
			Aleve	C
UNKNOWN	585	DAY		

Date:07/02/04ISR Number: 4389598-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anhedonia
Initial or Prolonged	Anxiety
Other	Asthenia
	Back Injury
	Back Pain
	Balance Disorder
	Blood Pressure Increased
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Depression
	Disorder Of Globe
	Dizziness
	Dyspepsia
	Dyspnoea
	Electrocardiogram T Wave Inversion
	Emotional Disorder
	Emotional Distress

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Gait Disturbance					
		Gastrooesophageal Reflux Disease					
		Gaze Palsy		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hernia		Vicodin Tablets	C		
UNKNOWN							
		Hypertension		Clonidine	C		
UNKNOWN							
		Hyperthyroidism		Desyrel	C		
UNKNOWN							
		Insomnia		Clonidine	C		
UNKNOWN							
		Intervertebral Disc		Skelaxin	C		
UNKNOWN							
		Protrusion					
		Lacunar Infarction					
		Mental Disorder					
		Muscle Contracture					
		Muscle Spasms					
		Muscle Strain					
		Musculoskeletal Stiffness					
		Neck Pain					
		Neuritis					
		Oedema Peripheral					
		Pain In Extremity					
		Paraesthesia					
		Peripheral Vascular Disorder					
		Radiculopathy					
		Renal Failure					
		Road Traffic Accident					
		Spinal Osteoarthritis					
		Stress					
		Transient Ischaemic Attack					
		Treatment Noncompliance					
		Ventricular Hypertrophy					
		Vertigo Positional					
		Vomiting					

Date:07/02/04ISR Number: 4389604-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00236
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Fosamax	SS		ORAL		
			Ibuprofen	SS		ORAL		
			Furosemide	C		ORAL		
			Nitrazepam	C		ORAL		
			Senna	C		ORAL		

Date:07/02/04ISR Number: 4389610-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Agoraphobia
	Anger
	Angina Pectoris
	Anxiety Disorder
	Arthralgia

		Asthenia					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure		Atenolol	C		
UNKNOWN							
		Inadequately Controlled		Soma	C		
UNKNOWN							
		Blood Triglycerides Increased					
		Cardiac Disorder					
		Chronic Fatigue Syndrome					
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Depression					
		Diastolic Dysfunction					
		Dyspepsia					
		Dyspnoea					
		Ejection Fraction Decreased					
		Gamma-Glutamyltransferase Increased					
		Gout					
		Haematochezia					
		High Density Lipoprotein Decreased					
		Hypercholesterolaemia					
		Hypertension					
		Hypoaesthesia					
		Injection Site Nodule					
		Injury					
		Insomnia					
		Joint Swelling					
		Left Ventricular End-Diastolic Pressure Increased					
		Lung Disorder					
		Lymphadenopathy					
		Mastoiditis					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Pain In Extremity					
		Palpitations					
		Personality Disorder					
		Rectal Haemorrhage					
		Refusal Of Treatment By					

Patient
Scar
Social Phobia
Varicose Vein
Ventricular Dysfunction
Ventricular Hypertrophy
Ventricular Hypokinesia
Weight Increased

Date:07/02/04ISR Number: 4389613-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01390
Age:45 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT
Acute Myocardial
Infarction
Angina Unstable
Anxiety
Arthritis
Asthenia
Atelectasis
Belligerence
Breath Sounds Decreased
Cardiac Failure
Congestive
Cardiogenic Shock
Chest Pain
Coagulopathy
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Restenosis
Deep Vein Thrombosis
Dental Caries
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Dilatation Atrial
Disease Recurrence
Disturbance In Attention
Dizziness
Drug Hypersensitivity
Dyspepsia
Dyspnoea Exertional
Fall
Feeling Abnormal
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Graft Complication
Haematoma
Headache
Hepatic Cyst
Hepatic Steatosis
Hiatus Hernia
Hyperhidrosis
Injury
Insomnia

Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Joint Dislocation
Left Ventricular
End-Diastolic Pressure
Increased
Lung Disorder
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Nephrolithiasis
Pain

	Pain In Extremity						
	Periodontal Disease						
	Post Laminectomy Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Post Procedural		Vioxx	PS	Merck & Co., Inc	ORAL	380	DAY
	Haemorrhage		Aspirin	C			UNKNOWN	
	Post Thrombotic Syndrome		Plavix	C			UNKNOWN	
	Prothrombin Time		Coumadin	C			UNKNOWN	
	Prolonged		Cardizem	C			UNKNOWN	
	Pulmonary Congestion		Maxair	C			RESPIRATORY (INHALATION)	
	Radiculopathy							
	Rash							
	Refusal Of Treatment By Patient							
	Respiratory Rate Increased							
	Scar							
	Sleep Apnoea Syndrome							
	Suicidal Ideation							
	Tooth Extraction							
	Tricuspid Valve Incompetence							
	Umbilical Hernia							
	Vomiting							

Date:07/02/04ISR Number: 4389618-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0307NOR00012
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Scotoma							

Date:07/02/04ISR Number: 4389622-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Aspiration
	Atrial Fibrillation
	Breast Tenderness
	Cardio-Respiratory Arrest
	Coagulopathy
	Coronary Artery Disease
	Depression
	Diarrhoea
	Diverticulum
	Dyspnoea Exertional
	Extradural Abscess
	Fatigue
	Haematochezia
	Hypersensitivity
	Hypokalaemia
	Intervertebral Disc
	Disorder
	Intervertebral Discitis
	Multi-Organ Failure
	Myocardial Infarction
	Pancreatitis
	Renal Tubular Necrosis

	Sepsis						
	Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	45 DAY
	Ventricular Tachycardia		Tylenol With Codeine #3	C			UNKNOWN
			Percocet	C			UNKNOWN
			Ascorbic Acid	C			UNKNOWN
			Vitamin E	C			UNKNOWN
			Zocor	C			UNKNOWN
			Beta Carotene	C			UNKNOWN
			Centrum	C			UNKNOWN

Date:07/02/04ISR Number: 4389623-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Blood Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Bronchitis		Tylenol	C			
	Disability						
	Emotional Distress						
	Fall						
	Gait Spastic						
	Obstruction						
	Peripheral Circulatory Failure						
	Road Traffic Accident						

Date:07/02/04ISR Number: 4389624-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00078
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Hypertension		Lortab	C			UNKNOWN	
	Polyuria		Aspirin	C			UNKNOWN	
	Upper Limb Fracture							

Date:07/02/04ISR Number: 4389625-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01895
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Other	Infarction
	Aortic Atherosclerosis
	Arthralgia
	Bronchitis
	Bursitis
	Cardiomegaly
	Coronary Artery
	Atherosclerosis
	Epstein-Barr Virus
	Infection
	Feeling Abnormal
	Hypertension
	Neck Pain
	Onychomycosis

	Osteoarthritis						
	Pharyngitis						
	Pneumonia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pneumonitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Calcification		Vicoprofen	C				UNKNOWN
	Rhinitis Allergic							
	Sciatica							
	Sinusitis							
	Tendonitis							
	Vomiting							

Date:07/02/04ISR Number: 4393127-4Report Type:Expedited (15-DaCompany Report #DE-JNJFOC-20040600014
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Psychotic Disorder	Foreign Health	Durogesic (Fentanyl) Patch	PS			TRANSDERMAL	TRANSDERMAL
		Professional Company Representative	Vioxx (Rofecoxib)	SS				

Date:07/06/04ISR Number: 4390112-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	394 DAY	
	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	394 DAY	
Disability	Atrial Fibrillation		Adderall Tablets	C				UNKNOWN
	Cardiac Failure		Cefzil	C				UNKNOWN
	Congestive		Biaxin Xl	C				UNKNOWN
	Cerebrovascular Accident		Entex La	C		ORAL		
	Congestive Cardiomyopathy		Ibuprofen	C				UNKNOWN

Depression
Hypertension
Insomnia
Intracardiac Thrombus
Mitral Valve Incompetence
Pneumonia
Sinus Tachycardia
Stress
Tricuspid Valve
Incompetence

Date:07/06/04ISR Number: 4390118-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris Blood Cholesterol Increased Cardiac Failure Congestive Dyspepsia Dyspnoea Emotional Distress Sleep Apnoea Syndrome	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/04ISR Number: 4390120-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion							
	Emotional Distress							
	Headache							
	Nervous System Disorder							
	Visual Disturbance							

Date:07/06/04ISR Number: 4390122-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aneurysm	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Tylenol	C			UNKNOWN	
	Cerebral Haemorrhage		Albuterol	C			UNKNOWN	
	Chest Wall Pain		Amoxicillin	C			UNKNOWN	
	Deep Vein Thrombosis		Aspirin	C			UNKNOWN	
	Depression		Lotensin	C			UNKNOWN	119 DAY
	Dyspepsia		Correctol					
	Eczema		(Bisacodyl)	C			UNKNOWN	
	Emotional Distress		Baycol	C			UNKNOWN	
	Gastrointestinal Disorder		Doxepin					
	Hypertension		Hydrochloride	C			UNKNOWN	
	Hypokalaemia		Calan	C			UNKNOWN	
	Injury		Hydrochlorothiazide	C			UNKNOWN	
	Respiratory Alkalosis		Maxzide	C			UNKNOWN	

	Sinusitis	Dyazide	C
UNKNOWN			
	Sputum Abnormal	Dyazide	C
UNKNOWN			
	Transient Ischaemic	Medrol	C
UNKNOWN			
	Attack	Singulair	C
UNKNOWN			
	Wheezing	Pravachol	C
UNKNOWN	1210 DAY		

Date:07/06/04ISR Number: 4390124-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Aortic Dilatation
	Back Pain
	Cellulitis
	Cerebral Atherosclerosis
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Dizziness
	Drug Hypersensitivity
	Dyspepsia
	Dysphagia
	Dyspnoea
	Ear Pain
	Eructation
	Fall

		Fatigue Generalised Anxiety Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage Intracranial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
97	DAY						
		Headache	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Hiatus Hernia Hypersensitivity		[Therapy Unspecified]	C		
UNKNOWN							
		Hypertension Hypoaesthesia		Doxepin Hydrochloride	C		
UNKNOWN							
		Insomnia		Zanaflex	C		
UNKNOWN							
		Joint Effusion		Ultram	C		
UNKNOWN							
		Joint Injury		Neurontin	C		
UNKNOWN							
		Joint Sprain		Serzone	C		
UNKNOWN							
		Local Swelling		Oxycodone	C		
UNKNOWN							
		Oesophagitis Pain Panic Attack Pharyngolaryngeal Pain Psoriasis Pulmonary Congestion Retinal Ischaemia Rhinitis Rhinitis Allergic Sleep Apnoea Syndrome Ventricular Extrasystoles Visual Acuity Reduced Visual Disturbance					

Date:07/06/04ISR Number: 4390131-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						

Initial or Prolonged	Infarction	Professional	Griseofulvin	C
UNKNOWN				
	Anhedonia			
	Anxiety			
	Drug Ineffective			
	Emotional Distress			
	Injury			
	Pain			
	Pelvic Haematoma			
	Stress			

Date:07/06/04ISR Number: 4390132-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Valve Incompetence
	Arrhythmia
	Supraventricular
	Back Pain
	Blood Cholesterol
	Increased
	Bronchitis
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Coronary Artery Disease

	Dyspnoea						
	Emotional Distress						
	Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Mitral Valve Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Diazide	C			UNKNOWN
	Overdose		Metoprolol	C			UNKNOWN
	Pneumonia		Zocor	C		ORAL	
	Pruritus		Lopressor	C			UNKNOWN
	Rash Papular		Lopressor	C			UNKNOWN
	Sebaceous Gland Disorder						
	Thrombosis						
	Upper Respiratory Tract Infection						

Date:07/06/04ISR Number: 4390133-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0404FRA00009
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY
Life-Threatening	Bone Marrow Depression	Professional	Aspirin	C		ORAL	
Hospitalization - Initial or Prolonged	Bronchopulmonary Aspergillosis		Citalopram	C		ORAL	
	Cheilitis						
	Cough						
	Facial Palsy						
	Haemoptysis						
	Oedema						
	Pallor						
	Pancytopenia						

Date:07/06/04ISR Number: 4390135-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00174
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Myocardial

Hospitalization - Initial or Prolonged	Infarction Asthenia Circulatory Collapse Crackles Lung Death Dizziness Dyspnoea Fluid Overload Hypotension Increased Upper Airway Secretion Malaise Oedema Peripheral Pain In Extremity Paraproteinaemia Renal Amyloidosis Renal Impairment Respiratory Distress Sepsis Therapeutic Response Decreased Ventricular Dysfunction Ventricular Failure

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	58	DAY
	Aspirin	C			UNKNOWN	
	Atorvastatin Calcium	C			UNKNOWN	
	Furosemide	C			UNKNOWN	
	Lansoprazole	C			UNKNOWN	
	Metoprolol	C			UNKNOWN	

Date:07/06/04ISR Number: 4390138-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02188
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Dry Throat Hepatic Enzyme Increased Influenza Pruritus Rash		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/04ISR Number: 4390139-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02220
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arrhythmia Back Injury Blood Cholesterol Increased Cardiac Valve Disease Chronic Fatigue Syndrome Depression Diabetes Mellitus							

Dizziness
Emotional Distress
Heart Rate Irregular
Hypersensitivity
Myocardial Infarction
Nausea
Oedema Peripheral
Pericarditis
Rheumatic Fever
Sleep Apnoea Syndrome

Date:07/06/04ISR Number: 4390141-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00208
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Haemorrhage		Amitriptyline					
	Haemodynamic Instability		Hydrochloride	C		ORAL		
	Haemoglobin Decreased		Nifedipine	C		ORAL		
	Rectal Haemorrhage							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/04ISR Number: 4390142-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00169
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Hepatitis Cholestatic	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Ramipril	SS			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Torsemide	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	
			Nisoldipine	C			UNKNOWN	

Date:07/06/04ISR Number: 4390143-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Methotrexate	C				

Date:07/06/04ISR Number: 4390147-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00212
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	907 DAY	
Hospitalization -		Professional	Aspirin	SS		ORAL	1117 DAY	
Initial or Prolonged			Omeprazole	C			UNKNOWN	
Disability								
Other								

Date:07/06/04ISR Number: 4390664-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01385
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Premarin	C				
UNKNOWN								
Other	Cardiac Murmur		Lasix (Furosemide)	C				
UNKNOWN								
	Coronary Artery Disease		Prevacid	C		ORAL		
	Gastric Disorder		Synthroid	C		ORAL		
	Gastritis		Potassium (Unspecified)	C				
	Hyperlipidaemia							
UNKNOWN								
	Hypertension							
	Kyphosis							
	Lung Neoplasm							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Oesophageal Spasm							
	Rotator Cuff Syndrome							
	Spinal Osteoarthritis							

Date:07/06/04ISR Number: 4390669-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00767
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Darvocet-N	C				
UNKNOWN								
			Augmentin	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

	Lotensin	C	UNKNOWN
	Lasix (Furosemide)	C	UNKNOWN
	Lopid	C	UNKNOWN
	Glyburide	C	UNKNOWN
	Glucophage	C	UNKNOWN
	Centrum Silver	C	UNKNOWN
	Actos	C	UNKNOWN

Date:07/06/04ISR Number: 4390671-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Arthropathy		Premarin	C				UNKNOWN
Other	Atrial Fibrillation		Estratab	C				UNKNOWN
	Cardiac Aneurysm		Menest	C				UNKNOWN
	Corneal Deposits		Armour Thyroid Tablets	C				UNKNOWN
	Haematuria							
	Haemorrhage		Trazodone Hydrochloride	C				UNKNOWN
	Hypertension							
	Hypertensive Crisis		Garlic Extract	C				UNKNOWN
	Musculoskeletal Disorder		Synthroid	C				UNKNOWN
	Oedema Peripheral		Methotrexate	C				UNKNOWN
	Pain In Extremity							
	Paraesthesia							
	Renal Cyst							
	Transient Ischaemic Attack							

Date:07/06/04ISR Number: 4390673-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00005
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		47 DAY
Initial or Prolonged			Aspirin	SS		ORAL		1143 DAY

Date:07/06/04ISR Number: 4390726-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		573 DAY
Initial or Prolonged	Cough		Celebrex	C				UNKNOWN
Disability	Dehydration		Lasix (Furosemide)	C				UNKNOWN
	Depression		Hydrocodone Hydrochloride	C				UNKNOWN
	Haemorrhagic Stroke		Spironolactone	C				UNKNOWN
	Nasal Congestion		Demadex	C				UNKNOWN
	Thrombocytopenia		Ibuprofen	C				UNKNOWN
			Lozol	C				UNKNOWN
			Synthroid	C				UNKNOWN

Date:07/06/04ISR Number: 4393537-5Report Type:Direct Company Report #CTU 222264
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Upper Gastrointestinal		Rofecoxib	PS		ORAL		50 MG PO QD
Initial or Prolonged	Haemorrhage							

Date:07/06/04ISR Number: 4395030-2Report Type:Expedited (15-DaCompany Report #WAES 0406USA01535
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Abnormal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Cardiac Failure						MG/DAILY/PO	
Initial or Prolonged	Epistaxis		Diltiazem Msd	C				
Disability	Influenza Like Illness							
	Obstruction							
	Pharyngolaryngeal Pain							
	Pneumonia							
	Rash Erythematous							
	Rash Pruritic							
	Renal Disorder							

Date:07/07/04ISR Number: 4390770-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02286
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Prempro	C			UNKNOWN	
	Hair Colour Changes		Synthroid	C			UNKNOWN	

Date:07/07/04ISR Number: 4390771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	696 DAY	
Initial or Prolonged	Aortic Calcification		Reglan	SS			UNKNOWN	
Disability	Blood Pressure Increased		Celebrex	C			UNKNOWN	
	Cerebellar Infarction		Catapres	C			UNKNOWN	

	Cholecystitis	Flonase	C
UNKNOWN			
	Cognitive Disorder	Prilosec	C
UNKNOWN			
	Deafness Neurosensory	Lopid	C
UNKNOWN			
	Diabetes Mellitus	Robaxin	C
UNKNOWN			
	Non-Insulin-Dependent		
	Diabetic Neuropathy		
	Dystonia		
	Fall		
	Glossitis		
	Haematochezia		
	Haemorrhoids		
	Hiatus Hernia		
	Orthostatic Hypotension		
	Pseudodementia		
	Radiculopathy		
	Tremor		

Date:07/07/04ISR Number: 4391166-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aggression
Other	Anxiety
	Bursitis
	Carpal Tunnel Syndrome
	Constipation
	Depression

		Diarrhoea					
		Fatigue					
		Heart Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Dislocation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
29	DAY						
		Onychomycosis		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Paranoia		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Sacroiliitis		Vioxx	SS	Merck & Co., Inc	ORAL
29	DAY						
		Squamous Cell Carcinoma		Lithium Carbonate	C		
UNKNOWN							
		Stomach Discomfort					
		Suicidal Ideation					

Date:07/07/04ISR Number: 4391168-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation	Professional	Allopurinol	C		
UNKNOWN						
Other	Cardiac Failure		Allopurinol	C		
UNKNOWN						
	Congestive		Aspirin	C		
UNKNOWN						
	Chest Pain		Lipitor	C		
UNKNOWN						
	Chronic Obstructive		Lotensin	C		
UNKNOWN						
	Pulmonary Disease		Coreg	C		
UNKNOWN						
	Coronary Artery Occlusion		Celebrex	C		
UNKNOWN						
	Diabetic Foot		Clopidogrel			
	Diverticulum		Bisulfate	C		
UNKNOWN						
	Emotional Distress		Cardizem	C		
UNKNOWN						

	Erectile Dysfunction	Pepcid	C
UNKNOWN			
	Gouty Arthritis	Fluvastatin Sodium	C
UNKNOWN			
	Ischaemic Cardiomyopathy	Furosemide	C
UNKNOWN			
	Mitral Valve Incompetence	Neurontin	C
UNKNOWN			
	Mitral Valve Prolapse	Glipizide	C
UNKNOWN			
	Myocardial Infarction	Glycine	C
UNKNOWN			
	Oedema Peripheral	Insulin	C
UNKNOWN			
	Open Angle Glaucoma	Glucophage	C
UNKNOWN			
	Overdose	Coumadin	C
UNKNOWN			
	Peptic Ulcer	Trazodone	
	Peripheral Occlusive	Hydrochloride	C
UNKNOWN			
	Disease	Spironolactone	C
UNKNOWN			
	Pulmonary Hypertension	Nitroglycerin	C
UNKNOWN			
	Pulmonary Oedema	Actos	C
UNKNOWN			
	Renal Failure		
	Respiratory Failure		
	Sleep Apnoea Syndrome		
	Sleep Disorder		
	Syncope		
	Vascular Graft Occlusion		
	Vascular Occlusion		

Date:07/07/04ISR Number: 4391170-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00212
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		907 DAY
Hospitalization -		Professional	Aspirin	SS		ORAL		1117 DAY
Initial or Prolonged			Omeprazole	C				
UNKNOWN								
Disability								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/04ISR Number: 4391172-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Acute Prerenal Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Acute Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthma		Flexeril	C				
	Atelectasis		Brethine	C				
	Cardiac Failure		Vasotec	C				
	Congestive		Lasix (Furosemide)	C				
	Cardiac Murmur		Glipizide	C				
	Depression		Actos	C				
	Fatigue		K-Dur	C				
	Heart Rate Increased		Altace	C				
	Heart Rate Irregular							
	Hypothyroidism							
	Injury							
	Mitral Valve Incompetence							
	Myocardial Ischaemia							
	Osteoarthritis							
	Pericardial Effusion							
	Pneumonia							
	Pulmonary Oedema							
	Respiratory Disorder							
	Sinus Tachycardia							
	Sleep Apnoea Syndrome							
	Tachycardia							
	Tricuspid Valve Incompetence							

Date:07/07/04ISR Number: 4391763-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Aspiration
	Atrial Fibrillation
	Blood Triglycerides
	Increased
	Breast Tenderness
	Cardio-Respiratory Arrest
	Coagulopathy
	Coronary Artery Disease
	Depression
	Diarrhoea
	Diverticulum
	Dyspnoea Exertional
	Extradural Abscess
	Fatigue
	Haematochezia
	Hypersensitivity
	Hypokalaemia
	Intervertebral Disc
	Disorder
	Intervertebral Discitis
	Mitral Valve Incompetence

		Multi-Organ Failure					
		Myocardial Infarction					
		Pancreatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Tubular Necrosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY						
		Sepsis	Professional	Tylenol With Codeine			
		Upper Respiratory Tract		#3	C		
UNKNOWN							
		Infection		Percocet	C		
UNKNOWN							
		Ventricular Fibrillation		Ascorbic Acid	C		
UNKNOWN							
		Ventricular Tachycardia		Vitamin E	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Beta Carotene	C		
UNKNOWN							
				Centrum	C		
UNKNOWN							

Date:07/07/04ISR Number: 4391766-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
340	DAY						
Life-Threatening		Cardiac Arrest	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
Hospitalization -		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
		Cystocele		Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
		Hepatomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
		Myocardial Infarction		Ditropan	C		
UNKNOWN							
		Neck Pain		Vicodin Tablets	C		
UNKNOWN							
		Pleural Adhesion		Proventil Repetabs			

	Pulmonary Oedema			And Tablets	C		
UNKNOWN							
	Stress Incontinence			Zithromax	C		
UNKNOWN							
	Vaginal Prolapse			Benzonatate	C		
UNKNOWN							
				Tussi-12	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Voltaren	C		
UNKNOWN							
				Prempro	C		
UNKNOWN		41	DAY				
				Tequin	C		
UNKNOWN							
				Hydroxyzine Hydrochloride	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Lorabid	C		
UNKNOWN							
				Claritin-D	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Triamcinolone	C		
UNKNOWN							
				Remeron	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Promethazine	C		
UNKNOWN							

Date:07/07/04ISR Number: 4391768-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00033
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/04ISR Number: 4391769-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		710 DAY
Initial or Prolonged	Carotid Artery Stenosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		710 DAY
	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Aspirin	C				UNKNOWN
	Gastrooesophageal Reflux Disease							
	Hyperlipidaemia							
	Localised Infection							
	Nasal Congestion							
	Rash Erythematous							
	Skin Laceration							

Date:07/07/04ISR Number: 4391771-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Wall Pain		Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
	Constipation							
	Emotional Distress							
	Flank Pain		Antimicrobial (Unspecified)	C				UNKNOWN
	Gastrooesophageal Reflux Disease							
			Butalbital	C				UNKNOWN
	Haematuria							
	Haemorrhoids							
	Injury							
	Intervertebral Disc Protrusion							
	Irritable Bowel Syndrome							
	Micturition Urgency							
	Nausea							

Nephrolithiasis
Non-Cardiac Chest Pain
Oesophageal Spasm
Pharyngolaryngeal Pain
Pollakiuria
Pyelonephritis
Rectal Haemorrhage
Renal Colic
Skin Discolouration

Date:07/07/04ISR Number: 4391774-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aphasia
Other	Bradycardia
	Cardiac Arrest
	Cholecystitis Chronic
	Cholelithiasis
	Dizziness
	Eye Disorder
	Eye Haemorrhage

		Eye Injury Headache Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Ischaemic Stroke	Professional	Norvasc	C		
UNKNOWN							
		Loss Of Employment		Ecotrin	C		
UNKNOWN							
		Pneumoperitoneum		Lipitor	C		
UNKNOWN							
		Self-Medication		Caltrate + D	C		
UNKNOWN							
		Sinusitis Stress Syncope Vasovagal Transient Ischaemic Attack Treatment Noncompliance Vascular Calcification Vertigo					

Date:07/07/04ISR Number: 4391777-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01845
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
22	MON						
		Duodenal Ulcer	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
22	MON						
		Haemorrhage		Lexapro	C		
UNKNOWN							
		Dyspnoea		Nexium	C		
UNKNOWN							
		Gastritis		Ultram	C		
RESPIRATORY							
(INHALATION)							
				Advair	C		
UNKNOWN							
				Benicar	C		
UNKNOWN							

Date:07/07/04ISR Number: 4391778-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Other	Arthralgia
	Arthritis
	Back Pain
	Blood Pressure Increased
	Cardiomegaly
	Cartilage Injury
	Catheter Site Related Reaction
	Chest Pain
	Chills
	Chondropathy
	Chronic Obstructive Pulmonary Disease
	Cough
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Dyskinesia
	Dyspnoea
	Gastric Disorder
	Gastrointestinal Haemorrhage
	Gout
	Haematochezia

Dose	Duration						
		Headache					
		Hyperhidrosis					
		International Normalised Ratio Increased	Report Source	Product	Role	Manufacturer	Route
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Intestinal Haemorrhage		Albuterol	C		
UNKNOWN		Intestinal Obstruction		Combivent	C		
UNKNOWN		Joint Swelling		Atenolol	C		
UNKNOWN		Local Swelling		Wellbutrin	C		
UNKNOWN		Musculoskeletal Pain		Celebrex	C		
UNKNOWN		Myositis		Advair	C		
UNKNOWN		Nasal Congestion		Furosemide	C		
UNKNOWN		Neck Pain		Diazide	C		
UNKNOWN		Oedema		Lithium Sulfate	C		
UNKNOWN		Osteoarthritis		Sandostatin	C		
UNKNOWN		Pain		Protonix	C		
UNKNOWN		Post Procedural		Prednisone	C		
UNKNOWN		Complication		Prochlorperazine	C		
UNKNOWN		Prothrombin Time		Aciphex	C		
UNKNOWN		Prolonged					
		Pulmonary Embolism					
		Rectal Haemorrhage					
		Restrictive Pulmonary Disease					
		Rheumatoid Arthritis					
		Rhinorrhoea					
		Sleep Apnoea Syndrome					
		Swelling					
		Systemic Lupus Erythematosus					
		Ulcer					

Date:07/07/04ISR Number: 4391779-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Atelectasis
Disability	Atrial Fibrillation
Other	Blood Cholesterol
	Increased
	Bradycardia
	Cardiac Murmur
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery
	Reocclusion
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Diverticulitis Intestinal
	Haemorrhagic
	Drug Hypersensitivity
	Hyperlipidaemia
	Hypertension
	International Normalised
	Ratio Increased
	Intervertebral Disc
	Degeneration
	Mitral Valve Incompetence
	Myocardial Infarction

	Palpitations						
	Pleural Effusion						
	Prothrombin Time	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Prolonged	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Pulmonary Oedema	Professional	Zocor	SS		ORAL	
	Renal Failure Chronic		Percocet	C			UNKNOWN
	Respiratory Distress		Atenolol	C			UNKNOWN
	Tachyarrhythmia		Folic Acid	C			UNKNOWN
	Tricuspid Valve		Ambien	C			UNKNOWN
	Incompetence		Ismo	C			UNKNOWN
	Ventricular Hypertrophy		Methotrexate	C			UNKNOWN
			Oxycodone Hydrochloride	C			UNKNOWN
			Prednisone	C		ORAL	

Date:07/07/04ISR Number: 4391867-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00018
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	60 DAY
Hospitalization -	Gastritis		Felodipine	C		ORAL	
Initial or Prolonged	Reflux Oesophagitis		Indapamide	C		ORAL	
			Irbesartan	C		ORAL	

Date:07/07/04ISR Number: 4393389-3Report Type:Direct Company Report #CTU 222301
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY
Initial or Prolonged	Increased						ORAL

	Fall Mental Status Changes		Prinivil 2.5 Mg Merck	SS	Merck	ORAL 2.5 MG DAILY ORAL
			Glucophage	C		

Date:07/07/04ISR Number: 4393824-0Report Type:Expedited (15-DaCompany Report #GBWYE867030JUN04
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route Dose Duration
Other	Retinal Haemorrhage	Health Professional Other	Methotrexate (Methotrexate)	PS		
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS		
			Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	SS		
			Humira (Adalimumab)	SS		SUBCUTANEOUS 40 G/M^2 1X PER 2 WK
			Premarin (Conjugated Estrogens)	SS		

				Rofecoxib (Rofecoxib)	SS		

Date:07/07/04ISR Number: 4394773-4Report Type:Expedited (15-DaCompany Report #GBR-2004-0001028
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Foreign	Oxycontin Tablets					
Hospitalization -	Convulsion	Health	(Oxycodone					
Initial or Prolonged	Delirium	Professional	Hydrochloride) Cr					
Disability	Disorientation	Other	Tablet	PS		ORAL	40 MG, DAILY,	
Other	Hallucination							
ORAL								
	Mental Disorder		Laroxyl					
	Paranoia		(Amitriptyline Hydrochloride)	SS		ORAL	5 DROP,	
							DAILY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL		
ORAL								
			Aspegic (Acetylsalicylate Lysine)	C				
			Fosamax (Alendronate Sodium)	C				
			Mono-Tildiem	C				
			Topalgic "Houde"	C				
			Rivotril (Clonazepam)	C				
			Equanil (Meprobamate)	C				
			Urispas (Flavoxate Hydrochloride)	C				

Date:07/07/04ISR Number: 4396082-6Report Type:Expedited (15-DaCompany Report #FR-2004-028049
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Sotalol					

Initial or Prolonged	Body Temperature Increased Diarrhoea Haemodynamic Instability Renal Failure Vomiting	Health Professional Other	(Sotalol Hydrochloride)	PS		ORAL 240 MG, 1X/DAY, ORAL
			Plavix (Clopidogrel Sulfate)	SS		ORAL 75 MG, 1X/DAY,ORAL
			Vastarel "Biopharma" (Trimetazidine Hydrochloride)	SS	"Biopharma"	ORAL 3 UNK, 1X/DAY, ORAL
			Vioxx (Rofecoxib)	SS		ORAL 25 MG, 1X/DAY, ORAL
			Tanakan (Ginkgo Biloba Extract)	SS		ORAL 120 MG, 1X/DAY, ORAL
			Elisor (Pravastatin Sodium)	SS		ORAL 20 MG, 1X/DAY, ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/04ISR Number: 4392880-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Glucose Increased		Nitroglycerin	C			UNKNOWN	
	Blood Pressure Increased		Tolinase	C			UNKNOWN	
	Cerebrovascular Accident		Verapamil	C			UNKNOWN	
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Dizziness							
	Drug Ineffective							
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Gait Disturbance							
	Hyperhidrosis							
	Injury							
	International Normalised Ratio Decreased							
	Intervertebral Disc Displacement							
	Intervertebral Disc Protrusion							
	Limb Discomfort							
	Lymphadenitis							
	Muscle Spasms							
	Musculoskeletal Chest Pain							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain In Extremity							
	Palpitations							
	Paraesthesia							
	Paronychia							
	Pleuritic Pain							
	Productive Cough							
	Pulmonary Embolism							
	Pyrexia							
	Respiratory Rate							

	Increased
	Respiratory Tract
	Infection
	Sciatica
	Treatment Noncompliance
	Varicose Vein

Date:07/08/04ISR Number: 4392886-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Other	Anoxic Encephalopathy
	Anxiety
	Blood Cholesterol
	Increased

		Blood Pressure Fluctuation					
		Bone Graft	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
		Convulsion		Tylenol With Codeine			
		Coronary Artery Disease		#4	C		
UNKNOWN							
		Coronary Artery Occlusion		Tylenol With Codeine			
		Deep Vein Thrombosis		#4	C		
UNKNOWN							
		Gastric Disorder		Celebrex	C		
UNKNOWN							
		Gastrooesophageal Reflux		Arthrotec	C		ORAL
		Disease		Arthrotec	C		ORAL
		Haematocrit Decreased		Arthrotec	C		ORAL
		Haemoglobin Decreased		Premarin	C		
UNKNOWN							
		Hypertension		Provera	C		
UNKNOWN							
		Hypokalaemia		Daypro	C		
UNKNOWN							
		Lumbar Spinal Stenosis					
		Myocardial Infarction					
		Palpitations					
		Pleuritic Pain					
		Pneumonia Aspiration					
		Postoperative Ileus					
		Pulmonary Embolism					
		Pulmonary Oedema					
		Shock					
		Sinus Tachycardia					
		Spinal Fusion Surgery					
		Syphilis					

Date:07/08/04ISR Number: 4392887-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
Initial or Prolonged		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						

Disability	Atherosclerosis	Xanax	C
UNKNOWN			
	Haematoma	Aspirin	C
UNKNOWN			
	Myocardial Infarction	Lipitor	C
UNKNOWN			
	Panic Disorder	Wellbutrin	C
UNKNOWN			
		Celebrex	C
UNKNOWN	4 DAY		
		Plavix	C
UNKNOWN			
		Folic Acid	C
UNKNOWN			
		Toprol Xl Tablets	C
UNKNOWN			
		Lopressor	C
UNKNOWN			
		Pyridoxine	C
UNKNOWN			

Date:07/08/04ISR Number: 4392888-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00038
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Levothyroxine Sodium	C		ORAL
Initial or Prolonged			Moxonidine	C		ORAL
			Ramipril	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/04ISR Number: 4392890-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02080
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disorientation		Synthroid	C				
UNKNOWN								
	Dyspepsia							
	Endometrial Hypertrophy							
	Fatigue							
	Feeling Abnormal							
	Gastrooesophageal Reflux							
	Disease							
	Hyperhidrosis							
	Hypertension							
	Menorrhagia							
	Migraine							
	Myalgia							
	Nausea							
	Ovarian Cyst							
	Polyp							
	Sleep Disorder							
	Syncope							
	Upper Respiratory Tract							
	Infection							
	Uterine Pain							
	Vertigo							
	Vomiting							

Date:07/08/04ISR Number: 4392892-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Arthralgia
Disability	Arthropod Bite
	Back Pain
	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Cerumen Impaction
	Chest Pain
	Dizziness

Dyspnoea
Dysuria
Fall
Headache
Hodgkin'S Disease
Hyperhidrosis
Hypertension
Intervertebral Disc
Degeneration
Joint Swelling
Labile Hypertension
Labyrinthitis
Myocardial Infarction
Non-Hodgkin'S Lymphoma
Oedema Peripheral
Skin Cancer
Thrombophlebitis
Vertigo

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
	Vioxx	SS	Merck & Co., Inc	ORAL	18	MON
	Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

Date:07/08/04ISR Number: 4392896-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aura		Vioxx	PS	Merck & Co., Inc	ORAL	138	DAY
Other	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL	138	DAY
	Emotional Distress		Dilantin	C			UNKNOWN	
	Encephalomalacia		Zoloft	C			UNKNOWN	
	Excoriation							
	Feeling Abnormal							
	Grand Mal Convulsion							
	Headache							
	Intervertebral Disc Displacement							
	Lumbar Vertebral Fracture							
	Nasal Septum Deviation							
	Nasal Turbinate Hypertrophy							
	Nose Deformity							
	Otitis Media							
	Road Traffic Accident							
	Tremor							

Date:07/08/04ISR Number: 4393290-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Tylenol With Codeine	C				
UNKNOWN								
Other	Blood Disorder		Domeboro	C				
AURICULAR								
	Blood Glucose Decreased							
(OTIC)								
	Blood Sodium Decreased		Amoxicillin	C				
UNKNOWN								
	Constipation		Augmentin	C				
UNKNOWN								
	Dizziness		Lotrisone	C				
UNKNOWN								
	Fall		Clonazepam	C				
UNKNOWN								
	Gastric Disorder		Diabeta	C		ORAL		
	Gastrointestinal Disorder		Triamcinolone	C				
UNKNOWN								
	Hypertension		Coumadin	C				
UNKNOWN								
	Lumbar Spinal Stenosis		Coumadin	C				
UNKNOWN								
	Myocardial Infarction		Vitamin E	C				
UNKNOWN								
	Nausea		Triamterene	C				
UNKNOWN								
	Pneumonia		Lactulose	C				
UNKNOWN								
	Skin Infection		Prevacid	C				
UNKNOWN								
	Sleep Disorder		Levobunolol Hydrochloride	C				
OPHTHALMIC								
			Zestril	C				
UNKNOWN								
			Reglan	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								
			Ranitidine	C		ORAL		

Date:07/08/04ISR Number: 4393336-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0406NOR00029
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Erosive Duodenitis							

Date:07/08/04ISR Number: 4393337-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01514
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		[Therapy					
	Exostosis		Unspecified]	C				
UNKNOWN							1478 DAY	
	Femoral Artery Occlusion		Herbs (Unspecified)	C				
UNKNOWN							840 DAY	
	Gastrooesophageal Reflux		Prilosec	C				
UNKNOWN								
	Disease							
	Haemorrhoids							
	Hypertension							
	Joint Sprain							
	Lacunar Infarction							
	Meniscus Lesion							
	Oesophagitis							
	Osteoarthritis							
	Pain In Extremity							
	Peripheral Vascular							
	Disorder							
	Rectal Polyp							
	Synovitis							
	Transient Ischaemic							
	Attack							

Date:07/08/04ISR Number: 4395616-5Report Type:Expedited (15-DaCompany Report #2004221437US
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased Blood Sodium Decreased Confusional State Stomach Discomfort Viral Infection Vomiting	Consumer	Detrol (Tolterodine) Tablet Rofecoxib (Rofecoxib) Tablet Levoxyl (Levothyroxine Sodium) Monopril	PS SS C C		ORAL ORAL		

Date:07/08/04ISR Number: 4395658-XReport Type:Expedited (15-DaCompany Report #2004221437US
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased Blood Sodium Decreased Confusional State Stomach Discomfort Viral Infection Vomiting	Consumer	Detrol (Tolterodine) Tablet Rofecoxib (Rofecoxib) Tablet Levoxyl (Levothyroxine Sodium)	PS SS C		ORAL ORAL		

			Monopril	C		

Date:07/09/04ISR Number: 4393338-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01339
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/09/04ISR Number: 4393339-XReport Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12624763
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Elisor Tabs 20 Mg	PS	Bristol-Myers Squibb Company	ORAL	Duration of Therapy: "few years"	
	Haemodynamic Instability							
	Pyrexia							
	Vomiting							
			Sotalex Tabs 80 Mg	SS	Comptoir Medical Du Cambodge	ORAL	Duration of Therapy: "few years"	
			Plavix	SS	Regulatory Health Authority South Africa	ORAL		
			Vastarel	SS		ORAL	Dose Value: 3 Unit; Duration of Therapy: "few years"	

			Vioxx	SS		ORAL
15 DAY						
			Tanakan	SS		ORAL

Date:07/09/04ISR Number: 4393651-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02061
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease					
	Emotional Distress					
	Hyperlipidaemia					
	Myocardial Infarction					
	Sinus Arrhythmia					

Date:07/09/04ISR Number: 4393659-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00074
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
	Alopecia
	Anaemia
	Asthenia
	Blood Creatinine
	Increased
	Contusion
	Death

		Decreased Appetite					
		Dizziness					
		Dizziness Postural	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Failure To Thrive		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Salivary Gland Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL
		Skin Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Retention		Azopt Drops	C		
UNKNOWN							
		Urinary Tract Infection		Ocupress	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							

Date:07/09/04ISR Number: 4393662-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Premarin	C		
UNKNOWN							
		Degeneration		Ultram	C		ORAL
		Meniscus Lesion		Vitamins			
		Mixed Incontinence		(Unspecified)	C		
UNKNOWN							
		Myalgia		Ultram	C		
UNKNOWN							
		Myositis		Allegra	C		
UNKNOWN							
		Post Thrombotic Syndrome		Lasix (Furosemide)	C		
UNKNOWN		366 DAY					
				Plaquenil	C		ORAL
				Plaquenil	C		ORAL

			Accupril	C		
UNKNOWN	535 DAY					

Date:07/09/04ISR Number: 4393664-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01618
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
470 DAY						
Other	Atrial Fibrillation		Norvasc	C		
UNKNOWN						
	Cardiac Disorder		Clonazepam	C		
UNKNOWN						
	Cerebral Infarction		Lanoxin	C		
UNKNOWN						
	Epigastric Discomfort		Zoloft	C		
UNKNOWN						
	Gastrooesophageal Reflux		Vasotec	C		ORAL
	Disease		Primidone	C		
UNKNOWN						
	Leukocytosis					

Date:07/09/04ISR Number: 4393665-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Anxiety
	Arterial Disorder
	Atrial Septal Defect

		Cardiac Aneurysm					
		Cerebral Infarction					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Aspirin	C		
UNKNOWN	668 DAY						
		Emotional Distress		Warfarin	C		
UNKNOWN	96 DAY						
		Haemorrhoids		Neurontin	C		
UNKNOWN							
		Intracranial Aneurysm					
		Lacunar Infarction					
		Myocardial Infarction					
		Pain					
		Spinal Osteoarthritis					

Date:07/09/04ISR Number: 4393668-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Aortic Atherosclerosis		[Therapy			
		Arthralgia		Unspecified]	C		
UNKNOWN	10 YR						
		Back Pain		Endocet	C		
UNKNOWN							
		Cardiomegaly		Elavil	C		
UNKNOWN							
		Chromaturia		Tenormin	C		
UNKNOWN							
		Dry Mouth		Vancenase	C		
UNKNOWN							
		Fatigue		Premarin	C		
UNKNOWN	9872 DAY						
		Fluid Retention		Prevacid	C		
UNKNOWN							
		Gastrooesophageal Reflux		Synthroid	C		
UNKNOWN							
		Disease		Prinivil	C		ORAL
1501 DAY							
		Haematoma		Methocarbamol	C		
UNKNOWN							

	Haemorrhoidal Haemorrhage		Prilosec	C		
UNKNOWN						
	Hypersensitivity					
	Hypertension					
	Hypoaesthesia					
	Joint Effusion					
	Lung Disorder					
	Migraine					
	Myalgia					
	Nausea					
	Oedema Peripheral					
	Pain In Extremity					
	Road Traffic Accident					
	Urine Odour Abnormal					

Date:07/09/04ISR Number: 4393672-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0407AUS00006
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Endometrial Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
			Atorvastatin Calcium	C		ORAL
			Vasotec	C		ORAL

Date:07/09/04ISR Number: 4393741-6Report Type:Expedited (15-DaCompany Report #04P-167-0262108-00
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage		Augmentin	PS	Glaxosmithkline	ORAL
			Adalimumab	SS		
SUBCUTANEOUS 40MG per day						
			Fluoxetine	SS		
UNKNOWN						

Rofecoxib	SS			UNKNOWN
Methotrexate	SS			UNKNOWN
Co-Dydramol	SS	Glaxosmithkline		UNKNOWN
Premarin	SS			UNKNOWN
Clavulin	C	Glaxosmithkline		UNKNOWN
Paramol-118	C			UNKNOWN

Date:07/09/04ISR Number: 4394012-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Aspirin	C				UNKNOWN
Other	Congestive		Atenolol	C				UNKNOWN
	Constipation		Cyclobenzaprine Hydrochloride	C		ORAL		
	Coronary Artery Atherosclerosis		Lasix (Furosemide)	C				UNKNOWN
	Coronary Artery Disease		Novolin	C				SUBCUTANEOUS
	Gastrooesophageal Reflux		Ultram	C				UNKNOWN
	Disease		Novolin	C				SUBCUTANEOUS
	Herpes Zoster		Zestril	C				UNKNOWN
	Hypertension		Procardia	C				UNKNOWN
	Injury		Trental	C				UNKNOWN
	Intervertebral Disc Degeneration		Potassium (Unspecified)	C				UNKNOWN
	Lumbar Radiculopathy		Ranitidine	C				UNKNOWN

	Lung Neoplasm Myocardial Infarction Pneumonitis Renal Artery Stenosis Silent Myocardial Infarction Spinal Column Stenosis Urinary Tract Infection

Date:07/09/04ISR Number: 4394021-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Connective Tissue Inflammation Coronary Artery Disease Depression Dyspnoea Emotional Distress Fatigue Heart Rate Irregular Injury Intervertebral Disc Degeneration Intervertebral Disc Protrusion Libido Disorder Micturition Disorder Mitral Valve Prolapse Normochromic Normocytic
Disability	

Anaemia
Sleep Apnoea Syndrome
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vicodin Tablets	C				
					UNKNOWN	

Date:07/09/04ISR Number: 4394023-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Rate Irregular		Aspirin	C				
UNKNOWN								
	Transient Ischaemic		Lanoxin	C				
UNKNOWN								
	Attack		Zocor	C				
UNKNOWN								
	Visual Acuity Reduced		Zestril	C				
UNKNOWN								

Date:07/09/04ISR Number: 4394024-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02008
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infarction		Vicodin Tablets	C				
UNKNOWN								
	Arthralgia		Vitamins					
	Blood Cholesterol		(Unspecified)	C				
UNKNOWN								
	Increased		Aspirin	C				
UNKNOWN								
	Bronchitis		Lipitor	C				
UNKNOWN								
	Chest Pain							
	Coronary Artery Disease							
	Dermatitis Contact							
	Diabetes Mellitus							

Drug Hypersensitivity
Dyspnoea
Eye Pain
Fall
Gastroenteritis Viral
Prostatic Specific
Antigen Abnormal

Date:07/09/04ISR Number: 4394027-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00104
Age:66 YR Gender:Female I/FU:F

Outcome PT
Other Angina Pectoris
Arthralgia
Arthritis
Arthropathy
Asthenia
Back Pain
Blood Cholesterol
Increased
Bursitis
Carotid Artery Disease
Chest Discomfort
Disorientation
Dizziness
Drug Ineffective
Dyspnoea Exertional

		Electrocardiogram Abnormal					
		Electrocardiogram Poor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		R-Wave Progression		Vioxx	PS	Merck & Co., Inc	ORAL
		Electrocardiogram St		Aspirin	C		
UNKNOWN							
		Segment Depression		Aspirin	C		
UNKNOWN							
		Epistaxis		Lomotil	C		
UNKNOWN							
		Fatigue		Insulin	C		
UNKNOWN							
		Gingival Bleeding		Avandia	C		
UNKNOWN							
		Headache		Zocor	C		ORAL
		Heart Rate Increased		Kenalog	C		
INTRAMUSCULAR							
		Hypertension		Zocor	C		ORAL
635	DAY						
		Hypoglycaemia		Zocor	C		ORAL
		Increased Tendency To		Synthroid	C		
UNKNOWN							
		Bruise		Melatonin	C		
UNKNOWN							
		Influenza		Pamelor	C		
UNKNOWN							
		Ingrowing Nail		Prilosec	C		
UNKNOWN							
		Injury					
		Joint Sprain					
		Laboratory Test Abnormal					
		Lymphadenopathy					
		Muscle Fatigue					
		Muscle Spasms					
		Muscle Strain					
		Musculoskeletal Stiffness					
		Myalgia					
		Myocardial Ischaemia					
		Nausea					
		Night Cramps					
		Nocturia					
		Oedema					
		Oedema Peripheral					
		Osteopenia					
		Osteoporosis					
		Palpitations					

Rheumatoid Arthritis
Sciatica
Sinus Disorder
Spinal Osteoarthritis
Sympathetic Posterior
Cervical Syndrome
Tachycardia
Tendon Rupture
Tendonitis
Transient Ischaemic
Attack
Weight Increased
Wheezing

Date:07/09/04ISR Number: 4394030-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Empty Sella Syndrome
	Fibromyalgia
	Headache

	Hepatic Lesion						
	Hypertension						
	Labyrinthitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lumbar Spinal Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Lung Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Urinary Retention		Vioxx	SS	Merck & Co., Inc	ORAL	
			Tylenol With Codeine	C			UNKNOWN

Date:07/09/04ISR Number: 4394031-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	93 DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C			UNKNOWN
Other	Bundle Branch Block Left		Ecotrin	C			UNKNOWN
	Chest Discomfort		Viagra	C			UNKNOWN
	Coronary Artery Disease		Calan Sr	C			UNKNOWN
	Dehydration		Zocor	C			UNKNOWN
	Diverticulum Intestinal		Celebrex	C			UNKNOWN
	Haemorrhagic		Advil	C			UNKNOWN
	Emotional Distress						
	Gastritis Atrophic						
	Helicobacter Infection						
	Neck Pain						
	Neuropathy Peripheral						
	Rotator Cuff Syndrome						
	Stent Occlusion						

Date:07/09/04ISR Number: 4394033-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		552 DAY
Initial or Prolonged	Abdominal Distension		Aleve	SS				UNKNOWN
Disability	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		552 DAY
	Anxiety		Tylenol	C				UNKNOWN
	Back Pain		Paxil	C				UNKNOWN
	Calculus Ureteric						2 MON	
	Cognitive Disorder							
	Confusional State							
	Constipation							
	Dizziness							
	Emotional Distress							
	Haematochezia							
	Hypertension							
	Influenza Like Illness							
	Lethargy							
	Renal Cyst							
	Transient Ischaemic Attack							

Date:07/09/04ISR Number: 4394035-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT
Abdominal Pain
Anaemia
Angina Pectoris
Angina Unstable
Aortic Aneurysm
Aortic Disorder
Aortic Valve Sclerosis
Arrhythmia
Arthralgia
Asthenia
Atrial Fibrillation
Back Pain
Benign Prostatic
Hyperplasia
Blindness Transient
Blindness Unilateral
Blood Urea Increased
Bradycardia
Cardiac Failure
Congestive
Cardiac Valve Vegetation
Cardiovascular
Deconditioning
Cerebrovascular Accident
Cerebrovascular Disorder
Chest Pain
Chills
Closed Head Injury
Coordination Abnormal
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Dehydration
Diabetes Mellitus
Non-Insulin-Dependent
Diarrhoea
Diastolic Dysfunction
Dilatation Atrial
Dizziness
Drug Toxicity
Dyspnoea
Electrocardiogram Poor
R-Wave Progression

Embolism
Emotional Distress
Extrasystoles
Fall
Feeling Abnormal
Feeling Hot And Cold
Flank Pain
Gait Disturbance
Gastrointestinal Motility
Disorder
Heart Rate Irregular
Injury
Ischaemia
Joint Stiffness

		Leukocytosis					
		Loss Of Employment					
		Malaise	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve		Vioxx	PS	Merck & Co., Inc	ORAL
		Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Imuran			
		Mitral Valve Stenosis		(Azathioprine)	C		
UNKNOWN							
		Motor Dysfunction		Chloracon	C		
UNKNOWN							
		Muscular Weakness		Celebrex	C		
UNKNOWN							
		Myocardial Infarction		Tagamet	C		
UNKNOWN							
		Myocardial Ischaemia		Cyanocobalamin	C		
UNKNOWN							
		Nausea		Lanoxin	C		
UNKNOWN							
		Neck Pain		Tiazac	C		
UNKNOWN							
		Oedema Peripheral		Cartia (Diltiazem			
		Oesophageal Disorder		Hydrochloride)	C		
UNKNOWN							
		Oral Candidiasis		Folic Acid	C		
UNKNOWN							
		Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Pneumonia		Glipizide	C		
UNKNOWN							
		Polymyalgia Rheumatica		Motrin	C		
UNKNOWN							
		Polyuria		Insulin	C		
UNKNOWN							
		Pulmonary Embolism		Insulin Human,			
		Pulmonary Toxicity		Isophane	C		
UNKNOWN							
		Pyrexia		Imdur	C		
UNKNOWN							
		Skin Ulcer		Methotrexate	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Niacin	C		
UNKNOWN							
		Swelling		Vitamin E	C		
UNKNOWN							
		Temporal Arteritis		Flomax (Tamsulosin			

	Thrombosis	Hydrochloride)	C
UNKNOWN			
	Tricuspid Valve Incompetence	Potassium (Unspecified)	C
UNKNOWN			
	Urinary Tract Infection	Prednisone	C
UNKNOWN			
	Vascular Pseudoaneurysm		
	Vasculitis		
	Ventricular Dysfunction		
	Ventricular Hypertrophy		
	Vision Blurred		
	Visual Acuity Reduced		
	Visual Disturbance		
	Visual Field Defect		
	Vomiting		
	Wandering Pacemaker		

Date:07/09/04ISR Number: 4394040-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Aneurysm
	Aneurysm Ruptured
	Antinuclear Antibody Positive
	Aortic Atherosclerosis
	Aortic Dissection
	Asthenia
	Atelectasis
	Chest Pain
	Depression
	Disturbance In Attention

		Diverticulitis					
		Dizziness					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Enterobacter Infection		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		General Physical		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Condition Abnormal		Amoxicillin	C		
UNKNOWN							
		Haematocrit Decreased		Viagra	C		
UNKNOWN							
		Haemoglobin Increased		Chlorhexidine			
		Haemorrhage		Hydrochloride	C		
UNKNOWN							
		Hyperhidrosis		Hydrocodone			
		Hyperlipidaemia		Bitartrate	C		
UNKNOWN							
		Hypertension		Lorazepam	C		
UNKNOWN							
		Hypoaesthesia					
		Iliac Artery Thrombosis					
		Impaired Healing					
		Injury					
		Irritability					
		Keloid Scar					
		Loss Of Employment					
		Lung Consolidation					
		Pain					
		Pharyngolaryngeal Pain					
		Platelet Count Increased					
		Pneumonia					
		Prothrombin Time					
		Prolonged					
		Rash Pruritic					
		Self Esteem Decreased					
		Sexual Dysfunction					
		Sputum Culture Positive					
		Thinking Abnormal					
		Tooth Extraction					
		Vascular Injury					

Date:07/09/04ISR Number: 4394044-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00844
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury							
	Back Pain							
	Cerebrovascular Accident							
	Dementia Alzheimer'S Type							
	Dysuria							
	Emotional Distress							
	Facial Pain							
	Fall							
	Gastroenteritis							
	Hypertension							
	Injury							
	Intervertebral Disc							
	Protrusion							
	Renal Cyst							
	Subarachnoid Haemorrhage							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/04ISR Number: 4394050-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia Macrocytic		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia Of Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Lipitor	C			UNKNOWN	
	Cardiac Murmur		Celebrex	C			UNKNOWN	
	Depression		Zoloft	C			UNKNOWN	
	Diverticular Perforation		Triamterene	C			UNKNOWN	
	Dizziness		Voltaren	C			UNKNOWN	
	Gastritis		Duragesic	C			TOPICAL	
	Gastrointestinal		Dyazide	C			UNKNOWN	
	Haemorrhage		Metoprolol	C			UNKNOWN	
	Gastrooesophageal Reflux		Lopressor	C			UNKNOWN	
	Disease		Prilosec	C			UNKNOWN	
	Hyperlipidaemia		Denavir	C			UNKNOWN	
	Hypertension							
	Muscle Spasms							
	Nausea							
	Osteoarthritis							
	Palpitations							
	Polyp Colorectal							
	Rectal Haemorrhage							
	Respiratory Rate Increased							
	Small Intestinal Haemorrhage							

Date:07/09/04ISR Number: 4394053-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02315
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		220 DAY
Initial or Prolonged	Aortic Stenosis		Tylenol	C				UNKNOWN
Disability	Aortic Valve Incompetence		Codeine	C				UNKNOWN
	Atelectasis		Vasotec	C		ORAL		
	Atrial Fibrillation		Premarin	C				UNKNOWN
	Constipation		Premarin	C				UNKNOWN
	Depression		Zocor	C		ORAL		
	Dyspnoea Exertional		Hydrocodone Hydrochloride	C				UNKNOWN
	Insomnia							
	Intervertebral Disc		Levsin	C				UNKNOWN
	Degeneration		Synthroid	C		ORAL		
	Lung Neoplasm		Prilosec	C		ORAL		
	Medical Device Complication							
	Nocturia							
	Osteopenia							
	Osteoporosis							
	Postoperative Infection							
	Postoperative Thoracic							
	Procedure Complication							
	Syncope							
	Temperature Intolerance							
	Urinary Incontinence							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/04ISR Number: 4394054-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00157
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	1 DAY
			Oxycodone Hydrochloride	C			UNKNOWN	1 DAY
			Propofol	C			UNKNOWN	1 DAY
			Remifentanil Hydrochloride	C			UNKNOWN	1 DAY

Date:07/09/04ISR Number: 4394055-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01718
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc Disorder							

Date:07/09/04ISR Number: 4394056-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Other	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic Hyperplasia

Cardiac Failure
Congestive
Cerebellar Syndrome
Cerebral Haemorrhage
Confusional State
Coronary Artery Disease
Deafness Neurosensory
Dehydration
Depression
Diabetes Mellitus
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fibrous Histiocytoma
Gastritis Haemorrhagic
Headache
Hiatus Hernia
Hypertension
Inner Ear Disorder
Leukocytosis
Mitral Valve Incompetence

	Myocardial Infarction						
	Oedema						
	Pneumonia Escherichia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Post Procedural		Vioxx	PS	Merck & Co., Inc	ORAL	100 DAY
	Complication		Vioxx	SS	Merck & Co., Inc	ORAL	
	Prothrombin Time		Vioxx	SS	Merck & Co., Inc	ORAL	
	Prolonged		Vioxx	SS	Merck & Co., Inc	ORAL	100 DAY
	Pupillary Disorder		Neurontin	C			UNKNOWN
	Renal Failure		Glucosamine	C			UNKNOWN
	Respiratory Failure		Prilosec	C			UNKNOWN
	Sepsis						
	Subarachnoid Haemorrhage						
	Syncope						
	Transient Ischaemic						
	Attack						
	Tremor						
	Tricuspid Valve						
	Incompetence						
	Varicose Vein						
	Ventricle Rupture						
	Ventricular Tachycardia						
	Vertigo Positional						
	Vision Blurred						

Date:07/09/04ISR Number: 4394059-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00049
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Monoplegia		Acetaminophen And				
	Neck Pain		Codeine Phosphate	C		ORAL	
	Post Coital Bleeding		Felbinac	C			TOPICAL

Date:07/09/04ISR Number: 4394060-4Report Type:Expedited (15-DaCompany Report #DK-MERCK-0402DNK00026
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY

Date:07/09/04ISR Number: 4394061-6Report Type:Expedited (15-DaCompany Report #MY-MERCK-0407MYS00001
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Fosamax	SS		ORAL		
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
			Celecoxib	SS		ORAL		

Date:07/09/04ISR Number: 4394062-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0407CHE00004
Age:34 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Fluid Retention
	Pleural Effusion
	Proteinuria

	Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:07/09/04ISR Number: 4394063-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01659
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Weight Increased		Lipitor	C			UNKNOWN	
			Detrol La	C			UNKNOWN	

Date:07/09/04ISR Number: 4394064-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00165
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Adipic Acid	C			UNKNOWN	
	Congestive		Proscar	C		ORAL		
	Oedema Peripheral		Neurontin	C			UNKNOWN	
	Pain		Synthroid	C			UNKNOWN	
	Pelvic Fracture		Lorazepam	C			UNKNOWN	
	Somnolence		Provigil	C			UNKNOWN	
	Stress		Flomax (Morniflumate)	C			UNKNOWN	

Date:07/09/04ISR Number: 4394065-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00501
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Hydrodiuril	C		ORAL		
	Hypertension		Cozaar	C		ORAL		

Date:07/09/04ISR Number: 4394069-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Intestinal
	Acute Myocardial
Other	Infarction
	Atherosclerosis
	Bundle Branch Block Right
	Cardiomyopathy
	Cervicobrachial Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Diverticular Perforation
	Drug Hypersensitivity
	Myeloproliferative
	Disorder
	Polycythaemia
	Prostatic Specific
	Antigen Increased
	Ventricular Dysfunction

	Viral Infection Viral Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY

Date:07/09/04ISR Number: 4394072-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 319 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged 319 DAY	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability UNKNOWN	Angina Pectoris		Xanax	C			
Other UNKNOWN	Anxiety		Valium	C			
	Arthralgia		Diovan	C			
UNKNOWN	Asthenia		Ibuprofen	C			
UNKNOWN	Atrioventricular Block		Humulin N	C			
UNKNOWN	Complete		Synthroid	C			
UNKNOWN	Blood Glucose Increased Bradycardia Cardiogenic Shock Coronary Artery Disease Coronary Artery Occlusion Coronary Artery Stenosis Costochondritis Cyst Decreased Activity Diabetes Mellitus Dizziness Dressler'S Syndrome Drug Ineffective Ejection Fraction Decreased Emotional Disorder Headache						

Herpes Zoster
Hypertension
Hypotension
Impaired Work Ability
Injury
Lung Disorder
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Non-Cardiac Chest Pain
Oedema Peripheral
Osteoarthritis
Stress

Date:07/09/04ISR Number: 4396415-0Report Type:Expedited (15-DaCompany Report #HQWYE842301JUL04
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cholangitis Cytolytic Hepatitis Gallbladder Pain Smooth Muscle Antibody Positive	Health Professional Other	Inipomp (Pantoprazole, Tablet, Delayed Release)	PS		ORAL	40 MG 1X PER 1 DAY; ORAL	44 DAY
			Estradiol (Estradiol,)	SS				

RESPIRATORY

(INHALATION) INHALATION 1323 DAY

Pilosuryl (Mouse-Ear Hawkweed/Phyllantus Emblica,) SS ORAL "1.5 DOSE FORM"; ORAL 105 DAY

Progesterone (Progesterone,) SS ORAL 100 MG 1X PER 1 DAY; ORAL 1323 DAY

Vioxx (Rofecoxib, Tablet) SS ORAL SEE IMAGE 11 DAY

. C

. C

Lorazepam (Lorazepam) C

Date:07/10/04ISR Number: 4394075-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0401FRA00075
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cytolytic Hepatitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Hepatitis Cholestatic	Professional	Acetaminophen	SS		ORAL	11	DAY

Date:07/10/04ISR Number: 4394077-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bipolar Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL	135	DAY
	Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	135	DAY
	Haemorrhoids		Depakote	C			UNKNOWN	
	Myocardial Infarction		Lisinopril	C			UNKNOWN	

				Lithium Sulfate	C		
UNKNOWN							

Date:07/10/04ISR Number: 4394078-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00425
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Closed Head Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Demyelination	Professional	Remicade	SS			INTRAVENOUS	
	Depressed Level Of					DRIP	871 DAY	
	Consciousness		Remicade	SS			INTRAVENOUS	
	Dyspnoea					DRIP		
	Ear Discomfort		Ascorbic Acid	C			UNKNOWN	
	Fall		Calcium (Unspecified) And Vitamin D (Unspecified)	C			UNKNOWN	
	Glioma							
	Hypoaesthesia							
	Loss Of Consciousness							
	Paraesthesia		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C			UNKNOWN	
	Rheumatoid Arthritis							
	Tinnitus							
			Levoxyl	C			UNKNOWN	
			Medrol	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Pyridoxine	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Dicyclomine					

	Hydrochloride	C	
UNKNOWN			
	Bentyl	C	
UNKNOWN			
	Premarin	C	
UNKNOWN			
	Folic Acid	C	
UNKNOWN			

Date:07/12/04ISR Number: 4394356-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/04ISR Number: 4394358-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01287
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Cataract		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease		Aciphex	C		ORAL		
	Coronary Artery Stenosis		Restoril	C				
UNKNOWN								
	Ejection Fraction Decreased							
	Miosis							
	Myocardial Infarction							
	Optic Ischaemic Neuropathy							
	Sinus Bradycardia							
	Sinus Disorder							
	Soft Tissue Injury							
	Tension Headache							
	Vascular Occlusion							
	Ventricular Hypokinesia							

Date:07/12/04ISR Number: 4394642-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
Other	Adenomyosis
	Amnesia
	Angina Pectoris
	Anorexia
	Anxiety
	Aortic Dilatation
	Aortic Valve Incompetence
	Arthralgia
	Arthritis
	Asthenia
	Atrioventricular Block
	Back Pain
	Blood Potassium Decreased
	Bronchitis
	Bundle Branch Block Left
	Cardiac Valve Disease
	Cardiomyopathy
	Cellulitis
	Chest Pain

Complex Regional Pain
Syndrome
Condition Aggravated
Constipation
Convulsion
Costochondritis
Dental Caries
Depression
Dilatation Atrial
Dilatation Ventricular
Diverticulitis
Dizziness
Drug Withdrawal Syndrome
Duodenal Ulcer
Duodenitis
Dyspnoea Exertional
Encephalopathy
Fatigue
Feeling Abnormal
Feeling Of Despair
Gastritis
Grand Mal Convulsion
Haematoma
Haematoma Infection
Haemorrhoids
Headache
Helicobacter Gastritis
Hypertension
Hypertensive Crisis
Hypokalaemia
Irritable Bowel Syndrome
Joint Contracture
Laceration
Malignant Hypertension
Memory Impairment
Micturition Urgency
Myocardial Infarction
Myocardial Ischaemia
Nausea
Night Sweats
Oedema Peripheral
Oesophagitis
Orthopnoea
Osteoarthritis
Pain In Extremity
Palpitations
Pelvic Inflammatory

Disease
Pharyngolaryngeal Pain
Psychotic Disorder
Renal Failure
Salpingitis
Sensory Loss
Sinus Headache
Supraventricular
Tachycardia
Swelling Face
Tinnitus
Tongue Injury
Treatment Noncompliance
Tricuspid Valve

		Incompetence					
		Upper Respiratory Tract Infection					
		Uterine Leiomyoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Wound Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Cardura	C		
UNKNOWN							
				Normodyne	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Flagyl	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							
				Procardia Xl	C		
UNKNOWN							

Date:07/12/04ISR Number: 4394667-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Valve Incompetence		Diazide	C		
UNKNOWN							
		Arrhythmia		Zocor	C		ORAL
		Supraventricular		Lopressor	C		
UNKNOWN							
		Arthralgia		Lopressor	C		
UNKNOWN							
		Atrial Fibrillation					
		Atrial Flutter					
		Atrial Thrombosis					
		Back Pain					
		Blood Cholesterol Increased					
		Blood Pressure Increased					
		Bronchitis					
		Cardiac Failure					
		Congestive					
		Cerebral Ischaemia					
		Cerebrovascular Accident					

Cerebrovascular Disorder
Coronary Artery Disease
Dilatation Atrial
Dyspnoea
Electrocardiogram
Abnormal
Emotional Distress
Heart Rate Irregular
Injury
Mitral Valve Incompetence
Myocardial Infarction
Overdose
Palpitations
Pleural Effusion
Pneumonia
Pruritus
Rash Papular
Sebaceous Gland Disorder
Thrombosis
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Ventricular Hypertrophy

Date:07/12/04ISR Number: 4394669-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Jaw	Health	Vioxx	PS	Merck & Co., Inc	ORAL		846 DAY
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		846 DAY
Disability	Anxiety		[Therapy Unspecified]	C				UNKNOWN
	Blood Cholesterol		Vicodin Tablets	C				UNKNOWN
	Increased		Xanax	C				UNKNOWN
	Blood Creatine		Covera	C				UNKNOWN
	Phosphokinase Increased		Trimox	C				UNKNOWN
	Cardiac Murmur		Atenolol	C				UNKNOWN
	Carotid Artery Stenosis		Soma	C				UNKNOWN
	Coronary Artery Disease		Relafen	C				UNKNOWN
	Depression							
	Dizziness							
	Drug Hypersensitivity							
	Duodenal Ulcer							
	Haemorrhage							
	Duodenitis							
	Food Poisoning							
	Gastroenteritis							
	Gout							
	Hypertension							
	Loss Of Consciousness							
	Myocardial Infarction							
	Oesophageal Disorder							
	Osteoarthritis							
	Otitis Media							
	Overdose							
	Somnolence							

Date:07/12/04ISR Number: 4394671-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02131
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		46 DAY
Other	Congestive Cardiomyopathy		Isosorbide Mononitrate	C				UNKNOWN
	Dilatation Atrial		Lisinopril	C				UNKNOWN
	Dilatation Ventricular Pulmonary Hypertension		Terazosin Hydrochloride	C				UNKNOWN
	Ventricular Dysfunction Ventricular Hypertrophy		Actos	C		ORAL		
			Potassium (Unspecified)	C				UNKNOWN
			Aciphex	C				UNKNOWN

Date:07/12/04ISR Number: 4394672-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00125
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY

Date:07/12/04ISR Number: 4394674-1Report Type:Expedited (15-DaCompany Report #NL-MERCK-0407NLD00009
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pericardial Effusion Pleural Effusion		Vioxx Amitriptyline Hydrochloride	PS C	Merck & Co., Inc	ORAL ORAL		

Date:07/12/04ISR Number: 4394675-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0407AUS00001
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/12/04ISR Number: 4394676-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00168
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/04ISR Number: 4394678-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00411
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/04ISR Number: 4394679-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02086
Age:91 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort

Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Balance Disorder
Disability	Cardiac Failure
Other	Cerebral Atherosclerosis
	Chronic Obstructive Pulmonary Disease
	Constipation
	Death
	Decubitus Ulcer
	Depression
	Dry Skin
	Dyspnoea
	Fall
	Fracture Displacement
	Gastrooesophageal Reflux Disease
	Haematochezia
	Haematoma
	Haemorrhage
	Hyperkeratosis
	Hypoacusis
	Ilium Fracture
	Inflammation

	Muscle Spasms						
	Nausea						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pelvic Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Respiratory Tract	Professional	Valium	C			UNKNOWN
	Infection		Vasotec	C		ORAL	
	Senile Dementia		Vasotec	C		ORAL	
	Spinal Compression		Ferrous Sulfate	C			UNKNOWN
	Fracture		Timoptic	C			OPHTHALMIC
	Syncope		Ultram	C			UNKNOWN
	Tinea Pedis		Miacalcin	C			UNKNOWN
	Vulval Erythema		Hydrodiuril	C		ORAL	
	Vulval Oedema		Morphine	C			UNKNOWN
	Weight Decreased		Deltasone	C			UNKNOWN

Date:07/12/04ISR Number: 4394686-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 401 DAY	Aortic Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Aortic Valve Sclerosis	Professional	Aspirin	C			UNKNOWN
Disability	Chest Pain		Aspirin	C			UNKNOWN
Other	Chronic Fatigue Syndrome		Tagamet	C			UNKNOWN
	Depression		Premarin	C			UNKNOWN
	Dizziness		Hytrin	C			UNKNOWN
	Duodenitis		Estratab	C			UNKNOWN
	Endocarditis		L-Thyroxin	C			UNKNOWN

	Gallbladder Disorder	Ranitidine	C
UNKNOWN			
	Gastritis Gastrooesophageal Reflux Disease Generalised Anxiety Disorder Haematuria Herpes Zoster Hypertension Hypertensive Crisis Hypoacusis Hypokalaemia Irritable Bowel Syndrome Lacunar Infarction Laryngitis Migraine With Aura Mitral Valve Calcification Mitral Valve Incompetence Non-Cardiac Chest Pain Panic Disorder Sleep Apnoea Syndrome Tension Headache Thalamus Haemorrhage Transient Ischaemic Attack Upper Respiratory Tract Infection		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4394692-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00115
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum Intestinal							
	Duodenal Ulcer							
	Gastric Ulcer							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Haemorrhoids							
	Headache							
	Helicobacter Pylori							
	Identification Test							
	Positive							
	Perforated Ulcer							
	Pseudodiverticular							
	Disease							
	Sleep Disorder							
	Stress							

Date:07/12/04ISR Number: 4394694-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00105
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Trazodone Hydrochloride	C				
UNKNOWN								

Date:07/12/04ISR Number: 4394697-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02740
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Disability	Adverse Event		Vicodin Tablets	C				
UNKNOWN								

	Asthma		Albuterol	C		
UNKNOWN						
	Back Pain		Aerobid	C		
UNKNOWN						
	Bedridden		Glucophage	C		
UNKNOWN						
	Dyskinesia					
	Joint Swelling					
	Pain					
	Swelling					

Date:07/12/04ISR Number: 4394699-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00067
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrointestinal	Professional	Aspirin	SS		
UNKNOWN						
	Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4394700-XReport Type:Expedited (15-DaCompany Report #PT-MERCK-0407PRT00003
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Dyspnoea		Albuterol Sulfate	C				
	Face Oedema		Sulfamethoxazole And Trimethoprim	C			UNKNOWN	
	Localised Oedema							
	Nausea		Tiotropium Bromide	C			UNKNOWN	
			Betamethasone Dipropionate	C			UNKNOWN	

Date:07/12/04ISR Number: 4394701-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Medication Error		[Therapy Unspecified]	SS				
	Overdose							

Date:07/12/04ISR Number: 4394703-5Report Type:Expedited (15-DaCompany Report #IE-MERCK-0407GBR00019
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		
			Pravastatin Sodium	C				

Date:07/12/04ISR Number: 4395233-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01070525
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Dreams		Vioxx	PS	Merck & Co., Inc	ORAL		252 DAY
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		65 DAY
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		252 DAY
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		65 DAY
	Cerebrovascular Accident		Vicodin Tablets	C				UNKNOWN
	Depression		Elavil	C				UNKNOWN
	Disturbance In Attention		Atenolol	C				UNKNOWN
	Dizziness		Lipitor	C				UNKNOWN
	Fall		Celebrex	C				UNKNOWN
	Fear		Plavix	C				UNKNOWN
	Headache		Calan Sr	C				UNKNOWN
	Muscle Strain		Ultram	C				UNKNOWN
	Nephrosclerosis		Zoloft	C				UNKNOWN
	Nocturia		Zoloft	C				UNKNOWN
	Pain		Flexeril	C				UNKNOWN
	Renal Failure Acute		Flexeril	C			21 DAY	UNKNOWN
	Respiratory Disorder		Flexeril	C			13 DAY	UNKNOWN
	Rotator Cuff Syndrome		Premarin	C				UNKNOWN
	Spinal Column Stenosis		Pepcid	C		ORAL		
	Stress		Dyazide	C				UNKNOWN
	Therapeutic Response		Accupril	C				UNKNOWN
	Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4395235-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chromaturia		Norvasc	C			UNKNOWN	
	Contusion		Aspirin	C			UNKNOWN	
	Coronary Artery		Lipitor	C			UNKNOWN	
	Restenosis		Monopril	C			UNKNOWN	
	Cough		Indocin (Indomethacin)	C			UNKNOWN	
	Decreased Appetite							
	Depressed Mood		Toprol Xl Tablets	C			UNKNOWN	
	Diarrhoea		Lopressor	C			UNKNOWN	
	Disturbance In Attention		Naproxen	C			UNKNOWN	
	Diverticulum Intestinal Haemorrhagic							
	Drug Ineffective							
	Dyspnoea							
	Fatigue							
	Fluid Retention							
	Hypertension							
	Hypoaesthesia							
	Insomnia							
	Iron Deficiency							
	Libido Decreased							
	Lung Neoplasm							
	Myocardial Infarction							
	Nausea							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Paraesthesia							
	Pneumonia							
	Prostatic Specific Antigen Increased							
	Proteinuria							

Renal Cyst
Rheumatoid Arthritis
Rhinitis Allergic
Stress
Tendon Rupture
Umbilical Hernia
Ventricular Extrasystoles

Date:07/12/04ISR Number: 4395244-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome
Disability

PT
Acne
Antibody Test Positive
Anxiety
Asthenia
Chest Discomfort
Chest Pain
Diabetes Mellitus
Dysuria
Gastritis
Gastrooesophageal Reflux
Disease

	Hemiparesis						
	Hypoaesthesia						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Joint Dislocation		[Therapy					
	Joint Effusion		Unspecified]	C			UNKNOWN	144 DAY
	Joint Range Of Motion		Tylenol	C			UNKNOWN	
	Decreased		Darvocet-N	C			UNKNOWN	
	Joint Sprain		Soma	C			UNKNOWN	
	Lipoma							
	Myalgia							
	Spinal Osteoarthritis							
	Stress							

Date:07/12/04ISR Number: 4395246-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Sular	C			UNKNOWN	
	Bone Disorder		Micardis	C			UNKNOWN	
	Chest Pain							
	Chronic Fatigue Syndrome							
	Emotional Distress							
	Fatigue							
	Injury							
	Large Intestinal Ulcer							
	Haemorrhage							
	Nausea							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Rotator Cuff Syndrome							

Spinal Disorder
Stomach Discomfort

Date:07/12/04ISR Number: 4395249-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Intestinal
Disability	Anaemia
Other	Anaemia Macrocytic
	Anaemia Of Chronic Disease
	Angiodysplasia
	Asthenia
	Bronchitis
	Bronchitis Chronic
	Cardiac Murmur
	Cervicobrachial Syndrome
	Chest Discomfort
	Contusion
	Decreased Appetite
	Depression
	Diverticular Perforation
	Dizziness

	Dyspepsia						
	Dyspnoea Exertional						
	Epigastric Discomfort	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arteriovenous		Vioxx	SS	Merck & Co., Inc	ORAL		
	Malformation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Lipitor	C			UNKNOWN	
	Disease		Celebrex	C			UNKNOWN	
	Injury		Zoloft	C			UNKNOWN	
	Muscle Spasms		Triamterene	C			UNKNOWN	
	Nausea		Voltaren	C			UNKNOWN	
	Osteoarthritis		Duragesic	C			TOPICAL	
	Palpitations		Dyazide	C			UNKNOWN	
	Polyp Colorectal		Metoprolol	C			UNKNOWN	
	Rectal Haemorrhage		Lopressor	C			UNKNOWN	
	Small Intestinal		Prilosec	C			UNKNOWN	
	Haemorrhage		Denavir	C			UNKNOWN	

Date:07/12/04ISR Number: 4395260-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02577
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/04ISR Number: 4395264-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00571
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pitting Oedema		Amiodarone	C			UNKNOWN	
	Pleural Effusion		Diovan	C			UNKNOWN	
	Sleep Disorder Due To		Amiodarone	C			UNKNOWN	
	General Medical		Azmacort	C			RESPIRATORY	
	Condition, Insomnia Type						(INHALATION)	
			Toprol Xl Tablets	C			UNKNOWN	

Date:07/12/04ISR Number: 4395270-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00223
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lower Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
			Furosemide	C			UNKNOWN	
	Lung Neoplasm Malignant		Warfarin	C			UNKNOWN	
	Pulmonary Fibrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4395272-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0406NLD00006
Age:96 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Perforation		Acetaminophen	C		ORAL		
			Furosemide	C		ORAL		
			Hypromellose	C		OPHTHALMIC		
			Nortriptyline Hydrochloride	C		ORAL		

Date:07/12/04ISR Number: 4395273-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0407CAN00027
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							

Date:07/12/04ISR Number: 4395275-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01909
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							

Date:07/12/04ISR Number: 4395276-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulation Factor Viii		Vioxx	PS	Merck & Co., Inc	ORAL	117 DAY	
	Level Decreased		Ginkgo Biloba					
	Coagulation Time		Extract	SS		ORAL		
	Prolonged		Zocor	SS		ORAL		
	Haematoma		Hydrochlorothiazide And Lisinopril	SS		ORAL		

Date:07/12/04ISR Number: 4395277-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/04ISR Number: 4398927-2Report Type:Expedited (15-DaCompany Report #WAES 0310FIN00006
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY, PO	
	Dizziness	Other						
	Vertigo		Tab Ibuprofen	SS		ORAL	1000 MG/DAILY, PO	25 DAY
	Vomiting							
			Amlodipine Besylate	C				
			Hydrochlorothiazide	C				
			Valsartan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/04ISR Number: 4404121-9Report Type:Direct Company Report #CTU 223153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx Merck	PS	Merck	ORAL	DAILY ORAL	
Hospitalization - Initial or Prolonged	Haemorrhage							

Date:07/13/04ISR Number: 4395876-0Report Type:Expedited (15-DaCompany Report #PHNR2004AU01183
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Estalis Continuous	PS	Novartis Sector: Pharma		TRANSDERMAL	
	Cardiomegaly							
	Dyspnoea Exertional		Avandia	SS		ORAL	4 mg, QD	
	Face Oedema		Glimepiride	SS		ORAL	4 mg, QD	
	Oedema Peripheral		Celecoxib	SS		ORAL	200 mg, QD	567 DAY
			Rofecoxib	SS			25 mg, QD	46080MIN
			Omeprazole	C				
			Allopurinol	C				
			Coversyl	C				
			Minax	C				
			Digoxin	C				
			Salbutamol	C				
			Sertraline	C				
			Frusemide	C				

Date:07/13/04ISR Number: 4395920-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Activated Partial		Aspirin	C				668 DAY

Disability	Thromboplastin Time	Warfarin	C
UNKNOWN			
Other	Prolonged	Neurontin	C
UNKNOWN			
	Anxiety		
	Arterial Disorder		
	Atrial Septal Defect		
	Cardiac Aneurysm		
	Cerebral Infarction		
	Chest Pain		
	Diverticulum		
	Dyspnoea		
	Emotional Distress		
	Haemorrhoids		
	Intracranial Aneurysm		
	Lacunar Infarction		
	Myocardial Infarction		
	Pain		
	Spinal Osteoarthritis		

Date:07/13/04ISR Number: 4395923-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Distension
Disability	Abdominal Pain
	Anxiety

Back Pain Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Calculus Ureteric	Health	Vioxx	PS	Merck & Co., Inc	ORAL	552 DAY
Change Of Bowel Habit	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	552 DAY
Cognitive Disorder		Aleve	SS			UNKNOWN
Confusional State		Paxil	C			UNKNOWN 2 MON
Constipation		Tylenol	C			UNKNOWN
Disorientation Dizziness Emotional Distress Global Amnesia Haematochezia Hypertension Impaired Work Ability Influenza Like Illness Injury Lethargy Nephrocalcinosis Rectal Haemorrhage Renal Cyst Road Traffic Accident Syncope Transient Ischaemic Attack						

Date:07/13/04ISR Number: 4395927-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Asthma
Other	Cardiomegaly
	Carotid Artery Occlusion
	Cerebrovascular Accident
	Chest Pain
	Concussion
	Constipation
	Contusion

Depression
Drug Abuser
Excoriation
Fall
Gastrooesophageal Reflux
Disease
Hyperlipidaemia
Laceration
Melaena
Microcytic Anaemia
Oedema Peripheral
Orthostatic Hypotension
Pain
Pain In Extremity
Pulmonary Congestion
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation
Tibia Fracture
Urinary Tract Infection

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Darvocet-N	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Soma	C		ORAL	UNKNOWN	
	Diflunisal	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Estratest	C			UNKNOWN	
	Allegra	C			UNKNOWN	
	Rebetron	C			UNKNOWN	3 DAY
	Nortriptyline	C			UNKNOWN	
	Accupril	C			UNKNOWN	
	Rebetol	C			UNKNOWN	

Date:07/13/04ISR Number: 4395933-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Alanine Aminotransferase Increased
	Amnesia
	Antiphospholipid Syndrome
	Aspartate Aminotransferase Increased
	Biliary Dyskinesia
	Blood Cholesterol

Increased
Blood Immunoglobulin M
Increased
Body Temperature
Decreased
Body Temperature
Increased
Cardiolipin Antibody
Positive
Cerebrovascular Accident
Cholecystitis
Cholecystitis Chronic
Chronic Fatigue Syndrome
Colonic Polyp
Complicated Migraine
Confusional State
Contusion
Disturbance In Attention
Diverticulum
Dysarthria
Dyspepsia
Emotional Distress
Erythema
Eye Pain
Gastroenteritis Viral
Haemorrhagic Ovarian Cyst
Haemorrhoids

		Hypercoagulation					
		Injury					
		International Normalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ratio Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		International Normalised	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Ratio Increased		Allegra	C		
UNKNOWN							
		Irritability					
		Menorrhagia					
		Mitral Valve Disease					
		Nervousness					
		Ovarian Cyst					
		Protein S Increased					
		Rectal Haemorrhage					
		Tearfulness					
		Thinking Abnormal					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					

Date:07/13/04ISR Number: 4395935-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00105
Age:88 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Jaundice Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
Initial or Prolonged				Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
				Acetaminophen	C		ORAL
				Acetaminophen	C		ORAL
				Aspirin	C		ORAL
				Spironolactone	C		ORAL
				Gliclazide	C		ORAL
				Nicorandil	C		ORAL
				Omeprazole	C		ORAL

Date:07/13/04ISR Number: 4395936-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Occlusion
	Diverticulum Intestinal
	Gastritis
	Gastrointestinal Haemorrhage
	Haematuria
	Haemorrhoids
	Hypertension
	Myocardial Infarction
	Pain
	Pain In Extremity
	Proctitis
	Stress

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Thrombosis Upper Gastrointestinal Haemorrhage					
532	DAY	Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Urinary Tract Infection		[Therapy Unspecified]	C		
UNKNOWN		Weight Decreased		Tylenol	C		
UNKNOWN				Proventil	C		
UNKNOWN				Buspar	C		
UNKNOWN				Cipro	C		
UNKNOWN				Tranxene	C		
UNKNOWN				Diphenhydramine Citrate	C		
UNKNOWN				Epi-Pen	C		
UNKNOWN				Allegra	C		
UNKNOWN				Duratuss	C		
UNKNOWN				Hydroxyzine Pamoate	C		
UNKNOWN				Motrin	C		
UNKNOWN				Loperamide Hydrochloride	C		
UNKNOWN				Methylprednisolone	C		
UNKNOWN				Nasonex	C		
UNKNOWN				Elocon	C		
UNKNOWN				Actonel	C		
UNKNOWN				Ultram	C		

Date:07/13/04ISR Number: 4396486-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis							
	Arthropathy							
	Cardiac Murmur							
	Chest Pain							
	Contusion							
	Dyspnoea							
	Emotional Distress							
	Fatigue							
	Gastric Disorder							
	Haemorrhage							
	Neoplasm Malignant							
	Palpitations							
	Panic Disorder							
	Peptic Ulcer							
	Swelling							
	Urine Odour Abnormal							

Date:07/13/04ISR Number: 4396490-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00021
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hepatic Neoplasm		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Chondroitin	C		ORAL		
			Fenofibrate	C		ORAL		

Hydrochlorothiazide And Lisinopril	C		ORAL
Raloxifene Hydrochloride	C		ORAL

Date:07/13/04ISR Number: 4396491-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00650
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Maxzide	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

Date:07/13/04ISR Number: 4396492-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Tylenol	C			UNKNOWN	
	Blood Pressure Increased		Zyrtec	C			UNKNOWN	
	Chest Pain		Zyrtec	C			UNKNOWN	
	Diabetes Mellitus							
	Dyspepsia							
	Emotional Distress							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Liver Disorder							
	Nausea							
	Pancreatitis							

Date:07/13/04ISR Number: 4396501-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00126
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/04ISR Number: 4396503-9Report Type:Expedited (15-DaCompany Report #AE-MERCK-0407USA00674
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/04ISR Number: 4396505-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00707
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	228	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/04ISR Number: 4397958-6Report Type:Expedited (15-DaCompany Report #2010247
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemoglobin Decreased	Study					MG/DAILY/PO	
	Sepsis	Health	Aspirin	C				
	Tachycardia	Professional						

Date:07/13/04ISR Number: 4397959-8Report Type:Expedited (15-DaCompany Report #WAES 0405USA00128
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Cholelithiasis	Health					MG/DAILY/PO	
Other	Chromaturia	Professional	Tab Tracleer 62.5 Mg	SS		ORAL	SEE IMAGE PO	
	Diarrhoea		Cardizem	C				
	Gastric Ulcer		Coumadin	C				
	Jaundice		Diovan	C				
	Liver Function Test		Fosamax	C				
	Abnormal		Lasix (Furosemide)	C				
	Nasopharyngitis		Lopressor	C				
	Pharyngolaryngeal Pain		Norvasc	C				
	Pruritus		Premarin	C				
	Pyrexia		Reglan	C				
			Synthroid	C				
			Zantac	C				
			Aspirin	C				
			Digoxin	C				
			Nitroglycerin	C				
			Prednisone	C				
			..	C				
			..	C				
			..	C				
			..	C				

Date:07/13/04ISR Number: 4397962-8Report Type:Expedited (15-DaCompany Report #WAES 00021230
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alopecia	Consumer	Tab Vioxx	PS		ORAL	PO	
			Prempro	C				
			Relafen	C				
			Synthroid	C				

Date:07/13/04ISR Number: 4398112-4Report Type:Expedited (15-DaCompany Report #2004CG01324
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coagulation Factor Viii	Foreign	Zestoretic	PS		ORAL	1 DF QD PO	5 WK
Initial or Prolonged	Level Decreased	Health	Tanakan	SS		ORAL	2 DF QD PO	5 WK
	Coagulation Time	Professional	Zocor	SS		ORAL	10 MG QD PO	
	Prolonged	Other	Vioxx	SS		ORAL	25 MG QD PO	
	Haematoma							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/04ISR Number: 4397246-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea							
	Headache							
	Injury							
	Myocardial Infarction							

Date:07/14/04ISR Number: 4397264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bacterial Infection		Lipitor	C				
UNKNOWN								
Other	Bipolar I Disorder		Lipitor	C				
UNKNOWN								
	Chest Pain		Avapro	C				
UNKNOWN								
	Flank Pain		Geodon	C				
UNKNOWN								
	Incisional Hernia		Levoxyl	C				
UNKNOWN								
	Nephrolithiasis		Prilosec	C				
UNKNOWN								
	Renal Failure		Paxil	C				
UNKNOWN								
	Schizoaffective Disorder							
	Sepsis							
	Urinary Retention							
	Urinary Tract Infection							
	Urosepsis							

Date:07/14/04ISR Number: 4397274-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY						
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
261 DAY						
	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL
	Contusion		Tylenol	C		
UNKNOWN						
	Dyspepsia		Combivent	C		
RESPIRATORY						
	Emotional Distress					
(INHALATION)						
	Gastric Ulcer		Allopurinol	C		
UNKNOWN						
	Gastritis		Celebrex	C		
UNKNOWN						
	Gastrointestinal		Estradiol	C		
UNKNOWN						
	Haemorrhage		Vitamin E	C		
UNKNOWN						
	Meniscus Lesion		Diovan	C		
UNKNOWN						
	Patella Fracture		Ultram	C		
UNKNOWN						
	Patellofemoral Pain		Bactrim Ds Tablets	C		
UNKNOWN						
	Syndrome		Glucosamine	C		
UNKNOWN						
	Pyrexia		Avalide	C		
UNKNOWN						
	Therapeutic Response		Atrovent	C		
UNKNOWN						
	Decreased		Claritin	C		
UNKNOWN						
	Wound Infection		Niferex	C		
UNKNOWN						
			Potassium (Unspecified)	C		
UNKNOWN						
			Pyridoxine	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/04ISR Number: 4397276-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		44 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder With Mixed Anxiety And		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		44 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
	Back Pain		Vicodin Tablets	C				UNKNOWN
	Blood Pressure Increased		Hydrocodone Bitartrate	C				UNKNOWN
	Blood Triglycerides Increased		Relafen	C				UNKNOWN
	Bone Pain							
	Breast Pain							
	Chest Pain							
	Chondromalacia							
	Contusion							
	Coronary Artery Atherosclerosis							
	Dizziness							
	Drug Hypersensitivity							
	Dyspepsia							
	Extrasystoles							
	Fatigue							
	Injury							
	Joint Sprain							
	Keratoacanthoma							
	Kyphosis							
	Musculoskeletal Stiffness							
	Pericarditis							
	Pneumonia							
	Skin Lesion							
	Tension Headache							
	Upper Respiratory Tract Infection							
	Wound							

Date:07/14/04ISR Number: 4397281-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00105
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	Jaundice Cholestatic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
	Pancreatic Carcinoma		Acetaminophen	C		ORAL		
			Acetaminophen	C		ORAL		
			Aspirin	C		ORAL		
			Spironolactone	C		ORAL		
			Gliclazide	C		ORAL		
			Nicorandil	C		ORAL		
			Omeprazole	C		ORAL		

Date:07/14/04ISR Number: 4397283-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02378
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anorexia
	Anxiety

	Blood Cholesterol Increased						
	Bradycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	
	Cystitis		[Therapy				
	Dyspepsia		Unspecified]	C			UNKNOWN
	Dyspnoea		Valium	C			UNKNOWN
	Emotional Distress		Nexium	C			UNKNOWN
	Erosive Oesophagitis		Paxil	C			UNKNOWN
	Faeces Discoloured						
	Gastritis						
	Gastrointestinal Ulcer						
	Gastrooesophageal Reflux Disease						
	Haematochezia						
	Haemorrhoids						
	Heart Rate Irregular						
	Hypertension						
	Nasopharyngitis						
	Nausea						
	Oedema Peripheral						
	Otitis Media						
	Pain						
	Peptic Ulcer						
	Urinary Tract Infection						
	Vomiting						
	Weight Decreased						
	Weight Increased						

Date:07/14/04ISR Number: 4397286-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0309GBR00024
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Coronary Artery Atherosclerosis		Estradiol Valerate And Norethindrone	C		ORAL	

Coronary Artery Disease Omeprazole C ORAL
1 DAY
Pulmonary Congestion
Sudden Death

Date:07/14/04ISR Number: 4397287-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
Disability	Anaemia
Other	Anxiety
	Atelectasis
	Blood Cholesterol Increased
	Bundle Branch Block Right
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Confusional State
	Conversion Disorder
	Convulsion

		Coronary Artery Disease Coronary Artery Occlusion Coronary Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetes Mellitus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Inadequate Control		Aspirin	C		
UNKNOWN							
		Diabetic Ketoacidosis		Lasix (Furosemide)	C		
UNKNOWN							
		Emotional Distress		Glucotrol Xl	C		
UNKNOWN							
		Fall		Glyburide	C		
UNKNOWN							
		Gait Disturbance		Ativan	C		
UNKNOWN							
		Hypertension		Lopressor	C		
UNKNOWN							
		Hypokalaemia		Orphenadrine	C		
UNKNOWN							
		Influenza Like Illness Intervertebral Disc Degeneration Loss Of Consciousness Mitral Valve Incompetence Myocardial Infarction Myocardial Ischaemia Nasopharyngitis Oedema Peripheral Palpitations Post Procedural Complication Pulmonary Congestion Rotator Cuff Syndrome Scar Sinus Tachycardia Stress Supraventricular Tachycardia Syncope Tachyarrhythmia Transient Ischaemic Attack Treatment Noncompliance Tremor Urinary Incontinence Urinary Tract Infection					

Vision Blurred

Date:07/14/04ISR Number: 4397897-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Band Neutrophil Percentage Increased
Other	Cerebral Atrophy
	Cerebral Ischaemia
	Cerebrovascular Accident
	Confabulation
	Decreased Appetite
	Eczema
	Gastrointestinal Disorder
	Hypertension
	Injury
	Kyphosis
	Lung Adenocarcinoma
	Monocyte Percentage Increased

		Nocturia					
		Non-Small Cell Lung Cancer Metastatic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis Allergic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Sciatica	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic Attack		Vitamins (Unspecified)	C		
UNKNOWN							

Date:07/14/04ISR Number: 4397899-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
Other	Adenomyosis
	Amnesia
	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Atrioventricular Block
	Back Pain
	Bronchitis
	Cardiac Valve Disease
	Cardiomyopathy
	Cellulitis
	Chest Pain
	Complex Regional Pain Syndrome
	Constipation
	Convulsion
	Costochondritis
	Dental Caries
	Diverticulitis
	Duodenal Ulcer
	Duodenitis
	Dyspnoea Exertional
	Encephalopathy
	Fatigue
	Gastritis
	Grand Mal Convulsion
	Haematoma Infection
	Haemorrhoids
	Helicobacter Gastritis

Hypertension
Hypertensive Crisis
Hypokalaemia
Irritable Bowel Syndrome
Joint Contracture
Laceration
Malignant Hypertension
Memory Impairment
Micturition Urgency
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema Peripheral
Oesophagitis
Orthopnoea
Osteoarthritis
Pain In Extremity

		Palpitations					
		Renal Failure					
		Salpingitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sensory Loss	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Supraventricular	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Tachycardia		Cardura	C		
UNKNOWN							
		Upper Respiratory Tract		Normodyne	C		
UNKNOWN							
		Infection		Prevacid	C		
UNKNOWN							
		Vaginal Discharge		Flagyl	C		
UNKNOWN							
		Vulvovaginal Discomfort		Minoxidil	C		
UNKNOWN							
				Procardia Xl	C		
UNKNOWN							

Date:07/14/04ISR Number: 4397907-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Acne	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY							
		Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY							
		Chest Pain		[Therapy			
		Diabetes Mellitus		Unspecified]	C		
UNKNOWN		144 DAY					
		Dysuria		Tylenol	C		
UNKNOWN							
		Gastritis		Darvocet-N	C		
UNKNOWN							
		Gastrooesophageal Reflux		Soma	C		
UNKNOWN							
		Disease					
		Hemiparesis					
		Hypoaesthesia					
		Joint Dislocation					
		Joint Sprain					
		Lipoma					
		Spinal Osteoarthritis					

Date:07/14/04ISR Number: 4397908-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01861
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		428 DAY
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Fall		Lopid	C				UNKNOWN
	Gastric Outlet		Diovan	C				UNKNOWN
	Obstruction		Skelaxin	C				UNKNOWN
	Gastric Ulcer Haemorrhage		Aciphex	C				UNKNOWN

Date:07/14/04ISR Number: 4397909-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00218
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Initial or Prolonged	Haemorrhage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		29 DAY
	Duodenal Ulcer Perforation							

Date:07/14/04ISR Number: 4397910-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	73	DAY
Cholelithiasis	Professional	Roxicet	C			UNKNOWN	799 DAY
Coronary Artery Disease		Proscar	C			UNKNOWN	
Coronary Artery Occlusion		Zantac	C			UNKNOWN	
Hernia							
Hypertension							
Myocardial Infarction							
Panic Disorder							
Syncope							

Date:07/14/04ISR Number: 4397911-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00069
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		[Therapy Unspecified]	C			UNKNOWN	
	Cerebrovascular Accident		Tylenol Extra Strength	C			UNKNOWN	
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Gastric Disorder							
	Haematochezia							
	Headache							
	Hypertension							
	Nausea							

Date:07/14/04ISR Number: 4397912-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Atrial Fibrillation		Zocor	SS		ORAL
	Blood Cholesterol		Percocet	C		
UNKNOWN						
Other	Increased		Atenolol	C		
UNKNOWN						
	Bradycardia		Folic Acid	C		
UNKNOWN						
	Coronary Artery Disease		Motrin	C		
UNKNOWN						
	Coronary Artery Reocclusion		Vitamins (Unspecified)	C		
UNKNOWN						
	Deep Vein Thrombosis		Ambien	C		
UNKNOWN						
	Diverticulitis Intestinal		Temazepam	C		
UNKNOWN						
	Haemorrhagic		Ismo	C		
UNKNOWN						
	Diverticulum		Methotrexate	C		
UNKNOWN						
	Haemorrhoids		Oxycodone Hydrochloride	C		
	Hyperlipidaemia					
UNKNOWN						
	Hypertension		Prednisone	C		ORAL
	Intervertebral Disc Degeneration					
	Myocardial Infarction					
	Polyp					
	Renal Failure Chronic					
	Respiratory Distress					
	Sigmoiditis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/04ISR Number: 4397913-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00842
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Flonase	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	

Date:07/14/04ISR Number: 4397914-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0407AUS00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/04ISR Number: 4397915-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0407NOR00041
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	
	Asthenia		Acetaminophen And Codeine	C			UNKNOWN	
	Diarrhoea							
	Syncope							

Date:07/14/04ISR Number: 4397916-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
	Cartilage Injury
Other	Chest Pain
	Chills
	Chronic Obstructive

Pulmonary Disease
Cough
Deep Vein Thrombosis
Dyspnoea
Gastric Disorder
Gout
Headache
Hyperhidrosis
Intestinal Haemorrhage
Intestinal Obstruction
Local Swelling
Myositis
Nasal Congestion
Neck Pain
Oedema
Osteoarthritis
Pain
Pulmonary Embolism
Rectal Haemorrhage
Restrictive Pulmonary
Disease
Rheumatoid Arthritis
Rhinorrhoea
Sleep Apnoea Syndrome
Swelling

		Systemic Lupus Erythematosus Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Albuterol	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Advair	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Diazide	C		
UNKNOWN							
				Lithium Sulfate	C		
UNKNOWN							
				Sandostatin	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Prochlorperazine	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:07/14/04ISR Number: 4397917-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Discomfort	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Abdominal Pain Upper		[Therapy			
		Alopecia		Unspecified]	C		
UNKNOWN							
		Arrhythmia		Insulin	C		
UNKNOWN							

Blood Pressure Increased
Chest Pain
Chronic Fatigue Syndrome
Drug Hypersensitivity
Dyspnoea
Emotional Distress
Gallbladder Disorder
Glaucoma
Gout
Hernia
Large Intestinal Ulcer
Haemorrhage
Oedema
Oesophageal Ulcer
Haemorrhage
Osteoarthritis
Rheumatoid Arthritis
Weight Decreased

Date:07/14/04ISR Number: 4397918-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Blood Disorder
	Bronchitis
	Disability
	Emotional Distress
	Fall
	Gait Spastic
	Obstruction
	Peripheral Circulatory

Failure
Road Traffic Accident

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Tylenol	C				

UNKNOWN

Date:07/14/04ISR Number: 4397919-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00115
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum Intestinal							
	Duodenal Ulcer							
	Gastric Ulcer							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Haemorrhoids							
	Headache							
	Helicobacter Pylori							
	Identification Test							
	Positive							
	Perforated Ulcer							
	Pseudodiverticular							
	Disease							
	Sleep Disorder							
	Stress							

Date:07/14/04ISR Number: 4397920-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0402GBR00203
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Nitroglycerin	C				
Initial or Prolonged Disability								

Date:07/14/04ISR Number: 4397921-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00993
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Asthenia
	Cardiac Failure Congestive
	Colonic Polyp
	Conjunctival Haemorrhage
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Dermatitis Contact
	Diverticulum Intestinal
	Ecchymosis
	Erectile Dysfunction

	Fatigue Haemorrhoids Impaired Work Ability	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	697 DAY
	Lung Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL	697 DAY
	Pelvic Pain Ventricular Dysfunction		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN
			Wellbutrin	C			UNKNOWN
			Viagra	C			UNKNOWN
			Avandia	C			UNKNOWN
			Duratuss	C			UNKNOWN
			Blephamide Ointment	C			UNKNOWN

Date:07/14/04ISR Number: 4397922-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00083
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY
Initial or Prolonged	Renal Failure Chronic		Albuterol	C			RESPIRATORY (INHALATION)
			Amiodarone	C		ORAL	
			Bendroflumethiazide	C		ORAL	
			Fluticasone Propionate And Salmeterol Xinafoate	C			RESPIRATORY (INHALATION)
			Furosemide	C		ORAL	
			Gliclazide	C		ORAL	
			Spironolactone	C		ORAL	

	Warfarin	C	ORAL
	Gliclazide	C	ORAL
	Ipratropium Bromide	C	
RESPIRATORY			
(INHALATION)			
	Isosorbide Mononitrate	C	ORAL
	Levothyroxine Sodium	C	ORAL
	Cozaar	C	ORAL
	Omeprazole	C	ORAL

Date:07/14/04ISR Number: 4397923-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00157
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Post Procedural Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Oxycodone Hydrochloride	C		
UNKNOWN 1 DAY						
			Propofol	C		
UNKNOWN 1 DAY						
			Remifentanil Hydrochloride	C		
UNKNOWN 1 DAY						

Date:07/14/04ISR Number: 4398205-1Report Type:Direct Company Report #CTU 222831
Age:56 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Chest Pain
	Flank Pain

	Flatulence Haematemesis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Aspirin	PS		ORAL	81 MG PO DAILY
			Vioxx	SS			50 MG QD PRN
			Percocet	C			
			Catapres	C			
			Erythropoetin	C			
			Hectorol	C			
			Phoslo	C			
			70/30 Insulin	C			
			Dialyvite	C			
			Minoxidil	C			
			Metoprolol	C			
			Quinine	C			

Date:07/15/04ISR Number: 4398400-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Asthma	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	22 DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
	Chronic Obstructive		Aspirin	C			UNKNOWN
	Pulmonary Disease		Aspirin	C			UNKNOWN
	Deep Vein Thrombosis		Detrol	C		ORAL	
	Drug Hypersensitivity		Lotensin	C		ORAL	
	Emotional Distress		Zyrtec	C		ORAL	
	Epistaxis		Flonase	C			RESPIRATORY
	Gastrooesophageal Reflux						(INHALATION)
	Disease		Hydro-Chlor	C			UNKNOWN

	Heart Rate Irregular	Prednisone	C	ORAL
	Lung Disorder			
	Oedema Peripheral			
	Oropharyngeal Swelling			
	Swelling Face			
	Swollen Tongue			

Date:07/15/04ISR Number: 4398401-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
Other	Anxiety
	Aortic Valve Incompetence
	Atrial Fibrillation
	Blood Pressure Inadequately Controlled
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chest Pain
	Chondrocalcinosis Pyrophosphate
	Colon Cancer Recurrent

		Colonic Polyp					
		Coronary Artery Disease					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional	Premarin	C		
UNKNOWN							
		Dysphagia		Glipizide	C		
UNKNOWN							
		Emotional Distress					
		Gastritis					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hypoaesthesia Oral					
		Inner Ear Disorder					
		Mitral Valve Incompetence					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Renal Cyst					
		Renal Failure					
		Syncope					
		Thrombophlebitis					
		Tooth Infection					
		Tricuspid Valve					
		Incompetence					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vein Pain					
		Vertigo					

Date:07/15/04ISR Number: 4398403-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Disability	Amnesia
Other	Aura
	Blood Cholesterol
	Increased
	Chest Discomfort
	Convulsion
	Cough

Drug Level Decreased
Dyspepsia
Dyspnoea
Emotional Distress
Encephalomalacia
Excoriation
Fall
Feeling Abnormal
Grand Mal Convulsion
Head Injury
Headache
Heart Rate Increased
Hyperventilation
Hypoglycaemia
Intervertebral Disc
Displacement
Lumbar Vertebral Fracture
Metabolic Disorder

	Nasal Septum Deviation Nasal Turbinate Hypertrophy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Nose Deformity	Health	Vioxx	PS	Merck & Co., Inc	ORAL	138 DAY
	Otitis Media	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	138 DAY
	Palpitations		Dilantin	C			UNKNOWN
	Road Traffic Accident		Zoloft	C			UNKNOWN
	Somnolence Tremor						

Date:07/15/04ISR Number: 4398404-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03198
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 8 DAY	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Upper Gastrointestinal Haemorrhage	Professional	Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	SS			UNKNOWN
			Ibuprofen	SS			UNKNOWN
			Allopurinol	C			UNKNOWN
			Accupril	C			UNKNOWN
			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN

Date:07/15/04ISR Number: 4398405-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01112
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization -	Anaemia

Initial or Prolonged Disability	Anxiety Arteriosclerosis Atrial Fibrillation Bronchitis Acute Carotid Artery Stenosis Cerebrovascular Accident Chest Pain Constipation Convulsion Diarrhoea Dysphagia Emotional Distress Fall Gastritis Helicobacter Pylori Identification Test Positive Hypertension Hypomagnesaemia Meningioma Mental Disorder Due To A General Medical Condition Neurodermatitis Osteoporosis Paraesthesia Peripheral Vascular Disorder Tachycardia

		Transient Ischaemic Attack					
		Upper Limb Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Decreased	Professional	Synthroid	C		
UNKNOWN							

Date:07/15/04ISR Number: 4398406-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0407CHE00017
Age:72 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Hepatocellular Damage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Jaundice	Professional	Dipyrone	SS		ORAL
Other				Trazodone Hydrochloride	SS		ORAL
43	DAY						
				Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL
21	DAY						
				Bisacodyl	C		ORAL
				Folic Acid	C		ORAL
21	DAY						
				Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL

Date:07/15/04ISR Number: 4398978-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Alcohol Poisoning
Initial or Prolonged	Alcohol Withdrawal
Disability	Syndrome
Other	Alcoholic Liver Disease
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Chest Pain
	Chronic Fatigue Syndrome

Chronic Obstructive
Pulmonary Disease
Colonic Polyp
Deep Vein Thrombosis
Dermatitis
Diverticulum
Fall
Gastritis
Gastrointestinal
Haemorrhage
Gout
Haemorrhoids
Hepatic Encephalopathy
Hypernatraemia
Hypertension
Myocardial Infarction
Oesophagitis
Palpitations
Peritonitis Bacterial
Pneumonia Aspiration
Renal Failure Acute
Respiratory Failure

	Syncope Varices Oesophageal						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/15/04ISR Number: 4398987-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 7 DAY	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged 7 DAY	Antiphospholipid Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability UNKNOWN	Back Disorder		Allegra	C			
Other	Blood Cholesterol Increased Cerebrovascular Accident Cholecystitis Chronic Fatigue Syndrome Colonic Polyp Contusion Diverticulum Dyspepsia Emotional Distress Gastroenteritis Viral Haemorrhoids Hypoaesthesia Impaired Work Ability Injury Menorrhagia Migraine Nervousness Ovarian Cyst Radiculopathy Transient Ischaemic Attack Urinary Tract Infection						

Date:07/15/04ISR Number: 4398988-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Back Disorder
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Blood Triglycerides Increased
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Clostridium Colitis
	Convulsion
	Depression
	Dizziness
	Emotional Distress
	Fibrosis

Dose	Duration	Reaction	Report Source	Product	Role	Manufacturer	Route
		Fluid Retention					
		Gastrooesophageal Reflux Disease					
		Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
560	DAY						
		Headache		Alprazolam	C		
UNKNOWN							
		Hyperlipidaemia		Amitriptyline Hydrochloride	C		
		Hypoxia					
UNKNOWN							
		Ileus		Amitriptyline Hydrochloride	C		
		Injury					
UNKNOWN							
		Lumbar Radiculopathy		Celexa	C		
UNKNOWN							
		Myocardial Infarction		Lexapro	C		
UNKNOWN							
		Nephrolithiasis		Nexium	C		
UNKNOWN							
		Oedema		Lasix (Furosemide)	C		
UNKNOWN							
		Pneumonia		Zanaflex	C		
UNKNOWN							
		Pneumonia Aspiration		Ambien	C		
UNKNOWN							
		Pneumonia Pneumococcal		Diovan	C		
UNKNOWN							
		Rash		Ultram	C		
UNKNOWN							
		Renal Failure Acute		Torsemide	C		
UNKNOWN							
		Rhabdomyolysis		Lasix (Furosemide)	C		
UNKNOWN							
		Rhinitis		Neurontin	C		
UNKNOWN							
		Sinusitis		Zaroxolyn	C		
UNKNOWN							
		Spinal Compression		Aleve	C		
UNKNOWN							
		Fracture		Nortriptyline	C		
UNKNOWN							
		Staphylococcal Infection		Oxycontin	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:07/15/04ISR Number: 4398998-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		[Therapy					
	Cardiac Disorder		Unspecified]	C			UNKNOWN	
	Cardiac Flutter		Remicade	C			UNKNOWN	
	Condition Aggravated		Injectable Gold					
	Emotional Distress		(Unspecified)	C			UNKNOWN	
	Fear		Methotrexate	C			UNKNOWN	
	Gastric Disorder							
	Headache							
	Nausea							
	Swelling							
	Uterine Disorder							

Date:07/15/04ISR Number: 4398999-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02008
Age:88 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Arthralgia
	Asthma
	Blood Cholesterol Increased
	Bronchitis
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion

		Dermatitis Contact					
		Diabetes Mellitus					
		Drug Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Eye Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vicodin Tablets	C		
UNKNOWN							
		Gastroenteritis Viral		Vitamins			
		Injury		(Unspecified)	C		
UNKNOWN							
		Nausea		Aspirin	C		
UNKNOWN							
		Prostatic Specific		Lipitor	C		
UNKNOWN							
		Antigen Abnormal					
		Prostatic Specific					
		Antigen Increased					
		Self-Medication					
		Ventricular Tachycardia					

Date:07/15/04ISR Number: 4399002-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00068
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Breast Disorder					
		Cardiac Disorder					
		Chest Pain					
		Emotional Distress					
		Gastric Disorder					
		Heart Rate Increased					
		Heart Rate Irregular					
		Hypertension					
		Nervousness					
		Peptic Ulcer					
		Stress					

Date:07/15/04ISR Number: 4399003-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		[Therapy					
	Gastric Disorder		Unspecified]	C				
UNKNOWN								
	Hypertension							
	Oedema Peripheral							
	Sleep Apnoea Syndrome							

Date:07/15/04ISR Number: 4399007-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia
Other	Arthropathy
	Breast Cyst
	Bursitis
	Chest Discomfort
	Closed Head Injury
	Complex Regional Pain Syndrome

		Concussion					
		Contusion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Extrasystoles		Vioxx	SS		ORAL
33	DAY						
		Fall		Vioxx	SS		ORAL
33	DAY						
		Fatigue		Bayer Aspirin	C		ORAL
		Gingival Disorder		Bayer Aspirin	C		ORAL
		Haematochezia		Vitamins			
		Haemorrhage		(Unspecified)	C		
UNKNOWN							
		Headache					
		Heart Rate Irregular					
		Hypercholesterolaemia					
		Hypertension					
		Lumbar Spinal Stenosis					
		Nausea					
		Nerve Injury					
		Palpitations					
		Post-Traumatic Stress					
		Disorder					
		Sleep Disorder					
		Syncope					
		Tachycardia					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Vasodilatation					
		Vomiting					

Date:07/15/04ISR Number: 4399012-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02509
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY					
Initial or Prolonged	Acute Myocardial		Methotrexate	C		
UNKNOWN						

	Infarction	Berplex Plus	C
UNKNOWN			
	Angina Pectoris	Prednisone	C
UNKNOWN			
	Asthenia		
	Back Pain		
	Blood Triglycerides		
	Increased		
	Calculus Ureteric		
	Coronary Artery		
	Atherosclerosis		
	Coronary Artery Stenosis		
	Feeling Abnormal		
	Haematocrit Decreased		
	Hypercholesterolaemia		
	Hyperhidrosis		
	Hypotension		
	Intestinal Mass		
	Oesophagitis		
	Oral Pain		
	Orthopnoea		
	Pericarditis		
	Ventricular Fibrillation		
	Ventricular Tachycardia		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/04ISR Number: 4399013-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other UNKNOWN	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Benign Prostatic Hyperplasia		Zocor	SS		ORAL		
	Bladder Obstruction		[Therapy Unspecified]	C				
	Cardiac Failure Congestive		Tylenol Arthritis Extended Relief	C				
	Cellulitis		Aspirin	C				
	Chronic Obstructive Pulmonary Disease		Diltiazem Msd	C				
			Glyburide	C				
	Constipation Coronary Artery Disease		Hydrocodone Bitartrate	C				
	Cough		Glucophage	C				
	Duodenal Ulcer		Accupril	C				
	Emotional Distress Gastric Ulcer Gastrooesophageal Reflux Disease Interstitial Lung Disease Leukocytosis Meniscus Lesion Monarthritis Myocardial Infarction Pain In Extremity Renal Failure Renal Tubular Necrosis Rhabdomyolysis Rotator Cuff Syndrome							

Date:07/15/04ISR Number: 4399018-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00097
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	247	DAY
	Increased Blood Sodium Decreased Liver Function Test Abnormal		Amitriptyline Hydrochloride	C		ORAL		

Date:07/15/04ISR Number: 4399019-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Aspartate Aminotransferase Increased
Other	Blood Pressure Inadequately Controlled Carotid Artery Occlusion Cerebral Infarction Comminuted Fracture Depression Diabetes Mellitus Non-Insulin-Dependent Diastolic Dysfunction

		Dysphoria					
		Eye Injury					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Lipitor	C		
UNKNOWN							
		Pain In Extremity		Lipitor	C		
UNKNOWN							
		Rib Fracture					
		Road Traffic Accident					
		Syncope					
		Upper Respiratory Tract					
		Infection					
		Weight Increased					

Date:07/15/04ISR Number: 4399024-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00057
Age:70 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY							
				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Tiotropium Bromide	C		
RESPIRATORY							
(INHALATION)							

Date:07/15/04ISR Number: 4406757-8Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-293
Age:55 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinal Haemorrhage	Foreign	Methotrexate			
			Health	(Methotrexate)	PS		
			Professional	Augmentin			

		Distributor Other	(Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS
			Fluoxetine Hydrochloride	SS
			Humira (Adalimumab)	SS
SUBCUTANEOUS	40 G/M^2 1X PER 2 WK, SC			
			Premarin (Conjugated Estrogens, Unspec)	SS
			Rofecoxib	SS
			Clavulin(Amoxicillin Trihydrate/Clavulanate Potassium)	C
			Paramol-118(Dihydrocodeine Bitartrate/Paracetamol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/04ISR Number: 4406803-1Report Type:Expedited (15-DaCompany Report #BE-JNJFOC-20040403935
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Hepatitis Toxic	Foreign Health Professional	Durogesic (Fentanyl) Patch Vioxx (Rofecoxib) Lioresal (Baclofen) Fluanxol (Flupentixol Dihydrochloride) Paracetamol (Paracetamol)	PS SS C C C		TRANSDERMAL	25 MG	TANSDERMAL

Date:07/15/04ISR Number: 4423897-8Report Type:Periodic Company Report #2003143510US
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephrotic Syndrome Oedema	Consumer Health Professional	Celebrex (Celecoxib) Capsule Vioxx (Rofecoxib) Ultram (Tramadol Hydrochloride) Ketorolac (Ketorolac) Vicoprofen (Hydrocodone	PS SS SS SS		ORAL ORAL ORAL ORAL	100 MG, BID, PRN, ORAL SEE IMAGE 50 MG, Q 6 HRS, PRN, ORAL 10 MG, Q 6HRS, PRN, ORAL	

	Bitartrate, Ibuprofen)	SS	ORAL
1 TAB, Q 8 HRS, ORAL			
	Hydrocodone W/Acetamonophen (Paracetamol, Hydrocodone Bitartrate)	SS	ORAL
5/500, Q 6 HRS, PRN, ORAL			
	Acetaminophen W/Codeine (Codeine, Paracetamol)	SS	ORAL
1 TO 2 ATBS Q 6 HRS, PRN, ORAL			
	Motrin (Ibuprofen)	SS	
	Excedrin (Salicylamide)	SS	

Date:07/16/04ISR Number: 4399573-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Blood Cholesterol Increased
Other	Cardiac Failure Congestive

		Constipation					
		Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Exostosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Aspirin	C		
UNKNOWN							
		Disease		Atenolol	C		
UNKNOWN							
		Herpes Zoster		Trental	C		
UNKNOWN							
		Hyperlipidaemia		Potassium			
		Hypertension		(Unspecified)	C		
UNKNOWN							
		Lumbar Radiculopathy		Cyclobenzaprine			
		Lung Neoplasm		Hydrochloride	C		ORAL
		Myocardial Infarction		Ultram	C		
UNKNOWN							
		Pneumonitis		Lasix (Furosemide)	C		
UNKNOWN							
		Renal Artery Stenosis		Novolin	C		
SUBCUTANEOUS							
		Silent Myocardial		Novolin	C		
SUBCUTANEOUS							
		Infarction		Zestril	C		
UNKNOWN							
		Spinal Column Stenosis		Procardia	C		
UNKNOWN							
		Urinary Tract Infection		Ranitidine	C		
UNKNOWN							

Date:07/16/04ISR Number: 4399580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
319 DAY						
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
319 DAY						
Disability	Cyst		Xanax	C		
UNKNOWN						
Other	Diabetes Mellitus		Valium	C		
UNKNOWN						

	Drug Ineffective		Diovan	C		
UNKNOWN						
	Hypertension		Ibuprofen	C		
UNKNOWN						
	Lung Disorder		Humulin N	C		
UNKNOWN						
	Myocardial Infarction		Synthroid	C		
UNKNOWN						
	Non-Cardiac Chest Pain					
	Oedema Peripheral					
	Osteoarthritis					

Date:07/16/04ISR Number: 4399581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL	135	DAY
Hospitalization -	Bipolar Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	135	DAY
Initial or Prolonged	Blood Pressure Increased		Depakote	C				
UNKNOWN								
	Emotional Distress		Zestril	C				
UNKNOWN								
	Haemorrhoids		Lithium Sulfate	C				
UNKNOWN								
	Myocardial Infarction							

Date:07/16/04ISR Number: 4399584-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01389
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depressed Level Of	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Consciousness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Percocet	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/04ISR Number: 4399587-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00056
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		76 DAY
Initial or Prolonged	Varicose Vein	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		76 DAY
			Digitoxin	C				UNKNOWN
			Furosemide	C		ORAL		
			Furosemide	C		ORAL		
			Ibuprofen	C		ORAL		
			Ibuprofen	C		ORAL		
			Tramadol Hydrochloride	C				UNKNOWN
			Insulin Lispro, Biphasic Isophane [Injection]	C				UNKNOWN
			Methotrexate	C		ORAL		
			Metoprolol	C				UNKNOWN
			Nitrendipine	C				UNKNOWN
			Quinapril Hydrochloride	C				UNKNOWN

Date:07/16/04ISR Number: 4399588-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Alopecia	Professional						
Other	Anxiety Disorder							
	Arthritis							
	Arthropathy							
	Cardiac Murmur							
	Chest Pain							
	Contusion							
	Dyspnoea							

Emotional Distress
Fatigue
Gastric Disorder
Haemorrhage
Keloid Scar
Nausea
Neoplasm Malignant
Palpitations
Panic Disorder
Peptic Ulcer
Skin Lesion
Swelling
Urine Odour Abnormal
Vomiting

Date:07/16/04ISR Number: 4399590-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00120
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		1423 DAY
Life-Threatening	Perforation		Acetaminophen And Propoxyphene Hydrochloride	C				
Hospitalization - Initial or Prolonged								UNKNOWN
Disability			Aspirin	C				
								UNKNOWN
Other			Bendroflumethiazide	C				
								UNKNOWN

	Betamethasone	C
TOPICAL		
	Warfarin	C
UNKNOWN		
	Simvastatin	C
UNKNOWN		
	Digoxin	C
UNKNOWN		
	Doxazosin Mesylate	C
UNKNOWN		
	Perindopril	C
UNKNOWN		

Date:07/16/04ISR Number: 4399593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
Disability	Back Disorder							
Other	Back Pain							
	Burning Sensation							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Chronic Obstructive							
	Pulmonary Disease							
	Convulsion							
	Coronary Artery Disease							
	Cough							
	Dizziness							
	Dyspnoea							
	Erectile Dysfunction							
	Fatigue							
	Headache							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Lung Neoplasm							
	Lymphadenopathy							
	Mediastinal							

Major Depression
Muscle Spasms
Myocardial Infarction
Nausea
Osteoarthritis
Paraesthesia
Peripheral Coldness
Postnasal Drip
Sleep Disorder
Syncope
Tooth Loss
Ulnar Nerve Palsy

Date:07/16/04ISR Number: 4399597-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome PT
Other Adrenal Adenoma
Arthritis
Blood Cholesterol
Increased
Cataract
Chronic Fatigue Syndrome

		Constipation					
		Cystitis					
		Cystitis Glandularis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea	Professional	Tylenol	C		ORAL
		Emotional Distress		Pravachol	C		
UNKNOWN							
		Gastrointestinal Ulcer					
		Haematuria					
		Nausea					
		Osteoporosis					
		Parotid Gland Enlargement					
		Stress Incontinence					
		Thyroid Neoplasm					
		Urethral Caruncle					
		Urinary Tract Infection					

Date:07/16/04ISR Number: 4399599-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adjustment Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
		Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vicodin Tablets	C		
UNKNOWN							
		Blood Urine Present		Effexor Xr	C		
UNKNOWN							
		Cataract		Ecotrin	C		
UNKNOWN							
		Chest Wall Pain		Wellbutrin Sr	C		
UNKNOWN							
		Depression		Prevacid	C		
UNKNOWN							
		Dizziness		Pravachol	C		
UNKNOWN							
		Eye Disorder		Accupril	C		
UNKNOWN							
		Faecal Incontinence					
		Flank Pain					

Gastric Disorder
Gastric Haemorrhage
Groin Pain
Haemorrhoids
Herpes Virus Infection
Influenza
Intervertebral Disc
Degeneration
Joint Stiffness
Meniere'S Disease
Muscle Strain
Pain In Extremity
Road Traffic Accident
Rotator Cuff Syndrome
Spinal Column Stenosis
Tendonitis
Ulcer
Viral Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/16/04ISR Number: 4399602-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Jaw	Health	Vioxx	PS	Merck & Co., Inc	ORAL		846 DAY
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		846 DAY
Disability	Anxiety		[Therapy Unspecified]	C				UNKNOWN
	Blood Cholesterol Increased		Vicodin Tablets	C				UNKNOWN
	Blood Creatine Phosphokinase Increased		Xanax	C				UNKNOWN
	Cardiac Disorder		Covera	C				UNKNOWN
	Cardiac Murmur		Trimox	C				UNKNOWN
	Carotid Artery Stenosis		Atenolol	C				UNKNOWN
	Coronary Artery Disease		Soma	C				UNKNOWN
	Dental Caries		Relafen	C				UNKNOWN
	Depression							
	Diarrhoea							
	Dizziness							
	Drug Hypersensitivity							
	Duodenal Ulcer Haemorrhage							
	Duodenitis							
	Food Poisoning							
	Gastroenteritis							
	Gout							
	Hypertension							
	Loss Of Consciousness							
	Medication Error							
	Myocardial Infarction							
	Oesophageal Disorder							
	Osteoarthritis							
	Otitis Media							
	Overdose							
	Paraesthesia							
	Peptic Ulcer Haemorrhage							

Sinus Tachycardia
Somnolence
Tooth Infection
Toxicologic Test Abnormal

Date:07/16/04ISR Number: 4400031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
Disability	Arthralgia
Other	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Carotid Artery Disease
	Carotid Artery Stenosis
	Chest Discomfort
	Chest Pain
	Coagulopathy
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Dyspnoea
	Ejection Fraction Decreased
	Emotional Distress

		Exostosis					
		Gout					
		Impaired Work Ability	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
9	MON						
		International Normalised		Vioxx	SS	Merck & Co., Inc	ORAL
9	MON						
		Ratio Decreased		Tylenol	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Aspirin	C		
UNKNOWN							
		Mobility Decreased		Aspirin	C		
UNKNOWN							
		Myocardial Infarction		Atenolol	C		
UNKNOWN							
		Neck Pain		Coumadin	C		
UNKNOWN							
		Osteoarthritis		Coumadin	C		
UNKNOWN							
		Pain In Extremity		Indocin			
		Platelet Count Decreased		(Indomethacin)	C		
UNKNOWN							
		Renal Failure Chronic		Isosorbide	C		
UNKNOWN							
		Sinusitis		Isosorbide	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Nitroglycerin	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:07/16/04ISR Number: 4400055-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00435
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Cardiac Failure		Antineoplastic			
Other	Congestive		(Unspecified)	SS		
UNKNOWN						
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Diffuse Large B-Cell		Vioxx	SS	Merck & Co., Inc	ORAL
	Lymphoma Recurrent		Vicodin Tablets	C		
UNKNOWN						

	Disturbance In Attention	Vitamins		
	Ejection Fraction	(Unspecified)	C	
UNKNOWN				
	Decreased	Ambien	C	
UNKNOWN				
	Gastric Disorder	Flexeril	C	ORAL
	Major Depression	Flexeril	C	ORAL
	Seborrhoeic Keratosis	Meclomen	C	
UNKNOWN				
	Sleep Disorder	Prilosec	C	
UNKNOWN				
	Upper Respiratory Tract Infection			

Date:07/16/04ISR Number: 4400056-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Angina Pectoris
	Anxiety
	Aspiration
	Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Arrest
	Chest Pain
	Coronary Artery Disease
	Depression
	Emotional Distress
	Gastritis
	Hypertension
	Lethargy

		Myocardial Infarction Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
297 DAY							
				Aspirin	SS		
UNKNOWN							
				Plavix	SS		
UNKNOWN		1 YR					
				Vioxx	SS	Merck & Co., Inc	ORAL
297 DAY							
				Heparin	SS		
INTRAVENOUS							
				Vicodin Tablets	C		
UNKNOWN		339 DAY					
				Lipitor	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							

Date:07/16/04ISR Number: 4400058-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cardiac Valve Disease Coronary Artery Occlusion		Tylenol Extra Strength	C		
UNKNOWN							
		Dysphagia		Percocet	C		
UNKNOWN							

	Emotional Distress		Aspirin	C
UNKNOWN				
	Fatigue		Soma	C
UNKNOWN				
	Gastrooesophageal Reflux		Cardizem Cd	C
UNKNOWN				
	Disease		Ferrous Sulfate	C
UNKNOWN				
	Haematoma		Lasix (Furosemide)	C
UNKNOWN				
	Hypercholesterolaemia		Lasix (Furosemide)	C
UNKNOWN				
	Hypertension		Lasix (Furosemide)	C
UNKNOWN				
	Irritable Bowel Syndrome		Aleve	C
UNKNOWN				
	Myocardial Infarction		Nitroglycerin	C
UNKNOWN				
	Pain		Paxil	C
UNKNOWN				
			Paxil	C
UNKNOWN	42	DAY		
			Paxil	C
UNKNOWN				
			Paxil	C
UNKNOWN	145	DAY		
			K-Dur	C
UNKNOWN				
			Accupril	C
UNKNOWN	18	DAY		
			Accupril	C
UNKNOWN	38	DAY		
			Accupril	C
UNKNOWN	152	DAY		

Date:07/16/04ISR Number: 4400059-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Aneurysm
Other	Aortic Valve Sclerosis
	Arteriovenous Fistula
	Blood Albumin Increased
	Blood Cholesterol Increased
	Blood Pressure Systolic Increased
	Bundle Branch Block Left

		Chest Discomfort Coronary Artery Disease Dehydration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
93	DAY						
		Haemorrhagic		Tylenol	C		
UNKNOWN							
		Electrocardiogram Poor		Ecotrin	C		
UNKNOWN							
		R-Wave Progression		Viagra	C		
UNKNOWN							
		Emotional Distress		Calan Sr	C		
UNKNOWN							
		Gastritis		Zocor	C		
UNKNOWN							
		Gastritis Atrophic		Celebrex	C		
UNKNOWN							
		Gastrointestinal		Advil	C		
UNKNOWN							
		Haemorrhage Glycosylated Haemoglobin Increased Haematochezia Helicobacter Infection Injury Iron Deficiency Anaemia Mitral Valve Incompetence Myocardial Ischaemia Neck Pain Neuropathy Peripheral Pleural Calcification Rotator Cuff Syndrome Stent Occlusion Ventricular Hypokinesia Weight Increased					

Date:07/16/04ISR Number: 4400063-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Acute Myocardial Infarction
Disability	Anxiety

Arthralgia
Blood Cholesterol
Increased
Blood Pressure Diastolic
Decreased
Blood Triglycerides
Increased
Bundle Branch Block Right
Calcinosis
Chest Discomfort
Cholelithiasis
Coronary Artery Disease
Coronary Artery Occlusion
Dizziness
Dyspnoea
Electrocardiogram St-T
Change
Fatigue
Flank Pain
Haemodynamic Instability
Hernia
Hypertension
Low Density Lipoprotein
Increased

Myocardial Infarction
Myocardial Ischaemia
Non-Cardiac Chest Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	73	DAY
	Roxicet	C			UNKNOWN	799 DAY
	Proscar	C			UNKNOWN	
	Zantac	C			UNKNOWN	

Panic Disorder
Respiratory Rate
Increased
Syncope
Treatment Noncompliance
Ventricular Hypokinesia

Date:07/16/04ISR Number: 4400065-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Strangulated Hernia
	Acute Prerenal Failure
	Anaemia
	Antinuclear Antibody Positive
	Atherosclerosis
	Benign Prostatic Hyperplasia
	Blood Glucose Increased
	Blood Sodium Decreased
	Bundle Branch Block Left
	Bundle Branch Block Right
	Cardiac Failure Congestive
	Cardiac Murmur
	Carotid Bruit
	Carpal Tunnel Syndrome
	Cerumen Impaction
	Change Of Bowel Habit
	Colon Neoplasm
	Colonic Polyp
	Constipation
	Contusion
	Deafness

Deafness Neurosensory
Dehydration
Diarrhoea
Electrocardiogram
Abnormal
Eustachian Tube Disorder
Gastric Ulcer
Gastric Ulcer Haemorrhage
Gastritis
Gastritis Erosive
Gastroenteritis
Gastrointestinal Disorder
Gastrointestinal Mucosal
Disorder
Haematochezia
Haemorrhoids
Hiatus Hernia
Hypoacusis
Ileus
Melaena

		Metaplasia					
		Musculoskeletal Stiffness					
		Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectal Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure		Vicodin Tablets	C		
UNKNOWN							
		Small Intestinal		Zyloprim	C		
UNKNOWN							
		Obstruction		Xanax	C		
UNKNOWN							
		Sudden Hearing Loss		Ecotrin	C		
UNKNOWN							
		Thrombocytopenia		Aspirin	C		
UNKNOWN							
		Upper Gastrointestinal		Lipitor	C		
UNKNOWN							
		Haemorrhage		Ultram	C		
UNKNOWN							
		Urinary Retention		Carisoprodol	C		
UNKNOWN							
		Ventricular Dysfunction		Vasotec	C		
UNKNOWN							
		Ventricular Hypertrophy		Micronase	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Centrum	C		
UNKNOWN							

Date:07/16/04ISR Number: 4400066-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebral Haemangioma		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Convulsion		Celebrex	C		
UNKNOWN							
Other		Emotional Distress					
		Haemarthrosis					
		Headache					
		Joint Effusion					

Ligament Injury
Ligament Sprain

Date:07/16/04ISR Number: 4400067-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03194
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Angina Unstable
	Aortic Dilatation
	Arthritis
	Asthenia
	Atelectasis
	Atrial Fibrillation
	Atrioventricular Block
	First Degree
	Back Pain
	Blood Cholesterol
	Increased
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Decreased Appetite
	Depression
	Dilatation Atrial

Drug Ineffective
Fall
Hyperlipidaemia
Hypertension
Inguinal Hernia
Intracardiac Thrombus
Mitral Valve Incompetence
Musculoskeletal
Discomfort
Myocardial Infarction
Pleural Effusion
Pulmonary Fibrosis
Pulmonary Hypertension
Stress
Supraventricular
Extrasystoles
Thrombosis
Tricuspid Valve
Incompetence
Urinary Retention
Ventricular Hypertrophy

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/16/04ISR Number: 4400068-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability

PT
Anaemia
Anxiety
Basal Cell Carcinoma
Benign Vascular Neoplasm
Burning Sensation
Cerebrovascular Accident
Conversion Disorder
Dizziness
Emotional Distress
Ganglion
Generalised Anxiety Disorder
Haemorrhoids
Hallucination
Hemiparesis
Hiatus Hernia
Hypertension
Hypoaesthesia

Hypokalaemia
Hyporeflexia
Lacunar Infarction
Liver Function Test
Abnormal
Loss Of Consciousness
Movement Disorder
Oesophageal Spasm
Orthostatic Hypotension
Pain In Extremity
Palpitations
Post Procedural
Complication
Psychosomatic Disease
Stress
Suicidal Ideation

	Syncope Tinnitus						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Ventolin (Albuterol)	C			RESPIRATORY	
							(INHALATION)	
			Aspirin	C			UNKNOWN	
			Celexa	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Aerobid	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Claritin	C			UNKNOWN	
			Niacin	C			UNKNOWN	14671DAY

Date:07/16/04ISR Number: 4400070-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01829
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	466 DAY	
Hospitalization -	Cerebrovascular Accident		Aspirin	C			UNKNOWN	
Initial or Prolonged	Emotional Distress		Lasix (Furosemide)	C		ORAL		
	Glomerulonephritis Membranous		Indocin (Indomethacin)	C			UNKNOWN	
	Gout		K-Dur	C		ORAL		
	Hyperglycaemia							
	Medication Error							
	Nephrolithiasis							
	Oedema Peripheral							
	Pneumonia							
	Renal Failure							
	Sleep Apnoea Syndrome							

Urethral Stricture

Date:07/16/04ISR Number: 4400077-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/16/04ISR Number: 4400078-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01375
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mental Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization -	Migraine		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged Disability	Visual Disturbance							

Date:07/16/04ISR Number: 4400081-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Chest Pain
	Dehydration
	Eye Irritation
	Hepatic Enzyme Increased

	Rash Pruritic Skin Lesion						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	254 DAY
			Lipitor	C			UNKNOWN
			Prinivil	C		ORAL	
			Zocor	C		ORAL	
			Protonix	C			UNKNOWN

Date:07/19/04ISR Number: 4401567-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia Of Chronic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY
Initial or Prolonged	Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Blood Calcium Increased		[Therapy				
	Carotid Artery Disease		Unspecified]	C			UNKNOWN
	Colitis		[Therapy				
	Coronary Artery Disease		Unspecified]	C			UNKNOWN
	Eczema		Aspirin	C			UNKNOWN
	Gastric Ulcer Haemorrhage		Lipitor	C			UNKNOWN
	Gastritis		Pepto-Bismol	C			UNKNOWN
	Helicobacter Pylori		Chondroitin Sulfate				
	Identification Test		Sodium And				
	Positive		Glucosamine				
	Impaired Fasting Glucose		Hydrochloride	C			UNKNOWN
	Infection		Vitamin E	C			UNKNOWN
	Intermittent Claudication		Vitamin B				
	Joint Sprain		(Unspecified)	C			UNKNOWN
	Myocardial Infarction		Vasoretic	C		ORAL	
	Oesophagitis		Vasoretic	C		ORAL	

	Peripheral Vascular	Neurontin	C
UNKNOWN			
	Disorder	Prevacid	C
UNKNOWN			
	Renal Failure Chronic	Centrum	C
UNKNOWN			
	Stress	Inderal	C
UNKNOWN			
	Tachycardia		
	Ventricular Arrhythmia		

Date:07/19/04ISR Number: 4401580-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Accident At Work
Disability	Ankle Fracture
Other	Back Injury
	Chest Pain
	Depression
	Dry Mouth
	Dysgeusia
	Dyspnoea
	Emotional Disorder
	Erectile Dysfunction
	Headache
	Heart Rate Irregular
	Hypertension
	Intervertebral Disc
	Degeneration
	Intervertebral Disc

		Protrusion					
		Joint Injury					
		Joint Sprain					
		Major Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myofascial Pain Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Orchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis					
		Pain					
		Palpitations					
		Patellofemoral Pain					
		Syndrome					
		Pruritus					
		Pyrexia					
		Tachycardia					
		Tendonitis					
		Tinnitus					
		Urinary Incontinence					

Date:07/19/04ISR Number: 4401582-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02515
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
274 DAY							
Hospitalization -		Infarction	Professional	Albuterol	C		
UNKNOWN							
Initial or Prolonged		Acute Respiratory Failure		Ecotrin	C		
UNKNOWN							
		Anxiety		Lipitor	C		
UNKNOWN							
		Arthritis		Premarin	C		
UNKNOWN							
		Cardiac Arrest		Vitamins			
		Hypoxic Encephalopathy		(Unspecified)	C		
UNKNOWN							
		Tenosynovitis		Zocor	C		ORAL
		Ventricular Fibrillation		Prozac	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							

Date:07/19/04ISR Number: 4401584-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	56 DAY	
	Atrial Fibrillation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	156 DAY	
	Blood Cholesterol		Aspirin	C			UNKNOWN	
	Increased		Celebrex	C			UNKNOWN	
	Carotid Artery Stenosis							
	Cellulitis							
	Dyslipidaemia							
	Hypertension							
	Ischaemic Stroke							
	Spondylitis							
	Transient Ischaemic Attack							

Date:07/19/04ISR Number: 4401785-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Aortic Stenosis
	Arrhythmia

		Arterial Stenosis					
		Atrial Fibrillation					
		Azotaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Allopurinol	C		
UNKNOWN							
		Chest Pain		Allopurinol	C		
UNKNOWN							
		Chronic Obstructive		Aspirin	C		
UNKNOWN							
		Pulmonary Disease		Lipitor	C		
UNKNOWN							
		Circulatory Collapse		Lotensin	C		
UNKNOWN							
		Coronary Artery Disease		Coreg	C		
UNKNOWN							
		Coronary Artery Occlusion		Celebrex	C		
UNKNOWN							
		Coronary Artery Stenosis		Clopidogrel			
		Dehydration		Bisulfate	C		
UNKNOWN							
		Diabetic Foot		Cardizem	C		
UNKNOWN							
		Diverticulum		Pepcid	C		
UNKNOWN							
		Emotional Distress		Fluvastatin Sodium	C		
UNKNOWN							
		Erectile Dysfunction		Furosemide	C		
UNKNOWN							
		Gouty Arthritis		Neurontin	C		
UNKNOWN							
		Gouty Tophus		Glipizide	C		
UNKNOWN							
		Hypotension		Glycine	C		
UNKNOWN							
		Hypothyroidism		Insulin	C		
UNKNOWN							
		Injury		Glucophage	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Coumadin	C		
UNKNOWN							
		Localised Infection		Trazodone			
		Mitral Valve Incompetence		Hydrochloride	C		
UNKNOWN							
		Mitral Valve Prolapse		Spironolactone	C		
UNKNOWN							

	Myasthenia Gravis	Nitroglycerin	C
UNKNOWN			
	Myocardial Infarction	Actos	C
UNKNOWN			
	Myocardial Ischaemia		
	Non-Cardiac Chest Pain		
	Oedema Peripheral		
	Open Angle Glaucoma		
	Osteomyelitis		
	Overdose		
	Peptic Ulcer		
	Peripheral Coldness		
	Peripheral Occlusive		
	Disease		
	Pulmonary Hypertension		
	Pulmonary Oedema		
	Rectal Haemorrhage		
	Renal Failure		
	Respiratory Arrest		
	Respiratory Failure		
	Sleep Apnoea Syndrome		
	Sleep Disorder		
	Syncope		
	Vascular Graft Occlusion		
	Vascular Occlusion		
	Ventricular Dysfunction		
	Vitreous Haemorrhage		

Date:07/19/04ISR Number: 4401790-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Biliary Neoplasm
Other	Bronchiectasis
	Calcinosis

		Cellulitis					
		Cholelithiasis					
		Chronic Obstructive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Collapse Of Lung		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Fosamax	C		
UNKNOWN							
		Coronary Artery Disease		Premarin	C		
UNKNOWN							
		Diverticulum		Robaxin	C		ORAL
		Drug Ineffective		Prilosec	C		
UNKNOWN							
		Duodenitis					
		Ear Pain					
		Emphysema					
		Erosive Oesophagitis					
		Gastritis Haemorrhagic					
		Hepatitis					
		Hypersensitivity					
		Lung Neoplasm					
		Mycobacterium Avium					
		Complex Infection					
		Myocardial Infarction					
		Nausea					
		Otitis Externa					
		Pruritus					
		Rash Morbilliform					
		Rash Vesicular					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Vitreous Floaters					
		Weight Decreased					

Date:07/19/04ISR Number: 4401791-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Distension
Disability	Abdominal Pain
	Abnormal Faeces
	Anxiety
	Back Pain

Calculus Ureteric
Cardiovascular Disorder
Cognitive Disorder
Confusional State
Constipation
Disorientation
Dizziness
Dysuria
Emotional Distress
Flank Pain
Global Amnesia
Haematochezia
Hypertension
Influenza Like Illness
Injury
Lethargy
Nausea
Nephrocalcinosis
Nephrolithiasis

	Renal Cyst Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	552	DAY
			Aleve	SS			UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	552	DAY
			Tylenol	C			UNKNOWN	
			Paxil	C			UNKNOWN	2 MON

Date:07/19/04ISR Number: 4401792-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Aspirin	C			UNKNOWN	
	Attack		Zocor	C			UNKNOWN	
	Visual Acuity Reduced		Lanoxin	C			UNKNOWN	
			Zestril	C			UNKNOWN	

Date:07/19/04ISR Number: 4401793-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02981
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Acute Pulmonary Oedema
Other	Anaemia
	Anxiety
	Arteriosclerosis
	Back Injury
	Cardiac Failure
	Congestive

Cataract
Cholelithiasis
Contusion
Coronary Artery Disease
Cystitis
Dehydration
Drug Ineffective
Electrocardiogram Qt
Prolonged
Fall
Fat Embolism
Femur Fracture
Gastroenteritis
Gastrooesophageal Reflux
Disease
Hypertension
Laceration
Lacunar Infarction
Nausea
Pain
Pollakiuria
Renal Failure
Rotator Cuff Syndrome
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation

		Toe Deformity Urinary Tract Infection Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Amitriptyline Hydrochloride	SS		ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Buspirone Hydrochloride	C		
UNKNOWN							
				Aricept	C		ORAL
				Fluoxetine	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Metoclopramide	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Premarin	C		ORAL
				Valium	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							

Date:07/19/04ISR Number: 4401796-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intestinal Obstruction							
	Meningitis Viral							
	Oesophageal Disorder							

Date:07/19/04ISR Number: 4401797-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03170
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Affective Disorder
	Alcohol Poisoning
Disability	Alcohol Withdrawal
Other	Syndrome
	Alcoholic Liver Disease
	Anxiety
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Chest Pain
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Deep Vein Thrombosis
	Depression

		Dermatitis					
		Diverticulum					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal					
		Haemorrhage					
		Gout					
		Haemorrhoids					
		Hepatic Encephalopathy					
		Hypernatraemia					
		Hypertension					
		Myocardial Infarction					
		Oesophagitis					
		Palpitations					
		Peritonitis Bacterial					
		Pneumonia Aspiration					
		Renal Failure Acute					
		Respiratory Failure					
		Syncope					
		Varices Oesophageal					

Date:07/19/04ISR Number: 4401799-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01296
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
15	MON						
Initial or Prolonged		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
Disability		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Bunion		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
15	MON						
		Cerebrovascular Accident		Lipitor	C		
UNKNOWN							
		Chest Pain		Covera	C		
UNKNOWN							
		Diabetes Mellitus		Premarin	C		ORAL
		Dizziness		Allegra	C		
UNKNOWN							
		Fall		Claritin-D 12 Hour	C		ORAL

	Hot Flush		Adalat	C		ORAL
	Hypertension		Zantac	C		
UNKNOWN						
	Infection					
	Pain					

Date:07/19/04ISR Number: 4401801-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00078
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Adenoma		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Initial or Prolonged	Gastric Ulcer		Aspirin	C		
UNKNOWN						
	Gastrooesophageal Reflux					
	Disease					
	Hiatus Hernia					
	Melaena					
	Metaplasia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/04ISR Number: 4404117-7Report Type:Expedited (15-DaCompany Report #2004-07-0363
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Abnormal	Foreign	Celestene					
	Diabetic Ketoacidosis	Health	(Betamethasone)					
	Dyspepsia	Professional	Tablets "Like					
	Leukocytosis	Other	Celestone Syrup"	PS		ORAL	ORAL	
	Pancreatitis Necrotising		Vioxx (Rofecoxib)					
			Oral, Not Otherwise					
			Specified	SS		ORAL	ORAL	
			Ultram Oral	SS		ORAL	ORAL	

Date:07/19/04ISR Number: 4404139-6Report Type:Expedited (15-DaCompany Report #8157
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign	Methotrexate	PS				
		Health	Premarin	SS				
		Professional	Augmentin	SS				
		Other	Co-Dydramol	SS				
			Fluoxetine	SS				
			Humira	SS			SUBCUTANEOUS	40 MG
							FORTNIGHTLY	
							SC	
			Rofecoxib	SS				

Date:07/20/04ISR Number: 4402198-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02003
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anal Fistula	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Arthritis	Tylenol	C		
UNKNOWN					
	Cardiac Failure	Vicodin Tablets	C		
UNKNOWN					
	Congestive	Aspirin	C		ORAL
	Cardio-Respiratory Arrest	Calcium			
	Cerebrovascular Disorder	(Unspecified)	C		
UNKNOWN					
	Condition Aggravated	Digoxin	C		ORAL
	Coronary Artery Disease	Digoxin	C		ORAL
	Culture Urine Positive	Premarin	C		
UNKNOWN					
	Depression	Folic Acid	C		
UNKNOWN					
	Dizziness	Lasix (Furosemide)	C		ORAL
	Gallbladder Disorder	Lasix (Furosemide)	C		ORAL
	Headache	Lasix (Furosemide)	C		
INTRAVENOUS					
	Hyperkalaemia	Lasix (Furosemide)	C		ORAL
	Hypotension	Insulin, Isophane	C		
SUBCUTANEOUS					
	Injury	Iron (Unspecified)	C		
UNKNOWN					
	Insomnia	Isordil	C		ORAL
	Lethargy	Zestril	C		ORAL
	Malaise	Mevacor	C		ORAL
	Nausea	Vitamins			
	Pneumonia	(Unspecified)	C		
UNKNOWN					
	Renal Failure Acute	Vitamin E	C		
UNKNOWN					
	Sepsis	Tolinase	C		ORAL
	Urinary Tract Infection	Provera	C		
UNKNOWN					
	Uterine Leiomyoma	Provera	C		
UNKNOWN					
	Vomiting	Pentasa	C		ORAL
		Lopressor	C		
INTRAVENOUS					
		Lopressor	C		ORAL

	Lopressor	C		
INTRAVENOUS				
	Lopressor	C		ORAL
	Nitroglycerin	C		
SUBLINGUAL				
	Potassium (Unspecified)	C		
UNKNOWN				
	Prednisone	C		ORAL
	Pyridoxine	C		
UNKNOWN				

Date:07/20/04ISR Number: 4402202-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Flutter	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased Appetite		Zantac	C				
UNKNOWN								
	Depression		Aspirin	C		ORAL		
	Dizziness		Clonidine	C		ORAL		
	Drug Ineffective		Metabolife 356	C				
UNKNOWN								
	Dyspnoea		Hydrochlorothiazide	C		ORAL		
	Emotional Distress		Adalat	C		ORAL		
	Headache		Klor-Con	C		ORAL		
	Heart Rate Irregular							
	Oedema Peripheral							
	Osteoarthritis							
	Palpitations							
	Renal Impairment							
	Thrombosis							
	Weight Increased							

Date:07/20/04ISR Number: 4402204-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Respiratory

Hospitalization - Initial or Prolonged	Distress Syndrome
Other	Anaemia
	Anoxic Encephalopathy
	Anxiety
	Blood Pressure Fluctuation
	Cardiac Arrest
	Cardio-Respiratory Arrest
	Coma
	Convulsion
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Disease Progression
	Gastric Disorder
	Headache
	Hypertension
	Hypokalaemia
	Lumbar Spinal Stenosis
	Myocardial Infarction
	Palpitations
	Pneumonia Aspiration
	Postoperative Ileus

		Pulmonary Embolism					
		Pulmonary Oedema					
		Shock	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Tylenol With Codeine			
		Spondylolisthesis		#4	C		
UNKNOWN							
		Acquired		Tylenol With Codeine			
		Syphilis		#4	C		
UNKNOWN							
		Tricuspid Valve		Celebrex	C		
UNKNOWN							
		Incompetence		Arthrotec	C		ORAL
		Ventricular Fibrillation		Arthrotec	C		ORAL
		Ventricular Hypokinesia		Arthrotec	C		ORAL
				Premarin	C		
UNKNOWN							
				Provera	C		
UNKNOWN							
				Daypro	C		
UNKNOWN							

Date:07/20/04ISR Number: 4402206-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL
135 DAY						
Hospitalization -	Bipolar Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
135 DAY						
Initial or Prolonged	Blood Pressure Increased		[Therapy			
	Emotional Distress		Unspecified]	C		
UNKNOWN						
	Haemorrhoids		Depakote	C		
UNKNOWN						
	Myocardial Infarction		Zestril	C		
UNKNOWN						
			Lithium Sulfate	C		
UNKNOWN						

Date:07/20/04ISR Number: 4402207-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00099
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Melaena	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C		ORAL		

Date:07/20/04ISR Number: 4402208-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02541
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Apap	C				
UNKNOWN								
	Increased Cerebrovascular Accident		Amitriptyline Hydrochloride	C				
UNKNOWN								
	Chest Pain		Soma	C				
UNKNOWN								
	Dyspepsia		Soma	C				
UNKNOWN								
	Dyspnoea		Codeine	C				
UNKNOWN								
	Generalised Anxiety		Flexeril	C				
UNKNOWN								
	Disorder		Flexeril	C				
UNKNOWN								
	Nausea Syncope Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/04ISR Number: 4402210-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Convulsion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cystitis		Propulsid	C		
UNKNOWN						
	Depression		Estrogens			
	Emotional Distress		(Unspecified)	C		
UNKNOWN						
	Herpes Zoster					
	Injury					
	Intervertebral Disc					
	Displacement					
	Nervousness					
	Stomach Discomfort					
	Thyroid Disorder					
	Uterine Cancer					
	Weight Decreased					

Date:07/20/04ISR Number: 4402214-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization -	Activated Partial
Initial or Prolonged	Thromboplastin Time
Other	Prolonged
	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Cardiac Failure
	Congestive
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Confusional State
	Convulsion
	Coronary Artery Disease
	Deafness Neurosensory
	Dehydration

Depression
Diabetes Mellitus
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fibrous Histiocytoma
Gastritis Haemorrhagic
Headache
Hiatus Hernia
Hypermetropia
Hypertension
Inner Ear Disorder
Leukocytosis
Mitral Valve Incompetence
Myocardial Infarction
Oedema

		Pneumonia Escherichia					
		Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Presbyopia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Prothrombin Time	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Prolonged		Vioxx	SS	Merck & Co., Inc	ORAL
		Pupillary Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Renal Failure		Neurontin	C		
UNKNOWN							
		Respiratory Failure		Glucosamine	C		
UNKNOWN							
		Sepsis		Prilosec	C		
UNKNOWN							
		Subarachnoid Haemorrhage					
		Syncope					
		Transient Ischaemic Attack					
		Tremor					
		Tricuspid Valve Incompetence					
		Varicose Vein					
		Ventricle Rupture					
		Ventricular Tachycardia					
		Vertigo Positional					

Date:07/20/04ISR Number: 4402215-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Cholesterol		Aspirin	C		
UNKNOWN						
Other	Increased		Lasix (Furosemide)	C		
UNKNOWN						
	Chest Discomfort		Glucotrol Xl	C		
UNKNOWN						
	Chronic Obstructive		Glyburide	C		
UNKNOWN						
	Pulmonary Disease		Ativan	C		
UNKNOWN						

	Cognitive Disorder	Lopressor	C
UNKNOWN			
	Convulsion	Orphenadrine	C
UNKNOWN			
	Coronary Artery Disease Depression Diabetes Mellitus Inadequate Control Diabetic Ketoacidosis Emotional Distress Hypertension Hypokalaemia Intervertebral Disc Degeneration Myocardial Infarction Nasopharyngitis Palpitations Rotator Cuff Syndrome Supraventricular Tachycardia Transient Ischaemic Attack Urinary Tract Infection Vision Blurred		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/04ISR Number: 4402262-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		91 DAY
Initial or Prolonged	Infarction	Professional	Vicodin Tablets	C				UNKNOWN
Disability	Anaemia		Aspirin	C				UNKNOWN
Other	Arrhythmia		Lipitor	C				UNKNOWN
	Arthritis		Capoten	C				UNKNOWN
	Brachial Plexus Lesion		Plavix	C				UNKNOWN
	Bronchitis Acute		Lasix (Furosemide Sodium)	C				UNKNOWN
	Cardiac Failure							
	Congestive		Amaryl	C				UNKNOWN
	Cardiogenic Shock		Glipizide	C				UNKNOWN
	Cardiomyopathy		Prevacid	C				UNKNOWN
	Chronic Obstructive		Glucophage	C				UNKNOWN
	Pulmonary Disease		Lopressor	C				UNKNOWN
	Colonic Polyp		Nitrol (Nitroglycerin)	C				UNKNOWN
	Convulsion							
	Coronary Artery Disease		Altace	C				UNKNOWN
	Coronary Artery Occlusion							
	Decubitus Ulcer							
	Diabetic Neuropathy							
	Dysphagia							
	Dyspnoea							
	Electrocardiogram St Segment Depression							
	Electrolyte Imbalance							
	Faecaloma							
	Folate Deficiency							
	Gastrointestinal Haemorrhage							

Herpes Zoster
Hypertension
Influenza
Ischaemic Cardiomyopathy
Liver Function Test
Abnormal
Malnutrition
Myocardial Infarction
Oedema
Pericarditis
Pneumonia
Pneumonia Aspiration
Post Herpetic Neuralgia
Pulmonary Oedema
Pyrexia
Radiculitis Brachial
Respiratory Failure
Restlessness
Rotator Cuff Syndrome
Staphylococcal Infection
Stent Occlusion
Thrombocytopenia
Treatment Noncompliance
Ventricular Extrasystoles
Ventricular Hypokinesia
Vitamin B12 Deficiency

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/04ISR Number: 4402316-1Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12641478
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Health	Elisor	PS	Bristol-Myers Squibb			
Life-Threatening	Septic Shock	Professional			Company	ORAL		
	Shock		Coversyl	SS		ORAL		
			Vioxx	SS		ORAL		
			Mopral	SS		ORAL		

Date:07/20/04ISR Number: 4402476-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	733 DAY	
Hospitalization - Initial or Prolonged	Infarction Adverse Event		[Therapy Unspecified]	C			UNKNOWN	
	Angina Unstable		Aspirin	C			UNKNOWN	
	Anxiety		Atenolol	C			UNKNOWN	
	Aortic Aneurysm		Zocor	C			UNKNOWN	
	Back Pain		Celebrex	C			UNKNOWN	
	Blood Triglycerides Increased		Plavix	C			UNKNOWN	
	Cardiac Failure Congestive		Prinivil	C		ORAL		
	Cardiac Valve Disease							
	Cerebral Infarction							
	Cholelithiasis							
	Depressed Level Of Consciousness							
	Depression							
	Diverticulum							
	Feeling Hot							
	Haematuria							
	Haemorrhage							
	Hepatic Cyst							

High Density Lipoprotein
Decreased
Hyperhidrosis
Injury
Low Density Lipoprotein
Increased
Myocardial Infarction
Nephrosclerosis
Renal Mass
Stress
Ventricular Tachycardia
Vision Blurred

Date:07/20/04ISR Number: 4402477-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00929
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Aortic Calcification
	Apathy
	Asthenia
	Blood Cholesterol Increased
	Blood Pressure Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Triglycerides Increased					
		Carotid Artery Stenosis					
		Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
696	DAY						
		Cerebellar Infarction		Reglan	SS		
UNKNOWN							
		Cerebrovascular Accident		Celebrex	C		
UNKNOWN							
		Cerebrovascular Disorder		Catapres	C		
UNKNOWN							
		Chest Discomfort		Flonase	C		
UNKNOWN							
		Cholecystitis		Prilosec	C		
UNKNOWN							
		Cognitive Disorder		Lopid	C		
UNKNOWN							
		Deafness Neurosensory		Robaxin	C		
UNKNOWN							
		Decreased Interest					
		Diabetes Mellitus					
		Diabetes Mellitus Non-Insulin-Dependent					
		Diabetic Neuropathy					
		Dizziness					
		Dystonia					
		Fall					
		Fatigue					
		Glossitis					
		Haematochezia					
		Haemorrhoids					
		Hiatus Hernia					
		High Density Lipoprotein Decreased					
		Hypoglycaemia					
		Low Density Lipoprotein Increased					
		Major Depression					
		Neuropathy Peripheral					
		Orthostatic Hypotension					
		Pain In Extremity					
		Pseudodementia					
		Radiculopathy					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Somnolence					

Treatment Noncompliance
Tremor

Date:07/20/04ISR Number: 4402478-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Glucose Increased
Disability	Blood Potassium Increased
Other	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Diabetes Mellitus
	Inadequate Control
	Gastrointestinal
	Infection
	Hyperparathyroidism
	Secondary

Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Insomnia							
Ischaemic Cardiomyopathy							
Meniere'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL	422 DAY	
Mitral Valve Incompetence		Lasix (Furosemide)	SS			UNKNOWN	
Myalgia		Zestril	SS			UNKNOWN	
Nerve Compression		Zestril	SS			UNKNOWN	406 DAY
Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Pharyngitis		Tylenol	C			UNKNOWN	
Renal Failure Acute		Calcium					
Renal Failure Chronic		(Unspecified)	C			UNKNOWN	
Seasonal Allergy		Plavix	C			UNKNOWN	
Silent Myocardial		Naproxen	C			UNKNOWN	
Infarction		Temazepam	C			UNKNOWN	
Sinusitis		Spironolactone	C			UNKNOWN	
Skin Ulcer		Zocor	C		ORAL		
Tricuspid Valve		Miacalcin	C			UNKNOWN	
Incompetence		Zantac	C			UNKNOWN	
Urinary Tract Infection		Nitro	C			UNKNOWN	
Ventricular Dysfunction		Motrin	C			UNKNOWN	
		Prinivil	C			UNKNOWN	
		Glucotrol	C			UNKNOWN	
		Cardizem	C			UNKNOWN	
		Prozac	C			UNKNOWN	

Date:07/20/04ISR Number: 4402480-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01296
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/04ISR Number: 4402481-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01189
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
	Throat Tightness							

Date:07/20/04ISR Number: 4404762-9Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY;	
Hospitalization -	Myocardial Infarction	Study					PO	
Initial or Prolonged	Ventricular Dysfunction	Health Professional	Amlodipine Besylate	C				

Date:07/21/04ISR Number: 4402819-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01717
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Blood Cholesterol
Initial or Prolonged	Increased
Disability	Blood Pressure Increased
	Diabetes Mellitus
	Gout
	Inner Ear Disorder

	Pollakiuria					
	Ulcer					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:07/21/04ISR Number: 4403485-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adjustment Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
	Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vicodin Tablets	C		
UNKNOWN						
	Blood Urine Present		Effexor Xr	C		
UNKNOWN						
	Cataract		Ecotrin	C		
UNKNOWN						
	Chest Wall Pain		Wellbutrin Sr	C		
UNKNOWN						
	Depression		Prevacid	C		
UNKNOWN						
	Dizziness		Pravachol	C		
UNKNOWN						
	Eye Disorder		Accupril	C		
UNKNOWN						
	Faecal Incontinence					
	Flank Pain					
	Gastric Disorder					
	Gastric Haemorrhage					
	Groin Pain					
	Haemorrhoids					
	Herpes Virus Infection					
	Influenza					
	Intervertebral Disc					
	Degeneration					
	Joint Stiffness					
	Meniere'S Disease					
	Muscle Strain					

Pain In Extremity
Road Traffic Accident
Rotator Cuff Syndrome
Spinal Column Stenosis
Tendonitis
Ulcer
Viral Infection

Date:07/21/04ISR Number: 4403487-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Anorexia
Other	Anxiety
	Asthenia
	Bacterial Infection
	Bipolar I Disorder
	Chest Pain
	Chills
	Emotional Distress
	Flank Pain
	Hydronephrosis

		Incisional Hernia					
		Medication Error					
		Nephrolithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure Acute	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Schizoaffective Disorder		Lipitor	C		
UNKNOWN							
		Sepsis		Lipitor	C		
UNKNOWN							
		Staphylococcal Infection		Avapro	C		
UNKNOWN							
		Urinary Retention		Geodon	C		
UNKNOWN							
		Urinary Tract Infection		Prevacid	C		
UNKNOWN							
		Urosepsis		Levoxyl	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:07/21/04ISR Number: 4403489-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00991
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Activities Of Daily	Health	Vioxx	PS	Merck & Co., Inc	ORAL
450 DAY							
Initial or Prolonged		Living Impaired	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
450 DAY							
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Anaemia		Lorcet Plus	C		
UNKNOWN							
		Blood Pressure Increased		Combivent	C		
UNKNOWN							
		Cardiac Failure		Aspirin	C		
UNKNOWN							
		Congestive		Lipitor	C		
UNKNOWN							
		Cardiomyopathy		Rhinocort	C		
UNKNOWN							

	Chronic Obstructive	Wellbutrin	C
UNKNOWN			
	Pulmonary Disease	Coreg	C
UNKNOWN			
	Coronary Artery Disease	Tagamet	C
UNKNOWN			
	Depression	Biaxin	C
UNKNOWN			
	Gout	Plavix	C
UNKNOWN			
	Hepatic Enzyme Increased	Cyclobenzaprine	
	Hypercholesterolaemia	Hydrochloride	C
UNKNOWN			
	Hypokalaemia	Valium	C
UNKNOWN			
	Irritability	Valium	C
UNKNOWN			
	Libido Decreased	Benadryl	C
UNKNOWN			
	Myocardial Infarction	Prempro	C
UNKNOWN			
	Pulmonary Oedema	Advair	C
UNKNOWN			
	Respiratory Failure	Prolex Dh	C
UNKNOWN			
	Suicidal Ideation	Mavik	C
UNKNOWN			
	Syncope Vasovagal	Detrol	C
UNKNOWN			
		Micardis	C
UNKNOWN			
		Hydrocodone	
		Hydrochloride	C
UNKNOWN			
		Motrin	C
UNKNOWN			
		Motrin	C
UNKNOWN			
		Toprol Xl Tablets	C
UNKNOWN			
		Daypro	C
UNKNOWN			

Date:07/21/04ISR Number: 4403493-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02074
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Angina Unstable
	Aortic Valve Incompetence
	Bone Cyst

Bronchitis

		Coronary Artery Stenosis					
		Depression					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Initial Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Wellbutrin	C		
UNKNOWN							
		Overdose		Flexeril	C		ORAL
		Pleurisy		Enbrel	C		
SUBCUTANEOUS							
		Rheumatoid Arthritis		Ambien	C		
UNKNOWN							
		Rotator Cuff Syndrome		Pepcid	C		ORAL
		Upper Respiratory Tract		Folic Acid	C		
UNKNOWN							
		Infection		Glucosamine	C		
UNKNOWN							
				Plaquenil	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							

Date:07/21/04ISR Number: 4403501-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01194
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/21/04ISR Number: 4403504-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00777
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Oedema Peripheral					
	Renal Failure					

Date:07/21/04ISR Number: 4403516-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Cancer Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/04ISR Number: 4403518-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/04ISR Number: 4403919-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Atrial Fibrillation
Other	Blood Cholesterol Increased
	Bradycardia
	Coronary Artery Disease
	Coronary Artery

		Reocclusion					
		Deep Vein Thrombosis					
		Diverticulitis Intestinal Haemorrhagic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhoids	Professional	Zocor	SS		ORAL
		Hyperlipidaemia		Percocet	C		
UNKNOWN							
		Hypertension		Atenolol	C		
UNKNOWN							
		Intervertebral Disc		Folic Acid	C		
UNKNOWN							
		Degeneration		Motrin	C		
UNKNOWN							
		Myocardial Infarction		Vitamins			
		Polyp		(Unspecified)	C		
UNKNOWN							
		Renal Failure Chronic		Ambien	C		
UNKNOWN							
		Respiratory Distress		Temazepam	C		
UNKNOWN							
		Sigmoiditis		Ismo	C		
UNKNOWN							
		Wound Dehiscence		Methotrexate	C		
UNKNOWN							
				Oxycodone Hydrochloride	C		
UNKNOWN							
				Prednisone	C		ORAL

Date:07/21/04ISR Number: 4403922-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407USA00645
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other		Death	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Arthroplasty					

Date:07/21/04ISR Number: 4403924-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arrhythmia		Sular	C				
	Asthenia		Micardis	C				
	Blood Pressure Increased							
	Bone Disorder							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Cyst							
	Emotional Distress							
	Fatigue							
	Hyperlipidaemia							
	Hypertension							
	Hypokalaemia							
	Large Intestinal Ulcer							
	Haemorrhage							
	Nausea							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Osteoarthritis							
	Rotator Cuff Syndrome							
	Spinal Disorder							
	Stomach Discomfort							
	Vitamin B12 Deficiency							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4403934-7Report Type:Expedited (15-DaCompany Report #US-MERCK-99092264
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cataract	Health	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Hallucination	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
	Hallucination, Visual		Tenormin	C		ORAL		
	Visual Disturbance		Cardura	C		ORAL		

Date:07/21/04ISR Number: 4404174-8Report Type:Direct Company Report #CTU 223254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS			50 MG DAILY	2 WK
Other	Back Pain		Vicodin	C				
	Bedridden		Glucophage	C				
	Condition Aggravated		Albuterol Inhaler	C				
	Disease Recurrence		Aerobid Inhaler	C				
	Generalised Oedema							
	Hypersensitivity							
	Intervertebral Disc Protrusion							
	Loss Of Employment							
	Neoplasm							
	Wheezing							

Date:07/21/04ISR Number: 4430072-XReport Type:Periodic Company Report #WAES 0306USA00847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430074-3Report Type:Periodic Company Report #WAES 0306USA00848
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430076-7Report Type:Periodic Company Report #WAES 0306USA00849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430080-9Report Type:Periodic Company Report #WAES 0306USA00850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430082-2Report Type:Periodic Company Report #WAES 0306USA00851
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430084-6Report Type:Periodic Company Report #WAES 0306USA00852
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430087-1Report Type:Periodic Company Report #WAES 0306USA00853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430089-5Report Type:Periodic Company Report #WAES 0306USA00854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430091-3Report Type:Periodic Company Report #WAES 0306USA00855
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430094-9Report Type:Periodic Company Report #WAES 0306USA00856
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430097-4Report Type:Periodic Company Report #WAES 0306USA00878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430098-6Report Type:Periodic Company Report #WAES 0306USA00879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430100-1Report Type:Periodic Company Report #WAES 0306USA00880
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430102-5Report Type:Periodic Company Report #WAES 0306USA00882
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430104-9Report Type:Periodic Company Report #WAES 0306USA00883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430107-4Report Type:Periodic Company Report #WAES 0306USA00884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430109-8Report Type:Periodic Company Report #WAES 0306USA00885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430110-4Report Type:Periodic Company Report #WAES 0306USA00844
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430114-1Report Type:Periodic Company Report #WAE 0306USA00845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430115-3Report Type:Periodic Company Report #WAES 0306USA00846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430120-7Report Type:Periodic Company Report #WAES 0306USA00857
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430121-9Report Type:Periodic Company Report #WAES 0306USA00858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430123-2Report Type:Periodic Company Report #WAES 0306USA00859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430124-4Report Type:Periodic Company Report #WAES 0306USA00860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430126-8Report Type:Periodic Company Report #WAES 0306USA00861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430127-XReport Type:Periodic Company Report #WAES 0306USA00862
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430128-1Report Type:Periodic Company Report #WAES 0306USA00863
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430130-XReport Type:Periodic Company Report #WAES 0306USA00864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:07/21/04ISR Number: 4430131-1Report Type:Periodic Company Report #WAES 0306USA00865
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:07/21/04ISR Number: 4430135-9Report Type:Periodic Company Report #WAES 0306USA00808
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Injury Consumer Tab Vioxx Unk PS ORAL
PO

Date:07/21/04ISR Number: 4430138-4Report Type:Periodic Company Report #WAES 0306USA00809
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Injury Consumer Tab Vioxx PS ORAL
PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430140-2Report Type:Periodic Company Report #WAES 0306USA00810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430141-4Report Type:Periodic Company Report #WAES 0306USA00811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430143-8Report Type:Periodic Company Report #WAES 0306USA00812
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430145-1Report Type:Periodic Company Report #WAES 0306USA00813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430146-3Report Type:Periodic Company Report #WAES 0306USA00814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430149-9Report Type:Periodic Company Report #WAES 0306USA00815
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430151-7Report Type:Periodic Company Report #WAES 0306USA00816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430152-9Report Type:Periodic Company Report #WAES 0306USA00817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430154-2Report Type:Periodic Company Report #WAES 0306USA0018
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430321-8Report Type:Periodic Company Report #WAES 0306USA00829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430322-XReport Type:Periodic Company Report #WAES 0306USA00830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430323-1Report Type:Periodic Company Report #WAES 0306USA00831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430324-3Report Type:Periodic Company Report #WAES 0306USA00832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430325-5Report Type:Periodic Company Report #WAES 0306USA00833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430326-7Report Type:Periodic Company Report #WAES 0304USA00834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430327-9Report Type:Periodic Company Report #WAES 0306USA00835
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430328-0Report Type:Periodic Company Report #WAES 0306USA00836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430329-2Report Type:Periodic Company Report #WAES 0306USA00837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430330-9Report Type:Periodic Company Report #WAES 0306USA00838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430331-0Report Type:Periodic Company Report #WAES 0306USA00839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430332-2Report Type:Periodic Company Report #WAES 0306USA00840
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430333-4Report Type:Periodic Company Report #WAES 0306USA00841
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430334-6Report Type:Periodic Company Report #WAES 0306USA00842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430335-8Report Type:Periodic Company Report #WAES 0306USA00843
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430336-XReport Type:Periodic Company Report #WAES 0306USA00781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430337-1Report Type:Periodic Company Report #WAES 0306USA00783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430338-3Report Type:Periodic Company Report #WAES 0306USA00784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430339-5Report Type:Periodic Company Report #WAES 0306USA00786
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430340-1Report Type:Periodic Company Report #WAES 0306USA00787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430341-3Report Type:Periodic Company Report #WAES0306USA00788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430342-5Report Type:Periodic Company Report #WAES0306USA00789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430343-7Report Type:Periodic Company Report #WAES0306USA00790
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430344-9Report Type:Periodic Company Report #WAES0306USA00791
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430345-0Report Type:Periodic Company Report #WAES0306USA00792
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430346-2Report Type:Periodic Company Report #WAES0306USA00793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430347-4Report Type:Periodic Company Report #WAES0306USA00794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430348-6Report Type:Periodic Company Report #WAES0306USA00795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430349-8Report Type:Periodic Company Report #WAES0306USA00796
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430350-4Report Type:Periodic Company Report #WAES0306USA00797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430351-6Report Type:Periodic Company Report #WAES0306USA00798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430352-8Report Type:Periodic Company Report #WAES0306USA00799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430353-XReport Type:Periodic Company Report #WAES0306USA00800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430354-1Report Type:Periodic Company Report #WAES0306USA00801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430355-3Report Type:Periodic Company Report #WAES0306USA00802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430356-5Report Type:Periodic Company Report #WAES0306USA00803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430357-7Report Type:Periodic Company Report #WAES0306USA00804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430358-9Report Type:Periodic Company Report #WAES0306USA00805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430359-0Report Type:Periodic Company Report #WAES0306USA00807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430360-7Report Type:Periodic Company Report #WAES0306USA00686
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430361-9Report Type:Periodic Company Report #WAES 0306USA00648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430362-0Report Type:Periodic Company Report #WAES 0306USA00649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430363-2Report Type:Periodic Company Report #WAES 0306USA00650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430364-4Report Type:Periodic Company Report #WAES 0306USA00653
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430365-6Report Type:Periodic Company Report #WAES 0306USA00654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430366-8Report Type:Periodic Company Report #WAES 0306USA00482
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged			Neurontin	C				
			Zanaflex	C				

Date:07/21/04ISR Number: 4430367-XReport Type:Periodic Company Report #WAES 0305USA02823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive Renal Failure	Professional Company Representative						

Date:07/21/04ISR Number: 4430368-1Report Type:Periodic Company Report #WAES 0306USA00690
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430369-3Report Type:Periodic Company Report #WAES 0306USA00693
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430370-XReport Type:Periodic Company Report #WAES 0306USA00695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430371-1Report Type:Periodic Company Report #WAES 0306USA00699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430372-3Report Type:Periodic Company Report #WAES 0306USA00702
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430373-5Report Type:Periodic Company Report #WAES 0306USA00705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430374-7Report Type:Periodic Company Report #WAES 0306USA00706
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430375-9Report Type:Periodic Company Report #WAES 0306USA00626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430378-4Report Type:Periodic Company Report #WAES 0306USA00627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430379-6Report Type:Periodic Company Report #WAES 0306USA00629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430381-4Report Type:Periodic Company Report #WAES 0306USA00630
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430384-XReport Type:Periodic Company Report #WAES 0306USA00631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430385-1Report Type:Periodic Company Report #WAES 0306USA00632
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430386-3Report Type:Periodic Company Report #WAES 0306USA00633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430387-5Report Type:Periodic Company Report #WAES 0306USA00634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430388-7Report Type:Periodic Company Report #WAES 0306USA00635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430389-9Report Type:Periodic Company Report #WAES 0306USA00636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430390-5Report Type:Periodic Company Report #WAES 0306USA00637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430393-0Report Type:Periodic Company Report #WAES 0306USA00638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430396-6Report Type:Periodic Company Report #WAES 0306USA00639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430397-8Report Type:Periodic Company Report #WAES 0306USA00640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430403-0Report Type:Periodic Company Report #WAES 0306USA00641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430410-8Report Type:Periodic Company Report #WAES 0306USA00642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430411-XReport Type:Periodic Company Report #WAES 0306USA00687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430413-3Report Type:Periodic Company Report #WAES 0306USA00688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430415-7Report Type:Periodic Company Report #WAES 0402USA00137
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Hepatic Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/04ISR Number: 4430416-9Report Type:Periodic Company Report #WAES 0309USA00886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430417-0Report Type:Periodic Company Report #WAES 0309USA00444
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Perforation	Health Professional Company	Tab Vioxx Unk	PS		ORAL	PO	

Representative

Date:07/21/04ISR Number: 4430419-4Report Type:Periodic Company Report #WAES 0309USA00118
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	
		Professional	Tab Vioxx 25 Mg	SS				
			Tab Vioxx 25 Mg	C				
			Accupril	C				
			Hydrodiuril	C				
			Lanoxin	C				
			Zocor	C				
			Atenolol	C				
			Minerals (=)					
			Vitamink	C				

Date:07/21/04ISR Number: 4430420-0Report Type:Periodic Company Report #WAES 0309USA00099
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatitis Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -		Professional						
Initial or Prolonged		Company Representative	Coumadin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430421-2Report Type:Periodic Company Report #WAES 0309USA00049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	[Therapy Unspecified]	C				

Date:07/21/04ISR Number: 4430423-6Report Type:Periodic Company Report #WAES 0309USA00005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Congestive Renal Failure	Professional Company Representative						

Date:07/21/04ISR Number: 4430425-XReport Type:Periodic Company Report #WAES 0309USA02714
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Professional Company Representative	[Therapy Unspecified]	C				

Date:07/21/04ISR Number: 4430426-1Report Type:Periodic Company Report #WAES 0308USA02516
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	SEE IMAGE	

Hospitalization -	Professional	Bextra	SS		ORAL
PO					
Initial or Prolonged	Company	Fosamax	C		
Disability	Representative	Hydrodiuril	C		
		Lotrel	C		
		Miacalcin	C		
		Neurontin	C		
		Calcium (+) Vitamin K	C		

Date:07/21/04ISR Number: 4430427-3Report Type:Periodic Company Report #WAES0306USA00689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Polytraumatism	Consumer	Tab Vioxx Unk	PS		ORAL
PO						

Date:07/21/04ISR Number: 4430442-XReport Type:Periodic Company Report #WAES 0306USA02061
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pancreatitis	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
SEE IMAGE						
Initial or Prolonged			Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430443-1Report Type:Periodic Company Report #WAES 0306USA02002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430444-3Report Type:Periodic Company Report #WAES 0306US01910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430445-5Report Type:Periodic Company Report #WAES 0306USA01521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rectal Haemorrhage Stevens-Johnson Syndrome	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/BID/PO	

Date:07/21/04ISR Number: 4430446-7Report Type:Periodic Company Report #WAES0305USA01992
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	

Hospitalization - Initial or Prolonged	Haemorrhage	Professional	Prevacid	C

Date:07/21/04ISR Number: 4430447-9Report Type:Periodic Company Report #WAES0305USA02127
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Health	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative	Glucophage	C				
Disability								
Other								

Date:07/21/04ISR Number: 4430448-0Report Type:Periodic Company Report #WAES0305USA00202
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	DAILY/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Calan	C				
			Zoloft	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430449-2Report Type:Periodic Company Report #WAES0304USA02573
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Respiratory Tract Infection	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/04ISR Number: 4430450-9Report Type:Periodic Company Report #WAES0304USA02111
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea	Company Representative	Coumadin	C				
			Aspirin	C				

Date:07/21/04ISR Number: 4430451-0Report Type:Periodic Company Report #WAES0304USA02096
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430452-2Report Type:Periodic Company Report #WAES0304USA01305
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Gastrointestinal	Professional				
MG/DAILY/PO						
	Haemorrhage		Coumadin	C		
	Neoplasm Malignant		Aspirin	C		

Date:07/21/04ISR Number: 4430453-4Report Type:Periodic Company Report #WAES0303USA02493
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cataract	Consumer	Tab Vioxx 50 Mg	PS		ORAL
25 & 50						
Initial or Prolonged	Depression	Health				
MG/DAILY/PO						
Disability	Gastritis	Professional	Ambien	C		
	Gastrooesophageal Reflux		Ativan	C		
	Disease		Flexeril	C		
	Hypertension		Imitrex	C		
	Impaired Gastric Emptying		Monistat	C		
	Migraine		Nasonex	C		
	Prolactinoma		Topamax	C		
	Reflux Oesophagitis		Wellbutrin	C		
	Stevens-Johnson Syndrome					
	Toxic Epidermal					
	Necrolysis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430454-6Report Type:Periodic Company Report #WAES0302USA00100
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fibromyalgia	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Gastric Haemorrhage							
	Thrombosis							

Date:07/21/04ISR Number: 4430455-8Report Type:Periodic Company Report #WAES0301USA03198
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Health					MG/DAILY/PO	
		Professional	Accupril	C				
			Allopurinol	C				

Date:07/21/04ISR Number: 4430456-XReport Type:Periodic Company Report #WAES 0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
	Atherosclerosis		Effexor Xr	C				
	Depression		Lotensin	C				
	Hypertension		Remeron	C				
	Liver Disorder		Valium	C				
	Osteoporosis		Wellbutrin	C				
	Pain In Extremity		Acetaminophen (+)					
	Polyneuropathy		Hydrocodone Bi	C				
	Renal Failure		Estradiol	C				

Date:07/21/04ISR Number: 4430457-1Report Type:Periodic Company Report #WAES 0210USA02696
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
Initial or Prolonged Disability		Professional Company Representative	Motrin	C				
Other								

Date:07/21/04ISR Number: 4430458-3Report Type:Periodic Company Report #WAES 0204USA00036
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Renal Failure Acute	Professional Company Representative	Darvocet-N	C				
			Atenolol	C				
			Prednisone	C				

Date:07/21/04ISR Number: 4430459-5Report Type:Periodic Company Report #WAES 0203USA03167
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source
Other	Hyperkalaemia	Literature
	Renal Failure Acute	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	4 WK
Metoprolol	C				

Date:07/21/04ISR Number: 4430460-1Report Type:Periodic Company Report #WAES 0203USA03169
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Literature	Tab Vioxx 25 Mg	PS			PO	3 WK
		Health Professional Company Representative	Hydrodiuril	C				
			Furosemide	C				

Date:07/21/04ISR Number: 4430461-3Report Type:Periodic Company Report #WAES 0405USA01511
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional	Tab Vioxx 25mg	PS		ORAL	PO	1449 MG/3WK ON/1WK
			Study Drug (Unspecified)	SS				
			Zometa 4mg	SS		INTRAVENOUS	IV	
			Aredia	C				

Date:07/21/04ISR Number: 4430462-5Report Type:Periodic Company Report #WAES 0405USA01351
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Haemorrhage	Professional Company Representative				

Date:07/21/04ISR Number: 4430463-7Report Type:Periodic Company Report #WAES 0405USA01384
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25MG/PO						
Initial or Prolonged		Professional Company Representative				

Date:07/21/04ISR Number: 4430464-9Report Type:Periodic Company Report #WAES 0405USA01030
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Consumer	Tab Vioxx Unk	PS		ORAL
50MG/DAILY/PO						
Disability	Fatigue		Lotrel	C		
	Hypertension		Atenolol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430465-0Report Type:Periodic Company Report #WAES 0405USA01038
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
		Company Representative	Ibuprofen	C				

Date:07/21/04ISR Number: 4430466-2Report Type:Periodic Company Report #WAES 0405USA00944
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430467-4Report Type:Periodic Company Report #WAES 0405USA00698
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430468-6Report Type:Periodic Company Report #WAES 0405USA00629
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Haemorrhage	Professional					
MG/DAILY/PO							
		Company Representative	Aspirin	C			

Date:07/21/04ISR Number: 4430469-8Report Type:Periodic Company Report #WAES 0405USA00539
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombocytopenia	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Hospitalization -		Professional						
MG/DAILY/PO;								
Initial or Prolonged								
12.4								
MG/BID/PO								

Date:07/21/04ISR Number: 4430470-4Report Type:Periodic Company Report #WAES 0405USA00394
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL		
PO								
Initial or Prolonged	Haemorrhage	Professional Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430471-6Report Type:Periodic Company Report #WAES 0405USA00402
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancytopenia	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	3 MON
			Lasix (Furosemide)	C				
			Synthroid	C				
			Digoxin	C				
			Potassium	C				

Date:07/21/04ISR Number: 4430472-8Report Type:Periodic Company Report #WAES 0405USA00190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health	Tab Vioxx	PS		ORAL	PO	1 DAY
		Professional						
		Company						
		Representative						

Date:07/21/04ISR Number: 4430473-XReport Type:Periodic Company Report #WAES 0405USA00047
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
			Diovan	C				
			Fosamax	C				
			Plendil	C				
			Prednisone	C				

Date:07/21/04ISR Number: 4430474-1Report Type:Periodic Company Report #WAES 0405USA00116
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Lopressor	C				
			Prinzide	C				

Date:07/21/04ISR Number: 4430475-3Report Type:Periodic Company Report #WAES 0405USA00120
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Nausea							
			Norvasc	C				
			Plavix	C				
			Xalatan	C				
			Ziac	C				

Date:07/21/04ISR Number: 4430476-5Report Type:Periodic Company Report #WAES 0401USA01725
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx Unk	PS		ORAL
PO						

Date:07/21/04ISR Number: 4430477-7Report Type:Periodic Company Report #WAES 0401USA01458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Haemorrhage	Professional				
MG/DAILY/PO	1 MON					
		Company Representative				

Date:07/21/04ISR Number: 4430478-9Report Type:Periodic Company Report #WAES 0401USA01368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hospitalisation	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company Representative				

Date:07/21/04ISR Number: 4430479-0Report Type:Periodic Company Report #WAES 0401USA01210
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Hepatic Enzyme Increased	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Other	Jaundice	Professional				
MG/DAILY/PO						
	Nausea	Company	Tylenol	C		

Representative

Date:07/21/04ISR Number: 4430480-7Report Type:Periodic Company Report #WAES 0401USA01176
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4430481-9Report Type:Periodic Company Report #WAES 0401USA00994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Company	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ PO;	
Initial or Prolonged	Overdose	Representative					50 MG, 50	
		Other					MG/PO	

Date:07/21/04ISR Number: 4430482-0Report Type:Periodic Company Report #WAES 0401USA00924
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Life-Threatening	Anaphylactic Reaction	Health
	Hypertension	Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx 50 Mg	PS		ORAL
50 MG/DAILY/PO						
			Celebrex	C		

Date:07/21/04ISR Number: 4430483-2Report Type:Periodic Company Report #WAES 0401USA00739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional Company Representative				

Date:07/21/04ISR Number: 4430484-4Report Type:Periodic Company Report #WAES 0401USA00567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
	Haemorrhage	Professional Company Representative				

Date:07/21/04ISR Number: 4430485-6Report Type:Periodic Company Report #WAES 0401USA00227
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hypertension	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						

Company
Representative

Date:07/21/04ISR Number: 4430486-8Report Type:Periodic Company Report #WAES 0401USA00241
Age:69 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430487-XReport Type:Periodic Company Report #WAES0401USA00215
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
Hospitalization - Initial or Prolonged Disability			Motrin	C				
			Norvasc	C				

Date:07/21/04ISR Number: 4430488-1Report Type:Periodic Company Report #WAES0312USA02409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Company Representative						

Date:07/21/04ISR Number: 4430489-3Report Type:Periodic Company Report #WAES0312USA02358
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hallucination, Visual	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
			Diazide	C				
			Lanoxin	C				
			Aspirin	C				
			Thyroid	C				

Date:07/21/04ISR Number: 4430490-XReport Type:Periodic Company Report #WAES0312USA02239
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Corgard	C				
			Lipitor	C				

Date:07/21/04ISR Number: 4430491-1Report Type:Periodic Company Report #WAE0312USA02038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
Initial or Prolonged		Professional					MG/DAILY/PO	
Other		Company Representative						

Date:07/21/04ISR Number: 4430492-3Report Type:Periodic Company Report #WAES0312USA01791
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Bextra	C				

Date:07/21/04ISR Number: 4430493-5Report Type:Periodic Company Report #WAES0312USA01411
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Tab Vioxx 25 Mg	PS		ORAL	PO	
			Diovan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430494-7Report Type:Periodic Company Report #WAES0312USA01409
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Perforation	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
		Company Representative						

Date:07/21/04ISR Number: 4430495-9Report Type:Periodic Company Report #WAES0312USA01327
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Hypertension	Company Representative	Hydrodiuril	C				
			Zocor	C				
			Aspirin	C				
			Verapamil	C				

Date:07/21/04ISR Number: 4430496-0Report Type:Periodic Company Report #WAES 0312USA01094
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:07/21/04ISR Number: 4430497-2Report Type:Periodic Company Report #WAES 0312USA01072
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastrointestinal	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Haemorrhage					
MG/DAILY/PO						
			Norvasc	C		
			Tarka	C		
			Furosemide	C		

Date:07/21/04ISR Number: 4430498-4Report Type:Periodic Company Report #WAES 0312USA00928
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Haemorrhage	Professional				
MG/DAILY/PO;						
Initial or Prolonged	Gastric Polyps	Company				
SEE IMAGE						
Other		Representative	Avalide	C		
			Avapro	C		
			Glucophage	C		
			Tricor	C		
			Allopurinol	C		
			Fish Oil	C		
			Vitamins	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430499-6Report Type:Periodic Company Report #WAES 0312USA00829
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Cap Celebrex	SS		ORAL	PO	

Date:07/21/04ISR Number: 4430500-XReport Type:Periodic Company Report #WAES 0312USA008923
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Urinary Tract Infection						MG/DAILY/PO	
			Keflex	SS				

Date:07/21/04ISR Number: 4430501-1Report Type:Periodic Company Report #WAES 0312USA00306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Plavix	C				

Date:07/21/04ISR Number: 4430502-3Report Type:Periodic Company Report #WAES 0312USA00336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
		Professional Company						

Representative

Date:07/21/04ISR Number: 4430503-5Report Type:Periodic Company Report #WAES 0311USA02840
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Voxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4430504-7Report Type:Periodic Company Report #WAES 0311USA02819
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 50 Mg	PS		ORAL	50	
		Professional					MG/DAILY/PO	
		Company Representative	Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430505-9Report Type:Periodic Company Report #WAES 0311USA02717
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Reminyl	C				

Date:07/21/04ISR Number: 4430647-8Report Type:Periodic Company Report #WAES 0404USA02432
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430648-XReport Type:Periodic Company Report #WAES 0404USA02366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	
			Cipro	C				

Date:07/21/04ISR Number: 4430649-1Report Type:Periodic Company Report #WAES 0404USA02187
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	PO	

Professional
Company
Representative

Date:07/21/04ISR Number: 4430652-1Report Type:Periodic Company Report #WAES 0403USA01678
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
		Company Representative	Coumadin	C				

Date:07/21/04ISR Number: 4430653-3Report Type:Periodic Company Report #WAES 0403USA01694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional						
		Company Representative						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430654-5Report Type:Periodic Company Report #WAES 0403USA01662
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Enzyme Increased	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional	Bupivacaine Hcl	SS				

Date:07/21/04ISR Number: 4430656-9Report Type:Periodic Company Report #WAES 0403USA01595
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:07/21/04ISR Number: 4430657-0Report Type:Periodic Company Report #WAES 0401USA01790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyperkalaemia	Health	Tab Vioxx	PS		ORAL	SEE IMAGE	1 YR
		Professional Company Representative						

Date:07/21/04ISR Number: 4430659-4Report Type:Periodic Company Report #WAES 0404USA01684
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization -	Haemorrhage	Professional						

Initial or Prolonged	Company Representative	Lipitor	C
		Plavix	C
		Prevacid	C
		Singulair	C
		Aspirin	C
		Enalapril Maleate	C

Date:07/21/04ISR Number: 4430662-4Report Type:Periodic Company Report #WAES 0404USA01550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Prescribed Overdose	Health	Tab Vioxx	PS		ORAL	100	
Hospitalization -	Renal Failure Acute	Professional					MG/DAILY/PO	
Initial or Prolonged		Company Representative	Maxalt (Rizatriptan Benzoate)	C				

Date:07/21/04ISR Number: 4430664-8Report Type:Periodic Company Report #WAES 0404USA01555
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
	Oedema	Professional					MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4430666-1Report Type:Periodic Company Report #WAES 0404USA01474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	

Date:07/21/04ISR Number: 4430668-5Report Type:Periodic Company Report #WAES 0404USA01331
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Haemorrhage	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged			Celebrex	SS				
			Avapro	C				
			Glucophase	C				
			Humulin	C				
			Lasix (Furosemide)	C				
			Lipitor	C				
			Norvasc	C				
			Wellbutrin	C				
			Tramadol Hydrochloride	C				

Date:07/21/04ISR Number: 4430670-3Report Type:Periodic Company Report #WAES 0404USA01296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional	Aleve	C				
		Company Representative	Fosamax	C				

Date:07/21/04ISR Number: 4430672-7Report Type:Periodic Company Report #WAES 0404USA01190
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastroenteritis Viral	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Renal Failure Acute	Professional Company Representative						

Date:07/21/04ISR Number: 4430673-9Report Type:Periodic Company Report #WAES 0404USA01134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:07/21/04ISR Number: 4430674-0Report Type:Periodic Company Report #WAES 0404USA01066
Age:22 YR Gender: I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Renal Failure Acute	Health Professional Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 50 Mg	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430675-2Report Type:Periodic Company Report #WAES 0404USA01031
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hospitalisation	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430676-4Report Type:Periodic Company Report #WAES 0403USA01559
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Failure	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Other			Dyazide	C				

Date:07/21/04ISR Number: 4430685-5Report Type:Periodic Company Report #WAES 0403USA01457
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx Unk	PS		ORAL	PO	
			Coumadin	C				
			Furosemide	C				

Date:07/21/04ISR Number: 4430686-7Report Type:Periodic Company Report #WAES 0403USA01476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	1X/PO	1 DAY

Date:07/21/04ISR Number: 4430689-2Report Type:Periodic Company Report #WAES 0403USA01297
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypersensitivity	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Synthroid	C				
			Zestoretic	C				

Date:07/21/04ISR Number: 4430690-9Report Type:Periodic Company Report #WAES 0403USA01240
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Platelet Count Decreased	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430692-2Report Type:Periodic Company Report #WAES 0403USA01040
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4430693-4Report Type:Periodic Company Report #WAES 0403USA00035
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	

Date:07/21/04ISR Number: 4430694-6Report Type:Periodic Company Report #WAES 0403USA00012
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/04ISR Number: 4430695-8Report Type:Periodic Company Report #WAES 0402USA01691
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Other		Professional				
MG/DAILY/PO						
		Company Representative	Lidoderm	C		
			Premarin	C		
			Skelaxin	C		
			Zetia	C		

Date:07/21/04ISR Number: 4430696-XReport Type:Periodic Company Report #WAES 0402USA01693
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Perforation		Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged						
MG/BID/PO						

Date:07/21/04ISR Number: 4430697-1Report Type:Periodic Company Report #WAES 0402USA00545
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 12.5 Mg	PS		ORAL
12.5						
Initial or Prolonged	Perforation	Professional				
MG/DAILY/PO						
		Company Representative	Fosamax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430700-9Report Type:Periodic Company Report #WAES 0402USA00474
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/BID/PO	1 YR
Initial or Prolonged	Haemorrhage	Professional Company Representative	Motrin	C				

Date:07/21/04ISR Number: 4430702-2Report Type:Periodic Company Report #WAES 0402USA00417
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction	Health	Tab Vioxx	PS		ORAL	Unk	PO
	Drug Hypersensitivity	Professional Company Representative	Naprosyn	SS			Unk	
	Rash							
	Swelling							

Date:07/21/04ISR Number: 4430704-6Report Type:Periodic Company Report #WAES 0402USA00420
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional Company Representative	Tab Zocor	SS		ORAL	Unk	PO

Date:07/21/04ISR Number: 4430705-8Report Type:Periodic Company Report #WAES 0402USA00394
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Gastric Ulcer Haemorrhage	Health	Tab Vioxx Unk	PS		ORAL
25-50						
Hospitalization -		Professional				
MG/DAILY/PO						
Initial or Prolonged		Company	Zoloft	C		
Other		Representative				

Date:07/21/04ISR Number: 4430707-1Report Type:Periodic Company Report #WAES 0402USA00327
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hospitalisation	Health	Tab Vioxx 50 Mg	PS		ORAL
50						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company				
		Representative				

Date:07/21/04ISR Number: 4430709-5Report Type:Periodic Company Report #WAES 0401USA02225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancreatitis	Health	Tab Vioxx 25 Mg	PS		ORAL
PO						
	Upper Gastrointestinal	Professional				
	Haemorrhage	Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4430711-3Report Type:Periodic Company Report #WAES 0401USA02115
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	12.5 MG/DAILY/PO	

Date:07/21/04ISR Number: 4430712-5Report Type:Periodic Company Report #WAES 0401USA02105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	50 MG/1X/PO	

Date:07/21/04ISR Number: 4431619-XReport Type:Periodic Company Report #WAES0306USA00868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431620-6Report Type:Periodic Company Report #WAES0306USA00869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431621-8Report Type:Periodic Company Report #WAES0306USA00870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431622-XReport Type:Periodic Company Report #WAES 0306USA00871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431623-1Report Type:Periodic Company Report #WAES0306USA00872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431624-3Report Type:Periodic Company Report #WAES0306USA00873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4431625-5Report Type:Periodic Company Report #WAES0306USA00874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431626-7Report Type:Periodic Company Report #WAES0306USA00875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431627-9Report Type:Periodic Company Report #WAES0306USA00876
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431628-0Report Type:Periodic Company Report #WAES0306USA00877
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431629-2Report Type:Periodic Company Report #WAES 0402USA01672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/	

Initial or Prolonged	Haemorrhage	Professional					
DAILY/PO 3 MON							
		Company Representative					

Date:07/21/04ISR Number: 4431630-9Report Type:Periodic Company Report #WAES 0402USA01465
Age:75 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	[Therapy Unspecified]	C				

Date:07/21/04ISR Number: 4431631-0Report Type:Periodic Company Report #WAES 0402USA01305
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pancreatitis	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged		Professional						
			Herbs (Unspecified)	C				
Disability								

Date:07/21/04ISR Number: 4431632-2Report Type:Periodic Company Report #WAES 0402USA01315
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Celebrex Unk	SS				

Date:07/21/04ISR Number: 4431633-4Report Type:Periodic Company Report #WAES 0402USA01393
Age:39 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional Company Representative	[Therapy Unspecified]	C				

Date:07/21/04ISR Number: 4431634-6Report Type:Periodic Company Report #WAES 0402USA01129
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional Company Representative					MG/DAILY/PO	

Date:07/21/04ISR Number: 4431635-8Report Type:Periodic Company Report #WAES 0402USA00721
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Tab Vioxx 50 Mg	PS		ORAL	PO; 50	

	Back Pain	Health				
MG/BID/PO						
	Condyloma Acuminatum	Professional	Tab Vioxx 25 Mg	SS		ORAL
25 MG/BID/PO						
	Drug Ineffective		Motrin	C		
	Heart Rate Increased		Neuroton	C		
	Hypoaesthesia		Risperdal	C		
	Overdose		Vicodin Tablets	C		
	Post-Traumatic Stress		Zyprexa	C		
	Disorder		Glucosamine	C		
	Sensory Loss		Lithium Acetate	C		

Date:07/21/04ISR Number: 4431636-XReport Type:Periodic Company Report #WAES 0401USA01915
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Murmur	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged	Gastrointestinal	Professional				
MG/DAILY/PO						
	Haemorrhage	Company	Azmacort	C		
		Representative	Darvocet-N	C		
			Fosamax	C		
			Klonopin	C		
			Levoxyl	C		
			Singulair	C		
			Volmax	C		
			Xanax	C		
			Zoloft	C		
			Cyclophosphamide	C		

Famotidine	C	
Tamoxifen Citrate	C	
Triamterene	C	

Date:07/21/04ISR Number: 4431637-1Report Type:Periodic Company Report #WAES 0401USA01824
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4431638-3Report Type:Periodic Company Report #WAES 0401USA01813
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Murmur	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Gastrointestinal Haemorrhage	Company Representative	Ultram	C				
	Gastrooesophageal Reflux Disease		Mineral Oil	C				
			Triamcinolone	C				

Date:07/21/04ISR Number: 4431639-5Report Type:Periodic Company Report #WAES 0404USA00455
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4431640-1Report Type:Periodic Company Report #WAES 0404USA00232
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
		Health						
		Professional	Mevacor	C			MG/DAILY/PO	
			Prinivil	C				
			Synthroid	C				
			Aspirin	C				
			Atenolol	C				
			Folic Acid	C				
			Iron	C				
			Niacin	C				
			Vitamin E	C				
			Zinc Sulfate	C				

Date:07/21/04ISR Number: 4431641-3Report Type:Periodic Company Report #WAES 0404USA00133
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional
		Company

Representative

Product	Role	Manufacturer	Route	Dose	Duration
Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/DAILY/PO	
Fosamax	C				

Date:07/21/04ISR Number: 4431642-5Report Type:Periodic Company Report #WAES 0404USA00026
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4431643-7Report Type:Periodic Company Report #WAES 0403USA02212
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG/PRN/PO	
		Company Representative	Coumadin	C				
			Plavix	C				
			Protonix	C				
			Heparin	C				

Date:07/21/04ISR Number: 4431644-9Report Type:Periodic Company Report #WAES 0403USA02075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
	Perforation	Professional				
MG/DAILY/PO						
		Company Representative	Aspirin Unk	SS		

Date:07/21/04ISR Number: 4431645-0Report Type:Periodic Company Report #WAES 0403USA01992
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abdominal Pain	Consumer	Tab Vioxx 25 Mg	PS		ORAL
SEE IMAGE						
Hospitalization - Initial or Prolonged	Gastric Haemorrhage					
	Gastritis					

Date:07/21/04ISR Number: 4431646-2Report Type:Periodic Company Report #WAES 0403USA01997
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hepatic Enzyme Increased	Health	Tab Vioxx Unk	PS		ORAL
PO						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4431647-4Report Type:Periodic Company Report #WAES 0403USA01925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4431648-6Report Type:Periodic Company Report #WAES 0403USA01897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Company	Tab Vioxx Unk	PS		ORAL	PO	
		Representative Other						

Date:07/21/04ISR Number: 4433017-1Report Type:Periodic Company Report #WAES0306YSA00819
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433018-3Report Type:Periodic Company Report #WAES0306USA00820
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433019-5Report Type:Periodic Company Report #WAES0306USA00821
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433020-1Report Type:Periodic Company Report #WAES0306USA00822
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433021-3Report Type:Periodic Company Report #WAES0306USA00823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433022-5Report Type:Periodic Company Report #WAES0306USA00824
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK, PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4433023-7Report Type:Periodic Company Report #WAES0306USA00825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK, PO	

Date:07/21/04ISR Number: 4433024-9Report Type:Periodic Company Report #WAES0306USA00826
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK, PO	

Date:07/21/04ISR Number: 4433025-0Report Type:Periodic Company Report #WAES0306USA00827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433026-2Report Type:Periodic Company Report #WAES0306USA00828
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	UNK, UNK; PO	

Date:07/21/04ISR Number: 4433027-4Report Type:Periodic Company Report #WAES 0308USA02365
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:07/21/04ISR Number: 4433028-6Report Type:Periodic Company Report #WAES 0308USA02120
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative						

Date:07/21/04ISR Number: 4433029-8Report Type:Periodic Company Report #WAES 0308USA02078
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						

Date:07/21/04ISR Number: 4433030-4Report Type:Periodic Company Report #WAES 0308USA01835
Age:37 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Alanine Aminotransferase Increased

	Aspartate Aminotransferase Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO; 25 MG/DAILY/PO

Date:07/21/04ISR Number: 4433031-6Report Type:Periodic Company Report #WAES 0308USA01771
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Nephritis Interstitial	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Hospitalization - Initial or Prolonged	Renal Failure Acute	Professional					
Other		Company Representative	Altace	C			
			Darvocet-N	C			
			Humalog	C			
			Ciprofloxacin	C			

Date:07/21/04ISR Number: 4433032-8Report Type:Periodic Company Report #WAES 0308USA01569
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO
Disability		Professional					
Other		Company Representative	Arava	C			
			Elavil	C			
			Norvasc	C			
			Synthroid	C			

Date:07/21/04ISR Number: 4433033-XReport Type:Periodic Company Report #WAES 0308USA01257
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative						

Date:07/21/04ISR Number: 4433034-1Report Type:Periodic Company Report #WAES 0308USA00867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Reaction	Health	Tab Vioxx	PS		ORAL	PO	
Hospitalization - Initial or Prolonged		Professional Company Representative						

Date:07/21/04ISR Number: 4433035-3Report Type:Periodic Company Report #WAES 0308USA00748
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Other		Professional Company Representative	Fosamax	C				
			Levoxyl	C				
			Lipitor	C				

Neurontin	C
Prilosec	C
Prozac	C
Toprol Xl Tablets	C

Date:07/21/04ISR Number: 4433036-5Report Type:Periodic Company Report #WAES 0308USA00713
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4433037-7Report Type:Periodic Company Report #WAES 0306USA01201
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4433038-9Report Type:Periodic Company Report #WAES 0306USA00902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4433039-0Report Type:Periodic Company Report #WAES 0308USA00677
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative						

Date:07/21/04ISR Number: 4433040-7Report Type:Periodic Company Report #WAES 0308USA00477
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peptic Ulcer	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Aciphex	C				
			Diovan	C				
			Glucophage	C				
			Paxil	C				
			Pravachol	C				
			Ritalin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4433041-9Report Type:Periodic Company Report #WAES 0308USA00224
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Health Professional	Tab Vioxx 25mg	PS		ORAL	25 MG/DAILY/PO	
		Company Representative	Tylenol With Codeine	C				

Date:07/21/04ISR Number: 4433042-0Report Type:Periodic Company Report #WAES 0380USA00160
Age:18 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional	Tab Vioxx Unk	PS		OPHTHALMIC	50 MG/DAILY/PO	5 DAY
		Company Representative						

Date:07/21/04ISR Number: 4433043-2Report Type:Periodic Company Report #WAES 0307USA03428
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	PO	
	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4433044-4Report Type:Periodic Company Report #WAES 030IUSA00036
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional	Coumadin	C		
		Company	Naprosyn	C		
		Representative				

Date:07/21/04ISR Number: 4433045-6Report Type:Periodic Company Report #WAES 0307USA03594
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspepsia	Consumer	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged						
MG/DAILY/PO						
			Lipitor	C		
			Prilosec	C		
			Synthroid	C		
			Bisoprolol Fumarate			
			(+) Hydrochl	C		
			Gemfibrozil	C		

Date:07/21/04ISR Number: 4433046-8Report Type:Periodic Company Report #WAES 0306USA01191
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure	Health	Tab Vioxx 25mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
		Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4433047-XReport Type:Periodic Company Report #WAES0307USA01957
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/1X/PO	
		Professional	Tab Vioxx 25 Mg	SS		ORAL	25 MG/ PRN/	
			Altace	C				

Date:07/21/04ISR Number: 4433048-1Report Type:Periodic Company Report #WAES0307USA01800
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	PO	
Hospitalization - Initial or Prolonged Disability	Haemorrhage	Professional Company Representative	Coumadin	C				

Date:07/21/04ISR Number: 4433049-3Report Type:Periodic Company Report #WAES0307USA01107
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Nephritis Interstitial	Health	Tab Vioxx 50 Mg	PS		ORAL	50 MG/ DAILY/ PO	
		Professional Company Representative	Nonsteroidal Anti-Inflammatory	C				

Date:07/21/04ISR Number: 4433050-XReport Type:Periodic Company Report #WAES0307USA00159
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL
25 MG/ DAILY/						
Initial or Prolonged	Gastrointestinal	Professional				
PO						
	Haemorrhage	Company	Plavix	C		
		Representative	Robaxin	C		
			Tylenol	C		
			Tramadol			
			Hydrochloride	C		

Date:07/21/04ISR Number: 4433051-1Report Type:Periodic Company Report #WAES0307USA00133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional				
		Company				
		Representative				

Date:07/21/04ISR Number: 4433052-3Report Type:Periodic Company Report #WAES0307USA00008
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angioneurotic Oedema	Health	Tab Vioxx 25 Tablet	PS		ORAL
25 TABLET/						
		Professional				
DAILY/ PO						
		Company	Tab Vioxx 25 Tablet	SS		ORAL
25 TABLET/						
		Representative				
DAILY/ PO						
			Allegra	C		

				Flonase	C		

Date:07/21/04ISR Number: 4433053-5Report Type:Periodic Company Report #WAES0306USA02844
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Zocor	C				

Date:07/21/04ISR Number: 4433054-7Report Type:Periodic Company Report #WAES 0306USA02625
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Health	Tab Vioxx Unk	PS		ORAL	PO	
		Professional	Tab Remifemin	SS		ORAL	BID/ PO	
			Zoloft	SS				
			Vitamins	SS		ORAL	PO	
			Ascorbic Acid	SS		ORAL	PO	
			Herbs	SS				

Date:07/21/04ISR Number: 4433055-9Report Type:Periodic Company Report #WAES0306USA02588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx Unk	PS		ORAL	DAILY/ PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4433056-0Report Type:Periodic Company Report #WAES0306USA02280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/ DAILY/ PO	

Date:07/21/04ISR Number: 4434547-9Report Type:Periodic Company Report #WAES 0311USA02620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/04ISR Number: 4434548-0Report Type:Periodic Company Report #WAES 0311USA02424
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional

		Company Representative				
			Product	Role	Manufacturer	Route
Dose	Duration					
			Tab Vioxx	PS		ORAL
PO						

Date:07/21/04ISR Number: 4434549-2Report Type:Periodic Company Report #WAES 0311USA02238
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Haemorrhage	Professional				
MG/DAILY/PO						
Initial or Prolonged		Company Representative				

Date:07/21/04ISR Number: 4434550-9Report Type:Periodic Company Report #WAES 0311USA02264
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Hepatitis	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Other		Professional				
MG/DAILY/PO						
		Company Representative	Levoxyl	C		
			Motrin	C		
			Teveten (Eprosartan)	C		
			Amitriptyline Hydrochloride	C		
			Atenolol	C		

Date:07/21/04ISR Number: 4434551-0Report Type:Periodic Company Report #WAES 0309USA02731
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL PO

Date:07/21/04ISR Number: 4434552-2Report Type:Periodic Company Report #WAES 0309USA02687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Tab Vioxx	PS		ORAL PO		
			Celebrex	SS				

Date:07/21/04ISR Number: 4434553-4Report Type:Periodic Company Report #WAES 0309USA01465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL PO		
			Levoxyl	C				
			Premarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434554-6Report Type:Periodic Company Report #WAES 0309USA01494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Corneal Disorder	Health	Tab Vioxx	PS		ORAL	PO	
	Stevens-Johnson Syndrome	Professional						
	Thermal Burn	Company Representative						

Date:07/21/04ISR Number: 4434555-8Report Type:Periodic Company Report #WAES 0309USA01292
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastrointestinal	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25	
	Haemorrhage						MG/DAILY/PO	
			Aygestin	C				
			Premarin	C				
			Pravastatin Sodium	C				

Date:07/21/04ISR Number: 4434556-XReport Type:Periodic Company Report #WAES 0311USA02160
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Enzyme Increased	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Advair	C				
			Prinivil	C				
			Protonix	C				
			Zelnorm	C				
			Doxepin Hydrochloride	C				

Date:07/21/04ISR Number: 4434557-1Report Type:Periodic Company Report #WAES 0311USA01996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pancreatitis	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434558-3Report Type:Periodic Company Report #WAES 0311USA02016
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional Company Representative	Fosamax	C				
Disability			Hydrodiuril	C				
Other			Lipitpr	C				
			Neurontin	C				
			Protonix	C				
			Synthroid	C				
			Tylenol	C				
			Aspirin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434559-5Report Type:Periodic Company Report #WAES 0311USA01878
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Overdose	Professional					MG/DAILY/PO	
		Company Representative	Tylenol	SS				

Date:07/21/04ISR Number: 4434560-1Report Type:Periodic Company Report #WAES 0311USA01814
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company Representative	Nexium	C				
			Synthroid	C				
			Xanax	C				

Date:07/21/04ISR Number: 4434561-3Report Type:Periodic Company Report #WAES 0311USA01832
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Medication Error	Health	Tab Vioxx 50 Mg	PS		ORAL	PO	
Initial or Prolonged	Renal Failure	Professional	Hydralazine	C				
		Company Representative	Metoprolol	C				

Date:07/21/04ISR Number: 4434562-5Report Type:Periodic Company Report #WAES 0311USA01781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Pancreatitis	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative				

Date:07/21/04ISR Number: 4434563-7Report Type:Periodic Company Report #WAES 0311USA01412
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -		Professional				
MG/DAILY/PO						
Initial or Prolonged		Company Representative	Prevacid	C		
			Prednison	C		
			Trazodone Hydrochloride	C		

Date:07/21/04ISR Number: 4434564-9Report Type:Periodic Company Report #WAES 0311USA01040
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Renal Failure	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Professional Company Representative	Bextra	C		
			Nonsteroidal Anti-Inflammatory	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434565-0Report Type:Periodic Company Report #WAES 0311USA00868
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4434566-2Report Type:Periodic Company Report #WAES 0311USA00506
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional Company Representative					MG/DAILY/PO	

Date:07/21/04ISR Number: 4434567-4Report Type:Periodic Company Report #WAES 0311USA00493
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer	Health	Tab Vioxx	PS		ORAL	PO	
		Professional Company Representative	Fioricet With Codeine	C				
			Lipitor	C				
			Vitamins (Unspecified)	C				

Date:07/21/04ISR Number: 4434568-6Report Type:Periodic Company Report #WAES 0310USA03392
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Hepatitis	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Professional				
MG/DAILY/PO						
Other		Company	Quinineso4	SS		
		Representative	Premarin	C		
			Synthroid	C		
			Prednisone	C		

Date:07/21/04ISR Number: 4434569-8Report Type:Periodic Company Report #WAES 0311USA00006
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL
25						
		Professional				
MG/DAILY/PO						
		Company	Aleve	SS		
Q2H						
		Representative				

Date:07/21/04ISR Number: 4434570-4Report Type:Periodic Company Report #WAES 0310USA03325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Haemorrhage	Professional				
		Company				
		Representative				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434571-6Report Type:Periodic Company Report #WAES 0310USA03294
Age:65 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/04ISR Number: 4434572-8Report Type:Periodic Company Report #WAES 0310USA02762
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Professional Company Representative	Lotensin	SS				

Date:07/21/04ISR Number: 4434573-XReport Type:Periodic Company Report #WAES 0310USA02720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure Acute	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Initial or Prolonged		Professional Company Representative						

Date:07/21/04ISR Number: 4434574-1Report Type:Periodic Company Report #WAES 0310USA02662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL	PO	

Professional
Company
Representative

Date:07/21/04ISR Number: 4434575-3Report Type:Periodic Company Report #WAES 0310USA02621
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Gastrointestinal	Professional					MG/DAILY/PO	
	Haemorrhage	Company Representative						

Date:07/21/04ISR Number: 4434576-5Report Type:Periodic Company Report #WAES 0310USA02555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Haemorrhage	Professional					MG/DAILY/PO	
	Pancreatitis	Company Representative						

Date:07/21/04ISR Number: 4434577-7Report Type:Periodic Company Report #WAES 0310USA02377
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatitis	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434578-9Report Type:Periodic Company Report #WAES 0310USA02338
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/HS/PO	
Initial or Prolonged Disability Other	Herpes Simplex Hypersensitivity	Professional	Benadryl	C				
			Clarinex	C				
			Hydrodiuril	C				
			Prevacid	C				
			Singulair	C				
			Tagamet	C				
			Allergenic Extract Immunotherapy (Unspecified)	C				
			Potassium Chloride	C				
			Zinc (Unspecified)	C				

Date:07/21/04ISR Number: 4434579-0Report Type:Periodic Company Report #WAES 0310USA02274
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434580-7Report Type:Periodic Company Report #WAES 0310USA02034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434581-9Report Type:Periodic Company Report #WAES 0310USA01862
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stevens-Johnson Syndrome	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:07/21/04ISR Number: 4434582-0Report Type:Periodic Company Report #WAES 0310USA01853
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/PO	

Date:07/21/04ISR Number: 4434583-2Report Type:Periodic Company Report #WAES 0310USA01832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancytopenia	Health Professional Company Representative	Tab Vioxx 50 Mg	PS		ORAL	50 MG/DAILY/PO	

Date:07/21/04ISR Number: 4434584-4Report Type:Periodic Company Report #WAES 0310USA01742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Haemorrhage	Health Professional Company Representative	Tab Vioxx 50 Mg Antimicrobial (Unspecified)	PS C		ORAL	50 MG/DAILY/PO	

Date:07/21/04ISR Number: 4434585-6Report Type:Periodic Company Report #WAES 0310USA01593
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged		Professional	Tab Vioxx 25 Mg	SS		ORAL
25						
		Company				
MG/DAILY/PO						
		Representative	Levoxyl	C		
			Proventil	C		
			Prozac	C		

Date:07/21/04ISR Number: 4434586-8Report Type:Periodic Company Report #WAES 0310USA01583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension	Health	Tab Vioxx 12.5 Mg	PS		ORAL
PO						
Initial or Prolonged		Professional				
		Company				
		Representative				

Date:07/21/04ISR Number: 4434587-XReport Type:Periodic Company Report #WAES 0310USA01351
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pancreatitis	Health	Tab Vioxx	PS		ORAL
PO						
		Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434588-1Report Type:Periodic Company Report #WAES 0310USA01211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4434589-3Report Type:Periodic Company Report #WAES 0310USA01086
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Tab Vioxx	PS		ORAL	PO	
		Company Representative						

Date:07/21/04ISR Number: 4434590-XReport Type:Periodic Company Report #WAES 0310USA01071
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL	12.5	
	Face Oedema	Health					MG/DAILY/PO	
	Hypertension	Professional Company Representative	Monopril	SS				
			Wellbutrin	C				
			Xanax	C				

Date:07/21/04ISR Number: 4434591-1Report Type:Periodic Company Report #WAES 0310USA01013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	

Initial or Prolonged	Haemorrhage	Professional Company Representative					

Date:07/21/04ISR Number: 4434592-3Report Type:Periodic Company Report #WAES 0310USA00940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx 25 Mg	PS		ORAL	25 MG/PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative						

Date:07/21/04ISR Number: 4434593-5Report Type:Periodic Company Report #WAES 0310USA00917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal	Health	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Haemorrhage	Professional Company Representative	Warfarin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434594-7Report Type:Periodic Company Report #WAES 0310USA00847
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Crisis	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434595-9Report Type:Periodic Company Report #WAES 0310USA00119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434596-0Report Type:Periodic Company Report #WAES 0310USA00111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434597-2Report Type:Periodic Company Report #WAES 0310USA00112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Tab Vioxx	PS		ORAL	PO	
	Renal Failure							

Date:07/21/04ISR Number: 4434598-4Report Type:Periodic Company Report #WAES 0307USA03187
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 25 MG, DAILY, Initial or Prolonged PO	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx 25 Mg	PS	Therapy Unspecified	ORAL C

Date:07/21/04ISR Number: 4434599-6Report Type:Periodic Company Report #WAES 0307USA03063
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other PO	Renal Failure	Health Professional Company Representative	Tab Vioxx 25 Mg	PS		ORAL		

Date:07/21/04ISR Number: 4434600-XReport Type:Periodic Company Report #WAES 0307USA02790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other PO	Renal Failure Acute	Consumer Company Representative	Tab Vioxx 25 Mg	PS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434601-1Report Type:Periodic Company Report #WAES 0307USA02634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - PO	Renal Failure	Health	Tab Vioxx 25 Mg	PS		ORAL		
Initial or Prolonged		Professional Company Representative						

Date:07/21/04ISR Number: 4434602-3Report Type:Periodic Company Report #WAES 0307USA02494
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer Haemorrhage	Consumer	Tab Vioxx 50 Mg	PS		ORAL	50 MG, DAILY,	
Hospitalization - PO								
Initial or Prolonged			Captopril	C				
Disability			Evista	C				
			Glucotrol	C				
			Zocor	C				
			Clonidine	C				
			Verapamil	C				

Date:07/21/04ISR Number: 4434603-5Report Type:Periodic Company Report #WAES 0307USA02257
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx 12.5 Mg	PS		ORAL	12.5 MG,	
		Professional						
DAILY, PO								
		Company Representative						

Date:07/21/04ISR Number: 4434604-7Report Type:Periodic Company Report #WAES 0307USA01976
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nephritis Interstitial	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
		Company Representative	Allegra	C				
			Deconamine	C				
			Zestril	C				
			Zocor	C				
			Potassium Chloride	C				

Date:07/21/04ISR Number: 4434605-9Report Type:Periodic Company Report #WAES 0307USA01974
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal	Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY, PO	
Hospitalization - Initial or Prolonged	Haemorrhage							
Other		Company Representative	Lortab	C				
			Percocet	C				
			Skelaxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434606-0Report Type:Periodic Company Report #WAES 0307USA01914
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Health Professional Company Representative	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434607-2Report Type:Periodic Company Report #WAES 0306USA00893
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434608-4Report Type:Periodic Company Report #WAES 0306USA00894
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Injury	Consumer	Tab Vioxx Unk	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434609-6Report Type:Periodic Company Report #WAES 0306USA00895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury Metrorrhagia	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434610-2Report Type:Periodic Company Report #WAES 0306USA00896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Injury							

Date:07/21/04ISR Number: 4434611-4Report Type:Periodic Company Report #WAES 0306USA00897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx Unk	PS		ORAL	DAILY/PO	

Date:07/21/04ISR Number: 4434612-6Report Type:Periodic Company Report #WAES 0306USA00898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434613-8Report Type:Periodic Company Report #WAES 0306USA00899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434614-XReport Type:Periodic Company Report #WAES 0306USA00900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434615-1Report Type:Periodic Company Report #WAES 0306USA00866
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx Unk	PS		ORAL	PO	
	Injury							

Date:07/21/04ISR Number: 4434616-3Report Type:Periodic Company Report #WAES 0306USA00867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Polytraumatism	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434617-5Report Type:Periodic Company Report #WAES 0306USA00915
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Tab Vioxx	PS		ORAL	PO	
	Injury							

Date:07/21/04ISR Number: 4434618-7Report Type:Periodic Company Report #WAES 0306USA00917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability Polytraumatism Consumer Tab Vioxx PS ORAL
PO

Date:07/21/04ISR Number: 4434619-9Report Type:Periodic Company Report #WAES 0306USA00926
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Polytraumatism Consumer Tab Vioxx PS ORAL
PO

Date:07/21/04ISR Number: 4434620-5Report Type:Periodic Company Report #WAES 0306USA00886
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Polytraumatism Consumer Tab Vioxx PS ORAL
PO

Date:07/21/04ISR Number: 4434621-7Report Type:Periodic Company Report #WAES 0306USA00887
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Disability Injury Consumer Tab Vioxx PS ORAL
PO

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/04ISR Number: 4434622-9Report Type:Periodic Company Report #WAES 0306USA00888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434623-0Report Type:Periodic Company Report #WAES 0306USA00889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434624-2Report Type:Periodic Company Report #WAES 0306USA00890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434625-4Report Type:Periodic Company Report #WAES 0306USA00891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/21/04ISR Number: 4434626-6Report Type:Periodic Company Report #WAES 0306USA00892
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury	Consumer	Tab Vioxx	PS		ORAL	PO	

Date:07/22/04ISR Number: 4404103-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Anaemia
	Angina Unstable
	Azotaemia
	Bronchitis
	Cardiac Failure
	Congestive
	Carotid Artery Stenosis
	Central Line Infection
	Cerebral Artery Occlusion
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Restenosis
	Decreased Appetite
	Diarrhoea
	Dressler'S Syndrome
	Faecal Occult Blood
	Positive
	Faeces Discoloured
	Gastrointestinal
	Haemorrhage

		Hyperbilirubinaemia Hyperlipidaemia Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
		Peripheral Vascular	Professional	Allopurinol	C		
UNKNOWN							
		Disorder		Aspirin	C		
UNKNOWN							
		Respiratory Failure		Aricept	C		
UNKNOWN							
		Skin Candida		Glucotrol	C		
UNKNOWN							
		Subclavian Artery Stenosis					

Date:07/22/04ISR Number: 4404652-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
319 DAY						
Initial or Prolonged	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
319 DAY						
Disability	Cyst		Xanax	C		
UNKNOWN						
Other	Diabetes Mellitus		Valium	C		
UNKNOWN						
	Drug Ineffective		Diovan	C		
UNKNOWN						
	Hypertension		Ibuprofen	C		
UNKNOWN						
	Lung Disorder		Humulin N	C		
UNKNOWN						
	Myocardial Infarction		Synthroid	C		
UNKNOWN						
	Non-Cardiac Chest Pain Oedema Peripheral Osteoarthritis					

Date:07/22/04ISR Number: 4404654-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Arthropathy	Professional	Premarin	C			UNKNOWN	
Other	Atrial Fibrillation		Estratab	C			UNKNOWN	
	Cardiac Aneurysm		Menest	C			UNKNOWN	
	Corneal Deposits		Armour Thyroid Tablets	C			UNKNOWN	
	Haematuria							
	Haemorrhage		Trazodone Hydrochloride	C			UNKNOWN	
	Hypertension							
	Hypertensive Crisis		Garlic Extract	C			UNKNOWN	
	Jaw Disorder		Synthroid	C			UNKNOWN	
	Musculoskeletal Disorder		Methotrexate	C			UNKNOWN	
	Oedema Peripheral							
	Pain In Extremity							
	Paraesthesia							
	Renal Cyst							
	Transient Ischaemic Attack							

Date:07/22/04ISR Number: 4404667-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Adrenal Mass
	Angina Unstable

Antinuclear Antibody
Positive
Aortic Valve Incompetence
Asthenia
Back Pain
Bacteriuria
Bronchitis Acute
Cardiac Failure
Congestive
Cataract
Cerebral Ischaemia
Conjunctivitis
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Cystitis
Deafness
Depression
Dermatitis
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinal Oedema
Diabetic Retinopathy
Drug Intolerance
Dyspnoea
Escherichia Urinary Tract
Infection
Fall
Fatigue
Gastrooesophageal Reflux
Disease
Headache
Hearing Impaired
Hypertension
Hypoglycaemia
Injury
Lacunar Infarction
Lipids Increased
Lung Neoplasm
Maculopathy
Mass
Metabolic Alkalosis
Metastases To Lung
Mitral Valve Incompetence
Nocturia
Pleural Effusion

Proteinuria
Pulmonary Hypertension
Pulmonary Mass
Radius Fracture
Rectal Haemorrhage
Renal Cyst
Renal Failure Chronic
Respiratory Failure
Road Traffic Accident
Scoliosis
Seasonal Allergy
Sinusitis
Skin Lesion
Spinal Column Stenosis

		Stasis Dermatitis					
		Stress					
		Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve		Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence		Darvocet-N	C		
UNKNOWN							
		Vaginal Infection		Amitriptyline			
		Ventricular Extrasystoles		Hydrochloride	C		
UNKNOWN							
		Ventricular Hypertrophy		Aspirin	C		
UNKNOWN							
		Ventricular Hypokinesia		Atenolol	C		
UNKNOWN							
		Weight Increased		Pepcid	C		
UNKNOWN							
		Wrist Fracture		Lasix (Furosemide)	C		
UNKNOWN							
				Hydrodiuril	C		
UNKNOWN							
				Vitamins			
				(Unspecified)	C		
UNKNOWN							
				Dyrenium	C		
UNKNOWN							
				Insulin, Biphasic			
				Isophane [Injection]	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Alupent	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Potassium			
				(Unspecified)	C		
UNKNOWN							

Date:07/22/04ISR Number: 4404670-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper

Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Anxiety
	Atrial Septal Defect
	Bradycardia
	Breast Pain
	Cardiac Aneurysm
	Cardiac Failure
	Congestive
	Cellulitis
	Cerebral Infarction
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Diverticulum
	Drug Dependence
	Dyspnoea
	Emotional Distress
	Haemorrhoids
	Headache
	Hypertrophy Breast
	Injury
	Intermittent Claudication
	Intracranial Aneurysm
	Lacunar Infarction
	Major Depression
	Myocardial Infarction
	Oedema Peripheral
	Pain

		Pollakiuria					
		Spinal Osteoarthritis					
		Suicidal Ideation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Vicodin Tablets	C		
UNKNOWN							
		Varices Oesophageal		Norvasc	C		
UNKNOWN							
		Weight Increased		Aspirin	C		
UNKNOWN		668 DAY					
				Monopril	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN		96 DAY					
				Coumadin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							

Date:07/22/04ISR Number: 4404673-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Affective Disorder		Yasmin	SS		
UNKNOWN	14 DAY					
Disability	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
	Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Sandimmun	C		
UNKNOWN						
	Gastritis		Sandimmun	C		
UNKNOWN						

	Heart Rate Irregular	Prelone Syrup	C
UNKNOWN			
	Hot Flush	Prednisone	C
UNKNOWN			
	Hypochromic Anaemia	Prelone Syrup	C
UNKNOWN			
	Insomnia	Hormonal	
	Intracranial Venous Sinus	Contraceptives	
	Thrombosis	(Unspecified)	C
INTRAMUSCULAR			
	Joint Effusion	Sandimmun	C
UNKNOWN			
	Nausea		
	Pharyngolaryngeal Pain		
	Rash		
	Sinus Tachycardia		
	Subarachnoid Haemorrhage		
	Uterine Leiomyoma		
	Vomiting		

Date:07/22/04ISR Number: 4404675-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01836
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Congestive					

Date:07/22/04ISR Number: 4404676-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02740
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
Disability	Asthma
	Back Pain

		Dyskinesia					
		Hyperprolactinaemia					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL
18	DAY						
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
18	DAY						
		Pain		Vicodin Tablets	C		
UNKNOWN							
		Swelling		Albuterol	C		
UNKNOWN							
				Aerobid	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							

Date:07/22/04ISR Number: 4404679-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Costochondritis		[Composition			
		Depression		Unspecified]	C		
UNKNOWN							
		Diabetes Mellitus		Baycol	C		
UNKNOWN							
		Inadequate Control		Actos	C		
UNKNOWN							
		Dizziness					
		Drug Hypersensitivity					
		Drug Ineffective					
		Emotional Distress					
		Fatigue					
		General Physical Health					
		Deterioration					
		Hypertension					

Insomnia
Macular Oedema
Muscle Spasms
Myalgia
Neuritis
Neuropathy Peripheral
Oedema Peripheral
Pain
Peripheral Vascular
Disorder
Restless Legs Syndrome
Retinopathy
Road Traffic Accident
Serum Ferritin Decreased
Tachycardia

Date:07/22/04ISR Number: 4404680-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
	Anxiety
	Back Pain
	Cardiomyopathy
	Cerebrovascular Accident

		Depression					
		Emotional Distress					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nerve Graft		Vicodin Tablets	C		
UNKNOWN							
		Neuropathy		Soma	C		
UNKNOWN							
		Sleep Disorder		Klonopin	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Effexor Xr	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Remeron	C		
UNKNOWN							
				Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Risperdal	C		
UNKNOWN							

Date:07/22/04ISR Number: 4404682-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02547
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Atrial Fibrillation		Tylenol With Codeine			
	Cerebral Haemorrhage		#3	C		
UNKNOWN						
	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						

	Convulsion	Aspirin	C
UNKNOWN			
	Depression	Aspirin	C
UNKNOWN			
	Dyspepsia	Aspirin	C
UNKNOWN			
	Gout	Digoxin	C
UNKNOWN			
	Hypokalaemia	Lasix (Furosemide)	C
UNKNOWN			
	Injury	Lasix (Furosemide)	C
UNKNOWN			
	Stress	Coumadin	C
UNKNOWN			
		Magnesium (Unspecified)	C
UNKNOWN			
		Methotrexate	C
UNKNOWN			
		Protonix	C
UNKNOWN			
		Dilantin	C
UNKNOWN			
		K-Dur	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Propafenone Hydrochloride	C
UNKNOWN			

Date:07/22/04ISR Number: 4404685-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01242
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN	Thrombosis		Lotrel	C				
UNKNOWN			Coumadin	C				
UNKNOWN			Zostrix	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/04ISR Number: 4404944-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anaemia		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Anal Fissure		Norvasc	C			UNKNOWN	
	Anxiety		Celebrex	C			UNKNOWN	
	Arthralgia		Clonidine	C			UNKNOWN	
	Atherosclerosis		Prozac	C			UNKNOWN	
	Blindness		Flonase	C			UNKNOWN	
	Blindness Transient		Glucotrol	C			UNKNOWN	
	Blood Creatine		Avandia	C			UNKNOWN	
	Phosphokinase Mb		Hyzaar	C		ORAL		
	Increased		Imdur	C			UNKNOWN	
	Blood Urine Present		Claritin	C			UNKNOWN	
	Cervical Spinal Stenosis		Glucophage	C			UNKNOWN	
	Chest Pain		Methocarbamol	C			UNKNOWN	
	Coronary Artery		Glyset	C			UNKNOWN	
	Atherosclerosis		Nitroglycerin	C			SUBLINGUAL	
	Diabetic Neuropathy							
	Difficulty In Walking							
	Dizziness							
	Emotional Distress							
	Fall							
	Gastrointestinal Haemorrhage							
	Gastrooesophageal Reflux Disease							
	Haematochezia							
	Haemoptysis							
	Loss Of Consciousness							

Myocardial Ischaemia
Pleuritic Pain
Pneumonia
Proctalgia
Prostatitis
Rectal Haemorrhage
Stress
Syncope

Date:07/22/04ISR Number: 4404953-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00179
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Aspirin	SS		ORAL		
	Melaena		Clopidogrel Bisulfate	SS		ORAL		
	Oesophagitis		Alfuzosin Hydrochloride	C		ORAL		
			Senna	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lactulose	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/04ISR Number: 4404955-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00202
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leukopenia		Vioxx	PS	Merck & Co., Inc	ORAL	36	DAY
	Neutropenia		Citalopram	C		ORAL		
			Pantoprazole	C		ORAL		
			Prednisolone Acetate	C		OPHTHALMIC		

Date:07/22/04ISR Number: 4404957-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0407CHE00023
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/22/04ISR Number: 4404960-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Tylenol	C			UNKNOWN	
Disability	Bradycardia		Aspirin	C			UNKNOWN	
	Cardiac Failure		Premarin	C			UNKNOWN	
	Chest Pain		Lasix (Furosemide Sodium)	C			UNKNOWN	
	Feeling Abnormal							
	Transient Ischaemic Attack		Lasix (Furosemide Sodium)	C			UNKNOWN	
			Avalide	C			UNKNOWN	
			Motrin	C			UNKNOWN	

Naproxen C
UNKNOWN

Date:07/22/04ISR Number: 4404965-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00125
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged			Vitamins (Unspecified)	C				
UNKNOWN								

Date:07/22/04ISR Number: 4404966-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Aortic Valve Sclerosis
Disability	Cerebrovascular Accident
Other	Delusion
	Depression
	Dizziness
	Fatigue
	Feeling Abnormal
	Glucose Tolerance
	Impaired
	Hallucination
	Hernia
	Hyperlipidaemia
	Hypertension

		Insomnia					
		Male Sexual Dysfunction					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nocturia		Vioxx	PS	Merck & Co., Inc	ORAL
585 DAY							
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
585 DAY							
		Panic Attack		Lorcet 10/650	C		
UNKNOWN			283 DAY				
		Periarthritis		Hydrocodone			
		Somnolence		Bitartrate	C		
UNKNOWN			201 DAY				
		Varicose Vein		Ambien	C		
UNKNOWN							
		Ventricular Hypertrophy		Ibuprofen	C		
UNKNOWN							
				Cozaar	C		
UNKNOWN							

Date:07/22/04ISR Number: 4404975-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01289
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/22/04ISR Number: 4404981-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Nephritis Interstitial		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Disability	Renal Failure Chronic		Acetaminophen	C		
UNKNOWN						
Other			Tramadol			
			Hydrochloride	C		
UNKNOWN						

Date:07/22/04ISR Number: 4404982-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01441
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/04ISR Number: 4404999-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
Other	Calculus Ureteric
	Calculus Urinary
	Cold Sweat
	Coronary Artery Occlusion
	Diverticulitis
	Fatigue
	Hepatic Cyst
	Injury
	Nausea
	Nervousness
	Obstructive Uropathy
	Pneumonia Influenzal
	Pulmonary Arterial
	Pressure Increased
	Tricuspid Valve
	Incompetence
	Ventricular Hypertrophy

Ventricular Hypokinesia
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Advil	C			UNKNOWN	
	Advil	C			UNKNOWN	

Date:07/22/04ISR Number: 4405207-5Report Type:Direct Company Report #CTU 223373
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Encephalopathy		Vioxx Chronic	PS			25MG QAM	
	Gastrointestinal		Zyprexa	C				
	Haemorrhage		Elavil	C				
	Post Procedural		Klonopin	C				
	Haemorrhage		Depakote	C				
	Postoperative		Actos	C				
	Constipation		Vasotec	C				
	Postoperative Fever		Lasix	C				
	Postoperative Ileus		Flomax	C				
	Shock Haemorrhagic		Zocor	C				
	Upper Gastrointestinal		Lexapro	C				
	Haemorrhage		Cefazolin	C				
			Prozac	C				
			Colchicine	C				

Date:07/22/04ISR Number: 4405236-1Report Type:Direct Company Report #CTU 223340
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diarrhoea		Vioxx 25 Mg	PS		ORAL	25 MG ONCE A DAY ORAL	
	Fatigue							
	Nausea		Prozac	C				
	Pain		Roboxitine	C				
	Restlessness		Lamictal	C				

Date:07/23/04ISR Number: 4405132-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome	PT
Other	Angiopathy
	Arthritis
	Blood Pressure Increased
	Cardiac Disorder
	Cardiac Murmur
	Cardiomegaly
	Chest Pain
	Condition Aggravated
	Convulsion
	Cystitis
	Deep Vein Thrombosis
	Depression
	Diarrhoea

Eye Haemorrhage
Fatigue
Gallbladder Disorder
Gastrointestinal Disorder
Hypercholesterolaemia
Hypertension
Hypertonic Bladder
Immune System Disorder
Kidney Infection
Lung Disorder
Migraine
Myocardial Infarction
Nausea
Parathyroid Disorder
Pericardial Effusion
Thyroid Disorder
Urinary Tract Infection
Uterine Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Effexor	C			UNKNOWN	

Date:07/23/04ISR Number: 4406454-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Abdominal Discomfort
Accident At Work
Ankle Fracture
Anxiety
Back Injury
Chest Pain
Constipation
Depression
Dry Mouth
Dysgeusia
Dyspnoea
Emotional Disorder
Erectile Dysfunction
Headache
Heart Rate Irregular
Hypertension
Intervertebral Disc Degeneration
Intervertebral Disc Protrusion

Joint Injury
Joint Sprain
Major Depression
Myofascial Pain Syndrome
Nausea
Orchitis
Osteoarthritis
Pain
Palpitations
Patellofemoral Pain
Syndrome
Pruritus
Pyrexia
Radiculitis Lumbosacral
Tachycardia
Tendonitis
Tinnitus

Urinary Incontinence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/23/04ISR Number: 4406458-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00115
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diverticulum Intestinal		[Therapy					
	Duodenal Ulcer		Unspecified]	C				
UNKNOWN								
	Gastric Ulcer		Vicodin Tablets	C				
UNKNOWN								
	Gastritis		Effexor	C				
UNKNOWN								
	Gastrointestinal		Desyrel	C				
UNKNOWN								
	Haemorrhage		Flexeril	C		ORAL		
	Haemorrhoids		Neurontin	C				
UNKNOWN								
	Headache							
	Helicobacter Pylori							
	Identification Test							
	Positive							
	Perforated Ulcer							
	Pseudodiverticular							
	Disease							
	Sleep Disorder							
	Stress							

Date:07/23/04ISR Number: 4406461-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
27 DAY								

Initial or Prolonged	Abdominal Pain	[Therapy	
Disability	Coordination Abnormal	Unspecified]	SS
UNKNOWN			
	Diarrhoea	Yasmin	SS
UNKNOWN			
	Dizziness	Tylenol	C
UNKNOWN			
	Emotional Distress	Skelaxin	C
UNKNOWN			
	Headache	Paxil	C
UNKNOWN			
	Ischaemic Cerebral	Advil	C
UNKNOWN			
	Infarction	Fioricet Tablets	C
UNKNOWN			
	Migraine		
	Nausea		
	Photophobia		
	Vomiting		

Date:07/23/04ISR Number: 4406463-XReport Type:Expedited (15-DaCompany Report #US-MERCK-00080891
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Dyspepsia
Initial or Prolonged	Ear Infection
	Faecal Occult Blood
	Positive
	Faeces Discoloured
	Gastritis Erosive
	Gastrooesophageal Reflux

		Disease					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Pharyngolaryngeal Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Fosamax	PS	Merck & Co., Inc	ORAL
				Fosamax	SS	Merck & Co., Inc	ORAL
				Fosamax	SS	Merck & Co., Inc	ORAL
				Naproxen	SS		
UNKNOWN							
				Vioxx	SS		ORAL
				Tylenol	C		
UNKNOWN							
				Procardia	C		
UNKNOWN							
				Propoxyphene	C		
UNKNOWN							

Date:07/23/04ISR Number: 4406465-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02548
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Tylenol	C		
UNKNOWN							
		Myocardial Infarction		Pepcid	C		ORAL

Date:07/23/04ISR Number: 4406466-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
424 DAY							
Initial or Prolonged		Coronary Artery Disease		Respaire	C		
UNKNOWN							
Other		Cough		Flonase	C		
UNKNOWN							
		Dermatitis		Minocycline	C		
UNKNOWN							
		Diabetes Mellitus		Piroxicam	C		
UNKNOWN							

	Insulin-Dependent	Prednisone	C
UNKNOWN			
	Diastolic Dysfunction	Zantac	C
UNKNOWN			
	Foot Deformity		
	Hyperlipidaemia		
	Hypertension		
	Myocardial Infarction		
	Oedema Peripheral		
	Pulmonary Oedema		
	Rheumatoid Arthritis		
	Rhinitis Allergic		
	Rotator Cuff Syndrome		
	Seborrhoeic Keratosis		
	Skin Ulcer		
	Syncope		

Date:07/23/04ISR Number: 4406497-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Unstable
Disability	Arthritis
Other	Blood Pressure Abnormal
	Cardiac Valve Disease
	Chest Pain
	Coronary Artery Occlusion
	Dysphagia
	Emotional Distress
	Fatigue

		Gastrooesophageal Reflux Disease					
		Haematoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypercholesterolaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Irritable Bowel Syndrome		Tylenol Extra Strength	C		
		Myocardial Infarction					
UNKNOWN							
		Oedema Peripheral		Percocet	C		
UNKNOWN							
		Pain		Aspirin	C		
UNKNOWN							
		Tremor		Soma	C		
UNKNOWN							
				Cardizem Cd	C		
UNKNOWN							
				Ferrous Sulfate	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		42 DAY					
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		145 DAY					
				K-Dur	C		
UNKNOWN							
				Accupril	C		
UNKNOWN		18 DAY					
				Accupril	C		
UNKNOWN		38 DAY					
				Accupril	C		
UNKNOWN		152 DAY					

Date:07/23/04ISR Number: 4406798-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Percocet	C		ORAL		
	Cervicobrachial Syndrome		Elavil	C		ORAL		
	Death		Baclofen	C		ORAL		
	Depression		Dulcolax	C			UNKNOWN	
	Injury		Wellbutrin	C		ORAL		
	Oedema		Tegretol	C		ORAL		
	Post Procedural		Soma	C		ORAL		
	Complication		Colace	C		ORAL		
			Neurontin	C		ORAL		
			Vistaril	C		ORAL		
			Vistaril	C		ORAL		
			Ativan	C		ORAL		
			Magnesia [Milk Of]	C			UNKNOWN	
			Mexiletine Hydrochloride	C		ORAL		
			Ms Contin	C		ORAL		
			Compazine	C			UNKNOWN	
			Compazine	C			UNKNOWN	
			Coumadin	C		ORAL		
			Fleet Enema	C			UNKNOWN	
			Seroquel	C			UNKNOWN	
			Seroquel	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/04ISR Number: 4406800-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01895
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Infarction		Vicoprofen	C				
UNKNOWN								
	Aortic Atherosclerosis							
	Arthralgia							
	Bronchitis							
	Bursitis							
	Cardiomegaly							
	Coronary Artery							
	Atherosclerosis							
	Epstein-Barr Virus							
	Infection							
	Feeling Abnormal							
	Hypertension							
	Neck Pain							
	Onychomycosis							
	Osteoarthritis							
	Pharyngitis							
	Pneumonia							
	Pneumonitis							
	Pulmonary Calcification							
	Rhinitis Allergic							
	Sciatica							
	Sinusitis							
	Tendonitis							
	Vascular Calcification							
	Vomiting							

Date:07/23/04ISR Number: 4406801-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder

Cardiac Failure
Congestive
Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Diplopia
Disturbance In Attention
Diverticulitis
Dizziness
Dyspnoea
Emotional Distress
Gastrooesophageal Reflux
Disease
Haematemesis
Haematoma
Hyperlipidaemia
Hypersensitivity

	Hypertension						
	Impaired Work Ability						
	Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lactose Intolerance		Vioxx	PS	Merck & Co., Inc	ORAL	220 DAY
	Muscle Contractions		Vioxx	SS	Merck & Co., Inc	ORAL	220 DAY
	Involuntary		Propacet	C			UNKNOWN
	Myalgia		Wellbutrin	C			UNKNOWN
	Non-Cardiac Chest Pain		Prevacid	C			UNKNOWN
	Osteoarthritis						
	Pulmonary Oedema						
	Retroperitoneal						
	Haemorrhage						
	Stent Occlusion						
	Syncope						
	Tendonitis						
	Tinnitus						
	Urticaria						
	Ventricular Fibrillation						
	Vision Blurred						
	Visual Acuity Reduced						
	Wheezing						

Date:07/23/04ISR Number: 4406810-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	552 DAY
Initial or Prolonged	Abdominal Distension		Aleve	SS			UNKNOWN
Disability	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL	552 DAY
	Anxiety		Tylenol	C			UNKNOWN
	Back Pain		Paxil	C			UNKNOWN 2 MON
	Calculus Ureteric						
	Cognitive Disorder						

Confusional State
Constipation
Disorientation
Dizziness
Emotional Distress
Haematochezia
Hypertension
Influenza Like Illness
Lethargy
Nephrolithiasis
Renal Cyst
Transient Ischaemic
Attack

Date:07/23/04ISR Number: 4406812-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Carotid Artery Disease
	Chronic Obstructive Pulmonary Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coronary Artery Occlusion					
		Diverticulum Intestinal Gastritis					
		Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY						
		Haemorrhage		[Therapy Unspecified]	C		
		Haematuria					
UNKNOWN							
		Haemorrhoids		Tylenol	C		
UNKNOWN							
		Hypertension		Proventil	C		
UNKNOWN							
		Myocardial Infarction		Buspar	C		
UNKNOWN							
		Pain		Cipro	C		
UNKNOWN							
		Pain In Extremity		Tranxene	C		
UNKNOWN							
		Proctitis		Diphenhydramine Citrate	C		
		Stress					
UNKNOWN							
		Thrombosis		Epi-Pen	C		
UNKNOWN							
		Upper Gastrointestinal		Allegra	C		
UNKNOWN							
		Haemorrhage		Duratuss	C		
UNKNOWN							
		Upper Respiratory Tract		Hydroxyzine Pamoate	C		
UNKNOWN							
		Infection		Motrin	C		
UNKNOWN							
		Urinary Tract Infection		Loperamide Hydrochloride	C		
		Volvulus Of Bowel					
UNKNOWN							
		Weight Decreased		Methylprednisolone	C		
UNKNOWN							
				Nasonex	C		
UNKNOWN							
				Elocon	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							

Date:07/23/04ISR Number: 4406818-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arthralgia
Other	Blood Glucose Increased
	Blood Pressure Increased
	Cardiac Failure
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Decreased Appetite
	Drug Effect Decreased
	Dyspepsia
	Dyspnoea
	Feeling Abnormal
	Hyperhidrosis
	Immobile
	Injury
	Intervertebral Disc
	Displacement
	Limb Discomfort
	Limb Injury
	Lymphadenitis
	Muscle Spasms
	Musculoskeletal Chest
	Pain
	Myalgia
	Myocardial Infarction
	Nausea

		Oedema Peripheral					
		Pain In Extremity					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paronychia		Vioxx	PS	Merck & Co., Inc	ORAL
		Platelet Count Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Pleuritic Pain		Nitroglycerin	C		
UNKNOWN							
		Productive Cough		Tolinase	C		
UNKNOWN							
		Pyrexia		Verapamil	C		
UNKNOWN							
		Respiratory Rate					
		Increased					
		Respiratory Tract					
		Infection					
		Respiratory Tract					
		Infection Viral					
		Sciatica					
		Treatment Noncompliance					
		Varicose Vein					

Date:07/23/04ISR Number: 4406822-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00819
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/23/04ISR Number: 4406823-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Arteriospasm Coronary		Claritin-D	C		
UNKNOWN		1758 DAY					
		Dyspepsia		Nasonex	C		
UNKNOWN		764 DAY					
		Tachyarrhythmia		Naprosyn	C		
UNKNOWN							

UNKNOWN	Bactrim	C
UNKNOWN	Chondroitin	C
UNKNOWN	Evening Primrose Oil	C
UNKNOWN	Humibid	C
UNKNOWN	Prevacid	C
UNKNOWN	Maxzide	C
UNKNOWN	Entex La	C
UNKNOWN	Glucosamine	C
UNKNOWN	Voltaren	C
UNKNOWN	Darvocet-N	C
UNKNOWN	Inderal La	C
UNKNOWN	Inderal La	C
UNKNOWN	Pseudoephedrine	C
UNKNOWN	Zantac	C
UNKNOWN		

Date:07/23/04ISR Number: 4406825-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00183
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		808 DAY
Initial or Prolonged			Bendroflumethiazide	C		ORAL		
			Codeine Phosphate	C		ORAL		
			Sertraline Hydrochloride	C		ORAL		
			Rosuvastatin Calcium	C		ORAL		

			Lactulose	C		ORAL

Date:07/23/04ISR Number: 4406826-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02546
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Glyburide	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Aleve	C			UNKNOWN	
			Paxil	C			UNKNOWN	

Date:07/23/04ISR Number: 4406827-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01914
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Aspirin	C			UNKNOWN	
	Duodenal Ulcer		Zocor	C		ORAL		
	Faeces Discoloured		Cozaar	C		ORAL		
	Fatigue		Singulair	C		ORAL		
	Gastrointestinal Haemorrhage							
	Melaena							
	Oesophagitis							

Self-Medication
Syncope

Date:07/23/04ISR Number: 4406828-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02529
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Ultracet	C				
UNKNOWN								
	Increased		Premarin	C				
UNKNOWN								
	Cardiac Disorder		Zoloft	C				
UNKNOWN								
	Depression		Bextra	C				
UNKNOWN								
	Dyspnoea		Bextra	C				
UNKNOWN								
	Hepatitis B		Dyazide	C				
UNKNOWN								
	Hypersensitivity		Skelaxin	C				
UNKNOWN								
	Neck Pain							

Date:07/23/04ISR Number: 4406829-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02551
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Back Pain
	Cardiac Arrest
	Chest Pain

	Fungal Infection Hypercholesterolaemia Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tendonitis		Vioxx	PS	Merck & Co., Inc	ORAL	129 DAY
			Combivent	C			RESPIRATORY (INHALATION)
			Aspirin	C			UNKNOWN
			Zestril	C			UNKNOWN
			Zocor	C		ORAL	
			Hytrin	C			UNKNOWN
			Zestril	C			UNKNOWN
			Naprosyn	C			UNKNOWN
			Zantac	C			UNKNOWN

Date:07/23/04ISR Number: 4406830-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00049
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY
Initial or Prolonged	Pco2 Decreased Renal Failure Acute		[Therapy Unspecified]	SS			TOPICAL 11 DAY
	Urticaria		Acetaminophen And Propoxyphene Hydrochloride	SS		ORAL	11 DAY
			Lansoprazole	SS		ORAL	11 DAY

Date:07/23/04ISR Number: 4406831-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
Disability	Acute Pulmonary Oedema
Other	Amnesia
	Anaemia
	Anxiety
	Arrhythmia
	Asthenia
	Atelectasis
	Blood Cholesterol Increased
	Bundle Branch Block Right
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Confusional State
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Crackles Lung
	Cyanosis
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Ketoacidosis
	Dilatation Atrial
	Dysaesthesia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dyspnoea					
		Electrocardiogram St-T Segment Abnormal					
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Emphysema		Vioxx	SS	Merck & Co., Inc	ORAL
		Erythema		Aspirin	C		
UNKNOWN							
		Extrasystoles		Lasix (Furosemide)	C		
UNKNOWN							
		Groin Pain		Glucotrol Xl	C		
UNKNOWN							
		Hyperglycaemia		Glyburide	C		
UNKNOWN							
		Hyperhidrosis		Ativan	C		
UNKNOWN							
		Hyperlipidaemia		Lopressor	C		
UNKNOWN							
		Hypertension		Orphenadrine	C		
UNKNOWN							
		Hypoaesthesia					
		Hypokalaemia					
		Intervertebral Disc Degeneration					
		Loss Of Consciousness					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasopharyngitis					
		Pain In Extremity					
		Palpitations					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pyrexia					
		Respiratory Rate Increased					
		Rotator Cuff Syndrome					
		Sinus Tachycardia					
		Speech Disorder					
		Stress Incontinence					
		Supraventricular Extrasystoles					
		Supraventricular Tachycardia					
		Syncope					
		Tetany					

Transient Ischaemic
Attack
Tremor
Urinary Tract Infection
Urine Odour Abnormal
Ventricular Extrasystoles
Ventricular Hypertrophy
Ventricular Hypokinesia
Vision Blurred

Date:07/23/04ISR Number: 4406837-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00068
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombophlebitis		Diacerein	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/04ISR Number: 4406838-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	314	DAY

Date:07/23/04ISR Number: 4406840-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Activated Partial Thromboplastin Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
			Claritin-D	SS		ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vicodin Es Tablets	C		ORAL		
	Aortic Atherosclerosis		Ambien	C		ORAL		
	Aortic Valve Sclerosis		Percocet	C		ORAL		
	Apnoea		Zoloft	C		ORAL		
	Blood Bilirubin Increased		Zoloft	C		ORAL		
	Blood Cholesterol Increased		Ceftin	C		ORAL		
	Blood Glucose Increased							
	Cardiac Flutter							
	Carpal Tunnel Syndrome							
	Coronary Artery Disease							
	Electrocardiogram T Wave Amplitude Decreased							
	Emotional Distress							
	Fatigue							
	Gallop Rhythm Present							
	Hypertension							
	Hypertensive Heart Disease							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Mitral Valve Stenosis							
	Nasal Turbinate Hypertrophy							
	Oxygen Saturation Decreased							
	Sleep Apnoea Syndrome							

Thrombosis
Trigger Finger
Ventricular Extrasystoles
Ventricular Hypokinesia

Date:07/23/04ISR Number: 4406847-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01168
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Tylenol	C				
Other	Knee Arthroplasty		Atenolol	C			UNKNOWN	
			Celexa	C			UNKNOWN	
			Hydrochlorothiazide And Triamterene	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/23/04ISR Number: 4406851-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/23/04ISR Number: 4406855-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/23/04ISR Number: 4406877-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Acquired Cardiac Septal Defect
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Other	Acute Myocardial Infarction
	Amnesia
	Apnoea
	Arrhythmia
	Asthenia
	Atrioventricular Block
	Balance Disorder
	Benign Prostatic Hyperplasia
	Blood Osmolarity Increased
	Cardiac Failure Congestive
	Cardiac Murmur
	Carotid Artery Stenosis
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Cerebral Ischaemia
	Cerebrovascular Accident

Chest Pain
Coagulopathy
Cold Sweat
Coma
Confusional State
Convulsion
Coronary Artery Disease
Coronary Artery
Thrombosis
Deafness Neurosensory
Dehydration
Depression
Diabetes Mellitus
Disseminated
Intravascular Coagulation
Dizziness
Dysphagia
Dyspnoea
Ejection Fraction

Decreased
Embolic Cerebral
Infarction
Fall
Fatigue
Fibrous Histiocytoma
Flatulence
Gastritis Haemorrhagic
Haematoma
Haemodialysis
Haemodynamic Instability
Headache
Hiatus Hernia
Hyperhidrosis
Hypermetropia
Hypertension
Hypoaesthesia
Inner Ear Disorder
Insomnia
Intracranial Pressure
Increased
Intraventricular
Haemorrhage
Leukocytosis
Limb Discomfort
Loss Of Consciousness
Metabolic Disorder
Mitral Valve Incompetence
Multi-Organ Failure
Myocardial Infarction
Nausea
Neck Pain
Non-Cardiac Chest Pain
Oedema
Oedema Peripheral
Platelet Count Decreased
Pneumonia Escherichia
Post Procedural
Complication
Presbyopia
Prothrombin Time
Prolonged
Pupillary Disorder
Refraction Disorder
Renal Failure
Respiratory Failure
Restlessness
Scar

Sepsis
Sleep Apnoea Syndrome
Subarachnoid Haemorrhage
Syncope
Transient Ischaemic
Attack
Tremor
Tricuspid Valve
Incompetence
Varicose Vein
Ventricle Rupture
Ventricular Dysfunction
Ventricular Tachycardia
Vertigo Positional

	Vision Blurred					
	Visual Disturbance					
	Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY					
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY					
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Neurontin	C		
UNKNOWN						
			Glucosamine	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						

Date:07/23/04ISR Number: 4406906-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01614
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:07/24/04ISR Number: 4407030-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00104
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Sinusitis
Other	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Back Pain
	Blood Triglycerides
	Increased
	Breast Mass

Bursitis
Carotid Artery Disease
Carotid Artery Stenosis
Cataract
Chest Discomfort
Condition Aggravated
Coronary Artery Disease
Dizziness
Drug Ineffective
Dyspnoea Exertional
Epistaxis
Ganglion
Gastrooesophageal Reflux
Disease
Gingival Bleeding
Headache
Heart Rate Increased
Hyperglycaemia
Hypertension
Hypoglycaemia
Increased Tendency To
Bruise
Influenza
Ingrowing Nail

		Injury					
		Lymphadenopathy					
		Middle Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Aspirin	C		
UNKNOWN							
		Myalgia		Aspirin	C		
UNKNOWN							
		Myocardial Ischaemia		Lomotil	C		
UNKNOWN							
		Nausea		Insulin	C		
UNKNOWN							
		Night Cramps		Zocor	C		ORAL
		Nocturia		Zocor	C		ORAL
635 DAY							
		Oedema		Kenalog	C		
INTRAMUSCULAR							
		Oedema Peripheral		Zocor	C		ORAL
		Palpitations		Zocor	C		ORAL
		Rheumatoid Arthritis		Avandia	C		
UNKNOWN							
		Sinus Disorder		Synthroid	C		
UNKNOWN							
		Sinusitis		Melatonin	C		
UNKNOWN							
		Tachycardia		Pamelor	C		
UNKNOWN							
		Tendon Rupture		Prilosec	C		
UNKNOWN							
		Tendonitis					
		Transient Ischaemic					
		Attack					
		Ventricular Extrasystoles					
		Weight Increased					
		Wheezing					

Date:07/24/04ISR Number: 4407031-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01736
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/26/04ISR Number: 4407645-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02530
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Ultracet	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	
			Ultram	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	
			Butalbital	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	

Date:07/26/04ISR Number: 4407646-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03191
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Antinuclear Antibody Positive
Other	Arthritis
	Autoimmune Disorder
	Blood Homocysteine Increased
	Carotid Artery Aneurysm
	Cataract

		Cataract Operation					
		Cerebrovascular Accident					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ischaemic Cerebral		Vioxx	PS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
		Posterior Capsule		Aspirin	C		
UNKNOWN							
		Opacification		Aspirin	C		
UNKNOWN							
		Pruritus		Plaquenil	C		
UNKNOWN							
		Transient Ischaemic		Prednisone	C		
UNKNOWN							
		Attack					
		Vasculitis					

Date:07/26/04ISR Number: 4407650-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00094
Age:29 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
		Adverse Event		[Composition			
		Arthrodesis		Unspecified]	C		
UNKNOWN							
		Basedow'S Disease		Midrin	C		ORAL
		Body Tinea		Keflex	C		ORAL
		Bronchitis Chronic		Accuretic	C		
UNKNOWN							
		Cellulitis		Prevacid	C		
UNKNOWN							
		Depression		Claritin-D 12 Hour	C		ORAL
		Diarrhoea					
		Essential Hypertension					
		Facial Palsy					
		Gastrooesophageal Reflux					
		Disease					
		Herpes Simplex					
		Herpes Simplex Ophthalmic					
		Hordeolum					
		Otitis Media Acute					
		Pelvic Inflammatory					
		Disease					

Pharyngitis
Pleurisy
Thyroiditis
Urinary Tract Infection

Date:07/26/04ISR Number: 4407659-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00229
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		13 DAY
Initial or Prolonged	Cardiac Failure		Avandamet	SS				UNKNOWN
Other	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		13 DAY
	Overdose		Lipitor	C				UNKNOWN
	Treatment Noncompliance		Cardura	C		ORAL		134 DAY
			Lasix (Furosemide)	C		ORAL		75 DAY
			Diovan	C		ORAL		
			Metoprolol	C		ORAL		
			Klor-Con	C		ORAL		
			Amaryl	C		ORAL		
			Hydrochlorothiazide	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:07/26/04ISR Number: 4407660-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
Other	Adenomyosis
	Amnesia
	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Atrioventricular Block
	Back Pain
	Bronchitis
	Cardiac Valve Disease
	Cardiomyopathy
	Cellulitis
	Chest Pain
	Complex Regional Pain Syndrome
	Constipation
	Convulsion
	Costochondritis
	Dental Caries
	Diverticulitis
	Duodenal Ulcer
	Duodenitis
	Dyspnoea Exertional
	Encephalopathy
	Fatigue
	Gastritis
	Grand Mal Convulsion
	Haematoma Infection
	Haemorrhoids
	Helicobacter Gastritis
	Hypertension
	Hypertensive Crisis
	Hypokalaemia
	Irritable Bowel Syndrome
	Joint Contracture
	Laceration
	Malignant Hypertension
	Memory Impairment
	Micturition Urgency
	Myocardial Infarction
	Myocardial Ischaemia
	Nausea

Oedema Peripheral
Oesophagitis
Orthopnoea
Osteoarthritis
Pain In Extremity
Palpitations
Peptic Ulcer
Renal Failure
Salpingitis
Sensory Loss
Supraventricular
Tachycardia
Upper Respiratory Tract
Infection
Vaginal Discharge

Vulvovaginal Discomfort

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Normodyne	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Flagyl	C			UNKNOWN	
	Cardura	C			UNKNOWN	
	Minoxidil	C			UNKNOWN	
	Procardia Xl	C			UNKNOWN	

Date:07/26/04ISR Number: 4407703-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00111
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	285 DAY	
Life-Threatening	Perforation		Vioxx	SS	Merck & Co., Inc	ORAL	285 DAY	
Hospitalization - RESPIRATORY			Albuterol	C			Initial or Prolonged (INHALATION)	
Other			Amlodipine Besylate	C			UNKNOWN	
			Bisoprolol Fumarate	C			UNKNOWN	
			Fosinopril Sodium	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

Date:07/26/04ISR Number: 4407705-7Report Type:Expedited (15-DaCompany Report #AE-MERCK-0407USA01274
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Left Ventricular Failure		Aspirin	C		ORAL		
Initial or Prolonged	Oedema Peripheral		Diamicron Mr	C		ORAL		
Other	Pulmonary Oedema		Zocor	C		ORAL		
			Glucophage	C		ORAL		
			Coversyl	C		ORAL		

Date:07/26/04ISR Number: 4407706-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02131
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Congestive	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	46	DAY
Other	Cardiomyopathy		Isosorbide Mononitrate	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Terazosin Hydrochloride	C			UNKNOWN	
			Actos	C		ORAL		
			Potassium (Unspecified)	C			UNKNOWN	
			Aciphex	C			UNKNOWN	

Date:07/26/04ISR Number: 4407708-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease		Arthrotec	C				
UNKNOWN								
	Depression		Zocor	C		ORAL		
	Emotional Distress		Glucophage	C				
UNKNOWN								

Date:07/26/04ISR Number: 4407709-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
156 DAY								
Initial or Prolonged	Cerebrovascular Stenosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
9 MON								
Disability	Headache		[Therapy					
Other	Hypercholesterolaemia		Unspecified]	C				
UNKNOWN	585 DAY							
	Hypersensitivity		Tylenol	C				
UNKNOWN	585 DAY							
	Sinusitis		Ortho-Novum	C				
UNKNOWN								
	Temporomandibular Joint		Necon	C				
UNKNOWN								
	Syndrome		Zoloft	C				
UNKNOWN								
	Transient Ischaemic		Advil	C				
UNKNOWN	585 DAY							
	Attack		Motrin	C				
UNKNOWN	585 DAY							
			Methylphenidate	C				
UNKNOWN								
			Naproxen	C				
UNKNOWN	585 DAY							
			Aleve	C				
UNKNOWN	585 DAY							

Date:07/26/04ISR Number: 4407711-2Report Type:Expedited (15-DaCompany Report #AE-MERCK-0407USA00674
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/04ISR Number: 4407718-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02542
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Tylenol	C			UNKNOWN	
	Gastrooesophageal Reflux		Vicodin Tablets	C			UNKNOWN	
	Disease		Calcium					
	Headache		(Unspecified)	C			UNKNOWN	
	Intervertebral Disc		Zoloft	C			UNKNOWN	
	Degeneration		Trazodone					
	Osteomalacia		Hydrochloride	C			UNKNOWN	
			Vitamin D (Unspecified)	C			UNKNOWN	
			Ultram	C			UNKNOWN	
			Ortho-Novum 7/7/7	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Lithobid	C			UNKNOWN	
			Methadone Hcl	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	
			Paxil	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/04ISR Number: 4408037-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chromaturia		Norvasc	C			UNKNOWN	
	Contusion		Aspirin	C			UNKNOWN	
	Coronary Artery		Lipitor	C			UNKNOWN	
	Restenosis		Monopril	C			UNKNOWN	
	Cough		Indocin (Indomethacin)	C			UNKNOWN	
	Decreased Appetite							
	Depressed Mood		Toprol Xl Tablets	C			UNKNOWN	
	Diarrhoea		Lopressor	C			UNKNOWN	
	Disturbance In Attention		Naproxen	C			UNKNOWN	
	Diverticulum Intestinal Haemorrhagic							
	Drug Ineffective							
	Dyspnoea							
	Fatigue							
	Fluid Retention							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Insomnia							
	Iron Deficiency							
	Libido Decreased							
	Lung Neoplasm							
	Myocardial Infarction							
	Nausea							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Paraesthesia							
	Pneumonia							
	Prostatic Specific Antigen Increased							

Proteinuria
Renal Cyst
Rheumatoid Arthritis
Rhinitis Allergic
Stress
Tendon Rupture
Umbilical Hernia
Ventricular Extrasystoles

Date:07/26/04ISR Number: 4408039-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Aneurysm
Other	Arteriovenous Fistula
	Arthropathy
	Bundle Branch Block Left
	Calcinosis
	Chest Discomfort
	Coronary Artery Disease
	Dehydration
	Diverticulum Intestinal
	Haemorrhagic

		Emotional Distress Gastritis Atrophic Helicobacter Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
93	DAY						
		Degeneration		Tylenol	C		
UNKNOWN							
		Intervertebral Disc		Ecotrin	C		
UNKNOWN							
		Protrusion		Viagra	C		
UNKNOWN							
		Neck Pain		Calan Sr	C		
UNKNOWN							
		Neuropathy Peripheral		Zocor	C		
UNKNOWN							
		Renal Cyst		Celebrex	C		
UNKNOWN							
		Rotator Cuff Syndrome		Advil	C		
UNKNOWN							
		Sciatica Scoliosis Spinal Column Stenosis Stent Occlusion					

Date:07/26/04ISR Number: 4408043-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
Disability	Coagulation Factor Viii		Ambien	C		
UNKNOWN						
Other	Level Increased		Ma Huang Extract	C		
UNKNOWN	1523 DAY					
	Depression Emotional Distress Haemoptysis Influenza Insomnia International Normalised Ratio Increased					

Pain
Protein C Increased
Pulmonary Embolism
Pulmonary Hypertension
Renal Cyst
Suicidal Ideation
Upper Respiratory Tract
Infection

Date:07/26/04ISR Number: 4408044-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bacterial Infection		Lipitor	C				
UNKNOWN								
Other	Bipolar I Disorder		Lipitor	C				
UNKNOWN								
	Chest Pain		Avapro	C				
UNKNOWN								
	Flank Pain		Geodon	C				
UNKNOWN								
	Incisional Hernia		Prevacid	C				
UNKNOWN								
	Nephrolithiasis		Levoxyl	C				
UNKNOWN								
	Renal Failure		Prilosec	C				
UNKNOWN								
	Schizoaffective Disorder		Paxil	C				
UNKNOWN								
	Sepsis							
	Urinary Retention							
	Urinary Tract Infection							
	Urosepsis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/04ISR Number: 4408050-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01002
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blindness Cortical		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Coordination Abnormal		Zyloprim	C		ORAL
Other	Excoriation		Aspirin	C		ORAL
	Hypertension		Tenormin	C		ORAL
	Retinal Haemorrhage		Tenormin	C		ORAL
	Sensation Of Heaviness		Buspar	C		ORAL
	Transient Ischaemic		Celebrex	C		ORAL
	Attack		Ambien	C		
UNKNOWN						
			Plavix	C		ORAL
			Hydrochlorothiazide	C		ORAL
			Indocin			
			(Indomethacin)	C		ORAL
			Cozaar	C		ORAL
			Slow-K	C		ORAL
			Pravachol	C		
UNKNOWN						

Date:07/26/04ISR Number: 4408054-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01618
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
470 DAY						
Other	Atrial Fibrillation		Norvasc	C		
UNKNOWN						
	Cardiac Disorder		Clonazepam	C		
UNKNOWN						
	Cerebral Infarction		Lanoxin	C		
UNKNOWN						
	Coma		Zoloft	C		
UNKNOWN						
	Epigastric Discomfort		Vasotec	C		ORAL
	Gastrooesophageal Reflux		Primidone	C		
UNKNOWN						
	Disease					
	Humerus Fracture					
	Leukocytosis					

Vomiting
White Blood Cell Count
Increased

Date:07/26/04ISR Number: 4408055-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00024
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL	143	DAY
			Clobetasone Butyrate	C		TOPICAL		
			Hydrocortisone Butyrate	C		TOPICAL		
			Omeprazole	C		ORAL		

Date:07/26/04ISR Number: 4408056-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00144
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Other	Convulsion
	Feeling Cold
	Hiccups

	Hot Flush						
	Hypertension						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY

Date:07/26/04ISR Number: 4408059-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/26/04ISR Number: 4408061-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	77 DAY

Date:07/26/04ISR Number: 4408062-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01683
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Hospitalization -	Congestive		Acebutolol	C		ORAL	
Initial or Prolonged	Diarrhoea		Tylenol With Codeine	C		ORAL	
Other	Faecal Occult Blood		Augmentin	C		ORAL	
	Positive		Augmentin	C			
UNKNOWN							6 DAY
	Hypertension		Aspirin	C		ORAL	

	Hypothyroidism		Lipitor	C		ORAL
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		
UNKNOWN						
			Effexor Xr	C		ORAL
			Vitamins (Unspecified)	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Flexeril	C		ORAL
			Premarin	C		
UNKNOWN						
			Ferrous Sulfate	C		ORAL
			Folic Acid	C		ORAL
			Provera	C		
UNKNOWN						
			Maxalt (Rizatriptan Benzoate)	C		ORAL

Date:07/26/04ISR Number: 4408064-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/26/04ISR Number: 4408065-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/04ISR Number: 4408066-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		475 DAY

Date:07/26/04ISR Number: 4408067-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00199
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disseminated Intravascular Coagulation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Estradiol Valerate	C				
Other								

Date:07/26/04ISR Number: 4408069-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY

Date:07/26/04ISR Number: 4408070-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1056 DAY

Date:07/26/04ISR Number: 4408092-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Aspartate Aminotransferase Increased
Other	Benign Breast Neoplasm
	Blood Pressure Inadequately Controlled
	Carotid Artery Occlusion
	Cerebral Infarction
	Comminuted Fracture
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Diastolic Dysfunction
	Dysphoria
	Eye Injury
	Fall

	Fatigue					
	Haematoma					
	Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
	Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
	Rib Fracture		Lipitor	C		
UNKNOWN						
	Road Traffic Accident		Lipitor	C		
UNKNOWN						
	Syncope					
	Upper Respiratory Tract Infection					
	Weight Increased					

Date:07/26/04ISR Number: 4428197-8Report Type:Periodic Company Report #USA040362259
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Headache	Consumer	Forteo(Teriparatide)	PS		
20 UG/1 DAY						
	Muscle Spasms		Vioxx(Rofecoxib)	SS		
			Bisoprolol	C		
			Skelaxin (Metaxalone)	C		

Date:07/27/04ISR Number: 4408702-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01739
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
5 MON						

Date:07/27/04ISR Number: 4408703-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104508
Age:49 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Abdominal Distension Accidental Overdose Anxiety Arthralgia Asthenia Back Injury Back Pain Blood Glucose Increased Blood Pressure Fluctuation Cardiovascular Disorder Closed Head Injury Concussion Constipation Coordination Abnormal Depression Dysphonia Dyspnoea Emotional Distress Facial Bones Fracture Head Injury Headache Hypercholesterolaemia Hyperlipidaemia

		Laceration					
		Loss Of Consciousness					
		Muscle Atrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasal Septum Deviation		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Turbinate		Zocor	C		
UNKNOWN							
		Hypertrophy					
		Nasopharyngeal Disorder					
		Neck Pain					
		Neuropathy Peripheral					
		Nodule					
		Nose Deformity					
		Obesity					
		Oedema					
		Pain					
		Polytraumatism					
		Renal Failure					
		Skin Laceration					
		Sleep Apnoea Syndrome					
		Somnolence					

Date:07/27/04ISR Number: 4408798-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03194
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Atelectasis					
		Atrial Fibrillation					
		Atrioventricular Block					
		First Degree					
		Bundle Branch Block Right					
		Cardiac Failure					
		Congestive					
		Cardiomegaly					
		Cerebrovascular Accident					
		Coronary Artery Disease					
		Depression					
		Drug Ineffective					
		Electrocardiogram					
		Abnormal					
		Fall					

Hyperlipidaemia
Hypertension
Inguinal Hernia
Myocardial Infarction
Pleural Effusion
Pulmonary Fibrosis
Pulmonary Hypertension
Thrombosis
Tricuspid Valve
Incompetence
Urinary Retention

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/04ISR Number: 4408800-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00140
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		[Therapy					
	Arthropathy		Unspecified]	C				UNKNOWN
	Blood Pressure Increased		Percocet	C				UNKNOWN
	Drug Ineffective							
	Emotional Distress							
	Fibromyalgia							
	Headache							
	Hypersensitivity							
	Hypoaesthesia							
	Osteoarthritis							
	Pain							
	Paraesthesia							
	Productive Cough							
	Pulmonary Congestion							

Date:07/27/04ISR Number: 4408801-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00037
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Acetaminophen	C		ORAL		
	Cognitive Disorder							
	Mood Swings							

Date:07/27/04ISR Number: 4408802-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00163
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Potassium Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							
	Electrocardiogram Qt Prolonged							

Date:07/27/04ISR Number: 4408807-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY

Date:07/27/04ISR Number: 4408810-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	47	DAY

Date:07/27/04ISR Number: 4408813-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	50	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/04ISR Number: 4408815-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/04ISR Number: 4409094-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective		[Therapy					
	Emotional Distress		Unspecified]	C				
UNKNOWN								
	Haemorrhoids		Depakote	C				
UNKNOWN								
	Hyperglycaemia		Nexium	C				
UNKNOWN								
	Lumbar Radiculopathy		Zestril	C				
UNKNOWN								
	Myocardial Infarction		Lithium Sulfate	C				
UNKNOWN								
	Upper Respiratory Tract		Robaxin	C				
UNKNOWN								
	Infection							

Date:07/28/04ISR Number: 4409281-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Akinesia		Vioxx	PS	Merck & Co., Inc	ORAL		
340 DAY								
Life-Threatening	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
340 DAY								
Hospitalization -	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
340 DAY								
Initial or Prolonged	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
340 DAY								

Coronary Artery	Vioxx	SS	Merck & Co., Inc	ORAL
340 DAY				
Atherosclerosis	Vioxx	SS	Merck & Co., Inc	ORAL
340 DAY				
Coronary Artery Occlusion	Vicodin Tablets	C		
UNKNOWN				
Cystocele	Proventil Repetabs			
Dyspnoea	And Tablets	C		
UNKNOWN				
Electrocardiogram St	Zithromax	C		
UNKNOWN				
Segment Abnormal	Benzonatate	C		
UNKNOWN				
Fibromyalgia	Tussi-12	C		
UNKNOWN				
Hepatomegaly	Soma	C		
UNKNOWN				
Implant Site Haemorrhage	Zyrtec	C		
UNKNOWN				
Intervertebral Disc	Cipro	C		
UNKNOWN				
Disorder	Voltaren	C		
UNKNOWN				
Muscle Spasms	Prempro	C		
UNKNOWN 41 DAY				
Myocardial Infarction	Tequin	C		
UNKNOWN				
Myocardial Ischaemia	Hydroxyzine			
Neck Pain	Hydrochloride	C		
UNKNOWN				
Oxygen Saturation	Prevacid	C		
UNKNOWN				
Decreased	Lorabid	C		
UNKNOWN				
Pelvic Prolapse	Claritin-D	C		
UNKNOWN				
Pleural Adhesion	Lorazepam	C		
UNKNOWN				
Pulmonary Oedema	Remeron	C		
UNKNOWN				
Rhonchi	Triamcinolone	C		
UNKNOWN				
Scoliosis	Prilosec	C		
UNKNOWN				
Sinus Tachycardia	Ditropan	C		
UNKNOWN				
Stress Incontinence	Ditropan	C		
UNKNOWN				
Sudden Cardiac Death	Promethazine	C		
UNKNOWN				
Vaginal Prolapse				
Ventricular Dysfunction				
Ventricular Hypertrophy				

Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/04ISR Number: 4409282-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Captopril	C				
UNKNOWN								
Other	Cholecystitis		Celebrex	C				
UNKNOWN								
	Cholelithiasis		Plavix	C				
UNKNOWN								
	Chronic Obstructive		Pepcid Ac	C		ORAL		
	Airways Disease		Lasix (Furosemide)	C				
UNKNOWN								
	Exacerbated		Ambien	C				
UNKNOWN								
	Coma		Zoloft	C				
UNKNOWN								
	Coronary Artery Disease		Glyburide	C				
UNKNOWN								
	Depressed Level Of		Synthroid	C				
UNKNOWN								
	Consciousness		Lorazepam	C				
UNKNOWN								
	Diabetes Mellitus		Meclizine	C				
UNKNOWN								
	Inadequate Control		Phenergan					
	Dizziness		Tablets/Suppositorie					
	Dyspepsia		s	C				
UNKNOWN								
	Dyspnoea							
	Epigastric Discomfort							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Hyperhidrosis							
	Hyperkalaemia							
	Microcytic Anaemia							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Pallor							
	Pulmonary Oedema							
	Pupillary Reflex Impaired							
	Rales							

Renal Failure
Respiratory Depression
Respiratory Distress
Vomiting
Wheezing

Date:07/28/04ISR Number: 4409283-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01641
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Embolism		[Therapy Unspecified]	C				
	Thrombosis							
Disability			Hormones (Unspecified)	C				
UNKNOWN								

Date:07/28/04ISR Number: 4409818-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00176
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		197 DAY
Hospitalization - Initial or Prolonged	Renal Tubular Necrosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/04ISR Number: 4409820-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/04ISR Number: 4409829-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00064
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Agitation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Tylenol	C			UNKNOWN	
	Cardiomyopathy		Saw Palmetto	C			UNKNOWN	
	Cellulitis		Ultram	C			UNKNOWN	
	Cerebral Ischaemia		Lipitor	C			UNKNOWN	
	Chronic Obstructive		Lumigan	C			UNKNOWN	
	Pulmonary Disease		Corticosteroids					
	Colitis Ischaemic		(Unspecified)	C			PARENTERAL	
	Coronary Artery Disease		Betagan	C			UNKNOWN	
	Delirium		Relafen	C			UNKNOWN	
	Depression		Paxil	C			UNKNOWN	
	Diarrhoea							
	Drug Hypersensitivity							
	Gastroenteritis							
	Headache							
	Inguinal Hernia							
	Iron Deficiency Anaemia							
	Liver Function Test Abnormal							

Myocardial Infarction
Osteoarthritis
Osteoporosis
Periorbital Haematoma
Spinal Column Stenosis
Staphylococcal Sepsis

Date:07/28/04ISR Number: 4409831-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	462	DAY

Date:07/28/04ISR Number: 4409833-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0407CAN00085
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
Initial or Prolonged	Peptic Ulcer							

Date:07/28/04ISR Number: 4409836-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/04ISR Number: 4410437-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Percocet	SS				
Disability	Arthropod Sting		Alcohol	SS				
Other	Cardiac Failure		Xanax	SS				
	Coronary Artery Disease		Ambien	SS				
	Diabetes Mellitus		Soma	C				
	Gastrooesophageal Reflux		Advil	C				
	Disease		Imdur	C				
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Intentional Misuse							
	Major Depression							
	Myocardial Infarction							
	Spondylitis							
	Stent Occlusion							
	Suicide Attempt							
	Swelling Face							
	Tooth Disorder							

Date:07/28/04ISR Number: 4410438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Acute Pulmonary Oedema
Other	Anaemia Postoperative
	Angina Unstable
	Anxiety
	Aortic Valve Incompetence
	Atrial Fibrillation
	Azotaemia
	Blood Amylase Increased
	Blood Glucose Increased
	Blood Pressure Inadequately Controlled
	Cardiac Disorder
	Cardiac Failure Acute
	Cardiac Failure Congestive
	Chest Pain
	Chondrocalcinosis Pyrophosphate
	Chondrocalcinosis Pyrophosphate
	Colon Cancer Recurrent
	Colonic Polyp
	Constipation
	Coronary Artery Disease

		Coronary Artery Occlusion					
		Dehydration					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional	Premarin	C		
UNKNOWN							
		Dysphagia		Glipizide	C		
UNKNOWN							
		Emotional Distress					
		Faecal Occult Blood					
		Positive					
		Gastritis					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hypoaesthesia Oral					
		Injury					
		Inner Ear Disorder					
		Intracardiac Thrombus					
		Joint Injury					
		Lipase Increased					
		Meniscus Lesion					
		Microangiopathy					
		Mitral Valve Incompetence					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Renal Cyst					
		Renal Failure					
		Syncope					
		Thrombophlebitis					
		Thrombosis					
		Tooth Disorder					
		Tooth Infection					
		Tricuspid Valve					
		Incompetence					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vein Pain					
		Vertigo					
		Visual Disturbance					
		Weight Decreased					

Date:07/28/04ISR Number: 4410439-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Upper
Other	Anxiety
	Back Pain
	Blood Pressure Increased
	Carpal Tunnel Syndrome
	Condition Aggravated
	Contusion
	Convulsion
	Cystitis
	Depression
	Diarrhoea
	Diverticulum Intestinal

		Dizziness					
		Dupuytren'S Contracture					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Fall	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Propulsid	C		
UNKNOWN							
		Herpes Zoster		Estrogens			
		Hypothyroidism		(Unspecified)	C		
UNKNOWN							
		Intervertebral Disc Displacement					
		Irritable Bowel Syndrome					
		Lumbar Radiculopathy					
		Meniscus Lesion					
		Muscle Spasms					
		Nausea					
		Nervousness					
		Osteoarthritis					
		Radius Fracture					
		Scoliosis					
		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Uterine Cancer					
		Weight Decreased					

Date:07/28/04ISR Number: 4410440-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00842
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Ineffective	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Flonase	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							

Date:07/28/04ISR Number: 4410441-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Hernia
Other	Abdominal Pain
	Abdominal Pain Upper
	Aortic Atherosclerosis
	Arthralgia
	Asthma
	Back Pain
	Blood Cholesterol
	Increased
	Burning Sensation
	Bursitis
	Cardiomegaly
	Chromaturia
	Deep Vein Thrombosis
	Dry Mouth
	Fatigue
	Fluid Retention
	Gastrooesophageal Reflux
	Disease

		Haemarthrosis					
		Haemorrhoidal Haemorrhage					
		Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypersensitivity	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension	Professional	[Therapy			
		Incision Site		Unspecified]	C		
UNKNOWN		10 YR					
		Complication		Endocet	C		
UNKNOWN							
		Joint Effusion		Elavil	C		
UNKNOWN							
		Lung Disorder		Tenormin	C		
UNKNOWN							
		Migraine		Vancenase	C		
UNKNOWN							
		Mononeuritis		Premarin	C		
UNKNOWN		9872 DAY					
		Myalgia		Prevacid	C		
UNKNOWN							
		Neuropathy Peripheral		Synthroid	C		
UNKNOWN							
		Oedema Peripheral		Prinivil	C		ORAL
1285 DAY							
		Rectocele		Prinivil	C		ORAL
217 DAY							
		Road Traffic Accident		Prinivil	C		ORAL
		Spinal Osteoarthritis		Methocarbamol	C		
UNKNOWN							
		Splenic Cyst		Prilosec	C		
UNKNOWN							
		Thrombophlebitis					
		Superficial					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urine Odour Abnormal					
		Wound					
		Wound Dehiscence					

Date:07/28/04ISR Number: 4410442-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthritis		Tylenol Extra Strength	C				
UNKNOWN	Blood Pressure Abnormal		Percocet	C				
UNKNOWN	Cardiac Valve Disease		Aspirin	C				
UNKNOWN	Chest Pain		Soma	C				
UNKNOWN	Coronary Artery Occlusion		Cardizem Cd	C				
UNKNOWN	Dysphagia		Ferrous Sulfate	C				
UNKNOWN	Emotional Distress		Lasix (Furosemide)	C				
UNKNOWN	Fatigue		Lasix (Furosemide)	C				
UNKNOWN	Gastrooesophageal Reflux		Lasix (Furosemide)	C				
UNKNOWN	Disease		Aleve	C				
UNKNOWN	Haematoma		Nitroglycerin	C				
UNKNOWN	Hypercholesterolaemia		Paxil	C				
UNKNOWN	Hypertension		Paxil	C				
UNKNOWN	Irritable Bowel Syndrome		Paxil	C			42	DAY
UNKNOWN	Myocardial Infarction		Paxil	C				
UNKNOWN	Oedema Peripheral		Paxil	C			145	DAY
UNKNOWN	Pain		K-Dur	C				
UNKNOWN	Tremor		Accupril	C			18	DAY
UNKNOWN			Accupril	C			38	DAY
UNKNOWN			Accupril	C			152	DAY

Date:07/28/04ISR Number: 4410443-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00645
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthropathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Other	Cardiac Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	1	WK
	Death		[Therapy Unspecified]	C		UNKNOWN		
			[Therapy Unspecified]	C		UNKNOWN		
			Oxycontin	C		UNKNOWN		

Date:07/28/04ISR Number: 4410444-XReport Type:Expedited (15-DaCompany Report #TH-MERCK-0407THA00006
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Cardiac Failure Congestive	Professional						

Date:07/28/04ISR Number: 4410445-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	UNKNOWN		
Initial or Prolonged	Angina Unstable	Professional	Allopurinol	C		UNKNOWN		
Other	Azotaemia		Aspirin	C		UNKNOWN		
	Bronchitis		Aricept	C		UNKNOWN		
	Cardiac Failure		Glucotrol	C		UNKNOWN		

Congestive
Cardiomegaly
Carotid Artery Stenosis
Central Line Infection
Cerebral Artery Occlusion
Chest Pain
Chronic Obstructive
Pulmonary Disease
Coronary Artery
Restenosis
Decreased Appetite
Diarrhoea
Dressler'S Syndrome
Faecal Occult Blood
Positive
Faeces Discoloured
Gastrointestinal
Haemorrhage
Hyperbilirubinaemia
Hyperlipidaemia
Hypertension
Mitral Valve Incompetence
Myocardial Infarction
Peripheral Vascular
Disorder
Respiratory Failure
Skin Candida
Subclavian Artery
Stenosis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/04ISR Number: 4410447-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00043
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Autoimmune Thyroiditis		Acetaminophen And Propoxyphene Hydrochloride	SS		ORAL		
	Haemoglobin Decreased		Domperidone	SS		ORAL		
	Hepatic Cirrhosis		Fluvastatin Sodium	SS		ORAL		
	Hepatitis		Acebutolol Hydrochloride	SS		ORAL		
	Hepatomegaly		Fluvastatin Sodium	SS		ORAL		
	Rhabdomyolysis		Lansoprazole	SS		ORAL		

Date:07/28/04ISR Number: 4410448-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02549
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
	Cerebral Haemorrhage		Tylenol	C			UNKNOWN	
	Cerebrovascular Accident		Percogesic	C			UNKNOWN	
	Emotional Disorder		Aspirin	C			UNKNOWN	
	Fatigue		Tenormin	C			UNKNOWN	1734 DAY
	Headache		Neurontin	C			UNKNOWN	
	Injury		Zocor	C			UNKNOWN	
	Mental Impairment		Vitamins (Unspecified)	C			UNKNOWN	
	Pain In Extremity		Zoloft	C			UNKNOWN	
	Vomiting		Advil	C			UNKNOWN	
			Motrin	C			UNKNOWN	

Levoxyl C
UNKNOWN

Aleve C
UNKNOWN

Date:07/28/04ISR Number: 4410449-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
Disability	Aortic Stenosis
	Arrhythmia
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Connective Tissue
	Inflammation
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dilatation Atrial
	Dyspnoea
	Dyspnoea Exertional
	Emotional Distress
	Fatigue
	Heart Rate Increased
	Heart Rate Irregular
	Injury
	Intervertebral Disc
	Degeneration
	Intervertebral Disc

		Protrusion					
		Libido Disorder					
		Micturition Disorder					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Prolapse	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Normochromic Normocytic	Professional	Vicodin Tablets	C		
UNKNOWN							
		Anaemia					
		Pulmonary Valve Stenosis					
		Sleep Apnoea Syndrome					
		Spinal Compression					
		Fracture					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Weight Increased					

Date:07/28/04ISR Number: 4410450-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00169
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY							
Initial or Prolonged		Hepatitis Cholestatic	Professional	Ramipril	SS		
UNKNOWN							
				Atorvastatin Calcium	C		
UNKNOWN							
				Torsemide	C		
UNKNOWN							
				Clopidogrel Bisulfate	C		
UNKNOWN							
				Nisoldipine	C		
UNKNOWN							

Date:07/28/04ISR Number: 4410451-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01750
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/28/04ISR Number: 4410696-6Report Type:Direct Company Report #CTU 223761
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Inflammation Thrombosis		Vioxx By Fargo, Nd Doctors And Area Pharmacies	PS				

Date:07/28/04ISR Number: 4413430-9Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-312
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema Diarrhoea Exposure To Toxic Agent	Study Distributor Other	Methotrexate (Methotrexate, Tablet)	PS		ORAL	10 MG 1X PER 1 WK, ORAL	
			Enbrel (Etanercept, Injection)	SS		SUBCUTANEOUS	25 MG 2X PER 1 WK, SC	
			Oxycontin (Oxycodone Hydrochloride)	SS		ORAL	10 MG, ORAL	
			Vioxx (Rofecoxib, Tablet)	SS		ORAL	25 MG 1X PER 1 DAY, ORAL	

			Prednisone (Prednisone)	C		
			Tylenol W/Codeine No. 3 (Codeine Phosphate/Paracetamol)	C		
			Valium (Diazepam)	C		
			Klonopin (Clonazepam)	C		
			Acetylsalicylic Acid)	C		
			Accupril (Quinapril Hydrochloride)	C		
			Atenolol (Atenolol)	C		
			Lipitor (Atorvastatin)	C		

Date:07/28/04ISR Number: 4413758-2Report Type:Expedited (15-DaCompany Report #200410478BNE
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Foreign	Aspirin (Acetylsalicylic Acid)	PS		ORAL	75 MG, TOTAL	
	Haematemesis	Health Professional					DAILY, ORAL	
	Haemoglobin Decreased							
	Melaena	Other						
	Oesophagitis		Clopidogrel	SS		ORAL	75 MG, TOTAL DAILY, ORAL	
			Rofecoxib	SS		ORAL	12.5 MG, TOTAL DAILY, ORAL	
			Amitriptyline	C				
			Senna	C				
			Lactulose	C				
			Alfuzosin	C				
			Bendrofluazide	C				
			Tramadol	C				

Date:07/28/04ISR Number: 4413857-5Report Type:Expedited (15-DaCompany Report #BE-JNJFOC-20040403935
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cytomegalovirus Antibody Positive	Foreign Health	Durogesic (Fentanyl) Patch	PS		TRANSDERMAL	TRANSDERMAL	
	Drug Interaction Epstein-Barr Virus Antibody	Professional	Durogesic (Fentanyl) Patch	SS		RESTARTED	WITHOUT NSAID	
	Hepatitis Toxic		Vioxx (Rofecoxib)	SS		25 MG		
	Jaundice		Lioresal (Baclofen)	C				
			Fluanxol (Flupentixol Dihydrochloride)	C				
			Paracetamol (Paracetamol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/04ISR Number: 4414146-5Report Type:Expedited (15-DaCompany Report #200410493BNE
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Foreign Health Professional	Aspirin (Acetylsalicylic Acid)	PS		ORAL	150 MG, TOTAL	
	Renal Failure Acute	Other					DAILY, ORAL	
			Rofecoxib	SS		ORAL	25 MG, TOTAL	
							DAILY , ORAL	
			Co-Codamol	C				
			Tramadol	C				
			Cod Liver Oil	C				

Date:07/29/04ISR Number: 4410452-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Tenderness
Hospitalization -	Adenomatous Polyposis
Initial or Prolonged	Coli
Disability	Anaemia
	Aortic Atherosclerosis
	Aortic Stenosis
	Arthralgia
	Aspiration
	Asthenia
	B-Cell Small Lymphocytic
	Lymphoma
	Biopsy Bone Marrow
	Abnormal
	Cancer Pain
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Cardiovascular Disorder
	Colonic Polyp
	Crepitations
	Depressed Level Of
	Consciousness

Depression
Diabetes Mellitus
Diastolic Dysfunction
Diverticulum
Dyspnoea Exertional
Dyspnoea Paroxysmal
Nocturnal
Emotional Distress
Emphysema
Facial Palsy
Fall
Fatigue
Femur Fracture
Flank Pain
Fluid Retention
Gastrointestinal
Haemorrhage
Haematuria
Haemorrhage Intracranial
Haemorrhoids
Hemiparesis

		Hyperhidrosis					
		Hypertension					
		Influenza	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia	Professional	Pepcid	C		ORAL
		Lung Disorder		Lasix (Furosemide)	C		
UNKNOWN							
		Lymphadenopathy		Neurontin	C		
UNKNOWN							
		Lymphadenopathy		Ibuprofen	C		
UNKNOWN							
		Mediastinal		Zestril	C		
UNKNOWN							
		Marrow Hyperplasia		Lithium Carbonate	C		
UNKNOWN							
		Mass					
		Nasopharyngitis					
		Nausea					
		Non-Hodgkin'S Lymphoma					
		Non-Hodgkin'S Lymphoma					
		Stage Iv					
		Oedema Peripheral					
		Oesophagitis Haemorrhagic					
		Orthopnoea					
		Pain In Extremity					
		Pathological Fracture					
		Pitting Oedema					
		Platelet Function Test					
		Abnormal					
		Pleural Effusion					
		Pneumonia Aspiration					
		Proctitis					
		Productive Cough					
		Pulmonary Hypertension					
		Pulse Absent					
		Pyrexia					
		Rectal Haemorrhage					
		Rectal Polyp					
		Respiratory Distress					
		Respiratory Failure					
		Respiratory Rate					
		Increased					
		Sepsis					
		Septic Shock					
		Sinus Tachycardia					
		Sinusitis					

Splenomegaly
Sputum Discoloured
Stomatitis
Ventricular Hypertrophy
Vomiting
Wheezing

Date:07/29/04ISR Number: 4410807-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anaemia
	Arrhythmia
	Asthenia
	Blood Pressure Increased
	Chest Pain
	Chronic Fatigue Syndrome
	Cyst

		Emotional Distress Hyperlipidaemia Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Lortab	C		
UNKNOWN							
		Protrusion		Proventil	C		
RESPIRATORY							
		Large Intestinal Ulcer					
(INHALATION)							
		Haemorrhage		Micardis	C		
UNKNOWN							
		Nasopharyngitis		Sular	C		
UNKNOWN							
		Nausea Oedema Oesophageal Ulcer Haemorrhage Osteoarthritis Road Traffic Accident Spinal Disorder Spinal Osteoarthritis Stomach Discomfort Strabismus Upper Respiratory Tract Infection Vitamin B12 Deficiency					

Date:07/29/04ISR Number: 4410810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Arthropathy Atrial Fibrillation Back Pain Basal Cell Carcinoma Blood Urea Increased Bronchitis Bursitis Chest Pain Condition Aggravated Cough Disease Recurrence

Drug Ineffective
Drug Intolerance
Dyspepsia
Dyspnoea
Ecchymosis
Electrocardiogram St
Segment Depression
Headache
Heart Rate Increased
Hepatitis
Hypertension
Hyperthyroidism
Hypokalaemia
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Dislocation
Migraine
Muscle Spasms

		Myalgia					
		Myopathy					
		Nasal Septum Deviation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Jaw		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Palpitations		[Therapy			
		Pneumonia		Unspecified]	C		
UNKNOWN							
		Radiculitis Cervical		Acyclovir	C		
UNKNOWN							
		Rectocele		Vitamins			
		Recurrent Cancer		(Unspecified)	C		
UNKNOWN							
		Respiratory Tract		Aspirin	C		
UNKNOWN							
		Infection		Lipitor	C		
UNKNOWN							
		Rotator Cuff Syndrome		Calcium			
		Sinusitis		(Unspecified)	C		
UNKNOWN							
		Spinal Osteoarthritis		Premarin	C		
UNKNOWN							
		Stress Incontinence					
		Temporal Arteritis					
		Temporomandibular Joint					
		Syndrome					
		Tooth Disorder					
		Troponin Increased					
		Urinary Retention					
		Ventricular Extrasystoles					
		Viral Upper Respiratory					
		Tract Infection					
		Visual Disturbance					

Date:07/29/04ISR Number: 4410817-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00777
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL

Other	Dyspnoea	Vioxx	SS	Merck & Co., Inc	
UNKNOWN					
	Hypertension	Tylenol With Codeine #4	C		ORAL
	Oedema Peripheral	Lomotil	C		ORAL
	Renal Failure	Phenergan With Codeine	C		ORAL
		Valium	C		ORAL
		Advair	C		
RESPIRATORY					
(INHALATION)					

Date:07/29/04ISR Number: 4410833-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00068
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Other	Arrhythmia
	Blood Cholesterol Increased
	Breast Disorder
	Chest Pain
	Emotional Distress
	Gastric Disorder
	Heart Rate Irregular
	Hypertension
	Nervousness
	Peptic Ulcer

	Stress						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/29/04ISR Number: 4411354-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Haemangioma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular		Celebrex	C				
UNKNOWN								
Other	Arteriovenous							
	Malformation							
	Convulsion							
	Emotional Distress							
	Haemarthrosis							
	Ligament Injury							
	Ligament Sprain							

Date:07/29/04ISR Number: 4411362-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00178
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholecystitis Chronic		Vioxx	PS	Merck & Co., Inc	ORAL	61	DAY
Initial or Prolonged	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	61	DAY
	Hepatitis C							

Date:07/29/04ISR Number: 4411363-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Disorder		Tylenol	C		
UNKNOWN						
	Bronchitis					
	Disability					
	Emotional Distress					
	Fall					
	Gait Spastic					
	Intermittent Claudication					
	Obstruction					
	Peripheral Circulatory					
	Failure					
	Road Traffic Accident					

Date:07/29/04ISR Number: 4411368-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00501
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Non-Cardiac Chest Pain		Hydrodiuril	C		ORAL
			Cozaar	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/04ISR Number: 4411369-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00257
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Gastrointestinal Erosion Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/29/04ISR Number: 4411370-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		242 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		242 DAY
Disability	Arteriospasm Coronary		Darvocet-N	C				UNKNOWN
	Dyspepsia		Chondroitin	C				UNKNOWN
	Ovarian Cystectomy		Voltaren	C				UNKNOWN
	Tachyarrhythmia		Evening Primrose Oil	C				UNKNOWN
			Glucosamine	C				UNKNOWN
			Humibid	C				UNKNOWN
			Entex La	C				UNKNOWN
			Maxzide	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Bactrim	C				UNKNOWN
			Claritin-D	C				UNKNOWN
			Nasonex	C			1758 DAY	UNKNOWN
			Naprosyn	C			764 DAY	UNKNOWN

Inderal La	C	UNKNOWN
Inderal La	C	UNKNOWN
Pseudoephedrine	C	UNKNOWN
Zantac	C	UNKNOWN

Date:07/29/04ISR Number: 4411464-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00179
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Aspirin	SS		ORAL		
	Melaena		Clopidogrel Bisulfate	SS		ORAL		
	Oesophagitis		Alfuzosin Hydrochloride	C		ORAL		
			Senna	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Lactulose	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

Date:07/29/04ISR Number: 4411465-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00111
Age:83 YR Gender:Male I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	285	DAY
Perforation		Vioxx	SS	Merck & Co., Inc	ORAL	285	DAY
		Albuterol	C			RESPIRATORY (INHALATION)	
		Amlodipine Besylate	C			UNKNOWN	
		Bisoprolol Fumarate	C			UNKNOWN	
		Fosinopril Sodium	C			UNKNOWN	
		Ibuprofen	C			UNKNOWN	

Date:07/29/04ISR Number: 4413564-9Report Type:Expedited (15-DaCompany Report #B0339617A
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Complete	Foreign Literature	Lithium Salt (Lithium Salt)	PS			200 MG /TWICE Required PER DAY	12 YR
	Blood Pressure Diastolic	Health						
Intervention to Prevent Permanent Impairment/Damage	Decreased Blood Pressure Increased	Professional	Rofecoxib (Rofecoxib)	SS			25 MG/TWICE PER DAY	8 DAY
	Drug Toxicity							
	Dysarthria		Carbamazepine	C				
	Electrocardiogram T Wave Inversion		Pimpamperone	C				
			Mirtazapine	C				
	Extrapyramidal Disorder		Propranolol Hydrochloride	C				
	Headache							
	Nausea		Paracetamol	C				
	Pain In Extremity							
	Sinus Arrest							
	Sinus Bradycardia							

Somnolence
Vomiting

Date:07/29/04ISR Number: 4415034-0Report Type:Expedited (15-DaCompany Report #8496
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema	Study	Methotrexate	PS		ORAL	10 MG WEEKLY	
	Diarrhoea						PO	
	Exposure To Toxic Agent		Oxycontin	SS		ORAL	10 MG ALT	
							DAYS PO	
			Vioxx	SS		ORAL	25 MG DAILY	
							PO	
			Enbrel	SS			SUBCUTANEOUS	25 MG 2/WK,
							SC	
			Prednisone	C				
			Tylenol W/Codeine	C				
			Valiuim	C				
			Klonopin	C				
			Acetylsalicylic Acid	C				
			Accupril	C				
			Atenolol	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/04ISR Number: 4411553-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		9 DAY
	Bladder Spasm		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
	Bronchial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		13 DAY
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		13 DAY
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		9 DAY
	Contusion		Tylenol	C				UNKNOWN
	Dysuria		Parafon Forte	C				UNKNOWN
	Embolic Stroke		Serevent	C				RESPIRATORY (INHALATION)
	Emotional Distress							
	Fall		Proventil	C				RESPIRATORY (INHALATION)
	Hypertension							
	Joint Injury		Aspirin	C				UNKNOWN
	Migraine		Lioresal	C				UNKNOWN
	Myofascial Pain Syndrome		Valium	C				UNKNOWN
	Nerve Compression		Demerol	C				UNKNOWN
	Oedema Peripheral		Ditropan	C				UNKNOWN
	Pollakiuria		Inderal	C				UNKNOWN
	Rotator Cuff Syndrome							
	Urinary Tract Infection							

Date:07/30/04ISR Number: 4411618-4Report Type:Expedited (15-DaCompany Report #PHRM2004FR02378
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Macrocytic		Lescol	PS	Novartis Sector: Pharma	ORAL	80 mg/day	
	Antinuclear Antibody							
	Positive		Domperidone	SS		ORAL		
	Aplastic Anaemia		Ogast	SS		ORAL		
	Aspartate		Vioxx	SS		ORAL		
	Aminotransferase		Di-Antalvic	SS		ORAL		
	Increased		Sectral	SS	Aventis	ORAL	100 mg/day	
	Autoimmune Thyroiditis							
	Cholestasis							
	Coagulation Factor V							
	Level Decreased							
	Cytolytic Hepatitis							
	Hepatic Cirrhosis							
	Hepatomegaly							
	Hypoalbuminaemia							
	Prothrombin Level							
	Decreased							
	Serum Ferritin Increased							
	Smooth Muscle Antibody							
	Positive							

Date:07/30/04ISR Number: 4411850-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Anaemia
Disability	Anxiety
	Arthralgia
	Back Pain
	Cardiac Murmur

		Chest Pain					
		Cholesterol Granuloma					
		Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea	Professional	Lorcet Plus	C		
UNKNOWN							
		Erythema					
		Heart Rate Irregular					
		Hyperlipidaemia					
		Hypoacusis					
		Hypoaesthesia					
		Insomnia					
		Labile Hypertension					
		Muscle Spasms					
		Nail Disorder					
		Nausea					
		Oedema					
		Osteoarthritis					
		Rhinitis Allergic					
		Rhinorrhoea					
		Spherocytic Anaemia					
		Tachycardia					

Date:07/30/04ISR Number: 4411856-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea	Professional				
		Headache					
		Myocardial Infarction					

Date:07/30/04ISR Number: 4411857-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Anoxic Encephalopathy	Professional	Tylenol With Codeine			
Initial or Prolonged		Anxiety		#4	C		
UNKNOWN							

Other	Cardio-Respiratory Arrest	Tylenol With Codeine #4	C		
UNKNOWN	Convulsion				
UNKNOWN	Coronary Artery Occlusion	Celebrex	C		
	Deep Vein Thrombosis	Arthrotec	C		ORAL
	Gastric Disorder	Arthrotec	C		ORAL
	Hypertension	Arthrotec	C		ORAL
UNKNOWN	Hypokalaemia	Premarin	C		
UNKNOWN	Lumbar Spinal Stenosis	Provera	C		
UNKNOWN	Myocardial Infarction	Daypro	C		
	Palpitations				
	Pneumonia Aspiration				
	Postoperative Ileus				
	Pulmonary Oedema				
	Shock				
	Syphilis				

Date:07/30/04ISR Number: 4411935-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Arthritis
Other	Asthenia
	Asthma
	Atherosclerosis
	Benign Prostatic Hyperplasia
	Bladder Obstruction
	Cardiac Failure Congestive
	Cardiomegaly
	Cellulitis
	Chondromalacia
	Chondrosis
	Chronic Obstructive Pulmonary Disease
	Condition Aggravated
	Constipation
	Coronary Artery Disease
	Cough
	Depressed Level Of Consciousness
	Diabetes Mellitus Inadequate Control
	Duodenal Ulcer
	Emotional Distress
	Gastric Ulcer
	Gastrooesophageal Reflux Disease
	Haemodialysis
	Hyperhidrosis
	Hypocalcaemia
	Hypotonia
	Hypoxia
	Injury
	Insomnia
	Interstitial Lung Disease
	Leukocytosis
	Limb Injury
	Meniscus Lesion
	Mental Status Changes
	Metabolic Acidosis
	Monarthritis

Muscle Spasms
Muscular Weakness
Myocardial Infarction
Obstructive Uropathy
Oedema Peripheral
Pain
Pain In Extremity
Pneumonia
Rash Erythematous
Rash Maculo-Papular
Renal Failure
Renal Tubular Necrosis
Rhabdomyolysis
Rotator Cuff Syndrome
Sepsis

		Skin Hyperpigmentation					
		Tachycardia					
		Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Vascular Calcification	Professional	Zocor	SS		ORAL
		Ventricular Hypertrophy		[Therapy			
		Weight Increased		Unspecified]	C		
UNKNOWN							
				Tylenol Arthritis			
				Extended Relief	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Diltiazem Msd	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Hydrocodone			
				Bitartrate	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Date:07/30/04ISR Number: 4411937-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Benign Neoplasm	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Tylenol	C		
UNKNOWN							
		Coronary Artery		Acetaminophen And			
		Restenosis		Propoxyphene			
		Depression		Napsylate	C		
UNKNOWN							
		Dermatitis		Xanax	C		
UNKNOWN							
		Epicondylitis		Aspirin	C		
UNKNOWN							

	Exostosis	Librax Capsules	C
UNKNOWN			
	Gastroenteritis Viral	Cyclobenzaprine	
	Generalised Anxiety	Hydrochloride	C
UNKNOWN			
	Disorder	Allegra	C
UNKNOWN			
	Gout	Prilosec	C
UNKNOWN			
	Haematoma	Zantac	C
UNKNOWN			
	Hypercholesterolaemia		
	Hypertension		
	Insomnia		
	Intervertebral Disc		
	Degeneration		
	Lung Neoplasm		
	Myocardial Infarction		
	Myositis		
	Osteochondrosis		
	Pain In Extremity		
	Rectal Haemorrhage		
	Rotator Cuff Syndrome		
	Sleep Disorder		
	Tendonitis		
	Tinnitus		
	Urinary Tract Infection		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/30/04ISR Number: 4411940-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00048
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukocytoclastic Vasculitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Insulin Human	C		INTRAMUSCULAR		
			Piretanide	C		ORAL		
			Ramipril	C		ORAL		

Date:07/30/04ISR Number: 4411941-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	244	DAY
	Abdominal Strangulated		Vicodin Tablets	C			UNKNOWN	
Other	Hernia		Zyloprim	C			UNKNOWN	
	Acute Prerenal Failure		Xanax	C			UNKNOWN	
	Anaemia		Ecotrin	C			UNKNOWN	
	Benign Prostatic		Aspirin	C			UNKNOWN	
	Hyperplasia		Lipitor	C			UNKNOWN	
	Cardiac Failure		Ultram	C			UNKNOWN	
	Congestive		Carisoprodol	C			UNKNOWN	
	Carotid Bruit		Vasotec	C			UNKNOWN	
	Carpal Tunnel Syndrome		Micronase	C			UNKNOWN	
	Colonic Polyp		Prevacid	C			UNKNOWN	
	Deafness Neurosensory		Glucophage	C			UNKNOWN	
	Gastric Ulcer Haemorrhage		Centrum	C			UNKNOWN	

Gastritis
Gastritis Erosive
Gastroenteritis
Haemorrhoids
Hiatus Hernia
Intervertebral Disc
Degeneration
Renal Failure
Small Intestinal
Obstruction
Spinal Column Stenosis
Spinal Osteoarthritis
Thrombocytopenia

Date:07/30/04ISR Number: 4411942-5Report Type:Expedited (15-DaCompany Report #BE-MERCK-0407BEL00011
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1083 DAY	
			Furosemide	C		ORAL		
			Spironolactone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:07/30/04ISR Number: 4411944-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00260
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dyspnoea
	Gastrointestinal Ulcer
	Oesophagitis

Syncope

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Professional	Ibuprofen	SS		ORAL		
	Ibuprofen	SS		ORAL		
	Acetaminophen	C		ORAL		
	Atorvastatin Calcium	C		ORAL		

Date:07/30/04ISR Number: 4411945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Darvocet-N	C				
UNKNOWN								
	Cardiomegaly		Wellbutrin	C				
UNKNOWN								
	Carotid Artery Occlusion		Soma	C		ORAL		
	Cerebrovascular Accident		Diflunisal	C				
UNKNOWN								
	Chest Pain		Premarin	C				
UNKNOWN								
	Concussion		Ultram	C				
UNKNOWN								
	Constipation		Estratest	C				
UNKNOWN								
	Contusion		Allegra	C				
UNKNOWN								
	Depression		Rebetron	C				
UNKNOWN							3	DAY
	Drug Abuser		Nortriptyline	C				
UNKNOWN								
	Excoriation		Accupril	C				
UNKNOWN								
	Fall		Rebetol	C				
UNKNOWN								
	Gastrointestinal Haemorrhage							
	Gastrooesophageal Reflux							

Disease
Hyperlipidaemia
Laceration
Macrocytosis
Melaena
Microcytic Anaemia
Oedema Peripheral
Orthostatic Hypotension
Pain
Pain In Extremity
Pneumonia
Pulmonary Congestion
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation
Tibia Fracture
Urinary Tract Infection
Weight Increased

Date:07/30/04ISR Number: 4411954-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00078
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Gastric Adenoma Gastric Ulcer Gastrooesophageal Reflux Disease

	Hiatus Hernia Melaena Metaplasia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
		Professional	Aspirin	C		ORAL	
			Deanol Tartrate And Ginseng And Minerals (Unspecified) And Rutin And Vitamins (Unspecified)	C		ORAL	
			Magnesium (Unspecified)	C			UNKNOWN

Date:07/30/04ISR Number: 4412326-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03247
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Arthritis		Celebrex	SS			
Other	Cardiac Arrest		Aspirin	C			UNKNOWN
	Coronary Artery Occlusion		Cardizem Cd	C			UNKNOWN
	Cough		Zestril	C			UNKNOWN
	Gastrooesophageal Reflux		Zestril	C			UNKNOWN
	Disease		Nitroglycerin	C			UNKNOWN
	Hyperlipidaemia Hypokalaemia Myocardial Infarction Renal Failure Acute Thrombocytopenia						

Date:07/30/04ISR Number: 4412339-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Acute Myocardial Infarction
	Asthenia
	Back Injury
	Benign Breast Neoplasm
	Blood Potassium Increased
	Bronchitis
	Carcinoma In Situ Of Skin
	Chest Pain
	Coronary Artery Disease
	Deep Vein Thrombosis
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Enterocele
	Fall
	Gastrointestinal Infection
	Gastrooesophageal Reflux Disease
	Headache
	Hiatus Hernia
	Hypoaesthesia

		Osteoarthritis					
		Pulmonary Embolism					
		Radius Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Ulna Fracture		Tylenol	C		
UNKNOWN							
		Urinary Tract Infection		Z-Pak	C		
UNKNOWN							
		Visual Disturbance		Cipro	C		
UNKNOWN							
				Diuretic (Unspecified)	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Advil	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Asacol	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Quinidine	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							

Date:07/30/04ISR Number: 4412345-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Adrenal Adenoma
	Angina Pectoris
	Arthritis
	Blood Cholesterol Increased
	Bronchitis

Cardiac Murmur
Cataract
Cellulitis
Chest Pain
Chronic Fatigue Syndrome
Constipation
Cystitis
Cystitis Glandularis
Dizziness
Dyspepsia
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Ear Infection
Electrocardiogram
Abnormal
Emotional Distress
Gastrointestinal Ulcer
Gastrooesophageal Reflux
Disease
Haematuria
Hypercholesterolaemia
Increased Tendency To
Bruise
Mitral Valve Incompetence
Nausea
Osteoporosis
Palpitations
Parotid Gland Enlargement

	Peptic Ulcer						
	Rhinitis Allergic						
	Stress Incontinence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Thyroid Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL	
	Tooth Abscess		Tylenol	C		ORAL	
	Urethral Caruncle		Pravachol	C			UNKNOWN
	Urinary Tract Infection						

Date:07/30/04ISR Number: 4412346-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0407NOR00044
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
	Vomiting		Fosamax	C		ORAL	
			Aspirin And Magnesium Oxide	C			UNKNOWN
			Benserazide Hydrochloride And Levodopa	C			UNKNOWN
			Calcium Carbonate	C			UNKNOWN
			Zopiclone	C			UNKNOWN
			Flupentixol Hydrochloride	C			UNKNOWN
			Isosorbide Mononitrate	C			UNKNOWN
			Cozaar	C		ORAL	

Date:07/30/04ISR Number: 4412347-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02310
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY

Initial or Prolonged				[Therapy Unspecified]	C		
UNKNOWN							

Date:07/30/04ISR Number: 4412349-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00044
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypotension		Hydrochlorothiazide And Lisinopril	SS		ORAL		
	Renal Failure Acute		Mianserin Hydrochloride	SS		ORAL	7	DAY
			Oxazepam	SS		ORAL	7	DAY
			Fenofibrate	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		

Date:07/30/04ISR Number: 4412351-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02393
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Tylenol	C				
UNKNOWN								
	Therapeutic Response		Lotrel	C				
UNKNOWN								
	Decreased		Glucosamine	C				
UNKNOWN								

			Levoxyl	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Pravachol	C		
UNKNOWN						

Date:07/30/04ISR Number: 4412401-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
	Chromaturia		Allopurinol	C		
UNKNOWN						
	Contusion		Norvasc	C		
UNKNOWN						
	Coronary Artery		Ecotrin	C		
UNKNOWN						
	Restenosis		Lipitor	C		
UNKNOWN						
	Cough		Monopril	C		
UNKNOWN						
	Decreased Appetite		Lasix (Furosemide)	C		
UNKNOWN						
	Depressed Mood		Indocin			
	Diarrhoea		(Indomethacin)	C		
UNKNOWN						
	Disturbance In Attention		Toprol Xl Tablets	C		
UNKNOWN						
	Diverticulum Intestinal		Lopressor	C		
UNKNOWN						
	Haemorrhagic		Naproxen	C		
UNKNOWN						
	Drug Ineffective		Prilosec	C		
UNKNOWN						
	Dyspnoea		K-Dur	C		
UNKNOWN						
	Fatigue					
	Fluid Retention					
	Hypertension					
	Hypoaesthesia					

Insomnia
Iron Deficiency
Libido Decreased
Lung Neoplasm
Myocardial Infarction
Nausea
Non-Cardiac Chest Pain
Oedema Peripheral
Paraesthesia
Pneumonia
Prostatic Specific
Antigen Increased
Proteinuria
Renal Cyst
Rheumatoid Arthritis
Rhinitis Allergic
Stress
Tendon Rupture
Umbilical Hernia
Ventricular Extrasystoles

Date:07/30/04ISR Number: 4412410-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00235
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		[Therapy Unspecified]	C				
	Irritable Bowel Syndrome							
	Nausea		Tylenol	C				
	Vomiting		Darvocet-N	C				

	Emergen C	C
UNKNOWN		
	Astelin	C
UNKNOWN		
	Meridia	C
UNKNOWN		
	Valtrex	C
UNKNOWN		
	Zomig	C
UNKNOWN		
	Imitrex	C
UNKNOWN		
	Stadol	C
UNKNOWN		
	Zyrtec	C
UNKNOWN		
	Allegra	C
UNKNOWN		
	Claritin	C
UNKNOWN		
	Anaprox	C
UNKNOWN		

Date:07/30/04ISR Number: 4415191-6Report Type:Expedited (15-DaCompany Report #8157
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign	Methotrexate	PS				
		Health	Premarin	SS				
		Professional	Augmentin	SS				
		Other	Co-Dydramol	SS				
			Fluoxetine	SS				
			Humira	SS				
			Rofecoxib	SS				

Date:07/31/04ISR Number: 4412562-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Anxiety	Prevacid	C	
UNKNOWN				
Other	Arthralgia	Zocor	C	ORAL
	Back Pain			
	Blood Cholesterol			
	Increased			
	Chest Pain			
	Closed Head Injury			
	Constipation			
	Convulsion			
	Costochondritis			
	Depression			
	Dyspepsia			
	Dysuria			
	Erectile Dysfunction			
	Eye Disorder			
	Fall			
	Gastrooesophageal Reflux			
	Disease			
	Haemorrhage			
	Head Injury			
	Hypertension			
	Kidney Infection			
	Migraine			
	Oedema Peripheral			
	Oesophageal Disorder			
	Palpitations			
	Renal Disorder			
	Ulcer			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/31/04ISR Number: 4412563-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaphylactic Reaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL
34 DAY						
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
34 DAY						
	Carpal Tunnel Syndrome		Detrol	C		ORAL
	Cerebrovascular Accident		Prednisone	C		ORAL
	Chronic Obstructive		Aspirin	C		
UNKNOWN						
	Pulmonary Disease		Aspirin	C		
UNKNOWN						
	Deep Vein Thrombosis		Lotensin	C		ORAL
	Diastolic Dysfunction		Zyrtec	C		ORAL
	Drug Ineffective		Flonase	C		
RESPIRATORY						
	Emotional Distress					
(INHALATION)						
	Epistaxis		Hydro-Chlor	C		
UNKNOWN						
	Feeling Abnormal					
	Gastrooesophageal Reflux					
	Disease					
	Heart Rate Irregular					
	Lung Disorder					
	Muscle Spasms					
	Oedema Peripheral					
	Osteoarthritis					
	Swelling Face					

Date:08/02/04ISR Number: 4412810-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00065
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bursitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
	Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL

	Intervertebral Disc	Zyrtec	C
UNKNOWN			
	Protrusion	Flonase	C
UNKNOWN			
	Lacunar Infarction	Glyburide	C
UNKNOWN			
	Nerve Injury		
	Pain In Extremity		
	Rhinitis Allergic		
	Somnolence		
	Spinal Column Stenosis		
	Stomach Discomfort		

Date:08/02/04ISR Number: 4412811-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00044
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Face Injury	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypotension		Hydrochlorothiazide And Lisinopril	SS		ORAL		
	Renal Failure Acute		Mianserin Hydrochloride	SS		ORAL	7 DAY	
			Oxazepam	SS		ORAL	7 DAY	
			Fenofibrate	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/04ISR Number: 4412812-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00116
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		[Therapy					
	Diabetes Mellitus		Unspecified]	C				
UNKNOWN								
	Emotional Distress		Hydrocodone/Apap	C				
UNKNOWN								
	Glucose Tolerance		Cipro	C				
UNKNOWN								
	Impaired		Zoloft	C				
UNKNOWN								
	Headache		Detrol	C				
UNKNOWN								
	Nausea		Smz-Tmp	C				
UNKNOWN								
	Nephrolithiasis		Diphenhydramine					
	Stent Placement		Hydrochloride	C				
UNKNOWN								
	Stomach Discomfort		Ortho Tri-Cyclen	C				
UNKNOWN								
	Systemic Lupus		Phenazopyridine					
	Erythematosus		Hydrochloride	C				
UNKNOWN								

Date:08/02/04ISR Number: 4412816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
350 DAY								
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
350 DAY								
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc			
UNKNOWN	27 DAY							
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Restenosis		Vioxx	SS	Merck & Co., Inc			
UNKNOWN	27 DAY							

	Diabetes Mellitus	[Therapy	
	Diverticulitis	Unspecified]	C
UNKNOWN			
	Dysphonia	Norco	C
UNKNOWN			
	Dyspnoea	Aspirin	C
UNKNOWN			
	Emotional Distress	Atenolol	C
UNKNOWN			
	Facet Joint Syndrome	Tenormin	C
UNKNOWN			
	Hand Fracture	Celebrex	C
UNKNOWN			
	Hyperlipidaemia	Celebrex	C
UNKNOWN			
	Hypertension	Chlorthalidone	C
UNKNOWN			
	Insomnia	Diovan	C
UNKNOWN			
	Intervertebral Disc	Ultram	C
UNKNOWN			
	Protrusion	Avandia	C
UNKNOWN			
	Lumbar Spinal Stenosis	Hygroton	C
UNKNOWN			
	Muscle Strain	Cyclobenzaprine	
	Nervousness	Hydrochloride	C
UNKNOWN			
	Pneumothorax	Cardizem	C
UNKNOWN			
	Raynaud'S Phenomenon	Propecia	C
UNKNOWN			
	Respiratory Failure	Glucovance	C
UNKNOWN			
	Somnolence	Hydrocodone	
		Hydrochloride	C
UNKNOWN			
		Altace	C
UNKNOWN			

Date:08/02/04ISR Number: 4413125-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Agitation
	Angina Pectoris

		Anoxic Encephalopathy					
		Anxiety					
		Atrioventricular Block	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complete	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	MON						
		Axillary Vein Thrombosis	Professional	Alprazolam	C		
UNKNOWN							
		Back Pain		Clonidine	C		
UNKNOWN							
		Cardiac Failure		Estrogens,			
		Congestive		Conjugated And			
		Cardiogenic Shock		Progesterone	C		
UNKNOWN							
		Cardiomyopathy		Insulin	C		
UNKNOWN							
		Carotid Artery Occlusion		Zestril	C		
UNKNOWN							
		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Claustrophobia					
		Colitis Ischaemic					
		Coma					
		Constipation					
		Coronary Artery Disease					
		Cough					
		Diabetes Mellitus					
		Diabetes Mellitus					
		Insulin-Dependent					
		Diabetic Retinopathy					
		Escherichia Urinary Tract					
		Infection					
		Fall					
		Gastritis					
		Haematoma					
		Haemorrhage					
		Haemorrhoidal Haemorrhage					
		Hepatic Failure					
		Hepatitis B					
		Hyperglycaemia					
		Hypertension					
		Hypothyroidism					
		Injury					
		Ischaemic Cardiomyopathy					
		Low Cardiac Output					
		Syndrome					
		Mitral Valve Incompetence					

Muscle Tightness
Myocardial Infarction
Nephropathy
Osteoarthritis
Pain In Extremity
Pulmonary Hypertension
Rash
Renal Cyst
Renal Failure Acute
Silent Myocardial
Infarction
Tendonitis
Tricuspid Valve
Incompetence
Urinary Tract Infection

Date:08/02/04ISR Number: 4413129-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Betaxolol Ophthalmic Solution	C			UNKNOWN	
	Chest Pain		Calcitonin	C			UNKNOWN	
	Coronary Artery Disease		Digoxin	C			UNKNOWN	
	Dysarthria		Docusate Sodium	C			UNKNOWN	
	Embolism		Trusopt	C			OPHTHALMIC	
	Epistaxis		Vitamin E	C			UNKNOWN	
	Faeces Discoloured		Warfarin	C			UNKNOWN	1284 DAY
	Haematemesis		Zocor	C			UNKNOWN	
	Hypertension		Folic Acid	C			UNKNOWN	
	Injury		Lasix (Furosemide)	C			UNKNOWN	1680 DAY
	Lacunar Infarction		Isosorbide	C			UNKNOWN	
	Melaena		Potassium (Unspecified)	C			UNKNOWN	
	Muscle Spasms		Psyllium Husk	C			UNKNOWN	
	Myalgia							
	Polymyalgia Rheumatica							
	Productive Cough							
	Rheumatoid Arthritis							
	Transient Ischaemic Attack							
	Vascular Graft Occlusion							

Date:08/02/04ISR Number: 4413130-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00446
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Blood Pressure Increased Headache Ingrowing Nail Toe Deformity	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/02/04ISR Number: 4413132-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02536
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Asthenia Asthma Atherosclerosis Blood Cholesterol Increased Cerebrovascular Accident Depression Drug Hypersensitivity Eye Pain Gastrooesophageal Reflux Disease Gout Headache High Density Lipoprotein Decreased Hypoacusis Hypoaesthesia Irritability

		Low Density Lipoprotein Increased					
		Memory Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Prolapse	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Darvocet-N	C		
UNKNOWN							
		Renal Function Test		Clonidine	C		ORAL
		Abnormal		Tiazac	C		
UNKNOWN							
		Vision Blurred		Avalide	C		
UNKNOWN							
				Avalide	C		
UNKNOWN							
				Avalide	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							

Date:08/02/04ISR Number: 4413137-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00650
Age:88 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abasia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pain	Professional	Maxzide	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							

Date:08/02/04ISR Number: 4413138-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01261
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Professional	Hydralazine	C		
UNKNOWN							

				Tamoxifen Citrate	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Date:08/02/04ISR Number: 4413139-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02325
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Transient Ischaemic		Skelaxin	C				
UNKNOWN								
	Attack							

Date:08/02/04ISR Number: 4413140-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01614
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:08/02/04ISR Number: 4413141-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00067
Age: Gender:Male I/FU:F

Outcome	PT
Death	Adverse Event
	Gastrointestinal Ulcer
	Haemorrhage

Unevaluable Event

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS			UNKNOWN	

Date:08/02/04ISR Number: 4413143-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blister		Vioxx	SS	Merck & Co., Inc	ORAL		
	Condition Aggravated		Atenolol	C			UNKNOWN	
	Depression		Celebrex	C			UNKNOWN	
	Drug Hypersensitivity		Flexeril	C			UNKNOWN	
	Emotional Distress		Arthrotec	C		ORAL		
	Faeces Discoloured		Hydrodiuril	C		ORAL		
	Furuncle							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Injury							
	Neck Pain							
	Oedema Peripheral							
	Road Traffic Accident							
	Sleep Apnoea Syndrome							

Date:08/02/04ISR Number: 4413171-8Report Type:Expedited (15-DaCompany Report #04P-167-0262108-00
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Consumer	Augmentin	PS	Glaxosmithkline		UNKNOWN	
			Adalimumab	SS			SUBCUTANEOUS	40MG Every

two weeks

	Fluoxetine	SS	
UNKNOWN			
	Rofecoxib	SS	
UNKNOWN			
	Methotrexate	SS	
UNKNOWN			
	Co-Dydramol	SS	Glaxosmithkline
UNKNOWN			
	Premarin	SS	
UNKNOWN			
	Clavulin	C	Glaxosmithkline
UNKNOWN			
	Paramol-118	C	
UNKNOWN			

Date:08/02/04ISR Number: 4413197-4Report Type:Direct Company Report #CTU 224069
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
Initial or Prolonged	Gastric Ulcer						ORAL	
	Haemoglobin Decreased		Aspirin	SS		ORAL	ORAL	
	Medication Error		Lisinopril	C				
	Melaena		Lasix	C				
			Flomax	C				
			Toprol Xl	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/04ISR Number: 4413510-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
Initial or Prolonged	Arteriovenous Fistula		Tylenol	C				UNKNOWN
Other	Arthropathy		Ecotrin	C				UNKNOWN
	Bundle Branch Block Left		Viagra	C				UNKNOWN
	Calcinosis		Calan Sr	C				UNKNOWN
	Chest Discomfort		Zocor	C				UNKNOWN
	Coronary Artery Disease		Celebrex	C				UNKNOWN
	Dehydration		Advil	C				UNKNOWN
	Diverticulum Intestinal Haemorrhagic							
	Emotional Distress							
	Gastritis Atrophic							
	Gastrooesophageal Reflux Disease							
	Helicobacter Infection							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Neck Pain							
	Neuropathy Peripheral							
	Renal Cyst							
	Rotator Cuff Syndrome							
	Sciatica							
	Scoliosis							
	Spinal Column Stenosis							
	Stent Occlusion							

Date:08/02/04ISR Number: 4413517-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00075
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Rhinocort	C				
RESPIRATORY								
	Dyspnoea							
(INHALATION)								
	Haematochezia		Celebrex	C				
UNKNOWN								
	Haemorrhage		Flexeril	C		ORAL		
			Spironolactone	C				
UNKNOWN								
			Advair	C				
RESPIRATORY								
(INHALATION)								
			Nifedical Xl	C				
UNKNOWN								
			Omeprazole	C				
UNKNOWN								

Date:08/02/04ISR Number: 4413525-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
	Abdominal Pain
Other	Abnormal Faeces
	Adenomyosis
	Amnesia
	Angina Pectoris
	Anorexia
	Anxiety
	Aortic Valve Incompetence

Arrhythmia
Arthralgia
Arthritis
Asthenia
Atrioventricular Block
Auditory Recruitment
Back Pain
Bronchitis
Cardiac Valve Disease
Cardiomyopathy
Cellulitis
Chest Discomfort
Chest Pain
Coma
Complex Regional Pain
Syndrome
Constipation
Convulsion
Costochondritis
Cough
Dental Caries
Dermatitis
Diarrhoea
Diastolic Dysfunction
Dilatation Atrial
Dilatation Ventricular
Diverticulitis
Dizziness
Drug Withdrawal Syndrome
Duodenal Ulcer
Duodenitis
Dyspepsia
Dysphagia
Dyspnoea
Dyspnoea Exertional
Dysuria
Emotional Distress
Encephalopathy
Face Oedema
Fatigue
Feeling Abnormal
Gastritis
Grand Mal Convulsion
Haematoma Infection
Haemorrhage
Haemorrhoids
Helicobacter Gastritis

Hyperhidrosis
Hypertension
Hypertensive Crisis
Hypoaesthesia
Hypokalaemia
Hypotension
Infusion Site Pain
Infusion Site Reaction
Infusion Site Swelling
Irritable Bowel Syndrome
Joint Contracture
Laceration
Leiomyoma
Loss Of Consciousness

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Malignant Hypertension					
		Melaena					
		Memory Impairment					
		Mental Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Mental Status Changes		Vioxx	SS	Merck & Co., Inc	ORAL
		Micturition Urgency		Cardura	C		
UNKNOWN							
		Mitral Valve Incompetence		Normodyne	C		
UNKNOWN							
		Myocardial Infarction		Prevacid	C		
UNKNOWN							
		Myocardial Ischaemia		Flagyl	C		
UNKNOWN							
		Nausea		Minoxidil	C		
UNKNOWN							
		Neck Pain		Procardia Xl	C		
UNKNOWN							
		Non-Cardiac Chest Pain					
		Nuclear Magnetic					
		Resonance Imaging Brain					
		Abnormal					
		Oedema					
		Oedema Peripheral					
		Oesophagitis					
		Orthopnoea					
		Osteoarthritis					
		Ovarian Cyst					
		Pain In Extremity					
		Palpitations					
		Paranoia					
		Pelvic Inflammatory					
		Disease					
		Peptic Ulcer					
		Pharyngolaryngeal Pain					
		Pyrexia					
		Rash Generalised					
		Refusal Of Treatment By					
		Patient					
		Renal Failure					
		Salpingitis					
		Sensory Loss					
		Staring					
		Suicidal Ideation					
		Supraventricular					
		Tachycardia					
		Tinnitus					

Tonic Clonic Movements
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Uterine Enlargement
Vaginal Discharge
Vaginal Haemorrhage
Ventricular Hypertrophy
Vision Blurred
Vulvovaginal Discomfort

Date:08/02/04ISR Number: 4413603-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00143
Age:51 YR Gender:Female I/FU:F

Outcome PT
Disability Arthritis
Cardiac Disorder
Chest Pain
Cyst

		Dyspepsia					
		Emotional Distress					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Intraspinal Abscess					
		Palpitations					

Date:08/02/04ISR Number: 4413605-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
	Bradyarrhythmia		Vicodin Tablets	C		
UNKNOWN						
	Coronary Artery Disease		Aspirin	C		ORAL
	Coronary Artery		Lipitor	C		ORAL
	Restenosis		Plavix	C		ORAL
41 DAY						
	Drug Ineffective		Plavix	C		ORAL
	Hypertension		Plavix	C		ORAL
41 DAY						
	Hypotension		Flomax (Tamsulosin			
	Injury		Hydrochloride)	C		
UNKNOWN						
	Ischaemic Cardiomyopathy		Plavix	C		ORAL
	Mitral Valve Incompetence		Colace	C		
UNKNOWN						
	Musculoskeletal Chest		Prevacid	C		
UNKNOWN						
	Pain		Synthroid	C		
UNKNOWN						
	Musculoskeletal		Prinivil	C		ORAL
	Discomfort		Zestril	C		
UNKNOWN						
	Myocardial Infarction					
	Prostatic Disorder					
	Pulmonary Embolism					
	Rash					
	Sick Sinus Syndrome					
	Sinus Bradycardia					

Date:08/02/04ISR Number: 4413640-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0407BRA00073
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged	Cough		Captopril	C		ORAL		
	Oedema		Ciprofloxacin	C		ORAL		

Date:08/02/04ISR Number: 4416552-1Report Type:Expedited (15-DaCompany Report #B0339413A
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Foreign	Commit Nicotine					
Initial or Prolonged		Consumer	Polacrilex Lozenge (Nicotine Polacrilex)	PS		BUCCAL	4	MG/TRANSBUCCAL
			Diclofenac Sodium	SS				
			Rofecoxib	SS				
			Raloxifene Hydrochloride	C				
			Simvastatin	C				
			Moclobemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/04ISR Number: 4413847-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angiopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Aortic Valve Incompetence		Robaxin	C				
UNKNOWN								
	Cardiac Disorder		Effexor	C				
UNKNOWN								
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cardiomegaly							
	Coagulation Time							
	Prolonged							
	Coronary Artery Disease							
	Cystitis							
	Deep Vein Thrombosis							
	Depression							
	Diarrhoea							
	Eye Haemorrhage							
	Fatigue							
	Fluid Retention							
	Gallbladder Disorder							
	Gastrointestinal Disorder							
	Hypercholesterolaemia							
	Hypertension							
	Hypertensive							
	Cardiomyopathy							
	Hypertonic Bladder							
	Immune System Disorder							
	Ischaemic Cardiomyopathy							
	Kidney Infection							
	Lung Disorder							
	Macular Degeneration							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nausea							
	Orthostatic Hypotension							
	Osteoporosis							
	Parathyroid Tumour Benign							
	Pericardial Effusion							
	Pulmonary Hypertension							
	Supraventricular							

Extrasystoles
Syncope
Thyroid Disorder
Urinary Tract Infection
Uterine Disorder

Date:08/03/04ISR Number: 4413849-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01950
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Aspartate Aminotransferase Increased
Other	Benign Breast Neoplasm
	Blood Pressure

		Inadequately Controlled					
		Carotid Artery Occlusion					
		Cerebral Infarction					
		Comminuted Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetes Mellitus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphoria		Lipitor	C		
UNKNOWN							
		Eye Injury		Lipitor	C		
UNKNOWN							
		Fall					
		Fatigue					
		Haematoma					
		Hyperlipidaemia					
		Hypoaesthesia					
		Joint Sprain					
		Pain					
		Pain In Extremity					
		Rib Fracture					
		Road Traffic Accident					
		Syncope					
		Upper Respiratory Tract					
		Infection					
		Weight Increased					

Date:08/03/04ISR Number: 4413854-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Cholesterol Increased					
		Blood Creatinine Increased					
		Cardiac Failure Congestive					
		Congestive Cardiomyopathy					
		Dyspnoea					
		Emotional Distress					
		Fatigue					
		Gastrooesophageal Reflux Disease					

Impaired Work Ability
Sinus Bradycardia
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Ventricular Extrasystoles
Ventricular Hypertrophy

Date:08/03/04ISR Number: 4414012-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome PT
Other Abdominal Discomfort
Abdominal Pain Upper
Alopecia
Arrhythmia
Blood Pressure Increased
Chest Pain

		Chronic Fatigue Syndrome					
		Drug Hypersensitivity					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gallbladder Disorder	Professional	[Therapy			
		Gout		Unspecified]	C		
UNKNOWN							
		Hernia		Insulin	C		
UNKNOWN							
		Large Intestinal Ulcer					
		Haemorrhage					
		Oedema					
		Oesophageal Ulcer					
		Haemorrhage					
		Osteoarthritis					
		Rheumatoid Arthritis					
		Weight Decreased					

Date:08/03/04ISR Number: 4414059-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bronchiectasis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Diverticulum		Fosamax	C		
UNKNOWN							
		Drug Ineffective		Amitriptyline			
		Duodenitis		Hydrochloride	C		ORAL
		Ear Pain		Norvasc	C		ORAL
		Erosive Oesophagitis		Wellbutrin Sr	C		ORAL
		Gastritis Haemorrhagic		Lampren	C		ORAL
		Hepatitis		Diphenhydramine			
		Limb Discomfort		Tannate	C		ORAL
		Lung Neoplasm		Docusate Sodium	C		ORAL
		Mycobacterium Avium		Premarin	C		ORAL
		Complex Infection		Ethambutol			
		Myocardial Infarction		Hydrochloride	C		ORAL
		Nausea		Robaxin	C		ORAL

	Oedema Peripheral	Prilosec	C	UNKNOWN
	Otitis Externa	Rifampin	C	ORAL
	Pruritus			
	Rash Morbilliform			
	Rash Vesicular			
	Upper Respiratory Tract Infection			
	Urinary Tract Infection			

Date:08/03/04ISR Number: 4414406-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00069
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Arthropathy
	Blood Cholesterol Increased
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Dyspnoea

	Gastric Disorder Haematochezia Headache Hypertension Nausea Ocular Vascular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL
UNKNOWN				C		
			Tylenol Extra Strength	C		
UNKNOWN						

Date:08/03/04ISR Number: 4414408-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Anxiety
Other	Arthralgia
	Asthma
	Atherosclerosis
	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Brain Oedema
	Cardiomegaly
	Carotid Artery Occlusion
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Concussion
	Constipation
	Contusion
	Depression
	Drug Abuser
	Excoriation
	Fall
	Fatigue
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux Disease
	Headache
	Hyperlipidaemia

Ischaemic Stroke
Laceration
Limb Injury
Macrocytosis
Melaena
Microcytic Anaemia
Mitral Valve Incompetence
Myalgia
Oedema Peripheral
Orthostatic Hypotension
Pain
Pain In Extremity
Pneumonia
Polydipsia
Polyuria
Pulmonary Congestion
Skin Ulcer
Spinal Compression

		Fracture					
		Suicidal Ideation					
		Tibia Fracture					
		Urinary Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Soma	C		ORAL
				Diflunisal	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Estratest	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Rebetron	C		
UNKNOWN		3	DAY				
				Accupril	C		
UNKNOWN							
				Rebetol	C		
UNKNOWN							

Date:08/03/04ISR Number: 4414412-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Bruit
Disability	Abdominal Discomfort
Other	Accident At Work
	Acute Myocardial Infarction
	Adhesion
	Alcohol Withdrawal Syndrome
	Alcoholism
	Anaemia
	Anxiety
	Arthralgia

Arthropathy
Biliary Neoplasm
Bronchitis
Cardiac Failure
Congestive
Cerebrovascular Accident
Convulsion
Coronary Artery Disease
Depression
Drug Dependence
Drug Ineffective
Dysuria
Emotional Distress
Facet Joint Syndrome
Faecal Occult Blood
Positive
Fatigue
Headache
Hepatitis C
Hyperlipidaemia
Hypertension
Insomnia
Intervertebral Disc
Protrusion
Loss Of Consciousness
Lumbar Spinal Stenosis

		Micturition Urgency					
		Mouth Ulceration					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Myofascial Pain Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Panic Attack		Vioxx	SS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		Lortab	C		
UNKNOWN							
		Pollakiuria		Acetaminophen And			
		Prostatitis		Hydrocodone			
		Pyrexia		Bitartrate	C		
UNKNOWN							
		Rash Erythematous		Trazodone			
		Rash Pruritic		Hydrochloride	C		
UNKNOWN							
		Spinal Osteoarthritis		Amitriptyline			
		Syncope		Hydrochloride	C		
UNKNOWN		874 DAY					
		Urinary Tract Infection		Celebrex	C		
UNKNOWN		362 DAY					
		Vision Blurred		Neurontin	C		
UNKNOWN							
				Hydrocodone			
				Bitartrate	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN		2 DAY					
				Robaxin	C		
UNKNOWN		957 DAY					

Date:08/03/04ISR Number: 4414418-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Headache		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Transient Ischaemic		Percocet	C		
UNKNOWN						

	Attack		Hormones (Unspecified)	C		
UNKNOWN						

Date:08/03/04ISR Number: 4414419-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bacterial Infection		Lipitor	C		
UNKNOWN						
Other	Bipolar I Disorder		Lipitor	C		
UNKNOWN						
	Chest Pain		Avapro	C		
UNKNOWN						
	Fatigue		Geodon	C		
UNKNOWN						
	Flank Pain		Prevacid	C		
UNKNOWN						
	Incisional Hernia		Levoxyl	C		
UNKNOWN						
	Nephrolithiasis		Prilosec	C		
UNKNOWN						
	Renal Failure		Paxil	C		
UNKNOWN						
	Schizoaffective Disorder					
	Sepsis					
	Urinary Retention					
	Urinary Tract Infection					
	Urosepsis					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/04ISR Number: 4414429-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Augmentin	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Cystitis		Zoloft	C			UNKNOWN	
	Depression		Temazepam	C			UNKNOWN	
	Dizziness		Zocor	C		ORAL		
	Emotional Distress		Tenormin	C			UNKNOWN	
	Erectile Dysfunction		Tenormin	C			UNKNOWN	
	Gastritis		Tagamet	C			UNKNOWN	
	Haematemesis		Plavix	C			UNKNOWN	
	Hypertension		Motrin	C			UNKNOWN	
	Injury		Relafen	C			UNKNOWN	
	Mediastinitis		Nitrostat	C			UNKNOWN	
	Nausea							
	Oedema Peripheral							
	Pain In Extremity							
	Plantar Fasciitis							
	Pleural Effusion							
	Postoperative Infection							
	Postpericardiotomy Syndrome							
	Spinal Osteoarthritis							
	Tricuspid Valve Incompetence							
	Ulnar Nerve Injury							
	Venous Thrombosis Limb							

Date:08/03/04ISR Number: 4414431-7Report Type:Expedited (15-DaCompany Report #IT-MERCK-0407ITA00052
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
			[Therapy Unspecified]	C			UNKNOWN	

Date:08/03/04ISR Number: 4414433-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma
Other	Coronary Artery Disease
	Cough
	Dermatitis
	Diabetes Mellitus
	Insulin-Dependent
	Diastolic Dysfunction
	Foot Deformity
	Hyperlipidaemia
	Hypertension
	Myocardial Infarction

		Oedema Peripheral					
		Pulmonary Oedema					
		Rheumatoid Arthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
424	DAY						
		Rotator Cuff Syndrome		Respaire	C		
UNKNOWN							
		Seborrhoeic Keratosis		Flonase	C		
UNKNOWN							
		Skin Ulcer		Minocycline	C		
UNKNOWN							
		Syncope		Piroxicam	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/03/04ISR Number: 4414442-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02310
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
Initial or Prolonged				Albuterol	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Serevent	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							

Date:08/03/04ISR Number: 4414444-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL

	Adverse Event		Tylenol	C		
UNKNOWN						
	Blood Pressure Increased		Zyrtec	C		
UNKNOWN						
	Chest Pain		Zyrtec	C		
UNKNOWN						
	Diabetes Mellitus					
	Dyspepsia					
	Emotional Distress					
	Gastric Disorder					
	Gastrooesophageal Reflux					
	Disease					
	Liver Disorder					
	Memory Impairment					
	Nausea					
	Pancreatitis					

Date:08/03/04ISR Number: 4414506-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00235
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		379 DAY
Other	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		379 DAY
	Migraine With Aura		Vicodin Tablets	C				
UNKNOWN								
	Retinal Vein Occlusion		Celebrex	C				
UNKNOWN								
	Rotator Cuff Syndrome							

Date:08/03/04ISR Number: 4414507-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Alopecia							
Anxiety Disorder							
Arthropathy							
Cardiac Murmur							
Contusion							
Dyspnoea							
Electrocardiogram St Segment Abnormal							
Emotional Distress							
Fatigue							
Gastric Disorder							
Haemorrhage							
Hypertension							
Keloid Scar							
Meniscus Lesion							
Monarthritis							
Nausea							
Neoplasm Malignant							
Non-Cardiac Chest Pain							
Osteoarthritis							
Palpitations							
Panic Disorder							
Peptic Ulcer							
Skin Lesion							
Swelling							
Urine Abnormality							
Urine Odour Abnormal							
Vomiting							

Date:08/03/04ISR Number: 4414971-0Report Type:Direct Company Report #CTU 224136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS		ORAL	12.5 MG PO	DAILY
	Chest Pain							

Date:08/03/04ISR Number: 4417575-9Report Type:Expedited (15-DaCompany Report #GBWYE931327JUL04
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Health Professional	Advil (Ibuprofen, 0)	PS		ORAL	400 MG 3X PER 1 DAY ORAL; 600 MG 3X PER 1 DAY	
	Dyspnoea							
	Gastrointestinal Ulcer	Other						
	Haemoglobin Decreased							
	Oesophagitis		Vioxx (Rofecoxib, Tablet)	SS		ORAL	25 MG 1X PER 1 DAY ORAL	
	Syncope							
			Lipitor (Atorvastatin)	C				
			Paracetamol (Paracetamol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/04ISR Number: 4418031-4Report Type:Expedited (15-DaCompany Report #GB-JNJFOC-20040707784
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Foreign Health	Ibuprofen (Ibuprofen) Unknown	PS		ORAL	400 MG, 3 IN	1 DAY, ORAL;
	Dyspnoea							
	Gastrointestinal Ulcer	Professional						
	Haemoglobin Decreased							
	Oesophagitis							
	Syncope		Rofecoxib (Rofecoxib) Tablets	SS		ORAL	600 MG, 3 IN 1 DAY, ORAL	25 MG, 1 IN 1 DAY, ORAL
			Lipitor (Atorvastatin)	C				
			Paracetamol (Paracetamol) Unknown	C				

Date:08/03/04ISR Number: 4418056-9Report Type:Expedited (15-DaCompany Report #S04-GER-03331-01
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign Health	Cipralex (Escitalopram)	PS		ORAL	10 MG QD PO	
		Professional Other	Vioxx (Rofecoxib)	SS				
			Propecia (Finasteride)	C				

Date:08/04/04ISR Number: 4414681-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anaemia

Other	Anxiety
	Atherosclerosis
	Back Pain
	Blindness
	Blood Creatine
	Phosphokinase Mb
	Increased
	Blood Urine Present
	Chest Pain
	Diabetic Neuropathy
	Dyspepsia
	Emotional Distress
	Fall
	Gastrointestinal
	Haemorrhage
	Gastrooesophageal Reflux
	Disease
	Haematochezia
	Loss Of Consciousness
	Myocardial Ischaemia
	Pneumonia
	Proctalgia
	Prostatitis
	Rectal Haemorrhage
	Spinal Column Stenosis
	Stress

Syncope

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Norvasc	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Clonidine	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Glucotrol	C			UNKNOWN	
	Avandia	C			UNKNOWN	
	Hyzaar	C		ORAL		
	Imdur	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Glucophage	C			UNKNOWN	
	Methocarbamol	C			UNKNOWN	
	Glyset	C			UNKNOWN	
	Nitroglycerin	C			SUBLINGUAL	

Date:08/04/04ISR Number: 4415154-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		

Other	Dysphagia	Psyllium Husk	C
UNKNOWN			
	Ear Pain	Zocor	C
UNKNOWN			
	Epistaxis	Vitamin E	C
UNKNOWN			
	Facial Pain	Warfarin	C
UNKNOWN	1284 DAY		
	Hypertension	Betaxolol Ophthalmic	
	Lacunar Infarction	Solution	C
UNKNOWN			
	Muscle Spasms	Calcitonin	C
UNKNOWN			
	Myalgia	Digoxin	C
UNKNOWN			
	Pain In Jaw	Docusate Sodium	C
UNKNOWN			
	Productive Cough	Trusopt	C
OPHTHALMIC			
	Rheumatoid Arthritis	Folic Acid	C
UNKNOWN			
		Lasix (Furosemide)	C
UNKNOWN	1680 DAY		
		Isosorbide	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			

Date:08/04/04ISR Number: 4415170-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00206
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Angioneurotic Oedema							

Date:08/04/04ISR Number: 4415189-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anaemia
	Arrhythmia

		Asthenia					
		Blood Pressure Increased					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Fatigue Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cyst	Professional	Lortab	C		
UNKNOWN							
		Emotional Distress		Proventil	C		
RESPIRATORY							
		Hyperlipidaemia					
(INHALATION)							
		Hypertension		Micardis	C		
UNKNOWN							
		Hypokalaemia		Sular	C		
UNKNOWN							
		Intervertebral Disc					
		Protrusion					
		Large Intestinal Ulcer					
		Haemorrhage					
		Nasopharyngitis					
		Nausea					
		Oedema					
		Oesophageal Ulcer					
		Haemorrhage					
		Osteoarthritis					
		Road Traffic Accident					
		Spinal Disorder					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Strabismus					
		Upper Respiratory Tract					
		Infection					
		Vitamin B12 Deficiency					

Date:08/04/04ISR Number: 4415243-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Cyanocobalamin	C		
UNKNOWN							
		Cerebrovascular Accident					
		Eating Disorder					
		Emotional Distress					

Gastric Ulcer Haemorrhage
Hypertension
Infection
Thrombosis

Date:08/04/04ISR Number: 4415548-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03247
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Other	Arthritis
	Blood Creatinine Increased
	Cardiac Arrest
	Coronary Artery Occlusion
	Cough
	Gastrooesophageal Reflux Disease
	Hyperlipidaemia
	Hypokalaemia
	Myocardial Infarction
	Palpitations

Thrombocytopenia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Celebrex	SS			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Cardizem Cd	C			UNKNOWN	
	Zestril	C			UNKNOWN	
	Zestril	C			UNKNOWN	
	Nitroglycerin	C			UNKNOWN	

Date:08/04/04ISR Number: 4415551-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00105
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Hormones (Unspecified)	C			UNKNOWN	
	Fall		Maxzide	C			UNKNOWN	
	Gastric Disorder		Mobic	C			UNKNOWN	
	Hysterectomy		Trazodone Hydrochloride	C			UNKNOWN	
	Mitral Valve Prolapse		Toprol Xl Tablets	C			UNKNOWN	
	Supraventricular Tachycardia		Toprol Xl Tablets	C			UNKNOWN	
	Upper Limb Fracture							
	Weight Increased							

Date:08/04/04ISR Number: 4415562-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		[Therapy					
	Dizziness		Unspecified]	C			UNKNOWN	
	Frequent Bowel Movements		Lortab	C			UNKNOWN	
	Hypertension		Coumadin	C			UNKNOWN	
	Kidney Infection		Prinivil	C			UNKNOWN	
	Nausea		K-Dur	C			UNKNOWN	

Date:08/04/04ISR Number: 4415696-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Balance Disorder		Methotrexate	SS		ORAL		
Initial or Prolonged	Dizziness		Folic Acid	C		ORAL		
Disability	Drug Interaction							
Other	Drug Toxicity							
	Epistaxis							
	Malaise							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/04ISR Number: 4416063-3Report Type:Direct Company Report #CTU 224172
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastric Ulcer		Warfarin	PS		
	Gastrointestinal Haemorrhage		Bc Powders	SS		
			Vioxx	SS		
	International Normalised Ratio Increased					

Date:08/04/04ISR Number: 4416133-XReport Type:Direct Company Report #CTU 224169
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dizziness		Coumadin	PS		ORAL PO
	International Normalised Ratio Increased		Vioxx	SS		ORAL PO
			Aspirin	SS		
	Melaena					
	Self-Medication					

Date:08/04/04ISR Number: 4421160-2Report Type:Expedited (15-DaCompany Report #GBWYE867030JUN04
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage	Foreign Health Professional Other	Methotrexate (Methotrexate)	PS		
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS		
			Fluoxetine Hydrochloride (Fluoxetine			

		Hydrochloride)	SS
		Humira (Adalimumab)	SS
SUBCUTANEOUS	40 G/M^2 1X PER 2 WK SC		
		Premarin (Conjugated Estrogens, Unspec)	SS
		Rofecoxib (Rofecoxib)	SS
		Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C
		Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/04ISR Number: 4421161-4Report Type:Expedited (15-DaCompany Report #GBWYE931327JUL04
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Foreign	Advil					
	Dyspnoea	Health	(Ibuprofen)	PS		ORAL	400 MG 3X PER	
	Gastrointestinal Ulcer	Professional					1 DAY ORAL;	
	Haemoglobin Decreased	Other					600 MG 3X PER	
	Oesophagitis						1 DAY	
	Syncope		Vioxx					
	Thrombosis		(Rofecoxib)	SS		ORAL	25 MG 1X PER	
							1 DAY ORAL	11 DAY
			Lipitor					
			(Atorvastatin)	C				
			Paracetamol					
			(Paracetamol)	C				

Date:08/04/04ISR Number: 4421606-XReport Type:Expedited (15-DaCompany Report #A01200403374
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroduodenal Ulcer	Health	(Clopidogrel) -					
	Haematemesis	Professional	Tablet - 75 Mg	PS		ORAL	75 MG OD	
	Melaena		(Acetylsalicylic					
	Oesophagitis		Acid)	SS		ORAL	75 MG OD	
			(Rofecoxib)	SS		ORAL	12.5 MG OD	
			Amitriptyline	C				
			Senna	C				
			Lactulose	C				
			Alfuzosin	C				
			Bendrofluazide	C				
			Tramadol	C				

Date:08/05/04ISR Number: 4416280-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0201USA00228
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Prinivil	SS		ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Fibrillation		Prinivil	SS		ORAL		
	Cerebrovascular Accident		Diazepam	C			198 DAY	
	Coronary Artery Disease		Premarin	C			UNKNOWN	
	Drug Hypersensitivity		Calcium (Unspecified)	C			UNKNOWN	
	Hypertension							
	Mitral Valve Incompetence							
	Pharyngolaryngeal Pain							
	Supraventricular Tachycardia							
	Tendonitis							
	Transient Ischaemic Attack							
	Tricuspid Valve Incompetence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4416281-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00086
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Convulsion							
	Depression							
	Emotional Distress							
	Renal Failure							

Date:08/05/04ISR Number: 4416283-8Report Type:Expedited (15-DaCompany Report #BE-MERCK-0407BEL00012
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Althiazide And Spironolactone	C		ORAL		
	Mitral Valve Incompetence		Amiodarone Hydrochloride	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Aspirin	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Fenofibrate	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL		

Date:08/05/04ISR Number: 4416284-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02294
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Aspirin	C				
UNKNOWN								

Disability	Blood Pressure Increased	Celebrex	C
UNKNOWN			
Other	Cerebrovascular Accident	Glyburide	C
UNKNOWN			
	Chest Pain	Prinivil	C
UNKNOWN			
	Confusional State		
	Dementia		
	Depression		
	Disorientation		
	Dyspnoea		
	Emotional Distress		
	Fall		
	Gastroenteritis		
	Hypoglycaemia		
	Hypomagnesaemia		
	Injury		
	Irritability		
	Lacunar Infarction		
	Osteopenia		
	Polymyalgia Rheumatica		
	Troponin Increased		
	Urticaria		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4416287-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01144
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		333 DAY
Disability	Faecal Occult Blood		Vioxx	SS	Merck & Co., Inc	ORAL		333 DAY
Other	Positive Gastrointestinal Haemorrhage		Fosamax	C		ORAL		

Date:08/05/04ISR Number: 4416407-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis Blood Cholesterol Increased Cardiac Valve Disease Dementia Alzheimer'S Type Diabetes Mellitus Glaucoma Hepatocellular Damage Hypertension Insomnia Parkinson'S Disease Rheumatoid Arthritis Vomiting	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/04ISR Number: 4416718-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atelectasis Bronchitis		[Therapy Unspecified]	C				UNKNOWN
	Contusion		Antimicrobial					

	Depression	(Unspecified)	C
UNKNOWN			
	Dizziness	Soma	C
UNKNOWN			
	Faeces Discoloured	Estrogens	
	Fall	(Unspecified)	C
UNKNOWN	1036 DAY		
	Gastric Haemorrhage	Herbs (Unspecified)	C
UNKNOWN			
	Haematochezia	Imdur	C
UNKNOWN			
	Haemorrhoids	Nitro	C
UNKNOWN			
	Heart Rate Irregular		
	Hyperhidrosis		
	Injury		
	Loss Of Consciousness		
	Pain In Extremity		
	Palpitations		
	Rib Fracture		
	Road Traffic Accident		
	Tremor		
	Upper Gastrointestinal Haemorrhage		
	Urinary Tract Infection		
	Viral Infection		

Date:08/05/04ISR Number: 4416719-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
Initial or Prolonged	Arteriovenous Fistula	Professional	Tylenol	C				UNKNOWN
Other	Arthropathy		Ecotrin	C				UNKNOWN
	Bundle Branch Block Left		Viagra	C				UNKNOWN
	Calcinosis		Calan Sr	C				UNKNOWN
	Chest Discomfort		Zocor	C				UNKNOWN
	Coronary Artery Disease		Celebrex	C				UNKNOWN
	Dehydration		Advil	C				UNKNOWN
	Diverticulum Intestinal Haemorrhagic							
	Emotional Distress							
	Gastritis Atrophic							
	Gastrooesophageal Reflux Disease							
	Helicobacter Infection							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Neck Pain							
	Neuropathy Peripheral							
	Otitis Externa							
	Renal Cyst							
	Rotator Cuff Syndrome							
	Sciatica							
	Scoliosis							
	Spinal Column Stenosis							
	Stent Occlusion							

Date:08/05/04ISR Number: 4416723-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Colitis Ulcerative Constipation Deep Vein Thrombosis Depression Headache Insomnia Iron Deficiency Anaemia Muscle Spasms Pneumonia Pulmonary Embolism Rectal Ulcer Reflux Oesophagitis Tremor	Health Professional	Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4416724-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02888
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		44 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder With Mixed Anxiety And		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		44 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		113 DAY
	Back Pain		Vicodin Tablets	C				UNKNOWN
	Blood Pressure Increased		Hydrocodone Bitartrate	C				UNKNOWN
	Blood Triglycerides Increased		Relafen	C				UNKNOWN
	Bone Pain							
	Breast Pain							
	Chest Pain							
	Chondromalacia							
	Contusion							
	Coronary Artery Atherosclerosis							
	Dizziness							
	Drug Hypersensitivity							
	Dyspepsia							
	Extrasystoles							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Groin Pain							
	Hypersensitivity							
	Joint Sprain							
	Keratoacanthoma							
	Kyphosis							
	Micturition Urgency							
	Musculoskeletal Stiffness							
	Nasopharyngitis							
	Pain In Extremity							
	Pericarditis							
	Pneumonia							

Pollakiuria
Prostatic Disorder
Tension Headache
Upper Respiratory Tract
Infection
Wound

Date:08/05/04ISR Number: 4416731-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0407CAN00027
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Magnesium Decreased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	97	DAY
Initial or Prolonged	Blood Potassium Decreased	Professional						
	Myalgia							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4416732-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Norvasc	C				
Disability	Asthenia		Lotrel	C			UNKNOWN	
	Blood Cholesterol		Coreg	C			UNKNOWN	
	Increased		Clonidine	C			UNKNOWN	
	Blood Creatinine		Clonidine	C		ORAL		
	Increased		Digitek	C			UNKNOWN	
	Bronchitis		Zocor	C		ORAL		
	Cardiac Failure		Spironolactone	C			UNKNOWN	
	Congestive		Nexium	C			UNKNOWN	
	Congestive Cardiomyopathy		Lisinopril	C			UNKNOWN	
	Cough		Reglan	C			UNKNOWN	
	Depression		Minoxidil	C			UNKNOWN	
	Dyspepsia		Minoxidil	C			UNKNOWN	1 DAY
	Emotional Distress		Minoxidil	C			UNKNOWN	
	Erectile Dysfunction							
	Facial Palsy							
	Gastroenteritis Viral							
	Gastrooesophageal Reflux Disease							
	Haemoglobin Decreased							
	Hypertension							
	Insomnia							
	Nasal Congestion							
	Neck Injury							
	Rhinorrhoea							
	Road Traffic Accident							
	Sinus Bradycardia							
	Sinusitis							
	Sleep Apnoea Syndrome							

Supraventricular
Extrasystoles
Upper Respiratory Tract
Infection
Ventricular Extrasystoles

Date:08/05/04ISR Number: 4416739-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00411
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer Haemorrhage Haematemesis Hypotension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:08/05/04ISR Number: 4416740-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4416742-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00025
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oropharyngeal Swelling							
Disability								

Date:08/05/04ISR Number: 4416743-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01717
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased							
	Diabetes Mellitus							
	Feeling Abnormal							
	Gout							
	Inner Ear Disorder							
	Pollakiuria							
	Ulcer							

Date:08/05/04ISR Number: 4416744-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00402
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Thromboplastin Time	Professional	Coreg	C				
UNKNOWN								
	Prolonged		Lanoxin	C		ORAL		
	Anaemia		Lasix (Furosemide)	C		ORAL		
	Azotaemia		Coumadin	C		ORAL		
	Blood Creatinine		Synthroid	C		ORAL		
	Increased		Potassium					
	Blood Urea Increased		(Unspecified)	C				
UNKNOWN								
	International Normalised							
	Ratio Increased							

Myelodysplastic Syndrome
Pancytopenia
Prothrombin Time
Prolonged

Date:08/05/04ISR Number: 4416746-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Abdominal Pain
	Aortic Occlusion
	Blood Disorder
	Bronchitis
	Disability
	Emotional Distress
	Fall
	Gait Spastic
	Gout
	Intermittent Claudication
	Nasopharyngitis
	Obstruction

	Peripheral Circulatory Failure						
	Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Tylenol	C			UNKNOWN

Date:08/05/04ISR Number: 4416772-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03194
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL	552 DAY
Initial or Prolonged	Abdominal Distension	Professional	Aleve	SS			UNKNOWN
Disability	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL	552 DAY
	Anxiety		Tylenol	C			UNKNOWN
	Back Pain		Paxil	C			UNKNOWN 2 MON
	Calculus Ureteric						
	Cognitive Disorder						
	Confusional State						
	Constipation						
	Dizziness						
	Emotional Distress						
	Gastrooesophageal Reflux Disease						
	Haematochezia						
	Hypertension						
	Influenza Like Illness						
	Injury						
	Lethargy						
	Nephrolithiasis						
	Renal Cyst						
	Transient Ischaemic Attack						

Date:08/05/04ISR Number: 4416796-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00078
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
	Emotional Distress		Lortab	C			UNKNOWN	
	Hypertension		Aspirin	C			UNKNOWN	
	Overdose							
	Polyuria							
	Upper Limb Fracture							

Date:08/05/04ISR Number: 4419725-7Report Type:Direct Company Report #CTU 224339
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Epistaxis		Vioxx 25 Mg Merk & Co. Inc	PS	Merck & Co, Inc	ORAL	1 TABLET DAILY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/04ISR Number: 4424037-1Report Type:Expedited (15-DaCompany Report #GBWYE931327JUL04
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Dyspnoea Gastrointestinal Ulcer Haemorrhage Haemoglobin Decreased Oesophagitis Overdose Syncope	Foreign Health Professional Other	Advil (Ibuprofen)	PS		ORAL	400 MG 3X PER 1 DAY ORAL; 600MG /3 X DAY	
			Vioxx (Rofecoxib, Tablet, 0)	SS		ORAL	25 MG 1X PER 1 DAY ORAL	11 DAY
			Lipitor (Atorvastatin)	C				
			Paracetamol (Paracetamol)	C				

Date:08/06/04ISR Number: 4416895-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Abdominal Pain Anxiety Disorder Back Injury Chest Discomfort Chest Pain Chromaturia Contusion Coronary Artery Restenosis Cough Decreased Appetite Dehydration Depressed Mood Diarrhoea Disturbance In Attention Diverticulum Intestinal

Haemorrhagic
Drug Ineffective
Dyspnoea
Fatigue
Fluid Retention
Haemorrhoids
Hypertension
Hypoaesthesia
Insomnia
Iron Deficiency
Libido Decreased
Lung Neoplasm
Myocardial Infarction
Nausea
Non-Cardiac Chest Pain
Oedema Peripheral
Paraesthesia
Pneumonia
Prostatic Specific
Antigen Increased
Proteinuria
Renal Cyst
Rheumatoid Arthritis

		Rhinitis Allergic					
		Stress					
		Tendon Rupture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Treatment Noncompliance	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Umbilical Hernia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Allopurinol	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Ecotrin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Indocin (Indomethacin)	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							

Date:08/06/04ISR Number: 4416896-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00838
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atonic Urinary Bladder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atrial Fibrillation		Aspirin	C		
UNKNOWN							
Disability		Bronchopneumonia		Glucosamine	C		
UNKNOWN							

Other	Burns Second Degree	Hytrin	C
UNKNOWN			
	Cardiac Failure	Levothyroxine Sodium	C
UNKNOWN			
	Congestive		
	Coronary Artery Disease		
	Deafness Neurosensory		
	Depression		
	Emotional Distress		
	Haematuria		
	Haemorrhagic Stroke		
	Incontinence		
	Intentional Self-Injury		
	Lobar Pneumonia		
	Myocardial Infarction		
	Myofascial Pain Syndrome		
	Neurogenic Bladder		
	Staphylococcal Infection		
	Suicide Attempt		

Date:08/06/04ISR Number: 4417129-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Deep Vein Thrombosis
Initial or Prolonged	Depression
Other	Diabetes Mellitus
	Dyspnoea
	Hypercholesterolaemia
	Hypertension
	Intervertebral Disc
	Degeneration
	Meniscus Lesion

		Mixed Incontinence					
		Myalgia					
		Myositis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post Thrombotic Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Premarin	C		
UNKNOWN							
				Ultram	C		ORAL
				Vitamins (Unspecified)	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN	366 DAY						
				Plaquenil	C		ORAL
				Plaquenil	C		ORAL
				Accupril	C		
UNKNOWN	535 DAY						

Date:08/06/04ISR Number: 4417139-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00141
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Amnesia		Diltiazem			
Disability	Blood Triglycerides		Hydrochloride	C		
UNKNOWN						
	Increased					
	Emotional Distress					
	Gastrointestinal Disorder					
	Headache					
	Hypertension					
	Nausea					
	Panic Disorder					
	Sleep Apnoea Syndrome					
	Tachycardia					

Date:08/06/04ISR Number: 4417140-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00842
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Therapeutic Response	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Flonase	C		
UNKNOWN						
			Glucosamine	C		
UNKNOWN						

Date:08/06/04ISR Number: 4417143-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Discomfort
	Abdominal Pain Upper
	Alopecia
	Arrhythmia
	Blood Pressure Increased
	Chest Pain

		Chronic Fatigue Syndrome					
		Drug Hypersensitivity					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gallbladder Disorder	Professional	[Therapy			
		Gout		Unspecified]	C		
UNKNOWN							
		Hernia		Insulin	C		
UNKNOWN							
		Large Intestinal Ulcer					
		Haemorrhage					
		Oedema					
		Oesophageal Ulcer					
		Haemorrhage					
		Osteoarthritis					
		Rheumatoid Arthritis					
		Weight Decreased					

Date:08/06/04ISR Number: 4417146-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00143
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Toxicity	Professional	Elavil	SS		
UNKNOWN							
		Transient Ischaemic					
		Attack					

Date:08/06/04ISR Number: 4417148-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00140
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		[Therapy			
		Drug Ineffective		Unspecified]	C		
UNKNOWN							
		Emotional Distress		Percocet	C		
UNKNOWN							
		Fibromyalgia					

Headache
Hypersensitivity
Hypoaesthesia
Osteoarthritis
Pain
Paraesthesia
Productive Cough
Pulmonary Congestion

Date:08/06/04ISR Number: 4417150-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00440
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		6 WK
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		6 WK
Disability	Alopecia Arthropathy Kidney Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/04ISR Number: 4417159-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Prevacid	C				
UNKNOWN								
Other	Arthralgia		Zocor	C		ORAL		
	Back Pain							
	Blood Cholesterol Increased							
	Chest Pain							
	Closed Head Injury							
	Constipation							
	Convulsion							
	Costochondritis							
	Depression							
	Dyspepsia							
	Dysuria							
	Erectile Dysfunction							
	Eye Disorder							
	Fall							
	Gastrooesophageal Reflux Disease							
	Haemorrhage							
	Head Injury							
	Hypertension							
	Kidney Infection							
	Migraine							
	Oedema Peripheral							
	Oesophageal Disorder							
	Palpitations							
	Renal Disorder							
	Ulcer							

Date:08/06/04ISR Number: 4417183-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
	Affective Disorder
Disability	Anaemia
	Angina Pectoris
	Angiogram Cerebral

Abnormal
Anhedonia
Arthralgia
Blindness
Brain Oedema
Cavernous Sinus
Thrombosis
Cerebral Infarction
Cerebrovascular Accident
Chest Discomfort
Colonic Polyp
Concussion
Constipation
Coordination Abnormal
Deep Vein Thrombosis
Depressed Mood
Depression
Diabetes Mellitus

		Non-Insulin-Dependent					
		Diarrhoea					
		Diplopia					
		Disturbance In Attention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysfunctional Uterine	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Bleeding	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Ear Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Eczema		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Emotional Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Yasmin	SS		
UNKNOWN		14	DAY				
		Fibromyalgia		Sandimmun	C		
UNKNOWN							
		Fungal Infection		Prednisone	C		
UNKNOWN							
		Gait Disturbance		Sandimmun	C		
UNKNOWN							
		Gastritis		Hormonal			
		Gastrointestinal Motility		Contraceptives			
		Disorder		(Unspecified)	C		
INTRAMUSCULAR							
		Haemorrhoidal Haemorrhage		Prelone Syrup	C		
UNKNOWN							
		Head Injury		Prelone Syrup	C		
UNKNOWN							
		Headache		Sandimmun	C		
UNKNOWN							
		Heart Rate Irregular					
		Hot Flush					
		Hydrocephalus					
		Hypoaesthesia					
		Hypochromic Anaemia					
		Impaired Driving Ability					
		Impaired Work Ability					
		Insomnia					
		Intracranial Venous Sinus					
		Thrombosis					
		Joint Effusion					
		Joint Swelling					
		Menstruation Irregular					
		Migraine					
		Muscular Weakness					
		Musculoskeletal Stiffness					
		Nausea					

Neck Pain
Nervous System Disorder
Optic Nerve Injury
Papilloedema
Paraesthesia
Pharyngolaryngeal Pain
Photophobia
Rash
Rectal Haemorrhage
Sinus Tachycardia
Sneezing
Speech Disorder
Subarachnoid Haemorrhage
Superior Sagittal Sinus
Thrombosis
Tinnitus
Urticaria
Uterine Enlargement
Uterine Leiomyoma
Visual Disturbance
Visual Field Defect
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/06/04ISR Number: 4421875-6Report Type:Direct Company Report #CTU 224449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
	Haematemesis							
	Melaena		Aspirin 81 Mg	SS		ORAL	81 MG DAILY	
	Nausea							
	Vomiting							

Date:08/07/04ISR Number: 4417825-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00186
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	807 DAY	
Hospitalization - Initial or Prolonged	Dyspnoea Exertional	Professional	Aspirin	SS		ORAL		
	Haemoglobin Decreased		Furosemide	C		ORAL		
	Melaena		Valsartan	C		ORAL		
	Upper Gastrointestinal		Metoprolol Succinate	C		ORAL		
	Haemorrhage		Moxonidine	C		ORAL		

Date:08/07/04ISR Number: 4417826-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00115
Age:43 YR Gender:Male I/FU:F

Outcome	PT
	Abdominal Distension
	Abdominal Pain Upper
	Anxiety
	Back Pain
	Bone Disorder
	Burning Sensation
	Colonic Polyp
	Constipation
	Depression
	Diverticulum Intestinal
	Duodenal Ulcer

Dysgeusia
Dyspepsia
Dysuria
Ear Pain
Eructation
Fatigue
Gait Disturbance
Gastrooesophageal Reflux
Disease
Glaucoma
Haematochezia
Haemorrhoids
Headache
Helicobacter Pylori
Identification Test
Positive
Hyperhidrosis
Hypermetropia
Hypoaesthesia
Intervertebral Disc
Degeneration
Irritability
Local Swelling
Melaena

		Muscle Spasms					
		Myofascial Pain Syndrome					
		Nasal Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Night Sweats		Vicodin Tablets	C		
UNKNOWN							
		Optic Nerve Cupping		Flexeril	C		ORAL
		Pain In Extremity		Effexor	C		
UNKNOWN							
		Prostatic Disorder		Desyrel	C		
UNKNOWN							
		Pseudodiverticular		Neurontin	C		
UNKNOWN							
		Disease		Aciphex	C		
UNKNOWN							
		Radicular Pain					
		Rectal Haemorrhage					
		Rhinitis Allergic					
		Sensation Of Foreign Body					
		Sexual Dysfunction					
		Sinus Congestion					
		Sleep Disorder					
		Stomach Discomfort					
		Stress					
		Tinnitus					
		Upper Respiratory Tract					
		Infection					
		Visual Disturbance					

Date:08/07/04ISR Number: 4417829-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00235
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Carpal Tunnel Syndrome	Professional	[Therapy			
		Chest Pain		Unspecified]	C		
UNKNOWN							
		Conjunctivitis Infective		Tylenol	C		
UNKNOWN							
		Drug Ineffective		Darvocet-N	C		
UNKNOWN							

	Dyspnoea	Emergen C	C
UNKNOWN			
	Ear Discomfort	Astelin	C
UNKNOWN			
	Emotional Distress	Meridia	C
UNKNOWN			
	Fatigue	Valtrex	C
UNKNOWN			
	Hypotension	Zomig	C
UNKNOWN			
	Irritable Bowel Syndrome	Imitrex	C
UNKNOWN			
	Migraine	Stadol	C
UNKNOWN			
	Nasal Congestion	Zyrtec	C
UNKNOWN			
	Nasal Sinus Drainage	Allegra	C
UNKNOWN			
	Nausea	Claritin	C
UNKNOWN			
	Otitis Media	Anaprox	C
UNKNOWN			
	Pharyngitis		
	Pharyngolaryngeal Pain		
	Postnasal Drip		
	Proctitis Herpes		
	Productive Cough		
	Rhinitis Allergic		
	Sinusitis		
	Vomiting		

Date:08/07/04ISR Number: 4417841-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Alopecia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anaemia		[Therapy					
Other	Arthritis		Unspecified]	C				
UNKNOWN								
	Arthropathy		Folic Acid	C				
UNKNOWN								
	Cardiac Disorder		Remicade	C				
UNKNOWN								
	Cardiac Flutter		Injectable Gold					
	Dysmenorrhoea		(Unspecified)	C				
UNKNOWN								
	Headache		Methotrexate	C				
UNKNOWN								
	Menorrhagia		Methotrexate	C				
UNKNOWN								
	Nausea							
	Postoperative Ileus							
	Swelling							
	Uterine Leiomyoma							

Date:08/09/04ISR Number: 4420870-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
71 DAY								
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
33 DAY								
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
33 DAY								
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
71 DAY								
	Back Pain		[Therapy					
	Balance Disorder		Unspecified]	C				
UNKNOWN								
	Blood Pressure Decreased		Elavil	C				
UNKNOWN								

	Bronchitis	Atenolol	C
UNKNOWN			
	Bursitis	Trazodone Hydrochloride	C
	Cardiomegaly		
UNKNOWN			
	Chest Pain	Atenolol	C
UNKNOWN			
	Chest Wall Pain	Lonox	C
UNKNOWN			
	Constipation	Dyazide	C
UNKNOWN			
	Coordination Abnormal	Hydrocortisone	C
UNKNOWN			
	Diabetes Mellitus	Zestril	C
UNKNOWN			
	Diabetes Mellitus	Paxil	C
UNKNOWN			
	Non-Insulin-Dependent		
	Diastolic Dysfunction		
	Gastrooesophageal Reflux		
	Disease		
	Haemorrhage		
	Hypogonadism		
	Insomnia		
	Intervertebral Disc		
	Degeneration		
	Metabolic Syndrome		
	Nephritis		
	Panic Attack		
	Pericardial Effusion		
	Septic Shock		
	Sinusitis		
	Tendonitis		
	Therapeutic Agent		
	Toxicity		
	Ventricular Hypertrophy		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/04ISR Number: 4420876-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Neoplasm Of Skin		Atenolol	C			UNKNOWN	
	Drug Hypersensitivity		Celebrex	C			UNKNOWN	
	Emotional Distress		Flexeril	C			UNKNOWN	
	Faeces Discoloured		Arthrotec	C		ORAL		
	Furuncle		Hydrodiuril	C		ORAL		
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Hyperkeratosis							
	Hypertension							
	Neck Pain							
	Oedema Peripheral							
	Road Traffic Accident							
	Skin Papilloma							
	Sleep Apnoea Syndrome							
	Tooth Disorder							

Date:08/09/04ISR Number: 4420877-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00235
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	379 DAY	
Other	Emotional Distress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	379 DAY	
	Hypertension		Vicodin Tablets	C			UNKNOWN	
	Migraine With Aura		Celebrex	C			UNKNOWN	
	Retinal Vein Occlusion							
	Rotator Cuff Syndrome							

Date:08/09/04ISR Number: 4420881-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00065
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
	Degeneration		Zyrtec	C			UNKNOWN	
	Intervertebral Disc		Flonase	C			UNKNOWN	
	Protrusion		Glyburide	C			UNKNOWN	
	Lacunar Infarction							
	Nerve Injury							
	Pain In Extremity							
	Rhinitis Allergic							
	Somnolence							
	Spinal Column Stenosis							
	Stomach Discomfort							

Date:08/09/04ISR Number: 4420883-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
		Angina Unstable		Amiodarone	C			UNKNOWN	
		Aortic Aneurysm		Imuran (Azathioprine)	C			UNKNOWN	
		Arrhythmia							
		Arthralgia		Chloracon	C			UNKNOWN	
		Asthenia		Celebrex	C			UNKNOWN	
		Atrial Fibrillation		Tagamet	C			UNKNOWN	
		Basal Cell Carcinoma		Cyanocobalamin	C			UNKNOWN	
		Benign Prostatic Hyperplasia		Lanoxin	C			UNKNOWN	
		Cardiac Failure Congestive		Tiazac	C			UNKNOWN	
		Cerebrovascular Accident		Cartia (Diltiazem Hydrochloride)	C			UNKNOWN	
		Chest Pain		Folic Acid	C			UNKNOWN	
		Closed Head Injury		Lasix (Furosemide)	C			UNKNOWN	
		Coronary Artery Disease		Glipizide	C			UNKNOWN	
		Dehydration		Motrin	C			UNKNOWN	
		Diarrhoea		Insulin	C			UNKNOWN	
		Dizziness		Insulin Human, Isophane	C			UNKNOWN	
		Drug Toxicity		Imdur	C			UNKNOWN	
		Emotional Distress		Methotrexate	C			UNKNOWN	
		Emphysema		Vitamin E	C			UNKNOWN	
		Fall		Flomax (Tamsulosin					

	Feeling Hot And Cold	Hydrochloride)	C
UNKNOWN			
	Heart Rate Irregular	Niacin	C
UNKNOWN			
	Hypoacusis	Potassium	
	Leukocytosis	(Unspecified)	C
UNKNOWN			
	Lobar Pneumonia	Prednisone	C
UNKNOWN			
	Myocardial Infarction		
	Nausea		
	Nerve Degeneration		
	Oesophageal Disorder		
	Oral Candidiasis		
	Pain		
	Polymyalgia Rheumatica		
	Pyrexia		
	Refractory Anaemia		
	Skin Ulcer		
	Sleep Apnoea Syndrome		
	Temporal Arteritis		
	Thrombosis		
	Urinary Tract Infection		
	Vomiting		
	Wandering Pacemaker		

Date:08/09/04ISR Number: 4420952-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Back Pain
Initial or Prolonged	Bronchitis
	Cerebrovascular Accident
	Constipation
	Dyspepsia
	Dyspnoea
	Eczema Infected

		Emotional Distress					
		Fractured Coccyx					
		Gastritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hemiparesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasopharyngitis		Benadryl	C		
UNKNOWN							
		Oedema Peripheral		Motrin	C		
UNKNOWN							
		Pain In Extremity		Paxil	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Paxil	C		
UNKNOWN							
		Pneumonia					
		Sinus Congestion					
		Sinusitis					
		Syncope					
		Thyroid Pain					
		Vision Blurred					

Date:08/09/04ISR Number: 4420969-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY							
		Arthropod Bite		Vioxx	SS	Merck & Co., Inc	ORAL
245 DAY							
		Arthropod Sting		Fosamax	C		ORAL
		Bursitis		Valium	C		
UNKNOWN							
		Chest Pain		Neurontin	C		
UNKNOWN							
		Chest Wall Pain		Neurontin	C		
UNKNOWN							
		Chronic Sinusitis		Valtrex	C		
UNKNOWN							
		Conjunctivitis		Neurontin	C		
UNKNOWN							
		Constipation		Glucosamine	C		
UNKNOWN							
		Coronary Artery Disease		Nitrostat	C		
UNKNOWN							

	Dyspepsia	Evista	C
UNKNOWN			
	Fall		
	Fracture Nonunion		
	Generalised Anxiety Disorder		
	Influenza		
	Joint Sprain		
	Libido Decreased		
	Multiple Fractures		
	Oedema Peripheral		
	Osteoporosis		
	Panic Disorder		
	Road Traffic Accident		
	Sebaceous Hyperplasia		
	Thoracic Outlet Syndrome		
	Viral Pharyngitis		
	Weight Increased		

Date:08/09/04ISR Number: 4420970-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Atrial Fibrillation
	Bronchitis
	Coagulation Factor Viii Level Increased
	Depression

	Emotional Distress						
	Fatigue						
	Headache	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Influenza		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	International Normalised		Ma Huang Extract	C			UNKNOWN	1523 DAY
	Ratio Increased		Ambien	C			UNKNOWN	
	Pain							
	Protein C Increased							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Renal Cyst							
	Suicidal Ideation							
	Upper Respiratory Tract							
	Infection							

Date:08/09/04ISR Number: 4420972-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blepharitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C			UNKNOWN	
	Heart Rate Irregular		Zocor	C			UNKNOWN	
	Macular Degeneration		Lanoxin	C			UNKNOWN	
	Transient Ischaemic		Zestril	C			UNKNOWN	
	Attack							
	Visual Acuity Reduced							

Date:08/09/04ISR Number: 4420973-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
Disability	Anaemia
Other	Angina Unstable
	Anxiety
	Atelectasis
	Back Pain
	Blood Cholesterol Increased
	Bundle Branch Block Right
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Confusional State
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Ketoacidosis
	Emotional Distress
	Emphysema
	Hyperlipidaemia

		Hypertension					
		Hypokalaemia					
		Influenza Like Illness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Degeneration		Aspirin	C		
UNKNOWN							
		Loss Of Consciousness		Lasix (Furosemide)	C		
UNKNOWN							
		Mitral Valve Incompetence		Glucotrol Xl	C		
UNKNOWN							
		Myocardial Infarction		Glyburide	C		
UNKNOWN							
		Myocardial Ischaemia		Ativan	C		
UNKNOWN							
		Nasopharyngitis		Lopressor	C		
UNKNOWN							
		Pain		Orphenadrine	C		
UNKNOWN							
		Pain In Extremity					
		Palpitations					
		Rotator Cuff Syndrome					
		Scar					
		Stress Incontinence					
		Supraventricular					
		Extrasystoles					
		Supraventricular					
		Tachycardia					
		Syncope					
		Tetany					
		Transient Ischaemic					
		Attack					
		Treatment Noncompliance					
		Tremor					
		Urinary Tract Infection					
		Urine Odour Abnormal					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Vision Blurred					

Date:08/09/04ISR Number: 4420975-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Intestinal Obstruction							
	Meningitis Viral							
	Oesophageal Disorder							
	Urinary Tract Infection							

Date:08/09/04ISR Number: 4420976-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Catheter Site Infection
Disability	Cerebellar Ataxia
Other	Cerebellar Atrophy
	Chest Wall Abscess
	Emotional Distress
	Encephalitis Brain Stem
	Herpes Ophthalmic
	Herpes Zoster
	Hodgkin'S Disease Nodular
	Sclerosis Stage

		Unspecified					
		Intervertebral Disc Displacement					
		Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lymphadenopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Meningitis Herpes	Professional				
		Meningitis Viral					
		Pruritus					
		Staphylococcal Sepsis					
		Vestibulitis					
		Vomiting					

Date:08/09/04ISR Number: 4420978-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Brain Stem Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Bunion		[Therapy			
Other		Cardiac Failure		Unspecified]	C		
UNKNOWN							
		Congestive		[Therapy			
		Cardiomegaly		Unspecified]	C		
UNKNOWN							
		Carotid Artery Occlusion		Avandia	C		ORAL
		Carotid Artery Stenosis		Avandia	C		ORAL
		Cataract		Vicoprofen	C		ORAL
		Cerebrovascular Accident		Glucophage	C		ORAL
		Choking		Glucophage	C		ORAL
		Contusion					
		Coronary Artery Disease					
		Dysphagia					
		Dyspnoea					
		Glaucoma					
		Hemianopia Homonymous					
		Hypoaesthesia					
		Intervertebral Disc Protrusion					
		Lumbar Spinal Stenosis					
		Nasopharyngitis					
		Neuropathy Peripheral					
		Osteoarthritis					
		Pain In Extremity					

Road Traffic Accident
Spinal Osteoarthritis
Toe Deformity
Whiplash Injury

Date:08/09/04ISR Number: 4420980-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Anxiety
	Asthenia
	Back Pain
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Convulsion
	Depression
	Diabetes Mellitus

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Non-Insulin-Dependent Dysphagia Dyspnoea Eye Irritation					
		Fatigue	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Darvocet-N	C		
UNKNOWN							
		Infection		Norvasc	C		
UNKNOWN	395 DAY						
		Wheezing		Lotrel	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN	831 DAY						
				Lipitor	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN	831 DAY						
				Lipitor	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Clorazepate Dipotassium	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Zetia	C		ORAL
				Zetia	C		ORAL
				Tricor	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Glucovance	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Zocor	C		ORAL
				Zocor	C		ORAL
				Hydrodiuril	C		ORAL
				Ibuprofen	C		
UNKNOWN							

Robaxin	C	ORAL
Toprol Xl Tablets	C	ORAL
Toprol Xl Tablets	C	ORAL
Prilosec	C	
Paxil	C	

UNKNOWN

UNKNOWN

Date:08/09/04ISR Number: 4420981-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Alopecia
Other	Amnesia
	Arthropathy
	Cardiac Murmur
	Contusion
	Delirium
	Disability
	Dyspnoea
	Electrocardiogram St Segment Abnormal
	Emotional Distress
	Fatigue
	Gastric Disorder
	Haemorrhage
	Hypertension
	Keloid Scar
	Major Depression
	Meniscus Lesion
	Migraine Without Aura
	Monarthritis

		Nausea Neoplasm Malignant Non-Cardiac Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis Palpitations Panic Disorder With Agoraphobia Peptic Ulcer Skin Lesion Swelling Tension Headache Transient Ischaemic Attack Urine Abnormality Urine Odour Abnormal Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/09/04ISR Number: 4420982-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort Anaemia Arrhythmia Asthenia Blood Pressure Increased Chest Discomfort Chest Pain Chronic Fatigue Syndrome Cyst Dizziness Dyspnoea Emotional Distress Hyperlipidaemia Hypertension Hypoaesthesia Hypokalaemia Intervertebral Disc Protrusion Joint Swelling Large Intestinal Ulcer Haemorrhage Musculoskeletal Discomfort

Nasopharyngitis
Nausea
Neck Pain
Oedema
Oesophageal Ulcer
Haemorrhage
Osteoarthritis
Pain In Extremity
Paraesthesia
Road Traffic Accident
Spinal Disorder
Spinal Osteoarthritis
Stomach Discomfort
Strabismus
Upper Respiratory Tract
Infection

Vitamin B12 Deficiency

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Lortab	C		
UNKNOWN			Albuterol	C		
RESPIRATORY (INHALATION)			Proventil	C		
UNKNOWN			Micardis	C		
UNKNOWN			Micardis Hct	C		
UNKNOWN			Sular	C		
UNKNOWN	4 DAY		Sular	C		ORAL

Date:08/09/04ISR Number: 4420986-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0408BRA00010
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia Haematemesis Nausea Oesophageal Varices Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Adiphenine Hydrochloride And Dipyrone And Promethazine	C			UNKNOWN	
			Cephalexin	C			UNKNOWN	

Date:08/09/04ISR Number: 4421235-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Initial or Prolonged	Arthropathy	Premarin	C
UNKNOWN			
Other	Atrial Fibrillation	Estratab	C
UNKNOWN			
	Cardiac Aneurysm	Menest	C
UNKNOWN			
	Corneal Deposits	Armour Thyroid	
	Haematuria	Tablets	C
UNKNOWN			
	Haemorrhage	Trazodone	
	Hypertension	Hydrochloride	C
UNKNOWN			
	Hypertensive Crisis	Garlic Extract	C
UNKNOWN			
	Jaw Disorder	Synthroid	C
UNKNOWN			
	Musculoskeletal Disorder	Methotrexate	C
UNKNOWN			
	Oedema Peripheral		
	Pain In Extremity		
	Paraesthesia		
	Renal Cyst		
	Transient Ischaemic		
	Attack		

Date:08/09/04ISR Number: 4421242-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization -	Bipolar Disorder
Initial or Prolonged	Drug Ineffective
	Emotional Distress
	Haemorrhoids
	Hyperglycaemia
	Lumbar Radiculopathy
	Myocardial Infarction

	Upper Respiratory Tract Infection					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						
			Depakote	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						
			Lithium Carbonate	C		
UNKNOWN						
			Robaxin	C		
UNKNOWN						

Date:08/09/04ISR Number: 4421305-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104492
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol Increased					
	Bursitis					
	Carotid Artery Stenosis					
	Cellulitis					
	Cerebrovascular Accident					
	Extrasystoles					
	Granuloma					
	Hyperlipidaemia					
	Hypertension					
	Osteoarthritis					
	Osteoporosis					
	Pain In Extremity					
	Tendon Injury					
	Ventricular Extrasystoles					
	Ventricular Hypertrophy					

Date:08/09/04ISR Number: 4421319-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Benign Prostatic		Tylenol	C				
UNKNOWN								
Other	Hyperplasia							
	Cataract							
	Cellulitis							
	Cerebellar Infarction							
	Chalazion							
	Chest Pain							
	Coronary Artery Disease							
	Dyslipidaemia							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Lacunar Infarction							
	Vestibular Disorder							

Date:08/09/04ISR Number: 4421321-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	297 DAY	
Initial or Prolonged	Angina Pectoris		Aspirin	SS			UNKNOWN	
Disability	Anxiety		Plavix	SS			UNKNOWN	1 YR
	Aspiration		Vioxx	SS	Merck & Co., Inc	ORAL	297 DAY	
	Atherosclerosis		Heparin	SS			INTRAVENOUS	
	Blood Cholesterol		Vicodin Tablets	C			UNKNOWN	339 DAY
	Increased		Lipitor	C			UNKNOWN	
	Blood Triglycerides		Zoloft	C			UNKNOWN	
	Increased		Niacin	C			UNKNOWN	
	Cardiac Arrest		Metoprolol	C			UNKNOWN	
	Chest Pain		Monopril	C			UNKNOWN	
	Coronary Artery Disease		Celebrex	C			UNKNOWN	
	Depression Dysthymic Disorder Emotional Distress		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Gastritis Hypertension Lethargy Lumbar Radiculopathy Myocardial Infarction Upper Gastrointestinal Haemorrhage Ventricular Fibrillation							

Date:08/09/04ISR Number: 4421324-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Asthenia
	Back Injury
	Cerebrovascular Accident
	Cervical Spasm
	Chest Pain
	Chronic Fatigue Syndrome
	Coordination Abnormal
	Depression
	Dyspnoea
	Dysuria
	Emotional Disorder
	Gastrooesophageal Reflux Disease
	Headache
	Hernia
	Hypertension
	Insomnia
	Intervertebral Disc Protrusion
	Lacunar Infarction
	Muscle Contracture
	Neck Pain
	Oedema Peripheral
	Peripheral Vascular Disorder
	Radiculopathy
	Road Traffic Accident
	Spinal Osteoarthritis

	Tinnitus					
	Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Vertigo Positional		Vioxx	PS	Merck & Co., Inc	ORAL
	Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
	Weight Decreased		Vicodin Tablets	C		
UNKNOWN						
			Clonidine	C		
UNKNOWN						
			Desyrel	C		
UNKNOWN						
			Clonidine	C		
UNKNOWN						
			Skelaxin	C		
UNKNOWN						

Date:08/09/04ISR Number: 4424713-0Report Type:Expedited (15-DaCompany Report #GB-JNJFOC-20040707784
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Circulatory Collapse	Foreign	Ibuprofen			
	Dyspnoea	Health	(Ibuprofen)	PS		ORAL
400 MG, 3 IN						
	Gastrointestinal Ulcer	Professional				
1 DAY, ORAL						
	Haemoglobin Decreased		Rofecoxib			
	Oesophagitis		(Rofecoxib) Tablets	SS		ORAL
25 MG, 1 IN 1						
	Syncope					
DAY, ORAL						
			Lipitor			
			(Atorvastatin)	C		
			Paracetamol	C		

Date:08/10/04ISR Number: 4422241-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time
Disability	Shortened

Acute Myocardial
Infarction
Anaemia
Angina Pectoris
Anxiety
Blood Cholesterol
Increased
Bradycardia
Calculus Urinary
Cardiac Failure
Congestive
Carotid Artery Disease
Carotid Artery Stenosis
Chronic Obstructive
Pulmonary Disease
Coronary Artery Occlusion
Coronary Artery
Thrombosis
Diverticulum Intestinal
Emotional Distress
Fluid Overload
Gastritis
Gastritis Haemorrhagic
Gastrointestinal
Haemorrhage
Haematuria
Haemorrhoids

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypertension					
		Hypotension					
		Myocardial Infarction					
		Osteoporosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY						
		Pain	Professional	[Therapy			
		Pain In Extremity		Unspecified]	C		
UNKNOWN							
		Palpitations		Tylenol	C		
UNKNOWN							
		Platelet Count Increased		Proventil	C		
UNKNOWN							
		Proctitis		Buspar	C		
UNKNOWN							
		Stress		Cipro	C		
UNKNOWN							
		Thrombosis		Tranxene	C		
UNKNOWN							
		Tobacco Abuse		Diphenhydramine			
		Upper Gastrointestinal		Citrate	C		
UNKNOWN							
		Haemorrhage		Epi-Pen	C		
UNKNOWN							
		Upper Respiratory Tract		Allegra	C		
UNKNOWN							
		Infection		Duratuss	C		
UNKNOWN							
		Urinary System X-Ray		Hydroxyzine Pamoate	C		
UNKNOWN							
		Abnormal		Motrin	C		
UNKNOWN							
		Urinary Tract Infection		Loperamide			
		Weight Decreased		Hydrochloride	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Nasonex	C		
UNKNOWN							
				Elocon	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							

Date:08/10/04ISR Number: 4422251-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Occlusion		[Therapy Unspecified]	C				
	Dermal Cyst		Vicodin Tablets	C				
	Emotional Distress		Ultram	C				
	Erectile Dysfunction		Soma	C				
	Hypersensitivity		Celebrex	C				
	Inguinal Hernia							
	Muscle Tightness							
	Myocardial Infarction							
	Pneumonitis							
	Prostatic Specific Antigen Increased							

Date:08/10/04ISR Number: 4422253-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0306FRA00016
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Purpura	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	299	DAY
	Skin Ulcer		Amlodipine Maleate	SS		ORAL	46	DAY
			Enalapril Maleate And Hydrochlorothiazide	SS		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/04ISR Number: 4422254-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
							7	DAY
Disability	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Colitis Ulcerative							
	Constipation							
	Cough							
	Deep Vein Thrombosis							
	Depression							
	Drug Interaction							
	Dyspnoea							
	Headache							
	Insomnia							
	Iron Deficiency Anaemia							
	Muscle Spasms							
	Oedema Peripheral							
	Pharyngolaryngeal Pain							
	Pneumonia							
	Postmenopausal							
	Haemorrhage							
	Pulmonary Congestion							
	Pulmonary Embolism							
	Rectal Ulcer							
	Reflux Oesophagitis							
	Renal Failure							
	Tremor							
	Weight Decreased							

Date:08/10/04ISR Number: 4422255-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Acute Stress Disorder

Other	Anaemia
	Atherosclerosis
	Back Pain
	Blindness
	Blood Creatine
	Phosphokinase Mb
	Increased
	Blood Urine Present
	Chest Pain
	Diabetes Mellitus
	Inadequate Control
	Diabetic Neuropathy
	Dyspepsia
	Emotional Distress
	Fall
	Gastrointestinal
	Haemorrhage
	Gastrooesophageal Reflux

		Disease					
		Haematochezia					
		Localised Infection					
		Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia	Professional	Acetaminophen And			
		Proctalgia		Hydrocodone			
		Prostatitis		Bitartrate	C		
UNKNOWN							
		Rectal Haemorrhage		Norvasc	C		
UNKNOWN							
		Spinal Column Stenosis		Celebrex	C		
UNKNOWN							
		Syncope		Clonidine	C		
UNKNOWN							
		Urethral Discharge		Prozac	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Avandia	C		
UNKNOWN							
				Hyzaar	C		ORAL
				Imdur	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Methocarbamol	C		
UNKNOWN							
				Glyset	C		
UNKNOWN							
				Nitroquick	C		
SUBLINGUAL							

Date:08/10/04ISR Number: 4422256-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00004
Age:96 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Professional	Aspirin	SS		ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/10/04ISR Number: 4422257-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02301
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/04ISR Number: 4422259-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01189
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular	Health	Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
	Throat Tightness	Professional						

Date:08/10/04ISR Number: 4422262-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0407CHE00043
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	89 DAY	
Initial or Prolonged	Perforated Ulcer							

Date:08/10/04ISR Number: 4422263-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0408NOR00005
Age:20 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
Initial or Prolonged	Nephritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/04ISR Number: 4422270-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
Other	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Contusion		Tylenol	C			UNKNOWN	
	Dyspepsia		Combivent	C			RESPIRATORY (INHALATION)	
	Emotional Distress							
	Gastric Ulcer		Allopurinol	C			UNKNOWN	
	Gastritis		Celebrex	C			UNKNOWN	
	Gastrointestinal		Estradiol	C			UNKNOWN	
	Haemorrhage		Vitamin E	C			UNKNOWN	
	Meniscus Lesion		Diovan	C			UNKNOWN	
	Patella Fracture		Ultram	C			UNKNOWN	
	Patellofemoral Pain		Bactrim Ds Tablets	C			UNKNOWN	
	Syndrome		Glucosamine	C			UNKNOWN	
	Pyrexia		Avalide	C			UNKNOWN	
	Therapeutic Response		Atrovent	C			UNKNOWN	
	Decreased		Claritin	C			UNKNOWN	
	Wound Infection		Niferex	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	

			Pyridoxine	C		
UNKNOWN						

Date:08/10/04ISR Number: 4422277-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
573 DAY						
Initial or Prolonged	Cough	Professional	Celebrex	C		
UNKNOWN						
Disability	Dehydration		Lasix (Furosemide)	C		
UNKNOWN	615 DAY					
	Depression		Hydrocodone			
	Haemorrhagic Stroke		Hydrochloride	C		
UNKNOWN						
	Nasal Congestion		Spironolactone	C		
UNKNOWN						
	Thrombocytopenia		Demadex	C		
UNKNOWN	615 DAY					
			Ibuprofen	C		
UNKNOWN						
			Lozol	C		
UNKNOWN	615 DAY					
			Synthroid	C		
UNKNOWN						

Date:08/10/04ISR Number: 4422283-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Angina Pectoris
Other	Angina Unstable
	Angiopathy
	Aortic Valve Incompetence
	Asthenia
	Bacteria Urine Identified
	Blood Calcium Increased
	Blood Pressure Diastolic
	Decreased
	Blood Pressure Increased
	Bundle Branch Block Left
	Cardiac Disorder
	Cardiac Failure

Congestive
Cardiac Murmur
Cardiomegaly
Chest Pain
Chest Wall Pain
Coagulation Time
Prolonged
Convulsion
Coronary Artery Disease
Cystitis
Deep Vein Thrombosis
Depression
Diarrhoea
Dizziness Postural
Dyspnoea
Dyspnoea Exertional
Dysuria
Ejection Fraction
Decreased
Extrasystoles
Eye Haemorrhage
Fatigue
Fluid Retention
Gallbladder Disorder
Gastrointestinal Disorder
Heart Valve Calcification
Hypercholesterolaemia
Hypertension
Hypertensive
Cardiomyopathy
Hypertonic Bladder
Hypothyroidism
Immune System Disorder
International Normalised
Ratio Increased
Ischaemic Cardiomyopathy
Kidney Infection
Klebsiella Infection
Lung Disorder
Macular Degeneration
Migraine
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema Peripheral
Orthostatic Hypotension
Osteoporosis

Parathyroid Tumour Benign
Pericardial Effusion
Prothrombin Time
Prolonged
Pulmonary Hypertension
Stress Incontinence
Supraventricular
Extrasystoles
Syncope
Therapy Non-Responder
Thyroid Disorder
Urinary Incontinence
Urinary Tract Infection
Uterine Disorder

Ventricular Extrasystoles
Weight Decreased
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Midrin	C			UNKNOWN	
	Elavil	C		ORAL		
	Norvasc	C			UNKNOWN	
	Celexa	C			UNKNOWN	
	Effexor	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Levothyroxine Sodium	C			UNKNOWN	
	Robaxin	C			UNKNOWN	
	Phenobarbital	C			UNKNOWN	

Date:08/10/04ISR Number: 4422285-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris
	Angina Unstable
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive Cardiomegaly
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Reocclusion
	Coronary Artery

Restenosis
Diplopia
Diverticulitis
Dizziness
Dyspepsia
Dyspnoea
Family Stress
Gastrooesophageal Reflux
Disease
Haematemesis
Haematoma
Haemoptysis
Hyperlipidaemia
Hypersensitivity
Hypertension
Lactose Intolerance
Muscle Contractions
Involuntary
Myalgia
Myocardial Ischaemia
Non-Cardiac Chest Pain
Osteoarthritis
Pulmonary Oedema
Retroperitoneal

	Haemorrhage						
	Stent Occlusion						
	Stress						
	Syncope	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tendonitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	220 DAY
	Tinnitus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	220 DAY
	Tongue Biting		Propacet	C			UNKNOWN
	Urticaria		Wellbutrin	C			UNKNOWN
	Ventricular Fibrillation		Prevacid	C			UNKNOWN
	Vision Blurred						
	Visual Acuity Reduced						
	Wheezing						

Date:08/10/04ISR Number: 4422290-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Connective Tissue	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Disorder		Vicodin Tablets	C			UNKNOWN
	Depression		Xanax	C			UNKNOWN
	Diabetes Mellitus		Elavil	C		ORAL	
	Dizziness		Aspirin	C			UNKNOWN
	Drug Ineffective		Aspirin	C			UNKNOWN
	Fall		Lotensin	C			UNKNOWN
	Gastritis		Zoloft	C			UNKNOWN
	Generalised Anxiety		Captopril	C			UNKNOWN
	Disorder		Neurontin	C			UNKNOWN
	Haemorrhoids		Heparin	C			UNKNOWN

	Hypertension		Hydro-Chlor	C		
UNKNOWN						
	Idiopathic		Insulin	C		
UNKNOWN						
	Thrombocytopenic Purpura		Ms Contin	C		
UNKNOWN						
	Intestinal Obstruction		Zantac	C		
UNKNOWN						
	Joint Lock					
	Malaise					
	Melaena					
	Nervousness					
	Pain					
	Stomach Discomfort					
	Tremor					
	Vomiting					

Date:08/10/04ISR Number: 4422292-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00036
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rash Generalised		Bendroflumethiazide	C		
UNKNOWN						
	Staphylococcal Infection		Enalapril Maleate	C		
UNKNOWN						
	Wound Secretion		Floxacillin	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Paroxetine	C		
UNKNOWN						

Date:08/10/04ISR Number: 4422293-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02536
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Atherosclerosis

		Cardiac Murmur					
		Cerebrovascular Accident					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Hypersensitivity	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Eye Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Gout		Darvocet-N	C		
UNKNOWN							
		Headache		Clonidine	C		ORAL
		High Density Lipoprotein		Tiazac	C		
UNKNOWN							
		Decreased		Avalide	C		
UNKNOWN							
		Hypoacusis		Avalide	C		
UNKNOWN							
		Hypoaesthesia		Avalide	C		
UNKNOWN							
		Irritability		Zestril	C		
UNKNOWN							
		Lipids Increased					
		Low Density Lipoprotein					
		Increased					
		Memory Impairment					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Nephrolithiasis					
		Renal Failure					
		Renal Function Test					
		Abnormal					
		Vision Blurred					

Date:08/10/04ISR Number: 4422296-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block

Benign Prostatic
Hyperplasia
Cardiac Failure
Congestive
Cerebellar Syndrome
Cerebral Haemorrhage
Chondromalacia
Confusional State
Convulsion
Coronary Artery Disease
Deafness Neurosensory
Dehydration
Depression
Diabetes Mellitus
Drug Ineffective
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fatigue

		Fibrous Histiocytoma					
		Flatulence					
		Gastritis Haemorrhagic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache	Health	Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Hiatus Hernia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypermetropia		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Inner Ear Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukocytosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Meniscus Lesion		Neurontin	C		
UNKNOWN							
		Mitral Valve Incompetence		Glucosamine	C		
UNKNOWN							
		Myocardial Infarction		Prilosec	C		
UNKNOWN							
		Oedema					
		Osteonecrosis					
		Pain					
		Pneumonia Escherichia					
		Post Procedural					
		Complication					
		Presbyopia					
		Prothrombin Time					
		Prolonged					
		Pupillary Disorder					
		Renal Failure					
		Respiratory Failure					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Transient Ischaemic					
		Attack					
		Tremor					
		Tricuspid Valve					
		Incompetence					
		Varicose Vein					
		Ventricle Rupture					
		Ventricular Tachycardia					
		Vertigo Positional					

Date:08/10/04ISR Number: 4422356-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00990
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
Disability	Angina Pectoris
Other	Angiogram Abnormal
	Anhedonia
	Anxiety
	Arthralgia
	Asthenia
	Autonomic Neuropathy
	Back Disorder
	Back Pain
	Bradycardia
	Burning Sensation
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Convulsion

Coronary Artery Disease
Coronary Artery Stenosis
Cough
Crepitations
Crying
Decreased Appetite
Depressed Mood
Diarrhoea
Dissociation
Disturbance In Attention
Dizziness
Drug Hypersensitivity
Drug Ineffective
Dyspnoea
Dyspnoea Exertional
Electrocardiogram
Repolarisation
Abnormality
Emotional Disorder
Erectile Dysfunction
Fatigue
Fear
Feelings Of Worthlessness
Flat Affect
Headache
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Hypotension
Impaired Work Ability
Intervertebral Disc
Protrusion
Irritability
Jugular Vein Distension
Labyrinthitis
Lung Neoplasm
Lymphadenopathy
Mediastinal
Meniere'S Disease
Mental Disorder
Mitral Valve Incompetence
Muscle Spasms
Musculoskeletal
Discomfort
Myocardial Infarction
Nausea
Nervousness

Osteoarthritis
Oxygen Saturation
Decreased
Pain
Pain In Extremity
Paraesthesia
Peripheral Coldness
Postnasal Drip
Renal Cyst
Scar
Self Esteem Decreased
Sleep Disorder
Speech Disorder
Spinal Osteoarthritis

	Suicidal Ideation						
	Syncope						
	Tearfulness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tooth Loss	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY
	Tricuspid Valve	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	8 DAY
	Incompetence						
	Ulnar Nerve Palsy						
	Ventricular Extrasystoles						
	Ventricular Hypokinesia						

Date:08/10/04ISR Number: 4422638-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01988
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Faeces Discoloured	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Gastritis	Professional	Norvasc	C			
UNKNOWN							
Initial or Prolonged	Haematochezia		Enbrel	C			
SUBCUTANEOUS							
	Haematocrit Decreased		Lidoderm	C			
UNKNOWN							
	Syncope		Prinivil	C		ORAL	

Date:08/10/04ISR Number: 4422645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebral Haemangioma	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Convulsion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Emotional Distress		Celebrex	C			
UNKNOWN							
Other	Haemarthrosis						
	Ligament Injury						
	Ligament Sprain						

Date:08/10/04ISR Number: 4422654-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01380
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization -	Right Ventricular Failure	Professional	Advicor	SS		ORAL	15	DAY
Initial or Prolonged			Toprol Xl Tablets	C			UNKNOWN	
Disability			Coumadin	C			UNKNOWN	
			Altace	C			UNKNOWN	

Date:08/10/04ISR Number: 4422658-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0408BRA00010
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haematemesis Nausea Oesophageal Varices Haemorrhage		Adiphenine Hydrochloride And Dipyrone And Promethazine	C			UNKNOWN	
			Cephalexin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/04ISR Number: 4422659-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01210
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Haemorrhage		Actonel	SS		ORAL		
			Actonel	SS		ORAL		
	Haematemesis		Aricept	C				UNKNOWN
			Prozac	C				UNKNOWN
			Zyprexa	C				UNKNOWN

Date:08/10/04ISR Number: 4422662-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyskinesia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Carbidopa And Levodopa	C		ORAL		
			Pergolide	C		ORAL		

Date:08/10/04ISR Number: 4424252-7Report Type:Direct Company Report #CTU 224653
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Swelling		Vioxx 25mg	PS			1 TAB DAILY	
	Heart Rate Increased							
	Palpitations							
	Rash							
	Throat Tightness							

Date:08/10/04ISR Number: 4425716-2Report Type:Expedited (15-DaCompany Report #WAES 01112854
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Aortic Aneurysm
Hospitalization - Initial or Prolonged	Aortic Calcification
Disability	Aortic Valve Disease
	Aortic Valve Stenosis
	Atelectasis
	Basal Cell Carcinoma
	Benign Prostatic Hyperplasia
	Bladder Disorder
	Bladder Obstruction
	Blood Pressure Increased
	Cardiac Murmur
	Cardiac Stress Test Abnormal
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Dilatation Atrial
	Dilatation Ventricular
	Ejection Fraction Decreased
	Electrocardiogram

		Abnormal					
		Emphysema					
		Exostosis					
		Haematuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemodynamic Instability	Study	Tab Vioxx 25 Mg	PS		ORAL
25							
		Ischaemic Cardiomyopathy	Health				
MG/DAILY/PO							
		Mitral Valve Incompetence	Professional	Tab Acetaminophen	SS		ORAL
325 MG/PRN/PO							
		Myocardial Infarction		Effexor	C		
		Nausea		Zocor	C		
		Osteoarthritis		Aspirin	C		
		Pleural Effusion					
		Pleural Fibrosis					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Cyst					
		Scar					
		Skin Lesion					
		Spinal Osteoarthritis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Ventricular Tachycardia					

Date:08/10/04ISR Number: 4426048-9Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-293
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinal Haemorrhage	Foreign	Methotrexate			
			Health	(Methotrexate,			
			Professional	Unspec)	PS		
			Distributor	Augmentin			
			Other	(Amoxicillin			
				Sodium/Clavulanate			
				Potassium,			
				Injection)	SS		
				Co-Dydramol			
				(Dihydrocodeine			
				Bitartrate/Paracetam			
				ol)	SS		
				Fluoxetine			

				Hydrochloride (Fluoxetine Hydrochloride)	SS		
				Humira (Adalimumab)	SS		
SUBCUTANEOUS	40 G/M^2 1X PER 2 WK, SC						
				Premarin (Conjugated Estrogens, Unspec)	SS		
				Rofecoxib (Rofecoxib)	SS		

Date:08/10/04ISR Number: 4426325-1Report Type:Expedited (15-DaCompany Report #A01200403374
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastroduodenal Ulcer Haematemesis	Health Professional	Clopidogrel - Tablet - 75 Mg	PS		ORAL	75 MG OD	
	Melaena		Acetylsalicylic Acid	SS		ORAL	75 MG OD	
	Oesophagitis		Rofecoxib	SS		ORAL	12.5 MG OD	
			Amitriptyline	C				

			Senna	C		
			Lactulose	C		
			Alfuzosin	C		
			Bendrofluazide	C		
			Tramadol	C		

Date:08/11/04ISR Number: 4423130-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0407AUS00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/04ISR Number: 4423142-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00150
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Unilateral Hypoacusis		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:08/11/04ISR Number: 4423147-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00052
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C			UNKNOWN	
			Aspirin	C		ORAL		
			Haloperidol	C			UNKNOWN	
			Temazepam	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

			Paroxetine	C			
UNKNOWN							

Date:08/11/04ISR Number: 4423708-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bipolar I Disorder		Lipitor	C				
UNKNOWN								
Other	Chest Pain		Lipitor	C				
UNKNOWN								
	Deep Vein Thrombosis		Avapro	C				
UNKNOWN								
	Fatigue		Geodon	C				
UNKNOWN								
	Flank Pain		Prevacid	C				
UNKNOWN								
	Gastritis		Levoxyl	C				
UNKNOWN								
	Hydronephrosis		Prilosec	C				
UNKNOWN								
	Incisional Hernia		Paxil	C				
UNKNOWN								
	Nephrolithiasis							
	Renal Failure							
	Schizoaffective Disorder							
	Sepsis							
	Staphylococcal Infection							
	Urinary Retention							
	Urinary Tract Infection							
	Urosepsis							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/04ISR Number: 4423719-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Adrenal Adenoma		Tylenol	C		ORAL		
	Angina Pectoris		Pravachol	C				
UNKNOWN								
	Arthritis							
	Blood Cholesterol Increased							
	Bronchitis							
	Cardiac Murmur							
	Cataract							
	Cellulitis							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Constipation							
	Cystitis							
	Cystitis Glandularis							
	Dizziness							
	Dyspepsia							
	Dyspnoea							
	Dyspnoea Paroxysmal Nocturnal							
	Ear Infection							
	Electrocardiogram Abnormal							
	Emotional Distress							
	Gastrointestinal Ulcer							
	Gastrooesophageal Reflux Disease							
	Haematuria							
	Headache							
	Hypercholesterolaemia							
	Increased Tendency To Bruise							
	Mitral Valve Incompetence							
	Nausea							
	Osteoporosis							
	Palpitations							
	Parotid Gland Enlargement							
	Peptic Ulcer							
	Rhinitis Allergic							
	Stress Incontinence							
	Thyroid Neoplasm							

Tooth Abscess
Urethral Caruncle
Urinary Tract Infection

Date:08/11/04ISR Number: 4423722-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00094
Age:29 YR Gender:Female I/FU:F

Outcome PT
Other Abscess
Arthrodesis
Basedow'S Disease
Body Tinea
Bronchitis Chronic
Cellulitis
Depression
Diarrhoea

		Essential Hypertension					
		Facial Palsy					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Herpes Simplex	Professional	[Composition			
		Herpes Simplex Ophthalmic		Unspecified]	C		
UNKNOWN							
		Hordeolum		Midrin	C		ORAL
		Otitis Media Acute		Keflex	C		ORAL
		Pelvic Inflammatory		Tiazac	C		
UNKNOWN							
		Disease		Hydrodiuril	C		ORAL
		Pharyngitis		Accuretic	C		
UNKNOWN							
		Pleurisy		Prevacid	C		
UNKNOWN							
		Post Procedural		Synthroid	C		
UNKNOWN							
		Complication		Claritin-D 12 Hour	C		ORAL
		Thyroiditis		Accupril	C		
UNKNOWN							
		Urinary Tract Infection					

Date:08/11/04ISR Number: 4423725-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00069
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthropathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Albumin Decreased	Professional	Ascriptin	C		
UNKNOWN							
		Blood Chloride Decreased		Capoten	C		
UNKNOWN							
		Blood Cholesterol		Colace	C		
UNKNOWN							
		Increased		[Therapy			
		Blood Glucose Increased		Unspecified]	C		
UNKNOWN							
		Blood Pressure Increased		Verelan	C		
UNKNOWN							
		Body Temperature		Tylenol Extra			
		Decreased		Strength	C		
UNKNOWN							

	Cerebrovascular Accident	Combivent	C
RESPIRATORY			
	Chest Pain		
(INHALATION)			
	Dizziness	Cardura	C
UNKNOWN			
	Dyspnoea	Esidrix	C
UNKNOWN			
	Emphysema		
	Gastric Disorder		
	Haematochezia		
	Haematocrit Decreased		
	Haemoglobin Decreased		
	Headache		
	Hyperhidrosis		
	Hypertension		
	Joint Range Of Motion Decreased		
	Knee Deformity		
	Nausea		
	Optic Ischaemic Neuropathy		
	Osteoarthritis		
	Oxygen Saturation Decreased		
	Platelet Count Increased		

Date:08/11/04ISR Number: 4423727-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00007
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Aortic Aneurysm

		Atrial Septal Defect					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
93	DAY						
		Cellulitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
93	DAY						
		Cerebrovascular Accident		Tylenol	C		
UNKNOWN							
		Chronic Obstructive		Darvocet-N	C		
UNKNOWN							
		Pulmonary Disease		Xanax	C		
UNKNOWN							
		Depression		Zoloft	C		
UNKNOWN		2 WK					
		Drug Ineffective		Zoloft	C		
UNKNOWN							
		Fear		Zoloft	C		
UNKNOWN		764 DAY					
		Hypertension		Xanax	C		
UNKNOWN							
		Oedema Peripheral		Alphagan	C		
OPHTHALMIC							
		Panic Disorder With		Xalatan	C		
OPHTHALMIC							
		Agoraphobia		Synthroid	C		
UNKNOWN							

Date:08/11/04ISR Number: 4423729-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0408USA00823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Acetaminophen	C		
UNKNOWN						
	Cardiac Murmur		Garlic Extract	C		
UNKNOWN						
	Chest Pain		Glucosamine			
	Headache		Hydrochloride	C		
UNKNOWN						
	Oedema		Herbs (Unspecified)	C		
UNKNOWN						

	Oedema Peripheral		Levothyroxine Sodium	C			
UNKNOWN							
	Pericardial Effusion		Phenytoin	C			
UNKNOWN							
			Pravastatin Sodium	C			
UNKNOWN							

Date:08/11/04ISR Number: 4423732-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00482
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Oedema Peripheral		Acetaminophen	C				
UNKNOWN								
			Chondroitin Sulfate Sodium And Glucosamine Sulfate	C				
UNKNOWN								
			Dyazide	C				
UNKNOWN								
			Mevacor	C		ORAL		

Date:08/11/04ISR Number: 4423737-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Eye Swelling		Synthroid	C				
UNKNOWN								
	Rash							
	Swelling Face							

Date:08/11/04ISR Number: 4426766-2Report Type:Expedited (15-DaCompany Report #2004052381
Age: Gender:Female I/FU:I

Outcome	PT
Other	Dizziness
	Fibromyalgia

Spinal Cord Injury

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Consumer	Neurontin (Gabapentin)	PS		
			Rofecoxib (Rofecoxib)	SS		
			All Other Therapeutic Products (All Other Therapeutic Products)	SS		
			All Other Therapeutic Products (All Other Therapeutic Products)	SS		
			Allergy Medication (Allergy Medication)	C		

Date:08/11/04ISR Number: 4426908-9Report Type:Expedited (15-DaCompany Report #GBWYE867030JUN04
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Health Professional Other	Methotrexate (Methotrexate, Unspec, 0)	PS				
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection, 0)	SS				
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, 0)	SS				
			Fluoxetine Hydrochloride (Fluoxetine Hydrochloride, 0)	SS				
			Humira (Adalimumab, 0)	SS		SUBCUTANEOUS	40 G/M^2	1X

PER 2 WK SC

Premarin (Conjugated Estrogens, Unspec, 0)	SS
Rofecoxib (Rofecoxib, 0)	SS
Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C
Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/04ISR Number: 4424358-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Choking		Aspirin	C				
Disability	Depression		Restoril	C				UNKNOWN
	Diverticulum							
	Erosive Duodenitis							
	Fatigue							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Hiatus Hernia							
	Hypertension							
	Hypoacusis							
	Oesophageal Rupture							
	Pancreatitis							
	Renal Cyst							
	Supraventricular Extrasystoles							
	Thromboembolic Stroke							
	Transient Ischaemic Attack							

Date:08/12/04ISR Number: 4424369-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00057
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
			Albuterol	C				RESPIRATORY (INHALATION)
			Tiotropium Bromide	C				RESPIRATORY (INHALATION)

Date:08/12/04ISR Number: 4424372-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Acute Respiratory Failure
Disability	Adjustment Disorder With
Other	Depressed Mood
	Anxiety
	Arthralgia
	Atrioventricular Block
	Blood Alcohol Increased
	Bradycardia
	Bundle Branch Block
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Catheter Related
	Complication
	Cellulitis
	Cervicobrachial Syndrome
	Chills
	Congestive Cardiomyopathy
	Coronary Artery Disease
	Depression

		Difficulty In Walking					
		Drug Hypersensitivity					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epicondylitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Fall	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Feeling Abnormal					
		Gastrooesophageal Reflux					
		Disease					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypotension					
		Hypoxic Encephalopathy					
		Injury					
		Laceration					
		Limb Injury					
		Lung Infiltration					
		Malaise					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Neck Pain					
		Nervousness					
		Neurogenic Bladder					
		Neurogenic Bowel					
		Pulmonary Oedema					
		Pyrexia					
		Quadriplegia					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinus Bradycardia					
		Spinal Cord Injury					
		Ulcer					
		Urinary Tract Infection					
		Urosepsis					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Wheezing					
		Wound Infection					

Date:08/12/04ISR Number: 4424381-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00008
Age:76 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Delirium	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	
	Renal Failure Acute		Morphine	SS			
UNKNOWN							
			Morphine	SS			
UNKNOWN							

Date:08/12/04ISR Number: 4424382-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0406CAN00143
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Toxicity		Elavil	SS				
UNKNOWN								
	Medication Error		Methotrexate	SS				
UNKNOWN								
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/04ISR Number: 4424383-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Antiphospholipid Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Disability	Back Disorder		Allegra	C				UNKNOWN
Other	Blood Cholesterol Increased							
	Cerebrovascular Accident							
	Cholecystitis							
	Chronic Fatigue Syndrome							
	Colonic Polyp							
	Contusion							
	Diverticulum							
	Dyspepsia							
	Emotional Distress							
	Gastroenteritis Viral							
	Haemorrhoids							
	Hypoaesthesia							
	Menorrhagia							
	Migraine							
	Nervousness							
	Ovarian Cyst							
	Transient Ischaemic Attack							
	Urinary Tract Infection							

Date:08/12/04ISR Number: 4424387-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00235
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain Upper	Professional	[Therapy					
	Carpal Tunnel Syndrome		Unspecified]	C				UNKNOWN
	Chest Pain		Tylenol	C				UNKNOWN
	Conjunctivitis Infective		Darvocet-N	C				UNKNOWN

	Dyspnoea	Emergen C	C
UNKNOWN			
	Ear Discomfort	Astelin	C
UNKNOWN			
	Emotional Distress	Meridia	C
UNKNOWN			
	Fatigue	Valtrex	C
UNKNOWN			
	Gastroenteritis	Zomig	C
UNKNOWN			
	Hypotension	Imitrex	C
UNKNOWN			
	Irritable Bowel Syndrome	Stadol	C
UNKNOWN			
	Migraine	Zyrtec	C
UNKNOWN			
	Nasal Congestion	Allegra	C
UNKNOWN			
	Nasal Sinus Drainage	Claritin	C
UNKNOWN			
	Nausea	Anaprox	C
UNKNOWN			
	Otitis Media		
	Pharyngitis		
	Pharyngolaryngeal Pain		
	Postnasal Drip		
	Proctitis Herpes		
	Productive Cough		
	Rhinitis Allergic		
	Sinusitis		
	Vomiting		

Date:08/12/04ISR Number: 4424829-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA01895
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Infarction	Professional	Vicoprofen	C		
UNKNOWN						
	Aortic Atherosclerosis					
	Arthralgia					
	Bronchitis					
	Bursitis					
	Cardiomegaly					
	Coronary Artery					
	Atherosclerosis					
	Epstein-Barr Virus					
	Infection					
	Feeling Abnormal					
	Hypertension					
	Neck Pain					
	Onychomycosis					
	Osteoarthritis					
	Pharyngitis					
	Pneumonia					
	Pneumonitis					
	Pulmonary Calcification					
	Rhinitis Allergic					
	Sciatica					
	Sinusitis					
	Tendonitis					
	Vomiting					

Date:08/12/04ISR Number: 4424830-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02523
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Coronary Artery Stenosis		Toprol Xl Tablets	C		
UNKNOWN						
	Depression					
	Fear					
	Myocardial Infarction					

Date:08/12/04ISR Number: 4424836-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02049
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 26 DAY	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Azotaemia	Professional	Glucophage	SS				
UNKNOWN	Bursitis		Glucophage	SS				
UNKNOWN	Cerebrovascular Accident		[Therapy Unspecified]	C				
UNKNOWN	Fall		Aspirin	C				
UNKNOWN	Head Injury		Aspirin	C				
UNKNOWN	Hypoglycaemia		Coenzyme Q10	C				
UNKNOWN	Mental Status Changes		Zantac	C				
UNKNOWN			Actos	C				
UNKNOWN			Lipitor	C				
UNKNOWN			Persantine	C				
UNKNOWN			Amaryl	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/04ISR Number: 4424838-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
Disability	Cardiac Failure		Coumadin	C				UNKNOWN
Other	Congestive		Coumadin	C				UNKNOWN
	Cardiac Valve Disease		Tylenol	C				UNKNOWN
	Carotid Artery Disease		Aspirin	C				UNKNOWN
	Carotid Artery Stenosis		Aspirin	C				UNKNOWN
	Deep Vein Thrombosis		Atenolol	C				UNKNOWN
	Emotional Distress		Indocin					
	Gout		(Indomethacin)	C				UNKNOWN
	Ischaemic Cardiomyopathy		Isosorbide	C				UNKNOWN
	Myocardial Infarction		Isosorbide	C				UNKNOWN
	Neck Pain		Nitroglycerin	C				UNKNOWN
	Platelet Count Decreased		Nitroglycerin	C				UNKNOWN
	Renal Failure Chronic							
	Sinusitis							
	Sleep Apnoea Syndrome							

Date:08/12/04ISR Number: 4424842-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0406DEU00064
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Life-Threatening	Gammopathy	Professional	Digitoxin	C		ORAL		

	Hepatic Failure		Enoxaparin Sodium	C			
SUBCUTANEOUS		7 DAY					
	Renal Failure		Furosemide	C			ORAL
			Thioctic Acid	C			
INTRAVENOUS							
			Torsemide	C			ORAL
			Spironolactone	C			
UNKNOWN		1 DAY					
			Insulin Human	C			
SUBCUTANEOUS							
			Ramipril	C			ORAL

Date:08/12/04ISR Number: 4424843-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY	
			Aspirin	C			UNKNOWN	
			Statin (Unspecified)	C			UNKNOWN	

Date:08/12/04ISR Number: 4424849-4Report Type:Expedited (15-DaCompany Report #IE-MERCK-0408GBR00075
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cryptogenic Organizing Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Alendronate Sodium	C		ORAL		
			Budesonide	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Citalopram	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	
			Tramadol					

Hydrochloride	C	UNKNOWN
Tinzaparin Sodium	C	UNKNOWN
Fentanyl	C	TOPICAL
Furosemide	C	UNKNOWN
Iron (Unspecified)	C	UNKNOWN
Pramipexole	C	UNKNOWN
Prednisolone	C	UNKNOWN

Date:08/12/04ISR Number: 4424850-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00009
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Hospitalization - Initial or Prolonged	Tachyarrhythmia	Professional						

Date:08/12/04ISR Number: 4424851-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Systolic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	156 DAY	
Initial or Prolonged	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	9 MON	
Disability	Cerebral Infarction		[Therapy Unspecified]	C	UNKNOWN			
Other	Cerebrovascular Stenosis		Tylenol	C	UNKNOWN		585 DAY	
	Gliosis		Ortho-Novum	C	UNKNOWN		585 DAY	
	Headache		Necon	C	UNKNOWN			
	Hydrocephalus							

	Hypercholesterolaemia	Zoloft	C
UNKNOWN			
	Hypersensitivity	Advil	C
UNKNOWN	585 DAY		
	Low Density Lipoprotein	Motrin	C
UNKNOWN	585 DAY		
	Increased	Methylphenidate	C
UNKNOWN			
	Nausea	Naproxen	C
UNKNOWN	585 DAY		
	Personality Disorder	Aleve	C
UNKNOWN	585 DAY		
	Sinusitis		
	Temporomandibular Joint Syndrome		
	Transient Ischaemic Attack		

Date:08/12/04ISR Number: 4424853-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00119
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemoglobin Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/04ISR Number: 4424854-8Report Type:Expedited (15-DaCompany Report #RO-MERCK-0408HUN00004
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/04ISR Number: 4424855-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Angina Unstable	Professional	Allopurinol	C				UNKNOWN
Other	Atelectasis		Aspirin	C				UNKNOWN
	Azotaemia		Aricept	C				UNKNOWN
	Bronchitis		Glucotrol	C				UNKNOWN
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Carotid Artery Stenosis							
	Central Line Infection							
	Cerebral Artery Occlusion							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Chest Pain							
	Cholelithiasis							
	Chronic Obstructive							
	Airways Disease							
	Exacerbated							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery							
	Restenosis							
	Decreased Appetite							
	Device Failure							
	Diarrhoea							
	Dressler'S Syndrome							
	Electrocardiogram St							
	Segment Elevation							
	Faecal Occult Blood							
	Positive							
	Faeces Discoloured							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Hyperbilirubinaemia							
	Hyperlipidaemia							
	Hypertension							

Hypotonia
Lung Neoplasm
Mitral Valve Incompetence
Myocardial Infarction
Peptic Ulcer
Peripheral Vascular
Disorder
Respiratory Failure
Skin Candida
Staphylococcal Infection
Subclavian Artery
Stenosis
Ventricular Hypertrophy

Date:08/12/04ISR Number: 4424880-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00076
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		169 DAY
			Aspirin	C		ORAL		

			Carbomer	C		
OPHTHALMIC						
			Zopiclone	C		ORAL
			Senna	C		ORAL
			Dexamethasone And Neomycin Sulfate And Polymyxin B Sulfate	C		
OPHTHALMIC						

Date:08/12/04ISR Number: 4424882-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00364
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening						
Hospitalization - Initial or Prolonged						

Date:08/12/04ISR Number: 4424884-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00591
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
	Weight Increased		Lisinopril	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						

Date:08/12/04ISR Number: 4424916-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00053
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL
48 DAY						
	Oropharyngeal Swelling		Amiloride Hydrochloride And			

			Hydrochlorothiazide	C		ORAL
			Atropine Sulfate And Diphenoxylate Hydrochloride	C		ORAL
			Estrone	C		ORAL

Date:08/12/04ISR Number: 4427423-9Report Type:Expedited (15-DaCompany Report #CIP04001155
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive	Health Professional	Asacol (Mesalamine) Tablet, 400mg	PS		ORAL
ORAL						
	Chest Pain		Vioxx (Rofecoxib)	SS		ORAL
25 MG AS						
	Pericardial Effusion					
NEEDED ORAL						
	Pericarditis		Advil (Ibuprofen)	SS		ORAL
AS NEEDED						
	Red Blood Cell					
ORAL						
	Sedimentation Rate Increased		Multivitamin (Vitamins Nos)	SS		
4 TABLET 3						
DAILY						
			Benadryl "Pfizer Warner Lambert"	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/04ISR Number: 4425213-4Report Type:Expedited (15-DaCompany Report #FR-JNJFOC-20040800663
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Remicade	PS		INTRAVENOUS		
Initial or Prolonged	Hallucination, Visual		Remicade	SS		INTRAVENOUS		
	Paranoia		Vioxx	SS				

Date:08/13/04ISR Number: 4425231-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Abnormal Behaviour
Disability	Abnormal Dreams
Other	Activated Partial Thromboplastin Time Prolonged
	Anxiety
	Atrial Hypertrophy
	Atrial Septal Defect
	Back Pain
	Bipolar Disorder
	Bradycardia
	Breast Pain
	Cardiac Aneurysm
	Cardiac Disorder
	Cardiac Failure Congestive
	Cellulitis
	Cerebral Atrophy
	Cerebral Infarction
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Restenosis
	Cough
	Crying
	Depression
	Diverticulum
	Drug Dependence
	Dyspepsia

Dyspnoea
Emotional Distress
Flashback
Haemorrhoids
Hallucination, Auditory
Hallucination, Visual
Headache
Heart Rate Increased
Hypertension
Hypertrophy Breast
Injury
Insomnia
Intermittent Claudication
Intracranial Aneurysm
Irritability
Lacunar Infarction
Major Depression
Micturition Urgency
Myocardial Infarction

		Nervousness					
		Obsessive-Compulsive Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Paranoia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pollakiuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Portal Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Post-Traumatic Stress		Vicodin Tablets	C		
UNKNOWN							
		Disorder		Norvasc	C		
UNKNOWN							
		Pulmonary Hypertension		Aspirin	C		
UNKNOWN		668 DAY					
		Restlessness		Zithromax	C		ORAL
4	DAY						
		Road Traffic Accident		Cogentin	C		ORAL
		Self-Injurious Ideation		Tegretol-Xr	C		ORAL
		Spinal Osteoarthritis		Monopril	C		ORAL
		Stress		Neurontin	C		
UNKNOWN							
		Suicidal Ideation		Lithium Carbonate	C		ORAL
		Supraventricular		Lithium Carbonate	C		ORAL
		Extrasystoles		Claritin-D	C		
UNKNOWN							
		Thromboembolic Stroke		Ativan	C		
UNKNOWN							
		Transient Ischaemic		Ativan	C		
UNKNOWN							
		Attack		Zyprexa	C		ORAL
		Tricuspid Valve		Zyprexa	C		ORAL
		Incompetence		Zyprexa	C		ORAL
		Upper Respiratory Tract		Seroquel	C		
UNKNOWN							
		Infection		Navane	C		ORAL
		Varices Oesophageal		Coumadin	C		
UNKNOWN							
		Ventricular Extrasystoles		Coumadin	C		
UNKNOWN							
		Ventricular Hypertrophy		Coumadin	C		
UNKNOWN		96 DAY					
		Weight Increased					

Date:08/13/04ISR Number: 4425243-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Prerenal Failure
	Adverse Event
	Asthenia
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cataract Nuclear
	Chest Pain
	Depression
	Diabetes Mellitus
	Dizziness
	Emotional Distress
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Gout
	Haemorrhage
	Headache
	Hypertension
	Hypovolaemia
	Local Swelling
	Nausea

		Oedema Peripheral Pyelonephritis Sepsis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Sleep Disorder Soft Tissue Infection		[Therapy Unspecified]	C		
UNKNOWN							
		Urinary Tract Infection		[Therapy Unspecified]	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Nifedipine	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:08/13/04ISR Number: 4425254-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain Lower Anxiety		Vioxx Prevacid	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
Other		Arthralgia Back Pain Blood Cholesterol Increased Chest Pain Closed Head Injury Constipation Convulsion Costochondritis Depression Dyspepsia Dysuria Enterocolitis Haemorrhagic Erectile Dysfunction Eye Disorder Fall Gastrooesophageal Reflux Disease		Zocor	C		ORAL

Haemorrhage
Head Injury
Hypertension
Kidney Infection
Migraine
Oedema Peripheral
Oesophageal Disorder
Palpitations
Renal Disorder
Ulcer

Date:08/13/04ISR Number: 4425260-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Contusion
	Coronary Artery Disease
	Dizziness
	Emotional Distress
	Fall

		Fatigue					
		Therapeutic Response Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							
				Altace	C		
UNKNOWN							

Date:08/13/04ISR Number: 4425261-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0402DEU00057
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Asthenia		Bisoprolol Fumarate	SS		ORAL
Initial or Prolonged	Cardiac Failure		Diazepam	SS		ORAL
6 DAY						
	Confusional State		Paroxetine	SS		ORAL
10 DAY						
	Drug Interaction		Glyburide	SS		ORAL
	Somnolence		Allopurinol	C		ORAL
	Urinary Tract Infection		Aspirin	C		ORAL
			Metformin Hydrochloride	C		ORAL

Date:08/13/04ISR Number: 4425262-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00205
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Ultracet	C		ORAL
Disability			Zanaflex	C		ORAL
Other			Effexor Xr	C		ORAL

				Effexor Xr	C		ORAL
				Norflex	C		ORAL
				Protonix	C		ORAL

Date:08/13/04ISR Number: 4425264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02043
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Hydralazine	SS		ORAL		
	Oedema Peripheral		Commit	SS				
	Pulmonary Oedema		Albuterol Sulfate	C				
UNKNOWN								
	Weight Increased		Advair	C				
UNKNOWN								
			Verapamil	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								

Date:08/13/04ISR Number: 4425266-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00481
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dialysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/04ISR Number: 4427967-XReport Type:Expedited (15-DaCompany Report #S04-USA-04729-01
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Tongue Ulceration	Consumer	Lexapro (Escitalopram)	PS		ORAL	20 MG QD PO	
			Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
			Zoloft (Sertraline Hydrochloride)	SS		ORAL	150 MG QD PO	
			Topamax (Topiramate)	SS			25 MG QD	
			Vioxx (Rofecoxib)	SS			25 MG QD	
			Zocor	C				
			Nexium (Esomeprazole)	C				
			Mirapex	C				

Date:08/13/04ISR Number: 4428094-8Report Type:Expedited (15-DaCompany Report #2004053486
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia Pain In Extremity	Consumer	Neurontin (Gabapentin)	PS				
			Celecoxib (Celecoxib)	SS				
			Morphine Sulfate (Morphine Sulfate)	SS				
			Carisoprodol (Carisoprodol)	SS				
			Naproxen (Naproxen)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Dextroprppoxyphene (Dextroprppoxyphene0	C				

Date:08/13/04ISR Number: 4429525-XReport Type:Expedited (15-DaCompany Report #LTI2004A00188
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Erythema Nausea Pco2 Decreased Rash Pustular Renal Failure Acute Urticaria Generalised	Health Professional Other	Ogast (Lansoprazole) (1 Dosage Forms, Capsules)	PS		ORAL	1 DF (1 DF, 1 IN 2) ORAL	
			Baume Aroma (Baume Aroma) (Cream)	SS		CUTANEOUS	CUTANEOUS	
			Vioxx (Rofecoxib) (1 Dosage Forms, Tablets)	SS		ORAL	25 MG (25 MG, 1 IN 1 D) ORAL	
			Dialgirex (Aporex) (1 Dosage Forms, Capsules)	SS		ORAL	ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/04ISR Number: 4426454-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0211FRA00072
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Goitre		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hyperthyroidism		Interferon Beta-1a	SS		
SUBCUTANEOUS	509 DAY					
			Acenocoumarol	C		ORAL
			Calcium Carbonate	C		ORAL
			Etidronate Disodium	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Prazepam	C		ORAL
			Omeprazole	C		ORAL
			Fenofibrate	C		ORAL
			Hydrocortisone	C		ORAL

Date:08/15/04ISR Number: 4426455-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Aortic Dilatation
	Apraxia
	Areflexia
	Back Pain
	Blindness Unilateral
	Blood Pressure Increased
	Bone Pain
	Cellulitis
	Cerebral Atherosclerosis
	Cerebral Haemorrhage
	Chest Pain
	Cognitive Disorder
	Confusional State
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Dyscalculia

Dyspepsia
Dysphagia
Dyspnoea
Ear Pain
Electrocardiogram
Abnormal
Electrocardiogram Q Waves
Electrocardiogram St
Segment Depression
Electrocardiogram St
Segment Elevation
Emotional Distress
Eructation
Fall
Fatigue
Generalised Anxiety
Disorder
Haemorrhage Intracranial

		Haemorrhagic Cerebral Infarction					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
97	DAY						
		Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Hypertension		[Therapy			
		Hypoaesthesia		Unspecified]	C		
UNKNOWN							
		Hyporeflexia		Doxepin			
		Insomnia		Hydrochloride	C		
UNKNOWN							
		Joint Effusion		Zanaflex	C		
UNKNOWN							
		Joint Injury		Ultram	C		
UNKNOWN							
		Joint Sprain		Neurontin	C		
UNKNOWN							
		Learning Disorder		Serzone	C		
UNKNOWN							
		Local Swelling		Oxycodone	C		
UNKNOWN							
		Memory Impairment					
		Meniscus Lesion					
		Mitral Valve Prolapse					
		Nasal Congestion					
		Oesophagitis					
		Osteoarthritis					
		Pain					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Psoriasis					
		Pulmonary Congestion					
		Reading Disorder					
		Retinal Degeneration					
		Retinal Ischaemia					
		Rhinitis					
		Rhinitis Allergic					
		Sleep Apnoea Syndrome					
		Tenderness					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					
		Visual Acuity Reduced					
		Visual Disturbance					

Date:08/15/04ISR Number: 4426456-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Adjustment Disorder
Other	Adjustment Disorder With Depressed Mood
	Affective Disorder
	Alopecia
	Anaemia
	Angina Unstable
	Ankylosing Spondylitis
	Arthralgia
	Back Pain
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Concussion
	Condition Aggravated
	Constipation

		Depression					
		Drug Ineffective					
		Dysphagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysphoria		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Dyspnoea		Microzide	SS		
UNKNOWN							
		Facet Joint Syndrome		Microzide	SS		
UNKNOWN							
		Facial Bones Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Prinzide	SS		ORAL
26	HR						
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
24	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
99	DAY						
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercalcaemia		Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY						
		Hyperkalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
99	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
24	DAY						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Hypothyroidism		Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY						
		Insomnia		Vicodin Es Tablets	C		
UNKNOWN							
		Intervertebral Disc		Analgesic Or			
		Degeneration		Anesthetic			
		Intervertebral Disc		(Unspecified)	C		
PARENTERAL		1	DAY				
		Displacement		Beconase	C		
UNKNOWN							
		Intervertebral Disc		Prevacid	C		
UNKNOWN							
		Protrusion		Claritin	C		
UNKNOWN							
		Jaw Disorder		Effexor	C		
UNKNOWN							
		Limb Injury		Trazodone			
		Muscle Spasms		Hydrochloride	C		
UNKNOWN							
		Myofascial Pain Syndrome		Trazodone			

	Nausea	Hydrochloride	C
UNKNOWN			
	Neck Pain	Imitrex	C
UNKNOWN			
	Nephritis Interstitial	Claritin	C
UNKNOWN			
	Oedema Peripheral	Prevacid	C
UNKNOWN			
	Oesophageal Stenosis	Zestoretic	C
UNKNOWN			
	Osteopenia	Celebrex	C
UNKNOWN			
	Osteoporosis	Valium	C
UNKNOWN			
	Palpitations	Estratest	C
UNKNOWN			
	Peripheral Sensory	Estratest	C
UNKNOWN			
	Neuropathy		
	Polyarthritis		
	Psoriatic Arthropathy		
	Raynaud'S Phenomenon		
	Reflux Oesophagitis		
	Reiter'S Syndrome		
	Renal Failure		
	Sacroiliitis		
	Scoliosis		
	Sleep Disorder		
	Spondyloarthropathy		
	Urinary Tract Pain		
	Weight Increased		

Date:08/15/04ISR Number: 4426457-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0402GBR00197
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Ulcer		Aspirin	SS		ORAL		
Initial or Prolonged	Haematemesis		Aspirin	SS		ORAL		
	Oesophageal Ulcer		Allopurinol	C		ORAL		
			Furosemide	C		ORAL		
			Indoramin	C		ORAL		

			Lisinopril	C		ORAL

Date:08/15/04ISR Number: 4426458-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01315
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Agitation		Persantine	C		
UNKNOWN	Blood Potassium Decreased		Divalproex Sodium	C		
UNKNOWN	Brain Scan Abnormal		Divalproex Sodium	C		
UNKNOWN	Delirium		Docusate Sodium	C		
UNKNOWN	Delusion		Ferrous Sulfate	C		ORAL
UNKNOWN	Depressed Level Of Consciousness		Latanoprost	C		
UNKNOWN	Drug Ineffective		Olanzapine	C		ORAL
UNKNOWN	Fear		Trazodone Hydrochloride	C		
UNKNOWN	Haematocrit Decreased		Trazodone Hydrochloride	C		
UNKNOWN	Haemoglobin Decreased		Olanzapine	C		
UNKNOWN	Hallucinations, Mixed		Olanzapine	C		
UNKNOWN	Impaired Self-Care		Olanzapine	C		
UNKNOWN	Insomnia		Protonix	C		
UNKNOWN	Iron Deficiency Anaemia		Paroxetine	C		
UNKNOWN	Lacunar Infarction		Paroxetine	C		
UNKNOWN	Memory Impairment		Pilocarpine	C		
UNKNOWN	Mental Status Changes					
	Oral Intake Reduced					
	Paranoia					
	Serum Ferritin Increased					
	Treatment Noncompliance					

Date:08/15/04ISR Number: 4426459-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aortic Occlusion		Tylenol	C				
UNKNOWN								
	Blood Disorder							
	Bronchitis							
	Contusion							
	Disability							
	Emotional Distress							
	Gait Spastic							
	Gout							
	Intermittent Claudication							
	Nasopharyngitis							
	Obstruction							
	Peripheral Circulatory Failure							
	Road Traffic Accident							
	Skin Laceration							

Date:08/15/04ISR Number: 4426460-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
		Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
		Cough		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
		Dysthymic Disorder		[Therapy					
		Fall		Unspecified]	C			UNKNOWN	
		Fibromyalgia		Vicodin Tablets	C			UNKNOWN	
		Gravitational Oedema		Elavil	C		ORAL		
		Hypertension		Analgesic Or					
		Increased Tendency To		Anesthetic					
		Bruise		(Unspecified)	C			UNKNOWN	
		Lacunar Infarction		Aspirin	C		ORAL		
		Lower Respiratory Tract		Vitamins					
		Infection		(Unspecified)	C			UNKNOWN	
		Migraine		Vitamin E	C			UNKNOWN	
		Neuralgia		Calcium Carbonate	C			UNKNOWN	
		Oedema Peripheral		Premarin	C			UNKNOWN	
		Osteopenia		Lasix (Furosemide)	C			UNKNOWN	
		Osteoporosis		Neurontin	C			UNKNOWN	
		Pain In Extremity		Oxycontin	C			UNKNOWN	
		Radius Fracture		Paxil	C		ORAL		

	Renal Disorder		Actonel	C			
UNKNOWN							
	Rotator Cuff Syndrome						
	Sinusitis						
	Spinal Osteoarthritis						
	Stress						
	Tendonitis						
	Urinary Tract Infection						

Date:08/15/04ISR Number: 4426461-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00052
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C				
UNKNOWN								
			Aspirin	C		ORAL		
			Haloperidol	C				
UNKNOWN								
			Temazepam	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								
			Paroxetine	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/04ISR Number: 4426462-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Amnesia		Elavil	C			UNKNOWN	
	Cardiac Murmur		Norvasc	C			UNKNOWN	
	Carpal Tunnel Syndrome		Effexor	C			UNKNOWN	
	Chondromalacia		Ultram	C			UNKNOWN	
	Contusion		Hydrocodone Bitartrate	C			UNKNOWN	
	Delirium		Propranolol Hydrochloride	C			UNKNOWN	
	Disability							
	Dyspnoea							
	Electrocardiogram St Segment Abnormal							
	Emotional Distress							
	Essential Hypertension							
	Fatigue							
	Fibromyalgia							
	Gastric Disorder							
	Haemorrhage							
	Headache							
	Hypoaesthesia							
	Keloid Scar							
	Major Depression							
	Meniscus Lesion							
	Migraine Without Aura							
	Monarthritis							
	Nausea							
	Neck Pain							
	Neoplasm Malignant							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Pain In Extremity							
	Palpitations							
	Panic Disorder With Agoraphobia							
	Paraesthesia							
	Peptic Ulcer							

Rotator Cuff Syndrome
Skin Lesion
Swelling
Synovitis
Tenosynovitis
Tension Headache
Transient Ischaemic
Attack
Urine Abnormality
Urine Odour Abnormal
Vomiting

Date:08/15/04ISR Number: 4426463-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00607
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Pulmonary Embolism							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/04ISR Number: 4426464-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/04ISR Number: 4426466-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00446
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Bunion							
	Contusion							
	Gastroenteritis Viral							
	Headache							
	Ingrowing Nail							
	Joint Sprain							
	Pain In Extremity							
	Prescribed Overdose							
	Toe Deformity							
	Vomiting							

Date:08/16/04ISR Number: 4426680-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0407AUS00066
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Acetaminophen	C				
UNKNOWN								
	Cardiac Murmur		Garlic Extract	C				
UNKNOWN								
	Chest Pain		Glucosamine					
	Headache		Hydrochloride	C				
UNKNOWN								
	Oedema		Herbs (Unspecified)	C				
UNKNOWN								
	Oedema Peripheral		Levothyroxine Sodium	C				
UNKNOWN								

	Pericardial Effusion		Phenytoin	C		
UNKNOWN						
			Pravastatin Sodium	C		
UNKNOWN						

Date:08/16/04ISR Number: 4426681-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01938
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Alanine Aminotransferase	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Allopurinol	SS		ORAL
	Aspartate		Aspirin	C		
UNKNOWN						
	Aminotransferase		Vitamins			
	Increased		(Unspecified)	C		
UNKNOWN						
	Blood Alkaline		Neurontin	C		
UNKNOWN						
	Phosphatase Increased					
	Blood Bilirubin Increased					
	Pleurisy					

Date:08/16/04ISR Number: 4426686-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Adrenal Adenoma
	Angina Pectoris

		Arthritis Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Murmur	Professional	Tylenol	C		ORAL
		Cataract		Pravachol	C		
UNKNOWN							
		Cellulitis Chest Pain Chronic Fatigue Syndrome Constipation Cystitis Cystitis Glandularis Dizziness Dyspepsia Dyspnoea Dyspnoea Paroxysmal Nocturnal Ear Infection Electrocardiogram Abnormal Emotional Distress Gastrointestinal Ulcer Gastrooesophageal Reflux Disease Haematuria Headache Hypercholesterolaemia Increased Tendency To Bruise Mitral Valve Incompetence Nausea Osteoporosis Palpitations Parotid Gland Enlargement Peptic Ulcer Rhinitis Allergic Stress Incontinence Thyroid Neoplasm Tooth Abscess Urethral Caruncle Urinary Tract Infection					

Date:08/16/04ISR Number: 4426688-7Report Type:Expedited (15-DaCompany Report #BE-MERCK-0407BEL00036
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		419 DAY
Initial or Prolonged	Hysterectomy		Vioxx	SS	Merck & Co., Inc	ORAL		419 DAY
Other			Fosamax	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Zoledronic Acid	C		INTRAVENOUS DRIP		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/04ISR Number: 4426692-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01980
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	71 DAY	
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	33 DAY	
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	33 DAY	
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL	71 DAY	
	Back Pain		[Therapy Unspecified]	C			UNKNOWN	
	Balance Disorder							
	Blood Pressure Decreased		Elavil	C			UNKNOWN	
	Bronchitis		Atenolol	C			UNKNOWN	
	Bursitis		Trazodone Hydrochloride	C			UNKNOWN	
	Cardiomegaly							
	Chest Pain		Atenolol	C			UNKNOWN	
	Chest Wall Pain		Lonox	C			UNKNOWN	
	Constipation		Dyazide	C			UNKNOWN	
	Coordination Abnormal		Hydrocortisone	C			UNKNOWN	
	Depression		Zestril	C			UNKNOWN	
	Diabetes Mellitus		Paxil	C			UNKNOWN	
	Diabetes Mellitus Non-Insulin-Dependent							
	Diastolic Dysfunction							
	Gastrooesophageal Reflux Disease							
	Haemodialysis							
	Haemorrhage							
	Hypogonadism							
	Injury							
	Insomnia							
	Intervertebral Disc Degeneration							

Metabolic Syndrome
Nephritis
Panic Attack
Pericardial Effusion
Septic Shock
Sinusitis
Tendonitis
Therapeutic Agent
Toxicity
Ventricular Hypertrophy

Date:08/16/04ISR Number: 4426694-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01059
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/16/04ISR Number: 4426695-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00028
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Left Ventricular Failure		Amitriptyline Hydrochloride	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Nifedipine	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/04ISR Number: 4426696-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0408USA00823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Oedema	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Cardiac Disorder		Acetaminophen	C				
	Cardiac Murmur		Garlic Extract	C				
	Chest Pain		Glucosamine Hydrochloride	C				
	Headache		Herbs (Unspecified)	C				
	Oedema		Levothyroxine Sodium	C				
	Oedema Peripheral		Phenytoin	C				
			Pravastatin Sodium	C				

Date:08/16/04ISR Number: 4426697-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0408CAN00012
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Loss Of Consciousness		Prinivil	C				

Date:08/16/04ISR Number: 4426698-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0408CAN00010
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Meningitis Aseptic		Aspirin	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Insulin Human, Isophane	C		SUBCUTANEOUS		

			Insulin Lispro	C		
SUBCUTANEOUS						

Date:08/16/04ISR Number: 4426992-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02003
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anal Fistula	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthritis		Tylenol	C		
UNKNOWN						
Other	Cardiac Failure		Vicodin Tablets	C		
UNKNOWN						
	Congestive		Aspirin	C		ORAL
	Cardio-Respiratory Arrest		Calcium			
	Cerebrovascular Disorder		(Unspecified)	C		
UNKNOWN						
	Coronary Artery Disease		Digoxin	C		ORAL
	Culture Urine Positive		Digoxin	C		ORAL
	Depression		Premarin	C		
UNKNOWN						
	Gallbladder Disorder		Folic Acid	C		
UNKNOWN						
	Headache		Lasix (Furosemide)	C		ORAL
	Hyperkalaemia		Lasix (Furosemide)	C		ORAL
	Hypotension		Lasix (Furosemide)	C		
INTRAVENOUS						
	Insomnia		Lasix (Furosemide)	C		ORAL
	Myocardial Infarction		Insulin, Isophane	C		
SUBCUTANEOUS						
	Nausea		Iron (Unspecified)	C		
UNKNOWN						
	Pneumonia		Isordil	C		ORAL
	Renal Failure Acute		Zestril	C		ORAL
	Sepsis		Mevacor	C		ORAL
	Urinary Tract Infection		Vitamins			
	Uterine Leiomyoma		(Unspecified)	C		
UNKNOWN						
	Vomiting		Vitamin E	C		
UNKNOWN						

Tolinase	C		ORAL
Provera	C		
UNKNOWN			
Provera	C		
UNKNOWN			
Pentasa	C		ORAL
Lopressor	C		
INTRAVENOUS			
Lopressor	C		ORAL
Lopressor	C		
INTRAVENOUS			
Lopressor	C		ORAL
Nitroglycerin	C		
SUBLINGUAL			
Potassium (Unspecified)	C		
UNKNOWN			
Prednisone	C		ORAL
Pyridoxine	C		
UNKNOWN			

Date:08/16/04ISR Number: 4426994-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Activities Of Daily	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Aspirin	C				
UNKNOWN								
	Blood Pressure Increased		Tylenol	C				
UNKNOWN								
	Bunion							
	Cardiac Failure							
	Congestive							
	Constipation							
	Drug Intolerance							
	Fall							
	Gastric Disorder							
	Headache							
	Hypertensive Heart							
	Disease							
	Injury							

Intervertebral Disc
Disorder
Joint Sprain
Limb Discomfort
Muscle Spasms
Myalgia
Myocardial Infarction
Nocturia
Onychomycosis
Osteoarthritis
Pain
Pulmonary Granuloma
Renal Failure
Rotator Cuff Syndrome
Seborrhoeic Keratosis
Sinusitis
Wound Infection

Date:08/16/04ISR Number: 4427004-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cancer Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Cardio-Respiratory Arrest	Professional	Lasix (Furosemide)	C				UNKNOWN
Colonic Polyp		Neurontin	C				UNKNOWN
Depression		Ibuprofen	C				UNKNOWN
Diabetes Mellitus		Pepcid	C		ORAL		
Diverticulum		Zestril	C				UNKNOWN
Dyspnoea Exertional		Lithium Carbonate	C				UNKNOWN
Facial Palsy							
Fall							
Flank Pain							
Fluid Retention							
Haemorrhoids							
Hemiparesis							
Insomnia							
Myocardial Infarction							
Nausea							
Non-Hodgkin'S Lymphoma							
Oedema Peripheral							
Oesophagitis Haemorrhagic							
Pathological Fracture							
Pneumonia Aspiration							
Pulmonary Hypertension							
Rectal Haemorrhage							
Rectal Polyp							
Sepsis							
Septic Shock							
Sinusitis							
Stomatitis							
Ventricular Hypertrophy							

Date:08/16/04ISR Number: 4427005-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Carpal Tunnel Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Distress		Proventil	C		
UNKNOWN						
	Hypokalaemia		Aspirin	C		
UNKNOWN						
	Memory Impairment		Aspirin	C		
UNKNOWN						
	Muscle Spasms		Coreg	C		
UNKNOWN						
	Myocardial Infarction		Foltx	C		
UNKNOWN						
	Pyrexia		Zestril	C		
UNKNOWN						
	Umbilical Hernia		Niaspan	C		
UNKNOWN						
	Ventricular Tachycardia		Pravachol	C		ORAL
141 DAY						
			Pravachol	C		ORAL
			Metamucil	C		
UNKNOWN						

Date:08/16/04ISR Number: 4427007-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02107
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain Upper
Other	Adverse Event

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Angioneurotic Oedema Anxiety Atrioventricular Block Second Degree Blood Creatine Phosphokinase Increased Blood Pressure Increased Cerebrovascular Accident Chest Pain Depression Dizziness Drug Hypersensitivity Dyspnoea Fatigue Hypertension Insomnia Intervertebral Disc Degeneration Lipids Abnormal Menopausal Symptoms Myalgia Nasal Congestion Nausea Neck Pain Osteoarthritis Osteochondrosis Pain Palpitations Paraesthesia Pleurisy Pulmonary Valve Incompetence Respiration Abnormal Restrictive Pulmonary Disease Rhabdomyolysis Spinal Column Stenosis	Health Professional	Vioxx Tylenol Lasix (Furosemide) Lasix (Furosemide) Ginkgo Biloba Extract Coumadin Ginseng Naproxen Klor-Con Slow-K	PS C C C C C C C C C	Merck & Co., Inc	ORAL
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							
UNKNOWN							

Throat Tightness
Treatment Noncompliance
Tricuspid Valve
Incompetence
Vaccination Complication
Vascular Resistance
Systemic
Vomiting

Date:08/16/04ISR Number: 4427008-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02007
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adenomyosis
Other	Anaemia
	Blood Cholesterol Increased
	Cervicitis
	Chest Pain
	Haemorrhagic Ovarian Cyst
	Hyperhidrosis
	Leiomyoma

		Low Density Lipoprotein Increased					
		Metaplasia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
		Nausea	Professional	[Therapy			
		Ovarian Cyst		Unspecified]	C		
UNKNOWN							
		Pain		Claritin	C		
UNKNOWN							
		8	MON				
		Palpitations					
		Pelvic Pain					
		Tachycardia					
		Thrombosis					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Ventricular Tachycardia					

Date:08/16/04ISR Number: 4427026-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02142
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
	Disease		Allopurinol	C		
UNKNOWN						
	Hypercholesterolaemia		Keflex	C		
UNKNOWN						
	Myocardial Infarction		Hydrochlorothiazide	C		
UNKNOWN						
	Nausea		Indocin			
	Sinusitis		(Indomethacin)	C		ORAL
	Vomiting		Synthroid	C		
UNKNOWN						

Date:08/16/04ISR Number: 4427029-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Respiratory Failure
	Adrenal Insufficiency
	Anaemia
	Anaemia Of Chronic Disease
	Arteriosclerosis
	Asthenia
	Asthma
	Bacterial Infection
	Blood Erythropoietin Decreased
	Bronchitis Acute
	Candidiasis
	Cellulitis
	Cholecystitis Chronic
	Cholesterosis
	Colitis
	Decubitus Ulcer
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Duodenitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Faecal Incontinence					
		Fungaemia					
		Gastritis					
		Gastrointestinal Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Catapres	C		
UNKNOWN	347 DAY						
		Gastrooesophageal Reflux		Lasix (Furosemide)	C		
UNKNOWN							
		Disease		Micardis	C		
UNKNOWN							
		Glaucoma		Lasix (Furosemide)	C		
UNKNOWN							
		Gynaecomastia		Cozaar	C		
UNKNOWN							
		Haemorrhoids					
		Headache					
		Hepatic Steatosis					
		Hiatus Hernia					
		Hypercoagulation					
		Hyperglycaemia					
		Hypertension					
		Incisional Hernia					
		Inguinal Hernia					
		Injury					
		Malnutrition					
		Metabolic Acidosis					
		Myocardial Infarction					
		Obesity					
		Oesophagitis					
		Optic Neuropathy					
		Otitis Media					
		Pickwickian Syndrome					
		Pneumonia					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Renal Failure					
		Renal Failure Acute					
		Rheumatoid Arthritis					
		Sepsis					
		Syncope Vasovagal					
		Thrombocytopenia					
		Umbilical Hernia					
		Urinary Incontinence					
		Urinary Tract Infection					
		Vertigo					

Date:08/16/04ISR Number: 4427034-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Back Pain
Other	Calculus Urinary
	Cardiac Murmur
	Chest Wall Pain
	Constipation
	Diarrhoea
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Haematuria
	Haemorrhoids
	Headache
	Injury
	Intervertebral Disc

		Protrusion					
		Irritable Bowel Syndrome					
		Musculoskeletal Pain					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain		Analgesic Or			
		Pyelonephritis		Anesthetic			
		Pyrexia		(Unspecified)	C		
UNKNOWN							
		Rectal Haemorrhage		Antimicrobial			
		Sinusitis		(Unspecified)	C		
UNKNOWN							
		Skin Discolouration		Butalbital	C		
UNKNOWN							
		Vision Blurred					
		Vomiting					

Date:08/16/04ISR Number: 4427038-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia	Professional	Lortab	C		
UNKNOWN							
		Arrhythmia		Albuterol	C		
UNKNOWN							
		Asthenia		Proventil	C		
RESPIRATORY							
		Blood Pressure Increased					
(INHALATION)							
		Chest Discomfort		Micardis	C		
UNKNOWN							
		Chest Pain		Micardis Hct	C		
UNKNOWN							
		Chronic Fatigue Syndrome		Sular	C		
UNKNOWN		4 DAY					
		Cyst		Sular	C		ORAL
		Dizziness					
		Dyspnoea					
		Emotional Distress					
		Hyperlipidaemia					
		Hypertension					
		Hypoaesthesia					

Hypokalaemia
Intervertebral Disc
Protrusion
Joint Swelling
Large Intestinal Ulcer
Haemorrhage
Loss Of Consciousness
Meniscus Lesion
Musculoskeletal
Discomfort
Nasopharyngitis
Nausea
Neck Pain
Oedema
Oesophageal Ulcer
Haemorrhage
Osteoarthritis
Pain In Extremity
Paraesthesia
Road Traffic Accident
Spinal Disorder
Spinal Osteoarthritis
Stomach Discomfort
Strabismus
Upper Respiratory Tract
Infection
Vitamin B12 Deficiency

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/04ISR Number: 4427046-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		220 DAY
Initial or Prolonged	Acute Myocardial	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		220 DAY
Disability	Infarction		Propacet	C				UNKNOWN
Other	Angina Pectoris		Wellbutrin	C				UNKNOWN
	Anxiety		Prevacid	C				UNKNOWN
	Back Injury							
	Cardiac Arrest							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Coronary Artery Disease							
	Coronary Artery							
	Restenosis							
	Diplopia							
	Diverticulitis							
	Dizziness							
	Dyspnoea							
	Gastrooesophageal Reflux							
	Disease							
	Haematemesis							
	Haematoma							
	Hyperlipidaemia							
	Hypersensitivity							
	Hypertension							
	Lactose Intolerance							
	Muscle Contractions							
	Involuntary							
	Myalgia							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Postoperative Infection							
	Pulmonary Oedema							
	Retroperitoneal							
	Haemorrhage							
	Stent Occlusion							
	Syncope							

Tendon Rupture
Tendonitis
Tinnitus
Urticaria
Ventricular Fibrillation
Vision Blurred
Visual Acuity Reduced
Wheezing

Date:08/16/04ISR Number: 4427054-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02551
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Back Pain
Other	Blood Glucose Increased
	Cardiac Arrest
	Chest Pain
	Depression
	Fungal Infection
	Hypercholesterolaemia

		Hypertension					
		Injury					
		Low Density Lipoprotein	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
129 DAY							
		Myalgia	Professional	Combivent	C		
RESPIRATORY							
		Myocardial Infarction					
(INHALATION)							
		Tendonitis		Aspirin	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zocor	C		ORAL
				Hytrin	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/16/04ISR Number: 4427057-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00104
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Sinusitis
Other	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Breast Mass
	Bursitis
	Carotid Artery Disease
	Carotid Artery Stenosis
	Cataract
	Coronary Artery Disease
	Deafness Neurosensory
	Dizziness
	Drug Ineffective
	Dyspnoea Exertional
	Epistaxis

Ganglion
Gastrooesophageal Reflux
Disease
Gingival Bleeding
Headache
Hyperglycaemia
Hypertension
Hypoglycaemia
Increased Tendency To
Bruise
Influenza
Ingrowing Nail
Injury
Lymphadenopathy
Muscle Fatigue
Muscle Spasms
Musculoskeletal Stiffness
Myalgia
Nasal Septum Deviation
Nausea
Night Cramps
Nocturia
Oedema
Oedema Peripheral
Palpitations

	Rheumatoid Arthritis						
	Sinus Disorder						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tendon Rupture	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Tendonitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Tinnitus		Aspirin	C			UNKNOWN
	Transient Ischaemic		Aspirin	C			UNKNOWN
	Attack		Lomotil	C			UNKNOWN
	Vertigo Positional		Insulin	C			UNKNOWN
	Weight Increased		Zocor	C		ORAL	
			Zocor	C		ORAL	635 DAY
			Kenalog	C			INTRAMUSCULAR
			Zocor	C		ORAL	
			Zocor	C		ORAL	
			Avandia	C			UNKNOWN
			Synthroid	C			UNKNOWN
			Melatonin	C			UNKNOWN
			Pamelor	C			UNKNOWN
			Prilosec	C			UNKNOWN

Date:08/16/04ISR Number: 4427064-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	
	Myocardial Infarction						
	Renal Injury						

Date:08/16/04ISR Number: 4427065-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Alcoholism
	Balance Disorder
	Complex Partial Seizures
	Constipation
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Decreased
	Emotional Distress
	Fall
	Fatigue
	Gingival Hyperplasia
	Hepatic Enzyme Increased
	Hepatic Steatosis
	Hyperlipidaemia
	Hypernatraemia
	Hypertension
	Hypoacusis
	Injury
	Myocardial Infarction
	Nail Pitting
	Nasal Polyps

		Neck Pain					
		Osteoporosis					
		Periarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Psoriasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Rash	Professional	Ms Contin	SS		
UNKNOWN							
		Sepsis		Aspirin	C		
UNKNOWN							
		Spinal Osteoarthritis		Vitamins			
		Synovitis		(Unspecified)	C		
UNKNOWN							
		Tinnitus		Tegretol	C		
UNKNOWN							
		Vaginal Infection		Depakote	C		
UNKNOWN							
		Weight Increased					
		Wrist Fracture					

Date:08/16/04ISR Number: 4427070-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/16/04ISR Number: 4427072-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00966
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/16/04ISR Number: 4427073-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01068
Age:67 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
		Infarction					
		Coronary Artery Disease					

Dyspepsia
Dyspnoea
Haemorrhage
Loss Of Consciousness
Melaena
Ulcer Haemorrhage

Date:08/16/04ISR Number: 4427075-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Anxiety
Hospitalization - Initial or Prolonged	Aortic Aneurysm
Other	Arthralgia
	Asthma
	Atrial Fibrillation
	Bradycardia
	Bronchitis
	Bronchospasm
	Death
	Disorientation
	Hypotension
	Interstitial Lung Disease
	Labile Hypertension
	Myocardial Infarction

	Neuropathy						
	Spinal Column Stenosis						
	Spinal Compression	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Tracheal Obstruction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Percocet	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Zestril	C			UNKNOWN	

Date:08/16/04ISR Number: 4427077-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/04ISR Number: 4427100-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Bronchitis
	Bursitis
	Cardiac Failure
	Congestive
	Chest Pain
	Cholecystitis
	Cystitis
	Diabetes Mellitus
	Inadequate Control
	Drug Hypersensitivity
	Duodenitis

Dyslipidaemia
Dysstasia
Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Gastritis
Hypertensive Crisis
Hypertrophic
Cardiomyopathy
Injury
Insomnia
Iron Deficiency Anaemia
Irritable Bowel Syndrome
Lactose Intolerance
Macular Degeneration
Malaise
Myalgia
Myocardial Infarction
Pain
Pain In Extremity
Parotitis

		Pharyngolaryngeal Pain					
		Renal Failure Chronic					
		Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Salivary Gland Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Skin Cancer		Cozaar	C		ORAL
		Spinal Osteoarthritis		Diovan	C		
UNKNOWN							
		Urinary Incontinence		Methotrexate	C		
UNKNOWN							
		Urinary Tract Infection		Prednisone	C		
UNKNOWN							
		Ventricular Dysfunction					

Date:08/16/04ISR Number: 4427845-6Report Type:Expedited (15-DaCompany Report #2004039285
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Potassium Decreased	Consumer	Norvasc (Amlodipine)	PS		ORAL
(1 IN 1 D),							
		Blood Pressure	Health				
ORAL							
		Inadequately Controlled	Professional	Rofecoxib			
		Drug Interaction		(Rofecoxib)	SS		ORAL
25 MG (25 MG,							
		Erythema					
1 IN 1 D),							
		Heart Rate Decreased					
ORAL							
		Oedema		Atenolol (Atenolol)	SS		ORAL
ORAL							
		Rash		Hydrochlorothiazide (Hydrochlorothiazide)	C		

Date:08/16/04ISR Number: 4429695-3Report Type:Expedited (15-DaCompany Report #2004053291
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia	Foreign	Lipitor					
	Arthralgia	Health	(Atorvastatin)	PS		ORAL	20 MG (20 MG,	
	Ascites	Professional					1 IN 1 D),	
	Coagulopathy						ORAL	
	Cognitive Disorder		Rofecoxib					
	Hepatic Failure		(Rofecoxib)	SS			25 MG (25 MG,	
	Hepatitis						1 IN 1 D)	
	Muscle Atrophy		Ibuprofen					
	Renal Failure		(Ibuprofen)	C				
	Sleep Disorder		Paracetamol					
	Varices Oesophageal		(Paracetamol)	C				

Date:08/16/04ISR Number: 4429742-9Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia	Foreign	Methotrexate					
Hospitalization -	Balance Disorder	Health	(Methotrexate,					
Initial or Prolonged	Dizziness	Professional	Unspec)	PS		ORAL	5MG 2 X PER	
Disability	Drug Interaction	Distributor					1 DAY, ORAL	
	Epistaxis	Other	Rofecoxib					
	Feeling Abnormal		(Rofecoxib)	SS		ORAL	12.5 MG 1 X	
	Loss Of Consciousness						PER 1 DAY,	
	Therapeutic Agent						ORAL	
	Toxicity		Folic Acid (Folic Acid)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427215-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427506-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01051542
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Other	Emotional Distress		Ibuprofen	C				UNKNOWN
	Hyperhidrosis							
	Hypersensitivity							
	Muscular Weakness							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							

Date:08/17/04ISR Number: 4427513-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Disability	Adnexa Uteri Mass
Other	Anxiety
	Azotaemia
	Blepharitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cellulitis
	Cervicitis
	Cough
	Cystitis
	Diarrhoea
	Emotional Distress

Endometrial Hyperplasia
Epistaxis
Fallopian Tube Cyst
Fistula
Fluid Retention
Hypertension
Infection
Irritable Bowel Syndrome
Lower Extremity Mass
Meniscus Lesion
Mobility Decreased
Mood Swings
Myocardial Infarction
Nervousness
Neuropathic Pain
Non-Cardiac Chest Pain
Osteoarthritis
Ovarian Fibrosis
Pain In Extremity
Palpitations
Peau D'Orange
Pharyngolaryngeal Pain

		Pickwickian Syndrome					
		Pneumonia					
		Post Procedural	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Oedema	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Retching		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
401	DAY						
		Weight Increased		Ultram	C		
UNKNOWN							
				Ventolin (Albuterol Sulfate)	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Vasotec	C		ORAL
				Cenestin	C		
UNKNOWN							
				Lodine Xl	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427517-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02027
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL
	Blindness Unilateral		Premarin	C		
UNKNOWN						

	Cerebrovascular Accident	Motrin	C
UNKNOWN			
	Emotional Distress	Progesterone	C
UNKNOWN			
	Eye Pain		
	Headache		
	Hypoaesthesia		
	Injury		
	Medication Error		
	Optic Atrophy		
	Optic Disc Disorder		
	Optic Ischaemic		
	Neuropathy		
	Optic Neuritis		
	Osteoarthritis		
	Spinal Osteoarthritis		
	Spondylitis		
	Urinary Tract Infection		
	Vision Blurred		
	Visual Disturbance		

Date:08/17/04ISR Number: 4427520-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01982
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427521-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 6 MON	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 6 MON	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Atrial Fibrillation 1523 DAY		Ma Huang Extract	C		
Other UNKNOWN	Bronchitis		Ambien	C		
	Coagulation Factor Viii Level Increased					
	Depression					
	Emotional Distress					
	Fatigue					
	Headache					
	Influenza					
	Insomnia					
	International Normalised Ratio Increased					
	Myocardial Infarction					
	Pain					
	Protein C Increased					
	Pulmonary Embolism					
	Pulmonary Hypertension					
	Renal Cyst					
	Suicidal Ideation					
	Upper Respiratory Tract Infection					

Date:08/17/04ISR Number: 4427524-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104508
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Accidental Overdose	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Arthralgia		Zocor	C		
	Asthenia					
	Back Injury					
	Back Pain					

Closed Head Injury
Concussion
Constipation
Depression
Emotional Distress
Facial Bones Fracture
Head Injury
Headache
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Laceration
Muscle Atrophy
Nasal Congestion
Nasal Septum Deviation
Neuropathy Peripheral
Nodule
Nose Deformity
Obesity
Pain
Sleep Apnoea Syndrome
Somnolence

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427525-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01072444
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Hydrocodin	SS				
UNKNOWN								
	Disturbance In Attention							
	Fatigue							
	Headache							
	Hypertension							
	Insomnia							
	Intervertebral Disc							
	Protrusion							
	Low Density Lipoprotein							
	Increased							
	Musculoskeletal Stiffness							
	Neck Pain							
	Paraesthesia							
	Thinking Abnormal							

Date:08/17/04ISR Number: 4427526-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Benign Prostatic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		[Therapy					
	Cardiac Failure		Unspecified]	C				
UNKNOWN								
	Congestive		Coumadin	C		ORAL		
	Cellulitis		Vicodin Es Tablets	C				
UNKNOWN								
	Chronic Obstructive		Restoril	C				
UNKNOWN								
	Pulmonary Disease		Zestril	C				
UNKNOWN								
	Confusion Postoperative							
	Constipation							
	Cor Pulmonale							

Dilatation Atrial
Dilatation Ventricular
Duodenal Ulcer
Haemorrhage
Duodenitis
Gastric Ulcer
Myocardial Infarction
Oesophagitis
Onychomycosis
Osteoarthritis
Pericardial Effusion
Pleural Effusion
Rash
Restrictive Pulmonary
Disease
Rib Fracture
Vitreous Floaters

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427528-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01989
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/17/04ISR Number: 4427529-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01993
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/17/04ISR Number: 4427533-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02055
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	33	DAY
Initial or Prolonged	Angina Unstable	Professional	Ascorbic Acid	C			UNKNOWN	
Other	Aortic Valve Incompetence		Hydrochlorothiazide And Triamterene	C			UNKNOWN	
	Atrial Fibrillation							
	Cerebrovascular Accident		Acyclovir	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Vitamin B Complex	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
	Emotional Distress		Vitamin D (Unspecified)	C			UNKNOWN	
	Headache							
	Heart Rate Increased		Vitamin A	C			UNKNOWN	
	Heart Rate Irregular		Adalat	C			UNKNOWN	
	Hypercholesterolaemia		Phenazopyridine					

	Hypertension		Hydrochloride	C			
UNKNOWN							
	Hypertensive Crisis						
	Lacunar Infarction						
	Mitral Valve Incompetence						
	Transient Ischaemic						
	Attack						
	Tricuspid Valve						
	Incompetence						

Date:08/17/04ISR Number: 4427535-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02052
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol	Professional	Lotrel	C		ORAL		
	Increased		Amoxil	C				
UNKNOWN								
	Carotid Artery Stenosis		Wellbutrin	C				
UNKNOWN								
	Carpal Tunnel Syndrome		Wellbutrin	C				
UNKNOWN							5	DAY
	Cerebral Infarction		Celebrex	C				
UNKNOWN								
	Dizziness		Klonopin	C				
UNKNOWN								
	Hypertension		Clonidine	C		ORAL		
249 DAY								
	Intracranial Aneurysm		Clonidine	C		ORAL		
	Peptic Ulcer		Catapres Tts	C				
UNKNOWN								
			Labetalol Hydrochloride	C		ORAL		
			Labetalol Hydrochloride	C		ORAL		
			Prevacid	C				
UNKNOWN								
			Claritin	C				
UNKNOWN								

			Naprelan	C		
UNKNOWN						
			Paxil	C		ORAL
			Dilantin	C		ORAL
			Ranitidine	C		ORAL
			Zoloft	C		ORAL

Date:08/17/04ISR Number: 4427536-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00352
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 MON	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthropathy	Professional	Premarin	C		
UNKNOWN						
Other	Atrial Fibrillation		Estratab	C		
UNKNOWN						
	Cardiac Aneurysm		Menest	C		
UNKNOWN						
	Cerebrovascular Accident		Armour Thyroid			
	Corneal Deposits		Tablets	C		
UNKNOWN						
	Haematuria		Trazodone			
	Haemorrhage		Hydrochloride	C		
UNKNOWN						
	Hypertension		Garlic Extract	C		
UNKNOWN						
	Hypertensive Crisis		Synthroid	C		
UNKNOWN						
	Jaw Disorder		Methotrexate	C		
UNKNOWN						
	Musculoskeletal Disorder					
	Oedema Peripheral					
	Pain In Extremity					
	Paraesthesia					
	Renal Cyst					
	Transient Ischaemic Attack					

Date:08/17/04ISR Number: 4427537-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02053
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Bronchitis	Professional						
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Epididymitis							
	Foot Fracture							
	Foreign Body Trauma							
	Heart Rate Increased							
	Hypersensitivity							
	Injury							
	Myocardial Infarction							
	Occupational Exposure To Toxic Agent							
	Rash							
	Tinea Cruris							
	Viral Rash							

Date:08/17/04ISR Number: 4427538-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anuria
	Chest Pain
	Dizziness

	Emotional Distress						
	Hypertension						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prostatitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rheumatoid Arthritis		Coumadin	C				
UNKNOWN								
	Thrombosis							

Date:08/17/04ISR Number: 4427539-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02069
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Congestive		[Therapy					
	Cholelithiasis		Unspecified]	C				
UNKNOWN								
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	Injury							
	Myocardial Infarction							
	Renal Impairment							
	Urinary Tract Infection							

Date:08/17/04ISR Number: 4427541-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Clostridium Colitis		Tylenol	C				
UNKNOWN								
	Decreased Appetite		Ascorbic Acid	C				
UNKNOWN								

	Dizziness	Aspirin	C
UNKNOWN			
	Drug Ineffective	Atenolol	C
UNKNOWN			
	Dyspepsia	Zocor	C
UNKNOWN			
	Feeling Jittery	Vitamin E	C
UNKNOWN			
	Gout	Coenzyme Q10	C
UNKNOWN			
	Insomnia	Lotensin	C
UNKNOWN			
	Intervertebral Disc	Colchicine	C
UNKNOWN			
	Degeneration	Glucosamine	C
UNKNOWN			
	Mood Altered	Aleve	C
UNKNOWN			
	Osteoarthritis	Nonsteroidal	
	Pain	Anti-Inflammatory	
	Scoliosis	Drug (Unspecified)	C
UNKNOWN			
	Spondylolisthesis	Omega-3	C
UNKNOWN			
	Acquired	Zantac	C
UNKNOWN			

Date:08/17/04ISR Number: 4427544-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Other	Acute Myocardial Infarction
	Anaemia
	Aortic Valve Stenosis
	Arthralgia

		Asthenia Carotid Artery Disease Cataract Cerebral Infarction Cerebrovascular Accident Confusional State Coronary Artery Disease Dementia Difficulty In Walking Dizziness Drug Hypersensitivity Enzyme Abnormality Eye Disorder Fall Insomnia International Normalised Ratio Decreased Joint Swelling Laceration Lethargy Mental Status Changes Myocardial Ischaemia Nuclear Magnetic Resonance Imaging Brain Abnormal Pain In Extremity Renal Cyst Seasonal Allergy Urinary Tract Infection	Report Source Health Professional	Product Vioxx	Role PS	Manufacturer Merck & Co., Inc	Route ORAL
Dose	Duration						

Date:08/17/04ISR Number: 4427545-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02086
Age:91 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Balance Disorder
	Cardiac Failure
Disability	Cerebral Atherosclerosis
Other	Chronic Obstructive Pulmonary Disease
	Constipation
	Death
	Decubitus Ulcer

Depression
Dry Skin
Dyspnoea
Fall
Fracture Displacement
Gastrooesophageal Reflux
Disease
Haematochezia
Haematoma
Haemorrhage
Hyperkeratosis
Hypoacusis
Ilium Fracture
Inflammation
Muscle Spasms
Myocardial Infarction

		Nausea					
		Pain					
		Pelvic Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL
		Infection		Valium	C		
UNKNOWN							
		Senile Dementia		Vasotec	C		ORAL
		Spinal Compression		Vasotec	C		ORAL
		Fracture		Ferrous Sulfate	C		
UNKNOWN							
		Syncope		Timoptic	C		
OPHTHALMIC							
		Tinea Pedis		Ultram	C		
UNKNOWN							
		Vulval Erythema		Miacalcin	C		
UNKNOWN							
		Vulval Oedema		Hydrodiuril	C		ORAL
		Weight Decreased		Morphine	C		
UNKNOWN							
				Deltasone	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427550-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02094
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY							
Other		Arthropathy		Aspirin	C		
UNKNOWN							
		Cardiac Murmur		Cosopt	C		
UNKNOWN							
		Feeling Cold		Xalatan	C		
UNKNOWN							
		Gastric Haemorrhage		Synthroid	C		
UNKNOWN							
		Haemorrhage		Cozaar	C		
UNKNOWN							
		Headache		Naprosyn	C		
UNKNOWN							
		Hot Flush		Nitro-Dur	C		
UNKNOWN							

	Hypertension		Prilosec	C		
UNKNOWN						
	Myocardial Infarction					

Date:08/17/04ISR Number: 4427553-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02122
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chlamydial Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Depression		Acetaminophen	C		
UNKNOWN						
Other	Diarrhoea		Vicodin Tablets	C		
UNKNOWN						
	Musculoskeletal Stiffness					
	Pain					
	Scrotal Pain					
	Sleep Disorder					
	Suicidal Ideation					
	Syncope					
	Tachycardia					

Date:08/17/04ISR Number: 4427555-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02146
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Adverse Event
	Arrhythmia
	Arthropathy
	Atrial Fibrillation
	Diverticulitis
	Gastrointestinal Disorder
	Heart Rate Irregular

Hypertension
Muscle Spasms
Myalgia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Prostate Cancer

Date:08/17/04ISR Number: 4427557-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Aphasia
Other	Asthenia
	Balance Disorder
	Blood Cholesterol Increased
	Blood Testosterone Decreased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Confusional State
	Coordination Abnormal
	Delusion
	Difficulty In Walking
	Disturbance In Attention
	Dizziness
	Ear Pain
	Encephalitis Viral
	Facial Pain
	Fall
	Gait Disturbance
	Headache
	Hemiparesis
	Hypertension
	Hypoaesthesia
	Hypoaesthesia Oral
	Hyponatraemia
	Joint Sprain
	Labyrinthitis
	Mental Disorder
	Mental Disorder Due To A General Medical Condition
	Migraine

Muscle Spasms
Muscular Weakness
Neuralgia
Nuclear Magnetic
Resonance Imaging Brain
Abnormal
Otitis Media
Paraesthesia
Photophobia
Polyneuropathy
Respiratory Rate
Increased
Sensory Disturbance
Temporomandibular Joint
Syndrome
Tinnitus
Transient Ischaemic

		Attack Tri-Iodothyronine Free Increased Vertigo	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Ranitidine	C		
UNKNOWN							
				Temazepam	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Effexor Xr	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Amoxicillin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Benadryl	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Hypericin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Claritin	C	UNKNOWN
Ativan	C	UNKNOWN
Meclizine	C	UNKNOWN
Skelaxin	C	UNKNOWN
Univasc	C	UNKNOWN
Naproxen	C	UNKNOWN

Date:08/17/04ISR Number: 4427561-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aura
Other	Blood Cholesterol Increased
	Chest Discomfort
	Convulsion
	Cough
	Dyspnoea
	Emotional Distress
	Encephalomalacia
	Excoriation
	Feeling Abnormal
	Grand Mal Convulsion
	Headache
	Hypertension
	Intervertebral Disc Displacement
	Lumbar Vertebral Fracture
	Nasal Septum Deviation
	Nasal Turbinate Hypertrophy
	Nose Deformity
	Otitis Media
	Road Traffic Accident

Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	138 DAY	
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	138 DAY	
	Dilantin	C			UNKNOWN	
	Zoloft	C			UNKNOWN	

Date:08/17/04ISR Number: 4427563-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Disability	Anaemia
Other	Angiopathy
	Anxiety
	Arthralgia
	Arthritis Bacterial
	Arthropathy
	Asthenia
	Back Pain
	Blood Bilirubin Increased
	Blood Urea Increased
	Bone Lesion
	Bone Neoplasm
	Cardiac Murmur
	Cerebrovascular Accident
	Chest Pain
	Cholesterol Granuloma
	Chronic Fatigue Syndrome
	Depression
	Drug Dependence
	Dyspnoea
	Erythema
	Fatigue
	Haemolysis
	Haemorrhage
	Heart Rate Irregular
	Hip Arthroplasty
	Hyperlipidaemia

Hypoacusis
Hypoaesthesia
Injury
Insomnia
Joint Range Of Motion
Decreased
Labile Hypertension
Muscle Spasms
Nail Disorder
Nausea
Oedema
Osteoarthritis
Pain
Protein Urine Present
Rhinitis Allergic
Rhinorrhoea
Spherocytic Anaemia
Splenectomy
Tachycardia
Urinary Sediment Present

		White Blood Cells Urine Positive					
		Whole Blood Transfusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Lorcet Plus	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427565-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
	Costochondritis		[Composition			
	Depression		Unspecified]	C		
UNKNOWN						
	Diabetes Mellitus		Baycol	C		
UNKNOWN						
	Inadequate Control		Actos	C		
UNKNOWN						
	Disturbance In Attention					
	Dizziness					
	Drug Hypersensitivity					
	Drug Ineffective					
	Emotional Distress					
	Fatigue					
	Fibromyalgia					
	General Physical Health					
	Deterioration					
	Hypertension					
	Insomnia					
	Joint Sprain					
	Macular Oedema					
	Muscle Spasms					
	Myalgia					
	Myocardial Infarction					
	Neuritis					

Neuropathy Peripheral
Oedema Peripheral
Pain
Peripheral Vascular
Disorder
Restless Legs Syndrome
Retinal Oedema
Retinopathy
Road Traffic Accident
Serum Ferritin Decreased
Tachycardia
Weight Decreased

Date:08/17/04ISR Number: 4427567-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00433
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Disability	Arthralgia
Other	Back Injury
	Cerebrovascular Accident

		Drug Ineffective					
		Dyspnoea					
		Ear Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Rate Irregular	Professional	Soma	C		
UNKNOWN							
		Hypoaesthesia		Naprosyn	C		
UNKNOWN							
		Intervertebral Disc Disorder					
		Lumbar Spinal Stenosis					
		Movement Disorder					
		Musculoskeletal Stiffness					
		Myofascial Pain Syndrome					
		Non-Cardiac Chest Pain					
		Ocular Icterus					
		Onychomycosis					
		Rotator Cuff Syndrome					
		Viral Infection					

Date:08/17/04ISR Number: 4427569-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amenorrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY							
Initial or Prolonged		Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY							
Disability		Arthralgia		Albuterol	C		
RESPIRATORY							
Other		Cardiac Failure					
(INHALATION)							
		Congestive		Augmentin	C		
UNKNOWN							
		Carpal Tunnel Syndrome		Vitamins			
		Complex Regional Pain		(Unspecified)	C		
UNKNOWN							
		Syndrome		Allegra	C		
UNKNOWN							
		Dehydration		Flonase	C		
UNKNOWN							
		Depression		Toradol	C		
UNKNOWN							

Diverticulum
Emotional Distress
Fear
Gastritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hiatus Hernia
Hypersensitivity
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Joint Swelling
Menorrhagia
Myocardial Infarction
Ovarian Cyst
Prescribed Overdose
Skin Laceration
Sleep Apnoea Syndrome
Tachycardia
Uterine Haemorrhage

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427573-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00435
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure	Professional	Antineoplastic					
Other	Congestive		(Unspecified)	SS				
UNKNOWN								
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diffuse Large B-Cell		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lymphoma Recurrent		Vicodin Tablets	C				
UNKNOWN								
	Disturbance In Attention		Vitamins					
	Ejection Fraction		(Unspecified)	C				
UNKNOWN								
	Decreased		Ambien	C				
UNKNOWN								
	Gastric Disorder		Flexeril	C		ORAL		
	Major Depression		Flexeril	C		ORAL		
	Myocardial Infarction		Meclomen	C				
UNKNOWN								
	Seborrhoeic Keratosis		Prilosec	C				
UNKNOWN								
	Sleep Disorder							
	Upper Respiratory Tract							
	Infection							

Date:08/17/04ISR Number: 4427574-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive	Professional	Vicodin Tablets	C				
UNKNOWN								
Disability	Connective Tissue							
Other	Inflammation							
	Coronary Artery Disease							
	Depression							
	Dyspnoea							
	Emotional Distress							
	Fatigue							
	Heart Rate Irregular							
	Intervertebral Disc							

Degeneration
Intervertebral Disc
Protrusion
Libido Disorder
Micturition Disorder
Mitral Valve Prolapse
Myocardial Infarction
Normochromic Normocytic
Anaemia
Sleep Apnoea Syndrome
Spinal Compression
Fracture
Weight Increased

Date:08/17/04ISR Number: 4427575-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Atelectasis
	Bronchitis
	Contusion
	Depression

		Fall					
		Gastric Haemorrhage					
		Haematochezia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhoids	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Rate Irregular	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Soma	C		
UNKNOWN							
		Pain In Extremity		Estrogens			
		Rib Fracture		(Unspecified)	C		
UNKNOWN		1036 DAY					
		Road Traffic Accident		[Therapy			
		Upper Gastrointestinal		Unspecified]	C		
UNKNOWN							
		Haemorrhage		Antimicrobial			
		Urinary Tract Infection		(Unspecified)	C		
UNKNOWN							
		Viral Infection		Herbs (Unspecified)	C		
UNKNOWN							
				Imdur	C		
UNKNOWN							
				Nitro	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427576-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA02979
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blepharitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cataract	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						
	Heart Rate Irregular		Zocor	C		
UNKNOWN						
	Macular Degeneration		Lanoxin	C		
UNKNOWN						
	Myocardial Infarction		Zestril	C		
UNKNOWN						
	Transient Ischaemic					
	Attack					
	Visual Acuity Reduced					

Date:08/17/04ISR Number: 4427577-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00826
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Other	Abasia
	Anxiety
	Asthenia
	Blood Chloride Increased
	Blood Glucose Increased
	Blood Ph Increased
	Cerebrovascular Accident
	Chronic Fatigue Syndrome
	Confusional State
	Crying
	Depression
	Disturbance In Attention
	Dyspnoea
	Haematocrit Decreased
	Headache
	Herpes Zoster
	Hypertension
	Hyperventilation
	Immobile
	Injury
	International Normalised
	Ratio Decreased
	Intervertebral Disc
	Degeneration
	Loss Of Libido

		Nausea					
		Oedema Peripheral					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Personality Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Post-Traumatic Stress		Vicodin Tablets	C		
UNKNOWN							
		Disorder		Beta Carotene	C		
UNKNOWN							
		Sinus Bradycardia		Zyrtec	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Flonase	C		
UNKNOWN							
		Sleep Disorder		Neurontin	C		
UNKNOWN							
		Spinal Osteoarthritis		Garlic Extract	C		
UNKNOWN							
		Suicidal Ideation		Ginkgo Biloba			
		Syncope		Extract	C		
UNKNOWN							
		Treatment Noncompliance		Glyburide	C		
UNKNOWN							
		Tremor		Maxzide	C		
UNKNOWN							
		Vision Blurred		Vitamins			
				(Unspecified)	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Calan	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Temazepam	C		
UNKNOWN							
				Zocor	C		ORAL
				Atrovent	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Ocuvite	C		
UNKNOWN							

				Naprosyn	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN							
				Pyridoxine	C		
UNKNOWN							
				Altace	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427578-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00071
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Malaise							
	Neoplasm Malignant							
	Prescribed Overdose							

Date:08/17/04ISR Number: 4427579-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00115
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death	Professional	Diethylpropion					
	Myocardial Infarction		Hydrochloride	C				
UNKNOWN								
			Prinzide	C				
UNKNOWN								
			Arava	C				
UNKNOWN								
			Phendimetrazine					
			Hydrochloride	C				
UNKNOWN								
			Amitriptyline					
			Hydrochloride	C				
UNKNOWN								
			Meridia	C				
UNKNOWN								
			Phentermine	C				
UNKNOWN								
			Phenylpropanolamine	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		62 DAY
Initial or Prolonged	Angina Unstable	Professional	Aspirin	C				UNKNOWN
Other	Cardiomegaly		Atenolol	C				UNKNOWN
	Coronary Artery Disease		Pepcid	C				UNKNOWN
	Depression		Zocor	C		ORAL		
	Gastrooesophageal Reflux		Glyburide	C				UNKNOWN
	Disease		Motrin	C				UNKNOWN
	Injury		Prinivil	C		ORAL		
	Migraine							
	Rash Pruritic							
	Scrotal Abscess							
	Syncope Vasovagal							

Date:08/17/04ISR Number: 4427581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Aortic Dissection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Other	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Circulatory Collapse		Amoxicillin	C				UNKNOWN
	Depression		Viagra	C				UNKNOWN
	Disturbance In Attention		Chlorhexidine					
	Diverticulitis		Hydrochloride	C				UNKNOWN
	Dizziness		Hydrocodone					

	Emotional Distress	Bitartrate	C
UNKNOWN			
	Enterobacter Infection	Lorazepam	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	General Physical Condition Abnormal		
	Hyperhidrosis		
	Hypertension		
	Iliac Artery Thrombosis		
	Impaired Healing		
	Irritability		
	Keloid Scar		
	Myocardial Infarction		
	Pain		
	Platelet Count Decreased		
	Pneumonia		
	Prothrombin Time Prolonged		
	Rash Pruritic		
	Self Esteem Decreased		
	Sexual Dysfunction		
	Vascular Injury		

Date:08/17/04ISR Number: 4427582-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angioneurotic Oedema
	Cellulitis
Other	Chest Pain

		Depression					
		Gastrointestinal Injury					
		Gout	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Intervertebral Disc	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
21	DAY						
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL
21	DAY						
		Oedema Peripheral		Zithromax	C		
UNKNOWN							
	7	DAY					
		Palpitations		Cardizem	C		
UNKNOWN							
		Pneumonia		Ismo	C		
UNKNOWN							
		Skin Discolouration		Morphine Sulfate	C		ORAL
		Synovitis		Ms Contin	C		ORAL
				Ms Contin	C		
UNKNOWN							
				Ms Contin	C		
UNKNOWN							

Date:08/17/04ISR Number: 4427584-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Dysphagia		Betaxolol Ophthalmic			
	Ear Pain		Solution	C		
UNKNOWN						
	Epistaxis		Calcitonin	C		
UNKNOWN						
	Facial Pain		Digoxin	C		
UNKNOWN						
	Hypertension		Docusate Sodium	C		
UNKNOWN						
	Lacunar Infarction		Trusopt	C		
OPHTHALMIC						
	Muscle Spasms		Vitamin E	C		
UNKNOWN						

	Myalgia		Warfarin	C
UNKNOWN		1284 DAY		
	Pain In Jaw		Zocor	C
UNKNOWN				
	Productive Cough		Folic Acid	C
UNKNOWN				
	Renal Injury		Lasix (Furosemide)	C
UNKNOWN		1680 DAY		
	Rheumatoid Arthritis		Isosorbide	C
UNKNOWN				
			Potassium (Unspecified)	C
UNKNOWN				
			Psyllium Husk	C
UNKNOWN				

Date:08/17/04ISR Number: 4427586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cardio-Respiratory Arrest		Vicoprofen	C		
UNKNOWN						
	Cardiomegaly		Methocarbamol	C		
UNKNOWN						
	Coronary Artery Atherosclerosis					
	Coronary Artery Thrombosis					
	Myocardial Infarction					
	Pulmonary Oedema					
	Splenomegaly					
	Sudden Death					
	Ventricular Fibrillation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427589-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02528
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427590-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02529
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Ultracet	C				
UNKNOWN								
	Increased		Premarin	C				
UNKNOWN								
	Cardiac Disorder		Zoloft	C				
UNKNOWN								
	Depression		Bextra	C				
UNKNOWN								
	Dyspnoea		Bextra	C				
UNKNOWN								
	Hepatitis B		Dyazide	C				
UNKNOWN								
	Hypersensitivity		Skelaxin	C				
UNKNOWN								
	Myocardial Infarction							
	Neck Pain							

Date:08/17/04ISR Number: 4427591-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02533
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
26 DAY								
	Cerebrovascular Accident							
	Emotional Distress							
	Hypertension							
	Myocardial Infarction							
	Stress							

Date:08/17/04ISR Number: 4427592-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acute Stress Disorder
	Anaemia
	Anal Fissure
	Anxiety
	Atherosclerosis
	Back Pain
	Benign Prostatic Hyperplasia
	Blindness
	Blood Creatine Phosphokinase Abnormal
	Blood Creatine Phosphokinase Mb Increased
	Blood Urine
	Blood Urine Present
	Bronchitis Acute
	Calculus Ureteric
	Cellulitis
	Cervical Spinal Stenosis
	Chest Pain
	Diabetes Mellitus

		Inadequate Control					
		Diabetic Neuropathy					
		Diabetic Retinopathy					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress	Professional	Claritin	C		
UNKNOWN							
		Fall		Glucophage	C		
UNKNOWN							
		Gait Disturbance		Methocarbamol	C		
UNKNOWN							
		Gastritis Erosive		Acetaminophen And			
		Gastrointestinal		Hydrocodone			
		Haemorrhage		Bitartrate	C		
UNKNOWN							
		Gastrooesophageal Reflux		Norvasc	C		
UNKNOWN							
		Disease		Clonidine	C		
UNKNOWN							
		Haematochezia		Flonase	C		
UNKNOWN							
		Haematuria		Neurontin	C		
UNKNOWN							
		Haemoptysis		Imdur	C		
UNKNOWN							
		Haemorrhoids		Humalog	C		
SUBCUTANEOUS							
		Hiatus Hernia		Humalog	C		
SUBCUTANEOUS							
		Hypochromic Anaemia		Humulin N	C		
UNKNOWN							
		Localised Infection		Humulin N	C		
UNKNOWN							
		Loss Of Consciousness		Hyzaar	C		ORAL
		Myocardial Ischaemia		Glucotrol Xl	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Osteoarthritis		Prozac	C		
UNKNOWN							
		Pharyngitis		Celebrex	C		
UNKNOWN							
		Pneumonia		Darvocet-N	C		
UNKNOWN							
		Prostatitis		Avandia	C		
UNKNOWN							

	Rectal Haemorrhage	Glyset	C
UNKNOWN			
	Spinal Column Stenosis	Nitroquick	C
SUBLINGUAL			
	Stress		
	Syncope		
	Urethral Discharge		

Date:08/17/04ISR Number: 4427595-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02531
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amaurosis Fugax
Disability	Angiopathy
	Anxiety
	Aphasia
	Atrial Fibrillation
	Back Pain
	Balance Disorder
	Blindness Transient
	Blood Potassium Increased
	Bone Pain
	Burning Sensation
	Cardiac Flutter
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Discomfort
	Chest Pain
	Coagulopathy
	Contusion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Diarrhoea
	Diplopia
	Diverticulum

		Dizziness					
		Dizziness Postural					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram St-T	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Change	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram T Wave		Prempro	C		
UNKNOWN							
		Inversion		Synthroid	C		
UNKNOWN							
		Emotional Distress					
		Epistaxis					
		Fatigue					
		Glycosylated Haemoglobin					
		Increased					
		Haemoptysis					
		Haemorrhage					
		Headache					
		Hypercholesterolaemia					
		Hyperchromic Anaemia					
		Hyperlipidaemia					
		Hypertension					
		Injury					
		International Normalised					
		Ratio Decreased					
		Irritable Bowel Syndrome					
		Joint Sprain					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Muscle Strain					
		Myofascitis					
		Nausea					
		Occult Blood Positive					
		Pain					
		Pain In Extremity					
		Palpitations					
		Phlebitis					
		Polyp Colorectal					
		Radicular Pain					
		Retinal Vascular Disorder					
		Road Traffic Accident					
		Sinus Bradycardia					
		Stress					
		Supraventricular					
		Extrasystoles					
		Supraventricular					
		Tachycardia					

Tenderness
Thalassaemia
Thrombosis
Transient Ischaemic
Attack
Ventricular Tachycardia
Vision Blurred
Visual Acuity Reduced
Vomiting

Date:08/17/04ISR Number: 4427605-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02538
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427606-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02509
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Abdominal Pain Upper	Professional	Methotrexate	C			UNKNOWN	
	Acute Myocardial		Berplex Plus	C			UNKNOWN	
	Infarction		Prednisone	C			UNKNOWN	
	Angina Pectoris							
	Asthenia							
	Back Pain							
	Blood Pressure Diastolic Increased							
	Blood Triglycerides Increased							
	Calculus Ureteric							
	Cardiac Arrest							
	Chest Discomfort							
	Chest Pain							
	Cold Sweat							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Dyspnoea							
	Electrocardiogram Abnormal							
	Electrocardiogram St Segment Elevation							
	Electrocardiogram St-T Change							
	Feeling Abnormal							
	Hypercholesterolaemia							
	Hyperhidrosis							
	Hypotension							
	Myocardial Ischaemia							
	Nausea							
	Obstruction							
	Oesophagitis							
	Oral Pain							
	Orthopnoea							
	Pericarditis							

Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Hypokinesia
Ventricular Tachycardia

Date:08/17/04ISR Number: 4427607-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome PT
Disability Abdominal Pain
Other Abdominal Pain Upper
Anxiety
Arrhythmia
Cardiac Failure
Congestive
Chest Pain
Congestive Cardiomyopathy
Depression
Diastolic Dysfunction

		Dilatation Atrial					
		Fatigue					
		Generalised Anxiety	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematochezia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension					
		Injury					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Nocturia					
		Palpitations					
		Tachycardia					
		Treatment Noncompliance					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					

Date:08/17/04ISR Number: 4427610-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00617
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/17/04ISR Number: 4427611-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00709
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Other	Agoraphobia
	Anger
	Anxiety
	Arthralgia
	Asthenia
	Cerebrovascular Accident
	Cervix Carcinoma
	Condyloma Acuminatum
	Crying
	Depression
	Disturbance In Attention
	Dyskinesia

Dyspnoea
Excoriation
Fatigue
Fear
Hypersomnia
Hypertension
Increased Appetite
Irritability
Joint Injury
Joint Range Of Motion
Decreased
Joint Stiffness
Learning Disorder
Mental Impairment
Mood Swings
Musculoskeletal Stiffness
Obesity
Panic Disorder

		Personality Disorder					
		Post Procedural Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post-Traumatic Stress Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
		Reading Disorder					
		Road Traffic Accident					
		Sleep Apnoea Syndrome					
		Social Avoidant Behaviour					
		Swelling Face					
		Tremor					
		Tuberculosis					
		Vision Blurred					
		Weight Increased					

Date:08/17/04ISR Number: 4427612-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Aggression	Health	Vioxx	PS	Merck & Co., Inc	ORAL
29	DAY						
Other		Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
29	DAY						
		Diarrhoea		Lithium Carbonate	C		
UNKNOWN							
		Fatigue					
		Heart Injury					
		Heart Rate Irregular					
		Joint Dislocation					
		Myocardial Infarction					
		Onychomycosis					
		Paranoia					
		Rotator Cuff Syndrome					
		Sacroiliitis					
		Squamous Cell Carcinoma					
		Stomach Discomfort					

Suicidal Ideation

Date:08/17/04ISR Number: 4427613-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427614-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427615-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00639
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Injury							

Date:08/17/04ISR Number: 4427616-0Report Type:Expedited (15-DaCompany Report #IE-MERCK-0406GBR00184
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Impairment	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	SS		ORAL		
			Bumetanide	SS		ORAL		
			Dexamethasone	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	
			Oxytetracycline	C			UNKNOWN	
			Pantoprazole Sodium	C			UNKNOWN	

Date:08/17/04ISR Number: 4427618-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00618
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427620-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Injury

Date:08/17/04ISR Number: 4427621-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427622-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00640
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:08/17/04ISR Number: 4427624-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00632
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427625-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427626-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01232
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Consumer	Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Aggression		Norvasc	C			UNKNOWN	
	Angina Unstable		Lotrel	C			UNKNOWN	
	Anxiety		Venlafaxine Hydrochloride	C			UNKNOWN	
	Anxiety Disorder							
	Arthralgia		Celebrex	C			UNKNOWN	
	Asthenia		Lorazepam	C			UNKNOWN	
	Back Pain							
	Cardiac Disorder							
	Cardiac Murmur							
	Carotid Artery Stenosis							
	Carotid Bruit							
	Carpal Tunnel Syndrome							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Atherosclerosis							
	Deafness							
	Dementia							
	Depression							
	Dizziness							
	Dyskinesia							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	Hepatitis B							
	Hypertension							

Joint Sprain
Myocardial Ischaemia
Neuropathy Peripheral
Osteoporosis
Otitis Media
Pain In Extremity
Palpitations
Panic Disorder
Pelvic Pain
Peripheral Vascular
Disorder
Prescribed Overdose
Rheumatoid Arthritis
Schizophrenia, Paranoid
Type
Toe Deformity
Treatment Noncompliance
Tremor
Varicose Vein
Venous Insufficiency

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427627-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00887
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427628-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00655
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427630-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427631-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00892
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427632-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0408CHE00012
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 5 DAY	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Enterocolitis Haemorrhagic							

Date:08/17/04ISR Number: 4427633-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00888
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427634-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00889
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427635-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01164
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4427636-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00890
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427651-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00764
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Retinal Haemorrhage		Hytrin	C			UNKNOWN	
	Retinal Oedema							
	Retinal Vein Occlusion							
	Tendon Rupture							

Date:08/17/04ISR Number: 4427676-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4427679-2Report Type:Expedited (15-DaCompany Report #US-MERCK-99101089
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea							
	Flatulence							
	Myocardial Infarction							

Date:08/17/04ISR Number: 4427680-9Report Type:Expedited (15-DaCompany Report #BE-MERCK-0407BEL00012
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arrhythmia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Atrial Fibrillation		Althiazide And Spironolactone	C		ORAL
	Mitral Valve Incompetence		Amiodarone Hydrochloride	C		ORAL
			Amlodipine Besylate	C		ORAL
			Aspirin	C		ORAL
			Sotalol Hydrochloride	C		ORAL
			Bisoprolol Fumarate	C		ORAL
			Fenofibrate	C		ORAL
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4428017-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		340 DAY
Life-Threatening	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
Initial or Prolonged	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		340 DAY
	Coronary Artery Occlusion		Claritin-D	C				UNKNOWN
	Cystocele		Triamcinolone	C				UNKNOWN
	Dilatation Ventricular		Zyrtec	C				UNKNOWN
	Dyspnoea		Proventil Repetabs And Tablets	C				UNKNOWN
	Electrocardiogram St Segment Abnormal		Vicodin Tablets	C				UNKNOWN
	Fibromyalgia		Lorabid	C				UNKNOWN
	Haemorrhage		Prevacid	C				UNKNOWN
	Heart Rate Increased		Hydroxyzine Hydrochloride	C				UNKNOWN
	Hepatic Steatosis		Tequin	C				UNKNOWN
	Hepatitis		Prempro	C				UNKNOWN
	Hepatomegaly		Voltaren	C			41 DAY	UNKNOWN
	Muscle Spasms		Cipro	C				UNKNOWN
	Myocardial Infarction		Tussi-12	C				UNKNOWN
	Myocardial Ischaemia		Benzonatate	C				UNKNOWN
	Oxygen Saturation							

	Decreased	Zithromax	C
UNKNOWN			
	Pelvic Prolapse	Soma	C
UNKNOWN			
	Pleural Adhesion	Lorazepam	C
UNKNOWN			
	Procedural Complication	Remeron	C
UNKNOWN			
	Pulmonary Oedema	Prilosec	C
UNKNOWN			
	Rhonchi	Ditropan	C
UNKNOWN			
	Sinus Tachycardia	Ditropan	C
UNKNOWN			
	Stress Incontinence	Promethazine	C
UNKNOWN			
	Sudden Cardiac Death		
	Vaginal Prolapse		
	Ventricular Dysfunction		
	Wheezing		

Date:08/17/04ISR Number: 4428021-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104522
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fluctuation							
	Cardiovascular Disorder							
	Convulsion							
	Dementia Alzheimer'S Type							
	Oedema							
	Renal Failure							

Date:08/17/04ISR Number: 4428023-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Other	Anaemia
	Bladder Obstruction
	Cerebral Atherosclerosis

		Cerebral Atrophy					
		Cerebral Infarction					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Encephalomalacia		Vioxx	PS	Merck & Co., Inc	ORAL
		Epistaxis		Vioxx	SS	Merck & Co., Inc	ORAL
		Erectile Dysfunction		[Therapy			
		Gastrointestinal		Unspecified]	C		
UNKNOWN							
		Haemorrhage		Albuterol	C		
RESPIRATORY							
		Haemoptysis					
(INHALATION)							
		Haemorrhoids		Albuterol	C		ORAL
		Headache		Allopurinol	C		
UNKNOWN							
		Hypertension		Ecotrin	C		
UNKNOWN							
		International Normalised		Atenolol	C		
UNKNOWN							
		Ratio Decreased		Palgic D	C		ORAL
		Nasal Septum Deviation		Mavik	C		ORAL
		Pneumonia		Mavik	C		ORAL
		Prostate Cancer		Celebrex	C		
UNKNOWN							
		Rectal Haemorrhage		Docusate Calcium	C		
UNKNOWN							
		Rectal Polyp		Guaifenex La	C		
UNKNOWN							
		Scleral Haemorrhage		Hydrodiuril	C		ORAL
		Sinusitis		Ibuprofen	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:08/17/04ISR Number: 4428031-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
1 MON						
Hospitalization -	Congestive					

Initial or Prolonged

Date:08/17/04ISR Number: 4428033-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00094
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Other	Abscess
	Arthrodesis
	Basedow'S Disease
	Body Tinea
	Bronchitis Chronic
	Cellulitis
	Depression
	Diarrhoea
	Dysphagia
	Essential Hypertension
	Facial Palsy
	Gastrooesophageal Reflux
	Disease
	Herpes Simplex
	Herpes Simplex Ophthalmic
	Hordeolum
	Insomnia
	Oedema Peripheral
	Otitis Media Acute
	Pelvic Inflammatory
	Disease
	Pharyngitis
	Pleurisy

		Post Procedural Complication Thyroiditis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Increased		[Composition Unspecified]	C		
UNKNOWN							
				Midrin	C		ORAL
				Keflex	C		ORAL
				Tiazac	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Accuretic	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Claritin-D 12 Hour	C		ORAL
				Accupril	C		
UNKNOWN							

Date:08/17/04ISR Number: 4428038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/17/04ISR Number: 4428039-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00087
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Caecitis		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/17/04ISR Number: 4428040-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00163
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death		Magnesium (Unspecified)	C				
	Electrocardiogram Qt Prolonged		Potassium (Unspecified)	C				
	Infection							
	Loss Of Consciousness							
	Prescribed Overdose							
	Tongue Discolouration							

Date:08/17/04ISR Number: 4428041-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00873
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4428049-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA02339
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Rectal Haemorrhage		Aleve	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4428050-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Amnesia		Elavil	C				UNKNOWN
	Arthralgia		Norvasc	C				UNKNOWN
	Cardiac Murmur		Effexor	C				UNKNOWN
	Carpal Tunnel Syndrome		Ultram	C				UNKNOWN
	Chondromalacia		Hydrocodone Bitartrate	C				UNKNOWN
	Contusion		Propranolol Hydrochloride	C				UNKNOWN
	Delirium							
	Disability							
	Dyspnoea							
	Electrocardiogram St Segment Abnormal							
	Emotional Distress							
	Essential Hypertension							
	Fatigue							
	Fibromyalgia							
	Gastric Disorder							
	Haemorrhage							
	Headache							
	Hypoaesthesia							
	Keloid Scar							
	Major Depression							
	Meniscus Lesion							
	Migraine Without Aura							
	Monarthritis							
	Nausea							
	Neck Pain							
	Neoplasm Malignant							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Pain In Extremity							
	Palpitations							
	Panic Disorder With Agoraphobia							
	Paraesthesia							

Peptic Ulcer
Rotator Cuff Syndrome
Skin Lesion
Swelling
Synovitis
Tenosynovitis
Tension Headache
Transient Ischaemic
Attack
Urine Abnormality
Urine Odour Abnormal
Vomiting

Date:08/17/04ISR Number: 4428051-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4428055-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	115	DAY

Date:08/17/04ISR Number: 4428056-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00055
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anal Haemorrhage		Budesonide	C			UNKNOWN	
	Asthma		Formoterol Fumarate	C			UNKNOWN	
	Blood Immunoglobulin E		Theophylline	C			UNKNOWN	
	Increased		Pantoprazole Sodium	C			UNKNOWN	
	Bronchitis Bacterial							
	Bronchopulmonary Aspergillosis							
	Condition Aggravated							
	Diverticulum							
	Enterocolitis							
	Gastrointestinal Disorder							
	Ileitis							
	Respiratory Disorder							
	Staphylococcal Infection							
	Varicose Vein							

Date:08/17/04ISR Number: 4428137-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Allopurinol	C			UNKNOWN	

	Chest Pain	Advil	C	
UNKNOWN				
	Dermatitis	Indocin		
	Diarrhoea	(Indomethacin)	C	ORAL
	Drug Ineffective	Noritate	C	
UNKNOWN				
	Dyspnoea			
	Emotional Distress			
	Fatigue			
	Gouty Arthritis			
	Headache			
	Hypoaesthesia			
	Hypotension			
	Intercostal Neuralgia			
	Mental Disorder			
	Nausea			
	Paraesthesia			
	Rosacea			
	Silent Myocardial			
	Infarction			
	Sinusitis			
	Spinal Osteoarthritis			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/04ISR Number: 4428145-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acidosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Astigmatism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chills		Accupril	C			UNKNOWN	
	Coronary Artery Disease		Lipitor	C			UNKNOWN	3142 DAY
	Cough		Lotensin	C			UNKNOWN	
	Diverticulum		Lotensin	C			UNKNOWN	
	Flank Pain		Vasotec	C		ORAL	3507 DAY	
	Gastritis		Vasotec	C		ORAL	3507 DAY	
	Haemorrhoids		Prozac	C			UNKNOWN	
	Hiatus Hernia		Prozac	C			UNKNOWN	
	Hyperhidrosis		Prozac	C			UNKNOWN	
	Hypermetropia		Ginseng	C			UNKNOWN	
	Rhinorrhoea		Naproxen	C			UNKNOWN	
			Accupril	C			UNKNOWN	

Date:08/17/04ISR Number: 4428153-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	66 DAY	
Initial or Prolonged	Blood Bilirubin Increased		Vioxx	SS	Merck & Co., Inc	ORAL	66 DAY	

Cardiac Valve Disease
Change Of Bowel Habit
Coronary Artery
Atherosclerosis
Dyspnoea
Hand Fracture
Myocardial Infarction
Rectal Haemorrhage
Renal Failure

Date:08/17/04ISR Number: 4428154-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Tylenol	C				
Disability	Bradycardia		Aspirin	C				
Other	Cardiac Failure		Premarin	C				
	Cerebrovascular Accident		Lasix (Furosemide Sodium)	C				
	Chest Pain							
	Feeling Abnormal		Lasix (Furosemide Sodium)	C				
	Myocardial Infarction							
	Transient Ischaemic		Avalide	C				
	Attack		Motrin	C				
			Naproxen	C				

Date:08/17/04ISR Number: 4428155-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02539
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:08/17/04ISR Number: 4428156-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00645
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/04ISR Number: 4431079-9Report Type:Expedited (15-DaCompany Report #2003GB02479
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute	Foreign	Omeprazole	PS		ORAL	20 MG PO	
Required	Coronary Artery	Health	Rofecoxib	SS		ORAL	50MG PO	
Intervention to	Atherosclerosis	Professional	Climagest	C				
Prevent Permanent	Coronary Artery Occlusion	Other						
Impairment/Damage	Coronary Artery Stenosis							
	Myocardial Ischaemia							
	Pulmonary Oedema							
	Sudden Death							

Date:08/18/04ISR Number: 4428597-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Atrial Fibrillation
Disability	Basal Cell Carcinoma
Other	Blood Creatinine
	Increased

Breast Cyst
Cardiolipin Antibody
Positive
Cerebrovascular Accident
Colonic Polyp
Coronary Artery Disease
Depression
Dyspepsia
Ear Pain
Ecchymosis
Episcleritis
Faeces Discoloured
Fall
Felty'S Syndrome
Gastrooesophageal Reflux
Disease
Haemorrhoidal Haemorrhage
Herpes Zoster
Hiatus Hernia
Hypertension
Hypertonic Bladder
Immunoglobulins Decreased
Insomnia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Keratitis Herpetic					
		Laryngitis Viral					
		Leukopenia					
		Lymphoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Mental Impairment	Professional	Remicade	SS		
INTRAVENOUS							
		Migraine		Remicade	SS		
INTRAVENOUS							
		Mitral Valve Incompetence		Methotrexate	SS		
UNKNOWN							
		Mouth Injury		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Vioxx	SS	Merck & Co., Inc	ORAL
		Orthostatic Hypotension		Methotrexate	SS		
UNKNOWN							
		Overdose		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pancytopenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Platelet Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Prostatitis		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Renal Disorder		[Therapy			
		Renal Pain		Unspecified]	C		
UNKNOWN							
		Rheumatoid Arthritis		Tylenol	C		
UNKNOWN							
		Rib Fracture		Acyclovir	C		
INTRAVENOUS							
		Sinusitis		Proventil	C		ORAL
		Thrombocytopenia		Allopurinol	C		
UNKNOWN							
		Transient Ischaemic		Elavil	C		ORAL
		Attack		Fiorinal With			
		Trigger Finger		Codeine	C		
UNKNOWN							
		Viral Pharyngitis		Azathioprine	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							

UNKNOWN	Prednisone	C
UNKNOWN	K-Dur	C
UNKNOWN	Prilosec	C
UNKNOWN	Purinethol	C
UNKNOWN	Tegretol	C
UNKNOWN	Tegretol	C
UNKNOWN	Tegretol	C
UNKNOWN	Carbamazepine	C
UNKNOWN	Zyrtec	C
UNKNOWN	Hydroxychloroquine Sulfate	C
UNKNOWN	Advil	C
UNKNOWN		

Date:08/18/04ISR Number: 4428606-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00840
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Anoxic Encephalopathy
	Atelectasis
	Atrioventricular Block Complete
	Axillary Vein Thrombosis
	Back Pain
	Cardiogenic Shock
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Colitis Ischaemic
	Constipation
	Coronary Artery Disease

		Cough					
		Diabetes Mellitus Insulin-Dependent	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetic Retinopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	MON						
		Fall	Professional	Alprazolam	C		
UNKNOWN							
		Gastritis		Clonidine	C		
UNKNOWN							
		Haematoma		Estrogens, Conjugated And			
		Haemorrhoidal Haemorrhage					
		Hepatic Failure		Progesterone	C		
UNKNOWN							
		Hepatitis B		Insulin	C		
UNKNOWN							
		Hyperglycaemia		Zestril	C		
UNKNOWN							
		Ischaemic Cardiomyopathy					
		Mitral Valve Incompetence					
		Muscle Tightness					
		Myocardial Infarction					
		Pain In Extremity					
		Pulmonary Hypertension					
		Rash					
		Renal Cyst					
		Renal Failure Acute					
		Silent Myocardial Infarction					
		Tendonitis					
		Tricuspid Valve Incompetence					
		Urinary Tract Infection					

Date:08/18/04ISR Number: 4428608-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01614
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN						

Date:08/18/04ISR Number: 4428611-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia Of Chronic Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Lipitor	C			UNKNOWN	
	Diverticular Perforation		Celebrex	C			UNKNOWN	
	Gastritis		Zoloft	C			UNKNOWN	
	Gastrointestinal		Triamterene	C			UNKNOWN	
	Haemorrhage		Voltaren	C			UNKNOWN	
	Gastrooesophageal Reflux		Duragesic	C			TOPICAL	
	Disease		Dyazide	C			UNKNOWN	
	Muscle Spasms		Metoprolol	C			UNKNOWN	
	Osteoarthritis		Lopressor	C			UNKNOWN	
	Polyp Colorectal		Prilosec	C			UNKNOWN	
	Rectal Haemorrhage		Denavir	C			UNKNOWN	
	Small Intestinal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/04ISR Number: 4428614-3Report Type:Expedited (15-DaCompany Report #BE-MERCK-0407BEL00036
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		419 DAY
Initial or Prolonged	Uterine Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL		419 DAY
Other			Fosamax	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Tamoxifen Citrate	C		ORAL		
			Zoledronic Acid	C		INTRAVENOUS DRIP		

Date:08/18/04ISR Number: 4428785-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris	Professional	Voltaren	SS		UNKNOWN		
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Candidiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Lymphocytic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis		Prempro	C		UNKNOWN		
	Gastrointestinal Haemorrhage							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Hypertension							
	Meniscus Lesion							
	Mitral Valve Prolapse							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Overdose							
	Peptic Ulcer							

Pneumonia
Reflux Oesophagitis
Stress
Tricuspid Valve
Incompetence
Ulcer Haemorrhage
Urinary Tract Infection
Ventricular Dysfunction
Vomiting
Wound Infection
Staphylococcal

Date:08/18/04ISR Number: 4428800-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0408CHE00019
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Dyspnoea	Professional						
	Formication							
	Hallucination, Visual							
	Panic Reaction							
	Tension							

Date:08/18/04ISR Number: 4428801-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0408CAN00055
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	46	DAY
Initial or Prolonged		Professional	Calcium (Unspecified)	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Vitamin D (Unspecified)	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	

Date:08/18/04ISR Number: 4429060-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Cordarone	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Dilacor Xr	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Cozaar	C			UNKNOWN	
			K-Dur	C			UNKNOWN	

Date:08/18/04ISR Number: 4429061-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anxiety Disorder
	Back Injury
	Chest Discomfort
	Chest Pain
	Chromaturia
	Contusion
	Coronary Artery Restenosis
	Cough
	Decreased Appetite
	Dehydration
	Depressed Mood
	Diarrhoea
	Disturbance In Attention
	Diverticulum Intestinal Haemorrhagic
	Drug Ineffective
	Dyspnoea
	Fatigue
	Fluid Retention
	Haemorrhoids
	Hypertension
	Hypoaesthesia
	Insomnia
	Iron Deficiency
	Libido Decreased
	Lung Neoplasm
	Myocardial Infarction
	Nausea

		Non-Cardiac Chest Pain Oedema Peripheral Paraesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Prostatic Specific		Vioxx	SS	Merck & Co., Inc	ORAL
		Antigen Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Proteinuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Cyst		Allopurinol	C		
UNKNOWN							
		Rheumatoid Arthritis		Norvasc	C		
UNKNOWN							
		Rhinitis Allergic		Ecotrin	C		
UNKNOWN							
		Stress		Lipitor	C		
UNKNOWN							
		Tendon Rupture		Monopril	C		
UNKNOWN							
		Treatment Noncompliance		Lasix (Furosemide)	C		
UNKNOWN							
		Umbilical Hernia Ventricular Extrasystoles		Indocin (Indomethacin)	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							

Date:08/18/04ISR Number: 4429062-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Anoxic Encephalopathy		Tylenol With Codeine			
Initial or Prolonged		Anxiety		#4	C		
UNKNOWN							
Other		Cardio-Respiratory Arrest		Tylenol With Codeine			

	Convulsion	#4	C	
UNKNOWN				
	Coronary Artery Occlusion	Celebrex	C	
UNKNOWN				
	Deep Vein Thrombosis	Arthrotec	C	ORAL
	Gastric Disorder	Arthrotec	C	ORAL
	Hypertension	Arthrotec	C	ORAL
	Hypokalaemia	Premarin	C	
UNKNOWN				
	Lumbar Spinal Stenosis	Provera	C	
UNKNOWN				
	Myocardial Infarction	Daypro	C	
UNKNOWN				
	Palpitations			
	Pneumonia Aspiration			
	Postoperative Ileus			
	Pulmonary Embolism			
	Pulmonary Oedema			
	Shock			
	Syphilis			

Date:08/18/04ISR Number: 4429065-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Adrenal Adenoma
	Angina Pectoris
	Arthritis
	Blood Cholesterol
	Increased
	Bronchitis
	Cardiac Murmur
	Cataract
	Cellulitis

		Chest Pain					
		Chronic Fatigue Syndrome					
		Constipation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cystitis Glandularis		Tylenol	C		ORAL
		Dizziness		Pravachol	C		
UNKNOWN							
		Dyspepsia					
		Dyspnoea					
		Dyspnoea Paroxysmal					
		Nocturnal					
		Ear Infection					
		Electrocardiogram					
		Abnormal					
		Emotional Distress					
		Gastrointestinal Ulcer					
		Gastrooesophageal Reflux					
		Disease					
		Haematuria					
		Headache					
		Hypercholesterolaemia					
		Increased Tendency To					
		Bruise					
		Mitral Valve Incompetence					
		Nausea					
		Osteoporosis					
		Palpitations					
		Parotid Gland Enlargement					
		Peptic Ulcer					
		Rhinitis Allergic					
		Stress Incontinence					
		Thyroid Neoplasm					
		Tooth Abscess					
		Urethral Caruncle					
		Urinary Tract Infection					

Date:08/18/04ISR Number: 4429069-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01718
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 1 DAY		Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Abdominal Pain Lower		Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache					
	Insomnia					
	Intervertebral Disc Disorder					
	Pain In Extremity					

Date:08/18/04ISR Number: 4429070-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00096
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Benign Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL
17 DAY						
Initial or Prolonged	Hypertension					

Date:08/18/04ISR Number: 4429071-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Blood Pressure Decreased
	Cardiac Failure
	Congestive
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Chondromalacia
	Confusional State
	Convulsion
	Coronary Artery Disease
	Deafness Neurosensory
	Dehydration
	Depression
	Diabetes Mellitus
	Drug Ineffective
	Dysphagia
	Dyspnoea
	Ejection Fraction
	Decreased
	Embolic Cerebral
	Infarction
	Fatigue
	Fibrous Histiocytoma
	Flatulence
	Gastritis Haemorrhagic
	Headache
	Hiatus Hernia
	Hypermetropia
	Hypertension
	Inner Ear Disorder
	Leukocytosis
	Meniscus Lesion
	Mitral Valve Incompetence
	Myocardial Infarction
	Oedema

Osteonecrosis
Pain
Pneumonia Escherichia
Post Procedural
Complication
Presbyopia
Prothrombin Time
Prolonged
Pupillary Disorder
Renal Failure Acute
Respiratory Failure
Sepsis
Subarachnoid Haemorrhage
Syncope
Transient Ischaemic

		Attack					
		Tremor					
		Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Varicose Vein		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Ventricle Rupture		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Vertigo Positional		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Neurontin	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:08/18/04ISR Number: 4430750-2Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-293
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinal Haemorrhage	Foreign	Methotrexate(Methotrexate, Unspec)	PS		
			Health Professional	Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS		
			Distributor	Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS		
			Other	Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	SS		
				Humira (Adalimumab)	SS		
SUBCUTANEOUS	40 MG/M^2 1X						
PER 2 WEK ,							
SC							

			Premarin (Conjugated Estrogens, Unspec)	SS		
			Rofecoxib (Rofecoxib)	SS		
			Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C		
			Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C		

Date:08/18/04ISR Number: 4430771-XReport Type:Expedited (15-DaCompany Report #2004-07-0363
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetic Ketoacidosis Leukocytosis Pancreatic Necrosis Pancreatitis Acute	Foreign Health Professional Other	Celestene (Betamethasone) Tablets "Like Celestone Syrup"	PS		ORAL	ORAL	
			Vioxx (Rofecoxib) Oral, Not Otherwise Specified	SS		ORAL	ORAL	

				Ultram Oral	SS		ORAL
ORAL							

Date:08/18/04ISR Number: 4432487-2Report Type:Expedited (15-DaCompany Report #HQWYE100209AUG04
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Erythema Elevatum Diutinum	Consumer	Effexor Xr (Venlafaxine Hydrochloride, Capsule, Extended Release)	PS		ORAL
SEE IMAGE						
			Ibuprofen (Ibuprofen)	SS		
AS NEEDED						
			Vioxx (Rofecoxib, Tablet)	SS		
AS NEEDED						
			Trazodone (Trazodone)	C		
			Cuprimine (Penicillamine)	C		
			Urocit-K (Potassium Citrate)	C		
			Sodium Bicarbonate (Sodium Bicarbonate)	C		
			Captopril (Captopril)	C		
			Phenergan (Promethazine Hydrochloride)	C		
			Clonazepam (Clonazepam)	C		
			Wellbutrin (Amfebutamone Hydrochloride)	C		

Date:08/19/04ISR Number: 4429417-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00109
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anuria		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged			Acebutolol	C				UNKNOWN
			Amitriptyline Hydrochloride	C				UNKNOWN
			Diclofenac	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			Levodopa	C				UNKNOWN

Date:08/19/04ISR Number: 4429419-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/04ISR Number: 4429420-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00876
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Loss Of Consciousness		Ultracet	C				
UNKNOWN								
Disability	Myocardial Infarction		Aspirin	C				
UNKNOWN								
			Metoprolol-Bc	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

Date:08/19/04ISR Number: 4429428-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Celebrex	C				
UNKNOWN								
	Anxiety							
	Aortic Atherosclerosis							
	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Bronchitis							
	Bundle Branch Block							
	Cardiomyopathy							
	Carotid Artery Stenosis							
	Cervicobrachial Syndrome							
	Cholecystitis Acute							
	Coronary Artery Disease							
	Depression							
	Dermatitis Allergic							
	Diarrhoea							
	Femoral Artery Occlusion							
	Gastritis							
	Gastrooesophageal Reflux Disease							

Hypertension
Hypokinesia
Irritable Bowel Syndrome
Lung Neoplasm
Metabolic Encephalopathy
Mitral Valve Incompetence
Myocardial Infarction
Peripheral Vascular
Disorder
Pulmonary Hypertension
Sexual Dysfunction
Sleep Disorder
Staphylococcal Infection
Tricuspid Valve
Incompetence
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/04ISR Number: 4429561-3Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage		Augmentin	PS	Glaxosmithkline		UNKNOWN	
			Premarin	SS			UNKNOWN	
			Co-Dydramol	SS	Glaxosmithkline		UNKNOWN	
			Fluoxetine	SS			UNKNOWN	
			Methotrexate	SS			UNKNOWN	
			Rofecoxib	SS			UNKNOWN	
			Humira	SS			UNKNOWN	

Date:08/19/04ISR Number: 4429650-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
Other	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Contusion		Tylenol	C			UNKNOWN	
	Dyspepsia		Combivent	C			RESPIRATORY (INHALATION)	
	Emotional Distress							
	Gastric Ulcer		Allopurinol	C			UNKNOWN	
	Gastritis		Celebrex	C			UNKNOWN	
	Gastrointestinal		Estradiol	C			UNKNOWN	

	Haemorrhage	Vitamin E	C
UNKNOWN			
	Meniscus Lesion	Diovan	C
UNKNOWN			
	Patella Fracture	Ultram	C
UNKNOWN			
	Patellofemoral Pain	Bactrim Ds Tablets	C
UNKNOWN			
	Syndrome	Glucosamine	C
UNKNOWN			
	Pyrexia	Avalide	C
UNKNOWN			
	Therapeutic Response	Atrovent	C
UNKNOWN			
	Decreased	Claritin	C
UNKNOWN			
	Wound Infection	Niferex	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			
		Pyridoxine	C
UNKNOWN			

Date:08/19/04ISR Number: 4429655-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Choking
	Depression
	Diverticulum
	Erosive Duodenitis
	Fatigue
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hypertension
	Hypoacusis
	Oesophageal Rupture
	Pancreatitis
	Renal Cyst
	Supraventricular Extrasystoles

	Thromboembolic Stroke Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				UNKNOWN
			Restoril	C				UNKNOWN

Date:08/19/04ISR Number: 4429657-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Disability	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Basal Cell Carcinoma Bronchitis		[Therapy Unspecified]	C				UNKNOWN
	Bursitis		Acyclovir	C				UNKNOWN
	Chest Pain Cough		Vitamins (Unspecified)	C				UNKNOWN
	Drug Ineffective		Aspirin	C				UNKNOWN
	Dyspepsia		Lipitor	C				UNKNOWN
	Ecchymosis Hypertension		Calcium (Unspecified)	C				UNKNOWN
	Hypokalaemia		Premarin	C				UNKNOWN
	Intervertebral Disc Degeneration Intervertebral Disc Protrusion Migraine Non-Cardiac Chest Pain Pneumonia							

	Radiculitis Cervical
	Rectocele
	Respiratory Tract Infection
	Rotator Cuff Syndrome
	Tooth Disorder
	Viral Upper Respiratory Tract Infection

Date:08/19/04ISR Number: 4429659-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Claw Toe
Other	Acute Myocardial Infarction
	Angina Unstable
	Arthropathy
	Back Pain
	Blood Pressure Increased
	Bursitis
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Diabetes Mellitus Non-Insulin-Dependent
	Diarrhoea
	Headache

	Monarthritis Myocardial Infarction Tendonitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C		ORAL	
			Alfentanil Hydrochloride	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Zocor	C		ORAL	
			Lotensin	C		ORAL	
			Plavix	C		ORAL	
			Metoprolol	C		ORAL	

Date:08/19/04ISR Number: 4429660-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02029
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	9 MON
Disability	Cardiac Failure		Tylenol	C			UNKNOWN
Other	Congestive		Aspirin	C			UNKNOWN
	Cardiac Valve Disease		Aspirin	C			UNKNOWN
	Carotid Artery Disease		Atenolol	C			UNKNOWN
	Carotid Artery Stenosis		Coumadin	C			UNKNOWN
	Deep Vein Thrombosis		Coumadin	C			UNKNOWN
	Emotional Distress Gout		Indocin (Indomethacin)	C			UNKNOWN
	Impaired Work Ability		Isosorbide	C			UNKNOWN
	Injury		Isosorbide	C			UNKNOWN

	Ischaemic Cardiomyopathy	Nitroglycerin	C
UNKNOWN			
	Myocardial Infarction	Nitroglycerin	C
UNKNOWN			
	Neck Pain		
	Platelet Count Decreased		
	Renal Failure Chronic		
	Sinusitis		
	Sleep Apnoea Syndrome		

Date:08/19/04ISR Number: 4429661-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Activated Partial
Other	Thromboplastin Time
	Prolonged
	Anaemia
	Anxiety
	Arteriospasm Coronary
	Biliary Neoplasm
	Blood Albumin Decreased
	Bronchiectasis
	Bursitis
	Cellulitis
	Cholelithiasis
	Constipation
	Coronary Artery Disease
	Coronary Artery Occlusion
	Deep Vein Thrombosis

		Diverticulum					
		Drug Hypersensitivity					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Ear Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Erosive Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Excoriation		Vioxx	SS	Merck & Co., Inc	ORAL
		Fear		Vioxx	SS	Merck & Co., Inc	ORAL
		Gallbladder Disorder		Fosamax	C		
UNKNOWN							
		Gastritis Haemorrhagic		Amitriptyline			
		Hepatitis		Hydrochloride	C		ORAL
		Hypotension		Norvasc	C		ORAL
		Limb Discomfort		Wellbutrin Sr	C		ORAL
		Lung Neoplasm		Lampren	C		ORAL
		Malnutrition		Diphenhydramine			
		Mycobacterium Avium		Tannate	C		ORAL
		Complex Infection		Docusate Sodium	C		ORAL
		Myocardial Infarction		Premarin	C		ORAL
		Nausea		Ethambutol			
		Oedema Peripheral		Hydrochloride	C		ORAL
		Oesophagitis Ulcerative		Robaxin	C		ORAL
		Oral Intake Reduced		Prilosec	C		
UNKNOWN							
		Otitis Externa		Rifampin	C		ORAL
		Pruritus					
		Pruritus Generalised					
		Pulmonary Calcification					
		Pulmonary Cavitation					
		Pulmonary Mass					
		Rash Morbilliform					
		Rash Vesicular					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Vitreous Floaters					
		Vomiting					
		Weight Decreased					
		White Blood Cell Count Decreased					

Date:08/19/04ISR Number: 4429662-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01618
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Atrial Fibrillation
Other	Cardiac Disorder
	Cerebral Infarction
	Coma
	Coronary Artery Atherosclerosis
	Drug Screen Positive
	Epigastric Discomfort
	Fall
	Gastrointestinal Disorder
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux Disease
	Humerus Fracture

		Hypokalaemia Pneumonitis White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
466	DAY						
				Norvasc	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Vasotec	C		ORAL
				Zoloft	C		
UNKNOWN							
				Emla	C		
UNKNOWN							
				Centrum Silver	C		
UNKNOWN							
				Primidone	C		
UNKNOWN							

Date:08/19/04ISR Number: 4429663-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00845
Age:26 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Anxiety
	Aspartate Aminotransferase Increased
	Blood Creatine Phosphokinase Increased
	Blood Lactate Dehydrogenase Increased
	Coma
	Confusional State
	Contusion
	Convulsion
	Coordination Abnormal
	Dehydration
	Difficulty In Walking
	Dizziness
	Dysarthria

Dyspepsia
Electrocardiogram T Wave
Inversion
Emotional Distress
Fall
Fatigue
Gait Disturbance
Head Injury
Hyperhidrosis
Hypertension
Hypothyroidism
Injury
Joint Swelling
Loss Of Consciousness
Migraine
Nausea
Neuroma
Oedema Peripheral
Osteoarthritis
Palpitations
Photophobia
Road Traffic Accident
Sinus Congestion
Spinal Osteoarthritis

	Syncope						
	Tongue Biting						
	Tremor	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL	437 DAY
	Vomiting		Atenolol	SS			UNKNOWN
			Vioxx	SS	Merck & Co., Inc	ORAL	437 DAY

Date:08/19/04ISR Number: 4429665-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01304
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR
			Synthroid	C			UNKNOWN
			Zocor	C			UNKNOWN
			Prilosec	C			UNKNOWN

Date:08/19/04ISR Number: 4429666-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00028
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Left Ventricular Failure		Amitriptyline Hydrochloride	C		ORAL	
	Sudden Death		Bendroflumethiazide	C		ORAL	
			Nifedipine	C		ORAL	

Date:08/19/04ISR Number: 4429667-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		573 DAY
Initial or Prolonged	Coagulopathy		Celebrex	C				UNKNOWN
Disability	Cough		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				UNKNOWN
	Dehydration							
	Depression							
	Haemorrhagic Stroke							
	Nasal Congestion		Lasix (Furosemide)	C				UNKNOWN
	Thrombocytopenia		Hydrocodone Hydrochloride	C				UNKNOWN
			Demadex	C				UNKNOWN
			Spironolactone	C				UNKNOWN
			Ibuprofen	C				UNKNOWN
			Lozol	C				UNKNOWN
			Synthroid	C				UNKNOWN

Date:08/19/04ISR Number: 4429668-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01189
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Maculo-Papular		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
	Throat Tightness							

Date:08/19/04ISR Number: 4429669-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00096
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	270	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	270	DAY
	Influenza		Tylenol	C			UNKNOWN	
	Intervertebral Disc		Flexeril	C		ORAL	279	DAY
	Degeneration		Ultram	C		ORAL	270	DAY
	Intervertebral Disc		Valium	C		ORAL	1	DAY
	Protrusion		Advil	C			UNKNOWN	
	Therapeutic Response Decreased							

Date:08/19/04ISR Number: 4429670-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0408ISR00027
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Benign Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Hypertension		[Therapy					
	Drug Effect Decreased		Unspecified]	C			INTRAVENOUS	
	Drug Ineffective							
	Laboratory Test Abnormal							
	Nephritis Interstitial							
	Nerve Root Compression							
	Overweight							
	Renal Failure							
	Renal Failure Acute							
	Renal Tubular Necrosis							

Date:08/19/04ISR Number: 4429671-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02536
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Atherosclerosis
	Cardiac Murmur
	Cerebrovascular Accident
	Depression
	Drug Hypersensitivity
	Exostosis
	Eye Pain
	Gastrooesophageal Reflux Disease
	Gout
	Headache
	High Density Lipoprotein Decreased
	Hypoacusis
	Hypoaesthesia
	Ingrowing Nail
	Irritability
	Lipids Increased
	Low Density Lipoprotein Increased
	Memory Impairment
	Mitral Valve Incompetence
	Mitral Valve Prolapse
	Myocardial Infarction
	Nephrolithiasis

	Renal Failure Renal Function Test Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Darvocet-N	C			UNKNOWN
			Clonidine	C		ORAL	
			Tiazac	C			UNKNOWN
			Avalide	C			UNKNOWN
			Avalide	C			UNKNOWN
			Avalide	C			UNKNOWN
			Zestril	C			UNKNOWN

Date:08/19/04ISR Number: 4429672-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Hospitalization -	Haemorrhage		Prilosec	C			UNKNOWN
Initial or Prolonged							

Date:08/19/04ISR Number: 4429674-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0408ISR00026
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	1 WK
Initial or Prolonged	Increased Dialysis Generalised Oedema						

Date:08/19/04ISR Number: 4429675-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0408ISR00029
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Dipyrone	C			UNKNOWN	

Date:08/19/04ISR Number: 4431763-7Report Type:Expedited (15-DaCompany Report #LTI2004A00190
Age:56 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Macrocytic
	Antinuclear Antibody Positive
	Autoimmune Thyroiditis
	Cholestasis
	Cytolytic Hepatitis
	Drug Specific Antibody Present
	Factor V Deficiency
	Gait Disturbance
	Hepatic Cirrhosis
	Hepatitis
	Hepatomegaly
	Hyaluronic Acid Increased

		Hypoalbuminaemia Laboratory Test Abnormal Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhabdomyolysis Serum Ferritin Increased Smooth Muscle Antibody Positive Thrombin Time Prolonged	Health Professional Other	Ogast (Lansoprazole) Domperidone (Domperidone) Lescol (Fluvastatin Sodium) (Tablets)	PS SS SS		ORAL
40 MG, ORAL;							
80 MG							
				Vioxx (Rofecoxib)	SS		
				Di-Antalvic (Aporex)	SS		
				Sectral (Acebutolol Hydrochloride) (200 Milligram, Tablets)	SS		ORAL
100 MG, ORAL							

Date:08/20/04ISR Number: 4429679-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Drug Ineffective		[Therapy Unspecified]	C		
UNKNOWN						
	Emotional Distress					
UNKNOWN						
	Haemorrhoids		Depakote	C		
UNKNOWN						
	Hyperglycaemia		Nexium	C		
UNKNOWN						
	Lumbar Radiculopathy		Zestril	C		
UNKNOWN						
	Myocardial Infarction		Lithium Carbonate	C		
UNKNOWN						
	Upper Respiratory Tract Infection		Robaxin	C		
UNKNOWN						

Date:08/20/04ISR Number: 4430022-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Strangulated Hernia
	Acute Prerenal Failure
	Anaemia
	Antinuclear Antibody Positive
	Arrhythmia Supraventricular
	Atherosclerosis
	Benign Prostatic Hyperplasia
	Biopsy Stomach Abnormal
	Blood Creatine Increased
	Blood Glucose Increased
	Blood Pressure Systolic Increased
	Blood Sodium Decreased
	Blood Urea Increased
	Bundle Branch Block Left
	Bundle Branch Block Right
	Cardiac Failure Congestive
	Carotid Bruit
	Carpal Tunnel Syndrome

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cerumen Impaction Colonic Polyp Constipation					
244	DAY	Deafness Neurosensory	Health	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Dehydration	Professional	Vicodin Tablets	C		
UNKNOWN		Diarrhoea		Zyloprim	C		
UNKNOWN		Diastolic Dysfunction		Xanax	C		
UNKNOWN		Eustachian Tube		Ecotrin	C		
UNKNOWN		Dysfunction		Aspirin	C		
UNKNOWN		Facet Joint Syndrome		Lipitor	C		
UNKNOWN		Faecal Occult Blood		Ultram	C		
UNKNOWN		Positive		Carisoprodol	C		
UNKNOWN		Gait Disturbance		Vasotec	C		
UNKNOWN		Gastric Ulcer		Micronase	C		
UNKNOWN		Gastric Ulcer Haemorrhage		Prevacid	C		
UNKNOWN		Gastritis		Glucophage	C		
UNKNOWN		Gastritis Erosive		Centrum	C		
UNKNOWN		Gastroenteritis Gastrointestinal Disorder Haematocrit Decreased Haemoglobin Decreased Haemorrhoids Hiatus Hernia Hypoacusis Incisional Hernia, Obstructive Intervertebral Disc Degeneration Limb Injury Melaena Microcytic Anaemia Mitral Valve Incompetence					

Nausea
Pyrexia
Refusal Of Treatment By
Patient
Renal Failure
Rotator Cuff Syndrome
Scoliosis
Small Intestinal
Obstruction
Spinal Column Stenosis
Spinal Osteoarthritis
Sudden Hearing Loss
Thrombocytopenia
Tricuspid Valve
Incompetence
Upper Gastrointestinal
Haemorrhage
Urinary Retention
Ventricular Hypertrophy
Vomiting

Date:08/20/04ISR Number: 4430028-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Atelectasis

		Bronchitis					
		Contusion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Haemorrhage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		[Therapy			
		Haemorrhoids		Unspecified]	C		
UNKNOWN							
		Heart Rate Irregular		Antimicrobial			
		Myocardial Infarction		(Unspecified)	C		
UNKNOWN							
		Pain In Extremity		Soma	C		
UNKNOWN							
		Rib Fracture		Estrogens			
		Road Traffic Accident		(Unspecified)	C		
UNKNOWN		1036 DAY					
		Upper Gastrointestinal		Herbs (Unspecified)	C		
UNKNOWN							
		Haemorrhage		Imdur	C		
UNKNOWN							
		Urinary Tract Infection		Nitro	C		
UNKNOWN							
		Viral Infection					

Date:08/20/04ISR Number: 4430032-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01112
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anaemia	Professional	Synthroid	C		
UNKNOWN						
Initial or Prolonged	Anxiety					
Disability	Arteriosclerosis					
	Atrial Fibrillation					
	Bronchitis Acute					
	Carotid Artery Stenosis					
	Cerebrovascular Accident					
	Chest Pain					
	Constipation					
	Convulsion					
	Diarrhoea					
	Dysphagia					
	Emotional Distress					

Fall
Gastritis
Helicobacter Pylori
Identification Test
Positive
Humerus Fracture
Hypertension
Hypomagnesaemia
Meningioma
Mental Disorder Due To A
General Medical Condition
Neurodermatitis
Osteoporosis
Paraesthesia
Peripheral Vascular
Disorder
Tachycardia
Transient Ischaemic
Attack
Urinary Tract Infection
Weight Decreased

Date:08/20/04ISR Number: 4430034-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Abnormal Behaviour
Other	Accident
	Accident At Home
	Activated Partial Thromboplastin Time Prolonged
	Antiphospholipid Antibodies
	Anxiety
	Atrial Septal Defect
	Back Pain
	Balance Disorder
	Bipolar Disorder
	Bradycardia
	Breast Pain
	Cardiac Aneurysm
	Cardiac Disorder
	Cardiac Failure Congestive
	Cardiac Stress Test Abnormal
	Cellulitis
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Confusional State
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Dilatation Atrial
	Dilatation Ventricular
	Diverticulum
	Drug Dependence
	Dyspepsia
	Dyspnoea
	Emotional Distress
	Flashback
	Gait Disturbance
	Haemorrhoids
	Headache

Hypercoagulation
Hypertrophy Breast
Injury
Intermittent Claudication
Intracranial Aneurysm
Irritability
Lacunar Infarction
Major Depression
Micturition Urgency
Myocardial Infarction
Nervousness
Nightmare
Obsessive-Compulsive
Disorder
Oedema Peripheral

		Pain					
		Pain In Extremity					
		Pollakiuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Portal Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Post-Traumatic Stress	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Psychotic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Restlessness		Vioxx	SS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Vicodin Tablets	C		
UNKNOWN							
		Self-Injurious Ideation		Norvasc	C		
UNKNOWN							
		Spinal Osteoarthritis		Aspirin	C		
UNKNOWN		668 DAY					
		Stress		Zithromax	C		ORAL
4 DAY							
		Suicidal Ideation		Cogentin	C		ORAL
		Supraventricular		Tegretol-Xr	C		ORAL
		Extrasystoles		Monopril	C		ORAL
		Supraventricular		Neurontin	C		
UNKNOWN							
		Tachycardia		Lithium Carbonate	C		ORAL
		Thromboembolic Stroke		Lithium Carbonate	C		ORAL
		Transient Ischaemic		Claritin-D	C		
UNKNOWN							
		Attack		Ativan	C		
UNKNOWN							
		Tricuspid Valve		Ativan	C		
UNKNOWN							
		Incompetence		Zyprexa	C		ORAL
		Upper Respiratory Tract		Zyprexa	C		ORAL
		Infection		Zyprexa	C		ORAL
		Varices Oesophageal		Seroquel	C		
UNKNOWN							
		Ventricular Extrasystoles		Navane	C		ORAL
		Weight Increased		Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN		96 DAY					

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Angina Unstable
	Aortic Dilatation
	Aortic Valve Incompetence
	Blood Cholesterol Increased
	Blood Glucose Increased
	Bone Cyst
	Bronchitis
	Condition Aggravated
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Dilatation Atrial
	Dry Skin
	Emotional Distress
	Heart Rate Increased
	Hyperlipidaemia
	Hypertension
	Initial Insomnia
	Injury
	Myocardial Infarction
	Nocturia
	Oedema Peripheral
	Overdose

		Pericarditis					
		Pleurisy					
		Rheumatoid Arthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rotator Cuff Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Scar	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		White Blood Cell Count		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Wellbutrin	C		
UNKNOWN							
				Flexeril	C		ORAL
				Ambien	C		
UNKNOWN							
				Viagra	C		
UNKNOWN							
				Enbrel	C		
SUBCUTANEOUS							
				Pepcid	C		ORAL
				Folic Acid	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Plaquenil	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							

Date:08/20/04ISR Number: 4430041-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00491
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anaemia
	Asthenia
	Atherosclerosis Obliterans
	Atrophy
	Blood Pressure Systolic Increased
	Brain Scan Abnormal
	Bundle Branch Block Right
	Cardiac Failure
	Congestive

Cardiomyopathy
Cataract
Chest Pain
Cholelithiasis
Chronic Sinusitis
Confusional State
Dehydration
Delirium
Depression
Dizziness
Drug Hypersensitivity
Dry Gangrene
Dyspnoea
Fall
Fatigue
Gangrene
Gastric Ulcer
Gastritis
Glaucoma
Helicobacter Infection
Herpes Zoster
Hypoaesthesia
Hypokalaemia
Hypovolaemia

		Interstitial Lung Disease					
		Leg Amputation					
		Limb Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mastitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Meningioma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Albuterol Sulfate	C		
RESPIRATORY							
		Muscle Spasms					
(INHALATION)							
		Myocardial Infarction		Fosamax	C		ORAL
		Myopathy		Amlodipine Besylate	C		ORAL
		Nausea		Aspirin	C		ORAL
		Oedema Peripheral		Atorvastatin Calcium	C		
UNKNOWN							
		Oesophagitis		Beclomethasone			
		Orthostatic Hypotension		Dipropionate	C		
RESPIRATORY							
		Paraesthesia					
(INHALATION)							
		Peripheral Occlusive		Lotensin	C		
UNKNOWN							
		Disease		Calcium Carbonate	C		ORAL
		Pneumonia		Baycol	C		
UNKNOWN							
		Post Procedural Pain		Diphenhydramine			
		Pulmonary Embolism		Hydrochloride	C		ORAL
		Renal Cyst		Estrogens			
		Renal Failure Acute		(Unspecified)	C		ORAL
		Respiratory Distress		Folic Acid	C		ORAL
		Sinus Tachycardia		Hydrodiuril	C		ORAL
		Skin Ulcer		Hydroxychloroquine			
		Soft Tissue Injury		Sulfate	C		ORAL
		Supraventricular		Indocin			
		Extrasystoles		(Indomethacin)	C		
UNKNOWN							
		Syncope		Ipratropium Bromide	C		
UNKNOWN							
		Tachycardia		Isosorbide			
		Tachypnoea		Mononitrate	C		ORAL
		Transient Ischaemic		Misoprostol	C		ORAL
		Attack		Naproxen	C		ORAL
		Upper Gastrointestinal		Prednisone	C		ORAL
		Haemorrhage					
		Vasculitis					
		Ventricular Hypertrophy					
		Vomiting					

Weight Decreased

Date:08/20/04ISR Number: 4430045-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00133
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Fosamax	SS		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Alfacalcidol	C		ORAL		
			Calcium Carbonate	C		ORAL		

Date:08/20/04ISR Number: 4430049-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abdominal Pain Upper
	Alopecia
	Arrhythmia
	Blood Pressure Increased

	Cardiomegaly					
	Chest Pain					
	Cholecystitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cholelithiasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Chronic Fatigue Syndrome	Professional	[Therapy			
	Diverticulitis		Unspecified]	C		
UNKNOWN						
	Diverticulum		Insulin	C		
UNKNOWN						
	Diverticulum Intestinal					
	Dizziness					
	Drug Hypersensitivity					
	Dyspnoea					
	Emotional Distress					
	Empyema					
	Gout					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Headache					
	Hernia					
	Hypertension					
	Ischaemia					
	Large Intestinal Ulcer					
	Haemorrhage					
	Lobar Pneumonia					
	Multiple Allergies					
	Oedema					
	Oesophageal Ulcer					
	Haemorrhage					
	Osteoarthritis					
	Pleural Effusion					
	Pleural Fibrosis					
	Procedural Hypertension					
	Pulmonary Congestion					
	Renal Cyst					
	Rheumatoid Arthritis					
	Scoliosis					
	Sinus Headache					
	Vertigo					
	Weight Decreased					

Date:08/20/04ISR Number: 4430071-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Prerenal Failure
	Adverse Event
	Asthenia
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cataract Nuclear
	Chest Pain
	Diabetes Mellitus
	Dizziness
	Emotional Distress
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Gout

	Haemorrhage						
	Headache						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertensive Crisis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Hypertensive Heart Disease	Professional	[Therapy Unspecified]	C			UNKNOWN
	Hypovolaemia		[Therapy				
	Local Swelling		Unspecified]	C			UNKNOWN
	Major Depression		Lotrel	C		ORAL	
	Nausea		Celexa	C		ORAL	
	Oedema Peripheral		Maxzide	C			UNKNOWN
	Pyelonephritis		Lopressor	C		ORAL	
	Renal Failure Chronic		Nasonex	C			RESPIRATORY (INHALATION)
	Sepsis						
	Sinusitis		Nifedipine	C			UNKNOWN
	Sleep Disorder		Nitrostat	C			UNKNOWN
	Soft Tissue Infection						
	Urinary Tract Infection						

Date:08/20/04ISR Number: 4430079-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0408USA01664
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
	Chest Pain						

Date:08/20/04ISR Number: 4430083-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01717
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	

Disability	Blood Pressure Increased
	Cardiac Disorder
	Coordination Abnormal
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dizziness
	Gout
	Inner Ear Disorder
	Mental Status Changes
	Metabolic Syndrome
	Obesity
	Pollakiuria
	Ulcer
	Vertebrobasilar
	Insufficiency

Date:08/20/04ISR Number: 4430394-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT
Other	Drug Hypersensitivity
	Hypertension
	Injury
	Intestinal Obstruction
	Meningitis Viral
	Oesophageal Disorder

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/20/04ISR Number: 4430412-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01101060
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess		[Therapy Unspecified]	C				
	Arthralgia							
	Cellulitis		Aspirin	C				
	Cervicitis		Lipitor	C		ORAL		
	Chest Pain		Tiazac	C				
	Constipation		Detrol	C				
	Deep Vein Thrombosis		Meridia	C				
	Depression		Cardura	C				
	Face Oedema		Motrin	C				
	Gastroenteritis		Zestril	C				
	Generalised Oedema							
	Haematemesis							
	Headache							
	Hyperlipidaemia							
	Iliac Vein Occlusion							
	Postoperative Infection							
	Productive Cough							
	Pulmonary Granuloma							
	Sleep Apnoea Syndrome							
	Uterine Leiomyoma							
	Venous Stenosis							
	Wheezing							
	Wound Dehiscence							

Date:08/20/04ISR Number: 4430414-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Valve Incompetence
	Choking
	Dehydration
	Dementia
	Depression
	Diverticulum
	Duodenitis
	Erosive Duodenitis
	Fatigue
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Heart Rate Increased
	Heat Stroke
	Hiatus Hernia
	Hypertension
	Hypoacusis
	Lacunar Infarction
	Mitral Valve Incompetence

	Oesophageal Rupture						
	Pancreatitis						
	Renal Cyst	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Supraventricular		Vioxx	PS	Merck & Co., Inc	ORAL		
	Extrasystoles		Aspirin	C				UNKNOWN
	Thromboembolic Stroke		Restoril	C				UNKNOWN
	Transient Ischaemic							
	Attack							
	Weight Decreased							

Date:08/20/04ISR Number: 4430418-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Ms Contin	SS				UNKNOWN
Other	Balance Disorder		Aspirin	C				UNKNOWN
	Complex Partial Seizures		Vitamins					
	Constipation		(Unspecified)	C				UNKNOWN
	Depressed Level Of		Tegretol	C				UNKNOWN
	Consciousness		Depakote	C				UNKNOWN
	Depressed Mood							
	Diarrhoea							
	Dizziness							
	Drug Hypersensitivity							
	Drug Ineffective							
	Drug Level Decreased							
	Emotional Distress							
	Fall							
	Fatigue							
	Gingival Hyperplasia							
	Headache							
	Hepatic Enzyme Increased							
	Hepatic Steatosis							
	Hyperlipidaemia							
	Hypernatraemia							

Hypertension
Hypoacusis
Myocardial Infarction
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Periarthritis
Psoriasis
Rash
Sepsis
Spinal Osteoarthritis
Synovitis
Tinnitus
Vaginal Infection
Weight Increased
Wrist Fracture

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/04ISR Number: 4430422-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Benign Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Tylenol	C			UNKNOWN	
	Coronary Artery Restenosis		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN	
	Depression		Xanax	C			UNKNOWN	
	Dermatitis		Aspirin	C			UNKNOWN	
	Epicondylitis		Librax Capsules	C			UNKNOWN	
	Exostosis		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Gastroenteritis Viral		Allegra	C			UNKNOWN	
	Generalised Anxiety Disorder		Prilosec	C			UNKNOWN	
	Gout		Zantac	C			UNKNOWN	
	Haematoma							
	Hypercholesterolaemia							
	Hypertension							
	Insomnia							
	Intervertebral Disc Degeneration							
	Lung Neoplasm							
	Myocardial Infarction							
	Myositis							
	Osteochondrosis							
	Pain In Extremity							
	Radiculitis Cervical							
	Rectal Haemorrhage							
	Rotator Cuff Syndrome							
	Sleep Disorder							
	Spinal Osteoarthritis							
	Tendonitis							
	Tinnitus							

Urinary Tract Infection

Date:08/20/04ISR Number: 4430424-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anaemia
	Arrhythmia
	Asthenia
	Asthma
	Blood Pressure Increased
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Fatigue Syndrome
	Cyst
	Dizziness
	Drug Ineffective
	Dyspnoea
	Emotional Distress
	Hyperlipidaemia
	Hypertension
	Hypoaesthesia

Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hypokalaemia							
Influenza							
Intervertebral Disc Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL		
Intervertebral Disc Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL		
		Lortab	C			UNKNOWN	
Joint Swelling		Albuterol	C			UNKNOWN	
Large Intestinal Ulcer Haemorrhage		Proventil	C			RESPIRATORY (INHALATION)	
Loss Of Consciousness		Micardis	C			UNKNOWN	
Meniscus Lesion		Celebrex	C			UNKNOWN	
Musculoskeletal Discomfort		Micardis Hct	C			UNKNOWN	
		Sular	C			UNKNOWN	4 DAY
Nasopharyngitis Nausea Neck Pain Neuropathy Peripheral Oedema Oesophageal Ulcer Haemorrhage Osteoarthritis Pain In Extremity Paraesthesia Post Procedural Nausea Post Procedural Pain Road Traffic Accident Spinal Disorder Spinal Osteoarthritis Stomach Discomfort Strabismus Upper Respiratory Tract Infection Vitamin B12 Deficiency		Sular	C		ORAL		

Date:08/20/04ISR Number: 4430428-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00060
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening			Amlodipine Besylate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atenolol	C		ORAL		
			Atorvastatin Calcium	C		ORAL		

Date:08/20/04ISR Number: 4430429-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Unstable
Other	Arthritis
	Blood Glucose Increased
	Blood Pressure Abnormal
	Cardiac Valve Disease
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Dysphagia

		Emotional Distress					
		Fatigue					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Tylenol Extra			
		Hypertension		Strength	C		
UNKNOWN							
		Irritable Bowel Syndrome		Percocet	C		
UNKNOWN							
		Myocardial Infarction		Aspirin	C		
UNKNOWN							
		Oedema Peripheral		Soma	C		
UNKNOWN							
		Pain		Cardizem Cd	C		
UNKNOWN							
		Post Procedural Haematoma		Ferrous Sulfate	C		
UNKNOWN							
		Post Procedural		Lasix (Furosemide)	C		
UNKNOWN							
		Haemorrhage		Lasix (Furosemide)	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Lasix (Furosemide)	C		
UNKNOWN							
		Snoring		Aleve	C		
UNKNOWN							
		Tremor		Nitroglycerin	C		
UNKNOWN							
		White Blood Cell Count		Paxil	C		
UNKNOWN							
		Increased		Paxil	C		
UNKNOWN		42 DAY					
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		145 DAY					
				K-Dur	C		
UNKNOWN							
				Accupril	C		
UNKNOWN		18 DAY					
				Accupril	C		
UNKNOWN		38 DAY					
				Accupril	C		
UNKNOWN		152 DAY					

Date:08/20/04ISR Number: 4430430-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01341
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tongue Ulceration		Lexapro	SS		ORAL		
			Lexapro	SS		ORAL		
			Zoloft	SS		ORAL		
			Topamax	SS			UNKNOWN	
			Nexium	C			UNKNOWN	
			Mirapex	C			UNKNOWN	
			Zocor	C		ORAL		

Date:08/20/04ISR Number: 4430431-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00109
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Cold		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Muscle Twitching							
	Tremor							

Date:08/20/04ISR Number: 4430434-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Hernia
Hospitalization -	Anaemia
Initial or Prolonged	Anorexia
Other	Anxiety
	Asthenia
	Bacterial Sepsis
	Bipolar I Disorder

		Chest Pain					
		Chills					
		Deep Vein Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Lipitor	C		
UNKNOWN							
		Flank Pain		Lipitor	C		
UNKNOWN							
		Gastritis		Avapro	C		
UNKNOWN							
		Hydronephrosis		Geodon	C		
UNKNOWN							
		Hydroureter		Prevacid	C		
UNKNOWN							
		Hypertension		Levoxyl	C		
UNKNOWN							
		Incisional Hernia		Prilosec	C		
UNKNOWN							
		Malaise		Paxil	C		
UNKNOWN							
		Metabolic Acidosis					
		Nausea					
		Nephrolithiasis					
		Pyrexia					
		Renal Atrophy					
		Renal Failure					
		Renal Failure Acute					
		Schizoaffective Disorder					
		Sepsis					
		Staphylococcal Infection					
		Ureteric Stenosis					
		Urinary Retention					
		Urinary Tract Infection					
		Urosepsis					
		Vomiting					
		Weight Increased					

Date:08/20/04ISR Number: 4430435-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00110
Age:82 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Gastric Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - Initial or Prolonged	Peritonitis Septic Shock	Aspirin	SS	ORAL

Date:08/20/04ISR Number: 4430436-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00235
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
	Carpal Tunnel Syndrome
	Chest Pain
	Conjunctivitis Infective
	Dyspnoea
	Ear Discomfort
	Emotional Distress
	Fatigue
	Gastroenteritis
	Hypotension
	Irritable Bowel Syndrome
	Migraine
	Nasal Congestion
	Nasal Sinus Drainage
	Nausea
	Otitis Media

		Pharyngitis Pharyngolaryngeal Pain Postnasal Drip	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Proctitis Herpes Productive Cough Rhinitis Allergic		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Sinusitis		Tylenol	C		
UNKNOWN							
		Vomiting		Darvocet-N	C		
UNKNOWN							
				Emergen C	C		
UNKNOWN							
				Astelin	C		
UNKNOWN							
				Meridia	C		
UNKNOWN							
				Valtrex	C		
UNKNOWN							
				Zomig	C		
UNKNOWN							
				Imitrex	C		
UNKNOWN							
				Stadol	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Anaprox	C		
UNKNOWN							

Date:08/20/04ISR Number: 4430437-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01059
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR							
		Platelet Count Decreased		Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/20/04ISR Number: 4430438-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0408ISR00029
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Dipyrone	C			UNKNOWN	

Date:08/20/04ISR Number: 4430440-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Proventil	C			UNKNOWN	
	Hypokalaemia		Aspirin	C			UNKNOWN	
	Large Intestine		Aspirin	C			UNKNOWN	
	Perforation		Coreg	C			UNKNOWN	
	Memory Impairment		Foltx	C			UNKNOWN	
	Muscle Spasms		Zestril	C			UNKNOWN	
	Myocardial Infarction		Niaspan	C			UNKNOWN	
	Pyrexia		Pravachol	C		ORAL	141 DAY	
	Umbilical Hernia		Pravachol	C		ORAL		
	Ventricular Tachycardia		Metamucil	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/20/04ISR Number: 4430441-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	73	DAY
Initial or Prolonged	Asthenia		Roxicet	C			UNKNOWN	799 DAY
Disability	Cholelithiasis		Proscar	C			UNKNOWN	
	Coronary Artery Disease		Zantac	C			UNKNOWN	
	Coronary Artery Occlusion							
	Hernia							
	Hypertension							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Panic Disorder							
	Syncope							

Date:08/21/04ISR Number: 4430644-2Report Type:Periodic Company Report #WAES 0305USA00539
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure	Health	Tab Vioxx	PS		ORAL	PO	
		Professional						
		Company						
		Representative						

Date:08/21/04ISR Number: 4430650-8Report Type:Periodic Company Report #WAES 0404USA02141
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis Aseptic	Health	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Professional					MG/DAILY/PO	
		Company						
		Representative						

Date:08/21/04ISR Number: 4430699-5Report Type:Periodic Company Report #WAES 0402USA00554
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion	Health Professional	Tab Vioxx Unk Phenobarbital	PS C		ORAL	PO	

Date:08/23/04ISR Number: 4430824-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02008
Age:88 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Acute Myocardial Infarction Arthralgia Blood Cholesterol Increased Bronchitis Chest Pain Coronary Artery Disease Dermatitis Contact Diabetes Mellitus Drug Hypersensitivity Dyspnoea

		Eye Pain Fall Gastroenteritis Viral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prostatic Specific Antigen Abnormal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vicodin Tablets	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:08/23/04ISR Number: 4430826-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Aortic Stenosis
	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coagulation Time
	Prolonged
	Colonic Polyp
	Coronary Artery Occlusion
	Dehydration
	Diabetic Foot
	Diabetic Retinopathy
	Diverticulum
	Emotional Distress
	Epistaxis
	Erectile Dysfunction
	Gouty Arthritis
	Hypothyroidism
	Injury
	Ischaemic Cardiomyopathy
	Mitral Valve Incompetence

Mitral Valve Prolapse
Myasthenia Gravis
Myocardial Infarction
Neuropathic Pain
Oedema Peripheral
Open Angle Glaucoma
Overdose
Palpitations
Peptic Ulcer
Peripheral Occlusive
Disease
Pulmonary Hypertension
Pulmonary Oedema
Renal Failure
Respiratory Failure
Sleep Apnoea Syndrome
Sleep Disorder
Syncope
Vascular Graft Occlusion
Vascular Occlusion

Ventricular Extrasystoles
Vitreous Haemorrhage

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Allopurinol	C		
UNKNOWN			Allopurinol	C		
UNKNOWN			Aspirin	C		
UNKNOWN			Lipitor	C		
UNKNOWN			Lotensin	C		
UNKNOWN			Coreg	C		
UNKNOWN			Celebrex	C		
UNKNOWN			Clopidogrel Bisulfate	C		
UNKNOWN			Cardizem	C		
UNKNOWN			Pepcid	C		
UNKNOWN			Fluvastatin Sodium	C		
UNKNOWN			Furosemide	C		
UNKNOWN			Neurontin	C		
UNKNOWN			Glipizide	C		
UNKNOWN			Glycine	C		
UNKNOWN			Insulin	C		
UNKNOWN			Glucophage	C		
UNKNOWN			Coumadin	C		
UNKNOWN			Trazodone Hydrochloride	C		
UNKNOWN			Spironolactone	C		

			Nitroglycerin	C		
UNKNOWN						
			Actos	C		
UNKNOWN						

Date:08/23/04ISR Number: 4430827-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Alopecia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anaemia		Remicade	C		
UNKNOWN						
Other	Arthritis		Injectable Gold			
	Arthropathy		(Unspecified)	C		
UNKNOWN						
	Bronchitis		[Therapy			
	Cardiac Disorder		Unspecified]	C		
UNKNOWN						
	Cardiac Flutter		Folic Acid	C		
UNKNOWN						
	Dysmenorrhoea		Methotrexate	C		
UNKNOWN						
	Emotional Distress		Methotrexate	C		
UNKNOWN						
	Headache					
	Menorrhagia					
	Nausea					
	Postoperative Ileus					
	Swelling					
	Uterine Leiomyoma					

Date:08/23/04ISR Number: 4430833-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Respiratory Failure
Initial or Prolonged	Anaphylactic Reaction
Other	Angioneurotic Oedema
	Aortic Atherosclerosis
	Asthenia

		Asthma					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiomegaly	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Pulmonary Disease		Aspirin	C		
UNKNOWN							
		Cytomegalovirus Colitis		Aspirin	C		
UNKNOWN							
		Deep Vein Thrombosis		Detrol	C		ORAL
		Diastolic Dysfunction		Lotensin	C		ORAL
		Disseminated		Zyrtec	C		ORAL
		Cytomegaloviral Infection		Flonase	C		
RESPIRATORY							
		Drug Ineffective					
(INHALATION)							
		Emotional Distress		Hydro-Chlor	C		
UNKNOWN							
		Epistaxis		Prednisone	C		ORAL
		Feeling Abnormal					
		Gastrointestinal Haemorrhage					
		Gastrooesophageal Reflux Disease					
		Heart Rate Irregular					
		Hepatic Enzyme Increased					
		Ileus					
		Intestinal Ischaemia					
		Leukocytosis					
		Muscle Spasms					
		Myopathy Steroid					
		Nosocomial Infection					
		Oedema Peripheral					
		Osteoarthritis					
		Pneumonia Cytomegaloviral					
		Pulmonary Oedema					
		Staphylococcal Infection					
		Swelling Face					
		Syphilis					

Date:08/23/04ISR Number: 4430834-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01717
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
Disability	Cardiac Disorder
	Coordination Abnormal
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dizziness
	Drug Ineffective
	Dry Skin
	Fibromyalgia
	Gout
	Inner Ear Disorder
	Mental Status Changes
	Metabolic Syndrome
	Obesity
	Pollakiuria
	Raynaud'S Phenomenon
	Sinusitis
	Ulcer
	Upper Respiratory Tract

Infection
Vertebrobasilar
Insufficiency

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/23/04ISR Number: 4430835-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		435 DAY
Initial or Prolonged	Congestive		Darvocet-N	C				UNKNOWN
Disability	Emotional Disorder		Albuterol	C				UNKNOWN
Other	Myocardial Infarction		Combivent	C				UNKNOWN
	Renal Failure		Metab-O-Lite	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Coreg	C				UNKNOWN
			Ceftin	C				UNKNOWN
			Prempro	C				UNKNOWN
			Theophylline	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Hydrodiuril	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Zestril	C				UNKNOWN

				Claritin	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Date:08/23/04ISR Number: 4430839-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00025
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oropharyngeal Swelling							
Disability								

Date:08/23/04ISR Number: 4430840-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00130
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Hypertensive Crisis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
			Valsartan	SS		ORAL		
			Hydrodiuril	C				
UNKNOWN								

Date:08/23/04ISR Number: 4430921-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02107
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain Upper
Other	Adverse Event
	Angioneurotic Oedema
	Anxiety
	Atrioventricular Block

		Second Degree Blood Creatine Phosphokinase Increased					
		Breast Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Bundle Branch Block		Tylenol	C		
UNKNOWN							
		Cellulitis		Lasix (Furosemide)	C		
UNKNOWN							
		Cerebrovascular Accident		Lasix (Furosemide)	C		
UNKNOWN							
		Chest Pain		Ginkgo Biloba Extract	C		
		Depression					
UNKNOWN							
		Dizziness		Coumadin	C		
UNKNOWN							
		Dyspepsia		Ginseng	C		
UNKNOWN							
		Epigastric Discomfort		Naproxen	C		
UNKNOWN							
		Fatigue		Klor-Con	C		
UNKNOWN							
		Hypertension		Slow-K	C		
UNKNOWN							
		Intervertebral Disc Degeneration Lipids Abnormal Nasal Congestion Nasopharyngitis Nausea Neck Pain Osteoarthritis Osteochondrosis Palpitations Paraesthesia Pleurisy Pulmonary Valve Incompetence Sinus Tachycardia Spinal Column Stenosis Throat Tightness Tricuspid Valve Incompetence Upper Respiratory Tract Infection Vaginal Mycosis Vomiting					

Date:08/23/04ISR Number: 4430923-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
	Bladder Prolapse	Professional	Aspirin	C				UNKNOWN
	Blood Pressure Increased		Diovan	C				UNKNOWN
	Cystocele		Premarin	C				UNKNOWN
	Headache							
	Injury							
	Lung Neoplasm							
	Ovarian Mass							
	Rectocele							
	Skin Lesion							
	Stress Incontinence							
	Therapy Non-Responder							
	Vaginal Prolapse							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/04ISR Number: 4430924-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vicodin Tablets	C			UNKNOWN	
	Blood Pressure Increased		Aspirin	C		ORAL		
	Cardiac Disorder		Lipitor	C		ORAL		
	Congestive Cardiomyopathy		Plavix	C		ORAL	41 DAY	
	Coronary Artery Disease		Plavix	C		ORAL		
	Coronary Artery Occlusion		Plavix	C		ORAL	41 DAY	
	Coronary Artery Restenosis		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Dilatation Atrial		Plavix	C		ORAL		
	Dizziness		Colace	C			UNKNOWN	
	Hypertension		Prevacid	C			UNKNOWN	
	Hypotension		Synthroid	C			UNKNOWN	
	Injury		Prinivil	C		ORAL		
	Ischaemic Cardiomyopathy		Zestril	C			UNKNOWN	
	Mitral Valve Incompetence							
	Musculoskeletal Discomfort							
	Myocardial Infarction							
	Prostatic Disorder							
	Rash							
	Scar							
	Sick Sinus Syndrome							
	Sinus Bradycardia							
	Therapy Non-Responder							

Date:08/23/04ISR Number: 4430925-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00140
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						
Hospitalization - Initial or Prolonged						

Date:08/23/04ISR Number: 4430927-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00145
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dementia		Vioxx	PS	Merck & Co., Inc	ORAL
			Aspirin	C		ORAL
			Atenolol	C		ORAL
			Digoxin	C		ORAL
			Furosemide	C		ORAL

Date:08/23/04ISR Number: 4430930-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01235
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
22 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY						

Date:08/23/04ISR Number: 4430931-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00154
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Etidronate Disodium	SS		ORAL		
	Hiatus Hernia		Acetaminophen And Codeine Phosphate	C				
	Oesophagitis							
	Portal Hypertensive		Amlodipine Besylate	C				
	Gastropathy		Folic Acid	C				
			Lansoprazole	C		ORAL		
			Thiamine	C		ORAL		
			Lansoprazole	C		ORAL		
			Hydroxyzine Hydrochloride	C		ORAL		
			Atenolol	C				
			Calcium Carbonate And Cholecalciferol	C		ORAL		

Date:08/23/04ISR Number: 4430932-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0408NOR00013
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Faeces Discoloured		Acetaminophen	C				
	Gastric Ulcer		Lactulose	C		ORAL		
	Helicobacter Infection		Mianserin Hydrochloride	C		ORAL		

Date:08/23/04ISR Number: 4430933-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00043
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antinuclear Antibody	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Positive	Professional	Acebutolol		
	Autoimmune Thyroiditis		Hydrochloride	SS	ORAL
	Haemoglobin Decreased		Acetaminophen And		
	Hepatic Cirrhosis		Propoxyphene		
	Hepatitis		Hydrochloride	SS	ORAL
	Hepatomegaly		Domperidone	SS	ORAL
	Rhabdomyolysis		Fluvastatin Sodium	SS	ORAL
	Serum Ferritin Increased		Fluvastatin Sodium	SS	ORAL
			Lansoprazole	SS	ORAL

Date:08/23/04ISR Number: 4430934-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acrochordon
Initial or Prolonged	Angina Unstable
Other	Angiopathy
	Aortic Valve Incompetence
	Arteriosclerosis
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomegaly
	Cerebral Atrophy

		Cerebral Ischaemia					
		Coagulation Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Corneal Deposits	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Cystitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Midrin	C		
UNKNOWN							
		Diarrhoea		Elavil	C		ORAL
		Eye Haemorrhage		Norvasc	C		
UNKNOWN							
		Fatigue		Effexor	C		
UNKNOWN							
		Fluid Retention		Celexa	C		
UNKNOWN							
		Gallbladder Disorder		Premarin	C		
UNKNOWN							
		Gastrointestinal Disorder		Levothyroxine Sodium	C		
UNKNOWN							
		Gastrooesophageal Reflux		Robaxin	C		
UNKNOWN							
		Disease		Phenobarbital	C		
UNKNOWN							
		Hypercholesterolaemia					
		Hypertension					
		Hypertensive					
		Cardiomyopathy					
		Hypertonic Bladder					
		Immune System Disorder					
		Ischaemic Cardiomyopathy					
		Kidney Infection					
		Lung Disorder					
		Macular Degeneration					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Orthostatic Hypotension					
		Osteoporosis					
		Parathyroid Tumour Benign					
		Pericardial Effusion					
		Pulmonary Hypertension					
		Renal Mass					
		Spinal Osteoarthritis					
		Supraventricular					

Extrasystoles
Syncope
Urinary Tract Infection
Uterine Disorder

Date:08/23/04ISR Number: 4430935-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00142
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastrointestinal	Professional	Aspirin	SS		ORAL		
Initial or Prolonged	Haemorrhage		Enalapril Maleate	C		ORAL		

Date:08/23/04ISR Number: 4430936-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01410
Age:41 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
	Chills		Tylenol With Codeine					
	Constipation		#3	C		ORAL	14	DAY
	Fatigue		Zyrtec	C		ORAL		
	Nausea		Depakote	C		ORAL		
	Pain		Effexor Xr	C		ORAL		
	Pruritus		Nexium	C		ORAL		
	Pyrexia		Skelaxin	C		ORAL	14	DAY
	Vomiting							

Date:08/23/04ISR Number: 4430937-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00481
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/23/04ISR Number: 4430938-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01479
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
	Haemodialysis			C			UNKNOWN	
	Pericarditis Uraemic							

Date:08/23/04ISR Number: 4430939-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00165
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthenia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Benign Prostatic		Adipic Acid	C		
UNKNOWN						
	Hyperplasia		Proscar	C		ORAL
	Cardiac Failure		Neurontin	C		
UNKNOWN						
	Congestive		Synthroid	C		
UNKNOWN						
	Cellulitis		Lorazepam	C		
UNKNOWN						
	Diabetes Mellitus		Provigil	C		
UNKNOWN						
	Diarrhoea		Flomax			
	Erectile Dysfunction		(Morniflumate)	C		
UNKNOWN						
	Faecal Occult Blood		Macrobid	C		
UNKNOWN						
	Positive					
	Hypothyroidism					
	Joint Swelling					
	Lymphoproliferative					
	Disorder					
	Oedema Peripheral					
	Pain					
	Pelvic Fracture					
	Pneumonia Bacterial					
	Somnolence					
	Stress					
	Syncope					
	Urinary Retention					
	Urinary Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/23/04ISR Number: 4430940-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01993
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
Other	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY

Date:08/23/04ISR Number: 4430941-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Activated Partial Thromboplastin Time Prolonged
	Anaemia
	Anxiety
	Arteriospasm Coronary
	Biliary Neoplasm
	Blood Albumin Decreased
	Bronchiectasis
	Bursitis
	Cellulitis
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Collapse Of Lung
	Constipation
	Coronary Artery Disease
	Deep Vein Thrombosis
	Diverticulum
	Drug Hypersensitivity
	Drug Ineffective
	Duodenitis
	Emphysema
	Erosive Oesophagitis
	Excoriation
	Gastric Ulcer Haemorrhage
	Gastritis Haemorrhagic
	Hepatitis
	Hypotension
	Limb Discomfort

Lung Neoplasm
Malnutrition
Mycobacterium Avium
Complex Infection
Myocardial Infarction
Nausea
Oedema Peripheral
Oesophagitis Ulcerative
Oral Intake Reduced
Otitis Externa
Pain In Extremity
Pruritus
Pulmonary Calcification
Pulmonary Cavitation
Pulmonary Mass
Rash Morbilliform
Rash Vesicular
Upper Respiratory Tract
Infection

	Urinary Tract Infection						
	Visual Disturbance						
	Vomiting	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Fosamax	C			UNKNOWN	
			Amitriptyline Hydrochloride	C		ORAL		
			Norvasc	C		ORAL		
			Wellbutrin Sr	C		ORAL		
			Lampren	C		ORAL		
			Diphenhydramine Tannate	C		ORAL		
			Docusate Sodium	C		ORAL		
			Premarin	C		ORAL		
			Ethambutol Hydrochloride	C		ORAL		
			Robaxin	C		ORAL		
			Prilosec	C			UNKNOWN	
			Rifampin	C		ORAL		

Date:08/23/04ISR Number: 4432860-2Report Type:Expedited (15-DaCompany Report #UKP04000328
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Foreign	Didronel Pmo (Etidronate Disodium,/Calcium Carbonate Cyclical) Tablet, 400/1250mg	PS		ORAL	DAILY, ORAL	
	Blood Urea Decreased	Health Professional						
	Haematemesis	Other						
	Haemoglobin Decreased							
	Hiatus Hernia							
	Oesophagitis		Vioxx (Rofecoxib)	SS		ORAL	12.5 MG, DAILY, ORAL	
	Portal Hypertensive							
	Gastropathy		Lansoprazole (Lansoprazole)	C				

Calcichew D3	C
Hydroxyzine (Hydroxyzine)	C
Thiamine (Thiamine)	C
Atenolol (Atenolol)	C
Co-Codamol (Codeine Phosphate)	C
Folic Acid (Folic Acid)	C
Amlodipine (Amlodipine)	C

Date:08/24/04ISR Number: 4431138-0Report Type:Expedited (15-DaCompany Report #PHBS2004BR09721
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cystostomy Haemorrhage Urinary Tract	Health Professional	Exelon	PS	Novartis Sector: Pharma	ORAL	1.5 mg, BID	43920MIN
Other	Hepatic Encephalopathy		Exelon	SS	Novartis Sector: Pharma	ORAL	3 mg, Q12H	
			Vioxx	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/04ISR Number: 4431276-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00144
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Ear Infection							
	Feeling Cold							
	Haemorrhoids							
	Hiccups							
	Hot Flush							
	Hypertension							
	Hypoaesthesia							
	Muscle Strain							
	Post-Traumatic Headache							
	Rash							
	Road Traffic Accident							
	Tendonitis							

Date:08/24/04ISR Number: 4431310-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abdominal Pain Lower
	Abdominal Pain Upper
	Alopecia
	Arrhythmia
	Atelectasis
	Blood Pressure Increased
	Cardiomegaly
	Chest Pain
	Cholecystitis
	Cholelithiasis
	Chronic Fatigue Syndrome
	Computerised Tomogram
	Abnormal
	Diarrhoea

Diverticulitis
Dizziness
Drug Hypersensitivity
Dyspnoea
Emotional Distress
Empyema
Gout
Haematocrit Decreased
Haemoglobin Decreased
Headache
Hernia
Hypertension
Interstitial Lung Disease
Ischaemia
Large Intestinal Ulcer
Haemorrhage
Lung Infiltration
Nausea
Oedema

		Oesophageal Ulcer					
		Haemorrhage					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Pleural Fibrosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		[Therapy			
		Post Procedural		Unspecified]	C		
UNKNOWN							
		Complication		Insulin	C		
UNKNOWN							
		Postnasal Drip					
		Pulmonary Congestion					
		Pyrexia					
		Renal Cyst					
		Rheumatoid Arthritis					
		Scoliosis					
		Sinus Congestion					
		Sinus Headache					
		Vertigo					
		Weight Decreased					

Date:08/24/04ISR Number: 4431317-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Anxiety
	Asthenia
	Atherosclerosis
	Back Pain
	Balance Disorder
	Blood Pressure
	Inadequately Controlled
	Blood Pressure Increased
	Body Temperature
	Decreased
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Condition Aggravated
	Confusional State
	Convulsion
	Depression

Diabetes Mellitus
Non-Insulin-Dependent
Disorientation
Dizziness
Dyskinesia
Dyspepsia
Dysphagia
Dyspnoea
Epidermal Naevus
Eructation
Eye Irritation
Eye Pruritus
Fatigue
Hypoaesthesia
Insomnia
Irritability
Lacrimation Increased
Memory Impairment

		Mixed Hyperlipidaemia					
		Muscle Spasms					
		Muscle Twitching	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Night Sweats		Vioxx	SS	Merck & Co., Inc	ORAL
		Ocular Hyperaemia		Darvocet-N	C		
UNKNOWN							
		Oedema Peripheral		Norvasc	C		
UNKNOWN		395 DAY					
		Oesophageal Disorder		Lotrel	C		
UNKNOWN							
		Pain		Aspirin	C		
UNKNOWN							
		Pain In Extremity		Lipitor	C		
UNKNOWN		831 DAY					
		Paraesthesia		Lipitor	C		
UNKNOWN							
		Productive Cough		Lipitor	C		
UNKNOWN		831 DAY					
		Sleep Apnoea Syndrome		Lipitor	C		
UNKNOWN							
		Sputum Discoloured		Plavix	C		
UNKNOWN							
		Tremor		Clorazepate			
		Upper Respiratory Tract		Dipotassium	C		
UNKNOWN							
		Infection		Nexium	C		
UNKNOWN							
		Vascular Dementia		Zetia	C		ORAL
		Wheezing		Zetia	C		ORAL
				Tricor	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Glucovance	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Zocor	C		ORAL
				Zocor	C		ORAL
				Hydrodiuril	C		ORAL
				Ibuprofen	C		
UNKNOWN							

Robaxin	C	ORAL
Toprol Xl Tablets	C	ORAL
Toprol Xl Tablets	C	ORAL
Prilosec	C	
Paxil	C	

UNKNOWN

UNKNOWN

Date:08/24/04ISR Number: 4431331-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02101
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anaemia
Other	Anxiety
	Arthritis
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Cardiomyopathy
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Convulsion
	Coronary Artery Disease
	Decubitus Ulcer
	Diabetic Neuropathy
	Dysphagia
	Dyspnoea
	Electrolyte Imbalance
	Faecaloma

		Gastrointestinal Haemorrhage					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Herpes Zoster		Vioxx	PS	Merck & Co., Inc	ORAL
91	DAY						
		Hypertension		Vicodin Tablets	C		
UNKNOWN							
		Influenza		Aspirin	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Lipitor	C		
UNKNOWN							
		Liver Function Test		Capoten	C		
UNKNOWN							
		Abnormal		Plavix	C		
UNKNOWN							
		Lobar Pneumonia		Lasix (Furosemide			
		Malnutrition		Sodium)	C		
UNKNOWN							
		Myocardial Infarction		Amaryl	C		
UNKNOWN							
		Oedema		Glipizide	C		
UNKNOWN							
		Pericarditis		Prevacid	C		
UNKNOWN							
		Pneumonia Aspiration		Glucophage	C		
UNKNOWN							
		Post Herpetic Neuralgia		Lopressor	C		
UNKNOWN							
		Pulmonary Oedema		Nitrol			
		Pyrexia		(Nitroglycerin)	C		
UNKNOWN							
		Radiculitis Brachial		Altace	C		
UNKNOWN							
		Respiratory Failure					
		Rotator Cuff Syndrome					
		Sinus Disorder					
		Staphylococcal Infection					
		Stent Occlusion					
		Stress					
		Thrombocytopenia					
		Treatment Noncompliance					

Date:08/24/04ISR Number: 4431333-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0408NOR00010
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
			Trimethoprim	SS		ORAL		
	Blood Potassium Increased		Aspirin And Magnesium Oxide	C		ORAL		
	Blood Urea Increased		Estriol	C		ORAL		
	Glycosylated Haemoglobin Increased		Glipizide	C		ORAL		
	Hyperglycaemia		Levothyroxine Sodium	C		ORAL		
			Lovastatin	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Methenamine Hippurate	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

Date:08/24/04ISR Number: 4431335-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Arthralgia
	Balance Disorder
	Cellulitis
	Clostridium Colitis
	Decreased Appetite
	Dizziness

		Drug Ineffective Dyspepsia Feeling Jittery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gout		Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
		Mood Altered		Tylenol	C		
UNKNOWN							
		Osteoarthritis		Ascorbic Acid	C		
UNKNOWN							
		Pain		Aspirin	C		
UNKNOWN							
		Scoliosis		Atenolol	C		
UNKNOWN							
		Spondylolisthesis		Zocor	C		
UNKNOWN							
		Acquired		Vitamin E	C		
UNKNOWN							
				Coenzyme Q10	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Colchicine	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		
UNKNOWN							
				Omega-3	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/24/04ISR Number: 4431549-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	125	DAY
Initial or Prolonged	Deep Vein Thrombosis		Coricidin	C			UNKNOWN	
	Epistaxis		Allegra-D	C			UNKNOWN	
	Gastrooesophageal Reflux		Flonase	C			UNKNOWN	
	Disease		Westcort	C			UNKNOWN	
	Gynaecomastia		Singulair	C			UNKNOWN	
	Pulmonary Embolism		Elidel	C			UNKNOWN	
	Skin Ulcer							
	Sleep Apnoea Syndrome							
	Venous Stasis							

Date:08/24/04ISR Number: 4431556-0Report Type:Expedited (15-DaCompany Report #IE-MERCK-0408GBR00177
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C			UNKNOWN	

Date:08/24/04ISR Number: 4431557-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00036
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Rash Generalised		Bendroflumethiazide	C			UNKNOWN	
	Wound Infection		Enalapril Maleate	C			UNKNOWN	
	Staphylococcal		Floxacillin	C			UNKNOWN	
	Wound Secretion		Levothyroxine Sodium	C			UNKNOWN	
			Paroxetine	C			UNKNOWN	

Date:08/24/04ISR Number: 4431558-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		573 DAY
Initial or Prolonged	Coagulopathy		Celebrex	C				UNKNOWN
Disability	Cough		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				UNKNOWN
	Dehydration							
	Depression							
	Haemorrhagic Stroke							
	Hemianopia Homonymous		Lasix (Furosemide)	C				UNKNOWN
	Nasal Congestion		Hydrocodone Hydrochloride	C				UNKNOWN
	Thrombocytopenia							
			Demadex	C				UNKNOWN
			Spironolactone	C				UNKNOWN
			Ibuprofen	C				UNKNOWN
			Lozol	C				UNKNOWN
			Synthroid	C				UNKNOWN

Date:08/24/04ISR Number: 4431562-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01304
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Synthroid	C				UNKNOWN
			Zocor	C				UNKNOWN
			Prilosec	C				UNKNOWN

Date:08/24/04ISR Number: 4431567-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0408NOR00012
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Uric Acid Increased		Vioxx	PS	Merck & Co., Inc	ORAL	39	DAY
Initial or Prolonged	Renal Failure Acute		Metformin	C		ORAL		

Date:08/24/04ISR Number: 4431568-7Report Type:Expedited (15-DaCompany Report #RO-MERCK-0408HUN00004
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Renal Failure							
Disability								

Date:08/24/04ISR Number: 4431569-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Other	Myocardial Infarction							

Date:08/24/04ISR Number: 4431572-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01616
Age: Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/24/04ISR Number: 4431600-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebellar Syndrome		Soma	C				
UNKNOWN								
	Cerebrovascular Accident		Lamisil	C				
UNKNOWN								
	Chest Pain		Motrin	C				
UNKNOWN								
	Choking							
	Chondromalacia							
	Coordination Abnormal							
	Depression							
	Dysphagia							
	Eye Irritation							
	Gait Disturbance							
	Hemiparesis							
	Hypertension							
	Impaired Driving Ability							
	Injury							
	Ischaemia							
	Joint Range Of Motion Decreased							
	Mastoiditis							
	Microangiopathy							
	Muscle Strain							
	Musculoskeletal Discomfort							
	Nausea							

Nervous System Disorder
Oedema Peripheral
Prothrombin Time
Prolonged
Sinus Polyp
Speech Disorder
Transient Ischaemic
Attack
Visual Acuity Reduced

Date:08/24/04ISR Number: 4433391-6Report Type:Expedited (15-DaCompany Report #200410493BNE
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Gastrointestinal Haemorrhage	Foreign Health Professional	Aspirin (Acetylsalicylic Acid)	PS		ORAL	150 MG, TOTAL	
	Renal Failure Acute	Other					DAILY, ORAL	
	Thrombosis		Rofecoxib	SS		ORAL	25 MG, TOTAL	

DAILY, ORAL

Co-Codamol	C		
Tramadol	C		
Cod Liver Oil	C		

Date:08/24/04ISR Number: 4433788-4Report Type:Expedited (15-DaCompany Report #LTI2004A00190
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Macrocytic Antinuclear Antibody Positive Autoimmune Thyroiditis Cholestasis Cytolytic Hepatitis Gait Disturbance Hepatic Cirrhosis Hepatomegaly Hyaluronic Acid Increased Prothrombin Time Ratio Increased Smooth Muscle Antibody Positive	Foreign Health Professional Other	Ogast (Lansoprazole)	PS			40 MG, ORAL; 80 MG. OCCLUSIVE DRESSING TECHNIQUE	
			Domperidone (Domperidone)	SS				
			Lescol (Fluvastatin Sodium) (Tablets)	SS				
			Vioxx (Rofecoxib)	SS				
			Di-Antalvic (Aporex)	SS				
			Sectral (Acebutolol Hydrochloride)	SS		ORAL	100 MG, ORAL	

Date:08/24/04ISR Number: 4433895-6Report Type:Direct Company Report #CTU 225485
Age:17 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chills Hyperhidrosis Hypothermia		Rofecoxib 25 Mg Merck	PS	Merck	ORAL	25 MG BID ORAL	
			Miralax	C				
			Vicodin	C				

Date:08/25/04ISR Number: 4431683-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA02799
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Aneurysm
Other	Arteriovenous Fistula
	Arthropathy
	Bundle Branch Block Left
	Calcinosis
	Chest Discomfort
	Coronary Artery Disease
	Dehydration
	Diverticulum Intestinal Haemorrhagic
	Emotional Distress
	Gastritis Atrophic
	Gastrooesophageal Reflux Disease
	Helicobacter Infection
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Neck Pain
	Neuropathy Peripheral

		Otitis Externa					
		Renal Cyst					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sciatica		Vioxx	PS	Merck & Co., Inc	ORAL
93	DAY						
		Scoliosis		Tylenol	C		
UNKNOWN							
		Spinal Column Stenosis		Ecotrin	C		
UNKNOWN							
		Stent Occlusion		Viagra	C		
UNKNOWN							
				Calan Sr	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Advil	C		
UNKNOWN							

Date:08/25/04ISR Number: 4432246-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/25/04ISR Number: 4432249-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00078
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
Other		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
		Back Pain		Lortab	C		
UNKNOWN							
		Bronchitis		Aspirin	C		
UNKNOWN							
		Chest Pain					
		Constipation					

Emotional Distress
Feeling Abnormal
Groin Pain
Hypercholesterolaemia
Hypertension
Influenza
Osteoarthritis
Overdose
Polyuria
Rectal Haemorrhage
Rotator Cuff Syndrome
Sexual Dysfunction
Upper Limb Fracture

Date:08/25/04ISR Number: 4432251-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00721
Age:36 YR Gender:Male I/FU:F

Outcome PT
Disability Anxiety
Arthralgia
Back Pain
Chondromalacia
Condyloma Acuminatum
Drug Ineffective
Heart Rate Increased
Hypoaesthesia
Joint Injury
Neck Injury
Overdose
Post-Traumatic Stress

	Disorder						
	Road Traffic Accident						
	Rotator Cuff Syndrome						
	Sensory Loss	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C			UNKNOWN	
			Neuroton	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Lithium Acetate	C			UNKNOWN	
			Zyprexa	C			UNKNOWN	
			Risperdal	C		ORAL		

Date:08/25/04ISR Number: 4432258-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02528
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Depression		Mylanta & Mylanta Ds	C			UNKNOWN	
	Fear		Herbs (Unspecified)	C			UNKNOWN	
	Myocardial Infarction		Prostata	C			UNKNOWN	
	Oedema Peripheral		Motrin	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Protonix	C			UNKNOWN	

Date:08/25/04ISR Number: 4432259-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00876
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Ultracet	C				
UNKNOWN								
Disability	Atrial Fibrillation		Aspirin	C				
UNKNOWN								
	Gastritis		Celebrex	C				
UNKNOWN								
	Loss Of Consciousness		Metoprolol-Bc	C				
UNKNOWN								
	Myocardial Infarction		Protonix	C				
UNKNOWN								
	Syncope							
	Upper Gastrointestinal Haemorrhage							

Date:08/25/04ISR Number: 4432891-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02539
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization -	Acidosis
Initial or Prolonged	Aortic Aneurysm
Disability	Aortic Valve Incompetence
Other	Back Disorder
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiogenic Shock

		Carotid Artery Stenosis					
		Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hepatic Congestion		Hydrochlorothiazide	C		
UNKNOWN							
		Hepatic Necrosis		Prilosec	C		
UNKNOWN							
		Hypercalciuria					
		Hypotension					
		Injury					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Pleural Effusion					
		Renal Tubular Necrosis					
		Splenic Infarction					
		Thromboembolic Stroke					
		Transient Ischaemic Attack					
		Tricuspid Valve Incompetence					
		Ventricular Fibrillation					

Date:08/25/04ISR Number: 4432896-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Atelectasis
	Back Disorder
	Blood Cholesterol Increased
	Blood Ph Decreased
	Blood Pressure Decreased
	Blood Triglycerides Increased
	Bronchitis
	Bronchopneumonia
	Cardiomegaly
	Cardiovascular Disorder
	Cerebrovascular Accident
	Chest Pain

Chronic Fatigue Syndrome
Clostridial Infection
Clostridium Colitis
Convulsion
Depression
Dizziness
Emotional Distress
Fatigue
Fibrosis
Fluid Retention
Gastrooesophageal Reflux
Disease
Haematochezia
Headache
Hyperlipidaemia
Hypokalaemia
Hypotension
Hypoxia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Ileus					
		Intervertebral Disc Protrusion					
560	DAY	Lobar Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Lumbar Radiculopathy		Alprazolam	C		
UNKNOWN		Malaise		Amitriptyline Hydrochloride	C		
UNKNOWN		Mitral Valve Incompetence					
UNKNOWN		Mitral Valve Prolapse		Amitriptyline Hydrochloride	C		
UNKNOWN		Myocardial Infarction					
UNKNOWN		Nephrolithiasis		Celexa	C		
UNKNOWN		Oedema		Lexapro	C		
UNKNOWN		Oedema Peripheral		Nexium	C		
UNKNOWN		Pneumonia		Lasix (Furosemide)	C		
UNKNOWN		Pneumonia Aspiration		Zanaflex	C		
UNKNOWN		Pneumonia Pneumococcal		Ambien	C		
UNKNOWN		Radiculitis		Diovan	C		
UNKNOWN		Rash		Ultram	C		
UNKNOWN		Renal Failure Acute		Torsemide	C		
UNKNOWN		Respiratory Failure		Lasix (Furosemide)	C		
UNKNOWN		Rhabdomyolysis		Neurontin	C		
UNKNOWN		Sinus Tachycardia		Zaroxolyn	C		
UNKNOWN		Sinusitis		Aleve	C		
UNKNOWN		Spinal Compression		Nortriptyline	C		
UNKNOWN		Fracture		Oxycontin	C		
UNKNOWN		Staphylococcal Infection		Potassium Chloride	C		
UNKNOWN		Streptococcal Infection					

Swelling

Date:08/25/04ISR Number: 4432910-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
	Cyst
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Emotional Distress
	Gastrooesophageal Reflux
	Disease
	Hiatus Hernia
	Ileal Ulcer
	Ileitis
	Intervertebral Disc
	Degeneration
	Large Intestinal
	Obstruction
	Large Intestinal Ulcer
	Large Intestine
	Perforation
	Metabolic Acidosis
	Multi-Organ Failure
	Necrotising Colitis
	Osteoarthritis
	Pleural Effusion
	Renal Cortical Necrosis
	Renal Cyst
	Renal Failure Acute
	Renal Tubular Necrosis
	Respiratory Failure

	Septic Shock Small Intestine Ulcer Vasospasm	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Wound Infection		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	15 DAY
			Ecotrin	C		ORAL	
			Lipitor	C			UNKNOWN
			Zebeta	C			UNKNOWN
			Ziac	C			UNKNOWN
			Vasotec	C		ORAL	
			Vasotec	C		ORAL	
			Hydrochlorothiazide	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Relafen	C			UNKNOWN

Date:08/25/04ISR Number: 4432912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Acute Stress Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Anaemia Anal Fissure Atherosclerosis		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN
	Back Pain		Darvocet-N	C			UNKNOWN
	Benign Prostatic		Norvasc	C			UNKNOWN
	Hyperplasia		Celebrex	C			UNKNOWN
	Blindness		Clonidine	C			UNKNOWN
	Blood Creatine		Prozac	C			UNKNOWN

	Phosphokinase Mb	Flonase	C	
UNKNOWN				
	Increased	Lasix (Furosemide)	C	
UNKNOWN				
	Blood Urine Present	Neurontin	C	
UNKNOWN				
	Bronchitis Acute	Glucotrol Xl	C	
UNKNOWN				
	Cellulitis	Hyzaar	C	ORAL
	Chest Pain	Humulin N	C	
UNKNOWN				
	Diabetes Mellitus	Humulin N	C	
UNKNOWN				
	Inadequate Control	Humalog	C	
SUBCUTANEOUS				
	Diabetic Neuropathy	Humalog	C	
SUBCUTANEOUS				
	Diabetic Retinopathy	Imdur	C	
UNKNOWN				
	Emotional Distress	Claritin	C	
UNKNOWN				
	Fall	Avandia	C	
UNKNOWN				
	Gastritis Erosive	Glucophage	C	
UNKNOWN				
	Gastrointestinal	Methocarbamol	C	
UNKNOWN				
	Haemorrhage	Glyset	C	
UNKNOWN				
	Gastrooesophageal Reflux	Nitroquick	C	
SUBLINGUAL				
	Disease			
	Haematuria			
	Haemorrhoids			
	Hiatus Hernia			
	Leukocytosis			
	Localised Infection			
	Loss Of Consciousness			
	Microcytosis			
	Myocardial Ischaemia			
	Pharyngitis			
	Pneumonia			
	Prostatitis			
	Spinal Column Stenosis			
	Syncope			
	Urethral Discharge			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/25/04ISR Number: 4432915-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01311
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/25/04ISR Number: 4432917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01641
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability Other	Oral Lichen Planus		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tylenol Extended Relief Caplets	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Cimetidine	C			UNKNOWN	
			Imitrex	C			UNKNOWN	
			Estradiol	C			UNKNOWN	
			Lorazepam	C			UNKNOWN	
			Paxil	C			UNKNOWN	

Date:08/25/04ISR Number: 4432921-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lymphoedema		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/25/04ISR Number: 4433754-9Report Type:Expedited (15-DaCompany Report #2004039285
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased	Consumer	Norvasc (Amlodipine)	PS		ORAL	(1 IN 1V D) ,	
	Blood Pressure Increased	Health						
	Drug Interaction	Professional	Rofecoxib (Refecoxib)	SS		ORAL	25 MG (25 MG,	
	Erythema							
	Heart Rate Decreased						1 IN 1 D),	
	Oedema							
	Rash		Atenolol (Atenolol)	SS		ORAL	ORAL	
			Hydrochlorothiazide (Hydrochlorothiazide)	C				

Date:08/25/04ISR Number: 4433820-8Report Type:Direct Company Report #CTU 225658
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema		Rofecoxib	PS				
			Alendronate	C				
			Capsaicin	C				
			Famciclovir	C				
			Flunciclovir	C				
			Flunisolide 250 Mcg/Menthol	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4433194-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		487 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		487 DAY
Disability	Arteriospasm Coronary		Darvocet-N	C				UNKNOWN
	Back Injury		Chondroitin	C				UNKNOWN
	Difficulty In Walking		Voltaren	C				UNKNOWN
	Dyspepsia		Evening Primrose Oil	C				UNKNOWN
	Intervertebral Disc		Glucosamine	C				UNKNOWN
	Displacement		Humibid	C				UNKNOWN
	Mitral Valve Incompetence		Entex La	C				UNKNOWN
	Neuralgia		Maxzide	C				UNKNOWN
	Oedema		Prevacid	C				UNKNOWN
	Palpitations		Bactrim	C				UNKNOWN
	Sacroiliitis		Claritin-D	C				UNKNOWN
	Tachyarrhythmia		Nasonex	C			1758 DAY	UNKNOWN
	Tricuspid Valve		Naprosyn	C			764 DAY	UNKNOWN
	Incompetence		Inderal La	C				UNKNOWN
	Ventricular Hypokinesia		Inderal La	C				UNKNOWN
	Weight Increased		Pseudoephedrine	C				UNKNOWN
			Zantac	C				UNKNOWN

Date:08/26/04ISR Number: 4433636-2Report Type:Expedited (15-DaCompany Report #PHRM2004FR02378
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Macrocytic		Lescol	PS	Novartis Sector: Pharma	ORAL	80 mg/day	
	Antinuclear Antibody							
	Positive		Domperidone	SS		ORAL		
	Aplastic Anaemia		Ogast	SS		ORAL		
	Aspartate		Vioxx	SS		ORAL		
	Aminotransferase		Di-Antalvic	SS		ORAL		
	Increased		Sectral "Aventis"	SS		ORAL	100 mg/day	
	Autoimmune Hepatitis							
	Autoimmune Thyroiditis							
	Cholestasis							
	Coagulation Factor V							
	Level Decreased							
	Cytolytic Hepatitis							
	Hepatic Cirrhosis							
	Hepatomegaly							
	Hypoalbuminaemia							
	Prothrombin Level							
	Decreased							
	Renal Failure							
	Rhabdomyolysis							
	Serum Ferritin Increased							
	Smooth Muscle Antibody							
	Positive							

Date:08/26/04ISR Number: 4433726-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Other	Activities Of Daily
	Living Impaired
	Amnesia
	Anhedonia

		Anxiety					
		Aortic Valve Sclerosis					
		Asthenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
56	DAY						
		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
156	DAY						
		Increased		Aspirin	C		
UNKNOWN							
		Blood Pressure Systolic		Ultram	C		
UNKNOWN							
		Increased		Celebrex	C		
UNKNOWN							
		Cardiovascular Disorder					
		Carotid Artery Disease					
		Carotid Artery Stenosis					
		Cellulitis					
		Cerebrovascular Accident					
		Cervicobrachial Syndrome					
		Chest Pain					
		Dysarthria					
		Dyslipidaemia					
		Dyspepsia					
		Ejection Fraction					
		Decreased					
		Emotional Distress					
		Facial Palsy					
		Furuncle					
		Hyperhidrosis					
		Hypoaesthesia					
		Ischaemic Stroke					
		Mitral Valve Disease					
		Musculoskeletal					
		Discomfort					
		Pain					
		Paraesthesia					
		Renal Disorder					
		Renal Failure					
		Skin Ulcer					
		Spinal Osteoarthritis					
		Spondylitis					
		Stress					
		Tachycardia					
		Transient Ischaemic					
		Attack					

Date:08/26/04ISR Number: 4433738-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00103
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Cardiac Murmur
	Chromaturia
	Diarrhoea
	Dyspepsia
	Dyspnoea
	Dysuria
	Faeces Discoloured
	Flank Pain
	Gastritis
	Headache
	Heart Rate Irregular
	Hypertension
	Nodule

		Orthopnoea					
		Panic Disorder					
		Rash	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Swelling		Vioxx	PS	Merck & Co., Inc	ORAL
		Systemic Lupus		Celebrex	C		
UNKNOWN							
		Erythematosus		Avalide	C		
UNKNOWN							
		Thrombosis		Prednisone	C		
UNKNOWN							
		Vasculitis					

Date:08/26/04ISR Number: 4433743-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
112 DAY							
		Anxiety		Darvocet-N	C		
UNKNOWN							
		Aortic Stenosis		Propranolol			
		Cardiac Disorder		Hydrochloride	C		
UNKNOWN							
		Depression					
		Dyspepsia					
		Gastric Disorder					
		Impaired Work Ability					
		Injury					
		Liver Function Test					
		Abnormal					
		Mitral Valve Stenosis					
		Myocardial Infarction					
		Thrombosis					

Date:08/26/04ISR Number: 4433748-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0408CHE00021
Age:42 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Exanthem		Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY							

Face Oedema	Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY				
	Doxycycline	C		ORAL
10 DAY				

Date:08/26/04ISR Number: 4433787-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Benign Prostatic Hyperplasia
	Choking
	Cough
	Depression
	Diverticulum
	Dysuria
	Erosive Duodenitis
	Fatigue
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hypertension
	Hypoacusis
	Oesophageal Rupture
	Pancreatitis

		Renal Cyst					
		Rhinorrhoea					
		Supraventricular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL
		Thromboembolic Stroke		Aspirin	C		
UNKNOWN							
		Transient Ischaemic		Restoril	C		
UNKNOWN							
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:08/26/04ISR Number: 4434323-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Affective Disorder		Yasmin	SS		
UNKNOWN	14 DAY					
Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetes Mellitus		Sandimmun	C		
UNKNOWN						
	Non-Insulin-Dependent		Sandimmun	C		
UNKNOWN						
	Dyspepsia		Prelone Syrup	C		
UNKNOWN						
	Eczema		Prednisone	C		
UNKNOWN						
	Gastritis		Prelone Syrup	C		
UNKNOWN						
	Haemorrhoidal Haemorrhage		Hormonal			
	Head Injury		Contraceptives			

	Headache	(Unspecified)	C
INTRAMUSCULAR			
	Heart Rate Irregular	Sandimmun	C
UNKNOWN			
	Hot Flush		
	Hypochromic Anaemia		
	Insomnia		
	Intracranial Venous Sinus Thrombosis		
	Joint Effusion		
	Migraine		
	Musculoskeletal Stiffness		
	Nausea		
	Neck Pain		
	Osteoarthritis		
	Pharyngolaryngeal Pain		
	Rash		
	Sinus Tachycardia		
	Subarachnoid Haemorrhage		
	Uterine Enlargement		
	Uterine Leiomyoma		
	Visual Disturbance		
	Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4434328-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01072444
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident	Professional	Hydrocodin	SS				
UNKNOWN								
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disturbance In Attention							
	Fatigue							
	Headache							
	Hypertension							
	Injury							
	Insomnia							
	Intervertebral Disc							
	Protrusion							
	Low Density Lipoprotein							
	Increased							
	Musculoskeletal Stiffness							
	Neck Pain							
	Paraesthesia							
	Thinking Abnormal							

Date:08/26/04ISR Number: 4434330-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01618
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiomegaly		Albuterol	C				
UNKNOWN								
	Cerebrovascular Accident		Verapamil	C				
UNKNOWN								
	Chest Pain		Tolinase	C				
UNKNOWN								
	Chronic Obstructive		Nitroglycerin	C				
UNKNOWN								
	Pulmonary Disease							
	Coronary Artery Disease							
	Dyspepsia							
	Dyspnoea							
	Hyperhidrosis							
	Hypertension							

Intervertebral Disc
Displacement
Limb Discomfort
Lumbar Radiculopathy
Lymphadenitis
Musculoskeletal Chest
Pain
Myalgia
Myocardial Infarction
Oedema Peripheral
Pain In Extremity
Palpitations
Paronychia
Productive Cough
Pyrexia
Radiculopathy
Respiratory Tract
Infection
Sciatica
Therapy Non-Responder
Treatment Noncompliance
Varicose Vein

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4434335-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	138 DAY	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	138 DAY	
	Arrhythmia		[Therapy Unspecified]	C			UNKNOWN	
	Cardiac Failure							
	Congestive		Tylenol	C			UNKNOWN	
	Cerebrovascular Accident		Phoslo	C			UNKNOWN	
	Chest Pain		Digoxin	C			UNKNOWN	48 DAY
	Condition Aggravated		Digoxin	C			UNKNOWN	
	Constipation		Digoxin	C			UNKNOWN	
	Dizziness		Terazosin Hydrochloride	C			UNKNOWN	
	Feeling Abnormal							
	Feeling Hot		Cardizem	C			UNKNOWN	
	Hyperhidrosis		Epogen	C			UNKNOWN	
	Hyperlipidaemia		Lasix (Furosemide)	C			UNKNOWN	
	Hypertension		Apresoline	C			UNKNOWN	
	Ingrowing Nail		Infed	C			UNKNOWN	
	Injury		Zemplar	C			UNKNOWN	
	Malaise							
	Onychomycosis							
	Palpitations							
	Renal Failure Chronic							
	Skin Lesion							
	Urinary Tract Infection							

Date:08/26/04ISR Number: 4434337-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Cardiac Murmur
	Cerebral Atherosclerosis
	Cerebrovascular Accident
	Coronary Artery Disease
	Dilatation Atrial
	Dysphagia
	Ear Pain
	Epistaxis
	Facial Pain
	Haematocrit Decreased
	Haemoglobin Decreased
	Haemorrhage
	Hypertension
	Injury
	International Normalised
	Ratio Increased
	Lacunar Infarction
	Microangiopathy
	Muscle Spasms
	Myalgia
	Osteoarthritis
	Pain In Jaw
	Pleural Fibrosis
	Polymyalgia Rheumatica
	Productive Cough
	Prothrombin Time
	Prolonged
	Renal Injury

Dose	Duration	Rheumatoid Arthritis Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN				Betaxolol Ophthalmic Solution	C		
UNKNOWN				Calcitonin	C		
UNKNOWN				Digoxin	C		
UNKNOWN				Docusate Sodium	C		
OPHTHALMIC				Trusopt	C		
UNKNOWN				Vitamin E	C		
UNKNOWN	1284 DAY			Warfarin	C		
UNKNOWN				Zocor	C		
UNKNOWN				Folic Acid	C		
UNKNOWN	1680 DAY			Lasix (Furosemide)	C		
UNKNOWN				Isosorbide	C		
UNKNOWN				Potassium (Unspecified)	C		
UNKNOWN				Psyllium Husk	C		

Date:08/26/04ISR Number: 4434338-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
	Acute Prerenal Failure
	Aortic Valve Disease
	Aortic Valve Incompetence
	Asthenia
	Back Pain

Bundle Branch Block Left
Cardiac Disorder
Cardiac Failure
Congestive
Cardiomegaly
Change Of Bowel Habit
Chest Pain
Chills
Constipation
Contusion
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Ostial Stenosis
Depression
Diarrhoea
Dilatation Ventricular
Dizziness
Dyspnoea Exertional
Ejection Fraction
Decreased
Eye Pain
Fall
Fatigue
Glaucoma
Haematocrit Decreased
Haemoglobin Decreased
Hyperlipidaemia
Hypertension
Hypotension

		Ischaemic Cardiomyopathy					
		Joint Sprain					
		Mitral Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Calcification		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Disease		Lasix (Furosemide)	SS		
UNKNOWN							
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Lasix (Furosemide)	SS		
INTRAVENOUS							
		Nephropathy Toxic		Vioxx	SS	Merck & Co., Inc	ORAL
		Ocular Hyperaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oral Fungal Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Orthostatic Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Oxygen Saturation		Plavix	C		
UNKNOWN							
		Decreased		Advil	C		
UNKNOWN							
		Pericardial Effusion		Lopressor	C		
UNKNOWN							
		Pleural Effusion		Timoptic	C		
OPHTHALMIC							
		Pneumonitis		Zocor	C		ORAL
2	MON						
		Procedural Hypotension		Zocor	C		ORAL
		Productive Cough		Pilocarpine	C		
UNKNOWN							
		Pulmonary Oedema		Salagen Tablets	C		
UNKNOWN							
		Pulmonary Valve		Salagen Tablets	C		
UNKNOWN							
		Incompetence		Centrum	C		
UNKNOWN							
		Pyrexia		Lotemax	C		
OPHTHALMIC							
		Renal Failure		Plaquenil	C		
UNKNOWN							
		Respiratory Distress		Femhrt	C		
UNKNOWN							
		Rosacea					
		Rotator Cuff Syndrome					
		Sputum Discoloured					
		Tendonitis					
		Tooth Injury					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					

Ventricular Hypokinesia
Visual Acuity Reduced

Date:08/26/04ISR Number: 4434343-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Aspirin	C			UNKNOWN	
	Emotional Distress		Lipitor	C		ORAL		
	Hypertension		Captopril	C		ORAL		
	Myalgia		Captopril	C			UNKNOWN	
	Myocardial Infarction		Baycol	C		ORAL		
	Pain In Extremity		Baycol	C		ORAL		
			Estrogens (Unspecified)	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Hydrodiuril	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Claritin	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Aleve	C			UNKNOWN	
			Nitroquick	C			SUBLINGUAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4434344-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00174
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia Swelling Face Swollen Tongue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/26/04ISR Number: 4434348-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00364
Age:94 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/26/04ISR Number: 4434349-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tenormin	C				
UNKNOWN								
Disability	Cerebrovascular Accident		Zoloft	C				
UNKNOWN								
	Emotional Distress		Estrogens (Unspecified)	C				
UNKNOWN								

Date:08/26/04ISR Number: 4434350-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01458
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lotrel	C				
UNKNOWN								

Date:08/26/04ISR Number: 4434351-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01484
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Feeling Hot		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Rash		Atenolol	C				UNKNOWN
	Vomiting		Statin (Unspecified)	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN

Date:08/26/04ISR Number: 4434353-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anxiety
	Arthralgia
	Benign Neoplasm Of Skin
	Blister
	Depression
	Drug Hypersensitivity
	Emotional Distress
	Faeces Discoloured
	Furuncle
	Gastric Disorder

	Gastrooesophageal Reflux Disease						
	Hyperkeratosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neck Pain		Atenolol	C			UNKNOWN
	Oedema Peripheral		Celebrex	C			UNKNOWN
	Road Traffic Accident		Flexeril	C			UNKNOWN
	Skin Papilloma		Arthrotec	C		ORAL	
	Sleep Apnoea Syndrome		Hydrodiuril	C		ORAL	
	Tooth Disorder						

Date:08/26/04ISR Number: 4434354-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01464
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Congestive						

Date:08/26/04ISR Number: 4434356-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper
	Alopecia
	Amnesia
	Arthralgia
	Cardiac Murmur
	Carpal Tunnel Syndrome
	Chondromalacia
	Contusion
	Delirium
	Disability
	Dyspnoea
	Electrocardiogram St Segment Abnormal
	Emotional Distress

Essential Hypertension
Fatigue
Fibromyalgia
Gastric Disorder
Haemorrhage
Headache
Hypoaesthesia
Keloid Scar
Major Depression
Meniscus Lesion
Migraine Without Aura
Monarthritis
Nausea
Neck Pain
Neoplasm Malignant
Non-Cardiac Chest Pain
Osteoarthritis
Pain In Extremity
Palpitations
Panic Disorder With
Agoraphobia
Paraesthesia

		Peptic Ulcer					
		Rotator Cuff Syndrome					
		Skin Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Swelling		Vioxx	PS	Merck & Co., Inc	ORAL
		Synovitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tenosynovitis		Elavil	C		
UNKNOWN							
		Tension Headache		Norvasc	C		
UNKNOWN							
		Transient Ischaemic		Effexor	C		
UNKNOWN							
		Attack		Ultram	C		
UNKNOWN							
		Urinary Tract Disorder		Hydrocodone			
		Urine Odour Abnormal		Bitartrate	C		
UNKNOWN							
		Vomiting		Propranolol			
				Hydrochloride	C		
UNKNOWN							

Date:08/26/04ISR Number: 4434429-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01985
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Death		[Therapy			
Other	Dyspnoea		Unspecified]	C		
UNKNOWN						
	Epigastric Discomfort		Tylenol	C		
UNKNOWN						
	Myocardial Infarction		Ventolin (Albuterol)	C		
UNKNOWN						
	Stomach Discomfort		Mylanta & Mylanta Ds	C		
UNKNOWN						
	Vomiting		Celebrex	C		
UNKNOWN						
			Catapres	C		
UNKNOWN						
			Pepcid	C		ORAL
			Dyazide	C		
UNKNOWN						

			Motrin	C		
UNKNOWN						
			Orudis	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						
			Cytotec	C		
UNKNOWN						
			Naproxen	C		
UNKNOWN						
			Procardia	C		
UNKNOWN						
			Xenical	C		
UNKNOWN						
			Actifed	C		
UNKNOWN						
			Meridia	C		
UNKNOWN						
			Azmacort	C		
UNKNOWN						

Date:08/26/04ISR Number: 4434432-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0309DEU00168
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatitis Exfoliative		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY
			Diclofenac	C				
UNKNOWN		3	DAY					
			Atorvastatin Calcium	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Pantoprazole Sodium	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/26/04ISR Number: 4435073-3Report Type:Direct Company Report #CTU 225715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS			1 PER DAY	
	Feeling Abnormal							

Date:08/26/04ISR Number: 4435131-3Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Health Professional	Premarin (Conjugated Estrogens, Unspec, 0)	PS				
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS				
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS				
			Fluoxetine (Fluoxetine)	SS				
			Humira (Adalimumab)	SS				
			Methotrexate (Methotrexate, Unspec)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C				
			Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C				

Date:08/27/04ISR Number: 4434646-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02538
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Anxiety		Vicodin Tablets	C				UNKNOWN
Other	Hypertension		Effexor	C				UNKNOWN
	Myocardial Infarction		Estrogens (Unspecified)	C				UNKNOWN
	Stress							

Date:08/27/04ISR Number: 4434648-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01112
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
Disability	Arteriosclerosis
	Atrial Fibrillation

		Blood Thyroid Stimulating Hormone Decreased					
		Bronchitis Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Tylenol	C		
UNKNOWN							
		Chest Pain		Synthroid	C		
UNKNOWN							
		Constipation					
		Convulsion					
		Diarrhoea					
		Duodenitis					
		Dysphagia					
		Emotional Distress					
		Fall					
		Gastritis					
		Head Injury					
		Helicobacter Pylori					
		Identification Test					
		Positive					
		Humerus Fracture					
		Hypertension					
		Hypomagnesaemia					
		Meningioma					
		Mental Disorder Due To A					
		General Medical Condition					
		Neurodermatitis					
		Osteoporosis					
		Paraesthesia					
		Peripheral Vascular					
		Disorder					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vomiting					
		Weight Decreased					

Date:08/27/04ISR Number: 4435148-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Aortic Valve Sclerosis

Disability	Bronchitis Chronic
Other	Chest Pain
	Cholelithiasis
	Chronic Fatigue Syndrome
	Depression
	Dizziness
	Duodenitis
	Endocarditis
	Gallbladder Disorder
	Gastritis
	Gastrooesophageal Reflux
	Disease
	Generalised Anxiety
	Disorder
	Haematuria
	Herpes Zoster
	Hypertension
	Hypertensive Crisis

		Hypoacusis					
		Hypokalaemia					
		Irritable Bowel Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Laryngitis	Professional	Aspirin	C		
UNKNOWN							
		Migraine With Aura		Aspirin	C		
UNKNOWN							
		Mitral Valve		Tagamet	C		
UNKNOWN							
		Calcification		Premarin	C		
UNKNOWN							
		Mitral Valve Incompetence		Hytrin	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Estratab	C		
UNKNOWN							
		Panic Disorder		L-Thyroxin	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Ranitidine	C		
UNKNOWN							
		Tension Headache					
		Thalamus Haemorrhage					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					

Date:08/27/04ISR Number: 4435155-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Valve Incompetence	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Aspirin	C		ORAL
		Coronary Artery		Lipitor	C		ORAL
		Restenosis		Plavix	C		ORAL
41	DAY						
		Hypertension		Plavix	C		ORAL
		Hypotension		Plavix	C		ORAL
41	DAY						
		Ischaemic Cardiomyopathy		Plavix	C		ORAL
		Mitral Valve Incompetence		Flomax (Tamsulosin			

	Musculoskeletal	Hydrochloride)	C	
UNKNOWN				
	Discomfort	Colace	C	
UNKNOWN				
	Myocardial Infarction	Prevacid	C	
UNKNOWN				
	Prostatic Disorder	Synthroid	C	
UNKNOWN				
	Rash	Vicodin Tablets	C	
UNKNOWN				
	Sick Sinus Syndrome	Prinivil	C	ORAL
		Zestril	C	
UNKNOWN				

Date:08/27/04ISR Number: 4435159-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthropathy
Other	Back Pain
	Blood Pressure Increased
	Bronchitis
	Carpal Tunnel Syndrome
	Contusion
	Convulsion
	Cough
	Cystitis
	Depression
	Diarrhoea
	Diverticulum Intestinal
	Dizziness
	Emotional Distress

		Fall					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhoids	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Herpes Zoster	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypothyroidism		Propulsid	C		
UNKNOWN							
		Intervertebral Disc Displacement		Estrogens (Unspecified)	C		
UNKNOWN							
		Irritable Bowel Syndrome					
		Lumbar Radiculopathy					
		Meniscus Lesion					
		Muscle Spasms					
		Nervousness					
		Osteoarthritis					
		Paraesthesia					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Radius Fracture					
		Rhinorrhoea					
		Sinus Congestion					
		Stomach Discomfort					
		Weight Decreased					

Date:08/27/04ISR Number: 4435165-9Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0408USA01664
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Chest Pain	Professional				

Date:08/27/04ISR Number: 4435168-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408ZAF00037
Age:78 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Chest Pain					

Date:08/27/04ISR Number: 4435190-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aneurysm
Initial or Prolonged	Cardiac Disorder
Other	Cellulitis
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Duodenal Ulcer
	Haemorrhage
	Eating Disorder
	Emotional Distress
	Facial Palsy
	Foot Fracture
	Hemiparesis
	Hypertension
	Infarction
	Leg Amputation
	Pain In Extremity

		Peripheral Ischaemia Peripheral Vascular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Toe Deformity		Cyanocobalamin	C		
UNKNOWN							
		Transient Ischaemic Attack Wound Dehiscence					

Date:08/27/04ISR Number: 4435195-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
611 DAY							
Hospitalization -		Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
611 DAY							
Initial or Prolonged		Bipolar Disorder		Midrin	C		
UNKNOWN							
Disability		Blood Cholesterol		Tricor	C		
UNKNOWN							
		Increased		Neurontin	C		
UNKNOWN							
		Blood Triglycerides		Hydrochlorothiazide	C		
UNKNOWN							
		Increased		Zanaflex	C		
UNKNOWN							
		Cervicobrachial Syndrome Emotional Distress		Trazodone Hydrochloride	C		
UNKNOWN							
		Fatigue		Maxzide	C		
UNKNOWN							
		Hypertension Hypoaesthesia		Hydrocodone Hydrochloride	C		
UNKNOWN							
		Intervertebral Disc		Lidoderm	C		
UNKNOWN							
		Degeneration		Ativan	C		
UNKNOWN							
		Laboratory Test Abnormal		Remeron	C		
UNKNOWN							
		Menorrhagia					

Menstrual Disorder
Myofascial Pain Syndrome
Neck Pain
Oedema Peripheral
Pelvic Pain
Renal Failure
Tibia Fracture

Date:08/27/04ISR Number: 4435304-XReport Type:Direct Company Report #CTU 225790
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrasystoles		Vioxx	PS		ORAL	DAY ORAL	
			Synthroid	C				
			Ogen	C				

Date:08/27/04ISR Number: 4435516-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
Disability	Adnexa Uteri Mass
Other	Anxiety
	Azotaemia
	Blepharitis
	Candidiasis
	Cardiac Failure
	Congestive

		Cellulitis					
		Cervicitis					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401 DAY							
		Diarrhoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3 MON							
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
401 DAY							
		Endometrial Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Epistaxis		Vioxx	SS	Merck & Co., Inc	ORAL
		Fallopian Tube Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
3 MON							
		Fistula		Ventolin (Albuterol			
		Fluid Retention		Sulfate)	C		
UNKNOWN							
		Gastritis		Tenormin	C		
UNKNOWN							
		Helicobacter Pylori		Ultram	C		
UNKNOWN							
		Identification Test		Vasotec	C		ORAL
		Positive		Cenestin	C		
UNKNOWN							
		Hypertension		Lodine Xl	C		
UNKNOWN							
		Infection		Lasix (Furosemide			
		Irritable Bowel Syndrome		Sodium)	C		
UNKNOWN							
		Lower Extremity Mass		Ditropan	C		
UNKNOWN							
		Meniscus Lesion		K-Dur	C		
UNKNOWN							
		Mobility Decreased		Quinine Sulfate	C		
UNKNOWN							
		Mood Swings					
		Myocardial Infarction					
		Nervousness					
		Neuropathic Pain					
		Non-Cardiac Chest Pain					
		Osteoarthritis					
		Ovarian Fibrosis					
		Pain In Extremity					
		Palpitations					
		Peau D'Orange					
		Pharyngolaryngeal Pain					
		Pickwickian Syndrome					

Pneumonia
Post Procedural
Haemorrhage
Pulmonary Oedema
Retching
Supraventricular
Tachycardia
Upper Respiratory Tract
Infection
Urinary Tract Infection
Weight Increased

Date:08/27/04ISR Number: 4435522-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Allergic Sinusitis
Other	Aspiration
	Atelectasis
	Atrial Fibrillation
	Blood Triglycerides
	Increased
	Bone Marrow Depression
	Breast Tenderness
	Cardio-Respiratory Arrest

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coagulopathy Coronary Artery Disease Depression					
45	DAY	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Disseminated Intravascular Coagulation	Professional	Tylenol With Codeine #3	C		
UNKNOWN		Diverticulum		Percocet	C		
UNKNOWN		Dyspepsia		Ascorbic Acid	C		
UNKNOWN		Dyspnoea Exertional		Vitamin E	C		
UNKNOWN		Electrocardiogram		Zocor	C		
UNKNOWN		Abnormal		Beta Carotene	C		
UNKNOWN		Extradural Abscess		Centrum	C		
		Fatigue Fibrin D Dimer Increased Haematochezia Hepatic Function Abnormal Hyperlipidaemia Hypersensitivity Hypokalaemia Hypokinesia Hypotension Ileus Intervertebral Disc Disorder Intervertebral Discitis Mitral Valve Incompetence Multi-Organ Failure Myocardial Infarction Nausea Osteomyelitis Otitis Media Pancreatitis Pericardial Effusion Radiculitis Renal Failure Renal Tubular Necrosis Sepsis Thrombocytopenia					

Toxic Shock Syndrome
Upper Respiratory Tract
Infection
Urinary Tract Infection
Vaginal Haemorrhage
Ventricular Fibrillation
Ventricular Tachycardia

Date:08/27/04ISR Number: 4435523-2Report Type:Expedited (15-DaCompany Report #MY-MERCK-0408MYS00013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			[Therapy					
Other			Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/04ISR Number: 4435524-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02120
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arterial Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides Increased		[Therapy Unspecified]	C		
UNKNOWN						
	Coronary Artery Occlusion		Vicodin Tablets	C		
UNKNOWN						
	Dermal Cyst		Ultram	C		
UNKNOWN						
	Emotional Distress		Soma	C		
UNKNOWN						
	Erectile Dysfunction		Celebrex	C		
UNKNOWN						
	Fatigue					
	High Density Lipoprotein Decreased					
	Hypersensitivity					
	Inguinal Hernia					
	Injury					
	Muscle Tightness					
	Myocardial Infarction					
	Pneumonitis					
	Prostatic Specific Antigen Increased					

Date:08/27/04ISR Number: 4435525-6Report Type:Expedited (15-DaCompany Report #IE-MERCK-0408GBR00075
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 9 DAY	Cryptogenic Organizing	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 9 DAY	Pneumonia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other			[Therapy Unspecified]	C		
UNKNOWN						
			Albuterol Sulfate And Ipratropium			

UNKNOWN	Bromide	C	
	Fosamax	C	ORAL
	Budesonide	C	
UNKNOWN			
	Calcium Carbonate	C	
UNKNOWN			
	Citalopram	C	
UNKNOWN			
	Esomeprazole Magnesium	C	
UNKNOWN			
	Tramadol Hydrochloride	C	
UNKNOWN			
	Tinzaparin Sodium	C	
UNKNOWN			
	Fentanyl	C	
TOPICAL			
	Ferrous Sulfate	C	
UNKNOWN			
	Fluticasone Propionate	C	
UNKNOWN			
	Furosemide	C	
UNKNOWN			
	Piperacillin Sodium And Tazobactam Sodium	C	
UNKNOWN			
	Pramipexole	C	
UNKNOWN			
	Prednisolone	C	
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/27/04ISR Number: 4435526-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Abdominal Pain Upper	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Alopecia		[Therapy					
	Arrhythmia		Unspecified]	C				
UNKNOWN								
	Back Pain		Insulin	C				
UNKNOWN								
	Blood Pressure Increased							
	Breast Mass							
	Cardiomegaly							
	Chest Pain							
	Cholecystitis							
	Chronic Fatigue Syndrome							
	Chronic Obstructive							
	Pulmonary Disease							
	Diverticulitis							
	Drug Hypersensitivity							
	Dyspnoea							
	Emotional Distress							
	Gout							
	Hernia							
	Hypertension							
	Ischaemia							
	Large Intestinal Ulcer							
	Haemorrhage							
	Ligament Sprain							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Osteoarthritis							
	Osteopenia							
	Osteoporosis							
	Otorrhoea							
	Pleural Effusion							
	Pneumonia							
	Renal Cyst							
	Rheumatoid Arthritis							
	Scoliosis							
	Sleep Disorder							
	Temporomandibular Joint							
	Syndrome							

Vertigo
Weight Decreased

Date:08/27/04ISR Number: 4435528-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome PT
Other Abdominal Pain
Adrenal Adenoma
Angina Pectoris
Arthritis
Blood Cholesterol
Increased
Bronchitis
Cardiac Murmur
Cataract
Cellulitis
Chest Pain

		Chronic Fatigue Syndrome					
		Constipation					
		Cystitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis Glandularis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Tylenol	C		ORAL
		Dyspnoea		Fosamax	C		
UNKNOWN							
		Dyspnoea Paroxysmal		Tagamet	C		
UNKNOWN							
		Nocturnal		Pravachol	C		
UNKNOWN							
		Ear Infection					
		Electrocardiogram					
		Abnormal					
		Emotional Distress					
		Gastrointestinal Ulcer					
		Gastrooesophageal Reflux					
		Disease					
		Gingival Pain					
		Haematuria					
		Headache					
		Hypercholesterolaemia					
		Increased Tendency To					
		Bruise					
		Mitral Valve Incompetence					
		Nausea					
		Osteoporosis					
		Palpitations					
		Parotid Gland Enlargement					
		Peptic Ulcer					
		Rhinitis Allergic					
		Stress Incontinence					
		Thyroid Neoplasm					
		Tooth Abscess					
		Urethral Caruncle					
		Urinary Tract Infection					

Date:08/28/04ISR Number: 4435721-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0408FRA00043
Age:50 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Death	Acidosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY						
Hospitalization - Initial or Prolonged	Blood Glucose Increased	Professional	Amiloride And Furosemide	SS		ORAL
	Body Temperature Decreased		Amiloride And Furosemide	SS		ORAL
	Drug Ineffective		Atenolol	C		ORAL
	Feeling Abnormal		Betahistine Hydrochloride	C		ORAL
	Hyperkalaemia		Fenofibrate	C		ORAL
	Hyponatraemia		Fenofibrate	C		ORAL
	Osteoarthritis		Levothyroxine Sodium	C		ORAL
	Oxygen Saturation Decreased		Melilot And Rutin	C		ORAL
	Renal Failure Acute		Prednisone	C		ORAL

Date:08/28/04ISR Number: 4435722-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00187
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Wheezing		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
			Diazepam	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/28/04ISR Number: 4435731-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Left		[Therapy					
	Cardiac Arrest		Unspecified]	C				
UNKNOWN								
	Cardiac Failure		Coumadin	C		ORAL		
	Congestive		Vicodin Es Tablets	C				
UNKNOWN								
	Cellulitis		Restoril	C				
UNKNOWN								
	Chronic Obstructive		Zestril	C				
UNKNOWN								
	Pulmonary Disease							
	Clavicle Fracture							
	Confusion Postoperative							
	Constipation							
	Cor Pulmonale							
	Dilatation Atrial							
	Dilatation Ventricular							
	Duodenal Ulcer							
	Haemorrhage							
	Duodenitis							
	Gastric Ulcer							
	Gastrooesophageal Reflux							
	Disease							
	Injury							
	Myocardial Infarction							
	Neuropathy Peripheral							
	Oesophagitis							
	Onychomycosis							
	Osteoarthritis							
	Pericardial Effusion							
	Pleural Effusion							
	Rash							
	Restless Legs Syndrome							
	Restrictive Pulmonary							
	Disease							
	Rib Fracture							
	Road Traffic Accident							
	Vitreous Floaters							

Date:08/30/04ISR Number: 4437007-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00068
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Cholesterol Increased
	Blood Pressure Increased
	Breast Disorder
	Cellulitis
	Chest Pain
	Emotional Distress
	Gastric Disorder
	Heart Rate Irregular
	Nausea
	Nervousness
	Peptic Ulcer
	Rash
	Swelling Face

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	283 DAY	
	Norvasc	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Premarin	C		ORAL		

Date:08/30/04ISR Number: 4437014-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01072444
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Basal Cell Carcinoma		Hydrocodin	SS			UNKNOWN	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression							
	Diarrhoea							
	Disturbance In Attention							
	Epidermal Naevus							
	Fall							
	Fatigue							
	Headache							
	Hypertension							
	Insomnia							
	Intervertebral Disc Protrusion							
	Low Density Lipoprotein Increased							
	Musculoskeletal Stiffness							
	Neck Pain							
	Paraesthesia							
	Pigmentation Disorder							
	Road Traffic Accident							
	Skin Laceration							
	Skin Lesion							
	Thinking Abnormal							
	Vomiting							
	Wound Complication							

Date:08/30/04ISR Number: 4437020-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00918
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Anxiety
	Blood Potassium Decreased
	Blood Sodium Decreased
	Burning Sensation
	Cardiac Murmur
	Coronary Artery Occlusion
	Dyspepsia
	Electrocardiogram St Segment Elevation
	Emotional Distress
	Epigastric Discomfort
	Fatigue
	Nausea

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	32	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/30/04ISR Number: 4437021-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00338
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	84	DAY
Hospitalization - Initial or Prolonged	Cardiac Arrest		[Therapy Unspecified]	C				
	Cardiomegaly							
Disability	Cholelithiasis		Fiorinal	C				
	Emphysema							
	Hepatomegaly							
	Hyperlipidaemia							
	Pulmonary Congestion							

Date:08/30/04ISR Number: 4437022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Acute Pulmonary Oedema
Disability	Amnesia
Other	Anaemia
	Angina Pectoris
	Anxiety
	Arrhythmia
	Asthenia
	Atelectasis
	Blood Cholesterol Increased

Bundle Branch Block Right
Cerebrovascular Accident
Chest Discomfort
Chronic Obstructive
Pulmonary Disease
Cognitive Disorder
Confusional State
Convulsion
Coronary Artery Disease
Coronary Artery Stenosis
Cystocele
Depression
Diabetes Mellitus
Inadequate Control
Diabetic Ketoacidosis
Emotional Distress
Emphysema
Extrasystoles
Hyperlipidaemia
Hypertension
Hypokalaemia
Influenza
Intervertebral Disc

		Degeneration					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasopharyngitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Post Procedural		Aspirin	C		
UNKNOWN							
		Complication		Lasix (Furosemide)	C		
UNKNOWN							
		Pulmonary Congestion		Glucotrol Xl	C		
UNKNOWN							
		Pulmonary Oedema		Glyburide	C		
UNKNOWN							
		Respiratory Rate		Ativan	C		
UNKNOWN							
		Increased		Lopressor	C		
UNKNOWN							
		Rotator Cuff Syndrome		Orphenadrine	C		
UNKNOWN							
		Sinus Tachycardia					
		Spondylolisthesis					
		Acquired					
		Supraventricular					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Ventricular Hypertrophy					
		Vision Blurred					

Date:08/30/04ISR Number: 4437024-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00142
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Acute Stress Disorder
Other	Anaemia
	Anaemia Postoperative
	Anal Fissure
	Anxiety
	Atherosclerosis
	Back Pain
	Benign Prostatic
	Hyperplasia

Blindness
Blood Creatine
Phosphokinase Abnormal
Blood Creatine
Phosphokinase Mb
Increased
Blood Urine Present
Bronchitis Acute
Calculus Ureteric
Cardiomegaly
Cellulitis
Chest Pain
Diabetes Mellitus
Inadequate Control
Diabetic Neuropathy
Diabetic Retinopathy
Dizziness
Dyspepsia
Emotional Distress
Fall
Gastritis Erosive
Gastrointestinal
Haemorrhage

		Gastrooesophageal Reflux Disease					
		Haematuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemoptysis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhoids		Acetaminophen And Hydrocodone Bitartrate	C		
		Hepatomegaly					
		Hiatus Hernia					
UNKNOWN							
		Leukocytosis		Darvocet-N	C		
UNKNOWN							
		Localised Infection		Norvasc	C		
UNKNOWN							
		Loss Of Consciousness		Celebrex	C		
UNKNOWN							
		Microcytosis		Clonidine	C		
UNKNOWN							
		Myocardial Ischaemia		Prozac	C		
UNKNOWN							
		Neck Pain		Flonase	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Oedema Peripheral		Neurontin	C		
UNKNOWN							
		Osteoarthritis		Glucotrol Xl	C		
UNKNOWN							
		Pharyngitis		Hyzaar	C		ORAL
		Pneumonia		Humulin N	C		
UNKNOWN							
		Prostatitis		Humulin N	C		
UNKNOWN							
		Rectal Haemorrhage		Humalog	C		
SUBCUTANEOUS							
		Spinal Column Stenosis		Humalog	C		
SUBCUTANEOUS							
		Syncope		Imdur	C		
UNKNOWN							
		Urethral Discharge		Claritin	C		
UNKNOWN							
				Avandia	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Methocarbamol	C		
UNKNOWN							

			Glyset	C			
UNKNOWN							
			Nitroquick	C			
SUBLINGUAL							

Date:08/30/04ISR Number: 4437025-6Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0408ZAF00040
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		
6 MON								
Initial or Prolonged	Hypertension		Atorvastatin Calcium	C		ORAL		
	Reflux Oesophagitis							

Date:08/30/04ISR Number: 4437026-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Atenolol	C				
UNKNOWN								
	Carpal Tunnel Syndrome		Zyrtec	C				
UNKNOWN								
	Coronary Artery		Celexa	C				
UNKNOWN								
	Atherosclerosis		Flonase	C				
UNKNOWN								
	Drug Ineffective		Hydrocodone					
	Dyslipidaemia		Bitartrate	C				
UNKNOWN								
	Fall		Levsin	C				
UNKNOWN								
	Muscular Weakness		Indocin					
	Peripheral Coldness		(Indomethacin)	C		ORAL		
	Road Traffic Accident		Naproxen	C				
UNKNOWN								
	Rotator Cuff Syndrome		Prilosec	C				
UNKNOWN								
	Scapula Fracture		Oxycontin	C				
UNKNOWN								
	Skin Laceration		Aciphex	C				
UNKNOWN								
	Trigger Finger							

Date:08/30/04ISR Number: 4437449-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03194
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atelectasis							
	Atrial Fibrillation							
	Atrioventricular Block							
	First Degree							
	Bundle Branch Block Right							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Depression							
	Drug Ineffective							
	Dyspnoea Exertional							
	Electrocardiogram							
	Abnormal							
	Fall							
	Fluid Retention							
	Hyperlipidaemia							
	Hypertension							
	Inguinal Hernia							
	Injury							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Pleural Effusion							
	Pulmonary Fibrosis							
	Pulmonary Hypertension							
	Sinus Bradycardia							
	Thrombosis							
	Tricuspid Valve							
	Incompetence							
	Urinary Retention							

Date:08/30/04ISR Number: 4437450-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain

Disability	Adverse Event
	Anorexia
	Aortic Occlusion
	Asthenia
	Back Pain
	Blood Disorder
	Bronchitis
	Cerebral Atrophy
	Chest Pain
	Constipation
	Contusion
	Disability
	Emotional Distress
	Excoriation
	Fall
	Gait Spastic
	Gout

		Headache					
		Hyperlipidaemia					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intermittent Claudication		Vioxx	PS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein		Tylenol	C		
UNKNOWN							
		Increased					
		Lung Infiltration					
		Malaise					
		Muscle Spasticity					
		Nasopharyngitis					
		Obstruction					
		Painful Respiration					
		Peripheral Circulatory					
		Failure					
		Peroneal Nerve Palsy					
		Poor Peripheral					
		Circulation					
		Road Traffic Accident					
		Skin Laceration					
		Weight Decreased					

Date:08/30/04ISR Number: 4437453-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00482
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
96 DAY							
		Arthritis		Acetaminophen	C		
UNKNOWN							
		Difficulty In Walking		Chondroitin Sulfate			
		Joint Swelling		Sodium And			
		Monarthritis		Glucosamine Sulfate	C		
UNKNOWN							
		Oedema Peripheral		Dyazide	C		
UNKNOWN							
		Treatment Noncompliance		Mevacor	C		ORAL
				Prilosec	C		
UNKNOWN							

Date:08/30/04ISR Number: 4437455-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/30/04ISR Number: 4437456-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01737
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
			Tylenol	C				UNKNOWN
			Xanax	C				UNKNOWN
			Synthroid	C				UNKNOWN

Date:08/30/04ISR Number: 4437457-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Post Procedural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/04ISR Number: 4437458-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Angina Pectoris		Norvasc	C			UNKNOWN	
	Asthenia		Lotrel	C			UNKNOWN	
	Back Pain		Coreg	C			UNKNOWN	
	Blood Cholesterol		Clonidine	C			UNKNOWN	
	Increased		Clonidine	C		ORAL		
	Blood Creatinine		Digitek	C			UNKNOWN	
	Increased		Zocor	C		ORAL		
	Bronchitis		Spironolactone	C			UNKNOWN	
	Cardiac Failure		Nexium	C			UNKNOWN	
	Congestive		Lisinopril	C			UNKNOWN	
	Condition Aggravated		Reglan	C			UNKNOWN	
	Congestive Cardiomyopathy		Minoxidil	C			UNKNOWN	
	Cough		Minoxidil	C			UNKNOWN	1 DAY
	Depression		Minoxidil	C			UNKNOWN	
	Diastolic Dysfunction							
	Dyspepsia							
	Dyspnoea Paroxysmal Nocturnal							
	Emotional Distress							
	Erectile Dysfunction							
	Facial Palsy							
	Gastroenteritis Viral							
	Gastrooesophageal Reflux Disease							
	Haemoglobin Decreased							
	Hypertension							
	Hypertensive Cardiomyopathy							
	Insomnia							

Mitral Valve Incompetence
Nasal Congestion
Neck Injury
Neck Pain
Productive Cough
Pulmonary Valve
Incompetence
Rhinorrhoea
Road Traffic Accident
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Upper Respiratory Tract
Infection
Ventricular Extrasystoles

Date:08/30/04ISR Number: 4437460-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Unstable
Disability	Arthritis
Other	Blood Pressure Abnormal
	Cardiac Valve Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain					
		Coronary Artery Occlusion					
		Dysphagia					
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux Disease		Tylenol Extra Strength	C		
UNKNOWN							
		Haematoma		Percocet	C		
UNKNOWN							
		Hypercholesterolaemia		Aspirin	C		
UNKNOWN							
		Hypertension		Soma	C		
UNKNOWN							
		Irritable Bowel Syndrome		Cardizem Cd	C		
UNKNOWN							
		Myocardial Infarction		Ferrous Sulfate	C		
UNKNOWN							
		Oedema Peripheral		Lasix (Furosemide)	C		
UNKNOWN							
		Oesophageal Spasm		Lasix (Furosemide)	C		
UNKNOWN							
		Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Tremor		Aleve	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		42 DAY					
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		145 DAY					
				K-Dur	C		
UNKNOWN							
				Accupril	C		
UNKNOWN		18 DAY					
				Accupril	C		
UNKNOWN		38 DAY					
				Accupril	C		
UNKNOWN		152 DAY					

Date:08/30/04ISR Number: 4437465-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01882
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea							
	Feeling Abnormal							
	Gastrointestinal Disorder							
	Hypoacusis							
	Pain							

Date:08/30/04ISR Number: 4437467-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01698
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/30/04ISR Number: 4437469-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0408ESP00015
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Toxicity		Bentazepam	C				
UNKNOWN								
	Jaundice Cholestatic		Sertraline Hydrochloride	C				
	Renal Failure Acute							
UNKNOWN								
	Vanishing Bile Duct Syndrome		Mianserin Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/04ISR Number: 4437587-9Report Type:Direct Company Report #CTU 225853
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx 25 Mg Merck	PS	Merck	ORAL	1 DAILY	DAILY
	Chest Pain							
ORAL								

Date:08/30/04ISR Number: 4439035-1Report Type:Expedited (15-DaCompany Report #2004-07-0363
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain	Foreign	Celestene					
Hospitalization -	Alcohol Use	Health	(Betamethasone)					
Initial or Prolonged	Blood Glucose Abnormal	Professional	Tablets 'Like					
	Blood Triglycerides	Other	Celestone Syrup"	PS		ORAL		
ORAL								
	Increased		Vioxx (Rofecoxib)					
	Cough		Oral, Not Otherwise					
	Diabetic Ketoacidosis		Specified	SS		ORAL		
ORAL								
	Dyspnoea		Ultram Oral, Not					
	Ileus		Otherwise Specified	SS		ORAL		
ORAL								
	Leukocytosis							
	Pancreatic Necrosis							
	Pancreatitis Acute							
	Pleurisy							

Date:08/30/04ISR Number: 4439610-4Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Health	Premarin (Conjugated					
		Professional	Estrogens, Unspec,					
			0)	PS				
			Augmentin					
			(Amoxicillin					
			Sodium/Clavulanate					

Potassium, Injection, 0)	SS
Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, , 0)	SS
Fluoxetine (Fluoxetine,,)	SS
Humira (Adalimumab, , 0)	SS
Methotrexate (Methotrexate, Unspec, 0)	SS
Rofecoxib (Rofecoxib, , 0)	SS
Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C
Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/30/04ISR Number: 4443785-0Report Type:Expedited (15-DaCompany Report #WAES 0408USA01593
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alkaline	Study	Tab Vioxx	PS		ORAL	PO	
	Phosphatase Increased	Health Professional Other						

Date:08/30/04ISR Number: 4443787-4Report Type:Expedited (15-DaCompany Report #WAES 0405USA02046
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Study	Tab Fosamax 70 Mg	PS		ORAL	PO	
Initial or Prolonged	Gastric Ulcer	Health	Tab Vioxx	SS		ORAL	PO	
	Syncope	Professional	Inj Enbrel 25 Mg	SS		SUBCUTANEOUS	25 MG/2XW/SC	
	Upper Gastrointestinal Haemorrhage		Hydrodiuril	C				
			Azathioprine	C				
			Calcium	C				
			Hydroxychlorooquine Sulfate	C				
			Prednisone	C				
			Ranitidine Hydrochloride	C				
			Tramadol Hydrochloride	C				

Date:08/30/04ISR Number: 4443791-6Report Type:Expedited (15-DaCompany Report #WAES 0408USA01593
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Alkaline	Study	Tab Vioxx	PS		ORAL	PO	
	Phosphatase Increased	Health Professional Other						

Date:08/31/04ISR Number: 4437880-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00968
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain
Disability	Amnesia
Other	Apathy
	Apraxia
	Arachnoiditis
	Asthenia
	Autonomic Nervous System
	Imbalance
	Back Pain
	Balance Disorder
	Bladder Disorder
	Blood Bilirubin Increased
	Blood Bilirubin
	Unconjugated Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Bradycardia
	Buttock Pain

Calcinosis
Cerebellar Haemorrhage
Cerebellar Infarction
Cerebellar Syndrome
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Citrobacter Infection
Cognitive Disorder
Computerised Tomogram
Abnormal
Constipation
Coordination Abnormal
Culture Urine Positive
Decreased Appetite
Dehydration
Dementia
Depressed Level Of
Consciousness
Depression
Diaphragm Muscle Weakness
Diplopia
Disturbance In Attention
Diverticulum
Dizziness
Dysphagia
Early Satiety
Enterobacter Infection
Fall
Fatigue
Feeling Cold
Femur Fracture
Gastritis
Gastrointestinal Pain
Haemorrhagic Stroke
Hallucination, Visual
Hiatus Hernia
Hyperglycaemia
Hypoaesthesia
Hyponatraemia
Impaired Driving Ability
Impaired Work Ability
Inappropriate
Antidiuretic Hormone
Secretion
Infection
Injury

Interstitial Lung Disease
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Sprain
Lipoma
Lung Neoplasm
Malaise
Mental Status Changes
Muscle Contracture
Muscle Hypertrophy
Muscular Weakness
Nausea

		Neuropathic Pain					
		Nuclear Magnetic Resonance Imaging	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
19	DAY						
		Nuclear Magnetic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Resonance Imaging Brain		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Valium	C		
UNKNOWN							
		Nystagmus		Neurontin	C		
UNKNOWN							
		Obstructive Airways		Neurontin	C		
UNKNOWN							
		Disorder		Neurontin	C		
UNKNOWN							
		Oesophageal Disorder		Neurontin	C		
UNKNOWN							
		Otitis Media		Avapro	C		
UNKNOWN							
		Pain		Misoprostol	C		
UNKNOWN							
		Pelvic Pain		Macrodantin	C		
UNKNOWN							
		Piriformis Syndrome		Nortriptyline	C		
UNKNOWN							
		Pneumonia		Nortriptyline	C		
UNKNOWN							
		Pollakiuria					
		Post Polio Syndrome					
		Proctalgia					
		Proctitis					
		Prostatitis					
		Pseudomonas Infection					
		Pulmonary Calcification					
		Pyelonephritis					
		Pyrexia					
		Radiculopathy					
		Rectal Cramps					
		Rectal Tenesmus					
		Respiratory Rate Increased					
		Rhinitis Allergic					
		Scoliosis					
		Sinusitis					
		Sleep Apnoea Syndrome					

Spinal Column Stenosis
Spinal Osteoarthritis
Staphylococcal Infection
Thoracic Vertebral
Fracture
Urethral Stricture
Urinary Sediment Present
Urinary Tract Infection
Bacterial
Urinary Tract Infection
Pseudomonal
Urinary Tract Obstruction
Vertigo
Vomiting

Date:08/31/04ISR Number: 4437885-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Cerebrovascular Accident
Hospitalization - Initial or Prolonged	Chest Discomfort
	Compression Fracture
	Depression
	Drug Ineffective
	Hypoaesthesia
	Pain In Extremity

		Paraesthesia					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Percocet	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:08/31/04ISR Number: 4437886-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA00267
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
117 DAY							
		Coronary Artery Disease		Pravachol	C		
UNKNOWN							
		Feeling Abnormal		Pravachol	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/31/04ISR Number: 4437887-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Back Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Aspirin	C		
UNKNOWN							
		Cardiac Disorder		Lipitor	C		ORAL
		Condition Aggravated		Captopril	C		ORAL
		Emotional Distress		Captopril	C		
UNKNOWN							
		Gastritis Erosive		Baycol	C		ORAL
		Gastrointestinal Disorder		Baycol	C		ORAL
		Haemorrhoids		Estrogens (Unspecified)	C		
		Hiatus Hernia					
UNKNOWN							

	Hypertension	Allegra	C
UNKNOWN			
	Myalgia	Hydrodiuril	C
UNKNOWN			
	Myocardial Infarction	Motrin	C
UNKNOWN			
	Pain In Extremity	Claritin	C
UNKNOWN			
		Metoprolol	C
UNKNOWN			
		Metoprolol	C
UNKNOWN			
		Metoprolol	C
UNKNOWN			
		Aleve	C
UNKNOWN			
		Nitroquick	C
SUBLINGUAL			

Date:08/31/04ISR Number: 4437888-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory Failure
Hospitalization - Initial or Prolonged	Anaphylactic Reaction
Other	Angioneurotic Oedema
	Aortic Atherosclerosis
	Arrhythmia
	Asthenia
	Asthma
	Blood Cholesterol Increased
	Bronchitis
	Cardiac Disorder
	Cardiomegaly
	Carpal Tunnel Syndrome

		Cerebrovascular Accident					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Cytomegalovirus Colitis		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Disseminated		Aspirin	C		
UNKNOWN							
		Cytomegaloviral Infection		Aspirin	C		
UNKNOWN							
		Drug Ineffective		Detrol	C		ORAL
		Dyspnoea		Lotensin	C		ORAL
		Emotional Distress		Zyrtec	C		ORAL
		Epistaxis		Flonase	C		
RESPIRATORY							
		Feeling Abnormal					
(INHALATION)							
		Gastrointestinal		Hydro-Chlor	C		
UNKNOWN							
		Haemorrhage		Prednisone	C		ORAL
		Gastrooesophageal Reflux Disease					
		Heart Rate Irregular					
		Hepatic Enzyme Increased					
		Hypoventilation					
		Hypoxia					
		Ileus					
		Injury					
		Intestinal Ischaemia					
		Leukocytosis					
		Muscle Spasms					
		Myopathy Steroid					
		Osteoarthritis					
		Pneumonia Cytomegaloviral					
		Pulmonary Oedema					
		Rectal Ulcer					
		Rhinitis Allergic					
		Staphylococcal Infection					
		Swelling Face					
		Syphilis					

Date:08/31/04ISR Number: 4437892-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00120
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1423 DAY
Life-Threatening	Perforation	Professional	Acetaminophen And Propoxyphene Hydrochloride	C				
Hospitalization - Initial or Prolonged			Aspirin	C				
Disability			Bendroflumethiazide	C				
Other			Betamethasone	C				
			Simvastatin	C				
			Warfarin	C				
			Digoxin	C				
			Doxazosin Mesylate	C				
			Olive Oil	C				
			Perindopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4437900-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01315
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delirium	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Persantine	C				UNKNOWN
			Divalproex Sodium	C				UNKNOWN
			Divalproex Sodium	C				UNKNOWN
			Docusate Sodium	C				UNKNOWN
			Ferrous Sulfate	C		ORAL		
			Latanoprost	C				UNKNOWN
			Olanzapine	C		ORAL		
			Trazodone Hydrochloride	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Olanzapine	C				UNKNOWN
			Olanzapine	C				UNKNOWN
			Protonix	C				UNKNOWN
			Paroxetine	C				UNKNOWN
			Paroxetine	C				UNKNOWN
			Pilocarpine	C				UNKNOWN

Date:08/31/04ISR Number: 4437916-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02044
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive							
Hospitalization -								

Initial or Prolonged
Disability

Date:08/31/04ISR Number: 4437917-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
Other	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL	261 DAY	
	Contusion		Tylenol	C			UNKNOWN	
	Dyspepsia		Combivent	C			RESPIRATORY (INHALATION)	
	Emotional Distress							
	Gastric Ulcer		Allopurinol	C			UNKNOWN	
	Gastritis		Celebrex	C			UNKNOWN	
	Gastrointestinal		Polycitra-K	C			UNKNOWN	
	Haemorrhage		Estradiol	C			UNKNOWN	
	Meniscus Lesion		Glucosamine	C			UNKNOWN	
	Patella Fracture Patellofemoral Pain		Vitamins (Unspecified)	C			UNKNOWN	
	Syndrome		Vitamin E	C			UNKNOWN	
	Pyrexia		Diovan	C			UNKNOWN	
	Therapeutic Response		Ultram	C			UNKNOWN	
	Decreased		Bactrim Ds Tablets	C			UNKNOWN	
	Wound Infection		Avalide	C			UNKNOWN	
			Atrovent	C			UNKNOWN	
			Avapro	C			UNKNOWN	
			Claritin	C			UNKNOWN	

				Potassium (Unspecified)	C		
UNKNOWN							
				Pyridoxine	C		
UNKNOWN							

Date:08/31/04ISR Number: 4438497-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acrochordon		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Alopecia		Aspirin	C				
UNKNOWN								
	Bladder Prolapse		Diovan	C				
UNKNOWN								
	Blood Pressure Increased		Premarin	C				
UNKNOWN								
	Cystocele							
	Dermatitis Contact							
	Fungal Skin Infection							
	Headache							
	Injury							
	Lichen Planus							
	Lung Neoplasm							
	Ovarian Mass							
	Rectocele							
	Seborrhoeic Dermatitis							
	Seborrhoeic Keratosis							
	Skin Lesion							
	Stress Incontinence							
	Urinary Incontinence							
	Vaginal Prolapse							
	Wrist Deformity							

Date:08/31/04ISR Number: 4438503-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01899
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Purulent Discharge							

Date:08/31/04ISR Number: 4438511-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00133
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Fosamax	SS		ORAL		
	Haemorrhage		Acetaminophen And Codeine Phosphate	C		ORAL		
	Helicobacter Infection		Alfacalcidol	C		ORAL		
	Oesophageal Ulcer		Calcium Carbonate	C		ORAL		
	Oesophagitis							

Date:08/31/04ISR Number: 4438512-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00055
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Budesonide	C			UNKNOWN	
			Formoterol Fumarate	C			UNKNOWN	
			Theophylline	C			UNKNOWN	
			Pantoprazole Sodium	C			UNKNOWN	

Date:08/31/04ISR Number: 4438514-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/31/04ISR Number: 4438516-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00888
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Cellulitis		Duragesic	C			TOPICAL	122 DAY
	Headache		Methadone Hcl	C		ORAL		42 DAY
	Meningitis Viral		Oxycodone	C		ORAL		
	Muscle Twitching							
	Nausea							
	Pain							
	Tremor							

Date:08/31/04ISR Number: 4438517-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Captopril	C				UNKNOWN
Other	Cholelithiasis		Celebrex	C				UNKNOWN
	Chronic Obstructive		Plavix	C				UNKNOWN
	Pulmonary Disease		Pepcid Ac	C		ORAL		
	Coronary Artery Disease		Lasix (Furosemide)	C				UNKNOWN

	Diabetes Mellitus	Ambien	C
UNKNOWN			
	Inadequate Control	Zoloft	C
UNKNOWN			
	Dizziness	Glyburide	C
UNKNOWN			
	Dyspepsia	Synthroid	C
UNKNOWN			
	Gastritis	Lorazepam	C
UNKNOWN			
	Gastrointestinal	Meclizine	C
UNKNOWN			
	Haemorrhage	Phenergan	
	Hyperkalaemia	Tablets/Suppositorie	
	Microcytic Anaemia	s	C
UNKNOWN			
	Myocardial Infarction		
	Renal Failure		

Date:08/31/04ISR Number: 4438521-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain Upper
	Acute Prerenal Failure
	Aortic Valve Disease
	Aortic Valve Incompetence
	Arterial Disorder
	Asthenia
	Back Pain
	Bundle Branch Block Left
	Cardiac Disorder
	Cardiac Failure
	Congestive

		Cardiomegaly					
		Change Of Bowel Habit					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cholelithiasis		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		Lasix (Furosemide)	SS		
UNKNOWN							
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Lasix (Furosemide)	SS		
INTRAVENOUS							
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Ostial Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Crepitations		Vioxx	SS	Merck & Co., Inc	ORAL
		Crying		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Plavix	C		
UNKNOWN							
		Diarrhoea		Advil	C		
UNKNOWN							
		Dilatation Ventricular		Lopressor	C		
UNKNOWN							
		Discomfort		Timoptic	C		
OPHTHALMIC							
		Dizziness		Zocor	C		ORAL
2	MON						
		Dyspnoea Exertional		Zocor	C		ORAL
		Ejection Fraction		Pilocarpine	C		
UNKNOWN							
		Decreased		Salagen Tablets	C		
UNKNOWN							
		Eye Disorder		Salagen Tablets	C		
UNKNOWN							
		Eye Pain		Centrum	C		
UNKNOWN							
		Fall		Lotemax	C		
OPHTHALMIC							
		Fatigue		Plaquenil	C		
UNKNOWN							
		Gingival Bleeding		Femhrt	C		
UNKNOWN							
		Glaucoma					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Hyperlipidaemia					
		Hypertension					
		Ischaemic Cardiomyopathy					
		Joint Sprain					
		Mitral Valve					

Calcification
Mitral Valve Disease
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Nephropathy Toxic
Oral Fungal Infection
Orthostatic Hypotension
Pericardial Effusion
Pleural Effusion
Pneumonitis
Procedural Hypotension
Pulmonary Oedema
Pulmonary Valve
Incompetence
Renal Disorder
Renal Failure
Respiratory Distress
Rosacea
Rotator Cuff Syndrome
Synovitis
Tooth Fracture
Tricuspid Valve
Incompetence
Ventricular Dysfunction
Visual Acuity Reduced
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/31/04ISR Number: 4438524-3Report Type:Expedited (15-DaCompany Report #MY-MERCK-0408MYS00013
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Amoxicillin And Clavulanate Potassium	C			UNKNOWN	
			Ciprofloxacin Hydrochloride	C			UNKNOWN	

Date:08/31/04ISR Number: 4439872-3Report Type:Expedited (15-DaCompany Report #04P-167-0270891-00
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Eye Haemorrhage	Foreign Health Professional	Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab) (Adalimumab)	PS		SUBCUTANEOUS	40 MG, SUBCUTANEOUS	
			Estrogens Conjugated	SS				
			Clavulin	SS				
			Paramol-118	SS				
			Fluoxetine	SS				
			Methotrexate	SS				
			Rofecoxib	SS				

Date:09/01/04ISR Number: 4438700-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00025
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization -		Professional	Allopurinol	C		ORAL		

Initial or Prolonged
Other

Date:09/01/04ISR Number: 4439010-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01618
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		466 DAY
Hospitalization -	Atrial Fibrillation		Norvasc	C				UNKNOWN
Initial or Prolonged	Cardiac Disorder		Clonazepam	C				UNKNOWN
Other	Cerebral Infarction		Lanoxin	C				UNKNOWN
	Epigastric Discomfort		Vasotec	C		ORAL		
	Gastrointestinal		Zoloft	C				UNKNOWN
	Haemorrhage		Emla	C				UNKNOWN
	Gastrooesophageal Reflux		Centrum Silver	C				UNKNOWN
	Disease		Primidone	C				UNKNOWN
	Humerus Fracture							
	Hypokalaemia							
	Pneumonitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/04ISR Number: 4439014-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Accident At Work		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anger							
	Ankle Fracture							
	Anxiety							
	Back Injury							
	Chest Pain							
	Constipation							
	Costochondritis							
	Depression							
	Dry Mouth							
	Dysgeusia							
	Dyspnoea							
	Eating Disorder							
	Emotional Disorder							
	Erectile Dysfunction							
	Headache							
	Heart Rate Irregular							
	Hypertension							
	Insomnia							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Joint Effusion							
	Joint Injury							
	Joint Sprain							
	Major Depression							
	Meniscus Lesion							
	Myofascial Pain Syndrome							
	Nausea							
	Neck Pain							
	Orchitis							
	Osteoarthritis							
	Pain							
	Palpitations							
	Patellofemoral Pain Syndrome							
	Pruritus							
	Pyrexia							
	Radiculitis Lumbosacral							
	Spinal Fracture							

Tachycardia
Tendonitis
Tinnitus
Urinary Incontinence
Weight Abnormal

Date:09/01/04ISR Number: 4439015-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Anxiety
Other	Arthralgia
	Back Pain
	Blood Cholesterol

		Increased					
		Chest Pain					
		Closed Head Injury					
		Constipation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Costochondritis		Prevacid	C		
UNKNOWN							
		Depression		Zocor	C		ORAL
		Dyspepsia					
		Dysuria					
		Enterocolitis					
		Haemorrhagic					
		Erectile Dysfunction					
		Eye Disorder					
		Fall					
		Gastrooesophageal Reflux					
		Disease					
		Haemorrhage					
		Head Injury					
		Hypertension					
		Kidney Infection					
		Migraine					
		Muscle Spasms					
		Oedema Peripheral					
		Oesophageal Disorder					
		Palpitations					
		Renal Disorder					
		Ulcer					

Date:09/01/04ISR Number: 4439016-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Blood Pressure Decreased
	Cardiac Failure
	Congestive

Cerebellar Syndrome
Cerebral Haemorrhage
Chondromalacia
Confusional State
Convulsion
Coronary Artery Disease
Deafness Neurosensory
Dehydration
Depression
Diabetes Mellitus
Drug Ineffective
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction

		Fatigue					
		Fibrous Histiocytoma					
		Flatulence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis Haemorrhagic		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypermetropia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Inner Ear Disorder		Neurontin	C		
UNKNOWN							
		Leukocytosis		Glucosamine	C		
UNKNOWN							
		Meniscus Lesion		Prilosec	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Oedema					
		Osteonecrosis					
		Pain					
		Pneumonia Escherichia					
		Presbyopia					
		Prothrombin Time					
		Prolonged					
		Pupillary Disorder					
		Renal Failure Acute					
		Respiratory Failure					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Transient Ischaemic					
		Attack					
		Tremor					
		Tricuspid Valve					
		Incompetence					
		Varicose Vein					
		Ventricle Rupture					
		Ventricular Tachycardia					
		Vertigo Positional					

Date:09/01/04ISR Number: 4439298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02044
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged Disability	Congestive Death		[Therapy Unspecified]	C				

Date:09/01/04ISR Number: 4439299-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00006
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability Other	Cerebral Infarction Cerebrovascular Stenosis Headache Hypercholesterolaemia Hypersensitivity Nausea Paraesthesia Sinusitis

		Temporomandibular Joint Syndrome					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
156	DAY			Vioxx	PS	Merck & Co., Inc	ORAL
9	MON			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		585 DAY		[Therapy Unspecified]	C		
UNKNOWN		585 DAY		Tylenol	C		
UNKNOWN				Ortho-Novum	C		
UNKNOWN				Necon	C		
UNKNOWN				Zoloft	C		
UNKNOWN		585 DAY		Advil	C		
UNKNOWN		585 DAY		Motrin	C		
UNKNOWN				Methylphenidate	C		
UNKNOWN		585 DAY		Naproxen	C		
UNKNOWN		585 DAY		Aleve	C		

Date:09/01/04ISR Number: 4439301-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02199
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/01/04ISR Number: 4439302-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome PT

Other	Abdominal Pain
	Adrenal Adenoma
	Angina Pectoris
	Arthralgia
	Arthritis
	Blood Cholesterol
	Increased
	Bronchitis
	Cardiac Murmur
	Cataract
	Cellulitis
	Chest Pain
	Chronic Fatigue Syndrome
	Constipation
	Cystitis
	Cystitis Glandularis
	Dizziness
	Dyspepsia
	Dyspnoea
	Dyspnoea Paroxysmal
	Nocturnal
	Ear Infection
	Electrocardiogram
	Abnormal
	Emotional Distress
	Gastrointestinal Ulcer
	Gastrooesophageal Reflux
	Disease
	Gingival Pain
	Haematuria

		Headache					
		Hypercholesterolaemia					
		Increased Tendency To	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bruise		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Tylenol	C		ORAL
		Parotid Gland Enlargement		Fosamax	C		
UNKNOWN							
		Peptic Ulcer		Tagamet	C		
UNKNOWN							
		Rhinitis Allergic		Pravachol	C		
UNKNOWN							
		Stress Incontinence					
		Thyroid Neoplasm					
		Tooth Abscess					
		Urethral Caruncle					
		Urinary Tract Infection					

Date:09/01/04ISR Number: 4439305-7Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0408ZAF00040
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Hypertension		Atorvastatin Calcium	C		ORAL
	Reflux Oesophagitis					

Date:09/01/04ISR Number: 4439312-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0408NOR00014
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemoglobin Decreased		Aspirin And			
	Melaena		Magnesium Oxide	SS		ORAL

Date:09/01/04ISR Number: 4439395-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Benign Prostatic Hyperplasia
	Choking
	Cough
	Depression
	Diverticulum
	Dysuria
	Erosive Duodenitis
	Fatigue
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hypertension
	Hypoacusis
	Oesophageal Rupture
	Pancreatitis
	Renal Cyst
	Rhinorrhoea
	Supraventricular

	Extrasystoles Thromboembolic Stroke Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
	Urinary Retention		Restoril	C			UNKNOWN	
	Urinary Tract Disorder Urinary Tract Infection							

Date:09/01/04ISR Number: 4439396-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00441
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort Anaemia Arrhythmia Asthenia Asthma Blood Pressure Increased Carpal Tunnel Syndrome Chest Discomfort Chest Pain Chronic Fatigue Syndrome Cyst Dizziness Drug Ineffective Dyspnoea Emotional Distress Hyperlipidaemia Hypertension Hypoaesthesia Hypokalaemia Influenza Intervertebral Disc Degeneration Intervertebral Disc Protrusion Joint Swelling Large Intestinal Ulcer Haemorrhage Loss Of Consciousness Meniscus Lesion

Musculoskeletal
Discomfort
Nasopharyngitis
Nausea
Neck Pain
Neuropathy Peripheral
Oedema
Oesophageal Ulcer
Haemorrhage
Osteoarthritis
Pain In Extremity
Paraesthesia
Post Procedural Nausea
Post Procedural Pain
Road Traffic Accident
Spinal Disorder
Spinal Osteoarthritis
Stomach Discomfort

		Strabismus Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vitamin B12 Deficiency		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Lortab	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Proventil	C		
RESPIRATORY							
(INHALATION)							
				Micardis	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Micardis Hct	C		
UNKNOWN							
				Sular	C		
UNKNOWN		4 DAY					
				Sular	C		ORAL

Date:09/01/04ISR Number: 4439397-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL
		Anaemia Arthritis		[Therapy Unspecified]	C		
UNKNOWN							
		Bronchitis		Folic Acid	C		
UNKNOWN							
		Cardiac Disorder		Remicade	C		
UNKNOWN							
		Cardiac Flutter Dysmenorrhoea		Injectable Gold (Unspecified)	C		
UNKNOWN							
		Emotional Distress		Methotrexate	C		
UNKNOWN							

	Headache		Methotrexate	C			
UNKNOWN							
	Menorrhagia						
	Nausea						
	Post Procedural						
	Complication						
	Swelling						
	Upper Respiratory Tract						
	Infection						
	Uterine Leiomyoma						

Date:09/01/04ISR Number: 4443166-XReport Type:Expedited (15-DaCompany Report #2004039285
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Potassium Decreased	Consumer	Norvasc (Amlodipine)	PS		ORAL	5 MG (5 MG, 1	
	Blood Pressure	Health					IN 1 D), ORAL	
	Inadequately Controlled	Professional	Rofecoxib					
	Drug Interaction		(Rofecoxib)	SS		ORAL	25 MG (25 MG,	
	Erythema						1 IN 1 D),	
	Heart Rate Decreased						ORAL	
	Oedema Peripheral		Atenolol (Atenolol)	SS		ORAL	ORAL	
	Rash		Hydrochlorothiazide	C				
	Self-Medication		Isosorbide Dinitrate	C				
	Stasis Dermatitis		Dyazide (Hydrochlorothiazide, Triamterene)	C				
			Risedronate Sodium	C				
			Potassium Chloride	C				
			Furosemide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/02/04ISR Number: 4439871-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00138
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Acrochordon		Atenolol	C				
UNKNOWN								
	Angioneurotic Oedema		Celebrex	C				
UNKNOWN								
	Anxiety		Flexeril	C				
UNKNOWN								
	Arthralgia		Arthrotec	C		ORAL		
	Arthritis		Hydrodiuril	C		ORAL		
	Back Injury							
	Benign Neoplasm Of Skin							
	Blister							
	Blood Pressure Inadequately Controlled							
	Cheilitis							
	Depression							
	Drug Hypersensitivity							
	Dysfunctional Uterine Bleeding							
	Emotional Distress							
	Faeces Discoloured							
	Fibromyalgia							
	Furuncle							
	Gastric Disorder							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Gout							
	Gouty Arthritis							
	Head Injury							
	Headache							
	Herpes Simplex							
	Herpes Virus Infection							
	Hyperkeratosis							
	Hypersensitivity							
	Hypertension							
	Injury							
	Intervertebral Disc Protrusion							
	Latex Allergy							
	Muscle Spasms							

Muscle Strain
Neck Pain
Nodule On Extremity
Oedema Mouth
Oedema Peripheral
Pain Trauma Activated
Pruritus
Rhinitis
Rhinitis Allergic
Road Traffic Accident
Skin Nodule
Skin Papilloma
Sleep Apnoea Syndrome
Stomatitis
Swelling Face
Tooth Disorder
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/02/04ISR Number: 4439875-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	RESPIRATORY (INHALATION)	
	Anxiety		Ventolin (Albuterol)	C				
Disability	Basal Cell Carcinoma							
	Benign Vascular Neoplasm		Aspirin	C				
UNKNOWN								
	Burning Sensation		Celexa	C				
UNKNOWN								
	Cerebrovascular Accident		Lexapro	C				
UNKNOWN								
	Conversion Disorder		Aerobid	C				
UNKNOWN								
	Dizziness		Synthroid	C				
UNKNOWN								
	Emotional Distress		Claritin	C				
UNKNOWN								
	Ganglion		Niacin	C				
UNKNOWN							14671	DAY
	Generalised Anxiety Disorder							
	Haemorrhoids							
	Hallucination							
	Hemiparesis							
	Hiatus Hernia							
	Hypertension							
	Hypoaesthesia							
	Hypokalaemia							
	Hyporeflexia							
	Lacunar Infarction							
	Liver Function Test Abnormal							
	Loss Of Consciousness							
	Movement Disorder							
	Oesophageal Spasm							
	Orthostatic Hypotension							
	Pain In Extremity							
	Palpitations							
	Post Procedural Complication							
	Psychosomatic Disease							
	Stress							

Suicidal Ideation
Syncope
Tinnitus

Date:09/02/04ISR Number: 4439892-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Abnormal Sensation In Eye
	Asthenopia
	Brain Stem Syndrome
	Cerebrovascular Accident
	Constipation
	Dyspepsia
	Emotional Distress
	Facial Palsy
	Haematochezia
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Keratoconjunctivitis
	Sicca
	Night Blindness

	Osteopenia						
	Peptic Ulcer						
	Photosensitivity Reaction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rotator Cuff Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Simple Partial Seizures	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Urine Flow Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL	
	Visual Acuity Reduced		Plendil	C			UNKNOWN
	Weight Increased		Dyazide	C			UNKNOWN

Date:09/02/04ISR Number: 4439896-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00625
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL	19 DAY
Hospitalization -	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	19 DAY
Initial or Prolonged	Blood Alkaline		Tylenol	C			UNKNOWN
Disability	Phosphatase Increased		Lomotil	C			UNKNOWN
	Catheter Site Discharge		Prednisone	C			UNKNOWN 3 DAY
	Cholelithiasis		Prednisone	C		ORAL	3 DAY
	Dehydration		Prednisone	C			UNKNOWN
	Gastritis						
	Hydronephrosis						
	Joint Effusion						
	Metastatic Neoplasm						
	Oesophageal Stenosis						
	Oesophagitis						
	Pneumonia						
	Renal Failure Acute						
	Respiratory Arrest						
	Septic Shock						
	Small Intestinal Obstruction						
	Upper Gastrointestinal						

Haemorrhage
Urinary Tract Infection

Date:09/02/04ISR Number: 4439902-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00078
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Disability	Asthenia
Other	Back Pain
	Bronchitis
	Chest Pain
	Constipation
	Dental Caries
	Emotional Distress
	Feeling Abnormal
	Groin Pain
	Hypercholesterolaemia
	Hypertension
	Influenza
	Joint Dislocation
	Osteoarthritis
	Overdose
	Polyuria
	Rectal Haemorrhage

		Rotator Cuff Syndrome Sexual Dysfunction Tooth Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Limb Fracture	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
				Lortab	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:09/02/04ISR Number: 4439905-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00078
Age:80 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastric Adenoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
Initial or Prolonged		Gastric Ulcer Gastrooesophageal Reflux Disease Helicobacter Gastritis Hiatus Hernia Melaena Metaplasia	Professional	Aspirin	C		ORAL
				Deanol Tartrate And Ginseng And Minerals (Unspecified) And Rutin And Vitamins (Unspecified)	C		ORAL
				Magnesium (Unspecified)	C		
UNKNOWN							

Date:09/02/04ISR Number: 4439908-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02208
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Lasix (Furosemide Sodium)	SS		
UNKNOWN							

Date:09/02/04ISR Number: 4439909-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00257
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hyperhidrosis	Professional	Methotrexate	SS		ORAL		
Initial or Prolonged	Myalgia		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
	Pneumonitis		Amiloride Hydrochloride And Furosemide	C		ORAL		
			Aspirin	C		ORAL		
			Omeprazole	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Ferrous Sulfate	C		ORAL		
			Folic Acid	C		ORAL		

Date:09/02/04ISR Number: 4440081-2Report Type:Expedited (15-DaCompany Report #US-MERCK-00051679
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anxiety Disorder
Hospitalization -	Bronchitis
Initial or Prolonged	Cardiac Disorder
Disability	Cerebrovascular Accident
	Insomnia

	Ulcer					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:09/02/04ISR Number: 4440083-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00066
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Abdominal Strangulated	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Hernia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol		Tylenol	C		
UNKNOWN						
	Increased		Lortab	C		
UNKNOWN						
	Blood Pressure Increased		Elavil	C		
UNKNOWN						
	Constipation		Celebrex	C		
UNKNOWN						
	Depression		Baycol	C		
UNKNOWN						
	Diabetes Mellitus		Zyrtec	C		
UNKNOWN						
	Diverticulum		Flexeril	C		
UNKNOWN						
	Dyspnoea		Clarinex	C		
UNKNOWN						
	Emotional Distress		Zocor	C		
UNKNOWN						
	Fibromyalgia		Nexium	C		
UNKNOWN						
	Gastric Disorder		Allegra	C		
UNKNOWN						
	Gastritis Erosive		Hydrochlorothiazide	C		
UNKNOWN						
	Gastrooesophageal Reflux		Prevacid	C		
UNKNOWN						
	Disease		Skelaxin	C		
UNKNOWN						
	Nervousness		Aleve	C		
UNKNOWN						

	Nocturia	Protonix	C
UNKNOWN			
	Oedema Peripheral		
	Oesophageal Disorder		
	Paraesthesia		
	Rotator Cuff Syndrome		
	Wheezing		

Date:09/02/04ISR Number: 4440086-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain Lower
Disability	Abdominal Pain Upper
Other	Adjustment Disorder
	Adverse Event
	Anxiety
	Appendix Disorder
	Blood Pressure Increased
	Chest Pain
	Complex Regional Pain
	Syndrome
	Crying
	Decreased Appetite
	Decreased Interest
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dizziness
	Dyspepsia
	Emotional Distress
	Endoscopic Retrograde

Cholangiopancreatography
Abnormal
Feeling Guilty
Gallbladder Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Tylenol	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	

Gastric Disorder
Gastrooesophageal Reflux
Disease
Headache
Hypertension
Insomnia
Libido Decreased
Liver Disorder
Major Depression
Nausea
Neurodermatitis
Pancreatitis
Pancreatitis Chronic
Radiculitis Lumbosacral
Weight Decreased

Date:09/02/04ISR Number: 4440087-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02090
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization - Initial or Prolonged	Thromboplastin Time Prolonged
Disability	Activities Of Daily
Other	Living Impaired
	Anaemia
	Aortic Stenosis
	Aphasia
	Atrial Fibrillation
	Blood Creatinine Increased
	Blood Glucose Increased
	Blood Urea Increased
	Calcinosis
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly

Cataract
Cellulitis
Cerebral Artery Occlusion
Death
Dehydration
Depressed Level Of
Consciousness
Depression
Diarrhoea
Difficulty In Walking
Dyspnoea
Echocardiogram Abnormal
Electrocardiogram St-T
Change
Erosive Duodenitis
Faecal Incontinence
Fall
Fatigue
Gastric Ulcer

		Gastrointestinal Haemorrhage					
		Grand Mal Convulsion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematochezia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematoma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypernatraemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL
		International Normalised		Aspirin	C		
UNKNOWN							
		Ratio Increased		Digoxin	C		
UNKNOWN							
		Laceration		Coumadin	C		
UNKNOWN							
		Lobar Pneumonia		Diltiazem			
		Lower Gastrointestinal		Hydrochloride	C		
UNKNOWN							
		Haemorrhage		Lasix (Furosemide)	C		
UNKNOWN							
		Macular Degeneration		Hydrochlorothiazide			
		Mental Impairment		And Triamterene	C		
UNKNOWN							
		Mitral Valve Incompetence		Lopressor	C		
UNKNOWN							
		Muscle Necrosis		Potassium			
		Neutrophil Percentage		(Unspecified)	C		
UNKNOWN							
		Increased					
		Oedema Peripheral					
		Peptic Ulcer					
		Peptic Ulcer Haemorrhage					
		Pneumonia					
		Postictal State					
		Pulmonary Arterial					
		Pressure Increased					
		Pulmonary Vascular					
		Disorder					
		Rectal Haemorrhage					
		Sinus Tachycardia					
		Skin Laceration					
		Skin Necrosis					
		Therapeutic Agent					
		Toxicity					
		Tricuspid Valve					
		Incompetence					
		Troponin I Increased					
		Upper Gastrointestinal					

	Haemorrhage Urinary Tract Infection Weight Decreased White Blood Cell Count Increased Wound Dehiscence

Date:09/02/04ISR Number: 4440088-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Acute Prerenal Failure Adverse Event Asthenia Blood Cholesterol Increased Cardiac Failure Congestive Cataract Nuclear Chest Pain Dementia

		Diabetes Mellitus					
		Dizziness					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Eye Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Disorder		[Therapy			
		Gastrooesophageal Reflux		Unspecified]	C		
UNKNOWN							
		Disease		[Therapy			
		Gout		Unspecified]	C		
UNKNOWN							
		Haemorrhage		Lotrel	C		ORAL
		Headache		Celexa	C		ORAL
		Hypertension		Maxzide	C		
UNKNOWN							
		Hypertensive Crisis		Lopressor	C		ORAL
		Hypertensive Heart		Nasonex	C		
RESPIRATORY							
		Disease					
(INHALATION)							
		Hypovolaemia		Nifedipine	C		
UNKNOWN							
		Local Swelling		Nitrostat	C		
UNKNOWN							
		Major Depression					
		Memory Impairment					
		Nausea					
		Oedema Peripheral					
		Pseudodementia					
		Pyelonephritis					
		Renal Failure Chronic					
		Sepsis					
		Sinusitis					
		Sleep Disorder					
		Soft Tissue Infection					
		Urinary Tract Infection					

Date:09/02/04ISR Number: 4440089-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00114
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Alopecia
	Amnesia
	Cardiac Murmur

Carpal Tunnel Syndrome
Chondromalacia
Colon Cancer
Contusion
Delirium
Dyspnoea
Electrocardiogram St
Segment Abnormal
Emotional Distress
Essential Hypertension
Fatigue
Fibromyalgia
Gastritis
Gastrooesophageal Reflux
Disease
Haemorrhage
Headache
Hypersensitivity
Hypoaesthesia
Keloid Scar
Major Depression
Meniscus Lesion
Migraine Without Aura

		Monarthritis					
		Nausea					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Cardiac Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteopenia		Elavil	C		
UNKNOWN							
		Osteoporosis		Norvasc	C		
UNKNOWN							
		Pain In Extremity		Effexor	C		
UNKNOWN							
		Palpitations		Ultram	C		
UNKNOWN							
		Panic Disorder With		Hydrocodone			
		Agoraphobia		Bitartrate	C		
UNKNOWN							
		Paraesthesia		Propranolol			
		Paranoia		Hydrochloride	C		
UNKNOWN							
		Peptic Ulcer					
		Rhinitis Allergic					
		Rotator Cuff Syndrome					
		Skin Lesion					
		Swelling					
		Synovitis					
		Tenosynovitis					
		Tension Headache					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urinary Incontinence					
		Urine Odour Abnormal					
		Vomiting					

Date:09/02/04ISR Number: 4440090-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00443
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain Upper
Other	Alopecia
	Arrhythmia
	Back Pain

Breast Mass
Cardiomegaly
Chest Pain
Cholecystitis
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Diverticulitis
Drug Hypersensitivity
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Emotional Distress
Exostosis
Foot Fracture
Fungal Infection
Gout
Haemorrhoids
Hernia
Hypertension
Ischaemia
Large Intestinal Ulcer

	Haemorrhage						
	Ligament Sprain						
	Oedema						
	Oesophageal Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY
	Osteoarthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Osteopenia		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY
	Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Otorrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Plantar Fasciitis		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY
	Pleural Effusion		[Therapy				
	Pneumonia		Unspecified]	C			UNKNOWN
	Renal Cyst		Insulin	C			UNKNOWN
	Rheumatoid Arthritis						
	Scoliosis						
	Seasonal Allergy						
	Sinusitis						
	Sleep Disorder						
	Temporomandibular Joint						
	Syndrome						
	Tendonitis						
	Vertigo						
	Weight Decreased						

Date:09/02/04ISR Number: 4440091-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00140
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Blood Pressure Increased		[Therapy				
	Cellulitis		Unspecified]	C			UNKNOWN
	Chest Pain		Percocet	C			UNKNOWN
	Depression						
	Emotional Distress						
	Fatigue						
	Fibromyalgia						

Headache
Hypersensitivity
Hypoaesthesia
Insomnia
Muscular Weakness
Musculoskeletal Stiffness
Osteoarthritis
Pain
Paraesthesia
Productive Cough
Pulmonary Congestion
Road Traffic Accident
Suture Insertion

Date:09/02/04ISR Number: 4440092-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Accident At Home
Other	Activated Partial Thromboplastin Time Prolonged

		Anxiety					
		Atrial Septal Defect					
		Balance Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bipolar Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Borderline Personality		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Breast Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Aneurysm		Vicodin Tablets	C		
UNKNOWN							
		Cardiac Failure		Norvasc	C		
UNKNOWN							
		Congestive		Aspirin	C		
UNKNOWN		668 DAY					
		Cellulitis		Zithromax	C		ORAL
4	DAY						
		Cerebral Infarction		Cogentin	C		ORAL
		Chest Pain		Tegretol-Xr	C		ORAL
		Coronary Artery Disease		Monopril	C		ORAL
		Coronary Artery		Neurontin	C		
UNKNOWN							
		Restenosis		Lithium Carbonate	C		ORAL
		Diverticulum		Coumadin	C		
UNKNOWN		96 DAY					
		Drug Abuser		Coumadin	C		
UNKNOWN							
		Drug Dependence		Coumadin	C		
UNKNOWN							
		Dyspnoea		Navane	C		ORAL
		Emotional Distress		Lithium Carbonate	C		ORAL
		Fibromyalgia		Claritin-D	C		
UNKNOWN							
		Haemorrhoids		Ativan	C		
UNKNOWN							
		Headache		Ativan	C		
UNKNOWN							
		Hyperkalaemia		Zyprexa	C		ORAL
		Hypertrophy Breast		Zyprexa	C		ORAL
		Hyponatraemia		Seroquel	C		
UNKNOWN							
		Injury					
		Intermittent Claudication					
		Intracranial Aneurysm					
		Lacunar Infarction					
		Leukocytosis					

Major Depression
Myocardial Infarction
Obsessive-Compulsive
Disorder
Oedema Peripheral
Overdose
Pain
Pollakiuria
Pulmonary Hypertension
Spinal Osteoarthritis
Suicidal Ideation
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Varices Oesophageal
Weight Increased

Date:09/02/04ISR Number: 4440093-9Report Type:Expedited (15-DaCompany Report #MY-MERCK-0407MYS00001
Age:84 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Fosamax	SS		ORAL		
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
			Fosamax	SS		ORAL		

Date:09/02/04ISR Number: 4440094-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/02/04ISR Number: 4440095-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	48	HR
Hospitalization - Initial or Prolonged	Atrial Fibrillation							
	Cardiac Failure Congestive							
	Rectal Haemorrhage							

Date:09/02/04ISR Number: 4440097-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02352
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:09/02/04ISR Number: 4440098-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02322
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/02/04ISR Number: 4440099-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01311
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive							

Date:09/02/04ISR Number: 4440100-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00808
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Arterial Occlusive
Hospitalization -	Disease
Initial or Prolonged	Blood Pressure Increased
Disability	Diabetes Mellitus
	Diarrhoea

	Fibromyalgia						
	Headache						
	Nail Discolouration	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Osteoporosis		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
	Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY
	Peripheral Coldness		Propranolol				
	Transient Ischaemic		Hydrochloride	C			UNKNOWN
	Attack		Diovan	C			UNKNOWN

Date:09/02/04ISR Number: 4440101-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02240
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	
Disability	Dyspnoea		[Therapy				
	Fatigue		Unspecified]	C			UNKNOWN
	Pharyngolaryngeal Pain		Vitamins				
	Pyrexia		(Unspecified)	C			UNKNOWN
	Rhinorrhoea		Ibuprofen	C			UNKNOWN

Date:09/02/04ISR Number: 4440103-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Ageusia
Disability	Anorexia
Other	Anosmia
	Aortic Valve
	Calcification
	Arthralgia
	Arthropathy
	Bronchitis
	Cardiomegaly

Coagulation Factor Viii
Level Increased
Colon Adenoma
Condition Aggravated
Deep Vein Thrombosis
Depression
Drug Ineffective
Dysgeusia
Dyspnoea
Emotional Distress
Fatigue
Hypercholesterolaemia
Hypercoagulation
Hypertension
Injury
Osteopenia
Osteoporosis
Oxygen Saturation
Decreased
Parosmia
Protein S Decreased
Pulmonary Embolism
Pyrexia
Rectal Haemorrhage
Renal Cyst

		Renal Disorder					
		Rhinitis					
		Skeletal Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
161	DAY						
		Weight Decreased		Acetaminophen	C		
UNKNOWN							
		Weight Increased		Aspirin	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Niaspan	C		
UNKNOWN							

Date:09/02/04ISR Number: 4440104-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00117
Age:76 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Adverse Event					
		Anaemia					
		Anxiety					
		Arthritis					
		Cardiac Disorder					
		Chest Pain					
		Depression					
		Diabetes Mellitus					
		Emotional Distress					
		Gastrooesophageal Reflux					
		Disease					
		Herpes Zoster					
		Insomnia					
		Multiple Myeloma					
		Nervousness					
		Neutropenia					

Oedema Peripheral
Sleep Apnoea Syndrome
Tremor

Date:09/02/04ISR Number: 4445653-7Report Type:Expedited (15-DaCompany Report #GBWYE780225MAY04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage	Health Professional	Premarin (Conjugated Estrogens, Unspec, 0)	PS		
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection, 0)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol, ,0)	SS		
			Fluoxetine (Fluoxetine, ,0)	SS		
			Humira (Adalimumab, ,0)	SS		
			Methotrexate			

(Methotrexate, Unspec, 0)	SS
Rofecoxib (Rofecoxib, , 0)	SS
Clavulin (Amoxicillin Trihydrate/Calvulanate Potassium)	C
Paramol-18 (Dihydrocodeine Bitartrate/Paracetamol)	C

Date:09/02/04ISR Number: 4446679-XReport Type:Expedited (15-DaCompany Report #WAES 0408USA01590
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease	Study	Tab Vioxx Unk	PS		ORAL	PO	
		Health Professional						

Date:09/02/04ISR Number: 4446683-1Report Type:Expedited (15-DaCompany Report #WAES 0408USA50147
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antinuclear Antibody	Study	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Positive	Health					MG/DAILY/PO	
	Blood Albumin Decreased	Professional	Acetaminophen	C				
	Blood Creatinine Increased		Terazosin Hydrochloride	C				
	Henoch-Schonlein Purpura		Triamcinolone	C				
	Rash		Vitamin B Complex	C				

Date:09/02/04ISR Number: 4446684-3Report Type:Expedited (15-DaCompany Report #WAES 0208USA02045
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Infarction	Health					MG/DAILY/PO	
	Menorrhagia	Professional	Tab Acetaminophen					
	Necrosis		325 Mg	SS		ORAL	325 MG/PRN/PO	
	Uterine Leiomyoma		Antioxidants	C				
	Uterine Polyp		Calcium	C				
	Uterine Prolapse		Dimenhydrinate	C				
	Vaginal Haemorrhage		Tamoxifen	C				
			Vitamins	C				

Date:09/03/04ISR Number: 4440505-0Report Type:Expedited (15-DaCompany Report #PHFR2004GB03352
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Glomerular Filtration Rate Decreased		Voltarol	PS	Novartis Sector: Pharma	ORAL	75 mg, BID	7200 MIN
	Hyperkalaemia		Rofecoxib	SS		ORAL	25 mg, QD	
			Domperidone	C			UNKNOWN	20 mg, TID
			Warfarin	C			UNKNOWN	
			Cetirizine	C			UNKNOWN	10 mg, QD
			Lansoprazole	C			UNKNOWN	30 mg, QD

		Paracetamol	C		
UNKNOWN	1 g, QID				
		Gabapentin	C		ORAL
300 mg, TID					
		Oramorph	C		ORAL
5-10 mg prn					
		Fentanyl	C		
TOPICAL	25 ug, QH				
		Amitriptyline	C		ORAL
50 mg, QD					
		Cisplatin	C		
UNKNOWN	UNK, UNK				

Date:09/03/04ISR Number: 4443254-8Report Type:Direct Company Report #CTU 226291
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Respiratory Failure		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG	DAILY
Initial or Prolonged	Dyspnoea							
Required	Hypoxia		Diltiazem	C				
Intervention to	Lung Infiltration		Isosorbide	C				
Prevent Permanent	Pulmonary Oedema		Warfarin	C				
Impairment/Damage			Digoxin	C				
			Duoneb	C				
			Primidone	C				
			Prednisone	C				
			Pantoprazole	C				
			Senna/Dss	C				
			Oxycodone	C				
			Linezolid	C				

Date:09/03/04ISR Number: 4445714-2Report Type:Expedited (15-DaCompany Report #2004-BP-07191AU
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ectopic Pregnancy	Health	Mobic (Meloxicam)					
Hospitalization -	Mouth Ulceration	Professional	(Ta)	PS		ORAL		
7.5 MG PO								

Initial or Prolonged		Other	Vioxx (Rofecoxib)	SS		ORAL
25 MG PO						

Date:09/03/04ISR Number: 4445892-5Report Type:Expedited (15-DaCompany Report #2004230591US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthma	Consumer	Bextra(Valdecoxib)			
Hospitalization -	Condition Aggravated		Tablet	PS		
Initial or Prolonged	Respiratory Arrest		Celecoxib			
			(Celecoxib)Capsule	SS		
			Vioxx	SS		

Date:09/07/04ISR Number: 4441772-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Lower
Other	Anhedonia
	Anxiety
	Arthralgia
	Back Pain
	Blood Cholesterol
	Increased
	Bronchitis Acute
	Bursitis

		Chest Discomfort					
		Chest Pain					
		Concussion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Constipation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Convulsion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Costochondritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Prevacid	C		
UNKNOWN							
		Drug Ineffective		Zocor	C		ORAL
		Duodenal Ulcer					
		Dysuria					
		Enterocolitis					
		Haemorrhagic					
		Erectile Dysfunction					
		Eye Disorder					
		Fall					
		Flatulence					
		Gastric Ulcer					
		Gastrooesophageal Reflux					
		Disease					
		Haematochezia					
		Haemorrhage					
		Head Injury					
		Hypertension					
		Hypogonadism					
		Kidney Infection					
		Migraine					
		Muscle Spasms					
		Nausea					
		Oedema Peripheral					
		Oesophageal Disorder					
		Palpitations					
		Renal Disorder					
		Syncope					
		Ulcer					

Date:09/07/04ISR Number: 4441776-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Adverse Event
Disability	Anorexia

Aortic Occlusion
Arthralgia
Blood Disorder
Bronchitis
Cerebral Atrophy
Cervical Myelopathy
Constipation
Contusion
Disability
Emotional Distress
Gait Spastic
Gout
Headache
Intermittent Claudication
Lung Infiltration
Nasopharyngitis
Obstruction

		Painful Respiration					
		Peripheral Circulatory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peroneal Nerve Palsy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Skin Laceration		Tylenol	C		
UNKNOWN							
		Weight Decreased					

Date:09/07/04ISR Number: 4441777-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0308FRA00033
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diarrhoea		Chondroitin Sulfate Sodium	C		ORAL
	Phlebitis		Fluvastatin Sodium	C		ORAL
	Vomiting		Irbesartan	C		ORAL
			Omeprazole	C		ORAL

Date:09/07/04ISR Number: 4441778-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02171
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
	Muscular Weakness					
	Pain					
	Palpitations					
	Swelling					

Date:09/07/04ISR Number: 4441780-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Brain Stem Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bunion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Cardiac Failure	[Therapy		
Other	Congestive	Unspecified]	C	
UNKNOWN				
	Cardiomegaly	[Therapy		
	Carotid Artery Stenosis	Unspecified]	C	
UNKNOWN				
	Cataract	Avandia	C	ORAL
	Contusion	Avandia	C	ORAL
	Coronary Artery Disease	Vicoprofen	C	ORAL
	Fall	Glucophage	C	ORAL
	Glaucoma	Glucophage	C	ORAL
	Hypoaesthesia			
	Lumbar Spinal Stenosis			
	Nasopharyngitis			
	Neuropathy Peripheral			
	Osteoarthritis			
	Road Traffic Accident			
	Rotator Cuff Syndrome			
	Spinal Osteoarthritis			
	Toe Deformity			
	Whiplash Injury			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/04ISR Number: 4441787-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00009
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure	Professional						

Date:09/07/04ISR Number: 4441792-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:09/07/04ISR Number: 4441794-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA02158
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aspiration	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Foreign Body Aspiration	Professional						
Disability	Gastrooesophageal Reflux Disease							
Other	Lung Disorder Lung Injury Vomiting							

Date:09/07/04ISR Number: 4441822-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00440
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	6	WK

Initial or Prolonged 6 WK Disability	Alopecia Arrhythmia Blood Pressure Increased Chondromalacia Dizziness Large Intestinal Ulcer Haemorrhage Nausea Oedema Oesophageal Ulcer Haemorrhage Patellofemoral Pain Syndrome Upper Respiratory Tract Infection Urinary Incontinence Urinary Tract Infection Vaginitis Bacterial Vulvovaginitis Trichomonal	Vioxx	SS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/07/04ISR Number: 4442534-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0409AUS00006
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vertigo		Acetaminophen	C		ORAL		
			Atorvastatin Calcium	C				
			Lansoprazole	C				
			Lansoprazole	C				

Date:09/07/04ISR Number: 4442550-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acrochordon	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Alopecia	Professional	Aspirin	C				
	Blood Pressure Increased		Diovan	C				
	Cystocele		Premarin	C				
	Dermatitis Contact							
	Fungal Skin Infection							
	Headache							
	Lichen Planus							
	Lung Neoplasm							
	Ovarian Mass							
	Rectocele							
	Seborrhoeic Dermatitis							
	Seborrhoeic Keratosis							
	Skin Lesion							
	Vaginal Prolapse							
	Wrist Deformity							

Date:09/07/04ISR Number: 4442556-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01842
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	386 DAY	
Initial or Prolonged		Professional	Maxzide	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Calan Sr	C			UNKNOWN	
			Xenical	C			UNKNOWN	

Date:09/07/04ISR Number: 4442561-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00013
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amenorrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hormone Level Abnormal		Paxil	C			UNKNOWN	

Date:09/07/04ISR Number: 4443152-XReport Type:Direct Company Report #CTU 226443
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Agitation
Disability	Anorexia
Required	Bed Rest
Intervention to	Blood Pressure Increased
Prevent Permanent	Chest Pain
Impairment/Damage	Dizziness

	Dyspepsia						
	Feeling Abnormal						
	Haemoptysis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemorrhage		Vioxx 50 Mg Merck	PS	Merck	ORAL	1/4 PILL ONCE A DAY ORAL
	Hypoaesthesia						
	Impaired Work Ability						
	Joint Swelling						
	Listless						
	Pain						
	Pulmonary Oedema						
	Respiration Abnormal						
	Wheezing						

Date:09/07/04ISR Number: 4446155-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00010
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	
Life-Threatening	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
Hospitalization -	Death		Acetaminophen	C		ORAL	
Initial or Prolonged	Oedema		Bisoprolol	C			UNKNOWN
	Renal Failure Acute		Hydrochlorothiazide	C			UNKNOWN
			Lisinopril	C			UNKNOWN
			Methotrexate	C			UNKNOWN
			Omeprazole	C		ORAL	

Date:09/07/04ISR Number: 4446157-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02092
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Disability	Aortic Calcification
	Arthralgia
	Arthritis

Blood Chloride Increased
Cardiomegaly
Carotid Artery Stenosis
Cerebellar Syndrome
Cerebral Infarction
Cerebral Ischaemia
Cerebrovascular Accident
Chest Pain
Coordination Abnormal
Depression
Eye Irritation
Gait Disturbance
Hypertension
Impaired Driving Ability
Impaired Work Ability
Injury
Joint Range Of Motion
Decreased
Mastoiditis
Musculoskeletal
Discomfort
Nausea
Nervous System Disorder
Nuclear Magnetic

	Resonance Imaging Brain Abnormal Oedema Peripheral Sensory Disturbance	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Soma	C			UNKNOWN
			Lamisil	C			UNKNOWN
			Motrin	C			UNKNOWN

Date:09/07/04ISR Number: 4446181-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00075
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 3 YR	Interstitial Lung Disease		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Metformin Hydrochloride	C		ORAL	

Date:09/08/04ISR Number: 4444163-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Adrenal Adenoma
	Angina Pectoris
	Arthralgia
	Arthritis
	Articular Calcification
	Back Pain
	Bronchitis
	Cardiomegaly
	Carotid Artery Atheroma

Cataract
Cellulitis
Chest Pain
Cholelithiasis
Chronic Fatigue Syndrome
Conjunctival Cyst
Constipation
Contusion
Cystitis
Cystitis Glandularis
Dilatation Atrial
Dizziness
Dizziness Postural
Dyspepsia
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Ear Infection
Electrocardiogram St
Segment Abnormal
Emotional Distress
Gastrointestinal Ulcer

		Gastrooesophageal Reflux Disease					
		Gingival Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gingival Swelling	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematuria	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased Tendency To		Tylenol	C		ORAL
		Bruise		Fosamax	C		
UNKNOWN							
		Mitral Valve		Tagamet	C		
UNKNOWN							
		Calcification		Pravachol	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Nausea					
		Nephrolithiasis					
		Nocturia					
		Nocturnal Dyspnoea					
		Osteoporosis					
		Palpitations					
		Parotid Gland Enlargement					
		Peptic Ulcer					
		Procedural Complication					
		Rhinitis Allergic					
		Salivary Gland Calculus					
		Stress Incontinence					
		Sweat Gland Tumour					
		Swelling Face					
		Thyroid Neoplasm					
		Tobacco Abuse					
		Tooth Abscess					
		Urethral Caruncle					
		Urinary Tract Infection					
		Visual Acuity Reduced					

Date:09/08/04ISR Number: 4444172-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 8 DAY		Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased	Professional	Diclofenac Sodium	SS		ORAL

	Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Bradycardia Gamma-Glutamyltransferase Increased		Tizanidine Hydrochloride	SS		ORAL
3 DAY						
			Herbs (Unspecified)	C		ORAL

Date:09/08/04ISR Number: 4444180-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00854
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Costochondritis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastric Disorder		Aspirin	C		
UNKNOWN						
	Hypertension		Senokot (Senna)	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/04ISR Number: 4444183-6Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00011
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Spasm	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Valdecoxib	C		ORAL		

Date:09/08/04ISR Number: 4444187-3Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00009
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Embolism	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

Date:09/08/04ISR Number: 4444190-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01009
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Lortab	C			UNKNOWN	
	Condition Aggravated		Combivent	C			UNKNOWN	
	Hypercalcaemia		Aspirin	C			UNKNOWN	
	Renal Failure		Coreg	C			UNKNOWN	
	Sepsis		Lasix (Furosemide					
	Treatment Noncompliance		Sodium)	C			UNKNOWN	
	Weight Increased		Azmacort	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	

			Nitroglycerin	C		
UNKNOWN						
			Benicar	C		
UNKNOWN						
			Oxygen	C		
UNKNOWN						

Date:09/08/04ISR Number: 4445028-0Report Type:Direct Company Report #CTU 226587
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Feeling Abnormal		Ibuprofen 800 Mg	PS		
2-3 TABS TID						
Initial or Prolonged	Hyperhidrosis		Vioxx 25 Mg	SS		
25 MG DAILY						
	Hyperkalaemia		Lisinopril 20 Mg			
	Hypotension		Daily	SS		
	Metabolic Acidosis		Several	C		
	Nausea					
	Oxygen Saturation					
	Decreased					
	Renal Failure Acute					
	Vomiting					

Date:09/08/04ISR Number: 4446177-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0401DEU00098
Age:67 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Anorexia
Initial or Prolonged	Decreased Appetite
	Drug Interaction
	Nausea
	Polymyalgia Rheumatica

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Enalapril Maleate	SS		ORAL		
	Theophylline	SS		ORAL		
	Torsemide	SS		ORAL		
	Leflunomide	SS		ORAL		

12 DAY

Date:09/08/04ISR Number: 4446912-4Report Type:Expedited (15-DaCompany Report #DSA_24864_2004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased	Foreign Health Professional Other	Tavor	PS				
	Blood Alkaline Phosphatase Increased		Clomipramine	SS				
	Gamma-Glutamyltransferase Increased		Novaminsulfon-Ratiopharm	SS				
	Idiopathic Thrombocytopenic Purpura		Rofecoxib	SS				
	Infection		Unspecified Ace Inhibitor	C				
			Unspecified Beta Blocker	C				
			Piritramide	C				
			Tramadol	C				
			Ranitidine	C				
			Certoparin Sodium	C				
			Insulin	C				
			Furosemide	C				
			Piperacillin	C				
			Sulbactam	C				
			Gentamicin	C				
			Sufentanil	C				
			Midazolam	C				

Date:09/09/04ISR Number: 4444789-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia

Anaemia Macrocytic
Anxiety
Asthenia
Back Injury
Blood Triglycerides
Increased
Bronchitis
Carotid Artery Disease
Cerebrovascular Accident
Chest Pain
Chronic Obstructive
Pulmonary Disease
Compression Fracture
Depression
Drug Ineffective
Dyspnoea
Haematochezia
Headache
Hypercholesterolaemia

	Hyperhidrosis						
	Hypoaesthesia						
	Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Migraine	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Myofascial Pain Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	78 DAY
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neoplasm Malignant		Vioxx	SS	Merck & Co., Inc	ORAL	78 DAY
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pharyngolaryngeal Pain		Zovirax	C			UNKNOWN
	Rash		Trimox	C			UNKNOWN
	Red Blood Cell		Celebrex	C			UNKNOWN
	Sedimentation Rate		Zyrtec	C			UNKNOWN
	Increased		Plavix	C		ORAL	
	Rhinitis Allergic		Nexium	C			UNKNOWN
	Sinusitis		Paxil	C			UNKNOWN 533 DAY
	Stress		Prednisone	C			UNKNOWN
	Thrombocytopenia						
	Transient Ischaemic Attack						

Date:09/09/04ISR Number: 4444791-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00168
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Upper Gastrointestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Haemorrhage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Other							

Date:09/09/04ISR Number: 4444792-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02208
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Lasix (Furosemide Sodium)	SS		
UNKNOWN						

Date:09/09/04ISR Number: 4444793-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Arrest
Hospitalization - Initial or Prolonged	Cardiac Failure
Other	Congestive Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diabetes Mellitus Inadequate Control
	Dizziness
	Dyspepsia
	Fatigue
	Gastritis
	Gastrointestinal Haemorrhage
	Hyperkalaemia

		Microcytic Anaemia Myocardial Infarction Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vertigo Positional		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Captopril	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Pepcid Ac	C		ORAL
				Lasix (Furosemide)	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Phenergan Tablets/Suppositories	C		
UNKNOWN							

Date:09/09/04ISR Number: 4444797-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00130
Age:45 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Death		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Ventricular Extrasystoles		Glucophage	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							

Date:09/09/04ISR Number: 4445314-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Percocet	C		ORAL		
	Cervicobrachial Syndrome		Elavil	C		ORAL		
	Death		Baclofen	C		ORAL		
	Depression		Dulcolax	C			UNKNOWN	
	Oedema		Wellbutrin	C		ORAL		
			Tegretol	C		ORAL		
			Soma	C		ORAL		
			Colace	C		ORAL		
			Neurontin	C		ORAL		
			Vistaril	C		ORAL		
			Vistaril	C		ORAL		
			Ativan	C		ORAL		
			Magnesia [Milk Of]	C			UNKNOWN	
			Mexiletine Hydrochloride	C		ORAL		
			Ms Contin	C		ORAL		
			Compazine	C			UNKNOWN	
			Compazine	C			UNKNOWN	
			Coumadin	C		ORAL		
			Fleet Enema	C			UNKNOWN	
			Seroquel	C			UNKNOWN	
			Seroquel	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/04ISR Number: 4445317-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Norvasc	C				
Disability	Asthenia		Lotrel	C			UNKNOWN	
	Blood Cholesterol		Coreg	C			UNKNOWN	
	Increased		Clonidine	C			UNKNOWN	
	Blood Creatinine		Clonidine	C		ORAL		
	Increased		Digitek	C			UNKNOWN	
	Bronchitis		Zocor	C		ORAL		
	Cardiac Failure		Spironolactone	C			UNKNOWN	
	Congestive		Nexium	C			UNKNOWN	
	Congestive Cardiomyopathy		Lisinopril	C			UNKNOWN	
	Cough		Reglan	C			UNKNOWN	
	Depression		Minoxidil	C			UNKNOWN	
	Dyspepsia		Minoxidil	C			UNKNOWN	1 DAY
	Emotional Distress		Minoxidil	C			UNKNOWN	
	Erectile Dysfunction							
	Facial Palsy							
	Gastroenteritis Viral							
	Gastrooesophageal Reflux Disease							
	Haemoglobin Decreased							
	Hypertension							
	Insomnia							
	Nasal Congestion							
	Neck Injury							
	Rhinorrhoea							
	Road Traffic Accident							
	Sinus Bradycardia							
	Sinusitis							
	Sleep Apnoea Syndrome							

Supraventricular
Extrasystoles
Upper Respiratory Tract
Infection
Ventricular Extrasystoles

Date:09/09/04ISR Number: 4445321-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Conjunctivitis		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
	Coronary Artery Disease		Fosamax	C		ORAL		
	Cough		Hydrodiuril	C		ORAL		
	Depression							
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							

Date:09/09/04ISR Number: 4445327-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT
Abdominal Pain
Abdominal Pain Lower
Anhedonia
Anxiety
Arthralgia
Back Injury
Back Pain
Blood Cholesterol
Increased
Bronchitis Acute
Bursitis
Chest Discomfort
Chest Pain
Colitis Ulcerative
Concussion
Condition Aggravated
Constipation
Convulsion
Costochondritis
Decreased Appetite
Depression
Diarrhoea
Dizziness
Dizziness Postural
Drug Ineffective
Duodenal Ulcer
Dysuria
Emotional Distress
Enterocolitis
Haemorrhagic
Erectile Dysfunction
Extrasystoles
Eye Disorder
Fall
Flatulence
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Haematochezia
Haemorrhage
Haemorrhoids
Head Injury
Headache
Hypertension

Hypertriglyceridaemia
Hypoglycaemia
Hypogonadism
Kidney Infection
Loss Of Consciousness
Migraine
Muscle Spasms
Nausea
Oedema Peripheral
Oesophageal Disorder
Pain
Palpitations
Renal Disorder
Syncope

	Ulcer						
	Ulna Fracture						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C			UNKNOWN	
			Zocor	C		ORAL		

Date:09/09/04ISR Number: 4445340-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00122
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		[Therapy Unspecified]	C			UNKNOWN	
	Arthritis							
	Asthenia		Tylenol	C			UNKNOWN	
	Bladder Disorder		Lortab	C			UNKNOWN	
	Breast Mass		Amoxil	C			UNKNOWN	
	Bronchitis		Folic Acid	C			UNKNOWN	
	Cardiac Disorder		Mylicon	C			UNKNOWN	
	Cardiac Flutter		Remicade	C			UNKNOWN	
	Constipation		Injectable Gold (Unspecified)	C			UNKNOWN	
	Dizziness							
	Dysmenorrhoea		Methotrexate	C			UNKNOWN	
	Emotional Distress		Methotrexate	C			UNKNOWN	
	Headache		Naprosyn	C			UNKNOWN	
	Menorrhagia		Metamucil	C			UNKNOWN	

Nausea
Post Procedural
Complication
Swelling
Upper Respiratory Tract
Infection
Uterine Leiomyoma
Weight Decreased

Date:09/09/04ISR Number: 4445342-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00153
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/09/04ISR Number: 4445378-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00275
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lotrel	C				
Other			Plavix	C				
			Zetia	C		ORAL		
			Synthroid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/09/04ISR Number: 4447920-XReport Type:Direct Company Report #CTU 226738
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Influenza Like Illness		Vioxx 25 Mg. Merck	PS	Merck	ORAL	25 MG	DAILY
	Pain							
ORAL								
			Trazodone	C				
			Zyrtec	C				

Date:09/09/04ISR Number: 4448400-8Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-252
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign Health Professional Distributor	Methotrexate (Methotrexate, Unspec)	PS				
			Premarin (Conjugated Estrogens, Unspec)	SS				
			Augmentin (Amoxicillin Sodium/Clavulanante Potassium, Injectin)	SS				
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS				
			Fluoxetine (Fluoxetine)	SS				
			Humira (Adalimumab)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C				
			Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C				

Date:09/09/04ISR Number: 4448569-5Report Type:Expedited (15-DaCompany Report #8157
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign	Methotrexate	PS				
		Other	Premarin	SS				
			Augmentin	SS				
			Co-Dydramol	SS				
			Fluoxetine	SS				
			Humira	SS				
			Rofecoxib	SS				

Date:09/09/04ISR Number: 4448732-3Report Type:Expedited (15-DaCompany Report #2004-BP-07358AU
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyponatraemia	Health Professional	Micardis Tablets (Telmisartan) (Ta)	PS		ORAL	PO	2 DAY
		Other	Frusemide					

				(Furosemide) (Ta)	SS		ORAL
20 MG (20 MGONCE DAILY) ,PO; 18/DE	2	DAY					
				Vioxx (Rofecoxib) (Ta)	SS		ORAL
25 MG (25 MG, 25 MG ONCE DAILY), PO							
				Thyroxine	C		
				Cefaclor (Cefaclor)	C		
				Pantoprazole (Pantoprazole)	C		
				Mianserin (Mianserin)	C		
				Ms Contin (Morphine Sulfate)	C		
				Kapanol (Morphine Sulfate)	C		

Date:09/09/04ISR Number: 4448746-3Report Type:Expedited (15-DaCompany Report #2004-BP-07131AU
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoglobin Abnormal Hypercalcaemia Renal Failure Acute	Foreign Health Professional Other	Persantin Tablets (Dipyridamole) (Ta)	PS		ORAL	400 MG (, 400MG DAILY) PO	
			Quick-Eze (Quick-Eze) (Nr)	SS		ORAL	(,DAILY) PO	
			Rofecoxib (Rofecoxib) (Ta)	SS		ORAL	PO	
			Frusemide (Furosemide) (Ta)	SS		ORAL	40 MG (, 40MG	

DAILY) PO

Aspirin (Acetylsalicylic Acid) (Ta)	SS	ORAL

150 MG

(,150MG

DAILY) PO

Diltiazem (Diltiazem) (Ta)	SS	ORAL

80 MG (, 80MG

DAILY) PO

Potassium Chloride (Potassium Chloride)	C

Date:09/10/04ISR Number: 4445964-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Arrhythmia
	Cardiac Failure
	Congestive
	Chest Pain
	Dizziness
	Feeling Hot
	Hyperhidrosis
	Ingrowing Nail
	Malaise
	Onychomycosis

		Palpitations Renal Failure Chronic Skin Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL
138 DAY							
			Professional	Vioxx	SS	Merck & Co., Inc	ORAL
138 DAY							
				[Therapy Unspecified]	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Phoslo	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN		48 DAY					
				Digoxin	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Terazosin Hydrochloride	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Epogen	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Apresoline	C		
UNKNOWN							
				Infed	C		
UNKNOWN							
				Zemplar	C		
UNKNOWN							

Date:09/10/04ISR Number: 4445965-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Acute Prerenal Failure Adverse Event Angina Pectoris

Asthenia
Blood Cholesterol
Increased
Cardiac Failure
Congestive
Cataract Nuclear
Chest Pain
Coronary Artery Disease
Dementia
Diabetes Mellitus
Dizziness
Dyspnoea
Emotional Distress
Eye Pain
Gastric Disorder
Gastrooesophageal Reflux
Disease
Gout
Haemorrhage
Headache
Hyperlipidaemia
Hypertension
Hypertensive Crisis
Hypertensive Heart
Disease
Hypovolaemia
Local Swelling
Major Depression
Memory Impairment
Nausea
Oedema Peripheral

		Pseudodementia					
		Pyelonephritis					
		Renal Failure Chronic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sepsis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Sinusitis	Professional	[Therapy			
		Sleep Disorder		Unspecified]	C		
UNKNOWN							
		Soft Tissue Infection		[Therapy			
		Urinary Tract Infection		Unspecified]	C		
UNKNOWN							
				Lotrel	C		ORAL
				Celexa	C		ORAL
				Maxzide	C		
UNKNOWN							
				Lopressor	C		ORAL
				Nasonex	C		
RESPIRATORY							
(INHALATION)							
				Nifedipine	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:09/10/04ISR Number: 4445981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00155
Age:80 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/10/04ISR Number: 4445982-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA01617
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Diarrhoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Medication Error		Xanax	C		
UNKNOWN							

	Urinary Tract Infection	Zanaflex	C
UNKNOWN			
		Topamax	C
UNKNOWN			
		Senokot (Senna)	C
UNKNOWN			
		Methadone Hcl	C
UNKNOWN			
		Morphine	C
UNKNOWN			
		Aciphex	C
UNKNOWN			

Date:09/10/04ISR Number: 4445983-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00114
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diarrhoea	Professional	Celecoxib	SS		ORAL
	Generalised Oedema		Cefpodoxime Proxetil	C		ORAL

Date:09/10/04ISR Number: 4446622-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Aneurysm
Disability	Arteriovenous
Other	Malformation
	Cerebral Haemangioma
	Convulsion

	Emotional Distress Haemarthrosis Ligament Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ligament Sprain		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Celebrex	C			UNKNOWN

Date:09/10/04ISR Number: 4446624-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	611 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	611 DAY
Initial or Prolonged	Bipolar Disorder		Midrin	C			UNKNOWN
Disability	Blood Cholesterol		Tricor	C			UNKNOWN
	Increased		Neurontin	C			UNKNOWN
	Blood Triglycerides		Hydrochlorothiazide	C			UNKNOWN
	Increased		Zanaflex	C			UNKNOWN
	Cervicobrachial Syndrome Condition Aggravated		Trazodone Hydrochloride	C			UNKNOWN
	Diarrhoea		Maxzide	C			UNKNOWN
	Emotional Distress Fatigue		Hydrocodone Hydrochloride	C			UNKNOWN
	Hypertension		Lidoderm	C			UNKNOWN
	Hysterectomy		Ativan	C			UNKNOWN
	Intervertebral Disc		Remeron	C			UNKNOWN
	Degeneration Menorrhagia Menstrual Disorder						

Myofascial Pain Syndrome
Neck Pain
Nerve Compression
Oedema
Oedema Peripheral
Pelvic Pain
Radiculitis
Renal Failure
Renal Failure Acute
Tibia Fracture

Date:09/10/04ISR Number: 4446625-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Agitation
Other	Alcoholism
	Anticonvulsant Drug Level
	Decreased
	Arthralgia
	Balance Disorder
	Belligerence
	Cholelithiasis
	Complex Partial Seizures
	Condition Aggravated
	Constipation
	Depressed Level Of
	Consciousness
	Depressed Mood

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Diarrhoea					
		Dizziness					
		Drug Hypersensitivity					
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Level Decreased		Ms Contin	SS		
UNKNOWN							
		Emotional Distress		Aspirin	C		
UNKNOWN							
		Fall		Vitamins			
		Fatigue		(Unspecified)	C		
UNKNOWN							
		Folliculitis		Tegretol	C		
UNKNOWN							
		Gingival Hyperplasia		Depakote	C		
UNKNOWN							
		Grand Mal Convulsion					
		Headache					
		Hepatic Enzyme Increased					
		Hepatic Steatosis					
		Hyperlipidaemia					
		Hypernatraemia					
		Hypertension					
		Hypoacusis					
		Injury					
		Intervertebral Disc					
		Degeneration					
		Low Density Lipoprotein					
		Increased					
		Memory Impairment					
		Meningitis					
		Migraine					
		Myocardial Infarction					
		Nail Pitting					
		Nasal Polyps					
		Neck Pain					
		Osteoarthritis					
		Osteopenia					
		Osteoporosis					
		Otitis Media					
		Periarthritis					
		Psoriasis					
		Pyrexia					
		Radius Fracture					
		Rash					
		Respiratory Failure					
		Respiratory Papilloma					

Sepsis
Spinal Osteoarthritis
Stupor
Synovitis
Therapy Non-Responder
Tinnitus
Vaginal Infection
Vertigo
Vomiting
Weight Increased
Wrist Fracture

Date:09/10/04ISR Number: 4446628-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/10/04ISR Number: 4446631-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01641
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Embolism		[Therapy					
Initial or Prolonged	Thrombosis		Unspecified]	C				
UNKNOWN								
Disability			Hormones					
			(Unspecified)	C				
UNKNOWN								

Date:09/10/04ISR Number: 4446632-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00236
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy					
			Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Amaryl	C				
UNKNOWN								

Date:09/10/04ISR Number: 4446634-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01129
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Darvocet-N	C		ORAL		
Initial or Prolonged	Cholecystitis Chronic		Darvocet-N	C		ORAL		
Other	Cholelithiasis		Amitriptyline					
	Depression		Hydrochloride	C				
AURICULAR								
	Fracture Delayed Union							
(OTIC)								
	Gastric Ulcer Haemorrhage		Amitriptyline					
	Ileal Ulcer		Hydrochloride	C				
UNKNOWN								

	Injury	Timoptic	C	
OPHTHALMIC				
	Liver Function Test	Aspirin	C	
UNKNOWN				
	Abnormal	Lipitor	C	ORAL
	Malnutrition	Calcium		
	Sepsis	(Unspecified)	C	
UNKNOWN				
	Small Intestinal	Centrum	C	
UNKNOWN				
	Haemorrhage			
	Upper Gastrointestinal			
	Haemorrhage			
	Wrist Fracture			

Date:09/10/04ISR Number: 4446635-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Aortic Dilatation
	Back Pain
	Cellulitis
	Cerebral Atherosclerosis
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Dizziness
	Drug Hypersensitivity

		Dyspepsia					
		Dysphagia					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ear Pain		Vioxx	PS	Merck & Co., Inc	ORAL
97	DAY						
		Eructation		Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Fall		Acetaminophen And			
		Fatigue		Oxycodone			
		Generalised Anxiety		Hydrochloride	C		ORAL
		Disorder		Doxepin			
		Haemorrhage Intracranial		Hydrochloride	C		
UNKNOWN							
		Headache		Ultram	C		ORAL
		Hiatus Hernia		Zanaflex	C		
UNKNOWN							
		Hypersensitivity		Neurontin	C		ORAL
		Hypertension		Serzone	C		ORAL
		Hypoaesthesia					
		Insomnia					
		Joint Effusion					
		Joint Injury					
		Joint Sprain					
		Local Swelling					
		Oesophagitis					
		Pain					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Psoriasis					
		Pulmonary Congestion					
		Retinal Ischaemia					
		Rhinitis					
		Rhinitis Allergic					
		Sleep Apnoea Syndrome					
		Ventricular Extrasystoles					
		Visual Acuity Reduced					
		Visual Disturbance					

Date:09/10/04ISR Number: 4446645-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged Disability	Adverse Event	Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN	Anxiety	Tylenol	C		
Other	Appendix Disorder	Zyrtec	C		
UNKNOWN	Blood Pressure Increased	Zyrtec	C		
UNKNOWN	Chest Pain Complex Regional Pain Syndrome Dizziness Duodenitis Emotional Distress Gastric Polyps Gastritis Gastrooesophageal Reflux Disease Headache Hepatic Cirrhosis Major Depression Nausea Neurodermatitis Pancreatitis Chronic Radiculitis Lumbosacral				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/04ISR Number: 4446646-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Initial or Prolonged	Acute Myocardial		Prozac	C				UNKNOWN
Disability	Infarction		Oxycodone	C				UNKNOWN
	Acute Respiratory Failure		Zoloft	C				UNKNOWN
	Arthralgia		Diovan	C				UNKNOWN
	Cardiac Failure		Ultram	C				UNKNOWN
	Congestive		Zantac	C		ORAL		
	Cardiogenic Shock		Maxalt (Rizatriptan Benzoate)	C		ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Coronary Artery Disease							
	Emotional Distress							
	Encephalopathy							
	Fatigue							
	Folliculitis							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypercholesterolaemia							
	Intervertebral Disc Protrusion							
	Ischaemic Cardiomyopathy							
	Ischaemic Hepatitis							
	Lung Infiltration							
	Migraine							
	Multi-Organ Failure							
	Muscle Spasms							
	Oedema Peripheral							
	Panic Disorder							
	Renal Failure Acute							
	Tendonitis							
	Thyroid Neoplasm							
	Ulcer Haemorrhage							
	Urinary Tract Infection							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Visual Disturbance

Date:09/10/04ISR Number: 4446653-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00069
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
	Chest Pain		Tylenol Extra Strength	C			UNKNOWN	
	Dizziness							
	Dyspnoea		Combivent	C			RESPIRATORY (INHALATION)	
	Emphysema							
	Gastric Disorder		Ascriptin	C			UNKNOWN	
	Haematochezia		Verelan	C			UNKNOWN	
	Headache		Capoten	C			UNKNOWN	
	Hypertension		Colace	C			UNKNOWN	
	Nausea		Cardura	C			UNKNOWN	
	Trigger Finger		Esidrix	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/10/04ISR Number: 4446654-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00257
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea Gastrointestinal Erosion Haematochezia Pallor Rectal Haemorrhage Rectal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/10/04ISR Number: 4446657-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02240
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

Date:09/10/04ISR Number: 4446658-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00488
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/10/04ISR Number: 4446659-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00273
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 2 WK	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Blood Pressure Increased		Aspirin	C		
	Headache		Vitamins (Unspecified)	C		
UNKNOWN						

Date:09/10/04ISR Number: 4446660-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01458
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
			Lotrel	C		
UNKNOWN						

Date:09/10/04ISR Number: 4446670-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00233
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY						
	Abnormal Faeces					
	Gastrointestinal Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/04ISR Number: 4448002-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acrochordon	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
Initial or Prolonged	Anxiety		Aspirin	C		ORAL		
Other	Aortic Valve Incompetence		Bumex	C		ORAL		
	Cardiac Failure		Lamisil	C		ORAL		
	Congestive		Premarin	C		ORAL		
	Cerebrovascular Accident		Prinivil	C		ORAL		
	Depression							
	Diarrhoea							
	Dizziness							
	Dyspnoea							
	Emotional Distress							
	Fall							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Heart Rate Irregular							
	Hyperglycaemia							
	Injury							
	Intervertebral Disc							
	Displacement							
	Oedema							
	Onychomycosis							
	Oropharyngeal Spasm							
	Parkinson'S Disease							
	Peripheral Vascular							
	Disorder							
	Renal Failure							
	Sciatica							
	Seborrhoeic Keratosis							
	Sleep Apnoea Syndrome							
	Stomach Discomfort							
	Swelling Face							
	Transient Ischaemic							
	Attack							
	Tremor							
	Urinary Tract Infection							
	Vascular Stenosis							
	Vertigo							

Date:09/13/04ISR Number: 4448011-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Anxiety
	Arthropathy
	Atelectasis
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Depression
	Dizziness
	Hemiparesis
	Hypersensitivity
	Hypertension
	Osteoarthritis
	Rash Macular

Uterine Disorder

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/13/04ISR Number: 4448012-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN	Asthenia		Aspirin	C				
Disability	Benign Prostatic		Restoril	C				
UNKNOWN	Hyperplasia							
	Choking							
	Circulatory Collapse							
	Cough							
	Depression							
	Diverticulum							
	Dysuria							
	Erosive Duodenitis							
	Fatigue							
	Gastritis Erosive							
	Gastrooesophageal Reflux							
	Disease							
	Haematemesis							
	Heat Stroke							
	Hiatus Hernia							
	Hypertension							
	Hypoacusis							
	Injury							
	Muscle Atrophy							
	Oesophageal Rupture							
	Pancreatitis							
	Prostate Induration							
	Renal Cyst							
	Rhinorrhoea							
	Supraventricular							
	Extrasystoles							
	Thromboembolic Stroke							
	Transient Ischaemic							
	Attack							

Upper Respiratory Tract
Infection
Urinary Retention
Urinary Tract Disorder
Urinary Tract Infection
Weight Decreased

Date:09/13/04ISR Number: 4448013-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00307
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/04ISR Number: 4448014-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00447
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:09/13/04ISR Number: 4448015-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00001
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
26 DAY								
Initial or Prolonged	Atrial Flutter	Professional	Digoxin	SS		ORAL		
	Bradycardia		Digoxin	SS		ORAL		
	Cardioactive Drug Level		Diltiazem					
	Increased		Hydrochloride	SS		ORAL		
	Drug Interaction		Diltiazem					
	Hypercholesterolaemia		Hydrochloride	SS		ORAL		
	Hypothyroidism		Perindopril Erbumine	SS		ORAL		
	Nausea		Allopurinol	C		ORAL		
	Nodal Arrhythmia		Fluindione	C		ORAL		
	Renal Failure		Levothyroxine Sodium	C		ORAL		
	Vomiting		Potassium Chloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Oxerutins	C		ORAL		
			Furosemide	C		ORAL		
			Fluindione	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		

Date:09/13/04ISR Number: 4448016-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00100
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acrochordon
Initial or Prolonged	Angina Unstable
Other	Angiopathy
	Aortic Valve Incompetence

Arteriosclerosis
Blood Calcium Increased
Blood Pressure Systolic
Increased
Bundle Branch Block
Bundle Branch Block Left
Calcinosis
Cardiac Disorder
Cardiac Failure
Congestive
Cardiac Murmur
Cardiomegaly
Cerebral Atrophy
Cerebral Ischaemia
Chest Pain
Coagulation Time
Prolonged
Condition Aggravated
Contusion
Convulsion

Corneal Deposits
Coronary Artery Disease
Coronary Artery Stenosis
Crying
Cystitis
Deep Vein Thrombosis
Depression
Diarrhoea
Dizziness Postural
Electrocardiogram St-T
Change
Electrocardiogram T Wave
Abnormal
Eye Disorder
Eye Haemorrhage
Fall
Fatigue
Fluid Overload
Fluid Retention
Foot Fracture
Gallbladder Disorder
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Hypercholesterolaemia
Hypertension
Hypertensive
Cardiomyopathy
Hypertonic Bladder
Immune System Disorder
Insomnia
International Normalised
Ratio Increased
Ischaemic Cardiomyopathy
Kidney Infection
Klebsiella Infection
Loss Of Consciousness
Lung Disorder
Macular Degeneration
Migraine
Mitral Valve Disease
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Myoglobin Blood Increased
Nausea
Oedema Peripheral

Orthostatic Hypotension
Osteoporosis
Papilloma Excision
Parathyroid Tumour Benign
Pericardial Effusion
Prothrombin Time
Prolonged
Pulmonary Hypertension
Renal Mass
Spinal Osteoarthritis
Stress Incontinence
Supraventricular
Extrasystoles
Supraventricular

	Tachycardia						
	Syncope						
	Thyroid Disorder						
	Urge Incontinence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Urinary Incontinence	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Urinary Tract Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Uterine Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Weight Decreased		Midrin	C			UNKNOWN
	Weight Increased		Elavil	C		ORAL	
			Norvasc	C			UNKNOWN
			Effexor	C			UNKNOWN
			Celexa	C			UNKNOWN
			Premarin	C			UNKNOWN
			Levothyroxine Sodium	C			UNKNOWN
			Robaxin	C			UNKNOWN
			Phenobarbital	C			UNKNOWN

Date:09/13/04ISR Number: 4448019-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Hospitalization - Initial or Prolonged							

Date:09/13/04ISR Number: 4448053-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00247
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Arteriosclerosis
Disability	Balance Disorder

Blood Cholesterol
Increased
Breast Fibrosis
Cerebral Infarction
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Dyspnoea
Dyspnoea Exertional
Emphysema
Encephalomalacia
Facial Palsy
Gait Disturbance
Hand Fracture
Hepatic Cyst
Intraductal Papilloma Of
Breast
Mitral Valve Incompetence
Obstructive Airways
Disorder
Oxygen Saturation
Decreased
Pericardial Effusion
Pericardial Fibrosis
Pulmonary Hypertension
Pulmonary Vascular
Disorder

	Rash						
	Sinus Bradycardia						
	Sinus Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Spirometry Abnormal	Health	Vioxx	PS	Merck & Co., Inc	ORAL	147 DAY
	Tricuspid Valve	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	147 DAY
	Incompetence		Elavil	C			UNKNOWN
	Wheezing		Aspirin	C			UNKNOWN
			Bromfenex (Brompheniramine Maleate (+) Pseudoephedrine Hydrochloride)	C			UNKNOWN
			Zyrtec	C			UNKNOWN
			Flexeril	C			UNKNOWN
			Prempro	C			UNKNOWN
			Deconsal	C			UNKNOWN
			Skelaxin	C			UNKNOWN
			Nasonex	C			UNKNOWN
			Potassium (Unspecified)	C			UNKNOWN
			Inderal	C			UNKNOWN

Date:09/13/04ISR Number: 4448272-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01730
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Acidosis		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	

	Astigmatism	Vioxx	SS	Merck & Co., Inc	ORAL	
	Back Pain	Vioxx	SS	Merck & Co., Inc	ORAL	
	Blood Pressure Increased	Lipitor	C			
UNKNOWN	3142 DAY					
	Cardiac Disorder	Lotensin	C			
UNKNOWN						
	Cardiac Ventricular	Lotensin	C			
UNKNOWN						
	Disorder	Vasotec	C		ORAL	
3507 DAY						
	Cataract	Vasotec	C		ORAL	
3507 DAY						
	Chest Discomfort	Prozac	C			
UNKNOWN						
	Chills	Prozac	C			
UNKNOWN						
	Coronary Artery Disease	Prozac	C			
UNKNOWN						
	Coronary Artery Occlusion	Ginseng	C			
UNKNOWN						
	Coronary Artery	Naproxen	C			
UNKNOWN						
	Restenosis	Accupril	C			
UNKNOWN						
	Cough	Accupril	C			
UNKNOWN						
	Diverticulum					
	Fatigue					
	Flank Pain					
	Gastritis					
	Gastrooesophageal Reflux					
	Disease					
	Haemorrhoids					
	Helicobacter Gastritis					
	Hiatus Hernia					
	Hyperhidrosis					
	Hypermetropia					
	Myocardial Ischaemia					
	Osteoarthritis					
	Pleuritic Pain					
	Rhinorrhoea					
	Rotator Cuff Syndrome					

Date:09/13/04ISR Number: 4448273-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00270
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/13/04ISR Number: 4448274-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02199
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	26	DAY
	Cardiac Failure		Clonidine	C			UNKNOWN	
	Congestive		Diazide	C			UNKNOWN	
	Cyanosis		Singulair	C		ORAL		

Date:09/13/04ISR Number: 4448275-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Celebrex	C			UNKNOWN	4 YR
	Nasal Mucosal Disorder							
	Pyrexia							
	Sinus Disorder							

Date:09/13/04ISR Number: 4448277-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00079
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Left Ventricular Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirin	C		ORAL
			Atenolol	C		ORAL
			Simvastatin	C		ORAL
			Cimetidine	C		ORAL
			Gliclazide	C		ORAL
			Metformin	C		ORAL

Date:09/13/04ISR Number: 4448278-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00271
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Clonidine	C		
UNKNOWN						
Initial or Prolonged			Lanoxin	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Lopid	C		
UNKNOWN						
			Lopressor	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/04ISR Number: 4448292-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00055
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		705 DAY
	Melaena							

Date:09/13/04ISR Number: 4448350-7Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-252
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage	Foreign Health Professional Distributor Other	Methotrexate (Methotrexate, Unspec)	PS			SUBCUTANEOUS	40 G/M^2 1X PER 2 WK, SC
			Premarin (Conjugated Estrogens, Unspec)	SS				
			Augmentin (Amoxicillin Sodium /Clavulanate Potassium, Injection)	SS				
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS				
			Fluoxetine (Fluoxetine)	SS				
			Humira (Adalimumab)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C				
			Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C				

Date:09/13/04ISR Number: 4449319-9Report Type:Expedited (15-DaCompany Report #2004231254US
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Literature	Celebrex (Celecoxib)					
	Acute Respiratory Failure	Health	Capsule	PS			100 MG, BID	
	Hypertensive	Professional	Rofecoxib Rofecoxib)					
	Cardiomyopathy		Tablet	SS			25 MG QD	
	Medication Error		Atorvastatin	C				
	Respiratory Acidosis							

Date:09/13/04ISR Number: 4449383-7Report Type:Expedited (15-DaCompany Report #2004061793
Age: Gender:Female I/FU:I

Outcome	PT
Other	Anxiety
	Back Disorder
	Drug Ineffective
	Fibromyalgia

	Hip Surgery Knee Operation Nervousness	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Pain Paralysis	Consumer	Zoloft (Sertraline)	PS		
			Rofecoxib (Rofecoxib)	SS		
U/HR						
			Hydrocodone (Hydrocodone)	SS		

Date:09/13/04ISR Number: 4449560-5Report Type:Direct Company Report #CTU 226911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Creatinine Increased		Rofecoxib 25 Mg Merck	PS	Merck	ORAL
12.5 MG DAILY						
ORAL						

Date:09/13/04ISR Number: 4449616-7Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-372
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Pain Bone Marrow Depression Diarrhoea	Foreign Health Professional	Rheumatrex (Methotrexate, Capsule)	PS		ORAL
6 MG 1X PER 1						
	Haemodialysis	Distributor				
WK, ORAL						
	Retinal Haemorrhage Urine Output Decreased		Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS		
			Fluoxetine			

		(Fluoxetine)	SS
		Humira (Adalimumab)	SS
SUBCUTANEOUS	40 G/M^2 1X PER 2 WK, SC		
		Rofecoxib (Rofecoxib)	SS
		Enalapril	C
		Allozym (Allopurinol)	C
		Voltaren (Diclofenac Sodium)	C
		Mucosta (Rebamipide)	C
		Atelec (Cilnidipine)	C
		Clavulin (Amoxicillin Trihydrate/Clavulanate Potassium)	C
		Paramol-118 (Dihydrocodeine Bitartrate/Paracetamol)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/13/04ISR Number: 4449618-0Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-252
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage	Foreign Health Professional Distributor Other	Methotrexate (Methotrexate, Unspec)	PS		
			Premarin (Conjugated Estrogens, Unspec)	SS		
			Augmentin (Amoxicillin Sodium/Clavulanate Potassium, Injection)	SS		
			Co-Dydramol (Dihydrocodeine Bitartrate/Paracetamol)	SS		
			Fluoxetine (Fluoxetine)	SS		
			Humira (Adalimumab)	SS		
SUBCUTANEOUS 40 G/M^2 1X						
PER 2 WK, SC						
			Rofecoxib (Rofecoxib)	SS		
			Clavulin(Amoxicillin Trihydrate/Clavulanate Potassium)	C		
			Paramol-118(Dihydrocodeine Bitartrate/Paracetamol)	C		

Date:09/14/04ISR Number: 4448421-5Report Type:Expedited (15-DaCompany Report #PHBS2004CH11775
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Voltaren	PS	Novartis Sector: Pharma	
UNKNOWN 4320 MIN						
Other	Aspartate		Sirdalud	SS		
UNKNOWN 6 mg/day 4320 MIN						

	Aminotransferase	Vioxx	SS
UNKNOWN	4320 MIN		
	Increased	Herbal Extracts Nos	SS
	Blood Alkaline		
	Phosphatase Increased		
	Bradycardia		
	Chest Discomfort		
	Diarrhoea		
	Drug Interaction		
	Dyspnoea		
	Fibrin D Dimer Increased		
	Gamma-Glutamyltransferase		
	Increased		
	Haemangioma Of Liver		
	Hepatic Enzyme Increased		
	Hepatic Lesion		
	Hyperhidrosis		
	Liver Disorder		
	Pleural Effusion		
	Pulmonary Hypertension		
	Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/04ISR Number: 4448424-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0407NZL00013
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Amitriptyline Hydrochloride	C				
	Local Swelling							
	Mouth Ulceration		Anastrozole	C				
	Oedema Peripheral		Omeprazole	C				

Date:09/14/04ISR Number: 4448425-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Benadryl	C				
	Bronchitis		Motrin	C				
	Cerebral Infarction		Paxil	C				
	Cerebrovascular Accident		Paxil	C				
	Constipation							
	Drug Withdrawal Syndrome							
	Dyspepsia							
	Dyspnoea							
	Eczema Infected							
	Emotional Distress							
	Fractured Coccyx							
	Gastritis							
	Headache							
	Hemiparesis							
	Nasopharyngitis							
	Oedema Peripheral							
	Pain In Extremity							
	Pharyngolaryngeal Pain							
	Pneumonia							
	Polytraumatism							

Rash
Sinus Congestion
Sinusitis
Syncope
Thyroid Pain
Vision Blurred

Date:09/14/04ISR Number: 4449446-6Report Type:Expedited (15-DaCompany Report #PERI00204003056
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia Cardioactive Drug Level	Foreign Health	Coversyl (Perindopril)	PS		ORAL	4 MG QD PO	
	Increased	Professional	Vioxx (Rofecoxib)	SS		ORAL	DAILY, PO	
	Drug Interaction Embolism	Other	Hemigoxine Nativelle (Digoxine)	SS		ORAL	2 DF DAILY PO	
	Loss Of Consciousness Pallor Peripheral Ischaemia		Bi-Tildiem (Diltiazem Hydrochloride)	SS		ORAL	2 DF DAILY PO	
	Renal Failure		Previscan (Fluindione)	C				
			Levothyrox (Levothyroxine Sodium)	C				

			Amlor (Amlodipine Besilate)	C		
			Lasilix (Furosemide)	C		
			Diffu K (Potassium Chloride)	C		
			Zyloric "Fresenius" (Allopurinol)	C		
			Relvene (Rutoside)	C		
			Tahor (Atorvastatin)	C		
			Eupantol (Pantoprazole)	C		
			Fixical D3 (Fixical D3)	C		

Date:09/14/04ISR Number: 4450194-7Report Type:Expedited (15-DaCompany Report #04P-062-0261391-00
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma Drug Ineffective Poisoning Suicide Attempt	Foreign Health Professional	Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab)	PS		SUBCUTANEOUS	40 MG, 1 IN 2 WK,	SUBCUTANEOUS
			Clomipramine	SS		ORAL	250 MG, ONCE,	PER ORAL
			Rofecoxib	SS		ORAL		PER ORAL
			Methotrexate Sodium	C				
			Sulfasalazine	C				
			Hydroxychloroquine	C				
			Leflunomide	C				
			Methylprednisolone	C				
			Etanercept	C				
			Celecoxib	C				

Date:09/14/04ISR Number: 4450658-6Report Type:Expedited (15-DaCompany Report #2004063259
Age: Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Neurontin					
	Oesophageal Ulcer		(Gabapentin)	PS				
			Motrin (Ibuprofen)	SS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:09/14/04ISR Number: 4451195-5Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00102
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis	Foreign	Tab Vioxx					
Initial or Prolonged	Haemoglobin Decreased	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Sepsis	Other						
PO								144 DAY
	Tachycardia		Aspirin	C				

Date:09/14/04ISR Number: 4451215-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization -	Dyspnoea	Study						
Initial or Prolonged	Electrocardiogram Q Wave Abnormal	Health Professional	Amlodipine Besylate	C				
	Feeling Abnormal							
	Ventricular Dysfunction							

Date:09/14/04ISR Number: 4451222-5Report Type:Expedited (15-DaCompany Report #WAES 0408USA02183
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Arthralgia
	Arthritis
	Asthenia
	Blood Bicarbonate Increased
	Blood Chloride Decreased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Inadequately Controlled
	Blood Thyroid Stimulating Hormone Increased
	Brain Natriuretic Peptide Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Coronary Artery Atherosclerosis
	Cough
	Dehydration
	Diarrhoea
	Dyspnoea
	Erosive Duodenitis
	Gastric Disorder
	Gastrointestinal

Haemorrhage
Gastrooesophageal Reflux
Disease
Haematocrit Decreased
Haemoglobin Decreased
Hiatus Hernia
Hypochromasia
Laboratory Test Abnormal
Mean Cell Haemoglobin
Decreased
Mean Cell Volume
Decreased
Microcytosis
Oedema Peripheral
Oesophagitis
Pallor
Platelet Count Decreased
Serum Ferritin Decreased
Supraventricular

		Extrasystoles Surgery Vomiting White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased	Study	Tab Vioxx 25 Mg	PS		ORAL
25							
			Health				
MG/DAILY/PO							
			Professional	Tab Acetaminophen 325 Mg	SS		ORAL
325 MG/PRN/PO							
				Tab Acetaminophen 325 Mg	SS		ORAL
325 MG/PRN/PO							
				Ambien	C		
				Toprol Xl	C		
				Allopurinol	C		
				Aspirin	C		
				Gemfibrozil	C		
				Hydrochlorothiazide	C		
				Ibuprofen	C		
				Isosorbide Mononitrate	C		
				Lansoprazole	C		
				Levothyroxine Sodium	C		
				Lisinopril	C		
				Nitroglycerin	C		
				Pantoprazole	C		
				Paroxetine	C		
				Trazodone Hydrochloride	C		

Date:09/15/04ISR Number: 4449872-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02292
Age:83 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL
217 DAY							
Hospitalization -		Acute Myocardial	Professional	Vicodin Tablets	C		
UNKNOWN							
Initial or Prolonged		Infarction		Fosamax	C		
UNKNOWN							
		Arteriosclerosis		Aspirin	C		
UNKNOWN							

	Cardiac Failure	Buspar	C
UNKNOWN			
	Congestive	Vitamin E	C
UNKNOWN			
	Cardiogenic Shock	Vitamins	
	Cardiomegaly	(Unspecified)	C
UNKNOWN			
	Cerebrovascular Accident	Calcium	
	Dementia Alzheimer'S Type	(Unspecified) And	
	Fall	Vitamin D	
	Pneumonia Aspiration	(Unspecified)	C
UNKNOWN			
	Sepsis	Docusate Sodium	C
UNKNOWN			
	Tachycardia	Prevacid	C
UNKNOWN			
		Zyprexa	C
UNKNOWN			

Date:09/15/04ISR Number: 4449874-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00704
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia							
Initial or Prolonged	Gastric Ulcer							
Disability	Haematemesis							
	Haematochezia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/04ISR Number: 4449875-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00688
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Hepatic Function Abnormal							
	Protein C Deficiency							

Date:09/15/04ISR Number: 4449876-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00617
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Hospitalization -	Abdominal Pain Upper							
Initial or Prolonged	Atrial Fibrillation							
Other	Cardiac Failure							
	Congestive							
	Haematochezia							
	Vomiting							

Date:09/15/04ISR Number: 4449878-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00750
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Percogesic	C				
UNKNOWN								
			Ultracet	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Beta Carotene	C				
UNKNOWN								
			Dicyclomine Hydrochloride	C				
UNKNOWN								
			Lexapro	C				
UNKNOWN								

Hydrocodone Hydrochloride	C	UNKNOWN
Lorazepam	C	UNKNOWN
Ambien	C	UNKNOWN
Vitamins (Unspecified)	C	UNKNOWN
Trazodone Hydrochloride	C	UNKNOWN
Mobic	C	UNKNOWN
Remeron	C	UNKNOWN
Nortriptyline	C	UNKNOWN
Prilosec	C	UNKNOWN
Trileptal	C	UNKNOWN
Potassium (Unspecified)	C	UNKNOWN
Propoxyphene Hydrochloride	C	UNKNOWN

Date:09/15/04ISR Number: 4449892-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00454
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/15/04ISR Number: 4449893-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00629
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zestril	C				
UNKNOWN								

Date:09/15/04ISR Number: 4450092-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
18 MON								
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
18 MON								
Disability	Arthropod Bite		Hydrocodone					
	Back Pain		Bitartrate And					
	Blood Glucose Increased		Acetaminophen	C				
UNKNOWN								
	Cardiac Failure							
	Congestive							
	Cerumen Impaction							
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Dysuria							
	Fall							
	Headache							
	Hodgkin'S Disease							
	Hyperhidrosis							
	Hypertension							
	Intervertebral Disc							
	Degeneration							
	Joint Swelling							
	Labile Hypertension							
	Labyrinthitis							
	Myocardial Infarction							
	Non-Hodgkin'S Lymphoma							
	Oedema Peripheral							
	Osteopenia							
	Skin Cancer							

Thrombophlebitis
Vertigo
Weight Increased

Date:09/15/04ISR Number: 4450099-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Abnormal Faeces
Hospitalization - Initial or Prolonged	Agonal Rhythm
Other	Anaemia
	Atherosclerosis
	Benign Prostatic Hyperplasia
	Blister
	Blood Pressure Systolic Increased
	Bundle Branch Block Left
	Cardiac Arrest
	Cardiac Failure Congestive

Cardiac Murmur
Cardiomegaly
Cardiomyopathy
Cellulitis
Chest Injury
Chronic Obstructive
Airways Disease
Exacerbated
Chronic Obstructive
Pulmonary Disease
Clavicle Fracture
Coma
Confusion Postoperative
Constipation
Contusion
Cor Pulmonale
Cyanosis
Decreased Activity
Diaphragmatic Paralysis
Dilatation Atrial
Dilatation Ventricular
Dizziness
Duodenal Ulcer
Haemorrhage
Duodenitis
Dyspnoea
Dyspnoea Exertional
Dysuria
Embolism
Erythema
Faecal Occult Blood
Positive
Faeces Discoloured
Fungal Infection
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Helicobacter Pylori
Identification Test
Positive
Hypoventilation
Injury
Melaena
Myocardial Infarction
Neuropathy Peripheral
Obstructive Airways
Disorder

Oedema Peripheral
Oesophagitis
Onychomycosis
Osteoarthritis
Oxygen Saturation
Decreased
Pain In Extremity
Pallor
Pericardial Effusion
Pitting Oedema
Pleural Effusion
Pollakiuria
Pulmonary Embolism
Pulmonary Hypertension

		Pupil Fixed					
		Rales					
		Rash	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Restless Legs Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Restrictive Pulmonary		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		[Therapy			
		Rib Fracture		Unspecified]	C		
UNKNOWN							
		Road Traffic Accident		Coumadin	C		ORAL
		Skin Discolouration		Vicodin Es Tablets	C		
UNKNOWN							
		Therapy Non-Responder		Restoril	C		
UNKNOWN							
		Tricuspid Valve		Zestril	C		
UNKNOWN							
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Vitreous Floaters					
		Wheezing					

Date:09/15/04ISR Number: 4450372-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Benign Prostatic		Tylenol	C		
UNKNOWN							
Other		Hyperplasia					
		Cataract					
		Cellulitis					
		Cerebellar Infarction					
		Chalazion					
		Chest Pain					
		Coronary Artery Disease					
		Dyslipidaemia					
		Gastric Disorder					
		Gastrooesophageal Reflux					
		Disease					

Hypertension
Lacunar Infarction
Vestibular Disorder

Date:09/15/04ISR Number: 4450375-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Chest Pain
	Coronary Artery Disease
	Coronary Artery

	Restenosis						
	Diplopia						
	Diverticulitis						
	Dizziness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	220 DAY
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL	220 DAY
	Disease		Propacet	C			UNKNOWN
	Haematemesis		Wellbutrin	C			UNKNOWN
	Haematoma		Prevacid	C			UNKNOWN
	Hyperlipidaemia						
	Hypersensitivity						
	Hypertension						
	Lactose Intolerance						
	Muscle Contractions Involuntary						
	Myalgia						
	Non-Cardiac Chest Pain						
	Osteoarthritis						
	Postoperative Infection						
	Pulmonary Oedema						
	Retroperitoneal Haemorrhage						
	Stent Occlusion						
	Syncope						
	Tendon Rupture						
	Tendonitis						
	Tinnitus						
	Urticaria						
	Ventricular Fibrillation						
	Vision Blurred						
	Visual Acuity Reduced						
	Wheezing						

Date:09/15/04ISR Number: 4450391-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00019
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Colitis Ischaemic		Alfuzosin				

	Gastritis		Hydrochloride	C		ORAL
	Proctocolitis		Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL
	Rectal Haemorrhage		Chondroitin Sulfate Sodium	C		ORAL
			Sertraline Hydrochloride	C		ORAL
			Clorazepate Dipotassium	C		ORAL
			Vasotec	C		ORAL
			Vaseretic	C		ORAL

Date:09/15/04ISR Number: 4450394-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00020
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Haematemesis		Aspirin	SS		ORAL
	Oesophagitis		Betahistine Hydrochloride	C		ORAL

Calcium Carbonate And Cholecalciferol	C	ORAL
Clomethiazole Edisylate	C	ORAL
Hypericin	C	ORAL
Thioridazine	C	ORAL
Lorazepam	C	ORAL
Methaqualone Hydrochloride	C	ORAL
Pantoprazole	C	ORAL
Piretanide And Ramipril	C	ORAL

Date:09/15/04ISR Number: 4450395-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00744
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	MON	
			Clarinex	C			UNKNOWN	
			Synthroid	C		ORAL		

Date:09/15/04ISR Number: 4450398-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00040
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bromazepam	C		ORAL		

Date:09/15/04ISR Number: 4451281-XReport Type:Direct Company Report #CTU 227090
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx 25mg Tablet	PS		ORAL	25MG	DAILY
	Chills					ORAL		

	Convulsion					
	Diarrhoea					
	Dizziness					
	Drug Hypersensitivity					
	Erythema					
	Food Poisoning					
	Formication					
	Haematochezia					
	Hypoaesthesia					
	Pain Of Skin					
	Vomiting					

Date:09/15/04ISR Number: 4451451-0Report Type:Expedited (15-DaCompany Report #2004062831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthralgia	Consumer	Neurontin			
	Back Pain		(Gabapentin)	PS		
	Osteoarthritis		Oxycocet (Oxycodone			
	Pain In Extremity		Hydrochloride,			
			Paracetamol)	SS		
			Paroxetine			
			Hydrochloride			

(Paroxetine Hydrochloride)	SS
Rofecoxib (Rofecoxib)	SS
Methylphenidate Hydrochloried (Methylphenidate Hydrochloride)	SS
Fentanyl(Fentanyl)	SS

Date:09/15/04ISR Number: 4452046-5Report Type:Direct Company Report #CTU 227240
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Actos	PS		ORAL	30 MG PO QD	
Initial or Prolonged (<2 MOS)	Dyspnoea Exertional		Vioxx	SS				22 MON
	Fluid Retention		Omeprazole	C				
	Pickwickian Syndrome		Monopril	C				
	Weight Increased		Zocor	C				
			Synthroid	C				
			Cortisone	C				
			Humalog Insulin	C				

Date:09/16/04ISR Number: 4451351-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00880
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Supraventricular		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia							
Other								

Date:09/16/04ISR Number: 4451353-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00043
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diarrhoea		Diclofenac Sodium	C		ORAL		

			Fluconazole	C		ORAL
			Lansoprazole	C		ORAL

Date:09/16/04ISR Number: 4451354-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01673
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Halo Vision		Vioxx	PS	Merck & Co., Inc	ORAL
	Scotoma		Acetaminophen	C		ORAL
			Atenolol	C		ORAL
			Baclofen	C		ORAL
			Vitamins (Unspecified)	C		ORAL
			Interferon Beta	C		
INTRAMUSCULAR						
			Levothyroxine Sodium	C		ORAL
			Omeprazole	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/04ISR Number: 4451355-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00894
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:09/16/04ISR Number: 4451691-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	560	DAY
Disability	Anxiety		Alprazolam	C			UNKNOWN	
Other	Back Disorder		Amitriptyline Hydrochloride	C			UNKNOWN	
	Blood Cholesterol Increased		Amitriptyline Hydrochloride	C			UNKNOWN	
	Blood Pressure Decreased		Celexa	C			UNKNOWN	
	Blood Triglycerides Increased		Lexapro	C			UNKNOWN	
	Bronchitis		Nexium	C			UNKNOWN	
	Cardiomegaly		Lasix (Furosemide)	C			UNKNOWN	
	Cerebrovascular Accident		Zanaflex	C			UNKNOWN	
	Chest Pain		Ambien	C			UNKNOWN	
	Chronic Fatigue Syndrome		Diovan	C			UNKNOWN	
	Circulatory Collapse		Ultram	C			UNKNOWN	
	Clostridium Colitis		Torsemide	C			UNKNOWN	
	Convulsion		Lasix (Furosemide)	C			UNKNOWN	

	Depression	Neurontin	C
UNKNOWN			
	Dizziness	Zaroxolyn	C
UNKNOWN			
	Emotional Distress	Aleve	C
UNKNOWN			
	Fibrosis	Nortriptyline	C
UNKNOWN			
	Fluid Retention	Oxycontin	C
UNKNOWN			
	Gastrooesophageal Reflux	Potassium Chloride	C
UNKNOWN			
	Disease		
	Haematochezia		
	Headache		
	Hyperlipidaemia		
	Hypoxia		
	Ileus		
	Lumbar Radiculopathy		
	Myocardial Infarction		
	Nephrolithiasis		
	Oedema		
	Pneumonia		
	Pneumonia Aspiration		
	Pneumonia Pneumococcal		
	Rash		
	Renal Failure Acute		
	Rhabdomyolysis		
	Sinusitis		
	Spinal Compression		
	Fracture		
	Staphylococcal Infection		

Date:09/16/04ISR Number: 4451697-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00147
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypersensitivity		Synthroid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/04ISR Number: 4451699-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00538
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		34 DAY
Hospitalization -	Congestive		Tylenol	C				UNKNOWN
Initial or Prolonged	Pleural Effusion		Lipitor	C		ORAL		
Disability			Tums	C				UNKNOWN
			Provera	C				UNKNOWN

Date:09/16/04ISR Number: 4451703-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00750
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea At Rest		Percogesic	C				UNKNOWN
	Electrocardiogram		Ultracet	C				UNKNOWN
	Abnormal		Aspirin	C				UNKNOWN
			Beta Carotene	C				UNKNOWN
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				UNKNOWN
			Dicyclomine Hydrochloride	C				UNKNOWN
			Lexapro	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			Hydrocodone Hydrochloride	C				UNKNOWN

Lorazepam	C	UNKNOWN
Mobic	C	UNKNOWN
Remeron	C	UNKNOWN
Nortriptyline	C	UNKNOWN
Prilosec	C	UNKNOWN
Trileptal	C	UNKNOWN
Potassium (Unspecified)	C	UNKNOWN
Propoxyphene Hydrochloride	C	UNKNOWN
Trazodone Hydrochloride	C	UNKNOWN
Vitamin E	C	UNKNOWN
Vitamins (Unspecified)	C	UNKNOWN
Ambien	C	UNKNOWN

Date:09/16/04ISR Number: 4451704-6Report Type:Expedited (15-DaCompany Report #PT-MERCK-0409PRT00011
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eyelid Oedema Rash Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/16/04ISR Number: 4451708-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01168
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Ulcer Perforation		Tylenol	C				
UNKNOWN								
Initial or Prolonged	Gastrointestinal		Atenolol	C				
UNKNOWN								
Other	Haemorrhage		Celexa	C				
UNKNOWN								
			Hydrochlorothiazide And Triamterene	C				
UNKNOWN								

Date:09/16/04ISR Number: 4451710-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00753
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
457 DAY								
Hospitalization -	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
457 DAY								
Initial or Prolonged	Flatulence		Actonel	C				
UNKNOWN								
Disability	Gastric Ulcer Perforation							
Other	Oedema Peripheral							

Date:09/16/04ISR Number: 4452212-9Report Type:Direct Company Report #CTU 227313
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Rofecoxib 25mg					
Initial or Prolonged	Pulmonary Embolism		Merck	PS	Merck	ORAL		
25 MG DAILY								
ORAL								
			Metoprolol Xl	C				
			Aspirin	C				
			Triamcinolone	C				

			Warfarin	C		

Date:09/16/04ISR Number: 4452466-9Report Type:Expedited (15-DaCompany Report #200412666GDS
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Haematemesis Oesophagitis	Foreign Health Professional Other	Aspirin Cardio (Acetylsalicylic Acid)	PS		ORAL	300 MG, TOTAL DAILY, ORAL	
			Rofecoxib	SS		ORAL	ORAL	
			Diphenhydramine/Lorazepam	C				
			Thioridazine	C				
			Piretanide/Ramipril	C				
			Pantoprazole	C				
			Lorazepam	C				
			Colecalciferol/Ca	C				
			Betahistine	C				

Date:09/16/04ISR Number: 4454327-8Report Type:Direct Company Report #CTU 227385
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS		ORAL	25 MG ORALLY	
							1 TAB DAILY	2 YR
			Cardia Xt	C				

				Dyazide	C		

Date:09/17/04ISR Number: 4452230-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/17/04ISR Number: 4455088-9Report Type:Expedited (15-DaCompany Report #WAES 0409SWE00006
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY., PO	22 DAY
		Other						
			Alfuzosin Hydrochloride	C				
			Atenolol	C				

Date:09/20/04ISR Number: 4453264-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulation Factor Viii Level Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	117 DAY	
	Coagulation Time Prolonged		Ginkgo Biloba Extract	SS		ORAL		
	Haematoma		Zocor	SS		ORAL		
			Hydrochlorothiazide And Lisinopril	SS		ORAL		

Date:09/20/04ISR Number: 4453265-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00444
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
			Dilantin	C			UNKNOWN	

Date:09/20/04ISR Number: 4453275-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Initial or Prolonged	Cardioactive Drug Level	Professional	Digoxin	SS		ORAL		
	Increased		Digoxin	SS		ORAL		
	Drug Interaction		Diltiazem Hydrochloride	SS		ORAL		
	Renal Failure		Diltiazem Hydrochloride	SS		ORAL		
			Perindopril Erbumine	SS		ORAL		
			Allopurinol	C		ORAL		
			Fluindione	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Potassium Chloride	C		ORAL		
			Pantoprazole	C		ORAL		
			Oxerutins	C		ORAL		

Furosemide	C			ORAL
Fluindione	C			ORAL
Amlodipine Besylate	C			ORAL
Atorvastatin Calcium	C			ORAL
Calcium Carbonate And Cholecalciferol	C			ORAL

Date:09/20/04ISR Number: 4453280-0Report Type:Expedited (15-DaCompany Report #NL-MERCK-0409NLD00005
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chromaturia		Zocor	PS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS		ORAL		
	Muscle Spasms		Aspirin Calcium	C		ORAL		
	Oedema		Atenolol	C		ORAL		
			Digoxin	C		ORAL		
			Diltiazem Hydrochloride	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Methimazole	C		ORAL		
			Penicillin G Benzhydrylamine	C			INTRAMUSCULAR	

Date:09/20/04ISR Number: 4453281-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Chloride Decreased		Tylenol	C				UNKNOWN
Disability	Bursitis		Aspirin	C				UNKNOWN
	Coronary Artery Aneurysm		Combipatch	C				UNKNOWN
	Coronary Artery Disease		Ibuprofen	C				UNKNOWN
	Coronary Artery Occlusion		Advil	C				UNKNOWN

	High Density Lipoprotein	Motrin	C
UNKNOWN			
	Increased	Minocycline	C
UNKNOWN			
	Hypertension		
	Myocardial Infarction		
	Platelet Count Decreased		
	Stress		
	Tendonitis		

Date:09/20/04ISR Number: 4453282-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Anaemia
	Anxiety
	Aortic Stenosis
	Arterial Stenosis
	Back Pain
	Blood Creatine
	Phosphokinase Mb
	Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Creatinine Increased					
		Blood Pressure Systolic Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Buttock Pain		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Cardiac Failure		Aspirin	C		
UNKNOWN		Congestive		Atenolol	C		
		Condition Aggravated		Cyclobenzaprine Hydrochloride	C		ORAL
		Constipation					
UNKNOWN		Coronary Artery Atherosclerosis		Lasix (Furosemide)	C		
SUBCUTANEOUS				Novolin	C		
UNKNOWN		Coronary Artery Occlusion		Ultram	C		
SUBCUTANEOUS		Coronary Artery Stenosis		Novolin	C		
UNKNOWN		Diabetic Neuropathy		Zestril	C		
UNKNOWN		Dry Skin		Procardia	C		
UNKNOWN		Exostosis		Trental	C		
UNKNOWN		Femoral Arterial Stenosis		Potassium (Unspecified)	C		
UNKNOWN		Gastrooesophageal Reflux Disease		Ranitidine	C		
		Haematocrit Decreased					
		Haemoglobin Increased					
		Herpes Zoster					
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Hypoaesthesia					
		Injury					
		Intermittent Claudication					
		Lumbar Radiculopathy					
		Lung Neoplasm					
		Muscle Spasms					
		Muscle Tightness					
		Musculoskeletal Stiffness					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Oedema Peripheral					

Pain
Pain In Extremity
Pallor
Peripheral Vascular
Disorder
Pneumonia
Pneumonitis
Pulmonary Mass
Rales
Renal Artery Stenosis
Respiratory Rate
Increased
Rhonchi
Silent Myocardial
Infarction
Spinal Column Stenosis
Urinary Tract Infection
Ventricular Hypokinesia

Date:09/20/04ISR Number: 4453284-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00084
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Face		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Swollen Tongue		Aspirin	C		ORAL		

			Aspirin	C		ORAL

Date:09/20/04ISR Number: 4453285-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 26 DAY	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardioactive Drug Level	Professional	Digoxin	SS		ORAL
	Increased		Digoxin	SS		ORAL
	Drug Interaction		Diltiazem Hydrochloride	SS		ORAL
	Renal Failure		Diltiazem Hydrochloride	SS		ORAL
			Perindopril Erbumine	SS		ORAL
			Allopurinol	C		ORAL
			Fluindione	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Potassium Chloride	C		ORAL
			Pantoprazole	C		ORAL
			Oxerutins	C		ORAL
			Furosemide	C		ORAL
			Fluindione	C		ORAL
			Amlodipine Besylate	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL

Date:09/20/04ISR Number: 4453307-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0409NLD00005
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chromaturia	Health	Zocor	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fatigue	Professional	Vioxx	SS		ORAL
	Muscle Spasms		Aspirin Calcium	C		ORAL
	Oedema		Atenolol	C		ORAL
			Digoxin	C		ORAL
			Diltiazem Hydrochloride	C		ORAL
			Esomeprazole Magnesium	C		ORAL

			Methimazole	C		ORAL
			Penicillin G Benzhydrylamine	C		
INTRAMUSCULAR						

Date:09/20/04ISR Number: 4453312-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 117 DAY	Coagulation Factor Viii	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Level Decreased	Professional	Ginkgo Biloba Extract	SS		ORAL
	Coagulation Time Prolonged		Zocor	SS		ORAL
	Haematoma		Hydrochlorothiazide And Lisinopril	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453313-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00444
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
			Dilantin	C		UNKNOWN		

Date:09/20/04ISR Number: 4453314-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Stenosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Disease		Aspirin	C		UNKNOWN		
Other	Arterial Stenosis Limb		Atenolol	C		UNKNOWN		
	Atherosclerosis		Cyclobenzaprine Hydrochloride	C		ORAL		
	Back Pain							
	Blood Pressure Systolic		Lasix (Furosemide)	C		UNKNOWN		
	Increased		Novolin	C		SUBCUTANEOUS		
	Cardiac Failure		Ultram	C		UNKNOWN		
	Congestive		Novolin	C		SUBCUTANEOUS		
	Condition Aggravated		Zestril	C		UNKNOWN		
	Constipation		Procardia	C		UNKNOWN		
	Coronary Artery		Trental	C		UNKNOWN		
	Atherosclerosis		Potassium (Unspecified)	C		UNKNOWN		
	Coronary Artery Disease							
	Coronary Artery Occlusion		Ranitidine	C		UNKNOWN		
	Coronary Artery Stenosis							

Diabetic Neuropathy
Exostosis
Gastrooesophageal Reflux
Disease
Herpes Zoster
Hyperlipidaemia
Hypertension
Injury
Intermittent Claudication
Lumbar Radiculopathy
Lung Neoplasm
Muscle Spasms
Muscle Tightness
Myocardial Infarction
Pain In Extremity
Peripheral Vascular
Disorder
Pneumonia
Pneumonitis
Renal Artery Stenosis
Renal Failure Chronic
Silent Myocardial
Infarction
Spinal Column Stenosis
Urinary Retention
Urinary Tract Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453317-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Aneurysm		Tylenol	C				
Disability	Coronary Artery Disease		Aspirin	C				
	Hypertension		Combipatch	C				
	Myocardial Infarction		Ibuprofen	C				
	Palpitations		Advil	C				
	Stress		Motrin	C				
	Supraventricular		Minocycline	C				
	Extrasystoles							
	Tendonitis							

Date:09/20/04ISR Number: 4453318-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nerve Compression		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				

Date:09/20/04ISR Number: 4453478-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 117 DAY	Coagulation Factor Viii	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Level Decreased	Professional	Ginkgo Biloba Extract	SS		ORAL
	Coagulation Time Prolonged		Zocor	SS		ORAL
	Haematoma		Hydrochlorothiazide And Lisinopril	SS		ORAL

Date:09/20/04ISR Number: 4453479-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00444
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
		Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
			Dilantin	C				
UNKNOWN								

Date:09/20/04ISR Number: 4453480-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00084
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Face	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Swollen Tongue	Professional	Aspirin	C		ORAL		
			Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453482-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Nerve Compression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		[Therapy Unspecified]	C			UNKNOWN	
	Therapy Non-Responder		[Therapy Unspecified]	C			UNKNOWN	

Date:09/20/04ISR Number: 4453483-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Bursitis		Tylenol	C			UNKNOWN	
Disability	Coronary Artery Aneurysm		Aspirin	C			UNKNOWN	
	Coronary Artery Disease		Combipatch	C			UNKNOWN	
	Coronary Artery Occlusion		Ibuprofen	C			UNKNOWN	
	Electrocardiogram T Wave		Advil	C			UNKNOWN	
	Inversion		Motrin	C			UNKNOWN	
	High Density Lipoprotein		Minocycline	C			UNKNOWN	
	Increased							
	Hypertension							
	Myocardial Infarction							
	Palpitations							
	Platelet Count Decreased							
	Stress							
	Tendonitis							

Date:09/20/04ISR Number: 4453485-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02026
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Anaemia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Aspirin	C				
Other UNKNOWN	Congestive		Atenolol	C				
	Constipation		Cyclobenzaprine Hydrochloride	C		ORAL		
	Coronary Artery Atherosclerosis		Lasix (Furosemide)	C				
	Coronary Artery Disease		Novolin	C				
	Diabetic Neuropathy		Ultram	C				
	Exostosis		Novolin	C				
	Gastrooesophageal Reflux		Zestril	C				
	Disease		Procardia	C				
	Herpes Zoster		Trental	C				
	Hyperlipidaemia Hypertension		Potassium (Unspecified)	C				
	Lumbar Radiculopathy		Ranitidine	C				
	Lung Neoplasm							
	Myocardial Infarction							
	Pneumonitis							
	Renal Artery Stenosis							
	Renal Failure Chronic							
	Silent Myocardial Infarction							
	Spinal Column Stenosis							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453487-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0409NLD00005
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chromaturia		Zocor	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fatigue		Vioxx	SS		ORAL
	Muscle Spasms		Aspirin Calcium	C		ORAL
	Oedema		Atenolol	C		ORAL
			Digoxin	C		ORAL
			Diltiazem Hydrochloride	C		ORAL
			Esomeprazole Magnesium	C		ORAL
			Methimazole	C		ORAL
			Penicillin G Benzhydrylamine	C		
INTRAMUSCULAR						

Date:09/20/04ISR Number: 4453495-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 26 DAY	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardioactive Drug Level	Professional	Digoxin	SS		ORAL
	Increased		Digoxin	SS		ORAL
	Condition Aggravated		Diltiazem Hydrochloride	SS		ORAL
	Drug Interaction		Diltiazem Hydrochloride	SS		ORAL
	Electrocardiogram T Wave Inversion		Perindopril Erbumine	SS		ORAL
	Malaise		Allopurinol	C		ORAL
	Nausea		Fluindione	C		ORAL
	Nodal Arrhythmia		Levothyroxine Sodium	C		ORAL
	Renal Failure		Potassium Chloride	C		ORAL
	Vomiting		Pantoprazole	C		ORAL
			Oxerutins	C		ORAL
			Furosemide	C		ORAL
			Fluindione	C		ORAL
			Amlodipine Besylate	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL

Date:09/20/04ISR Number: 4453864-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Adrenal Adenoma
	Aneurysm
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Complex Regional Pain Syndrome
	Depression
	Diverticulum
	Dizziness
	Emotional Distress
	Hyperlipidaemia

	Hypoaesthesia						
	Joint Dislocation						
	Large Cell Carcinoma Of	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	The Respiratory Tract	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Stage Unspecified	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Pneumothorax		Darvocet-N	C			UNKNOWN
	Stress Incontinence		Amitriptyline				
	Ventricular Extrasystoles		Hydrochloride	C			UNKNOWN
			Meclizine	C			UNKNOWN

Date:09/20/04ISR Number: 4453867-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Initial or Prolonged	Back Pain		Aspirin	C			UNKNOWN
	Cardiomegaly		Lipitor	C			UNKNOWN
	Carotid Artery Stenosis		Prozac	C			UNKNOWN
	Cerebrovascular Accident		Metformin	C			UNKNOWN
	Cholelithiasis		Glucophage	C			UNKNOWN
	Coccydynia		Prilosec	C			UNKNOWN
	Coordination Abnormal						
	Dysstasia						
	Fall						
	Gastrooesophageal Reflux Disease						
	Headache						
	Intention Tremor						
	Intervertebral Disc Degeneration						
	Intervertebral Disc Disorder						
	Mitral Valve Incompetence						

Non-Cardiac Chest Pain
Pericardial Effusion
Spinal Column Stenosis
Spinal Compression
Fracture
Transient Ischaemic
Attack
Ventricular Hypokinesia
Vomiting

Date:09/20/04ISR Number: 4453871-7Report Type:Expedited (15-DaCompany Report #US-MERCK-00051679
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Hypertension							
	Insomnia							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453873-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00052
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Dihydrocodeine Bitartrate	C				
			Aspirin	C		ORAL		
			Haloperidol	C				
			Temazepam	C				
			Ibuprofen	C				
			Paroxetine	C				

Date:09/20/04ISR Number: 4453875-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00021
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colon Cancer Metastatic Dyspepsia Hepatic Neoplasm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Chondroitin	C		ORAL		
			Fenofibrate	C		ORAL		
			Hydrochlorothiazide And Lisinopril	C		ORAL		
			Raloxifene Hydrochloride	C		ORAL		

Date:09/20/04ISR Number: 4453876-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01262
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 2 YR	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder Dyspepsia Nephrolithiasis					

Date:09/20/04ISR Number: 4453877-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01731
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 DAY	Arthritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 3 DAY	Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Tylenol Extra Strength	C		ORAL
	Chest Pain		Robitussin	C		ORAL
	Headache					
	Hyperlipidaemia					
	Hypertension					
	Lumbar Spinal Stenosis					
	Nausea					
	Tremor					
	Viral Infection					
	Vitreous Floaters					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/20/04ISR Number: 4453878-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00614
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dermatomyositis		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Face Oedema							
	Heart Rate Irregular							
	Hepatic Enzyme Increased							
	Insomnia							
	Muscle Spasms							
	Oedema Peripheral							
	Pain							
	Pyrexia							
	Urinary Retention							

Date:09/20/04ISR Number: 4453884-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol	Health	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Initial or Prolonged	Increased	Professional	Tylenol	C			UNKNOWN	
Disability	Blood Triglycerides		Tylenol With Codeine					
	Increased		#3	C		ORAL		
	Hypertension		Vicodin Tablets	C			UNKNOWN	
	Joint Swelling		Ecotrin	C			UNKNOWN	
	Myocardial Infarction							

Date:09/20/04ISR Number: 4453886-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00629
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Loss Of Consciousness	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Road Traffic Accident		Lipitor	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						

Date:09/20/04ISR Number: 4453895-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00007
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Aneurysm
	Atrial Septal Defect
	Back Pain
	Bronchitis
	Cellulitis
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Depression
	Drug Hypersensitivity
	Drug Ineffective
	Fear
	Hypercholesterolaemia
	Ischaemic Stroke
	Oedema Peripheral
	Panic Disorder With Agoraphobia
	Spondylolisthesis

Acquired

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
93 DAY		Health	Vioxx	PS	Merck & Co., Inc	ORAL
93 DAY		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN			Tylenol	C		
UNKNOWN			Darvocet-N	C		
UNKNOWN			Xanax	C		
UNKNOWN	2 WK		Zoloft	C		
UNKNOWN			Zoloft	C		
UNKNOWN	764 DAY		Zoloft	C		
UNKNOWN			Xanax	C		
OPHTHALMIC			Alphagan	C		
OPHTHALMIC			Xalatan	C		
UNKNOWN			Synthroid	C		

Date:09/20/04ISR Number: 4453911-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization - Initial or Prolonged	Abdominal Hernia
Other	Abdominal Pain
	Activated Partial Thromboplastin Time Prolonged
	Acute Respiratory Failure
	Adrenal Insufficiency
	Anaemia Of Chronic Disease
	Arteriosclerosis
	Arthralgia

Asthenia
Asthma
Bacterial Infection
Blood Albumin Decreased
Blood Erythropoietin
Decreased
Bronchitis Acute
Candidiasis
Cardiac Failure
Congestive
Cellulitis
Cholecystitis Chronic
Cholesterosis
Coagulopathy
Colitis
Decubitus Ulcer
Deep Vein Thrombosis
Diarrhoea
Diverticulum
Duodenitis
Dyspepsia
Embolism
Escherichia Infection
Eye Disorder
Faecal Incontinence
Fibrosis
Fungaemia
Gastric Haemorrhage

Gastric Ulcer
Gastritis
Gastritis Erosive
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Gynaecomastia
Haematemesis
Haematoma
Haemorrhoids
Headache
Hepatic Steatosis
Hiatus Hernia
Hypercapnia
Hypercoagulation
Hyperglycaemia
Hypertension
Hypoproteinaemia
Hypotension
Hypoxia
Incisional Hernia
Inguinal Hernia
Injury
International Normalised
Ratio Increased
Malnutrition
Metabolic Acidosis
Myocardial Infarction
Normochromic Normocytic
Anaemia
Obesity
Oesophagitis
Optic Neuropathy
Otitis Media
Panniculitis
Pickwickian Syndrome
Pneumonia
Post Procedural
Complication
Prothrombin Time
Prolonged
Pseudomonas Infection
Pulmonary Congestion
Pulmonary Embolism
Pulmonary Hypertension

Pulmonary Oedema
Pyrexia
Renal Failure
Renal Failure Acute
Rheumatoid Arthritis
Sepsis
Sputum Culture Positive
Staphylococcal
Bacteraemia
Syncope Vasovagal
Thrombocytopenia
Thrombosis
Umbilical Hernia
Urinary Incontinence

		Urinary Tract Infection					
		Vertigo					
		White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Catapres	C		
UNKNOWN	347 DAY						
				Lasix (Furosemide)	C		
UNKNOWN							
				Micardis	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Cozaar	C		
UNKNOWN							

Date:09/20/04ISR Number: 4453919-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01985
Age:35 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Death		[Therapy Unspecified]	C		
Other		Dyspnoea					
UNKNOWN							
		Epigastric Discomfort		Tylenol	C		
UNKNOWN							
		Injury		Ventolin (Albuterol)	C		
UNKNOWN							
		Myocardial Infarction		Mylanta & Mylanta Ds	C		
UNKNOWN							
		Stomach Discomfort		Celebrex	C		
UNKNOWN							
		Ventricular Hypertrophy		Catapres	C		
UNKNOWN							
		Vomiting		Pepcid	C		ORAL
				Dyazide	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Orudis	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							

	Zestril	C
UNKNOWN		
	Cytotec	C
UNKNOWN		
	Naproxen	C
UNKNOWN		
	Procardia	C
UNKNOWN		
	Xenical	C
UNKNOWN		
	Actifed	C
UNKNOWN		
	Meridia	C
UNKNOWN		
	Azmacort	C
UNKNOWN		

Date:09/20/04ISR Number: 4453921-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Abdominal Pain Upper
Other	Accident At Home
	Activated Partial Thromboplastin Time Prolonged
	Alcohol Use
	Angina Pectoris
	Antiphospholipid Antibodies
	Anxiety
	Arthritis
	Atherosclerosis
	Atrial Septal Defect
	Back Pain
	Balance Disorder
	Bipolar Disorder
	Borderline Personality

Disorder
Bradycardia
Breast Pain
Bursitis
Cardiac Aneurysm
Cardiac Disorder
Cardiac Failure
Congestive
Carotid Artery Occlusion
Cellulitis
Cerebral Atrophy
Cerebral Infarction
Cerebral Ischaemia
Cerebrovascular Accident
Chest Pain
Condition Aggravated
Confusional State
Coronary Artery Disease
Coronary Artery
Restenosis
Cough
Diastolic Dysfunction
Dilatation Atrial
Dilatation Ventricular
Diverticulum
Dizziness
Drug Abuser
Drug Dependence
Dysarthria
Dyspepsia
Dysphagia
Dyspnoea
Dyspnoea Exertional
Electrocardiogram Poor
R-Wave Progression
Electrocardiogram St-T
Change
Emotional Distress
Erythema
Fear
Fibromyalgia
Flashback
Haemorrhoids
Headache
Hemiparesis
Homans' Sign
Hypercoagulation
Hyperhidrosis

Hyperkalaemia
Hypertrophy Breast
Hypoaesthesia
Hypokalaemia
Hyponatraemia
Hypoxia
Injury
Insomnia
Intermittent Claudication
Intracranial Aneurysm
Irritability
Lacunar Infarction
Leukocytosis
Major Depression

		Micturition Urgency					
		Multiple Drug Overdose					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nervousness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Nightmare	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Obsessive-Compulsive		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vicodin Tablets	C		
UNKNOWN							
		Pain In Extremity		Norvasc	C		
UNKNOWN							
		Paraesthesia		Aspirin	C		
UNKNOWN		668 DAY					
		Personality Disorder		Zithromax	C		ORAL
4 DAY							
		Pollakiuria		Cogentin	C		ORAL
		Portal Hypertension		Tegretol-Xr	C		ORAL
		Psychotic Disorder		Monopril	C		ORAL
		Pulmonary Hypertension		Neurontin	C		
UNKNOWN							
		Restlessness		Lithium Carbonate	C		ORAL
		Road Traffic Accident		Coumadin	C		
UNKNOWN		96 DAY					
		Self-Injurious Ideation		Coumadin	C		
UNKNOWN							
		Spinal Osteoarthritis		Coumadin	C		
UNKNOWN							
		Stress		Navane	C		ORAL
		Suicidal Ideation		Lithium Carbonate	C		ORAL
		Supraventricular		Claritin-D	C		
UNKNOWN							
		Extrasystoles		Ativan	C		
UNKNOWN							
		Supraventricular		Ativan	C		
UNKNOWN							
		Tachycardia		Zyprexa	C		ORAL
		Thromboembolic Stroke		Zyprexa	C		ORAL
		Transient Ischaemic		Seroquel	C		
UNKNOWN							
		Attack					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					

Varices Oesophageal
Ventricular Extrasystoles
Vertigo
Vision Blurred
Weight Increased

Date:09/20/04ISR Number: 4454335-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anoxic Encephalopathy
	Anxiety
Other	Cardio-Respiratory Arrest
	Convulsion
	Coronary Artery Occlusion
	Deep Vein Thrombosis
	Gastric Disorder
	Hypertension
	Hypokalaemia
	Lumbar Spinal Stenosis
	Myocardial Infarction
	Palpitations
	Pneumonia Aspiration
	Postoperative Ileus
	Pulmonary Embolism

Pulmonary Oedema
Shock
Syphilis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Tylenol With Codeine #4	C			UNKNOWN	
	Tylenol With Codeine #4	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Arthrotec	C		ORAL		
	Arthrotec	C		ORAL		
	Arthrotec	C		ORAL		
	Premarin	C			UNKNOWN	
	Provera	C			UNKNOWN	
	Daypro	C			UNKNOWN	

Date:09/20/04ISR Number: 4454340-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Aortic Aneurysm
Other	Atelectasis
	Blood Pressure Fluctuation
	Bronchitis
	Cardiomegaly
	Cataract
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Chronic Sinusitis
	Colon Cancer
	Coronary Artery Disease
	Deep Vein Thrombosis
	Dyspepsia
	Dysphagia
	Dyspnoea

Ecchymosis
Emotional Distress
Essential Tremor
Faeces Discoloured
Fibromyalgia
Fluid Overload
Gastric Ulcer Haemorrhage
Gastritis
Gastroenteritis Viral
Gastrointestinal
Haemorrhage
Hypertension
Iron Deficiency Anaemia
Macular Degeneration
Myocardial Infarction
Oesophageal Pain
Osteoarthritis
Osteoporosis
Pyrexia
Renal Cyst
Rheumatic Fever
Rhinitis Allergic

		Stress Incontinence					
		Venous Stasis					
		Vertigo	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Aspirin	SS		ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Ciprofloxacin	C		
UNKNOWN							
				Ciprofloxacin	C		
UNKNOWN							
				Hyzaar	C		ORAL
				Dyazide	C		
UNKNOWN							
				Isosorbide	C		
UNKNOWN							
				Ativan	C		ORAL
				Nitroglycerin	C		
UNKNOWN							
				Oxybutynin	C		ORAL
				Propranolol Hydrochloride	C		
UNKNOWN							
				Quinine	C		
UNKNOWN							

Date:09/20/04ISR Number: 4454343-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Chest Pain

Coronary Artery Disease
Coronary Artery
Restenosis
Diplopia
Diverticulitis
Dizziness
Dyspnoea
Epicondylitis
Gastrooesophageal Reflux
Disease
Haematemesis
Haematoma
Hyperlipidaemia
Hypersensitivity
Hypertension
Lactose Intolerance
Mitral Valve
Calcification
Muscle Contractions
Involuntary
Myalgia
Non-Cardiac Chest Pain
Osteoarthritis
Postoperative Infection
Pulmonary Oedema

		Retroperitoneal Haemorrhage					
		Stent Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope	Health	Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Tendon Rupture	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY						
		Tendonitis		Propacet	C		
UNKNOWN							
		Tinnitus		Wellbutrin	C		
UNKNOWN							
		Urticaria		Prevacid	C		
UNKNOWN							
		Ventricular Fibrillation					
		Vision Blurred					
		Visual Acuity Reduced					
		Wheezing					

Date:09/20/04ISR Number: 4454349-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00057
Age:61 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Feeling Drunk	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
Initial or Prolonged		Nausea	Professional	Acetaminophen And Caffeine And Propoxyphene Hydrochloride	SS		ORAL
		Somnolence					
		Vertigo					
		Vomiting					
3	DAY						
				Bromazepam	C		ORAL
				Fenofibrate	C		ORAL
				Zolpidem Tartrate	C		ORAL
				Fosinopril Sodium And Hydrochlorothiazide	C		ORAL
				Insulin Lispro	C		
PARENTERAL							
				Rilmenidine Phosphate	C		ORAL

Date:09/20/04ISR Number: 4454354-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Disability	Anaemia
	Anorexia
	Arthralgia
	Arthropathy
	Asthma
	Atelectasis
	Blood Lactate
	Dehydrogenase Increased
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Colitis Ulcerative
	Constipation
	Cough
	Crepitations
	Deep Vein Thrombosis
	Depression
	Difficulty In Walking

		Drug Interaction					
		Dysarthria					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Headache	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Hemiparesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertonia					
		Hypoaesthesia					
		Insomnia					
		Iron Deficiency Anaemia					
		Muscle Spasms					
		Oedema Peripheral					
		Orthopnoea					
		Paraesthesia					
		Pericardial Effusion					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Postmenopausal					
		Haemorrhage					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Rectal Ulcer					
		Reflux Oesophagitis					
		Renal Failure					
		Tremor					
		Weight Decreased					
		Wheezing					

Date:09/20/04ISR Number: 4454355-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0407NZL00013
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Breast Cancer Metastatic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Mouth Ulceration	Professional	Amitriptyline			
		Oedema Peripheral		Hydrochloride	C		ORAL
		Vena Cava Embolism		Anastrozole	C		ORAL
				Omeprazole	C		ORAL

Date:09/20/04ISR Number: 4454357-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00351
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Diverticulum		Bayer Aspirin	SS		ORAL		
	Gastrointestinal Haemorrhage		Plavix	SS		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Metoprolol Succinate	C		ORAL		

Date:09/20/04ISR Number: 4454363-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
	Oedema							

Date:09/21/04ISR Number: 4454792-6Report Type:Expedited (15-DaCompany Report #US-MERCK-00080818
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
			Celebrex	SS		ORAL	30 DAY	
			Celebrex	SS		ORAL	30 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
			Aspirin	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Pravastatin Sodium	C			UNKNOWN	
			Isosorbide Dinitrate	C			UNKNOWN	
			Chondroitin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

Date:09/21/04ISR Number: 4454793-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY	
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY	
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY	
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY	
	Clostridium Colitis		[Therapy Unspecified]	C			UNKNOWN	
	Decreased Appetite						6 DAY	

	Dizziness	Tylenol	C
UNKNOWN			
	Drug Ineffective	Ascorbic Acid	C
UNKNOWN			
	Dyspepsia	Aspirin	C
UNKNOWN			
	Feeling Jittery	Atenolol	C
UNKNOWN			
	Gout	Lotensin	C
UNKNOWN			
	Insomnia	Cefadroxil	C
UNKNOWN	6 DAY		
	Intervertebral Disc	Colchicine	C
UNKNOWN			
	Degeneration	Diclofenac	C
UNKNOWN			
	Mood Altered	Vitamin E	C
UNKNOWN			
	Osteoarthritis	Coenzyme Q10	C
UNKNOWN			
	Pain	Zocor	C
UNKNOWN			
	Scoliosis	Glucosamine	C
UNKNOWN			
	Spondylolisthesis	Metronidazole	C
UNKNOWN			
	Acquired	Aleve	C
UNKNOWN			
		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C
UNKNOWN			
		Omega-3	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Zantac	C
UNKNOWN			

Date:09/21/04ISR Number: 4455234-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01101310
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Bladder Obstruction
Other	Cerebral Atherosclerosis
	Cerebral Infarction
	Cervical Spinal Stenosis
	Epistaxis
	Haemorrhoids

		Headache					
		Intervertebral Disc Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Septum Deviation		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		[Therapy			
		Prostate Cancer		Unspecified]	C		
UNKNOWN							
		Rectal Haemorrhage		Albuterol	C		
RESPIRATORY							
		Rectal Polyp					
(INHALATION)							
		Scleral Haemorrhage		Albuterol	C		ORAL
		Sinusitis		Allopurinol	C		
UNKNOWN							
				Ecotrin	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Palgic D	C		ORAL
				Mavik	C		ORAL
				Mavik	C		ORAL
				Celebrex	C		
UNKNOWN							
				Docusate Calcium	C		
UNKNOWN							
				Guaifenex La	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Ibuprofen	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:09/21/04ISR Number: 4455246-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01882
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea					
		Feeling Abnormal					

Gastrointestinal Disorder
Haemorrhage
Hypoacusis
Myocardial Infarction
Pain

Date:09/21/04ISR Number: 4455247-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Alveolitis Fibrosing
	Anxiety
	Arthralgia
	Arthropathy
	Atelectasis
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Depression
	Dermatomyositis
	Diarrhoea
	Dizziness
	Haemoptysis
	Hemiparesis
	Hypersensitivity
	Hypertension
	Interstitial Lung Disease

	Obstructive Airways Disorder						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL	
	Paraesthesia						
	Pulmonary Fibrosis						
	Rash Macular						
	Uterine Disorder						

Date:09/21/04ISR Number: 4455249-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	21 DAY
Other	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	21 DAY
	Gastrointestinal Injury		Zithromax	C			UNKNOWN 7 DAY
	Gout		Cardizem	C			UNKNOWN
	Insomnia		Ismo	C			UNKNOWN
	Intervertebral Disc Disorder		Morphine Sulfate	C		ORAL	
			Ms Contin	C		ORAL	
	Joint Injury		Ms Contin	C			UNKNOWN
	Oedema Peripheral		Ms Contin	C			UNKNOWN
	Palpitations						
	Pneumonia						
	Skin Discolouration						
	Synovitis						

Date:09/21/04ISR Number: 4455251-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00132
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	55	DAY
Life-Threatening	Duodenal Ulcer		Amlodipine Besylate	C		ORAL		
Hospitalization -	Haemorrhage		Dipyrone	C		ORAL	135	DAY
Initial or Prolonged	Gastric Ulcer Haemorrhage		Furosemide Sodium	C		ORAL	475	DAY
	Nervous System Disorder							

Date:09/21/04ISR Number: 4455254-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01899
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Purulent Discharge							

Date:09/21/04ISR Number: 4455255-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01737
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	27	DAY
Initial or Prolonged	Gastritis		Tylenol	C			UNKNOWN	
	Gastrooesophageal Reflux		Xanax	C			UNKNOWN	
	Disease		Synthroid	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/04ISR Number: 4455256-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00054
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematoma		Fluindione	SS		ORAL
	Rectal Haemorrhage		Fluindione	SS		ORAL
	Transient Ischaemic		Digoxin	C		ORAL
	Attack		Ramipril	C		ORAL
			Ramipril	C		ORAL
			Digoxin	C		ORAL

Date:09/21/04ISR Number: 4455257-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Norvasc	C		
UNKNOWN						
Disability	Asthenia		Lotrel	C		
UNKNOWN						
	Blood Cholesterol		Coreg	C		
UNKNOWN						
	Increased		Clonidine	C		
UNKNOWN						
	Blood Creatinine		Clonidine	C		ORAL
	Increased		Digitek	C		
UNKNOWN						
	Bronchitis		Zocor	C		ORAL
	Cardiac Failure		Spironolactone	C		
UNKNOWN						
	Congestive		Nexium	C		
UNKNOWN						
	Congestive Cardiomyopathy		Lisinopril	C		
UNKNOWN						
	Contusion		Reglan	C		
UNKNOWN						
	Cough		Minoxidil	C		
UNKNOWN						
	Depression		Minoxidil	C		
UNKNOWN	1 DAY					
	Dyspepsia		Minoxidil	C		
UNKNOWN						

Emotional Distress
Erectile Dysfunction
Facial Palsy
Fall
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Hypertension
Insomnia
Nasal Congestion
Neck Injury
Pain
Rhinorrhoea
Road Traffic Accident
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Swelling
Upper Respiratory Tract
Infection
Ventricular Extrasystoles

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/21/04ISR Number: 4455260-8Report Type:Expedited (15-DaCompany Report #ES-MERCK-0409ESP00015
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Captopril	SS		ORAL		
	Hyperkalaemia		Diltiazem Hydrochloride	C		ORAL		
	Renal Failure Acute		Glimepiride	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:09/21/04ISR Number: 4455261-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00133
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Eruption		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
			Albuterol	C		RESPIRATORY (INHALATION)		
			Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
			Prednisolone	C		ORAL	6	DAY

Date:09/21/04ISR Number: 4455262-1Report Type:Expedited (15-DaCompany Report #IE-MERCK-0409GBR00131
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL	57	DAY
	Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL	57	DAY
			Bisoprolol Fumarate	C		UNKNOWN		

			Doxazosin Mesylate	C		
UNKNOWN						
			Eprosartan	C		
UNKNOWN						
			Fluoxetine Hydrochloride	C		
UNKNOWN						
			Pantoprazole Sodium	C		
UNKNOWN						
			Pravastatin Sodium	C		
UNKNOWN						

Date:09/21/04ISR Number: 4455264-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0409SWE00014
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Desogestrel And Ethinyl Estradiol	SS		ORAL
	Renal Artery Thrombosis		Omeprazole	SS		ORAL

Date:09/21/04ISR Number: 4455265-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain
	Bronchitis
	Cerebrovascular Accident
	Constipation
	Drug Withdrawal Syndrome
	Dyspepsia
	Dyspnoea

		Eczema Infected					
		Emotional Distress					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Hemiparesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hip Fracture		Benadryl	C		
UNKNOWN							
		Nasopharyngitis		Motrin	C		
UNKNOWN							
		Oedema Peripheral		Paxil	C		
UNKNOWN							
		Pain In Extremity		Paxil	C		
UNKNOWN							
		Pharyngolaryngeal Pain					
		Pneumonia					
		Sinus Congestion					
		Sinusitis					
		Syncope					
		Thyroid Pain					
		Vision Blurred					

Date:09/21/04ISR Number: 4456699-7Report Type:Expedited (15-DaCompany Report #2004064679
Age:53 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Drug Ineffective	Consumer	Lipitor			
		Heart Rate Increased		(Atorvastatin)	PS		ORAL
ORAL							
		Muscle Atrophy		Celecoxib			
		Myalgia		(Celecoxib)	SS		ORAL
(200 MG) ORAL							
		Palpitations		Valdecoxib			
		Rhabdomyolysis		(Valdecoxib)	SS		ORAL
ORAL							
				Rofecoxib			
				(Rofecoxib)	SS		ORAL
ORAL							
				Montelukast			
				(Montelukast)	C		
				Telmisartan			
				(Telmisartan)	C		

Date:09/22/04ISR Number: 4455872-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00043
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accidental Overdose	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Diclofenac Sodium	C		ORAL		
			Fluconazole	C		ORAL		
			Lansoprazole	C		ORAL		

Date:09/22/04ISR Number: 4455874-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA01789
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Feeling Abnormal	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C			UNKNOWN	
			Arava	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/04ISR Number: 4455875-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Abdominal Pain		Prevacid	C		
Disability	Acute Sinusitis					
	Adverse Event					
	Barrett'S Oesophagus					
	Benign Duodenal Neoplasm					
	Blood Pressure Increased					
	Brunner'S Gland Hyperplasia					
	Carpal Tunnel Syndrome					
	Chest Pain					
	Costochondritis					
	Dermatitis Allergic					
	Gastrooesophageal Reflux Disease					
	Lipids Increased					
	Liver Function Test Abnormal					
	Pain					
	Sensation Of Pressure					

Date:09/22/04ISR Number: 4455884-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00162
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastritis		Bendroflumethiazide	C		ORAL
			Lacidipine	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Lansoprazole	C		ORAL
			Lisinopril	C		ORAL

Date:09/22/04ISR Number: 4455885-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00105
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	General Physical Health	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Deterioration		Acetaminophen	C		ORAL		
	Jaundice Cholestatic		Acetaminophen	C		ORAL		
	Pancreatic Carcinoma		Aspirin	C		ORAL		
			Spironolactone	C		ORAL		
			Gliclazide	C		ORAL		
			Nicorandil	C		ORAL		
			Omeprazole	C		ORAL		

Date:09/22/04ISR Number: 4455886-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01147
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Forteo	C				
UNKNOWN								
	Unevaluable Event							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/04ISR Number: 4455887-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00184
Age:51 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY
	Diarrhoea		Lorazepam	C		ORAL		
	Feeling Abnormal							

Date:09/22/04ISR Number: 4455888-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01145
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lipitor	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:09/22/04ISR Number: 4455889-7Report Type:Expedited (15-DaCompany Report #IT-MERCK-0409ITA00019
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Toxic Skin Eruption		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY

Date:09/22/04ISR Number: 4455892-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00071
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Duodenal Ulcer	Professional	Prednisone	SS		ORAL		

Date:09/22/04ISR Number: 4456284-7Report Type:Expedited (15-DaCompany Report #BE-MERCK-0406BEL00035
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vascular Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	7 DAY
			Celecoxib	C		ORAL		
			Enoxaparin Sodium	C				
			Zolpidem Tartrate	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Methylprednisolone	C		ORAL	7 DAY	

Date:09/22/04ISR Number: 4456287-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02208
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lasix (Furosemide Sodium)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/22/04ISR Number: 4456290-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00649
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Asthenia		Toprol Xl Tablets	SS				
UNKNOWN								
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Tylenol	C				
UNKNOWN								
	Hyperlipidaemia		Aspirin	C				
UNKNOWN								
	Iatrogenic Injury		Wellbutrin Sr	C				
UNKNOWN								
	Oedema Peripheral		Keflex	C				
UNKNOWN								
	Pain In Extremity		Pepcid	C		ORAL		
	Palpitations							
	Pulmonary Hypertension							
	Supraventricular							
	Tachycardia							

Date:09/22/04ISR Number: 4456294-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
12 DAY								
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
1 DAY								
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
72 DAY								
	Dehydration		Lipitor	C				
UNKNOWN								
	Ear Infection		Zocor	C		ORAL		
	Eye Irritation		Prinivil	C		ORAL		
	Hepatic Enzyme Increased		Protonix	C				
UNKNOWN								
	Rash Pruritic							
	Skin Lesion							

Date:09/22/04ISR Number: 4456300-2Report Type:Expedited (15-DaCompany Report #PT-MERCK-0409PRT00012
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Inadequate Control		Acarbose	C		ORAL	17	MON
	Hepatosplenomegaly		Terbinafine	C		ORAL		

Date:09/22/04ISR Number: 4456301-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/22/04ISR Number: 4457440-4Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040903661
Age:67 YR Gender:Female I/FU:I

Outcome	PT
Death	Alanine Aminotransferase Increased
Hospitalization - Initial or Prolonged	Ammonia Increased
Other	Anion Gap Increased
	Aspartate Aminotransferase Increased
	Base Excess Negative

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Bicarbonate Decreased					
		Blood Bilirubin Increased					
		Blood Chloride Decreased	Literature	Tylenol (Acetaminophen)			
		Blood Creatinine Increased	Health Professional	Unspecified	PS		ORAL
ORAL							
		Blood Glucose Decreased		Rofecoxib (Rofecoxib)	SS		ORAL
ORAL							
		Blood Lactic Acid Increased		Albuterol (Salbutamol)	SS		ORAL
ORAL							
		Blood Ph Decreased		Ipratroprium (Ipratropium)	SS		ORAL
ORAL							
		Blood Potassium Increased		Lansoprazole (Lansoprazole)	SS		ORAL
ORAL							
		Blood Urea Increased		Guaifenesin (Guaifenesin)	SS		ORAL
ORAL							
		Brain Death		Raloxifene (Raloxifene)	SS		ORAL
ORAL							
		Coma		Fluticasone (Fluticasone)	SS		ORAL
ORAL							
		Convulsion		Benazepril (Benazepril)	SS		
		Depressed Level Of Consciousness		Amlodipine	SS		ORAL
ORAL							
		General Physical Health Deterioration					
		Heart Rate Increased					
		Hypotension					
		International Normalised Ratio Increased					
		Mental Impairment					
		Pco2 Decreased					
		Posturing					
		Prothrombin Time Prolonged					
		Respiratory Rate Increased					

Date:09/22/04ISR Number: 4457922-5Report Type:Expedited (15-DaCompany Report #04P-167-0270891-00
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Eye Haemorrhage	Foreign Health Professional	Humira 40 Mg/0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab)(Adalimumab)	PS		SUBCUTANEOUS	40 MG,	
			Estrogens Conjugated	SS		SUBCUTANEOUS		
			Clavulin	SS				
			Paramol-118	SS				
			Fluoxetine	SS				
			Methotrexate	SS				
			Rofecoxib	SS				
			Clavulin	C				
			Panadeine Co	C				

Date:09/23/04ISR Number: 4456928-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02789
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Adjustment Disorder
Hospitalization - Initial or Prolonged	Asthenia
	Back Pain
	Colon Adenoma
	Depression

		Dermatitis Allergic					
		Diverticulum Intestinal					
		Haemorrhagic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Eye Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal Tract	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Large Intestinal Ulcer		Lortab	C		
UNKNOWN							
		Haemorrhage		Vitamins			
		Lower Gastrointestinal		(Unspecified)	C		
UNKNOWN							
		Haemorrhage		Vitamin B Complex	C		ORAL
		Muscle Spasms		Ascorbic Acid	C		
UNKNOWN							
		Paraesthesia		Aspirin	C		
UNKNOWN							
		Prothrombin Time		Uniretic	C		
UNKNOWN							
		Prolonged					
		Radiculopathy					
		Rash Generalised					
		Rash Maculo-Papular					
		Rash Pruritic					
		Rectal Haemorrhage					
		Road Traffic Accident					
		Syncope					

Date:09/23/04ISR Number: 4456929-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01394
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
Other		Bursitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
261	DAY						
		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL
261	DAY						
		Contusion		Tylenol	C		
UNKNOWN							

	Dyspepsia	Combivent	C
RESPIRATORY			
	Emotional Distress		
(INHALATION)			
	Gastric Ulcer	Allopurinol	C
UNKNOWN			
	Gastritis	Celebrex	C
UNKNOWN			
	Gastrointestinal	Polycitra-K	C
UNKNOWN			
	Haemorrhage	Estradiol	C
UNKNOWN			
	Intestinal Polyp	Glucosamine	C
UNKNOWN			
	Meniscus Lesion	Vitamins	
	Patella Fracture	(Unspecified)	C
UNKNOWN			
	Patellofemoral Pain	Vitamin E	C
UNKNOWN			
	Syndrome	Diovan	C
UNKNOWN			
	Pyrexia	Ultram	C
UNKNOWN			
	Therapeutic Response	Bactrim Ds Tablets	C
UNKNOWN			
	Decreased	Avalide	C
UNKNOWN			
	Wound Infection	Atrovent	C
UNKNOWN			
		Avapro	C
UNKNOWN			
		Claritin	C
UNKNOWN			
		Niferex	C
UNKNOWN			
		Potassium	
		(Unspecified)	C
UNKNOWN			
		Pyridoxine	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/04ISR Number: 4456934-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthralgia		Vicodin Tablets	C			UNKNOWN	
	Confusional State		Xanax	C			UNKNOWN	
	Connective Tissue Disorder		Elavil	C		ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	
	Contusion		Aspirin	C			UNKNOWN	
	Depression		Lotensin	C			UNKNOWN	
	Diabetes Mellitus		Zoloft	C			UNKNOWN	
	Dizziness		Captopril	C			UNKNOWN	
	Drug Ineffective		Neurontin	C			UNKNOWN	
	Dysphoria		Heparin	C			UNKNOWN	
	Fall		Hydro-Chlor	C			UNKNOWN	
	Fibromyalgia		Insulin	C			UNKNOWN	
	Gastritis		Ms Contin	C			UNKNOWN	
	Gastrointestinal Haemorrhage		Zantac	C			UNKNOWN	
	Generalised Anxiety Disorder							
	Haemorrhoids							
	Hypertension							
	Idiopathic Thrombocytopenic Purpura							
	Injury							
	Intestinal Obstruction							
	Joint Lock							
	Malaise							
	Melaena							
	Nervousness							

Pain
Petechiae
Platelet Count Decreased
Stomach Discomfort
Thrombocytopenia
Tremor
Vomiting

Date:09/23/04ISR Number: 4456935-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00117
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Adverse Event
Other	Anaemia
	Anxiety
	Arteriosclerosis
	Arthritis
	Atelectasis
	Bone Neoplasm Malignant
	Bronchiectasis
	Cardiac Disorder
	Chest Pain
	Coronary Artery Disease
	Death
	Decreased Appetite
	Depressed Level Of Consciousness

		Depression					
		Diabetes Mellitus					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux Disease	Professional				
		Herpes Zoster					
		Insomnia					
		Multiple Myeloma					
		Nervousness					
		Neutropenia					
		Oedema Peripheral					
		Pancytopenia					
		Plasmacytosis					
		Pneumonia					
		Sleep Apnoea Syndrome					
		Tremor					
		Weight Decreased					

Date:09/23/04ISR Number: 4456939-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00025
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Epistaxis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
41 DAY						
Hospitalization -	Haematuria	Professional	Amlodipine Maleate	C		
UNKNOWN						
Initial or Prolonged	Renal Failure Acute		Amlodipine Maleate	C		
UNKNOWN						
			Bisoprolol	C		
UNKNOWN						
			Bisoprolol	C		
UNKNOWN						
			Sotalol Hydrochloride	C		
UNKNOWN						
			Glimepiride	C		
UNKNOWN						
			Phenprocoumon	C		
UNKNOWN						
			Phenprocoumon	C		
UNKNOWN						

			Ranitidine	C			
UNKNOWN							

Date:09/23/04ISR Number: 4456941-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00992
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 227 DAY	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Asthma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebral Infarction		Aspirin	C		
UNKNOWN						
	Cerebrovascular Accident		Cortisone (Cortisone Acetate)	C		
	Decubitus Ulcer					
UNKNOWN						
	Depression		Vasotec	C		ORAL
	Hypothyroidism		Prempro	C		
UNKNOWN	299 DAY					
	Muscle Spasms		Allegra-D	C		
UNKNOWN						
	Pain In Extremity		Amaryl	C		
UNKNOWN						
	Proteinuria		Levoxyl	C		
UNKNOWN						
	Urinary Tract Infection		Claritin-D	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Univasc	C		
UNKNOWN						
			Nitrostat	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/04ISR Number: 4456942-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02316
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy Renal Failure Acute	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/23/04ISR Number: 4456943-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Other	Abdominal Discomfort Activated Partial Thromboplastin Time Prolonged Acute Respiratory Distress Syndrome Allergic Sinusitis Aortic Valve Sclerosis Arrhythmia Supraventricular Arteriosclerosis Arthralgia Aspartate Aminotransferase Increased Aspiration Asthenia Atelectasis Atrial Fibrillation Back Pain Bilirubin Conjugated Increased Blood Albumin Decreased Blood Alkaline Phosphatase Increased Blood Bilirubin Increased Blood Cholesterol Increased Blood Homocysteine Increased Blood Lactate Dehydrogenase Increased Blood Pressure

Inadequately Controlled
Blood Triglycerides
Increased
Bone Marrow Depression
Breast Tenderness
Cardiac Flutter
Cardio-Respiratory Arrest
Cataract
Chest Wall Pain
Cholelithiasis
Coagulopathy
Coronary Artery Disease
Dehydration
Depression
Diarrhoea
Diverticulum
Drug Eruption

Drug Hypersensitivity
Dyspepsia
Dyspnoea Exertional
Electrocardiogram
Abnormal
Electrocardiogram St-T
Change
Erythema
Eustachian Tube Disorder
Extradural Abscess
Fatigue
Feeling Abnormal
Fibrin D Dimer Increased
Gallbladder Disorder
Groin Pain
Haematochezia
Hepatic Function Abnormal
Hyperlipidaemia
Hypersensitivity
Hypokalaemia
Hypokinesia
Hypotension
Ileus
Infection
Influenza Like Illness
Injury
International Normalised
Ratio Increased
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Intervertebral Discitis
Keratoconjunctivitis
Sicca
Liver Tenderness
Low Density Lipoprotein
Increased
Macular Degeneration
Mastitis
Mitral Valve Incompetence
Mucosal Dryness
Multi-Organ Failure
Muscle Spasms
Myalgia
Myocardial Infarction
Nausea

Oedema
Osteomyelitis
Otitis Media
Pain
Pancreatic Atrophy
Pancreatitis
Pericardial Effusion
Pleural Effusion
Postnasal Drip
Prothrombin Time
Prolonged
Pulmonary Oedema
Radicular Pain
Rash

	Renal Failure						
	Renal Failure Acute						
	Renal Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Tubular Necrosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	45 DAY
	Rhinitis Allergic	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	45 DAY
	Self-Medication		Tylenol With Codeine				
	Sepsis		#3	C			UNKNOWN
	Shift To The Left		Percocet	C			UNKNOWN
	Sinus Headache		Zocor	C			UNKNOWN
	Throat Irritation		Vitamin E	C			UNKNOWN
	Thrombocytopenia		Ascorbic Acid	C			UNKNOWN
	Toxic Shock Syndrome		Beta Carotene	C			UNKNOWN
	Upper Respiratory Tract		Centrum	C			UNKNOWN
	Infection						
	Ureteric Obstruction						
	Urinary Tract Infection						
	Vaginal Haemorrhage						
	Ventricular Arrhythmia						
	Ventricular Fibrillation						
	Ventricular Hypokinesia						
	Ventricular Tachycardia						
	Vision Blurred						
	Vomiting						
	White Blood Cell Count Increased						

Date:09/23/04ISR Number: 4456947-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00140
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Hospitalization - Initial or Prolonged	Prescribed Overdose	Professional					

Disability

Date:09/23/04ISR Number: 4458945-2Report Type:Direct Company Report #CTU 227957
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - SEE IMAGE Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Coronary Artery Occlusion Coronary Artery Thrombosis Myocardial Infarction		Vioxx 25 Mg & 50mg - Merck	PS	Merck			

Date:09/23/04ISR Number: 4458962-2Report Type:Direct Company Report #CTU 227875
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS		ORAL	25 MG ORALLY 1 TAB DAILY/	1 1/2 YEARS
			Cardia Xt	C				
			Dyazide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/04ISR Number: 4459679-0Report Type:Direct Company Report #CTU 227893
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck	ORAL	50MG	DAY
	Palpitations							
	Tachycardia							

Date:09/23/04ISR Number: 4460500-5Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040903505
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Literature	Cyclobenzaprine					
Hospitalization - Initial or Prolonged	Aspiration	Health Professional	(Cyclobenzaprine Hydrochloride)					
	Drug Interaction							
Other	Potentiation		Unknown	PS		ORAL	300 MG, 1 IN	1 DAY, ORAL
	Drug Screen Positive							
	Drug Toxicity		Acetaminophen/Tramadol (Tramadol/Apap)	SS			30 G/3 G	
	Lung Disorder							
	Multiple Drug Overdose		Amitriptyline (Amitriptyline)	SS		ORAL	700 MG, 1 IN	1 DAY, ORAL
	Sedation							
	Self-Medication							
	Suicide Attempt		Tizanidine (Tizanidine)	SS		ORAL	120 MG, 1 IN	1 DAY, ORAL
	Vomiting							
			Rofecoxib (Rofecoxib)	SS		ORAL	750 MG, 1 IN	1 DAY, ORAL
			Omeprazole (Omeprazole)	SS		ORAL	300 MG, 1 IN	

1 DAY, ORAL

Date:09/23/04ISR Number: 4462361-7Report Type:Expedited (15-DaCompany Report #1220002
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Arthritis
	Barrett'S Oesophagus
	Blood Chloride Decreased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Inadequately Controlled
	Blood Thyroid Stimulating Hormone Increased
	Brain Natriuretic Peptide Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Coronary Artery Atherosclerosis
	Dehydration
	Diarrhoea
	Dyspnoea
	Erosive Duodenitis
	Gastric Disorder
	Gastrointestinal Haemorrhage

		Gastrooesophageal Reflux Disease					
		Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypochromasia	Study	Tab Vioxx 25 Mg	PS		ORAL
25 MG							
		Microcytosis	Health				
/DAILY/PO							
		Oedema Peripheral	Professional	Tab Acetaminophen			
		Oesophagitis		325 Mg	SS		ORAL
325 MG/PRN/PO							
		Supraventricular		Tab Acetaminophen			
		Extrasystoles		325 Mg	SS		ORAL
325 MG/PRN/PO							
		Troponin Increased		Ambien	C		
		Vomiting		Toprol Xl Tablets	C		
				Allopurinol	C		
				Aspirin	C		
				Gemfibrozil	C		
				Hydrochlorothiazide	C		
				Ibuprofen	C		
				Isosorbide Mononitrate	C		
				Lansoprazole	C		
				Levothyroxine Sodium	C		
				Lisinopril	C		
				Nitroglycerin	C		
				Pantoprazole	C		
				Paroxetine	C		
				Trazodone Hydrochloride	C		

Date:09/24/04ISR Number: 4457815-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00820
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Pain	Professional	Calcium			
Disability		Dermal Cyst		(Unspecified)	C		
UNKNOWN							
		Family Stress		Soma	C		
UNKNOWN							
		Hypoaesthesia		Celebrex	C		
UNKNOWN							

	Oedema Peripheral		Zyrtec	C
UNKNOWN				
	Postoperative Infection		Estradiol	C
UNKNOWN				
			Ultram	C
UNKNOWN				
			Hydrochlorothiazide And Triamterene	C
UNKNOWN				
			Motrin	C
UNKNOWN		1 DAY		
			Motrin	C
UNKNOWN				
			Altace	C
UNKNOWN				

Date:09/24/04ISR Number: 4457819-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01324
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/24/04ISR Number: 4457820-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00636
Age:35 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable	Professional	Tylenol	C				UNKNOWN
	Bronchitis		Aspirin	C				UNKNOWN
	Cholelithiasis		Celebrex	C				UNKNOWN
	Dermal Cyst		Nexium	C				UNKNOWN
	Duodenitis		Toprol Xl Tablets	C				UNKNOWN
	Dyspnoea							
	Eczema							
	Gastritis							
	Helicobacter Gastritis							
	Otitis Media							
	Pleurisy							
	Sinusitis							

Date:09/24/04ISR Number: 4457822-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00640
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adrenal Adenoma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adrenal Cyst		Xanax	C				UNKNOWN
	Adverse Event		Aspirin	C				UNKNOWN
	Arterial Occlusive		Premarin	C				UNKNOWN
	Disease		Lasix (Furosemide)	C				UNKNOWN
	Back Pain		Detrol	C				UNKNOWN
	Cardiomegaly		Maxzide	C				UNKNOWN
	Chest Pain		Prevacid	C				UNKNOWN

	Cholecystitis	Claritin-D	C
UNKNOWN			
	Cholelithiasis	Nitropatch	C
UNKNOWN			
	Dilatation Atrial		
	Hepatic Steatosis		
	Incontinence		
	Injury		
	Mitral Valve Incompetence		
	Thyroid Disorder		
	Umbilical Hernia		
	Ventricular Hypertrophy		

Date:09/24/04ISR Number: 4457823-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abnormal Sensation In Eye
Disability	Asthenopia
	Brain Stem Syndrome
	Cerebrovascular Accident
	Constipation
	Dyspepsia
	Emotional Distress
	Facial Palsy
	Haematochezia
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Keratoconjunctivitis

	Sicca						
	Night Blindness						
	Osteopenia						
	Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Photosensitivity Reaction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Rotator Cuff Syndrome	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Simple Partial Seizures		Vioxx	SS	Merck & Co., Inc	ORAL	
	Urine Flow Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Vision Blurred		Plendil	C			UNKNOWN
	Visual Acuity Reduced		Dyazide	C			UNKNOWN
	Weight Increased						

Date:09/24/04ISR Number: 4457824-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00816
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cerebrovascular Accident	Professional					
Disability	Hypertension						
	Vasculitis						

Date:09/24/04ISR Number: 4457825-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01976
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	106 DAY
Initial or Prolonged	Glaucoma	Professional	Tylenol	C			UNKNOWN
	Non-Cardiac Chest Pain		Bayer Aspirin	C			UNKNOWN
	Thyroid Disorder						
	Tooth Extraction						

Date:09/24/04ISR Number: 4457828-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA00267
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL	117 DAY	
	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	117 DAY	
	Feeling Abnormal		Pravachol	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Zantac	C			UNKNOWN	

Date:09/24/04ISR Number: 4457829-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01316
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:09/24/04ISR Number: 4457831-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00817
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Rigidity
Other	Acute Sinusitis
	Adjustment Disorder With Anxiety
	Adverse Event

Dose	Duration						
		Anaemia Vitamin B12 Deficiency					
		Anxiety	Report Source	Product	Role	Manufacturer	Route
		Back Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
		Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Bladder Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain					
		Conjunctivitis					
		Constipation					
		Drug Ineffective					
		Dysphagia					
		Fatigue					
		Flat Affect					
		Flatulence					
		Fungal Infection					
		Gallbladder Disorder					
		Gastritis					
		Gastrooesophageal Reflux Disease					
		Hot Flush					
		Increased Upper Airway Secretion					
		Insomnia					
		Migraine					
		Muscle Strain					
		Muscle Twitching					
		Muscular Weakness					
		Nausea					
		Neck Pain					
		Neuropathy					
		Pain In Extremity					
		Pernicious Anaemia					
		Pharyngolaryngeal Pain					
		Pleurisy					
		Pyrexia					
		Rhinitis Allergic					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinus Congestion					
		Speech Disorder					
		Stress					
		Tonsillar Disorder					
		Trigger Finger					
		Upper Respiratory Tract Infection					

Vaginal Infection
Vaginal Ulceration
Vertigo
Vitreous Detachment
Weight Decreased

Date:09/24/04ISR Number: 4457834-7Report Type:Expedited (15-DaCompany Report #IE-MERCK-0409GBR00130
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agitation	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Confusional State		Chloramphenicol	C			OPHTHALMIC	
	Disturbance In Attention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4457835-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00827
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atrial Fibrillation		Darvocet-N	C				
Disability	Atrial Septal Defect		Albuterol	C		RESPIRATORY (INHALATION)		
Other	Chest Pain							
	Fluid Retention		Xanax	C			UNKNOWN	
	Pain In Extremity		Xanax	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			St. Joseph Adult Chewable Aspirin	C			UNKNOWN	
			Serevent	C		RESPIRATORY (INHALATION)		
			Uniphyl	C			UNKNOWN	
			Restoril	C			UNKNOWN	
			Lotensin	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Flovent	C			UNKNOWN	
			Mobic	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Paxil	C			UNKNOWN	

Date:09/24/04ISR Number: 4457836-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01496
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Cipro	C				
Initial or Prolonged UNKNOWN			Celexa	C				
Disability UNKNOWN			Flagyl	C				
Other								

Date:09/24/04ISR Number: 4457837-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01731
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:09/24/04ISR Number: 4457838-4Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00010
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hepatic Necrosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Levothyroxine Sodium	C		ORAL		
Initial or Prolonged			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		ORAL	2	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4457839-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aneurysm		Cyanocobalamin	C				
UNKNOWN								
Other	Anxiety							
	Cardiac Disorder							
	Cellulitis							
	Cerebrovascular Accident							
	Chronic Obstructive Pulmonary Disease							
	Disturbance In Attention							
	Duodenal Ulcer							
	Haemorrhage							
	Eating Disorder							
	Emotional Distress							
	Facial Palsy							
	Foot Fracture							
	Hemiparesis							
	Hypertension							
	Infarction							
	Leg Amputation							
	Limb Injury							
	Pain In Extremity							
	Peripheral Ischaemia							
	Peripheral Vascular Disorder							
	Thrombosis							
	Toe Deformity							
	Transient Ischaemic Attack							
	Wound Dehiscence							

Date:09/24/04ISR Number: 4457840-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Aspiration		Acetaminophen And Tramadol					
	Completed Suicide							

Other	Depressed Level Of	Hydrochloride	SS	
UNKNOWN				
	Consciousness	Elavil	SS	ORAL
	Drug Toxicity	Tizanidine		
	Intentional Misuse	Hydrochloride	SS	ORAL
	Vomiting	Flexeril	SS	ORAL
		Omeprazole	SS	ORAL

Date:09/24/04ISR Number: 4457841-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Bruit
	Abdominal Discomfort
Disability	Accident At Work
Other	Acute Myocardial Infarction
	Adhesion
	Akinesia
	Alcohol Withdrawal

Syndrome
Alcoholism
Anaemia
Anxiety
Arthralgia
Arthropathy
Back Pain
Biliary Neoplasm
Bronchitis
Bronchopneumonia
Cardiac Disorder
Cardiac Failure
Congestive
Cerebrovascular Accident
Condition Aggravated
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Drug Dependence
Drug Ineffective
Dyspnoea
Dysuria
Emotional Distress
Facet Joint Syndrome
Faecal Occult Blood
Positive
Fatigue
Headache
Hepatitis C
Hyperlipidaemia
Hypertension
Impaired Work Ability
Inadequate Analgesia
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Loss Of Consciousness
Lumbar Spinal Stenosis
Micturition Urgency
Mitral Valve Incompetence
Mouth Ulceration
Muscle Spasms
Myocardial Infarction

Myocardial Ischaemia
Myofascial Pain Syndrome
Neck Pain
Neuropathy Peripheral
Osteoarthritis
Pain
Panic Attack
Paraesthesia
Peripheral Vascular
Disorder
Pneumonia
Pneumonia Viral
Pollakiuria
Prostatitis

		Pyrexia						
		Radiculitis Lumbosacral						
		Rash Erythematous	Report Source	Product	Role	Manufacturer	Route	Dose
	Duration							
		Rash Pruritic	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
		Spinal Osteoarthritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL	
		Surgery		Vioxx	SS	Merck & Co., Inc	ORAL	
		Syncope		Vioxx	SS	Merck & Co., Inc	ORAL	
		Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL	
		Tremor		Lortab	C			
UNKNOWN								
		Urinary Tract Infection		Acetaminophen And				
		Ventricular Dysfunction		Hydrocodone				
		Vision Blurred		Bitartrate	C			
UNKNOWN								
				Trazodone				
				Hydrochloride	C			
UNKNOWN								
				Amitriptyline				
				Hydrochloride	C			
UNKNOWN		874	DAY					
				Celebrex	C			
UNKNOWN		362	DAY					
				Neurontin	C			
UNKNOWN								
				Hydrocodone				
				Bitartrate	C			
UNKNOWN								
				Ibuprofen	C			
UNKNOWN								
				Lorazepam	C			
UNKNOWN		2	DAY					
				Robaxin	C			
UNKNOWN		957	DAY					

Date:09/24/04ISR Number: 4457845-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0409NOR00012
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Hospitalization -	C-Reactive Protein	Health	Vioxx	PS	Merck & Co., Inc		
UNKNOWN							
Initial or Prolonged	Increased	Professional					
	General Physical Health						

Deterioration
Influenza Like Illness
Liver Function Test
Abnormal
Musculoskeletal Stiffness

Date:09/24/04ISR Number: 4458151-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety							
	Arthropathy							
	Contusion							
	Fall							
	Gastric Haemorrhage							
	Hypertension							
	Joint Sprain							
	Osteoarthritis							
	Upper Respiratory Tract Infection							

Date:09/24/04ISR Number: 4458152-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00855
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Adenoidal Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Adverse Event		Norvasc	C		ORAL
	Aspartate Aminotransferase Increased		Norvasc	C		ORAL
			Clonidine	C		ORAL
			Zantac	C		ORAL
	Blood Calcium Increased					
	Blood Pressure Increased					
	Calculus Urinary					
	Diarrhoea					
	Dyspnoea					
	Fatigue					
	Flank Pain					
	Haematuria					
	Headache					
	Hydrocele					
	Hypercalcaemia					
	Inguinal Hernia					
	Injury					
	Macroglossia					
	Nephrolithiasis					
	Obstruction					
	Pain					
	Sleep Apnoea Syndrome					
	Snoring					
	Somnolence					
	Testicular Pain					
	Tonsillar Hypertrophy					
	Urine Sodium Increased					
	Varicocele					
	Ventricular Extrasystoles					
	Weight Increased					

Date:09/24/04ISR Number: 4458153-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01470
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Oedema					

Date:09/24/04ISR Number: 4458157-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Tylenol	C			UNKNOWN	
	Emotional Distress		Algae (As Drug)	C			UNKNOWN	
	Oedema Peripheral		Aspirin	C		ORAL		
	Palpitations		Pepcid	C			UNKNOWN	
	Scoliosis		Ibuprofen	C			UNKNOWN	
	Sinus Bradycardia		Adalat	C		ORAL		
	Weight Increased		Klor-Con	C		ORAL		
			Zantac	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4458158-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Norco	C				
Disability	Anxiety		Allopurinol	C				
	Blood Cholesterol		Xanax	C				
	Increased		Aspirin	C				
	Blood Creatine		Soma	C				
	Phosphokinase Increased		Plavix	C				
	Bronchitis		Colchicine	C				
	Cardiac Failure		Diltiazem					
	Congestive		Hydrochloride	C				
	Coronary Artery		Folic Acid	C				
	Atherosclerosis		Indocin					
	Coronary Artery Disease		(Indomethacin)	C		ORAL		
	Depression		Imdur	C				
	Dyspnoea		Lecithin And Protein					
	Fatigue		(Unspecified)	C				
	Feeling Abnormal		Levothroid	C				
	Gastrooesophageal Reflux		Levothroid	C				
	Disease		Levothroid	C				
	Gouty Arthritis		Levothroid	C				
	Influenza		Toprol Xl Tablets	C				
	Limb Injury		Diovan	C				
	Malignant Hypertension		Diovan	C				
	Myocardial Ischaemia		Zocor	C		ORAL		

Nasal Discomfort Nitro-Dur C
UNKNOWN

Oedema Peripheral
Palpitations
Rhinitis Allergic
Skin Lesion
Sleep Apnoea Syndrome
Tinnitus
Upper Respiratory Tract
Infection

Date:09/24/04ISR Number: 4458161-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability
Other

PT
Adverse Event
Alveolitis Fibrosing
Amnesia
Anxiety
Arthralgia
Arthropathy
Atelectasis
Atherosclerosis
Blood Pressure Increased
Cardiac Failure
Cardiac Failure
Congestive
Carotid Artery Disease
Carpal Tunnel Syndrome
Chronic Obstructive
Pulmonary Disease
Connective Tissue
Disorder
Cough

		Depression					
		Dermatomyositis					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diastolic Dysfunction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness	Professional				
		Drug Hypersensitivity					
		Gastrooesophageal Reflux					
		Disease					
		Haemoptysis					
		Heart Sounds Abnormal					
		Hypersensitivity					
		Hypertension					
		Injury					
		Insomnia					
		Interstitial Lung Disease					
		Lung Infiltration					
		Lymphadenopathy					
		Malaise					
		Memory Impairment					
		Obsessive-Compulsive					
		Disorder					
		Obstructive Airways					
		Disorder					
		Oedema Peripheral					
		Osteopenia					
		Pain In Extremity					
		Paraesthesia					
		Polymyositis					
		Pulmonary Fibrosis					
		Pulmonary Oedema					
		Rash					
		Rash Macular					
		Rheumatoid Arthritis					
		Spinal Osteoarthritis					
		Swelling					
		Visual Field Defect					

Date:09/24/04ISR Number: 4458163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Adverse Event	Professional	Coumadin	C
UNKNOWN				
Disability	Benign Prostatic Hyperplasia Bladder Diverticulum Bladder Trabeculation Cardiac Failure Congestive Cardiomyopathy Coronary Artery Disease Mitral Valve Incompetence Tricuspid Valve Incompetence			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4458164-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00019
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastritis		Alfuzosin Hydrochloride	C		ORAL
	Rectal Haemorrhage		Ascorbic Acid And Vitamin B (Unspecified)	C		ORAL
			Chondroitin Sulfate Sodium	C		ORAL
			Sertraline Hydrochloride	C		ORAL
			Clorazepate Dipotassium	C		ORAL
			Enalapril Maleate	C		ORAL
			Enalapril Maleate And Hydrochlorothiazide	C		ORAL

Date:09/24/04ISR Number: 4458395-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00796
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthropathy		Aleve	C		
UNKNOWN						
	Cartilage Injury					
	Cervicobrachial Syndrome					
	Depression					
	Facet Joint Syndrome					
	Injury					
	Intervertebral Disc Protrusion					
	Muscle Atrophy					
	Muscular Weakness					
	Neck Pain					
	Oedema Peripheral					
	Osteoarthritis					
	Paraesthesia					
	Spinal Disorder					

Date:09/24/04ISR Number: 4458396-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01693
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Disability	Dyspnoea		Corticosteroids (Unspecified)	C				UNKNOWN
	Photosensitivity Reaction							
	Pruritus		Sunscreen (Unspecified)	C				UNKNOWN
	Skin Depigmentation							
	Swelling		Triamcinolone	C				UNKNOWN
			Protonix	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/04ISR Number: 4458398-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01831
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Health Professional	Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:09/24/04ISR Number: 4458399-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Lipitor	C				UNKNOWN
	Atherosclerosis		Monopril	C				UNKNOWN
	Cardiac Disorder		Glyburide	C				UNKNOWN
	Cardiac Murmur		Hydrodiuril	C		ORAL		
	Cardiac Stress Test		Imdur	C				UNKNOWN
	Abnormal							
	Chest Pain							
	Coronary Artery Disease							
	Drug Effect Decreased							
	Gastrooesophageal Reflux Disease							
	Injury							
	Intermittent Claudication							
	Myocardial Ischaemia							
	Pain In Extremity							
	Palpitations							
	Peripheral Vascular Disorder							
	Pleural Fibrosis							
	Rotator Cuff Syndrome							
	Scar							
	Sleep Apnoea Syndrome							
	Ventricular Dysfunction							
	Ventricular Hypertrophy							

Date:09/24/04ISR Number: 4458401-1Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00009
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiogenic Shock	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Coronary Artery Embolism		Bezafibrate	C		ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Metformin	C		ORAL		
	Myocardial Infarction		Nifedipine	C		ORAL		
			Quinapril Hydrochloride	C		ORAL		

Date:09/24/04ISR Number: 4458402-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01224
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
	Blood Cholesterol Increased
Disability	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Depression

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Diabetes Mellitus Non-Insulin-Dependent					
		Ear Disorder					
		Emotional Distress	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
798	DAY						
		Eye Infection		Vioxx	SS	Merck & Co., Inc	ORAL
798	DAY						
		Fear		Tylenol	C		
UNKNOWN							
		Hypertension		Acetaminophen And Hydrocodone Bitartrate	C		
		Myocardial Infarction					
		Nasopharyngitis					
UNKNOWN							
		Neuralgia		Acetic Acid	C		
AURICULAR							
		Oedema Peripheral					
(OTIC)							
		Peptic Ulcer		Albuterol	C		
UNKNOWN							
		Rash		Amlodipine Maleate	C		
UNKNOWN							
		Sleep Disorder		Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Baclofen	C		
UNKNOWN							
				Beconase	C		
UNKNOWN							
				Artificial Tears	C		
UNKNOWN							
				Bupropion Hydrochloride	C		
UNKNOWN							
				Carbamide Peroxide	C		
UNKNOWN							
				Clopidogrel Bisulfate	C		
UNKNOWN							
				Clotrimazole	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							

	Neurontin	C	
UNKNOWN			
	Ambien	C	
UNKNOWN			
	Tetracycline	C	
UNKNOWN			
	Zocor	C	ORAL
	Advil	C	
UNKNOWN			
	Lansoprazole	C	
UNKNOWN			
	Lovastatin	C	
UNKNOWN			
	Methocarbamol	C	
UNKNOWN			
	Metoprolol	C	
UNKNOWN			
	Metoprolol	C	
UNKNOWN			
	Mirtazapine	C	
UNKNOWN			
	Nitroglycerin	C	
UNKNOWN			
	Nystatin	C	
UNKNOWN			
	Olopatadine Hydrochloride	C	
OPHTHALMIC			
	Phenylpropanolamine	C	
UNKNOWN			
	Pseudoephedrine	C	
UNKNOWN			
	Psyllium Husk	C	ORAL
	Rabeprazole Sodium	C	
UNKNOWN			

Date:09/24/04ISR Number: 4458404-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
	Anxiety Disorder
	Arthralgia
	Blood Cholesterol Increased
	Blood Glucose Increased
	Chronic Fatigue Syndrome
	Coronary Artery Disease
	Depression

		Dyspepsia					
		Dyspnoea					
		Gout	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		High Density Lipoprotein	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased		Atenolol	C		
UNKNOWN							
		Hypertension		Soma	C		
UNKNOWN							
		Hypoaesthesia					
		Insomnia					
		Joint Swelling					
		Lung Disorder					
		Lymphadenopathy					
		Mastoiditis					
		Myocardial Infarction					
		Pain In Extremity					
		Palpitations					
		Personality Disorder					
		Rectal Haemorrhage					
		Social Phobia					
		Varicose Vein					

Date:09/24/04ISR Number: 4458407-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Brain Stem Infarction
Initial or Prolonged	Bronchitis
Disability	Bunion
Other	Cardiac Failure
	Congestive
	Cardiomegaly
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cataract
	Cerebrovascular Accident
	Contusion
	Coronary Artery Disease
	Diplopia
	Dysphagia
	Fall
	Gait Disturbance
	Glaucoma
	Hypoaesthesia

Impaired Self-Care
Intervertebral Disc
Protrusion
Lacunar Infarction
Lumbar Spinal Stenosis
Monarthritis
Nasopharyngitis
Neuropathy Peripheral
Osteoarthritis
Pleurisy
Postnasal Drip
Road Traffic Accident
Rotator Cuff Syndrome
Sneezing
Snoring
Spinal Osteoarthritis
Strabismus
Toe Deformity

		Ventricular Hypertrophy Vision Blurred Whiplash Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Avandia	C		ORAL
				Avandia	C		ORAL
				Vicoprofen	C		ORAL
				Glucophage	C		ORAL
				Glucophage	C		ORAL

Date:09/24/04ISR Number: 4458413-8Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00011
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Coronary Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arteriospasm Coronary	Professional	Valdecoxib	SS		ORAL

Date:09/24/04ISR Number: 4461601-8Report Type:Direct Company Report #CTU 228001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure		Vioxx 25mg Merck	PS	Merck	ORAL
1 TABLET						
Initial or Prolonged	Inadequately Controlled					
DAILY ORAL						
Disability	Chest Pain Gallbladder Disorder Heart Rate Decreased					

Date:09/24/04ISR Number: 4462059-5Report Type:Expedited (15-DaCompany Report #S04-USA-04729-01
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration Tongue Ulceration	Consumer	Lexapro (Escitalopram)	PS		ORAL	20 MG QD PO	
			Lexapro (Escitalopram)	SS		ORAL	10 MG QD PO	
			Zoloft (Sertraline Hydrochloride)	SS		ORAL	150 MG QD PO	
			Topamax (Topiramate)	SS			25 MG QD	
			Vioxx (Rofecoxib)	SS			25 MG QD	
			Zocor	C				
			Nexium (Esomeprazole)	C				
			Mirapex	C				

Date:09/27/04ISR Number: 4459327-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Anxiety Back Injury Blood Pressure Systolic Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY	Cardiac Disorder		Propacet	C		
UNKNOWN		Cardiac Failure		Wellbutrin	C		
UNKNOWN		Congestive		Prevacid	C		
UNKNOWN		Cardiomegaly Chest Pain Coronary Artery Disease Coronary Artery Occlusion Coronary Artery Restenosis Diplopia Diverticulitis Dizziness Dyspnoea Erythema Gastrooesophageal Reflux Disease Haematemesis Haematoma Hiatus Hernia Hyperlipidaemia Hypersensitivity Hypertension Lactose Intolerance Mitral Valve Disease Muscle Contractions Involuntary Myalgia Necrosis Non-Cardiac Chest Pain Oedema Osteoarthritis Postoperative Infection Procedural Site Reaction Pulmonary Oedema Purulence Retroperitoneal					

Haemorrhage
Sleep Disorder
Stent Occlusion
Syncope
Tendon Rupture
Tendonitis
Tinnitus
Urticaria
Ventricular Extrasystoles
Ventricular Fibrillation
Vision Blurred
Visual Acuity Reduced
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/04ISR Number: 4459328-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02187
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Acute Coronary Syndrome							
	Angina Unstable							
	Bronchitis							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Constipation							
	Diverticulitis							
	Drug Hypersensitivity							
	Emotional Distress							
	Fatigue							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Haemorrhagic Disorder							
	Hypersensitivity							
	Ileus Paralytic							
	Limb Injury							
	Lumbar Radiculopathy							
	Lumbar Vertebral Fracture							
	Paraesthesia							
	Pulmonary Hypertension							
	Restless Legs Syndrome							
	Skin Laceration							
	Spinal Compression							
	Fracture							
	Thrombocytopenia							
	Transient Ischaemic							
	Attack							
	Upper Respiratory Tract							
	Infection							
	Urinary Incontinence							

Date:09/27/04ISR Number: 4459329-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00654
Age:73 YR Gender:Female I/FU:F

Outcome	PT

Other	Abdominal Distension
	Angina Pectoris
	Anorexia
	Anxiety
	Apnoea
	Arthropod Sting
	Asthenia
	Back Pain
	Balance Disorder
	Bladder Disorder
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis
	Bronchitis Acute
	Cardiac Failure

	Congestive						
	Carpal Tunnel Syndrome						
	Cellulitis						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2
MON							
	Cough	Professional	Aspirin	C			
UNKNOWN							
	Deep Vein Thrombosis		Avalide	C			
UNKNOWN	2 MON						
	Diarrhoea		Synthroid	C		ORAL	
	Dizziness		Vitamin E	C			
UNKNOWN							
	Drug Ineffective		Prilosec	C			
UNKNOWN							
	Dysphagia		Pyridoxine	C			
UNKNOWN							
	Dysphonia						
	Epistaxis						
	Fatigue						
	Feeling Abnormal						
	Flatulence						
	Haemorrhoids						
	Heart Rate Increased						
	Hypersensitivity						
	Injury						
	Insomnia						
	Musculoskeletal Stiffness						
	Myocardial Ischaemia						
	Nasal Disorder						
	Nasopharyngitis						
	Nausea						
	Neck Pain						
	Nephropathy						
	Nervousness						
	Nocturia						
	Oedema Peripheral						
	Paralysis						
	Proctalgia						
	Renal Disorder						
	Renal Failure Chronic						
	Renal Tubular Necrosis						
	Sinus Disorder						
	Skin Cancer						
	Snoring						
	Somnolence						
	Tinnitus						

Tonsillar Disorder
Tremor
Ulcer
Urinary Incontinence
Urinary Tract Infection

Date:09/27/04ISR Number: 4459330-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01423
Age:45 YR Gender:Female I/FU:I

Outcome PT
Other Arthropathy
Back Disorder
Bladder Disorder
Blood Pressure Increased
Contusion
Hepatomegaly
Insomnia
Nephrolithiasis
Prescribed Overdose
Rash

Stomach Discomfort

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vicodin Tablets	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Amitriptyline Hydrochloride	C			UNKNOWN	
	Antimicrobial (Unspecified)	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Soma	C			UNKNOWN	
	Clonopin	C			UNKNOWN	
	Valium	C			UNKNOWN	
	Motrin	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	Detrol La	C			UNKNOWN	
	Zocor	C		ORAL		
	Zoloft	C			UNKNOWN	
	Ibuprofen	C			UNKNOWN	
	Robaxin	C			UNKNOWN	
	Methocarbamol	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Oxytrol	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Prednisone	C			UNKNOWN	

Date:09/27/04ISR Number: 4459333-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02103
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		394 DAY
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		394 DAY
Disability	Atrial Fibrillation		Adderall Tablets	C				UNKNOWN
	Cardiac Failure		Cefzil	C				UNKNOWN
	Congestive		Biaxin Xl	C				UNKNOWN
	Cerebrovascular Accident		Entex La	C		ORAL		
	Congestive Cardiomyopathy		Ibuprofen	C				UNKNOWN
	Depression							
	Dilatation Atrial							
	Ejection Fraction							
	Decreased							
	Hypertension							
	Insomnia							
	Intracardiac Thrombus							
	Mitral Valve Incompetence							
	Pneumonia							
	Respiratory Rate							
	Increased							
	Sinus Tachycardia							
	Stress							
	Tricuspid Valve							
	Incompetence							
	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/04ISR Number: 4459334-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN			Aspirin	C				
UNKNOWN								

Date:09/27/04ISR Number: 4459335-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vicodin Tablets	C		ORAL		
	Asthenia		Flexeril	C		ORAL		
	Back Pain		Flexeril	C		ORAL		
	Buttock Pain							
	Condition Aggravated							
	Cyst							
	Deep Vein Thrombosis							
	Diarrhoea							
	Difficulty In Walking							
	Drug Ineffective							
	Emotional Distress							
	Exercise Capacity Decreased							
	Fall							
	Gastritis							
	Haematochezia							
	Hiatus Hernia							
	Inadequate Analgesia							
	Injury							
	Insomnia							
	Intervertebral Disc Protrusion							
	Limb Discomfort							
	Nausea							
	Oedema Peripheral							
	Pain In Extremity							

Radiculitis Lumbosacral
Sacroiliitis
Therapy Non-Responder
Vomiting

Date:09/27/04ISR Number: 4459336-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Adverse Event
Other	Anxiety
	Appendix Disorder
	Blood Pressure Increased
	Chest Pain
	Complex Regional Pain Syndrome
	Diabetes Mellitus Non-Insulin-Dependent

	Dizziness						
	Duodenitis						
	Emotional Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastric Polyps	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Gastritis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Gastrooesophageal Reflux		Tylenol	C			UNKNOWN
	Disease		Zyrtec	C			UNKNOWN
	Headache		Zyrtec	C			UNKNOWN
	Hepatic Cirrhosis						
	Major Depression						
	Nausea						
	Neurodermatitis						
	Pancreatitis Chronic						
	Radiculitis Lumbosacral						
	Syncope						

Date:09/27/04ISR Number: 4459337-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00847
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL	
							5 DAY
Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Arthralgia						
	Arthropathy						
	Back Pain						
	Blood Alkaline						
	Phosphatase Increased						
	Blood Cholesterol						
	Increased						
	Blood Culture Positive						
	Blood Potassium Increased						
	Caustic Injury						
	Cellulitis						
	Drug Ineffective						
	Erythema						
	Hyperlipidaemia						
	Inguinal Hernia						
	Injury						

Insomnia
Joint Swelling
Low Density Lipoprotein
Increased
Lymphadenopathy
Mean Cell Volume
Increased
Muscle Spasms
Onychomycosis
Osteomyelitis
Pulse Absent
Rhinitis Allergic
Sinus Congestion
Staphylococcal Infection
Subcutaneous Abscess
Tinea Pedis
Visual Acuity Reduced

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/04ISR Number: 4459350-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00795
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anhedonia		Tylenol	C			UNKNOWN	
	Arthralgia		Darvocet-N	C			UNKNOWN	
	Back Pain		Dulcolax	C			UNKNOWN	
	Cardiomegaly		Os-Cal D	C			UNKNOWN	
	Chest Discomfort		Flexeril	C			UNKNOWN	
	Chest Pain		Ambien	C			UNKNOWN	
	Condition Aggravated		Diovan	C			UNKNOWN	
	Deep Vein Thrombosis		Prempro	C			UNKNOWN	
	Dementia		Tricor	C			UNKNOWN	
	Dementia Alzheimer'S Type		Levothroid	C			UNKNOWN	
	Depression		Niacin	C			UNKNOWN	
	Depressive Symptom		Potassium (Unspecified)	C		ORAL		
	Dermatitis							
	Dermatitis Contact							
	Discomfort							
	Dyspnoea							
	Dyspnoea Exertional							
	Exostosis							
	Fatigue							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Haematoma							
	Hypertonic Bladder							
	Injury							
	Insomnia							
	Intermittent Claudication							
	Intervertebral Disc Degeneration							

Livedo Reticularis
Lumbar Radiculopathy
Myalgia
Nerve Compression
Oedema Peripheral
Osteoarthritis
Osteoporosis
Procedural Site Reaction
Rash
Sciatica
Seroma
Skin Ulcer
Spinal Claudication
Spinal Column Stenosis
Spinal Compression
Fracture
Thrombophlebitis
Superficial
Venous Insufficiency
Vertigo Positional

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/04ISR Number: 4459549-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Disability	Angina Unstable		Xanax	C				UNKNOWN
	Arthralgia		Aspirin	C				UNKNOWN
	Arthropathy		Lipitor	C				UNKNOWN
	Blood Triglycerides		Wellbutrin	C				UNKNOWN
	Increased		Celebrex	C				UNKNOWN
	Condition Aggravated		Plavix	C				UNKNOWN
	Coronary Artery Aneurysm		Folic Acid	C				UNKNOWN
	Coronary Artery		Toprol Xl Tablets	C				UNKNOWN
	Atherosclerosis		Lopressor	C				UNKNOWN
	Coronary Artery Occlusion		Pyridoxine	C				UNKNOWN
	Coronary Artery Thrombosis							
	Ecchymosis							
	Embolism							
	Emotional Disorder							
	Feeling Abnormal							
	Groin Pain							
	Haematoma							
	Major Depression							
	Myocardial Infarction							
	Panic Disorder							
	Refusal Of Treatment By Patient							
	Stress							
	Vision Blurred							

Date:09/27/04ISR Number: 4459551-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00454
Age:24 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rhabdomyolysis		Vioxx	PS	Merck & Co., Inc	ORAL	17 WK	

Date:09/27/04ISR Number: 4459553-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00707
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Blood Alkaline Phosphatase Increased
	Blood Potassium Decreased
	Condition Aggravated
	Coronary Artery Disease
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Erectile Dysfunction
	Haematocrit Decreased
	Hypertension
	International Normalised Ratio Decreased
	Micturition Disorder
	Myocardial Infarction
	Platelet Count Decreased

	Prothrombin Time Shortened						
	Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL	228 DAY
	White Blood Cell Count Increased		Lipitor	C		ORAL	
			Flexeril	C		ORAL	
			Neurontin	C		ORAL	
			Valtrex	C		ORAL	77 DAY
			Viagra	C		ORAL	
			Niaspan	C		ORAL	
			Paxil	C			UNKNOWN

Date:09/27/04ISR Number: 4459561-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0409SWE00027
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Initial or Prolonged	Renal Failure		Acetaminophen	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Cyanocobalamin	C			UNKNOWN
			Epoetin Beta	C			UNKNOWN
			Folic Acid	C			UNKNOWN
			Zoledronic Acid	C			UNKNOWN
			Levomepromazine	C			UNKNOWN
			Nitrazepam	C			UNKNOWN
			Oxycodone Hydrochloride	C			UNKNOWN
			Oxycodone Hydrochloride	C			UNKNOWN

Date:09/28/04ISR Number: 4461261-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01470
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Off Label Use Pulmonary Oedema							

Date:09/28/04ISR Number: 4461266-5Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0409ZAF00009
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiogenic Shock	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Coronary Artery Embolism		Bezafibrate	C		ORAL		
Hospitalization - Initial or Prolonged	High Density Lipoprotein		Metformin	C		ORAL		
	Increased Hypertension		Nifedipine	C		ORAL		
	Myocardial Infarction		Quinapril Hydrochloride	C		ORAL		

Date:09/28/04ISR Number: 4461270-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01704
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/28/04ISR Number: 4461271-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Ceftin	C				
UNKNOWN								
Disability	Cough		Guaifenesin	C				
UNKNOWN								
Other	Dilatation Atrial							
	Emotional Distress							
	Meningioma							
	Myocardial Infarction							
	Retinal Artery Occlusion							

Date:09/28/04ISR Number: 4461274-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization - Initial or Prolonged	Infarction							
Other								

Date:09/28/04ISR Number: 4461275-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01812
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:09/28/04ISR Number: 4461276-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01716
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Arthropathy	Professional
	Asthenia	
	Diarrhoea	
	Dyspnoea	
	Fibromyalgia	
	Foot Fracture	
	Gastric Haemorrhage	
	Gastritis Erosive	
	Hypercholesterolaemia	
	Hypertension	
	Hypoglycaemia	
	Iron Deficiency	
	Knee Arthroplasty	
	Microcytic Anaemia	
	Upper Gastrointestinal	
	Haemorrhage	

Date:09/28/04ISR Number: 4461277-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Discomfort
Other	Abdominal Pain

Anaemia Of Chronic
Disease
Angina Pectoris
Anxiety
Arthralgia
Asthenia
Asthma
Atherosclerosis
Back Pain
Blood Pressure
Inadequately Controlled
Breast Disorder
Breath Sounds Decreased
Bronchitis
Bursitis
Calcinosis
Cardiac Failure
Congestive
Cardiomegaly
Chest Discomfort
Chest Pain
Chest X-Ray Abnormal
Cholecystitis
Computerised Tomogram
Condition Aggravated
Congestive Cardiomyopathy
Constipation
Cough
Crepitations
Cystitis
Diabetes Mellitus
Inadequate Control
Diabetic Neuropathy
Diabetic Retinopathy
Diarrhoea
Difficulty In Walking
Drug Hypersensitivity
Drug Ineffective
Duodenitis
Dyslipidaemia
Dyspepsia
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Dysstasia
Ecchymosis
Ejection Fraction

Decreased
Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Feeling Abnormal
Flatulence
Fluid Retention
Gastritis
Glycosylated Haemoglobin
Increased
Gout
Haematoma
Headache

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hemianopia Homonymous					
		Hyperglycaemia					
		Hypertensive Crisis					
		Hypertrophic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Cardiomyopathy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Injury		Cozaar	C		ORAL
		Insomnia		Diovan	C		
UNKNOWN							
		Iron Deficiency Anaemia		Methotrexate	C		
UNKNOWN							
		Irritable Bowel Syndrome		Prednisone	C		
UNKNOWN							
		Joint Effusion					
		Joint Swelling					
		Lactose Intolerance					
		Macular Degeneration					
		Malaise					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Myalgia					
		Myocardial Infarction					
		Oedema Peripheral					
		Orthopnoea					
		Pain					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pitting Oedema					
		Polyuria					
		Pulmonary Oedema					
		Renal Failure Chronic					
		Restless Legs Syndrome					
		Rheumatoid Arthritis					
		Salivary Gland Disorder					
		Skin Cancer					
		Skin Disorder					
		Skin Nodule					
		Spinal Osteoarthritis					
		Swelling					
		Synovitis					
		Treatment Noncompliance					
		Urinary Incontinence					
		Urinary Tract Infection					
		Ventricular Dysfunction					

Vision Blurred
Wheezing
White Blood Cell Count
Increased

Date:09/28/04ISR Number: 4461431-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholestasis		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
			[Therapy Unspecified]	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/28/04ISR Number: 4461436-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
Other	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
	Cerebrovascular Accident		Zithromax	C			UNKNOWN	7 DAY
	Chest Pain		Cardizem	C			UNKNOWN	
	Depression		Ismo	C			UNKNOWN	
	Drug Ineffective		Morphine Sulfate	C		ORAL		
	Emotional Distress		Ms Contin	C		ORAL		
	Erythema		Ms Contin	C			UNKNOWN	
	Face Lift		Ms Contin	C			UNKNOWN	
	Gastrointestinal Injury							
	Gout							
	Hyperhidrosis							
	Injury							
	Insomnia							
	Intervertebral Disc Disorder							
	Oedema Peripheral							
	Pain							
	Palpitations							
	Pneumonia							
	Radiculopathy							
	Skin Discolouration							
	Synovitis							

Date:09/28/04ISR Number: 4461438-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort

Initial or Prolonged	Abdominal Pain
Other	Angina Pectoris
	Anxiety
	Atherosclerosis
	Back Pain
	Bladder Disorder
	Blood Erythropoietin Decreased
	Breath Sounds Decreased
	Bronchitis
	Cardiac Failure Congestive
	Cerebral Infarction
	Cerebral Ischaemia
	Cerebrovascular Accident
	Cholecystitis
	Cough
	Cyst
	Cystitis
	Diabetes Mellitus Inadequate Control
	Diabetic Retinopathy
	Difficulty In Walking
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective

		Duodenitis					
		Dyslipidaemia					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Gastritis		Cozaar	C		ORAL
		Gastrointestinal Motility		Diovan	C		
UNKNOWN							
		Disorder		Methotrexate	C		
UNKNOWN							
		Glycosylated Haemoglobin		Prednisone	C		
UNKNOWN							
		Increased					
		Gout					
		Haematoma					
		Headache					
		Hemianopia Homonymous					
		Hyperglycaemia					
		Hypertensive Crisis					
		Hypertrophic					
		Cardiomyopathy					
		Hyperuricaemia					
		Injury					
		Insomnia					
		Iron Deficiency Anaemia					
		Lactose Intolerance					
		Macular Degeneration					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Mouth Haemorrhage					
		Myalgia					
		Myocardial Infarction					
		Oedema Peripheral					
		Pain In Extremity					
		Pelvic Prolapse					
		Pharyngolaryngeal Pain					
		Polyuria					
		Pulmonary Oedema					
		Renal Failure					
		Restless Legs Syndrome					
		Rheumatoid Arthritis					
		Salivary Gland Disorder					
		Skin Disorder					

Surgery
Synovitis
Treatment Noncompliance
Urinary Incontinence
Urinary Tract Infection
Ventricular Dysfunction
Vision Blurred
Visual Acuity Reduced
Wheezing

Date:09/28/04ISR Number: 4461443-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01849
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Movement Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Lotrel	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Flomax (Tamsulosin					

	Hydrochloride)	C
UNKNOWN		
	Detrol La	C
UNKNOWN		
	Plavix	C
UNKNOWN		
	Prilosec	C
UNKNOWN		
	Primidone	C
UNKNOWN		

Date:09/28/04ISR Number: 4461468-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Propulsid	C				
UNKNOWN								
	Bronchitis		Estrogens					
	Burning Sensation		(Unspecified)	C				
UNKNOWN								
	Cardiomegaly							
	Carpal Tunnel Syndrome							
	Contusion							
	Convulsion							
	Coronary Artery Disease							
	Cystitis							
	Cystourethrocele							
	Depression							
	Diarrhoea							
	Diverticulum Intestinal							
	Dizziness							
	Dyspepsia							
	Dysuria							
	Emotional Distress							
	Fall							
	Gastric Disorder							
	Haemorrhoids							
	Herpes Zoster							
	Intervertebral Disc Displacement							
	Irritable Bowel Syndrome							
	Lumbar Radiculopathy							
	Meniscus Lesion							

Micturition Urgency
Muscle Spasms
Nausea
Nocturia
Osteoarthritis
Pain In Extremity
Paraesthesia
Pharyngitis
Pneumonia
Post Procedural
Complication
Rhinorrhoea
Scoliosis
Sensation Of Foreign Body
Spinal Osteoarthritis
Stomach Discomfort
Therapy Non-Responder
Thyroid Disorder
Weight Decreased

Date:09/28/04ISR Number: 4462590-2Report Type:Expedited (15-DaCompany Report #200412666GDS
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign	Aspirin Cardio					
	Gastrointestinal Toxicity	Health	(Acetylsalicylic					
	Haematemesis	Professional	Acid)	PS		ORAL	300 MG, TOTAL	
	Oesophagitis	Other					DAILY, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Diphenhydramine/Lora					
			zepam	C				
			Melleretten	C				
			Piretanide/Ramipril	C				
			Zurcal	C				
			Temesta	C				
			Colecalciferol/Ca	C				
			Betaserc	C				
			Distraneurine	C				
			Somnium	C				
			Trialix	C				
			Calcimagon	C				
			Jarsin	C				

Date:09/28/04ISR Number: 4462600-2Report Type:Expedited (15-DaCompany Report #2004233696ZA
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome	Foreign	Bextra (Valdecoxib)					
	Arteriospasm Coronary	Health	Tablet	PS		ORAL	40 MG, QD,	
	Electrocardiogram St	Professional					ORAL	
	Segment Elevation	Other	Rofecoxib(Rofecoxib)	SS		ORAL	25 MG, QD,	
	Hyperhomocysteinaemia						ORAL	

Date:09/28/04ISR Number: 4464732-1Report Type:Direct Company Report #CTU 228205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Rofecoxib 50 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Duodenal Ulcer						ORAL	
	Haemorrhage							
	Haemoglobin Decreased							

Date:09/28/04ISR Number: 4512738-6Report Type:Periodic Company Report #04P-163-0265813-00
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Humira 40 Mg/ 0.8 Ml					
	Diarrhoea		Pre-Filled Syringe					
	Dyspepsia		(Humira)					
	Influenza Like Illness		(Adalimumab)	PS		SUBCUTANEOUS	40 MG, 1 IN 2	
	Paranasal Sinus						WK,	
	Hypersecretion						SUBCUTANEOUS	
	Somnolence		Meloxicam	SS				
			Rofecoxib	SS				
			Risedronate Sodium	C				
			Prednisone	C				

Date:09/29/04ISR Number: 4462143-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Acute Pulmonary Oedema
Other	Anaemia
	Angina Unstable
	Anxiety
	Aortic Valve Incompetence
	Arthralgia
	Atrial Fibrillation
	Azotaemia
	Blood Amylase Increased
	Blood Glucose Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Cardiac Failure Acute
	Cardiac Failure
	Congestive
	Cardiomegaly
	Chest Discomfort
	Chest Pain
	Chondrocalcinosis
	Chondrocalcinosis
	Pyrophosphate
	Chronic Gastrointestinal
	Bleeding
	Clostridium Colitis
	Colon Cancer Recurrent
	Colon Cancer Stage Ii
	Colonic Polyp
	Condition Aggravated
	Constipation
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Dehydration
	Diarrhoea
	Diplopia
	Dizziness
	Dyspepsia
	Dysphagia
	Dyspnoea
	Echocardiogram Abnormal
	Electrocardiogram Q Wave

Abnormal
Emotional Disorder
Emotional Distress
Fatigue
Feeling Abnormal
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Headache
Heart Rate Irregular
Hypertension
Hypoaesthesia Oral
Injury

		Inner Ear Disorder					
		Intracardiac Thrombus					
		Joint Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Sprain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Left Ventricular	Professional	Premarin	C		
UNKNOWN							
		End-Diastolic Pressure		Glipizide	C		
UNKNOWN							
		Increased					
		Lipase Increased					
		Meniscus Lesion					
		Microangiopathy					
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Oral Infection					
		Osteoarthritis					
		Photosensitivity Reaction					
		Pleuritic Pain					
		Post Procedural					
		Complication					
		Renal Cyst					
		Renal Failure					
		Syncope					
		Thrombophlebitis					
		Thrombosis					
		Tooth Infection					
		Tricuspid Valve					
		Incompetence					
		Umbilical Hernia					
		Urinary Tract Infection					
		Vein Pain					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Vertigo					
		Vision Blurred					
		Weight Decreased					

Date:09/29/04ISR Number: 4462150-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0409NOR00019
Age:71 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Blood Pressure	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Fluctuation	Professional	Aspirin And			

Initial or Prolonged	Gastric Ulcer Haematemesis Melaena Tachycardia		Magnesium Oxide	SS	ORAL

Date:09/29/04ISR Number: 4462151-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebral Artery		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Fosamax	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Ecotrin	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Pepcid	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4462152-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00223
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Lower Respiratory Tract Infection		Furosemide	C				
			Warfarin	C				
	Lung Neoplasm Malignant							
	Pulmonary Fibrosis							

Date:09/29/04ISR Number: 4462154-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0409CAN00070
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		106 DAY
	Haemoglobin Decreased		Prednisone	SS		ORAL		
	Helicobacter Pylori Identification Test		Hydroxychloroquine Sulfate	C				
	Positive		Methotrexate	C				
	Upper Gastrointestinal Haemorrhage							

Date:09/29/04ISR Number: 4462156-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0409NOR00020
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		DAY
	Melaena		Citalopram Hydrobromide	SS				
			Acetaminophen And Codeine Phosphate	C				

Date:09/29/04ISR Number: 4462495-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthritis
	Arthropathy
	Candidiasis
	Chronic Lymphocytic Leukaemia
	Coronary Artery Disease
	Gastritis
	Gastrointestinal Haemorrhage
	Heart Rate Irregular
	Hyperlipidaemia
	Hypertension
	Meniscus Lesion
	Mitral Valve Prolapse
	Myocardial Infarction
	Oedema Peripheral
	Osteoarthritis
	Overdose
	Peptic Ulcer
	Pneumonia

		Reflux Oesophagitis					
		Stress					
		Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ulcer Haemorrhage	Professional	Voltaren	SS		
UNKNOWN							
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
		Wound Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Staphylococcal		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Acetaminophen And Codeine Phosphate	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Napsylate	C		ORAL
				Prempro	C		
UNKNOWN							
				Carisoprodol	C		ORAL

Date:09/29/04ISR Number: 4462507-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA00193
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Valve Sclerosis		Tylenol	C		
UNKNOWN							
		Arrhythmia		Aspirin	C		
UNKNOWN							
		Blood Pressure Increased					
		Bradycardia					
		Cardiac Murmur					
		Cardio-Respiratory Arrest					
		Cough					
		Drug Ineffective					
		Grand Mal Convulsion					
		Hypertension					

Hypotonia
Joint Crepitation
Joint Lock
Joint Stiffness
Joint Swelling
Livedo Reticularis
Mitral Valve Incompetence
Mydriasis
Pulse Absent
Pupil Fixed
Sudden Death
Ventricular Fibrillation
Ventricular Tachycardia

Date:09/29/04ISR Number: 4462508-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization - Initial or Prolonged	Bipolar Disorder
	Blood Pressure Increased

		Cardiovascular Disorder					
		Drug Ineffective					
		Dysstasia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haematemesis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		[Therapy			
		Hyperglycaemia		Unspecified]	C		
UNKNOWN							
		Hypoaesthesia		Depakote	C		
UNKNOWN							
		Lumbar Radiculopathy		Nexium	C		
UNKNOWN							
		Myocardial Infarction		Zestril	C		
UNKNOWN							
		Pain In Extremity		Lithium Carbonate	C		
UNKNOWN							
		Renal Disorder		Robaxin	C		
UNKNOWN							
		Renal Failure					
		Upper Respiratory Tract					
		Infection					
		Vomiting					

Date:09/29/04ISR Number: 4462509-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain		Heparin	SS		
UNKNOWN						
Disability	Blindness		Provera	SS		
UNKNOWN						
Other	Cataract		[Therapy			
	Cerebrovascular Accident		Unspecified]	C		
UNKNOWN						
	Depression		Tylenol With Codeine			
	Endometrial Hyperplasia		#3	C		
UNKNOWN						
	Epistaxis		Captopril	C		
UNKNOWN						
	Flushing		Capozide	C		
UNKNOWN						

	Gastrooesophageal Reflux	Cisapride	C
UNKNOWN			
	Disease	Glyburide	C
UNKNOWN			
	Gout		
	Haemorrhage Intracranial		
	Headache		
	Hemianopia Homonymous		
	Herpes Zoster		
	Hyperhidrosis		
	Hypertension		
	Joint Injury		
	Nasal Congestion		
	Nausea		
	Pain		
	Pallor		
	Pneumonia		
	Postmenopausal		
	Haemorrhage		
	Rash		
	Rift Valley Fever		
	Sciatica		
	Tachycardia		
	Thyroid Mass		
	Uterine Polyp		
	Vaginal Haemorrhage		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4462514-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00160
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Depressed Level Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Amitriptyline Hydrochloride	SS		ORAL		
			Hydromorphone Hydrochloride	SS		ORAL		
			Hydromorphone Hydrochloride	SS		ORAL		
			Aspirin	C		ORAL		
			Oxycodone Hydrochloride	C				
			Xipamide	C		ORAL		
			Sodium Picosulfate	C		ORAL		
			Ramipril	C		ORAL		
			Fentanyl	C		TOPICAL		
			Fluticasone Propionate	C		RESPIRATORY (INHALATION)		
			Gabapentin	C		ORAL		

Date:09/29/04ISR Number: 4462515-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Allopurinol	C		UNKNOWN		
Other	Azotaemia		Ascorbic Acid	C		UNKNOWN		
	Bronchitis		Vitamin E	C		UNKNOWN		
	Cardiac Failure		Aspirin	C		UNKNOWN		
	Congestive		Aricept	C		UNKNOWN		
	Central Line Infection							

Cerebral Artery Occlusion
Chest Pain
Chronic Obstructive
Pulmonary Disease
Coronary Artery
Restenosis
Decreased Appetite
Diarrhoea
Dressler'S Syndrome
Faecal Occult Blood
Positive
Faeces Discoloured
Gastrointestinal
Haemorrhage
Hyperbilirubinaemia
Hyperlipidaemia
Hypertension
Myocardial Infarction
Peripheral Vascular
Disorder
Radiculopathy
Respiratory Failure
Skin Candida
Subclavian Artery
Stenosis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4462522-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00158
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer Haemorrhage		Clopidogrel Bisulfate	SS		ORAL		
			Enoxaparin Sodium	SS		SUBCUTANEOUS		
			Escitalopram Oxalate	SS		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Moxifloxacin Hydrochloride	C		ORAL	11	DAY
			Zocor	C		ORAL		
			Pantoprazole Sodium	C		ORAL		

Date:09/29/04ISR Number: 4462525-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL	10	DAY
Disability	Calcinosis							
	Coronary Artery Disease							
	Electrocardiogram Repolarisation Abnormality							
	Emotional Distress							
	Haemoglobin Decreased							
	Joint Range Of Motion Decreased							
	Joint Swelling							
	Myocardial Infarction							
	Rotator Cuff Syndrome							
	Sinusitis							
	Tendonitis							
	Upper Respiratory Tract Infection							

Date:09/29/04ISR Number: 4462526-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03198
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arteriovenous Malformation Blood Chloride Increased Blood Glucose Increased Blood Pressure Decreased Blood Urea Increased Bowel Sounds Abnormal Diverticulum Intestinal Dizziness Postural Dry Skin Duodenal Ulcer Essential Hypertension Haemodynamic Instability Haemorrhoids Lymphocyte Count Increased Polyp Prothrombin Time

		Prolonged Skin Turgor Decreased Tachycardia Upper Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
				Excedrin (Acetaminophen (+) Aspirin (+) Caffeine)	SS		
UNKNOWN							
				Ibuprofen	SS		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Flomax (Tamsulosin Hydrochloride)	C		
UNKNOWN							

Date:09/29/04ISR Number: 4462527-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01964
Age:47 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
DAY							
		Congestive		Premarin	C		
UNKNOWN							
		Pulmonary Function Test Abnormal					

Date:09/29/04ISR Number: 4462531-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01621
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:09/29/04ISR Number: 4462533-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01959
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Therapeutic Response Decreased		Hydrochlorothiazide And Triamterene	C				
	Therapeutic Response Delayed							

Date:09/29/04ISR Number: 4462534-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Porphyria Acute		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Warfarin	C			UNKNOWN	
			Indocin (Indomethacin)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/29/04ISR Number: 4462535-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Hypersensitivity Haemorrhage							

Date:09/29/04ISR Number: 4462557-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00827
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Darvocet-N	C			UNKNOWN	
Disability	Atrial Fibrillation		Albuterol	C		RESPIRATORY (INHALATION)		
Other	Atrial Septal Defect							
	Bursitis		Xanax	C			UNKNOWN	
	Chest Discomfort		Xanax	C			UNKNOWN	
	Chest Pain		Norvasc	C			UNKNOWN	
	Dyspnoea		St. Joseph Adult Chewable Aspirin	C			UNKNOWN	
	Fluid Retention							
	Musculoskeletal Discomfort		Serevent	C		RESPIRATORY (INHALATION)		
	Nasal Sinus Drainage		Uniphyl	C			UNKNOWN	
	Otitis Externa		Restoril	C			UNKNOWN	
	Pain In Extremity		Lotensin	C			UNKNOWN	
	Reflux Oesophagitis		Allegra	C			UNKNOWN	
	Road Traffic Accident		Flovent	C			UNKNOWN	

	Sinus Disorder	Mobic	C
UNKNOWN			
		Paxil	C
UNKNOWN			
		Paxil	C
UNKNOWN			

Date:09/29/04ISR Number: 4462565-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Alveolitis Fibrosing
Other	Anxiety
	Arthralgia
	Arthropathy
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Carpal Tunnel Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Collagen-Vascular Disease
	Depression
	Dermatomyositis
	Diarrhoea
	Diverticulum
	Dizziness
	Dysphasia
	Gastritis
	Gastrointestinal Motility
	Disorder
	Gastrooesophageal Reflux
	Disease
	Haemoptysis

		Haemorrhoids					
		Hypersensitivity					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Interstitial Lung Disease					
		Irritable Bowel Syndrome					
		Malaise					
		Memory Impairment					
		Obsessive-Compulsive					
		Disorder					
		Obstructive Airways					
		Disorder					
		Oesophageal Candidiasis					
		Pain In Extremity					
		Paraesthesia					
		Polymyositis					
		Pulmonary Fibrosis					
		Pulmonary Oedema					
		Rash					
		Rash Macular					
		Rheumatoid Arthritis					
		Visual Field Defect					

Date:09/29/04ISR Number: 4464106-3Report Type:Direct Company Report #CTU 228300
Age:39 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Pruritus		Vioxx 25mg Merck	PS	Merck	
25 MG QD							
Initial or Prolonged		Rash		Skelaxin 400mg			
Other		Swelling		Carniell	SS	Carniell	
400 MG TID							

Date:09/29/04ISR Number: 4464712-6Report Type:Direct Company Report #CTU 228311
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Renal Impairment		Rofecoxib	PS		
Initial or Prolonged				Apap	C		
				Asa	C		

Calcitriol	C
Carbiodpa/Levodopa	C
Ferrous Sulfate	C
Furosemide	C
Ipratropium	C
Metoprolol	C
Nephrocaps	C
Promod	C
Paroxetine	C
Simvastatin	C
Verapamil	C
Vit E	C

Date:09/29/04ISR Number: 4465255-6Report Type:Expedited (15-DaCompany Report #2004061793
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Pressure Decreased
Other	Delirium Tremens

	Drug Ineffective Fibromyalgia Hip Surgery	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Knee Operation	Consumer	Zoloft (Sertraline)	PS		
8 YR						
	Nervousness Pain		Rofecoxib (Rofecoxib)	SS		
U/HR						
	Paralysis Post Procedural Complication Restless Legs Syndrome		Hydrocodone (Hydrocodone)	SS		
			Oxycodone Hydrochloride (Oxycodone Hydrochloride)	SS		
			All Other Therapeutic Products	C		
			Tizanidine Hydrochloride	C		

Date:09/29/04ISR Number: 4467021-4Report Type:Direct Company Report #CTU 228310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspnoea		Sotalol 80 Mg	PS		ORAL
120 MG BID						
Initial or Prolonged	Oedema Peripheral					
ORAL						
			Rofecoxib	SS		ORAL
25 MG DAILY						
ORAL						
			Warfarin	C		
			Furosemide	C		
			Lisinopril	C		
			Simvastatin	C		
			Terazosin	C		
			Loratadine	C		
			Rabeprazole	C		
			Vit E	C		
			Salsalate	C		

Date:09/30/04ISR Number: 4463154-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		73 DAY
Initial or Prolonged	Asthenia	Professional	Roxicet	C				
UNKNOWN								799 DAY
Disability	Blood Cholesterol		Proscar	C				
UNKNOWN								
	Increased		Terazosin					
	Blood Triglycerides		Hydrochloride	C				
UNKNOWN								
	Increased		Zantac	C				
UNKNOWN								
	Chest Pain							
	Cholelithiasis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hernia							
	Hypertension							
	Myocardial Infarction							
	Panic Disorder							
	Syncope							

Date:09/30/04ISR Number: 4463156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01102
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL	378 DAY	
Other	Deep Vein Thrombosis	Professional	Femhrt	C			UNKNOWN	
	Diverticulum							
	Finger Deformity							
	Hepatic Cyst							
	Peripheral Embolism							
	Renal Failure Acute							
	Uterine Leiomyoma							

Date:09/30/04ISR Number: 4463158-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01977
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Hypersensitivity							

Date:09/30/04ISR Number: 4463161-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Angina Pectoris
	Asthenia
	Blood Cholesterol Increased
	Blood Creatinine Increased
	Bronchitis
	Cardiac Failure Congestive
	Congestive Cardiomyopathy
	Contusion
	Cough
	Depression

Dizziness
Dyspepsia
Emotional Distress
Erectile Dysfunction
Facial Palsy
Fall
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Hypertension
Insomnia
Nasal Congestion
Neck Injury
Pain
Rhinorrhoea
Road Traffic Accident
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles

		Swelling Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Extrasystoles	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Norvasc	C		
UNKNOWN							
				Lotrel	C		
UNKNOWN							
				Coreg	C		
UNKNOWN							
				Clonidine	C		
UNKNOWN							
				Clonidine	C		ORAL
				Digitek	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Zocor	C		ORAL
				Lisinopril	C		
UNKNOWN							
				Reglan	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							

Date:09/30/04ISR Number: 4463164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03247
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Angina Unstable Arthritis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Celebrex	SS		
UNKNOWN						
Other	Blood Creatinine		Aspirin	C		
UNKNOWN						

	Increased		Cardizem Cd	C
UNKNOWN				
	Cardiac Arrest		Zestril	C
UNKNOWN				
	Coronary Artery Occlusion		Zestril	C
UNKNOWN				
	Cough		Nitroglycerin	C
UNKNOWN				
	Gastrooesophageal Reflux Disease			
	Hyperlipidaemia			
	Hypokalaemia			
	Myocardial Infarction			
	Palpitations			
	Stress			
	Thrombocytopenia			

Date:09/30/04ISR Number: 4463497-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
37 DAY						
	Drug Ineffective		Vicodin Tablets	C		ORAL
	Fall		Clonidine	C		ORAL
	Gastric Haemorrhage					
	Haematocrit Decreased					
	Joint Sprain					
	Meniscus Lesion					
	Upper Respiratory Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/04ISR Number: 4463504-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00820
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Calcium (Unspecified)	C				
Disability	Arthralgia							
UNKNOWN	Back Pain		Soma	C				
UNKNOWN	Body Height Decreased		Celebrex	C				
UNKNOWN	Dermal Cyst		Zyrtec	C				
UNKNOWN	Family Stress		Estradiol	C				
UNKNOWN	Hypoaesthesia		Ultram	C				
UNKNOWN	Intervertebral Disc Degeneration		Hydrochlorothiazide And Triamterene	C				
UNKNOWN	Oedema Peripheral		Motrin	C				
UNKNOWN							1	DAY
UNKNOWN	Pharyngitis		Motrin	C				
UNKNOWN	Postoperative Infection		Altace	C				
UNKNOWN	Pseudomonas Infection							
	Renal Impairment							
	Rhinitis							
	Scoliosis							
	Sinusitis							
	Temporomandibular Joint Syndrome							
	Upper Respiratory Tract Infection							

Date:09/30/04ISR Number: 4463508-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0409SWE00026
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Injury Asphyxiation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Suicide Attempt							

Date:09/30/04ISR Number: 4463509-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0409NOR00021
Age:99 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Acetaminophen	C		ORAL		
	Haematemesis		Cimetidine	C		ORAL		
	Melaena		Clonazepam	C		ORAL		
			Dipyrone	C		ORAL		
			Dipyrone	C		ORAL		
			Estriol	C		ORAL		
			Oxazepam	C		ORAL		

Date:09/30/04ISR Number: 4463510-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01205
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Asterixis
	Chest Pain
	Clostridium Colitis
	Dehydration
	Dyspnoea
	Fluid Retention
	Increased Upper Airway

	Secretion						
	Oedema						
	Open Wound						
	Pyrexia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
	Respiratory Failure		Allopurinol	C		ORAL	
	Skin Ulcer		Atenolol	C			UNKNOWN
	Tremor		Atenolol	C			UNKNOWN
			Lipitor	C			UNKNOWN
			Bumex	C			UNKNOWN
			Colace	C			UNKNOWN
			Lovenox	C			SUBCUTANEOUS
			Neurontin	C			UNKNOWN
			Glipizide	C			UNKNOWN
			Lantus	C			UNKNOWN

Date:09/30/04ISR Number: 4463512-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:09/30/04ISR Number: 4463513-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00044
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Melaena	Health	Vioxx	PS	Merck & Co., Inc	ORAL	48 DAY
Initial or Prolonged	Petechiae	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Thrombocytopenia		Vioxx	SS	Merck & Co., Inc	ORAL	

				Spiruline	SS		ORAL
1 DAY							
				Spiruline	SS		ORAL
1 DAY							
				Risedronate Sodium	C		ORAL

Date:09/30/04ISR Number: 4463516-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00275
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Initial or Prolonged		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
3 YR						
Other			Percocet	C		
UNKNOWN						
			Lotrel	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Zanaflex	C		
UNKNOWN						
			Zetia	C		ORAL
			Synthroid	C		
UNKNOWN						
			Skelaxin	C		
UNKNOWN						
			Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN						

Date:09/30/04ISR Number: 4463519-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Angina Unstable
Other	Asthma
	Bronchitis

		Cardiac Valve Disease					
		Chest Pain					
		Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		[Therapy			
		Atherosclerosis		Unspecified]	C		
UNKNOWN							
		Coronary Artery Disease		Albuterol	C		
UNKNOWN							
		Depression		Proventil	C		
RESPIRATORY							
		Diarrhoea					
(INHALATION)							
		Dyspnoea		Zocor	C		
UNKNOWN							
		Gastrooesophageal Reflux		Antimicrobial			
		Disease		(Unspecified)	C		
UNKNOWN							
		Haematoma		Amaryl	C		
UNKNOWN							
		Myocardial Infarction		Glipizide	C		
UNKNOWN							
		Nausea		Glucophage	C		
UNKNOWN							
		Oedema Peripheral					
		Viral Infection					

Date:10/01/04ISR Number: 4464141-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
Disability	Arthritis
	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Bone Pain
	Bronchitis
	Burning Sensation
	Cerebral Atrophy
	Cerebrovascular Accident
	Conversion Disorder
	Coordination Abnormal

Depression
Dizziness
Dry Skin
Emotional Distress
Facial Palsy
Fall
Fatigue
Ganglion
Generalised Anxiety
Disorder
Haemorrhoids
Hallucination
Hemiparesis
Hiatus Hernia
Hypertension
Hypoaesthesia
Hypokalaemia
Hyporeflexia
Inflammation
Injury
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion

		Lacunar Infarction					
		Liver Function Test Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL
		Menopausal Symptoms		Ventolin (Albuterol)	C		
RESPIRATORY							
		Movement Disorder					
(INHALATION)							
		Oesophageal Spasm		Aspirin	C		
UNKNOWN							
		Orthostatic Hypotension		Celexa	C		
UNKNOWN							
		Pain In Extremity		Lexapro	C		
UNKNOWN							
		Palpitations		Aerobid	C		
UNKNOWN							
		Panniculitis		Synthroid	C		
UNKNOWN							
		Post Procedural		Claritin	C		
UNKNOWN							
		Complication		Niacin	C		
UNKNOWN		14671DAY					
		Psychosomatic Disease					
		Stress					
		Suicidal Ideation					
		Syncope					
		Tinnitus					
		Vision Blurred					

Date:10/01/04ISR Number: 4464142-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebral Haemangioma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Emotional Distress		Celebrex	C		
UNKNOWN						
Other	Haemarthrosis					
	Ligament Injury					
	Ligament Sprain					

Date:10/01/04ISR Number: 4464143-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00846
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anhedonia
	Aortic Valve Incompetence
	Asthenia
	Asthma
	Chest Pain
	Decreased Appetite
	Depression
	Dilatation Atrial
	Dilatation Ventricular
	Fatigue
	Feeling Jittery
	Headache
	Insomnia
	Libido Decreased
	Low Density Lipoprotein Increased
	Mitral Valve Incompetence
	Ovarian Cyst
	Pulmonary Arterial Pressure Increased
	Respiratory Distress
	Sleep Apnoea Syndrome
	Trichomoniasis

		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:10/01/04ISR Number: 4464235-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00007
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL
93 DAY						
Initial or Prolonged	Atrial Septal Defect	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
93 DAY						
	Back Pain		Tylenol	C		
UNKNOWN						
	Bronchitis		Darvocet-N	C		
UNKNOWN						
	Cellulitis		Xanax	C		
UNKNOWN						
	Chronic Obstructive		Zoloft	C		
UNKNOWN	2 WK					
	Pulmonary Disease		Zoloft	C		
UNKNOWN						
	Coronary Artery Disease		Zoloft	C		
UNKNOWN	764 DAY					
	Depression		Xanax	C		
UNKNOWN						
	Drug Hypersensitivity		Alphagan	C		
OPHTHALMIC						
	Drug Ineffective		Xalatan	C		
OPHTHALMIC						
	Fear		Synthroid	C		
UNKNOWN						
	Hypercholesterolaemia					
	Hypoxia					
	Ischaemic Stroke					
	Obstructive Airways Disorder					
	Oedema Peripheral					
	Panic Disorder With Agoraphobia					

Spondylolisthesis
Acquired

Date:10/01/04ISR Number: 4464341-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00816
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anxiety
Other	Back Pain
	Bronchitis
	Bronchitis Acute
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Cough
	Dyspnoea
	Electrocardiogram Poor R-Wave Progression
	Haematocrit Decreased
	Headache
	Hypersensitivity
	Hypertension
	Increased Upper Airway Secretion
	Infarction
	Insomnia
	Monarthritis

		Muscle Spasms					
		Nasopharyngitis					
		Neuroleptic Malignant	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain					
		Pharyngolaryngeal Pain					
		Sinusitis					
		Spondylitis					
		Stress					
		Vasculitis					
		Vomiting					

Date:10/01/04ISR Number: 4464343-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL
45 DAY						
Hospitalization -	Distress Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
45 DAY						
Initial or Prolonged	Allergic Sinusitis		Tylenol With Codeine			
Other	Aspiration		#3	C		
UNKNOWN						
	Atrial Fibrillation		Percocet	C		
UNKNOWN						
	Blood Triglycerides		Zocor	C		
UNKNOWN						
	Increased		Vitamin E	C		
UNKNOWN						
	Breast Tenderness		Ascorbic Acid	C		
UNKNOWN						
	Cardio-Respiratory Arrest		Beta Carotene	C		
UNKNOWN						
	Coagulopathy		Centrum	C		
UNKNOWN						
	Coronary Artery Disease					
	Depression					
	Diarrhoea					
	Diverticulum					
	Dyspepsia					
	Dyspnoea Exertional					
	Electrocardiogram					
	Abnormal					

Extradural Abscess
Fatigue
Haematochezia
Hypersensitivity
Hypokalaemia
Hypokinesia
Influenza Like Illness
Intervertebral Disc
Disorder
Intervertebral Discitis
Mitral Valve Incompetence
Multi-Organ Failure
Myocardial Infarction
Nausea
Otitis Media
Pancreatitis
Renal Failure
Renal Pain
Renal Tubular Necrosis
Sepsis
Upper Respiratory Tract
Infection
Urinary Tract Infection
Ventricular Fibrillation
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4464345-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01002
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Cortical		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Erectile Dysfunction		Zyloprim	C		ORAL		
	Excoriation		Aspirin	C		ORAL		
	Fat Tissue Increased		Tenormin	C		ORAL		
	Hypertension		Tenormin	C		ORAL		
	Injury		Buspar	C		ORAL		
	Retinal Haemorrhage		Celebrex	C		ORAL		
	Transient Ischaemic		Ambien	C				
UNKNOWN								
	Attack		Plavix	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Indocin (Indomethacin)	C		ORAL		
			Cozaar	C		ORAL		
			Slow-K	C		ORAL		
			Pravachol	C				
UNKNOWN								

Date:10/01/04ISR Number: 4464347-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00649
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Asthenia		Toprol Xl Tablets	SS				
UNKNOWN								
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Tylenol	C				
UNKNOWN								
	Hyperlipidaemia		Aspirin	C				
UNKNOWN								
	Iatrogenic Injury		Wellbutrin Sr	C				
UNKNOWN								
	Oedema Peripheral		Keflex	C				
UNKNOWN								
	Pain In Extremity		Pepcid	C		ORAL		
	Palpitations							
	Pulmonary Hypertension							
	Supraventricular							

Tachycardia

Date:10/01/04ISR Number: 4464348-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 319 DAY	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 319 DAY	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Coronary Artery Disease		Xanax	C		
Other UNKNOWN	Diabetes Mellitus		Valium	C		
	Drug Ineffective		Diovan	C		
UNKNOWN						
	Hypertension		Ibuprofen	C		
UNKNOWN						
	Lung Disorder		Humulin N	C		
UNKNOWN						
	Myocardial Infarction		Synthroid	C		
UNKNOWN						
	Non-Cardiac Chest Pain					
	Oedema Peripheral					
	Osteoarthritis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4464349-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		213 DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		59 DAY
Disability	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		81 DAY
Other	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		60 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		213 DAY
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		81 DAY
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		17 DAY
	Eye Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Furuncle		Vioxx	SS	Merck & Co., Inc	ORAL		8 DAY
	Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL		60 DAY
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		59 DAY
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		8 DAY
	Hypercalcaemia		Vioxx	SS	Merck & Co., Inc	ORAL		17 DAY
	Laryngitis		Lipitor	C				UNKNOWN
	Muscle Spasms		Cardura	C				UNKNOWN
	Myocardial Ischaemia		Monopril	C				UNKNOWN
	Nausea		Glucotrol	C				UNKNOWN
	Palpitations		Hydrodiuril	C		ORAL		
	Peripheral Vascular		Hydrodiuril	C		ORAL		
	Disorder		Imdur	C				UNKNOWN
	Rash Macular		Toprol Xl Tablets	C		ORAL		
	Renal Failure Chronic							
	Rhinitis Allergic							
	Rotator Cuff Syndrome							

Sinusitis
Sleep Apnoea Syndrome

Date:10/01/04ISR Number: 4464353-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00206
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Convulsion		Dexamethasone	C			UNKNOWN	
	Erythema		Tramadol					
	Feeling Hot		Hydrochloride	C			UNKNOWN	
	Hyperhidrosis							
	Hypersensitivity							
	Lacrimation Increased							
	Oedema Peripheral							
	Shock							

Date:10/01/04ISR Number: 4464354-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02045
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Congestive							
Initial or Prolonged	Feeling Abnormal							
Disability	Paralysis							

Date:10/01/04ISR Number: 4464355-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01870
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	12	DAY
Initial or Prolonged	Cardiac Disorder		Vicodin Tablets	C			UNKNOWN	
	Chest Pain		Xanax	C			UNKNOWN	
	Coronary Artery Disease		Wellbutrin	C			UNKNOWN	
	Drug Ineffective		Zyban	C			UNKNOWN	
	Dyspnoea		Flexeril	C			UNKNOWN	
	Fatigue		Arthrotec	C			UNKNOWN	
	Insomnia							

Date:10/01/04ISR Number: 4464356-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00993
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Infarction		Tylenol	C			UNKNOWN	
Disability	Akinesia		Tylenol	C			UNKNOWN	
	Bradycardia		Percocet	C			UNKNOWN	
	Coronary Artery Stenosis		Maalox	C			UNKNOWN	
	Depression		Imitrex	C			UNKNOWN	
	Ejection Fraction		Advil	C			UNKNOWN	
	Decreased		Advil	C			UNKNOWN	

	Emotional Distress		Medrol	C		
UNKNOWN						
	Fatigue					
	Gastritis					
	Gastrooesophageal Reflux					
	Disease					
	Hypercholesterolaemia					
	Hypotension					
	Intervertebral Disc					
	Degeneration					
	Intervertebral Disc					
	Protrusion					
	Urinary Retention					
	Ventricular Tachycardia					

Date:10/01/04ISR Number: 4464357-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01852
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Disability			[Therapy			
			Unspecified]	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:10/01/04ISR Number: 4464358-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00155
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4464359-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02064
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cognitive Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Dissociation		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Mental Impairment							
	Vision Blurred							

Date:10/01/04ISR Number: 4464360-8Report Type:Expedited (15-DaCompany Report #IE-MERCK-0408GBR00177
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eosinophilia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Bisoprolol Fumarate	C			UNKNOWN	
			Valsartan	C			UNKNOWN	
			Bumetanide	C			UNKNOWN	

Date:10/01/04ISR Number: 4464362-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Lower
Other	Anhedonia
	Anxiety
	Arthralgia
	Back Pain
	Blood Cholesterol Increased
	Bronchitis Acute
	Bursitis
	Chest Discomfort
	Chest Pain

Concussion
Constipation
Convulsion
Costochondritis
Depression
Diarrhoea
Dizziness
Drug Ineffective
Duodenal Ulcer
Dysuria
Enterocolitis
Haemorrhagic
Erectile Dysfunction
Eye Disorder
Fall
Flatulence
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Haematochezia
Haemorrhage
Head Injury
Hypertension
Hypertriglyceridaemia
Hypogonadism

	Kidney Infection						
	Major Depression						
	Migraine	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oesophageal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Overdose		Prevacid	C			UNKNOWN
	Palpitations		Zocor	C		ORAL	
	Renal Disorder						
	Syncope						
	Ulcer						
	Ulna Fracture						

Date:10/01/04ISR Number: 4465871-1Report Type:Direct Company Report #CTU 228527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Required	Blood Cholesterol		Vioxx 25mg Merck	PS	Merck	ORAL	.5 TABLET
Intervention to	Abnormal						ONCE DAILY
Prevent Permanent	Blood Triglycerides						ORAL
Impairment/Damage	Increased						

Date:10/01/04ISR Number: 4465875-9Report Type:Direct Company Report #CTU 228524
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain		Vioxx 1/4 To 1/2				
	Disorientation		Lowest Dosage	PS			1 TIME A DAY
	Dizziness						FEW TIMES

Date:10/01/04ISR Number: 4465969-8Report Type:Direct Company Report #CTU 228563
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS			1 PILL	
Initial or Prolonged	Carotid Bruit							
Other	Cerebrovascular Accident							
	Disorientation							
	Fibromuscular Dysplasia							

Date:10/01/04ISR Number: 4465970-4Report Type:Direct Company Report #CTU 228562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx 25mg Merck	PS	Merck	ORAL	1 TABLET	
	Chest Pain						ONCE DAY	
	Contraindication To						ORAL	
	Medical Treatment		Advair	SS	Glaxosmithkline	ORAL	1 INHALE	
	Respiration Abnormal						TWICE DAY	
							ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4465972-8Report Type:Direct Company Report #CTU 228560
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx 25mg Merck	PS	Merck	ORAL	1 TABLET	
	Haemorrhage						TWICE A DAY	
							ORAL	

Date:10/01/04ISR Number: 4465973-XReport Type:Direct Company Report #CTU 228559
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Bedridden		Vioxx	PS				
	Depression							

Date:10/01/04ISR Number: 4466633-1Report Type:Direct Company Report #CTU 228558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx Merck	PS	Merck		1 PILL	
Hospitalization -	Hypertension						MORNING ORAL	
Initial or Prolonged	Malaise							
S								
Disability								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/01/04ISR Number: 4466634-3Report Type:Direct Company Report #CTU 228557
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Difficulty In Walking		Vioxx			
	Dizziness		I Think			
	Dysstasia		25 Mg - Not Sure	PS		
DENTAL 1 PILL	PER					
DAY DENTAL						

Date:10/01/04ISR Number: 4466635-5Report Type:Direct Company Report #CTU 228555
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg Tablet			
Hospitalization -			Merck And Co	PS	Merck And Co	ORAL
ONE 25 MG						
Initial or Prolonged						
TABLET ORAL						
Disability						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4466636-7Report Type:Direct Company Report #CTU 228553
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged 1 DAILY	Cardiac Disorder Coronary Artery Disease		Vioxx 25 Mg Merck And Co Inc	PS	Merck And Co Inc	
			Plavix	C		
			Soma	C		
			Zanaflex	C		
			Lipitor	C		
			Toprol	C		
			Lexapro	C		
			Avinza	C		

Date:10/01/04ISR Number: 4466638-0Report Type:Direct Company Report #CTU 228550
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1 DAY ORAL	Chest Pain		Vioxx 25 Mg Merck	PS	Merck	ORAL
Initial or Prolonged	Dyspnoea Feeling Abnormal Heart Rate Increased					

Date:10/01/04ISR Number: 4466639-2Report Type:Direct Company Report #CTU 228549
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx Not Sure			
Hospitalization - ONE A DAY ORAL	Congestive		Now-25 Mg-	PS		ORAL
Initial or Prolonged	Cardiac Operation					
Other Required Intervention to Prevent Permanent Impairment/Damage	Pulmonary Oedema					

Date:10/01/04ISR Number: 4466640-9Report Type:Direct Company Report #CTU 228547
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS			ONCE PER DAY	

Date:10/01/04ISR Number: 4466652-5Report Type:Direct Company Report #CTU 228545
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25-Mg Merck	PS	Merck	ORAL	25 MG DAILY	
Hospitalization - Initial or Prolonged	Congestive Coronary Artery Surgery					ORAL		
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4466653-7Report Type:Direct Company Report #CTU 228544
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS		ORAL	BID PO	
Hospitalization - Initial or Prolonged	Fear							
Required Intervention to Prevent Permanent Impairment/Damage	Respiratory Arrest							

Date:10/01/04ISR Number: 4466655-0Report Type:Direct Company Report #CTU 228542
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 12.5mg M S D	PS	M S D	ORAL	1 TABLET DAILY ORAL	

Date:10/01/04ISR Number: 4466656-2Report Type:Direct Company Report #CTU 228540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx 50 Mg Merck					
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain		& Co.	PS	Merck & Co.	ORAL	50 MG BID ORAL	
	Condition Aggravated							
	Depression		Celebrex	SS		ORAL	200MG TID ORAL	
	Drug Ineffective							
	Dyspnoea							
	Eating Disorder							
	Gastric Disorder							
	Pain							
	Peptic Ulcer Haemorrhage							

Date:10/01/04ISR Number: 4466662-8Report Type:Direct Company Report #CTU 228533
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Electrocardiogram		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG	ONCE
Required	Abnormal						DAILY	ORAL
Intervention to Prevent Permanent Impairment/Damage								

Date:10/01/04ISR Number: 4466667-7Report Type:Direct Company Report #CTU 228531
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper		Vioxx	PS				
	Heart Rate Increased							

Date:10/01/04ISR Number: 4466696-3Report Type:Direct Company Report #CTU 228499
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Death	Abdominal Pain
	Feeling Abnormal

	Myocardial Infarction						
	Pain						
	Speech Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx 25mg Merck	PS	Merck	ORAL	1 PER DAY	
							ORAL	

Date:10/01/04ISR Number: 4466698-7Report Type:Direct Company Report #CTU 228497
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx Rofecoxib					
	Feeling Hot		Merck	PS	Merck	ORAL	1 1 A DAY	
	Headache						ORAL	
	Nasopharyngitis							

Date:10/01/04ISR Number: 4466701-4Report Type:Direct Company Report #CTU 228494
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Surgery		Vioxx 25 Mg/ Merck	PS	Merck	ORAL	25 MG ONE A DAY ORAL	
Hospitalization -								
Initial or Prolonged			Celebrex	SS		ORAL	ONE A DAY ORAL	
Disability								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/01/04ISR Number: 4466702-6Report Type:Direct Company Report #CTU 228493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG ONCE	
Required	Burning Sensation						DAILY ORAL	
Intervention to	Cardiac Disorder		Arava	C				
Prevent Permanent	Chest Discomfort		Atenolol	C				
Impairment/Damage	Chest Pain							
	Dizziness							
	Gastritis							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Nausea							
	Neck Pain							
	Oesophagitis							
	Paraesthesia							

Date:10/01/04ISR Number: 4466713-0Report Type:Direct Company Report #CTU 228525
Age:57 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Toxicity		Vioxx 2.5 Merck	PS	Merck	ORAL	1 TABLET	
	Renal Failure						DAILY	ORAL

Date:10/01/04ISR Number: 4466714-2Report Type:Direct Company Report #CTU 228523
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 25 Milligrams Merk	PS	Merk	ORAL	1 DAILY	ORAL

Date:10/01/04ISR Number: 4466716-6Report Type:Direct Company Report #CTU 228521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Kidney Infection		Vioxx 50 Mg	PS			50 2X DAILY	

Date:10/01/04ISR Number: 4466718-XReport Type:Direct Company Report #CTU 228520
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx 25 Mg	PS		ORAL	1X DAILY	
Hospitalization - Initial or Prolonged	Infarction						ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Ejection Fraction Decreased							
	Impaired Work Ability							

Date:10/01/04ISR Number: 4466720-8Report Type:Direct Company Report #CTU 228518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain Upper		Vioxx Have Bottle			
Other	Cardiac Disorder		Somewheres? Unknown	PS		ORAL
ONE FOR PAIN						
	Cerebrovascular Accident					
ORAL						
	Ear Pain		Celebrex 250mg			
	Eye Pain		Unkknown At This			
	Feeling Hot		Time	SS		ORAL
ONE TO THREE						
	Gastric Disorder					
PAIN/						
	Headache					
DAILY/PAI						
	Intraocular Pressure Test					
ORAL						
	Abnormal					
	Myocardial Infarction					
	Neck Pain					
	Pain					
	Tinnitus					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4466723-3Report Type:Direct Company Report #CTU 228517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Dizziness Headache Respiratory Distress		Vioxx Merck	PS	Merck			

Date:10/01/04ISR Number: 4466725-7Report Type:Direct Company Report #CTU 228516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Palpitations		Vioxx 25 Mg Merck	PS	Merck		1 DAILY	

Date:10/01/04ISR Number: 4466728-2Report Type:Direct Company Report #CTU 228515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other Required Intervention to Prevent Permanent Impairment/Damage	Convulsion Headache		Vioxx 25 Mgs Merck	PS	Merck		1 DAILY	

Date:10/01/04ISR Number: 4466806-8Report Type:Direct Company Report #CTU 228513
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck		UNKNOWN	AS NEEDED AS NEEDED

Other
UNKNOWN
Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:10/01/04ISR Number: 4466815-9Report Type:Direct Company Report #CTU 228510
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Ulcer Pain		Vioxx 50 Mg Daily / 1/2 Tab Merck	PS	Merck	ORAL	25 MG DAILY	

ORAL

Date:10/01/04ISR Number: 4466816-0Report Type:Direct Company Report #CTU 228508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Disorder Cardiospasm Heart Rate Irregular		Vioxx Merck	PS	Merck			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4467022-6Report Type:Direct Company Report #CTU 228491
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx 25mg Merck	PS	Merck		1 TAB DAILY	
Initial or Prolonged Disability	Transient Ischaemic Attack							

Date:10/01/04ISR Number: 4467023-8Report Type:Direct Company Report #CTU 228490
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx 25mg					
	Cardiac Disorder		Merck-Medco	PS	Merck-Medco			
	Drug Interaction							
	Fluid Retention							

Date:10/01/04ISR Number: 4467025-1Report Type:Direct Company Report #CTU 228488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx 25 Mg Merck	PS	Merck		ONE PER DAY	
Initial or Prolonged	Dyspnoea							
Other	Urinary Incontinence							

Date:10/01/04ISR Number: 4467027-5Report Type:Direct Company Report #CTU 228487
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25mg Merck	PS	Merck	ORAL	25 MG	ONCE
	Extrasystoles						A DAY	ORAL
	Palpitations							

Date:10/01/04ISR Number: 4467031-7Report Type:Direct Company Report #CTU 228481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blister		Vioxx	PS			DAILY	
	Feeling Abnormal							
	Gastrointestinal Disorder							
	Onychomycosis							
	Pyrexia							
	Rash							

Date:10/01/04ISR Number: 4467653-3Report Type:Direct Company Report #CTU 228787
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONCE DAILY	
	Ventricular Extrasystoles							
ORAL								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/04ISR Number: 4467748-4Report Type:Expedited (15-DaCompany Report #DSA_24997_2004
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Foreign	Bi-Tildiem	PS		ORAL	180 MG Q DAY	
Initial or Prolonged	Increased	Health					PO	
	Blood Glucose Increased	Professional	Hemigoxine Nativelle	SS		ORAL	0.25 MG Q DAY	
	Blood Potassium Increased	Other					PO	
	Blood Sodium Increased		Coversyl	SS		ORAL	4 MG Q DAY PO	
	Blood Urea Increased		Vioxx	SS		ORAL	25 MG Q DAY	
	Bradycardia						PO	
	C-Reactive Protein		Previscan	C				
	Increased		Levothyrox	C				
	Creatinine Renal		Amlor	C				
	Clearance Decreased		Lasilix	C				
	Drug Interaction		Diffu K	C				
	Electrocardiogram T Wave		Zyloric "Faes"	C				
	Inversion		Relvene	C				
	Hypoaesthesia		Tahor	C				
	International Normalised		Eupantol	C				
	Ratio Increased		Fixical Vitamine D3	C				
	Loss Of Consciousness							
	Myoglobin Blood Increased							
	Nausea							
	Nodal Arrhythmia							
	Overdose							
	Pallor							
	Peripheral Coldness							
	Peripheral Ischaemia							
	Platelet Disorder							
	Renal Failure							
	Vomiting							
	White Blood Cell Disorder							

Date:10/01/04ISR Number: 4467893-3Report Type:Expedited (15-DaCompany Report #WAES 0408USA02183
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Arthritis
	Barrett'S Oesophagus
	Blood Bicarbonate Increased
	Blood Chloride Decreased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Inadequately Controlled
	Blood Thyroid Stimulating Hormone Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Conjunctival Discolouration
	Coronary Artery Atherosclerosis
	Cough
	Dehydration
	Diarrhoea
	Dyspnoea

	Erosive Duodenitis						
	Gastric Disorder						
	Gastrointestinal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemorrhage	Study	Tab Vioxx 25 Mg	PS		ORAL	25
	Gastrooesophageal Reflux	Health					MG/DAILY/PO
	Disease	Professional	Tab Acetaminophen				
	Hiatus Hernia		325 Mg	SS		ORAL	325 MG/PRN/PO
	Hypochromasia		Tab Acetaminophen				
	Microcytosis		325 Mg	SS		ORAL	325 MG/PRN/PO
	Oedema Peripheral		Ambien	C			
	Pallor		Toprol Xl	C			
	Supraventricular		Allopurinol	C			
	Extrasystoles		Aspirin	C			
	Vomiting		Gemfibrozil	C			
			Hydrochlorothiazide	C			
			Ibuprofen	C			
			Isosorbide				
			Mononitrate	C			
			Lansoprazole	C			
			Levothyroxine Sodium	C			
			Lisinopril	C			
			Nitroglycerin	C			
			Pantoprazole	C			
			Paroxetine	C			
			Trazodone				
			Hydrochloride	C			

Date:10/04/04ISR Number: 4465296-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Initial or Prolonged	Infarction		[Therapy				
	Anhedonia		Unspecified]	C			UNKNOWN
	Anxiety		Griseofulvin	C			UNKNOWN
	Aortic Valve Incompetence						

Coronary Artery Occlusion
Drug Ineffective
Emotional Distress
Hyperlipidaemia
Hypokinesia
Injury
Pain
Pelvic Haematoma
Stress

Date:10/04/04ISR Number: 4465307-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00831
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
	Asthenia
	Atelectasis
	Breast Cancer Stage I
	Chest Pain
	Dehydration
	Dysphagia
	Gastritis

		Hypertension					
		Hyperthyroidism					
		Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypothyroidism		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Neoplasm					
		Neuropathy					
		Orthostatic Hypotension					
		Palpitations					
		Vestibular Neuronitis					
		Viral Upper Respiratory					
		Tract Infection					
		Weight Decreased					

Date:10/04/04ISR Number: 4465308-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00640
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Adrenal Cyst		Xanax	C		
UNKNOWN							
		Adverse Event		Aspirin	C		
UNKNOWN							
		Arterial Occlusive		Cipro	C		
UNKNOWN							
		Disease		Propulsid	C		
UNKNOWN							
		Arthralgia		Premarin	C		
UNKNOWN							
		Back Pain		Detrol	C		
UNKNOWN							
		Blood Triglycerides		Lasix (Furosemide)	C		
UNKNOWN							
		Increased		Maxzide	C		
UNKNOWN							
		Cardiac Failure		Prevacid	C		
UNKNOWN							
		Congestive		Claritin-D	C		
UNKNOWN							
		Cardiomegaly		Nitropatch	C		
UNKNOWN							

	Cellulitis	Prilosec	C
UNKNOWN			
	Chest Pain		
	Cholecystitis		
	Cholelithiasis		
	Depression		
	Dilatation Atrial		
	Dizziness		
	Dyspnoea		
	Flatulence		
	Glucose Tolerance		
	Impaired		
	Goitre		
	Haemorrhoids		
	Hepatic Steatosis		
	Incontinence		
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Nasopharyngitis		
	Osteoarthritis		
	Polytraumatism		
	Productive Cough		
	Umbilical Hernia		
	Urinary Incontinence		
	Vaginal Infection		
	Ventricular Hypertrophy		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4465310-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00826
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vicodin Tablets	C			UNKNOWN	
	Cerebrovascular Accident		Beta Carotene	C			UNKNOWN	
	Chronic Fatigue Syndrome		Zyrtec	C			UNKNOWN	
	Confusional State		Flonase	C			UNKNOWN	
	Depression		Neurontin	C			UNKNOWN	
	Disturbance In Attention		Garlic Extract	C			UNKNOWN	
	Dyspnoea		Ginkgo Biloba Extract	C			UNKNOWN	
	Headache		Glyburide	C			UNKNOWN	
	Herpes Zoster		Maxzide	C			UNKNOWN	
	Hypertension		Vitamins (Unspecified)	C			UNKNOWN	
	Hyperventilation		Vitamin E	C			UNKNOWN	
	Injury		Calan	C			UNKNOWN	
	Loss Of Libido		Verapamil	C			UNKNOWN	
	Nausea		Temazepam	C			UNKNOWN	
	Oedema Peripheral		Zocor	C		ORAL	UNKNOWN	
	Palpitations		Atrovent	C			UNKNOWN	
	Panic Attack		Lorazepam	C			UNKNOWN	
	Personality Disorder		Ocuvite	C			UNKNOWN	
	Post-Traumatic Stress							
	Disorder							

	Psychiatric Symptom		Naprosyn	C		
UNKNOWN						
	Sleep Apnoea Syndrome		Naprosyn	C		
UNKNOWN						
	Sleep Disorder		Pyridoxine	C		
UNKNOWN						
	Suicidal Ideation		Altace	C		
UNKNOWN						
	Syncope					
	Treatment Noncompliance					
	Tremor					
	Vision Blurred					

Date:10/04/04ISR Number: 4465311-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00835
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blue Toe Syndrome		Darvocet-N	C		
UNKNOWN						
Other	Chest Pain		Elavil	C		
UNKNOWN						
	Coronary Artery Disease		Soma	C		
UNKNOWN						
	Fall					
	Fibula Fracture					
	Intermittent Claudication					
	Myocardial Infarction					
	Tarsal Tunnel Syndrome					
	Therapeutic Response					
	Decreased					

Date:10/04/04ISR Number: 4465312-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00885
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Cardiomegaly

		Chest Pain Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Steatosis Hiatus Hernia Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/04/04ISR Number: 4465313-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged UNKNOWN Disability		Adverse Event Breast Cancer In Situ Breast Pain Chest Pain Dizziness Dizziness Postural Osteoporosis Polytraumatism Pulmonary Fibrosis Seroma Sinusitis Tinnitus Vertebrobasilar Insufficiency Vertigo		Vioxx Spironolactone	PS C	Merck & Co., Inc	ORAL

Date:10/04/04ISR Number: 4465314-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper Angina Pectoris Asthenia Blood Cholesterol Increased Blood Creatinine Increased Bronchitis Cardiac Failure

Congestive
Congestive Cardiomyopathy
Contusion
Cough
Depression
Dizziness
Dyspepsia
Emotional Distress
Erectile Dysfunction
Facial Palsy
Fall
Gait Disturbance
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Hypertension
Insomnia
Mitral Valve Incompetence

		Nasal Congestion					
		Neck Injury					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Valve		Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence		Norvasc	C		
UNKNOWN							
		Rhinorrhoea		Lotrel	C		
UNKNOWN							
		Road Traffic Accident		Coreg	C		
UNKNOWN							
		Sinus Bradycardia		Clonidine	C		
UNKNOWN							
		Sinusitis		Clonidine	C		ORAL
		Sleep Apnoea Syndrome		Digitek	C		
UNKNOWN							
		Supraventricular		Nexium	C		
UNKNOWN							
		Extrasystoles		Spironolactone	C		
UNKNOWN							
		Swelling		Zocor	C		ORAL
		Upper Respiratory Tract		Lisinopril	C		
UNKNOWN							
		Infection		Reglan	C		
UNKNOWN							
		Ventricular Extrasystoles		Lopressor	C		
UNKNOWN							
		Ventricular Hypertrophy		Minoxidil	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							
				Minoxidil	C		
UNKNOWN							

Date:10/04/04ISR Number: 4465318-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00781
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Aneurysm					
Disability	Aortic Occlusion					
Other	Asthenia					
	Atelectasis					
	Atrioventricular Block					

Complete
Breath Sounds Decreased
Cardiomyopathy
Chest Pain
Crepitations
Dyspepsia
Dyspnoea
Headache
Hypertension
Hypoaesthesia
Ileus
Intermittent Claudication
Limb Discomfort
Myocardial Infarction
Pain In Extremity
Peripheral Vascular
Disorder
Polytraumatism
Renal Tubular Necrosis
Vision Blurred

Date:10/04/04ISR Number: 4465320-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00792
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Asthenia
	Asthma
	Balance Disorder

		Benign Intracranial Hypertension					
		Bronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Cough					
		Depression					
		Dizziness					
		Fatigue					
		Hypothyroidism					
		Increased Upper Airway Secretion					
		Injury					
		Mass					
		Muscle Atrophy					
		Muscle Spasms					
		Myalgia					
		Myositis					
		Nervousness					
		Pain					
		Papilloedema					
		Polytraumatism					
		Skin Disorder					
		Spinal Column Stenosis					
		Urticaria					

Date:10/04/04ISR Number: 4465322-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00895
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Dermal Cyst		Claritin-D	C		
UNKNOWN							
		Diplopia		Robaxin	C		
UNKNOWN							
		Dizziness					
		Headache					
		Malaise					
		Menorrhagia					
		Polytraumatism					
		Sinusitis					

Date:10/04/04ISR Number: 4465324-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
			Aspirin	C		ORAL		
			Doxepin Hydrochloride	C		ORAL		
			Triazolam	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4465325-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/04/04ISR Number: 4465329-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01894
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Enbrel	C				
UNKNOWN								

Date:10/04/04ISR Number: 4465330-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00266
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL	23	DAY
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Ramipril	C		ORAL		

Date:10/04/04ISR Number: 4465331-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0409CAN00110
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/04/04ISR Number: 4465334-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage							

Date:10/04/04ISR Number: 4465689-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Amnesia
Other	Anaemia
	Angiopathy
	Anxiety
	Arrhythmia
	Arthralgia
	Arthritis Bacterial
	Back Injury
	Back Pain
	Blood Urea Increased

		Cardiac Murmur					
		Cerebrovascular Accident					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cholesterol Granuloma		Vioxx	PS	Merck & Co., Inc	ORAL
		Chronic Fatigue Syndrome		Lorcet Plus	C		ORAL
		Cough		Ambien	C		ORAL
		Depression					
		Drug Dependence					
		Dyspnoea					
		Emotional Distress					
		Erythema					
		Erythropoiesis Abnormal					
		Heart Rate Irregular					
		Hyperlipidaemia					
		Hypoacusis					
		Hypoaesthesia					
		Injury					
		Insomnia					
		Intervertebral Disc					
		Protrusion					
		Iron Deficiency					
		Joint Injury					
		Labile Hypertension					
		Mixed Hyperlipidaemia					
		Muscle Spasms					
		Nail Disorder					
		Nausea					
		Neuritis					
		Oedema					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Post Procedural					
		Complication					
		Protein Urine Present					
		Radiculitis					
		Rhinitis Allergic					
		Rhinorrhoea					
		Spherocytic Anaemia					
		Tachycardia					
		Urinary Sediment Present					
		White Blood Cells Urine					
		Positive					

Date:10/04/04ISR Number: 4465692-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0409NOR00012
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Increased							
	General Physical Health							
	Deterioration							
	Hepatic Enzyme Increased							
	Influenza Like Illness							
	Musculoskeletal Stiffness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4465694-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		66 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		66 DAY
	Blood Bilirubin Increased							
	Cardiac Valve Disease							
	Change Of Bowel Habit							
	Chest Pain							
	Coronary Artery Atherosclerosis							
	Dyspnoea							
	Hand Fracture							
	Myocardial Infarction							
	Rectal Haemorrhage							
	Renal Failure							

Date:10/04/04ISR Number: 4465695-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00248
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blister		Vioxx	SS	Merck & Co., Inc	ORAL		23 DAY
	Hallucination		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Acetaminophen	C		ORAL		
	Rash		Acetaminophen And Codeine Phosphate	C				UNKNOWN
			Betamethasone	C				TOPICAL
			Cephalexin	C				UNKNOWN
			Rosiglitazone Maleate	C		ORAL		
			Diazepam	C				UNKNOWN
			Fluticasone Propionate And					

			Salmeterol Xinafoate	C
RESPIRATORY				
(INHALATION)				
			Furosemide	C
UNKNOWN				
			Ibuprofen	C
TOPICAL				
			Ketoconazole	C
TOPICAL				

Date:10/04/04ISR Number: 4465698-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02170
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Heart Rate Irregular		Vicodin Tablets	C				
UNKNOWN								
	Prescribed Overdose		Combivent	C				
UNKNOWN								
	Ventricular Extrasystoles		Advair	C				
UNKNOWN								

Date:10/04/04ISR Number: 4465706-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1430	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4465710-9Report Type:Expedited (15-DaCompany Report #EG-MERCK-0409USA02114
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged			Lornoxicam	SS		ORAL	8	DAY
			Myolastan	C				
UNKNOWN							8	DAY

Date:10/04/04ISR Number: 4467098-6Report Type:Expedited (15-DaCompany Report #2004070205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Malaise	Consumer	Neurontin					
	Spinal Cord Injury		(Gabapentin)	PS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:10/04/04ISR Number: 4467107-4Report Type:Direct Company Report #CTU 228596
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx 100 Mg	PS				
DAILY (AS I								
	Haemorrhage							
RECALL)								
	Haematocrit Decreased							
	Haemoglobin Decreased							

Date:10/04/04ISR Number: 4467654-5Report Type:Direct Company Report #CTU 228788
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Breast Disorder		Vioxx	PS		ORAL		
1 PER DAY								

Dyspepsia
ORAL
Hyperaesthesia

Date:10/04/04ISR Number: 4467655-7Report Type:Direct Company Report #CTU 228789
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx - Rofecoxib - 25 Mg 02241108	PS			ONE A DAY	

Date:10/04/04ISR Number: 4467656-9Report Type:Direct Company Report #CTU 228790
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx .25 Mg	PS			DAILY	
Hospitalization - Initial or Prolonged			Celebrex	SS				
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4467657-0Report Type:Direct Company Report #CTU 228791
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx Merck	PS	Merck	ORAL	DAILY ORAL	
	Sudden Death		Hypertension Medication	C				

Date:10/04/04ISR Number: 4467658-2Report Type:Direct Company Report #CTU 228792
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS		ORAL	25 MG T TIME	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis							

Date:10/04/04ISR Number: 4467659-4Report Type:Direct Company Report #CTU 228793
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx 25 Mg	PS			1 A DAY	

Date:10/04/04ISR Number: 4467677-6Report Type:Direct Company Report #CTU 228761
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx 25 Mg Merck	PS	Merck			
	Sudden Death							

Date:10/04/04ISR Number: 4467682-XReport Type:Direct Company Report #CTU 228767
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Deep Vein Thrombosis Erythema Oedema Peripheral Pain In Extremity Therapy Non-Responder Thrombosis		Vioxx 25 Mg Merek & Co. Inc.	PS	Merek And Co. Inc.		1 OR 2 ONCE DAILY	

Date:10/04/04ISR Number: 4467683-1Report Type:Direct Company Report #CTU 228769
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx 25mg Mereck	PS	Mereck	ORAL	25MG BID ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4467685-5Report Type:Direct Company Report #CTU 228771
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx Merck	PS	Merck		DAILY	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Fall							

Date:10/04/04ISR Number: 4467686-7Report Type:Direct Company Report #CTU 228774
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx Merck	PS	Merck	ORAL	1 PILL AS NEEDED ORAL	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Dysphagia							
Disability	Facial Palsy Retching							

Date:10/04/04ISR Number: 4467687-9Report Type:Direct Company Report #CTU 228777
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS			1 @ DAY	
Hospitalization - Initial or Prolonged								
Other								

Date:10/04/04ISR Number: 4467718-6Report Type:Direct Company Report #CTU 228781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx Merck Mk-0663					

Intervention to	Cerebrovascular Accident		Blind Study	PS	Merck	ORAL
DAILY ORAL						
Prevent Permanent	Dizziness		Placebo	SS		
Impairment/Damage	Liver Disorder					
	Renal Disorder					

Date:10/04/04ISR Number: 4467719-8Report Type:Direct Company Report #CTU 228784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Congenital Anomaly	Arthropathy		Vioxx 50 Mg Tablet			
	Condition Aggravated		Msd Msd	PS	Msd	ORAL
1 TABLET PER						
	Drug Ineffective					
DAY ORAL						
	Pain		Bextra 25 Mg Tablet	SS		ORAL
1 TABLET PER						
DAY ORAL						

Date:10/04/04ISR Number: 4467720-4Report Type:Direct Company Report #CTU 228785
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Hypertension		Vioxx 50 Mg Merck	PS	Merk	ORAL
ONCE PER DAY						
Intervention to						
ORAL						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4467722-8Report Type:Direct Company Report #CTU 228786
Age:64 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25mg Merck	PS	Merck		1 DAILY	
Initial or Prolonged	Speech Disorder							

Date:10/04/04ISR Number: 4467945-8Report Type:Direct Company Report #CTU 228576
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urine		Vioxx	PS			25 MG	
Required Intervention to Prevent Permanent Impairment/Damage	Cyst		Celebrex	SS				
	Hypertension							
	Liver Disorder							
	Oedema Peripheral							

Date:10/04/04ISR Number: 4467984-7Report Type:Direct Company Report #CTU 228746
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx 25 Mg Merck	PS	Merck		ONE	1-2
Initial or Prolonged	Atrial Fibrillation							
Required Intervention to Prevent Permanent Impairment/Damage	Cardiac Valve Disease							

Date:10/04/04ISR Number: 4467986-0Report Type:Direct Company Report #CTU 228745
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx Merck	PS	Merck		DAILY	

Date:10/04/04ISR Number: 4467989-6Report Type:Direct Company Report #CTU 228743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
Initial or Prolonged	Coronary Artery Disease						ORAL	
Disability	Coronary Artery Occlusion							
	Dyspnoea							
	Surgical Procedure							
	Repeated							

Date:10/04/04ISR Number: 4467991-4Report Type:Direct Company Report #CTU 228741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg Merck	PS	Merck	ORAL	25MG TWICE	
Hospitalization -							DAILY ORAL	
Initial or Prolonged								
Disability								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4467993-8Report Type:Direct Company Report #CTU 228740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx Mrk 110	PS	Mrk 110	ORAL	1 PILL	1-2 TIMES ORAL

Date:10/04/04ISR Number: 4468092-1Report Type:Direct Company Report #CTU 228776
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder		Vioxx	PS		ORAL	ORAL	

Date:10/04/04ISR Number: 4468093-3Report Type:Direct Company Report #CTU 228775
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx 25 Mg	PS		ORAL	25 - 50 MG ORAL	
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Congestive Cardiomegaly Dyspnoea							

Date:10/04/04ISR Number: 4468094-5Report Type:Direct Company Report #CTU 228773
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx - Rofecoxib -					

Hospitalization -	Myocardial Infarction		25 Mg Merck And Co.	PS	Merck And Co.	ORAL
25 MG ONCE						
Initial or Prolonged						
DAILY ORAL						
Required			Ziac	C		
Intervention to			Pamelor	C		
Prevent Permanent			Zanaflex	C		
Impairment/Damage			Skelaxin	C		
			Buspar	C		
			Enteric Coated			
			Aspirin	C		
			Centrum Silver			
			Vitamins	C		
			Prostata	C		

Date:10/04/04ISR Number: 4468095-7Report Type:Direct Company Report #CTU 228772
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx 25mg Merck	PS	Merck	
1 X DAILY						
Initial or Prolonged						

Date:10/04/04ISR Number: 4468096-9Report Type:Direct Company Report #CTU 228770
Age:50 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Required
Intervention to
Prevent Permanent PT Report Source Product Role Manufacturer Route
Dose Duration
Impairment/Damage Chest Pain Vioxx 25mg Sometime
Deep Vein Thrombosis 50mg Merck PS Merck
EPIDURAL 1 TAB 25 MG
Dyspepsia
DAILY
Embolism
EPIDURAL
Flatulence

Date:10/04/04ISR Number: 4468098-2Report Type:Direct Company Report #CTU 228768
Age:47 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Life-Threatening Chest Pain Vioxx 25mg Merck
Hospitalization - Myocardial Infarction Human PS Merck Human
1 DAILY
Initial or Prolonged
Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:10/04/04ISR Number: 4468101-XReport Type:Direct Company Report #CTU 228765
Age:21 YR Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Dizziness Vioxx 25mg Merck PS Merck ORAL
1 1 A DAY
Headache
ORAL

Date:10/04/04ISR Number: 4468129-XReport Type:Direct Company Report #CTU 228764
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Polyp		Vioxx 50mg	PS		ORAL	ORAL	
Hospitalization - Initial or Prolonged	Irritable Bowel Syndrome Mitral Valve Prolapse Palpitations		Vioxx 25 Mg	SS				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/04/04ISR Number: 4468131-8Report Type:Direct Company Report #CTU 228762
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure		Vioxx 25 Mg / 50 Mg					
Hospitalization - Initial or Prolonged	Fluctuation Chest Injury		Merk	PS	Merk	ORAL	25 - 50 MG	DAILY ORAL
Disability	Fall							
Other	Head Injury							
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4468133-1Report Type:Direct Company Report #CTU 228756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrasystoles		Vioxx 25 Mg Merck	PS	Merck		ONE TABLET	
	Heart Rate Increased						ONCE DAILY	
	Palpitations							

Date:10/04/04ISR Number: 4468135-5Report Type:Direct Company Report #CTU 228755
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx Tablet Merck	PS	Merck			
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/04/04ISR Number: 4468137-9Report Type:Direct Company Report #CTU 228753
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS			2 X PER DAY	
Hospitalization -			Celebrex	SS			2 X PER DAY	
Initial or Prolonged			Bextra	C				
Disability								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/04/04ISR Number: 4468140-9Report Type:Direct Company Report #CTU 228751
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx 25 Mg	PS			ONCE / DAY	
	Platelet Function Test Abnormal							

Date:10/04/04ISR Number: 4468141-0Report Type:Direct Company Report #CTU 228750
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx Dont Remember					
Disability	Myocardial Infarction		Merk	PS	Merk		UNKNOWN	DONT REMEMBER
Required Intervention to Prevent Permanent Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/04/04ISR Number: 4468144-6Report Type:Direct Company Report #CTU 228748
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Generalised Oedema		Vioxx 25 Mg	PS		ORAL	25MG DAY ORAL	
	Road Traffic Accident		Vioxx 50 Mg	SS		ORAL	50 MG DAY ORAL	

Date:10/04/04ISR Number: 4470446-4Report Type:Direct Company Report #CTU 228905
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Test Abnormal		Vioxx 50mg.	PS		INTRACERVICAL	2 TO 3 PER	
Congenital Anomaly	Condition Aggravated							DAY
Required	Diabetes Mellitus							INTRACERVI
Intervention to	Diarrhoea		Celebrex	SS		INTRACERVICAL	2 TO 3 PER	
Prevent Permanent	Dizziness							DAY
Impairment/Damage	Headache							INTRACERVI
	Hypertension							
	Impaired Driving Ability							
	Nausea							
	Stomach Discomfort							
	Urine Analysis Abnormal							
	Vision Blurred							

Date:10/05/04ISR Number: 4466250-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00014
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	UNKNOWN		3 YR

Date:10/05/04ISR Number: 4466252-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00614
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/04ISR Number: 4466253-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
Other	Anxiety Asthenia Cardiac Disorder Cellulitis Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Duodenal Ulcer Haemorrhage Eating Disorder Emotional Distress Facial Palsy Foot Fracture

	Haemorrhage						
	Hemiparesis						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Leg Amputation		Cyanocobalamin	C				UNKNOWN
	Micturition Urgency							
	Peripheral Ischaemia							
	Peripheral Vascular Disorder							
	Thrombosis							
	Toe Amputation							
	Toe Deformity							
	Transient Ischaemic Attack							
	Weight Decreased							
	Wound Dehiscence							

Date:10/05/04ISR Number: 4466254-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/04ISR Number: 4466260-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00105
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/04ISR Number: 4466262-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00261
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Haematemesis Melaena		Acetaminophen And Codeine Phosphate Amitriptyline Hydrochloride	C C		ORAL ORAL

Date:10/05/04ISR Number: 4466263-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00107
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 10 DAY	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Attack					

Date:10/05/04ISR Number: 4466442-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Disability	Anxiety
	Blood Cholesterol

		Increased Blood Creatine Phosphokinase Increased					
		Bronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Zocor	C		ORAL
		Coronary Artery		Diovan	C		
UNKNOWN							
		Atherosclerosis		Diovan	C		
UNKNOWN							
		Coronary Artery Disease		Norco	C		
UNKNOWN							
		Depression		Allopurinol	C		
UNKNOWN							
		Dyspnoea		Xanax	C		
UNKNOWN							
		Fatigue		Aspirin	C		
UNKNOWN							
		Feeling Abnormal		Soma	C		
UNKNOWN							
		Gastrooesophageal Reflux		Plavix	C		
UNKNOWN							
		Disease		Colchicine	C		
UNKNOWN							
		Gouty Arthritis		Diltiazem			
		Influenza		Hydrochloride	C		
UNKNOWN							
		Limb Injury		Folic Acid	C		
UNKNOWN							
		Malignant Hypertension		Indocin			
		Myocardial Ischaemia		(Indomethacin)	C		ORAL
		Nasal Discomfort		Imdur	C		
UNKNOWN							
		Oedema Peripheral		Lecithin And Protein			
		Palpitations		(Unspecified)	C		
UNKNOWN							
		Rhinitis Allergic		Levothroid	C		
UNKNOWN							
		Skin Lesion		Levothroid	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Levothroid	C		
UNKNOWN							
		Tinnitus		Levothroid	C		
UNKNOWN							
		Upper Respiratory Tract		Toprol Xl Tablets	C		
UNKNOWN							

Infection Nitro-Dur C
UNKNOWN

Date:10/05/04ISR Number: 4466448-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Aneurysm
Hospitalization - Initial or Prolonged	Aortic Dissection
Disability	Asthenia
	Depression
	Disturbance In Attention
	Diverticulitis
	Dizziness
	Emotional Distress
	Enterobacter Infection
	Gastrooesophageal Reflux Disease
	General Physical Condition Abnormal
	Haematocrit Decreased
	Haemoglobin Decreased
	Hypertension
	Iliac Artery Thrombosis
	Impaired Healing
	Irritability
	Keloid Scar
	Malaise
	Myocardial Infarction
	Pain
	Pneumonia
	Rash Pruritic
	Self Esteem Decreased
	Sexual Dysfunction

		Sinus Bradycardia Sputum Culture Positive Vascular Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Amoxicillin	C		
UNKNOWN							
				Viagra	C		
UNKNOWN							
				Chlorhexidine Hydrochloride	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							

Date:10/05/04ISR Number: 4466450-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris		Levaquin	C		ORAL
	Blood Pressure Increased		Zestril	C		ORAL
	Convulsion		Glucophage	C		ORAL
			Methylprednisolone	C		
UNKNOWN						

Date:10/05/04ISR Number: 4466451-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00760
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL

Angina Pectoris
Blood Pressure Increased
Convulsion

Date:10/05/04ISR Number: 4466452-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00840
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Premarin	C				
UNKNOWN								
Disability	Arthritis							
	Chest Pain							
	Constipation							
	Diarrhoea							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Injury							
	Muscular Weakness							
	Myalgia							
	Nocturia							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/04ISR Number: 4466453-8Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00013
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

UNKNOWN

Date:10/05/04ISR Number: 4466454-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00021
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/04ISR Number: 4466455-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/05/04ISR Number: 4466456-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00002
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematochezia		Acarbose	C		ORAL		
			Gliclazide	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:10/05/04ISR Number: 4466457-5Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00001
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization - Initial or Prolonged			Augmentin	C		ORAL		
Disability			Betamethasone Dipropionate And Gentamicin Sulfate	C		TOPICAL		
			Betamethasone Sodium Phosphate And Gentamicin Sulfate	C		TOPICAL		

Date:10/05/04ISR Number: 4466458-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00006
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C		UNKNOWN		
			Nifedipine	C		UNKNOWN		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/04ISR Number: 4466459-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Pulmonary Embolism							

Date:10/05/04ISR Number: 4466460-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/05/04ISR Number: 4466461-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bone Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		89 DAY
	Dyspnoea							
	Inflammation							
	Lung Disorder							
	Rash							

Date:10/05/04ISR Number: 4466463-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00021
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Rupture		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								

Date:10/05/04ISR Number: 4466464-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00003
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Infarction							

Date:10/05/04ISR Number: 4466465-4Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00023
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Initial or Prolonged	Sepsis							

Date:10/05/04ISR Number: 4466466-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00001
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Infliximab	SS		INTRAVENOUS DRIP		
			Atenolol	C			UNKNOWN	
			Calcium Carbonate	C			UNKNOWN	

				Warfarin Sodium	C		
UNKNOWN							
				Prednisolone	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							

Date:10/05/04ISR Number: 4466467-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02449
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1288 DAY						
Hospitalization -			Lexapro	C		
UNKNOWN						
Initial or Prolonged			Proscar	C		ORAL
			Zocor	C		ORAL
			Flomax			
			(Morniflumate)	C		
UNKNOWN						

Date:10/05/04ISR Number: 4466468-XReport Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00002
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Methylprednisolone	C		ORAL
			Losec (Omeprazole)	C		ORAL

Date:10/05/04ISR Number: 4466499-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00009
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:10/05/04ISR Number: 4469117-XReport Type:Direct Company Report #CTU 228794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 12.5 Mg Tablet					
Hospitalization -			Msd	PS	Msd	ORAL	12.5 MG , 1 X	
Initial or Prolonged							DAY , ORAL	
			Plavix	C				

Date:10/05/04ISR Number: 4469187-9Report Type:Direct Company Report #CTU 228815
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Flutter		Vioxx 50 Mg Merk					
	Hypertension		114	PS		ORAL	50 MG ONE	
	Palpitations						DAILY ORAL	
	Stress							

Date:10/05/04ISR Number: 4469189-2Report Type:Direct Company Report #CTU 228818
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/04ISR Number: 4469193-4Report Type:Direct Company Report #CTU 228827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx 25 Mg Merck & Co	PS	Merck & Co	ORAL	ONE PER DAY	
						ORAL		

Date:10/05/04ISR Number: 4469243-5Report Type:Direct Company Report #CTU 228829
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx 25 Mg Merck	PS	Merck	ORAL	1 TAB DAILY	
Hospitalization - Initial or Prolonged	Disease					ORAL		
Disability	Coronary Artery Reocclusion							
Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction							
	Thrombosis							

Date:10/05/04ISR Number: 4469255-1Report Type:Direct Company Report #CTU 228835
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx 25 Mg	PS			DAILY	
	Dyspnoea		Vioxx 25 Mg	SS				

Date:10/05/04ISR Number: 4469437-9Report Type:Direct Company Report #CTU 228860
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Haemorrhagic Stroke		Vioxx 25 Mg. Tab				
Hospitalization -			Merck	PS	Merck	ORAL	
25 MG PER							
Initial or Prolonged							
DAY ORAL							
Disability							

Date:10/05/04ISR Number: 4469485-9Report Type:Direct Company Report #CTU 228843
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Ventricular Tachycardia		Vioxx 25 Mg	PS				
12.5 MG 2 A								
Intervention to								
DAY								
Prevent Permanent								
Impairment/Damage								

Date:10/05/04ISR Number: 4469487-2Report Type:Direct Company Report #CTU 228845
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Diplopia		Vioxx Merck	PS	Merck	ORAL		
1 DAILY ORAL								
Intervention to	Disorder Of Globe							
Prevent Permanent	Thrombosis							
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/04ISR Number: 4469565-8Report Type:Direct Company Report #CTU 228880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis Ischaemic		Vioxx 25mg	PS		ORAL	1 TABLET	
Hospitalization -							DAILY	ORAL
Initial or Prolonged								

Date:10/05/04ISR Number: 4470444-0Report Type:Direct Company Report #CTU 228900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Arterial Stent		Vioxx	PS		ORAL	1 DAILY	
Hospitalization -	Insertion							
Initial or Prolonged			Celebrex	C				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/05/04ISR Number: 4470516-0Report Type:Direct Company Report #CTU 228893
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx 40 Mg	PS		ORAL	1 TAB 1 X DAY	
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/05/04ISR Number: 4470521-4Report Type:Direct Company Report #CTU 228896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG ONCE A DAY ORAL	

Date:10/05/04ISR Number: 4470593-7Report Type:Expedited (15-DaCompany Report #ZANA001346
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Other	Aspartate Aminotransferase Increased
	Blood Alkaline Phosphatase Increased
	Bradycardia
	Chest Discomfort
	Diarrhoea
	Drug Interaction
	Drug Level Increased
	Dyspnoea
	Fibrin D Dimer Increased
	Gamma-Glutamyltransferase

	Increased Haemangioma Hepatic Enzyme Increased Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoperfusion Pleural Effusion	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL	6 MG DAILY
	Pulmonary Hypertension	Professional					ORAL
	Vomiting	Other	Voltaren (Diclofenac Sodium)	SS			
			Vioxx (Rofecoxib)	SS			
			Herbal Extracrs Nos (Herbal Extracts Nos)	SS			

Date:10/05/04ISR Number: 4471111-XReport Type:Expedited (15-DaCompany Report #WAES 0403FRA00044
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Duodenal Ulcer	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY 8 DAY
	Perforation	Other	Tab Placebo	SS			8 DAY
	Gastritis		Tab Ibuprofen	SS		ORAL	1 DAY
	Helicobacter Infection		Acetaminophen	C			
	Peritonitis		Cortisone	C			

Date:10/06/04ISR Number: 4467191-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00038
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	

Date:10/06/04ISR Number: 4467192-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	5 YR
			[Therapy Unspecified]	C				

Date:10/06/04ISR Number: 4467193-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Abdominal Pain Upper
Other	Anaemia
	Aneurysm
	Angina Pectoris
	Aortic Valve Incompetence
	Arrhythmia
	Asthma
	Atherosclerosis
	Candidiasis
	Cardiac Disorder
	Cardiac Murmur
	Chest Pain
	Chronic Lymphocytic Leukaemia

		Coronary Artery Disease					
		Diarrhoea					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram T Wave Inversion	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Voltaren	SS		
UNKNOWN							
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Impaired Work Ability		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Acetaminophen And			
		Joint Sprain		Codeine Phosphate	C		
UNKNOWN							
		Lymphadenopathy		Acetaminophen And			
		Melaena		Propoxyphene			
		Mitral Valve		Napsylate	C		ORAL
		Calcification		Prempro	C		
UNKNOWN							
		Mitral Valve Incompetence		Carisoprodol	C		ORAL
		Mitral Valve Prolapse					
		Movement Disorder					
		Oedema Peripheral					
		Osteoarthritis					
		Peptic Ulcer					
		Post Procedural Complication					
		Reflux Oesophagitis					
		Rhonchi					
		Stress					
		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Vomiting					
		Weight Decreased					
		White Blood Cell Count Increased					
		Wound Infection					

Staphylococcal

Date:10/06/04ISR Number: 4467198-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00743
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				
Other	Adverse Event		Lipitor	C				
	Angina Pectoris		Celexa	C				
	Blood Pressure Increased		Cardizem Cd	C				
	Convulsion		Cardizem Cd	C				
	Coronary Artery		Levsin	C				
	Restenosis		Prilosec	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467200-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:10/06/04ISR Number: 4467201-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00040
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:10/06/04ISR Number: 4467202-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01002
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Cortical	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Zyloprim	C		ORAL		
Other	Erectile Dysfunction		Aspirin	C		ORAL		
	Excoriation		Tenormin	C		ORAL		
	Fat Tissue Increased		Tenormin	C		ORAL		
	Hypertension		Buspar	C		ORAL		
	Injury		Celebrex	C		ORAL		
	Retinal Haemorrhage		Ambien	C				
UNKNOWN								
	Transient Ischaemic Attack		Plavix	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Indocin (Indomethacin)	C		ORAL		
			Cozaar	C		ORAL		
			Slow-K	C		ORAL		
			Pravachol	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467215-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Arthralgia
	Asthenia
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Coronary Artery Atherosclerosis
	Drug Ineffective
	Dyslipidaemia
	Fall
	Muscular Weakness
	Night Sweats
	Peripheral Coldness
	Pyrexia
	Road Traffic Accident
	Rotator Cuff Syndrome
	Scapula Fracture

		Skin Laceration Trigger Finger Umbilical Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Atenolol	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN							
				Levsin	C		
UNKNOWN							
				Indocin (Indomethacin)	C		ORAL
				Naproxen	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:10/06/04ISR Number: 4467217-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00071
Age:27 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/06/04ISR Number: 4467219-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467220-1Report Type:Expedited (15-DaCompany Report #GE-MERCK-0410DEU00038
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Burning Sensation	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vascular Stenosis							

Date:10/06/04ISR Number: 4467222-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00011
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged			Acenocoumarol	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Azathioprine	C			UNKNOWN	
			Digoxin	C			UNKNOWN	
			Torsemide	C			UNKNOWN	
			Tolbutamide	C			UNKNOWN	
			Mesalamine	C			UNKNOWN	
			Methylprednisolone	C			UNKNOWN	
			Pantoprazole	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467223-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467224-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00070
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467225-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00037
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467226-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00012
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations Vasculitis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Ameride	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/06/04ISR Number: 4467227-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Erythema Multiforme	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Photosensitivity Reaction		Enalapril Maleate	SS		ORAL		
	Pruritus							

Date:10/06/04ISR Number: 4467229-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467230-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00049
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467231-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00034
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467232-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00023
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		1731 DAY

Date:10/06/04ISR Number: 4467234-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		3 YR

Date:10/06/04ISR Number: 4467235-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00075
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/06/04ISR Number: 4467236-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00286
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Antimicrobial (Unspecified)	C			UNKNOWN	
			Proscar	C		ORAL		
			Hydrodiuril	C			UNKNOWN	
			Sporanox	C			UNKNOWN	

Date:10/06/04ISR Number: 4467237-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00433
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Disability	Arthralgia
Other	Back Injury
	Cerebrovascular Accident
	Drug Ineffective
	Dyspnoea
	Ear Pain
	Fall
	Heart Rate Irregular
	Hypoaesthesia
	Injury
	Intervertebral Disc

		Disorder					
		Lumbar Spinal Stenosis					
		Movement Disorder					
		Musculoskeletal Stiffness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myofascial Pain Syndrome	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain	Professional	Soma	C		
UNKNOWN							
		Ocular Icterus		Naprosyn	C		
UNKNOWN							
		Onychomycosis					
		Rotator Cuff Syndrome					
		Viral Infection					

Date:10/06/04ISR Number: 4467238-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00062
Age:77 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Vicodin Tablets	C		
UNKNOWN							
		Attack		Valium	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							

Date:10/06/04ISR Number: 4467239-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00079
Age:45 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Pulmonary Embolism		Vicodin Tablets	C		
UNKNOWN							
Disability				Prinivil	C		
UNKNOWN							

Date:10/06/04ISR Number: 4467240-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00076
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Other								

Date:10/06/04ISR Number: 4467241-9Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00025
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/06/04ISR Number: 4467242-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00055
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	113	DAY
Hospitalization - Initial or Prolonged			Norvasc	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Terazosin Hydrochloride	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	

				Lantus	C		
UNKNOWN							
				Humalog	C		
UNKNOWN							

Date:10/06/04ISR Number: 4467244-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00309
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
DAY								
Initial or Prolonged			Celexa	C				
UNKNOWN								
			Clonazepam	C				
UNKNOWN								
			Estradiol	C				
UNKNOWN								
			Syntest Ds	C				
UNKNOWN								
			Advair	C				
UNKNOWN								
			Singulair	C				
UNKNOWN								
			Actonel	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467246-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00358
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Phenobarbital	C				
UNKNOWN								
Disability	Attack		Dilantin	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467254-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00093
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Eye Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Memory Impairment		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oxygen Saturation Decreased							

Date:10/06/04ISR Number: 4467430-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02107
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain Upper
Other	Adverse Event
	Angioneurotic Oedema
	Anxiety
	Atrioventricular Block Second Degree
	Blood Creatine Phosphokinase Increased
	Breast Pain
	Bronchitis
	Bundle Branch Block
	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Depression
	Diarrhoea
	Dizziness
	Fatigue
	Helicobacter Pylori

		Identification Test Positive Hypertension Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc Degeneration		Vioxx Lasix (Furosemide)	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Lipids Abnormal		Lasix (Furosemide)	C		
UNKNOWN							
		Nasal Congestion Nasopharyngitis		Ginkgo Biloba Extract	C		
UNKNOWN							
		Neck Pain		Tylenol	C		
UNKNOWN							
		Osteoarthritis		Coumadin	C		
UNKNOWN							
		Osteochondrosis		Ginseng	C		
UNKNOWN							
		Palpitations		Naproxen	C		
UNKNOWN							
		Paraesthesia		Klor-Con	C		
UNKNOWN							
		Pleurisy		Slow-K	C		
UNKNOWN							
		Pulmonary Valve Incompetence Sinus Tachycardia Spinal Column Stenosis Throat Tightness Tricuspid Valve Incompetence Upper Respiratory Tract Infection Vaginal Mycosis Vomiting					

Date:10/06/04ISR Number: 4467434-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Arthralgia
Disability	Aspergillosis Blood Sodium Decreased Bronchitis

Carotid Artery Stenosis
Carpal Tunnel Syndrome
Cerebrovascular Accident
Complicated Migraine
Conversion Disorder
Convulsion
Drug Dependence
Drug Ineffective
Eyelid Ptosis
Hypercholesterolaemia
Hypersensitivity
Hypertriglyceridaemia
Hypotension
Intention Tremor
Iris Disorder
Major Depression
Melas Syndrome
Migraine
Migraine With Aura
Muscle Spasms
Neuritis
Night Sweats
Nystagmus
Oesophageal Spasm
Pigmented Naevus

		Road Traffic Accident					
		Skeletal Injury					
		Skin Hypopigmentation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Laceration		Vioxx	PS	Merck & Co., Inc	ORAL
		Syncope					
		Tremor					
		Tunnel Vision					
		Vasculitis					
		Visual Disturbance					

Date:10/06/04ISR Number: 4467437-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Testosterone		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Decreased		Tylenol	C		
UNKNOWN							
Other		Cerebrovascular Accident		Vicodin Tablets	C		
UNKNOWN							
		Chronic Fatigue Syndrome		Amoxicillin	C		
UNKNOWN							
		Encephalitis Viral		Aspirin	C		
UNKNOWN							
		Hypertension		Tenormin	C		
UNKNOWN							
		Hyponatraemia		Zithromax	C		
UNKNOWN							
		Joint Sprain		Wellbutrin	C		
UNKNOWN							
		Mental Disorder		Celexa	C		
UNKNOWN							
		Migraine		Plavix	C		
UNKNOWN							
		Otitis Media		Benadryl	C		
UNKNOWN							
		Temporomandibular Joint		Premarin	C		
UNKNOWN							
		Syndrome		Neurontin	C		
UNKNOWN							
		Transient Ischaemic		Glucosamine	C		
UNKNOWN							

	Attack	Hypericin	C
UNKNOWN			
	Tri-Iodothyronine Free	Ibuprofen	C
UNKNOWN			
	Increased	Claritin	C
UNKNOWN			
	Vertigo	Ativan	C
UNKNOWN			
		Ambien	C
UNKNOWN			
		Effexor Xr	C
UNKNOWN			
		Trazodone Hydrochloride	C
UNKNOWN			
		Temazepam	C
UNKNOWN			
		Meclizine	C
UNKNOWN			
		Skelaxin	C
UNKNOWN			
		Univasc	C
UNKNOWN			
		Naproxen	C
UNKNOWN			
		Ranitidine	C
UNKNOWN			

Date:10/06/04ISR Number: 4467438-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467439-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00739
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
Other	Anxiety
	Blood Pressure Increased

		Chest Pain					
		Convulsion					
		Decreased Appetite	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dementia		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression					
		Dizziness					
		Fall					
		Feeling Abnormal					
		Gait Disturbance					
		Headache					
		Heart Rate Irregular					
		Hepatic Steatosis					
		Hypertension					
		Insomnia					
		Lacunar Infarction					
		Liver Function Test					
		Abnormal					
		Memory Impairment					
		Mental Disorder Due To A					
		General Medical Condition					
		Pain In Extremity					
		Renal Cyst					
		Renal Failure					
		Sinus Disorder					
		Tinnitus					
		Vascular Dementia					
		Vision Blurred					

Date:10/06/04ISR Number: 4467440-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01964
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
DAY							
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
				Premarin	C		
UNKNOWN							

Date:10/06/04ISR Number: 4467441-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01731
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
Disability	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Osteoarthritis		Avapro	C		ORAL		
	Sleep Apnoea Syndrome							
	Ventricular Extrasystoles							

Date:10/06/04ISR Number: 4467442-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02586
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467443-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00874
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Hypertension							
	Monarthritis							
	Rotator Cuff Syndrome							
	Synovial Disorder							

Date:10/06/04ISR Number: 4467444-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Convulsion							
	Hypertension							
	Hypertonic Bladder							

Date:10/06/04ISR Number: 4467445-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00200
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		457 DAY
Initial or Prolonged	Overdose		Azathioprine	SS		ORAL		72 DAY
Other	Pain		Mirtazapine	SS		ORAL		61 DAY
	Pancytopenia		Ramipril	SS		ORAL		
	Suicide Attempt		Calcium Carbonate And Cholecalciferol	C		ORAL		
			Risedronate Sodium	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Prednisolone	C		ORAL		

Date:10/06/04ISR Number: 4467446-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Abdominal Pain
Other	Activated Partial
	Thromboplastin Time
	Prolonged
	Acute Respiratory Failure
	Adrenal Insufficiency
	Anaemia Of Chronic
	Disease
	Arteriosclerosis
	Asthenia
	Asthma
	Bacterial Infection
	Beta Haemolytic
	Streptococcal Infection
	Blood Erythropoietin
	Decreased
	Bronchitis Acute

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Candidiasis					
		Cellulitis					
		Cholecystitis Chronic					
		Cholesterosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Colitis		Catapres	C		
UNKNOWN	347 DAY						
		Decubitus Ulcer		Lasix (Furosemide)	C		
UNKNOWN							
		Deep Vein Thrombosis		Micardis	C		
UNKNOWN							
		Diarrhoea		Lasix (Furosemide)	C		
UNKNOWN							
		Diverticulum		Cozaar	C		
UNKNOWN							
		Duodenitis					
		Faecal Incontinence					
		Fungaemia					
		Gastric Ulcer					
		Gastritis					
		Gastritis Erosive					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Glaucoma					
		Gynaecomastia					
		Haematoma					
		Haemorrhoids					
		Headache					
		Hepatic Steatosis					
		Hiatus Hernia					
		Hypercoagulation					
		Hyperglycaemia					
		Hypertension					
		Hypoproteinaemia					
		Hypotension					
		Incisional Hernia					
		Inguinal Hernia					
		Malnutrition					
		Metabolic Acidosis					
		Myocardial Infarction					
		Obesity					
		Oesophagitis					
		Optic Neuropathy					
		Otitis Media					
		Pickwickian Syndrome					

Pneumonia
Prothrombin Time
Prolonged
Pulmonary Embolism
Pulmonary Hypertension
Renal Failure
Renal Failure Acute
Rheumatoid Arthritis
Sepsis
Syncope Vasovagal
Thrombocytopenia
Umbilical Hernia
Urinary Incontinence
Urinary Tract Infection
Vertigo

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467450-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00029
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged			Methyldopa	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467451-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00011
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467452-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02691
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability	Transient Ischaemic Attack							

Date:10/06/04ISR Number: 4467454-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00063
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertensive Crisis		Captopril	C				
UNKNOWN								
Initial or Prolonged			Digoxin	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467455-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467456-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00104
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							1338 DAY	
Hospitalization - Initial or Prolonged			Carvedilol	C				
UNKNOWN								
			Cilazapril	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467457-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00079
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
4 DAY								
			Vioxx	SS	Merck & Co., Inc	ORAL		
4 DAY								
			Aspirin	C				
UNKNOWN								
			Omeprazole	C				
UNKNOWN								

			Ranitidine	C			
UNKNOWN							

Date:10/06/04ISR Number: 4467458-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Respiratory Disorder		Estrogens (Unspecified)	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467460-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00024
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Coronary Artery Stenosis							

Date:10/06/04ISR Number: 4467461-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00032
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467462-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00116
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Initial or Prolonged Vioxx SS Merck & Co., Inc
UNKNOWN 427 DAY
Propatyl Nitrate C
UNKNOWN

Date:10/06/04ISR Number: 4467464-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder							

Date:10/06/04ISR Number: 4467466-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00042
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467467-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Treatment Noncompliance		Aspirin	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

Nitroglycerin C
UNKNOWN

Date:10/06/04ISR Number: 4467468-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00055
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged			Clopidogrel Bisulfate	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467469-8Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00010
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Silent Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467470-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00041
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Visual Disturbance		Methotrexate	C				
UNKNOWN								

Date:10/06/04ISR Number: 4467471-6Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 3 DAY Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/06/04ISR Number: 4467472-8Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00015
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebral Infarction Chest Pain		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN						

Date:10/06/04ISR Number: 4467473-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00046
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dizziness Myocardial Infarction Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467474-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00006
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Terazosin Hydrochloride	C			UNKNOWN	
			Bendroflumethiazide	C			UNKNOWN	
			Dothiepin Hydrochloride	C			UNKNOWN	

Date:10/06/04ISR Number: 4467475-3Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00008
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Chest Discomfort Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467476-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00009
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bendroflumethiazide	C			UNKNOWN	
			Simvastatin	C			UNKNOWN	
			Enalapril Maleate	C			UNKNOWN	

Date:10/06/04ISR Number: 4467477-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00005
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Triazolam	C		ORAL		
			Estrogens (Unspecified)	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/06/04ISR Number: 4467478-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Musculoskeletal Discomfort		[Therapy Unspecified]	C				
UNKNOWN								
	Shoulder Operation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467479-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00018
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/06/04ISR Number: 4467483-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/06/04ISR Number: 4467486-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00012
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467488-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00017
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/06/04ISR Number: 4467489-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00027
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Myocardial Infarction Vioxx PS Merck & Co., Inc
UNKNOWN 4 YR
Initial or Prolonged Sulfasalazine C
UNKNOWN

Date:10/06/04ISR Number: 4467490-XReport Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00013
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

Date:10/06/04ISR Number: 4467492-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467493-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00016
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467494-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467495-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00018
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/06/04ISR Number: 4467496-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00159
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467498-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00126
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cerebrovascular Accident		Tylenol	C		ORAL		
	Depressed Level Of Consciousness		Tylenol With Codeine #3	C			UNKNOWN	
	Hyperhidrosis		Tylenol Pm	C			UNKNOWN	
	Loss Of Consciousness		Os-Cal	C			UNKNOWN	
	Pyrexia		Lexapro	C			UNKNOWN	

			Synvisc	C		
PARENTERAL						
			Valproic Acid	C		ORAL
			Synvisc	C		
PARENTERAL						
			Synvisc	C		
PARENTERAL						
			Prevacid	C		
UNKNOWN						
			Ativan	C		
UNKNOWN						
			Roxanol	C		
UNKNOWN						

Date:10/06/04ISR Number: 4467499-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00310
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Headache		[Therapy			
	Malaise		Unspecified]	C		
UNKNOWN						
	Nausea		Fosamax	C		
UNKNOWN						
	Pain		Cartia (Aspirin)	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Benicar	C		
UNKNOWN						
			Potassium			
			(Unspecified)	C		
UNKNOWN						
			Zantac	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467501-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Supraventricular		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:10/06/04ISR Number: 4467502-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00135
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:10/06/04ISR Number: 4467503-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction							
Hospitalization - Initial or Prolonged								
Disability								

Date:10/06/04ISR Number: 4467506-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00317
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eructation		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Flatulence		Metoprolol	C				
	Tachycardia		Inderal	C			UNKNOWN	

Date:10/06/04ISR Number: 4467508-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00332
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/06/04ISR Number: 4467509-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00163
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Disorder		[Therapy Unspecified]	C				
	Chest Pain							
	Myocardial Infarction		Aspirin	C				
	Triple Vessel Bypass Graft		Calcium (Unspecified)	C				
	Weight Decreased		Nexium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4467510-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Back Disorder							
	Cardiac Disorder							

Date:10/06/04ISR Number: 4467519-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00031
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
			Isosorbide Mononitrate	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Prinivil	C		ORAL		
			Metoprolol	C			UNKNOWN	

Date:10/06/04ISR Number: 4467531-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00100
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
			Alendronate Sodium	C		ORAL		
Other			Calcitriol	C			UNKNOWN	

Date:10/06/04ISR Number: 4467536-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00043
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Intestinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error							

Date:10/06/04ISR Number: 4469077-1Report Type:Direct Company Report #CTU 228995
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colon Cancer		Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Hospitalization - Initial or Prolonged	Iron Deficiency Anaemia							

Date:10/06/04ISR Number: 4469079-5Report Type:Direct Company Report #CTU 228996
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain		Vioxx 12.5 Merck	PS	Merck	ORAL	12.5 QD ORAL	
	Dyspnoea							
	Nephrolithiasis							
	Pain							
	Pollakiuria							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4469083-7Report Type:Direct Company Report #CTU 228997
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS				
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/06/04ISR Number: 4469086-2Report Type:Direct Company Report #CTU 228998
Age:51 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx 25mg	PS		ORAL	25MG DAILY	
Initial or Prolonged	Hypertension							
ORAL								

Date:10/06/04ISR Number: 4470684-0Report Type:Direct Company Report #CTU 228988
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx 25mg Merc	PS	Merc		1 A DAY	
Initial or Prolonged	Dizziness							
Required	Feeling Abnormal							
Intervention to	Flatulence							
Prevent Permanent	Hyperhidrosis							
Impairment/Damage	Hypoaesthesia							
	Inflammation							
	Nausea							
	Oesophageal Disorder							
	Oral Intake Reduced							
	Pain							
	Palpitations							

Date:10/06/04ISR Number: 4470687-6Report Type:Direct Company Report #CTU 228989
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONE A DAY	
Required							ORAL	
Intervention to Prevent Permanent Impairment/Damage			Plavix	C				

Date:10/06/04ISR Number: 4470694-3Report Type:Direct Company Report #CTU 228991
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Chest Pain		Vioxx 25 Mg Merck					
Intervention to Prevent Permanent Impairment/Damage	Medication Error		And Co	PS	Merck And Co	ORAL	1 TABLET ORAL	
	Pharmaceutical Product Complaint							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/04ISR Number: 4470764-XReport Type:Direct Company Report #CTU 228976
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx Merck	PS	Merck			
	Breast Pain		Meridia	SS			15 MG	
	Pain							

Date:10/06/04ISR Number: 4470766-3Report Type:Direct Company Report #CTU 228977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Condyloma Acuminatum		Vioxx 25 Mg	PS		ORAL	25 MG DAY	
	Skin Papilloma							

Date:10/06/04ISR Number: 4470769-9Report Type:Direct Company Report #CTU 228968
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONE DAILY	
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction							

Date:10/06/04ISR Number: 4470828-0Report Type:Direct Company Report #CTU 228985
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx 50mg Merck	PS	Merck	ORAL	1	
Initial or Prolonged	Procedural Complication					TABLET		
Required			Vioxx	SS	Merck	ORAL	1	
Intervention to						TABLET		
Prevent Permanent			Prednisone	C				
Impairment/Damage			Prilosec	C				
			Methotrexate	C				
			Actonel	C				
			Remicade	C				

Date:10/06/04ISR Number: 4471368-5Report Type:Expedited (15-DaCompany Report #2004UW19873
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Chest Sound	Literature	Elavil	PS		ORAL	700 MG DAILY;	
Hospitalization -	Aggression	Health				PO		
Initial or Prolonged	Aspiration	Professional	Vioxx	SS		ORAL	750 MG DAILY;	
Required	Completed Suicide					PO		
Intervention to	Depressed Level Of		Flexeril	SS		ORAL	300 MG DAILY;	
Prevent Permanent	Consciousness					PO		
Impairment/Damage	Drug Toxicity		Acetaminophen	SS			30 G	
	Intentional Misuse		Tramadol					
	Sedation		Hydrochloride	SS			3G	
	Vomiting		Tizanidine					

			Hydrochloride	SS		ORAL
120 MG DAILY; PO						
			Omeprazole	SS		ORAL
300 MG DAILY; PO						

Date:10/06/04ISR Number: 4471895-0Report Type:Expedited (15-DaCompany Report #2004-BP-08410RO
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged	Study Health Professional	Dexamethasone Tablets Usp, 4 Mg (Dexamethasone)	PS		ORAL
40 MG/DAY, PO						
	Dehydration Disease Progression Dyspnoea		Genasense (Bcl-2 Antisense Oligonucleotide)	SS		
INTRAVENOUS 7 MG/KG/DAY, IV						
	Fluid Intake Reduced					
	General Physical Health Deterioration		Vioxx (Rofecoxib)	SS		ORAL
25 MG QD (25 MG), PO						
	Haemodialysis Haemoptysis Oliguria Pain Pathological Fracture Prothrombin Time Prolonged Renal Failure Acute Respiratory Arrest Tenderness Thirst Tibia Fracture		Multivitamins(Multivitamins)	C		
			Lisinopril W/Hydrochlorothiazide (Prinzide)	C		
			Verapamil (Verapamil)	C		
			Levothyroxine(Levothyroxine)	C		
			Potassium Chloride(Potassium Chloride)	C		
			Nizatidine(Nizatidine)	C		
			Epoetin Alfa(Epoetin Alfa)	C		
			Calcium Carbonate(Calcium			

Carbonate)	C
Pamidronate(Pamidronate Disodium)	C
Heparin (Heparin)	C
Co-Trimoxazole(Bactrim)	C
Dolasetron(Dolasetron)	C

Date:10/07/04ISR Number: 4468191-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Cardiac Disorder Cerebrovascular Accident							

Date:10/07/04ISR Number: 4468192-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Percocet	C			UNKNOWN	
	Pain In Extremity		Premarin	C			UNKNOWN	
	Paraesthesia							

Date:10/07/04ISR Number: 4468193-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468194-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00636
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Tylenol	C			UNKNOWN	
Disability	Bronchitis		Tylenol With Codeine #3	C			UNKNOWN	
	Chest Pain		Aspirin	C			UNKNOWN	
	Chest Wall Pain		Celebrex	C			UNKNOWN	
	Cholelithiasis		Nexium	C			UNKNOWN	
	Dermal Cyst		Toprol Xl Tablets	C			UNKNOWN	
	Duodenitis							
	Dyspnoea							
	Eczema							
	Electrocardiogram Abnormal							

Epistaxis
Gastritis
Helicobacter Gastritis
Hepatic Cyst
Injury
Laceration
Nasal Congestion
Otitis Media
Pleurisy
Sinusitis
Victim Of Crime

Date:10/07/04ISR Number: 4468197-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00006
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Gliclazide	C				
			Metformin Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468198-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02005
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abnormal Sensation In Eye		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenopia		Plendil	C			UNKNOWN	
	Benign Neoplasm Of Skin		Dyazide	C			UNKNOWN	
	Blood Cholesterol Increased							
	Blood Pressure Inadequately Controlled							
	Blood Pressure Increased							
	Brain Stem Syndrome							
	Carpal Tunnel Syndrome							
	Cerebrovascular Accident							
	Cervicobrachial Syndrome							
	Constipation							
	Dyspepsia							
	Emotional Distress							
	Facial Palsy							
	Fatigue							
	Haematochezia							
	Hyperlipidaemia							
	Hypersensitivity							
	Hypertension							
	Injury							
	Keratoconjunctivitis							
	Sicca							
	Mitral Valve Incompetence							
	Myoclonus							
	Night Blindness							
	Osteoarthritis							
	Osteopenia							
	Peptic Ulcer							
	Photosensitivity Reaction							
	Rotator Cuff Syndrome							
	Sensation Of Foreign Body							
	Simple Partial Seizures							
	Tricuspid Valve Incompetence							
	Urine Flow Decreased							

Vision Blurred
Visual Acuity Reduced
Weight Increased

Date:10/07/04ISR Number: 4468200-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00032
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx [Composition Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
			Zantac	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468212-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468213-0Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Injury		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/07/04ISR Number: 4468221-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00205
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	9 DAY	
Disability	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	9 DAY	
			Acetaminophen	C			UNKNOWN	
			Mefenamic Acid	C			UNKNOWN	

Date:10/07/04ISR Number: 4468223-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00148
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Rofecoxib	PS	Merck & Co., Inc		UNKNOWN	639 DAY

Initial or Prolonged	Condition Aggravated		Enalapril Maleate	C		
UNKNOWN						
Other	Hypertension					

Date:10/07/04ISR Number: 4468224-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00173
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other			Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirina	C		
UNKNOWN						
			Atorvastatin Calcium	C		
UNKNOWN						
			Higroton	C		
UNKNOWN						
			Diamicron	C		
UNKNOWN						

Date:10/07/04ISR Number: 4468225-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	
UNKNOWN 3 YR						
Initial or Prolonged						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468227-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00045
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gait Disturbance		Alendronate Sodium	C		ORAL	UNKNOWN	
	Insomnia		Aspirin And Dipyridamole	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Blood Thinner (Unspecified)	C			UNKNOWN	

Date:10/07/04ISR Number: 4468242-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Estrogens (Unspecified)	C			UNKNOWN	
			Moclobemide	C			UNKNOWN	

Date:10/07/04ISR Number: 4468244-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Cardiac Failure		[Therapy Unspecified]	C			UNKNOWN	
	Congestive		[Therapy					

Unspecified] C
UNKNOWN

Date:10/07/04ISR Number: 4468245-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00137
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468246-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468247-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Cardiac Failure Congestive		[Therapy Unspecified]	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468248-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468250-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00097
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
			Hydrochlorothiazide	C				UNKNOWN
			Simvastatin	C				UNKNOWN
			Warfarin Sodium	C				UNKNOWN
			Iron (Unspecified)	C				UNKNOWN
			Lansoprazole	C				UNKNOWN

Date:10/07/04ISR Number: 4468251-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00090
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Congestive		Atorvastatin Calcium	C				UNKNOWN
	Myocardial Infarction		Bupropion Hydrochloride	C				UNKNOWN
			Cyanocobalamin	C				UNKNOWN

			Furosemide	C		
UNKNOWN						
			Hydroxychloroquine Sulfate	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Warfarin Sodium	C		
UNKNOWN						
			Isosorbide Dinitrate	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Metoprolol	C		
UNKNOWN						
			Mirtazapine	C		
UNKNOWN						
			Potassium Chloride	C		
UNKNOWN						

Date:10/07/04ISR Number: 4468253-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00068
Age:79 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Acetaminophen And Codeine Phosphate	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						
			Clonazepam	C		
UNKNOWN						
			Fluticasone Propionate	C		
UNKNOWN						
			Sumatriptan Succinate	C		
UNKNOWN						
			Furosemide	C		
UNKNOWN						
			Naproxen	C		
UNKNOWN						
			Risedronate Sodium	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468254-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468255-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00017
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea							

Date:10/07/04ISR Number: 4468256-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00034
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

Date:10/07/04ISR Number: 4468257-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00102
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diclofenac Resinate	C		ORAL		

Date:10/07/04ISR Number: 4468259-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00101
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:10/07/04ISR Number: 4468260-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00018
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

UNKNOWN

Date:10/07/04ISR Number: 4468261-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00020
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468262-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00021
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468263-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							

Date:10/07/04ISR Number: 4468265-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468266-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:10/07/04ISR Number: 4468267-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00026
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Atrial Fibrillation

Date:10/07/04ISR Number: 4468269-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00026
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468270-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00128
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		101 DAY

Date:10/07/04ISR Number: 4468271-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00025
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx [Therapy	PS	Merck & Co., Inc			UNKNOWN

Unspecified] C
UNKNOWN

Aspirin C
UNKNOWN

Atenolol C
UNKNOWN

Date:10/07/04ISR Number: 4468272-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:10/07/04ISR Number: 4468273-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00023
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Sepsis							

Date:10/07/04ISR Number: 4468275-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00029
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Rofecoxib	PS	Merck & Co., Inc			
UNKNOWN							2	YR
Initial or Prolonged			Insulin	C				
UNKNOWN								
Disability								

Date:10/07/04ISR Number: 4468276-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00014
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atrial Fibrillation		Aspirin	C			UNKNOWN	
			Cafinitrinia	C			UNKNOWN	
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	
			Carvedilol	C			UNKNOWN	
			Dolalgial	C			UNKNOWN	
			Sertraline Hydrochloride	C			UNKNOWN	
			Tiklid	C			UNKNOWN	
			Aldactone	C			UNKNOWN	
			Digoxin	C			UNKNOWN	
			Seguril	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Pravastatin Sodium	C			UNKNOWN	

Date:10/07/04ISR Number: 4468290-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00027
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mesenteric Artery		Vioxx	SS	Merck & Co., Inc	ORAL	10 YR	
	Embolism							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468295-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00130
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged								

Date:10/07/04ISR Number: 4468296-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State							
	Renal Disorder							
	Suicidal Ideation							

Date:10/07/04ISR Number: 4468297-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00005
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Vioxx	SS	Merck & Co., Inc			
Initial or Prolonged								

Date:10/07/04ISR Number: 4468298-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00022
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:10/07/04ISR Number: 4468299-3Report Type:Expedited (15-DaCompany Report #TW-MERCK-0410TWN00001
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1005 DAY	
Initial or Prolonged								

Date:10/07/04ISR Number: 4468300-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00028
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR
Initial or Prolonged	Dizziness		Thiamine	C			UNKNOWN	

Date:10/07/04ISR Number: 4468302-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00042
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Intestinal Perforation Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468303-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Speech Disorder		Prozac	C				
UNKNOWN								
	Transient Ischaemic Attack							

Date:10/07/04ISR Number: 4468308-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00497
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atenolol	C				
UNKNOWN								
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability								

Date:10/07/04ISR Number: 4468309-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00108
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	MON
Hospitalization -			Synthroid	C				
UNKNOWN								
Initial or Prolonged								

Date:10/07/04ISR Number: 4468310-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00463
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					

Initial or Prolonged Unspecified] C
UNKNOWN
Disability

Date:10/07/04ISR Number: 4468311-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00071
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C				
UNKNOWN								
			Cozaar	C				
UNKNOWN								

Date:10/07/04ISR Number: 4468313-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deep Vein Thrombosis							
Other	Haematochezia							
	Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468314-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Rofecoxib	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Heart Rate Irregular		Diazepam	C				UNKNOWN

Date:10/07/04ISR Number: 4468315-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Hospitalization - Initial or Prolonged								

Date:10/07/04ISR Number: 4468316-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00216
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				UNKNOWN
Disability								

Date:10/07/04ISR Number: 4468323-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
Hospitalization - Initial or Prolonged								
Other								

Date:10/07/04ISR Number: 4468331-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00315
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy					
Hospitalization -			Unspecified]	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/07/04ISR Number: 4468334-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00468
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
							1	YR
Hospitalization -	Quadruple Vessel Bypass		Glucophage	C				
UNKNOWN								
Initial or Prolonged	Graft		Acupril	C				
UNKNOWN								

Date:10/07/04ISR Number: 4468336-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00029
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Estrogens (Unspecified)	C				
			Prevacid	C				

Date:10/07/04ISR Number: 4468339-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00003
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Rofecoxib	PS	Merck & Co., Inc	ORAL	14 DAY	
Initial or Prolonged	Diarrhoea	Professional	Acetaminophen	C				
	Duodenal Ulcer		Benserazide Hydrochloride And Levodopa	C				
	Gastric Ulcer		Estriol	C				
	Melaena		Folic Acid	C				
	Oesophageal Ulcer		Zolpidem Tartrate	C				
			Levothyroxine Sodium	C				
			Methenamine Hippurate	C				
			Mirtazapine	C				
			Oxazepam	C				

Date:10/07/04ISR Number: 4468346-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00003
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Atenolol	C				
UNKNOWN								
	Neck Pain		Lotensin	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								

Date:10/07/04ISR Number: 4468665-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Atrial Fibrillation
	Atrial Septal Defect
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure
	Congestive
	Chest Pain
	Congestive Cardiomyopathy
	Convulsion
	Dizziness
	Electrocardiogram St
	Segment Abnormal
	Electrocardiogram T Wave
	Abnormal
	Fatigue
	Hypercholesterolaemia
	Hyperlipidaemia

		Irritable Bowel Syndrome					
		Low Density Lipoprotein Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis		[Therapy			
		Orthostatic Hypotension		Unspecified]	C		
UNKNOWN							
		Osteoarthritis		Elavil	C		
UNKNOWN							
		Respiratory Tract		Aspirin	C		
UNKNOWN							
		Congestion		Diovan	C		
UNKNOWN							
		Sinus Tachycardia		Estrace	C		
UNKNOWN							
		Supraventricular		Allegra	C		
UNKNOWN							
		Extrasystoles		Hyoscyamine	C		
UNKNOWN							
		Viral Myocarditis					
		Weight Increased					

Date:10/07/04ISR Number: 4468668-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00610
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Blood Pressure Increased					
		Convulsion					
		Dizziness					
		Drug Ineffective					
		Fall					
		Headache					
		Lumbar Spinal Stenosis					
		Myocardial Infarction					
		Oedema Peripheral					
		Plantar Fasciitis					
		Spinal Osteoarthritis					
		Ventricular Dysfunction					

Date:10/07/04ISR Number: 4468669-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00655
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Tylenol Sinus	C				UNKNOWN
Other	Angina Pectoris		Lipitor	C				UNKNOWN
	Angle Closure Glaucoma		Amaryl	C		ORAL		
	Anxiety		Toprol Xl Tablets	C		ORAL		
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Chest Pain							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Depression							
	Gastric Ulcer Haemorrhage							
	Hypercholesterolaemia							
	Hypertension							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468670-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adnexa Uteri Mass		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Anxiety Disorder							
	Appendix Disorder							
	Arthralgia							
	Breast Abscess							
	Chest Pain							
	Complex Regional Pain Syndrome							
	Diabetes Mellitus Non-Insulin-Dependent							
	Dizziness							
	Duodenitis							
	Emotional Distress							
	Faecal Occult Blood Positive							
	Gastric Polyps							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hepatic Cirrhosis							
	Hot Flush							
	Hypertension							
	Ischaemia							
	Major Depression							
	Muscle Spasms							
	Nausea							
	Neck Pain							
	Neurodermatitis							
	Obesity							
	Pancreatitis Chronic							
	Pruritus Generalised							
	Radiculitis Lumbosacral							
	Syncope							
	Tibia Fracture							
	Upper Respiratory Tract Infection							
	Urinary Incontinence							

Urinary Tract Infection
Vaginal Candidiasis
Visual Disturbance

Date:10/07/04ISR Number: 4468671-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
Other	Atrial Fibrillation
	Cardiac Murmur
	Chest Pain
	Colonic Polyp
	Cyst

		Diarrhoea					
		Diverticulum Intestinal					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
213	DAY						
		Eye Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Furuncle		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Hypercalcaemia		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Laryngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Nausea		Lipitor	C		
UNKNOWN							
		Palpitations		Cardura	C		
UNKNOWN							
		Pancreatitis Acute		Monopril	C		
UNKNOWN							
		Peripheral Vascular		Glucotrol	C		
UNKNOWN							
		Disorder		Hydrodiuril	C		ORAL
		Polytraumatism		Hydrodiuril	C		ORAL
		Rash Macular		Imdur	C		
UNKNOWN							
		Renal Failure Chronic		Toprol Xl Tablets	C		ORAL
		Rhinitis Allergic					
		Rotator Cuff Syndrome					
		Sinusitis					
		Sleep Apnoea Syndrome					

Date:10/07/04ISR Number: 4468672-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00048
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx [Composition Unspecified]	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	

Date:10/07/04ISR Number: 4468676-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02165
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Hypersensitivity		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Face Oedema							
	Gravitational Oedema							
	Haematemesis		Estrogens (Unspecified)	C			UNKNOWN	
	Oedema Peripheral							
	Pitting Oedema		Prilosec	C			UNKNOWN	
	Swelling							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468678-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Acute Sinusitis		Prevacid	C				
UNKNOWN								
	Adverse Event		Ultram	C				
UNKNOWN								
	Barrett'S Oesophagus							
	Benign Duodenal Neoplasm							
	Blood Pressure Increased							
	Brunner'S Gland							
	Hyperplasia							
	Chest Pain							
	Costochondritis							
	Dermatitis Allergic							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux							
	Disease							
	Lipids Increased							
	Liver Function Test							
	Abnormal							
	Pain							
	Sensation Of Pressure							
	Tendonitis							

Date:10/07/04ISR Number: 4468681-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
	Cartilage Injury
Other	Chest Pain
	Chills
	Chronic Obstructive
	Pulmonary Disease
	Cough
	Deep Vein Thrombosis
	Dyspnoea
	Gastric Disorder
	Gout
	Headache

Hyperhidrosis
Intestinal Haemorrhage
Intestinal Obstruction
Local Swelling
Myositis
Nasal Congestion
Neck Pain
Oedema
Osteoarthritis
Pain
Pulmonary Embolism
Rectal Haemorrhage
Restrictive Pulmonary
Disease
Rheumatoid Arthritis
Rhinorrhoea
Sleep Apnoea Syndrome
Swelling
Systemic Lupus

Erythematosus
Ulcer

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Albuterol	C			UNKNOWN	
	Combivent	C			UNKNOWN	
	Atenolol	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Advair	C			UNKNOWN	
	Furosemide	C			UNKNOWN	
	Diazide	C			UNKNOWN	
	Lithium Sulfate	C			UNKNOWN	
	Sandostatin	C			UNKNOWN	
	Protonix	C			UNKNOWN	
	Prednisone	C			UNKNOWN	
	Prochlorperazine	C			UNKNOWN	
	Aciphex	C			UNKNOWN	

Date:10/07/04ISR Number: 4468683-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	49	DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	72	DAY

	Cholelithiasis		Lipitor	C			
UNKNOWN							
	Dehydration		Zocor	C			ORAL
	Dyspepsia		Prinivil	C			ORAL
	Ear Infection		Protonix	C			
UNKNOWN							
	Eye Irritation						
	Haematuria						
	Hepatic Enzyme Increased						
	Rash Pruritic						
	Skin Lesion						

Date:10/07/04ISR Number: 4468684-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00030
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/07/04ISR Number: 4468685-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00067
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Headache		Atenolol	C		ORAL		
	Myocardial Infarction		Enalapril Maleate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468687-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00073
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Angina Pectoris							
Other								

Date:10/07/04ISR Number: 4468688-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00011
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Celecoxib	C		ORAL		
			Chlorthalidone	C		ORAL		

Date:10/07/04ISR Number: 4468689-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01183
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Oedema							
	Oedema Peripheral							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:10/07/04ISR Number: 4468692-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00114
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vomiting		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/07/04ISR Number: 4468693-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00079
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
	Chest Pain		[Therapy Unspecified]	C			UNKNOWN	
	Infarction		[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Cyclobenzaprine Hydrochloride	C			UNKNOWN	
			Meperidine Hydrochloride	C			UNKNOWN	
			Metformin	C			UNKNOWN	
			Omeprazole Magnesium	C			UNKNOWN	
			Quinine Sulfate	C			UNKNOWN	
			Ramipril	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468695-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468696-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00084
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Red Blood Cell Sedimentation Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Temporal Arteritis		[Therapy Unspecified]	C			UNKNOWN	

Date:10/07/04ISR Number: 4468698-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468699-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00078
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea							
	Hypersensitivity							
Disability	Leukocytosis							
Other	Pyrexia							
	Shock							

Date:10/07/04ISR Number: 4468700-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468701-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea Hypertension Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468702-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00109
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468703-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468704-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Depression							
	Injury							
	Pulmonary Embolism							
	Stress							

Date:10/07/04ISR Number: 4468705-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00045
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Overdose							

Date:10/07/04ISR Number: 4468706-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00052
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/07/04ISR Number: 4468707-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		112 DAY

Date:10/07/04ISR Number: 4468708-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00044
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Comminuted Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diplopia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness							
	Fall							
	Hyperhidrosis							
	Prescribed Overdose							
	Spinal Fracture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468709-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00014
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colitis Ulcerative		Rofecoxib	PS	Merck & Co., Inc	ORAL		679 DAY
			Butylscopolamine Bromide	C				UNKNOWN
			Tramadol Hydrochloride	C				UNKNOWN

Date:10/07/04ISR Number: 4468710-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00106
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Therapy Unspecified]	C				UNKNOWN
	Heart Rate Irregular							
	Pain In Extremity		Clonazepam	C				UNKNOWN
			Premarin	C				UNKNOWN
			Serzone	C				UNKNOWN
			Dexofen	C				UNKNOWN

Date:10/07/04ISR Number: 4468711-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00026
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy					

			Unspecified]	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						

Date:10/07/04ISR Number: 4468712-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00027
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
	Pain In Extremity		[Therapy Unspecified]	C		
UNKNOWN						
			Adolonta	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						

Date:10/07/04ISR Number: 4468713-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468714-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468715-7Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00006
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Axillary Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	20 DAY	

Date:10/07/04ISR Number: 4468716-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00024
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN	4 YR	
Other			Diclofenac Sodium	C		UNKNOWN		
			Glucosamine	C		UNKNOWN		
			Metoprolol Tartrate	C		UNKNOWN		

Date:10/07/04ISR Number: 4468718-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00020
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	UNKNOWN	2 YR	
	Cerebrovascular Accident							

Skin Discolouration

Date:10/07/04ISR Number: 4468720-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/07/04ISR Number: 4468721-2Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00003
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/07/04ISR Number: 4468722-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00163
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4468724-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Morphine	C				
UNKNOWN								
Initial or Prolonged								

Date:10/07/04ISR Number: 4468727-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00148
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/07/04ISR Number: 4468728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							
	Joint Swelling							

Date:10/07/04ISR Number: 4468730-3Report Type:Expedited (15-DaCompany Report #US-MERCK-99121539
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -	Myocardial Infarction							
Initial or Prolonged	Photosensitivity Reaction							
	Rash							
	Swelling							
	Triple Vessel Bypass							
	Graft							

Date:10/07/04ISR Number: 4468738-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00022
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				UNKNOWN
			Zocor	C				UNKNOWN
			Cilazapril	C				UNKNOWN

Date:10/07/04ISR Number: 4468751-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00035
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Hepatomegaly							
	Sudden Hearing Loss							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4470781-XReport Type:Direct Company Report #CTU 229086
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONE DAILY	
Hospitalization - ORAL								
Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/07/04ISR Number: 4470783-3Report Type:Direct Company Report #CTU 229087
Age:25 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx 25mg	PS		ORAL	2 1 ORAL	

Date:10/07/04ISR Number: 4470785-7Report Type:Direct Company Report #CTU 229085
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Viagra	PS		ORAL	AS NEEDED	
	Cerebrovascular Accident						ORAL	
			Vioxx	SS		ORAL	DAILY ORAL	
			Tia	C				

Date:10/07/04ISR Number: 4470801-2Report Type:Direct Company Report #CTU 229079
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Dyspnoea Vioxx 10 Or 20mg?
Low Dose Merck PS Merck ORAL
ONCE DAILY

ORAL

Date:10/07/04ISR Number: 4470803-6Report Type:Direct Company Report #CTU 229063
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardio-Respiratory Arrest		Vioxx 12.5	PS			12.5 MG / DAY	3 YR
Hospitalization - Initial or Prolonged	Hemiplegia							
	Myocardial Infarction							
Disability	Nerve Injury							
	Procedural Complication							

Date:10/07/04ISR Number: 4471422-8Report Type:Direct Company Report #CTU 229088
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx 25mg	PS		ORAL	1 25MG TAB	
	Circulatory Collapse						DAILY ORAL	
Disability	Confusional State							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4469204-6Report Type:Expedited (15-DaCompany Report #CA-SOLVAY-00204003537
Age:26983 DYGender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Hyperkalaemia	Health Professional	Coversyl	PS		ORAL	Daily dose: 4 milligram(s)	
			Blinded Therapy [Perindopril/Indapamide Vs Placebo]	SS		ORAL	Daily dose: 2 dosage form	
			Vioxx	SS		ORAL	Daily dose: unknown	
			Naprosyn	SS		ORAL	Daily dose: 750 milligram(s)	
			Imodium	C		ORAL	Daily dose: unknown	
			Serax	C			UNKNOWN	Daily dose: unknown
			Dilantin	C		ORAL	Daily dose: unknown	
			Xalatan	C			UNKNOWN	Daily dose: unknown
			Entrophen	C		ORAL	Daily dose: unknown	
			Prozac	C		ORAL	Daily dose:	

unknown

Tenormin	C	ORAL

Daily dose:

unknown

Lipitor	C	ORAL

Daily dose:

unknown

Synthroid	C	ORAL

Daily dose:

unknown

Date:10/08/04ISR Number: 4469640-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00941
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469657-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris Angina Unstable Anxiety Bacterial Infection Convulsion Coronary Artery Disease Coronary Artery Stenosis Heart Rate Decreased Hyperlipidaemia Hypertension Tricuspid Valve Incompetence

		Ventricular Extrasystoles Ventricular Hypertrophy					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/08/04ISR Number: 4469658-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00005
Age:44 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							

Date:10/08/04ISR Number: 4469660-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00831
Age:54 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event	Professional	Os-Cal	C		ORAL
Disability		Anxiety		Hydrochlorothiazide			
Other		Asthenia		And Triamterene	C		ORAL
		Asthma		Centrum	C		ORAL
		Atelectasis					
		Breast Cancer Stage I					
		Bronchitis Acute					
		Chest Pain					
		Chronic Sinusitis					
		Colonic Polyp					
		Dehydration					
		Depression					
		Diverticulum					
		Dysphagia					
		Essential Hypertension					
		Gastritis					
		Haemorrhoids					
		Hepatic Steatosis					
		Hyperglycaemia					
		Hyperthyroidism					
		Hypokalaemia					

Hypothyroidism
Lung Neoplasm
Menopause
Nasal Septum Deviation
Neuropathy
Oedema Peripheral
Orthostatic Hypotension
Osteoarthritis
Polydipsia
Rhinitis Allergic
Sciatica
Vertigo Positional
Vestibular Neuronitis
Viral Upper Respiratory
Tract Infection

Date:10/08/04ISR Number: 4469661-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01052039
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Dizziness							
	Feeling Abnormal							
	Headache							
	Nausea							
	Syncope							
	Vertigo							
	Vomiting							

Date:10/08/04ISR Number: 4469667-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Tolperisone Hydrochloride	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	

Date:10/08/04ISR Number: 4469668-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00184
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469670-6Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00015
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction Chest Pain	Health Professional	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:10/08/04ISR Number: 4469673-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00035
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469675-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00002
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Chapped Lips Glossodynia Oral Pain		Vioxx Celiprolol Hydrochloride Coloxyl	PS C C	Merck & Co., Inc	ORAL ORAL		
UNKNOWN								
			Felodipine Prinivil Nitrolingual Spray	C C C		ORAL ORAL		
UNKNOWN								

			Losec (Omeprazole)	C		ORAL

Date:10/08/04ISR Number: 4469676-7Report Type:Expedited (15-DaCompany Report #TH-MERCK-0409THA00022
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 DAY	Rash		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 2 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
			Acetaminophen And Orphenadrine Citrate	C		ORAL
1 DAY						
			Atenolol	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Nifedipine	C		ORAL
			Ondansetron Hydrochloride	C		
INTRAVENOUS						
			Phenytoin	C		ORAL

Date:10/08/04ISR Number: 4469678-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0312FRA00040
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abscess Limb	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris	Professional	Infliximab	SS		
INTRAVENOUS	465 DAY					
	Arthritis Bacterial		Vioxx	SS	Merck & Co., Inc	ORAL
	Bacterial Infection		Prednisone	SS		
UNKNOWN						
	Beta Haemolytic		Acetaminophen	C		
UNKNOWN						
	Streptococcal Infection		Tramadol Hydrochloride	C		ORAL
	Postoperative Infection		Isradipine	C		ORAL
	Staphylococcal Infection		Leflunomide	C		ORAL
			Omeprazole	C		
UNKNOWN						

Date:10/08/04ISR Number: 4469680-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00040
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:10/08/04ISR Number: 4469681-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00363
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Amitriptyline Hydrochloride	C				
	Drug Hypersensitivity							
UNKNOWN								

Date:10/08/04ISR Number: 4469682-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00090
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469683-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abasia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Adverse Event							
Other	Angina Pectoris							
	Arthritis							
	Arthropathy							
	Back Pain							
	Benign Lung Neoplasm							
	Bladder Disorder							
	Blood Pressure Increased							
	Cardiovascular Disorder							
	Cauda Equina Syndrome							
	Convulsion							
	Death							
	Intestinal Functional Disorder							
	Knee Operation							
	Lung Cyst Benign							
	Paraparesis							
	Radiculopathy							
	Spinal Osteoarthritis							
	Spondylolisthesis							
	Acquired							

Date:10/08/04ISR Number: 4469687-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00092
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/08/04ISR Number: 4469688-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00531
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged Disability	Hiatus Hernia Oesophageal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/08/04ISR Number: 4469689-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469690-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00135
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4469697-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/08/04ISR Number: 4469699-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00551
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/08/04ISR Number: 4469704-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00174
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/08/04ISR Number: 4469705-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00036
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Amazide	C		ORAL		
	Palpitations		Cartia (Aspirin)	C		ORAL		
	Post Procedural Complication		Lipex	C		ORAL		
			Calcium (Unspecified)	C		ORAL		

			Losec (Omeprazole)	C		ORAL

Date:10/08/04ISR Number: 4469708-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469709-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00129
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged	Memory Impairment Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4469711-6Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00020
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469713-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00134
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased							
Other	Dyspnoea							

Date:10/08/04ISR Number: 4469714-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00045
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	751 DAY	

Date:10/08/04ISR Number: 4469715-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00550
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4469732-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00554
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:10/08/04ISR Number: 4470209-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Aspirin	C		
UNKNOWN						
Other	Blood Pressure Increased		Lipitor	C		
UNKNOWN						
	Chest Discomfort		Zocor	C		ORAL
	Convulsion		Zocor	C		ORAL
	Coronary Artery Stenosis		Plavix	C		
UNKNOWN						
	Diaphragmatic Hernia		Prilosec	C		
UNKNOWN						
	Haematoma					
	Headache					
	Hypoaesthesia					
	Hypotension					
	Induration					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Neck Pain					
	Paraesthesia					
	Radiculopathy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470213-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:10/08/04ISR Number: 4470214-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gallbladder Disorder		Flomax (Tamsulosin					
	Gout		Hydrochloride)	C				
UNKNOWN								
	Hernia		Wellbutrin	C				
UNKNOWN								
	Hodgkin'S Disease		Diazepam	C				
UNKNOWN								
	Hypercholesterolaemia		Plendil	C				
UNKNOWN								
	Myalgia		Flonase	C				
UNKNOWN								
	Nephritis Interstitial		Claritin-D	C				
UNKNOWN								
	Nephrosclerosis		Pravachol	C				
UNKNOWN								
	Renal Disorder							
	Renal Failure							
	Renal Failure Acute							
	Renal Tubular Necrosis							
	Sinusitis							

Date:10/08/04ISR Number: 4470216-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00852
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthritis		Darvocet-N	C				
	Atrioventricular Block		Ambien	C				
	First Degree		Celebrex	C		ORAL		
	Back Pain		Toprol Xl Tablets	C				
	Blood Pressure Systolic Increased							
	Bronchitis							
	Coronary Artery Disease							
	Cough							
	Drug Hypersensitivity							
	Dyspnoea							
	Fatigue							
	Intermittent Claudication							
	Nodal Arrhythmia							
	Polytraumatism							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470217-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Levaquin	C		ORAL		
	Blood Pressure Increased		Zestril	C		ORAL		
	Carotid Artery Stenosis		Glucophage	C		ORAL		
	Convulsion		Methylprednisolone	C				
UNKNOWN								
	Hypercholesterolaemia							
	Intermittent Claudication							

Date:10/08/04ISR Number: 4470218-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
Other	Arrhythmia
	Arthralgia
	Asthenia
	Atherosclerosis
	Atrial Fibrillation
	Blister
	Blood Calcium Increased
	Blood Parathyroid Hormone Increased
	Blood Pressure Inadequately Controlled
	Bone Disorder
	Cardiac Murmur
	Chest Pain
	Chest X-Ray Abnormal
	Colonic Polyp
	Conjunctival Haemorrhage
	Cough
	Crepitations
	Dermatitis Contact
	Diarrhoea
	Diastolic Dysfunction
	Dilatation Atrial
	Diverticulum Intestinal
	Dysgeusia

Dyspepsia
Dyspnoea
Eye Haemorrhage
Fatigue
Frequent Bowel Movements
Furuncle
Gastroenteritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Headache
Hepatic Cyst
Hepatic Steatosis
Hiatus Hernia
Hypercalcaemia
Hypertension
Injury
Intermittent Claudication

		Joint Range Of Motion Decreased					
		Joint Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Laryngitis		Vioxx	PS	Merck & Co., Inc	ORAL
213	DAY						
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
		Pancreatitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash Macular		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Renal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Sinus Headache		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Sinusitis		Lipitor	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Cardura	C		
UNKNOWN							
		Tricuspid Valve		Monopril	C		
UNKNOWN							
		Incompetence		Glucotrol	C		
UNKNOWN							
		Ulcer		Hydrodiuril	C		ORAL
		Ventricular Hypertrophy		Hydrodiuril	C		ORAL
				Imdur	C		
UNKNOWN							
				Toprol Xl Tablets	C		ORAL

Date:10/08/04ISR Number: 4470222-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00272
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	SS		ORAL		
			Diclofenac	SS		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Bisoprolol	C		ORAL		

Date:10/08/04ISR Number: 4470224-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0312FRA00040
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis Bacterial		Infliximab	SS			INTRAVENOUS	465 DAY
	Bacterial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Wound Infection		Prednisone	SS			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Tramadol Hydrochloride	C		ORAL		
			Isradipine	C		ORAL		
			Leflunomide	C		ORAL		
			Omeprazole	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470225-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00875
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Benztropine Mesylate	C		ORAL		
	Asthma		Tagamet	C		ORAL		
	Bronchitis Acute		Clonidine Hydrochloride	C		ORAL		
	Constipation		Humibid Dm	C		ORAL		
	Dysphagia		Depakote	C		ORAL		
	Dystonia		Depakote	C		ORAL		
	Gastrooesophageal Reflux Disease		Zoloft	C		ORAL		
	Hiatus Hernia		Ambien	C		ORAL		
	Oesophagitis		Septra Ds	C		ORAL		
	Upper Respiratory Tract Infection		Depakote	C		ORAL		
			Colace	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Haldol	C		ORAL		
			Nystatin	C		TOPICAL		
			Phenergan Tablets/Suppositories	C		ORAL		

Date:10/08/04ISR Number: 4470226-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00051
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Flecainide Acetate	C		UNKNOWN		
	International Normalised Ratio Increased							
	Palpitations							
	Social Avoidant Behaviour							

Date:10/08/04ISR Number: 4470228-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Alendronate Sodium	C				
UNKNOWN								
	Difficulty In Walking							
	Memory Impairment							

Date:10/08/04ISR Number: 4470229-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01977
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							3	DAY
	Chest Pain							
	Hypersensitivity							

Date:10/08/04ISR Number: 4470230-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00065
Age:68 YR Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Emphysema		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction		[Therapy					
	Pneumonia		Unspecified]	C				
UNKNOWN								

Date:10/08/04ISR Number: 4470231-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00038
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Rofecoxib	PS	Merck & Co., Inc	ORAL	4	MON
Initial or Prolonged	Cerebrovascular Accident		Propranolol					
	Coma		Hydrochloride	C				
UNKNOWN								
	Depression							
	Memory Impairment							

Date:10/08/04ISR Number: 4470232-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01736
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Darvocet-N	C				
UNKNOWN								
	Pulmonary Disease		Tenormin	C				
UNKNOWN								
	Emotional Distress		Premarin	C				
UNKNOWN								
	Gastrooesophageal Reflux		Vitamins					
	Disease		(Unspecified)	C				
UNKNOWN								
	Myocardial Infarction		Humulin U Ultralente	C				
UNKNOWN								
			Humalog	C				
UNKNOWN								

			Prevacid	C			
UNKNOWN							

Date:10/08/04ISR Number: 4470234-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00066
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Fibrillation		Warfarin	C				
UNKNOWN								
	Cerebrovascular Accident							
	Myocardial Infarction							
	Visual Disturbance							

Date:10/08/04ISR Number: 4470236-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00060
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Aspirin	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								
			Sulfasalazine	C				
UNKNOWN								
			Pravastatin Sodium	C				
UNKNOWN								
			Prednisolone	C				
UNKNOWN								
			Ramipril	C				
UNKNOWN								

Date:10/08/04ISR Number: 4470237-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00068
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Haemorrhage		Acetaminophen And Codeine Phosphate	C				
	Myocardial Infarction							
			Estrogens (Unspecified)	C				
			Hydrochlorothiazide And Triamterene	C				

Date:10/08/04ISR Number: 4470239-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drooling		Aspirin	C				
	Gait Disturbance		Diabex	C		ORAL		
	Transient Ischaemic Attack							

Date:10/08/04ISR Number: 4470244-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:10/08/04ISR Number: 4470246-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00044
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
354 DAY						
Hospitalization -			Chlorpropamide	C		
UNKNOWN						
Initial or Prolonged						

Date:10/08/04ISR Number: 4470247-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00058
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
119 DAY						
Initial or Prolonged	Myocardial Infarction		Telmisartan	C		
UNKNOWN						
	Rectal Haemorrhage					
	Urinary Tract Infection					

Date:10/08/04ISR Number: 4470249-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00091
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Stent Occlusion		Aspirin	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						
			Clopidogrel Bisulfate	C		
UNKNOWN						
			Tamoxifen Citrate	C		
UNKNOWN						
			Vitamin D			

	(Unspecified)	C
UNKNOWN		
	Verapamil	C
UNKNOWN		
	Rosuvastatin Calcium	C
UNKNOWN		
	Indapamide	C
UNKNOWN		
	Ramipril	C
UNKNOWN		

Date:10/08/04ISR Number: 4470250-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00133
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged								

Date:10/08/04ISR Number: 4470251-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged								

Date:10/08/04ISR Number: 4470252-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00063
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470254-4Report Type:Expedited (15-DaCompany Report #PL-MERCK-0410POL00001
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Iron Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Capecitabine	C		ORAL	13	DAY
	Myocardial Infarction							

Date:10/08/04ISR Number: 4470255-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:10/08/04ISR Number: 4470256-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00008
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
			Acetaminophen And Belladonna And Caffeine And Opium	C		ORAL		
			Acitretin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470257-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470258-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR
Life-Threatening								

Date:10/08/04ISR Number: 4470259-3Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00014
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Henoch-Schonlein Purpura		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Renal Failure Acute		Acenocoumarol	C		ORAL		
			Digoxin	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Ramipril	C		ORAL		

Date:10/08/04ISR Number: 4470261-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00059
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/08/04ISR Number: 4470262-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00052
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00007
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL	38 DAY	
Hospitalization - Initial or Prolonged	Dysphagia		Anusol Suppositories/Ointment	C			UNKNOWN	
	Eye Rolling		Aricept	C			UNKNOWN	
	Feeling Abnormal		Senokot (Senna)	C			UNKNOWN	
	Feeling Hot		Detrol	C			UNKNOWN	
	Hypertension		Zoloft	C			UNKNOWN	
	Mental Status Changes		Neurontin	C			UNKNOWN	
	Motor Dysfunction		Zyprexa	C			UNKNOWN	
	Pulse Abnormal							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470265-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1430 DAY

Date:10/08/04ISR Number: 4470270-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lymphoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Malignant Neoplasm Of Orbit							

Date:10/08/04ISR Number: 4470272-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00134
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470273-8Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470274-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00286
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

			[Therapy Unspecified]	C		
UNKNOWN						
			Antimicrobial (Unspecified)	C		
UNKNOWN						
			Proscar	C		ORAL
			Hydrodiuril	C		
UNKNOWN						
			Sporanox	C		
UNKNOWN						

Date:10/08/04ISR Number: 4470276-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00249
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Aspirin	C		
UNKNOWN						
Initial or Prolonged			Metformin	C		
UNKNOWN						
Disability			Toprol Xl Tablets	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						

Date:10/08/04ISR Number: 4470277-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00299
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470278-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00217
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Life-Threatening								
Hospitalization - Initial or Prolonged								

Date:10/08/04ISR Number: 4470279-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00269
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:10/08/04ISR Number: 4470280-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00268
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		[Therapy Unspecified]	C			UNKNOWN	
	Diabetes Mellitus							
	Drug Hypersensitivity		Amitriptyline Hydrochloride	C			UNKNOWN	
	Gastric Haemorrhage							
			Zoloft	C			UNKNOWN	

Cimetidine C
UNKNOWN

Skelaxin C
UNKNOWN

Date:10/08/04ISR Number: 4470287-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00528
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/08/04ISR Number: 4470288-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00731
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ischaemic Stroke		Prempro	C				
UNKNOWN								
Initial or Prolonged								

Date:10/08/04ISR Number: 4470289-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00170
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Death	Chest Pain
	Dizziness

		Feeling Abnormal Hyperhidrosis Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Prinivil	C		
UNKNOWN							

Date:10/08/04ISR Number: 4470290-8Report Type:Expedited (15-DaCompany Report #PR-MERCK-0410USA00459
Age:59 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON							
Initial or Prolonged		Hypertensive Crisis		Lipitor	C		
UNKNOWN							
		Pancreatitis		Zestril	C		
UNKNOWN							

Date:10/08/04ISR Number: 4470291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00586
Age:72 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Fosamax	C		
UNKNOWN							

Date:10/08/04ISR Number: 4470294-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00630
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Premphase	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							

Date:10/08/04ISR Number: 4470295-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00346
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oesophageal Haemorrhage		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/08/04ISR Number: 4470296-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00614
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Headache		Potassium (Unspecified)	C				
UNKNOWN	Pain In Extremity							
	Pain In Jaw		Vitamins (Unspecified)	C				
	Thrombosis							
UNKNOWN								

Date:10/08/04ISR Number: 4470298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00643
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4470299-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rebound Effect		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Ultram	C			UNKNOWN	
			Tylenol With Codeine #3	C			UNKNOWN	

Date:10/08/04ISR Number: 4470300-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/08/04ISR Number: 4470301-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00748
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Clonazepam	C			UNKNOWN	
	Sensation Of Heaviness		Zocor	C		ORAL		
			Neurontin	C			UNKNOWN	

Date:10/08/04ISR Number: 4470311-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00033
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coma Drug Hypersensitivity Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK

Date:10/08/04ISR Number: 4470313-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00301
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		[Therapy Unspecified]	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Flovent	C			UNKNOWN	

Date:10/08/04ISR Number: 4470314-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00749
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia Cardiac Valve Disease
Disability	Chest Pain Dyspepsia

		Heart Rate Increased					
		Intervertebral Disc Operation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL
				Nexium	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Crestor	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Reglan	C		
UNKNOWN							

Date:10/08/04ISR Number: 4470316-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00853
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							

Date:10/08/04ISR Number: 4470336-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00040
Age:68 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscle Spasms					

Date:10/08/04ISR Number: 4471503-9Report Type:Direct Company Report #CTU 229182
Age:48 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Life-Threatening	Dyspnoea		Vioxx 25 Mereck	PS	Mereck	ORAL
25 MG ONCE A						
Hospitalization -	Pulmonary Embolism					
DAY ORAL						
Initial or Prolonged	Thrombosis					
Disability						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:10/08/04ISR Number: 4471508-8Report Type:Direct Company Report #CTU 229150
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased		Vioxx 50 Mg	PS		
50 MG ONCE A						
Other						
DAY						

Date:10/08/04ISR Number: 4472088-3Report Type:Expedited (15-DaCompany Report #2004051151
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Crohn'S Disease	Consumer	Neurontin (Tablets)			
	Drug Ineffective	Health	(Gabapentin)	PS		ORAL
1800 MG (600						
	Neuropathic Pain	Professional				
MG, 3 IN 1						
	Neuropathy					
D), ORAL						
	Osteosclerosis		Celecoxib			
			(Celecoxib)	SS		
			Rofecoxib			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Rofecoxib) SS

Date:10/08/04ISR Number: 4473836-9Report Type:Direct Company Report #CTU 229152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS			X2 = 50 MG 25 MG , 1 TIME	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/08/04ISR Number: 4473840-0Report Type:Direct Company Report #CTU 229137
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx - 25 Mg Walgreens - Gulfport, Ms	PS		ORAL	(1) TABLET BY MOUTH DAILY	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/08/04ISR Number: 4473843-6Report Type:Direct Company Report #CTU 229142
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS			25 MG 1 PER DAY	
Other	Chest Pain							

Required	Fear		Vioxx	SS
50 MG SAMPLE				
Intervention to	Sleep Disorder			
PACK				
Prevent Permanent				
Impairment/Damage				

Date:10/08/04ISR Number: 4473845-XReport Type:Direct Company Report #CTU 229145
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypersensitivity		Vioxx By Merck	PS	Merck	ORAL
25 MG - ONE						
Initial or Prolonged						
TAB 1/ DAY						
Required						
ORAL						
Intervention to			Calcium	C		
Prevent Permanent			Vitamins	C		
Impairment/Damage			Glucosamine/Chondroi			
			tin	C		

Date:10/08/04ISR Number: 4473857-6Report Type:Direct Company Report #CTU 229187
Age:45 YR Gender:Female I/FU:I

Outcome
Other
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abasia Activities Of Daily Living Impaired Chest Pain Gastric Haemorrhage Grip Strength Decreased Hyperaesthesia Impaired Work Ability Inflammation Joint Swelling Oedema Peripheral Palpitations Weight Increased		Vioxx 25 Mg Merck Co, Inc	PS	Merck Co, Inc	ORAL	25 MG BID	ORAL

Date:10/08/04ISR Number: 4473871-0Report Type:Direct Company Report #CTU 229199
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain Chest Discomfort Condition Aggravated Hypoaesthesia Treatment Noncompliance		Vioxx 25 Mgs	PS		ORAL	25 MGS ORAL	

Date:10/08/04ISR Number: 4473872-2Report Type:Direct Company Report #CTU 229200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Chest Discomfort Hyperhidrosis Nausea Tinnitus		Vioxx	PS		ORAL	1 DAY ORAL	

Date:10/08/04ISR Number: 4473873-4Report Type:Direct Company Report #CTU 229201
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ulcer Haemorrhage		Vioxx 50 Mg. Merck	PS	Merck	ORAL	50 MG DAILY	
Initial or Prolonged								
ORAL								

Date:10/08/04ISR Number: 4473885-0Report Type:Direct Company Report #CTU 229170
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx 25mg Merck & Co, Inc.	PS	Merck & Co, Inc.	ORAL	1 PER DAY	
	Vision Blurred							
	Visual Acuity Reduced							
	Vitreous Floaters							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/08/04ISR Number: 4473902-8Report Type:Direct Company Report #CTU 229172
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx 50 Mg	PS		ORAL	50 MG 1-2 /DAY ORAL	
	Dyspnoea							
	Heart Rate Increased							

Date:10/08/04ISR Number: 4473903-XReport Type:Direct Company Report #CTU 229173
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONCE DAILY ORAL	
Other	Palpitations							

Date:10/08/04ISR Number: 4474210-1Report Type:Expedited (15-DaCompany Report #T04-GER-06043-01
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Sodium Decreased	Foreign Study	Cipralex (Escitalopram)	PS		ORAL	10 MG QD PO	
	Drug Interaction							
	Gastrointestinal Ulcer	Health Professional Other	Clexane (Heparin-Fraction, Sodium Salt)	SS		SUBCUTANEOUS	20 MG QD, SC	
	Haemorrhage							
	Haemorrhagic Diathesis							
			Iscover (Clopidogrel Sulfate)	SS		ORAL	75 MG QD PO	
			Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD PO	
			Avalox (Moxifloxacin Hydrochloride)	C				
			Disalunil (Hydrochlorothiazide)	C				

			Pantozol (Pantoprazole Sodium)	C		
			Zocor (Simvastatin)	C		

Date:10/11/04ISR Number: 4470913-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Aspirin	C			UNKNOWN	
	Blood Pressure Increased		Calcium (Unspecified)	C			UNKNOWN	
	Convulsion		Digoxin	C			UNKNOWN	
	Inner Ear Disorder		Folic Acid	C			UNKNOWN	
	Vertigo		Claritin	C			UNKNOWN	
			Pravachol	C			UNKNOWN	

Date:10/11/04ISR Number: 4470914-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA00564
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cognitive Disorder
Disability	Hemiparesis
	Ischaemic Stroke
	Migraine

		Transient Ischaemic Attack					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Wellbutrin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Premarin	C		ORAL
				Allegra	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Lopid	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Mobic	C		
UNKNOWN							
				Metformin	C		
UNKNOWN							
				Inderal	C		
UNKNOWN							

Date:10/11/04ISR Number: 4470915-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Adverse Event	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Amnesia		Captopril Msd	C		ORAL
	Blood Pressure Increased		Spironolactone	C		
UNKNOWN						
	Breast Cancer In Situ		Toprol Xl Tablets	C		ORAL
	Breast Pain					
	Bronchitis					
	Bursitis					
	Chest Pain					

Colonic Polyp
Contusion
Dizziness
Exostosis
Haemorrhoids
Hypertension
Hypertensive
Encephalopathy
Loss Of Consciousness
Nausea
Osteoarthritis
Osteoporosis
Pain In Extremity
Plantar Fasciitis
Polytraumatism
Pulmonary Fibrosis
Rash
Rhinitis
Seasonal Allergy
Seroma
Tendonitis
Tinnitus
Transient Ischaemic
Attack
Vertebrobasilar
Insufficiency
Vertigo Positional

Date:10/11/04ISR Number: 4470916-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea Paroxysmal		Folic Acid	C			UNKNOWN	
	Nocturnal		Arava	C			UNKNOWN	
	Hypertension		Methotrexate	C			UNKNOWN	441 DAY
	Insomnia		Aredia	C			UNKNOWN	
	Melaena		Prednisone	C			UNKNOWN	10 MON
	Myocardial Infarction		Inderal	C			UNKNOWN	
	Nightmare		Inderal	C			UNKNOWN	
	Palpitations		Inderal La	C			UNKNOWN	
	Panic Attack							
	Phlebitis Superficial							
	Pulmonary Embolism							
	Pulmonary Hypertension							
	Stress							
	Thrombosis							
	Tricuspid Valve Incompetence							
	Upper Respiratory Tract Infection							
	Weight Increased							

Date:10/11/04ISR Number: 4470917-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00064
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Aspirin And Dipyridamole	C
UNKNOWN	Zocor	C
UNKNOWN	Lansoprazole	C
UNKNOWN		

Date:10/11/04ISR Number: 4470918-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01738
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Anxiety
	Aortic Valve Incompetence
	Arteriosclerosis
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cardiac Valve Disease
	Cardiogenic Shock
	Chest Discomfort
	Chest Pain
	Cholelithiasis
	Chronic Fatigue Syndrome

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coronary Artery Disease					
		Coronary Artery Restenosis					
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Ostial Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Disturbance In Attention		[Therapy Unspecified]	C		ORAL
		Dizziness		Ultram	C		ORAL
		Electrocardiogram St Segment Depression		Lipitor	C		ORAL
		Electrocardiogram St Segment Elevation		Clonazepam	C		ORAL
		Emotional Distress		Plavix	C		ORAL
		Gastrooesophageal Reflux Disease		Allegra	C		ORAL
		Haematoma		Diovan Hct	C		ORAL
		Headache					
		Heart Disease Congenital					
		High Density Lipoprotein Decreased					
		Hyperlipidaemia					
		Hypertension					
		Hypoperfusion					
		Hypotension					
		Ischaemic Cardiomyopathy					
		Liver Function Test Abnormal					
		Low Density Lipoprotein Increased					
		Mitral Valve Calcification					
		Myocardial Fibrosis					
		Myocardial Ischaemia					
		Osteoarthritis					
		Post Procedural Complication					
		Respiratory Failure					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:10/11/04ISR Number: 4470919-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01877
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Death	Burning Sensation
Hospitalization -	Cardiomegaly
Initial or Prolonged	Coronary Artery
Other	Atherosclerosis
	Coronary Artery
	Thrombosis
	Cyanosis
	Death
	Fall
	Femur Fracture
	Gout
	Hip Fracture
	Limb Discomfort

	Lower Limb Deformity						
	Myocardial Fibrosis						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Nephrolithiasis						
	Oedema Peripheral						
	Pain In Extremity						
	Pericardial Effusion						
	Pulmonary Congestion						
	Ventricular Hypertrophy						

Date:10/11/04ISR Number: 4470920-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Angina Pectoris						
	Blood Pressure Increased						
	Conjunctivitis Allergic						
	Convulsion						
	Ear Discomfort						
	Headache						
	Hypersensitivity						
	Neoplasm Skin						
	Rash						
	Sinusitis						
	Thrombosis						
	Vertigo						

Date:10/11/04ISR Number: 4470921-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00069
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
	Dyspnoea Exertional		Clopidogrel Bisulfate	C			UNKNOWN
	Eructation		Lansoprazole	C			UNKNOWN
	Flatulence		Simvastatin	C		ORAL	
	Gynaecomastia						

	Oesophageal Disorder		Simvastatin	C		ORAL
			Simvastatin	C		ORAL
			Rabeprazole Sodium	C		

UNKNOWN

Date:10/11/04ISR Number: 4470922-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							
	Feeling Abnormal							

Date:10/11/04ISR Number: 4470927-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
Arthralgia		Heparin	SS			UNKNOWN	
Back Pain		Provera	SS			UNKNOWN	
Blindness		[Therapy Unspecified]	C			UNKNOWN	
Bronchitis							
Cataract		Tylenol With Codeine #3	C			UNKNOWN	
Cerebrovascular Accident							
Depression		Captopril	C			UNKNOWN	
Diverticulum		Capozide	C			UNKNOWN	
Endometrial Hyperplasia		Cisapride	C			UNKNOWN	
Epistaxis		Glyburide	C			UNKNOWN	
Flushing							
Gastrooesophageal Reflux Disease							
Gout							
Haemorrhage Intracranial							
Headache							
Hemianopia Homonymous							
Herpes Zoster							
Hyperhidrosis							
Hypersensitivity							
Hypertension							
Joint Injury							
Nasal Congestion							
Nausea							
Pain							
Pallor							
Pneumonia							
Postmenopausal Haemorrhage							
Rash							
Rift Valley Fever							
Sciatica							
Tachycardia							
Thyroid Mass							

Uterine Polyp
Vaginal Haemorrhage

Date:10/11/04ISR Number: 4470928-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Amaurosis Fugax
	Angina Pectoris
	Aortic Valve Incompetence
	Back Pain
	Benign Neoplasm Of Skin
	Blood Cholesterol
	Increased
	Blood Pressure Increased
	Cardiolipin Antibody
	Positive
	Convulsion
	Dizziness
	Dyspnoea
	Ecchymosis

		Headache Palpitations Periorbital Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sensory Level Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
4	WK						
		Thyroid Disorder		Vioxx	SS	Merck & Co., Inc	
UNKNOWN			2 DAY				
		Ventricular Hypertrophy					

Date:10/11/04ISR Number: 4470940-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00076
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/11/04ISR Number: 4470941-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00079
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY					
			Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY					
			Aspirin	C		
UNKNOWN						
			Omeprazole	C		
UNKNOWN						
			Ranitidine	C		
UNKNOWN						

Date:10/11/04ISR Number: 4470942-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00002
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebral Infarction		Furosemide	C		ORAL
Initial or Prolonged	Pneumonia		Prednisolone	C		ORAL

Tachyarrhythmia
Upper Gastrointestinal
Haemorrhage

Date:10/11/04ISR Number: 4470943-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00061
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Confusional State		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Hemiplegia		Propranolol Hydrochloride	C			UNKNOWN	
			Captopril	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

Date:10/11/04ISR Number: 4470944-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00071
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vomiting		Acetaminophen	C			UNKNOWN	
			Paroxetine Hydrochloride	C			UNKNOWN	

Date:10/11/04ISR Number: 4470946-7Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00017
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Furosemide Sodium	C				
UNKNOWN								
			Gliclazide	C				
UNKNOWN								
			Hydrochlorothiazide And Valsartan	C				
UNKNOWN								
			Simvastatin	C				
UNKNOWN								
			Metformin Hydrochloride	C				
UNKNOWN								
			Paroxetine Hydrochloride	C				
UNKNOWN								
			Phenprocoumon	C				
UNKNOWN								

Date:10/11/04ISR Number: 4470948-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00992
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
227 DAY								
Initial or Prolonged	Asthma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Constipation		Cortisone (Cortisone Acetate)	C				
	Decubitus Ulcer							
UNKNOWN								
	Depression		Vasotec	C		ORAL		
	Hypothyroidism		Prempro	C				
UNKNOWN	299 DAY							
	Muscle Spasms		Allegra-D	C				
UNKNOWN								
	Pain In Extremity		Amaryl	C				
UNKNOWN								

	Proteinuria	Levoxyl	C
UNKNOWN			
	Stress Incontinence	Claritin-D	C
UNKNOWN			
	Urinary Tract Infection	Toprol Xl Tablets	C
UNKNOWN			
		Univasc	C
UNKNOWN			
		Nitrostat	C
UNKNOWN			

Date:10/11/04ISR Number: 4470951-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Actinic Keratosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Adverse Event	Professional	Coumadin	C		
UNKNOWN						
Disability	Benign Prostatic		Coumadin	C		
UNKNOWN						
	Hyperplasia					
	Bladder Diverticulum					
	Bladder Trabeculation					
	Cardiac Failure					
	Congestive					
	Coronary Artery Disease					
	Hypercapnia					
	Ischaemic Cardiomyopathy					
	Mitral Valve Incompetence					
	Tricuspid Valve					
	Incompetence					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4470952-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00063
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebrovascular Accident							
Disability	Dizziness							
	Speech Disorder							
	Swelling							
	Walking Disability							

Date:10/11/04ISR Number: 4470955-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00693
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Disorder							
	Bone Infection							
	Disability							
	Pain							
	Tooth Loss							

Date:10/11/04ISR Number: 4470960-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Life-Threatening								

Date:10/11/04ISR Number: 4470961-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470962-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Retinal Infarction							

Date:10/11/04ISR Number: 4470963-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00217
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470966-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00190
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4470972-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00153
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hepatic Cirrhosis							

Date:10/11/04ISR Number: 4470974-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00273
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged			Methyldopate Hydrochloride	C				
UNKNOWN								
Disability								
Other								

Date:10/11/04ISR Number: 4470976-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/11/04ISR Number: 4470977-7Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00016
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Furosemide Sodium	C				
UNKNOWN								
			Levothyroxine Sodium	C				
UNKNOWN								

Metildigoxin	C	UNKNOWN
[Composition Unspecified]	C	UNKNOWN
Hydrochlorothiazide And Carvedilol	C	UNKNOWN
Carvedilol	C	UNKNOWN
Molsidomine	C	UNKNOWN
Nicorandil	C	UNKNOWN
Pantoprazole Sodium	C	UNKNOWN

Date:10/11/04ISR Number: 4470985-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Haemorrhage Headache Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470988-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00882
Age:83 YR Gender:Female I/FU:I

Outcome	PT
Death	Cardio-Respiratory Arrest
Other	Cerebrovascular Accident

		Chronic Obstructive Pulmonary Disease					
		Sepsis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
72	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
72	DAY						
				Albuterol And Ipratropium Bromide	C		
UNKNOWN							
				Colace	C		
UNKNOWN							
				Doxepin Hydrochloride	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Stelazine	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Levsin	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Morphine	C		ORAL
				Actonel	C		
UNKNOWN							

Date:10/11/04ISR Number: 4470990-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00321
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Biliary Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hepatic Enzyme Increased		Soma	C		
UNKNOWN						
Disability	Rash					

Date:10/11/04ISR Number: 4470991-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00175
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470992-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00206
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470993-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00209
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4470994-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00711
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4470995-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Arrest							
	Cardiac Disorder							
	Cardiovascular Disorder							
	Multi-Organ Disorder							
	Pain							
	Polytraumatism							

Date:10/11/04ISR Number: 4470996-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00947
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blindness		[Therapy Unspecified]	C				UNKNOWN
Disability	Blood Pressure Abnormal							
	Blood Pressure Increased		[Therapy Unspecified]	C				UNKNOWN
	Cataract							
	Cerebrovascular Accident		Lotrel	C				UNKNOWN
	Drug Intolerance		Diovan	C				UNKNOWN
	Hot Flush		Celebrex	C				UNKNOWN
	Psychomotor Hyperactivity		Plavix	C				UNKNOWN
	Visual Disturbance							

Date:10/11/04ISR Number: 4470997-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00709
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vascular Calcification		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
			Aspirin	C			UNKNOWN	
			Prevacid	C			UNKNOWN	

Date:10/11/04ISR Number: 4470998-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471183-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abscess Intestinal
Other	Atherosclerosis
	Chest Discomfort
	Cold Sweat

		Diverticulitis					
		Drug Hypersensitivity					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Darvocet-N	C		
UNKNOWN							
		Hypercholesterolaemia		Aspirin	C		
UNKNOWN							
		Hypertension		Lipitor	C		
UNKNOWN							
		Joint Injury		Metformin	C		
UNKNOWN							
		Liver Disorder		Zantac	C		
UNKNOWN							
		Myocardial Infarction					
		Non-Cardiac Chest Pain					
		Non-Hodgkin'S Lymphoma					
		Pharyngolaryngeal Pain					
		Post Laminectomy Syndrome					
		Pyrexia					
		Simple Partial Seizures					
		Tuberculosis					
		Vertigo Positional					
		Vomiting					

Date:10/11/04ISR Number: 4471189-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia					
Disability		Aspergillosis					
		Bronchitis					
		Cerebrovascular Accident					
		Complicated Migraine					
		Drug Dependence					
		Drug Ineffective					
		Hypercholesterolaemia					
		Hypertriglyceridaemia					
		Hypotension					
		Iris Disorder					
		Major Depression					

Migraine
Migraine With Aura
Muscle Spasms
Neuropathic Pain
Night Sweats
Nystagmus
Oesophageal Spasm
Pigmented Naevus
Road Traffic Accident
Skeletal Injury
Skin Hypopigmentation
Skin Laceration
Syncope
Tremor

Date:10/11/04ISR Number: 4471195-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00037
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx Cartia (Aspirin)	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

	Valium	C	UNKNOWN
	Premarin	C	UNKNOWN
	Avapro	C	UNKNOWN
	Effexor	C	UNKNOWN
	Thyroxin	C	UNKNOWN
	Metoprolol	C	UNKNOWN
	Pravachol	C	UNKNOWN

Date:10/11/04ISR Number: 4471199-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Affect Lability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Enbrel	C				UNKNOWN
	Atherosclerosis		Enbrel	C				UNKNOWN
	Back Pain		Prozac	C				UNKNOWN
	Blood Cholesterol		Azulfidine	C				UNKNOWN
	Increased		Trazodone					
	Cellulitis		Hydrochloride	C				UNKNOWN
	Cerebrovascular Accident		Prozac	C				UNKNOWN
	Chest Pain		Prozac	C				UNKNOWN
	Coronary Artery		Prilosec	C				UNKNOWN
	Restenosis		Prednisone	C				UNKNOWN
	Coronary Artery Stenosis							
	Dizziness Postural							
	Feeling Abnormal							
	Fluid Retention							

Gastrointestinal Pain
Gastrooesophageal Reflux
Disease
Groin Pain
Gynaecomastia
Hiatus Hernia
Hypertension
Myocardial Infarction
Nephrolithiasis
Post Procedural
Complication
Psoriatic Arthropathy
Rhinitis Seasonal
Therapeutic Response
Decreased

Date:10/11/04ISR Number: 4471201-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00015
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Speech Disorder		[Composition					
			Unspecified]	C		ORAL		
			Fosamax	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471202-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00710
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Osteo-Bi-Flex	C			UNKNOWN	
	Convulsion		Ecotrin	C			UNKNOWN	
	Dehydration		Diazide	C			UNKNOWN	
	Depression		Hydrea	C			UNKNOWN	
	Fall		Synthroid	C			UNKNOWN	
	Fatigue		Prinivil	C			UNKNOWN	
	Haematoma		Procardia Xl	C			UNKNOWN	
	Hypokalaemia		Compazine	C			UNKNOWN	
	Insomnia							
	Mental Status Changes							
	Nausea							
	Oedema Peripheral							
	Pyelonephritis							
	Urinary Tract Infection							

Date:10/11/04ISR Number: 4471206-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0212USA02514
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
	Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	11 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		

Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY

Date:10/11/04ISR Number: 4471207-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Activities Of Daily Living Impaired
	Blood Cholesterol Increased
	Blood Pressure Increased
	Bunion
	Cardiac Failure
	Congestive
	Constipation
	Drug Intolerance
	Fall
	Gastric Disorder
	Headache
	Hypersensitivity
	Hypertensive Heart Disease
	Injury
	Intervertebral Disc Disorder
	Joint Sprain
	Limb Discomfort

		Muscle Spasms					
		Myalgia					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nocturia		Vioxx	PS	Merck & Co., Inc	ORAL
		Onychomycosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Granuloma		Tylenol	C		
UNKNOWN							
		Renal Failure		Aspirin	C		
UNKNOWN							
		Rotator Cuff Syndrome					
		Seborrhoeic Keratosis					
		Sinusitis					
		Skin Discolouration					
		Wound Infection					

Date:10/11/04ISR Number: 4471213-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01740
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Acute Myocardial		Vicodin Tablets	C		
UNKNOWN							
		Infarction		Clonidine	C		
UNKNOWN							
		Anxiety					
		Arthralgia					
		Arthropathy					
		Atrial Fibrillation					
		Blood Triglycerides					
		Increased					
		Cardiomegaly					
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Cystitis					
		Depression					
		Dermatitis Contact					
		Diabetes Mellitus					
		Inadequate Control					
		Diabetic Nephropathy					
		Gastrooesophageal Reflux					

Disease
General Physical Health
Deterioration
Hepatic Enzyme Increased
Hepatic Steatosis
Hypercholesterolaemia
Hypertension
Joint Sprain
Migraine
Pernicious Anaemia
Sinusitis
Upper Respiratory Tract
Infection
Ventricular Fibrillation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471216-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01484
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Fatigue		[Therapy					
	Hepatic Enzyme Increased		Unspecified]	C				
UNKNOWN								
	Hepatitis C		Zoloft	C				
UNKNOWN								
	Hepatocellular Damage							

Date:10/11/04ISR Number: 4471217-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00038
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Irritability		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Pravastatin Sodium	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471218-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Balance Disorder							
	Cerebrovascular Accident							
	Lung Disorder							

Date:10/11/04ISR Number: 4471220-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00209
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure		Amitriptyline Hydrochloride	C				
Hospitalization -			Amitriptyline Hydrochloride	C				
Initial or Prolonged			Penicillin (Unspecified)	C				

Date:10/11/04ISR Number: 4471222-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:10/11/04ISR Number: 4471223-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00062
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Rofecoxib	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471224-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471226-6Report Type:Expedited (15-DaCompany Report #AR-MERCK-0410ARG00002
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	C		ORAL		
			Prednisone	C		ORAL		
			Prednisone	C		ORAL		

Date:10/11/04ISR Number: 4471227-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0212USA00351
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
Hospitalization -	Menorrhagia		Vioxx	SS	Merck & Co., Inc	ORAL	1 WK	
Initial or Prolonged	Uterine Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1 WK	
Disability			Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
			[Therapy Unspecified]	C		UNKNOWN		
			[Therapy Unspecified]	C		UNKNOWN		
			Axid	C		UNKNOWN		

Date:10/11/04ISR Number: 4471229-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00056
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 MON
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	1 MON
			Enalapril Maleate And Hydrochlorothiazide	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	

Date:10/11/04ISR Number: 4471230-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00020
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Amlodipine Besylate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Bromazepam	C			UNKNOWN	
			Calcium Carbonate	C			UNKNOWN	
			Cyanocobalamin And Pyridoxine And Thiamine	C			UNKNOWN	
			Teriparatide	C			UNKNOWN	
			Etoricoxib	C			UNKNOWN	
			Hydroxychloroquine Sulfate	C			UNKNOWN	

			Leflunomide	C		UNKNOWN
			Methotrexate	C		UNKNOWN
			Omeprazole	C		UNKNOWN
			Prednisone	C		UNKNOWN

Date:10/11/04ISR Number: 4471234-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00045
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gait Disturbance		Alendronate Sodium	C		ORAL		
	Insomnia		Aspirin And Dipyridamole	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Blood Thinner (Unspecified)	C			UNKNOWN	

Date:10/11/04ISR Number: 4471235-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00014
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged			Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
Disability			Enalapril Maleate	C		ORAL		

Date:10/11/04ISR Number: 4471236-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471237-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00254
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Apnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise		Fluimucil	C				
	Tachycardia		Seretide	C				
			Singulair	C		ORAL		

Date:10/11/04ISR Number: 4471239-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00021
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Syncope		[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				
			Zyloric	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471240-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00164
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope		Aspirin	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471241-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471243-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00236
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neck Mass							
	Palpitations							

Date:10/11/04ISR Number: 4471244-8Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00017
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations							

Date:10/11/04ISR Number: 4471247-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00106
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471248-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00018
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Diclofenac	C		ORAL		
			Methotrexate	C		ORAL		
			Spironolactone	C		ORAL		
			Naproxen	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/11/04ISR Number: 4471249-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00040
Age:77 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Burns Third Degree
	Skin Graft

	Transient Ischaemic Attack					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Calcium (Unspecified)	C		
UNKNOWN						
			Escin	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						
			Ginkgo Biloba Extract	C		
UNKNOWN						
			Melilot And Rutin	C		
UNKNOWN						

Date:10/11/04ISR Number: 4471251-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00111
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Difficulty In Walking		[Therapy			
	Disorientation		Unspecified]	C		
UNKNOWN						

Date:10/11/04ISR Number: 4471257-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00108
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
	Vertigo					

Date:10/11/04ISR Number: 4471258-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00011
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Aphasia		Vioxx	PS	Merck & Co., Inc			3 MON
Initial or Prolonged UNKNOWN	Migraine		Aspirin	C				
			Sumatriptan Succinate	C				

Date:10/11/04ISR Number: 4471260-6Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471261-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00035
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening UNKNOWN			Albuterol	C				
Hospitalization - UNKNOWN			Atorvastatin Calcium	C				
Initial or Prolonged UNKNOWN			Dipyridamole	C				
Disability UNKNOWN			Tolbutamide	C				
			Zopiclone	C				
			Insulin Glargine	C				

				Levothyroxine Sodium	C		
UNKNOWN							
				Prednisolone	C		
UNKNOWN							

Date:10/11/04ISR Number: 4471262-XReport Type:Expedited (15-DaCompany Report #KR-MERCK-0410KOR00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aceclofenac	C		ORAL	1	WK
			Aceclofenac	C		ORAL		

Date:10/11/04ISR Number: 4471264-3Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00060
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Albuterol Sulfate And Ipratropium Bromide	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Beclomethasone Dipropionate	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471267-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Chronic Obstructive		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL		

	Pulmonary Disease		Unspecified]	C		
UNKNOWN						
	Cough					
	Depression					
	Eye Pain					
	Hypertonic Bladder					
	Oedema					
	Oedema Peripheral					

Date:10/11/04ISR Number: 4471268-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Initial or Prolonged	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
2 YR						
	Vision Blurred					

Date:10/11/04ISR Number: 4471270-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00167
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Synthroid	C		
UNKNOWN						
Initial or Prolonged	Pericarditis					
Disability	Pneumonia					
	Tachycardia					

Date:10/11/04ISR Number: 4471273-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00062
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471274-6Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/11/04ISR Number: 4471276-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00033
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Bendroflumethiazide	C			UNKNOWN	
			Zocor	C		ORAL		

Date:10/11/04ISR Number: 4471279-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00063
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Duodenal Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Albuterol	C			RESPIRATORY (INHALATION)	

	Haematemesis		Furosemide	C		ORAL
			Salmeterol	C		
RESPIRATORY						
(INHALATION)						
			Lactulose	C		ORAL
			Mebeverine Hydrochloride	C		ORAL

Date:10/11/04ISR Number: 4471280-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00232
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy					
Hospitalization - UNKNOWN			Unspecified]	C				
Initial or Prolonged			[Therapy					
Disability UNKNOWN			Unspecified]	C				

Date:10/11/04ISR Number: 4471281-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00042
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	464	DAY
	Pain		Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471282-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00401
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Norvasc	C				
UNKNOWN								
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability			Prevacid	C				
UNKNOWN								
			Altace	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471283-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00164
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								
Life-Threatening								

Date:10/11/04ISR Number: 4471284-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00137
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471286-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00172
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				
UNKNOWN								
			Sotalol					

			Hydrochloride	C		
UNKNOWN						
			Atorvastatin Calcium	C		
UNKNOWN						

Date:10/11/04ISR Number: 4471287-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00407
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471288-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Dizziness Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471289-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00234
Age:69 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1735 DAY	
	Cerebrovascular Accident		Atenolol	C			UNKNOWN	
	Dyspnoea		Lipitor	C			UNKNOWN	
	Vascular Calcification		Dyazide	C			UNKNOWN	
	Visual Acuity Reduced		Synthroid	C			UNKNOWN	

Date:10/11/04ISR Number: 4471290-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged	Oedema Peripheral		Celebrex	C			UNKNOWN	

Date:10/11/04ISR Number: 4471291-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00345
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471293-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00559
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Transient Ischaemic Citrical C
UNKNOWN
Other Attack Diovan C
UNKNOWN
Plavix C
UNKNOWN

Date:10/11/04ISR Number: 4471294-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471295-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471296-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00458
Age:51 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Xanax	C			UNKNOWN	
			Benadryl	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Humalog	C			UNKNOWN	

Date:10/11/04ISR Number: 4471297-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Arrest							
	Cardiac Disorder							
	Organ Failure							
	Pain							
	Polytraumatism							
	Vascular Injury							

Date:10/11/04ISR Number: 4471299-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00725
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Celebrex	C			UNKNOWN	
Initial or Prolonged								

Date:10/11/04ISR Number: 4471300-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00739
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Lotrel	C				
UNKNOWN								

Date:10/11/04ISR Number: 4471301-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

Date:10/11/04ISR Number: 4471302-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471303-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00396
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prednisone	C				
	Blood Pressure Increased							
	Bundle Branch Block Left							

Date:10/11/04ISR Number: 4471304-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00331
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Crohn'S Disease							
	Dyspnoea Exertional							
	Gastrointestinal Haemorrhage							
	Ileal Ulcer							
	Pulmonary Hypertension							

Date:10/11/04ISR Number: 4471307-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00461
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/11/04ISR Number: 4471308-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00411
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
3 MON						
			Albuterol	C		
RESPIRATORY						
(INHALATION)						
			Diovan	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						

Date:10/11/04ISR Number: 4471309-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00831
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Initial or Prolonged						
Other						

Date:10/11/04ISR Number: 4471312-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00742
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR						
Initial or Prolonged	Vascular Bypass Graft		[Therapy Unspecified]	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/11/04ISR Number: 4471313-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Mouth Injury		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
			Atenolol	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Metformin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Actos	C			UNKNOWN	

Date:10/11/04ISR Number: 4471314-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00556
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Hydrochlorothiazide	C			UNKNOWN	
Initial or Prolonged			Triamterene	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

Date:10/11/04ISR Number: 4471315-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00447
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Ulcer Haemorrhage

Date:10/11/04ISR Number: 4471316-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Tachycardia							

Date:10/11/04ISR Number: 4471318-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/11/04ISR Number: 4471319-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02726
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Tylenol	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	
			Duoneb	C			RESPIRATORY (INHALATION)	
			Lipitor	C			UNKNOWN	
			Pulmicort	C			UNKNOWN	
			Calcium					

	(Unspecified)	C
UNKNOWN		
	Cipro	C
UNKNOWN		
	Enalapril Maleate	C
UNKNOWN		
	Lasix (Furosemide)	C
UNKNOWN		
	Accolate	C
UNKNOWN		
	Lantus	C
UNKNOWN		
	Humalog	C
UNKNOWN		
	Claritin	C
UNKNOWN		
	Metformin	C
UNKNOWN		
	Oxygen	C
UNKNOWN		
	Paxil	C
UNKNOWN		
	Prednisone	C
UNKNOWN		

Date:10/11/04ISR Number: 4471322-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00827
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:10/11/04ISR Number: 4471324-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage							

Date:10/11/04ISR Number: 4471326-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00840
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		902 DAY
Hospitalization -	Coronary Artery Occlusion		Vicodin Tablets	C				UNKNOWN
Initial or Prolonged			Xanax	C				UNKNOWN
Disability			Wellbutrin	C				UNKNOWN
			Zocor	C				UNKNOWN
			Niaspan	C				UNKNOWN
			Seroquel	C				UNKNOWN
			Aciphex	C				UNKNOWN

Date:10/11/04ISR Number: 4471327-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00005
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Transient Ischaemic Attack		Aspirin	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Glimepiride	C		ORAL		2 YR
			Propranolol Hydrochloride	C		ORAL		

Date:10/11/04ISR Number: 4471334-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00126
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471607-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00781
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Adverse Event Aortic Aneurysm Aortic Occlusion Asthenia Breath Sounds Decreased Cardiomyopathy Chest Pain Crepitations Device Failure Dizziness Dyspepsia Dyspnoea Erectile Dysfunction Headache Hypertension Hypoaesthesia Ileus Intermittent Claudication Limb Discomfort Muscle Spasms Myocardial Infarction Peripheral Vascular Disorder Polytraumatism Post Procedural Complication Renal Tubular Necrosis Treatment Noncompliance Vision Blurred	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471616-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Distension Abdominal Pain Acute Sinusitis Adverse Event Arthralgia Barrett'S Oesophagus

Benign Duodenal Neoplasm
Blood Pressure Increased
Bronchospasm
Brunner'S Gland
Hyperplasia
Chest Pain
Chills
Costochondritis
Dermatitis Allergic
Gastrointestinal Pain
Gastrooesophageal Reflux
Disease
Headache
Helicobacter Infection
Lipids Increased
Liver Function Test
Abnormal

		Neck Pain					
		Otitis Media					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Pharyngitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Pyrexia		Norvasc	C		
UNKNOWN							
		Rhinitis Allergic		Pulmicort	C		
UNKNOWN							
		Sensation Of Pressure		Celebrex	C		
UNKNOWN							
		Sinus Congestion		Ultram	C		
UNKNOWN							
		Sinusitis		Estradiol	C		
UNKNOWN							
		Tendonitis		Maxzide	C		
UNKNOWN							
		Upper Respiratory Tract		Prevacid	C		
UNKNOWN							
		Infection		Singulair	C		
UNKNOWN							

Date:10/12/04ISR Number: 4471622-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01745
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Lotrel	C		
UNKNOWN							
		Coronary Artery Disease		Aspirin	C		
UNKNOWN							
		Coronary Artery Occlusion		Lipitor	C		
UNKNOWN							
		Depression		Zyrtec	C		
UNKNOWN							
		Emotional Distress		Foltx	C		
UNKNOWN							
		General Physical Health		Clarinex	C		
UNKNOWN							

	Deterioration		Prozac	C		
UNKNOWN						
	Hernia		Furosemide	C		
UNKNOWN						
	Myocardial Infarction		Levaquin	C		
UNKNOWN						
	Oedema Peripheral		Potassium			
	Sinus Disorder		(Unspecified)	C		
UNKNOWN						

Date:10/12/04ISR Number: 4471628-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction					
Initial or Prolonged						

Date:10/12/04ISR Number: 4471629-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00157
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Bromazepam	C		ORAL
			Cilostazol	C		ORAL
			Simvastatin	C		
UNKNOWN						
			Enalapril Maleate	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471632-XReport Type:Expedited (15-DaCompany Report #US-MERCK-00080818
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract	Health	Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
		Professional	Celebrex	SS		ORAL	30 DAY	
			Celebrex	SS		ORAL	30 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
			Chondroitin	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Isosorbide Dinitrate	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Pravastatin Sodium	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

Date:10/12/04ISR Number: 4471633-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00212
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471634-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00091
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL	130	DAY

Date:10/12/04ISR Number: 4471654-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01464
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Other	Congestive	Professional	Wellbutrin	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Ativan	C			UNKNOWN	

Date:10/12/04ISR Number: 4471655-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00180
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL	261	DAY
Hospitalization - Initial or Prolonged	Ventricular Hypertrophy		Atenolol	C		ORAL	UNKNOWN	
			Dorzolamide Hydrochloride And Timolol Maleate	C			UNKNOWN	
			Irbesartan	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471656-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00202
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:10/12/04ISR Number: 4471657-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00146
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ovarian Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Hospitalization -			Epoetin Alfa	C				UNKNOWN
Initial or Prolonged			Morphine	C				UNKNOWN

Date:10/12/04ISR Number: 4471658-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01296
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Body Temperature Increased		Clonidine	C		ORAL		
	Carotid Artery Stenosis		Zocor	C		ORAL		
	Cerebral Artery Occlusion		Flomax (Tamsulosin Hydrochloride)	C		ORAL		
	Cerebrovascular Accident		Zocor	C		ORAL		
	Cough		Toprol Xl Tablets	C		ORAL		
	Diastolic Dysfunction							
	Dilatation Atrial							
	Emotional Distress							
	Insomnia							
	Lacunar Infarction							
	Mitral Valve Calcification							
	Mitral Valve Incompetence							

Nocturia
Palpitations
Rhinorrhoea
Right Ventricular
Systolic Pressure
Decreased
Sinusitis
Supraventricular
Extrasystoles
Urinary Incontinence
Ventricular Extrasystoles
Ventricular Hypertrophy
Weight Increased

Date:10/12/04ISR Number: 4471659-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00332
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Soma	C				
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471660-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00714
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471662-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00671
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Fosamax	C			UNKNOWN	
	Dyspnoea		Norvasc	C			UNKNOWN	
	Fall		Zoloft	C			UNKNOWN	
	Fatigue		Citracal	C			UNKNOWN	
	Throat Tightness							

Date:10/12/04ISR Number: 4471664-1Report Type:Expedited (15-DaCompany Report #CO-MERCK-0410COL00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:10/12/04ISR Number: 4471665-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00224
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY

Date:10/12/04ISR Number: 4471666-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00024
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:10/12/04ISR Number: 4471667-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Dizziness Dyspnoea General Physical Health Deterioration Hypertension Lung Disorder Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471668-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00286
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		65 DAY
Initial or Prolonged			Amiodarone Hydrochloride	C				
UNKNOWN								

Date:10/12/04ISR Number: 4471669-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged	Cardiac Disorder							
	Cerebrovascular Accident							

Date:10/12/04ISR Number: 4471670-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00176
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Injury		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
	Pain							
	Perforated Ulcer							

Date:10/12/04ISR Number: 4471671-9Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:10/12/04ISR Number: 4471672-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depressed Mood		Aspirin	C				
UNKNOWN								
	Diarrhoea							
	Malaise							
	Myocardial Infarction							
	Tremor							

Date:10/12/04ISR Number: 4471673-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ulcer		Prilosec	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/12/04ISR Number: 4471674-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00119
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Captopril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471675-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00979
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Oedema Peripheral		Premarin	C			UNKNOWN	
			Amaryl	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Glucophage	C			UNKNOWN	

Date:10/12/04ISR Number: 4471676-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00864
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471677-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471678-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00865
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		

	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/12/04ISR Number: 4471681-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471682-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00860
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	32 DAY	
Hospitalization -	Congestive		Bumetanide	C			UNKNOWN	
Initial or Prolonged	Difficulty In Walking		Prempro	C			UNKNOWN	
Disability	Dizziness		Cozaar	C		ORAL		
	Tremor		Toprol Xl Tablets	C			UNKNOWN	

Date:10/12/04ISR Number: 4471683-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471684-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00866
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension							
Initial or Prolonged	Muscle Injury							
	Oedema Peripheral							

Date:10/12/04ISR Number: 4471685-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00329
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged								
Other								

Date:10/12/04ISR Number: 4471688-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
Initial or Prolonged	Hypertension		Levoxyl	C				
UNKNOWN								
Disability								

Date:10/12/04ISR Number: 4471689-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00862
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Visual Acuity Reduced		Prevacid	C				
UNKNOWN								

Disability Ativan C
UNKNOWN

Date:10/12/04ISR Number: 4471690-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00328
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Darvocet-N	C				
UNKNOWN								
Initial or Prolonged			Fosamax	C		ORAL		
Disability			Zoloft	C				
UNKNOWN								
Other			Cardizem	C				
UNKNOWN								
			Primidone	C				
UNKNOWN								

Date:10/12/04ISR Number: 4471691-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Tylenol	C				
UNKNOWN								
			Percocet	C				
UNKNOWN								
			Inderal	C				
UNKNOWN								

Date:10/12/04ISR Number: 4471692-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01076
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471693-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01072
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
Other			Lipitor	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Colchicine	C			UNKNOWN	
			Furosemide	C			UNKNOWN	

Date:10/12/04ISR Number: 4471696-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01045
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Prevacid	C			UNKNOWN	

Date:10/12/04ISR Number: 4471698-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01162
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Aspirin	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Dipyridamole	C		
UNKNOWN						
			Indocin (Indomethacin)	C		
UNKNOWN						
			Isosorbide	C		
UNKNOWN						
			Triamterene	C		
UNKNOWN						
			Mevacor	C		ORAL
			Naproxen	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						
			Quinidine	C		
UNKNOWN						

Date:10/12/04ISR Number: 4471700-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01157
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Sudden Cardiac Death					
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471701-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01193
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Amiodarone Hydrochloride	C				
UNKNOWN								
			Zocor	C		ORAL		

Date:10/12/04ISR Number: 4471702-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01191
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:10/12/04ISR Number: 4471729-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00157
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471735-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Depression							
	Tinnitus							

Date:10/12/04ISR Number: 4471736-1Report Type:Expedited (15-DaCompany Report #GR-MERCK-0410GRC00012
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			Simvastatin	C		ORAL		
			Aspirin	C		ORAL		

Date:10/12/04ISR Number: 4471737-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00281
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flupirtine Maleate	C				
UNKNOWN								
Other			Tilidine Hydrochloride And Naloxone Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4471738-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00282
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471740-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00170
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471741-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00255
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4471742-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00274
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		[Therapy					
	Palpitations		Unspecified]	C				
UNKNOWN								

Date:10/12/04ISR Number: 4471763-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00978
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
Disability	Difficulty In Walking Muscle Spasms Musculoskeletal Stiffness Oedema Peripheral Pain In Extremity Vasodilatation						

Date:10/12/04ISR Number: 4471782-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00148
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	843 DAY	
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Metoprolol Tartrate	C		ORAL		

Date:10/12/04ISR Number: 4471818-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00235
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Allegra	C			UNKNOWN	
			Crestor	C			UNKNOWN	

			Zoloft	C		
UNKNOWN						
			Evista	C		
UNKNOWN						

Date:10/12/04ISR Number: 4472109-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00086
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Betamethasone	C		
UNKNOWN						
			Deflazacort	C		
UNKNOWN						

Date:10/12/04ISR Number: 4472112-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00084
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Transient Ischaemic					
	Attack					

Date:10/12/04ISR Number: 4472114-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris					
	Arteriosclerosis					
	Asthma					
	Benign Prostatic					
	Hyperplasia					
	Blood Cholesterol					
	Increased					

Cerebrovascular Accident
Convulsion
Gastrooesophageal Reflux
Disease
Genital Rash
Hydronephrosis
Hypertension
Hypertonic Bladder
Nocturia
Nodule
Penile Neoplasm
Penile Vein Thrombosis
Rash
Refusal Of Examination

Date:10/12/04ISR Number: 4472128-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00089
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1001 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00640
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN	Adrenal Cyst		Xanax	C				
UNKNOWN	Adverse Event		Aspirin	C				
UNKNOWN	Arterial Occlusive		Cipro	C				
UNKNOWN	Disease		Propulsid	C				
UNKNOWN	Arthralgia		Premarin	C				
UNKNOWN	Back Pain		Detrol	C				
UNKNOWN	Blood Triglycerides		Lasix (Furosemide)	C				
UNKNOWN	Increased		Maxzide	C				
UNKNOWN	Cardiac Failure		Prevacid	C				
UNKNOWN	Congestive		Claritin-D	C				
UNKNOWN	Cardiomegaly		Nitropatch	C				
UNKNOWN	Cellulitis		Prilosec	C				
UNKNOWN	Chest Pain							
	Cholecystitis							
	Cholelithiasis							
	Depression							
	Dilatation Atrial							
	Dizziness							
	Dyspnoea							
	Flatulence							
	Glucose Tolerance							
	Impaired							
	Haemorrhoids							
	Hepatic Steatosis							
	Incontinence							
	Mitral Valve Incompetence							
	Myocardial Infarction							

Nasopharyngitis
Osteoarthritis
Productive Cough
Vaginal Infection
Ventricular Hypertrophy

Date:10/12/04ISR Number: 4472134-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00229
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diplegia		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Other			Levothyroxine Sodium	C			UNKNOWN	

Date:10/12/04ISR Number: 4472135-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00226
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion Headache Hypotension Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472137-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00235
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		1150 DAY
Hospitalization - Initial or Prolonged	Coronary Artery Disease Coronary Artery Stenosis							

Date:10/12/04ISR Number: 4472138-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00009
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		DAY

Date:10/12/04ISR Number: 4472152-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00053
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Circulatory Collapse Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472153-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA00479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472154-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00317
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eructation		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL	12	DAY
	Palpitations		Nexium	C			UNKNOWN	
	Tachycardia		Insulin	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Inderal	C			UNKNOWN	

Date:10/12/04ISR Number: 4472155-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00534
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	7	YR
Hospitalization -	Cardiac Failure		Methadone Hcl	C			UNKNOWN	
Initial or Prolonged	Congestive		Prilosec	C			UNKNOWN	
Other	Circulatory Collapse							
	Dyspnoea							
	International Normalised							
	Ratio Increased							
	Peripheral Embolism							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472161-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00075
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Life-Threatening	Gastric Ulcer Perforation		[Therapy					
Hospitalization -	Guillain-Barre Syndrome		Unspecified]	C				
UNKNOWN								
Initial or Prolonged	Hallucination		Insulin	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472162-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00083
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	0	YR
Initial or Prolonged	Myocardial Ischaemia							
Other								

Date:10/12/04ISR Number: 4472164-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Disability	Atherosclerosis		Xanax	C				
UNKNOWN								
	Haematoma		Aspirin	C				
UNKNOWN								
	Mitral Valve Incompetence		Lipitor	C				
UNKNOWN								
	Myocardial Infarction		Wellbutrin	C				
UNKNOWN								
	Panic Disorder		Celebrex	C				
UNKNOWN							4	DAY

	Tricuspid Valve		Plavix	C		
UNKNOWN						
	Incompetence		Folic Acid	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Lopressor	C		
UNKNOWN						
			Pyridoxine	C		
UNKNOWN						

Date:10/12/04ISR Number: 4472165-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00080
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dyspnoea		Avapro	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						

Date:10/12/04ISR Number: 4472169-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00093
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
	Pneumonia					
	Vomiting					

Date:10/12/04ISR Number: 4472170-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472173-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00298
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472174-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00194
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Tendonitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Enoxaparin Sodium	C				
PARENTERAL								

Date:10/12/04ISR Number: 4472175-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00239
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Minimal Lesion							

Date:10/12/04ISR Number: 4472177-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00202
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472181-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00001
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY						
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY						
	Hyperhidrosis					
	Menopause					
	Mouth Haemorrhage					
	Tachycardia					

Date:10/12/04ISR Number: 4472187-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00552
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aortic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Disorder		[Therapy			
Initial or Prolonged	Chest Pain		Unspecified]	C		
UNKNOWN						
Disability			Calcium			
Other			(Unspecified)	C		
UNKNOWN						
			Vitamin E	C		
UNKNOWN						
			Fish Oil			
			(Unspecified)	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472188-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00553
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		MON

Date:10/12/04ISR Number: 4472189-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00561
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

UNKNOWN

Date:10/12/04ISR Number: 4472192-XReport Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00027
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			4 YR
			Sulfasalazine	C				

UNKNOWN

Date:10/12/04ISR Number: 4472193-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00044
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased							
	Cardiac Valve Disease							
	Hypertension							
	Tachycardia							

Date:10/12/04ISR Number: 4472194-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472199-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00609
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Pain		[Therapy					
	Dyspnoea		Unspecified]	C				
UNKNOWN								
	Myocardial Infarction		Ambien	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472200-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00540
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Sarcoidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	C		ORAL		
			Lipitor	C				
UNKNOWN								

Prednisone C
UNKNOWN

Date:10/12/04ISR Number: 4472203-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00541
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged	Dyspnoea							
Other	Pulmonary Embolism							

Date:10/12/04ISR Number: 4472204-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00743
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Buspirone Hydrochloride	C				
	Blood Glucose Increased							
	Blood Pressure Increased							

UNKNOWN

Date:10/12/04ISR Number: 4472205-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472206-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00858
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					

Initial or Prolonged				Unspecified]	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							

Date:10/12/04ISR Number: 4472209-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00705
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Pressure Increased		Percocet	C				
UNKNOWN								
Initial or Prolonged	Dysgraphia		Lotrel	C				
UNKNOWN								
Disability	Headache		Ambien	C				
UNKNOWN								
	Intracranial Aneurysm		Duragesic	C				
UNKNOWN								
	Obsessive-Compulsive Disorder							

Date:10/12/04ISR Number: 4472210-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472212-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00688
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:10/12/04ISR Number: 4472214-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00662
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472215-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00661
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472217-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00672
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Dizziness		Vioxx Accupril	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								
Other	Dysstasia Feeling Hot Hyperhidrosis Pallor Tremor							

Date:10/12/04ISR Number: 4472218-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hernia		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
Disability			Xanax	C				
UNKNOWN								
Other			Zestril	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472221-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00545
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pericarditis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472222-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00678
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			Allegra	C				
UNKNOWN								
Disability			Metoprolol	C				
UNKNOWN								
			Bextra	C				
UNKNOWN								
			Crestor	C				
UNKNOWN								
			Niaspan	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472224-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:10/12/04ISR Number: 4472225-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00934
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Date:10/12/04ISR Number: 4472226-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00857
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Calcium (Unspecified)	C				
			Soma	C				
			Cardizem	C				
			Zocor	C				
			Zestril	C				
			Toprol Xl Tablets	C				

Date:10/12/04ISR Number: 4472228-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00702
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bone Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Death		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Hepatic Neoplasm Malignant Jaundice							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472229-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00943
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Paraesthesia		Percocet	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Buspar	C			UNKNOWN	
			Zocor	C		ORAL		
			Trifluoperazine Hydrochloride	C			UNKNOWN	
			Azmacort	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Etodolac	C			UNKNOWN	
			Atrovent	C			UNKNOWN	
			Niacin	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Propranolol Hydrochloride	C			UNKNOWN	

Date:10/12/04ISR Number: 4472231-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00955
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Disability

Date:10/12/04ISR Number: 4472232-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00944
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			Digoxin	C				
UNKNOWN								
Disability			Nexium	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Altace	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472239-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01002
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
6 WK								
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
3 WK								
			Glucosamine	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Aleve	C				
UNKNOWN								
			Evista	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472240-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01004
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Albuterol	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Trusopt	C				
UNKNOWN								
Disability			Premarin	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472242-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01021
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							
	Quadruple Vessel Bypass Graft							

Date:10/12/04ISR Number: 4472244-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01023
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Darvocet-N	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Combivent	C				
UNKNOWN								
Disability			Allegra	C				
UNKNOWN								
			Guaifenesin	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472245-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00950
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability				C		ORAL		

Date:10/12/04ISR Number: 4472246-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01189
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucotrol	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472248-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00802
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree
Other	Chills
	Electrocardiogram St Segment Abnormal
	Global Amnesia

		Hypertension					
		Injury					
		Ischaemic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
109	DAY						
		Nausea		Estrace	C		
UNKNOWN							
		Transient Ischaemic		Lasix (Furosemide)	C		
UNKNOWN							
		Attack		Synthroid	C		
UNKNOWN							
		Urinary Tract Infection		Potassium (Unspecified)	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							

Date:10/12/04ISR Number: 4472252-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01186
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Pacemaker					
Initial or Prolonged	Insertion					
Disability	Cerebrovascular Accident					

Date:10/12/04ISR Number: 4472253-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01185
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -						
Initial or Prolonged						

Date:10/12/04ISR Number: 4472254-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01033
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472255-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01163
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472256-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01187
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Embolism							
Disability	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472257-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:10/12/04ISR Number: 4472258-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01190
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C				
Initial or Prolonged Disability			Zocor	C		ORAL		

Date:10/12/04ISR Number: 4472259-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01042
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/12/04ISR Number: 4472261-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:10/12/04ISR Number: 4472262-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Cerebrovascular Accident							

Date:10/12/04ISR Number: 4472263-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Increased							

Date:10/12/04ISR Number: 4472264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01349
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/12/04ISR Number: 4472265-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472266-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01196
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472267-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:10/12/04ISR Number: 4472271-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00537
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage		Neurontin	C				
UNKNOWN								
Disability	Visual Field Defect		Vitamins (Unspecified)	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								

Date:10/12/04ISR Number: 4472278-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00027
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fluindione	SS		ORAL		
	Aspartate Aminotransferase							

		Increased					
		Prothrombin Level					
		Decreased					

Date:10/12/04ISR Number: 4472308-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01069
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							

Date:10/12/04ISR Number: 4472683-1Report Type:Direct Company Report #CTU 229269
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypovolaemia		Lisinopril	PS		ORAL	10 MG PO	
Initial or Prolonged	Oedema						DAILY	
	Pain		Rofecoxib	SS		ORAL	25 MG PO BID	
	Renal Disorder		Paxil	C				
	Renal Failure Acute		Metoprolol	C				
			Dilaudid	C				
			Lasix	C				
			Lovenox	C				
			Azithromycin	C				
			Vancomycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472712-5Report Type:Direct Company Report #CTU 229449
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Chest Pain		Vioxx 25mg Tablet					
Required	Condition Aggravated		Merck & Co	PS	Merck & Co		1 DAILY	
Intervention to	Pain		Effexor	C				
Prevent Permanent			Abilify	C				
Impairment/Damage			Klonopin	C				
			Elavil	C				
			Gabitril	C				
			Ultram	C				
			Vioxx	C				

Date:10/12/04ISR Number: 4472717-4Report Type:Direct Company Report #CTU 229451
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Irregular		Vioxx 25mg Merck	PS	Merck	ORAL	ONE DAILY	
Initial or Prolonged	Hypertension							
ORAL								

Date:10/12/04ISR Number: 4472719-8Report Type:Direct Company Report #CTU 229452
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Gastrooesophageal Reflux		Vioxx 25 Mg Tab					
Intervention to	Disease		-Me-	PS	Me		1 PER DAY	
Prevent Permanent	Heart Rate Increased							
Impairment/Damage								

Date:10/12/04ISR Number: 4472758-7Report Type:Direct Company Report #CTU 229441
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - 1 PER DAY Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx 25 Mg Usnh Okinawa	PS	Usnh Okinawa			

Date:10/12/04ISR Number: 4472762-9Report Type:Direct Company Report #CTU 229446
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS				

Date:10/12/04ISR Number: 4472764-2Report Type:Direct Company Report #CTU 229425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx 25mg	PS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472770-8Report Type:Direct Company Report #CTU 229431
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx 50 Mg	PS			ONE DAILY	
Initial or Prolonged	Cardiac Failure		Vioxx 25 Mg	SS			ONE DAILY	
Required Intervention to Prevent Permanent Impairment/Damage	Congestive Coronary Artery Disease Fatigue Hypertension Loss Of Consciousness							

Date:10/12/04ISR Number: 4472782-4Report Type:Direct Company Report #CTU 229412
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx 25mg Merck	PS	Merck	ORAL	TABLET ORAL	
	Sudden Death							

Date:10/12/04ISR Number: 4472786-1Report Type:Direct Company Report #CTU 229420
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Micturition Urgency		Vioxx	PS				
	Pollakiuria		Cortisone Injection	C				
	Urge Incontinence		Bextra	C				

Date:10/12/04ISR Number: 4472787-3Report Type:Direct Company Report #CTU 229421
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 50 Mg Tab					
Required	Dizziness		Merck And Co. Inc	PS	Merck And Co. Inc	ORAL	1 TAB DAILY	

Intervention to Fear
ORAL
Prevent Permanent Vision Blurred
Impairment/Damage

Date:10/12/04ISR Number: 4472788-5Report Type:Direct Company Report #CTU 229422
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx 50 Mg	PS		ORAL	1 TABLET 2 A	Other
							DAY ORAL	

Date:10/12/04ISR Number: 4472789-7Report Type:Direct Company Report #CTU 229423
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder		Vioxx	PS				
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4472791-5Report Type:Direct Company Report #CTU 229402
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG ONCE	
	Perforation						DAILY ORAL	
	Iatrogenic Injury							
	Myocardial Infarction							
	Procedural Complication							

Date:10/12/04ISR Number: 4472795-2Report Type:Direct Company Report #CTU 229405
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx (-Rofexcoxib-) 25 Mg Merck & Co., Inc.	PS	Merck & Co., Inc	ORAL	25 MG 1 PER DAY ORAL	
Hospitalization - Initial or Prolonged								
Disability								

Date:10/12/04ISR Number: 4472798-8Report Type:Direct Company Report #CTU 229408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure		Vioxx 50 Mg	PS		ORAL	50 MG DAILY ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Inadequately Controlled							

Date:10/12/04ISR Number: 4472850-7Report Type:Direct Company Report #CTU 229394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx 50mg	PS		ORAL	1 TABLET PER DAY ORAL	

Date:10/12/04ISR Number: 4472857-XReport Type:Direct Company Report #CTU 229399
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Headache		Vioxx 25 Mg	PS			1	1
	Stomach Discomfort							

Date:10/12/04ISR Number: 4472858-1Report Type:Direct Company Report #CTU 229400
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg	PS				

Date:10/12/04ISR Number: 4472859-3Report Type:Direct Company Report #CTU 229217
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY ORAL	
			Neurontin	C				

			Trazadone	C		
			Lexipro	C		
			Meltrexone	C		
			Privigil	C		

Date:10/12/04ISR Number: 4472873-8Report Type:Direct Company Report #CTU 229335
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Upper Gastrointestinal Haemorrhage		Rofecoxib (Vioxx) 25 Mg Qd	PS				
			Clopidogrel 75 Mg Qd	SS				
			Coated Asa	SS				

Date:10/12/04ISR Number: 4472900-8Report Type:Direct Company Report #CTU 229392
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx 25 Mg	PS		ORAL	1 CD EVERY	
	Palpitations						DAY ORAL	

Date:10/12/04ISR Number: 4474307-6Report Type:Direct Company Report #CTU 229434
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS		ORAL	25 MG DAILY BY MOUTH	
	Chest Pain							
Required Intervention to Prevent Permanent Impairment/Damage	Coronary Artery Occlusion		Folic Acid	C				
			Mevacor	C				
			Trental	C				
			Imdur	C				
			Toprol-Xl	C				
			Vit B6	C				
			Fish Oil	C				

Vit C	C
Vit E	C

Date:10/13/04ISR Number: 4472927-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00713
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
Other	Blood Pressure Increased
	Cervicobrachial Syndrome
	Condition Aggravated
	Convulsion
	Depression
	Headache
	Intervertebral Disc Protrusion
	Lumbar Radiculopathy
	Memory Impairment
	Nausea
	Post Procedural Complication
	Refusal Of Examination

	Rotator Cuff Syndrome						
	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Celexa	C				UNKNOWN
			Klonopin	C				UNKNOWN
			Prilosec	C				UNKNOWN

Date:10/13/04ISR Number: 4472932-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00149
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1 YR	Coronary	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Revascularisation							
	Dizziness							
	Myocardial Infarction							
	Palpitations							
	Vomiting							

Date:10/13/04ISR Number: 4472934-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00155
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Flushing		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472936-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00156
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Aspirin	C				UNKNOWN

	Paraesthesia		Bromazepam	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Propatyl Nitrate	C		
SUBLINGUAL						
			Propranolol Hydrochloride	C		
UNKNOWN						

Date:10/13/04ISR Number: 4472937-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00168
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholestasis	Health	Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
	Hepatocellular Damage	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
			Acetyldigoxin	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Enalapril Maleate And Hydrochlorothiazide	C		ORAL		
			Glimepiride	C		ORAL		
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL		
			Pantoprazole Sodium	C		ORAL		

			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C	ORAL

Date:10/13/04ISR Number: 4472941-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00092
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Digesic	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:10/13/04ISR Number: 4472956-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00182
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472957-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident Visual Field Defect		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472961-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00181
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Loss Of Consciousness	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Palpitations		Norvasc	C			UNKNOWN	
			Avalide	C			UNKNOWN	
			Paxil	C			UNKNOWN	

Date:10/13/04ISR Number: 4472962-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00018
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		[Therapy					
	Diabetes Mellitus		Unspecified]	C			UNKNOWN	
	Fatigue		[Therapy					
	Kidney Infection		Unspecified]	C			UNKNOWN	
	Migraine							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4472964-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00318
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472968-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00302
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Migraine		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472969-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00085
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction		Lipex	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			Cartia (Aspirin)	C			UNKNOWN	
			Arava	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Losec (Omeprazole)	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

Date:10/13/04ISR Number: 4472982-3Report Type:Expedited (15-DaCompany Report #CO-MERCK-0410COL00013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:10/13/04ISR Number: 4472983-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00304
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472984-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Omeprazole	C			UNKNOWN	
			Tolperisone Hydrochloride	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4472986-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00557
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472988-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00507
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/13/04ISR Number: 4472989-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00163
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - 149 DAY	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		[Therapy Unspecified]	C			UNKNOWN	
	Contusion							
	Eating Disorder		Aspirin	C			UNKNOWN	
	Myocardial Infarction		Calcium (Unspecified)	C			UNKNOWN	
	Stress							
	Weight Decreased		Nexium	C			UNKNOWN	

Date:10/13/04ISR Number: 4472990-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00044
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472991-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01166
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Voltaren	C				
UNKNOWN								

Date:10/13/04ISR Number: 4472992-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00722
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4472995-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00441
Age:38 YR Gender:Male I/FU:I

Outcome	PT
Other	Back Disorder
	Cardiac Failure

Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473004-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	PARENTERAL	UNKNOWN
			[Therapy Unspecified]	C				
			Coumadin	C				
			Tylenol	C				

Date:10/13/04ISR Number: 4473005-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Face	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
			[Therapy Unspecified]	SS			UNKNOWN	

Date:10/13/04ISR Number: 4473081-7Report Type:Expedited (15-DaCompany Report #FI-MERCK-0410FIN00008
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473555-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00830
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc		UNKNOWN	

Date:10/13/04ISR Number: 4473556-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00745
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose							
	Tachycardia							

Date:10/13/04ISR Number: 4473558-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00736
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lotrel	C				
Disability			Aspirin	C			UNKNOWN	

			Flexeril	C		
UNKNOWN						

Date:10/13/04ISR Number: 4473563-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00839
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Lisinopril	C				
UNKNOWN								
	Dizziness		Metoprolol	C				
UNKNOWN								
	Renal Pain							

Date:10/13/04ISR Number: 4473565-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00892
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Renal Injury							
Other								

Date:10/13/04ISR Number: 4473568-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01038
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anaemia							
Initial or Prolonged	Fluid Retention							
Other	Headache							
	Platelet Count Decreased							
	Weight Decreased							

Date:10/13/04ISR Number: 4473570-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00868
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspepsia		[Therapy Unspecified]	C				
Disability			[Therapy Unspecified]	C				
			Vitamins (Unspecified)	C				
			Timoptic	C				
			Synthroid	C				

Date:10/13/04ISR Number: 4473571-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01142
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
Disability			Atorvastatin Calcium	C				
			Celebrex	C				
			Gabapentin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473573-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular							
	Iron Deficiency							
	Ulcer Haemorrhage							

Date:10/13/04ISR Number: 4473574-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Celebrex	C				
Disability								

Date:10/13/04ISR Number: 4473577-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01180
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Other								

Date:10/13/04ISR Number: 4473578-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01029
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Lortab	C				
UNKNOWN								

	Headache		Percocet	C		
UNKNOWN						
	Pain In Extremity		Bumex	C		
UNKNOWN						
			Klonopin	C		
UNKNOWN						
			Flexeril	C		ORAL
			Neurontin	C		
UNKNOWN						
			Altace	C		
UNKNOWN						

Date:10/13/04ISR Number: 4473580-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473582-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01338
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473584-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:10/13/04ISR Number: 4473585-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01358
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly Dyspnoea Pneumonia Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473586-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00074
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473587-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01211
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473588-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00121
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Vioxx	PS	Merck & Co., Inc	
UNKNOWN					
		Ascorbic Acid	C		
UNKNOWN					
		Plavix	C		
UNKNOWN					
		Vitamin E	C		
UNKNOWN					
		Vastin	C		
UNKNOWN					
		Folic Acid	C		
UNKNOWN					

Date:10/13/04ISR Number: 4473590-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01341
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Fall					
Initial or Prolonged	Myocardial Infarction					

Date:10/13/04ISR Number: 4473591-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473592-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Irregular Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473593-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Gastric Disorder Tremor		Vioxx [Therapy Unspecified] Toprol Xl Tablets	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

Date:10/13/04ISR Number: 4473594-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00880
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Supraventricular Tachycardia Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473595-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01918
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Artery		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

	Fosamax	C
UNKNOWN		
	Zocor	C
UNKNOWN		
	Ecotrin	C
UNKNOWN		
	Plavix	C
UNKNOWN		
	Pepcid	C
UNKNOWN		

Date:10/13/04ISR Number: 4473596-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00855
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adenoidal Disorder
	Adverse Event
Disability	Aspartate Aminotransferase Increased
	Blood Potassium Decreased
	Calculus Urinary
	Contusion
	Diarrhoea
	Haematochezia
	Headache
	Hydrocele
	Hypercalcaemia
	Inguinal Hernia

		Lipoma					
		Macroglossia					
		Obstruction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Apnoea Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Tendon Rupture		Norvasc	C		ORAL
		Testicular Pain		Norvasc	C		ORAL
		Tonsillar Hypertrophy		Clonidine	C		ORAL
		Umbilical Hernia		Prevacid	C		
UNKNOWN							
		Urine Sodium Increased		Zantac	C		ORAL
		Varicocele					
		Ventricular Extrasystoles					
		Weight Increased					

Date:10/13/04ISR Number: 4473597-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris					
		Appendix Disorder					
		Arthropathy					
		Cardiac Disorder					
		Chest Pain					
		Convulsion					
		Coronary Artery Disease					
		Diabetes Mellitus					
		Gastric Ulcer					
		Gastrointestinal					
		Haemorrhage					
		Gout					
		Haemorrhage					
		Hypertension					
		Melaena					
		Monarthritis					
		Myocardial Infarction					
		Tonsillar Disorder					

Date:10/13/04ISR Number: 4473598-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/13/04ISR Number: 4473599-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03341
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Gastrooesophageal Reflux Disease		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Pulmonary Embolism		Darvocet-N	C			UNKNOWN	
			Ortho-Cyclen	C			UNKNOWN	
			Iron (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473600-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00043
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
	Malaise		[Therapy Unspecified]	C			UNKNOWN	
			Digoxin	C			UNKNOWN	

Date:10/13/04ISR Number: 4473604-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00028
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473605-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:10/13/04ISR Number: 4473607-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00284
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Disability			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Captopril	C		ORAL		

Date:10/13/04ISR Number: 4473608-5Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00006
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/13/04ISR Number: 4473609-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Atrial Fibrillation Dyspnoea Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473610-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00333
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Rofecoxib	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473611-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00300
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473619-XReport Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00003
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473620-6Report Type:Expedited (15-DaCompany Report #SI-MERCK-0410HUN00007
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
			Metformin	C		ORAL		

Date:10/13/04ISR Number: 4473623-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00250
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Hytrin	C				UNKNOWN

Date:10/13/04ISR Number: 4473624-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-0410NLD00009
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1598 DAY
Hospitalization -			Anafranil	C				UNKNOWN
Initial or Prolonged			Orap	C				UNKNOWN
Disability								

Date:10/13/04ISR Number: 4473625-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00016
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		27 DAY

Date:10/13/04ISR Number: 4473627-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00337
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473629-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00338
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473640-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00399
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Facial Paresis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Paraesthesia		Aspirin	C				
UNKNOWN								

Date:10/13/04ISR Number: 4473641-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00449
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Lipitor	C				
UNKNOWN								
Disability			Zyrtec	C				
UNKNOWN								
Other								

Date:10/13/04ISR Number: 4473643-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00532
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/13/04ISR Number: 4473644-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00698
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Norvasc	C			UNKNOWN	
	Paraesthesia		Celexa	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Metformin	C			UNKNOWN	

Date:10/13/04ISR Number: 4473646-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473648-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00721
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473651-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00719
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
Disability	Nausea		Aspirin	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Cozaar	C		ORAL		

Date:10/13/04ISR Number: 4473652-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00003
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Atenolol	C		ORAL		

Date:10/13/04ISR Number: 4473654-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00730
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral							

Date:10/13/04ISR Number: 4473657-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00682
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oesophageal Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thrombosis		Lovastatin	C				
UNKNOWN								
Initial or Prolonged			Metoprolol	C				
UNKNOWN								

Date:10/13/04ISR Number: 4473659-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00369
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		[Therapy					
	Feeling Hot And Cold		Unspecified]	C				
UNKNOWN								
	Micturition Disorder		Percocet	C				
UNKNOWN								
	Nausea		Fentanyl	C				
UNKNOWN								
	Oesophageal Pain		Rebif	C				
UNKNOWN								
	Palpitations		Prevacid	C				
UNKNOWN								
			Oxycodone					
			Hydrochloride	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473660-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4473672-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01373
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Rectal Haemorrhage		[Composition					
UNKNOWN	Urinary Tract Infection		Unspecified]	C				

Date:10/13/04ISR Number: 4473673-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01465
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Joint Swelling		Hydrodiuril	C		ORAL		
UNKNOWN	Weight Increased		Levoxyl	C				
Disability			Prinivil	C		ORAL		

Date:10/13/04ISR Number: 4473677-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00726
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		[Therapy					
			Unspecified]	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:10/13/04ISR Number: 4473693-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Acute Pulmonary Oedema
Disability	Anxiety
Other	Asthenia
	Blood Cholesterol
	Increased
	Bundle Branch Block
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Convulsion
	Coronary Artery Disease
	Cystocele
	Depression
	Diabetes Mellitus
	Inadequate Control
	Diabetic Ketoacidosis
	Emotional Distress
	Emphysema
	Hypertension

		Hypokalaemia					
		Intervertebral Disc Degeneration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Aspirin	C		
UNKNOWN							
		Rotator Cuff Syndrome		Lasix (Furosemide)	C		
UNKNOWN							
		Supraventricular		Glucotrol Xl	C		
UNKNOWN							
		Extrasystoles		Glyburide	C		
UNKNOWN							
		Supraventricular		Ativan	C		
UNKNOWN							
		Tachycardia		Lopressor	C		
UNKNOWN							
		Transient Ischaemic		Orphenadrine	C		
UNKNOWN							
		Attack					
		Urinary Tract Infection					
		Ventricular Extrasystoles					
		Vision Blurred					

Date:10/13/04ISR Number: 4473701-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	
UNKNOWN	2 DAY					
Initial or Prolonged	Dyspnoea		Mylanta & Mylanta Ds	C		
UNKNOWN						
	Feeling Abnormal					

Date:10/13/04ISR Number: 4473702-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00234
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:10/13/04ISR Number: 4473705-4Report Type:Expedited (15-DaCompany Report #KR-MERCK-0410KOR00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aceclofenac	C		ORAL	1	WK
			Aceclofenac	C		ORAL		

Date:10/13/04ISR Number: 4473714-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00715
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Malignant Neoplasm Of		Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged	Spinal Cord		Norvasc	C				
UNKNOWN								
Disability			Vasotec	C		ORAL		
			Premarin	C				
UNKNOWN								
			Restoril	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		
			Toradol	C				
UNKNOWN								
			Robaxin	C				
UNKNOWN								
			Quinine	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/13/04ISR Number: 4473751-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/13/04ISR Number: 4474183-1Report Type:Direct Company Report #CTU 229481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Atrial Flutter Dyspnoea Fluid Retention Joint Swelling Pain In Jaw Tachycardia		Vioxx 50 Mg Merck Bextra	PS C	Merck	ORAL	50 MG ONCE DAILY ORAL	

Date:10/13/04ISR Number: 4475123-1Report Type:Direct Company Report #CTU 229517
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vision Blurred		Vioxx 25mg Merck	PS	Merck		1 DAILY	

Date:10/13/04ISR Number: 4475240-6Report Type:Direct Company Report #CTU 229482
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to	Cardiac Enzymes Increased Drug Ineffective Heart Rate Decreased Procedural Complication Supraventricular		Vioxx 50 Mg Merck	PS	Merck		50 MG NIGHTLY	

Prevent Permanent Impairment/Damage	Tachycardia

Date:10/13/04ISR Number: 4475252-2Report Type:Direct Company Report #CTU 229572
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx 30mg	PS			2 TWICE A DAY	
	Cerebrovascular Accident							
	Headache							

Date:10/13/04ISR Number: 4475269-8Report Type:Direct Company Report #CTU 229570
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx-50mg-Merck+Co.	PS	Merck+Co.		1 EVERY DAY	
Hospitalization - Initial or Prolonged								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474334-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Clonidine Hydrochloride	C			UNKNOWN	
			Indapamide And Perindopril Erbumine	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	
			Quinine	C			UNKNOWN	

Date:10/14/04ISR Number: 4474335-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02316
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Failure Acute		[Therapy Unspecified]	C			UNKNOWN	
			Lortab	C			UNKNOWN	

Date:10/14/04ISR Number: 4474336-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atelectasis
Disability	Blood Cholesterol Increased
Other	Burning Sensation
	Bursitis
	Cardiac Ventricular Disorder
	Carotid Artery Stenosis
	Chronic Obstructive

Pulmonary Disease
Decreased Activity
Decreased Appetite
Deep Vein Thrombosis
Depression
Diabetes Mellitus
Drug Ineffective
Dyspnoea
Epicondylitis
Faeces Discoloured
Fatigue
Hypercholesterolaemia
Hypertension
Inflammation
Injury
Intervertebral Disc
Degeneration
Low Density Lipoprotein
Increased
Malignant Melanoma
Meniscus Lesion
Menopausal Symptoms
Menopause
Mitral Valve Incompetence
Mixed Incontinence

		Monocyte Count Decreased					
		Myalgia					
		Myositis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neutrophil Count		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Normochromic Normocytic		Vioxx	SS	Merck & Co., Inc	ORAL
		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteomyelitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Premarin	C		
UNKNOWN							
		Polymyalgia Rheumatica		Vitamins			
		Post Thrombotic Syndrome		(Unspecified)	C		
UNKNOWN							
		Skin Discolouration		Allegra	C		
UNKNOWN							
		Skin Lesion		Lasix (Furosemide)	C		
UNKNOWN		366 DAY					
		Syncope		Plaquenil	C		ORAL
		Tendonitis		Ultram	C		ORAL
		Tricuspid Valve		Ultram	C		
UNKNOWN							
		Incompetence		Plaquenil	C		ORAL
		Weight Decreased		Accupril	C		
UNKNOWN		535 DAY					

Date:10/14/04ISR Number: 4474338-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00100
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/14/04ISR Number: 4474339-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01882
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea					

Feeling Abnormal
Gastrointestinal Disorder
Haemorrhage
Hypoacusis
Myocardial Infarction
Pain

Date:10/14/04ISR Number: 4474340-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00115
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thromboembolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474341-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA02393
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Tylenol	C			UNKNOWN	
	Decreased		Lotrel	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	

Levoxyl	C	UNKNOWN
Toprol Xl Tablets	C	UNKNOWN
Pravachol	C	UNKNOWN

Date:10/14/04ISR Number: 4474344-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00076
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474345-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00114
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474353-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00329
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Cardiac Disorder Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474354-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00344
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474355-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00297
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474357-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:10/14/04ISR Number: 4474358-1Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00021
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474362-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Wall Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Muscle Spasms		[Therapy Unspecified]	C				
			Clonazepam	C				
			Crestor	C				
			Effexor	C				
			Furosemide	C				
			Potassium (Unspecified)	C				

Date:10/14/04ISR Number: 4474363-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Myocardial Infarction							

Date:10/14/04ISR Number: 4474364-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00373
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Morphine	C				
UNKNOWN								
Initial or Prolonged	Balance Disorder							
Disability	Cardio-Respiratory Arrest							
	Myocardial Infarction							

Date:10/14/04ISR Number: 4474365-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00381
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Tachycardia							

Date:10/14/04ISR Number: 4474366-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00542
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged	Transient Ischaemic		Nexium	C				UNKNOWN
	Attack		Paxil	C				UNKNOWN
			Pravachol	C				UNKNOWN

Date:10/14/04ISR Number: 4474367-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00409
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Dizziness		Aspirin	C				UNKNOWN
	Headache		Zocor	C		ORAL		
	Hypertension		Levoxyl	C				UNKNOWN
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474368-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Venous Insufficiency Venous Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474369-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00029
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pneumonia		Estrogens (Unspecified)	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474370-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00343
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Headache Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474372-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00738
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474373-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01078
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Pacerone	C			UNKNOWN	
	Myocardial Infarction		Aspirin	C			UNKNOWN	
	Thrombosis		Plavix	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Warfarin	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Altace	C			UNKNOWN	
			Zantac	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474374-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00893
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Diuretic					
Initial or Prolonged	Myocardial Infarction		(Unspecified)	C				
UNKNOWN								
Disability			Primalan	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474376-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00900
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lopressor	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474377-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
1 WK								
	Sudden Cardiac Death							

Date:10/14/04ISR Number: 4474378-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00923
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Monopril	C				
UNKNOWN								

Initial or Prolonged Red Blood Cell Count Isosorbide C
UNKNOWN
Disability Decreased

Date:10/14/04ISR Number: 4474379-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00896
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged								

Date:10/14/04ISR Number: 4474382-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00886
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	YR
Hospitalization -								
Initial or Prolonged								

Date:10/14/04ISR Number: 4474384-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00922
Age:69 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Pepcid	C			UNKNOWN	
	Disease		Zocor	C			UNKNOWN	
	Joint Swelling							

Date:10/14/04ISR Number: 4474385-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01123
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Increased							
	Dizziness							
	Feeling Abnormal							
	Headache							
	Sleep Disorder							

Date:10/14/04ISR Number: 4474386-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474387-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00912
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysarthria		Nadolol	C			UNKNOWN	
	Headache							
	Hypoaesthesia							
	Paraesthesia							

Sensory Loss
Visual Field Defect

Date:10/14/04ISR Number: 4474388-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Poor Peripheral		Coreg	C				
UNKNOWN								
	Circulation		Nitroglycerin	C				
UNKNOWN								
			Benicar	C				
UNKNOWN								
			Actos	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474389-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474393-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01178
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Actonel	C				
UNKNOWN								
Initial or Prolonged								
Disability								
Other								

Date:10/14/04ISR Number: 4474394-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01153
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Fosamax	C				
UNKNOWN								
Disability			Ecotrin	C				
UNKNOWN								
Congenital Anomaly			Calcium (Unspecified)	C				
UNKNOWN								
			Zyrtec-D	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Lexapro	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Zetia	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Cozaar	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474396-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00928
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Ejection Fraction		Norvasc	C				UNKNOWN
Disability	Decreased		Atenolol	C				UNKNOWN
Other	Injury		Vasotec	C				UNKNOWN
	Myocardial Infarction		Lasix (Furosemide)	C				UNKNOWN
	Oedema Peripheral							

Date:10/14/04ISR Number: 4474397-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01164
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474398-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Optic Ischaemic Neuropathy							
	Renal Injury							

Date:10/14/04ISR Number: 4474399-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00898
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Congestive		Aspirin	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474400-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01197
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Other								

Date:10/14/04ISR Number: 4474401-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00938
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY
Hospitalization - Initial or Prolonged	Hallucination		Ocuvite	C			UNKNOWN	
Disability	Myocardial Infarction							

Date:10/14/04ISR Number: 4474403-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01205
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Tylenol	C		
UNKNOWN						
			Ativan	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						

Date:10/14/04ISR Number: 4474404-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01206
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain		[Therapy			
Initial or Prolonged	Dyspnoea		Unspecified]	C		
UNKNOWN						
Other	Pain In Extremity		Norvasc	C		
UNKNOWN						
			Benazepril Hydrochloride	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Mevacor	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Actos	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474405-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01199
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Stent Occlusion							

Date:10/14/04ISR Number: 4474409-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder	Professional	Aspirin	C				UNKNOWN
	Constipation		Lipitor	C		ORAL		
	Cow'S Milk Intolerance		Captopril	C		ORAL		
	Emotional Distress		Captopril	C				UNKNOWN
	Gastritis Erosive		Baycol	C		ORAL		
	Haemorrhoids		Baycol	C		ORAL		
	Hiatus Hernia		Estrogens (Unspecified)	C				UNKNOWN
	Hypertension							
	Myalgia		Allegra	C				UNKNOWN
	Myocardial Infarction		Hydrodiuril	C				UNKNOWN
	Pain In Extremity		Motrin	C				UNKNOWN
			Claritin	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Aleve	C				UNKNOWN
			Nitroquick	C		SUBLINGUAL		

Date:10/14/04ISR Number: 4474418-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01203
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive							
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:10/14/04ISR Number: 4474419-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01198
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Tegretol	C				
UNKNOWN								
Initial or Prolonged	Cardiac Murmur		Lasix (Furosemide)	C				
UNKNOWN								
Disability	Chest Pain		Neurontin	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474420-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01202
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474434-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01207
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474443-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00022
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged								
Other								

Date:10/14/04ISR Number: 4474448-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Antimicrobial (Unspecified)	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Influenza Virus Split Virion 3v Vaccine Inactivated	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474449-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00116
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Methotrexate	C		
UNKNOWN						

Date:10/14/04ISR Number: 4474450-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00720
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Remicade	C		
UNKNOWN						
Initial or Prolonged			Prednisone	C		
UNKNOWN						
Disability						

Date:10/14/04ISR Number: 4474454-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00027
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
10 YR						
	Mesenteric Artery		Norvasc	C		
UNKNOWN						
	Embolism		Wellbutrin	C		
UNKNOWN						
	Mesenteric Occlusion		Zyrtec	C		
UNKNOWN						
	Oedema Peripheral		Vasotec	C		ORAL
	Post Procedural		Plendil	C		
UNKNOWN						
	Complication		Prevacid	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474497-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01179
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Zyrtec	C				UNKNOWN
			Vasotec	C				UNKNOWN
			Zocor	C		ORAL		
			Actonel	C				UNKNOWN

Date:10/14/04ISR Number: 4474498-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01204
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Stage Unspecified		Norvasc	C				UNKNOWN
Disability								

Date:10/14/04ISR Number: 4474499-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01208
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	36 HR	
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
Disability								

Date:10/14/04ISR Number: 4474500-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01487
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypotension		[Therapy Unspecified]	C				
	White Blood Cell Count							
	Decreased		Valtrex	C				
			[Therapy Unspecified]	C				

Date:10/14/04ISR Number: 4474502-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01906
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474504-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Fluctuation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Therapy Unspecified]	C				
	Heart Valve Insufficiency							
	Nausea		Vicodin Tablets	C				
			Lexapro	C				
			Avandia	C				
			Glucovance	C				
			Nizatidine	C				

			Quinine	C			
UNKNOWN							

Date:10/14/04ISR Number: 4474794-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00014
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization - Initial or Prolonged	Infarction		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
Disability			Enalapril Maleate	C		ORAL		

Date:10/14/04ISR Number: 4474795-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01519
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Captopril	C				
UNKNOWN								
Other	Cholelithiasis		Celebrex	C				
UNKNOWN								
	Chronic Obstructive		Plavix	C				
UNKNOWN								
	Pulmonary Disease		Pepcid Ac	C		ORAL		
	Coronary Artery Disease		Lasix (Furosemide)	C				
UNKNOWN								
	Diabetes Mellitus		Ambien	C				
UNKNOWN								
	Inadequate Control		Zoloft	C				
UNKNOWN								
	Dizziness		Glyburide	C				
UNKNOWN								
	Dyspepsia		Synthroid	C				
UNKNOWN								
	Fatigue		Lorazepam	C				
UNKNOWN								
	Gastritis		Meclizine	C				
UNKNOWN								

	Gastrointestinal		Phenergan				
	Haemorrhage		Tablets/Suppositorie				
	Hyperkalaemia		s	C			
UNKNOWN							
	Microcytic Anaemia						
	Myocardial Infarction						
	Renal Failure						
	Vertigo Positional						

Date:10/14/04ISR Number: 4474801-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01032321
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Lipitor	C				
UNKNOWN								
	Oedema		Hydrodiuril	C				
UNKNOWN								
	Oedema Peripheral		Synthroid	C				
UNKNOWN								
	Ventricular Hypertrophy							

Date:10/14/04ISR Number: 4474803-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00300
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474804-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Infarction		[Therapy					
	Anxiety		Unspecified]	C				UNKNOWN
	Drug Ineffective		Beconase Aq	C				UNKNOWN
	Emotional Distress		Isoptin	C				UNKNOWN
	Hyperlipidaemia		Griseofulvin	C				UNKNOWN
	Pain							
	Pelvic Haematoma							
	Stress							
	Tinea Infection							

Date:10/14/04ISR Number: 4474805-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Disability	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Colitis Ulcerative							
	Constipation							
	Cough							
	Deep Vein Thrombosis							
	Depression							
	Drug Interaction							
	Dyspnoea							
	Headache							
	Insomnia							

Iron Deficiency Anaemia
Muscle Spasms
Oedema Peripheral
Pericardial Effusion
Pharyngolaryngeal Pain
Pneumonia
Postmenopausal
Haemorrhage
Pulmonary Congestion
Pulmonary Embolism
Pulmonary Hypertension
Rectal Ulcer
Reflux Oesophagitis
Renal Failure
Tremor
Weight Decreased

Date:10/14/04ISR Number: 4474807-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474808-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00235
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C		ORAL		
Initial or Prolonged			Isosorbide Mononitrate	C		ORAL		

Date:10/14/04ISR Number: 4474814-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00304
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							

Date:10/14/04ISR Number: 4474815-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00231
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Malaise		Venalot	C				
UNKNOWN								
	Varicose Ulceration		Daflon (Diosmin (+) Hesperidin)	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474816-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00299
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474818-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Lung Neoplasm Malignant							

Date:10/14/04ISR Number: 4474819-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:10/14/04ISR Number: 4474820-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00363
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474822-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00722
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474824-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00746
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474836-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-00125597
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Chest Discomfort							
	Dizziness							
	Fear							
	Hyperhidrosis							
	Visual Disturbance							
	Weight Increased							

Date:10/14/04ISR Number: 4474837-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474839-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00018
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		81 DAY
			Fluticasone Propionate And Salmeterol Xinafoate	C		RESPIRATORY (INHALATION)		
			Indomethacin	C		UNKNOWN		

Date:10/14/04ISR Number: 4474842-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00372
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474843-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474844-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00960
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged								
Disability								

Date:10/14/04ISR Number: 4474845-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01996
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Biliary Colic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Biliary Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholecystitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis Erosive		Aluminum Hydroxide And Magnesium Trisilicate	C				
	Hiatus Hernia							
	Hypertension							
	Oesophagitis		Prevacid	C				
	Umbilical Hernia							

Date:10/14/04ISR Number: 4474847-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00101
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oesophagitis		Aluminum Hydroxide And Dimethicone And Magnesium Hydroxide	C				

UNKNOWN

Date:10/14/04ISR Number: 4474849-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00179
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	367	DAY
Life-Threatening	Vomiting		Cinnarizine	C			UNKNOWN	
Hospitalization - Initial or Prolonged			Coumarin And Troxerutin	C			UNKNOWN	
Other			Nifedipine	C			UNKNOWN	

Date:10/14/04ISR Number: 4474873-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00010
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR
Life-Threatening								

Date:10/14/04ISR Number: 4474874-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00748
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Tenderness
	Chest Pain
	Fatigue

Muscle Tightness
Sensation Of Heaviness

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Ascorbic Acid	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Clonazepam	C			UNKNOWN	
	Zocor	C		ORAL		
	Cyanocobalamin	C			UNKNOWN	
	Neurontin	C			UNKNOWN	
	Glucosamine	C			UNKNOWN	

Date:10/14/04ISR Number: 4474876-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00610
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased							
	Bundle Branch Block Right							
	Coccydynia							
	Convulsion							
	Dizziness							
	Drug Ineffective							
	Fall							
	Headache							
	Lumbar Spinal Stenosis							
	Myocardial Infarction							
	Oedema Peripheral							
	Plantar Fasciitis							
	Pneumonia							
	Spinal Osteoarthritis							
	Upper Respiratory Tract Infection							
	Ventricular Dysfunction							

Date:10/14/04ISR Number: 4474881-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Adrenal Adenoma
	Aneurysm
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Complex Regional Pain Syndrome
	Depression
	Diverticulum
	Dizziness
	Emotional Distress
	Hyperlipidaemia
	Hypoaesthesia
	Joint Dislocation
	Large Cell Carcinoma Of The Respiratory Tract Stage Unspecified

		Pneumothorax Stress Incontinence Ventricular Extrasystoles	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
143	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
143	DAY						
				Darvocet-N	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							

Date:10/14/04ISR Number: 4474883-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Provera	C		
UNKNOWN						

Date:10/14/04ISR Number: 4474884-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01025
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Glucophage	C		
UNKNOWN						

Date:10/14/04ISR Number: 4474885-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Panic Attack		Hydrocodone			

Initial or Prolonged			Hydrochloride	C			
UNKNOWN							
Disability			Zoloft	C			
UNKNOWN							

Date:10/14/04ISR Number: 4474887-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01059
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Klonopin	C				
UNKNOWN								
Initial or Prolonged			Toradol	C				
UNKNOWN								
Disability								

Date:10/14/04ISR Number: 4474888-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01332
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization -								
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474889-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01133
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Hypertension		Flexeril	C				
Initial or Prolonged Disability								

Date:10/14/04ISR Number: 4474891-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00236
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability								

Date:10/14/04ISR Number: 4474892-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474893-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00747
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged Disability	Blood Pressure Increased Transient Ischaemic Attack							

Date:10/14/04ISR Number: 4474894-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01400
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:10/14/04ISR Number: 4474895-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01466
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Aspirin	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Glipizide	C				
UNKNOWN								
			Vitamin E	C				
UNKNOWN								
			Toprol Xl Tablets	C		ORAL		
			Paxil	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474896-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01690
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspepsia		Tylenol	C				
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								
Disability			Plavix	C				
UNKNOWN								
			Zocor	C		ORAL		
			Pepcid	C				
UNKNOWN								
			Prinivil	C		ORAL		
			Nutrin	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474897-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Surgery							

Date:10/14/04ISR Number: 4474898-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474899-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00394
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/14/04ISR Number: 4474900-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00036
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Lower Limb Deformity					
	Myocardial Infarction					
	Osteomyelitis					

Date:10/14/04ISR Number: 4474901-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00349
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Deep Vein Thrombosis					
Initial or Prolonged						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474902-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00369
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474903-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00993
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474904-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00940
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Blood Thinner (Unspecified)	C				UNKNOWN
			Zocor	C		ORAL		
			Zyrtec	C				UNKNOWN
			Plavix	C				UNKNOWN
			Actonel	C				UNKNOWN

Date:10/14/04ISR Number: 4474905-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00984
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Cerebrovascular Accident	Aspirin	C
Initial or Prolonged UNKNOWN	Coordination Abnormal	Atenolol	C
Disability UNKNOWN		Lasix (Furosemide)	C
		Cozaar	C
UNKNOWN		Potassium (Unspecified)	C
UNKNOWN		Quinine	C
UNKNOWN			

Date:10/14/04ISR Number: 4474906-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00942
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Life-Threatening								
Hospitalization - Initial or Prolonged								
Disability								

Date:10/14/04ISR Number: 4474907-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00958
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474908-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474909-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00292
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474910-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474911-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01170
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cervical Cord Compression Migraine Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01339
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Arthropathy	Vioxx	PS	Merck & Co., Inc	
UNKNOWN					
Hospitalization -	Electrocardiogram	Metformin	C		
UNKNOWN					
Initial or Prolonged	Abnormal	Altace	C		
UNKNOWN					

Date:10/14/04ISR Number: 4474913-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01469
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/14/04ISR Number: 4474914-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01484
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy					
Hospitalization -			Unspecified]	C				
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								
Disability			Sucralfate	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474915-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00857
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Foot Fracture							
	Impaired Healing							

Date:10/14/04ISR Number: 4474916-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00222
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Disability								

Date:10/14/04ISR Number: 4474917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01584
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474918-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00232
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis							
	Neck Pain							
	Palpitations							

Date:10/14/04ISR Number: 4474919-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01668
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN								
			Flexeril	C		ORAL		
			Nexium	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Advair	C				
UNKNOWN								

Date:10/14/04ISR Number: 4474920-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01585
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Hospitalization - Initial or Prolonged			[Composition Unspecified]	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474922-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01167
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474923-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01563
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474924-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00153
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474926-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/14/04ISR Number: 4474933-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00271
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Diarrhoea Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Oedema Peripheral

Date:10/14/04ISR Number: 4474938-3Report Type:Expedited (15-DaCompany Report #CO-MERCK-0410COL00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Cafiaspirina	SS				
UNKNOWN								
	Haemorrhage		Clopidogrel					
	Myocardial Infarction		Bisulfate	SS				
UNKNOWN								

Date:10/14/04ISR Number: 4474940-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01372
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hemiplegia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Labetalol					
Disability	Prostatic Disorder		Hydrochloride	C				
UNKNOWN								
	Transurethral							
	Prostatectomy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4474942-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01043
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Cerebrovascular Accident							
Other	Haemorrhage							
	Myocardial Infarction							
	Oedema Peripheral							
	Renal Failure							
	Respiratory Tract Infection							
	Urinary Tract Infection							

Date:10/14/04ISR Number: 4474945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01330
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Transient Ischaemic Attack							
Hospitalization - Initial or Prolonged								
Disability								

Date:10/14/04ISR Number: 4474950-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00959
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Methotrexate	C				
Initial or Prolonged								

Date:10/14/04ISR Number: 4475363-1Report Type:Direct Company Report #CTU 229605
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS			1 PILL PER DAY	
Hospitalization - Initial or Prolonged	Congestive							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/14/04ISR Number: 4475364-3Report Type:Direct Company Report #CTU 229606
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal Ulcer		Vioxx 25mg	PS			1 DAILY	
Hospitalization - Initial or Prolonged	Haemorrhage							
	Malaise							
Required Intervention to Prevent Permanent Impairment/Damage	Mobility Decreased							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/14/04ISR Number: 4475490-9Report Type:Direct Company Report #CTU 229628
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS		ORAL	DAILY ORAL	

Date:10/14/04ISR Number: 4477630-4Report Type:Expedited (15-DaCompany Report #2004051682
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Difficulty In Walking	Consumer	Neurontin					
	Disease Progression	Health	(Gabapentin)	PS		ORAL	900 MG (300	
	Myelopathy	Professional					MG, 3 IN 1	
	Oedema Peripheral						D), ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C				
			Fluticasone Propionate (Fluticasone Propionate)	C				
			Atorvastatin (Atorvastatin)	C				
			Gezor (Hydrochlorothiazide, Quinapril Hydrochloride)	C				
			Propranolol Hydrochloride (Propranolol Hydrochloride)	C				
			Baclofen (Baclofen)	C				
			Sertraline Hydrochloride (Sertraline Hydrochloride)	C				

			Alprazolam (Alprazolam)	C		
			Potassium Chloride (Potassium Chloride)	C		
			Furosemide (Furosemide)	C		

Date:10/14/04ISR Number: 4478479-9Report Type:Expedited (15-DaCompany Report #230129M04USA
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Rebif (Interferon					
Hospitalization -	Congestive	Health	Beta)	PS				
SUBCUTANEOUS							44 MCG, 3 IN	
Initial or Prolonged	Cardiomyopathy	Professional						
1 WEEKS,								
	Fatigue							
SUBCUTANEOUS								
	Viral Pericarditis		Vioxx (Rofecoxib)	SS				
			Glucophage (Metformin Hydrochloride)	C				
			Lexapro (Escitalopram)	C				
			Actos (Pioglitazone)	C				

			Ditropan (Oxybutynin)	C		
			Dexedrine (Dexamfetamine Sulfate)	C		

Date:10/15/04ISR Number: 4475494-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01082423
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		362 DAY
	Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Cardizem	C				UNKNOWN
			Estradiol	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Prilosec	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Claritin	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN

Date:10/15/04ISR Number: 4475495-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		487 DAY
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		487 DAY

Disability	Arteriospasm Coronary	Darvocet-N	C
UNKNOWN			
	Back Injury	Chondroitin	C
UNKNOWN			
	Dyspepsia	Voltaren	C
UNKNOWN			
	Intervertebral Disc	Evening Primrose Oil	C
UNKNOWN			
	Displacement	Glucosamine	C
UNKNOWN			
	Neuralgia	Humibid	C
UNKNOWN			
	Sacroiliitis	Entex La	C
UNKNOWN			
	Tachyarrhythmia	Maxzide	C
UNKNOWN			
	Weight Increased	Prevacid	C
UNKNOWN			
		Bactrim	C
UNKNOWN			
		Claritin-D	C
UNKNOWN	1758 DAY		
		Nasonex	C
UNKNOWN	764 DAY		
		Naprosyn	C
UNKNOWN			
		Inderal La	C
UNKNOWN			
		Inderal La	C
UNKNOWN			
		Pseudoephedrine	C
UNKNOWN			
		Zantac	C
UNKNOWN			

Date:10/15/04ISR Number: 4475496-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Colonic Polyp							
	Dysphonia							
	Intervertebral Disc Protrusion							
	Spinal Column Stenosis							
	Spinal Cord Compression							
	Vocal Cord Thickening							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475498-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02064
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dissociation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Mental Impairment	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Vision Blurred							

Date:10/15/04ISR Number: 4475499-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Abdominal Pain
Other	Abdominal Pain Upper
	Aortic Atherosclerosis
	Arteriosclerosis
	Arthralgia
	Asthenia
	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Burning Sensation
	Bursitis
	Cardiomegaly
	Chest Wall Pain
	Chromaturia
	Deep Vein Thrombosis
	Dizziness
	Dry Mouth
	Fatigue
	Fluid Retention
	Gastrooesophageal Reflux Disease
	Haemarthrosis
	Haematocrit Decreased
	Haematoma
	Haemoglobin Decreased
	Haemorrhoidal Haemorrhage
	Haemorrhoids
	Hepatic Steatosis

Hiatus Hernia
Hypersensitivity
Hypertension
Hypoaesthesia
Incision Site
Complication
Injury
Intervertebral Disc
Degeneration
Joint Effusion
Joint Injury
Lung Disorder
Migraine
Mitral Valve Incompetence
Mononeuritis
Myalgia
Nausea
Oedema Peripheral
Osteoarthritis

	Pain In Extremity						
	Pulmonary Hypertension						
	Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Rectocele	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Road Traffic Accident	Professional	[Therapy				
	Spinal Osteoarthritis		Unspecified]	C			
UNKNOWN	10 YR						
	Splenic Cyst		Endocet	C			
UNKNOWN							
	Swelling		Elavil	C			
UNKNOWN							
	Thrombophlebitis		Tenormin	C			
UNKNOWN							
	Superficial		Vancenase	C			
UNKNOWN							
	Tricuspid Valve		Premarin	C			
UNKNOWN	9872 DAY						
	Incompetence		Prevacid	C			
UNKNOWN							
	Upper Respiratory Tract		Synthroid	C			
UNKNOWN							
	Infection		Prinivil	C		ORAL	
1285 DAY							
	Urine Odour Abnormal		Prinivil	C		ORAL	
217 DAY							
	Ventricular Dysfunction		Prinivil	C		ORAL	
	Ventricular Hypertrophy		Methocarbamol	C			
UNKNOWN							
	Vomiting		Prilosec	C			
UNKNOWN							
	Wound						
	Wound Dehiscence						

Date:10/15/04ISR Number: 4475502-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00064
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Hospitalization -	Brain Stem Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Bunion		[Therapy				
Other	Cardiac Failure		Unspecified]	C			
UNKNOWN							
	Congestive		[Therapy				

	Cardiomegaly	Unspecified]	C	
UNKNOWN				
	Carotid Artery Occlusion	Avandia	C	ORAL
	Carotid Artery Stenosis	Avandia	C	ORAL
	Cataract	Vicoprofen	C	ORAL
	Cerebrovascular Accident	Glucophage	C	ORAL
	Contusion	Glucophage	C	ORAL
	Coronary Artery Disease			
	Dermal Cyst			
	Diplopia			
	Fall			
	Glaucoma			
	Hypoaesthesia			
	Lumbar Spinal Stenosis			
	Monarthritis			
	Nasopharyngitis			
	Neuropathy Peripheral			
	Osteoarthritis			
	Pleurisy			
	Road Traffic Accident			
	Rotator Cuff Syndrome			
	Seborrhoeic Keratosis			
	Spinal Osteoarthritis			
	Strabismus			
	Toe Deformity			
	Ventricular Hypertrophy			
	Vision Blurred			
	Whiplash Injury			

Date:10/15/04ISR Number: 4475504-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Anxiety
Other	Aortic Atherosclerosis
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Asthenopia
	Binocular Eye Movement Disorder
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Blood Urine
	Bronchitis Chronic
	Cataract
	Cerebral Infarction
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Pain
	Cholelithiasis
	Chronic Fatigue Syndrome
	Cognitive Disorder
	Colonic Polyp
	Depression
	Diplopia
	Diverticulum Intestinal
	Dizziness
	Duodenitis
	Dyspnoea
	Electrocardiogram St-T Change
	Endocarditis
	Fatigue
	Gallbladder Disorder
	Gastritis
	Gastrooesophageal Reflux Disease
	Generalised Anxiety Disorder
	Haematuria
	Hemianopia Homonymous
	Herpes Zoster

Heterophoria
Hypertension
Hypertensive Crisis
Hypoacusis
Hypokalaemia
Injury
Irritable Bowel Syndrome
Labile Hypertension
Lacunar Infarction
Laryngitis
Low Density Lipoprotein
Increased
Migraine With Aura
Mitral Valve
Calcification

		Mitral Valve Incompetence					
		Non-Cardiac Chest Pain					
		Panic Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prothrombin Time	Health	Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Shortened	Professional	Aspirin	C		
UNKNOWN							
		Restlessness		Aspirin	C		
UNKNOWN							
		Rhinitis Seasonal		Tagamet	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Premarin	C		
UNKNOWN							
		Strabismus		Hytrin	C		
UNKNOWN							
		Tension Headache		Estratab	C		
UNKNOWN							
		Thalamus Haemorrhage		L-Thyroxin	C		
UNKNOWN							
		Transient Ischaemic		Ranitidine	C		
UNKNOWN							
		Attack					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypertrophy					

Date:10/15/04ISR Number: 4475505-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Atherosclerosis		Reopro	C		
UNKNOWN							
		Blood Cholesterol		Tylenol	C		
UNKNOWN							
		Increased		Cordarone	C		
UNKNOWN							
		Cardiac Failure		Aspirin	C		ORAL
		Congestive		Atenolol	C		
UNKNOWN							
		Cardio-Respiratory Arrest		Buspar	C		
UNKNOWN							

	Cardiogenic Shock	Claforan	C
UNKNOWN			
	Chest Pain	Celexa	C
UNKNOWN			
	Convulsion	Dopamine Hydrochloride	C
	Haematuria		
UNKNOWN			
	Hypertension	Vasotec	C
UNKNOWN			
	Lung Infiltration	Pepcid	C
UNKNOWN			
	Myalgia	Prozac	C
UNKNOWN			
	Orthostatic Hypotension	Prozac	C
UNKNOWN			
	Papilloma	Dalmane	C
UNKNOWN			
	Ventricular Fibrillation	Neurontin	C
UNKNOWN			
	Ventricular Tachycardia	Atrovent	C
UNKNOWN			
		Magnesium Sulfate	C
UNKNOWN			
		Restoril	C
UNKNOWN			

Date:10/15/04ISR Number: 4475506-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104486
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Activities Of Daily Living Impaired
	Blood Cholesterol Increased
	Blood Pressure Increased
	Bunion
	Cardiac Failure Congestive
	Constipation
	Drug Intolerance
	Fall

		Gastric Disorder					
		Headache					
		Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertensive Heart	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Tylenol	C		
UNKNOWN							
		Limb Discomfort		Aspirin	C		
UNKNOWN							
		Muscle Spasms					
		Myalgia					
		Myocardial Infarction					
		Nocturia					
		Onychomycosis					
		Osteoarthritis					
		Pain					
		Pulmonary Granuloma					
		Renal Failure					
		Rotator Cuff Syndrome					
		Seborrhoeic Keratosis					
		Sinusitis					
		Wound Infection					

Date:10/15/04ISR Number: 4475507-1Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00016
Age:41 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Protrusion					
		Nausea					
		Overdose					
		Swelling					
		Vomiting					

Date:10/15/04ISR Number: 4475508-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00091
Age:60 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Aspirin	C		
UNKNOWN			Atorvastatin Calcium	C		
UNKNOWN			Metoprolol Tartrate	C		

Date:10/15/04ISR Number: 4475509-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blindness Unilateral	Consumer	Rofecoxib	PS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Rofecoxib	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Rofecoxib	SS	Merck & Co., Inc	ORAL

Date:10/15/04ISR Number: 4475510-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00267
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475511-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00224
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Life-Threatening								
Other								

Date:10/15/04ISR Number: 4475512-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00233
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder							
Disability	Feeling Abnormal							

Date:10/15/04ISR Number: 4475513-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00053
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	697	DAY
Initial or Prolonged	Difficulty In Walking		Lexotan	C				
UNKNOWN								
Other	Myocardial Infarction		Higroton	C				
UNKNOWN								
	Oedema Peripheral		Cipramil	C				
UNKNOWN								
			Daonil	C				
UNKNOWN								
			Gopten	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Glucoformin	C				
UNKNOWN								
			Corgard	C				
UNKNOWN								

				Xenical	C		
UNKNOWN							

Date:10/15/04ISR Number: 4475514-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00388
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
	Erythema		Vioxx	SS	Merck & Co., Inc	ORAL
	Paralysis		[Therapy			
	Somnolence		Unspecified]	C		
UNKNOWN						
	Tachycardia		Plavix	C		
UNKNOWN						
			L-Thyroxin	C		
UNKNOWN						
			Beloc-Zok	C		
UNKNOWN						

Date:10/15/04ISR Number: 4475516-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00201
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
			Gabapentin	C		ORAL
			Insulin	C		
UNKNOWN						
			Metformin	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475518-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00063
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertensive Crisis		Captopril	C				
UNKNOWN								
Initial or Prolonged			Digoxin	C				
UNKNOWN								

Date:10/15/04ISR Number: 4475519-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00109
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional	Celecoxib	SS				
UNKNOWN								

Date:10/15/04ISR Number: 4475528-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475529-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00013
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Evening Primrose Oil	C				
UNKNOWN								
			Zopiclone	C				
UNKNOWN								
			Vitamins					

			(Unspecified)	C		
UNKNOWN						
			Felodipine	C		ORAL
			Hydrochlorothiazide	C		
UNKNOWN						

Date:10/15/04ISR Number: 4475530-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00044
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chronic Lymphocytic		Vioxx	PS	Merck & Co., Inc	ORAL
17 DAY						
Initial or Prolonged	Leukaemia		Aspirin And Caffeine			
	Dermatitis Bullous		And Propoxyphene			
	Haemorrhage		Hydrochloride	C		ORAL
17 DAY						
	Petechiae		Tetrazepam	C		ORAL
17 DAY						
	Thrombocytopenia		Valsartan	C		ORAL
17 DAY						
			Omeprazole	C		ORAL
17 DAY						

Date:10/15/04ISR Number: 4475531-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00328
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Vicodin Tablets	C		
UNKNOWN						
Initial or Prolonged	Pancreatitis		Darvocet-N	C		
UNKNOWN						
Disability	Sepsis		Fosamax	C		ORAL
Other			Flexeril	C		ORAL
			Zoloft	C		
UNKNOWN						

			Flexeril	C			ORAL
			Cardizem	C			
UNKNOWN							
			Primidone	C			
UNKNOWN							

Date:10/15/04ISR Number: 4475532-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/15/04ISR Number: 4475533-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00430
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 5 YR	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness					
Other	Hypertension					
	Prostatectomy					
	Prostatic Disorder					

Date:10/15/04ISR Number: 4475535-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00962
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			[Therapy			
Disability			Unspecified]	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Calcium			
			(Unspecified)	C		
UNKNOWN						

				Effexor	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Librium	C		
UNKNOWN							
				Advair	C		
UNKNOWN							
				Phenytoin	C		
UNKNOWN							
				Dilantin	C		
UNKNOWN							

Date:10/15/04ISR Number: 4475536-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00744
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56 MON	
			Lipitor	C				
UNKNOWN								
			Lanoxin	C				
UNKNOWN								
			Zetia	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Gemfibrozil	C				
UNKNOWN								
			Lisinopril	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475537-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01172
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Wall Pain		Bumex	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			Trusopt	C			OPHTHALMIC	
			K-Dur	C			UNKNOWN	
			Quinine	C			UNKNOWN	

Date:10/15/04ISR Number: 4475539-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00670
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	2 WK	
Hospitalization -	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL	2 WK	
Initial or Prolonged			[Therapy Unspecified]	C			UNKNOWN	

Date:10/15/04ISR Number: 4475540-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475541-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00964
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								

Date:10/15/04ISR Number: 4475542-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00329
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Convulsion		Aspirin	C				
UNKNOWN								
Other			Glucotrol Xl	C				
UNKNOWN								
			Zocor	C		ORAL		
			Avandia	C				
UNKNOWN								
			Acupril	C				
UNKNOWN								

Date:10/15/04ISR Number: 4475543-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00313
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/15/04ISR Number: 4475545-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00006
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea		Acetaminophen And Codeine Phosphate	C		ORAL		
	Transient Ischaemic Attack		Aspirin	C		ORAL		
			Terazosin Hydrochloride	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Dothiepin Hydrochloride	C		ORAL		

Date:10/15/04ISR Number: 4475546-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00110
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Fatigue							
	Myocardial Infarction							

Date:10/15/04ISR Number: 4475547-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00411
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Albuterol	C		RESPIRATORY (INHALATION)		
			Diovan	C		UNKNOWN		
			Norvasc	C		UNKNOWN		

Date:10/15/04ISR Number: 4475549-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01368
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/15/04ISR Number: 4475550-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475551-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01377
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Aciphex	C				
UNKNOWN								
			Verapamil	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475552-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475553-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01441
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475554-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00866
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aortic Disorder Hypertension Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475556-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01513
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			Codeine	C				
UNKNOWN								

Date:10/15/04ISR Number: 4475559-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475560-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01195
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	284 DAY	
	Heart Valve Stenosis		[Therapy Unspecified]	C			UNKNOWN	
			Fosamax	C		ORAL		
			Nexium	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Hydro-Chlor	C			UNKNOWN	

Date:10/15/04ISR Number: 4475562-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01093
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
			Lipitor	C			UNKNOWN	

			Prozac	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Zonegran	C		
UNKNOWN						
			Levoxyl	C		
UNKNOWN						
			Skelaxin	C		
UNKNOWN						
			Kadian	C		
UNKNOWN						

Date:10/15/04ISR Number: 4475564-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01092
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -			Lotrel	C				
UNKNOWN								
Initial or Prolonged			Hytrin	C				
UNKNOWN								
Disability								

Date:10/15/04ISR Number: 4475565-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01376
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4475566-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00716
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Headache							
Other								

Date:10/15/04ISR Number: 4475571-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01365
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:10/15/04ISR Number: 4475572-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01439
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
							892	DAY
Hospitalization -	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
Initial or Prolonged	Hypertension		Atenolol	C				
UNKNOWN								
Disability	Myocardial Infarction		Lipitor	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								
			Prinivil	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4475573-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01398
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Memory Impairment		Lipitor	C				
	Mental Impairment							
	Speech Disorder							

Date:10/15/04ISR Number: 4475575-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01440
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Flexeril	C				
			Zoloft	C				

Date:10/15/04ISR Number: 4475577-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01461
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged	Chest Pain		Lorcet Plus	C				
	Cold Sweat		Xanax	C				
	Headache		Neurontin	C				
	Hypertension		Prinivil	C				
			Effexor	C				
			Ultram	C				
			Glucophage	C				

Actos C
UNKNOWN

Zantac C
UNKNOWN

Date:10/15/04ISR Number: 4475580-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00011
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/15/04ISR Number: 4476622-9Report Type:Direct Company Report #CTU 229689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Actonel 35mg Aventis	PS	Aventis	ORAL	TABLET ONCE	A WEEK
			Vioxx 25mg Merck	SS	Merck	ORAL	TABLET ONCE	A DAY
			Glycolax	C				
			Zetia	C				
			Kutrase	C				
			Docusate Sodium	C				
			Prevacid	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/15/04ISR Number: 4476650-3Report Type:Direct Company Report #CTU 229668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Increased Renal Impairment		Vioxx Usual- On A Day Merck	PS	Merck	ORAL	ONE A DAY ORAL	

Date:10/15/04ISR Number: 4476713-2Report Type:Direct Company Report #CTU 229706
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Choking Sensation		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG ORAL	ONCE

Date:10/15/04ISR Number: 4476740-5Report Type:Direct Company Report #CTU 229674
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Cerebrovascular Accident Paralysis		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAILY ORAL	ONCE

Date:10/15/04ISR Number: 4478989-4Report Type:Expedited (15-DaCompany Report #WAES 0409CHL00003
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right	Foreign	Tab Vioxx					

Initial or Prolonged	Coronary Artery Disease	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY						
	Myocardial Ischaemia	Health				
PO 86 DAY						
		Professional	Cinnarizine	C		
			Clonazepam	C		
			Dorzolamide Hcl	C		
			Tamsulosin Hydrochloride	C		
			Timolol	C		
			Zopiclone	C		

Date:10/15/04ISR Number: 4479075-XReport Type:Expedited (15-DaCompany Report #WAES 0404NZL00026
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Diverticulum	Foreign	Tab Vioxx 25mg	PS		ORAL
25MG/DAILY/PO						
Initial or Prolonged	Gastritis	Study	Tamsulosin			
	Hiatus Hernia	Health	Hydrochloride	C		
	Melaena	Professional				

Date:10/15/04ISR Number: 4479077-3Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00025
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Failure Acute	Foreign	Tab Vioxx 25 Mg	PS		ORAL
25						
Initial or Prolonged		Study				
MG/DAILY/PO						
		Health	Aspirin	C		
		Professional	Bisoprolol	C		

			Simvastatin	C			

Date:10/15/04ISR Number: 4479336-4Report Type:Expedited (15-DaCompany Report #WAES 401USA50103
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia	Study	Tab Rofecoxib 25 Mg	PS		ORAL	25	
Initial or Prolonged	Erythema	Health					MG/DAILY/PO	
	Gastric Disorder	Professional	Calcium (Unspecified)	C				
	Haematocrit Decreased		Diltiazem Hydrochloride	C				
	Haemoglobin Decreased		Hydrochlorothiazide	C				
	Neutrophil Count Increased		Lisinopril	C				
	Upper Gastrointestinal Haemorrhage		Potassium Chloride	C				
	Varices Oesophageal		Propranolol Hydrochloride	C				
			Vitamins (Unspecified)	C				

Date:10/15/04ISR Number: 4479341-8Report Type:Expedited (15-DaCompany Report #WAES 0410USA50112
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Coronary Artery Occlusion	Health					MG/DAILY/PO	
Initial or Prolonged Disability	Feeling Abnormal	Professional	Amlodipine Besylate	C				
	Myocardial Infarction		Aspirin	C				
			Rabeprazole Sodium	C				
			Vitamins (Unspecified)	C				

Date:10/16/04ISR Number: 4476295-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Anaemia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Other	Angle Closure Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		
	Faeces Discoloured		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Haemodialysis		Tiazac	C				UNKNOWN
	Headache		Advil	C				UNKNOWN
	Muscle Spasms							
	Myocardial Infarction							
	Nephrolithiasis							
	Osteoarthritis							
	Pharyngolaryngeal Pain							
	Renal Artery Atherosclerosis							
	Renal Artery Stenosis							
	Renal Failure Chronic							
	Wound Infection Staphylococcal							

Date:10/16/04ISR Number: 4476296-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00146
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Hospitalization -	Ovarian Cancer		Epoetin Alfa	C				UNKNOWN
Initial or Prolonged			Morphine	C				UNKNOWN

Date:10/16/04ISR Number: 4476302-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00020
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Amlodipine Besylate	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Bromazepam	C				UNKNOWN
			Calcium Carbonate	C				UNKNOWN
			Teriparatide	C				UNKNOWN
			Cyanocobalamin And Pyridoxine And Thiamine	C				UNKNOWN
			Etoricoxib	C				UNKNOWN
			Hydroxychloroquine Sulfate	C				UNKNOWN
			Leflunomide	C				UNKNOWN
			Methotrexate	C				UNKNOWN

				Omeprazole	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

Date:10/16/04ISR Number: 4476303-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00655
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Amnesia	Professional	Tylenol Sinus	C		
UNKNOWN						
Other	Angina Pectoris		Lipitor	C		
UNKNOWN						
	Angle Closure Glaucoma		Flexeril	C		ORAL
	Anxiety		Amaryl	C		ORAL
	Arthropathy		Toprol Xl Tablets	C		ORAL
	Blood Pressure Increased					
	Cartilage Hypertrophy					
	Cerebrovascular Accident					
	Chest Pain					
	Convulsion					
	Coronary Artery Disease					
	Coronary Artery Stenosis					
	Depression					
	Gastric Ulcer Haemorrhage					
	Hypercholesterolaemia					
	Hypertension					
	Intervertebral Disc Disorder					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476307-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02050
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Other	Gastric Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lung Neoplasm Malignant		Vioxx	SS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Decreased		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Lortab	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			Elavil	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Verapamil Hydrochloride	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Flexeril	C			UNKNOWN	
			Depakote	C			UNKNOWN	

	Duragesic	C
UNKNOWN		
	Advil	C
UNKNOWN		
	Prevacid	C
UNKNOWN		
	Oxycodone	C
UNKNOWN		
	Zantac	C
UNKNOWN		

Date:10/16/04ISR Number: 4476308-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Back Injury
Other	Benign Prostatic Hyperplasia
	Bladder Neck Sclerosis
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Haemolysis
	Haemorrhoidal Haemorrhage
	Hyperkalaemia
	Hyperlipidaemia
	Hypertension
	Liver Function Test Abnormal
	Palpitations
	Renal Failure Acute
	Rheumatoid Arthritis
	Rhinitis Allergic
	Stress
	Tooth Abscess

Urethral Stricture
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health	Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
Professional	Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Deconamine	C			UNKNOWN	
	Lisinopril	C			UNKNOWN	
	Meclizine	C			UNKNOWN	
	Aciphex	C			UNKNOWN	

Date:10/16/04ISR Number: 4476309-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
Disability	Arthritis
Other	Blindness
	Bronchitis
	Catheter Site Haemorrhage
	Cholecystitis Chronic
	Cholelithiasis
	Coronary Artery Disease
	Drug Ineffective
	Duodenal Scarring
	Emotional Distress
	Fibromyalgia
	Gastritis
	Gastrooesophageal Reflux Disease
	Haematuria
	Herpes Simplex
	Hiatus Hernia
	Hypermetropia
	Hyperreflexia
	Hypersensitivity
	Inguinal Hernia
	Irritable Bowel Syndrome
	Joint Contracture

Mental Disorder
Morton'S Neuroma
Muscle Contractions
Involuntary
Myocardial Infarction
Nasopharyngitis
Nausea
Neck Pain
Nephrolithiasis
Overdose
Polycythaemia
Presbyopia
Road Traffic Accident
Skin Discolouration
Skin Laceration
Tympanic Membrane
Perforation
Upper Respiratory Tract
Infection
Vertigo Positional
Vision Blurred
Vitreous Floaters

		Vomiting Whiplash Injury Wound Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Vioxx	SS	Merck & Co., Inc	
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Acetaminophen	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Codeine	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Sulfasalazine	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Gabapentin	C		
UNKNOWN							
				Lovastatin	C		
UNKNOWN							
				Lovastatin	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							

Compazine C
UNKNOWN

Seroquel C
UNKNOWN

Date:10/16/04ISR Number: 4476310-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Bronchitis
	Cardiac Failure Congestive
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Depression
	Dyspnoea
	Fatigue
	Feeling Abnormal
	Gastrooesophageal Reflux Disease
	Gouty Arthritis
	Influenza
	Limb Injury
	Malignant Hypertension

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Myocardial Ischaemia Nasal Discomfort Oedema Peripheral					
		Palpitations Rhinitis Allergic	Health Professional	Vioxx Norco	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Skin Lesion		Allopurinol	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Xanax	C		
UNKNOWN							
		Tinnitus		Aspirin	C		
UNKNOWN							
		Upper Respiratory Tract		Soma	C		
UNKNOWN							
		Infection		Plavix	C		
UNKNOWN							
				Colchicine	C		
UNKNOWN							
				Diltiazem Hydrochloride	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Indocin (Indomethacin)	C		ORAL
				Imdur	C		
UNKNOWN							
				Lecithin And Protein (Unspecified)	C		
UNKNOWN							
				Levothroid	C		
UNKNOWN							
				Levothroid	C		
UNKNOWN							
				Levothroid	C		
UNKNOWN							
				Levothroid	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Zocor	C		ORAL

			Nitro-Dur	C		
UNKNOWN						

Date:10/16/04ISR Number: 4476311-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Blood Pressure Increased		Lortab	C		
UNKNOWN						
	Convulsion		Folic Acid	C		
UNKNOWN						
	Ear Disorder		Skelaxin	C		
UNKNOWN						
	Eye Disorder		Methotrexate	C		
UNKNOWN						
	Fibromyalgia		Ultram	C		
UNKNOWN						
	Headache		Triamcinolone	C		
UNKNOWN						
	Heart Rate Increased		Sodium Folate	C		
UNKNOWN						
	Hypoaesthesia		Toprol Xl Tablets	C		
UNKNOWN						
	Kidney Infection		Nitropaste	C		
UNKNOWN						
	Nausea		Prednisone	C		
UNKNOWN						
	Palpitations		Prednisone	C		
UNKNOWN						
	Rash					
	Renal Disorder					
	Stress					
	Upper Respiratory Tract Infection					
	Weight Decreased					

Date:10/16/04ISR Number: 4476312-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age: Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Angina Pectoris

		Blood Pressure Increased					
		Bradycardia					
		Cholelithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Aspirin	C		
UNKNOWN							
		Dilatation Atrial		Calcium			
		Dyspnoea		(Unspecified)	C		
UNKNOWN							
		Fatigue		Digoxin	C		
UNKNOWN							
		Inner Ear Disorder		Folic Acid	C		
UNKNOWN							
		Myocardial Infarction		Claritin	C		
UNKNOWN							
		Non-Hodgkin'S Lymphoma		Pravachol	C		
UNKNOWN							
		Vertigo					

Date:10/16/04ISR Number: 4476313-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01618
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
466 DAY							
Hospitalization -		Atrial Fibrillation	Professional	Norvasc	C		
UNKNOWN							
Initial or Prolonged		Cardiac Disorder		Clonazepam	C		
UNKNOWN							
Other		Cerebral Infarction		Lanoxin	C		
UNKNOWN							
		Coma		Vasotec	C		ORAL
		Constipation		Zoloft	C		
UNKNOWN							
		Drug Screen Positive		Emla	C		
UNKNOWN							
		Epigastric Discomfort		Centrum Silver	C		
UNKNOWN							
		Fall		Primidone	C		
UNKNOWN							
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					

Disease
Headache
Humerus Fracture
Hypokalaemia
Incontinence
Leukocytosis
Muscle Spasms
Pneumonia Aspiration
Pneumonitis
Vomiting

Date:10/16/04ISR Number: 4476314-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Zydone	C			UNKNOWN	
	Convulsion		Elavil	C			UNKNOWN	
	Intervertebral Disc Disorder		Zanaflex	C		ORAL		
			Prozac	C		ORAL		
	Lumbar Radiculopathy		Aleve	C			UNKNOWN	
	Spinal Osteoarthritis		Prilosec	C		ORAL		
	Urinary Tract Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476316-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00112
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Chest Pain							
	Colonic Stenosis							
	Fatigue							
	Malnutrition							
	Ventricular Tachycardia							

Date:10/16/04ISR Number: 4476317-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00099
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
Initial or Prolonged	Hemiplegia		Leflunomide	C				
Disability			Methotrexate	C				UNKNOWN
			Prednisolone	C				UNKNOWN

Date:10/16/04ISR Number: 4476318-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00120
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476319-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00119
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coma		Warfarin	C				UNKNOWN

Initial or Prolonged

Date:10/16/04ISR Number: 4476320-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00077
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Norvasc	C			UNKNOWN	
			Baclofen	C			UNKNOWN	
			Dothep	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Clexane (Enoxaparin Sodium)	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	
			Quinine	C			UNKNOWN	

Date:10/16/04ISR Number: 4476321-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00118
Age:73 YR Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aneurysm Death Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
		[Therapy Unspecified]	C				UNKNOWN
		[Therapy Unspecified]	C				UNKNOWN
		Acetaminophen	C				UNKNOWN
		Aspirin	C				UNKNOWN
		Irbesartan	C				UNKNOWN

Date:10/16/04ISR Number: 4476322-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Adverse Event
	Anaemia
	Angina Unstable
	Anxiety
	Arthropathy
	Back Pain
	Bacterial Infection
	Barrett'S Oesophagus
	Cartilage Injury
	Chest Pain
	Cholelithiasis
	Convulsion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dermatitis Contact
	Dizziness
	Dysuria
	Gastritis
	Hepatic Enzyme Increased
	Hypercholesterolaemia
	Hyperlipidaemia

Hypersensitivity
Hypertension
Lethargy
Lipoma
Lymphadenopathy
Migraine
Neuralgia
Oedema Peripheral
Oesophagitis
Osteoarthritis
Palpitations
Pyrexia
Red Blood Cell
Sedimentation Rate
Increased
Spondylolisthesis
Acquired
Therapeutic Response
Decreased
Tricuspid Valve
Incompetence

	Upper Respiratory Tract Infection						
	Ventricular Hypertrophy	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	White Blood Cell Count Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Es Tablets	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Hydrodiuril	C		ORAL		

Date:10/16/04ISR Number: 4476323-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00117
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		[Therapy Unspecified]	C				UNKNOWN

Date:10/16/04ISR Number: 4476324-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00091
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				UNKNOWN
			Atorvastatin Calcium	C				UNKNOWN
			Metoprolol Tartrate	C				UNKNOWN

Date:10/16/04ISR Number: 4476325-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00097
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Alendronate Sodium	C				UNKNOWN
Initial or Prolonged	Cerebrovascular Accident		Amitriptyline Hydrochloride	C				UNKNOWN
	Myocardial Ischaemia		Aspirin	C				UNKNOWN
	Ventricular Dysfunction		Furosemide	C				UNKNOWN
			Temazepam	C				UNKNOWN
			Tiratricol	C				UNKNOWN
			Levothyroxine Sodium	C				UNKNOWN
			Metoclopramide	C				UNKNOWN
			Olanzapine	C				UNKNOWN
			Pimeclone Hydrochloride	C				UNKNOWN

Date:10/16/04ISR Number: 4476326-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476327-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00010
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476328-6Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00016
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476329-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Vein Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:10/16/04ISR Number: 4476330-4Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476331-6Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00010
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476332-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00180
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cardiac Operation		Atorvastatin Calcium	C				
Initial or Prolonged								

Date:10/16/04ISR Number: 4476333-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00291
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		1157 DAY
	Cervical Polyp		Cinnarizine	C		ORAL		
			Omeprazole	C		ORAL		
			Phenytoin	C		ORAL		

Date:10/16/04ISR Number: 4476334-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00013
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block Complete		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476335-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00128
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Stanolone	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476336-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00123
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/16/04ISR Number: 4476337-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00063
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertensive Crisis		Captopril	C				
UNKNOWN								
Initial or Prolonged			Digoxin	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476338-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00305
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Captopril	C			UNKNOWN	
	Intracranial Aneurysm		Famotidine	C			UNKNOWN	
	Visual Disturbance							
	Vomiting							

Date:10/16/04ISR Number: 4476339-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00302
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc		UNKNOWN	1 DAY
	Coma							
	Death							
	Increased Bronchial Secretion							

Date:10/16/04ISR Number: 4476340-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00327
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476341-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00294
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			[Therapy Unspecified]	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Amlodipine Besylate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Butylscopolamine Bromide	C			UNKNOWN	
			Vioxx	C		ORAL		
			Vioxx	C		ORAL		
			Sulbutiamine	C			UNKNOWN	
			Vioxx	C		ORAL		
			Vioxx	C		ORAL		
			Chlorthalidone	C			UNKNOWN	
			Cloxazolam	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	
			Piracetam	C			UNKNOWN	
			Propafenone Hydrochloride	C			UNKNOWN	
			Propranolol Hydrochloride	C			UNKNOWN	

Date:10/16/04ISR Number: 4476342-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00308
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Chest Pain							

Date:10/16/04ISR Number: 4476343-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476344-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00299
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476345-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00330
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476346-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00306
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atacand	C			UNKNOWN	
			Sandimmun	C			UNKNOWN	
			Nepresol (Dihydralazine Sulfate)	C			UNKNOWN	
			L-Thyroxin	C			UNKNOWN	
			Cellcept	C			UNKNOWN	

Date:10/16/04ISR Number: 4476347-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00346
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476348-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00351
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal Palpitations Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476349-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476350-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00266
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476351-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476352-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00233
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476353-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00105
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation							
	Blood Pressure Increased							
	Insomnia							
	Palpitations							
	Prescribed Overdose							

Date:10/16/04ISR Number: 4476354-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00390
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Disability								

Date:10/16/04ISR Number: 4476355-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01062655
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL	91	DAY
	Dyspepsia		Naproxen	C				
UNKNOWN								
	Ischaemic Cardiomyopathy							

Joint Range Of Motion
Decreased
Musculoskeletal Stiffness
Myocardial Infarction

Date:10/16/04ISR Number: 4476356-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00370
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476357-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00366
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476358-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476359-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00391
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476360-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00375
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476361-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00365
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476362-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00392
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/16/04ISR Number: 4476363-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00399
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ramipril	C				
UNKNOWN								
Disability								

Date:10/16/04ISR Number: 4476364-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00387
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476365-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476366-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Procedural Complication							
	Vision Blurred							

Date:10/16/04ISR Number: 4476367-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00430
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Osteonecrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/16/04ISR Number: 4476368-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00424
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/16/04ISR Number: 4476369-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Aneurysm

Other	Angina Unstable
	Anorexia
	Anxiety
	Anxiety Disorder
	Aortic Aneurysm
	Asthenia
	Cardiac Disorder
	Carotid Artery Occlusion
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Decubitus Ulcer
	Depression
	Diabetes Mellitus
	Duodenal Ulcer
	Duodenal Ulcer
	Haemorrhage
	Eating Disorder
	Emotional Distress
	Emphysema
	Facial Palsy
	Fall

		Foot Fracture					
		Gastric Ulcer					
		Gastroenteritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Hemiparesis		Norvasc	C		
UNKNOWN							
		Hypertension		Aggrenox	C		
UNKNOWN							
		Intestinal Functional		Cyanocobalamin	C		
UNKNOWN							
		Disorder		Zocor	C		
UNKNOWN							
		Leg Amputation		Lorazepam	C		
UNKNOWN							
		Micturition Urgency		Reglan	C		
UNKNOWN							
		Myocardial Infarction					
		Nausea					
		Peripheral Ischaemia					
		Peripheral Vascular					
		Disorder					
		Pyrexia					
		Thrombosis					
		Toe Amputation					
		Toe Deformity					
		Transient Ischaemic					
		Attack					
		Upper Gastrointestinal					
		Haemorrhage					
		Ventricular Hypertrophy					
		Vomiting					
		Wound Dehiscence					

Date:10/16/04ISR Number: 4476370-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Venous Thrombosis Limb		Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/16/04ISR Number: 4476371-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00422
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertensive Heart Disease		Pantoprazole Sodium	C				
	Oedema							

Date:10/16/04ISR Number: 4476372-9Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00013
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C		ORAL		
			Topiramate	C		ORAL		
			[Therapy Unspecified]	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476373-0Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00013
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Dyspepsia		Aspirin	C		ORAL		
	Hypoaesthesia		Cyanocobalamin	C		ORAL		
	Vision Blurred		Folic Acid	C		ORAL		

Date:10/16/04ISR Number: 4476374-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00004
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Omeprazole	C		ORAL		

Date:10/16/04ISR Number: 4476375-4Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/16/04ISR Number: 4476376-6Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00052
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Alendronate Sodium	C		ORAL		

			Aspirin	C		ORAL
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL

Date:10/16/04ISR Number: 4476377-8Report Type:Expedited (15-DaCompany Report #PL-MERCK-0410POL00004
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia Haemolytic		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Autoimmune		[Therapy			
Initial or Prolonged			Unspecified]	C		ORAL
Disability			Atorvastatin Calcium	C		ORAL
Other			Carvedilol	C		ORAL
			Trimetazidine	C		ORAL
			Diosmin And Hesperidin	C		ORAL
			Metoprolol Tartrate	C		ORAL
			Perindopril Erbumine	C		ORAL

Date:10/16/04ISR Number: 4476378-XReport Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Rofecoxib	PS	Merck & Co., Inc			UNKNOWN

Date:10/16/04ISR Number: 4476379-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00400
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/16/04ISR Number: 4476380-8Report Type:Expedited (15-DaCompany Report #PL-MERCK-0410POL00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:10/16/04ISR Number: 4476381-XReport Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476382-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00727
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476383-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476384-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00967
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/16/04ISR Number: 4476385-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00111
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	C				

UNKNOWN

			Simvastatin	C			ORAL
			Irbesartan	C			
UNKNOWN							

Date:10/16/04ISR Number: 4476386-9Report Type:Expedited (15-DaCompany Report #FI-MERCK-0410FIN00006
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Venous Thrombosis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476387-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00966
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Triamterene	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Diltiazem Hydrochloride	C				
UNKNOWN								
			Glyburide	C				
UNKNOWN								

				Prinivil	C		
UNKNOWN							
				Metformin	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							

Date:10/16/04ISR Number: 4476388-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00562
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Headache		Teveten (Eprosartan)	C				
UNKNOWN								
			Maxzide	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476389-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00969
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability			Lipitor	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Altace	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476390-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00847
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Liver Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Loss Of Consciousness		[Therapy					
Initial or Prolonged	Renal Disorder		Unspecified]	C				
UNKNOWN								
Disability	Tooth Fracture							

Date:10/16/04ISR Number: 4476391-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00779
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional	Tylenol With Codeine					
			#3	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Colace	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Pepcid	C				
UNKNOWN								
			Magnesia [Milk Of]	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476392-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ocular Vascular Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional						

Date:10/16/04ISR Number: 4476393-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00961
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Chest Pain		[Therapy Unspecified]	C				
Disability	Coronary Artery Occlusion Vascular Calcification		[Therapy Unspecified]	C				
			Albuterol	C				
			Albuterol	C				
			Fosamax	C				
			Chloracon	C				
			Calcium (Unspecified)	C				
			Flovent	C				
			Vitamins (Unspecified)	C				
			Advair	C				
			Folic Acid	C				
			Lasix (Furosemide)	C				
			Imdur	C				
			Prevacid	C				
			Flomax (Morniflumate)	C				
			Prednisone	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476394-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01228
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Colitis Ischaemic	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Extrasystoles		Toprol Xl Tablets	C		
Other	Palpitations					

Date:10/16/04ISR Number: 4476395-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01168
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/16/04ISR Number: 4476396-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01083
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Local Swelling	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Mass		Lotrel	C		
UNKNOWN						
	Pain In Extremity					

Date:10/16/04ISR Number: 4476397-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01212
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Cough, Cold, And Flu Therapies (Unspecified)	C		
UNKNOWN						

Date:10/16/04ISR Number: 4476398-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01091
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Heart Rate Increased		Fosamax	C		ORAL	UNKNOWN	
	Myocardial Infarction		Atenolol	C			UNKNOWN	
			Fluoxetine	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Hydrodiuril	C		ORAL		
			Singulair	C		ORAL		

Date:10/16/04ISR Number: 4476399-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00535
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Joint Swelling	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY	
	Rash		Estradiol	C			UNKNOWN	
			Triam-A	C			UNKNOWN	
			Paroxetine	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476400-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01169
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death	Professional						

Date:10/16/04ISR Number: 4476401-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00280
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cerebrovascular Accident		Methotrexate	C		ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/16/04ISR Number: 4476402-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01213
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Unevaluable Event		Lipitor	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Hydrochlorothiazide And Lisinopril	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Lisinopril	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476403-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01391
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activities Of Daily Living Impaired	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Osteo-Bi-Flex	C				
UNKNOWN								
Initial or Prolonged	Chest Discomfort		Os-Cal	C				
UNKNOWN								
Disability	Cough		Thyroid	C				
UNKNOWN								
	Cyanosis		Vitamins					
	Dyspnoea		(Unspecified)	C				
UNKNOWN								
	Headache		Zyrtec	C				
UNKNOWN								
	Pain		Nexium	C				
UNKNOWN								
	Pain In Extremity							
	Peripheral Coldness							
	Sleep Disorder							
	Thyroid Mass							
	Tinnitus							

Date:10/16/04ISR Number: 4476404-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476405-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01337
Age:94 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pruritus		[Therapy					
Initial or Prolonged	Red Blood Cell Count		Unspecified]	C				
UNKNOWN								
Disability	Decreased		Zocor	C		ORAL		

Date:10/16/04ISR Number: 4476406-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:10/16/04ISR Number: 4476407-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional						

Date:10/16/04ISR Number: 4476408-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01097
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Increased		Wellbutrin	C				
UNKNOWN								
Initial or Prolonged	Malaise		Zyrtec	C				
UNKNOWN								
Disability			Advair	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

			Singulair	C		ORAL

Date:10/16/04ISR Number: 4476409-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01356
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
			Ultram	C				

UNKNOWN

UNKNOWN

Date:10/16/04ISR Number: 4476410-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01174
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Atherosclerosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
			Nortriptyline	C				

UNKNOWN

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476411-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01107
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertension		Vicodin Tablets	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476412-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Palpitations	Professional						

Date:10/16/04ISR Number: 4476413-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01508
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cholelithiasis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gallbladder Operation							
	Generalised Oedema							
	Unevaluable Event							

Date:10/16/04ISR Number: 4476414-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01510
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Diovan	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476415-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01676
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476416-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00101
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ecg Signs Of Myocardial	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ischaemia		Aluminum Hydroxide					
	Oesophagitis		And Dimethicone And					
			Magnesium Hydroxide	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476417-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01599
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
UNKNOWN								
Initial or Prolonged			Neurontin	C				
UNKNOWN								
Disability			Prilosec	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/16/04ISR Number: 4476418-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01253
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization -		Professional	Lipitor	C		ORAL		
Initial or Prolonged			Atarax	C		ORAL		
Other			Prevacid	C		ORAL		

Date:10/16/04ISR Number: 4476419-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01683
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Swelling	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Cozaar	C		ORAL		

Date:10/16/04ISR Number: 4476420-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01741
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Other								

Date:10/16/04ISR Number: 4476421-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01740
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Arterial Stent	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Insertion		[Therapy					
Initial or Prolonged	Coronary Artery Disease		Unspecified]	C				
UNKNOWN								
	Renal Failure							

Date:10/16/04ISR Number: 4476422-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01592
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476423-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01691
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476424-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01680
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lipitor	C				
UNKNOWN								
Initial or Prolonged			Lexapro	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Topamax	C				
UNKNOWN								

				Imitrex	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Inderal	C		
UNKNOWN							

Date:10/16/04ISR Number: 4476425-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01591
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								

Date:10/16/04ISR Number: 4476426-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01670
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/16/04ISR Number: 4476428-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00427
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476430-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01774
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/16/04ISR Number: 4476432-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01775
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Hospitalization -	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Dyspnoea		Premarin	C				UNKNOWN
Disability	Myocardial Infarction		Effexor	C				UNKNOWN
	Overdose							
	Pain							
	Palpitations							
	Suicidal Ideation							

Date:10/16/04ISR Number: 4476433-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00389
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477153-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthropod Bite							
	Asthma							
	Blood Pressure Increased							
	Bronchitis							
	Cardiomegaly							
	Chronic Obstructive Pulmonary Disease							
	Contusion							
	Convulsion							
	Coronary Artery Occlusion							
	Depression							
	Dysarthria							
	Dysphagia							
	Dysphonia							
	Dysuria							
	Encephalopathy							
	Fall							
	Foot Fracture							
	Fractured Coccyx							
	Gastrooesophageal Reflux Disease							
	Haematuria							
	Head Injury							
	Headache							
	Hypertensive Crisis							
	Hypotension							
	Insomnia							
	Intervertebral Disc Disorder							
	Joint Sprain							
	Labile Hypertension							
	Loss Of Consciousness							
	Malaise							
	Mental Impairment							
	Myalgia							
	Nausea							
	Osteoarthritis							
	Respiratory Distress							
	Seborrhoeic Keratosis							
	Skeletal Injury							

Skin Papilloma
Sleep Walking
Upper Respiratory Tract
Infection
Urinary Tract Infection
Urticaria

Date:10/18/04ISR Number: 4477155-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Alcoholic Seizure
	Anaemia
	Anion Gap Increased

		Blood Pressure Fluctuation					
		Cardiovascular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Change Of Bowel Habit	Health	Vioxx	PS	Merck & Co., Inc	ORAL
34	DAY						
		Duodenitis	Professional				
		Encephalopathy					
		Grand Mal Convulsion					
		Haematemesis					
		Headache					
		Hordeolum					
		Hypokalaemia					
		Influenza					
		Limb Injury					
		Oedema					
		Pruritus					
		Renal Failure					
		Tenosynovitis Stenosans					
		Vision Blurred					
		Weight Decreased					

Date:10/18/04ISR Number: 4477156-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00888
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Anaemia		Aspirin	C		
UNKNOWN							
Initial or Prolonged		Anxiety		Cefadroxil	C		
UNKNOWN							
Disability		Bacteria Urine Identified		Clonidine	C		
UNKNOWN							
		Brain Neoplasm		Meclizine	C		
UNKNOWN							
		Clostridium Colitis		Accupril	C		
UNKNOWN							
		Coronary Artery Disease					
		Death					
		Decubitus Ulcer					
		Dementia					
		Dysarthria					
		Faecaloma					
		Feeding Disorder					

Hemiparesis
Hypotension
Oedema Peripheral
Oral Fungal Infection
Osteoarthritis
Peripheral Vascular
Disorder
Pneumonia
Rectal Haemorrhage
Renal Failure
Respiratory Distress
Venous Insufficiency
Wound Infection
Pseudomonas
Wound Infection
Staphylococcal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477158-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Phosphokinase Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Disability	Cerebrovascular Accident		Zocor	SS		ORAL		83 DAY
	Dermatitis		Acetaminophen	C				UNKNOWN
	Fatigue		Vitamins					
	Headache		(Unspecified)	C				UNKNOWN
	Hyperhidrosis		Calcium					
	Hyperplasia		(Unspecified)	C				UNKNOWN
	Insomnia		Hydrodiuril	C		ORAL		
	Lipoma		Claritin	C				UNKNOWN
	Mitochondrial Myopathy							
	Myalgia							
	Myopathy							
	Pain In Extremity							
	Paraesthesia							
	Pharyngitis							
	Restless Legs Syndrome							
	Skin Lesion							

Date:10/18/04ISR Number: 4477159-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00833
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angioneurotic Oedema	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Arthralgia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
Other	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Depression		Elavil	C		ORAL		

	Drug Hypersensitivity	Aspirin	C	
UNKNOWN				
	Gastrointestinal Injury	Zithromax	C	
UNKNOWN	7 DAY			
	Gout	Buspar	C	
UNKNOWN				
	Hypertension	Cardizem	C	
UNKNOWN				
	Insomnia	Prozac	C	
UNKNOWN				
	Intervertebral Disc	Neurontin	C	
UNKNOWN				
	Disorder	Ismo	C	
UNKNOWN				
	Joint Injury	Morphine Sulfate	C	ORAL
	Oedema Peripheral	Ms Contin	C	ORAL
	Palpitations	Ms Contin	C	
UNKNOWN				
	Pneumonia	Ms Contin	C	
UNKNOWN				
	Rash			
	Skin Discolouration			
	Synovitis			
	Urine Output Decreased			

Date:10/18/04ISR Number: 4477163-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104491
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Anxiety
Initial or Prolonged	Breast Mass
Disability	Cardiac Murmur
	Disturbance In Attention
	Fatigue
	Flatulence
	Fungal Infection

	Headache						
	Hypercalcaemia						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Nausea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Respiratory Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Subarachnoid Haemorrhage		Tylenol	C			UNKNOWN
	Urticaria		Tavist-D	C			UNKNOWN
	Vomiting		Afrin Nasal Spray	C			UNKNOWN

Date:10/18/04ISR Number: 4477165-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01741
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY
	Blood Potassium Decreased		Klonopin	C			UNKNOWN
	Bradycardia		Pepcid	C		ORAL	
	Cardiac Arrest		Prozac	C			UNKNOWN 2924 DAY
	Cardiogenic Shock						
	Coronary Artery Disease						
	Emotional Distress						
	Gastritis						
	Haemorrhoids						
	Hyperhomocysteinaemia						
	Hypokalaemia						
	Ischaemic Cardiomyopathy						
	Malaise						
	Otitis Media						
	Scleritis						
	Sepsis						
	Upper Limb Fracture						
	Urinary Tract Infection						
	Ventricular Dysfunction						
	Ventricular Fibrillation						
	Ventricular Tachycardia						

Date:10/18/04ISR Number: 4477166-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY
Initial or Prolonged	Increased							
Other	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cardiomyopathy							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Haemoglobin Decreased							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Pericarditis							
	Post Procedural Complication							
	Pulmonary Oedema							
	Rales							
	Wound Secretion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477168-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00201
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Convulsion							
	Feeling Abnormal							
	Hypoaesthesia							
	Insomnia							
	Intraocular Pressure Test Abnormal							
	Pain In Extremity							

Date:10/18/04ISR Number: 4477170-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		582 DAY
Initial or Prolonged	Infarction	Professional	Proventil	C				UNKNOWN
	Acute Sinusitis		Ziac	C				UNKNOWN
	Asthenia		Rhinocort	C				UNKNOWN
	Blood Cholesterol		Zyrtec	C				UNKNOWN
	Increased		Pancof	C				UNKNOWN
	Cardiac Failure		Celexa	C				UNKNOWN
	Congestive		Allfen Dm	C				UNKNOWN
	Coronary Artery Disease		Pepcid	C		ORAL		
	Coronary Artery Occlusion		Diovan	C				UNKNOWN
	Crying		Nasacort	C				UNKNOWN
	Depression		Ultram	C				UNKNOWN
	Dizziness		Serevent	C				UNKNOWN

	Emotional Distress		Folic Acid	C		
UNKNOWN						
	Glucose Tolerance		Tequin	C		
UNKNOWN						
	Impaired		Hyzaar	C		ORAL
	Nasopharyngitis		Marcof Expectorant	C		
UNKNOWN						
	Nervousness		Atrovent	C		
UNKNOWN						
	Otitis Media		Claritin	C		
UNKNOWN						
	Pain		Avelox	C		
UNKNOWN						
	Pain In Extremity					
	Swelling					

Date:10/18/04ISR Number: 4477171-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00130
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477172-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00278
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
	Renal Failure Chronic					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477173-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00283
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/18/04ISR Number: 4477176-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00148
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc		UNKNOWN	639 DAY
Initial or Prolonged	Condition Aggravated		Enalapril Maleate	C			UNKNOWN	
Other	Hypertension							

Date:10/18/04ISR Number: 4477177-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00174
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged	Dysphagia	Professional						
	Facial Palsy							
	Hypersensitivity							
	Vision Blurred							

Date:10/18/04ISR Number: 4477178-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
	Blindness Unilateral							

Carotid Artery Occlusion
Cerebrovascular Accident

Date:10/18/04ISR Number: 4477179-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00093
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Extrasystoles Haematemesis Myocardial Infarction Overdose		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:10/18/04ISR Number: 4477180-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00275
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477181-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphthous Stomatitis Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477182-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477183-0Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00014
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Cerebral Infarction Flushing		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477184-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00126
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ademetionine Sulfate Tosylate	C		ORAL		
			Amylase And Bromelains And Chymotrypsin And Lipase And Pancreatin And	C		ORAL		
			Aspirin	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Tamsulosin					

Hydrochloride	C		ORAL
Silibinin	C		ORAL
Lormetazepam	C		ORAL
Pantoprazole Sodium	C		ORAL
Perindopril Erbumine	C		ORAL

Date:10/18/04ISR Number: 4477186-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00020
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477187-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00214
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy Dementia Alzheimer'S Type Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477188-XReport Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00004
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477189-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00259
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477190-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00032
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Propafenone Hydrochloride	C		ORAL		

Date:10/18/04ISR Number: 4477193-3Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00008
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pneumonia							
Initial or Prolonged	Pneumonitis							

Renal Impairment

Date:10/18/04ISR Number: 4477194-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00919
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Fall Feeding Disorder Gait Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477196-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00985
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cardiac Disorder		Celebrex	C				
Initial or Prolonged Disability	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477197-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01116
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Librax Capsules	C				
UNKNOWN								
Initial or Prolonged			Tranxene	C				
UNKNOWN								
Disability			Nexium	C				
UNKNOWN								
			Ultram	C				
UNKNOWN								
			Asacol	C				
UNKNOWN								
			Remeron	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477198-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00876
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dry Throat		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Lipitor	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Levothroid	C				
UNKNOWN								
			Omeprazole	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477199-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00667
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		

	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Benign Colonic Neoplasm		Norvasc	C		
UNKNOWN						
	Colonic Polyp		Sinemet	C		
UNKNOWN						
	Fall		Synthroid	C		
UNKNOWN						
	Neuropathy Peripheral		Benicar	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477201-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00739
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Lotrel	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477202-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis		Plavix	SS		ORAL
			Atenolol	C		ORAL
			Zocor	C		ORAL
			Tildiem	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477204-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:10/18/04ISR Number: 4477205-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01414
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL	1969 DAY	
Initial or Prolonged	Myocardial Infarction		Estratest	C			UNKNOWN	
Disability								

Date:10/18/04ISR Number: 4477208-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01405
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Initial or Prolonged								

Date:10/18/04ISR Number: 4477209-4Report Type:Expedited (15-DaCompany Report #MY-MERCK-0410MYS00008
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
			Celecoxib	C		ORAL		
			Valdecoxib	C			UNKNOWN	

Date:10/18/04ISR Number: 4477211-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00763
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bacteria Urine Identified		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Darvocet-N	C			UNKNOWN	
	Increased		Elavil	C		ORAL		
	Blood Triglycerides		Lipitor	C			UNKNOWN	
	Increased		Lasix (Furosemide)	C			UNKNOWN	
	Cardiac Flutter		Procardia	C			UNKNOWN	
	Low Density Lipoprotein		Prilosec	C			UNKNOWN	
	Decreased		K-Dur	C			UNKNOWN	
	Overdose							
	White Blood Cells Urine							
	Positive							

Date:10/18/04ISR Number: 4477213-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01444
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Trental	C			UNKNOWN	
Disability			Zocor	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477214-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01401
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc		UNKNOWN	5 MON
	Mobility Decreased							
	Monoplegia							
	Pollakiuria							
	Stomach Discomfort							

Date:10/18/04ISR Number: 4477216-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01393
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	106 DAY	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Hydrochlorothiazide	C		ORAL		

Date:10/18/04ISR Number: 4477217-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01194
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lopressor	C				
			Zocor	C		ORAL		

Date:10/18/04ISR Number: 4477218-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01379
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea							

Hypoaesthesia

Date:10/18/04ISR Number: 4477219-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01650
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C		ORAL		
			Ultracet	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Zocor	C		ORAL		
			Atenolol	C			UNKNOWN	
			Tavist	C		ORAL		
			Lasix (Furosemide)	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477221-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01458
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Headache		Tiazac	C				
UNKNOWN								
Initial or Prolonged			Maxzide	C				
UNKNOWN								
Disability								

Date:10/18/04ISR Number: 4477222-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01454
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diarrhoea							
Disability	Fatigue							
	Muscular Weakness							
	Pain In Extremity							
	Pneumonia Mycoplasmal							
	Vomiting							

Date:10/18/04ISR Number: 4477223-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/18/04ISR Number: 4477224-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01725
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		[Therapy					

			Unspecified]	C		
UNKNOWN						
			Dilantin	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477225-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01709
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Emotional Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Aspirin	C		
UNKNOWN						
Disability	Procedural Hypotension		Plavix	C		
UNKNOWN						
			Altace	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477229-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00759
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477230-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01447
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective							
	Dyspnoea							
	Renal Disorder							

Date:10/18/04ISR Number: 4477235-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -	Vomiting		Aspirin	C				UNKNOWN
Initial or Prolonged	Weight Decreased		Ethyl Salicylate	C				UNKNOWN
Disability			Lopid	C				UNKNOWN
			Quinine	C				UNKNOWN

Date:10/18/04ISR Number: 4477239-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Splenic Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				UNKNOWN
			Levoxyl	C				UNKNOWN
			Prednisone	C				UNKNOWN

Date:10/18/04ISR Number: 4477240-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01728
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lotensin	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477242-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01450
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN			Lipitor	C				
Disability			Blood Thinner (Unspecified)	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								
			Vasotec	C		ORAL		
			Glucotrol Xl	C				
UNKNOWN								
			Potassium (Unspecified)	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477243-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02027
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Abdominal Pain
Disability	Diarrhoea
	Dizziness

	Hallucination						
	Mouth Ulceration						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Insulin	C				UNKNOWN

Date:10/18/04ISR Number: 4477277-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		373 DAY
Initial or Prolonged	Infarction		Lipitor	C				UNKNOWN
	Coronary Artery		Tranxene	C				UNKNOWN
	Atherosclerosis		Prozac	C				UNKNOWN
	Emotional Distress		Zantac	C				UNKNOWN
	Obstructive Airways Disorder							

Date:10/18/04ISR Number: 4477279-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01784
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/18/04ISR Number: 4477281-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01770
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
	Arterial Disorder		Glucophage	C		
UNKNOWN						
	Headache		Diovan	C		
UNKNOWN						
	Transient Ischaemic		Primidone	C		
UNKNOWN						
	Attack					
	Tremor					

Date:10/18/04ISR Number: 4477282-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01829
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
2 WK						
Initial or Prolonged	Myocardial Infarction					
Other						

Date:10/18/04ISR Number: 4477283-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01804
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Klonopin	C		
UNKNOWN						
Other			Nexium	C		
UNKNOWN						
			Effexor	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477284-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01956
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1478 DAY
Hospitalization -			Toprol Xl Tablets	C				UNKNOWN
Initial or Prolonged			Prilosec	C				UNKNOWN
			Paxil	C				UNKNOWN
			Altace	C				UNKNOWN

Date:10/18/04ISR Number: 4477287-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01783
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Actos	C				UNKNOWN
Disability								

Date:10/18/04ISR Number: 4477289-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01735
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1190 DAY
Hospitalization -	Ulcer Haemorrhage		Allopurinol	C				UNKNOWN
Initial or Prolonged			Ridaura	C				UNKNOWN

Date:10/18/04ISR Number: 4477290-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Prerenal Failure
	Adverse Event
	Angina Pectoris
	Asthenia
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Cataract Nuclear
	Chest Pain
	Coronary Artery Disease
	Dementia
	Diabetes Mellitus Non-Insulin-Dependent
	Dizziness
	Dyspnoea
	Emotional Distress
	Eye Pain
	Fibromyalgia
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Gout
	Haemorrhage
	Headache
	Hyperlipidaemia
	Hypertension

		Hypertensive Crisis					
		Hypertensive Heart Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypovolaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Local Swelling	Professional	[Therapy			
		Major Depression		Unspecified]	C		
UNKNOWN							
		Memory Impairment		[Therapy			
		Mitral Valve Incompetence		Unspecified]	C		
UNKNOWN							
		Nausea		Lotrel	C		ORAL
		Oedema Peripheral		Celexa	C		ORAL
		Osteoarthritis		Maxzide	C		
UNKNOWN							
		Pseudodementia		Lopressor	C		ORAL
		Pyelonephritis		Nasonex	C		
RESPIRATORY							
		Renal Failure Chronic					
(INHALATION)							
		Respiratory Failure		Nifedipine	C		
UNKNOWN							
		Rhinitis Allergic		Nitrostat	C		
UNKNOWN							
		Sepsis					
		Sinusitis					
		Sleep Disorder					
		Soft Tissue Infection					
		Transient Ischaemic Attack					
		Urinary Tract Infection					

Date:10/18/04ISR Number: 4477299-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01117
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	White Blood Cell Count		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased					

Date:10/18/04ISR Number: 4477817-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Acute Prerenal Failure
Other	Anaemia
	Angina Pectoris
	Angina Unstable
	Anxiety
	Arrhythmia
	Arthritis
	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cardiomegaly
	Cardiomyopathy
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Condition Aggravated
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diabetes Mellitus

		Inadequate Control					
		Gallbladder Disorder					
		Gastritis					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infection		Vioxx	PS	Merck & Co., Inc	ORAL
422	DAY						
		Gastrooesophageal Reflux		Lasix (Furosemide)	SS		
UNKNOWN							
		Disease		Zestril	SS		
UNKNOWN							
		Headache		Niacin	SS		
UNKNOWN							
		Hypercholesterolaemia		Zestril	SS		
UNKNOWN			406 DAY				
		Hyperkalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Tylenol	C		
UNKNOWN							
		Hyperparathyroidism		Calcium			
		Secondary		(Unspecified)	C		
UNKNOWN							
		Hypertension		Plavix	C		
UNKNOWN							
		Impaired Driving Ability		Nitro	C		
UNKNOWN							
		Impaired Self-Care		Temazepam	C		
UNKNOWN							
		Injury		Spironolactone	C		
UNKNOWN							
		Insomnia		Zocor	C		ORAL
		Ischaemic Cardiomyopathy		Miacalcin	C		
UNKNOWN							
		Ischaemic Stroke		Zantac	C		
UNKNOWN							
		Meniere'S Disease		Naproxen	C		
UNKNOWN							
		Mitral Valve Incompetence		Motrin	C		
UNKNOWN							
		Myalgia		Prinivil	C		
UNKNOWN							
		Nerve Compression		Glucotrol	C		
UNKNOWN							
		Oesophagitis		Cardizem	C		
UNKNOWN							
		Osteoarthritis		Prozac	C		
UNKNOWN							
		Osteoporosis					
		Peptic Ulcer					

Peripheral Nerve
Decompression
Peripheral Vascular
Disorder
Pharyngitis
Pleural Effusion
Pruritus
Pulmonary Oedema
Pulmonary Vascular
Disorder
Renal Disorder
Renal Failure Acute
Renal Failure Chronic
Renal Injury
Seasonal Allergy
Silent Myocardial
Infarction
Sinusitis
Skin Ulcer
Thyroid Disorder
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Urinary Tract Infection
Ventricular Dysfunction
Ventricular Hypertrophy
Viral Infection
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477823-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02073
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				
UNKNOWN								
Disability	Anaemia		Glipizide	C				
UNKNOWN								
Other	Angina Unstable							
	Anxiety							
	Aortic Valve Incompetence							
	Atrial Fibrillation							
	Azotaemia							
	Cardiac Failure Acute							
	Cardiac Failure Congestive							
	Chest Pain							
	Chondrocalcinosis Pyrophosphate							
	Colon Adenoma							
	Colon Cancer Recurrent							
	Colonic Polyp							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Diarrhoea							
	Diplopia							
	Dizziness							
	Dysphagia							
	Dyspnoea							
	Emotional Distress							
	Fatigue							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Gastrooesophageal Reflux Disease							
	Headache							
	Heart Rate Irregular							
	Helicobacter Infection							
	Hypertension							
	Hypoaesthesia Oral							
	Inner Ear Disorder							
	Intracardiac Thrombus							
	Joint Injury							
	Mitral Valve Incompetence							

Osteoarthritis
Photosensitivity Reaction
Pleuritic Pain
Pulmonary Oedema
Renal Cyst
Renal Failure
Syncope
Thrombophlebitis
Tooth Infection
Tricuspid Valve
Incompetence
Umbilical Hernia
Urinary Tract Infection
Vein Pain
Ventricular Extrasystoles
Vertigo

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477830-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00172
Age:58 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Swelling							
	Pain In Extremity							
	Peripheral Embolism							

Date:10/18/04ISR Number: 4477835-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Norvasc	C				
UNKNOWN								
Disability	Asthenia		Lotrel	C				
UNKNOWN								
	Blood Cholesterol		Coreg	C				
UNKNOWN								
	Increased		Clonidine	C				
UNKNOWN								
	Blood Creatinine		Clonidine	C		ORAL		
	Increased		Digitek	C				
UNKNOWN								
	Bronchitis		Nexium	C				
UNKNOWN								
	Cardiac Failure		Spironolactone	C				
UNKNOWN								
	Congestive		Zocor	C		ORAL		
	Congestive Cardiomyopathy		Lisinopril	C				
UNKNOWN								
	Contusion		Reglan	C				
UNKNOWN								
	Cough		Lopressor	C				
UNKNOWN								
	Depression		Minoxidil	C				
UNKNOWN								
	Dizziness		Minoxidil	C				
UNKNOWN								
	Dyspepsia		Minoxidil	C				
UNKNOWN								
	Emotional Distress							

Erectile Dysfunction
Facial Palsy
Fall
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Hypertension
Insomnia
Nasal Congestion
Neck Injury
Pain
Rhinorrhoea
Road Traffic Accident
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Swelling
Upper Respiratory Tract
Infection
Ventricular Extrasystoles

Date:10/18/04ISR Number: 4477845-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Angle Closure Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL		
Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		
Faeces Discoloured		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Headache		Tiazac	C			UNKNOWN	
Muscle Spasms		Advil	C			UNKNOWN	
Myocardial Infarction							
Nephrolithiasis							
Osteoarthritis							
Pharyngolaryngeal Pain							
Renal Artery Atherosclerosis							
Renal Artery Stenosis							
Renal Failure Chronic							
Wound Infection Staphylococcal							

Date:10/18/04ISR Number: 4477847-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Coronary Syndrome
Other	Anxiety
	Blood Triglycerides Increased
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chills
	Chronic Obstructive Pulmonary Disease
	Contusion

Deafness Bilateral
Dyspnoea
Dysuria
Epistaxis
Fall
Gingival Bleeding
Haematochezia
Heart Rate Irregular
Hypertension
International Normalised
Ratio Decreased
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Limb Discomfort
Menstrual Disorder
Neck Pain
Oedema Peripheral
Osteoarthritis
Peroneal Nerve Palsy
Radiculitis

		Sciatica					
		Silent Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Stress Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Coumadin	SS		
UNKNOWN							
		Attack		Coumadin	SS		
UNKNOWN							
		Urinary Tract Infection		[Therapy			
		Wheezing		Unspecified]	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Bayer Aspirin	C		
UNKNOWN							
				Bayer Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Ticlid	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Anzemet	C		
UNKNOWN							
				Vasotec	C		ORAL
				Isordil	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:10/18/04ISR Number: 4477862-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03247
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Angina Unstable
	Arthritis
	Back Injury
	Blood Creatinine Increased
	Cardiac Arrest
	Contusion
	Coronary Artery Occlusion
	Cough
	Diabetes Mellitus Non-Insulin-Dependent
	Fatigue
	Gastrooesophageal Reflux Disease
	Hyperlipidaemia
	Hypokalaemia
	Insomnia
	Joint Injury
	Migraine
	Musculoskeletal Discomfort
	Myocardial Infarction
	Palpitations
	Plantar Fasciitis
	Sciatica
	Stress
	Tendonitis
	Thrombocytopenia

		Upper Respiratory Tract Infection					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Celebrex	SS		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Cardizem Cd	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:10/18/04ISR Number: 4477863-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00178
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
624 DAY						

Date:10/18/04ISR Number: 4477865-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00173
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
	Fatigue		Vitamins			
	Myocardial Infarction		(Unspecified)	C		
UNKNOWN						
	Peripheral Vascular Disorder					
	Vascular Occlusion					

Date:10/18/04ISR Number: 4477867-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	49	DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	72	DAY
	Cholelithiasis		Lipitor	C			UNKNOWN	
	Dehydration		Zocor	C		ORAL		
	Dyspepsia		Prinivil	C		ORAL		
	Dyspnoea		Protonix	C			UNKNOWN	
	Ear Infection							
	Eye Irritation							
	Haematuria							
	Hepatic Enzyme Increased							
	Rash Pruritic							
	Skin Lesion							

Date:10/18/04ISR Number: 4477868-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00303
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	93	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477871-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00323
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	C		ORAL		
			Depakene	C		ORAL		1 DAY

Date:10/18/04ISR Number: 4477873-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Palpitations							

Date:10/18/04ISR Number: 4477875-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Aneurysm							
	Haemorrhage							

Date:10/18/04ISR Number: 4477877-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00334
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477878-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00196
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Renal Impairment		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Atenol	C			UNKNOWN	
			Capoten	C			UNKNOWN	
			Simvastatin	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Isosorbide Mononitrate	C			UNKNOWN	

Date:10/18/04ISR Number: 4477880-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00290
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Captopril	C			UNKNOWN	
Other	Tachycardia		Isosorbide Dinitrate	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477882-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00038
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Irritability		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Pravastatin Sodium	C			UNKNOWN	

Date:10/18/04ISR Number: 4477883-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00334
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Intracranial Aneurysm							
	Monoplegia							

Date:10/18/04ISR Number: 4477884-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00317
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477886-8Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477888-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00018
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477889-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Heparin	C				

UNKNOWN

Date:10/18/04ISR Number: 4477890-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00269
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea							
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477891-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		21 DAY
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		47 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		34 DAY
	Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:10/18/04ISR Number: 4477894-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00032
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

Date:10/18/04ISR Number: 4477895-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00273
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477897-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00395
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fluid Retention							
	Prescribed Overdose							

Date:10/18/04ISR Number: 4477899-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00033
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	1042 DAY	
Hospitalization - Initial or Prolonged			Acetaminophen And Codeine Phosphate	C			UNKNOWN	
			Zocor	C		ORAL		
			Bendroflumethiazide	C			UNKNOWN	

Date:10/18/04ISR Number: 4477901-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477903-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00033
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477905-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00074
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Levothyroxine Sodium	C				
			Omeprazole	C				

Date:10/18/04ISR Number: 4477906-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00012
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen	C		ORAL		
			Terazosin Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Celiprolol Hydrochloride	C		ORAL		
			Fluoxetine Hydrochloride	C		ORAL		

Date:10/18/04ISR Number: 4477907-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00281
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477908-4Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00005
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Autonomic Nervous System Imbalance		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Acetaminophen	C		ORAL		
	Haemorrhage		Triazolam	C		ORAL		
			Estrogens, Conjugated	C		ORAL		
			Omeprazole	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477910-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00464
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aphthous Stomatitis							
	Asthenia							
	Diarrhoea							
	Dizziness							
	Ear Pain							
	Face Oedema							
	Fatigue							
	Flatulence							
	Insomnia							
	Laboratory Test Abnormal							
	Muscle Spasms							
	Osteoarthritis							
	Pruritus							
	Vitamin B12 Deficiency							

Date:10/18/04ISR Number: 4477912-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00028
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Dizziness		Thiamine	C		ORAL		

Date:10/18/04ISR Number: 4477913-8Report Type:Expedited (15-DaCompany Report #SI-MERCK-0410HUN00009
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Face		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Date:10/18/04ISR Number: 4477915-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00050
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
			Beclomethasone Dipropionate	C		
RESPIRATORY						
(INHALATION)						
			Betamethasone	C		ORAL
			Salmeterol Xinafoate	C		
RESPIRATORY						
(INHALATION)						
			Insulin	C		
SUBCUTANEOUS						
			Loratadine	C		ORAL

Date:10/18/04ISR Number: 4477919-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01435
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL
			Tylenol With Codeine #3	C		
Disability	Cerebrovascular Accident					
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477926-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477927-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01079
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477928-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00299
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal Coronary Artery Occlusion Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:10/18/04ISR Number: 4477929-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00949
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Chest Pain Hernia Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN
Disability			Xanax	C				UNKNOWN
Other			Zestril	C				UNKNOWN

Date:10/18/04ISR Number: 4477935-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01126
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Irregular							

Date:10/18/04ISR Number: 4477937-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01127
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Clavicle Fracture		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Generalised Oedema		Percocet	C			UNKNOWN	
	Pain In Extremity		Klonopin	C			UNKNOWN	
	Sensory Disturbance		Crestor	C			UNKNOWN	
			Zonegran	C			UNKNOWN	
			Efexor	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

			Provigil	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						
			Potassium Chloride	C		
UNKNOWN						

Date:10/18/04ISR Number: 4477938-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01146
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Neurontin	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/18/04ISR Number: 4477940-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01448
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/18/04ISR Number: 4477941-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00658
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rebound Effect		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy					

				Unspecified]	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							

Date:10/18/04ISR Number: 4477946-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Dyspnoea							
	Ejection Fraction Decreased							

Date:10/18/04ISR Number: 4477947-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01695
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477950-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477951-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01715
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Thrombosis		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
	Intracardiac Thrombus			C				UNKNOWN
	Thrombosis		Coumadin	C				UNKNOWN
			Celebrex	C				UNKNOWN

Date:10/18/04ISR Number: 4477954-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01866
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477956-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02018
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Hospitalization -	Congestive		Lipitor	C				UNKNOWN
Initial or Prolonged	Chest Pain		Cardizem Cd	C				UNKNOWN

Disability
UNKNOWN

Avapro	C	
Synthroid	C	
Aciphex	C	

UNKNOWN

UNKNOWN

Date:10/18/04ISR Number: 4477957-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01689
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/18/04ISR Number: 4477958-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01694
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477960-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01562
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477966-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01647
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:10/18/04ISR Number: 4477968-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477970-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01666
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
	Dizziness							
	Eye Pain							
	Headache							
	Hypoaesthesia							

Date:10/18/04ISR Number: 4477971-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477973-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01619
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477974-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01993
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Genital Disorder Female		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Synthroid	C				
UNKNOWN								
Disability								

Date:10/18/04ISR Number: 4477975-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01943
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477977-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01756
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
			Aspirin	C				
			Zoloft	C				
			Atacand	C				
			Ditropan	C				

Date:10/18/04ISR Number: 4477978-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01722
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477979-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02036
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Gemfibrozil	C				
			Protonix	C				
			Pravachol	C				

Date:10/18/04ISR Number: 4477981-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01648
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477984-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02155
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/18/04ISR Number: 4477986-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02156
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disturbance In Attention							
Other	Memory Impairment							

Date:10/18/04ISR Number: 4477988-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02220
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4477993-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02114
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				
UNKNOWN								

Date:10/18/04ISR Number: 4477995-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00011
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON
Initial or Prolonged	Migraine		Aspirin	C		ORAL		
			Sumatriptan Succinate	C		ORAL		

Date:10/18/04ISR Number: 4478230-2Report Type:Direct Company Report #CTU 229823
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Aggrenox	PS			1	BID
Initial or Prolonged	Haematemesis		Vioxx	SS			25MG	QD
	Melaena		Plendil	C				
	Ulcer		Pepto Bismol	C				
			Alka Seltzer	C				
			Enalapril	C				
			Zocor	C				
			Aricept	C				
			Zoloft	C				
			Kcl	C				
			Lasix	C				
			Allegra	C				
			Mvi	C				

Date:10/18/04ISR Number: 4478331-9Report Type:Direct Company Report #CTU 229783
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coronary Artery Disease Oesophageal Ulcer		Vioxx 50 Mg Tab Msd Merck + Co	PS	Merck + Co		1 TAB DAILY	

Date:10/18/04ISR Number: 4478365-4Report Type:Direct Company Report #CTU 229873
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Cardiac Disorder Myocardial Infarction Thrombosis		Vioxx 50mg Merck	PS	Merck	ORAL	50 MG DAILY ORAL	ONCE

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4478417-9Report Type:Direct Company Report #CTU 229857
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Distension		Vioxx	PS		ORAL	25 MG DAILY	
Hospitalization - Initial or Prolonged								

Date:10/18/04ISR Number: 4478421-0Report Type:Direct Company Report #CTU 229807
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain		Vioxx	Unknown				
	Abdominal Pain Upper		Merick ?	PS	Merick			

Date:10/18/04ISR Number: 4478520-3Report Type:Direct Company Report #CTU 229874
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatinine Increased		Vioxx	PS		ORAL	50 MG PO DAILY	8 DAY
	Hyperkalaemia		Insulin	C				
			Paroxetine	C				
			Metformin	C				
			Trazodone	C				
			Epoetin	C				
			Enoxaparin	C				
			Cyclobenzaprine	C				
			Gabapentin	C				
			Loperamide	C				
			Lansoprazole	C				
			Ferrous Sulfate	C				
			Magnesium Oxide	C				
			Pioglitazone	C				

Multivitamin	C
Oxycodone	C
Baclofen	C
Metoclopramide	C
Oxybutynin	C
Ondansetron	C
Acetaminophen (Prn)	C

Date:10/18/04ISR Number: 4478530-6Report Type:Direct Company Report #CTU 229896
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Aortic Atherosclerosis		Vioxx 30 Mg	PS		ORAL	1 DAILY ORAL	
Intervention to Prevent Permanent Impairment/Damage	Blood Pressure Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/18/04ISR Number: 4478543-4Report Type:Direct Company Report #CTU 229774
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx 40mg Mereck	PS	Mereck	ORAL	40 MG ONCE A	
Hospitalization -	Coronary Artery Occlusion						DAY ORAL	
Initial or Prolonged								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:10/18/04ISR Number: 4478545-8Report Type:Direct Company Report #CTU 229776
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG ONCE	
							DAILY ORAL	

Date:10/18/04ISR Number: 4480059-6Report Type:Expedited (15-DaCompany Report #2003015276
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy	Consumer	Geodon (Ziprasidone)	PS		ORAL	2 IN 1 D,	
Initial or Prolonged	Blood Potassium Decreased						ORAL	
Disability	Blood Pressure		Erythromycin					
Other	Fluctuation		(Erythromycin)					
	Blood Pressure		(Erythromycin)	SS				
	Immeasurable		Rofecoxib					
	Cerebrovascular Accident		(Rofecoxib)	SS		ORAL	50 MG (2 IN 1	
	Coma						D), ORAL	
	Dizziness		Oxycocet					

Drug Interaction	(Paracetamol, Oxycodone Hydrochloride)	SS
Feeling Abnormal	Temazepam (Temazepam)	SS
Hypertension	Cyclobenzaprine Hydrochloride (Cyclobenzaprine Hydrochloride)	SS
Kidney Infection	Fluoxetine Hydrochloride (Fluoxetine Hydrochloride)	C
Laboratory Test Abnormal	Omeprazole (Omeprazole)	C
Migraine	Diazepam (Diazepam)	C
Nasopharyngitis	Sucralfate (Sucralfate)	C
Pain	Metoclopramide (Metoclopramide)	C
Tooth Abscess	Phentermine (Phentermine)	C
Tremor	Paracetamol (Paracetamol)	C
Ulcer	Antihistamines (Antihistamines)	C
Uterine Neoplasm	:Benzfetamine Hydrochloride	
Weight Fluctuation		

(Benzfetamine	C
Ketorolac Tromethamine (Ketorolac Tromethamine)	C
Estrogens Conjugated (Estrogens Conjugated)	C
Lotrel (Amlodipine, Benazepril Hydrochloride)	C
Cotylenol (Paracetamol, Chlorphenamine Maleate, Dextromethorphan	C
Medinite (Ethanol, Paracetamol, Dextromethorphan Hydrobromide, Ephedrine Sulfate,	C
Furosemide (Furosemide)	C
Bupropion Hydrochloride (Bupropion Hydrochloride)	C
Zolpidem Tartrate (Zolpidem Tartrate)	C
Topiramate (Topiramate)	C
Propacet (Paracetamol, Dextropropoxyphene Napsilate)	C
Oxycodone Hydrochloride (Oxycodone Hydrochloride)	C
All Other Therapeutic Products	C

Date:10/18/04ISR Number: 4480069-9Report Type:Expedited (15-DaCompany Report #2004075607
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired	Consumer	Zoloft (Sertraline)	PS		ORAL	50 MG (50 MG, 1 IN 1 D), ORAL	
	Blood Pressure Increased							
	Dysphagia		Neurontin (Gabapentin)					
	Dyspnoea							
	Heart Rate Irregular		(Gabapentin)	SS		ORAL	ORAL	
	Immobile		Olanzapine (Olanzapine)	SS		ORAL	ORAL	
	Prescribed Overdose							
	Weight Decreased		Tolterodine L-Tartrate (Tolterodine L-Tartrate)	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS				
			Atenolol (Atenolol)	C				

Multivitamins (Ascorbic Acid/Ergocalciferol/ Folic Acid/Nicotinamide/Pa	C
Senna Fruit (Senna Fruit)	C
Donepezil Hydrochloride (Donepezil Hydrochloride)	C
Hemorid For Women Cream (Aloe Vera, Paraffin, Liquid	
Phenylephrine Hydrochloride,	C
All Other Therapeutic Products	C

Date:10/18/04ISR Number: 4480444-2Report Type:Expedited (15-DaCompany Report #2004075431
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Neurontin					
	Knee Arthroplasty		(Gabapentin)	PS			600 MG	
	Osteoporosis		Fentanyl (Fentanyl)	SS			75 MCG	
			Ibuprofen (Ibuprofen)	SS				
			Rofecoxib (Rofecoxib)	SS				
			Helianthus Tuberosus (Helianthus Tuberosus	SS				
			All Other Therapeutic Products	SS				

Date:10/19/04ISR Number: 4478559-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01739
Age:60 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Adverse Event Anxiety Asbestosis Bronchitis Burning Sensation Cardiac Arrest Cardiac Failure Congestive Chest Pain Chronic Sinusitis Coronary Artery Atherosclerosis Coronary Artery Disease Emotional Distress Eye Pruritus Hepatic Steatosis Lacrimation Increased

		Lower Respiratory Tract Infection					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Papilloedema		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pruritus		Pepcid	C		
UNKNOWN							
		Sinusitis		Aspirin	C		
UNKNOWN							
		Upper Respiratory Tract		Flexeril	C		ORAL
		Infection		Zocor	C		ORAL
		Ventricular Fibrillation		[Therapy			
		Viral Infection		Unspecified]	C		
UNKNOWN							

Date:10/19/04ISR Number: 4478570-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00209
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Cardiac Failure		Penicillin			
Hospitalization -			(Unspecified)	C		
UNKNOWN						
Initial or Prolonged			Amitriptyline			
			Hydrochloride	C		
UNKNOWN						
			Amitriptyline			
			Hydrochloride	C		
UNKNOWN						

Date:10/19/04ISR Number: 4478571-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Nadolol	C		
UNKNOWN						
	Transient Ischaemic Attack					

Date:10/19/04ISR Number: 4478573-2Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00021
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/19/04ISR Number: 4478574-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00306
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:10/19/04ISR Number: 4478576-8Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00002
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Cardiac Disorder Coronary Artery

Insufficiency

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Levothyroxine Sodium	C				
							UNKNOWN	

Date:10/19/04ISR Number: 4478578-1Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00010
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Epilepsy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypotension		[Therapy Unspecified]	C				
							UNKNOWN	

Date:10/19/04ISR Number: 4478579-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
353 DAY								
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
353 DAY								

Date:10/19/04ISR Number: 4478580-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Disability	Aneurysm
	Aneurysm Ruptured
	Antinuclear Antibody
	Positive
	Aortic Dissection

Asthenia
Atelectasis
Condition Aggravated
Depression
Disturbance In Attention
Diverticulitis
Dizziness
Emotional Distress
Enterobacter Infection
Gastrooesophageal Reflux
Disease
General Physical
Condition Abnormal
Haematocrit Decreased
Haemoglobin Decreased
Hypertension
Iliac Artery Thrombosis
Impaired Healing
Injury
Irritability
Keloid Scar
Lung Infiltration
Myocardial Infarction
Pain

		Pneumonia					
		Prothrombin Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Self Esteem Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Sexual Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Stress		Lorazepam	C		
UNKNOWN							
		Vascular Injury		Amoxicillin	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN							
				Viagra	C		
UNKNOWN							
				Chlorhexidine Hydrochloride	C		
UNKNOWN							

Date:10/19/04ISR Number: 4478585-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/19/04ISR Number: 4478586-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hypertensive Crisis		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
	Malaise		Captopril	C		ORAL

Date:10/19/04ISR Number: 4478587-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00258
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/19/04ISR Number: 4478588-4Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Acenocoumarol	C		ORAL		
Disability								

Date:10/19/04ISR Number: 4478590-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01415
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Influenza							
Initial or Prolonged	Oedema Peripheral							
Disability	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4478591-4Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00023
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pyelonephritis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Candesartan					
Initial or Prolonged	Sepsis		Cilexetil	C		ORAL		
			Indapamide	C		ORAL		
			Aspirin	C		ORAL		
			Etidronate Disodium	C		ORAL		
			Calcium (Unspecified)	C		ORAL		

Date:10/19/04ISR Number: 4478592-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00492
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/19/04ISR Number: 4478593-8Report Type:Expedited (15-DaCompany Report #PT-MERCK-0410PRT00002
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Date:10/19/04ISR Number: 4478594-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01921
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Heart Rate Irregular							
	Transient Ischaemic Attack							

Date:10/19/04ISR Number: 4478595-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00435
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Aortic Valve Incompetence Chronic Obstructive Pulmonary Disease Congestive Cardiomyopathy Mitral Valve Incompetence Obesity Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/19/04ISR Number: 4478596-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00060
Age:55 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Hemiplegia		Irbesartan	C		ORAL		

Date:10/19/04ISR Number: 4478597-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01380
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization - Initial or Prolonged	Confusional State							
	Myocardial Infarction							
	Ulcer Haemorrhage							

Date:10/19/04ISR Number: 4478600-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00039
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiogenic Shock		Metformin	C		ORAL		
	Myocardial Infarction		Gliclazide	C		RECTAL		
	Renal Failure		Acarbose	C		ORAL		
			Benfluorex Hydrochloride	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Atenolol	C		ORAL		

Date:10/19/04ISR Number: 4478601-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01771
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/19/04ISR Number: 4478603-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01893
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Asthenia		Fosamax	C		
UNKNOWN						
Initial or Prolonged	Cardiac Disorder		Vicodin Tablets	C		
UNKNOWN						
	Coma					
	Dehydration					
	Fatigue					
	Intestinal Obstruction					
	Pain					

Date:10/19/04ISR Number: 4478605-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01442
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4478606-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01841
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/19/04ISR Number: 4478607-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01839
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dizziness							

Date:10/19/04ISR Number: 4478609-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01483
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/19/04ISR Number: 4478611-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00280
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cerebrovascular Accident		Methotrexate	C		ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:10/19/04ISR Number: 4478612-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01827
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Xanax	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	

Date:10/19/04ISR Number: 4478625-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02044
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Prilosec	C			UNKNOWN	
			Vasotec	C		ORAL		

				Ditropan Xl	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							

Date:10/19/04ISR Number: 4478626-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00016
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/19/04ISR Number: 4478627-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02039
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	
			Zocor	C		ORAL		

Date:10/19/04ISR Number: 4478629-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02032
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Keratoconjunctivitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Sicca		Soma	C			UNKNOWN	
	Palpitations							

Date:10/19/04ISR Number: 4478631-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01888
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
11 MON						
			Zoloft	C		
UNKNOWN						
			Nortriptyline	C		
UNKNOWN						

Date:10/19/04ISR Number: 4478633-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01438
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Glucotrol	C		
UNKNOWN						
Initial or Prolonged						
Disability						

Date:10/19/04ISR Number: 4478642-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02045
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4479004-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00324
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		133 DAY
Hospitalization -	Haemorrhage		Acetaminophen	C				UNKNOWN
Initial or Prolonged	Haematemesis							

Date:10/19/04ISR Number: 4479005-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged			Acetaminophen	C				UNKNOWN
			Tegretol	C				UNKNOWN
			Lasix (Furosemide Sodium)	C				UNKNOWN
			Slow-K	C				UNKNOWN
			Nexium	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:10/19/04ISR Number: 4479006-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00331
Age:25 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aplastic Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/19/04ISR Number: 4479007-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00323
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	C		ORAL		1 DAY
			Depakene	C		ORAL		

Date:10/19/04ISR Number: 4479009-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00176
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatine Phosphokinase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							

Date:10/19/04ISR Number: 4479010-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00307
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Dizziness							
Other	Dyspnoea							
	Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4479012-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Nitroglycerin	C				
UNKNOWN								
	Epilepsy							
	Overdose							

Date:10/19/04ISR Number: 4479014-1Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00010
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/19/04ISR Number: 4479018-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02120
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Nexium	C				
UNKNOWN								
	Hypotension							

Date:10/19/04ISR Number: 4479022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:10/19/04ISR Number: 4479023-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01675
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Sustiva	C				
UNKNOWN								
	Dyspnoea		Zerit	C				
UNKNOWN								
	Upper Respiratory Tract		Epivir	C				
UNKNOWN								
	Infection		Gemfibrozil	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								
			Percocet	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/19/04ISR Number: 4479025-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01801
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
Initial or Prolonged	Dizziness							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4479027-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02118
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Clovix	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Vitamin B Complex	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Allegra	C			UNKNOWN	

Date:10/19/04ISR Number: 4479031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01738
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Norvasc	C			UNKNOWN	
	Attack		Prilosec	C			UNKNOWN	

Date:10/19/04ISR Number: 4479032-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00058
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Increased		Candesartan					
	Dehydration		Cilexetil	C			UNKNOWN	
	Epistaxis		Pravastatin Sodium	C			UNKNOWN	
	Thrombosis							

Date:10/19/04ISR Number: 4479034-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00019
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Loperamide Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		
			Ferrous Sulfate	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Enalapril Maleate	C		ORAL		

Date:10/19/04ISR Number: 4479041-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02208
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4479043-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01745
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Norvasc	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			Plavix	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:10/19/04ISR Number: 4479055-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/19/04ISR Number: 4479057-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/19/04ISR Number: 4479279-6Report Type:Direct Company Report #CTU 229940
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vasculitis		Vioxx	PS				
BACKPAIN								
Other			Meloxicam	SS				

Required Intervention to Prevent Permanent Impairment/Damage			Ibuprofen	C
			Zocor	C
			Felodipine	C

Date:10/19/04ISR Number: 4480640-4Report Type:Expedited (15-DaCompany Report #WAES 0410ESP00013
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Foreign Consumer	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY; 50 MG/DAILY	
			Topiramate	C				

Date:10/19/04ISR Number: 4480642-8Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00148
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Condition Aggravated	Foreign	Tab Vioxx (Rofecoxib)	PS			50 MG/DAILY	639 DAY
Other	Hypertension		Enalapril Maleate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4480643-XReport Type:Expedited (15-DaCompany Report #WAES 0410BRA00101
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ecg Signs Of Myocardial Ischaemia Oesophagitis	Foreign Consumer	Tab Vioxx (Rofecoxib) Aluminum Hydroxide (+) Dimethicone (+) M	PS C		ORAL		

Date:10/19/04ISR Number: 4480645-3Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00063
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Congestive Cardiomyopathy Hypertensive Crisis		Tab Vioxx (Rofecoxib) Captopril Digoxin	PS C C		ORAL	50 MG/DAILY	

Date:10/19/04ISR Number: 4481001-4Report Type:Expedited (15-DaCompany Report #WAES 0410USA00562
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased Headache	Consumer	Tab Vioxx Maxzide Teveten (Eprosartan)	PS C C		ORAL	50 MG DAILY PO	

Date:10/19/04ISR Number: 4481002-6Report Type:Expedited (15-DaCompany Report #WAES 0410USA00535
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral	Consumer	Tab Vioxx	PS		ORAL	25 MG BID PO	

	Rash		Triam-A	C			
			Estradiol	C			
			Paroxetine	C			

Date:10/19/04ISR Number: 4483492-1Report Type:Direct Company Report #CTU 230013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx					
	Abdominal Pain Upper		Strongest Mg					
	Faeces Discoloured		Free Clinic	PS		ORAL	ONCE DAY	
	Feeling Abnormal						ORAL	
	Oedema Peripheral							
	Palpitations							
	Swelling							

Date:10/19/04ISR Number: 4483495-7Report Type:Direct Company Report #CTU 230016
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphonia		Vioxx 25 Mg					
	Laryngeal Leukoplakia		Meric	PS	Meric		1 DAYLY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/19/04ISR Number: 4483497-0Report Type:Direct Company Report #CTU 229959
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Dizziness		Vioxx	PS			1 DAILY	
Intervention to Prevent Permanent Impairment/Damage	Dyspepsia Palpitations							

Date:10/19/04ISR Number: 4483501-XReport Type:Direct Company Report #CTU 229962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urine		Vioxx	PS			1 X DAY	
Hospitalization -	Dyspepsia		Celebrex	SS			1X DAY	
Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Gastrointestinal Disorder Gastrooesophageal Reflux Disease Urinary Tract Infection							

Date:10/19/04ISR Number: 4483505-7Report Type:Direct Company Report #CTU 229966
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25 Mg Merck	PS	Merck		1 X DAY	
Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Hemiplegia							

Date:10/19/04ISR Number: 4483521-5Report Type:Direct Company Report #CTU 229972
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ulcer Haemorrhage		Vioxx	PS		ORAL	1 DAY ORAL	
Hospitalization - Initial or Prolonged								

Date:10/19/04ISR Number: 4483542-2Report Type:Direct Company Report #CTU 230000
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Arrhythmia		Vioxx 25 Mg Merck	PS	Merck	ORAL	ONCE A DAY ORALLY	
	Blood Pressure Increased							
	Chest Pain							
	Dyspnoea							
	Low Density Lipoprotein Increased							

Date:10/20/04ISR Number: 4479610-1Report Type:Expedited (15-DaCompany Report #TW-MERCK-0410TWN00011
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ventricular Fibrillation							

Date:10/20/04ISR Number: 4479613-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00950
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability				C		ORAL		

Date:10/20/04ISR Number: 4479616-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01500
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4479617-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00022
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Electrocardiogram Abnormal							

Date:10/20/04ISR Number: 4479622-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01768
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Infarction		Norvasc	C				
UNKNOWN								

Date:10/20/04ISR Number: 4479624-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01766
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gallbladder		Neurontin	C				
UNKNOWN								
Initial or Prolonged	Non-Functioning		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/20/04ISR Number: 4479626-5Report Type:Expedited (15-DaCompany Report #US-MERCK-00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Asthenia
Disability	Balance Disorder
	Blood Creatine

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Phosphokinase Increased					
		Brain Stem Infarction					
		Bursitis					
		Cerebellar Infarction					
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
4	DAY						
		Condition Aggravated		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Crying		Zocor	SS		ORAL
83	DAY						
		Death Of Parent		Hydrodiuril	C		ORAL
		Dermatitis		Acetaminophen	C		
UNKNOWN							
		Dermatomyositis		Claritin	C		
UNKNOWN							
		Difficulty In Walking		Vitamins			
		Drug Effect Decreased		(Unspecified)	C		
UNKNOWN							
		Erythema		Calcium			
		Face Oedema		(Unspecified)	C		
UNKNOWN							
		Fall					
		Fatigue					
		Feeling Drunk					
		Haematuria					
		Headache					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hyperplasia					
		Hypertension					
		Impatience					
		Insomnia					
		Intracranial Aneurysm					
		Labyrinthitis					
		Lacunar Infarction					
		Lipoma					
		Mitochondrial Myopathy					
		Myalgia					
		Myopathy					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Pharyngitis					
		Photosensitivity Reaction					
		Restless Legs Syndrome					
		Skin Lesion					

Systemic Lupus
Erythematosus
Tendonitis
Vestibular Disorder
Vomiting

Date:10/20/04ISR Number: 4479627-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02088
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure Acute Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4479628-9Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00024
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pericardial Effusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cephradine	C				
UNKNOWN								

Date:10/20/04ISR Number: 4479629-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00885
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Abdominal Pain							
	Adverse Event							
	Cardiomegaly							
	Chest Pain							
	Gastrooesophageal Reflux Disease							
	Hepatic Steatosis							
	Hiatus Hernia							
	Polytraumatism							

Date:10/20/04ISR Number: 4479630-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-01067901
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Toxicity		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Headache		Butylscopolamine Bromide	C				
	Nausea							
UNKNOWN								

Date:10/20/04ISR Number: 4479633-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00283
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/20/04ISR Number: 4479634-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01499
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Disorder		[Therapy Unspecified]	C				
	Vascular Occlusion							
UNKNOWN								
Disability								

Date:10/20/04ISR Number: 4479637-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01765
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4479638-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00202
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:10/20/04ISR Number: 4479639-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02093
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Chest Pain		Zocor	C			UNKNOWN	
	Feeling Abnormal		Diovan	C			UNKNOWN	
	Vein Pain							

Date:10/20/04ISR Number: 4479640-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01871
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4479641-1Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00007
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged			Enalapril Maleate And					

Hydrochlorothiazide C
UNKNOWN

Date:10/20/04ISR Number: 4479643-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA00267
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		117 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		117 DAY
	Feeling Abnormal		Pravachol	C				UNKNOWN
			Pravachol	C				UNKNOWN
			Zantac	C				UNKNOWN

Date:10/20/04ISR Number: 4479644-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01715
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain Upper
	Adrenal Adenoma
	Angina Pectoris
	Arthralgia
	Arthritis
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Increased
	Bronchitis

		Cardiac Murmur					
		Cataract					
		Cellulitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Conjunctival Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Pravachol	C		
UNKNOWN							
		Cystitis		Tylenol	C		ORAL
		Cystitis Glandularis		Fosamax	C		
UNKNOWN							
		Dilatation Atrial		Tagamet	C		
UNKNOWN							
		Dizziness					
		Dyspepsia					
		Dyspnoea					
		Dyspnoea Paroxysmal					
		Nocturnal					
		Ear Discomfort					
		Ear Infection					
		Electrocardiogram					
		Abnormal					
		Emotional Distress					
		Gastrointestinal Ulcer					
		Gastrooesophageal Reflux					
		Disease					
		Gingival Pain					
		Gingival Swelling					
		Haematuria					
		Haemorrhagic Diathesis					
		Headache					
		Hypercholesterolaemia					
		Increased Tendency To					
		Bruise					
		Mitral Valve Incompetence					
		Nausea					
		Osteoporosis					
		Palpitations					
		Parotid Gland Enlargement					
		Peptic Ulcer					
		Rhinitis Allergic					
		Salivary Gland Calculus					
		Stress Incontinence					
		Sweat Gland Tumour					
		Thyroid Neoplasm					

Tooth Abscess
Urethral Caruncle
Urinary Tract Infection
Visual Acuity Reduced

Date:10/20/04ISR Number: 4479665-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00322
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebrovascular Accident		Vioxx Fenoterol Hydrobromide And Ipratropium Bromide	PS C	Merck & Co., Inc	ORAL RESPIRATORY (INHALATION)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4479697-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01767
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Plavix	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480129-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Soma	C				
UNKNOWN								
Disability	Angina Unstable		Atenolol	C				
UNKNOWN								
	Anxiety Disorder							
	Arthralgia							
	Blood Cholesterol							
	Increased							
	Blood Glucose Increased							
	Chronic Fatigue Syndrome							
	Coronary Artery Disease							
	Depression							
	Dyspepsia							
	Dyspnoea							
	Gout							
	High Density Lipoprotein							
	Decreased							
	Hypertension							
	Hypoaesthesia							
	Insomnia							
	Joint Swelling							
	Lung Disorder							
	Lymphadenopathy							
	Mastoiditis							
	Myocardial Infarction							
	Pain In Extremity							
	Palpitations							
	Personality Disorder							
	Rectal Haemorrhage							

Social Phobia
Varicose Vein

Date:10/20/04ISR Number: 4480133-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Cardiac Disorder
	Cardiomegaly
	Carpal Tunnel Syndrome
	Coronary Artery Atherosclerosis
	Coronary Artery Stenosis
	Dilatation Ventricular

		Drug Ineffective					
		Dyslipidaemia					
		Exostosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Cold	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Naproxen	C		
UNKNOWN							
		Compression		Indocin			
		Mitral Valve		(Indomethacin)	C		ORAL
		Calcification		Zyrtec	C		
UNKNOWN							
		Mitral Valve Incompetence		Prilosec	C		
UNKNOWN							
		Muscle Atrophy		Celexa	C		
UNKNOWN							
		Myalgia		Aciphex	C		
UNKNOWN							
		Night Sweats		Atenolol	C		
UNKNOWN							
		Osteoarthritis		Oxycontin	C		
UNKNOWN							
		Pain		Hydrocodone			
		Peripheral Coldness		Bitartrate	C		
UNKNOWN							
		Postoperative Adhesion		Levsin	C		
UNKNOWN							
		Pyrexia		Flonase	C		
UNKNOWN							
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Scapula Fracture					
		Sinus Bradycardia					
		Skin Laceration					
		Spinal Osteoarthritis					
		Supraventricular					
		Extrasystoles					
		Tendonitis					
		Therapy Non-Responder					
		Trigger Finger					
		Umbilical Hernia					
		Ventricular Dysfunction					

Date:10/20/04ISR Number: 4480145-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00625
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Blood Pressure Increased		Ultram	SS			UNKNOWN	
	Convulsion		Xanax	C			UNKNOWN	
	Facial Pain		Vicodin Es Tablets	C			UNKNOWN	
	Hypoaesthesia		Amitriptyline Hydrochloride	C			UNKNOWN	
	Oral Pain		Neurontin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Glucotrol	C			UNKNOWN	

Date:10/20/04ISR Number: 4480146-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Blood Pressure Increased
	Chest Discomfort
	Convulsion
	Coronary Artery Stenosis

		Diaphragmatic Hernia					
		Headache					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction	Professional	Plavix	C		
UNKNOWN							
		Myocardial Ischaemia		Prilosec	C		
UNKNOWN							
		Neck Pain		Lipitor	C		
UNKNOWN							
		Paraesthesia		Zocor	C		ORAL
		Post Procedural Haematoma		Zocor	C		ORAL
				Aspirin	C		
UNKNOWN							

Date:10/20/04ISR Number: 4480151-6Report Type:Expedited (15-DaCompany Report #US-MERCK-00010882
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Nerve Injury	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Tinnitus	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Premarin	C		
UNKNOWN							

Date:10/20/04ISR Number: 4480157-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:84 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Convulsion					
		Emotional Distress					
		Headache					
		Nervous System Disorder					
		Visual Disturbance					

Date:10/20/04ISR Number: 4480160-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00363
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc		UNKNOWN	1184 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc		UNKNOWN	1184 DAY

Date:10/20/04ISR Number: 4480161-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00831
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Adverse Event
Disability	Anxiety
Other	Asthenia
	Asthma
	Atelectasis
	Breast Cancer Stage I
	Bronchitis Acute
	Chest Pain
	Chronic Sinusitis
	Colonic Polyp
	Dehydration
	Depression
	Diverticulum

		Dysphagia					
		Erosive Oesophagitis					
		Essential Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhoids	Professional	Os-Cal	C		ORAL
		Hepatic Steatosis		Centrum	C		ORAL
		Hyperglycaemia		Hydrochlorothiazide			
		Hyperthyroidism		And Triamterene	C		ORAL
		Hypokalaemia					
		Hypothyroidism					
		Lung Neoplasm					
		Menopause					
		Nasal Septum Deviation					
		Neuropathy					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Osteoarthritis					
		Polydipsia					
		Rhinitis Allergic					
		Sciatica					
		Vertigo Positional					
		Vestibular Neuronitis					
		Viral Upper Respiratory					
		Tract Infection					

Date:10/20/04ISR Number: 4480162-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00840
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event	Professional	Premarin	C		
UNKNOWN							
Disability		Chest Pain		Neurontin	C		
UNKNOWN							
		Constipation		Vicodin Tablets	C		
UNKNOWN							
		Diarrhoea		Vicodin Tablets	C		
UNKNOWN							
		Gastritis		Hydrodiuril	C		ORAL
		Gastrooesophageal Reflux					
		Disease					
		Hypertension					
		Muscular Weakness					

Myalgia
Nocturia
Rectal Haemorrhage

Date:10/20/04ISR Number: 4480164-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00349
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Appendicitis	Consumer	Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 DAY
Hospitalization -	Lung Infection		Vioxx	SS	Merck & Co., Inc		UNKNOWN	4 DAY
Initial or Prolonged	Postpartum Depression		Acetaminophen	C			UNKNOWN	

Date:10/20/04ISR Number: 4480166-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00354
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Chest Pain Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4480167-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00331
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Convulsion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Infarction		Aspirin	C		ORAL
			Captopril	C		ORAL

Date:10/20/04ISR Number: 4480169-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00888
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Anaemia	Professional	Meclizine	C		
Initial or Prolonged UNKNOWN	Anxiety		Accupril	C		
Disability UNKNOWN	Bacteria Urine Identified		Clonidine	C		
UNKNOWN	Brain Neoplasm		Aspirin	C		
UNKNOWN	Chest Wall Pain		Cefadroxil	C		
	Clostridium Colitis					
	Coronary Artery Disease					
	Death					
	Decubitus Ulcer					
	Dementia					
	Dysarthria					
	Faecaloma					
	Feeding Disorder					
	Hemiparesis					
	Hypotension					
	Oedema Peripheral					
	Oral Fungal Infection					
	Osteoarthritis					
	Peripheral Vascular Disorder					
	Pneumonia					
	Rectal Haemorrhage					
	Renal Failure					
	Respiratory Distress					
	Venous Insufficiency					

Wound Infection
Pseudomonas
Wound Infection
Staphylococcal

Date:10/20/04ISR Number: 4480171-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00179
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Zocor	C		ORAL		
Initial or Prolonged	Neck Pain		Telmisartan	C		ORAL		
Other								

Date:10/20/04ISR Number: 4480174-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00357
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Artery Occlusion							
Other	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4480175-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Lower		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Zocor	C		ORAL		
	Back Pain		Prevacid	C				
UNKNOWN								
	Blood Cholesterol Increased							
	Bronchitis Acute							
	Bursitis							
	Chest Discomfort							
	Chest Pain							
	Concussion							
	Constipation							
	Convulsion							
	Costochondritis							
	Depression							
	Diarrhoea							
	Dizziness							
	Drug Ineffective							
	Duodenal Ulcer							
	Dysuria							
	Enterocolitis							
	Haemorrhagic							
	Erectile Dysfunction							
	Eye Disorder							
	Fall							
	Flatulence							
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							
	Haematochezia							
	Haemorrhage							
	Head Injury							
	Hypertension							
	Hypertriglyceridaemia							
	Hypogonadism							
	Kidney Infection							
	Major Depression							
	Migraine							
	Muscle Spasms							

Nausea
Oedema Peripheral
Oesophageal Disorder
Overdose
Palpitations
Renal Disorder
Syncope
Ulcer
Ulna Fracture

Date:10/20/04ISR Number: 4480178-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480180-2Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00011
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriospasm Coronary Chest Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Prednisone	C				
	Hypertension		Methotrexate	C				UNKNOWN

Date:10/20/04ISR Number: 4480181-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00292
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain In Extremity							

Date:10/20/04ISR Number: 4480184-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480185-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01761
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Ulcer	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	UNKNOWN
	Perforation		Prozac	C				
Disability	Overdose		[Therapy Unspecified]	C				UNKNOWN

Date:10/20/04ISR Number: 4480186-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:10/20/04ISR Number: 4480187-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00287
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Refusal Of Examination		Hyzaar	C		ORAL	UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Oxybutynin Chloride	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Omeprazole Magnesium	C			UNKNOWN	
			Mirtazapine	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

			Ascorbic Acid	C			
UNKNOWN							

Date:10/20/04ISR Number: 4480189-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00269
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea							
	Stomach Discomfort							

Date:10/20/04ISR Number: 4480190-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00298
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Myocardial Infarction		Bisoprolol Fumarate	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN								
			Pravastatin Sodium	C				
UNKNOWN								
			Acetaminophen And Oxycodone Hydrochloride	C				
UNKNOWN								
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480191-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00033
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Amyloidosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		[Therapy Unspecified]	C		ORAL		

Date:10/20/04ISR Number: 4480192-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00039
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Pulmonary Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Metformin	C		ORAL		
Hospitalization -			Gliclazide	C				
RECTAL								
Initial or Prolonged			Acarbose	C		ORAL		
			Benfluorex Hydrochloride	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Atenolol	C		ORAL		

Date:10/20/04ISR Number: 4480194-2Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00003
Age:44 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
			[Composition Unspecified]	C		ORAL	3	YR

Date:10/20/04ISR Number: 4480195-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00040
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Muscle Spasms							

Date:10/20/04ISR Number: 4480196-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480198-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00508
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel Syndrome	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chronic Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Condition Aggravated		Phenprocoumon	C				
UNKNOWN								
	Diverticular Perforation							
	Diverticulitis							
	Fibromyalgia							

Musculoskeletal Pain
Polyneuropathy
Spinal Disorder

Date:10/20/04ISR Number: 4480199-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00164
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Initial or Prolonged		Professional	Tamoxifen Citrate	C		ORAL		
			Lansoprazole	C		ORAL		
			Acetaminophen	C		ORAL		
			Furosemide	C		ORAL		

Date:10/20/04ISR Number: 4480200-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00171
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain	Professional						

Date:10/20/04ISR Number: 4480201-7Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00020
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rheumatic Heart Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480202-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00345
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480209-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00052
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged		Professional	Spironolactone	C		ORAL		
			Furosemide	C		ORAL		

Date:10/20/04ISR Number: 4480210-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Arrest	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480211-XReport Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00022
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:10/20/04ISR Number: 4480212-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01686
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vascular Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
		Professional	Lipitor	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:10/20/04ISR Number: 4480213-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01477
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea							
Initial or Prolonged	Fatigue							
Disability	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4480214-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00007
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intervertebral Disc Protrusion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Atorvastatin Calcium	C		ORAL		
			Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Furosemide	C		ORAL		

Date:10/20/04ISR Number: 4480215-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01650
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ultracet	C			UNKNOWN	
Disability			Tavist	C		ORAL		
			Xanax	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			[Therapy Unspecified]	C		ORAL		
			Prevacid	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Zocor	C		ORAL		

Date:10/20/04ISR Number: 4480217-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00447
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Ulcer Haemorrhage	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480218-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypoaesthesia	Consumer	Vioxx Vioxx Aleve	PS SS C	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

UNKNOWN

Date:10/20/04ISR Number: 4480225-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01475
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged			Norvasc	C				
Disability			Urecholine	C				
			Vaseretic	C				

UNKNOWN
UNKNOWN
UNKNOWN

Date:10/20/04ISR Number: 4480226-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01773
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480228-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01473
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/20/04ISR Number: 4480230-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01798
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Potassium (Unspecified)	C			UNKNOWN	
			Cartia (Diltiazem Hydrochloride)	C			UNKNOWN	
			Hydrodiuril	C		ORAL		
			Prinivil	C		ORAL		

Date:10/20/04ISR Number: 4480231-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01755
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Thrombosis		Cardizem	C				UNKNOWN
			Digitek	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:10/20/04ISR Number: 4480232-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Tachycardia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480234-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01790
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4480235-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480236-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Aortic Valve Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480237-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01754
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Hormones (Unspecified)	C				
	Transient Ischaemic Attack		[Therapy Unspecified]	C				

Date:10/20/04ISR Number: 4480238-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02060
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Asthenia Dyspnoea Hypertension Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	

Date:10/20/04ISR Number: 4480241-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01786
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Discomfort		Hydrodiuril	C		ORAL		
	Pain In Extremity		Methadone Hydrochloride	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Prilosec	C			UNKNOWN	

Date:10/20/04ISR Number: 4480242-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01780
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Coumadin	C			UNKNOWN	
Disability			Sulfasalazine	C			UNKNOWN	
			Nifedipine	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	

Folic Acid	C	UNKNOWN
Tramadol Hydrochloride	C	UNKNOWN
Exelon	C	UNKNOWN
Atenolol	C	UNKNOWN
Prozac	C	UNKNOWN
Ditropan Xl	C	UNKNOWN
Allegra	C	UNKNOWN
Omeprazole	C	UNKNOWN
Pravachol	C	UNKNOWN
Gastrointestinal Preparations (Unspecified)	C	UNKNOWN
Calcium (Unspecified)	C	UNKNOWN
Aleve	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN
Humira	C	UNKNOWN
Enulose	C	UNKNOWN
Monopril	C	UNKNOWN

Date:10/20/04ISR Number: 4480244-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01836
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -				Norvasc	C		
UNKNOWN							
Initial or Prolonged				Synthroid	C		
UNKNOWN							
Disability							

Date:10/20/04ISR Number: 4480245-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02062
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction	Professional	Valium	C		
UNKNOWN						
Initial or Prolonged			Coumadin	C		
UNKNOWN						
Disability						
Other						

Date:10/20/04ISR Number: 4480246-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02057
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Premarin	C		
UNKNOWN						
			Altace	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Isosorbide Mononitrate Er	C		
UNKNOWN						

Date:10/20/04ISR Number: 4480248-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02096
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Flexeril	C				
UNKNOWN								
			Singulair	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480249-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01822
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Coumadin	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			Nitro	C				
UNKNOWN								
			Tylenol With Codeine					
			#3	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Diuretic					
			(Unspecified)	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480250-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01813
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Fosamax	C		ORAL	UNKNOWN	
			Ultram	C				
			Metoprolol	C				
			[Therapy Unspecified]	C				

Date:10/20/04ISR Number: 4480256-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02237
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480258-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480259-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02185
Age:62 YR Gender:Female I/FU:I

Outcome	PT
Disability	Cardiovascular Disorder
	Cerebrovascular Accident

		Duodenal Ulcer Fall Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rotator Cuff Syndrome Transient Ischaemic Attack	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/20/04ISR Number: 4480261-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Disability	Adverse Event Hepatocellular Damage Renal Failure Renal Injury	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/20/04ISR Number: 4480262-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/20/04ISR Number: 4480263-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02246
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/20/04ISR Number: 4480264-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02126
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Transient Ischaemic Attack		Zantac	C				
			Glucosamine	C			UNKNOWN	

Date:10/20/04ISR Number: 4480266-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480267-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02244
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
	Chest Pain							
Disability	Coronary Artery Occlusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4480268-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02262
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480270-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02192
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cerebrovascular Accident Pulmonary Embolism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480271-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Stenosis Blister Oedema Peripheral Skin Discolouration	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:10/20/04ISR Number: 4480273-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02127
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480274-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01814
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480280-7Report Type:Expedited (15-DaCompany Report #NL-MERCK-0410NLD00017
Age:64 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction							

Date:10/20/04ISR Number: 4480293-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01816
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Extrasystoles		Bextra	C				
UNKNOWN								
Disability	Heart Rate Irregular		Toprol Xl Tablets	C				
UNKNOWN								
	Hypertension		Flomax (Morniflumate)	C				
UNKNOWN								

				Prevacid	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Fish Oil (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							

Date:10/20/04ISR Number: 4480294-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01789
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
			Fosamax	C		ORAL		
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480296-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Closed Head Injury	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Effexor	C				
UNKNOWN								
	Loss Of Consciousness		[Therapy Unspecified]	C				
	Syncope							
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/20/04ISR Number: 4480297-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Polytraumatism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/20/04ISR Number: 4480916-0Report Type:Direct Company Report #CTU 230072
Age: Gender:Female I/FU:I

Outcome	PT
	Abdominal Pain Upper
	Anorexia
	Asthenia
	Blood Pressure Increased
	Chest Pain
	Chills
	Cold Sweat
	Dyspepsia
	Dyspnoea
	Facial Pain
	Fatigue
	General Physical Health Deterioration
	Headache
	Hyperhidrosis
	Nausea

		Pain In Extremity					
		Palpitations					
		Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting		Vioxx	PS		
		Weight Decreased					

Date:10/20/04ISR Number: 4480991-3Report Type:Direct Company Report #CTU 230104
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx 25 Mg	PS		ORAL
1 CAPSULE						
	Post Procedural					
DAILY ORALLY						
	Complication					
	Rectal Haemorrhage					
	Ulcer Haemorrhage					

Date:10/20/04ISR Number: 4481017-8Report Type:Direct Company Report #CTU 230103
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haemorrhage		Vioxx	PS		
50 MG DAILY						
Hospitalization -	Ulcer Haemorrhage					
Initial or Prolonged						
Disability						

Date:10/20/04ISR Number: 4481030-0Report Type:Direct Company Report #CTU 230097
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx 25 Mg	PS		
25 MG 1X DA						
Hospitalization -	Infarction					
Initial or Prolonged						

Date:10/20/04ISR Number: 4482048-4Report Type:Direct Company Report #CTU 230129
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS			1ADAY	
	Hyperhidrosis							
	Respiratory Tract Congestion							
	Speech Disorder							

Date:10/20/04ISR Number: 4482051-4Report Type:Direct Company Report #CTU 230130
Age:39 YR Gender:Female I/FU:I

Outcome	PT
Disability	Cardiac Disorder
Required	Chest Pain
Intervention to	Dyspnoea
Prevent Permanent	Gastric Disorder
Impairment/Damage	Heart Rate Irregular
	Hypertension
	Hypoaesthesia
	Joint Swelling
	Palpitations

	Renal Disorder					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx 25 Mg Merck & Company	PS	Merck & Company	
25 MG	1 TIME					
A DAY OTHER						
			.	C		

Date:10/20/04ISR Number: 4482163-5Report Type:Direct Company Report #CTU 230133
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Blood Cholesterol		Vioxx 25 Mg Merck	PS	Merck	ORAL
1 TABLET						
Initial or Prolonged	Increased					
EVERY 12						
	Myocardial Infarction					
HOURS ORAL						

Date:10/20/04ISR Number: 4482188-XReport Type:Expedited (15-DaCompany Report #K200401540
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Intermittent Claudication	Foreign	Altace Capsules			
Initial or Prolonged	Post Procedural	Health	(Ramipril) Capsule,			
	Complication	Professional	10mg	PS		ORAL
10 MG, QD,						
	Renal Failure	Other				
ORAL						
	Renal Tubular Necrosis		Vioxxakut			
	Vascular Occlusion		(Rofecoxib) 50mg	SS		ORAL
50 MG, QD,						
ORAL						
			Diclocil (Dicloxacillin Sodium Monohydrate)			

		6 G	SS
INTRAVENOUS	6 G, QD,		
INTRAVENOUS			
		Panodil (Paracetamol)	C
		Dextropropoxyphene (Dextropropoxyphene)	C
		Innohep	C

Date:10/21/04ISR Number: 4481102-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00739
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Amnesia
	Angina Pectoris
	Anxiety
	Blood Bilirubin Unconjugated Increased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Carotid Artery Stenosis
	Cerebral Atrophy
	Cerebral Disorder
	Chest Pain
	Convulsion
	Decreased Appetite
	Depression

		Dizziness					
		Fall					
		Feeling Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gait Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular					
		Hepatic Function Abnormal					
		Hepatic Steatosis					
		Hepatitis A Antibody					
		Abnormal					
		Hypertension					
		Insomnia					
		Lacunar Infarction					
		Liver Function Test					
		Abnormal					
		Memory Impairment					
		Mental Disorder Due To A					
		General Medical Condition					
		Mental Status Changes					
		Pain In Extremity					
		Renal Cyst					
		Renal Failure					
		Sinus Disorder					
		Tinnitus					
		Vascular Dementia					
		Ventricular Hypertrophy					
		Vision Blurred					

Date:10/21/04ISR Number: 4481104-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00064
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1127 DAY							
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
1127 DAY							

Date:10/21/04ISR Number: 4481105-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00941
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux Disease							
	Hemiplegia							
	Hot Flush							
	Hypertension							
	Nasopharyngitis							
	Nervousness							
	Osteoarthritis							
	Pain In Extremity							
	Panic Disorder							
	Rhinitis Allergic							
	Sleep Disorder							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481106-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							3	YR

Date:10/21/04ISR Number: 4481107-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Acute Coronary Syndrome
	Angina Unstable
	Anxiety
	Asthenia
	Atelectasis
	Back Pain
	Balance Disorder
	Blood Pressure Increased
	Blood Triglycerides Increased
	Bronchitis
	Cardiac Murmur
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chills
	Chronic Obstructive Pulmonary Disease
	Coagulopathy
	Contusion
	Deafness Bilateral
	Deafness Neurosensory
	Diarrhoea
	Difficulty In Walking
	Dizziness
	Drug Effect Decreased
	Dyspnoea
	Dysuria
	Epistaxis
	Faeces Discoloured
	Fall

Gastrointestinal Disorder
Gingival Bleeding
Haematochezia
Haemorrhage
Heart Rate Irregular
Hemiparesis
Hypertension
Hypoaesthesia
Injury
Insomnia
International Normalised
Ratio Decreased
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Iron Deficiency Anaemia
Limb Discomfort

		Lung Disorder					
		Menstrual Disorder					
		Mouth Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Nerve Compression		Vioxx	SS	Merck & Co., Inc	ORAL
		Odynophagia		Coumadin	SS		
UNKNOWN							
		Oedema		Coumadin	SS		
UNKNOWN							
		Oedema Peripheral		Tenormin	C		
UNKNOWN							
		Orthopnoea		Tenormin	C		
UNKNOWN							
		Osteoarthritis		Vicodin Tablets	C		
UNKNOWN							
		Palpitations		Nitrostat	C		
UNKNOWN							
		Paraesthesia		Albuterol	C		
UNKNOWN							
		Peroneal Nerve Palsy		Naproxen	C		
UNKNOWN							
		Post Procedural		Vasotec	C		ORAL
		Complication		Lopressor	C		
UNKNOWN							
		Radiculitis		Digoxin	C		
UNKNOWN							
		Renal Disorder		Ticlid	C		
UNKNOWN							
		Restrictive Pulmonary		Tylenol	C		
UNKNOWN							
		Disease		[Therapy			
		Sciatica		Unspecified]	C		
UNKNOWN							
		Sensory Loss		Isordil	C		
UNKNOWN							
		Silent Myocardial		Anzemet	C		
UNKNOWN							
		Infarction		Restoril	C		
UNKNOWN							
		Sleep Disorder		Bayer Aspirin	C		
UNKNOWN							
		Stress Incontinence		Aspirin	C		
UNKNOWN							
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					

Wheezing

Date:10/21/04ISR Number: 4481116-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00472
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Encephalopathy							

Date:10/21/04ISR Number: 4481121-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00374
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Chest Pain		Aminophylline	C				
UNKNOWN								
	Headache							
	Infection							
	Oedema Peripheral							

Date:10/21/04ISR Number: 4481123-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00324
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	133	DAY
Hospitalization -	Haemorrhage		Acetaminophen	C				
UNKNOWN								
Initial or Prolonged	Haematemesis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481124-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00373
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Uterine Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481125-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		422 DAY
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Zestril	SS				UNKNOWN
Other	Blood Glucose Increased		Lasix (Furosemide)	SS				UNKNOWN
	Cardiac Failure		Zestril	SS				UNKNOWN
	Congestive		Niacin	SS			406 DAY	UNKNOWN
	Cardiomegaly		Cardizem	C				UNKNOWN
	Cerebrovascular Accident		Prozac	C				UNKNOWN
	Chronic Obstructive		Motrin	C				UNKNOWN
	Pulmonary Disease		Tylenol	C				UNKNOWN
	Coronary Artery Disease		Plavix	C				UNKNOWN
	Cyst		Miacalcin	C				UNKNOWN
	Diabetes Mellitus		Zocor	C		ORAL		
	Inadequate Control		Glucotrol	C				UNKNOWN
	Fatigue		Zantac	C				UNKNOWN
	Gastroenteritis Viral		Naproxen	C				UNKNOWN
	Gastrointestinal		Spironolactone	C				UNKNOWN

	Infection	Calcium	
	Hyperkalaemia	(Unspecified)	C
UNKNOWN			
	Hyperlipidaemia	Temazepam	C
UNKNOWN			
	Hyperparathyroidism	Nitro	C
UNKNOWN			
	Secondary	Prinivil	C
UNKNOWN			
	Injury		
	Insomnia		
	Ischaemic Cardiomyopathy		
	Meniere'S Disease		
	Mitral Valve Incompetence		
	Myalgia		
	Nerve Compression		
	Osteoporosis		
	Pharyngitis		
	Pharynx Discomfort		
	Pleural Effusion		
	Pruritus		
	Pulmonary Oedema		
	Renal Disorder		
	Renal Failure Acute		
	Renal Failure Chronic		
	Seasonal Allergy		
	Silent Myocardial		
	Infarction		
	Sinusitis		
	Skin Ulcer		
	Transient Ischaemic		
	Attack		
	Tricuspid Valve		
	Incompetence		
	Urinary Tract Infection		
	Ventricular Dysfunction		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481128-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00436
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Atrial Fibrillation Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481129-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00308
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Abnormal Blood Pressure Fluctuation Cardiac Disorder Cardiac Failure Cardiovascular Disorder Chest Discomfort Dyspnoea Extrasystoles Fluid Retention Gastric Haemorrhage Gastric Ulcer Gastritis							

Date:10/21/04ISR Number: 4481140-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:10/21/04ISR Number: 4481142-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00254
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Creatine Phosphokinase Mb Increased	Consumer	Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Creatinine		Pravastatin Sodium	C			UNKNOWN	
	Increased		Glyburide	C			UNKNOWN	15 YR
	Chest Pain Eye Haemorrhage		Metformin Hydrochloride	C			UNKNOWN	15 YR
	Gout Hot Flush		Hydrochlorothiazide And Lisinopril	C			UNKNOWN	
	Renal Failure Retinal Vein Occlusion		Pioglitazone Hydrochloride	C			UNKNOWN	
	Visual Disturbance		Pioglitazone Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481144-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00383
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		14 DAY
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Dizziness		Atenolol	C		ORAL		
Other	Hypertensive Crisis		Thiocolchicoside	C		ORAL		20 DAY

Date:10/21/04ISR Number: 4481148-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00196
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/21/04ISR Number: 4481149-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00939
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability			Synthroid	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481151-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00162
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
		Professional	Aspirin	C				
UNKNOWN								

			Acetaminophen	C		
UNKNOWN						
			Dietary Supplement (Unspecified)	C		
UNKNOWN						

Date:10/21/04ISR Number: 4481152-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00109
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
			Celecoxib	SS		
UNKNOWN						

Date:10/21/04ISR Number: 4481153-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00232
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening			[Therapy Unspecified]	C		
Hospitalization - UNKNOWN						
Initial or Prolonged Disability			[Therapy Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481154-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00096
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Losec (Omeprazole)	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Betaloc	C			UNKNOWN	
			Panadol	C		ORAL		
			Bendrofluazide Tablets	C			UNKNOWN	

Date:10/21/04ISR Number: 4481155-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00268
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Cimetidine	C			UNKNOWN	
	Diabetes Mellitus		Skelaxin	C			UNKNOWN	
	Drug Hypersensitivity		Zoloft	C			UNKNOWN	
	Gastric Haemorrhage		Amitriptyline Hydrochloride	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/21/04ISR Number: 4481156-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00894
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Asthenia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
2 YR						
Initial or Prolonged	Chest Pain	Professional				
	Hypoaesthesia					
	Pyrexia					

Date:10/21/04ISR Number: 4481157-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00030
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Professional	Quinapril			
			Hydrochloride	C		
UNKNOWN 497 DAY						

Date:10/21/04ISR Number: 4481158-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01201
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Glucose Fluctuation	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Heart Valve Insufficiency		Glucovance	C		
UNKNOWN						
	Nausea		Quinine	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Lexapro	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Nizatidine	C		
UNKNOWN						
			Avandia	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481160-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Celebrex	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/21/04ISR Number: 4481161-5Report Type:Expedited (15-DaCompany Report #SI-MERCK-0410HUN00009
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Swelling Face	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
		Professional						

Date:10/21/04ISR Number: 4481162-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01788
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea Exertional		Fosamax	C		ORAL		
Disability	Mobility Decreased		Nitroglycerin	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481163-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01727
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Prinivil	C				
UNKNOWN								
	Pruritus Generalised		Bisoprolol	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481165-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01834
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Dyspnoea							
	Heart Rate Increased							

Date:10/21/04ISR Number: 4481166-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01785
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization - Initial or Prolonged		Professional						
Other								

Date:10/21/04ISR Number: 4481167-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01604
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Folic Acid	C				
UNKNOWN								

				Gemfibrozil	C		
UNKNOWN							
				Nifedipine	C		
UNKNOWN							
				Namenda	C		
UNKNOWN							

Date:10/21/04ISR Number: 4481168-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01546
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481170-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01803
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Discomfort		Zoloft	C				
			[Therapy Unspecified]	C				
			Hydrochlorothiazide	C				
			Plavix	C				
			Zocor	C				
			Zetia	C				
			Toprol Xl Tablets	C				
			[Therapy Unspecified]	C				
			Aspirin	C				

Date:10/21/04ISR Number: 4481171-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01583
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		1 YR

Date:10/21/04ISR Number: 4481172-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481173-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA01922
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Heart Injury Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481174-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02261
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481175-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02422
Age:20 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Chest Pain							
	Dyspnoea							
	Fluid Retention							
	Loss Of Consciousness							
	Pulmonary Congestion							

Date:10/21/04ISR Number: 4481176-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02423
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death		Actos	C			UNKNOWN	
			Zocor	C		ORAL		
			Antineoplastic (Unspecified)	C			UNKNOWN	

Date:10/21/04ISR Number: 4481179-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:10/21/04ISR Number: 4481180-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02407
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -	Drug Ineffective	Neurontin	C
UNKNOWN			
Initial or Prolonged		Norvasc	C
UNKNOWN			
		Lasix (Furosemide)	C
UNKNOWN			
		Coumadin	C
UNKNOWN			
		Ticlopidine Hydrochloride	C
UNKNOWN			

Date:10/21/04ISR Number: 4481181-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:10/21/04ISR Number: 4481202-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01626
Age:50 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged Disability								
	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypotension		Plavix	C			UNKNOWN	
	Myocardial Infarction		Altace	C			UNKNOWN	
	Procedural Hypotension		Aspirin	C			UNKNOWN	

Date:10/21/04ISR Number: 4481206-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01797
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Transient Ischaemic		Plavix	C			UNKNOWN	
	Attack							
	Visual Acuity Reduced							

Date:10/21/04ISR Number: 4481634-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00067
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Fosamax	C		ORAL		
Disability	Cerebrovascular Disorder		Atorvastatin Calcium	C		ORAL		
	Difficulty In Walking		Pitavastatin Calcium	C			UNKNOWN	
	Glioblastoma Multiforme		Calcium Citrate	C			UNKNOWN	
	Memory Impairment		Ergocalciferol	C			UNKNOWN	
	Speech Disorder		Nizatidine	C			UNKNOWN	

	Visual Field Defect	Amiloride Hydrochloride And Hydrochlorothiazide	C
UNKNOWN			

Date:10/21/04ISR Number: 4481639-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Amaurosis Fugax
	Angina Pectoris
	Angiopathy
	Antibody Test Positive
	Aortic Embolus
	Aortic Stenosis
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Arrhythmia
	Atrial Septal Defect
	Back Pain
	Benign Neoplasm Of Skin
	Bicuspid Aortic Valve
	Blindness Transient
	Blindness Unilateral
	Blood Cholesterol Increased
	Blood Pressure Increased

		Cardiolipin Antibody Positive					
		Carotid Artery Dissection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coagulopathy	Health	Vioxx	PS	Merck & Co., Inc	
UNKNOWN	2 DAY						
		Convulsion	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
4 WK							
		Dizziness					
		Dyspnoea					
		Ecchymosis					
		Headache					
		High Density Lipoprotein Increased					
		Low Density Lipoprotein Increased					
		Mitral Valve Incompetence					
		Mitral Valve Stenosis					
		Muscle Twitching					
		Myokymia					
		Palpitations					
		Periorbital Disorder					
		Sensation Of Pressure					
		Sensory Level Abnormal					
		Sinus Bradycardia					
		Thyroid Disorder					
		Transient Ischaemic Attack					
		Tricuspid Valve Incompetence					
		Ventricular Hypertrophy					
		Ventricular Septal Defect					
		Visual Disturbance					

Date:10/21/04ISR Number: 4481642-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00170
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/21/04ISR Number: 4481643-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00175
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481644-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00100
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction Stent Placement	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481646-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00126
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Irbesartan	C				UNKNOWN
			Atorvastatin Calcium	C				UNKNOWN
			Aspirin Calcium	C		ORAL		UNKNOWN
			Aspirin Calcium	C		ORAL		UNKNOWN
			Fluvoxamine Maleate	C				UNKNOWN

Date:10/21/04ISR Number: 4481647-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-01108618
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Decreased Appetite							
	Haemorrhage							
	Vomiting							
	Weight Decreased							

Date:10/21/04ISR Number: 4481648-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00167
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Swelling		Sertraline Hydrochloride	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:10/21/04ISR Number: 4481650-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder	Professional	Baycol	C		ORAL		
	Chest Pain		Baycol	C		ORAL		
	Cow'S Milk Intolerance		Aspirin	C				
UNKNOWN								
	Emotional Distress		Nitroquick	C				
SUBLINGUAL								
	Flank Pain		Metoprolol	C				
UNKNOWN								
	Gastritis Erosive		Metoprolol	C				
UNKNOWN								
	Haemorrhoids		Metoprolol	C				
UNKNOWN								
	Helicobacter Infection		Captopril	C		ORAL		
	Hiatus Hernia		Captopril	C				
UNKNOWN								
	Hypertension		Hydrodiuril	C				
UNKNOWN								
	Myalgia		Claritin	C				
UNKNOWN								
	Myocardial Infarction		Motrin	C				
UNKNOWN								
	Nausea		Estrogens					
	Pain In Extremity		(Unspecified)	C				
UNKNOWN								
	Weight Decreased		Allegra	C				
UNKNOWN								
			Lipitor	C		ORAL		
			Aleve	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481654-0Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00039
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Computerised Tomogram Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481657-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Dyspnoea Myocardial Infarction Neoplasm Malignant	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Date:10/21/04ISR Number: 4481658-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481659-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00029
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Oedema Peripheral	Consumer	Vioxx Diuretic (Unspecified)	PS C	Merck & Co., Inc	ORAL		
UNKNOWN							1	DAY

Date:10/21/04ISR Number: 4481661-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00026
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481662-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00335
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Phlebothrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Disability			Sertraline Hydrochloride	C		ORAL		

Date:10/21/04ISR Number: 4481664-3Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:10/21/04ISR Number: 4481665-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00367
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Diltiazem Hydrochloride	C		ORAL		

Date:10/21/04ISR Number: 4481666-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	129 DAY	

Date:10/21/04ISR Number: 4481671-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00535
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
	Cardiac Failure	Professional						
	Congestive Cardiomyopathy							
	Coronary Artery Stenosis							

Date:10/21/04ISR Number: 4481672-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	

Date:10/21/04ISR Number: 4481673-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris	Other	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Restenosis							

Date:10/21/04ISR Number: 4481675-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Cardiac Disorder Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481676-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00539
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481677-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00542
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Monoparesis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481678-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00494
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Delusion Hallucination, Olfactory Hepatitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:10/21/04ISR Number: 4481679-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Pulmonary Embolism Thrombosis	Other	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481685-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00029
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
			Digoxin	C			UNKNOWN	

Date:10/21/04ISR Number: 4481686-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00167
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL	63 DAY	
		Professional	Aspirin	C		ORAL		
			Heparinoid And Salicylic Acid	C		TOPICAL		
			Ramipril	C		ORAL		
			Ranitidine	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:10/21/04ISR Number: 4481687-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00487
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal	Other	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481688-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism	Other	Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged Disability	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:10/21/04ISR Number: 4481691-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
	Myocardial Infarction							

Date:10/21/04ISR Number: 4481692-8Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00015
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose							
	Self-Medication							

Date:10/21/04ISR Number: 4481694-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00065
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Enzymes Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain							

Date:10/21/04ISR Number: 4481695-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00430
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteonecrosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481696-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00030
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
			Acetaminophen	C		ORAL		

Date:10/21/04ISR Number: 4481697-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481699-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00349
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorectal Infection		Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 DAY
Hospitalization -	Appendicitis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	4 DAY
Initial or Prolonged	Eructation		Acetaminophen	C			UNKNOWN	
	Flatulence							
	Lung Infection							
	Pain							
	Postpartum Depression							
	Splenic Infection							

Date:10/21/04ISR Number: 4481700-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00538
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise		Isosorbide Dinitrate	C		ORAL		
	Electrocardiogram		Iodine	C		ORAL		
	Abnormal		Flupirtine Maleate	C			UNKNOWN	
	Psychosomatic Disease		Tetrazepam	C		ORAL		
	Scan Myocardial Perfusion							
	Abnormal							

Date:10/21/04ISR Number: 4481701-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/21/04ISR Number: 4481705-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01456
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481707-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00726
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/21/04ISR Number: 4481708-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01665
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481709-0Report Type:Expedited (15-DaCompany Report #KR-MERCK-0410KOR00020
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	76	DAY

Date:10/21/04ISR Number: 4481710-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01664
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Flank Pain		Darvocet-N	C			UNKNOWN	

Date:10/21/04ISR Number: 4481713-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00516
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481714-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01461
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	190	DAY
Initial or Prolonged	Cold Sweat		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL	190	DAY
	Hypertension		Lorcet Plus	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Ultram	C			UNKNOWN	

Actos	C		
UNKNOWN			
Prinivil	C		
UNKNOWN			
Effexor	C		
UNKNOWN			
Xanax	C		
UNKNOWN			
Zantac	C		
UNKNOWN			
Neurontin	C		
UNKNOWN			
Percocet	C		
UNKNOWN			
Methadone Hydrochloride	C		
UNKNOWN			
Celebrex	C		ORAL

Date:10/21/04ISR Number: 4481715-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01199
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:10/21/04ISR Number: 4481717-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01687
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Disability	Difficulty In Walking
	Joint Crepitation
	Joint Stiffness
	Musculoskeletal Stiffness
	Neck Pain

		Oedema Peripheral Pain In Jaw Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Hydrocortisone	C		
UNKNOWN							

Date:10/21/04ISR Number: 4481723-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01809
Age:47 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Plavix	C		
UNKNOWN							
		Attack		Premarin	C		
UNKNOWN							
				Levothyroxine Sodium	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Carbatrol	C		
UNKNOWN							
				Aggrenox	C		
UNKNOWN							
				Crestor	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:10/21/04ISR Number: 4481728-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01476
Age:35 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged				Percocet	C		
UNKNOWN							

Disability

Date:10/21/04ISR Number: 4481729-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01776
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481730-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01688
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pacerone	C				UNKNOWN
			Atenolol	C				UNKNOWN

Date:10/21/04ISR Number: 4481733-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01764
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481734-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01762
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Neurontin	C				
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								
Disability			Aleve	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481739-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State							

Date:10/21/04ISR Number: 4481741-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								
Initial or Prolonged								

Date:10/21/04ISR Number: 4481743-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01744
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tenormin	C				
			Vicodin Tablets	C		ORAL		
			Temazepam	C				

Date:10/21/04ISR Number: 4481744-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01557
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure		Megace	C				
	Inadequately Controlled		Allegra	C				
	Blood Pressure Increased		Nasacort	C				
	Cardiac Flutter		Menest	C				
	Joint Swelling		Valium	C				
	Tachycardia		Tenormin	C				
	Weight Increased		Percocet	C				
			Oxycontin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Facial Palsy							

Date:10/21/04ISR Number: 4481747-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02107
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481748-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01964
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Altace	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		
			Coumadin	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Proscar	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481750-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01769
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR
Initial or Prolonged	Cardiac Disorder		Wellbutrin	C			UNKNOWN	
	Chest Pain		Fosamax	C			UNKNOWN	
	Dyspnoea		Zocor	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Lomotil	C			UNKNOWN	

Date:10/21/04ISR Number: 4481752-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA01924
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Injury							
	Myocardial Infarction							
	Thrombosis							

Date:10/21/04ISR Number: 4481753-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02290
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481754-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481756-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		[Therapy					
	Chest Pain		Unspecified]	C				
UNKNOWN								
			Zocor	C		ORAL		

Date:10/21/04ISR Number: 4481763-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481764-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01927
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Neoplasm Malignant		Plavix	C				
UNKNOWN								
Initial or Prolonged								

Date:10/21/04ISR Number: 4481767-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02383
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea Malaise		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481768-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02330
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481769-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481773-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02377
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481774-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02375
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Glucophage	C				
UNKNOWN								
Initial or Prolonged			Avandia	C				
UNKNOWN								
Disability			Lipitor	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481775-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481783-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02454
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Fatigue		Prevacid	C			
UNKNOWN							
			Lopressor	C			
UNKNOWN							
			Lipitor	C			
UNKNOWN							
			Lopid	C			
UNKNOWN							

Date:10/21/04ISR Number: 4481784-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02442
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea							
Initial or Prolonged	Pulmonary Embolism							

Date:10/21/04ISR Number: 4481785-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481786-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02456
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Sulfasalazine	C				
UNKNOWN								

Levalbuterol
Hydrochloride C
UNKNOWN

Hytrin C
UNKNOWN

Date:10/21/04ISR Number: 4481788-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02592
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481789-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02586
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481790-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02590
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481791-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02376
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:10/21/04ISR Number: 4481793-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02693
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thrombosis		Coumadin	C				
UNKNOWN								
Initial or Prolonged			Tylenol	C				
UNKNOWN								
Disability			Bextra	C				
UNKNOWN								

Date:10/21/04ISR Number: 4481794-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02686
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
807 DAY								
Initial or Prolonged	Breast Cancer Female		Nolvadex	C				
UNKNOWN								
	Chest Pain		Theophylline	C				
UNKNOWN								
	Syncope		Prinivil	C		ORAL		
			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/21/04ISR Number: 4481796-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02618
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		[Therapy					
	Dyspepsia		Unspecified]	C				
UNKNOWN								
	Dyspnoea							
	Heart Rate Irregular							
	Myocardial Infarction							
	Nephrolithiasis							

Date:10/21/04ISR Number: 4481797-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/21/04ISR Number: 4481806-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Chest Discomfort							
Disability	Hepatic Enzyme Increased							
	Liver Disorder							
	Scar							

Date:10/21/04ISR Number: 4481814-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02164
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

Haemorrhage

Date:10/21/04ISR Number: 4481817-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02339
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Zocor	C		ORAL		

Date:10/21/04ISR Number: 4483624-5Report Type:Expedited (15-DaCompany Report #2004AL000599
Age:36 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Completed Suicide Multiple Drug Overdose Respiratory Arrest	Literature	Children'S Apap Elixir (Acetaminophe) (Alpharma)	PS	Alpharma	ORAL	PO	
			Infants' Apap Drops (Acetaminophen) (Alpharma)	SS	Alpharma	ORAL	PO	
			Atenolol	SS		ORAL	PO	

			Chlordiazepoxide	SS		ORAL
PO						
			Rofecoxib	SS		ORAL
PO						

Date:10/21/04ISR Number: 4483663-4Report Type:Expedited (15-DaCompany Report #2004AL000598
Age:67 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Intentional Misuse	Literature	Children'S Apap Elixir (Acetaminophen) (Alpharma)	PS	Alpharma	ORAL
PO						
			Infants' Apap Drops (Acetaminophen) (Alpharma)	SS	Alpharma	ORAL
PO						
			Amlodipine/Benazepril	SS		ORAL
PO						
			Rofecoxib	SS		ORAL
PO						

Date:10/21/04ISR Number: 4485264-0Report Type:Direct Company Report #CTU 230170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Coronary Artery Occlusion		Vioxx Rofecoxib			
Required	Decreased Activity		Merck	PS	Merck	
BUCCAL 25 MG BY						
Intervention to						
DAY BUCCAL						
Prevent Permanent			Piascledine	C		
Impairment/Damage			Noctran	C		

Date:10/21/04ISR Number: 4485268-8Report Type:Direct Company Report #CTU 230161
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Ischaemic Neuropathy		Vioxx	PS				4 WK

Date:10/21/04ISR Number: 4486519-6Report Type:Expedited (15-DaCompany Report #K200401547
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction Pancytopenia Suicide Attempt	Foreign Study Health Professional	Altace Capsules (Ramipril) Capsule, 2.5 Mg	PS		ORAL	2.5 MG, QD, ORAL	
		Other	Imurek(Azathioprine) Tablet, 100mg	SS		ORAL	100 MG, QD, ORAL	
			Remergil (Mirtazapine) Tablet, 45mg	SS		ORAL	45 MG, QD, ORAL	
			Vioxx (Rofecoxib) Tablet, 25 Mg	SS		ORAL	25 MG, QD, ORAL	
			Actonel (Risedronate Sodium)	C				
			Calcimagon-D3 (Colefcalciferol					

Carbonate)Chewable Tablet	C
Pantozol (Pantoprazole Sodim)Tablet	C
Prednisolon (Prednisolone) Tablet	C

Date:10/22/04ISR Number: 4482306-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00069
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		252 DAY
	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		557 DAY
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage							
	Chest Pain							
	Condition Aggravated							
	Depression							
	Diarrhoea							
	Diplopia							
	Disturbance In Attention							
	Dizziness							
	Epilepsy							
	Essential Hypertension							
	Fatigue							
	Gastric Disorder							
	Gastrointestinal Disorder							
	Headache							
	Hypertensive Crisis							
	Leukopenia							
	Nausea							
	Neck Pain							
	Paraesthesia							
	Ruptured Cerebral Aneurysm							
	Somnolence							
	Subarachnoid Haemorrhage							
	Syncope							
	Thrombocytopenia							
	Tinnitus							

Date:10/22/04ISR Number: 4482310-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00411
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Skin Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482311-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00330
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Feeling Abnormal Syncope Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL	73 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482312-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482313-0Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00015
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lacunar Infarction		Corticosteroids (Unspecified)	C		PARENTERAL		
			Glucosamine Hydrochloride	C		UNKNOWN		
			Hyaluronate Sodium	C		PARENTERAL		

Date:10/22/04ISR Number: 4482314-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00358
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
Hospitalization - Initial or Prolonged	Renal Failure							
Other								

Date:10/22/04ISR Number: 4482315-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00027
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Initial or Prolonged	Anxiety	Levoglutamide	C		ORAL
	Dizziness	Domperidone	C		ORAL
		[Therapy Unspecified]	C		ORAL

Date:10/22/04ISR Number: 4482316-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:10/22/04ISR Number: 4482317-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00629
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - 1 DAY	Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Road Traffic Accident		Zestril	C		
Disability UNKNOWN	Sinus Arrest		Lipitor	C		
Other	Sinus Bradycardia					

Date:10/22/04ISR Number: 4482318-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01169
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Synthroid	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	

Date:10/22/04ISR Number: 4482319-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01206
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Celebrex	C			UNKNOWN	
Initial or Prolonged	Dyspnoea		Allegra	C			UNKNOWN	
Other	Pain In Extremity		Plavix	C			UNKNOWN	
	Post Procedural Complication		Benazepril Hydrochloride	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Mevacor	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Actos	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

			Metformin	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						

Date:10/22/04ISR Number: 4482320-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00454
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Electrocardiogram T Wave Inversion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482321-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia Cardiac Disorder Cough Cystitis Noninfective Diarrhoea Pruritus Vomiting		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:10/22/04ISR Number: 4482322-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00509
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482323-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:10/22/04ISR Number: 4482326-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00530
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biliary Cirrhosis Primary		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Hypertension		Levoxyl	C				
UNKNOWN								
	Transient Ischaemic		Premarin	C				
UNKNOWN								
	Attack		Cyclobenzaprine Hydrochloride	C				
UNKNOWN								
			Cyclobenzaprine Hydrochloride	C				
UNKNOWN								
			Iron (Unspecified)	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482340-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00510
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482347-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01544
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Hospitalization - Initial or Prolonged	Lung Neoplasm Malignant							
Other								

Date:10/22/04ISR Number: 4482354-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01661
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482355-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482357-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01651
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Bextra	C				
	Coronary Artery Stenosis		Glucosamine	C				
			Relafen	C				

Date:10/22/04ISR Number: 4482358-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01590
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Gastric Disorder							
	General Symptom							
	Rectal Haemorrhage							
	Skin Discolouration							
	Thrombosis							
	Transient Ischaemic Attack							

Date:10/22/04ISR Number: 4482359-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01602
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
			Insulin	C				
Disability			[Composition					
Other			Unspecified]	C				

Date:10/22/04ISR Number: 4482361-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01680
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Imitrex	C				
UNKNOWN							822	DAY
Initial or Prolonged			Inderal La	C		ORAL		
Other			Premarin	C				
UNKNOWN								
			Prevacid	C		ORAL		
			Lipitor	C				
UNKNOWN								
			Topamax	C		ORAL		
			Lexapro	C		ORAL		
			Parafon Forte	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482362-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01586
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
6 MON								
Initial or Prolonged	Lymphoedema		Vioxx	SS	Merck & Co., Inc	ORAL		
1 YR								
	Oedema		Vioxx	SS	Merck & Co., Inc	ORAL		
6 MON								
			Vioxx	SS	Merck & Co., Inc	ORAL		
1 YR								
			Coumadin	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Prinivil	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482363-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01539
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization - Initial or Prolonged	Dyspnoea							
	Oedema Peripheral							

Date:10/22/04ISR Number: 4482364-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00499
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Hot And Cold		[Therapy					
	Pulmonary Embolism		Unspecified]	C				
	Tachycardia							

Date:10/22/04ISR Number: 4482416-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01758
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Urine Present		Vioxx	SS	Merck & Co., Inc	ORAL		
	Burning Sensation		Xanax	C				
	Cerebrovascular Accident		[Therapy					
	Dyspnoea		Unspecified]	C				
	Fall		Aspirin	C				
	Fatigue		Seroquel	C				
	Hypoaesthesia		Premarin	C				
	Muscle Spasms		Lamictal	C				
	Myalgia							
	Transient Ischaemic							

Attack

Date:10/22/04ISR Number: 4482419-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01800
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Drug Ineffective		Dilantin	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Diovan	C			UNKNOWN	

Date:10/22/04ISR Number: 4482420-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01997
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hyzaar	C			UNKNOWN	

Date:10/22/04ISR Number: 4482421-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01750
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482422-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01995
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Urea Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Injury		Lopid	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Covera-Hs	C			UNKNOWN	

Date:10/22/04ISR Number: 4482424-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02014
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482425-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01367
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Toprol Xl Tablets	C			UNKNOWN	
	Gastrooesophageal Reflux Disease		[Therapy Unspecified]	C			UNKNOWN	
	Non-Cardiac Chest Pain		Tylenol	C			UNKNOWN	
	Tremor							

Date:10/22/04ISR Number: 4482426-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01760
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Xanax	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482427-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01759
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		[Therapy Unspecified]	C				
UNKNOWN								
	Visual Disturbance							

Date:10/22/04ISR Number: 4482428-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482430-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02123
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Left Ventricular Failure		Methotrexate	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Oedema		Enbrel	C				
UNKNOWN								
	Retinal Haemorrhage		Prednisone	C				
UNKNOWN								
	Retinal Vasculitis		Neurontin	C				
UNKNOWN								
	Tachycardia		Diovan	C				
UNKNOWN								
			Caltrate	C				
UNKNOWN								
			Foradil	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482431-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02017
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vasotec	C				
UNKNOWN								
	Congestive		Lanoxin	C				
UNKNOWN								
	Dyspnoea		Aldomet (Methyldopa)	C				
UNKNOWN								
			Potassium (Unspecified)	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			[Therapy					

			Unspecified]	C		
UNKNOWN						

Date:10/22/04ISR Number: 4482432-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02114
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Prilosec	C		
UNKNOWN						
			Antimicrobial (Unspecified)	C		
UNKNOWN						
			Antimicrobial (Unspecified)	C		
UNKNOWN						

Date:10/22/04ISR Number: 4482435-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02181
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hypertension		Maxalt (Rizatriptan Benzoate)	C		ORAL
Initial or Prolonged	Hypoaesthesia		[Therapy Unspecified]	C		
Disability						
UNKNOWN						

Date:10/22/04ISR Number: 4482436-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01782
Age:72 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise							
	Myocardial Infarction							
	Sepsis							

Date:10/22/04ISR Number: 4482437-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02249
Age:91 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Gastric Disorder							
	Rectal Haemorrhage							
	Skin Discolouration							
	Thrombosis							
	Transient Ischaemic Attack							

Date:10/22/04ISR Number: 4482439-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02219
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:10/22/04ISR Number: 4482440-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482441-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02232
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization -	Disorientation		Atenolol	C			UNKNOWN	
Initial or Prolonged	Gastric Disorder		Ambien	C			UNKNOWN	
Disability	Palpitations		[Therapy Unspecified]	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/22/04ISR Number: 4482442-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03111
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Urinary Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Aspirin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482444-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00361M
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Exposure During		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pregnancy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Etilefrine Hydrochloride	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482445-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02281
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Loss Of Consciousness		Oxycontin	C				
UNKNOWN								
Initial or Prolonged	Road Traffic Accident		Imuran (Azathioprine)	C				
Disability								
UNKNOWN								

Date:10/22/04ISR Number: 4482446-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02403
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Muscular Weakness		Zoloft	C				
UNKNOWN								
			Prinzide	C				
UNKNOWN								
			Flexeril	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Vicodin Tablets	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482448-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02259
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Chest Pain							
Hospitalization -	Death							
Initial or Prolonged	Facial Palsy							

Date:10/22/04ISR Number: 4482449-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02694
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	1340 DAY	
Initial or Prolonged	Gastric Disorder		Tramadol Msd	C			UNKNOWN	
			Lipram	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	

Date:10/22/04ISR Number: 4482450-0Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00020
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Initial or Prolonged	Hypertension		Clomipramine					
Disability	Optic Disc Vascular		Hydrochloride	C		ORAL		
Other	Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482452-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cellulitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Tylenol With Codeine	C				
UNKNOWN								
	Hepatic Lesion							
	Hypertension							
	Labyrinthitis							
	Lumbar Spinal Stenosis							
	Lung Neoplasm							
	Pneumonia							
	Urinary Retention							

Date:10/22/04ISR Number: 4482454-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02256
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Behcet'S Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Discomfort		Xanax	C				
UNKNOWN								
	Chest Pain		Pentoxyl	C				
UNKNOWN								
	Dyspnoea		Prednisone	C				
UNKNOWN								
	Early Morning Awakening		Depakote	C				
UNKNOWN								
	Fall		Hydrocortone	C		ORAL		
	Hypoaesthesia		Clonazepam	C				
UNKNOWN								
	Pain In Extremity		Colchicine	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482483-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02718
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prednisone	C				
UNKNOWN								
Initial or Prolonged	Neuropathy		Vasotec	C		ORAL		
Disability			Zoloft	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Lopressor	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482484-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00361B1
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc			
			Vioxx	SS	Merck & Co., Inc			
			Etilefrine Hydrochloride	C				

Date:10/22/04ISR Number: 4482485-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00709
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Blood Pressure Increased
Other	Convulsion
	Coronary Artery Disease

	Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482486-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Haemangioma	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Convulsion		Celebrex	C				
UNKNOWN								
Other	Emotional Distress							
	Haemarthrosis							
	Joint Effusion							
	Ligament Injury							
	Ligament Sprain							
	Scar							

Date:10/22/04ISR Number: 4482488-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00792
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia	Professional						
Disability	Benign Intracranial							
	Hypertension							
	Bronchitis							
	Cerebral Ischaemia							
	Deafness							
	Depression							
	Dizziness							
	Endolymphatic Hydrops							
	Fatigue							
	Headache							
	Increased Upper Airway							
	Secretion							
	Injury							
	Muscle Atrophy							

Muscle Spasms
Myalgia
Myositis
Nervousness
Oedema Peripheral
Pain
Papilloedema
Polytraumatism
Skin Disorder
Spinal Column Stenosis

Date:10/22/04ISR Number: 4482491-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Arteriosclerosis
	Arthralgia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Asthma					
		Benign Prostatic Hyperplasia					
		Blood Cholesterol Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Blood Potassium Decreased		Levothyroxine Sodium	C		
UNKNOWN							
		Cerebrovascular Accident		Cardizem	C		
UNKNOWN							
		Colon Adenoma		Prilosec	C		
UNKNOWN							
		Colonic Polyp		Lipitor	C		
UNKNOWN							
		Convulsion		Triamterene	C		
UNKNOWN							
		Dyspnoea		Plavix	C		
UNKNOWN							
		Ejection Fraction Decreased		Aspirin	C		
UNKNOWN							
		Electrocardiogram St-T Change					
		Gastrooesophageal Reflux Disease					
		Genital Rash					
		Haematuria					
		Haemorrhoids					
		Hydronephrosis					
		Hypertension					
		Hypertonic Bladder					
		Hypoaesthesia					
		Micturition Urgency					
		Neurodermatitis					
		Nocturia					
		Nodule					
		Pain In Extremity					
		Penile Vein Thrombosis					
		Pollakiuria					
		Proteinuria					
		Pruritus					
		Rash					
		Vertigo					

Date:10/22/04ISR Number: 4482492-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Testosterone Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Skelaxin	C				
Other	Cerebrovascular Accident		Vicodin Tablets	C			UNKNOWN	
	Chronic Fatigue Syndrome		Effexor Xr	C			UNKNOWN	
	Encephalitis Viral		Univasc	C			UNKNOWN	
	Hypertension		Benadryl	C			UNKNOWN	
	Hyponatraemia		Wellbutrin	C			UNKNOWN	
	Joint Sprain		Celexa	C			UNKNOWN	
	Mental Disorder		Ibuprofen	C			UNKNOWN	
	Migraine		Temazepam	C			UNKNOWN	
	Otitis Media		Ambien	C			UNKNOWN	
	Temporomandibular Joint Syndrome		Trazodone Hydrochloride	C			UNKNOWN	
	Transient Ischaemic Attack		Naproxen	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
	Tri-Iodothyronine Free Increased		Tenormin	C			UNKNOWN	
			Ativan	C			UNKNOWN	
	Vertigo		Ranitidine	C			UNKNOWN	
			Premarin	C			UNKNOWN	

	Meclizine	C	UNKNOWN
	Aspirin	C	UNKNOWN
	Plavix	C	UNKNOWN
	Neurontin	C	UNKNOWN
	Zithromax	C	UNKNOWN
	Claritin	C	UNKNOWN
	Amoxicillin	C	UNKNOWN
	Glucosamine	C	UNKNOWN
	Hypericin	C	UNKNOWN

Date:10/22/04ISR Number: 4482496-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	125	DAY
Initial or Prolonged	Chest Pain	Professional	Coricidin	C			UNKNOWN	
Other	Cough		Allegra-D	C			UNKNOWN	
	Deep Vein Thrombosis		Flonase	C			UNKNOWN	
	Dyspnoea		Singulair	C			UNKNOWN	
	Epistaxis		Elidel	C			UNKNOWN	
	Gastrooesophageal Reflux		Westcort	C			UNKNOWN	
	Disease							
	Gynaecomastia							
	Pulmonary Embolism							
	Skin Ulcer							
	Sleep Apnoea Syndrome							
	Venous Stasis							

Date:10/22/04ISR Number: 4482502-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00827
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		St. Joseph Adult Chewable Aspirin	C				
Disability	Atrial Fibrillation							
Other	Atrial Septal Defect		Norvasc	C				
	Bursitis		Paxil	C				
	Chest Discomfort		Paxil	C				
	Chest Pain		Lotensin	C				
	Chondromalacia		Xanax	C				
	Dyspnoea		Xanax	C				
	Fluid Retention		Restoril	C				
	Musculoskeletal		Darvocet-N	C				
	Discomfort		Allegra	C				
	Nasal Sinus Drainage		Flovent	C				
	Otitis Externa		Uniphyl	C				
	Pain In Extremity		Serevent	C				
	Reflux Oesophagitis							
	Road Traffic Accident		Albuterol	C				
	Sinus Disorder							
			Mobic	C				

Date:10/22/04ISR Number: 4482510-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482515-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02233
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482546-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Lorcet Plus	C		ORAL		
	Anxiety		Ambien	C		ORAL		
Other	Arthralgia							
	Back Injury							
	Back Pain							
	Cardiac Murmur							
	Cerebrovascular Accident							
	Chest Pain							
	Cholesterol Granuloma							
	Chronic Fatigue Syndrome							
	Depression							
	Dyspnoea							
	Erythema							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Hypoacusis							
	Hypoaesthesia							
	Insomnia							
	Intervertebral Disc Protrusion							
	Labile Hypertension							
	Muscle Spasms							
	Nail Disorder							
	Nausea							
	Neuritis							
	Oedema							
	Osteoarthritis							
	Radiculitis							
	Rhinitis Allergic							
	Rhinorrhoea							
	Spherocytic Anaemia							

Tachycardia

Date:10/22/04ISR Number: 4482552-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01957
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Other	Anxiety
	Asthenia
	Blood Cholesterol Increased
	Blood Pressure Inadequately Controlled
	Bronchitis
	Cachexia
	Cataract
	Cerebrovascular Accident

		Chest Pain					
		Constipation					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dehydration	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Depression	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Zyrtec	C		
UNKNOWN							
		Diverticulitis		Premarin	C		
UNKNOWN							
		Fatigue		Soma	C		
UNKNOWN							
		Gastroenteritis Viral		[Therapy			
		Gastrointestinal Disorder		Unspecified]	C		
UNKNOWN							
		Headache		Percocet	C		
UNKNOWN							
		Increased Tendency To		Ocuflox	C		
UNKNOWN							
		Bruise		Prednisone	C		
OPHTHALMIC							
		Irritable Bowel Syndrome		Ultram	C		
UNKNOWN							
		Micturition Disorder		Oxycodone	C		
UNKNOWN							
		Migraine		Acetaminophen	C		
UNKNOWN							
		Neurodermatitis		Motrin	C		
UNKNOWN							
		Normochromic Normocytic		Lamisil	C		
UNKNOWN							
		Anaemia		Estrace	C		
UNKNOWN							
		Oedema Peripheral		Cyanocobalamin	C		
UNKNOWN							
		Osteopenia					
		Pain					
		Pneumonia					
		Renal Failure Acute					
		Stomach Discomfort					

Date:10/22/04ISR Number: 4482838-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01099
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		56 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		156 DAY
Other	Atrial Fibrillation		Celebrex	C				UNKNOWN
	Blood Cholesterol		Ultram	C				UNKNOWN
	Increased		Aspirin	C				UNKNOWN
	Cardiomegaly							
	Carotid Artery Stenosis							
	Cellulitis							
	Dyslipidaemia							
	Emotional Distress							
	Ischaemic Stroke							
	Pain							
	Pulmonary Congestion							
	Pulmonary Fibrosis							
	Spondylitis							
	Transient Ischaemic Attack							
	Ventricular Extrasystoles							

Date:10/22/04ISR Number: 4482840-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Blood Albumin Decreased
Other	Blood Cholesterol
	Increased
	Bronchial Infection
	Bronchiectasis

	Bronchitis						
	Bronchitis Chronic						
	Candidiasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	
	Congestive		Premarin	C			UNKNOWN
	Cerebrovascular Accident		Singulair	C			UNKNOWN
	Chronic Obstructive		Azmacort	C			RESPIRATORY
	Pulmonary Disease						(INHALATION)
	Conjunctivitis						
	Corneal Disorder						
	Drug Hypersensitivity						
	Dyspepsia						
	Fall						
	Hiatus Hernia						
	Nausea						
	Oedema Peripheral						
	Oxygen Saturation						
	Decreased						
	Pain						
	Pneumonia						
	Pseudomonas Infection						
	Skin Laceration						
	Tremor						

Date:10/22/04ISR Number: 4482848-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00744
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc		UNKNOWN
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Depression		Vioxx	SS	Merck & Co., Inc		UNKNOWN

	Drug Ineffective	Prednisone	C	
UNKNOWN				
	International Normalised	Prednisone	C	
UNKNOWN				
	Ratio Decreased	Vicodin Tablets	C	
UNKNOWN				
	Lacunar Infarction	Methotrexate	C	
UNKNOWN				
	Lung Neoplasm	Methotrexate	C	
UNKNOWN				
	Mitral Valve Incompetence	Folic Acid	C	
UNKNOWN				
	Prothrombin Time Abnormal	Folic Acid	C	
UNKNOWN				
	Transient Ischaemic	Lasix (Furosemide)	C	
UNKNOWN				
	Attack	Lasix (Furosemide)	C	ORAL
		Centrum Silver	C	
UNKNOWN				
		Cal-Citrate	C	
UNKNOWN				
		Lovenox	C	
UNKNOWN				
		Coumadin	C	
UNKNOWN				
		Plavix	C	
UNKNOWN				
		Zoloft	C	
UNKNOWN				
		Aciphex	C	
UNKNOWN				

Date:10/22/04ISR Number: 4482852-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Alveolitis Fibrosing
Disability	Anxiety
Other	Arthralgia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arthropathy Cardiac Failure Congestive Carotid Artery Disease Carpal Tunnel Syndrome Chest Pain Chronic Obstructive Pulmonary Disease Collagen-Vascular Disease Depression Dermatomyositis Diarrhoea Diverticulum Dizziness Dysphasia Dyspnoea Fibromyalgia Gastritis Gastrointestinal Motility Disorder Gastrooesophageal Reflux Disease Haemoptysis Haemorrhoids Hypersensitivity Hypertension Insomnia Interstitial Lung Disease Irritable Bowel Syndrome Malaise Memory Impairment Musculoskeletal Stiffness Obsessive-Compulsive Disorder Obstructive Airways Disorder Oesophageal Candidiasis Pain In Extremity Paraesthesia Polymyositis Pulmonary Fibrosis Pulmonary Oedema Rash Rash Macular Rash Pruritic Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL

Visual Field Defect
Weight Decreased

Date:10/22/04ISR Number: 4482854-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00835
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Other	Blue Toe Syndrome
	Chest Pain
	Coronary Artery Disease
	Fall
	Fibula Fracture
	Intermittent Claudication

		Myocardial Infarction Tarsal Tunnel Syndrome Therapeutic Response	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							

Date:10/22/04ISR Number: 4482855-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00844
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Adverse Event Femur Fracture Polytraumatism Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/22/04ISR Number: 4482856-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Hospitalization - Initial or Prolonged Other	Adverse Event Angina Pectoris Arthritis Arthropathy Back Pain Bladder Disorder Blood Pressure Increased Cardiovascular Disorder Convulsion Death Intestinal Functional Disorder Lung Cyst Benign Radiculopathy		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/22/04ISR Number: 4482858-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01061779
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Bradycardia Cardiac Disorder Chest Pain Dyspnoea Feeling Of Despair Insomnia Pain Palpitations Sinus Arrest Stress Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482859-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00757
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Celebrex	C			UNKNOWN	21 DAY
	Convulsion		Celebrex	C		ORAL	85 DAY	
	Ejaculation Disorder		Paxil	C			UNKNOWN	
			Paxil	C			UNKNOWN	4 WK
			Paxil	C			UNKNOWN	
			Elavil	C		ORAL		
			Darvocet-N	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	

Date:10/22/04ISR Number: 4482860-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00755
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris							
Initial or Prolonged	Blood Pressure Increased							
Other	Cardio-Respiratory Arrest							
	Convulsion							
	Coronary Artery Disease							
	Hypertension							
	Sudden Cardiac Death							

Date:10/22/04ISR Number: 4482862-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Abscess		Effexor Xr	C
UNKNOWN				
Other	Adverse Event			
	Angina Pectoris			
	Atelectasis			
	Blood Cholesterol			
	Increased			
	Bronchitis			
	Cardiac Failure			
	Congestive			
	Convulsion			
	Hypertension			
	Tubo-Ovarian Abscess			

Date:10/22/04ISR Number: 4482863-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00874
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Blood Cholesterol					
	Increased					
	Hypertension					
	Monarthritis					
	Polytraumatism					
	Rotator Cuff Syndrome					
	Synovial Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482866-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00938
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:10/22/04ISR Number: 4482868-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00933
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Synthroid	C		ORAL		
Other	Convulsion		Vicodin Tablets	C				
UNKNOWN								
	Intervertebral Disc		Vitamins					
	Protrusion		(Unspecified)	C				
UNKNOWN								
	Lumbar Spinal Stenosis							
	Transient Ischaemic							
	Attack							

Date:10/22/04ISR Number: 4482869-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0408FRA00043
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
							4	DAY
Hospitalization -	Blood Glucose Increased		Amiloride And					
Initial or Prolonged	Body Temperature		Furosemide	SS		ORAL		
	Decreased		Amiloride And					
	Drug Ineffective		Furosemide	SS		ORAL		
	Hyperkalaemia		Prednisone	C		ORAL		
	Hyponatraemia		Betahistine					
	Renal Failure Acute		Hydrochloride	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Melilot And Rutin	C		ORAL		
			Atenolol	C		ORAL		

Fenofibrate	C	ORAL
Fenofibrate	C	ORAL

Date:10/22/04ISR Number: 4482871-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acquired Claw Toe
	Anaemia
	Angina Pectoris
	Biopsy Oesophagus Abnormal
	Blood Cholesterol Increased
	Blood Test Abnormal
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Change Of Bowel Habit
	Chest Pain
	Choking
	Cholelithiasis

		Colonic Polyp					
		Colorectal Cancer					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Deafness		Vioxx	PS	Merck & Co., Inc	ORAL
49	DAY						
		Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL
72	DAY						
		Dizziness		Zocor	C		ORAL
		Dyspepsia		Protonix	C		
UNKNOWN							
		Dyspnoea		Lipitor	C		
UNKNOWN							
		Ear Infection		Prinivil	C		ORAL
		Emotional Disorder					
		Eye Irritation					
		Fall					
		Gastritis					
		Haematuria					
		Hemiparesis					
		Hepatic Enzyme Increased					
		Hypertension					
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Ischaemic Cerebral					
		Infarction					
		Lacunar Infarction					
		Liver Function Test					
		Abnormal					
		Osteoarthritis					
		Peroneal Nerve Palsy					
		Rash Pruritic					
		Rectal Haemorrhage					
		Scab					
		Skin Lesion					
		Urinary Tract Infection					
		Urticaria					

Date:10/22/04ISR Number: 4482872-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged	Aneurysm
Other	Angina Unstable
	Anorexia
	Anxiety
	Anxiety Disorder
	Aortic Aneurysm
	Asthenia
	Cardiac Disorder
	Carotid Artery Occlusion
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Decubitus Ulcer
	Depression
	Diabetes Mellitus
	Duodenal Ulcer
	Duodenal Ulcer
	Haemorrhage
	Eating Disorder
	Emotional Distress

		Emphysema					
		Facial Palsy					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Foot Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Ulcer		Cyanocobalamin	C		
UNKNOWN							
		Gastroenteritis		Reglan	C		
UNKNOWN							
		Haemorrhage		Norvasc	C		
UNKNOWN							
		Hemiparesis		Lorazepam	C		
UNKNOWN							
		Hypertension		Aggrenox	C		
UNKNOWN							
		Intestinal Functional		Zocor	C		
UNKNOWN							
		Disorder					
		Leg Amputation					
		Micturition Urgency					
		Myocardial Infarction					
		Nausea					
		Peripheral Ischaemia					
		Peripheral Vascular					
		Disorder					
		Pyrexia					
		Thrombosis					
		Toe Amputation					
		Toe Deformity					
		Transient Ischaemic					
		Attack					
		Upper Gastrointestinal					
		Haemorrhage					
		Ventricular Hypertrophy					
		Vomiting					
		Wound Dehiscence					

Date:10/22/04ISR Number: 4482878-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02171
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscular Weakness					

Musculoskeletal Stiffness
Pain
Palpitations
Swelling

Date:10/22/04ISR Number: 4482880-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00380
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Acetaminophen And Codeine Phosphate	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:10/22/04ISR Number: 4482881-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Disability	Cardiac Disorder
	Chest Pain

	Depression						
	Dizziness						
	Frequent Bowel Movements	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Kidney Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Prinivil	C			UNKNOWN	
			K-Dur	C			UNKNOWN	
			Lortab	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/22/04ISR Number: 4482882-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00376
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
Initial or Prolonged			Acetaminophen	C		ORAL	10	DAY
Other			Codeine	C		ORAL	10	DAY

Date:10/22/04ISR Number: 4482884-4Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00003
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								
Disability								

Date:10/22/04ISR Number: 4482885-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00382
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Methyldopa	C		ORAL		
Other	Platelet Count Decreased		Levothyroxine Sodium	C		ORAL		

Date:10/22/04ISR Number: 4482886-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Angina Pectoris
Other	Blood Glucose Increased
	Blood Pressure Increased
	Cardiomegaly
	Cerebrovascular Accident
	Conjunctivitis Allergic
	Convulsion
	Deep Vein Thrombosis
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspnoea
	Ear Pain
	Fatigue
	Headache
	Hepatic Steatosis
	Herpes Zoster

		Hypoglycaemia					
		Injection Site Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lipomatosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Strabismus		Coumadin	C		
UNKNOWN							
		Subcutaneous Abscess		Risperdal	C		
UNKNOWN							
		Syncope		Prozac	C		
UNKNOWN							
		Thrombophlebitis		Elavil	C		ORAL
		Superficial		Effexor	C		
UNKNOWN							
		Transient Ischaemic		Effexor	C		
UNKNOWN							
		Attack					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:10/22/04ISR Number: 4482890-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00342
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 YR	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:10/22/04ISR Number: 4482891-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00328
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Atrial Fibrillation					
Hospitalization -	Cardiogenic Shock					
Initial or Prolonged	Confusional State					
Other	Death					
	Hemiparesis					
	Nervous System Disorder					

Syncope

Date:10/22/04ISR Number: 4482892-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Arthropathy
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Carpal Tunnel Syndrome
	Contusion
	Convulsion
	Cough
	Cystitis
	Cystourethrocele
	Depression
	Diarrhoea
	Diverticulum Intestinal
	Dizziness
	Emotional Distress
	Gastrooesophageal Reflux
	Disease

	Haemorrhoids						
	Herpes Zoster						
	Hypothyroidism	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL	
	Displacement		Vioxx	SS	Merck & Co., Inc	ORAL	
	Irritable Bowel Syndrome		Estrogens				
	Lumbar Radiculopathy		(Unspecified)	C			UNKNOWN
	Meniscus Lesion		Propulsid	C			UNKNOWN
	Muscle Spasms						
	Nervousness						
	Nocturia						
	Osteoarthritis						
	Paraesthesia						
	Pharyngolaryngeal Pain						
	Pneumonia						
	Radius Fracture						
	Sinus Congestion						
	Stomach Discomfort						
	Weight Decreased						

Date:10/22/04ISR Number: 4482896-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00180
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:10/22/04ISR Number: 4482897-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00268
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR
			Vioxx	SS	Merck & Co., Inc	ORAL	4 YR
			[Therapy Unspecified]	C			UNKNOWN

Date:10/22/04ISR Number: 4482899-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00075
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Lipex	C		ORAL		
	Myocardial Infarction							

Date:10/22/04ISR Number: 4482900-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Renal Disorder		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482901-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00392
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:10/22/04ISR Number: 4482903-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00066
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	763	DAY
Initial or Prolonged	Varicose Ulceration		Celecoxib	SS		ORAL	160	DAY
	Vascular Purpura							

Date:10/22/04ISR Number: 4482904-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Poisoning		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Cyanocobalamin	C		PARENTERAL		

Date:10/22/04ISR Number: 4482906-0Report Type:Expedited (15-DaCompany Report #PH-MERCK-0410PHL00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482907-2Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00042
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		1741 DAY
Initial or Prolonged	Myocardial Infarction		Verapamil Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		

Date:10/22/04ISR Number: 4482909-6Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/22/04ISR Number: 4482910-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482911-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00302
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Bextra	C			UNKNOWN	
	Pain In Extremity		Metoprolol	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	
			Insulin	C			UNKNOWN	

Date:10/22/04ISR Number: 4482913-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00017
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Facial Paresis		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR

Date:10/22/04ISR Number: 4482914-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00473
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack							

Date:10/22/04ISR Number: 4482922-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00541
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Methotrexate	C				
UNKNOWN								
Other								

Date:10/22/04ISR Number: 4482923-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00409
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Levoxyl	C				
UNKNOWN								
	Headache		Aspirin	C				
UNKNOWN								
	Hypertension		Zocor	C		ORAL		
	Oedema Peripheral							

Date:10/22/04ISR Number: 4482924-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01093
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Zonegran	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								

			Levoxyl	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Skelaxin	C		
UNKNOWN						
			Kadian	C		
UNKNOWN						

Date:10/22/04ISR Number: 4482925-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00345
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
29 DAY						
Disability	Fall		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Skin Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
29 DAY						
	Thermal Burn		Vioxx	SS	Merck & Co., Inc	ORAL
			Centrum	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			K-Dur	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						
			Lexapro	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Cordarone	C		
UNKNOWN						
			Robaxin	C		
UNKNOWN						

			Lorcet Plus	C		
UNKNOWN						
			Aggrenox	C		
UNKNOWN						
			Atenolol	C		
UNKNOWN						
			Prilosec	C		ORAL
			Hydrochlorothiazide	C		
UNKNOWN						
			Feldene	C		
UNKNOWN						
			Altace	C		
UNKNOWN						
			Pravachol	C		
UNKNOWN						
			Wellbutrin	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Duragesic	C		
UNKNOWN						
			Flexeril	C		ORAL

Date:10/22/04ISR Number: 4482926-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02109
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Fatigue		[Therapy			
Initial or Prolonged	Gastric Haemorrhage		Unspecified]	C		
UNKNOWN						
Disability			Metformin	C		
UNKNOWN						
			[Therapy			
			Unspecified]	C		
UNKNOWN						
			[Therapy			
			Unspecified]	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Flomax			
			(Morniflumate)	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Trusopt	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482928-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01561
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Chest Discomfort							
Disability	Hepatic Enzyme Increased							
	Hepatocellular Damage							

Date:10/22/04ISR Number: 4482929-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Closed Head Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Effexor	C				
UNKNOWN								
	Loss Of Consciousness		Atenolol	C				
UNKNOWN								
	Syncope		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482930-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00731
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ischaemic Stroke		Prempro	C				
UNKNOWN								
Initial or Prolonged								

Date:10/22/04ISR Number: 4482932-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/22/04ISR Number: 4482933-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01998
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	WK
	Diarrhoea		Indocin					
	Gastric Disorder		(Indomethacin)	C			UNKNOWN	
	Myocardial Infarction		Colchicine	C			UNKNOWN	
	Therapy Non-Responder		Prednisone	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Insulin	C			UNKNOWN	

Date:10/22/04ISR Number: 4482938-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00839
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Prinivil	C			UNKNOWN	
	Dizziness		Metoprolol	C			UNKNOWN	
	Renal Pain							

Date:10/22/04ISR Number: 4482939-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00661
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Road Traffic Accident							

Date:10/22/04ISR Number: 4482941-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01033
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	SS			UNKNOWN	
	Confusional State		Xanax	SS			UNKNOWN	
	Drug Withdrawal Syndrome		Tenormin	C			UNKNOWN	
	Pyrexia		Zocor	C			UNKNOWN	
	Viral Infection		Premarin	C			UNKNOWN	
			Lopid	C			UNKNOWN	

Date:10/22/04ISR Number: 4482942-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00743
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Buspirone Hydrochloride	C			UNKNOWN	
	Blood Glucose Increased							
	Blood Pressure Increased							
	Gastric Disorder							

Date:10/22/04ISR Number: 4482943-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00759
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Disability	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Other	Myocardial Infarction							

Date:10/22/04ISR Number: 4482947-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02405
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Diovan	C				UNKNOWN
Initial or Prolonged			Prozac	C				UNKNOWN
			Zocor	C				UNKNOWN

Date:10/22/04ISR Number: 4482948-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01999
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Death	Brain Death
Hospitalization -	Cough
Initial or Prolonged	Dry Mouth
	Haemorrhage Intracranial
	Headache
	Hypertension

	Lung Infiltration Nodule Pleural Effusion	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Congestion		Vioxx	PS	Merck & Co., Inc	ORAL	54	DAY
	Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	54	DAY
			Blinded Therapy	SS			UNKNOWN	70 DAY
			Lipitor	C			UNKNOWN	568 DAY
			Wellbutrin	C			UNKNOWN	
			Ultram	C			UNKNOWN	
			Celexa	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Estratest	C			UNKNOWN	3778 DAY

Date:10/22/04ISR Number: 4482952-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01957
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482953-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02105
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other UNKNOWN	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Altace	C				

			Toprol Xl Tablets	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Accolate	C		
UNKNOWN						
			Benadryl	C		
UNKNOWN						
			Fioricet Tablets	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Lexapro	C		
UNKNOWN						
			Evista	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

Date:10/22/04ISR Number: 4482955-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02370
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
			Hytrin	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482957-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							
	Loss Of Consciousness							

Date:10/22/04ISR Number: 4482958-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02369
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
			Singulair	C			UNKNOWN	UNKNOWN
	Myocardial Infarction		Isosorbide	C			UNKNOWN	UNKNOWN
			Prinivil	C			UNKNOWN	UNKNOWN
			Prozac	C			UNKNOWN	UNKNOWN
			Furosemide	C			UNKNOWN	UNKNOWN
			Alprazolam	C			UNKNOWN	UNKNOWN
			Skelaxin	C			UNKNOWN	UNKNOWN
			Plavix	C			UNKNOWN	UNKNOWN
			Humulin	C			UNKNOWN	UNKNOWN
			Aspirin	C			UNKNOWN	UNKNOWN
			Toprol Xl Tablets	C			UNKNOWN	UNKNOWN
			Lipitor	C			UNKNOWN	UNKNOWN
			Amaryl	C			UNKNOWN	UNKNOWN
			Nexium	C			UNKNOWN	UNKNOWN
			Nitrolingual	C			UNKNOWN	UNKNOWN

				Combivent	C		
UNKNOWN							

Date:10/22/04ISR Number: 4482959-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02392
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/22/04ISR Number: 4482960-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
610 DAY								

Date:10/22/04ISR Number: 4482962-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02364
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prednisone	C				
UNKNOWN								
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482963-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02119
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Sudden Cardiac Death		Enduronyl	C				
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
			Zofran	C				
			Fluorouracil	C				
			Mitomycin	C				

Date:10/22/04ISR Number: 4482964-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01349
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Acuity Reduced		[Composition Unspecified]	C				
			Calcium (Unspecified)	C				
			Vitamins (Unspecified)	C				

Date:10/22/04ISR Number: 4482968-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02430
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hip Fracture		Atenolol	C				

	Transient Ischaemic		Lasix (Furosemide)	C			
UNKNOWN							
	Attack						
	Upper Limb Fracture						

Date:10/22/04ISR Number: 4482969-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02419
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Theo-Dur	C				
UNKNOWN								
			Accolate	C				
UNKNOWN								

Date:10/22/04ISR Number: 4482970-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00750
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482971-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482974-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysplasia		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
Initial or Prolonged	Emotional Distress		[Therapy					
Disability	Ischaemic Cerebral		Unspecified]	SS				UNKNOWN
Other	Infarction		Yasmin	SS				UNKNOWN
	Migraine		Paxil	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Advil	C				UNKNOWN
			Skelaxin	C				UNKNOWN
			Fioricet Tablets	C				UNKNOWN

Date:10/22/04ISR Number: 4482975-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02406
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Disability								

Date:10/22/04ISR Number: 4482976-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02410
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Eye Haemorrhage Retinal Vascular Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482978-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02626
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Pepcid	C		ORAL		

Date:10/22/04ISR Number: 4482979-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02617
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482980-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02614
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Lotensin	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Tiazac	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:10/22/04ISR Number: 4482983-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02387
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Stent Occlusion		Altace	C			UNKNOWN	
Disability			Plavix	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Lasix (Furosemide Sodium)	C			UNKNOWN	

Date:10/22/04ISR Number: 4482987-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02697
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Gastric Disorder		Zestril	C			
Initial or Prolonged							

Date:10/22/04ISR Number: 4482988-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02877
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4482989-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02116
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization - UNKNOWN			Cozaar	C				
Initial or Prolonged			[Therapy					
Disability UNKNOWN			Unspecified]	C				

Date:10/22/04ISR Number: 4482991-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4482992-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/22/04ISR Number: 4483005-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01832
Age:100 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/22/04ISR Number: 4483012-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02095
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Paxil Cr	C				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Zocor	C				
UNKNOWN								
Disability	Muscle Spasms		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/22/04ISR Number: 4483019-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02433
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Oxycodone	C				
UNKNOWN								

Zoloft C
UNKNOWN

Date:10/22/04ISR Number: 4483657-9Report Type:Direct Company Report #CTU 230257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fear		Vioxx	PS		ORAL	25MG 1 X DAY	
Hospitalization -	Gastric Ulcer Perforation							
Initial or Prolonged								
Other								

Date:10/22/04ISR Number: 4483702-0Report Type:Direct Company Report #CTU 230238
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx 25 Mg	PS			1 PER DAY	
	Heart Rate Increased							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4483930-4Report Type:Direct Company Report #CTU 230310
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG 1	
Hospitalization -	Disease						TABLET DAILY	
Initial or Prolonged	Haemorrhage						ORAL	
Disability	Myocardial Infarction							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/22/04ISR Number: 4485058-6Report Type:Direct Company Report #CTU 230325
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx Sample Packs					
Hospitalization -			Merck	PS	Merck	ORAL	ONE SIX HOURS	
Initial or Prolonged							ORAL	
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/22/04ISR Number: 4485272-XReport Type:Direct Company Report #CTU 230267
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Tamponade		Vioxx 25 Mg Msd	PS	Msd	ORAL	25 MG QD ORAL	
	Chest Pain		Cpap	C				
	Myocardial Rupture		Effexor	C				
	Sudden Death		Lorazepam	C				
			Celebrex	C				

Nifedical	C
Premarin	C
Levaquin	C
Oxycodone	C
Promethazine	C
Sulindac	C
Prednisone	C

Date:10/22/04ISR Number: 4485281-0Report Type:Direct Company Report #CTU 230262
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Throat Tightness		Rofecoxib 25 Mg	PS		ORAL	25 MG DAILY	ORAL

Date:10/22/04ISR Number: 4485282-2Report Type:Direct Company Report #CTU 230252
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS			25 MG 1 DAILY	
Initial or Prolonged	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4485297-4Report Type:Direct Company Report #CTU 230306
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx Merck	PS	Merck		AS NEEDED	

Date:10/22/04ISR Number: 4485299-8Report Type:Direct Company Report #CTU 230307
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pancreatic Carcinoma Metastatic		Vioxx Merck	PS	Merck			

Date:10/22/04ISR Number: 4485462-6Report Type:Expedited (15-DaCompany Report #2004AL000735
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide Intentional Misuse	Literature	Metformin Hydrochloride Tablets, 500 Mg, 850 Mg And 1000mg (Purepac)	PS		ORAL	PO	
			Amlodipine/Benazepril	SS		ORAL	PO	
			Rofecoxib	SS		ORAL	PO	

Date:10/22/04ISR Number: 4489540-7Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Cholesterol	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	

		Increased	Health				
PO	35 DAY						
		Haematocrit Decreased	Professional	Omeprazole	C		
		Haemoglobin Decreased	Other				
		Low Density Lipoprotein Increased					
		Memory Impairment					
		Myocardial Ischaemia					

Date:10/22/04ISR Number: 4489544-4Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery	Foreign	Tab Vioxx					
Hospitalization -	Insufficiency	Study	(Rofecoxib)	PS		ORAL	1 MG/DAILY,	
Initial or Prolonged	Coronary Artery Stenosis	Health						
PO	134 DAY							
	Gastric Ulcer	Professional	Post-Trial Therapy	C				
	Ventricular Hypokinesia	Other						

Date:10/22/04ISR Number: 4489545-6Report Type:Expedited (15-DaCompany Report #WAES 0410ZAF00004
Age:67 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abscess Limb
Initial or Prolonged	Blood Chloride Decreased
Disability	Blood Creatinine

	Increased Blood Urea Increased Diabetes Mellitus Inadequate Control	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertensive Heart Disease	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,
	Platelet Count Increased	Health					PO
		Professional Other	Atenolol	C			
			Colchicine	C			
			Enalapril Maleate-Hctz	C			
			Gliclazide	C			
			Insulin Human, Isophane	C			
			Prazosin Hcl	C			

Date:10/22/04ISR Number: 4490023-9Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00425
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris	Foreign	Tab Vioxx				
	Blood Cholesterol	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY 35 DAY
	Increased	Health	Omeprazole	C			
	Blood Triglycerides	Professional					
	Increased						
	Electrocardiogram						
	Abnormal						
	Haematocrit Decreased						
	Haemoglobin Decreased						
	Joint Swelling						
	Low Density Lipoprotein						
	Increased						
	Memory Impairment						

Date:10/22/04ISR Number: 4490024-0Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Life-Threatening	Coronary Artery	Foreign	Tab Vioxx			
Hospitalization -	Insufficiency	Study	(Rofecoxib)	PS		ORAL
1 MG/DAILY 134 DAY						
Initial or Prolonged	Gastric Ulcer	Health	Post-Trial Therapy	C		
	Ventricular Hypokinesia	Professional				

Date:10/22/04ISR Number: 4490025-2Report Type:Expedited (15-DaCompany Report #WAES 0410ZAF00004
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abscess Limb	Foreign	Tab Vioxx			
Initial or Prolonged	Blood Chloride Decreased	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY 315 DAY						
Disability	Blood Creatinine	Health	Atenolol	C		
	Increased	Professional	Colchicine	C		
	Blood Urea Increased		Enalapril			
	Diabetes Mellitus		Maleate-Hctz	C		
	Inadequate Control		Gliclazide	C		
	Hypertensive Heart		Insulin Human,			
	Disease		Isophane	C		
	Platelet Count Increased		Prazosin Hcl	C		
	White Blood Cell Count					
	Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4490771-0Report Type:Expedited (15-DaCompany Report #WAES 0408BRA00035
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG, DAILY	
Hospitalization -	Aortic Valve Incompetence	Study					PO	
Initial or Prolonged	Bronchopneumonia	Health	Tab Acetaminophen					
Disability	Cardiac Failure	Professional	325 Mg	SS		ORAL	325 MG, PRN ,	
	Congestive						PO	
	Chest Pain		Acetaminophen	C				
	Coronary Artery Disease		Alendronate Sodium	C				
	Dyspnoea		Calcium Carbonate	C				
	Hypertension		Chlorthalidone	C				
	Mitral Valve		Enalapril Maleate	C				
	Calcification		Magnesia (Milk Of)	C				
	Tricuspid Valve		Nortriptyline					
	Incompetence		Hydrochloride	C				
	Ventricular Dysfunction		Vitamins	C				

Date:10/22/04ISR Number: 4490773-4Report Type:Expedited (15-DaCompany Report #WAES 0408BRA00035
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25	
Hospitalization -	Aortic Valve Incompetence	Study					MG/DAILY/PO	
Initial or Prolonged	Bronchopneumonia	Health	Tab Acetaminophen					
Disability	Cardiac Failure	Professional	325 Mg	SS		ORAL	325 MG/PRN/PO	
	Congestive		Acetaminophen	C				
	Chest Pain		Alendronate Sodium	C				
	Coronary Artery Disease		Calcium Carbonate	C				
	Dyspnoea		Chlorthalidone	C				
	Mitral Valve		Enalapril Maleate	C				
	Calcification		Magnesia (Milk Of)	C				
	Pulmonary Hypertension		Nortriptyline					
	Tricuspid Valve		Hydrochloride	C				
	Incompetence		Vitamins	C				

Date:10/25/04ISR Number: 4483995-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Cholesterol		Atenolol	C			UNKNOWN	
	Increased		Prozac	C			UNKNOWN	
	Cardiac Failure		Prozac	C			UNKNOWN	
	Congestive		Tylenol	C			UNKNOWN	
	Cardio-Respiratory Arrest		Buspar	C			UNKNOWN	
	Cardiogenic Shock		Atrovent	C			UNKNOWN	
	Chest Pain		Magnesium Sulfate	C			UNKNOWN	
	Convulsion		Claforan	C			UNKNOWN	
	Haematuria		Cordarone	C			UNKNOWN	
	Hypertension		Pepcid	C			UNKNOWN	
	Lung Infiltration		Reopro	C			UNKNOWN	
	Myalgia		Dopamine Hydrochloride	C			UNKNOWN	
	Myocardial Infarction		Restoril	C			UNKNOWN	
	Orthostatic Hypotension		Aspirin	C		ORAL		
	Papilloma		Celexa	C			UNKNOWN	
	Ventricular Tachycardia		Neurontin	C			UNKNOWN	

				Dalmane	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484000-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arthrodesis		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Carotid Artery Stenosis		Baclofen	C		ORAL
	Cerebrovascular Accident		Ativan	C		ORAL
	Cervicobrachial Syndrome		Soma	C		ORAL
	Death		Wellbutrin	C		ORAL
	Depression		Dulcolax	C		
UNKNOWN						
	Oedema		Tegretol	C		ORAL
			Ms Contin	C		ORAL
			Colace	C		ORAL
			Vistaril	C		ORAL
			Vistaril	C		ORAL
			Seroquel	C		
UNKNOWN						
			Seroquel	C		ORAL
			Mexiletine Hydrochloride	C		ORAL
			Coumadin	C		ORAL
			Percocet	C		ORAL
			Fleet Enema	C		
UNKNOWN						
			Magnesia [Milk Of]	C		
UNKNOWN						
			Compazine	C		
UNKNOWN						
			Compazine	C		
UNKNOWN						
			Neurontin	C		ORAL
			Elavil	C		ORAL

Date:10/25/04ISR Number: 4484011-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Affective Disorder
	Anaemia
	Angina Pectoris
	Cerebrovascular Accident
	Colonic Polyp
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspepsia
	Eczema
	Gastritis
	Haemorrhoidal Haemorrhage
	Head Injury
	Headache
	Heart Rate Irregular
	Hot Flush
	Hypochromic Anaemia
	Insomnia
	Intracranial Venous Sinus
	Thrombosis
	Joint Effusion
	Migraine

		Musculoskeletal Stiffness					
		Nausea					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Subarachnoid Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Uterine Enlargement		Vioxx	SS	Merck & Co., Inc	ORAL
		Uterine Leiomyoma		Yasmin	SS		
UNKNOWN		14	DAY				
		Vaginal Haemorrhage		Sandimmun	C		
UNKNOWN							
		Visual Disturbance		Sandimmun	C		
UNKNOWN							
		Vomiting		Sandimmun	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Hormonal Contraceptives (Unspecified)	C		
INTRAMUSCULAR							
				Prelone Syrup	C		
UNKNOWN							
				Prelone Syrup	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484016-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anaemia					
Disability	Angioneurotic Oedema					
Other	Bronchitis					
	Chest Pain					
	Constipation					
	Deep Vein Thrombosis					
	Depression					
	Diabetes Mellitus					

Non-Insulin-Dependent
Diverticulum
Dyspnoea
Fatigue
Gastric Disorder
Gastric Outlet
Obstruction
Hypertension
Neuropathy Peripheral
Non-Cardiac Chest Pain
Oedema Peripheral
Peptic Ulcer
Polytraumatism
Restrictive Pulmonary
Disease
Stress Incontinence
Tendonitis
Ventricular Dysfunction

Date:10/25/04ISR Number: 4484020-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00788
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Adverse Event

		Anxiety					
		Aortic Atherosclerosis					
		Blood Pressure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inadequately Controlled		Vioxx	PS	Merck & Co., Inc	ORAL
		Breast Cancer In Situ		Vioxx	SS	Merck & Co., Inc	ORAL
		Calcinosis		Corgard	C		
UNKNOWN							
		Colon Adenoma		Maxzide	C		
UNKNOWN							
		Colon Polypectomy		Maxzide	C		
UNKNOWN							
		Constipation		Prevacid	C		
UNKNOWN							
		Decreased Appetite		Prevacid	C		
UNKNOWN							
		Diarrhoea		Zoloft	C		
UNKNOWN							
		Dizziness		Celebrex	C		
UNKNOWN							
		Drug Ineffective		Librax Capsules	C		
UNKNOWN							
		Fall		Pravachol	C		
UNKNOWN							
		Fatigue		Flexeril	C		
UNKNOWN							
		Food Poisoning		Darvocet-N	C		
UNKNOWN							
		Gastrointestinal Tract					
		Adenoma					
		Haematochezia					
		Haemorrhoids					
		Headache					
		Hypotension					
		Injury					
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Joint Injury					
		Lethargy					
		Medication Error					
		Nausea					
		Nervousness					
		Nystagmus					
		Osteoarthritis					
		Pain					
		Rectal Haemorrhage					
		Skin Discolouration					

Sleep Disorder
Somnolence
Tension
Treatment Noncompliance
Vertigo Positional
Vomiting

Date:10/25/04ISR Number: 4484021-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00723
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Wygesic Tablets	C			UNKNOWN	
	Cerebrovascular Accident		Relafen	C			UNKNOWN	
	Condition Aggravated		Ultram	C			UNKNOWN	
	Convulsion							
	Cough							
	Drug Ineffective							
	Hypoaesthesia							
	Muscle Spasms							
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence	Health	Vioxx	PS	Merck & Co., Inc	ORAL		401 DAY
Initial or Prolonged	Aortic Valve Sclerosis	Professional	Hytrin	C				UNKNOWN
Disability	Binocular Eye Movement		Estratab	C				UNKNOWN
Other	Disorder		Ranitidine	C				UNKNOWN
	Bronchitis Chronic		Aspirin	C				UNKNOWN
	Carpal Tunnel Syndrome		Aspirin	C				UNKNOWN
	Cataract		L-Thyroxin	C				UNKNOWN
	Cerebrovascular Accident		Tagamet	C				UNKNOWN
	Chest Pain		Premarin	C				UNKNOWN
	Cholelithiasis							
	Chronic Fatigue Syndrome							
	Coronary Artery Disease							
	Depression							
	Dizziness							
	Drug Hypersensitivity							
	Duodenitis							
	Endocarditis							
	Gallbladder Disorder							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							
	Haematuria							
	Hemianopia Homonymous							
	Herpes Zoster							
	Hypertension							
	Hypertensive Crisis							
	Hypoacusis							
	Hypokalaemia							
	Hyponatraemia							
	Irritable Bowel Syndrome							
	Labile Hypertension							

Lacunar Infarction
Laryngitis
Migraine With Aura
Mitral Valve
Calcification
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Panic Disorder
Rhinitis Seasonal
Sleep Apnoea Syndrome
Strabismus
Tension Headache
Thalamus Haemorrhage
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection

Date:10/25/04ISR Number: 4484024-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Angina Unstable

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arteriospasm Coronary					
		Arthralgia					
		Back Pain					
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Coronary Artery Disease		Aspirin	C		
UNKNOWN							
		Cystocele		Aspirin	C		
UNKNOWN							
		Deep Vein Thrombosis		Lipitor	C		
UNKNOWN							
		Dehydration		Prometrium	C		
UNKNOWN							
		Diverticulitis		Vivelle	C		
TOPICAL							
		Diverticulum		Vivelle	C		
TOPICAL							
		Dysfunctional Uterine		Zyrtec	C		
UNKNOWN							
		Bleeding		Fioricet Tablets	C		
UNKNOWN							
		Dyspepsia		Fioricet Tablets	C		
UNKNOWN							
		Dyspnoea		Ambien	C		
UNKNOWN							
		Dysuria		Motrin	C		
UNKNOWN							
		Flank Pain		Paxil	C		
UNKNOWN							
		Gastroenteritis		Prilosec	C		
UNKNOWN							
		Generalised Anxiety		Alprazolam	C		
UNKNOWN							
		Disorder		Vitamin E	C		
UNKNOWN							
		Haematuria		Gnc Womens Ultra			
		Haemorrhoids		Mega	C		
UNKNOWN							
		Hot Flush		Lecithin	C		
UNKNOWN							
		Menopausal Symptoms					
		Myocardial Infarction					
		Nausea					
		Neck Pain					
		Non-Cardiac Chest Pain					
		Phlebitis Superficial					

Postoperative Ileus
Rectal Polyp
Rhinitis Allergic
Rosacea
Sinusitis
Stress Incontinence
Urinary Tract Infection
Venous Insufficiency
Vertigo
Weight Increased

Date:10/25/04ISR Number: 4484026-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Anaemia
Other	Anaemia Postoperative
	Angina Pectoris
	Aortic Aneurysm
	Aortic Valve Incompetence
	Arrhythmia
	Arthralgia
	Arthritis
	Arthropathy
	Asthma
	Bursitis
	Candidiasis
	Cardiac Disorder
	Cardiac Murmur
	Chronic Lymphocytic Leukaemia

		Contusion					
		Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Voltaren	SS		
UNKNOWN							
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Prempro	C		
UNKNOWN							
		Heart Rate Irregular		Acetaminophen And			
		Hiatus Hernia		Propoxyphene			
		Hyperlipidaemia		Napsylate	C		ORAL
		Hypertension		Carisoprodol	C		ORAL
		Injury		Acetaminophen And			
		Joint Sprain		Codeine Phosphate	C		
UNKNOWN							
		Knee Arthroplasty					
		Lymphadenopathy					
		Meniscus Lesion					
		Mitral Valve Calcification					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Oesophagitis					
		Osteoarthritis					
		Overdose					
		Peptic Ulcer					
		Pneumonia					
		Reflux Oesophagitis					
		Stress					
		Tricuspid Valve Incompetence					
		Ulcer Haemorrhage					
		Upper Respiratory Tract Infection					

Urinary Tract Infection
Ventricular Dysfunction
Ventricular Hypertrophy
Vomiting
Weight Decreased
White Blood Cell Count
Increased
Wound Infection
Staphylococcal

Date:10/25/04ISR Number: 4484031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:73 YR Gender:Male I/FU:F

Outcome PT
Other Adverse Event
Angina Pectoris
Appendix Disorder

	Arthropathy					
	Cardiac Disorder					
	Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Convulsion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Professional	Cardizem	C		
UNKNOWN						
	Diabetes Mellitus		Zyloprim	C		
UNKNOWN						
	Dyspnoea		Altace	C		
UNKNOWN						
	Gastric Ulcer		Pravachol	C		
UNKNOWN						
	Gastrointestinal		Aspirin	C		
UNKNOWN						
	Haemorrhage		Glucophage	C		
UNKNOWN						
	Gout		Avandia	C		
UNKNOWN						
	Haemorrhage		Vitamin E	C		
UNKNOWN						
	Hypertension		Ascorbic Acid	C		
UNKNOWN						
	Melaena		Vitamin B			
	Monarthritis		(Unspecified)	C		
UNKNOWN						
	Myocardial Infarction		Omega-3	C		
UNKNOWN						
	Tachycardia		Vitamins			
	Tonsillar Disorder		(Unspecified)	C		
UNKNOWN						

Date:10/25/04ISR Number: 4484032-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00614
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Vitamin B12 Deficiency
Other	Angina Pectoris
	Arthritis
	Asthenia
	Blood Potassium Decreased
	Bronchitis Acute
	Carotid Bruit
	Cerebrovascular Accident

Claustrophobia
Conjunctivitis
Convulsion
Coronary Artery Stenosis
Dental Caries
Diarrhoea
Dizziness
Dyspnoea Exertional
Foot Fracture
Gastrointestinal
Haemorrhage
Goitre
Headache
Hyperkeratosis
Hypertension
Hypoaesthesia
Intermittent Claudication
Keratoconjunctivitis
Sicca
Lobar Pneumonia
Mammogram Abnormal
Mucosal Ulceration
Myocardial Infarction
Normal Pressure
Hydrocephalus
Orthopnoea
Peptic Ulcer
Peripheral Vascular

	Disorder						
	Rash Macular						
	Skin Lesion						
	Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Dysfunction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Vision Blurred	Professional	Prevacid	C		ORAL	
	Vulvovaginitis		Premarin	C		ORAL	
	Trichomonal		Trental	C		ORAL	
			Prednisone	C		ORAL	
			Aquaphor Ointment	C		TOPICAL	

Date:10/25/04ISR Number: 4484036-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	611 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	611 DAY
Initial or Prolonged	Bipolar Disorder		Ativan	C			UNKNOWN
Disability	Blood Cholesterol		Hydrochlorothiazide	C			UNKNOWN
	Increased		Hydrocodone				
	Blood Triglycerides		Hydrochloride	C			UNKNOWN
	Increased		Maxzide	C			UNKNOWN
	Cervicobrachial Syndrome		Neurontin	C			UNKNOWN
	Chest Pain		Remeron	C			UNKNOWN
	Diarrhoea		Trazodone				
	Emotional Distress		Hydrochloride	C			UNKNOWN
	Fatigue		Tricor	C			UNKNOWN
	Intervertebral Disc		Zanaflex	C			UNKNOWN
	Degeneration		Midrin	C			UNKNOWN
	Intervertebral Disc		Lidoderm	C			UNKNOWN

Protrusion
Lower Limb Fracture
Menstrual Disorder
Menstruation Irregular
Myofascial Pain Syndrome
Neck Pain
Nerve Compression
Oedema Peripheral
Pelvic Pain
Renal Failure
Renal Failure Acute
Tibia Fracture

Date:10/25/04ISR Number: 4484037-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome PT
Disability Adverse Event
Other Amnesia
Anaemia
Bronchitis
Cerebrovascular Accident
Chest Pain
Depression
Difficulty In Walking
Disorientation
Dysarthria
Dysstasia
Fall
Gastrointestinal

		Haemorrhage					
		Herpes Simplex					
		Hypersensitivity					
		Neuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polyuria		Vioxx	PS	Merck & Co., Inc	ORAL
		Subcutaneous Abscess		Zantac	C		
UNKNOWN							
		Syncope		Reglan	C		
UNKNOWN							
		Tongue Disorder		Dicyclomine			
		Urinary Incontinence		Hydrochloride	C		
UNKNOWN							
				Procardia	C		
UNKNOWN							
				Vicodin Es Tablets	C		
UNKNOWN							
				Vicodin Es Tablets	C		
UNKNOWN							
				Arthrotec	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							
				Adalat	C		
UNKNOWN							
				Quinine	C		
UNKNOWN							
				Crixivan	C		ORAL
				Crixivan	C		ORAL
				Combivir	C		
UNKNOWN							
				Bactrim	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Diflucan	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484038-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00845
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Pain Lower Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Atrial Fibrillation					

Other	Chest Pain
	Coronary Artery Disease
	Diarrhoea
	Diverticulum Intestinal
	Headache
	Irritable Bowel Syndrome
	Myocardial Infarction

Date:10/25/04ISR Number: 4484040-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00843
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
	Anaemia
	Arrhythmia
	Blood Pressure Increased
	Bronchitis
	Complex Regional Pain
	Syndrome
	Dyspnoea Exertional
	Epicondylitis
	Fall
	Fibula Fracture
	Mononeuropathy
	Musculoskeletal Stiffness
	Oedema
	Palpitations
	Rhinitis Allergic
	Sinus Headache
	Tachycardia

		Upper Respiratory Tract Infection					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vitamins (Unspecified)	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Effexor Xr	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Micardis	C		
UNKNOWN							
				Verapamil Hydrochloride	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Atarax	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484042-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Adhesions Adverse Event	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Prednisone	C		
Other	Angina Pectoris		[Therapy Unspecified]	C		
UNKNOWN						
	Blood Pressure Increased		Zantac	C		ORAL
	Blood Pressure Systolic Increased					
	Chronic Obstructive Airways Disease Exacerbated					
	Convulsion					
	Diverticulum Intestinal					
	Dizziness					

Hiatus Hernia
Hypochromic Anaemia
Pelvic Peritoneal
Adhesions

Date:10/25/04ISR Number: 4484043-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00348
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thrombosis		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:10/25/04ISR Number: 4484044-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Murmur Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484046-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00353
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Renal Failure		Diclofenac Sodium	C			UNKNOWN	

Date:10/25/04ISR Number: 4484048-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00182
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysarthria		Atenolol	C			UNKNOWN	
	Dysgraphia		Irbesartan	C			UNKNOWN	
	Feeling Abnormal		Omeprazole	C			UNKNOWN	
	Speech Disorder							
	Tremor							

Date:10/25/04ISR Number: 4484049-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00083
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Angina Pectoris
Disability	Asthenia
	Blood Cholesterol Increased
	Blood Creatinine Increased
	Bronchitis
	Cardiac Failure Congestive
	Congestive Cardiomyopathy
	Contusion
	Cough
	Depression

Dizziness
Dyspepsia
Emotional Distress
Erectile Dysfunction
Facial Palsy
Fall
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Hypertension
Insomnia
Nasal Congestion
Neck Injury
Pain
Retching
Rhinorrhoea
Road Traffic Accident
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Swelling

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Upper Respiratory Tract Infection Ventricular Extrasystoles	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Norvasc	C		
				Zocor	C		ORAL
UNKNOWN				Digitek	C		
				Coreg	C		
UNKNOWN				Clonidine	C		
UNKNOWN				Clonidine	C		ORAL
				Lisinopril	C		
UNKNOWN				Spironolactone	C		
UNKNOWN				Nexium	C		
UNKNOWN				Reglan	C		
UNKNOWN				Minoxidil	C		
UNKNOWN				Minoxidil	C		
UNKNOWN				Lotrel	C		
UNKNOWN				Lopressor	C		
UNKNOWN				Hydrocodone/Apap	C		
UNKNOWN				Baclofen	C		
UNKNOWN				Levaquin	C		
UNKNOWN				Levaquin	C		
UNKNOWN				Palgic D	C		
UNKNOWN				[Therapy Unspecified]	C		
UNKNOWN				Diethylpropion Hydrochloride	C		
UNKNOWN							

Naproxen	C	UNKNOWN
Carisoprodol	C	UNKNOWN
Metoprolol	C	UNKNOWN

Date:10/25/04ISR Number: 4484060-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00534
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Arthropathy Cardiovascular Disorder Colonic Polyp Dizziness Intestinal Haemorrhage Joint Effusion Palpitations Polyneuropathy Idiopathic Progressive Stomach Discomfort Tendonitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484090-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00474
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484092-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							
	Hyperhidrosis							
	Myocardial Infarction							
	Pallor							
	Visual Disturbance							

Date:10/25/04ISR Number: 4484095-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Depression							
	Disturbance In Attention							
	Dizziness							
	Lacunar Infarction							
	Tinnitus							

Date:10/25/04ISR Number: 4484096-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00398
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Methotrexate	C			UNKNOWN	
	Dyspnoea		Methotrexate	C			UNKNOWN	
	Erythema		Methotrexate	C			UNKNOWN	
	Fall		Methotrexate	C			UNKNOWN	
	Fatigue		Cortisone	C			UNKNOWN	
	Gastritis Erosive		Cortisone	C			UNKNOWN	

Herpes Zoster
Hypertension
Lumbar Vertebral Fracture
Nerve Injury
Nervousness
Ocular Hyperaemia
Pericardial Effusion
Pleural Effusion
Pyrexia
Tachycardia
Vertigo

Date:10/25/04ISR Number: 4484107-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00609
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Ibuprofen	C				
UNKNOWN								
	Chest Pain		[Therapy					
	Dyspnoea		Unspecified]	C				
UNKNOWN								
	Myocardial Infarction		Ambien	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484108-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484110-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00062
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484111-0Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00010
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
Disability Other			[Composition Unspecified]	C		ORAL	1	WK

Date:10/25/04ISR Number: 4484113-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00481
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484115-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01609
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Stem Syndrome	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Nausea		Fluoxetine	C				UNKNOWN
Disability	Vomiting		Neurontin	C				UNKNOWN
Other			Docusate Sodium	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Oxybutynin	C				UNKNOWN
			Aciphex	C				UNKNOWN
			Coumadin	C				UNKNOWN
			Desmopressin (Desmopressin Acetate)	C				UNKNOWN
			Ddavp	C				UNKNOWN
			Cyclobenzaprine Hydrochloride	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Hydrocodone Hydrochloride	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484116-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484117-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00313
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:10/25/04ISR Number: 4484119-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00611
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484122-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484123-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01730
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Zocor	C		
UNKNOWN						
			Zetia	C		
UNKNOWN						

Date:10/25/04ISR Number: 4484124-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00012
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Subarachnoid Haemorrhage					

Date:10/25/04ISR Number: 4484125-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02009
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiovascular Disorder					
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484131-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02011
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Estradiol	C				
UNKNOWN								

Date:10/25/04ISR Number: 4484132-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01988
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dizziness		Prednisone	C				
UNKNOWN								
	Dyspnoea							
	Pain In Extremity							

Date:10/25/04ISR Number: 4484133-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Myocardial Infarction							

Date:10/25/04ISR Number: 4484137-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Cerebrovascular Accident		Celebrex	SS				
UNKNOWN								
	Decreased Appetite		Lotensin	C				
UNKNOWN								

Fatigue

Date:10/25/04ISR Number: 4484139-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01843
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fibromyalgia		Avandia	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Embolism		Glucophage	C				
UNKNOWN								
Disability			Prevacid	C				
UNKNOWN								
			Effexor Xr	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Klonopin	C				
UNKNOWN								
			Elavil	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/25/04ISR Number: 4484142-0Report Type:Expedited (15-DaCompany Report #TW-MERCK-0410TWN00018
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Bladder Cancer

Headache

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C		ORAL		
			Celebrex	C		ORAL		
			Depakine	C		ORAL		
			Depakine	C		ORAL		
			Nexium	C		ORAL		

Date:10/25/04ISR Number: 4484144-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02117
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
UNKNOWN								
			Fosamax	C		ORAL		

Date:10/25/04ISR Number: 4484145-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02216
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/25/04ISR Number: 4484147-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02458
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Norvasc	C				
UNKNOWN								
			Prinivil	C		ORAL		

			Atenolol	C		
UNKNOWN						
			Hydrodiuril	C		ORAL
			Nexium	C		
UNKNOWN						

Date:10/25/04ISR Number: 4484148-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02012
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			[Therapy			
Initial or Prolonged			Unspecified]	C		
UNKNOWN						
Disability						

Date:10/25/04ISR Number: 4484154-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02283
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
6 YR						
Hospitalization -	Adverse Event		Aspirin	C		
UNKNOWN						
Initial or Prolonged	Depressed Level Of		Atenolol	C		
UNKNOWN						
Disability	Consciousness		Hydrochlorothiazide	C		
UNKNOWN						
	Heart Rate Irregular		Norvasc	C		
UNKNOWN						

				[Therapy Unspecified]	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484155-9Report Type:Expedited (15-DaCompany Report #TN-MERCK-0410USA02336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Corvasal	C				
UNKNOWN								
			Tenormine	C				
UNKNOWN								
			Vastarel	C				
UNKNOWN								

Date:10/25/04ISR Number: 4484156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Antiphospholipid Syndrome		Advil	C		ORAL		
	Asthenia		Prempro	C				
UNKNOWN								
	Back Disorder		Prilosec	C				
UNKNOWN								
	Blood Pressure Increased		Synthroid	C				
UNKNOWN								
	Cerebrovascular Accident		Diovan	C				
UNKNOWN								
	Convulsion		Dimethyl Sulfone	C				
UNKNOWN								
	Cow'S Milk Intolerance		Gaviscon Antacid					
	Diabetes Mellitus		Tablets	C				
UNKNOWN								
	Non-Insulin-Dependent		Hydrocodone					
	Dizziness		Hydrochloride	C				
UNKNOWN								
	Drug Hypersensitivity		[Therapy					
	Gastrooesophageal Reflux		Unspecified]	C		ORAL		

Disease
Hemiparesis
Ischaemia
Labyrinthitis
Muscle Spasms
Neck Injury
Tinnitus
Tongue Ulceration
Urticaria Generalised
Vasculitis

Date:10/25/04ISR Number: 4484157-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02019
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx [Composition Unspecified]	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Allegra	C			UNKNOWN	
			Cozaar	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484158-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02411
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Dyspnoea							
	Haemorrhage							
	Oedema Peripheral							
	Pain							

Date:10/25/04ISR Number: 4484159-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02282
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:10/25/04ISR Number: 4484160-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02255
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Insulin	C				
UNKNOWN								
Initial or Prolonged	Congestive							
Disability	Feeling Abnormal							
	Pain							
	Renal Failure							

Date:10/25/04ISR Number: 4484162-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02615
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Levoxyl	C				
UNKNOWN								
Initial or Prolonged								

Date:10/25/04ISR Number: 4484164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02610
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
718 DAY								
Hospitalization -	Congestive		Spironolactone	C				
UNKNOWN								
Initial or Prolonged			Furosemide	C				
UNKNOWN								
			Amiodarone	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								
			Motrin	C				
UNKNOWN								
			Tylenol	C				
UNKNOWN								

				[Therapy Unspecified]	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484165-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack							

Date:10/25/04ISR Number: 4484167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02487
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484173-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02254
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fall		Ultracet	C				
UNKNOWN								
	Headache							
	Hepatic Enzyme Increased							
	Intervertebral Disc Protrusion							
	Paralysis							
	Renal Impairment							
	Retinal Haemorrhage							

Date:10/25/04ISR Number: 4484174-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02218
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C				
							UNKNOWN	

Date:10/25/04ISR Number: 4484175-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02704
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Mobic	C				
							UNKNOWN	
			Folic Acid	C				
							UNKNOWN	
			Prozac	C				
							UNKNOWN	
			Methotrexate	C				
							UNKNOWN	
			Clonazepam	C				
							UNKNOWN	
			Provigil	C				
							UNKNOWN	
			Hydrocodone Hydrochloride	C				
							UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484178-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02635
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Embolism		Prilosec	C				
UNKNOWN								
Initial or Prolonged	Ulcer							

Date:10/25/04ISR Number: 4484180-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02622
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fluctuation		Darvocet-N	C				
UNKNOWN								
Initial or Prolonged	Depression							
Disability	Hypertension							
	Hypotension							
	Impaired Healing							

Date:10/25/04ISR Number: 4484182-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02703
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Date:10/25/04ISR Number: 4484184-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03010
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Tylenol	C				
UNKNOWN								
	Fatigue							

Date:10/25/04ISR Number: 4484185-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03197
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Darvocet-N	C				
Disability								

Date:10/25/04ISR Number: 4484187-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02707
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gallbladder Disorder		Atenolol	C				
	Herpes Zoster		Prinivil	C		ORAL		
	Liver Disorder		Lipitor	C			UNKNOWN	
	Pneumonia		Levoxyl	C			UNKNOWN	
	Urinary Tract Infection		Klor-Con	C			UNKNOWN	
			Hydrodiuril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484188-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03248
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:10/25/04ISR Number: 4484211-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00871
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Costochondritis		Vioxx	PS	Merck & Co., Inc	ORAL	81	DAY
	Muscle Spasms		Effexor	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	
			Crestor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Lortab	C			UNKNOWN	

Date:10/25/04ISR Number: 4484213-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Procedural Complication							
	Vision Blurred							

Date:10/25/04ISR Number: 4484406-0Report Type:Expedited (15-DaCompany Report #PHBS2003CH11264
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrioventricular Block Complete Blood Creatinine Increased Chills Creatinine Renal Clearance Decreased Drug Level Increased Dysarthria Electrocardiogram T Wave Inversion Extrapyramidal Disorder Fall Headache Hypokinesia Hypotension Kyphosis Lordosis Malaise Myalgia Nausea Osteochondrosis Pain In Extremity Pancytopenia

		Renal Impairment Sinus Arrest Sinus Bradycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence Tremor	Health Professional	Tegretol Cr	PS	Novartis Sector: Pharma	ORAL
400 mg, BID							
		Vomiting		Tegretol Cr	SS	Novartis Sector: Pharma	ORAL
400 mg, BID							
				Priadel	SS		
200 mg, BID							
				Priadel	SS		
UNKNOWN	200 mg, BID						
				Vioxx	SS		
UNKNOWN	25 mg, BID	11520MIN					
				Dipiperon	C		
UNKNOWN	60 mg/day						
				Mirtazapine	C		
UNKNOWN	30 mg/day						
				Imovane	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484705-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00697
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Angina Unstable		Tenormin	C		
UNKNOWN						
	Blood Pressure Increased		Tenormin	C		
UNKNOWN						
	Convulsion		Baycol	C		
UNKNOWN						
	Coronary Artery Disease		Ogen	C		
UNKNOWN						
	Myocardial Infarction		Lipitor	C		
UNKNOWN						
	Ventricular Hypertrophy		Atenolol	C		
UNKNOWN						

Date:10/25/04ISR Number: 4484709-XReport Type:Expedited (15-DaCompany Report #IT-MERCK-0406ITA00034
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged	Gastritis Haemorrhagic		Carbamazepine	C		ORAL		
Other	Haematemesis							
	Melaena							
	Occult Blood Positive							

Date:10/25/04ISR Number: 4484711-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Acute Respiratory
Initial or Prolonged	Distress Syndrome
Other	Acute Respiratory Failure
	Alanine Aminotransferase
	Increased
	Anaphylactic Reaction
	Angioneurotic Oedema
	Aortic Atherosclerosis
	Aortic Calcification
	Arrhythmia
	Arthralgia
	Asthenia
	Asthma
	Back Pain
	Bacteraemia
	Blood Alkaline

Phosphatase Increased
Blood Calcium Decreased
Blood Cholesterol
Increased
Blood Creatine
Phosphokinase Increased
Blood Culture Positive
Blood Ph Decreased
Blood Triglycerides
Increased
Bronchitis
Cardiac Disorder
Cardiomegaly
Carpal Tunnel Syndrome
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Chronic Sinusitis
Coronary Artery Disease
Cough
Cytomegalovirus Colitis
Deep Vein Thrombosis
Depressed Level Of
Consciousness
Diastolic Dysfunction
Dilatation Atrial
Disseminated
Cytomegaloviral Infection
Diverticulum Intestinal
Drug Hypersensitivity
Drug Ineffective
Dyspepsia
Dysphagia
Dyspnoea
Dyspnoea Exertional
Ear Pain
Emotional Distress
Epistaxis
Facial Pain
Fatigue
Feeling Abnormal
Gamma-Glutamyltransferase
Increased
Gastritis
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease

Haemoptysis
Haemorrhoids
Headache
Heart Rate Irregular
Hepatic Enzyme Increased
Hepatic Steatosis
High Density Lipoprotein
Decreased
Hypertension
Hypoperfusion
Hypoventilation
Hypoxia
Ileus
Injury

		Intestinal Ischaemia					
		Joint Crepitation					
		Leukocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL
		Multiple Allergies		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Myopathy Steroid		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Nausea		Zyrtec	C		ORAL
		Nosocomial Infection		Aspirin	C		
UNKNOWN							
		Occult Blood Positive		Aspirin	C		
UNKNOWN							
		Oedema Peripheral		Hydro-Chlor	C		
UNKNOWN							
		Osteoarthritis		Benazepril			
		Oxygen Saturation		Hydrochloride And			
		Decreased		Hydrochlorothiazide	C		ORAL
		Pain In Extremity		Prednisone	C		ORAL
		Pharyngeal Oedema		Flonase	C		
RESPIRATORY							
		Platelet Count Decreased					
(INHALATION)							
		Pneumonia Cytomegaloviral		Detrol	C		ORAL
		Po2 Decreased		Lipitor	C		
UNKNOWN							
		Proctitis					
		Productive Cough					
		Pulmonary Haemorrhage					
		Pulmonary Oedema					
		Rectal Haemorrhage					
		Rectal Ulcer					
		Renal Infarct					
		Rhinitis Allergic					
		Rhinorrhoea					
		Self-Medication					
		Sinusitis					
		Sputum Discoloured					
		Staphylococcal Infection					
		Swelling Face					
		Swollen Tongue					
		Syphilis					
		Tachycardia					
		Tachypnoea					
		Troponin I Increased					

Ventricular Hypertrophy
Wheezing
Wound Infection

Date:10/25/04ISR Number: 4484717-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00182
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysarthria		Atenolol	C			UNKNOWN	
	Dysgraphia		Irbesartan	C			UNKNOWN	
	Feeling Abnormal		Omeprazole	C			UNKNOWN	
	Speech Disorder							
	Tremor							

Date:10/25/04ISR Number: 4484719-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00245
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Fluid Retention

	Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484720-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0408FRA00043
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Body Temperature		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Decreased Drug Ineffective		Amiloride And Furosemide	SS		ORAL		
	Hyperkalaemia		Amiloride And Furosemide	SS		ORAL		
	Hyponatraemia		Prednisone	C		ORAL		
	Renal Failure Acute		Betahistine Hydrochloride	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Melilot And Rutin	C		ORAL		
			Atenolol	C		ORAL		
			Fenofibrate	C		ORAL		
			Fenofibrate	C		ORAL		

Date:10/25/04ISR Number: 4484721-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00244
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Atenolol	C				
UNKNOWN								
	Loss Of Consciousness							
	Stomach Discomfort							

Date:10/25/04ISR Number: 4484722-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00180
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484723-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		31 DAY

Date:10/25/04ISR Number: 4484724-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00108
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		218 DAY
Other	Gastrointestinal Stromal Tumour							

Date:10/25/04ISR Number: 4484725-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
Initial or Prolonged	Chest Discomfort		Amlodipine Besylate	C				UNKNOWN
Other	Duodenal Polyp		Fosinopril Sodium	C				UNKNOWN
	Myocardial Infarction		Moxonidine	C				UNKNOWN

Date:10/25/04ISR Number: 4484731-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0409GBR00272
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ulcer Haemorrhage		Diclofenac	SS		ORAL		
			Aspirin	SS		ORAL		
			Bendroflumethiazide	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Bisoprolol	C		ORAL		
			Propoxyphene Hydrochloride And Acetaminophen	C		ORAL		

Date:10/25/04ISR Number: 4484732-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00341
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness							
	Dizziness							

Date:10/25/04ISR Number: 4484735-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Dyspepsia Hypertension Pain In Extremity Vomiting							

Date:10/25/04ISR Number: 4484736-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00006
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Attack							

Date:10/25/04ISR Number: 4484737-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484739-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:10/25/04ISR Number: 4484740-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00342
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484741-6Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00030
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484742-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00342
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:10/25/04ISR Number: 4484743-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00366
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Initial or Prolonged Myocardial Infarction

Date:10/25/04ISR Number: 4484744-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Congestive Drug Ineffective		Venlafaxine Hydrochloride	C				

UNKNOWN

Date:10/25/04ISR Number: 4484755-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00529
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastritis Hyperhidrosis Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484756-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00319
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective							
	Ocular Vascular Disorder							
	Visual Disturbance							

Date:10/25/04ISR Number: 4484757-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00515
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Dizziness							
	Thrombosis							

Date:10/25/04ISR Number: 4484758-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00528
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Rheumatoid Nodule		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Sudden Death							
Initial or Prolonged								

Date:10/25/04ISR Number: 4484760-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00363
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484762-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00524
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484763-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00520
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/25/04ISR Number: 4484764-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00069
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Aneurysm
	Anxiety
	Cerebral Haemorrhage

		Chest Pain					
		Depression					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Disturbance In Attention		Vioxx	SS	Merck & Co., Inc	ORAL
252	DAY						
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
557	DAY						
		Epilepsy					
		Essential Hypertension					
		Fatigue					
		Gastrointestinal Disorder					
		Headache					
		Hypertensive Crisis					
		Leukopenia					
		Nausea					
		Neck Pain					
		Paraesthesia					
		Ruptured Cerebral					
		Aneurysm					
		Somnolence					
		Subarachnoid Haemorrhage					
		Syncope					
		Thrombocytopenia					
		Tinnitus					

Date:10/25/04ISR Number: 4484776-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/25/04ISR Number: 4484777-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00527
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Venous Occlusion					

Date:10/25/04ISR Number: 4484779-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00586
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Intestinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:10/25/04ISR Number: 4484780-5Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00059
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484782-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00584
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness							
	Hyperhidrosis							
	Retching							

Date:10/25/04ISR Number: 4484784-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00196
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Pizotyline Malate	C		ORAL		
			Omeprazole	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Rosuvastatin Calcium	C		ORAL		
			Amlodipine Besylate	C		ORAL		

Date:10/25/04ISR Number: 4484785-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00029
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
			Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Betahistine Hydrochloride	C		ORAL		

Date:10/25/04ISR Number: 4484786-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00015
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Oedema							

Date:10/25/04ISR Number: 4484787-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00938
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY
Hospitalization - UNKNOWN	Hallucination		Ocuvite	C				
Initial or Prolonged Disability	Myocardial Infarction							

Date:10/25/04ISR Number: 4484789-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00523
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Fluid Retention							
	Skin Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484791-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01837
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Glyburide	C			UNKNOWN	
			Prinivil	C		ORAL	UNKNOWN	
			Pravachol	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Clonidine	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Singulair	C		ORAL	UNKNOWN	
			Tetracycline	C			UNKNOWN	
			Klor-Con	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/25/04ISR Number: 4484792-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00225
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Felodipine	C			UNKNOWN	
			Simvastatin	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Bendroflumethiazide	C			UNKNOWN	

Date:10/25/04ISR Number: 4484793-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00012
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484795-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

Date:10/25/04ISR Number: 4484796-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00199
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484798-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00201
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Aspirin	C		ORAL		
			Atenolol	C		ORAL		
			Trandolapril	C		ORAL		
			Doxazosin Mesylate	C		ORAL		
			Glyburide	C		ORAL		
			Zocor	C			UNKNOWN	
			Bendroflumethiazide	C			UNKNOWN	
			Nifedipine	C			UNKNOWN	

Date:10/25/04ISR Number: 4484799-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00592
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Amlodipine Besylate	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Ramipril	C		ORAL		

Date:10/25/04ISR Number: 4484803-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00531
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Enalapril Maleate And Hydrochlorothiazide	C			UNKNOWN	
Other	Cerebrovascular Accident							
	Depression							
	Epilepsy		Enalapril Maleate	C			UNKNOWN	
	Headache							
	Hypertensive Crisis							
	Nausea							

		Tinnitus Transient Ischaemic Attack					

Date:10/25/04ISR Number: 4484805-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00211
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
	Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		

Date:10/25/04ISR Number: 4484808-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484809-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
1 YR								
Initial or Prolonged	Disease							
	Vomiting							

Date:10/25/04ISR Number: 4484811-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00213
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
331 DAY								
	Attack		Gabapentin	C				
UNKNOWN								
			Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)								
			Ipratropium Bromide	C				
RESPIRATORY								
(INHALATION)								
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Albuterol	C				
RESPIRATORY								
(INHALATION)								
			Salmeterol	C				
RESPIRATORY								
(INHALATION)								
			Beclomethasone Dipropionate	C				
RESPIRATORY								
(INHALATION)								
			Clopidogrel					

				Bisulfate	C		
UNKNOWN							
				Nicorandil	C		
UNKNOWN							
				Isosorbide Mononitrate	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Perindopril	C		
UNKNOWN							
				Simvastatin	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Acetaminophen	C		
UNKNOWN							
				Oxygen	C		
UNKNOWN							
				Valdecoxib	C		
UNKNOWN							
				Lansoprazole	C		
UNKNOWN							

Date:10/25/04ISR Number: 4484812-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02629
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pneumonia		Vitamins (Unspecified)	C				
UNKNOWN								

Date:10/25/04ISR Number: 4484815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02414
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Nasonex	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								
			Potassium Chloride	C				
UNKNOWN								
			Zocor	C		ORAL		

	Aspirin	C	
UNKNOWN			
	Plavix	C	
UNKNOWN			
	Glyburide	C	
UNKNOWN			
	Isosorbide Mononitrate Er	C	
UNKNOWN			
	Vistaril	C	
UNKNOWN			
	Atenolol Msd	C	ORAL
	Desyrel	C	
UNKNOWN			
	Protonix	C	
UNKNOWN			
	Neurontin	C	
UNKNOWN			
	Nitrol (Nitroglycerin)	C	
UNKNOWN			
	Claritin	C	
UNKNOWN			
	Dicyclomine Hydrochloride	C	
UNKNOWN			
	Soma	C	
UNKNOWN			
	Levsin	C	
UNKNOWN			
	Darvocet-N	C	
UNKNOWN			
	Combivent	C	
UNKNOWN			
	Advair	C	
UNKNOWN			
	[Therapy Unspecified]	C	
UNKNOWN			
	Hydrocortisone Acetate	C	
TOPICAL			
	Patanol	C	
UNKNOWN			
	Avandia	C	
UNKNOWN			

Clonidine C
UNKNOWN

Date:10/25/04ISR Number: 4484816-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02475
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Aspirin	C				
Disability			Plavix	C				UNKNOWN
			Zocor	C		ORAL		
			Actos	C				UNKNOWN

Date:10/25/04ISR Number: 4484817-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA02589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484819-7Report Type:Expedited (15-DaCompany Report #NL-MERCK-0410NLD00029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:10/25/04ISR Number: 4484820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02571
Age:66 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Lipitor	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Insulin	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:10/25/04ISR Number: 4484821-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02639
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization -	Cerebrovascular Accident		Ziac	C				UNKNOWN
Initial or Prolonged Disability								

Date:10/25/04ISR Number: 4484826-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02978
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged	Ulcer Haemorrhage							
	Unevaluable Event							

Date:10/25/04ISR Number: 4484828-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastric Ulcer		Lipitor	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Actonel	C			UNKNOWN	

Date:10/25/04ISR Number: 4484829-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02945
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484832-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02991
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
			Loestrin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484833-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02642
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Difficulty In Walking		Aspirin	C				
UNKNOWN								
Initial or Prolonged	Hypertension		Lasix (Furosemide)	C				
UNKNOWN								
Disability	Oedema Peripheral		Metolazone	C				
UNKNOWN								
	Pain		Klor-Con	C				
UNKNOWN								
	Sepsis							
	Urinary Tract Infection							

Date:10/25/04ISR Number: 4484834-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Increased							
	Cerebrovascular Accident							
	Mental Impairment							

Date:10/25/04ISR Number: 4484836-7Report Type:Expedited (15-DaCompany Report #PR-MERCK-0410USA02666
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Rythmol	C				
UNKNOWN								
	Cerebrovascular Accident							

Date:10/25/04ISR Number: 4484837-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02747
Age:21 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastric Haemorrhage		Lortab	C				
	Intestinal Haemorrhage							

Date:10/25/04ISR Number: 4484838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484840-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02981
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON	
Hospitalization - Initial or Prolonged			Lorcet Plus	C			UNKNOWN	
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484841-0Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	732	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Leflunomide	C		ORAL	366	DAY
			Methylprednisolone	C		ORAL	366	DAY
			Omeprazole	C		ORAL	366	DAY
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
			Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)	763	DAY

Date:10/25/04ISR Number: 4484842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02467
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Balance Disorder Dysarthria Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484843-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03001
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02727
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock Tremor		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484846-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03196
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/25/04ISR Number: 4484847-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03003
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Haematochezia Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484848-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03134
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Potassium (Unspecified)	C				
	Head Discomfort		Hydrodiuril	C				
	Hypoaesthesia		Ranitidine-Bc	C				

Date:10/25/04ISR Number: 4484850-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03151
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Hospitalization - Initial or Prolonged	Disease		[Therapy Unspecified]	C				
	Dyspnoea		Prinivil	C				
			Prevacid	C				
			Lasix (Furosemide)	C				
			Darvocet-N	C				
			Triazolam	C				

Date:10/25/04ISR Number: 4484851-3Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00020
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
	Hypertension		Clomipramine					

Disability	Retinal Vascular Occlusion		Hydrochloride	C		ORAL

Date:10/25/04ISR Number: 4484852-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Congestive					
	Chest Pain					
	Hypotension					
	Pain					
	Pain In Jaw					
	Renal Disorder					
	Syncope					
	Tachycardia					

Date:10/25/04ISR Number: 4484856-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00023
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness					
	Sinus Bradycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4484857-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03189
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Norvasc	C				
Initial or Prolonged			Altace	C				
Disability			Pravachol	C				
			[Therapy Unspecified]	C				
			Nexium	C				
			Bextra	C				

Date:10/25/04ISR Number: 4484858-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Percocet	C				
Disability	Faeces Discoloured							
	Meningitis							
	Palpitations							
	Transient Ischaemic Attack							

Date:10/25/04ISR Number: 4484867-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02460
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Aspirin C
UNKNOWN

Date:10/25/04ISR Number: 4485365-7Report Type:Direct Company Report #CTU 230400
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS			DAILY	
Hospitalization - Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/25/04ISR Number: 4485384-0Report Type:Direct Company Report #CTU 230387
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Gastric Ulcer		Vioxx	PS		ORAL	1 ONCE A DAY	
Intervention to	Haematochezia					ORAL		
Prevent Permanent	Helicobacter Infection							
Impairment/Damage	Polyp							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/25/04ISR Number: 4485386-4Report Type:Direct Company Report #CTU 230388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg	PS				
ONE COURSE								
Hospitalization - Initial or Prolonged								
Congenital Anomaly								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/25/04ISR Number: 4485400-6Report Type:Direct Company Report #CTU 230373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx 25mg Merek &					
	Dyspnoea		Co	PS	Merck & Co	ORAL		
25 MG DAILY								
ORAL								

Date:10/25/04ISR Number: 4487632-XReport Type:Expedited (15-DaCompany Report #2004079228
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Neurontin					
	Knee Operation		(Gabapentin)	PS				
900 MG (300								
	Pain							
MG , 3 IN 1								
	Pain In Extremity							
D)								
	Shoulder Operation		Valdecoxib					
	Spinal Fusion Surgery		(Valdecoxib)	SS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:10/25/04ISR Number: 4487638-0Report Type:Expedited (15-DaCompany Report #2004004556
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Fatigue	Consumer	Zoloft (Sertraline)	PS		ORAL	50 MG (50 MG, 1 IN 1 D),	
	Feeling Abnormal	Health						
	Hepatitis C	Professional						
	Hepatocellular Damage		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D),	
	Liver Disorder							
	Pruritus							
			Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:10/25/04ISR Number: 4488748-4Report Type:Expedited (15-DaCompany Report #2004050571
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Anaesthetic Complication
	Borrelia Infection

		Caesarean Section Drug Exposure During Pregnancy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension Respiratory Disorder	Foreign Health	Zyrtec (Tablets) (Cetirizine)	PS		
(10 MG, 1 IN 2 D)							
		Unintended Pregnancy	Professional				
		Uterine Dilation And Curettage		Diclofenac (Diclofenac Sodium)	SS		
200 MG (100 MG, 2 D)							
				Rofecoxib (Rofecoxib)	SS		
100 MG (50 MG, 2 IN 1 D)							
				Tramadol (Tramadol)	C		
				All Other Therapeutic Products (All Other Therapeutic Products)	C		

Date:10/25/04ISR Number: 4489958-2Report Type:Expedited (15-DaCompany Report #2004075607
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired	Consumer	Zoloft (Sertraline)	PS		ORAL
50 MG (50 MG, 1 IN 1 D), ORAL						
Other	Aphagia					
	Blood Pressure Increased Dysphagia		Neurontin (Gabapentin)	SS		ORAL
ORAL						
	Dyspnoea Mobility Decreased		Olanzapine (Olanzapine)	SS		ORAL
ORAL						
	Pulse Abnormal Unevaluable Event		Tolterodine L-Tartrate			

	Weight Decreased	(Tolterodine L-Tartrate)	SS	ORAL
ORAL		Rofecoxib (Rofecoxib)	SS	
		Atenolol (Atenolol)	C	
		Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C	
		Senna Fruit (Senna Fruit)	C	
		Donepezil Hydrochloride (Donepezil Hydrochloride)	C	
		All Other Therapeutic Products (All Other Therapeutic Products)	C	
		Hemorid For Women Cream (Aloe Vera, Paraffin, Liquid, Phenylephrine Hydrochloride,	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485514-0Report Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12741492
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Metformin Hcl	PS	Bristol-Myers Squibb			
	Intentional Misuse	Professional			Company	ORAL		
			Rofecoxib	SS		ORAL		
			Amlodipine Besylate+Benazepril	SS		ORAL		

Date:10/26/04ISR Number: 4485575-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01959
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Therapeutic Response	Professional	Hydrochlorothiazide					
	Decreased		And Triamterene	C				
UNKNOWN								
	Therapeutic Response							
	Delayed							

Date:10/26/04ISR Number: 4485576-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
37 DAY								
	Back Pain		Vicodin Tablets	C		ORAL		
	Chest Wall Pain		Clonidine	C		ORAL		
	Contusion							
	Depression							
	Drug Ineffective							
	Fall							
	Gastric Haemorrhage							
	Haematocrit Decreased							
	Joint Effusion							
	Joint Sprain							
	Meniscus Lesion							

Upper Respiratory Tract
Infection

Date:10/26/04ISR Number: 4485595-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00126
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Irbesartan	C				
			Atorvastatin Calcium	C				
			Aspirin Calcium	C		ORAL		
			Aspirin Calcium	C		ORAL		
			Fluvoxamine Maleate	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485603-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00125
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Voltaren	C				
			Voltaren	C				

Date:10/26/04ISR Number: 4485606-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Dilacor Xr	C				
			Furosemide	C				
			K-Dur	C				
			Cozaar	C				
			Aspirin	C				
			Cordarone	C				
			Lipitor	C				

Date:10/26/04ISR Number: 4485613-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00026
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485614-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00403
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Appendicitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:10/26/04ISR Number: 4485615-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00210
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Calcium Carbonate And Cholecalciferol	C				
			Metoprolol	C				
			Nitrazepam	C				
			Sulfasalazine	C				
			Sulfasalazine	C				
			Deflazacort	C				

Date:10/26/04ISR Number: 4485616-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00407
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
			Minerals (Unspecified) And					

Vitamins (Unspecified)	C	ORAL
Bromopride	C	ORAL
Vasotec	C	ORAL
Amiodarone Hydrochloride	C	ORAL
Iron (Unspecified) And Vitamins (Unspecified)	C	ORAL

Date:10/26/04ISR Number: 4485617-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Facial Palsy Facial Paresis Speech Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485619-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Heart Valve Insufficiency		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485620-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00207
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485621-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485623-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485624-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00604
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Hypertension Hypertensive Crisis	Consumer	Vioxx Calcium Citrate And Cholecalciferol Ginkgo Biloba Extract	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

			Isoptin	C		ORAL

Date:10/26/04ISR Number: 4485625-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485627-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01751
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C			UNKNOWN	
			Micardis	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/26/04ISR Number: 4485628-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00940
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction Thrombosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			Actonel	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	

				Blood Thinner (Unspecified)	C		
UNKNOWN							

Date:10/26/04ISR Number: 4485630-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02285
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Lotrel	C				
UNKNOWN								
	Dyspnoea		Paxil	C				
UNKNOWN								
	Vascular Stenosis							

Date:10/26/04ISR Number: 4485631-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02365
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Fluid Retention		Aspirin	C				
UNKNOWN								
	Nasal Oedema		Lanoxin	C				
UNKNOWN								
	Oedema Peripheral							
	Stomach Discomfort							
	Walking Disability							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485632-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00939
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Rectal Prolapse		Lipitor	C				
Disability			Synthroid	C				UNKNOWN
Other			Calcium (Unspecified)	C				UNKNOWN
			Premarin	C				UNKNOWN
			Elavil	C		ORAL		
			Detrol	C				UNKNOWN

Date:10/26/04ISR Number: 4485634-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00606
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Atrial Flutter		Marcumar	C				
	Atrial Thrombosis							

Date:10/26/04ISR Number: 4485635-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01741
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:10/26/04ISR Number: 4485636-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02417
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Skin Discolouration		Actal	C				
	Visual Disturbance							

Date:10/26/04ISR Number: 4485637-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02415
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Arrest	Professional	Coumadin	C				
Hospitalization -	Cerebral Infarction		Aspirin	C				
Initial or Prolonged	Haemorrhagic Stroke		Allopurinol Msd	C		ORAL		
Disability	Spinal Cord Haemorrhage		Verapamil Msd Lp	C		ORAL		
	Thrombotic Stroke		Cozaar	C		ORAL		
			Lasix (Furosemide)	C				
			Digoxin	C				

Date:10/26/04ISR Number: 4485638-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02658
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485639-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02691
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485640-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02486
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Neoplasm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	38 MON	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		[Therapy Unspecified]	C				
UNKNOWN								
Disability								
Other								

Date:10/26/04ISR Number: 4485641-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03017
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Cotazym	C				
UNKNOWN								
Disability								

Date:10/26/04ISR Number: 4485643-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02600
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive Cerebrovascular Accident							
	Death							
	Difficulty In Walking							

Fatigue

Date:10/26/04ISR Number: 4485644-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02688
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Overdose		Aspirin	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Ultram	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Zocor	C		ORAL		
			Celebrex	C			UNKNOWN	
			Mobic	C			UNKNOWN	
			Mavik	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02690
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485646-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02651
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zocor	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:10/26/04ISR Number: 4485647-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02668
Age:72 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/26/04ISR Number: 4485648-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02963
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Disability

Date:10/26/04ISR Number: 4485649-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02973
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Pravachol	C				
UNKNOWN								
Initial or Prolonged			Lotrel	C				
UNKNOWN								
Disability			Plavix	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Glipizide	C				
UNKNOWN								
			Levobunolol Hydrochloride	C				
UNKNOWN								

Date:10/26/04ISR Number: 4485650-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02813
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485651-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03031
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Prozac	C				
UNKNOWN								

Date:10/26/04ISR Number: 4485652-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03030
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Flutter	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
3 MON								
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
3 MON								
			Aspirin	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/26/04ISR Number: 4485653-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485654-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02961
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Respiratory Disorder							

Initial or Prolonged
Disability

Date:10/26/04ISR Number: 4485656-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Disability	Ejection Fraction Decreased Myocardial Infarction							

Date:10/26/04ISR Number: 4485657-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03026
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability			Prinivil [Therapy Unspecified]	C C		ORAL		
UNKNOWN								

Date:10/26/04ISR Number: 4485658-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:10/26/04ISR Number: 4485659-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03119
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lung Neoplasm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	865	DAY
Initial or Prolonged	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	865	DAY
Disability	Renal Disorder		Flexeril	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Ismo	C			UNKNOWN	
			Corgard	C			UNKNOWN	

Date:10/26/04ISR Number: 4485660-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485661-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03423
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged				[Therapy Unspecified]	C		
UNKNOWN							
Disability							

Date:10/26/04ISR Number: 4485662-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03164
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Irregular	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN			Serevent	C				
UNKNOWN			Proventil	C				
UNKNOWN			Atrovent	C				

Date:10/26/04ISR Number: 4485663-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03415
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
UNKNOWN	Fluid Retention		Nexium	C				
UNKNOWN	Oedema Peripheral		Synthroid	C				
UNKNOWN			Coreg	C				
UNKNOWN			Buspirone Hydrochloride	C				
UNKNOWN			Plavix	C				
UNKNOWN			Prinivil	C				
UNKNOWN			Provigil	C				

				Actonel	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Alprazolam	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Detrol	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							

Date:10/26/04ISR Number: 4485666-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03295
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Vein Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485667-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
			[Therapy Unspecified]	C				
UNKNOWN								
			Valium	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								
			Detrol	C				
UNKNOWN								
			Celexa	C				
UNKNOWN								
			Amitriptyline					

				Hydrochloride	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							

Date:10/26/04ISR Number: 4485669-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03419
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain Diabetes Mellitus Non-Insulin-Dependent		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485671-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03425
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Isosorbide	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								
			Meclizine	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Alprazolam	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								
			Darvon	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4485672-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:10/26/04ISR Number: 4485674-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03144
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4485675-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00349
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Appendicitis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Lung Infection		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Postpartum Depression		Acetaminophen	C				
UNKNOWN								

Date:10/26/04ISR Number: 4485677-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03432
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								

Date:10/26/04ISR Number: 4485679-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03426
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		502 DAY
Initial or Prolonged	Back Disorder		Lantus	C				UNKNOWN
	Cardiac Disorder		Insulin	C				UNKNOWN
	Dyspnoea		Glucophage	C				UNKNOWN
	Fatigue		Aceon	C				UNKNOWN
	Myocardial Infarction		Toprol Xl Tablets	C				UNKNOWN

Date:10/26/04ISR Number: 4485742-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03443
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:10/26/04ISR Number: 4485749-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02440
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486100-9Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Rofecoxib	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral							
	Pulmonary Infarction							
	Thrombosis							

Date:10/26/04ISR Number: 4486104-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00867
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive							
	Cardiomegaly							
	Dyspnoea							
	Hypertension							
	Hypoxia							
	Meniscus Lesion							
	Osteoarthritis							
	Sinus Bradycardia							

Date:10/26/04ISR Number: 4486105-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	62	DAY
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	29	DAY
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL	62	DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Lithium Carbonate	C				
UNKNOWN								

Fatigue
Heart Injury
Heart Rate Irregular
Injury
Joint Dislocation
Myocardial Infarction
Onychomycosis
Osteoarthritis
Paranoia
Rotator Cuff Syndrome
Sacroiliitis
Squamous Cell Carcinoma
Stomach Discomfort
Suicidal Ideation

Date:10/26/04ISR Number: 4486109-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00195
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486110-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01693
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Disability	Back Injury		Protonix	C			UNKNOWN	
	Blindness		Triamcinolone	C			UNKNOWN	
	Dry Skin		Sunscreen (Unspecified)	C			UNKNOWN	
	Dyspnoea		Corticosteroids (Unspecified)	C			UNKNOWN	
	Fatigue							
	Loss Of Consciousness							
	Nightmare							
	Photosensitivity Reaction							
	Polyp							
	Pruritus							
	Road Traffic Accident							
	Skin Depigmentation							
	Skin Discolouration							
	Swelling							

Date:10/26/04ISR Number: 4486113-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			[Therapy Unspecified]	C				

Date:10/26/04ISR Number: 4486114-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Aortic Valve Sclerosis
Disability	Asthenia

Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Colon Adenoma
	Colonic Polyp
	Conversion Disorder
	Delusion
	Depression
	Dizziness
	Emotional Distress
	Fatigue
	Feeling Abnormal
	Gastrointestinal Dysplasia
	Gastrointestinal Haemorrhage
	Glucose Tolerance Impaired
	Hallucination
	Hernia
	High Density Lipoprotein Decreased
	Hyperlipidaemia

		Hypersomnia Hypertension Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
585	DAY						
		Male Sexual Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
585	DAY						
		Mitral Valve Incompetence		Lorcet 10/650	C		
UNKNOWN		283 DAY					
		Neck Pain		Cozaar	C		
UNKNOWN							
		Neuropathy Peripheral		Hydrocodone			
		Neurosis		Bitartrate	C		
UNKNOWN		201 DAY					
		Nocturia		Ibuprofen	C		
UNKNOWN							
		Nuclear Magnetic		Ambien	C		
UNKNOWN							
		Resonance Imaging Brain Abnormal Oedema Peripheral Osteoarthritis Panic Attack Periarthritis Somnolence Stress Tendonitis Varicose Vein Ventricular Hypertrophy Very Low Density Lipoprotein Increased					

Date:10/26/04ISR Number: 4486116-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia Scarring
Other	Angina Pectoris
	Antiphospholipid Syndrome
	Asthenia
	Back Disorder
	Balance Disorder
	Blood Pressure Increased
	Cerebrovascular Accident

Complement Factor C3
Decreased
Complement Factor C4
Decreased
Convulsion
Cow'S Milk Intolerance
Diabetes Mellitus
Non-Insulin-Dependent
Diarrhoea
Dizziness
Drug Hypersensitivity
Gait Disturbance
Gastrooesophageal Reflux
Disease
Hemiparesis
Hyperglycaemia
Ischaemia
Labyrinthitis
Muscle Spasms
Neck Injury
Tinnitus
Tongue Ulceration
Urticaria

		Urticaria Generalised Vasculitis Vertigo	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Advil	C		ORAL
				Prempro	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Dimethyl Sulfone	C		
UNKNOWN							
				Gaviscon Antacid Tablets	C		
UNKNOWN							
				Hydrocodone Hydrochloride	C		
UNKNOWN							
				[Therapy Unspecified]	C		ORAL

Date:10/26/04ISR Number: 4486117-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
Disability		Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure Congestive Cerebrovascular Accident Chest Pain Chronic Obstructive Pulmonary Disease Colitis Ulcerative Constipation Cough Deep Vein Thrombosis					

Depression
Drug Interaction
Dyspnoea
Headache
Insomnia
Iron Deficiency Anaemia
Muscle Spasms
Oedema Peripheral
Pericardial Effusion
Pharyngolaryngeal Pain
Pneumonia
Postmenopausal
Haemorrhage
Pulmonary Congestion
Pulmonary Embolism
Pulmonary Hypertension
Rectal Ulcer
Reflux Oesophagitis
Renal Failure
Tremor
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486118-6Report Type:Expedited (15-DaCompany Report #DK-MERCK-0410DNK00016
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
			Bendroflumethiazide And Potassium Chloride	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486119-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00246
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Trimethoprim	C				
UNKNOWN								
			Rifampin	C		ORAL		
			Isoniazid	C		ORAL		

Date:10/26/04ISR Number: 4486122-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:10/26/04ISR Number: 4486123-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00243
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/26/04ISR Number: 4486124-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00043
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486125-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00353
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Renal Failure		Diclofenac Sodium	C			UNKNOWN	

Date:10/26/04ISR Number: 4486127-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00390
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Arrest		Cloxazolam	C			UNKNOWN	
Other	Pancreatic Disorder							
	Respiratory Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486128-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486134-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00017
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	4	YR

Date:10/26/04ISR Number: 4486135-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01680
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Imitrex	C				
UNKNOWN							822	DAY
Initial or Prolonged			Inderal La	C		ORAL		
Other			Premarin	C				
UNKNOWN								
			Prevacid	C		ORAL		
			Lipitor	C				
UNKNOWN								
			Topamax	C		ORAL		
			Lexapro	C		ORAL		
			Parafon Forte	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486136-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00387
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Multi-Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Uterine Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		
			Butylscopolamine Bromide	C		ORAL		

Date:10/26/04ISR Number: 4486137-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00461
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN Initial or Prolonged			Naprosyn	C				
Disability								

Date:10/26/04ISR Number: 4486138-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00876
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Disability	Bronchitis
	Dry Throat
	Dysphonia

	Headache Treatment Noncompliance						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C			UNKNOWN	
			Levothroid	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	

Date:10/26/04ISR Number: 4486140-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy Balance Disorder Dizziness Fatigue Malaise Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486141-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02248
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Gastric Disorder		Lotrel	C			UNKNOWN	
Disability	Movement Disorder		Aspirin	C			UNKNOWN	
			Flonase	C			UNKNOWN	
			Tenormin	C			UNKNOWN	

Date:10/26/04ISR Number: 4486142-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02715
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486144-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01695
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486145-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01179
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Zocor	C		ORAL		
	Dyspnoea		Zyrtec	C				
UNKNOWN								
			Vasotec	C				
UNKNOWN								
			Actonel	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486146-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		27 DAY
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		

Date:10/26/04ISR Number: 4486152-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03070
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Overdose		[Therapy Unspecified]	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486153-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization - Initial or Prolonged Disability	Triple Vessel Bypass Graft							

Date:10/26/04ISR Number: 4486158-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02765
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Hypertension		Tylenol	C
Initial or Prolonged UNKNOWN			Advil	C
UNKNOWN			Lortab	C
UNKNOWN			Prevacid	C
UNKNOWN			[Therapy Unspecified]	C

Date:10/26/04ISR Number: 4486159-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased Blood Pressure Decreased Glossodynia Rectal Haemorrhage Swollen Tongue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486160-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02732
Age:38 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Hydroxyzine Hydrochloride	C				
	Thrombosis		Lamictal	C				
			Trazodone Hydrochloride	C				
			Lexapro	C				
			Prevacid	C				
			Loratadine	C				
			Coumadin	C				
			Albuterol	C				
			Advair	C				
			Valtrex	C				

Date:10/26/04ISR Number: 4486162-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02890
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486163-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00249
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	402	DAY

Other	Visual Field Defect	Bisoprolol	C
UNKNOWN			
		Dothiepin Hydrochloride	C
UNKNOWN			
		Acetaminophen And Propoxyphene Hydrochloride	C
UNKNOWN			
		Prochlorperazine Maleate	C
UNKNOWN			

Date:10/26/04ISR Number: 4486165-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03068
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Mevacor	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/26/04ISR Number: 4486167-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02766
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486168-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03080
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1477 DAY
Hospitalization -			Glucophage	C				UNKNOWN
Initial or Prolonged			Premarin	C				UNKNOWN
Disability			Prilosec	C				UNKNOWN
			Cyanocobalamin	C				UNKNOWN

Date:10/26/04ISR Number: 4486169-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03221
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cognitive Disorder		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C				
Disability								

Date:10/26/04ISR Number: 4486177-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03460
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Disability	Haematemesis		Nitro	C				UNKNOWN
	Pain		Elavil	C				UNKNOWN
			Xanax	C				UNKNOWN
			Zantac	C				UNKNOWN

				Prinivil	C		
UNKNOWN							
				Cartia (Aspirin)	C		
UNKNOWN							

Date:10/26/04ISR Number: 4486179-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03465
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Plaquenil	C		
UNKNOWN						
Disability			Lipitor	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						
			Diuretic (Unspecified)	C		
UNKNOWN						

Date:10/26/04ISR Number: 4486180-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03258
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Synthroid	C		
UNKNOWN						
Disability			Ultracet	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486182-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03366
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Tricor	C				
UNKNOWN								
Initial or Prolonged	Dizziness		Crestor	C				
UNKNOWN								
Disability	Myocardial Infarction		Plavix	C				
UNKNOWN								
			Prinivil	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Imdur	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486184-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03382
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rash		Ambien	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486185-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486186-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03222
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Aleve	C				
UNKNOWN								

Date:10/26/04ISR Number: 4486188-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Haematochezia		Lanoxin	C				
UNKNOWN								
	Thyroid Neoplasm		Synthroid	C				
UNKNOWN								
			Cardizem	C				
UNKNOWN								
			Clonidine	C				
UNKNOWN								
			Zyrtec	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Darvocet-N	C				
UNKNOWN								
			Ventolin (Albuterol)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486189-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-99108250
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY

Date:10/26/04ISR Number: 4486190-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03285
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dialysis		Clonidine	C				UNKNOWN
	Myocardial Infarction		Insulin	C				UNKNOWN
Other	Renal Failure		Procardia	C				UNKNOWN
			Tylenol	C				UNKNOWN

Date:10/26/04ISR Number: 4486192-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03478
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				UNKNOWN

Date:10/26/04ISR Number: 4486194-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03282
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Hydrocodone					

	Dyspnoea	Bitartrate	C
UNKNOWN			
	Rash		

Date:10/26/04ISR Number: 4486195-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00888
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization - Initial or Prolonged	Anaemia
	Anxiety
Disability	Aphasia
	Bacteria Urine Identified
	Brain Neoplasm
	Chest Wall Pain
	Clostridium Colitis
	Coronary Artery Disease
	Death
	Decubitus Ulcer
	Dementia
	Faecaloma
	Feeding Disorder
	Hypotension
	Oedema Peripheral
	Oral Fungal Infection
	Osteoarthritis
	Peripheral Vascular Disorder

		Pneumonia					
		Polytraumatism					
		Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Respiratory Distress		Meclizine	C		
UNKNOWN							
		Venous Insufficiency		Accupril	C		
UNKNOWN							
		Wound Infection		Clonidine	C		
UNKNOWN							
		Pseudomonas		Aspirin	C		
UNKNOWN							
		Wound Infection		Cefadroxil	C		
UNKNOWN							
		Staphylococcal					

Date:10/26/04ISR Number: 4486196-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03481B1
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abnormal Labour		Vioxx	PS	Merck & Co., Inc	
5 YR						
Hospitalization -	Brain Damage		[Therapy			
Initial or Prolonged	Cardiac Disorder		Unspecified]	C		
Disability	Complication Of Delivery					
	Congenital Brain Damage					
	Drug Exposure During					
	Pregnancy					
	Pregnancy					
	Pulmonary Embolism					
	Respiratory Disorder					

Date:10/26/04ISR Number: 4486198-8Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00016
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
	Sudden Death					

Date:10/26/04ISR Number: 4486199-XReport Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/26/04ISR Number: 4486200-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03476
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -			Celebrex	C				
Initial or Prolonged			Bextra	C				
Disability			Lexapro	C				
			Thyroid	C				
			Aspirin	C				
			Synthroid	C				
			Diabeta	C				
			Fibercon	C				
			Colace	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4486202-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00513
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Meniere'S Disease		Tramadol Hydrochloride	C		ORAL		
	Sudden Hearing Loss		Betahistine Mesylate	C				
	Tinnitus		Atorvastatin Calcium	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Aspirin	C		ORAL		
			Hydroxychloroquine Sulfate	C		ORAL		

Date:10/26/04ISR Number: 4486209-XReport Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00038
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Vision Blurred		Vioxx	C		ORAL	2	DAY

Date:10/26/04ISR Number: 4486210-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03481M
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Labour		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -	Cardiac Disorder		[Therapy					
Initial or Prolonged	Congenital Brain Damage		Unspecified]	C				
UNKNOWN								
Disability	Drug Exposure During Pregnancy							
	Neonatal Disorder							
	Pregnancy							
	Pulmonary Embolism							
	Respiratory Disorder							

Date:10/26/04ISR Number: 4486565-2Report Type:Direct Company Report #CTU 230474
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis		Vioxx	PS		ORAL	1 TABLET DAILY ORAL	

Date:10/26/04ISR Number: 4489534-1Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Health Professional Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	367 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/26/04ISR Number: 4490077-XReport Type:Expedited (15-DaCompany Report #WAES 0410USA50161
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
		Health Professional	Mevacor	C				
			Albuterol	C				
			Ascorbic Acid	C				
			Calcium (Unspecified)	C				
			Chondroitin Sulfate Sodium	C				
			Clarithromycin	C				
			Flunisolide	C				
			Glucosamine Hydrochloride	C				
			Guaifenesin (+) Phenylephrine	C				
			Hydrochlorothiazide (+) Triamter	C				
			Hyoscyamine	C				
			Ipratroprium Bromide	C				
			Lisinopril	C				
			Prednisone	C				
			Quinine Sulfate	C				
			Sertraline Hydrochloride	C				
			Sildenafil Citrate	C				
			Vitamin E	C				
			Vitamins (Unspecified)	C				

Date:10/26/04ISR Number: 4490782-5Report Type:Expedited (15-DaCompany Report #WAES 0409CHL00003
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY PO	
	Aortic Disorder	Study						

	Myocardial Ischaemia	Health Professional	Cinnarizine	C
			Clonazepam	C
			Dorzolamide Hydrochloride	C
			Tamsulosin Hydrochloride	C
			Timolol	C
			Zopiclone	C

Date:10/27/04ISR Number: 4486754-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00098
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Angina Unstable
	Aortic Aneurysm
	Arrhythmia
	Arthralgia
	Asthenia
	Atrial Fibrillation

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Basal Cell Carcinoma					
		Benign Prostatic Hyperplasia					
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Glipizide	C		
UNKNOWN							
		Chest Pain		Tagamet	C		
UNKNOWN							
		Closed Head Injury		Prednisone	C		
UNKNOWN							
		Coronary Artery Disease		Lasix (Furosemide)	C		
UNKNOWN							
		Dehydration		Lanoxin	C		
UNKNOWN							
		Diarrhoea		Imuran			
		Dizziness		(Azathioprine)	C		
UNKNOWN							
		Drug Toxicity		Tiazac	C		
UNKNOWN							
		Emotional Distress		Flomax (Tamsulosin			
		Emphysema		Hydrochloride)	C		
UNKNOWN							
		Fall		Motrin	C		
UNKNOWN							
		Feeling Hot And Cold		Cartia (Diltiazem			
		Heart Rate Irregular		Hydrochloride)	C		
UNKNOWN							
		Hypoacusis		Chloracon	C		
UNKNOWN							
		Leukocytosis		Imdur	C		
UNKNOWN							
		Lobar Pneumonia		Methotrexate	C		
UNKNOWN							
		Myocardial Infarction		Celebrex	C		
UNKNOWN							
		Nausea		Potassium			
		Nerve Degeneration		(Unspecified)	C		
UNKNOWN							
		Oesophageal Disorder		Vitamin E	C		
UNKNOWN							
		Oral Candidiasis		Cyanocobalamin	C		
UNKNOWN							
		Pain		Folic Acid	C		
UNKNOWN							
		Polymyalgia Rheumatica		Insulin Human,			

	Pyrexia	Isophane	C
UNKNOWN			
	Skin Ulcer	Insulin	C
UNKNOWN			
	Sleep Apnoea Syndrome	Niacin	C
UNKNOWN			
	Temporal Arteritis	Amiodarone	C
UNKNOWN			
	Thrombosis		
	Urinary Tract Infection		
	Vomiting		
	Wandering Pacemaker		

Date:10/27/04ISR Number: 4486757-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Acanthosis
	Acute Myocardial Infarction
	Aggression
	Amnesia
	Anoxic Encephalopathy
	Apnoea
	Atherosclerosis
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Cardiac Arrest
	Cardiac Failure Congestive
	Cardio-Respiratory Arrest
	Cardiogenic Shock
	Chest Pain
	Convulsion

		Coronary Artery Occlusion					
		Dizziness					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperkeratosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Atenolol	C		
UNKNOWN							
		Lung Infiltration		Prozac	C		
UNKNOWN							
		Myalgia		Prozac	C		
UNKNOWN							
		Myocardial Infarction		Tylenol	C		
UNKNOWN							
		Orthostatic Hypotension		Buspar	C		
UNKNOWN							
		Papilloma		Atrovent	C		
UNKNOWN							
		Pulse Absent		Magnesium Sulfate	C		
UNKNOWN							
		Sinus Tachycardia		Claforan	C		
UNKNOWN							
		Syncope		Cordarone	C		
UNKNOWN							
		Ventricular Fibrillation		Pepcid	C		
UNKNOWN							
		Ventricular Hypokinesia		Reopro	C		
UNKNOWN							
		Ventricular Tachycardia		Dopamine Hydrochloride	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Aspirin	C		ORAL
				Celexa	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Dalmane	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							

Date:10/27/04ISR Number: 4486763-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00741
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
Disability	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	12	DAY
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Constipation		Iron (Unspecified)	SS			UNKNOWN	
	Coronary Artery		Celebrex	SS			UNKNOWN	95 DAY
	Atherosclerosis		Tylenol	C			UNKNOWN	790 DAY
	Coronary Artery		Triamcinolone	C			TOPICAL	366 DAY
	Restenosis		Lipitor	C			UNKNOWN	790 DAY
	Fall		Tylenol	C			UNKNOWN	
	Hyperlipidaemia							
	Hypertension							
	Iron Deficiency Anaemia							
	Joint Injury							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Rash							
	Rectal Haemorrhage							
	Stress							
	Ulcer							

Date:10/27/04ISR Number: 4486767-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Back Pain
	Blood Glucose Increased

		Blood Pressure Increased					
		Cardiomegaly					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Conjunctivitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Coumadin	C		
UNKNOWN							
		Non-Insulin-Dependent		Risperdal	C		
UNKNOWN							
		Dyspnoea		Prozac	C		
UNKNOWN							
		Ear Pain		Elavil	C		ORAL
		Fatigue		Effexor	C		
UNKNOWN							
		Headache		Effexor	C		
UNKNOWN							
		Hepatic Steatosis		Glucophage	C		
UNKNOWN							
		Herpes Zoster					
		Hypoglycaemia					
		Impaired Gastric Emptying					
		Injection Site					
		Haemorrhage					
		Lipomatosis					
		Mastoiditis					
		Migraine					
		Pain In Extremity					
		Phlebitis					
		Rash					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					
		Syncope					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:10/27/04ISR Number: 4486771-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0309CAN00088
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Heart Injury Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486772-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00519
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486773-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00552
Age:58 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486775-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00545
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							
	Myocardial Infarction							

Date:10/27/04ISR Number: 4486776-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486777-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00553
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:10/27/04ISR Number: 4486778-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00029
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Diuretic (Unspecified)	C		

UNKNOWN 1 DAY

Date:10/27/04ISR Number: 4486779-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00543
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Musculoskeletal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486780-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00026
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486781-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00874
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Diarrhoea							
	Exostosis							
	Hypertension							
	Monarthritis							
	Rotator Cuff Syndrome							
	Synovial Disorder							
	Thoracic Vertebra Injury							

Date:10/27/04ISR Number: 4486782-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00955
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Joint Crepitation		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Joint Effusion		Darvocet-N	C				
UNKNOWN								
Disability	Myocardial Infarction							
	Neck Pain							

Date:10/27/04ISR Number: 4486783-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00064
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/27/04ISR Number: 4486784-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Flutter		Vioxx	SS	Merck & Co., Inc	ORAL
	Ventricular Fibrillation					

Date:10/27/04ISR Number: 4486785-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/27/04ISR Number: 4486786-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00621
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486787-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00620
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Methotrexate	C				
UNKNOWN								
	Cerebrosclerosis							

Date:10/27/04ISR Number: 4486788-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00709
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								
Initial or Prolonged	Pain In Extremity		Prevacid	C				
UNKNOWN								
	Unevaluable Event		Aspirin	C				
UNKNOWN								
	Vascular Calcification							

Date:10/27/04ISR Number: 4486789-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00575
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
25 DAY								
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Esomeprazole Magnesium	C				
UNKNOWN								
			Enalapril Maleate	C		ORAL		

Date:10/27/04ISR Number: 4486790-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01442
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486791-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00071
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stent Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin Lysine	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Fluvastatin Sodium	C		ORAL		

Date:10/27/04ISR Number: 4486792-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486793-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01253
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization -			Lipitor	C		ORAL		
Initial or Prolonged			Prevacid	C		ORAL		
Other			Atarax	C		ORAL		

Date:10/27/04ISR Number: 4486794-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00625
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486795-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01197
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Celebrex	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:10/27/04ISR Number: 4486796-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00565
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		

Initial or Prolonged Osteoarthritis
Pulmonary Embolism
Synovitis

Date:10/27/04ISR Number: 4486797-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00579
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486798-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01828
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486799-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00962
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tinnitus		Vicodin Tablets	C			UNKNOWN	
Disability			Phenytoin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Effexor	C			UNKNOWN	
			Librium	C			UNKNOWN	
			Dilantin	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Advair	C			UNKNOWN	

Date:10/27/04ISR Number: 4486806-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02745
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:10/27/04ISR Number: 4486807-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebrovascular Accident Eye Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/27/04ISR Number: 4486808-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02911
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Arterial Occlusive		Lipitor	C		
Initial or Prolonged UNKNOWN	Disease		Norvasc	C		
Disability UNKNOWN	Cardiac Failure Congestive		[Therapy Unspecified]	C		
	Diabetes Mellitus		A.S.A.	C		
	Loss Of Consciousness					

Date:10/27/04ISR Number: 4486809-7Report Type:Expedited (15-DaCompany Report #MX-MERCK-0410MEX00003
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - UNKNOWN	Deep Vein Thrombosis 425 DAY		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged Disability			Methotrexate	C		ORAL
			Prednisone	C		ORAL
			Fosamax	C		ORAL
			Ranitidine	C		ORAL
			Candesartan	C		ORAL
			Leflunomide	C		ORAL
1486 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486813-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02713
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486814-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03604
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Embolism		Estrogens					
Initial or Prolonged	Suicidal Ideation		(Unspecified)	C				
UNKNOWN								

Date:10/27/04ISR Number: 4486815-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03620
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysgeusia		Zestril	C				
UNKNOWN								
	Epistaxis							
	Myocardial Infarction							

Date:10/27/04ISR Number: 4486819-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02906
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Analgesic Or					
Disability	Heart Rate Increased		Anesthetic					
Other	Middle Insomnia		(Unspecified)	C				
UNKNOWN								
	Polyp		[Therapy					

	Polypectomy		Unspecified]	C		
UNKNOWN						
	Suffocation Feeling					
	Weight Decreased					

Date:10/27/04ISR Number: 4486820-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/27/04ISR Number: 4486821-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03625
Age:89 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Pneumonia		[Therapy Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4486822-XReport Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00021
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged			Methotrexate	C		ORAL		
Other			Acetaminophen And Codeine Phosphate	C		ORAL		
			Chloroquine	C		ORAL		
			Folic Acid	C		ORAL		

Date:10/27/04ISR Number: 4486824-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03628
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lotrel	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:10/27/04ISR Number: 4486825-5Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486848-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00615
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4486878-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02771
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	42 DAY	
	Feeling Abnormal		Ultracet	C			UNKNOWN	
	Pain		Piroxicam	C			UNKNOWN	
	Renal Disorder		Diclofenac	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Fluoxetine	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/27/04ISR Number: 4486879-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03378
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	946 DAY	
Initial or Prolonged	Hypertension		Plavix	C			UNKNOWN	
	Syncope		Bextra	C			UNKNOWN	

			Vitamins (Unspecified)	C			
UNKNOWN							

Date:10/27/04ISR Number: 4487347-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00475
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Peripheral Embolism							
Other	Renal Disorder							

Date:10/27/04ISR Number: 4487348-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01010
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Other	Cold Sweat		Baycol	C				
UNKNOWN								
	Contusion		Motrin	C				
UNKNOWN								
	Drug Hypersensitivity		Vicodin Tablets	C				
UNKNOWN								
	Emotional Distress		Celebrex	C				
UNKNOWN								
	Fall							
	Heart Rate Increased							
	Hypertension							
	Injury							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Myocardial Infarction							
	Pain In Extremity							
	Palpitations							
	Respiratory Disorder							
	Respiratory Rate							

Increased
Rib Fracture
Rotator Cuff Syndrome

Date:10/27/04ISR Number: 4487352-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01402
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Death	Angina Pectoris
Life-Threatening	Blood Cholesterol
Hospitalization -	Increased
Initial or Prolonged	Cardiac Arrest
	Coronary Artery
	Atherosclerosis
	Cystocele
	Dilatation Ventricular
	Fibromyalgia
	Hepatic Steatosis
	Hepatomegaly
	Muscle Spasms
	Myocardial Infarction
	Pleural Adhesion
	Pneumonia
	Pulmonary Oedema

		Scoliosis Sinus Tachycardia Stress Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sudden Cardiac Death	Health	Vioxx	PS	Merck & Co., Inc	ORAL
340	DAY						
		Vaginal Prolapse	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
		Ventricular Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
340	DAY						
				Hydroxyzine Hydrochloride	C		
UNKNOWN							
				Triamcinolone	C		
UNKNOWN							
				Voltaren	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Benzonatate	C		
UNKNOWN							
				Proventil Repetabs And Tablets	C		
UNKNOWN							
				Lorabid	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Claritin-D	C		
UNKNOWN							
				Tequin	C		
UNKNOWN							

				Tussi-12	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Prempro	C		
UNKNOWN		41	DAY				
				Remeron	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Promethazine	C		
UNKNOWN							

Date:10/27/04ISR Number: 4487357-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00097
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Furosemide	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Myocardial Ischaemia		Pimeclone Hydrochloride	C				
	Pancreatic Neoplasm							
UNKNOWN								
	Ventricular Dysfunction		Tiratricol	C				
UNKNOWN								
			Olanzapine	C				
UNKNOWN								
			Levothyroxine Sodium	C				
UNKNOWN								
			Temazepam	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								
			Alendronate Sodium	C				
UNKNOWN								
			Metoclopramide	C				
UNKNOWN								

Date:10/27/04ISR Number: 4487359-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00848
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event

Oedema
Osteoarthritis
Pain In Extremity

	Transient Ischaemic Attack					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/27/04ISR Number: 4487360-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03537
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Abdominal Pain	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Abnormal Faeces		Vioxx	SS	Merck & Co., Inc	ORAL
	Bowel Movement Irregularity		[Therapy Unspecified]	C		
UNKNOWN						
	Constipation		Flonase	C		
UNKNOWN						
	Depression		Premarin	C		
UNKNOWN						
	Diarrhoea		Hydroxychloroquine Sulfate	C		
	Disease Recurrence					
UNKNOWN						
	Dysphagia		Zoloft	C		
UNKNOWN						
	Ear Congestion		Ambien	C		
UNKNOWN						
	Flank Pain		Daypro	C		
UNKNOWN						
	Gastric Disorder		Claritin	C		
UNKNOWN						
	Gastrooesophageal Reflux Disease					
	Haematuria					
	Haemorrhoids					
	Headache					
	Hypersensitivity					
	Hypoacusis					
	Labyrinthitis					
	Nephrolithiasis					
	Nystagmus					
	Oesophageal Disorder					
	Ovarian Cyst					
	Panic Disorder					

Peptic Ulcer
Phlebolith
Proctalgia
Rectal Haemorrhage
Rheumatoid Arthritis
Rhinitis Allergic
Systemic Lupus
Erythematosus
Tinnitus
Urethral Stricture
Vertigo

Date:10/27/04ISR Number: 4487362-4Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00017
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		547 DAY
	Myocardial Infarction							

Date:10/27/04ISR Number: 4487364-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00032
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	3927 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	3047 DAY	
			Zantac	C			UNKNOWN	
			Caltrate	C		ORAL		
			[Composition Unspecified]	C				

Date:10/27/04ISR Number: 4487365-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00406
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Macular Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Fenofibrate	C		ORAL		
			Pentoxifylline	C		ORAL		
			Aspirin	C		ORAL		
			Nafronyl Oxalate	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		

Date:10/27/04ISR Number: 4487366-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00443
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 YR

Date:10/27/04ISR Number: 4487371-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00256
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Lansoprazole	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Aspirin	C		ORAL		

Date:10/27/04ISR Number: 4487372-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 3 YR	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487374-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arterial Thrombosis Dizziness Eyelid Ptosis Procedural Complication Vision Blurred	Health Professional	Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

Date:10/27/04ISR Number: 4487376-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Anxiety Cardiac Valve Disease Dementia Swelling Thrombosis Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	

Date:10/27/04ISR Number: 4487377-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02987
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Dyspnoea		Vioxx Hormones (Unspecified) [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

Date:10/27/04ISR Number: 4487382-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dementia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fall		Lotensin	C				
Initial or Prolonged Disability	Loss Of Consciousness		Bisoprolol Fumarate And Hydrochlorothiazide	C				
	Rib Fracture		Nubain	C				
			Prozac	C				
			Wellbutrin	C				
			Keppra	C				
			Valium	C				

Date:10/27/04ISR Number: 4487383-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02680
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487385-5Report Type:Expedited (15-DaCompany Report #KR-MERCK-0410KOR00024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:10/27/04ISR Number: 4487386-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Cardizem	C				
UNKNOWN								
	Carotid Artery Occlusion		Zyloprim	C				
UNKNOWN								
	Chest Pain		Altace	C				
UNKNOWN								
	Convulsion		Pravachol	C				
UNKNOWN								
	Coronary Artery Disease		Aspirin	C				
UNKNOWN								
	Diabetes Mellitus		Glucophage	C				
UNKNOWN								
	Dyspnoea		Vitamin E	C				
UNKNOWN								
	Gastric Ulcer		Ascorbic Acid	C				
UNKNOWN								
	Gastrointestinal		Omega-3	C				
UNKNOWN								
	Haemorrhage		Centrum	C				
UNKNOWN								
	Glycosylated Haemoglobin		Vitamin B Complex	C				
UNKNOWN								
	Increased		Avandia	C				
UNKNOWN								
	Haemorrhage		Viagra	C				
UNKNOWN								
	Herpes Zoster		Imdur	C				
UNKNOWN								
	Hypertension							
	Melaena							

Monarthritis
Myocardial Infarction
Tachycardia

Date:10/27/04ISR Number: 4487388-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00421
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4487389-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Food Poisoning	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Radiographic Contrast Medium (Unspecified)	SS				
Other	Peripheral Vascular Disorder							
UNKNOWN	Renal Disorder							

Date:10/27/04ISR Number: 4487390-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487391-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00351
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Pulmonary Oedema		Acetaminophen	C				UNKNOWN
	Renal Failure							

Date:10/27/04ISR Number: 4487392-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00255
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1556 DAY
Disability								

Date:10/27/04ISR Number: 4487393-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02237
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Disorder		Paroxetine Hydrochloride	C				UNKNOWN
			Protonix	C				UNKNOWN
			Xanax	C				UNKNOWN

Date:10/27/04ISR Number: 4487394-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02953
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

	Overdose		Oxycontin	C		
UNKNOWN						
	Pain In Extremity		Vicodin Tablets	C		
UNKNOWN						
			Valium	C		
UNKNOWN						
			Advair	C		
UNKNOWN						
			Combivent	C		
UNKNOWN						
			Vaseretic	C		ORAL
			Imitrex	C		
UNKNOWN						
			Loratadine	C		
UNKNOWN						
			Lidoderm	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Cyclobenzaprine Hydrochloride	C		
UNKNOWN						
			Nicotrol	C		
UNKNOWN						
			Hydrocortisone	C		
UNKNOWN						
			Cicloven	C		
UNKNOWN						

Date:10/27/04ISR Number: 4487395-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00640
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Death					
Hospitalization - Initial or Prolonged						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487396-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery		Depakote	C				
UNKNOWN								
Initial or Prolonged	Atherosclerosis		Prozac	C				
UNKNOWN								
Disability	Difficulty In Walking							
	Muscle Spasms							

Date:10/27/04ISR Number: 4487400-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01205
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Aortic Valve Incompetence	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ativan	C				
UNKNOWN								
			Tylenol	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

Date:10/27/04ISR Number: 4487402-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/27/04ISR Number: 4487403-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03442
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 18 MON	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Attack		Premarin	C		
			Hyzaar	C		
UNKNOWN						

Date:10/27/04ISR Number: 4487404-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03377
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:10/27/04ISR Number: 4487406-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Ineffective		Plavix	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487407-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02935
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Death							

Date:10/27/04ISR Number: 4487408-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02988
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Dyspnoea		Tricor	C				UNKNOWN
	Pain In Extremity		Toprol Xl Tablets	C				UNKNOWN
			Cozaar	C				UNKNOWN
			Verapamil	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:10/27/04ISR Number: 4487410-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03446
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Norvasc	C				
Disability								

Date:10/27/04ISR Number: 4487411-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03399
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Lipitor	C				
UNKNOWN								
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Benzonatate	C				
UNKNOWN								
			Endodan	C				
UNKNOWN								
			Ranitidine	C				
UNKNOWN								
			Sudafed	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								
			Valproic Acid	C				
UNKNOWN								
			Quinine Sulfate	C				
UNKNOWN								
			Gastrointestinal Preparations (Unspecified)	C				
UNKNOWN								
			Theophylline	C				
UNKNOWN								

Date:10/27/04ISR Number: 4487412-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00702
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Death	Bone Neoplasm Malignant
	Death

	Hepatic Neoplasm Malignant Jaundice	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	1	YR

Date:10/27/04ISR Number: 4487414-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03367
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization - UNKNOWN	Chest Discomfort		Premarin	C				
Initial or Prolonged UNKNOWN	Heart Rate Irregular		Synthroid	C				
Disability								

Date:10/27/04ISR Number: 4487418-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03300
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged UNKNOWN	Fall		Aciphex	C				
	Pelvic Fracture		Tamoxifen Citrate	C				
UNKNOWN	Upper Limb Fracture		Gastrointestinal Preparations (Unspecified)	C		ORAL		

Date:10/27/04ISR Number: 4487420-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL

Date:10/27/04ISR Number: 4487421-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-99108250
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY
Initial or Prolonged Disability		Professional						

Date:10/27/04ISR Number: 4487424-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03684
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487425-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03589
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiovascular Disorder							

Date:10/27/04ISR Number: 4487428-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00020
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Memory Impairment		Vioxx	SS	Merck & Co., Inc	ORAL		
	Speech Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Etoricoxib	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Cyanocobalamin And Pyridoxine And Thiamine	C		ORAL		
			Prednisone	C		ORAL		
			Methotrexate	C		ORAL		
			Leflunomide	C		ORAL		
			Hydroxychloroquine Sulfate	C		ORAL		
			Bromazepam	C		ORAL		
			Omeprazole	C		ORAL		
			Calcium Carbonate	C		ORAL		
			Teriparatide	C		ORAL		

Date:10/27/04ISR Number: 4487431-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03566
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged								

Date:10/27/04ISR Number: 4487432-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03598
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Ineffective Treatment Noncompliance		[Therapy Unspecified]	C				
UNKNOWN								
Disability			Celebrex	C				
UNKNOWN								
Other								

Date:10/27/04ISR Number: 4487438-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03560
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
Disability								
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/27/04ISR Number: 4487439-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00403
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Appendicitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/27/04ISR Number: 4487456-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00424
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fatigue		Adiphenine Hydrochloride And Dipyrone And Promethazine	C		ORAL	DAY	
	Myocardial Infarction		Propatyl Nitrate	C		ORAL		
	Oedema Peripheral		Aspirin	C		ORAL		

Date:10/27/04ISR Number: 4487777-4Report Type:Direct Company Report #CTU 230520
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx Tabs 25 Mg					
Hospitalization - Initial or Prolonged			Merck & Co. Inc.	PS	Merck & Co. Inc.			

Date:10/27/04ISR Number: 4487806-8Report Type:Direct Company Report #CTU 230531
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ruptured Cerebral		Vioxx 25mg	PS				
Hospitalization -	Aneurysm							

25 MG TABLET / ONCE A DAY

Initial or Prolonged	Vioxx 50 Mg	SS
50 MG TABLET		
Disability		
/ ONCE DAY		
Required	Serzone	C
Intervention to	Premphase	C
Prevent Permanent		
Impairment/Damage		

Date:10/27/04ISR Number: 4487863-9Report Type:Direct Company Report #CTU 230583
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea		Aspirin	PS				
	Vomiting		Vioxx	SS				

Date:10/27/04ISR Number: 4490088-4Report Type:Expedited (15-DaCompany Report #2004239428US
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Blood Cholesterol
Other	Increased
	Blood Potassium Increased
	Blood Triglycerides

	Increased Cardiac Arrest Cardiac Failure Congestive	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain Coronary Artery Disease	Consumer	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL	
	Drug Ineffective		Rofecoxib (Rofecoxib)	SS				
			Lisinopril	C				
			Vicodin	C				
			Neurontin	C				
			Asa	C				
			Synthroid (Levothyroxine Sodium)	C				
			Lasix	C				
			Multivitamins, Plain	C				

Date:10/28/04ISR Number: 4487947-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00100
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

Date:10/28/04ISR Number: 4487960-8Report Type:Expedited (15-DaCompany Report #SG-MERCK-0410SGP00008
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1 WK	
Hospitalization - Initial or Prolonged	Renal Impairment		Zestril	C		ORAL		

Date:10/28/04ISR Number: 4487961-XReport Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00331
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Aspirin	C		ORAL		
			Captopril	C		ORAL		

Date:10/28/04ISR Number: 4487963-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00694
Age:81 YR Gender:Female I/FU:I

Outcome	PT
Other	Anxiety
	Aphonia
	Arthralgia
	Balance Disorder
	Blindness Unilateral
	Cerebrovascular Accident
	Chest Discomfort
	Dyspnoea
	Fluid Retention
	Headache
	Hearing Impaired
	Hyperhidrosis
	Insomnia

	Muscle Spasms						
	Pain In Extremity						
	Palpitations	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4487964-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00035
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Disprin	C		ORAL		
			Propranolol Hydrochloride	C		ORAL		
			Propranolol Hydrochloride	C		ORAL		
			Dipyridamole	C				
			Losec (Omeprazole)	C				

Date:10/28/04ISR Number: 4487965-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00023
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death		Arava	C		ORAL		
			Methotrexate	C		ORAL		
			Calcort	C		ORAL		

Date:10/28/04ISR Number: 4487967-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00149
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Prozac	C				
UNKNOWN								
	Speech Disorder							
	Transient Ischaemic Attack							
	Vertigo							

Date:10/28/04ISR Number: 4487980-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03143
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Fosamax	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								

Date:10/28/04ISR Number: 4487981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
6 MON								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4487983-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02662
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abnormal Behaviour Adverse Event Asthenia Confusional State Decreased Activity Hypertension Stress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4487985-2Report Type:Expedited (15-DaCompany Report #KR-MERCK-0410KOR00020
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		76 DAY

Date:10/28/04ISR Number: 4487986-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03614
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4487990-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03632
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
			Amiloride					

			Hydrochloride	C			
UNKNOWN							
			Coumadin	C			
UNKNOWN							

Date:10/28/04ISR Number: 4487991-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03444
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Coumadin	C				
UNKNOWN								
Initial or Prolonged			Lasix (Furosemide)	C				
UNKNOWN								
			Digitek	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								
			Actos	C				
UNKNOWN								

Date:10/28/04ISR Number: 4487992-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03156
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4487995-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03337
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Inadequate Control							
	Infection							
	Joint Sprain							
	Overdose							
	Paresis							
	Toe Amputation							
	Treatment Noncompliance							

Date:10/28/04ISR Number: 4487996-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03187
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

Date:10/28/04ISR Number: 4487997-9Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Acenocoumarol	C		ORAL		

Date:10/28/04ISR Number: 4488001-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Heart Rate Irregular Flexeril C
UNKNOWN

Date:10/28/04ISR Number: 4488002-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00393
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Fatigue							

Date:10/28/04ISR Number: 4488003-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00078
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			General Anesthesia (Unspecified)	C				
INTRAVENOUS							1	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4488005-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03154
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Dizziness							
	Fatigue							

Date:10/28/04ISR Number: 4488006-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03146
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Coumadin	C				
UNKNOWN								
Initial or Prolonged	Fatigue		Lasix (Furosemide					
	Loss Of Consciousness		Sodium)	C				
UNKNOWN								
	Lung Disorder		Digitek	C				
UNKNOWN								
	Myocardial Infarction		Elavil	C				
UNKNOWN								
	Syncope		Lipitor	C				
UNKNOWN								
			Combivent	C				
UNKNOWN								
			Advair	C				
UNKNOWN								

Date:10/28/04ISR Number: 4488007-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02684
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Arrest		Hydrodiuril	C		ORAL		
			Metoprolol	C				
UNKNOWN								

Date:10/28/04ISR Number: 4488008-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02740
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vitamins (Unspecified)	C				
UNKNOWN			Neurontin	C				
UNKNOWN								

Date:10/28/04ISR Number: 4488009-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01025
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucophage	C				
UNKNOWN								

Date:10/28/04ISR Number: 4488010-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03139
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4488011-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03175
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Rotator Cuff Syndrome		Evista	C				
Initial or Prolonged UNKNOWN			Welchol	C				
Disability								

Date:10/28/04ISR Number: 4488012-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03635
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4488022-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03334
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Dysarthria		Synthroid	C				
Initial or Prolonged UNKNOWN	Swelling		Atacand	C				
Disability UNKNOWN	Swelling Face		Norvasc	C				

Date:10/28/04ISR Number: 4488023-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03619
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Life-Threatening	Cardiac Disorder
Hospitalization - Initial or Prolonged	Cerebrovascular Accident

Date:10/28/04ISR Number: 4488025-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03788
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:10/28/04ISR Number: 4488026-3Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00010
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
Disability			[Composition Unspecified]	C		ORAL	1	WK
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4488027-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03662
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4488028-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03790
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Hospitalization - Initial or Prolonged	Congestive							

Date:10/28/04ISR Number: 4488031-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/28/04ISR Number: 4488032-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03667
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		214 DAY
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		214 DAY
	Leg Amputation		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	

Date:10/28/04ISR Number: 4488545-XReport Type:Direct Company Report #CTU 230692
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Systolic		Vioxx 25 Mg (Merck)	PS	Merck		25 MG EACH	
	Increased						DAY	
			Nexium	C				
			Detrol	C				
			Flomax	C				
			Baby Aspirin	C				

Date:10/28/04ISR Number: 4490252-4Report Type:Expedited (15-DaCompany Report #2004081489
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Consumer	Neurontin					
Life-Threatening	Blood Pressure		(Gabapentin)	PS		ORAL	ORAL	
Disability	Fluctuation		Rofecoxib					
	Cardiovascular Disorder		(Rofecoxib)	SS		ORAL	ORAL	
	Cerebrovascular Disorder							
	Injury							
	Oedema							
	Overdose							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/28/04ISR Number: 4491818-8Report Type:Direct Company Report #CTU 230727
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Urine Present		Vioxx 25mg	PS		ORAL	1 TAB	1 TIME
	Hypertension						PER DAY	
							ORAL	

Date:10/29/04ISR Number: 4488804-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00030079
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Indocin					
Initial or Prolonged	Respiratory Disorder		(Indomethacin)	C				
UNKNOWN								
	Weight Increased							

Date:10/29/04ISR Number: 4488808-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Anorexia
	Arthralgia
	Arthritis
	Arthropathy
	Back Pain
	Benign Prostatic
	Hyperplasia
	Bladder Disorder
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiovascular Disorder
	Carotid Bruit
	Carpal Tunnel Syndrome

Chest Pain
Constipation
Convulsion
Death
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Dry Mouth
Epididymal Cyst
Erectile Dysfunction
Fatigue
Flatulence
Hyperhidrosis
Intervertebral Disc
Degeneration
Intestinal Functional
Disorder
Oedema Peripheral
Osteitis
Radiculopathy
Scoliosis
Skin Lesion
Spinal Column Stenosis

Stress
Testicular Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Neurontin	C			UNKNOWN	
	Lactulose	C		ORAL		
	Glucophage	C			UNKNOWN	
	Glyburide	C			UNKNOWN	
	Lotrel	C			UNKNOWN	

Date:10/29/04ISR Number: 4488810-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Discomfort
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Other	Acute Respiratory Distress Syndrome
	Acute Sinusitis
	Angina Pectoris
	Aortic Valve Sclerosis
	Arteriosclerosis
	Arthralgia
	Aspartate Aminotransferase Increased
	Aspiration
	Asthenia
	Atelectasis
	Atrial Fibrillation
	Back Pain
	Blood Albumin Decreased
	Blood Alkaline Phosphatase Increased
	Blood Bilirubin Increased
	Blood Bilirubin Unconjugated Increased
	Blood Cholesterol

Increased
Blood Homocysteine
Increased
Blood Lactate
Dehydrogenase Increased
Blood Pressure
Inadequately Controlled
Blood Sodium Decreased
Blood Triglycerides
Increased
Breast Tenderness
Cardiac Flutter
Cardio-Respiratory Arrest
Chest Wall Pain
Cholelithiasis
Coagulopathy
Colitis Ischaemic
Coronary Artery Disease
Dehydration
Depression

Dermatitis
Diarrhoea
Disseminated
Intravascular Coagulation
Diverticulum
Drug Eruption
Drug Hypersensitivity
Dyspepsia
Dyspnoea Exertional
Ejection Fraction
Decreased
Electrocardiogram
Abnormal
Erythema
Eustachian Tube Disorder
Extradural Abscess
Fatigue
Feeling Abnormal
Fibrin D Dimer Increased
Fibrinolysis
Groin Pain
Haematochezia
Haemorrhage
Hepatic Function Abnormal
Hyperlipidaemia
Hypersensitivity
Hypokalaemia
Hypokinesia
Hypotension
Infection
Inflammation
Influenza
Influenza Like Illness
International Normalised
Ratio Increased
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Intervertebral Discitis
Liver Disorder
Macular Degeneration
Mitral Valve Incompetence
Mucosal Dryness
Mucosal Ulceration
Multi-Organ Failure
Muscle Spasms

Myalgia
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema
Osteoarthritis
Osteomyelitis
Otitis Media
Pancreatic Atrophy
Pancreatitis
Pericardial Effusion
Pleural Effusion
Postnasal Drip
Prothrombin Time

		Prolonged Pulmonary Oedema					
		Radicular Pain					
		Radiculitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash		Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY						
		Rash Morbilliform		Vioxx	SS	Merck & Co., Inc	ORAL
45	DAY						
		Renal Failure		Zocor	C		
UNKNOWN							
		Renal Failure Acute		Vitamin E	C		
UNKNOWN							
		Renal Pain		Centrum	C		
UNKNOWN							
		Renal Tubular Necrosis		Beta Carotene	C		
UNKNOWN							
		Self-Medication		Percocet	C		
UNKNOWN							
		Sepsis		Tylenol With Codeine			
		Sinus Headache		#3	C		
UNKNOWN							
		Tenderness		Ascorbic Acid	C		
UNKNOWN							
		Thrombocytopenia					
		Thrombosis					
		Toxic Shock Syndrome					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Vaginal Haemorrhage					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		Ventricular Hypokinesia					
		Ventricular Tachycardia					
		Vision Blurred					
		Vitamin K Deficiency					
		White Blood Cell Count Increased					

Date:10/29/04ISR Number: 4488811-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00796
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged Disability UNKNOWN Other	Arthropathy Cartilage Injury Cerebrovascular Accident Cervicobrachial Syndrome Chest Pain Coronary Artery Disease Depression Dyslipidaemia Gastrooesophageal Reflux Disease Hypertension Insomnia Intervertebral Disc Protrusion Meningioma Muscle Spasms Neck Pain Oedema Peripheral Osteoarthritis Paraesthesia Simple Partial Seizures Spinal Disorder	Vioxx Aleve	SS C	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488812-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00822
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Lescol	C			UNKNOWN	
	Protrusion		Diazide	C			UNKNOWN	
	Musculoskeletal Discomfort							
	Musculoskeletal Pain							
	Osteoarthritis							

Date:10/29/04ISR Number: 4488813-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00758
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Darvocet-N	C			UNKNOWN	
	Convulsion							
	Drug Ineffective							
	Neck Injury							
	Somnolence							

Date:10/29/04ISR Number: 4488814-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00397
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	145 DAY	
Life-Threatening	Cardiac Failure		Digoxin	C			UNKNOWN	
Disability	Cardiomyopathy		Amiloride					

	Feeling Abnormal		Hydrochloride And Hydrochlorothiazide	C		
UNKNOWN						

Date:10/29/04ISR Number: 4488815-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00402
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Overdose					

Date:10/29/04ISR Number: 4488816-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00036
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rash Generalised		Enalapril Maleate	C		
UNKNOWN						
	Wound Secretion		Bendroflumethiazide	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Paroxetine	C		
UNKNOWN						
			Floxacillin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488817-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00866
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis							
	Dehydration							
	Polytraumatism							
	Sepsis							
	Urinary Tract Infection							

Date:10/29/04ISR Number: 4488818-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vicodin Tablets	C		ORAL		
	Arthropathy		Flexeril	C		ORAL		
	Asthenia		Flexeril	C		ORAL		
	Back Pain							
	Buttock Pain							
	Cyst							
	Deep Vein Thrombosis							
	Diarrhoea							
	Difficulty In Walking							
	Drug Effect Decreased							
	Emotional Distress							
	Fall							
	Feeling Abnormal							
	Gastritis							
	Haematochezia							
	Hiatus Hernia							
	Hypoaesthesia							
	Inadequate Analgesia							
	Injury							
	Insomnia							
	Intervertebral Disc Protrusion							
	Limb Discomfort							
	Muscle Spasms							
	Nausea							
	Oedema Peripheral							

Osteoarthritis
Pain In Extremity
Post Laminectomy Syndrome
Radiculitis Lumbosacral
Sacroiliitis
Vomiting

Date:10/29/04ISR Number: 4488819-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abscess
Initial or Prolonged	Anaemia
Other	Arthralgia
	Atrial Fibrillation
	Atrial Flutter
	Blood Pressure Increased

		Cardiac Failure					
		Congestive					
		Carotid Bruit	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Clostridium Colitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive Cardiomyopathy		Zestril	C		ORAL
		Convulsion		Glucophage	C		ORAL
		Diabetic Microangiopathy		Methylprednisolone	C		
UNKNOWN							
		Diabetic Neuropathy		Levaquin	C		ORAL
		Diarrhoea					
		Dysphonia					
		Gastrointestinal					
		Haemorrhage					
		Graft Thrombosis					
		Hypercholesterolaemia					
		Hyperkalaemia					
		Hypoxic Encephalopathy					
		Insomnia					
		Ischaemia					
		Ischaemic Hepatitis					
		Myocardial Ischaemia					
		Pulmonary Hypertension					
		Pyrexia					
		Renal Failure					
		Renal Failure Acute					
		Sinus Arrest					
		Sinus Bradycardia					
		Vertigo					
		Weight Decreased					
		Weight Fluctuation					
		Weight Increased					

Date:10/29/04ISR Number: 4488820-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00790
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Soma	C		ORAL
		Bronchitis Acute		Promethazine	C		
UNKNOWN							
		Convulsion		Hyoscyamine	C		
UNKNOWN							

Drug Ineffective
Ear Pain
Fall
Headache
Joint Injury
Malaise
Meralgia Paraesthetica
Osteoarthritis

Date:10/29/04ISR Number: 4488821-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00439
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488822-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00442
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488823-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00440
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:10/29/04ISR Number: 4488824-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00840
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Premarin	C				
UNKNOWN								
Disability	Anaemia		Neurontin	C				
UNKNOWN								
	Chest Pain		Vicodin Tablets	C				
UNKNOWN								
	Constipation		Vicodin Tablets	C				
UNKNOWN								
	Dermatitis Contact		Hydrodiuril	C		ORAL		
	Diarrhoea							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Muscular Weakness							
	Myalgia							
	Nocturia							
	Osteoarthritis							
	Polytraumatism							
	Rectal Haemorrhage							

Date:10/29/04ISR Number: 4488825-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Musculoskeletal Stiffness							
	Pruritus							
	Syncope							

Date:10/29/04ISR Number: 4488826-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00605
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		504 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Metoprolol Succinate	C		ORAL		
	Myocardial Infarction							
	Stent Occlusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488827-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00650
Age:92 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488828-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488829-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00657
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488830-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00653
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488831-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00632
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							
	Thrombosis							

Date:10/29/04ISR Number: 4488832-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00643
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488833-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00674
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488834-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00700
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:10/29/04ISR Number: 4488835-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Therapeutic Response Decreased							

Date:10/29/04ISR Number: 4488836-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00064
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cranial Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Musculoskeletal Discomfort		[Therapy Unspecified]	C			UNKNOWN	1 DAY

Date:10/29/04ISR Number: 4488837-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00042
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:10/29/04ISR Number: 4488838-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00617
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488839-8Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00023
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	732 DAY	
			Leflunomide	C		ORAL	366 DAY	
			Methylprednisolone	C		ORAL	366 DAY	
			Omeprazole	C		ORAL	366 DAY	
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
			Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)	763 DAY	

Date:10/29/04ISR Number: 4488840-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00022
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488841-6Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00050
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosamax	C				UNKNOWN
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN
			Acetaminophen And Codeine Phosphate	C				UNKNOWN

Date:10/29/04ISR Number: 4488843-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00069
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		658 DAY
Initial or Prolonged Disability	Coma		Naftazone	C		ORAL		
			Avocado Oil And Soybean Oil	C		ORAL		
			Levothyroxine Sodium	C		ORAL		

Date:10/29/04ISR Number: 4488844-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00088
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY
	Hypertension						
	Oedema						

Date:10/29/04ISR Number: 4488845-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL	698 DAY	
	Carotid Artery Disease		Orlistat	C		ORAL		

Date:10/29/04ISR Number: 4488846-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00671
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Osteonecrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488847-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00701
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction							
Hospitalization - Initial or Prolonged								

Date:10/29/04ISR Number: 4488849-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
			Phenprocoumon	C		ORAL		

Date:10/29/04ISR Number: 4488850-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00285
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	69	DAY
Other	Malaise		Betahistine Hydrochloride	C		ORAL		
			Atenolol And Nifedipine	C		ORAL		

Date:10/29/04ISR Number: 4488851-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0410NOR00020
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death		Penicillin V Potassium	C				
	Duodenal Ulcer						UNKNOWN	1 WK
	Haemorrhage		Metronidazole	C		ORAL	1	WK

	Haematemesis		Metoprolol Tartrate	C		ORAL
	Melaena		Acetaminophen	C		
UNKNOWN						
	Oxygen Saturation		Zopiclone	C		
UNKNOWN						
	Decreased		Estradiol	C		
UNKNOWN						
	Respiratory Disorder		Dorzolamide Hydrochloride And Timolol Maleate	C		
UNKNOWN						
			Pivampicillin Hydrochloride	C		ORAL
			Tramadol Hydrochloride	C		
UNKNOWN						
			Furosemide	C		
UNKNOWN						

Date:10/29/04ISR Number: 4488853-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00018
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 12 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Levothyroxine Sodium	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488854-4Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall							
	Palpitations							

Date:10/29/04ISR Number: 4488855-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00046
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Codeine	C		ORAL		
	Heart Rate Irregular		Loratadine	C		ORAL		
	Palpitations		Ferrous Sulfate	C		ORAL		
			Doxycycline	C		ORAL		
			Doxycycline	C		ORAL		

Date:10/29/04ISR Number: 4488856-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01449
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Pain							
	Dyspnoea							
	Ejection Fraction Decreased							

Date:10/29/04ISR Number: 4488857-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01097
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Heart Injury		Wellbutrin	C				

Initial or Prolonged	Heart Rate Increased		Prevacid	C			
UNKNOWN							
Disability	Malaise		Singulair	C			ORAL
			Zyrtec	C			
UNKNOWN							
			Advair	C			
UNKNOWN							

Date:10/29/04ISR Number: 4488859-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01107
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Mitral Valve Disease		Vicodin Tablets	C				
UNKNOWN								

Date:10/29/04ISR Number: 4488860-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01602
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Insulin	C				
UNKNOWN								
Disability			[Composition					
Other			Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488861-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00159
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488862-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02620
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Electrocardiogram		[Therapy					
Hospitalization -	Abnormal		Unspecified]	C				
UNKNOWN								
Initial or Prolonged	Lung Neoplasm Malignant		Allopurinol	C				
UNKNOWN								
Disability			[Therapy					
			Unspecified]	C				
UNKNOWN								
			Pepcid	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								
			Rezulin	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								
			Relafen	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Potassium					
			(Unspecified)	C				
UNKNOWN								
			Lodine	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								

Date:10/29/04ISR Number: 4488863-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02741
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Coumadin	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Zocor	C		ORAL		
			Fish Oil (Unspecified)	C			UNKNOWN	

Date:10/29/04ISR Number: 4488864-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		66 MON

Date:10/29/04ISR Number: 4488865-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01816
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Extrasystoles		Bextra	C			UNKNOWN	
Disability	Heart Rate Irregular		Toprol Xl Tablets	C			UNKNOWN	
	Hypertension		Flomax (Morniflumate)	C			UNKNOWN	
			Prevacid	C			UNKNOWN	

	Clonazepam	C
UNKNOWN		
	Aciphex	C
UNKNOWN		
	Fish Oil (Unspecified)	C
UNKNOWN		
	Aspirin	C
UNKNOWN		
	Tylenol	C
UNKNOWN		

Date:10/29/04ISR Number: 4488866-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Dyspnoea Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488867-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488868-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488869-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01539
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Dyspnoea		Prevacid	C				
	Electrocardiogram Abnormal							
	Feeling Abnormal							
	Oedema Peripheral							

Date:10/29/04ISR Number: 4488870-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02925
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Fluid Retention		Bextra	C			UNKNOWN	
	Headache		Klonopin	C			UNKNOWN	
	Hypertension		Premarin	C			UNKNOWN	
	Joint Swelling		Zanaflex	C			UNKNOWN	
	Memory Impairment		Nexium	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Wellbutrin Xl	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4488871-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03352
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488872-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02748
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Pravachol	C				
UNKNOWN								
			Combivent	C				
UNKNOWN								

Date:10/29/04ISR Number: 4488874-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00054
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Infarction							

Date:10/29/04ISR Number: 4488875-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02881
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:10/29/04ISR Number: 4488876-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03340
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Lortab	C				
UNKNOWN								
Hospitalization -			Soma	C				
UNKNOWN								
Initial or Prolonged			Xanax	C				
UNKNOWN								
Disability			Zocor	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Prilosec	C		ORAL		
			Paxil	C				
UNKNOWN								
			Wellbutrin	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								

Date:10/29/04ISR Number: 4488877-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03268
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488880-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03356
Age:72 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Atenolol	C				UNKNOWN
	Hypertension							
	Oedema Peripheral							

Date:10/29/04ISR Number: 4488881-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03673
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Pepcid	C		ORAL		
			Nexium	C				UNKNOWN
			Gemfibrozil	C				UNKNOWN

Date:10/29/04ISR Number: 4488882-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03622
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vicodin Tablets	C				UNKNOWN
	Fatigue							

Date:10/29/04ISR Number: 4488891-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00281
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Clopidogrel					

Bisulfate	C			ORAL
Bisoprolol	C			ORAL
Atorvastatin Calcium	C			ORAL

Date:10/29/04ISR Number: 4488892-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00241
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4488893-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03152
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Uterine Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged			Levoxyl	C			UNKNOWN	
Disability			Amaryl	C			UNKNOWN	
			Humalog Mix 75/25	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489025-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Albumin Decreased		Premarin	C				
UNKNOWN								
Other	Blood Cholesterol		Singulair	C				
UNKNOWN								
	Increased		Azmacort	C				
RESPIRATORY								
	Bronchial Infection							
(INHALATION)								
	Bronchiectasis							
	Bronchitis							
	Bronchitis Chronic							
	Candidiasis							
	Cardiac Disorder							
	Cardiac Failure Acute							
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chronic Obstructive							
	Pulmonary Disease							
	Conjunctivitis							
	Corneal Disorder							
	Diarrhoea							
	Drug Hypersensitivity							
	Dyspepsia							
	Fall							
	Hiatus Hernia							
	Hypoxia							
	Injury							
	Lobar Pneumonia							
	Mitral Valve Incompetence							
	Muscle Spasms							
	Nausea							
	Oedema Peripheral							
	Oxygen Saturation Decreased							
	Pain							
	Palpitations							
	Pneumonia							
	Pseudomonas Infection							
	Pulmonary Hypertension							
	Skin Laceration							

Sputum Culture Positive
Tremor

Date:10/29/04ISR Number: 4489034-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00617
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Anxiety Disorder
	Asthenia
	Benign Breast Neoplasm
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiac Failure Congestive
	Cataract
	Chronic Obstructive

		Pulmonary Disease					
		Convulsion					
		Depression					
		Ear Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fibromyalgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Glyburide	C		ORAL
		Disease		Glucophage	C		ORAL
		Mitral Valve Disease		Tylenol Extra			
		Pain		Strength	C		
UNKNOWN							
		Peptic Ulcer		Accupril	C		ORAL
		Periarthritis		Fer-Sul	C		ORAL
		Seasonal Allergy		Benadryl	C		
UNKNOWN							
		Spinal Column Stenosis		Prevacid	C		
UNKNOWN							
		Spinal Osteoarthritis		Enalapril Maleate	C		
UNKNOWN							
		Stress		Adalat	C		
UNKNOWN							
		Syncope		Lescol	C		
UNKNOWN							
		Tinea Capitis					

Date:10/29/04ISR Number: 4489036-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Lortab	C		
UNKNOWN							
		Chest Discomfort		Soma	C		
UNKNOWN							
		Convulsion					
		Coronary Artery Disease					
		Hot Flush					
		Hyperlipidaemia					
		Myocardial Infarction					
		Radial Tunnel Syndrome					
		Rotator Cuff Syndrome					

Date:10/29/04ISR Number: 4489037-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acquired Claw Toe		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Acute Myocardial Infarction		Zocor	C		ORAL		
	Angina Unstable		Plavix	C		ORAL		
	Arthropathy		Lotensin	C		ORAL		
	Back Pain		Metoprolol	C		ORAL		
	Blood Pressure Increased		Alfentanil Hydrochloride	C				
	Bursitis		[Therapy Unspecified]	C		ORAL		
	Carotid Artery Stenosis		Aspirin	C				
	Cerebrovascular Accident							
	Diabetes Mellitus Non-Insulin-Dependent							
	Diarrhoea							
	Haemarthrosis							
	Headache							
	Injury							
	Myocardial Infarction							
	Tendonitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489044-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01062240
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Oxycodone	C			UNKNOWN	
	Hypotension		Lansoprazole	C			UNKNOWN	
	Medication Error		Prozac	C			UNKNOWN	
	Pain		Fexofenadine Hydrochloride	C			UNKNOWN	
	Pain In Jaw							
	Renal Disorder		Fluoxetine	C			UNKNOWN	
	Syncope							
	Tachycardia							

Date:10/29/04ISR Number: 4489045-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00653
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Claritin	C			UNKNOWN	
	Chest Pain		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Dizziness							
	Hyperlipidaemia							
	Hypertension							
	Hypertonic Bladder							
	Insomnia							
	Limb Injury							
	Polytraumatism							
	Rash Pruritic							
	Tinea Infection							

Date:10/29/04ISR Number: 4489046-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Estrace	C				
UNKNOWN								
Other	Atelectasis		Aspirin	C				
UNKNOWN								
	Atrial Fibrillation		Allegra	C				
UNKNOWN								
	Blood Pressure Increased		Hyoscyamine	C				
UNKNOWN								
	Bronchitis		Elavil	C				
UNKNOWN								
	Cardiac Failure		Diovan	C				
UNKNOWN								
	Congestive Chest Pain		[Therapy Unspecified]	C				
UNKNOWN								
	Congestive Cardiomyopathy		Robitussin-Dm	C				
UNKNOWN								
	Convulsion							
	Dizziness							
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Irritable Bowel Syndrome							
	Nasopharyngitis							
	Osteoarthritis							
	Palpitations							
	Squamous Cell Carcinoma							
	Tachycardia							
	Viral Myocarditis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489047-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00567
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Prerenal Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Lasix (Furosemide)	SS			UNKNOWN	
	Congestive		Lasix (Furosemide)	SS			INTRAVENOUS	
	Change Of Bowel Habit		Lopressor	C			UNKNOWN	
	Chest Pain		Salagen Tablets	C			UNKNOWN	
	Cholelithiasis		Salagen Tablets	C			UNKNOWN	
	Coronary Artery Disease		Plaquenil	C			UNKNOWN	
	Depression		Femhrt	C			UNKNOWN	
	Glaucoma		Lotemax	C			OPHTHALMIC	
	Haemorrhage		Timoptic	C			OPHTHALMIC	
	Hypercholesterolaemia		Advil	C			UNKNOWN	
	Hyperlipidaemia		Centrum	C			UNKNOWN	
	Hypertension		Plavix	C			UNKNOWN	
	Iritis		Zocor	C		ORAL		
	Ischaemic Cardiomyopathy		Zocor	C		ORAL	2 MON	
	Joint Sprain		Pilocarpine	C			UNKNOWN	
	Mitral Valve Calcification							
	Mitral Valve Incompetence							
	Mitral Valve Sclerosis							
	Myocardial Infarction							
	Nephropathy Toxic							
	Oral Fungal Infection							

Orthostatic Hypotension
Pericardial Effusion
Pneumonitis
Pulmonary Oedema
Pulmonary Valve
Incompetence
Respiratory Distress
Rosacea
Rotator Cuff Syndrome
Synovitis
Tricuspid Valve
Incompetence
Ventricular Dysfunction

Date:10/29/04ISR Number: 4489048-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00639
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
Disability	Adverse Event
	Asthenia
	Barrett'S Oesophagus
	Bradycardia
	Chest Discomfort
	Chest Pain
	Conjunctivitis
	Cough
	Depression

		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dry Skin		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Tenormin	C		
UNKNOWN							
		Ear Pain		Ultram	C		
UNKNOWN							
		Erythema		Soma	C		
UNKNOWN							
		Fungal Infection		Synthroid	C		
UNKNOWN							
		Gastritis		Estradiol	C		
UNKNOWN							
		Gastrointestinal Motility		Claritin	C		
UNKNOWN							
		Disorder		Verapamil	C		
UNKNOWN							
		Gastrooesophageal Reflux		Hydrochlorothiazide	C		
UNKNOWN							
		Disease		Isosorbide	C		
UNKNOWN							
		Headache		Restoril	C		
UNKNOWN							
		Heat Rash		Aspirin	C		
UNKNOWN							
		Hyperhidrosis		Lipitor	C		
UNKNOWN							
		Ingrowing Nail		Detrol	C		
UNKNOWN							
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Intervertebral Disc Space					
		Narrowing					
		Lymph Node Pain					
		Malaise					
		Musculoskeletal					
		Discomfort					
		Nausea					
		Nodule					
		Onychomycosis					
		Pain In Jaw					
		Periorbital Cellulitis					

Polytraumatism
Post Concussion Syndrome
Pyrexia
Rash Vesicular
Rhinitis Allergic
Sinus Congestion
Sinusitis
Snoring
Somnolence
Swelling Face
Syncope
Vomiting
Weight Increased

Date:10/29/04ISR Number: 4489049-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00755
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Angina Pectoris							
Other	Blood Pressure Increased							
	Cardio-Respiratory Arrest							
	Convulsion							
	Coronary Artery Disease							
	Hypertension							
	Sudden Cardiac Death							

Date:10/29/04ISR Number: 4489050-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00792
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Prilosec	C				
UNKNOWN								
Disability	Benign Intracranial Hypertension							
	Bronchitis							
	Cerebral Ischaemia							
	Deafness							
	Depression							
	Diabetes Mellitus							
	Dizziness							
	Endolymphatic Hydrops							
	Fatigue							
	Headache							
	Increased Upper Airway Secretion							
	Injury							
	Muscle Atrophy							
	Muscle Spasms							
	Myalgia							
	Myositis							
	Nervousness							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Pain							
	Papilloedema							
	Pruritus							
	Skin Disorder							
	Spinal Column Stenosis							

Date:10/29/04ISR Number: 4489051-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00798
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Asthenia
	Back Pain
	Barrett'S Oesophagus
	Breast Cyst

Breast Pain
Bronchitis
Carpal Tunnel Syndrome
Cervicobrachial Syndrome
Coordination Abnormal
Cystitis
Diabetes Mellitus
Diarrhoea
Dizziness
Dysphagia
Epistaxis
Gastrooesophageal Reflux
Disease
Headache
Helicobacter Gastritis
Hiatus Hernia
Injury
Intervertebral Disc

		Degeneration					
		Irritable Bowel Syndrome					
		Joint Sprain					
		Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain		Robaxin	C		
UNKNOWN							
		Oedema Peripheral		Lotrel	C		
UNKNOWN							
		Pain In Extremity					
		Pharyngitis					
		Pleurisy					
		Polytraumatism					
		Road Traffic Accident					
		Sinusitis					
		Syncope					
		Vaginal Candidiasis					
		Vaginal Infection					

Date:10/29/04ISR Number: 4489052-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00938
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Adverse Event		Amitriptyline			
		Angina Pectoris		Hydrochloride	C		
UNKNOWN							
		Blood Pressure Increased					
		Convulsion					
		Coronary Artery Disease					
		Drug Ineffective					
		Gastrooesophageal Reflux					
		Disease					
		Hypercholesterolaemia					
		Sleep Apnoea Syndrome					
		Somnolence					

Date:10/29/04ISR Number: 4489053-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:62 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Abdominal Adhesions
Other	Abdominal Pain
	Adverse Event
	Anaemia
	Angina Pectoris
	Asthenia
	Carotid Arterial Embolus
	Carotid Artery Stenosis
	Carotid Bruit
	Convulsion
	Coronary Artery Disease
	Diverticulum Intestinal
	Dizziness
	Dysphagia
	Dyspnoea
	Gastric Ulcer
	Gastrointestinal
	Haemorrhage
	Headache
	Hiatus Hernia
	Hypertension

		Hypoaesthesia					
		Hypochromic Anaemia					
		Neck Mass	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Peritoneal		Vioxx	PS	Merck & Co., Inc	ORAL
		Adhesions		Cozaar	C		ORAL
		Peripheral Vascular		Cardizem	C		
UNKNOWN							
		Disorder		Premarin	C		ORAL
		Pharyngolaryngeal Pain		Darvocet-N	C		
UNKNOWN							
		Subcutaneous Haematoma		Ecotrin	C		ORAL
		Transient Ischaemic		Ecotrin	C		ORAL
		Attack					
		Vertebral Artery Stenosis					

Date:10/29/04ISR Number: 4489054-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00071
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Duodenal Ulcer		Prednisone	SS		ORAL

Date:10/29/04ISR Number: 4489055-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00845
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event					
Disability		Animal Bite					
Other		Atrial Fibrillation					
		Bursitis					
		Chest Pain					
		Coronary Artery Disease					
		Diarrhoea					
		Diverticulum Intestinal					
		Ear Pain					
		Headache					
		Insomnia					
		Irritable Bowel Syndrome					
		Lymphadenopathy					

Myocardial Infarction
Nodule
Pharyngitis Streptococcal
Pollakiuria
Polytraumatism
Rash Macular
Syncope
Urinary Tract Infection
Viral Infection

Date:10/29/04ISR Number: 4489056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Blood Pressure Increased
	Chest Discomfort
	Colonic Polyp
	Convulsion

		Coronary Artery Stenosis					
		Diaphragmatic Hernia					
		Diverticulum	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Myocardial Ischaemia		Plavix	C		
UNKNOWN							
		Post Procedural Haematoma		Prilosec	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Zocor	C		ORAL
				Zocor	C		ORAL
				Aspirin	C		
UNKNOWN							

Date:10/29/04ISR Number: 4489058-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00933
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety		Synthroid	C		ORAL
Other		Blood Cholesterol		Vicodin Tablets	C		
UNKNOWN							
		Increased		Vitamins			
		Blood Pressure Increased		(Unspecified)	C		
UNKNOWN							
		Cataract		Zocor	C		ORAL
		Convulsion		Darvocet-N	C		
UNKNOWN							
		Depression		Elavil	C		
UNKNOWN							
		Headache		Alprazolam	C		
UNKNOWN							
		Hypoaesthesia		Clarinex	C		
UNKNOWN							

	Insomnia	Ambien	C
UNKNOWN			
	Intervertebral Disc	Aspirin	C
UNKNOWN			
	Protrusion	Zoloft	C
UNKNOWN			
	Joint Swelling	[Composition	
	Lumbar Spinal Stenosis	Unspecified]	C
UNKNOWN			
	Nervousness		
	Oedema Peripheral		
	Paraesthesia		
	Retinal Vein Occlusion		
	Tension		
	Transient Ischaemic		
	Attack		

Date:10/29/04ISR Number: 4489059-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00783
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anxiety
Disability	Arthralgia
	Atrial Fibrillation
	Benign Prostatic
	Hyperplasia
	Bronchitis
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cellulitis

		Constipation					
		Cough					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL
293	DAY						
		Dilatation Ventricular		Aspirin	C		ORAL
		Drug Ineffective		Synthroid	C		ORAL
		Dyspnoea		Norvasc	C		
UNKNOWN							
		Food Poisoning		Albuterol	C		
RESPIRATORY							
		Herpes Simplex					
(INHALATION)							
		Hypertension		Toprol Xl Tablets	C		
UNKNOWN							
		Hypothyroidism					
		Influenza					
		International Normalised					
		Ratio Increased					
		Intervertebral Disc					
		Protrusion					
		Mitral Valve Incompetence					
		Mood Altered					
		Muscle Spasms					
		Myalgia					
		Nocturia					
		Nodule					
		Osteoarthritis					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Postnasal Drip					
		Prostatic Specific					
		Antigen Increased					
		Proteinuria					
		Pulmonary Congestion					
		Pulmonary Eosinophilia					
		Pulmonary Hypertension					
		Pyrexia					
		Rash					
		Road Traffic Accident					
		Spinal Column Stenosis					
		Spinal Cord Compression					
		Spinal Disorder					
		Spinal Osteoarthritis					

Temporomandibular Joint
Syndrome
Tinnitus
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Ventricular Hypertrophy
Viral Infection

Date:10/29/04ISR Number: 4489062-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01894
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Enbrel	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489063-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00399
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Pressure Increased							
Initial or Prolonged	Chest Pain							

Date:10/29/04ISR Number: 4489064-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02529
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS		ORAL		
Disability	Anxiety		Bextra	C				
UNKNOWN								
	Blood Cholesterol		Bextra	C				
UNKNOWN								
	Increased		Ultracet	C				
UNKNOWN								
	Bursitis		Dyazide	C				
UNKNOWN								
	Coronary Artery Disease		Prevacid	C				
UNKNOWN								
	Depression		Zoloft	C				
UNKNOWN								
	Diverticulum Intestinal		Premarin	C				
UNKNOWN								
	Drug Hypersensitivity		Skelaxin	C				
UNKNOWN								
	Fatigue		Prilosec	C		ORAL		
	Haemangioma Of Liver		Ditropan Xl	C				
UNKNOWN								
	Headache							
	Hyperlipidaemia							
	Hypertension							
	Insomnia							
	Myocardial Infarction							
	Nasopharyngitis							
	Night Sweats							
	Oedema Peripheral							
	Otitis Externa							
	Palpitations							

Panic Attack
Pelvic Pain
Pharyngitis
Pruritus
Rash
Urinary Retention
Urinary Tract Infection
Vaginitis Atrophic
Vertigo Positional

Date:10/29/04ISR Number: 4489065-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Stenosis
Other	Arthralgia
	Arthropathy
	Asthenia
	Back Pain
	Bursitis
	Buttock Pain
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Cerebral Ischaemia
	Cerebrovascular Accident

		Chest Pain					
		Choking Sensation					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Crying		Vioxx	PS	Merck & Co., Inc	ORAL
9 MON							
		Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
9 MON							
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drooling		Altace	C		
UNKNOWN							
		Dysphagia		Lipitor	C		
UNKNOWN							
		Emphysema		Analgesic Or			
		Facial Palsy		Anesthetic			
		Fatigue		(Unspecified)	C		
UNKNOWN							
		Feeling Abnormal		Premarin	C		
UNKNOWN							
		Fibromyalgia		Zoloft	C		
UNKNOWN		582 DAY					
		Headache		Hydrodiuril	C		ORAL
		Hyperhidrosis		Atenolol	C		
UNKNOWN							
		Hyperlipidaemia		Amitriptyline			
		Hypertension		Hydrochloride	C		
UNKNOWN							
		Impaired Work Ability		Amitriptyline			
		Insomnia		Hydrochloride	C		
UNKNOWN							
		Lacunar Infarction		Amitriptyline			
		Lumbar Radiculopathy		Hydrochloride	C		
UNKNOWN		17 DAY					
		Mastication Disorder		Amitriptyline			
		Meniscus Lesion		Hydrochloride	C		
UNKNOWN							
		Muscular Weakness		Amitriptyline			
		Nausea		Hydrochloride	C		
UNKNOWN							
		Pain		Amitriptyline			
		Pain In Extremity		Hydrochloride	C		
UNKNOWN		17 DAY					
		Peripheral Vascular		Celebrex	C		
UNKNOWN							
		Disorder					
		Productive Cough					

Rebound Hypertension
Respiratory Rate
Increased
Sensory Disturbance
Sinusitis
Sleep Disorder
Spondylolisthesis
Acquired
Spondylolysis
Stomach Discomfort
Stress
Tongue Paralysis
Treatment Noncompliance
Vision Blurred
Weight Decreased
Weight Increased
Wheezing

Date:10/29/04ISR Number: 4489066-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00395
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		423 DAY
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest Lung Neoplasm Malignant		Adiphenine Hydrochloride And Dipyrone And Promethazine	C		ORAL		423 DAY

Date:10/29/04ISR Number: 4489067-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00432
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Pain		Vioxx Levothyroxine Sodium	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:10/29/04ISR Number: 4489068-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0309CAN00088
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Heart Injury Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489069-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00093
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Extrasystoles Haematemesis Myocardial Infarction Overdose		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:10/29/04ISR Number: 4489070-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00355
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Hospitalization - Initial or Prolonged	Congestive Dizziness Dysgeusia		Amlodipine Besylate	C		ORAL		

Oedema Peripheral
Renal Failure Acute

Date:10/29/04ISR Number: 4489071-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Angina Pectoris
	Angiopathy
	Anxiety
	Arrhythmia
	Balance Disorder
	Bladder Pain
	Cough
	Cystitis Noninfective
	Dermatitis Allergic
	Dizziness
	Duodenal Ulcer
	Dyspepsia
	Fall
	Gastric Disorder
	Gastric Haemorrhage
	Gastric Ph Decreased

	Gastric Ulcer						
	Headache						
	Incontinence	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ligament Sprain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity							
	Palpitations							
	Renal Pain							
	Tinnitus							
	Ventricular Fibrillation							

Date:10/29/04ISR Number: 4489073-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure							
	Fall							
	Heart Rate Irregular							
	Hip Fracture							
	Myocardial Infarction							
	Shock							

Date:10/29/04ISR Number: 4489075-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00699
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Sjogren'S Syndrome		Etilefrine					
	Vasculitis		Hydrochloride	C		ORAL		
			Aspirin	C		ORAL		

Date:10/29/04ISR Number: 4489076-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00677
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Cardiac Failure
Myocardial Infarction
Tachyarrhythmia

Date:10/29/04ISR Number: 4489077-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00511
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		1434 DAY
Hospitalization -	Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL		1434 DAY
Initial or Prolonged	Fall Thoracic Vertebral Fracture Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489078-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00533
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis							
	Speech Disorder							
	Syncope							
	Vocal Cord Neoplasm							

Date:10/29/04ISR Number: 4489113-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00105
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		34 DAY
	Panic Attack		Nitrofurantoin	C		ORAL		
			Estrogens, Conjugated And Medroxyprogesterone Acetate	C				UNKNOWN
			Triazolam	C				UNKNOWN

Date:10/29/04ISR Number: 4489116-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00369
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:10/29/04ISR Number: 4489117-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Oxycodone Hydrochloride	C			UNKNOWN	
			Tolperisone Hydrochloride	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Flupirtine Maleate	C			UNKNOWN	

Date:10/29/04ISR Number: 4489119-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00689
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489120-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02932
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	425 DAY	UNKNOWN
			Lumigan	C				
Disability			Lasix (Furosemide)	C				

				Levoxyl	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:10/29/04ISR Number: 4489121-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Dizziness							
	Rash							

Date:10/29/04ISR Number: 4489122-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00017
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			Atorvastatin Calcium	C				
UNKNOWN								
			Metoprolol Tartrate	C				
UNKNOWN								
			Acetaminophen	C				
UNKNOWN								
			Warfarin Sodium	C				
UNKNOWN								
			Furosemide Sodium	C				
UNKNOWN								
			Oxazepam	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								
			Fosinopril Sodium	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489123-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00270
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lanolin Alcohols And Mineral Oil	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Azathioprine	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Meptazinol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Simvastatin	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	
			Celecoxib	C			UNKNOWN	

Date:10/29/04ISR Number: 4489124-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489125-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA01924
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Heart Injury Myocardial Infarction Peripheral Occlusive Disease Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489127-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489128-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02696
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Disorder Disability Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489129-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02972
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged	Diarrhoea Headache Nausea Transient Ischaemic Attack Weight Decreased		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489130-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03015
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Weight Decreased		Glucosamine	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Evista	C				UNKNOWN

Date:10/29/04ISR Number: 4489131-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02929
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489133-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02931
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Evista	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	
			Torsemide	C			UNKNOWN	
			Carbatrol	C			UNKNOWN	
			Dicyclomine Hydrochloride	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:10/29/04ISR Number: 4489134-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03155
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Metformin	C			UNKNOWN	

Initial or Prolonged	Poor Peripheral		Isosorbide	C		
UNKNOWN						
Disability	Circulation		Zocor	C		ORAL
			Atenolol	C		
UNKNOWN						
			Etodolac	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						

Date:10/29/04ISR Number: 4489135-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:10/29/04ISR Number: 4489136-7Report Type:Expedited (15-DaCompany Report #MX-MERCK-0410MEX00003
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
425 DAY						
Initial or Prolonged			Methotrexate	C		ORAL
Disability			Prednisone	C		ORAL
			Fosamax	C		ORAL
			Ranitidine	C		ORAL
			Candesartan	C		ORAL
			Leflunomide	C		ORAL
1486 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489137-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02726
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Protona	C			UNKNOWN	

Date:10/29/04ISR Number: 4489139-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03511
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amputation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Infective Thrombosis							
Other	Thrombosis							

Date:10/29/04ISR Number: 4489140-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03394
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Rupture							
	Coronary Artery Disease							
	Myocardial Infarction							

Date:10/29/04ISR Number: 4489141-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489142-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03544
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Asthma		Naproxen	C				
UNKNOWN								
	Dizziness		Percocet	C				
UNKNOWN								
	Ear Pain		Tylenol	C				
UNKNOWN								
	Haematochezia							
	Joint Swelling							
	Pain							
	Swelling Face							
	Urinary Tract Infection							

Date:10/29/04ISR Number: 4489143-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03218
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Tachycardia							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489144-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489145-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03482
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C			UNKNOWN	
Initial or Prolonged			Potassium (Unspecified)	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Prinzide	C		ORAL		
			Diltiazem Hydrochloride	C			UNKNOWN	
			Lasix (Furosemide Sodium)	C			UNKNOWN	
			Lantus	C			UNKNOWN	

Date:10/29/04ISR Number: 4489146-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03796
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489147-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03398
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Desipramine Hydrochloride	SS			UNKNOWN	
	Blood Sodium Decreased							
	Cerebrovascular Accident		Lopressor	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Cholestyramine Resin	C			UNKNOWN	

Date:10/29/04ISR Number: 4489148-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:10/29/04ISR Number: 4489149-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03618
Age:53 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Bronchitis		Lipitor	C			UNKNOWN	
Chest Pain		Plavix	C			UNKNOWN	
Respiratory Tract		Diovan	C			UNKNOWN	
Infection		Metoclopramide	C			UNKNOWN	
		Lisinopril	C			UNKNOWN	

Date:10/29/04ISR Number: 4489150-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03396
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Hydrocortone	C		ORAL		
Disability	Photosensitivity Reaction		Ambien	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489151-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03631
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	526 DAY	
Hospitalization -	Myocardial Infarction		[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:10/29/04ISR Number: 4489152-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03606
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Chest Pain		Hydrocortisone	C				
Initial or Prolonged	Hypertension							
	Mood Swings							

Date:10/29/04ISR Number: 4489158-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00885
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Disability	Abdominal Distension
	Abdominal Hernia
	Abdominal Pain Lower
	Abdominal Pain Upper
	Adverse Event
	Angina Unstable
	Aspartate
	Aminotransferase
	Increased
	Blood Pressure Systolic
	Increased
	Bradycardia
	Cardiomegaly
	Dehydration
	Diverticulum

		Dizziness					
		Duodenitis					
		Gastritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Diazide	C		
UNKNOWN							
		Hepatic Steatosis		Atenolol	C		
UNKNOWN							
		Hiatus Hernia		Skelaxin	C		
UNKNOWN							
		Hypokalaemia					
		Neck Pain					
		Oesophagitis					
		Polytraumatism					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Somnolence					
		Weight Increased					

Date:10/29/04ISR Number: 4489160-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00698
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Tilidine			
		Inguinal Hernia		Hydrochloride	C		ORAL
		Insomnia		Chlormezanone	C		ORAL
				Moxonidine	C		ORAL
				Distigmine Bromide	C		ORAL
				Timolol	C		ORAL
				Metoclopramide	C		ORAL

Date:10/29/04ISR Number: 4489161-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01780
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - Initial or Prolonged	Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN	Coumadin	C		
Disability	Sulfasalazine	C		
UNKNOWN	Nifedipine	C		
UNKNOWN	Methotrexate	C		
UNKNOWN	Folic Acid	C		
UNKNOWN	Tramadol Hydrochloride	C		
UNKNOWN	Exelon	C		
UNKNOWN	Atenolol	C		
UNKNOWN	Prozac	C		
UNKNOWN	Ditropan Xl	C		
UNKNOWN	Allegra	C		
UNKNOWN	Omeprazole	C		
UNKNOWN	Pravachol	C		
UNKNOWN	Gastrointestinal Preparations (Unspecified)	C		
UNKNOWN	Calcium (Unspecified)	C		
UNKNOWN	Aleve	C		
UNKNOWN	[Therapy			

			Unspecified]	C		
UNKNOWN						
			Humira	C		
UNKNOWN						
			Enulose	C		
UNKNOWN						
			Monopril	C		
UNKNOWN						

Date:10/29/04ISR Number: 4489162-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02640
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489167-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02955
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Norvasc	C				
UNKNOWN								
	Pyrexia							

Date:10/29/04ISR Number: 4489173-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03158
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Celebrex	SS				
UNKNOWN								
Other	Dementia Alzheimer'S Type							
	Hypertension							
	Myocardial Infarction							
	Neck Pain							
	Pain In Extremity							

Date:10/29/04ISR Number: 4489227-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02484
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Confusional State		Lipitor	C				
UNKNOWN								
Other	Hypoaesthesia							
	Musculoskeletal Stiffness							
	Transient Ischaemic							
	Attack							

Date:10/29/04ISR Number: 4489229-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Back Pain
	Blister
	Blood Cholesterol
	Increased
	Blood Pressure Increased
	Contusion
	Convulsion

		Coronary Artery Disease					
		Eye Disorder					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL
698	DAY						
		Hypoaesthesia		Lortab	C		
UNKNOWN							
		Joint Swelling		Prednisone	C		
UNKNOWN							
		Kidney Infection		Prednisone	C		
UNKNOWN							
		Myocardial Infarction		Nitropaste	C		
UNKNOWN							
		Nausea		Sodium Folate	C		
UNKNOWN							
		Palpitations		Ultram	C		
UNKNOWN							
		Phlebitis		Triamcinolone	C		
UNKNOWN							
		Pyrexia		Skelaxin	C		
UNKNOWN							
		Rash		Methotrexate	C		
UNKNOWN							
		Renal Disorder		Folic Acid	C		
UNKNOWN							
		Stress		Toprol Xl Tablets	C		
UNKNOWN							
		Tachycardia					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Weight Decreased					

Date:10/29/04ISR Number: 4489233-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Aspirin	C		
UNKNOWN						
Other	Adverse Event		Monopril	C		
UNKNOWN						

	Anaemia	Hydrochlorothiazide	C
UNKNOWN			
	Angina Pectoris		
	Angiopathy		
	Barrett'S Oesophagus		
	Blood Pressure Increased		
	Cerebrovascular Accident		
	Chest Pain		
	Constipation		
	Convulsion		
	Coronary Artery Disease		
	Coronary Artery		
	Restenosis		
	Eating Disorder		
	Erosive Oesophagitis		
	Gastrointestinal		
	Haemorrhage		
	Haematemesis		
	Hyperlipidaemia		
	Hypoaesthesia		
	Myocardial Ischaemia		
	Osteoarthritis		
	Transient Ischaemic		
	Attack		

Date:10/29/04ISR Number: 4489237-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00784
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Activated Partial
Initial or Prolonged	Thromboplastin Time
Disability	Prolonged

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Adverse Drug Reaction Adverse Event	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Arthralgia							
Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Azotaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Back Pain		Norvasc	C			UNKNOWN	
Breast Mass		Hydrochlorothiazide	C			UNKNOWN	
Dehydration		Diovan	C			UNKNOWN	
Diabetes Mellitus		Pravachol	C			UNKNOWN	
Diverticulum		Gemfibrozil	C			UNKNOWN	
Dyskinesia							
Dyslipidaemia							
Dysuria							
Eczema							
Fatigue							
Hepatitis							
Herpes Zoster							
Influenza							
International Normalised							
Ratio Increased							
Myalgia							
Oedema Peripheral							
Pollakiuria							
Prothrombin Time							
Prolonged							
Pyrexia							
Radiculopathy							
Rectal Haemorrhage							
Rhabdomyolysis							
Seborrhoeic Keratosis							
Spondylolisthesis							
Acquired							
Vomiting							
Weight Decreased							

Date:10/29/04ISR Number: 4489239-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
Other	Adrenal Mass
	Angina Unstable
	Asthenia
	Bacteriuria
	Bronchitis Acute
	Cardiac Failure Congestive
	Cataract
	Conjunctivitis
	Coronary Artery Disease
	Cystitis
	Depression
	Dermatitis
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Escherichia Urinary Tract

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Infection					
		Fall					
		Fatigue					
		Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Hydrodiuril	C		
UNKNOWN							
		Hearing Impaired		Lasix (Furosemide)	C		
UNKNOWN							
		Hypertension		Synthroid	C		
UNKNOWN							
		Hypoglycaemia		Insulin, Biphasic Isophane [Injection]	C		
		Injury					
UNKNOWN							
		Lacunar Infarction		Pepcid	C		
UNKNOWN							
		Lipids Increased		Dyrenium	C		
UNKNOWN							
		Maculopathy		Potassium (Unspecified)	C		
		Mass					
UNKNOWN							
		Metabolic Alkalosis		Amitriptyline Hydrochloride	C		
		Nocturia					
UNKNOWN							
		Pleural Effusion		Zaroxolyn	C		
UNKNOWN							
		Proteinuria		Darvocet-N	C		
UNKNOWN							
		Pulmonary Hypertension		Aspirin	C		
UNKNOWN							
		Radius Fracture		Niacin	C		
UNKNOWN							
		Rectal Haemorrhage		Vitamins (Unspecified)	C		
		Renal Cyst					
UNKNOWN							
		Renal Failure Chronic		Alupent	C		
UNKNOWN							
		Road Traffic Accident		Atenolol	C		
UNKNOWN							
		Scoliosis					
		Seasonal Allergy					
		Sinusitis					
		Skin Lesion					
		Spinal Column Stenosis					
		Stasis Dermatitis					
		Vaginal Infection					
		Ventricular Hypertrophy					

Weight Increased
Wrist Fracture

Date:10/29/04ISR Number: 4489242-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bipolar I Disorder		Avapro	C				
UNKNOWN								
Other	Chest Pain		Paxil	C				
UNKNOWN								
	Deep Vein Thrombosis		Geodon	C				
UNKNOWN								
	Fatigue		Lipitor	C				
UNKNOWN								
	Flank Pain		Lipitor	C				
UNKNOWN								
	Gastritis		Prilosec	C				
UNKNOWN								
	Hydronephrosis		Levoxyl	C				
UNKNOWN								
	Incisional Hernia		Prevacid	C				
UNKNOWN								
	Nephrolithiasis							
	Renal Failure Acute							
	Schizoaffective Disorder							
	Sepsis							
	Staphylococcal Infection							
	Urinary Retention							
	Urinary Tract Infection							
	Urosepsis							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489250-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00773
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides Increased		Amitriptyline Hydrochloride	C			UNKNOWN	
	Bronchitis		Verapamil	C			UNKNOWN	
	Cardiac Failure		Metoprolol Tartrate	C			UNKNOWN	
	Congestive		Enalapril Maleate	C			UNKNOWN	
	Cardiomegaly		Prilosec	C			UNKNOWN	
	Chest Pain		Glucophage	C		ORAL		
	Chronic Obstructive Pulmonary Disease		Prochlorperazine	C			UNKNOWN	
	Convulsion		Doxepin Hydrochloride	C			UNKNOWN	
	Depression		Fioricet Tablets	C			UNKNOWN	
	Dizziness		Echinacea	C			UNKNOWN	
	Dyspnoea Exertional		Garlic Extract	C			UNKNOWN	
	Hallucination		Ascorbic Acid	C			UNKNOWN	
	High Density Lipoprotein Decreased		Vitamins (Unspecified)	C			UNKNOWN	
	Lumbar Spinal Stenosis		Prednisone	C			UNKNOWN	
	Lung Disorder		Insulin	C			UNKNOWN	
	Myocardial Ischaemia							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Productive Cough							
	Pulmonary Hypertension							

Scar
Spinal Column Stenosis
Transient Ischaemic
Attack
Ventricular Dysfunction

Date:10/29/04ISR Number: 4489252-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Claritin	C			UNKNOWN	
	Blood Pressure Increased		Aspirin	C			UNKNOWN	
	Bradycardia		Pravachol	C			UNKNOWN	
	Cholelithiasis		Calcium (Unspecified)	C			UNKNOWN	
	Convulsion							
	Coronary Artery Disease		Folic Acid	C			UNKNOWN	
	Dyspnoea		Digoxin	C			UNKNOWN	
	Fatigue							
	Inner Ear Disorder							
	Myocardial Infarction							
	Non-Hodgkin'S Lymphoma							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489253-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00710
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthenia		Procardia Xl	C			UNKNOWN	
	Blood Pressure Increased		Prinivil	C			UNKNOWN	
	Bone Disorder		Diazide	C			UNKNOWN	
	Cerebral Atrophy		Synthroid	C			UNKNOWN	
	Cerebrovascular Accident		Ecotrin	C			UNKNOWN	
	Contusion		Hydrea	C			UNKNOWN	
	Convulsion		Osteo-Bi-Flex	C			UNKNOWN	
	Dehydration		Compazine	C			UNKNOWN	
	Depressed Level Of Consciousness							
	Depression							
	Diet Refusal							
	Extensor Plantar Response							
	Fall							
	Fatigue							
	Haematoma							
	Hepatic Lesion							
	Hypokalaemia							
	Insomnia							
	Joint Injury							
	Mental Status Changes							
	Mood Altered							
	Nausea							
	Nervous System Disorder							
	Oedema Peripheral							
	Paralysis							
	Pyelonephritis							
	Urinary Tract Infection							

Date:10/29/04ISR Number: 4489257-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00793
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Injury		Ambien	C		ORAL		
	Insomnia		Ambien	C		ORAL		
	Intervertebral Disc		Aspirin	C			UNKNOWN	
	Degeneration		Toprol Xl Tablets	C			UNKNOWN	
	Medication Error		Ditropan Xl	C			UNKNOWN	
	Mitral Valve Incompetence		Lortab	C		ORAL		
	Oedema		Zantac	C			UNKNOWN	
	Osteoarthritis		Cardizem	C			UNKNOWN	
	Pain		Detrol	C		ORAL		
	Palpitations		Norvasc	C		ORAL		
	Spinal Osteoarthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489260-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00836
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		493 DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		493 DAY
Disability	Anastomotic Stenosis		Carafate	C		ORAL		
Other	Anastomotic Ulcer		Atenolol	C		ORAL		
	Biliary Dilatation		Reglan	C		ORAL		
	Blood Pressure Increased		Theo-Dur	C		ORAL		
	Bursitis		Aldactone	C		ORAL		
	Candidiasis		Phenergan Tablets/Suppositories	C		ORAL	RESPIRATORY	(INHALATION)
	Carotid Artery Stenosis							
	Carpal Tunnel Syndrome							
	Colonic Polyp		Flovent	C			RESPIRATORY	(INHALATION)
	Coronary Artery Disease							
	Dysphagia		Combivent	C			RESPIRATORY	(INHALATION)
	Headache							
	Hyperlipidaemia		Elavil	C		ORAL		
	Impaired Gastric Emptying		Nitrostat	C			SUBLINGUAL	
	Myocardial Ischaemia		Buspar	C		ORAL		
	Oedema		Methadone Hydrochloride	C		ORAL		
	Orthostatic Hypotension							
	Osteoarthritis		Serevent Diskhaler	C			RESPIRATORY	(INHALATION)
	Pain							
	Peptic Ulcer Haemorrhage		Flonase	C			RESPIRATORY	(INHALATION)
	Prothrombin Level Increased		Zantac	C			UNKNOWN	
	Syncope		Iron (Unspecified)	C		ORAL		
	Tenosynovitis		Fosfree	C			UNKNOWN	
	Upper Respiratory Tract Infection		Ultram	C		ORAL		
	Vestibular Neuronitis							

Date:10/29/04ISR Number: 4489262-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00829
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rotator Cuff Syndrome		Darvocet-N	C			UNKNOWN	
	Tendon Disorder		Skelaxin	C			UNKNOWN	
			Fioricet Tablets	C			UNKNOWN	
			Hydrocodone Bitartrate	C			UNKNOWN	

Date:10/29/04ISR Number: 4489265-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00803
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia Macrocytic
Other	Anxiety
	Arthralgia
	Balance Disorder
	Blood Cholesterol Increased

		Bone Pain					
		Bronchitis					
		Candidiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Electrolyte Imbalance		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Serevent	C		
UNKNOWN							
		Herpes Simplex		Flovent	C		
UNKNOWN							
		Hypertension		Singulair	C		ORAL
		Hypoglycaemia		Topamax	C		
UNKNOWN							
		Joint Injury		Effexor	C		
UNKNOWN							
		Menopause		Claritin	C		
UNKNOWN							
		Migraine		Klonopin	C		
UNKNOWN							
		Neuralgia		Imitrex Nasal Spray	C		
UNKNOWN							
		Pneumonia		Skelaxin	C		
UNKNOWN							
		Rhinitis Allergic		Cyanocobalamin	C		
PARENTERAL							
		Rosacea		Zyrtec	C		
UNKNOWN							
		Simple Partial Seizures		Beclovent	C		
UNKNOWN							
		Spinal Disorder		Zestril	C		
UNKNOWN							
		Staphylococcal Infection		Detrol	C		
UNKNOWN							
		Tendon Injury		Mysoline	C		
UNKNOWN							
		Urge Incontinence		Prilosec	C		
UNKNOWN							
		Urinary Tract Infection					
		Weight Decreased					

Date:10/29/04ISR Number: 4489279-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged Disability	Adverse Event
	Amnesia
	Angina Pectoris
	Anxiety
	Asthenia
	Blood Pressure Increased
	Breast Cancer In Situ
	Breast Pain
	Bronchitis
	Bursitis
	Carotid Artery Atheroma
	Chest Pain
	Colon Polypectomy
	Colonic Polyp
	Contusion
	Diverticulum Intestinal
	Dizziness
	Drug Eruption
	Dyslipidaemia
	Exostosis
	Fatigue
	Fibrocystic Breast Disease
	Haemorrhoids
	Hot Flush
	Hyperhidrosis
	Hypertension
	Hypertensive Encephalopathy
	Injury
	Intermittent Claudication

		Limb Discomfort					
		Limb Injury					
		Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Spironolactone	C		
UNKNOWN							
		Pain In Extremity		Captopril Msd	C		ORAL
		Palpitations		Toprol Xl Tablets	C		ORAL
		Plantar Fasciitis					
		Pulmonary Congestion					
		Pulmonary Fibrosis					
		Pulmonary Hypertension					
		Rash					
		Refusal Of Treatment By Patient					
		Rhinitis					
		Rhinitis Allergic					
		Seasonal Allergy					
		Seroma					
		Sinusitis					
		Supraventricular Tachycardia					
		Tendonitis					
		Tinnitus					
		Transient Ischaemic Attack					
		Tremor					
		Ventricular Hypertrophy					
		Vertebrobasilar Insufficiency					
		Vertigo Positional					
		Weight Decreased					

Date:10/29/04ISR Number: 4489282-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00892
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Unstable					
		Arthritis					
		Breathing-Related Sleep Disorder					

Cataract
Chest Pain
Coronary Artery Disease
Cough
Diabetes Mellitus
Eye Disorder
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Lung Neoplasm Malignant
Neoplasm
Palpitations
Peripheral Vascular
Disorder
Pyrexia
Stress Fracture
Weight Increased

Date:10/29/04ISR Number: 4489284-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00900
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		79 DAY
Initial or Prolonged	Abscess		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		79 DAY
Other	Axillary Mass		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Synthroid	C				UNKNOWN
	Blood Pressure Increased		Synthroid	C				UNKNOWN
	Breast Mass		Ambien	C				UNKNOWN
	Cataract		Celexa	C				UNKNOWN
	Colon Adenoma		Maxzide	C				UNKNOWN
	Costovertebral Angle		Hydrochlorothiazide	C				UNKNOWN
	Tenderness		Prevacid	C				UNKNOWN
	Diverticulum							
	Haematochezia							
	Haemorrhoids							
	Ileus							
	Incisional Hernia							
	Mucosal Membrane Hyperplasia							
	Muscle Strain							
	Pain In Extremity							
	Polyp							
	Renal Cyst							
	Rhinitis Allergic							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Vitreous Floaters							

Date:10/29/04ISR Number: 4489288-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00821
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Chest Pain Chronic Obstructive Pulmonary Disease Coronary Artery Disease Diabetes Mellitus Non-Insulin-Dependent Dyspnoea Hypokalaemia Influenza Like Illness Obesity Pain Paranoid Personality Disorder Polytraumatism Pyrexia Spermatocele Spinal Disorder Ventricular Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489291-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00294
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Oedema Peripheral							
Disability	Pain In Extremity							
	Peripheral Vascular Disorder							
	Thrombosis							

Date:10/29/04ISR Number: 4489294-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00022
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1094 DAY

Date:10/29/04ISR Number: 4489295-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1128 DAY
	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		1128 DAY
Other	Acute Myocardial Infarction		Effexor	C				
UNKNOWN							247	DAY
			Nortriptyline	C				
UNKNOWN							233	DAY
	Chest Pain		Trazodone Hydrochloride	C				
	Coronary Artery Occlusion							
UNKNOWN								
	Coronary Artery Restenosis							
	Diverticulum							
	Emotional Distress							
	Gastritis							
	Gastroduodenitis							

Haematuria
Hyperlipidaemia
Hypertension
Myocardial Infarction
Nephrolithiasis

Date:10/29/04ISR Number: 4489300-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00796
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Anxiety
Other	Arthropathy
	Asthenia
	Cartilage Injury
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Coronary Artery Disease
	Depression
	Dizziness
	Dyslipidaemia
	Facial Palsy
	Gastrooesophageal Reflux Disease
	Gliosis

		Hyperglycaemia					
		Hypertension					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Protrusion		Aleve	C		
UNKNOWN							
		Meningioma					
		Muscle Atrophy					
		Muscle Spasms					
		Neck Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Paraesthesia					
		Rotator Cuff Syndrome					
		Simple Partial Seizures					
		Soliloquy					
		Spinal Column Stenosis					
		Spinal Disorder					
		Tendon Disorder					
		Treatment Noncompliance					

Date:10/29/04ISR Number: 4489301-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Colon Neoplasm		Lasix (Furosemide)	C		
UNKNOWN		1218 DAY					
		Emotional Distress		Tagamet	C		
UNKNOWN							
		Femur Fracture		Estropipate	C		
UNKNOWN		3956 DAY					
		Liver Disorder		Potassium (Unspecified)	C		
UNKNOWN							
				Drixoral	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Tiazac	C		
UNKNOWN							

	Hydrochlorothiazide	C
UNKNOWN		
	Iron (Unspecified)	C
UNKNOWN		
	Cyanocobalamin	C
UNKNOWN		
	Aspirin	C
UNKNOWN		
	Ascorbic Acid	C
UNKNOWN		
	Vitamin E	C
UNKNOWN		
	Magnesium (Unspecified)	C
UNKNOWN		
	Calcium (Unspecified)	C
UNKNOWN		

Date:10/29/04ISR Number: 4489303-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain Upper
	Acute Sinusitis
	Anxiety
	Arthritis
	Arthropathy
	Back Pain
	Blood Pressure Increased
	Bone Disorder
	Bronchitis

		Cardiomegaly					
		Carpal Tunnel Syndrome					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Estrogens			
		Cystitis		(Unspecified)	C		
UNKNOWN							
		Cystourethrocele		Propulsid	C		
UNKNOWN							
		Depression					
		Diarrhoea					
		Diverticulum Intestinal					
		Dizziness					
		Dupuytren'S Contracture					
		Dyspepsia					
		Dysuria					
		Eating Disorder					
		Emotional Distress					
		Fall					
		Gastric Disorder					
		Gastrooesophageal Reflux					
		Disease					
		Haemorrhoids					
		Herpes Zoster					
		Hypothyroidism					
		Insomnia					
		Intervertebral Disc					
		Displacement					
		Irritable Bowel Syndrome					
		Knee Arthroplasty					
		Lumbar Radiculopathy					
		Meniscus Lesion					
		Micturition Urgency					
		Muscle Spasms					
		Nausea					
		Nervousness					
		Nocturia					
		Osteoarthritis					
		Pain In Extremity					
		Paraesthesia					
		Pharyngitis					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Pyrexia					
		Radius Fracture					

Rhinorrhoea
Scoliosis
Sensation Of Foreign Body
Sinus Congestion
Spinal Column Stenosis
Spinal Osteoarthritis
Stomach Discomfort
Therapy Non-Responder
Thyroid Disorder
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489310-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				
UNKNOWN								
Other	Carotid Artery Stenosis		Celebrex	C				
UNKNOWN								
	Cerebral Infarction							
	Cerebrovascular Accident							
	Drug Ineffective							
	Haemorrhoids							
	Hemianopia							
	Hypoaesthesia							
	Injury							
	International Normalised Ratio Increased							
	Intracranial Aneurysm							
	Subarachnoid Haemorrhage							
	Urinary Retention							

Date:10/29/04ISR Number: 4489311-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489312-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Chest Pain							
	Tachycardia							

Date:10/29/04ISR Number: 4489314-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00756
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489315-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00712
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue							
	Myalgia							
	Pruritus							

Date:10/29/04ISR Number: 4489316-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00331
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Aspirin	C		ORAL		
			Captopril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489317-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00760
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489321-4Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00016
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489322-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00402
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489323-8Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00036
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY

Date:10/29/04ISR Number: 4489325-1Report Type:Expedited (15-DaCompany Report #MY-MERCK-0410MYS00008
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	35	DAY
Life-Threatening	Pulmonary Oedema		Celebrex	C		ORAL	46	DAY
Disability								

Date:10/29/04ISR Number: 4489327-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02453
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Increased							
	Cerebrovascular Accident							
	Mental Impairment							

Date:10/29/04ISR Number: 4489328-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489329-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02873
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amitriptyline Hydrochloride	C				UNKNOWN
			Methadone Hydrochloride	C				UNKNOWN
			Oxycodone	C				UNKNOWN
			Ambien	C				UNKNOWN
			Neurontin	C				UNKNOWN

Date:10/29/04ISR Number: 4489330-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02645
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489332-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00912
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Nadolol	C				UNKNOWN
	Dysarthria		Nexium	C				UNKNOWN
	Headache		Aspirin	C				UNKNOWN
	Hypoaesthesia		Estrace	C				UNKNOWN
	Palpitations							

Paraesthesia
Sensory Loss
Visual Field Defect

Date:10/29/04ISR Number: 4489333-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00403
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489334-2Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00018
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 81 DAY	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Fluticasone Propionate And Salmeterol Xinafoate	C				
RESPIRATORY								
(INHALATION)								
			Indomethacin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489335-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00537
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage		Vitamins (Unspecified)	C				
Disability	Visual Field Defect							
UNKNOWN			Neurontin	C				
UNKNOWN			Zestril	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489336-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00967
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY

Date:10/29/04ISR Number: 4489337-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02902
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Panic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Vision Blurred		Hydrocodone Hydrochloride	C				
UNKNOWN			Synthroid	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489339-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02874
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489340-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02920
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lipitor	C				
			Zyprexa	C				
			Coumadin	C				
			Prilosec	C				
			Effexor	C				
			Aspirin	C				
			Neurontin	C				

Date:10/29/04ISR Number: 4489341-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03163
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Prevacid	C				
Initial or Prolonged	Hyperhidrosis		Vasotec	C		ORAL		
Disability			Covera-Hs	C				
			[Therapy Unspecified]	C				

				Celebrex	C		
UNKNOWN	2 WK						

Date:10/29/04ISR Number: 4489342-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03225
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489343-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02915
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Motor Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Oedema Peripheral		Insulin	C				
UNKNOWN								
Disability	Pain In Extremity		Glucophage	C				
UNKNOWN								
	Pulmonary Embolism		Nexium	C				
UNKNOWN								
			Potassium Chloride	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Hydroxyzine Hydrochloride	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								
			Coreg	C				
UNKNOWN								
			Lopid	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Humulin	C				
UNKNOWN								

			Demadex	C			
UNKNOWN							
			Combivent	C			
UNKNOWN							
			Flovent	C			
UNKNOWN							
			Lorcet 10/650	C			
UNKNOWN							

Date:10/29/04ISR Number: 4489344-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00077
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON

Date:10/29/04ISR Number: 4489346-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03228
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1372 DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		1372 DAY
	Feeling Abnormal		Prilosec	C				
UNKNOWN								
	Pain		Vasotec	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Levaquin	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								
			Singulair	C				
UNKNOWN								
			Soma	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								
			Lortab	C				
UNKNOWN								
			Codeine	C				
UNKNOWN								

[Therapy Unspecified] C
UNKNOWN

Date:10/29/04ISR Number: 4489347-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03523
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		202 DAY
Hospitalization - Initial or Prolonged	Heart Rate Increased							

Date:10/29/04ISR Number: 4489348-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03407
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stomach Discomfort		Zantac	C				
UNKNOWN								
			Fosamax	C		ORAL		

Date:10/29/04ISR Number: 4489349-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03120
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C		ORAL		
	Transient Ischaemic Attack		Zocor	C		ORAL		

Date:10/29/04ISR Number: 4489350-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:10/29/04ISR Number: 4489352-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03530
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - INTRAVENOUS			Remicade	C				
Initial or Prolonged Disability						DRIP		

Date:10/29/04ISR Number: 4489353-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03514
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489354-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03515
Age:93 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bedridden		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure		[Therapy					
Disability	Congestive		Unspecified]	C				
UNKNOWN								
	Eating Disorder Symptom		[Therapy					
	Lethargy		Unspecified]	C				
UNKNOWN								
	Somnolence							

Date:10/29/04ISR Number: 4489355-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03524
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489356-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03259
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State							
	Feeling Abnormal							
	Nervousness							

Date:10/29/04ISR Number: 4489357-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03391
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angioplasty		Vioxx	PS	Merck & Co., Inc	ORAL		

	Cardiac Disorder		[Therapy Unspecified]	C		
UNKNOWN						

Date:10/29/04ISR Number: 4489358-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03663
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489360-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03330
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Triple Vessel Bypass Graft							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489361-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA03431
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4489362-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03583
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tremor		Flomax (Morniflumate)	C				
UNKNOWN								

Date:10/29/04ISR Number: 4489363-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03860
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diabetes Mellitus							
Initial or Prolonged	Fatigue							
Disability	Headache							
	Hypertension							
	Oedema Peripheral							
	Thrombosis							

Date:10/29/04ISR Number: 4489364-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03740
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Dilantin	C				
UNKNOWN								
			Vitamins					

(Unspecified) C
UNKNOWN

Date:10/29/04ISR Number: 4489365-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03577
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	1 YR

Date:10/29/04ISR Number: 4489366-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03634
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder Cerebrovascular Accident Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4489367-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Headache							
	Hypertension							

Date:10/29/04ISR Number: 4489368-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:10/29/04ISR Number: 4489369-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03745
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	279	DAY
Hospitalization -			Glipizide	C				UNKNOWN
Initial or Prolonged			Captopril	C				UNKNOWN
Disability								

Date:10/29/04ISR Number: 4489370-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01852
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Haemorrhoids		Aspirin	C				UNKNOWN
	Intestinal Haemorrhage		[Therapy					

Unspecified] C
UNKNOWN

Date:10/29/04ISR Number: 4489372-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03573
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Hospitalization - Initial or Prolonged Disability			Singulair	C		ORAL		

Date:10/29/04ISR Number: 4489373-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00305
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:10/29/04ISR Number: 4491887-5Report Type:Direct Company Report #CTU 230816
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 50 Mg	PS			1 TABLET PER DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/29/04ISR Number: 4491921-2Report Type:Direct Company Report #CTU 230812
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS		ORAL	ORAL	
Hospitalization - Initial or Prolonged	Hypertension							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:10/29/04ISR Number: 4492496-4Report Type:Expedited (15-DaCompany Report #2004081303
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Knee Arthroplasty	Consumer	Neurontin (Gabapentin)	PS				
			Zoloft (Sertraline)	SS				
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	SS				
			Rofecoxib (Rofecoxib)	SS				
			All Other Therapeutic Products	SS				

Date:11/01/04ISR Number: 4489725-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00634
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Premarin	C				
Disability	Depressive Symptom							
Other	Gastrooesophageal Reflux Disease							
	Hypertension							
	Iron Deficiency Anaemia							

Menopausal Symptoms
Migraine
Musculoskeletal Stiffness
Polycystic Ovaries
Uterine Leiomyoma

Date:11/01/04ISR Number: 4489726-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA01603
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Angina Pectoris
	Angina Unstable
	Anxiety
	Back Injury
	Bone Pain
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure

		Congestive Cardiomegaly Chest Pain Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
220	DAY						
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
220	DAY						
		Coronary Artery Occlusion		Wellbutrin	C		
UNKNOWN							
		Coronary Artery		Prevacid	C		
UNKNOWN							
		Restenosis		Propacet	C		
UNKNOWN							
		Diplopia Disturbance In Attention Diverticulitis Dizziness Drug Effect Decreased Drug Hypersensitivity Dyspnoea Epicondylitis Family Stress Gastrooesophageal Reflux Disease Haematemesis Haematoma Headache Hiatus Hernia Hyperlipidaemia Hypersensitivity Hypertension Hypotension Insomnia Lactose Intolerance Localised Infection Loss Of Consciousness Mitral Valve Calcification Muscle Contractions Involuntary Myalgia Myocardial Ischaemia Nausea Neck Pain Non-Cardiac Chest Pain Osteoarthritis					

Pallor
Postoperative Infection
Pulmonary Oedema
Retroperitoneal
Haemorrhage
Stent Occlusion
Syncope
Tendon Rupture
Tendonitis
Tinnitus
Tongue Biting
Urticaria
Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Hypokinesia
Vision Blurred
Visual Acuity Reduced
Vomiting
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489727-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		84 DAY
Initial or Prolonged	Angina Unstable		Aspirin	C				UNKNOWN
	Arteriospasm Coronary		Aspirin	C				UNKNOWN
	Arthralgia		Lipitor	C				UNKNOWN
	Back Pain		Prometrium	C				UNKNOWN
	Chest Pain		Vivelle	C				TOPICAL
	Coronary Artery Disease		Vivelle	C				TOPICAL
	Cystocele		Zyrtec	C				UNKNOWN
	Deep Vein Thrombosis		Fioricet Tablets	C				UNKNOWN
	Dehydration		Fioricet Tablets	C				UNKNOWN
	Diverticulitis		Ambien	C				UNKNOWN
	Diverticulum		Motrin	C				UNKNOWN
	Dysfunctional Uterine		Paxil	C				UNKNOWN
	Bleeding		Prilosec	C				UNKNOWN
	Dyspepsia		Alprazolam	C				UNKNOWN
	Dyspnoea		Vitamin E	C				UNKNOWN
	Dysuria		Gnc Womens Ultra Mega	C				UNKNOWN
	Flank Pain							
	Gastroenteritis		Lecithin	C				UNKNOWN
	Generalised Anxiety Disorder							
	Haematuria							
	Haemorrhoids							
	Hot Flush							

Injury
Menopausal Symptoms
Myocardial Infarction
Nausea
Neck Pain
Non-Cardiac Chest Pain
Phlebitis Superficial
Postoperative Ileus
Rectal Polyp
Rhinitis Allergic
Rosacea
Sinusitis
Stress Incontinence
Urinary Tract Infection
Venous Insufficiency
Vertigo
Weight Increased

Date:11/01/04ISR Number: 4489728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Atherosclerosis Basedow'S Disease Colonic Polyp Diverticulum Haemorrhoids Mass		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489729-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01104492
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis							
	Carotid Artery Stenosis							
	Cellulitis							
	Cerebral Atherosclerosis							
	Cerebrovascular Accident							
	Chondrocalcinosis							
	Extrasystoles							
	Granuloma							
	Hyperlipidaemia							
	Hypertension							
	Joint Effusion							
	Oedema							
	Osteoarthritis							
	Osteoporosis							
	Pain In Extremity							
	Peripheral Vascular Disorder							
	Renal Failure							
	Tendon Injury							
	Tendonitis							
	Ventricular Extrasystoles							
	Ventricular Hypertrophy							

Date:11/01/04ISR Number: 4489730-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00713
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Agitation		Klonopin	C				
UNKNOWN								
Disability	Angina Pectoris		Celexa	C				
UNKNOWN								
Other	Blood Pressure Increased		Prilosec	C				
UNKNOWN								

Cervicobrachial Syndrome
Convulsion
Depression
Headache
Intervertebral Disc
Protrusion
Irritability
Lumbar Radiculopathy
Memory Impairment
Myofascial Pain Syndrome
Nausea
Rotator Cuff Syndrome
Vomiting

Date:11/01/04ISR Number: 4489731-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	362	DAY
Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	362	DAY
Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Drug Ineffective		Aspirin	C		ORAL		
Dyspnoea		Adalat	C		ORAL		
Emotional Distress		Klor-Con	C		ORAL		
Oedema Peripheral		Zantac	C			UNKNOWN	
Palpitations		Pepcid	C			UNKNOWN	
Renal Failure		Tylenol	C			UNKNOWN	
Rotator Cuff Syndrome		Ibuprofen	C			UNKNOWN	
Scoliosis		Algae (As Drug)	C			UNKNOWN	
Sensory Loss							
Sinus Bradycardia							
Weight Increased							

Date:11/01/04ISR Number: 4489733-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00717
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acrochordon
	Adhesion
	Angina Pectoris
	Arthralgia
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Carotid Artery Stenosis
	Chest Pain
	Chronic Sinusitis
	Convulsion
	Decreased Activity

Diverticulum
Dizziness
Dyspnoea Exertional
Essential Tremor
Fall
Fibromyalgia
Flank Pain
Folliculitis
Gastroenteritis
Headache
Hyperglycaemia
Joint Contracture
Libido Decreased
Memory Impairment
Muscle Spasms
Myalgia
Nausea
Neuropathy Peripheral
Oedema Peripheral
Orthostatic Hypotension
Otitis Media Acute
Pain In Extremity
Pruritus

		Pyrexia					
		Restless Legs Syndrome					
		Rhinitis Allergic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sciatica		Vioxx	PS	Merck & Co., Inc	ORAL
		Skin Lesion		Lipitor	C		
UNKNOWN							
		Syncope		Levothyroxine Sodium	C		
UNKNOWN							
		Transient Ischaemic		Prevacid	C		
UNKNOWN							
		Attack		Estratest	C		
UNKNOWN							
		Upper Respiratory Tract		Vicodin Tablets	C		
UNKNOWN							
		Infection		Fluoxetine			
		Urinary Tract Infection		Hydrochloride	C		
UNKNOWN							
		Visual Acuity Reduced					

Date:11/01/04ISR Number: 4489739-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00697
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Angina Unstable		Tenormin	C		
UNKNOWN							
		Blood Pressure Increased		Tenormin	C		
UNKNOWN							
		Convulsion		Baycol	C		
UNKNOWN							
		Coronary Artery Disease		Ogen	C		
UNKNOWN							
		Electrocardiogram		Lipitor	C		
UNKNOWN							
		Repolarisation		Atenolol	C		
UNKNOWN							
		Abnormality					
		Myocardial Infarction					
		Ventricular Hypertrophy					

Date:11/01/04ISR Number: 4489740-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00648
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adhesion
Other	Adverse Event
	Aerophagia
	Anaphylactic Reaction
	Breast Pain
	Coronary Artery
	Atherosclerosis
	Decreased Appetite
	Depressed Level Of
	Consciousness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Intolerance
	Dysphagia
	Dysuria
	Gastrointestinal Motility
	Disorder
	Glossodynia
	Headache
	Helicobacter Infection
	Hot Flush
	Limb Injury
	Lipomatosis
	Lymphadenopathy
	Malaise
	Microcytic Anaemia

		Migraine					
		Nasal Congestion					
		Nasal Polyps	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Septum Deviation		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasal Turbinate		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Odynophagia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophageal Candidiasis		Promethazine	C		
UNKNOWN							
		Oesophagitis Ulcerative		Furosemide	C		
UNKNOWN							
		Oral Candidiasis		Ambien	C		
UNKNOWN							
		Pain		Alprazolam	C		
UNKNOWN							
		Palpitations		Aciphex	C		
UNKNOWN							
		Pancreatic Insufficiency		Prilosec	C		
UNKNOWN							
		Photosensitivity Reaction		Bel-Phen-Ergot S			
		Rheumatoid Arthritis		Tabs	C		
UNKNOWN							
		Sinusitis		Butalbital	C		
UNKNOWN							
		Sjogren'S Syndrome		Acetaminophen And			
		Stress		Caffeine	C		
UNKNOWN							
		Subcutaneous Nodule		Buspar	C		
UNKNOWN							
		Syncope		[Therapy			
		Thirst		Unspecified]	C		
UNKNOWN							
		Urethral Disorder		Lipitor	C		
UNKNOWN							
		Urinary Tract Infection		Premarin	C		
UNKNOWN							
		Vaginal Discharge		Synthroid	C		
UNKNOWN							
		Vomiting		Estratest	C		
UNKNOWN							
				Indapamide	C		
UNKNOWN							

Dulcolax C
UNKNOWN

Diflucan C
UNKNOWN

Date:11/01/04ISR Number: 4489749-2Report Type:Expedited (15-DaCompany Report #DEWYE114518OCT04
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Enbrel	PS		SUBCUTANEOUS		43 DAY
Hospitalization -	Increased		Enbrel	SS				43 DAY
Initial or Prolonged	Blood Creatine		Vioxx	SS		ORAL		827 DAY
	Phosphokinase Increased		Budesonide	C		ORAL		98 DAY
	C-Reactive Protein Increased							
	Dehydration							
	Demyelination							
	Depressed Level Of Consciousness							
	Diarrhoea							
	Korsakoff'S Psychosis							
	Non-Alcoholic Myoglobin Blood Increased							
	White Blood Cell Count Increased							

Date:11/01/04ISR Number: 4489750-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00729
Age:60 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vasotec	C		ORAL		
	Arthralgia		Lipitor	C			UNKNOWN	
	Atrial Flutter		Aspirin	C			UNKNOWN	
	Basal Ganglion		Verelan	C			UNKNOWN	
	Degeneration		Nitrostat	C			UNKNOWN	
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Chest Discomfort							
	Convulsion							
	Coronary Artery							
	Atherosclerosis							
	Dyspepsia							
	Dyspnoea							
	Ear Disorder							
	Fall							
	Headache							
	Hiatus Hernia							
	Hypoaesthesia							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Paraesthesia							
	Renal Impairment							
	Ventricular Dysfunction							
	Vertigo							

Date:11/01/04ISR Number: 4489751-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00750
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							
	Intervertebral Disc							

Degeneration

Date:11/01/04ISR Number: 4489753-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00721
Age:35 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Affective Disorder
	Aggression
	Angina Pectoris
	Anxiety
	Bipolar Disorder
	Blood Pressure Increased
	Bronchitis
	Convulsion
	Delusion
	Delusional Disorder, Persecutory Type
	Depression
	Fluid Retention

		Hallucinations, Mixed					
		Hypertension					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
		Protrusion					
		Joint Sprain					
		Osteoarthritis					
		Restlessness					
		Road Traffic Accident					
		Sciatica					
		Spinal Osteoarthritis					

Date:11/01/04ISR Number: 4489756-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00818
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Valve Incompetence					
Disability		Bundle Branch Block Left					
Other		Cardiac Arrest					
		Coronary Artery					
		Atherosclerosis					
		Coronary Artery Occlusion					
		Coronary Artery Stenosis					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Dilatation Atrial					
		Dilatation Ventricular					
		Dizziness					
		Ejection Fraction					
		Decreased					
		Hyperlipidaemia					
		Hypertension					
		Hypertriglyceridaemia					
		Hypotension					
		Ischaemic Cardiomyopathy					
		Mitral Valve Incompetence					
		Oedema Peripheral					
		Polytraumatism					
		Ventricular Dysfunction					
		Ventricular Fibrillation					

Date:11/01/04ISR Number: 4489757-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00807
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Lower
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia
Disability	Anorexia
	Arrhythmia
	Atrial Flutter
	Azotaemia
	Bacteria Urine Identified
	Bladder Disorder
	Blood Pressure Increased
	Bronchial Carcinoma
	Candidiasis
	Cardio-Respiratory Arrest

		Cardiomegaly Carotid Bruit Chest Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cholelithiasis		Vioxx	PS	Merck & Co., Inc	ORAL
1151 DAY							
		Coronary Artery		Naprosyn	SS		
UNKNOWN							
		Atherosclerosis Dehydration Dysphagia Dyspnoea Epicondylitis Gammopathy Gastrooesophageal Reflux Disease Groin Pain Haematuria Hypotension Interstitial Lung Disease Jaundice Mitral Valve Incompetence Mitral Valve Prolapse Multi-Organ Failure Muscle Spasms Nephropathy Toxic Neuralgia Oedema Peripheral Pleural Effusion Pneumonia Pneumothorax Pulmonary Oedema Respiratory Failure Rheumatoid Arthritis Sepsis Sepsis Syndrome Subcutaneous Emphysema Tachycardia Upper Respiratory Tract Infection Urinary Tract Infection Urosepsis Venous Insufficiency Ventricular Hypertrophy Vocal Cord Paralysis Weight Decreased					

Date:11/01/04ISR Number: 4489758-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00830
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Alopecia
	Arthralgia
	Asthenia
	Back Injury
	Bronchospasm
	Chest Discomfort
	Chest Pain
	Chest Wall Pain
	Cough
	Cystitis

		Depression					
		Dyspnoea					
		Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Paxil	C		
UNKNOWN							
		Gastrooesophageal Reflux		Albuterol	C		
UNKNOWN							
		Disease		Methocarbamol	C		
UNKNOWN							
		Hypersomnia		[Therapy			
		Hypertension		Unspecified]	C		
UNKNOWN							
		Insomnia		Potassium			
		Intervertebral Disc		(Unspecified)	C		
UNKNOWN							
		Degeneration		Premarin	C		
UNKNOWN							
		Lumbar Radiculopathy		Calcium			
		Migraine		(Unspecified)	C		
UNKNOWN							
		Myalgia		Vasotec	C		ORAL
		Oedema Peripheral		Ultram	C		
UNKNOWN							
		Osteoarthritis		Hydrochlorothiazide	C		
UNKNOWN							
		Polytraumatism					
		Sacroiliitis					
		Sleep Apnoea Syndrome					
		Somnolence					
		Vaginal Infection					

Date:11/01/04ISR Number: 4489761-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00891
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Abuser		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Paxil	C		ORAL
		Hypoaesthesia		Norvasc	C		ORAL
		Injury		Labetalol			

	Joint Stiffness	Hydrochloride	C
UNKNOWN			
	Lower Respiratory Tract	Hyzaar	C
UNKNOWN			
	Infection	Humulin 70/30	C
SUBCUTANEOUS	243 DAY		
	Obesity	Humulin 70/30	C
SUBCUTANEOUS	243 DAY		
	Pain		
	Pain In Extremity		
	Paraesthesia		
	Penile Pain		
	Renal Cyst		

Date:11/01/04ISR Number: 4489771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00744
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Antinuclear Antibody Positive
	Blood Pressure Increased
	Bursitis
	Convulsion
	Coronary Artery Disease
	Depression
	Drug Ineffective
	International Normalised

		Ratio Decreased					
		Joint Injury					
		Joint Swelling					
		Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Osteopenia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Prothrombin Time Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Scoliosis		Prednisone	C		
UNKNOWN							
		Transient Ischaemic		Prednisone	C		
UNKNOWN							
		Attack		Vicodin Tablets	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		ORAL
				Centrum Silver	C		
UNKNOWN							
				Cal-Citrate	C		
UNKNOWN							
				Lovenox	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:11/01/04ISR Number: 4489773-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00714
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess		Effexor Xr	C				
UNKNOWN								
Other	Adverse Event							
	Angina Pectoris							
	Atelectasis							
	Blood Cholesterol Increased							
	Bronchitis							
	Cardiac Failure							
	Congestive							
	Convulsion							
	Hand Fracture							
	Hypertension							
	Rotator Cuff Syndrome							
	Trigger Finger							
	Tubo-Ovarian Abscess							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489776-5Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00038
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Chest Pain		Amoxicillin	C				UNKNOWN
	Gastrointestinal Haemorrhage		Cefoperazone Sodium And Sulbactam Sodium	C				UNKNOWN
	Headache							
	Mouth Ulceration							
	Proctitis							

Date:11/01/04ISR Number: 4489777-7Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		510 DAY
	Cerebrovascular Disorder							

Date:11/01/04ISR Number: 4489778-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489780-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00423
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Oedema Peripheral		Propranolol					

Pain In Extremity Hydrochloride C
UNKNOWN YR

Date:11/01/04ISR Number: 4489781-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00139
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident At Work
Disability	Acute Sinusitis
Other	Arthralgia
	Asthenia
	Benign Neoplasm
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis Acute
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Conjunctivitis
	Dizziness
	Emotional Distress
	Epidermal Naevus
	Fatigue
	High Density Lipoprotein Decreased
	Hypertension
	Hypoaesthesia

		Low Density Lipoprotein Increased					
		Malaise	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
		Paraesthesia		Vioxx	SS		ORAL
1	DAY						
		Pharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Temperature Intolerance					
		Transient Ischaemic Attack					
		Vascular Stenosis					

Date:11/01/04ISR Number: 4489803-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00871
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other	Coronary Artery Disease	Professional				

Date:11/01/04ISR Number: 4489805-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02937
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Renal Failure					

Date:11/01/04ISR Number: 4489806-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00228
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Hepatic Failure		Pravastatin Sodium	C		
Initial or Prolonged UNKNOWN	Hepatitis Fulminant		Bisoprolol	C		
	Herpes Simplex					

Date:11/01/04ISR Number: 4489807-2Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00036
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Hypertension		Clindamycin Phosphate	C		INTRAVENOUS		
	Hypertensive Heart Disease		Fleroxacin	C		INTRAVENOUS		
	Hypoaesthesia							
	Loss Of Consciousness							
	Protein Urine Present							
	Supraventricular Extrasystoles							

Date:11/01/04ISR Number: 4489809-6Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00033
Age: Gender: I/FU:I

Outcome	PT
Other	Bundle Branch Block Right
	Dysphoria
	Electrocardiogram T Wave Abnormal

	Insomnia						
	Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Fentanyl	C			TOPICAL	

Date:11/01/04ISR Number: 4489810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01696
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder	Professional	Alcohol	SS			UNKNOWN	
Initial or Prolonged	Chest Discomfort		Toprol Xl Tablets	C			UNKNOWN	
Disability	Hepatic Enzyme Increased							
	Liver Disorder							

Date:11/01/04ISR Number: 4489811-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02966
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Facial Palsy		Synthroid	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/01/04ISR Number: 4489813-8Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00261
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/01/04ISR Number: 4489814-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Headache		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension		Tiazac	C		
UNKNOWN						
	Nausea					
	Rash					

Date:11/01/04ISR Number: 4489816-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00739
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other			Lotrel	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489817-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489819-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02933
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Plavix	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:11/01/04ISR Number: 4489820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02982
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death		Lanoxin	C			UNKNOWN	
Initial or Prolonged	Sleep Disorder		Wellbutrin	C			UNKNOWN	
	Tobacco Abuse		Coreg	C			UNKNOWN	
			Advair	C			UNKNOWN	
			Combivent	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Tarka	C			UNKNOWN	

Date:11/01/04ISR Number: 4489822-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03282
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma Chest Pain Dyspnoea Rash Pruritic	Consumer	Vioxx Hydrocodone Bitartrate	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:11/01/04ISR Number: 4489823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02990
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489825-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02977
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Congestive		Vioxx [Therapy Unspecified] Metoprolol Prinivil	SS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489826-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02993
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pneumonia		Acyclovir	C				
UNKNOWN								
Initial or Prolonged			Valium	C				
UNKNOWN								
Disability			Flovent	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Oxandrin	C				
UNKNOWN								

Date:11/01/04ISR Number: 4489827-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03387
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			
			Vicodin Tablets	C				

Date:11/01/04ISR Number: 4489829-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03269
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder							
	Hypertension							
	Hypotension							
	Insomnia							
	Multi-Organ Disorder							
	Syncope							

Date:11/01/04ISR Number: 4489830-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03353
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		[Therapy Unspecified]	C				
UNKNOWN			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/01/04ISR Number: 4489831-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03066
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Pulmonary Oedema	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489833-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acquired Porphyria		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489834-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03559
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zocor	C				
UNKNOWN								
Initial or Prolonged			Plavix	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/01/04ISR Number: 4489835-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03558
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Synthroid	C				
UNKNOWN								
	Hypertension		Zoloft	C				
UNKNOWN								
	Nausea		Xanax	C				
UNKNOWN								
	Overdose							
	Vomiting							

Date:11/01/04ISR Number: 4489837-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03065
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Oedema	Professional						

Date:11/01/04ISR Number: 4489838-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03840
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Lortab	C				
UNKNOWN								
Initial or Prolonged			Skelaxin	C				
UNKNOWN								
			Tizanidine Hydrochloride	C				
UNKNOWN								

Date:11/01/04ISR Number: 4489840-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03611
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
20 DAY								
Initial or Prolonged	Attack		Prilosec	C				
UNKNOWN								

Date:11/01/04ISR Number: 4489842-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03393
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Singulair	C		ORAL		
Disability			Allegra	C				
UNKNOWN								
Other			Diovan	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		
			Nexium	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

			Fosamax	C		ORAL
			Glucophage	C		
UNKNOWN						
			Detrol	C		
UNKNOWN						
			Atenolol	C		
UNKNOWN						
			Veralan	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						

Date:11/01/04ISR Number: 4489843-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03557
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Toprol Xl Tablets	C		
UNKNOWN						
Initial or Prolonged			Promethazine	C		
UNKNOWN						
Disability			Estratest	C		
UNKNOWN						
			Nystatin	C		
UNKNOWN						
			Endocet	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						

Date:11/01/04ISR Number: 4489844-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03842
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening						
Disability						

Date:11/01/04ISR Number: 4489845-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03897
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		1725 DAY
Hospitalization - UNKNOWN	Congestive		Tylenol	C				
Initial or Prolonged	Cardiomegaly							
Disability	Cerebrovascular Accident							
	Hypertension							
	Myocardial Infarction							

Date:11/01/04ISR Number: 4489847-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03851
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
	Tachycardia							

Date:11/01/04ISR Number: 4489848-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03917
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blindness Transient		Serzone	C				
UNKNOWN								
	Thrombosis		Klor-Con	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Digoxin	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4489850-3Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON

Date:11/01/04ISR Number: 4489851-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03996
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Allopurinol	C				UNKNOWN
Disability			Flomax (Morniflumate)	C				UNKNOWN
			Effexor	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:11/01/04ISR Number: 4489852-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03967
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489853-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04027
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Actonel	C				UNKNOWN

Hospitalization - UNKNOWN		Pravachol	C
Initial or Prolonged UNKNOWN		Oxybutynin	C
Disability			

Date:11/01/04ISR Number: 4489855-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03984
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489856-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04014
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4489859-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Anaemia
Other	Angina Pectoris

		Arthralgia					
		Blood Pressure Increased					
		Bundle Branch Block Left	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Prevacid	C		
UNKNOWN							
		Limb Discomfort		Amitriptyline			
		Post Procedural Haematoma		Hydrochloride	C		ORAL
				Atenolol	C		ORAL
				Atenolol	C		ORAL
				Nitroglycerin	C		
SUBLINGUAL							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		ORAL
				Zantac	C		ORAL
				Plavix	C		
UNKNOWN							

Date:11/01/04ISR Number: 4489861-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00251
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Captopril	C		
UNKNOWN						
	Oedema Peripheral		Captopril	C		
UNKNOWN						

Date:11/01/04ISR Number: 4490218-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0212USA00230
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
222 DAY						
Initial or Prolonged	Arthralgia		Humulin	C		
UNKNOWN						
Disability	Coronary Artery Disease		Humulin	C		
UNKNOWN						

	Coronary Artery Stenosis	Clotrimazole	C
UNKNOWN			
	Dizziness	Neurotonin Capsules	C
UNKNOWN			
	Dyspepsia	Vicoprofen	C
UNKNOWN			
	Dysphagia		
	Gastric Ulcer		
	Myocardial Infarction		
	Oesophagitis		
	Pain		
	Reflux Oesophagitis		
	Spinal Osteoarthritis		
	Vomiting		
	Weight Increased		

Date:11/01/04ISR Number: 4490220-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess
Initial or Prolonged	Abdominal Pain
Other	Adenomyosis
	Amnesia
	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Atrioventricular Block
	Back Pain

		Bronchitis					
		Cardiac Valve Disease					
		Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Complex Regional Pain		Normodyne	C		
UNKNOWN							
		Syndrome		Prevacid	C		
UNKNOWN							
		Constipation		Flagyl	C		
UNKNOWN							
		Convulsion		Minoxidil	C		
UNKNOWN							
		Costochondritis		Procardia Xl	C		
UNKNOWN							
		Dental Caries		Cardura	C		
UNKNOWN							
		Dermatitis					
		Diverticulitis					
		Duodenal Ulcer					
		Duodenitis					
		Dyspnoea Exertional					
		Encephalopathy					
		Fatigue					
		Gastritis					
		Grand Mal Convulsion					
		Haematoma Infection					
		Haemorrhoids					
		Helicobacter Gastritis					
		Hypertension					
		Hypertensive Crisis					
		Hypokalaemia					
		Hypotension					
		Irritable Bowel Syndrome					
		Joint Contracture					
		Laceration					
		Malignant Hypertension					
		Melaena					
		Memory Impairment					
		Micturition Urgency					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Oedema					
		Oedema Peripheral					
		Oesophagitis					

Orthopnoea
Osteoarthritis
Pain In Extremity
Palpitations
Pelvic Inflammatory
Disease
Peptic Ulcer
Pyrexia
Salpingitis
Sensory Loss
Supraventricular
Tachycardia
Upper Respiratory Tract
Infection
Vaginal Discharge
Vaginal Haemorrhage
Vulvovaginal Discomfort

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4490271-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0312NOR00013
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Haemorrhage							

Date:11/01/04ISR Number: 4490272-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00639
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Pepcid	C				
UNKNOWN								
	Chest Pain		Albuterol	C				
UNKNOWN								
	Coronary Artery Disease		Atrovent	C				
UNKNOWN								
	Diabetes Mellitus		Lisinopril	C				
UNKNOWN								
	Non-Insulin-Dependent		Aspirin	C				
UNKNOWN								
	Disorientation							
	Drug Hypersensitivity							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hypertension							
	Hyperventilation							
	Hypoxia							
	Neurodermatitis							
	Osteoarthritis							
	Stress							
	Thrombosis							
	Transient Ischaemic							
	Attack							
	Vertebral Artery Stenosis							
	Vertigo							

Date:11/01/04ISR Number: 4490276-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Respiratory
Hospitalization -	Distress Syndrome
Initial or Prolonged	Acute Respiratory Failure
Other	Anaphylactic Reaction
	Angioneurotic Oedema
	Aortic Atherosclerosis
	Arrhythmia
	Asthenia
	Asthma
	Blood Cholesterol
	Increased
	Bronchitis
	Cardiac Disorder
	Cardiomegaly
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Cytomegalovirus Colitis
	Deep Vein Thrombosis

		Diastolic Dysfunction					
		Disseminated Cytomegaloviral Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Epistaxis		Zyrtec	C		ORAL
		Feeling Abnormal		Aspirin	C		
UNKNOWN							
		Gastrointestinal		Aspirin	C		
UNKNOWN							
		Haemorrhage		Hydro-Chlor	C		
UNKNOWN							
		Gastrooesophageal Reflux		Benazepril			
		Disease		Hydrochloride And			
		Haemoptysis		Hydrochlorothiazide	C		ORAL
		Heart Rate Irregular		Prednisone	C		ORAL
		Hepatic Enzyme Increased		Flonase	C		
RESPIRATORY							
		Hypoventilation					
(INHALATION)							
		Hypoxia		Detrol	C		ORAL
		Ileus		Lipitor	C		
UNKNOWN							
		Injury					
		Intestinal Ischaemia					
		Leukocytosis					
		Muscle Spasms					
		Myopathy Steroid					
		Osteoarthritis					
		Pneumonia Cytomegaloviral					
		Pulmonary Oedema					
		Rectal Haemorrhage					
		Rectal Ulcer					
		Rhinitis Allergic					
		Sinusitis					
		Staphylococcal Infection					
		Swelling Face					
		Swollen Tongue					
		Syphilis					

Date:11/01/04ISR Number: 4490278-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0402NOR00012
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490279-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00640
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Insulin Human, Isophane	C		SUBCUTANEOUS		
	Congestive		Prednisone	C		UNKNOWN		
	Convulsion		Zaroxolyn	C		UNKNOWN		
	Leukocytosis		Lipitor	C		UNKNOWN		
	Rash		Spironolactone	C		UNKNOWN		
	Respiratory Failure		Wellbutrin Sr	C		UNKNOWN		
	Spleen Disorder		Premphase	C		UNKNOWN		
			Actonel	C		UNKNOWN		
			Plaquenil	C		UNKNOWN		
			Colace	C		UNKNOWN		

			K-Dur	C			
UNKNOWN							
			Ultram	C			ORAL
			Lasix (Furosemide)	C			
UNKNOWN							
			Azathioprine	C			ORAL
			Diflucan	C			
UNKNOWN							
			Zyban	C			
UNKNOWN							
			Actigall	C			
UNKNOWN							

Date:11/01/04ISR Number: 4490281-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00075
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Life-Threatening	Coma		Insulin	C				
UNKNOWN								
Hospitalization -	Gastric Ulcer Perforation		[Therapy					
Initial or Prolonged	Guillain-Barre Syndrome		Unspecified]	C				
UNKNOWN								
	Hallucination							
	Meningitis							

Date:11/01/04ISR Number: 4490282-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00840
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anaemia		Premarin	C				
UNKNOWN								
	Chest Pain		Neurontin	C				
UNKNOWN								
	Constipation		Vicodin Tablets	C				
UNKNOWN								
	Dermatitis Contact		Vicodin Tablets	C				
UNKNOWN								

	Diarrhoea		Hydrodiuril	C	ORAL
	Gastritis		Aspirin	C	
UNKNOWN					
	Gastrooesophageal Reflux		Biaxin Xl	C	
UNKNOWN					
	Disease				
	Hypertension				
	Muscular Weakness				
	Myalgia				
	Nocturia				
	Osteoarthritis				
	Rectal Haemorrhage				

Date:11/01/04ISR Number: 4490284-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00386
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Acetaminophen And Carbinoxamine Maleate And Phenylephrine Hydrochloride	C		ORAL
			Tramadol Hydrochloride	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4490285-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00368
Age:94 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged	Contusion		Morphine	C			UNKNOWN	
	Fatigue		Elavil	C			UNKNOWN	
	Oedema Peripheral		Ramipril	C			UNKNOWN	
	Pericardial Effusion		Lithium Carbonate	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Corticosteroids (Unspecified)	C			UNKNOWN	

Date:11/01/04ISR Number: 4490287-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00385
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Aspirin	C			UNKNOWN	
Other			Nifedipine	C			UNKNOWN	

Date:11/01/04ISR Number: 4490288-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:11/01/04ISR Number: 4490289-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00085
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Hospitalization -	Myocardial Infarction		Arava	C				UNKNOWN
Initial or Prolonged			Metoprolol	C				UNKNOWN
Other			Cartia (Aspirin)	C				UNKNOWN
			Losec (Omeprazole)	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Lipex	C				UNKNOWN
			Xanax	C				UNKNOWN
			Zoloft	C				UNKNOWN

Date:11/01/04ISR Number: 4490291-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00672
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490292-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00705
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pupils Unequal		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Syncope		Etanercept	C		ORAL		
			Esomeprazole Sodium	C				
PARENTERAL								
			[Therapy					

Unspecified] C
UNKNOWN

Date:11/01/04ISR Number: 4490294-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00396
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL	200	DAY
Initial or Prolonged	Skin Ulcer							

Date:11/01/04ISR Number: 4490295-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/01/04ISR Number: 4490296-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							

Date:11/01/04ISR Number: 4490297-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00765
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basilar Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Vertebral Artery Stenosis							
Disability								

Date:11/01/04ISR Number: 4490298-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00708
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490299-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00024
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	1562 DAY	
			Clopidogrel Bisulfate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

Date:11/01/04ISR Number: 4490300-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00762
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Failure Silent Myocardial Infarction

	Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490301-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00306
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drop Attacks		Vioxx	PS	Merck & Co., Inc	ORAL		
1298 DAY								
Initial or Prolonged	Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL		
1298 DAY								
			Zopiclone	C		ORAL		
			Omeprazole	C		ORAL		
			Indapamide	C		ORAL		

Date:11/01/04ISR Number: 4490302-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03763
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Zyrtec	C				
UNKNOWN								
	Weight Increased		Atenolol	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/01/04ISR Number: 4490303-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00693
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Ultram	C				
UNKNOWN								
	Depression		Lorcet Plus	C				
UNKNOWN								
	Disability		Viagra	C				
UNKNOWN								
	Erectile Dysfunction		Neurontin	C				
UNKNOWN								
	Fibromyalgia		Neurontin	C				
UNKNOWN								
	Insomnia		Prozac	C				
UNKNOWN								
	Intervertebral Disc		Prozac	C				
UNKNOWN								
	Displacement		Lorazepam	C				
UNKNOWN								
	Lip Ulceration		Lorazepam	C				
UNKNOWN								
	Lipoma		Hydrocodone					
	Nasal Congestion		Bitartrate	C				
UNKNOWN								
	Neck Pain		Allegra	C				
UNKNOWN								
	Pain		Zocor	C		ORAL		
	Paranasal Sinus		Zocor	C		ORAL		
	Hypersecretion		Lipitor	C				
UNKNOWN								
	Perirectal Abscess							
	Rotator Cuff Syndrome							
	Sinus Congestion							
	Tooth Loss							

Date:11/01/04ISR Number: 4490304-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00044
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490305-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03865
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490306-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00711
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490307-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00022
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL	47 DAY	
	Diplopia		Furosemide Sodium	C			UNKNOWN	
	Dysarthria		Atenolol	C			UNKNOWN	
	Tongue Biting							

Date:11/01/04ISR Number: 4490308-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490309-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/01/04ISR Number: 4490310-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03761
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Muscle Spasms Scar Swelling Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4490311-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02377
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Verapamil	C				UNKNOWN
	Hypertension		Furosemide	C				UNKNOWN
	Myocardial Infarction		Potassium (Unspecified)	C				UNKNOWN
			Terazosin Hydrochloride	C				UNKNOWN
			Omeprazole	C				UNKNOWN
			Plavix	C				UNKNOWN
			Rosuvastatin Calcium	C				UNKNOWN
			Candesartan	C				UNKNOWN

Date:11/01/04ISR Number: 4490312-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03792
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Neurontin	C				UNKNOWN
Disability			Insulin	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Diabeta	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN

Date:11/01/04ISR Number: 4490313-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rectal Haemorrhage							
	Ulcer Haemorrhage							

Date:11/01/04ISR Number: 4490314-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03912
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphthous Stomatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
							UNKNOWN	
			Hormonal Contraceptives (Unspecified)	C				
							UNKNOWN	

Date:11/01/04ISR Number: 4490315-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-0410NLD00036
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Ethinyl Estradiol And Levonorgestrel	C				
							UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4491290-8Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00504
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Study	Alfuzosin					
		Health	Hydrochloride	C				
		Professional	Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil					
			Dihydrochloride	C				

Date:11/01/04ISR Number: 4491304-5Report Type:Direct Company Report #CTU 230841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blister		Vioxx	PS		ORAL	ORAL	
Required	Cellulitis		Unna Boot Therapy	C				
Intervention to	Erythema							
Prevent Permanent	Impaired Work Ability							
Impairment/Damage	Oedema Peripheral							

Date:11/01/04ISR Number: 4491310-0Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00029
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Urea Decreased	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	103 DAY
Initial or Prolonged	Confusional State	Study						
	Headache	Health						
	Ischaemic Stroke	Professional						
	Mean Cell Haemoglobin	Other						
	Concentration Increased							
	Mean Cell Haemoglobin							
	Increased							
	Platelet Count Decreased							

Date:11/01/04ISR Number: 4491406-3Report Type:Direct Company Report #CTU 230893
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Voxx 25 Mg	PS		ORAL	25 MG ORAL	

Date:11/01/04ISR Number: 4491496-8Report Type:Expedited (15-DaCompany Report #WAES 0410FIN00010
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	C-Reactive Protein Increased	Study Health Professional	Beclomethasone Dipropionate	C				
	Hypoaesthesia		Salmeterol Xinafoate	C				
	Transient Ischaemic Attack		Tadalafil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/01/04ISR Number: 4492388-0Report Type:Direct Company Report #CTU 230949
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg / Merck	PS	Merck		1 X DAILY	
Hospitalization - Initial or Prolonged			Premarin	C				

Date:11/01/04ISR Number: 4493031-7Report Type:Expedited (15-DaCompany Report #2004240470GB
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL	
		Professional Other	Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:11/02/04ISR Number: 4490559-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00890
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Intervertebral Disc Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490562-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00640
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Adrenal Adenoma
	Adrenal Cyst
	Adverse Event
	Arterial Occlusive

Disease
Arthralgia
Back Pain
Blood Triglycerides
Increased
Cardiac Failure
Congestive
Cardiomegaly
Cellulitis
Chest Pain
Cholecystitis
Cholelithiasis
Depression
Dilatation Atrial
Dizziness
Dyspnoea
Flatulence
Glucose Tolerance
Impaired
Haemorrhoids
Hepatic Steatosis
Incontinence
Injury
Mitral Valve Incompetence

		Myocardial Infarction					
		Nasopharyngitis					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Productive Cough		Vioxx	PS	Merck & Co., Inc	ORAL
		Vaginal Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
				Detrol	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Claritin-D	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Nitropatch	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Propulsid	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:11/02/04ISR Number: 4490565-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00632
Age:26 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Thrombosis		Percocet	C		
UNKNOWN							
		Myocardial Infarction					

Date:11/02/04ISR Number: 4490566-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490567-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00706
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
	Deep Vein Thrombosis							
	Diastolic Dysfunction							
	Dilatation Atrial							
	Hypertension							
	International Normalised							
	Ratio Decreased							
	Limb Injury							
	Pain In Extremity							
	Patellofemoral Pain							
	Syndrome							
	Pleurisy							
	Post Thrombotic Syndrome							
	Pulmonary Embolism							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4490570-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Coagulopathy							
	Dyspnoea							
	Emotional Distress							
	Gastric Disorder							
	Glaucoma							
	Haematochezia							
	Haemorrhagic Diathesis							
	Hypertension							
	Joint Swelling							
	Myocardial Infarction							
	Obesity							
	Oedema Peripheral							
	Osteoarthritis							

Date:11/02/04ISR Number: 4490571-1Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00069
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
515 DAY								
Initial or Prolonged	Visual Disturbance		Glucophage	C		ORAL		
Other								

Date:11/02/04ISR Number: 4490572-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00419
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490573-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00645
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Roxicet	C			UNKNOWN	
	Convulsion		Mobic	C			UNKNOWN	
	Dyspnoea		Neurontin	C			UNKNOWN	
	Rheumatoid Arthritis							

Date:11/02/04ISR Number: 4490574-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00077
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4490587-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490588-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02235
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Closed Head Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Effexor	C				
UNKNOWN								
	Loss Of Consciousness		[Therapy					
	Post Concussion Syndrome		Unspecified]	C				
UNKNOWN								
	Syncope		Atenolol	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			Oxycodone	C				
UNKNOWN								

Date:11/02/04ISR Number: 4490589-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03811
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
2 MON								
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysgraphia		Vioxx	SS	Merck & Co., Inc	ORAL		
2 MON								
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Macular Degeneration							
	Mental Impairment							
	Prescribed Overdose							
	Transient Ischaemic							

Attack
Walking Disability

Date:11/02/04ISR Number: 4490590-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03719
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Convulsion							
Initial or Prolonged	Renal Failure							

Date:11/02/04ISR Number: 4490592-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03480
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Essential Hypertension		Enbrel	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4490593-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03706
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysphagia		Premarin	C				
UNKNOWN								

Date:11/02/04ISR Number: 4490594-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03924
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
565 DAY								
Initial or Prolonged			Tylenol	C				
UNKNOWN								

Date:11/02/04ISR Number: 4490595-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03615
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hormonal Contraceptives (Unspecified)	C				
UNKNOWN								
			Hormonal Contraceptives (Unspecified)	C				
UNKNOWN								

Date:11/02/04ISR Number: 4490596-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01716
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Diarrhoea							

Fibromyalgia
Foot Fracture
Hypercholesterolaemia
Hypertension
Hypoglycaemia
Iron Deficiency
Microcytic Anaemia
Upper Gastrointestinal
Haemorrhage

Date:11/02/04ISR Number: 4490597-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Disease
Other	Arrhythmia
	Atherosclerosis
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Coronary Artery Disease
	Gallbladder Disorder
	Heart Rate Irregular
	Hypertension
	Injury

Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	726	DAY
	Levoxyl	C			UNKNOWN	
	Hydrochlorothiazide	C			UNKNOWN	
	Cardizem	C			UNKNOWN	
	Lovastatin	C			UNKNOWN	
	Premarin	C			UNKNOWN	

Date:11/02/04ISR Number: 4490598-XReport Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00050
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Adronat	C			UNKNOWN	
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	

Date:11/02/04ISR Number: 4490599-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03517
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Rebif	SS				
	Cardiomyopathy		Glucophage	C			UNKNOWN	

	Viral Pericarditis		Lexapro	C
UNKNOWN				
			Actos	C
UNKNOWN				
			Ditropan	C
UNKNOWN				
			Dexedrine	C
UNKNOWN				

Date:11/02/04ISR Number: 4490603-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490604-2Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4490605-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anaemia
Other	Angina Pectoris
	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiomegaly

		Cerebrovascular Accident					
		Conjunctivitis Allergic					
		Convulsion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Coumadin	C		
UNKNOWN							
		Ear Pain		Risperdal	C		
UNKNOWN							
		Fatigue		Prozac	C		
UNKNOWN							
		Headache		Elavil	C		ORAL
		Hepatic Steatosis		Effexor	C		
UNKNOWN							
		Herpes Zoster		Effexor	C		
UNKNOWN							
		Hypoglycaemia		Glucophage	C		
UNKNOWN							
		Impaired Gastric Emptying					
		Injection Site					
		Haemorrhage					
		Lipomatosis					
		Mastoiditis					
		Migraine					
		Pain In Extremity					
		Phlebitis					
		Rash					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					
		Syncope					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:11/02/04ISR Number: 4490632-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Lortab	C		
UNKNOWN						
	Chest Discomfort		Soma	C		
UNKNOWN						
	Convulsion		Viagra	C		
UNKNOWN						
	Coronary Artery Disease					
	Hot Flush					
	Myocardial Infarction					
	Pulmonary Hypertension					
	Radial Tunnel Syndrome					
	Rotator Cuff Syndrome					
	Thrombosis					

Date:11/02/04ISR Number: 4490641-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00370
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Metoprolol Tartrate	C		ORAL
	Dizziness		Estrogens (Unspecified)	C		ORAL
			Vitamin E Acetate			

D-Form	C		ORAL
Fosamax	C		ORAL

Date:11/02/04ISR Number: 4491027-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 5 DAY	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 17 MON	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cerebrovascular Disorder		Hydrodiuril	SS		ORAL
	Dizziness		Methotrexate	C		
UNKNOWN	2219 DAY					
	Ear Discomfort		Folic Acid	C		ORAL
	Peripheral Coldness		Toprol Xl Tablets	C		ORAL
	Sinusitis					
	Stomach Discomfort					
	Transient Ischaemic Attack					

Date:11/02/04ISR Number: 4491032-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable
Disability	Atelectasis
Other	Atrial Fibrillation
	Back Pain
	Blood Cholesterol Increased
	Blood Creatinine Increased
	Bradycardia
	Colonic Polyp
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Reocclusion
	Coronary Bypass Thrombosis

Deep Vein Thrombosis
Diverticulitis Intestinal
Haemorrhagic
Diverticulum
Dysaesthesia
Haemorrhoids
Hyperlipidaemia
Hypertension
Intervertebral Disc
Degeneration
Mitral Valve Incompetence
Myocardial Infarction
Polyp
Pulmonary Oedema
Pyrexia
Renal Failure Chronic
Respiratory Distress
Sigmoiditis
Tricuspid Valve
Incompetence

		Ventricular Hypertrophy Visual Acuity Reduced Wound Dehiscence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Zocor	SS		ORAL
				Methotrexate	C		
UNKNOWN							
				Prednisone	C		ORAL
				Atenolol	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Temazepam	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Ismo	C		
UNKNOWN							
				Oxycodone Hydrochloride	C		
UNKNOWN							

Date:11/02/04ISR Number: 4491034-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Aspiration		Flexeril	SS		ORAL
Other	Completed Suicide Depressed Level Of Consciousness		Acetaminophen And Tramadol Hydrochloride	SS		
UNKNOWN						
	Drug Toxicity		Omeprazole	SS		ORAL
	Intentional Misuse		Elavil	SS		ORAL
	Vomiting		Tizanidine Hydrochloride	SS		ORAL

Date:11/02/04ISR Number: 4491036-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatitis C							
	Hypertension							
	Injury							
	Intervertebral Disc Displacement							
	Intervertebral Disc Protrusion							
	Joint Injury							
	Myocardial Infarction							

Date:11/02/04ISR Number: 4491037-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00130
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dysphasia		Zocor	C		ORAL		
	Hemiparesis		Isosorbide Mononitrate	C		ORAL		
Disability			Prazosin Hydrochloride	C		ORAL		

			Prazosin Hydrochloride	C		ORAL

Date:11/02/04ISR Number: 4491047-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491049-1Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00009
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

Date:11/02/04ISR Number: 4491052-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00049
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged			Antimicrobial (Unspecified)	C				
UNKNOWN								

Date:11/02/04ISR Number: 4491054-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00243
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Lymphoma		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL		
Other	Peptic Ulcer Haemorrhage		Unspecified]	C				
UNKNOWN								

				[Therapy Unspecified]	C		
UNKNOWN							

Date:11/02/04ISR Number: 4491055-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00420
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491059-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00655
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Prilosec	C				
UNKNOWN								
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4491060-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00695
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Asthenia Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491061-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491062-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Back Pain Bone Swelling Circulatory Collapse Headache Nausea Palpitations Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491071-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00418
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx Clopidogrel Bisulfate	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:11/02/04ISR Number: 4491072-7Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00054
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged								

Date:11/02/04ISR Number: 4491074-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01683
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Cozaar	C		ORAL		

Date:11/02/04ISR Number: 4491075-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03966
Age:64 YR Gender:Female I/FU:I

Outcome	PT
Disability	Connective Tissue
Other	Disorder

	Eye Swelling Oropharyngeal Swelling Vasculitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C			UNKNOWN	
			Macrobid	C			UNKNOWN	
			Maxzide	C			UNKNOWN	

Date:11/02/04ISR Number: 4491076-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03947
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491078-8Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00029
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Cardiac Failure		Digoxin	C			UNKNOWN	
	Dyspnoea Exertional Electrocardiogram Abnormal Oedema Peripheral		Potassium Bicarbonate And Sodium Alginate	C		ORAL		

Date:11/02/04ISR Number: 4491079-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03948
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491080-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03968
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death UNKNOWN	Acute Myocardial Infarction		Vioxx Sulfasalazine Lotensin	PS C C	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491082-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03885
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/02/04ISR Number: 4491083-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04030
Age:67 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	SS		ORAL		
			Amlodipine Besylate And Benazepril Hydrochloride	SS		ORAL		

Date:11/02/04ISR Number: 4491084-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03972
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Glyburide	C				
	Heart Rate Irregular		Nexium	C				
			Metformin	C				
			Lipitor	C				
			Allegra	C				
			Albuterol	C				
			Aspirin	C				

Date:11/02/04ISR Number: 4491085-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03726
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vicodin Tablets	C				
	Hypoaesthesia							

Date:11/02/04ISR Number: 4491087-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03849
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Vicodin Tablets	C				
UNKNOWN								
Other								

Date:11/02/04ISR Number: 4491088-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03970
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:11/02/04ISR Number: 4491089-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03689
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Disability	Angina Pectoris
	Cardiac Disorder
	Cardiac Flutter

		General Symptom Respiratory Tract Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Aminophylline	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							

Date:11/02/04ISR Number: 4491090-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00304
Age:64 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Basedow'S Disease Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
				Diuretic (Unspecified)	C		
UNKNOWN							

Date:11/02/04ISR Number: 4491092-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03879
Age:78 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cerebrovascular Accident Triple Vessel Bypass Graft		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/02/04ISR Number: 4491093-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03859
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death		Levothroid	C				
	Weight Decreased		Lanoxin	C				
			Prinivil	C				
			Lescol	C				

Date:11/02/04ISR Number: 4491097-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04173
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Donnatal	C				
			Prednisone	C				
			Flexeril	C				
			Diovan	C				
			Zantac	C				

Date:11/02/04ISR Number: 4491098-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04149
Age:77 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/02/04ISR Number: 4491099-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03963
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cervix Disorder		Celebrex	C				
UNKNOWN								
Disability	Chest Pain		Prilosec	C				
UNKNOWN								
Other			[Therapy Unspecified]	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								
			Verapamil Msd Lp	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Naprosyn	C				
UNKNOWN								
			Thymol	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			[Therapy					

			Unspecified]	C		
UNKNOWN						
			Atenolol Msd	C		
UNKNOWN						

Date:11/02/04ISR Number: 4491100-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
	Constipation					
	Disability					
	Hypertension					

Date:11/02/04ISR Number: 4491101-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03942
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Crestor	C		
UNKNOWN						

Date:11/02/04ISR Number: 4491104-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04142
Age: Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Cardiac Aneurysm
Disability	Gastrooesophageal Reflux

Disease

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	[Therapy Unspecified]	C			UNKNOWN	
	Atenolol	C			UNKNOWN	
	Loratadine	C			UNKNOWN	
	Mobic	C			UNKNOWN	
	Premarin	C			UNKNOWN	

Date:11/02/04ISR Number: 4491106-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/02/04ISR Number: 4491107-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04386
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:11/02/04ISR Number: 4491116-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Heart Rate Increased Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR

Date:11/02/04ISR Number: 4491124-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03729
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Claritin	C			UNKNOWN	

Date:11/02/04ISR Number: 4492557-XReport Type:Direct Company Report #CTU 231088
Age:69 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Bilirubin Conjugated

Increased
Blood Bilirubin Increased
Hepatocellular Damage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rofecoxib 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	ORAL
	Furosemide	C				
	Metoprolol	C				
	Pantoprazole	C				
	Isosoribide Dinitrate	C				
	Warfarin	C				
	Simvastatin	C				
	Nortriptyline	C				
	Hydrocodone/Acetaminophen	C				
	Tramadol	C				
	Diphenhydramine	C				
	Atrovent	C				
	Fluticasone Roal Inhaler	C				
	Oxycodone	C				
	Ondansetron	C				
	Bisacodyl	C				
	Magnesium Hydroxide	C				

Date:11/02/04ISR Number: 4492701-4Report Type:Direct Company Report #CTU 231055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx 12.5 Mg Tablet	PS				
Other	Cerebrovascular Accident							
	Convulsion							

Date:11/02/04ISR Number: 4492800-7Report Type:Expedited (15-DaCompany Report #WAES 0410ZAF00004
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Abscess Limb	Foreign	Tab Vioxx 25 Mg	PS	ORAL
25					
Initial or Prolonged	Blood Chloride Increased	Study			
MG/DAILY/PO					
Disability	Blood Creatinine	Health	Atenolol	C	
	Increased	Professional	Colchicine	C	
	Blood Urea Increased		Enalapril Maleate		
	Diabetes Mellitus		(+) Hydrochlor?	C	
	Inadequate Control		Gliclazide	C	
	Hypertensive Heart		Insulin Human,		
	Disease		Isophane	C	
	Platelet Count Increased		Prazosin		
	White Blood Cell Count		Hydrochloride	C	
	Increased				

Date:11/02/04ISR Number: 4492836-6Report Type:Direct Company Report #CTU 230993
Age:54 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx 25 Mg Merck Shar	PS	Merck Shar	ORAL	25MG DAILY	ORAL

Date:11/02/04ISR Number: 4493246-8Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00504
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort	Foreign	Tab Vioxx	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Coronary Artery Occlusion	Study					PO	
	Myocardial Infarction	Health Professional	Alfuzosin Hydrochloride	C				
			Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil Dihydrochloride	C				

Date:11/02/04ISR Number: 4493248-1Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00504
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction	Foreign	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged		Study	Alfuzosin					
		Health Professional	Hydrochloride	C				
			Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil Dihydrochloride	C				

Date:11/02/04ISR Number: 4493940-9Report Type:Direct Company Report #CTU 231066
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Coronary Artery Surgery		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG 1/DAY ORAL	

Date:11/02/04ISR Number: 4494032-5Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Foreign	Tab Vioxx 50 Mg	PS		ORAL	50 MG DAILY	
Initial or Prolonged	Cardiac Failure	Study					PO	
Disability	Congestive Heart Rate Increased	Health Professional	Tab 0663-Blinded Therapy	SS		ORAL	PO	
	Orthopnoea		Tab Blinded Therapy	SS		ORAL	PO	
			Acetaminophen Amitriptyline	C				

Hydrochloride C

Date:11/03/04ISR Number: 4491681-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lopressor	C				
UNKNOWN								
	Blood Cholesterol Increased							
	Cardiomyopathy							
	Coronary Artery Thrombosis							
	High Density Lipoprotein Decreased							
	Hypertension							
	Low Density Lipoprotein Increased							

Date:11/03/04ISR Number: 4491685-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00940
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Convulsion							

Date:11/03/04ISR Number: 4491686-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00617
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
Other	Anxiety Disorder
	Asthenia
	Benign Breast Neoplasm
	Blood Cholesterol Increased

Blood Pressure Increased
Cardiac Failure
Congestive
Cardiomegaly
Cataract
Chronic Obstructive
Pulmonary Disease
Convulsion
Coronary Artery Disease
Depression
Ear Pain
Fibromyalgia
Insomnia
Mitral Valve Disease
Mitral Valve Incompetence
Pain
Peptic Ulcer
Periarthritis
Seasonal Allergy
Spinal Column Stenosis

		Spinal Osteoarthritis					
		Stress					
		Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tinea Capitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Glyburide	C		ORAL
				Glucophage	C		ORAL
				Tylenol Extra Strength	C		
UNKNOWN							
				Accupril	C		ORAL
				Fer-Sul	C		ORAL
				Benadryl	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Adalat	C		
UNKNOWN							
				Lescol	C		
UNKNOWN							

Date:11/03/04ISR Number: 4491707-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02414
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Dyspnoea		Claritin	C		
UNKNOWN							
		Skin Irritation		Dicyclomine Hydrochloride	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Vistaril	C		
UNKNOWN							

UNKNOWN	Desyrel	C	
UNKNOWN	Patanol	C	
TOPICAL	Hydrocortisone Acetate	C	
UNKNOWN	[Therapy Unspecified]	C	
UNKNOWN	Advair	C	
UNKNOWN	Combivent	C	
UNKNOWN	Darvocet-N	C	
UNKNOWN	Levsin	C	
UNKNOWN	Soma	C	
UNKNOWN	Protonix	C	
UNKNOWN	Nitrol (Nitroglycerin)	C	
UNKNOWN	Neurontin	C	
UNKNOWN	Nasonex	C	
UNKNOWN	Atenolol Msd	C	ORAL
UNKNOWN	Isosorbide Mononitrate Er	C	
UNKNOWN	Plavix	C	
UNKNOWN	Zocor	C	ORAL
UNKNOWN	Glucophage	C	
UNKNOWN	Avandia	C	
UNKNOWN	Clonidine	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4491717-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00024
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Sotalol Hydrochloride	C				
UNKNOWN								

Date:11/03/04ISR Number: 4491718-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Claritin-D	C				
UNKNOWN								
	Cholecystectomy		Flomax (Tamsulosin Hydrochloride)	C				
	Dehydration							
UNKNOWN								
	Depression		Flonase	C				
UNKNOWN								
	Emotional Distress		Diazepam	C				
UNKNOWN								
	Gallbladder Disorder		Plendil	C				
UNKNOWN								
	Gout		Pravachol	C				
UNKNOWN								
	Hernia		Wellbutrin	C				
UNKNOWN								
	Hodgkin'S Disease							
	Hypercholesterolaemia							
	Myalgia							
	Nephrosclerosis							
	Pain							
	Procedural Site Reaction							
	Renal Failure Acute							
	Renal Impairment							
	Renal Injury							

Renal Tubular Necrosis
Scar
Sinusitis

Date:11/03/04ISR Number: 4491720-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491721-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00757
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Peripheral Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491722-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00617
Age:52 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury		Endocet	C			UNKNOWN	
	Myocardial Infarction		Smz-Tmp	C			UNKNOWN	
			Augmentin	C			UNKNOWN	
			Hydrocodone/Apap	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Diflucan	C			UNKNOWN	

Date:11/03/04ISR Number: 4491726-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01542
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Premarin	C			UNKNOWN	
Other	Gastric Haemorrhage		Tiazac	C			UNKNOWN	
	Headache		Valium	C			UNKNOWN	
	Heart Rate Increased							
	Oedema Peripheral							

Date:11/03/04ISR Number: 4491733-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03716
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Synthroid	C			UNKNOWN	
Initial or Prolonged			Norvasc	C			UNKNOWN	

			Lasix (Furosemide)	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Chloracon	C		
UNKNOWN						
			Iron (Unspecified)	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Vasopressin	C		
UNKNOWN						

Date:11/03/04ISR Number: 4491735-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03685
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1121 DAY	
Hospitalization -	Coronary Artery Disease		Plavix	C			UNKNOWN	
Initial or Prolonged			Zocor	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Glucotrol	C			UNKNOWN	
			Biaxin	C			UNKNOWN	

Date:11/03/04ISR Number: 4491736-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03674
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
	Intracranial Aneurysm		Albuterol	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	

Date:11/03/04ISR Number: 4491737-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491739-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03775
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zoloft	C				
UNKNOWN								

Date:11/03/04ISR Number: 4491740-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04079
Age:50 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL		
			Metformin	SS				
UNKNOWN								
			Amlodipine Besylate And Benazepril Hydrochloride	SS				
UNKNOWN								

Date:11/03/04ISR Number: 4491741-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00962
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tinnitus		Vicodin Tablets	C				
UNKNOWN								
Disability			Phenytoin	C				
UNKNOWN								
			[Therapy					

	Unspecified]	C
UNKNOWN		
	Ambien	C
UNKNOWN		
	Effexor	C
UNKNOWN		
	Librium	C
UNKNOWN		
	Dilantin	C
UNKNOWN		
	Calcium (Unspecified)	C
UNKNOWN		
	Advair	C
UNKNOWN		

Date:11/03/04ISR Number: 4491742-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03731
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491743-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03732
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea							
	Metrorrhagia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4491744-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04278
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:11/03/04ISR Number: 4491745-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491746-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colonic Polyp							
	Duodenal Ulcer							
	Haemorrhage							
	Eating Disorder							
	Nausea							

Date:11/03/04ISR Number: 4491747-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00180
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491748-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491749-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04371
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Ziac	C				
UNKNOWN								
Initial or Prolonged	Chest Pain		Potassium					
Disability	Depression		(Unspecified)	C				
UNKNOWN								
	Dyspepsia		Allegra	C				
UNKNOWN								
	Nausea		Zocor	C				
UNKNOWN								
	Swelling		Nexium	C				
UNKNOWN								
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4491750-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Palpitations							

Date:11/03/04ISR Number: 4491751-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03724
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Peripheral Vascular		Nexium	C				UNKNOWN
	Disorder		Ativan	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Darvocet-N	C				UNKNOWN

Date:11/03/04ISR Number: 4491752-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00109
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
Other								

Date:11/03/04ISR Number: 4491753-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491754-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Hydrocodone Bitartrate	C				UNKNOWN
			Glucovance	C				UNKNOWN

Date:11/03/04ISR Number: 4491756-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00394
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4491798-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04280
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492199-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00636
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Celebrex	C				
Disability	Bronchitis		Tylenol	C				
	Chest Pain		Aspirin	C				
	Chest Wall Pain		Nexium	C				
	Cholelithiasis		Toprol Xl Tablets	C				
	Dermal Cyst		Tylenol With Codeine #3	C				
	Duodenitis							
	Dyspnoea							
	Eczema							
	Electrocardiogram Abnormal							
	Epistaxis							
	Gastritis							
	Helicobacter Gastritis							
	Laceration							
	Otitis Media							
	Pleurisy							
	Sinusitis							
	Victim Of Crime							

Date:11/03/04ISR Number: 4492202-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Alveolitis Fibrosing
Disability	Anxiety
Other	Arthralgia
	Arthropathy
	Cardiac Failure Congestive
	Carotid Artery Disease
	Carpal Tunnel Syndrome

Chest Pain
Chronic Obstructive
Pulmonary Disease
Collagen-Vascular Disease
Depression
Dermatomyositis
Diarrhoea
Diverticulum
Dizziness
Dysphasia
Dyspnoea
Fibromyalgia
Gastritis
Gastrointestinal Motility
Disorder
Gastrooesophageal Reflux
Disease
Haemoptysis
Haemorrhoids
Hypersensitivity
Hypertension
Insomnia
Interstitial Lung Disease

Irritable Bowel Syndrome
Malaise
Memory Impairment
Musculoskeletal Stiffness
Obsessive-Compulsive
Disorder
Obstructive Airways
Disorder
Oesophageal Candidiasis
Pain In Extremity
Paraesthesia
Polymyositis
Polytraumatism
Pulmonary Fibrosis
Pulmonary Oedema
Rash
Rash Macular
Rash Pruritic
Rheumatoid Arthritis
Visual Field Defect
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492206-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

PT
Abdominal Pain
Acquired Claw Toe
Anaemia
Arthritis
Blood Cholesterol
Increased
Blood Pressure
Inadequately Controlled
Cerebrovascular Accident
Chest Pain
Cholelithiasis
Colonic Polyp
Coronary Artery Disease
Deafness
Dehydration
Diverticulum
Dyspepsia
Dyspnoea

Ear Infection
Emotional Disorder
Eye Irritation
Gastritis
Haematuria
Helicobacter Gastritis
Hepatic Enzyme Increased
Hypertension
Intestinal Polyp
Irritable Bowel Syndrome
Lacunar Infarction
Peroneal Nerve Palsy
Rash Pruritic
Reflux Oesophagitis
Scab
Skin Lesion

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	49	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	72	DAY
	Zocor	C		ORAL		
	Protonix	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Prinivil	C		ORAL		

Date:11/03/04ISR Number: 4492209-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00285
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lipids Abnormal Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492210-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Anxiety
Disability	Arthritis
	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Blood Pressure Orthostatic Decreased
	Bronchitis
	Burning Sensation
	Cerebral Infarction
	Cerebrovascular Accident
	Conversion Disorder
	Depression
	Dizziness

Dry Skin
Emotional Distress
Fall
Fatigue
Feeling Jittery
Ganglion
Generalised Anxiety
Disorder
Haemorrhoids
Hallucination
Hemiparesis
Hiatus Hernia
Hypertension
Hypoaesthesia
Hypokalaemia
Hyporeflexia
Inflammation
Injury
Insomnia
Lacunar Infarction
Liver Function Test
Abnormal
Loss Of Consciousness

	Menopausal Symptoms						
	Movement Disorder						
	Oesophageal Spasm	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Orthostatic Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL	
	Pain In Extremity		Synthroid	C			UNKNOWN
	Palpitations		Aspirin	C			UNKNOWN
	Panniculitis		Celexa	C			UNKNOWN
	Post Procedural		Niacin	C			UNKNOWN 14671DAY
	Complication		Lexapro	C			UNKNOWN
	Psychosomatic Disease		Claritin	C			UNKNOWN
	Skin Cancer		Ventolin (Albuterol)	C			RESPIRATORY (INHALATION)
	Stress						
	Suicidal Ideation		Aerobid	C			UNKNOWN
	Syncope						
	Tinnitus						
	Tremor						
	Weight Decreased						

Date:11/03/04ISR Number: 4492211-4Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00036
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Pericardial Effusion						
	Pleural Effusion						

Date:11/03/04ISR Number: 4492213-8Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00030
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Goitre Hypertensive Heart Disease		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY

Date:11/03/04ISR Number: 4492214-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00474
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		743 DAY
			Aspirin	C		ORAL		
			Xipamide	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Escitalopram Oxalate	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Estrogens (Unspecified)	C		ORAL		

Date:11/03/04ISR Number: 4492215-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00492
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492217-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00282
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort							
	Headache							
	Overdose							

Date:11/03/04ISR Number: 4492218-7Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00074
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Phenprocoumon	C			UNKNOWN	
			Amlodipine Maleate	C			UNKNOWN	
			Molsidomine	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

Date:11/03/04ISR Number: 4492222-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Occlusion							
	Dry Mouth							
	Heart Rate Increased							
	Myocardial Infarction							
	Nausea							
	Thyroid Gland Cancer							

Date:11/03/04ISR Number: 4492223-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia Cerebral Haemorrhage Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492224-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00281
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pemphigus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492226-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00293
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Rabeprazole Sodium	C		ORAL		
			Simvastatin	C				
			Bendroflumethiazide	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492228-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00105
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/03/04ISR Number: 4492229-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00693
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492230-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00778
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Aneurysm Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492231-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:11/03/04ISR Number: 4492232-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00768
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	General Symptom		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492234-5Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00060
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Albuterol Sulfate And Ipratropium Bromide	C			UNKNOWN	
			Beclomethasone Dipropionate	C			UNKNOWN	

Date:11/03/04ISR Number: 4492237-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00294
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Formication		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Pruritus		Amitriptyline Hydrochloride	C			UNKNOWN	
			Dihydrocodeine Bitartrate	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	

Date:11/03/04ISR Number: 4492238-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00052
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Cardiac Failure Congestive Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492241-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01866
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492242-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01619
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492243-6Report Type:Expedited (15-DaCompany Report #IT-MERCK-0410ITA00061
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Stenosis Atherosclerosis Carotid Artery Occlusion Hyperhidrosis Ischaemic Cardiomyopathy Loss Of Consciousness Malaise		Vioxx	PS	Merck & Co., Inc	ORAL		1407 DAY

Date:11/03/04ISR Number: 4492245-XReport Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR

Date:11/03/04ISR Number: 4492246-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00025
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1632 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Tolterodine Tartrate	C			UNKNOWN	
			Cetirizine Hydrochloride	C			UNKNOWN	

Date:11/03/04ISR Number: 4492247-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01993
Age:47 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Clostridium Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Uterine Leiomyoma		Synthroid	C				

UNKNOWN

Date:11/03/04ISR Number: 4492250-3Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00063
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Occlusion							
Other	Hypertension							

Date:11/03/04ISR Number: 4492251-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00026
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diabetes Mellitus		Acetaminophen	C				
UNKNOWN								
	Myocardial Infarction							

Date:11/03/04ISR Number: 4492252-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02422
Age:20 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
3 DAY								
	Chest Pain							
	Dyspnoea							
	Loss Of Consciousness							
	Pulmonary Congestion							

Date:11/03/04ISR Number: 4492255-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03736
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prevacid	C				
UNKNOWN								
Initial or Prolonged			Lipitor	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								

Date:11/03/04ISR Number: 4492257-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03735
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Levoxyl	C				
UNKNOWN								
Disability			Diovan	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492260-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492261-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03723
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Ulcer Visual Field Defect		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492262-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492264-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03671
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								

Date:11/03/04ISR Number: 4492265-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492268-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03938
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Muscle Twitching		[Therapy					
	Pancreatic Disorder		Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:11/03/04ISR Number: 4492270-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03876
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Stem Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492271-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03802
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Nitro	C				

UNKNOWN

Date:11/03/04ISR Number: 4492272-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03831
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON

Date:11/03/04ISR Number: 4492273-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03751
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Occlusion		Glucophage	C				

UNKNOWN

Date:11/03/04ISR Number: 4492275-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04299
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	151	DAY
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:11/03/04ISR Number: 4492281-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03878
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Lexapro	C				
UNKNOWN								
Initial or Prolonged	Pericardial Effusion							
Disability								

Date:11/03/04ISR Number: 4492282-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04095
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Composition					
Disability			Unspecified]	C				
UNKNOWN								

Date:11/03/04ISR Number: 4492283-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04277
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic							
	Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492284-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03864
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	93	DAY
	Cardiac Stress Test		[Therapy					
	Abnormal		Unspecified]	C			UNKNOWN	
	Chest Pain							
	Drug Ineffective							
	Dyspnoea							
	Heart Injury							
	Myalgia							
	Palpitations							

Date:11/03/04ISR Number: 4492287-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03931
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Seroquel	C			UNKNOWN	
			Cardis	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Meclizine	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	

Date:11/03/04ISR Number: 4492288-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04094
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged	Congestive Myalgia		[Therapy Unspecified]	C			UNKNOWN	
Disability	Renal Disorder		[Composition Unspecified]	C			UNKNOWN	
			Anadrol	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

Date:11/03/04ISR Number: 4492292-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04390
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease		[Therapy Unspecified]	C			UNKNOWN	
Disability	Chest Pain							

Date:11/03/04ISR Number: 4492294-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04336
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Nexium	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4492296-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04340
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/03/04ISR Number: 4492297-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04389
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalat	C				
UNKNOWN								

Date:11/03/04ISR Number: 4492307-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00104
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/03/04ISR Number: 4492804-4Report Type:Direct Company Report #CTU 231122
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eosinophil Count		Vioxx Tablets	PS				
ONE TAB DAILY								
	Increased							

Date:11/03/04ISR Number: 4493601-6Report Type:Direct Company Report #CTU 231136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Arrhythmia Vioxx 25 Mg Merck PS Merck
OROPHARINGEAL 1 TABLET PER
Initial or Prolonged Chest Pain
DAY
Other Ventricular Extrasystoles
ONOPHARING

Date:11/03/04ISR Number: 4493603-XReport Type:Direct Company Report #CTU 231141
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx 12.5 Mg Merck	PS	Merck	
ONE A DAY						
Initial or Prolonged	Diarrhoea					
EVERY MORNING						
	Drug Withdrawal Syndrome					
	Dyspnoea					
	Hypoaesthesia					
	Pain					
	Vomiting					
	Weight Decreased					

Date:11/03/04ISR Number: 4493757-5Report Type:Direct Company Report #CTU 231227
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Flutter		Vioxx	PS		
DAILY AS						
NEEDED						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4492702-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4492898-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Chest Pain							
	Tachycardia							

Date:11/04/04ISR Number: 4492904-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Acute Myocardial Infarction
	Adverse Event
	Aortic Stenosis
	Aortic Valve Calcification
	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Triglycerides Increased
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Diabetes Mellitus

Inadequate Control
Diabetic Neuropathy
Diarrhoea
Dilatation Atrial
Dyspepsia
Dyspnoea Paroxysmal
Nocturnal
Ejection Fraction
Decreased
Electrocardiogram St
Segment Depression
Escherichia Sepsis
Glycosylated Haemoglobin
Increased
Hypertension
Intermittent Claudication
Mitral Valve
Calcification
Mitral Valve Incompetence
Myocardial Infarction

		Oedema Peripheral Orthopnoea Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Occlusive Disease Renal Failure Respiratory Rate Increased Sciatica Spinal Column Stenosis Transient Ischaemic Attack Tricuspid Valve Incompetence Urinary Tract Infection Urosepsis Uterine Infection		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/04/04ISR Number: 4492907-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/04/04ISR Number: 4492908-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00040
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Perforated Ulcer		Bromazepam	C		ORAL

Date:11/04/04ISR Number: 4492909-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Eczema		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fluid Retention					

Pruritus

Date:11/04/04ISR Number: 4492910-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00021
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization - UNKNOWN	Death		Carbamazepine	C				
Initial or Prolonged	Diarrhoea							
	Oedema							

Date:11/04/04ISR Number: 4492911-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Anaemia
	Angina Pectoris

		Back Pain					
		Barrett'S Oesophagus					
		Blood Pressure Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Colonic Polyp		Aspirin	C		
UNKNOWN							
		Constipation		Monopril	C		
UNKNOWN							
		Convulsion		Hydrochlorothiazide	C		
UNKNOWN							
		Coronary Artery Disease					
		Coronary Artery					
		Restenosis					
		Diverticulum Intestinal					
		Erosive Oesophagitis					
		Haemorrhoids					
		Hiatus Hernia					
		Hyperlipidaemia					
		Hypoaesthesia					
		Myocardial Ischaemia					
		Osteoarthritis					
		Rash Erythematous					

Date:11/04/04ISR Number: 4492912-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01715
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Coumadin	C		
UNKNOWN							
		Thrombosis		Celebrex	C		
UNKNOWN							
		Intracardiac Thrombus		[Therapy			
		Thrombosis		Unspecified]	C		
UNKNOWN							

Date:11/04/04ISR Number: 4492913-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01996
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Biliary Colic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Biliary Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cholecystitis Chronic		Aluminum Hydroxide And Magnesium Trisilicate	C			UNKNOWN	
	Gastritis Erosive							
	Hyperlipidaemia							
	Hypertension		Prevacid	C			UNKNOWN	
	Insomnia							
	Oesophagitis							
	Umbilical Hernia							

Date:11/04/04ISR Number: 4492914-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00109
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4492915-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Abnormal Faeces		Prevacid	C				
UNKNOWN								
	Acute Sinusitis		Ultram	C				
UNKNOWN								
	Adverse Event		Norvasc	C				
UNKNOWN								
	Arthralgia		Pulmicort	C				
UNKNOWN								
	Barrett'S Oesophagus		Celebrex	C				
UNKNOWN								
	Benign Duodenal Neoplasm		Maxzide	C				
UNKNOWN								
	Blood Pressure Increased		Estradiol	C				
UNKNOWN								
	Bronchospasm		Singulair	C				
UNKNOWN								
	Brunner'S Gland Hyperplasia							
	Chest Pain							
	Constipation							
	Costochondritis							
	Dermatitis Allergic							
	Diarrhoea							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux Disease							
	Headache							
	Helicobacter Infection							
	Lipids Increased							
	Liver Function Test Abnormal							
	Melaena							
	Neck Pain							
	Otitis Media							
	Pain							
	Pain In Extremity							
	Pharyngitis							
	Pyrexia							
	Rhinitis Allergic							
	Sensation Of Pressure							

	Sinus Congestion					
	Sinusitis					
	Tendonitis					
	Upper Respiratory Tract Infection					

Date:11/04/04ISR Number: 4492919-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04330
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Lortab	C				
Initial or Prolonged Disability								

Date:11/04/04ISR Number: 4492920-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Borrelia Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deafness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vertigo							

Date:11/04/04ISR Number: 4492921-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00003
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/04/04ISR Number: 4492922-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00014
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4492925-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00002
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4492927-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03720
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Thrombosis		Amaryl	C				
Initial or Prolonged UNKNOWN			Glucophage Xr	C				
Disability								

Date:11/04/04ISR Number: 4492930-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00001
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Areflexia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage	Professional	Fluindione	SS		ORAL		
	Drug Interaction		Prazosin	C		ORAL		
	Electroencephalogram		Enalapril Maleate	C				
	Abnormal		Amiodarone	C		ORAL		
	Haemoglobin Decreased		Digoxin	C		ORAL		
	Heart Rate Decreased		Indapamide	C		ORAL		
	Heart Rate Irregular		Insulin Human, Isophane	C		SUBCUTANEOUS		
			Fenofibrate	C		ORAL		

Date:11/04/04ISR Number: 4492931-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02407
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Ineffective		Neurontin	C				
UNKNOWN								
Initial or Prolonged			Norvasc	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Ticlopidine Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4492934-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00169
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Intracardiac Thrombus		Celebrex	C				
UNKNOWN								

Date:11/04/04ISR Number: 4492936-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00002
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
400 DAY								
Initial or Prolonged			Hyzaar	C		ORAL		
Disability			Cetirizine Hydrochloride	C				
UNKNOWN								

Date:11/04/04ISR Number: 4492937-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00163
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/04/04ISR Number: 4492938-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
1 YR								
Initial or Prolonged	Increased		Celecoxib	C		ORAL		
	Blood Pressure Increased		Ramipril	C		ORAL		
	Oedema Peripheral							
	Protein Urine Present							
	Weight Increased							

Date:11/04/04ISR Number: 4492940-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00178
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4492941-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00030
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
	Loss Of Consciousness		Prednisolone	C		ORAL		
			Enalapril Maleate	C		ORAL		

Date:11/04/04ISR Number: 4492942-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4492944-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lanoxin	C				UNKNOWN
	Hypertension		Fosamax	C		ORAL		
	Oedema Peripheral		Coumadin	C				UNKNOWN

Date:11/04/04ISR Number: 4492945-1Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Abnormal		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Hypertension							

Date:11/04/04ISR Number: 4492947-5Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00004
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Gliclazide	C		ORAL		
	Myocardial Infarction							

Date:11/04/04ISR Number: 4492978-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4492979-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04373
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Formication		Prinivil	C			UNKNOWN	
	Hypertension		Premarin	C			UNKNOWN	
	Hypoaesthesia Pain In Extremity		[Therapy Unspecified]	C			UNKNOWN	
			Xanax	C			UNKNOWN	

Date:11/04/04ISR Number: 4492983-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00001
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Myxoma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493357-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Arthralgia
Disability	Back Pain
Other	Balance Disorder

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blindness Blood Glucose Increased Bronchitis					
676	DAY	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Cataract		Provera	SS		
UNKNOWN		Cerebrovascular Accident		Heparin	SS		
UNKNOWN		Convulsion		Captopril	C		
UNKNOWN		Depression		Glyburide	C		
UNKNOWN		Diverticulum Dizziness		[Therapy Unspecified]	C		
UNKNOWN		Endometrial Hyperplasia		Cisapride	C		
UNKNOWN		Epistaxis Flushing		Tylenol With Codeine #3	C		
UNKNOWN		Gastrooesophageal Reflux		Capozide	C		
UNKNOWN		Disease Gout Haemorrhage Intracranial Headache Hemianopia Homonymous Herpes Zoster Hyperhidrosis Hypersensitivity Hypertension Joint Injury Loss Of Consciousness Meningioma Nasal Congestion Nausea Pain Pallor Pneumonia Postmenopausal Haemorrhage Rash Rift Valley Fever Sciatica Spinal Column Stenosis					

Tachycardia
Thyroid Mass
Uterine Polyp
Vaginal Haemorrhage
Visual Field Defect

Date:11/04/04ISR Number: 4493363-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02122
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
	Blood Pressure Systolic Increased
Disability	Chest Pain
Other	Chlamydial Infection
	Depressed Mood
	Depression
	Diarrhoea
	Epididymitis
	Feeling Of Despair
	Groin Pain
	Hyperhidrosis
	Hypoaesthesia

		Injury					
		Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vicodin Tablets	C		
UNKNOWN							
		Nausea		Acetaminophen	C		
UNKNOWN							
		Pain					
		Paraesthesia					
		Scrotal Pain					
		Sensation Of Pressure					
		Sleep Disorder					
		Suicidal Ideation					
		Syncope					
		Tachycardia					
		Varicocele					

Date:11/04/04ISR Number: 4493366-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00752
Age:85 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris					
		Blood Pressure Increased					
		Convulsion					
		Death					

Date:11/04/04ISR Number: 4493369-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02622
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Fluctuation		Darvocet-N	C		
UNKNOWN							
Initial or Prolonged		Depression					
Disability		Hypertension					
		Hypotension					
		Impaired Healing					

Date:11/04/04ISR Number: 4493372-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00355
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Hospitalization - Initial or Prolonged	Congestive Dizziness Dysgeusia Oedema Peripheral Pyrexia Renal Failure Acute		Amlodipine Besylate	C		ORAL		

Date:11/04/04ISR Number: 4493376-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00095
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Malignant Neoplasm Of Orbit		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	

Other

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4493377-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02093
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	Chest Pain		Zocor	C			UNKNOWN	
	Feeling Abnormal		Diovan	C		ORAL		
	Vein Pain		Amoxil	C		ORAL		
			Lescol	C		ORAL		
			Klor-Con	C		ORAL		
			Ibuprofen	C		ORAL		
			Tiazac	C		ORAL		
			Prevacid	C		ORAL		
			Aspirin	C		ORAL		
			Hydrocodone Hydrochloride	C			UNKNOWN	
			Carisoprodol	C		ORAL		

Date:11/04/04ISR Number: 4493378-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00780
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493380-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00494
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Increased Delusion		Venlafaxine Hydrochloride	SS		ORAL	39	DAY

	Hallucination, Olfactory		Trimipramine Maleate	SS	ORAL
39 DAY					
	Hepatitis		Lorazepam	C	ORAL
39 DAY					
	Hepatocellular Damage		Carbimazole	C	ORAL
	Lipase Increased		Tamsulosin Hydrochloride	C	
UNKNOWN					
			Simvastatin	C	
UNKNOWN					

Date:11/04/04ISR Number: 4493382-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00050
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Hospitalization -			Omeprazole	C		
UNKNOWN						
Initial or Prolonged						

Date:11/04/04ISR Number: 4493387-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00449
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Cardiac Flutter
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Chest Pain
Disability	Diarrhoea
Other	Dizziness
	Dyspnoea

	Headache Hypoaesthesia Pain In Extremity	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lipitor	C				UNKNOWN
			Zyrtec	C				UNKNOWN

Date:11/04/04ISR Number: 4493388-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02610
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		718 DAY
Hospitalization -	Congestive		Aldactone	C				UNKNOWN
Initial or Prolonged	Gastrooesophageal Reflux		Lasix (Furosemide)	C				UNKNOWN
	Disease		Amiodarone	C				UNKNOWN
			Lopressor	C				UNKNOWN
			Nitroglycerin	C				UNKNOWN
			Motrin	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Prinivil	C		ORAL		
			Protonix	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:11/04/04ISR Number: 4493390-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00692
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/04/04ISR Number: 4493391-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04311
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		[Therapy					
Initial or Prolonged	Attack		Unspecified]	C				
UNKNOWN								
Disability			[Therapy					
			Unspecified]	C				
UNKNOWN								
			Patanol	C				
UNKNOWN								

Date:11/04/04ISR Number: 4493392-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04305
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				
UNKNOWN								

Date:11/04/04ISR Number: 4493393-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04307
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Methotrexate	C				
UNKNOWN								
Initial or Prolonged	Muscle Spasms		Prednisone	C				
UNKNOWN								
Disability	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4493394-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04310
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Defaecation Urgency		Lopressor	C				UNKNOWN
			Pepcid Ac	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:11/04/04ISR Number: 4493395-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03119
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lung Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		865 DAY
Initial or Prolonged	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		865 DAY
Disability	Renal Disorder		Flexeril	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Ismo	C				UNKNOWN
			Corgard	C				UNKNOWN

Date:11/04/04ISR Number: 4493396-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04141
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization -			Zocor	C				UNKNOWN
Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
Disability								

			Norvasc	C			
UNKNOWN							
			Tramadol Hydrochloride	C			
UNKNOWN							
			Aspirin	C			
UNKNOWN							

Date:11/04/04ISR Number: 4493398-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04325
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
Disability								

Date:11/04/04ISR Number: 4493399-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04319
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	87	DAY
Initial or Prolonged	Chest Pain		Furosemide	C				
UNKNOWN								
Other	Dyspnoea		Nortriptyline	C				
UNKNOWN								
	Gastritis		Avapro	C				
UNKNOWN								
			Zocor	C		ORAL		
			Atenolol	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4493400-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493402-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04023
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493404-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493405-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00008
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lipitor	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/04/04ISR Number: 4493406-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04331
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Vitamins					

	Heart Rate Irregular		(Unspecified)	C			
UNKNOWN							

Date:11/04/04ISR Number: 4493408-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00061
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Dilantin	C		
UNKNOWN						
Initial or Prolonged			Zocor	C		
UNKNOWN						
			Moexipril Hydrochloride	C		
UNKNOWN						

Date:11/04/04ISR Number: 4493409-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00029
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Confusional State		Sertraline Hydrochloride	C		
Disability	Transient Ischaemic					
UNKNOWN						
	Attack		Perindopril	C		
UNKNOWN						
			Estrogens, Conjugated	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4493410-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00016
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lymphoproliferative		Vioxx	PS	Merck & Co., Inc	ORAL		1273 DAY
	Disorder		Dihydrocodeine	C		ORAL		
			Acetaminophen	C				UNKNOWN
			Acetaminophen	C		ORAL		
			Benzydamine Hydrochloride	C		ORAL		
			Lisinopril	C		ORAL		
			Amlodipine Maleate	C		ORAL		

Date:11/04/04ISR Number: 4493411-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00001
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose							

Date:11/04/04ISR Number: 4493413-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Dyspnoea							

Date:11/04/04ISR Number: 4493418-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/04/04ISR Number: 4493419-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00078
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability			Nexium	C				
UNKNOWN								

Date:11/04/04ISR Number: 4493420-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00007
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

[Therapy
Unspecified] C
UNKNOWN

Date:11/04/04ISR Number: 4493424-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00007
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		22 MON
Initial or Prolonged			Risedronate Sodium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Oxazepam	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Aspirin	C		ORAL		
			Nitroglycerin	C		TOPICAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Lansoprazole	C		ORAL		
			Verapamil	C		ORAL		

Date:11/04/04ISR Number: 4493426-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/04/04ISR Number: 4493442-XReport Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00042
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Initial or Prolonged	Balance Disorder Chest Discomfort Dyskinesia Loss Of Consciousness Speech Disorder		Etodolac	C		ORAL

Date:11/04/04ISR Number: 4493443-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00065
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Glucagon	C		
UNKNOWN						
Disability						

Date:11/04/04ISR Number: 4493444-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00262
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Uterine Leiomyoma		Humalog	C		
UNKNOWN						
			Cimetidine	C		
UNKNOWN						

Metformin	C	UNKNOWN
Verapamil	C	UNKNOWN
Metoclopramide	C	UNKNOWN
Benazepril Hydrochloride	C	UNKNOWN

Date:11/04/04ISR Number: 4494370-6Report Type:Direct Company Report #CTU 231345
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia Paraesthesia		Vioxx 25 Mg Merck And Co	PS	Merck And Co		1-25 MG TAB DAILY BY MOUTH	5 YR

Date:11/04/04ISR Number: 4494387-1Report Type:Direct Company Report #CTU 231349
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx- 25 Mg	PS			ONCE A DAY AS NEEDED	
Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:11/04/04ISR Number: 4494408-6Report Type:Direct Company Report #CTU 231304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx 25 Mg (Took 50 Mg For 2 Months)	PS			ONCE A DAY, SOMEDAY TWICE	
			Norvasc	C				
			Hyzaar	C				
			Ambien	C				
			Benadryl	C				
			Prilosec	C				

Date:11/04/04ISR Number: 4494429-3Report Type:Direct Company Report #CTU 231351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal		Vioxx 25 Mg	PS			1-25 MG AT BEDTIME	
	Nephritis Interstitial							

Date:11/04/04ISR Number: 4494939-9Report Type:Direct Company Report #CTU 231321
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx 25 Mg Merck	PS	Merck		ONE A DAY 25 MG	
	Fear							
	Headache							
	Neck Pain							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/04/04ISR Number: 4494941-7Report Type:Direct Company Report #CTU 231328
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx Merck	PS	Merck		25 MG ONCE DAILY [WHEN FIRST CAME TO MARKET UNTIL DAY OF	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage								

Date:11/04/04ISR Number: 4494942-9Report Type:Direct Company Report #CTU 231329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Feeling Abnormal		Vioxx 25 Mg	PS			25 MG DAILY UNTIL THEY INCREASED IT TO 50 MG DAILY	
	Insomnia							
	Nervous System Disorder							
	Paraesthesia							
	Respiratory Disorder							

Date:11/04/04ISR Number: 4497409-7Report Type:Expedited (15-DaCompany Report #2004062831
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	No Adverse Drug Effect	Consumer	Neurontin (Gabapentin) Oxycocet (Oxycodone Hydrochloride,	PS				

				Paracetamol)	SS		
				Paroxetine Hydrochloride (Paroxetine Hydrochloride)	SS		
				Rofecoxib (Rofecoxib)	SS		
				Methylphenidate Hydrochloride (Methylphenidate Hydrochloride)	SS		
				Fentanyl (Fentanyl)	SS		

Date:11/04/04ISR Number: 4497415-2Report Type:Expedited (15-DaCompany Report #2004063259
Age: Gender:Unknown I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Oesophageal Ulcer	Consumer	Neurontin (Gabapentin)	PS				
			Motrin (Ibuprofen)	SS				
			Rofecoxib (Rofecoxib)	SS				

Date:11/05/04ISR Number: 4494051-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00754
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							

Date:11/05/04ISR Number: 4494056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00690
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aphonia							
	Arrhythmia							
	Back Pain							
	Burning Sensation							
	Bursitis							
	Gastritis							
	Headache							
	Hypertension							
	Joint Dislocation							
	Meniscus Lesion							
	Osteoarthritis							
	Pain In Extremity							
	Pyrexia							
	Rheumatoid Arthritis							
	Sciatica							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Sneezing							
	Synovitis							
	Tarsal Tunnel Syndrome							

Date:11/05/04ISR Number: 4494058-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00865
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Chest Discomfort	Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain	Vioxx	SS	Merck & Co., Inc	ORAL
	Depression	Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetes Mellitus Non-Insulin-Dependent	Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea				
	Effusion				
	Hyperlipidaemia				
	Muscle Strain				
	Osteoarthritis				
	Skin Lesion				
	Superficial Injury Of Eye				
	Thirst				
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494059-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Zydone	C				
UNKNOWN								
	Convulsion		Prozac	C		ORAL		
	Coronary Artery Disease		Prilosec	C		ORAL		
	Joint Dislocation		Elavil	C				
UNKNOWN								
	Lumbar Radiculopathy		Zanaflex	C		ORAL		
	Myocardial Infarction		Aleve	C				
UNKNOWN								
	Spinal Osteoarthritis							
	Urinary Tract Disorder							

Date:11/05/04ISR Number: 4494061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Barrett'S Oesophagus		Zocor	SS		ORAL		
Disability	Benign Prostatic		[Therapy					
Other	Hyperplasia		Unspecified]	C				
UNKNOWN								
	Bladder Obstruction		Tylenol Arthritis					
	Cardiac Failure		Extended Relief	C				
UNKNOWN								
	Congestive		Diltiazem Msd	C				
UNKNOWN								
	Cellulitis		Aspirin	C				
UNKNOWN								
	Chronic Obstructive		Hydrocodone					
	Pulmonary Disease		Bitartrate	C				
UNKNOWN								
	Constipation		Accupril	C				
UNKNOWN								
	Coronary Artery Disease		Glucophage	C				
UNKNOWN								
	Cough		Glyburide	C				
UNKNOWN								

Duodenal Ulcer
Emotional Distress
Gastrooesophageal Reflux
Disease
Haemodialysis
Hiatus Hernia
Injury
Interstitial Lung Disease
Leukocytosis
Meniscus Lesion
Monarthritis
Myocardial Infarction
Oesophageal Ulcer
Pain In Extremity
Renal Failure
Renal Tubular Necrosis
Rhabdomyolysis
Rotator Cuff Syndrome

Date:11/05/04ISR Number: 4494067-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization - Initial or Prolonged	Back Disorder
Other	Cerebrovascular Accident
	Chest Discomfort
	Depression

	Drug Ineffective Pain In Extremity Paraesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Postoperative Infection		Vioxx	PS	Merck & Co., Inc	ORAL	
	Staphylococcal Infection		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Premarin	C			UNKNOWN
			Percocet	C			UNKNOWN

Date:11/05/04ISR Number: 4494070-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00040
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer Perforation Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	
			Bromazepam	C		ORAL	

Date:11/05/04ISR Number: 4494072-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00330
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:11/05/04ISR Number: 4494073-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00018
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
			Aspirin	C		ORAL	
			Gastrointestinal Preparations (Unspecified)	C		ORAL	
			Bendroflumethiazide	C		ORAL	
			Bendroflumethiazide	C		ORAL	

Simvastatin	C	ORAL
Omeprazole	C	ORAL
Cholecalciferol	C	ORAL
Etidronate Disodium	C	ORAL
Calcium (Unspecified)	C	ORAL
Acetaminophen	C	ORAL
Allopurinol	C	ORAL

Date:11/05/04ISR Number: 4494074-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Blood Glucose Abnormal
	Cardiac Failure Congestive
	Cerebrovascular Accident
	Cholelithiasis
	Colon Neoplasm
	Decubitus Ulcer
	Depression

		Diverticulitis					
		Electrolyte Imbalance					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
		Femur Fracture		Tagamet	C		
UNKNOWN							
		Gastritis Erosive		Estropipate	C		
UNKNOWN	3956 DAY						
		Insomnia		Drixoral	C		
UNKNOWN							
		Liver Disorder		Tiazac	C		
UNKNOWN							
		Obesity		Iron (Unspecified)	C		
UNKNOWN							
		Pneumatosis Cystoides		Aspirin	C		
UNKNOWN							
		Intestinalis		Vitamin E	C		
UNKNOWN							
		Rash		Calcium			
		Reflux Oesophagitis		(Unspecified)	C		
UNKNOWN							
				Magnesium			
				(Unspecified)	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN	1218 DAY						
				Potassium			
				(Unspecified)	C		
UNKNOWN							

Date:11/05/04ISR Number: 4494075-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00044
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Vioxx	SS	Merck & Co., Inc	ORAL	75 DAY
	Cyproterone Acetate	C		ORAL	

Date:11/05/04ISR Number: 4494076-3Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00036
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cyanosis		Losec (Omeprazole)	C		ORAL		
	Hypertension		Cartia (Aspirin)	C		ORAL		
	Palpitations		Lipex	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Amazide	C		ORAL		
			Flecainide Acetate	C		ORAL		

Date:11/05/04ISR Number: 4494077-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01038
Age:19 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Anaemia
	Chest Wall Pain
Other	Fluid Retention
	Headache
	Nausea
	Oedema Peripheral
	Pain
	Thrombotic
	Thrombocytopenic Purpura

Weight Decreased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Hormonal Contraceptives (Unspecified)	C				

UNKNOWN

Date:11/05/04ISR Number: 4494078-7Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00051
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494083-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02458
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
			Prinivil	C		ORAL		
			Atenolol	C				
			Hydrodiuril	C		ORAL		
			Nexium	C				

UNKNOWN

Date:11/05/04ISR Number: 4494084-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00423
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY

Initial or Prolonged			Propranolol Hydrochloride	C		
UNKNOWN	YR					

Date:11/05/04ISR Number: 4494085-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01126
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain					
Disability	Heart Rate Irregular					
	Hypertrophy					
	Limb Injury					
	Rotator Cuff Syndrome					

Date:11/05/04ISR Number: 4494087-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02109
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Fatigue		[Therapy			
Initial or Prolonged	Gastric Haemorrhage		Unspecified]	C		
UNKNOWN						
Disability	Oesophageal Ulcer		Metformin	C		
UNKNOWN						
			[Therapy			

	Unspecified]	C	UNKNOWN
	[Therapy Unspecified]	C	UNKNOWN
	Zocor	C	UNKNOWN
	Flomax (Morniflumate)	C	UNKNOWN
	Aspirin	C	UNKNOWN
	Trusopt	C	UNKNOWN
	Vicodin Tablets	C	UNKNOWN

Date:11/05/04ISR Number: 4494089-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03715
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494090-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01829
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Acute Myocardial Infarction Blood Cholesterol Increased Cardiac Arrest Diabetes Mellitus Lipids Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494091-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03129
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Hospitalization - Initial or Prolonged	Blood Triglycerides Increased		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Percocet	C				
Disability	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Chest Pain		Paxil	C			UNKNOWN	
	Faeces Discoloured		Naproxen	C			UNKNOWN	
	Meningitis		Misoprostol	C			UNKNOWN	
	Neurological Symptom		Nasonex	C			UNKNOWN	
	Palpitations		Mirapex	C			UNKNOWN	
	Tachycardia		Hydrocodone/Apap	C			UNKNOWN	
	Transient Ischaemic		Gemfibrozil	C			UNKNOWN	
	Attack		Dicloxacillin	C			UNKNOWN	
	Ventricular Hypertrophy		Fluoxetine	C			UNKNOWN	

Date:11/05/04ISR Number: 4494092-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lipitor	C				
			Metformin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	

Date:11/05/04ISR Number: 4494093-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03676
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Neurontin	C			UNKNOWN	
			Atenolol And Hydrochlorothiazide	C			UNKNOWN	
			Mavik	C			UNKNOWN	
			Celexa	C			UNKNOWN	

Date:11/05/04ISR Number: 4494095-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03709
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Disability								

Date:11/05/04ISR Number: 4494096-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03757
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastrooesophageal Reflux		Toprol Xl Tablets	C			UNKNOWN	
Disability	Disease		Glucophage	C			UNKNOWN	
	Hypertension		Albuterol	C			UNKNOWN	
	Ulcer							

Date:11/05/04ISR Number: 4494097-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03832
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494099-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04179
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx Synthroid	SS C	Merck & Co., Inc	ORAL		
UNKNOWN								
Disability								

Date:11/05/04ISR Number: 4494103-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03808
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Hospitalization - Initial or Prolonged			[Composition Unspecified]	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494104-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04251
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization - Initial or Prolonged Disability	Chest Pain Dyspnoea							

Date:11/05/04ISR Number: 4494105-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Emotional Distress Fear Of Disease Heart Injury Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494108-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494109-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Hypertension Myocardial Infarction Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		24 MON

Date:11/05/04ISR Number: 4494110-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04381
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Atenolol	C				
Initial or Prolonged UNKNOWN	Physical Disability		Estradiol	C				
Disability UNKNOWN			[Therapy Unspecified]	C				
UNKNOWN			Protonix	C				
UNKNOWN			Potassium (Unspecified)	C				
UNKNOWN			Acyclovir	C				
UNKNOWN			Tylenol With Codeine #3	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494111-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494112-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494113-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00007
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Impaired Work Ability		Enalapril Maleate	C			UNKNOWN	

Date:11/05/04ISR Number: 4494114-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00030
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Cardiac Failure Congestive Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494116-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/05/04ISR Number: 4494117-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03702
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/05/04ISR Number: 4494118-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04176
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		[Therapy Unspecified]	C				
Disability	Dizziness							
UNKNOWN								
	Haematemesis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494119-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Death							

Date:11/05/04ISR Number: 4494120-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04398
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/05/04ISR Number: 4494121-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04275
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			[Therapy Unspecified]	C			UNKNOWN	
			Mobic	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Ambien	C			UNKNOWN	

Date:11/05/04ISR Number: 4494130-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00167
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Cerebrovascular Accident
Cerebrovascular Disorder
Myocardial Infarction

Date:11/05/04ISR Number: 4494131-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00165
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494132-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0403AUS00318
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arthralgia Back Pain Convulsion		Vioxx Venlafaxine Hydrochloride	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
	Fatigue		Pantoprazole Sodium	C			UNKNOWN	
	Nasopharyngitis		Atorvastatin Calcium	C			UNKNOWN	
	Sepsis Urinary Retention		Aspirin And Dipyridamole	C			UNKNOWN	
	Urinary Tract Infection		Metoprolol Tartrate	C			UNKNOWN	
			Bicalutamide	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494133-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494134-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00613
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion Diabetes Mellitus							

Date:11/05/04ISR Number: 4494135-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494144-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00071
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Benazepril Hydrochloride	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

Date:11/05/04ISR Number: 4494153-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03701
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	4	MON
	Hypoaesthesia		Os-Cal	C			UNKNOWN	
	Musculoskeletal Stiffness		Tylenol	C			UNKNOWN	
	Pain		Centrum	C			UNKNOWN	
			Pepcid	C		ORAL		

Date:11/05/04ISR Number: 4494157-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04423
Age:54 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Chest Pain
	Cold Sweat
	Dizziness
	Dyspnoea

	Fatigue Vein Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				UNKNOWN

Date:11/05/04ISR Number: 4494533-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Lortab	C				UNKNOWN
	Chest Discomfort		Soma	C				UNKNOWN
	Convulsion		Viagra	C				UNKNOWN
	Coronary Artery Disease		Vicodin Tablets	C				UNKNOWN
	Coronary Artery		Temazepam	C				UNKNOWN
	Restenosis							
	Hot Flush							
	Myocardial Infarction							
	Pulmonary Hypertension							
	Radial Tunnel Syndrome							
	Rotator Cuff Syndrome							
	Thrombosis							

Date:11/05/04ISR Number: 4494537-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Aortic Calcification
	Aortic Valve Disease

Aortic Valve Incompetence
Arthralgia
Blood Glucose Increased
Blood Pressure Systolic
Increased
Cardiac Disorder
Carotid Artery Occlusion
Chest Discomfort
Chest Pain
Convulsion
Coronary Artery Disease
Coronary Artery Stenosis
Diabetes Mellitus
Dyspnoea
Dyspnoea Exertional
Faecal Occult Blood
Positive
Feeling Abnormal
Gastric Ulcer
Gastrointestinal
Haemorrhage
Glycosylated Haemoglobin
Increased
Haemorrhage

		Herpes Zoster					
		Hypertension					
		Lung Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Melaena		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vitamin E	C		
UNKNOWN							
		Monarthritis		Ascorbic Acid	C		
UNKNOWN							
		Myocardial Infarction		Omega-3	C		
UNKNOWN							
		Myocardial Ischaemia		Centrum	C		
UNKNOWN							
		Pain		Zyloprim	C		
UNKNOWN							
		Pallor		Pravachol	C		
UNKNOWN							
		Pleural Effusion		Glucophage	C		
UNKNOWN							
		Respiratory Rate		Aspirin	C		
UNKNOWN							
		Increased		Altace	C		
UNKNOWN							
		Sinus Tachycardia		Cardizem	C		
UNKNOWN							
		Tricuspid Valve		Vitamin B Complex	C		
UNKNOWN							
		Incompetence		Avandia	C		
UNKNOWN							
		Ventilation/Perfusion		Viagra	C		
UNKNOWN							
		Scan Abnormal		Imdur	C		
UNKNOWN							
		Ventricular Hypokinesia					

Date:11/05/04ISR Number: 4494541-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00750
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris		Ultram	C		
UNKNOWN							

	Blood Pressure Increased		Zestril	C		
UNKNOWN						
	Convulsion					
	Death					

Date:11/05/04ISR Number: 4494545-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00653
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Diastolic		Vioxx	SS	Merck & Co., Inc	ORAL
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain		Claritin	C		
UNKNOWN						
	Depression		Analgesic Or			
	Dizziness		Anesthetic			
	Exostosis		(Unspecified)	C		
UNKNOWN						
	Hyperlipidaemia					
	Hypertension					
	Hypotension					
	Insomnia					
	Limb Injury					
	Pain In Extremity					
	Prostatitis					
	Proteinuria					
	Suicidal Ideation					
	Tendon Rupture					
	Tinea Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494546-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00729
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vasotec	C		ORAL		
Disability	Arthralgia		Lipitor	C				
UNKNOWN								
Other	Atrial Flutter		Aspirin	C				
UNKNOWN								
	Basal Ganglion		Verelan	C				
UNKNOWN								
	Degeneration		Nitrostat	C				
UNKNOWN								
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chest Discomfort							
	Convulsion							
	Coronary Artery							
	Atherosclerosis							
	Dyspepsia							
	Dyspnoea							
	Ear Disorder							
	Fall							
	Headache							
	Hiatus Hernia							
	Hypoaesthesia							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Palpitations							
	Paraesthesia							
	Peptic Ulcer							
	Renal Impairment							
	Urinary Retention							
	Ventricular Dysfunction							
	Vertigo							

Date:11/05/04ISR Number: 4494548-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Actinic Keratosis	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Adverse Event	Coumadin	C		
Disability	Benign Prostatic	Coumadin	C		
UNKNOWN					
	Hyperplasia				
	Bladder Diverticulum				
	Bladder Trabeculation				
	Blood Pressure Increased				
	Cardiac Failure				
	Congestive				
	Coronary Artery				
	Atherosclerosis				
	Hypercapnia				
	Ischaemic Cardiomyopathy				
	Mitral Valve Incompetence				
	Neoplasm				
	Polytraumatism				
	Tricuspid Valve				
	Incompetence				
	Urinary Retention				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494553-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00206
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Fenofibrate	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Bisoprolol	C		ORAL		
			Omeprazole	C		ORAL		
			Allopurinol	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:11/05/04ISR Number: 4494555-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00091
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL		186 DAY
			Repaglinide	C		ORAL		

Date:11/05/04ISR Number: 4494556-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vicodin Tablets	C		ORAL		
	Asthenia		Flexeril	C		ORAL		
	Back Pain		Flexeril	C		ORAL		
	Buttock Pain							
	Cyst							
	Diarrhoea							
	Difficulty In Walking							
	Drug Ineffective							
	Exercise Tolerance Decreased							
	Fall							
	Gastritis							

Haematochezia
Hiatus Hernia
Hypoaesthesia
Injury
Insomnia
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Limb Discomfort
Muscle Spasms
Nausea
Oedema Peripheral
Osteoarthritis
Pain In Extremity
Post Laminectomy Syndrome
Radiculitis Lumbosacral
Sacroiliitis
Scar
Vomiting

Date:11/05/04ISR Number: 4494559-6Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00038
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anal Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Rupture							
	Chest Pain							
	Cholecystitis							
	Gastrointestinal Haemorrhage							
	Gastrointestinal Ulcer							
	Haematochezia							
	Haemoglobin Decreased							
	Headache							
	Mouth Ulceration							
	Proctitis							

Date:11/05/04ISR Number: 4494560-2Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00033
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysphoria		Fentanyl	C				
	Dyspnoea		Acetaminophen And Propoxyphene Napsylate	C				
	Electrocardiogram T Wave Abnormal		Indomethacin	C				
	Insomnia		Red Sage	C				
	Nausea							
	Vomiting							

Date:11/05/04ISR Number: 4494561-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00236
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		

Disability	Coronary Artery Disease

Date:11/05/04ISR Number: 4494563-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02996
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Accident At Work
Disability	Adhesiolysis
Other	Anger
	Ankle Fracture
	Anxiety
	Back Injury
	Chest Pain
	Constipation
	Coronary Artery Disease
	Costochondritis
	Depression
	Diabetes Mellitus
	Discomfort
	Dry Mouth
	Dysgeusia
	Dyspnoea

		Eating Disorder					
		Emotional Disorder					
		Erectile Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Cold		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache					
		Heart Rate Irregular					
		Hypertension					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Effusion					
		Joint Injury					
		Joint Sprain					
		Major Depression					
		Meniscus Lesion					
		Musculoskeletal Stiffness					
		Myofascial Pain Syndrome					
		Nausea					
		Neck Pain					
		Orchitis					
		Osteoarthritis					
		Pain					
		Palpitations					
		Patellofemoral Pain					
		Syndrome					
		Pruritus					
		Pyrexia					
		Radiculitis Lumbosacral					
		Spinal Cord Compression					
		Spinal Fracture					
		Spinal Fusion Surgery					
		Tachycardia					
		Tendonitis					
		Tinnitus					
		Urinary Incontinence					
		Weight Abnormal					

Date:11/05/04ISR Number: 4494564-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02931
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Evista	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	
			Torsemide	C			UNKNOWN	
			Carbatrol	C			UNKNOWN	
			Dicyclomine Hydrochloride	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	

[Therapy
Unspecified] C
UNKNOWN

Date:11/05/04ISR Number: 4494565-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00714
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cyanocobalamin	C				UNKNOWN
			Folic Acid	C				UNKNOWN
			Thiamine	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Glyburide	C				UNKNOWN
			Hydrodiuril	C		ORAL		
			Aspirin	C				UNKNOWN
			Periostat	C				UNKNOWN

Date:11/05/04ISR Number: 4494566-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00842
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Suicidal Ideation							

Date:11/05/04ISR Number: 4494568-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00392
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494569-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04126
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea							
	Overdose							

Date:11/05/04ISR Number: 4494570-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04123
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
			Baclofen	C			UNKNOWN	UNKNOWN
			Methocarbamol	C			UNKNOWN	UNKNOWN
			Amitriptylin	C			UNKNOWN	UNKNOWN
			Furosemide	C			UNKNOWN	UNKNOWN
			Folic Acid	C			UNKNOWN	UNKNOWN
			Oxycontin	C			UNKNOWN	UNKNOWN
			Dicyclomine Hydrochloride	C			UNKNOWN	UNKNOWN
			Zovirax	C			UNKNOWN	UNKNOWN
			Crestor	C			UNKNOWN	UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN	UNKNOWN
			Advair	C			UNKNOWN	UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494571-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00096
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	270 DAY	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	270 DAY	
	Influenza		Ultram	C		ORAL	270 DAY	
	Therapeutic Response		Flexeril	C		ORAL	279 DAY	
	Decreased		Tylenol	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Valium	C		ORAL	1 DAY	

Date:11/05/04ISR Number: 4494573-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00074
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Losec (Omeprazole Magnesium)	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Premarin	C			UNKNOWN	

Date:11/05/04ISR Number: 4494574-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03064
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Anxiety
	Depression
	Emotional Distress
	Myocardial Infarction
	Pain
	Thrombosis

Date:11/05/04ISR Number: 4494575-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03891
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Menorrhagia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Polymenorrhoea							
	Stomach Discomfort							

Date:11/05/04ISR Number: 4494576-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04125
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Headache							
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494577-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04134
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Insulin	C				
UNKNOWN								
	Coronary Artery Disease							
	Myocardial Infarction							

Date:11/05/04ISR Number: 4494578-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494580-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04137
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		Lasix (Furosemide)	C				
UNKNOWN								
Other	Myocardial Infarction		Valium	C				
UNKNOWN								
	Tachycardia		Lortab	C				
UNKNOWN								
	Ventricular Extrasystoles		Skelaxin	C				
UNKNOWN								

Date:11/05/04ISR Number: 4494583-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04296
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged			Norvasc	C			
UNKNOWN							
Disability			K-Dur	C			
UNKNOWN							
			Aspirin	C			
UNKNOWN							
			Zantac	C			
UNKNOWN							
			Imdur	C			
UNKNOWN							
			Vasotec	C			
UNKNOWN							

Date:11/05/04ISR Number: 4494584-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04359
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Pulmonary Embolism		Lipitor	C				
UNKNOWN								
Initial or Prolonged			Lisinopril	C				
UNKNOWN								

Date:11/05/04ISR Number: 4494586-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04399
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Loss Of Consciousness		Tylenol	C				
UNKNOWN								
			Phenobarbital	C				
UNKNOWN								
			Dilantin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494587-0Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00031
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON
	Myocardial Infarction							
	Sudden Death							

Date:11/05/04ISR Number: 4494589-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0411AUT00003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Cardiac Failure							

Date:11/05/04ISR Number: 4494590-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Oedema							
Initial or Prolonged								

Date:11/05/04ISR Number: 4494594-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00046
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR

Date:11/05/04ISR Number: 4494595-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00086
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Diovan	C				
			Furosemide	C				
			Digitek	C				
			Fosamax	C				
			Casodex	C				
			Pravachol	C				
			Cardizem	C				
			Coumadin	C				

Date:11/05/04ISR Number: 4494596-1Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494597-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00014
Age:62 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Dyspnoea
Disability	Heart Rate Irregular

Pain In Extremity

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Lipitor	C			UNKNOWN	
	Drazifon	C			UNKNOWN	
	Triamterene	C			UNKNOWN	
	Actonel	C			UNKNOWN	

Date:11/05/04ISR Number: 4494599-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00025
Age:18 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastritis		Indomethacin	SS				
	Hyperkalaemia							
	Hypernatraemia							
	Irritability							
	Malaise							
	Metabolic Acidosis							
	Prescribed Overdose							
	Renal Failure Acute							
	Vomiting							

Date:11/05/04ISR Number: 4494600-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00045
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia Alzheimer'S Type		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/05/04ISR Number: 4494601-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00236
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Norvasc	C				
	Dyspnoea		Fluvoxamine Maleate	C				

Date:11/05/04ISR Number: 4494602-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04306
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1518 DAY	
Hospitalization - Initial or Prolonged	Myocardial Infarction		Synthroid	C			UNKNOWN	

Date:11/05/04ISR Number: 4494603-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cold Sweat							
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494604-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00225
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gallbladder Disorder		Baclofen	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

Date:11/05/04ISR Number: 4494610-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00019
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
Initial or Prolonged			Zocor	C		ORAL		

Date:11/05/04ISR Number: 4494613-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
536 DAY								
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
214 DAY								
Other	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
536 DAY								
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
214 DAY								
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Buspar	C		ORAL		
405 DAY								
			Lortab	C		ORAL		
573 DAY								

			Ziac	C	ORAL
322 DAY					
			Vicodin Tablets	C	ORAL
			Lipitor	C	ORAL
			Valium	C	ORAL
214 DAY					
			Talwin	C	ORAL
24 DAY					
			Ultram	C	ORAL
9 DAY					
			Skelaxin	C	ORAL
14 DAY					
			Tenyl	C	
UNKNOWN	36 DAY				

Date:11/05/04ISR Number: 4494615-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00052
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Pulmonary Embolism		Lortab	C		
UNKNOWN						
Initial or Prolonged						

Date:11/05/04ISR Number: 4494617-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00267
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY						
Initial or Prolonged						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/04ISR Number: 4494945-4Report Type:Direct Company Report #CTU 231416
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx 25mg Merck	PS	Merck	ORAL	HALF OF 25MG	
Hospitalization -	Coronary Artery Occlusion						DAILY ORAL	
Initial or Prolonged	Dyspnoea							
	Dyspnoea Exertional							
	Headache							
	Hypertension							
	Swelling							
	Urinary Tract Disorder							

Date:11/05/04ISR Number: 4494960-0Report Type:Direct Company Report #CTU 231398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Fear		Vioxx 50 Mg					
Intervention to	Hypertensive Crisis		Merck	PS	Merck	ORAL	1 TAB PO	
Prevent Permanent	Infected Cyst						EVERY DAY	
Impairment/Damage	Morbid Thoughts						ORAL	
	Renal Cyst							

Date:11/05/04ISR Number: 4494975-2Report Type:Direct Company Report #CTU 231404
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg					
Hospitalization -	Myocardial Infarction		Merck	PS	Merck		25MG	
Initial or Prolonged							DAY	
Disability			Vioxx	SS			50MG DAY	
Required								

Intervention to
Prevent Permanent
Impairment/Damage

Date:11/08/04ISR Number: 4495536-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01444
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Perforation		Trental	C				
UNKNOWN								
Disability	Myocardial Infarction		Zocor	C		ORAL		

Date:11/08/04ISR Number: 4495625-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00004
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Cholesterol
Disability	Increased
Other	Breast Disorder
	Cardiac Murmur
	Cardiac Valve Disease
	Cervicobrachial Syndrome
	Depression
	Dizziness
	Dyspnoea

		Dysuria					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Celebrex	C		
UNKNOWN							
		Disorder		Vicodin Tablets	C		
UNKNOWN							
		Micturition Urgency		Percocet	C		
UNKNOWN							
		Muscle Strain		Darvocet-N	C		
UNKNOWN							
		Nocturia		Soma	C		
UNKNOWN							
		Osteoarthritis		Oxycontin	C		
UNKNOWN							
		Osteopenia		Ibuprofen	C		
UNKNOWN							
		Pollakiuria		Aleve	C		
UNKNOWN							
		Sleep Apnoea Syndrome					

Date:11/08/04ISR Number: 4495644-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anorexia
Other	Atrial Fibrillation
	Blood Albumin Decreased
	Blood Cholesterol Increased
	Bronchial Infection
	Bronchiectasis
	Bronchitis
	Bronchitis Chronic
	Candidiasis
	Cardiac Disorder
	Cardiac Failure Congestive
	Cerebrovascular Accident
	Chills
	Chronic Obstructive

Pulmonary Disease
Conjunctivitis
Corneal Disorder
Diarrhoea
Drug Hypersensitivity
Dry Mouth
Dyspepsia
Fall
Fatigue
Head Discomfort
Hiatus Hernia
Hypoxia
Injury
Lobar Pneumonia
Mitral Valve Incompetence
Muscle Spasms
Nausea
Oedema Peripheral
Oxygen Saturation
Decreased
Pain
Palpitations
Pneumonia
Pseudomonas Infection

		Pulmonary Hypertension					
		Skin Laceration					
		Sputum Culture Positive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tremor		Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Decreased		Premarin	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							
				Azmacort	C		
RESPIRATORY							
(INHALATION)							

Date:11/08/04ISR Number: 4495667-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
586 DAY							
Initial or Prolonged		Adverse Event		Claritin	C		
UNKNOWN							
Disability		Angina Pectoris		Aspirin	C		
UNKNOWN							
Other		Benign Prostatic		Pravachol	C		
UNKNOWN							
		Hyperplasia		Calcium			
		Blood Pressure Increased		(Unspecified)	C		
UNKNOWN							
		Bradycardia		Folic Acid	C		
UNKNOWN							
		Bronchitis Acute		Digoxin	C		
UNKNOWN							
		Cholelithiasis		Naprosyn	C		ORAL
		Chronic Obstructive		Keflex	C		ORAL
		Pulmonary Disease		Allegra	C		ORAL
		Convulsion		Elocon	C		
UNKNOWN							
		Coronary Artery Disease		Lopressor	C		ORAL
		Depression		Darvocet-N	C		ORAL
		Dermatitis Atopic		Pravachol	C		
UNKNOWN							
		Diverticulum		Lanoxin	C		ORAL
		Dyspnoea		Lortab	C		ORAL

Fatigue	Clarinex	C	ORAL
Gastrooesophageal Reflux	Zocor	C	ORAL
Disease	Nexium	C	ORAL
Haemorrhoids	Paxil	C	ORAL
Hiatus Hernia			
Inner Ear Disorder			
Intervertebral Disc			
Degeneration			
Lumbar Spinal Stenosis			
Lung Neoplasm			
Myocardial Infarction			
Neuroma			
Non-Hodgkin'S Lymphoma			
Palpitations			
Renal Abscess			
Rhinitis Allergic			
Salivary Gland Cancer			
Vertigo			
Weight Decreased			

Date:11/08/04ISR Number: 4495676-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00689
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adnexa Uteri Pain
Other	Adverse Event
	Arthralgia
	Back Pain
	Benign Breast Neoplasm

	Cataract						
	Cataract Operation						
	Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ovarian Cyst						
	Sciatica						

Date:11/08/04ISR Number: 4495677-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00512
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 26 DAY	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged UNKNOWN	Chest Pain		Synthroid	C			
	Fluid Retention		Allopurinol	C			
UNKNOWN	Pain In Extremity						
	Weight Increased						

Date:11/08/04ISR Number: 4495678-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain Upper
Disability	Anorexia
Other	Aortic Atherosclerosis
	Arthralgia
	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine Increased
	Breast Cyst
	Bronchitis
	Cachexia
	Cardiolipin Antibody Positive
	Carotidynia
	Carpal Tunnel Syndrome

Cerebrovascular Accident
Chest Discomfort
Chest Pain
Colonic Polyp
Contusion
Coronary Artery Disease
Depression
Disease Recurrence
Drug Eruption
Dyspepsia
Ear Pain
Ecchymosis
Episcleritis
Epistaxis
Faeces Discoloured
Fall
Felty'S Syndrome
Fluid Overload
Gastrooesophageal Reflux
Disease
Haematoma

		Haemorrhage					
		Haemorrhoidal Haemorrhage					
		Head Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Herpes Simplex		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hypertension		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Immunoglobulins Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Influenza Like Illness		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		International Normalised		Methotrexate	SS		
UNKNOWN							
		Ratio Decreased		Methotrexate	SS		
UNKNOWN							
		International Normalised		Remicade	SS		
INTRAVENOUS							
		Ratio Increased		Remicade	SS		
INTRAVENOUS							
		Keratitis Herpetic		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis Viral		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukopenia		Triamterene	C		
UNKNOWN							
		Lymphoma		Prilosec	C		
UNKNOWN							
		Mental Impairment		Zyrtec	C		
UNKNOWN							
		Migraine		Proventil	C		ORAL
		Mitral Valve Incompetence		Carbamazepine	C		
UNKNOWN							
		Mouth Injury		Acyclovir	C		
INTRAVENOUS							
		Nausea		Hydroxychloroquine			
		Nocturia		Sulfate	C		
UNKNOWN							
		Orthostatic Hypotension		Advil	C		
UNKNOWN							
		Overdose		[Therapy			

	Pain	Unspecified]	C	
UNKNOWN				
	Pancytopenia	Purinethol	C	
UNKNOWN				
	Platelet Disorder	Elavil	C	ORAL
	Platelet Function Test	Prednisone	C	
UNKNOWN				
	Abnormal Prostatitis	Fiorinal With Codeine	C	
UNKNOWN				
	Pyrexia	K-Dur	C	
UNKNOWN				
	Rash	Allopurinol	C	
UNKNOWN				
	Renal Disorder	Azathioprine	C	
UNKNOWN				
	Renal Pain	Tylenol	C	
UNKNOWN				
	Rheumatoid Arthritis	Tegretol	C	
UNKNOWN				
	Rib Fracture	Tegretol	C	
UNKNOWN				
	Sepsis	Tegretol	C	
UNKNOWN				
	Sinusitis			
	Sleep Disorder			
	Temporomandibular Joint Syndrome			
	Tenosynovitis			
	Thrombocytopenia			
	Tongue Biting			
	Transient Ischaemic Attack			
	Trigger Finger			
	Vasculitis			
	Viral Infection			
	Viral Pharyngitis			
	Weight Decreased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495685-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amyotrophy		Plavix	SS				
UNKNOWN								
Other	Angina Pectoris		Captopril Msd	C		ORAL		
	Atherosclerosis		Synthroid	C				
UNKNOWN								
	Cerebral Artery Stenosis		Evista	C				
UNKNOWN								
	Cerebral Infarction		Amitriptyline Hydrochloride	C				
	Cerebrovascular Accident							
UNKNOWN								
	Coagulopathy		Glucotrol Xl	C				
UNKNOWN								
	Convulsion		Prilosec	C		ORAL		
	Coronary Artery		Humulin	C				
UNKNOWN								
	Atherosclerosis							
	Diabetes Mellitus							
	Inadequate Control							
	Diabetic Neuropathy							
	Diverticulum							
	Dizziness							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Haemorrhoidal Haemorrhage							
	Hypertension							
	Orthostatic Hypotension							
	Pharyngitis							
	Respiratory Tract Infection							
	Subcutaneous Abscess							
	Syncope							
	Upper Respiratory Tract Infection							

Date:11/08/04ISR Number: 4495687-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adrenal Disorder		Valium	C				
UNKNOWN								
Initial or Prolonged	Adverse Event		Sk-Erythromycin	C				
UNKNOWN								
Disability	Axillary Mass		Cyanocobalamin	C				
PARENTERAL								
Other	Csf Shunt Removal		Nitrostat	C				
UNKNOWN								
	Discomfort		Synthroid	C				
UNKNOWN								
	Fall		Paxil	C				
UNKNOWN								
	Gastroenteritis		Lanoxin	C				
UNKNOWN								
	Haemorrhoids		Salagen Tablets	C				
UNKNOWN								
	Helicobacter Gastritis		Claritin	C				
UNKNOWN								
	Iron Deficiency Anaemia		Zofran	C				
UNKNOWN								
	Nausea		Miacalcin	C				
UNKNOWN								
	Polytraumatism		Neurontin	C				
UNKNOWN								
	Road Traffic Accident		Vitamin E	C				
UNKNOWN								
	Shunt Infection		Premarin	C				
UNKNOWN								
	Wound Dehiscence		Aciphex	C				
UNKNOWN								
			Detrol La	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			K-Dur	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			Primidone	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/08/04ISR Number: 4495690-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02301
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Intervertebral Disc Protrusion		Meperidine Hydrochloride	C			UNKNOWN	
	Pain		Cytotec	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Doxycycline	C			UNKNOWN	
			Valium	C			UNKNOWN	
			Viagra	C			UNKNOWN	
							406 DAY	

Date:11/08/04ISR Number: 4495691-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00094
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthrodesis		Accuretic	C			UNKNOWN	
	Basedow'S Disease		Keflex	C		ORAL		
	Body Tinea		Claritin-D 12 Hour	C		ORAL		
	Bronchitis Chronic		Midrin	C		ORAL		
	Cellulitis		Prevacid	C			UNKNOWN	
	Choking Sensation		[Composition Unspecified]	C			UNKNOWN	
	Depression							
	Diarrhoea		Tiazac	C			UNKNOWN	

	Essential Hypertension		Synthroid	C			
UNKNOWN							
	Facial Palsy		Hydrodiuril	C			ORAL
	Gastrooesophageal Reflux		Accupril	C			
UNKNOWN							
	Disease						
	Herpes Simplex						
	Herpes Simplex Ophthalmic						
	Hordeolum						
	Otitis Media Acute						
	Pelvic Inflammatory						
	Disease						
	Pharyngitis						
	Pleurisy						
	Post Procedural						
	Complication						
	Thyroiditis						
	Urinary Tract Infection						

Date:11/08/04ISR Number: 4495696-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00106
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Carotid Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Medicinalproduct Not Specified By Sender	C		ORAL		
			Medicinalproduct Not Specified By Sender	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495698-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00845
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Abdominal Pain Lower Adverse Event Atherosclerosis Atrial Fibrillation Bursitis Chest Pain Coronary Artery Disease Dyspnoea Exertional Hiatus Hernia Hypoaesthesia Myocardial Infarction Nodule Pharyngitis Streptococcal Syncope Urinary Tract Infection Ventricular Hypertrophy Viral Infection		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495699-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00096
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Betaloc	C				
			Panadol	C		ORAL	UNKNOWN	
			Bendrofluazide Tablets	C				
			Losec (Omeprazole Magnesium)	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Enalapril Maleate	C			UNKNOWN	
			Lipex	C			UNKNOWN	

Date:11/08/04ISR Number: 4495700-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Erythema		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		[Therapy Unspecified]	C				
	Headache							
	Hypertension		Methotrexate	C				
	Menstrual Disorder							

Date:11/08/04ISR Number: 4495702-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00038
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Limb Injury		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
	Vision Blurred							

Date:11/08/04ISR Number: 4495703-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00018
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Aspirin	C		ORAL		
			Gastrointestinal Preparations (Unspecified)	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Zocor	C		ORAL		
			Omeprazole	C		ORAL		
			Cholecalciferol	C		ORAL		
			Etidronate Disodium	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Acetaminophen	C		ORAL		
			Allopurinol	C		ORAL		

Date:11/08/04ISR Number: 4495704-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00069
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 658 DAY	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Increased Blood Alkaline Phosphatase Increased		Naftazone	C		ORAL		
			Avocado Oil And Soybean Oil	C		ORAL		
	Cardiomegaly		Levothyroxine Sodium	C		ORAL		
	Cerebral Infarction							
	Diplopia							
	Dysglobulinaemia							
	Gamma-Glutamyltransferase Increased							
	Headache							
	Vertebrobasilar Insufficiency							

Date:11/08/04ISR Number: 4495706-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02014
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495707-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01180
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495708-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02697
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		147 DAY
Hospitalization -	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		147 DAY
Initial or Prolonged	Chills		Zestril	C				UNKNOWN
	Coronary Artery Occlusion		Aspirin	C				UNKNOWN
	Coronary Artery Stenosis		Tenormin	C				UNKNOWN
	Dyspepsia		Allegra	C				UNKNOWN
	Hyperhidrosis							
	Stomach Discomfort							

Date:11/08/04ISR Number: 4495710-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00409
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		283 DAY
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		58 DAY
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		283 DAY
	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		58 DAY
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis		Levoxyl	C				UNKNOWN

	Headache	Aspirin	C	
UNKNOWN				
	Heart Rate Decreased	Zocor	C	ORAL
	Hyperlipidaemia			
	Hypertension			
	Hypothyroidism			
	Joint Stiffness			
	Labile Hypertension			
	Leukocytoclastic			
	Vasculitis			
	Monarthritis			
	Muscle Spasms			
	Musculoskeletal Pain			
	Myalgia			
	Neuropathy			
	Oedema Peripheral			
	Osteoarthritis			
	Pain			
	Pharyngolaryngeal Pain			
	Rash			
	Rotator Cuff Syndrome			
	Skin Ulcer			
	Stomach Discomfort			
	Subclavian Vein			
	Thrombosis			
	Systemic Lupus			
	Erythematosus			
	Treatment Noncompliance			
	Vaginal Mycosis			
	Weight Increased			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495711-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00414
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Synthroid	C				
Disability			Glipizide	C				
			Hydrodiuril	C				
			Thioridazine	C				

Date:11/08/04ISR Number: 4495714-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04016
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract Nuclear		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Conjunctivitis		Prilosec	C				
	Depression		Zocor	C		ORAL		
	Dermatitis Contact		Atenolol	C				
	Drug Intolerance		Librax Capsules	C				
	Duodenitis		Nasocort	C				
	Fatigue							
	Gastritis							
	Headache							
	Hemianopia Homonymous							
	Keratoconjunctivitis							
	Sicca							
	Rhinorrhoea							

711 DAY

711 DAY

UNKNOWN

UNKNOWN

UNKNOWN

RESPIRATORY (INHALATION)

Date:11/08/04ISR Number: 4495718-9Report Type:Expedited (15-DaCompany Report #KR-MERCK-0411KOR00003
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:11/08/04ISR Number: 4495719-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04349
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability			Plavix	C				
UNKNOWN								
			Arava	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Remicade	C				
UNKNOWN								

Date:11/08/04ISR Number: 4495723-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00080
Age: Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Cerebrovascular
Disability	Insufficiency

Gastric Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Zocor	C			UNKNOWN	
	Hydrocodone Bitartrate	C			UNKNOWN	
	Hydrocodone Bitartrate	C			UNKNOWN	

Date:11/08/04ISR Number: 4495726-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495727-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00438
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc		UNKNOWN	938 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc		UNKNOWN	938 DAY
Other	Hypoaesthesia		Atenolol	C			UNKNOWN	
	Thrombosis		Imdur	C			UNKNOWN	
	Visual Field Defect		Hydrochlorothiazide	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Plavix	C			UNKNOWN	

				Aspirin	C		
UNKNOWN							

Date:11/08/04ISR Number: 4495728-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C				
UNKNOWN								
			Bendroflumethiazide	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Acetaminophen	C				
UNKNOWN								

Date:11/08/04ISR Number: 4495729-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00181
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495730-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03833
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - 1 WK	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Lipitor	C				
UNKNOWN								
Other	Overdose		Neurontin	C				
UNKNOWN								
	Pulmonary Oedema		Metoprolol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495734-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00280
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Seroquel	C				
			Diazide	C				
			Altace	C				
			[Therapy Unspecified]	C				

Date:11/08/04ISR Number: 4495736-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495737-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00431
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Toprol Xl Tablets	C				

Date:11/08/04ISR Number: 4495739-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00416
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Hydrodiuril	C		ORAL		
Initial or Prolonged			Prinivil	C		ORAL		
Disability			Zocor	C		ORAL		

			Plavix	C		
UNKNOWN						
			Elavil	C		
UNKNOWN						

Date:11/08/04ISR Number: 4495740-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00324
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other						

Date:11/08/04ISR Number: 4495741-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiomegaly		[Therapy			
	Chest Pain		Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4495742-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00384
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Leg Amputation		Coumadin	C				
UNKNOWN								
Disability			Vitamins (Unspecified)	C				
UNKNOWN								

Date:11/08/04ISR Number: 4495747-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4495749-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00446
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/08/04ISR Number: 4496075-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01356
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Confusional State		Ultram	C		ORAL		
	Diverticulum		Nexium	C		ORAL		
Disability	Embolic Stroke		Zanaflex	C		ORAL		
Other	Gastroenteritis		Ambien	C		ORAL		
	Headache							

Hyperlipidaemia
Hyperthyroidism
Memory Impairment
Peripheral Vascular
Disorder
Rotator Cuff Syndrome
Syncope
Upper Respiratory Tract
Infection

Date:11/08/04ISR Number: 4496076-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Angina Unstable
	Arteriospasm Coronary
	Arthralgia
	Back Pain
	Chest Pain
	Coronary Artery Disease
	Cystocele
	Deep Vein Thrombosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dehydration					
		Diverticulitis					
		Diverticulum					
		Dysfunctional Uterine		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Bleeding		Aspirin	C		
UNKNOWN							
		Dyspepsia		Aspirin	C		
UNKNOWN							
		Dyspnoea		Lipitor	C		
UNKNOWN							
		Dysuria		Prometrium	C		
UNKNOWN							
		Flank Pain		Vivelle	C		
TOPICAL							
		Gastroenteritis		Vivelle	C		
TOPICAL							
		Generalised Anxiety		Zyrtec	C		
UNKNOWN							
		Disorder		Fioricet Tablets	C		
UNKNOWN							
		Haematuria		Fioricet Tablets	C		
UNKNOWN							
		Haemorrhoids		Ambien	C		
UNKNOWN							
		Hot Flush		Motrin	C		
UNKNOWN							
		Injury		Paxil	C		
UNKNOWN							
		Menopausal Symptoms		Prilosec	C		
UNKNOWN							
		Myocardial Infarction		Alprazolam	C		
UNKNOWN							
		Nausea		Vitamin E	C		
UNKNOWN							
		Neck Pain		Gnc Womens Ultra Mega	C		
		Non-Cardiac Chest Pain					
UNKNOWN							
		Phlebitis Superficial		Lecithin	C		
UNKNOWN							
		Postoperative Ileus					
		Rectal Polyp					
		Rhinitis Allergic					
		Rosacea					
		Sinusitis					
		Stress Incontinence					

Urinary Tract Infection
Venous Insufficiency
Vertigo
Weight Increased

Date:11/08/04ISR Number: 4496077-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		237 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		237 DAY
	Anxiety		Seroquel	C				UNKNOWN
	Back Disorder		Hydrochlorothiazide	C				UNKNOWN
	Blood Triglycerides		Soma	C				UNKNOWN
	Increased		Premarin	C				UNKNOWN
	Chest Pain		Ambien	C				UNKNOWN
	Coronary Artery Thrombosis		Doxepin Hydrochloride	C				UNKNOWN
	Hallucination		Flexeril	C		ORAL		
	Hypertension		Hydrocodone Hydrochloride	C				UNKNOWN
	Panic Disorder							
	Sleep Apnoea Syndrome		Prozac	C				UNKNOWN

Date:11/08/04ISR Number: 4496079-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00329
Age:53 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Blood Cholesterol
Initial or Prolonged	Increased
	Blood Pressure Increased
	Chest Pain

		Deep Vein Thrombosis					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
		Irritable Bowel Syndrome		Dipiproverine Dihydrochloride	C		
		Pulmonary Embolism					
UNKNOWN							
		Sensory Loss		Bendroflumethiazide	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:11/08/04ISR Number: 4496080-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03163
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Prevacid	C		
UNKNOWN						
Initial or Prolonged	Hyperhidrosis		Vasotec	C		ORAL
Disability			Covera-Hs	C		
UNKNOWN						
			Diuretic (Unspecified)	C		
UNKNOWN						
			Procardia Xl	C		
UNKNOWN						

Date:11/08/04ISR Number: 4496083-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01208
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
36 HR						
Hospitalization -	Face Injury		[Therapy Unspecified]	C		
Initial or Prolonged	Fall					
UNKNOWN						
Disability						

Date:11/08/04ISR Number: 4496084-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00050
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Hospitalization - UNKNOWN			Omeprazole	C				
Initial or Prolonged								

Date:11/08/04ISR Number: 4496086-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00021
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged								

Date:11/08/04ISR Number: 4496087-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04361
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fluctuation		Hyzaar	C		ORAL		
	Dizziness		[Therapy					
	Hypotension		Unspecified]	C				
UNKNOWN								
	Syncope							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496088-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		138 DAY
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		138 DAY
	Amnesia		Dilantin	C				UNKNOWN
	Anticonvulsant Drug Level		Zoloft	C				UNKNOWN
	Below Therapeutic							
	Anxiety							
	Aura							
	Back Pain							
	Blood Cholesterol Increased							
	Bradyphrenia							
	Chest Discomfort							
	Cognitive Disorder							
	Condition Aggravated							
	Confusional State							
	Convulsion							
	Cough							
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Encephalomalacia							
	Excoriation							
	Fall							
	Feeling Abnormal							
	Grand Mal Convulsion							
	Head Injury							
	Headache							
	Hypertension							
	Injury							
	Insomnia							
	Intervertebral Disc Displacement							
	Intervertebral Disc Protrusion							
	Loss Of Consciousness							
	Lumbar Vertebral Fracture							
	Nasal Septum Deviation							
	Nasal Turbinate							

Hypertrophy
Nose Deformity
Otitis Media
Palpitations
Photopsia
Road Traffic Accident
Sexual Dysfunction
Somnolence
Spinal Compression
Fracture
Stress
Subdural Haematoma
Tremor
White Blood Cell Count
Increased

Date:11/08/04ISR Number: 4496089-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04117
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496090-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00407
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:11/08/04ISR Number: 4496091-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00015
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Varicose Vein							
	Vision Blurred							

Date:11/08/04ISR Number: 4496092-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Cardiac Arrest							
	Cardiac Disorder							
	Coronary Artery Occlusion							

Date:11/08/04ISR Number: 4496093-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00011
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR

Date:11/08/04ISR Number: 4496094-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Intestinal Functional Disorder		Aspirin	C				UNKNOWN
	Transient Ischaemic Attack							

Date:11/08/04ISR Number: 4496095-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00006
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496096-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02668
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Disorientation Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496097-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00007
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
			Estradiol And Norethindrone Acetate	C		ORAL		
			Clotrimazole	C		VAGINAL		
			Atenolol And Chlorthalidone	C		ORAL		
			Diclofenac Epolamine	C		TOPICAL		

Date:11/08/04ISR Number: 4496098-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00008
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
			Methotrexate	SS		ORAL	5	YR
			Prednisolone	C		ORAL		
			Phenprocoumon	C		ORAL		

Date:11/08/04ISR Number: 4496099-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04362
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C			UNKNOWN	
			Coreg	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/08/04ISR Number: 4496100-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00012
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496101-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00003
Age:72 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL	18	DAY
		Spironolactone	C		ORAL		
		Bisoprolol Fumarate	C		ORAL		
		Digoxin	C		ORAL		
		Budesonide And Formoterol Fumarate	C		RESPIRATORY (INHALATION)		
		Tiotropium Bromide	C		RESPIRATORY (INHALATION)		
		Furosemide	C		ORAL		
		Perindopril Erbumine	C		ORAL		
		Aspirin Calcium	C		ORAL		
		Proscar	C		ORAL		

Date:11/08/04ISR Number: 4496102-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00013
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	68	DAY

Date:11/08/04ISR Number: 4496103-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00044
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1823	DAY

Date:11/08/04ISR Number: 4496104-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00030
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		463 DAY
	Dysarthria		Amitriptyline Hydrochloride	C		ORAL		
	Transient Ischaemic Attack		Loratadine	C		ORAL		

Date:11/08/04ISR Number: 4496105-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00012
Age:69 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Hydroxychloroquine Sulfate	C				UNKNOWN
			Albuterol	C				RESPIRATORY (INHALATION)
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN
			Budesonide And Formoterol Fumarate	C				RESPIRATORY (INHALATION)

			Dermatologic (Unspecified)	C		TOPICAL
			Folic Acid	C		ORAL
			Tiotropium Bromide	C		RESPIRATORY (INHALATION)
			Amitriptyline Hydrochloride	C		UNKNOWN
			Aspirin	C		UNKNOWN
			Simvastatin	C		UNKNOWN
			Acetaminophen	C		UNKNOWN

Date:11/08/04ISR Number: 4496106-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00059
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496107-3Report Type:Expedited (15-DaCompany Report #DK-MERCK-0411DNK00008
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1531 DAY
Initial or Prolonged	Hemiparesis		Vioxx	SS	Merck & Co., Inc	ORAL		1531 DAY
			Lansoprazole	C		ORAL		
			Bendroflumethiazide And Potassium Chloride	C		ORAL		
			Procyclidine Hydrochloride	C		ORAL		
			Estradiol Benzoate	C		ORAL		
			Tramadol					

			Hydrochloride	C		ORAL
			Zopiclone	C		ORAL
			Oxazepam	C		ORAL
			Zuclopenthixol Hydrochloride	C		ORAL

Date:11/08/04ISR Number: 4496108-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00047
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrointestinal Haemorrhage Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Date:11/08/04ISR Number: 4496109-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00029
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Methotrexate	C		
UNKNOWN						
			Plaquenil	C		
UNKNOWN						
			Folic Acid	C		
UNKNOWN						
			Caltrate	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496110-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00034
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		461 DAY
	Confusional State		Atenolol	C		ORAL		
	Dysphagia		Bendroflumethiazide	C		ORAL		

Date:11/08/04ISR Number: 4496111-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00033
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		571 DAY
	Facial Paresis		Vioxx	SS	Merck & Co., Inc	ORAL		571 DAY
	Paraesthesia		Lansoprazole	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Aspirin	C		ORAL		
			Sulfasalazine	C		ORAL		

Date:11/08/04ISR Number: 4496112-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00005
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Erythema		Estradiol And					
	Pain In Extremity		Norethindrone					
	Swelling		Acetate	SS		ORAL		
			Methotrexate	C				UNKNOWN
			Furosemide	C				UNKNOWN
			Metoprolol Tartrate	C		ORAL		
			Lisinopril	C		ORAL		
			Insulin	C				INTRAVENOUS YR

Date:11/08/04ISR Number: 4496113-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Actos	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

Date:11/08/04ISR Number: 4496114-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00037
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombotic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C			UNKNOWN	
Initial or Prolonged			Prilosec	C			UNKNOWN	
Disability			Florital	C			UNKNOWN	

Date:11/08/04ISR Number: 4496115-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00051
Age:72 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Loss Of Consciousness Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496116-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00049
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lipitor	C				
	Transient Ischaemic		Plavix	C				
	Attack		Detrol La	C				
			Vagifem	C				
			Librium	C				
			Elavil	C		ORAL		
			Glucosamine	C				

Date:11/08/04ISR Number: 4496117-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00066
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

Date:11/08/04ISR Number: 4496118-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00143
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Methotrexate	C				UNKNOWN
	Headache		Diovan	C				UNKNOWN
			Folic Acid	C				UNKNOWN

Date:11/08/04ISR Number: 4496119-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496120-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496121-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00193
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypoaesthesia		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
Disability								

Date:11/08/04ISR Number: 4496122-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00191
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Lozol	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								
			Amaryl	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:11/08/04ISR Number: 4496123-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00207
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	YR
Hospitalization -	Chest Pain		Aspirin	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction							
	Palpitations							

Date:11/08/04ISR Number: 4496124-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496125-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00209
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496126-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/08/04ISR Number: 4496127-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Injury		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496128-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00212
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Hospitalization - UNKNOWN	Thrombosis		Celexa	C				
Initial or Prolonged UNKNOWN			Dynacirc	C				
Disability			Zocor	C		ORAL		

Date:11/08/04ISR Number: 4496129-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00111
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Heart Rate Irregular		Aspirin	C				
Initial or Prolonged	Loss Of Consciousness		[Therapy					
Disability UNKNOWN			Unspecified]	C				

Date:11/08/04ISR Number: 4496130-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00043
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Ibuprofen	C				
Initial or Prolonged	Transient Ischaemic		[Therapy					
Disability UNKNOWN	Attack		Unspecified]	C				
			Neurontin	C				
UNKNOWN								
			Buspar	C				
UNKNOWN								

Date:11/08/04ISR Number: 4496131-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00039
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lipitor	C				
			Toprol Xl Tablets	C				
			Zoloft	C				
			Lisinopril	C				
			Plavix	C				
			Tricor	C				
			Aspirin	C				

Date:11/08/04ISR Number: 4496132-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00326
Age: Gender:Male I/FU:I

Outcome	PT
Disability	Blood Pressure Increased
Other	Cardiac Procedure
	Complication
	Carotid Artery Disease
	Chills
	Deafness
	Depression
	Heart Rate Increased
	Loss Of Libido
	Lung Infection
	Lung Injury
	Myocardial Infarction

		Oedema Peripheral					
		Pain					
		Peripheral Vascular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
18	MON						
		Pyrexia					
		Rash					
		Sexual Dysfunction					
		Visual Disturbance					

Date:11/08/04ISR Number: 4496133-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00580
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Living Impaired		Cardura	C		
UNKNOWN						
Initial or Prolonged	Blood Pressure		Zocor	C		
UNKNOWN						
Disability	Fluctuation		Micardis	C		
UNKNOWN						
	Heart Rate Abnormal					
	Heart Rate Decreased					

Date:11/08/04ISR Number: 4496134-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00410
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Gastrointestinal					
Initial or Prolonged	Haemorrhage					
Disability						

Date:11/08/04ISR Number: 4496135-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00551
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
2 YR							

Date:11/08/04ISR Number: 4496136-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00276
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		[Therapy					
Initial or Prolonged	Haemorrhage		Unspecified]	C				
UNKNOWN								
Disability	Myocardial Infarction							

Date:11/08/04ISR Number: 4496137-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00283
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive							
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/08/04ISR Number: 4496138-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		1279 DAY
	Gastric Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		1279 DAY
	Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL		1279 DAY
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		1279 DAY
	Urinary Incontinence							

Date:11/08/04ISR Number: 4496139-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00274
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blister		[Therapy					
	Bradycardia		Unspecified]	C				UNKNOWN
	Chest Pain		Aspirin	C				UNKNOWN
	Confusional State		Celexa	C				UNKNOWN
	Fatigue							
	Transient Ischaemic							
	Attack							

Date:11/08/04ISR Number: 4496140-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/08/04ISR Number: 4496142-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00849
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
UNKNOWN								
Initial or Prolonged			Digitek	C				
UNKNOWN								
Disability			Acupril	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/08/04ISR Number: 4496143-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00462
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Zocor	C				
UNKNOWN								
	Dyspepsia							
	Dyspnoea							

Date:11/08/04ISR Number: 4496195-4Report Type:Direct Company Report #CTU 231428
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Asthenia
	Balance Disorder

	Cerebrovascular Accident Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vision Blurred		Vioxx 25 Mg	PS			1 / DAY

Date:11/08/04ISR Number: 4496365-5Report Type:Direct Company Report #CTU 231492
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx 25mg Merck	PS	Merck	ORAL	25MG ONCE
Hospitalization -	Gastroenteritis Viral						DAILY ORAL
Initial or Prolonged	Oedema Peripheral		Diamox	C			
Disability			Klor Com	C			
Required			Prozac	C			
Intervention to			Clonodine	C			
Prevent Permanent			Lisinopril	C			
Impairment/Damage			Blood Thinners	C			

Date:11/08/04ISR Number: 4496378-3Report Type:Direct Company Report #CTU 231500
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain		Vioxx Merck	PS	Merck		

Date:11/08/04ISR Number: 4498571-2Report Type:Expedited (15-DaCompany Report #2004225786US
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Pressure Increased	Consumer	Detrol				
Initial or Prolonged	Diarrhoea	Health	La(Tolterodine)				
Other	Dysuria	Professional	Capsule, Prolonged				
	Joint Swelling		Release	PS			4 MG, QD

	Oedema Peripheral		Vioxx (Rofecoxib)	SS			
QD							
	Renal Failure Acute		Hytrin (Terazozin				
	Urinary Retention		Hydrochloride)	C			
			Vasotec	C			
			Hydrochlorothiazide	C			
			Dyazide	C			

Date:11/08/04ISR Number: 4498626-2Report Type:Expedited (15-DaCompany Report #2004-BP-10675BP
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Health	Mobic (Meloxicam)					
Initial or Prolonged	Musculoskeletal Stiffness	Professional	Tablets	PS		ORAL	7.5 MG, PO	
			Vioxx (Rofecoxib)	SS				
			Coumadin	C				

Date:11/09/04ISR Number: 4496716-1Report Type:Expedited (15-DaCompany Report #MY-MERCK-0410MYS00008
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	35 DAY	
Life-Threatening	Myocardial Infarction		Celebrex	C		ORAL	46 DAY	
Disability	Pulmonary Oedema							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496721-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/09/04ISR Number: 4496724-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04338
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496726-4Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00021
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	4	YR

Date:11/09/04ISR Number: 4496727-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00033
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Stenosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496728-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 117 DAY	Coagulation Factor Viii	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Level Decreased	Zocor	SS		ORAL
	Coagulation Time Prolonged	Ginkgo Biloba Extract	SS		ORAL
	Haematoma	Hydrochlorothiazide And Lisinopril	SS		ORAL

Date:11/09/04ISR Number: 4496729-XReport Type:Expedited (15-DaCompany Report #IL-MERCK-0410ISR00051
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Rofecoxib	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hemiparesis					
Other	Transient Ischaemic Attack					

Date:11/09/04ISR Number: 4496734-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abscess Limb
Initial or Prolonged	Basal Cell Carcinoma
Disability	Cardiac Murmur
Other	Cerebrovascular Accident

		Conjunctivitis					
		Coronary Artery Disease					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Ingrowing Nail		Vioxx	SS	Merck & Co., Inc	ORAL
53	DAY						
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Sexual Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
53	DAY						
		Sleep Apnoea Syndrome		Fosamax	C		ORAL
				Hydrodiuril	C		ORAL

Date:11/09/04ISR Number: 4496735-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Anxiety
	Arthritis
	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Bone Pain
	Bronchitis
	Burning Sensation
	Cerebrovascular Accident
	Conversion Disorder
	Coordination Abnormal
	Depression
	Dizziness
	Dry Skin
	Emotional Distress
	Fall
	Fatigue
	Ganglion
	Generalised Anxiety Disorder
	Haemorrhoids
	Hallucination
	Hemiparesis
	Hiatus Hernia
	Hypertension
	Hypoaesthesia
	Hypokalaemia
	Hyporeflexia

Inflammation
Injury
Insomnia
Lacunar Infarction
Liver Function Test
Abnormal
Loss Of Consciousness
Menopausal Symptoms
Movement Disorder
Oesophageal Spasm
Orthostatic Hypotension
Pain In Extremity
Palpitations
Post Procedural
Complication
Psychosomatic Disease
Stress
Suicidal Ideation

	Syncope Tinnitus Torticollis	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Tremor		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Synthroid	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Celexa	C			UNKNOWN
			Niacin	C			UNKNOWN
14671DAY			Lexapro	C			UNKNOWN
			Claritin	C			UNKNOWN
			Ventolin (Albuterol)	C			RESPIRATORY (INHALATION)
			Aerobid	C			UNKNOWN

Date:11/09/04ISR Number: 4496736-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00760
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Life-Threatening	Thoracic Vertebral		Vioxx	PS	Merck & Co., Inc	ORAL	409 DAY
Hospitalization -	Fracture		Sertraline				
Initial or Prolonged	Transient Ischaemic		Hydrochloride	C		ORAL	
Other	Attack		Lisinopril	C		ORAL	
			Risedronate Sodium	C		ORAL	

Date:11/09/04ISR Number: 4496738-0Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00018
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Hospitalization -	Headache		Vioxx	PS	Merck & Co., Inc		UNKNOWN

Initial or Prolonged Heart Rate Increased
Vision Blurred

Date:11/09/04ISR Number: 4496743-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00085
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496744-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00041
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496745-8Report Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496747-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00043
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496749-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00056
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496750-1Report Type:Expedited (15-DaCompany Report #CO-MERCK-0411COL00002
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496751-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00006
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Oropharyngeal Swelling Swollen Tongue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496752-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Initial or Prolonged Stent Placement

Date:11/09/04ISR Number: 4496753-7Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00012
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496770-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00272
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking Heart Rate Decreased Posture Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496772-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00284
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Other	Blood Pressure Increased Cardiac Failure

Congestive
Cerebrovascular Accident
Palpitations

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Tylenol	C			UNKNOWN	
	Mobic	C			UNKNOWN	

Date:11/09/04ISR Number: 4496773-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00221
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 3 YR	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Aspirin	C			UNKNOWN	
Other			Tylenol	C			UNKNOWN	
			Digoxin	C			UNKNOWN	
			Metformin	C			UNKNOWN	
			Glipizide	C			UNKNOWN	
			Warfarin	C			UNKNOWN	
			Lasix (Furosemide Sodium)	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Zocor	C			UNKNOWN	

Date:11/09/04ISR Number: 4496774-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00616
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL	
21 DAY							
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	
6 DAY							

Date:11/09/04ISR Number: 4496775-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00164
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
5 MON								
Hospitalization -			Paxil	C				
UNKNOWN								
Initial or Prolonged			Premarin	C				
UNKNOWN								
			Fluocinonide	C				
UNKNOWN								
			Macrobid	C				
UNKNOWN								
			Amoxicillin	C				
UNKNOWN								
			Smz-Tmp	C				
UNKNOWN								
			Q-Bid La	C				
UNKNOWN								
			Clonazepam	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496776-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00216
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Nexium	C				
UNKNOWN								
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496777-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496778-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00299
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				
UNKNOWN								
			Lexapro	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496779-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00011
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Methotrexate	C				
UNKNOWN								
Disability			Folic Acid	C				
UNKNOWN								
			Valium	C				
UNKNOWN								
			Buspar	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Hydrocodone Hydrochloride	C				
UNKNOWN								
			Megace	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496780-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00293
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Refusal Of Treatment By Patient		Vioxx	SS	Merck & Co., Inc	ORAL		
			Hyzaar	C		ORAL		
			Potassium (Unspecified)	C				
			Theo-Dur	C				
			Allegra	C				
			Singulair	C		ORAL		
			Serevent	C				
			Proventil	C				
			Thyroid	C				

Date:11/09/04ISR Number: 4496781-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00641
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Paxil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496782-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496783-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00509
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496784-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496785-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:11/09/04ISR Number: 4496786-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00400
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged	Asthenia Eating Disorder Irritability Nervousness Ocular Neoplasm							

Date:11/09/04ISR Number: 4496787-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00740
Age:15 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496788-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00397
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496789-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00461
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prednisone	C				UNKNOWN
Initial or Prolonged			Insulin	C				UNKNOWN
			Diuretic (Unspecified)	C				UNKNOWN
			Digoxin	C				UNKNOWN
			Methotrexate	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			Coreg	C				UNKNOWN
			Plaquenil	C				UNKNOWN
			Zoloft	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:11/09/04ISR Number: 4496790-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00792
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				UNKNOWN
Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN

Date:11/09/04ISR Number: 4496791-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496792-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00746
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Synthroid	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Clonidine	C			UNKNOWN	
			Adalat	C			UNKNOWN	

Date:11/09/04ISR Number: 4496793-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00742
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							

Date:11/09/04ISR Number: 4496794-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00036
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496795-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00747
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Lotrel	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496796-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00579
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Methotrexate	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496912-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acquired Claw Toe
	Anaemia
	Angina Pectoris
	Barrett'S Oesophagus
	Blood Cholesterol
	Increased
	Blood Pressure
	Inadequately Controlled
	Cerebrovascular Accident
	Chest Pain
	Cholelithiasis
	Colonic Polyp
	Condition Aggravated
	Coronary Artery Disease
	Dehydration

Diverticulum
Diverticulum Intestinal
Dizziness
Dyspepsia
Dyspnoea
Ear Infection
Emotional Disorder
Eye Irritation
Haematuria
Helicobacter Gastritis
Hepatic Enzyme Increased
Hypertension
Ingrowing Nail
Intestinal Polyp
Irritable Bowel Syndrome
Lacunar Infarction
Peroneal Nerve Palsy
Rash Pruritic
Reflux Oesophagitis
Renal Disorder
Renal Impairment
Scab
Skin Disorder

	Skin Lesion Urinary Tract Infection						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	49 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	72 DAY
			Zocor	C		ORAL	
			Protonix	C			UNKNOWN
			Lipitor	C			UNKNOWN
			Prinivil	C		ORAL	

Date:11/09/04ISR Number: 4496913-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00710
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Asthenia		Procardia Xl	C			UNKNOWN
	Blood Pressure Increased		Prinivil	C			UNKNOWN
	Blunted Affect		Diazide	C			UNKNOWN
	Cerebral Atrophy		Synthroid	C			UNKNOWN
	Cerebrovascular Accident		Ecotrin	C			UNKNOWN
	Contusion		Hydrea	C			UNKNOWN
	Convulsion		Osteo-Bi-Flex	C			UNKNOWN
	Dehydration		Compazine	C			UNKNOWN
	Depressed Level Of Consciousness Depression Disorientation Extensor Plantar Response						

Fall
Fatigue
Haematoma
Hypokalaemia
Insomnia
Joint Injury
Mental Status Changes
Nausea
Oedema Peripheral
Pyelonephritis
Urinary Tract Infection

Date:11/09/04ISR Number: 4496916-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00760
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:11/09/04ISR Number: 4496924-XReport Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00103
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Zopiclone	C		ORAL		

Date:11/09/04ISR Number: 4496926-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00209
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged			Tramadol Hydrochloride	C		ORAL	UNKNOWN	
			Dipyrone	C		ORAL	UNKNOWN	
			Atenolol And Chlorthalidone Hydrochlorothiazide And Ramipril	C		ORAL	UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Aspirin And Dipyridamole	C			UNKNOWN	
			Tetrazepam	C			UNKNOWN	
			Dexamethasone Sodium Phosphate	C			UNKNOWN	48 HR

Date:11/09/04ISR Number: 4496928-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00033
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		24 WK
Initial or Prolonged	Rash		Mebeverine Hydrochloride	C		ORAL	RESPIRATORY	
	Shock		Estradiol	C		ORAL		
	Swelling Face		Budesonide	C			(INHALATION)	
			Tiotropium Bromide	C			RESPIRATORY	

(INHALATION)

	Ipratropium Bromide And Fenoterol Hydrobromide	C
RESPIRATORY		
(INHALATION)		
	Formoterol Fumarate	C
RESPIRATORY		
(INHALATION)		

Date:11/09/04ISR Number: 4496929-9Report Type:Expedited (15-DaCompany Report #CL-MERCK-0410CHL00009
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Acenocoumarol	C		ORAL		
Disability								

Date:11/09/04ISR Number: 4496932-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00958
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Actonel	C		ORAL		
Initial or Prolonged			Norvasc	C		ORAL		
Disability			Atenolol	C		ORAL		
Other			Synthroid	C		ORAL		
			Premarin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496933-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00959
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Methotrexate	C				
Initial or Prolonged			Folic Acid	C				
			Aspirin	C				
			Plaquenil	C				

Date:11/09/04ISR Number: 4496934-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00539
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Levothyroxine Sodium	C				
			Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
			Opipramol Hydrochloride	C				
			Goldenrod	C				

Date:11/09/04ISR Number: 4496935-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03946
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	128	DAY
Hospitalization -	Convulsion		Protonix	C				

Initial or Prolonged	Myocardial Infarction	Rite Aid Col-Rite	
Disability	Renal Disorder	Stool Softener	C
UNKNOWN			
	Transient Ischaemic	Clonidine	C
UNKNOWN			
	Attack	Diovan	C
UNKNOWN			
		Norvasc	C
UNKNOWN			
		Hydrodiuril	C
UNKNOWN			
		Wellbutrin Sr	C
UNKNOWN			
		Combivent	C
UNKNOWN			
		Advair	C
UNKNOWN			
		Theophylline	C
UNKNOWN			
		Aspirin	C
UNKNOWN			
		Bisacodyl	C
UNKNOWN			
		Metoclopramide	C
UNKNOWN			

Date:11/09/04ISR Number: 4496936-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00034
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypertension		Morphine Sulfate	C		
UNKNOWN						
			Dipyrone	C		
UNKNOWN						
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		
UNKNOWN						
			Pantoprazole Sodium	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496937-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Sinusitis		Claritin-D	C			UNKNOWN	
	Cyst		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Depression		Flonase	C			UNKNOWN	
	Gallbladder Disorder		Diazepam	C			UNKNOWN	
	Gout		Plendil	C			UNKNOWN	
	Hernia		Pravachol	C			UNKNOWN	
	Hodgkin'S Disease		Wellbutrin	C			UNKNOWN	
	Myalgia							
	Myopathy							
	Renal Failure							
	Renal Failure Acute							
	Renal Tubular Necrosis							
	Tension Headache							

Date:11/09/04ISR Number: 4496938-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00030
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nephritis		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Renal Failure Acute		Ibuprofen	SS			UNKNOWN	2 DAY
	Renal Infarct		Ibuprofen	SS			UNKNOWN	2 DAY

Date:11/09/04ISR Number: 4496939-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Atorvastatin Calcium	C			UNKNOWN	

Date:11/09/04ISR Number: 4496940-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00073
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:11/09/04ISR Number: 4496941-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01487
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	88	DAY
Hospitalization -	Cardiac Arrest		Valtrex	C			UNKNOWN	
Initial or Prolonged	Full Blood Count Decreased		[Therapy Unspecified]	C			UNKNOWN	
	Hypotension		[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496942-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00071
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc			UNKNOWN
			Chlormezanone	C		ORAL		

Date:11/09/04ISR Number: 4496943-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01206
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Celebrex	C				UNKNOWN
Initial or Prolonged	Dyspnoea		Allegra	C				UNKNOWN
Other	Pain In Extremity		Plavix	C				UNKNOWN
	Post Procedural Complication		Benazepril Hydrochloride	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Mevacor	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Actos	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Metformin	C				UNKNOWN
			Prozac	C				UNKNOWN

Date:11/09/04ISR Number: 4496944-5Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00009
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496945-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00094
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block Second Degree		Vioxx	PS	Merck & Co., Inc	ORAL		
	Syncope							

Date:11/09/04ISR Number: 4496946-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00049
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
267 DAY								
	Attack		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Methotrexate	C		ORAL		
			Prednisolone	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496947-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00083
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496948-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00068
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Pulmonary Oedema		Ramipril	C			UNKNOWN	
			Mevacor	C		ORAL		
			Celecoxib	C			UNKNOWN	

Date:11/09/04ISR Number: 4496949-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00138
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Norvasc	C			UNKNOWN	
Initial or Prolonged	Visual Acuity Reduced		Synthroid	C			UNKNOWN	

Date:11/09/04ISR Number: 4496950-0Report Type:Expedited (15-DaCompany Report #DK-MERCK-0411DNK00011
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	750	DAY
Initial or Prolonged			Candesartan					

Disability			Cilexetil	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Carisoprodol	C		
UNKNOWN						
			Acetaminophen	C		ORAL

Date:11/09/04ISR Number: 4496951-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:11/09/04ISR Number: 4496952-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00304
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Overdose							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4496953-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00309
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Motrin	C				
UNKNOWN								
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496954-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00219
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Rate Irregular		Lisinopril	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496955-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00306
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Excedrin P.M.	C		ORAL		
Disability	Coronary Artery Stenosis		Ibuprofen	C				
UNKNOWN								
			Cortizone-5	C				
UNKNOWN								
			Darvon	C				
UNKNOWN								
			Prinzide	C				
UNKNOWN								

			Advil	C			
UNKNOWN							

Date:11/09/04ISR Number: 4496956-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00724
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Norvasc	C				
UNKNOWN								
Initial or Prolonged	Headache		Zestoretic	C				
UNKNOWN								
Disability	Hypertension		Zocor	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496957-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00310
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								

Date:11/09/04ISR Number: 4496958-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Dizziness							

Date:11/09/04ISR Number: 4496959-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00394
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Norvasc	C				
UNKNOWN								
Initial or Prolonged			Toprol Xl Tablets	C				
UNKNOWN								
Disability			Altace	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496960-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00084
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Cell Carcinoma							
	Stage Unspecified							

Date:11/09/04ISR Number: 4496961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00385
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Insomnia		Lipitor	C				
UNKNOWN								
			Avandia	C				
UNKNOWN								

				Bextra	C		
UNKNOWN							

Date:11/09/04ISR Number: 4496962-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00562
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Ulcer Haemorrhage		Enalapril Maleate	C		
UNKNOWN						
Initial or Prolonged			Hydrodiuril	C		
UNKNOWN						
			Atenolol	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:11/09/04ISR Number: 4496963-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/09/04ISR Number: 4496964-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00570
Age:72 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Enzymatic Therapy Trimax	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496965-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00770
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Facial Palsy		Vioxx	SS	Merck & Co., Inc	ORAL		
			Atenolol	C				
UNKNOWN								
			Prinivil	C		ORAL		
			Lasix (Furosemide)	C				
UNKNOWN								

Date:11/09/04ISR Number: 4496966-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00649
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/09/04ISR Number: 4496967-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00713
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
UNKNOWN								

Initial or Prolonged			Prozac	C		
UNKNOWN						

Date:11/09/04ISR Number: 4496968-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00777
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/09/04ISR Number: 4496969-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00755
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		[Therapy Unspecified]	C		
UNKNOWN						

Date:11/09/04ISR Number: 4496970-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04335
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
508 DAY						
Hospitalization -	Myocardial Infarction		Zocor	C		ORAL
Initial or Prolonged			Altace	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

	Aciphex	C	
UNKNOWN			
	Prinivil	C	ORAL
	Folic Acid	C	
UNKNOWN			

Date:11/09/04ISR Number: 4496973-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01123
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Increased							
	Dizziness							
	Feeling Abnormal							
	Headache							
	Oedema Peripheral							
	Sleep Disorder							

Date:11/09/04ISR Number: 4498031-9Report Type:Direct Company Report #CTU 231561
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx 25 Mg Merck	PS	Merck	ORAL	1 TABLET	
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack						TWICE DAILY	
Required Intervention to Prevent Permanent Impairment/Damage	Tremor						ORAL	

Date:11/09/04ISR Number: 4498052-6Report Type:Direct Company Report #CTU 231555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Chest Pain		Vioxx 50mg	PS		ORAL
25-50MG						
Initial or Prolonged	Oedema					
DAILY PRN						
	Weight Increased					
ORAL						

Date:11/09/04ISR Number: 4498056-3Report Type:Direct Company Report #CTU 231596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Transient Ischaemic		Vioxx 12.5 Mg.			
Hospitalization -	Attack		Merck	PS	Merck	
1-2PER DAY						
Initial or Prolonged						

Date:11/09/04ISR Number: 4498057-5Report Type:Direct Company Report #CTU 231598
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Headache		Vioxx 25mg Merck	PS	Merck	ORAL
1 DAILY ORAL						
Initial or Prolonged	Heart Rate Increased					
Other	Hypertension					
Required	Vertigo					
Intervention to						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/09/04ISR Number: 4498686-9Report Type:Direct Company Report #CTU 231626
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx 25 Mg					
	Chest Pain		Tablets-By Merck	PS	Merck		1 TABLET	
	Dizziness						DAILY	
	Dyspepsia							
	Neck Pain							
	Pruritus							

Date:11/09/04ISR Number: 4501520-1Report Type:Expedited (15-DaCompany Report #2004CG01324
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anti Factor Viii Antibody	Foreign	Zestoretic	PS		ORAL	1 DF QD PO	5 WK
Initial or Prolonged	Positive	Health	Tanakan	SS		ORAL	2 DF QD PO	5 WK
	Coagulation Factor Viii	Professional	Zocor	SS		ORAL	10 MG QD PO	
	Level Decreased	Other	Vioxx	SS		ORAL	25 MG QD PO	
	Coagulation Time Prolonged							
	Coagulation Time Shortened							
	Haematoma							
	Intermittent Claudication							
	Von Willebrand'S Disease							

Date:11/10/04ISR Number: 4497438-3Report Type:Expedited (15-DaCompany Report #US-MERCK-00060586
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension					

Date:11/10/04ISR Number: 4497440-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00050869
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
			Hydrodiuril	C		
UNKNOWN						

Date:11/10/04ISR Number: 4497446-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00866
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Oedema Peripheral		Maxair	C		
UNKNOWN						
			Imitrex Tablets	C		
UNKNOWN						
			Lomotil	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

				[Therapy Unspecified]	C		
UNKNOWN							
				Klor-Con	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							

Date:11/10/04ISR Number: 4497449-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00509
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Falithrom	C				
UNKNOWN								
			Molsidomine	C				
UNKNOWN								
			Hydrochlorothiazide And Ramipril	C				
UNKNOWN								
			Isosorbide Mononitrate	C				
UNKNOWN								
			Nebilet	C				
UNKNOWN								
			Arelix Ace	C				
UNKNOWN								
			Sodium Monofluorophosphate	C				
UNKNOWN								
			Calcium Gluconate	C				
UNKNOWN								
			Calcium Carbonate	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497450-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104517
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Anger	Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY
	Arthralgia	Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY
	Balance Disorder	Vioxx	SS	Merck & Co., Inc	ORAL	
	Cellulitis	Glucosamine	C			UNKNOWN
	Clostridium Colitis	Colchicine	C			UNKNOWN
	Confusional State	Lotensin	C			UNKNOWN
	Decreased Appetite	Zocor	C			UNKNOWN
	Disorientation	Tylenol	C			UNKNOWN
	Dizziness	Diclofenac	C			UNKNOWN
	Drug Ineffective	Prednisone	C			UNKNOWN
	Dyspepsia	Metronidazole	C			UNKNOWN
	Feeling Jittery	[Therapy Unspecified]	C			UNKNOWN
	Gout	Cefadroxil	C			UNKNOWN
	Injury	Vitamin E	C			UNKNOWN
	Insomnia	Ascorbic Acid	C			UNKNOWN
	Intervertebral Disc Degeneration	Aleve	C			UNKNOWN
	Memory Impairment	Aspirin	C			UNKNOWN
	Mood Altered	Atenolol	C			UNKNOWN
	Osteoarthritis	Zantac	C			UNKNOWN
	Pain	Omega-3	C			UNKNOWN
	Scoliosis	Coenzyme Q10	C			UNKNOWN
	Spondylolisthesis	Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C			UNKNOWN
	Viral Infection					
	Vision Blurred					

Date:11/10/04ISR Number: 4497451-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00134
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Reversible Ischaemic Neurological Deficit		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Atorvastatin Calcium	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	
			Carbamazepine	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	

Date:11/10/04ISR Number: 4497452-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01668
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Nexium	C			UNKNOWN	
	Blood Urea Increased		Allegra	C			UNKNOWN	
	Renal Disorder		Advair	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Flexeril	C		ORAL		

Date:11/10/04ISR Number: 4497453-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01116
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Asacol	C				
UNKNOWN								
Initial or Prolonged			Librax Capsules	C				
UNKNOWN								
Disability			Nexium	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								
			Ultram	C				
UNKNOWN								
			Tranxene	C				
UNKNOWN								
			Remeron	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497454-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00235
Age:31 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
Other	Arthralgia
	Astigmatism
	Balance Disorder
	Blindness Unilateral
	Dizziness
	Dry Eye
	Emotional Distress
	Eye Irritation
	Eye Pain
	Eye Pruritus
	Headache
	Hypertension
	Hypoaesthesia

		Injury					
		Migraine With Aura					
		Myopia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
379	DAY						
		Ocular Hyperaemia		Vioxx	SS	Merck & Co., Inc	ORAL
379	DAY						
		Optic Atrophy		Vicodin Tablets	C		
UNKNOWN							
		Photosensitivity Reaction		Celebrex	C		
UNKNOWN							
		Platelet Count Decreased					
		Retinal Haemorrhage					
		Retinal Vein Occlusion					
		Rotator Cuff Syndrome					
		Vomiting					

Date:11/10/04ISR Number: 4497455-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00759
Age:95 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Drug Ineffective		Pepcid	C		ORAL
Initial or Prolonged		Hip Fracture		Iron (Unspecified)	C		
UNKNOWN							
		Oedema Peripheral					

Date:11/10/04ISR Number: 4497456-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03676
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Sleep Disorder		Neurontin	C		
UNKNOWN							
				Mavik	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Atenolol And			

			Chlorthalidone	C		
UNKNOWN						

Date:11/10/04ISR Number: 4497457-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01829
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
466 DAY						
Hospitalization -	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						
Initial or Prolonged	Emotional Distress		Indocin			
	Glomerulonephritis		(Indomethacin)	C		
UNKNOWN						
	Membranous		Lasix (Furosemide)	C		ORAL
	Gout		K-Dur	C		ORAL
	Hyperglycaemia					
	Medication Error					
	Nephrolithiasis					
	Oedema Peripheral					
	Pneumonia					
	Renal Failure					
	Sleep Apnoea Syndrome					
	Urethral Stricture					

Date:11/10/04ISR Number: 4497458-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00252
Age:18 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Phlebothrombosis Superior Vena Caval Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4497460-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00220
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Synthroid	C				
	Renal Disorder							

Date:11/10/04ISR Number: 4497461-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00356
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Diovan	C				
Disability			Zocor	C				
			Metoprolol	C				
			Advair	C				
			Procrit	C				
			Atrovent	C				
			Xanax	C				
			Isosorbide Mononitrate	C				

			Gemfibrozil	C
UNKNOWN				
			Oxycontin	C
UNKNOWN				
			Albuterol	C
UNKNOWN				
			Cefuroxime	C
UNKNOWN				
			Prednisone	C
UNKNOWN				
			Ambien	C
UNKNOWN				
			Lexapro	C
UNKNOWN				

Date:11/10/04ISR Number: 4497462-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Bundle Branch Block Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/10/04ISR Number: 4497463-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00141
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Synthroid	C		
UNKNOWN						
Initial or Prolonged			[Therapy			
Disability			Unspecified]	C		
UNKNOWN						

Date:11/10/04ISR Number: 4497464-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Atrial Fibrillation		Celecoxib	C				
UNKNOWN							6	MON
	Gastrointestinal Ulcer							

Date:11/10/04ISR Number: 4497465-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	573	DAY

Date:11/10/04ISR Number: 4497466-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04389
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalat	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497467-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00407
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
UNKNOWN								
			Plaquenil	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

	Vasotec	C
UNKNOWN		
	Flexeril	C
UNKNOWN		
	Effexor	C
UNKNOWN		

Date:11/10/04ISR Number: 4497474-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Aneurysm
	Angina Unstable
	Anorexia
	Anxiety
	Anxiety Disorder
	Aortic Aneurysm
	Asthenia
	Cardiac Disorder
	Carotid Artery Occlusion
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Colonic Polyp
	Decubitus Ulcer
	Depression
	Diabetes Mellitus
	Duodenal Ulcer
	Duodenal Ulcer
	Haemorrhage
	Eating Disorder

	Emotional Distress					
	Emphysema					
	Facial Palsy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Fall		Vioxx	PS	Merck & Co., Inc	ORAL
	Foot Fracture		Cyanocobalamin	C		
UNKNOWN						
	Gastric Ulcer		Reglan	C		
UNKNOWN						
	Gastroenteritis		Norvasc	C		
UNKNOWN						
	Haemorrhage		Lorazepam	C		
UNKNOWN						
	Hemiparesis		Aggrenox	C		
UNKNOWN						
	Hypertension		Zocor	C		
UNKNOWN						
	Intestinal Functional					
	Disorder					
	Leg Amputation					
	Micturition Urgency					
	Myocardial Infarction					
	Nausea					
	Peripheral Ischaemia					
	Peripheral Vascular					
	Disorder					
	Pyrexia					
	Thrombosis					
	Toe Amputation					
	Toe Deformity					
	Transient Ischaemic					
	Attack					
	Upper Gastrointestinal					
	Haemorrhage					
	Ventricular Hypertrophy					
	Vomiting					
	Wound Dehiscence					

Date:11/10/04ISR Number: 4497478-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00708
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

	Ovarian Cancer		Lexapro	C		
UNKNOWN						

Date:11/10/04ISR Number: 4497479-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01014
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL
Disability				C		
UNKNOWN						

Date:11/10/04ISR Number: 4497480-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Breast Disorder Haemorrhage Musculoskeletal Stiffness Prothrombin Level Increased		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4497482-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4497483-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00838
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Peripheral Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Metoprolol	C				
UNKNOWN								
Initial or Prolonged			Digitek	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497485-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00944
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zocor	C		ORAL		
Initial or Prolonged			Singulair	C		ORAL		
			Diovan	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497486-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411USA00847
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/10/04ISR Number: 4497487-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00997
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
Hospitalization - Initial or Prolonged Disability	Cardiovascular Disorder Grand Mal Convulsion Leg Amputation Oedema Peripheral							

Date:11/10/04ISR Number: 4497499-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00668
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Triple Vessel Bypass Graft		Avandia	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Vytorin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4497540-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03963
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Disorder		Plavix	C				
UNKNOWN								
Disability	Chest Pain		[Therapy Unspecified]	C				
Other								
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Verapamil Hydrochloride	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Thymol	C				
UNKNOWN								
			Naprosyn	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								

Date:11/10/04ISR Number: 4497596-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00147
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Contusion		Plavix	SS		ORAL		
	Drug Ineffective		Plavix	SS		ORAL		
			Bayer Aspirin	SS		ORAL		
			Fosamax	C		ORAL		

Date:11/10/04ISR Number: 4498123-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Acute Pulmonary Oedema
Disability	Anxiety
Other	Asthenia
	Blood Cholesterol Increased
	Bundle Branch Block
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Cognitive Disorder
	Convulsion
	Coronary Artery Disease
	Cystocele
	Depression
	Diabetes Mellitus
	Inadequate Control

	Diabetic Ketoacidosis						
	Emotional Distress						
	Emphysema	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Lasix (Furosemide)	C			UNKNOWN	
	Degeneration		Aspirin	C			UNKNOWN	
	Myocardial Infarction		Orphenadrine	C			UNKNOWN	
	Nasopharyngitis		Ativan	C			UNKNOWN	
	Palpitations		Lopressor	C			UNKNOWN	
	Rotator Cuff Syndrome		Glyburide	C			UNKNOWN	
	Supraventricular		Glucotrol Xl	C			UNKNOWN	
	Extrasystoles						
	Supraventricular						
	Tachycardia						
	Transient Ischaemic						
	Attack						
	Urinary Tract Infection						
	Ventricular Extrasystoles						
	Vision Blurred						

Date:11/10/04ISR Number: 4498132-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00115
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thromboembolic Stroke							

Date:11/10/04ISR Number: 4498137-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 4 YR	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain Headache Oedema Peripheral					

Date:11/10/04ISR Number: 4498138-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498139-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03199
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dysuria Urinary Tract Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498145-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00772
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Pressure Increased					
Other	Cerebrovascular Accident					
	Chronic Obstructive					
	Pulmonary Disease					
	Convulsion					
	Coordination Abnormal					
	Fall					
	Hemiparesis					
	Joint Range Of Motion					
	Decreased					
	Mobility Decreased					
	Pain In Extremity					
	Peroneal Nerve Palsy					
	Sensory Disturbance					
	Visual Disturbance					

Date:11/10/04ISR Number: 4498147-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aortic Valve Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Arthralgia					
	Carotid Artery Disease					
	Cerebrovascular Accident					
	Coronary Artery Disease					
	Decreased Appetite					
	Dementia					
	Difficulty In Walking					
	Dizziness					
	Drug Hypersensitivity					
	Dry Mouth					
	Faecaloma					
	Fall					
	Injury					
	Insomnia					
	Joint Swelling					
	Laceration					

Myocardial Ischaemia
Pain In Extremity
Parkinson'S Disease
Renal Cyst
Seasonal Allergy
Skin Ulcer
Urinary Retention
Urinary Tract Infection

Date:11/10/04ISR Number: 4498148-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00056
Age: Gender:Female I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
Other	Feeling Abnormal
	Gastric Disorder
	Therapeutic Product

	Ineffective						
	Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498152-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Cerebrovascular Accident							
	Electrocardiogram Abnormal							
	Facial Palsy							
	Heart Rate Irregular							
	Hypoaesthesia							
	Myocardial Infarction							
	Transient Ischaemic Attack							

Date:11/10/04ISR Number: 4498153-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00004
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
Other	Myocardial Infarction							

Date:11/10/04ISR Number: 4498154-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00090
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Axillary Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lymphadenopathy							
	Pulmonary Microemboli							

Venous Thrombosis Limb
Visual Acuity Reduced
Visual Field Defect

Date:11/10/04ISR Number: 4498155-6Report Type:Expedited (15-DaCompany Report #PR-MERCK-0410USA02666
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhagic Stroke		Rythmol	C				UNKNOWN
	Hypertensive Crisis		[Therapy Unspecified]	C				UNKNOWN

Date:11/10/04ISR Number: 4498156-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02467
Age:69 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Balance Disorder							
	Depression							
	Dizziness							
	Fatigue							
	Headache							
	Hypersomnia							
	Hypertension							
	Myocardial Infarction							
	Transient Ischaemic Attack							

Date:11/10/04ISR Number: 4498157-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03517
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Rebif	SS				
SUBCUTANEOUS							1	WK
Initial or Prolonged	Cardiomyopathy		Glucophage	C				
UNKNOWN								
	Fatigue		Lexapro	C				
UNKNOWN								
	Viral Pericarditis		Actos	C				
UNKNOWN								
			Ditropan	C				
UNKNOWN								
			Dexedrine	C				
UNKNOWN								

Date:11/10/04ISR Number: 4498158-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00285
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

	Hypertensive Crisis	Bicalutamide	C
UNKNOWN			
	Renal Injury	Losartan Potassium	C
UNKNOWN			
		Metoprolol Succinate	C
UNKNOWN			
		Zolpidem Tartrate	C
UNKNOWN			
		Pantoprazole Sodium	C
UNKNOWN			
		Ampicillin Sodium And Sulbactam Sodium	C
UNKNOWN			
		Gentamicin	C
UNKNOWN			
		Ciprofloxacin	C
UNKNOWN			

Date:11/10/04ISR Number: 4498159-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00206
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Closed Head Injury Concussion Contusion Excoriation Joint Sprain Subarachnoid Haemorrhage Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498160-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:11/10/04ISR Number: 4498161-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498162-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00011
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
				C				
UNKNOWN								

Date:11/10/04ISR Number: 4498163-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00426
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/10/04ISR Number: 4498164-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00519
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Death							
Disability	Eating Disorder							
	Lung Disorder							
	Oesophageal Discomfort							
	Stomach Discomfort							
	Vomiting							

Date:11/10/04ISR Number: 4498165-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00489
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
489 DAY								
Initial or Prolonged	Eructation		Prednisolone	C				
UNKNOWN								
	Nausea		Calcium Gluconate					
	Pain		And Calcium					
	Ventricular Extrasystoles		Phosphate Tribasic					
			And Cholecalciferol	C		ORAL		
			Metoprolol Succinate	C				
UNKNOWN								
			Metoprolol Succinate	C				
UNKNOWN								
			Pantoprazole Sodium	C				
UNKNOWN								
			Telmisartan	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498169-6Report Type:Expedited (15-DaCompany Report #PL-MERCK-0411POL00002
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:11/10/04ISR Number: 4498170-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	Life-Threatening	

Date:11/10/04ISR Number: 4498172-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00575
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged	Haemorrhage		[Therapy Unspecified]	C				
Disability								

Date:11/10/04ISR Number: 4498173-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00197
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	141 DAY	
	Chest Pain							
	Dizziness							
	Muscle Spasms							

Date:11/10/04ISR Number: 4498175-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00423
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/10/04ISR Number: 4498176-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00420
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cholecystectomy		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Lipitor	C				
Initial or Prolonged UNKNOWN	Road Traffic Accident		Cardura	C				
			Propulsid	C				
			Pepcid	C		ORAL		
			Prilosec	C		ORAL		
			Demadex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498177-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00109
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Molsidomine	C				
UNKNOWN								
	Exercise Capacity		Isosorbide					
	Decreased		Mononitrate	C				
UNKNOWN								
	Syncope		Aspirin	C				
UNKNOWN								

Date:11/10/04ISR Number: 4498178-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00068
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
126 DAY								
Initial or Prolonged								
Disability								

Date:11/10/04ISR Number: 4498179-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00073
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498181-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism		Celebrex	SS				
UNKNOWN								

Date:11/10/04ISR Number: 4498184-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00522
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498186-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Renal Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:11/10/04ISR Number: 4498187-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00809
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Disease		Lisinopril	C				
Initial or Prolonged	Chest Pain		Vicodin Tablets	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498189-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498190-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00202
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Isosorbide	C				
UNKNOWN								
Initial or Prolonged			Diltiazem					
Disability			Hydrochloride	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								
			Digitek	C				
UNKNOWN								

Date:11/10/04ISR Number: 4498191-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00357
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:11/10/04ISR Number: 4498192-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged

Date:11/10/04ISR Number: 4498194-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00705
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Nexium	C				
UNKNOWN								
Initial or Prolonged	Overdose		Vicodin Tablets	C		ORAL		
Disability			Naproxen	C				
UNKNOWN								

Date:11/10/04ISR Number: 4498195-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00915
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498196-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00554
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Zocor	C		ORAL		
Initial or Prolonged			Synthroid	C				
UNKNOWN								
Disability								

Date:11/10/04ISR Number: 4498198-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498199-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00576
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Prilosec	C				
UNKNOWN								
Initial or Prolonged			Aggrenox	C				
UNKNOWN								
Disability								

Date:11/10/04ISR Number: 4498200-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00520
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bronchitis Chronic							
	Renal Failure							

Date:11/10/04ISR Number: 4498201-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ejection Fraction Decreased Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498202-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00756
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Prednisone	C				
Initial or Prolonged UNKNOWN			Allegra	C				
Disability UNKNOWN			Aspirin	C				

Date:11/10/04ISR Number: 4498208-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01461
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx Analgesic Or	PS	Merck & Co., Inc	ORAL		

Anesthetic
(Unspecified) C
UNKNOWN

Date:11/10/04ISR Number: 4498209-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00710
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Levothroid	C				
UNKNOWN								
Initial or Prolonged								

Date:11/10/04ISR Number: 4498213-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01449
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/10/04ISR Number: 4498214-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Fatigue							
	Medication Error							

Date:11/10/04ISR Number: 4498215-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01062
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vasotec	C		ORAL		
Initial or Prolonged			Lipitor	C				
UNKNOWN								

Disability

Date:11/10/04ISR Number: 4498216-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01462
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking Overdose Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498217-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00858
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Discomfort Chest Pain		Zocor Prevacid	C C		ORAL		
UNKNOWN								
Disability	Depression		Ambien	C				
UNKNOWN								
			Oxycontin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498218-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00761
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Flatulence		Hydrodiuril	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:11/10/04ISR Number: 4498219-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00822
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Neck Pain							
Initial or Prolonged								
Disability								

Date:11/10/04ISR Number: 4498220-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00909
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:11/10/04ISR Number: 4498223-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00782
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Suture Rupture		Vioxx	PS	Merck & Co., Inc	ORAL		
3 DAY								
Initial or Prolonged	Vomiting		Lescol	C				
UNKNOWN								
			Verapamil	C				
UNKNOWN								

Date:11/10/04ISR Number: 4498224-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00923
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Asthenia Cerebrovascular Accident Hypoaesthesia Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/10/04ISR Number: 4498225-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01469
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Hydrodiuril	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/10/04ISR Number: 4498226-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00996
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/10/04ISR Number: 4498227-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:11/10/04ISR Number: 4498228-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01384
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							

Date:11/10/04ISR Number: 4498909-6Report Type:Direct Company Report #CTU 231758
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS		ORAL	25 MG PO X 1/DAY	
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Convulsion		Zocor	C				
			Cardiazem Cd	C				
			Glucophage	C				

Date:11/10/04ISR Number: 4499040-6Report Type:Direct Company Report #CTU 231736
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastrointestinal Haemorrhage		Rofecoxib	PS		ORAL	25 MG PO DAILY	

Date:11/11/04ISR Number: 4499084-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Acute Myocardial Infarction
	Adverse Event
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Coronary Artery Disease
	Depression

		Diabetes Mellitus Inadequate Control Diabetic Neuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea	Other	Vioxx	PS	Merck & Co., Inc	ORAL
		Escherichia Sepsis Hypertension Intermittent Claudication Mitral Valve Incompetence Myocardial Infarction Oedema Peripheral Osteoarthritis Peripheral Occlusive Disease Pleural Effusion Pulmonary Oedema Renal Failure Sciatica Spinal Column Stenosis Stress Incontinence Transient Ischaemic Attack Urinary Tract Infection Urosepsis Uterine Infection					

Date:11/11/04ISR Number: 4499093-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00054
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Atorvastatin Calcium	C		ORAL
			Isradipine	C		ORAL
			Levothyroxine Sodium And Potassium Iodide	C		ORAL
			Metoprolol Succinate	C		ORAL

Date:11/11/04ISR Number: 4499094-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00844
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cardiac Failure Congestive Tachycardia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499096-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA00382
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability Other	Abdominal Pain Lower Carpal Tunnel Syndrome Diverticular Perforation Diverticulitis Emotional Distress Hypokalaemia Large Intestine

	Perforation						
	Memory Impairment						
	Muscle Spasms						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pyrexia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Umbilical Hernia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Niaspan	C			UNKNOWN
			Coreg	C			UNKNOWN
			Zestril	C			UNKNOWN
			Foltx	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Pravachol	C		ORAL	141 DAY
			Pravachol	C		ORAL	
			Proventil	C			UNKNOWN
			Metamucil	C			UNKNOWN

Date:11/11/04ISR Number: 4499097-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Back Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cerebrovascular Accident	Professional					
Other	Gait Disturbance						
	Lumbar Radiculopathy						
	Spinal Cord Disorder						

Date:11/11/04ISR Number: 4499098-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00096
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biliary Cirrhosis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	37	DAY
Initial or Prolonged	Hepatitis A							

Date:11/11/04ISR Number: 4499099-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00139
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Other	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/11/04ISR Number: 4499100-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00310
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hip Fracture	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								

Date:11/11/04ISR Number: 4499102-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00093
Age:74 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Death	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis							
	Mitral Valve Stenosis							
	Pelvic Venous Thrombosis							
	Pulmonary Microemboli							
	Renal Impairment							
	Visual Acuity Reduced							

Date:11/11/04ISR Number: 4499103-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00900
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening		Professional	Pravachol	C				
UNKNOWN								
Disability			Lopressor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Vitamin E	C				
UNKNOWN								

Date:11/11/04ISR Number: 4499104-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00615
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Glucose Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Headache		Avandia	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Glipizide	C				
UNKNOWN								
Disability			Hyzaar	C		ORAL		
			Effexor	C				
UNKNOWN								
			Detrol	C				
UNKNOWN								

				Valium	C		
UNKNOWN							
				Crestor	C		
UNKNOWN							

Date:11/11/04ISR Number: 4499105-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00258
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Drowning	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Road Traffic Accident		[Therapy Unspecified]	C		
UNKNOWN						

Date:11/11/04ISR Number: 4499106-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00266
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
202 DAY						
Hospitalization -	Hypertension		Actos	C		
UNKNOWN						
Initial or Prolonged			A.S.A.	C		
UNKNOWN						
Disability			Effexor	C		
UNKNOWN						
			Mevacor	C		
UNKNOWN						
			Aricept	C		
UNKNOWN						
			Allpyral	C		
UNKNOWN						
			Temazepam	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499107-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499108-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00015
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Facial Palsy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Lacunar Infarction		Corticosteroids (Unspecified)	C		PARENTERAL		
			Glucosamine Hydrochloride	C		UNKNOWN		
			Hyaluronate Sodium	C		PARENTERAL		

Date:11/11/04ISR Number: 4499110-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00958
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Palpitations		Synthroid	C		UNKNOWN		
			Norvasc	C		UNKNOWN		
			Toprol Xl Tablets	C		UNKNOWN		
			Plaquenil	C		UNKNOWN		

Date:11/11/04ISR Number: 4499111-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Neoplasm Malignant Renal Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499112-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00959
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499113-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Disease Coronary Artery Disease Myocardial Infarction Renal Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499115-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00808
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Tachycardia		Gemfibrozil	C				
UNKNOWN								
Initial or Prolonged			Bumetanide	C				
UNKNOWN								
Disability			Digoxin	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Potassium Chloride	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								

Date:11/11/04ISR Number: 4499116-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00983
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
							1	YR
Hospitalization -	Lethargy							
Initial or Prolonged	Myocardial Infarction							

Date:11/11/04ISR Number: 4499117-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01088
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Unevaluable Event							
Initial or Prolonged	Vision Blurred							
Disability								

Date:11/11/04ISR Number: 4499134-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01599
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:11/11/04ISR Number: 4499136-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01799
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499137-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00628
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
	Cough		Glucophage	C			UNKNOWN	
	Drug Ineffective		Diovan	C			UNKNOWN	
	Dyspnoea		Norvasc	C			UNKNOWN	
	Eye Disorder							
	General Physical Health Deterioration							
	Tremor							
	Wheezing							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499138-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00954
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Metoprolol	C				
	Fall		Zocor	C				
	Infection		Lasix (Furosemide)	C				
	Palpitations							

Date:11/11/04ISR Number: 4499139-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01109
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disability	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	6	YR
Hospitalization - Initial or Prolonged	Fall		Celebrex	C				
	Hypertension		Zestril	C				
Disability			Zocor	C				
			Hydrochlorothiazide	C				
			Toprol Xl Tablets	C				
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				

Date:11/11/04ISR Number: 4499141-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01436
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Atrial Fibrillation	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Initial or Prolonged							

Date:11/11/04ISR Number: 4499142-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01105
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
		Professional						

Date:11/11/04ISR Number: 4499143-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01357
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Attack		Flonase	C				
UNKNOWN								

Date:11/11/04ISR Number: 4499145-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Dilantin	C				
UNKNOWN								
Initial or Prolonged			Zoloft	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499168-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02383
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise							

Date:11/11/04ISR Number: 4499275-2Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908829
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aggression		Ultracet	PS				
OROPHARINGEAL								
	Aspiration		Cyclobenzaprine	SS				
OROPHARINGEAL								
	Completed Suicide		Amitriptyline	SS				
OROPHARINGEAL								
	Depressed Level Of		Tizanidine	SS				
	Consciousness		Rofecoxib	SS				
	Drug Toxicity		Omeprazole	SS				
	Intentional Misuse							
	Lung Crepitation							
	Sedation							
	Vomiting							

Date:11/11/04ISR Number: 4499350-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
487 DAY								
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
487 DAY								
Disability	Arrhythmia		Inderal La	C				
UNKNOWN								
	Arteriospasm Coronary		Inderal La	C				
UNKNOWN								
	Back Injury		Claritin-D	C				
UNKNOWN	1758 DAY							

	Back Pain	Humibid	C
UNKNOWN			
	Blood Pressure Decreased	Prevacid	C
UNKNOWN			
	Bone Pain	Nasonex	C
UNKNOWN	764 DAY		
	Buttock Pain	Darvocet-N	C
UNKNOWN			
	Chest Pain	Bactrim	C
UNKNOWN			
	Chondromalacia	Pseudoephedrine	C
UNKNOWN			
	Discomfort	Maxzide	C
UNKNOWN			
	Dyspepsia	Naprosyn	C
UNKNOWN			
	Intervertebral Disc	Entex La	C
UNKNOWN			
	Displacement	Voltaren	C
UNKNOWN			
	Low Density Lipoprotein	Evening Primrose Oil	C
UNKNOWN			
	Increased	Glucosamine	C
UNKNOWN			
	Meniscus Lesion	Chondroitin	C
UNKNOWN			
	Mitral Valve Incompetence	Zantac	C
UNKNOWN			
	Muscle Spasms	Sudafed	C
UNKNOWN			
	Neuralgia	Aspirin	C
UNKNOWN			
	Oedema	Norco	C
UNKNOWN			
	Osteoarthritis		
	Pleuritic Pain		
	Post Procedural Pain		
	Sacroiliitis		
	Tachyarrhythmia		
	Tachycardia		
	Tricuspid Valve Incompetence		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499352-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carotid Artery Stenosis		Aspirin	C		ORAL		
Other	Circulatory Collapse		Prevacid	C		ORAL		
	Coronary Artery Disease		Nasacort	C				
UNKNOWN								
	Deafness		Avapro	C				
UNKNOWN								1681 DAY
	Dyspnoea Exertional		Tylenol	C				
UNKNOWN								
	Emotional Distress		Flexeril	C		ORAL		
	Femur Fracture		Ativan	C				
UNKNOWN								1344 DAY
	Gastrointestinal Disorder		Atenolol	C		ORAL		
	Injury		Plavix	C				
UNKNOWN								366 DAY
	Migraine		Vicodin Tablets	C				
UNKNOWN								
	Myocardial Infarction		Celexa	C				
UNKNOWN								1839 DAY
	Nasal Polyps		Niacin	C				
UNKNOWN								1830 DAY
	Nasal Turbinate		Zantac	C				
UNKNOWN								
	Hypertrophy		Tums	C				
UNKNOWN								
	Stress		Titralac Antacid	C				
UNKNOWN								
	Vestibular Disorder							
	Vestibular Neuronitis							

Date:11/11/04ISR Number: 4499353-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anoxic Encephalopathy		Atenolol	C				
UNKNOWN								

	Atherosclerosis		Prozac	C			
UNKNOWN							
	Blood Cholesterol		Prozac	C			
UNKNOWN							
	Increased		Tylenol	C			
UNKNOWN							
	Cardiac Failure		Buspar	C			
UNKNOWN							
	Congestive		Atrovent	C			
UNKNOWN							
	Cardio-Respiratory Arrest		Magnesium Sulfate	C			
UNKNOWN							
	Cardiogenic Shock		Claforan	C			
UNKNOWN							
	Chest Pain		Cordarone	C			
UNKNOWN							
	Convulsion		Pepcid	C			
UNKNOWN							
	Haematuria		Reopro	C			
UNKNOWN							
	Hypertension		Dopamine				
	Lung Infiltration		Hydrochloride	C			
UNKNOWN							
	Myalgia		Restoril	C			
UNKNOWN							
	Myocardial Infarction		Aspirin	C			ORAL
	Orthostatic Hypotension		Celexa	C			
UNKNOWN							
	Papilloma		Neurontin	C			
UNKNOWN							
	Skin Laceration		Dalmane	C			
UNKNOWN							
	Ventricular Arrhythmia		Vasotec	C			
UNKNOWN							
	Ventricular Tachycardia						

Date:11/11/04ISR Number: 4499354-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00929
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris Blood Pressure Increased Cerebrovascular Accident Convulsion Drug Hypersensitivity Sensory Loss		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499355-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrial Flutter		Dilacor Xr	C				
UNKNOWN								
Initial or Prolonged	Cardiac Failure		Cozaar	C				
UNKNOWN								
Other	Congestive		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease		Furosemide	C				
UNKNOWN								
	Cough		Cordarone	C				
UNKNOWN								
	Myocardial Infarction		Lipitor	C				
UNKNOWN								
	Oedema Peripheral							
	Rhinitis Allergic							

Date:11/11/04ISR Number: 4499356-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00697
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Tenormin	C				
UNKNOWN								
	Convulsion		Tenormin	C				
UNKNOWN								
	Coronary Artery Disease		Baycol	C				
UNKNOWN								
	Electrocardiogram		Ogen	C				
UNKNOWN								
	Abnormal		Lipitor	C				
UNKNOWN								
	Myocardial Infarction		Atenolol	C				
UNKNOWN								
	Myocardial Ischaemia							
	Ventricular Hypertrophy							

Date:11/11/04ISR Number: 4499357-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00338
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	84 DAY	
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiac Arrest		Fiorinal	C				
Disability	Cardiomegaly		[Therapy Unspecified]	C			UNKNOWN	
	Cholelithiasis							
	Coronary Artery Atherosclerosis							
	Dermal Cyst							
	Emphysema							
	Hepatomegaly							
	Hyperlipidaemia							
	Myocardial Infarction							
	Pulmonary Congestion							
	Ventricular Hypertrophy							

Date:11/11/04ISR Number: 4499359-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02873
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Sudden Death		Amitriptyline Hydrochloride	C			UNKNOWN	
			Methadone Hydrochloride	C			UNKNOWN	
			Oxycodone	C			UNKNOWN	
			Ambien	C			UNKNOWN	

				Neurontin	C		
UNKNOWN							

Date:11/11/04ISR Number: 4499360-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00109
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	SS				
UNKNOWN								
	Myocardial Infarction							
	Pericardial Disease							
	Pericardial Haemorrhage							

Date:11/11/04ISR Number: 4499362-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00178
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
							646 DAY	
Life-Threatening			Leflunomide	C				
UNKNOWN								

Date:11/11/04ISR Number: 4499363-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02282
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:11/11/04ISR Number: 4499364-2Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00003
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499366-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02370
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
			Hytrin	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:11/11/04ISR Number: 4499367-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03129
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Amnesia
Hospitalization - Initial or Prolonged	Blood Triglycerides Increased
Disability	Cerebrovascular Accident
	Chest Pain

		Faeces Discoloured Meningitis Neurological Symptom	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Percocet	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Misoprostol	C		
UNKNOWN							
				Nasonex	C		
UNKNOWN							
				Mirapex	C		
UNKNOWN							
				Hydrocodone/Apap	C		
UNKNOWN							
				Gemfibrozil	C		
UNKNOWN							
				Dicloxacillin	C		
UNKNOWN							
				Fluoxetine	C		
UNKNOWN							

Date:11/11/04ISR Number: 4499368-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03177
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Coronary Syndrome
Other	Anxiety
	Back Pain
	Blood Triglycerides Increased
	Cardiac Murmur
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Chills

Chronic Obstructive
Pulmonary Disease
Contusion
Deafness Bilateral
Dyspnoea
Dysuria
Epistaxis
Fall
Gingival Bleeding
Haematochezia
Heart Rate Irregular
Hypertension
Injury
International Normalised
Ratio Decreased
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Limb Discomfort
Menstrual Disorder
Neck Pain
Oedema Peripheral
Osteoarthritis
Peroneal Nerve Palsy
Radiculitis
Sciatica
Silent Myocardial

		Infarction Sleep Disorder Stress Incontinence Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Tract Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Wheezing		Coumadin	SS		
UNKNOWN							
				Coumadin	SS		
UNKNOWN							
				Isordil	C		
UNKNOWN							
				Anzemet	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Vasotec	C		ORAL
				[Therapy Unspecified]	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Ticlid	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Bayer Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:11/11/04ISR Number: 4499376-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01801
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Dizziness		Cardura	C				UNKNOWN
Other	Dyspnoea		Hyzaar	C				UNKNOWN
	Electrocardiogram		Synthroid	C				UNKNOWN
	Ambulatory Abnormal		Protonix	C				UNKNOWN
	Sinus Bradycardia		Dicyclomine Hydrochloride	C				UNKNOWN
	Syncope							
	Visual Disturbance							

Date:11/11/04ISR Number: 4499377-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00054
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Verapamil Hydrochloride	C				UNKNOWN

Date:11/11/04ISR Number: 4499378-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00086
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499379-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:11/11/04ISR Number: 4499380-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:11/11/04ISR Number: 4499381-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	24	MON
Initial or Prolonged								

Date:11/11/04ISR Number: 4499382-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00115
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Myocardial Infarction							
	Renal Disorder							

Date:11/11/04ISR Number: 4499383-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
			Atorvastatin Calcium	C			UNKNOWN	

Date:11/11/04ISR Number: 4499384-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00473
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Transient Ischaemic Attack		Propranolol Hydrochloride	C		ORAL		
			Talinolol	C		ORAL		
			Omeprazole	C		ORAL		
			Olmesartan Medoxomil	C		ORAL		
			Fluvastatin Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499385-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00115
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1016 DAY	
	Infarction							
	Sudden Death							

Date:11/11/04ISR Number: 4499386-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Gastric Disorder							
	Hernia							

Date:11/11/04ISR Number: 4499387-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00417
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Prevacid	C				
UNKNOWN								
	Carotid Artery Disease							
	Chest Pain							
	Dizziness							
	Electrocardiogram							
	Abnormal							
	Myocardial Infarction							
	Oedema Peripheral							

Date:11/11/04ISR Number: 4499388-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00206
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Closed Head Injury Concussion Contusion Excoriation Fall Headache Hypoaesthesia Joint Sprain Loss Of Consciousness Pain Personality Change Subarachnoid Haemorrhage Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499389-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00166
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499390-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00121
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		538 DAY
Life-Threatening			Cardizem	C				UNKNOWN
Hospitalization -			Prozac	C				UNKNOWN
Initial or Prolonged			Aspirin	C				UNKNOWN
Disability			Zocor	C		ORAL		
			Hytrin	C				UNKNOWN
			Trusopt	C				OPHTHALMIC
			Darvocet-N	C				UNKNOWN
			Xanax	C				UNKNOWN

Date:11/11/04ISR Number: 4499391-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00215
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								

Date:11/11/04ISR Number: 4499392-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00134
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/11/04ISR Number: 4499393-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00126
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acarbose	C			UNKNOWN	
			Ramipril	C			UNKNOWN	
			Metformin	C			UNKNOWN	

Date:11/11/04ISR Number: 4499394-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03912
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphthous Stomatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Hormonal Contraceptives (Unspecified)	C			UNKNOWN	

Date:11/11/04ISR Number: 4499395-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00537
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499396-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00145
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499397-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499398-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00654
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Intestinal Haemorrhage		Vioxx Toprol Xl Tablets	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Clonidine [Therapy Unspecified]	C C			UNKNOWN UNKNOWN	

Date:11/11/04ISR Number: 4499399-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00880
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499400-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00647
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Life-Threatening	Death		[Therapy Unspecified]	C				
Hospitalization - UNKNOWN								
Initial or Prolonged Disability								

Date:11/11/04ISR Number: 4499402-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00948
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysphagia		Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN	Transient Ischaemic		Prevacid	C				
UNKNOWN	Attack		Lipitor	C				
UNKNOWN			Pletal	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499403-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00790
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		[Therapy Unspecified]	C				UNKNOWN
			Premarin	C				UNKNOWN
			Provera	C				UNKNOWN

Date:11/11/04ISR Number: 4499404-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00798
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Feeling Abnormal		Verapamil	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Embolism							

Date:11/11/04ISR Number: 4499406-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Emotional Distress							
	Unevaluable Event							

Date:11/11/04ISR Number: 4499407-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01005
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
6 MON								

Hospitalization - UNKNOWN	Fluctuation	Protonix	C
Initial or Prolonged UNKNOWN	Chronic Obstructive	Deflazacort	C
	Pulmonary Disease	Combivent	C
UNKNOWN			
	Heart Rate Abnormal	Enalapril Maleate	C
UNKNOWN			
	Heart Rate Increased	Hydrochlorothiazide	C
UNKNOWN			
	Heart Rate Irregular	Dioxone	C
UNKNOWN			
	Hypertension	Verapamil	
	Hypotension	Hydrochloride	C
UNKNOWN			
	Somnolence	Albuterol	C
UNKNOWN			

Date:11/11/04ISR Number: 4499410-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01433
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - UNKNOWN	Cerebrovascular Accident		Duragesic	C				
Initial or Prolonged Disability UNKNOWN			[Therapy Unspecified]	C				

Date:11/11/04ISR Number: 4499411-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01441
Age:79 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain Pyrexia Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499413-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01435
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Dry Mouth Thirst		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/11/04ISR Number: 4499414-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01037
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged UNKNOWN Disability UNKNOWN	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C				
			Norvasc	C				
			Allopurinol	C				
			Metoclopramide	C				
			[Therapy Unspecified]	C				
			Synthroid	C				
			Benicar Hct	C				

Date:11/11/04ISR Number: 4499415-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00881
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Haemorrhage		Glucotrol	C				
Initial or Prolonged	Myocardial Infarction							

Date:11/11/04ISR Number: 4499416-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00862
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Chest Pain		Tenoret	C				
Initial or Prolonged	Gastric Haemorrhage							
Disability								

Date:11/11/04ISR Number: 4499419-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499421-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01603
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Memory Impairment		Methotrexate	C				
	Paralysis							

Date:11/11/04ISR Number: 4499426-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01034
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Flexeril	C				
	Cerebral Haemorrhage		Neurontin	C				
Disability	Cerebrovascular Accident							
	Myocardial Infarction							
	Paralysis							

Date:11/11/04ISR Number: 4499428-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01133
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
Disability			[Therapy Unspecified]	C				

Date:11/12/04ISR Number: 4499931-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Alopecia
Disability	Arthralgia
Other	Back Pain
	Blindness
	Bronchitis
	Cataract
	Cerebrovascular Accident
	Depression
	Diverticulum
	Endometrial Hyperplasia
	Epistaxis
	Flushing
	Gastrooesophageal Reflux Disease
	Gout
	Haemorrhage Intracranial
	Headache
	Hemianopia Homonymous
	Herpes Zoster
	Hyperhidrosis
	Hypersensitivity
	Hypertension
	Joint Injury
	Nasal Congestion
	Nausea
	Pain

		Pallor					
		Pneumonia					
		Postmenopausal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage	Health	Vioxx	PS	Merck & Co., Inc	ORAL
676	DAY						
		Rash	Professional	Provera	SS		
UNKNOWN							
		Rift Valley Fever		Heparin	SS		
UNKNOWN							
		Sciatica		Captopril	C		
UNKNOWN							
		Tachycardia		Glyburide	C		
UNKNOWN							
		Thyroid Mass		[Therapy			
		Uterine Polyp		Unspecified]	C		
UNKNOWN							
		Vaginal Haemorrhage		Cisapride	C		
UNKNOWN							
				Tylenol With Codeine			
				#3	C		
UNKNOWN							
				Capozide	C		
UNKNOWN							

Date:11/12/04ISR Number: 4499934-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00004
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased		Celebrex	C		
UNKNOWN						
Other	Breast Disorder		Vicodin Tablets	C		
UNKNOWN						
	Cardiac Murmur		Percocet	C		
UNKNOWN						
	Cardiac Valve Disease		Darvocet-N	C		
UNKNOWN						
	Cervicobrachial Syndrome		Soma	C		
UNKNOWN						
	Depression		Oxycontin	C		
UNKNOWN						

	Dizziness	Ibuprofen	C
UNKNOWN			
	Dyspnoea	Aleve	C
UNKNOWN			
	Dysuria		
	Gastrooesophageal Reflux		
	Disease		
	Heart Rate Irregular		
	Hypertension		
	Intervertebral Disc		
	Disorder		
	Micturition Urgency		
	Muscle Strain		
	Nocturia		
	Osteoarthritis		
	Osteopenia		
	Pollakiuria		
	Rotator Cuff Syndrome		
	Sleep Apnoea Syndrome		

Date:11/12/04ISR Number: 4499937-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Valve Incompetence
	Arrhythmia
	Supraventricular
	Back Pain
	Blood Cholesterol
	Increased
	Bronchitis
	Cardiac Failure
	Congestive

		Cerebrovascular Accident					
		Cerebrovascular Disorder					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum Intestinal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Diazide	C		
UNKNOWN							
		Heart Rate Irregular		Lopressor	C		
UNKNOWN							
		Mitral Valve Incompetence		Lopressor	C		
UNKNOWN							
		Myocardial Infarction		Zocor	C		ORAL
		Overdose					
		Pneumonia					
		Pruritus					
		Rash Papular					
		Sebaceous Gland Disorder					
		Thrombosis					
		Upper Respiratory Tract Infection					

Date:11/12/04ISR Number: 4499938-9Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00065
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
15	MON						
Initial or Prolonged		Facial Palsy		Vioxx	SS	Merck & Co., Inc	ORAL
15	MON						
		Fatigue		Mefenamic Acid	C		
UNKNOWN							
		Loss Of Consciousness		Amitriptyline			
		Memory Impairment		Hydrochloride	C		
UNKNOWN							
		Sluggishness		Candesartan			
		Speech Disorder		Cilexetil	C		
UNKNOWN							
		Tremor		Liotrix	C		
UNKNOWN							
				Paroxetine	C		
UNKNOWN							
				Analgesic Or Anesthetic			

			(Unspecified)	C
UNKNOWN	3	DAY		
			Tramadol Hydrochloride	C
UNKNOWN				
			Diclofenac Sodium And Orphenadrine Citrate	C
UNKNOWN	12	DAY		

Date:11/12/04ISR Number: 4499940-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00842
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Suicidal Ideation	Professional						

Date:11/12/04ISR Number: 4499941-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Amnesia
	Anxiety
	Asthenia
	Asthma

		Atherosclerosis					
		Back Disorder					
		Back Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Glucose Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
252 DAY							
		Blood Potassium Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
252 DAY							
		Blood Triglycerides		Seroquel	C		
UNKNOWN							
		Increased		Seroquel	C		
UNKNOWN							
		Bronchitis Acute		Hydrochlorothiazide	C		
UNKNOWN							
		Cardiomyopathy		Soma	C		
UNKNOWN							
		Catheter Site Haemorrhage		Premarin	C		
UNKNOWN							
		Chest Pain		Altace	C		
UNKNOWN							
		Chronic Obstructive		Vicodin Tablets	C		
UNKNOWN							
		Pulmonary Disease		Cyanocobalamin	C		
UNKNOWN							
		Constipation		Prevacid	C		
UNKNOWN							
		Coordination Abnormal		Toprol Xl Tablets	C		
UNKNOWN							
		Coronary Artery Disease		Toprol Xl Tablets	C		
UNKNOWN		8 DAY					
		Coronary Artery		Plavix	C		
UNKNOWN							
		Thrombosis		Zocor	C		
UNKNOWN							
		Crying		Lipitor	C		
UNKNOWN		112 DAY					
		Depression		Foltx	C		
UNKNOWN							
		Dizziness		Potassium			
		Dysphagia		(Unspecified)	C		
UNKNOWN							
		Euthyroid Sick Syndrome		Linseed Oil	C		
UNKNOWN							
		Fatigue		Nitroglycerin	C		
UNKNOWN							
		Fibromyalgia		Aspirin	C		
UNKNOWN							

	Gastroenteritis	Folic Acid	C	
UNKNOWN				
	Hallucination	Neurontin	C	
UNKNOWN				
	Headache	Ambien	C	
UNKNOWN				
	Herpes Simplex	Doxepin		
	Hyperhidrosis	Hydrochloride	C	
UNKNOWN				
	Hypertension	Flexeril	C	ORAL
	Insomnia	Hydrocodone		
	Intervertebral Disc	Hydrochloride	C	
UNKNOWN				
	Degeneration	Prozac	C	
UNKNOWN				
	Irritable Bowel Syndrome	Prozac	C	
UNKNOWN				
	Ischaemic Cardiomyopathy			
	Kyphosis			
	Myofascial Pain Syndrome			
	Nasal Disorder			
	Nasal Polyps			
	Nausea			
	Neck Pain			
	Night Sweats			
	Pain			
	Panic Disorder			
	Phonophobia			
	Photophobia			
	Platelet Disorder			
	Post Procedural Haematoma			
	Rheumatoid Arthritis			
	Skin Cancer			
	Sleep Apnoea Syndrome			
	Sleep Disorder			
	Spondylolisthesis			
	Therapy Non-Responder			
	Thyroid Disorder			
	Tinnitus			
	Tremor			
	Vascular Pseudoaneurysm			
	Vision Blurred			
	Vomiting			

Date:11/12/04ISR Number: 4499944-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00714
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Esomeprazole Magnesium	C			UNKNOWN	
			Amlodipine Besylate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:11/12/04ISR Number: 4499945-6Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00069
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL	515 DAY	
Initial or Prolonged	Visual Disturbance	Professional	Metformin Hydrochloride	C		ORAL		
Other								

Date:11/12/04ISR Number: 4499949-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	584 DAY	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Norvasc	C			UNKNOWN	
	Blood Pressure Increased		Celebrex	C			UNKNOWN	
	Convulsion		Clonidine	C			UNKNOWN	
	Muscle Spasms		Demadex	C			UNKNOWN	
	Pain In Extremity		Digitek	C			UNKNOWN	

	Potassium (Unspecified)	C
UNKNOWN		
	Aspirin	C
UNKNOWN		
	Accupril	C
UNKNOWN		

Date:11/12/04ISR Number: 4499950-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01962
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Back Pain
	Cardiomegaly
	Cardiovascular Disorder
	Colonic Pseudo-Obstruction
	Hypertensive Heart Disease
	Hyponatraemia
	Hypovolaemia
	Ileus
	Intervertebral Disc Disorder
	Leukocytosis
	Nausea
	Pain In Extremity
	Post Procedural Complication
	Post-Traumatic Stress Disorder

		Pulmonary Embolism Renal Failure Small Intestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Obstruction Upper Respiratory Tract Infection Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/12/04ISR Number: 4499951-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02156
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Other		Cerebrovascular Accident Disturbance In Attention Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/12/04ISR Number: 4499954-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA00479
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/12/04ISR Number: 4499955-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00539
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:11/12/04ISR Number: 4499957-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499958-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA03431
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499959-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00830
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Alopecia
	Arthralgia
	Asthenia
	Back Injury
	Bronchospasm

		Chest Discomfort					
		Chest Pain					
		Chest Wall Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cough	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cystitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Ultram	C		
UNKNOWN							
		Dyspnoea		Methocarbamol	C		
UNKNOWN							
		Dyspnoea Exertional		Vasotec	C		ORAL
		Fatigue		[Therapy			
		Gastritis		Unspecified]	C		
UNKNOWN							
		Gastrooesophageal Reflux		Calcium			
		Disease		(Unspecified)	C		
UNKNOWN							
		Hypersomnia		Potassium			
		Hypertension		(Unspecified)	C		
UNKNOWN							
		Insomnia		Premarin	C		
UNKNOWN							
		Intervertebral Disc		Paxil	C		
UNKNOWN							
		Degeneration		Albuterol	C		
UNKNOWN							
		Lumbar Radiculopathy		Hydrochlorothiazide	C		
UNKNOWN							
		Migraine					
		Myalgia					
		Oedema Peripheral					
		Osteoarthritis					
		Sacroiliitis					
		Sleep Apnoea Syndrome					
		Somnolence					
		Vaginal Infection					

Date:11/12/04ISR Number: 4499962-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00625
Age:72 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy			

Unspecified] C
UNKNOWN

Date:11/12/04ISR Number: 4499964-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01396
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499965-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499966-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4499967-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00024
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499968-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03387M
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		1247 DAY
	Postoperative Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		1247 DAY
			Vicodin Tablets	C				UNKNOWN
			Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
			Antimicrobial (Unspecified)	C				UNKNOWN

Date:11/12/04ISR Number: 4499970-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nexium	C				UNKNOWN

Date:11/12/04ISR Number: 4499972-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA02589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499973-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499974-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00889
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Norvasc	C			UNKNOWN	
Disability			Hydrocortisone	C			UNKNOWN	

Date:11/12/04ISR Number: 4499975-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03387B1
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			
			Vioxx	SS	Merck & Co., Inc			

1247 DAY

		Vioxx	SS	Merck & Co., Inc
		Vioxx	SS	Merck & Co., Inc
1247 DAY				
		Vicodin Tablets	C	
		Analgesic Or Anesthetic (Unspecified)	C	
		Antimicrobial (Unspecified)	C	

Date:11/12/04ISR Number: 4499976-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01122
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499978-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00888
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499979-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01038
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499981-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01123
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4499983-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction							

Date:11/12/04ISR Number: 4499984-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01501
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Oxycontin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4499988-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01764
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			
	Drug Exposure During		Vioxx	SS	Merck & Co., Inc			1247 DAY
	Pregnancy		Vioxx	SS	Merck & Co., Inc			
	Intra-Uterine Death		Vioxx	SS	Merck & Co., Inc			1247 DAY
			Vicodin Tablets	C				
			Analgesic Or Anesthetic (Unspecified)	C				
			Antimicrobial (Unspecified)	C				

Date:11/12/04ISR Number: 4499989-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00949
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Lopressor	C				

Date:11/12/04ISR Number: 4500281-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Affective Disorder
	Anaemia
	Angina Pectoris
	Colonic Polyp
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspepsia
	Eczema
	Gastritis

Haemorrhoidal Haemorrhage
Head Injury
Headache
Heart Rate Irregular
Hot Flush
Hypochromic Anaemia
Insomnia
Intracranial Venous Sinus
Thrombosis
Joint Effusion
Migraine
Musculoskeletal Stiffness
Nausea
Neck Pain
Osteoarthritis
Pharyngolaryngeal Pain
Rash
Sinus Tachycardia
Subarachnoid Haemorrhage
Uterine Enlargement
Uterine Leiomyoma
Vaginal Haemorrhage

Visual Disturbance
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	6 MON	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Yasmin	SS			UNKNOWN	14 DAY
	Sandimmun	C			UNKNOWN	
	Lexapro	C			UNKNOWN	
	Sandimmun	C			UNKNOWN	
	Sandimmun	C			UNKNOWN	
	Prednisone	C			UNKNOWN	
	Hormonal Contraceptives (Unspecified)	C			INTRAMUSCULAR	
	Prelone Syrup	C			UNKNOWN	
	Prelone Syrup	C			UNKNOWN	

Date:11/12/04ISR Number: 4500283-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anxiety Arthralgia Aspergillosis Bronchitis Cerebrovascular Accident Complicated Migraine Conversion Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Drug Dependence
Drug Ineffective
Hypercholesterolaemia
Hypertriglyceridaemia
Hypotension
Injury
Iris Disorder
Major Depression
Migraine
Migraine With Aura
Muscle Spasms
Neuropathic Pain
Night Sweats
Nystagmus
Oesophageal Spasm
Pigmented Naevus
Road Traffic Accident
Skeletal Injury
Skin Hypopigmentation
Skin Laceration
Syncope
Tremor

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500284-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00638
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Crying		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Norflex	C				
	Non-Insulin-Dependent		Polaramine	C				
	Fibromyalgia		Alprazolam	C				
	Glaucoma		Nitroquick	C				
	Hallucination, Auditory		Pepcid	C				
	Hyperkalaemia		Diovan Hct	C				
	Injury		Hydrocodone/Apap	C				
	Limb Injury		Fosamax	C				
	Oedema Peripheral		Pravachol	C				

Date:11/12/04ISR Number: 4500285-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01752
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	51	DAY
Initial or Prolonged	Infarction		Tenormin	C				
Disability	Anal Inflammation							
Other	Anxiety Disorder							
	Back Injury							
	Back Pain							
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Cervical Spasm							

Colonic Polyp
Constipation
Convulsion
Coordination Abnormal
Coronary Artery Occlusion
Depression
Dermatitis
Haematochezia
Haemorrhoids
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Memory Impairment
Mental Status Changes
Muscle Spasms
Obesity
Oedema Peripheral
Paraesthesia
Pharyngitis
Rhinitis
Sensory Disturbance
Sinus Polyp
Sleep Apnoea Syndrome
Stomach Discomfort
Stress
Upper Respiratory Tract
Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500301-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00966
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Ovcon	C				
UNKNOWN								
	Infarction		Ibuprofen	C				
UNKNOWN								
	Anxiety		Amitriptyline					
	Arterial Thrombosis		Hydrochloride	C				
UNKNOWN								
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Occlusion							
	Electrocardiogram Change							
	Fatigue							
	Hyperhidrosis							
	Limb Discomfort							
	Myocardial Infarction							
	Palpitations							

Date:11/12/04ISR Number: 4500303-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
49 DAY								
Initial or Prolonged	Acquired Claw Toe		Vioxx	SS	Merck & Co., Inc	ORAL		
1 DAY								
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
72 DAY								
	Increased		Zocor	C		ORAL		
	Cerebrovascular Accident		Protonix	C				
UNKNOWN								
	Chest Pain		Lipitor	C				
UNKNOWN								
	Cholelithiasis		Prinivil	C		ORAL		
	Dehydration							
	Diverticulum							
	Dyspepsia							
	Dyspnoea							
	Ear Infection							

Eye Irritation
Haematuria
Hepatic Enzyme Increased
Hypertension
Ingrowing Nail
Intestinal Polyp
Irritable Bowel Syndrome
Peroneal Nerve Palsy
Rash Pruritic
Renal Impairment
Skin Disorder
Skin Lesion
Urinary Tract Infection

Date:11/12/04ISR Number: 4500305-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00823
Age: Gender:Female I/FU:F

Outcome PT
Other Acrochordon
Anal Sphincter Atony
Arthralgia
Arthropathy
Back Pain
Blood Cholesterol
Increased

		Bronchitis					
		Candidiasis					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Faecal Incontinence					
		Gastrooesophageal Reflux					
		Disease					
		Hyperglycaemia					
		Hyperkeratosis					
		Hypertension					
		Joint Swelling					
		Lyme Disease					
		Muscle Spasms					
		Muscular Weakness					
		Myalgia					
		Obesity					
		Oedema Peripheral					
		Paraesthesia					
		Peptic Ulcer					
		Polytraumatism					
		Reproductive Tract					
		Disorder					
		Rhinitis Allergic					
		Sinusitis					
		Transient Ischaemic					
		Attack					
		Urinary Incontinence					
		Urinary Tract Infection					
		Weight Increased					

Date:11/12/04ISR Number: 4500310-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00887
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Contusion					
		Dizziness					
		Drug Ineffective					
		Fatigue					
		Injury					
		Insomnia					
		Intervertebral Disc					

Disorder
Joint Sprain
Ligament Sprain
Osteoarthritis
Post-Traumatic Headache
Radiculitis Cervical
Spinal Column Stenosis
Spinal Osteoarthritis
Stress
Thyroid Cyst

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500312-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00111
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Simvastatin	C		ORAL		
			Irbesartan	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500314-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00951
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Hypoaesthesia							
	Pain In Extremity							

Date:11/12/04ISR Number: 4500315-2Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00010
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Thrombosis		[Composition Unspecified]	C		ORAL		
Disability							1	WK

Date:11/12/04ISR Number: 4500316-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00173
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/12/04ISR Number: 4500321-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00640
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Death							
Hospitalization - Initial or Prolonged								

Date:11/12/04ISR Number: 4500322-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01377
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Verapamil	C				
UNKNOWN								
	Pericardial Effusion		Aciphex	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500324-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00396
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C			UNKNOWN	
	Blood Pressure Increased							
	Bundle Branch Block Left							

Date:11/12/04ISR Number: 4500326-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02617
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Effect Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Myocardial Rupture							

Date:11/12/04ISR Number: 4500327-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02747
Age:21 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		2 WK
	Gastric Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		2 WK
Other	Gastrointestinal Haemorrhage		Lortab	C		ORAL		
			Medrol Dosepak	C		ORAL		8 DAY
	Intestinal Haemorrhage		Medrol Dosepak	C		ORAL		
			Norflex	C		ORAL		12 DAY
			Celebrex	C				UNKNOWN
			Ultram	C		ORAL		6 DAY
			Toradol	C				INTRAMUSCULAR

Date:11/12/04ISR Number: 4500329-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01903
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Pexeva	C				
			Klonopin	C				
			Temazepam	C				
			Trazodone Hydrochloride	C				
			Trileptal	C				

Date:11/12/04ISR Number: 4500330-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03367
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
Hospitalization -	Chest Discomfort		Premarin	C				
Initial or Prolonged	Heart Rate Irregular		Synthroid	C				
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500332-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01722
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500334-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00187
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		61 DAY
Initial or Prolonged	Cardiac Failure		Fluoxetine	C				UNKNOWN
Disability	Fall		Acetaminophen And					
Other	Heart Rate Irregular		Dihydrocodeine					
	Hip Fracture		Bitartrate	C				UNKNOWN
	Mitral Valve Incompetence		Ramipril	C				UNKNOWN
	Myocardial Infarction							
	Shock							

Date:11/12/04ISR Number: 4500335-8Report Type:Expedited (15-DaCompany Report #DK-MERCK-0411DNK00006
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Musculoskeletal Stiffness		Vioxx	PS	Merck & Co., Inc	ORAL		142 DAY

Date:11/12/04ISR Number: 4500337-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Initial or Prolonged

Date:11/12/04ISR Number: 4500338-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04331
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vitamins					
Initial or Prolonged	Heart Rate Irregular		(Unspecified)	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500339-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02036
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Pravachol	C				
UNKNOWN								
			Gemfibrozil	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500342-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00427
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500343-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00565
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Premarin	C			UNKNOWN	
	Tachycardia		Zocor	C		ORAL		
Disability	Thrombosis		Atenolol	C			UNKNOWN	
			Provera	C			UNKNOWN	
			Valium	C			UNKNOWN	
			Hydrocodone Bitartrate	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			Corticotropin	C			PARENTERAL	
			Potassium (Unspecified)	C			UNKNOWN	
			Symmetrel	C			UNKNOWN	

Date:11/12/04ISR Number: 4500344-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00588
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN			Norvasc	C		
Initial or Prolonged Disability UNKNOWN			[Therapy Unspecified]	C		
			Plavix	C		
UNKNOWN						
			Atenolol	C		
UNKNOWN						

Date:11/12/04ISR Number: 4500347-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00007
Age:12 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		154 DAY
Other	Death		Methotrexate	C		ORAL		154 DAY
	Prescribed Overdose		[Therapy Unspecified]	C		ORAL		154 DAY
			Spiruline	C		ORAL		

Date:11/12/04ISR Number: 4500348-6Report Type:Expedited (15-DaCompany Report #DK-MERCK-0411DNK00009
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		1696 DAY
			Citalopram Hydrobromide	C		ORAL		
			Escitalopram Oxalate	C		ORAL		
			Diazepam	C		ORAL		
			Propoxyphene Hydrochloride	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500349-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Clopidogrel					
Initial or Prolonged			Bisulfate	C				
UNKNOWN								
			Irbesartan	C				
UNKNOWN								
			Irbesartan	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500352-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	DAY
Hospitalization -			Prevacid	C				
UNKNOWN								
Initial or Prolonged			Pravachol	C				
UNKNOWN								
Disability			Fosamax	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500353-XReport Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Catheterisation Cardiac		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Stent Placement							

Date:11/12/04ISR Number: 4500354-1Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500357-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500359-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500360-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Keratitis		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500361-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/12/04ISR Number: 4500363-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00007
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Deflazacort	C		ORAL		
			Omeprazole	C		ORAL		
			Magaldrate	C		ORAL		
			Lorazepam	C		ORAL		
			Zolpidem Tartrate	C		ORAL		
			Pentoxifylline	C		ORAL		
			Troxerutin	C		ORAL		

Date:11/12/04ISR Number: 4500364-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00772
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lipitor	C				
UNKNOWN								
	Dyspnoea							

Date:11/12/04ISR Number: 4500365-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00826
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nexium	C				
UNKNOWN								

Disability				[Therapy Unspecified]	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Levothyroxine Sodium	C		
UNKNOWN							
				Lescol	C		
UNKNOWN							

Date:11/12/04ISR Number: 4500366-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500368-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500369-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00728
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Premarin	C				
Other	Hypertension		Spironolactone	C				
	Nausea		Prevacid	C				
	Transient Ischaemic Attack		Flonase	C				
	Vertigo							
	Visual Disturbance							

Date:11/12/04ISR Number: 4500370-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00836
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neck Pain		[Therapy Unspecified]	C				

Date:11/12/04ISR Number: 4500373-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500374-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00955
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Proventil	C		
UNKNOWN						
			Azmacort	C		
UNKNOWN						

Date:11/12/04ISR Number: 4500376-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00860
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vicodin Tablets	C		
UNKNOWN						
	Hypersensitivity		Diovan	C		
UNKNOWN						
	Hypertension					

Date:11/12/04ISR Number: 4500377-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01003
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Insulin	C		
UNKNOWN						
Initial or Prolonged			[Therapy			
			Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500378-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00735
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

Date:11/12/04ISR Number: 4500380-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00855
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Disorder							
Disability								

Date:11/12/04ISR Number: 4500381-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00827
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Large Intestine Perforation							
	Myocardial Infarction							

Date:11/12/04ISR Number: 4500382-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00833
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C				
UNKNOWN								
Disability								

Date:11/12/04ISR Number: 4500384-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Coronary Artery Occlusion Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500385-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00734
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500386-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00771
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500394-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01009
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Haemorrhage		Actonel	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500395-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01076
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							

Date:11/12/04ISR Number: 4500396-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01024
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
10 DAY								
	Onychomycosis							
	Skin Exfoliation							
	Skin Fissures							

Date:11/12/04ISR Number: 4500398-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Lipitor	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500399-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500400-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Blood Glucose Increased
Other	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diabetes Mellitus
	Inadequate Control
	Ejection Fraction
	Decreased
	Gastrointestinal

		Infection					
		Hyperparathyroidism					
		Secondary					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
422	DAY						
		Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Meniere'S Disease		Zestril	SS		
UNKNOWN							
		Metabolic Disorder		Lasix (Furosemide)	SS		
UNKNOWN							
		Mitral Valve Incompetence		Zestril	SS		
UNKNOWN		406 DAY					
		Myalgia		Niacin	SS		
UNKNOWN							
		Nerve Compression		Cardizem	C		
UNKNOWN							
		Osteoporosis		Prozac	C		
UNKNOWN							
		Pharyngitis		Motrin	C		
UNKNOWN							
		Pruritus		Tylenol	C		
UNKNOWN							
		Renal Failure Acute		Plavix	C		
UNKNOWN							
		Renal Failure Chronic		Miacalcin	C		
UNKNOWN							
		Seasonal Allergy		Zocor	C		ORAL
		Silent Myocardial		Glucotrol	C		
UNKNOWN							
		Infarction		Zantac	C		
UNKNOWN							
		Sinusitis		Naproxen	C		
UNKNOWN							
		Skin Ulcer		Spironolactone	C		
UNKNOWN							
		Transient Ischaemic		Calcium			
		Attack		(Unspecified)	C		
UNKNOWN							
		Tricuspid Valve		Temazepam	C		
UNKNOWN							
		Incompetence		Nitro	C		
UNKNOWN							
		Urinary Tract Infection		Prinivil	C		
UNKNOWN							
		Ventricular Dysfunction					

Date:11/12/04ISR Number: 4500402-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01473
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Betapace	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500403-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

Date:11/12/04ISR Number: 4500405-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								

Date:11/12/04ISR Number: 4500406-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral							

Date:11/12/04ISR Number: 4500407-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01455
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Neurontin	C				
Disability			Percocet	C				

Date:11/12/04ISR Number: 4500408-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01477
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
	Paraesthesia		Vytorin	C				
	Rash Generalised		Lexapro	C				
			Nexium	C				

Date:11/12/04ISR Number: 4500411-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01045
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypoaesthesia							
	Myocardial Infarction							
Disability								

Date:11/12/04ISR Number: 4500412-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01010
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Life-Threatening Hospitalization - Initial or Prolonged							

Date:11/12/04ISR Number: 4500413-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01026
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability Other	Cerebrovascular Accident Gastrointestinal Disorder Retinal Vascular Thrombosis Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/12/04ISR Number: 4500415-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01476
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening UNKNOWN Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500424-8Report Type:Expedited (15-DaCompany Report #PR-MERCK-0410USA00459
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Hypertensive Crisis		Lipitor	C			UNKNOWN	
	Pancreatitis		Zestril	C			UNKNOWN	

Date:11/12/04ISR Number: 4500437-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00882
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Life-Threatening			[Therapy Unspecified]	C			UNKNOWN	
Hospitalization -								
Initial or Prolonged								

Date:11/12/04ISR Number: 4500445-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/12/04ISR Number: 4500619-3Report Type:Direct Company Report #CTU 231779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Haemorrhage Intracranial Vioxx PS
QD
Hospitalization -
Initial or Prolonged
Disability
Required
Intervention to
Prevent Permanent
Impairment/Damage

Date:11/12/04ISR Number: 4500622-3Report Type:Direct Company Report #CTU 231795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Renal Impairment		Vioxx - 25 Mg. -			
Disability			Merck And Co., Inc.	PS	Merck And Co., Inc.	
25 MG.1 TAB						
Required						
DAILY						
Intervention to						
Prevent Permanent						
Impairment/Damage						

Date:11/12/04ISR Number: 4500700-9Report Type:Direct Company Report #CTU 231781
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg	PS		
1 A DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/12/04ISR Number: 4500770-8Report Type:Direct Company Report #CTU 231847
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS			25 MG X 2	
Initial or Prolonged	Feeding Disorder							
	Hemiparesis							
	Speech Disorder							

Date:11/12/04ISR Number: 4507594-6Report Type:Expedited (15-DaCompany Report #WAES 0410SWE00020
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Vioxx	PS		ORAL	25 MG/ DAILY/	
Initial or Prolonged	Atherosclerosis	Study					PO	
	Coronary Angioplasty	Health						
		Professional						
		Other						

Date:11/12/04ISR Number: 4507642-3Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Foreign	Tab Vioxx					
Initial or Prolonged	Congestive	Study	(Rofecoxib)	PS		ORAL	50 MG/DAILY	
Disability	Dyspnoea	Health						
PO							80	DAY
	Dyspnoea Paroxysmal	Professional	Acetaminophen	C				
	Nocturnal		Amitriptyline					
	Orthopnoea		Hydrochloride	C				
			Blinded Therapy	C				
			Blinded Therapy	C				
			Bromazepam	C				
			Captopril	C				
			Celecoxib	C				
			Hydrochlorothiazide	C				

			Leflunomide	C		
			Omeprazole	C		

Date:11/15/04ISR Number: 4500819-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00025
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Dermatitis Bullous		Tizanidine Hydrochloride	SS		ORAL
	Pyrexia					

Date:11/15/04ISR Number: 4500820-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00111
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	General Physical Health Deterioration					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4500821-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00536
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4500824-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00532
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4500825-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00738
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucophage	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								

Date:11/15/04ISR Number: 4500829-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00722
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Hydrochlorothiazide	C				
UNKNOWN								
Disability	Laboratory Test Abnormal		[Therapy					
	Platelet Count Increased		Unspecified]	C				
UNKNOWN								

Weight Decreased

Date:11/15/04ISR Number: 4500830-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01648
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amputation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis							
Disability								

Date:11/15/04ISR Number: 4500831-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01517
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		Valium	C				
UNKNOWN								
	Loss Of Consciousness		Ambien	C				
UNKNOWN								
	Oedema Peripheral							
	Pain In Extremity							
	Palpitations							
	Road Traffic Accident							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4500834-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00989
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Actonel	C				
UNKNOWN								
	Difficulty In Walking		Motrin	C				
UNKNOWN								
	Hyperhidrosis		[Therapy					
	Pain In Extremity		Unspecified]	C				
UNKNOWN								
	Weight Decreased		Antimicrobial					
			(Unspecified)	C				
UNKNOWN								

Date:11/15/04ISR Number: 4500835-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00950
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL		
	Loss Of Consciousness		Premarin	C				
UNKNOWN								
			Glyburide	C				
UNKNOWN								

Date:11/15/04ISR Number: 4500836-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01486
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:11/15/04ISR Number: 4500838-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01480
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Wellbutrin	C				
UNKNOWN								
Disability			Potassium Chloride	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:11/15/04ISR Number: 4500839-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01479
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		[Therapy Unspecified]	C				
Disability								
UNKNOWN								

Date:11/15/04ISR Number: 4500840-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01669
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Swelling		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Disability			Norco	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4500841-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00974
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Lopressor	C				UNKNOWN
			Proscar	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:11/15/04ISR Number: 4500844-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01677
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
Hospitalization - Initial or Prolonged	Dizziness		Hydrochlorothiazide	C				UNKNOWN
			Lexapro	C				UNKNOWN
			Synthroid	C				UNKNOWN

Date:11/15/04ISR Number: 4500845-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01683
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/15/04ISR Number: 4500846-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01989
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:11/15/04ISR Number: 4500847-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01681
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Dehydration		Fosamax	C		ORAL		
Hospitalization - UNKNOWN	Gastroenteritis		Synthroid	C				
Initial or Prolonged	Salmonella							
	Myocardial Infarction							
	Renal Failure							

Date:11/15/04ISR Number: 4500848-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
72 DAY								
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4500849-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01684
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/15/04ISR Number: 4500852-0Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00057
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aseptic Necrosis Bone		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation							
	Coronary Artery Disease							

Date:11/15/04ISR Number: 4500853-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Lopressor	C				
UNKNOWN								
	Thrombosis							
	Gastrooesophageal Reflux Disease							

Date:11/15/04ISR Number: 4500857-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4500858-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01421
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Pneumonia		Norflex	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/15/04ISR Number: 4500860-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0207USA02823
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anoxic Encephalopathy
Other	Anxiety
	Cardio-Respiratory Arrest
	Convulsion
	Coronary Artery Occlusion
	Deep Vein Thrombosis
	Difficulty In Walking
	Gastric Disorder

		Hypertension					
		Hypokalaemia					
		Lumbar Spinal Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations		Tylenol With Codeine			
		Pneumonia Aspiration		#4	C		
UNKNOWN							
		Postoperative Ileus		Tylenol With Codeine			
		Pulmonary Embolism		#4	C		
UNKNOWN							
		Pulmonary Oedema		Premarin	C		
UNKNOWN							
		Shock		Provera	C		
UNKNOWN							
		Syphilis		Celebrex	C		
UNKNOWN							
				Arthrotec	C		ORAL
				Arthrotec	C		ORAL
				Arthrotec	C		ORAL
				Daypro	C		
UNKNOWN							

Date:11/15/04ISR Number: 4500861-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00616
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris					
Other		Blood Pressure Increased					
		Bronchitis Acute					
		Chest Pain					
		Chronic Obstructive					
		Pulmonary Disease					
		Convulsion					
		Hypercholesterolaemia					
		Ischaemic Cardiomyopathy					
		Ulnar Nerve Injury					

Date:11/15/04ISR Number: 4500863-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Anxiety
	Aortic Valve Incompetence
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Cerebrovascular Accident
	Chest Discomfort
	Deafness
	Depression
	Diarrhoea
	Dizziness
	Dyspnoea
	Emotional Distress
	Fall
	Gastrooesophageal Reflux Disease
	Headache
	Heart Rate Irregular
	Hyperglycaemia
	Injury
	Intervertebral Disc Displacement

		Mental Disorder					
		Nephrolithiasis					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Onychomycosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Oropharyngeal Spasm		Aspirin	C		ORAL
		Parkinson'S Disease		Premarin	C		ORAL
		Peripheral Vascular		Prinivil	C		ORAL
		Disorder		Bumex	C		ORAL
		Pneumothorax		Lamisil	C		ORAL
		Renal Failure					
		Sciatica					
		Seborrhoeic Keratosis					
		Sleep Apnoea Syndrome					
		Stomach Discomfort					
		Swelling Face					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urinary Tract Infection					
		Vascular Stenosis					
		Vertigo					
		Visual Acuity Reduced					

Date:11/15/04ISR Number: 4500864-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00609
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris					
		Blood Pressure Increased					
		Convulsion					

Date:11/15/04ISR Number: 4500865-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00795
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Anaemia
	Arthralgia
	Cataract
	Chest Discomfort

Chest Pain
Deep Vein Thrombosis
Dementia
Depressive Symptom
Dermatitis
Dyspnoea
Dyspnoea Exertional
Gastric Disorder
Hypertonic Bladder
Intervertebral Disc
Degeneration
Lumbar Radiculopathy
Myalgia
Nerve Compression
Osteoporosis
Rash
Sciatica
Skin Ulcer

		Spinal Claudication					
		Spinal Compression Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombophlebitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Superficial		Vioxx	SS	Merck & Co., Inc	ORAL
		Venous Insufficiency		Levothroid	C		
UNKNOWN							
		Vertigo Positional		Diovan	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							
				Os-Cal D	C		
UNKNOWN							
				Potassium (Unspecified)	C		ORAL
				Tylenol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Dulcolax	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							

Date:11/15/04ISR Number: 4500873-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00715
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Angina Pectoris		Serzone	C		
UNKNOWN							
		Arthropathy		Fiorinal	C		
UNKNOWN							
		Articular Calcification					
		Blood Pressure Increased					
		Cardiac Disorder					

Cerebrovascular Accident
Condition Aggravated
Convulsion
Depression
Drug Effect Decreased
Drug Ineffective
Feeling Abnormal
Fibromyalgia
Infectious Mononucleosis
Inflammatory Bowel
Disease
Intervertebral Disc
Degeneration
Migraine
Muscle Spasms
Pneumonia
Pyrexia
Respiratory Failure
Spondylolisthesis
Tuberculin Test Positive

Date:11/15/04ISR Number: 4500874-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess
Other	Anaemia
	Arthralgia
	Atrial Fibrillation

		Atrial Flutter					
		Blood Pressure Increased					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Congestive		Vioxx	PS	Merck & Co., Inc	ORAL
		Carotid Bruit		Zestril	C		ORAL
		Clostridium Colitis		Glucophage	C		ORAL
		Congestive Cardiomyopathy		Methylprednisolone	C		
UNKNOWN							
		Convulsion		Levaquin	C		ORAL
		Diabetes Mellitus					
		Inadequate Control					
		Diabetic Microangiopathy					
		Diabetic Neuropathy					
		Diarrhoea					
		Diverticulum					
		Dysphonia					
		Ear Infection					
		Gastrointestinal					
		Haemorrhage					
		Graft Thrombosis					
		Hypercholesterolaemia					
		Hyperkalaemia					
		Hypoxic Encephalopathy					
		Insomnia					
		Ischaemia					
		Ischaemic Hepatitis					
		Myocardial Ischaemia					
		Polyp					
		Pulmonary Hypertension					
		Pyrexia					
		Renal Failure					
		Renal Failure Acute					
		Sinus Arrest					
		Sinus Bradycardia					
		Urinary Tract Infection					
		Vertigo					
		Weight Decreased					
		Weight Increased					

Date:11/15/04ISR Number: 4500882-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00639
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension

Initial or Prolonged Disability	Abdominal Pain
	Adverse Event
	Asthenia
	Barrett'S Oesophagus
	Chest Pain
	Chills
	Conjunctivitis
	Cough
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dizziness
	Dyspnoea
	Ear Pain
	Erythema
	Fluid Retention
	Fungal Infection

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Gastritis					
		Gastrointestinal Motility Disorder					
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Heat Rash		Tenormin	C		
UNKNOWN							
		Hyperhidrosis		Ultram	C		
UNKNOWN							
		Hypoacusis		Soma	C		
UNKNOWN							
		Influenza		Synthroid	C		
UNKNOWN							
		Ingrowing Nail		Estradiol	C		
UNKNOWN							
		Insomnia		Claritin	C		
UNKNOWN							
		Intervertebral Disc		Verapamil	C		
UNKNOWN							
		Degeneration		Hydrochlorothiazide	C		
UNKNOWN							
		Intervertebral Disc		Isosorbide	C		
UNKNOWN							
		Protrusion		Restoril	C		
UNKNOWN							
		Intervertebral Disc Space		Aspirin	C		
UNKNOWN							
		Narrowing		Lipitor	C		
UNKNOWN							
		Lymph Node Pain		Detrol	C		
UNKNOWN							
		Malaise					
		Musculoskeletal Discomfort					
		Nausea					
		Nodule					
		Onychomycosis					
		Pain In Jaw					
		Periorbital Cellulitis					
		Pyrexia					
		Rash					
		Rhinitis Allergic					
		Sinus Congestion					
		Sinusitis					

Snoring
Somnolence
Swelling Face
Syncope
Temperature Intolerance
Urinary Tract Infection
Urticaria
Vomiting
Weight Increased

Date:11/15/04ISR Number: 4500896-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:11/15/04ISR Number: 4500897-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00821
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Chest Pain
Disability	Chronic Obstructive

	Pulmonary Disease						
	Coronary Artery Disease						
	Diabetes Mellitus						
	Non-Insulin-Dependent	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypokalaemia							
	Influenza Like Illness							
	Obesity							
	Pain							
	Paranoid Personality Disorder							
	Polytraumatism							
	Pyrexia							
	Spermatocele							
	Spinal Disorder							
	Ventricular Dysfunction							

Date:11/15/04ISR Number: 4500921-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Plavix	C				
UNKNOWN								
	Cerebral Infarction		Flovent	C				
RESPIRATORY (INHALATION)								
	Chest Wall Pain							
	Cholelithiasis		Levoxyl	C				
UNKNOWN								
	Chronic Obstructive		Levoxyl	C				
UNKNOWN								
	Pulmonary Disease		Tylenol With Codeine					
	Coronary Artery Disease		#3	C				
UNKNOWN								
	Decreased Appetite		Prednisone	C				
UNKNOWN								
	Depression		Advair	C				
UNKNOWN								
	Dizziness		Monopril	C				
UNKNOWN								

	Emotional Distress	Azmacort	C
UNKNOWN			
	Face Injury	Aspirin	C
UNKNOWN			
	Gastrooesophageal Reflux	Nexium	C
UNKNOWN			
	Disease	Ventolin (Albuterol)	C
RESPIRATORY			
	Hypertensive Heart		
(INHALATION)			
	Disease	Ranitidine	C
UNKNOWN			
	Hypothyroidism	Hydroxychloroquine	
	Insomnia	Sulfate	C
UNKNOWN			
	Nausea		
	Nervousness		
	Renal Failure Chronic		
	Swelling Face		
	Upper Respiratory Tract		
	Infection		
	Uterine Disorder		

Date:11/15/04ISR Number: 4500925-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00793
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Aortic Valve Incompetence
	Arthralgia
	Diastolic Dysfunction

		Diverticulum					
		Dyspepsia					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epigastric Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
61	DAY						
		Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL
136	DAY						
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
61	DAY						
		Urticaria Papular		Vioxx	SS	Merck & Co., Inc	ORAL
136	DAY						
				Ambien	C		ORAL
				Ambien	C		ORAL
				Aspirin	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							
				Lortab	C		ORAL
				Zantac	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Detrol	C		ORAL
				Norvasc	C		ORAL

Date:11/15/04ISR Number: 4500938-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00963
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
350	DAY						

Initial or Prolonged Disability	Blood Cholesterol Increased Cerebrovascular Accident Chronic Fatigue Syndrome Depression Generalised Anxiety Disorder Pollakiuria		Aspirin	C		ORAL

Date:11/15/04ISR Number: 4500939-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 115 DAY	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Back Pain		Haldol	C		
Other UNKNOWN	Cartilage Injury Coronary Artery Disease Depression Eructation Gout Intervertebral Disc Protrusion Myocardial Infarction Neck Pain Pain In Extremity Weight Increased		Hydrocodone Bitartrate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4500941-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00926
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anxiety							
Other	Arthralgia							
	Back Pain							
	Balance Disorder							
	Bladder Disorder							
	Bronchitis							
	Cardiac Disorder							
	Chest Pain							
	Constipation							
	Deafness							
	Depression							
	Diplopia							
	Dizziness							
	Dysphagia							
	Dyspnoea							
	Extrasystoles							
	Gastritis							
	Haematochezia							
	Haemorrhoids							
	Headache							
	Hyperhidrosis							
	Hypertension							
	Hypoaesthesia							
	Intervertebral Disc Degeneration							
	Intestinal Functional Disorder							
	Meniscus Lesion							
	Muscle Spasms							
	Neck Pain							
	Nocturia							
	Personality Change							
	Polyp							
	Polytraumatism							
	Rash							
	Renal Impairment							
	Restless Legs Syndrome							
	Sleep Apnoea Syndrome							
	Snoring							
	Stress							
	Tinnitus							

Vertigo Labyrinthine
Weight Decreased
Weight Increased

Date:11/15/04ISR Number: 4500945-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00941
Age: Gender:Female I/FU:F

Outcome PT
Other Adverse Event
Angina Pectoris
Arthritis
Blood Pressure Increased
Cerebrovascular Accident
Convulsion
Gastrooesophageal Reflux

	Disease						
	Hemiplegia						
	Hot Flush						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nervousness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
	Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Disorder							
	Upper Respiratory Tract Infection							

Date:11/15/04ISR Number: 4500947-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02529
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Vioxx	SS		ORAL		
Disability	Anxiety		Bextra	C				
UNKNOWN								
	Blood Cholesterol		Bextra	C				
UNKNOWN								
	Increased		Ultracet	C		ORAL		
	Bursitis		Dyazide	C				
UNKNOWN								
	Coronary Artery Disease		Prevacid	C				
UNKNOWN								
	Depression		Zoloft	C				
UNKNOWN								
	Diverticulum Intestinal		Premarin	C				
UNKNOWN								
	Drug Hypersensitivity		Skelaxin	C		ORAL		
	Fatigue		Prilosec	C		ORAL		
	Haemangioma Of Liver		Ditropan Xl	C				
UNKNOWN								
	Headache							
	Hyperlipidaemia							
	Hypertension							
	Insomnia							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Nasopharyngitis							

Night Sweats
Oedema Peripheral
Otitis Externa
Palpitations
Panic Attack
Pelvic Pain
Pharyngitis
Pruritus
Rash
Urinary Retention
Urinary Tract Infection
Vaginitis Atrophic
Vertigo Positional

Date:11/15/04ISR Number: 4500948-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome PT
Other Anxiety
Arthralgia
Asthenia
Asthma
Back Pain

		Cough					
		Depression					
		Dupuytren'S Contracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyslipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
363 DAY							
		Erectile Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
363 DAY							
		Hypoaesthesia		Zantac	C		
UNKNOWN							
		Impulse-Control Disorder		Celexa	C		
UNKNOWN							
		Myocardial Infarction		Albuterol	C		
RESPIRATORY							
		Pain In Extremity					
(INHALATION)							
		Premature Ejaculation		Vicodin Tablets	C		ORAL
		Pulmonary Congestion					
		Purulent Discharge					
		Restless Legs Syndrome					
		Rhinitis Allergic					
		Rhonchi					
		Self-Injurious Ideation					
		Sinus Disorder					
		Sleep Apnoea Syndrome					
		Spinal Column Stenosis					
		Upper Respiratory Tract Infection					
		Weight Increased					
		Wheezing					

Date:11/15/04ISR Number: 4500969-0Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00022
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Malaise		Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations		Erythromycin Stearate	C		
UNKNOWN							
				Omeprazole	C		ORAL

Date:11/15/04ISR Number: 4500971-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00847
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia
Disability	Arthralgia
	Arthropathy
	Back Pain
	Blood Alkaline
	Phosphatase Increased
	Blood Cholesterol
	Increased
	Blood Potassium Increased
	Caustic Injury
	Cellulitis
	Drug Effect Decreased
	Drug Ineffective
	Hyperlipidaemia
	Inguinal Hernia
	Injury
	Insomnia
	Joint Swelling
	Low Density Lipoprotein

		Increased Lymphadenopathy					
		Lymphoedema					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Onychomycosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Staphylococcal Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Subcutaneous Abscess		Vioxx	SS	Merck & Co., Inc	ORAL
		Tinea Pedis					
		Visual Acuity Reduced					

Date:11/15/04ISR Number: 4500978-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02741
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Coumadin	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Zocor	C		ORAL
			Fish Oil (Unspecified)	C		
UNKNOWN						

Date:11/15/04ISR Number: 4500979-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0309GBR00024
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY					
	Coronary Artery Disease		Omeprazole	C		ORAL
1	DAY					
	Myocardial Ischaemia		Estradiol Valerate And Norethindrone	C		ORAL
	Pulmonary Congestion					
	Sudden Death					

Date:11/15/04ISR Number: 4500980-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02009
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asbestosis		Vioxx	PS	Merck & Co., Inc	ORAL		1095 DAY
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		1095 DAY
Other	Atrial Fibrillation		Verapamil	C				UNKNOWN
	Back Disorder		Neurontin	C				UNKNOWN
	Cardiomegaly		Darvocet-N	C				UNKNOWN
	Dyspnoea							
	Emphysema							
	Hyperhidrosis							
	Palpitations							
	Pericardial Calcification							
	Surgery							
	Tuberculosis							

Date:11/15/04ISR Number: 4500982-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01341
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Mouth Ulceration		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tongue Ulceration		Zoloft	SS		ORAL		

			Topamax	SS			
UNKNOWN							
			Lexapro	SS			ORAL
			Lexapro	SS			ORAL
			Zocor	C			ORAL
			Nexium	C			
UNKNOWN							
			Mirapex	C			
UNKNOWN							

Date:11/15/04ISR Number: 4500983-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02771
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	42	DAY
Hospitalization -	Arthralgia		Ultracet	C				
UNKNOWN								
Initial or Prolonged	Bone Disorder		Piroxicam	C				
UNKNOWN								
Disability	Cerebrovascular Accident		[Therapy					
	Diabetes Mellitus		Unspecified]	C				
UNKNOWN								
	Dyspnoea		Hydrochlorothiazide	C				
UNKNOWN								
	Feeling Abnormal		Verapamil	C				
UNKNOWN								
	Hypertension		Fluoxetine	C				
UNKNOWN								
	Renal Failure		Insulin	C				
UNKNOWN								
	Wheezing		[Therapy					
			Unspecified]	C				
UNKNOWN								
			Theophylline	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			Potassium					

			(Unspecified)	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						
			Skelaxin	C		
UNKNOWN						
			Nabumetone	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Diclofenac Potassium	C		
UNKNOWN						
			Flovent	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:11/15/04ISR Number: 4500984-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00080
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Calcium (Unspecified)	C				
UNKNOWN								
			Estrogens (Unspecified)	C				
UNKNOWN								

Date:11/15/04ISR Number: 4500986-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00174
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure Increased
Hospitalization - Initial or Prolonged	Blood Sodium Decreased
	Brain Oedema
Disability	Cerebral Haematoma
	Cerebral Haemorrhage

		Cerebrovascular Accident					
		Cognitive Disorder					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ejection Fraction		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram T Wave		[Therapy			
		Abnormal		Unspecified]	C		
UNKNOWN							
		Embolism		Toradol	C		ORAL
		Haemorrhagic Stroke		Catapres	C		
TOPICAL							
		Medication Error		Oxycontin	C		
UNKNOWN							
		Mental Disorder Due To A		Restoril	C		
UNKNOWN							
		General Medical Condition		Verapamil	C		
UNKNOWN							
		Mental Status Changes		Paxil	C		
UNKNOWN							
		Metastasis					
		Respiratory Rate					
		Increased					
		Sleep Disorder					
		Suicidal Ideation					

Date:11/15/04ISR Number: 4500987-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410USA01922
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder					
	Heart Injury					
	Myocardial Infarction					

Date:11/15/04ISR Number: 4501020-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03366
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - UNKNOWN	Chest Pain	Tricor	C
Initial or Prolonged UNKNOWN	Dizziness	Crestor	C
Disability UNKNOWN	Myocardial Infarction	Plavix	C
		Prinivil	C
UNKNOWN			
		Nexium	C
UNKNOWN			
		Norvasc	C
UNKNOWN			
		Imdur	C
UNKNOWN			
		Metoprolol	C
UNKNOWN			
		Aspirin	C
UNKNOWN			
		Nitroglycerin	C
UNKNOWN			

Date:11/15/04ISR Number: 4501024-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00139
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501025-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety
	Arthritis

		Blindness Unilateral					
		Eye Haemorrhage					
		Gout	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Post-Traumatic Stress Disorder					

Date:11/15/04ISR Number: 4501027-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02963
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged						
Disability						

Date:11/15/04ISR Number: 4501428-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Brunner'S Gland		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Hyperplasia		Propoxyphene			
	Bundle Branch Block Left		Hydrochloride	C		
UNKNOWN						
	Cardiac Disorder		Lanoxin	C		
UNKNOWN						
	Cardiac Failure		Lasix (Furosemide)	C		
UNKNOWN						
	Cataract		K-Dur	C		
UNKNOWN						
	Deafness Neurosensory		Darvocet-N	C		
UNKNOWN						
	Diarrhoea					
	Duodenitis					
	Ear Disorder					
	Food Poisoning					

Gastritis
Gastrointestinal
Haemorrhage
Haematochezia
Haemorrhage
Haemorrhoids
Heart Rate Irregular
Hiatus Hernia
Hypoacusis
Injury
Lower Gastrointestinal
Haemorrhage
Palpitations
Rectal Haemorrhage
Supraventricular
Tachycardia
Upper Gastrointestinal
Haemorrhage
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501430-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Unstable		Lipitor	C				1304 DAY
Disability	Anxiety		Motrin	C			UNKNOWN	
Other	Atrioventricular Block		Naproxen	C			UNKNOWN	
	Blood Glucose Increased		Tylenol	C			UNKNOWN	
	Cataract		Premarin	C			UNKNOWN	
	Chest Pain		Aspirin	C			UNKNOWN	
	Conjunctivitis Infective		Aspirin	C			UNKNOWN	
	Contusion		Synthroid	C			UNKNOWN	
	Diplopia		Synthroid	C			UNKNOWN	
	Dyspnoea		Micronase	C			UNKNOWN	
	Emotional Distress		Glucophage	C			UNKNOWN	
	Feeling Cold		Nitroglycerin	C			UNKNOWN	
	Hot Flush		Refresh	C			OPHTHALMIC	
	Injury		[Therapy					
	Nasopharyngitis		Unspecified]	C			OPHTHALMIC	
	Nausea							
	Pain							
	Palpitations							
	Pigmented Naevus							
	Pinguecula							
	Somnolence							
	Upper Respiratory Tract Infection							

Date:11/15/04ISR Number: 4501434-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Bronchitis
	Cardiac Failure Congestive
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Depression
	Dyspnoea
	Fatigue
	Feeling Abnormal
	Gastrooesophageal Reflux Disease
	Gouty Arthritis
	Influenza
	Limb Injury
	Malignant Hypertension
	Myocardial Ischaemia
	Nasal Discomfort
	Oedema Peripheral
	Palpitations
	Polytraumatism

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Rhinitis Allergic Skin Lesion Sleep Apnoea Syndrome					
		Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Upper Respiratory Tract		Toprol Xl Tablets	C		
UNKNOWN		Infection		Imdur	C		
UNKNOWN				Nitro-Dur	C		
UNKNOWN				Diovan	C		
UNKNOWN				Diovan	C		
UNKNOWN				Diltiazem Hydrochloride	C		
UNKNOWN				Plavix	C		
UNKNOWN				Zocor	C		ORAL
UNKNOWN				Aspirin	C		
UNKNOWN				Xanax	C		
UNKNOWN				Folic Acid	C		
UNKNOWN				Allopurinol	C		
UNKNOWN				Lecithin And Protein (Unspecified)	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Soma	C		
UNKNOWN				Indocin (Indomethacin)	C		ORAL
UNKNOWN				Colchicine	C		
UNKNOWN				Norco	C		

				Levothroid	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:11/15/04ISR Number: 4501439-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00848
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
	Osteoarthritis					
	Pain In Extremity					
	Transient Ischaemic Attack					

Date:11/15/04ISR Number: 4501440-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00017
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL
	Brain Damage		Simvastatin	C		
UNKNOWN						
			Furosemide Sodium	C		
UNKNOWN						
			Bisoprolol Fumarate	C		ORAL
			Metformin Hydrochloride	C		
UNKNOWN						
			Gliclazide	C		
UNKNOWN						
			Paroxetine Hydrochloride	C		
UNKNOWN						

Phenprocoumon	C	UNKNOWN
Hydrochlorothiazide And Valsartan	C	UNKNOWN
Xipamide	C	UNKNOWN

Date:11/15/04ISR Number: 4501442-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00895
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Claritin-D	C			UNKNOWN	
Disability	Constipation		Robaxin	C			UNKNOWN	
Other	Csf Cell Count Abnormal							
	Dermal Cyst							
	Diplopia							
	Dizziness							
	Dyspnoea							
	Headache							
	Malaise							
	Menorrhagia							
	Polytraumatism							
	Sinusitis							

Date:11/15/04ISR Number: 4501445-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00752
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							

Date:11/15/04ISR Number: 4501447-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00831
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Adverse Event
Disability	Anaemia
Other	Anxiety
	Asthenia
	Asthma
	Atelectasis
	Back Pain
	Breast Cancer Stage I
	Bronchitis Acute
	Chest Pain
	Chronic Sinusitis
	Colonic Polyp
	Crying
	Dehydration
	Depression
	Diarrhoea
	Diverticulum
	Dysphagia
	Erosive Oesophagitis
	Gastritis

		Haemorrhoids					
		Hepatic Steatosis					
		Hot Flush	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperglycaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperthyroidism		Os-Cal	C		ORAL
		Hypokalaemia		Centrum	C		ORAL
		Hypothyroidism		Hydrochlorothiazide			
		Irritable Bowel Syndrome		And Triamterene	C		ORAL
		Lung Neoplasm		Adalat	C		
UNKNOWN							
		Menopause		Zoloft	C		
UNKNOWN							
		Nasal Septum Deviation		Ativan	C		
UNKNOWN							
		Neuropathy		Elavil	C		
UNKNOWN							
		Oedema Peripheral					
		Orthostatic Hypotension					
		Osteoarthritis					
		Polydipsia					
		Polytraumatism					
		Rhinitis Allergic					
		Sciatica					
		Sinus Headache					
		Upper Respiratory Tract					
		Infection					
		Vertigo Positional					
		Vestibular Neuronitis					
		Viral Upper Respiratory					
		Tract Infection					

Date:11/15/04ISR Number: 4501451-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Amnesia		Zantac	C		
UNKNOWN							
		Anaemia		Reglan	C		
UNKNOWN							
		Back Pain		Dicyclomine			
		Bronchitis		Hydrochloride	C		
UNKNOWN							

	Cerebrovascular Accident	Procardia	C	
UNKNOWN				
	Chest Pain	Vicodin Es Tablets	C	
UNKNOWN				
	Depression	Vicodin Es Tablets	C	
UNKNOWN				
	Difficulty In Walking	Arthrotec	C	
UNKNOWN				
	Disorientation	Ditropan Xl	C	
UNKNOWN				
	Dysarthria	Adalat	C	
UNKNOWN				
	Dysstasia	Quinine	C	
UNKNOWN				
	Fall	Crixivan	C	ORAL
	Gastrointestinal	Crixivan	C	ORAL
	Haemorrhage	Combivir	C	
UNKNOWN				
	Herpes Simplex	Bactrim	C	
UNKNOWN				
	Hypersensitivity	Allegra	C	
UNKNOWN				
	Neuropathy	Diflucan	C	
UNKNOWN				
	Polytraumatism			
	Polyuria			
	Subcutaneous Abscess			
	Syncope			
	Tongue Disorder			
	Urinary Incontinence			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501452-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00184
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemianopia		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501453-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0410CHE00043
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501456-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00899
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Atenolol	C				
Disability	Cough		Maxzide	C				
	Drug Intolerance		Clonidine	C				
	Dyspepsia		Ambien	C				
	Dysuria							
	Fibrosis							
	Hyperglycaemia							
	Infection							
	Nausea							
	Oropharyngeal Swelling							
	Osteoarthritis							
	Palpitations							
	Periarthritis							
	Pharyngolaryngeal Pain							
	Polytraumatism							
	Thirst							
	Tinnitus							

Toothache
Vomiting
Weight Abnormal

Date:11/15/04ISR Number: 4501458-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00122
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Drug Interaction		Phenprocoumon	SS		ORAL		
Other	Gastritis Erosive		Tramadol Hydrochloride	SS		ORAL		
	Gastrointestinal Haemorrhage		Phenprocoumon	SS		ORAL		
	Haematemesis		Xipamide	C		ORAL		
	Melaena		Metoprolol Succinate	C		ORAL		
	Mucosal Haemorrhage		Digitoxin	C		ORAL		
	Nausea							
	Petechiae							
	Prothrombin Time Prolonged							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501459-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00792
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Prilosec	C				
UNKNOWN								
Disability	Benign Intracranial Hypertension							
	Bronchitis							
	Cerebral Ischaemia							
	Deafness							
	Depression							
	Diabetes Mellitus							
	Dizziness							
	Endolymphatic Hydrops							
	Fatigue							
	Headache							
	Increased Upper Airway Secretion							
	Injury							
	Muscle Atrophy							
	Muscle Spasms							
	Myalgia							
	Myositis							
	Nervousness							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Pain							
	Polytraumatism							
	Pruritus							
	Skin Disorder							
	Spinal Column Stenosis							

Date:11/15/04ISR Number: 4501460-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00206
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501461-XReport Type:Expedited (15-DaCompany Report #NL-MERCK-0410NLD00009
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1598 DAY
Hospitalization -			Orap	C		ORAL		
Initial or Prolonged			Anafranil	C		ORAL		
Disability								

Date:11/15/04ISR Number: 4501462-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03425
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Isosorbide	C				UNKNOWN
Other	Dementia		Aciphex	C				UNKNOWN
			Meclizine	C				UNKNOWN

			Metoprolol	C		
UNKNOWN						
			Pravachol	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Alprazolam	C		
UNKNOWN						
			Furosemide	C		
UNKNOWN						
			Darvon	C		
UNKNOWN						

Date:11/15/04ISR Number: 4501463-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00207
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:11/15/04ISR Number: 4501464-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03726
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vicodin Tablets	C				
UNKNOWN								
	Hypoaesthesia							

Date:11/15/04ISR Number: 4501465-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00187
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
61 DAY								
Initial or Prolonged	Cardiac Failure		Fluoxetine	C				
UNKNOWN								
Disability	Fall		Acetaminophen And					

Other	Heart Rate Irregular		Dihydrocodeine			
	Hip Fracture		Bitartrate	C		
UNKNOWN						
	Mitral Valve Incompetence		Ramipril	C		
UNKNOWN						
	Myocardial Infarction					
	Shock					

Date:11/15/04ISR Number: 4501466-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02232
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Hospitalization -	Disorientation		Atenolol	C		
UNKNOWN						
Initial or Prolonged	Gastric Disorder		Ambien	C		
UNKNOWN						
Disability	Loss Of Consciousness		[Therapy			
	Palpitations		Unspecified]	C		
UNKNOWN						
	Vomiting		Nitroglycerin	C		
UNKNOWN						
			[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:11/15/04ISR Number: 4501467-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03719
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Arthritis
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Convulsion
	Headache

Kidney Infection
Renal Failure

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501468-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02709
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery		Depakote	C				
UNKNOWN								
Initial or Prolonged	Atherosclerosis		Prozac	C				
UNKNOWN								
Disability	Difficulty In Walking							
	Muscle Spasms							

Date:11/15/04ISR Number: 4501469-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02973
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
20	DAY							
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
20	DAY							
			Pravachol	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Glipizide	C				
UNKNOWN								
			Levobunolol					

				Hydrochloride	C		
UNKNOWN							

Date:11/15/04ISR Number: 4501472-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501473-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501475-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01032
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
	Hypertension		Allegra	C				
			Protonix	C				
			Benadryl	C				
			Levothroid	C				
			Hydrochlorothiazide	C				
			Coumadin	C				
UNKNOWN								

				Prinivil	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							

Date:11/15/04ISR Number: 4501476-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01002
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cataract Operation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Maxalt (Rizatriptan					
Initial or Prolonged	Dizziness		Benzoate)	C		ORAL		
	Headache							

Date:11/15/04ISR Number: 4501477-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged								

Date:11/15/04ISR Number: 4501479-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00842
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Nexium	C				
UNKNOWN								
			Proscar	C		ORAL		

Date:11/15/04ISR Number: 4501480-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:11/15/04ISR Number: 4501481-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01395
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Injury							
	Myocardial Infarction							

Date:11/15/04ISR Number: 4501483-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:11/15/04ISR Number: 4501484-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01406
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Transient Ischaemic

Attack

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/15/04ISR Number: 4501485-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01085
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON
	Chest Pain		Zanaflex	C			UNKNOWN	
	Renal Pain							

Date:11/15/04ISR Number: 4501487-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01405
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Plavix	C			UNKNOWN	
Initial or Prolonged			Aspirin	C			UNKNOWN	
Disability			Lotrel	C			UNKNOWN	
			Clonidine	C			UNKNOWN	
			Pravachol	C			UNKNOWN	

Date:11/15/04ISR Number: 4501488-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00890
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Hospitalization -	Cerebrovascular Accident		[Therapy			
Initial or Prolonged			Unspecified]	C		
UNKNOWN						
Disability						

Date:11/15/04ISR Number: 4501492-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00967
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
	Loss Of Consciousness		[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:11/15/04ISR Number: 4501502-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01627
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Congestive		Furosemide	C		
UNKNOWN						
Initial or Prolonged			Tarka	C		
UNKNOWN						
Disability			Proventil	C		
UNKNOWN						
			Pulmicort	C		
UNKNOWN						

Date:11/15/04ISR Number: 4501503-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01401
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea		Fosamax	C		ORAL		
	Malignant Melanoma		Amitriptyline Hydrochloride	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Ascorbic Acid	C			UNKNOWN	

Date:11/15/04ISR Number: 4501506-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01525
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C			UNKNOWN	
Disability			Prinivil	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:11/15/04ISR Number: 4501507-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01536
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged	Difficulty In Walking		Thyroid	C			UNKNOWN	
	Gastric Disorder		Cardizem	C			UNKNOWN	
Disability	Loss Of Consciousness		Protonix	C			UNKNOWN	

Weight Decreased

Date:11/15/04ISR Number: 4501508-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Myocardial Infarction							
Other								

Date:11/15/04ISR Number: 4501509-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01621
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Gemfibrozil	C				
UNKNOWN								
Initial or Prolonged			Levoxyl	C				
UNKNOWN								

Date:11/15/04ISR Number: 4501511-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Tylenol	C				
UNKNOWN								
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501512-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501513-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blindness Transient Cerebrovascular Accident Transient Ischaemic Attack Visual Acuity Reduced		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501514-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Blood Pressure Increased		Albuterol	C				
Initial or Prolonged UNKNOWN	Heart Rate Increased		Atrovent	C				
Disability UNKNOWN			Prednisone	C				
Other								

Date:11/15/04ISR Number: 4501516-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01622
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged	Disease							

Other	Chest Pain Vomiting						

Date:11/15/04ISR Number: 4501517-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01537
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Chest Pain Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501523-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01532
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501525-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01663
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Methotrexate	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								

Date:11/15/04ISR Number: 4501527-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01630
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia							
Disability	Transient Ischaemic							
	Attack							

Date:11/15/04ISR Number: 4501528-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01668
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Tiazac	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

Date:11/15/04ISR Number: 4501529-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02097
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								

Initial or Prolonged
Disability
Other

Date:11/15/04ISR Number: 4501530-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01703
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Chest Pain Dyspnoea Neck Pain Pain In Extremity Pallor		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501532-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01631
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zocor	C				
UNKNOWN								
Initial or Prolonged			Zestril	C				
UNKNOWN								
Disability			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501533-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01647
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Norvasc	C				
UNKNOWN								
Initial or Prolonged	Oedema Peripheral		[Therapy					
	Paraesthesia		Unspecified]	C				
UNKNOWN								
			Vitamin E	C				
UNKNOWN								
			Ascorbic Acid	C				
UNKNOWN								
			Vitamin B Complex	C				
UNKNOWN								

Date:11/15/04ISR Number: 4501543-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00213
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501548-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00907
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Disorder							
Hospitalization -								
Initial or Prolonged								
Disability								
Other								

Date:11/15/04ISR Number: 4501558-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Anxiety Fear Hypertension Myocardial Infarction Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501565-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/15/04ISR Number: 4501645-0Report Type:Direct Company Report #CTU 232010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx 25 Mg	PS				
Other	Chest Discomfort							

2 FOR 5 DAYS
THEN 1 A DAY

[1 DOSE

ONLY]

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/04ISR Number: 4501764-9Report Type:Direct Company Report #CTU 232004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx				25 Mg	
Hospitalization -	Deep Vein Thrombosis		Merck & Co., Inc.	PS	Merck & Co., Inc.	ORAL	1 TABLET	
Initial or Prolonged	Dyspnoea						DAILY	ORAL
	Pulmonary Embolism		Premarin				0.625 Mg	
			Wyeth	SS	Wyeth	ORAL	1 TABLET	
							DAILY	ORAL

Date:11/15/04ISR Number: 4501986-7Report Type:Direct Company Report #CTU 231935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Behaviour		Vioxx	PS		ORAL	25 MC,	
Required	Activities Of Daily						DAILY,ORAL	
Intervention to	Living Impaired		Demulen	C				
Prevent Permanent	Alopecia							
Impairment/Damage	Asthenia							
	Convulsion							
	Depressed Level Of							
	Consciousness							
	Disturbance In Attention							
	Fatigue							
	Fibromyalgia							
	Haemorrhage							
	Hyperaesthesia							
	Hypoaesthesia							
	Memory Impairment							
	Mental Impairment							
	Muscle Spasms							
	Muscle Tightness							
	Muscle Twitching							
	Myalgia							
	Nervous System Disorder							
	Thinking Abnormal							

Date:11/15/04ISR Number: 4501987-9Report Type:Direct Company Report #CTU 231938
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea Palpitations		Vioxx 25mg Merck & Co., Inc.	PS	Merck & Co., Inc.	ORAL	25MG 1X DAILY	
							ORAL	

Date:11/15/04ISR Number: 4503909-3Report Type:Expedited (15-DaCompany Report #2003036888
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Disability	Actinic Keratosis
Other	Arthralgia
	Arthritis
	Aseptic Necrosis Bone
	Asthenia
	Blood Chloride Decreased
	Bone Density Decreased
	Constipation
	Contusion

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dermatitis Contact Difficulty In Walking Dysphagia					
40 MG (1 IN 1 D)		Eczema Electrolyte Imbalance Fall Gait Disturbance Gastrooesophageal Reflux Disease Genital Rash Haematochezia	Consumer Health Professional	Lipitor (Atorvastatin) Rofecoxib (Rofecoxib) Prednisone (Prednisone)	PS SS SS		
10 MG (1 IN 1 D)		Hip Arthroplasty Hypertension Hypokalaemia Hyponatraemia Hypothyroidism Lower Respiratory Tract Infection Muscle Atrophy Muscle Strain Myalgia Myopathy Oedema Osteopenia Osteoporosis Pain Pain In Extremity Polymyositis Postmenopausal Haemorrhage Rash Rhinitis Allergic Sleep Disorder Tenderness Urinary Tract Infection Vulval Ulceration Walking Aid User Weight Increased		Potassium (Potassium) Amlodipine Besilate (Amlodipine Besilate) Dyazide (Hydrochlorothiazide, Triamterene) Levothyroxine Sodium(Levothyroxine Sodium) Centrum Silver (Ascorbic Acid, Calcium, Minerals Nos, Retinol, Tocopheryl Acetate, Acetylsalicylic Acid (Acetylsalicylic Acid) Vitamin B (Vitamin B) Ascorbic Acid (Ascorbic Acid) Tocopherol Methylcellulose (Methylcellulose) Piroxicam(Piroxicam) Ferrous Sulfate (Ferrous Sulfate)	C C C C C C C C C		

Date:11/15/04ISR Number: 4507644-7Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00147
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 532 DAY
	Coronary Artery Atherosclerosis	Health Professional						
	Myocardial Rupture							

Date:11/16/04ISR Number: 4501880-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01516
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Coumadin	C				
Initial or Prolonged Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4501930-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00017
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Myocardial Infarction							

Date:11/16/04ISR Number: 4502046-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00616
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Ultram	C				
UNKNOWN								
	Bronchitis Acute							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Convulsion							
	Drug Ineffective							
	Hypercholesterolaemia							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Pharyngitis							
	Sinusitis							
	Ulnar Nerve Injury							
	Upper Respiratory Tract Infection							

Date:11/16/04ISR Number: 4502049-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00610
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Zocor	C				
UNKNOWN								
Other	Back Pain		Skelaxin	C				
UNKNOWN								

	Blood Pressure Increased	Ultram	C
UNKNOWN			
	Bundle Branch Block Right	Furosemide	C
UNKNOWN			
	Cervicobrachial Syndrome	Zestril	C
UNKNOWN			
	Coccydynia	Hydrocodone/Apap	C
UNKNOWN			
	Convulsion	Lopressor	C
UNKNOWN			
	Dizziness	Imdur	C
UNKNOWN			
	Drug Ineffective	Digoxin	C
UNKNOWN			
	Fall	Aspirin	C
UNKNOWN			
	Gait Disturbance	Aerobid	C
UNKNOWN			
	Headache	Albuterol	C
UNKNOWN			
	Hypoaesthesia	Ipratropium Bromide	C
UNKNOWN			
	Lumbar Spinal Stenosis		
	Myocardial Infarction		
	Oedema Peripheral		
	Osteoarthritis		
	Pain In Extremity		
	Plantar Fasciitis		
	Pneumonia		
	Spinal Osteoarthritis		
	Upper Respiratory Tract Infection		
	Ventricular Dysfunction		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502055-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
586 DAY								
Initial or Prolonged	Adverse Event		Claritin	C				
UNKNOWN								
Disability	Angina Pectoris		Aspirin	C				
UNKNOWN								
Other	Benign Prostatic		Pravachol	C				
UNKNOWN								
	Hyperplasia		Calcium					
	Blood Pressure Increased		(Unspecified)	C				
UNKNOWN								
	Bradycardia		Folic Acid	C				
UNKNOWN								
	Bronchitis Acute		Digoxin	C				
UNKNOWN								
	Cholelithiasis		Naprosyn	C		ORAL		
	Chronic Obstructive		Keflex	C		ORAL		
	Pulmonary Disease		Allegra	C		ORAL		
	Convulsion		Elocon	C				
UNKNOWN								
	Coronary Artery Disease		Lopressor	C		ORAL		
	Depression		Darvocet-N	C		ORAL		
	Dermatitis Atopic		Pravachol	C				
UNKNOWN								
	Diverticulum		Lanoxin	C		ORAL		
	Dyspnoea		Lortab	C		ORAL		
	Fatigue		Clarinex	C		ORAL		
	Gastrooesophageal Reflux		Zocor	C		ORAL		
	Disease		Nexium	C		ORAL		
	Haemorrhoids		Paxil	C		ORAL		
	Hiatus Hernia		Vitamin E	C				
UNKNOWN								
	Inner Ear Disorder							
	Intervertebral Disc							
	Degeneration							
	Lumbar Spinal Stenosis							
	Lung Neoplasm							
	Myocardial Infarction							
	Neuroma							
	Non-Hodgkin'S Lymphoma							
	Palpitations							
	Renal Abscess							

Rhinitis Allergic
Salivary Gland Cancer
Vertigo
Weight Decreased

Date:11/16/04ISR Number: 4502058-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00820
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
	Arthralgia
	Back Pain
	Depression
	Dermal Cyst
	Family Stress
	Gastritis
	Hypertension
	Hypoaesthesia
	Intervertebral Disc Degeneration
	Irritability
	Oedema Peripheral
	Pharyngitis
	Plantar Fasciitis

		Polytraumatism Postoperative Infection Renal Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Temporomandibular Joint	Professional	Motrin	C		
UNKNOWN		1 DAY					
		Syndrome		Motrin	C		
UNKNOWN							
		Upper Respiratory Tract		Celebrex	C		
UNKNOWN							
		Infection		Soma	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Hydrochlorothiazide And Triamterene	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Estradiol	C		
UNKNOWN							

Date:11/16/04ISR Number: 4502059-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00846
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Anaemia Anhedonia Aortic Valve Incompetence Asthenia Asthma Chest Pain Decreased Appetite Depression Dilatation Atrial Dilatation Ventricular Fatigue Feeling Jittery	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Headache
Insomnia
Libido Decreased
Low Density Lipoprotein
Increased
Mitral Valve Incompetence
Ovarian Cyst
Polytraumatism
Pulmonary Arterial
Pressure Increased
Respiratory Distress
Sleep Apnoea Syndrome
Trichomoniasis
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Urinary Tract Infection
Vaginal Haemorrhage

Date:11/16/04ISR Number: 4502060-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00689
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adnexa Uteri Pain
Other	Adverse Event

		Anxiety					
		Arthralgia					
		Back Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Breast Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Cataract	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis					
		Ovarian Cyst					
		Sciatica					
		Tinnitus					

Date:11/16/04ISR Number: 4502061-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00852
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Adverse Event		Celebrex	C		ORAL
	Arthritis		Darvocet-N	C		
UNKNOWN						
	Atrioventricular Block		Ambien	C		
UNKNOWN						
	Back Pain		Toprol Xl Tablets	C		
UNKNOWN						
	Blood Pressure Systolic		Florone	C		
UNKNOWN						
	Increased		Flexeril	C		
UNKNOWN						
	Bronchitis		Aspirin	C		
UNKNOWN						
	Cerebrovascular Accident		Serzone	C		
UNKNOWN						
	Coronary Artery Disease		Prilosec	C		
UNKNOWN						
	Cough		Glucotrol Xl	C		
UNKNOWN						
	Dyspnoea		Zestril	C		
UNKNOWN						
	Facet Joint Syndrome		Lipitor	C		
UNKNOWN						
	Fatigue					
	Gastroenteritis Viral					
	Intermittent Claudication					
	Palpitations					

Serum Serotonin Decreased
Spinal Column Stenosis
Syncope

Date:11/16/04ISR Number: 4502062-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00886
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Abdominal Distension
	Abdominal Pain Lower
	Abdominal Tenderness
	Adverse Event
	Arthralgia
	Asthenia
	Atrial Fibrillation
	Blood Pressure Diastolic Decreased
	Bronchitis
	Chest Pain
	Constipation
	Cough
	Diverticulum
	Dyspnoea
	Eye Pain
	Fatigue
	Flatulence

		Gastric Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Increased	Health	Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Heart Rate Irregular	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperhidrosis		Estrogens, Conjugated	C		
		Hypertensive Heart Disease		Desyrel	C		
UNKNOWN							
		Injury		Aspirin	C		
UNKNOWN							
		Lymphadenopathy		Msm Complete	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Nausea					
		Neck Pain					
		Oesophageal Spasm					
		Pain In Extremity					
		Palpitations					
		Tricuspid Valve Incompetence					
		Ventricular Hypertrophy					

Date:11/16/04ISR Number: 4502063-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Disability	Amnesia
	Angina Pectoris
	Blood Pressure Increased
	Breast Cancer In Situ
	Breast Pain
	Bronchitis
	Bursitis
	Chest Pain
	Colonic Polyp
	Contusion
	Deafness Neurosensory
	Dizziness
	Endolymphatic Hydrops

Exostosis
Fatigue
Haemangioma
Haemorrhoids
Hypertension
Hypertensive
Encephalopathy
Limb Discomfort
Loss Of Consciousness
Nausea
Osteoarthritis
Osteoporosis
Pain In Extremity
Palatal Disorder
Palpitations
Plantar Fasciitis
Pulmonary Fibrosis
Rash
Rhinitis
Seasonal Allergy
Seroma

		Tendonitis					
		Tinnitus					
		Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Vertebrobasilar	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Insufficiency		Spironolactone	C		
UNKNOWN							
		Vertigo Positional		Captopril Msd	C		ORAL
				Toprol Xl Tablets	C		ORAL

Date:11/16/04ISR Number: 4502064-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00871
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Acute Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY							
Other		Adverse Event	Professional	Tylenol With Codeine			
		Angina Pectoris		#4	C		ORAL
		Bronchitis Acute		Doxy-100	C		ORAL
		Coronary Artery Disease					
		Dermatitis Exfoliative					
		Haemorrhoids					
		Hypertension					
		Labyrinthitis					
		Onychomycosis					
		Peripheral Vascular					
		Disorder					

Date:11/16/04ISR Number: 4502065-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00775
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris	Professional	Prempro	C		
UNKNOWN							
		Anxiety		Dyazide	C		
UNKNOWN							
		Arthropathy		Aspirin	C		
UNKNOWN							
		Carpal Tunnel Syndrome					

Cerebral Atherosclerosis
Cerebrovascular Accident
Cerebrovascular Disorder
Complicated Migraine
Convulsion
Depression
Ganglion
Hypercholesterolaemia
Hypertension
Hypoaesthesia
Lacunar Infarction
Neck Pain
Syncope
Tinel'S Sign
Transient Ischaemic
Attack
Trigger Finger
Wrist Fracture

Date:11/16/04ISR Number: 4502066-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Acute Coronary Syndrome Acute Myocardial Infarction Adverse Event Blood Cholesterol Increased Cardiac Failure Congestive Cerebrovascular Accident Confusional State Coronary Artery Disease Depression Diabetes Mellitus Inadequate Control Diabetic Neuropathy Diarrhoea Escherichia Sepsis Hypertension Intermittent Claudication Mitral Valve Incompetence Myocardial Infarction Oedema Peripheral Osteoarthritis Peripheral Occlusive Disease Pulmonary Oedema Renal Failure Renal Failure Acute Sciatica Spinal Column Stenosis Stress Incontinence Transient Ischaemic Attack Urinary Tract Infection Urosepsis Uterine Infection	Other	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502067-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00888
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		670 DAY
Initial or Prolonged	Back Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		670 DAY
Disability	Blood Cholesterol Increased Dyspepsia Gastrooesophageal Reflux Disease Hypertension Intervertebral Disc Protrusion Myocardial Infarction Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502068-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00889
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Disorientation		Aspirin	C				UNKNOWN
	Fatigue		Darvocet-N	C				UNKNOWN
	Generalised Anxiety		Naproxen	C				UNKNOWN
	Disorder		Ibuprofen	C				UNKNOWN
	Memory Impairment							

Date:11/16/04ISR Number: 4502069-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00022
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Potassium Decreased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		INTRAVENOUS DRIP
	Drug Interaction		Quinapril Hydrochloride	SS		ORAL		
	Hyponatraemia		Glimepiride	SS		ORAL		
			Dipyrone	SS		ORAL		
			Piretanide	SS		ORAL		
			Acyclovir	C		ORAL		
			Procaine Hydrochloride	C		ORAL		
			Thioctic Acid	C		ORAL		
			Hydroxyzine Hydrochloride	C		ORAL		
			Bisoprolol	C		ORAL		
			Tolperisone Hydrochloride	C		ORAL		

Date:11/16/04ISR Number: 4502070-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00892
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Arthritis
Other	Asthenia
	Breathing-Related Sleep Disorder
	Cataract
	Chest Pain
	Constipation
	Coronary Artery Disease
	Cough
	Eye Disorder
	Hypercholesterolaemia
	Hyperlipidaemia
	Lung Neoplasm Malignant
	Mass
	Myocardial Infarction
	Neoplasm
	Palpitations
	Peripheral Vascular Disorder
	Pyrexia
	Stress Fracture
	Umbilical Hernia

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502071-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00892
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR	
	Chest Pain		Nexium	C			UNKNOWN	
	Dyspnoea		Acetaminophen	C			UNKNOWN	
	Hypertension							
	Myocardial Infarction							
	Pain In Extremity							
	Stress							

Date:11/16/04ISR Number: 4502072-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0403CHE00022
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Health	Vioxx	PS	Merck & Co., Inc	ORAL	13 DAY	
Initial or Prolonged	Dyspnoea	Professional	Acenocoumarol	SS		ORAL		
	Gastritis Erosive		Methylprednisolone Acetate	SS			PARENTERAL	61 DAY
			Methylprednisolone Acetate	SS			PARENTERAL	61 DAY
			Digoxin	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Spironolactone	C		ORAL		

				Torsemide	C		ORAL
52 DAY							
				Levothyroxine Sodium	C		ORAL
				Glimepiride	C		ORAL
				Nitroglycerin	C		ORAL
12 MON							
				Molsidomine	C		ORAL
12 MON							
				Clonazepam	C		ORAL

Date:11/16/04ISR Number: 4502073-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alcohol Use	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Neurontin	C			UNKNOWN	
	Depression		Ibuprofen	C			UNKNOWN	
	Fall		Claritin	C			UNKNOWN	
	Fatigue		Premarin	C			UNKNOWN	
	Gastrooesophageal Reflux		Cephalexin	C			UNKNOWN	
	Disease		Skelaxin	C			UNKNOWN	
	Hypertension		Trazodone Hydrochloride	C			UNKNOWN	
	Intervertebral Disc Protrusion		Zovirax	C			UNKNOWN	
	Thrombosis		Methylprednisolone	C			UNKNOWN	
	Transient Ischaemic Attack		Propoxyphene Hydrochloride	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502074-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00890
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Initial or Prolonged	Anxiety Disorder	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
Other	Back Pain		Procardia	C			UNKNOWN	
	Blood Cholesterol Increased		Estrogens (Unspecified)	C			UNKNOWN	
	Brain Neoplasm Benign		Plavix	C			UNKNOWN	6 DAY
	Carotid Artery Occlusion		Aspirin	C			UNKNOWN	
	Cerebrovascular Accident		Aleve	C			UNKNOWN	
	Colon Neoplasm		Aleve	C			UNKNOWN	
	Coronary Artery Occlusion		Tylenol	C			UNKNOWN	
	Emotional Distress		Tylenol	C			UNKNOWN	
	Generalised Anxiety Disorder		Hydrocodone Hydrochloride	C			UNKNOWN	
	Headache		Soma	C			UNKNOWN	
	Injury		Vicodin Tablets	C			UNKNOWN	
	Migraine		Vicodin Tablets	C			UNKNOWN	
	Myocardial Infarction		Flexeril	C			UNKNOWN	
	Neck Pain		Lorcet Plus	C			UNKNOWN	
	Osteoarthritis		Lorcet Plus	C			UNKNOWN	
	Post Procedural		Klonopin	C			UNKNOWN	
	Haemorrhage		Zyprexa	C			UNKNOWN	
	Sinus Disorder		Temazepam	C			UNKNOWN	

	Spinal Osteoarthritis		Prilosec	C			
UNKNOWN							
			Avelox	C			
UNKNOWN							
			Estropipate	C			
UNKNOWN							
			Carafate	C			
UNKNOWN							
			Amoxil	C			
UNKNOWN							
			Butalbital	C			
UNKNOWN							
			Claritin	C			
UNKNOWN							
			Fosamax	C			ORAL
			Cefalexin	C			
UNKNOWN							
			Atenolol	C			
UNKNOWN							
			Isosorbide	C			
UNKNOWN							
			Histinex D	C			
UNKNOWN							
			Ultram	C			
UNKNOWN							
			[Therapy Unspecified]	C			
UNKNOWN							
			Phenergan (Promethazine Hydrochloride)	C			
UNKNOWN							
			Nitroglycerin	C			
UNKNOWN							

Date:11/16/04ISR Number: 4502075-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00104
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							4	YR

Date:11/16/04ISR Number: 4502076-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4 YR
			Levothyroxine Sodium	C			UNKNOWN
			Prednisone	C			UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502077-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0408CAN00015
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase Increased	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate Aminotransferase Increased		Rosuvastatin Calcium	SS		ORAL		
			Rosuvastatin Calcium	SS		ORAL		
			Zetia	SS		ORAL		
			Ascorbic Acid	C			UNKNOWN	
	Blood Creatine		Atenolol	C			UNKNOWN	
	Phosphokinase Increased		Allopurinol	C			UNKNOWN	
	Drug Interaction		Folic Acid	C			UNKNOWN	
			Quinapril Hydrochloride	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	
			Niacin	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	

Date:11/16/04ISR Number: 4502078-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00887
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Motrin	C			UNKNOWN	
Disability	Increased		Tylenol	C			UNKNOWN	
Other	Depression		[Therapy Unspecified]	C			UNKNOWN	
	Myocardial Infarction							
	Nausea		Ultram	C			UNKNOWN	

Stress

Date:11/16/04ISR Number: 4502079-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03015
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Lacunar Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Weight Decreased	Professional	Glucosamine	C				
Initial or Prolonged			Atenolol	C				
Other			Evista	C		ORAL		
			Prinivil	C		ORAL		
			Celexa	C		ORAL		

Date:11/16/04ISR Number: 4502080-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00148
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Health	Vioxx	PS	Merck & Co., Inc	ORAL	843	DAY
Hospitalization -	Cardiac Failure	Professional	Metoprolol Tartrate	C		ORAL		
Initial or Prolonged	Congestive							
Disability	Cerebral Ischaemia							

Date:11/16/04ISR Number: 4502083-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02014
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:11/16/04ISR Number: 4502084-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00099
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		1406 DAY
Hospitalization -	Renal Disorder		Phenobarbital	C				UNKNOWN
Initial or Prolonged	Renal Failure Chronic		[Therapy Unspecified]	C				UNKNOWN

Date:11/16/04ISR Number: 4502085-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00772
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Extrasystoles	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502088-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502089-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502090-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:11/16/04ISR Number: 4502092-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident	Other	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502093-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00011
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction	Professional	Clopidogrel Bisulfate	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Bisoprolol Fumarate And Hydrochlorothiazide	C		ORAL		
			Furosemide Sodium	C		ORAL		

			Lisinopril	C		ORAL
			Metformin Hydrochloride	C		ORAL
			Sertraline Hydrochloride	C		ORAL
			Insulin	C		
UNKNOWN						

Date:11/16/04ISR Number: 4502094-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dizziness	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Loss Of Consciousness		Levothyroxine Sodium	C		
UNKNOWN						
	Palpitations		Atorvastatin Calcium	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:11/16/04ISR Number: 4502096-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastric Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Initial or Prolonged	Loss Of Consciousness					

Date:11/16/04ISR Number: 4502097-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	
UNKNOWN						

Date:11/16/04ISR Number: 4502100-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00209
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Venous Thrombosis Limb	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502102-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cerebrovascular Accident	Other	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502106-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00936
Age: Gender:Male I/FU:I

Outcome	PT
Other	Barrett'S Oesophagus Dizziness Dysplasia Dyspnoea Gastric Ulcer

Haemoglobin Decreased

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/16/04ISR Number: 4502107-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Death							

Date:11/16/04ISR Number: 4502108-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01430
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Lotrel	C				
UNKNOWN								
Initial or Prolonged	Neck Pain		Tenex	C				
UNKNOWN								
			Morphine	C				
UNKNOWN								

Date:11/16/04ISR Number: 4502109-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01429
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		[Therapy					
Initial or Prolonged	Insomnia		Unspecified]	C				
UNKNOWN								
Disability	Loss Of Consciousness							

Date:11/16/04ISR Number: 4502111-9Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502112-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Hydrochlorothiazide	C				
Initial or Prolonged			Lipitor	C				
			Metoprolol	C				
			Prevacid	C				
			Isosorbide	C				
			Flovent	C				
			Serevent	C				
			Albuterol	C				
			Aspirin	C				
			Centrum	C				
			Tylenol	C				
			Metoclopramide					

Hydrochloride C
UNKNOWN

Date:11/16/04ISR Number: 4502113-2Report Type:Expedited (15-DaCompany Report #MX-MERCK-0411USA00650
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Venous Thrombosis Limb	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Folic Acid	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/16/04ISR Number: 4502116-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01412
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Chest Pain							
	Ulcer							

Date:11/16/04ISR Number: 4502117-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01676
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Catapres	C				
UNKNOWN								
	Pain In Extremity		Glucotrol Xl	C				
UNKNOWN								
	Vomiting							

Date:11/16/04ISR Number: 4502118-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02022
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Ocuvite	C				
			Aspirin	C			UNKNOWN	

Date:11/16/04ISR Number: 4502121-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02021
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Meningitis	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rash							
	Rectal Haemorrhage							

Date:11/16/04ISR Number: 4502122-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01569
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502125-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00019
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Health	Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Cardiomyopathy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Pulmonary Oedema		Prednisolone	C		UNKNOWN		

Date:11/16/04ISR Number: 4502126-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Disability	Abnormal Faeces
	Acute Sinusitis
	Adverse Event
	Arthralgia
	Asthenia
	Barrett'S Oesophagus
	Benign Duodenal Neoplasm
	Blood Pressure Increased
	Bronchospasm
	Brunner'S Gland
	Hyperplasia
	Chest Pain
	Chills
	Constipation
	Costochondritis
	Cough
	Dermatitis Allergic
	Diarrhoea
	Dyspnoea
	Ear Pain
	Epicondylitis
	Flatulence
	Gastrointestinal Pain
	Gastrooesophageal Reflux
	Disease
	Headache
	Helicobacter Gastritis

Helicobacter Infection
Hepatic Function Abnormal
Hypoaesthesia
Injury
Lipids Increased
Liver Function Test
Abnormal
Melaena
Nausea
Neck Pain
Otitis Media
Pain
Pain In Extremity
Paraesthesia
Pharyngitis
Postnasal Drip
Pyrexia
Rhinitis Allergic
Rhinorrhoea
Sensation Of Pressure

		Sinus Congestion					
		Sinus Headache					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sputum Discoloured	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Tendonitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Prevacid	C		
UNKNOWN							
		Infection		Ultram	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Pulmicort	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Estradiol	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							

Date:11/16/04ISR Number: 4502161-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00520
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebral Artery Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebral Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Nicotine Dependence		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Theophylline	C		
UNKNOWN							
				Silibinin	C		
UNKNOWN							
				Tramadol Hydrochloride	C		
UNKNOWN							
				Tramadol Hydrochloride	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							

Spironolactone	C		
UNKNOWN			
Atenolol	C		
UNKNOWN			
Oil Of Lavender	C		
UNKNOWN			
Fosamax	C		ORAL
Calcitonin	C		
UNKNOWN			
Calcium (Unspecified)	C		
UNKNOWN			

Date:11/16/04ISR Number: 4502731-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00641
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Thrombosis							

Date:11/16/04ISR Number: 4502732-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0306FRA00008
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Back Pain
Hospitalization - Initial or Prolonged	Confusional State
	Haemodynamic Instability
	Intervertebral Discitis
	Localised Infection
	Quadriplegia
	Respiratory Distress
	Sepsis

Staphylococcal Infection
Tenosynovitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	15 YR
	Betamethasone	SS				
	Prednisone	SS		ORAL	UNKNOWN	1 DAY
	Methylprednisolone Sodium Succinate	SS				
	Terbutaline Sulfate	C			UNKNOWN	
	Ipratropium Bromide	C			UNKNOWN	
	Fluticasone Propionate And Salmeterol Xinafoate	C			UNKNOWN	
	Rilmenidene	C			UNKNOWN	
	Glimepiride	C			UNKNOWN	

Date:11/16/04ISR Number: 4502733-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00186
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Vein Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502737-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01022160
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
	Headache							
	Meningitis Aseptic						UNKNOWN	

Musculoskeletal Stiffness
Urinary Tract Infection

Date:11/16/04ISR Number: 4502738-4Report Type:Expedited (15-DaCompany Report #US-MERCK-00060586
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Spinal Laminectomy							
	Stent Placement							

Date:11/16/04ISR Number: 4502739-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00100
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Citalopram Hydrobromide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502740-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01619
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502741-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00218
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502742-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00126
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR	
			Imipramine Hydrochloride	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	

Date:11/16/04ISR Number: 4502743-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502745-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502747-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00038
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502748-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00234
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502749-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00016
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		193 DAY
Initial or Prolonged	Diarrhoea		Ibuprofen	C				UNKNOWN
	Tachycardia		Acetaminophen And Codeine Phosphate	C				UNKNOWN

Date:11/16/04ISR Number: 4502750-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01398
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Death							

Date:11/16/04ISR Number: 4502751-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03465
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Plaquenil	C				UNKNOWN
Disability			Lipitor	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Nexium	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Plavix	C				UNKNOWN
			Premarin	C				UNKNOWN
			Diuretic					

(Unspecified) C
UNKNOWN

Date:11/16/04ISR Number: 4502752-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00030
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:11/16/04ISR Number: 4502753-0Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:11/16/04ISR Number: 4502754-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01504
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Stem Infarction		Zyprexa	C				
UNKNOWN								
Other	Locked-In Syndrome		[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502755-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01583
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
							1	YR

Date:11/16/04ISR Number: 4502756-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00232
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thinking Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502757-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	YR

Date:11/16/04ISR Number: 4502758-XReport Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00013
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
							1559	DAY
			Amiloride	C		ORAL		
			Prednisolone	C		ORAL		
			Lansoprazole	C		ORAL		
			Fosamax	C		ORAL		
			Psyllium Husk	C		ORAL		
			Tiotropium Bromide	C				
							RESPIRATORY	
							(INHALATION)	
			Fluticasone					

Propionate And
Salmeterol Xinafoate C
RESPIRATORY

(INHALATION)

Date:11/16/04ISR Number: 4502759-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01509
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypoaesthesia		Valium	C				
UNKNOWN								
Initial or Prolonged	Thrombosis		Effexor	C				
UNKNOWN								
Disability								

Date:11/16/04ISR Number: 4502760-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01736
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Avapro	C				
UNKNOWN								
			Cardura	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Plaquenil	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			K-Dur	C				
UNKNOWN								

				Ultracet	C		
UNKNOWN							

Date:11/16/04ISR Number: 4502761-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01510
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
1249 DAY								
Initial or Prolonged			Lanoxin	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/16/04ISR Number: 4502762-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01567
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Antimicrobial (Unspecified)	C				
UNKNOWN								

Date:11/16/04ISR Number: 4502763-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01734
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Amnesia Myocardial Infarction		Vioxx Accupril Trazodone Hydrochloride Paxil [Therapy Unspecified]	PS C C C C	Merck & Co., Inc	ORAL UNKNOWN UNKNOWN UNKNOWN UNKNOWN

Date:11/16/04ISR Number: 4502764-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01505
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Asthenia Hypoaesthesia Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		6 YR

Date:11/16/04ISR Number: 4502765-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01508
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx Lipitor Prevacid Cefuroxime Clonazepam	PS C C C C	Merck & Co., Inc	ORAL		3 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502766-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01964
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502767-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01657
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Amnesia		Glucophage	C				
UNKNOWN								
	Dysphemia							
	Headache							
	Heart Rate Increased							
	Hypoaesthesia							
	Weight Decreased							

Date:11/16/04ISR Number: 4502768-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02120
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				
UNKNOWN								
			Evista	C				
UNKNOWN								

Date:11/16/04ISR Number: 4502769-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/16/04ISR Number: 4502770-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02036
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/16/04ISR Number: 4502771-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01685
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Occlusion		Lipitor	C		ORAL		
	Dyspnoea		Prinivil	C		ORAL		
			Toprol Xl Tablets	C		ORAL		
			Actos	C				
			[Therapy Unspecified]	C				

UNKNOWN

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502772-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02098
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	651	DAY
Hospitalization -			Risperdal	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/16/04ISR Number: 4502774-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00007
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
			Estradiol And Norethindrone Acetate	C		ORAL		
			Clotrimazole	C				
VAGINAL								
			Atenolol And Chlorthalidone	C		ORAL		
			Diclofenac Epolamine	C				
TOPICAL								

Date:11/16/04ISR Number: 4502775-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00469
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Punctate Keratitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Subdural Haematoma		Dilantin	C				
UNKNOWN								
			Urecholine	C		ORAL		
			Toprol Xl Tablets	C				
UNKNOWN								

Famvir C
UNKNOWN

Date:11/16/04ISR Number: 4502787-6Report Type:Direct Company Report #CTU 232043
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Testicular Pain		Vioxx	PS		ORAL	ORAL	

Date:11/16/04ISR Number: 4502847-XReport Type:Direct Company Report #CTU 232084
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activities Of Daily		Vioxx 12 Mil	PS		ORAL	2 PILLS ORAL	
Other	Living Impaired		Baxtra 6 Mil	SS		ORAL	2 PILLS ORAL	
	Arthralgia							
	Arthritis							
	Asthenia							
	Difficulty In Walking							
	Feeling Abnormal							
	Impaired Work Ability							
	Myalgia							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4502851-1Report Type:Direct Company Report #CTU 232086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysgraphia		Vioxx 12.5 Mg Merck	PS	Merck	ORAL	12.5 MG TWICE	
	Parkinson'S Disease						A DAY ORAL	
	Tremor		Celexa	C				
			Cartia Xt	C				
			Clonazepam	C				
			Cardizem Cd	C				
			Dexedrine	C				
			Miacalcin Spray	C				
			Wellbutrin Sr	C				

Date:11/16/04ISR Number: 4502928-0Report Type:Direct Company Report #CTU 232186
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx 12.5 Merck	PS	Merck			
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Burning Sensation		.	C				
	Cardiac Disorder							
	Dizziness							
	Dyspnoea Exertional							
	Electrocardiogram Abnormal							
	Fatigue							
	Heart Rate Decreased							
	Heart Rate Increased							
	Influenza							
	Muscle Disorder							
	Palpitations							

Date:11/16/04ISR Number: 4502931-0Report Type:Direct Company Report #CTU 232189
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bundle Branch Block Right		Vioxx 50mg Merck	PS	Merck	ORAL	25MG	2 X

Hospitalization -	Chest Pain
Initial or Prolonged	Coronary Artery Occlusion
Required	Coronary Artery
Intervention to	Thrombosis
Prevent Permanent	Hypoaesthesia
Impairment/Damage	

Date:11/16/04ISR Number: 4502964-4Report Type:Direct Company Report #CTU 232180
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Blood Pressure Increased		Vioxx 50 Mg Merck	PS	Merck	ORAL	50 MG	DAILY
Intervention to	Fibromuscular Dysplasia					ORAL		
Prevent Permanent			Synthroid	C				
Impairment/Damage								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/16/04ISR Number: 4503067-5Report Type:Direct Company Report #CTU 232092
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Voxx 50 Mg Merk And Co	PS	Merk And Co			

Date:11/16/04ISR Number: 4503069-9Report Type:Direct Company Report #CTU 232126
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 25 Mg	PS			TWICE A DAY	

Date:11/16/04ISR Number: 4503072-9Report Type:Direct Company Report #CTU 232132
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
			Vioxx 50 Mg	SS		ORAL		

Date:11/16/04ISR Number: 4504196-2Report Type:Direct Company Report #CTU 232049
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Required	Arrhythmia		Vioxx -Con'T Remember Mg Medco	PS	Medco		1 A DAY	

Intervention to
Prevent Permanent
Impairment/Damage

Date:11/16/04ISR Number: 4504200-1Report Type:Direct Company Report #CTU 232051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypotension		Vioxx	PS		ORAL	25 MG /D PO	
	Palpitations							

Date:11/16/04ISR Number: 4505328-2Report Type:Expedited (15-DaCompany Report #2004088201
Age:68 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
Other	Atrioventricular Block Complete
	Blood Pressure Decreased
	Blood Pressure Increased
	Drug Interaction
	Drug Level Above Therapeutic
	Dysarthria

		Extrapyramidal Disorder					
		Fall					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Kyphosis	Foreign	Lithium (Lithium)	PS		
400 MG (200							
		Lordosis	Literature				
MG , 2 IN 1							
		Nausea					
D)	12 YR						
		Pain In Extremity		Rofecoxib			
		Pancytopenia		(Rofecoxib)	SS		
590 MG (25							
		Renal Impairment					
MG, 2 IN 1 D)							
		Sinus Arrest		Carbamazepine			
		Sinus Bradycardia		(Carbamazepine)	C		
		Somnolence		Pipamperone			
		Spinal Disorder		(Pipamperone)	C		
		Therapeutic Agent		Zopliclone			
		Toxicity		(Zoplicone)	C		
		Tremor		Mirtazapine			
		Vomiting		(Mirtazapine)	C		

Date:11/17/04ISR Number: 4503173-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiomyopathy		Premarin	C		
UNKNOWN							
		Carotid Artery Stenosis		Effexor Xr	C		
UNKNOWN							
		Cerebral Artery Stenosis		Remeron	C		ORAL
		Cerebrovascular Accident		Vicodin Tablets	C		
UNKNOWN							
		Drug Abuser		Soma	C		
UNKNOWN							
		Drug Ineffective		Seroquel	C		ORAL
		Ejection Fraction		Phenergan			
		Decreased		(Promethazine			
		Emotional Distress		Hydrochloride)	C		
UNKNOWN							

	Heart Rate Increased		Klonopin	C		
UNKNOWN						
	Injury		Klonopin	C		
UNKNOWN						
	Nervous System Disorder		Risperdal	C		ORAL
	Neuropathy		Zestril	C		ORAL
	Sinusitis		Zocor	C		
UNKNOWN						
			Celebrex	C		ORAL
30 DAY						
			Lanoxin	C		ORAL
			Plavix	C		ORAL
			Aspirin	C		ORAL
			Vistaril	C		
UNKNOWN						
			Geodon	C		
UNKNOWN						

Date:11/17/04ISR Number: 4503174-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01102728
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dementia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Xalatan	C		
OPHTHALMIC						
			Atenolol	C		
UNKNOWN						
			Verapamil	C		
UNKNOWN						
			Hydrodiuril	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Prinivil	C		
UNKNOWN						
			Timolol	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503176-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01829
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		466 DAY
Hospitalization -	Aphasia		Aspirin	C				UNKNOWN
Initial or Prolonged	Cerebrovascular Accident		Indocin					
	Emotional Distress		(Indomethacin)	C				UNKNOWN
	Glomerulonephritis		Lasix (Furosemide)	C		ORAL		
	Membranous		K-Dur	C		ORAL		
	Gout							
	Hyperglycaemia							
	Medication Error							
	Nephrolithiasis							
	Oedema Peripheral							
	Pneumonia							
	Renal Failure							
	Sleep Apnoea Syndrome							
	Urethral Stricture							

Date:11/17/04ISR Number: 4503183-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00052
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Arava	SS		ORAL		
	Aspartate		Arava	SS		ORAL		
	Aminotransferase		Calcium Carbonate					
	Increased		And Cholecalciferol	C		ORAL		
	Blood Alkaline		Fosamax	C		ORAL		2227 DAY
	Phosphatase Increased		Prednisolone	C		ORAL		
	Gamma-Glutamyltransferase		Tramadol					
	Increased		Hydrochloride	C		ORAL		
	Glutamate Dehydrogenase							
	Increased							

Date:11/17/04ISR Number: 4503186-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00038
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		112 MON
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Propranolol Hydrochloride	C				
UNKNOWN	Coma							237 DAY
Disability	Depression		Omeprazole	C				
UNKNOWN								
	Gait Disturbance							
	Memory Impairment							

Date:11/17/04ISR Number: 4503187-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0403DEU00196
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Erosive Oesophagitis		Zolmitriptan	SS		ORAL		
Initial or Prolonged	Mesenteric Artery		Zolmitriptan	SS		ORAL		
Other	Stenosis		Sumatriptan	SS				
UNKNOWN								
	Peritoneal Adhesions		Propranolol Hydrochloride	C		ORAL		
			Corticosteroids (Unspecified)	C		ORAL		

			Drofenine Hydrochloride And Propyphenazone	C		RECTAL

Date:11/17/04ISR Number: 4503189-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01780
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombocythaemia		Coumadin	C				
UNKNOWN								
Disability			Sulfasalazine	C				
UNKNOWN								
Other			Nifedipine	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Tramadol Hydrochloride	C				
UNKNOWN								
			Exelon	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			Ditropan Xl	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Omeprazole	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Gastrointestinal Preparations (Unspecified)	C				
UNKNOWN								
			Calcium					

				(Unspecified)	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Humira	C		
UNKNOWN							
				Enulose	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							

Date:11/17/04ISR Number: 4503190-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01866
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503191-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01198
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Neurontin	C				
UNKNOWN								
Initial or Prolonged	Cardiac Murmur		Tegretol	C				
UNKNOWN								
Disability	Chest Pain		Isosorbide	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503192-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00098
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503193-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00363
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503194-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01376
Age:95 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pain							

Date:11/17/04ISR Number: 4503195-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00032
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Spinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR

Date:11/17/04ISR Number: 4503196-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01903
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Diarrhoea		Pexeva	C		
UNKNOWN						
			Klonopin	C		
UNKNOWN						
			Temazepam	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Trileptal	C		
UNKNOWN						

Date:11/17/04ISR Number: 4503198-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02932
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 425 DAY	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Attack		Lumigan	C		
UNKNOWN						
Disability			Lasix (Furosemide)	C		
UNKNOWN						
			Levoxyl	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503200-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03378
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		946 DAY
Initial or Prolonged	Fatigue		Plavix	C				UNKNOWN
	Hypertension		Bextra	C				UNKNOWN
	Syncope		Vitamins (Unspecified)	C				UNKNOWN
	Tremor							

Date:11/17/04ISR Number: 4503201-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01491
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypoaesthesia		[Therapy Unspecified]	C				UNKNOWN
Disability	Loss Of Consciousness		Estrogens (Unspecified)	C				UNKNOWN
			Diuretic (Unspecified)	C				UNKNOWN

Date:11/17/04ISR Number: 4503203-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02718
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Neuropathy		Prednisone	C				UNKNOWN
			Vasotec	C		ORAL		
			Zoloft	C				UNKNOWN

Lipitor	C		
UNKNOWN			
Lopressor	C		
UNKNOWN			

Date:11/17/04ISR Number: 4503204-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00330
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503205-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00299
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anxiety
	Asthenia
	Cardiac Failure
	Chest Pain
	Constipation
	Disturbance In Attention
	Headache
	Hypertension
	Metabolic Disorder
	Oedema Peripheral
	Palpitations
	Renal Failure

Vision Blurred
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Captopril	C			UNKNOWN	
	Levothyroxine Sodium	C			UNKNOWN	
	Tamsulosin Hydrochloride	C			UNKNOWN	
	Benzthiazide And Triamterene	C			UNKNOWN	
	Harpagophytum Procumbens	C			UNKNOWN	
	Tramadol Hydrochloride	C			UNKNOWN	
	Buprenorphine Hydrochloride	C			UNKNOWN	

Date:11/17/04ISR Number: 4503206-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01598
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension Myocardial Infarction							
Disability								

Date:11/17/04ISR Number: 4503209-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02019
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		

	Pain In Extremity		Bisoprolol	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Lotrel	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						

Date:11/17/04ISR Number: 4503210-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01969
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
	Fatigue		[Therapy			
	Heart Rate Irregular		Unspecified]	C		
UNKNOWN						
			Antineoplastic			
			(Unspecified)	C		
UNKNOWN						

Date:11/17/04ISR Number: 4503211-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01692
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Operation		[Therapy			
Initial or Prolonged			Unspecified]	C		
UNKNOWN						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503212-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02132
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503214-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503217-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01978
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Gastric Disorder		Axert	C				
UNKNOWN								
	Loss Of Consciousness		Singulair	C		ORAL		
			Maxifen	C				
UNKNOWN								
			Famotidine	C				
UNKNOWN								
			Zapex	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503218-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02039
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Stent Placement		Zoloft	C				
UNKNOWN								

Initial or Prolonged				[Therapy Unspecified]	C		
Disability							
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							

Date:11/17/04ISR Number: 4503219-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01996
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Proscar	C		ORAL		
			Flomax (Tamsulosin Hydrochloride)	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503220-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02448
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503222-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01753
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia							
	Back Disorder							
	Drug Ineffective							
	Oral Infection							
	Tooth Loss							
	Vomiting							

Date:11/17/04ISR Number: 4503227-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02165
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperhidrosis							

Date:11/17/04ISR Number: 4503229-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Coumadin	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503230-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503234-0Report Type:Expedited (15-DaCompany Report #PT-MERCK-0411PRT00004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Stroke Volume Decreased							

Date:11/17/04ISR Number: 4503236-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/17/04ISR Number: 4503237-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02349
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503282-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01461
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Analgesic Or Anesthetic (Unspecified)	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503754-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00770
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Tenderness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Baycol	C		ORAL		
	Angina Pectoris		Glynase Prestab					
	Arthritis		Tablets	C		ORAL		
	Blood Glucose Abnormal		Levothroid	C		ORAL		
	Blood Pressure Increased		Imdur	C				
UNKNOWN								
	Cerebrovascular Accident		Procardia Xl	C		ORAL		
	Convulsion		Metoprolol	C				
UNKNOWN								
			Lasix (Furosemide)	C		ORAL		
			Aspirin	C				
UNKNOWN								
			Glucophage	C		ORAL		
			Synthroid	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503755-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
	Anxiety
Other	Aortic Valve Incompetence
	Bronchitis
	Cardiac Failure
	Congestive

Carotid Artery Disease
Cerebrovascular Accident
Chest Discomfort
Chronic Obstructive
Pulmonary Disease
Cognitive Disorder
Deafness
Depression
Diarrhoea
Dizziness
Dyspnoea
Emotional Distress
Fall
Gastrooesophageal Reflux
Disease
Gout
Headache
Heart Rate Irregular
Hyperglycaemia
Injury
Intervertebral Disc
Displacement
Mental Disorder
Nephrolithiasis

		Oedema					
		Onychomycosis					
		Oropharyngeal Spasm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Parkinson'S Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Peripheral Vascular	Professional	Aspirin	C		ORAL
		Disorder		Premarin	C		ORAL
		Pneumothorax		Prinivil	C		ORAL
		Renal Failure		Bumex	C		ORAL
		Sciatica		Lamisil	C		ORAL
		Seborrhoeic Keratosis					
		Sleep Apnoea Syndrome					
		Stomach Discomfort					
		Swelling Face					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urinary Tract Infection					
		Vascular Stenosis					
		Vertigo					
		Visual Acuity Reduced					

Date:11/17/04ISR Number: 4503757-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00808
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
	Arthralgia
	Blood Cholesterol
	Increased
	Bronchitis
	Chest Discomfort
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Conjunctivitis
	Depression
	Diarrhoea
	Diverticulitis
	Dizziness
	Ejection Fraction
	Decreased
	Haematoma

Hypertension
Insomnia
Lipoma
Lobar Pneumonia
Malaise
Myalgia
Nausea
Nephrolithiasis
Nodule
Osteopenia
Pain
Polytraumatism
Productive Cough
Rash
Sinusitis
Skin Lesion

		Syncope					
		Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Tract Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Vomiting	Professional	Alprazolam	C		
UNKNOWN							
		Weight Increased		Prilosec	C		
UNKNOWN							
				Estratest	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:11/17/04ISR Number: 4503782-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Other		Amnesia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Anaemia		Vicodin Es Tablets	C		
UNKNOWN							
		Arthralgia		Arthrotec	C		
UNKNOWN							
		Asthenia		Ditropan Xl	C		
UNKNOWN							
		Atelectasis		Adalat	C		
UNKNOWN							
		Back Pain		Zantac	C		
UNKNOWN							
		Bronchitis		Dicyclomine			
		Cerebrovascular Accident		Hydrochloride	C		
UNKNOWN							
		Chest Pain		Vicodin Es Tablets	C		
UNKNOWN							
		Depression		Skelaxin	C		ORAL
		Difficulty In Walking		Desyrel	C		
UNKNOWN							
		Disorientation		Diflucan	C		
UNKNOWN							
		Dysarthria		Allegra	C		
UNKNOWN							
		Dyspnoea		Procardia	C		
UNKNOWN							

	Dysstasia	Reglan	C	
UNKNOWN				
	Fall	Quinine	C	
UNKNOWN				
	Gastrointestinal	Crixivan	C	ORAL
	Haemorrhage	Crixivan	C	ORAL
	Hypersensitivity	Combivir	C	
UNKNOWN				
	Injury	Bactrim	C	
UNKNOWN				
	Neuropathy			
	Pain In Extremity			
	Polyneuropathy			
	Polyuria			
	Pulmonary Fibrosis			
	Syncope			
	Tongue Disorder			
	Urinary Incontinence			

Date:11/17/04ISR Number: 4503783-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Disability	Cardiac Disorder
	Chest Pain
	Depression
	Dizziness
	Fall
	Frequent Bowel Movements
	Glucose Tolerance
	Impaired
	Headache
	Hypertension
	Intervertebral Disc
	Degeneration

		Kidney Infection					
		Nausea					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Stomach Discomfort	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Prinivil	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:11/17/04ISR Number: 4503785-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0404GBR00106
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dizziness	Health	Vioxx	PS	Merck & Co., Inc	ORAL
19 DAY						
Hospitalization -	Faeces Discoloured	Professional	Aspirin	SS		ORAL
841 DAY						
Initial or Prolonged	Gastrointestinal		Furosemide	C		ORAL
	Haemorrhage		Levothyroxine Sodium	C		ORAL
			Lisinopril	C		ORAL
			Isosorbide Mononitrate	C		ORAL
			Gliclazide	C		ORAL
			Metformin	C		ORAL

Date:11/17/04ISR Number: 4503786-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00920
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris					
	Blood Pressure Increased					

Convulsion

Date:11/17/04ISR Number: 4503787-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00012
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Glomerulonephritis Membranous		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/17/04ISR Number: 4503790-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00179
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Pain		Simvastatin	C		ORAL		
	Myocardial Infarction		Telmisartan	C		ORAL		
Other	Neck Pain		Calcium Carbonate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503793-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00993
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged	Infarction	Professional	Advil	C			UNKNOWN	
Disability	Depression		Advil	C			UNKNOWN	
	Fatigue		Tylenol	C			UNKNOWN	
	Gastritis		Tylenol	C			UNKNOWN	
	Hypercholesterolaemia		Imitrex	C			UNKNOWN	
	Psoriasis		Percocet	C			UNKNOWN	
	Seborrhoeic Dermatitis		Medrol	C			UNKNOWN	
	Urinary Retention		Maalox	C			UNKNOWN	
	Ventricular Tachycardia							

Date:11/17/04ISR Number: 4503795-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Arrhythmia
Other	Arthralgia
	Atherosclerosis
	Atrial Fibrillation
	Blister
	Blood Pressure
	Inadequately Controlled
	Cardiac Murmur
	Chest Pain
	Chest X-Ray Abnormal
	Colonic Polyp
	Coronary Artery Disease
	Crepitations
	Dermatitis Contact

Diarrhoea
Diastolic Dysfunction
Dilatation Atrial
Diverticulum Intestinal
Dyspepsia
Dyspnoea
Eye Haemorrhage
Fatigue
Frequent Bowel Movements
Furuncle
Gastritis
Gastroenteritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Headache
Hepatic Cyst
Hepatic Steatosis
Hiatus Hernia
Hypercalcaemia
Hypertension
Intermittent Claudication
Joint Range Of Motion
Decreased
Joint Swelling
Laryngitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Muscle Spasms					
		Myocardial Ischaemia					
		Nausea					
213	DAY	Palpitations	Health	Vioxx	PS	Merck & Co., Inc	ORAL
59	DAY	Pancreatitis Acute	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY	Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY	Rash Macular		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY	Renal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY	Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY	Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY	Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Scar		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY	Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY	Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Hydrodiuril	C		ORAL
UNKNOWN		Ventricular Hypertrophy		Glucotrol	C		
UNKNOWN				Lipitor	C		
				Hydrodiuril	C		ORAL
				Toprol Xl Tablets	C		ORAL
UNKNOWN				Monopril	C		
UNKNOWN				Imdur	C		
UNKNOWN				Cardura	C		

Date:11/17/04ISR Number: 4503800-2Report Type:Expedited (15-DaCompany Report #IT-MERCK-0308ITA00017
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ascites	Professional	Esomeprazole					
Initial or Prolonged	Disseminated		Magnesium	SS		ORAL		
	Intravascular Coagulation		Hydrochlorothiazide					
	General Physical Health		And Ramipril	SS		ORAL		
	Deterioration							
	Hepatic Failure							
	Hepatic Necrosis							
	Hepatorenal Syndrome							
	Jaundice Cholestatic							
	Oliguria							

Date:11/17/04ISR Number: 4503802-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01343
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acquired Claw Toe
	Bacteria Urine Identified
	Blood Cholesterol
	Increased
	Blood Urine Present
	Cerebrovascular Accident
	Cerumen Impaction
	Chest Pain
	Cholelithiasis
	Conjunctivitis
	Conjunctivitis Allergic
	Dehydration

		Dermatitis Allergic					
		Diverticulum					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL
49	DAY						
		Ear Infection	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Eye Irritation		Vioxx	SS	Merck & Co., Inc	ORAL
72	DAY						
		Haematuria		Zocor	C		ORAL
		Hepatic Enzyme Increased		Protonix	C		
UNKNOWN							
		Hypertension		Lipitor	C		
UNKNOWN							
		Ingrowing Nail		Prinivil	C		ORAL
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Occult Blood Positive					
		Oedema Peripheral					
		Otitis Externa					
		Peroneal Nerve Palsy					
		Rash Pruritic					
		Renal Failure					
		Skin Disorder					
		Skin Lesion					
		Urinary Tract Infection					

Date:11/17/04ISR Number: 4503803-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00497
Age:79 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Anorexia	Professional	Certoparin Sodium	C		
UNKNOWN		35 DAY					
		Cardiac Disorder		Beloc-Zok	C		
UNKNOWN							
		Cough		Bifiteral	C		
UNKNOWN							
		Cystitis Noninfective		Cibacen	C		
UNKNOWN							
		Diarrhoea					
		Hypertension					
		Pruritus					

Vomiting

Date:11/17/04ISR Number: 4503809-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00079
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory
Life-Threatening	Distress Syndrome
Hospitalization -	Aspiration
Initial or Prolonged	Asthma
	Body Temperature
	Decreased
	Bradycardia
	Bundle Branch Block Right
	Chest Pain
	Cold Sweat
	Coma
	Dehydration
	Drug Hypersensitivity
	Dyspnoea
	Ejection Fraction
	Abnormal
	Haemorrhagic Stroke
	Ischaemic Stroke
	Respiratory Arrest

Tachycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Metformin	C			UNKNOWN	
	Quinine Sulfate	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Ramipril	C			UNKNOWN	
	Omeprazole Magnesium	C		ORAL		
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Meperidine Hydrochloride	C			UNKNOWN	
	Lorazepam	C			SUBLINGUAL	
	Lorazepam	C			SUBLINGUAL	
	Atorvastatin Calcium	C		ORAL		
	Glyburide	C		ORAL		

Date:11/17/04ISR Number: 4503811-7Report Type:Expedited (15-DaCompany Report #HK-MERCK-0410HKG00010
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
Disability	Ischaemic Stroke		[Composition					
Other			Unspecified]	C		ORAL	1	WK

Date:11/17/04ISR Number: 4503812-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00466
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503813-0Report Type:Expedited (15-DaCompany Report #FI-MERCK-0411FIN00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Decreased		Vioxx	PS	Merck & Co., Inc		UNKNOWN	Initial or Prolonged

Date:11/17/04ISR Number: 4503814-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03010
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea Fatigue	Health Professional	Vioxx Tylenol	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:11/17/04ISR Number: 4503816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01599
Age:42 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged Disability	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
			Prilosec	C				
			Aspirin	C				
			Neurontin	C				

Date:11/17/04ISR Number: 4503817-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02403
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
	Muscular Weakness		Zoloft	C				
			Prinzide	C				
			Flexeril	C				
			Prilosec	C				
			Vicodin Tablets	C				
			Xanax	C				

Date:11/17/04ISR Number: 4503818-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03196
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Mass							

Date:11/17/04ISR Number: 4503820-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00104
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
		Professional	Statin (Unspecified)	C		ORAL		

Date:11/17/04ISR Number: 4503821-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00026
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea	Health	Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY
Initial or Prolonged	Drug Interaction	Professional	Celecoxib	SS		ORAL	44	DAY
	Renal Failure Acute		Buthiazide	SS		ORAL	6	MON
			Tizanidine Hydrochloride	SS		ORAL	44	DAY
			Oxprenolol Hydrochloride	SS		ORAL	6	YR
			Ascorbic Acid And Vitamin B (Unspecified)	C			UNKNOWN	
			Enterococcus Faecium (As Drug)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503822-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00169
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intracardiac Thrombus	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Celebrex	C				
UNKNOWN								
	Sudden Cardiac Death							

Date:11/17/04ISR Number: 4503824-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01149
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Phenobarbital	C				
UNKNOWN								
Initial or Prolonged	Loss Of Consciousness		Dilantin	C				
UNKNOWN								
Disability								

Date:11/17/04ISR Number: 4503826-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01168
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Insomnia		Synthroid	C				
UNKNOWN								
Disability	Thrombosis		Prozac	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503827-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00925
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prevacid	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503828-2Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503830-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04095
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503831-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503832-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01711
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Detrol	C				
UNKNOWN								
Initial or Prolonged			Prilosec	C				
UNKNOWN								
Disability			Oxycontin	C				
UNKNOWN								
			Flonase	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Hyzaar	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Diflucan	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								

Date:11/17/04ISR Number: 4503836-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01547
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503838-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01723
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Extrasystoles							
	Fall							

Hyperhidrosis
Palpitations
Tachycardia
Tremor

Date:11/17/04ISR Number: 4503839-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01749
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Calcium (Unspecified)	C			UNKNOWN	
			Dimethyl Sulfone	C			UNKNOWN	
			Chondroitin	C			UNKNOWN	
			Estrogens (Unspecified)	C			UNKNOWN	

Date:11/17/04ISR Number: 4503844-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02020
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Nexium	C			UNKNOWN	
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503845-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01962
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pneumonia Pulmonary Oedema		Vioxx Hydrochlorothiazide Lisinopril	PS C C	Merck & Co., Inc	ORAL		UNKNOWN UNKNOWN

Date:11/17/04ISR Number: 4503846-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503847-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:11/17/04ISR Number: 4503849-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Gastric Disorder Myocardial Infarction Oedema Peripheral Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503850-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01751
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							

Date:11/17/04ISR Number: 4503851-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01977
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Renal Failure		Insulin	C				
Initial or Prolonged UNKNOWN			Paxil	C				
Disability UNKNOWN			Diovan	C				

Date:11/17/04ISR Number: 4503852-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01612
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Nervous System Disorder		Zoloft	C				
Initial or Prolonged UNKNOWN			Seroquel	C				
Disability								

Date:11/17/04ISR Number: 4503855-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02381
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Renal Failure Acute Weight Decreased		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503856-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503857-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Muscle Spasms Rash Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503859-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02137
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability UNKNOWN	Dysuria Feeling Abnormal Gastrointestinal Disorder Oedema Peripheral Palpitations		Vioxx Altace	PS C	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503860-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503861-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01748
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Myocardial Infarction							

Date:11/17/04ISR Number: 4503862-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01961
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/17/04ISR Number: 4503867-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02594
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503869-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/17/04ISR Number: 4503870-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02383
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14 MON	
Hospitalization - Initial or Prolonged Disability			Vioxx	SS	Merck & Co., Inc	ORAL	12 MON	

Date:11/17/04ISR Number: 4504423-1Report Type:Direct Company Report #CTU 232336
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS				

Date:11/18/04ISR Number: 4504336-5Report Type:Expedited (15-DaCompany Report #DEWYE114518OCT04
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Alanine Aminotransferase	Health	Enbrel	PS	
SUBCUTANEOUS	43 DAY				
Hospitalization - 43 DAY	Decreased	Professional	Enbrel	SS	
Initial or Prolonged 827 DAY	Aspartate		Vioxx	SS	ORAL
	Aminotransferase		Budesonide	C	ORAL
98 DAY					
	Decreased Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased C-Reactive Protein Increased Convulsion Dehydration Demyelination Depressed Level Of Consciousness Diarrhoea Encopresis Korsakoff'S Psychosis Non-Alcoholic Myoglobin Blood Increased Speech Disorder Vomiting White Blood Cell Count Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504447-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Carpal Tunnel Syndrome							
	Convulsion							
	Lumbar Radiculopathy							
	Radiculopathy							

Date:11/18/04ISR Number: 4504448-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00104
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
Other	Acute Sinusitis
	Anxiety
	Arthropathy
	Back Injury
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Cardiomegaly
	Carpal Tunnel Syndrome
	Contusion
	Convulsion
	Cough
	Cystitis
	Cystourethrocele
	Depression
	Diarrhoea
	Diverticulum
	Diverticulum Intestinal
	Dizziness
	Dyspepsia
	Emotional Distress
	Fall
	Gastrooesophageal Reflux
	Disease
	Haemorrhoids
	Herpes Zoster
	Hypothyroidism

Injury
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Displacement
Irritable Bowel Syndrome
Lumbar Radiculopathy
Lung Infiltration
Meniscus Lesion
Muscle Spasms
Nausea
Nocturia
Osteoarthritis
Paraesthesia
Pharyngitis
Pharyngolaryngeal Pain

		Pneumonia					
		Radius Fracture					
		Rhinorrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
		Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Thyroid Disorder		Estrogens			
		Weight Decreased		(Unspecified)	C		
UNKNOWN							
				Propulsid	C		
UNKNOWN							

Date:11/18/04ISR Number: 4504456-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03146
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dyspnoea		Coumadin	C		
UNKNOWN						
Initial or Prolonged	Fatigue		Lasix (Furosemide			
	Loss Of Consciousness		Sodium)	C		
UNKNOWN						
	Lung Disorder		Digitek	C		
UNKNOWN						
	Myocardial Infarction		Elavil	C		
UNKNOWN						
	Syncope		Lipitor	C		
UNKNOWN						
			Combivent	C		
UNKNOWN						
			Advair	C		
UNKNOWN						

Date:11/18/04ISR Number: 4504457-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Anaemia
Disability	Blood Glucose Abnormal
	Brain Stem Infarction
	Cardiac Failure

Congestive
Cardiomegaly
Cerebellar Infarction
Cerebrovascular Accident
Cholelithiasis
Colon Neoplasm
Coma
Decubitus Ulcer
Depression
Diverticulitis
Electrolyte Imbalance
Emotional Distress
Fall
Femur Fracture
Gastritis Erosive
Ileus
Insomnia
Lacunar Infarction
Liver Disorder
Obesity
Ophthalmoplegia
Pleural Effusion
Pneumatosis Cystoides
Intestinalis
Pneumonitis
Rash
Reflux Oesophagitis

Small Intestinal Obstruction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	1218 DAY
	Lasix (Furosemide)	C			UNKNOWN	
	Tagamet	C			UNKNOWN	
	Estropipate	C			UNKNOWN	3956 DAY
	Potassium (Unspecified)	C			UNKNOWN	
	Drixoral	C			UNKNOWN	
	Elavil	C			UNKNOWN	
	Tiazac	C			UNKNOWN	
	Hydrochlorothiazide	C			UNKNOWN	
	Iron (Unspecified)	C			UNKNOWN	
	Cyanocobalamin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Ascorbic Acid	C			UNKNOWN	
	Vitamin E	C			UNKNOWN	
	Magnesium (Unspecified)	C			UNKNOWN	
	Calcium (Unspecified)	C			UNKNOWN	

Date:11/18/04ISR Number: 4504461-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01091
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 419 DAY	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Anal Skin Tags Depression Diverticulitis Fibrocystic Breast Disease Ischaemic Stroke Rectal Ulcer					

Date:11/18/04ISR Number: 4504462-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00689
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adnexa Uteri Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Adverse Event Anxiety Arthralgia Back Pain Breast Pain Cataract Osteoarthritis Sciatica Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504464-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01664
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Flank Pain		Darvocet-N	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504465-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01877
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Oxycodone	C		ORAL	6	DAY
	Coronary Artery		Docusate Sodium	C		ORAL		
	Atherosclerosis		Ascorbic Acid	C		ORAL		
	Coronary Artery		Ferrous Sulfate	C		ORAL		
	Thrombosis		Coumadin	C			UNKNOWN	
	Cyanosis							
	Death							
	Depressed Mood							
	Device Failure							
	Fatigue							
	Femur Fracture							
	Gout							
	Hip Fracture							
	Joint Swelling							
	Limb Discomfort							
	Myocardial Fibrosis							
	Myocardial Haemorrhage							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nephrolithiasis							
	Oedema Peripheral							
	Pain In Extremity							
	Pulmonary Congestion							
	Sleep Disorder							
	Spinal Osteoarthritis							
	Tenderness							
	Thermal Burn							

Date:11/18/04ISR Number: 4504466-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		

Chest Pain
Convulsion
Irritable Bowel Syndrome
Urinary Tract Disorder

Date:11/18/04ISR Number: 4504470-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Back Pain
	Cardiac Disorder
	Cardiomegaly
	Carpal Tunnel Syndrome

		Chest Pain					
		Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Decreased Activity		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease Recurrence		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyslipidaemia		Naproxen	C		
UNKNOWN							
		Dyspnoea		Indocin			
		Electrocardiogram		(Indomethacin)	C		ORAL
		Abnormal		Zyrtec	C		
UNKNOWN							
		Extravasation		Prilosec	C		
UNKNOWN							
		Fall		Celexa	C		
UNKNOWN							
		High Density Lipoprotein		Aciphex	C		
UNKNOWN							
		Decreased		Atenolol	C		
UNKNOWN							
		Hyperhidrosis		Oxycontin	C		
UNKNOWN							
		Hypoaesthesia		Hydrocodone			
		Injury		Bitartrate	C		
UNKNOWN							
		Intervertebral Disc		Levsin	C		
UNKNOWN							
		Displacement		Flonase	C		
UNKNOWN							
		Joint Crepitation					
		Loose Body In Joint					
		Mitral Valve Calcification					
		Mitral Valve Incompetence					
		Muscle Atrophy					
		Muscle Injury					
		Muscular Weakness					
		Myalgia					
		Myocardial Ischaemia					
		Neck Pain					
		Night Sweats					
		Pain In Extremity					
		Pain In Jaw					
		Pallor					
		Peripheral Coldness					

Procedural Site Reaction
Pyrexia
Road Traffic Accident
Rotator Cuff Syndrome
Scapula Fracture
Sinus Bradycardia
Skin Laceration
Spinal Osteoarthritis
Supraventricular
Extrasystoles
Tendonitis
Therapy Non-Responder
Trigger Finger
Umbilical Hernia
Ventricular Dysfunction
Ventricular Hypokinesia

Date:11/18/04ISR Number: 4504476-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02186
Age:39 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK

Date:11/18/04ISR Number: 4504477-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Contusion							
	Cystitis							
	Decreased Appetite							
	Diarrhoea							
	Fungal Infection							
	Vomiting							
	Weight Decreased							

Date:11/18/04ISR Number: 4504479-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial							
Other	Infarction							
	Adverse Event							
	Blood Cholesterol							
	Increased							
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Confusional State							
	Coronary Artery Disease							
	Depression							
	Diabetes Mellitus							
	Inadequate Control							
	Diabetic Neuropathy							
	Diarrhoea							

Escherichia Sepsis
Hypertension
Intermittent Claudication
Mitral Valve Incompetence
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Peripheral Occlusive
Disease
Pulmonary Oedema
Renal Failure
Renal Failure Acute
Sciatica
Spinal Column Stenosis
Stress Incontinence
Transient Ischaemic
Attack
Urinary Tract Infection
Urosepsis
Uterine Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504487-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01107
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Mitral Valve Disease		Vicodin Tablets	C				
UNKNOWN								
Other								

Date:11/18/04ISR Number: 4504488-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01519
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504491-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504492-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03566
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization -	Disease		Nexium	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Glucophage	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504493-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00130
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Ibuprofen	C				
UNKNOWN								
Initial or Prolonged			Aluminum Hydroxide And Magnesium Trisilicate	C				
UNKNOWN								
			Fluticasone Propionate	C				
UNKNOWN								
			Irbesartan	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Bendroflumethiazide	C				
UNKNOWN								
			Ranitidine	C				
UNKNOWN								
			Sotalol Hydrochloride	C				
UNKNOWN								
			Lercanidipine	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504494-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00047
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Stevens-Johnson Syndrome		Celecoxib	SS		ORAL	6	DAY

Date:11/18/04ISR Number: 4504495-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00038
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	112	MON
Hospitalization -	Cerebrovascular Accident		Propranolol					
Initial or Prolonged	Coma		Hydrochloride	C				
UNKNOWN		237	DAY					
Disability	Depression		Omeprazole	C				
UNKNOWN								
Other	Gait Disturbance							
	Memory Impairment							

Date:11/18/04ISR Number: 4504496-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01587
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:11/18/04ISR Number: 4504497-8Report Type:Expedited (15-DaCompany Report #IT-MERCK-0411ITA00021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ischaemic Cardiomyopathy							

Date:11/18/04ISR Number: 4504498-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01708
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Reminyl	C				
			[Therapy Unspecified]	C				

Date:11/18/04ISR Number: 4504499-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00007
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
			Risedronate Sodium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Oxazepam	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Aspirin	C		ORAL		
			Nitroglycerin	C		TOPICAL		
			Trimetazidine Hydrochloride	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Lansoprazole	C		ORAL		

				Verapamil	C		ORAL

Date:11/18/04ISR Number: 4504500-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504501-7Report Type:Expedited (15-DaCompany Report #HU-MERCK-0411HUN00011
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Enalapril Maleate	C		ORAL		

Date:11/18/04ISR Number: 4504502-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02482
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Synthroid	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Lotrel	C			UNKNOWN	

Date:11/18/04ISR Number: 4504503-0Report Type:Expedited (15-DaCompany Report #MX-MERCK-0411USA00650
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Venous Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -			Folic Acid	C			
UNKNOWN							
Initial or Prolonged			Atacand	C			
UNKNOWN							
Disability							

Date:11/18/04ISR Number: 4504504-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02205
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Disturbance		Lipitor	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504505-4Report Type:Expedited (15-DaCompany Report #MX-MERCK-0410MEX00003
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
612 DAY								
Hospitalization -			Methotrexate	C		ORAL		
Initial or Prolonged			Prednisone	C		ORAL		
Disability			Alendronate Sodium	C		ORAL		
			Ranitidine	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Leflunomide	C		ORAL		
1486 DAY								

			Folic Acid	C			
UNKNOWN							

Date:11/18/04ISR Number: 4504506-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02144
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Convulsion							

Date:11/18/04ISR Number: 4504507-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02029
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Benicar	C				
Initial or Prolonged Disability								

Date:11/18/04ISR Number: 4504705-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4 WK	
	Amaurosis Fugax		Vioxx	SS	Merck & Co., Inc			
UNKNOWN							2 DAY	
	Angina Pectoris							
	Aortic Dissection							
	Aortic Stenosis							
	Aortic Valve Disease							
	Aortic Valve Incompetence							
	Back Pain							
	Benign Neoplasm Of Eyelid							
	Blindness Transient							
	Blood Cholesterol							

Increased
Blood Pressure Increased
Cardiolipin Antibody
Positive
Coagulopathy
Convulsion
Dilatation Ventricular
Dizziness
Dyspnoea
Ecchymosis
Headache
Palpitations
Periorbital Disorder
Sensory Level Abnormal
Sinus Bradycardia
Thyroid Disorder
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Ventricular Septal Defect

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504709-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00671
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504710-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acanthosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Atenolol	C				
	Aggression		Prozac	C				
	Amnesia		Prozac	C				
	Anoxic Encephalopathy		Tylenol	C				
	Atherosclerosis		Buspar	C				
	Blood Cholesterol Increased		Atrovent	C				
			Magnesium Sulfate	C				
	Cardiac Failure		Claforan	C				
	Congestive		Cordarone	C				
	Cardio-Respiratory Arrest		Pepcid	C				
	Cardiogenic Shock		Reopro	C				
	Chest Pain		Dopamine Hydrochloride	C				
	Convulsion							
	Coronary Artery Disease		Restoril	C				
	Coronary Artery Occlusion		Aspirin	C		ORAL		

	Coronary Artery Stenosis	Celexa	C
UNKNOWN			
	Dizziness	Neurontin	C
UNKNOWN			
	Haematuria	Dalmane	C
UNKNOWN			
	Hyperkeratosis	Vasotec	C
UNKNOWN			
	Hypertension		
	Ischaemic Cardiomyopathy		
	Lung Infiltration		
	Myalgia		
	Myocardial Infarction		
	Nausea		
	Orthostatic Hypotension		
	Papilloma		
	Skin Laceration		
	Syncope		
	Ventricular Fibrillation		
	Ventricular Hypokinesia		
	Ventricular Tachycardia		
	Vomiting		

Date:11/18/04ISR Number: 4504711-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Alanine Aminotransferase
	Increased
	Aneurysm
	Angina Unstable
	Anxiety

		Arthralgia					
		Arthropathy					
		Arthroscopic Surgery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Aspartate		Vioxx	PS	Merck & Co., Inc	ORAL
		Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Bundle Branch Block Right		Zestril	C		
UNKNOWN		2170 DAY					
		Cardiac Failure		Zestril	C		
UNKNOWN		2170 DAY					
		Congestive		Tenormin	C		
UNKNOWN							
		Chest Pain		Tenormin	C		
UNKNOWN							
		Congestive Cardiomyopathy		Glucophage	C		
UNKNOWN							
		Coronary Artery Disease		Micronase	C		
UNKNOWN							
		Coronary Artery Occlusion		Lanoxin	C		
UNKNOWN		1051 DAY					
		Coronary Artery		[Therapy			
		Restenosis		Unspecified]	C		
UNKNOWN							
		Coronary Artery Stenosis		Aciphex	C		
UNKNOWN							
		Crepitations					
		Depression					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Diabetic Nephropathy					
		Diabetic Neuropathy					
		Diabetic Retinopathy					
		Discomfort					
		Disease Recurrence					
		Drug Effect Decreased					
		Drug Ineffective					
		Fall					
		Glycosylated Haemoglobin					
		Increased					

Hepatitis
Herpes Zoster
Hypercholesterolaemia
Hypoglycaemia
Hypotension
Hypoxia
Infection
Intervertebral Disc
Disorder
Ischaemic Cardiomyopathy
Knee Operation
Muscle Atrophy
Myocardial Infarction
Myocardial Ischaemia
Pain
Pneumonia
Renal Cyst
Sensory Disturbance
Sepsis
Sexual Dysfunction
Ventricular Extrasystoles
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504719-3Report Type:Expedited (15-DaCompany Report #PE-MERCK-01109472
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchospasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Difficulty In Walking		Celecoxib	C		ORAL		
	Drug Ineffective							
	Fatigue							
	Headache							
	Hypertension							
	Myocardial Ischaemia							
	Syncope							
	Tachycardia							

Date:11/18/04ISR Number: 4504721-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Toprol Xl Tablets	C				
UNKNOWN								
Disability	Anxiety		Imdur	C				
UNKNOWN								
	Blood Cholesterol		Nitro-Dur	C				
UNKNOWN								
	Increased		Diovan	C				
UNKNOWN								
	Blood Creatine		Diovan	C				
UNKNOWN								
	Phosphokinase Increased		Diltiazem					
	Bronchitis		Hydrochloride	C				
UNKNOWN								
	Cardiac Failure		Plavix	C				
UNKNOWN								
	Congestive		Zocor	C		ORAL		
	Coronary Artery		Aspirin	C				
UNKNOWN								
	Atherosclerosis		Xanax	C				
UNKNOWN								

	Coronary Artery Disease	Folic Acid	C
UNKNOWN			
	Depression	Allopurinol	C
UNKNOWN			
	Dyspnoea	Lecithin And Protein	
	Fatigue	(Unspecified)	C
UNKNOWN			
	Feeling Abnormal	Levothroid	C
UNKNOWN			
	Gastrooesophageal Reflux	Levothroid	C
UNKNOWN			
	Disease	Levothroid	C
UNKNOWN			
	Gouty Arthritis	Soma	C
UNKNOWN			
	Influenza	Indocin	
	Limb Injury	(Indomethacin)	C ORAL
	Malignant Hypertension	Colchicine	C
UNKNOWN			
	Myocardial Ischaemia	Norco	C
UNKNOWN			
	Nasal Discomfort	Levothroid	C
UNKNOWN			
	Oedema Peripheral	[Therapy	
	Palpitations	Unspecified]	C
UNKNOWN			
	Polytraumatism	[Therapy	
	Rhinitis Allergic	Unspecified]	C
UNKNOWN			
	Skin Lesion	Vitamins	
	Sleep Apnoea Syndrome	(Unspecified)	C
UNKNOWN			
	Tinnitus		
	Upper Respiratory Tract		
	Infection		

Date:11/18/04ISR Number: 4504724-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00730
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Blood Pressure Increased

	Convulsion Costochondritis Orthopnoea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504725-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Estrace	C				
UNKNOWN								
Other	Atelectasis		Aspirin	C				
UNKNOWN								
	Atrial Fibrillation		Allegra	C				
UNKNOWN								
	Blood Pressure Increased		Hyoscyamine	C				
UNKNOWN								
	Bronchitis		Elavil	C				
UNKNOWN								
	Cardiac Failure		Diovan	C				
UNKNOWN								
	Congestive Chest Pain		[Therapy Unspecified]	C				
UNKNOWN								
	Congestive Cardiomyopathy		Robitussin-Dm	C				
UNKNOWN								
	Convulsion Dizziness Hypercholesterolaemia Hyperlipidaemia Irritable Bowel Syndrome Nasopharyngitis Osteoarthritis Palpitations Squamous Cell Carcinoma Tachycardia Viral Myocarditis							

Date:11/18/04ISR Number: 4504728-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00843
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Vitamins (Unspecified)	C				
	Blood Pressure Increased							
	Bronchitis		Verapamil	C				
	Carpal Tunnel Syndrome		Hydrochlorothiazide	C				
	Complex Regional Pain		Effexor Xr	C				
	Syndrome		Premarin	C				
	Dyspnoea Exertional		Micardis	C				
	Epicondylitis		Verapamil Hydrochloride	C				
	Fall							
	Fibula Fracture		Ultram	C				
	Mononeuropathy		Atarax	C				
	Musculoskeletal Stiffness							
	Oedema							
	Osteochondrosis							
	Palpitations							
	Polytraumatism							
	Rhinitis Allergic							
	Sinus Headache							
	Tachycardia							
	Upper Respiratory Tract Infection							

Date:11/18/04ISR Number: 4504730-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00846
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Angina Pectoris Anhedonia Aortic Valve Incompetence Asthenia Asthma Chest Pain Decreased Appetite Depression Dilatation Atrial Dilatation Ventricular Fatigue Feeling Jittery Headache Insomnia Libido Decreased Low Density Lipoprotein Increased Mitral Valve Incompetence Ovarian Cyst Polytraumatism Pulmonary Arterial Pressure Increased Respiratory Distress Sleep Apnoea Syndrome Trichomoniasis Tricuspid Valve Incompetence Upper Respiratory Tract Infection Urinary Tract Infection Vaginal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504731-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02301
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Erectile Dysfunction		Meperidine					

Initial or Prolonged	Intervertebral Disc	Hydrochloride	C
UNKNOWN			
	Protrusion	Cytotec	C
UNKNOWN			
	Pain	Celebrex	C
UNKNOWN			
	Prostatitis	Acetaminophen	C
UNKNOWN			
		Oxycontin	C
UNKNOWN			
		Neurontin	C
UNKNOWN			
		Doxycycline	C
UNKNOWN			
		Valium	C
UNKNOWN			
		Viagra	C
UNKNOWN	406 DAY		

Date:11/18/04ISR Number: 4504732-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00638
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Disability	Back Injury

		Cataract					
		Chest Pain					
		Crying	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Foot Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Hallucination, Auditory		Norflex	C		
UNKNOWN							
		Hyperkalaemia		Polaramine	C		
UNKNOWN							
		Hypertension		Alprazolam	C		
UNKNOWN							
		Injury		Nitroquick	C		
UNKNOWN							
		Limb Injury		Pepcid	C		
UNKNOWN							
		Oedema Peripheral		Diovan Hct	C		
UNKNOWN							
				Hydrocodone/Apap	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							

Date:11/18/04ISR Number: 4504734-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01731
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY					
Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY					
	Asthenia		Tylenol Extra			
	Blood Cholesterol		Strength	C		ORAL
	Increased		Robitussin	C		ORAL
	Blood Pressure Increased					
	Blood Triglycerides					
	Increased					
	Bursitis					
	Cerebrovascular Accident					

Chest Pain
Diarrhoea
Feeling Abnormal
Headache
Hyperlipidaemia
Hypertension
Lumbar Spinal Stenosis
Nausea
Pain In Extremity
Personality Change
Total Cholesterol/Hdl
Ratio Increased
Transient Ischaemic
Attack
Tremor
Viral Infection
Vitreous Floaters

Date:11/18/04ISR Number: 4504735-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00528
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		624 DAY
Hospitalization - Initial or Prolonged	Rheumatoid Nodule Sudden Cardiac Death		Hydromorphone Hydrochloride	C		ORAL		8 DAY
			Torsemide	C			UNKNOWN	222 DAY
			Methotrexate Sodium	C			UNKNOWN	

			Glyburide	C
UNKNOWN				
			Oxycodone Hydrochloride	C
UNKNOWN	259	DAY		
			Glimepiride	C
UNKNOWN	152	DAY		
			Prednisolone	C
UNKNOWN	259	DAY		
			Hydrochlorothiazide And Valsartan	C
UNKNOWN	71	DAY		

Date:11/18/04ISR Number: 4504736-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00978
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		13 MON
	Difficulty In Walking		Celebrex	C				UNKNOWN
	Dyspnoea							
	Fall							
	Hypoaesthesia							
	Joint Stiffness							
	Muscle Spasms							
	Musculoskeletal Stiffness							
	Oedema Peripheral							
	Pain In Extremity							
	Sensation Of Heaviness							
	Sleep Disorder Due To General Medical Condition, Insomnia Type							
	Vasculitis							
	Vein Disorder							

Date:11/18/04ISR Number: 4504739-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00823
Age: Gender:Female I/FU:F

Outcome PT

Other	Acrochordon
	Anal Sphincter Atony
	Arthralgia
	Arthropathy
	Atrioventricular Block
	First Degree
	Back Pain
	Bronchitis
	Candidiasis
	Chest Pain
	Deep Vein Thrombosis
	Electrocardiogram St-T
	Change
	Faecal Incontinence
	Gastrooesophageal Reflux
	Disease
	Hyperglycaemia
	Hyperkeratosis
	Joint Swelling
	Lyme Disease
	Mitral Valve Incompetence
	Muscle Spasms
	Muscular Weakness
	Myalgia
	Obesity

		Oedema Peripheral Paraesthesia Peptic Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polytraumatism Reproductive Tract Disorder Rhinitis Allergic Sinusitis Transient Ischaemic Attack Tricuspid Valve Incompetence Ureteral Disorder Urinary Incontinence Urinary Tract Infection Ventricular Hypertrophy Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/18/04ISR Number: 4504740-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00242
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Candesartan Cilexetil	C		
UNKNOWN							
		Dermatitis		Acetaminophen And Aspirin And Caffeine And Hydrocodone Bitartrate	C		
UNKNOWN							
		Dizziness		Celecoxib	C		ORAL
		Vasculitic Rash		Zocor	C		ORAL
				Perindopril Erbumine	C		
UNKNOWN							

Date:11/18/04ISR Number: 4504741-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00065
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Cardiac Enzymes Increased	Vioxx	PS	Merck & Co., Inc	ORAL
2 YR					
Initial or Prolonged	Chest Pain				
	Extrasystoles				

Date:11/18/04ISR Number: 4504742-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01306
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Anxiety
Disability	Blood Potassium Decreased
	Blood Pressure Decreased
	Bronchitis
	Calcinosis
	Coronary Artery Disease
	Emotional Distress
	Haemoglobin Decreased
	Heart Rate Decreased
	Heart Sounds Abnormal
	Injury
	Myocardial Infarction

		Oedema Peripheral					
		Rotator Cuff Syndrome					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tendonitis		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Infection					

Date:11/18/04ISR Number: 4504743-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01964
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening			Altace	C		
UNKNOWN						
			Atenolol	C		
UNKNOWN						
			Hydrodiuril	C		ORAL
			Coumadin	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Proscar	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:11/18/04ISR Number: 4504744-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03175
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Disease		Evista	C		
UNKNOWN						
Initial or Prolonged	Cardiac Arrest		Welchol	C		
UNKNOWN						
Disability	Cardio-Respiratory Arrest					

Rotator Cuff Repair

Date:11/18/04ISR Number: 4504745-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01745
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Right		Norvasc	C				
	Hemiparesis		Hydrochlorothiazide	C				
	Neuropathy Peripheral		Plavix	C				
	Restless Legs Syndrome		Aspirin	C				
	Spinal Column Stenosis		Neurontin	C				
	Transient Ischaemic		Dilantin	C				
	Attack							
	Umbilical Hernia							

Date:11/18/04ISR Number: 4504746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02756
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C				
			[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504747-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02189
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		[Therapy					
	Chest Pain		Unspecified]	C				
UNKNOWN								
	Heart Rate Irregular		Zocor	C		ORAL		

Date:11/18/04ISR Number: 4504748-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01997
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Hyzaar	C				
UNKNOWN								
Initial or Prolonged			Hydrochlorothiazide	C		ORAL		
Disability			Cozaar	C		ORAL		
Other								

Date:11/18/04ISR Number: 4504749-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00140
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression							
	Emotional Distress							
	Hypertension							
	Vasculitis							
	Visual Acuity Reduced							

Date:11/18/04ISR Number: 4504750-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03573
Age:17 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY
Hospitalization - Initial or Prolonged	Condition Aggravated		Singulair	C		ORAL	
Disability							

Date:11/18/04ISR Number: 4504751-XReport Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00019
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504752-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00100
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Citalopram Hydrobromide	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504753-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Burning Sensation Cerebrovascular Accident Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504754-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03476
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease		Celebrex	C			UNKNOWN	
			Bextra	C			UNKNOWN	
			Lexapro	C		ORAL		
			Synthroid	C		ORAL		
			Aspirin	C			UNKNOWN	
			Diabeta	C			UNKNOWN	
			Fibercon	C			UNKNOWN	
			Colace	C			UNKNOWN	
			Prevacid	C		ORAL		

Date:11/18/04ISR Number: 4504755-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00139
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
Initial or Prolonged Disability	Arrhythmia Deep Vein Thrombosis Depression Mood Swings		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504756-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00144
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							
	Transient Ischaemic Attack							

Date:11/18/04ISR Number: 4504757-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00017
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Hepatic Trauma							
	Hepatotoxicity							

Date:11/18/04ISR Number: 4504758-2Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504759-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00325
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Death		Insulin	C				UNKNOWN
			Leflunomide	C				UNKNOWN

Date:11/18/04ISR Number: 4504760-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00335
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		590 DAY
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		590 DAY
Disability			Acetyldigoxin	C		ORAL		
			Acetyldigoxin	C		ORAL		
			Carvedilol	C		ORAL		
			Piretanide	C		ORAL		
			Piretanide	C		ORAL		

Date:11/18/04ISR Number: 4504761-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00025
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Levothyroxine Sodium	C				UNKNOWN
	Diplopia		Loratadine	C				UNKNOWN

Date:11/18/04ISR Number: 4504762-4Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0410ZAF00027
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Iliac Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		2058 YR
Initial or Prolonged			Levothyroxine Sodium	C		ORAL		
Disability			Zolpidem Tartrate	C		ORAL		
			Minerals (Unspecified) And Vitamins (Unspecified)	C		ORAL		

Date:11/18/04ISR Number: 4504763-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01555
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Synthroid	C				
UNKNOWN								
Hospitalization -								
Initial or Prolonged								
Disability								

Date:11/18/04ISR Number: 4504764-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01540
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504765-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00654
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Intestinal Haemorrhage		Toprol Xl Tablets	C			UNKNOWN	
	Myocardial Infarction		Clonidine	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/18/04ISR Number: 4504766-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01743
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Humira	C			UNKNOWN	
Initial or Prolonged			Synthroid	C			UNKNOWN	
Disability			Glyburide	C			UNKNOWN	
			Tenormin	C			UNKNOWN	
			Maxzide	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

Date:11/18/04ISR Number: 4504767-3Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00046
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Hospitalization -	Hepatitis							
Initial or Prolonged	Myocarditis							

Date:11/18/04ISR Number: 4504768-5Report Type:Expedited (15-DaCompany Report #CO-MERCK-0411COL00006
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Vioxx	SS	Merck & Co., Inc	ORAL	4	YR

Date:11/18/04ISR Number: 4504769-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00039
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Visual Acuity Reduced		Levothyroxine Sodium	C		ORAL		

Date:11/18/04ISR Number: 4504770-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiovascular Disorder							
	Death							
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504772-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01464
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504773-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504774-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01933
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504775-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01451
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Cell Carcinoma		Coumadin	C			UNKNOWN	
	Stage Unspecified		Darvocet-N	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/18/04ISR Number: 4504776-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:11/18/04ISR Number: 4504777-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02119
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Cerebrovascular Accident
Disability	Chest Pain
	Facial Palsy

Muscle Spasms

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Colchicine	C			UNKNOWN	

Date:11/18/04ISR Number: 4504778-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02022
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Ocuvite	C				
			Aspirin	C			UNKNOWN	

Date:11/18/04ISR Number: 4504779-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504780-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504782-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02641
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Glyburide	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Accupril	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/18/04ISR Number: 4504783-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02573
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Neurontin	C			UNKNOWN	
			Flomax (Morniflumate)	C			UNKNOWN	
			Proscar	C			UNKNOWN	
			Singulair	C			UNKNOWN	
			Prilosec	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504785-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01950
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
UNKNOWN								
Other								

Date:11/18/04ISR Number: 4504786-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01949
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/18/04ISR Number: 4504789-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01947
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability	Transient Ischaemic Attack							

Date:11/18/04ISR Number: 4504790-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02511
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - UNKNOWN	Cerebrovascular Accident		Prinivil	C				
Initial or Prolonged UNKNOWN	Chest Pain		Plavix	C				

Disability	Myocardial Infarction		Glucophage	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Aggrenox	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						

Date:11/18/04ISR Number: 4504791-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02121
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Palpitations		Norvasc	C		
UNKNOWN						
Initial or Prolonged			Actos	C		
UNKNOWN						
Disability						

Date:11/18/04ISR Number: 4504793-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01948
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening			Procrit	C		
UNKNOWN						
Hospitalization -			Lorazepan	C		
UNKNOWN						
Initial or Prolonged			Oxycontin	C		
UNKNOWN						
Disability			Oxycodone	C		
UNKNOWN						
			[Therapy Unspecified]	C		
PARENTERAL						

[Therapy Unspecified] C
INTRAVENOUS

Thalidomide C
UNKNOWN

Date:11/18/04ISR Number: 4504795-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02512
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Lortab	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504798-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/18/04ISR Number: 4504803-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL	50	DAY
	Headache		Carbamazepine	C		ORAL		

Date:11/18/04ISR Number: 4504805-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00020
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	120	DAY

Initial or Prolonged	Apathy	Warfarin Sodium	C
UNKNOWN			
	Cerebral Infarction	Digoxin	C
UNKNOWN			
	Disturbance In Attention	Losartan Potassium	C
UNKNOWN			
	Fatigue	Metoprolol Tartrate	C
UNKNOWN			
	Gait Disturbance	Bendroflumethiazide	
	Personality Change	And Potassium	
	Sleep Disorder	Chloride	C
UNKNOWN			

Date:11/18/04ISR Number: 4504812-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0411ISR00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							2	YR
Initial or Prolonged								

Date:11/18/04ISR Number: 4504827-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01968
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bladder Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vitamins					
	Congestive		(Unspecified)	C				
UNKNOWN								
	Renal Failure		Potassium Chloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4504829-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02211
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer		Neurontin	C				
UNKNOWN								

Date:11/18/04ISR Number: 4504831-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02399
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Emotional Distress							
	Hearing Disability							
	Myocardial Infarction							

Date:11/18/04ISR Number: 4505230-6Report Type:Direct Company Report #CTU 232405
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diarrhoea		Vioxx	PS		ORAL		
QD PO								
Hospitalization -	Hypovolaemia							
Initial or Prolonged	Renal Failure Acute							
Other	Vomiting							

Date:11/18/04ISR Number: 4507412-6Report Type:Expedited (15-DaCompany Report #2004090165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Crohn'S Disease	Consumer	Celebrex (Celecoxib)	PS		ORAL		
200 MG (200								
	Drug Hypersensitivity							
MG, DAILY								
	Transient Ischaemic							
INTERVAL:								

Attack
EVERY DAY),

ORAL

	Arthrotec (Diclofenac Sodium, Misoprostol)	SS	ORAL

(DAILY

INTERVAL:

EVERY DAY),

ORAL

	Rofecoxib (Rofecoxib)	SS	ORAL

ORAL

	Diuretics (Diuretics)	C
	Betamethasone (Betamethasone)	C

Date:11/19/04ISR Number: 4505497-4Report Type:Expedited (15-DaCompany Report #CA-ROCHE-351657
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Aortic Atherosclerosis
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
	Blister
	Coma
	Confusional State
	Coronary Artery

	Atherosclerosis						
	Dehydration						
	Diarrhoea						
	Gastritis Erosive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemoglobin Increased		Capecitabine	PS	Roche	ORAL	GIVEN AS
	Hypovolaemic Shock						TWICE DAILY
	International Normalised						INTERMITTENT
	Ratio Decreased						TREATMENT
	International Normalised						CONSISTING OF 43 DAY
	Ratio Increased		Oxaliplatin	SS	Roche		INTRAVENOUS GIVEN ON DAY
	Nausea						ONE OF A
	Renal Cyst						THREE WEEK
	Somnolence						CYCLE 29 DAY
	Upper Gastrointestinal		Vioxx	SS			UNKNOWN
	Haemorrhage		Coumadin	C			
	Vomiting		Vitamina E	C			
			Vitamin C	C			
			Multivitamin	C			
			Vitamin B Complex	C			
			Unspecified Drug	C			

Date:11/19/04ISR Number: 4505627-4Report Type:Expedited (15-DaCompany Report #US-MERCK-00010148
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2 DAY
Initial or Prolonged	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	2 DAY
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Helicobacter Pylori		Trental	C		ORAL	
	Identification Test		Prilosec	C			UNKNOWN

	Positive	Zocor	C	ORAL
	Myocardial Infarction			
	Nausea			
	Vomiting			
	Weight Decreased			

Date:11/19/04ISR Number: 4505628-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Affect Lability
	Anaemia
	Atherosclerosis
	Back Pain
	Blood Cholesterol Increased
	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Dizziness Postural
	Feeling Abnormal
	Fluid Retention
	Gastrointestinal Pain
	Gastrooesophageal Reflux Disease

		Groin Pain					
		Gynaecomastia					
		Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Nephrolithiasis		Azulfidine	C		
UNKNOWN							
		Post Procedural		Prilosec	C		
UNKNOWN							
		Complication		Enbrel	C		
UNKNOWN							
		Psoriatic Arthropathy		Enbrel	C		
UNKNOWN							
		Rhinitis Seasonal		Prednisone	C		
UNKNOWN							
		Therapeutic Response		Prozac	C		
UNKNOWN							
		Decreased		Prozac	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							

Date:11/19/04ISR Number: 4505630-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02024
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angiopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Carotid Artery Stenosis	Professional	Avapro	C		
UNKNOWN		1681 DAY					
Other		Circulatory Collapse		Niacin	C		
UNKNOWN		1830 DAY					
		Coronary Artery Disease		Tylenol	C		
UNKNOWN							
		Deafness		Celexa	C		
UNKNOWN		1839 DAY					
		Dyspnoea Exertional		Flexeril	C		ORAL
		Emotional Distress		Vicodin Tablets	C		
UNKNOWN							
		Femur Fracture		Ativan	C		
UNKNOWN		1344 DAY					

	Gastrointestinal Disorder	Plavix	C	
UNKNOWN	366 DAY			
	Migraine	Atenolol	C	ORAL
	Myocardial Infarction	Aspirin	C	ORAL
	Myocardial Ischaemia	Prevacid	C	ORAL
	Nasal Polyps	Nasacort	C	
UNKNOWN				
	Nasal Turbinate	Zantac	C	
UNKNOWN				
	Hypertrophy	Tums	C	
UNKNOWN				
	Stress	Titralac Antacid	C	
UNKNOWN				
	Vestibular Neuronitis			

Date:11/19/04ISR Number: 4505634-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Adverse Event
Other	Angina Unstable
	Anxiety
	Aortic Aneurysm
	Atherosclerosis
	Atrial Fibrillation
	Back Pain
	Blood Potassium Decreased
	Blood Triglycerides
	Increased
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cholelithiasis
	Depression

		Disseminated Intravascular Coagulation					
		Diverticulum	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Embolic Stroke	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Encephalopathy	Professional	Prinivil	C		ORAL
		Endocarditis		Atenolol	C		
UNKNOWN							
		Feeling Hot		[Therapy			
		Haematuria		Unspecified]	C		
UNKNOWN							
		Haemorrhage		Aspirin	C		
UNKNOWN							
		Hepatic Cyst		Plavix	C		
UNKNOWN							
		High Density Lipoprotein		Zocor	C		
UNKNOWN							
		Decreased		Celebrex	C		
UNKNOWN							
		Injury					
		Ischaemic Cardiomyopathy					
		Low Density Lipoprotein					
		Increased					
		Myocardial Infarction					
		Nephrosclerosis					
		Oedema Peripheral					
		Renal Mass					
		Sinus Bradycardia					
		Sinus Tachycardia					
		Splenic Infarction					
		Stress					
		Ventricular Tachycardia					
		Vision Blurred					

Date:11/19/04ISR Number: 4505637-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
319 DAY						
Initial or Prolonged	Cataract	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
319 DAY						
Disability	Chronic Obstructive		Humulin N	C		
UNKNOWN						

Other	Pulmonary Disease	Ibuprofen	C
UNKNOWN			
	Constipation	Diovan	C
UNKNOWN			
	Coronary Artery Disease	Xanax	C
UNKNOWN			
	Diabetes Mellitus	Valium	C
UNKNOWN			
	Non-Insulin-Dependent	Synthroid	C
UNKNOWN			
	Diarrhoea		
	Drug Ineffective		
	Hiatus Hernia		
	Hyperlipidaemia		
	Hypertension		
	Insomnia		
	Irritable Bowel Syndrome		
	Lung Neoplasm		
	Myocardial Infarction		
	Non-Cardiac Chest Pain		
	Oedema Peripheral		
	Osteoarthritis		
	Spondylolisthesis		

Date:11/19/04ISR Number: 4505639-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00616
Age:42 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Aphasia		Ultram	C			UNKNOWN	
	Basophil Count Increased		Lipitor	C		ORAL		
	Blood Pressure Increased		Aspirin	C			UNKNOWN	
	Bronchitis Acute		Nitroglycerin	C			SUBLINGUAL	
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Convulsion							
	Drug Ineffective							
	Haemoptysis							
	Headache							
	Hypercholesterolaemia							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Neutrophil Count Increased							
	Paresis							
	Pharyngitis							
	Sinusitis							
	Ulnar Nerve Injury							
	Upper Respiratory Tract Infection							
	Visual Disturbance							
	White Blood Cell Count Increased							

Date:11/19/04ISR Number: 4505640-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess	Professional	Effexor Xr	C			UNKNOWN	
Other	Adverse Event							
	Angina Pectoris							

Atelectasis
Blood Cholesterol
Increased
Bronchitis
Cardiac Failure
Congestive
Convulsion
Hand Fracture
Hypertension
Rotator Cuff Syndrome
Trigger Finger
Tubo-Ovarian Abscess

Date:11/19/04ISR Number: 4505644-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Disability	Aggression
Other	Anxiety
	Arthralgia

	Bursitis						
	Carpal Tunnel Syndrome						
	Cellulitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain	Health	Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY
	Constipation	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	29 DAY
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY
	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Heart Rate Irregular		Lithium Carbonate	C			UNKNOWN
	Joint Dislocation						
	Myocardial Infarction						
	Nerve Injury						
	Onychomycosis						
	Osteoarthritis						
	Pain In Extremity						
	Paranoia						
	Pharyngolaryngeal Pain						
	Post-Traumatic Stress Disorder						
	Rash						
	Rotator Cuff Syndrome						
	Sacroiliitis						
	Sputum Abnormal						
	Squamous Cell Carcinoma						
	Stomach Discomfort						
	Suicidal Ideation						

Date:11/19/04ISR Number: 4505646-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00032
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Coronary Artery Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	290 DAY
Initial or Prolonged	Hyperhidrosis		Tolperisone				
Other	Myalgia		Hydrochloride	C			UNKNOWN
	Myocardial Infarction		Esomeprazole				

Pain In Jaw Magnesium C
UNKNOWN
Toothache

Date:11/19/04ISR Number: 4505647-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00818
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
Disability	Adverse Event
Other	Aortic Valve Incompetence
	Bronchitis
	Bundle Branch Block Left
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dilatation Atrial
	Dilatation Ventricular

		Dizziness					
		Dyspnoea Exertional					
		Dyspnoea Paroxysmal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nocturnal	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Ejection Fraction	Professional				
		Decreased					
		Hyperlipidaemia					
		Hypertension					
		Hypertriglyceridaemia					
		Hypotension					
		Ischaemic Cardiomyopathy					
		Metabolic Acidosis					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Oedema Peripheral					
		Orthopnoea					
		Polytraumatism					
		Respiratory Acidosis					
		Ventricular Dysfunction					
		Ventricular Fibrillation					

Date:11/19/04ISR Number: 4505649-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00101
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Professional	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged						
Disability						

Date:11/19/04ISR Number: 4505650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01092
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Hospitalization -	Infarction	Professional	Lotrel	C		
UNKNOWN						
Initial or Prolonged	Coronary Artery Stenosis		Hytrin	C		
UNKNOWN						

Ejection Fraction
Decreased

Date:11/19/04ISR Number: 4505652-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00036
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block	Health	Vioxx	PS	Merck & Co., Inc	ORAL		26 DAY
Initial or Prolonged	First Degree	Professional	Diclofenac Sodium	SS				
RECTAL							2	DAY
	Chest Pain		Zolpidem Tartrate	C		ORAL		
			Simvastatin	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Acebutolol Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505653-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00298
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Pantozol	C		ORAL		
			Aspirin	C		ORAL		
			Proscar	C		ORAL		
			Avalox	C		ORAL	5	DAY

Date:11/19/04ISR Number: 4505654-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00866
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Wall Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Adverse Event	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Risperdal	C			UNKNOWN	
	Asthenia		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Asthma							
	Benign Prostatic Hyperplasia							
	Bronchitis Acute							
	Cervical Vertebral Fracture							
	Constipation							
	Difficulty In Walking							
	Dyspnoea							
	Eye Disorder							
	Herpes Zoster							
	Hypoaesthesia							
	Incontinence							
	Joint Injury							
	Nausea							
	Oedema Peripheral							
	Paranasal Sinus Hypersecretion							
	Peripheral Coldness							
	Personality Disorder							
	Road Traffic Accident							

Senile Dementia
Sleep Apnoea Syndrome
Somnolence
Urinary Retention

Date:11/19/04ISR Number: 4505655-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02879
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dementia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dysphoria	Professional	Lotensin	C				
UNKNOWN								
Initial or Prolonged	Fall		Ziac	C				
UNKNOWN								
Disability	Loss Of Consciousness		Nubain	C				
INTRAMUSCULAR								
	Renal Disorder		Nubain	C				
UNKNOWN								
	Rib Fracture		Prozac	C				
UNKNOWN								
			Wellbutrin Sr	C				
UNKNOWN								
			Valium	C				
UNKNOWN								
			Keppra	C		ORAL		
			Keppra	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505657-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00214
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Prescribed Overdose	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505658-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00049
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		267 DAY
			Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Methotrexate	C		ORAL		
			Prednisolone	C		ORAL		

Date:11/19/04ISR Number: 4505660-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01843
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fibromyalgia		Avandia	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Embolism		Glucophage	C				
UNKNOWN								
Disability			Prevacid	C				
UNKNOWN								
			Effexor Xr	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Klonopin	C				
UNKNOWN								
			Elavil	C				
UNKNOWN								
			Vitamins					

		(Unspecified)	C	
UNKNOWN				
		Lasix (Furosemide)	C	
UNKNOWN				
		[Therapy Unspecified]	C	
UNKNOWN				

Date:11/19/04ISR Number: 4505661-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01444
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Trental	C				
UNKNOWN								
Disability			Zocor	C		ORAL		

Date:11/19/04ISR Number: 4505663-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00781
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Aortic Aneurysm
Disability	Aortic Occlusion
Other	Asthenia
	Breath Sounds Decreased
	Cardiomyopathy
	Chest Pain
	Crepitations
	Device Failure
	Dizziness

		Dyspepsia Dyspnoea Erectile Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache Hypertension Hypoaesthesia Ileus Intermittent Claudication Limb Discomfort Muscle Spasms Myocardial Infarction Peripheral Vascular Disorder Post Procedural Complication Renal Tubular Necrosis Vision Blurred	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/19/04ISR Number: 4505669-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01620
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arterial Occlusive Disease	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN			Lipitor	C		
Initial or Prolonged Disability	Coronary Artery Occlusion					

Date:11/19/04ISR Number: 4505670-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00033
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 1425 DAY	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN			Methotrexate	C		
Other			Omega-3 Marine Triglycerides	C		
UNKNOWN						

Date:11/19/04ISR Number: 4505672-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02140
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Increased		[Therapy					
Initial or Prolonged	Kidney Infection		Unspecified]	C				
UNKNOWN								
Disability								

Date:11/19/04ISR Number: 4505673-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01745
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C				
UNKNOWN								
Initial or Prolonged			Nabumetone	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								

			Crestor	C			
UNKNOWN							
			Levoxyl	C			
UNKNOWN							

Date:11/19/04ISR Number: 4505674-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00367
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/19/04ISR Number: 4505675-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00014
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Acetaminophen	C				
UNKNOWN								
	Renal Failure							

Date:11/19/04ISR Number: 4505676-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02415
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Extradural Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Haemorrhagic Stroke		Coumadin	C				
UNKNOWN								
	Thrombotic Stroke		Aspirin	C				
UNKNOWN								
			Allopurinol Msd	C		ORAL		
			Verapamil Msd Lp	C		ORAL		
			Cozaar	C		ORAL		

			Lasix (Furosemide)	C			
UNKNOWN							
			Digoxin	C			
UNKNOWN							
			Enalapril Maleate	C			
UNKNOWN							

Date:11/19/04ISR Number: 4505681-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
584 DAY								
Initial or Prolonged	Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Pain		Norvasc	C				
UNKNOWN								
	Blood Pressure Increased		Celebrex	C				
UNKNOWN								
	Cardiac Failure		Clonidine	C				
UNKNOWN								
	Congestive		Demadex	C				
UNKNOWN								
	Convulsion		Digitek	C				
UNKNOWN								
	Muscle Spasms		Potassium					
	Pain In Extremity		(Unspecified)	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Accupril	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505682-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02142
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Haemorrhage	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhage		[Therapy Unspecified]	C				
	Intestinal Haemorrhage							
Disability			[Therapy Unspecified]	C				

UNKNOWN

Date:11/19/04ISR Number: 4505683-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01133
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Flexeril	C				
Disability								

UNKNOWN

Date:11/19/04ISR Number: 4505687-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia Alzheimer'S Type	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505688-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02296
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505689-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02344
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Headache		Flonase	C			UNKNOWN	
	Heart Rate Increased							
	Pain							

Date:11/19/04ISR Number: 4505692-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02212
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Aneurysm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prilosec	C			UNKNOWN	
Initial or Prolonged			Avalide	C			UNKNOWN	
Disability			Pravachol	C			UNKNOWN	
			Quinine	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Melatonin	C			UNKNOWN	
			Glucotrol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505693-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505694-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01619
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Palpitations		Allegra	C				
UNKNOWN								
Initial or Prolonged			Ambien	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:11/19/04ISR Number: 4505696-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505697-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01703
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea Hypertension Neck Pain Pain Pain In Extremity							

Pallor

Date:11/19/04ISR Number: 4505698-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01359
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Murmur Respiratory Disorder Urinary Tract Infection	Consumer	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

Date:11/19/04ISR Number: 4505699-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505700-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02384
Age:44 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Hypertension		Celebrex	C			UNKNOWN	
	Myocardial Infarction							

Date:11/19/04ISR Number: 4505701-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Mitral Valve Prolapse							

Date:11/19/04ISR Number: 4505702-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02148
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								

Date:11/19/04ISR Number: 4505703-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02415
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							

Date:11/19/04ISR Number: 4505705-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505706-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02571
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
Hospitalization -			Acupril	C			UNKNOWN	
Initial or Prolonged			Hydrodiuril	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Celebrex	C			UNKNOWN	

Date:11/19/04ISR Number: 4505709-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02647
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Infection Cardiac Valve Disease Cerebral Haemorrhage Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505711-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02694
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
Life-Threatening			Celebrex	C				
UNKNOWN								

Date:11/19/04ISR Number: 4505712-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							
	Polytraumatism							

Date:11/19/04ISR Number: 4505713-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02581
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Indapamide	C				
UNKNOWN								
Initial or Prolonged			Benicar	C				
UNKNOWN								
Disability								

Date:11/19/04ISR Number: 4505725-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Amnesia
	Angina Pectoris
	Anxiety

Arthralgia
Asthenia
Autonomic Nervous System
Imbalance
Blood Pressure Increased
Breast Cancer In Situ
Breast Microcalcification
Breast Pain
Breast Tenderness
Bronchitis
Bursitis
Carotid Artery Disease
Carotid Artery Stenosis
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Colonic Polyp
Contusion
Deafness Neurosensory
Deafness Unilateral
Diaphragmatic Disorder
Disorientation
Diverticulum
Dizziness
Dyspnoea

		Ear Discomfort					
		Endolymphatic Hydrops					
		Exostosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Fibrocystic Breast		Spironolactone	C		
UNKNOWN							
		Disease		Captopril Msd	C		ORAL
		Flatulence		Toprol Xl Tablets	C		ORAL
		Gliosis					
		Global Amnesia					
		Granuloma					
		Haemangioma					
		Haemorrhoids					
		Hot Flush					
		Hyperhidrosis					
		Hyperplasia					
		Hypertension					
		Hypertensive					
		Encephalopathy					
		Ischaemia					
		Limb Discomfort					
		Limb Injury					
		Loss Of Consciousness					
		Metaplasia					
		Migraine					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Neoplasm Recurrence					
		Nuclear Magnetic					
		Resonance Imaging Brain					
		Abnormal					
		Osteoarthritis					
		Osteoporosis					
		Pain In Extremity					
		Palatal Disorder					
		Palpitations					
		Plantar Fasciitis					
		Pulmonary Congestion					
		Pulmonary Fibrosis					
		Radiation Injury					
		Rash					
		Refusal Of Treatment By					
		Patient					
		Rhinitis					

Scotoma
Seasonal Allergy
Seroma
Sinus Disorder
Supraventricular
Tachycardia
Tendonitis
Transient Ischaemic
Attack
Tremor
Ventricular Hypertrophy
Vertebrobasilar
Insufficiency
Visual Disturbance

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4505776-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4505778-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01448
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Haemorrhage		Coumadin	C				
UNKNOWN								
Other			Lasix (Furosemide)	C				
UNKNOWN								
			Analgesic Or Anesthetic (Unspecified)	C				
UNKNOWN								

Date:11/19/04ISR Number: 4506196-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Anaemia
Other	Angle Closure Glaucoma
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Atrial Fibrillation
	Blood Calcium Decreased
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Catheter Related
	Infection
	Cholelithiasis
	Coronary Artery Disease
	Dehydration

Faeces Discoloured
Haemodialysis
Headache
Hypokalaemia
Hypomagnesaemia
Incision Site
Complication
Mitral Valve Disease
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Nephrolithiasis
Nephropathy Toxic
Osteoarthritis
Pharyngolaryngeal Pain
Post Procedural
Complication
Renal Artery
Atherosclerosis
Renal Artery Stenosis
Renal Failure Chronic
Renal Tubular Disorder
Steal Syndrome

	Transplant Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Wound Infection	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Staphylococcal	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN
			Tiazac	C			UNKNOWN
			Advil	C			

Date:11/19/04ISR Number: 4506198-9Report Type:Expedited (15-DaCompany Report #PE-MERCK-01109472
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bronchospasm	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY
Disability	Drug Ineffective		Celecoxib	C		ORAL	3 DAY
	Dyspnoea						
	Fatigue						
	Headache						
	Hypertension						
	Myocardial Ischaemia						
	Syncope						
	Tachycardia						

Date:11/19/04ISR Number: 4506199-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00635
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged Disability Other	Adverse Event Anxiety Bronchitis Delusional Disorder, Persecutory Type Depression Dyspnoea Gastrooesophageal Reflux Disease Hiatus Hernia Lobar Pneumonia Osteoporosis Panic Attack Schizophrenia, Paranoid Type Tooth Disorder	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/19/04ISR Number: 4506202-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA02027
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Other	Acute Respiratory Distress Syndrome Allergic Sinusitis Aspiration Atrial Fibrillation Blood Triglycerides

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Increased Breast Tenderness					
		Cardio-Respiratory Arrest					
		Coagulopathy					
45	DAY	Colitis Ischaemic	Health	Vioxx	PS	Merck & Co., Inc	ORAL
45	DAY	Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Depression		Zocor	C		
UNKNOWN		Diarrhoea		Vitamin E	C		
UNKNOWN		Diverticulum		Centrum	C		
UNKNOWN		Dyspepsia		Beta Carotene	C		
UNKNOWN		Dyspnoea Exertional		Percocet	C		
UNKNOWN		Electrocardiogram Abnormal		Tylenol With Codeine #3	C		
UNKNOWN		Extradural Abscess		Ascorbic Acid	C		
		Fatigue					
		Haematochezia					
		Hypersensitivity					
		Hypokalaemia					
		Hypokinesia					
		Influenza Like Illness					
		Intervertebral Disc Disorder					
		Intervertebral Discitis					
		Mitral Valve Incompetence					
		Multi-Organ Failure					
		Myocardial Infarction					
		Nausea					
		Otitis Media					
		Pancreatitis					
		Renal Failure					
		Renal Pain					
		Renal Tubular Necrosis					
		Sepsis					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:11/19/04ISR Number: 4506205-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00819
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Arthralgia
	Biliary Neoplasm
	Blood Glucose Increased
	Blood Pressure Increased
	Bone Disorder
	Bronchitis
	Bronchitis Acute
	Cardiomegaly
	Chills
	Cough
	Diarrhoea
	Haemarthrosis
	Hand Fracture
	Heart Rate Increased
	Hip Arthroplasty
	Hypokalaemia
	Influenza

		Injury					
		Joint Effusion					
		Joint Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lethargy	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Limb Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Monarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Amoxicillin	C		
UNKNOWN							
		Pain In Extremity		Lortab	C		
UNKNOWN							
		Pco2 Decreased					
		Pharyngolaryngeal Pain					
		Postoperative Infection					
		Pyrexia					
		Respiratory Rate					
		Increased					
		Sinusitis					
		Tibia Fracture					
		Traumatic Arthritis					
		Vomiting					

Date:11/19/04ISR Number: 4506206-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00767
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety					
		Back Pain					
		Cerebral Atherosclerosis					
		Convulsion					
		Depression					
		Headache					
		Hypercholesterolaemia					
		Hypertension					
		Intervertebral Disc Degeneration					
		Muscle Spasms					
		Myocardial Infarction					
		Neck Pain					
		Road Traffic Accident					
		Skin Disorder					
		Spinal Osteoarthritis					

Vertigo

Date:11/19/04ISR Number: 4506209-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00836
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
Other	Anastomotic Stenosis
	Anastomotic Ulcer
	Biliary Dilatation
	Blood Pressure Increased
	Bursitis
	Candidiasis
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Colonic Polyp
	Coronary Artery Disease

		Dysphagia					
		Headache					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Impaired Gastric Emptying	Health	Vioxx	PS	Merck & Co., Inc	ORAL
493	DAY						
		Myocardial Ischaemia	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
493	DAY						
		Oedema		Carafate	C		ORAL
		Orthostatic Hypotension		Atenolol	C		ORAL
		Osteoarthritis		Reglan	C		ORAL
		Pain		Theo-Dur	C		ORAL
		Peptic Ulcer Haemorrhage		Aldactone	C		ORAL
		Prothrombin Level		Phenergan			
		Increased		Tablets/Suppositorie			
		Syncope		s	C		ORAL
		Tenosynovitis		Flovent	C		
RESPIRATORY							
		Upper Respiratory Tract					
(INHALATION)							
		Infection		Combivent	C		
RESPIRATORY							
		Vestibular Neuronitis					
(INHALATION)							
				Elavil	C		ORAL
				Nitrostat	C		
SUBLINGUAL							
				Buspar	C		ORAL
				Methadone			
				Hydrochloride	C		ORAL
				Serevent Diskhaler	C		
RESPIRATORY							
(INHALATION)							
				Flonase	C		
RESPIRATORY							
(INHALATION)							
				Zantac	C		
UNKNOWN							
				Iron (Unspecified)	C		ORAL
				Fosfree	C		
UNKNOWN							
				Ultram	C		ORAL

Date:11/19/04ISR Number: 4506212-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vicodin Tablets	C		ORAL		
	Back Pain		Flexeril	C		ORAL		
	Buttock Pain		Flexeril	C		ORAL		
	Diarrhoea							
	Difficulty In Walking							
	Fall							
	Gastritis							
	Haematochezia							
	Hiatus Hernia							
	Insomnia							
	Intervertebral Disc							
	Protrusion							
	Limb Discomfort							
	Nausea							
	Oedema Peripheral							
	Osteoarthritis							
	Post Laminectomy Syndrome							
	Radiculitis Lumbosacral							
	Sacroiliitis							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506215-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03334
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident	Professional	Synthroid	C				
UNKNOWN								
Initial or Prolonged	Swelling		Norvasc	C				
UNKNOWN								
Disability	Swelling Face		Ativan	C				
UNKNOWN								
	Transient Ischaemic Attack							

Date:11/19/04ISR Number: 4506217-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
350 DAY								
Initial or Prolonged	Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
350 DAY								
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc			
UNKNOWN	27 DAY							
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Restenosis		Vioxx	SS	Merck & Co., Inc			
UNKNOWN	27 DAY							
	Diabetes Mellitus		Tenormin	C				
UNKNOWN								
	Diverticulitis		Diovan	C				
UNKNOWN								
	Dysphonia		Propecia	C				
UNKNOWN								
	Dyspnoea		Atenolol	C				
UNKNOWN								
	Emotional Distress		Norco	C				
UNKNOWN								
	Facet Joint Syndrome		Chlorthalidone	C				
UNKNOWN								

	Hand Fracture	Celebrex	C
UNKNOWN			
	Hyperlipidaemia	Celebrex	C
UNKNOWN			
	Hypertension	Cyclobenzaprine	
	Insomnia	Hydrochloride	C
UNKNOWN			
	Intervertebral Disc	Ultram	C
UNKNOWN			
	Protrusion	Hydrocodone	
	Lumbar Spinal Stenosis	Hydrochloride	C
UNKNOWN			
	Muscle Strain	[Therapy	
	Nervousness	Unspecified]	C
UNKNOWN			
	Pneumothorax	Avandia	C
UNKNOWN			
	Raynaud'S Phenomenon	Glucovance	C
UNKNOWN			
	Respiratory Failure	Hygroton	C
UNKNOWN			
	Somnolence	Cardizem	C
UNKNOWN			
		Altace	C
UNKNOWN			
		Aspirin	C
UNKNOWN			

Date:11/19/04ISR Number: 4506218-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris					
	Blood Pressure Increased					
	Convulsion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506220-XReport Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00035
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		510 DAY
	Cerebral Haemorrhage		Nitrendipine	C		ORAL		
	Epistaxis		Piperazine	C		ORAL		
	Haematuria		[Therapy					
	Mouth Haemorrhage		Unspecified]	C		ORAL		
			[Therapy					
			Unspecified]	C		ORAL		
			[Therapy					
			Unspecified]	C		ORAL		

Date:11/19/04ISR Number: 4506221-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03337
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Inadequate Control							
Disability	Difficulty In Walking							
	Infection							
	Joint Sprain							
	Oedema Peripheral							
	Overdose							
	Toe Amputation							
	Treatment Noncompliance							

Date:11/19/04ISR Number: 4506222-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Death							

Date:11/19/04ISR Number: 4506224-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04149
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Arthralgia
Hospitalization -	Cellulitis
Initial or Prolonged	Coronary Artery Disease
Other	Dermatitis Allergic
	Diabetes Mellitus
	Groin Pain
	Hypercholesterolaemia
	Hypertension
	Laceration
	Myocardial Infarction
	Oedema Peripheral
	Osteoarthritis
	Pharyngitis
	Renal Failure
	Spinal Osteoarthritis
	Viral Upper Respiratory

Tract Infection

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506226-0Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00046
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Other	Distress Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Hepatic Failure		Cefazolin	C			INTRAVENOUS	6 DAY
	Hepatitis Myocarditis		[Therapy Unspecified]	C			INTRAVENOUS	6 DAY
	Pneumonia Primary		Ofloxacin	C			INTRAVENOUS	6 DAY
	Atypical Renal Failure		[Therapy Unspecified]	C			INTRAVENOUS	6 DAY
	Respiratory Failure		Dexamethasone	C			UNKNOWN	4 DAY
			Azithromycin	C			UNKNOWN	4 DAY

Date:11/19/04ISR Number: 4506227-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02109
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Chest Pain		Glucophage	C				
Initial or Prolonged Disability	Diverticulum Gastric Diverticulum Intestinal		Zocor	C		ORAL		
Other UNKNOWN	Fatigue		Flomax (Morniflumate)	C				

	Gastric Haemorrhage	Aspirin	C	
UNKNOWN				
	Large Intestinal Ulcer	Trusopt	C	
UNKNOWN				
	Oesophageal Ulcer	Vicodin Tablets	C	ORAL
	Rectal Haemorrhage	Metoprolol	C	ORAL
		Monopril	C	
UNKNOWN				
		Maxzide	C	
UNKNOWN				
		Albuterol	C	
UNKNOWN				
		Plendil	C	
UNKNOWN				
		Nitroglycerin	C	
UNKNOWN				

Date:11/19/04ISR Number: 4506228-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Atherosclerosis
	Attention Deficit/Hyperactivity Disorder
	Blood Cholesterol Increased
	Chest Pain
	Chronic Fatigue Syndrome
	Coronary Artery Occlusion
	Depression
	Ejection Fraction Decreased

	Gastrooesophageal Reflux Disease						
	Generalised Anxiety Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
	Haemorrhoidal Haemorrhage		Wellbutrin	C			UNKNOWN
	Hypertension		[Therapy Unspecified]	C			UNKNOWN
	Insomnia						
	Panic Disorder		Paxil	C			UNKNOWN
	Phlebitis Superficial		Aspirin	C			UNKNOWN
			Ibuprofen	C			UNKNOWN

Date:11/19/04ISR Number: 4506231-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01448
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	
			Premarin	C			UNKNOWN
Disability							

Date:11/19/04ISR Number: 4506232-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:11/19/04ISR Number: 4506233-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01714
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Disability	Arthralgia Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/19/04ISR Number: 4506234-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01993
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization -	Renal Pain		Nexium	C				UNKNOWN
Initial or Prolonged			Furosemide	C				UNKNOWN
Disability			Glucotrol	C				UNKNOWN
			Tizanidine Hydrochloride	C				UNKNOWN
			Fosamax	C				UNKNOWN

Date:11/19/04ISR Number: 4506235-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00028
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Methotrexate	C				UNKNOWN
	Dizziness		Acetaminophen	C				UNKNOWN
	Fall		Prednisolone	C				UNKNOWN
	Fatigue Hip Fracture		Propoxyphene Napsylate	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506237-5Report Type:Expedited (15-DaCompany Report #HK-MERCK-0411HKG00006
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Hypotension		Amiloride Hydrochloride And Hydrochlorothiazide	SS		ORAL		2 YR
	Syncope							
	Vision Blurred							
			Acetylcysteine	C		ORAL		7 YR
			Aspirin	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		3 YR
			Atorvastatin Calcium	C		ORAL		2 YR
			Acrivastine	C		ORAL		2 YR
			Esomeprazole Magnesium	C		ORAL		2 YR
			Metoprolol Succinate	C		ORAL		2 YR
			Irbesartan	C		ORAL		2 YR
			Betahistine Mesylate	C		ORAL		2 YR

Date:11/19/04ISR Number: 4506238-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:11/19/04ISR Number: 4506239-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506240-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00180
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506241-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01986
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Arterial Stent Insertion	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vitamins (Unspecified)	C				
Disability			Protonix	C				
			Lipitor	C				
			Zoloft	C				
			Lorazepam	C				

Date:11/19/04ISR Number: 4506243-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02213
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Retinal Vein Occlusion							

Date:11/19/04ISR Number: 4506244-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:11/19/04ISR Number: 4506245-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02180
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Valve Stenosis		Plavix	C				UNKNOWN
			Foltx	C				UNKNOWN

Date:11/19/04ISR Number: 4506246-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02110
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Movement Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Disability	Pain		[Therapy Unspecified]	C				UNKNOWN
	Thrombosis		[Therapy Unspecified]	C				UNKNOWN

Date:11/19/04ISR Number: 4506247-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Celebrex	C				
UNKNOWN								

Date:11/19/04ISR Number: 4506249-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01716
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Life-Threatening			Cardizem	C				
UNKNOWN								
Hospitalization -			Zestoretic	C		ORAL		
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability			Diabeta	C				
UNKNOWN								
			Nitro-Dur	C				
UNKNOWN								
			Atenolol Msd	C		ORAL		
			Elavil	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506254-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02011
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Joint Swelling Nervousness Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506255-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506257-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506259-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02319
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebral Disorder Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506260-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02237
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506261-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02061
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	1 YR
	Thrombosis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	1 YR

Date:11/19/04ISR Number: 4506262-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506263-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02101
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506266-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Cardiomegaly Malaise		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506267-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506268-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02617
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening Hospitalization - Initial or Prolonged Disability	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506269-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4506270-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02228
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Atrioventricular Block		Vioxx Codeine	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								
Disability	Cardiac Disorder							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506278-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Leukaemia		[Therapy					
Initial or Prolonged	Traumatic Haemorrhage		Unspecified]	SS				
UNKNOWN								

Date:11/19/04ISR Number: 4506279-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02580
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							

Date:11/19/04ISR Number: 4506282-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02727
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
458 DAY								
Initial or Prolonged	Loss Of Consciousness		Cozaar	C		ORAL		
1554 DAY								
			Norvasc	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								

Date:11/19/04ISR Number: 4506285-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/19/04ISR Number: 4506295-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00785
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris	Professional				
	Blood Pressure Increased					
	Convulsion					

Date:11/19/04ISR Number: 4506315-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02805
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Congestive		Lasix (Furosemide)	C		
UNKNOWN						
Initial or Prolonged	Limb Discomfort		Albuterol	C		
UNKNOWN						
Disability	Movement Disorder		Lisinopril	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Digitora	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Karvedilol	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/19/04ISR Number: 4506316-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02711
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/19/04ISR Number: 4509488-9Report Type:Expedited (15-DaCompany Report #2004090157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Hospitalization -	Coronary Artery Surgery		Bextra (Valdecoxib)	SS		ORAL	ORAL	
Initial or Prolonged	Dyspepsia Nephrolithiasis		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Thrombosis		Meloxicam (Meloxicam)	SS		ORAL	ORAL	

Date:11/19/04ISR Number: 4512414-XReport Type:Expedited (15-DaCompany Report #WAES 0411USA00662
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ulcerative	Study	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged	Condition Aggravated Pyoderma Gangrenosum	Literature Health Professional	Corticosteroids (Unspecified)	C				

Date:11/19/04ISR Number: 4512415-1Report Type:Expedited (15-DaCompany Report #WAES 0411USA00661
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Condition Aggravated	Foreign	Tab Vioxx	PS		ORAL
PO						
Initial or Prolonged	Crohn'S Disease	Literature Health Professional	Mercaptopurine	C		

Date:11/19/04ISR Number: 4512807-0Report Type:Direct Company Report #CTU 232504
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Ischaemia		Vioxx 25 Mg Qd	PS		
25 MG QD						
	Palpitations					

Date:11/19/04ISR Number: 4512850-1Report Type:Direct Company Report #CTU 232472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Required	Angina Pectoris		Vioxx 25mg			
Intervention to	Cardiac Disorder		Merck & Co	PS	Merck & Co	ORAL
2 TABLETS						
Prevent Permanent	Heart Rate Increased					
DAY ORAL						
Impairment/Damage	Heart Rate Irregular					

Date:11/22/04ISR Number: 4506461-1Report Type:Expedited (15-DaCompany Report #EMADSS2003001873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis Acute		Remicade	PS				
Initial or Prolonged	Hepatic Fibrosis					DRIP	2	DAY
	Hepatic Steatosis		Remicade	SS				
	Hepatitis					DRIP	2	DAY
	Hepatocellular Damage		Zoloft	SS				
	Vasculitis		Losec	SS				
			Vioxx	SS				
			Methotrexate	SS				
			Folacin	C				
			Folacin	C				
			Daonil	C				

Date:11/22/04ISR Number: 4506624-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00694
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Quinine	C				
Disability	Aneurysm		Betoptic	C				
Other	Angina Pectoris		Calcium (Unspecified)	C				
	Cardiomegaly							
	Convulsion		Vitamins (Unspecified)	C				
	Haemorrhagic Stroke							
	Ileus							

Postoperative Ileus
Small Intestinal
Obstruction
Viith Nerve Paralysis
White Blood Cell Count
Increased

Date:11/22/04ISR Number: 4506633-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Asthenia
	Blood Disorder
	Blood Glucose Decreased
	Blood Sodium Decreased
	Cardiac Failure Chronic
	Cardiomyopathy
	Constipation
	Dizziness
	Fall
	Gastric Disorder
	Gastrointestinal Disorder
	Gastrooesophageal Reflux
	Disease
	Hypercholesterolaemia
	Hypertension
	Injury
	Lumbar Spinal Stenosis
	Lung Infiltration
	Myocardial Infarction
	Myocardial Ischaemia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Nausea Pneumonia Sick Sinus Syndrome					
		Skin Infection		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Sleep Disorder		Coumadin	C		
UNKNOWN		Therapy Non-Responder		Coumadin	C		
UNKNOWN				Augmentin	C		
UNKNOWN				Clonazepam	C		
UNKNOWN				Aciphex	C		
UNKNOWN				Zestril	C		
UNKNOWN				Diabeta	C		ORAL
				Tylenol With Codeine	C		
UNKNOWN				Reglan	C		
UNKNOWN				Ranitidine	C		ORAL
				Vitamin E	C		
UNKNOWN				Triamterene	C		
UNKNOWN				Levobunolol Hydrochloride	C		
OPHTHALMIC				Domeboro	C		
AURICULAR (OTIC)				Amoxicillin	C		
UNKNOWN				Lactulose	C		
UNKNOWN				Lotrisone	C		
UNKNOWN				Triamcinolone	C		
UNKNOWN				Prevacid	C		
UNKNOWN							

Outcome	PT
Other	Anaemia
	Aortic Valve Stenosis
	Aptyalism
	Arthralgia
	Atelectasis
	Bradycardia
	Carotid Artery Disease
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Confusional State
	Coronary Artery Disease
	Decreased Appetite
	Decubitus Ulcer
	Delirium
	Delusion
	Dementia
	Depressed Level Of Consciousness
	Difficulty In Walking
	Dizziness
	Drug Hypersensitivity
	Dry Mouth
	Dyspnoea
	Electrocardiogram Poor R-Wave Progression
	Electrolyte Imbalance
	Enzyme Abnormality
	Eye Disorder
	Faecaloma
	Fall

		Injury					
		Insomnia					
		International Normalised	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ratio Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		International Normalised					
		Ratio Increased					
		Joint Swelling					
		Laceration					
		Lethargy					
		Memory Impairment					
		Mobility Decreased					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Pain In Extremity					
		Parkinson'S Disease					
		Peroneal Nerve Palsy					
		Post Procedural					
		Complication					
		Renal Cyst					
		Seasonal Allergy					
		Skin Ulcer					
		Urinary Retention					
		Urinary Tract Infection					

Date:11/22/04ISR Number: 4506636-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY							
Initial or Prolonged		Infarction		Griseofulvin	C		
UNKNOWN							
		Anhedonia		[Therapy			
		Anxiety		Unspecified]	C		
UNKNOWN							
		Aortic Dilatation		Isoptin	C		
UNKNOWN							
		Aortic Valve Incompetence		Beconase Aq	C		
UNKNOWN							
		Coronary Artery Occlusion					
		Drug Ineffective					
		Emotional Distress					
		Fatigue					

Hyperkeratosis
Hyperlipidaemia
Injury
Pain
Pelvic Haematoma
Stress
Tinea Infection

Date:11/22/04ISR Number: 4506637-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03195
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Other	Abdominal Pain
	Angina Unstable
	Arteriospasm Coronary
	Arthralgia
	Back Pain
	Barrett'S Oesophagus
	Chest Pain
	Cholecystitis Chronic

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coronary Artery Disease					
		Cystocele					
		Deep Vein Thrombosis					
		Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL
84	DAY						
		Depression		Aspirin	C		
UNKNOWN							
		Diverticulitis		Aspirin	C		
UNKNOWN							
		Diverticulum		Lipitor	C		
UNKNOWN							
		Dysfunctional Uterine		Prometrium	C		
UNKNOWN							
		Bleeding		Vivelle	C		
TOPICAL							
		Dyspepsia		Vivelle	C		
TOPICAL							
		Dyspnoea		Zyrtec	C		
UNKNOWN							
		Dysuria		Fioricet Tablets	C		
UNKNOWN							
		Flank Pain		Fioricet Tablets	C		
UNKNOWN							
		Gastroenteritis		Ambien	C		
UNKNOWN							
		Gastrooesophageal Reflux		Motrin	C		
UNKNOWN							
		Disease		Paxil	C		
UNKNOWN							
		Generalised Anxiety		Prilosec	C		
UNKNOWN							
		Disorder		Alprazolam	C		
UNKNOWN							
		Haematuria		Vitamin E	C		
UNKNOWN							
		Haemorrhoids		Gnc Womens Ultra Mega	C		
		Headache					
UNKNOWN							
		Hot Flush		Lecithin	C		
UNKNOWN							
		Hyperlipidaemia					
		Hypersensitivity					
		Incisional Drainage					
		Incisional Hernia					
		Inflammation					
		Injury					

Menopausal Symptoms
Myocardial Infarction
Nausea
Neck Pain
Non-Cardiac Chest Pain
Phlebitis Superficial
Post Procedural Pain
Postoperative Ileus
Rectal Polyp
Rhinitis Allergic
Rosacea
Sinusitis
Stress Incontinence
Urinary Tract Infection
Venous Insufficiency
Vertigo
Weight Increased

Date:11/22/04ISR Number: 4506642-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00609
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Blood Pressure Increased
Other	Chest Pain
	Convulsion
	Coronary Artery Disease
	Hyperlipidaemia
	Hypertension
	Myocardial Infarction
	Pericarditis
	Tricuspid Valve

	Incompetence						
	Ventricular Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Monopril	C			UNKNOWN	
			Estrace	C			UNKNOWN	

Date:11/22/04ISR Number: 4506643-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia							
	Blood Pressure Increased							
	Convulsion							
	Cyst							
	Fall							
	Muscle Atrophy							

Date:11/22/04ISR Number: 4506644-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		698 DAY
Initial or Prolonged	Infarction		Lortab	C			UNKNOWN	
Other	Adverse Event		Prednisone	C			UNKNOWN	
	Angina Pectoris		Prednisone	C			UNKNOWN	
	Anxiety		Nitropaste	C			UNKNOWN	
	Back Pain		Sodium Folate	C			UNKNOWN	
	Blister		Ultram	C			UNKNOWN	

	Blood Cholesterol	Triamcinolone	C
UNKNOWN			
	Increased	Skelaxin	C
UNKNOWN			
	Blood Pressure Increased	Methotrexate	C
UNKNOWN			
	Contusion	Folic Acid	C
UNKNOWN			
	Convulsion	Toprol Xl Tablets	C
UNKNOWN			
	Coronary Artery Disease	Elavil	C
UNKNOWN			
	Eye Disorder		
	Headache		
	Heart Rate Increased		
	Hypercholesterolaemia		
	Hypoaesthesia		
	Joint Swelling		
	Kidney Infection		
	Myocardial Infarction		
	Nausea		
	Palpitations		
	Phlebitis		
	Pyrexia		
	Rash		
	Renal Disorder		
	Stress		
	Tachycardia		
	Upper Respiratory Tract Infection		
	Urinary Tract Infection		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506648-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00754
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Activated Partial		Fosamax	C		ORAL
Other	Thromboplastin Time		Aspirin	C		
UNKNOWN						
	Prolonged					
	Acute Myocardial					
	Infarction					
	Anaemia					
	Angina Pectoris					
	Asthenia					
	Blood Calcium Decreased					
	Blood Glucose Increased					
	Blood Potassium Decreased					
	Blood Pressure Increased					
	Blood Sodium Decreased					
	Blood Urea Increased					
	Bronchopneumonia					
	Confusional State					
	Convulsion					
	Duodenal Ulcer					
	Lung Infiltration					
	Myocardial Ischaemia					
	Pain					
	Pruritus					
	Vomiting					
	White Blood Cell Count					
	Increased					

Date:11/22/04ISR Number: 4506653-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Adverse Event
	Anaemia
	Angina Pectoris
	Barrett'S Oesophagus
	Bone Density Decreased

Breast Cyst
Cataract Operation
Cerebrovascular Accident
Cerebrovascular Disorder
Chest Pain
Colonic Polyp
Constipation
Contusion
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery
Restenosis
Diverticulum Intestinal
Electrocardiogram St
Segment Depression
Erosive Oesophagitis

		Fall					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhoids		Vioxx	PS	Merck & Co., Inc	ORAL
319	DAY						
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
319	DAY						
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypothyroidism		Aspirin	C		
UNKNOWN							
		Lung Disorder		Monopril	C		
UNKNOWN							
		Lymphangitis		Hydrochlorothiazide	C		
UNKNOWN							
		Medication Error					
		Meniscus Lesion					
		Myocardial Ischaemia					
		Oesophageal Ulcer					
		Osteoarthritis					
		Rash Erythematous					
		Renal Failure					

Date:11/22/04ISR Number: 4506654-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00772
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased		Flonase	C		
UNKNOWN						
Disability	Cerebrovascular Accident		Allegra	C		ORAL
Other	Chronic Obstructive		Pepcid	C		ORAL
	Pulmonary Disease					
	Convulsion					
	Eye Swelling					
	Hypersensitivity					
	Peroneal Nerve Palsy					
	Pruritus					

Date:11/22/04ISR Number: 4506658-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adrenal Disorder		Valium	C				
UNKNOWN								
Initial or Prolonged	Adverse Event		Sk-Erythromycin	C				
UNKNOWN								
Disability	Axillary Mass		Cyanocobalamin	C				
PARENTERAL								
Other	Breast Disorder		Nitrostat	C				
UNKNOWN								
	Csf Shunt Removal		Synthroid	C				
UNKNOWN								
	Discomfort		Paxil	C				
UNKNOWN								
	Fall		Lanoxin	C				
UNKNOWN								
	Gastroenteritis		Salagen Tablets	C				
UNKNOWN								
	Haemorrhoids		Claritin	C				
UNKNOWN								
	Helicobacter Gastritis		Zofran	C				
UNKNOWN								
	Hyperlipidaemia		Miacalcin	C				
UNKNOWN								
	Iron Deficiency Anaemia		Neurontin	C				
UNKNOWN								
	Myocardial Infarction		Vitamin E	C				
UNKNOWN								
	Nausea		Premarin	C				
UNKNOWN								
	Polytraumatism		Aciphex	C				
UNKNOWN								
	Road Traffic Accident		Detrol La	C				
UNKNOWN								
	Shunt Infection		Lasix (Furosemide)	C				
UNKNOWN								
	Wound Dehiscence		K-Dur	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			Primidone	C				
UNKNOWN								
			[Therapy					

Unspecified] C
UNKNOWN

Date:11/22/04ISR Number: 4506659-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00809
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arthritis							
Other	Bladder Neck Obstruction							
	Cystitis							
	Dermatitis Contact							
	Dysuria							
	Gastrooesophageal Reflux Disease							
	Pharyngolaryngeal Pain							
	Polytraumatism							
	Sinusitis							
	Testicular Disorder							
	Testicular Torsion							

Date:11/22/04ISR Number: 4506660-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00775
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Prempro	C				
UNKNOWN								
	Anxiety		Dyazide	C				
UNKNOWN								
	Appendix Disorder		Aspirin	C				
UNKNOWN								
	Arthritis							
	Arthropathy							
	Back Disorder							
	Back Pain							
	Bunion							
	Carpal Tunnel Syndrome							
	Cerebral Atherosclerosis							
	Cerebrovascular Accident							
	Cerebrovascular Disorder							
	Complicated Migraine							

Convulsion
Depression
Ganglion
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Hypoaesthesia
Lacunar Infarction
Neck Pain
Osteoarthritis
Syncope
Tinel'S Sign
Tonsillar Disorder
Transient Ischaemic
Attack
Trigger Finger
Wrist Fracture

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506663-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00795
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Levothroid	C				
UNKNOWN								
Disability	Anhedonia		Diovan	C				
UNKNOWN								
Other	Arthralgia		Niacin	C				
UNKNOWN								
	Cataract		Prempro	C				
UNKNOWN								
	Chest Discomfort		Tricor	C				
UNKNOWN								
	Chest Pain		Os-Cal D	C				
UNKNOWN								
	Deep Vein Thrombosis		Potassium (Unspecified)	C		ORAL		
	Dementia							
	Depressive Symptom		Tylenol	C				
UNKNOWN								
	Dermatitis		Ambien	C				
UNKNOWN								
	Dyspnoea		Dulcolax	C				
UNKNOWN								
	Dyspnoea Exertional		Flexeril	C				
UNKNOWN								
	Gastric Disorder		Darvocet-N	C				
UNKNOWN								
	Hypertonic Bladder							
	Intervertebral Disc Degeneration							
	Lumbar Radiculopathy							
	Myalgia							
	Nerve Compression							
	Osteoporosis							
	Polytraumatism							
	Rash							
	Sciatica							
	Skin Ulcer							
	Spinal Claudication							
	Spinal Compression Fracture							
	Thrombophlebitis Superficial							
	Venous Insufficiency							

Vertigo Positional

Date:11/22/04ISR Number: 4506669-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00852
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event
	Arthralgia
	Arthritis
	Back Pain
	Blood Pressure Systolic Increased
	Bronchitis
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Cough
	Dyspnoea
	Ear Discomfort
	Facet Joint Syndrome
	Fatigue
	Flushing
	Gastroenteritis Viral

		Hypersensitivity					
		Intermittent Claudication					
		Paraesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Road Traffic Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Serum Serotonin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Celebrex	C		ORAL
		Upper Respiratory Tract		Darvocet-N	C		
UNKNOWN							
		Infection		Ambien	C		
UNKNOWN							
		Ventricular Hypokinesia		Toprol Xl Tablets	C		
UNKNOWN							
				Florone	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Glucotrol Xl	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:11/22/04ISR Number: 4506672-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00933
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris		Synthroid	C		ORAL
Other		Anxiety		Vitamins			
		Blood Cholesterol		(Unspecified)	C		
UNKNOWN							
		Increased		Zocor	C		ORAL
		Bronchitis Acute		Darvocet-N	C		
UNKNOWN							
		Cataract		Elavil	C		
UNKNOWN							

	Conjunctivitis	Alprazolam	C	
UNKNOWN				
	Convulsion	Clarinex	C	
UNKNOWN				
	Depression	Ambien	C	
UNKNOWN				
	Dyspepsia	Aspirin	C	
UNKNOWN				
	Essential Hypertension	Zoloft	C	
UNKNOWN				
	Fatigue	[Composition		
	Gastrointestinal	Unspecified]	C	
UNKNOWN				
	Inflammation	Prilosec	C	
UNKNOWN				
	Headache	Amitriptyline		
	Hypoaesthesia	Hydrochloride	C	
UNKNOWN				
	Insomnia	Paxil	C	
UNKNOWN				
	Intervertebral Disc	Xanax	C	ORAL
	Protrusion	Vicodin Tablets	C	ORAL
	Joint Swelling	Lomotil	C	ORAL
	Lumbar Spinal Stenosis	Bactrim	C	
UNKNOWN				
	Malaise	Phenergan		
	Nervousness	Tablets/Suppositorie		
	Night Cramps	s	C	ORAL
	Oedema Peripheral	Duratuss	C	ORAL
	Otitis Media Acute	Gentamicin Sulfate	C	
OPHTHALMIC				
	Paraesthesia	Amoxil	C	ORAL
	Retinal Vein Occlusion			
	Tension			
	Transient Ischaemic			
	Attack			
	Vertigo Positional			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506673-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00854
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alcohol Poisoning							
	Alcohol Use							
	Chest Discomfort							
	Chest Pain							
	Cough							
	Cystitis							
	Dizziness							
	Dyspnoea							
	Dysuria							
	Exostosis							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Nerve Root Lesion							
	Palpitations							
	Polytraumatism							

Date:11/22/04ISR Number: 4506679-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02196
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anaemia		Altace	SS		ORAL		
	Coordination Abnormal		Aspirin	SS		ORAL		
	Depression		Peg-Intron	SS			SUBCUTANEOUS	40 DAY
	Drug Level Increased		Lithium Carbonate	SS			UNKNOWN	
	Drug Toxicity		Lithium Carbonate	SS			UNKNOWN	
	Haematocrit Decreased		Rebetol	SS		ORAL	40 DAY	
	Jaundice		Geodon	C		ORAL		
	Mental Status Changes		Zyprexa	C		ORAL		
	Therapeutic Agent		Lexapro	C		ORAL		
	Toxicity		Protonix	C		ORAL		
			Neurontin	C		ORAL		

Clonazepam	C	ORAL
Hydrocodone/Apap	C	ORAL
Phenergan Tablets/Suppositories	C	ORAL

Date:11/22/04ISR Number: 4506681-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Convulsion
	Coronary Artery Disease
	Hypertension
	Joint Dislocation
	Lumbar Radiculopathy
	Myocardial Infarction
	Pulmonary Oedema
	Spinal Osteoarthritis
	Stent Occlusion

Urinary Tract Disorder

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Zydone	C			UNKNOWN	
			Prozac	C		ORAL		
			Prilosec	C		ORAL		
			Elavil	C			UNKNOWN	
			Zanaflex	C		ORAL		
			Aleve	C			UNKNOWN	

Date:11/22/04ISR Number: 4506686-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00110
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	572 DAY	
Disability			Donepezil Hydrochloride	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Acetaminophen	C		ORAL		
			Ibuprofen	C			TOPICAL	

Date:11/22/04ISR Number: 4506687-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00355
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Hospitalization - Initial or Prolonged	Congestive Dizziness Dysgeusia Haemodialysis Oedema Peripheral Pyrexia		Amlodipine Besylate	C		ORAL		

Renal Failure Acute

Date:11/22/04ISR Number: 4506688-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03152
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Urinary Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Uterine Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Disability			Levoxyl	C				UNKNOWN
			Amaryl	C				UNKNOWN
			Humalog Mix 75/25	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:11/22/04ISR Number: 4506690-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01539
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization -	Chest Pain
Initial or Prolonged	Coronary Artery Occlusion
	Coronary Ostial Stenosis
	Dyspnoea
	Dyspnoea Exertional

		Electrocardiogram Q Waves					
		Electrocardiogram St Segment Elevation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
YR							
		Goitre		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Prevacid	C		
UNKNOWN							
		Injury		Bextra	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Myalgia					
		Nasal Congestion					
		Oedema Peripheral					
		Pain In Extremity					
		Palpitations					
		Sleep Disorder					
		Tricuspid Valve Incompetence					
		Viral Infection					

Date:11/22/04ISR Number: 4506692-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01754
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Hormones (Unspecified)	C		
		Hemiparesis					
UNKNOWN							
		Migraine		[Therapy Unspecified]	C		
UNKNOWN							
				Hydrochlorothiazide And Lisinopril	C		
UNKNOWN							
				Lovastatin	C		
UNKNOWN							
				Estrogens (Unspecified)	C		
UNKNOWN							

Date:11/22/04ISR Number: 4506694-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03095
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Atrial Flutter
	Cardiac Failure
	Congestive
	Cardiac Stress Test
	Abnormal
	Chest Pain
	Diarrhoea
	Drug Ineffective
	Dysphonia
	Dyspnoea Exertional
	Feeling Abnormal
	Gastrointestinal Disorder
	Gastrooesophageal Reflux
	Disease
	Hiatus Hernia
	Hyperhidrosis
	Ischaemia
	Mitral Valve Incompetence
	Nausea
	Oedema Peripheral

	Pain In Extremity						
	Pneumonia						
	Productive Cough	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tricuspid Valve		Vioxx	PS	Merck & Co., Inc	ORAL		
	Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506695-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01675
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	103 DAY	
Hospitalization -	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL	103 DAY	
Initial or Prolonged	Cardiac Arrest		Oxycontin	C			UNKNOWN	637 DAY
	Coma		Endocet	C			UNKNOWN	
	Myocardial Infarction		Percocet	C			UNKNOWN	
	Pain In Extremity		Nitroquick	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Topamax	C			UNKNOWN	
			Duragesic	C			UNKNOWN	
			Amitriptylin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Effexor	C			UNKNOWN	

Date:11/22/04ISR Number: 4506696-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04016
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Distension
	Amnesia

Back Pain
Blood Pressure Systolic
Increased
Carotid Artery Stenosis
Cataract Nuclear
Cerebrovascular Accident
Conjunctivitis
Crying
Decreased Appetite
Depression
Dermatitis Contact
Drug Intolerance
Duodenitis
Dyspepsia
Eructation
Extrasystoles
Eye Pruritus
Fatigue
Feeling Abnormal
Flatulence
Gastritis
Headache
Hemianopia Homonymous
Hyperlipidaemia
Keratoconjunctivitis
Sicca
Lacrimation Increased
Micturition Urgency
Nausea
Palpitations

		Pharyngitis					
		Pollakiuria					
		Rash Papular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL
711	DAY						
		Reading Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
711	DAY						
		Rhinorrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Prilosec	C		
UNKNOWN							
		Ureteric Stenosis		Zocor	C		ORAL
		Urinary Hesitation		Atenolol	C		
UNKNOWN							
		Vertebral Artery Stenosis		Librax Capsules	C		
UNKNOWN							
		Vision Blurred		Nasocort	C		
RESPIRATORY							
		Visual Acuity Reduced					
(INHALATION)							
		Visual Disturbance					
		Visual Field Defect					

Date:11/22/04ISR Number: 4506698-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01713
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/22/04ISR Number: 4506699-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01709
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Congestive					
	Cerebrovascular Accident					

Date:11/22/04ISR Number: 4506700-7Report Type:Expedited (15-DaCompany Report #HU-MERCK-0411HUN00011
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Enalapril Maleate	C		ORAL		

Date:11/22/04ISR Number: 4506702-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01985
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Oxycontin	C				

Date:11/22/04ISR Number: 4506703-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506704-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02037
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Detrol La	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Apresoline	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
			Methocarbamol	C			UNKNOWN	
			Celexa	C			UNKNOWN	

Date:11/22/04ISR Number: 4506706-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Lung Disorder							
	Weight Decreased							

Date:11/22/04ISR Number: 4506707-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02578
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/22/04ISR Number: 4506708-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02105
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Palpitations		Norvasc	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Diazepam	C		
UNKNOWN						

Date:11/22/04ISR Number: 4506710-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01197
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coronary Artery Surgery		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Vioxx	SS	Merck & Co., Inc	ORAL
Other			Celebrex	C		
UNKNOWN						
			Darvocet-N	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506711-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00079
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Prinivil	C				
UNKNOWN								
Disability			Vicodin Tablets	C				
UNKNOWN								

Date:11/22/04ISR Number: 4506712-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00983
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Occlusion		Synthroid	C				
UNKNOWN								
Initial or Prolonged	Lethargy		Darvocet-N	C				
UNKNOWN								
	Myocardial Infarction		Ambien	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Ativan	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Zocor	C		ORAL		
			Donnatal	C				
UNKNOWN								
			Ginkgo Biloba Extract	C				
UNKNOWN								
			Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				
UNKNOWN								

Date:11/22/04ISR Number: 4506714-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02238
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506715-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02557
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506716-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Adverse Event Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506718-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02155
Age:48 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Glioblastoma		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
		Verapamil	C				UNKNOWN
		Singulair	C		ORAL		
		Advair	C				UNKNOWN
		Maxalt (Rizatriptan Benzoate)	C				UNKNOWN
		Imitrex Nasal Spray	C				RESPIRATORY (INHALATION)

Date:11/22/04ISR Number: 4506719-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02210
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dilatation Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Cozaar	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Norvasc	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:11/22/04ISR Number: 4506720-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02157
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Arrhythmia		Potassium					

	Weight Decreased		(Unspecified)	C
UNKNOWN				
			[Therapy Unspecified]	C
UNKNOWN				
			Cozaar	C
UNKNOWN				
			Prednisone	C
UNKNOWN				

Date:11/22/04ISR Number: 4506721-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02566
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Cardiac Failure Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506723-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02665
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cystitis Interstitial Nephrolithiasis Ovarian Cyst Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506724-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02709
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506725-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506726-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506728-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02946
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking Pain In Extremity		Vioxx Vasotec [Therapy Unspecified] [Therapy Unspecified]	PS C C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN UNKNOWN	

Date:11/22/04ISR Number: 4506729-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02968
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Lasix (Furosemide)	C				
UNKNOWN								
Initial or Prolonged	Attack		Pravachol	C				
UNKNOWN								
Disability			Aggrenox	C				
UNKNOWN								
			Soma	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								
			Demerol	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								

Date:11/22/04ISR Number: 4506731-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02784
Age:81 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1542 DAY	
			Coumadin	C				UNKNOWN
			Diovan	C				UNKNOWN
			Fosamax	C		ORAL		
			Coreg	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Zocor	C		ORAL		
			Pravacol	C				UNKNOWN

Date:11/22/04ISR Number: 4506732-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02856
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ibuprofen	C				UNKNOWN

Date:11/22/04ISR Number: 4506733-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02797
Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Lethargy		Synthroid	C				UNKNOWN
	Palpitations							

Date:11/22/04ISR Number: 4506734-2Report Type:Expedited (15-DaCompany Report #EC-MERCK-0411PER00015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tachycardia		Prednisone	C				
			Enalapril Maleate	C				

Date:11/22/04ISR Number: 4506750-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4506751-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02730
Age:78 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Blindness Unilateral		[Therapy Unspecified]	C			UNKNOWN	
	Blister							
	Blood Pressure Increased		[Therapy Unspecified]	C			UNKNOWN	
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4506752-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02806
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Swelling		Lipitor	C				
UNKNOWN								
	Weight Increased							

Date:11/22/04ISR Number: 4507048-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Disability	Arthralgia
Other	Atherosclerosis
	Atrial Fibrillation
	Blister
	Blood Pressure Inadequately Controlled
	Cardiac Murmur
	Chest Pain
	Colonic Polyp
	Conjunctival Haemorrhage
	Coronary Artery Disease
	Dermatitis Contact
	Diarrhoea
	Diastolic Dysfunction
	Dilatation Atrial
	Diverticulum Intestinal
	Dysgeusia
	Dyspepsia
	Dyspnoea
	Eye Haemorrhage
	Fatigue
	Furuncle
	Gastroenteritis
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Headache
	Hepatic Cyst
	Hepatic Steatosis

Hiatus Hernia
Hypercalcaemia
Hypertension
Injury
Intermittent Claudication
Laryngitis
Muscle Spasms
Myocardial Ischaemia
Nausea
Palpitations
Pancreatitis Acute
Peripheral Vascular
Disorder
Pulmonary Calcification
Pulmonary Fibrosis
Rash Macular
Rectal Polyp
Renal Cyst

Dose	Duration	Renal Failure Chronic Rhinitis Allergic Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
		Scar		Vioxx	PS	Merck & Co., Inc	ORAL
213	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Imdur	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Hydrodiuril	C		ORAL
				Toprol Xl Tablets	C		ORAL
				Cardura	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507057-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00855
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adenoidal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Norvasc	C		ORAL		
	Aspartate Aminotransferase Increased		Norvasc	C		ORAL		
			Clonidine	C		ORAL		
			Zantac	C		ORAL		
	Blood Potassium Decreased		Prevacid	C				
UNKNOWN								
	Calculus Urinary							
	Contusion							
	Diarrhoea							
	Haematochezia							
	Headache							
	Hydrocele							
	Hypercalcaemia							
	Inguinal Hernia							
	Lipoma							
	Macroglossia							
	Obstruction							
	Polytraumatism							
	Sleep Apnoea Syndrome							
	Tendon Rupture							
	Testicular Pain							
	Tonsillar Hypertrophy							
	Umbilical Hernia							
	Urine Sodium Increased							
	Varicocele							
	Ventricular Extrasystoles							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507062-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00810
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Haematuria		Zestril	C		ORAL		
	Humerus Fracture		Vicodin Tablets	C				
UNKNOWN								
	Injury		Tiazac	C				
UNKNOWN								
	Normochromic Normocytic Anaemia							
	Oedema Peripheral							
	Spinal Cord Injury Cauda Equina							
	Urinary Tract Infection							

Date:11/22/04ISR Number: 4507063-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00233
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Reversible Ischaemic		Chlorambucil	C				
UNKNOWN								
	Neurological Deficit		Allopurinol	C				
UNKNOWN								
			Valdecoxib	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507065-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01829
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
466 DAY								
Hospitalization -	Cardiac Aneurysm		Aspirin	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Indocin					

	Colonic Polyp		(Indomethacin)	C		
UNKNOWN						
	Diverticulum		Lasix (Furosemide)	C		ORAL
	Emotional Distress		K-Dur	C		ORAL
	Gastric Ulcer					
	Glomerulonephritis					
	Membranous					
	Gout					
	Haemorrhoids					
	Hiatus Hernia					
	Hyperglycaemia					
	Medication Error					
	Nephrolithiasis					
	Oedema Peripheral					
	Pneumonia					
	Renal Cyst					
	Renal Failure					
	Sleep Apnoea Syndrome					
	Urethral Stricture					

Date:11/22/04ISR Number: 4507066-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00483
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
556 DAY						
Hospitalization -	Myocardial Infarction		[Therapy			
Initial or Prolonged			Unspecified]	C		
UNKNOWN						

			Hormones (Unspecified)	C			
UNKNOWN							

Date:11/22/04ISR Number: 4507068-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Coumadin	C				
UNKNOWN								
	Blood Glucose Increased		Risperdal	C				
UNKNOWN								
	Blood Pressure Increased		Prozac	C				
UNKNOWN								
	Cardiomegaly		Elavil	C		ORAL		
	Cerebrovascular Accident		Effexor	C				
UNKNOWN								
	Conjunctivitis Allergic		Effexor	C				
UNKNOWN								
	Convulsion		Glucophage	C				
UNKNOWN								
	Deep Vein Thrombosis							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Dyspnoea							
	Ear Pain							
	Fatigue							
	Headache							
	Hepatic Steatosis							
	Herpes Zoster							
	Hypoglycaemia							
	Impaired Gastric Emptying							
	Injection Site							
	Haemorrhage							
	Lipomatosis							
	Mastoiditis							
	Migraine							
	Pain In Extremity							
	Phlebitis							
	Rash							
	Retinopathy							

Sinusitis
Strabismus
Subcutaneous Abscess
Syncope
Thrombophlebitis
Superficial
Transient Ischaemic
Attack
Urinary Tract Infection
Vaginal Haemorrhage

Date:11/22/04ISR Number: 4507073-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Arthralgia
	Blood Pressure Increased
	Bundle Branch Block Left
	Carotid Artery Stenosis

		Congestive Cardiomyopathy					
		Convulsion					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Limb Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Post Procedural Haematoma		Prevacid	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		ORAL
				Atenolol	C		ORAL
				Atenolol	C		ORAL
				Nitroglycerin	C		
SUBLINGUAL							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		ORAL
				Zantac	C		ORAL
				Plavix	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507074-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00744
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
56 MON							
				Lisinopril	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Gemfibrozil	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Zetia	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507075-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00625
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebral Infarction		Metoprolol Succinate	C				
Disability	Syncope		Pantoprazole Sodium	C			UNKNOWN	
	Transient Ischaemic Attack							

Date:11/22/04ISR Number: 4507076-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02629
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Pneumonia		Vitamins (Unspecified)	C				

Date:11/22/04ISR Number: 4507078-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03129
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Amnesia
	Asthenia
Disability	Back Pain
	Blood Triglycerides Increased

		Cerebrovascular Accident					
		Chest Pain					
		Coma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Percocet	C		
UNKNOWN							
		Dysarthria		Lipitor	C		
UNKNOWN							
		Dyspepsia		Paxil	C		
UNKNOWN							
		Eye Disorder		Naproxen	C		
UNKNOWN							
		Faeces Discoloured		Misoprostol	C		
UNKNOWN							
		Fatigue		Nasonex	C		
UNKNOWN							
		Headache		Mirapex	C		
UNKNOWN							
		Heart Rate Increased		Hydrocodone/Apap	C		
UNKNOWN							
		Hemiparesis		Gemfibrozil	C		
UNKNOWN							
		Hypertension		Dicloxacillin	C		
UNKNOWN							
		Lung Disorder		Fluoxetine	C		
UNKNOWN							
		Meningitis					
		Meningitis Bacterial					
		Nausea					
		Neurological Symptom					
		Oedema Peripheral					
		Optic Nerve Injury					
		Palpitations					
		Paraesthesia					
		Pulmonary Oedema					
		Respiratory Tract Infection					
		Skin Reaction					
		Speech Disorder					
		Stomach Discomfort					
		Tinnitus					
		Transient Ischaemic Attack					
		Ventricular Hypertrophy					

Vertigo
Vision Blurred
Visual Disturbance

Date:11/22/04ISR Number: 4507079-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02219
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Other								

Date:11/22/04ISR Number: 4507080-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02873
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Death		Amitriptyline Hydrochloride	C				UNKNOWN
			Methadone Hydrochloride	C				UNKNOWN
			Oxycodone	C				UNKNOWN
			Ambien	C				UNKNOWN
			Neurontin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507081-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00235
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	1150 DAY	
Hospitalization -	Coronary Artery Disease		Adalimumab	C			UNKNOWN	
Initial or Prolonged	Coronary Artery Stenosis		Methotrexate	C			UNKNOWN	
Disability			Methylprednisolone	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	
			Vasotec	C			UNKNOWN	
			Metoprolol Succinate	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Fluvastatin Sodium	C			UNKNOWN	

Date:11/22/04ISR Number: 4507082-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01745
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	37 MON	
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL	37 MON	
	Atrioventricular Block		Norvasc	C			UNKNOWN	
	Blood Glucose Increased		Hydrochlorothiazide	C			UNKNOWN	
	Blood Potassium Decreased		Plavix	C			UNKNOWN	
	Blood Pressure Increased		Aspirin	C			UNKNOWN	
	Blood Pressure Systolic		Neurontin	C			UNKNOWN	

	Increased		Dilantin	C		
UNKNOWN						
	Bundle Branch Block Right					
	Cerebrovascular Accident					
	Convulsion					
	Migraine					
	Neuropathy Peripheral					
	Restless Legs Syndrome					
	Spinal Column Stenosis					
	Transient Ischaemic					
	Attack					
	Umbilical Hernia					

Date:11/22/04ISR Number: 4507084-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03187
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Failure							
Disability								
Other								

Date:11/22/04ISR Number: 4507085-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00369
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507086-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00214
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507088-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cerebrovascular Accident Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507089-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03378
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 946 DAY Initial or Prolonged UNKNOWN	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Plavix	C				
	Hypertension		Bextra	C				
	Syncope		Vitamins (Unspecified)	C				
	Thrombosis							
	Tremor							

Date:11/22/04ISR Number: 4507090-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Headache		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507092-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00947
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blindness		Celebrex	C				
UNKNOWN								
Initial or Prolonged	Blindness Transient		Plavix	C				
UNKNOWN								
Disability	Blood Pressure Abnormal		[Therapy					
	Blood Pressure Increased		Unspecified]	C				
UNKNOWN								
	Cataract		[Therapy					
	Cerebrovascular Accident		Unspecified]	C				
UNKNOWN								
	Hot Flush		Lotrel	C				
UNKNOWN								
	Psychomotor Hyperactivity		Diovan	C				
UNKNOWN								
	Visual Disturbance							

Date:11/22/04ISR Number: 4507093-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04110
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dizziness							
	Nervousness							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507094-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00404
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507095-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00178
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bisacodyl	C				UNKNOWN
			Acetaminophen And Codeine Phosphate	C				UNKNOWN

Date:11/22/04ISR Number: 4507096-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00030
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	
			Lisinopril	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Furosemide	C				UNKNOWN

Date:11/22/04ISR Number: 4507098-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00381
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1043 DAY						
Hospitalization -						
Initial or Prolonged						

Date:11/22/04ISR Number: 4507099-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00032
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
1473 DAY						
Initial or Prolonged	Myocardial Infarction		Flunitrazepam	C		
UNKNOWN						

Date:11/22/04ISR Number: 4507100-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01699
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
1365 DAY						
Initial or Prolonged	Dyspnoea		Vasotec	C		ORAL
			Metoprolol	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						

Date:11/22/04ISR Number: 4507101-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01738
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Cardiac Failure
Initial or Prolonged	Congestive

		Hypokalaemia					
		Hyponatraemia					
		Metabolic Alkalosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Cardiac Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Pleural Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
				Lasix (Furosemide Sodium)	C		ORAL
				Lopressor	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507103-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01401
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Dyspnoea		Fosamax	C		ORAL
Initial or Prolonged		Malignant Melanoma		Amitriptyline Hydrochloride	C		
		Pneumonia Viral					
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507104-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01469
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Premarin	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Hydrodiuril	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507105-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00954
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		86 DAY
Initial or Prolonged	Dizziness		Metoprolol	C				
UNKNOWN								
	Fall		Zocor	C				
UNKNOWN								
	Infection		Lasix (Furosemide)	C				
UNKNOWN								
	Palpitations		Plavix	C				
UNKNOWN								
	Vestibular Disorder		Actonel	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507107-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00031
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Budesonide	C				
UNKNOWN								
			Terbutaline Sulfate	C				
UNKNOWN								
			Acetaminophen	C				
UNKNOWN								
			Propoxyphene Napsylate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507110-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02324
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507111-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02283
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Glucotrol	C				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Avandia	C				
UNKNOWN								
Disability			Ziac	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507113-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02301
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
Hospitalization -	Hearing Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	30	MON
Initial or Prolonged	Heart Injury							
Disability	Myocardial Infarction							
	Pneumonia							

Date:11/22/04ISR Number: 4507114-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02313
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Verapamil	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507115-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02310
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Zoloft	C				
UNKNOWN								
Initial or Prolonged			Allegra	C				
UNKNOWN								
Disability			Plaquenil	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								
			Topamax	C				
UNKNOWN								
			Amaryl	C				
UNKNOWN								
			Seroquel	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507116-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02304
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prednisone	C				
UNKNOWN								
Initial or Prolonged			Magnesium					
Disability			(Unspecified)	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
RESPIRATORY								

(INHALATION)

Date:11/22/04ISR Number: 4507117-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02290
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Atenolol	C			UNKNOWN	
	Hypercholesterolaemia		Lisinopril	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Crestor	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	

Date:11/22/04ISR Number: 4507119-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02211
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bacterial Infection		Neurontin	C			UNKNOWN	
	Ulcer							

Date:11/22/04ISR Number: 4507120-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02187
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocarditis		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization -								

Initial or Prolonged
Disability
Other

Date:11/22/04ISR Number: 4507121-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02342
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization - Initial or Prolonged	Stage Unspecified		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/22/04ISR Number: 4507122-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02469
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetic Ketoacidosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Heart Rate Increased		Metformin	SS				
	Hyperventilation		Omeprazole	C			UNKNOWN	
	Hypovolaemia		Amitriptyline Hydrochloride	C			UNKNOWN	
	Lactic Acidosis							
	Renal Impairment		Metoprolol	C			UNKNOWN	
	Respiratory Rate Increased							
	Tachypnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507124-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00034
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		361 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		1345 DAY
			Amlodipine Besylate	C				UNKNOWN
			Spironolactone	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Zocor	C				UNKNOWN
			Tramadol Hydrochloride	C				UNKNOWN
			Terbutaline Sulfate	C				UNKNOWN
			Budesonide	C				UNKNOWN
			Acetaminophen	C				UNKNOWN

Date:11/22/04ISR Number: 4507125-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02360
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Thyroid	C				UNKNOWN
Initial or Prolonged			Levothyroxine Sodium	C				UNKNOWN
Disability			Norvasc	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:11/22/04ISR Number: 4507126-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02516
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx Femara	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:11/22/04ISR Number: 4507127-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02523
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged Disability	Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:11/22/04ISR Number: 4507128-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507130-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02347
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Cardiac Death		Vioxx Glucophage [Therapy	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

				Unspecified]	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507131-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Prevacid	C				
UNKNOWN								
Hospitalization - Initial or Prolonged			Tylenol With Codeine #3	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								
			Motrin	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507135-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02598
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Arrest		[Therapy Unspecified]	C				
	Death							
UNKNOWN								

Date:11/22/04ISR Number: 4507136-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02622
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Toprol Xl Tablets	SS		ORAL		
	Drug Interaction							
	Hypertension							
	Tachycardia							

Date:11/22/04ISR Number: 4507140-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02600
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/22/04ISR Number: 4507141-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507142-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02525
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		[Therapy Unspecified]	C				
	Dyspnoea							
	Fluid Retention							
	Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507143-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02623
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diovan	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507144-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02707
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:11/22/04ISR Number: 4507145-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02666
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Occlusion							
Disability	Myocardial Infarction							

Date:11/22/04ISR Number: 4507146-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02377
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Singulair	C		ORAL		

Date:11/22/04ISR Number: 4507147-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colonic Haemorrhage Feeling Abnormal Gastrointestinal Motility Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507148-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02499
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507154-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Atrial Fibrillation		Vioxx Norvasc	PS C	Merck & Co., Inc	ORAL		
UNKNOWN	Procedural Complication		Metoprolol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02756
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507157-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02823
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507159-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02833
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive							
Initial or Prolonged	Cerebrovascular Accident							
Disability								

Date:11/22/04ISR Number: 4507160-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							

Date:11/22/04ISR Number: 4507162-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02830
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged			Fosamax	C			
UNKNOWN							
Other							

Date:11/22/04ISR Number: 4507163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02901
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02944
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Vertigo		Synthroid	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507166-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:11/22/04ISR Number: 4507168-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03001
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Fatigue Heart Rate Irregular Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507169-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02780
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Cerebrovascular Accident Haematocrit Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507170-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507173-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02993
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Premarin	C				
UNKNOWN								
Initial or Prolonged			Glipizide	C				
UNKNOWN								
Other			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507174-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02765
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prozac	C				
UNKNOWN								
Initial or Prolonged			Avandia	C				
UNKNOWN								
Disability			Zocor	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507175-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/22/04ISR Number: 4507176-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ovarian Cyst Ruptured		Wellbutrin	C				
UNKNOWN								
			Nortriptyline	C				
UNKNOWN								
			Endocet	C				
UNKNOWN								
			Naproxen	C				
UNKNOWN								
			Keflex	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507178-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507185-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03035
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507186-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03021
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Arrhythmia Cardiac Disorder Cardiac Failure Congestive		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507187-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507189-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507190-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03089
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507191-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03027
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ulcer Haemorrhage		Lorazepan	C				
UNKNOWN								
Initial or Prolonged			Isorbid	C				
UNKNOWN								
Disability								

Date:11/22/04ISR Number: 4507192-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03022
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Neuroton	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								
			Ventolin (Albuterol)	C				
UNKNOWN								

Date:11/22/04ISR Number: 4507193-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507194-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03002
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertension		Soma	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507195-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03080
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							
	Unevaluable Event							

Date:11/22/04ISR Number: 4507197-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02839
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:11/22/04ISR Number: 4507202-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00816
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Abdominal Pain Upper
Disability	Aortic Atherosclerosis
Other	Arthralgia
	Back Pain
	Blood Cholesterol Increased
	Cardiomegaly
	Chromaturia
	Dry Mouth
	Fatigue
	Fluid Retention
	Gastrooesophageal Reflux Disease
	Haemarthrosis
	Haematocrit Decreased
	Haemoglobin Decreased
	Haemorrhoidal Haemorrhage
	Hepatic Steatosis
	Hiatus Hernia
	Hypersensitivity

Hypertension
Hypoaesthesia
Injury
Joint Effusion
Lung Disorder
Migraine
Mitral Valve Incompetence
Myalgia
Nausea
Oedema Peripheral
Osteoarthritis
Pain In Extremity
Road Traffic Accident
Thrombophlebitis
Superficial
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection

		Urine Odour Abnormal					
		Ventricular Dysfunction					
		Ventricular Hypertrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL
		Wound		Tenormin	C		
UNKNOWN							
		Wound Dehiscence		Premarin	C		
UNKNOWN	9872 DAY						
				[Therapy Unspecified]	C		
UNKNOWN	10 YR						
				Prinivil	C		ORAL
1285 DAY							
				Prinivil	C		ORAL
217 DAY							
				Prinivil	C		ORAL
				Prilosec	C		
UNKNOWN							
				Endocet	C		
UNKNOWN							
				Vancenase	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Methocarbamol	C		
UNKNOWN							

Date:11/22/04ISR Number: 4507207-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02433
Age:82 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Death		Vitamins			
Other		Decreased Appetite		(Unspecified)	C		
UNKNOWN							
		Eczema					
		Gastrointestinal Disorder					
		Hypertension					

Kyphosis
Non-Small Cell Lung
Cancer Metastatic
Rhinitis Allergic
Sciatica

Date:11/22/04ISR Number: 4507209-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03006
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/22/04ISR Number: 4507210-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00512
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Initial or Prolonged	Adverse Event		Synthroid	C			UNKNOWN	
	Chest Pain		Allopurinol	C			UNKNOWN	
	Feeling Abnormal							
	Fluid Retention							
	Pain In Extremity							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4507211-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02800
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Ativan	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/22/04ISR Number: 4507214-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02289
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Full Blood Count		Vioxx	PS	Merck & Co., Inc	ORAL		
3 DAY								
Initial or Prolonged	Decreased							
	Rectal Haemorrhage							

Date:11/22/04ISR Number: 4507221-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/22/04ISR Number: 4507229-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02836
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Alupent	C				
UNKNOWN								

Date:11/22/04ISR Number: 4508885-5Report Type:Direct Company Report #CTU 232700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg Merck	PS	Merck	ORAL	25MG QD	
Hospitalization - ORAL Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage								

Date:11/22/04ISR Number: 4508979-4Report Type:Direct Company Report #CTU 232604
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Chest Pain Condition Aggravated		Vioxx 25 Mg Merck	PS	Merck			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/22/04ISR Number: 4509021-1Report Type:Direct Company Report #CTU 232551
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx 50 Mg 2x	PS				
	Back Pain							
	Chest Pain							
	Dizziness							
	Dyspnoea							

Date:11/22/04ISR Number: 4509023-5Report Type:Direct Company Report #CTU 232553
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Amnesia		Vioxx	PS			DAILY 25 MG	
	Cerebrovascular Accident							
	Dysarthria							
	Myocardial Infarction							

Date:11/22/04ISR Number: 4511207-7Report Type:Direct Company Report #CTU 232761
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activities Of Daily		Vioxx 50 Mg Merck	PS	Merck	ORAL	1 TAB DAILY	
Hospitalization - Initial or Prolonged	Living Impaired						ORAL	
Disability	Anxiety							
	Arrhythmia							
	Atrial Fibrillation							
	Blood Pressure Decreased							
	Bundle Branch Block Left							
	Cardiac Disorder							
	Cerebrovascular Accident							
	Cystitis							
	Depressed Level Of Consciousness							
	Ejection Fraction Decreased							

Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Hyperhidrosis
Hypertension
Myocardial Infarction
Pallor
Prostate Infection
Shock

Date:11/22/04ISR Number: 4511211-9Report Type:Direct Company Report #CTU 232749
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Bextra 10 Mg Pfizer	PS	Pfizer		1 A DAY	
			Vioxx 25 Mg Merck	SS	Merck		1 A DAY	
			Enalapril	C				
			Atonolol	C				
			Afeditab	C				

				Zocor	C		
				Metforman	C		

Date:11/22/04ISR Number: 4511237-5Report Type:Direct Company Report #CTU 232745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg	PS			DAILY	
			Lipitor	C				
			Centrum Vitamin	C				

Date:11/23/04ISR Number: 4507872-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00031
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthralgia		Premarin	C				
	Arthropathy		Norvasc	C				
	Atrial Fibrillation		Nexium	C				
	Deep Vein Thrombosis							
	Hyperlipidaemia							
	Hypertension							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							

Date:11/23/04ISR Number: 4507875-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00562
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	16	DAY

Other	Hypertension	Vioxx	SS	Merck & Co., Inc	ORAL
16 DAY					
	Oedema	Teveten (Eprosartan)	C		ORAL
		Maxzide	C		ORAL
		[Therapy Unspecified]	C		ORAL

Date:11/23/04ISR Number: 4507876-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00793
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Disability	Aortic Valve Incompetence
	Arthralgia
	Diastolic Dysfunction
	Diverticulum
	Dizziness
	Dyspepsia
	Dyspnoea
	Epigastric Discomfort
	Herpes Zoster
	Hypertonic Bladder
	Insomnia
	Intervertebral Disc

		Degeneration					
		Medication Error					
		Mitral Valve Incompetence					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Urticaria Papular		Vioxx	SS	Merck & Co., Inc	ORAL
61	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
136	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Lortab	SS		ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
61	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
136	DAY						
				Ambien	C		ORAL
				Ambien	C		ORAL
				Aspirin	C		
UNKNOWN							
				Norvasc	C		ORAL
				Detrol	C		ORAL
				Cardizem	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							

Date:11/23/04ISR Number: 4507883-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00402
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					

Myocardial Infarction

Date:11/23/04ISR Number: 4507884-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03775
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zoloft	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507885-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02763
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Gastrointestinal		Lipitor	C				
UNKNOWN								
Other	Haemorrhage		Lexapro	C				
UNKNOWN								
	Hyperhidrosis		Lisinopril	C				
UNKNOWN								
	Hypotension		Actonel	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507886-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03337
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Inadequate Control							
	Infection							
	Joint Sprain							
	Oedema Peripheral							
	Overdose							
	Toe Amputation							
	Treatment Noncompliance							

Date:11/23/04ISR Number: 4507887-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02895
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Trazodone					
	Skin Discolouration		Hydrochloride	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507888-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00403
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Oedema							

Date:11/23/04ISR Number: 4507889-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00039
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
969 DAY								

Initial or Prolonged	Heart Injury	Vioxx	SS	Merck & Co., Inc	ORAL
969 DAY					
Disability	Myocardial Infarction	Vioxx	SS	Merck & Co., Inc	ORAL
969 DAY					
		Vioxx	SS	Merck & Co., Inc	ORAL
969 DAY					
		Lipitor	C		
UNKNOWN					
		Toprol Xl Tablets	C		
UNKNOWN					
		Zoloft	C		
UNKNOWN					
		Lisinopril	C		
UNKNOWN					
		Plavix	C		
UNKNOWN					
		Tricor	C		
UNKNOWN					
		Aspirin	C		
UNKNOWN					

Date:11/23/04ISR Number: 4507890-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Carotid Artery Stenosis
Other	Embolism
	Haematoma
	Hypertension
	Injury
	Ischaemia
	Laceration
	Polytraumatism

		Retinal Vascular Thrombosis					
		Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Skin Laceration		Accupril	C		
UNKNOWN	2373 DAY						
		Tracheal Disorder		Lipitor	C		
UNKNOWN	2371 DAY						
		Transient Ischaemic Attack		Hydrochlorothiazide Tablets (Usp 23)	C		
UNKNOWN							
				Sodium Folate	C		
UNKNOWN							

Date:11/23/04ISR Number: 4507921-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02173
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Pain		Lotrel	C		
UNKNOWN						
	Swelling					

Date:11/23/04ISR Number: 4507922-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Death					
	Unevaluable Event					

Date:11/23/04ISR Number: 4507924-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/23/04ISR Number: 4507925-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507926-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02706
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507928-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02705
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507929-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02542
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507930-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02743
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Multiple Myeloma		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Pravacol	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507932-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02334
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Maxzide	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507933-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diarrhoea							
Disability	Myocardial Infarction							

Date:11/23/04ISR Number: 4507934-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02748
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dizziness							
Disability								

Date:11/23/04ISR Number: 4507936-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02752
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507942-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02520
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Estratest	C				
UNKNOWN								
			Verapamil Msd Lp	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								
			Hyzaar	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507943-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02121
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								
Other								

Date:11/23/04ISR Number: 4507944-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02629
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Diltiazem Hydrochloride	C				
UNKNOWN								
			Cartia Xt	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507946-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03372
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
	Haematochezia		Synthroid	C			UNKNOWN	
	Haemorrhoids		Clonidine	C			UNKNOWN	
	Helicobacter Infection		Nexium	C			UNKNOWN	
	Rectal Haemorrhage		Ventolin (Albuterol)	C			UNKNOWN	
	Thyroid Neoplasm		[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	
			Cardizem La	C			UNKNOWN	

Date:11/23/04ISR Number: 4507947-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02245
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colon Cancer Haemorrhoids		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507948-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507949-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02496
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507950-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507952-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02704
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4507957-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02877
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Acute Myocardial Infarction Arrhythmia Coronary Artery Atherosclerosis Hypertensive Heart Disease		Vioxx	PS	Merck & Co., Inc	ORAL

4 DAY

Date:11/23/04ISR Number: 4507958-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02883
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Dose Duration

Date:11/23/04ISR Number: 4507959-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Dose Duration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507960-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02998
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Paxil	C				
UNKNOWN								
	Dyspnoea							
	Laboratory Test Abnormal							
	Paraesthesia							

Date:11/23/04ISR Number: 4507963-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03145
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Fosamax	C				
UNKNOWN								
Initial or Prolonged	Movement Disorder		Lipitor	C				
UNKNOWN								
Disability	Visual Disturbance							

Date:11/23/04ISR Number: 4507966-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:11/23/04ISR Number: 4507967-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer Haemorrhage							

Date:11/23/04ISR Number: 4507969-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	573 DAY	
Hospitalization -	Thrombosis		Warfarin	C			UNKNOWN	
Initial or Prolonged			Prednisone	C			UNKNOWN	
			Quinine	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Celexa	C			UNKNOWN	
			Remeron	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Ferrous Gluconate	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	

Date:11/23/04ISR Number: 4507970-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03098
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	117 DAY	
Initial or Prolonged	Eye Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1642 DAY	
Disability	Micturition Urgency							
Other	Visual Acuity Reduced							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4507996-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03036
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Fall Heart Rate Increased		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:11/23/04ISR Number: 4507997-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03243
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Indocin (Indomethacin)	C				
UNKNOWN								

Date:11/23/04ISR Number: 4507998-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03144
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:11/23/04ISR Number: 4508011-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02411
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Asthenia Cerebrovascular Accident Dyspnoea Haemorrhage Oedema Peripheral Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509203-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Adverse Event
Other	Angina Unstable
	Anxiety
	Aortic Aneurysm
	Atherosclerosis
	Atrial Fibrillation
	Atrial Hypertrophy
	Back Pain
	Blood Potassium Decreased
	Blood Pressure Decreased
	Blood Triglycerides
	Increased
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cardiac Valve Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cardiomegaly					
		Cerebellar Infarction					
		Cerebral Infarction					
		Cholelithiasis		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Prinivil	C		ORAL
		Disseminated		Atenolol	C		
UNKNOWN							
		Intravascular Coagulation		[Therapy			
		Diverticulum		Unspecified]	C		
UNKNOWN							
		Dizziness		Aspirin	C		
UNKNOWN							
		Embolic Stroke		Plavix	C		
UNKNOWN							
		Encephalopathy		Zocor	C		
UNKNOWN							
		Endocarditis		Celebrex	C		
UNKNOWN							
		Feeling Hot					
		Haematuria					
		Haemorrhage					
		Hepatic Cyst					
		High Density Lipoprotein					
		Decreased					
		Hypertension					
		Infection					
		International Normalised					
		Ratio Decreased					
		Ischaemic Cardiomyopathy					
		Low Density Lipoprotein					
		Increased					
		Myocardial Infarction					
		Nephrosclerosis					
		Oedema Peripheral					
		Prostate Cancer					
		Prothrombin Time					
		Shortened					
		Renal Mass					
		Sinus Bradycardia					
		Sinus Tachycardia					
		Splenic Infarction					
		Stress					
		Supraventricular					
		Extrasystoles					
		Syncope					
		Ventricular Tachycardia					

Vision Blurred

Date:11/23/04ISR Number: 4509208-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02059
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acanthosis
Other	Actinic Keratosis
	Asthenia
	Blood Disorder
	Blood Glucose Decreased
	Blood Sodium Decreased
	Cardiac Failure Chronic
	Cardiomyopathy
	Constipation
	Dizziness
	Dysplasia
	Eczema
	Fall

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Gastric Disorder					
		Gastrointestinal Disorder					
		Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Coumadin	C		
UNKNOWN							
		Hypertension		Coumadin	C		
UNKNOWN							
		Injury		Augmentin	C		
UNKNOWN							
		Lumbar Spinal Stenosis		Clonazepam	C		
UNKNOWN							
		Lung Infiltration		Aciphex	C		
UNKNOWN							
		Myocardial Infarction		Zestril	C		
UNKNOWN							
		Myocardial Ischaemia		Diabeta	C		ORAL
		Nausea		Tylenol With Codeine	C		
UNKNOWN							
		Pneumonia		Reglan	C		
UNKNOWN							
		Psoriasis		Ranitidine	C		ORAL
		Rosacea		Vitamin E	C		
UNKNOWN							
		Sick Sinus Syndrome		Triamterene	C		
UNKNOWN							
		Skin Infection		Levobunolol Hydrochloride	C		
		Sleep Disorder					
OPHTHALMIC							
		Squamous Cell Carcinoma		Domeboro	C		
AURICULAR							
(OTIC)							
				Amoxicillin	C		
UNKNOWN							
				Lactulose	C		
UNKNOWN							
				Lotrisone	C		
UNKNOWN							
				Triamcinolone	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:11/23/04ISR Number: 4509212-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00737
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509223-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00448
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged Disability	Blood Potassium Decreased Gastrointestinal Disorder		Hyzaar	C		ORAL		
Other	Hypertension Therapy Non-Responder Vomiting		Calcium (Unspecified) And Vitamin D (Unspecified)	C				
UNKNOWN			Premphase	C		ORAL		

Date:11/23/04ISR Number: 4509224-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00829
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event Back Pain Carpal Tunnel Syndrome Nausea Neck Pain Rotator Cuff Syndrome

Tendon Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Darvocet-N	C			UNKNOWN	
	Skelaxin	C			UNKNOWN	
	Fioricet Tablets	C			UNKNOWN	
	Hydrocodone Bitartrate	C			UNKNOWN	

Date:11/23/04ISR Number: 4509225-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00016
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		966 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		966 DAY
			Metformin	C			UNKNOWN	
			Rosiglitazone Maleate	C			UNKNOWN	

Date:11/23/04ISR Number: 4509226-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00060
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Aspirin Lysine	SS		ORAL		
			Fenofibrate	C		ORAL		
			Atenolol	C		ORAL		

Amlodipine Besylate	C			ORAL
Hydrochlorothiazide And Irbesartan	C			ORAL

Date:11/23/04ISR Number: 4509227-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00062481
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Lasix	C				
UNKNOWN								
Disability	Fluid Retention		Lotensin	C				
UNKNOWN								
	Oedema Peripheral		Coreg	C				
UNKNOWN								
	Swelling Face		Aldactone	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Lanoxin	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509228-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Atrial Fibrillation
Other	Blood Parathyroid Hormone

		Increased					
		Cardiac Murmur					
		Chest Pain					
		Colonic Polyp	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
59	DAY						
		Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Eye Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Furuncle		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Hypercalcaemia		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis		Imdur	C		
UNKNOWN							
		Muscle Spasms		Monopril	C		
UNKNOWN							
		Myocardial Ischaemia		Lipitor	C		
UNKNOWN							
		Nausea		Glucotrol	C		
UNKNOWN							
		Palpitations		Hydrodiuril	C		ORAL
		Pancreatitis Acute		Hydrodiuril	C		ORAL
		Peripheral Vascular		Toprol Xl Tablets	C		ORAL
		Disorder		Cardura	C		
UNKNOWN							
		Polytraumatism					
		Rash Macular					
		Renal Cyst					
		Renal Failure Chronic					

Rhinitis Allergic
Rotator Cuff Syndrome
Sinusitis
Sleep Apnoea Syndrome

Date:11/23/04ISR Number: 4509233-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0405FRA00006
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage							

Date:11/23/04ISR Number: 4509234-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Venous Thrombosis Limb		Prednisone	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Heparin	C		PARENTERAL	24	DAY
			Amikacin Sulfate	C		ORAL		
			Ibuprofen	C		ORAL	23	DAY
			Gabapentin	C		ORAL		
			Esomeprazole Magnesium	C		ORAL	185	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509237-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Zydone	C				
UNKNOWN								
	Convulsion		Prozac	C		ORAL		
	Coronary Artery Disease		Prilosec	C		ORAL		
	Coronary Artery Stenosis		Elavil	C				
UNKNOWN								
	Depression		Zanaflex	C		ORAL		
	Hypertension		Aleve	C				
UNKNOWN								
	Joint Dislocation							
	Lumbar Radiculopathy							
	Mental Status Changes							
	Myocardial Infarction							
	Narcotic Intoxication							
	Overdose							
	Pulmonary Oedema							
	Renal Failure Chronic							
	Somnolence							
	Spinal Osteoarthritis							
	Stent Occlusion							
	Urinary Tract Disorder							

Date:11/23/04ISR Number: 4509240-4Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00002
Age:29 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
3	DAY							

Date:11/23/04ISR Number: 4509242-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00072
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypothyroidism		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Rash Papular	Doxazosin Mesylate	SS	ORAL
		Acetaminophen And Tramadol Hydrochloride	SS	ORAL
		Hydroxyzine Hydrochloride	SS	ORAL
		Amiodarone	SS	
INTRAVENOUS				
		Betahistine Hydrochloride	SS	ORAL
		Fosinopril Sodium	C	ORAL
		Clonidine Hydrochloride	C	ORAL
		Amlodipine Besylate	C	ORAL
		Pravastatin Sodium	C	ORAL
		Loprazolam Mesylate	C	ORAL
		Acenocoumarol	C	ORAL
		Potassium Chloride	C	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509243-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02972
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Hospitalization -	Headache		Aspirin	C				
Initial or Prolonged	Nausea		Ultram	C				
	Rash							
	Stomach Discomfort							
	Transient Ischaemic Attack							
	Weight Decreased							

Date:11/23/04ISR Number: 4509244-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00133
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Palpitations		Budesonide	C				
	Transient Ischaemic Attack							

Date:11/23/04ISR Number: 4509246-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00174
Age:35 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

Date:11/23/04ISR Number: 4509247-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00071
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Leukopenia		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
Hospitalization - Initial or Prolonged	Neutropenia		Tramadol Hydrochloride	C		ORAL	41 DAY	
			Ketoprofen	C		ORAL		
			Ketoprofen	C		ORAL		
			Tetrazepam	C		ORAL		
			Lansoprazole	C				

Date:11/23/04ISR Number: 4509248-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00192
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509249-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01076
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509250-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01477
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Flovent	C				
UNKNOWN								
Initial or Prolonged	Diaphragmatic Disorder		Vitamins					
Disability	Dyspnoea		(Unspecified)	C				
UNKNOWN								
	Ejection Fraction		Pancrease					
	Abnormal		(Pancreatin)	C		ORAL		
	Fatigue		Levsinex Timecaps	C				
UNKNOWN								
	Heart Alternation		Serevent	C				
UNKNOWN								
	Myocardial Infarction							

Date:11/23/04ISR Number: 4509251-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00099
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchopneumonia		Vioxx	PS	Merck & Co., Inc	ORAL		
1406 DAY								
Hospitalization -	Cerebrovascular Accident		Phenobarbital	C				
UNKNOWN								
Initial or Prolonged	Multi-Organ Failure		[Therapy					
	Renal Disorder		Unspecified]	C				
UNKNOWN								
	Renal Failure Chronic							
	Septic Shock							

Date:11/23/04ISR Number: 4509253-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00246
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
18 DAY								
Initial or Prolonged	Oedema Peripheral		Celebrex	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509254-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04179
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Synthroid	C				
UNKNOWN								
Disability	Aortic Valve Incompetence							
	Atrial Fibrillation							
	Bursitis							
	Cardiac Output Decreased							
	Cardiomegaly							
	Coronary Artery Disease							
	Dilatation Atrial							
	Dilatation Ventricular							
	Insomnia							
	Mitral Valve Incompetence							
	Pericardial Effusion							
	Pleural Effusion							
	Rales							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509255-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03735
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Levoxyl	C				
UNKNOWN								
Disability			Diovan	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509256-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00857
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chills		Cardizem	C				
UNKNOWN								
	Coronary Artery		Toprol Xl Tablets	C				
UNKNOWN								
	Atherosclerosis		Zestril	C				
UNKNOWN								
	Cough		Zocor	C				
UNKNOWN								
	Dizziness		Soma	C				
UNKNOWN								
	Dyspnoea Exertional		Calcium					
	Fluid Retention		(Unspecified)	C				
UNKNOWN								
	Gingival Disorder							
	Headache							
	Hearing Impaired							
	Loss Of Consciousness							
	Lymphadenopathy							
	Musculoskeletal Chest							
	Pain							
	Musculoskeletal							
	Discomfort							
	Pyrexia							
	Rhinorrhoea							
	Sweat Gland Disorder							
	Tooth Disorder							
	Visual Disturbance							

Weight Increased

Date:11/23/04ISR Number: 4509261-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00461
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON	
Hospitalization -			Prednisone	C				
Initial or Prolonged			Insulin	C				
			Diuretic (Unspecified)	C				
			Digoxin	C				
			Methotrexate	C				
			Hydrochlorothiazide	C				
			Coreg	C				
			Plaquenil	C				
			Zoloft	C				
			Lipitor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509262-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01738
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypokalaemia		Lasix (Furosemide					
	Hyponatraemia		Sodium)	C		ORAL		
	Metabolic Alkalosis		Lopressor	C				
UNKNOWN								
	Non-Cardiac Chest Pain		Pravachol	C				
UNKNOWN								
	Pleural Effusion		Coumadin	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509266-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02427
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509267-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00306
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Excedrin P.M.	C		ORAL		
Disability	Coronary Artery Stenosis		Ibuprofen	C				
UNKNOWN								

Cortizone-5	C	UNKNOWN
Darvon	C	UNKNOWN
Prinzide	C	UNKNOWN
Advil	C	UNKNOWN

Date:11/23/04ISR Number: 4509268-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00180
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509269-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02319
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebral Disorder Cerebrovascular Accident Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509270-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02529
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Lorazepam	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:11/23/04ISR Number: 4509272-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02531
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	336 DAY
	Heart Rate Irregular		Paxil	C			UNKNOWN	
	Suicide Attempt							

Date:11/23/04ISR Number: 4509273-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02515
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Tamoxifen Citrate	C			UNKNOWN	
			Femara	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Hyzaar	C			UNKNOWN	

				Xanax	C		
UNKNOWN							

Date:11/23/04ISR Number: 4509274-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509276-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02768
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509277-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02662
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypothyroidism		[Therapy Unspecified]	C				
UNKNOWN	Poor Peripheral Circulation		Cardizem	C				
UNKNOWN			Lipitor	C				
UNKNOWN			Protonix	C				
UNKNOWN			Levothyroxine Sodium	C				
UNKNOWN			Allegra	C				
UNKNOWN			Ultracet	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509278-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02616
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Atenolol	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Ultram	C			UNKNOWN	

Date:11/23/04ISR Number: 4509279-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02744
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Toprol Xl Tablets	C			UNKNOWN	
Initial or Prolonged	Cerebrovascular Accident		Plavix	C			UNKNOWN	
			Atacand	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Ditropan	C			UNKNOWN	
			Reminyl	C			UNKNOWN	
			Crestor	C			UNKNOWN	
			Singulair	C		ORAL		
			Glucovance	C			UNKNOWN	

Date:11/23/04ISR Number: 4509287-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03030
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Chest Pain		Enbrel	C				
Initial or Prolonged UNKNOWN			Synthroid	C				
Disability								

Date:11/23/04ISR Number: 4509288-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02579
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Decreased Appetite							
	Myocardial Infarction							
	Weight Decreased							

Date:11/23/04ISR Number: 4509289-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02777
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02848
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:11/23/04ISR Number: 4509292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02952
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL	480 DAY	

Date:11/23/04ISR Number: 4509294-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02773
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	2 MON	
	Myocardial Infarction							

Date:11/23/04ISR Number: 4509296-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02866
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia							
	Cardiac Failure							
	Difficulty In Walking							

Date:11/23/04ISR Number: 4509297-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02849
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged								

Date:11/23/04ISR Number: 4509298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02654
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Paxil	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509300-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03171
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509302-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03097
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Effexor	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Entex	C			UNKNOWN	

Date:11/23/04ISR Number: 4509303-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03031
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON	
	Haemorrhage		Accupril	C			UNKNOWN	
	Fall		Synthroid	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Evista	C			UNKNOWN	

Date:11/23/04ISR Number: 4509304-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02845
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL	1980 DAY	
Disability	Erythema		Vioxx	SS	Merck & Co., Inc	ORAL		

	Immune System Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
1980 DAY						
	Oral Mucosal Eruption		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain		Prednisone	C		
UNKNOWN						
	Swelling		[Therapy			
	Tooth Extraction		Unspecified]	C		
UNKNOWN						

Date:11/23/04ISR Number: 4509306-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dyspnoea		Depakote	C		
UNKNOWN						
Initial or Prolonged	Pain In Extremity		Ibuprofen	C		
UNKNOWN						
Disability						

Date:11/23/04ISR Number: 4509308-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03148
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY						

Date:11/23/04ISR Number: 4509309-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03161
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident					
Initial or Prolonged						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509310-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03150
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Brain Neoplasm Cerebrovascular Accident Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509319-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509321-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03049
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509322-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03186
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509324-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03251
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

	Difficulty In Walking		Aspirin	C		
UNKNOWN						
	Hypoxia		Lipitor	C		
UNKNOWN						
	Vertigo		Fish Oil (Unspecified)	C		
UNKNOWN						
			Ascorbic Acid	C		
UNKNOWN						

Date:11/23/04ISR Number: 4509325-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00078
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Adenoma		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Aspirin	C		ORAL		
	Disease		Aspirin	C		ORAL		
	Hiatus Hernia		Magnesium (Unspecified)	C				
	Melaena							
UNKNOWN								
	Metaplasia		Deanol Tartrate And Ginseng And Minerals (Unspecified) And Rutin And Vitamins (Unspecified)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509327-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization -			Coumadin	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/23/04ISR Number: 4509328-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03194
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea		Zocor	C		ORAL		
	Vertigo		Levoxyl	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509330-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03244
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Injury							
Initial or Prolonged	Hepatocellular Damage							
Disability	Renal Disorder							

Date:11/23/04ISR Number: 4509331-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03240
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eye Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eye Swelling		Hydrocodone					

	Ocular Vascular Disorder		Bitartrate	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Triamterene	C		
UNKNOWN						
			Humulin 70/30	C		
UNKNOWN						

Date:11/23/04ISR Number: 4509333-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03201
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ulcer Haemorrhage		Effexor	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:11/23/04ISR Number: 4509334-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03249
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Injury		Nexium	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								

Levoxyl	C	UNKNOWN
Mobic	C	UNKNOWN
Cardis	C	UNKNOWN
Clarinex	C	UNKNOWN
Primidone	C	UNKNOWN
Folgard	C	UNKNOWN
Lexapro	C	UNKNOWN

Date:11/23/04ISR Number: 4509335-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03157
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mitral Valve Prolapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Skin Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stomatitis							

Date:11/23/04ISR Number: 4509337-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03205
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cholelithiasis		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Pancreatic Haemorrhage		Coumadin	C				
UNKNOWN								
Disability			Lasix (Furosemide)	C				
UNKNOWN								
Other								

Date:11/23/04ISR Number: 4509338-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03250
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Increased		[Therapy					
Initial or Prolonged	Thrombosis		Unspecified]	C				
UNKNOWN								
Disability								

Date:11/23/04ISR Number: 4509339-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03202
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Neurontin	C				
UNKNOWN								
Initial or Prolonged			Furosemide	C				
UNKNOWN								
Disability			Celexa	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509341-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03268
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509342-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03260
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Avapro	C				
UNKNOWN								
Initial or Prolonged			Glucotrol	C				
UNKNOWN								
Disability			Prevacid	C				
UNKNOWN								
			Actos	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509343-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4509345-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03264
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Confusional State		Levoxyl	C				
UNKNOWN								
	Flushing							
	Headache							
	Nervousness							
	Sensation Of Heaviness							

Date:11/23/04ISR Number: 4509346-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03261
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -			Lipitor	C			
UNKNOWN							
Initial or Prolonged			Prevacid	C			
UNKNOWN							
Disability			Elavil	C			
UNKNOWN							
			Darvocet-N	C			
UNKNOWN							

Date:11/23/04ISR Number: 4509347-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03298
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
240 DAY								
Life-Threatening	Death		Oxycodone	C				
UNKNOWN								
Hospitalization -			Lortab	C				
UNKNOWN								
Initial or Prolonged			Flomax (Tamsulosin Hydrochloride)	C				
UNKNOWN								

Date:11/23/04ISR Number: 4509348-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03308
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peripheral Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lopressor	C				
UNKNOWN								
			Cilostazol	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Mobic	C				
UNKNOWN								
			Verapamil	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/23/04ISR Number: 4509367-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Aphasia Cardio-Respiratory Arrest Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/23/04ISR Number: 4512091-8Report Type:Expedited (15-DaCompany Report #2004091215
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Upper Aphasia Cerebrovascular Accident Coronary Artery Occlusion Dyspepsia Haematochezia Muscle Spasms Pharmaceutical Product Complaint Treatment Noncompliance	Consumer	Lipitor (Atorvastatin)	PS				
			Neurontin (Gabapentin)	SS		ORAL	2400 MG (400 MG, 2 IN 1 D), ORAL	
			Gabapentin (Gabapentin)	SS		ORAL	1600 MG (400 MG, 2 IN 1 D), ORAL	
			Rofexoxib (Rofecoxib)	SS				
			Simvastatin (Simvastatin)	SS				
			Minoxidil (Minoxidil)	C				

Date:11/23/04ISR Number: 4512221-8Report Type:Expedited (15-DaCompany Report #2004094530
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Atrioventricular Block	Foreign	Amlor (Amlodipine)	PS	ORAL
(1 D), ORAL					
Hospitalization -	Complete	Health	Acebutolol		
Initial or Prolonged	Diarrhoea	Professional	Hydrochloride		
Other	Hyperkalaemia		(Acebutolol		
	Hypothyroidism		Hydrochloride)	SS	ORAL
400 MG (400					
	Metabolic Acidosis				
MG, 1 IN 1					
	Syncope				
D), ORAL					
			Rofecoxib		
			(Rofecoxib)	SS	ORAL
ORAL					
			Aldactazine		
			(Altizide,		
			Spironolactone)	C	
			Glibenclamide		
			(Glibenclamide)	C	

Date:11/23/04ISR Number: 4512420-5Report Type:Expedited (15-DaCompany Report #WAES 0306USA00867
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Cardiac Failure
	Congestive
	Dyspnoea
	Hypertension
	Hypoxia

	Injury Meniscus Lesion Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rotator Cuff Syndrome	Consumer	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO
	Sinus Bradycardia	Health	Tab Vioxx	SS		ORAL	25
	Therapeutic Response	Professional					MG/DAILY/PO
	Decreased						

Date:11/23/04ISR Number: 4512424-2Report Type:Expedited (15-DaCompany Report #WAES 0411ITA00005
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arrhythmia	Foreign	Tab Vioxx 25 Mg	PS		ORAL	PO
Initial or Prolonged	Chest Pain	Study	Zocor	C			
	Syncope	Health	Aspirin	C			
		Professional	Atenolol	C			
			Eicosapentaenoic Acid	C			
			Ramipril	C			

Date:11/23/04ISR Number: 4512425-4Report Type:Expedited (15-DaCompany Report #WAES 0410SWE00020
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris	Foreign	Tab Vioxx 25mg	PS		ORAL	25
Initial or Prolonged	Chest Pain	Study					MG/DAILY/PO
		Health Professional					

Date:11/23/04ISR Number: 4512896-3Report Type:Direct Company Report #CTU 232913
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking		Vioxx - Merck + Co	PS	Merck + Co		1 TABLET DAILY - TWICE WEEKLY	2 YR
Required Intervention to Prevent Permanent Impairment/Damage								

Date:11/23/04ISR Number: 4527747-0Report Type:Periodic Company Report #2003033444
Age: Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Symptom
	Arthralgia
	Back Pain
	Blood Triglycerides Increased
	Condition Aggravated
	Constipation
	Drug Ineffective
	Dysuria
	Gastrooesophageal Reflux Disease
	Low Density Lipoprotein Increased
	Myalgia

		Myoglobinuria					
		Nausea					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity	Consumer	Lipitor			
		Rhabdomyolysis		(Atorvastatin)	PS		
10 MG							
		Stomach Discomfort		Rofecoxib			
		Vomiting		(Rofecoxib)	SS		
				Hydrocodone			
				(Hydrocodone)	SS		
				Vicodin (Hydrocodone			
				Bitartrate,			
				Paracetamol)	SS		
				Aporex			
				(Dextropropoxyphene			
				Hydrochloride,			
				Paracetamol)	SS		
				Tizanidine			
				Hydrochloride			
				(Tizanidine			
				Hydrochloride)	C		
				Ondansetron			
				Hydrochloride			
				(Ondansetron			
				Hydrochloride)	C		
				Bupropion			
				Hydrochloride			
				(Bupropion			
				Hydrochloride)	C		
				Sertraline			
				Hydrochloride			
				(Sertraline			
				Hydrochloride)	C		
				Ibuprofen			
				(Ibuprofen)	C		
				Diazepam (Diazepam)	C		

Date:11/24/04ISR Number: 4510167-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02513
Age:65 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL

	Norvasc	C
UNKNOWN		
	Accupril	C
UNKNOWN		
	[Composition Unspecified]	C
UNKNOWN		

Date:11/24/04ISR Number: 4510168-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Alveolitis Fibrosing
Other	Anxiety
	Arthralgia
	Arthropathy
	Bronchitis
	Bursitis
	Cardiac Failure

		Congestive Carotid Artery Disease Carpal Tunnel Syndrome Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive Pulmonary Disease Cognitive Disorder Collagen-Vascular Disease Depression Dermatomyositis Diarrhoea Diverticulum Dizziness Drug Eruption Dysphasia Dyspnoea Fibromyalgia Gastritis Gastrointestinal Motility Disorder Gastrooesophageal Reflux Disease Haemoptysis Haemorrhoids Hypersensitivity Hypertension Insomnia Interstitial Lung Disease Irritable Bowel Syndrome Malaise Memory Impairment Muscle Spasms Musculoskeletal Stiffness Neuropathy Peripheral Obsessive-Compulsive Disorder Obstructive Airways Disorder Oesophageal Candidiasis Pain Pain In Extremity Paraesthesia Polymyositis Pulmonary Fibrosis Pulmonary Oedema Rash Rash Macular	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Rash Pruritic
Rheumatoid Arthritis
Tendon Injury
Vision Blurred
Visual Field Defect
Weight Decreased

Date:11/24/04ISR Number: 4510191-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03729
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510192-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Body Temperature Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Body Temperature Increased							
	Central Nervous System Enteroviral Infection							
	Cold Sweat							
	Csf Test Abnormal							
	Dehydration							
	Dizziness							
	Drug Hypersensitivity							
	Dyspepsia							
	Dyspnoea							
	Dysuria							
	Eye Pain							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Intestinal Obstruction							
	Meningitis							
	Meningitis Viral							
	Musculoskeletal Stiffness							
	Nausea							
	Neck Pain							
	Oesophageal Disorder							
	Pain							
	Photophobia							
	Sensation Of Pressure							
	Urinary Tract Infection							
	Vomiting							

Date:11/24/04ISR Number: 4510193-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00655
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	90	DAY

Hospitalization - 90 DAY	Personality Change		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Therapeutic Response		Lipitor	C		
Disability UNKNOWN	Unexpected		Allegra	C		

Date:11/24/04ISR Number: 4510197-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00061102
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation		Nicorette	SS		
Other	Bronchitis		Nicorette	SS		
	Dyspnoea		Flovent	C		
UNKNOWN						
			Combivent	C		
UNKNOWN						
			Zantac	C		
UNKNOWN						
			Azmacort	C		
UNKNOWN						
			Serevent	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Antimicrobial			

Therapy (Composition Unspecified) C

UNKNOWN

Date:11/24/04ISR Number: 4510202-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Atherosclerosis
	Aortic Valve Incompetence
	Arrhythmia
	Arrhythmia Supraventricular
	Arthralgia
	Atrial Fibrillation
	Atrial Flutter
	Back Pain
	Blood Cholesterol Increased
	Bronchitis
	Cardiac Disorder
	Cardiac Enzymes Increased
	Cardiac Failure Congestive
	Cardiac Ventricular Disorder
	Carotid Artery Disease
	Cerebral Ischaemia
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Discomfort
	Chest Pain
	Coronary Artery Disease
	Dilatation Atrial
	Diverticulum Intestinal
	Dysarthria
	Dyspnoea
	Dyspnoea Exertional
	Electrocardiogram St Segment Depression
	Electrocardiogram T Wave Inversion
	Emotional Distress
	Eustachian Tube Obstruction

Fatigue
Flank Pain
Haematuria
Heart Rate Irregular
Hydronephrosis
Hypertension
Hypertrophy
Injury
Intracardiac Thrombus
Lipids Increased
Lung Infiltration
Mitral Valve Incompetence
Myocardial Infarction
Neoplasm
Overdose
Pneumonia

		Pruritus					
		Rash Papular					
		Renal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scar		Vioxx	PS	Merck & Co., Inc	ORAL
		Sebaceous Gland Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Speech Disorder		Diazide	C		
UNKNOWN							
		Thrombosis		Lopressor	C		
UNKNOWN							
		Transient Ischaemic		Lopressor	C		
UNKNOWN							
		Attack		Zocor	C		ORAL
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypertrophy					

Date:11/24/04ISR Number: 4510249-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02879
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Complex Regional Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Dementia		Lotensin	C		
UNKNOWN							
		Depression		Ziac	C		
UNKNOWN							
		Dysphoria		Nubain	C		
INTRAMUSCULAR							
		Fall		Prozac	C		ORAL
		Loss Of Consciousness		Prozac	C		ORAL
		Polytraumatism		Wellbutrin Sr	C		ORAL
		Renal Impairment		Wellbutrin Sr	C		ORAL
		Rib Fracture		Valium	C		ORAL
				Valium	C		ORAL
				Keppra	C		ORAL
				Keppra	C		ORAL

Date:11/24/04ISR Number: 4510250-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02233
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510252-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03757
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Toprol Xl Tablets	C				
Disability	Disease		Glucophage	C				
	Hypertension		Albuterol	C				
	Somatisation Disorder		[Therapy Unspecified]	C				
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510253-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01995
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Urea Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Injury		Lopid	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Covera-Hs	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								
			Ultram	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510254-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00075
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Hearing Loss							
	Tinnitus							

Date:11/24/04ISR Number: 4510256-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00671
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Norvasc	C				
UNKNOWN								
	Dyspnoea		Zoloft	C				
UNKNOWN								
	Fall		Citracal	C				
UNKNOWN								
	Fatigue		Fosamax	C				
UNKNOWN								
	Throat Tightness							

Date:11/24/04ISR Number: 4510262-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Prevacid	C			UNKNOWN	
	Arthralgia		Amitriptyline Hydrochloride	C		ORAL	SUBLINGUAL	
	Blood Pressure Increased		Atenolol	C		ORAL		
	Bundle Branch Block Left		Atenolol	C		ORAL		
	Carotid Artery Stenosis		Nitroquick	C			UNKNOWN	
	Convulsion		Aspirin	C			UNKNOWN	
	Coronary Artery Disease		Lipitor	C		ORAL		
	Limb Discomfort		Zantac	C		ORAL		
	Post Procedural Haematoma		Plavix	C			UNKNOWN	
			Amaryl	C			UNKNOWN	
			Baycol	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510264-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Aneurysm	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Fosamax	C				
UNKNOWN								
Other	Asthenia		Percocet	C				
UNKNOWN								
	Asthma		Zestril	C				
UNKNOWN								
	Atherosclerosis		Zestril	C				
UNKNOWN								
	Atrial Fibrillation		Diltiazem					
	Bradycardia		Hydrochloride	C				
UNKNOWN								
	Bronchitis							
	Bronchospasm							
	Cardiac Murmur							
	Cardiomegaly							
	Chronic Obstructive							
	Pulmonary Disease							
	Compression Fracture							
	Death							
	Difficulty In Walking							
	Disorientation							
	Hypoaesthesia							
	Hypotension							
	Interstitial Lung Disease							
	Labile Hypertension							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Neuropathy							
	Overdose							
	Pain In Extremity							
	Renal Artery Stenosis							
	Spinal Column Stenosis							
	Spinal Compression							
	Fracture							
	Tracheal Obstruction							
	Tricuspid Valve							
	Incompetence							
	Vascular Calcification							
	Ventricular Hypertrophy							

Date:11/24/04ISR Number: 4510265-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Irregular Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510267-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02933
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Refusal Of Treatment By Patient	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Plavix	C			UNKNOWN	
	Transient Ischaemic Attack		Aspirin	C			UNKNOWN	
	Visual Field Defect							

Date:11/24/04ISR Number: 4510270-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Amnesia
	Angina Pectoris
	Arthralgia
	Arthropathy
	Autonomic Nervous System Imbalance
	Blister Infected
	Blood Pressure Increased
	Body Temperature Increased
	Breast Cancer In Situ
	Breast Fibrosis
	Breast Microcalcification
	Breast Pain
	Bronchitis
	Bursitis
	Carotid Artery Stenosis
	Cataract
	Cerebral Ischaemia
	Chest Discomfort
	Chest Pain
	Colonic Polyp
	Confusional State
	Congenital Eye Naevus
	Contusion
	Convulsion
	Cough
	Diaphragmatic Disorder
	Disorientation
	Diverticulum
	Dyslipidaemia
	Dyspnoea Exertional
	Ear Discomfort
	Endolymphatic Hydrops
	Exostosis
	Facial Pain
	Fatigue
	Feeling Abnormal
	Flatulence
	Haemangioma
	Haemorrhoids

Hot Flush
Hyperhidrosis
Hypertension
Hypertensive
Encephalopathy
Inflammation
Infusion Related Reaction
Injury
Intermittent Claudication
Limb Discomfort
Limb Injury
Loss Of Consciousness
Lung Disorder
Myocardial Ischaemia
Nausea

		Neoplasm Recurrence					
		Nuclear Magnetic Resonance Imaging Brain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Spironolactone	C		
UNKNOWN							
		Pain In Extremity		Captopril Msd	C		ORAL
		Palatal Disorder		Toprol Xl Tablets	C		ORAL
		Palpitations					
		Plantar Fasciitis					
		Pulmonary Fibrosis					
		Rash					
		Refusal Of Treatment By Patient					
		Rhinitis					
		Rotator Cuff Syndrome					
		Scotoma					
		Seasonal Allergy					
		Seroma					
		Sinusitis					
		Supraventricular Tachycardia					
		Syncope					
		Tendonitis					
		Transient Ischaemic Attack					
		Vertebrobasilar Insufficiency					
		Visual Disturbance					
		Vitreous Detachment					

Date:11/24/04ISR Number: 4510290-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00019
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
Initial or Prolonged				Baclofen	C		
				Oxycontin	C		

Date:11/24/04ISR Number: 4510291-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03181
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Norvasc	C			UNKNOWN	
	Rash		Zoloft	C			UNKNOWN	
	Skin Haemorrhage		Lisinopril	C			UNKNOWN	
	Swelling		Crestor	C			UNKNOWN	
	Urticaria							

Date:11/24/04ISR Number: 4510293-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03212
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Norvasc	C			UNKNOWN	
Disability	Congestive Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510295-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00068
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial	Health	Vioxx	PS	Merck & Co., Inc	ORAL		126 DAY
Initial or Prolonged Disability	Infarction	Professional						

Date:11/24/04ISR Number: 4510296-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Unevaluable Event							

Date:11/24/04ISR Number: 4510297-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00283
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Second Degree	Professional	Lasix (Furosemide)	C		ORAL		
Initial or Prolonged	Cardiac Failure		Potassium					
Disability	Congestive		(Unspecified)	C				
UNKNOWN								
	Cardiomegaly		Metoprolol	C				
UNKNOWN								
	Coronary Artery Disease		Naprosyn	C				
UNKNOWN								
	Ejection Fraction		Aspirin	C				
UNKNOWN								
	Decreased							

Date:11/24/04ISR Number: 4510299-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00419
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angina Unstable Chest Pain General Physical Health Deterioration		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/24/04ISR Number: 4510300-2Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00029
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:11/24/04ISR Number: 4510304-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Medication Error Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510305-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02388
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
			Allegra	C			UNKNOWN	

Date:11/24/04ISR Number: 4510306-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00190
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Thromboembolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510307-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Respiratory Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510309-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pancreatic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510311-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03178
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colon Injury Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510312-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	

Date:11/24/04ISR Number: 4510313-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02842
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Coronary Artery Disease		Vioxx Proscar	PS C	Merck & Co., Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510316-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03169
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prednisone	C				
UNKNOWN								
Initial or Prolonged			Synthroid	C				
UNKNOWN								
Disability			Hydroxychloroquine Sulfate	C				
UNKNOWN								
			Estra-D	C				
UNKNOWN								
			Actonel	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Calcium (Unspecified)	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510319-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/24/04ISR Number: 4510321-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03257
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diarrhoea	Professional	Premarin	C				
UNKNOWN								

Initial or Prolonged	Generalised Oedema		Levoxyl	C
UNKNOWN				
Disability	Swelling		Lasix (Furosemide)	C
UNKNOWN				
			Lotrel	C
UNKNOWN				
			Prevacid	C
UNKNOWN				
			Prozac	C
UNKNOWN				
			Isosorbide	C
UNKNOWN				
			Potassium (Unspecified)	C
UNKNOWN				
			Calcium (Unspecified)	C
UNKNOWN				

Date:11/24/04ISR Number: 4510322-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03166
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia		Celebrex	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510326-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510353-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00065
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Facial Paresis		Vioxx	PS	Merck & Co., Inc	ORAL		219 DAY
Initial or Prolonged	Pleural Mesothelioma		Vioxx	SS	Merck & Co., Inc	ORAL		219 DAY
	Trigeminal Nerve Disorder							

Date:11/24/04ISR Number: 4510460-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0351046A
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Deroxat	PS	Glaxosmithkline	ORAL	20MG Per day	
Initial or Prolonged	Blood Alkaline		Efferalgan	SS	Glaxosmithkline	ORAL	4UNIT per day	
	Phosphatase Increased		Nexen	SS	Glaxosmithkline	ORAL		
	Blood Amylase Increased		Vioxx	SS		ORAL	1UNIT Per day	
	Gamma-Glutamyltransferase		Topalgic (France)	SS		ORAL	2UNIT per day	
	Increased		Art	SS		ORAL	50MG Per day	
	Pancreatitis Necrotising							

Date:11/24/04ISR Number: 4510760-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:11/24/04ISR Number: 4510764-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Adverse Event Angina Pectoris Anxiety Blood Cholesterol Increased Blood Creatine Phosphokinase Increased Bronchitis Cardiac Failure Congestive Coronary Artery Atherosclerosis Coronary Artery Disease Depression Dyspnoea Fatigue Feeling Abnormal Gastrooesophageal Reflux Disease Gouty Arthritis Influenza Limb Injury Malignant Hypertension Myocardial Ischaemia Nasal Discomfort Oedema Peripheral Palpitations Polytraumatism Rhinitis Allergic

		Skin Lesion Sleep Apnoea Syndrome Tinnitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Respiratory Tract Infection	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Toprol Xl Tablets	C		
UNKNOWN				Imdur	C		
UNKNOWN				Nitro-Dur	C		
UNKNOWN				Diovan	C		
UNKNOWN				Diovan	C		
UNKNOWN				Diltiazem Hydrochloride	C		
UNKNOWN				Plavix	C		
UNKNOWN				Zocor	C		ORAL
UNKNOWN				Aspirin	C		
UNKNOWN				Xanax	C		
UNKNOWN				Folic Acid	C		
UNKNOWN				Allopurinol	C		
UNKNOWN				Lecithin And Protein (Unspecified)	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Levothroid	C		
UNKNOWN				Soma	C		
UNKNOWN				Indocin (Indomethacin)	C		ORAL
UNKNOWN				Colchicine	C		
UNKNOWN				Norco	C		

	Levothroid	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		
	Vitamins (Unspecified)	C
UNKNOWN		

Date:11/24/04ISR Number: 4510766-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00743
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Acute Sinusitis
	Adverse Event
	Angina Pectoris
	Blood Glucose Increased
	Blood Pressure Increased
	Convulsion
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Electrocardiogram St-T Segment Elevation
	Erectile Dysfunction
	Myocardial Infarction
	Rhinitis Allergic
	Sinus Bradycardia
	Tricuspid Valve Incompetence
	Upper Respiratory Tract

Infection
Urticaria
Ventricular Tachycardia
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lipitor	C			UNKNOWN	
	Prilosec	C		ORAL		
	Cardizem Cd	C			UNKNOWN	
	Cardizem Cd	C			UNKNOWN	
	Levsin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Celexa	C			UNKNOWN	

Date:11/24/04ISR Number: 4510770-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Distension
	Abdominal Pain Upper
	Adverse Event
	Angina Pectoris
	Anxiety
	Aortic Atherosclerosis
	Aspiration
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis
	Bundle Branch Block
	Cardiomyopathy
	Carotid Artery Stenosis
	Cervicobrachial Syndrome
	Cholecystitis Acute
	Conjunctivitis Allergic
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression

Dermatitis Allergic
Dermatitis Atopic
Diarrhoea
Dilatation Atrial
Ejection Fraction
Decreased
Femoral Artery Occlusion
Food Allergy
Gastritis
Gastrooesophageal Reflux
Disease
Hypertension
Hypokinesia
Irritable Bowel Syndrome
Lung Neoplasm
Metabolic Encephalopathy
Mitral Valve Incompetence
Multiple Allergies
Myocardial Infarction
Myocardial Ischaemia
Pericardial Effusion
Peripheral Vascular

	Disorder						
	Pneumonia						
	Pulmonary Hypertension						
	Pulmonary Valve	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rhinitis Allergic		Celebrex	C			UNKNOWN
	Sexual Dysfunction						
	Sleep Disorder						
	Staphylococcal Infection						
	Stress						
	Tricuspid Valve Incompetence						
	Ventricular Fibrillation						
	Ventricular Tachycardia						

Date:11/24/04ISR Number: 4510772-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Fibromyalgia		Tylenol With Codeine	C			UNKNOWN
	Hepatic Lesion						
	Hypertension						
	Hypoaesthesia						
	Incision Site Complication						
	Injury						
	Labyrinthitis						
	Lumbar Spinal Stenosis						
	Lung Neoplasm						
	Pain In Extremity						
	Pneumonia						
	Urinary Retention						
	Wound Infection						

Date:11/24/04ISR Number: 4510775-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00775
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event
	Angina Pectoris
	Anxiety
	Appendix Disorder
	Arthropathy
	Bunion
	Carpal Tunnel Syndrome
	Cerebral Atherosclerosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Complicated Migraine
	Convulsion
	Depression
	Ganglion
	Hypercholesterolaemia
	Hyperlipidaemia
	Hypertension

		Hypoaesthesia					
		Lacunar Infarction					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
		Tinel'S Sign		Prempro	C		
UNKNOWN							
		Tonsillar Disorder		Dyazide	C		
UNKNOWN							
		Transient Ischaemic		Aspirin	C		
UNKNOWN							
		Attack					
		Trigger Finger					
		Wrist Fracture					

Date:11/24/04ISR Number: 4510781-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia					
Disability		Angioneurotic Oedema					
Other		Bronchitis					
		Chest Pain					
		Constipation					
		Deep Vein Thrombosis					
		Depression					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Diverticulum					
		Dyspnoea					
		Fatigue					
		Gastric Disorder					
		Gastric Outlet					
		Obstruction					
		Hypertension					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Peptic Ulcer					
		Polytraumatism					
		Pruritus Generalised					
		Restrictive Pulmonary					
		Disease					

Stress Incontinence
Swelling
Tendonitis
Ventricular Dysfunction
Vision Blurred

Date:11/24/04ISR Number: 4510785-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00781
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Aortic Aneurysm
Other	Aortic Occlusion
	Asthenia
	Breath Sounds Decreased
	Cardiomyopathy
	Chest Pain
	Crepitations
	Device Failure

		Dizziness Dyspepsia Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erectile Dysfunction Headache Hypertension Hypoaesthesia Ileus Intermittent Claudication Limb Discomfort Muscle Spasms Myocardial Infarction Peripheral Vascular Disorder Polytraumatism Post Procedural Complication Renal Tubular Necrosis Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/24/04ISR Number: 4510793-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00809
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability Other		Abdominal Injury Adverse Event Anaemia Arthritis Bladder Neck Obstruction Chest Injury Corneal Abrasion Cystitis Dermatitis Contact Gastritis Erosive Gastrooesophageal Reflux Disease Hiatus Hernia Melaena Muscle Spasms Oesophagitis Pharyngolaryngeal Pain Polytraumatism Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL

Testicular Disorder
Testicular Torsion

Date:11/24/04ISR Number: 4510795-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
	Cerebrovascular Accident
Disability	Chest Pain
	Drug Ineffective
	Gastric Disorder
	Headache
	Hypertension
	Joint Dislocation
	Labyrinthitis

		Lower Limb Fracture					
		Overdose					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pharyngolaryngeal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Pilonidal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
				Glucophage Xr	C		ORAL
				Glucophage Xr	C		
UNKNOWN							
				Glucophage Xr	C		ORAL
				Lidocaine And Triamcinolone Acetonide	C		
PARENTERAL	1 DAY						

Date:11/24/04ISR Number: 4510797-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
Other		Amyotrophy		Plavix	SS		
UNKNOWN							
		Angina Pectoris		Captopril Msd	C		ORAL
		Atherosclerosis		Glucotrol Xl	C		
UNKNOWN							
		Blood Pressure Inadequately Controlled		Amitriptyline Hydrochloride	C		
UNKNOWN							
		Bursitis		Evista	C		
UNKNOWN							
		Cardiovascular Disorder		Synthroid	C		
UNKNOWN							
		Cerebral Artery Stenosis		Prilosec	C		ORAL
		Cerebral Disorder		Humulin	C		
UNKNOWN							
		Cerebral Infarction					
		Cerebrovascular Accident					
		Coagulopathy					
		Convulsion					
		Coronary Artery					

Atherosclerosis
Diabetes Mellitus
Inadequate Control
Diabetic Neuropathy
Diverticulum
Dizziness
Gastritis
Gastrointestinal
Haemorrhage
Haemorrhoidal Haemorrhage
Hypertension
Insulin Resistant
Diabetes
Lacunar Infarction
Orthostatic Hypotension
Pharyngitis
Rotator Cuff Syndrome
Subcutaneous Abscess
Syncope
Tendonitis
Upper Respiratory Tract
Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510798-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00835
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		1849 DAY
Initial or Prolonged	Blue Toe Syndrome		Darvocet-N	C				UNKNOWN
Other	Chest Pain		Soma	C		ORAL		
	Coronary Artery Disease		Soma	C				UNKNOWN
	Fall		Elavil	C				UNKNOWN
	Fibula Fracture		Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
	Intermittent Claudication							
	Myocardial Infarction							
	Tarsal Tunnel Syndrome							
	Therapeutic Response Decreased							

Date:11/24/04ISR Number: 4510799-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00862
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alanine Aminotransferase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Creatine Phosphokinase Increased							
	Blood Potassium Increased							
	Carpal Tunnel Syndrome							
	Hypertension							
	Intervertebral Disc Protrusion							
	Lumbar Spinal Stenosis							
	Osteoarthritis							
	Pain							
	Platelet Count Decreased							
	Spinal Osteoarthritis							

Date:11/24/04ISR Number: 4510801-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00839
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
	Arthralgia
	Breast Discharge
	Cervical Spasm
	Chest Pain
	Diarrhoea
	Duodenitis
	Dysfunctional Uterine Bleeding
	Gastritis
	Hyperhidrosis
	Hypersensitivity
	Hypertension
	Ileus
	Iron Deficiency Anaemia
	Joint Stiffness
	Menometrorrhagia
	Migraine
	Muscle Twitching

		Neck Pain					
		Pain					
		Panic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Inflammatory		Vioxx	PS	Merck & Co., Inc	ORAL
110	DAY						
		Disease					
		Peripheral Coldness					
		Polytraumatism					
		Raynaud'S Phenomenon					
		Restless Legs Syndrome					
		Tinnitus					
		Vaginal Infection					

Date:11/24/04ISR Number: 4510802-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00843
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Arrhythmia		Vitamins			
		Blood Pressure Increased		(Unspecified)	C		
UNKNOWN							
		Bronchitis		Verapamil	C		
UNKNOWN							
		Carpal Tunnel Syndrome		Hydrochlorothiazide	C		
UNKNOWN							
		Complex Regional Pain		Effexor Xr	C		
UNKNOWN							
		Syndrome		Premarin	C		
UNKNOWN							
		Dyspnoea Exertional		Micardis	C		
UNKNOWN							
		Epicondylitis		Verapamil			
		Fall		Hydrochloride	C		
UNKNOWN							
		Fibula Fracture		Ultram	C		
UNKNOWN							
		Mononeuropathy		Atarax	C		
UNKNOWN							
		Musculoskeletal Stiffness					
		Oedema					
		Palpitations					
		Polytraumatism					
		Rhinitis Allergic					

Sinus Headache
Tachycardia
Upper Respiratory Tract
Infection

Date:11/24/04ISR Number: 4510803-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Amnesia
Disability	Anaemia
Other	Arthralgia
	Asthenia
	Atelectasis
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Cerebrovascular Accident
	Chest Pain
	Cyst
	Depression
	Difficulty In Walking
	Disorientation
	Dysarthria
	Dyspnoea

		Dysstasia					
		Fall					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Genital Pruritus Female		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Diflucan	C		
UNKNOWN							
		Hypersensitivity		Zantac	C		
UNKNOWN							
		Impaired Healing		Dicyclomine			
		Injury		Hydrochloride	C		
UNKNOWN							
		Muscle Spasms		Vicodin Es Tablets	C		
UNKNOWN							
		Neuropathy		Arthrotec	C		
UNKNOWN							
		Neuropathy Peripheral		Adalat	C		
UNKNOWN							
		Pain In Extremity		Crixivan	C		ORAL
		Pneumonia		Allegra	C		
UNKNOWN							
		Polyuria		Bactrim	C		
UNKNOWN							
		Pulmonary Fibrosis		Combivir	C		
UNKNOWN							
		Syncope		Crixivan	C		ORAL
		Tongue Coated		Quinine	C		
UNKNOWN							
		Tongue Discolouration		Ditropan Xl	C		
UNKNOWN							
		Tongue Disorder		Vicodin Es Tablets	C		
UNKNOWN							
		Urinary Incontinence		Procardia	C		
UNKNOWN							
		Vaginal Burning Sensation		Reglan	C		
UNKNOWN							
		Vision Blurred		Desyrel	C		
UNKNOWN							
				Skelaxin	C		ORAL

Date:11/24/04ISR Number: 4510808-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00881
Age:46 YR Gender:Female I/FU:F

Outcome PT

Hospitalization -
Initial or Prolonged
Disability
Other

Abdominal Adhesions
Adjustment Disorder
Adnexa Uteri Mass
Adverse Event
Angina Pectoris
Anxiety Disorder
Appendix Disorder
Back Pain
Breast Abscess
Chest Pain
Complex Regional Pain
Syndrome
Diabetes Mellitus
Non-Insulin-Dependent
Dizziness
Duodenitis
Dysuria
Emotional Distress
Exostosis
Faecal Occult Blood
Positive
Gastric Polyps
Gastritis
Gastrooesophageal Reflux
Disease
Headache
Hepatic Cirrhosis
Hot Flush
Hypertension
Ischaemia
Major Depression

		Muscle Spasms					
		Nausea					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neurodermatitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Obesity	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pancreatitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
		Plantar Fasciitis					
		Pruritus Generalised					
		Radiculitis Lumbosacral					
		Syncope					
		Tibia Fracture					
		Upper Respiratory Tract Infection					
		Urinary Incontinence					
		Urinary Tract Infection					
		Vaginal Candidiasis					
		Visual Disturbance					

Date:11/24/04ISR Number: 4510809-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Body Tinea					
		Cardiovascular Disorder					
		Carotid Artery Stenosis					
		Coronary Artery Disease					
		Dermatitis					
		Eczema					
		Epidermal Necrosis					
		Erythema Multiforme					
		Granuloma Annulare					
		Hypertension					
		Leukocytoclastic Vasculitis					
		Nail Bed Bleeding					
		Onycholysis					
		Psoriasis					
		Renal Failure					
		Vasculitis					

Date:11/24/04ISR Number: 4510813-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Cardiomyopathy
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Constipation
	Cough
	Cubital Tunnel Syndrome
	Decreased Appetite
	Diarrhoea
	Emotional Distress
	Feeling Hot And Cold
	Headache
	Injury

		Nervous System Disorder					
		Neuropathy					
		Nocturia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Tension	Professional	Klonopin	C		
UNKNOWN							
		Visual Disturbance		Klonopin	C		
UNKNOWN							
				Risperdal	C		ORAL
				Zestril	C		ORAL
				Zocor	C		
UNKNOWN							
				Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Remeron	C		ORAL
				Seroquel	C		ORAL
				Soma	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Effexor Xr	C		
UNKNOWN							
				Celebrex	C		ORAL
30 DAY							
				Lanoxin	C		ORAL
				Plavix	C		ORAL
				Aspirin	C		ORAL
				Vistaril	C		
UNKNOWN							
				Geodon	C		
UNKNOWN							

Date:11/24/04ISR Number: 4510814-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00171
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain					

Date:11/24/04ISR Number: 4510817-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Arthralgia
	Asthenia
	Back Pain
	Bone Cyst
	Buttock Pain
	Diarrhoea
	Difficulty In Walking
	Fall
	Gastritis
	Haematochezia
	Hiatus Hernia
	Hypoaesthesia
	Inadequate Analgesia
	Injury
	Insomnia
	Intervertebral Disc
	Protrusion
	Limb Discomfort
	Muscle Spasms
	Nausea
	Oedema Peripheral

		Osteoarthritis					
		Pain In Extremity					
		Post Laminectomy Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radiculitis Lumbosacral		Vioxx	PS	Merck & Co., Inc	ORAL
		Sacroiliitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Vicodin Tablets	C		ORAL
		Weight Increased		Flexeril	C		ORAL
				Flexeril	C		ORAL

Date:11/24/04ISR Number: 4510821-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Balance Disorder					
Other		Benign Prostatic					
		Hyperplasia					
		Blood Triglycerides					
		Increased					
		Cerebrovascular Accident					
		Gait Disturbance					
		Hypoaesthesia					
		Lumbar Radiculopathy					
		Nausea					
		Neck Pain					
		Oedema Peripheral					
		Skin Papilloma					
		Sleep Apnoea Syndrome					
		Spinal Cord Disorder					
		Tachycardia					
		Vomiting					

Date:11/24/04ISR Number: 4510822-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00052
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Vioxx	SS	Merck & Co., Inc	ORAL
				Lisinopril	C		ORAL

	Aspirin	C		
UNKNOWN				
	Omeprazole	C		ORAL
	Protonix	C		ORAL

Date:11/24/04ISR Number: 4510826-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00065
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 219 DAY	Facial Paresis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 219 DAY	Pleural Mesothelioma		Vioxx	SS	Merck & Co., Inc	ORAL
	Trigeminal Nerve Disorder					

Date:11/24/04ISR Number: 4510827-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01218
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Drug Effect Decreased

		Dysphonia					
		Faeces Discoloured					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fundoplication		Vioxx	PS	Merck & Co., Inc	ORAL
		Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Helicobacter Pylori		Cartia (Aspirin)	C		
UNKNOWN							
		Identification Test		Isosorbide	C		
UNKNOWN							
		Positive		Loratadine	C		
UNKNOWN							
		Mental Status Changes					
		Neck Pain					
		Oedema Peripheral					
		Oesophageal Stenosis					
		Therapeutic Response					
		Decreased					

Date:11/24/04ISR Number: 4510829-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01953
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease					
		Epicondylitis					
		Gastrooesophageal Reflux					
		Disease					
		Herpes Simplex					
		Hypercholesterolaemia					
		Hypertension					
		Intervertebral Disc					
		Degeneration					
		Muscle Injury					
		Periarthritis					
		Seborrhoeic Keratosis					
		Telangiectasia					
		Tenosynovitis					
		Ventricular Tachycardia					

Date:11/24/04ISR Number: 4510831-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1127 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Arthropathy		Viagra	C				UNKNOWN
	Coronary Artery Disease		Amoxicillin	C				UNKNOWN
	Depression		Plavix	C				UNKNOWN
	Erectile Dysfunction		Ambien	C				UNKNOWN
	Hypercholesterolaemia		Trazodone Hydrochloride	C				UNKNOWN
	Hypertension							
	Laceration		Ibuprofen	C				UNKNOWN
	Peroneal Nerve Palsy		Zanaflex	C				UNKNOWN
	Pleuritic Pain		Altace	C				UNKNOWN
			Diazepam	C				UNKNOWN
			Hydrocodone Bitartrate	C				UNKNOWN

					Hydrocodone Bitartrate	C		
UNKNOWN		14	MON					
					Oxycontin	C		
UNKNOWN		14	MON					

Date:11/24/04ISR Number: 4510832-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00383
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Phlebitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510846-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02014
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510847-9Report Type:Expedited (15-DaCompany Report #MX-MERCK-0410MEX00003
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	612 DAY	
Hospitalization - Initial or Prolonged			Methotrexate	C		ORAL		
			Prednisone	C		ORAL		
Disability			Alendronate Sodium	C		ORAL		
			Ranitidine	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Leflunomide	C		ORAL	1486 DAY	
			Folic Acid	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510848-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00066
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged			Nebivolol	SS		ORAL		
			Cyamemazine	SS		ORAL		
			Paroxetine Hydrochloride	SS		ORAL		
			Clonazepam	SS		ORAL		

Date:11/24/04ISR Number: 4510850-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00168
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510851-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00426
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Disorder							

Date:11/24/04ISR Number: 4510852-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03272
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510853-4Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510855-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00343
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
Hospitalization - Initial or Prolonged	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY

Date:11/24/04ISR Number: 4510856-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00424
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510857-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope							

Date:11/24/04ISR Number: 4510859-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04389
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
			Adalat	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510860-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00047
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Prednisolone	C		ORAL		
	Speech Disorder		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
	Vertigo		Sulfasalazine	C		ORAL		
			Loratadine	C		ORAL		

Date:11/24/04ISR Number: 4510861-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02668
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Procardia Xl	C				UNKNOWN
Initial or Prolonged			Lodine Xl	C				UNKNOWN
Disability			Tricor	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Ativan	C				UNKNOWN
			Allopurinol	C				UNKNOWN
			Clonidine	C				UNKNOWN
			Buspar	C				UNKNOWN
			Tenormin	C				UNKNOWN
			Paxil	C				UNKNOWN
			Neurontin	C				UNKNOWN

Date:11/24/04ISR Number: 4510864-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411USA02753
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510866-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00028
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
21 MON								
Initial or Prolonged	Myocardial Infarction							
Other								

Date:11/24/04ISR Number: 4510868-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Difficulty In Walking		Hydrocortisone	C				
UNKNOWN								
Initial or Prolonged	Intestinal Functional		[Therapy					
Disability	Disorder		Unspecified]	C				
UNKNOWN								
	Speech Disorder		Coumadin	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Prempro	C				
UNKNOWN								
			Furo	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510869-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02535
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
			Lisinopril	C				UNKNOWN

Date:11/24/04ISR Number: 4510870-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02804
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dizziness		[Therapy					
	Dyspnoea		Unspecified]	C				UNKNOWN
	Headache		[Therapy					
			Unspecified]	C				UNKNOWN
			Meclizine	C				UNKNOWN

Date:11/24/04ISR Number: 4510871-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02876
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiomyopathy							
Initial or Prolonged	Ventricular Tachycardia							

Date:11/24/04ISR Number: 4510872-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02868
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510873-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Colitis Red Blood Cell Count Decreased Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510876-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03040
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Fatigue Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510878-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02941
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510879-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02942
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:11/24/04ISR Number: 4510880-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03100
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
			Vasotec	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510882-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03034
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tooth Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

			Dilantin	C		
UNKNOWN						
			Lovastatin	C		
UNKNOWN						
			Lisinopril	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510884-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02624
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Fluid Retention		Micardis Hct	C		
UNKNOWN						
	Heart Rate Increased		Diovan	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510885-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02755
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dyspnoea					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510886-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510887-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Zocor	C		ORAL		69 MON

Date:11/24/04ISR Number: 4510889-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03183
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510890-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03159
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthropathy		Zocor	C		ORAL		
Initial or Prolonged	Cholelithiasis		Protonix	C				
UNKNOWN								
Other	Postoperative Infection							

Date:11/24/04ISR Number: 4510891-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03191
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Amnesia	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Coma	[Therapy Unspecified]	C		
UNKNOWN					
Disability	Deafness Loss Of Consciousness	[Therapy Unspecified]	C		
UNKNOWN					
	Paralysis	Paxil	C		
UNKNOWN					
	Thrombosis	Influenza Virus Vaccine (Unspecified)	C		
UNKNOWN					

Date:11/24/04ISR Number: 4510892-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial Infarction Arrhythmia Coronary Artery Atherosclerosis Hypertensive Heart Disease		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510895-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03146
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Impaired Work Ability		Darvocet-N	C				UNKNOWN
Disability	Obstruction		Diovan	C				UNKNOWN
	Pain In Extremity		Hydrochlorothiazide	C				UNKNOWN
	Peripheral Vascular Disorder		Atenolol	C				UNKNOWN

Date:11/24/04ISR Number: 4510896-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:11/24/04ISR Number: 4510897-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03175
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction							
Hospitalization - Initial or Prolonged								
Disability								

Date:11/24/04ISR Number: 4510898-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03174
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Convulsion	Vioxx	PS	Merck & Co., Inc	ORAL
11 DAY					
UNKNOWN		Ultracet	C		
UNKNOWN		Cyclobenzaprine Hydrochloride	C		
UNKNOWN		Neurontin	C		
UNKNOWN		Hydrocodone Bitartrate	C		

Date:11/24/04ISR Number: 4510899-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02292
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Arteriosclerosis
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cardiomegaly
	Cerebrovascular Accident
	Dementia Alzheimer'S Type
	Fall
	General Physical Health Deterioration
	Pneumonia Aspiration
	Sepsis

Tachycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	217	DAY
	Zyprexa	C			UNKNOWN	
	Buspar	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Fosamax	C			UNKNOWN	
	Calcium (Unspecified) And Vitamin D (Unspecified)	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Docusate Sodium	C			UNKNOWN	
	Vitamin E	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Aspirin	C			UNKNOWN	

Date:11/24/04ISR Number: 4510900-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03280
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Stress		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Dilantin	C			UNKNOWN	
			Ramipril	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

				Famotidine	C		
UNKNOWN							

Date:11/24/04ISR Number: 4510901-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03176
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Muscle Contractions		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Involuntary		Mobic	C		
UNKNOWN						
Disability	Oedema Peripheral		Zocor	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510902-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03218
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Lichen Planus		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/24/04ISR Number: 4510903-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03282
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Diuretic (Unspecified)	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510904-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03369
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510905-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03312
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:11/24/04ISR Number: 4510906-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03427
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/24/04ISR Number: 4510907-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00233
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fall		Chlorambucil	C				
UNKNOWN								

	Forearm Fracture		Allopurinol	C		
UNKNOWN						
			Valdecoxib	C		
UNKNOWN						
			Amylase And Bromelains And Chymotrypsin And Lipase And Pancreatin And	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510908-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03406
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization - Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510909-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Lisipril	C				UNKNOWN
			Premarin	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Singulair	C				UNKNOWN
			Metoprolol	C				UNKNOWN

Date:11/24/04ISR Number: 4510910-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03204
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
Hospitalization - Initial or Prolonged	Chest Pain		[Therapy Unspecified]	C				UNKNOWN
	Coma							
Disability	Myocardial Infarction		Prilosec	C				UNKNOWN

Date:11/24/04ISR Number: 4510911-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	

Date:11/24/04ISR Number: 4510912-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510913-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Limb Operation Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510914-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03363
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Thrombosis		Amoxicillin	C				
Initial or Prolonged UNKNOWN			Lopressor	C				
Disability UNKNOWN			Norvasc	C				

Date:11/24/04ISR Number: 4510915-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510916-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03412
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Nexium	C				
UNKNOWN								
Other			Synthroid	C				
UNKNOWN								

Date:11/24/04ISR Number: 4510918-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Malignant		[Therapy Unspecified]	C				
Hospitalization -								
UNKNOWN								
Initial or Prolonged			Premarin	C				
UNKNOWN								
			Aldara	C				
UNKNOWN								
			Propranolol Hydrochloride	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Hydrocortisone	C				
UNKNOWN								
			Dilaudid	C				
UNKNOWN								
			Meclizine	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Senokot (Senna)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

			Cipro	C		
UNKNOWN						
			Sulfadiazine	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Ranitidine	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Levaquin	C		
UNKNOWN						
			Stadol	C		
UNKNOWN						

Date:11/24/04ISR Number: 4510919-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03404
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4510921-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03572
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/24/04ISR Number: 4510922-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00050
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Chest Pain		Irbesartan	SS		ORAL		
	Malaise		Fenofibrate	SS		ORAL		
	Sudden Death							

Date:11/24/04ISR Number: 4510927-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03142
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/24/04ISR Number: 4513049-5Report Type:Direct Company Report #CTU 232979
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck	ORAL	ONCE A DAY	
	Cardiac Disorder						ORALLY	
	Thrombosis							

Date:11/24/04ISR Number: 4513690-XReport Type:Expedited (15-DaCompany Report #WAES 0411USA02093
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Foreign	Tab Vioxx					
Hospitalization -	Decreased	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Aspartate	Health						
PO							827 DAY	
	Aminotransferase	Professional	Inj Enbrel					

		Increased		(Etanercept)	SS	
SUBCUTANEOUS	25 MG/2XW SC 43 DAY					
		Blood Creatine Phosphokinase Increased		Budesonide	C	
		Blood Creatine Phosphokinase Mb Increased				
		Dehydration				
		Demyelination				
		Depressed Level Of Consciousness				
		Diarrhoea				
		Korsakoff'S Psychosis				
		Non-Alcoholic Myoglobin Blood Increased				
		White Blood Cell Count Increased				

Date:11/24/04ISR Number: 4513703-5Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00020
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Diverticulum	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	
	Haemoglobin Decreased	Health Professional						
	Rectal Haemorrhage		Tab Aspirin	SS		ORAL	75 MG, PO	
			Lansoprazole	C				

			Lisinopril	C		
			Prazosin	C		
			Simvastatin	C		

Date:11/24/04ISR Number: 4514112-5Report Type:Expedited (15-DaCompany Report #2004093749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident	Foreign	Nicotine Patch			
		Consumer	(Nicotine)	PS		
TRANSDERMAL 1 PATCH DAILY						
PRN,						
TRANSDERMAL						
			Rofecoxib			
			(Rofecoxib)	SS		ORAL
ORAL						
			Salbutamol			
			(Salbutamol)	C		
			Fluticasone Propionate (Fluticasone Propionate)	C		
			Ipratropium Bromide (Ipratropium Bromide)	C		

Date:11/24/04ISR Number: 4514398-7Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx 25 Mg	PS		ORAL
25						
Hospitalization -	Dyspnoea	Study				
MG/DAILY/PO						
Initial or Prolonged	Malaise	Health	Amlodipine Besylate	C		
	Ventricular Dysfunction	Professional				

Date:11/24/04ISR Number: 4514405-1Report Type:Expedited (15-DaCompany Report #WAES 0411ITA00005
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia	Foreign Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Chest Pain							
	Syncope	Health Professional	Aspirin	C				
			Atenolol	C				
			Eicospentaenoic Acid	C				
			Ramipril	C				
			Simvastatin	C				

Date:11/26/04ISR Number: 4514258-1Report Type:Expedited (15-DaCompany Report #02/02158-USE
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blindness
	Blood Cholesterol
Other	Increased
	Blood Triglycerides
	Increased
	Breath Sounds Decreased
	Coma
	Coordination Abnormal

		Deep Vein Thrombosis					
		Depression					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Insulin-Dependent	Health	Yasmin			
		Dyspepsia	Professional	(Drospirenone,			
		Electrocardiogram St	Company	Ethinylestradiol)			
		Segment Abnormal	Representative	Film Tablet	PS		ORAL
1 TAB/DAY,							
		Electrocardiogram T Wave	Other				
ORAL							
		Abnormal		Vioxx (Rofecoxib)	SS		ORAL
SEE IMAGE							
		Fall		Sandimmune			
		Fibromyalgia		(Ciclosporin)	C		
		Headache		Hormonal			
		Heart Rate Irregular		Contraceptives For			
		Hydrocephalus		Systemic Use	C		
		International Normalised					
		Ratio Decreased					
		Joint Effusion					
		Lung Disorder					
		Memory Impairment					
		Muscle Disorder					
		Nausea					
		Optic Nerve Disorder					
		Polycystic Ovaries					
		Rash					
		Sex Hormone Binding					
		Globulin Decreased					
		Sinus Tachycardia					
		Subarachnoid Haemorrhage					
		Thrombotic Stroke					
		Tinnitus					
		Tunnel Vision					
		Uterine Enlargement					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Vision Blurred					
		Visual Field Defect					
		Vomiting					

Date:11/26/04ISR Number: 4514530-5Report Type:Expedited (15-DaCompany Report #STA-AE-04-MTX-587
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea Hyperhidrosis Myalgia	Foreign Health Professional	Methotrexate (Methotrexate, Tablet)	PS		ORAL	20 MG 1X PER	1 WK, ORAL
	Pneumonitis	Distributor						
		Other	Vioxx (Rofecoxib, Tablet)	SS		ORAL	25 MG	ORAL
			Folic Acid (Folic Acid)	C				
			Co-Proxamol (Dextroproppxyphene Hydrochloride/Paracetamol)	C				
			Omeprazole (Omeprazole)	C				
			Atorvastatin (Atorvastatin)	C				
			Co-Amilofruse (Amiloride					

Hydrochloride/Furosemide)	C
Ferrous Sulfate (Ferrous Sulfate)	C
Aspirin (Acetylsalicylic Acid)	C

Date:11/26/04ISR Number: 4529774-6Report Type:Periodic Company Report #SU-2004-002639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain	Consumer	Benicar	PS		ORAL	20 MG QD PO	
	Back Pain		Benicar	SS		ORAL	40 MG QD PO	
	Dry Mouth		Benicar	SS		ORAL	20 MG QD PO	
	Oral Mucosal Blistering		Vioxx	SS				
			Premarin	C				

Date:11/29/04ISR Number: 4511722-6Report Type:Expedited (15-DaCompany Report #200414288FR
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Bicarbonate Decreased		Lasilix	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Haematuria		Coversyl	SS		ORAL		
	Hyperkalaemia		Vioxx	SS		ORAL		
	Proteinuria							
	Renal Failure Acute							

Date:11/29/04ISR Number: 4511731-7Report Type:Expedited (15-DaCompany Report #200414349FR
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased		Claforan	PS	Aventis Pharmaceuticals Inc.	INTRAVENOUS		

	Bradycardia	Vancomycine	SS
INTRAVENOUS			
	Grand Mal Convulsion	Dafalgan	SS ORAL
	Hypertension	Vioxx	SS ORAL
	Meningitis	Morphine	
	Nodal Arrhythmia	Chlorhydrate	SS ORAL
	Nodal Rhythm	Acupan	SS
INTRAVENOUS			
	Respiratory Failure	Troxerutin	C
	Reversible Posterior	Stresam	C
	Leukoencephalopathy	Stilnox	C
	Syndrome		

Date:11/29/04ISR Number: 4511833-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event
	Blood Cholesterol
	Abnormal
	Bursitis
	Cardiac Failure
	Congestive
	Cardiovascular Disorder
	Chest Wall Pain

		Decreased Activity					
		Drug Hypersensitivity					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fibula Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Head Injury		Osteo-Bi-Flex	C		
UNKNOWN							
		Headache		Estrace	C		
UNKNOWN							
		Hypertension		Vitamins			
		Kidney Infection		(Unspecified)	C		
UNKNOWN							
		Laryngitis		Flagyl	C		
UNKNOWN							
		Muscle Spasms		Cipro	C		
UNKNOWN							
		Oedema					
		Osteoarthritis					
		Pharyngolaryngeal Pain					
		Renal Failure					
		Rheumatic Fever					
		Rheumatoid Arthritis					
		Sleep Disorder					
		Stress					
		Tendonitis					
		Urinary Tract Infection					
		Varicose Vein					
		Vertigo					
		Viral Upper Respiratory					
		Tract Infection					
		Visual Disturbance					

Date:11/29/04ISR Number: 4511838-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Clinoril	SS		ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Robaxin	C		ORAL

	Diverticulum	Premarin	C	ORAL
	Drug Ineffective	Prilosec	C	
UNKNOWN				
	Duodenitis	Fosamax	C	
UNKNOWN				
	Erosive Oesophagitis	Amitriptyline		
	Gastritis Haemorrhagic	Hydrochloride	C	ORAL
	Hepatitis	Diphenhydramine		
	Limb Discomfort	Tannate	C	ORAL
	Lung Neoplasm	Docusate Sodium	C	ORAL
	Malnutrition	Norvasc	C	ORAL
	Mycobacterium Avium	Wellbutrin Sr	C	ORAL
	Complex Infection	Rifampin	C	ORAL
	Myocardial Infarction	Ethambutol		
	Oedema Peripheral	Hydrochloride	C	ORAL
	Otitis Externa	Lampren	C	ORAL
	Pruritus			
	Rash Morbilliform			
	Rash Vesicular			
	Upper Respiratory Tract			
	Infection			
	Urinary Tract Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4511847-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Zoloft	C			UNKNOWN	
	Coronary Artery Disease		Tenormin	C			UNKNOWN	
	Cystitis		Tenormin	C			UNKNOWN	
	Depression		Temazepam	C			UNKNOWN	
	Dizziness		Tagamet	C			UNKNOWN	
	Duodenal Ulcer		Aspirin	C			UNKNOWN	
	Emotional Distress		Augmentin	C			UNKNOWN	
	Erectile Dysfunction		Zocor	C		ORAL		
	Gastritis		Motrin	C			UNKNOWN	
	Gastroenteritis		Plavix	C			UNKNOWN	
	Helicobacter		Relafen	C			UNKNOWN	
	Haematemesis		Nitrostat	C			UNKNOWN	
	Haemorrhoids							
	Hypercalcaemia							
	Hyperparathyroidism							
	Hypertension							
	Injury							
	Mediastinitis							
	Nausea							
	Oedema Peripheral							
	Pain In Extremity							
	Plantar Fasciitis							
	Pleural Effusion							
	Postoperative Infection							
	Postpericardiotomy							

Syndrome
Spinal Osteoarthritis
Tricuspid Valve
Incompetence
Ulnar Nerve Injury
Venous Thrombosis Limb
Vomiting

Date:11/29/04ISR Number: 4511848-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00770
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Baycol	C		ORAL		
	Arthritis		Glynase Prestab Tablets	C		ORAL		
	Blood Pressure Increased		Levothroid	C		ORAL		
	Cerebrovascular Accident		Imdur	C			UNKNOWN	
	Convulsion		Procardia Xl	C		ORAL		
	Eructation		Metoprolol	C			UNKNOWN	
	Gastrooesophageal Reflux		Lasix (Furosemide)	C		ORAL		
	Disease		Aspirin	C			UNKNOWN	
	Sinus Arrhythmia		Glucophage	C		ORAL		
	Sinus Bradycardia		Synthroid	C			UNKNOWN	
	Weight Decreased		Tylenol With Codeine #3	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4511850-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthropod Bite							
	Asthma							
	Blood Pressure Increased							
	Bronchitis							
	Cardiomegaly							
	Chronic Obstructive							
	Pulmonary Disease							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Depression							
	Dysarthria							
	Dysphagia							
	Dysphonia							
	Dysuria							
	Encephalopathy							
	Fall							
	Foot Fracture							
	Fractured Coccyx							
	Gastrooesophageal Reflux							
	Disease							
	Haematuria							
	Head Injury							
	Hypertensive Crisis							
	Hypotension							
	Insomnia							
	Joint Sprain							
	Malaise							
	Mental Impairment							
	Myalgia							
	Nausea							
	Neck Pain							
	Osteoarthritis							
	Pain In Extremity							
	Respiratory Distress							
	Road Traffic Accident							
	Seborrhoeic Keratosis							
	Skeletal Injury							
	Skin Papilloma							

Sleep Walking
Upper Respiratory Tract
Infection
Urinary Tract Infection
Urticaria

Date:11/29/04ISR Number: 4511852-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00654
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anorexia
Other	Anxiety
	Arthropod Sting
	Asthenia

	Blister Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Blood Triglycerides		Vioxx	PS	Merck & Co., Inc	ORAL
2	MON					
	Increased		Avalide	C		
UNKNOWN	2 MON					
	Bronchitis		Prilosec	C		
UNKNOWN						
	Bronchitis Acute		Synthroid	C		ORAL
	Cardiac Failure		Aspirin	C		
UNKNOWN						
	Congestive		Pyridoxine	C		
UNKNOWN						
	Carpal Tunnel Syndrome		Vitamin E	C		
UNKNOWN						
	Cellulitis					
	Chest Pain					
	Cough					
	Deep Vein Thrombosis					
	Dyspnoea					
	Epistaxis					
	Fatigue					
	Heart Rate Increased					
	Hypertension					
	Insomnia					
	Nail Disorder					
	Nasopharyngitis					
	Nephropathy					
	Palpitations					
	Polytraumatism					
	Renal Failure Chronic					
	Renal Impairment					
	Skin Cancer					
	Tinnitus					
	Tonsillar Disorder					
	Tremor					
	Urinary Tract Infection					

Date:11/29/04ISR Number: 4511854-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00784
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Drug Reaction

Initial or Prolonged Disability	Adverse Event
	Arthralgia
	Asthenia
	Azotaemia
	Back Pain
	Breast Mass
	Dehydration
	Diabetes Mellitus
	Diverticulum
	Dyskinesia
	Dysuria
	Eczema
	Fatigue
	Gallbladder Enlargement
	Hepatitis
	Herpes Zoster
	Hypertensive Emergency
	Hypertrophy
	Influenza
	Intervertebral Disc Displacement
	Intervertebral Disc

	Protrusion						
	Myalgia						
	Oedema Peripheral						
	Pollakiuria	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rectal Haemorrhage		Norvasc	C			
UNKNOWN							
	Rhabdomyolysis		Hydrochlorothiazide	C			
UNKNOWN							
	Scoliosis		Diovan	C			
UNKNOWN							
	Seborrhoeic Keratosis		Pravachol	C			
UNKNOWN							
	Spinal Osteoarthritis		Gemfibrozil	C			
UNKNOWN							
	Splenic Cyst						
	Spondylolisthesis						
	Tendonitis						
	Vomiting						
	Weight Decreased						

Date:11/29/04ISR Number: 4511855-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00805
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Aortic Valve Incompetence		Lotrel	C		ORAL	
Other	Arthropathy		Lasix (Furosemide)	C			
UNKNOWN							
	Atherosclerosis		Nolvadex	C			
UNKNOWN							
	Cardiac Failure						
	Congestive						
	Cervical Polyp						
	Cholelithiasis						
	Fall						
	Gallbladder Disorder						
	Hyperplasia						
	Hypertension						
	Mitral Valve Incompetence						
	Pneumonia						
	Polytraumatism						

Postmenopausal
Haemorrhage
Renal Failure
Sinus Disorder
Tricuspid Valve
Incompetence
Uterine Leiomyoma
Uterine Polyp
Vaginal Ulceration
Wrist Fracture

Date:11/29/04ISR Number: 4511856-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00816
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anxiety
Other	Back Pain
	Bronchitis
	Bronchitis Acute
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease

		Cough					
		Dyspnoea					
		Electrocardiogram Poor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		R-Wave Progression		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypersensitivity					
		Hypertension					
		Hypotension					
		Increased Upper Airway					
		Secretion					
		Infarction					
		Insomnia					
		Monarthritis					
		Muscle Spasms					
		Nasal Congestion					
		Nasopharyngitis					
		Neuroleptic Malignant					
		Syndrome					
		Oedema Peripheral					
		Pain					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Polyarthritis					
		Polytraumatism					
		Rheumatoid Arthritis					
		Sinusitis					
		Spondylitis					
		Stress					
		Swelling Face					
		Urinary Tract Infection					
		Vasculitis					
		Vomiting					

Date:11/29/04ISR Number: 4511857-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00785
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased					
		Convulsion					

Date:11/29/04ISR Number: 4511858-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00867
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Anaemia Postoperative
	Aortic Valve Sclerosis
	Bradycardia
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomegaly
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Diabetic Retinopathy
	Diastolic Dysfunction

		Dyspnoea Exertional					
		Facial Palsy					
		Goitre	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL
		Interstitial Lung Disease					
		Ischaemic Cardiomyopathy					
		Macular Degeneration					
		Neuropathy Peripheral					
		Osteoarthritis					
		Polytraumatism					
		Primary Hypothyroidism					
		Pulmonary Hypertension					
		Restrictive Pulmonary					
		Disease					
		Right Ventricular Failure					
		Rotator Cuff Syndrome					
		Skin Cancer					
		Sleep Apnoea Syndrome					
		Thyroid Neoplasm					
		Ventricular Hypertrophy					

Date:11/29/04ISR Number: 4511870-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03537
Age:49 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Abnormal Faeces		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		[Therapy			
		Depression		Unspecified]	C		
UNKNOWN							
		Diarrhoea		Flonase	C		
UNKNOWN							
		Dysphagia		Premarin	C		
UNKNOWN							
		Gastric Disorder		Hydroxychloroquine			
		Gastrooesophageal Reflux		Sulfate	C		
UNKNOWN							
		Disease		Zoloft	C		
UNKNOWN							
		Haemorrhoids		Ambien	C		
UNKNOWN							

	Headache	Daypro	C
UNKNOWN			
	Irritable Bowel Syndrome	Claritin	C
UNKNOWN			
	Labyrinthitis		
	Ovarian Cyst		
	Panic Disorder		
	Peptic Ulcer		
	Proctalgia		
	Rectal Haemorrhage		
	Rheumatoid Arthritis		
	Rhinitis Allergic		
	Systemic Lupus		
	Erythematosus		
	Urethral Stricture		
	Vertigo		

Date:11/29/04ISR Number: 4511871-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time
Disability	Prolonged

		Acute Myocardial Infarction					
		Angina Pectoris	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Aortic Valve Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Bilirubin Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Claritin-D	SS		ORAL
		Coronary Artery Disease		Ceftin	C		ORAL
		Emotional Distress		Percocet	C		ORAL
		Gallop Rhythm Present		Vicodin Es Tablets	C		ORAL
		Hyperlipidaemia		Ambien	C		ORAL
		Hypertension		Zoloft	C		ORAL
		Hypertensive Heart Disease		Zoloft	C		ORAL
		Limb Discomfort					
		Mitral Valve Disease					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Musculoskeletal Discomfort					
		Sleep Apnoea Syndrome					
		Tenosynovitis					
		Thrombosis					
		Trigger Finger					

Date:11/29/04ISR Number: 4511883-9Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00057
Age:81 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
336 DAY							
		Condition Aggravated					
		Coronary Artery Disease					

Date:11/29/04ISR Number: 4511884-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00940
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL

	Angina Pectoris	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased	Soma	C		
UNKNOWN					
	Convulsion	Medrol	C		
UNKNOWN					
	Neck Pain	Vicodin Tablets	C		
UNKNOWN					
	Phlebothrombosis	Aciphex	C		
UNKNOWN					
	Rotator Cuff Syndrome	Coumadin	C		
UNKNOWN					

Date:11/29/04ISR Number: 4511885-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02123
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Pulmonary Oedema
Hospitalization -	Cardiac Arrest
Initial or Prolonged	Cardiomyopathy
Disability	Depression
Other	Dyspnoea
	Eye Disorder
	Fatigue
	Left Ventricular Failure

		Macular Oedema					
		Mitral Valve Incompetence					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Methotrexate	C		
UNKNOWN							
		Respiratory Failure		Enbrel	C		
UNKNOWN							
		Retinal Haemorrhage		Prednisone	C		
UNKNOWN							
		Retinal Vasculitis		Neurontin	C		
UNKNOWN							
		Supraventricular		Diovan	C		
UNKNOWN							
		Tachycardia		Caltrate	C		
UNKNOWN							
		Visual Acuity Reduced		Foradil	C		
UNKNOWN							
		Weight Decreased		Aspirin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:11/29/04ISR Number: 4511886-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02966
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
137 DAY							
Other		Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
8 DAY							
		Cataract		Vioxx	SS	Merck & Co., Inc	ORAL
137 DAY							
		Facial Palsy		Vioxx	SS	Merck & Co., Inc	ORAL
8 DAY							
		Peripheral Nerve		Synthroid	C		
UNKNOWN							
		Transposition		Prevacid	C		
UNKNOWN							
		Post Procedural		Thyroid	C		ORAL
		Complication		Altocor	C		
UNKNOWN							

	Wrist Fracture	Zetia	C
UNKNOWN			
		Allegra	C
UNKNOWN			
		Nasonex	C
RESPIRATORY			
(INHALATION)			
		Lasix (Furosemide Sodium)	C
UNKNOWN			
		Klonopin	C
UNKNOWN			
		Paxil Cr	C
UNKNOWN			

Date:11/29/04ISR Number: 4511888-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Anxiety
	Arthralgia
	Back Pain
	Benign Prostatic Hyperplasia
	Cholecystectomy
	Chronic Sinusitis
	Condition Aggravated
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Cyst
	Dehydration
	Depression
	Gallbladder Disorder
	Gout
	Hodgkin'S Disease
	Inguinal Hernia

		Musculoskeletal Discomfort Myalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Myopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Nephritis Interstitial		Vioxx	SS	Merck & Co., Inc	ORAL
		Prostatic Specific		Vioxx	SS	Merck & Co., Inc	ORAL
		Antigen Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Rectal Examination		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Claritin-D	C		
UNKNOWN							
		Renal Disorder		Flomax (Tamsulosin			
		Renal Failure		Hydrochloride)	C		
UNKNOWN							
		Renal Failure Acute		Flonase	C		
UNKNOWN							
		Renal Tubular Necrosis		Diazepam	C		
UNKNOWN							
		Scar		Plendil	C		
UNKNOWN							
		Synovial Cyst		Pravachol	C		
UNKNOWN							
		Tension Headache		Wellbutrin	C		
UNKNOWN							

Date:11/29/04ISR Number: 4511889-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00862
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Amaurosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebrovascular Accident		Prevacid	C		
UNKNOWN							
Disability		Headache		Ativan	C		
UNKNOWN							
		Scotoma		Celebrex	C		
UNKNOWN							
		Visual Acuity Reduced					

Date:11/29/04ISR Number: 4511890-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03353
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		[Therapy Unspecified]	C				
	Congestive							
	Dyspnoea		[Therapy Unspecified]	C				
	Rectal Haemorrhage							
	Refusal Of Treatment By Patient							
	Treatment Noncompliance							

Date:11/29/04ISR Number: 4511892-XReport Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00077
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error							
	Respiratory Arrest							
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4511893-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02095
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Paxil Cr	C		ORAL		
Initial or Prolonged	Dyspnoea		Zocor	C		ORAL		
Disability	Muscle Spasms		[Therapy Unspecified]	C				
UNKNOWN								

Date:11/29/04ISR Number: 4511900-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00451
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Verapamil	C		ORAL		
Initial or Prolonged			Propafenone Hydrochloride	C		ORAL		
Disability			Pantoprazole Sodium	C		ORAL		
			Acetyldigoxin	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		

Date:11/29/04ISR Number: 4511902-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00037
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
1080 DAY								
Initial or Prolonged	Dizziness		Verapamil Hydrochloride	C				
UNKNOWN								
			Atorvastatin Calcium	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Amiloride Hydrochloride	C				
UNKNOWN								

	Lansoprazole	C
UNKNOWN		
	Furosemide Sodium	C
UNKNOWN		
	Glipizide	C
UNKNOWN		
	Metformin	C
UNKNOWN		

Date:11/29/04ISR Number: 4511903-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02653
Age:75 YR Gender:Male I/FU:I

Outcome	PT
Death	Acute Myocardial
Other	Infarction
	Agitation
	Cardiogenic Shock
	Cardiomegaly
	Confusional State
	Coronary Artery
	Atherosclerosis
	Coronary Artery Occlusion
	Electromechanical
	Dissociation
	Gastric Ulcer Haemorrhage
	Hydrocele
	Hypotension
	Metabolic Acidosis
	Renal Atrophy

		Restlessness Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Zoloft	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				A.S.A.	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							

Date:11/29/04ISR Number: 4511904-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02887
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/29/04ISR Number: 4511905-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00441
Age:67 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/29/04ISR Number: 4511906-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03029
Age:46 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL

	Dizziness		Advil	C			
UNKNOWN							
	Vomiting						

Date:11/29/04ISR Number: 4511919-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03376
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder		Premarin	C				
UNKNOWN								
			Vitamin D (Unspecified)	C				
UNKNOWN								

Date:11/29/04ISR Number: 4511920-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	27	DAY

Date:11/29/04ISR Number: 4511921-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00028
Age:56 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Dysphagia
Initial or Prolonged	Hypopharyngeal Neoplasm

		Laryngeal Neoplasm Odynophagia					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/29/04ISR Number: 4511923-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abnormal Clotting Factor Adverse Event Arrhythmia Coagulopathy Hypertension Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/29/04ISR Number: 4511924-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03388
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Myocardial Infarction		[Therapy Unspecified]	C		
UNKNOWN						

Date:11/29/04ISR Number: 4511925-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Splenic Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:11/29/04ISR Number: 4511927-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Double Vessel Bypass Graft		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4511928-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02344
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Headache		Flonase	C			UNKNOWN	
	Heart Rate Increased Pain							

Date:11/29/04ISR Number: 4511929-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	6	YR
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4511930-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03304
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	2100 DAY	
			Kerlone	C			UNKNOWN	

Date:11/29/04ISR Number: 4511935-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4511936-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4511939-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03403
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Altace	C				
Disability			Nitroglycerin	C			UNKNOWN	
			Alprazolam	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Trazodone					

			Hydrochloride	C		
UNKNOWN						
			Pentoxifylline	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Cymbalta	C		
UNKNOWN						

Date:11/29/04ISR Number: 4511940-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03526
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:11/29/04ISR Number: 4511941-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03177
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL	240	DAY
	Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL	240	DAY
	Urinary Bladder		Vicodin Tablets	C				
UNKNOWN								
	Haemorrhage		Tranex	C				
UNKNOWN								
			Ultram	C				
UNKNOWN								
			Ascorbic Acid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4511943-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03405
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Plaquenil	C				
			Metoprolol	C				UNKNOWN

Date:11/29/04ISR Number: 4511944-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Disability	Nausea		Atacand	C				UNKNOWN
	Syncope							

Date:11/29/04ISR Number: 4511945-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03619
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cardiovascular Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4511947-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03711
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4511949-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Dyspnoea							

Date:11/29/04ISR Number: 4512185-7Report Type:Expedited (15-DaCompany Report #FR-ROCHE-386940
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatic Steatosis		Rivotril	PS	Roche	ORAL		
Initial or Prolonged	Hepatitis		Deroxat	SS		ORAL		
	Hepatitis Alcoholic		Vioxx	SS		ORAL		
	Hepatomegaly		Tercian	SS		ORAL		
			Investigational Drug Nos	SS		ORAL		

DRUG NAME:

TEMERIT

Date:11/29/04ISR Number: 4512568-5Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00046
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory
Other	Distress Syndrome

	Haemodialysis						
	Hepatic Failure						
	Hepatitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocarditis		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
	Pneumonia Primary		Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY
	Atypical		Cefazolin	C			
	Renal Failure		[Therapy Unspecified]	C			
	Respiratory Failure		Ofloxacin	C			
	Dexamethasone		Azithromycin				

Date:11/29/04ISR Number: 4512574-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc		UNKNOWN
Other	Arteriosclerosis		Levothyroxine Sodium	C			UNKNOWN
	Arthralgia		Cardizem	C			UNKNOWN
	Asthma		Prilosec	C			UNKNOWN
	Benign Prostatic		Lipitor	C			UNKNOWN
	Hyperplasia		Triamterene	C			UNKNOWN
	Blood Cholesterol		Plavix	C			UNKNOWN
	Increased		Aspirin	C			UNKNOWN

Cerebrovascular Accident
Colonic Polyp
Convulsion
Gastrooesophageal Reflux
Disease
Haematuria
Haemorrhoids
Hydronephrosis
Hypertension
Hypertonic Bladder
Neurodermatitis
Nocturia
Nodule
Pain In Extremity
Pneumonia
Proteinuria
Rash

Date:11/29/04ISR Number: 4512577-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00097
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Clopidogrel Bisulfate	C			UNKNOWN	
			Irbesartan	C			UNKNOWN	
			Irbesartan	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512579-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03720
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Amaryl	C		
UNKNOWN						
Disability			Glucophage Xr	C		
UNKNOWN						

Date:11/29/04ISR Number: 4512580-6Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00038
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anal Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arterial Rupture					
	Chest Pain					
	Cholecystitis					
	Gastrointestinal					
	Haemorrhage					
	Gastrointestinal Ulcer					
	Haemoglobin Decreased					
	Headache					
	Mouth Ulceration					
	Proctitis					
	Tongue Ulceration					

Date:11/29/04ISR Number: 4512582-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00171
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain					

Date:11/29/04ISR Number: 4512583-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00065
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Facial Paresis		Vioxx	PS	Merck & Co., Inc	ORAL		219 DAY
Initial or Prolonged	Pleural Mesothelioma		Vioxx	SS	Merck & Co., Inc	ORAL		219 DAY
	Trigeminal Nerve Disorder		Dipyrone	C		ORAL		
			Prednisone	C				

Date:11/29/04ISR Number: 4512584-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00275
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Other	Fear		Plavix	C				UNKNOWN
	Myocardial Infarction		Synthroid	C				UNKNOWN
			Zetia	C		ORAL		
			Lotrel	C				UNKNOWN
			Zanaflex	C				UNKNOWN
			Skelaxin	C				UNKNOWN
			Phenergan (Promethazine Hydrochloride)	C				UNKNOWN
			Percocet	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512585-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00040
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gallbladder Disorder		Nexium	C				
UNKNOWN								
Other	Procedural Complication		Triphasil	C				
UNKNOWN								

Date:11/29/04ISR Number: 4512586-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00058
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Morphine	C		ORAL		
Disability	Cardiomegaly		Molsidomine	C		ORAL		
	Coronary Artery		Aspirin	C		ORAL		
	Atherosclerosis		Ramipril	C		ORAL		
	Coronary Artery Occlusion		Allopurinol	C		ORAL		
	Coronary Artery Stenosis		Metoprolol	C		ORAL		
	Myocardial Infarction		Bisacodyl	C		ORAL		
	Overdose		Omeprazole	C				
UNKNOWN								
	Ventricular Dysfunction							

Date:11/29/04ISR Number: 4512593-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00708
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Lexapro	C				
UNKNOWN								
	Cerebrovascular Accident							
	Chest Pain							
	Difficulty In Walking							
	Eating Disorder							
	Gastric Haemorrhage							

General Symptom
Oedema Peripheral
Ovarian Cancer

Date:11/29/04ISR Number: 4512595-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00177
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Faeces		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged Disability	Bladder Disorder							
	Constipation							
	Emotional Distress							
	Faeces Discoloured							
	Fatigue							
	Hypersensitivity							
	Inflammation							
	Mental Disorder							
	Photosensitivity Reaction							
	Sleep Disorder							
	Spinal Cord Disorder							

Date:11/29/04ISR Number: 4512596-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Amaurosis Fugax
	Angina Pectoris
	Angiopathy
	Antibody Test Positive
	Aortic Atherosclerosis
	Aortic Dilatation
	Aortic Dissection
	Aortic Embolus
	Aortic Stenosis
	Aortic Valve Incompetence
	Aortic Valve Stenosis
	Arthralgia
	Autoimmune Thyroiditis
	Back Pain
	Benign Neoplasm Of Eyelid
	Bicuspid Aortic Valve
	Blindness Transient
	Blindness Unilateral
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiolipin Antibody Positive
	Carotid Artery Disease
	Cartilage Injury
	Cervical Vertebra Injury
	Chest Pain
	Coagulopathy
	Convulsion
	Coronary Artery Stenosis
	Dilatation Ventricular
	Dizziness
	Dyspnoea
	Ecchymosis
	Eyelid Disorder
	Fatigue
	Flushing
	Headache
	High Density Lipoprotein Increased
	Hypoaesthesia
	Hypothyroidism

Inflammation
Intervertebral Disc
Disorder
Joint Dislocation
Low Density Lipoprotein
Increased
Mitral Valve Incompetence
Mitral Valve Stenosis
Muscle Spasms
Muscle Twitching
Myalgia
Myokymia
Osteoarthritis
Palpitations
Paraesthesia

	Periorbital Disorder						
	Sensation Of Pressure						
	Sensory Level Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	4	WK
	Stress		Vioxx	SS	Merck & Co., Inc	UNKNOWN		2 DAY
	Thyroiditis							
	Transient Ischaemic Attack							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							
	Ventricular Septal Defect Acquired							

Date:11/29/04ISR Number: 4512598-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00412
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations							

Date:11/29/04ISR Number: 4512599-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Other	Bronchopneumonia							
	Circulatory Collapse							
	Decerebration							
	Haemodynamic Instability							
	Myocardial Infarction							
	Pneumonia Aspiration							
	Renal Failure							
	Sepsis							

Date:11/29/04ISR Number: 4512600-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00429
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4512602-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Hospitalization - Initial or Prolonged	Drug Exposure During Pregnancy Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512603-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Mitral Valve Disease							
	Myocardial Infarction							

Date:11/29/04ISR Number: 4512604-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00192
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Aspirin	C		ORAL		
	Pain		Atenolol	C		ORAL		
			Atenolol	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Simvastatin	C		ORAL		
			Quinine	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Dihydrocodeine	C		ORAL		

Date:11/29/04ISR Number: 4512607-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00084
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
	Blood Pressure Increased							
	Cerebral Ischaemia							
	Dizziness							
	Hypoaesthesia							
	Lip Discolouration							
	Nausea							

Date:11/29/04ISR Number: 4512616-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00047
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Prednisolone	C		ORAL		
	Epilepsy		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
	Gamma-Glutamyltransferase Increased		Sulfasalazine	C		ORAL		
			Loratadine	C		ORAL		

Date:11/29/04ISR Number: 4512621-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03361
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Dyspnoea		Lipitor	C				
Initial or Prolonged UNKNOWN			Atenolol	C				
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512622-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4512624-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03401
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		[Therapy					
Initial or Prolonged	Cerebrovascular Accident		Unspecified]	C				
UNKNOWN								
Disability	Gastric Haemorrhage							

Date:11/29/04ISR Number: 4512625-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03044
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/29/04ISR Number: 4512627-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Angiopathy							
	Cardiac Disorder							
	Injury							
	Multi-Organ Disorder							
	Pain							
	Palpitations							

Date:11/29/04ISR Number: 4512628-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03351
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			Plavix	C				

UNKNOWN

Date:11/29/04ISR Number: 4512629-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03400
Age:50 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Anxiety
Hospitalization - Initial or Prolonged	Bone Disorder
	Epistaxis
Disability	Faeces Discoloured
	Faeces Pale
	Hypertension
	Liver Disorder
	Menorrhagia
	Muscle Spasms
	Nerve Degeneration

Platelet Count Decreased
Platelet Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	
	Vioxx	SS	Merck & Co., Inc	ORAL	10 MON	
	[Therapy Unspecified]	C			UNKNOWN	
	Flexeril	C			UNKNOWN	
	Zanaflex	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Vicoprofen	C			UNKNOWN	
	Atenolol	C			UNKNOWN	
	Celexa	C			UNKNOWN	

Date:11/29/04ISR Number: 4512632-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03398
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Menstruation Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4512633-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03407
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache Hypertension Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tylenol With Codeine #4	C			UNKNOWN	

Date:11/29/04ISR Number: 4512634-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03470
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:11/29/04ISR Number: 4512635-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03539
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:11/29/04ISR Number: 4512636-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	
Initial or Prolonged	Congestive Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4512638-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03411
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4512640-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03582
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	273 DAY	
Hospitalization - Initial or Prolonged	Mitral Valve Incompetence		Miacalcin	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Nadolol	C			UNKNOWN	

Date:11/29/04ISR Number: 4512642-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03460
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON	

Date:11/29/04ISR Number: 4512643-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03431
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dementia							

Disability

Date:11/29/04ISR Number: 4512646-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03520
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN								
Disability								

Date:11/29/04ISR Number: 4512647-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/29/04ISR Number: 4512673-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03396
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
Disability	Chest Pain		Glucophage	C				
UNKNOWN								
	Dyspnoea		[Therapy					
	Irritability		Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/29/04ISR Number: 4515040-1Report Type:Direct Company Report #CTU 233150
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypoacusis		Vioxx 12.5 Mg Merck	PS	Merck	ORAL	2 TABS DAILY	
						ORAL		

Date:11/29/04ISR Number: 4515156-XReport Type:Direct Company Report #CTU 233181
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx 25mg Merck &					
Hospitalization -	Colon Cancer		Co Inc.	PS	Merck & Co Inc.			
Initial or Prolonged	Myocardial Infarction							
Disability	Pulmonary Thrombosis							
Required	Thrombosis							
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:11/29/04ISR Number: 4516272-9Report Type:Expedited (15-DaCompany Report #WAES 0310GBR00110
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypotension	Foreign	Tab Vioxx					
Hospitalization -	Leiomyoma	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	23 DAY
Initial or Prolonged	Multi-Organ Failure	Other	Tab Aspirin	SS		ORAL	75 MG	
	Transfusion Reaction		Atenolol	C				
	Upper Gastrointestinal		Ramipril	C				
	Haemorrhage		Simvastatin	C				

Date:11/30/04ISR Number: 4513139-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Lopressor	C				
UNKNOWN								
	Injury							

Date:11/30/04ISR Number: 4513148-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00921
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Anaemia
	Angina Pectoris
	Aortic Valve Sclerosis
	Atrial Fibrillation
	Blood Pressure Increased
	Cardiac Murmur
	Carotid Artery Disease
	Cerebrovascular Accident
	Colonic Polyp

		Convulsion					
		Cough					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Avalide	C		
UNKNOWN							
		Diverticulum Intestinal		Cardura	C		
UNKNOWN							
		Dizziness					
		Fatigue					
		Feeling Abnormal					
		Frequent Bowel Movements					
		Gastritis Erosive					
		Haemorrhoids					
		Mitral Valve Incompetence					
		Mitral Valve Sclerosis					
		Oesophageal Disorder					
		Pyrexia					
		Sick Sinus Syndrome					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Wheezing					

Date:11/30/04ISR Number: 4513151-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00635
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety					
Disability		Bronchitis					
Other		Cardiovascular Disorder					
		Chronic Obstructive					
		Pulmonary Disease					
		Dental Caries					
		Depression					
		Diabetes Mellitus					
		Dyspnoea					
		Faecaloma					
		Fall					
		Gastrooesophageal Reflux					
		Disease					
		Herpes Zoster					

Hiatus Hernia
Hypokalaemia
Lobar Pneumonia
Oedema Peripheral
Osteoarthritis
Osteoporosis
Panic Attack
Pneumonia
Polytraumatism
Schizophrenia, Paranoid
Type
Sinus Bradycardia
Supraventricular
Tachycardia
Tooth Disorder
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513156-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Abnormal Faeces		Prevacid	C				
UNKNOWN								
	Acute Sinusitis		Ultram	C				
UNKNOWN								
	Adverse Event		Norvasc	C				
UNKNOWN								
	Arthralgia		Pulmicort	C				
UNKNOWN								
	Barrett'S Oesophagus		Celebrex	C				
UNKNOWN								
	Benign Duodenal Neoplasm		Maxzide	C				
UNKNOWN								
	Blood Pressure Increased		Estradiol	C				
UNKNOWN								
	Bronchospasm		Singulair	C				
UNKNOWN								
	Brunner'S Gland Hyperplasia							
	Chest Pain							
	Chills							
	Constipation							
	Costochondritis							
	Dermatitis Allergic							
	Diarrhoea							
	Ear Pain							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux Disease							
	Headache							
	Helicobacter Infection							
	Hypertension							
	Lipids Increased							
	Liver Function Test Abnormal							
	Melaena							
	Neck Pain							
	Otitis Media							
	Pain							
	Pain In Extremity							
	Pharyngitis							

Proteinuria
Pyrexia
Rhinitis Allergic
Sensation Of Pressure
Sinus Congestion
Sinusitis
Tendonitis
Upper Respiratory Tract
Infection

Date:11/30/04ISR Number: 4513161-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Brain Oedema
Other	Cardio-Respiratory Arrest
	Cardiomegaly
	Coronary Artery
	Atherosclerosis
	Coronary Artery
	Thrombosis
	Myocardial Infarction
	Pulmonary Oedema

Splenomegaly
Sudden Death
Ventricular Fibrillation

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vicoprofen	C			UNKNOWN	
	Methocarbamol	C			UNKNOWN	

Date:11/30/04ISR Number: 4513162-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess
Other	Anaemia
	Arthralgia
	Atrial Fibrillation
	Atrial Flutter
	Blood Pressure Increased
	Cardiac Failure Chronic
	Cardiac Failure Congestive
	Carotid Bruit
	Clostridium Colitis
	Congestive Cardiomyopathy
	Convulsion
	Diabetes Mellitus Inadequate Control
	Diabetic Microangiopathy
	Diabetic Neuropathy
	Diarrhoea
	Diverticulum
	Dysphonia
	Ear Infection
	Furuncle
	Gastrointestinal Haemorrhage
	Graft Thrombosis
	Hyperammonaemia
	Hypercholesterolaemia
	Hyperkalaemia
	Hyponatraemia
	Hypotension
	Hypoxic Encephalopathy

Insomnia
Ischaemia
Ischaemic Hepatitis
Myocardial Ischaemia
Oedema Peripheral
Pain In Extremity
Polyp
Pulmonary Hypertension
Pyrexia
Renal Failure
Renal Failure Acute
Sinus Arrest
Sinus Bradycardia
Thrombocytopenia
Urinary Tract Infection
Vertigo
Vocal Cord Paralysis
Vomiting

		Weight Decreased					
		Weight Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Zestril	C		ORAL
				Glucophage	C		ORAL
				Methylprednisolone	C		
UNKNOWN							
				Levaquin	C		ORAL

Date:11/30/04ISR Number: 4513179-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
37 DAY						
	Arthralgia		Vicodin Tablets	C		ORAL
	Arthropathy		Clonidine	C		ORAL
	Back Injury					
	Back Pain					
	Cardiomegaly					
	Chest Pain					
	Chest Wall Pain					
	Contusion					
	Depression					
	Difficulty In Walking					
	Drug Ineffective					
	Excoriation					
	Fall					
	Gastric Haemorrhage					
	Haematocrit Decreased					
	Haemoglobin Decreased					
	Hypertension					
	Injury					
	Intervertebral Disc Displacement					
	Joint Effusion					
	Joint Range Of Motion Decreased					
	Joint Sprain					
	Joint Swelling					

Meniscus Lesion
Muscle Disorder
Muscle Strain
Osteoarthritis
Treatment Noncompliance
Upper Respiratory Tract
Infection

Date:11/30/04ISR Number: 4513186-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Asthma
	Back Pain
	Cardiac Failure
	Congestive

		Cardiomyopathy					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
584	DAY						
		Gastrooesophageal Reflux Disease		Vioxx	SS	Merck & Co., Inc	ORAL
				Celebrex	C		
UNKNOWN							
		Hyperlipidaemia		Clonidine	C		
UNKNOWN							
		Hypertension		Demadex	C		
UNKNOWN							
		Hypertensive Heart Disease		Digitek	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
		Muscle Spasms		Accupril	C		
UNKNOWN							
		Pain In Extremity					
		Spinal Osteoarthritis					
		Tendonitis					

Date:11/30/04ISR Number: 4513189-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03382
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Lacunar Infarction		Ambien	C		
UNKNOWN						
	Rash		Lipitor	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						

Date:11/30/04ISR Number: 4513190-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00299
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL

	Asthenia	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure	Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain	Vioxx	SS	Merck & Co., Inc	ORAL
	Constipation	Vioxx	SS	Merck & Co., Inc	ORAL
	Disturbance In Attention	Captopril	C		
UNKNOWN					
	Headache	Levothyroxine Sodium	C		
UNKNOWN					
	Hypertension	Tamsulosin			
	Metabolic Disorder	Hydrochloride	C		
UNKNOWN					
	Oedema Peripheral	Benzthiazide And			
	Palpitations	Triamterene	C		
UNKNOWN					
	Renal Failure	Harpagophytum			
	Vision Blurred	Procumbens	C		
UNKNOWN					
	Weight Increased	Tramadol			
		Hydrochloride	C		
UNKNOWN					
		Buprenorphine			
		Hydrochloride	C		
UNKNOWN					

Date:11/30/04ISR Number: 4513191-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Bronchitis
	Cardiomyopathy
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Constipation
	Cough

		Cubital Tunnel Syndrome					
		Decreased Appetite					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Feeling Hot And Cold		Premarin	C		
UNKNOWN							
		Headache		Effexor Xr	C		
UNKNOWN							
		Hyperlipidaemia		Remeron	C		ORAL
		Injury		Vicodin Tablets	C		
UNKNOWN							
		Lower Respiratory Tract		Soma	C		
UNKNOWN							
		Infection		Seroquel	C		ORAL
		Nasopharyngitis		Phenergan			
		Nervous System Disorder		(Promethazine			
		Neuropathy		Hydrochloride)	C		
UNKNOWN							
		Nocturia		Klonopin	C		
UNKNOWN							
		Sinusitis		Klonopin	C		
UNKNOWN							
		Tension		Risperdal	C		ORAL
		Visual Disturbance		Zestril	C		ORAL
				Zocor	C		
UNKNOWN							
				Celebrex	C		ORAL
30 DAY							
				Lanoxin	C		ORAL
				Plavix	C		ORAL
				Aspirin	C		ORAL
				Vistaril	C		
UNKNOWN							
				Geodon	C		
UNKNOWN							

Date:11/30/04ISR Number: 4513193-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Amnesia
Other	Anaemia
	Anal Fistula

Aneurysm Ruptured
Angina Pectoris
Anxiety
Appendicitis Perforated
Arthralgia
Atelectasis
Colitis Ulcerative
Convulsion
Coronary Artery Disease
Defaecation Urgency
Depression
Dermatitis
Drug Ineffective
Faecal Incontinence
Fall
Flatulence
Headache
Hypertension
Impaired Healing
Inflammatory Bowel
Disease
Intestinal Perforation
Intestinal Spasm
Intracranial Aneurysm
Joint Injury
Pain
Perianal Abscess

		Perirectal Abscess					
		Pneumoperitoneum					
		Proctalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Proctitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL
		Pruritus Ani		Vioxx	SS	Merck & Co., Inc	ORAL
		Sepsis					

Date:11/30/04ISR Number: 4513194-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00075
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue					
		Inflammation					
		Sudden Hearing Loss					
		Tinnitus					
		Tooth Disorder					

Date:11/30/04ISR Number: 4513198-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00636
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 479 DAY		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
				Isosorbide Dinitrate	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Magnesium Aspartate	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Atorvastatin Calcium	C		
UNKNOWN							

Date:11/30/04ISR Number: 4513199-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Other	Adverse Event
	Anaemia
	Angina Pectoris
	Angina Unstable
	Anxiety
	Arthralgia
	Arthropathy
	Back Pain
	Bacterial Infection
	Barrett'S Oesophagus
	Blood Pressure Increased
	Breast Pain
	Cartilage Injury
	Chest Pain
	Chest Wall Pain
	Cholelithiasis
	Condition Aggravated
	Convulsion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Cough

		Depression					
		Dermatitis Contact					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Hydrodiuril	C		ORAL
		Dyspnoea		Norvasc	C		
UNKNOWN							
		Dysuria		Vicodin Es Tablets	C		
UNKNOWN							
		Electrocardiogram St					
		Segment Depression					
		Gastritis					
		Headache					
		Heart Rate Decreased					
		Hepatic Enzyme Increased					
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypertension					
		Hypertriglyceridaemia					
		Hypoaesthesia					
		Lethargy					
		Lipase Increased					
		Lipoma					
		Lymphadenopathy					
		Migraine					
		Nausea					
		Neuralgia					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Oesophagitis					
		Osteoarthritis					
		Pain In Extremity					
		Palpitations					
		Pharyngolaryngeal Pain					
		Platelet Count Increased					
		Pleural Fibrosis					
		Polyneuropathy					
		Pyrexia					
		Red Blood Cell					
		Sedimentation Rate					
		Increased					
		Spondylolisthesis					
		Staphylococcal Infection					
		Temporomandibular Joint					

Syndrome
Therapeutic Response
Decreased
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Ventricular Extrasystoles
Ventricular Hypertrophy
Vomiting
White Blood Cell Count
Increased
Wound Infection
Staphylococcal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4513209-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess		Effexor Xr	C				
UNKNOWN								
Other	Adverse Event							
	Angina Pectoris							
	Atelectasis							
	Blood Cholesterol Increased							
	Blood Glucose Decreased							
	Bronchitis							
	Cardiac Failure Congestive							
	Cervical Cyst							
	Chest Pain							
	Convulsion							
	Dyspnoea							
	Facial Palsy							
	Gastrooesophageal Reflux Disease							
	Hand Fracture							
	Headache							
	Hypertension							
	Hypokalaemia							
	Leukocytosis							
	Nausea							
	Palpitations							
	Pneumonitis							
	Rotator Cuff Syndrome							
	Trigger Finger							
	Tubo-Ovarian Abscess							
	Umbilical Hernia							
	Vomiting							

Date:11/30/04ISR Number: 4513217-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA03057
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	39	DAY

Hospitalization -	Infarction	Soma	C
UNKNOWN			
Initial or Prolonged	Brain Death	Elavil	C
UNKNOWN			
	Cardiac Arrest	Esgic-Plus Tablets	C
UNKNOWN			
	Coronary Artery Disease		
	Hypoxic Encephalopathy		

Date:11/30/04ISR Number: 4513218-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00894
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Chest Pain
Disability	Coronary Artery Disease
	Cystitis Glandularis
	Fall
	Hypertension
	Hypothyroidism
	Osteoarthritis
	Radius Fracture

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513222-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00886
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 7 DAY	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Abdominal Distension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Abdominal Pain Lower		Estrogens, Conjugated	C				
	Abdominal Tenderness							
UNKNOWN	Adverse Event		Desyrel	C				
UNKNOWN	Arthralgia		Aspirin	C				
UNKNOWN	Atrial Fibrillation		Msm Complete	C				
	Blood Pressure Increased							
	Bronchitis							
	Cardiac Enzymes Increased							
	Constipation							
	Cough							
	Diverticulum							
	Diverticulum Intestinal							
	Dyspnoea							
	Eye Pain							
	Fatigue							
	Flatulence							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Headache							
	Heart Rate Irregular							
	Hyperhidrosis							
	Hypertensive Heart Disease							
	Injury							
	Lymphadenopathy							
	Mitral Valve Incompetence							

Myocardial Ischaemia
Nausea
Neck Pain
Oesophageal Spasm
Pain In Extremity
Palpitations
Sinusitis
Tachyarrhythmia
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Date:11/30/04ISR Number: 4513225-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00553
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Constipation		Fluocortolone					
Other	Grand Mal Convulsion		Caproate	C		ORAL		
			Sitosterols	C		ORAL		
			Beclomethasone					

Dipropionate C
RESPIRATORY
(INHALATION)

Salmeterol Xinafoate C
RESPIRATORY
(INHALATION)

Ipratropium Bromide C
RESPIRATORY
(INHALATION)

Date:11/30/04ISR Number: 4513226-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04398
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513229-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03254
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Disorientation		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:11/30/04ISR Number: 4513232-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00174
Age:35 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Other	Infarction Death							

Date:11/30/04ISR Number: 4513234-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00428
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							

Date:11/30/04ISR Number: 4513235-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00036
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Electrocardiogram St		Metoprolol Tartrate	C			UNKNOWN	
	Segment Depression							
	Epilepsy							
	Myocardial Infarction							
	Myocardial Ischaemia							

Date:11/30/04ISR Number: 4513238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02765
Age:53 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Blindness Transient		Vioxx	SS	Merck & Co., Inc	ORAL		
Cardiac Failure		Prozac	C			UNKNOWN	
Congestive		Avandia	C			UNKNOWN	
Carotid Artery Occlusion		Zocor	C			UNKNOWN	
Heart Injury		Glucophage	C			UNKNOWN	
Myocardial Infarction							

Date:11/30/04ISR Number: 4513239-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00079
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ileal Perforation		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization - Initial or Prolonged	Peritonitis		Methylprednisolone Sodium Succinate	SS		INTRAVENOUS DRIP	9	DAY
	Pneumoperitoneum		Perindopril Erbumine	SS		ORAL	9	YR
			Nitroglycerin	SS		TOPICAL	9	YR
			Etanercept	SS		SUBCUTANEOUS	3	YR
			Aspirin Lysine	SS		ORAL	9	YR
			Verapamil Hydrochloride	C		ORAL		
			Rosuvastatin Calcium	C		ORAL		

Date:11/30/04ISR Number: 4513240-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00343
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Hospitalization - Initial or Prolonged	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		22 DAY

Date:11/30/04ISR Number: 4513243-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00074
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Rofecoxib	PS	Merck & Co., Inc	ORAL		
	Encephalopathy		Troxerutin	C		ORAL		
	Grand Mal Convulsion		Etifoxine	C		ORAL		
	Hypertension		Zolpidem Tartrate	C		ORAL		
	Meningitis							

Date:11/30/04ISR Number: 4513270-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03341
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cyst		[Therapy					
	Eructation		Unspecified]	C				
UNKNOWN								
	Hypertension							
	Insomnia							
	Nasal Congestion							
	Weight Decreased							

Date:11/30/04ISR Number: 4513271-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00880
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Disorder							
Disability	Cardiac Failure							
	Congestive							
	Pericardial Effusion							

Date:11/30/04ISR Number: 4513273-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513274-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03531
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513275-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03453
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/30/04ISR Number: 4513276-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03438
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Dyspnoea							
	Hyperhidrosis							
	Pain							
	Respiratory Disorder							

Date:11/30/04ISR Number: 4513278-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03353
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acupril	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Metformin	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

			Zocor	C		
UNKNOWN						

Date:11/30/04ISR Number: 4513280-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513283-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cardiac Disorder Cardiac Failure Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513284-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Disorder Cardiac Disorder Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513286-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513287-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513288-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4513289-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03346
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myalgia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514352-5Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00059
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514354-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00779
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage							
	Hemiplegia							

Date:11/30/04ISR Number: 4514355-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00711
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Allopurinol	C		ORAL		
Initial or Prolonged	Coronary Artery Stenosis							
Disability								

Date:11/30/04ISR Number: 4514356-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00338
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	613	DAY
Hospitalization -			Lithium Carbonate	C		ORAL		
Initial or Prolonged								

Date:11/30/04ISR Number: 4514357-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03442
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
Initial or Prolonged	Atrial Septal Defect		Vioxx	SS	Merck & Co., Inc	ORAL		18 MON
Congenital Anomaly	Hemiparesis		Premarin	C				UNKNOWN
	Hypoaesthesia		Hyzaar	C				UNKNOWN
	Iliac Artery Embolism							
	Transient Ischaemic Attack							

Date:11/30/04ISR Number: 4514358-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coagulation Factor Viii		Vioxx	PS	Merck & Co., Inc	ORAL		117 DAY
Initial or Prolonged	Level Decreased		Zocor	SS		ORAL		
	Coagulation Time Prolonged		Ginkgo Biloba Extract	SS		ORAL		
	Haematoma		Hydrochlorothiazide And Lisinopril	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514359-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03443
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:11/30/04ISR Number: 4514362-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00206
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:11/30/04ISR Number: 4514364-1Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00019
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1156	DAY
Hospitalization - Initial or Prolonged			Althiazide And Spironolactone	C		ORAL		
Other			Etoricoxib	C		ORAL		
			Cifenline Succinate	C		ORAL		
			Gliquidone	C		ORAL		
			Hydralazine	C		ORAL		
			Losartan Potassium	C		ORAL		
			Loperamide Hydrochloride	C		ORAL		
			Mesalamine	C		ORAL		
			Fluticasone Propionate And Salmeterol Xinafoate	C		RESPIRATORY (INHALATION)		
			Singulair	C		ORAL		

Albuterol C
RESPIRATORY

(INHALATION)

Date:11/30/04ISR Number: 4514365-3Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intestinal Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:11/30/04ISR Number: 4514371-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03511
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Zoloft	C				
UNKNOWN								
Disability								

Date:11/30/04ISR Number: 4514373-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00496
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Tramadol Hydrochloride	C		ORAL		

Date:11/30/04ISR Number: 4514374-4Report Type:Expedited (15-DaCompany Report #SI-MERCK-0411HUN00011
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Enalapril Maleate	C		ORAL		

Date:11/30/04ISR Number: 4514375-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00456
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/30/04ISR Number: 4514377-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00487
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/30/04ISR Number: 4514378-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00383
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Phlebitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514385-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00472
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514387-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03543
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C				
UNKNOWN								
Initial or Prolonged			Zyrtec	C				
UNKNOWN								
Disability			Estratest	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514388-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03645
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death		Aspirin	C				UNKNOWN
	Embolism		Lipitor	C				UNKNOWN
	Myocardial Infarction		Lisinopril	C				UNKNOWN

Date:11/30/04ISR Number: 4514390-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03646
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:11/30/04ISR Number: 4514391-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03558
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Thrombosis		Atenolol	C				UNKNOWN
			Diovan	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Crestor	C				UNKNOWN

Date:11/30/04ISR Number: 4514392-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00043
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:11/30/04ISR Number: 4514394-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Heart Rate Irregular Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514395-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03708
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514397-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514399-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514400-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00486
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Stenosis Blood Pressure Immeasurable Temporal Arteritis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514401-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03519
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/30/04ISR Number: 4514406-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03852
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Chlordiazepoxide	C				
UNKNOWN								
Initial or Prolonged			Ecotrin	C				
UNKNOWN								
Disability			Plavix	C				
UNKNOWN								
			Singulair	C		ORAL		
			Fosamax	C		ORAL		

			Pulmicort	C		
UNKNOWN						

Date:11/30/04ISR Number: 4514407-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Blood Pressure Increased							
	Cardiac Disorder							
	Gastric Disorder							
	Myocardial Infarction							

Date:11/30/04ISR Number: 4514409-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03820
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		[Therapy					
Initial or Prolonged	Attack		Unspecified]	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514410-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514411-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514413-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03893
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514417-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03748
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514418-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03862
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514419-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03840
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Plavix	C				
Initial or Prolonged Disability								

Date:11/30/04ISR Number: 4514421-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514422-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/30/04ISR Number: 4514423-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03829
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension							
	Myocardial Infarction							
Disability								

Date:11/30/04ISR Number: 4514424-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Bextra	C		ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:11/30/04ISR Number: 4514425-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03884
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:11/30/04ISR Number: 4514426-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Myocardial Infarction							
	Polytraumatism							

Date:11/30/04ISR Number: 4514427-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03824
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN			Glucophage	C				
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:11/30/04ISR Number: 4515238-2Report Type:Direct Company Report #CTU 233207
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS		ORAL	BID PO	

Date:11/30/04ISR Number: 4515241-2Report Type:Direct Company Report #CTU 233209
Age:76 YR Gender:Male I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
	Coronary Artery Disease
	Hypoaesthesia

	Lung Disorder						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS				EVERYDAY

Date:11/30/04ISR Number: 4515245-XReport Type:Direct Company Report #CTU 233212
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required 1 A DAY Intervention to Prevent Permanent Impairment/Damage	Cardiac Operation		Vioxx	PS				

Date:11/30/04ISR Number: 4515251-5Report Type:Direct Company Report #CTU 233216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 25 Mg	PS			DAILY TO BID	
			Celebrex 200 Mg (In Between)	SS			BID	
			Norco	C				
			Vicodin	C				
			Morphine	C				
			Atvan	C				
			Dexamethasone	C				
			Compazine	C				
			Zofran	C				
			Anzemet	C				
			Aloxi	C				
			Gemzar	C				
			Carboplatin	C				
			Velcode	C				
			Taxol	C				
			Taxotere	C				
			Iressa	C				

Date:11/30/04ISR Number: 4515262-XReport Type:Direct Company Report #CTU 233259
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - DAILY Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx 50 Mg Merck	PS	Merck			

Date:11/30/04ISR Number: 4515288-6Report Type:Direct Company Report #CTU 233275
Age: Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required

Intervention to
Prevent Permanent
Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Disease		Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Coronary Artery Occlusion						ORAL	
	Failure Of Implant							

Date:11/30/04ISR Number: 4518020-5Report Type:Expedited (15-DaCompany Report #WAES 0411DEU00393
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine	Foreign	Tab Vioxx					
Hospitalization -	Phosphokinase Mb	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Increased	Health						
PO							827	DAY
	C-Reactive Protein	Professional	Inj Etanercept	SS				
SUBCUTANEOUS							25 MG/2XW SC	43 DAY
	Increased		Budesonide	C				
	Dehydration							
	Demyelination							
	Depressed Level Of							
	Consciousness							
	Diarrhoea							
	Korsakoff'S Psychosis							
	Non-Alcoholic							
	Myoglobin Blood Increased							
	White Blood Cell Count							
	Increased							

Date:11/30/04ISR Number: 4518028-XReport Type:Expedited (15-DaCompany Report #WAES 0411USA02093
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Creatine	Foreign	Tab Vioxx					
Hospitalization -	Phosphokinase Mb	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

Initial or Prolonged	Increased	Health		
PO 827 DAY				
	C-Reactive Protein Increased	Professional	Inj Enbrel (Etanercept)	SS
SUBCUTANEOUS 25 MG/2XW SC 43 DAY				
	Dehydration		Budesonide	C
	Demyelination			
	Depressed Level Of Consciousness			
	Diarrhoea			
	Korsakoff'S Psychosis			
	Non-Alcoholic			
	Myoglobin Blood Increased			
	White Blood Cell Count Increased			

Date:11/30/04ISR Number: 4519359-XReport Type:Expedited (15-DaCompany Report #WAES 01052039
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Disorder
	Dizziness
	Feeling Abnormal
	Headache
	Nausea
	Syncope
	Vertigo

Vomiting

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS		ORAL	25 MG DAILY	PO

Date:12/01/04ISR Number: 4514925-XReport Type:Expedited (15-DaCompany Report #AU-BRISTOL-MYERS SQUIBB COMPANY-12733861
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Overdose Respiratory Distress	Health Professional	Hydrea	PS	Bristol-Myers Squibb Company	ORAL	500 mg daily	Other commenced in May 2000. "5 gram to 20 gram"
			Lamotrigine	SS		ORAL		
			Rofecoxib	SS				
			Temazepam	SS				

Date:12/01/04ISR Number: 4514934-0Report Type:Expedited (15-DaCompany Report #FR-SOLVAY-00204004191
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colitis		Coversyl	PS		ORAL	Daily dose: 2 milligram(s)	3248 DAY
	Gastrointestinal Disorder							
	Monarthritis		Solu-Medrol	SS		INTRAVENOUS	Daily dose: 60	
	Peritonitis							

Pneumoperitoneum
milligram(s) 9 DAY
Small Intestinal Diafusor SS
UNKNOWN Daily dose:
Perforation
10

milligram(s) 3248 DAY
Vioxx SS ORAL
Daily dose:

25

milligram(s) 7 DAY
Kardegic SS ORAL
Daily dose:

160

milligram(s) 3248 DAY
Enbrel SS
SUBCUTANEOUS Daily dose:

unknown 1167 DAY
Isoptin C ORAL
Daily dose:

unknown
Crestor C ORAL
Daily dose:

unknown

Date:12/01/04ISR Number: 4515052-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00539
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Levothyroxine Sodium	C				
UNKNOWN								
	Coronary Artery Disease		Nonsteroidal					
	Coronary Artery Stenosis		Anti-Inflammatory					
	Myocardial Infarction		Drug (Unspecified)	C				
UNKNOWN								
	Stress Incontinence		Opipramol					
	Ventricular Dyskinesia		Hydrochloride	C				
UNKNOWN								
			Goldenrod	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515057-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00088
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Peripheral Vascular		Natrilix	C				
UNKNOWN								
Initial or Prolonged	Disorder		Delix Plus	C				
UNKNOWN								
			Omnic	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Kerlone	C				
UNKNOWN								
			Marcumar	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515059-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Operation							

Date:12/01/04ISR Number: 4515060-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00065
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								
Initial or Prolonged								

Date:12/01/04ISR Number: 4515061-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00242
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain		Candesartan Cilexetil	C		
	Dermatitis		Acetaminophen And Aspirin And Caffeine And Hydrocodone Bitartrate	C		
	Dizziness		Celecoxib	C		ORAL
	Vasculitic Rash		Zocor	C		ORAL
			Perindopril Erbumine	C		

UNKNOWN

UNKNOWN

UNKNOWN

Date:12/01/04ISR Number: 4515062-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00048
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain		Estrogens, Conjugated	C		
	General Physical Health Deterioration					

UNKNOWN

Date:12/01/04ISR Number: 4515064-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515065-6Report Type:Expedited (15-DaCompany Report #PH-MERCK-0410PHL00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/01/04ISR Number: 4515066-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03580
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Lipitor	C				UNKNOWN
	Pain In Extremity		[Therapy Unspecified]	C				UNKNOWN
	Vasoconstriction		Toprol Xl Tablets	C				UNKNOWN
			Wellbutrin	C				UNKNOWN
			Prozac	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Hydrocodone Hydrochloride	C				UNKNOWN

Date:12/01/04ISR Number: 4515067-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00325
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	104 DAY	
	Sudden Cardiac Death		Insulin	C				PARENTERAL
			Leflunomide	C		ORAL		

				Etanercept	C		
PARENTERAL							
				Prednisolone	C		ORAL
				Amlodipine Besylate	C		ORAL
				Esomeprazole Magnesium	C		ORAL
				Calcium Carbonate And Cholecalciferol	C		ORAL

Date:12/01/04ISR Number: 4515068-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00042
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1117 DAY
Initial or Prolonged								

Date:12/01/04ISR Number: 4515069-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:12/01/04ISR Number: 4515070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03512
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515074-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03807
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Sensation Of Heaviness		Lotrel	C				
UNKNOWN								
Initial or Prolonged			Hydrochlorothiazide	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515077-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03854
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coma		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
Disability	Renal Failure							

Date:12/01/04ISR Number: 4515078-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03837
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
			Nexium	C				
UNKNOWN								
			Warfarin	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Hydroxychloroquine Sulfate	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								

				Probenecid	C		
UNKNOWN							

Date:12/01/04ISR Number: 4515079-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03847
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:12/01/04ISR Number: 4515082-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03813
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Occlusion		Zetia	C		ORAL		
Initial or Prolonged	Pain In Extremity							
Disability								

Date:12/01/04ISR Number: 4515684-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Angina Pectoris
	Anxiety

		Arrhythmia					
		Balance Disorder					
		Bladder Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cough		Vioxx	PS	Merck & Co., Inc	ORAL
		Cystitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cystitis Noninfective					
		Dermatitis Allergic					
		Dizziness					
		Duodenal Ulcer					
		Dyspepsia					
		Fall					
		Gastric Disorder					
		Gastric Ph Decreased					
		Gastric Ulcer					
		Haematuria					
		Headache					
		Helicobacter Gastritis					
		Hypersensitivity					
		Hypertonic Bladder					
		Incontinence					
		Intestinal Haemorrhage					
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Knee Deformity					
		Ligament Sprain					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Palpitations					
		Reflux Oesophagitis					
		Renal Pain					
		Tinnitus					
		Urinary Incontinence					
		Ventricular Fibrillation					

Date:12/01/04ISR Number: 4515692-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01091
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL
419 DAY						
Hospitalization -	Anal Skin Tags					
Initial or Prolonged	Cardiovascular Disorder					

Disability	Depression Fibrocystic Breast Disease Ischaemic Stroke Migraine Rectal Ulcer Renal Failure

Date:12/01/04ISR Number: 4515698-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00481
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis International Normalised Ratio Decreased Prothrombin Time Shortened

Venous Insufficiency

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	45	DAY

Date:12/01/04ISR Number: 4515700-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00346
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:12/01/04ISR Number: 4515701-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00234
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/01/04ISR Number: 4515707-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00275
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia							
	Cold Sweat							
	Hyperthyroidism							
	Palpitations							

Date:12/01/04ISR Number: 4515708-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		53 DAY
	Basal Cell Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
	Conjunctivitis		Fosamax	C		ORAL		
	Coronary Artery Disease		Hydrodiuril	C		ORAL		
	Cough							
	Depression							
	Ingrowing Nail							
	Injury							
	Pain In Extremity							
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							

Date:12/01/04ISR Number: 4515713-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00217
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515714-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00511
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		281 DAY
Hospitalization -	Infarction		Almotriptan Malate	SS		ORAL		308 DAY
Initial or Prolonged	Myocardial Infarction		Oxycodone	C				UNKNOWN

Date:12/01/04ISR Number: 4515715-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00003
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Infarction							

Date:12/01/04ISR Number: 4515716-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00430
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Intervertebral Disc							
Other	Protrusion							

Date:12/01/04ISR Number: 4515719-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00031
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Other	Asthenia							
	Bronchopneumonia							
	Haemodynamic Instability							
	Myocardial Infarction							

Pneumonia Aspiration
Renal Failure
Sepsis

Date:12/01/04ISR Number: 4515720-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00158
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatic Function Abnormal		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Liver Function Test		Zocor	C		ORAL		
	Abnormal		Zocor	C		ORAL		
	Thrombocytopenia		Atenolol	C				
UNKNOWN								
			Accupril	C				
UNKNOWN								
			Fluoxetine	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515721-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00517
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Disorder							

Date:12/01/04ISR Number: 4515723-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00087
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Renal Failure		Zopiclone	C			UNKNOWN	
Hospitalization -			Zopiclone	C			UNKNOWN	
Initial or Prolonged			Quinapril Hydrochloride	C			UNKNOWN	
			Opipramol Hydrochloride	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	32 DAY

Date:12/01/04ISR Number: 4515724-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00765
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basilar Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							
Disability	Migraine							
	Vertebral Artery Stenosis							

Date:12/01/04ISR Number: 4515725-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00480
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/01/04ISR Number: 4515728-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00047
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Stevens-Johnson Syndrome		Celecoxib	SS		ORAL	6	DAY

Date:12/01/04ISR Number: 4515729-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03589
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Composition Unspecified]	C				
UNKNOWN								
Disability								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515732-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01677
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Hydrochlorothiazide	C				
UNKNOWN								
Initial or Prolonged			Lexapro	C				
UNKNOWN								
Disability			Synthroid	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515733-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03556
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Lung Disorder		Zetia	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Oedema		Lisinopril	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Blood Thinner (Unspecified)	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515734-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/01/04ISR Number: 4515736-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03523
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemoptysis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/01/04ISR Number: 4515737-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03554
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Stomach Discomfort		[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			Glyburide	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515745-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04009
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
Hospitalization -	Congestive		Atacand	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Premarin	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515747-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

Date:12/01/04ISR Number: 4515748-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03848
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON	
			Digoxin	C			UNKNOWN	
			Lotrel	C			UNKNOWN	

Date:12/01/04ISR Number: 4515749-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03527
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Fosamax	C			UNKNOWN	
Initial or Prolonged			Primidone	C			UNKNOWN	
Disability			Zoloft	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Thyroid	C			UNKNOWN	
			Furosemide	C			UNKNOWN	

Date:12/01/04ISR Number: 4515750-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03998
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspnoea							

Date:12/01/04ISR Number: 4515751-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03870
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Wall Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Supraventricular		Effexor	C				
UNKNOWN								
Initial or Prolonged	Tachycardia		Flomax (Tamsulosin Hydrochloride)	C				
Disability								
UNKNOWN								
			Allegra	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515753-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03592
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Thrombosis		Corticosteroids (Unspecified)	C				
	Thrombosis							
UNKNOWN								
			Neurontin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515754-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04014
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		[Therapy					
Initial or Prolonged	Nephrolithiasis		Unspecified]	C				
UNKNOWN								
Disability								

Date:12/01/04ISR Number: 4515755-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/01/04ISR Number: 4515756-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03590
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Medication Error		Influenza Virus					
Initial or Prolonged	Myocardial Infarction		Vaccine					
Disability	Stomach Discomfort		(Unspecified)	C				
UNKNOWN								
			Zyrtec	C				
UNKNOWN								

Date:12/01/04ISR Number: 4515757-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03873
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
8 DAY								
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
4 MON								

Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
8 DAY						
Disability	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
4 MON						
	Feeling Abnormal		Lorazepam	C		
UNKNOWN						
	Procedural Complication					
	Renal Cell Carcinoma					
	Stage Unspecified					
	Scar					

Date:12/01/04ISR Number: 4515758-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03814
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
	Convulsion					
	Oedema Peripheral					
	Rash					
	Urticaria					

Date:12/01/04ISR Number: 4515797-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4515804-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03598
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C				
UNKNOWN								
Initial or Prolonged			[Composition					
Disability			Unspecified]	C				
UNKNOWN								

Date:12/01/04ISR Number: 4517665-6Report Type:Direct Company Report #CTU 233426
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx Tablet 25 Mg +					
Initial or Prolonged	Fall		50 Mg	PS				
25 MG + 50 MG								
VIOXX								

Date:12/01/04ISR Number: 4517736-4Report Type:Direct Company Report #CTU 233427
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS				

Date:12/01/04ISR Number: 4517737-6Report Type:Direct Company Report #CTU 233428
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arterial Thrombosis		Vioxx 25 Mg Tablet					
Required	Eye Haemorrhage		Msd	PS	Msd			
Intervention to	Impaired Work Ability							
Prevent Permanent	Visual Disturbance							
Impairment/Damage								

Date:12/01/04ISR Number: 4517738-8Report Type:Direct Company Report #CTU 233425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS		ORAL	12.5 MG PO QD	
Hospitalization - Initial or Prolonged	Infarction		Synthroid	C				
	Cardiac Failure		Vasotec	C				
	Congestive		Protonix	C				
	Pneumonia		Lasix	C				
	Respiratory Failure		Amiodarone	C				

Date:12/01/04ISR Number: 4517787-XReport Type:Direct Company Report #CTU 233419
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS			50 MG DAILY IN TABLET	
	Congestive							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4517794-7Report Type:Direct Company Report #CTU 233418
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx 25 Mg	PS		ORAL	1 TABLET /	
	Arthropathy						DAY / ORAL	
	Back Disorder		Coumadin	C				
	Nephrolithiasis		Actonel	C				
			Aspirin	C				
			Tums	C				
			Vit E	C				

Date:12/01/04ISR Number: 4519885-3Report Type:Direct Company Report #CTU 233409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Mevacor 40 Mg					
Initial or Prolonged	Blood Pressure		Merck	PS	Merck	ORAL	1 DAY	
Disability	Fluctuation						ORAL	
Other	Blood Triglycerides		Vioxx 25 Mg					
Required	Increased		Merck	SS	Merck	ORAL	1 DAY	
Intervention to	Chest Pain						ORAL	
Prevent Permanent	Chronic Fatigue Syndrome		Mevacor-Erythromycin	C				
Impairment/Damage	Condition Aggravated		Niacin	C				
	Depression		Zyrtec	C				
	Drug Effect Decreased		Librax	C				
	Fatigue		Dilex	C				
	Feeling Abnormal		Albuterol Inhaler	C				
	Fibromyalgia		Lexapro	C				
	Gallbladder Disorder		Prilosec	C				
	Hormone Level Abnormal		Imitrex	C				
	Hypertension		Sonata	C				
	Hypoaesthesia		Ambien	C				
	Hypotension		Lortab	C				
	Hysterectomy		Darvocet	C				
	Insomnia		Elavil	C				
	Irritable Bowel Syndrome		Buspar	C				

Loss Of Employment
Muscle Disorder
Muscular Weakness
Myalgia
Nervousness
Osteoarthritis
Pain
Panic Attack
Psychomotor Hyperactivity
Suicidal Ideation
Surgery
Tachycardia
Thinking Abnormal
Upper Respiratory Tract
Infection
Vision Blurred
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/01/04ISR Number: 4519890-7Report Type:Direct Company Report #CTU 233414
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 50mg	PS				
Hospitalization - Initial or Prolonged								

Date:12/02/04ISR Number: 4516595-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02909
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Inderal	C				
UNKNOWN								
	Cellulitis		Inderal	C				
UNKNOWN								
	Contusion		Methotrexate	C				
UNKNOWN							441	DAY
	Deep Vein Thrombosis		Arava	C				
UNKNOWN								
	Diarrhoea		Folic Acid	C				
UNKNOWN								
	Diastolic Dysfunction		Aredia	C				
UNKNOWN								
	Dyspnoea Paroxysmal		Prednisone	C				
UNKNOWN							10	MON
	Nocturnal		Inderal La	C				
UNKNOWN								
	Fatigue							
	Hypertension							
	Injury							
	Insomnia							
	Melaena							
	Myocardial Infarction							
	Nightmare							
	Palpitations							
	Panic Attack							

Phlebitis Superficial
Pulmonary Embolism
Pulmonary Hypertension
Sleep Disorder
Stress
Tachycardia
Thrombosis
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Weight Increased

Date:12/02/04ISR Number: 4516599-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00387
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		58 DAY
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Isosorbide Mononitrate	C			UNKNOWN	
			Nifedipine	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4516602-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Naproxen	C			UNKNOWN	
	Cardiac Disorder		Indocin					
	Carpal Tunnel Syndrome		(Indomethacin)	C		ORAL		
	Coronary Artery		Zyrtec	C			UNKNOWN	
	Atherosclerosis		Prilosec	C			UNKNOWN	
	Drug Ineffective		Celexa	C			UNKNOWN	
	Dyslipidaemia		Aciphex	C			UNKNOWN	
	Dyspnoea		Atenolol	C			UNKNOWN	
	Electrocardiogram St		Oxycontin	C			UNKNOWN	
	Segment Elevation		Hydrocodone					
	Facet Joint Syndrome		Bitartrate	C			UNKNOWN	
	Fall		Levsin	C			UNKNOWN	
	Headache		Flonase	C			UNKNOWN	
	Hyperhidrosis							
	Injury							
	Muscular Weakness							
	Night Sweats							
	Peripheral Coldness							
	Pyrexia							
	Road Traffic Accident							
	Rotator Cuff Syndrome							
	Scapula Fracture							
	Sinus Bradycardia							
	Skin Laceration							
	Therapy Non-Responder							
	Trigger Finger							
	Umbilical Hernia							

Date:12/02/04ISR Number: 4516607-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Arthralgia
	Balance Disorder
	Complex Partial Seizures
	Constipation
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Decreased
	Emotional Distress
	Fall
	Fatigue
	Gingival Hyperplasia
	Headache
	Hepatic Enzyme Increased
	Hepatic Steatosis
	Hyperlipidaemia

		Hypernatraemia					
		Hypertension					
		Hypoacusis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Ms Contin	SS		
UNKNOWN							
		Nail Pitting		Depakote	C		
UNKNOWN							
		Nasal Polyps		Tegretol	C		
UNKNOWN							
		Neck Pain		Aspirin	C		
UNKNOWN							
		Osteoporosis		Vitamins			
		Otitis Media		(Unspecified)	C		
UNKNOWN							
		Periarthritis					
		Psoriasis					
		Rash					
		Sepsis					
		Spinal Osteoarthritis					
		Synovitis					
		Tinnitus					
		Vaginal Infection					
		Weight Decreased					
		Weight Increased					
		Wrist Fracture					

Date:12/02/04ISR Number: 4516613-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00052
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged						

Date:12/02/04ISR Number: 4516614-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00550
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization -	Angina Pectoris	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Initial or Prolonged	Myocardial Infarction		Ramipril	C		
UNKNOWN						
			Metoprolol Succinate	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:12/02/04ISR Number: 4516615-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00228
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						

Date:12/02/04ISR Number: 4516623-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00454
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Electrocardiogram T Wave		Nitroglycerin	C		
UNKNOWN						
	Inversion		Amlodipine Besylate	C		
UNKNOWN						
			Hydrochlorothiazide And Irbesartan	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Fluticasone			

Propionate And
Salmeterol Xinafoate C
UNKNOWN

Equilin Sodium
Sulfate And Estrone
Sodium Sulfate C
UNKNOWN

Date:12/02/04ISR Number: 4516624-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03655
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain							
	Deafness							
	Hypertension							
	Musculoskeletal Stiffness							
	Oedema Peripheral							
	Tinnitus							
	Vision Blurred							

Date:12/02/04ISR Number: 4516626-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00589
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	12	DAY

Date:12/02/04ISR Number: 4516628-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00688
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myelodysplastic Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C				

UNKNOWN

Date:12/02/04ISR Number: 4516629-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04137
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Lasix (Furosemide)	C			UNKNOWN	
	Tachycardia		Valium	C			UNKNOWN	
	Ventricular Extrasystoles		Lortab	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	

Date:12/02/04ISR Number: 4516630-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03598
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Ineffective		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C			UNKNOWN	
Disability			[Composition					
Other			Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4516631-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4516632-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00460
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure		[Therapy					
Hospitalization -	Hypertensive Heart		Unspecified]	C				
UNKNOWN								
Initial or Prolonged	Disease							

Date:12/02/04ISR Number: 4516633-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02319
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Disorder							
	Cerebrovascular Accident							
	Loss Of Consciousness							
	Myocardial Infarction							

Date:12/02/04ISR Number: 4516634-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03574
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Aneurysm		Lanoxin	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Lipitor	C				
UNKNOWN								
Disability	Haemorrhage		Toprol Xl Tablets	C				
UNKNOWN								

				Plavix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							

Date:12/02/04ISR Number: 4516635-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00057
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Glucosamine	C		
UNKNOWN						

Date:12/02/04ISR Number: 4516636-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Ulcer		Vicodin Tablets	C		
UNKNOWN						
Initial or Prolonged			[Therapy			
Disability			Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4516637-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02310
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Amnesia		Zoloft	C				
UNKNOWN								
Initial or Prolonged	Anaemia		Allegra	C				
UNKNOWN								
Disability	Cardiac Disorder		Plaquenil	C				
UNKNOWN								
	Coronary Artery Disease		Xanax	C				
UNKNOWN								
	Hypotension		Topamax	C				
UNKNOWN								
	Malaise		Amaryl	C				
UNKNOWN								
	Renal Failure		Seroquel	C				
UNKNOWN								

Date:12/02/04ISR Number: 4516638-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03573
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Amnesia		Vitamins					
Disability	Cerebrovascular Accident		(Unspecified)	C				
UNKNOWN								
	Visual Field Defect							

Date:12/02/04ISR Number: 4516640-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:12/02/04ISR Number: 4516643-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00145
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/02/04ISR Number: 4516644-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03577
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Rectal Haemorrhage		Atenolol Msd	C		ORAL		
	Regurgitation Of Food		Premarin	C			UNKNOWN	
			Potassium (Unspecified)	C			UNKNOWN	
			Lasix (Furosemide Sodium)	C			UNKNOWN	

Date:12/02/04ISR Number: 4516645-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03989
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Back Pain
	Cardiac Failure

		Congestive Joint Swelling Neck Pain Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
1212 DAY							
				Toprol Xl Tablets	C		
UNKNOWN							
				Vas	C		
UNKNOWN							
				Warfarin	C		
UNKNOWN							
				Cartia Xt	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:12/02/04ISR Number: 4516646-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04085
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/02/04ISR Number: 4516647-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03601
Age:62 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Attack		Flexeril	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Dextrostat	C		
UNKNOWN							

Date:12/02/04ISR Number: 4516648-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4516649-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03626
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily Living Impaired Cardiomegaly Cerebrovascular Accident Depression Lung Disorder Pulmonary Embolism Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4516650-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cerebrovascular Accident Death Dyspnoea Myocardial Infarction Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4516651-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03828
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Hospitalization -	Fall		Lotensin	C			UNKNOWN	
Initial or Prolonged	Hip Fracture		Depakote	C			UNKNOWN	
Disability			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:12/02/04ISR Number: 4516652-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03628
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:12/02/04ISR Number: 4516653-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00531
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4516655-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00001
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Clopidogrel Bisulfate	C	UNKNOWN
Ranitidine	C	UNKNOWN
Ramipril	C	UNKNOWN
Meloxicam	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN

Date:12/02/04ISR Number: 4516657-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	58	MON
	Asthenia							
	Back Disorder							
	Carpal Tunnel Syndrome							
	Depression							
	Fibromyalgia							
	Pain							
	Rheumatoid Arthritis							
	Sjogren'S Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4516658-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517176-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00249
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Metformin	C				
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								
Disability			Toprol Xl Tablets	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517177-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
257 DAY								
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
257 DAY								
Disability	Cerebral Ischaemia		Tenormin	C				
UNKNOWN								
	Cerebrovascular Accident		Zoloft	C				
UNKNOWN								
	Depression		Estrogens					
	Dizziness		(Unspecified)	C				
UNKNOWN								
	Emotional Distress							
	Fatigue							
	Hypercholesterolaemia							
	Hypertension							
	Injury							

Insomnia
Libido Decreased
Menopausal Symptoms
Osteoarthritis
Rheumatoid Arthritis
Sleep Disorder
Tachycardia
Thrombosis
Vulvovaginal Dryness

Date:12/02/04ISR Number: 4517178-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Occlusion Cerebrovascular Accident Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	
			Tolperisone Hydrochloride	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Flupirtine Maleate	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517179-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00697
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Balance Disorder		Fluoxetine	C		ORAL		
Other	Bone Swelling		Doxepin Hydrochloride	C		ORAL		
	Cerebral Disorder							
	Dizziness							
	Fall							
	Headache							
	Nausea							
	Palpitations							
	Vomiting							
	Whiplash Injury							

Date:12/02/04ISR Number: 4517181-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01032321
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Hydrodiuril	C				UNKNOWN
	Oedema		Synthroid	C				UNKNOWN
	Oedema Peripheral		Lipitor	C				UNKNOWN
	Ventricular Hypertrophy							

Date:12/02/04ISR Number: 4517182-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Back Pain		Aspirin	C				UNKNOWN
Other	Cardiomegaly		Lipitor	C				UNKNOWN

	Cerebrovascular Accident	Metformin	C
UNKNOWN			
	Chest Discomfort	Prozac	C
UNKNOWN			
	Cholelithiasis	Prilosec	C
UNKNOWN			
	Coordination Abnormal	Glucophage	C
UNKNOWN			
	Drug Hypersensitivity		
	Fall		
	Gastrooesophageal Reflux Disease		
	Hiatus Hernia		
	Hypertension		
	Intention Tremor		
	Intervertebral Disc Degeneration		
	Sinus Disorder		
	Spinal Column Stenosis		
	Spinal Compression Fracture		
	Transient Ischaemic Attack		
	Vertigo		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517187-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:12/02/04ISR Number: 4517188-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00067
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Subdural Haemorrhage							

Date:12/02/04ISR Number: 4517189-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		18 MON
Disability	Arthralgia		Acetaminophen And Hydrocodone Bitartrate	C				
	Arthropod Bite							
	Back Pain							
	Blood Glucose Increased							
	Cardiac Failure							
	Congestive							
	Cerumen Impaction							
	Chest Pain							
	Dizziness							
	Drug Hypersensitivity							
	Dyspnoea							
	Dysuria							
	Fall							
	Headache							
	Hearing Impaired							

UNKNOWN

Hodgkin'S Disease
Hyperhidrosis
Hypertension
Injury
Intervertebral Disc
Degeneration
Joint Swelling
Labile Hypertension
Labyrinthitis
Myocardial Infarction
Non-Hodgkin'S Lymphoma
Oedema Peripheral
Osteopenia
Skin Cancer
Thrombophlebitis
Vertigo
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517198-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00530
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517199-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00107
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Benazepril Hydrochloride And Hydrochlorothiazide	C		ORAL		
			Benazepril Hydrochloride And Hydrochlorothiazide	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Ranitidine	C		ORAL		
			Isosorbide Mononitrate	C		ORAL		
			Molsidomine	C		ORAL		

Date:12/02/04ISR Number: 4517200-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00243
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc			UNKNOWN
	Attack		Prednisolone	C				UNKNOWN

Date:12/02/04ISR Number: 4517202-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01495
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:12/02/04ISR Number: 4517203-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03378
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vitamins (Unspecified)	C				
	Syncope							
	Thrombosis							
	Transient Ischaemic Attack							
	Tremor							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517204-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01010
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Elavil	C		ORAL	3	DAY
Disability			Neurontin	C		ORAL	13	DAY
Other			Soma	C		ORAL		

Date:12/02/04ISR Number: 4517205-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00529
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction							
Disability								

Date:12/02/04ISR Number: 4517210-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02285
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Lotrel	C				
UNKNOWN								
	Vasoconstriction		Paxil	C				
UNKNOWN								
			Detrol	C				
UNKNOWN								
			Albuterol	C				
UNKNOWN								
			Demadex	C				
UNKNOWN								
			Mobic	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517211-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00519
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intestinal Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Oesophageal Discomfort							
Hospitalization - Initial or Prolonged	Pancreatitis							
	Pneumonia Aspiration							
Disability	Respiratory Failure							
Other	Stomach Discomfort							

Date:12/02/04ISR Number: 4517213-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0411NZL00035
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Transient Ischaemic Attack		Acetaminophen	C		ORAL	UNKNOWN	
			Amitriptyline Hydrochloride	C				

Date:12/02/04ISR Number: 4517214-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00275
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517215-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03599
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Coumadin	C				
UNKNOWN								
Initial or Prolonged			Metoprolol	C				
UNKNOWN								
Disability								

Date:12/02/04ISR Number: 4517216-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00740
Age:15 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:12/02/04ISR Number: 4517218-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00040
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Acetaminophen	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517219-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02142
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C		ORAL		
Initial or Prolonged			Lozol	C		ORAL		
Other								

Date:12/02/04ISR Number: 4517220-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03579
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hyperhidrosis		Norvasc	C				
UNKNOWN								
			Ziac	C				
UNKNOWN								
			Acetaminophen	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517221-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01728
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Lopressor	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Coumadin	C				
UNKNOWN								
Disability			Vitamins					
Other			(Unspecified)	C				
UNKNOWN								
			Amiodarone	C				
UNKNOWN								
			Niaspan	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517223-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01627
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Furosemide	C				
UNKNOWN								
Initial or Prolonged			Tarka	C				
UNKNOWN								
Disability			Proventil	C				
UNKNOWN								
			Pulmicort	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517224-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02205
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Lipitor	C				
UNKNOWN								
	Cerebrovascular Accident		Lotrel	C				
UNKNOWN								
	Chest Pain		Aspirin	C				
UNKNOWN								
	Diastolic Dysfunction							
	Visual Acuity Reduced							

Date:12/02/04ISR Number: 4517226-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01630
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia							
Disability	Transient Ischaemic							
	Attack							

Date:12/02/04ISR Number: 4517227-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Disorder Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517229-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Fall		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517230-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00043
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Ibuprofen	C				UNKNOWN
Disability	Transient Ischaemic Attack		[Therapy Unspecified]	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Buspar	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517231-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03700
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Abnormal							
	Cardiac Failure							
	Congestive							
	Dysgraphia							
	Dyspnoea							
	Faeces Discoloured							
	Local Swelling							
	Oedema Peripheral							
	Somnolence							
	Tooth Disorder							
	Weight Increased							

Date:12/02/04ISR Number: 4517234-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03670
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:12/02/04ISR Number: 4517237-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00031
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Insulin	C				
SUBCUTANEOUS								
	Chest Pain		Atorvastatin Calcium	C		ORAL		
	Stent Occlusion		Ramipril	C				
UNKNOWN								
			Midazolam	C		ORAL		
			Aspirin	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		

			Nitroglycerin	C			
UNKNOWN							
			Omeprazole	C			ORAL
			Ibuprofen	C			ORAL

Date:12/02/04ISR Number: 4517239-7Report Type:Expedited (15-DaCompany Report #MY-MERCK-0411MYS00008
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL		
			Metformin Hydrochloride	C		ORAL	1	YR
			Gliclazide	C		ORAL	1	YR

Date:12/02/04ISR Number: 4517240-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00041
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
			Pramipexole					

			Dihydrochloride	SS		
UNKNOWN						
			Acetaminophen	C		
UNKNOWN						
			Benserazide Hydrochloride And Levodopa	C		
UNKNOWN						
			Carbidopa And Levodopa	C		
UNKNOWN						
			Etilefrine Hydrochloride	C		
UNKNOWN						

Date:12/02/04ISR Number: 4517241-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03839
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			Ambien	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517243-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Carotid Artery Disease Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517244-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Cerebrovascular Accident

Date:12/02/04ISR Number: 4517245-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03842
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Nexium	C				
UNKNOWN								
			Clarinex	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517246-4Report Type:Expedited (15-DaCompany Report #PR-MERCK-0411USA03845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Insulin	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517247-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03979
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Cardiac Disorder
Initial or Prolonged	Ejection Fraction
Other	Decreased

Hyperlipidaemia
Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517248-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03800
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pain							

Date:12/02/04ISR Number: 4517250-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03797
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
			Verapamil Hydrochloride	C			UNKNOWN	
			Prempro	C			UNKNOWN	

Date:12/02/04ISR Number: 4517251-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03819
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	

Date:12/02/04ISR Number: 4517252-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03985
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517253-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/02/04ISR Number: 4517254-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03988
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Myocardial Infarction		Vioxx Lasix (Furosemide)	PS C	Merck & Co., Inc	ORAL		
Other	Parathyroid Tumour Benign		Diovan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/04ISR Number: 4517255-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04166
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C				
UNKNOWN								
Initial or Prolonged			Atenolol	C				
UNKNOWN								
Disability			Digitek	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517257-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04114
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Hydrochlorothiazide	C				
UNKNOWN								
Initial or Prolonged			Pepcid	C		ORAL		
Disability			Lisinopril	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517258-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04007
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Haemorrhage							
	Intracranial Aneurysm							

Date:12/02/04ISR Number: 4517260-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04147
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Disability								

Date:12/02/04ISR Number: 4517262-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04111
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ileus Paralytic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/02/04ISR Number: 4517272-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00396
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Prednisone	C				
UNKNOWN								
	Bundle Branch Block Left		Prilosec	C				
UNKNOWN								
			Klonopin	C				
UNKNOWN								
			Darvocet-N	C				
UNKNOWN								
			Vicodin Es Tablets	C				
UNKNOWN								

				Zoladex	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Paxil Cr	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:12/02/04ISR Number: 4517288-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04169
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Lotensin	C		
UNKNOWN						
Initial or Prolonged			Lotrel	C		
UNKNOWN						
Disability			Meclizine Hydrochloride	C		
Other						
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Lorazepam	C		
UNKNOWN						
			Avandia	C		
UNKNOWN						
			Insulin	C		
UNKNOWN						

Date:12/02/04ISR Number: 4517674-7Report Type:Direct Company Report #CTU 233491
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Headache		Vioxx - 10 Mg	PS		
1 PER DAY						
Initial or Prolonged	Hypoaesthesia Oral					
Other	Paraesthesia					

Date:12/02/04ISR Number: 4519804-XReport Type:Direct Company Report #CTU 233494
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Amnesia		Vioxx	PS				
	Cardiac Pacemaker							
	Insertion							
	Chest Pain							
	Coronary Artery Occlusion							
	Dizziness							
	Fatigue							
	Hypoaesthesia							
	Paraesthesia							
	Tongue Paralysis							

Date:12/02/04ISR Number: 4519904-4Report Type:Direct Company Report #CTU 233446
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epistaxis		Indomethacin 75mg	PS		ORAL	75MG DAILY	
	Gastrointestinal Haemorrhage		Rofecoxib 25mg	SS		ORAL	25MG DAILY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4517801-1Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12776092
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Aprovel Tabs 300 Mg	PS	Bristol-Myers Squibb Company	ORAL		
Life-Threatening	Chest Pain							
	Malaise		Lipanthyl	SS		ORAL		
	Sudden Death		Vioxx	SS		ORAL		

Date:12/03/04ISR Number: 4517814-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Prinivil	C		ORAL		
	Coronary Artery		Aspirin	C		ORAL		
	Restenosis		Plavix	C		ORAL	41	DAY
	Hypertension		Plavix	C		ORAL		
	Hypotension		Plavix	C		ORAL	41	DAY
	Ischaemic Cardiomyopathy		Plavix	C		ORAL		
	Mitral Valve Incompetence		Lipitor	C		ORAL		
	Musculoskeletal		Synthroid	C			UNKNOWN	
	Discomfort		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Myocardial Infarction							
	Prostatic Disorder		Colace	C			UNKNOWN	
	Rash		Vicodin Tablets	C			UNKNOWN	
	Sick Sinus Syndrome		Prevacid	C			UNKNOWN	
			Zestril	C			UNKNOWN	

Date:12/03/04ISR Number: 4517815-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Activated Partial Thromboplastin Time Prolonged
	Anxiety
	Back Pain
	Blood Cholesterol Increased
	Bronchitis
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Constipation
	Cough
	Dermatitis
	Dyspepsia
	Dyspnoea
	Eczema Infected
	Emotional Distress
	Fall
	Fractured Coccyx
	Gastritis
	Goitre
	Hemiparesis

		Hyperlipidaemia					
		Hyperthyroidism					
		Hypothyroidism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		International Normalised		Vioxx	SS	Merck & Co., Inc	ORAL
		Ratio Increased		Motrin	C		
UNKNOWN							
		Low Density Lipoprotein		Paxil	C		
UNKNOWN							
		Increased		Paxil	C		
UNKNOWN							
		Nasopharyngitis		Benadryl	C		
UNKNOWN							
		Nicotine Dependence		Correctol (Docusate			
		Oedema Peripheral		Sodium (+)			
		Osteoarthritis		Phenolphthalein)	C		
UNKNOWN							
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Prothrombin Time					
		Prolonged					
		Rash					
		Sinus Congestion					
		Sinusitis					
		Syncope					
		Thyroid Mass					
		Thyroid Pain					
		Transient Ischaemic					
		Attack					
		Vision Blurred					

Date:12/03/04ISR Number: 4517820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00760
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Ankle Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Tylenol With Codeine	C		
UNKNOWN							
		Dizziness					

Empty Sella Syndrome
Fibromyalgia
Gait Disturbance
Hepatic Cyst
Hepatic Lesion
Hypertension
Incision Site
Complication
Injury
Intervertebral Disc
Protrusion
Labyrinthitis
Liver Disorder
Lumbar Spinal Stenosis
Lung Cyst Benign
Lung Neoplasm
Pneumonia
Syncope
Urinary Retention
Wound Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4517823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Abdominal Pain Acute Coronary Syndrome Aortic Bruit Aortic Valve Incompetence Appendix Disorder Atherosclerosis Blood Pressure Increased Bronchitis Carotid Artery Occlusion Carpal Tunnel Syndrome Cataract Cerebrovascular Accident Convulsion Coronary Artery Disease Cough Depressed Mood Dilatation Atrial Diverticulum Emotional Distress Gastritis Atrophic Gastrooesophageal Reflux Disease Granuloma Haematuria Headache Hepatic Cyst Hernia Homocystinaemia Hypercholesterolaemia Hypokalaemia Kidney Small Lung Disorder Metaplasia Mitral Valve Incompetence Myocardial Infarction Myocardial Ischaemia Nervous System Disorder Osteoarthritis Osteoporosis Renal Artery Stenosis Rotator Cuff Syndrome Spinal Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL		

Tonsillar Disorder
Tricuspid Valve
Incompetence
Uterine Disorder
Ventricular Dysfunction
Ventricular Hypertrophy
Visual Disturbance

Date:12/03/04ISR Number: 4517825-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02538
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anxiety
Other	Dizziness

	Hyperglycaemia						
	Hypertension						
	Hypokalaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
	Liver Disorder		Vicodin Tablets	C			UNKNOWN
	Medication Error		Estrogens				
	Myocardial Infarction		(Unspecified)	C			UNKNOWN
	Stress		Effexor	C			UNKNOWN
	Vulvovaginal Dryness		Relafen	C			UNKNOWN

Date:12/03/04ISR Number: 4517826-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	573 DAY
Initial or Prolonged	Coagulopathy		Synthroid	C			UNKNOWN
Disability	Cough		Spironolactone	C			UNKNOWN
	Dehydration		Hydrocodone				
	Depression		Hydrochloride	C			UNKNOWN
	Emotional Distress		Ibuprofen	C			UNKNOWN
	Gallbladder Enlargement		Celebrex	C			UNKNOWN
	Haemorrhagic Stroke		Demadex	C			UNKNOWN 615 DAY
	Hemianopia Homonymous		Lasix (Furosemide)	C			UNKNOWN 615 DAY
	Hepatitis C		Lozol	C			UNKNOWN 615 DAY
	Hepatomegaly		Chondroitin Sulfate				
	Nasal Congestion		Sodium And				
	Splenomegaly		Glucosamine				
	Thrombocytopenia		Hydrochloride	C			UNKNOWN

Visual Field Defect

Date:12/03/04ISR Number: 4517828-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Disability	Anxiety		Celebrex	C				
UNKNOWN								4 DAY
	Coronary Artery Aneurysm		Aspirin	C				
UNKNOWN								
	Coronary Artery		Lipitor	C				
UNKNOWN								
	Atherosclerosis		Toprol Xl Tablets	C				
UNKNOWN								
	Coronary Artery Occlusion		Plavix	C				
UNKNOWN								
	Depression		Pyridoxine	C				
UNKNOWN								
	Ecchymosis		Folic Acid	C				
UNKNOWN								
	Haematoma		Xanax	C				
UNKNOWN								
	Mitral Valve Incompetence		Wellbutrin	C				
UNKNOWN								
	Myocardial Infarction		Lopressor	C				
UNKNOWN								
	Panic Disorder							
	Tricuspid Valve Incompetence							

Date:12/03/04ISR Number: 4517830-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00024
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Triglycerides Increased
	Cardiac Arrest
	Cardio-Respiratory Arrest

		Cyanosis					
		Dilatation Atrial					
		Ear Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Atacand	C		
UNKNOWN							
		Mitral Valve Incompetence		Ziac	C		
UNKNOWN							
		Pulmonary Hypertension		Zyrtec	C		
UNKNOWN							
		Rotator Cuff Syndrome		Lipitor	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Aspirin	C		
UNKNOWN							
		Somnolence		Tums	C		
UNKNOWN							
		Sudden Death					
		Tendonitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Vomiting					
		Weight Increased					

Date:12/03/04ISR Number: 4517831-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anorexia
	Arthritis
	Asthenia
	Back Pain
	Bronchitis
	Bursitis
	Cardiac Disorder
	Caustic Injury
	Chest Pain
	Constipation
	Depression
	Dizziness
	Drug Eruption

Dysphonia
Ecchymosis
Epistaxis
Fall
Frequent Bowel Movements
Gastritis
Glucose Tolerance
Impaired
Headache
Helicobacter Infection
Hypertension
Insomnia
Intervertebral Disc
Degeneration
Joint Crepitation
Kidney Infection
Labyrinthitis
Muscle Strain
Nasopharyngitis
Nausea
Oedema Peripheral
Osteoarthritis

	Otitis Media					
	Pain					
	Pharyngitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
	Sleep Disorder		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
	Syncope		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Vertigo		Prinivil	C		
UNKNOWN						
	Vision Blurred		K-Dur	C		
UNKNOWN						
	Vomiting		Lortab	C		
UNKNOWN						
			Coumadin	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Lasix (Furosemide Sodium)	C		
UNKNOWN						

Date:12/03/04ISR Number: 4517835-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00118
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Aneurysm
Other	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Contusion
	Coronary Artery Disease
	Diabetes Mellitus
	Inadequate Control
	Fall
	Fungal Skin Infection
	Gastroenteritis
	Gastrointestinal

Infection
Hyperparathyroidism
Secondary
Injury
Insomnia
Ischaemic Cardiomyopathy
Meniere'S Disease
Mitral Valve Incompetence
Myalgia
Nerve Compression
Osteoporosis
Pharyngitis
Pruritus
Renal Failure Acute
Renal Failure Chronic
Seasonal Allergy
Silent Myocardial
Infarction
Sinusitis
Skin Ulcer
Spinal Osteoarthritis
Transient Ischaemic
Attack
Tricuspid Valve

Incompetence
Urinary Tract Infection
Ventricular Dysfunction

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
	422 DAY		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Zestril	SS		
UNKNOWN			Lasix (Furosemide)	SS		
UNKNOWN			Zestril	SS		
UNKNOWN	406 DAY		Niacin	SS		
UNKNOWN			Cardizem	C		
UNKNOWN			Prozac	C		
UNKNOWN			Motrin	C		
UNKNOWN			Tylenol	C		
UNKNOWN			Plavix	C		
UNKNOWN			Potassium (Unspecified)	C		
UNKNOWN			Aspirin	C		
UNKNOWN			Isosorbide	C		
UNKNOWN			Coreg	C		
UNKNOWN			Prilosec	C		
UNKNOWN			Lorazepam	C		
UNKNOWN			Miacalcin	C		
UNKNOWN			Zocor	C		ORAL
			Glucotrol	C		
UNKNOWN			Vitamins (Unspecified)	C		
UNKNOWN			Chondroitin Sulfate			

			Sodium And Glucosamine Hydrochloride And Manganese Ascorbate	C		
UNKNOWN						
			Zantac	C		
UNKNOWN						
			Naproxen	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						
			Temazepam	C		
UNKNOWN						
			Nitro	C		
UNKNOWN						
			Prinivil	C		
UNKNOWN						

Date:12/03/04ISR Number: 4517837-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00345
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		29 DAY
	Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Skin Disorder		Centrum	C				
UNKNOWN								
	Syncope		Lasix (Furosemide)	C				
UNKNOWN								
	Thermal Burn		K-Dur	C				
UNKNOWN								
	Transient Ischaemic		Lipitor	C				
UNKNOWN								
	Attack		Bextra	C				
UNKNOWN								
			Bextra	C				
UNKNOWN								
			Lexapro	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								

	Cordarone	C
UNKNOWN		
	Robaxin	C
UNKNOWN		

Lorcet Plus	C		UNKNOWN
Aggrenox	C		UNKNOWN
Atenolol	C		UNKNOWN
Prilosec	C	ORAL	
Hydrochlorothiazide	C		UNKNOWN
Feldene	C		UNKNOWN
Altace	C		UNKNOWN
Pravachol	C		UNKNOWN
Wellbutrin	C		UNKNOWN
Prozac	C		UNKNOWN
Duragesic	C		UNKNOWN
Flexeril	C	ORAL	

Date:12/03/04ISR Number: 4517838-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00083
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	0	YR
Initial or Prolonged	Hypertension							

Date:12/03/04ISR Number: 4517839-4Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00089
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1001	DAY
Initial or Prolonged								

Date:12/03/04ISR Number: 4517840-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00605
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		504 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Metoprolol Succinate	C		ORAL		UNKNOWN
	Myocardial Infarction		Magnesium (Unspecified)	C				
	Stent Occlusion							

Date:12/03/04ISR Number: 4517841-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02430
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Hip Fracture		Atenolol	C				
	Transient Ischaemic Attack		Lasix (Furosemide)	C				UNKNOWN
	Upper Limb Fracture							

Date:12/03/04ISR Number: 4517842-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01160
Age: Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer		Prilosec	C				
UNKNOWN								

Date:12/03/04ISR Number: 4517843-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02600
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Depakote	C		ORAL		
Initial or Prolonged	Cardiac Failure		K-Dur	C		ORAL		
Other	Congestive		Levothyroxine Sodium	C		ORAL		
	Cerebrovascular Accident		Premarin	C				
UNKNOWN								
	Convulsion		Lanoxin	C		ORAL		
	Death		Lanoxin	C		ORAL		
	Difficulty In Walking		Coumadin	C		ORAL		
	Dyspnoea		Cozaar	C		ORAL		
	Dyspnoea Paroxysmal		Spironolactone	C				
UNKNOWN								
	Nocturnal		Lasix (Furosemide					
	Fatigue		Sodium)	C		ORAL		
	General Physical Health		Prozac	C		ORAL		
	Deterioration		Surfak	C				
UNKNOWN								
	Hypomagnesaemia		Claritin	C				
UNKNOWN								
	Hypothyroidism		Magnesium					
	Oedema Peripheral		(Unspecified)	C		ORAL		
	Orthopnoea							
	Palpitations							
	Peripheral Embolism							
	Syncope							
	Toe Deformity							
	Tricuspid Valve							
	Incompetence							
	Urinary Tract Infection							
	Venous Insufficiency							

Date:12/03/04ISR Number: 4517844-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01776
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517846-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00210
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Nitrazepam	C			UNKNOWN	
			Sulfasalazine	C			UNKNOWN	
			Sulfasalazine	C			UNKNOWN	
			Deflazacort	C			UNKNOWN	

Date:12/03/04ISR Number: 4517867-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00241
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:12/03/04ISR Number: 4517868-0Report Type:Expedited (15-DaCompany Report #SI-MERCK-0411HUN00011
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
			Enalapril Maleate	C		ORAL		

Date:12/03/04ISR Number: 4517869-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00059
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Paroxetine Hydrochloride	C			UNKNOWN	
			Loratadine	C			UNKNOWN	

Date:12/03/04ISR Number: 4517871-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00236
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Parathyroid Hormone		Vioxx	PS	Merck & Co., Inc	ORAL	907	DAY
	Increased		Epoetin Alfa	SS		SUBCUTANEOUS	957	DAY
	Refractory Anaemia		Allopurinol	SS		ORAL	2074	DAY

	Reticulocyte Count		Leuprolide Acetate	SS		
UNKNOWN						
	Decreased		Darbepoetin Alfa	SS		
SUBCUTANEOUS						
	Therapy Non-Responder		Cozaar	C		ORAL
			Omeprazole Magnesium	C		ORAL
			Hydrochlorothiazide And Spironolactone	C		ORAL
			Digoxin	C		ORAL
			Warfarin	C		ORAL
			Ramipril	C		ORAL
			Calcitriol	C		ORAL
			Zetia	C		ORAL
			Ferrous Fumarate	C		ORAL

Date:12/03/04ISR Number: 4517872-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00060
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517873-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03731
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4517874-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00242
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517875-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00248
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking							
	Diplopia							
	Gait Disturbance							
	Headache							

Date:12/03/04ISR Number: 4517879-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04236
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517880-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00202
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Calcification		Diltiazem					
Initial or Prolonged	Aortic Valve Incompetence		Hydrochloride	C				
UNKNOWN								
Disability	Chest Pain		Synthroid	C				
UNKNOWN								
	Mitral Valve Disease		Imdur	C				
UNKNOWN								

	Pneumonia Aspiration		Protonix	C		
UNKNOWN						
	Pulmonary Valve		Digitek	C		
UNKNOWN						
	Incompetence		Darvocet-N	C		
UNKNOWN						
	Tricuspid Valve		Prilosec	C		
UNKNOWN						
	Incompetence		Tiazac	C		
UNKNOWN						
	Ventricular Hypertrophy		Nexium	C		
UNKNOWN						
			Cozaar	C		ORAL

Date:12/03/04ISR Number: 4517881-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/03/04ISR Number: 4517882-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03730
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
	Drug Interaction		Dilantin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4517883-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03716
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Hypertension							
	Mitral Valve Disease							

Date:12/03/04ISR Number: 4517885-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00056
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Drug Ineffective							
	Feeling Abnormal							
	Gastric Disorder							
	Weight Decreased							

Date:12/03/04ISR Number: 4517886-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02929
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517889-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03353
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Acupril	C				
Disability			Lopressor	C			UNKNOWN	
			Metformin	C			UNKNOWN	

			Furosemide	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						

Date:12/03/04ISR Number: 4517890-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00710
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Basilar Artery Stenosis		Levothroid	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident							

Date:12/03/04ISR Number: 4517891-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00178
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atelectasis
Initial or Prolonged	Bronchitis
	Computerised Tomogram
	Abnormal
	Fatigue
	International Normalised
	Ratio Increased

	Pneumonia						
	Pulmonary Embolism						
	Scoliosis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Micardis	C		ORAL		
			Atenolol	C		ORAL		
			Zocor	C		ORAL		
			Protonix	C				UNKNOWN
			Flexeril	C				UNKNOWN
			Diazepam	C				UNKNOWN
			Carafate	C				UNKNOWN

Date:12/03/04ISR Number: 4517892-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00212
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization -	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Celexa	C				UNKNOWN
			Dynacirc	C				UNKNOWN
			Zocor	C		ORAL		
			Prozac	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Klonopin	C				UNKNOWN
			Ultram	C				UNKNOWN
			Ultram	C				UNKNOWN

				Risperdal	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:12/03/04ISR Number: 4517893-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00625
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						

Date:12/03/04ISR Number: 4517894-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03832
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthritis Infective		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arthropathy		Glucophage	C		
UNKNOWN						
Initial or Prolonged	Pulmonary Embolism		Lisinopril-Bc	C		
UNKNOWN						
Disability			Glyburide	C		
UNKNOWN						

Date:12/03/04ISR Number: 4517895-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02211
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Bacterial Infection		Neurontin	C		
UNKNOWN						
	Ulcer					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4517896-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04107
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Life-Threatening	Cerebrovascular Accident		Acupril	C			UNKNOWN	
Other	Gastrointestinal Obstruction Vomiting							

Date:12/03/04ISR Number: 4517897-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Cerebrovascular Accident		Celebrex	C			UNKNOWN	
	Myocardial Infarction		Bextra	C			UNKNOWN	

Date:12/03/04ISR Number: 4517898-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03811
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Levoxyl	C			UNKNOWN	
Disability								

Date:12/03/04ISR Number: 4517899-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Arthropathy Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/03/04ISR Number: 4517901-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03978
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517902-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517915-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Irbesartan	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Glucosamine	C			UNKNOWN	

Date:12/03/04ISR Number: 4517917-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04237
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue							

Date:12/03/04ISR Number: 4517921-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03894
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Cerebrovascular Accident		Celebrex	C			UNKNOWN	
	Myocardial Infarction							

Date:12/03/04ISR Number: 4517922-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Other	Cardiac Failure
	Congestive
	Chest Pain
	Hypertension
	Loss Of Consciousness
	Mitral Valve Incompetence
	Pericardial Effusion

Date:12/03/04ISR Number: 4517934-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4517935-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00709
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Sclerosis
	Back Pain
	Chest Discomfort
	Coronary Artery Disease
	Coronary Artery Stenosis
	Haematoma

		Hyperlipidaemia Hypertension Lung Infiltration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Prevacid	C		
UNKNOWN							
		Pain In Extremity		Aspirin	C		
UNKNOWN							
		Rectal Haemorrhage		Polyethylene Glycol			
		Vascular Calcification		3350	C		
UNKNOWN							
		Ventricular Hypertrophy		Calcium			
				(Unspecified)	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Vitamins			
				(Unspecified)	C		
UNKNOWN							

Date:12/03/04ISR Number: 4518484-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01378
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Breast Microcalcification		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON					
Hospitalization -	Cardiac Failure		Aspirin	C		
UNKNOWN						
Initial or Prolonged	Congestive		Lopid	C		
UNKNOWN						
Disability	Duodenitis		Quinine	C		
UNKNOWN						
	Gastritis		Ethyl Salicylate	C		
UNKNOWN						
	Gastrooesophageal Reflux Disease Ulcer Vomiting Weight Decreased					

Date:12/03/04ISR Number: 4518490-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03341
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Albumin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization - Initial or Prolonged	Blood Alkaline Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Lactate Dehydrogenase Increased		Ortho-Cyclen	C			UNKNOWN	
	Blood Ph Increased		Iron (Unspecified)	C			UNKNOWN	
	Coma		Darvocet-N	C			UNKNOWN	
	Convulsion							
	Deep Vein Thrombosis							
	Dizziness							
	Fall							
	Fatigue							
	Gastrointestinal Pain							
	Headache							
	Injury							
	Mydriasis							
	Nausea							
	Pallor							
	Paraesthesia							
	Pulmonary Embolism							
	Sinus Tachycardia							
	Therapy Non-Responder							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518493-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00105
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		32 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		32 DAY
	Palpitations		Estrogens, Conjugated And Medroxyprogesterone Acetate	C		ORAL		
	Panic Attack							
	Psychotic Disorder							
	White Blood Cell Count Decreased		Triazolam	C		ORAL		46 DAY
			Nitrofurantoin	C		ORAL		

Date:12/03/04ISR Number: 4518495-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00021
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Aspirin	C				UNKNOWN
	Cardiogenic Shock		Clopidogrel Bisulfate	C				UNKNOWN
	Dyspnoea							
	Myocardial Infarction		Valsartan	C				UNKNOWN
			Atenolol	C				UNKNOWN

Date:12/03/04ISR Number: 4518497-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518504-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00759
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Basal Cell Carcinoma		Pepcid	C		ORAL		
Initial or Prolonged	Cerebrovascular Accident		Iron (Unspecified)	C				
UNKNOWN								
	Drug Ineffective							
	Hip Fracture							
	Injury							
	Oedema Peripheral							
	Seborrhoeic Keratosis							
	Solar Elastosis							
	Squamous Cell Carcinoma							
	Visual Disturbance							

Date:12/03/04ISR Number: 4518505-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00046
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
20 MON								
	Cardiomegaly							
	Intracardiac Thrombus							
	Myocardial Infarction							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518506-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03966
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Condition Aggravated		Vioxx	SS	Merck & Co., Inc	ORAL		
	Connective Tissue Disorder		Vitamins (Unspecified)	C				UNKNOWN
	Eye Swelling		Macrobid	C				UNKNOWN
	Generalised Oedema		Maxzide	C		ORAL		
	Orbital Oedema		Prednisone	C				UNKNOWN
	Oropharyngeal Swelling		Medrol	C				UNKNOWN
	Swelling Face							
	Vasculitis							

Date:12/03/04ISR Number: 4518508-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03191
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebral Thrombosis		Influenza Virus Vaccine					
Disability	Cerebrovascular Accident		(Unspecified)	SS				UNKNOWN
	Coma		[Therapy Unspecified]	C				UNKNOWN
	Deafness		[Therapy Unspecified]	C				UNKNOWN
	Fall		Paxil	C				UNKNOWN
	Hypoacusis							
	Loss Of Consciousness							
	Paralysis							
	Thrombosis							

Date:12/03/04ISR Number: 4518509-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00798
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Feeling Abnormal		Verapamil	C				
UNKNOWN								
	Pulmonary Embolism							

Date:12/03/04ISR Number: 4518510-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00270
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	373	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	22	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	373	DAY
			Zopiclone	C		ORAL		
			Psyllium Husk	C		ORAL		
			Ibuprofen	C				
			Estradiol	C			TOPICAL	
			Dydrogesterone And Estradiol	C		ORAL	VAGINAL	
			Amitriptyline Hydrochloride	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518512-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02516
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Femara	C				
UNKNOWN								

Date:12/03/04ISR Number: 4518513-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
	Acute Myocardial Infarction		Diovan	C				
UNKNOWN								
Disability	Acute Respiratory Failure		Ultram	C				
UNKNOWN								
	Arthralgia		Oxycodone	C				
	Cardiac Failure		Zantac	C		ORAL		
	Congestive Cardiogenic Shock		Prozac	C				
	Cerebrovascular Accident		Maxalt (Rizatriptan Benzoate)	C		ORAL		
	Chest Pain		Zoloft	C				
	Coronary Artery Disease							
	Dizziness							
	Emotional Distress							
	Encephalopathy							
	Fatigue							
	Folliculitis							
	Gastrooesophageal Reflux Disease							
	Headache							
	Heart Rate Increased							
	Hypercholesterolaemia							
	Hypertension							
	Intervertebral Disc Protrusion							
	Ischaemic Cardiomyopathy							

Ischaemic Hepatitis
Loss Of Consciousness
Lumbar Radiculopathy
Lung Infiltration
Migraine
Multi-Organ Failure
Muscle Spasms
Oedema Peripheral
Panic Disorder
Renal Failure Acute
Tendonitis
Thyroid Neoplasm
Ulcer Haemorrhage
Urinary Tract Infection
Ventricular Fibrillation
Ventricular Tachycardia
Visual Disturbance

Date:12/03/04ISR Number: 4518520-8Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00042
Age: Gender:Female I/FU:I

Outcome PT
Other Cardiac Disorder
General Physical Health

Deterioration
Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518521-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:12/03/04ISR Number: 4518522-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Anaemia
	Anxiety
	Arthritis
	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Bone Pain
	Bronchitis
	Burning Sensation
	Cerebrovascular Accident
	Conversion Disorder
	Coordination Abnormal
	Depression
	Dizziness
	Dry Skin
	Emotional Distress
	Fall
	Fatigue
	Ganglion
	Generalised Anxiety Disorder
	Haemorrhoids
	Hallucination
	Hemiparesis
	Hiatus Hernia
	Hypertension

Hypoaesthesia
Hypokalaemia
Hyporeflexia
Inflammation
Insomnia
Lacunar Infarction
Liver Function Test
Abnormal
Loss Of Consciousness
Menopausal Symptoms
Movement Disorder
Oesophageal Spasm
Orthostatic Hypotension
Pain In Extremity
Palpitations
Post Procedural
Complication
Psychosomatic Disease
Stress

	Suicidal Ideation						
	Syncope						
	Tinnitus	Report Source	Product	Role	Manufacturer	Route	Dose
Duration							
	Torticollis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Tremor		Synthroid	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Celexa	C			UNKNOWN
			Niacin	C			UNKNOWN
14671DAY			Lexapro	C			UNKNOWN
			Claritin	C			UNKNOWN
			Ventolin (Albuterol)	C			RESPIRATORY (INHALATION)
			Aerobid	C			UNKNOWN

Date:12/03/04ISR Number: 4518523-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01537
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	782 DAY	
Hospitalization - Initial or Prolonged	Chest Pain							
	Coronary Artery Stenosis							

Date:12/03/04ISR Number: 4518525-7Report Type:Expedited (15-DaCompany Report #IE-MERCK-0411GBR00251
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dysaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Diazepam	C				

Psyllium Husk	C	UNKNOWN
Amiloride Hydrochloride And Hydrochlorothiazide	C	UNKNOWN
Celiprolol Hydrochloride	C	UNKNOWN
Acetaminophen And Caffeine And Codeine Phosphate	C	UNKNOWN

Date:12/03/04ISR Number: 4518526-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03955
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518528-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03874
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518529-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518530-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03860
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:12/03/04ISR Number: 4518533-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03967
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Acupril	C				UNKNOWN
Disability			Calcium (Unspecified)	C				UNKNOWN

Date:12/03/04ISR Number: 4518534-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03810
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
Disability								

Date:12/03/04ISR Number: 4518536-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03994
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Benicar	C				
UNKNOWN								
Initial or Prolonged			Ambien	C				
UNKNOWN								
Disability								

Date:12/03/04ISR Number: 4518537-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03976
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
12 MON								
Initial or Prolonged	Chest Pain		[Therapy					
	Nervous System Disorder		Unspecified]	C				
UNKNOWN								
	Nervousness							
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518538-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03990
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL	47 MON	
Disability	Cyst		Prilosec	C			UNKNOWN	
	Dyspnoea		Clarinex	C			UNKNOWN	
	Fatigue							
	Joint Swelling							
	Muscular Weakness							
	Tachycardia							

Date:12/03/04ISR Number: 4518544-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00027
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angiogram Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Aspirin	C				
UNKNOWN								
Disability			Lisinopril	C				
UNKNOWN								

Date:12/03/04ISR Number: 4518545-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04133
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:12/03/04ISR Number: 4518547-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/03/04ISR Number: 4518549-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03995
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Angina Pectoris		Neuroton	C			UNKNOWN	
	Arthralgia		Aspirin	C			UNKNOWN	
	Back Pain		Trazodone Hydrochloride	C			UNKNOWN	
	Blood Cholesterol Increased		Primeral	C			UNKNOWN	
	Cardiac Disorder		Vitamin E	C			UNKNOWN	
	Fatigue							
	Hypertension							
	Joint Swelling							
	Neck Pain							
	Rash							

Date:12/03/04ISR Number: 4518550-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04168
Age:54 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Dyspepsia
Disability	Eating Disorder

	Gastrointestinal Disorder						
	Haematemesis						
	Headache	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Stomach Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:12/03/04ISR Number: 4518551-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04115
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Valium	C			UNKNOWN	
	Palpitations							
	Syncope							
	Vomiting							

Date:12/03/04ISR Number: 4518552-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04129
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive		Celebrex	C			UNKNOWN	
	Sepsis							

Date:12/03/04ISR Number: 4518555-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03880
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction							

Date:12/03/04ISR Number: 4518556-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04011
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518557-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00010
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Congestive		[Therapy Unspecified]	C			YR UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518558-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04163
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Intervertebral Disc		Ambien	C				UNKNOWN
	Operation		Zoloft	C				UNKNOWN
			Maxalt (Rizatriptan Benzoate)	C				UNKNOWN

Date:12/03/04ISR Number: 4518560-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00026
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Pepcid	C		ORAL		
	Quadruple Vessel Bypass		Prevacid	C				UNKNOWN
	Graft							

Date:12/03/04ISR Number: 4518561-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:12/03/04ISR Number: 4518562-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518564-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00063
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	

Date:12/03/04ISR Number: 4518566-XReport Type:Expedited (15-DaCompany Report #FI-MERCK-0412FIN00002
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	953 DAY	
			Ibuprofen	C		ORAL		

Date:12/03/04ISR Number: 4518577-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/03/04ISR Number: 4518580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00035
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	
Hospitalization -			Zoloft	C				
UNKNOWN								
Initial or Prolonged Disability								

Date:12/03/04ISR Number: 4518581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:12/03/04ISR Number: 4518582-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:12/03/04ISR Number: 4518590-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01262
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Calcinosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Cardiac Disorder							
	Dyspepsia							
	Hypertension							
	Nephrolithiasis							

Date:12/03/04ISR Number: 4518594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04019
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON
	Anxiety		Prevacid	C			UNKNOWN	
	Back Pain							
	Confusional State							
	Depression							
	Dyspepsia							
	Hypertension							
	Prostate Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/03/04ISR Number: 4518916-4Report Type:Direct Company Report #CTU 233625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthralgia		Vioxx	PS			1 QD	
	Myalgia							

Date:12/03/04ISR Number: 4518924-3Report Type:Direct Company Report #CTU 233620
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS			25 MG DAILY	
Initial or Prolonged	Congestive		Vioxx	SS			12 MG IN	
							HOSP.	

Date:12/03/04ISR Number: 4519776-8Report Type:Direct Company Report #CTU 233559
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Embolism		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG	
	Quadriplegia						PRN-Q-DAY	
	Respiratory Failure						ORAL	
	Spinal Cord Infarction							

Date:12/03/04ISR Number: 4520508-8Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Consumer	Neurontin					

Initial or Prolonged	Cardiac Disorder	Health	(Gabapentin)	PS	ORAL
1800 MG					
Other	Chest Pain	Professional			
(TID), ORAL					
	Chills		Lipitor		
	Condition Aggravated		(Atorvastatin)	SS	ORAL
20 MG					
	Drug Tolerance Decreased				
(DAILY), ORAL					
	Erectile Dysfunction		Lithium (Lithium)		
	Facial Pain		(Lithium)	SS	
	Feeling Cold		Naproxen (Naproxen)	SS	
	General Physical Health		Rofecoxib		
	Deterioration		(Rofecoxib)	SS	
	Gingival Pain		Amoxicillin		
	Glossodynia		(Amoxicillin)	SS	ORAL
1000 MG					
	Neck Pain				
(BID), ORAL					
	Oesophageal Spasm		All Other		
	Pain In Jaw		Therapeutic Products		
	Sleep Disorder		(All Other		
	Tooth Abscess		Therapeutic		
	Tremor		Products)	C	
			Levothyroxine Sodium		
			(Levothyroxine		
			Sodium)	C	
			Vitamins (Vitamins)	C	
			Diltiazem		
			Hydrochloride		
			(Diltiazem		
			Hydrochloride)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519067-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Myocardial Infarction							

Date:12/06/04ISR Number: 4519185-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00015
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		[Therapy					
Other	Asthenia		Unspecified]	C				
UNKNOWN								
	Cerebral Infarction							
	Chest Pain							
	Complex Partial Seizures							
	Feeling Abnormal							
	Headache							
	Hypoacusis							
	Loss Of Consciousness							
	Myalgia							
	Tinnitus							

Date:12/06/04ISR Number: 4519196-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02377
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Verapamil	C				
UNKNOWN								
	Hypertension		Furosemide	C				
UNKNOWN								
	Myocardial Infarction		Potassium					
			(Unspecified)	C				
UNKNOWN								
			Terazosin					

Hydrochloride	C	UNKNOWN
Omeprazole	C	UNKNOWN
Plavix	C	UNKNOWN
Rosuvastatin Calcium	C	UNKNOWN
Candesartan	C	UNKNOWN

Date:12/06/04ISR Number: 4519200-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00012
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	
Hospitalization - Initial or Prolonged	Thyroid Disorder							

Date:12/06/04ISR Number: 4519202-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02454
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Blood Pressure Inadequately Controlled
	Cerebrovascular Accident
	Chest Pain

		Dyspnoea Fatigue Joint Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Macular Degeneration		Prevacid	C		
UNKNOWN							
		Oedema Peripheral		Lopressor	C		
UNKNOWN							
		Transient Ischaemic		Lipitor	C		
UNKNOWN							
		Attack		Lopid	C		
UNKNOWN							
				Calcium (Unspecified) And Vitamin D (Unspecified)	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							

Date:12/06/04ISR Number: 4519203-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04078
Age:66 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening				Zoloft	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Phenytoin	C		
UNKNOWN							

			Hydrochlorothiazide	C		
UNKNOWN						
			Lotensin	C		
UNKNOWN						
			Doriden	C		
UNKNOWN						
			Tylenol With Codeine #3	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						
			Ferrous Sulfate	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Loratadine	C		
UNKNOWN						

Date:12/06/04ISR Number: 4519204-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00227
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Face Oedema		Hydromorphone Hydrochloride	C				
	Oedema Peripheral							
UNKNOWN								
	Pain		Hydromorphone Hydrochloride	C				
UNKNOWN								
			Hydromorphone Hydrochloride	C				
UNKNOWN								
			Alprazolam	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								
			Azithromycin	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519206-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03557
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Chronic Granulomatous		Promethazine	C				
UNKNOWN								
Disability	Disease		Estratest	C				
UNKNOWN								
	Chronic Obstructive		Nystatin	C				
UNKNOWN								
	Pulmonary Disease		Endocet	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

Date:12/06/04ISR Number: 4519208-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04151
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519209-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00258
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:12/06/04ISR Number: 4519210-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03864
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
13 MON						
Hospitalization - Initial or Prolonged Disability						

Date:12/06/04ISR Number: 4519220-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01683
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Helicobacter Infection		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Nausea		Cozaar	C		ORAL
	Oedema		Evista	C		ORAL
	Pulmonary Embolism		Norvasc	C		ORAL
	Tachycardia		Aspirin	C		ORAL
	Tachypnoea		Miacalcin	C		
UNKNOWN						
			Miacalcin	C		
UNKNOWN						
			Celebrex	C		ORAL
			Hyzaar	C		ORAL
			Premarin	C		
UNKNOWN						
			Percocet	C		
UNKNOWN						
			Glucosamine	C		
UNKNOWN						
			Chondroitin Sulfate Sodium	C		
UNKNOWN						
			Linseed Oil	C		
UNKNOWN						

			Vitamins (Unspecified)	C		
UNKNOWN						
			Vitamin B (Unspecified)	C		
UNKNOWN						
			Ascorbic Acid	C		
UNKNOWN						
			Vitamin E	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						
			Vitamin D (Unspecified)	C		
UNKNOWN						

Date:12/06/04ISR Number: 4519222-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519548-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Glucophage Xr	C		ORAL		
	Inadequate Control		Glucophage Xr	C				
UNKNOWN								
	Dizziness		Glucophage Xr	C		ORAL		
	Drug Ineffective		Lidocaine And					
	Electrocardiogram T Wave		Triamcinolone					
	Inversion		Acetonide	C				
PARENTERAL							1	DAY
	Emotional Distress							
	Gastric Disorder							

Haemoglobin Decreased
Headache
Hypertension
Injury
Joint Dislocation
Labyrinthitis
Lower Limb Fracture
Mitral Valve Incompetence
Overdose
Pain
Pharyngolaryngeal Pain
Photophobia
Pilonidal Cyst
Rhinorrhoea
Sinus Disorder
Sinusitis
Treatment Noncompliance
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Vertigo
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519558-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00694
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aphonia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blindness Unilateral							
	Cerebrovascular Accident							
	Chest Discomfort							
	Dysacusis							
	Dyspnoea							
	Fluid Retention							
	Headache							
	Hearing Impaired							
	Hyperhidrosis							
	Insomnia							
	Maculopathy							
	Muscle Spasms							
	Pain In Extremity							
	Palpitations							
	Visual Disturbance							

Date:12/06/04ISR Number: 4519561-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased							

Date:12/06/04ISR Number: 4519562-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03481M
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Labour		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -	Cardiac Disorder		[Therapy					

Initial or Prolonged	Drug Exposure During		Unspecified]	C		
UNKNOWN						
Disability	Pregnancy					
	Postpartum Disorder					
	Pulmonary Embolism					
	Respiratory Disorder					
	Shoulder Dystocia					

Date:12/06/04ISR Number: 4519563-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03481B1
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Brain Damage		Vioxx	PS	Merck & Co., Inc	
5 YR						
Hospitalization -	Cardiac Disorder		[Therapy			
Initial or Prolonged	Drug Exposure During		Unspecified]	C		
Disability	Pregnancy					
	Postpartum Disorder					
	Pulmonary Embolism					
	Respiratory Disorder					
	Traumatic Delivery					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519565-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00375
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome							
	Disease Recurrence							
	Hypertension							
	Myocardial Infarction							
	Pseudoangina							

Date:12/06/04ISR Number: 4519575-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01003
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Insulin	C				UNKNOWN
	Confusional State		[Therapy Unspecified]	C				UNKNOWN
	Gastrointestinal Disorder							
	Transient Ischaemic Attack							

Date:12/06/04ISR Number: 4519576-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04118
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysgeusia		Digoxin	C				UNKNOWN
Disability	Memory Impairment		Synthroid	C				UNKNOWN
	Somnolence		Warfarin	C				UNKNOWN
			Lexapro	C				UNKNOWN

Date:12/06/04ISR Number: 4519577-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00471
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Implant Site Infection							
	Osteoarthritis							
	Postoperative Infection							
	Staphylococcal Infection							
	Urinary Tract Infection							
	Vertebral Artery Occlusion							

Date:12/06/04ISR Number: 4519578-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00580
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Cardura	C				
UNKNOWN								
Initial or Prolonged	Blood Pressure		Zocor	C				
UNKNOWN								
Disability	Fluctuation		Micardis	C				
UNKNOWN								
Other	Bradycardia							
	Heart Rate Abnormal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519580-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:12/06/04ISR Number: 4519582-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04162
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
			Norco	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:12/06/04ISR Number: 4519583-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00016
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR

Date:12/06/04ISR Number: 4519584-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04125
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		

	Abdominal Pain Upper		Plavix	SS
UNKNOWN				
	Anal Discomfort		Diuretic	
	Cardiac Disorder		(Unspecified)	C
UNKNOWN				
	Dysgeusia			
	Epistaxis			
	Headache			
	Thrombosis			

Date:12/06/04ISR Number: 4519585-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00006
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Amlodipine Besylate	C		ORAL
			Aspirin	C		ORAL
			Metoprolol Succinate	C		ORAL

Date:12/06/04ISR Number: 4519594-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00021
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL
14 DAY						
Life-Threatening	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
7 DAY						
Hospitalization - Initial or Prolonged						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519595-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00052
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Life-Threatening			Pravachol	C			UNKNOWN	
Hospitalization -			Aspirin	C			UNKNOWN	
Initial or Prolonged			Lorazepam	C			UNKNOWN	
Disability			Allegra	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Triamterene	C			UNKNOWN	

Date:12/06/04ISR Number: 4519596-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00016
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:12/06/04ISR Number: 4519597-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00023
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization -	Myocardial Infarction		Tricor	C			UNKNOWN	
Initial or Prolonged	Swelling		Niaspan	C			UNKNOWN	
Disability			Aspirin	C			UNKNOWN	
			Vasotec	C			UNKNOWN	

Date:12/06/04ISR Number: 4519600-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Cardiac Disorder							
	General Symptom							
	Myocardial Infarction							
	Nausea							
	Tremor							
	Unevaluable Event							

Date:12/06/04ISR Number: 4519601-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Abdominal Tenderness
Other	Arrhythmia
	Asthenia
	Brunner'S Gland Hyperplasia
	Bundle Branch Block Left
	Cardiac Disorder
	Cardiac Failure
	Cataract
	Deafness Neurosensory
	Deafness Unilateral
	Diarrhoea

	Diarrhoea Haemorrhagic						
	Duodenitis						
	Ear Discomfort	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Food Poisoning		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Propoxyphene					
	Haemorrhage		Hydrochloride	C			UNKNOWN	
	Haemorrhoids		Lanoxin	C			UNKNOWN	
	Heart Rate Irregular		Lasix (Furosemide)	C			UNKNOWN	
	Hiatus Hernia		K-Dur	C			UNKNOWN	
	Hypoacusis		Darvocet-N	C			UNKNOWN	
	Injury							
	Lower Gastrointestinal							
	Haemorrhage							
	Palpitations							
	Rectal Haemorrhage							
	Supraventricular							
	Tachycardia							
	Weight Decreased							

Date:12/06/04ISR Number: 4519603-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00035
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradyarrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							
	Myocardial Infarction							

Date:12/06/04ISR Number: 4519604-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00043
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fall		Atenolol	C				
UNKNOWN								

Malaise

Date:12/06/04ISR Number: 4519606-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00079
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519608-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Emotional Distress Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519609-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519610-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04265
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519611-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00046
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Arrhythmia Dysuria Myocardial Infarction Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519613-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Atherosclerosis
	Back Pain
	Blood Pressure

Inadequately Controlled
Bronchitis
Bursitis
Cardiac Failure
Congestive
Cardiomegaly
Cerebrovascular Accident
Chest Pain
Cholecystitis
Condition Aggravated
Confusional State
Congestive Cardiomyopathy
Constipation
Cough
Cystitis
Diabetes Mellitus
Inadequate Control
Diabetic Retinopathy
Diarrhoea
Diastolic Dysfunction
Dizziness
Drug Hypersensitivity

		Drug Ineffective					
		Duodenitis					
		Dyslipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Dysstasia		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Ecchymosis		Diovan	C		
UNKNOWN							
		Embolic Cerebral		Methotrexate	C		
UNKNOWN							
		Infarction		Prednisone	C		
UNKNOWN							
		Emotional Distress		Cozaar	C		ORAL
		Fatigue					
		Flatulence					
		Gastritis					
		Gout					
		Haemorrhage					
		Headache					
		Hemianopia Homonymous					
		Hypertensive Crisis					
		Hypertrophic					
		Cardiomyopathy					
		Insomnia					
		Iron Deficiency Anaemia					
		Irritable Bowel Syndrome					
		Joint Effusion					
		Lactose Intolerance					
		Macular Degeneration					
		Malaise					
		Marrow Hyperplasia					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Mouth Haemorrhage					
		Myalgia					
		Myocardial Infarction					
		Nodule On Extremity					
		Oedema Peripheral					
		Orthopnoea					
		Pain					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pitting Oedema					
		Pulmonary Oedema					

Renal Failure
Renal Failure Chronic
Restless Legs Syndrome
Rheumatoid Arthritis
Salivary Gland Disorder
Skin Cancer
Spinal Osteoarthritis
Synovitis
Treatment Noncompliance
Urinary Incontinence
Urinary Tract Infection
Ventricular Dysfunction
Vision Blurred
Wheezing
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/06/04ISR Number: 4519640-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00492
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus Intestinal Haemorrhage Intestinal Infarction Intestinal Ischaemia Mesenteric Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/06/04ISR Number: 4519646-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00228
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:12/06/04ISR Number: 4519647-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04399
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	8	YR
Initial or Prolonged	Dizziness		Tylenol	C				
UNKNOWN								
	Dysgraphia		Phenobarbital	C				
UNKNOWN								
	Feeling Abnormal		Dilantin	C				
UNKNOWN								
	Loss Of Consciousness							

Date:12/06/04ISR Number: 4520394-6Report Type:Direct Company Report #CTU 233705
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Difficulty In Walking		Vioxx 50mg Merck	PS	Merck	ORAL	50MG ORAL	
Initial or Prolonged	Gout		Vioxx 25mg Merck	SS	Merck	ORAL	25 MG ORAL	
Disability	Ligament Injury							
Required	Oedema Peripheral							
Intervention to	Tendon Disorder							
Prevent Permanent	Upper Respiratory Tract							
Impairment/Damage	Infection							
	Urinary Incontinence							

Date:12/06/04ISR Number: 4520407-1Report Type:Direct Company Report #CTU 233675
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bone Disorder		Vioxx	PS			DAILY	
	Feeling Abnormal							

Date:12/06/04ISR Number: 4520430-7Report Type:Direct Company Report #CTU 233734
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Triple Vessel Bypass		Vioxx Tabs	PS			12.5 - 1 PER	
	Graft							
							DAY	

Date:12/06/04ISR Number: 4525961-1Report Type:Expedited (15-DaCompany Report #WAES 0410USA50152
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatine	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
	Phosphokinase Increased	Health					PO	
	Carotid Artery Atheroma	Professional	Lisinopril	C				
	Contusion		Vitamins					
	Dizziness		(Unspecified)	C				
	Fall							
	Goitre							
	Head Injury							
	Intervertebral Disc Degeneration							
	Laceration							
	Lacunar Infarction							
	Loss Of Consciousness							
	Mediastinal Disorder							
	Pulmonary Arterial Pressure Increased							
	Pulmonary Calcification							
	Syncope							
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							

Date:12/06/04ISR Number: 4525962-3Report Type:Expedited (15-DaCompany Report #WAES 0410USA50152
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Blood Creatine	Health					PO	
	Phosphokinase Increased	Professional	Lisinopril	C				
	Carotid Artery Disease		Vitamins					
	Contusion		(Unspecified)	C				
	Dizziness							
	Fall							
	Head Injury							
	Intervertebral Disc							

Degeneration
Lacunar Infarction
Loss Of Consciousness
Osteosclerosis
Pulmonary Arterial Wedge
Pressure Increased
Pulmonary Calcification
Skin Laceration
Syncope
Tricuspid Valve
Incompetence
Ventricular Dysfunction

Date:12/07/04ISR Number: 4519954-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00578
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		543 DAY
Initial or Prolonged	Gait Disturbance		Vioxx	SS	Merck & Co., Inc	ORAL		543 DAY
Disability	Hemiapraxia		Acetylcysteine	C				UNKNOWN
			Theophylline	C				UNKNOWN

Salmeterol Xinafoate	C	UNKNOWN
Cromolyn Sodium And Reproterol Hydrochloride	C	UNKNOWN

Date:12/07/04ISR Number: 4519958-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02529
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Pain
	Abdominal Pain Upper
	Acute Myocardial Infarction
	Angina Unstable
	Angioneurotic Oedema
	Anxiety
	Atelectasis
	Blood Cholesterol Increased
	Bronchitis
	Bursitis
	Cardiomegaly
	Cardiovascular Disorder
	Chest Wall Pain
	Coronary Artery Disease
	Cough
	Deafness Neurosensory
	Depression
	Disease Recurrence
	Diverticulum Intestinal
	Dizziness
	Drug Hypersensitivity
	Dyspnoea Exertional
	Ear Pain
	Electrocardiogram Poor R-Wave Progression
	Fatigue
	Haemangioma Of Liver
	Headache
	Hepatitis B
	Hyperlipidaemia
	Hypertension
	Injury

Insomnia
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Myocardial Infarction
Nasopharyngitis
Night Sweats
Non-Cardiac Chest Pain
Oedema Mouth
Oedema Peripheral
Otitis Externa
Pain
Palpitations
Panic Attack
Pelvic Pain
Pharyngitis
Pleural Disorder
Post Procedural Pain

	Productive Cough						
	Pruritus						
	Qrs Axis Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	
	Spinal Osteoarthritis		Vioxx	SS		ORAL	
	Tinnitus		Bextra	C			UNKNOWN
	Tricuspid Valve		Bextra	C			UNKNOWN
	Incompetence		Ultracet	C		ORAL	
	Urinary Retention		Dyazide	C			UNKNOWN
	Urinary Tract Infection		Prevacid	C			UNKNOWN
	Vaginitis Atrophic		Levaquin	C		ORAL	
	Ventricular Dysfunction		Rocephin	C			INTRAMUSCULAR
	Vertigo Positional		Zoloft	C			UNKNOWN
			Premarin	C			UNKNOWN
			Skelaxin	C		ORAL	
			Prilosec	C		ORAL	
			Ditropan Xl	C			UNKNOWN

Date:12/07/04ISR Number: 4519962-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00236
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL	
	Airways Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Exacerbated		Vioxx	SS	Merck & Co., Inc	ORAL	
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tachyarrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Methotrexate	SS			UNKNOWN
			Corticosteroids				

			(Unspecified)	SS		
UNKNOWN						

Date:12/07/04ISR Number: 4519963-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01025
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Lacunar Infarction		Glucophage	C		
UNKNOWN						
			Reglan	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Insulin	C		
UNKNOWN						
			Aciphex	C		
UNKNOWN						
			Proventil	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Levoxyl	C		
UNKNOWN						

Date:12/07/04ISR Number: 4519964-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03751
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Non-Cardiac Chest Pain		Glucophage	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Evista	C		
UNKNOWN						

				Avandamet	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:12/07/04ISR Number: 4519967-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04267
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Intracranial Aneurysm							
	Paraesthesia							

Date:12/07/04ISR Number: 4519970-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00125
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Intestinal Haemorrhage		Ramipril	C		ORAL		
	Weight Decreased							

Date:12/07/04ISR Number: 4519971-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04098
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dyspepsia		Pepcid Ac	C		ORAL		
	Myocardial Infarction							
	Transient Ischaemic Attack							

Date:12/07/04ISR Number: 4519973-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00795
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia
Other	Arthralgia
	Cardiomegaly
	Cataract
	Chest Discomfort
	Chest Pain
	Deep Vein Thrombosis
	Dementia
	Depressive Symptom
	Dermatitis
	Dyspnoea
	Dyspnoea Exertional
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Hypertonic Bladder
	Intervertebral Disc Degeneration
	Lumbar Radiculopathy
	Myalgia
	Nerve Compression
	Osteoporosis

		Polytraumatism					
		Rash					
		Sciatica	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Claudication		Levothroid	C		
UNKNOWN							
		Spinal Column Stenosis		Diovan	C		
UNKNOWN							
		Spinal Compression		Niacin	C		
UNKNOWN							
		Fracture		Prempro	C		
UNKNOWN							
		Thrombophlebitis		Tricor	C		
UNKNOWN							
		Superficial		Os-Cal D	C		
UNKNOWN							
		Venous Insufficiency		Potassium			
		Vertigo Positional		(Unspecified)	C		ORAL
				Tylenol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Dulcolax	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							

Date:12/07/04ISR Number: 4519974-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00875
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anaemia		Zoloft	C		ORAL
	Asthma		Depakote	C		ORAL
	Bronchitis Acute		Depakote	C		ORAL
	Chest Pain		Depakote	C		ORAL
	Constipation		Humibid Dm	C		ORAL
	Dysphagia		Septra Ds	C		ORAL
	Dystonia		Phenergan			
	Gastrooesophageal Reflux		Tablets/Suppositorie			
	Disease		s	C		ORAL

	Hand Fracture	Nystatin	C	TOPICAL
	Hiatus Hernia	Clonidine		
	Oesophagitis	Hydrochloride	C	ORAL
	Polytraumatism	Tagamet	C	ORAL
	Rhinitis Allergic	Benztropine Mesylate	C	ORAL
	Upper Respiratory Tract	Haldol	C	ORAL
	Infection	Ambien	C	ORAL
	Weight Decreased	Lasix (Furosemide)	C	ORAL
		Colace	C	ORAL

Date:12/07/04ISR Number: 4519975-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04177
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Loss Of Consciousness		Lopressor	C				
Initial or Prolonged	Road Traffic Accident		Oxycontin	C				
Disability			Oxycodone	C				

Date:12/07/04ISR Number: 4519976-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03446
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Norvasc	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4519977-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03582
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		1088 DAY
Hospitalization -	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		1088 DAY
Initial or Prolonged			Miacalcin	C				UNKNOWN
Other			Fosamax	C				UNKNOWN
			Klor-Con	C				UNKNOWN
			Nadolol	C				UNKNOWN
			Doxepin Hydrochloride	C				UNKNOWN
			Imdur	C				UNKNOWN
			Zocor	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN

Date:12/07/04ISR Number: 4519978-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04370
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Nexium	C				UNKNOWN

Date:12/07/04ISR Number: 4519980-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04165
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Coronary Artery Disease	Aspirin	C
Initial or Prolonged UNKNOWN	Coronary Artery Occlusion	Altace	C
UNKNOWN	Dry Mouth	Lipitor	C
	Dyspnoea	Cyanocobalamin And Folic Acid And Pyridoxine Hydrochloride	C
UNKNOWN			

Date:12/07/04ISR Number: 4519983-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00006
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25	DAY

Date:12/07/04ISR Number: 4519984-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:12/07/04ISR Number: 4519985-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00073
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Fluctuation		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability UNKNOWN			Norvasc	C				
	Loss Of Consciousness							

Date:12/07/04ISR Number: 4519986-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Fall							

Date:12/07/04ISR Number: 4519987-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00026
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	557	DAY
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/07/04ISR Number: 4519988-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00101
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety							
	Diarrhoea							
	Dizziness							
	Dizziness Postural							
	Faeces Discoloured							
	Fall							
	Fatigue							
	Hepatic Cirrhosis							
	Localised Infection							
	Loss Of Consciousness							
	Rash							
	Renal Cyst							

Date:12/07/04ISR Number: 4519989-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00008
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4519990-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4519991-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00100
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Celebrex	C				
UNKNOWN								
	Pain In Extremity		Nexium	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4519996-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4519997-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00196
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain Dyspnoea Heart Rate Irregular Palpitations		Vioxx Synthroid	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:12/07/04ISR Number: 4519998-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00249
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520000-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00008
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly Dyspnoea Hyperhidrosis Hypertension Lethargy		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Somnolence

Date:12/07/04ISR Number: 4520001-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00255
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Oedema Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520002-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03580
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Lipitor	C				
UNKNOWN								
	Neck Pain		[Therapy					
	Pain In Extremity		Unspecified]	C				
UNKNOWN								
	Vasoconstriction		Toprol Xl Tablets	C				
UNKNOWN								
			Wellbutrin	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			[Therapy					

Unspecified] C
UNKNOWN

Hydrocodone
Hydrochloride C
UNKNOWN

Date:12/07/04ISR Number: 4520003-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520004-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520007-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00305
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520662-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00521
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520672-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Amaurosis Fugax
	Angina Pectoris
	Aortic Valve Incompetence
	Arthralgia
	Back Pain
	Benign Neoplasm Of Eyelid
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiolipin Antibody Positive
	Cervical Vertebra Injury
	Chest Pain
	Convulsion
	Dizziness
	Dyspnoea
	Ecchymosis
	Fatigue
	Flushing
	Headache
	Hypoaesthesia
	Hypothyroidism

	Myalgia						
	Palpitations						
	Paraesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Periorbital Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4 WK
	Sensory Level Abnormal		Vioxx	SS	Merck & Co., Inc		UNKNOWN 2 DAY
	Tendonitis						
	Thyroiditis						
	Ventricular Hypertrophy						

Date:12/07/04ISR Number: 4520674-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00792
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Asthenia		Prilosec	C			
UNKNOWN							
Disability	Benign Intracranial						
	Hypertension						
	Bronchitis						
	Cerebral Ischaemia						
	Deafness						
	Depression						
	Diabetes Mellitus						
	Dizziness						
	Endolymphatic Hydrops						
	Fatigue						
	Headache						
	Hypertension						
	Increased Upper Airway						
	Secretion						
	Injury						
	Muscle Atrophy						
	Muscle Spasms						
	Myalgia						
	Myositis						
	Nervousness						
	Non-Cardiac Chest Pain						
	Oedema Peripheral						
	Pain						
	Pruritus						
	Skin Disorder						

Spinal Column Stenosis

Date:12/07/04ISR Number: 4520676-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00888
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
Disability	Aphasia
	Bacteria Urine Identified
	Brain Neoplasm
	Chest Wall Pain
	Clostridium Colitis
	Coronary Artery Disease
	Death
	Decubitus Ulcer
	Dementia
	Faecaloma

		Feeding Disorder					
		Hyperglycaemia					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infected Skin Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Meclizine	C		
UNKNOWN							
		Oral Fungal Infection		Accupril	C		
UNKNOWN							
		Osteoarthritis		Clonidine	C		
UNKNOWN							
		Peripheral Vascular		Aspirin	C		
UNKNOWN							
		Disorder		Cefadroxil	C		
UNKNOWN							
		Pneumonia					
		Polytraumatism					
		Rectal Haemorrhage					
		Renal Failure					
		Respiratory Distress					
		Venous Insufficiency					
		Wound Infection					
		Pseudomonas					
		Wound Infection					
		Staphylococcal					

Date:12/07/04ISR Number: 4520678-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abscess
Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial
Other	Infarction
	Aortic Dilatation
	Apraxia
	Areflexia
	Arteriospasm Coronary
	Back Pain
	Blindness Unilateral
	Bone Pain
	Cardiac Disorder
	Cellulitis
	Cerebral Atherosclerosis
	Cerebral Infarction

Chest Discomfort
Chest Pain
Cognitive Disorder
Confusional State
Convulsion
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Dizziness
Drug Effect Decreased
Drug Hypersensitivity
Drug Ineffective
Dyspepsia
Dysphagia
Dyspnoea
Ear Pain
Electrocardiogram
Abnormal
Emotional Distress
Eructation
Exercise Tolerance

		Decreased					
		Eye Disorder					
		Fall					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Generalised Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
97	DAY						
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
97	DAY						
		Haemorrhage Intracranial		Neurontin	C		ORAL
		Headache		Ultram	C		ORAL
		Hiatus Hernia		Doxepin			
		Hyperhidrosis		Hydrochloride	C		
UNKNOWN							
		Hyperlipidaemia		Zanaflex	C		
UNKNOWN							
		Hypersensitivity		Serzone	C		ORAL
		Hypertension		Acetaminophen And			
		Hypoaesthesia		Oxycodone			
		Hyporeflexia		Hydrochloride	C		ORAL
		Impaired Work Ability					
		Insomnia					
		Joint Effusion					
		Joint Injury					
		Joint Sprain					
		Local Swelling					
		Meniscus Lesion					
		Mitral Valve Prolapse					
		Motor Dysfunction					
		Multiple Allergies					
		Myocardial Ischaemia					
		Nasal Congestion					
		Nausea					
		Oesophagitis					
		Optic Disc Drusen					
		Pain					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Psoriasis					
		Pulmonary Congestion					
		Reading Disorder					
		Retinal Ischaemia					
		Rhinitis					
		Rhinitis Allergic					
		Scar					
		Sleep Apnoea Syndrome					
		Tenderness					
		Ventricular Extrasystoles					

Ventricular Hypokinesia
Visual Acuity Reduced
Visual Disturbance

Date:12/07/04ISR Number: 4520680-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Angina Pectoris
	Anxiety
	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiomegaly
	Cerebrovascular Accident
	Claustrophobia

		Confusional State					
		Conjunctivitis Allergic					
		Convulsion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Depressed Mood		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Coumadin	C		
UNKNOWN							
		Diabetes Mellitus		Risperdal	C		
UNKNOWN							
		Non-Insulin-Dependent		Prozac	C		
UNKNOWN							
		Dyspnoea		Elavil	C		ORAL
		Ear Pain		Effexor	C		
UNKNOWN							
		Eye Pruritus		Effexor	C		
UNKNOWN							
		Fatigue		Glucophage	C		
UNKNOWN							
		Fear					
		Haematoma					
		Hallucination					
		Hallucination, Visual					
		Headache					
		Hepatic Steatosis					
		Herpes Zoster					
		Hypoglycaemia					
		Impaired Gastric Emptying					
		Injection Site					
		Haemorrhage					
		Irritability					
		Lacrimation Increased					
		Lipomatosis					
		Mastoiditis					
		Migraine					
		Mood Swings					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Phlebitis					
		Rash					
		Retinopathy					
		Seasonal Allergy					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					
		Suicidal Ideation					

Syncope
Thinking Abnormal
Thrombophlebitis
Superficial
Transient Ischaemic
Attack
Urinary Tract Infection
Vaginal Haemorrhage
Vertigo

Date:12/07/04ISR Number: 4520689-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00021
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4520695-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00250
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Hytrin	C				
UNKNOWN								
Initial or Prolonged								

Date:12/07/04ISR Number: 4520696-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/07/04ISR Number: 4520698-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00017
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder							
Disability	Heart Injury							
	Myocardial Infarction							

Date:12/07/04ISR Number: 4520699-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00743
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Buspirone					
	Back Pain		Hydrochloride	C				
UNKNOWN								
	Blood Glucose Increased		Allegra	C		ORAL		
	Blood Pressure Increased		Levoxyl	C		ORAL		
			Hydrochlorothiazide	C		ORAL		

Date:12/07/04ISR Number: 4520700-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03573
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Balance Disorder		Vitamins (Unspecified)	C				
	Cerebrovascular Accident							
	Visual Field Defect							

Date:12/07/04ISR Number: 4520702-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01647
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		1029 DAY
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Flomax (Tamsulosin Hydrochloride)	C				
	Ventricular Tachycardia							
Disability			Prinivil	C				
Other			Coumadin	C				
			Allopurinol	C				
			Potassium (Unspecified)	C				

	Prilosec	C	UNKNOWN
	Lasix (Furosemide)	C	UNKNOWN
	Atenolol	C	UNKNOWN
	Zocor	C	UNKNOWN
	Folic Acid	C	UNKNOWN

Date:12/07/04ISR Number: 4520703-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00007
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Atorvastatin Calcium	C		ORAL		
			Aspirin	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:12/07/04ISR Number: 4520704-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520706-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520707-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00698
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bronchospasm		Celexa	C				
UNKNOWN								
Initial or Prolonged	Bundle Branch Block Right		Norvasc	C				
UNKNOWN								
Disability	Cardiac Disorder		Allegra	C				
UNKNOWN								
Other	Chest Discomfort		Metformin	C				
UNKNOWN								
	Chest Pain		Lovastatin	C				
UNKNOWN								
	Dyspnoea		Bufferin	C				
UNKNOWN								
	Hypertension		Calcium					
	Incision Site		(Unspecified)	C				
UNKNOWN								
	Complication		Vitamins					
	Insomnia		(Unspecified)	C				
UNKNOWN								
	Muscle Spasms		Glucophage	C				
UNKNOWN								
	Myocardial Ischaemia							
	Palpitations							
	Paraesthesia							
	Pulmonary Hypertension							
	Sensation Of Heaviness							
	Urinary Tract Infection							
	Bacterial							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4520710-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00304
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Basedow'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Weight Decreased		Diuretic (Unspecified)	C				

UNKNOWN

Date:12/07/04ISR Number: 4520711-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00015
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			

UNKNOWN

Date:12/07/04ISR Number: 4520712-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00243
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Lexapro	C				
	Loss Of Consciousness		Micardis	C				
			Maxzide	C				
			Trazodone Hydrochloride	C				
			Lasix (Furosemide)	C				
			Skelaxin	C				
			Klor-Con	C				
			Prevacid	C				
			Buspar	C				

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN

Date:12/07/04ISR Number: 4520714-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00250
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthropathy Coronary Artery Disease Hernia Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520715-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00289
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY

Date:12/07/04ISR Number: 4520716-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4520718-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							
	Phaeochromocytoma							

Date:12/07/04ISR Number: 4520719-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00465
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Zocor	C		ORAL		
			Hydrodiuril	C		ORAL		

Date:12/07/04ISR Number: 4520720-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03851
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Tachycardia							

Date:12/07/04ISR Number: 4520721-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Renal Disorder							

Date:12/07/04ISR Number: 4520723-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00315
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Axillary Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coma		Allopurinol	C			UNKNOWN	
	Disability		Ec Naprosyn	C			UNKNOWN	
	Emotional Distress		Hydrocodone					
	Respiratory Rate		Hydrochloride	C			UNKNOWN	
	Decreased							

Date:12/07/04ISR Number: 4520724-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00036
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Oedema Peripheral		Calcium					
	Palpitations		(Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4520725-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520726-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00167
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520727-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00175
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520729-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00033
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Balance Disorder Blindness Unilateral Cerebrovascular Accident Dizziness Headache		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520730-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00194
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/07/04ISR Number: 4520734-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/07/04ISR Number: 4520760-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00462
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -			Lexapro	C			UNKNOWN	
Initial or Prolonged			Wellbutrin	C			UNKNOWN	
			Micardis	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Micardis Hct	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			Glucophage	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4521943-4Report Type:Direct Company Report #CTU 233780
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS				
	Dyspnoea							
	Eye Swelling							
	Injury							
	Swelling Face							

Date:12/07/04ISR Number: 4522342-1Report Type:Expedited (15-DaCompany Report #2004CG01324
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma	Foreign	Zestoretic	PS		ORAL	1 DF QD PO	5 WK
Initial or Prolonged	Intermittent Claudication	Health	Tanakan	SS		ORAL	2 DF QD PO	5 WK
	Von Willebrand'S Disease	Professional	Zocor	SS		ORAL	10 MG QD PO	
		Other	Vioxx	SS		ORAL	25 MG QD PO	

Date:12/07/04ISR Number: 4523008-4Report Type:Direct Company Report #CTU 233829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage		Vioxx 25 Merck	PS	Merck		ONE DAILY	
	Vein Pain							

Date:12/07/04ISR Number: 4523159-4Report Type:Direct Company Report #CTU 233760
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx 25 Mg Qd	PS				
	Myocardial Ischaemia							

Date:12/07/04ISR Number: 4523187-9Report Type:Direct Company Report #CTU 233753
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Facial Palsy		Vioxx	PS			25 MG X1 DAY	Initial or Prolonged

Date:12/07/04ISR Number: 4523188-0Report Type:Direct Company Report #CTU 233752
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS			25 MG /1 X	Initial or Prolonged
	Myocardial Infarction						DAY	5 YR

Date:12/07/04ISR Number: 4523189-2Report Type:Direct Company Report #CTU 233751
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25mg Mrk 110	PS	Merck	ORAL	25 MG PO	Required
							DAILY	
							Intervention to Prevent Permanent Impairment/Damage	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/07/04ISR Number: 4523202-2Report Type:Direct Company Report #CTU 233794
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx 20 Mg	PS			1 X	

Date:12/07/04ISR Number: 4525512-1Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00218
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Glucose Increased Cardiac Failure Congestive	Foreign Study Health Professional	Tab Vioxx (Rofecoxib) Gliclazide Lisinopril Metformin	PS C C C		ORAL	25 MG/DAILY	PO 17 DAY
	Haematocrit Decreased Protein Urine Present							

Date:12/07/04ISR Number: 4525513-3Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00029
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Urea Decreased Brain Oedema Ischaemic Stroke	Foreign Study Health	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 103 DAY
	Mean Cell Haemoglobin Concentration Increased Mean Cell Haemoglobin Increased Platelet Count Decreased	Professional						

Date:12/08/04ISR Number: 4521155-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	284 DAY	
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	284 DAY	
	Depression		Sulfamethoxazole And Trimethoprim	C			UNKNOWN	
	Dyspepsia		Serzone	C			UNKNOWN	
	Gastrooesophageal Reflux		Verapamil Msd Lp	C			UNKNOWN	
	Disease		Albuterol	C			UNKNOWN	
	Myocardial Infarction		Zyrtec	C			UNKNOWN	
	Pain		Prednisone	C			UNKNOWN	
	Panic Attack		Cephalexin	C			UNKNOWN	
			Augmentin	C			UNKNOWN	
			Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
			Meclizine	C			UNKNOWN	
			Vantin	C			UNKNOWN	
			Prometrium	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	
			Estradiol	C			UNKNOWN	
			Methylprednisolone	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Flonase	C			UNKNOWN	
			Promethazine	C			UNKNOWN	

UNKNOWN	Cyanocobalamin	C
UNKNOWN	Remeron	C
UNKNOWN	Aciphex	C
UNKNOWN	Tequin	C

Date:12/08/04ISR Number: 4521157-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Agitation
	Anxiety
	Aortic Aneurysm
	Aortic Calcification
	Aortic Valve Sclerosis
	Arthralgia
	Asthenia
	Asthma
	Atherosclerosis
	Atrial Fibrillation
	Back Pain
	Blood Blister
	Bradycardia
	Bronchitis
	Bronchospasm
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomegaly
	Chronic Obstructive
	Pulmonary Disease
	Confusional State
	Conjunctivitis Allergic
	Constipation
	Death
	Difficulty In Walking
	Disorientation
	Dizziness
	Drug Hypersensitivity
	Dyspepsia

Emotional Distress
Hypotension
Injury
Interstitial Lung Disease
Labile Hypertension
Laryngitis
Loss Of Consciousness
Mitral Valve Incompetence
Myocardial Calcification
Myocardial Infarction
Nausea
Neuropathy
Overdose
Pneumonia
Restlessness
Spinal Column Stenosis
Spinal Compression
Fracture
Syncope

		Tracheal Obstruction					
		Treatment Noncompliance					
		Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Retention		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Fosamax	C		
UNKNOWN							
		Vomiting		Percocet	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Diltiazem Hydrochloride	C		
UNKNOWN							

Date:12/08/04ISR Number: 4521160-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00672
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
825 DAY						
Initial or Prolonged	Cerebrovascular Accident		Fosamax	C		ORAL
	Fall		Escin	C		
UNKNOWN						
			Nafronyl Oxalate	C		ORAL
			Hydrochlorothiazide And Metoprolol Succinate	C		ORAL
			Phenprocoumon	C		ORAL
			Dihydralazine Sulfate And Hydrochlorothiazide And Reserpine	C		ORAL
			Calcium (Unspecified)	C		ORAL

Date:12/08/04ISR Number: 4521162-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00033
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatic Enzyme Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Atorvastatin Calcium	SS		ORAL		
			Atorvastatin Calcium	SS		ORAL		

Date:12/08/04ISR Number: 4521163-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Abdominal Pain Upper
Disability	Anaemia
Other	Anaemia Postoperative
	Angina Pectoris
	Aortic Valve Incompetence
	Arthritis
	Arthropathy
	Asthma
	Bursitis
	Candidiasis
	Cardiac Disorder
	Cardiac Murmur
	Chest Pain
	Chondropathy

		Chronic Lymphocytic Leukaemia					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Voltaren	SS		
UNKNOWN							
		Electrocardiogram T Wave		Vioxx	SS	Merck & Co., Inc	ORAL
		Inversion		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Prempro	C		
UNKNOWN							
		Haemorrhage		Acetaminophen And			
		Heart Rate Irregular		Propoxyphene			
		Hiatus Hernia		Napsylate	C		ORAL
		Hyperlipidaemia		Carisoprodol	C		ORAL
		Hypertension		Acetaminophen And			
		Impaired Work Ability		Codeine Phosphate	C		
UNKNOWN							
		Injury					
		Joint Sprain					
		Knee Arthroplasty					
		Mallory-Weiss Syndrome					
		Melaena					
		Meniscus Lesion					
		Mitral Valve Calcification					
		Mitral Valve Prolapse					
		Mitral Valve Stenosis					
		Movement Disorder					
		Myocardial Infarction					
		Oedema Peripheral					
		Oesophagitis					
		Osteoarthritis					
		Overdose					
		Peptic Ulcer					
		Pneumonia					
		Postoperative Infection					
		Reflux Oesophagitis					
		Rhonchi					
		Stress					

Tricuspid Valve
Incompetence
Ulcer Haemorrhage
Upper Respiratory Tract
Infection
Urinary Tract Infection
Ventricular Dysfunction
Ventricular Hypertrophy
Ventricular Hypokinesia
Vomiting
Weight Decreased
Wound Infection
Staphylococcal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521170-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02615
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Levoxyl	C		ORAL		
	Coronary Artery Disease		Lipitor	C		ORAL		
	Culture Urine Positive		Spironolactone	C			UNKNOWN	
	Escherichia Infection		Spironolactone	C			UNKNOWN	
	Musculoskeletal Chest Pain		Calcium (Unspecified)	C		ORAL		
	Visual Acuity Reduced		Prozac	C		ORAL		

Date:12/08/04ISR Number: 4521171-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00533
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL		420 DAY
Disability	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		420 DAY
	Chronic Obstructive Pulmonary Disease		Captopril And Hydrochlorothiazide	C		ORAL		1533 DAY
	Gait Disturbance		Diltiazem Hydrochloride	C		ORAL		2171 DAY
	Inner Ear Disorder							
	Laryngeal Oedema							
	Myocardial Ischaemia							
	Osteoarthritis							
	Speech Disorder							
	Syncope							
	Vascular Encephalopathy							
	Vocal Cord Neoplasm							

Date:12/08/04ISR Number: 4521176-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00001
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Myxoma		Vioxx	PS	Merck & Co., Inc	ORAL		799 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	

Date:12/08/04ISR Number: 4521177-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00796
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
Disability	Angina Unstable
Other	Anxiety
	Arthropathy
	Asthenia
	Cartilage Injury
	Cerebrovascular Accident
	Cervicobrachial Syndrome

		Condition Aggravated					
		Coronary Artery Disease					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyslipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Aleve	C		
UNKNOWN							
		Eructation					
		Fatigue					
		Gastritis Erosive					
		Gastrooesophageal Reflux					
		Disease					
		Gliosis					
		Haemorrhoids					
		Helicobacter Gastritis					
		Hyperglycaemia					
		Hypertension					
		Hypoaesthesia					
		Injury					
		Insomnia					
		Intervertebral Disc					
		Protrusion					
		Lumbar Radiculopathy					
		Meningioma					
		Muscle Spasms					
		Myalgia					
		Neck Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Paraesthesia					
		Rectal Haemorrhage					
		Rotator Cuff Syndrome					
		Simple Partial Seizures					
		Soliloquy					
		Spinal Column Stenosis					
		Spinal Disorder					

Date:12/08/04ISR Number: 4521178-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03709
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON					

Disability

Date:12/08/04ISR Number: 4521179-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04096
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Liver Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Total Lung Capacity		Premarin	C				
UNKNOWN								
	Decreased		Paroxetine	C				
UNKNOWN								
			Cyproheptadine Hydrochloride	C		ORAL		
			Famotidine	C		ORAL		
			Meclofenamate Sodium	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521181-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03145
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Fosamax	C				
UNKNOWN								
Initial or Prolonged	Hypoaesthesia		Lipitor	C				
UNKNOWN								
Disability	Visual Disturbance							

Date:12/08/04ISR Number: 4521183-9Report Type:Expedited (15-DaCompany Report #AT-MERCK-0411AUT00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
30 DAY								
Initial or Prolonged			Alendronate Sodium	C				
UNKNOWN								

Date:12/08/04ISR Number: 4521184-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00888
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Contusion							
	Nausea							

Date:12/08/04ISR Number: 4521185-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04144
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521186-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00817
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain
Other	Abdominal Rigidity
	Acute Sinusitis
	Adjustment Disorder With
	Anxiety
	Adverse Event
	Anaemia Vitamin B12
	Deficiency
	Anxiety
	Back Pain
	Balance Disorder
	Bladder Prolapse
	Bronchitis
	Chest Pain
	Conjunctivitis
	Constipation
	Drug Ineffective
	Dysphagia
	Fatigue
	Flat Affect
	Flatulence
	Fungal Infection
	Gallbladder Disorder

		Gastritis					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hot Flush		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased Upper Airway		Vioxx	SS	Merck & Co., Inc	ORAL
		Secretion		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Kidney Infection					
		Liver Function Test Abnormal					
		Migraine					
		Muscle Strain					
		Muscle Twitching					
		Muscular Weakness					
		Nausea					
		Neck Pain					
		Neuropathy					
		Pain In Extremity					
		Pernicious Anaemia					
		Pharyngolaryngeal Pain					
		Pleurisy					
		Pyrexia					
		Rhinitis Allergic					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinus Congestion					
		Speech Disorder					
		Stress					
		Tonsillar Disorder					
		Trigger Finger					
		Umbilical Hernia					
		Upper Respiratory Tract Infection					
		Vaginal Infection					
		Vaginal Ulceration					
		Vertigo					
		Vitreous Detachment					
		Weight Decreased					

Date:12/08/04ISR Number: 4521192-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aortic Valve Incompetence

Initial or Prolonged	Bronchitis
	Cardiomyopathy
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Constipation
	Cough
	Cubital Tunnel Syndrome
	Decreased Appetite
	Depression
	Diarrhoea
	Drug Abuser
	Drug Ineffective
	Ejection Fraction
	Decreased
	Emotional Distress
	Feeling Hot And Cold

		Headache					
		Hyperlipidaemia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Lower Respiratory Tract		Lanoxin	C		ORAL
		Infection		Plavix	C		ORAL
		Nasopharyngitis		Premarin	C		
UNKNOWN							
		Nervous System Disorder		Remeron	C		ORAL
		Neuropathy		Soma	C		
UNKNOWN							
		Nocturia		Phenergan			
		Road Traffic Accident		(Promethazine			
		Sexual Dysfunction		Hydrochloride)	C		
UNKNOWN							
		Sinusitis		Klonopin	C		
UNKNOWN							
		Tension		Zestril	C		ORAL
		Transient Ischaemic		Celebrex	C		ORAL
30 DAY							
		Attack		Zocor	C		
UNKNOWN							
		Urinary Incontinence		Geodon	C		
UNKNOWN							
		Visual Disturbance		Risperdal	C		ORAL
				Klonopin	C		
UNKNOWN							
				Seroquel	C		ORAL
				Vicodin Tablets	C		
UNKNOWN							
				Effexor Xr	C		
UNKNOWN							
				Aspirin	C		ORAL
				Vistaril	C		
UNKNOWN							

Date:12/08/04ISR Number: 4521193-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0410CHN00033
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL
3 DAY							

	Dysphoria		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Electrocardiogram T Wave		Fentanyl	C			TOPICAL
	Abnormal		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN
	Hyperhidrosis						
	Insomnia						
	Nausea		Indomethacin	C			UNKNOWN
	Supraventricular Tachycardia		Red Sage	C		ORAL	
	Tachycardia		Ethambutol Hydrochloride	C		ORAL	PARENTERAL 1 DAY
	Vomiting		Ethambutol Hydrochloride	C			
			Rifampin	C		ORAL	4 DAY
			Diazepam	C		ORAL	2 DAY
			Metoclopramide	C		ORAL	PARENTERAL 1 DAY
			Isoniazid	C		ORAL	
			Isoniazid	C			

Date:12/08/04ISR Number: 4521195-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521196-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00046
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Cardiomegaly							
	Intracardiac Thrombus							
	Myocardial Infarction							
	Thrombosis							

Date:12/08/04ISR Number: 4521199-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01996
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Chest Pain		Proscar	C		ORAL		
	Renal Colic		Flomax (Tamsulosin Hydrochloride)	C				

Date:12/08/04ISR Number: 4521200-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00030
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Pharyngolaryngeal Pain		Acetaminophen And Codeine Phosphate	C				

Date:12/08/04ISR Number: 4521201-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00034
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Failure							

Date:12/08/04ISR Number: 4521202-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Emphysema		Celecoxib	C				
UNKNOWN								
Initial or Prolonged	Malaise							
Other	Myocardial Infarction							

Date:12/08/04ISR Number: 4521203-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521204-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
			Rabeprazole Sodium	C			UNKNOWN	

Date:12/08/04ISR Number: 4521205-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00462
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Zocor	C			UNKNOWN	
	Dyspepsia		Prevacid	C			UNKNOWN	
	Dyspnoea							

Date:12/08/04ISR Number: 4521206-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521207-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00027
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy							

Date:12/08/04ISR Number: 4521208-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
							225	DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Respiratory Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
							225	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521210-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00226
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Discomfort							
Initial or Prolonged	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521211-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Exposure During		Vioxx	PS	Merck & Co., Inc			11 DAY
Congenital Anomaly	Pregnancy		Fluticasone Propionate And Salmeterol Xinafoate	SS				32 DAY
	Flat Feet							
	Pilonidal Cyst Congenital							
	Spinal Disorder		Fusidate Sodium	SS				8 DAY
			Pantoprazole	SS				15 DAY
			Prednisolone	C				5 DAY
			Cefuroxime	C				
			Ritiometan Magnesium	C				
			Biclotymol	C				
			Ambroxol	C				
			Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C				

Date:12/08/04ISR Number: 4521212-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00219
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Novolin R	C				UNKNOWN
Initial or Prolonged			Morphine	C				UNKNOWN
			Alprazolam	C				UNKNOWN
			Nexium	C				UNKNOWN

Date:12/08/04ISR Number: 4521213-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00009
Age:11 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Dizziness		Acetaminophen	C				UNKNOWN
	Erythema		Somatropin	C				UNKNOWN
	Headache		Calcium Carbonate	C				UNKNOWN
	Hyperhidrosis		Cetirizine Hydrochloride	C		ORAL		
	Muscle Rigidity		Etanercept	C				SUBCUTANEOUS
	Pallor		Methotrexate	C				UNKNOWN
	Palpitations		Omeprazole Magnesium	C		ORAL		
	Skin Swelling		Folic Acid	C		ORAL		

Date:12/08/04ISR Number: 4521214-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521215-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00189
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Hospitalization -	Vascular Rupture		Coumadin	C				
Initial or Prolonged			Lanoxin	C				
Disability			[Therapy Unspecified]	C				

Date:12/08/04ISR Number: 4521216-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00442
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	731	DAY
Hospitalization -	Coronary Artery Occlusion		Toprol Xl Tablets	C				
Initial or Prolonged			Medrol	C				
Disability			Folic Acid	C				
Other			Neurontin	C				
			Nexium	C				

Date:12/08/04ISR Number: 4521219-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea							

Date:12/08/04ISR Number: 4521221-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction							

Date:12/08/04ISR Number: 4521222-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Paralysis							

Date:12/08/04ISR Number: 4521223-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00049
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521226-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00538
Age:53 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol Msd	C				
UNKNOWN								

Date:12/08/04ISR Number: 4521367-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02516
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Femara	C				
UNKNOWN								

Date:12/08/04ISR Number: 4521373-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain							

Date:12/08/04ISR Number: 4521374-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00821
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atelectasis							
Disability	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery Disease							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Dyspnoea							
	Hypokalaemia							
	Influenza Like Illness							

Myocardial Infarction
Obesity
Pain
Paranoia
Paranoid Personality
Disorder
Polytraumatism
Post Procedural
Complication
Pyrexia
Spermatocele
Spinal Cord Disorder
Spinal Disorder
Ventricular Dysfunction

Date:12/08/04ISR Number: 4521379-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00105
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Varices		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Omeprazole	C		ORAL		
	Varices Oesophageal		Propranolol					

			Hydrochloride	C	ORAL

Date:12/08/04ISR Number: 4521380-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA01392
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/08/04ISR Number: 4521381-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00043
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Ibuprofen	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		[Therapy					
Disability	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
	Transient Ischaemic		Neurontin	C				
UNKNOWN								
	Attack		Buspar	C				
UNKNOWN								

Date:12/08/04ISR Number: 4521383-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00806
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							

Date:12/08/04ISR Number: 4521384-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04359
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Breast Mass		Lipitor	C				
Initial or Prolonged UNKNOWN	Flushing		Lisinopril	C				
Disability	Hypertension							
	Oedema Peripheral							
	Pulmonary Embolism							
	Uterine Disorder							

Date:12/08/04ISR Number: 4521385-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0411CHN00084
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
	Blood Pressure Increased							
	Cerebral Ischaemia							
	Cyanosis							
	Dizziness							
	Hypoaesthesia							
	Nausea							

Date:12/08/04ISR Number: 4521386-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00993
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Infarction		Advil	C				UNKNOWN
Disability	Body Height Decreased		Advil	C				UNKNOWN
	Bradycardia		Tylenol	C				UNKNOWN
	Depression		Tylenol	C				UNKNOWN
	Ejection Fraction		Imitrex	C				UNKNOWN
	Decreased		Percocet	C				UNKNOWN
	Emotional Distress		Medrol	C				UNKNOWN
	Fatigue		Maalox	C				UNKNOWN
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Hypercholesterolaemia							
	Hypotension							
	Psoriasis							
	Seborrhoeic Dermatitis							
	Urinary Retention							
	Ventricular Tachycardia							

Date:12/08/04ISR Number: 4521387-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00037
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C		ORAL		
Initial or Prolonged			Prilosec	C				UNKNOWN
Disability			Florital	C				UNKNOWN
Other			Topamax	C		ORAL		

			Fioricet Tablets	C		ORAL
			Ambien	C		ORAL

Date:12/08/04ISR Number: 4521389-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00044
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Comminuted Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Diplopia		Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness		Pantoprazole Sodium	C		
UNKNOWN						
	Fall		Doxepin			
	Hyperhidrosis		Hydrochloride	C		
UNKNOWN						
	Prescribed Overdose		Zopiclone	C		
UNKNOWN						
	Spinal Fracture		Oxycodone			
	Tinnitus		Hydrochloride	C		
UNKNOWN						
	Upper Limb Fracture					
	Vertigo					

Date:12/08/04ISR Number: 4521393-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00057
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Transient Ischaemic		Lescol Xl	C		
UNKNOWN						
Initial or Prolonged	Attack					
Disability						

Date:12/08/04ISR Number: 4521394-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00002
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C		ORAL		
							5	YR

Date:12/08/04ISR Number: 4521396-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02581
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Indapamide	C				
UNKNOWN								
Initial or Prolonged	Migraine		Benicar	C				
UNKNOWN								
Disability								

Date:12/08/04ISR Number: 4521397-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00011
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
1520 DAY								
	Cerebrovascular Accident							

Date:12/08/04ISR Number: 4521399-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00202
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aortic Valve		Synthroid	C				
UNKNOWN								

	Calcification	Protonix	C	
UNKNOWN				
	Asthma	Digitek	C	
UNKNOWN				
	Brain Natriuretic Peptide	Darvocet-N	C	
UNKNOWN				
	Increased	Prilosec	C	
UNKNOWN				
	Bronchospasm	Tiazac	C	
UNKNOWN				
	Cardiac Failure	Nexium	C	
UNKNOWN				
	Congestive	Cozaar	C	ORAL
	Chest Pain			
	Diastolic Dysfunction			
	Dilatation Atrial			
	Dyspnoea			
	Electrocardiogram T Wave			
	Amplitude Decreased			
	Electrocardiogram T Wave			
	Inversion			
	Emphysema			
	Haematocrit Decreased			
	Haemoglobin Decreased			
	Mitral Valve Incompetence			
	Pneumonia Aspiration			
	Pulmonary Valve			
	Incompetence			
	Rales			
	Tricuspid Valve			
	Incompetence			
	Ventricular Hypertrophy			
	Wheezing			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521404-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00213
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Lotrel	C				
	Faecal Incontinence		Lotensin	C				
	Fluid Retention		Norvasc	C				
	Oedema Peripheral		Premarin	C				
	Syncope		[Therapy Unspecified]	C				
			Pantoloc	C				
			Zoloft	C				

Date:12/08/04ISR Number: 4521405-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00062
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		4 WK
	Cardiac Failure Congestive							
	Myocardial Infarction							

Date:12/08/04ISR Number: 4521407-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia							
	Cerebrovascular Accident							
	Hemiparesis							

Speech Disorder

Date:12/08/04ISR Number: 4521408-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00095
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Post Procedural		Aspirin	C				
UNKNOWN								
Initial or Prolonged	Complication		Vitamins					
Disability	Staphylococcal Infection		(Unspecified)	C				
UNKNOWN								
Other								

Date:12/08/04ISR Number: 4521409-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00188
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Fosamax	C		ORAL		

Date:12/08/04ISR Number: 4521410-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00094
Age:74 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521411-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03576
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder Cardiac Valve Disease Cardiomegaly Dyspnoea Gastrointestinal Disorder Gout Lung Disorder Neuropathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521412-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00392
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
			Celebrex	C				
			Glucotrol	C				
			Norvasc	C				
			Lisinopril	C				
			Pravachol	C				

Date:12/08/04ISR Number: 4521413-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521414-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00304
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521415-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00231
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521417-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04093
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Renal Impairment		Nexium	C				UNKNOWN

Date:12/08/04ISR Number: 4521418-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00061
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain							
	Dyspnoea							

Date:12/08/04ISR Number: 4521419-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00413
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Synthroid	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:12/08/04ISR Number: 4521420-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/08/04ISR Number: 4521421-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00407
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Zocor	C		ORAL		
Initial or Prolonged	Attack		Zocor	C		ORAL		
			Protonix	C				UNKNOWN
			Depakote	C				UNKNOWN
			Plavix	C				UNKNOWN
			Clonazepam	C				UNKNOWN
			Flomax (Tamsulosin Hydrochloride)	C				UNKNOWN

Date:12/08/04ISR Number: 4521422-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00402
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521423-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00421
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		[Therapy Unspecified]	C				
UNKNOWN								

Date:12/08/04ISR Number: 4521424-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00517
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/08/04ISR Number: 4521433-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
457 DAY								
Hospitalization - Initial or Prolonged	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiopathy		Albuterol	C				
UNKNOWN								
Other	Asthma		Singulair	C				
UNKNOWN								
	Basal Cell Carcinoma		Amoxicillin	C				
UNKNOWN								
	Bronchitis		Correctol					
	Bronchitis Acute		(Bisacodyl)	C				
UNKNOWN								
	Bronchospasm		Hydrochlorothiazide	C				
UNKNOWN								
	Carotid Artery Stenosis		Aspirin	C				
UNKNOWN								
	Cerebral Haemorrhage		Medrol	C				
UNKNOWN								

	Chest Wall Pain	Maxzide	C
UNKNOWN			
	Deep Vein Thrombosis	Baycol	C
UNKNOWN			
	Depression	Doxepin	
	Dizziness	Hydrochloride	C
UNKNOWN			
	Dyspepsia	Lotensin	C
UNKNOWN	119 DAY		
	Eczema	Calan	C
UNKNOWN			
	Emotional Distress	Dyazide	C
UNKNOWN			
	Gastrointestinal Disorder	Dyazide	C
UNKNOWN			
	Hypertension	Pravachol	C
UNKNOWN	1210 DAY		
	Hypokalaemia	Tylenol	C
UNKNOWN			
	Mitral Valve Incompetence		
	Pupil Fixed		
	Respiratory Alkalosis		
	Sinusitis		
	Sputum Abnormal		
	Transient Ischaemic		
	Attack		
	Tricuspid Valve		
	Incompetence		
	Wheezing		

Date:12/08/04ISR Number: 4521435-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1660 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/08/04ISR Number: 4521436-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/08/04ISR Number: 4521790-3Report Type:Direct Company Report #CTU 233916
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Angina Pectoris		Vioxx Unknown					
Intervention to	Blood Pressure Increased		Assume Merck	PS	Merck			
Prevent Permanent	Chest Pain		Zocor	C				
Impairment/Damage	Decreased Activity		Roxicet	C				
	Dyspnoea Exertional							
	Fear							

Date:12/08/04ISR Number: 4525529-7Report Type:Expedited (15-DaCompany Report #WAES 0411USA03928
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Study	Tab Etoricoxib	PS		ORAL		
30								
Initial or Prolonged		Health						
MG/DAILY/PO								
		Professional	Tab Acetaminophen					
			325 Mg	SS		ORAL		
325 MG								
/PRN/PO								
			Tab Placebo	SS		ORAL		
PO								
			Tab Vioxx 25 Mg	SS		ORAL		
15								
MG/DAILY/PO								
			Effexor	C				

Tylenol Arthritis Extended Relie	C
Tylenol Sinus	C

Date:12/09/04ISR Number: 4522052-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00468
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Activated Partial Thromboplastin Time Prolonged
	Anaemia
	Anxiety
	Arteriospasm Coronary
	Biliary Neoplasm
	Blister
	Blood Albumin Decreased
	Bronchiectasis
	Bursitis
	Cellulitis
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Constipation

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Deep Vein Thrombosis					
		Diverticulum		Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Duodenitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Emphysema		Vioxx	SS	Merck & Co., Inc	ORAL
		Erosive Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Excoriation		Robaxin	C		ORAL
		Fear		Premarin	C		ORAL
		Flatulence		Prilosec	C		
UNKNOWN							
		Gallbladder Disorder		Fosamax	C		
UNKNOWN							
		Gastric Ulcer Haemorrhage		Amitriptyline			
		Gastritis Haemorrhagic		Hydrochloride	C		ORAL
		Hepatitis		Diphenhydramine			
		Limb Discomfort		Tannate	C		ORAL
		Lung Neoplasm		Docusate Sodium	C		ORAL
		Malnutrition		Norvasc	C		ORAL
		Mycobacterium Avium		Wellbutrin Sr	C		ORAL
		Complex Infection		Rifampin	C		ORAL
		Myocardial Infarction		Ethambutol			
		Nausea		Hydrochloride	C		ORAL
		Oedema Peripheral		Lampren	C		ORAL
		Oral Intake Reduced		Clinoril	C		ORAL
		Otitis Externa					
		Pruritus					
		Pulmonary Calcification					
		Pulmonary Cavitation					
		Pulmonary Mass					
		Rash Morbilliform					
		Rash Vesicular					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Visual Disturbance					
		Vitreous Floaters					
		Vomiting					
		Weight Decreased					
		White Blood Cell Count Decreased					

Date:12/09/04ISR Number: 4522054-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Anaemia
Disability	Anorexia
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Colitis Ulcerative
	Constipation
	Cough
	Deep Vein Thrombosis
	Depression

		Drug Interaction					
		Dyspnoea					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Iron Deficiency Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral					
		Pericardial Effusion					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Postmenopausal					
		Haemorrhage					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Rectal Ulcer					
		Reflux Oesophagitis					
		Renal Failure					
		Tremor					
		Weight Decreased					

Date:12/09/04ISR Number: 4522055-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00752
Age:85 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris					
		Blood Pressure Increased					
		Convulsion					
		Death					

Date:12/09/04ISR Number: 4522056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03167
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Adhesions
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Abdominal Pain
Other	Activated Partial
	Thromboplastin Time

Prolonged
Acute Respiratory Failure
Adrenal Insufficiency
Anaemia Of Chronic
Disease
Arteriosclerosis
Asthenia
Asthma
Bacterial Infection
Beta Haemolytic
Streptococcal Infection
Blood Bicarbonate
Decreased
Blood Erythropoietin
Decreased
Bronchitis Acute
Candidiasis
Cardiac Failure
Congestive

Cellulitis
Chest X-Ray Abnormal
Cholecystitis Chronic
Cholesterosis
Coagulopathy
Colitis
Condition Aggravated
Decubitus Ulcer
Deep Vein Thrombosis
Diarrhoea
Diverticulum
Duodenitis
Dyspepsia
Dyspnoea
Escherichia Infection
Faecal Incontinence
Fatigue
Fibrosis
Fungaemia
Gastric Ulcer
Gastritis
Gastritis Erosive
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Gynaecomastia
Haematoma
Haemoptysis
Haemorrhoids
Headache
Hepatic Steatosis
Hiatus Hernia
Hypercoagulation
Hyperglycaemia
Hypertension
Hypoproteinaemia
Hypotension
Incisional Hernia
Inguinal Hernia
Injury
International Normalised
Ratio Increased
Low Density Lipoprotein
Increased
Malnutrition

Metabolic Acidosis
Mucosal Haemorrhage
Myocardial Infarction
Normochromic Normocytic
Anaemia
Obesity
Oesophagitis
Optic Neuropathy
Osteoarthritis
Otitis Media
Pco2 Decreased
Pickwickian Syndrome
Pneumonia
Po2 Increased

		Postoperative Fever					
		Prothrombin Time Prolonged	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pseudomonas Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Embolism		Cozaar	C		
UNKNOWN							
		Pulmonary Hypertension		Micardis	C		
UNKNOWN							
		Renal Failure		Lasix (Furosemide)	C		
UNKNOWN							
		Renal Failure Acute		Lasix (Furosemide)	C		
UNKNOWN							
		Respiratory Failure		Catapres	C		
UNKNOWN		347 DAY					
		Rheumatoid Arthritis					
		Sepsis					
		Sleep Apnoea Syndrome					
		Sputum Culture Positive					
		Staphylococcal Sepsis					
		Syncope Vasovagal					
		Thrombocytopenia					
		Thrombosis					
		Umbilical Hernia					
		Urinary Incontinence					
		Urinary Tract Infection					
		Vertigo					
		White Blood Cell Count Increased					

Date:12/09/04ISR Number: 4522061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00902
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Back Disorder					
	Feeling Abnormal					
	Hallucination, Auditory					
	Polytraumatism					
	Suicidal Ideation					

Date:12/09/04ISR Number: 4522062-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Affective Disorder
	Anaemia
	Angina Pectoris
	Back Injury
	Back Pain
	Cerebrovascular Accident
	Colonic Polyp
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspepsia
	Eczema
	Gastritis
	Haemorrhoidal Haemorrhage
	Head Injury
	Headache
	Heart Rate Irregular
	Hot Flush

		Hypochromic Anaemia					
		Insomnia					
		Intracranial Venous Sinus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Joint Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscular Weakness		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Pain		Yasmin	SS		
UNKNOWN		14 DAY					
		Optic Nerve Injury		Sandimmun	C		
UNKNOWN							
		Osteoarthritis		Lexapro	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Sandimmun	C		
UNKNOWN							
		Rash		Sandimmun	C		
UNKNOWN							
		Sinus Tachycardia		Prednisone	C		
UNKNOWN							
		Subarachnoid Haemorrhage		Hormonal			
		Upper Motor Neurone		Contraceptives			
		Lesion		(Unspecified)	C		
INTRAMUSCULAR							
		Uterine Enlargement		Prelone Syrup	C		
UNKNOWN							
		Uterine Leiomyoma		Prelone Syrup	C		
UNKNOWN							
		Vaginal Haemorrhage					
		Visual Disturbance					
		Vomiting					

Date:12/09/04ISR Number: 4522065-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Gastric Outlet Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrointestinal Haemorrhage					

Haemoglobin Decreased

Date:12/09/04ISR Number: 4522066-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00524
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Chest Discomfort		Phenprocoumon	C				UNKNOWN
	Coronary Artery Disease		Prednisone	C				
	Dyspnoea							
	Palpitations							
	Tachycardia							
	Thrombosis							

Date:12/09/04ISR Number: 4522067-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00391
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		700 DAY
	Complete Cardiac Failure							
	Cerebrovascular Accident							

Date:12/09/04ISR Number: 4522068-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA02352
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C		ORAL		
			Levoxyl	C		ORAL		

Date:12/09/04ISR Number: 4522069-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		73 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Zantac	C				UNKNOWN
	Increased		Proscar	C				UNKNOWN
	Chest Discomfort		Roxicet	C				UNKNOWN
	Chest Pain		Terazosin Hydrochloride	C				799 DAY
	Cholelithiasis							UNKNOWN
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hernia							
	Hypertension							
	Myocardial Infarction							
	Nausea							
	Orthostatic Hypotension							
	Panic Disorder							
	Syncope							

Date:12/09/04ISR Number: 4522070-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02784
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1081 DAY

Hospitalization - UNKNOWN	Coumadin	C	
Initial or Prolonged UNKNOWN	Diovan	C	
Disability	Fosamax	C	ORAL
	Coreg	C	
UNKNOWN			
	Toprol Xl Tablets	C	
UNKNOWN			
	Zocor	C	ORAL
	Pravacol	C	
UNKNOWN			

Date:12/09/04ISR Number: 4522071-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00471
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis							
	Osteoarthritis							
	Postoperative Infection							
	Staphylococcal Infection							
	Urinary Tract Infection							
	Vertebral Artery Occlusion							
	Vertebral Artery Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522073-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00029
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:12/09/04ISR Number: 4522076-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00778
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522078-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02227
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Anxiety		Norvasc	C			UNKNOWN	
Disability	Blood Pressure Increased		Lipitor	C			UNKNOWN	
Other	Bradycardia		Caltrate + D	C			UNKNOWN	
	Carotid Artery Stenosis		Ecotrin	C			UNKNOWN	
	Cholecystitis Chronic		Plavix	C			UNKNOWN	
	Cholelithiasis							
	Eye Haemorrhage							
	Eye Injury							
	Hypertension							
	Ischaemic Stroke							
	Stress							
	Syncope Vasovagal							
	Transient Ischaemic Attack							

Vertigo Positional

Date:12/09/04ISR Number: 4522079-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged								
Other								

Date:12/09/04ISR Number: 4522081-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00007
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							

Date:12/09/04ISR Number: 4522082-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00051
Age:72 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Lasix (Furosemide Sodium)	C				
		Glucophage	C				

Date:12/09/04ISR Number: 4522083-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0412ITA00008
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		365 DAY
			Furosemide	C				
			Salmeterol	C				
			Methylprednisolone	C		ORAL		
			Rutin	C				
			Melilot	C				

Date:12/09/04ISR Number: 4522084-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00006
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		421 DAY

Date:12/09/04ISR Number: 4522085-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00086
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Operative Haemorrhage		Prilosec	C				
UNKNOWN								
Initial or Prolonged	Surgery		Teveten (Eprosartan)	C				
UNKNOWN								
			Acetaminophen And Hydrocodone Bitartrate	C				
UNKNOWN								

Date:12/09/04ISR Number: 4522086-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00004
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Coreg	C		ORAL		
Initial or Prolonged			Monopril	C				
UNKNOWN								
Disability			Aspirin	C				
UNKNOWN								
			Robaxin	C		ORAL		
			Lasix (Furosemide)	C				
UNKNOWN								

Date:12/09/04ISR Number: 4522087-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00007
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Acetaminophen	C				
UNKNOWN								
	Attack		Glucosamine	C				
UNKNOWN								

				Aspirin And Dipyridamole	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							

Date:12/09/04ISR Number: 4522088-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00090
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracardiac Thrombus Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522089-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00009
Age:11 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
Initial or Prolonged	Abdominal Pain		Acetaminophen	C				
UNKNOWN								
	Blood Alkaline		Somatropin	C				
UNKNOWN								
	Phosphatase Increased		Calcium Carbonate	C				
UNKNOWN								
	Blood Calcium Decreased		Cetirizine Hydrochloride	C		ORAL		
	Condition Aggravated							
	Dizziness		Etanercept	C				
SUBCUTANEOUS								
	Erythema		Methotrexate	C				
SUBCUTANEOUS								
	Headache		Omeprazole Magnesium	C		ORAL		
	Hyperhidrosis		Folic Acid	C		ORAL		
	Muscle Rigidity							
	Pallor							
	Palpitations							
	Rheumatoid Arthritis							
	Skin Swelling							
	White Blood Cell Count Decreased							

Date:12/09/04ISR Number: 4522090-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00034
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/09/04ISR Number: 4522091-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00195
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dementia Alzheimer'S Type		Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged	Hallucination		Ritalin	C				
UNKNOWN								
Disability	Persecutory Delusion		Celebrex	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522092-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00156
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident General Symptom		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522093-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00433
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:12/09/04ISR Number: 4522094-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522095-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00254
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged	Loss Of Consciousness		Vioxx Combipres	PS C	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522096-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
340 DAY

Date:12/09/04ISR Number: 4522098-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522100-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522101-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00648
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522102-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522104-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522106-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00644
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522107-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Coumadin	C				
Initial or Prolonged Disability								

Date:12/09/04ISR Number: 4522108-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00777
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522110-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00412
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522111-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522112-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00646
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00690
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aphonia	Professional						
	Arrhythmia							
	Back Pain							
	Burning Sensation							
	Bursitis							
	Gastritis							
	Headache							
	Hypertension							
	Joint Dislocation							
	Meniscus Lesion							
	Osteoarthritis							
	Pain In Extremity							
	Pyrexia							
	Rheumatoid Arthritis							
	Sciatica							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Sneezing							
	Synovitis							
	Tarsal Tunnel Syndrome							

Date:12/09/04ISR Number: 4522804-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00247
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Balance Disorder		Primidone	C				
UNKNOWN								
	Blood Pressure		Clonazepam	C				
UNKNOWN								
	Fluctuation		Ranitidine					
	Cerebrovascular Accident		Hydrochloride	C				
UNKNOWN								
	Dyspepsia		Fluticasone					
	Dysuria		Propionate	C				
UNKNOWN								
	Erectile Dysfunction							
	Sensory Loss							

Tremor

Date:12/09/04ISR Number: 4522809-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03017
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Cotazym	C				
UNKNOWN								
Disability	Hemiplegia							
	Nervous System Disorder							

Date:12/09/04ISR Number: 4522810-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
							37	DAY
Other	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hemiparesis							
	Memory Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522812-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
	Increased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY	
	Arrhythmia							
	Aspartate							
	Aminotransferase							
	Increased							
	Blood Creatine							
	Phosphokinase Increased							
	Blood Creatine							
	Phosphokinase Mb							
	Increased							
	Blood Creatinine							
	Increased							
	Blood Lactate							
	Dehydrogenase Increased							
	Blood Urea Increased							
	Chest Pain							
	Depression							
	Granulocyte Count							
	Increased							
	Injury							
	International Normalised							
	Ratio Decreased							
	Lymphocyte Percentage							
	Decreased							
	Monocyte Count Decreased							
	Palpitations							
	Prothrombin Time							
	Prolonged							
	Pulmonary Embolism							
	Stress							
	Tachycardia							
	White Blood Cell Count							
	Increased							

Date:12/09/04ISR Number: 4522813-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00835
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1849 DAY
Initial or Prolonged	Blue Toe Syndrome	Professional	Darvocet-N	C				UNKNOWN
Other	Cellulitis Pharyngeal		Soma	C		ORAL		
	Chest Pain		Soma	C				UNKNOWN
	Coronary Artery Disease		Elavil	C				UNKNOWN
	Fall		Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
	Fibula Fracture							
	Intermittent Claudication							
	Myocardial Infarction							
	Tarsal Tunnel Syndrome							
	Therapeutic Response Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522814-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00077
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Agranulocytosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization -	Septic Shock	Professional	Omeprazole	SS		ORAL		8 DAY
Initial or Prolonged			Perindopril	C		ORAL		8 DAY
			Pravastatin Sodium	C		ORAL		8 DAY

Date:12/09/04ISR Number: 4522819-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03735
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Levoxyl	C				UNKNOWN
Disability			Diovan	C				UNKNOWN

Date:12/09/04ISR Number: 4522821-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00750
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris	Professional	Ultram	C				UNKNOWN
	Blood Pressure Increased		Zestril	C				UNKNOWN
	Convulsion							
	Death							
	Psoriasis							

Date:12/09/04ISR Number: 4522822-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00064
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Pain In Extremity		Zocor	C				
	Syncope		Aspirin And Dipyridamole	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	

Date:12/09/04ISR Number: 4522823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01014
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	SUBCUTANEOUS	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Humulin N	C				
Disability			Hydrodiuril	C		ORAL		
Other			Prilosec	C		ORAL		
			Celexa	C			UNKNOWN	
			Norvasc	C		ORAL		
			Glucophage	C		ORAL		
			Lotensin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522827-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Intestinal Perforation							
	Paralysis							

Date:12/09/04ISR Number: 4522830-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03191
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebral Thrombosis	Professional	Influenza Virus					
Initial or Prolonged	Cerebrovascular Accident		Vaccine					
Disability	Coma		(Unspecified)	SS				
UNKNOWN								
	Deafness		[Therapy					
	Dementia		Unspecified]	C				
UNKNOWN								
	Fall		[Therapy					
	Loss Of Consciousness		Unspecified]	C				
UNKNOWN								
	Paralysis		Paxil	C				
UNKNOWN								
	Thrombosis							

Date:12/09/04ISR Number: 4522831-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00003
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
561 MON								
Hospitalization -								
Initial or Prolonged								

Date:12/09/04ISR Number: 4522832-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00438
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc		UNKNOWN	883 DAY
Initial or Prolonged	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc		UNKNOWN	55 DAY
Other	Hemianopia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	883 DAY
	Hemiparesis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	55 DAY
	Thrombosis		Atenolol	C			UNKNOWN	
			Imdur	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:12/09/04ISR Number: 4522834-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03215
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522835-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Death		Temazepam	C		ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
	Pneumonia							

Date:12/09/04ISR Number: 4522836-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03453
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pleurisy							
	Pneumonia							

Date:12/09/04ISR Number: 4522842-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00414
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Synthroid	C				
UNKNOWN								
Disability			Glipizide	C				
UNKNOWN								
			Hydrodiuril	C				
UNKNOWN								
			Thioridazine	C				
UNKNOWN								

Date:12/09/04ISR Number: 4522844-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00519
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Myocardial Infarction	Cardizem	C
Initial or Prolonged UNKNOWN	Overdose	Coumadin	C
Disability UNKNOWN		Lescol	C

Date:12/09/04ISR Number: 4522845-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522848-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00552
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Plavix	C				
Initial or Prolonged UNKNOWN			Allegra	C				
UNKNOWN			Biaxin	C				
UNKNOWN			Zithromax	C				
UNKNOWN			Levaquin	C				
UNKNOWN			Travatan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522850-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00531
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Coronary Artery Disease							
Hospitalization - Initial or Prolonged								
Disability								

Date:12/09/04ISR Number: 4522851-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Muscle Spasms		Neurontin	C				
Initial or Prolonged								
Disability								

Date:12/09/04ISR Number: 4522852-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00683
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vicodin Tablets	C				
UNKNOWN								
Disability	Thrombosis							

Date:12/09/04ISR Number: 4522853-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00373
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Chest Pain							

Date:12/09/04ISR Number: 4522854-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00548
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522855-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00555
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Thrombosis		Vasotec	C				
Initial or Prolonged UNKNOWN			Glyburide	C				
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/09/04ISR Number: 4522857-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00201
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vision Blurred		Norvasc	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								

Date:12/09/04ISR Number: 4522858-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00458
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/09/04ISR Number: 4522859-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00384
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coagulopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Coumadin	C				
UNKNOWN								
Disability	Impaired Healing		Vitamins (Unspecified)	C				
	Leg Amputation							
UNKNOWN								
	Peripheral Vascular Disorder							
	Skin Ulcer							

Date:12/09/04ISR Number: 4522860-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00503
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Estradiol	C				
Initial or Prolonged			Actonel	C				
			Detrol	C				
			Lipitor	C				
			Tegretol	C				
			Carbamazepine	C				

Date:12/09/04ISR Number: 4522864-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00686
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:12/09/04ISR Number: 4522865-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00724
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc			
			Percocet	C				
			[Therapy					

Unspecified] C
UNKNOWN

Date:12/09/04ISR Number: 4522867-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00674
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Thrombosis							

Date:12/09/04ISR Number: 4522868-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00651
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer Haemorrhage							

Date:12/09/04ISR Number: 4522869-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00684
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Norco	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								
			Indapamide	C				
UNKNOWN								

Date:12/09/04ISR Number: 4522870-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/09/04ISR Number: 4522888-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00404
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Impaired Healing		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diovan	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:12/09/04ISR Number: 4523220-4Report Type:Direct Company Report #CTU 233973
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx 25 Mg	PS			1 EVERY DAY	
Initial or Prolonged	Dyspnoea							
	Vital Functions Abnormal							

Date:12/09/04ISR Number: 4523225-3Report Type:Direct Company Report #CTU 233949
Age:58 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis		Vioxx 25 Mg X 2	PS		ORAL	PO 25 M X 2	

Date:12/09/04ISR Number: 4523226-5Report Type:Direct Company Report #CTU 233950
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS			50 MG/1X DAY	
Initial or Prolonged								

Date:12/09/04ISR Number: 4523344-1Report Type:Expedited (15-DaCompany Report #2004102565
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Initial or Prolonged	Body Height Decreased		Bextra (Valdecoxib)	SS		ORAL	(2 IN 1 D),	
Other	Gastric Disorder						ORAL	
	Infection		Rofecoxib					
	Large Intestinal		(Rofecoxib)	SS		ORAL	(1 IN 1 D),	
	Stricture						ORAL	
	Large Intestinal Ulcer		Montelukast					
	Haemorrhage		(Montelukast)	C				
	Large Intestine		Telmisartan					
	Perforation		(Telmisartan)	C				
	Oedema Peripheral		Amlodipine Besilate					
	Osteopenia		(Amlodipine					
	Pain In Extremity		Besilate)	C				
	Post Procedural							
	Complication							

Date:12/09/04ISR Number: 4523424-0Report Type:Direct Company Report #CTU 234034
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx 25 Mg	PS			25 MG DAILY	Initial or Prolonged

Date:12/09/04ISR Number: 4524101-2Report Type:Expedited (15-DaCompany Report #2004099920
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Eczema Toxic Skin Eruption	Foreign Health Professional	Atarax (Tablet) (Hydroxyzine Hydrochloride)	PS		ORAL	ORAL	
			Zoxan Lp (Doxazosin) (Doxazosin)	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Tramadol/Acetaminoph en (Paracetamol, Tramadol)	SS		ORAL	ORAL	
			Amiodarone Hydrochloride (Amiodarone					

			Hydrochloride)	SS		
INTRAVENOUS	INTRAVENOUS					
			Betahistine Hydrochloride (Betahistine Hydrochloride)	SS		ORAL
ORAL						
			Clonidine (Clonidine)	C		
			Amlodipine Besilate (Amlodipine Besilate)	C		
			Loprazolam Mesilate (Loprazolam Mesilate)	C		
			Acenocoumarol (Acenocoumarol)	C		
			Potassium Chloride (Potassium Chloride)	C		
			Fosinopril (Fosinopril)	C		
			Pravastatin (Pravastatin)	C		

Date:12/10/04ISR Number: 4523368-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY						
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY						
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY						
	Back Pain		Zestril	C		
UNKNOWN	2170 DAY					
	Benign Prostatic		Zestril	C		
UNKNOWN	2170 DAY					
	Hyperplasia		Tenormin	C		
UNKNOWN						

	Cardiac Failure	Tenormin	C
UNKNOWN			
	Congestive	Glucophage	C
UNKNOWN			
	Chest Pain	Micronase	C
UNKNOWN			
	Coronary Artery Disease	Lanoxin	C
UNKNOWN	1051 DAY		
	Coronary Artery Restenosis	[Therapy Unspecified]	C
UNKNOWN			
	Depression	Aciphex	C
UNKNOWN			
	Diabetes Mellitus Non-Insulin-Dependent Diabetic Nephropathy Diabetic Neuropathy Diabetic Retinopathy Drug Ineffective Fall Hepatitis Herpes Zoster Hypercholesterolaemia Infection Intervertebral Disc Disorder Ischaemic Cardiomyopathy Pneumonia Sepsis Sexual Dysfunction		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523375-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00694
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Quinine	C				
UNKNOWN								
Disability	Amnesia		Calcium (Unspecified)	C				
Other	Aneurysm							
UNKNOWN								
	Angina Pectoris		Vitamins (Unspecified)	C				
	Anxiety							
UNKNOWN								
	Arthralgia		Amitriptyline Hydrochloride	C		ORAL		
	Bursitis							
	Cardiomegaly		Axocet (Acetaminophen (+) Butalbital)	C				
	Carpal Tunnel Syndrome							
	Chest Wall Pain							
UNKNOWN								
	Convulsion		Paxil	C				
UNKNOWN								
	Diabetes Mellitus Non-Insulin-Dependent							
	Dyspepsia							
	Dysphonia							
	Facial Palsy							
	Fall							
	Haemorrhagic Stroke							
	Hand Fracture							
	Hypercholesterolaemia							
	Hypertriglyceridaemia							
	Hypoaesthesia							
	Ileus							
	Nasopharyngitis							
	Night Cramps							
	Ocular Discomfort							
	Oedema							
	Pain In Extremity							
	Paraesthesia							
	Pruritus							
	Rhinitis Allergic							
	Small Intestinal Obstruction							
	Throat Irritation							
	Upper Respiratory Tract Infection							

Date:12/10/04ISR Number: 4523379-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA02294
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Disability	Blood Pressure Increased
Other	Cerebrovascular Accident
	Chest Pain
	Dementia
	Depression
	Dyspnoea
	Emotional Distress
	Fall
	Gastroenteritis
	Hypoglycaemia
	Hypomagnesaemia
	Injury
	Irritability

Joint Stiffness
Lacunar Infarction
Musculoskeletal

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Discomfort					
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea					
	Glyburide	C			UNKNOWN	
	Osteopenia					
	Prinivil	C			UNKNOWN	
	Pneumonia Aspiration					
	Celebrex	C			UNKNOWN	
	Retching					
	Aspirin	C			UNKNOWN	
	Troponin Increased					
	Urticaria					

Date:12/10/04ISR Number: 4523380-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome
Disability

PT
Abdominal Pain
Abdominal Wall Mass
Anorexia
Anxiety
Arthralgia
Arthritis
Asthenia
Atherosclerosis
Back Pain
Blister
Blood Pressure
Inadequately Controlled
Bronchitis
Bursitis
Cardiac Disorder
Caustic Injury
Chemical Burn Of Skin
Chest Pain
Constipation
Cough
Depression
Diastolic Dysfunction
Diverticulum Intestinal
Dizziness
Drug Eruption

Dysphonia
Dysuria
Ecchymosis
Epistaxis
Exostosis
Eye Discharge
Fall
Frequent Bowel Movements
Gastritis
Glucose Tolerance
Impaired
Gout
Haemorrhoids
Headache
Helicobacter Infection
Hepatic Cirrhosis
Hypertension
Hyperuricaemia
Hypoaesthesia
Insomnia

		Intervertebral Disc Degeneration					
		Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Crepitation		Vioxx	SS	Merck & Co., Inc	ORAL
		Kidney Infection		Prinivil	C		
UNKNOWN							
		Labyrinthitis		K-Dur	C		
UNKNOWN							
		Muscle Strain		Lortab	C		
UNKNOWN							
		Nasopharyngitis		Coumadin	C		
UNKNOWN							
		Nausea		[Therapy			
		Oedema		Unspecified]	C		
UNKNOWN							
		Oedema Peripheral		Lasix (Furosemide			
		Osteoarthritis		Sodium)	C		
UNKNOWN							
		Otitis Media					
		Pain					
		Pharyngitis					
		Rash					
		Sinusitis					
		Sleep Disorder					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Syncope					
		Tricuspid Valve Incompetence					
		Urinary Incontinence					
		Vertigo					
		Vision Blurred					
		Vomiting					
		Weight Decreased					

Date:12/10/04ISR Number: 4523384-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00636
Age:35 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Unstable		Celebrex	C		
UNKNOWN							

Disability	Bronchitis	Tylenol	C
UNKNOWN			
	Chest Pain	Aspirin	C
UNKNOWN			
	Chest Wall Pain	Nexium	C
UNKNOWN			
	Cholelithiasis	Toprol Xl Tablets	C
UNKNOWN			
	Dermal Cyst	Tylenol With Codeine	
	Duodenitis	#3	C
UNKNOWN			
	Dyspnoea		
	Eczema		
	Electrocardiogram		
	Abnormal		
	Epistaxis		
	Gastritis		
	Helicobacter Gastritis		
	Laceration		
	Nasal Congestion		
	Otitis Media		
	Pleurisy		
	Polytraumatism		
	Sinusitis		
	Victim Of Crime		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523387-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL	350 DAY	
Initial or Prolonged	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc		UNKNOWN	27 DAY
	Anorectal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aphthous Stomatitis		Vioxx	SS	Merck & Co., Inc	ORAL	350 DAY	
	Apnoea		Propecia	C			UNKNOWN	
	Arterial Disorder		Atenolol	C			UNKNOWN	
	Arthralgia		Norco	C			UNKNOWN	
	Arthritis		Chlorthalidone	C			UNKNOWN	
	Atelectasis		Celebrex	C			UNKNOWN	
	Back Pain		Celebrex	C			UNKNOWN	
	Cardiac Valve Disease		Cyclobenzaprine					
	Coronary Artery		Hydrochloride	C			UNKNOWN	
	Atherosclerosis		Ultram	C			UNKNOWN	
	Coronary Artery Disease		Hydrocodone					
	Coronary Artery Occlusion		Hydrochloride	C			UNKNOWN	
	Coronary Artery		[Therapy					
	Restenosis		Unspecified]	C			UNKNOWN	
	Coronary Artery Stenosis		Tenormin	C			UNKNOWN	
	Diabetes Mellitus		Avandia	C			UNKNOWN	
	Diverticulitis		Glucovance	C			UNKNOWN	

	Dysphonia	Hygroton	C
UNKNOWN			
	Dyspnoea	Cardizem	C
UNKNOWN			
	Emotional Distress	Altace	C
UNKNOWN			
	Erectile Dysfunction	Aspirin	C
UNKNOWN			
	Facet Joint Syndrome	Diovan	C
UNKNOWN			
	Hand Fracture		
	Hyperlipidaemia		
	Hypertension		
	Insomnia		
	Intervertebral Disc Protrusion		
	Lumbar Spinal Stenosis		
	Lung Disorder		
	Muscle Disorder		
	Muscle Strain		
	Myocardial Ischaemia		
	Nervousness		
	Osteoarthritis		
	Pain In Extremity		
	Pleural Effusion		
	Pneumothorax		
	Raynaud'S Phenomenon		
	Respiratory Failure		
	Sciatica		
	Snoring		
	Somnolence		
	Thrombosis		
	Ventricular Hypokinesia		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523388-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc			
Other	Arteriosclerosis		Levothyroxine Sodium	C			UNKNOWN	
	Arthralgia		Cardizem	C			UNKNOWN	
	Asthma		Prilosec	C			UNKNOWN	
	Benign Prostatic		Lipitor	C			UNKNOWN	
	Hyperplasia		Triamterene	C			UNKNOWN	
	Blood Cholesterol		Plavix	C			UNKNOWN	
	Increased		Aspirin	C			UNKNOWN	
	Cataract							
	Cerebrovascular Accident							
	Colonic Polyp							
	Convulsion							
	Encephalomalacia							
	Eye Pain							
	Gastrooesophageal Reflux Disease							
	Haematuria							
	Haemorrhoids							
	Hydronephrosis							
	Hypertension							
	Hypertonic Bladder							
	Neurodermatitis							
	Nodule							
	Pain In Extremity							
	Pneumonia							
	Proteinuria							
	Rash							
	Rectal Haemorrhage							

Date:12/10/04ISR Number: 4523389-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00820
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN	Adverse Event		Motrin	C				
Disability	Arthralgia		Motrin	C			1	DAY
UNKNOWN	Back Pain		Celebrex	C				
UNKNOWN	Dermal Cyst		Soma	C				
UNKNOWN	Family Stress		Ultram	C				
UNKNOWN	Hypertension		Altace	C				
UNKNOWN	Hypoaesthesia		Zyrtec	C				
UNKNOWN	Intervertebral Disc Degeneration		Hydrochlorothiazide And Triamterene	C				
UNKNOWN	Oedema Peripheral		Calcium (Unspecified)	C				
UNKNOWN	Pharyngitis							
UNKNOWN	Plantar Fasciitis		Estradiol	C				
	Polytraumatism							
	Postoperative Infection							
	Rhinitis							
	Temporomandibular Joint Syndrome							
	Upper Respiratory Tract Infection							
	Wound Secretion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523390-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00080
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Captopril	C		ORAL		
	Chest Pain		Captopril	C			UNKNOWN	
	Cow'S Milk Intolerance		Hydrodiuril	C			UNKNOWN	
	Emotional Distress		Claritin	C			UNKNOWN	
	Flank Pain		Motrin	C			UNKNOWN	
	Gastritis Erosive		Baycol	C		ORAL		
	Gastrointestinal Disorder		Nitroquick	C			SUBLINGUAL	
	Haemorrhoids		Metoprolol	C			UNKNOWN	
	Helicobacter Infection		Metoprolol	C			UNKNOWN	
	Helicobacter Pylori		Metoprolol	C			UNKNOWN	
	Identification Test		Aspirin	C			UNKNOWN	
	Positive		Baycol	C		ORAL		
	Hiatus Hernia		Estrogens (Unspecified)	C			UNKNOWN	
	Hypertension							
	Myalgia		Allegra	C			UNKNOWN	
	Myocardial Infarction		Lipitor	C		ORAL		
	Nausea		Aleve	C			UNKNOWN	
	Pain In Extremity							
	Weight Decreased							

Date:12/10/04ISR Number: 4523393-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Lower
Other	Aneurysm

Angina Unstable
Anorexia
Anxiety
Anxiety Disorder
Aortic Aneurysm
Asthenia
Cardiac Disorder
Carotid Artery Occlusion
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Colonic Polyp
Decubitus Ulcer
Depression
Diabetes Mellitus
Duodenal Ulcer
Duodenal Ulcer
Haemorrhage
Eating Disorder
Emotional Distress
Emphysema
Facial Palsy
Fall
Foot Fracture
Gastric Ulcer
Gastroenteritis
Haemorrhage
Hemiparesis
Hypertension

		Intestinal Functional Disorder					
		Leg Amputation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Micturition Urgency		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Cyanocobalamin	C		
UNKNOWN							
		Myocardial Ischaemia		Reglan	C		
UNKNOWN							
		Nausea		Norvasc	C		
UNKNOWN							
		Peripheral Ischaemia		Lorazepam	C		
UNKNOWN							
		Peripheral Vascular		Aggrenox	C		
UNKNOWN							
		Disorder		Zocor	C		
UNKNOWN							
		Pyrexia					
		Thrombosis					
		Toe Amputation					
		Toe Deformity					
		Transient Ischaemic Attack					
		Upper Gastrointestinal Haemorrhage					
		Ventricular Hypertrophy					
		Vomiting					
		Wound Dehiscence					

Date:12/10/04ISR Number: 4523403-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00483
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
556 DAY						
Life-Threatening	Death		[Therapy			
Hospitalization -	Myocardial Infarction		Unspecified]	C		
UNKNOWN						
Initial or Prolonged			Hormones (Unspecified)	C		
UNKNOWN						

Date:12/10/04ISR Number: 4523404-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia Of Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Lipitor	C			UNKNOWN	
	Diverticular Perforation		Lopressor	C			UNKNOWN	
	Dyspnoea		Dyazide	C			UNKNOWN	
	Gastritis		Prilosec	C			UNKNOWN	
	Gastrointestinal		Duragesic	C			TOPICAL	
	Haemorrhage		Voltaren	C			UNKNOWN	
	Gastrooesophageal Reflux		Zoloft	C			UNKNOWN	
	Disease		Celebrex	C			UNKNOWN	
	Muscle Spasms		Triamterene	C			UNKNOWN	
	Osteoarthritis		Denavir	C			UNKNOWN	
	Polyp Colorectal		Metoprolol	C			UNKNOWN	
	Post Procedural Complication							
	Rectal Haemorrhage							
	Small Intestinal Haemorrhage							

Date:12/10/04ISR Number: 4523427-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01316
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		287 DAY
Initial or Prolonged	Cerebrovascular Accident							

Date:12/10/04ISR Number: 4523429-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		89 DAY
Initial or Prolonged	Nervousness		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
Other	Oedema Peripheral		Humulin N	C				UNKNOWN
	Pain In Extremity		Humulin R	C				UNKNOWN
			Naproxen	C		ORAL		
			Naproxen	C		ORAL		
			Livostin	C				OPHTHALMIC
			Prevacid	C		ORAL		
			Vasotec	C				UNKNOWN

Date:12/10/04ISR Number: 4523434-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Outlet		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Obstruction							
	Gastrointestinal							
	Haemorrhage							
	Haemoglobin Decreased							

Date:12/10/04ISR Number: 4523437-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00363
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Amitriptyline Hydrochloride	C				
	Drug Hypersensitivity							
	Mental Disorder							

Date:12/10/04ISR Number: 4523439-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02933
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Plavix	C				
	Transient Ischaemic		Aspirin	C				
	Attack							
	Visual Disturbance							

Date:12/10/04ISR Number: 4523442-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalimumab	SS				

			Methotrexate	SS		
UNKNOWN						
			Estrogens, Conjugated	SS		
UNKNOWN						
			Fluoxetine	SS		
UNKNOWN						
			Amoxicillin And Clavulanate Potassium	SS		
UNKNOWN						
			Acetaminophen And Dihydrocodeine Bitartrate	SS		
UNKNOWN						

Date:12/10/04ISR Number: 4523444-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00706
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Insulin, Biphasic Isophane [Injection]	C		
	Joint Effusion					
UNKNOWN						
	Myocardial Infarction		Simvastatin	C		
UNKNOWN						
	Overdose		Glimepiride	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Metoprolol	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:12/10/04ISR Number: 4523445-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523447-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04247
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523448-3Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00038
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intestinal Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	772 DAY	
Hospitalization - Initial or Prolonged Disability			Valproate Sodium	C		ORAL		
			Valproate Sodium	C		ORAL		

Date:12/10/04ISR Number: 4523450-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00049
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:12/10/04ISR Number: 4523452-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00033
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blindness Unilateral							
Disability	Cerebrovascular Accident							
	Dizziness							
	Headache							

Date:12/10/04ISR Number: 4523453-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523454-9Report Type:Expedited (15-DaCompany Report #FI-MERCK-0412FIN00004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue							
	Malaise							

Date:12/10/04ISR Number: 4523455-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased Depression Disturbance In Attention Dizziness Feeling Drunk Gait Disturbance Lacunar Infarction Tinnitus Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523456-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03070
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Hospitalization - Initial or Prolonged	Disease Chest Pain		[Therapy Unspecified]	C			UNKNOWN	
	Coronary Artery Disease		Toprol Xl Tablets	C			UNKNOWN	
			Altace	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523457-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04117
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombotic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523459-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03706
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dysphagia		Premarin	C				
UNKNOWN								

Date:12/10/04ISR Number: 4523461-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04299
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
151 DAY								
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:12/10/04ISR Number: 4523465-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00740
Age:12 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:12/10/04ISR Number: 4523466-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00810
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Gastrooesophageal Reflux Disease		Amitriptyline Hydrochloride	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Lortab	C		ORAL		
			Volmax	C		ORAL		
			Proventil	C				
RESPIRATORY								
(INHALATION)								
			Zovirax	C		ORAL		
			Wellbutrin Sr	C		ORAL		
			Dermadex	C		ORAL		
			Zaroxolyn	C		ORAL		
			K-Dur	C		ORAL		
			Aldactone	C		ORAL		
			Cefzil	C		ORAL		
			Tussionex (Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex)	C		ORAL		
			Plavix	C		ORAL		
			Dipyridamole	C				
UNKNOWN								
			Austyn	C				
RESPIRATORY								

(INHALATION)			
	Nasalcrom	C	
RESPIRATORY			
(INHALATION)			
	Claritin	C	ORAL
	Claritin	C	ORAL
	Tricor	C	ORAL
	Zocor	C	ORAL
	Imdur	C	ORAL
	Folic Acid	C	ORAL
	Toprol Xl Tablets	C	ORAL
	Trental	C	ORAL
	Procardia Xl	C	ORAL
	Prilosec	C	ORAL
	Aspirin	C	
UNKNOWN			
	Avelox	C	ORAL
	Erythromycin	C	ORAL
	Erythromycin	C	ORAL
	Humibid Dm	C	ORAL
	Levaquin	C	ORAL
	Levaquin	C	ORAL
	Flonase	C	
RESPIRATORY			
(INHALATION)			
	Diflucan	C	ORAL
	Skelaxin	C	ORAL
	Guaifenesin	C	ORAL
	Nexium	C	ORAL
	Zantac	C	ORAL
	Protonix	C	
UNKNOWN			
	Prozac	C	
UNKNOWN			
	Aciphex	C	ORAL
	Prevacid	C	
OPHTHALMIC			
	Celebrex	C	ORAL
	Colchicine	C	ORAL
	Prandin	C	
TOPICAL			
	Zetia	C	ORAL

Date:12/10/04ISR Number: 4523469-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03842
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523470-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01401
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Asthenia
	Back Pain
	Diarrhoea
	Dyspepsia
	Dyspnoea
	Malignant Melanoma
	Nausea
	Oedema Peripheral
	Pneumonia
	Respiratory Tract

	Infection Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Fosamax	C		ORAL	UNKNOWN
			Amitriptyline Hydrochloride	C			UNKNOWN
			Vitamin E	C			UNKNOWN
			Ascorbic Acid	C			

Date:12/10/04ISR Number: 4523472-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/10/04ISR Number: 4523475-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00143
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Gastritis Intervertebral Disc Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/10/04ISR Number: 4523476-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00011
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged			Paroxetine Hydrochloride	C		ORAL	

Date:12/10/04ISR Number: 4523478-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00246
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Paxil	C				
UNKNOWN								
Initial or Prolonged			Coumadin	C				
UNKNOWN								
Disability								

Date:12/10/04ISR Number: 4523480-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00451
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Tricor	C				
UNKNOWN								
Initial or Prolonged			Metoprolol	C				
UNKNOWN								
Disability			Aspirin	C				
UNKNOWN								
			Klor-Con	C				
UNKNOWN								
			Pravacol	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523481-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00511
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

Date:12/10/04ISR Number: 4523482-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00472
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:12/10/04ISR Number: 4523484-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive		Metformin	C				
UNKNOWN								
	Disease		Prinivil	C		ORAL		
	Chest Pain		Lovastatin	C				
UNKNOWN								
	Dyspnoea		Prinivil	C				
UNKNOWN								
	Headache							

Date:12/10/04ISR Number: 4523485-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00441
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Heart Valve Insufficiency		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			[Therapy					

Unspecified] C
UNKNOWN

Date:12/10/04ISR Number: 4523486-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00239
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bone Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Hydrocodone Bitartrate	C				
	Headache							
	Oedema Peripheral		Oxycontin	C				
			Diazepam	C				
			Cyclobenzaprine Hydrochloride	C				

Date:12/10/04ISR Number: 4523488-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Life-Threatening								
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523489-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00036
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
			Digoxin	C		ORAL		
			Spironolactone	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL	74	DAY
			Warfarin	C		ORAL		
			Hypromellose	C		OPHTHALMIC		
			Fosamax	C		ORAL		
			Loratadine	C		ORAL	18	DAY
			Acetaminophen And Codeine Phosphate	C		ORAL	88	DAY
			Furosemide	C		ORAL		
			Albuterol Sulfate And Ipratropium Bromide	C		RESPIRATORY (INHALATION)	74	DAY
			Albuterol Sulfate And Ipratropium Bromide	C		RESPIRATORY (INHALATION)	74	DAY
			Allopurinol	C		ORAL	46	DAY

Date:12/10/04ISR Number: 4523490-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523492-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523493-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:12/10/04ISR Number: 4523495-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523496-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Valve Insufficiency Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523497-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00469
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523498-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombophlebitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523500-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:12/10/04ISR Number: 4523501-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event

Amnesia
Angina Pectoris
Anxiety
Back Pain
Blister
Blood Cholesterol
Increased
Blood Pressure Increased
Cardiac Murmur
Contusion
Convulsion
Coronary Artery Disease
Eye Disorder
Headache
Heart Rate Increased
Hypercholesterolaemia
Hypoaesthesia
Joint Swelling
Kidney Infection
Myocardial Infarction
Nausea
Nephrolithiasis
Pain In Extremity
Pain In Jaw

	Palpitations						
	Phlebitis						
	Pyrexia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	698 DAY
	Rectal Haemorrhage		Lortab	C			UNKNOWN
	Renal Disorder		Prednisone	C			UNKNOWN
	Stress		Prednisone	C			UNKNOWN
	Tachycardia		Nitropaste	C			UNKNOWN
	Upper Respiratory Tract		Sodium Folate	C			UNKNOWN
	Infection		Ultram	C			UNKNOWN
	Urinary Tract Infection		Toprol Xl Tablets	C			UNKNOWN
	Weight Decreased		Triamcinolone	C			UNKNOWN
			Skelaxin	C			UNKNOWN
			Methotrexate	C			UNKNOWN
			Elavil	C			UNKNOWN
			Folic Acid	C			UNKNOWN

Date:12/10/04ISR Number: 4523508-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	

Date:12/10/04ISR Number: 4523509-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Enzymes Increased Myocardial Infarction Physical Disability							

Date:12/10/04ISR Number: 4523570-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00073
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/10/04ISR Number: 4523572-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00795
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nicotine	SS				

UNKNOWN

Date:12/10/04ISR Number: 4523632-9Report Type:Direct Company Report #CTU 234051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS			12.5 MG/2 X	
Initial or Prolonged								

DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/10/04ISR Number: 4523639-1Report Type:Direct Company Report #CTU 234053
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS			25 MG 1 X DAY	
Initial or Prolonged								

Date:12/10/04ISR Number: 4523656-1Report Type:Direct Company Report #CTU 234058
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25 Mg	PS			2 PER DAY	
Initial or Prolonged								

Date:12/10/04ISR Number: 4523658-5Report Type:Direct Company Report #CTU 234059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS			25 MG /1X DAY	
Initial or Prolonged								

Date:12/10/04ISR Number: 4523662-7Report Type:Direct Company Report #CTU 234060
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS			25 MG	30 DAY
Hospitalization -								
Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:12/10/04ISR Number: 4523757-8Report Type:Direct Company Report #CTU 234043
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Ineffective		Rofecoxib 50 Mg	PS		
25 MG DAILY						
Initial or Prolonged	Duodenal Ulcer		Aspirin Ec 325 Mg	SS		
325 MG DAILY						
	Gastrointestinal Haemorrhage					

Date:12/10/04ISR Number: 4525059-2Report Type:Expedited (15-DaCompany Report #2004076262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Consumer	Neurontin			
Initial or Prolonged	Drug Ineffective		(Gabapentin)	PS		
	Insomnia		Hydromorphone			
	Loss Of Consciousness		Hydrochloride			
	Malaise		(Hydromorphone			
	Pain		Hydrochloride)	SS		
	Pain In Extremity		Morphine (Morphine)	SS		
	Retching		Methocarbamol			
	Vomiting		(Methocarbamol)	SS		
			Rofecoxib			
			(Refecoxib)	SS		

Date:12/10/04ISR Number: 4525535-2Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Cholesterol Increased Blood Triglycerides Increased Dyspepsia Electrocardiogram Abnormal Electrocardiogram St Segment Depression Haematocrit Decreased Haemoglobin Decreased Low Density Lipoprotein Increased Memory Impairment Myocardial Ischaemia Total Cholesterol/Hdl Ratio Increased	Foreign Study Health Professional Other	Tab Vioxx (Rofecoxib) Omeprazole	PS C		ORAL	25 MG/DAILY PO	35 DAY

Date:12/10/04ISR Number: 4526285-9Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00233
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction	Foreign Study Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	

Date:12/10/04ISR Number: 4526543-8Report Type:Expedited (15-DaCompany Report #WAES 0411USA50121
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Bundle Branch Block	Study	Tab Vioxx 25 Mg	PS		ORAL 25 MG/DAILY/PO
	Coronary Artery Occlusion	Health Professional	Atorvastatin Calcium	C		
			Levothyroxine Sodium	C		
			Tamsulosin Hydrochloride	C		
			Testosterone	C		

Date:12/10/04ISR Number: 4526545-1Report Type:Expedited (15-DaCompany Report #WAES 0410USA50161
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Laboratory Test	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Interference	Health Professional	Albuterol	SS				
			Ascorbic Acid	C				
			Calcium	C				
			Chondroitin Sulfate Sodium	C				
			Clarithromycin	C				
			Flunisolide	C				
			Glucosamine Hydrochloride	C				

Guaifenesin (+) Phenylephrine Hy	C
Hydrochlorothiazide (+) Triamter	C
Hyoscyamine	C
Ipratropium Bromide	C
Lisinopril	C
Lovastatin	C
Prednisone	C
Quinine Sulfate	C
Sertraline Hydrochloride	C
Sildenafil Citrate	C
Vitamin E	C
Vitamins	C

Date:12/10/04ISR Number: 4527669-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral Headache Retinal Tear Retinal Vascular Thrombosis Skin Ulcer Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524656-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event Blood Cholesterol Abnormal Bursitis Candidiasis Cardiac Failure Congestive Cardiovascular Disorder Chest Wall Pain Condition Aggravated

Confusional State
Costochondritis
Cystocele
Decreased Activity
Drug Hypersensitivity
Faecal Incontinence
Fatigue
Feeling Cold
Fibula Fracture
Head Injury
Headache
Hot Flush
Hypertension
Incontinence
Intestinal Functional
Disorder
Kidney Infection

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Laryngitis					
		Libido Decreased					
		Mood Swings					
		Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema		Effexor	SS		
UNKNOWN							
		Osteoarthritis		Effexor	SS		
UNKNOWN							
		Ovarian Cyst		Osteo-Bi-Flex	C		
UNKNOWN							
		Pelvic Pain		Estrace	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Vitamins			
		Renal Disorder		(Unspecified)	C		
UNKNOWN							
		Renal Failure		Flagyl	C		
UNKNOWN							
		Rheumatic Fever		Cipro	C		
UNKNOWN							
		Rheumatoid Arthritis		Lotensin	C		
UNKNOWN							
		Rhinitis Allergic		Zyrtec	C		
UNKNOWN							
		Sinus Disorder		Detrol	C		
UNKNOWN							
		Sleep Disorder					
		Stress					
		Tendonitis					
		Urethritis					
		Urinary Tract Infection					
		Vaginal Candidiasis					
		Vaginal Infection					
		Vaginal Odour					
		Vaginitis Bacterial					
		Varicose Vein					
		Vein Disorder					
		Vertigo					
		Viral Upper Respiratory					
		Tract Infection					
		Visual Disturbance					
		Vulvovaginal Discomfort					
		Weight Increased					

Date:12/11/04ISR Number: 4524662-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02050
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Life-Threatening	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Gastric Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lung Neoplasm Malignant		Vioxx	SS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Lortab	C				UNKNOWN
	Decreased		Duragesic	C				UNKNOWN
			Celebrex	C				UNKNOWN
			Depakote	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Advil	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Elavil	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Flexeril	C				UNKNOWN
			Verapamil Hydrochloride	C				UNKNOWN
			Xanax	C				UNKNOWN
			Oxycodone	C				UNKNOWN
			Calcium					

	(Unspecified)	C
UNKNOWN		
	Vitamins (Unspecified)	C
UNKNOWN		
	Zantac	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		

Date:12/11/04ISR Number: 4524664-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Anxiety
	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Bone Pain
	Bronchitis
	Burning Sensation
	Cerebrovascular Accident
	Conversion Disorder
	Coordination Abnormal
	Depression
	Dizziness
	Dry Skin
	Emotional Distress
	Fall
	Fatigue
	Ganglion
	Generalised Anxiety Disorder
	Haemorrhoids
	Hallucination
	Hemiparesis
	Hiatus Hernia
	Hypertension
	Hypoaesthesia
	Hypokalaemia
	Hyporeflexia
	Inflammation

Injury
Insomnia
Lacunar Infarction
Liver Function Test
Abnormal
Loss Of Consciousness
Menopausal Symptoms
Migraine With Aura
Movement Disorder
Oesophageal Spasm
Orthostatic Hypotension
Pain In Extremity
Palpitations
Panniculitis
Post Procedural
Complication
Psychosomatic Disease
Stress
Suicidal Ideation
Syncope

Tinnitus
Torticollis
Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventolin (Albuterol)	C			RESPIRATORY	
					(INHALATION)	
	Synthroid	C			UNKNOWN	
	Celexa	C			UNKNOWN	
	Lexapro	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Niacin	C			UNKNOWN	14671DAY
	Aspirin	C			UNKNOWN	
	Aerobid	C			UNKNOWN	

Date:12/11/04ISR Number: 4524665-9Report Type:Expedited (15-DaCompany Report #US-MERCK-00010882
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nerve Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL	8 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	8 DAY	
			Premarin	C			UNKNOWN	

Date:12/11/04ISR Number: 4524669-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00614
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia

Initial or Prolonged	Anaemia Vitamin B12
Other	Deficiency
	Angina Pectoris
	Arthritis
	Asthenia
	Blood Potassium Decreased
	Bronchitis Acute
	Carotid Bruit
	Cerebrovascular Accident
	Claustrophobia
	Conjunctivitis
	Convulsion
	Coronary Artery Stenosis
	Dental Caries
	Diarrhoea
	Dizziness
	Dry Eye
	Dyspnoea Exertional
	Foot Fracture
	Gastrointestinal
	Haemorrhage
	Goitre
	Headache
	Hydrocephalus
	Hyperkeratosis
	Hypoaesthesia
	Intermittent Claudication
	Lobar Pneumonia
	Mammogram Abnormal
	Mucosal Ulceration

		Myocardial Infarction					
		Normal Pressure Hydrocephalus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Orthopnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Peptic Ulcer		Prevacid	C		ORAL
		Peripheral Vascular		Premarin	C		ORAL
		Disorder		Trental	C		ORAL
		Rash Macular		Prednisone	C		ORAL
		Skin Lesion		Aquaphor Ointment	C		
TOPICAL							
		Urinary Tract Infection					
		Ventricular Dysfunction					
		Vision Blurred					
		Vulvovaginitis					
		Trichomonal					

Date:12/11/04ISR Number: 4524670-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00857
Age:35 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Unstable		Zyrtec	C		ORAL
Disability		Anxiety		Skelaxin	C		ORAL
Other		Arthralgia		Tazac	C		ORAL
		Blood Pressure Increased					
		Chest Discomfort					
		Erythema					
		Fall					
		Foot Fracture					
		Headache					
		Hypertension					
		Impaired Healing					
		Pain					
		Pleurisy					
		Polytraumatism					
		Procedural Site Reaction					
		Tachycardia					
		Urinary Tract Infection					
		Viral Infection					

Date:12/11/04ISR Number: 4524671-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Diaphragmatic Eventration
Disability	Adverse Event
Other	Angina Pectoris
	Atrial Fibrillation
	Back Pain
	Blood Pressure Increased
	Cardiac Arrest
	Chest Discomfort
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diaphragmatic Disorder
	Disease Recurrence
	Feeling Abnormal

		Intervertebral Disc Degeneration					
		Intervertebral Disc Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
536	DAY						
		Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
536	DAY						
		Musculoskeletal		Vioxx	SS	Merck & Co., Inc	ORAL
		Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
214	DAY						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Radicular Pain		Vioxx	SS	Merck & Co., Inc	ORAL
214	DAY						
		Road Traffic Accident		Buspar	C		ORAL
405	DAY						
		Sudden Death		Lortab	C		ORAL
573	DAY						
				Lortab	C		ORAL
				Ziac	C		ORAL
322	DAY						
				Vicodin Tablets	C		ORAL
				Lipitor	C		ORAL
				Valium	C		ORAL
214	DAY						
				Talwin	C		ORAL
24	DAY						
				Ultram	C		ORAL
9	DAY						
				Skelaxin	C		ORAL
14	DAY						
				Tenyl	C		
UNKNOWN		36 DAY					
				Claritin	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							

Date:12/11/04ISR Number: 4524672-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged	Acute Respiratory Failure
Other	Adverse Event
	Amnesia
	Angina Pectoris
	Arthropod Bite
	Asthma
	Blood Pressure Increased
	Bronchitis
	Cardiomegaly
	Chronic Obstructive
	Pulmonary Disease
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Dysarthria
	Dysphagia
	Dysphonia
	Dysuria
	Encephalopathy
	Fall
	Foot Fracture
	Fractured Coccyx
	Gastrooesophageal Reflux
	Disease
	Haematuria
	Head Injury
	Hypertension
	Hypertensive Crisis
	Hypokalaemia

		Hyponatraemia					
		Hypotension					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Sprain		Vioxx	PS	Merck & Co., Inc	ORAL
		Malaise		Vioxx	SS	Merck & Co., Inc	ORAL
		Mental Impairment					
		Mental Status Changes					
		Mouth Cyst					
		Muscle Twitching					
		Myalgia					
		Myoclonus					
		Nausea					
		Neck Pain					
		Osteoarthritis					
		Pain In Extremity					
		Respiratory Distress					
		Road Traffic Accident					
		Seborrhoeic Keratosis					
		Skeletal Injury					
		Skin Papilloma					
		Sleep Walking					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Urticaria					

Date:12/11/04ISR Number: 4524673-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Anorexia
	Arthralgia
	Arthritis
	Arthropathy
	Back Pain
	Benign Prostatic
	Hyperplasia
	Bladder Disorder
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiac Arrest

Cardiovascular Disorder
Carotid Bruit
Carpal Tunnel Syndrome
Chest Pain
Constipation
Convulsion
Depression
Dry Mouth
Epididymal Cyst
Erectile Dysfunction
Fatigue
Flatulence
Hyperhidrosis
Intervertebral Disc
Degeneration
Intestinal Functional

	Disorder						
	Oedema Peripheral						
	Osteitis						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	
	Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL	
	Scoliosis		Neurontin	C			UNKNOWN
	Skin Lesion		Lactulose	C		ORAL	
	Spinal Column Stenosis		Glucophage	C			UNKNOWN
	Stress		Glyburide	C			UNKNOWN
	Testicular Pain		Lotrel	C			UNKNOWN

Date:12/11/04ISR Number: 4524674-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Anaemia						
Disability	Angioneurotic Oedema						
Other	Bronchitis						
	Chest Pain						
	Constipation						
	Deep Vein Thrombosis						
	Depression						
	Diabetes Mellitus						
	Non-Insulin-Dependent						
	Diverticulum						
	Dysphagia						
	Dyspnoea						
	Fatigue						
	Gastric Disorder						
	Gastric Outlet						
	Obstruction						
	Hypertension						
	Neuropathy Peripheral						
	Non-Cardiac Chest Pain						
	Oedema Peripheral						
	Oesophageal Obstruction						
	Osteoarthritis						
	Pain In Extremity						

Peptic Ulcer
Polytraumatism
Regurgitation Of Food
Restrictive Pulmonary
Disease
Stress Incontinence
Tendonitis
Treatment Noncompliance
Ventricular Dysfunction
Ventricular Wall
Thickening
Weight Decreased

Date:12/11/04ISR Number: 4524675-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00788
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Anxiety
	Aortic Atherosclerosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Arthralgia					
		Blood Pressure Inadequately Controlled					
		Breast Cancer In Situ		Vioxx	PS	Merck & Co., Inc	ORAL
		Calcinosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Chondromalacia		Corgard	C		
UNKNOWN							
		Constipation		Maxzide	C		
UNKNOWN							
		Diarrhoea		Maxzide	C		
UNKNOWN							
		Exostosis		Prevacid	C		
UNKNOWN							
		Fall		Prevacid	C		
UNKNOWN							
		Fatigue		Zoloft	C		
UNKNOWN							
		Food Poisoning		Celebrex	C		
UNKNOWN							
		Gastrointestinal Tract		Librax Capsules	C		
UNKNOWN							
		Adenoma		Pravachol	C		
UNKNOWN							
		Headache		Flexeril	C		
UNKNOWN							
		Hypersensitivity		Darvocet-N	C		
UNKNOWN							
		Hypertension		Antineoplastic			
		Hypoaesthesia		(Unspecified)	C		
UNKNOWN							
		Hypotension		Tylenol With Codeine			
		Intestinal Polyp		#3	C		
UNKNOWN							
		Irritable Bowel Syndrome					
		Joint Effusion					
		Joint Injury					
		Loose Body In Joint					
		Medication Error					
		Meniscus Lesion					
		Mucosal Inflammation					
		Nervousness					
		Nystagmus					
		Osteoarthritis					
		Pain					
		Peripheral Coldness					
		Rectal Haemorrhage					

Skin Discolouration
Sleep Disorder
Somnolence
Tension
Vaginal Discharge
Vertigo Positional
Vomiting

Date:12/11/04ISR Number: 4524676-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00813
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Anaemia
	Asthenia
	Bronchitis
	Constipation
	Costochondritis
	Dizziness
	Faecal Occult Blood Positive
	Gastritis
	Gastroenteritis Viral
	High Density Lipoprotein Decreased
	Hypertension

		Hypokalaemia					
		Hypomagnesaemia					
		Menorrhagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Polytraumatism					
		Sinusitis					
		Uterine Leiomyoma					

Date:12/11/04ISR Number: 4524677-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00802
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arteritis		Bumex	C		
UNKNOWN							
Disability		Carpal Tunnel Syndrome		Duracef	C		
UNKNOWN							
		Lung Disorder					
		Neuralgia					
		Radicular Pain					

Date:12/11/04ISR Number: 4524678-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00816
Age:33 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Asthenia
	Back Pain
	Blood Pressure
	Inadequately Controlled
	Blood Thyroid Stimulating
	Hormone Decreased
	Bronchitis
	Bronchitis Acute
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Cough
	Depression

Dizziness
Dyspnoea
Electrocardiogram Poor
R-Wave Progression
Essential Hypertension
Folliculitis
Headache
Hypersensitivity
Hypertension
Hypotension
Increased Upper Airway
Secretion
Infarction
Injury
Insomnia
Joint Swelling
Lower Respiratory Tract
Infection
Monarthritis
Muscle Spasms

		Nasal Congestion					
		Nasopharyngitis					
		Neuroleptic Malignant	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Polyarthritis					
		Proteinuria					
		Pruritus Generalised					
		Rheumatoid Arthritis					
		Sinusitis					
		Spondylitis					
		Stress					
		Swelling Face					
		Systemic Lupus					
		Erythematosus					
		Tearfulness					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Vasculitis					
		Viral Infection					
		Vomiting					
		White Blood Cell Count					
		Decreased					

Date:12/11/04ISR Number: 4524679-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Disability	Anxiety
	Blood Cholesterol
	Increased
	Bradycardia
	Bronchitis
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Chronic Obstructive
	Pulmonary Disease

Coronary Artery Disease
Coronary Artery Occlusion
Dermatitis
Diverticulum Intestinal
Gastritis
Gastrointestinal
Haemorrhage
Haematuria
Haemorrhoids
Hyperlipidaemia
Hypertension
Myocardial Infarction
Pain
Pain In Extremity
Palpitations
Proctitis

		Rash Pruritic Sinusitis Stress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY						
		Upper Gastrointestinal		Tylenol	C		
UNKNOWN							
		Haemorrhage		Motrin	C		
UNKNOWN							
		Upper Respiratory Tract		Ultram	C		
UNKNOWN							
		Infection		Nasonex	C		
UNKNOWN							
		Urinary Tract Infection		Elocon	C		
UNKNOWN							
		Weight Decreased		Hydroxyzine Pamoate	C		
UNKNOWN							
				Tranxene	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Loperamide Hydrochloride	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Proventil	C		
UNKNOWN							
				Duratuss	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Epi-Pen	C		
UNKNOWN							
				Diphenhydramine Citrate	C		
UNKNOWN							

Date:12/11/04ISR Number: 4524680-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		257 DAY
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Disability	Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		257 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Depression		Tenormin	C				UNKNOWN
	Dizziness		Zoloft	C				UNKNOWN
	Emotional Distress		Estrogens (Unspecified)	C				UNKNOWN
	Fatigue							
	Headache		Zanaflex	C				UNKNOWN
	Hypercholesterolaemia		Restoril	C				UNKNOWN
	Hypertension							
	Insomnia							
	Libido Decreased							
	Menopausal Symptoms							
	Osteoarthritis							
	Rheumatoid Arthritis							
	Sleep Disorder							
	Tachycardia							
	Vulvovaginal Dryness							

Date:12/11/04ISR Number: 4524681-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Back Pain
Initial or Prolonged	Balance Disorder
Other	Benign Prostatic Hyperplasia
	Blood Triglycerides

	Increased Cerebrovascular Accident Gait Disturbance Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lumbar Radiculopathy Nausea Neck Pain		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN
	Oedema Peripheral Skin Papilloma		Tylenol With Codeine #3	C			UNKNOWN
	Sleep Apnoea Syndrome Spinal Cord Disorder Tachycardia Vomiting						

Date:12/11/04ISR Number: 4524682-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Anaemia Anal Fistula Aneurysm Ruptured Angina Pectoris Anxiety Appendicitis Perforated Arthralgia Atelectasis Cerebral Artery Stenosis Cerebrovascular Accident Colitis Ulcerative Convulsion Coronary Artery Disease Defaecation Urgency Depression Dermatitis Drug Ineffective Faecal Incontinence Fall Flatulence Headache Hypertension						

Impaired Healing
Inflammatory Bowel
Disease
Intestinal Perforation
Intestinal Spasm
Intracranial Aneurysm
Joint Injury
Pain
Perianal Abscess
Perirectal Abscess
Pneumoperitoneum
Proctalgia
Proctitis Ulcerative
Pruritus Ani
Sepsis
Subarachnoid Haemorrhage

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/04ISR Number: 4524683-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abdominal Pain		Cozaar	C		ORAL
Other	Adverse Event		Cardizem	C		
UNKNOWN						
	Anaemia		Premarin	C		ORAL
	Angina Pectoris		Darvocet-N	C		
UNKNOWN						
	Asthenia		Ecotrin	C		ORAL
	Carotid Arterial Embolus		Ecotrin	C		ORAL
	Carotid Artery Stenosis					
	Carotid Bruit					
	Convulsion					
	Coronary Artery Disease					
	Diverticulum Intestinal					
	Dizziness					
	Dysphagia					
	Dyspnoea					
	Gastric Ulcer					
	Gastrointestinal					
	Haemorrhage					
	Headache					
	Hiatus Hernia					
	Hypertension					
	Hypoaesthesia					
	Hypochromic Anaemia					
	Neck Mass					
	Pelvic Peritoneal					
	Adhesions					
	Peripheral Vascular					
	Disorder					
	Pharyngolaryngeal Pain					
	Subcutaneous Haematoma					
	Transient Ischaemic					
	Attack					
	Vertebral Artery Stenosis					

Date:12/11/04ISR Number: 4524684-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome	PT

Hospitalization - Initial or Prolonged Disability	Acute Sinusitis Anaemia Blood Glucose Abnormal Cardiac Failure Congestive Cerebrovascular Accident Cholelithiasis Colon Cancer Colon Neoplasm Decubitus Ulcer Depression Diverticulitis Electrolyte Imbalance Emotional Distress Fall Femur Fracture Gastritis Erosive Insomnia Obesity

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Osteoarthritis Pneumatosis Cystoides Intestinalis					
		Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonitis		Lasix (Furosemide)	C		
UNKNOWN	1218 DAY						
		Rash		Tagamet	C		
UNKNOWN							
		Reflux Oesophagitis		Estropipate	C		
UNKNOWN	3956 DAY						
				Potassium (Unspecified)	C		
UNKNOWN							
				Drixoral	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Tiazac	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Magnesium (Unspecified)	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							

Date:12/11/04ISR Number: 4524685-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00885
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions Abdominal Distension

Disability	Abdominal Hernia
	Abdominal Pain
	Abdominal Pain Lower
	Abdominal Pain Upper
	Adverse Event
	Angina Unstable
	Aspartate
	Aminotransferase
	Increased
	Blood Creatine
	Phosphokinase Mb
	Increased
	Blood Glucose Increased
	Blood Pressure Systolic
	Increased
	Blood Urea Increased
	Bradycardia
	Cardiomegaly
	Chest Pain
	Dehydration
	Diverticulum
	Diverticulum Intestinal
	Dizziness
	Drug Ineffective
	Duodenitis
	Exostosis
	Gastritis
	Gastrooesophageal Reflux
	Disease
	Hepatic Steatosis
	Hiatus Hernia

		Hypokalaemia					
		Incisional Hernia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasopharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophagitis		Diazide	C		
UNKNOWN							
		Pain In Extremity		Atenolol	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Skelaxin	C		
UNKNOWN							
		Sinus Bradycardia					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Snoring					
		Somnolence					
		Tendonitis					
		Vomiting					
		Weight Increased					

Date:12/11/04ISR Number: 4524686-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00882
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Blood Cholesterol		Monopril	C		
UNKNOWN							
		Increased		Zocor	C		
UNKNOWN							
		Bursitis		Prozac	C		
UNKNOWN							
		Cardiac Valve Disease		Ultram	C		
UNKNOWN							
		Cataract		Motrin	C		
UNKNOWN							
		Chondromalacia		Ativan	C		
UNKNOWN							
		Conjunctival Haemorrhage		Analgesic Or			
		Diverticulitis		Anesthetic			
		Ear Congestion		(Unspecified)	C		
UNKNOWN							
		Fall		Muro 128 Ophthalmic			

	Joint Effusion	Ointment	C
OPHTHALMIC			
	Keratitis	Artificial Tears	C
OPHTHALMIC			
	Lumbar Radiculopathy	Lipitor	C
UNKNOWN			
	Lymphadenopathy	Estradiol	C
UNKNOWN			
	Meniscus Lesion		
	Osteoarthritis		
	Osteopetrosis		
	Road Traffic Accident		
	Spinal Column Stenosis		
	Syncope		

Date:12/11/04ISR Number: 4524687-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01953
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Cyst
	Abscess Neck
	Acute Myocardial Infarction
	Akinesia
	Arthralgia
	Atelectasis
	Chest Pain
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion

		Dermal Cyst					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemoglobin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Simplex		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia					
		Hypertension					
		Inflammation					
		Intervertebral Disc Degeneration					
		Muscle Injury					
		Neck Pain					
		Necrosis					
		Osteoarthritis					
		Pain In Extremity					
		Palpitations					
		Periarthritis					
		Prothrombin Time Prolonged					
		Rotator Cuff Syndrome					
		Scan Myocardial Perfusion Abnormal					
		Scar					
		Seborrhoeic Keratosis					
		Telangiectasia					
		Tenosynovitis					
		Ventricular Dyskinesia					
		Ventricular Extrasystoles					
		Ventricular Hypokinesia					
		Ventricular Tachycardia					
		Visual Disturbance					

Date:12/11/04ISR Number: 4524688-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Anxiety
	Arthralgia
	Back Pain
	Benign Prostatic Hyperplasia
	Cholecystitis

Cholelithiasis
Chronic Sinusitis
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Cyst
Depression
Gout
Hodgkin'S Disease
Inguinal Hernia
Myalgia
Myopathy
Prostatic Specific
Antigen Increased
Rectal Examination

	Abnormal						
	Renal Failure						
	Renal Failure Acute						
	Renal Tubular Necrosis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tension Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Claritin-D	C			UNKNOWN	
			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
			Flonase	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Plendil	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	

Date:12/11/04ISR Number: 4524689-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00049
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Cerebrovascular Disorder		Plavix	C			UNKNOWN	
	Confusional State		Detrol La	C			UNKNOWN	
	Fall		Vagifem	C			UNKNOWN	
	Gait Disturbance		Librium	C			UNKNOWN	
	Headache		Elavil	C		ORAL		

	Pain		Glucosamine	C			
UNKNOWN							
	Retinal Artery Occlusion						
	Transient Ischaemic						
	Attack						
	Vertigo						

Date:12/11/04ISR Number: 4524690-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01026
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Panic Attack		Zoloft	C				
UNKNOWN								
			Hydrocodone Hydrochloride	C				
UNKNOWN								

Date:12/11/04ISR Number: 4524691-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03003
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematochezia							
	Polyp							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/04ISR Number: 4524692-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00266
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Allopurinol	C			UNKNOWN	
			Silibinin	C			UNKNOWN	
			Cynara	C			UNKNOWN	

Date:12/11/04ISR Number: 4524693-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03589
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anorexia		Depoestradiol	C			INTRAMUSCULAR	
Other	Asthenia		Ambien	C			UNKNOWN	
	Blood Pressure Increased		Verapamil Msd Lp	C			UNKNOWN	
	Cardiac Failure		Detrol	C			UNKNOWN	
	Congestive		Prozac	C			UNKNOWN	
	Cardiovascular Disorder		Hydrochlorothiazide	C			UNKNOWN	
	Carotid Artery Atheroma		Zocor	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Agyrax (Meclizine Hydrochloride)	C			UNKNOWN	
	Confusional State		Paxil	C			UNKNOWN	
	Contusion		Potassium Chloride	C		ORAL		
	Cough		Calcium Carbonate	C			UNKNOWN	
	Decubitus Ulcer		Ascorbic Acid	C			UNKNOWN	

	Dementia	Terazosin	
	Depression	Hydrochloride	C
UNKNOWN			
	Disorientation	Trazodone	
	Diverticulitis	Hydrochloride	C
UNKNOWN			
	Dizziness	Pneumovax	
	Fall	(Pneumococcal 14v	
	Gastroenteritis	Polysaccharide	
	Hand Fracture	Vaccine)	C
UNKNOWN			
	Memory Impairment		
	Nausea		
	Oedema Peripheral		
	Open Wound		
	Osteoporosis		
	Pharyngolaryngeal Pain		
	Pyrexia		
	Rhinorrhoea		
	Sinus Congestion		
	Skin Disorder		
	Sleep Disorder		
	Stomach Discomfort		
	Urinary Tract Infection		
	Vomiting		

Date:12/11/04ISR Number: 4524694-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03966
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Disability	Blood Pressure Increased
Other	Connective Tissue
	Disorder
	Eye Swelling

	Generalised Oedema						
	Orbital Oedema						
	Oropharyngeal Swelling	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Swelling Face		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vasculitis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C			UNKNOWN	
			Macrobid	C			UNKNOWN	
			Maxzide	C		ORAL		
			Prednisone	C			UNKNOWN	
			Medrol	C			UNKNOWN	

Date:12/11/04ISR Number: 4524695-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00240
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Acetaminophen And Codeine Phosphate	C			UNKNOWN	
	Micturition Disorder		Cortisone	C			PARENTERAL	

Date:12/11/04ISR Number: 4524696-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00486
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoimmune Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure		Budesonide	C			UNKNOWN	
	Immeasurable		Albuterol Sulfate	C			UNKNOWN	
	Temporal Arteritis		Salmeterol Xinafoate	C			UNKNOWN	
			[Therapy					

			Unspecified]	C		
OPHTHALMIC						

Date:12/11/04ISR Number: 4524697-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04251
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524698-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02966
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		8 DAY
	Arthroscopy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		8 DAY
	Facial Palsy		Synthroid	C				UNKNOWN
	Peripheral Nerve		Prevacid	C				UNKNOWN
	Transposition		Thyroid	C		ORAL		
	Post Procedural		Altocor	C				UNKNOWN
	Complication		Zetia	C				UNKNOWN
	Wrist Fracture		Allegra	C				UNKNOWN
			Nasonex	C				
RESPIRATORY								
(INHALATION)								

			Lasix (Furosemide Sodium)	C		
UNKNOWN						
			Klonopin	C		
UNKNOWN						
			Paxil Cr	C		
UNKNOWN						

Date:12/11/04ISR Number: 4524699-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00080
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Insufficiency		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Zocor	C				
UNKNOWN								
	Hypersensitivity		Hydrocodone					
	Hypertension		Bitartrate	C				
UNKNOWN								
	Mental Impairment		Hydrocodone					
	Transient Ischaemic		Bitartrate	C				
UNKNOWN								
	Attack							

Date:12/11/04ISR Number: 4524700-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00242
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged	Renal Disorder							
Disability								

Date:12/11/04ISR Number: 4524701-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00260
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Hospitalization -			Lasix (Furosemide)	C		
UNKNOWN						
Initial or Prolonged			Atenolol	C		
UNKNOWN						
Disability			Plavix	C		
UNKNOWN						
			Altace	C		
UNKNOWN						
			Potassium Chloride	C		
UNKNOWN						

Date:12/11/04ISR Number: 4524702-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02530
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:12/11/04ISR Number: 4524703-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02319
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebral Disorder					
	Syncope					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/04ISR Number: 4524704-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01045
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia							

Date:12/11/04ISR Number: 4524705-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Peripheral Embolism							
	Pulmonary Embolism							

Date:12/11/04ISR Number: 4524706-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/11/04ISR Number: 4524707-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00010
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Aspirin	C				
UNKNOWN								
			Ramipril	C				
UNKNOWN								
			Metoprolol Tartrate	C				
UNKNOWN								

Date:12/11/04ISR Number: 4524708-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524709-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00447
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Dizziness		Detrol La	C			UNKNOWN	
Initial or Prolonged	Dyspnoea		Aspirin	C			UNKNOWN	
	Palpitations		Prozac	C			UNKNOWN	
			Zonegran	C			UNKNOWN	
			Limbitrol Tablets	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Benadryl	C			UNKNOWN	
			Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
			Lomotil	C			UNKNOWN	

			Oxycontin	C			
UNKNOWN							
			Midrin	C			
UNKNOWN							

Date:12/11/04ISR Number: 4524710-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00631
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Other	Back Pain		Advil	C				
UNKNOWN								
	Blood Cholesterol		A.S.A.	C				
UNKNOWN								
	Increased		A.S.A.	C		ORAL		
	Blood Triglycerides		A.S.A.	C				
UNKNOWN								
	Increased		A.S.A.	C				
UNKNOWN								
	Breast Discomfort		Ulcerin (Cimetidine)	C		ORAL		
	Carpal Tunnel Syndrome		Ulcerin (Cimetidine)	C		ORAL		
	Cerebrovascular Accident		Zestril	C				
UNKNOWN								
	Chest Pain		Plavix	C				
UNKNOWN								
	Chronic Obstructive Pulmonary Disease		Agyrax (Meclizine Hydrochloride)	C				
UNKNOWN								
	Costochondritis Cough		Agyrax (Meclizine Hydrochloride)	C				
UNKNOWN								
	Dry Mouth		Elavil	C				
UNKNOWN								
	Fatigue Feeling Abnormal		Trazodone Hydrochloride	C				
UNKNOWN								
	Gastrooesophageal Reflux		Protonix	C				
UNKNOWN								
	Disease		Protonix	C				
UNKNOWN								
	Headache		Protonix	C				
UNKNOWN								

	Hemiparesis		Zocor	C
UNKNOWN				
	Hypertension		Zocor	C
UNKNOWN				
	Hypoaesthesia Oral		Carafate	C
UNKNOWN				
	Hypotension		Lipitor	C
UNKNOWN				
	Increased Upper Airway		Hydrochlorothiazide	C
UNKNOWN				
	Secretion		Hydrochlorothiazide	C
UNKNOWN				
	Insomnia		Ecotrin	C
UNKNOWN				
	Monoplegia		Ecotrin	C
UNKNOWN				
	Musculoskeletal Chest		Nexium	C
UNKNOWN				
	Pain		Nexium	C
UNKNOWN				
	Pain		Aminophylline	C
UNKNOWN				
	Painful Respiration			
	Pleurisy			
	Transient Ischaemic			
	Attack			
	Upper Respiratory Tract			
	Infection			

Date:12/11/04ISR Number: 4524711-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00722
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Difficulty In Walking		[Composition			
	Pain In Extremity		Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/04ISR Number: 4524712-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00523
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524713-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00558
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY	
Hospitalization - Initial or Prolonged	Loss Of Consciousness							
Disability	Muscle Spasms							
	Neck Pain							

Date:12/11/04ISR Number: 4524714-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00650
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Ejection Fraction Decreased							
	Injury							
	Myocardial Infarction							

Date:12/11/04ISR Number: 4524715-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04267
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis		Trazodone Hydrochloride	C				
Disability	Cerebrovascular Accident							
UNKNOWN								
	Constipation							

Drug Intolerance
Fibromyalgia
Gastritis
Hypoaesthesia
Intracranial Aneurysm
Paraesthesia
Rotator Cuff Syndrome
Sleep Disorder
Vomiting

Date:12/11/04ISR Number: 4524716-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03250
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Deep Vein Thrombosis		Plendil	C		ORAL		
Initial or Prolonged	Heart Rate Increased		Coumadin	C				
UNKNOWN								
Disability			Humulin 70/30	C				
UNKNOWN								
			Catapres	C				
UNKNOWN								
			Reglan	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								
			Cortisone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/04ISR Number: 4524717-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00630
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Angina Pectoris		Vioxx	PS	Merck & Co., Inc			2 MON
Initial or Prolonged UNKNOWN	Atelectasis		Diclofenac Sodium	C				
	Atherosclerosis		Cyclobenzaprine Hydrochloride	C				
	Back Pain		Premarin	C				
	Blood Cholesterol Increased		Zocor	C				
	Blood Pressure Decreased		Sudafed	C				
	Cardiac Disorder		Guaifenesin	C				
	Chest Pain		Amoxicillin	C				
	Corneal Abrasion		Pravachol	C				
	Coronary Artery Disease		Lipitor	C				
	Electrocardiogram Abnormal							
	Hypertension							
	Myocardial Infarction							
	Pyrexia							

Date:12/11/04ISR Number: 4524718-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524719-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00504
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1369 YR

Date:12/11/04ISR Number: 4524720-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00508
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Angina Pectoris Cardiac Disorder Diabetes Mellitus Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524721-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00425
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Coronary Artery Restenosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/11/04ISR Number: 4524722-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00381
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL		

Unspecified] C
UNKNOWN

Date:12/11/04ISR Number: 4524723-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00410
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:12/11/04ISR Number: 4524724-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00730
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Stomach Discomfort							
Initial or Prolonged	Vertigo							

Date:12/11/04ISR Number: 4524725-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00432
Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Syncope		[Therapy					
	Tachycardia		Unspecified]	C				
UNKNOWN								
	Vomiting							

Date:12/13/04ISR Number: 4525048-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01091
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		419 DAY
Hospitalization -	Anal Fissure		Benadryl	C				UNKNOWN
Initial or Prolonged	Anal Skin Tags		Anacin	C				UNKNOWN
Disability	Anxiety		Zantac	C				UNKNOWN
	Anxiety Disorder		Protonix	C				UNKNOWN
	Blood Pressure Increased		Surfak	C				UNKNOWN
	Cardiovascular Disorder							
	Chest Pain							
	Constipation							
	Depression							
	Diverticulitis							
	Dysarthria							
	Dyspnoea							
	Fibrocystic Breast Disease							
	Haemorrhoids							
	Hypertension							
	Ischaemic Cerebral Infarction							
	Ischaemic Stroke							
	Rectal Ulcer							
	Renal Failure							

Date:12/13/04ISR Number: 4525055-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01113
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiovascular Disorder		Coumadin	SS				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Plavix	SS				
UNKNOWN								
Other	Chest Pain		Vitamins					
	Dizziness		(Unspecified)	C				
UNKNOWN								
	Dyspnoea		Aspirin	C				
UNKNOWN								
	Dyspnoea Exertional							
	Headache							
	Hyperlipidaemia							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Renal Failure							
	Tooth Disorder							
	Transient Ischaemic							
	Attack							
	Ventricular Extrasystoles							

Date:12/13/04ISR Number: 4525061-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01984
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization -	Atherosclerosis
Initial or Prolonged	Benign Prostatic
Other	Hyperplasia
	Bundle Branch Block Left
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cellulitis
	Chronic Obstructive
	Pulmonary Disease
	Clavicle Fracture
	Confusion Postoperative
	Constipation
	Cor Pulmonale

Dilatation Atrial
Dilatation Ventricular
Duodenal Ulcer
Haemorrhage
Duodenitis
Fatigue
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Hypothyroidism
Limb Immobilisation
Melaena
Myocardial Infarction
Neuropathy Peripheral
Oesophagitis
Onychomycosis
Osteoarthritis
Pericardial Effusion
Pleural Effusion
Polytraumatism
Rash

		Restless Legs Syndrome					
		Restrictive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rib Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Vitreous Floaters		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Zestril	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Vicodin Es Tablets	C		
UNKNOWN							
				Coumadin	C		ORAL
				[Therapy Unspecified]	C		
UNKNOWN							

Date:12/13/04ISR Number: 4525063-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01793
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
Disability	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Basal Cell Carcinoma		Aspirin	C		
UNKNOWN						
	Bronchitis		Lipitor	C		
UNKNOWN						
	Bursitis		Premarin	C		
UNKNOWN						
	Chest Pain		Calcium (Unspecified)	C		
	Cough					
UNKNOWN						
	Diarrhoea		Vitamins (Unspecified)	C		
	Disease Recurrence					
UNKNOWN						
	Drug Ineffective		[Therapy Unspecified]	C		
	Dyspepsia					
UNKNOWN						

	Ecchymosis	Acyclovir	C
UNKNOWN			
	Hypertension		
	Hypokalaemia		
	Injury		
	Intervertebral Disc		
	Degeneration		
	Intervertebral Disc		
	Protrusion		
	Migraine		
	Non-Cardiac Chest Pain		
	Pneumonia		
	Radiculitis Cervical		
	Rectocele		
	Respiratory Tract		
	Infection		
	Rotator Cuff Syndrome		
	Tooth Disorder		
	Viral Upper Respiratory		
	Tract Infection		

Date:12/13/04ISR Number: 4525076-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00846
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
	Anhedonia
	Aortic Valve Incompetence

		Arthralgia					
		Asthenia					
		Asthma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Ventricular		Ventolin (Albuterol)	C		
RESPIRATORY							
		Dyspnoea					
(INHALATION)							
		Fatigue		Nifedipine Er	C		ORAL
		Feeling Hot		Avalide	C		ORAL
		Feeling Jittery		Aspirin	C		ORAL
		Gastroenteritis		Claritin	C		ORAL
		Headache		Flovent	C		
UNKNOWN							
		Insomnia		Advair	C		ORAL
		Libido Decreased		Nasonex	C		
RESPIRATORY							
		Low Density Lipoprotein					
(INHALATION)							
		Increased		Niferex Forte	C		
OPHTHALMIC							
		Mitral Valve Incompetence		Phenergan Vc With			
		Ovarian Cyst		Codeine	C		ORAL
		Polytraumatism					
		Pulmonary Arterial					
		Pressure Increased					
		Respiratory Distress					
		Sleep Apnoea Syndrome					
		Swelling Face					
		Trichomoniasis					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:12/13/04ISR Number: 4525095-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02079
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Other	Amnesia
	Arthritis
	Benign Prostatic
	Hyperplasia
	Bone Lesion
	Bradycardia
	Cardiovascular Disorder
	Carotid Artery Stenosis
	Chronic Obstructive
	Pulmonary Disease
	Contusion
	Coronary Artery Disease
	Decreased Activity
	Decreased Appetite
	Depression
	Drug Hypersensitivity
	Excoriation
	Fall
	Gastric Ulcer
	Gastric Varices
	Glucose Tolerance

		Impaired					
		Hyperlipidaemia					
		Hypertension					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
		Protrusion					
		Lumbar Spinal Stenosis					
		Musculoskeletal Disorder					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nerve Root Compression					
		Nightmare					
		Osteoarthritis					
		Peripheral Vascular					
		Disorder					
		Pneumonia					
		Renal Failure					
		Rib Fracture					
		Rotator Cuff Syndrome					
		Shoulder Deformity					
		Spinal Decompression					
		Spinal Osteoarthritis					
		Tendonitis					
		Weight Decreased					

Date:12/13/04ISR Number: 4525104-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00791
Age:45 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Methotrexate	C		
UNKNOWN							
Disability		Adverse Event		Celebrex	C		
UNKNOWN							
		Angina Unstable		Deltasone	C		
UNKNOWN							
		Atelectasis		Folic Acid	C		
UNKNOWN							
		Chronic Obstructive		Procanbid	C		
UNKNOWN		2 WK					
		Pulmonary Disease		Tylenol	C		
UNKNOWN							
		Coronary Artery Disease		Aspirin	C		
UNKNOWN							

	Coronary Artery Occlusion	Aspirin	C	
UNKNOWN				
	Depression	Zantac	C	
UNKNOWN				
	Hyperlipidaemia	Proventil	C	
RESPIRATORY				
	Hypertension			
(INHALATION)				
	Hypertensive Heart	Vasotec	C	ORAL
	Disease	Lasix (Furosemide)	C	
INTRAVENOUS				
	Myocardial Infarction			
	Polytraumatism			

Date:12/13/04ISR Number: 4525107-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Adverse Event
Disability	Aortic Atherosclerosis
	Atrial Flutter
	Benign Prostatic Hyperplasia
	Bladder Diverticulum
	Bladder Trabeculation
	Blood Pressure Increased
	Cardiac Failure

	Congestive Cardiomyopathy						
	Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypercapnia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Ischaemic Cardiomyopathy		Coumadin	C			UNKNOWN
	Mitral Valve Incompetence		Coumadin	C			UNKNOWN
	Polytraumatism						
	Tricuspid Valve Incompetence						
	Urinary Retention						

Date:12/13/04ISR Number: 4525108-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00655
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
	Amnesia		Amaryl	C		ORAL	
Other	Angina Pectoris		Lipitor	C			UNKNOWN
	Angle Closure Glaucoma		Toprol Xl Tablets	C		ORAL	
	Anxiety		Tylenol Sinus	C			UNKNOWN
	Arthropathy		Flexeril	C		ORAL	
	Back Pain		Diazepam	C		ORAL	
	Blood Pressure Increased		Prevacid	C		ORAL	
	Cartilage Hypertrophy						
	Cerebrovascular Accident						
	Chest Pain						
	Convulsion						
	Coronary Artery Disease						
	Coronary Artery Stenosis						
	Depression						
	Dizziness						
	Faeces Discoloured						
	Gait Disturbance						
	Gastric Ulcer Haemorrhage						
	Headache						
	Hypercholesterolaemia						
	Hyperhidrosis						
	Hypertension						
	Intervertebral Disc						

Disorder
Joint Sprain
Memory Impairment
Myocardial Infarction
Nausea
Posture Abnormal

Date:12/13/04ISR Number: 4525110-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00841
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Alveolitis Fibrosing
Other	Anxiety
	Arthralgia
	Arthropathy
	Asthenia
	Bronchitis
	Bursitis
	Cardiac Failure

		Congestive					
		Carotid Artery Disease					
		Carpal Tunnel Syndrome					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Vioxx	C		ORAL
		Cognitive Disorder					
		Collagen-Vascular Disease					
		Depression					
		Dermatomyositis					
		Diarrhoea					
		Diverticulum					
		Dizziness					
		Drug Eruption					
		Dry Eye					
		Dry Mouth					
		Dysphasia					
		Dyspnoea					
		Fatigue					
		Fibromyalgia					
		Gastritis					
		Gastrointestinal Motility					
		Disorder					
		Gastrooesophageal Reflux					
		Disease					
		Haemoptysis					
		Haemorrhoids					
		Hypersensitivity					
		Hypertension					
		Insomnia					
		Interstitial Lung Disease					
		Irritable Bowel Syndrome					
		Malaise					
		Memory Impairment					
		Muscle Spasms					
		Musculoskeletal Stiffness					
		Neuropathy Peripheral					
		Obsessive-Compulsive					
		Disorder					
		Obstructive Airways					
		Disorder					
		Oesophageal Candidiasis					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Polymyositis					
		Polytraumatism					

Pulmonary Fibrosis
Pulmonary Oedema
Rash
Rash Macular
Rash Pruritic
Rheumatoid Arthritis
Tendon Injury
Vision Blurred
Visual Field Defect
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525130-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00710
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Procardia Xl	C				
UNKNOWN								
Disability	Cerebral Atrophy		Prinivil	C				
UNKNOWN								
Other	Cerebrovascular Accident		Diazide	C				
UNKNOWN								
	Conjunctivitis Allergic		Synthroid	C				
UNKNOWN								
	Contusion		Ecotrin	C				
UNKNOWN								
	Convulsion		Hydrea	C				
UNKNOWN								
	Dehydration		Osteo-Bi-Flex	C				
UNKNOWN								
	Depression		Compazine	C				
UNKNOWN								
	Dermatophytosis							
	Disorientation							
	Fall							
	Fatigue							
	Gastrooesophageal Reflux							
	Disease							
	Haematoma							
	Hypokalaemia							
	Injury							
	Insomnia							
	Mental Status Changes							
	Nausea							
	Neurogenic Bladder							
	Oedema Peripheral							
	Pneumonia							
	Pyelonephritis							
	Sepsis							
	Urinary Retention							
	Urinary Tract Infection							

Date:12/13/04ISR Number: 4525138-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03948
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:12/13/04ISR Number: 4525140-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Angina Pectoris
	Blister Infected
	Blood Pressure Increased
	Breast Cancer In Situ
	Breast Pain
	Bronchitis
	Bursitis
	Cataract
	Chest Pain
	Colonic Polyp
	Congenital Eye Naevus

		Contusion					
		Endolymphatic Hydrops					
		Exostosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemangioma		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Spironolactone	C		
UNKNOWN							
		Hypertensive		Captopril Msd	C		ORAL
		Encephalopathy		Toprol Xl Tablets	C		ORAL
		Limb Discomfort					
		Loss Of Consciousness					
		Nausea					
		Osteoarthritis					
		Osteoporosis					
		Pain In Extremity					
		Palatal Disorder					
		Palpitations					
		Plantar Fasciitis					
		Polytraumatism					
		Pulmonary Fibrosis					
		Rash					
		Rhinitis					
		Seasonal Allergy					
		Seroma					
		Tendonitis					
		Transient Ischaemic					
		Attack					
		Vertebrobasilar					
		Insufficiency					
		Vitreous Detachment					

Date:12/13/04ISR Number: 4525150-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris					
		Atrial Fibrillation					
		Atrioventricular Block					
		Body Tinea					
		Cardiovascular Disorder					
		Carotid Artery Stenosis					
		Coronary Artery Occlusion					

Dermatitis
Eczema
Epidermal Necrosis
Erythema Multiforme
Granuloma Annulare
Hypercholesterolaemia
Hypertension
Leukocytoclastic
Vasculitis
Myocardial Ischaemia
Nail Bed Bleeding
Onycholysis
Psoriasis
Renal Failure Chronic
Vasculitis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525160-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Anaemia Haemolytic		Vioxx	SS	Merck & Co., Inc	ORAL		8 MON
Disability	Autoimmune		Os-Cal + D	C				UNKNOWN
Other	Arthralgia		Slow-Mag	C				UNKNOWN
	Atelectasis		Potassium Chloride	C				UNKNOWN
	Azotaemia		Rocaltrol	C		ORAL		
	Blood Cholesterol		Synthroid	C				UNKNOWN
	Increased		Synthroid	C		ORAL		
	Blood Creatine		Prilosec	C				UNKNOWN
	Phosphokinase Increased		Reglan	C				UNKNOWN
	Cellulitis		Reglan	C				UNKNOWN
	Cerebrovascular Accident		Ambien	C				UNKNOWN
	Cholelithiasis		Ditropan Xl	C				UNKNOWN
	Coagulopathy		Amitriptyline					
	Cystocele		Hydrochloride	C				UNKNOWN
	Decreased Appetite		Claritin	C				UNKNOWN
	Disturbance In Attention		Claritin-D	C				UNKNOWN
	Drug Hypersensitivity		Lasix (Furosemide)	C				UNKNOWN
	Dysphagia		Slow-K	C				UNKNOWN
	Dyspnoea		Premarin	C				UNKNOWN
	Eye Pain		Quinine	C				UNKNOWN
	Fall		Flonase	C				UNKNOWN

	Gastritis Erosive	Tessalon Perles	C
UNKNOWN			
	Haematochezia	Percocet	C
UNKNOWN			
	Haemorrhage		
	Hypercalcaemia		
	Hyperglycaemia		
	Hypocalcaemia		
	Hypomagnesaemia		
	Injury		
	Insomnia		
	Irritable Bowel Syndrome		
	Neurogenic Bladder		
	Oesophageal Disorder		
	Pulmonary Granuloma		
	Pyrexia		
	Rectocele		
	Renal Failure		
	Renal Failure Acute		
	Sinusitis		
	Tinnitus		
	Tooth Disorder		
	Toothache		
	Tracheobronchitis		
	Transient Ischaemic		
	Attack		
	Upper Respiratory Tract		
	Infection		
	Viral Infection		
	Visual Disturbance		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525174-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00790
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Soma	C		ORAL		
	Bronchitis Acute		Levbid	C				
UNKNOWN								
	Condition Aggravated		Dilantin	C				
UNKNOWN								
	Conversion Disorder		Paxil Cr	C				
UNKNOWN								
	Convulsion		Elavil	C				
UNKNOWN								
	Diarrhoea		Claritin	C				
UNKNOWN								
	Drug Effect Decreased		Phenergan					
	Drug Ineffective		(Promethazine					
	Ear Pain		Hydrochloride)	C				
UNKNOWN								
	Exostosis		Protonix	C				
UNKNOWN								
	Fall		Carafate	C				
UNKNOWN								
	Feeling Abnormal		Aciphex	C				
UNKNOWN								
	Fistula		Lomotil	C				
UNKNOWN								
	Fractured Coccyx		Questran	C				
UNKNOWN								
	Gastrooesophageal Reflux		Atenolol	C				
UNKNOWN								
	Disease		Lasix (Furosemide)	C				
UNKNOWN								
	Haemorrhoidal Haemorrhage		Potassium					
	Headache		(Unspecified)	C				
UNKNOWN								
	Hepatic Steatosis		Premarin	C				
UNKNOWN								
	Hepatitis C		Paxil	C				
UNKNOWN								
	Hiatus Hernia		Synthroid	C				
UNKNOWN								

	Injury	Darvocet-N	C
UNKNOWN			
	Insomnia	Melatonina	C
UNKNOWN			
	Intervertebral Disc Protrusion		
	Irritable Bowel Syndrome		
	Joint Injury		
	Lactose Intolerance		
	Lacunar Infarction		
	Liver Function Test Abnormal		
	Malaise		
	Meralgia Paraesthetica		
	Monarthritis		
	Nervousness		
	Osteoarthritis		
	Pyrexia		
	Tremor		
	Vision Blurred		
	Weight Decreased		

Date:12/13/04ISR Number: 4525181-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Bronchitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cardiac Failure Congestive Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Coronary Artery Disease		Toprol Xl Tablets	C		
UNKNOWN		Depression		Imdur	C		
UNKNOWN		Dyspepsia		Nitro-Dur	C		
UNKNOWN		Dyspnoea		Diovan	C		
UNKNOWN		Fatigue		Diovan	C		
UNKNOWN		Feeling Abnormal Gastrooesophageal Reflux Disease		Diltiazem Hydrochloride Plavix	C C		
UNKNOWN		Gouty Arthritis Influenza		Zocor Aspirin	C C		ORAL
UNKNOWN		Limb Injury		Xanax	C		
UNKNOWN		Malignant Hypertension		Folic Acid	C		
UNKNOWN		Myocardial Ischaemia		Allopurinol	C		
UNKNOWN		Nasal Discomfort Oedema Peripheral Palpitations		Lecithin And Protein (Unspecified) Levothroid	C C		
UNKNOWN		Polytraumatism		Levothroid	C		
UNKNOWN		Rhinitis Allergic		Levothroid	C		
UNKNOWN		Skin Lesion		Soma	C		
UNKNOWN		Sleep Apnoea Syndrome Stress Tinnitus Upper Respiratory Tract		Indocin (Indomethacin) Colchicine Norco	C C C		ORAL
UNKNOWN							

	Infection	Levothroid	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Vitamins (Unspecified)	C
UNKNOWN			
		K-Dur	C
UNKNOWN			
		Lasix (Furosemide)	C
UNKNOWN			
		Zetia	C
UNKNOWN			
		Cardizem La	C
UNKNOWN			
		Lopressor	C
UNKNOWN			
		Prevacid	C
UNKNOWN			
		Lipotriad	C
UNKNOWN			
		Lexapro	C
UNKNOWN			
		Levoxyl	C
UNKNOWN			

Date:12/13/04ISR Number: 4525184-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00805
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Arthropathy
Other	Asthma
	Blindness Unilateral
	Blood Creatinine Increased
	Blood Urea Increased
	Bronchospasm
	Bursitis
	Candidiasis
	Cardiac Failure
	Congestive

		Cough					
		Dizziness					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
		Face Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Head Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hot Flush		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Knee Arthroplasty		Vioxx	SS	Merck & Co., Inc	ORAL
		Microcytic Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Lotrel	C		ORAL
		Pain		Lotrel	C		ORAL
		Palpitations		Lotrel	C		ORAL
		Pneumonia		Lasix (Furosemide)	C		
UNKNOWN							
		Pneumonia Haemophilus		Nolvadex	C		
UNKNOWN							
		Polytraumatism		Benicar	C		ORAL
397 DAY							
		Postmenopausal		Lipitor	C		ORAL
		Haemorrhage		Lipitor	C		ORAL
		Rash Generalised		Toprol Xl Tablets	C		ORAL
		Renal Failure		Singulair	C		ORAL
		Renal Failure Chronic		Prevacid	C		
UNKNOWN							
		Rhinitis Allergic		Prilosec	C		ORAL
		Sinus Disorder		Proventil Inhaler	C		
UNKNOWN							
		Skin Lesion		Evista	C		ORAL
		Stomach Discomfort		Claritin	C		ORAL
		Tachycardia		Vasoretic	C		ORAL
		Tinea Infection		Norvasc	C		ORAL
		Uterine Leiomyoma		Zoloft	C		ORAL
		Uterine Polyp		Zocor	C		ORAL
		Wrist Fracture		Lescol	C		ORAL
				Coreg	C		ORAL

Date:12/13/04ISR Number: 4525192-5Report Type:Expedited (15-DaCompany Report #AT-MERCK-0411AUT00022
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
	Protrusion		Alendronate Sodium	C				UNKNOWN
	Myocardial Infarction							
	Procedural Complication							

Date:12/13/04ISR Number: 4525195-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03171
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON
Initial or Prolonged	Congestive							
	Chest Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525196-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00530
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Angina Pectoris Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525197-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00408
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Unstable Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		131 DAY

Date:12/13/04ISR Number: 4525199-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00385
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
	Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
			Lipitor	C				UNKNOWN
			Avandia	C				UNKNOWN
			Bextra	C				UNKNOWN

Date:12/13/04ISR Number: 4525201-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00306
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Excedrin P.M.	C		ORAL
Disability	Coronary Artery Stenosis		Ibuprofen	C		
UNKNOWN						
			Cortizone-5	C		
UNKNOWN						
			Darvon	C		
UNKNOWN						
			Prinzide	C		
UNKNOWN						
			Advil	C		
UNKNOWN						

Date:12/13/04ISR Number: 4525203-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03212
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Norvasc	C		
UNKNOWN						
Disability	Congestive					
	Chest Pain					
	Hypertension					
	Loss Of Consciousness					
	Mitral Valve Incompetence					
	Pericardial Effusion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525204-9Report Type:Expedited (15-DaCompany Report #PH-MERCK-0412PHL00003
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:12/13/04ISR Number: 4525206-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03209
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization -	Oedema Peripheral		Coumadin	C				UNKNOWN
Initial or Prolonged	Pain In Extremity		Coumadin	C				UNKNOWN
Disability	Thrombosis		Prempro	C				UNKNOWN
			Klonopin	C				UNKNOWN
			Methadone Hydrochloride	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Percocet	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:12/13/04ISR Number: 4525208-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive							
	Chest Pain							
	Hypertension							
	Loss Of Consciousness							
	Mitral Valve Incompetence							
	Pericardial Effusion							

Date:12/13/04ISR Number: 4525209-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03202
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Congestive		Neurontin	C				
Initial or Prolonged UNKNOWN			Furosemide	C				
Disability UNKNOWN			Celexa	C				

Date:12/13/04ISR Number: 4525211-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Intestinal Perforation							
	Paralysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525214-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/13/04ISR Number: 4525227-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00080
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Mastitis		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	3	WK
			Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	43	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	3	WK
			Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY

Date:12/13/04ISR Number: 4525229-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00017
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Esomeprazole Magnesium	C				UNKNOWN
	Diplopia		Aspirin	C				UNKNOWN
	Transient Ischaemic		Levothyroxine Sodium	C				UNKNOWN
	Attack		Hydroxychloroquine Sulfate	C				UNKNOWN

Date:12/13/04ISR Number: 4525230-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00455
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased Chest Pain Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525231-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00225
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis Cardiac Failure Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525232-3Report Type:Expedited (15-DaCompany Report #PL-MERCK-0412POL00002
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ischaemic Cerebral		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Initial or Prolonged Disability	Infarction		Vioxx	SS	Merck & Co., Inc		UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525233-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00489
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Heart Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							

Date:12/13/04ISR Number: 4525235-9Report Type:Expedited (15-DaCompany Report #PH-MERCK-0412PHL00004
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:12/13/04ISR Number: 4525239-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525246-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525249-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00720
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Temporal Arteritis		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged	Thrombosis Thyroid Disorder

Date:12/13/04ISR Number: 4525251-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00695
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Metformin	C				
Initial or Prolonged UNKNOWN	Palpitations		Avandia	C				
Disability			Sotalol Hydrochloride	C				
UNKNOWN			Prevacid	C				
UNKNOWN			Diovan	C				
UNKNOWN								

Date:12/13/04ISR Number: 4525252-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00694
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525261-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525262-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00635
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525263-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525265-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525266-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525267-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00545
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525276-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525351-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00078
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525352-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00012
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hemiplegia		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Thrombosis		Ketoprofen	C			UNKNOWN	

Date:12/13/04ISR Number: 4525823-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01061779
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Bradycardia							
	Cardiac Disorder							
	Chest Pain							
	Dyspnoea							
	Insomnia							
	Pain							
	Palpitations							
	Sinus Arrest							
	Stress							
	Syncope							

Date:12/13/04ISR Number: 4525840-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper

Other	Anorexia
	Anxiety Disorder
	Aortic Aneurysm
	Back Injury
	Bronchitis
	Cardiomegaly
	Chest Discomfort
	Chest Pain
	Chromaturia
	Condition Aggravated
	Contusion
	Coronary Artery Atherosclerosis
	Coronary Artery Restenosis
	Cough
	Decreased Appetite
	Dehydration
	Depressed Mood
	Diarrhoea
	Disturbance In Attention
	Diverticulum Intestinal
	Diverticulum Intestinal

		Haemorrhagic					
		Drug Ineffective					
		Dyspnoea					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL
		Gout		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Norvasc	C		
UNKNOWN							
		Insomnia		Monopril	C		
UNKNOWN							
		Iron Deficiency		Indocin			
		Iron Deficiency Anaemia		(Indomethacin)	C		
UNKNOWN							
		Libido Decreased		Naproxen	C		
UNKNOWN							
		Loss Of Libido		Ecotrin	C		
UNKNOWN							
		Lung Neoplasm		Lopressor	C		
UNKNOWN							
		Muscle Tightness		Toprol Xl Tablets	C		
UNKNOWN							
		Musculoskeletal Chest		Lipitor	C		
UNKNOWN							
		Pain		Allopurinol	C		
UNKNOWN							
		Myocardial Infarction		Prilosec	C		
UNKNOWN							
		Nausea		Lasix (Furosemide)	C		
UNKNOWN							
		Non-Cardiac Chest Pain		K-Dur	C		
UNKNOWN							
		Oedema Peripheral					
		Paraesthesia					
		Pneumonia					
		Prostatic Specific					
		Antigen Increased					
		Proteinuria					
		Rectal Haemorrhage					
		Renal Cyst					
		Rheumatoid Arthritis					
		Rhinitis Allergic					
		Stress					
		Tendon Injury					
		Tendon Rupture					
		Treatment Noncompliance					

Umbilical Hernia
Ventricular Extrasystoles
Ventricular Hypertrophy
Ventricular Hypokinesia

Date:12/13/04ISR Number: 4525846-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02109
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Cancer Pain
Disability	Cardiac Failure
Other	Congestive
	Cardio-Respiratory Arrest
	Chronic Obstructive
	Pulmonary Disease
	Colonic Polyp
	Depression
	Diabetes Mellitus
	Diverticulum
	Dyspnoea Exertional
	Facial Palsy
	Fall
	Flank Pain
	Fluid Retention
	Haemorrhoids

		Hemiparesis					
		Injury					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Zestril	C		
UNKNOWN							
		Non-Hodgkin'S Lymphoma		Lasix (Furosemide)	C		
UNKNOWN							
		Oedema Peripheral		Lithium Carbonate	C		
UNKNOWN							
		Oesophagitis Haemorrhagic		Pepcid	C		ORAL
		Pathological Fracture		Ibuprofen	C		
UNKNOWN							
		Pneumonia Aspiration		Neurontin	C		
UNKNOWN							
		Pulmonary Hypertension		Paxil	C		
UNKNOWN							
		Rectal Haemorrhage		Potassium			
		Rectal Polyp		(Unspecified)	C		
UNKNOWN							
		Sepsis		Atrovent	C		
UNKNOWN							
		Septic Shock		Allopurinol	C		
UNKNOWN							
		Sinusitis		Keflex	C		
UNKNOWN							
		Stomatitis		Zofran	C		
UNKNOWN							
		Ventricular Hypertrophy		Reglan	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

Date:12/13/04ISR Number: 4525847-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA01392
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged						

Date:12/13/04ISR Number: 4525848-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104488
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Creatine
Hospitalization -	Phosphokinase Increased
Initial or Prolonged	Blood Pressure Decreased
	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease
	Confusional State
	Cough
	Dehydration
	Diarrhoea
	Encephalopathy
	Hypoglycaemia
	Influenza
	Injury
	Lymphadenopathy
	Metabolic Acidosis
	Nausea
	Oedema Peripheral
	Renal Failure Acute
	Sepsis
	Toxic Induced
	Encephalopathy
	Troponin Increased
	Urine Output Decreased
	Visual Acuity Reduced
	Vomiting

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Lasix (Furosemide Sodium)	C			UNKNOWN	
	Herbs (Unspecified)	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Capoten	C			UNKNOWN	
	Diamox	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Acetaminophen	C			UNKNOWN	1 DAY
	[Therapy Unspecified]	C			UNKNOWN	
	Acetaminophen And Codeine	C			UNKNOWN	

Date:12/13/04ISR Number: 4525850-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Aortic Stenosis
	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coagulation Time
	Prolonged
	Colonic Polyp
	Coronary Artery Disease

Coronary Artery Occlusion
Cough
Dehydration
Diabetic Foot
Diabetic Retinopathy
Diverticulum
Dyspnoea
Emotional Distress
Epistaxis
Erectile Dysfunction
Gouty Arthritis
Hypothyroidism
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Mitral Valve Prolapse
Myasthenia Gravis
Myocardial Infarction
Neuropathic Pain
Oedema Peripheral
Open Angle Glaucoma
Overdose
Palpitations
Peptic Ulcer
Peripheral Occlusive
Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Pulmonary Hypertension Pulmonary Oedema Renal Failure					
		Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Sleep Apnoea Syndrome		Insulin	C		
UNKNOWN		Sleep Disorder		Coreg	C		
UNKNOWN		Syncope		Aspirin	C		
UNKNOWN		Vascular Graft Occlusion		Allopurinol	C		
UNKNOWN		Vascular Occlusion		Allopurinol	C		
UNKNOWN		Ventricular Extrasystoles		Furosemide	C		
UNKNOWN		Vitreous Haemorrhage		Glipizide	C		
UNKNOWN				Actos	C		
UNKNOWN				Neurontin	C		
UNKNOWN				Spironolactone	C		
UNKNOWN				Lotensin	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Glucophage	C		
UNKNOWN				Pepcid	C		
UNKNOWN				Nitroglycerin	C		
UNKNOWN				Cardizem	C		
UNKNOWN				Clopidogrel Bisulfate	C		
UNKNOWN				Coumadin	C		
UNKNOWN				Glycine	C		
UNKNOWN				Fluvastatin Sodium	C		
UNKNOWN				Trazodone			

Hydrochloride C
UNKNOWN

Celebrex C
UNKNOWN

Date:12/13/04ISR Number: 4525853-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Angina Pectoris
	Benign Prostatic Hyperplasia
	Blood Pressure Increased
	Bradycardia
	Bronchitis Acute
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Convulsion
	Coronary Artery Disease
	Depression
	Dermatitis Atopic
	Diverticulum
	Dyspnoea
	Fatigue
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Hiatus Hernia
	Inner Ear Disorder
	Intervertebral Disc Degeneration
	Lumbar Spinal Stenosis
	Lung Neoplasm

		Myocardial Infarction					
		Neuroma					
		Non-Hodgkin'S Lymphoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
586	DAY						
		Renal Abscess		Claritin	C		
UNKNOWN							
		Rhinitis Allergic		Aspirin	C		
UNKNOWN							
		Salivary Gland Cancer		Pravachol	C		
UNKNOWN							
		Vertigo		Calcium			
		Weight Decreased		(Unspecified)	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Naprosyn	C		ORAL
				Keflex	C		ORAL
				Allegra	C		ORAL
				Elocon	C		
UNKNOWN							
				Lopressor	C		ORAL
				Darvocet-N	C		ORAL
				Pravachol	C		
UNKNOWN							
				Lanoxin	C		ORAL
				Lortab	C		ORAL
				Clarinex	C		ORAL
				Zocor	C		ORAL
				Nexium	C		ORAL
				Paxil	C		ORAL
				Vitamin E	C		
UNKNOWN							

Date:12/13/04ISR Number: 4525857-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00758
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Adverse Event
Other	Angina Pectoris
	Anxiety

Arthralgia
Aspiration
Asthma
Back Disorder
Blood Pressure Increased
Bronchitis
Cholelithiasis
Convulsion
Diplopia
Dizziness
Drug Ineffective
Dysphonia
Dyspnoea
Erythema
Excoriation
Eye Swelling
Facial Pain
Fall
Headache
Myocardial Infarction
Neck Injury
Oedema Peripheral
Pneumonia
Sinusitis
Somnolence
Swelling Face

Tremor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Allegra	C			UNKNOWN	
	Toprol Xl Tablets	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Albuterol	C			UNKNOWN	
	Glucovance	C			UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Chlorazepate	C			UNKNOWN	
	Vanceril	C			UNKNOWN	
	Advair	C			UNKNOWN	
	Darvocet-N	C			UNKNOWN	
	Kenalog	C			INTRAMUSCULAR	
	Vicodin Tablets	C			UNKNOWN	
	Avelox	C			UNKNOWN	
	Nasonex	C			UNKNOWN	
	Wellbutrin Xl	C			UNKNOWN	
	Propacet	C			UNKNOWN	

			Avandia	C		
UNKNOWN						
			Univasc	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Tranxene	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Flovent	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Hydrochlorothiazide And Triamterene	C		
UNKNOWN						
			Claritin	C		
UNKNOWN						
			Glucotrol Xl	C		
UNKNOWN						
			Vasotec	C		
UNKNOWN						
			Evista	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						

Date:12/13/04ISR Number: 4525860-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		611 DAY
Initial or Prolonged	Infarction		Prilosec	C		ORAL		
	Angina Unstable		Tylenol	C				
UNKNOWN								
	Anxiety		Inderal	C				
UNKNOWN								
	Cardiac Failure		Lipitor	C		ORAL		

	Congestive	Lipitor	C	
UNKNOWN				
	Coronary Artery Disease	Zithromax	C	
UNKNOWN				
	Ischaemic Cardiomyopathy	Zantac	C	ORAL
	Mixed Hyperlipidaemia	Nitrostat	C	
SUBLINGUAL				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525861-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Back Pain		Aspirin	C				UNKNOWN
Other	Cardiomegaly		Lipitor	C				UNKNOWN
	Cerebrovascular Accident		Metformin	C				UNKNOWN
	Chest Discomfort		Prozac	C				UNKNOWN
	Cholelithiasis		Prilosec	C				UNKNOWN
	Coordination Abnormal		Glucophage	C				UNKNOWN
	Drug Hypersensitivity							
	Fall							
	Gastrooesophageal Reflux Disease							
	Hiatus Hernia							
	Hypertension							
	Intention Tremor							
	Intervertebral Disc Degeneration							
	Sinus Disorder							
	Spinal Column Stenosis							
	Spinal Compression Fracture							
	Transient Ischaemic Attack							
	Vertigo							

Date:12/13/04ISR Number: 4525865-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess
Initial or Prolonged	Abdominal Distension
	Abdominal Pain
	Blood Creatinine Increased

Blood Urea Increased
Body Temperature
Decreased
Bowel Sounds Abnormal
Breath Sounds Decreased
Cyst
Diarrhoea
Diverticulum Duodenal
Dyspepsia
Emotional Distress
Extravasation
Flatulence
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Hiatus Hernia
Hypercholesterolaemia
Hypertension
Ileal Ulcer
Ileitis
Ileus
Intervertebral Disc
Degeneration
Intestinal Hypomotility

		Lactose Intolerance					
		Large Intestinal Obstruction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Large Intestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Large Intestine		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Perforation		Vasotec	C		ORAL
		Livedo Reticularis		Vasotec	C		ORAL
		Lung Infiltration		Lipitor	C		
UNKNOWN							
		Malabsorption		Ecotrin	C		ORAL
		Metabolic Acidosis		Hydrochlorothiazide	C		
UNKNOWN							
		Miosis		Prevacid	C		
UNKNOWN							
		Multi-Organ Failure		Relafen	C		
UNKNOWN							
		Nausea		Ziac	C		
UNKNOWN							
		Necrotising Colitis		Zebeta	C		
UNKNOWN							
		Osteoarthritis					
		Peripheral Ischaemia					
		Pleural Effusion					
		Proctitis					
		Purulence					
		Pyrexia					
		Rectal Ulcer					
		Renal Cortical Necrosis					
		Renal Cyst					
		Renal Disorder					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Respiratory Failure					
		Septic Shock					
		Sinus Tachycardia					
		Small Intestine Ulcer					
		Spinal Osteoarthritis					
		Vasospasm					
		Vomiting					
		White Blood Cell Count Increased					
		Wound Infection					

Date:12/13/04ISR Number: 4525866-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Other	Alanine Aminotransferase Increased Anxiety Arrhythmia Aspartate Aminotransferase Increased Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased Blood Creatinine Increased Blood Lactate Dehydrogenase Increased Blood Urea Increased Chest Pain Depression

		Discomfort					
		Dyspnoea					
		Electrocardiogram T Wave	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Granulocyte Count		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Hypoaesthesia					
		Injury					
		International Normalised					
		Ratio Increased					
		Mitral Valve Disease					
		Mitral Valve Incompetence					
		Monocyte Count Increased					
		Neck Pain					
		Pain In Extremity					
		Palpitations					
		Pulmonary Embolism					
		Stress					
		Tachycardia					
		Tricuspid Valve					
		Incompetence					
		Trismus					
		White Blood Cell Count					
		Increased					

Date:12/13/04ISR Number: 4525867-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00607
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease					
		Dizziness					
		Hyperhidrosis					
		Hypertension					
		Musculoskeletal Chest					
		Pain					
		Myocardial Infarction					
		Pallor					
		Supraventricular					

Tachycardia
Visual Disturbance

Date:12/13/04ISR Number: 4525869-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00052
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Candesartan Cilexetil	C			UNKNOWN	
			Benzbromarone	C			UNKNOWN	
			Molsidomine	C			UNKNOWN	
			Budesonide	C			UNKNOWN	
			Acetyldigoxin	C			UNKNOWN	
			Terbutaline Sulfate	C			UNKNOWN	
			Lercanidipine	C			UNKNOWN	
			Salmeterol Xinafoate	C			UNKNOWN	
			Xipamide	C			UNKNOWN	

	Ipratropium Bromide	C
UNKNOWN		
	Atorvastatin Calcium	C
UNKNOWN		
	Clopidogrel Bisulfate	C
UNKNOWN		
	Insulin Human	C
UNKNOWN		
	Metformin Hydrochloride	C
UNKNOWN		

Date:12/13/04ISR Number: 4525870-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00103
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525871-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00308
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Abnormal							
	Blood Pressure Fluctuation							
	Cardiac Disorder							
	Cardiac Failure							
	Cardiovascular Disorder							
	Chest Discomfort							
	Dyspnoea							
	Extrasystoles							
	Fluid Retention							
	Gastric Haemorrhage							
	Gastric Ulcer							
	Gastritis							

Date:12/13/04ISR Number: 4525877-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03726
Age:23 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		Vicodin Tablets	C		ORAL		
			Ambien	C		ORAL		

Date:12/13/04ISR Number: 4525879-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Hospitalization - Initial or Prolonged			[Composition Unspecified]	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525880-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04030
Age:67 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Intentional Misuse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Multiple Drug Overdose		Acetaminophen	SS		ORAL		
			Amlodipine Besylate And Benazepril Hydrochloride	SS		ORAL		
			Acetaminophen	SS		ORAL		

Date:12/13/04ISR Number: 4525881-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04079
Age:50 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide		Vioxx	PS	Merck & Co., Inc	ORAL		
	Multiple Drug Overdose		Metformin	SS		ORAL		
			Metformin	SS		ORAL		
			Metformin	SS		ORAL		
			Amlodipine Besylate And Benazepril Hydrochloride	SS		ORAL		
			Amlodipine Besylate And Benazepril Hydrochloride	SS		ORAL		
			Amlodipine Besylate And Benazepril Hydrochloride	SS		ORAL		

Date:12/13/04ISR Number: 4525882-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02618
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Bronchitis		Benicar	C				
Initial or Prolonged Disability UNKNOWN	Cardiac Valve Disease		Clarinex	C		ORAL		
	Chest Pain		Parafon Forte	C				

	Dyspepsia		Klonopin	C		
UNKNOWN						
	Dyspnoea		Elavil	C		
UNKNOWN						
	Heart Rate Irregular		Darvocet-N	C		
UNKNOWN						
	Myocardial Infarction		Singulair	C		
UNKNOWN						
	Nephrolithiasis		Atrovent	C		
UNKNOWN						
			Tequin	C		
UNKNOWN						

Date:12/13/04ISR Number: 4525883-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03968
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	355 DAY	
	Infarction		Sulfasalazine	C				
UNKNOWN								
	Cardiac Arrest		Lotensin	C				
UNKNOWN								

Date:12/13/04ISR Number: 4525907-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00230
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525908-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00031
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Depression Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525913-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02773
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON

Date:12/13/04ISR Number: 4525914-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00037
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension		Vioxx [Composition Unspecified] [Composition Unspecified]	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

Date:12/13/04ISR Number: 4525916-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00191
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly Fatigue Oedema Peripheral		Vioxx Lozol Zestril	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

				Amaryl	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:12/13/04ISR Number: 4525917-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03820
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drooling		[Therapy					
Initial or Prolonged	Hypoaesthesia		Unspecified]	C				
UNKNOWN								
Disability	Transient Ischaemic							
	Attack							

Date:12/13/04ISR Number: 4525919-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00858
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
							121	DAY
Hospitalization -	Chest Discomfort		Zocor	C		ORAL		
Initial or Prolonged	Chest Pain		Prevacid	C				
UNKNOWN								
Disability	Depression		Ambien	C				
UNKNOWN								
			Oxycontin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525920-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00086
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Diovan	C				
Other	Hypoaesthesia		Furosemide	C				
			Digitek	C				
			Fosamax	C				
			Casodex	C				
			Pravachol	C				
			Cardizem	C				
			Coumadin	C				

Date:12/13/04ISR Number: 4525922-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01968
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bladder Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive		Vitamins (Unspecified)	C				
	Renal Failure		Potassium Chloride	C				

Date:12/13/04ISR Number: 4525925-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00047
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Nervousness							

Date:12/13/04ISR Number: 4525927-1Report Type:Expedited (15-DaCompany Report #DK-MERCK-0412DNK00006
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia Erectile Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525928-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00017
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:12/13/04ISR Number: 4525930-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03824
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Glucophage	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/13/04ISR Number: 4525932-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00901
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		993 DAY
Disability			Lovenox	C				UNKNOWN
			Coumadin	C				UNKNOWN

Date:12/13/04ISR Number: 4525933-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00891
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525934-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00780
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/13/04ISR Number: 4525935-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00029
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Atherosclerosis		Zocor	SS		ORAL		
			Candesartan Cilexetil	SS		ORAL		
			Etanercept	SS			SUBCUTANEOUS	432 DAY
			Estradiol	SS			TOPICAL	
			Methotrexate	SS		ORAL		

Fosamax	C			ORAL
Dydrogesterone	C			ORAL
Calcium Carbonate And Cholecalciferol	C			ORAL

Date:12/13/04ISR Number: 4525936-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01088
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Discomfort							

Date:12/13/04ISR Number: 4525937-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00949
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Impaired Work Ability		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/13/04ISR Number: 4525939-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00723
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Injury		Lipitor	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Prevacid	C				
UNKNOWN								
Disability			Lisinopril	C				
UNKNOWN								
			Xanax	C				
UNKNOWN								

Date:12/13/04ISR Number: 4525940-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00713
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability							
	Thrombosis							
	Unevaluable Event							

Date:12/13/04ISR Number: 4525951-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Date:12/13/04ISR Number: 4526047-2Report Type:Direct Company Report #CTU 234161
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	Vamc Okc				

	Hemiparesis		Merck	PS	Merck		
50MG PER DAY							
	Impaired Work Ability						

Date:12/13/04ISR Number: 4526059-9Report Type:Direct Company Report #CTU 234170
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx 25mg	PS		ORAL	25MG DAILY	
	Hypersensitivity					ORAL		
	Impaired Driving Ability							
	Tinnitus							
	Vertigo							

Date:12/13/04ISR Number: 4526835-2Report Type:Expedited (15-DaCompany Report #2004105304
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity	Foreign	Celebrex (Celecoxib)	PS		ORAL	1 DF EVERY	
Initial or Prolonged	Injury	Health					DAY (1 IN 1	
	Leukocytoclastic	Professional					D), ORAL	
	Vasculitis		Vioxx (Rofecoxib)	SS		ORAL	1 DF EVERY	
	Skin Ulcer						DAY (1 IN 1	
	Vascular Purpura						D), ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526467-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03378
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
	Anxiety		Vitamins			
	Basal Cell Carcinoma		(Unspecified)	C		
UNKNOWN						
	Carpal Tunnel Syndrome		Plavix	C		ORAL
	Dizziness		Aspirin	C		ORAL
	Eyelid Oedema					
	Fatigue					
	Feeling Hot					
	Haemorrhage					
	Hypertension					
	Hypoaesthesia					
	Joint Swelling					
	Pain In Extremity					
	Skin Lesion					
	Speech Disorder					
	Squamous Cell Carcinoma					
	Stress					
	Syncope					
	Thrombosis					
	Transient Ischaemic					
	Attack					
	Tremor					

Date:12/14/04ISR Number: 4526471-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00939
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Rectal Prolapse		Lipitor	C		
UNKNOWN						
Disability			Synthroid	C		
UNKNOWN						
Other			Calcium			
			(Unspecified)	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						

Elavil	C	ORAL
Detrol	C	

UNKNOWN

Date:12/14/04ISR Number: 4526472-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Angina Pectoris
	Arthralgia
	Blood Pressure Increased
	Bursitis
	Cardiac Disorder
	Cardiac Operation
	Cerebrovascular Accident
	Convulsion
	Cyst
	Fall
	Headache
	Muscle Atrophy
	Musculoskeletal
	Discomfort

	Osteoarthritis						
	Sinus Operation						
	Thrombotic Stroke	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4526474-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02090
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cellulitis		Lopressor	C				
UNKNOWN								
	Cerebral Artery Occlusion		Lasix (Furosemide)	C				
UNKNOWN								
	Death		Digoxin	C				
UNKNOWN								
	Dehydration		Aspirin	C				
UNKNOWN								
	Depression		Coumadin	C				
UNKNOWN								
	Diarrhoea		Diltiazem					
	Erosive Duodenitis		Hydrochloride	C				
UNKNOWN								
	Fall		Potassium					
	Fatigue		(Unspecified)	C				
UNKNOWN								
	Grand Mal Convulsion		Hydrochlorothiazide					
	Haematoma		And Triamterene	C				
UNKNOWN								
	Hypernatraemia							
	Injury							
	International Normalised							
	Ratio Increased							
	Lower Gastrointestinal							
	Haemorrhage							
	Muscle Necrosis							
	Peptic Ulcer Haemorrhage							
	Pneumonia							

Skin Laceration
Skin Necrosis
Urinary Tract Infection
Weight Decreased
Wound Dehiscence

Date:12/14/04ISR Number: 4526475-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00605
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
504 DAY								
Initial or Prolonged	Stent Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
504 DAY								
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metoprolol Succinate	C		ORAL		
			Magnesium (Unspecified)	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526480-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00033
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blindness Unilateral							
Initial or Prolonged	Cerebrovascular Accident							
Disability	Dizziness							
	Headache							

Date:12/14/04ISR Number: 4526481-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01745
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Zyrtec	C			UNKNOWN	
	Depression		Lotrel	C			UNKNOWN	
	General Physical Health		Lipitor	C			UNKNOWN	
	Deterioration		Furosemide	C			UNKNOWN	
	Hernia		Potassium					
	Myocardial Infarction		(Unspecified)	C			UNKNOWN	
	Oedema Peripheral		Aspirin	C			UNKNOWN	
	Sinus Disorder		Clarinex	C			UNKNOWN	
			Foltx	C			UNKNOWN	
			Levaquin	C			UNKNOWN	

Date:12/14/04ISR Number: 4526482-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00061
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Dilantin	C				
UNKNOWN								
Initial or Prolonged			Zocor	C				
UNKNOWN								
			Moexipril Hydrochloride	C				
UNKNOWN								

Date:12/14/04ISR Number: 4526483-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00089
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	589 DAY	
Hospitalization -			Aspirin	C		ORAL		
Initial or Prolonged								

Date:12/14/04ISR Number: 4526484-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00570
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Enzymatic Therapy Trimax	C				
Initial or Prolonged								
UNKNOWN								
Disability			Paxil	C				
UNKNOWN								
Other			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526485-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03879
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
Disability	Dyspnoea		[Therapy					
	Gastrooesophageal Reflux		Unspecified]	C				
UNKNOWN								
	Disease		[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:12/14/04ISR Number: 4526486-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00021
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
28 MON								

Date:12/14/04ISR Number: 4526487-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411USA00847
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/14/04ISR Number: 4526488-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00020
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON
Hospitalization -			Topiramate	SS		ORAL	21 MON
Initial or Prolonged			Lornoxicam	C		ORAL	60 DAY

Date:12/14/04ISR Number: 4526489-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00881
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Glucotrol	C				UNKNOWN
Initial or Prolonged	Hypertension							
	Myocardial Infarction							
	Renal Failure Chronic							

Date:12/14/04ISR Number: 4526494-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00013
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		580 DAY
Initial or Prolonged	Stress		Nitroglycerin	C				UNKNOWN
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526495-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01521
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							
	Depressed Level Of Consciousness							
	Pericarditis							
	Pulmonary Oedema							
	Respiratory Tract Infection							
	Vascular Calcification							

Date:12/14/04ISR Number: 4526496-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00086
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Orlistat	C				UNKNOWN
	Dyspnoea		[Therapy Unspecified]	C				UNKNOWN
	Pain In Extremity							

Date:12/14/04ISR Number: 4526498-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00534
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Heart Injury							
	Myocardial Infarction							
Disability								

Date:12/14/04ISR Number: 4526499-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00736
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Hallucination Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4526500-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00911
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON
Initial or Prolonged	Flatulence Myocardial Infarction Nausea		[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526501-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00543
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Motrin	C				
UNKNOWN								
	Thyroid Disorder		Methadone Hcl	C				
UNKNOWN								
			Naproxen	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/14/04ISR Number: 4526502-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00753
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Temazepam	C				
UNKNOWN								
	Flushing							
	Hyperhidrosis							
	Paraesthesia							
	Vision Blurred							

Date:12/14/04ISR Number: 4526503-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/14/04ISR Number: 4526505-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00945
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Liver Disorder		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:12/14/04ISR Number: 4526506-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4526510-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01062
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Sudden Cardiac Death							

Date:12/14/04ISR Number: 4526511-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01061
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx Tylenol	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526529-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01381
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Glucose Increased							
	Coronary Artery Disease							
Disability	Cough							
	Myocardial Infarction							
	Nodal Arrhythmia							
	Pleural Effusion							
	Post Procedural Haemorrhage							
	Prostatic Specific Antigen Increased							

Date:12/14/04ISR Number: 4526530-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Other	Anaemia
	Angina Unstable
	Anxiety
	Arthropathy
	Back Pain
	Bacterial Infection
	Barrett'S Oesophagus
	Blood Pressure Increased
	Cartilage Injury
	Cataract
	Cervicobrachial Syndrome
	Chest Pain
	Cholelithiasis
	Convulsion
	Corneal Scar
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dermatitis Contact
	Dizziness
	Dysuria
	Gastritis

Hepatic Enzyme Increased
Hypercholesterolaemia
Hyperlipidaemia
Hypersensitivity
Hypertension
Lethargy
Lipase Increased
Lipoma
Lymphadenopathy
Migraine
Myocardial Infarction
Oedema Peripheral
Oesophagitis
Osteoarthritis
Palpitations
Pleural Fibrosis
Polyneuropathy

		Pyrexia					
		Red Blood Cell Sedimentation Rate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Spondylolisthesis		Hydrodiuril	C		ORAL
		Suicidal Ideation		Norvasc	C		
UNKNOWN							
		Therapeutic Response		Vicodin Es Tablets	C		
UNKNOWN							
		Decreased					
		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection					
		Ventricular Hypertrophy					
		Weight Decreased					
		White Blood Cell Count Increased					
		Wound Infection Staphylococcal					

Date:12/14/04ISR Number: 4526666-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0358933B
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Drug Exposure During		Seretide	PS	Glaxosmithkline	
32 DAY						
Congenital Anomaly	Pregnancy		Vioxx	SS		
11 DAY						
Other	Pilonidal Cyst Congenital		Fucidine	SS		
500MG Per day 8 DAY						
	Talipes		Pantoprazole	SS		
40MG Per day 15 DAY						
			Prednisolone	C	Glaxosmithkline	
3UNIT per day 5 DAY						
			Cefuroxim	C	Glaxosmithkline	
			Necyrane	C		
			Biclotymol	C		
			Ambroxol	C	Glaxosmithkline	
			Propofan	C		

Date:12/14/04ISR Number: 4526980-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00055
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		117 DAY
Hospitalization -	Cerebrovascular Accident		Humalog	C				UNKNOWN
Initial or Prolonged	Chest Wall Pain		Lantus	C				UNKNOWN
	Dizziness		Spironolactone	C				UNKNOWN
	Gastritis		Terazosin Hydrochloride	C				UNKNOWN
	Intercostal Neuralgia		Verapamil	C				UNKNOWN
	Oedema		Tricor	C				UNKNOWN
	Pain		Lipitor	C				UNKNOWN
	Radicular Syndrome		Norvasc	C				UNKNOWN
			Glucosamine	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Citracal	C				UNKNOWN
			Vitamin E	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN
			Aldactazide	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Methadone Hydrochloride	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526982-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01341
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dizziness							
	Fall							
	Mitral Valve Incompetence							
	Myocardial Infarction							

Date:12/14/04ISR Number: 4526983-7Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0210NZL00211
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
	Disorientation		Aspirin	C		ORAL		
	Road Traffic Accident		Atorvastatin Calcium	C		ORAL		
	Visual Acuity Reduced		Diltiazem Hydrochloride	C		ORAL		

Date:12/14/04ISR Number: 4526984-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	284	DAY
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	284	DAY
Other	Anxiety		Prevacid	C			UNKNOWN	
	Chest Pain		Methylprednisolone	C			UNKNOWN	
	Coronary Artery		Estradiol	C			UNKNOWN	
	Atherosclerosis		Clonazepam	C			UNKNOWN	
	Depression		Prometrium	C			UNKNOWN	

	Dyspnoea	Vantin	C
UNKNOWN			
	Dyspnoea Paroxysmal	Meclizine	C
UNKNOWN			
	Nocturnal Gastrooesophageal Reflux Disease	Hydrocodone Bitartrate And Acetaminophen	C
UNKNOWN			
	Hypertension Hypoaesthesia	Sulfamethoxazole And Trimethoprim	C
UNKNOWN			
	Mitral Valve Prolapse	Serzone	C
UNKNOWN			
	Myocardial Infarction	Verapamil Msd Lp	C
UNKNOWN			
	Myocardial Ischaemia	Albuterol	C
UNKNOWN			
	Orthopnoea	Zyrtec	C
UNKNOWN			
	Pain	Prednisone	C
UNKNOWN			
	Palpitations	Cephalexin	C
UNKNOWN			
	Panic Attack	Augmentin	C
UNKNOWN			
	Paraesthesia	Allegra	C
UNKNOWN			
	Stomach Discomfort	Flonase	C
UNKNOWN			
	Supraventricular	Promethazine	C
UNKNOWN			
	Tachycardia	Cyanocobalamin	C
UNKNOWN			
	Vaginal Haemorrhage	Remeron	C
UNKNOWN			
	Vision Blurred	Aciphex	C
UNKNOWN			
		Tequin	C
UNKNOWN			
		Cyanocobalamin	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4526990-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02433
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Non-Cardiac Chest Pain		Oxycodone	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								

Date:12/14/04ISR Number: 4526993-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00306
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drop Attacks		Vioxx	PS	Merck & Co., Inc	ORAL		
1298 DAY								
Initial or Prolonged	Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL		
1298 DAY								
			Zopiclone	C		ORAL		
			Omeprazole	C		ORAL		
			Indapamide	C		ORAL		

Date:12/14/04ISR Number: 4526995-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
252 DAY								
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
252 DAY								
	Infarction		Seroquel	C				
UNKNOWN								
	Amnesia		Seroquel	C				
UNKNOWN								
	Anxiety		Hydrochlorothiazide	C				
UNKNOWN								
	Asthma		Soma	C				
UNKNOWN								
	Back Disorder		Premarin	C				
UNKNOWN								

	Back Pain	Altace	C	
UNKNOWN				
	Blood Triglycerides	Vicodin Tablets	C	
UNKNOWN				
	Increased	Folic Acid	C	
UNKNOWN				
	Bronchitis Acute	Prevacid	C	
UNKNOWN				
	Chest Pain	Toprol Xl Tablets	C	
UNKNOWN				
	Chronic Obstructive	Toprol Xl Tablets	C	
UNKNOWN	8 DAY			
	Pulmonary Disease	Plavix	C	
UNKNOWN				
	Coronary Artery Disease	Zocor	C	
UNKNOWN				
	Coronary Artery	Lipitor	C	
UNKNOWN	112 DAY			
	Thrombosis	Foltx	C	
UNKNOWN				
	Euthyroid Sick Syndrome	Potassium		
	Fibromyalgia	(Unspecified)	C	
UNKNOWN				
	Gastroenteritis	Linseed Oil	C	
UNKNOWN				
	Hallucination	Nitroglycerin	C	
UNKNOWN				
	Headache	Aspirin	C	
UNKNOWN				
	Herpes Simplex	Neurontin	C	
UNKNOWN				
	Hypertension	Ambien	C	
UNKNOWN				
	Irritable Bowel Syndrome	Doxepin		
	Ischaemic Cardiomyopathy	Hydrochloride	C	
UNKNOWN				
	Nasal Disorder	Flexeril	C	ORAL
	Nausea	Prozac	C	
UNKNOWN				
	Neck Pain	Prozac	C	
UNKNOWN				
	Panic Disorder	Prozac	C	
UNKNOWN				
	Sleep Apnoea Syndrome			
	Spondylolisthesis			
	Vascular Pseudoaneurysm			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4527000-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00192
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Aspirin	C		ORAL		
	Pain		Atenolol	C		ORAL		
			Atenolol	C		ORAL		
			Enalapril Maleate	C		ORAL		
			Simvastatin	C		ORAL		
			Quinine	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Dihydrocodeine	C		ORAL		

Date:12/14/04ISR Number: 4527001-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00087
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Acute Prerenal Failure							
	Cardiogenic Shock							
	Cerebrovascular Accident							
	Intestinal Infarction							
	Multi-Organ Failure							
	Peripheral Embolism							
	Tachyarrhythmia							

Date:12/14/04ISR Number: 4527003-0Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0412NZL00011
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Transient		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4527005-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00084
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4527007-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00099
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	54	DAY
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Hydroxyzine Pamoate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4527008-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00508
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Epigastric Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Polyneuropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Soft Tissue Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Spinal Disorder		Phenprocoumon	C			UNKNOWN	
	Vomiting		Buprenorphine Hydrochloride	C			TOPICAL	3 DAY
			Pantoprazole Sodium	C			UNKNOWN	3 DAY
			Metoprolol Succinate	C			UNKNOWN	
			Letrozole	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Celecoxib	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	

Date:12/14/04ISR Number: 4527009-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Wall Mass
	Anorexia
	Anxiety
	Arthritis
	Asthenia
	Atherosclerosis

Back Pain
Blister
Bronchitis
Bursitis
Cardiac Disorder
Caustic Injury
Chest Pain
Constipation
Depression
Diastolic Dysfunction
Diverticulum Intestinal
Dizziness
Drug Eruption
Dysphonia
Dysuria
Ecchymosis
Epistaxis
Fall
Frequent Bowel Movements
Gastritis
Glucose Tolerance
Impaired
Gout
Haemorrhoids
Headache
Helicobacter Infection

		Hypertension Hypoaesthesia Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc Degeneration		Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL
		Intervertebral Disc		Prinivil	C		
UNKNOWN							
		Protrusion		K-Dur	C		
UNKNOWN							
		Joint Crepitation		Lortab	C		
UNKNOWN							
		Kidney Infection		Coumadin	C		
UNKNOWN							
		Labyrinthitis Muscle Strain		[Therapy Unspecified]	C		
UNKNOWN							
		Nasopharyngitis Nausea		Lasix (Furosemide Sodium)	C		
UNKNOWN							
		Oedema Peripheral Osteoarthritis Otitis Media Pain Pharyngitis Rash Sinusitis Sleep Disorder Stomach Discomfort Syncope Tricuspid Valve Incompetence Vertigo Vision Blurred Vomiting					

Date:12/14/04ISR Number: 4527017-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00083
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Angina Pectoris Cardiac Failure Fluid Retention Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/14/04ISR Number: 4527018-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00082
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/14/04ISR Number: 4527020-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Insufficiency							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4527021-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01676
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Catapres	C				UNKNOWN
	Pain In Extremity		Glucotrol Xl	C				UNKNOWN
	Vomiting							

Date:12/14/04ISR Number: 4527023-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01104
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Allegra	C				UNKNOWN

Date:12/14/04ISR Number: 4527024-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00613
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4527026-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00086
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged	Peripheral Vascular Disorder							
	Sudden Cardiac Death							

Date:12/14/04ISR Number: 4527028-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00892
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bacterial Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ulcer Haemorrhage		Nexium	C				
UNKNOWN								
Initial or Prolonged			Levothyroxine Sodium	C				
UNKNOWN								
Disability								

Date:12/14/04ISR Number: 4527029-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/14/04ISR Number: 4527031-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00895
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
11 MON								
			Celebrex	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4527032-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01185
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

Date:12/14/04ISR Number: 4527034-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4527041-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01075
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma Heart Rate Increased Heart Rate Irregular Rheumatoid Arthritis Rheumatoid Factor Increased Tremor		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/14/04ISR Number: 4527187-4Report Type:Direct Company Report #CTU 234242
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS			25	
Disability			Celebrex	SS			200	
Required Intervention to								

Prevent Permanent
Impairment/Damage

Date:12/14/04ISR Number: 4527189-8Report Type:Direct Company Report #CTU 234246
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS			12.5 - 25 MG	
Initial or Prolonged	Facial Palsy							
	Paraesthesia							

Date:12/14/04ISR Number: 4527244-2Report Type:Direct Company Report #CTU 234255
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Rofecoxib, 50mg Tab					
Hospitalization -			(Vioxx)	PS		ORAL	25 MG PER DAY	
Initial or Prolonged								
ORALLY								

Date:12/14/04ISR Number: 4527262-4Report Type:Direct Company Report #CTU 234253
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS				
Hospitalization - Initial or Prolonged								

Date:12/14/04ISR Number: 4527264-8Report Type:Direct Company Report #CTU 234256
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS			1 TAB DAILY	2 MON
	Diabetes Mellitus							
	Heart Rate Increased							

Date:12/14/04ISR Number: 4527324-1Report Type:Direct Company Report #CTU 234305
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx 50 Mg	PS		ORAL	ONCE DAILY	
	Nail Discolouration						ORAL	
Other	Respiratory Depth		Bextra 20 Mg	SS		ORAL	ONCE DAILY	
	Decreased						ORAL	

Date:12/14/04ISR Number: 4528945-2Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00025
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged	Cardiac Failure Acute	Study			
MG//DAILY/PO					
		Health	Zocor	C	
		Professional	Aspirin	C	
			Bisoprolol	C	
			Hydrochlorothiazide		
			(+) Ramipril	C	

Date:12/14/04ISR Number: 4528954-3Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Tab Vioxx					
	Blood Cholesterol	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Increased	Other						
PO							35	DAY
	Blood Triglycerides		Omeprazole	C				
	Increased							
	Electrocardiogram							
	Abnormal							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Low Density Lipoprotein							
	Increased							
	Memory Impairment							
	Myocardial Ischaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/14/04ISR Number: 4529553-XReport Type:Expedited (15-DaCompany Report #WAES 0410USA50112
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest	Study	Tab Vioxx 25 Mg	PS		ORAL	25MG/DAILY/PO	
Hospitalization - Initial or Prolonged Disability	Coronary Artery Occlusion	Health Professional	Amlodipine Besylate	C				
	Feeling Abnormal		Aspirin	C				
	Myocardial Infarction		Rabeprazole Sodium	C				
			Vitamins (Unspecified)	C				

Date:12/14/04ISR Number: 4535255-6Report Type:Periodic Company Report #2004097489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure Acute	Consumer	Bextra (Valdecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:12/15/04ISR Number: 4527635-XReport Type:Expedited (15-DaCompany Report #FRWYE173203NOV04
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colitis		Enbrel	PS			SUBCUTANEOUS	not specified 1168 DAY
	Diverticular Perforation		Coversyl	SS		ORAL		
	Drug Ineffective		Crestor	SS		ORAL		
	Gastritis		Glyceryl Trinitrate	SS			TRANSDERMAL	
	Gastrointestinal Disorder		Acetylsalicylate					
	General Physical Health		Lysine	SS		ORAL		
	Deterioration		Medrol	SS		ORAL		
	Monarthritis		Solu-Medrol	SS			INTRAVENOUS	
	Peritonitis		Vioxx	SS		ORAL		
	Small Intestinal Perforation		Isoptin	SS		ORAL		

Date:12/15/04ISR Number: 4527646-4Report Type:Expedited (15-DaCompany Report #US-AMGEN-US102908
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colitis		Enbrel	PS				
Hospitalization - Initial or Prolonged	Condition Aggravated		Coversyl	SS				
	Death		Solu-Medrol	SS				
	Gastrointestinal Disorder		Vioxx	SS				
	Intestinal Perforation							
	Peritonitis							
	Pneumoperitoneum							

Date:12/15/04ISR Number: 4527676-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00173
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/04ISR Number: 4527684-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01831
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cyanosis		Coumadin	C		ORAL		
	Loss Of Consciousness		Darvocet-N	C		ORAL		
	Sudden Cardiac Death		Allopurinol	C		ORAL		
			Bumex	C		ORAL		
			K-Dur	C		ORAL		
			Mevacor	C				

UNKNOWN

Date:12/15/04ISR Number: 4527685-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01843
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Avandia	C				
UNKNOWN								
Other	Fibromyalgia		Glucophage	C				
UNKNOWN								
	Platelet Count Increased		Prevacid	C				
UNKNOWN								
	Pulmonary Embolism		Effexor Xr	C				
UNKNOWN								
	Thrombosis		Coumadin	C		ORAL		
	White Blood Cell Count		Klonopin	C				
UNKNOWN								
	Increased		Elavil	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Serevent	C				
UNKNOWN								

			Flovent	C			
UNKNOWN							
			Ventolin (Albuterol)	C			
UNKNOWN							
			Glucotrol	C			
UNKNOWN							
			A.S.A.	C			ORAL
			Flonase	C			
UNKNOWN							

Date:12/15/04ISR Number: 4527686-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00104
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death		Insulin	C				
UNKNOWN								
			Etanercept	C				
SUBCUTANEOUS								
			Prednisolone	C				
UNKNOWN								
			Cholecalciferol And Calcium Carbonate	C				
UNKNOWN								
			Esomeprazole Magnesium	C				
UNKNOWN								

Date:12/15/04ISR Number: 4527687-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00228
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/04ISR Number: 4527688-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00018
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL		
			Levomepromazine	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Atenolol	C		ORAL		
			Metformin Hydrochloride	C		ORAL		

Date:12/15/04ISR Number: 4527689-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02164
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Effexor	C		ORAL		
	Osteoarthritis		Xanax	C		ORAL		
			Estratest	C		ORAL		

Date:12/15/04ISR Number: 4527692-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00050
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		[Composition Unspecified]	C				UNKNOWN
	Fall							
Other	Hip Fracture		[Composition Unspecified]	C				UNKNOWN
	Loss Of Consciousness							
	Pelvic Fracture		Calcium (Unspecified)	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN

[Composition
Unspecified] C
UNKNOWN

Date:12/15/04ISR Number: 4527799-8Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0358933A
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Exposure During		Seretide	PS	Glaxosmithkline			
RESPIRATORY								
(INHALATION)	Pregnancy							
	1 MON							
			Vioxx	SS		ORAL	11 DAY	
			Fucidine	SS		ORAL	500MG Per day	8 DAY
			Pantoprazole	SS			40MG Per day	15 DAY
			Prednisolone	C	Glaxosmithkline	ORAL	3UNIT per day	5 DAY
			Cefuroxim	C	Glaxosmithkline			
			Necyrane	C				
			Biclotymol	C				
			Ambroxol	C	Glaxosmithkline			
			Propofan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/04ISR Number: 4528146-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01010
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Cold Sweat		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Other	Contusion		Baycol	C				UNKNOWN
	Drug Hypersensitivity		Motrin	C				UNKNOWN
	Emotional Distress		Vicodin Tablets	C				UNKNOWN
	Fall		Celebrex	C				UNKNOWN
	Heart Rate Increased							
	Hypertension							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Myocardial Infarction							
	Palpitations							
	Respiratory Disorder							
	Respiratory Rate Increased							
	Rib Fracture							
	Rotator Cuff Syndrome							

Date:12/15/04ISR Number: 4528154-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Acute Myocardial Infarction							
Other	Arteriosclerosis							
	Atherosclerosis							
	Bundle Branch Block Right							
	Cardiomyopathy							
	Cervicobrachial Syndrome							

Chronic Obstructive
Pulmonary Disease
Conduction Disorder
Diverticular Perforation
Drug Hypersensitivity
Ejection Fraction
Decreased
Hypersensitivity
Injury
Muscle Spasms
Myocardial Ischaemia
Polycythaemia Vera
Prostatic Specific
Antigen Increased
Thrombosis
Treatment Noncompliance
Viral Infection

Date:12/15/04ISR Number: 4528158-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00115
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		778 DAY
	Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL		778 DAY

				Allopurinol	C		
UNKNOWN							
				Salix	C		
UNKNOWN							
				Levothyroxine Sodium	C		
UNKNOWN							
				Magnesium Oxide	C		
UNKNOWN							
				Dipyrone	C		
UNKNOWN							
				Benserazide Hydrochloride And Levodopa	C		
UNKNOWN							

Date:12/15/04ISR Number: 4528160-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00041
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Pramipexole Dihydrochloride	SS				
	Cardiac Failure							
UNKNOWN								
	Haemorrhage		Acetaminophen	C				
UNKNOWN								
			Benserazide Hydrochloride And Levodopa	C				
UNKNOWN								
			Carbidopa And Levodopa	C				
UNKNOWN								
			Etilefrine Hydrochloride	C				
UNKNOWN								

Date:12/15/04ISR Number: 4528162-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03763
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Asthenia	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Blood Pressure Increased	Zyrtec	C		
UNKNOWN	Bronchitis	Atenolol	C		
UNKNOWN	Bronchopneumonia	Prevacid	C		
UNKNOWN	Gastrooesophageal Reflux Disease	[Therapy Unspecified]	C		
	Myocardial Infarction				
	Sinusitis				
	Weight Increased				

Date:12/15/04ISR Number: 4528164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01230
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
	Cardiac Disorder
	Circulatory Collapse
	Dermatitis
	Electromechanical Dissociation
	Exsanguination
	Haematemesis
	Malaise
	Oesophageal Rupture
	Oesophageal Varices Haemorrhage
	Osteoarthritis
	Upper Gastrointestinal

		Haemorrhage Vertigo Positional					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Lotensin	C		
UNKNOWN							
				Vasotec	C		ORAL
				Tenormin	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Procardia	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Hytrin	C		
UNKNOWN							

Date:12/15/04ISR Number: 4528166-3Report Type:Expedited (15-DaCompany Report #DK-MERCK-0412DNK00007
Age:75 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
590 DAY							
				Aspirin	C		ORAL
				Tiotropium Bromide	C		
RESPIRATORY							
(INHALATION)							
				Omeprazole	C		ORAL

Date:12/15/04ISR Number: 4528168-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00774
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/15/04ISR Number: 4528170-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00048
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:12/15/04ISR Number: 4528171-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:12/15/04ISR Number: 4528173-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00652
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	316 DAY	
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Prednisone	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		
			Vitamin B (Unspecified)	C		ORAL		
			Hydrochlorothiazide And Triamterene	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/04ISR Number: 4528175-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01900
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		[Therapy Unspecified]	C				
Disability								
UNKNOWN								
Other			Plavix	C				
UNKNOWN								

Date:12/15/04ISR Number: 4528177-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Methotrexate	C				
UNKNOWN								
	Increased		Ibuprofen	C				
UNKNOWN								
	Coronary Artery Disease		Folic Acid	C				
UNKNOWN								
	Emotional Distress		Zocor	C				
UNKNOWN								
	Hypertension		Nitroquick	C				
UNKNOWN								
	Myocardial Infarction		Prilosec	C				
UNKNOWN								
			Leucovorin	C				
UNKNOWN								

Date:12/15/04ISR Number: 4528178-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00274
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
93 DAY								
	Blister		[Therapy					

	Bradycardia	Unspecified]	C
UNKNOWN			
	Chest Pain	Aspirin	C
UNKNOWN			
	Confusional State	Celexa	C
UNKNOWN			
	Fatigue		
	Transient Ischaemic Attack		

Date:12/15/04ISR Number: 4528180-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00873
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
Other	Arterial Injury
	Arthritis
	Blood Cholesterol Increased
	Cardiomyopathy
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Device Failure
	Diarrhoea
	Dizziness Postural
	Dyslipidaemia
	Dyspepsia
	Ejection Fraction Decreased

		Fatigue					
		Gastric Disorder					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
255	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
255	DAY						
		Hypotension		Tylenol	C		
UNKNOWN							
		Insomnia		Aspirin	C		
UNKNOWN							
		Joint Swelling					
		Liver Disorder					
		Post Procedural					
		Complication					
		Pyelonephritis					
		Pyrexia					
		Urinary Tract Infection					
		Vision Blurred					

Date:12/15/04ISR Number: 4528186-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00061
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
		Chest Pain		[Therapy			
		Sleep Disorder		Unspecified]	C		
UNKNOWN							

Date:12/15/04ISR Number: 4528187-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						

Coronary Artery
Atherosclerosis
Depression
Pulmonary Embolism
Stress
Tachycardia

Date:12/15/04ISR Number: 4528188-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							1	YR
Initial or Prolonged	Hyperventilation		Vioxx	SS	Merck & Co., Inc	ORAL		
2	MON							

Date:12/15/04ISR Number: 4528189-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00465
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			Hydrodiuril	C		ORAL		
			Vicodin Tablets	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								
			Flexeril	C				
UNKNOWN								
			Darvocet-N	C				
UNKNOWN								

			Percocet	C			
UNKNOWN							

Date:12/15/04ISR Number: 4528190-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00077
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:12/15/04ISR Number: 4528192-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/15/04ISR Number: 4528195-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Injury Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/15/04ISR Number: 4528197-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01054
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

			Norvasc	C		
UNKNOWN						
			Hyzaar	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:12/15/04ISR Number: 4528198-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00868
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Urinary Tract Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
			Hydrocodone Bitartrate	C		
UNKNOWN						

Date:12/15/04ISR Number: 4528201-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01213
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Vioxx	SS	Merck & Co., Inc	ORAL
			Norvasc	C		
UNKNOWN						

Date:12/15/04ISR Number: 4528202-4Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0412ZAF00012
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Hypertension		Levothyroxine Sodium	C		ORAL		
Disability	Retinal Vein Occlusion		Estrogens (Unspecified)	C		TOPICAL		

Date:12/15/04ISR Number: 4528203-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00923
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/15/04ISR Number: 4528204-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01216
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1371 DAY
Hospitalization -	Dizziness		Lipitor	C				UNKNOWN
Initial or Prolonged	Erectile Dysfunction		Serevent	C				UNKNOWN
	Mental Impairment		Hyzaar	C		ORAL		

Date:12/15/04ISR Number: 4528209-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00867
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Congestive	Flexeril	C
Initial or Prolonged Disability UNKNOWN	Hypertension Myocardial Infarction Renal Disorder	[Therapy Unspecified]	C

Date:12/15/04ISR Number: 4528210-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00947
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/15/04ISR Number: 4528240-1Report Type:Expedited (15-DaCompany Report #CO-MERCK-0412COL00015
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Nephritis Interstitial Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/15/04ISR Number: 4528906-3Report Type:Direct Company Report #CTU 234333
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hemiplegia		Vioxx 25 Mg	PS		
	Oral Pain					
	Pain In Extremity					

Date:12/15/04ISR Number: 4528981-6Report Type:Direct Company Report #CTU 234353
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia		Vioxx - 25 Mg			
Hospitalization - 1 PR DAY	Dyspepsia		Merck	PS	Merck	
Initial or Prolonged 1 PR. DAY	Fatigue		Bextra 10 Mg	SS		
	Gastrointestinal Disorder					
	Joint Swelling					
	Pneumonia					
	Respiratory Disorder					

Date:12/15/04ISR Number: 4529398-0Report Type:Direct Company Report #CTU 234372
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypoaesthesia		Vioxx	PS		
Hospitalization - PAIN	Myocardial Infarction		Celebrex	SS		
Initial or Prolonged Other	Palpitations					

Date:12/15/04ISR Number: 4529922-8Report Type:Direct Company Report #CTU 234365
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cardiac Disorder		Vioxx 25 Mg Tablet			

Msd PS Msd
1 EACH DAY

Date:12/15/04ISR Number: 4530063-4Report Type:Expedited (15-DaCompany Report #2004243586US
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Consumer	Celebrex (Celecoxib) Capsule	PS		ORAL	ORAL	
Disability	Blood Pressure Increased		Vioxx (Vioxx)	SS		ORAL	50 MG, SINGLE, ORAL	
	Blood Pressure Systolic Increased							
	Cerebrovascular Accident							
	Decreased Appetite							
	Drug Ineffective							
	Drug Interaction							
	Fatigue							

Date:12/15/04ISR Number: 4530070-1Report Type:Expedited (15-DaCompany Report #2004103390
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
	Drug Ineffective

		Medical Device Complication					
		Memory Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis	Consumer	Celecoxib(Celecoxib)	PS		ORAL
(1 D), ORAL							
		Post Procedural Pain		Bextra (Valocoxib)	SS		ORAL
10 MG (10 MG,							
1 IN 1 D),							
ORAL							
				Morphine Injection (Morphine Sulfate)	SS		
				Rofecoxib (Rofecoxib)	SS		
				Oxycocet (Oxycodone Hydrochloride, Paracetamol)	SS		
(6 IN 1 AS							
NECESSARY)							
				Metoprolol Tartrate (Metoprolol Tartrate)	C		
				Triamterene (Triamterene)	C		
				Atorvastatin 9atorvastatin)	C		
				Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C		
				All Other Therapeutic Proucts (All Other Therapetuic Products)	C		

Date:12/15/04ISR Number: 4530192-5Report Type:Expedited (15-DaCompany Report #HQWYE750003DEC04
Age:82 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged Other	Eczema Hypothyroidism	Health Professional Other	Cordarone (Amiodarone, Injection)	PS	
INTRAVENOUS 150 MG, FREQUENCY UNKNOWN; INTRAVENOUS					
			Amlor (Amlodipine Besilate,)	SS	ORAL
1 DF DAILY, ORAL					
			Atarax (Hydroxyzine Hydrochloride,)	SS	ORAL
25 MG, FREQUENCY UNKNOWN; ORAL					
			Catapressan (Clonidine,)	SS	ORAL
0.15 MG, FREQENCY UNKNOWN; ORAL					
			Doxazosin (Doxazosin,)	SS	
UNSPECIFIED; ORAL					
			Elisor (Pravastatin Sodium,)	SS	ORAL
UNSPECIFIED; ORAL					

	Fozitec (Fosinopril,)	SS	ORAL
20 MG, FREQUENCY UNKNOWN; ORAL			
	Havlane (Loprazolam Mesilate,)	SS	ORAL
1 MG, FREQUENCY UNKNOWN; ORAL			
	Kaleorid (Potassium Chloride)	SS	ORAL
UNSPECIFIED; ORAL			
	Paracetamol/Tramadol Hydrochloride (Paracetamol/Tramadol Hydrochloride,)	SS	ORAL
25 MG, FREQUENCY UNKNOWN; ORAL			
	Ser "Solvay" (Betahistine Hydrochloride,)	SS	ORAL
8 MG, FREQUENCY UNKNOWN; ORAL			
	Sintrom (Acenocoumarol,)	SS	
4 MG, FREQUENCY UNKOWN; ORAL			
	Vioxx (Rofecoxib, Tablet)	SS	ORAL
UNSPECIFIED;			

ORAL

Date:12/16/04ISR Number: 4528622-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY
Initial or Prolonged	Blood Creatinine		Vioxx	SS	Merck & Co., Inc	ORAL		254 DAY
Other	Increased Cardiac Failure Congestive Cardiac Murmur Cardiomyopathy Coronary Artery Disease Coronary Artery Occlusion Injury Myocardial Infarction Oedema Peripheral Pericarditis Wound Secretion							

Date:12/16/04ISR Number: 4528626-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Other	Aneurysm Anxiety Arthritis Blindness Unilateral Blood Triglycerides Increased

		Eye Haemorrhage					
		Gout					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Macular Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Pain In Extremity					
		Post-Traumatic Stress					
		Disorder					
		Retinal Haemorrhage					
		Retinal Vein Occlusion					

Date:12/16/04ISR Number: 4528629-0Report Type:Expedited (15-DaCompany Report #KR-MERCK-0411KOR00003
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Alendronate Sodium	C		
UNKNOWN						
Initial or Prolonged			Piroxicam	C		
UNKNOWN						
Other			Hyaluronate Sodium	C		
UNKNOWN						

Date:12/16/04ISR Number: 4528630-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00046
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
20 MON						
Hospitalization -	Cardiomegaly					
Initial or Prolonged	Intracardiac Thrombus					
	Myocardial Infarction					
	Thrombosis					

Date:12/16/04ISR Number: 4528631-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03530
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Remicade	C				
INTRAVENOUS								
Initial or Prolonged						DRIP		
Disability			[Therapy Unspecified]	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528632-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00984
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
1285 DAY								
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
1285 DAY								
Initial or Prolonged	Coordination Abnormal		Cozaar	C				
UNKNOWN								
Disability			Atenolol	C				
UNKNOWN								
			Quinine	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Potassium (Unspecified)	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528633-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00093
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperthyroidism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		
	Temperature Intolerance		Levothyroxine Sodium	C				
UNKNOWN								
	Tinnitus		Naloxone Hydrochloride And Tilidine Hydrochloride	C				
UNKNOWN								
			Tolperisone Hydrochloride	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528634-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03723
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Estratest	C		ORAL		
Disability			Paxil Cr	C		ORAL		
			Amaryl	C		ORAL		
			Cozaar	C		ORAL		

Date:12/16/04ISR Number: 4528635-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00224
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

Initial or Prolonged Disability UNKNOWN		Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Diarrhoea Hepatic Failure Hypertension Nausea Vomiting		[Therapy Unspecified]	C	

Date:12/16/04ISR Number: 4528647-2Report Type:Expedited (15-DaCompany Report #200421598GDDC
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other TRANSDERMAL		Cerebrovascular Accident		Nicotine Patch	PS	Glaxosmithkline	
				Vioxx	SS		ORAL
				Salbutamol	C	Glaxosmithkline	
				Fluticasone	C	Glaxosmithkline	
RESPIRATORY (INHALATION)							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4528658-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00005
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Diastolic Dysfunction					
	Dyspnoea					
	Exercise Tolerance Decreased					
	Hypertension					
	Hypertensive Heart Disease					
	Non-Cardiac Chest Pain					
	Tachycardia					

Date:12/16/04ISR Number: 4528659-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Withdrawal Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Neuroendocrine Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL
	Subileus					

Date:12/16/04ISR Number: 4528660-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00553
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Grand Mal Convulsion		Fluocortolone Caproate	C		ORAL
Other			Sitosterols	C		ORAL
			Beclomethasone Dipropionate	C		
RESPIRATORY (INHALATION)						
			Salmeterol Xinafoate	C		
RESPIRATORY						

(INHALATION)
Ipratropium Bromide C
RESPIRATORY

(INHALATION)
Pantoprazole Sodium C ORAL

Date:12/16/04ISR Number: 4528661-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:12/16/04ISR Number: 4528662-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00087
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
			Fluvastatin Sodium	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528663-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02629
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Diltiazem Hydrochloride	C				
	Osteopenia		Cartia Xt	C				
			Tylenol	C				
			Klonopin	C				
			Pravachol	C				

Date:12/16/04ISR Number: 4528664-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01133
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Paraplegia		[Therapy Unspecified]	C				
Hospitalization - Initial or Prolonged	Pneumonia		[Therapy Unspecified]	C				
Disability								

Date:12/16/04ISR Number: 4528665-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01338
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528666-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528668-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01309
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Plavix	C				
UNKNOWN								
Initial or Prolonged	Attack		Dicyclomine Hydrochloride	C				
UNKNOWN								
			Clidinium Bromide	C				
UNKNOWN								
			Avapro	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528669-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01096
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Disease Recurrence		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
Initial or Prolonged	Gallbladder Disorder Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4528670-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01084
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fall							
	Loss Of Consciousness							
	Tongue Disorder							
	Tooth Disorder							
	Transient Ischaemic Attack							

Date:12/16/04ISR Number: 4528671-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01312
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cyanocobalamin	C				
UNKNOWN								
Disability			Prednisone	C				
UNKNOWN								
Other			Levothyroxine Sodium	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Colchicine	C				
UNKNOWN								
			Zocor	C		ORAL		
			Lisinopril	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528672-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01099
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528673-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01210
Age:31 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Paraesthesia		Tizanidine					
Initial or Prolonged	Paraesthesia Oral		Hydrochloride	C				
UNKNOWN								
			Tramadol					
			Hydrochloride	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								
			Ultracet	C				
UNKNOWN								

Date:12/16/04ISR Number: 4528674-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Increased							

Date:12/16/04ISR Number: 4528675-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528676-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528677-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4528678-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01355
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Skin Discolouration		Verapamil	C				
Initial or Prolonged Disability UNKNOWN			Hydrochlorothiazide And Triamterene	C				

Date:12/16/04ISR Number: 4528679-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00035
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
18 MON						
	Hypoaesthesia		Rabeprazole Sodium	C		
UNKNOWN						

Date:12/16/04ISR Number: 4528680-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Disorder					
	Myocardial Infarction					

Date:12/16/04ISR Number: 4528684-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03031
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Prozac	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4529566-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01171
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Hospitalization - Initial or Prolonged			Propranolol Hydrochloride	C				
UNKNOWN								
Disability								

Date:12/16/04ISR Number: 4529569-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01208
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Diovan	C				
UNKNOWN								
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability								

Date:12/16/04ISR Number: 4529571-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01194
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Chest Pain		Buspar	C				
UNKNOWN								
	Coronary Artery		Zoloft	C				
UNKNOWN								
	Atherosclerosis		Claritin	C				
UNKNOWN								
	Deep Vein Thrombosis							
	Depression							
	Dyspnoea							
	Haemothorax							
	Nasopharyngitis							

Pleurisy
Pulmonary Artery
Thrombosis
Pulmonary Infarction
Rheumatoid Arthritis
Weight Increased

Date:12/16/04ISR Number: 4529576-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01314
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tylenol	C			UNKNOWN	
			Wellbutrin Sr	C			UNKNOWN	

Date:12/16/04ISR Number: 4529578-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01711
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Nitroglycerin	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Actos	C			UNKNOWN	
			Neurontin	C			UNKNOWN	

Nexium	C		
UNKNOWN			
Amitriptyline Hydrochloride	C		
UNKNOWN			
Metformin	C		
UNKNOWN			
Atenolol	C		
UNKNOWN			
Tricor	C		
UNKNOWN			
Novolin	C		
UNKNOWN			
Naproxen	C		
UNKNOWN			

Date:12/16/04ISR Number: 4529580-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00656
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		698 DAY
Initial or Prolonged	Infarction		Skelaxin	C				
UNKNOWN								
Other	Adverse Event		Methotrexate	C				
UNKNOWN								
	Amnesia		Folic Acid	C				
UNKNOWN								
	Angina Pectoris		Prednisone	C				
UNKNOWN								
	Anxiety		Nitropaste	C				
UNKNOWN								
	Back Pain		Ultram	C				
UNKNOWN								
	Blister		Triamcinolone	C				
UNKNOWN								
	Blood Cholesterol		Sodium Folate	C				
UNKNOWN								
	Increased		Prednisone	C				
UNKNOWN								
	Blood Pressure Increased		Lortab	C				
UNKNOWN								
	Cardiac Murmur		Toprol Xl Tablets	C				
UNKNOWN								

	Chest Discomfort	Elavil	C
UNKNOWN			
	Contusion		
	Convulsion		
	Coronary Artery Disease		
	Eye Disorder		
	Headache		
	Heart Rate Increased		
	Hypercholesterolaemia		
	Hypoaesthesia		
	Joint Swelling		
	Kidney Infection		
	Myocardial Infarction		
	Nausea		
	Nephrolithiasis		
	Pain In Extremity		
	Pain In Jaw		
	Palpitations		
	Phlebitis		
	Pyrexia		
	Rash		
	Rectal Haemorrhage		
	Renal Disorder		
	Stress		
	Tachycardia		
	Upper Respiratory Tract Infection		
	Urinary Tract Infection		
	Vasculitis		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4529598-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01177
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anterior Spinal Artery		Vioxx	PS	Merck & Co., Inc	ORAL	867 DAY	
Hospitalization -	Syndrome		Tenormin	C			UNKNOWN	
Initial or Prolonged			Lipitor	C			UNKNOWN	
Disability			Diovan	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:12/16/04ISR Number: 4529600-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01363
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diplegia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Monoplegia							
	Musculoskeletal Stiffness							
	Oedema Peripheral							
	Pain							

Date:12/16/04ISR Number: 4529601-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02530
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Wellbutrin	C			UNKNOWN	
	Asthenia		Wellbutrin	C			UNKNOWN	
	Cystitis		Nitroglycerin	C			UNKNOWN	
	Emotional Distress		Ultram	C			UNKNOWN	

	Hypothyroidism	Ultracet	C
UNKNOWN			
	Ingrowing Nail	Butalbital	C
UNKNOWN			
	Injury	Aspirin	C
UNKNOWN			
	Migraine		
	Migraine Without Aura		
	Myocardial Infarction		
	Obesity		
	Onychomycosis		
	Pain		
	Rhinitis		
	Upper Respiratory Tract Infection		

Date:12/16/04ISR Number: 4529607-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Anaemia
Disability	Blood Glucose Abnormal
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Cholelithiasis
	Clostridium Colitis
	Cognitive Disorder
	Colon Neoplasm
	Decubitus Ulcer

		Depression					
		Diverticulitis					
		Electrolyte Imbalance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Lasix (Furosemide)	C		
UNKNOWN		1218 DAY					
		Femur Fracture		Tagamet	C		
UNKNOWN							
		Gastritis Erosive		Estropipate	C		
UNKNOWN		3956 DAY					
		Insomnia		Potassium (Unspecified)	C		
		Obesity					
UNKNOWN							
		Pneumatosis Cystoides		Drixoral	C		
UNKNOWN							
		Intestinalis		Elavil	C		
UNKNOWN							
		Pneumonitis		Tiazac	C		
UNKNOWN							
		Rash		Hydrochlorothiazide	C		
UNKNOWN							
		Rash Pruritic		Iron (Unspecified)	C		
UNKNOWN							
		Reflux Oesophagitis		Cyanocobalamin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Magnesium (Unspecified)	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							

Date:12/16/04ISR Number: 4529609-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Coma		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Emotional Distress					
	Erectile Dysfunction					
	Gallbladder Disorder					
	Gastrooesophageal Reflux					
	Disease					
	Hepatic Failure					
	Hiatus Hernia					
	Hypertension					
	Intervertebral Disc					
	Disorder					
	Myocardial Infarction					
	Renal Disorder					
	Renal Failure					

Date:12/16/04ISR Number: 4529612-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00722
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4529613-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00173
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:12/16/04ISR Number: 4529617-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00094
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL		223 DAY
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc			
	Cardio-Respiratory Arrest		Toprol Xl Tablets	C				
	Chronic Obstructive		Toprol Xl Tablets	C				
	Pulmonary Disease		Norvasc	C				
	Convulsion		Norvasc	C				
	Coronary Artery Disease		Claritin-D	C		ORAL		
	Cough		Tylenol	C				
	Dyslipidaemia		Wellbutrin Sr	C				
	Emotional Distress		Albuterol	C				
	Insomnia		Norflex	C				
	Malaise		Norflex	C				
	Muscle Spasms		Naprosyn	C				
	Myocardial Infarction		Naprosyn	C				
	Obesity							
	Pneumonia							
	Pyrexia							
	Respiratory Failure							
	Upper Respiratory Tract Infection							
	Ventricular Fibrillation							

Date:12/16/04ISR Number: 4529620-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00433
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stent Occlusion		Hydrochlorothiazide And Ramipril	C		ORAL		
			Xipamide	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Aspirin	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		

Date:12/16/04ISR Number: 4529622-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Aspirin	C		ORAL		
Other	Dysphonia		Motrin	C		ORAL		
	Feeling Abnormal		Tylenol	C		ORAL		
	Heart Rate Irregular		Butalbital	C		ORAL		
	Intervertebral Disc		Guaifenex	C		ORAL		
	Protrusion		Clidinium Bromide	C		ORAL		
	Spinal Column Stenosis		Estropipate	C		ORAL		
	Spinal Cord Compression		Claritin-D	C		ORAL		
	Vocal Cord Thickening		Skelaxin	C		ORAL		
			Ketoconazole	C		ORAL		
			Prednisone	C		ORAL		
			Biaxin	C		ORAL		
			Diflucan	C				
UNKNOWN								
			Trimox	C		ORAL		

			Hydrocodone Bitartrate	C		ORAL
			Diovan	C		ORAL

Date:12/16/04ISR Number: 4529623-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00756
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Candidiasis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Prednisone	C				UNKNOWN
Other	Chest Pain		Allegra-D	C				UNKNOWN
	Crest Syndrome		Lamisil	C				UNKNOWN
	Dry Eye		Premarin	C				UNKNOWN
	Dry Mouth		Serevent	C				UNKNOWN
	Hypertension		Combivent	C				UNKNOWN
	Pituitary Tumour		Fosamax	C				UNKNOWN
	Sciatica		Calcium (Unspecified)	C				UNKNOWN
	Weight Decreased							

Date:12/16/04ISR Number: 4529624-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00007
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
Initial or Prolonged	Atrial Septal Defect		Vioxx	SS	Merck & Co., Inc	ORAL		93 DAY
Disability	Back Pain		Synthroid	C				UNKNOWN
	Bronchitis		Xanax	C				UNKNOWN
	Bursitis		Xanax	C				UNKNOWN

	Chronic Obstructive		Zoloft	C		
UNKNOWN	2 WK					
	Pulmonary Disease		Zoloft	C		
UNKNOWN	764 DAY					
	Coronary Artery Disease		Zoloft	C		
UNKNOWN						
	Depression		Tylenol	C		
UNKNOWN						
	Drug Hypersensitivity		Xalatan	C		
OPHTHALMIC						
	Drug Ineffective		Darvocet-N	C		
UNKNOWN						
	Fear		Alphagan	C		
OPHTHALMIC						
	Hypercholesterolaemia					
	Hypoxia					
	Ischaemic Stroke					
	Obstructive Airways					
	Disorder					
	Oedema Peripheral					
	Panic Disorder With					
	Agoraphobia					
	Scoliosis					
	Spondylolisthesis					
	Tendon Injury					

Date:12/16/04ISR Number: 4529632-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02282
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Synthroid	C		
UNKNOWN						
Disability			Naprosyn	C		
UNKNOWN						
			Seldane	C		
UNKNOWN						
			Tagamet	C		
UNKNOWN						
			Corticosteroids			

			(Unspecified)	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:12/16/04ISR Number: 4529633-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00026
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anoxic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Brain Damage		Betamethasone Acetate	C		PARENTERAL	1	DAY
	Cardiac Arrest							
Disability	Respiratory Arrest		Betamethasone Acetate	C		PARENTERAL	1	DAY
			Lidocaine	C		PARENTERAL	1	DAY
			Lidocaine	C		PARENTERAL	1	DAY

Date:12/16/04ISR Number: 4529634-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00302
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Migraine		Vioxx	SS	Merck & Co., Inc	ORAL		
	Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope		Fentanyl	C		TOPICAL		
	Tachycardia							
	Ventricular Extrasystoles							
	Vomiting							

Date:12/16/04ISR Number: 4529636-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02189
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		[Therapy					
	Chest Pain		Unspecified]	C				
UNKNOWN								
	Heart Rate Irregular		Zocor	C		ORAL		

Date:12/16/04ISR Number: 4529638-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00056
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebral Ischaemia		Levothyroxine Sodium	C				
UNKNOWN								
Initial or Prolonged	Memory Impairment							
	Pulmonary Oedema							

Date:12/16/04ISR Number: 4529639-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00120
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Compartment Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
594 DAY								
	Thrombosis		Allopurinol	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4529640-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00122
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ocular Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Diclofenac Sodium	C			UNKNOWN	
	Vision Blurred							

Date:12/16/04ISR Number: 4529642-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02624
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fluid Retention		Micardis Hct	C			UNKNOWN	
	Heart Rate Increased		Diovan	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	

Date:12/16/04ISR Number: 4529643-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00111
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/16/04ISR Number: 4529644-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00068
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
	Blood Creatinine							

Increased
Loss Of Consciousness
Osteoporosis
Renal Disorder
Urinary Retention

Date:12/16/04ISR Number: 4529645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00930
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/16/04ISR Number: 4529646-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01401
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Asthenia
	Back Pain
	Diarrhoea
	Dyspepsia

		Dyspnoea					
		Malignant Melanoma					
		Multiple Myeloma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Fosamax	C		ORAL
		Pneumonia		Amitriptyline			
		Respiratory Tract		Hydrochloride	C		
UNKNOWN							
		Infection		Vitamin E	C		
UNKNOWN							
		Vomiting		Ascorbic Acid	C		
UNKNOWN							

Date:12/16/04ISR Number: 4529648-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00779
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Myocardial Infarction					

Date:12/16/04ISR Number: 4529650-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00107
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/16/04ISR Number: 4529651-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00707
Age:60 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Myocardial Infarction					
		Thrombosis					
Disability							

Date:12/16/04ISR Number: 4529654-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00027
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		90 DAY

Date:12/16/04ISR Number: 4529655-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00700
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
Disability			[Therapy Unspecified]	C				UNKNOWN
			Prilosec	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/16/04ISR Number: 4529658-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00701
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 YR
Hospitalization - Initial or Prolonged								

Date:12/16/04ISR Number: 4529659-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01074
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:12/16/04ISR Number: 4530524-8Report Type:Expedited (15-DaCompany Report #WAES 0402GBR00089
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea	Foreign	Tab Vioxx					
	Fluid Retention	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oedema Peripheral	Health					PO	
		Professional	Lisinopril	C				
			Metformin	C				
			Polyethylene Glycol 3350	C				

Date:12/16/04ISR Number: 4531148-9Report Type:Expedited (15-DaCompany Report #2004CG02479
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome	Foreign	Atacand	PS				

Initial or Prolonged	Anxiety	Health	Zocor "Msd"	SS		
	Blood Pressure Systolic	Professional	Vioxx	SS		ORAL
1 DF DAILY PO						
	Increased	Other	Enbrel "Wyeth			
	Coronary Artery		Lederle"	SS	Wyeth Lederle	ORAL
1 DF DAILY PO						
	Atherosclerosis		Enbrel Wyeth			
	Coronary Artery Stenosis		Lederle"	SS	Wyeth Lederle	
SUBCUTANEOUS 25 MG BIWK SQ						
	Ejection Fraction		Oestrogel	SS		
	Decreased		Novatrex "Lederle"	SS	Lederle	
7.5 MG WEEK						
			Fosamax	C		
			Cacit D3	C		
			Duphaston	C		

Date:12/16/04ISR Number: 4531913-8Report Type:Expedited (15-DaCompany Report #2004104106
Age:67 YR Gender:Male I/FU:I

Outcome	PT
Other	Arthralgia
	Drug Ineffective
	Dyspnoea
	Eructation
	Fear
	Feeling Abnormal
	Hallucination, Visual
	Hepatic Cyst

		Hypertension Insomnia Middle Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL
200 MG (200							
		Rhinorrhoea					
MG, 1 D),							
ORAL							
				Rofecoxib (Rofecoxib)	SS		ORAL
ORAL							
				Caffeine (Caffeine)	SS		
				All Other Non-Therapeutic Products (All Other Non-Therapeutic Products)	SS		
				All Other Therapeutic Products (All Other Therapeutic Products)	SS		NASAL
NASAL							
				Naproxen (Naproxen)	SS		
1000 MG (500							
M, 2 IN 1 D)							
				Oxycocet (Oxycodone Hydrochloride, Paracetamol)	C		
				Lisinopril (Lisinopril)	C		
				Loratadine (Loratadine)	C		
				Aporex (Dextropropoxyphene Hydrochloride, Paracetamol)	C		
				Terazosin (Terazosin)	C		
				Hydrochlorothiazide (Hydrochlorothiazide)	C		
				Acetylsalicylic Acid (Acetylsalicylic			

Acid) C

Date:12/17/04ISR Number: 4530241-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Anxiety
	Arthralgia
	Back Injury
	Back Pain
	Chest Wall Pain
	Contusion
	Depression
	Drug Ineffective
	Fall
	Gastric Haemorrhage
	Haematocrit Decreased
	Joint Effusion
	Joint Injury
	Joint Sprain

		Meniscus Lesion Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
37	DAY						
				Vicodin Tablets	C		ORAL
				Clonidine	C		ORAL

Date:12/17/04ISR Number: 4530261-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01062655
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure Diastolic		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
91	DAY						
		Bundle Branch Block Right		Naproxen	C		
UNKNOWN							
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Drug Ineffective					
		Dyspepsia					
		Emotional Distress					
		Ischaemic Cardiomyopathy					
		Joint Range Of Motion Decreased					
		Musculoskeletal Stiffness					
		Myocardial Infarction					

Date:12/17/04ISR Number: 4530262-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00713
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Agitation		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Angina Pectoris		Klonopin	C		
UNKNOWN							
		Blood Pressure Increased		Celexa	C		
UNKNOWN							

	Convulsion	Prilosec	C	
UNKNOWN				
	Depression	Zantac	C	ORAL
	Headache	Vicodin Tablets	C	
UNKNOWN				
	Homicidal Ideation	Soma	C	
UNKNOWN				
	Hypoaesthesia	Fioricet Tablets	C	
UNKNOWN				
	Intervertebral Disc Protrusion	Cyclobenzaprine Hydrochloride	C	
TOPICAL				
	Irritability	Ketoprofen	C	
TOPICAL				
	Memory Impairment	Topamax	C	ORAL
	Nausea	Zanaflex	C	
UNKNOWN				
	Rotator Cuff Syndrome	Elavil	C	ORAL
	Vomiting			

Date:12/17/04ISR Number: 4530264-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Anaemia
	Angina Pectoris
	Atrial Fibrillation
	Atrioventricular Block
	Body Tinea

		Carotid Artery Stenosis					
		Coronary Artery Occlusion					
		Dermatitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diverticulum		Vioxx	PS	Merck & Co., Inc	ORAL
		Eczema					
		Epidermal Necrosis					
		Erythema Multiforme					
		Granuloma Annulare					
		Hypercholesterolaemia					
		Hypertension					
		Leukocytoclastic					
		Vasculitis					
		Myocardial Ischaemia					
		Nail Bed Bleeding					
		Onycholysis					
		Polyp					
		Pruritus Ani					
		Psoriasis					
		Renal Failure Chronic					
		Vasculitis					

Date:12/17/04ISR Number: 4530267-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA00247
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
147 DAY							
Initial or Prolonged		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
147 DAY							
Disability		Increased		Inderal	C		
UNKNOWN							
		Cerebrovascular Accident		Zyrtec	C		
UNKNOWN							
		Dyspnoea		Nasonex	C		
UNKNOWN							
		Hand Fracture		Prempro	C		
UNKNOWN							
		Hepatic Cyst		Elavil	C		
UNKNOWN							
		Obstructive Airways		Skelaxin	C		
UNKNOWN							
		Disorder		Bromfenex			
		Rash		(Brompheniramine			

	Wheezing	Maleate (+) Pseudoephedrine Hydrochloride)	C
UNKNOWN			
		Aspirin	C
UNKNOWN			
		Flexeril	C
UNKNOWN			
		Deconsal	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			

Date:12/17/04ISR Number: 4530268-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00575
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anaemia		[Therapy Unspecified]	C				
	Haemorrhage							
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530270-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04110
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Dizziness							
	Nervousness							
	Weight Decreased							

Date:12/17/04ISR Number: 4530271-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00699
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Collagen Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Laboratory Test Abnormal		Etilefrine					
	Sjogren'S Syndrome		Hydrochloride	C		ORAL		
	Vasculitis		Aspirin	C		ORAL		

Date:12/17/04ISR Number: 4530273-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02538
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Anxiety		Vicodin Tablets	C			UNKNOWN	
Other	Blood Pressure Increased		Estrogens					
	Headache		(Unspecified)	C			UNKNOWN	
	Hyperglycaemia		Effexor	C			UNKNOWN	
	Hypokalaemia		Relafen	C			UNKNOWN	
	Liver Disorder							
	Myocardial Infarction							
	Stress							
	Supraventricular Extrasystoles							

Ventricular Extrasystoles
Vulvovaginal Dryness

Date:12/17/04ISR Number: 4530275-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0207USA00488
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acne
Disability	Adverse Event
Other	Alopecia
	Blood Testosterone Decreased
	Cerebrovascular Accident
	Chronic Fatigue Syndrome
	Encephalitis Viral
	Hypertension
	Hyponatraemia
	Joint Sprain
	Mental Disorder
	Migraine
	Otitis Media
	Temporomandibular Joint Syndrome
	Transient Ischaemic

Attack
Tri-Iodothyronine Free
Increased
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Skelaxin	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Effexor Xr	C			UNKNOWN	
	Univasc	C			UNKNOWN	
	Benadryl	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Celexa	C			UNKNOWN	
	Ibuprofen	C			UNKNOWN	
	Temazepam	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Tenormin	C			UNKNOWN	
	Ativan	C			UNKNOWN	
	Ranitidine	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Meclizine	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Plavix	C			UNKNOWN	

			Neurontin	C			
UNKNOWN							
			Zithromax	C			
UNKNOWN							
			Claritin	C			
UNKNOWN							
			Amoxicillin	C			
UNKNOWN							
			Glucosamine	C			
UNKNOWN							
			Hypericin	C			
UNKNOWN							

Date:12/17/04ISR Number: 4530277-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03614
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:12/17/04ISR Number: 4530279-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00928
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Joint Dislocation		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Myocardial Infarction							
	Osteoarthritis							

Date:12/17/04ISR Number: 4530280-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00948
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysphagia		Vioxx	PS	Merck & Co., Inc	ORAL		
1213 DAY								
Initial or Prolonged	Transient Ischaemic		Prevacid	C				
UNKNOWN								
Other	Attack		Lipitor	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

				Pletal	C		
UNKNOWN							
				Vitamins (Unspecified)	C		ORAL
				Colace	C		
UNKNOWN							

Date:12/17/04ISR Number: 4530281-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00909
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY
Initial or Prolonged Disability	Hypercholesterolaemia							
	Myocardial Infarction							
	Pyrexia							

Date:12/17/04ISR Number: 4530286-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00530
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged			Prinivil	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Crestor	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/17/04ISR Number: 4530287-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00442
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	731	DAY
Hospitalization -	Blood Glucose Increased		Toprol Xl Tablets	C		ORAL		
Initial or Prolonged	Coronary Artery Occlusion		Medrol	C		ORAL		
Disability	Haematocrit Decreased		Folic Acid	C		ORAL		
Other	Haemoglobin Decreased		Neurontin	C		ORAL		
	Palpitations		Nexium	C		ORAL		

Date:12/17/04ISR Number: 4530289-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00808
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Tachycardia		Gemfibrozil	C				
UNKNOWN								
Initial or Prolonged			Bumetanide	C				
UNKNOWN								
Disability			Digoxin	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Potassium Chloride	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530291-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01217
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Faecal Incontinence							
Disability	Headache							

Date:12/17/04ISR Number: 4530293-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Increased							

Date:12/17/04ISR Number: 4530294-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00936
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Skin Irritation		Vioxx	SS	Merck & Co., Inc	ORAL		
			Diltiazem Hydrochloride	C				
			Lorazepam	C				
			Prinivil	C		ORAL		
			Atenolol	C				
			Paxil	C				
			Ambien	C				

Date:12/17/04ISR Number: 4530295-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01229
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL		
	Insomnia							

Date:12/17/04ISR Number: 4530297-9Report Type:Expedited (15-DaCompany Report #PL-MERCK-0412POL00003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Medication Error							

Date:12/17/04ISR Number: 4530303-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03573
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Carotid Artery Stenosis
	Cerebrovascular Accident
Disability	Gastrooesophageal Reflux Disease
	Hemianopia
	Hypercholesterolaemia
	Hypertension
	Productive Cough

	Pulmonary Congestion						
	Sinusitis						
	Tinnitus	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C			UNKNOWN	

Date:12/17/04ISR Number: 4530328-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01541
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Haemorrhage							

Date:12/17/04ISR Number: 4530329-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4530838-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Other	Abscess Intestinal
	Angina Unstable
	Appendicitis
	Atherosclerosis
	Chest Discomfort
	Cold Sweat
	Coronary Artery Disease
	Diverticulitis
	Dizziness

Drug Hypersensitivity
Dyspepsia
Dyspnoea
Fall
Gastritis
Hiatus Hernia
Hypercholesterolaemia
Hypertension
Injury
Joint Injury
Liver Disorder
Muscle Spasms
Myocardial Infarction
Non-Cardiac Chest Pain
Non-Hodgkin'S Lymphoma
Pharyngolaryngeal Pain
Post Laminectomy Syndrome
Pyrexia
Simple Partial Seizures
Transient Ischaemic
Attack

Tuberculosis
Vertigo Positional
Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Darvocet-N	C			UNKNOWN	
	Zantac	C			UNKNOWN	
	Metformin	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Aspirin	C			UNKNOWN	

Date:12/17/04ISR Number: 4530847-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event
	Blood Cholesterol
	Abnormal
	Bursitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cardiovascular Disorder
	Chest Wall Pain
	Confusional State
	Decreased Activity
	Drug Hypersensitivity
	Faecal Incontinence
	Fatigue
	Feeling Cold
	Fibula Fracture
	Head Injury
	Headache
	Hot Flush
	Hypertension
	Incontinence
	Intestinal Functional
	Disorder
	Kidney Infection

Laryngitis
Libido Decreased
Mood Swings
Muscle Spasms
Oedema
Osteoarthritis
Ovarian Cyst
Pelvic Pain
Pharyngolaryngeal Pain
Renal Failure
Rheumatic Fever
Rheumatoid Arthritis
Rotator Cuff Syndrome
Sleep Disorder
Stress
Tendonitis
Urinary Tract Infection
Vaginal Infection
Vaginal Odour
Vaginitis Bacterial
Varicose Vein

		Vein Disorder					
		Vertigo					
		Viral Upper Respiratory	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Visual Disturbance		Effexor	SS		
UNKNOWN							
		Vulvovaginal Discomfort		Effexor	SS		
UNKNOWN							
		Weight Increased		Osteo-Bi-Flex	C		
UNKNOWN							
				Estrace	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Flagyl	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Detrol	C		
UNKNOWN							

Date:12/17/04ISR Number: 4530855-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Arthralgia
	Balance Disorder
	Complex Partial Seizures
	Constipation
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Decreased
	Emotional Distress

Fall
Fatigue
Gingival Hyperplasia
Headache
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypernatraemia
Hypertension
Hypoacusis
Myocardial Infarction
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Otitis Media
Periarthritis
Psoriasis
Rash
Sepsis
Spinal Osteoarthritis
Synovitis
Tinnitus
Vaginal Infection
Weight Decreased
Weight Increased

Wrist Fracture

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Ms Contin	SS			UNKNOWN	
	Ms Contin	SS			UNKNOWN	
	Depakote	C			UNKNOWN	
	Tegretol	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Msir	C		ORAL		

Date:12/17/04ISR Number: 4530859-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00750
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intestinal Obstruction							
	Meningitis							
	Meningitis Viral							
	Oesophageal Disorder							
	Urinary Tract Infection							

Date:12/17/04ISR Number: 4530863-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02191
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aura		Vioxx	PS	Merck & Co., Inc	ORAL		138 DAY
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		138 DAY

	Increased	Dilantin	C
UNKNOWN			
	Carpal Tunnel Syndrome	Zoloft	C
UNKNOWN			
	Chest Discomfort Convulsion Cough Dyspnoea Emotional Distress Encephalomalacia Excoriation Feeling Abnormal Grand Mal Convulsion Headache Hypertension Intervertebral Disc Displacement Nasal Septum Deviation Nasal Turbinate Hypertrophy Nose Deformity Otitis Media Road Traffic Accident Thoracic Vertebral Fracture Tremor		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530868-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acquired Claw Toe		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial		Zocor	C		ORAL
Other	Infarction		Plavix	C		ORAL
	Angina Unstable		Lotensin	C		ORAL
	Arthropathy		Metoprolol	C		ORAL
	Back Pain		Alfentanil			
	Blood Pressure Increased		Hydrochloride	C		
UNKNOWN						
	Bursitis		[Therapy			
	Carotid Artery Stenosis		Unspecified]	C		ORAL
	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						
	Diabetes Mellitus					
	Non-Insulin-Dependent					
	Diarrhoea					
	Haemarthrosis					
	Headache					
	Monarthritis					
	Myocardial Infarction					
	Sleep Apnoea Syndrome					
	Tendonitis					

Date:12/17/04ISR Number: 4530897-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acrochordon
Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Bronchitis
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Deafness
	Depression

Diarrhoea
Dizziness
Dyspnoea
Emotional Distress
Fall
Gout
Headache
Heart Rate Irregular
Hyperglycaemia
Injury
Intervertebral Disc
Displacement
Mental Disorder
Nephrolithiasis
Oedema
Oropharyngeal Spasm
Parkinson'S Disease
Peripheral Vascular
Disorder

	Pneumothorax						
	Renal Failure						
	Sciatica	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Seborrhoeic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sleep Apnoea Syndrome		Aspirin	C		ORAL		
	Stomach Discomfort		Premarin	C		ORAL		
	Swelling Face		Prinivil	C		ORAL		
	Transient Ischaemic		Bumex	C		ORAL		
	Attack		Lamisil	C		ORAL		
	Tremor							
	Urinary Tract Infection							
	Vascular Stenosis							
	Vertigo							
	Visual Acuity Reduced							

Date:12/17/04ISR Number: 4530899-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
Initial or Prolonged	Aggression		Aspirin	C				
UNKNOWN								
Other	Arthropathy		Lipitor	C				
UNKNOWN								
	Asthenia		Metformin	C				
UNKNOWN								
	Back Pain		Prozac	C				
UNKNOWN								
	Cardiomegaly		Prilosec	C				
UNKNOWN								
	Carotid Artery Occlusion		Glucophage	C				
UNKNOWN								
	Cerebrovascular Accident		Wellbutrin	C				
UNKNOWN								
	Chest Discomfort							
	Chest Pain							
	Cholelithiasis							
	Coordination Abnormal							
	Dizziness							
	Drug Hypersensitivity							
	Fall							
	Gastrooesophageal Reflux							

Disease
Hiatus Hernia
Hypertension
Hypotension
Incontinence
Intention Tremor
Intervertebral Disc
Degeneration
Non-Cardiac Chest Pain
Respiratory Failure
Shock
Sinus Disorder
Spinal Column Stenosis
Spinal Compression
Fracture
Tongue Biting
Transient Ischaemic
Attack
Tremor
Vertigo
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530914-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Amnesia		Zantac	C			UNKNOWN	
Other	Anaemia		Reglan	C			UNKNOWN	
	Anxiety		Dicyclomine Hydrochloride	C			UNKNOWN	
	Back Pain		Procardia	C			UNKNOWN	
	Blood Pressure Increased		Vicodin Es Tablets	C			UNKNOWN	
	Bronchitis		Vicodin Es Tablets	C			UNKNOWN	
	Bursitis		Arthrotec	C			UNKNOWN	
	Cerebrovascular Accident		Ditropan Xl	C			UNKNOWN	
	Chest Pain		Adalat	C			UNKNOWN	
	Colonic Polyp		Quinine	C			UNKNOWN	
	Cyst		Crixivan	C		ORAL		
	Depression		Crixivan	C		ORAL		
	Difficulty In Walking		Combivir	C			UNKNOWN	
	Disorientation		Bactrim	C			UNKNOWN	
	Diverticulum		Allegra	C			UNKNOWN	
	Dysarthria		Diflucan	C			UNKNOWN	
	Dysstasia		Desyrel	C			UNKNOWN	
	Fall		Skelaxin	C		ORAL		
	Fracture Nonunion							
	Gastroenteritis							
	Gastrointestinal Haemorrhage							
	Genital Pruritus Female							
	Headache							
	Hip Fracture							

Hypersensitivity
Impaired Healing
Macrocytosis
Muscle Spasms
Neuropathy
Pneumonia
Polyuria
Sepsis
Syncope
Tachycardia
Tongue Discolouration
Tongue Disorder
Urinary Incontinence
Vaginal Burning Sensation
Vision Blurred

Date:12/17/04ISR Number: 4530919-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia
Other	Angioneurotic Oedema
	Bronchitis
	Chest Pain
	Constipation
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent

		Diverticulum					
		Dyspnoea					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastric Outlet		Vioxx	SS	Merck & Co., Inc	ORAL
		Obstruction					
		Haematocrit Decreased					
		Haemoglobin Decreased					
		Heart Rate Increased					
		Hypertension					
		Joint Sprain					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Oesophageal Obstruction					
		Osteoarthritis					
		Peptic Ulcer					
		Post Thrombotic Syndrome					
		Pruritus Generalised					
		Restrictive Pulmonary					
		Disease					
		Stress Incontinence					
		Tendon Disorder					
		Tendonitis					
		Tenosynovitis					
		Ventricular Dysfunction					
		Vision Blurred					

Date:12/17/04ISR Number: 4530923-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
143 DAY							
Initial or Prolonged		Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL
143 DAY							
Disability		Aneurysm		Amitriptyline			
		Cerebrovascular Accident		Hydrochloride	C		
UNKNOWN							
		Chronic Obstructive		Meclizine	C		
UNKNOWN							
		Pulmonary Disease		Darvocet-N	C		
UNKNOWN							

Colonic Polyp
Complex Regional Pain
Syndrome
Depression
Diverticulum
Dizziness
Emotional Distress
Hyperlipidaemia
Hypertension
Hypoaesthesia
Injury
Joint Dislocation
Large Cell Carcinoma Of
The Respiratory Tract
Stage Unspecified
Pneumothorax
Stress
Stress Incontinence
Ventricular Extrasystoles

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530924-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Abdominal Pain		Cozaar	C		ORAL		
	Adverse Event		Cardizem	C				
UNKNOWN								
	Anaemia		Darvocet-N	C				
UNKNOWN								
	Angina Pectoris		Ecotrin	C		ORAL		
	Anxiety		Ecotrin	C		ORAL		
	Asthenia		Premarin	C		ORAL		
	Blood Pressure Fluctuation							
	Carotid Arterial Embolus							
	Carotid Artery Stenosis							
	Carotid Bruit							
	Chest Discomfort							
	Chronic Obstructive Airways Disease Exacerbated							
	Convulsion							
	Coronary Artery Disease							
	Diverticulum Intestinal							
	Dizziness							
	Dysphagia							
	Dyspnoea							
	Essential Hypertension							
	Gastric Disorder							
	Gastric Ulcer							
	Gastrointestinal Haemorrhage							
	Headache							
	Hiatus Hernia							
	Hypertension							
	Hypoaesthesia							
	Hypochromic Anaemia							
	Lymphadenopathy							
	Monarthritis							
	Neck Mass							
	Oral Candidiasis							
	Pain In Extremity							
	Palpitations							
	Pelvic Peritoneal							

Adhesions
Peripheral Vascular
Disorder
Pharyngolaryngeal Pain
Rash Pruritic
Spinal Column Stenosis
Subcutaneous Haematoma
Transient Ischaemic
Attack
Vertebral Artery Stenosis
White Blood Cell Count
Increased

Date:12/17/04ISR Number: 4530925-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA02038
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		73 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Zantac	C				
UNKNOWN								
	Increased		Proscar	C				
UNKNOWN								
	Blood Triglycerides		Roxicet	C				
UNKNOWN								799 DAY
	Increased		Terazosin Hydrochloride	C				
	Bundle Branch Block Right							
UNKNOWN								
	Chest Discomfort							
	Chest Pain							
	Cholelithiasis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hernia							
	Hypertension							
	Myocardial Infarction							
	Nausea							
	Orthostatic Hypotension							
	Panic Disorder							
	Syncope							
	Viral Infection							

Date:12/17/04ISR Number: 4530926-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00870
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		125 DAY
Initial or Prolonged	Chest Pain		Coricidin	C				
UNKNOWN								
Other	Condition Aggravated		Allegra-D	C				
UNKNOWN								
	Cough		Flonase	C				
UNKNOWN								

	Deep Vein Thrombosis	Singulair	C
UNKNOWN			
	Dyspnoea	Elidel	C
UNKNOWN			
	Epistaxis	Westcort	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	Gynaecomastia		
	Injury		
	Pulmonary Embolism		
	Skin Ulcer		
	Sleep Apnoea Syndrome		
	Snoring		
	Thrombosis		
	Varicose Vein		
	Venous Insufficiency		
	Venous Stasis		

Date:12/17/04ISR Number: 4530930-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00601
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530931-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00688
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		[Therapy Unspecified]	C				
	Transient Ischaemic Attack							

Date:12/17/04ISR Number: 4530932-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Valsartan	C		ORAL		
			Furosemide	C		ORAL		
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Allopurinol	C		ORAL		

Date:12/17/04ISR Number: 4530933-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Emotional Distress							
	Erectile Dysfunction							
	Gallbladder Disorder							
	Gastrooesophageal Reflux Disease							
	Hepatic Failure							
	Hiatus Hernia							
	Hypertension							
	Intervertebral Disc Disorder							
	Myocardial Infarction							

Renal Disorder
Renal Failure

Date:12/17/04ISR Number: 4530935-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01739
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Adverse Event
	Anxiety
	Asbestosis
	Bronchitis
	Burning Sensation
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Sinusitis
	Coronary Artery

		Atherosclerosis					
		Coronary Artery Disease					
		Emotional Distress					
		Eye Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Steatosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Lacrimation Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Lower Respiratory Tract		Pepcid	C		
UNKNOWN							
		Infection		Aspirin	C		
UNKNOWN							
		Mitral Valve Prolapse		Flexeril	C		ORAL
		Papilloedema		Zocor	C		ORAL
		Pneumonia		[Therapy			
		Pruritus		Unspecified]	C		
UNKNOWN							
		Road Traffic Accident					
		Sinusitis					
		Upper Respiratory Tract					
		Infection					
		Ventricular Fibrillation					
		Viral Infection					

Date:12/17/04ISR Number: 4530936-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00552
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Bisoprolol	C		ORAL
		Tachyarrhythmia		Zocor	C		ORAL
				Aspirin	C		ORAL
				Isosorbide			
				Mononitrate	C		ORAL
				Torsemide	C		ORAL
				Betaxolol			
				Hydrochloride	C		ORAL
				Aspirin	C		ORAL

Date:12/17/04ISR Number: 4530938-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00173
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:12/17/04ISR Number: 4530941-6Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00029
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Temazepam	C		ORAL		
			Simvastatin	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Diazepam	C				
UNKNOWN								
			Metoprolol	C		ORAL		

Quetiapine Fumarate	C			ORAL
Quetiapine Fumarate	C			ORAL
Omeprazole	C			ORAL
Folic Acid	C			ORAL
Aspirin	C			ORAL
Naproxen	C			ORAL
Imipramine Hydrochloride	C			ORAL

Date:12/17/04ISR Number: 4530942-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01950
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
UNKNOWN								
Other								

Date:12/17/04ISR Number: 4530943-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
2 DAY								
	Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Guaifenesin	C				
UNKNOWN								
	Gastrooesophageal Reflux		Ceftin	C				
UNKNOWN								
	Disease		Aspirin	C		ORAL		
	Injury		Probeta (Dipivefrin Hydrochloride (+) Levobunolol Hydrochloride)	C				
	Meningioma							
	Myocardial Infarction							
	Paraesthesia							
OPHTHALMIC								
	Retinal Artery Occlusion		Diamox	C		ORAL		
	Wisdom Teeth Removal		Glucosamine	C		ORAL		
			Advil	C		ORAL		

Date:12/17/04ISR Number: 4530944-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00372
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Visual Acuity Reduced		Doxazosin Mesylate	C				
Disability			Aspirin	C			UNKNOWN	
			Ranitidine	C			UNKNOWN	

Date:12/17/04ISR Number: 4530946-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00407
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C			UNKNOWN	
			Plaquenil	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Vasotec	C			UNKNOWN	
			Flexeril	C			UNKNOWN	
			Effexor	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530947-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03361
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Lipitor	C				
UNKNOWN								
Initial or Prolonged	Hypertension		Atenolol	C				
UNKNOWN								
Disability								

Date:12/17/04ISR Number: 4530948-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02095
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Paxil Cr	C		ORAL		
Initial or Prolonged	Dyspnoea		Zocor	C		ORAL		
Disability	Muscle Spasms		[Therapy					
	Ventricular Hypertrophy		Unspecified]	C				
UNKNOWN								

Date:12/17/04ISR Number: 4530949-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00562
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Duodenal Ulcer		Enalapril Maleate	C				
UNKNOWN								
Initial or Prolonged	Gastric Ulcer		Hydrodiuril	C				
UNKNOWN								
Other	Gastrointestinal		Atenolol	C				
UNKNOWN								
	Haemorrhage		Aspirin	C				
UNKNOWN								

Date:12/17/04ISR Number: 4530951-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00275
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL	1634 DAY	
	Arrhythmia		Methimazole	C		ORAL		
	Cold Sweat							
	Hyperthyroidism							
	Palpitations							

Date:12/17/04ISR Number: 4530952-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00469
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pruritus		Urecholine	C		ORAL		
	Punctate Keratitis		Toprol Xl Tablets	C			UNKNOWN	
	Sensation Of Foreign Body		Famvir	C			UNKNOWN	
	Subdural Haematoma		Dilantin	C			UNKNOWN	
	Therapy Non-Responder							

Date:12/17/04ISR Number: 4530953-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02301
Age:52 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL	2	WK
	Hearing Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	30	MON
	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL	2	WK
	Impaired Work Ability							
	Myocardial Infarction							
	Pneumonia							

Date:12/17/04ISR Number: 4530954-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Hospitalization - Initial or Prolonged	Renal Artery Stenosis		[Composition Unspecified]	C				
UNKNOWN								
Disability								

Date:12/17/04ISR Number: 4530957-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00014
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Mitral Valve Disease							

Date:12/17/04ISR Number: 4530958-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02813
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Basilar Migraine		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Ischaemia		Ecotrin	SS				UNKNOWN
	Cerebrovascular Accident		Claritin-D	C				UNKNOWN
	Dizziness		Nasonex	C				UNKNOWN
	Dysstasia		Flonase	C				UNKNOWN
	Gait Disturbance							
	High Density Lipoprotein Decreased							
	Hyperhidrosis							
	Impaired Work Ability							
	Otitis Media							
	Rosacea							
	Stomach Discomfort							
	Tension Headache							
	Transient Ischaemic Attack							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530959-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03439
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:12/17/04ISR Number: 4530961-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01205
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Incision Site Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Polyp		Benicar	C				
UNKNOWN								
Initial or Prolonged	Post Procedural		A.S.A.	C				
UNKNOWN								
Disability	Haemorrhage							
Other								

Date:12/17/04ISR Number: 4530962-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01088
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased							
	Cardiac Disorder							
	Chest Discomfort							

Date:12/17/04ISR Number: 4530963-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4530965-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00014
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery		Atenolol	C		ORAL		
Other	Insufficiency		Hydrochlorothiazide	C		ORAL		
	Haemorrhagic Diathesis		Losartan Potassium	C		ORAL		
	Hypercholesterolaemia		Acetaminophen	C			UNKNOWN	
	Hypertension		Esomeprazole					
	Myocardial Infarction		Magnesium	C		ORAL		
	Myocardial Ischaemia							

Date:12/17/04ISR Number: 4530966-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0412ITA00027
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530967-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03842
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Discomfort		Nexium	C			UNKNOWN	
	Chest Pain		Clarinex	C			UNKNOWN	
	Dizziness		Aspirin	C			UNKNOWN	
	Gastrooesophageal Reflux		Cephalexin	C			UNKNOWN	
	Disease		Vitamins					
	Hypoaesthesia		(Unspecified)	C			UNKNOWN	
	Nausea							
	Paraesthesia							
	Vision Blurred							

Date:12/17/04ISR Number: 4530971-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00008
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ventricular Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Dipyrone	C		ORAL		22 DAY
			Metoclopramide	C		ORAL		22 DAY
			Aspirin	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		
			Calcium Carbonate	C			UNKNOWN	
			Alfacalcidol	C		ORAL		
			Ramipril	C		ORAL		
			Fentanyl	C			TOPICAL	
			Insulin	C			UNKNOWN	

Date:12/17/04ISR Number: 4530973-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03711
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4530974-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03738
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Inadequately Controlled		Vioxx	PS	Merck & Co., Inc	ORAL		
	Escherichia Bacteraemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Escherichia Urinary Tract Infection							
	Medication Error							

Date:12/17/04ISR Number: 4530975-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00119
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy					

Unspecified] C
UNKNOWN

Date:12/17/04ISR Number: 4530977-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		634 DAY
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		634 DAY
	Pneumonia							

Date:12/17/04ISR Number: 4530982-9Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00022
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		27 MON
Hospitalization -								
Initial or Prolonged								

Date:12/17/04ISR Number: 4530983-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01347
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cartilage Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cholelithiasis		Lanoxin	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Coumadin	C				
UNKNOWN								
Other			Toprol Xl Tablets	C				
UNKNOWN								
			Bumex	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								

Date:12/17/04ISR Number: 4530985-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01369
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4530986-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01839
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anaemia							
	Back Disorder							
	Blood Disorder							
	Cholelithiasis							
	Coagulopathy							
	Hepatitis C							
	Hypertension							
	Idiopathic							
	Thrombocytopenic Purpura							
	Liver Disorder							

Date:12/17/04ISR Number: 4530989-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01573
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cerebrovascular Accident		Prozac	C				
Initial or Prolonged UNKNOWN	Myocardial Infarction		Xanax	C				
Disability								

Date:12/17/04ISR Number: 4530992-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01343
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - UNKNOWN	Fluid Retention		Glucophage	C				
Initial or Prolonged UNKNOWN	Myocardial Infarction		Amaryl	C				
	Urinary Tract Infection							

Date:12/17/04ISR Number: 4530993-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01346
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Decreased Appetite							
	Headache							
	Malaise							

Date:12/17/04ISR Number: 4530994-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged
Disability

Date:12/17/04ISR Number: 4530995-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01328
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Hospitalization - Initial or Prolonged	Post Procedural Complication							

Date:12/17/04ISR Number: 4530996-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01817
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Dizziness Headache Increased Tendency To Bruise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4530998-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00065
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastroenteritis Viral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Glyburide	C			UNKNOWN	
	Degeneration		Flonase	C			UNKNOWN	
	Intervertebral Disc		Zyrtec	C			UNKNOWN	
	Protrusion							
	Lacunar Infarction							
	Libido Decreased							
	Nerve Injury							
	Pain In Extremity							
	Rhinitis Allergic							
	Sebaceous Hyperplasia							
	Somnolence							
	Spinal Column Stenosis							
	Stomach Discomfort							

Date:12/17/04ISR Number: 4530999-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:12/17/04ISR Number: 4531000-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01371
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Swelling							

Date:12/17/04ISR Number: 4531001-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01370
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4531011-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		373 DAY
Initial or Prolonged	Infarction		Lipitor	C				UNKNOWN
	Coronary Artery		Tranxene	C				UNKNOWN
	Atherosclerosis		Prozac	C				UNKNOWN
	Emotional Distress		Zantac	C				UNKNOWN
	Obstructive Airways Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/17/04ISR Number: 4531012-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01307
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/17/04ISR Number: 4531013-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00019
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Paresis		Levothyroxine Sodium	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Moclobemide	C		ORAL		
			Metoprolol Tartrate	C		ORAL		

Date:12/17/04ISR Number: 4531014-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Eyelid Disorder							
	Feeling Abnormal							
	Visual Disturbance							

Date:12/17/04ISR Number: 4531015-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage							
Disability								

Date:12/17/04ISR Number: 4532336-8Report Type:Expedited (15-DaCompany Report #2004047431
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Activities Of Daily
Initial or Prolonged	Living Impaired
Other	Asthenia
	Atrial Fibrillation
	Blood Electrolytes
	Decreased
	Blood Pressure Increased
	Blood Test Abnormal
	Difficulty In Walking
	Dizziness
	Drug Ineffective
	Drug Interaction
	Fatigue
	Feeling Abnormal
	Gastroenteritis Viral
	Hyperhidrosis
	Influenza Like Illness
	Malaise
	Pain
	Polymyalgia Rheumatica

Somnolence
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Tikosyn (Dofetilide)	PS		ORAL	1000 MCG (500 MCG, 2 IN 1 D), ORAL	
	Bextra	SS		ORAL	20 MG (20 MG, QD INTERVAL: EVERY DAY), ORAL	
	Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Hydrocodone (Hydrocodone)	SS				
	Diltiazem (Diltiazem)	C				
	Losartan Potassium (Losartan Potassium)	C				
	Lisinopril (Lisinopril)	C				
	Warfarin (Warfarin)	C				
	Omeprazole (Omeprazole)	C				
	Rofecoxib (Rofecoxib)	C				
	Simvastatin (Simvastatin)	C				
	Hydrocodone (Hydrocodone)	C				
	Vitamins (Vitamins)	C				

Date:12/17/04ISR Number: 4538343-3Report Type:Expedited (15-DaCompany Report #WAES 0412USA01023
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Increased	Study	Tab Vioxx	PS		ORAL 25 MG/DAILY/PO
	Chest Pain	Health Professional	Bextra	C		
	Dizziness Exertional		Magnesium	C		
	Electrocardiogram Abnormal		Vitamins	C		
	Electrocardiogram St Segment Depression					
	Fibromyalgia					
	Heart Rate Increased					
	Heart Rate Irregular					
	Hyperhidrosis					
	Nausea					
	Palpitations					
	Visual Disturbance					

Date:12/17/04ISR Number: 4538346-9Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00233
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign Study Health Professional	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
			Amlodipine Besylate	C				
			Aspirin	C				
			Bendroflumethiazide	C				
			Chondroitin Sulfate					

		Sodium (+)	C
		Cod Liver Oil	C

Date:12/17/04ISR Number: 4538358-5Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00038
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive	Foreign	Tab Vioxx					
	Haematemesis	Study	(Rofecoxib)	PS		ORAL	25 MG/ BID PO	
	Myocardial Infarction	Other	Aspirin	SS		ORAL	75 MG/ PO	
			Blinded Therapy	C				
			Diltiazem Hydrochloride	C				

Date:12/20/04ISR Number: 4531794-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00857
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Zyrtec	C		ORAL		
Other	Arthralgia							
	Back Pain							
	Blood Pressure Increased							
	Bronchitis							
	Chest Discomfort							
	Fall							
	Fatigue							
	Foot Fracture							
	Headache							
	Hypersensitivity							
	Hypertension							
	Impaired Healing							
	Muscle Spasms							
	Neck Pain							
	Nerve Compression							
	Neuropathy							
	Pharyngitis							
	Pleurisy							

Polytraumatism
Tachycardia
Upper Respiratory Tract Infection
Urinary Tract Infection
Viral Infection

Date:12/20/04ISR Number: 4531800-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03146
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Death	Anticoagulant Therapy
Life-Threatening	Balance Disorder
Hospitalization - Initial or Prolonged	Cardiac Arrest
Disability	Dizziness
	Dyspnoea
	Epistaxis
	Fatigue
	Loss Of Consciousness
	Lung Disorder

		Myocardial Infarction					
		Plasma Viscosity Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post Procedural		Vioxx	PS	Merck & Co., Inc	ORAL
		Complication		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Syncope		Coumadin	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Digitek	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Advair	C		
UNKNOWN							

Date:12/20/04ISR Number: 4531801-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL
4 DAY						
Initial or Prolonged	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY						
Disability	Angina Unstable		Celebrex	C		
UNKNOWN	4 DAY					
	Asthenia		Aspirin	C		
UNKNOWN						
	Cardiac Aneurysm		Lipitor	C		
UNKNOWN						
	Coronary Artery		Toprol Xl Tablets	C		
UNKNOWN						
	Atherosclerosis		Plavix	C		
UNKNOWN						
	Coronary Artery Disease		Pyridoxine	C		
UNKNOWN						

	Coronary Artery Occlusion	Folic Acid	C
UNKNOWN			
	Depression	Xanax	C
UNKNOWN			
	Drug Hypersensitivity	Wellbutrin	C
UNKNOWN			
	Ecchymosis	Lopressor	C
UNKNOWN			
	Groin Pain		
	Haematoma		
	Insomnia		
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Panic Disorder		
	Patellofemoral Pain		
	Syndrome		
	Tendonitis		
	Traumatic Arthropathy		
	Tricuspid Valve		
	Incompetence		
	Vision Blurred		

Date:12/20/04ISR Number: 4531802-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00640
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Upper
Disability	Adrenal Adenoma
Other	Adrenal Cyst
	Adverse Event
	Arterial Occlusive
	Disease
	Arthralgia
	Back Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Pressure Increased					
		Blood Triglycerides Increased					
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
		Cellulitis		Detrol	C		
UNKNOWN							
		Chest Pain		Prevacid	C		
UNKNOWN							
		Cholecystitis		Claritin-D	C		
UNKNOWN							
		Cholelithiasis		Premarin	C		
UNKNOWN							
		Depression		Maxzide	C		
UNKNOWN							
		Dilatation Atrial		Xanax	C		
UNKNOWN							
		Dizziness		Aspirin	C		
UNKNOWN							
		Dyspnoea		Nitropatch	C		
UNKNOWN							
		Flatulence		Lasix (Furosemide)	C		
UNKNOWN							
		Gastrooesophageal Reflux		Cipro	C		
UNKNOWN							
		Disease		Propulsid	C		
UNKNOWN							
		Glucose Tolerance		Prilosec	C		
UNKNOWN							
		Impaired					
		Haemorrhoids					
		Hepatic Steatosis					
		Incontinence					
		Joint Swelling					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Nasopharyngitis					
		Osteoarthritis					
		Poor Peripheral Circulation					
		Productive Cough					
		Vaginal Infection					
		Ventricular Hypertrophy					

Date:12/20/04ISR Number: 4531805-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accidental Needle Stick
	Adnexa Uteri Mass
	Anxiety
	Atelectasis
	Blood Pressure Decreased
	Cellulitis
	Coronary Artery Disease
	Cystitis
	Depression
	Emotional Distress
	Eyelid Ptosis
	Haemangioma
	Haematuria
	Macular Degeneration
	Myocardial Infarction
	Oedema Peripheral
	Osteoporosis
	Postnasal Drip
	Radiculopathy
	Renal Failure
	Sinus Bradycardia
	Sinusitis
	Spinal Column Stenosis

		Spinal Osteoarthritis Urethritis Visual Disturbance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							

Date:12/20/04ISR Number: 4531806-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02301
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Infarction		Meperidine			
Initial or Prolonged		Atherosclerosis		Hydrochloride	C		
UNKNOWN							
		Coma		Cytotec	C		
UNKNOWN							
		Coronary Artery		Celebrex	C		
UNKNOWN							
		Thrombosis		Acetaminophen	C		
UNKNOWN							
		Erectile Dysfunction		Oxycontin	C		
UNKNOWN							
		Intervertebral Disc		Neurontin	C		
UNKNOWN							
		Protrusion		Doxycycline	C		
UNKNOWN							
		Lung Infiltration		Valium	C		
UNKNOWN							

Pain Viagra C
UNKNOWN 406 DAY
Prostatitis

Date:12/20/04ISR Number: 4531807-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00918
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Anxiety
	Bereavement Reaction
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Sodium Decreased
	Coronary Artery Occlusion
	Dyspepsia
	Dyspnoea
	Emotional Distress
	Fatigue
	Haemoglobin Decreased
	High Density Lipoprotein Increased
	Hyperhidrosis
	Impaired Work Ability
	Low Density Lipoprotein Decreased
	Mitral Valve Incompetence
	Myocardial Infarction
	Nausea
	Post Procedural Complication

		Sluggishness					
		Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Dyskinesia		Vioxx	PS	Merck & Co., Inc	ORAL
32	DAY						
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
32	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:12/20/04ISR Number: 4531808-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01449
Age:52 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Pain					
Disability		Bundle Branch Block Left					
Other		Cardiomyopathy					
		Condition Aggravated					
		Congestive Cardiomyopathy					
		Dizziness					
		Dyspnoea					
		Ejection Fraction Decreased					
		Intervertebral Disc Protrusion					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Osteopenia					
		Palpitations					
		Supraventricular Extrasystoles					
		Tricuspid Valve Incompetence					
		Ventricular Hypokinesia					

Date:12/20/04ISR Number: 4531809-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01716
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged	Angina Unstable
Other	Asthma
	Bronchitis
	Cardiac Valve Disease
	Chest Pain
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Depression
	Diarrhoea
	Dyspnoea
	Gastrooesophageal Reflux
	Disease
	Haematoma
	Hyperhidrosis
	Myocardial Infarction
	Nausea

		Oedema Peripheral Viral Infection					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Glipizide	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Proventil	C		
RESPIRATORY							
(INHALATION)							
				Albuterol	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Antimicrobial (Unspecified)	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							

Date:12/20/04ISR Number: 4531813-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00604
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arthralgia		Ginkgo Biloba			
Initial or Prolonged	Cardiac Disorder		Extract	C		
UNKNOWN						
	Cardiovascular Disorder		Calcium Citrate And			
	Hypertension		Cholecalciferol	C		
UNKNOWN						
	Hypertensive Crisis		Nexium	C		
UNKNOWN						
	Pain In Extremity					

Date:12/20/04ISR Number: 4531815-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00087
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	C-Reactive Protein		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Increased		Zopiclone	C				
UNKNOWN								
Hospitalization -	General Physical Health		Quinapril					
Initial or Prolonged	Deterioration		Hydrochloride	C				
UNKNOWN								
	Intestinal Infarction		Opipramol					
	Leukocytosis		Hydrochloride	C				
UNKNOWN								
	Multi-Organ Failure		Esomeprazole					
			Magnesium	C				
UNKNOWN							32	DAY

Date:12/20/04ISR Number: 4531817-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00384
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amputation Revision		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coagulopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Diabetes Mellitus		Coumadin	C				
UNKNOWN								
	Impaired Healing		Vitamins					
	Intermittent Claudication		(Unspecified)	C				
UNKNOWN								
	Leg Amputation							
	Peripheral Vascular							
	Disorder							
	Post Procedural							
	Complication							
	Skin Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4531818-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Dysthymic Disorder		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Fall							
	Fibromyalgia							
	Gravitational Oedema		Premarin	C			UNKNOWN	
	Hypertension		[Therapy Unspecified]	C			UNKNOWN	
	Increased Tendency To							
	Bruise		Neurontin	C			UNKNOWN	
	Lacunar Infarction		Lasix (Furosemide)	C			UNKNOWN	
	Lower Respiratory Tract		Actonel	C			UNKNOWN	
	Infection		Vitamin E	C			UNKNOWN	
	Migraine		Calcium Carbonate	C			UNKNOWN	
	Neuralgia		Aspirin	C		ORAL		
	Oedema Peripheral		Paxil	C		ORAL		
	Osteopenia		Elavil	C		ORAL		
	Osteoporosis		Oxycontin	C			UNKNOWN	
	Pain In Extremity		Vicodin Tablets	C			UNKNOWN	

	Radius Fracture		Vitamins			
	Renal Disorder		(Unspecified)	C		
UNKNOWN						
	Rotator Cuff Syndrome					
	Sinusitis					
	Spinal Osteoarthritis					
	Stress					
	Tendonitis					
	Urinary Tract Infection					

Date:12/20/04ISR Number: 4531823-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02021
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Meningitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Muscle Spasms							
	Rash							
	Rectal Haemorrhage							
	Syncope							

Date:12/20/04ISR Number: 4531824-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00631
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Alcoholism
Other	Anxiety
	Back Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Cholesterol Increased					
		Blood Triglycerides Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Cerebrovascular Accident		Advil	C		
UNKNOWN							
		Chest Pain		A.S.A.	C		
UNKNOWN							
		Chronic Obstructive Pulmonary Disease		A.S.A.	C		ORAL
				A.S.A.	C		
UNKNOWN							
		Costochondritis		Ulcerin (Cimetidine)	C		ORAL
		Cough		Ulcerin (Cimetidine)	C		ORAL
		Disorientation		Zestril	C		
UNKNOWN							
		Drug Tolerance Increased		Plavix	C		
UNKNOWN							
		Dry Mouth Fatigue		Agyrax (Meclizine Hydrochloride)	C		
UNKNOWN							
		Feeling Abnormal Gastrooesophageal Reflux		Agyrax (Meclizine Hydrochloride)	C		
UNKNOWN							
		Disease		Elavil	C		
UNKNOWN							
		Headache Hemiparesis		Trazodone Hydrochloride	C		
UNKNOWN							
		Hypertension		Protonix	C		
UNKNOWN							
		Hypoaesthesia Oral		Protonix	C		
UNKNOWN							
		Hypotension		Protonix	C		
UNKNOWN							
		Increased Upper Airway		Zocor	C		
UNKNOWN							
		Secretion		Zocor	C		
UNKNOWN							
		Insomnia		Carafate	C		
UNKNOWN							
		Mitral Valve Incompetence		Lipitor	C		
UNKNOWN							
		Monoplegia		Hydrochlorothiazide	C		
UNKNOWN							

	Multiple Sclerosis	Hydrochlorothiazide	C
UNKNOWN			
	Musculoskeletal Chest	Ecotrin	C
UNKNOWN			
	Pain	Ecotrin	C
UNKNOWN			
	Nuclear Magnetic	Nexium	C
UNKNOWN			
	Resonance Imaging Brain	Nexium	C
UNKNOWN			
	Abnormal	Aminophylline	C
UNKNOWN			
	Pain		
	Painful Respiration		
	Pharyngolaryngeal Pain		
	Pleurisy		
	Sinus Bradycardia		
	Tobacco Abuse		
	Transient Ischaemic		
	Attack		
	Upper Respiratory Tract		
	Infection		
	Vision Blurred		

Date:12/20/04ISR Number: 4531830-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03988
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Lasix (Furosemide)	C		
UNKNOWN						
Other	Parathyroid Tumour Benign		Diovan	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4531831-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02019
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hypertension		Bisoprolol	C				
UNKNOWN								
	Pain In Extremity		Diovan	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								
			Metformin	C				
UNKNOWN								

Date:12/20/04ISR Number: 4531832-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00710
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arteriosclerosis		Levothroid	C				
UNKNOWN								
Initial or Prolonged	Basilar Artery Stenosis							
	Cerebrovascular Accident							

Date:12/20/04ISR Number: 4531833-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00606
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Flutter		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Thrombosis							

Date:12/20/04ISR Number: 4531835-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03146
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Bypass Operation		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged		Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
8 DAY							
Disability		Drug Ineffective		Darvocet-N	C		
UNKNOWN							
		Hypoaesthesia		Diovan	C		
UNKNOWN							
		Impaired Work Ability		Hydrochlorothiazide	C		
UNKNOWN							
		Obstruction		Atenolol	C		
UNKNOWN							
		Pain In Extremity		Naprosyn	C		
UNKNOWN							
		Peripheral Vascular		Flexeril	C		ORAL
		Disorder		Celebrex	C		
UNKNOWN							
		Plantar Fasciitis					

Date:12/20/04ISR Number: 4531836-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00089
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
		Circulatory Collapse		Diazepam	C		
UNKNOWN							
		Convulsion		Acetaminophen	C		
UNKNOWN							
		Disturbance In Attention					
		Feeling Abnormal					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4531838-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1127 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		1127 DAY
	Arthropathy		Viagra	C				UNKNOWN
	Condition Aggravated		Amoxicillin	C				UNKNOWN
	Coronary Artery Disease		Plavix	C				UNKNOWN
	Depression		Ambien	C				UNKNOWN
	Ejection Fraction Decreased		Trazodone Hydrochloride	C				UNKNOWN
	Erectile Dysfunction		Ibuprofen	C				UNKNOWN
	Hypercholesterolaemia		Zanaflex	C				UNKNOWN
	Hypertension		Altace	C				UNKNOWN
	Laceration		Diazepam	C				UNKNOWN
	Peroneal Nerve Palsy		Hydrocodone Bitartrate	C				UNKNOWN
	Pleuritic Pain		Hydrocodone Bitartrate	C			14 MON	UNKNOWN
			Oxycontin	C			14 MON	UNKNOWN

Date:12/20/04ISR Number: 4531840-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01000
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4531842-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01547
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4531843-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01539
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4531845-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532360-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00025
Age:79 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Fluid Retention Lung Disorder

Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Metoprolol Tartrate	C			UNKNOWN	
	Levothyroxine Sodium	C			UNKNOWN	
	Simvastatin	C		ORAL		

Date:12/20/04ISR Number: 4532363-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00024
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	816	DAY

Date:12/20/04ISR Number: 4532364-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00026
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Paraesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	14	DAY
Initial or Prolonged								

Date:12/20/04ISR Number: 4532375-7Report Type:Expedited (15-DaCompany Report #PR-MERCK-0412USA01317
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:12/20/04ISR Number: 4532377-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01351
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1148 DAY
Life-Threatening	Death		Fosamax	C		ORAL		
Hospitalization -	Hypertension		Plavix	C				UNKNOWN
Initial or Prolonged			Detrol	C				UNKNOWN
			Vasotec	C		ORAL		
			Aricept	C				UNKNOWN
			Cyanocobalamin	C				PARENTERAL
			Evista	C				UNKNOWN
			Meclizine	C				UNKNOWN
			Zithromax	C				UNKNOWN
			Sudafed	C				UNKNOWN
			Robitussin-Dm	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:12/20/04ISR Number: 4532380-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00029
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		1370 DAY
Initial or Prolonged	Angina Pectoris		Acetaminophen	C				UNKNOWN
Disability	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532382-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01336
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cystitis							
Disability								

Date:12/20/04ISR Number: 4532383-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01382
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:12/20/04ISR Number: 4532384-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01340
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Zoloft	C				UNKNOWN
Initial or Prolonged			Hydrochlorothiazide	C				UNKNOWN
Disability								

Date:12/20/04ISR Number: 4532385-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:12/20/04ISR Number: 4532389-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532391-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532392-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01614
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532394-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01611
Age:81 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arterial Occlusive Disease		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Unspecified]	C				
UNKNOWN								
	Dyspnoea							

Date:12/20/04ISR Number: 4532395-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01600
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Joint Swelling		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Thrombosis							
Disability								

Date:12/20/04ISR Number: 4532396-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01582
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/20/04ISR Number: 4532398-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01375
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532399-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00219
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder	Professional	Novolin R	C				
UNKNOWN								
Initial or Prolonged	Coronary Artery Disease		Morphine	C				
UNKNOWN								
Other	Diabetes Mellitus		Alprazolam	C				
UNKNOWN								
	Non-Insulin-Dependent		Nexium	C				
UNKNOWN								
	Drug Dependence							
	Electrocardiogram Q Wave Abnormal							
	Gastrooesophageal Reflux Disease							
	Myocardial Infarction							
	Sleep Apnoea Syndrome							
	Visual Disturbance							

Date:12/20/04ISR Number: 4532400-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01634
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
Initial or Prolonged	Transient Ischaemic		Plavix	C				
UNKNOWN								
Disability	Attack		Zocor	C		ORAL		
			Altace	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532402-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01627
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	5 YR
Initial or Prolonged			Hydrochlorothiazide	C			UNKNOWN	
Disability			Synthroid	C			UNKNOWN	

Date:12/20/04ISR Number: 4532404-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01626
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sick Sinus Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532409-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532410-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532411-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
2 YR							

Date:12/20/04ISR Number: 4532413-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532414-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01759
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532415-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01697
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532416-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01821
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Coumadin	C				
UNKNOWN								
Initial or Prolonged	Stomach Discomfort		Cozaar	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/20/04ISR Number: 4532418-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01700
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532419-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532424-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01919
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiogenic Shock		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Premarin	C				
UNKNOWN								
			Maxzide	C				
UNKNOWN								

			Prilosec	C		
UNKNOWN						

Date:12/20/04ISR Number: 4532425-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01757
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/20/04ISR Number: 4532427-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Injury							
	Myocardial Infarction							

Date:12/20/04ISR Number: 4532428-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Guaifenesin	C			UNKNOWN	
	Gastrooesophageal Reflux		Ceftin	C			UNKNOWN	
	Disease		Aspirin	C		ORAL		
	Meningioma		Probeta (Dipivefrin					
	Myocardial Infarction		Hydrochloride (+)					
	Paraesthesia		Levobunolol					
	Retinal Artery Occlusion		Hydrochloride)	C			OPHTHALMIC	
	Tooth Disorder		Diamox	C		ORAL		
			Glucosamine	C		ORAL		
			Advil	C		ORAL		

Date:12/20/04ISR Number: 4532429-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01806
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Disability	Dyspnoea		Norvasc	C			UNKNOWN	
	Prescribed Overdose							

Date:12/20/04ISR Number: 4532430-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01976
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532432-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01948
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thrombosis		Depakote	C				
UNKNOWN								
Initial or Prolonged	Uterine Cancer		Allopurinol	C				
UNKNOWN								
Disability			Synthroid	C				
UNKNOWN								
			Lexapro	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/20/04ISR Number: 4532433-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02040
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532434-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01990
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532435-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01941
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aciphex	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Clonidine	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	

Date:12/20/04ISR Number: 4532437-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety	Health	Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
Initial or Prolonged	Back Injury	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
Disability	Benign Prostatic		Meclizine	C			UNKNOWN	
Other	Hyperplasia		Deconamine	C			UNKNOWN	
	Bladder Neck Sclerosis		Aciphex	C			UNKNOWN	

	Cerebrovascular Accident	Lisinopril	C
UNKNOWN			
	Chest Pain		
	Dizziness		
	Haemolysis		
	Haemorrhoidal Haemorrhage		
	Hyperkalaemia		
	Hyperlipidaemia		
	Hypersensitivity		
	Hypertension		
	Liver Function Test		
	Abnormal		
	Oedema Peripheral		
	Palpitations		
	Renal Failure Acute		
	Rheumatoid Arthritis		
	Rhinitis Allergic		
	Stress		
	Tooth Abscess		
	Urethral Stricture		
	Urticaria		
	Vertigo		

Date:12/20/04ISR Number: 4532440-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Anaemia
Other	Angle Closure Glaucoma
	Cholelithiasis

	Dehydration						
	Faeces Discoloured						
	Headache	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms	Health	Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Myocardial Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
	Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
	Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
	Renal Artery		Vioxx	SS	Merck & Co., Inc	ORAL	
	Atherosclerosis		Tiazac	C			UNKNOWN
	Renal Artery Stenosis		Advil	C			UNKNOWN
	Renal Failure Chronic						
	Wound Infection						
	Staphylococcal						

Date:12/20/04ISR Number: 4532441-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00654
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Lower	Health	Vioxx	PS	Merck & Co., Inc	ORAL	2 MON
Initial or Prolonged	Angina Pectoris	Professional	Avalide	C			UNKNOWN
	2 MON						
Other	Anxiety		Prilosec	C			UNKNOWN
	Arthropod Sting		Synthroid	C		ORAL	
	Blister		Aspirin	C			UNKNOWN
	Bronchitis		Pyridoxine	C			UNKNOWN
	Bronchitis Acute		Vitamin E	C			UNKNOWN
	Cardiac Failure						
	Congestive						
	Carpal Tunnel Syndrome						
	Cellulitis						
	Deep Vein Thrombosis						

Epistaxis
Hypertension
Insomnia
Nasopharyngitis
Nephropathy
Renal Failure Chronic
Skin Cancer
Tinnitus
Tonsillar Disorder
Urinary Tract Infection

Date:12/20/04ISR Number: 4532442-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Aortic Aneurysm
Other	Atelectasis
	Blood Pressure Fluctuation
	Bronchitis
	Cardiomegaly
	Cataract
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Chronic Sinusitis
	Colon Cancer

		Coronary Artery Disease					
		Deep Vein Thrombosis					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysphagia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Ecchymosis		Aspirin	SS		ORAL
		Emotional Distress		Dyazide	C		
UNKNOWN							
		Essential Tremor		Oxybutynin	C		ORAL
		Faeces Discoloured		Propranolol			
		Fibromyalgia		Hydrochloride	C		
UNKNOWN							
		Fluid Overload		Isosorbide	C		
UNKNOWN							
		Gastric Ulcer Haemorrhage		Hyzaar	C		ORAL
		Gastritis		Ciprofloxacin	C		
UNKNOWN							
		Gastroenteritis Viral		Ciprofloxacin	C		
UNKNOWN							
		Gastrointestinal		Albuterol	C		
RESPIRATORY							
		Haemorrhage					
(INHALATION)							
		Hypertension		Nitroglycerin	C		
UNKNOWN							
		Iron Deficiency Anaemia		Ativan	C		ORAL
		Macular Degeneration		Quinine	C		
UNKNOWN							
		Myocardial Infarction					
		Oesophageal Pain					
		Osteoarthritis					
		Osteoporosis					
		Pseudoexfoliation Of Lens					
		Capsule					
		Pyrexia					
		Renal Cyst					
		Rheumatic Fever					
		Rhinitis Allergic					
		Stress Incontinence					
		Venous Stasis					
		Vertigo					
		Weight Decreased					

Date:12/20/04ISR Number: 4532445-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01966
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Contusion		Atenolol	C				
UNKNOWN								
Initial or Prolonged	Haemorrhage		Lexapro	C				
UNKNOWN								
Disability								

Date:12/20/04ISR Number: 4532447-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Lower
Disability	Back Pain
Other	Cardiac Murmur
	Chest Wall Pain
	Constipation
	Diarrhoea
	Dry Skin
	Emotional Distress
	Fear
	Flank Pain
	Frequent Bowel Movements

		Gastrooesophageal Reflux Disease					
		Haematuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemochromatosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhoids	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Antimicrobial			
		Hirsutism		(Unspecified)	C		
UNKNOWN							
		Injury		Analgesic Or			
		Intervertebral Disc		Anesthetic			
		Protrusion		(Unspecified)	C		
UNKNOWN							
		Lactose Intolerance		Butalbital	C		
UNKNOWN							
		Musculoskeletal Pain					
		Myocardial Infarction					
		Nausea					
		Neck Pain					
		Non-Cardiac Chest Pain					
		Pharyngolaryngeal Pain					
		Pyrexia					
		Rectal Haemorrhage					
		Sinusitis					
		Skin Discolouration					
		Skin Striae					
		Thyroid Neoplasm					
		Vision Blurred					
		Vomiting					
		Weight Increased					
		Weight Loss Poor					

Date:12/20/04ISR Number: 4532449-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01452
Age:70 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Lasix (Furosemide)	C		
UNKNOWN		1218 DAY					
Disability		Blood Glucose Abnormal		Tagamet	C		
UNKNOWN							
		Cardiac Failure		Estropipate	C		
UNKNOWN		3956 DAY					
		Congestive		Potassium			

	Cerebrovascular Accident	(Unspecified)	C
UNKNOWN			
	Cholelithiasis	Drixoral	C
UNKNOWN			
	Clostridium Colitis	Elavil	C
UNKNOWN			
	Cognitive Disorder	Tiazac	C
UNKNOWN			
	Colon Neoplasm	Hydrochlorothiazide	C
UNKNOWN			
	Decubitus Ulcer	Iron (Unspecified)	C
UNKNOWN			
	Depression	Cyanocobalamin	C
UNKNOWN			
	Diverticulitis	Aspirin	C
UNKNOWN			
	Electrolyte Imbalance	Ascorbic Acid	C
UNKNOWN			
	Emotional Distress	Vitamin E	C
UNKNOWN			
	Fall	Magnesium	
	Femur Fracture	(Unspecified)	C
UNKNOWN			
	Gastritis Erosive	Calcium	
	Insomnia	(Unspecified)	C
UNKNOWN			
	Obesity	Drixoral	C
UNKNOWN			
	Pneumatosis Cystoides Intestinalis		
	Pneumonitis		
	Rash		
	Reflux Oesophagitis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532450-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
Disability	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
	Back Pain		Zestril	C				
UNKNOWN								2170 DAY
	Benign Prostatic Hyperplasia		Zestril	C				
UNKNOWN								2170 DAY
			Tenormin	C				
UNKNOWN								
	Cardiac Failure		Tenormin	C				
UNKNOWN								
	Congestive		Glucophage	C				
UNKNOWN								
	Chest Pain		Micronase	C				
UNKNOWN								
	Coronary Artery Disease		Lanoxin	C				
UNKNOWN								1051 DAY
	Coronary Artery Restenosis		[Therapy Unspecified]	C				
UNKNOWN								
	Depression		Aciphex	C				
UNKNOWN								
	Diabetes Mellitus Non-Insulin-Dependent							
	Diabetic Nephropathy							
	Diabetic Neuropathy							
	Diabetic Retinopathy							
	Drug Ineffective							
	Fall							
	Hepatitis							
	Herpes Zoster							
	Hypercholesterolaemia							
	Infection							
	Intervertebral Disc Disorder							

Ischaemic Cardiomyopathy
Oedema Peripheral
Pneumonia
Sepsis
Sexual Dysfunction
Weight Increased

Date:12/20/04ISR Number: 4532453-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Combipatch	C				
Disability	Hypertension		Minocycline	C			UNKNOWN	
	Myocardial Infarction		Aspirin	C			UNKNOWN	
	Tendonitis		Ibuprofen	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Diazepam	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532454-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00636
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		479 DAY
Initial or Prolonged	Thrombosis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Isosorbide Dinitrate	C				UNKNOWN
			Allopurinol	C				UNKNOWN
			Furosemide	C				UNKNOWN
			Magnesium Aspartate	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Atorvastatin Calcium	C				UNKNOWN

Date:12/20/04ISR Number: 4532456-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00094
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy	Health	Vioxx	PS	Merck & Co., Inc	ORAL		223 DAY
Hospitalization -	Anxiety	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Cardio-Respiratory Arrest		Toprol Xl Tablets	C				UNKNOWN
	Chronic Obstructive		Toprol Xl Tablets	C				UNKNOWN
	Pulmonary Disease		Norvasc	C				UNKNOWN
	Convulsion		Norvasc	C				UNKNOWN
	Coronary Artery Disease		Claritin-D	C		ORAL		
	Cough		Tylenol	C				UNKNOWN
	Dyslipidaemia		Wellbutrin Sr	C				UNKNOWN

	Emotional Distress	Albuterol	C
UNKNOWN			
	Insomnia	Norflex	C
UNKNOWN			
	Malaise	Norflex	C
UNKNOWN			
	Myocardial Infarction	Naprosyn	C
UNKNOWN			
	Obesity	Naprosyn	C
UNKNOWN			
	Pneumonia		
	Pyrexia		
	Respiratory Failure		
	Upper Respiratory Tract Infection		
	Ventricular Fibrillation		

Date:12/20/04ISR Number: 4532461-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00394
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532462-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00054
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Pulmonary Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532463-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02784
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Other	Vioxx	PS	Merck & Co., Inc	ORAL		1542 DAY
Hospitalization -	Pain		Coumadin	C				UNKNOWN
Initial or Prolonged			Diovan	C				UNKNOWN
Disability			Fosamax	C		ORAL		
			Coreg	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Zocor	C		ORAL		
			Pravacol	C				UNKNOWN

Date:12/20/04ISR Number: 4532466-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00809
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -		Professional	Lisinopril	C				UNKNOWN
Initial or Prolonged			Vicodin Tablets	C		ORAL		
Other								

Date:12/20/04ISR Number: 4532467-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02511
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Hospitalization -	Cerebrovascular Accident	Professional	Prinivil	C				UNKNOWN
Initial or Prolonged	Chest Pain		Plavix	C				UNKNOWN

Disability	Myocardial Infarction		Glucophage	C
UNKNOWN				
			Vicodin Tablets	C
UNKNOWN				
			Aggrenox	C
UNKNOWN				
			Bextra	C
UNKNOWN				

Date:12/20/04ISR Number: 4532469-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00530
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction	Professional						

Date:12/20/04ISR Number: 4532470-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00055
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metformin Hydrochloride	C				
UNKNOWN								
			Lansoprazole	C				
UNKNOWN								
			Lithium Carbonate	C				
UNKNOWN								

Date:12/20/04ISR Number: 4532471-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00115
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	412 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	412 DAY	
			Allopurinol	C			UNKNOWN	
			Salix	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Magnesium Oxide	C			UNKNOWN	
			Dipyrone	C			UNKNOWN	
			Benserazide Hydrochloride And Levodopa	C			UNKNOWN	

Date:12/20/04ISR Number: 4532472-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03671
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abdominal Pain Upper	Health	Vioxx	PS	Merck & Co., Inc	ORAL	97 DAY	
	Bronchitis	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Norvasc	C			UNKNOWN	
	Rectal Haemorrhage		Atenolol	C			UNKNOWN	

Date:12/20/04ISR Number: 4532473-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00029
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		

	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebral Ischaemia					
	Cerebrovascular Accident					
	Electroencephalogram					
	Abnormal					
	Epilepsy					
	Meningioma					
	Nuclear Magnetic					
	Resonance Imaging Brain					
	Abnormal					

Date:12/20/04ISR Number: 4532478-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00109
Age:79 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Transient Ischaemic					
	Attack					

Date:12/20/04ISR Number: 4532481-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00014
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Surgery					
	Hypercholesterolaemia					
	Mitral Valve Disease					
	Mitral Valve Repair					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4532482-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00129
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Left Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema		Amlodipine Besylate	SS		ORAL		
	Tachyarrhythmia							

Date:12/20/04ISR Number: 4532487-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00015
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532488-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Palpitations							

Date:12/20/04ISR Number: 4532489-1Report Type:Expedited (15-DaCompany Report #CN-MERCK-0412CHN00024
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tinnitus							

Date:12/20/04ISR Number: 4532491-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01954
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/20/04ISR Number: 4532496-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03655
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY	
	Deafness		Vioxx	SS	Merck & Co., Inc	ORAL	60 DAY	
	Gastritis		Accupril	C		ORAL		
	Hypertension		Hydrochlorothiazide	C		ORAL		
	Musculoskeletal Stiffness		Norvasc	C				
UNKNOWN							255 DAY	
	Oedema Peripheral							
	Tinnitus							
	Vision Blurred							

Date:12/20/04ISR Number: 4532505-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02212
Age:63 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Aortic Dissection		Prilosec	C				UNKNOWN
Hepatic Function Abnormal		Avalide	C				UNKNOWN
Renal Cyst		Pravachol	C				UNKNOWN
Splenomegaly		Quinine Sulfate	C				UNKNOWN
		Toprol Xl Tablets	C				UNKNOWN
		Norvasc	C				UNKNOWN
		Melatonin	C				UNKNOWN
		Glucotrol Xl	C				UNKNOWN
		A.S.A.	C				UNKNOWN

Date:12/20/04ISR Number: 4532623-3Report Type:Direct Company Report #CTU 234632
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemia		'Vioxx 25 Mg/D-Merck	PS	Merck	ORAL	25 MG ONE QD PO	

Date:12/20/04ISR Number: 4532866-9Report Type:Direct Company Report #CTU 234712
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Drug Reaction		Vioxx Unknown					
	Arthralgia		Unknown	PS		ORAL	1 TAB/2 TAB	

Disability	Drug Tolerance Increased						
DAY/1WK/2							
	Fibromyalgia						
WK ORAL							
	Muscle Spasms		Wellbutrin				
	Myalgia		Unknown	Unknown	SS		ORAL
1 TAB DAY							
	Pruritus						
ORAL							
	Urticaria		Morphine		C		
			Antidepressants		C		

Date:12/20/04ISR Number: 4532962-6Report Type:Direct Company Report #CTU 234711
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure		Vioxx Merck	PS	Merck	
Hospitalization -	Myocardial Infarction		Viagra 25 Mg			
Initial or Prolonged			Pfizer	SS	Pfizer	
			Coumadin	C		
			Fioricet	C		
			Norvasc	C		

Date:12/20/04ISR Number: 4532986-9Report Type:Direct Company Report #CTU 234704
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dyspepsia		Vioxx .25	PS		
1 A DAY						
	Muscle Disorder					
	Palpitations					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/20/04ISR Number: 4533360-1Report Type:Direct Company Report #CTU 234634
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS			25 MLG	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Transient Ischaemic Attack							

Date:12/20/04ISR Number: 4534393-1Report Type:Direct Company Report #CTU 234653
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx 25mg					
Required	Increased		Merck/Va	PS	Merck/Va			
DENTAL	PILL						1 HALF	
Intervention to	Hepatocellular Damage							
DAILY DENTAL								
Prevent Permanent Impairment/Damage			Celebrex	C				

Date:12/20/04ISR Number: 4536102-9Report Type:Expedited (15-DaCompany Report #2004107519
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol	Consumer	Lipitor					
Other	Decreased		(Atorvastatin)	PS				
	Myocardial Infarction		Rofecoxib					
			(Rofecoxib)	SS				

Date:12/20/04ISR Number: 4536151-0Report Type:Expedited (15-DaCompany Report #2004097452
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
	Cardiac Stress Test	Health Professional						
	Abnormal							
	Coronary Artery Disease		Rofecoxib (Rofecoxib)	SS				
	Disease Recurrence		Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
	Dyspnoea		Citalopram Hydrobromide (Citalopram Hydrobromide)	C				
	Feeling Abnormal		Pioglitazone (Pioglitazone)	C				
	Vascular Graft Occlusion		Levothyroxine Sodium (Levothyroxine Sodium)	C				
			Lisinopril (Lisinopril)	C				
			Atenolol (Atenolol)	C				
			Clopidogrel Sulfate (Clopidogrel Sulfate)	C				
			Simvastatin					

(Simvastatin)	C
Oxycocet (Oxycodone Hydrochloride, Paracetamol)	C
Glyceryl Trinitrate (Glyceryl Trinitrate)	C
Baclofen (Baclofen)	C
Ezetimibe (Ezetimibe)	C

Date:12/20/04ISR Number: 4536542-8Report Type:Expedited (15-DaCompany Report #2004094530
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block	Foreign	Amlor (Amlodipine)	PS		ORAL	(1 IN 1 D),	
Hospitalization -	Complete	Health					ORAL	
Initial or Prolonged	Diarrhoea	Professional	Acebutolol Hydrochloride (Acebutolol Hydrochloride)	SS		ORAL	400 MG (400 MG, 1 IN 1 D), ORAL	
Other	Hyperkalaemia							
	Hypothyroidism							
	Metabolic Acidosis							
	Syncope							
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Aldactazine (Altizide, Spironolactone)	C				
			Glibenclamide (Glibenclamide)	C				

Date:12/20/04ISR Number: 4536976-1Report Type:Expedited (15-DaCompany Report #HQWYE739202DEC04
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cataract	Health	Effexor Xr					

	Eye Haemorrhage Retinal Haemorrhage Retinal Tear Unevaluable Event Vitreous Floaters	Professional Company Representative	(Venalfaxine Hydrochloride, Capsule, Extended Release)	PS	ORAL 150 MG 1X PER 1 DAY, ORAL
			Vioxx (Rofecoxib, Tablet)	SS	
			Effexor Xr (Venalfaxine Hydrochloride, Capsule, Extended Release)	SS	ORAL 112.5 MG 1X PER 1 DAY, ORAL
			Effexor Xr (Venalfaxine Hydrochloride, Capsule, Extended Release)	SS	ORAL 75 MG 1X PER 1 DAY, ORAL
			Effexor Xr (Venalfaxine Hydrochloride, Capsule, Extended		

Release) SS ORAL
37.5 MG 1X

PER 1 DAY,

ORAL

Ambien (Zolpidem
Tartrate) C
Lipitor
(Atorvastatin C

Date:12/20/04ISR Number: 4536979-7Report Type:Expedited (15-DaCompany Report #A02200403454
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation	Health Professional	Plavix - (Clopidogrel Sulfate) - Tablet - 75 Mg	PS		ORAL	75 MG OD, ORAL	5 YR
			Vioxx - (Rofecoxib) - Tablet - 25 Mg	SS		ORAL	25 MG OD, ORAL	10 DAY

Date:12/21/04ISR Number: 4533457-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00497
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
	Anorexia		Certoparin Sodium	C			UNKNOWN	35 DAY
	Cardiac Disorder		Beloc-Zok	C			UNKNOWN	
	Chest Discomfort		Bifiteral	C			UNKNOWN	
	Cough		Cibacen	C			UNKNOWN	

Cystitis Noninfective
Diarrhoea
Hypertension
Nausea
Pruritus
Urinary Tract Infection
Vomiting

Date:12/21/04ISR Number: 4533468-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
Disability	Angina Pectoris
Other	Arthritis
	Carpal Tunnel Syndrome
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Coronary Artery Disease
	Cystitis
	Depression
	Dizziness
	Duodenal Ulcer
	Emotional Distress
	Erectile Dysfunction
	Gastritis
	Gastroenteritis
	Helicobacter

		Haematemesis					
		Haemorrhoids					
		Hypercalcaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperparathyroidism		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Irritability		Vioxx	SS	Merck & Co., Inc	ORAL
		Mediastinitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Zoloft	C		
UNKNOWN							
		Plantar Fasciitis		Tenormin	C		
UNKNOWN							
		Pleural Effusion		Tenormin	C		
UNKNOWN							
		Postoperative Infection		Temazepam	C		
UNKNOWN							
		Postpericardiotomy		Tagamet	C		
UNKNOWN							
		Syndrome		Aspirin	C		
UNKNOWN							
		Spinal Osteoarthritis		Augmentin	C		
UNKNOWN							
		Tricuspid Valve		Zocor	C		ORAL
		Incompetence		Motrin	C		ORAL
		Ulnar Nerve Injury		Plavix	C		ORAL
		Venous Thrombosis Limb		Relafen	C		
UNKNOWN							
		Vomiting		Nitrostat	C		
UNKNOWN							
				Ultram	C		ORAL
				Ultracet	C		
UNKNOWN							
				Ultracet	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Trazodone			

	Hydrochloride	C
UNKNOWN		
	Trazodone Hydrochloride	C
UNKNOWN		
	Bextra	C
UNKNOWN		
	Bextra	C
UNKNOWN		
	Flexeril	C
UNKNOWN		
	Flexeril	C
UNKNOWN		

Date:12/21/04ISR Number: 4533471-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00882
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Blood Cholesterol Increased
	Bronchitis
	Bursitis
	Cardiac Valve Disease
	Cardiomegaly
	Cataract
	Chondromalacia
	Chronic Obstructive Pulmonary Disease
	Conjunctival Haemorrhage
	Diverticulitis
	Ear Congestion
	Fall
	Joint Effusion
	Keratitis

		Lumbar Radiculopathy					
		Lymphadenopathy					
		Meniscus Lesion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteopetrosis		Monopril	C		
UNKNOWN							
		Road Traffic Accident		Zocor	C		
UNKNOWN							
		Sinusitis		Muro 128 Ophthalmic			
		Spinal Column Stenosis		Ointment	C		
OPHTHALMIC							
		Syncope		Artificial Tears	C		
OPHTHALMIC							
				Lipitor	C		
UNKNOWN							
				Estradiol	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							

Date:12/21/04ISR Number: 4533475-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04179
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Synthroid	C		
UNKNOWN						
Disability	Coronary Artery Disease					
	Insomnia					

Date:12/21/04ISR Number: 4533477-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Angina Unstable
	Anxiety
	Application Site Irritation
	Application Site Pruritus
	Arthralgia
	Blood Glucose Increased
	Blood Urea Decreased
	Cardiac Murmur
	Chest Discomfort
	Chest Pain
	Coronary Artery Atherosclerosis
	Coronary Artery Stenosis
	Depression
	Dizziness
	Dyspnoea
	Dyspnoea Exertional
	Dyspnoea Paroxysmal Nocturnal
	Electrocardiogram Q Waves
	Exercise Tolerance Decreased
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Haemodilution							
Hyperhidrosis							
Hypertension							
Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	284	DAY
Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL	284	DAY
Myocardial Infarction		Prevacid	C			UNKNOWN	
Myocardial Ischaemia		Methylprednisolone	C			UNKNOWN	
Nausea		Estradiol	C		ORAL		
Nicotine Dependence		Clonazepam	C			UNKNOWN	
Operative Haemorrhage		Vantin	C			UNKNOWN	
Orthopnoea		Meclizine	C			UNKNOWN	
Pain		Acetaminophen And					
Palpitations		Hydrocodone					
Panic Attack		Bitartrate	C			UNKNOWN	
Paraesthesia		Sulfamethoxazole And					
Pericardial Effusion		Trimethoprim	C			UNKNOWN	
Pleuritic Pain		Serzone	C		ORAL	336	DAY
Stomach Discomfort		Serzone	C		ORAL		
Supraventricular		Albuterol	C			UNKNOWN	
Tachycardia		Zyrtec	C			UNKNOWN	
Vaginal Haemorrhage		Prednisone	C			UNKNOWN	
Vision Blurred		Cephalexin	C			UNKNOWN	
		Augmentin	C			UNKNOWN	
		Allegra	C			UNKNOWN	
		Flonase	C			UNKNOWN	
		Cyanocobalamin	C			PARENTERAL	
		Cyanocobalamin	C			PARENTERAL	

	Remeron	C	
UNKNOWN			
	Aciphex	C	
UNKNOWN			
	Tequin	C	
UNKNOWN			
	Diovan	C	ORAL
	Verapamil Msd Lp	C	ORAL
	A.S.A.	C	ORAL
	A.S.A.	C	ORAL
	Prometrium	C	ORAL
	Mobic	C	ORAL
	Promethazine	C	ORAL

Date:12/21/04ISR Number: 4533484-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00521
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure Congestive							
	Coronary Artery Disease							
	Hypertension							
	Myocardial Infarction							
	Pulmonary Congestion							
	Refusal Of Treatment By Patient							

Date:12/21/04ISR Number: 4533487-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00083
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Blood Pressure Increased

		Coronary Artery Occlusion					
		Coronary Artery Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Metoprolol	C		ORAL
		Myocardial Infarction					
		Nausea					
		Post Procedural Complication					
		Ventricular Dyskinesia					
		Vomiting					

Date:12/21/04ISR Number: 4533488-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00120
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/21/04ISR Number: 4533490-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00178
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
646 DAY						
Life-Threatening			Leflunomide	C		
UNKNOWN						

Date:12/21/04ISR Number: 4533491-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01014
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Memory Impairment		Humulin N	C		
SUBCUTANEOUS						
Disability	Transient Ischaemic		Hydrodiuril	C		ORAL

Other	Attack	Prilosec	C		ORAL
		Celexa	C		
UNKNOWN					
		Norvasc	C		ORAL
		Glucophage	C		ORAL
		Lotensin	C		ORAL

Date:12/21/04ISR Number: 4533505-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02653
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Infarction		Zoloft	C		
UNKNOWN						
	Cardiogenic Shock		Prednisone	C		
UNKNOWN						
	Coronary Artery		Prevacid	C		
UNKNOWN						
	Atherosclerosis		A.S.A.	C		
UNKNOWN						
	Coronary Artery Occlusion		Coumadin	C		
UNKNOWN						
	Hydrocele		Lopressor	C		
UNKNOWN						
	Lobar Pneumonia					
	Sudden Death					
	Upper Gastrointestinal Haemorrhage					

Date:12/21/04ISR Number: 4533506-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03353
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		385 DAY
Disability	Atrial Flutter		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		385 DAY
	Ingrowing Nail		Acupril	C		ORAL		
	Oedema Peripheral		Lopressor	C				UNKNOWN
	Onychomycosis		Metformin	C				UNKNOWN
	Peripheral Vascular		Furosemide	C				UNKNOWN
	Disorder		[Therapy					
	Tachycardia		Unspecified]	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Zocor	C		ORAL		

Date:12/21/04ISR Number: 4533507-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03649
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ankle Fracture							
Other	Asthma							
	Atrial Fibrillation							
	Bronchitis							
	Cardiac Disorder							
	Carpal Tunnel Syndrome							
	Cervicobrachial Syndrome							
	Chest Discomfort							
	Chest Pain							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Dyspnoea							
	Ejection Fraction							
	Decreased							

Fatigue
Gastrooesophageal Reflux
Disease
Hyperhidrosis
Hypertension
Infection
Migraine
Mitral Valve Incompetence
Myocardial Infarction
Neck Pain
Nerve Injury
Non-Cardiac Chest Pain
Palpitations
Sinus Disorder
Tachycardia
Tricuspid Valve
Incompetence
Ventricular Dysfunction
Ventricular Extrasystoles
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533509-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0412BRA00062
Age:92 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533510-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00018
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		223 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		223 DAY
Initial or Prolonged	Anaemia		Levothyroxine Sodium	C		ORAL		
	Cardiac Failure Acute		Bisoprolol	C		ORAL		
			Prednisolone	C		ORAL		
			Furosemide	C		ORAL		
			Levomepromazine	C		ORAL		
			Ferrous Sulfate	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Sertraline Hydrochloride	C		ORAL		

Date:12/21/04ISR Number: 4533511-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deafness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Vestibular Neuronitis							

Date:12/21/04ISR Number: 4533512-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01605
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Silent Myocardial Infarction		Vioxx Zyloprim	PS C	Merck & Co., Inc	ORAL

UNKNOWN

Date:12/21/04ISR Number: 4533514-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00057
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/21/04ISR Number: 4533515-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04267
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
Disability	Bronchitis
	Carotid Artery Aneurysm
	Constipation
	Depression
	Drug Dependence
	Emotional Disorder

	Gastritis						
	Hypoaesthesia						
	Intracranial Aneurysm	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rotator Cuff Syndrome		Trazodone					
	Sleep Disorder		Hydrochloride	C				UNKNOWN
	Visual Disturbance							
	Vomiting							

Date:12/21/04ISR Number: 4533517-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1631 DAY	

Date:12/21/04ISR Number: 4533518-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01977
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/21/04ISR Number: 4533520-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:12/21/04ISR Number: 4533521-1Report Type:Expedited (15-DaCompany Report #BR-MERCK-0411BRA00179
Age:23 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Paralysis							
	Rash							

Date:12/21/04ISR Number: 4533641-1Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0536980A
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Sensodyne Original					
Initial or Prolonged	Amnesia		Flavor Toothpaste	PS	Glaxosmithkline			
Disability	Cerebrovascular Accident		Vioxx	SS		ORAL		
	Feeling Abnormal							
	Walking Aid User							

Date:12/21/04ISR Number: 4533810-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Other	Alanine Aminotransferase Increased
	Antithrombin Iii

		Decreased Anxiety Arrhythmia Aspartate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Blood Calcium Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Blood Creatine Phosphokinase Increased Blood Creatinine Increased Blood Lactate Dehydrogenase Increased Blood Urea Increased Cardiac Murmur Carotid Bruit Chest Pain Coronary Artery Atherosclerosis Depression Dyspnoea Electrocardiogram T Wave Abnormal Granulocyte Count Increased Hypercoagulation Hypoaesthesia Lymphocyte Count Decreased Mitral Valve Incompetence Mitral Valve Stenosis Monocyte Count Increased Muscle Spasms Myoglobin Blood Present Palpitations Prothrombin Time Prolonged Pulmonary Embolism Stress Tachycardia Tricuspid Valve Incompetence White Blood Cell Count Increased					

Date:12/21/04ISR Number: 4533812-4Report Type:Expedited (15-DaCompany Report #PH-MERCK-0410PHL00002
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Perindopril	C		ORAL		
	Fall		Piracetam	C		ORAL		
	Radius Fracture		[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			[Therapy Unspecified]	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03199
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Trusopt	C		OPHTHALMIC		
	Dysphagia		Betaxolol Ophthalmic Solution	C		UNKNOWN		
	Ear Pain							
	Epistaxis		Lasix (Furosemide)	C		UNKNOWN	1680 DAY	
	Eye Pain		Isosorbide	C		UNKNOWN		
	Facial Pain		Zocor	C		UNKNOWN		
	Hypertension		Psyllium Husk	C		UNKNOWN		
	Lacunar Infarction		Folic Acid	C		UNKNOWN		
	Muscle Spasms		Docusate Sodium	C		UNKNOWN		
	Myalgia		Potassium (Unspecified)	C		UNKNOWN		
	Pain In Jaw							
	Productive Cough		Warfarin	C		UNKNOWN	1284 DAY	
	Renal Injury		Calcitonin	C		UNKNOWN		
	Rheumatoid Arthritis		Digoxin	C		UNKNOWN		
			Vitamin E	C		UNKNOWN		

Date:12/21/04ISR Number: 4533815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00871
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Costochondritis		Vioxx	PS	Merck & Co., Inc	ORAL	81	DAY
	Drug Ineffective		Effexor	C		UNKNOWN		

	Muscle Spasms	Clonazepam	C
UNKNOWN			
		Furosemide	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			
		Crestor	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Lortab	C
UNKNOWN			

Date:12/21/04ISR Number: 4533818-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00865
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Disability	Arthralgia
	Blood Pressure Increased
	Chest Discomfort
	Chest Pain
	Chronic Sinusitis
	Depression
	Diabetes Mellitus
	Dyspnoea
	Effusion
	Excoriation
	Eye Haemorrhage
	Eye Pain
	Headache
	Hyperlipidaemia
	Joint Effusion
	Malignant Melanoma
	Muscle Strain
	Ocular Hyperaemia
	Osteoarthritis

	Pain						
	Pharyngolaryngeal Pain						
	Skin Lesion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Superficial Injury Of Eye		Vioxx	PS	Merck & Co., Inc	ORAL	
	Thirst		Vioxx	SS	Merck & Co., Inc	ORAL	
	Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL	
	Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL	
	Visual Disturbance						
	Weight Increased						

Date:12/21/04ISR Number: 4533819-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01532
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	43 DAY
Initial or Prolonged			Synthroid	C			UNKNOWN
Disability							

Date:12/21/04ISR Number: 4533820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00705
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Chest Pain		Nexium	C			UNKNOWN
Initial or Prolonged	Overdose		Vicodin Tablets	C		ORAL	
Disability			Naproxen	C			UNKNOWN

Date:12/21/04ISR Number: 4533821-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02613
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY

	Haematochezia		Prilosec	C	ORAL
	Heart Rate Abnormal				
	Myocardial Infarction				

Date:12/21/04ISR Number: 4533822-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01601
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Singulair	C		ORAL
Disability			Doxepin			
			Hydrochloride	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Zyrtec	C		
UNKNOWN						
			Accolate	C		
UNKNOWN						
			Hydroxyzine			
			Hydrochloride	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533823-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03574
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Aneurysm		Lanoxin	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Lipitor	C				
UNKNOWN								
Disability	Haemorrhage		Toprol Xl Tablets	C				
UNKNOWN								
	Memory Impairment		Plavix	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								

Date:12/21/04ISR Number: 4533824-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							
Disability	Thrombosis							

Date:12/21/04ISR Number: 4533825-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03146
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Anticoagulant Therapy		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Balance Disorder		Coumadin	C				
UNKNOWN								
	Blood Disorder		Lasix (Furosemide					
	Cardiac Arrest		Sodium)	C				
UNKNOWN								
	Dizziness		Digitek	C				
UNKNOWN								

	Dyspnoea		Elavil	C
UNKNOWN				
	Epistaxis		Lipitor	C
UNKNOWN				
	Fatigue		Combivent	C
UNKNOWN				
	Loss Of Consciousness		Advair	C
UNKNOWN				
	Lung Disorder			
	Myocardial Infarction			
	Pain In Extremity			
	Pulmonary Embolism			
	Pulmonary Hypertension			
	Syncope			

Date:12/21/04ISR Number: 4533826-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02220
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain					
	Dyspnoea					
	Fibromyalgia					
	Neck Pain					
	Osteochondrosis					
	Rectal Haemorrhage					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533827-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01536
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Other								

Date:12/21/04ISR Number: 4533828-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01612
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
	Dermatitis Exfoliative							
	Dyspnoea							
	Feeling Cold							
	Feeling Hot							
	Hypoaesthesia							
	Liver Disorder							
	Oedema Peripheral							
	Pruritus							
	Skin Ulcer							
	Transient Ischaemic Attack							

Date:12/21/04ISR Number: 4533829-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533830-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01862
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/21/04ISR Number: 4533831-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01944
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Combivent	C				
UNKNOWN								
Initial or Prolonged			Thioridazine	C				
UNKNOWN								
Disability			Mellaril	C				
UNKNOWN								
			Vasotec	C				
UNKNOWN								
			Lorcet 10/650	C				
UNKNOWN								
			Doxycycline Hyclate	C				
UNKNOWN								

Date:12/21/04ISR Number: 4533832-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01770
Age:70 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blood Creatine Phosphokinase Increased		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON
		Rosiglitazone Maleate	C			UNKNOWN	
		Metoprolol	C			UNKNOWN	
		Synthroid	C			UNKNOWN	
		Tiazac	C			UNKNOWN	
		Ibuprofen	C			UNKNOWN	
		Plavix	C			UNKNOWN	
		Metformin	C			UNKNOWN	
		Aspirin	C			UNKNOWN	
		Glyburide	C			UNKNOWN	
		Isosorbide	C			UNKNOWN	
		Terazosin Hydrochloride	C			UNKNOWN	
		Levothyroxine Sodium	C			UNKNOWN	

Date:12/21/04ISR Number: 4533833-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Urinary Bladder Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533834-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533835-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533836-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01929
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Cardiac Murmur Chest Pain Dizziness Gastric Haemorrhage Hernia Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4533837-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01945
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Diazepam	C				UNKNOWN
Disability			Telenzepine	C				UNKNOWN
			Citalopram	C				UNKNOWN

Date:12/21/04ISR Number: 4533842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	199	DAY
Other	Myocardial Infarction Renal Failure							

Date:12/21/04ISR Number: 4533850-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/21/04ISR Number: 4533868-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01957
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Procedural Complication							
Disability								

Date:12/21/04ISR Number: 4533959-2Report Type:Direct Company Report #CTU 234818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Depression		Vioxx Merck	PS	Merck	ORAL	1EVERY OTHER D ORAL	
Hospitalization - Initial or Prolonged	Heart Rate Irregular							
Other	Suicidal Ideation							

Date:12/21/04ISR Number: 4534230-5Report Type:Direct Company Report #CTU 234813
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Frequent Bowel Movements		Vioxx Merck	PS	Merck			
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/21/04ISR Number: 4534474-2Report Type:Direct Company Report #CTU 234846
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx 25 Mg	PS			1 TAB 1X	DAILY
	Cerebrovascular Accident							
	Dizziness							
	Dysarthria							
	Facial Palsy							
	Infarction							
	Mobility Decreased							
	Oedema Peripheral							

Date:12/21/04ISR Number: 4534484-5Report Type:Direct Company Report #CTU 234849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm		Vioxx	PS			25 MG X 1 DAY	
	Blood Pressure							
	Obstruction							

Date:12/22/04ISR Number: 4535117-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Diaphragmatic		Vioxx	PS	Merck & Co., Inc	ORAL		536 DAY
Initial or Prolonged	Eventration		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		214 DAY
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		536 DAY
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		214 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		

	Convulsion		Buspar	C	ORAL
405 DAY					
	Coronary Artery Disease		Lortab	C	ORAL
573 DAY					
	Myocardial Infarction		Lortab	C	ORAL
			Ziac	C	ORAL
322 DAY					
			Vicodin Tablets	C	ORAL
			Lipitor	C	ORAL
			Valium	C	ORAL
214 DAY					
			Talwin	C	ORAL
24 DAY					
			Ultram	C	ORAL
9 DAY					
			Skelaxin	C	ORAL
14 DAY					
			Tenyl	C	
UNKNOWN		36 DAY			
			Claritin	C	
UNKNOWN					
			Serzone	C	
UNKNOWN					
			Carisoprodol	C	
UNKNOWN					
			Acetaminophen And Propoxyphene Hydrochloride	C	
UNKNOWN					
			Mobic	C	
UNKNOWN					
			Hydrocodone Hydrochloride	C	
UNKNOWN					
			Altace	C	
UNKNOWN					
			Toprol Xl Tablets	C	
UNKNOWN					
			Aspirin	C	
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535120-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
Disability	Atherosclerosis		Tylenol With Codeine					
	Blood Cholesterol		#3	C		ORAL		
	Increased		Vicodin Tablets	C				UNKNOWN
	Blood Glucose Increased		Tylenol	C				UNKNOWN
	Blood Pressure Decreased		Ecotrin	C				UNKNOWN
	Blood Triglycerides							
	Increased							
	Hypertension							
	Joint Swelling							
	Myocardial Infarction							
	Oxygen Saturation							
	Decreased							
	Pco2 Decreased							
	Weight Increased							

Date:12/22/04ISR Number: 4535121-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00818
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction							
Disability	Acute Pulmonary Oedema							
Other	Acute Respiratory Failure							
	Adverse Event							
	Aortic Valve Incompetence							
	Bundle Branch Block Left							
	Cardiac Failure							
	Congestive							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Stenosis							
	Diabetes Mellitus							

Non-Insulin-Dependent
Dilatation Atrial
Dilatation Ventricular
Dizziness
Hyperlipidaemia
Hypertension
Hypertriglyceridaemia
Hypotension
Implant Site Pain
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Myocardial Infarction
Oedema Peripheral
Polytraumatism
Ventricular Dysfunction
Ventricular Fibrillation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535122-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00820
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Motrin	C				
UNKNOWN							1	DAY
Disability	Arthralgia		Motrin	C				
UNKNOWN								
	Back Pain		Celebrex	C				
UNKNOWN								
	Bronchitis		Soma	C				
UNKNOWN								
	Dermal Cyst		Ultram	C				
UNKNOWN								
	Family Stress		Altace	C				
UNKNOWN								
	Hypertension		Zyrtec	C				
UNKNOWN								
	Hypoaesthesia		Hydrochlorothiazide And Triamterene	C				
	Intervertebral Disc Degeneration							
UNKNOWN								
	Oedema Peripheral		Calcium (Unspecified)	C				
UNKNOWN								
	Pharyngitis		Estradiol	C				
UNKNOWN								
	Plantar Fasciitis							
	Polytraumatism							
	Postoperative Infection							
	Rhinitis							
	Temporomandibular Joint Syndrome							
	Upper Respiratory Tract Infection							

Date:12/22/04ISR Number: 4535127-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00854
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alcohol Poisoning							
Disability	Alcohol Use							

Other	Chest Discomfort
	Chest Pain
	Circulatory Collapse
	Cough
	Cystitis
	Dizziness
	Dyspnoea
	Dysuria
	Exostosis
	Intervertebral Disc
	Degeneration
	Intervertebral Disc
	Protrusion
	Myocardial Infarction
	Nerve Root Lesion
	Palpitations
	Polytraumatism
	Syncope

Date:12/22/04ISR Number: 4535130-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00653
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Back Pain
	Chest Pain
	Depression

		Dizziness					
		Hernia Repair					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Claritin	C		
UNKNOWN							
		Prostatitis		Analgesic Or			
		Proteinuria		Anesthetic			
		Rash Pruritic		(Unspecified)	C		
UNKNOWN							
		Suicidal Ideation					
		Tendon Rupture					
		Tinea Infection					
		Treatment Noncompliance					

Date:12/22/04ISR Number: 4535131-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00130
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
776 DAY						
Hospitalization -	Myocardial Infarction					
Initial or Prolonged	Syncope					
Other	Ventricular Arrhythmia					

Date:12/22/04ISR Number: 4535132-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Coagulation Factor Viii		Vioxx	PS	Merck & Co., Inc	ORAL
117 DAY						
Initial or Prolonged	Level Decreased		Zocor	SS		ORAL
	Coagulation Time		Ginkgo Biloba			
	Prolonged		Extract	SS		ORAL
	Haematoma		Hydrochlorothiazide			
			And Lisinopril	SS		ORAL

Date:12/22/04ISR Number: 4535133-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00041
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		854 DAY
Life-Threatening			Allopurinol And Benzbromarone	C				
Hospitalization -								UNKNOWN
Initial or Prolonged			Gastrointestinal Preparations (Unspecified)	C				
								UNKNOWN
			Gastrointestinal Preparations (Unspecified)	C				
								UNKNOWN

Date:12/22/04ISR Number: 4535138-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04126
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea							
	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535139-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04299
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		107 DAY
Hospitalization -	Infarction		Lipitor	C		ORAL		
Initial or Prolonged	Ejection Fraction		Hydrodiuril	C		ORAL		325 DAY
Disability	Decreased							
Other	Feeling Abnormal							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							

Date:12/22/04ISR Number: 4535142-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Chloride Increased		Premarin	C				UNKNOWN
	Blood Glucose Increased		Percocet	C				UNKNOWN
	Blood Sodium Decreased							
	Cerebrovascular Accident							
	Chest Discomfort							
	Depression							
	Drug Ineffective							
	Headache							
	Hypoaesthesia							
	Myocardial Infarction							
	Pain In Extremity							
	Paraesthesia							
	Postoperative Infection							
	Staphylococcal Infection							
	Transient Ischaemic Attack							

Date:12/22/04ISR Number: 4535143-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00589
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Facial Palsy							
	Facial Paresis							
	Glycosylated Haemoglobin Increased							
	Speech Disorder							

Date:12/22/04ISR Number: 4535145-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00300
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		354 DAY
	Peripheral Occlusive		Plavix	C				UNKNOWN
	Disease		Allopurinol	C				UNKNOWN
			Prinivil	C		ORAL		
			Verapamil	C				UNKNOWN
			Lipitor	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535146-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01685
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL	1130 DAY	
Disability	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	1130 DAY	
	Coronary Artery Occlusion		Lipitor	C		ORAL	UNKNOWN	
	Dyspnoea		Prinivil	C		ORAL	UNKNOWN	
	Ventricular Hypokinesia		Toprol Xl Tablets	C		ORAL	UNKNOWN	
			Actos	C				
			[Therapy Unspecified]	C				

Date:12/22/04ISR Number: 4535147-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00053
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Initial or Prolonged	Gastrointestinal Ulcer		Celecoxib	C			UNKNOWN	6 MON
	Heart Rate Irregular		Candesartan Cilexetil	C			UNKNOWN	
			Valdecoxib	C			UNKNOWN	

Date:12/22/04ISR Number: 4535148-4Report Type:Expedited (15-DaCompany Report #FI-MERCK-0410FIN00006
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Venous		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis							

Date:12/22/04ISR Number: 4535150-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01841
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		869 DAY
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:12/22/04ISR Number: 4535151-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02848
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:12/22/04ISR Number: 4535152-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03341
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Disability	Blood Pressure Increased
	Cyst

		Drug Ineffective Eructation Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia Nasal Congestion Weight Decreased		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN							

Date:12/22/04ISR Number: 4535154-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04151
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Other	Acute Myocardial Infarction Cardiomegaly Coronary Artery Atherosclerosis Myocardial Infarction Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/22/04ISR Number: 4535157-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03848
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability 22 MON	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Digoxin	C		
UNKNOWN			Lotrel	C		

Date:12/22/04ISR Number: 4535158-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00131
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL

	Kidney Enlargement		Clonazepam	C		
UNKNOWN						
	Myocardial Infarction					
	Renal Pain					

Date:12/22/04ISR Number: 4535159-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 YR	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Muscle Disorder		Calcium (Unspecified)	C		
UNKNOWN						

Date:12/22/04ISR Number: 4535160-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535178-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535179-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535181-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Cardiac Disorder		[Therapy Unspecified]	C			UNKNOWN	
	Hepatomegaly		[Therapy Unspecified]	C			UNKNOWN	

Date:12/22/04ISR Number: 4535182-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01953
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535183-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02081
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Benign Neoplasm		Premarin	C				
	Rectocele		Synthroid	C				
			[Therapy Unspecified]	C				

Date:12/22/04ISR Number: 4535184-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00034
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C				
			Ramipril	C				
			Metoprolol Tartrate	C				

Date:12/22/04ISR Number: 4535185-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Renal Failure		[Therapy Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535186-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02072
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Haemorrhage		[Therapy					
Hospitalization -	Sepsis		Unspecified]	C				
UNKNOWN								
Initial or Prolonged	Ulcer							
Disability								

Date:12/22/04ISR Number: 4535189-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00023
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:12/22/04ISR Number: 4535191-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01984
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage Urinary Tract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic							
	Attack							

Date:12/22/04ISR Number: 4535192-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02070
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Acute Respiratory Failure		Isobide	C				
UNKNOWN								
Initial or Prolonged	Cardiac Arrest		Mevacor	C		ORAL		
Disability	Convulsion		Lisinopril	C				
UNKNOWN								

				Lasix (Furosemide)	C		
UNKNOWN							
				Metformin	C		
UNKNOWN							

Date:12/22/04ISR Number: 4535194-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0412BRA00068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Jejunal Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:12/22/04ISR Number: 4535195-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535196-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00059
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Life-Threatening								

Date:12/22/04ISR Number: 4535197-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Thrombosis		Lipitor	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535198-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535199-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535201-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02131
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Congestive
Cerebrovascular Accident

Date:12/22/04ISR Number: 4535202-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535203-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02185
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535212-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535213-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02139
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:12/22/04ISR Number: 4535215-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	330 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	152 DAY	

Date:12/22/04ISR Number: 4535235-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00329
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis							
	Hepatic Cyst							
	Irritable Bowel Syndrome							
	Non-Cardiac Chest Pain							
	Pulmonary Embolism							
	Sensory Loss							

Date:12/22/04ISR Number: 4535434-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Lower
Hospitalization - Initial or Prolonged	Agitation
	Anxiety
Other	Aortic Aneurysm
	Arthralgia
	Asthma

Atherosclerosis
Atrial Fibrillation
Blood Blister
Bradycardia
Bronchitis
Bronchospasm
Cardiac Failure
Congestive
Cardiomegaly
Cardiomyopathy
Chronic Obstructive
Pulmonary Disease
Confusional State
Conjunctivitis Allergic
Death
Disorientation
Drug Hypersensitivity
Dyspepsia
Herpes Simplex
Herpes Zoster
Hypotension
Injury
Interstitial Lung Disease

	Labile Hypertension						
	Medication Error						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neuropathy		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Spinal Column Stenosis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Spinal Compression		Fosamax	C			UNKNOWN	
	Fracture		Percocet	C			UNKNOWN	
	Tracheal Obstruction		Zestril	C			UNKNOWN	
	Vomiting		Zestril	C			UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	

Date:12/22/04ISR Number: 4535435-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00744
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Depression		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	International Normalised		Prednisone	C			UNKNOWN	
	Ratio Decreased		Prednisone	C			UNKNOWN	

	Joint Injury	Vicodin Tablets	C	
UNKNOWN				
	Joint Swelling	Methotrexate	C	
UNKNOWN				
	Lacunar Infarction	Methotrexate	C	
UNKNOWN				
	Lung Neoplasm	Folic Acid	C	
UNKNOWN				
	Mitral Valve Incompetence	Folic Acid	C	
UNKNOWN				
	Muscle Spasms	Lasix (Furosemide)	C	
UNKNOWN				
	Myocardial Infarction	Lasix (Furosemide)	C	ORAL
	Osteopenia	Centrum Silver	C	
UNKNOWN				
	Pain In Extremity	Cal-Citrate	C	
UNKNOWN				
	Prothrombin Time Abnormal	Lovenox	C	
UNKNOWN				
	Rash Maculo-Papular	Coumadin	C	
UNKNOWN				
	Rheumatoid Arthritis	Plavix	C	
UNKNOWN				
	Road Traffic Accident	Zoloft	C	
UNKNOWN				
	Transient Ischaemic	Aciphex	C	
UNKNOWN				
	Attack			

Date:12/22/04ISR Number: 4535436-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Back Pain
Disability	Cardiac Disorder
Other	Cardiac Murmur
	Chest Pain
	Chest Wall Pain
	Constipation
	Diarrhoea
	Dry Skin

		Dyspnoea Exertional					
		Emotional Distress					
		Frequent Bowel Movements	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematuria		Antimicrobial			
		Haemochromatosis		(Unspecified)	C		
UNKNOWN							
		Haemorrhoids		Analgesic Or			
		Headache		Anesthetic			
		Hirsutism		(Unspecified)	C		
UNKNOWN							
		Hyperlipidaemia		Butalbital	C		
UNKNOWN							
		Injury					
		Intervertebral Disc					
		Protrusion					
		Irritable Bowel Syndrome					
		Lactose Intolerance					
		Musculoskeletal Pain					
		Myocardial Infarction					
		Nausea					
		Neck Pain					
		Nephrolithiasis					
		Non-Cardiac Chest Pain					
		Pyelonephritis					
		Pyrexia					
		Rectal Haemorrhage					
		Renal Colic					
		Sinusitis					
		Skin Discolouration					
		Skin Striae					
		Spinal Osteoarthritis					
		Thrombosis					
		Thyroid Neoplasm					
		Vision Blurred					
		Vomiting					
		Weight Increased					
		Weight Loss Poor					

Date:12/22/04ISR Number: 4535437-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00750
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Ultram	C				
UNKNOWN								
	Anxiety		Zestril	C				
UNKNOWN								
	Blood Pressure Increased							
	Convulsion							
	Cough							
	Death							
	Depression							
	Encephalomalacia							
	Haemangioma							
	Nervousness							
	Psoriasis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535438-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00710
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Procardia Xl	C				
UNKNOWN								
Disability	Cerebral Atrophy		Prinivil	C				
UNKNOWN								
Other	Cerebrovascular Accident		Diazide	C				
UNKNOWN								
	Conjunctivitis Allergic		Synthroid	C				
UNKNOWN								
	Contusion		Ecotrin	C				
UNKNOWN								
	Convulsion		Hydrea	C				
UNKNOWN								
	Dehydration		Osteo-Bi-Flex	C				
UNKNOWN								
	Depression		Compazine	C				
UNKNOWN								
	Dermatophytosis							
	Disorientation							
	Fall							
	Fatigue							
	Gastrooesophageal Reflux							
	Disease							
	Haematoma							
	Hypokalaemia							
	Insomnia							
	Joint Injury							
	Mental Status Changes							
	Nausea							
	Neurogenic Bladder							
	Oedema Peripheral							
	Pneumonia							
	Pyelonephritis							
	Sepsis							
	Transient Ischaemic							
	Attack							
	Urinary Retention							
	Urinary Tract Infection							

Date:12/22/04ISR Number: 4535444-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00790
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Back Injury
Disability	Blood Pressure Increased
Other	Bronchitis Acute
	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease
	Convulsion
	Drug Effect Decreased
	Drug Ineffective
	Ear Pain
	Faecal Occult Blood
	Positive
	Fall
	Fractured Coccyx
	Gastrooesophageal Reflux
	Disease
	Haemorrhoids
	Headache
	Hepatitis C

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hiatus Hernia					
		Hyperlipidaemia					
		Hypertension					
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Liver Function Test		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Soma	C		ORAL
		Malaise		Levbid	C		
UNKNOWN							
		Meralgia Paraesthetica		Dilantin	C		
UNKNOWN							
		Monarthritis		Paxil Cr	C		
UNKNOWN							
		Nervousness		Elavil	C		
UNKNOWN							
		Osteoarthritis		Claritin	C		
UNKNOWN							
		Palpitations		Phenergan			
		Polytraumatism		(Promethazine			
		Pulmonary Fibrosis		Hydrochloride)	C		
UNKNOWN							
		Pyrexia		Protonix	C		
UNKNOWN							
		Syncope		Carafate	C		
UNKNOWN							
		Vision Blurred		Aciphex	C		
UNKNOWN							
		Weight Decreased		Lomotil	C		
UNKNOWN							
				Questran	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Potassium			
				(Unspecified)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							

Darvocet-N C
UNKNOWN

Melatonina C
UNKNOWN

Date:12/22/04ISR Number: 4535451-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00764
Age:37 YR Gender:Male I/FU:F

Outcome PT
Other Adverse Event
Amaurosis Fugax
Angina Pectoris
Aortic Valve Incompetence
Arthralgia
Back Pain
Benign Neoplasm Of Eyelid
Bicuspid Aortic Valve
Blindness Transient
Blood Cholesterol
Increased
Blood Pressure Increased
Cardiac Murmur
Cardiolipin Antibody
Positive
Cervical Vertebra Injury
Chest Pain
Convulsion
Dizziness
Dyspnoea
Ecchymosis
Fatigue
Flushing
Headache
Hypoaesthesia

		Hypothyroidism					
		Muscle Strain					
		Myalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
4	WK						
		Paraesthesia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN			2	DAY			
		Periorbital Disorder					
		Sensory Level Abnormal					
		Sinus Bradycardia					
		Tendonitis					
		Thyroiditis					
		Transient Ischaemic					
		Attack					
		Ventricular Hypertrophy					

Date:12/22/04ISR Number: 4535452-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02154
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anger		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Ankle Fracture		Sandostatin	C		
UNKNOWN						
Other	Arthritis		Atenolol	C		
UNKNOWN						
	Cartilage Injury		Prednisone	C		
UNKNOWN						
	Chest Pain		Diazide	C		
UNKNOWN						
	Chills		Furosemide	C		
UNKNOWN						
	Chronic Obstructive		Prochlorperazine	C		
UNKNOWN						
	Pulmonary Disease		Protonix	C		
UNKNOWN						
	Cognitive Disorder		Aciphex	C		
UNKNOWN						
	Confusional State		Advair	C		
UNKNOWN						
	Cough		Wellbutrin	C		
UNKNOWN						
	Deep Vein Thrombosis		Combivent	C		
UNKNOWN						

	Dysphasia	Albuterol	C	
UNKNOWN				
	Dyspnoea	Lithium Sulfate	C	
UNKNOWN				
	Emotional Disorder	Celebrex	C	
UNKNOWN				
	Fall	Paxil	C	
UNKNOWN				
	Gastric Disorder	Reminyl	C	ORAL
	Gout			
	Headache			
	Hyperhidrosis			
	Intestinal Haemorrhage			
	Intestinal Obstruction			
	Libido Increased			
	Local Swelling			
	Myositis			
	Nasal Congestion			
	Neck Pain			
	Oedema			
	Osteoarthritis			
	Pain			
	Pulmonary Embolism			
	Rectal Haemorrhage			
	Restrictive Pulmonary Disease			
	Rheumatoid Arthritis			
	Rhinorrhoea			
	Sleep Apnoea Syndrome			
	Swelling			
	Systemic Lupus Erythematosus			
	Ulcer			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535454-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00767
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event							
	Angina Pectoris							
	Anxiety							
	Arrhythmia							
	Back Pain							
	Blood Pressure Increased							
	Cerebral Atherosclerosis							
	Convulsion							
	Cyst							
	Depression							
	Dyspnoea							
	Headache							
	Intervertebral Disc Degeneration							
	Muscle Spasms							
	Neck Pain							
	Road Traffic Accident							
	Skin Disorder							
	Spinal Osteoarthritis							
	Vertigo							

Date:12/22/04ISR Number: 4535457-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Amnesia
	Anxiety
	Asthma
	Back Disorder
	Back Pain
	Blood Triglycerides Increased
	Bronchitis Acute
	Chest Pain
	Chronic Obstructive

Pulmonary Disease
Coronary Artery Disease
Coronary Artery
Thrombosis
Depression
Ejection Fraction
Decreased
Euthyroid Sick Syndrome
Fibromyalgia
Gastroenteritis
Haemorrhage
Hallucination
Headache
Herpes Simplex
Hyperlipidaemia
Hypertension
Irritable Bowel Syndrome

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Ischaemic Cardiomyopathy Nasal Disorder Nausea					
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
252 DAY							
		Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
252 DAY							
		Sleep Apnoea Syndrome		Seroquel	C		
UNKNOWN							
		Spondylolisthesis		Seroquel	C		
UNKNOWN							
		Vascular Pseudoaneurysm		Soma	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN		8 DAY					
				Plavix	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN		112 DAY					
				Foltx	C		
UNKNOWN							
				Linseed Oil	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							

			Altace	C		
UNKNOWN						
			Doxepin Hydrochloride	C		
UNKNOWN						
			Flexeril	C		ORAL
			Prozac	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						

Date:12/22/04ISR Number: 4535461-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Coumadin	C				
UNKNOWN								
Disability	Aortic Atherosclerosis		Coumadin	C				
UNKNOWN								
	Benign Prostatic Hyperplasia							
	Bladder Diverticulum							
	Bladder Trabeculation							
	Blood Pressure Increased							
	Cardiac Failure Congestive							
	Coronary Artery Atherosclerosis							
	Dyspnoea Exertional							
	Hypercapnia							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Nocturia							
	Polytraumatism							
	Pulmonary Oedema							
	Tricuspid Valve Incompetence							
	Urinary Retention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535462-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00791
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Methotrexate	C				
Disability	Adverse Event		Celebrex	C			UNKNOWN	
	Angina Unstable		Deltasone	C			UNKNOWN	
	Atelectasis		Folic Acid	C			UNKNOWN	
	Bronchitis		Procanbid	C			UNKNOWN	2 WK
	Chronic Obstructive Pulmonary Disease		Tylenol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Coronary Artery Occlusion		Zantac	C			UNKNOWN	
	Depression		Proventil	C			RESPIRATORY (INHALATION)	
	Hyperlipidaemia							
	Hypertension		Vasotec	C			ORAL	
	Hypertensive Heart Disease		Lasix (Furosemide)	C			INTRAVENOUS	
	Myocardial Infarction							
	Polytraumatism							

Date:12/22/04ISR Number: 4535464-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00844
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy							
Disability	Diverticulum							
Other	Femur Fracture							
	Goitre							

Menometrorrhagia
Polytraumatism
Road Traffic Accident
Uterine Leiomyoma

Date:12/22/04ISR Number: 4535466-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Arthralgia
	Blood Pressure Increased
	Bundle Branch Block Left
	Carotid Artery Stenosis
	Chest Pain
	Congestive Cardiomyopathy
	Convulsion
	Coronary Artery Disease
	Diverticulum
	Dysphagia
	Dyspnoea
	Ejection Fraction
	Decreased
	Hiatus Hernia
	Limb Discomfort
	Oesophagitis
	Polyp

Post Procedural Haematoma

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Prevacid	C			UNKNOWN	
	Amitriptyline Hydrochloride	C		ORAL		
	Atenolol	C		ORAL		
	Atenolol	C		ORAL		
	Nitroquick	C			SUBLINGUAL	
	Aspirin	C			UNKNOWN	
	Lipitor	C		ORAL		
	Zantac	C		ORAL		
	Plavix	C			UNKNOWN	
	Amaryl	C			UNKNOWN	
	Baycol	C			UNKNOWN	
	Pravachol	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

Date:12/22/04ISR Number: 4535468-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Valsartan	C		ORAL		
			Furosemide	C		ORAL		
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		

Allopurinol C ORAL

Date:12/22/04ISR Number: 4535469-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03129
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Amnesia
Disability	Asthenia
	Back Pain
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Chest Pain
	Coma
	Confusional State
	Constipation
	Dizziness
	Dyspepsia
	Eye Disorder
	Faeces Discoloured
	Fatigue
	Hallucination, Visual
	Headache
	Hypertension

		Lung Disorder					
		Meningitis					
		Meningitis Bacterial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON							
		Nervous System Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Neurological Symptom		Percocet	C		
UNKNOWN							
		Oedema Peripheral		Lipitor	C		
UNKNOWN							
		Optic Nerve Disorder		Paxil	C		
UNKNOWN							
		Palpitations		Naproxen	C		
UNKNOWN							
		Paraesthesia		Misoprostol	C		
UNKNOWN							
		Pulmonary Oedema		Nasonex	C		
UNKNOWN							
		Respiratory Tract		Mirapex	C		
UNKNOWN							
		Infection		Hydrocodone/Apap	C		
UNKNOWN							
		Skin Reaction		Gemfibrozil	C		
UNKNOWN							
		Stomach Discomfort		Dicloxacillin	C		
UNKNOWN							
		Tinnitus		Fluoxetine	C		
UNKNOWN							
		Transient Ischaemic		Ketoconazole	C		
UNKNOWN							
		Attack		Oxaprozin	C		
UNKNOWN							
		Ventricular Hypertrophy		Prevacid	C		
UNKNOWN							
		Vertigo		Wellbutrin	C		
UNKNOWN							
		Vision Blurred		Cytotec	C		
UNKNOWN							
				Bactroban	C		
UNKNOWN							
				Orphenadrine	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							

	Ambien	C	
UNKNOWN			
	Amlactin	C	
UNKNOWN			
	Polymyxin	C	
UNKNOWN			
	Topamax	C	
UNKNOWN			
	Zithromax	C	
UNKNOWN			
	Oxycontin	C	
UNKNOWN			
	Alprazolam	C	
UNKNOWN			

Date:12/22/04ISR Number: 4535470-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00538
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise		Isosorbide Dinitrate	C		ORAL		
	Electrocardiogram		Iodine	C		ORAL		
	Abnormal		Flupirtine Maleate	C				
UNKNOWN								
	Scan Myocardial Perfusion		Tetrazepam	C		ORAL		
	Abnormal		Tilidine					
	Somatoform Disorder		Hydrochloride	C		ORAL		
			Mometasone Furoate	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535471-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Angina Pectoris
	Anxiety
	Arrhythmia
	Balance Disorder
	Bladder Pain
	Cough
	Cystitis

		Cystitis Noninfective					
		Dermatitis					
		Dermatitis Allergic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Duodenal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia					
		Fall					
		Gastric Disorder					
		Gastric Ulcer					
		Haematuria					
		Headache					
		Helicobacter Gastritis					
		Hyperkeratosis					
		Hypertonic Bladder					
		Intestinal Haemorrhage					
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Knee Deformity					
		Ligament Sprain					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Palpitations					
		Reflux Oesophagitis					
		Renal Pain					
		Tinea Pedis					
		Tinnitus					
		Ventricular Fibrillation					

Date:12/22/04ISR Number: 4535473-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01207
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bronchitis Chronic		Vioxx	PS	Merck & Co., Inc	ORAL
		Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL
		Cataract		Xanax	C		
UNKNOWN							
		Coronary Artery Disease		Flonase	C		
UNKNOWN							
		Depression		Claritin	C		
UNKNOWN							
		Gastrooesophageal Reflux		Toprol Xl Tablets	C		
UNKNOWN							

	Disease	Lorazepam	C
UNKNOWN			
	Hypotrichosis	Estrace	C
UNKNOWN			
	Ischaemic Cardiomyopathy	Flurazepam	C
UNKNOWN			
	Mitral Valve Incompetence	Synthroid	C
UNKNOWN			
	Night Cramps	Altace	C
UNKNOWN			
	Oesophageal Candidiasis	Dalmane	C
UNKNOWN			
	Palpitations	Aspirin	C
UNKNOWN			
	Pulmonary Hypertension	Influenza Virus Vaccine (Unspecified)	C
	Silent Myocardial Infarction		
INTRAMUSCULAR			
	Tricuspid Valve Incompetence		
	Vertigo Positional		
	Vulval Haemorrhage		
	Weight Decreased		

Date:12/22/04ISR Number: 4535474-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00128
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deafness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oesophagitis							
	Transient Ischaemic Attack							

Date:12/22/04ISR Number: 4535475-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00375
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Oxycodone Hydrochloride	C		ORAL		
	Hypertension		Amitriptyline Hydrochloride	C		ORAL		
	Myocardial Infarction							
	Pseudoangina							
							428	DAY

Date:12/22/04ISR Number: 4535476-2Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00020
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
							679	YR
	Cerebrovascular Accident		Aspirin	C		ORAL		
	Skin Discolouration		[Therapy Unspecified]	C		ORAL		
			Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
			Zocor	C		ORAL		
			Omeprazole	C		ORAL		

Date:12/22/04ISR Number: 4535480-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00143
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Burning Sensation		Diovan	C				
UNKNOWN							3 YR	
	Chest Pain		Folic Acid	C				
UNKNOWN								
	Drug Effect Decreased		Methotrexate	C		ORAL		
3 YR								
	Headache		Aspirin	C		ORAL		
3 YR								
	Hyperhidrosis		[Therapy					
	Tremor		Unspecified]	C		ORAL		
3 YR								

Date:12/22/04ISR Number: 4535481-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01025
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535482-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00928
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Joint Dislocation							
Other	Myocardial Infarction							
	Osteoarthritis							

Date:12/22/04ISR Number: 4535483-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02777
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Darvocet-N	C				
UNKNOWN								
	Disease		Skelaxin	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535484-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04115
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Valium	C				
UNKNOWN								
	Palpitations							
	Syncope							
	Vomiting							

Date:12/22/04ISR Number: 4535485-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02837
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	
			Norvasc	C			
UNKNOWN							
			Metoprolol	C			
UNKNOWN							

Date:12/22/04ISR Number: 4535486-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00005
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		551 DAY
Initial or Prolonged			Norvasc	C		ORAL		
			Diovan Hct	C		ORAL		
			Foltx	C		ORAL		

Date:12/22/04ISR Number: 4535487-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00275
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Other	Fatigue		Plavix	C				
UNKNOWN								
	Fear		Synthroid	C				
UNKNOWN								
	Myocardial Infarction		Zetia	C		ORAL		
			Lotrel	C				
UNKNOWN								
			Zanaflex	C				
UNKNOWN								

				Skelaxin	C		
UNKNOWN							
				Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:12/22/04ISR Number: 4535488-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0411AUS00247
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure		Primidone	C				
UNKNOWN								
	Fluctuation		Clonazepam	C				
UNKNOWN								
	Cerebrovascular Accident		Ranitidine Hydrochloride	C				
	Dyspepsia							
UNKNOWN								
	Dysuria		Fluticasone Propionate	C				
	Erectile Dysfunction							
UNKNOWN								
	Tremor							

Date:12/22/04ISR Number: 4535490-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00552
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			Allegra	C				
UNKNOWN								
			Biaxin	C				
UNKNOWN								

			Zithromax	C		
UNKNOWN						
			Levaquin	C		
UNKNOWN						
			Travatan	C		
UNKNOWN						

Date:12/22/04ISR Number: 4535491-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00033
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Candesartan Cilexetil	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Cyanocobalamin And Folic Acid And Pyridoxine Hydrochloride	C		
UNKNOWN						

Date:12/22/04ISR Number: 4535492-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00018
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
223 DAY						
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
223 DAY						
Initial or Prolonged	Anaemia		Levothyroxine Sodium	C		ORAL
	Cardiac Failure Acute		Bisoprolol	C		ORAL
			Prednisolone	C		ORAL
			Furosemide	C		ORAL

Levomepromazine	C		ORAL
Ferrous Sulfate	C		ORAL
Acetaminophen And Propoxyphene Hydrochloride	C		ORAL
Sertraline Hydrochloride	C		ORAL

Date:12/22/04ISR Number: 4535493-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535494-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00136
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535496-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01775
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer		Pindolol	C				
UNKNOWN								
			Aspirin	C		ORAL		

Date:12/22/04ISR Number: 4535497-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01772
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
40 DAY								

Date:12/22/04ISR Number: 4535498-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02662
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypothyroidism		[Therapy Unspecified]	C				
	Poor Peripheral Circulation		Cardizem	C				
			Lipitor	C				
			Protonix	C				
			Levothyroxine Sodium	C				
			Allegra	C				
			Ultracet	C				

Date:12/22/04ISR Number: 4535500-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02668
Age:60 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN
		Procardia Xl	C			UNKNOWN	UNKNOWN
		Lodine Xl	C			UNKNOWN	UNKNOWN
		Tricor	C			UNKNOWN	UNKNOWN
		Prevacid	C			UNKNOWN	UNKNOWN
		Trazodone Hydrochloride	C			UNKNOWN	UNKNOWN
		Ativan	C			UNKNOWN	UNKNOWN
		Allopurinol	C			UNKNOWN	UNKNOWN
		Clonidine	C			UNKNOWN	UNKNOWN
		Buspar	C			UNKNOWN	UNKNOWN
		Tenormin	C			UNKNOWN	UNKNOWN
		Paxil	C			UNKNOWN	UNKNOWN
		Neurontin	C			UNKNOWN	UNKNOWN

Date:12/22/04ISR Number: 4535503-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01777
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:12/22/04ISR Number: 4535505-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ulcer Haemorrhage							

Date:12/22/04ISR Number: 4535506-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01937
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
	Headache		Claritin-D	C			UNKNOWN	
	Loss Of Consciousness		Valium	C			UNKNOWN	
	Pain In Extremity		Zantac	C			UNKNOWN	
	Renal Cyst		Patanol	C			UNKNOWN	
	Renal Impairment		Clonazepam	C			UNKNOWN	
			Lortab	C			UNKNOWN	
			Soma	C			UNKNOWN	
			Singulair	C			UNKNOWN	
			Hydrocortisone	C			UNKNOWN	
			Seroquel	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Albuterol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535507-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01866
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535509-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01997
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535510-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01865
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535511-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01938
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged UNKNOWN Disability	Cerebrovascular Accident		Vioxx Xanax Zoloft	PS C C	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535513-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535514-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02255
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Lipitor	C				
			Clarinex	C				
			Nexium	C				
			Xanax	C				
			Estrogens (Unspecified)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535515-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02236
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535517-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01863
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/22/04ISR Number: 4535518-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01955
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		[Therapy					
Other	Haemorrhage		Unspecified]	C				
UNKNOWN								
	Intervertebral Disc							
	Displacement							

Date:12/22/04ISR Number: 4535519-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Withdrawal Syndrome		Valium	C				
UNKNOWN								
	Oedema Peripheral		Vicoprofen	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535520-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02269
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535523-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/22/04ISR Number: 4535524-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02480
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nadolol	C				
UNKNOWN								
			Hydrodiuril	C		ORAL		
			Altace	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Glipizide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4535529-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00737
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Sinusitis		Cephalexin	C		ORAL		
Other	Adverse Event		Promethazine Hydrochloride	C				
	Angina Pectoris							
UNKNOWN	Blood Pressure Increased		Hydrocodone Hydrochloride	C				
	Bronchitis Acute							
UNKNOWN	Bunion							
	Chest Pain							
	Contusion							
	Convulsion							
	Drug Hypersensitivity							
	Facial Palsy							
	Fall							
	Foot Fracture							
	Headache							
	Joint Effusion							
	Joint Sprain							
	Meniscus Lesion							
	Migraine							
	Pharyngitis Streptococcal							
	Road Traffic Accident							
	Tibia Fracture							
	Tonsillitis							
	Urinary Tract Infection							

Date:12/22/04ISR Number: 4535533-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		584 DAY
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthma		Celebrex	C				
UNKNOWN	Back Pain		Clonidine	C				
UNKNOWN								

	Cardiac Failure	Demadex	C
UNKNOWN			
	Congestive	Digitek	C
UNKNOWN			
	Cardiomyopathy	Aspirin	C
UNKNOWN			
	Chronic Obstructive	Accupril	C
UNKNOWN			
	Pulmonary Disease		
	Convulsion		
	Gastrooesophageal Reflux		
	Disease		
	Hyperlipidaemia		
	Hypertension		
	Hypertensive Heart		
	Disease		
	Muscle Spasms		
	Pain In Extremity		
	Spinal Osteoarthritis		
	Tendonitis		

Date:12/22/04ISR Number: 4535536-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02242
Age:55 YR Gender:Male I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Malaise		[Therapy Unspecified]	C				
UNKNOWN								

Date:12/22/04ISR Number: 4535538-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03976
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
12 MON								
Initial or Prolonged	Chest Pain		[Therapy Unspecified]	C				
	Nervous System Disorder							
UNKNOWN								
	Nervousness							
	Renal Disorder							
	Unevaluable Event							

Date:12/22/04ISR Number: 4535539-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Coronary Artery Disease							
	Depression							
	Mood Swings							
	Panic Attack							
	Sleep Disorder							

Date:12/22/04ISR Number: 4535550-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01782
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Alcohol Use	Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Unstable	Vioxx	SS	Merck & Co., Inc	
UNKNOWN					
Other	Cerebrovascular Accident				
	Chest Pain				
	Coronary Artery Disease				
	Depression				
	Disease Progression				
	Dyslipidaemia				
	Dyspnoea				
	Flatulence				
	Gout				
	Hemiparesis				
	Hyperlipidaemia				
	Impaired Driving Ability				
	Local Swelling				
	Myocardial Infarction				
	Suicide Attempt				
	Ventricular Dysfunction				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4536578-7Report Type:Direct Company Report #CTU 234947
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx 25mg Merck	PS	Merck		25MG DAILY	
Life-Threatening	Cerebrovascular Accident							
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:12/22/04ISR Number: 4538666-8Report Type:Expedited (15-DaCompany Report #04-326
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness	Literature	Ibuprofen					
	Duodenal Ulcer	Health	(Ibuprofen)	PS				
	Dyspepsia	Professional	Rofecoxib					
	Faeces Discoloured		(Rofecoxib)	SS			25 MG	3 WK
	Gastritis		Muscle Relaxant					
	Haemoglobin Decreased		(Muscle Relaxants)	C				
	Helicobacter Pylori Identification Test Positive							
	Inadequate Analgesia							
	Upper Gastrointestinal Haemorrhage							

Date:12/22/04ISR Number: 4539058-8Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Neurontin					
	Back Pain	Health	(Gabapentin)	PS		ORAL	1800 MG (600 MG, 3 IN 1 D), ORAL	
Other	Chest Pain	Professional						
	Erectile Dysfunction							
	Facial Pain		Lipitor					

	Feeling Cold	(Atorvastatin)	SS	ORAL 20 MG (DAILY), ORAL
	Gastrooesophageal Reflux Disease	Lithium (Lithium)		
	Gingival Pain	(Lithium)	SS	
	Glossodynia	Naproxen (Naproxen)	SS	
	Hypersomnia	Rofecoxib		
	Irritability	(Rofecoxib)	SS	
	Nasopharyngitis	Amoxicillin		
	Neck Pain	(Amoxicillin)	SS	ORAL 1000 MG (BID), ORAL
	Nervous System Disorder			
	Oesophageal Spasm	Levothyroxine Sodium		
	Pain In Jaw	(Levothyroxine		
	Sleep Disorder	Sodium)	C	
	Somnolence	Vitamins (Vitamins)	C	
	Tooth Abscess	Diltiazem		
	Treatment Noncompliance	Hydrochloride		
	Tremor	(Diltiazem		
		Hydrochloride)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4539347-7Report Type:Expedited (15-DaCompany Report #2004240470GB
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Tamponade	Foreign	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Coronary Artery Thrombosis	Health Professional	Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Myocardial Infarction							

Date:12/23/04ISR Number: 4536736-1Report Type:Expedited (15-DaCompany Report #ES-JNJFOC-20041203249
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Topamax	PS			UNKNOWN	
Hospitalization -			Vioxx	SS			OROPHARINGEAL	
Initial or Prolonged			Acabel	C			OROPHARINGEAL	

Date:12/23/04ISR Number: 4537433-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00894
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Mass		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Humibid L.A.	C		ORAL		
Disability	Arthralgia		Detrol	C		ORAL		
	Chest Pain		Evista	C		ORAL		
	Coronary Artery Disease		Fosamax	C		ORAL		
	Cystitis Glandularis							
	Fall							
	Hypertension							
	Hypothyroidism							
	Injury							
	Osteoarthritis							
	Radius Fracture							
	Rhinitis							
	Spinal Osteoarthritis							

Urinary Tract Infection

Date:12/23/04ISR Number: 4537437-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00530
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Angina Pectoris Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537439-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00462
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	47	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	34	DAY
	Tachycardia Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537440-6Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00017
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		547 DAY
	Mental Impairment							
	Myocardial Infarction							

Date:12/23/04ISR Number: 4537441-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00963
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		350 DAY
Initial or Prolonged	Blood Cholesterol		Aspirin	C		ORAL		
Disability	Increased							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Chronic Fatigue Syndrome							
	Depression							
	Generalised Anxiety							
	Disorder							
	Mood Swings							
	Pollakiuria							
	Tricuspid Valve							
	Incompetence							

Date:12/23/04ISR Number: 4537444-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00598
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aortic Valve Stenosis							
	Coronary Artery Disease							
	Hypercholesterolaemia							

Date:12/23/04ISR Number: 4537451-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Back Pain
	Carpal Tunnel Syndrome
	Cerebral Ischaemia
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Chest Pain
	Depression
	Dizziness
	Emotional Distress
	Fatigue
	Headache
	Hypercholesterolaemia
	Hyperlipidaemia
	Hypertension
	Injury
	Insomnia
	Libido Decreased
	Lumbar Radiculopathy
	Mass

		Menopausal Symptoms Osteoarthritis Rheumatoid Arthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
257	DAY						
		Tachycardia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Vulvovaginal Dryness		Vioxx	SS	Merck & Co., Inc	ORAL
257	DAY						
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Estrogens (Unspecified)	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							

Date:12/23/04ISR Number: 4537454-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00357
Age:85 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged Disability		Dyspnoea Fatigue Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/23/04ISR Number: 4537455-8Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00042
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1462	DAY						
		Migraine					

Date:12/23/04ISR Number: 4537456-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02771
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	42 DAY	
Hospitalization - UNKNOWN	Arthralgia		Ultracet	C				
Initial or Prolonged UNKNOWN	Bone Disorder		Piroxicam	C				
Disability	Cerebrovascular Accident		[Therapy Unspecified]	C				
	Diabetes Mellitus		Hydrochlorothiazide	C				
	Dyspnoea		Verapamil	C				
	Feeling Abnormal		Fluoxetine	C				
	Hypertension		Insulin	C				
	Renal Failure		[Therapy Unspecified]	C				
	Wheezing		Theophylline	C				
			[Therapy Unspecified]	C				
			[Therapy Unspecified]	C				
			Potassium (Unspecified)	C				
			Metformin	C				
			Skelaxin	C				
			Nabumetone	C				
			[Therapy Unspecified]	C				
			Diclofenac Potassium	C				

				Flovent	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:12/23/04ISR Number: 4537457-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00698
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease Recurrence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Tilidine Hydrochloride	C		ORAL		
	Hypertension		Chlormezanone	C		ORAL		
	Inguinal Hernia		Moxonidine	C		ORAL		
	Insomnia		Distigmine Bromide	C		ORAL		
			Timolol	C		ORAL		
			Metoclopramide	C		ORAL		

Date:12/23/04ISR Number: 4537458-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03761
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Scar							
	Swelling							
	Thrombosis							

Date:12/23/04ISR Number: 4537459-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01663
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Methotrexate	C				
UNKNOWN								

Initial or Prolonged Disability			[Therapy Unspecified]	C		
UNKNOWN						
Other						

Date:12/23/04ISR Number: 4537460-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01668
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Urea Increased		Nexium	C		
UNKNOWN						
	Renal Disorder		Allegra	C		
UNKNOWN						
			Advair	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Flexeril	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537461-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01508
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Disability	Cardiac Failure		Lipitor	C				UNKNOWN
	Congestive		Prevacid	C				UNKNOWN
	Cardiac Murmur		Cefuroxime	C				UNKNOWN
	Dilatation Atrial		Clonazepam	C				UNKNOWN
	Lipids Increased							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Oedema							
	Pulmonary Arterial Pressure Increased							

Date:12/23/04ISR Number: 4537468-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01357
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Atenolol	C				UNKNOWN
	Breast Cancer		Actonel	C				UNKNOWN
	Breast Cancer Recurrent		Glucosamine	C				UNKNOWN
	Diastolic Dysfunction							
	Drug Ineffective							
	Hyperhidrosis							
	Mitral Valve Disease							
	Mitral Valve Incompetence							
	Muscle Spasms							
	Nausea							
	Tricuspid Valve Incompetence							

Date:12/23/04ISR Number: 4537469-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04423
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Chest Pain		Ativan	C				
	Cold Sweat							
	Dizziness							
	Dyspnoea							
	Fatigue							
	Vein Disorder							

Date:12/23/04ISR Number: 4537474-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00161
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1749 DAY
	Cerebral Ischaemia							
	Cerebrovascular Accident							
	Embolic Stroke							
	Hypertension							

Date:12/23/04ISR Number: 4537476-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00140
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537479-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00123
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
	Chest Discomfort							
	Chest Pain							
	Choking Sensation							
	Infarction							

Date:12/23/04ISR Number: 4537480-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00035
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1288	DAY
Initial or Prolonged								

Date:12/23/04ISR Number: 4537482-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00142
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537483-2Report Type:Expedited (15-DaCompany Report #BR-MERCK-0412BRA00075
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY	
	Depression		Vitamins (Unspecified)	C			UNKNOWN	
	Stress		Vitamins (Unspecified)	C			UNKNOWN	
			Fluoxetine	C			UNKNOWN	
			Suxibuzone	C			UNKNOWN	

Date:12/23/04ISR Number: 4537484-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00033
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Withdrawal Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neuroendocrine Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Subileus							

Date:12/23/04ISR Number: 4537495-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00631
Age:44 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration	Other
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL			
Anxiety		Vioxx	SS	Merck & Co., Inc				UNKNOWN
Back Pain		Ulcerin (Cimetidine)	C		ORAL			
Blood Cholesterol		Advil	C					UNKNOWN
Increased		A.S.A.	C		ORAL			
Blood Triglycerides		Ulcerin (Cimetidine)	C		ORAL			
Increased		Agyrax (Meclizine						
Cardiovascular Disorder		Hydrochloride)	C					UNKNOWN
Carpal Tunnel Syndrome		Trazodone						
Cerebrovascular Accident		Hydrochloride	C					UNKNOWN
Chest Pain		Protonix	C					UNKNOWN
Chronic Obstructive		Ecotrin	C					UNKNOWN
Pulmonary Disease		Ecotrin	C					UNKNOWN
Costochondritis		Hydrochlorothiazide	C					UNKNOWN
Cough		Hydrochlorothiazide	C					UNKNOWN
Dry Mouth		Lipitor	C					UNKNOWN
Fatigue		Carafate	C					UNKNOWN
Feeling Abnormal		Zocor	C					UNKNOWN
Gastrooesophageal Reflux		Zocor	C					UNKNOWN
Disease		Protonix	C					UNKNOWN
Headache		Aminophylline	C					UNKNOWN
Hemiparesis		Nexium	C					UNKNOWN
Hypertension		Nexium	C					UNKNOWN
Hypoaesthesia Oral		Protonix	C					UNKNOWN

	Hypotension	Elavil	C
UNKNOWN			
	Increased Upper Airway Secretion	Agyrax (Meclizine Hydrochloride)	C
UNKNOWN			
	Insomnia	A.S.A.	C
UNKNOWN			
	Monoplegia	A.S.A.	C
UNKNOWN			
	Multiple Sclerosis	Zestril	C
UNKNOWN			
	Musculoskeletal Chest	Plavix	C
UNKNOWN			
	Pain		
	Pain		
	Painful Respiration		
	Pleurisy		
	Renal Failure		
	Transient Ischaemic Attack		
	Upper Respiratory Tract Infection		
	Vision Blurred		

Date:12/23/04ISR Number: 4537505-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00051
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lasix (Furosemide Sodium)	C				
UNKNOWN								
			Glucophage	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537506-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01800
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Occlusion							
Initial or Prolonged	Myocardial Infarction							
Disability	Paralysis							
Other								

Date:12/23/04ISR Number: 4537508-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00530
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Hospitalization -	Chest Discomfort		Vioxx	SS	Merck & Co., Inc		UNKNOWN	DAY
Initial or Prolonged	Coronary Artery Disease		Prinivil	C			UNKNOWN	
	Myocardial Infarction		Atenolol	C			UNKNOWN	
	Neck Pain		Aspirin	C			UNKNOWN	
	Pain In Jaw		Crestor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:12/23/04ISR Number: 4537510-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00036
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	C			UNKNOWN	
			Aluminum Hydroxide And Magnesium					

			Carbonate	C			
UNKNOWN							

Date:12/23/04ISR Number: 4537511-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01822
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Hydrocortone	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:12/23/04ISR Number: 4537513-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01808
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:12/23/04ISR Number: 4537515-1Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0412NZL00029
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537517-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00162
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537518-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00141
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537521-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00686
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertensive Heart Disease							
Disability	Myocardial Infarction							

Date:12/23/04ISR Number: 4537522-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01610
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Hypertension	Premarin	C
Initial or Prolonged UNKNOWN	Loss Of Consciousness	Alprazolam	C
Disability UNKNOWN		Nitro	C

Date:12/23/04ISR Number: 4537537-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02201
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537539-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis Anaemia Angina Pectoris Atrial Fibrillation Atrioventricular Block Body Tinea

		Cardiovascular Disorder					
		Carotid Artery Stenosis					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Dermatitis					
		Diverticulum					
		Eczema					
		Epidermal Necrosis					
		Erythema Multiforme					
		Fluid Retention					
		Gastrointestinal Tract					
		Adenoma					
		Granuloma Annulare					
		Haemorrhoids					
		Hypercholesterolaemia					
		Hypertension					
		Leukocytoclastic					
		Vasculitis					
		Myocardial Ischaemia					
		Nail Bed Bleeding					
		Onycholysis					
		Polyp					
		Pruritus Ani					
		Psoriasis					
		Renal Failure Chronic					
		Vasculitis					
		Vertebral Artery Stenosis					

Date:12/23/04ISR Number: 4537542-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00472
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebral Infarction		Metoprolol	C		ORAL
		Disturbance In Attention		Allopurinol	C		ORAL
		Dizziness					
		Encephalopathy					
		Headache					
		Hypertension					
		Impaired Work Ability					
		Lacunar Infarction					
		Memory Impairment					
		Paralysis					

Stress
Vascular Encephalopathy

Date:12/23/04ISR Number: 4537543-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537545-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02202
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coagulopathy		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
Initial or Prolonged	Deep Vein Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537546-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02218
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		[Therapy Unspecified]	C				
UNKNOWN								

Date:12/23/04ISR Number: 4537552-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Spironolactone	C				
UNKNOWN								
	Blister Infected		Captopril Msd	C		ORAL		
	Blood Pressure Increased		Toprol Xl Tablets	C		ORAL		
	Breast Cancer In Situ							
	Breast Pain							
	Bronchitis							
	Bursitis							
	Cataract							
	Chest Pain							
	Colonic Polyp							
	Congenital Eye Naevus							
	Contusion							
	Endolymphatic Hydrops							
	Exostosis							
	Haemangioma							
	Haemorrhoids							
	Hypertension							
	Hypertensive Encephalopathy							
	Injury							
	Interstitial Lung Disease							
	Limb Discomfort							
	Loss Of Consciousness							
	Nausea							
	Osteoarthritis							
	Osteoporosis							
	Pain In Extremity							

Palatal Disorder
Palpitations
Plantar Fasciitis
Pulmonary Fibrosis
Pulmonary Hypertension
Rash
Respiratory Failure
Rhinitis
Seasonal Allergy
Seroma
Tendonitis
Transient Ischaemic
Attack
Vertebrobasilar
Insufficiency
Vitreous Detachment

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537566-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00662
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ischaemic Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lipitor	C				
	Lacunar Infarction		Coreg	C			UNKNOWN	
	Ophthalmoplegia		Lotrel	C			UNKNOWN	
			Zetia	C			UNKNOWN	MON
			Aspirin	C			UNKNOWN	
			Bextra	C			UNKNOWN	

Date:12/23/04ISR Number: 4537593-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00558
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY	
Hospitalization - Initial or Prolonged	Loss Of Consciousness							
Disability	Muscle Spasms							
	Neck Pain							
	Refusal Of Treatment By Patient							

Date:12/23/04ISR Number: 4537633-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02090
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged			Sulfasalazine	C				
Disability								

Date:12/23/04ISR Number: 4537638-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01973
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Aneurysm Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537640-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02123
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Dilatation Fatigue Insomnia Lethargy Myocardial Infarction Stress Tricuspid Valve Incompetence Ventricular Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537641-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01951
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematochezia		Motrin	C				
UNKNOWN								
Disability	Haemorrhage							
	Myocardial Infarction							
	Pain							

Date:12/23/04ISR Number: 4537642-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02100
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4537645-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02094
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy					
	Pain In Extremity		Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:12/23/04ISR Number: 4537646-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02101
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Acupril	C				UNKNOWN
	Attack		Insulin	C				UNKNOWN
			Pepcid	C				UNKNOWN

Date:12/23/04ISR Number: 4537647-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		130 DAY
Hospitalization - Initial or Prolonged	Congestive Myocardial Infarction							
Disability	Renal Failure							

Date:12/23/04ISR Number: 4537648-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02097
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/23/04ISR Number: 4537649-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01971
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/23/04ISR Number: 4538036-2Report Type:Direct Company Report #CTU 235031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS		ORAL	MAXIMUM X2	
	Diplopia						DAILY ORAL	
	Dizziness							
	Nausea							

Date:12/23/04ISR Number: 4538164-1Report Type:Direct Company Report #CTU 234992
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ventricular Extrasystoles		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG 5 X	
							PER MONTH	
							ORAL	
			Celebrex 400 Mg Pfizer	SS	Pfizer	ORAL	5 X PER MONTH	
							ORAL	

Date:12/23/04ISR Number: 4540117-4Report Type:Expedited (15-DaCompany Report #2004113030
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Colitis	Health	Solu-Medrol	
Hospitalization -	Gastrointestinal Disorder	Professional	(Methylprednisolone	
Initial or Prolonged	Peritonitis		Sodium Succinate)	PS
	Pneumoperitoneum		Perindopril	
	Small Intestinal		(Perindopril)	SS
2 MG (2 MG,				
	Perforation			
DAILY)				
			Glyceryl Trinitrate	
			(Glyceryl	
			Trinitrate)	SS
			Rofecoxib	
			(Rofecoxib)	SS
			Etanercept	
			(Etanercept)	SS
			Acetylsalicylate	
			Lysine	
			9acetylsalicylate	
			Lysine)	SS

Date:12/24/04ISR Number: 4537718-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02125
Age:73 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Cellulitis
Initial or Prolonged	Chest Pain
	Deep Vein Thrombosis
	Dyspnoea
	Epistaxis
	Fatigue

		Gastritis					
		Insomnia					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Flonase	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Inderal	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Fioricet Tablets	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Trental	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							

Date:12/24/04ISR Number: 4537719-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02398
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/24/04ISR Number: 4537720-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure					
Disability	Congestive					
	Transient Ischaemic					

Attack

Date:12/24/04ISR Number: 4537721-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

Date:12/24/04ISR Number: 4537722-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02206
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Contusion		Lisinopril	C			UNKNOWN	
	Dyspnoea		Hydrochlorothiazide	C			UNKNOWN	
	Hearing Impaired		Lescol	C			UNKNOWN	
	Hypotension		Aspirin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537727-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00827
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Adverse Event		St. Joseph Adult Chewable Aspirin	C				
	Arthralgia							
Other	Atrial Septal Defect		Norvasc	C				
	Bursitis		Paxil	C				
	Chest Discomfort		Paxil	C				
	Chest Pain		Lotensin	C				
	Chondromalacia		Xanax	C				
	Dilatation Atrial		Xanax	C				
	Dizziness		Restoril	C				
	Dyspnoea		Darvocet-N	C				
	Ear Infection		Allegra	C				
	Electrocardiogram St-T		Flovent	C				
	Change		Uniphyl	C				
	Eustachian Tube		Serevent	C				
	Dysfunction							
	Facial Pain		Albuterol	C				
	Fluid Retention							
	Headache		Mobic	C				
	Injury							
	Joint Swelling							
	Labyrinthitis							
	Mitral Valve Incompetence							
	Musculoskeletal Discomfort							

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
RESPIRATORY (INHALATION)
RESPIRATORY (INHALATION)
UNKNOWN

Nasal Sinus Drainage
Otitis Externa
Pain In Extremity
Pharyngolaryngeal Pain
Pulmonary Hypertension
Reflux Oesophagitis
Road Traffic Accident
Sinus Disorder
Sinusitis
Temporomandibular Joint
Syndrome
Tracheitis
Tricuspid Valve
Incompetence

Date:12/24/04ISR Number: 4537729-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02220
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain Gastric Disorder Urinary Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537732-0Report Type:Expedited (15-DaCompany Report #PH-MERCK-0410PHL00002
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Disability	Activated Partial Thromboplastin Time Prolonged

		Balance Disorder					
		Carotid Artery Stenosis					
		Cerebral Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Perindopril	C		ORAL
		Femur Fracture		Piracetam	C		ORAL
		Radius Fracture		[Therapy			
				Unspecified]	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		ORAL

Date:12/24/04ISR Number: 4537736-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acquired Claw Toe		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acute Myocardial		Zocor	C		ORAL
Other		Infarction		Plavix	C		ORAL
		Angina Unstable		Lotensin	C		ORAL
		Arthropathy		Metoprolol	C		ORAL
		Asthenia		Alfentanil			
		Back Pain		Hydrochloride	C		
UNKNOWN							
		Blood Pressure Increased		[Therapy			
		Bursitis		Unspecified]	C		ORAL
		Carotid Artery Stenosis		Aspirin	C		
UNKNOWN							
		Carpal Tunnel Syndrome					
		Cerebrovascular Accident					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Diabetic Neuropathy					
		Diabetic Retinopathy					
		Diarrhoea					
		Haemarthrosis					
		Headache					
		Injury					
		Monarthritis					
		Myocardial Infarction					
		Sleep Apnoea Syndrome					

Tendonitis

Date:12/24/04ISR Number: 4537744-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00879
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Lortab	C		ORAL		
	Contusion							
	Injury							
	Meniscus Lesion							
	Neck Injury							
	Pain In Extremity							
	Patellofemoral Pain Syndrome							

Date:12/24/04ISR Number: 4537745-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00848
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amenorrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Breast Lump Removal		Vioxx	SS	Merck & Co., Inc	ORAL		980 DAY
	Carotid Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervical Spasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Food Poisoning		Hydrochlorothiazide	C				UNKNOWN
	Hypertension		Norvasc	C				UNKNOWN
	Neck Injury		Ec Naprosyn	C				UNKNOWN
	Oedema		Ec Naprosyn	C				UNKNOWN
	Osteoarthritis							
	Pain In Extremity							
	Palpitations							
	Transient Ischaemic Attack							

Date:12/24/04ISR Number: 4537746-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00221
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Dyspnoea		Aspirin	C				UNKNOWN
Other			Tylenol	C				UNKNOWN
			Digoxin	C				UNKNOWN
			Metformin	C				UNKNOWN
			Glipizide	C				UNKNOWN
			Warfarin	C				UNKNOWN
			Lasix (Furosemide					

Sodium)	C	UNKNOWN
Vitamins (Unspecified)	C	UNKNOWN
Zocor	C	UNKNOWN

Date:12/24/04ISR Number: 4537747-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00701
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged	Angina Unstable Arthralgia Cardiac Failure Collagen Disorder Coronary Artery Disease Dyspnoea Hyperlipidaemia Hypertensive Cardiomyopathy Joint Swelling Myocardial Infarction Panniculitis Sudden Death		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537748-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00592
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Amlodipine Besylate	C		ORAL		
	Sudden Cardiac Death		Atorvastatin Calcium	C		ORAL		
			Ramipril	C		ORAL		
			Metoprolol Succinate	C		ORAL		
			Aspirin	C		ORAL		

Date:12/24/04ISR Number: 4537750-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00898
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cardiac Failure		Aspirin	C				
Initial or Prolonged UNKNOWN	Congestive		Atenolol	C				
Disability UNKNOWN	Hip Fracture		Vitamins (Unspecified)	C				

Date:12/24/04ISR Number: 4537752-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00140
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537753-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00263
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		145 DAY

	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
145 DAY						
	Blood Pressure Increased		Estrogens			
	Contusion		(Unspecified)	C		
UNKNOWN						
	Haematoma					
	Oedema Peripheral					

Date:12/24/04ISR Number: 4537754-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00144
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/24/04ISR Number: 4537755-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00069
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Initial or Prolonged						

Date:12/24/04ISR Number: 4537756-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02631
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Heart Rate Irregular Myocardial Infarction Oedema Peripheral							

Date:12/24/04ISR Number: 4537757-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00134
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537759-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02642
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537761-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00132
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537762-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01340
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Asthenia	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Back Injury	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomyopathy	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiovascular Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Chest Pain	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion	Hydrochlorothiazide	C		
UNKNOWN					
	Gastroenteritis	Zoloft	C		
UNKNOWN					
	Headache	[Therapy			
	Hernia	Unspecified]	C		
UNKNOWN					
	Hypertension	[Therapy			
	Ischaemia	Unspecified]	C		
UNKNOWN					
	Neck Injury				
	Vomiting				

Date:12/24/04ISR Number: 4537763-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00137
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/24/04ISR Number: 4537764-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00131
Age:62 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537765-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00143
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537766-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00135
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:12/24/04ISR Number: 4537769-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02621
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Norvasc	C			UNKNOWN	
			Lisinopril	C		ORAL		

Date:12/24/04ISR Number: 4537770-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00056
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Moxonidine	C		ORAL		
			Metoprolol	C		ORAL		

Date:12/24/04ISR Number: 4537771-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Depressed Mood Depression Disturbance In Attention Emotional Distress Expressive Language Disorder Mutism Social Avoidant Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537772-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00032
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Headache		Metoprolol Tartrate	C		ORAL		
	Pain In Extremity		Aspirin And					
	Transient Ischaemic		Magnesium Oxide	C		ORAL		
	Attack		Levothyroxine Sodium	C		ORAL		
			Lansoprazole	C		ORAL		

Date:12/24/04ISR Number: 4537773-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Celebrex	C				
UNKNOWN								

Date:12/24/04ISR Number: 4537774-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01768
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Nifedipine	C				
UNKNOWN								
	Drug Effect Decreased		Fosinopril Sodium	C				
UNKNOWN								
	Dyspnoea							

Date:12/24/04ISR Number: 4537775-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01742
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage		Vaseretic	C		ORAL		

		Heart Rate Irregular					
		Oedema Peripheral					

Date:12/24/04ISR Number: 4537776-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02004
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Osteoarthritis							

Date:12/24/04ISR Number: 4537777-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0412ITA00034
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc			
UNKNOWN	Infarction						2	YR
Initial or Prolonged			Carvedilol	C		ORAL		
Other	Angina Pectoris		Acenocoumarol	C		ORAL		
	Anxiety		Omeprazole	C		ORAL		
	Coronary Artery Occlusion		Sucralfate	C		ORAL		
	Depression		Amiodarone Hydrochloride	C		ORAL		
	Dilatation Ventricular		Amiodarone Hydrochloride	C		ORAL		
	Palpitations							
	Vascular Graft Occlusion							

			Lorazepam	C		ORAL
			Calcium Carbonate	C		
UNKNOWN						
			Clopidogrel Bisulfate	C		ORAL

Date:12/24/04ISR Number: 4537778-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02048
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 MON	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Other	Syncope					

Date:12/24/04ISR Number: 4537781-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02204
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN			Nitrofurantoin	C		
Initial or Prolonged UNKNOWN			Hydrochlorothiazide	C		
Disability			Ciprofloxacin Hydrochloride	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Fluoxetine	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						
			Docusate Sodium	C		
UNKNOWN						

			Omeprazole	C		
UNKNOWN						

Date:12/24/04ISR Number: 4537783-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death		[Therapy			
	Fall		Unspecified]	C		
UNKNOWN						
	Hip Fracture					

Date:12/24/04ISR Number: 4537784-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02268
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Prilosec	C		ORAL
			Fosamax	C		ORAL

Date:12/24/04ISR Number: 4537785-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
21 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537786-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Mass		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colon Operation							
	Cyst							
	Gastrointestinal Disorder							

Date:12/24/04ISR Number: 4537787-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537789-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02245
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Cortical		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Relpax	C			UNKNOWN	
			Topamax	C			UNKNOWN	

Date:12/24/04ISR Number: 4537790-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lymphoedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Phlebothrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Ibuprofen	C			UNKNOWN	
	Varicose Vein							

Date:12/24/04ISR Number: 4537791-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00700
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Fosamax	C		ORAL		
			Prednisolone	C				
			Calcium (Unspecified)	C				
			Enalapril Maleate	C				

Date:12/24/04ISR Number: 4537794-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537795-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537797-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537798-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:12/24/04ISR Number: 4537799-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537800-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:12/24/04ISR Number: 4537801-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537803-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02477
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537804-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03482
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Creatinine Increased
Hospitalization - Initial or Prolonged	Cardiac Stress Test Abnormal
	Proteinuria

Renal Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspirin	C			UNKNOWN	
	Potassium (Unspecified)	C			UNKNOWN	
	Lexapro	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Pravachol	C			UNKNOWN	
	Prinzide	C		ORAL		
	Diltiazem Hydrochloride	C			UNKNOWN	
	Lasix (Furosemide Sodium)	C			UNKNOWN	
	Lantus	C			UNKNOWN	

Date:12/24/04ISR Number: 4537805-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02800
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Ativan	C			UNKNOWN	
Initial or Prolonged Disability	Cardiomyopathy							

Date:12/24/04ISR Number: 4537806-4Report Type:Expedited (15-DaCompany Report #FI-MERCK-0410FIN00006
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Venous		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Thrombosis

Date:12/24/04ISR Number: 4537807-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00133
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537809-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01811
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	41 MON	

Date:12/24/04ISR Number: 4537810-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01744
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged Disability	Chest Pain		Vioxx Diovan	PS C	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537811-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02077
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
Disability	Chest Pain							
	Dyspnoea							
	Feeling Abnormal							
	Pain							
	Stress							

Date:12/24/04ISR Number: 4537813-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01927
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Ostial Stenosis		Plavix	C				
UNKNOWN								
Initial or Prolonged	Depression		Mavik	C				
UNKNOWN								
Other	Myocardial Infarction		Inderal	C				
UNKNOWN								
	Myocardial Ischaemia							
	Neoplasm Malignant							
	Ventricular Tachycardia							

Date:12/24/04ISR Number: 4537814-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00802
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arteritis		Bumex	C				
UNKNOWN								
Disability	Carpal Tunnel Syndrome		Duracef	C				
UNKNOWN								
	Cervicobrachial Syndrome							
	Contusion							
	Depression							
	Epicondylitis							

Intervertebral Disc
Protrusion
Lung Disorder
Neck Pain
Neuralgia
Osteoporosis
Radicular Pain
Road Traffic Accident

Date:12/24/04ISR Number: 4537816-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Antiphospholipid Syndrome
	Asthenia
	Back Disorder
	Balance Disorder
	Blood Pressure Increased
	Cerebrovascular Accident
	Convulsion
	Cow'S Milk Intolerance
	Diabetes Mellitus
	Non-Insulin-Dependent

		Dizziness					
		Drug Hypersensitivity					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
81	DAY						
		Hemiparesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Ischaemia		Advil	C		ORAL
		Labyrinthitis		Prempro	C		
UNKNOWN							
		Muscle Spasms		Prilosec	C		
UNKNOWN							
		Neck Injury		Synthroid	C		
UNKNOWN							
		Tinnitus		Diovan	C		
UNKNOWN							
		Tongue Ulceration		Dimethyl Sulfone	C		
UNKNOWN							
		Urticaria Generalised		Gaviscon Antacid			
		Vasculitis		Tablets	C		
UNKNOWN							
				Hydrocodone Hydrochloride	C		
UNKNOWN							
				[Therapy Unspecified]	C		ORAL

Date:12/24/04ISR Number: 4537818-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02977
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
69	MON					
Initial or Prolonged	Cerebrovascular Accident		Zocor	C		ORAL
	Chest Discomfort					
	Diplopia					
	Dizziness					
	Pain					
	Vision Blurred					

Date:12/24/04ISR Number: 4537819-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01171
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Fall Heart Rate Increased Hip Fracture Injury Loss Of Consciousness Myocardial Infarction Pain		Propranolol Hydrochloride	C		ORAL		

Date:12/24/04ISR Number: 4537823-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537825-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00130
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537828-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02530
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Wellbutrin	C			UNKNOWN	
Disability	Asthenia		Wellbutrin	C			UNKNOWN	
	Blood Triglycerides		Nitroglycerin	C			UNKNOWN	
	Increased		Ultram	C			UNKNOWN	
	Chest Pain		Ultracet	C			UNKNOWN	
	Cholecystitis Chronic		Butalbital	C			UNKNOWN	
	Cholelithiasis		Aspirin	C			UNKNOWN	
	Cystitis							
	Emotional Distress							
	Hyperlipidaemia							
	Hypertension							
	Hypothyroidism							
	Ingrowing Nail							
	Migraine							
	Migraine Without Aura							
	Myocardial Infarction							
	Obesity							
	Pain							
	Rhinitis							
	Upper Respiratory Tract Infection							

Date:12/24/04ISR Number: 4537829-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00902
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Suicidal Ideation							

Date:12/24/04ISR Number: 4537830-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00538
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise		Isosorbide Dinitrate	C		ORAL		
	Electrocardiogram		Iodine	C		ORAL		
	Abnormal		Flupirtine Maleate	C				
UNKNOWN								
	Somatoform Disorder		Tetrazepam	C		ORAL		
			Tilidine Hydrochloride	C		ORAL		
			Mometasone Furoate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537831-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		115 DAY
Initial or Prolonged	Back Pain		Haldol	C				UNKNOWN
Other	Coronary Artery Disease		Hydrocodone					
	Depression		Bitartrate	C				UNKNOWN
	Gout							
	Intervertebral Disc							
	Protrusion							
	Local Swelling							
	Myocardial Infarction							
	Neck Pain							
	Pain In Extremity							
	Post Procedural							
	Complication							
	Weight Increased							

Date:12/24/04ISR Number: 4537832-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02195
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537833-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00721
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Affective Disorder		Remeron	C				UNKNOWN
Other	Aggression		Elavil	C				UNKNOWN
	Angina Pectoris		Vicodin Tablets	C				UNKNOWN

	Anxiety	Soma	C
UNKNOWN			
	Bipolar Disorder Blood Pressure Increased Bronchitis Convulsion Delusion Delusional Disorder, Persecutory Type Depression Fluid Retention Hypertension Intervertebral Disc Protrusion Osteoarthritis Pain Road Traffic Accident Sciatica Spinal Osteoarthritis Stress		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537835-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00138
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537836-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00125
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Depression							
	Myocardial Infarction							

Date:12/24/04ISR Number: 4537837-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00795
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia
Other	Anhedonia
	Arthralgia
	Cardiomegaly
	Cataract
	Chest Discomfort
	Chest Pain
	Compression Fracture
	Condition Aggravated
	Deep Vein Thrombosis
	Dementia
	Dementia Alzheimer'S Type
	Depression
	Depressive Symptom
	Dermatitis
	Dyspnoea
	Dyspnoea Exertional
	Gastric Disorder
	Hypertonic Bladder
	Hypothyroidism
	Injury

Insomnia
Intervertebral Disc
Degeneration
Lumbar Radiculopathy
Lumbar Spinal Stenosis
Myalgia
Nerve Compression
Osteoarthritis
Osteoporosis
Phlebothrombosis
Post Procedural Haematoma
Radiculopathy
Rash
Sciatica
Seroma
Skin Ulcer
Spinal Claudication
Spinal Compression
Fracture

		Thrombophlebitis Superficial					
		Treatment Noncompliance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Venous Insufficiency		Vioxx	PS	Merck & Co., Inc	ORAL
		Vertigo Positional		Levothroid	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							
				Os-Cal D	C		
UNKNOWN							
				Potassium (Unspecified)	C		ORAL
				Tylenol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Dulcolax	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							

Date:12/24/04ISR Number: 4537839-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03854
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Coma		[Therapy			
Initial or Prolonged	Myocardial Infarction		Unspecified]	C		
UNKNOWN						
Disability	Renal Failure					

Date:12/24/04ISR Number: 4537843-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01091
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	419	DAY
Hospitalization -	Anal Fissure		Benadryl	C				
UNKNOWN								
Initial or Prolonged	Anal Skin Tags		Anacin	C				
UNKNOWN								
Disability	Anxiety Disorder		Zantac	C				
UNKNOWN								
	Chest Pain		Protonix	C				
UNKNOWN								
	Constipation		Surfak	C				
UNKNOWN								
	Depression							
	Diverticulitis							
	Dysarthria							
	Dyspnoea							
	Fibrocystic Breast Disease							
	Hypertension							
	Ischaemic Stroke							
	Rectal Ulcer							

Date:12/24/04ISR Number: 4537847-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00649
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Adverse Event
	Apnoea
	Asthenia
	Biliary Neoplasm

		Blood Cholesterol					
		Bradycardia					
		Calcinosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Cholecystitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholecystitis Acute		Toprol Xl Tablets	SS		
UNKNOWN							
		Cholelithiasis		Wellbutrin Sr	C		
UNKNOWN							
		Coma		Keflex	C		
UNKNOWN							
		Cyanosis		Aspirin	C		
UNKNOWN							
		Drug Effect Decreased		Tylenol	C		
UNKNOWN							
		Dry Mouth		Pepcid	C		ORAL
		Dyspnoea					
		Eating Disorder					
		Fatigue					
		Feeling Abnormal					
		Gastric Polyps					
		Hepatic Steatosis					
		Hyperlipidaemia					
		Iatrogenic Injury					
		Low Density Lipoprotein Increased					
		Nasopharyngitis					
		Nausea					
		Oedema Peripheral					
		Pain In Extremity					
		Palpitations					
		Pancreatitis					
		Pancreatitis Acute					
		Polytraumatism					
		Pulmonary Hypertension					
		Refusal Of Treatment By Patient					
		Supraventricular Extrasystoles					
		Supraventricular Tachycardia					
		Treatment Noncompliance					
		Very Low Density Lipoprotein Increased					
		Vomiting					
		Weight Decreased					

Weight Increased

Date:12/24/04ISR Number: 4537853-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00785
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenoma Benign		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bladder Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Digoxin	C		ORAL		
	Cardiomegaly		Pravastatin Sodium	C		ORAL		
	Convulsion		Cartia Xt	C		ORAL		
	Cystitis Noninfective		Pletal	C		ORAL		
	Myocardial Ischaemia		Vitamin E	C		ORAL		
	Nodule		Ascorbic Acid	C		ORAL		
	Prostatitis		Vitamins (Unspecified) And Minerals					

	(Unspecified)	C	ORAL
	Flomax (Morniflumate)	C	ORAL

Date:12/24/04ISR Number: 4537854-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01097
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537855-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged UNKNOWN	Abdominal Pain Abscess		Vioxx Effexor Xr	PS C	Merck & Co., Inc	ORAL		
Other	Adverse Event Angina Pectoris Atelectasis Blood Cholesterol Increased Blood Glucose Decreased Bronchitis Cardiac Failure Congestive Cervical Cyst Chest Pain Convulsion Dyspnoea Facial Palsy Gastrooesophageal Reflux Disease Hand Fracture Headache Hypertension Hypoaesthesia Hypokalaemia Leukocytosis Nausea Pain In Extremity							

Palpitations
Pneumonitis
Rotator Cuff Syndrome
Transient Ischaemic
Attack
Trigger Finger
Tubo-Ovarian Abscess
Umbilical Hernia
Vomiting

Date:12/24/04ISR Number: 4537861-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02140
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	General Symptom		[Therapy					
Initial or Prolonged	Heart Rate Increased		Unspecified]	C				
UNKNOWN								
Disability	Kidney Infection							

Date:12/24/04ISR Number: 4537863-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00139
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537865-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00012
Age:30 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acne		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Arthralgia		Darvocet-N	C			UNKNOWN	
	Chest Pain		Soma	C			UNKNOWN	
	Diabetes Mellitus		Tylenol	C			UNKNOWN	
	Dysuria		[Therapy Unspecified]	C			UNKNOWN	144 DAY
	Fatigue							
	Feeling Abnormal							
	Fibromyalgia							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Hemiparesis							
	Hypoaesthesia							
	Infection							
	Inflammation							
	Injury							
	Intervertebral Disc Degeneration							
	Irritable Bowel Syndrome							
	Joint Dislocation							
	Joint Effusion							
	Joint Sprain							
	Lipoma							
	Multiple Allergies							
	Myalgia							
	Pain In Extremity							

Pharyngitis
Pharyngolaryngeal Pain
Spinal Osteoarthritis
Trichomoniasis

Date:12/24/04ISR Number: 4537867-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03598
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Premarin	C		ORAL		
			Celexa	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Lotensin	C		ORAL		
			Lotensin	C		ORAL		
			Norvasc	C		ORAL		
			Norvasc	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537869-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00868
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Zantac	C			UNKNOWN	
	Back Injury		Reglan	C			UNKNOWN	
	Blood Pressure Increased		Dicyclomine Hydrochloride	C			UNKNOWN	
	Bronchitis							
	Bursitis		Procardia	C			UNKNOWN	
	Cerebrovascular Accident		Vicodin Es Tablets	C			UNKNOWN	
	Chest Pain		Vicodin Es Tablets	C			UNKNOWN	
	Colonic Polyp		Arthrotec	C			UNKNOWN	
	Cyst		Ditropan Xl	C			UNKNOWN	
	Depression		Adalat	C			UNKNOWN	
	Diarrhoea		Quinine	C			UNKNOWN	
	Difficulty In Walking		Crixivan	C		ORAL		
	Disorientation		Crixivan	C		ORAL		
	Diverticulum		Combivir	C			UNKNOWN	
	Dizziness		Bactrim	C			UNKNOWN	
	Drug Ineffective		Allegra	C			UNKNOWN	
	Dysarthria		Diflucan	C			UNKNOWN	
	Dyspnoea		Desyrel	C			UNKNOWN	
	Dysstasia		Skelaxin	C		ORAL		
	Fall		Xanax	C			UNKNOWN	
	Fracture Nonunion							
	Gastroenteritis							

Gastrointestinal
Haemorrhage
Genital Pruritus Female
Headache
Hip Fracture
Hypersensitivity
Hypertension
Hypoaesthesia
Impaired Healing
Injury
Insomnia
Intervertebral Disc
Protrusion
Loss Of Consciousness
Macrocytosis
Muscle Spasms
Neuropathy
Pneumonia
Polyuria
Pyrexia
Sepsis
Syncope
Tachycardia
Tongue Discolouration
Tongue Disorder
Urinary Incontinence
Vaginal Burning Sensation
Vision Blurred
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537873-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00632
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	37	DAY
	Arthralgia		Vicodin Tablets	C		ORAL		
	Arthritis		Clonidine	C		ORAL		
	Asthenia							
	Back Injury							
	Back Pain							
	Blood Pressure Increased							
	Cardiomegaly							
	Chest Pain							
	Chest Wall Pain							
	Contusion							
	Depression							
	Difficulty In Walking							
	Dizziness							
	Drug Ineffective							
	Excoriation							
	Fall							
	Gait Disturbance							
	Gastric Haemorrhage							
	Haematocrit Decreased							
	Injury							
	Intervertebral Disc Protrusion							
	Joint Crepitation							
	Joint Effusion							
	Joint Injury							
	Joint Range Of Motion Decreased							
	Joint Sprain							
	Loose Body In Joint							
	Meniscus Lesion							
	Muscle Spasms							
	Oedema Peripheral							
	Osteoarthritis							
	Tenderness							
	Upper Respiratory Tract Infection							

Date:12/24/04ISR Number: 4537879-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abscess
Other	Adverse Event
	Anaemia
	Angina Unstable
	Anxiety
	Arrhythmia
	Arthralgia
	Arthropathy
	Asthenia
	Back Pain
	Bacterial Infection
	Barrett'S Oesophagus

Blood Alkaline
Phosphatase Increased
Blood Pressure Increased
Breast Pain
Cartilage Injury
Cataract
Cervicobrachial Syndrome
Chest Pain
Chest Wall Pain
Cholelithiasis
Convulsion
Corneal Scar
Coronary Artery Disease
Coronary Artery Stenosis
Cough
Depression
Dermatitis Contact
Dizziness
Dyspepsia
Dysphagia
Dyspnoea
Dysuria
Eosinophil Count
Increased
Extradural Abscess
Fibrosis
Gamma-Glutamyltransferase
Increased
Gastritis
Haematocrit Decreased
Haemoglobin Decreased
Headache
Hepatic Enzyme Increased
Hypercholesterolaemia
Hyperlipidaemia
Hypersensitivity
Hypertension
Hypoaesthesia
Intervertebral Discitis
Lethargy
Lipase Increased
Lipoma
Lymphadenopathy
Lymphangitis
Medical Device Removal
Migraine
Muscle Mass

Myocardial Infarction
Nausea
Neck Pain
Neoplasm
Neuralgia
Nuclear Magnetic
Resonance Imaging
Abnormal
Oedema Peripheral
Oesophagitis
Osteoarthritis
Osteomyelitis
Pain In Extremity
Palpitations

	Pancreatitis						
	Pharyngolaryngeal Pain						
	Platelet Count Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pleural Fibrosis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Polyneuropathy		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pyrexia		Hydrodiuril	C		ORAL	
	Red Blood Cell		Norvasc	C			UNKNOWN
	Sedimentation Rate		Vicodin Es Tablets	C			UNKNOWN
	Increased						
	Rotator Cuff Syndrome						
	Spondylolisthesis						
	Suicidal Ideation						
	Tendon Disorder						
	Tendon Injury						
	Therapeutic Response						
	Decreased						
	Tricuspid Valve						
	Incompetence						
	Upper Respiratory Tract						
	Infection						
	Ventricular Extrasystoles						
	Ventricular Hypertrophy						
	Vomiting						
	Weight Decreased						
	White Blood Cell Count						
	Increased						
	Wound Infection						
	Staphylococcal						

Date:12/24/04ISR Number: 4537884-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc		UNKNOWN
Initial or Prolonged	Palpitations						

Date:12/24/04ISR Number: 4537885-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00784
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Adverse Drug Reaction
	Adverse Event
	Arthralgia
	Asthenia
	Azotaemia
	Back Pain
	Breast Mass
	Dehydration
	Diabetes Mellitus
	Diverticulum
	Dyskinesia
	Dysuria
	Eczema
	Faeces Discoloured
	Fatigue
	Gallbladder Enlargement
	Hepatitis
	Herpes Zoster
	Hypertensive Emergency

		Hypertrophy					
		Influenza					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Displacement		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Protrusion		Norvasc	C		
UNKNOWN							
		Myalgia		Hydrochlorothiazide	C		
UNKNOWN							
		Oedema Peripheral		Diovan	C		
UNKNOWN							
		Pollakiuria		Pravachol	C		
UNKNOWN							
		Pyrexia		Gemfibrozil	C		
UNKNOWN							
		Radiculopathy					
		Rectal Haemorrhage					
		Rhabdomyolysis					
		Scoliosis					
		Seborrhoeic Keratosis					
		Spinal Osteoarthritis					
		Splenic Cyst					
		Spondylolisthesis					
		Tendonitis					
		Vomiting					
		Weight Decreased					

Date:12/24/04ISR Number: 4537890-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00739
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Ammonia Increased
Other	Amnesia
	Angina Pectoris
	Anxiety
	Blood Bilirubin
	Unconjugated Increased
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Carotid Artery Stenosis
	Cerebral Atrophy
	Cerebral Disorder

Chest Pain
Convulsion
Decreased Appetite
Depression
Dizziness
Fall
Feeling Abnormal
Gait Disturbance
Headache
Heart Rate Irregular
Hepatic Function Abnormal
Hepatic Steatosis
Hepatitis A Antibody
Abnormal
Hypertension
Hypertensive Heart
Disease
Insomnia
Lacunar Infarction
Liver Function Test
Abnormal

		Memory Impairment					
		Mental Disorder Due To A General Medical Condition	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity					
		Pericardial Effusion					
		Renal Cyst					
		Renal Failure					
		Sinus Disorder					
		Tinnitus					
		Vascular Dementia					
		Ventricular Hypertrophy					
		Vision Blurred					

Date:12/24/04ISR Number: 4537891-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02210
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Dilatation Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Cozaar	C		
UNKNOWN			Lasix (Furosemide)	C		
UNKNOWN			Norvasc	C		
UNKNOWN			[Therapy Unspecified]	C		
UNKNOWN			Minoxidil	C		
UNKNOWN			Coumadin	C		
UNKNOWN			Metoprolol	C		
UNKNOWN						

Date:12/24/04ISR Number: 4537892-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower

Initial or Prolonged	Adverse Event
Other	Alopecia
	Anaemia
	Angina Pectoris
	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Blood Pressure Increased
	Bradycardia
	Chest Pain
	Coccydynia
	Colon Adenoma
	Colonic Polyp
	Convulsion
	Coronary Artery Disease
	Coronary Artery Insufficiency
	Dermatitis Exfoliative
	Dizziness
	Drug Ineffective
	Duodenal Ulcer
	Dyspnoea
	Dyspnoea Exertional
	Eczema
	Gastritis

		Gastrointestinal Arteriovenous Malformation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Hypotension		Zestril	SS		
UNKNOWN							
		International Normalised		Isosorbide	C		
UNKNOWN							
		Ratio Increased		Cardura	C		
UNKNOWN							
		Joint Sprain		Zocor	C		ORAL
		Myocardial Infarction		Aspirin	C		
UNKNOWN							
		Myocardial Ischaemia					
		Nasal Congestion					
		Nasal Polyps					
		Neck Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Postnasal Drip					
		Prothrombin Time Prolonged					
		Pulmonary Congestion					
		Reflux Oesophagitis					
		Rhinitis					
		Rhinitis Allergic					
		Rhinorrhoea					
		Sinusitis					
		Skin Lesion					
		Sleep Disorder					
		Weight Decreased					

Date:12/24/04ISR Number: 4537895-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00137
Age:38 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/24/04ISR Number: 4537897-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00654
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Angina Pectoris
	Anxiety
	Arthralgia
	Arthropod Sting
	Blister
	Bronchitis
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Carpal Tunnel Syndrome
	Cellulitis
	Chest Pain
	Conjunctival Hyperaemia
	Cough
	Deep Vein Thrombosis
	Dyspnoea
	Dysuria
	Epistaxis
	Facial Pain
	Fatigue

	Hypertension						
	Injury						
	Insomnia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL	154	MON
	Nephropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pharyngolaryngeal Pain		Avalide	C			UNKNOWN	2 MON
	Postnasal Drip		Prilosec	C			UNKNOWN	
	Pulse Abnormal		Synthroid	C		ORAL		
	Renal Failure Chronic		Aspirin	C			UNKNOWN	
	Skin Cancer		Pyridoxine	C			UNKNOWN	
	Tinnitus		Vitamin E	C			UNKNOWN	
	Tonsillar Disorder		Cipro	C		ORAL		
	Urinary Tract Infection		Duracef	C			UNKNOWN	
			Celestone	C			UNKNOWN	

Date:12/24/04ISR Number: 4537900-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00852
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Celebrex	C		ORAL		
	Arthralgia		Darvocet-N	C			UNKNOWN	
	Arthritis		Ambien	C			UNKNOWN	
	Atrioventricular Block		Toprol Xl Tablets	C			UNKNOWN	
	First Degree		Florone	C			UNKNOWN	
	Back Pain		Flexeril	C			UNKNOWN	
	Blood Pressure Systolic		Aspirin	C			UNKNOWN	

	Increased	Serzone	C
UNKNOWN			
	Bronchitis	Prilosec	C
UNKNOWN			
	Cerebrovascular Accident	Glucotrol Xl	C
UNKNOWN			
	Chronic Obstructive	Zestril	C
UNKNOWN			
	Pulmonary Disease	Lipitor	C
UNKNOWN			
	Coronary Artery Disease		
	Cough		
	Dizziness		
	Dyspnoea		
	Facet Joint Syndrome		
	Fatigue		
	Flushing		
	Gastroenteritis Viral		
	Hyperhidrosis		
	Hypersensitivity		
	Injury		
	Intermittent Claudication		
	Intervertebral Disc Degeneration		
	Lumbar Radiculopathy		
	Nodal Arrhythmia		
	Pain In Extremity		
	Paraesthesia		
	Peripheral Vascular Disorder		
	Productive Cough		
	Serum Serotonin Decreased		
	Sneezing		
	Spinal Column Stenosis		
	Upper Respiratory Tract Infection		
	Ventricular Dysfunction		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/04ISR Number: 4537902-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		560 DAY
Initial or Prolonged	Anxiety		Diovan	C				UNKNOWN
Disability	Back Disorder		Lasix (Furosemide)	C				UNKNOWN
Other	Blood Cholesterol		Lasix (Furosemide)	C				UNKNOWN
	Increased		Nexium	C				UNKNOWN
	Blood Pressure Decreased		Zaroxolyn	C				UNKNOWN
	Blood Triglycerides		Torsemide	C				UNKNOWN
	Increased		Oxycontin	C				UNKNOWN
	Bronchitis		Ultram	C				UNKNOWN
	Cardiomegaly		Neurontin	C				UNKNOWN
	Cerebrovascular Accident		Zanaflex	C				UNKNOWN
	Chest Pain		Celexa	C				UNKNOWN
	Chronic Fatigue Syndrome		Potassium Chloride	C				UNKNOWN
	Clostridium Colitis		Amitriptyline Hydrochloride	C				UNKNOWN
	Convulsion							
	Depression		Amitriptyline Hydrochloride	C				UNKNOWN
	Dizziness							
	Emotional Distress		Ambien	C				UNKNOWN
	Fibrosis		Aleve	C				UNKNOWN
	Fluid Retention		Lexapro	C				UNKNOWN
	Gastrooesophageal Reflux		Alprazolam	C				UNKNOWN
	Disease		Nortriptyline	C				UNKNOWN

Haematochezia
Headache
Hyperlipidaemia
Hypoxia
Ileus
Lumbar Radiculopathy
Myocardial Infarction
Nephrolithiasis
Oedema
Pneumonia
Pneumonia Aspiration
Pneumonia Pneumococcal
Rash
Renal Failure Acute
Rhabdomyolysis
Sinusitis
Spinal Compression
Fracture
Staphylococcal Infection

Date:12/24/04ISR Number: 4537907-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00770
Age:73 YR Gender:Male I/FU:F

Outcome PT
Other Abdominal Pain Upper
Adverse Event
Angina Pectoris
Arthritis
Blood Pressure Increased
Cerebrovascular Accident
Convulsion
Electrocardiogram St-T
Segment Abnormal
Gastrooesophageal Reflux
Disease

	Sinus Arrhythmia Sinus Bradycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Baycol	C		ORAL		
			Glynase Prestab Tablets	C		ORAL		
			Levothroid	C		ORAL		
			Imdur	C			UNKNOWN	
			Procardia Xl	C		ORAL		
			Metoprolol	C			UNKNOWN	
			Lasix (Furosemide)	C		ORAL		
			Aspirin	C			UNKNOWN	
			Glucophage	C		ORAL		
			Synthroid	C			UNKNOWN	
			Tylenol With Codeine #3	C			UNKNOWN	

Date:12/24/04ISR Number: 4537908-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00709
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Adverse Event Blood Glucose Increased Blood Pressure Increased Convulsion Coronary Artery Disease Coronary Artery Stenosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/24/04ISR Number: 4537912-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02876
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Initial or Prolonged	Atrial Fibrillation	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol Increased	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure Congestive	Vioxx	SS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
		Drysol	C		
UNKNOWN	Congestive Cardiomyopathy Coronary Artery Disease Depression Drug Ineffective Dyspnoea Headache Hyperhidrosis Hyperlipidaemia Insomnia Myocardial Infarction Palpitations Pericardial Effusion Pericarditis Seasonal Allergy Syncope Syncope Vasovagal Tendon Injury Ventricular Tachycardia Viral Infection				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/04ISR Number: 4542291-2Report Type:Expedited (15-DaCompany Report #2004113482
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Drug Ineffective		Rofecoxib (Rofecoxib)	SS				

Date:12/27/04ISR Number: 4542347-4Report Type:Expedited (15-DaCompany Report #2004097559
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Haemorrhage	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib	SS				
			Paracetamol	C				
			Valdecoxib	C				
			Paracetamol	C				
			Valdecoxib	C				

Date:12/27/04ISR Number: 4542475-3Report Type:Expedited (15-DaCompany Report #2004114350
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Celebrex (Celecoxib)	PS		ORAL	200 GM (200 MG 1 IN 1 D ORAL)	
	Coronary Artery Occlusion							
	Dizziness							
	Drug Ineffective		Rofecoxib(Rofecoxib)	SS		ORAL	25 MG (25 MG 1 IN 1 D) ORAL	
	Hyperhidrosis							
	Nausea							
	Pain		Lisinopril (Lisinopril)	C				
			Metorpolol (Metoprolol)	C				

				Lovastatin (Lovastatin)	C	
				Lansoprazole (Lansoprazole)	C	

Date:12/27/04ISR Number: 4542523-0Report Type:Expedited (15-DaCompany Report #2004116207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)	PS		
	Chest Pain					
	Dyspnoea		Rofecoxib (Rofecoxib)	SS		
	Gastrointestinal Ulcer					

Date:12/27/04ISR Number: 4549071-2Report Type:Periodic Company Report #04P-163-0262528-00
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Neoplasm Prostate	Consumer Health Professional	Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe (Humira) (Adalimumab) (Adalimumab)	PS		

SUBCUTANEOUS 40 MG, 1 IN 2

WK,

SUBCUTANEOUS

			Rofecoxib	SS		ORAL
PER ORAL						
			Methotrexate Sodium	C		
			Folic Acid	C		
			Paracetamol	C		
			Amitriptyline	C		
			Prednisone	C		
			Multivitamins	C		
			Tocopherol	C		
			Alendronate Sodium	C		
			Ergocalciferol	C		
			Calcium	C		
			Magnesium	C		

Date:12/28/04ISR Number: 4539457-4Report Type:Direct Company Report #USP 57011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Medication Error		Xanax	PS	Mylan	
TABLET						
			Vioxx	SS	M & D	
TABLET						

Date:12/28/04ISR Number: 4539644-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00318
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Prosthesis Implantation		Ciprofloxacin			
	Sepsis		Hydrochloride	C		ORAL
29 DAY						
			Leflunomide	C		ORAL
			Methylprednisolone	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Oxybutynin	C		ORAL
			Enoxaparin Sodium	C		
PARENTERAL						

Date:12/28/04ISR Number: 4539656-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00500
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain							
Initial or Prolonged	Deep Vein Thrombosis							
Other	Dyspnoea							

Date:12/28/04ISR Number: 4539657-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02036
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Pravachol	C			UNKNOWN	
			Gemfibrozil	C			UNKNOWN	
			Protonix	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4539658-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00512
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Asthenia Meniere'S Disease		Vioxx Venlafaxine Hydrochloride	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:12/28/04ISR Number: 4539659-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01665
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident Gastrointestinal Tract		Vioxx Zocor	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								
	Adenoma Transient Ischaemic		Vitamins (Unspecified)	C				
UNKNOWN								
	Attack							

Date:12/28/04ISR Number: 4539660-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00046
Age:23 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced Drug Exposure During Pregnancy		Vioxx Esomeprazole Magnesium	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:12/28/04ISR Number: 4539662-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0411NOR00039
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
7 DAY								
	Visual Acuity Reduced		Levothyroxine Sodium	C		ORAL		

Date:12/28/04ISR Number: 4539664-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/28/04ISR Number: 4539665-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00403
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Coronary Artery Disease							
	Dyspnoea Exertional							
	Fatigue							
	Pulmonary Oedema							
	Sleep Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4539666-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00033
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Perphenazine	C			UNKNOWN	
			Biperiden Hydrochloride	C			UNKNOWN	
			Pepcidin	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Clomipramine Hydrochloride	C			UNKNOWN	

Date:12/28/04ISR Number: 4539670-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00553
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Grand Mal Convulsion		Fluocortolone Caproate	C		ORAL		
Disability			Sitosterols	C		ORAL		
Other			Beclomethasone Dipropionate	C			RESPIRATORY (INHALATION)	
			Salmeterol Xinafoate	C			RESPIRATORY (INHALATION)	
			Ipratropium Bromide	C			RESPIRATORY (INHALATION)	
			Pantoprazole Sodium	C		ORAL		
			Prednisolone	C			UNKNOWN	

Date:12/28/04ISR Number: 4539671-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01974
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plaquenil	C				
UNKNOWN								
Initial or Prolonged								

Date:12/28/04ISR Number: 4539672-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00030
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Zopiclone	C		ORAL		
	Paraesthesia		Propiomazine Maleate	C				
UNKNOWN								
	Tic		Trimethoprim	C		ORAL		
			Trimeprazine Tartrate	C		ORAL		

Date:12/28/04ISR Number: 4539673-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4539674-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00631
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc			
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Levoxyl	C				
	Blood Creatine		Toprol Xl Tablets	C				
	Phosphokinase Increased		Toprol Xl Tablets	C				
	Bronchitis		Toprol Xl Tablets	C				
	Cardiac Failure		Imdur	C				
	Congestive		Imdur	C				
	Coronary Artery		Imdur	C				
	Atherosclerosis		Nitro-Dur	C				
	Coronary Artery Disease		Diovan	C				
	Depression		Diovan	C				
	Dyspepsia		Diltiazem Hydrochloride	C				
	Dyspnoea							
	Fatigue		Nitrolingual Spray	C				
	Feeling Abnormal		[Therapy Unspecified]	C				
	Gastrooesophageal Reflux							
	Disease		Plavix	C				
	Gouty Arthritis		Zocor	C		ORAL		
	Influenza		Zocor	C				
	Limb Injury		Aspirin	C				
	Malignant Hypertension		Xanax	C				

	Myocardial Ischaemia	Folic Acid	C	
UNKNOWN				
	Nasal Discomfort	Allopurinol	C	
UNKNOWN				
	Oedema Peripheral	Lecithin And Protein (Unspecified)	C	
	Palpitations			
UNKNOWN				
	Polytraumatism	Levothroid	C	
UNKNOWN				
	Rhinitis Allergic	Levothroid	C	
UNKNOWN				
	Skin Lesion	Levothroid	C	
UNKNOWN				
	Sleep Apnoea Syndrome	Soma	C	
UNKNOWN				
	Stress	Indocin (Indomethacin)	C	ORAL
	Tinnitus			
	Upper Respiratory Tract Infection	Indocin (Indomethacin)	C	
UNKNOWN				
		Colchicine	C	
UNKNOWN				
		Norco	C	
UNKNOWN				
		[Therapy Unspecified]	C	
UNKNOWN				
		[Therapy Unspecified]	C	
UNKNOWN				
		Vitamins (Unspecified)	C	
UNKNOWN				
		K-Dur	C	
UNKNOWN				
		Lasix (Furosemide)	C	
UNKNOWN				
		Zetia	C	
UNKNOWN				
		Cardizem La	C	
UNKNOWN				
		Lopressor	C	
UNKNOWN				
		Lopressor	C	
UNKNOWN				
		Prevacid	C	
UNKNOWN				
		Lipotriad	C	
UNKNOWN				
		Lexapro	C	
UNKNOWN				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4539676-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00534
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prevacid	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:12/28/04ISR Number: 4539677-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00028
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction		Tibolone	C		ORAL		
Disability			Felodipine	C		ORAL		
			Aspirin	C		ORAL		

Date:12/28/04ISR Number: 4539678-0Report Type:Expedited (15-DaCompany Report #US-MERCK-01060076
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
292 DAY								
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
292 DAY								
	Cataract Nuclear		Celebrex	SS				
UNKNOWN	337 DAY							
	Depression		Anafranil	C				
UNKNOWN								
	Dermatitis Allergic		Lidex	C				
UNKNOWN								
	Diabetes Mellitus		Proventil Inhaler	C				
RESPIRATORY								
	Non-Insulin-Dependent							
(INHALATION)								

	Drug Eruption		Lipitor	C			
UNKNOWN							
	Eczema						
	Erectile Dysfunction						
	Heart Injury						
	Hyperkeratosis						
	Hypertension						
	Infection						
	Lung Injury						
	Neoplasm Skin						
	Neurodermatitis						
	Open Angle Glaucoma						
	Paraesthesia						
	Sleep Disorder						
	Weight Increased						

Date:12/28/04ISR Number: 4539679-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00723
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Wygesic Tablets	C				
UNKNOWN								
	Convulsion		Relafen	C				
UNKNOWN								
	Drug Ineffective		Ultram	C				
UNKNOWN								
	Hypoaesthesia							
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4539680-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							
	Polytraumatism							

Date:12/28/04ISR Number: 4539682-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00754
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Fosamax	C		ORAL		
Other	Anaemia		Aspirin	C				
UNKNOWN								
	Angina Pectoris							
	Aortic Calcification							
	Asthenia							
	Blood Pressure Increased							
	Bronchopneumonia							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Confusional State							
	Convulsion							
	Coronary Artery Disease							
	Duodenal Ulcer							
	Fall							
	Hallucination							
	Leukocytosis							
	Lung Infiltration							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nausea							
	Pain							
	Pleural Effusion							
	Pruritus							
	Spinal Fracture							
	Urinary Tract Infection							
	Vomiting							

White Blood Cell Count
Increased

Date:12/28/04ISR Number: 4539683-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
	Adverse Event
Disability	Atherosclerosis
	Basedow'S Disease
	Colonic Polyp
	Diverticulum
	Flank Pain
	Haematuria
	Haemorrhoids
	Incontinence
	Mass

		Polytraumatism					
		Urinary Tract Infection					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/28/04ISR Number: 4539685-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00804
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorientation		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Ultram	C		
UNKNOWN							
		Polytraumatism		Diazepam	C		
UNKNOWN							
		Sleep Disorder		Vitamins			
		Uterine Disorder		(Unspecified)	C		
UNKNOWN							
		Weight Decreased					

Date:12/28/04ISR Number: 4539686-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00817
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain
Other	Abdominal Rigidity
	Acute Sinusitis
	Adjustment Disorder With
	Anxiety
	Adverse Event
	Anaemia Vitamin B12
	Deficiency
	Anxiety
	Arthralgia
	Back Pain
	Balance Disorder
	Bladder Prolapse
	Bronchitis
	Chest Pain
	Conjunctivitis

Constipation
Drug Ineffective
Dysphagia
Exostosis
Fatigue
Flat Affect
Flatulence
Fungal Infection
Gallbladder Disorder
Gastritis
Gastrooesophageal Reflux
Disease
Hot Flush
Hypoaesthesia
Increased Upper Airway
Secretion
Insomnia
Kidney Infection
Liver Function Test
Abnormal
Migraine

		Muscle Strain					
		Muscle Twitching					
		Muscular Weakness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Pernicious Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pharyngolaryngeal Pain					
		Pleurisy					
		Polytraumatism					
		Pyrexia					
		Rhinitis Allergic					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinus Congestion					
		Speech Disorder					
		Stress					
		Tendonitis					
		Tenosynovitis					
		Therapy Non-Responder					
		Tonsillar Disorder					
		Trigger Finger					
		Umbilical Hernia					
		Upper Respiratory Tract Infection					
		Vaginal Infection					
		Vaginal Ulceration					
		Vertigo					
		Vitreous Detachment					
		Weight Decreased					

Date:12/28/04ISR Number: 4539688-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00842
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Keflex	C		
UNKNOWN						
Disability	Arthralgia		Ziac	C		
UNKNOWN						

Other	Major Depression	Doxidan	C	
UNKNOWN				
	Migraine	Pepcid	C	ORAL
	Polytraumatism	Ambien	C	
UNKNOWN				
	Suicidal Ideation	Stadol	C	
UNKNOWN				
		Prozac	C	
UNKNOWN				

Date:12/28/04ISR Number: 4539690-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00838
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Symptom
Hospitalization -	Atonic Urinary Bladder
Initial or Prolonged	Atrial Fibrillation
Disability	Bronchopneumonia
Other	Burns Second Degree
	Cardiac Failure
	Congestive
	Cerebral Atrophy
	Cerebral Infarction

		Cerebrovascular Accident					
		Confusional State					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Deafness		Vioxx	PS	Merck & Co., Inc	ORAL
		Deafness Neurosensory		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Death		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Delirium		Vioxx	SS	Merck & Co., Inc	ORAL
		Dementia		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Drug Ineffective		Aspirin	C		
UNKNOWN							
		Dysuria		Levothyroxine Sodium	C		
UNKNOWN							
		Eczema		Levothyroxine Sodium	C		
UNKNOWN							
		Emotional Distress		Glucosamine	C		
UNKNOWN							
		General Physical Health		Hytrin	C		
UNKNOWN							
		Deterioration					
		Haematuria					
		Haemorrhagic Stroke					
		Hallucination, Visual					
		Heart Rate Irregular					
		Incontinence					
		Intentional Self-Injury					
		Lobar Pneumonia					
		Mitral Valve Incompetence					
		Mitral Valve Stenosis					
		Mood Disorder Due To A					
		General Medical Condition					
		Myocardial Infarction					
		Myofascial Pain Syndrome					
		Neurogenic Bladder					
		Pneumonia					
		Staphylococcal Infection					
		Tricuspid Valve					
		Incompetence					

Date:12/28/04ISR Number: 4539692-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00920
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization -	Affective Disorder
Initial or Prolonged	Alopecia
Other	Angina Pectoris
	Anxiety
	Autoimmune Disorder
	Benign Prostatic
	Hyperplasia
	Blood Pressure
	Inadequately Controlled
	Blood Pressure Increased
	Bronchopneumonia
	Bronchospasm
	Bundle Branch Block Right
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Convulsion
	Coronary Artery
	Atherosclerosis
	Cushing'S Syndrome
	Deafness

		Death					
		Depression					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
240	DAY						
		Emphysema		Vioxx	SS	Merck & Co., Inc	ORAL
		Epicondylitis					
		Erectile Dysfunction					
		Fall					
		Fibromyalgia					
		Gastrooesophageal Reflux					
		Disease					
		Generalised Anxiety					
		Disorder					
		Haemochromatosis					
		Head Injury					
		Hepatitis					
		Hepato-Lenticular					
		Degeneration					
		Hot Flush					
		Hyperlipidaemia					
		Hypersensitivity					
		Hypertension					
		Hyperventilation					
		Interstitial Lung Disease					
		Mental Impairment					
		Muscle Twitching					
		Myocardial Infarction					
		Nausea					
		Nephrolithiasis					
		Nodule					
		Palpitations					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Spinal Column Stenosis					
		Syncope					
		Tunnel Vision					
		Visual Disturbance					

Date:12/28/04ISR Number: 4539697-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Depression
	Hypertension
	Joint Dislocation
	Lumbar Radiculopathy
	Myocardial Infarction
	Narcotic Intoxication
	Overdose
	Poisoning
	Pulmonary Oedema

	Renal Failure Chronic						
	Spinal Osteoarthritis						
	Stent Occlusion	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Urinary Tract Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Zydone	C				UNKNOWN
			Prozac	C		ORAL		
			Prilosec	C		ORAL		
			Elavil	C				UNKNOWN
			Zanaflex	C		ORAL		
			Aleve	C				UNKNOWN

Date:12/28/04ISR Number: 4540129-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adhesion		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adrenal Disorder		Valium	C				UNKNOWN
Disability	Adverse Event		Sk-Erythromycin	C				UNKNOWN
Other	Anaemia		Cyanocobalamin	C				PARENTERAL
	Axillary Mass		Nitrostat	C				UNKNOWN
	Breast Cancer		Synthroid	C				UNKNOWN
	Breast Disorder		Paxil	C				UNKNOWN
	Cellulitis		Lanoxin	C				UNKNOWN
	Csf Shunt Removal		Salagen Tablets	C				UNKNOWN
	Cyst Aspiration		Claritin	C				UNKNOWN
	Discomfort		Zofran	C				UNKNOWN
	Faecal Occult Blood		Miacalcin	C				UNKNOWN

	Positive	Neurontin	C
UNKNOWN			
	Fall	Vitamin E	C
UNKNOWN			
	Gastroenteritis	Premarin	C
UNKNOWN			
	Haemorrhoids	Aciphex	C
UNKNOWN			
	Helicobacter Gastritis	Detrol La	C
UNKNOWN			
	Hyperlipidaemia	Lasix (Furosemide)	C
UNKNOWN			
	Iron Deficiency Anaemia	K-Dur	C
UNKNOWN			
	Myocardial Infarction	Lorazepam	C
UNKNOWN			
	Nausea	Primidone	C
UNKNOWN			
	Polytraumatism	[Therapy	
	Road Traffic Accident	Unspecified]	C
UNKNOWN			
	Shunt Infection		
	Wound Dehiscence		

Date:12/28/04ISR Number: 4540132-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Angina Pectoris
	Arrhythmia
	Benign Prostatic Hyperplasia
	Blood Pressure Increased
	Bradycardia
	Bronchitis Acute
	Cerebrovascular Accident
	Cholelithiasis
	Chronic Obstructive

		Pulmonary Disease					
		Convulsion					
		Coronary Artery Disease					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dermatitis Atopic		Vioxx	PS	Merck & Co., Inc	ORAL
586	DAY						
		Diverticulum		Claritin	C		
UNKNOWN							
		Dysgeusia		Aspirin	C		
UNKNOWN							
		Dyspnoea		Pravachol	C		
UNKNOWN							
		Emphysema		Calcium			
		Fatigue		(Unspecified)	C		
UNKNOWN							
		Gastrooesophageal Reflux		Folic Acid	C		
UNKNOWN							
		Disease		Digoxin	C		
UNKNOWN							
		Haemorrhoids		Naprosyn	C		ORAL
		Hepatic Cyst		Keflex	C		ORAL
		Hiatus Hernia		Allegra	C		ORAL
		Inner Ear Disorder		Elocon	C		
UNKNOWN							
		Intervertebral Disc		Lopressor	C		ORAL
		Degeneration		Darvocet-N	C		ORAL
		Lumbar Spinal Stenosis		Pravachol	C		
UNKNOWN							
		Lung Neoplasm		Lanoxin	C		ORAL
		Myocardial Infarction		Lortab	C		ORAL
		Neuroma		Clarinex	C		ORAL
		Non-Hodgkin'S Lymphoma		Zocor	C		ORAL
		Palpitations		Nexium	C		ORAL
		Peripheral Vascular		Paxil	C		ORAL
		Disorder		Vitamin E	C		
UNKNOWN							
		Pleural Effusion					
		Renal Abscess					
		Rhinitis Allergic					
		Salivary Gland Cancer					
		Splenomegaly					
		Spondylolisthesis					
		Vertigo					
		Weight Decreased					

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Amnesia
Other	Anaemia
	Anxiety
	Back Injury
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Cerebrovascular Accident
	Chest Pain
	Colonic Polyp
	Cyst
	Depression
	Diarrhoea
	Diastolic Dysfunction
	Difficulty In Walking
	Disorientation
	Diverticulum
	Dizziness
	Drug Ineffective
	Dysarthria

		Dyspnoea					
		Dysstasia					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fracture Nonunion		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Genital Pruritus Female		Zantac	C		
UNKNOWN							
		Headache		Reglan	C		
UNKNOWN							
		Hip Fracture		Dicyclomine			
		Hypersensitivity		Hydrochloride	C		
UNKNOWN							
		Hypertension		Procardia	C		
UNKNOWN							
		Hypoaesthesia		Vicodin Es Tablets	C		
UNKNOWN							
		Impaired Healing		Vicodin Es Tablets	C		
UNKNOWN							
		Insomnia		Arthrotec	C		
UNKNOWN							
		Intervertebral Disc		Ditropan Xl	C		
UNKNOWN							
		Protrusion		Adalat	C		
UNKNOWN							
		Loss Of Consciousness		Quinine	C		
UNKNOWN							
		Macrocytosis		Crixivan	C		ORAL
		Muscle Spasms		Crixivan	C		ORAL
		Neuropathy		Combivir	C		
UNKNOWN							
		Oedema Peripheral		Bactrim	C		
UNKNOWN							
		Pneumonia		Allegra	C		
UNKNOWN							
		Polyuria		Diflucan	C		
UNKNOWN							
		Productive Cough		Desyrel	C		
UNKNOWN							
		Pyrexia		Skelaxin	C		ORAL
		Sepsis		Xanax	C		
UNKNOWN							
		Syncope					
		Tachycardia					
		Tongue Discolouration					

Tongue Disorder
Urinary Incontinence
Vaginal Burning Sensation
Ventricular Hypertrophy
Vision Blurred
Vomiting

Date:12/28/04ISR Number: 4540142-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03175
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Infarction		Hydralazine	C				
UNKNOWN								
Hospitalization -	Anaemia		Lescol Xl	C				
UNKNOWN								
Initial or Prolonged	Blood Glucose Increased		Ditropan Xl	C				
UNKNOWN								
Disability	Cerebrovascular Accident							
	Deep Vein Thrombosis							
	Disseminated							
	Intravascular Coagulation							
	Gastrointestinal							
	Haemorrhage							
	Haematuria							
	Haemorrhagic Stroke							
	Pneumonia							
	Thrombocytopenia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4540144-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00777
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Biliary Dyskinesia		Lotensin	C				
Other	Blood Pressure Increased		[Therapy Unspecified]	C			UNKNOWN	
	Chest Pain							
	Convulsion							
	Coronary Artery Disease							
	Dizziness							
	Dysphagia							
	Headache							
	Hypertension							
	Nerve Compression							
	Palpitations							
	Urinary Tract Infection							

Date:12/28/04ISR Number: 4540147-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01195
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1117 DAY	
	Heart Valve Stenosis		Folic Acid	C			UNKNOWN	
	Lumbar Radiculopathy		Nexium	C			UNKNOWN	
	Radiculopathy		Fosamax	C			UNKNOWN	
			Hydro-Chlor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	
			Plaquenil	C			UNKNOWN	

Methotrexate C
UNKNOWN

Date:12/28/04ISR Number: 4540148-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00631
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain Upper
Other	Alcoholism
	Anxiety
	Back Pain
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Cardiovascular Disorder
	Carotid Artery Occlusion
	Carpal Tunnel Syndrome
	Cerebral Infarction
	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Convulsion
	Costochondritis
	Cough
	Dry Mouth

		Fatigue					
		Feeling Abnormal					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hemiparesis		Advil	C		
UNKNOWN							
		Hypertension		A.S.A.	C		
UNKNOWN							
		Hypoaesthesia Oral		A.S.A.	C		ORAL
		Hypotension		A.S.A.	C		
UNKNOWN							
		Increased Upper Airway		Ulcerin (Cimetidine)	C		ORAL
		Secretion		Ulcerin (Cimetidine)	C		ORAL
		Insomnia		Zestril	C		
UNKNOWN							
		Mitral Valve Incompetence		Plavix	C		
UNKNOWN							
		Monoplegia		Agyrax (Meclizine			
		Multiple Sclerosis		Hydrochloride)	C		
UNKNOWN							
		Muscle Strain		Agyrax (Meclizine			
		Musculoskeletal Chest		Hydrochloride)	C		
UNKNOWN							
		Pain		Elavil	C		
UNKNOWN							
		Pain		Trazodone			
		Painful Respiration		Hydrochloride	C		
UNKNOWN							
		Platelet Count Decreased		Protonix	C		
UNKNOWN							
		Pleurisy		Protonix	C		
UNKNOWN							
		Renal Failure		Protonix	C		
UNKNOWN							
		Sinus Bradycardia		Zocor	C		
UNKNOWN							
		Tobacco Abuse		Zocor	C		
UNKNOWN							
		Transient Ischaemic		Carafate	C		
UNKNOWN							
		Attack		Lipitor	C		
UNKNOWN							
		Upper Respiratory Tract		Hydrochlorothiazide	C		
UNKNOWN							

	Infection		Hydrochlorothiazide	C		
UNKNOWN						
	Uterine Leiomyoma		Ecotrin	C		
UNKNOWN						
	Vision Blurred		Ecotrin	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Aminophylline	C		
UNKNOWN						

Date:12/28/04ISR Number: 4540163-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00911
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	23 MON	
Initial or Prolonged	Angina Unstable		Lopressor	C				
UNKNOWN								
	Blood Pressure Systolic		Diovan	C				
UNKNOWN								
	Increased							
	Cardiac Failure							
	Congestive							
	Coronary Artery Disease							
	Diabetes Mellitus							
	Diarrhoea							
	Drug Ineffective							
	Flatulence							
	Gastrooesophageal Reflux							
	Disease							
	Hypertension							
	Pulmonary Oedema							
	Scan Myocardial Perfusion							
	Abnormal							
	Ventricular Hypokinesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4540164-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY	
	Arrhythmia							
	Aspartate							
	Aminotransferase							
	Increased							
	Blood Creatine							
	Phosphokinase Increased							
	Blood Lactate							
	Dehydrogenase Increased							
	Chest Pain							
	Coagulopathy							
	Coronary Artery							
	Atherosclerosis							
	Depression							
	Electrocardiogram T Wave							
	Abnormal							
	Hypoaesthesia							
	Injury							
	Lymphocyte Count							
	Decreased							
	Mitral Valve Incompetence							
	Monocyte Count Increased							
	Myoglobin Blood Present							
	Palpitations							
	Pulmonary Embolism							
	Stress							
	Tachycardia							
	Tricuspid Valve							
	Incompetence							
	White Blood Cell Count							
	Increased							

Date:12/28/04ISR Number: 4540167-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00869
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
Other	Anxiety
	Arthralgia
	Back Pain
	Chronic Obstructive Pulmonary Disease
	Decreased Appetite
	Dyspnoea
	Electrocardiogram Abnormal
	Electrocardiogram St Segment Depression
	Flatulence
	General Symptom
	Ischaemia
	Lumbar Spinal Stenosis
	Neck Pain
	Oedema Peripheral

	Pain In Extremity						
	Palpitations						
	Pharyngitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Cyst		Vioxx	PS	Merck & Co., Inc	ORAL	
	Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL	
	Seasonal Allergy		Celebrex	C		ORAL	
	Sinus Bradycardia		Norco	C			UNKNOWN
	Sinusitis		Flexeril	C			UNKNOWN
			Motrin	C			UNKNOWN

Date:12/28/04ISR Number: 4540173-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01217
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Cerebrovascular Accident						
Initial or Prolonged	Faecal Incontinence						
Disability	Headache						

Date:12/28/04ISR Number: 4540174-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00034
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON
Initial or Prolonged	Dysarthria						
Disability	Movement Disorder						

Date:12/28/04ISR Number: 4540176-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02625
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY

Hospitalization - 16 DAY Initial or Prolonged Disability			Vioxx	SS	Merck & Co., Inc	ORAL

Date:12/28/04ISR Number: 4540177-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02408
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/28/04ISR Number: 4540180-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02638
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain Headache		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/04ISR Number: 4540182-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/28/04ISR Number: 4540183-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02472
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Chest Pain Coronary Artery Disease Depression Dyspepsia Dyspnoea Generalised Anxiety Disorder Hyperlipidaemia Hypertension Myocardial Infarction Myocardial Ischaemia Oedema Pain In Jaw		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:12/28/04ISR Number: 4540191-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02619
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Dizziness Impaired Driving Ability		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:12/28/04ISR Number: 4540220-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00610
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Asthenia
	Back Pain
	Blood Pressure Increased
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cervicobrachial Syndrome
	Coccydynia
	Convulsion
	Coronary Artery Stenosis
	Dizziness
	Drug Ineffective
	Dyspepsia
	Fall
	Gait Disturbance
	Headache
	Hypercholesterolaemia
	Hypoaesthesia
	Hypoperfusion

		Left Ventricular Failure					
		Lumbar Spinal Stenosis					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Zocor	C		
UNKNOWN							
		Pain In Extremity		Skelaxin	C		
UNKNOWN							
		Plantar Fasciitis		Ultram	C		
UNKNOWN							
		Pneumonia		Furosemide	C		
UNKNOWN							
		Pulmonary Hypertension		Zestril	C		
UNKNOWN							
		Radiculopathy		Hydrocodone/Apap	C		
UNKNOWN							
		Spinal Osteoarthritis		Lopressor	C		
UNKNOWN							
		Upper Respiratory Tract		Imdur	C		
UNKNOWN							
		Infection		Digoxin	C		
UNKNOWN							
		Ventricular Dysfunction		Aspirin	C		
UNKNOWN							
		Ventricular Dyskinesia		Aerobid	C		
UNKNOWN							
		Weight Decreased		Albuterol	C		
UNKNOWN							
				Ipratropium Bromide	C		
UNKNOWN							

Date:12/28/04ISR Number: 4540230-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04059
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							

Date:12/28/04ISR Number: 4540231-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02635
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Hernia		Micronase	C			UNKNOWN	
	Ulcer							

Date:12/28/04ISR Number: 4541028-0Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00025
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Foreign	Tab Vioxx 25 Mg	PS		ORAL	256	
Initial or Prolonged	Blood Pressure Increased	Study					MG/DAILY/PO	
	Blood Pressure Systolic	Health	Aspirin	C				
	Increased	Professional	Bisoprolol	C				
	Dilatation Atrial		Hydrochlorothiazide					
	Effusion		(+) Ramipril	C				
	Extrasystoles		Simvastatin	C				
	Hypokinesia							
	Lung Infiltration							
	Mitral Valve Incompetence							

Date:12/28/04ISR Number: 4541048-6Report Type:Expedited (15-DaCompany Report #2004090165
Age: Gender:Female I/FU:F

Outcome	PT
Other	Asthenia
	Blood Pressure Increased
	Crohn'S Disease
	Dizziness
	Headache
	Hypoaesthesia Oral

		Influenza Like Illness Malaise Oesophageal Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paraesthesia Oral	Consumer	Celebrex (Celecoxib)	PS		ORAL
200 MG (200							
		Transient Ischaemic	Health				
MG, DAILY							
		Attack	Professional				
INTERVAL:							
		Vomiting					
EVERY DAY),							
ORAL							
				Rofecoxib (Rofecoxib)	SS		ORAL
ORAL							
				Diuretics (Diuretics)	C		
				Betamethsone (Betamethasone)	C		
				Prednisone (Prednisone)	C		
				Karvea Hct (Hydrochlorothiazide , Irbesartan)	C		

Date:12/28/04ISR Number: 4541050-4Report Type:Expedited (15-DaCompany Report #WAES 0412FIN00009
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Duodenal Ulcer	Foreign	Tab Etoricoxib 60 Mg	PS		ORAL
60						
Hospitalization -	Perforation	Health				
MG/DAILY/PO						
Initial or Prolonged	Myocardial Infarction	Professional	Tab Vioxx 12.5 Mg	SS		ORAL
PO						
	Pneumonia Aspiration		Tab Aspirin 100 Mg	SS		ORAL
100						
MG/DAILY/PO						
			Zocor	C		
			Acetaminophen	C		
			Allopurinol	C		

				Clopidogrel Bisulfate	C		
				Enalapril Maleate	C		
				Furosemide	C		
				Galantamine Hydrobromide	C		
				Isosorbide Mononitrate	C		
				Metoprolol	C		

Date:12/28/04ISR Number: 4541073-5Report Type:Expedited (15-DaCompany Report #2004097552
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Celebrex (Celecoxib)	PS		ORAL	ORAL	
		Health Professional	Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Folic Acid (Folic Acid)	C				

Date:12/28/04ISR Number: 4541105-4Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery	Foreign	Tab Rofecoxib	PS		ORAL	1 MG/DAILY	134 DAY
	Insufficiency	Study	Post-Trial Therapy	C				
	Ventricular Hypokinesia	Health Professional						

Date:12/28/04ISR Number: 4541300-4Report Type:Expedited (15-DaCompany Report #WAES 0412USA01867
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Chest Pain	Other					MG/DAILY/PO	
	Glaucoma		Prednisone 40 Mg	SS			40 MG/	
			Actonel	C				
			Lipitor	C				
			Plavix	C				
			Tums	C				
			Aspirin	C				
			Folic Acid	C				
			Methotrexate	C				
			Timolol	C				
			Vitamin E	C				

Date:12/29/04ISR Number: 4540811-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00798
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Asthenia
	Back Pain
	Barrett'S Oesophagus
	Breast Cyst
	Breast Pain
	Bronchitis

Carpal Tunnel Syndrome
Cervicobrachial Syndrome
Coordination Abnormal
Cystitis
Diabetes Mellitus
Diarrhoea
Dizziness
Dysphagia
Epistaxis
Erosive Oesophagitis
Gastrooesophageal Reflux
Disease
Headache
Helicobacter Gastritis
Hiatus Hernia
Irritable Bowel Syndrome
Loss Of Consciousness
Myocardial Ischaemia
Neck Injury
Neck Pain
Oedema Peripheral
Pain In Extremity

		Pharyngitis					
		Road Traffic Accident					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
		Vaginal Candidiasis		Robaxin	C		
UNKNOWN							
		Vaginal Infection		Lotrel	C		
UNKNOWN							

Date:12/29/04ISR Number: 4540812-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00806
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Adverse Event
	Angina Unstable
	Aortic Atherosclerosis
	Aortic Valve
	Calcification
	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Atelectasis
	Autonomic Neuropathy
	Back Pain
	Biliary Dilatation
	Blood Pressure Increased
	Bundle Branch Block Left
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Cardiac Flutter
	Cardiomegaly
	Cataract
	Cervical Spinal Stenosis
	Chills
	Cholelithiasis
	Cholelithiasis
	Obstructive
	Compression Fracture
	Constipation

Convulsion
Coronary Artery Disease
Coronary Artery
Restenosis
Coronary Artery Stenosis
Cough
Dehydration
Diabetes Mellitus
Inadequate Control
Diabetes Mellitus
Insulin-Dependent
Diabetic Retinopathy
Epigastric Discomfort
Fall
Fatigue
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease

		Haematoma					
		Headache					
		Impaired Gastric Emptying	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ketosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Ligament Injury		Nitroglycerin	C		
RESPIRATORY							
		Lumbar Radiculopathy					
(INHALATION)							
		Migraine		Imdur	C		ORAL
		Mitral Valve Incompetence		Humulin N	C		
SUBCUTANEOUS							
		Musculoskeletal Pain		Humulin N	C		
SUBCUTANEOUS							
		Myocardial Infarction		Cardizem	C		ORAL
		Myocardial Ischaemia		Potassium			
		Myositis		(Unspecified)	C		ORAL
		Nocturia		Pepcid	C		ORAL
		Oedema Peripheral		Ambien	C		ORAL
		Osteoarthritis		Propulsid	C		ORAL
		Osteoporosis		Aspirin	C		ORAL
		Pain In Extremity		Lipitor	C		ORAL
		Pulmonary Embolism		Glucophage	C		ORAL
		Pulmonary Hypertension		Lasix (Furosemide)	C		ORAL
		Pulmonary Oedema		Prozac	C		ORAL
		Retinal Detachment		Surfak	C		ORAL
		Tachypnoea		Triple Tannate			
		Tibia Fracture		Pediatric Suspension	C		
UNKNOWN							
		Tricuspid Valve					
		Incompetence					
		Vascular Calcification					

Date:12/29/04ISR Number: 4540826-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0406GBR00028
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
7 DAY						
	Renal Failure Chronic		Nitrazepam	C		ORAL
			Furosemide	C		ORAL

	Aspirin	C	
UNKNOWN			
	Acetaminophen And Propoxyphene Hydrochloride	C	ORAL
	Atorvastatin Calcium	C	ORAL
	Senna	C	ORAL
	Digoxin	C	ORAL
	Levothyroxine Sodium	C	ORAL
	Acetaminophen	C	ORAL
5 DAY			

Date:12/29/04ISR Number: 4540828-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0310GBR00310
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		278 DAY
	Haematemesis		Cimetidine	C		ORAL		

Date:12/29/04ISR Number: 4540830-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00682
Age:72 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intracardiac Thrombus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oesophageal Rupture		Metoprolol	C				
UNKNOWN								
	Thrombosis		Lovastatin	C				
UNKNOWN								

Date:12/29/04ISR Number: 4540831-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Valsartan	C		ORAL		
			Furosemide	C		ORAL		
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Allopurinol	C		ORAL		

Date:12/29/04ISR Number: 4540832-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acarodermatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Testosterone		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Decreased							
	Cardiac Failure							
	Cholecystitis							
	Cholelithiasis							
	Coma							
	Decreased Appetite							
	Emotional Distress							
	Erectile Dysfunction							
	Eye Infection							
	Fatigue							
	Gastrooesophageal Reflux Disease							

Haemodialysis
Headache
Hepatic Cirrhosis
Hepatic Failure
Hiatus Hernia
Hypertension
Impaired Gastric Emptying
Insomnia
Intervertebral Disc
Disorder
Myocardial Infarction
Nasal Septum Deviation
Rash
Renal Disorder
Renal Failure Acute
Testicular Mass
Weight Decreased
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4540835-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00163
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Bradycardia		Potassium					
	Bronchitis		(Unspecified)	C				
UNKNOWN								
	Cardiomegaly		Magnesium					
	Electrocardiogram Qt		(Unspecified)	C				
UNKNOWN								
	Prolonged							
	Emphysema							
	Haemorrhage							
	Infection							
	Injury Asphyxiation							
	Loss Of Consciousness							
	Nasopharyngitis							
	Prescribed Overdose							
	Sinus Arrhythmia							
	Sinus Tachycardia							
	Supraventricular							
	Extrasystoles							
	Tongue Discolouration							
	Tonsillar Hypertrophy							
	Tracheitis							

Date:12/29/04ISR Number: 4540836-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00755
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Atorvastatin Calcium	C				
UNKNOWN								

Date:12/29/04ISR Number: 4540838-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00003
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1 MON
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1 MON

Date:12/29/04ISR Number: 4540839-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00272
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
	Angina Pectoris		Silibinin	C		ORAL		
	Arrhythmia		Cynara	C		ORAL		
	Cardiac Failure		Ursodiol	C		ORAL		
	Dyspnoea		Crataegus	C		ORAL		
	Oedema		Ginkgo Biloba Extract	C		ORAL		
	Visual Acuity Reduced							

Date:12/29/04ISR Number: 4540845-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02532
Age:54 YR Gender:Female I/FU:I

Outcome	PT
Disability	Amnesia
	Cerebrovascular Accident

	Dysphagia Facial Palsy Mental Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN

Date:12/29/04ISR Number: 4540846-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00426
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/29/04ISR Number: 4540855-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/29/04ISR Number: 4540856-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00196
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Adverse Event Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/29/04ISR Number: 4540859-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03763
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Transient Ischaemic Attack							

Date:12/29/04ISR Number: 4540860-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01336
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON
Hospitalization - Initial or Prolonged Disability	Chest Pain Coronary Artery Disease Cystitis Headache Loss Of Consciousness Muscle Spasms Neck Pain Pain Pelvic Pain Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4540864-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02649
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:12/29/04ISR Number: 4540865-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemic Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4540867-XReport Type:Expedited (15-DaCompany Report #IT-MERCK-0412ITA00034
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
			Carvedilol	C		ORAL		
Other	Angina Pectoris		Acenocoumarol	C		ORAL		
	Anxiety		Omeprazole	C		ORAL		
	Cardiomyopathy		Sucralfate	C		ORAL		
	Congestive Cardiomyopathy		Amiodarone Hydrochloride	C		ORAL		
	Coronary Artery Occlusion		Amiodarone Hydrochloride	C		ORAL		
	Depression		Lorazepam	C		ORAL		
	Dilatation Ventricular		Calcium Carbonate	C				
	Supraventricular Extrasystoles		Clopidogrel Bisulfate	C		ORAL		
UNKNOWN								
	Vascular Graft Occlusion							
	Ventricular Extrasystoles							

Date:12/29/04ISR Number: 4540983-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00016
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		966 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		966 DAY
	Coronary Artery Disease		Metformin	C				UNKNOWN
	Coronary Artery Stenosis		Rosiglitazone Maleate	C				UNKNOWN
	Glycosylated Haemoglobin Increased		Allopurinol	C				UNKNOWN
	Low Density Lipoprotein Increased		Cozaar	C		ORAL		
	Myocardial Infarction							

Date:12/29/04ISR Number: 4541322-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Agitation
Other	Alanine Aminotransferase Increased
	Anticonvulsant Drug Level Decreased

Arthralgia
Aspartate
Aminotransferase
Increased
Aura
Balance Disorder
Belligerence
Blood Potassium Decreased
Blood Thyroid Stimulating
Hormone Decreased
Cholelithiasis
Colon Cancer
Complex Partial Seizures
Constipation
Deafness Neurosensory
Depressed Level Of
Consciousness
Depressed Mood
Diarrhoea
Dizziness
Drug Eruption
Drug Hypersensitivity
Drug Ineffective
Drug Level Decreased
Drug Screen Positive
Dyspnoea
Ear Discomfort
Emotional Distress
Factitious Disorder
Fall
Fatigue
Feeling Abnormal
Folliculitis
Gingival Hyperplasia
Grand Mal Convulsion
Headache
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypernatraemia
Hypertension
Hypoacusis
Injury
Low Density Lipoprotein
Increased
Mental Status Changes
Middle Ear Effusion

Muscle Twitching
Myocardial Infarction
Nail Pitting
Nasal Polyps
Neck Pain
Osteopenia
Osteoporosis
Otitis Media
Pain
Periarthritis
Psoriasis
Pyrexia
Radius Fracture
Rash

		Respiratory Failure					
		Respiratory Papilloma					
		Scab	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL
		Skin Discolouration		Ms Contin	SS		
UNKNOWN							
		Spinal Osteoarthritis		Ms Contin	SS		
UNKNOWN							
		Synovitis		Depakote	C		
UNKNOWN							
		Tinnitus		Tegretol	C		
UNKNOWN							
		Treatment Noncompliance		Aspirin	C		
UNKNOWN							
		Tremor		Vitamins			
		Urinary Incontinence		(Unspecified)	C		
UNKNOWN							
		Vaginal Infection		Msir	C		ORAL
		Vomiting					
		Weight Decreased					
		Weight Increased					
		Wrist Fracture					

Date:12/29/04ISR Number: 4541327-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Bruit
	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Acute Coronary Syndrome
	Aortic Bruit
	Aortic Valve Incompetence
	Appendix Disorder
	Arthralgia
	Atherosclerosis
	Blood Pressure Increased
	Bronchitis
	Carotid Artery Occlusion
	Carpal Tunnel Syndrome
	Cataract
	Cerebrovascular Accident
	Cerumen Impaction
	Constipation

Convulsion
Coronary Artery Disease
Cough
Cystitis Haemorrhagic
Depressed Mood
Dilatation Atrial
Diverticulum
Drug Hypersensitivity
Ear Pain
Emotional Distress
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux
Disease
Granuloma
Haematuria
Headache
Hepatic Cyst
Hernia
Hypercholesterolaemia
Hyperhomocysteinaemia
Hyperkalaemia

		Hypokalaemia					
		Infection					
		Kidney Small	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Metaplasia		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Neck Injury					
		Nervous System Disorder					
		Osteoarthritis					
		Osteoporosis					
		Pharyngolaryngeal Pain					
		Pulmonary Congestion					
		Renal Artery Stenosis					
		Renal Failure					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sciatica					
		Shoulder Operation					
		Skin Lesion					
		Spinal Osteoarthritis					
		Tachycardia					
		Tinnitus					
		Tonsillar Disorder					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Uterine Disorder					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:12/29/04ISR Number: 4541334-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acquired Claw Toe
Initial or Prolonged	Activated Partial
Other	Thromboplastin Time
	Shortened
	Acute Myocardial

Infarction
Angina Unstable
Arthropathy
Asthenia
Back Pain
Basal Cell Carcinoma
Blood Pressure Increased
Bursitis
Calcinosis
Carotid Artery Stenosis
Carpal Tunnel Syndrome
Cerebrovascular Accident
Coronary Artery
Dissection
Coronary Artery Occlusion
Coronary Artery Stenosis

		Coronary Ostial Stenosis					
		Dermatitis Contact					
		Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Insulin-Dependent		Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetic Neuropathy		Zocor	C		ORAL
		Diabetic Retinopathy		Plavix	C		ORAL
		Diarrhoea		Lotensin	C		ORAL
		Fall		Metoprolol	C		ORAL
		Haemarthrosis		Alfentanil			
		Haematoma		Hydrochloride	C		
UNKNOWN							
		Headache		[Therapy			
		Injury		Unspecified]	C		ORAL
		Intracardiac Thrombus		Aspirin	C		
UNKNOWN							
		Monarthritis					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Platelet Count Decreased					
		Prothrombin Level					
		Decreased					
		Sleep Apnoea Syndrome					
		Tendonitis					
		White Blood Cell Count					
		Decreased					

Date:12/29/04ISR Number: 4541340-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abscess Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
2 DAY						
Initial or Prolonged	Acute Myocardial					
Other	Infarction					
	Arteriospasm Coronary					
	Atherosclerosis					
	Bundle Branch Block Right					
	Cardiac Murmur					
	Cardiomyopathy					
	Cervicobrachial Syndrome					
	Chronic Obstructive					
	Pulmonary Disease					
	Cold Sweat					

Congestive Cardiomyopathy
Coronary Artery Disease
Dilatation Atrial
Diverticular Perforation
Diverticulitis
Drug Hypersensitivity
Fatigue
Haematocrit Decreased
Muscle Spasms
Myocardial Ischaemia
Prostatic Specific
Antigen Increased
Ventricular Dysfunction
Ventricular Hypokinesia
Viral Infection
Viral Upper Respiratory
Tract Infection
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4541341-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00108
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure		Ibuprofen	C			UNKNOWN	
	Fluctuation		Insulin	C			UNKNOWN	
	Bursitis							
	Cardiac Failure							
	Congestive							
	Chronic Obstructive							
	Pulmonary Disease							
	Colonic Polyp							
	Depression							
	Diverticulum							
	Dizziness							
	Drug Intolerance							
	Emotional Distress							
	Gastrointestinal							
	Haemorrhage							
	Glaucoma							
	Haemorrhoids							
	Hyperglycaemia							
	Hypoacusis							
	Hypoglycaemia							
	Insomnia							
	Intervertebral Disc							
	Protrusion							
	Intervertebral Disc Space							
	Narrowing							
	Ischaemic Cardiomyopathy							
	Kidney Infection							
	Lacunar Infarction							
	Lobar Pneumonia							
	Nasal Congestion							
	Prostatic Disorder							
	Prostatic Specific							
	Antigen Increased							
	Proteinuria							
	Pulmonary Oedema							
	Renal Failure Chronic							

Rhinitis Allergic
Thrombosis
Ventricular Arrhythmia
Vertigo
Viral Infection
Visual Acuity Reduced

Date:12/29/04ISR Number: 4541342-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00926
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Accident At Work
Other	Adverse Event
	Anxiety
	Apnoea
	Arthralgia

Back Pain
Balance Disorder
Bladder Disorder
Blood Magnesium Decreased
Bronchitis
Bursitis
Cardiac Disorder
Chest Pain
Chondromalacia
Colonic Polyp
Condition Aggravated
Constipation
Contusion
Deafness
Deafness Neurosensory
Depression
Diplopia
Dizziness
Dysphagia
Dyspnoea
Extrasystoles
Fluid Retention
Gastritis
Gastrointestinal Disorder
Genital Pruritus Female
Haematochezia
Haemorrhoids
Headache
Hyperhidrosis
Hypertension
Hypoaesthesia
Inflammation
Injury
Inner Ear Disorder
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Intestinal Functional
Disorder
Joint Dislocation
Joint Effusion
Joint Injury
Ligament Injury
Meniscus Lesion
Mood Altered

Multiple Allergies
Muscle Spasms
Myalgia
Neck Pain
Nervous System Disorder
Neuroma
Nocturia
Personality Change
Polyp
Rash
Renal Impairment
Restless Legs Syndrome
Sleep Apnoea Syndrome
Snoring

	Stress						
	Tachycardia						
	Tinnitus	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vaginal Discharge		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vertigo							
	Vertigo Labyrinthine							
	Weight Decreased							
	Weight Increased							

Date:12/29/04ISR Number: 4541348-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00605
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Stent Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	504	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	504	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metoprolol Succinate	C		ORAL		
			Magnesium (Unspecified)	C			UNKNOWN	

Date:12/29/04ISR Number: 4541349-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00652
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Methotrexate	C		ORAL		
			Prednisone	C		ORAL		
			Verapamil Hydrochloride	C		ORAL		
			Vitamin B (Unspecified)	C		ORAL		

			Hydrochlorothiazide And Triamterene	C		ORAL
			Flutamide	C		ORAL

Date:12/29/04ISR Number: 4541350-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00433
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Unstable Stent Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
			Isosorbide Dinitrate	C		ORAL
			Hydrochlorothiazide And Ramipril	C		ORAL
			Xipamide	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Pantoprazole Sodium	C		ORAL
			Aspirin	C		ORAL

Date:12/29/04ISR Number: 4541352-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00643
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Angina Unstable Coronary Artery Stenosis Hypertension Hypertensive Heart Disease Malignant Hypertension Myocardial Infarction Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541353-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00672
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	825	DAY
Disability			Fosamax	C		ORAL		
UNKNOWN			Escin	C				
			Nafronyl Oxalate	C		ORAL		
			Hydrochlorothiazide And Metoprolol Succinate	C		ORAL		
			Phenprocoumon	C		ORAL		
			Dihydralazine Sulfate And Hydrochlorothiazide And Reserpine	C		ORAL		
			Calcium (Unspecified)	C		ORAL		

Date:12/29/04ISR Number: 4541355-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00542
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

	Monoparesis		Theophylline	C		ORAL
			Aspirin	C		ORAL
			Allopurinol	C		ORAL
			Cromolyn Sodium And Reproterol Hydrochloride	C		
RESPIRATORY (INHALATION)						
			Furosemide And Spironolactone	C		ORAL

Date:12/29/04ISR Number: 4541356-9Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00052
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Alendronate Sodium	C		ORAL		

Aspirin	C		ORAL
Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL

Date:12/29/04ISR Number: 4541357-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		476 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		128 DAY
	Infarction		Prilosec	C		ORAL		
	Angina Unstable		Tylenol	C				UNKNOWN
	Anxiety		Inderal	C				UNKNOWN
	Cardiac Failure		Lipitor	C		ORAL		
	Congestive		Lipitor	C				UNKNOWN
	Coronary Artery Disease		Zithromax	C				UNKNOWN
	Diarrhoea		Zantac	C		ORAL		
	Hypercholesterolaemia		Nitrostat	C				SUBLINGUAL
	Injury							
	Ischaemic Cardiomyopathy							
	Mixed Hyperlipidaemia							
	Ventricular Dysfunction							

Date:12/29/04ISR Number: 4541359-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00487
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased							
	C-Reactive Protein Increased							

Cerebrovascular Accident
Hemianopia Homonymous
Hypertensive Crisis
Ischaemic Stroke
Transient Ischaemic
Attack

Date:12/29/04ISR Number: 4541360-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00855
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Arterial Occlusive Disease Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541361-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Abdominal Pain Upper Aggression Arthropathy

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
5	DAY		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Aspirin	C		
UNKNOWN			Lipitor	C		
UNKNOWN			Metformin	C		
UNKNOWN			Prozac	C		
UNKNOWN			Prilosec	C		
UNKNOWN			Glucophage	C		
UNKNOWN			Wellbutrin	C		

Back Pain
Cardiomegaly
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Cholelithiasis
Convulsion
Coordination Abnormal
Drug Hypersensitivity
Fall
Gastrooesophageal Reflux
Disease
Hiatus Hernia
Hypertension
Hypotension
Intention Tremor
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Mitral Valve Incompetence
Myocardial Infarction
Non-Cardiac Chest Pain
Pericardial Effusion
Respiratory Failure
Shock
Sinus Disorder
Spinal Column Stenosis
Spinal Compression
Fracture
Transient Ischaemic
Attack
Treatment Noncompliance
Ventricular Hypokinesia
Vertigo

Date:12/29/04ISR Number: 4541377-6Report Type:Expedited (15-DaCompany Report #AT-MERCK-0411AUT00022
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Initial or Prolonged	Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
	Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL		
			Alendronate Sodium	C			UNKNOWN	

Date:12/29/04ISR Number: 4541378-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02062
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Coronary Artery Disease
Disability	Dehydration
Other	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dizziness
	Essential Hypertension

		Food Poisoning					
		Gastritis					
		Gastroenteritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscle Spasms		Valium	C		
UNKNOWN							
		Myocardial Infarction		Coumadin	C		
UNKNOWN							
		Nausea					
		Vomiting					

Date:12/29/04ISR Number: 4541379-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04102
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Synthroid	C		
UNKNOWN							
		Chromaturia					
		Dysphagia					
		Dyspnoea					
		Fatigue					
		Headache					
		Hypertension					
		Rash					
		Urine Odour Abnormal					
		Vision Blurred					

Date:12/29/04ISR Number: 4541380-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02535
Age:75 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diastolic Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR							
		Dyspnoea		Lisinopril	C		ORAL
		Obstructive Airways					
		Disorder					

Date:12/29/04ISR Number: 4541381-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00164
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		[Therapy					
	Myocardial Infarction		Unspecified]	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541382-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00046
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Induced		Vioxx	PS	Merck & Co., Inc			
	Drug Exposure During		Esomeprazole					
	Pregnancy		Magnesium	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4541383-1Report Type:Expedited (15-DaCompany Report #DK-MERCK-0412DNK00018
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	673 DAY	
	Attack		Estradiol	C			UNKNOWN	

Date:12/29/04ISR Number: 4541384-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00753
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ocular Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541385-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00044
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperlipidaemia		Methylprednisolone	C		ORAL		
	Myocardial Infarction		Methotrexate Sodium	C		ORAL		

Date:12/29/04ISR Number: 4541386-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541387-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00039
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 1490 DAY	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Increased Cerebral Infarction Muscle Spasticity					

Date:12/29/04ISR Number: 4541388-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02405
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure Congestive		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL
UNKNOWN						

Date:12/29/04ISR Number: 4541389-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0412NLD00014
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident Gastric Haemorrhage		Vioxx Aspirin Calcium	PS C	Merck & Co., Inc	ORAL
UNKNOWN						
			Pantoprazole Sodium	C		ORAL
			Lisinopril	C		ORAL

Date:12/29/04ISR Number: 4541390-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02394
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Ulcer		Furosemide	C				UNKNOWN
Disability	Prescribed Overdose		Prevacid	C				UNKNOWN
			Diovan	C				UNKNOWN
			Verapamil	C				UNKNOWN
			Potassium (Unspecified)	C				UNKNOWN
			Alprazolam	C				UNKNOWN

Date:12/29/04ISR Number: 4541391-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00205
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Insufficiency							

Date:12/29/04ISR Number: 4541392-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00205
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Aspirin	SS		ORAL		
			Simvastatin	C		ORAL		
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL		
			Bisacodyl	C		ORAL		

			Domperidone	C		ORAL

Date:12/29/04ISR Number: 4541393-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02501
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541394-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:12/29/04ISR Number: 4541395-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00218
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4541396-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02404
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541397-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01213
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541398-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0412BRA00068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Jejunal Ulcer Perforation							
Initial or Prolonged								

Date:12/29/04ISR Number: 4541399-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00212
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
1314 DAY								
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
1314 DAY								
	Coronary Artery Occlusion							

Date:12/29/04ISR Number: 4541400-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00214
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiac Valve Disease							
	Fluid Retention							
	Intestinal Haemorrhage							

Date:12/29/04ISR Number: 4541401-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00219
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541402-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00073
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541403-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02090
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Disorder		Sulfasalazine	C				
UNKNOWN								
Other	Arterial Occlusive Disease							
	Blood Pressure Increased							
	Cardiac Disorder							
	Chest Pain							
	Coronary Artery Disease							
	Scar							
	Ventricular Hypokinesia							

Date:12/29/04ISR Number: 4541404-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02651
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
1493 DAY								
Hospitalization - Initial or Prolonged	Hemiparesis							
	Hydrocephalus							
Disability	Nervous System Disorder							

Date:12/29/04ISR Number: 4541405-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02729
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Oedema Peripheral Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY

Date:12/29/04ISR Number: 4541406-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02737
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Fluid Retention Renal Impairment Swelling		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:12/29/04ISR Number: 4541407-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02508
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Disability	Muscle Spasms Prescribed Overdose		Prevacid	C				UNKNOWN

Date:12/29/04ISR Number: 4541408-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541409-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02525
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged			Centrum Silver	C				
UNKNOWN								
Disability			Cephalexin	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541410-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Palpitations							

Date:12/29/04ISR Number: 4541411-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02528
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:12/29/04ISR Number: 4541412-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02656
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541413-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02670
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL	500	DAY
			Premarin	C			UNKNOWN	
			Altace	C			UNKNOWN	
			Prevacid	C			UNKNOWN	

Date:12/29/04ISR Number: 4541414-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02509
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4541415-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541416-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Disorder Cerebrovascular Accident Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541417-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02749
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Toprol Xl Tablets	C				
Initial or Prolonged UNKNOWN			Zestril	C				
Disability								
Other								

Date:12/29/04ISR Number: 4541418-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02746
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Plaquenil	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541419-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02750
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Blister		Lipitor	C				
UNKNOWN								
	Haemorrhage		[Therapy					
	Pulmonary Embolism		Unspecified]	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541420-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02766
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ulcer		Allegra	C				
UNKNOWN								
Disability			Prilosec	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Flonase	C				
UNKNOWN								
			Allergenic Extract	C				
UNKNOWN								

Date:12/29/04ISR Number: 4541421-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02805
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541422-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541426-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02878
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541428-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03967
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Fall		Vioxx Acupril	PS C	Merck & Co., Inc	ORAL		UNKNOWN
Other	Loss Of Consciousness Syncope		Calcium (Unspecified)	C				UNKNOWN

Date:12/29/04ISR Number: 4541429-0Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0412ZAF00019
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening						

Date:12/29/04ISR Number: 4541430-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02806
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/29/04ISR Number: 4541432-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02943
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/29/04ISR Number: 4541433-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02773
Age:80 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Sensation Of Heaviness		Zocor	C			UNKNOWN	
Spinal Osteoarthritis		Meclizine	C			UNKNOWN	
Transient Ischaemic		Premarin	C			UNKNOWN	
Attack		[Therapy Unspecified]	C			UNKNOWN	

Date:12/29/04ISR Number: 4541435-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03042
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541436-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02862
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	1577 DAY	
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	1577 DAY	
Other			Prevacid	C		ORAL		
			Plavix	C		ORAL		
			Alprazolam	C		ORAL		
			[Therapy Unspecified]	C		ORAL		

Date:12/29/04ISR Number: 4541437-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02769
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4541461-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01626
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Sick Sinus Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/29/04ISR Number: 4543507-9Report Type:Direct Company Report #CTU 235291
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anterior Spinal Artery Syndrome		Vioxx Mfd By Merck	PS	Merck		25 MG ONCE DAILY	
	Diplegia		Tenormin	C				
			Lipitor	C				
			Diovan	C				
			Nexium	C				
			Advil	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/04ISR Number: 4543809-6Report Type:Direct Company Report #CTU 235289
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS				
Hospitalization - Initial or Prolonged	Drug Hypersensitivity		Celebrex	SS				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:12/29/04ISR Number: 4543823-0Report Type:Direct Company Report #CTU 235280
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 25mg	PS	Merck + Co		1 TABL DAILY	
Other								

Date:12/29/04ISR Number: 4543853-9Report Type:Direct Company Report #CTU 235276
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx - (Rofecoxib)					
Hospitalization - Initial or Prolonged	Myocardial Infarction		50 Mg "Mrk114"	PS			25MG X 2 047	
Required Intervention to Prevent Permanent Impairment/Damage								

Date:12/29/04ISR Number: 4543854-0Report Type:Direct Company Report #CTU 235275
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abnormal Behaviour		Bextra	PS				
	Depression		Vioxx	SS				
	Drug Ineffective		Celebrex	SS				
	Insomnia							
	Weight Decreased							

Date:12/30/04ISR Number: 4541633-1Report Type:Expedited (15-DaCompany Report #CA-ROCHE-351657
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
	Blister
	Coagulopathy
	Coma
	Confusional State
	Dehydration
	Diarrhoea
	Gastritis Erosive
	Haematemesis
	Hypovolaemic Shock

		Nausea					
		Oral Intake Reduced					
		Renal Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence		Capecitabine	PS	Roche	ORAL
GIVEN AS							
		Upper Gastrointestinal					
TWICE DAILY							
		Haemorrhage					
INTERMITTENT							
		Vomiting					
TREATMENT							
CONSISTING OF	43 DAY						
				Oxaliplatin	SS	Roche	
INTRAVENOUS	GIVEN ON DAY						
ONE OF A							
THREE WEEK							
CYCLE	29 DAY						
				Vioxx	SS		
UNKNOWN							
				Coumadin	C		
				Vitamina E	C		
				Vitamin C	C		
				Multivitamin	C		
				Vitamin B Complex	C		
				Unspecified Drug	C		

Date:12/30/04ISR Number: 4542030-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:73 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Angina Pectoris		Cardizem	C		
UNKNOWN							
		Aortic Valve Incompetence		Zyloprim	C		
UNKNOWN							
		Appendicectomy		Altace	C		
UNKNOWN							

	Cardiac Disorder	Pravachol	C
UNKNOWN			
	Carotid Artery Occlusion	Aspirin	C
UNKNOWN			
	Chest Pain	Glucophage	C
UNKNOWN			
	Convulsion	Vitamin E	C
UNKNOWN			
	Coronary Artery Disease	Ascorbic Acid	C
UNKNOWN			
	Coronary Artery Stenosis	Omega-3	C
UNKNOWN			
	Diabetes Mellitus	Centrum	C
UNKNOWN			
	Dyspnoea	Vitamin B Complex	C
UNKNOWN			
	Gastric Ulcer	Avandia	C
UNKNOWN			
	Gastrointestinal	Viagra	C
UNKNOWN			
	Haemorrhage	Imdur	C
UNKNOWN			
	Glycosylated Haemoglobin Increased		
	Haemorrhage		
	Heart Rate Increased		
	Herpes Zoster		
	Hypertension		
	Melaena		
	Mitral Valve Incompetence		
	Monarthritis		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Respiratory Rate Increased		
	Sinus Tachycardia		
	Tachycardia		
	Tricuspid Valve Incompetence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542035-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		586 DAY
Initial or Prolonged	Adverse Event		Claritin	C				UNKNOWN
Disability	Angina Pectoris		Aspirin	C				UNKNOWN
Other	Arrhythmia		Pravachol	C				UNKNOWN
	Benign Prostatic Hyperplasia		Calcium (Unspecified)	C				UNKNOWN
	Blood Pressure Increased		Folic Acid	C				UNKNOWN
	Bradycardia		Digoxin	C				UNKNOWN
	Bronchitis Acute		Naprosyn	C		ORAL		
	Cerebrovascular Accident		Keflex	C		ORAL		
	Cholelithiasis		Allegra	C		ORAL		
	Chronic Obstructive Pulmonary Disease		Elocon	C				UNKNOWN
	Convulsion		Lopressor	C		ORAL		
	Coronary Artery Disease		Darvocet-N	C		ORAL		
	Cough		Pravachol	C				UNKNOWN
	Depression		Lanoxin	C		ORAL		
	Dermatitis Atopic		Lortab	C		ORAL		
	Diverticulum		Clarinex	C		ORAL		
	Dizziness		Zocor	C		ORAL		
	Dysgeusia		Nexium	C		ORAL		
	Dyspnoea		Paxil	C		ORAL		
	Emphysema		Vitamin E	C				UNKNOWN
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Haemorrhoids							
	Hepatic Cyst							
	Hiatus Hernia							
	Inner Ear Disorder							
	Intervertebral Disc Degeneration							

Lumbar Radiculopathy
Lumbar Spinal Stenosis
Lung Neoplasm
Myocardial Infarction
Neuroma
Non-Hodgkin'S Lymphoma
Palpitations
Peripheral Vascular
Disorder
Pleural Effusion
Renal Abscess
Renal Mass
Rhinitis Allergic
Salivary Gland Cancer
Splenomegaly
Spondylolisthesis
Vertigo
Weight Decreased

Date:12/30/04ISR Number: 4542042-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00082900
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Prostatitis Renal Failure Acute

Renal Tubular Necrosis
Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	158	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	158	DAY
	Levaquin	C			UNKNOWN	
	Cipro	C			UNKNOWN	
	Pyridium	C			UNKNOWN	
	Flomax (Morniflumate)	C			UNKNOWN	

Date:12/30/04ISR Number: 4542043-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02121
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Disability	Abdominal Pain
Other	Amenorrhoea
	Anxiety
	Arthralgia
	Back Pain
	Blood Ph Increased
	Blood Pressure Diastolic Increased
	Cardiac Failure Congestive
	Carpal Tunnel Syndrome
	Complex Regional Pain Syndrome
	Cough
	Dehydration
	Depression
	Diarrhoea
	Diverticulum
	Electrocardiogram Poor R-Wave Progression
	Emotional Distress
	Endometrial Hyperplasia

Endometrial Hypertrophy
Endometrial Neoplasm
Fall
Fear
Gastric Polyps
Gastritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Headache
Hiatus Hernia
Hyperhidrosis
Hypersensitivity
Hypoaesthesia
Inflammation
Injury
Intervertebral Disc
Disorder
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion

	Joint Injury Joint Swelling Laceration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Lumbar Radiculopathy		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY					
	Menorrhagia		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY					
	Myalgia		Augmentin	C		
UNKNOWN						
	Myocardial Infarction		Albuterol	C		
RESPIRATORY						
	Oedema Peripheral					
(INHALATION)						
	Ovarian Cyst		Allegra	C		
UNKNOWN						
	Oxygen Saturation		Flonase	C		
UNKNOWN						
	Decreased		Toradol	C		
UNKNOWN						
	Pain Peptic Ulcer		Vitamins (Unspecified)	C		
UNKNOWN						
	Prescribed Overdose Reflux Gastritis Road Traffic Accident Skin Laceration Sleep Apnoea Syndrome Tachycardia Uterine Haemorrhage Weight Increased Wound					

Date:12/30/04ISR Number: 4542059-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02079
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Amnesia Arthritis Azotaemia Benign Prostatic Hyperplasia Blood Cholesterol

Increased
Bradycardia
Cardiovascular Disorder
Carotid Artery Stenosis
Chronic Obstructive
Pulmonary Disease
Contusion
Coronary Artery Disease
Decreased Activity
Decreased Appetite
Depression
Drug Hypersensitivity
Excoriation
Fall
Gastric Varices
Glucose Tolerance
Impaired
Hepatic Cirrhosis
Hyperlipidaemia
Hypertension
Insomnia
Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Musculoskeletal Disorder

		Myocardial Ischaemia					
		Nerve Root Compression					
		Nightmare	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pericarditis					
		Peripheral Vascular					
		Disorder					
		Pneumonia					
		Renal Disorder					
		Renal Failure					
		Rib Fracture					
		Rotator Cuff Syndrome					
		Shoulder Deformity					
		Spinal Decompression					
		Spinal Osteoarthritis					
		Tendonitis					
		Thrombosis					
		Weight Decreased					

Date:12/30/04ISR Number: 4542062-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL
536 DAY							
Initial or Prolonged		Acquired Diaphragmatic		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Eventration		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
Other		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
536 DAY							
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
		Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Discomfort		Buspar	C		ORAL
405 DAY							
		Chest Pain		Lortab	C		ORAL
573 DAY							
		Convulsion		Lortab	C		ORAL
		Coronary Artery Disease		Ziac	C		ORAL
322 DAY							
		Coronary Artery Occlusion		Vicodin Tablets	C		ORAL

	Dyspnoea Exertional	Lipitor	C	ORAL
	Electrocardiogram P Wave	Valium	C	ORAL
214 DAY				
	Abnormal	Talwin	C	ORAL
24 DAY				
	Feeling Abnormal	Ultram	C	ORAL
9 DAY				
	Intervertebral Disc	Skelaxin	C	ORAL
14 DAY				
	Disorder	Tenyl	C	
UNKNOWN	36 DAY			
	Intervertebral Disc	Claritin	C	
UNKNOWN				
	Protrusion	Serzone	C	
UNKNOWN				
	Loss Of Consciousness	Carisoprodol	C	
UNKNOWN				
	Musculoskeletal Discomfort	Acetaminophen And Propoxyphene Hydrochloride	C	
	Myocardial Infarction			
UNKNOWN				
	Nodal Rhythm	Mobic	C	
UNKNOWN				
	Nuclear Magnetic Resonance Imaging	Hydrocodone Hydrochloride	C	
UNKNOWN				
	Abnormal	Altace	C	
UNKNOWN				
	Radicular Pain	Toprol Xl Tablets	C	
UNKNOWN				
	Road Traffic Accident	Aspirin	C	
UNKNOWN				
	Spinal Column Stenosis			
	Spinal Osteoarthritis			
	Tremor			
	Ventricular Extrasystoles			
	Ventricular Fibrillation			
	Ventricular Hypokinesia			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542065-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00790
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Soma	C		ORAL		
	Cardiac Failure		Levbid	C			UNKNOWN	
	Congestive		Dilantin	C			UNKNOWN	
	Cardio-Respiratory Arrest		Paxil Cr	C			UNKNOWN	
	Chronic Obstructive		Elavil	C			UNKNOWN	
	Pulmonary Disease		Claritin	C			UNKNOWN	
	Condition Aggravated		Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
	Convulsion							
	Diarrhoea							
	Drug Ineffective		Protonix	C			UNKNOWN	
	Ear Pain		Carafate	C			UNKNOWN	
	Exostosis		Aciphex	C			UNKNOWN	
	Faecal Occult Blood		Lomotil	C			UNKNOWN	
	Positive		Questran	C			UNKNOWN	
	Fall		Atenolol	C			UNKNOWN	
	Feeling Abnormal		Lasix (Furosemide)	C			UNKNOWN	
	Fractured Coccyx		Potassium (Unspecified)	C			UNKNOWN	
	Gastrooesophageal Reflux							
	Disease		Premarin	C			UNKNOWN	
	Haemorrhoids		Paxil	C			UNKNOWN	
	Headache		Synthroid	C			UNKNOWN	

	Hepatic Steatosis	Darvocet-N	C
UNKNOWN			
	Hepatitis C	Melatonina	C
UNKNOWN			
	Hiatus Hernia		
	Hyperlipidaemia		
	Hypertension		
	Injury		
	Insomnia		
	Joint Injury		
	Lactose Intolerance		
	Lacunar Infarction		
	Liver Function Test Abnormal		
	Malaise		
	Meralgia Paraesthetica		
	Monarthritis		
	Nausea		
	Nervousness		
	Osteoarthritis		
	Palpitations		
	Pulmonary Fibrosis		
	Pyrexia		
	Sinus Tachycardia		
	Sleep Apnoea Syndrome		
	Syncope		
	Tricuspid Valve Incompetence		
	Ventricular Extrasystoles		
	Vision Blurred		
	Vomiting		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542074-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01752
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Initial or Prolonged	Infarction		Tenormin	C				UNKNOWN
Disability	Anal Inflammation							
Other	Anxiety Disorder							
	Back Injury							
	Back Pain							
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Cervical Spasm							
	Colonic Polyp							
	Constipation							
	Convulsion							
	Coordination Abnormal							
	Coronary Artery Occlusion							
	Depression							
	Dermatitis							
	Haematochezia							
	Haemorrhoids							
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertension							
	Memory Impairment							
	Mental Status Changes							
	Muscle Spasms							
	Obesity							
	Oedema Peripheral							
	Paraesthesia							
	Pharyngitis							
	Rhinitis							
	Sensory Disturbance							
	Sinus Polyp							
	Sleep Apnoea Syndrome							
	Stomach Discomfort							
	Stress							
	Upper Respiratory Tract Infection							

Date:12/30/04ISR Number: 4542079-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Agitation
Other	Anaemia
	Anxiety
	Aortic Aneurysm
	Aortic Atherosclerosis
	Aortic Calcification
	Aortic Valve Sclerosis
	Arthralgia
	Asthma
	Atelectasis
	Atherosclerosis
	Atrial Fibrillation
	Back Pain
	Blood Blister

		Blood Potassium Increased					
		Blood Sodium Decreased					
		Bradycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Bronchospasm		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Cardiac Murmur		Fosamax	C		
UNKNOWN							
		Cardiomegaly		Percocet	C		
UNKNOWN							
		Chest Pain		Zestril	C		
UNKNOWN							
		Chronic Obstructive		Zestril	C		
UNKNOWN							
		Pulmonary Disease		Diltiazem			
		Condition Aggravated		Hydrochloride	C		
UNKNOWN							
		Confusional State					
		Conjunctivitis Allergic					
		Constipation					
		Death					
		Difficulty In Walking					
		Disorientation					
		Drug Hypersensitivity					
		Dyspepsia					
		Emotional Distress					
		Foreign Body Trauma					
		Herpes Simplex					
		Herpes Zoster					
		Hypotension					
		Injury					
		Interstitial Lung Disease					
		Intracardiac Thrombus					
		Labile Hypertension					
		Laryngitis					
		Loss Of Consciousness					
		Lung Disorder					
		Mental Status Changes					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Myocardial Calcification					
		Myocardial Infarction					

Nasopharyngitis
Nausea
Neuropathy
Osteoporosis
Pneumonia
Pulmonary Hypertension
Renal Artery Stenosis
Restlessness
Scar
Spinal Column Stenosis
Spinal Compression
Fracture
Sputum Discoloured
Syncope
Tracheal Obstruction
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Urinary Retention
Ventricular Hypertrophy
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542081-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00897
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Breast Mass							
	Chest Pain							
	Coronary Artery Disease							
	Electrocardiogram T Wave Abnormal							
	Hepatitis B Positive							
	Hyperlipidaemia							
	Hypertensive Heart Disease							
	Hypokalaemia							
	Polytraumatism							
	Tremor							

Date:12/30/04ISR Number: 4542082-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Antiphospholipid Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthenopia		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Guaifenesin	C			UNKNOWN	
	Bundle Branch Block Left		Ceftin	C			UNKNOWN	
	Bundle Branch Block Right		Aspirin	C		ORAL		
	Cardiolipin Antibody Positive		Probeta (Dipivefrin Hydrochloride (+) Levobunolol Hydrochloride)	C			OPHTHALMIC	
	Cerebrovascular Accident							
	Cough							
	Depression		Diamox	C		ORAL		
	Dilatation Atrial		Glucosamine	C		ORAL		
	Drug Effect Decreased		Advil	C		ORAL		
	Emotional Distress							
	Fear							

Gastrooesophageal Reflux
Disease
Headache
Hypercoagulation
Ingrowing Nail
Injury
Meningioma
Myocardial Infarction
Osteoarthritis
Paraesthesia
Retinal Artery Occlusion
Somnolence
Tooth Disorder
Trifascicular Block

Date:12/30/04ISR Number: 4542084-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT
Abdominal Pain
Adverse Event
Anal Polyp
Arthralgia
Atherosclerosis
Atrial Fibrillation
Blister
Blood Parathyroid Hormone
Increased
Blood Pressure
Inadequately Controlled
Cardiac Murmur
Chest Pain
Colonic Polyp
Condition Aggravated
Conjunctival Haemorrhage
Coronary Artery Disease
Dermatitis Contact
Diarrhoea
Diastolic Dysfunction
Dilatation Atrial
Diverticulum Intestinal
Drug Effect Decreased
Dysgeusia
Dyspepsia
Dyspnoea
Eye Haemorrhage
Fatigue
Furuncle
Gastritis
Gastroenteritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Headache
Hepatic Steatosis
Hiatus Hernia
Hypercalcaemia
Hypertension
Injury
Intermittent Claudication
Joint Swelling
Laryngitis
Lung Disorder

Muscle Spasms
Myocardial Ischaemia
Nausea
Pain In Extremity
Palpitations
Pancreatitis Acute
Peripheral Vascular
Disorder
Pulmonary Calcification
Rash Macular
Renal Cyst
Renal Failure Chronic
Rhinitis Allergic
Rotator Cuff Syndrome

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Scar					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Tricuspid Valve		Vioxx	PS	Merck & Co., Inc	ORAL
213	DAY						
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Imdur	C		
UNKNOWN							
				Monopril	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Hydrodiuril	C		ORAL
				Toprol Xl Tablets	C		ORAL
				Cardura	C		
UNKNOWN							

Date:12/30/04ISR Number: 4542091-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00209
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 7 DAY	Fall		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Head Injury		Tramadol Hydrochloride	C		ORAL		
	Ischaemic Stroke		Dipyrone	C		ORAL		
			Atenolol And Chlorthalidone	C		ORAL		
			Hydrochlorothiazide And Ramipril	C				
UNKNOWN			Amitriptyline Hydrochloride	C				
UNKNOWN			Aspirin And Dipyridamole	C				
UNKNOWN			Tetrazepam	C				
UNKNOWN			Dexamethasone Sodium Phosphate	C				
UNKNOWN			Metoprolol Succinate	C		ORAL	48	HR
			Lormetazepam	C		ORAL		

Date:12/30/04ISR Number: 4542092-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00126
Age:57 YR Gender:Female I/FU:F

Outcome	PT
	Alanine Aminotransferase Increased
	Aortic Valve Incompetence
	Blood Alkaline Phosphatase Increased
	Blood Amylase Increased
	Blood Bilirubin Increased

		Body Temperature Decreased					
		Carotid Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Low Density Lipoprotein		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Meningioma		Imipramine Hydrochloride	C		ORAL
		Transient Ischaemic Attack		Trazodone Hydrochloride	C		ORAL
				Acetaminophen And Codeine Phosphate	C		
UNKNOWN							
				Esomeprazole Magnesium	C		ORAL

Date:12/30/04ISR Number: 4542093-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02915
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Motor Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain In Extremity		Insulin	C		
UNKNOWN						
	Pulmonary Embolism		Glucophage	C		
UNKNOWN						
	Treatment Noncompliance		Nexium	C		
UNKNOWN						
			Potassium Chloride	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						
			Hydroxyzine Hydrochloride	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Coreg	C		
UNKNOWN						
			Lopid	C		
UNKNOWN						

UNKNOWN	Coumadin	C
UNKNOWN	Lasix (Furosemide)	C
UNKNOWN	Humulin	C
UNKNOWN	Demadex	C
UNKNOWN	Combivent	C
UNKNOWN	Flovent	C
UNKNOWN	Lorcet 10/650	C
UNKNOWN		

Date:12/30/04ISR Number: 4542095-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03761
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Scar							
	Swelling							
	Thrombosis							

Date:12/30/04ISR Number: 4542097-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00876
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Disability	Bronchitis
	Dry Throat
	Dysphonia
	Headache
	Pharyngolaryngeal Pain

Treatment Noncompliance

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C			UNKNOWN	
			Levothroid	C		ORAL		
			Folic Acid	C		ORAL		
			Methotrexate	C		ORAL		
			Prilosec	C		ORAL		
			Minocycline	C			UNKNOWN	

Date:12/30/04ISR Number: 4542099-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02186
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization -	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Chest Discomfort							
Other	Coronary Artery Thrombosis							
	Myocardial Infarction							

Date:12/30/04ISR Number: 4542100-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03598
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Upper Gastrointestinal		Premarin	C		ORAL		
Disability	Haemorrhage		Celexa	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Lotensin	C		ORAL		
			Lotensin	C		ORAL		
			Norvasc	C		ORAL		
			Norvasc	C		ORAL		

Date:12/30/04ISR Number: 4542102-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03832
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis Bacterial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective		Glucophage	C				
UNKNOWN								
Disability	Pulmonary Embolism		Lisinopril-Bc	C				
UNKNOWN								
	Stomach Discomfort		Glyburide	C				
UNKNOWN								
	Treatment Noncompliance		Provera	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Salsalate	C				
UNKNOWN							27	DAY
			Diclofenac	C				
UNKNOWN							16	DAY
			Diclofenac	C				
UNKNOWN							24	DAY
			Tylenol	C				
UNKNOWN							16	DAY
			Tylenol	C				
UNKNOWN							24	DAY
			Vicodin Tablets	C				
UNKNOWN							7	DAY

Date:12/30/04ISR Number: 4542103-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542105-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02899
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Occlusion		[Therapy Unspecified]	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542106-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03698
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1305 DAY	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Injury							
	Spinal Vascular Disorder							

Date:12/30/04ISR Number: 4542108-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01605
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zyloprim	C				
UNKNOWN								
	Spinal Disorder							

Date:12/30/04ISR Number: 4542111-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542113-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542115-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542124-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02779
Age:59 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Arrhythmia
Hospitalization - Initial or Prolonged	Electrocardiogram Abnormal

	Hypertension Tachycardia						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C			UNKNOWN

Date:12/30/04ISR Number: 4542125-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:12/30/04ISR Number: 4542127-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03979
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Hospitalization -	Death						
Initial or Prolonged	Ejection Fraction						
Disability	Decreased						
Other	Hyperlipidaemia						

Date:12/30/04ISR Number: 4542156-6Report Type:Expedited (15-DaCompany Report #FRWYE290617DEC04
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Coronary Syndrome		Enbrel	PS			SUBCUTANEOUS 432 DAY
Initial or Prolonged	Anxiety		Zocor	SS		ORAL	2 YR
	Blood Pressure Systolic		Atacand	SS		ORAL	
	Increased		Vioxx	SS		ORAL	
	Coronary Artery		Estradiol	SS			TRANSDERMAL

	Atherosclerosis		Novatrex	SS		ORAL
	Coronary Artery Stenosis		Fosamax	C		
	Ejection Fraction		Cacit	C		
	Decreased		Duphaston	C		
	Myocardial Ischaemia					

Date:12/30/04ISR Number: 4542562-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03829
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea							
Initial or Prolonged	Hypertension							
Disability	Myocardial Infarction							

Date:12/30/04ISR Number: 4542567-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0412DNK00021
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	40	MON
	Paraesthesia		Metoprolol Tartrate Bendroflumethiazide And Potassium	C		ORAL		

Chloride	C		ORAL
Amlodipine Besylate	C		ORAL
Prednisolone	C		ORAL

Date:12/30/04ISR Number: 4542569-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00026
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy Unspecified]	C				

557 DAY

UNKNOWN

Date:12/30/04ISR Number: 4542570-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03646
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Cardiac Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bacterial Infection							
	Cardiac Aneurysm							
	Cardiomegaly							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Dilatation Ventricular							
	Myocardial Infarction							
	Ventricular Dysfunction							

Date:12/30/04ISR Number: 4542572-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03990
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cyst		Prilosec	C				

UNKNOWN

	Dyspnoea	Clarinex	C
UNKNOWN			
	Fatigue	Claritin-D	C
UNKNOWN			
	Joint Swelling	Viagra	C
UNKNOWN			
	Muscular Weakness		
	Oedema Peripheral		
	Tachycardia		

Date:12/30/04ISR Number: 4542574-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03813
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Zetia	C		ORAL		
Initial or Prolonged	Pain In Extremity							
Disability								

Date:12/30/04ISR Number: 4542577-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00213
Age:40 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Sulfasalazine	C		ORAL		

Date:12/30/04ISR Number: 4542581-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00934
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Asthma		[Therapy					
	Back Disorder		Unspecified]	C			UNKNOWN	
	Chest Pain							
	Dysphagia							
	Dyspnoea							
	Heart Rate Increased							
	Hypertension							
	Stomach Discomfort							

Date:12/30/04ISR Number: 4542582-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00232
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							

Date:12/30/04ISR Number: 4542583-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01180
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - 4 DAY	Angina Unstable	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Cardiac Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion	Vioxx	SS	Merck & Co., Inc	ORAL
	Ischaemia	Vioxx	SS	Merck & Co., Inc	ORAL
	Migraine	Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction	Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Ischaemia	Vioxx	SS	Merck & Co., Inc	ORAL
4 DAY					
	Vascular Graft Occlusion	Vioxx	SS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
		Aspirin	C		
UNKNOWN					
		Ritalin	C		
UNKNOWN					
		Lipitor	C		
UNKNOWN					
		Tiazac	C		
UNKNOWN					
		Hytrin	C		
UNKNOWN					
		Lopressor	C		
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542593-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02654
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Increased		Tums	C				
UNKNOWN								
	Tachycardia		Nexium	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542594-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02633
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		[Therapy					
Initial or Prolonged	Heart Rate Decreased		Unspecified]	C				
UNKNOWN								
Disability	Vomiting		[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542595-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00041
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Atenolol	C		ORAL		
Disability								

Date:12/30/04ISR Number: 4542599-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542601-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02587
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		660 DAY
Initial or Prolonged	Anaemia		Toprol Xl Tablets	C				UNKNOWN
	Cardiac Enzymes Increased		Lipitor	C				UNKNOWN
	Chest Discomfort		Ecotrin	C				UNKNOWN
	Coronary Artery Occlusion							
	Dehydration							
	Dizziness							
	Gastrooesophageal Reflux Disease							
	Haematoma							
	Hypotension							
	Myocardial Infarction							
	Osteoarthritis							
	Peripheral Vascular Disorder							
	Procedural Complication							
	Vertigo							

Date:12/30/04ISR Number: 4542606-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00036
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hepatitis Cholestatic		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY

Date:12/30/04ISR Number: 4542608-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02634
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Aspirin	C				UNKNOWN
			Terazosin Hydrochloride	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN

Date:12/30/04ISR Number: 4542609-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02904
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Liver Disorder		Prednisone	C				UNKNOWN
	Overdose							

Date:12/30/04ISR Number: 4542610-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02616
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Other	Peritonitis		Coversyl	SS		ORAL
	Small Intestinal		Solu-Medrol	SS		
UNKNOWN						
	Perforation		Diafusor	SS		
UNKNOWN						
			Enbrel	SS		
UNKNOWN		1168 DAY				
			Kardegic	SS		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN		7 DAY				

Date:12/30/04ISR Number: 4542612-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02726
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Congestive					

Date:12/30/04ISR Number: 4542613-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arterial Injury		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain					
Initial or Prolonged	Coma					
	Death					
	Haemodynamic Instability					
	Laceration					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542614-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02890
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Diovan	C				
UNKNOWN								
Disability			Evista	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542616-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542617-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02771
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Glyburide	C				
UNKNOWN								
	Syncope		Toprol Xl Tablets	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542618-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
							4	MON
	Cardiac Disorder							

Date:12/30/04ISR Number: 4542620-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Arrhythmia
	Arthritis
	Asthenia
	Blood Cholesterol Increased
	Bronchitis
	Cardiac Valve Disease
	Cerebrovascular Accident
	Coronary Artery Disease
	Decreased Appetite
	Dementia Alzheimer'S Type
	Diabetes Mellitus Non-Insulin-Dependent
	Drug Interaction
	Dyspnoea
	Glaucoma
	Hepatocellular Damage
	Hypertension
	Hypoglycaemia
	Injury

		Insomnia					
		Low Density Lipoprotein Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Intake Reduced		Vioxx	PS	Merck & Co., Inc	ORAL
		Parkinson'S Disease					
		Renal Failure					
		Rheumatoid Arthritis					
		Somnolence					
		Sputum Discoloured					
		Urinary Incontinence					
		Vomiting					

Date:12/30/04ISR Number: 4542623-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02073
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
319 DAY						
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
319 DAY						
Disability	Asthma		Xanax	C		
UNKNOWN						
Other	Atrioventricular Block		Humulin N	C		
UNKNOWN						
	Complete		Diovan	C		
UNKNOWN						
	Bradycardia		Ibuprofen	C		
UNKNOWN						
	Bronchitis		Valium	C		
UNKNOWN						
	Bursitis		Synthroid	C		
UNKNOWN						
	Cardiogenic Shock					
	Cataract					
	Chronic Obstructive Pulmonary Disease					
	Constipation					
	Coronary Artery Disease					
	Coronary Ostial Stenosis					
	Costochondritis					
	Death Of Child					
	Deep Vein Thrombosis					
	Diabetes Mellitus					

Non-Insulin-Dependent
Diarrhoea
Dressler'S Syndrome
Drug Ineffective
Emotional Disorder
Gout
Herpes Zoster
Hiatus Hernia
Hyperlipidaemia
Hypertension
Hypotension
Insomnia
Irritable Bowel Syndrome
Lung Neoplasm
Mitral Valve Incompetence
Myocardial Infarction
Neck Mass
Non-Cardiac Chest Pain
Oedema Peripheral
Osteoarthritis
Spondylolisthesis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542628-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:12/30/04ISR Number: 4542629-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01864
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Viscosity Increased		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
	Electrocardiogram Poor		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	R-Wave Progression		Celebrex	C			UNKNOWN	
	Electrocardiogram Qt		Ativan	C			UNKNOWN	
	Prolonged		Taloxa	C			UNKNOWN	
	Heart Rate Increased		Glucophage	C			UNKNOWN	
	Lacunar Infarction		Avandia	C			UNKNOWN	
	Low Density Lipoprotein		Zestril	C			UNKNOWN	
	Increased		Norvasc	C			UNKNOWN	
	Oedema Peripheral		Voltaren	C			UNKNOWN	
	Qrs Axis Abnormal		Diuril	C		ORAL		
	Transient Ischaemic		Elavil	C		ORAL		
	Attack		Amaryl	C			UNKNOWN	
	Ventricular Hypertrophy							

Date:12/30/04ISR Number: 4542631-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Affective Disorder
	Anaemia
	Angina Pectoris
	Back Pain
	Blood Cholesterol Increased
	Cerebral Infarction
	Cerebrovascular Accident
	Coagulopathy
	Colonic Polyp
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Dyspepsia
	Eczema
	Gastritis
	Haemorrhoidal Haemorrhage
	Head Injury
	Headache
	Heart Rate Irregular
	Hirsutism
	Hot Flush
	Hypochromic Anaemia
	Insomnia
	Intracranial Venous Sinus Thrombosis
	Joint Effusion

		Migraine					
		Musculoskeletal Stiffness					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Optic Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Papilloedema		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Raynaud'S Phenomenon		Yasmin	SS		
UNKNOWN		14 DAY					
		Sinus Tachycardia		Sandimmun	C		
UNKNOWN							
		Sneezing		Lexapro	C		
UNKNOWN							
		Subarachnoid Haemorrhage		Sandimmun	C		
UNKNOWN							
		Uterine Enlargement		Sandimmun	C		
UNKNOWN							
		Uterine Leiomyoma		Prednisone	C		
UNKNOWN							
		Vaginal Haemorrhage		Hormonal			
		Visual Disturbance		Contraceptives			
		Vomiting		(Unspecified)	C		
INTRAMUSCULAR							
				Prelone Syrup	C		
UNKNOWN							
				Prelone Syrup	C		
UNKNOWN							

Date:12/30/04ISR Number: 4542635-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Calcinosis		Vicoprofen	C		
UNKNOWN							
		Cardiac Arrest		Methocarbamol	C		
UNKNOWN							
		Cardio-Respiratory Arrest					
		Cardiomegaly					

Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Thrombosis
Electromechanical
Dissociation
Myocardial Infarction
Pulmonary Congestion
Pulmonary Oedema
Splenomegaly
Sudden Death
Ventricular Fibrillation

Date:12/30/04ISR Number: 4542636-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00781
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Aortic Aneurysm
Other	Aortic Occlusion
	Asthenia
	Breath Sounds Decreased
	Cardiomyopathy
	Chest Pain
	Crepitations
	Device Failure
	Dizziness

		Dyspepsia					
		Dyspnoea					
		Erectile Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension					
		Hypoaesthesia					
		Ileus					
		Intermittent Claudication					
		Limb Discomfort					
		Muscle Spasms					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Polytraumatism					
		Post Procedural					
		Complication					
		Renal Tubular Necrosis					
		Vision Blurred					

Date:12/30/04ISR Number: 4542642-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00690
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Adverse Event					
		Aphonia					
		Arrhythmia					
		Arthralgia					
		Back Pain					
		Burning Sensation					
		Bursitis					
		Dyspepsia					
		Electrocardiogram T Wave					
		Amplitude Decreased					
		Gastritis					
		Headache					
		Hypertension					
		Injury					
		Joint Dislocation					
		Meniscus Lesion					
		Musculoskeletal					
		Discomfort					
		Nausea					

Neuritis
Osteoarthritis
Pain In Extremity
Pyrexia
Rheumatoid Arthritis
Sciatica
Sinusitis
Sleep Apnoea Syndrome
Sneezing
Synovitis
Tarsal Tunnel Syndrome

Date:12/30/04ISR Number: 4542643-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0306FRA00089
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL	12 DAY	
Hospitalization - Initial or Prolonged	Ascites		[Therapy Unspecified]	C				
	Cerebral Arteriovenous							
UNKNOWN	Malformation Haemorrhagic						12 DAY	
Other	Cholecystitis Infective							
	Gastric Cyst							
	Hypocalcaemia							
	Pancreatic Pseudocyst							
	Pancreatitis Acute							
	Pancreatitis Necrotising							
	Pleural Effusion							
	Post Procedural Complication							
	Subileus							
	Transient Ischaemic Attack							

Date:12/30/04ISR Number: 4542644-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00112
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
Disability	Aortic Valve Incompetence
Other	Arthritis
	Arthropathy
	Atherosclerosis
	Bursitis
	Candidiasis
	Cardiac Disorder
	Cardiac Murmur
	Chronic Lymphocytic Leukaemia
	Coronary Artery Disease
	Diarrhoea
	Dyspnoea
	Electrocardiogram Abnormal

Electrocardiogram T Wave
Inversion
Fall
Fatigue
Fluid Retention
Gastritis
Gastrointestinal
Haemorrhage
Heart Rate Irregular
Hiatus Hernia
Hyperlipidaemia
Hypertension
Hypokalaemia
Impaired Work Ability
Injury
Joint Sprain
Knee Arthroplasty
Mallory-Weiss Syndrome
Melaena

		Meniscus Lesion					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Peptic Ulcer		Voltaren	SS		
UNKNOWN							
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
		Reflux Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Prempro	C		
UNKNOWN							
		Ulcer Haemorrhage		Acetaminophen And			
		Urinary Tract Infection		Propoxyphene			
		Ventricular Dysfunction		Napsylate	C		ORAL
		Ventricular Hypertrophy		Carisoprodol	C		ORAL
		Vomiting		Acetaminophen And			
		Wound Infection		Codeine Phosphate	C		
UNKNOWN							
		Staphylococcal					

Date:12/30/04ISR Number: 4542647-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00752
Age:85 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris					
		Blood Pressure Increased					
		Convulsion					
		Death					
		Epistaxis					
		Multiple Allergies					
		Nasal Septum Disorder					

Date:12/30/04ISR Number: 4542648-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00827
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Anxiety
	Arthralgia
	Atrial Fibrillation
	Atrial Septal Defect
	Bursitis
	Cardiac Failure
	Congestive
	Chest Discomfort
	Chest Pain
	Chondromalacia
	Dizziness
	Dyspnoea
	Ear Infection
	Eustachian Tube
	Dysfunction
	Fluid Retention
	Headache

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Joint Swelling Labyrinthitis Musculoskeletal					
		Discomfort Musculoskeletal Pain Nasal Sinus Drainage		Vioxx St. Joseph Adult Chewable Aspirin	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Otitis Externa		Norvasc	C		
UNKNOWN							
		Otitis Media Acute		Paxil	C		
UNKNOWN							
		Pain In Extremity		Paxil	C		
UNKNOWN							
		Pyrexia		Lotensin	C		
UNKNOWN							
		Reflux Oesophagitis		Xanax	C		
UNKNOWN							
		Road Traffic Accident		Xanax	C		
UNKNOWN							
		Sinus Disorder		Restoril	C		
UNKNOWN							
		Sinusitis		Darvocet-N	C		
UNKNOWN							
		Temporomandibular Joint		Allegra	C		
UNKNOWN							
		Syndrome		Flovent	C		
UNKNOWN							
		Tracheitis		Uniphyl	C		
UNKNOWN							
				Serevent	C		
RESPIRATORY							
(INHALATION)							
				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Mobic	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Entex La	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							

Skelaxin C
UNKNOWN

Date:12/30/04ISR Number: 4542656-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00875
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anaemia
	Anxiety
	Arthralgia
	Asthma
	Back Pain
	Bronchitis Acute
	Cardiomegaly
	Chest Pain
	Choking
	Constipation
	Dysphagia
	Dystonia
	Dysuria
	Emotional Disorder
	Gastrooesophageal Reflux Disease
	Hand Fracture
	Head Discomfort
	Helicobacter Infection
	Hiatus Hernia
	Hypertension
	Insomnia
	Irritability
	Nervousness
	Oesophagitis
	Pleurisy
	Polytraumatism
	Psychotic Disorder

		Rash Generalised					
		Retching					
		Rhinitis Allergic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sarcoidosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Speech Disorder		Zoloft	C		ORAL
		Upper Respiratory Tract		Depakote	C		ORAL
		Infection		Depakote	C		ORAL
		Vaginal Discharge		Depakote	C		ORAL
		Vaginal Odour		Humibid Dm	C		ORAL
		Vomiting		Septra Ds	C		ORAL
		Weight Decreased		Nystatin	C		
TOPICAL							
				Clonidine			
				Hydrochloride	C		ORAL
				Tagamet	C		ORAL
				Benztropine Mesylate	C		ORAL
				Haldol	C		ORAL
				Ambien	C		ORAL
				Lasix (Furosemide)	C		ORAL
				Colace	C		ORAL
				Guaifenex Pse	C		
UNKNOWN							

Date:12/30/04ISR Number: 4542657-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Diovan	C		
UNKNOWN							
		Angina Pectoris		Zocor	C		
UNKNOWN							
		Atrial Fibrillation		Dapsone	C		
UNKNOWN							
		Atrioventricular Block		Toprol Xl Tablets	C		
UNKNOWN							
		Body Tinea					
		Cardiovascular Disorder					
		Carotid Artery Stenosis					
		Coronary Artery Occlusion					
		Dermatitis					
		Diverticulum					
		Eczema					

Epidermal Necrosis
Erythema Multiforme
Granuloma Annulare
Hypertension
Leukocytoclastic
Vasculitis
Myocardial Ischaemia
Nail Bed Bleeding
Onycholysis
Polyp
Pruritus Ani
Psoriasis
Renal Disorder
Renal Failure
Vasculitis

Date:12/30/04ISR Number: 4542661-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Haemophilia Coagulation Factor Viii

	Level Decreased						
	Coagulation Time Prolonged						
	Factor Viii Inhibition	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL	117	DAY
			Zocor	SS		ORAL		
			Ginkgo Biloba Extract	SS		ORAL		
			Hydrochlorothiazide And Lisinopril	SS		ORAL		

Date:12/30/04ISR Number: 4542662-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02422
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Chloride Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Insulin-Dependent		Vitamins (Unspecified)	C				
UNKNOWN								

Date:12/30/04ISR Number: 4542663-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01954
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	614	DAY
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiopathy		Accupril	C				
UNKNOWN		418 DAY						
	Blood Pressure Increased		Vasotec	C				
UNKNOWN		725 DAY						
	Cardiac Arrest		Enalapril Maleate	C				
UNKNOWN		323 DAY						
	Cardiomegaly		Verapamil	C				
UNKNOWN		418 DAY						
	Cellulitis		Glucovance	C				
UNKNOWN								

	Joint Sprain	Glucophage	C
UNKNOWN			
	Limb Injury	Glucotrol Xl	C
UNKNOWN			
	Myocardial Infarction	Allopurinol	C
UNKNOWN			
	Paraesthesia	Colchicine	C
UNKNOWN			
	Pulmonary Vascular	Benzonatate	C
UNKNOWN			
	Disorder		
	Skin Ulcer		
	Tinel'S Sign		

Date:12/30/04ISR Number: 4542664-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
Disability	Back Injury
Other	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Coordination Abnormal
	Diabetes Mellitus
	Inadequate Control
	Dyspnoea
	Ejaculation Disorder
	Erectile Dysfunction
	Eye Pain
	Hypertension

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypoaesthesia Joint Effusion Lacunar Infarction					
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Pigmentary Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Retinal Vein Occlusion		Naproxen	C		
UNKNOWN	82 DAY						
		Road Traffic Accident		Tylenol	C		
UNKNOWN							
		Sexual Dysfunction		Cipro	C		
UNKNOWN							
		Sinus Disorder		Xalatan	C		
UNKNOWN							
		Transient Ischaemic		Amaryl	C		
UNKNOWN							
		Attack		Hydrochlorothiazide	C		
UNKNOWN	1106 DAY						
		Whiplash Injury		Niacin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Cardura	C		
UNKNOWN	255 DAY						
				Avapro	C		
UNKNOWN	60 DAY						
				Metoprolol	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Betoptic	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							

Date:12/30/04ISR Number: 4542665-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Emotional Distress							
	Erosive Oesophagitis							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Hepatic Cyst							
	Hiatus Hernia							
	Myocardial Infarction							
	Oesophagitis							
	Refusal Of Treatment By Patient							
	Sensation Of Foreign Body							
	Stress							

Date:12/30/04ISR Number: 4542666-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00097
Age:31 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Unstable
	Anxiety
	Arrhythmia
	Arteriospasm Coronary
	Cardiac Failure
	Congestive
	Cholestasis
	Coronary Artery

	Thrombosis Dyslipidaemia Emotional Distress Ischaemic Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Joint Sprain		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
	Mitral Valve Incompetence		Arginine Glutamate	C			UNKNOWN
	Transaminases Increased		Tyrosine	C			UNKNOWN
			Vitamin B (Unspecified)	C			PARENTERAL
			Vitamins (Unspecified)	C			UNKNOWN
			Garlic Extract	C		ORAL	

Date:12/30/04ISR Number: 4542667-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02557
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	257 DAY
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc		UNKNOWN
Disability	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	257 DAY
	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Cerebral Ischaemia		Tenormin	C			UNKNOWN
	Cerebrovascular Accident		Zoloft	C			UNKNOWN
	Cervicobrachial Syndrome Chest Discomfort		Estrogens (Unspecified)	C			UNKNOWN
	Chest Pain		Zanaflex	C			UNKNOWN
	Depression		Restoril	C			UNKNOWN
	Dizziness Electrocardiogram St-T Change						

Emotional Distress
Fatigue
Feeling Abnormal
Headache
Heart Rate Increased
Hot Flush
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Hypocoagulable State
Injury
Insomnia
Libido Decreased
Lumbar Radiculopathy
Mass
Menopausal Symptoms
Neck Pain
Nuclear Magnetic
Resonance Imaging
Abnormal
Osteoarthritis
Platelet Disorder
Rheumatoid Arthritis
Sleep Disorder
Tachycardia
Thinking Abnormal
Thrombosis
Vomiting
Vulvovaginal Dryness

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542669-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00744
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		56 MON
Initial or Prolonged	Anxiety		Lisinopril	C				UNKNOWN
Other	Arthralgia		Lipitor	C				UNKNOWN
	Atrial Fibrillation		Gemfibrozil	C				UNKNOWN
	Blood Glucose Decreased		Coumadin	C				UNKNOWN
	Bronchitis		Metoprolol	C				UNKNOWN
	Cardiac Disorder		Zetia	C				UNKNOWN
	Cellulitis		Furosemide	C				UNKNOWN
	Cerumen Impaction		Lanoxin	C				UNKNOWN
	Constipation							
	Cough							
	Diabetes Mellitus Non-Insulin-Dependent							
	Diarrhoea							
	Dyspnoea Exertional							
	Ear Infection							
	Erectile Dysfunction							
	Gastroenteritis							
	Gastrooesophageal Reflux Disease							
	Gravitational Oedema							
	Haemorrhoids							
	Haemothorax							
	Hypertension							
	Hypoglycaemia							
	Hypotension							
	Insomnia							
	Intertrigo							
	Lymphadenitis							
	Myocardial Infarction							
	Nail Avulsion							
	Nausea							
	Neck Pain							

Nocturia
Oedema Peripheral
Osteoarthritis
Otorrhoea
Pain In Extremity
Pharyngitis
Postnasal Drip
Postoperative Infection
Rhinitis Allergic
Sinus Congestion
Skin Disorder
Skin Ulcer
Sleep Apnoea Syndrome
Throat Irritation
Upper Respiratory Tract
Infection
Venous Stasis
Viral Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4542673-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthma		Plavix	C			UNKNOWN	
	Back Disorder		Flovent	C			RESPIRATORY (INHALATION)	
	Back Pain							
	Blood Homocysteine		Levoxyl	C			UNKNOWN	
	Increased		Levoxyl	C			UNKNOWN	
	Cerebral Infarction		Tylenol With Codeine #3	C			UNKNOWN	
	Cerebral Parenchymal Calcification		Prednisone	C			UNKNOWN	
	Cerebrovascular Accident		Advair	C			UNKNOWN	
	Chest Wall Pain		Monopril	C			UNKNOWN	
	Cholelithiasis		Azmacort	C			UNKNOWN	
	Chronic Obstructive		Aspirin	C			UNKNOWN	
	Pulmonary Disease		Nexium	C			UNKNOWN	
	Condition Aggravated		Ventolin (Albuterol)	C			RESPIRATORY (INHALATION)	
	Coronary Artery Atherosclerosis		Ranitidine	C			UNKNOWN	
	Coronary Artery Disease		Hydroxychloroquine Sulfate	C			UNKNOWN	
	Decreased Appetite							
	Depression		Hydrochlorothiazide	C			UNKNOWN	
	Diarrhoea		Cozaar	C			UNKNOWN	

Dizziness
Electrocardiogram St-T
Change
Emotional Distress
Excoriation
Face Injury
Feeling Drunk
Gastrooesophageal Reflux
Disease
Hepatomegaly
Hypertensive Heart
Disease
Hypothyroidism
Insomnia
Lacunar Infarction
Nausea
Nervousness
Renal Cyst
Renal Failure Chronic
Swelling Face
Ulcer
Upper Respiratory Tract
Infection
Uterine Disorder

Date:12/30/04ISR Number: 4542674-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
	Depression
Disability	Disturbance In Attention
	Dizziness

		Feeling Drunk					
		Gait Disturbance					
		Hyperreflexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Tinnitus					

Date:12/30/04ISR Number: 4542675-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01809
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Intracranial Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacunar Infarction		Plavix	C		
UNKNOWN							
		Neuralgia		Premarin	C		
UNKNOWN							
		Post Procedural		Levothyroxine Sodium	C		
UNKNOWN							
		Complication		Celexa	C		
UNKNOWN							
		Subarachnoid Haemorrhage		Carbatrol	C		
UNKNOWN							
		Transient Ischaemic		Aggrenox	C		
UNKNOWN							
		Attack		Crestor	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:12/30/04ISR Number: 4542676-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00044
Age:28 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Accidental Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
1796 DAY							
Initial or Prolonged		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
1796 DAY							
		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL

	Cerebrovascular Accident	Lortab	C	
UNKNOWN				
	Chronic Fatigue Syndrome	Klonopin	C	ORAL
	Depression	Klonopin	C	ORAL
	Dysphagia	Elavil	C	ORAL
	Gastroenteritis	Elavil	C	ORAL
	Headache	Zoloft	C	
UNKNOWN				
	Hypokalaemia	Prilosec	C	ORAL
	Hypomagnesaemia	Fiorinal	C	
UNKNOWN				
	Joint Swelling	Serzone	C	
UNKNOWN				
	Nervous System Disorder	Vicodin Tablets	C	
UNKNOWN				
	Overdose	Tylenol	C	
UNKNOWN				
	Panic Attack	Naprosyn	C	
UNKNOWN				
	Renal Failure	Aspirin	C	
UNKNOWN				
	Sleep Apnoea Syndrome	Advil	C	
UNKNOWN				
	Snoring			
	Visual Disturbance			

Date:12/30/04ISR Number: 4542677-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged	Thrombophlebitis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Superficial		Prednisone	C		ORAL
	Thrombosis		Bisoprolol Fumarate	C		ORAL
			Pantoprazole Sodium	C		ORAL
			Heparin	C		
PARENTERAL 24 DAY						
			Amikacin Sulfate	C		ORAL
			Ibuprofen	C		ORAL
23 DAY						

			Gabapentin	C		ORAL
			Esomeprazole Magnesium	C		ORAL
185 DAY						

Date:12/30/04ISR Number: 4542679-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01675
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	103 DAY	
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	103 DAY	
Initial or Prolonged			Oxycontin	C			UNKNOWN	637 DAY
			Endocet	C			UNKNOWN	530 DAY
			Percocet	C			UNKNOWN	
			Nitroquick	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Topamax	C			UNKNOWN	
			Duragesic	C			UNKNOWN	42 DAY
			Amitriptylin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Effexor	C			UNKNOWN	

Date:12/30/04ISR Number: 4542681-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00065
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	351 YR	
Initial or Prolonged	Increased							

Low Density Lipoprotein
Increased
Myocardial Infarction
Ventricular Extrasystoles

Date:12/30/04ISR Number: 4542683-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02868
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Valve Disease		Norvasc	C				
UNKNOWN								
	Cardio-Respiratory Arrest							
	Coma							
	Coronary Artery Disease							
	Cyanosis							
	Dyspnoea							
	Feeling Cold							
	Hypertension							
	Sudden Death							
	Therapy Non-Responder							

Date:12/30/04ISR Number: 4542684-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00181
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Dyspepsia
Disability	Dyspnoea
	Palpitations

		Tachyarrhythmia Therapy Non-Responder					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
136	DAY						

Date:12/30/04ISR Number: 4542687-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00335
Age:83 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
557	DAY						
Initial or Prolonged		Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
557	DAY						
Disability				Acetyldigoxin	C		ORAL
				Acetyldigoxin	C		ORAL
				Carvedilol	C		ORAL
				Piretanide	C		ORAL
				Piretanide	C		ORAL

Date:12/30/04ISR Number: 4542688-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00920
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Carotid Artery Disease Coronary Artery Disease Myocardial Infarction Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:12/30/04ISR Number: 4542694-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02879
Age:57 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL

Other	Myocardial Infarction
	Polytraumatism

Date:12/30/04ISR Number: 4542696-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00616
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Aphasia
	Blood Pressure Increased
	Bronchitis Acute
	Chest Pain
	Convulsion
	Drug Ineffective
	Headache
	Hypercholesterolaemia
	Ischaemic Cardiomyopathy
	Myocardial Infarction
	Paresis
	Pharyngitis
	Sinusitis
	Ulnar Nerve Injury
	Upper Respiratory Tract

Infection
Visual Disturbance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Ultram	C			UNKNOWN	
	Lipitor	C		ORAL		
	Aspirin	C			UNKNOWN	
	Nitroglycerin	C			SUBLINGUAL	

Date:12/30/04ISR Number: 4542697-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02476
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arteriosclerosis							
	Asthenia							
	Atrophy							
	Back Disorder							
	Back Pain							
	Blood Glucose Increased							
	Cerebrovascular Accident							
	Chest Wall Abscess							
	Constipation							
	Cystitis							
	Dermatitis Atopic							
	Difficulty In Walking							
	Diverticulum							
	Duodenal Ulcer							
	Haemorrhage							
	Hypercholesterolaemia							
	Hypertension							
	Hypoaesthesia							
	Incontinence							
	Muscle Twitching							
	Myalgia							
	Myocardial Infarction							
	Otitis Media							
	Pain In Extremity							
	Pain In Jaw							

Palpitations
Renal Cyst
Seborrhoeic Dermatitis
Upper Respiratory Tract
Infection
Viral Infection

Date:12/30/04ISR Number: 4543139-2Report Type:Direct Company Report #CTU 235412
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck	ORAL	1 PILL PRN	
Initial or Prolonged	Cerebrovascular Accident							
			Premarin	SS		ORAL	1 PILL QD	

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/30/04ISR Number: 4544234-4Report Type:Expedited (15-DaCompany Report #2004116587
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia	Consumer	Celebrex (Celecoxib)	PS		ORAL	(100 MG) ORAL	
	Blood Pressure Increased		Rofecoxib					
	Condition Aggravated		(Rofecoxib)	SS		ORAL	(25 MG), ORAL	
	Self-Medication		Atenolol (Atenolol)	C				
			Bellaspon Retard (Belladonna Alkaloids, Ergotamine Tartrate, Phenobarbital)	C				
			Prazosin (Prazosin)	C				
			Dyazide (Hydrochlorothiazide, Triamterene)	C				
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C				

Date:01/03/05ISR Number: 4543387-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Other	Myocardial Infarction							

Date:01/03/05ISR Number: 4543392-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01106
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	48 DAY	
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL	48 DAY	

Disability	Benign Prostatic	Meclizine	C
UNKNOWN			
Other	Hyperplasia	Deconamine	C
UNKNOWN			
	Bladder Neck Sclerosis	Aciphex	C
UNKNOWN			
	Cerebrovascular Accident	Lisinopril	C
UNKNOWN			
	Chest Pain		
	Dizziness		
	Haemolysis		
	Haemorrhoidal Haemorrhage		
	Hyperkalaemia		
	Hyperlipidaemia		
	Hypersensitivity		
	Hypertension		
	Liver Function Test		
	Abnormal		
	Oedema Peripheral		
	Palpitations		
	Renal Failure Acute		
	Rheumatoid Arthritis		
	Rhinitis Allergic		
	Stress		
	Tooth Abscess		
	Urethral Stricture		
	Urticaria		
	Vertigo		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543399-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543400-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Upper Affect Lability Anaemia Anxiety Arthritis Atherosclerosis Azotaemia Back Pain Bladder Obstruction Blood Cholesterol Increased Blood Creatine Phosphokinase Mb Increased Blood Pressure Inadequately Controlled Cardiovascular Disorder Cellulitis Cerebral Artery Stenosis Cerebral Infarction Cerebrovascular Accident Chest Pain Chest X-Ray Abnormal Condition Aggravated Coronary Artery Restenosis Coronary Artery Stenosis Cough Depression Postoperative Diarrhoea Dizziness Postural

Erectile Dysfunction
Feeling Abnormal
Flatulence
Fluid Retention
Gastritis
Gastrointestinal Pain
Gastrooesophageal Reflux
Disease
Groin Pain
Gynaecomastia
Hiatus Hernia
Hydronephrosis
Hypercoagulation
Hypertension
Hypokalaemia
Insomnia
International Normalised

		Ratio Increased					
		Liver Disorder					
		Muscle Spasms					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Post Procedural		Azulfidine	C		
UNKNOWN							
		Cellulitis		Prilosec	C		
UNKNOWN							
		Post Procedural		Enbrel	C		
UNKNOWN							
		Complication		Enbrel	C		
UNKNOWN							
		Psoriatic Arthropathy		Prednisone	C		
UNKNOWN							
		Renal Failure		Prozac	C		
UNKNOWN							
		Rhinitis Allergic		Prozac	C		
UNKNOWN							
		Rhinitis Seasonal		Prozac	C		
UNKNOWN							
		Sinus Bradycardia		Trazodone			
		Sleep Apnoea Syndrome		Hydrochloride	C		
UNKNOWN							
		Stress					
		Therapeutic Response					
		Decreased					

Date:01/03/05ISR Number: 4543404-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abscess Limb
Disability	Adhesion
Other	Adrenal Insufficiency
	Adverse Event
	Amnesia
	Anxiety
	Axillary Mass
	Blood Cholesterol Increased
	Blood Glucose Increased

Breast Cancer
Cellulitis
Cerebral Ventricle
Dilatation
Chest Discomfort
Chest Pain
Connective Tissue
Disorder
Contusion
Coronary Artery Disease
Csf Shunt Removal
Cyst Aspiration
Depression
Diarrhoea
Discomfort
Dizziness
Dyspepsia
Dyspnoea
Eye Injury
Fall
Gastritis
Gastroenteritis
Haemorrhoids
Helicobacter Gastritis
Hydrocephalus

		Hyperlipidaemia					
		Hypothyroidism					
		Impaired Gastric Emptying	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased Tendency To		Vioxx	PS	Merck & Co., Inc	ORAL
		Bruise		Vioxx	SS	Merck & Co., Inc	ORAL
		Intestinal Hypomotility		Vioxx	SS	Merck & Co., Inc	ORAL
		Iron Deficiency Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Injury		Valium	C		
UNKNOWN							
		Limb Injury		Sk-Erythromycin	C		
UNKNOWN							
		Myocardial Infarction		Cyanocobalamin	C		
PARENTERAL							
		Nausea		Nitrostat	C		
UNKNOWN							
		Normal Pressure		Synthroid	C		
UNKNOWN							
		Hydrocephalus		Paxil	C		
UNKNOWN							
		Oedema Peripheral		Lanoxin	C		
UNKNOWN							
		Pain In Extremity		Salagen Tablets	C		
UNKNOWN							
		Radicular Pain		Claritin	C		
UNKNOWN							
		Road Traffic Accident		Zofran	C		
UNKNOWN							
		Scleroderma		Miacalcin	C		
UNKNOWN							
		Shunt Infection		Neurontin	C		
UNKNOWN							
		Spinal Compression		Vitamin E	C		
UNKNOWN							
		Fracture		Premarin	C		
UNKNOWN							
		Tinnitus		Aciphex	C		
UNKNOWN							
		Transaminases Increased		Detrol La	C		
UNKNOWN							
		Vertigo		Lasix (Furosemide)	C		
UNKNOWN							
		Wheezing		K-Dur	C		
UNKNOWN							
		Wound Dehiscence		Lorazepam	C		
UNKNOWN							

	Primidone	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		

Date:01/03/05ISR Number: 4543407-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00893
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
	Acute Sinusitis
	Adverse Event
	Arthralgia
	Asthenia
	Blood Creatine Phosphokinase Increased
	Blood Potassium Decreased
	Chest Pain
	Condition Aggravated
	Costochondritis
	Cough
	Cystitis
	Dizziness
	Dysphagia
	Fatigue
	Flank Pain
	Gastritis
	Gastrooesophageal Reflux Disease
	Haematocrit Decreased
	Haemoglobin Decreased
	Headache
	Helicobacter Infection

		Injury					
		Lower Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL
		Myalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Trazodone			
		Pelvic Pain		Hydrochloride	C		
UNKNOWN							
		Pulmonary Congestion					
		Respiratory Tract Congestion					
		Sinus Headache					
		Swelling					
		Ultrasound Kidney Abnormal					
		Urinary Tract Infection					
		Vaginal Mycosis					

Date:01/03/05ISR Number: 4543408-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00689
Age:44 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adnexa Uteri Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Glucophage	C		
UNKNOWN							
		Back Pain		Glucophage	C		
UNKNOWN							
		Cataract		Glucophage	C		
UNKNOWN							
		Diarrhoea					
		Headache					
		Joint Crepitation					
		Osteoarthritis					
		Sciatica					
		Varicose Vein					

Date:01/03/05ISR Number: 4543411-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
Other	Amyotrophy
	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Atherosclerosis
	Blood Pressure Increased
	Bursitis
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Chondromalacia
	Convulsion
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Cough

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Crepitations					
		Diabetes Mellitus Insulin-Dependent					
		Diabetic Neuropathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Dizziness		Plavix	SS		
UNKNOWN							
		Dysarthria		Captopril Msd	C		ORAL
		Fall		Glucotrol Xl	C		
UNKNOWN							
		Fatigue		Amitriptyline Hydrochloride	C		
		Glycosuria					
UNKNOWN							
		Haemorrhoidal Haemorrhage		Evista	C		
UNKNOWN							
		Hypertension		Synthroid	C		
UNKNOWN							
		Hypothyroidism		Prilosec	C		ORAL
		Joint Dislocation		Humulin	C		
UNKNOWN							
		Lacunar Infarction					
		Lumbar Radiculopathy					
		Meniscus Lesion					
		Mental Status Changes					
		Neuropathy Peripheral					
		Nuclear Magnetic Resonance Imaging Brain Abnormal					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Peroneal Nerve Injury					
		Pharyngitis					
		Radiculopathy					
		Respiratory Tract Infection					
		Rotator Cuff Syndrome					
		Sensation Of Pressure					
		Subcutaneous Abscess					
		Syncope					
		Tendonitis					

Date:01/03/05ISR Number: 4543414-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Anorexia
	Arthralgia
	Arthritis
	Arthropathy
	Back Pain
	Benign Prostatic
	Hyperplasia
	Bladder Disorder
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiac Arrest
	Cardiovascular Disorder
	Carotid Bruit
	Carpal Tunnel Syndrome
	Chest Pain
	Constipation
	Convulsion

	Depression						
	Dry Mouth						
	Epididymal Cyst	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Erectile Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL	
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL	
	Flatulence		Neurontin	C			UNKNOWN
	Hyperhidrosis		Lactulose	C		ORAL	
	Intervertebral Disc		Glucophage	C			UNKNOWN
	Degeneration		Glyburide	C			UNKNOWN
	Intestinal Functional		Lotrel	C			UNKNOWN
	Disorder						
	Oedema Peripheral						
	Osteitis						
	Osteoarthritis						
	Pulmonary Embolism						
	Radiculopathy						
	Scoliosis						
	Skin Lesion						
	Spinal Column Stenosis						
	Stress						
	Testicular Pain						

Date:01/03/05ISR Number: 4543421-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00609
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Blood Pressure Increased		Monopril	C			UNKNOWN
Other	Bursitis		Estrace	C			UNKNOWN
	Carbuncle						
	Cervical Root Pain						
	Chest Pain						
	Convulsion						
	Coronary Artery						
	Atherosclerosis						
	Coronary Artery Disease						
	Flatulence						

Hyperlipidaemia
Hypertension
Intervertebral Disc
Protrusion
Intervertebral Disc Space
Narrowing
Joint Stiffness
Muscle Spasms
Myalgia
Myocardial Infarction
Neuropathy Peripheral
Pericarditis
Sinusitis
Stress
Tension Headache
Tinel'S Sign
Tricuspid Valve
Incompetence
Ventricular Tachycardia
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543422-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00422
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertensive Heart Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pantoprazole Sodium	C			UNKNOWN	
	Oedema							

Date:01/03/05ISR Number: 4543423-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00338
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	607 DAY	
Hospitalization - Initial or Prolonged	Cerebral Artery Occlusion		Lithium Carbonate	C		ORAL	973 DAY	
			Enalapril Maleate And Hydrochlorothiazide	C		ORAL		
			Memantine Hydrochloride	C		ORAL		

Date:01/03/05ISR Number: 4543425-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01731
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Initial or Prolonged	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL	3 DAY	
	Arthralgia		Tylenol Extra Strength	C		ORAL		
	Arthritis		Robitussin	C		ORAL		
	Asthenia							
	Balance Disorder							
	Blood Glucose Abnormal							
	Bursitis							
	Cerebrovascular Accident							
	Confusional State							
	Difficulty In Walking							

Drug Intolerance
Hemiparesis
Hyperlipidaemia
Hypertension
Inappropriate Affect
Lumbar Spinal Stenosis
Otorrhoea
Rotator Cuff Syndrome
Transient Ischaemic
Attack
Tremor
Urinary Tract Infection
Viral Infection
Vitreous Floaters

Date:01/03/05ISR Number: 4543428-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Atherosclerosis
	Attention Deficit/Hyperactivity

	Disorder						
	Blood Cholesterol Increased						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chronic Fatigue Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
	Depression		[Therapy				
	Gastrooesophageal Reflux		Unspecified]	C			UNKNOWN
	Disease		Paxil	C			UNKNOWN
	Generalised Anxiety		Ibuprofen	C			UNKNOWN
	Disorder		Zoloft	C			UNKNOWN
	Haemorrhoidal Haemorrhage						
	Hypertension						
	Insomnia						
	Panic Disorder						
	Phlebitis Superficial						

Date:01/03/05ISR Number: 4543430-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01026
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	
Disability	Haematocrit Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Overdose		Zoloft	C			UNKNOWN
	Panic Attack		Hydrocodone				
	Stress		Hydrochloride	C			UNKNOWN

Date:01/03/05ISR Number: 4543431-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04133
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Disability							

Date:01/03/05ISR Number: 4543432-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04117
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Supraventricular		A.S.A.	C		ORAL		
Other	Arterial Stenosis		Lipitor	C		ORAL		
	Atherosclerosis		Norvasc	C		ORAL		
	Cardiac Murmur		Diovan	C		ORAL		
	Carotid Artery Stenosis		Plavix	C		ORAL		
	Cerebral Thrombosis							
	Cerebrovascular Accident							
	Embolic Cerebral							
	Infarction							
	Road Traffic Accident							
	Vascular Calcification							

Date:01/03/05ISR Number: 4543434-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03995
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Discomfort
	Abdominal Pain Upper
	Adverse Event

		Angina Pectoris					
		Arthralgia					
		Back Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Neuroton	C		
UNKNOWN							
		Cardiac Disorder		Aspirin	C		
UNKNOWN							
		Cataract		Trazodone			
		Drug Ineffective		Hydrochloride	C		
UNKNOWN							
		Dysphagia		Primeral	C		
UNKNOWN							
		Dyspnoea		Vitamin E	C		
UNKNOWN							
		Fatigue					
		Heart Rate Increased					
		Hypertension					
		Joint Swelling					
		Neck Pain					
		Oedema Peripheral					
		Oropharyngeal Swelling					
		Pigmentation Disorder					
		Rash					
		Weight Increased					

Date:01/03/05ISR Number: 4543435-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00025
Age:70 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Fibrillation		Aspirin	C		ORAL
		Myocardial Ischaemia		Aspirin	C		ORAL
				Pantoprazole Sodium	C		ORAL

Date:01/03/05ISR Number: 4543438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00051
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
	Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypoglycaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Palpitations		Lasix (Furosemide			
	Sexual Dysfunction		Sodium)	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						

Date:01/03/05ISR Number: 4543439-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00040
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Lamivudine And			
			Zidovudine	C		
UNKNOWN						
			Nelfinavir Mesylate	C		
UNKNOWN						
			Amitriptyline			
			Hydrochloride	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Dipyridamole	C		
UNKNOWN						
			Valacyclovir			
			Hydrochloride	C		
UNKNOWN						
			Propiomazine Maleate	C		
UNKNOWN						
			Carbamazepine	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543440-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02871
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Adverse Event		Ecotrin	C		ORAL
Initial or Prolonged	Arthralgia		Pravachol	C		ORAL
	Benign Prostatic		Prinivil	C		ORAL
	Hyperplasia					
	Blood Pressure Increased					
	Cerebral Haematoma					
	Facial Bones Fracture					
	Haemorrhage Intracranial					
	Hyperlipidaemia					
	Injury					
	Major Depression					
	Osteoarthritis					
	Pollakiuria					
	Polytraumatism					
	Skin Lesion					
	Unevaluable Event					

Date:01/03/05ISR Number: 4543441-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00293
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Hyzaar	C		ORAL
			Potassium (Unspecified)	C		
UNKNOWN						
			Theo-Dur	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Singulair	C		ORAL
			Serevent	C		
UNKNOWN						
			Proventil	C		
UNKNOWN						
			Thyroid	C		
UNKNOWN						

Date:01/03/05ISR Number: 4543444-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00777
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Keflex	C			UNKNOWN	
	Depression		Roxicet	C			UNKNOWN	
	Disorientation							
	Dry Mouth							
	Erectile Dysfunction							
	Face Oedema							
	Gastritis							
	Hypertensive Crisis							
	Insomnia							
	Nausea							
	Neurological Symptom							
	Oedema							
	Oedema Peripheral							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543445-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00867
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia Of Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchopneumonia		Flexeril	C		ORAL		
Disability	Calculus Urinary		Vasotec	C		ORAL		
Other	Cardiac Failure		Hyzaar	C		ORAL		
	Congestive		Tacrine					
	Cardiomyopathy		Hydrochloride	C		ORAL	7	DAY
	Chronic Obstructive		Flovent	C			UNKNOWN	
	Pulmonary Disease		Flonase	C			UNKNOWN	
	Cor Pulmonale		Lasix (Furosemide)	C		ORAL		
	Dehydration		Tylenol	C			UNKNOWN	
	Depression							
	Diarrhoea							
	Gout							
	Hyperkalaemia							
	Hyperphosphataemia							
	Hypertension							
	Hypertensive Heart							
	Disease							
	Hypertensive Nephropathy							
	Malignant Hypertension							
	Mitral Valve Incompetence							
	Myalgia							
	Myocardial Infarction							
	Nephrosclerosis							
	Renal Failure							
	Renal Failure Acute							
	Rhinitis Allergic							
	Sleep Apnoea Syndrome							
	Treatment Noncompliance							
	Tricuspid Valve							
	Incompetence							

Date:01/03/05ISR Number: 4543456-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01510
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1249 DAY
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		1249 DAY
Initial or Prolonged	Congestive		Lanoxin	C				UNKNOWN
Disability			Isosorbide	C				UNKNOWN
Other			Nexium	C				UNKNOWN
			Coumadin	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:01/03/05ISR Number: 4543458-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02958
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Syncope		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Neurontin	C				UNKNOWN
Disability			Protonix	C				UNKNOWN

Codeine C
UNKNOWN

Date:01/03/05ISR Number: 4543459-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543464-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01929
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Disability	Cardiac Valve Disease							
	Chest Pain							
	Dizziness							
	Gastric Haemorrhage							
	Hernia							
	Hypoaesthesia							

Date:01/03/05ISR Number: 4543516-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Congestive							

Date:01/03/05ISR Number: 4543754-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00335
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 590 DAY	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 590 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Acetyldigoxin	C		ORAL
			Acetyldigoxin	C		ORAL
			Carvedilol	C		ORAL
			Carvedilol	C		ORAL
			Piretanide	C		ORAL
			Piretanide	C		ORAL
			Aspirin	C		ORAL
			Levothyroxine Sodium	C		ORAL

Date:01/03/05ISR Number: 4543755-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03931
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Seroquel	C				UNKNOWN
	Joint Swelling		Cardis	C				UNKNOWN
	Somnolence		Lipitor	C				UNKNOWN
			Levoxyl	C				UNKNOWN
			Meclizine	C				UNKNOWN
			Protonix	C				UNKNOWN
			Wellbutrin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543756-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00346
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction		Interferon Alfa-2a	C		
PARENTERAL	1641 DAY					
	Rash					
	Ventricular Tachycardia					

Date:01/03/05ISR Number: 4543757-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00107
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Asthenia		Propoxyphene			
	Brunner'S Gland		Hydrochloride	C		
UNKNOWN						
	Hyperplasia		Lanoxin	C		
UNKNOWN						
	Bundle Branch Block Left		Lasix (Furosemide)	C		
UNKNOWN						
	Cardiac Disorder		K-Dur	C		
UNKNOWN						
	Cardiac Failure		Darvocet-N	C		
UNKNOWN						
	Cataract					
	Deafness Neurosensory					
	Diarrhoea					
	Diarrhoea Haemorrhagic					
	Duodenitis					
	Food Poisoning					
	Gastritis					
	Gastrointestinal					
	Haemorrhage					
	Haemorrhoids					
	Heart Rate Irregular					
	Hiatus Hernia					
	Hypoacusis					
	Iatrogenic Injury					
	Injury					

Lower Gastrointestinal
Haemorrhage
Rectal Haemorrhage
Red Blood Cell Count
Decreased
Supraventricular
Tachycardia
Upper Gastrointestinal
Haemorrhage
Weight Decreased

Date:01/03/05ISR Number: 4543758-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03734
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Non-Cardiac Chest Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543759-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		284 DAY
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		284 DAY
Other	Anxiety		A.S.A.	C		ORAL		
	Burning Sensation		Prometrium	C		ORAL		
	Chest Discomfort		Methylprednisolone	C				UNKNOWN
	Chest Pain		Clonazepam	C				UNKNOWN
	Condition Aggravated		Meclizine	C				UNKNOWN
	Coronary Artery Atherosclerosis		Sulfamethoxazole And Trimethoprim	C				UNKNOWN
	Coronary Artery Disease		Serzone	C		ORAL		
	Coronary Artery Stenosis		Cyanocobalamin	C				PARENTERAL
	Depression		Cyanocobalamin	C				PARENTERAL
	Dizziness		Flonase	C				UNKNOWN
	Dyspnoea		Allegra	C				UNKNOWN
	Dyspnoea Exertional		Augmentin	C				UNKNOWN
	Dyspnoea Paroxysmal		Cephalexin	C				UNKNOWN
	Nocturnal		Prednisone	C				UNKNOWN
	Gastrooesophageal Reflux		Zyrtec	C				UNKNOWN
	Disease		Albuterol	C				UNKNOWN
	Hyperhidrosis		A.S.A.	C		ORAL		
	Hypertension		Verapamil Msd Lp	C		ORAL		
	Hypoaesthesia		Diovan	C		ORAL		
	Mitral Valve Prolapse		Tequin	C				UNKNOWN
	Myocardial Infarction		Aciphex	C				UNKNOWN

	Nausea		Remeron	C			
UNKNOWN							
	Orthopnoea		Serzone	C			ORAL
336 DAY							
	Pain		Acetaminophen And				
	Palpitations		Hydrocodone				
	Panic Attack		Bitartrate	C			
UNKNOWN							
	Paraesthesia		Vantin	C			
UNKNOWN							
	Pleuritic Pain		Estradiol	C			ORAL
	Pruritus		Prevacid	C			
UNKNOWN							
	Stomach Discomfort		Mobic	C			ORAL
	Stress		Promethazine	C			ORAL
	Uterine Leiomyoma						
	Vaginal Haemorrhage						
	Vision Blurred						

Date:01/03/05ISR Number: 4543761-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0306FRA00089
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Ascites		Vioxx	PS	Merck & Co., Inc	ORAL
12 DAY						
Hospitalization -	Cerebral Arteriovenous		[Therapy			
Initial or Prolonged	Malformation Haemorrhagic		Unspecified]	C		
UNKNOWN	12 DAY					
Other	Cholecystitis Chronic					
	Gastric Disorder					
	Pancreatic Pseudocyst					
	Pancreatitis Acute					
	Pancreatitis Necrotising					
	Pleural Effusion					
	Pseudocyst					
	Respiratory Failure					
	Subileus					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543762-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01631
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Zocor	C				
UNKNOWN								
Disability			Zestril	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:01/03/05ISR Number: 4543763-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00012
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vasculitis		Acetaminophen	C		ORAL		
			Omeprazole	C		ORAL		
			Ameride	C		ORAL		

Date:01/03/05ISR Number: 4543765-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Claw Toe		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Zocor	C		ORAL		
Other	Infarction		Plavix	C		ORAL		
	Angina Unstable		Lotensin	C		ORAL		
	Arthropathy		Metoprolol	C		ORAL		
	Asthenia		Alfentanil					
	Back Pain		Hydrochloride	C				
UNKNOWN								
	Basal Cell Carcinoma		[Therapy					
	Blood Pressure Increased		Unspecified]	C		ORAL		
	Bursitis		Aspirin	C				
UNKNOWN								
	Carotid Artery Stenosis							
	Carpal Tunnel Syndrome							

Cerebrovascular Accident
Coronary Artery Disease
Coronary Artery
Restenosis
Dermatitis Contact
Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Neuropathy
Diabetic Retinopathy
Diarrhoea
Haemarthrosis
Headache
Hearing Impaired
Injury
Intermittent Claudication
Monarthritis
Myocardial Infarction
Neuropathy
Sleep Apnoea Syndrome
Tendonitis
Treatment Noncompliance
Vertigo
Vestibular Disorder

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543769-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00607
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness							
	Hyperhidrosis							
	Hypertension							
	Musculoskeletal Chest Pain							
	Neck Pain							
	Pallor							
	Supraventricular Tachycardia							
	Visual Disturbance							

Date:01/03/05ISR Number: 4543770-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02944
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability				C				
UNKNOWN								

Date:01/03/05ISR Number: 4543772-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02868
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Bronchitis	Vioxx	PS	Merck & Co., Inc	ORAL
	Bronchospasm	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardio-Respiratory Arrest	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Dehydration	Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea	Vioxx	SS	Merck & Co., Inc	ORAL
	Haemolytic Anaemia	Norvasc	C		
UNKNOWN					
	Hyperlipidaemia				
	Hypertension				
	Hypokalaemia				
	Hypovolaemia				
	Intention Tremor				
	Oedema				
	Orthostatic Hypotension				
	Sudden Death				
	Therapeutic Response Decreased				
	Upper Respiratory Tract Infection				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543773-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00073
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02580
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543775-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03065
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543776-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01994
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension Myocardial Infarction	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL		72 DAY

Date:01/03/05ISR Number: 4543777-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03101
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Zoloft	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:01/03/05ISR Number: 4543778-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:01/03/05ISR Number: 4543779-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02020
Age:58 YR Gender:Female I/FU:F

Outcome	PT
	Abdominal Pain
	Anxiety
	Arrhythmia
	Breast Cyst
	Bronchitis

	Cardiac Failure						
	Congestive						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cough	Health	Vioxx	PS	Merck & Co., Inc	ORAL	
	Depressive Symptom	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	
	Diarrhoea		Nexium	C			UNKNOWN
	Fall						
	Fungal Infection						
	Gastrooesophageal Reflux Disease						
	Hyperlipidaemia						
	Inguinal Hernia						
	Joint Injury						
	Menopausal Symptoms						
	Nasopharyngitis						
	Pain In Extremity						
	Palpitations						
	Paraesthesia						
	Sinusitis						
	Upper Respiratory Tract Infection						
	Urinary Incontinence						
	Urinary Tract Infection						
	Vaginal Infection						
	Vulva Cyst						

Date:01/03/05ISR Number: 4543780-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03232
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
	Chest Pain		Vicodin Tablets	C			UNKNOWN
	Pneumonia						

Date:01/03/05ISR Number: 4543781-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03194
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/03/05ISR Number: 4543782-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543783-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03190
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4543784-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:01/03/05ISR Number: 4543785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03195
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543786-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03215
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	46	MON
	Cardiac Disorder							
	Injury							
	Myocardial Infarction							

Date:01/03/05ISR Number: 4543787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543789-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/03/05ISR Number: 4543790-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03196
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/03/05ISR Number: 4543914-4Report Type:Expedited (15-DaCompany Report #GXKR2003GB00474
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased	Foreign Health	Atenolol (Ngx) (Atenolol)	PS			SEE IMAGE	
	Blood Pressure Decreased	Professional	Trimethoprim Sandoz					
	Blood Urea Increased	Other	(Ngx) (Trimethoprim)					
	Circulatory Collapse		Tablet	SS	Sandoz	ORAL	ORAL	
	Heart Rate Decreased		Co-Trimoxazole					
	Hyperkalaemia		(Co-Trimoxazole)	SS		ORAL	960 MG/DAY,	
							ORAL	
			Rofecoxib (Rofecoxib)	SS			25 MG, QD	
			Acetylsalicylic Acid					

(Aspirin) (Acetylsalicylic Acid)	C
Nitrazepam (Nitrazepam)	C
Gabapentin (Gabapentin)	C
Lansoprazole (Lansoprazole)	C
Alendronate Sodium (Alendronate Sodium)	C
Senna (Senna, Senna Alexandrina)	C
Co-Codamol (Codeine Phosphate, Paracetamol)	C
Lactulose (Lactulose)	C
Vitamin B Complex (Calcium Pantothenate, Nicotinamide, Pyridoxine	C
Ranitidine (Ranitidine)	C
Folic Acid (Folic Acid)	C
Viscotears (Carbomer)	C
Simvastatin (Simvastatin)	C

Date:01/03/05ISR Number: 4544472-0Report Type:Direct Company Report #CTU 235516
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx Merck	PS	Merck	ORAL	25 Mgm 25 MGM DAILY ORAL	
			Celebrex Pharmacia	SS	Pharmacia	ORAL	100 Mgm 100 MGM DAILY	

ORAL

Actos	C
Glipizide	C
Enalapril	C
Atenolol	C
Lipitor	C
Aciphex	C

Date:01/03/05ISR Number: 4544677-9Report Type:Direct Company Report #CTU 235530
Age: Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Arthralgia
Required	Chest Pain
Intervention to	Condition Aggravated
Prevent Permanent	Medication Error
Impairment/Damage	Pain In Extremity
	Pharmaceutical Product
	Complaint

Renal Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 25mg Merck	PS	Merck	ORAL	25 MG ONE DAILY ORAL	
	Celebex	SS		ORAL	25 MG ONE DAILY ORAL	

Date:01/03/05ISR Number: 4544848-1Report Type:Direct Company Report #CTU 235520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Cold Sweat Heart Rate Irregular Loss Of Consciousness		Vioxx 25mg	PS			1 DAILY	
			Cartiax	C				

Date:01/03/05ISR Number: 4545825-7Report Type:Expedited (15-DaCompany Report #2004118129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Renal Disorder	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				
			Gabapentin (Gabapentin)	C				
			Sertraline Hydrochloride (Sertraline Hydrochloride)	C				

Date:01/03/05ISR Number: 4545862-2Report Type:Expedited (15-DaCompany Report #2004118811
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Exostosis	Health Professional	Celebrex (Celecoxib)	PS		ORAL	200 MG (1 IN 1 D), ORAL	
	Skin Disorder							
	Surgery		Rofecoxib (Rofecoxib)	SS				
			Hydrochorothiazide (Hydrochlorothiazide)	C				
			Atenolol (Atenolol)	C				
			Donepezil Hydrochloride (Donepezil Hydrochloride)	C				
			Rabeprazole Sodium (Rabeprazole Sodium)	C				
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	C				
			Candesartan Cilexetil (Candesartan Cilexetil)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/05ISR Number: 4546265-7Report Type:Expedited (15-DaCompany Report #2004099920
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Eczema Toxic Skin Eruption	Foreign Health Professional	Atarax (Tablet) (Hydroxyzine Hydrochloride)	PS		ORAL	ORAL	
			Zoxan Lp (Doxazosin) (Doxazosin)	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Tramadol/Acetaminophen (Paracetamol, Tramadol)	SS		ORAL	ORAL	
			Amiodarone Hydrochloride (Amiodarone Hydrochloride)	SS		INTRAVENOUS	INTRAVENOUS	
			Betahistine Hydrochloride (Betahistine Hydrochloride)	SS		ORAL	ORAL	
			Clonidine (Clonidine)	C				
			Amlodipine Besylate (Amlodipine Besylate)	C				
			Loprazolam Mesilate (Loprazolam Mesilate)	C				
			Acenocoumarol (Acenocoumarol)	C				
			Potassium Chloride (Potassium Chloride)	C				
			Fosinopril (Fosinopril)	C				
			Pravastatin (Pravastatin)	C				

Date:01/04/05ISR Number: 4544027-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02021
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Meningitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Muscle Spasms							
	Rash							
	Rectal Haemorrhage							
	Syncope							

Date:01/04/05ISR Number: 4544028-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02105
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Palpitations		Norvasc	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Diazepam	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544030-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		252 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		252 DAY
	Infarction		Seroquel	C				UNKNOWN
	Amnesia		Seroquel	C				UNKNOWN
	Anxiety		Soma	C				UNKNOWN
	Asthma		Premarin	C				UNKNOWN
	Back Disorder		Ambien	C				UNKNOWN
	Back Pain		Neurontin	C				UNKNOWN
	Blood Triglycerides Increased		Potassium (Unspecified)	C				UNKNOWN
	Bronchitis Acute		Aspirin	C				UNKNOWN
	Chest Pain		Folic Acid	C				UNKNOWN
	Chronic Obstructive		Prevacid	C				UNKNOWN
	Pulmonary Disease		Toprol Xl Tablets	C				UNKNOWN
	Coronary Artery Disease		Toprol Xl Tablets	C				UNKNOWN
	Coronary Artery		Plavix	C			8 DAY	UNKNOWN
	Thrombosis		Zocor	C				UNKNOWN
	Euthyroid Sick Syndrome		Lipitor	C				UNKNOWN
	Fibromyalgia		Foltx	C			112 DAY	UNKNOWN
	Gastroenteritis		Linseed Oil	C				UNKNOWN
	Haemorrhage		Nitroglycerin	C				UNKNOWN

	Hallucination		Vicodin Tablets	C		
UNKNOWN						
	Headache		Altace	C		
UNKNOWN						
	Herpes Simplex		Doxepin			
	Hyperlipidaemia		Hydrochloride	C		
UNKNOWN						
	Hypertension		Flexeril	C		ORAL
	Irritable Bowel Syndrome		Prozac	C		
UNKNOWN						
	Ischaemic Cardiomyopathy		Prozac	C		
UNKNOWN						
	Nasal Disorder		Prozac	C		
UNKNOWN						
	Nausea					
	Neck Pain					
	Panic Disorder					
	Sleep Apnoea Syndrome					
	Spondylolisthesis					
	Vascular Pseudoaneurysm					

Date:01/04/05ISR Number: 4544034-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01194
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Chest Pain		Buspar	C		
UNKNOWN						
	Coronary Artery		Zoloft	C		
UNKNOWN						
	Atherosclerosis		Claritin	C		
UNKNOWN						
	Deep Vein Thrombosis					
	Depression					
	Dyspnoea					
	Haemothorax					
	Nasopharyngitis					
	Pleurisy					
	Pulmonary Artery					
	Thrombosis					
	Pulmonary Infarction					
	Rheumatoid Arthritis					
	Weight Increased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544038-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00086
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Disease							
	Myocardial Infarction							
	Peripheral Occlusive Disease							

Date:01/04/05ISR Number: 4544039-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00234
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamin E	C		ORAL		
			Esomeprazole					
			Magnesium	C		ORAL		

Date:01/04/05ISR Number: 4544041-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00407
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lisinopril	C		ORAL		
			Carvedilol	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		
			Aspirin	C		ORAL		
			Molsidomine	C		ORAL		

Date:01/04/05ISR Number: 4544043-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03403
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -			Altace	C		
UNKNOWN						
Initial or Prolonged			Nitroglycerin	C		
UNKNOWN						
Other			Alprazolam	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Pentoxifylline	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Cymbalta	C		
UNKNOWN						

Date:01/04/05ISR Number: 4544044-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Renal Impairment		Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
			Vioxx [Composition Unspecified]	SS C	Merck & Co., Inc	ORAL		
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544052-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angiopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Skin Discolouration							

Date:01/04/05ISR Number: 4544053-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02916
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Cardura	C				
Initial or Prolonged Disability								

Date:01/04/05ISR Number: 4544055-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03355
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544061-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03068
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/04/05ISR Number: 4544062-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00432
Age:10 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Syncope		[Therapy					
	Tachycardia		Unspecified]	C				
UNKNOWN								
	Vomiting							

Date:01/04/05ISR Number: 4544064-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03114
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Enalapril Maleate	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544065-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03255
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544066-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Ejection Fraction							
Other	Decreased							
	Myocardial Infarction							

Date:01/04/05ISR Number: 4544067-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03300
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544068-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03108
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fluctuation		Plavix	C				
UNKNOWN								
Initial or Prolonged	Gastric Haemorrhage		Coreg	C				
UNKNOWN								
Disability	Gastrointestinal Pain		Aspirin	C				
UNKNOWN								
	Myocardial Infarction							

Date:01/04/05ISR Number: 4544069-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544070-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544073-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03118
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Hospitalization -			Acupril	C				
UNKNOWN								
Initial or Prolonged			Hydrochlorothiazide	C				
UNKNOWN								
Disability			Klor-Con	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544074-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02911
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Warfarin	C				
UNKNOWN								
Initial or Prolonged			Atenolol	C				
UNKNOWN								
			Lisinopril	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544075-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02917
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hyperhidrosis		Diuretic (Unspecified)	C				
Disability			[Therapy Unspecified]	C				

UNKNOWN

UNKNOWN

Date:01/04/05ISR Number: 4544076-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00240
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Eye Disorder		Cortisone	C		ORAL		
Other	Feeling Abnormal							
	Loss Of Consciousness							

Date:01/04/05ISR Number: 4544077-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00231
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Chest Pain							
	Fluid Retention							
	General Symptom							
	Nausea							
	Stress							

Date:01/04/05ISR Number: 4544078-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03074
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Seroquel	C		
UNKNOWN						
Initial or Prolonged			Ludiomil	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						
			Glyburide	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Pepcid	C		ORAL

Date:01/04/05ISR Number: 4544079-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Deafness Unilateral		[Therapy			
	Vestibular Neuronitis		Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544082-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03356
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/04/05ISR Number: 4544083-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:01/04/05ISR Number: 4544107-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03233
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Synthroid	C				
UNKNOWN								
			Provera	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544308-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00115
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Injury		Prednisone	C				
UNKNOWN								
	Myocardial Infarction		Arava	C				
UNKNOWN								
			Amitriptyline					

	Hydrochloride	C
UNKNOWN		
	Prinzide	C
UNKNOWN		
	Phentermine	C
UNKNOWN		
	Phendimetrazine Hydrochloride	C
UNKNOWN		
	Diethylpropion Hydrochloride	C
UNKNOWN		
	Meridia	C
UNKNOWN		
	Phenylpropanolamine	C
UNKNOWN		

Date:01/04/05ISR Number: 4544313-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
	Angina Pectoris
	Anxiety
	Aortic Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis
	Bundle Branch Block
	Cardiomyopathy
	Carotid Artery Stenosis

		Cervicobrachial Syndrome					
		Cholecystitis Acute					
		Conjunctivitis Allergic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatitis Allergic		Celebrex	C		
UNKNOWN							
		Dermatitis Atopic					
		Diarrhoea					
		Femoral Artery Occlusion					
		Gastritis					
		Gastrooesophageal Reflux					
		Disease					
		Hypertension					
		Hypokinesia					
		Irritable Bowel Syndrome					
		Lung Neoplasm					
		Metabolic Encephalopathy					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Pulmonary Hypertension					
		Rash					
		Rhinitis Allergic					
		Sexual Dysfunction					
		Sleep Disorder					
		Staphylococcal Infection					
		Tricuspid Valve					
		Incompetence					
		Ventricular Tachycardia					

Date:01/04/05ISR Number: 4544314-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00338
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
606 DAY							
Hospitalization -		Cerebral Artery Occlusion		Lithium Carbonate	C		ORAL
Initial or Prolonged				Enalapril Maleate			
				And			
				Hydrochlorothiazide	C		ORAL
973 DAY							

Memantine Hydrochloride	C	ORAL

Date:01/04/05ISR Number: 4544316-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Arthritis
Other	Blood Pressure Abnormal
	Cardiac Valve Disease
	Chest Pain
	Chest Wall Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Occlusion
	Depression
	Dysphagia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Emotional Distress					
		Fatigue					
		Gastrooesophageal Reflux					
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Decreased		Cardizem Cd	C		
UNKNOWN							
		Herpes Zoster		K-Dur	C		
UNKNOWN							
		Hypertension		Accupril	C		
UNKNOWN		18 DAY					
		Hypotension		Accupril	C		
UNKNOWN		38 DAY					
		Insomnia		Accupril	C		
UNKNOWN		152 DAY					
		Irritable Bowel Syndrome		Paxil	C		
UNKNOWN							
		Myocardial Infarction		Paxil	C		
UNKNOWN		42 DAY					
		Oedema Peripheral		Paxil	C		
UNKNOWN							
		Oesophageal Spasm		Paxil	C		
UNKNOWN		145 DAY					
		Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Rash Pruritic		Lasix (Furosemide)	C		
UNKNOWN							
		Restless Legs Syndrome		Lasix (Furosemide)	C		
UNKNOWN							
		Somnolence		Soma	C		
UNKNOWN							
		Tremor		Aleve	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Ferrous Sulfate	C		
UNKNOWN							
				Tylenol Extra Strength	C		
UNKNOWN							

Date:01/04/05ISR Number: 4544317-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00778
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intracardiac Thrombus							
	Myocardial Infarction							

Date:01/04/05ISR Number: 4544318-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Other	Aneurysm
	Anxiety
	Arthralgia
	Arthritis
	Blindness Unilateral
	Blood Triglycerides Increased
	Crystal Arthropathy
	Drug Effect Decreased
	Eye Haemorrhage
	Gout
	Hyperlipidaemia
	Ischaemic Stroke
	Joint Range Of Motion Decreased
	Joint Swelling
	Low Density Lipoprotein Increased
	Macular Oedema
	Monarthritis

		Myocardial Infarction					
		Pain In Extremity					
		Papilloedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Post-Traumatic Stress		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Refusal Of Treatment By		Vioxx	SS	Merck & Co., Inc	
OPHTHALMIC		DAY					
		Patient		Vioxx	SS	Merck & Co., Inc	ORAL
		Retinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Retinal Vein Occlusion		Vioxx	SS	Merck & Co., Inc	
OPHTHALMIC		DAY					
		Seronegative Arthritis					
		Spondyloarthropathy					
		Synovitis					

Date:01/04/05ISR Number: 4544319-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01695
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Contusion					

Date:01/04/05ISR Number: 4544320-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00404
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
426 DAY						
Hospitalization -	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
426 DAY						
Initial or Prolonged	Impaired Work Ability		Levothyroxine Sodium	C		ORAL
Disability	Myocardial Infarction		Theophylline	C		ORAL
			Fenoterol Hydrobromide And Ipratropium Bromide	C		
RESPIRATORY						
(INHALATION)						
			Verapamil	C		ORAL
			Amitriptyline			

			Hydrochloride	C		ORAL
			Opipramol Hydrochloride	C		ORAL

Date:01/04/05ISR Number: 4544321-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03394
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Injury Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544322-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02940
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged Disability	Cerebrovascular Accident Overdose		Vioxx Zestril	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544323-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00188
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
	Headache		Warfarin	C				
UNKNOWN	Hypertension						8	YR

Date:01/04/05ISR Number: 4544324-6Report Type:Expedited (15-DaCompany Report #DK-MERCK-0412DNK00021
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		40 MON
	Paraesthesia		Metoprolol Tartrate	C		ORAL		
			Bendroflumethiazide And Potassium Chloride	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Prednisolone	C		ORAL		

Date:01/04/05ISR Number: 4544325-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02937
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544326-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00104
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Coronary Artery Stenosis		Atorvastatin Calcium	C		ORAL		
	Electrocardiogram St		Celiprolol					
	Segment Depression		Hydrochloride	C		ORAL		
	Exercise		Piretanide	C		ORAL		
	Electrocardiogram		Lercanidipine	C		ORAL		
	Abnormal							
	Myocardial Infarction							

Date:01/04/05ISR Number: 4544327-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02920
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Rheumatoid Arthritis		Glucophage	C				
UNKNOWN								
Initial or Prolonged								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544328-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02587
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		661 DAY
Initial or Prolonged	Anaemia		Toprol Xl Tablets	C				UNKNOWN
	Cardiac Enzymes Increased		Lipitor	C				UNKNOWN
	Dehydration		Ecotrin	C				UNKNOWN
	Dizziness							
	Haematoma							
	Heart Rate Increased							
	Hypotension							
	Myocardial Infarction							
	Obstructive Uropathy							
	Vertigo							

Date:01/04/05ISR Number: 4544329-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00955
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Proventil	C				UNKNOWN
			Azmacort	C				UNKNOWN

Date:01/04/05ISR Number: 4544330-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00062
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 4 WK	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure Congestive					
	Myocardial Infarction					

Date:01/04/05ISR Number: 4544331-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03350
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544332-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	30 MON	
	Transient Ischaemic Attack							

Date:01/04/05ISR Number: 4544333-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01986
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea Exertional		Vitamins					
Initial or Prolonged	Myocardial Ischaemia		(Unspecified)	C				
UNKNOWN								
Disability	Toothache		Protonix	C		ORAL		
	Ventricular Tachycardia		Lipitor	C		ORAL		
			Zoloft	C		ORAL		
			Lorazepam	C		ORAL		
			Atenolol	C		ORAL		
			Fiorinal	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544334-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged								
Disability								

Date:01/04/05ISR Number: 4544335-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03359
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:01/04/05ISR Number: 4544336-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544337-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03357
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544338-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03351
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/04/05ISR Number: 4544339-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00042
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/04/05ISR Number: 4544340-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03265
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability			Furosemide	C			UNKNOWN	
			Hydroxyzine Hydrochloride	C			UNKNOWN	
			Meclizine Hydrochloride	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Lescol	C			UNKNOWN	

Date:01/04/05ISR Number: 4544375-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis Infective
	Asthenia
Disability	Back Injury
Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Coagulopathy
	Diabetes Mellitus Inadequate Control
	Dizziness
	Drug Hypersensitivity
	Dysaesthesia
	Dysarthria
	Dyslipidaemia
	Dyspnoea
	Ejaculation Disorder
	Erectile Dysfunction
	Eye Pain

Feeling Abnormal
Grip Strength Decreased
Headache
High Density Lipoprotein
Increased
Hypertension
Hypoaesthesia
Joint Effusion
Lacunar Infarction
Muscle Spasms
Musculoskeletal Pain
Myofascial Spasm
Nausea
Neck Injury
Neck Pain
Pain
Pain In Extremity
Paraesthesia
Pigmentary Glaucoma
Reading Disorder
Retinal Oedema
Retinal Vein Occlusion

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Rhinorrhoea Road Traffic Accident Salivary Hypersecretion					
		Sinus Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL
		Whiplash Injury		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN				Accupril	C		
UNKNOWN		1106 DAY		Hydrochlorothiazide	C		
UNKNOWN				Metoprolol	C		
UNKNOWN				Betoptic	C		
UNKNOWN		82 DAY		Naproxen	C		
UNKNOWN				Augmentin	C		
UNKNOWN				Ibuprofen	C		
UNKNOWN				Aspirin	C		
UNKNOWN				Verapamil	C		
UNKNOWN				Cipro	C		
UNKNOWN				Allegra	C		
UNKNOWN				Tylenol	C		
UNKNOWN				Amaryl	C		
UNKNOWN				Xalatan	C		
UNKNOWN		60 DAY		Avapro	C		
UNKNOWN		255 DAY		Cardura	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Niacin	C		

Date:01/04/05ISR Number: 4544378-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03053
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C				
UNKNOWN								
Initial or Prolonged			Atenolol	C				
UNKNOWN								
			Elavil	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544404-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03282
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Neck Pain		Prilosec	C		ORAL		
Disability			Premarin	C				
UNKNOWN								

Date:01/04/05ISR Number: 4544922-XReport Type:Expedited (15-DaCompany Report #WAES 0410GBR00075
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Fluctuation	Foreign	Tab Vioxx					
Initial or Prolonged	Cardiac Failure	Study	(Rofecoxib)	PS		ORAL		
25 MG/DAILY								
	Congestive	Health	Aspirin	C				
	Cardiac Murmur	Professional	Atorvastatin Calcium	C				
	Hypoglycaemia		Escitalopram Oxalate	C				
	Mitral Valve Incompetence		Furosemide	C				
	Tricuspid Valve		Insulin, Biphasic					
	Incompetence		Isophane (Injection)	C				
			Metformin	C				
			Orlistat	C				
			Quinapril Hcl	C				

Sildenafil Citrate C

Date:01/04/05ISR Number: 4548071-6Report Type:Direct Company Report #CTU 235625
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx 25mg Merck	PS	Merck		AS NEEDED	
Hospitalization - Initial or Prolonged	Chest Pain							
	Coronary Artery Occlusion							
	Dyspnoea							
	Fatigue							

Date:01/05/05ISR Number: 4544808-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	582 DAY
			Pancof	C			UNKNOWN	
	Acute Sinusitis		Celexa	C			UNKNOWN	
	Angina Pectoris		Ziac	C			UNKNOWN	
	Asthenia		Ultram	C			UNKNOWN	
	Blood Cholesterol Increased		Claritin	C			UNKNOWN	
			Pepcid	C		ORAL		
	Cardiac Failure		Diovan	C			UNKNOWN	
	Congestive		Marcof Expectorant	C			UNKNOWN	
	Carpal Tunnel Syndrome		Atrovent	C			UNKNOWN	
	Coronary Artery Disease		Nasacort	C			UNKNOWN	
	Depression		Folic Acid	C			UNKNOWN	

	Dizziness		Tequin	C		
UNKNOWN						
	Emotional Distress		Allfen Dm	C		
UNKNOWN						
	Glucose Tolerance		Avelox	C		
UNKNOWN						
	Impaired		Zyrtec	C		
UNKNOWN						
	Nasopharyngitis		Hyzaar	C		ORAL
	Nervousness		Proventil	C		
UNKNOWN						
	Otitis Media		Serevent	C		
UNKNOWN						
	Pain		Rhinocort	C		
UNKNOWN						
	Pain In Extremity					
	Swelling					

Date:01/05/05ISR Number: 4544816-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00047
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 992 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Acetaminophen	C		
UNKNOWN						
Disability			Propoxyphene Napsylate	C		
UNKNOWN						
			Diltiazem Hydrochloride	C		
UNKNOWN						
			Enalapril Maleate	C		
UNKNOWN						
			Isosorbide Mononitrate	C		
UNKNOWN						
			Simvastatin	C		
UNKNOWN						
			Clopidogrel Bisulfate	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4544817-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myasthenia Gravis							

Date:01/05/05ISR Number: 4544821-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03735
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Disability	Cerebral Artery Occlusion		Levoxyl	C				
UNKNOWN								
	Cerebral Atrophy		Diovan	C				
UNKNOWN								
	Electrocardiogram Qt		Diltiazem Cd	C				
UNKNOWN								
	Corrected Interval		Proscar	C		ORAL		
	Prolonged		Anacin	C				
UNKNOWN								
	Gastritis		Motrin	C				
UNKNOWN								
	Heat Exhaustion							
	Mitral Valve Incompetence							
	Ventricular Hypertrophy							

Date:01/05/05ISR Number: 4544822-5Report Type:Expedited (15-DaCompany Report #FI-MERCK-0412FIN00021
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL		
1 DAY								
Initial or Prolonged	Ventricular Tachycardia		Midazolam Hydrochloride	C				
INTRAVENOUS							1	DAY

				Etilefrine Hydrochloride	C		
INTRAVENOUS	1	DAY					
				Propofol	C		
INTRAVENOUS	1	DAY					
				Fentanyl Citrate	C		
INTRAVENOUS	1	DAY					
				Rocuronium Bromide	C		
INTRAVENOUS	1	DAY					
				Cyclizine	C		ORAL
1	DAY						
				Metronidazole	C		
INTRAVENOUS	1	DAY					

Date:01/05/05ISR Number: 4544824-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00442
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	731	DAY
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Toprol Xl Tablets	C		ORAL		
	Fatigue		Medrol	C		ORAL		
Disability	Palpitations		Folic Acid	C		ORAL		
Other			Neurontin	C		ORAL		
			Nexium	C		ORAL		

Date:01/05/05ISR Number: 4544825-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00033
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Drug Withdrawal Syndrome
	Intestinal Dilatation

	Neuroendocrine Carcinoma Subileus						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4544828-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4544829-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03070
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4544832-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01953
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4544833-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03358
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/05/05ISR Number: 4544834-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03268
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:01/05/05ISR Number: 4544836-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03374
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Living Impaired							
	Breast Disorder							
	Cardiac Disorder							
	Difficulty In Walking							
	Respiratory Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4544837-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00001
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Coagulopathy		Acetaminophen	SS				
UNKNOWN								4 DAY
	General Symptom		Dalteparin Sodium	SS				
SUBCUTANEOUS								4 DAY
	Hepatocellular Damage		Diazepam	C		ORAL		4 DAY
	Thrombocytopenia		Thiamine Hydrochloride	C		ORAL		
			Haloperidol	C		ORAL		2 DAY

Date:01/05/05ISR Number: 4544838-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4544839-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00071
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Chlormezanone	C		ORAL		

Date:01/05/05ISR Number: 4544841-9Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00045
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Faecal Incontinence							

Disability	Gastrointestinal Disorder
	Intestinal Polyp
	Liver Disorder
	Renal Disorder
	Weight Increased

Date:01/05/05ISR Number: 4544850-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		289 DAY
Initial or Prolonged	Deep Vein Thrombosis							
	Renal Failure							

Date:01/05/05ISR Number: 4544852-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03263
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4544855-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00028
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Methotrexate	SS		ORAL		
	Dizziness		Acetaminophen	C				
UNKNOWN								
	Fall		Prednisolone	C				
UNKNOWN								
	Fatigue		Propoxyphene					
	Hip Fracture		Napsylate	C				
UNKNOWN								
	Pancytopenia							

Date:01/05/05ISR Number: 4544856-0Report Type:Expedited (15-DaCompany Report #PL-MERCK-0501POL00001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							2	YR
Hospitalization - Initial or Prolonged								

Date:01/05/05ISR Number: 4544864-XReport Type:Expedited (15-DaCompany Report #FI-MERCK-0501FIN00001
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/05/05ISR Number: 4545488-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
362 DAY								

Hospitalization - Initial or Prolonged 362 DAY	Arrhythmia	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebral Artery Thrombosis	Vioxx	SS	Merck & Co., Inc	ORAL
		Adalat	C		ORAL
	Cerebrovascular Accident	Klor-Con	C		ORAL
	Chest Pain	Zantac	C		
UNKNOWN					
	Depression	Aspirin	C		ORAL
	Drug Ineffective	Pepcid	C		
UNKNOWN					
	Dyspnoea	Tylenol	C		
UNKNOWN					
	Emotional Distress	Ibuprofen	C		
UNKNOWN					
	Oedema Peripheral	Algae (As Drug)	C		
UNKNOWN					
	Palpitations				
	Peptic Ulcer				
	Renal Failure				
	Rotator Cuff Syndrome				
	Scoliosis				
	Sensory Loss				
	Sinus Bradycardia				
	Thrombosis				
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4545502-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Adverse Event							
Other	Atherosclerosis							
	Basedow'S Disease							
	Cellulitis							
	Colonic Polyp							
	Diverticulum							
	Endocrine Ophthalmopathy							
	Haemorrhoids							
	Incontinence							
	Mass							
	Ovarian Cyst							
	Polytraumatism							
	Pyelonephritis							
	Urinary Tract Infection							

Date:01/05/05ISR Number: 4545508-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0410AUS00097
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Furosemide	C				
UNKNOWN								
Initial or Prolonged	Congestive		Aspirin	C				
UNKNOWN								
	Cerebrovascular Accident		Pimeclone					
	Myocardial Ischaemia		Hydrochloride	C				
UNKNOWN								
	Pancreatic Neoplasm		Tiratricol	C				
UNKNOWN								
	Post Procedural		Olanzapine	C				
UNKNOWN								
	Complication		Levothyroxine Sodium	C				
UNKNOWN								
	Ventricular Dysfunction		Temazepam	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								

Alendronate Sodium	C		ORAL
Metoclopramide	C		
UNKNOWN			
Acetaminophen	C		
UNKNOWN			
Ramipril	C		
UNKNOWN			
Venlafaxine Hydrochloride	C		
UNKNOWN			

Date:01/05/05ISR Number: 4545509-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Abdominal Pain
	Asthenia
	Asthma
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Contusion
	Dehydration
	Dementia Alzheimer'S Type
	Dizziness
	Gastritis
	Glaucoma
	Hepatocellular Damage

		Hypoglycaemia					
		Injury					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoporosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Paraesthesia					
		Parkinson'S Disease					
		Renal Failure					
		Rheumatoid Arthritis					
		Urinary Incontinence					
		Urinary Tract Infection					
		Vertigo					
		Vomiting					

Date:01/05/05ISR Number: 4545512-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00099
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 3 DAY		Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN		Bladder Spasm		Keflex	C		
Disability UNKNOWN		Cardiomegaly		Adenosine	C		
Other		Cellulitis		[Therapy			
		Cerebral Haemorrhage		Unspecified]	C		
UNKNOWN							
		Cerebrovascular Accident					
		Convulsion					
		Depression					
		Emotional Distress					
		Facial Pain					
		Fracture Malunion					
		Generalised Anxiety Disorder					
		Haemorrhage					
		Hypertension					
		Hypertriglyceridaemia					
		Hypotension					
		Nasal Congestion					
		Post-Traumatic Stress Disorder					
		Skin Laceration					
		Sleep Disorder					

Transient Ischaemic
Attack
Vaginal Mycosis
Ventricular Hypertrophy
White Blood Cell Count
Increased

Date:01/05/05ISR Number: 4545515-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Back Injury
Disability	Back Pain
Other	Cardiac Murmur
	Chest Pain
	Chest Wall Pain
	Constipation
	Diarrhoea
	Dry Skin

		Dyspnoea Exertional					
		Emotional Distress					
		Frequent Bowel Movements	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematuria		Antimicrobial			
		Haemochromatosis		(Unspecified)	C		
UNKNOWN							
		Headache		Analgesic Or			
		Hirsutism		Anesthetic			
		Hyperlipidaemia		(Unspecified)	C		
UNKNOWN							
		Injury		Butalbital	C		
UNKNOWN							
		Intervertebral Disc					
		Protrusion					
		Lactose Intolerance					
		Musculoskeletal Pain					
		Myocardial Infarction					
		Nausea					
		Neck Injury					
		Neck Pain					
		Nephrolithiasis					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Pain In Extremity					
		Pyelonephritis					
		Pyrexia					
		Rectal Haemorrhage					
		Sinusitis					
		Skin Discolouration					
		Skin Striae					
		Spinal Osteoarthritis					
		Thyroid Neoplasm					
		Vision Blurred					
		Vomiting					
		Weight Increased					
		Weight Loss Poor					

Date:01/05/05ISR Number: 4545521-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02117
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris

Anxiety
Arrhythmia
Arthralgia
Asthenia
Back Pain
Chest Pain
Dermatitis
Diarrhoea
Drug Ineffective
Dyspnoea
Emotional Distress
Eye Pain
Fatigue
Gouty Arthritis
Headache
Hypoaesthesia
Hypotension
Injury
Intercostal Neuralgia

		Lung Neoplasm					
		Mental Disorder					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Rosacea		Vioxx	SS	Merck & Co., Inc	ORAL
		Silent Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
		Infarction		Indocin			
		Sinusitis		(Indomethacin)	C		ORAL
		Skin Lesion		Allopurinol	C		
UNKNOWN							
		Spinal Osteoarthritis		Advil	C		
UNKNOWN							
				Noritate	C		
UNKNOWN							
				Lotrisone	C		
UNKNOWN							

Date:01/05/05ISR Number: 4545523-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0410SWE00022
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Borrelia Infection		Vioxx	PS	Merck & Co., Inc	ORAL
47	DAY						
Initial or Prolonged		Confusional State		Furosemide Sodium	C		
UNKNOWN							
		Diplopia		Atenolol	C		
UNKNOWN							
		Dysarthria					
		Facial Palsy					
		Grand Mal Convulsion					
		Musculoskeletal Stiffness					
		Tongue Biting					

Date:01/05/05ISR Number: 4545525-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00487
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL

	Blood Glucose Increased		Atenolol	C	ORAL
	C-Reactive Protein Increased		Captopril	C	ORAL
	Cerebrovascular Accident				
	Hemianopia Homonymous				
	Hemiparesis				
	Hypertensive Crisis				
	Ischaemic Stroke				
	Refusal Of Treatment By Patient				
	Visual Disturbance				

Date:01/05/05ISR Number: 4545527-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03240
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eye Haemorrhage		Hydrocodone Bitartrate	C			UNKNOWN	
	Eye Swelling		Nexium	C			UNKNOWN	
	Macular Oedema		Prozac	C			UNKNOWN	
	Ocular Vascular Disorder		Allegra	C			UNKNOWN	
	Retinal Vein Occlusion		Triamterene	C			UNKNOWN	
			Humulin 70/30	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4545528-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00860
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angioplasty		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vicodin Tablets	C				UNKNOWN
	Coronary Artery Occlusion		Diovan	C				UNKNOWN
	Hypersensitivity							
	Hypertension							
	Post Procedural Complication							
	Treatment Noncompliance							

Date:01/05/05ISR Number: 4545531-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04325
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Arteriosclerosis							
	Arthralgia							
Disability	Back Pain							
	Cerebrovascular Accident							
	Compression Fracture							
	Coronary Artery Surgery							
	Dizziness							
	Fall							
	Femoral Neck Fracture							
	Haematocrit Decreased							
	Hypotension							
	Medical Device Complication							
	Osteoarthritis							
	Osteoporosis							
	Pain In Extremity							
	Spinal Compression Fracture							

Date:01/05/05ISR Number: 4545532-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03093
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Loss Of Consciousness							5 YR

Date:01/05/05ISR Number: 4545534-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00052
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Memory Impairment		Vioxx	SS	Merck & Co., Inc	ORAL		
	Patella Fracture		Vioxx	SS	Merck & Co., Inc	ORAL		
	Speech Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Treatment Noncompliance		Aspirin	C		ORAL		
			Alendronate Sodium Calcium (Unspecified) And Vitamin D	C		ORAL		

			(Unspecified)	C		ORAL

Date:01/05/05ISR Number: 4545540-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03257
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Metformin Hydrochloride	C		
Disability	Hypertension					
UNKNOWN						
Other	Myocardial Infarction		Tramadol Hydrochloride	C		
UNKNOWN						
			Piroxicam	C		
UNKNOWN						
			Metoprolol Succinate	C		
UNKNOWN						
			Isosorbide Mononitrate	C		
UNKNOWN						
			Sertraline Hydrochloride	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Lisinopril	C		
UNKNOWN						
			Zocor	C		ORAL
			Morphine	C		
UNKNOWN						
			Omeprazole	C		
UNKNOWN						

Date:01/05/05ISR Number: 4545542-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01601
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL
			Singulair	C		ORAL
			Doxepin Hydrochloride	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						
			Zyrtec	C		
UNKNOWN						
			Accolate	C		
UNKNOWN						
			Hydroxyzine Hydrochloride	C		
UNKNOWN						

Date:01/05/05ISR Number: 4545543-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03214
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Myocardial Infarction							

Date:01/05/05ISR Number: 4545545-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00034
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Other	Death		Coumadin	C				
UNKNOWN								
	Fall							
	Heart Rate Irregular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4545546-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00005
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		246 DAY
Hospitalization -	Coronary Artery Stenosis		Aspirin	C		ORAL		
Initial or Prolonged	Myocardial Ischaemia		Atorvastatin Calcium	C		ORAL		
			Repaglinide	C		ORAL		
			Ramipril	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Mirtazapine	C		ORAL		
			Oxazepam	C				UNKNOWN
			Nitroglycerin	C				UNKNOWN

Date:01/05/05ISR Number: 4545550-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02943
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL		
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zyrtec	C		ORAL		
			Medrol Dosepak	C		ORAL		

Date:01/05/05ISR Number: 4545552-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03308
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Peripheral Vascular		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		15 MON
			Lopressor	C				UNKNOWN

Cilostazol	C	UNKNOWN
Lipitor	C	UNKNOWN
Mobic	C	UNKNOWN
Verapamil	C	UNKNOWN

Date:01/05/05ISR Number: 4545564-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia Atrial Fibrillation Drug Ineffective Heart Rate Decreased Hypertension Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	72	DAY

Date:01/05/05ISR Number: 4546440-1Report Type:Expedited (15-DaCompany Report #2004AL000599
Age:36 YR Gender:Female I/FU:F

Outcome	PT
Death Hospitalization - Initial or Prolonged	Acidosis Alanine Aminotransferase Increased Aspartate Aminotransferase

		Increased Blood Glucose Decreased Blood Ph Decreased Cardio-Respiratory Arrest	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coma Completed Suicide Heart Rate Decreased Hypotension	Health Professional	Children'S Apap Elixir (Acetaminophen) (Alpharma)	PS	Alpharma	ORAL
PO							
		International Normalised Ratio Increased Multiple Drug Overdose		Infants' Apap Drops (Acetaminophen) (Alpharma)	SS	Alpharma	ORAL
PO							
		Oxygen Saturation		Atenolol	SS		ORAL
PO							
		Decreased		Chlordiaepoxide	SS		ORAL
PO							
		Pupil Fixed		Rofecoxib	SS		ORAL
PO							
				Tramadol Hydrochloride Tablets, 50 Mg (Purepac)	SS	Purepac	ORAL
PO							
				Carisoprodol	SS		ORAL
PO							
				Paroxetine	SS		ORAL
PO							

Date:01/05/05ISR Number: 4546915-5Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00273
Age:75 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Silent Myocardial Infarction	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY,							
			Other				
PO	15 DAY						
				Acetaminophen	C		
				Aspirin	C		
				Lansoprazole	C		

Date:01/05/05ISR Number: 4546927-1Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00444
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY, PO	80 DAY
	Cardiac Failure							
	Congestive Heart Rate Increased	Other						
			Acetaminophen	C				
			Amitriptyline Hydrochloride	C				
			Blinded Therapy	C				
			Bromazepam	C				
			Captopril	C				
			Celecoxib	C				
			Hydrochlorothiazide	C				
			Leflunomide	C				
			Omeprazole	C				

Date:01/05/05ISR Number: 4547223-9Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Coronary Artery Insufficiency	Foreign Study	Vioxx (Rofecoxib)	PS		ORAL	1 MG/ DAILY PO	134 DAY
	Coronary Artery Occlusion	Health Professional Other						
	Ventricular Hypokinesia		Post-Trial Therapy	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/05/05ISR Number: 4547227-6Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00154
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Malignant Neoplasm Progression	Foreign Study	Vioxx					
	Myocardial Infarction	Health	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
	Oesophageal Carcinoma	Professional					PO	
		Other						

Date:01/05/05ISR Number: 4547229-XReport Type:Expedited (15-DaCompany Report #WAES 0412USA02731
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction	Foreign Study	Vioxx					
		Literature	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
		Health						
		Professional	Acetaminophen	C			PO	15 DAY
		Other	Aspirin	C				
			Lansoprazole	C				

Date:01/05/05ISR Number: 4547251-3Report Type:Expedited (15-DaCompany Report #2004120007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis	Consumer	Celebrex (Celecoxib)	PS				
	Knee Arthroplasty		Bextra (Valdecoxib)					
	Palpitations		(Valdecoxib)	SS				
			Rofecoxib (Rofecoxib)	SS				

Date:01/05/05ISR Number: 4548185-0Report Type:Direct Company Report #CTU 235743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS			25 MG 1 X DAY	
Initial or Prolonged	Dyspnoea		Cartiax	C				
	Heart Rate Irregular							
	Loss Of Consciousness							

Date:01/05/05ISR Number: 4548186-2Report Type:Direct Company Report #CTU 235742
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg	PS			1 OR 2 DAILY	
Hospitalization -	Convulsion							
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:01/05/05ISR Number: 4548541-0Report Type:Direct Company Report #CTU 235761
Age: Gender:Male I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other
Required PT Report Source Product Role Manufacturer Route
Dose Duration
Intervention to Cerebrovascular Accident Vioxx PS
25 MG FOR
Prevent Permanent Pulmonary Embolism
Impairment/Damage

Date:01/05/05ISR Number: 4548561-6Report Type:Direct Company Report #CTU 235758
Age:72 YR Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS
25 MG X 1 DAY

Date:01/05/05ISR Number: 4548590-2Report Type:Direct Company Report #CTU 235754
Age: Gender: I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Life-Threatening Impaired Work Ability 50 Mg Vioxx PS
1 / DAY
Hospitalization - Myocardial Infarction
Initial or Prolonged

Date:01/06/05ISR Number: 4546268-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02101
Age:53 YR Gender:Male I/FU:F

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Hospitalization - Bruxism Vioxx PS Merck & Co., Inc ORAL
Initial or Prolonged Cerebrovascular Accident Acupril C
UNKNOWN
Headache Insulin C
UNKNOWN
Muscle Spasms Pepcid C
UNKNOWN
Transient Ischaemic
Attack

Date:01/06/05ISR Number: 4546269-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Other	Anaemia
	Angina Pectoris
	Anxiety
	Arthralgia
	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased
	Bone Disorder
	Cardiomegaly
	Cerebrovascular Accident
	Conjunctivitis Allergic
	Convulsion
	Deep Vein Thrombosis
	Depressed Mood
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspnoea
	Ear Pain
	Fatigue

		Fear					
		Goitre					
		Hallucination	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoglycaemia		Coumadin	C		
UNKNOWN							
		Impaired Gastric Emptying		Risperdal	C		
UNKNOWN							
		Injection Site		Prozac	C		
UNKNOWN							
		Haemorrhage		Elavil	C		ORAL
		Irritability		Effexor	C		
UNKNOWN							
		Lipomatosis		Effexor	C		
UNKNOWN							
		Mastoiditis		Glucophage	C		
UNKNOWN							
		Migraine					
		Mood Swings					
		Nasal Congestion					
		Pain In Extremity					
		Phlebitis					
		Rash					
		Retinopathy					
		Seasonal Allergy					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					
		Suicidal Ideation					
		Syncope					
		Thinking Abnormal					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:01/06/05ISR Number: 4546275-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03281
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Pain							
	Headache							

Date:01/06/05ISR Number: 4546277-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02285
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Paxil	C			UNKNOWN	
	Vasoconstriction		Detrol	C			UNKNOWN	
			Lotrel	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Demadex	C			UNKNOWN	
			Mobic	C			UNKNOWN	

Date:01/06/05ISR Number: 4546286-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00002
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		147 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Metoprolol Tartrate	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Acetaminophen	C				UNKNOWN

Date:01/06/05ISR Number: 4546287-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00003
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		108 DAY
Initial or Prolonged			Enalapril Maleate	C				UNKNOWN
Disability			Metformin Hydrochloride	C				UNKNOWN

Date:01/06/05ISR Number: 4546288-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00025
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Fibrillation		Aspirin	C		ORAL		
	Myocardial Ischaemia		Aspirin	C		ORAL		
	Ventricular Fibrillation		Pantoprazole Sodium	C		ORAL		
	Ventricular Flutter							

Date:01/06/05ISR Number: 4546289-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03352
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546292-XReport Type:Expedited (15-DaCompany Report #IT-MERCK-0501ITA00001
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL	51	DAY
Initial or Prolonged	Membranous Nephrotic Syndrome Oedema							

Date:01/06/05ISR Number: 4546293-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Atherosclerosis
Disability	Blindness Unilateral
	Brain Stem Infarction
	Carotid Artery Stenosis
	Cerebral Artery Embolism
	Cerebral Haemorrhage
	Cerebral Infarction

	Cerebral Thrombosis						
	Cerebrovascular Accident						
	Constipation	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	710	DAY
	Excoriation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	710	DAY
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Aspirin	C			UNKNOWN	
	Headache							
	Hemianopia							
	Hyperlipidaemia							
	Limb Injury							
	Localised Infection							
	Musculoskeletal Stiffness							
	Nasal Congestion							
	Nervous System Disorder							
	Petechiae							
	Rash Erythematous							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Rhinitis Allergic							
	Skin Discolouration							
	Skin Laceration							
	Temperature Intolerance							
	Traumatic Arthritis							

Date:01/06/05ISR Number: 4546303-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							
Other	Gastric Disorder							
	Hepatocellular Damage							

Date:01/06/05ISR Number: 4546304-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00152
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/06/05ISR Number: 4546846-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00845
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Adverse Event
Other	Arrhythmia
	Atrial Fibrillation
	Blood Triglycerides Increased
	Bursitis
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Constipation
	Coronary Artery Disease

Diarrhoea
Feeling Abnormal
Flatulence
Laboratory Test Abnormal
Mitral Valve Prolapse
Myocardial Infarction
Nodule
Pharyngitis Streptococcal
Pollakiuria
Polytraumatism
Sick Sinus Syndrome
Syncope
Tricuspid Valve
Incompetence
Urinary Tract Infection
Ventricular Hypertrophy
Viral Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546858-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00803
Age:39 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Accident At Work
Adverse Event
Anaemia Macrocytic
Anxiety
Arthralgia
Arthropathy
Asthma
Back Pain
Balance Disorder
Bipolar Disorder
Blood Cholesterol Increased
Blood Magnesium Decreased
Blood Pressure Decreased
Blood Triglycerides Increased
Bone Graft
Bone Pain
Brain Oedema
Breast Disorder
Bronchitis
Candidiasis

Cerebral Infarction
Cerebrovascular Accident
Condition Aggravated
Contusion
Cough
Dizziness
Drug Screen Positive
Dyskinesia
Electrolyte Imbalance
Fall
Headache
Herpes Simplex
Hypertension
Hypoglycaemia
Impulsive Behaviour
Injury

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Insomnia					
		Intervertebral Disc Disorder					
		Joint Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Menopause		Serevent	C		
UNKNOWN							
		Migraine		Flovent	C		
UNKNOWN							
		Mitral Valve Incompetence		Singulair	C		ORAL
		Muscle Spasms		Topamax	C		
UNKNOWN							
		Neuralgia		Effexor	C		
UNKNOWN							
		Ovarian Cyst Ruptured		Claritin	C		
UNKNOWN							
		Piriformis Syndrome		Klonopin	C		
UNKNOWN							
		Pneumonia		Imitrex Nasal Spray	C		
UNKNOWN							
		Procedural Complication		Skelaxin	C		
UNKNOWN							
		Pulmonary Congestion		Cyanocobalamin	C		
PARENTERAL							
		Rhinitis Allergic		Zyrtec	C		
UNKNOWN							
		Rosacea		Beclovent	C		
UNKNOWN							
		Simple Partial Seizures		Zestril	C		
UNKNOWN							
		Spinal Disorder		Detrol	C		
UNKNOWN							
		Staphylococcal Infection		Mysoline	C		
UNKNOWN							
		Syncope		Prilosec	C		
UNKNOWN							
		Tendon Injury					
		Tremor					
		Tricuspid Valve Incompetence					
		Urge Incontinence					
		Urinary Tract Infection					
		Uterine Leiomyoma					
		Weight Decreased					

Date:01/06/05ISR Number: 4546861-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Angina Unstable
Other	Azotaemia
	Bronchitis
	Cardiac Failure
	Congestive
	Central Line Infection
	Cerebral Artery Occlusion
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Restenosis
	Decreased Appetite
	Diarrhoea
	Dressler'S Syndrome
	Faecal Occult Blood
	Positive
	Faeces Discoloured
	Gastrointestinal
	Haemorrhage
	Hyperbilirubinaemia
	Hyperlipidaemia
	Hypertension
	Myocardial Infarction
	Peripheral Vascular

	Disorder Radiculopathy Respiratory Failure Skin Candida	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Subclavian Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	
			Aricept	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Allopurinol	C			UNKNOWN
			Vitamin E	C			UNKNOWN
			Ascorbic Acid	C			UNKNOWN

Date:01/06/05ISR Number: 4546869-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1127 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
	Arthropathy		Viagra	C			UNKNOWN
	Blood Cholesterol		Amoxicillin	C			UNKNOWN
	Increased		Plavix	C			UNKNOWN
	Bursitis		Ambien	C			UNKNOWN
	Coronary Artery Disease Coronary Artery Stenosis		Trazodone Hydrochloride	C			UNKNOWN
	Depression		Ibuprofen	C			UNKNOWN
	Erectile Dysfunction		Zanaflex	C			UNKNOWN

	Hypercholesterolaemia	Altace	C
UNKNOWN			
	Hypertension	Diazepam	C
UNKNOWN			
	Laceration	Hydrocodone	
	Peroneal Nerve Palsy	Bitartrate	C
UNKNOWN			
	Pleuritic Pain	Hydrocodone	
	Ventricular Dysfunction	Bitartrate	C
UNKNOWN	14 MON		
		Oxycontin	C
UNKNOWN	14 MON		

Date:01/06/05ISR Number: 4546870-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00121
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
538 DAY						
Life-Threatening			Cardizem	C		
UNKNOWN						
Hospitalization -			Prozac	C		
UNKNOWN						
Initial or Prolonged			Aspirin	C		
UNKNOWN						
Disability			Zocor	C		ORAL
			Hytrin	C		
UNKNOWN						
			Trusopt	C		
OPHTHALMIC						
			Darvocet-N	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

Date:01/06/05ISR Number: 4546874-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01506
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Disability	Diarrhoea
Other	Haemorrhage
	Hypertension
	Hypoaesthesia
	Incontinence
	Nerve Compression

Paraesthesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Ultram	C			UNKNOWN	
	Tarka	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Evista	C			UNKNOWN	
	Oxytrol	C			UNKNOWN	

Date:01/06/05ISR Number: 4546876-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02770
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Decreased							
	Glossodynia							
	Rectal Haemorrhage							
	Swollen Tongue							

Date:01/06/05ISR Number: 4546877-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03579
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Norvasc	C		ORAL		
	Oedema Peripheral		Ziac	C		ORAL		
	Pain In Extremity		Prevacid	C		ORAL		
	Sluggishness		Lipitor	C		ORAL		

Date:01/06/05ISR Number: 4546895-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00073
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Face Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	25 DAY	
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	25 DAY	
	Medication Error		Catapres	C			UNKNOWN	
	Oedema Mouth		Lortab	C		ORAL		
	Pollakiuria							
	Swelling							
	Tongue Oedema							

Date:01/06/05ISR Number: 4546897-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00497
Age:79 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Anorexia
	Cardiac Disorder
	Chest Discomfort
	Cough
	Cystitis Noninfective
	Diarrhoea

	Hypertension					
	Myocardial Infarction					
	Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL
29 DAY						
	Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
29 DAY						
	Vomiting		Certoparin Sodium	C		
UNKNOWN	35 DAY					
			Beloc-Zok	C		
UNKNOWN						
			Bifiteral	C		
UNKNOWN						
			Cibacen	C		
UNKNOWN						

Date:01/06/05ISR Number: 4546911-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02097
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Aortic Stenosis
	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coagulation Time
	Prolonged
	Colon Adenoma
	Colonic Polyp
	Coronary Artery Disease
	Coronary Artery Occlusion
	Cough
	Dehydration
	Diabetic Foot
	Diabetic Nephropathy
	Diabetic Retinopathy
	Diverticulum
	Dyspnoea
	Emotional Distress
	Epistaxis

Erectile Dysfunction
Gouty Arthritis
Hyperkalaemia
Hypokalaemia
Hypothyroidism
Infusion Site Infection
Injury
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Mitral Valve Prolapse
Myasthenia Gravis
Myocardial Infarction
Neuropathic Pain
Oedema Peripheral
Open Angle Glaucoma
Overdose
Palpitations
Peptic Ulcer
Peripheral Occlusive
Disease
Pulmonary Hypertension
Pulmonary Oedema

Dose	Duration						
		Rectal Haemorrhage					
		Renal Failure					
		Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route
		Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Respiratory Failure		Insulin	C		
UNKNOWN		Sleep Apnoea Syndrome		Coreg	C		
UNKNOWN		Sleep Disorder		Aspirin	C		
UNKNOWN		Syncope		Allopurinol	C		
UNKNOWN		Vascular Graft Occlusion		Allopurinol	C		
UNKNOWN		Vascular Occlusion		Furosemide	C		
UNKNOWN		Ventricular Extrasystoles		Glipizide	C		
UNKNOWN		Vitreous Haemorrhage		Actos	C		
UNKNOWN				Neurontin	C		
UNKNOWN				Spironolactone	C		
UNKNOWN				Lotensin	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Glucophage	C		
UNKNOWN				Pepcid	C		
UNKNOWN				Nitroglycerin	C		
UNKNOWN				Cardizem	C		
UNKNOWN				Clopidogrel Bisulfate	C		
UNKNOWN				Coumadin	C		
UNKNOWN				Glycine	C		
UNKNOWN				Fluvastatin Sodium	C		
UNKNOWN				Trazodone			

			Hydrochloride	C			
UNKNOWN							
			Celebrex	C			
UNKNOWN							

Date:01/06/05ISR Number: 4546929-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03367
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization -	Chest Discomfort		Premarin	C				UNKNOWN
Initial or Prolonged	Heart Rate Irregular		Synthroid	C				UNKNOWN
Disability								

Date:01/06/05ISR Number: 4546930-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02872
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		474 MON
Hospitalization -	Embolic Stroke		Lanoxin	C		ORAL		
Initial or Prolonged	Oedema Peripheral		Aspirin	C		ORAL		
	Pain In Extremity		Viagra	C		ORAL		
			Lidex E	C				
TOPICAL								
			Diprosone	C				
TOPICAL								
			Lamisil	C		ORAL		
			Centrum Silver	C		ORAL		

Date:01/06/05ISR Number: 4546932-5Report Type:Expedited (15-DaCompany Report #FI-MERCK-0412FIN00002
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		953 DAY
	Blood Pressure Increased		Ibuprofen	C		ORAL		
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/05ISR Number: 4546933-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00105
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546934-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546935-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03306
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546936-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Adverse Event Atherosclerosis Cardiac Disorder Coronary Artery Disease Feeling Abnormal Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	

Date:01/06/05ISR Number: 4546941-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/06/05ISR Number: 4546943-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00114
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vasotec	C		ORAL		

Date:01/06/05ISR Number: 4546944-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00074
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dysuria		Flomax (Tamsulosin					
Initial or Prolonged			Hydrochloride)	C				
UNKNOWN								
Disability			Darvocet-N	C				
UNKNOWN								

Xanax C
UNKNOWN

Date:01/06/05ISR Number: 4546945-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546946-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00148
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546948-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00171
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546949-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546950-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546951-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00196
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:01/06/05ISR Number: 4546952-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/05ISR Number: 4546954-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546955-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546956-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Herpes Zoster Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546957-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Urinary Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546958-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00160
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546961-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00197
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546962-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00198
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/06/05ISR Number: 4546966-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00814
Age:76 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Aortic Atherosclerosis		Coumadin	C			UNKNOWN	
Aortic Stenosis		Coumadin	C			UNKNOWN	
Atrial Flutter							
Benign Prostatic Hyperplasia							
Bladder Diverticulum							
Bladder Trabeculation							
Blood Pressure Increased							
Cardiac Failure Congestive							
Cardiomegaly							
Coronary Artery Atherosclerosis							
Coronary Artery Occlusion							
Dilatation Atrial							
Dilatation Ventricular							
Dyspnoea							
Ejection Fraction Decreased							
Electrocardiogram St-T Change							
Heart Rate Irregular							
Hypercapnia							
Hypochloraemia							
Ischaemic Cardiomyopathy							
Metabolic Acidosis							
Mitral Valve Incompetence							
Neoplasm							
Nocturia							
Oedema Peripheral							
Prostatic Specific Antigen Increased							
Pulmonary Arterial Pressure Abnormal							
Pulmonary Oedema							
Rales							
Right Ventricular Systolic Pressure Increased							

Tachycardia
Tricuspid Valve
Incompetence
Urinary Retention
Ventricular Dysfunction

Date:01/06/05ISR Number: 4546967-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04013
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
	Headache							
	Hypertension							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/05ISR Number: 4546972-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03167
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/06/05ISR Number: 4549607-1Report Type:Expedited (15-DaCompany Report #2004113482
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis	Consumer	Celebrex (Celecoxib)	PS		ORAL		
ORAL								
	Condition Aggravated		Rofecoxib					
	Drug Resistance		(Rofecoxib)	SS				
	Pharmaceutical Product Complaint							

Date:01/07/05ISR Number: 4547230-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00706
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
	Deep Vein Thrombosis							
	Diastolic Dysfunction							
	Dilatation Atrial							
	Hypertension							
	Injury							
	Joint Injury							
	Limb Injury							
	Localised Infection							
	Musculoskeletal Chest Pain							
	Pain In Extremity							
	Patellofemoral Pain Syndrome							
	Post Thrombotic Syndrome							
	Pulmonary Embolism							

Ventricular Hypertrophy

Date:01/07/05ISR Number: 4547236-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00653
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Chest Pain
Other	Depression
	Dizziness
	Dysstasia
	Hyperlipidaemia
	Hypertension
	Hypertonic Bladder
	Insomnia
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Polytraumatism

	Prostatitis						
	Proteinuria						
	Rash Pruritic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Suicidal Ideation		Vioxx	PS	Merck & Co., Inc	ORAL	
	Tendon Rupture		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tinea Infection		Vioxx	SS	Merck & Co., Inc	ORAL	
	Treatment Noncompliance		Vioxx	SS	Merck & Co., Inc	ORAL	
			Claritin	C			UNKNOWN
			Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN

Date:01/07/05ISR Number: 4547240-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Atherosclerosis		Methotrexate	C		ORAL	
Disability	Back Pain		Ibuprofen	C			UNKNOWN
	Blood Cholesterol		Folic Acid	C			UNKNOWN
	Increased		Zocor	C		ORAL	
	Blood Triglycerides		Nitroquick	C			UNKNOWN
	Increased		Prilosec	C			UNKNOWN
	Cardiovascular Disorder		Leucovorin	C			UNKNOWN
	Chest Pain		Darvocet-N	C		ORAL	
	Condition Aggravated		Plavix	C		ORAL	
	Coronary Artery		Lopressor	C		ORAL	
	Atherosclerosis						
	Coronary Artery Disease						
	Coronary Artery Occlusion						
	Coronary Artery						
	Restenosis						
	Coronary Ostial Stenosis						
	Drug Ineffective						
	Dyspepsia						

Emotional Distress
Gastrooesophageal Reflux
Disease
High Density Lipoprotein
Decreased
Hyperlipidaemia
Hypertension
Multiple Allergies
Muscle Spasms
Myocardial Infarction
Oedema Peripheral
Pain In Extremity
Psoriasis
Psoriatic Arthropathy
Renal Failure

Date:01/07/05ISR Number: 4547248-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01630
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Diarrhoea
	Tachycardia
Disability	Transient Ischaemic

	Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:01/07/05ISR Number: 4547249-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00538
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	
	Electrocardiogram		Isosorbide Dinitrate	C		ORAL	
	Repolarisation		Iodine	C		ORAL	
	Abnormality		Flupirtine Maleate	C			UNKNOWN
	Scan Myocardial Perfusion		Tetrazepam	C		ORAL	
	Abnormal		Tilidine				
	Somatoform Disorder		Hydrochloride	C		ORAL	
			Mometasone Furoate	C			UNKNOWN

Date:01/07/05ISR Number: 4547250-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1128 DAY
Initial or Prolonged	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	1128 DAY
Other	Acute Myocardial		Effexor	C			UNKNOWN 247 DAY
	Infarction		Nortriptyline	C			UNKNOWN 233 DAY
	Arthralgia		Trazodone				
	Chest Pain		Hydrochloride	C			UNKNOWN
	Coronary Artery Occlusion						
	Coronary Artery						
	Restenosis						
	Cough						

Diastolic Dysfunction
Diverticulum
Emotional Distress
Fatigue
Gastritis
Gastroduodenitis
Haematocrit Decreased
Haematuria
Haemoglobin Decreased
Hyperlipidaemia
Hypertension
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Neck Pain
Nephrolithiasis
Pain
Platelet Count Decreased
Ventricular Hypertrophy
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547253-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02952
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL	480	DAY

Date:01/07/05ISR Number: 4547254-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00882
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abnormal Sensation In Eye		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adverse Event		Monopril	C				
UNKNOWN								
Initial or Prolonged	Angioneurotic Oedema		Zocor	C				
UNKNOWN								
Disability	Blood Cholesterol		Prozac	C				
UNKNOWN								
Other	Increased		Ultram	C				
UNKNOWN								
	Breast Mass		Motrin	C				
UNKNOWN								
	Bronchitis		Ativan	C				
UNKNOWN								
	Bursitis		Analgesic Or					
	Cardiac Valve Disease		Anesthetic					
	Cardiomegaly		(Unspecified)	C				
UNKNOWN								
	Cataract		Muro 128 Ophthalmic					
	Chondromalacia		Ointment	C				
OPHTHALMIC								
	Chronic Obstructive		Artificial Tears	C				
OPHTHALMIC								
	Pulmonary Disease		Lipitor	C				
UNKNOWN								
	Conjunctival Haemorrhage		Estradiol	C				
UNKNOWN								
	Constipation							
	Costochondritis							
	Cystitis							
	Diverticulitis							
	Diverticulum							
	Dyspnoea							

Ear Congestion
Fall
Heart Rate Increased
Joint Effusion
Keratitis
Lumbar Radiculopathy
Lymphadenopathy
Meniscus Lesion
Mitral Valve Incompetence
Osteoarthritis
Osteopetrosis
Photophobia
Polytraumatism
Respiratory Failure
Road Traffic Accident
Sinusitis
Spinal Column Stenosis
Syncope
Tricuspid Valve
Incompetence
Varicose Vein
Vulvovaginal Discomfort

Date:01/07/05ISR Number: 4547258-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00073
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
			Corticosteroids					

			(Unspecified)	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:01/07/05ISR Number: 4547260-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04133
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Celebrex	C				
UNKNOWN								

Date:01/07/05ISR Number: 4547261-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03544
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Naproxen	C				
UNKNOWN								
	Ear Pain		Percocet	C				
UNKNOWN								
	Gastrooesophageal Reflux		Tylenol	C				
UNKNOWN								
	Disease							
	Haematochezia							
	Joint Swelling							
	Pain							
	Swelling Face							
	Urinary Tract Infection							

Date:01/07/05ISR Number: 4547262-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Disability	Amyotrophy

Other	Anaemia
	Angina Pectoris
	Arthralgia
	Arthritis
	Atherosclerosis
	Bursitis
	Carotid Artery Stenosis
	Cerebral Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chondromalacia
	Coagulopathy
	Constipation
	Contusion
	Convulsion
	Coronary Artery Disease
	Crepitations
	Diabetes Mellitus
	Inadequate Control
	Diabetic Complication
	Diabetic Neuropathy
	Difficulty In Walking
	Diverticulum
	Dizziness

		Eye Injury					
		Faeces Discoloured					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Plavix	SS		
UNKNOWN							
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Haemorrhage		Humulin	C		
UNKNOWN							
		Haemorrhoidal Haemorrhage		Captopril Msd	C		ORAL
		Hand Fracture		Prilosec	C		ORAL
		Hypertension		Synthroid	C		
UNKNOWN							
		Hypotension		Glucotrol Xl	C		
UNKNOWN							
		Insulin Resistance		Evista	C		
UNKNOWN							
		Joint Dislocation		Amitriptyline			
		Joint Sprain		Hydrochloride	C		
UNKNOWN							
		Lacunar Infarction					
		Leukopenia					
		Ligament Sprain					
		Lumbar Radiculopathy					
		Meniscus Lesion					
		Mental Status Changes					
		Muscle Spasms					
		Myelodysplastic Syndrome					
		Nocturia					
		Osteoarthritis					
		Pain					
		Peroneal Nerve Injury					
		Pharyngitis					
		Radiculopathy					
		Subcutaneous Abscess					
		Syncope					
		Tendonitis					
		Thrombocytopenia					
		Upper Respiratory Tract					
		Infection					
		Visual Acuity Reduced					

Date:01/07/05ISR Number: 4547267-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03180
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL	559 DAY	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	559 DAY	
	Transient Ischaemic Attack		Levoxyl	C		ORAL	UNKNOWN	
			Diclofenac	C				
			Trazodone Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		
			Ambien	C		ORAL		
			Monopril	C		ORAL		
			Os-Cal + D	C		ORAL		
			Docusate Calcium	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Zyrtec	C		ORAL		
			Ibuprofen	C		ORAL		
			Norvasc	C			UNKNOWN	
			Ultram	C		ORAL		
			Vitamins (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547268-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03315
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Feeling Abnormal		Vioxx Original Formula	PS	Merck & Co., Inc	ORAL		
Disability			Sensodyne-Sc	SS				
UNKNOWN								

Date:01/07/05ISR Number: 4547270-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00364
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547271-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:01/07/05ISR Number: 4547272-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00014
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Aortic Valve Incompetence Atrial Fibrillation		Vioxx Ticlopidine Hydrochloride	PS C	Merck & Co., Inc	ORAL		
UNKNOWN			Carvedilol	C				
UNKNOWN			Digoxin	C				
UNKNOWN			Sertraline					

Hydrochloride	C	UNKNOWN
Caffeine, Citrated And Nitroglycerin	C	UNKNOWN
Nitroglycerin	C	UNKNOWN
Spironolactone	C	UNKNOWN
Clonixin Lysine	C	UNKNOWN
Furosemide	C	UNKNOWN
Aspirin	C	UNKNOWN
Pravastatin Sodium	C	UNKNOWN
Omeprazole	C	UNKNOWN
Calcium Carbonate And Cholecalciferol	C	UNKNOWN

Date:01/07/05ISR Number: 4547277-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00363
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547285-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00083
Age: Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Hospitalization - Initial or Prolonged Disability	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Haemorrhage							
	Myocardial Infarction							

Date:01/07/05ISR Number: 4547715-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00723
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Other	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Dilatation		Wygesic Tablets	C			UNKNOWN	
	Aortic Valve Sclerosis		Ultram	C			UNKNOWN	
	Atelectasis		Blood Thinner (Unspecified)	C			UNKNOWN	
	Atherosclerosis							
	Blood Lactate Dehydrogenase Increased							
	Blood Sodium Decreased							
	Blood Triglycerides Increased							
	Carotid Artery Stenosis							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Convulsion							
	Drug Ineffective							
	Fall							
	Fatigue							
	Gallbladder Disorder							
	Haematocrit Decreased							
	Haemorrhoids							
	Hypercholesterolaemia							
	Hypertension							
	Hypoaesthesia							
	Hyponatraemia							
	Intermittent Claudication							
	Lung Infiltration							

Malaise
Mitral Valve Incompetence
Musculoskeletal
Discomfort
Nausea
Pain In Extremity
Paraesthesia
Polyp Colorectal
Renal Cyst
Tricuspid Valve
Incompetence

Date:01/07/05ISR Number: 4547718-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02103
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Claw Toe
Other	Acute Myocardial Infarction
	Angina Unstable

		Arterial Insufficiency					
		Arthropathy					
		Asthenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Basal Cell Carcinoma		Zocor	C		ORAL
		Blood Pressure Increased		Plavix	C		ORAL
		Bursitis		Lotensin	C		ORAL
		Carotid Artery Stenosis		Metoprolol	C		ORAL
		Carpal Tunnel Syndrome		Alfentanil			
		Cerebrovascular Accident		Hydrochloride	C		
UNKNOWN							
		Coronary Artery Disease		[Therapy			
		Coronary Artery		Unspecified]	C		ORAL
		Restenosis		Aspirin	C		
UNKNOWN							
		Dermatitis Contact					
		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Diabetic Neuropathy					
		Diabetic Retinopathy					
		Diarrhoea					
		Haemarthrosis					
		Headache					
		Hearing Impaired					
		Injury					
		Intermittent Claudication					
		Joint Dislocation					
		Lumbar Radiculopathy					
		Monarthritis					
		Myocardial Infarction					
		Neuropathy Peripheral					
		Osteoarthritis					
		Rotator Cuff Syndrome					
		Sleep Apnoea Syndrome					
		Tendonitis					
		Vertigo					
		Vestibular Disorder					

Date:01/07/05ISR Number: 4547727-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00613
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Infarction
Other	Adverse Event
	Angina Pectoris
	Blood Pressure Increased
	Chronic Obstructive Pulmonary Disease
	Convulsion
	Feeling Abnormal
	Refusal Of Treatment By Patient
	Supraventricular Extrasystoles

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547730-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00102
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diclofenac Resinate	C		ORAL		

Date:01/07/05ISR Number: 4547732-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00885
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Disability	Abdominal Distension
	Abdominal Hernia
	Abdominal Pain Lower
	Abdominal Pain Upper
	Adverse Event
	Anaemia
	Angina Unstable
	Aspartate Aminotransferase Increased
	Blood Creatine Phosphokinase Mb Increased
	Blood Glucose Increased
	Blood Pressure Systolic Increased
	Blood Urea Increased
	Bradycardia
	Cardiomegaly
	Dehydration
	Diverticulum
	Diverticulum Intestinal
	Dizziness
	Drug Ineffective
	Duodenitis
	Exostosis
	Gastritis
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Hepatic Steatosis
	Hiatus Hernia

Hypersomnia
Hypokalaemia
Lower Gastrointestinal
Haemorrhage
Mitral Valve Incompetence
Nasopharyngitis
Neck Pain
Oesophagitis
Oxygen Saturation
Decreased
Pain In Extremity
Sinus Bradycardia
Sinusitis
Sleep Apnoea Syndrome
Snoring
Somnolence
Tendonitis

		Tricuspid Valve Incompetence					
		Vertigo	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Diazide	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							

Date:01/07/05ISR Number: 4547733-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00552
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Goitre		Bisoprolol	C		ORAL
		Helicobacter Pylori		Zocor	C		ORAL
		Identification Test		Aspirin	C		ORAL
		Positive		Isosorbide			
		Hyperthyroidism		Mononitrate	C		ORAL
		Tachyarrhythmia		Torsemide	C		ORAL
				Betaxolol			
				Hydrochloride	C		ORAL
				Aspirin	C		ORAL

Date:01/07/05ISR Number: 4547734-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00072
Age:82 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Dermatitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Hypothyroidism		Doxazosin Mesylate	SS		ORAL
		Rash Papular		Hydroxyzine			
				Hydrochloride	SS		ORAL
				Acetaminophen And			
				Tramadol			

Hydrochloride	SS	ORAL
Amiodarone	SS	ORAL
Betahistine Hydrochloride	SS	ORAL
Loprazolam Mesylate	C	ORAL
Pravastatin Sodium	C	ORAL
Acenocoumarol	C	ORAL
Fosinopril Sodium	C	ORAL
Amlodipine Besylate	C	ORAL
Clonidine Hydrochloride	C	ORAL
Potassium Chloride	C	ORAL

Date:01/07/05ISR Number: 4547735-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00806
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Confusional State		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547736-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00860
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Vicodin Tablets	C				UNKNOWN
	Hypersensitivity		Diovan	C				UNKNOWN
	Hypertension							
	Treatment Noncompliance							

Date:01/07/05ISR Number: 4547737-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00548
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Paxil	C		ORAL		
	Attack		Norvasc	C		ORAL		
			Atacand	C		ORAL		
			Aspirin	C		ORAL		

Date:01/07/05ISR Number: 4547738-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01305
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebral Artery Thrombosis		Diuretic (Unspecified)	C				UNKNOWN
	Cerebral Infarction		Clotrimazole	C				UNKNOWN
	Cerebrovascular Accident		Triamterene	C				UNKNOWN
	Coagulation Factor Viii		Tri-Norinyl	C				UNKNOWN
	Level Increased		Broncholate	C				UNKNOWN
	Convulsion							

Demyelination
Diabetes Mellitus
Hypercoagulation
Hypertensive Heart
Disease
Infection
Intracranial Aneurysm
Musculoskeletal Disorder
Neoplasm
Pain
Peptic Ulcer
Vasculitis

Date:01/07/05ISR Number: 4547741-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Cough
	Dyspnoea
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Migraine
	Mitral Valve Prolapse
	Nausea
	Small Intestinal Ulcer

Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Aspirin	C			UNKNOWN	
	Echinacea	C			UNKNOWN	1483 DAY
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Dicyclomine Hydrochloride	C			UNKNOWN	
	Nexium	C			UNKNOWN	

Date:01/07/05ISR Number: 4547742-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00768
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Cardiac Disorder Chest Pain Dizziness Dyspnoea Hypertension Malaise Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547743-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03000
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Videx	C			UNKNOWN	
	Chest Pain		Viracept	C			UNKNOWN	
	Coma		Viramune	C			UNKNOWN	
	Hiatus Hernia							
	Melaena							
	Palpitations							
	Pneumonia							
	Ulcer							

Date:01/07/05ISR Number: 4547744-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01703
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension							
	Neck Pain							
	Non-Cardiac Chest Pain							
	Oesophageal Spasm							
	Pain							
	Pain In Extremity							
	Pallor							
	Thyroxine Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547745-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0501BRA00012
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
Other								

Date:01/07/05ISR Number: 4547746-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00147
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547747-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00006
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY
Initial or Prolonged			Warfarin Sodium	C			UNKNOWN	
Disability			Furosemide	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	
			Vasotec	C			UNKNOWN	
			Sotalol Hydrochloride	C			UNKNOWN	

Date:01/07/05ISR Number: 4547748-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Cerebrovascular Accident							

Date:01/07/05ISR Number: 4547749-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:01/07/05ISR Number: 4547750-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00346
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prilosec	C				
UNKNOWN								
Initial or Prolonged			Avandia	C				
UNKNOWN								
Disability			Lipitor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4547751-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00003
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547752-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547754-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547755-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Disorder Death							

Date:01/07/05ISR Number: 4547756-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547757-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00034
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
			Quinapril Hydrochloride	C			UNKNOWN	
			Amlodipine Besylate	C			UNKNOWN	
			Diuretic (Unspecified)	C			UNKNOWN	
			Fenofibrate	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	

Date:01/07/05ISR Number: 4547758-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00441
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Appendix Disorder
Disability	Benign Breast Neoplasm
Other	Carotid Bruit
	Coronary Artery Disease
	Gallbladder Disorder
	Heart Valve Insufficiency

	Hyperlipidaemia Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Zocor	C		ORAL		
			Insulin	C			UNKNOWN	

Date:01/07/05ISR Number: 4547760-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547761-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547762-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00135
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain							

Date:01/07/05ISR Number: 4547763-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cardiac Disorder Nervous System Disorder Polytraumatism Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/07/05ISR Number: 4547765-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/07/05ISR Number: 4548688-9Report Type:Direct Company Report #CTU 235897
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Thrombosis		Vioxx	PS				

Date:01/07/05ISR Number: 4548695-6Report Type:Direct Company Report #CTU 235920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhagic Infarction		Vioxx				25 Mg	
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Haemorrhagic Stroke		Merck	PS	Merck	ORAL	1 DAILY	BY MOUTH
			Teragosen	C				
			Metformin	C				
			Aterol/Chlor	C				
			Generic For Tenoretic Uniretic	C				
			Gemfibroyil Generic For Lopid	C				
			Synthroid	C				
			Nexium	C				
			Glipizide	C				

Date:01/07/05ISR Number: 4548750-0Report Type:Direct Company Report #CTU 235929
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Dementia Alzheimer'S Type		Vioxx Merck	PS	Merck			

Date:01/07/05ISR Number: 4548785-8Report Type:Direct Company Report #CTU 235908
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg Merck	PS	Merck		ONCE DAILY	

Date:01/07/05ISR Number: 4549155-9Report Type:Direct Company Report #CTU 235913
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx 25mg Merck	PS	Merck	ORAL	25MG DAY ORAL	
Hospitalization - Initial or Prolonged								

Date:01/10/05ISR Number: 4548297-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00009
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Faeces
	Adjustment Disorder
Other	Anxiety

Arrhythmia
Supraventricular
Arthralgia
Atherosclerosis
Atrioventricular Block
Complete
Back Pain
Blood Pressure Increased
Blood Urine Present
Bundle Branch Block Right
Cataract
Chest Wall Pain
Concussion
Depression
Diabetes Mellitus
Diverticulum
Dizziness
Electrocardiogram St
Segment Depression
Electrocardiogram T Wave
Inversion
Eye Disorder
Faecal Incontinence
Fatigue
Flank Pain
Gastric Disorder
Gastric Haemorrhage
Gastrooesophageal Reflux
Disease
Groin Pain
Haematochezia
Haemorrhoids
Headache
Hepatic Cyst
Herpes Virus Infection
Hyperhidrosis
Hyperlipidaemia
Hypoaesthesia
Influenza
Injury
Intervertebral Disc
Degeneration
Medication Error
Meniere'S Disease
Mood Swings
Muscle Strain
Myocardial Ischaemia

Nausea
Pain In Extremity
Palpitations
Pancreatic Cyst
Rectal Haemorrhage
Renal Cyst
Road Traffic Accident
Rotator Cuff Syndrome
Spinal Column Stenosis
Spinal Osteoarthritis
Syncope Vasovagal
Tendonitis
Ulcer
Ventricular Dysfunction

Viral Infection
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	367	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	367	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	367	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	367	DAY
	Pravachol	C			UNKNOWN	
	Wellbutrin Sr	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Accupril	C			UNKNOWN	
	Ecotrin	C			UNKNOWN	
	Effexor Xr	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Altace	C			UNKNOWN	
	Lisinopril	C			UNKNOWN	
	Lipitor	C			UNKNOWN	

Date:01/10/05ISR Number: 4548302-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00734
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	13	DAY
Initial or Prolonged	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		

Hyperplasia	Vioxx	SS	Merck & Co., Inc	ORAL
Cholelithiasis	Vioxx	SS	Merck & Co., Inc	
UNKNOWN				
Depression	Vioxx	SS	Merck & Co., Inc	ORAL
13 DAY				
Dizziness	Vioxx	SS	Merck & Co., Inc	ORAL
Dry Mouth	Vioxx	SS	Merck & Co., Inc	ORAL
Emotional Distress	Vioxx	SS	Merck & Co., Inc	
UNKNOWN				
Erosive Duodenitis	Zestril	SS		
UNKNOWN				
Flatulence	Sectral	SS		
UNKNOWN				
Gastritis Erosive	Zestril	SS		
UNKNOWN				
Headache	Zestril	SS		
UNKNOWN				
Hypertension	Keflex	C		
UNKNOWN				
Renal Failure Acute	Tylenol	C		
UNKNOWN				
Tendonitis	Vitamin B Complex	C		
UNKNOWN				
	Xanax	C		
UNKNOWN				
	Cipro	C		
UNKNOWN				
	Tylenol With Codeine	C		
UNKNOWN				
	Aspirin	C		
UNKNOWN				

Date:01/10/05ISR Number: 4548304-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01631
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
	Affective Disorder
Disability	Anaemia
	Angina Pectoris
	Arthralgia
	Back Injury
	Back Pain
	Blindness Unilateral
	Blood Iron Abnormal

Cerebrovascular Accident
Cervicitis
Chest Discomfort
Coagulopathy
Colonic Polyp
Concussion
Confusional State
Constipation
Deep Vein Thrombosis
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diarrhoea
Diplopia
Disturbance In Attention
Dyspepsia
Ear Discomfort
Eczema
Emotional Disorder
Encephalomalacia
Exostosis
Fall
Fibromyalgia
Fungal Infection
Gait Disturbance
Gastritis
Haemorrhoidal Haemorrhage
Head Injury
Headache
Heart Rate Irregular
Hot Flush
Hydrocephalus
Hypertrophy
Hypoaesthesia
Hypochromic Anaemia
Infarction
Insomnia
Intracranial Venous Sinus
Thrombosis
Joint Effusion
Joint Swelling
Menometrorrhagia
Migraine
Muscular Weakness
Musculoskeletal Stiffness
Myalgia
Nausea

Neck Pain
Oedema Peripheral
Optic Nerve Disorder
Optic Nerve Injury
Osteoarthritis
Osteopenia
Papilloedema
Paraesthesia
Pharyngolaryngeal Pain
Photophobia
Rash
Rectal Haemorrhage
Sinus Tachycardia
Sneezing

		Subarachnoid Haemorrhage Superior Sagittal Sinus Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Tunnel Vision		Vioxx	SS	Merck & Co., Inc	ORAL
		Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL
		Uterine Enlargement		Vioxx	SS	Merck & Co., Inc	ORAL
6	MON						
		Uterine Leiomyoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Vaginal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Vision Blurred		Yasmin	SS		
UNKNOWN		14 DAY					
		Visual Disturbance		Sandimmun	C		
UNKNOWN							
		Visual Field Defect		Lexapro	C		
UNKNOWN							
		Vomiting		Sandimmun	C		
UNKNOWN							
				Sandimmun	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Hormonal Contraceptives (Unspecified)	C		
INTRAMUSCULAR							
				Prelone Syrup	C		
UNKNOWN							
				Prelone Syrup	C		
UNKNOWN							

Date:01/10/05ISR Number: 4548308-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03249
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Injury		Nexium	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							

		Levoxyl	C	
UNKNOWN				
		Mobic	C	
UNKNOWN				
		Cardis	C	
UNKNOWN				
		Clarinex	C	
UNKNOWN				
		Primidone	C	
UNKNOWN				
		Folgard	C	
UNKNOWN				
		Lexapro	C	
UNKNOWN				

Date:01/10/05ISR Number: 4548309-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03172
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4548310-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01355
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cyanosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Skin Discolouration		Verapamil	C		ORAL		
Disability			Dyazide	C		ORAL		
			Metoprolol	C		ORAL		
			Lexapro	C		ORAL		
			Tamoxifen Citrate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4548312-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00004
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4548313-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03368
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrioventricular Block							
	First Degree							
	Chest Pain							
	Dermatitis Contact							
	Dizziness							
	Drug Ineffective							
	Dry Socket							
	Facial Palsy							
	Hypertension							
	Osteoarthritis							
	Tooth Disorder							
	Vaginitis Atrophic							

Date:01/10/05ISR Number: 4548315-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00068
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Erysipelas		Fendiline					
	Headache		Hydrochloride	C				
UNKNOWN								
	Necrotising Fasciitis		Calcium Gluconate					
	No Therapeutic Response		And Calcium					
	Retinal Tear		Phosphate Tribasic					
	Retinal Vascular		And Cholecalciferol	C				
UNKNOWN								
	Thrombosis							
	Retinal Vein Occlusion							

Thrombosis

Date:01/10/05ISR Number: 4548316-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04306
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Anxiety
Disability	Cellulitis
Other	Chest Pain
	Coronary Artery Disease
	Depression
	Dermal Cyst
	Diabetes Mellitus Non-Insulin-Dependent
	Eustachian Tube Dysfunction
	Exostosis
	Fibrocystic Breast Disease
	Fibromyalgia

	Gastrooesophageal Reflux Disease					
	Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
161	DAY					
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
1298	DAY					
	Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY					
	Intervertebral Disc		Synthroid	C		
UNKNOWN						
	Protrusion		Synthroid	C		
UNKNOWN						
	Joint Sprain		Ogen	C		
UNKNOWN						
	Lumbar Spinal Stenosis		Zyrtec	C		
UNKNOWN						
	Medication Error		Doxycycline	C		
UNKNOWN	7 DAY					
	Muscle Spasms					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Oedema Peripheral					
	Osteoarthritis					
	Pulmonary Oedema					
	Seborrhoeic Keratosis					
	Sinusitis					
	Tendonitis					
	Vertigo Positional					

Date:01/10/05ISR Number: 4548318-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00288
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/10/05ISR Number: 4548319-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02530
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Bruit		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Artery Occlusion		Atenolol	C		ORAL		
	Contusion		Hydrochlorothiazide	C		ORAL		
	Fall		Aspirin	C		ORAL		
	Head Injury		Lipitor	C		ORAL		
	Hypokalaemia		Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
			Centrum Silver	C		ORAL		
			Ocuvite	C			UNKNOWN	
			Lisinopril	C		ORAL		
			Glipizide	C		ORAL		
			Fosamax	C		ORAL		

Date:01/10/05ISR Number: 4548320-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03212
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
Hospitalization - Initial or Prolonged	Aortic Stenosis
	Asthma
Disability	Cardiac Disorder
	Cardiac Failure
	Congestive

	Chest Pain						
	Hypertension						
	Iron Deficiency Anaemia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pericardial Effusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope		Norvasc	C				
UNKNOWN								

Date:01/10/05ISR Number: 4548321-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00352
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Colon Cancer		Lipitor	C				
UNKNOWN								
Initial or Prolonged	Coronary Artery Disease							
Disability	Coronary Artery Occlusion							
Other								

Date:01/10/05ISR Number: 4548323-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00350
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease		Lipitor	C				
UNKNOWN								
Initial or Prolonged	Hypertension		Nexium	C				
UNKNOWN								
Disability			Toprol Xl Tablets	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

Date:01/10/05ISR Number: 4548962-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01675
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Arteriosclerosis	Vioxx	PS	Merck & Co., Inc	ORAL
103 DAY					
Hospitalization -	Cardiac Arrest	Vioxx	SS	Merck & Co., Inc	ORAL
103 DAY					
Initial or Prolonged	Coma	Oxycontin	C		
UNKNOWN	637 DAY				
	Myocardial Infarction	Endocet	C		
UNKNOWN	530 DAY				
	Pupil Fixed	Percocet	C		
UNKNOWN					
	Therapy Non-Responder	Nitroquick	C		
UNKNOWN					
		Neurontin	C		
UNKNOWN					
		Topamax	C		
UNKNOWN					
		Duragesic	C		
UNKNOWN	42 DAY				
		Amitriptylin	C		
UNKNOWN					
		Norvasc	C		
UNKNOWN					
		Effexor	C		
UNKNOWN					

Date:01/10/05ISR Number: 4548967-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00951
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Disorder					
	Cardiac Disorder					
	Electrocardiogram Abnormal					
	Heart Rate Increased					
	Surgery					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4548972-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01964
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4548976-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00065
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema		Glucagon	C			UNKNOWN	
			Folic Acid	C		ORAL		

Date:01/10/05ISR Number: 4548987-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01954
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	599 DAY	
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiopathy		Colchicine	C			UNKNOWN	
	Arrhythmia		Vasotec	C			UNKNOWN	725 DAY
	Blood Pressure Systolic		Verapamil	C			UNKNOWN	418 DAY
	Increased		Glucophage	C			UNKNOWN	
	Bradycardia		Allopurinol	C			UNKNOWN	
	Cardiac Arrest		Glucotrol Xl	C			UNKNOWN	
	Cardiomegaly		Glucovance	C			UNKNOWN	
	Cellulitis		Enalapril Maleate	C			UNKNOWN	323 DAY
	Joint Sprain		Accupril	C			UNKNOWN	418 DAY

	Skin Ulcer		Benzonatate	C		
UNKNOWN						
	Ventricular Fibrillation					
	Weight Increased					

Date:01/10/05ISR Number: 4548989-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00098
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dyspnoea		Hydrocortone	C		
UNKNOWN						
	Speech Disorder		Propranolol Hydrochloride	C		
UNKNOWN						
			Wellbutrin	C		
UNKNOWN						
			Flexeril	C		ORAL

Date:01/10/05ISR Number: 4548990-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00129
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Jaw Disorder		Methotrexate	C		
UNKNOWN						
	Oedema Peripheral					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4548992-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00124
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Grand Mal Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:01/10/05ISR Number: 4548994-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00104
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Zetia	C		ORAL		

Date:01/10/05ISR Number: 4548996-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00199
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:01/10/05ISR Number: 4548997-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00074
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Grand Mal Convulsion		Vancomycin	SS				
INTRAVENOUS							3	DAY
	Hypertension		Morphine	SS		ORAL		
	Leukoencephalopathy		Acetaminophen	SS		ORAL		
	Meningitis		Cefotaxime Sodium	SS				
INTRAVENOUS								
			Nefopam Hydrochloride	SS				
INTRAVENOUS								
			Troxerutin	C		ORAL		

			Etifoxine	C		ORAL
			Zolpidem Tartrate	C		ORAL

Date:01/10/05ISR Number: 4549007-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00096
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Darvocet-N	C		
UNKNOWN						
Initial or Prolonged			[Therapy			
Disability			Unspecified]	C		
UNKNOWN						

Date:01/10/05ISR Number: 4549009-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
2 YR						
	Dyspnoea		Aspirin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4549010-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549011-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00201
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549013-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00250
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bronchitis		Hyzaar	C		ORAL		
	Chest Pain		Paxil	C				
UNKNOWN								
	Dyspnoea		Xanax	C				
UNKNOWN								

Date:01/10/05ISR Number: 4549014-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00261
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hot Flush		Methotrexate	C				
UNKNOWN								
	Palpitations		Nexium	C				
UNKNOWN								

	Pollakiuria		Salagen Tablets	C		
UNKNOWN						

Date:01/10/05ISR Number: 4549015-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00214
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Eye Disorder		[Therapy					
	Musculoskeletal Stiffness		Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:01/10/05ISR Number: 4549017-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
732 DAY								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4549019-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00206
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Micronase	C				
UNKNOWN								

Date:01/10/05ISR Number: 4549021-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00450
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:01/10/05ISR Number: 4549022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Death							
	Myocardial Infarction							

Date:01/10/05ISR Number: 4549026-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Impaired Work Ability							
	Loss Of Employment							
	Myocardial Infarction							

Date:01/10/05ISR Number: 4549028-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549030-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00510
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leg Amputation Musculoskeletal Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4549032-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00512
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Chest Pain Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549033-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549035-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549037-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549038-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00515
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549043-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549048-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00415
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549049-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/10/05ISR Number: 4549050-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549051-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00536
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549076-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01349
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Drug Reaction Cardiac Failure Congestive Waldenstrom'S Macroglobulinaemia		Vioxx Antineoplastic (Unspecified)	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:01/10/05ISR Number: 4549077-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00518
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/10/05ISR Number: 4549078-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00444
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged Disability	Chest Pain Feeling Abnormal Hypertension							

Date:01/10/05ISR Number: 4550405-3Report Type:Expedited (15-DaCompany Report #2004119665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Lock	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
	Myocardial Infarction							
	Pneumonia							
	Renal Disorder		Rofecoxib (Rofecoxib)	SS				
			Novolin 20/80 (Insulin Human, Insulin Isophane, Human Biosynthetic)	C				
			All Other Therapeutic Products (All Other Therapeutic					

Products) C

Date:01/10/05ISR Number: 4551784-3Report Type:Expedited (15-DaCompany Report #2005002092
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Colitis Erythema Gastritis Gastrointestinal Disorder Intestinal Perforation Monarthritis Peritonitis Pneumoperitoneum	Foreign Health Professional	Solu-Medrol (Methylprednisolone Sodium Succinate)	PS		INTRAVENOUS	60 MG (DAILY), INTRAVENOUS	
			Perindopril (Perindopril)	SS		ORAL	2 MG (DAILY), ORAL	
			Glyceryl Trinitrate (Glyceryl Trinitrate)	SS		TRANSDERMAL	10 MG (DAILY), TRANSDERMAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (DAILY), ORAL	
			Enbrel (Etanercept)	SS		SUBCUTANEOUS	25 MG (WEEKLY), SUBCUTANEOUSLY	
			Acetylsalicylate Lysine (Acetylsalicylate					

	Lysine)	SS	ORAL
160 MG			
(DAILY), ORAL			
	Amlodipine Besilate		
	(Amlodipine Besilate)	C	
	Verapamil Hydrochloride		
	(Verapamil Hydrochloride)	C	
	Simvastatin		
	(Simvastatin)	C	
	Rosuvastatin		
	(Rosuvastatin)	C	
	Methylprednisolone		
	(Methylprednisolone)	C	
	Hydroxychloroquine		
	(Hydroxychloroquine)	C	
	Aurotioprol		
	(Aurotioprol)	C	
	Methotrexate		
	(Methotrexate)	C	
	Nifuroxazide		
	(Nifuroxazide)	C	

				Trimebutine			
				(Trimebutine)	C		
				Ultralevure (Saccharomyces Boulardii)	C		
				Spasfon			
				(Phloroglucinol, Trimethylphloroglucinol)	C		

Date:01/10/05ISR Number: 4553843-8Report Type:Direct Company Report #CTU 236042
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx 25 Mg Merc	PS	Merc	ORAL	1 TAB	ONCE
	Blood Pressure Increased						DAILY	ORAL
	Feeling Abnormal							
	Pain							

Date:01/11/05ISR Number: 4549416-3Report Type:Expedited (15-DaCompany Report #200414349FR
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Claforan	PS	Aventis Pharmaceuticals Inc.		INTRAVENOUS	
	Encephalopathy							
	Hypertension		Vancomycine	SS			INTRAVENOUS	
	Leukoencephalopathy		Dafalgan	SS		ORAL		
	Meningitis		Vioxx	SS		ORAL		
	Nodal Rhythm		Morphine Chlorhydrate	SS		ORAL		
			Acupan	SS			INTRAVENOUS	
			Troxerutin	C				
			Stresam	C				
			Stilnox	C				

Date:01/11/05ISR Number: 4549533-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Discomfort		Premarin	C			UNKNOWN	
	Depression		Percocet	C			UNKNOWN	
	Dizziness							
	Drug Ineffective							
	Hypertension							
	Loss Of Consciousness							
	Myocardial Infarction							
	Pain In Extremity							
	Paraesthesia							
	Postoperative Infection							
	Staphylococcal Infection							
	Vitreous Floaters							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/05ISR Number: 4549545-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01379
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia							

Date:01/11/05ISR Number: 4549546-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00615
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
	Dizziness		[Composition Unspecified]	C				UNKNOWN

Date:01/11/05ISR Number: 4549547-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02942
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Coumadin	C				UNKNOWN
	Fall							
	Heart Rate Irregular							

Date:01/11/05ISR Number: 4549550-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0412CHE00023
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthroscopy	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		45 MON
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		

	Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
45 MON						
	Chest Pain		Omeprazole	C		ORAL
	Depressed Mood		Homeopathic			
	Dizziness		Medications			
	Dyspnoea		(Unspecified)	C		ORAL
	Fear					
	Headache					
	Knee Arthroplasty					
	Pain					
	Radicular Syndrome					

Date:01/11/05ISR Number: 4549551-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00033
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Hemiplegia		Tramadol			
			Hydrochloride	C		
UNKNOWN						

Date:01/11/05ISR Number: 4549552-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00053
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Gastric Ulcer Haemorrhage

Heart Rate Irregular

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	325 DAY		Celecoxib	C		
			Candesartan Cilexetil	C		
UNKNOWN						
			Valdecoxib	C		
UNKNOWN						

Date:01/11/05ISR Number: 4549553-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00031
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Insulin	C		
SUBCUTANEOUS						
	Electrocardiogram		Atorvastatin Calcium	C		ORAL
	Abnormal		Aspirin	C		ORAL
	Stent Occlusion		Nitroglycerin	C		
UNKNOWN						
			Omeprazole	C		ORAL
			Caffeine, Citrated And Nitroglycerin	C		
SUBLINGUAL						

Date:01/11/05ISR Number: 4549557-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00084M
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Drug Exposure During		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Pregnancy		Insulin	C		
UNKNOWN						
Initial or Prolonged	Myocardial Infarction					
Disability						

Date:01/11/05ISR Number: 4549559-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00085
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Diovan	C				
UNKNOWN								
Other	Drug Intolerance		Norvasc	C				
UNKNOWN								

Date:01/11/05ISR Number: 4549560-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00159
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Bextra	C				
UNKNOWN								
Initial or Prolonged			Nexium	C				
UNKNOWN								
Disability								

Date:01/11/05ISR Number: 4549561-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00034
Age:68 YR Gender:Male I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
Other	Death
	Fall

Heart Rate Irregular

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Coumadin	C			UNKNOWN	

Date:01/11/05ISR Number: 4549562-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00073
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Breast Operation							
	Myocardial Infarction							
	Thrombosis							

Date:01/11/05ISR Number: 4549563-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00158
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549564-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00182
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549565-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00084B1
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc			

Life-Threatening Hospitalization - Initial or Prolonged Disability	Drug Exposure During Pregnancy		Insulin	C

Date:01/11/05ISR Number: 4549566-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549567-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00161
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/11/05ISR Number: 4549568-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00575
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL		25 DAY
Initial or Prolonged		Professional	Vioxx	SS	Merck & Co., Inc	ORAL		
			Esomeprazole Magnesium	C				UNKNOWN
			Enalapril Maleate	C		ORAL		

Date:01/11/05ISR Number: 4549569-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00346
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prilosec	C				UNKNOWN
Initial or Prolonged			Avandia	C				UNKNOWN
Disability			Lipitor	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:01/11/05ISR Number: 4549570-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00513
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549572-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00425
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

	Ocular Vascular Disorder		Percocet	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						

Date:01/11/05ISR Number: 4549573-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00255
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident					
Initial or Prolonged	Diabetes Mellitus					
Disability	Hallucination					

Date:01/11/05ISR Number: 4549574-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00408
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Disease		Toprol Xl Tablets	C		
UNKNOWN						
	Chest Pain					
	Coronary Artery Disease					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/05ISR Number: 4549575-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00349
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Systolic Increased							
	Dysuria							
	Fluid Retention							
	Headache							
	Joint Swelling							
	Urinary Retention							

Date:01/11/05ISR Number: 4549576-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00418
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertension							

Date:01/11/05ISR Number: 4549577-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00487
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged								

Date:01/11/05ISR Number: 4549578-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00441
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Hospitalization -	Palpitations	Allegra	C
UNKNOWN			
Initial or Prolonged		Amitriptylin	C
UNKNOWN			
		Asacol	C
UNKNOWN			
		Atenolol	C
UNKNOWN			
		Detrol	C
UNKNOWN			
		Estratest H.S.	C
UNKNOWN			
		Nexium	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Ultracet	C
UNKNOWN			
		Zoloft	C
UNKNOWN			
		Oruvail	C
UNKNOWN			

Date:01/11/05ISR Number: 4549762-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anxiety
Disability	Arthralgia
	Back Pain
	Benign Prostatic
	Hyperplasia
	Cholecystitis

		Cholelithiasis					
		Chronic Sinusitis					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Gout		Vioxx	SS	Merck & Co., Inc	ORAL
		Hodgkin'S Disease		Claritin-D	C		
UNKNOWN							
		Inguinal Hernia		Flomax (Tamsulosin			
		Myalgia		Hydrochloride)	C		
UNKNOWN							
		Myopathy		Flonase	C		
UNKNOWN							
		Prostatic Specific		Diazepam	C		
UNKNOWN							
		Antigen Increased		Plendil	C		
UNKNOWN							
		Rectal Examination		Pravachol	C		
UNKNOWN							
		Abnormal		Wellbutrin	C		
UNKNOWN							
		Renal Failure					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Tension Headache					

Date:01/11/05ISR Number: 4549763-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Distension	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Abdominal Pain	Professional				
Other		Anaemia					
		Angina Unstable					
		Asthenia					
		Asthma					
		Bronchitis					
		Cardiomegaly					
		Carotid Artery Stenosis					
		Cerebrovascular Accident					

Constipation
Contusion
Dehydration
Dementia Alzheimer'S Type
Dizziness
Gastritis
Glaucoma
Goitre
Headache
Hepatocellular Damage
Hypoglycaemia
Insomnia
Osteoporosis
Parkinson'S Disease
Renal Failure
Rheumatoid Arthritis
Thyroid Neoplasm
Transient Ischaemic
Attack
Urinary Incontinence
Urinary Tract Infection
Vertigo
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/05ISR Number: 4549776-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02036
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Pravachol	C			UNKNOWN	
			Gemfibrozil	C			UNKNOWN	
			Protonix	C			UNKNOWN	

Date:01/11/05ISR Number: 4549780-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00609
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Insulin	C			UNKNOWN	
	Dyspnoea		Prednisone	C			UNKNOWN	
	Vomiting		Isosorbide Dinitrate	C			UNKNOWN	
			Acetylcysteine	C			UNKNOWN	
			Enalapril Maleate	C			UNKNOWN	

Date:01/11/05ISR Number: 4549781-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02417
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bite		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Actal	C			UNKNOWN	
Other	Drug Ineffective		Avandia	C			UNKNOWN	
	Facial Pain		Glyburide	C			UNKNOWN	

Hallucination, Visual
Headache
Hypoaesthesia
Medication Error
Neck Pain
Rash Maculo-Papular
Skin Discolouration

Date:01/11/05ISR Number: 4549782-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00705
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Nexium	C				
UNKNOWN								
Initial or Prolonged	Overdose		Vicodin Tablets	C		ORAL		
Disability			Naproxen	C				
UNKNOWN								

Date:01/11/05ISR Number: 4549784-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00984
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Hydrochlorothiazide	C				
UNKNOWN								
Initial or Prolonged			Lipitor	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								
			Flovent	C				
UNKNOWN								
			Serevent	C				
UNKNOWN								

			Albuterol	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Centrum	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						
			Metoclopramide Hydrochloride	C		
UNKNOWN						

Date:01/11/05ISR Number: 4549785-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00344
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Av Dissociation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hyperthyroidism					
Disability	Syncope					

Date:01/11/05ISR Number: 4549788-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01583
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Albuterol	C		
UNKNOWN						
Disability	Congestive		Atrovent	C		
UNKNOWN						
Other	Chronic Obstructive		Prednisone	C		
UNKNOWN						
	Pulmonary Disease		Coumadin	C		
UNKNOWN						
	Dyspnoea		Captopril	C		
UNKNOWN						
			Duoneb	C		
UNKNOWN						
			Restoril	C		
UNKNOWN						

			Oxygen	C		
UNKNOWN						

Date:01/11/05ISR Number: 4549789-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00008
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Congenital Anomaly		Vioxx	PS	Merck & Co., Inc	
11 DAY						
Congenital Anomaly	Drug Exposure During Pregnancy		Fluticasone Propionate And Salmeterol Xinafoate	SS		
	Flat Feet					
32 DAY						
	Spina Bifida		Fusidate Sodium	SS		
8 DAY						
	Spinal Disorder		Pantoprazole	SS		
15 DAY						
			Prednisolone	C		
5 DAY						
			Cefuroxime	C		
7 DAY						
			Ritiometan Magnesium	C		
			Biclotymol	C		
			Ambroxol	C		
			Acetaminophen And Caffeine And Propoxyphene Hydrochloride	C		

Date:01/11/05ISR Number: 4549791-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00213
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Chest Pain
	Dyspnoea

		Faecal Incontinence Fluid Retention Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Lotrel	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Pantoloc	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Nitro-Bid	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							

Date:01/11/05ISR Number: 4549792-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01491
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Hypoaesthesia		[Therapy Unspecified]	C		
Disability		Loss Of Consciousness					
UNKNOWN							
		Osteoarthritis		Estrogens (Unspecified)	C		
UNKNOWN							
				Diuretic (Unspecified)	C		
UNKNOWN							

Date:01/11/05ISR Number: 4549795-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00002
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Convulsion		Sotalol					
Other	Myocardial Infarction		Hydrochloride	C		ORAL		
	Ventricular Arrhythmia		Aspirin And					
			Magnesium Oxide	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:01/11/05ISR Number: 4549796-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02232
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization -	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Disorientation		Atenolol	C				UNKNOWN
Disability	Dizziness		Ambien	C				UNKNOWN
	Gastric Disorder		Diovan	C				UNKNOWN
	Loss Of Consciousness		Nitroglycerin	C				UNKNOWN
	Palpitations		Tamoxifen Citrate	C				UNKNOWN
	Stomach Discomfort		Protonix	C				UNKNOWN
	Syncope		Morphine Sulfate	C				UNKNOWN
	Transient Ischaemic Attack							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/05ISR Number: 4549797-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00087
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:01/11/05ISR Number: 4549798-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00088
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Hypotension		Piritramide	C		ORAL	1	DAY
	Urticaria		Prilocaine Hydrochloride	C				
UNKNOWN							1	DAY

Date:01/11/05ISR Number: 4549799-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549800-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00684
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pulmonary Disease		Norco	C				
UNKNOWN								
	Coronary Artery Disease		Zestril	C				
UNKNOWN								
	Coronary Artery Occlusion		Indapamide	C				
UNKNOWN								

Hypertensive Heart
Disease

Date:01/11/05ISR Number: 4549801-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00080
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549802-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Prevacid	C				
UNKNOWN								
Disability			Ranitidine	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								

Date:01/11/05ISR Number: 4549803-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03233
Age:67 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Dyspnoea		Synthroid	C			UNKNOWN	
		Provera	C			UNKNOWN	
		Premarin	C			UNKNOWN	
		Prilosec	C			UNKNOWN	
		Lipitor	C			UNKNOWN	
		Hydrochlorothiazide And Triamterene	C			UNKNOWN	

Date:01/11/05ISR Number: 4549804-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00615
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549805-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00682
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549806-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00608
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549808-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549809-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549810-0Report Type:Expedited (15-DaCompany Report #HR-MERCK-0501HUN00007
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	819 DAY	
Hospitalization - Initial or Prolonged	Chest Pain							
Disability	Dyspnoea							
	Fatigue							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/11/05ISR Number: 4549812-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00630
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/11/05ISR Number: 4549813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00556
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Carpal Tunnel Syndrome							
Other	Dizziness							
	Feeling Abnormal							
	Intracardiac Thrombus							
	Surgery							
	Thrombosis							

Date:01/11/05ISR Number: 4549820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00696
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/11/05ISR Number: 4550291-1Report Type:Direct Company Report #CTU 236139
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Disease		Vioxx -25 Mg	PS			1 DAILY	
Hospitalization - Initial or Prolonged	Cardiac Aneurysm							
Required	Cardiac Disorder							
Intervention to	Cardiac Stress Test							
Prevent Permanent	Abnormal							
	Cardiovascular Disorder							

Impairment/Damage	Drug Hypersensitivity Life Expectancy Shortened Myocardial Infarction Procedural Complication

Date:01/11/05ISR Number: 4550317-5Report Type:Direct Company Report #CTU 236141
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS			12.5 MG TAB	
Initial or Prolonged	Blindness Transient						DAILY	
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/12/05ISR Number: 4550188-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02010
Age: Gender:Female I/FU:F

Outcome	PT
Other	Blindness Unilateral Transient Ischaemic

	Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
		Consumer	Vioxx	PS	Merck & Co., Inc	ORAL	

Date:01/12/05ISR Number: 4550189-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00082
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Hypercholesterolaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Venous Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL	

Date:01/12/05ISR Number: 4550190-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03837
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Balance Disorder	Health	Vioxx	PS	Merck & Co., Inc	ORAL	3 MON
	Pain In Extremity	Professional	Vioxx	SS	Merck & Co., Inc	ORAL	3 MON
			Nexium	C			UNKNOWN
			Warfarin	C			UNKNOWN
			Pravachol	C			UNKNOWN
			Diovan	C			UNKNOWN
			Hydroxychloroquine Sulfate	C			UNKNOWN
			Neurontin	C			UNKNOWN
			Probenecid	C			UNKNOWN

Date:01/12/05ISR Number: 4550191-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Amnesia
	Apnoea
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Blood Pressure Decreased
	Cardiac Failure
	Congestive
	Cerebellar Syndrome
	Cerebral Haemorrhage
	Chondromalacia
	Confusional State
	Convulsion
	Coronary Artery Disease
	Deafness Neurosensory
	Dehydration
	Depression
	Diabetes Mellitus
	Drug Ineffective
	Dysphagia
	Dyspnoea

		Ejection Fraction Decreased					
		Embolic Cerebral Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
100	DAY		Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Fibrous Histiocytoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Gastritis Haemorrhagic		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Neurontin	C		
UNKNOWN							
		Hiatus Hernia		Prilosec	C		
UNKNOWN							
		Hypermetropia		Glucosamine	C		
UNKNOWN							
		Hypertension					
		Inner Ear Disorder					
		Leukocytosis					
		Loss Of Consciousness					
		Meniscus Lesion					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Oedema					
		Osteonecrosis					
		Pain					
		Pneumonia Escherichia					
		Presbyopia					
		Prothrombin Time Prolonged					
		Pupillary Disorder					
		Renal Failure Acute					
		Respiratory Failure					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Transient Ischaemic Attack					
		Tremor					
		Tricuspid Valve Incompetence					
		Varicose Vein					
		Ventricle Rupture					
		Ventricular Tachycardia					
		Vertigo Positional					

Date:01/12/05ISR Number: 4550192-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01612
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Nervous System Disorder		Zoloft	C				
UNKNOWN								
Initial or Prolonged			Seroquel	C				
UNKNOWN								
Disability								

Date:01/12/05ISR Number: 4550193-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00003
Age:69 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Blood Creatinine Increased
	Blood Urea Increased

	Coronary Artery Occlusion Dyspnoea Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Venous Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
			Hyzaar	C			UNKNOWN 9 YR
			Lansoprazole	C			UNKNOWN 11 YR
			Atorvastatin Calcium	C			UNKNOWN 7 YR
			Allopurinol	C			UNKNOWN 6 YR
			Atenolol	C			UNKNOWN 7 YR
			Levothyroxine Sodium	C			UNKNOWN 5 YR

Date:01/12/05ISR Number: 4550204-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:01/12/05ISR Number: 4550205-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00627
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C			UNKNOWN

Date:01/12/05ISR Number: 4550206-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00514
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550207-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550208-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00698
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:01/12/05ISR Number: 4550209-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00353
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4550211-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00697
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550212-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00707
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550213-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00704
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550214-5Report Type:Expedited (15-DaCompany Report #PR-MERCK-0501USA00644
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Damage Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550215-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00527
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Disability

Date:01/12/05ISR Number: 4550246-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02684
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		Hydrodiuril	C		ORAL		
	Sick Sinus Syndrome		Metoprolol	C				

UNKNOWN

Date:01/12/05ISR Number: 4550786-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00992
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Asthma
Disability	Cerebrovascular Accident
	Constipation
	Decubitus Ulcer
	Depression
	Hypothyroidism
	Muscle Spasms
	Pain In Extremity
	Pain In Jaw

		Proteinuria Stress Incontinence Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
227	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Vasotec	C		ORAL
				Prempro	C		
UNKNOWN		299 DAY					
				Allegra-D	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							
				Univasc	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							
				Claritin-D	C		
UNKNOWN							
				Cortisone (Cortisone Acetate)	C		
UNKNOWN							

Date:01/12/05ISR Number: 4550791-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00040
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gallbladder Disorder		Nexium	C		
UNKNOWN						
Other			Triphasil	C		
UNKNOWN						

Date:01/12/05ISR Number: 4550793-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Angina Pectoris
	Anxiety
	Aortic Disorder
	Arrhythmia
	Balance Disorder
	Bladder Pain
	Cough
	Cystitis
	Cystitis Noninfective
	Dermatitis
	Dermatitis Allergic
	Dermatophytosis
	Dizziness
	Duodenal Ulcer
	Dyspepsia
	Fall
	Gastric Disorder
	Gastric Ulcer
	Haematuria
	Headache
	Helicobacter Gastritis
	Hyperkeratosis
	Hypersensitivity
	Hypertonic Bladder
	Incontinence
	Intestinal Haemorrhage
	Intestinal Polyp

		Irritable Bowel Syndrome					
		Joint Sprain					
		Knee Deformity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ligament Sprain		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain					
		Pain In Extremity					
		Palpitations					
		Reflux Oesophagitis					
		Renal Pain					
		Tinea Pedis					
		Tinnitus					
		Ventricular Fibrillation					

Date:01/12/05ISR Number: 4550798-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00258
Age:44 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
		Inadequate Control		[Therapy			
		Diabetes Mellitus		Unspecified]	C		
UNKNOWN							
		Insulin-Dependent					
		Drowning					
		Road Traffic Accident					
		Ventricular Dysfunction					

Date:01/12/05ISR Number: 4550799-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02057
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
Disability		Liver Function Test		Combivent	C		
UNKNOWN							
		Abnormal					
		Palpitations					

Date:01/12/05ISR Number: 4550800-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
Other	Depression							
	Fall							
	Hemiparesis							
	Hyperlipidaemia							

Date:01/12/05ISR Number: 4550801-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4550804-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00010
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebral Atrophy		Metoprolol Tartrate	C				
			Amiloride Hydrochloride And Hydrochlorothiazide	C			UNKNOWN	

Date:01/12/05ISR Number: 4550805-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01669
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Swelling		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Disability			Norco	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:01/12/05ISR Number: 4550807-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00006
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blister		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
Initial or Prolonged	Impaired Healing		Warfarin Sodium	C			UNKNOWN	
Disability	Leg Amputation		Furosemide	C			UNKNOWN	
	Skin Discolouration		Spironolactone	C			UNKNOWN	
	Skin Ulcer		Vasotec	C			UNKNOWN	
	Wound Secretion		Sotalol					

Hydrochloride C
UNKNOWN

Date:01/12/05ISR Number: 4550808-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01477
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vytorin	C				
UNKNOWN								
	Paraesthesia		Lexapro	C				
UNKNOWN								
	Rash Generalised		Nexium	C				
UNKNOWN								
	Treatment Noncompliance							

Date:01/12/05ISR Number: 4550809-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Arrhythmia
Other	Arthralgia
	Back Pain
	Cerebrovascular Accident
	Colitis
	Colonic Polyp
	Dyspepsia
	Dysphonia
	Dyspnoea
	Emotional Distress
	Exostosis
	Fatigue

		Feeling Abnormal					
		Heart Rate Irregular					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Protrusion		Aspirin	C		ORAL
		Irritable Bowel Syndrome		Motrin	C		ORAL
		Joint Stiffness		Tylenol	C		ORAL
		Joint Swelling		Butalbital	C		ORAL
		Musculoskeletal		Guaifenex	C		ORAL
		Discomfort		Clidinium Bromide	C		ORAL
		Neck Pain		Estropipate	C		ORAL
		Radiculopathy		Claritin-D	C		ORAL
		Spinal Column Stenosis		Skelaxin	C		ORAL
		Spinal Cord Compression		Ketoconazole	C		ORAL
		Swelling		Prednisone	C		ORAL
		Vocal Cord Thickening		Biaxin	C		ORAL
		Weight Decreased		Diflucan	C		
UNKNOWN							
		Weight Increased		Trimox	C		ORAL
				Hydrocodone Bitartrate	C		ORAL
				Diovan	C		ORAL

Date:01/12/05ISR Number: 4550811-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02635
Age:74 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
2 YR							
		Extrasystoles		Micronase	C		
UNKNOWN							
		Faecal Occult Blood Positive					
		Gastrointestinal Haemorrhage					
		Gastrointestinal Ulcer					
		Hiatus Hernia					
		Ulcer					

Date:01/12/05ISR Number: 4550820-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00474
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Tramadol Hydrochloride	C				
UNKNOWN								
Disability			Alprazolam	C				
UNKNOWN								
			Ranitidine	C				
UNKNOWN								
			Lanoxin	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Zocor	C		ORAL		
			Lisinopril	C				
UNKNOWN								
			Citalopram	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4550821-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550822-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00565
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550826-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550827-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550829-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550830-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550831-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00588
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hot Flush		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia Oral		Corticosteroids (Unspecified)	C				
	Salivary Hypersecretion							
UNKNOWN								

Date:01/12/05ISR Number: 4550832-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550835-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00703
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder							
Initial or Prolonged	Coma							
Disability	Dyspnoea							
	Fatigue							
	Headache							
	Hypertension							
	Nausea							
	Palpitations							
	Ulcer Haemorrhage							
	Vomiting							

Date:01/12/05ISR Number: 4550836-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550837-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00684
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550839-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00385
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fatigue		Zocor	C		ORAL		
	Gastrooesophageal Reflux		Synthroid	C		ORAL		

	Disease		Lipitor	C		ORAL
	Haematuria		Niaspan	C		ORAL
	Liver Function Test		Zantac	C		
UNKNOWN						
	Abnormal		Prilosec	C		ORAL
	Malaise		Crestor	C		ORAL
	Osteoarthritis					
	Prostate Cancer					
	Thrombophlebitis					
	Wrist Fracture					

Date:01/12/05ISR Number: 4550840-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00586
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Vascular Rupture		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Keppra	C		
UNKNOWN						
			Cortef	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4550841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00614
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization - Initial or Prolonged	Dyspnoea Thrombosis		Calcium (Unspecified)	C				
UNKNOWN								
Disability								

Date:01/12/05ISR Number: 4550843-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00749
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		[Therapy Unspecified]	C				
Hospitalization - Initial or Prolonged								
UNKNOWN								

Date:01/12/05ISR Number: 4550844-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00624
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Date:01/12/05ISR Number: 4550845-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia Alzheimer'S Type		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550846-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00625
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive		Zocor	C		ORAL		
			Plavix	C				
			Aspirin	C				
			Labetalol Hydrochloride	C				

Date:01/12/05ISR Number: 4550847-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/12/05ISR Number: 4550873-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Amnesia

		Anxiety					
		Asthma					
		Back Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
252	DAY						
		Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
252	DAY						
		Increased		Seroquel	C		
UNKNOWN							
		Bronchitis Acute		Seroquel	C		
UNKNOWN							
		Chest Pain		Soma	C		
UNKNOWN							
		Chronic Obstructive		Premarin	C		
UNKNOWN							
		Pulmonary Disease		Ambien	C		
UNKNOWN							
		Coronary Artery Disease		Neurontin	C		
UNKNOWN							
		Coronary Artery Thrombosis		Potassium (Unspecified)	C		
UNKNOWN							
		Euthyroid Sick Syndrome		Aspirin	C		
UNKNOWN							
		Fibromyalgia		Folic Acid	C		
UNKNOWN							
		Gastroenteritis		Prevacid	C		
UNKNOWN							
		Haemorrhage		Toprol Xl Tablets	C		
UNKNOWN							
		Hallucination		Toprol Xl Tablets	C		
UNKNOWN			8 DAY				
		Headache		Plavix	C		
UNKNOWN							
		Herpes Simplex		Zocor	C		
UNKNOWN							
		Hyperlipidaemia		Lipitor	C		
UNKNOWN			112 DAY				
		Hypertension		Foltx	C		
UNKNOWN							
		Irritable Bowel Syndrome		Linseed Oil	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Nitroglycerin	C		
UNKNOWN							
		Nasal Disorder		Vicodin Tablets	C		
UNKNOWN							

	Nausea		Altace	C			
UNKNOWN							
	Neck Pain		Doxepin				
	Panic Disorder		Hydrochloride	C			
UNKNOWN							
	Sleep Apnoea Syndrome		Flexeril	C			ORAL
	Spondylolisthesis		Prozac	C			
UNKNOWN							
	Vascular Pseudoaneurysm		Prozac	C			
UNKNOWN							
			Prozac	C			
UNKNOWN							

Date:01/12/05ISR Number: 4553388-5Report Type:Expedited (15-DaCompany Report #2005005296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Abnormal	Foreign	Fragmin (Dalteparin)	PS		SUBCUTANEOUS	SUBCUTANEOUS	
Initial or Prolonged	Hepatocellular Damage	Health	Paracetamol					
	Hepatotoxicity	Professional	(Paracetamol)					
	Thrombocytopenia		(Paracetamol)	SS		ORAL	2 GRAM (1	
							GRAM, BID	
							INTERVAL:	
							DAILY), ORAL	
			Rofecoxib					
			(Rofecoxib)	SS		ORAL	50 MG (25 MG,	
							BID:	
							INTERVAL:	
							DAILY), ORAL	
			Diazepam (Diazepam)	C				
			Thiamine Hydrochloride (Thiamine Hydrochloride)	C				
			Haloperidol (Haloperidol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/12/05ISR Number: 4553785-8Report Type:Direct Company Report #CTU 236341
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Nausea Rash Upper Respiratory Tract Infection		Vioxx Merck And Co 25 Mg	PS	Merck And Co	ORAL	1 TAB ONCE DAILY ORALLY	Required
Intervention to Prevent Permanent Impairment/Damage								

Date:01/13/05ISR Number: 4551328-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02620
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Electrocardiogram Abnormal		[Therapy Unspecified]	C				
Hospitalization - Initial or Prolonged	Lung Neoplasm Malignant		Allopurinol	C				
Disability			[Therapy Unspecified]	C				
			Pepcid	C				
			Neurontin	C				
			Rezulin	C				
			Glucophage	C				
			Relafen	C				
			Prilosec	C				
			Potassium (Unspecified)	C				
			Lodine	C				

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN

			Furosemide	C			
UNKNOWN							

Date:01/13/05ISR Number: 4551332-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00502
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		587 DAY
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		587 DAY
Other	Diabetes Mellitus		Aspirin	C				
UNKNOWN								
	Non-Insulin-Dependent Gastritis		Bisoprolol Fumarate And Hydrochlorothiazide	C				
UNKNOWN								
	Hypertensive							
	Cardiomyopathy		Atorvastatin Calcium	C				
UNKNOWN								
	Myocardial Infarction							

Date:01/13/05ISR Number: 4551334-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00092
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:01/13/05ISR Number: 4551335-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00410
Age:47 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL	183	DAY
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL	183	DAY
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Plavix	C			UNKNOWN	
		Levothyroxine Sodium	C			UNKNOWN	
		Prilosec	C			UNKNOWN	
		Flexeril	C		ORAL		
		Flexeril	C		ORAL		
		Pravachol	C			UNKNOWN	
		Aspirin	C			UNKNOWN	
		Ascorbic Acid	C			UNKNOWN	
		Sinemet	C		ORAL		
		Clonazepam	C			UNKNOWN	
		Clonazepam	C			UNKNOWN	

Date:01/13/05ISR Number: 4551336-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01777
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Convulsion							
Initial or Prolonged	Myocardial Infarction							
Disability	Procedural Complication							
Other								

Date:01/13/05ISR Number: 4551339-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00563
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551341-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00561
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551349-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00043
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Deafness Unilateral Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4551350-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551351-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00679
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/13/05ISR Number: 4551353-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00576
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551356-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00595
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551357-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551421-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00562
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4551712-0Report Type:Expedited (15-DaCompany Report #FR-JNJFOC-20050101306
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pancreatitis Acute		Topalgic	PS				
OROPHARINGEAL								
Initial or Prolonged	Pancreatitis Necrotising		Efferalgan	SS				
OROPHARINGEAL								
			Deroxat	SS				
OROPHARINGEAL								
			Nexen	SS				
UNKNOWN								
			Vioxx	SS				
OROPHARINGEAL								
			Art 50	SS				
OROPHARINGEAL								

Date:01/13/05ISR Number: 4551717-XReport Type:Expedited (15-DaCompany Report #FR-JNJFOC-20050101830
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypothyroidism		Ixprim	PS				
OROPHARINGEAL								
Initial or Prolonged	Rash Papular		Vioxx	SS				
OROPHARINGEAL								
			Zoxon	SS				
OROPHARINGEAL								
			Atarax	SS				
OROPHARINGEAL								

INTRAVENOUS	Cordarone	SS
OROPHARINGEAL	Serc	SS
OROPHARINGEAL	Fozitec	C
OROPHARINGEAL	Catapressan	C
OROPHARINGEAL	Amlor	C
UNKNOWN	Elisor	C
UNKNOWN	Havlane	C
UNKNOWN	Sintrom	C
UNKNOWN	Kaleorid	C

Date:01/13/05ISR Number: 4552029-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00349
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		923 DAY
Initial or Prolonged	Deep Vein Thrombosis		Atorvastatin Calcium	C				UNKNOWN
Other			Bisoprolol Fumarate And Hydrochlorothiazide	C		ORAL		UNKNOWN
			Allopurinol	C				UNKNOWN
			Molsidomine	C				UNKNOWN
			Isosorbide Mononitrate	C				UNKNOWN

Date:01/13/05ISR Number: 4552033-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01486
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	138 DAY	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	138 DAY	
	Arrhythmia		Cardizem	C			UNKNOWN	
	Cardiac Failure		Lasix (Furosemide)	C			UNKNOWN	
	Congestive		Tylenol	C			UNKNOWN	
	Chest Pain		[Therapy Unspecified]	C			UNKNOWN	
	Constipation							
	Dizziness		Terazosin Hydrochloride	C			UNKNOWN	
	Feeling Hot							
	Hyperhidrosis		Epogen	C			UNKNOWN	
	Ingrowing Nail		Infed	C			UNKNOWN	
	Malaise		Zemplar	C			UNKNOWN	
	Onychomycosis		Phoslo	C			UNKNOWN	
	Palpitations		Digoxin	C			UNKNOWN	48 DAY
	Papilloma		Digoxin	C			UNKNOWN	
	Renal Failure Chronic		Digoxin	C			UNKNOWN	
	Skin Lesion		Apresoline	C			UNKNOWN	
	Urinary Tract Infection							

Date:01/13/05ISR Number: 4552038-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02515
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization - Initial or Prolonged	Infarction
	Acute Respiratory Failure
	Anxiety
	Aortic Valve Incompetence
	Arthritis
	Cardiac Arrest

		Coma					
		Convulsion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
274	DAY						
		Hypoxic Encephalopathy		Albuterol	C		
UNKNOWN							
		Mitral Valve Incompetence		Prozac	C		
UNKNOWN							
		Tenosynovitis		Premarin	C		
UNKNOWN							
		Ventricular Fibrillation		Ativan	C		
UNKNOWN							
				Ecotrin	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Zocor	C		ORAL

Date:01/13/05ISR Number: 4552043-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
Initial or Prolonged		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
Disability		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Emotional Distress		Aspirin	C		
UNKNOWN							
		Foot Fracture		Echinacea	C		
UNKNOWN		1483 DAY					
		Gastrooesophageal Reflux Disease		Cyclobenzaprine Hydrochloride	C		
UNKNOWN							

	Intervertebral Disc Degeneration	Dicyclomine Hydrochloride	C
UNKNOWN			
	Intervertebral Disc	Nexium	C
UNKNOWN			
	Protrusion Ligament Injury Malaise Migraine Mitral Valve Prolapse Nasal Congestion Nausea Pain Pharyngitis Pharyngolaryngeal Pain Small Intestinal Ulcer Haemorrhage Upper Respiratory Tract Infection		

Date:01/13/05ISR Number: 4552044-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain Bipolar I Disorder
Disability	Bladder Disorder
Other	Body Tinea Cerebral Artery Embolism Cerebral Artery Occlusion Chest Pain Chronic Fatigue Syndrome Depression Dyspnoea

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Fall Hemiparesis Hypoaesthesia					
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
38 DAY							
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
38 DAY							
		Loss Of Consciousness		Nizatidine	C		
UNKNOWN							
		Migraine		Klonopin	C		
UNKNOWN							
		Myocardial Infarction Neuropathic Pain		Trazodone Hydrochloride	C		
UNKNOWN							
		Rash		Seroquel	C		
UNKNOWN							
		Renal Failure Acute		Prozac	C		
UNKNOWN							
		Temperature Intolerance		Propranolol Hydrochloride	C		
UNKNOWN							
				Zocor	C		ORAL
809 DAY							
				Zocor	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN		473 DAY					
				Avonex	C		
INTRAMUSCULAR							
				Prochlorperazine	C		
UNKNOWN							
				Alprazolam	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN		976 DAY					
				Hydrocodone Bitartrate	C		
UNKNOWN		663 DAY					
				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN		840 DAY					
				Estraderm	C		
UNKNOWN		409 DAY					
				Duradrin	C		
UNKNOWN							

			Methotrexate	C		
UNKNOWN						
			Indomethacin	C		
UNKNOWN						
			Klor-Con	C		
UNKNOWN						
			Benadryl	C		
UNKNOWN						
			Zyprexa	C		ORAL
			Vitamin E	C		ORAL

Date:01/13/05ISR Number: 4552051-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		611 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		611 DAY
Initial or Prolonged	Bipolar Disorder		Ativan	C				UNKNOWN
Disability	Blood Cholesterol		Hydrochlorothiazide	C				UNKNOWN
	Increased Blood Triglycerides		Hydrocodone Hydrochloride	C				UNKNOWN
	Increased		Maxzide	C				UNKNOWN
	Cervicobrachial Syndrome		Neurontin	C				UNKNOWN
	Diarrhoea		Remeron	C				UNKNOWN
	Emotional Distress Fatigue		Trazodone Hydrochloride	C				UNKNOWN
	Intervertebral Disc		Tricor	C				UNKNOWN
	Degeneration		Zanaflex	C				UNKNOWN
	Menstrual Disorder		Midrin	C				UNKNOWN
	Myofascial Pain Syndrome		Lidoderm	C				UNKNOWN
	Nerve Injury Oedema Peripheral Pelvic Pain Renal Failure Tibia Fracture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4552054-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00074
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Morphine	SS		ORAL		
	Meningitis		Cefotaxime Sodium	SS			INTRAVENOUS	
			Nefopam Hydrochloride	SS			INTRAVENOUS	
			Vancomycin	SS			INTRAVENOUS	3 DAY
			Acetaminophen	SS		ORAL		
			Troxerutin	C		ORAL		
			Etifoxine	C		ORAL		
			Zolpidem Tartrate	C		ORAL		

Date:01/13/05ISR Number: 4552056-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00510
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure		Theophylline	C			UNKNOWN	
	Fluctuation		Albuterol	C			UNKNOWN	
	Headache		Budesonide And Formoterol Fumarate	C			UNKNOWN	
			Moxonidine	C			UNKNOWN	
			Indapamide	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Nitrendipine	C			UNKNOWN	

Date:01/13/05ISR Number: 4552058-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL		89 DAY
Initial or Prolonged	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
Other	Gastrooesophageal Reflux		Humulin N	C				UNKNOWN
	Disease		Humulin R	C				UNKNOWN
	Insomnia		Naproxen	C		ORAL		
	Ischaemic Stroke		Naproxen	C		ORAL		
	Nervousness		Livostin	C				OPHTHALMIC
	Neuropathy Peripheral		Prevacid	C		ORAL		
	Oedema Peripheral		Vasotec	C				UNKNOWN
	Pain In Extremity							
	Pollakiuria							
	Sinus Congestion							
	Sleep Apnoea Syndrome							
	Ventricular Hypertrophy							

Date:01/13/05ISR Number: 4552064-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00145
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain							
	Coronary Artery Disease							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4552066-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00082
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							
	Hypertensive Crisis							
	Mucous Membrane Disorder							
	Myocardial Infarction							
	Reflux Oesophagitis							
	Sinoatrial Block							

Date:01/13/05ISR Number: 4552068-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00104
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Sulfasalazine	C			UNKNOWN	
	Myocardial Infarction		Prednisolone	C			UNKNOWN	
	Visual Disturbance		Mesalamine	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	

Date:01/13/05ISR Number: 4552069-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04115
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Valium	C			UNKNOWN	
	Palpitations							
	Syncope							
	Vomiting							

Date:01/13/05ISR Number: 4552070-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02766
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum		Allegra	C				
Disability	Gastrooesophageal Reflux		Prilosec	C				
	Disease		Toprol Xl Tablets	C				
	Ulcer		Flonase	C				
			Allergenic Extract	C				

Date:01/13/05ISR Number: 4552071-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4552073-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00030
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL	18 DAY	
			Diclofenac Sodium And Misoprostol	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4552074-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00119
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C		ORAL		
			Ramipril	C		ORAL		
			Magnesium Oxide	C		ORAL		
			Simvastatin	C		ORAL		

Date:01/13/05ISR Number: 4552076-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01989
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive							
	Cerebrovascular Accident							
	Chronic Obstructive Pulmonary Disease							
	Congestive Cardiomyopathy							
	Hypertension							
	Mitral Valve Incompetence							
	Sick Sinus Syndrome							

Date:01/13/05ISR Number: 4552078-2Report Type:Expedited (15-DaCompany Report #EC-MERCK-0411PER00015
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tachycardia		Prednisone	C		ORAL		
			Enalapril Maleate	C		ORAL		

Date:01/13/05ISR Number: 4552080-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00882
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4552081-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR

Date:01/13/05ISR Number: 4552083-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00887
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/13/05ISR Number: 4552084-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00755
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1076 DAY	
Hospitalization - Initial or Prolonged	Palpitations		Imuran (Azathioprine)	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

Date:01/13/05ISR Number: 4552085-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4552088-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:01/13/05ISR Number: 4552090-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4552092-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/13/05ISR Number: 4553894-3Report Type:Direct Company Report #CTU 236630
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS		ORAL	12.5 ML DAILY	
Hospitalization - ORAL								
Initial or Prolonged								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/14/05ISR Number: 4552852-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00638
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Disability	Asthma
Other	Back Injury

		Back Pain					
		Cardiac Failure					
		Congestive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cataract		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Norflex	C		
UNKNOWN							
		Disease		Polaramine	C		
UNKNOWN							
		Glaucoma		Alprazolam	C		
UNKNOWN							
		Hallucination, Auditory		Nitroquick	C		
UNKNOWN							
		Hypertension		Pepcid	C		
UNKNOWN							
		Hypokalaemia		Diovan Hct	C		
UNKNOWN							
		Limb Injury		K-Dur	C		ORAL
		Musculoskeletal Pain		Fosamax	C		
UNKNOWN							
		Oedema Peripheral		Pravachol	C		
UNKNOWN							
		Peripheral Vascular		Volmax	C		ORAL
		Disorder		Albuterol	C		
UNKNOWN							
		Syncope		Prevacid	C		ORAL
		Venous Stasis		Accolate	C		ORAL
		Ventricular Extrasystoles					

Date:01/14/05ISR Number: 4552856-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00411
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Neurodermatitis					
		Skin Disorder					

Date:01/14/05ISR Number: 4552858-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00052
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacteria Urine No		Vioxx	PS	Merck & Co., Inc	ORAL		
	Organism Observed		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Alkaline		Vioxx	SS	Merck & Co., Inc	ORAL		
	Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Lactate		Alendronate Sodium	C		ORAL		
	Dehydrogenase Increased		Calcium					
	Carotid Artery Atheroma		(Unspecified) And					
	Cerebral Artery Occlusion		Vitamin D					
	Cerebral Infarction		(Unspecified)	C		ORAL		
	Cerebral Ischaemia							
	Patella Fracture							
	Pyuria							
	Supraventricular							
	Tachycardia							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/05ISR Number: 4552859-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Phlebothrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Prednisone	C		ORAL		
Disability			Bisoprolol Fumarate	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Heparin	C		PARENTERAL	24 DAY	
			Amikacin Sulfate	C		ORAL		
			Ibuprofen	C		ORAL		23 DAY
			Gabapentin	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		882 DAY

Date:01/14/05ISR Number: 4552861-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00436
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		26 DAY
	Fatigue		Eprosartan Mesylate And Hydrochlorothiazide	C		UNKNOWN		

Date:01/14/05ISR Number: 4552863-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00432
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Overdose		Zolpidem Tartrate	C		ORAL		
	Transient Ischaemic		Ranitidine	C		ORAL		9 DAY

Attack

Date:01/14/05ISR Number: 4552864-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00747
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Confusional State		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Premarin	C		ORAL		
	Migraine		Paxil	C		ORAL		
	Transient Ischaemic Attack		Prilosec	C		ORAL		
			Lortab	C		ORAL		
			Zomig	C		ORAL		

Date:01/14/05ISR Number: 4552865-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00011
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
			Clopidogrel Bisulfate	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Bisoprolol Fumarate And					

Hydrochlorothiazide	C		ORAL
Furosemide Sodium	C		ORAL
Lisinopril	C		ORAL
Metformin Hydrochloride	C		ORAL
Sertraline Hydrochloride	C		ORAL
Insulin	C		

UNKNOWN

Date:01/14/05ISR Number: 4552866-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00001
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Myxoma		Vioxx	PS	Merck & Co., Inc	ORAL		820 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Methotrexate	SS				UNKNOWN
			Prednisolone	C				UNKNOWN
			Folic Acid	C				UNKNOWN
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN

Date:01/14/05ISR Number: 4552867-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00027
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Fluindione	SS		ORAL		

Aspartate Aminotransferase Increased
Atrial Fibrillation
Cardiac Failure
Chest Pain
Drug Interaction
Dyspnoea
Hepatic Pain

International Normalised
Ratio Increased
Oedema Peripheral

Date:01/14/05ISR Number: 4552868-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01180
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		14 DAY
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		14 DAY
			Aspirin	C				UNKNOWN

	Ritalin	C	
UNKNOWN			
	Lipitor	C	ORAL
	Tiazac	C	ORAL
	Tiazac	C	ORAL
	Hytrin	C	
UNKNOWN			
	Lopressor	C	ORAL
	Lopressor	C	ORAL
	Zoloft	C	ORAL

Date:01/14/05ISR Number: 4552869-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abscess
Other	Anaemia
	Angina Pectoris
	Anxiety
	Arthralgia
	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased
	Cardiomegaly
	Cerebrovascular Accident
	Condition Aggravated
	Conjunctivitis Allergic
	Convulsion
	Deep Vein Thrombosis
	Depressed Mood
	Diabetes Mellitus
	Non-Insulin-Dependent
	Diabetic Neuropathy
	Dyspnoea
	Ear Pain
	Fatigue
	Fear
	Goitre
	Haematoma
	Hallucination
	Headache
	Hepatic Steatosis
	Herpes Zoster
	Hypoglycaemia

Impaired Gastric Emptying
Injection Site
Haemorrhage
Irritability
Lipomatosis
Mastoiditis
Migraine
Mood Swings
Pain In Extremity
Peripheral Sensory
Neuropathy
Phlebitis
Rash
Retinopathy
Seasonal Allergy
Sinusitis
Strabismus

		Subcutaneous Abscess					
		Suicidal Ideation					
		Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thinking Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombophlebitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Superficial		Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Coumadin	C		
UNKNOWN							
		Attack		Risperdal	C		
UNKNOWN							
		Urinary Tract Infection		Prozac	C		
UNKNOWN							
		Vaginal Haemorrhage		Elavil	C		ORAL
		Vertigo		Effexor	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							

Date:01/14/05ISR Number: 4552872-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00757
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL

Date:01/14/05ISR Number: 4552874-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02130
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthralgia		Accupril	C		
UNKNOWN	2373 DAY					
Other	Atherosclerosis		Lipitor	C		
UNKNOWN	2371 DAY					
	Burning Sensation		Hydrochlorothiazide			
	Carotid Artery Stenosis		Tablets (Usp 23)	C		
UNKNOWN						

	Contusion		Sodium Folate	C		
UNKNOWN						
	Embolism					
	Exostosis					
	Eye Disorder					
	Haematoma					
	Haemorrhage					
	Hypertension					
	Injury					
	Ischaemia					
	Joint Dislocation					
	Laceration					
	Myocardial Ischaemia					
	Osteoarthritis					
	Pain					
	Plantar Fasciitis					
	Road Traffic Accident					
	Rotator Cuff Syndrome					
	Tracheal Disorder					
	Transient Ischaemic					
	Attack					

Date:01/14/05ISR Number: 4552875-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/05ISR Number: 4552877-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00283
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acquired Diaphragmatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Eventration		Lasix (Furosemide)	C		ORAL		
Initial or Prolonged	Aortic Valve Sclerosis		Potassium					
Disability	Atrioventricular Block		(Unspecified)	C				
UNKNOWN								
	Second Degree		Metoprolol	C				
UNKNOWN								
	Cardiac Failure		Naprosyn	C				
UNKNOWN								
	Congestive		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Coronary Ostial Stenosis							
	Mitral Valve Incompetence							
	Tricuspid Valve							
	Incompetence							
	Ventricular Hypokinesia							

Date:01/14/05ISR Number: 4552878-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00243
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
1688 DAY								
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
1688 DAY								
Initial or Prolonged	Loss Of Consciousness		Lexapro	C				
UNKNOWN								
Disability			Micardis	C				
UNKNOWN								
Other			Maxzide	C				
UNKNOWN								
			Trazodone					
			Hydrochloride	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								

			Skelaxin	C		
UNKNOWN						
			Klor-Con	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Ativan	C		
UNKNOWN						
			Dyazide	C		
UNKNOWN						

Date:01/14/05ISR Number: 4552879-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00079
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization - Initial or Prolonged	Colitis Disease Recurrence		Methylprednisolone Sodium Succinate	SS		INTRAVENOUS		9 DAY
	Gastritis					DRIP		9 YR
	Ileal Perforation		Perindopril Erbumine	SS		ORAL		TOPICAL
	Monarthritis		Nitroglycerin	SS				9 YR
	Peritonitis		Etanercept	SS		SUBCUTANEOUS		3 YR
	Pneumoperitoneum		Aspirin Lysine	SS		ORAL		9 YR
			Verapamil Hydrochloride	C		ORAL		
			Rosuvastatin Calcium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/05ISR Number: 4552881-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00721
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552882-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552883-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00276
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:01/14/05ISR Number: 4552884-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00130
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552885-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00659
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Myocardial Infarction		Glucovance	C		
Initial or Prolonged UNKNOWN			Actos	C		
Disability UNKNOWN			Codeine	C		
			Darvocet-N	C		
UNKNOWN						

Date:01/14/05ISR Number: 4552887-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02616
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
Other	Peritonitis		Coversyl	SS		ORAL		
	Pneumoperitoneum		Solu-Medrol	SS				
UNKNOWN								
	Small Intestinal		Diafusor	SS				
UNKNOWN								
	Perforation		Enbrel	SS				
UNKNOWN							1168	DAY
			Kardegic	SS				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN							7	DAY

Date:01/14/05ISR Number: 4552889-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/14/05ISR Number: 4552890-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc		UNKNOWN	3 YR

Date:01/14/05ISR Number: 4552892-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552894-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00880
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552895-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00782
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552897-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/14/05ISR Number: 4552898-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1186 DAY
Other	Death							

Date:01/14/05ISR Number: 4552907-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/14/05ISR Number: 4553801-3Report Type:Direct Company Report #CTU 236902
Age:50 YR Gender:Male I/FU:I

Outcome	PT
Other	Chest Pain
	Fatigue
	Headache
	Loss Of Consciousness
	Muscle Spasms

	Pain						
	Renal Pain						
		Report Source	Product		Role	Manufacturer	Route
Dose	Duration						
			Vioxx		PS		
25 MG ONCE A							
DAY							

Date:01/14/05ISR Number: 4553823-2Report Type:Direct Company Report #CTU 236859
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product			Role	Manufacturer	Route
Dose	Duration							
Hospitalization -	Large Intestine		Vioxx	25mg	Merck	PS	Merck	ORAL
1 PO Q DAY								
Initial or Prolonged	Perforation							
Other								

Date:01/14/05ISR Number: 4553826-8Report Type:Direct Company Report #CTU 236900
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Cerebrovascular Accident		Celebrex	PS		
100 MG ONCE						
	Dizziness					
DAILY						
	Reading Disorder		Vioxx	SS		
12.5 MG ONCE						
	Visual Acuity Reduced					
DAILY						
	Visual Field Defect		Synthroid	C		
			Centrum Silver	C		
			Glucosamine	C		
			Tussionex	C		

Date:01/18/05ISR Number: 4553889-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00827
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		
	Insomnia		Zetia	C				
			Zocor	C				
			Norvasc	C				
			Toprol Xl Tablets	C				

Date:01/18/05ISR Number: 4553890-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00067
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4553895-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4553923-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00007
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Lactate		Atorvastatin Calcium	C		ORAL
	Dehydrogenase Increased		Aspirin	C		ORAL
	Brain Stem Ischaemia		Esomeprazole			
	Cerebrovascular Accident		Magnesium	C		ORAL
	Low Density Lipoprotein Increased					

Date:01/18/05ISR Number: 4553935-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00501
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiomegaly					
	Hepatitis					
	Hypertensive Heart Disease					
	Sudden Death					

Date:01/18/05ISR Number: 4554002-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01480
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Wellbutrin	C		
UNKNOWN						
Disability			Potassium Chloride	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						

Date:01/18/05ISR Number: 4554007-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554015-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00890
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:01/18/05ISR Number: 4554016-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardio-Respiratory Arrest Chest Pain Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554017-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00648
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain
Other	Adhesion
	Adverse Event
	Aerophagia
	Anaphylactic Reaction
	Anxiety
	Arthralgia
	Arthropathy
	Asthenia
	Atherosclerosis
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Breast Pain
	Burning Sensation
	Chills
	Condition Aggravated
	Constipation
	Coronary Artery Atherosclerosis
	Cystitis
	Decreased Appetite
	Depressed Level Of Consciousness
	Depression
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Intolerance
	Dysphagia
	Dyspnoea
	Dysuria
	Ear Pain
	Erythema
	Family Stress
	Feeling Abnormal
	Flatulence
	Foreign Body Trauma
	Gastric Disorder

Gastrointestinal Motility
Disorder
Glossodynia
Headache
Helicobacter Infection
Hot Flush
Hyperchlorhydria
Hyperhidrosis
Hypersensitivity
Injury
Insomnia
Limb Discomfort
Limb Injury
Lipomatosis
Lymphadenopathy

		Malaise					
		Microcytic Anaemia					
		Migraine	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Multiple Allergies		Vioxx	PS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Congestion		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Polyps		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Septum Deviation		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Nasal Turbinate		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Promethazine	C		
UNKNOWN							
		Neck Pain		Furosemide	C		
UNKNOWN							
		Neuropathy Peripheral		Ambien	C		
UNKNOWN							
		Odynophagia		Alprazolam	C		
UNKNOWN							
		Oedema Peripheral		Aciphex	C		
UNKNOWN							
		Oesophageal Candidiasis		Prilosec	C		
UNKNOWN							
		Oesophagitis Ulcerative		Bel-Phen-Ergot S			
		Oral Candidiasis		Tabs	C		
UNKNOWN							
		Osteoarthritis		Butalbital	C		
UNKNOWN							
		Pain		Acetaminophen And			
		Pain In Extremity		Caffeine	C		
UNKNOWN							
		Palpitations		Buspar	C		
UNKNOWN							
		Pancreatic Insufficiency		[Therapy			
		Pancreatitis		Unspecified]	C		
UNKNOWN							
		Photosensitivity Reaction		Lipitor	C		
UNKNOWN							
		Pruritus		Premarin	C		
UNKNOWN							
		Pyrexia		Synthroid	C		
UNKNOWN							
		Refusal Of Treatment By		Estratest	C		
UNKNOWN							
		Patient		Indapamide	C		
UNKNOWN							

	Rheumatoid Arthritis		Dulcolax	C		
UNKNOWN						
	Rhinitis		Diflucan	C		
UNKNOWN						
	Sinusitis					
	Sjogren'S Syndrome					
	Stress					
	Subcutaneous Nodule					
	Syncope					
	Systemic Lupus					
	Erythematosus					
	Temporomandibular Joint					
	Syndrome					
	Thirst					
	Urethral Disorder					
	Urinary Tract Infection					
	Urine Flow Decreased					
	Vaginal Discharge					
	Vomiting					

Date:01/18/05ISR Number: 4554022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00421
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder		Synthroid	C				
UNKNOWN								
	Fall							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554023-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01422
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554026-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554028-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01436
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged								

Date:01/18/05ISR Number: 4554029-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00206
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	396	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL	396	DAY
			Celecoxib	C		ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:01/18/05ISR Number: 4554030-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01421
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00840
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Anaemia
	Burning Sensation
	Chest Pain
	Constipation
	Dermatitis Contact
	Diarrhoea
	Gastritis
	Gastrooesophageal Reflux Disease
	Hypertension
	Lumbar Spinal Stenosis
	Muscle Tightness

	Muscular Weakness						
	Myalgia						
	Nocturia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
			Premarin	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Hydrodiuril	C		ORAL		
			Aspirin	C			UNKNOWN	
			Biaxin Xl	C			UNKNOWN	

Date:01/18/05ISR Number: 4554032-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02666
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/18/05ISR Number: 4554033-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01034
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

Date:01/18/05ISR Number: 4554034-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00667
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Colonic Neoplasm		Norvasc	C			UNKNOWN	
	Colonic Polyp		Benicar	C			UNKNOWN	
	Fall		Synthroid	C			UNKNOWN	
	Neuropathy Peripheral		Sinemet	C			UNKNOWN	

Date:01/18/05ISR Number: 4554035-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03707
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atelectasis		Vioxx	PS	Merck & Co., Inc	ORAL		
1422 DAY								
Initial or Prolonged	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased							
	Cardiac Disorder							
	Chest Pain							
	Diastolic Dysfunction							
	Feeling Abnormal							
	Hiatus Hernia							
	Lipase Increased							
	Syncope							
	Thyroid Neoplasm							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554036-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554037-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01929
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
							3	YR
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
							23	DAY
	Ear Pain		Vioxx	SS		ORAL		
	Fatigue							
	Gastric Haemorrhage							
	Gout							
	Hypoaesthesia							
	Joint Injury							
	Limb Injury							
	Medication Error							
	Rhinitis Allergic							

Date:01/18/05ISR Number: 4554038-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04098
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Pepcid Ac	C		ORAL		
Initial or Prolonged	Atrial Fibrillation		Aspirin	C		ORAL		
	Coronary Artery Disease		Zantac	C		ORAL		
	Gastrooesophageal Reflux		Altace	C		ORAL		
	Disease		Toprol Xl Tablets	C		ORAL		
	Sinus Disorder		Lopid	C		ORAL		

	Transient Ischaemic		Norvasc	C		
UNKNOWN						
	Attack					
	Ventricular Dysfunction					

Date:01/18/05ISR Number: 4554039-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01418
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension					

Date:01/18/05ISR Number: 4554040-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Respiratory Failure
Other	Adverse Event
	Amnesia
	Angina Unstable
	Arthralgia

Arthropod Bite
Asthma
Blood Pressure Increased
Bronchitis
Cardiomegaly
Chronic Obstructive
Pulmonary Disease
Clumsiness
Convulsion
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Difficulty In Walking
Dizziness
Dysarthria
Dysphagia
Dysphonia
Dysuria
Encephalopathy
Fall
Foot Fracture
Fractured Coccyx
Gastrooesophageal Reflux
Disease
Haematuria
Head Injury
Headache
Hypercholesterolaemia
Hypertension
Hypertensive Crisis
Hypoaesthesia
Hypokalaemia
Hyponatraemia
Hypotension
Insomnia
Joint Sprain
Malaise
Mental Impairment
Mental Status Changes
Migraine
Mouth Cyst
Muscle Spasms
Muscle Twitching
Myalgia
Myocardial Infarction
Myoclonus
Nausea

Neck Pain
Neuropathy
Neuropathy Peripheral
Night Sweats
Orthostatic Hypotension
Osteoarthritis
Pain In Extremity
Palpitations
Paraesthesia
Respiratory Distress
Road Traffic Accident
Seborrhoeic Keratosis
Skeletal Injury
Skin Papilloma

		Sleep Walking					
		Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Urinary Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Urticaria					

Date:01/18/05ISR Number: 4554041-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Lymphocytic Leukaemia					
		Dermatitis Contact					
		Diarrhoea					
		Eructation					
		Fatigue					
		Hot Flush					
		Hypercalcaemia					
		Insomnia					
		Lymphadenopathy					
		Neurodermatitis					
		Pollakiuria					
		Polyp					
		Rectal Haemorrhage					
		Restless Legs Syndrome					
		Tension Headache					
		Thyroid Neoplasm					
		Vomiting					

Date:01/18/05ISR Number: 4554042-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00621
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged				Vioxx	SS	Merck & Co., Inc	ORAL
				Diltiazem			

Disability			Hydrochloride	C		
UNKNOWN						
			Oxycodone Hydrochloride	C		
UNKNOWN						
			Sodium Bicarbonate And Sodium Chloride And Polyethylene Glycol 3350 And Potassium Chloride	C		
UNKNOWN						

Date:01/18/05ISR Number: 4554043-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00999
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Amitriptyline			
Initial or Prolonged	Myocardial Infarction		Hydrochloride	C		
UNKNOWN						
Disability	Pain		Lasix (Furosemide)	C		
UNKNOWN						
			Oxycontin	C		
UNKNOWN						
			Nitrostat	C		
UNKNOWN						

				Mobic	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							

Date:01/18/05ISR Number: 4554046-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00045
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal Disorder		Fluoxetine Hydrochloride	C			UNKNOWN	
	Intestinal Polyp							
	Liver Disorder		Flurazepam Hydrochloride	C			UNKNOWN	
	Oedema							
	Renal Disorder							
	Weight Increased							

Date:01/18/05ISR Number: 4554047-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00900
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	723 DAY	
Life-Threatening			Pravachol	C			UNKNOWN	
Disability			Lopressor	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	

Date:01/18/05ISR Number: 4554048-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							

Date:01/18/05ISR Number: 4554049-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00730
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Heart Rate Decreased		Lipitor	C				
UNKNOWN								
Initial or Prolonged	Loss Of Consciousness		Proscar	C				
UNKNOWN								
			Hytrin	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

Date:01/18/05ISR Number: 4554052-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00739
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zoloft	C				
UNKNOWN								
Initial or Prolonged			Pravachol	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Coreg	C				
UNKNOWN								
			Avapro	C				
UNKNOWN								

				Plavix	C		
UNKNOWN							
				Detrol La	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Ubidecarenone	C		
UNKNOWN							

Date:01/18/05ISR Number: 4554055-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		984 DAY
	Atherosclerosis		Acetaminophen And Hydrocodone Bitartrate	C				
	Depression							
	Hypertension							
UNKNOWN								
	Liver Disorder		Wellbutrin	C		ORAL		
	Osteoporosis		Valium	C		ORAL		
	Pain In Extremity		Estradiol	C		ORAL		
	Polyneuropathy		Remeron	C		ORAL		
	Renal Failure		Lotensin	C				
UNKNOWN								
			Effexor Xr	C		ORAL		

Date:01/18/05ISR Number: 4554056-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00098
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Prednisolone	C				
UNKNOWN								
	Nervousness		Bisoprolol	C				
UNKNOWN								
	Visual Disturbance		Ranitidine	C				
UNKNOWN								

			Aspirin	C		
UNKNOWN						
			Cimicifuga	C		
UNKNOWN						
			Levothyroxine Sodium	C		
UNKNOWN						
			Calcium Carbonate And Cholecalciferol	C		
UNKNOWN						

Date:01/18/05ISR Number: 4554057-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcohol Poisoning		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Injury		Neurontin	C		ORAL		
Initial or Prolonged	Back Pain		Wellbutrin	C				
UNKNOWN								
Disability	Belligerence							
	Convulsion							
	Drug Interaction							
	Limb Injury							
	Muscle Spasms							
	Musculoskeletal Discomfort							
	Neck Injury							
	Neck Pain							
	Overdose							
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554059-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00712
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Actinic Keratosis
Other	Adverse Event
	Angina Pectoris
	Anorexia
	Arthralgia
	Arthritis
	Arthropathy
	Asthenia
	Back Pain
	Benign Prostatic Hyperplasia
	Bladder Disorder
	Blood Glucose Increased
	Blood Pressure Increased
	Cardio-Respiratory Arrest
	Cardiovascular Disorder
	Carotid Artery Stenosis
	Carotid Bruit
	Carpal Tunnel Syndrome
	Cauda Equina Syndrome
	Chest Pain
	Chondropathy
	Circulatory Collapse
	Constipation
	Convulsion
	Depression
	Drug Effect Decreased
	Dry Mouth
	Epididymal Cyst
	Erectile Dysfunction
	Fatigue
	Flatulence
	Gastrointestinal Disorder
	Hyperhidrosis
	Hyperlipidaemia
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Intestinal Functional Disorder
	Malnutrition

Nervous System Disorder
Nervousness
Neuropathy Peripheral
Oedema Peripheral
Osteitis
Osteoarthritis
Paraparesis
Pulmonary Embolism
Radiculopathy
Scoliosis
Seborrhoeic Keratosis
Skin Lesion
Spinal Column Stenosis
Stress
Testicular Pain

	Tremor						
	Viral Infection						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Neurontin	C			UNKNOWN	
			Lactulose	C		ORAL		
			Glucophage	C			UNKNOWN	
			Glyburide	C			UNKNOWN	
			Lotrel	C			UNKNOWN	

Date:01/18/05ISR Number: 4554061-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00086
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
			Orlistat	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:01/18/05ISR Number: 4554062-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acarodermatitis
	Acute Prerenal Failure
	Agitation
	Angina Unstable
	Azotaemia
	Benign Prostatic Hyperplasia
	Bladder Obstruction
	Bronchitis
	Cardiac Failure

Congestive
Carotid Artery Stenosis
Central Line Infection
Cerebral Artery Occlusion
Chest Pain
Chronic Obstructive
Pulmonary Disease
Clavicle Fracture
Confusional State
Constipation
Contusion
Coronary Artery
Restenosis
Decreased Appetite
Dermatitis Contact
Diarrhoea
Dressler'S Syndrome
Duodenal Ulcer
Faecal Occult Blood
Positive
Faeces Discoloured
Gastritis
Gastrointestinal
Haemorrhage

		Hyperbilirubinaemia					
		Hyperkalaemia					
		Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophageal Ulcer		Aricept	C		
UNKNOWN							
		Peripheral Vascular		Aspirin	C		
UNKNOWN							
		Disorder		Allopurinol	C		
UNKNOWN							
		Radiculopathy		Vitamin E	C		
UNKNOWN							
		Renal Failure		Ascorbic Acid	C		
UNKNOWN							
		Renal Failure Acute					
		Renal Failure Chronic					
		Respiratory Failure					
		Skin Candida					
		Subclavian Artery					
		Stenosis					
		Urinary Tract Infection					
		Weight Decreased					

Date:01/18/05ISR Number: 4554068-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02245
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhoids					
	Scar					

Date:01/18/05ISR Number: 4554069-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04381
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aspartate		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Aminotransferase		Atenolol	C		
UNKNOWN						

	Increased	Estradiol	C
UNKNOWN			
	Back Pain Chest Pain	[Therapy Unspecified]	C
UNKNOWN			
	Chronic Obstructive	Protonix	C
UNKNOWN			
	Pulmonary Disease Coronary Artery Disease	Potassium (Unspecified)	C
UNKNOWN			
	Coronary Artery Stenosis	Acyclovir	C
UNKNOWN			
	Diarrhoea Dyspnoea	Tylenol With Codeine #3	C
UNKNOWN			
	Gastrooesophageal Reflux Disease Intestinal Functional Disorder Labile Hypertension Low Density Lipoprotein Increased Myocardial Infarction Myocardial Ischaemia Oedema Peripheral Peripheral Artery Aneurysm Physical Disability Stomach Discomfort		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554070-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02017
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vasotec	C				
	Congestive		Lanoxin	C				
	Dyspnoea		Aldomet (Methyldopa)	C				
			Potassium (Unspecified)	C				
			Lasix (Furosemide)	C				
			Coumadin	C				
			[Therapy Unspecified]	C				

Date:01/18/05ISR Number: 4554071-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01594
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Cough							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							
	Heart Rate Irregular							

Date:01/18/05ISR Number: 4554072-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00524
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Life-Threatening	Dyspnoea					
Hospitalization - Initial or Prolonged						
Disability						

Date:01/18/05ISR Number: 4554073-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00613
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Adverse Event					
	Angina Pectoris					
	Blood Pressure Increased					
	Convulsion					

Date:01/18/05ISR Number: 4554076-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554077-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00776
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Living Impaired							
	Arthropathy							
	Blood Pressure Abnormal							
	Diabetes Mellitus							
	Fatigue							
	Intervertebral Disc Displacement							
	Intervertebral Disc Protrusion							
	Osteoarthritis							
	Pain							
	Sciatica							
	Spinal Column Stenosis							

Date:01/18/05ISR Number: 4554078-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive Pulmonary Embolism							

Date:01/18/05ISR Number: 4554081-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554083-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02031
Age:78 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Aortic Valve Incompetence
	Bladder Disorder
	Cataract
	Closed Head Injury
	Contusion
	Dry Eye
	Dyspepsia
	Dyspnoea
	Dysuria
	Ear Pain
	Eye Haemorrhage
	Eye Pain
	Fall
	Glaucoma
	Headache
	Hearing Impaired
	Hypertension
	Hypokalaemia
	Injury
	Loose Body In Joint

		Migraine					
		Mitral Valve Incompetence					
		Nasal Turbinate	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Neurodermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Optic Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Prempro	C		
UNKNOWN							
		Paraesthesia Oral		Synthroid	C		
UNKNOWN							
		Peripheral Vascular		Fosamax	C		ORAL
		Disorder		Advil	C		
UNKNOWN							
		Polymyalgia Rheumatica		Claritin	C		
UNKNOWN							
		Retinal Vein Occlusion		Celebrex	C		
UNKNOWN							
		Reversible Airways		Hyaluronate Sodium	C		
PARENTERAL							
		Obstruction					
		Sinusitis					
		Skin Laceration					
		Syncope					
		Vision Blurred					

Date:01/18/05ISR Number: 4554084-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03330
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abscess Limb
Initial or Prolonged	Anaemia
Other	Asthenia
	Atrial Fibrillation
	Bifascicular Block
	Bile Duct Obstruction
	Bile Duct Stone
	Biliary Neoplasm
	Bradycardia
	Carcinoma In Situ
	Cardiac Failure
	Congestive
	Carotid Artery Stenosis
	Cellulitis

Cerebrovascular Accident
Cholecystitis
Cholelithiasis
Coronary Artery
Atherosclerosis
Dehydration
Depression Postoperative
Dressler'S Syndrome
Duodenal Ulcer
Dysgeusia
Fluid Retention
Gastritis
Gastrointestinal
Haemorrhage
Hyperlipidaemia
Hypertension
Hypotension
Hypothyroidism
Infection
Knee Arthroplasty
Myalgia
Myocardial Infarction

	Nausea						
	Pancreatitis Acute						
	Pancreatitis Chronic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL	
	Prostate Cancer		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pulmonary Congestion		Vioxx	SS	Merck & Co., Inc	ORAL	
	Renal Failure		Verapamil Msd Lp	C		ORAL	
	Sinus Arrhythmia		Imdur	C			UNKNOWN
	Urinary Retention		Prazosin-Bc	C			UNKNOWN
	Urinary Tract Infection		Zocor	C		ORAL	
	Weight Increased		Atacand	C			UNKNOWN
			Hydrochlorothiazide	C			UNKNOWN

Date:01/18/05ISR Number: 4554085-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02381
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	95 DAY
Hospitalization -	Deep Vein Thrombosis		[Therapy				
Initial or Prolonged	Renal Failure Acute		Unspecified]	C			UNKNOWN
Disability	Weight Decreased		Trazodone				
Other			Hydrochloride	C			UNKNOWN
			Elavil	C			UNKNOWN
			Clonazepam	C			UNKNOWN
			Levoxyl	C			UNKNOWN
			Glucophage	C			UNKNOWN
			Glucotrol	C			UNKNOWN
			Premarin	C			UNKNOWN
			Vitamins				

UNKNOWN	(Unspecified)	C
UNKNOWN	Aspirin	C
UNKNOWN	Avandia	C
UNKNOWN	Protonix	C
UNKNOWN	Valium	C
UNKNOWN	Lipitor	C
UNKNOWN	Neurontin	C
UNKNOWN	Methadone Hcl	C
UNKNOWN	Hydrodiuril	C
UNKNOWN	Univasc	C
UNKNOWN		

Date:01/18/05ISR Number: 4554086-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00685
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554088-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554089-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02022
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
	Back Pain		Lotensin	C			UNKNOWN	
	Basal Cell Carcinoma		Norvasc	C			UNKNOWN	
	Cataract		Zocor	C		ORAL		
	Cerebrovascular Accident		Aspirin	C			UNKNOWN	
	Dysgeusia		Advil	C			UNKNOWN	
	Gingival Recession		Avandia	C			UNKNOWN	
	Hypoaesthesia		Glyburide	C			UNKNOWN	
	Hypoaesthesia Oral							
	Osteoarthritis							
	Pain In Extremity							
	Palpitations							
	Paraesthesia							
	Rotator Cuff Syndrome							
	Scab							
	Seborrhoeic Keratosis							
	Sinusitis							
	Spinal Osteoarthritis							

Date:01/18/05ISR Number: 4554091-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03476
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Arthralgia
Other	Body Tinea
	Bronchitis
	Bronchospasm
	Cardiomegaly
	Cellulitis
	Chest Pain
	Chondromalacia

Coronary Artery Disease
Decubitus Ulcer
Dental Caries
Diabetes Mellitus
Non-Insulin-Dependent
Dizziness
Dyspnoea
Dysuria
Fatigue
Flank Pain
Headache
Herpes Zoster
Hiatus Hernia
Memory Impairment
Meniscus Lesion
Muscle Spasms
Orthopnoea
Orthostatic Hypotension
Otitis Media
Radiculitis Lumbosacral
Rash
Rhinitis
Staphylococcal Infection
Tinnitus

Urinary Tract Infection
Varicose Vein
Vertigo
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	171	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Celebrex	C			UNKNOWN	
	Bextra	C			UNKNOWN	
	Lexapro	C		ORAL		
	Synthroid	C		ORAL		
	Aspirin	C			UNKNOWN	
	Diabeta	C			UNKNOWN	
	Fibercon	C			UNKNOWN	
	Colace	C			UNKNOWN	
	Prevacid	C		ORAL		
	Relafen	C			UNKNOWN	
	Effexor	C			UNKNOWN	
	Aciphex	C			UNKNOWN	
	Zoloft	C			UNKNOWN	

Date:01/18/05ISR Number: 4554094-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Adverse Event
Other	Anaemia
	Angina Pectoris
	Angioneurotic Oedema
	Anxiety
	Atelectasis
	Bezoar
	Blood Pressure
	Inadequately Controlled

Body Temperature
Increased
Bronchitis
Cardiac Murmur
Cardiomegaly
Chest Discomfort
Chest Pain
Citrobacter Infection
Constipation
Contusion
Deep Vein Thrombosis
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diastolic Dysfunction
Diverticulum
Drug Ineffective
Dysphagia
Dyspnoea
Excoriation
Fall
Fatigue
Gastric Disorder
Gastric Outlet
Obstruction
Heart Rate Increased
Hyperhidrosis

		Hypertension					
		Hypertensive Heart Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		International Normalised Ratio Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain					
		Liver Function Test Abnormal					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Oesophageal Obstruction					
		Osteoarthritis					
		Pain					
		Peptic Ulcer					
		Post Thrombotic Syndrome					
		Productive Cough					
		Pulmonary Congestion					
		Restrictive Pulmonary Disease					
		Stress Incontinence					
		Tendonitis					
		Tenosynovitis					
		Treatment Noncompliance					
		Tricuspid Valve Incompetence					
		Urinary Tract Infection					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Weight Decreased					

Date:01/18/05ISR Number: 4554097-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02873
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Calcinosis		Amitriptyline Hydrochloride	C		
		Contusion					
UNKNOWN							
		Coronary Artery Disease		Methadone			

	Coronary Artery Stenosis	Hydrochloride	C
UNKNOWN			
	Excoriation	Oxycodone	C
UNKNOWN			
	Pulmonary Congestion	Ambien	C
UNKNOWN			
	Pulmonary Oedema	Neurontin	C
UNKNOWN			
	Sudden Death	[Therapy Unspecified]	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Tizanidine Hydrochloride	C
UNKNOWN			

Date:01/18/05ISR Number: 4554098-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Anorexia		Avapro	C				
Anxiety		Paxil	C				
Asthenia		Geodon	C				
Bacterial Sepsis		Lipitor	C				
Bipolar I Disorder		Lipitor	C				
Calculus Ureteric		Prilosec	C				
Chest Pain		Levoxyl	C				
Chills		Prevacid	C				
Condition Aggravated							
Cystitis							
Deep Vein Thrombosis							
Diarrhoea							
Emotional Distress							
Fatigue							
Flank Pain							
Gastritis							
Hydronephrosis							
Hydroureter							
Hypercalcaemia							
Hypercholesterolaemia							
Hyperparathyroidism							
Hypoperfusion							
Incisional Hernia							
Malaise							
Metabolic Acidosis							
Nausea							
Nephrolithiasis							
Pathogen Resistance							
Phlebolith							
Pyrexia							
Pyuria							
Renal Atrophy							
Renal Failure							

Renal Failure Acute
Schizoaffective Disorder
Sepsis
Staphylococcal Infection
Ureteric Stenosis
Urinary Retention
Urinary Tract Infection
Urosepsis
Vomiting
Weight Increased

Date:01/18/05ISR Number: 4554103-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Barrett'S Oesophagus Chest Pain Emotional Distress Gastritis Erosive Gastrointestinal Motility Disorder

	Gastrooesophageal Reflux Disease						
	Hepatic Cyst	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
	Oesophagitis						

Date:01/18/05ISR Number: 4554104-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	252 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL	252 DAY
Other	Infarction		Seroquel	C			UNKNOWN
	Amnesia		Seroquel	C			UNKNOWN
	Anxiety		Soma	C			UNKNOWN
	Asthma		Premarin	C			UNKNOWN
	Back Disorder		Ambien	C			UNKNOWN
	Back Pain		Neurontin	C			UNKNOWN
	Blood Triglycerides Increased		Potassium (Unspecified)	C			UNKNOWN
	Bronchitis Acute		Aspirin	C			UNKNOWN
	Cardiac Failure		Folic Acid	C			UNKNOWN
	Congestive		Prevacid	C			UNKNOWN
	Chest Pain		Toprol Xl Tablets	C			UNKNOWN
	Chronic Obstructive		Toprol Xl Tablets	C			UNKNOWN
	8 DAY						

	Pulmonary Disease	Plavix	C	
UNKNOWN				
	Coronary Artery Disease	Zocor	C	
UNKNOWN				
	Coronary Artery	Lipitor	C	
UNKNOWN	112 DAY			
	Thrombosis	Foltx	C	
UNKNOWN				
	Euthyroid Sick Syndrome	Linseed Oil	C	
UNKNOWN				
	Fibromyalgia	Nitroglycerin	C	
UNKNOWN				
	Gastroenteritis	Vicodin Tablets	C	
UNKNOWN				
	Haemorrhage	Altace	C	
UNKNOWN				
	Hallucination	Doxepin		
	Headache	Hydrochloride	C	
UNKNOWN				
	Herpes Simplex	Flexeril	C	ORAL
	Hyperlipidaemia	Prozac	C	
UNKNOWN				
	Hypertension	Prozac	C	
UNKNOWN				
	Irritable Bowel Syndrome	Prozac	C	
UNKNOWN				
	Ischaemic Cardiomyopathy			
	Nasal Disorder			
	Nausea			
	Neck Pain			
	Panic Disorder			
	Sleep Apnoea Syndrome			
	Spondylolisthesis			
	Vascular Pseudoaneurysm			

Date:01/18/05ISR Number: 4554105-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00375
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Blood Pressure Diastolic Increased
	Cervicobrachial Syndrome
	Chest Discomfort
	Hypertension

		Hypoaesthesia					
		Myocardial Infarction					
		Overdose	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pseudoangina		Vioxx	PS	Merck & Co., Inc	ORAL
		Psychosomatic Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Tachyarrhythmia		Oxycodone			
		Tachycardia		Hydrochloride	C		ORAL
				Amitriptyline			
				Hydrochloride	C		ORAL
428	DAY						
				Haloperidol	C		ORAL
				Theophylline	C		ORAL
				Fluticasone			
				Propionate And			
				Salmeterol Xinafoate	C		
RESPIRATORY							
(INHALATION)							
				Morphine	C		
UNKNOWN							
				Omeprazole	C		ORAL
				Cetirizine			
				Hydrochloride	C		ORAL
				Fentanyl	C		ORAL
				Dipyrone	C		ORAL
				Doxepin			
				Hydrochloride	C		ORAL

Date:01/18/05ISR Number: 4554109-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01339
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Disorder		Metformin	C		
UNKNOWN						
Initial or Prolonged	Electrocardiogram		Altace	C		
UNKNOWN						
	Abnormal					

Date:01/18/05ISR Number: 4554110-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		93 DAY
Initial or Prolonged	Increased		Prilosec	C				UNKNOWN
Disability	Cerebral Infarction		Flonase	C				UNKNOWN
	Chest Pain		Baclofen	C				UNKNOWN
	Drug Ineffective							
	Embolic Stroke							
	Prostatic Specific Antigen Increased							
	Ventricular Hypertrophy							
	Vertebrobasilar Insufficiency							

Date:01/18/05ISR Number: 4554111-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554113-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00706
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis							
	Diastolic Dysfunction							
	Dilatation Atrial							
	Hypertension							
	Injury							
	International Normalised							
	Ratio Decreased							
	Joint Injury							
	Limb Injury							
	Localised Infection							
	Musculoskeletal Chest							
	Pain							
	Pain In Extremity							
	Patellofemoral Pain							
	Syndrome							
	Post Thrombotic Syndrome							
	Pulmonary Embolism							
	Ventricular Hypertrophy							

Date:01/18/05ISR Number: 4554116-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554122-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00926
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower
	Adverse Event
	Aggression
	Anxiety
	Arthralgia
	Balance Disorder

Bronchitis
Bursitis
Cardiac Disorder
Chest Pain
Chondromalacia
Constipation
Contusion
Deafness
Deafness Neurosensory
Depression
Diplopia
Dysphagia
Dyspnoea
Extrasystoles
Fall
Femur Fracture
Fluid Retention
Gastritis
Haematochezia

	Haemorrhoids					
	Headache					
	Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypoaesthesia					
	Injury					
	Intervertebral Disc					
	Degeneration					
	Intervertebral Disc					
	Protrusion					
	Intestinal Functional					
	Disorder					
	Joint Effusion					
	Meniscus Lesion					
	Muscle Spasms					
	Muscle Strain					
	Myalgia					
	Nerve Injury					
	Nervous System Disorder					
	Neuroma					
	Nocturia					
	Personality Change					
	Polyp					
	Radicular Syndrome					
	Radiculopathy					
	Rash					
	Renal Failure					
	Restless Legs Syndrome					
	Sleep Apnoea Syndrome					
	Snoring					
	Stress					
	Tachycardia					
	Therapy Non-Responder					
	Tinnitus					
	Vertigo					
	Vertigo Labyrinthine					
	Weight Decreased					
	Weight Increased					

Date:01/18/05ISR Number: 4554126-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00966
Age:30 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged	Activities Of Daily Living Impaired Acute Coronary Syndrome Acute Myocardial Infarction Angina Pectoris Anxiety Arterial Thrombosis Atherosclerosis Blood Pressure Increased Bronchitis Acute Chest Discomfort Chest Pain Constipation Coronary Artery Occlusion Coronary Artery

		Thrombosis					
		Depression					
		Diabetes Mellitus					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
		Dyspepsia		Ovcon	C		
UNKNOWN							
		Electrocardiogram Change		Ibuprofen	C		
UNKNOWN							
		Fatigue		Amitriptyline			
		Feeling Abnormal		Hydrochloride	C		
UNKNOWN							
		Gastrooesophageal Reflux					
		Disease					
		Helicobacter Infection					
		Herpes Zoster					
		Hidradenitis					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hypersensitivity					
		Lethargy					
		Limb Discomfort					
		Myocardial Infarction					
		Nausea					
		Palpitations					
		Panic Attack					
		Paraesthesia					
		Peptic Ulcer					
		Rash					
		Respiratory Rate					
		Increased					
		Sinusitis					
		Sweat Gland Infection					
		Vomiting					

Date:01/18/05ISR Number: 4554128-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03757
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
94	DAY						
		Gastrooesophageal Reflux		Toprol Xl Tablets	C		
UNKNOWN							

	Disease		Glucophage	C		
UNKNOWN						
	Hypertension		Albuterol	C		
UNKNOWN						
	Somatisation Disorder		[Therapy			
	Ulcer		Unspecified]	C		
UNKNOWN						

Date:01/18/05ISR Number: 4554135-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00860
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atelectasis					
Disability	Cerebrovascular Accident					
Other	Depressed Level Of					
	Consciousness					
	Drug Hypersensitivity					
	Fall					
	Haematoma					
	Hypertension					
	Multiple Fractures					
	Muscle Spasms					
	Polytraumatism					
	Rib Fracture					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554138-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01002
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blindness Cortical		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cerebrovascular Accident		Buspar	C		ORAL
Other	Erectile Dysfunction		Cozaar	C		ORAL
	Excoriation		Zyloprim	C		ORAL
	Fat Tissue Increased		Indocin			
	Hypertension		(Indomethacin)	C		ORAL
	Injury		Tenormin	C		ORAL
	Retinal Haemorrhage		Tenormin	C		ORAL
	Transient Ischaemic		Pravachol	C		
UNKNOWN						
	Attack		Hydrochlorothiazide	C		ORAL
			Slow-K	C		ORAL
			Plavix	C		ORAL
			Aspirin	C		ORAL
			Ambien	C		
UNKNOWN						
			Celebrex	C		ORAL

Date:01/18/05ISR Number: 4554145-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Arteriosclerosis
	Arthralgia
	Asthma
	Benign Prostatic
	Hyperplasia
	Blood Cholesterol
	Increased
	Blood Creatine
	Phosphokinase Increased
	Cataract
	Cerebrovascular Accident
	Colon Adenoma
	Colonic Polyp
	Convulsion
	Dyspnoea

Electrocardiogram St-T
Change
Eye Pain
Gastrooesophageal Reflux
Disease
Genital Rash
Haematuria
Haemorrhage Intracranial
Haemorrhoids
Hydronephrosis
Hypertension
Hypertonic Bladder
Micturition Urgency
Neurodermatitis
Nocturia
Nodule
Pain In Extremity
Paralysis
Pharyngolaryngeal Pain

		Phlebothrombosis					
		Pneumonia					
		Pollakiuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Proteinuria		Vioxx	PS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Rectal Haemorrhage		Levothyroxine Sodium	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:01/18/05ISR Number: 4554147-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/18/05ISR Number: 4554150-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Aphthous Stomatitis		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Arthralgia					
	Blood Pressure Increased					
	Bronchitis Acute					
	Bursitis					
	Cardiac Disorder					
	Cerebrovascular Accident					

Contusion
Convulsion
Cyst
Fall
Laryngitis
Migraine
Muscle Atrophy
Musculoskeletal
Discomfort
Osteoarthritis
Otitis Media
Pain In Jaw
Panic Attack
Pharyngitis
Pyrexia
Sinus Disorder
Sinusitis
Thrombotic Stroke
Urinary Tract Infection
Viral Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554151-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL		584 DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Celebrex	C			UNKNOWN	
	Asthma		Clonidine	C			UNKNOWN	
	Back Pain		Demadex	C			UNKNOWN	
	Blood Chloride Increased		Digitek	C			UNKNOWN	
	Cardiac Failure		Aspirin	C			UNKNOWN	
	Congestive		Accupril	C			UNKNOWN	
	Cardiac Stress Test Abnormal							
	Cardiomyopathy							
	Chronic Obstructive Pulmonary Disease							
	Convulsion							
	Electrocardiogram St-T Segment Abnormal							
	Fall							
	Gastrooesophageal Reflux Disease							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hyperlipidaemia							
	Hypertension							
	Hypertensive Heart Disease							
	Mitral Valve Incompetence							
	Muscle Spasms							
	Pain In Extremity							
	Platelet Count Increased							
	Spinal Osteoarthritis							
	Swelling							
	Tendonitis							
	Tricuspid Valve Incompetence							
	White Blood Cell Count							

Increased

Date:01/18/05ISR Number: 4554155-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		643 DAY
Initial or Prolonged	Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tongue Disorder		Valsartan	C		ORAL		
	Urticaria		Furosemide	C		ORAL		
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Allopurinol	C		ORAL		

Date:01/18/05ISR Number: 4554156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00923
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Xenical	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554160-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00008
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		658 DAY
Initial or Prolonged	Clostridial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		1300 DAY
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		658 DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		1300 DAY
	Musculoskeletal Chest Pain		Hydrochlorothiazide And Valsartan	C		ORAL		175 DAY
	Myocardial Infarction							
	Pharyngolaryngeal Pain							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:01/18/05ISR Number: 4554161-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00338
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		84 DAY
Hospitalization -	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Fiorinal	C				UNKNOWN
Disability	Increased Cardiac Arrest		[Therapy Unspecified]	C				UNKNOWN
	Cardio-Respiratory Arrest		Neurontin	C		ORAL		
	Cardiomegaly							
	Chest Pain							
	Cholelithiasis							
	Circulatory Collapse							
	Coma							
	Coronary Artery Atherosclerosis							
	Coronary Artery Stenosis							
	Dermal Cyst							
	Dilatation Ventricular							

Dyspnoea
Emphysema
Heart Rate Increased
Hepatomegaly
Hyperlipidaemia
Low Density Lipoprotein
Increased
Myocardial Infarction
Pulmonary Congestion
Ventricular Hypertrophy
Very Low Density
Lipoprotein Abnormal
Vomiting

Date:01/18/05ISR Number: 4554162-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00716
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Disorder		Dilantin	C				
UNKNOWN								
Disability	Fatigue							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02651
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		1493 DAY
Hospitalization - Initial or Prolonged	Fall							
Disability	Hypertension							
	Normal Pressure Hydrocephalus							

Date:01/18/05ISR Number: 4554164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02224
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure Congestive							
	Headache							
	Palpitations							
	Transient Ischaemic Attack							

Date:01/18/05ISR Number: 4554165-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Other	Amnesia
	Anaemia
	Anal Fistula
	Aneurysm Ruptured
	Angina Unstable
	Anxiety
	Appendicitis Perforated
	Arthralgia
	Atelectasis
	Back Pain
	Cardiac Failure

Cerebral Artery Stenosis
Colitis Ulcerative
Contusion
Convulsion
Coronary Artery Disease
Cough
Defaecation Urgency
Depression
Dermatitis
Dizziness
Drug Ineffective
Faecal Incontinence
Fall
Flatulence
Headache
Hernia
Hyperlipidaemia
Hypertension
Hypotension
Ileitis

		Impaired Healing					
		Infection					
		Inflammatory Bowel	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Intestinal Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
		Intestinal Spasm					
		Intracranial Aneurysm					
		Joint Injury					
		Migraine					
		Musculoskeletal Chest					
		Pain					
		Pain					
		Pain In Extremity					
		Perianal Abscess					
		Perirectal Abscess					
		Pneumoperitoneum					
		Proctalgia					
		Proctitis Ulcerative					
		Pruritus Ani					
		Pyrexia					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Tachycardia					
		White Blood Cell Count					
		Increased					

Date:01/18/05ISR Number: 4554167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
Other	Arrhythmia
	Benign Prostatic
	Hyperplasia
	Blood Pressure Increased
	Bradycardia
	Bronchitis Acute
	Cerebrovascular Accident
	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease

Convulsion
Coronary Artery Disease
Cough
Depression
Dermatitis Atopic
Diverticulum
Dizziness
Dysgeusia
Dyspnoea
Emphysema
Fatigue
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hiatus Hernia
Inner Ear Disorder

		Intervertebral Disc Degeneration					
		Lumbar Radiculopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lumbar Spinal Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
586	DAY						
		Lung Neoplasm		Claritin	C		
UNKNOWN							
		Myocardial Infarction		Aspirin	C		
UNKNOWN							
		Neuroma		Pravachol	C		
UNKNOWN							
		Non-Hodgkin'S Lymphoma		Calcium			
		Palpitations		(Unspecified)	C		
UNKNOWN							
		Peptic Ulcer		Folic Acid	C		
UNKNOWN							
		Peripheral Vascular		Digoxin	C		
UNKNOWN							
		Disorder		Naprosyn	C		ORAL
		Pleural Effusion		Keflex	C		ORAL
		Renal Abscess		Allegra	C		ORAL
		Renal Cyst		Elocon	C		
UNKNOWN							
		Renal Mass		Lopressor	C		ORAL
		Rhinitis Allergic		Darvocet-N	C		ORAL
		Salivary Gland Cancer		Pravachol	C		
UNKNOWN							
		Splenomegaly		Lanoxin	C		ORAL
		Spondylolisthesis		Lortab	C		ORAL
		Vertigo		Clarinex	C		ORAL
		Weight Decreased		Zocor	C		ORAL
				Nexium	C		ORAL
				Paxil	C		ORAL
				Vitamin E	C		
UNKNOWN							

Date:01/18/05ISR Number: 4554168-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00064
Age:48 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/18/05ISR Number: 4554169-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00142
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		116 DAY
Initial or Prolonged	Prescribed Overdose							
	Syncope							

Date:01/18/05ISR Number: 4554170-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00511
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		1434 DAY
Hospitalization -	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		1434 DAY
Initial or Prolonged	Blood Sodium Decreased							
	Cardiovascular Disorder							
	Chest Discomfort							
	Confusional State							
	Depressed Mood							
	Disorientation							
	Disturbance In Attention							
	Fall							
	Sleep Apnoea Syndrome							
	Thoracic Vertebral Fracture							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554172-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00856
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554173-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00526
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Increased							

Date:01/18/05ISR Number: 4554176-6Report Type:Expedited (15-DaCompany Report #PH-MERCK-0410PHL00002
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Perindopril	C		ORAL		
	Fall		Piracetam	C		ORAL		
	Femur Fracture		[Therapy					
	Irritability		Unspecified]	C				
UNKNOWN								
	Radius Fracture		Aspirin	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C		ORAL		

Date:01/18/05ISR Number: 4554177-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Other	Accident At Work
	Arthralgia
	Cerebrovascular Accident
	Colitis Viral

Colonic Polyp
Diverticulitis
Dyspepsia
Dysphonia
Dyspnoea
Emotional Distress
Exostosis
Fatigue
Feeling Abnormal
Flatulence
Heart Rate Irregular
Insomnia
Intervertebral Disc
Injury
Intervertebral Disc
Protrusion
Irritable Bowel Syndrome
Musculoskeletal
Discomfort
Neck Injury
Neck Pain
Radiculopathy
Spinal Column Stenosis

		Spinal Cord Compression					
		Swelling					
		Vertigo	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vocal Cord Thickening		Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Aspirin	C		ORAL
				Motrin	C		ORAL
				Tylenol	C		ORAL
				Butalbital	C		ORAL
				Guaifenex	C		ORAL
				Clidinium Bromide	C		ORAL
				Estropipate	C		ORAL
				Claritin-D	C		ORAL
				Skelaxin	C		ORAL
				Ketoconazole	C		ORAL
				Prednisone	C		ORAL
				Biaxin	C		ORAL
				Diflucan	C		
UNKNOWN							
				Trimox	C		ORAL
				Hydrocodone Bitartrate	C		ORAL
				Diovan	C		ORAL

Date:01/18/05ISR Number: 4554576-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00813
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
		Amnesia		Atenolol And Chlorthalidone	C		ORAL
		Arthralgia		Ferrous Sulfate	C		ORAL
		Bronchitis					
		Chest Pain					
		Chest Wall Pain					
		Ear Pain					
		Gastritis					
		Gastroenteritis Viral					
		Haematemesis					
		Headache					
		High Density Lipoprotein Decreased					
		Hypokalaemia					

Hypomagnesaemia
Muscle Spasms
Nasal Congestion
Neck Pain
Pain In Extremity
Pain In Jaw
Pharyngitis
Pharyngolaryngeal Pain
Rash Pruritic
Sinusitis
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554590-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00807
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	1151 DAY	
Hospitalization - UNKNOWN	Adverse Event		Naprosyn	SS				
Initial or Prolonged Disability	Anaemia							
	Arrhythmia							
	Atrial Flutter							
	Azotaemia							
	Bronchial Carcinoma							
	Candidiasis							
	Cardio-Respiratory Arrest							
	Cardiomegaly							
	Carotid Bruit							
	Chest Discomfort							
	Cholelithiasis							
	Coronary Artery Atherosclerosis							
	Dysphagia							
	Dyspnoea							
	Epicondylitis							
	Gammopathy							
	Gastrooesophageal Reflux Disease							
	Haematuria							
	Hypotension							
	Interstitial Lung Disease							
	Jaundice							
	Leukocytosis							
	Multi-Organ Failure							
	Nephropathy Toxic							
	Neuralgia							
	Pulmonary Oedema							
	Renal Failure							
	Respiratory Failure							
	Rheumatoid Arthritis							
	Sepsis							
	Sepsis Syndrome							
	Tachycardia							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Urosepsis							

Venous Insufficiency
Weight Decreased

Date:01/18/05ISR Number: 4554591-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Disability	Adverse Event
Other	Angina Pectoris
	Anxiety
	Blood Cholesterol Increased
	Carotid Arterial Embolus
	Carotid Artery Disease
	Carotid Artery Stenosis
	Chronic Obstructive

		Pulmonary Disease					
		Convulsion					
		Coronary Artery Disease					
		Diverticulum Intestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Duodenal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Cozaar	C		ORAL
		Dysphagia		Cardizem	C		
UNKNOWN							
		Dyspnoea		Darvocet-N	C		
UNKNOWN							
		Essential Hypertension		Ecotrin	C		ORAL
		Gastrointestinal		Ecotrin	C		ORAL
		Candidiasis		Premarin	C		ORAL
		Gastrointestinal					
		Haemorrhage					
		Headache					
		Hiatus Hernia					
		Hypertension					
		Hypochromic Anaemia					
		Monarthritis					
		Myocardial Ischaemia					
		Neck Mass					
		Oral Candidiasis					
		Palpitations					
		Pelvic Peritoneal					
		Adhesions					
		Peptic Ulcer					
		Peripheral Vascular					
		Disorder					
		Pharyngolaryngeal Pain					
		Pruritus Generalised					
		Pulmonary Hypertension					
		Rash Pruritic					
		Subcutaneous Haematoma					
		Transient Ischaemic					
		Attack					
		Vertebral Artery Stenosis					

Date:01/18/05ISR Number: 4554596-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00933
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Sinusitis
Initial or Prolonged	Angina Pectoris

Other	Anxiety
	Blood Cholesterol
	Increased
	Bronchitis Acute
	Carotid Artery Stenosis
	Cataract
	Conjunctivitis
	Convulsion
	Depression
	Dyspepsia
	Essential Hypertension
	Fatigue
	Gastrointestinal
	Inflammation
	Headache
	Hypoaesthesia
	Insomnia
	Intervertebral Disc

		Protrusion					
		Joint Swelling					
		Lumbar Spinal Stenosis					
		Malaise	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nervousness		Vioxx	PS	Merck & Co., Inc	ORAL
		Neuropathy		Synthroid	C		ORAL
		Night Cramps		Vitamins			
		Oedema Peripheral		(Unspecified)	C		
UNKNOWN							
		Otitis Media Acute		Zocor	C		ORAL
		Paraesthesia		Darvocet-N	C		
UNKNOWN							
		Retinal Vein Occlusion		Elavil	C		
UNKNOWN							
		Tension		Alprazolam	C		
UNKNOWN							
		Transient Ischaemic		Clarinex	C		
UNKNOWN							
		Attack		Ambien	C		
UNKNOWN							
		Vertigo Positional		Aspirin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				[Composition Unspecified]	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Xanax	C		ORAL
				Vicodin Tablets	C		ORAL
				Lomotil	C		ORAL
				Bactrim	C		
UNKNOWN							
				Phenergan Tablets/Suppositories	C		ORAL
				Duratuss	C		ORAL
				Gentamicin Sulfate	C		
OPHTHALMIC							
				Amoxil	C		ORAL

Date:01/18/05ISR Number: 4554599-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02432
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL	93 DAY	
	Back Pain		Aspirin	C			UNKNOWN	
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Erectile Dysfunction							
	Exostosis							
	Fatigue							
	Headache							
	Hypertension							
	Labyrinthitis							
	Loss Of Consciousness							
	Syncope							
	Tachycardia							
	Testicular Cyst							
	Therapeutic Response Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554601-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00609
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Insulin	C				
	Constipation		Prednisone	C				
	Dyspnoea		Isosorbide Dinitrate	C				
	Vomiting		Acetylcysteine	C				
			Enalapril Maleate	C				

Date:01/18/05ISR Number: 4554602-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554604-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00866
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Capozide	C				

Date:01/18/05ISR Number: 4554605-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01977
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	66 DAY	
Hospitalization -	Death		Cozaar	C		ORAL		

Initial or Prolonged

Date:01/18/05ISR Number: 4554606-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00027
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angiogram Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Aspirin	C				
UNKNOWN								
Disability	Thrombosis		Lisinopril	C				
UNKNOWN								

Date:01/18/05ISR Number: 4554607-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00691
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Carotid Arterial Embolus		[Therapy					
Initial or Prolonged	Dyspnoea		Unspecified]	C				
UNKNOWN								
Disability	Musculoskeletal Disorder		[Therapy					
	Ovarian Disorder		Unspecified]	C				
UNKNOWN								
	Pulmonary Embolism							
	Uterine Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4554609-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebral Infarction							
Other	Cerebrovascular Accident							
	Depression							
	Hemiparesis							
	Hyperlipidaemia							

Date:01/18/05ISR Number: 4554610-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death							
Initial or Prolonged								

Date:01/18/05ISR Number: 4554612-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Date:01/18/05ISR Number: 4554613-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4554614-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00169
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1526 DAY	
	Coronary Artery Stenosis		Aspirin	C		ORAL		
			Pentaerythritol Tetranitrate	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Bisoprolol Fumarate	C		ORAL		

Date:01/18/05ISR Number: 4555132-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01296
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Carotid Artery Stenosis
	Cerebral Artery Occlusion
	Cerebral Atrophy
	Cerebral Ischaemia
	Cerebrovascular Accident
	Cough
	Diastolic Dysfunction
	Dilatation Atrial
	Emotional Distress

		Heat Exhaustion					
		Insomnia					
		Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve		Zocor	C		ORAL
		Calcification		Zocor	C		ORAL
		Mitral Valve Incompetence		Clonidine	C		ORAL
		Nocturia		Toprol Xl Tablets	C		ORAL
		Nystagmus		Flomax (Tamsulosin			
		Palpitations		Hydrochloride)	C		ORAL
		Rhinorrhoea		Ibuprofen	C		
UNKNOWN							
		Right Ventricular					
		Systolic Pressure					
		Decreased					
		Sinusitis					
		Supraventricular					
		Extrasystoles					
		Urinary Incontinence					
		Ventricular Dysfunction					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Weight Increased					

Date:01/18/05ISR Number: 4555133-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Angina Pectoris
Disability	Angina Unstable
Other	Atelectasis
	Atrial Fibrillation
	Back Pain
	Blood Cholesterol
	Increased
	Blood Creatinine
	Increased
	Bradycardia
	Cardiac Murmur
	Colitis
	Colonic Polyp
	Condition Aggravated
	Coronary Artery

Atherosclerosis
Coronary Artery Disease
Coronary Artery
Reocclusion
Coronary Artery Stenosis
Coronary Bypass
Thrombosis
Deep Vein Thrombosis
Diarrhoea
Diverticulitis
Diverticulitis Intestinal
Haemorrhagic
Diverticulum
Diverticulum Intestinal
Dizziness
Drug Hypersensitivity
Dysaesthesia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Family Stress					
		Fatigue					
		Haemorrhoids					
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Zocor	SS		ORAL
		Hypotension		Methotrexate	C		
UNKNOWN							
		International Normalised		Prednisone	C		ORAL
		Ratio Increased		Atenolol	C		
UNKNOWN							
		Intervertebral Disc		Percocet	C		
UNKNOWN							
		Degeneration		Temazepam	C		
UNKNOWN							
		Lower Gastrointestinal		Claritin Reditabs	C		
UNKNOWN							
		Haemorrhage		Zantac	C		ORAL
		Medical Device		Vitamins			
		Complication		(Unspecified)	C		
UNKNOWN							
		Myocardial Infarction		Motrin	C		
UNKNOWN							
		Palpitations		Folic Acid	C		
UNKNOWN							
		Pleural Effusion		Ambien	C		
UNKNOWN							
		Polyp		Ismo	C		
UNKNOWN							
		Prothrombin Time		Oxycodone			
		Prolonged		Hydrochloride	C		
UNKNOWN							
		Pulmonary Oedema					
		Pyrexia					
		Renal Failure Chronic					
		Renal Impairment					
		Respiratory Distress					
		Sigmoiditis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Visual Acuity Reduced					
		Weight Decreased					
		Wound Dehiscence					

Date:01/18/05ISR Number: 4555141-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Blood Cholesterol
Other	Abnormal
	Bursitis
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cardiovascular Disorder
	Chest Wall Pain
	Confusional State
	Decreased Activity
	Drug Hypersensitivity
	Faecal Incontinence
	Fatigue
	Feeling Cold
	Fibula Fracture
	Head Injury
	Headache
	Hot Flush
	Hypertension
	Incontinence
	Laryngitis
	Libido Decreased

		Mood Swings					
		Muscle Spasms					
		Musculoskeletal Chest	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Injury		Effexor	SS		
UNKNOWN							
		Oedema		Effexor	SS		
UNKNOWN							
		Ovarian Cyst		Osteo-Bi-Flex	C		
UNKNOWN							
		Pelvic Pain		Estrace	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Vitamins			
		Pulmonary Oedema		(Unspecified)	C		
UNKNOWN							
		Renal Failure		Vitamin B			
		Rotator Cuff Syndrome		(Unspecified)	C		
UNKNOWN							
		Sleep Disorder		Flagyl	C		
UNKNOWN							
		Stress		Cipro	C		
UNKNOWN							
		Stress Incontinence		Lotensin	C		
UNKNOWN							
		Tendonitis		Zyrtec	C		
UNKNOWN							
		Urinary Tract Infection		Detrol	C		
UNKNOWN							
		Vaginal Erosion					
		Vaginal Infection					
		Vaginal Odour					
		Varicose Vein					
		Vein Disorder					
		Vertigo					
		Viral Upper Respiratory					
		Tract Infection					
		Visual Disturbance					
		Vulvovaginal Discomfort					
		Weight Increased					

Date:01/18/05ISR Number: 4555144-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Bronchitis
	Cardiomyopathy
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Constipation
	Cough
	Cubital Tunnel Syndrome
	Decreased Appetite
	Diarrhoea
	Emotional Distress
	Feeling Hot And Cold
	Headache
	Hyperlipidaemia
	Insomnia
	Lower Respiratory Tract Infection
	Nasopharyngitis
	Nervous System Disorder
	Neuropathy
	Nocturia
	Road Traffic Accident
	Sexual Dysfunction
	Sinusitis
	Tension
	Transient Ischaemic

Attack
Urinary Incontinence
Visual Disturbance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Premarin	C			UNKNOWN	
	Effexor Xr	C			UNKNOWN	
	Remeron	C		ORAL		
	Vicodin Tablets	C			UNKNOWN	
	Soma	C			UNKNOWN	
	Seroquel	C		ORAL		
	Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
	Klonopin	C			UNKNOWN	
	Klonopin	C			UNKNOWN	
	Risperdal	C		ORAL		
	Zestril	C		ORAL		
	Zocor	C			UNKNOWN	
	Celebrex	C		ORAL	30 DAY	
	Lanoxin	C		ORAL		
	Plavix	C		ORAL		
	Aspirin	C		ORAL		
	Vistaril	C			UNKNOWN	
	Geodon	C			UNKNOWN	

Date:01/18/05ISR Number: 4555146-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00677
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		[Therapy					

Initial or Prolonged	Myocardial Infarction		Unspecified]	C		
UNKNOWN						
	Tachyarrhythmia					

Date:01/18/05ISR Number: 4555148-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Autonomic Nervous System Imbalance Blood Pressure Increased Depression Disturbance In Attention Dizziness Feeling Drunk Gait Disturbance Hyperreflexia Lacunar Infarction Psychosomatic Disease Stress Tinnitus Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555150-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01978
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Colitis Ulcerative		Axert	C				
UNKNOWN								
Initial or Prolonged	Loss Of Consciousness		Singulair	C		ORAL		
			Maxifen	C				
UNKNOWN								
			Famotidine	C				
UNKNOWN								
			Zapex	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

Date:01/18/05ISR Number: 4555155-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00424
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cyanosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Grand Mal Convulsion		Tramadol Hydrochloride	C				
UNKNOWN								
			Prednisolone	C				
UNKNOWN								
			Esomeprazole Magnesium	C				
UNKNOWN								
			Leflunomide	C				
UNKNOWN								
			Bisoprolol Fumarate	C				
UNKNOWN							18	DAY

Date:01/18/05ISR Number: 4555156-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00375
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Myocardial Infarction		Levothyroxine Sodium	C		
UNKNOWN						
			Acetaminophen	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Metoprolol	C		
UNKNOWN						
			Zocor	C		ORAL
			Ramipril	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						

Date:01/18/05ISR Number: 4555159-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00232
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1260 DAY	
			Piretanide	C			UNKNOWN	
			Atorvastatin Calcium	C		ORAL		
			Nifedipine	C			AURICULAR	
							(OTIC)	
			Fenofibrate	C			UNKNOWN	

Date:01/18/05ISR Number: 4555160-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00125
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anxiety
	Chest Pain
	Depression
	Impaired Work Ability
	Lethargy

		Life Expectancy Shortened Myocardial Infarction					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/18/05ISR Number: 4555161-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00383
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Disease Recurrence Phlebitis Skin Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/18/05ISR Number: 4555172-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02804
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Dizziness		[Therapy			
	Dyspnoea		Unspecified]	C		
UNKNOWN						
	Headache		[Therapy			
			Unspecified]	C		
UNKNOWN						
			Meclizine	C		
UNKNOWN						

Date:01/18/05ISR Number: 4555174-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01379
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Feeling Abnormal Hypoaesthesia					

Date:01/18/05ISR Number: 4555175-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01357
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555176-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00777
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
Disability	Cardiovascular Disorder		Tramadol Hydrochloride	C				UNKNOWN
	Chest Pain							
	Deep Vein Thrombosis		Tramadol Hydrochloride	C				UNKNOWN
	Disturbance In Attention							
	Dizziness		Dipyrone	C				UNKNOWN
	Intervertebral Disc		Dipyrone	C				UNKNOWN
	Protrusion		Dipyrone	C				UNKNOWN
	Memory Impairment		Cromolyn Sodium	C				UNKNOWN
	Pulmonary Embolism		Acetaminophen	C				UNKNOWN

				Aspirin	C		
UNKNOWN							
				Acetylcysteine	C		
UNKNOWN							
				Acetylcysteine	C		
UNKNOWN							

Date:01/18/05ISR Number: 4555179-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00249
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Traumatic Brain Injury							
Disability								

Date:01/18/05ISR Number: 4555180-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00094
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
901 DAY								
	Second Degree		Aspirin	C				
UNKNOWN								
	Syncope							

Date:01/18/05ISR Number: 4555182-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00853
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555183-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00891
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:01/18/05ISR Number: 4555184-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00069
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Valpromide	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Acepromazine And Aceprometazine And Clorazepate Dipotassium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4555186-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00874
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/18/05ISR Number: 4555187-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00013
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	76	DAY
Initial or Prolonged			Ramipril	C		ORAL		
			Simvastatin	C		ORAL		

Date:01/18/05ISR Number: 4555189-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/18/05ISR Number: 4555190-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0501ESP00017
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Tamponade		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Hospitalization -	Cardio-Respiratory Arrest							
Initial or Prolonged	Pericarditis							

Date:01/18/05ISR Number: 4555191-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00994
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:01/18/05ISR Number: 4555193-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01251
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cardiac Arrest Cardiac Disorder Injury Organ Failure Pain Vascular Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4555194-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01006
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:01/18/05ISR Number: 4555195-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00969
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fungal Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Oxygen	C				
RESPIRATORY (INHALATION)								
Hospitalization - Initial or Prolonged								
Disability								

Date:01/18/05ISR Number: 4555197-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01014
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555198-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01010
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Paxil	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

				Detrol La	C		
UNKNOWN							

Date:01/18/05ISR Number: 4555200-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00905
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Celebrex	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:01/18/05ISR Number: 4555201-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555203-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01217
Age: Gender:Female I/FU:I

Outcome	PT
Death	Adverse Event
Disability	Anxiety
Other	Death

	Emotional Distress Myocardial Infarction Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555205-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01245
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555208-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01766
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33 MON	

Date:01/18/05ISR Number: 4555209-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555210-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01570
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555211-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:01/18/05ISR Number: 4555212-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01728
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
	Convulsion		Ativan	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:01/18/05ISR Number: 4555213-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01771
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4555214-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01769
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555216-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Adverse Event Emotional Distress Pain Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555226-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555227-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01770
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555229-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555231-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	

Date:01/18/05ISR Number: 4555232-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01840
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555233-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Thrombosis							

Date:01/18/05ISR Number: 4555235-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:01/18/05ISR Number: 4555236-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555240-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01862
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON	

Date:01/18/05ISR Number: 4555242-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01836
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555243-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01896
Age:55 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/18/05ISR Number: 4555245-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Cardiac Disorder							
	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							

Date:01/18/05ISR Number: 4555247-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01870
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555249-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555250-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	330	DAY

Date:01/18/05ISR Number: 4555252-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Other	Myocardial Infarction							

Date:01/18/05ISR Number: 4555255-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01897
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555256-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01839
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555262-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/18/05ISR Number: 4555420-1Report Type:Direct Company Report #CTU 236993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Convulsion Transient Ischaemic Attack		Vioxx	PS		ORAL	DAILY	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/18/05ISR Number: 4555422-5Report Type:Direct Company Report #CTU 236992
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx 50mg	PS		ORAL	1/DAY	5 DAYS
Hospitalization -	Arterial Disorder							
Initial or Prolonged	Gastric Perforation		Lotrel	C				
Disability			Famvir	C				
Other								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/18/05ISR Number: 4555563-2Report Type:Direct Company Report #CTU 237085
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25 Mg	PS			1 PILL DAILY	
Hospitalization - Initial or Prolonged								
Other								

Date:01/18/05ISR Number: 4556552-4Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Accident
	Back Disorder
	Back Pain
	Blood Cholesterol Increased
	Chest Pain
	Chills
	Condition Aggravated
	Contusion
	Disorientation

Drug Effect Decreased
Drug Ineffective
Drug Intolerance
Erectile Dysfunction
Facial Pain
Feeling Abnormal
Feeling Cold
Gastrooesophageal Reflux
Disease
Gingival Disorder
Glossodynia
Hostility
Hyporeflexia
Impaired Healing
Injury
Irritability
Neck Pain
Oesophageal Spasm
Sedation
Sleep Disorder
Somnolence
Tooth Abscess

Treatment Noncompliance
Tremor
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (600 MG, 3 IN 1 D), ORAL	
Professional	Lipitor (Atorvastatin)	SS		ORAL	20 MG (1 IN 1 D), ORAL	
	Lithium (Lithium) (Lithium)	SS				
	Naproxen (Naproxen) (Naproxen)	SS				
	Rofecoxib (Rofecoxib)	SS				
	Amoxicillin (Amoxicillin)	SS		ORAL	1000 MG (1 IN 2 D), ORAL	
	All Other Therapeutic Products (All Other Therapeutic Products)	C				
	Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Vitamins (Vitamins)	C				
	Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C				

Date:01/18/05ISR Number: 4557821-4Report Type:Expedited (15-DaCompany Report #6012469
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable	Foreign	Concor	PS		ORAL	10,000 MG	
	Aortic Valve Disease	Health Professional Other	Seropram (Enteric-Coated) (Citalopram Hydrobromide)	SS		ORAL	40,000 MG	24 DAY
	Cerebrovascular Accident							
	Dilatation Atrial							
	Mitral Valve Incompetence							
	Myocardial Ischaemia		Vioxx	SS		ORAL	12,500 MG	12.5MH 1 IN 1 D
	Pulmonary Hypertension							
			Xanax (Alprazolam)	C				
			Aspirin (Acetylsalicylic Acid)	C				
			Magniscard (Magnnesium Aspartate Hcl	C				

Date:01/19/05ISR Number: 4555767-9Report Type:Expedited (15-DaCompany Report #PHNU2005DE00547
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased

	Infection Nephritis Interstitial Pyrexia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Co-Diovan	PS	Novartis Sector: Pharma	ORAL	1 DF, QD	
			Vioxx	SS				
			Acetylsalicylic Acid	C				
			Sortis	C				
			Concor	C				

Date:01/19/05ISR Number: 4555902-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00314
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Convulsive Threshold		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Lowered		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Headache		Lantus	C		SUBCUTANEOUS		
	Muscle Contractions		Humalog	C		SUBCUTANEOUS		
	Involuntary		Cenestin	C		ORAL		
	Tongue Disorder		Crestor	C		UNKNOWN		
			Lescol Xl	C		UNKNOWN		
			Zetia	C		ORAL		
			Lumigan	C		ORAL		

Date:01/19/05ISR Number: 4555905-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Feeling Abnormal							

Mass
Pain
Renal Cell Carcinoma
Stage Unspecified
Splenectomy

Date:01/19/05ISR Number: 4555906-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0411GBR00128
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Deafness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deafness Unilateral							
	Oesophagitis							
	Tinnitus							
	Transient Ischaemic Attack							

Date:01/19/05ISR Number: 4555909-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00895
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Blood Pressure Increased
	Fatigue
	Generalised Oedema

	Migraine						
	Pain In Extremity						
	Pain In Jaw	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Paraesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Xanax	C		ORAL		
			Relpax	C		ORAL		
			Lortab	C		ORAL		
			Hormonal Contraceptives (Unspecified)	C		ORAL		

Date:01/19/05ISR Number: 4555911-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1059 DAY	

Date:01/19/05ISR Number: 4555912-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00012
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Initial or Prolonged			Aspirin	C			UNKNOWN	

Date:01/19/05ISR Number: 4555913-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00781
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Ineffective		Insulin	C			UNKNOWN	
Initial or Prolonged	Renal Failure		Avandia	C			UNKNOWN	
Disability			[Therapy					

			Unspecified]	C			
UNKNOWN							
			Norvasc	C			
UNKNOWN							

Date:01/19/05ISR Number: 4555914-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01024
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29 MON	
Hospitalization - UNKNOWN			Altace	C				
Initial or Prolonged Disability								

Date:01/19/05ISR Number: 4555915-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00857
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555916-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00014
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Glucose Decreased		Insulin, Biphasic Isophane [Injection]	C			UNKNOWN	
	Bundle Branch Block Right							
	Heart Rate Increased		Enalapril Maleate	C			UNKNOWN	
	Myocardial Infarction		Acetaminophen	C			UNKNOWN	
	Urosepsis		Glyburide	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

Date:01/19/05ISR Number: 4555917-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00912
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort							
	Chest Pain							
	Headache							

Date:01/19/05ISR Number: 4555918-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30 MON	

Date:01/19/05ISR Number: 4555921-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02982
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Chronic Obstructive	Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Effusion	Lanoxin	C		
UNKNOWN					
	Electromechanical	Wellbutrin	C		
UNKNOWN					
	Dissociation	Coreg	C		
UNKNOWN					
	Emphysema	Advair	C		
UNKNOWN					
	General Physical Health	Combivent	C		
UNKNOWN					
	Deterioration	Furosemide	C		
UNKNOWN					
	Pulmonary Oedema	Tarka	C		
UNKNOWN					
	Respiratory Failure				
	Tobacco Abuse				

Date:01/19/05ISR Number: 4555927-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00096
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Pacemaker		Darvocet-N	C		
UNKNOWN						
Initial or Prolonged	Insertion		[Therapy			
Disability			Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4555931-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01419
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Zoloft	C			UNKNOWN	
			Claritin	C			UNKNOWN	

Date:01/19/05ISR Number: 4555932-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other	Congestive Death Myocardial Infarction							

Date:01/19/05ISR Number: 4555933-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Arterial Stent Insertion							

Date:01/19/05ISR Number: 4555934-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555935-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01915
Age:69 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		24 MON
	Stent Placement							

Date:01/19/05ISR Number: 4555938-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555939-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02352
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		57 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4555943-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01914
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ruptured Cerebral Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/19/05ISR Number: 4555945-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02351
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	367	DAY

Date:01/19/05ISR Number: 4555946-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02253
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Cerebrovascular Accident Convulsion Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555949-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555950-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01804
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/19/05ISR Number: 4555951-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01917
Age:76 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	

Date:01/19/05ISR Number: 4555952-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON	
	Thrombosis							

Date:01/19/05ISR Number: 4555953-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01916
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4555955-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4555986-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00868
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556207-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00803
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia Macrocytic
Other	Anxiety
	Arthralgia
	Arthropathy
	Asthma
	Balance Disorder
	Bipolar Disorder
	Blood Cholesterol Increased
	Blood Magnesium Decreased
	Blood Pressure Decreased
	Bone Pain
	Breast Disorder
	Bronchitis
	Candidiasis
	Cerebrovascular Accident
	Contusion
	Cough
	Dyskinesia
	Electrolyte Imbalance
	Fall
	Head Injury
	Herpes Simplex

Hypertension
Hypoglycaemia
Insomnia
Intervertebral Disc
Disorder
Joint Injury
Laceration
Menopause
Migraine
Neuralgia
Ovarian Cyst Ruptured
Piriformis Syndrome
Pneumonia
Pulmonary Congestion
Rhinitis Allergic
Rosacea
Simple Partial Seizures
Spinal Disorder
Staphylococcal Infection

		Tendon Injury Urge Incontinence Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Uterine Leiomyoma	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Decreased	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
				Serevent	C		
UNKNOWN							
				Flovent	C		
UNKNOWN							
				Singulair	C		ORAL
				Topamax	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							
				Imitrex Nasal Spray	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							
				Cyanocobalamin	C		
PARENTERAL							
				Zyrtec	C		
UNKNOWN							
				Beclovent	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Detrol	C		
UNKNOWN							
				Mysoline	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:01/19/05ISR Number: 4556219-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Acute Myocardial Infarction
Other	

Adverse Event
Blood Cholesterol
Increased
Cardiac Failure
Congestive
Cardiomegaly
Cerebrovascular Accident
Cerebrovascular Disorder
Confusional State
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Depression
Diabetes Mellitus
Inadequate Control
Diabetic Neuropathy
Diarrhoea
Escherichia Sepsis
Essential Hypertension
Intermittent Claudication
Lipoprotein Deficiency
Mitral Valve Disease
Mitral Valve Incompetence
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Peripheral Occlusive
Disease
Pulmonary Oedema
Renal Failure
Renal Failure Acute

		Sciatica Spinal Column Stenosis Stress Incontinence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic Attack Urinary Tract Infection Urosepsis Uterine Infection	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/19/05ISR Number: 4556225-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00701
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged	Angina Unstable Cardiac Failure Hyperlipidaemia Myocardial Infarction Panniculitis Sudden Death	Consumer	Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL

Date:01/19/05ISR Number: 4556227-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01108
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Disability	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/19/05ISR Number: 4556228-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aneurysm	Health Professional	Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthritis		Vioxx	SS	Merck & Co., Inc	
OPHTHALMIC	DAY					
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL

Cataract	Vioxx	SS	Merck & Co., Inc	ORAL
Eye Haemorrhage	Vioxx	SS	Merck & Co., Inc	
OPHTHALMIC DAY				
Gout				
Hyperlipidaemia				
Ischaemic Stroke				
Myocardial Infarction				
Pain In Extremity				
Post-Traumatic Stress Disorder				
Retinal Vein Occlusion				
Synovitis				

Date:01/19/05ISR Number: 4556229-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03537
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Other	Abdominal Pain
	Abnormal Faeces
	Constipation
	Depression
	Diarrhoea
	Dysphagia

		Gastric Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhoids	Health	Vioxx	PS	Merck & Co., Inc	ORAL
		Headache	Professional	Vioxx	SS	Merck & Co., Inc	ORAL
		Irritable Bowel Syndrome		[Therapy			
		Labyrinthitis		Unspecified]	C		
UNKNOWN							
		Ovarian Cyst		Flonase	C		
UNKNOWN							
		Panic Disorder		Premarin	C		
UNKNOWN							
		Peptic Ulcer		Hydroxychloroquine			
		Proctalgia		Sulfate	C		
UNKNOWN							
		Rectal Haemorrhage		Zoloft	C		
UNKNOWN							
		Rheumatoid Arthritis		Ambien	C		
UNKNOWN							
		Rhinitis Allergic		Daypro	C		
UNKNOWN							
		Systemic Lupus		Claritin	C		
UNKNOWN							
		Erythematosus					
		Urethral Stricture					
		Vertigo					

Date:01/19/05ISR Number: 4556230-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00111254
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspepsia		Cytotec	C		
UNKNOWN						

Date:01/19/05ISR Number: 4556233-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00214
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL

Hospitalization - Initial or Prolonged Disability	Prescribed Overdose	Professional

Date:01/19/05ISR Number: 4556234-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03268
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Life-Threatening	Acidosis
Hospitalization - Initial or Prolonged Disability	Activated Partial Thromboplastin Time Prolonged
	Acute Respiratory Distress Syndrome
	Apnoea
	Aspiration
	Atelectasis
	Blood Magnesium Increased
	Cardiac Arrest
	Cardiomegaly
	Coagulopathy
	Coma
	Convulsion
	Electrocardiogram Abnormal
	Feeling Abnormal

		Haemoglobin Decreased					
		Hyperglycaemia					
		Hypoxic Encephalopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		International Normalised	Health	Vioxx	PS	Merck & Co., Inc	ORAL
1061 DAY							
		Ratio Increased	Professional	Darvocet-N	C		ORAL
		Lung Infiltration		Coumadin	C		ORAL
		Oedema		Bentyl	C		ORAL
		Pulse Absent		Lasix (Furosemide			
		Renal Failure		Sodium)	C		ORAL
		Respiratory Failure		Codeine Phosphate			
		Therapy Non-Responder		And Guaifenesin	C		ORAL
		White Blood Cell Count		Flomax			
		Increased		(Morniflumate)	C		ORAL
				Lorazepam	C		ORAL
				Norvasc	C		ORAL
				Trazodone			
				Hydrochloride	C		ORAL
				Wellbutrin Sr	C		ORAL
				Aspirin	C		ORAL
				Combivent	C		
UNKNOWN							

Date:01/19/05ISR Number: 4556235-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01455
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Professional	Neurontin	C		
UNKNOWN							
Disability				Percocet	C		
UNKNOWN							

Date:01/19/05ISR Number: 4556236-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03580
Age:39 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Chest Discomfort	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Disability		Hypertension	Professional	Vioxx	SS	Merck & Co., Inc	ORAL

	Insulin Resistance	Lipitor	C
UNKNOWN			
	Neck Pain	[Therapy	
	Pain In Extremity	Unspecified]	C
UNKNOWN			
	Vasoconstriction	Toprol Xl Tablets	C
UNKNOWN			
		Wellbutrin	C
UNKNOWN			
		Prozac	C
UNKNOWN			
		[Therapy	
		Unspecified]	C
UNKNOWN			
		Hydrocodone	
		Hydrochloride	C
UNKNOWN			

Date:01/19/05ISR Number: 4556237-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01811
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion	Health	Vioxx	PS	Merck & Co., Inc	ORAL		1330 DAY
Hospitalization - Initial or Prolonged	Myocardial Infarction	Professional	Vioxx	SS	Merck & Co., Inc	ORAL		1330 DAY
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556238-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02750
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Blister		Lipitor	C				
UNKNOWN								
	Pulmonary Embolism		[Therapy Unspecified]	C				
UNKNOWN								

Date:01/19/05ISR Number: 4556239-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:01/19/05ISR Number: 4556240-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01682
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Condition Aggravated							
Disability	Dizziness							

Date:01/19/05ISR Number: 4556241-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01373
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	26 MON	
Hospitalization -	Disease		Paxil	C				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Amitriptyline					

Disability Hydrochloride C
UNKNOWN

Cyclobenzaprine Hydrochloride C
UNKNOWN

Esclim C
UNKNOWN

Fosamax C
UNKNOWN

Date:01/19/05ISR Number: 4556242-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01567
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556244-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01785
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556245-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556246-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00850
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556247-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01782
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable	Health	Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident	Professional	Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Disability	Chest Pain Coronary Artery Disease Depression Dyslipidaemia Dyspnoea Emotional Distress Flatulence Gout Hemiparesis Hyperlipidaemia Local Swelling Myocardial Infarction Suicide Attempt Ventricular Dysfunction							

Date:01/19/05ISR Number: 4556249-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00196
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation Diarrhoea Fatigue Osteomyelitis Pulmonary Embolism	Consumer	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556250-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00172
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556251-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01015
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556252-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01566
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556254-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556255-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/19/05ISR Number: 4556256-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556257-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/19/05ISR Number: 4556258-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556260-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Other	Death Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556261-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01847
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556262-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01823
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/19/05ISR Number: 4556263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01826
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556264-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556265-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556266-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:01/19/05ISR Number: 4556267-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556268-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01787
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556269-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01825
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:01/19/05ISR Number: 4556270-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556272-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556273-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556274-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556275-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01854
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556277-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01869
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556278-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/19/05ISR Number: 4556281-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01878
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:01/19/05ISR Number: 4556284-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01899
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556286-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01900
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556287-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01868
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556288-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556289-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556290-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/19/05ISR Number: 4556293-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556294-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556295-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	MIN

Date:01/19/05ISR Number: 4556296-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02220
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/19/05ISR Number: 4556297-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02224
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cerebrovascular Accident							

Date:01/19/05ISR Number: 4556298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02223
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Thrombosis							

Date:01/19/05ISR Number: 4556299-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02222
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							
	Paralysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556300-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02229
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:01/19/05ISR Number: 4556302-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02230
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	731	DAY

Date:01/19/05ISR Number: 4556303-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01901
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556305-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cardiac Arrest Cardiac Disorder Injury Multi-Organ Disorder Vascular Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556306-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02246
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:01/19/05ISR Number: 4556307-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02232
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1059	DAY

Date:01/19/05ISR Number: 4556314-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02294
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/19/05ISR Number: 4556315-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556316-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02228
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/19/05ISR Number: 4556317-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/19/05ISR Number: 4556318-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556319-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556320-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02250
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:01/19/05ISR Number: 4556321-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556322-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556323-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556325-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:01/19/05ISR Number: 4556326-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556327-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02280
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556329-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02323
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/19/05ISR Number: 4556330-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/19/05ISR Number: 4556331-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1096 DAY

Date:01/19/05ISR Number: 4556332-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR

Date:01/19/05ISR Number: 4556333-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4556334-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02325
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:01/19/05ISR Number: 4556336-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556338-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

Date:01/19/05ISR Number: 4556339-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:01/19/05ISR Number: 4556340-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02346
Age:29 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556342-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							

Date:01/19/05ISR Number: 4556343-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02361
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/19/05ISR Number: 4556344-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/19/05ISR Number: 4560122-1Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 367 DAY

Date:01/19/05ISR Number: 4576200-7Report Type:Periodic Company Report #A03200403526
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Contusion	Consumer	Plavix - Clopidogrel Sulfate - Tablet - 75 Mg	PS		ORAL	75 MG QD - ORAL	
			Aspirin "Bayer" - Acetylsalicylic Acid - Tablet - 81 Mg	SS		ORAL	81 MG QD - ORAL	
			Vioxx - Rofecoxib - Tablet - Unit Dose : Unknown	SS		ORAL	ORAL	
			Alendronate Sodium	C				

Date:01/19/05ISR Number: 4579107-4Report Type:Periodic Company Report #A03200402934
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal Haemorrhagic	Consumer	Plavix - Clopidogrel Sulfate - Tablet -					

	Faeces Discoloured	75 Mg	PS	ORAL
75 MG QD -				
ORAL				
		Aspirin "Bayer" - Acetylsalicylic Acid - Tablet - 325 Mg	SS	ORAL
325 MG QD -				
ORAL				
		Vioxx - Rofecoxib - Tablet - Unit Dose : Unknown	SS	ORAL
ORAL				
		Metformin Hydrochloride	C	
		Atorvastatin	C	
		Metoprolol Succinate	C	

Date:01/20/05ISR Number: 4556847-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01297
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Asthenia
	Bursitis
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Depression
	Dizziness

		Emphysema					
		Fibromyalgia					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL
9 MON							
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Labile Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
9 MON							
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Lumbar Radiculopathy		Altace	C		
UNKNOWN							
		Meniscus Lesion		Lipitor	C		
UNKNOWN							
		Nausea		Analgesic Or			
		Peripheral Vascular		Anesthetic			
		Disorder		(Unspecified)	C		
UNKNOWN							
		Sinusitis		Premarin	C		
UNKNOWN							
		Sleep Disorder		Zoloft	C		
UNKNOWN		582 DAY					
		Spondylolisthesis		Hydrodiuril	C		ORAL
		Spondylolysis		Atenolol	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN		17 DAY					
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN		17 DAY					
				Celebrex	C		
UNKNOWN							

Date:01/20/05ISR Number: 4556860-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00944
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Barrett'S Oesophagus		Premarin	C		ORAL		
	Bronchitis		Premarin	C		ORAL		
	Death		Premarin	C		ORAL		
	Duodenitis		Lopid	C			UNKNOWN	
	Gastritis Erosive		Ibuprofen	C			UNKNOWN	
	Haemorrhoids		Prevacid	C		ORAL		
	Intertrigo Candida		Prevacid	C		ORAL		
	Rhinitis Allergic		Prevacid	C			UNKNOWN	
	Upper Respiratory Tract		Prevacid	C			UNKNOWN	
	Infection		Zantac	C			UNKNOWN	

Date:01/20/05ISR Number: 4556861-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Adverse Event
Disability	Angina Pectoris
	Anxiety
	Aortic Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides

		Increased					
		Bronchitis					
		Bundle Branch Block					
		Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholecystitis Acute		Celebrex	C		
UNKNOWN							
		Conjunctivitis Allergic		Nexium	C		
UNKNOWN							
		Coronary Artery Disease					
		Depression					
		Dermatitis Allergic					
		Dermatitis Atopic					
		Diarrhoea					
		Femoral Artery Occlusion					
		Gastritis					
		Gastrooesophageal Reflux					
		Disease					
		Hypertension					
		Hypokinesia					
		Intervertebral Disc					
		Degeneration					
		Irritable Bowel Syndrome					
		Lung Neoplasm					
		Metabolic Encephalopathy					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Pulmonary Hypertension					
		Rash					
		Rhinitis Allergic					
		Sexual Dysfunction					
		Sleep Disorder					
		Staphylococcal Infection					
		Tricuspid Valve					
		Incompetence					
		Ventricular Tachycardia					

Date:01/20/05ISR Number: 4556864-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 89 DAY	Asthenia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged DAY	Gastrooesophageal Reflux	Vioxx	SS	Merck & Co., Inc	ORAL
Other UNKNOWN	Disease	Humulin N	C		
UNKNOWN	Hypoaesthesia	Humulin R	C		
	Hypotension	Naproxen	C		ORAL
	Insomnia	Naproxen	C		ORAL
OPHTHALMIC	Intervertebral Disc	Livostin	C		
	Degeneration	Prevacid	C		ORAL
UNKNOWN	Ischaemic Stroke	Vasotec	C		
	Muscle Spasms				
	Nasopharyngitis				
	Nephropathy				
	Neuropathy Peripheral				
	Oedema Peripheral				
	Pain In Extremity				
	Pollakiuria				
	Upper Respiratory Tract Infection				
	Ventricular Hypertrophy				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556874-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00891
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Paxil	C		ORAL		
	Drug Abuser		Norvasc	C		ORAL		
	Dyspepsia		Labetalol Hydrochloride	C			UNKNOWN	
	Hypertension		Hyzaar	C			UNKNOWN	
	Hypoaesthesia		Humulin 70/30	C			SUBCUTANEOUS	243 DAY
	Joint Stiffness		Humulin 70/30	C			SUBCUTANEOUS	243 DAY
	Lower Respiratory Tract Infection							
	Obesity							
	Pain							
	Pain In Extremity							
	Palpitations							
	Paraesthesia							
	Penile Pain							
	Renal Cyst							
	Swelling							
	Vision Blurred							
	Weight Increased							

Date:01/20/05ISR Number: 4556885-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01941
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Syncope		Aciphex	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

			Clonidine	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						

Date:01/20/05ISR Number: 4556886-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00688
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Synthroid	C				
UNKNOWN								

Date:01/20/05ISR Number: 4556891-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00146
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Cardiovascular Disorder
	Chest Pain
	Disorientation
	Dysphagia
	Fall
	Fatigue

		Forearm Fracture Nausea					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
725 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
725 DAY							
				Aspirin	C		ORAL
				Ranitidine Hydrochloride	C		ORAL
				Levothyroxine Sodium	C		ORAL

Date:01/20/05ISR Number: 4556896-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01611
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Amnesia		Lipitor	C		
Initial or Prolonged	Anaemia Arterial Occlusive Disease Chest Pain Coronary Artery Disease Dyspnoea Hernia Renal Failure					

Date:01/20/05ISR Number: 4556898-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00707
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
228 DAY						
Initial or Prolonged	Coronary Artery Disease		Neurontin	C		ORAL
Disability	Depression		Flexeril	C		ORAL
	Diabetes Mellitus		Viagra	C		ORAL
	Non-Insulin-Dependent		Lipitor	C		ORAL
	Erectile Dysfunction		Valtrex	C		ORAL
77 DAY						

	Hypertension		Niaspan	C		ORAL
	Hypertriglyceridaemia		Paxil	C		
UNKNOWN						
	Micturition Disorder					
	Myocardial Infarction					
	Renal Failure Acute					

Date:01/20/05ISR Number: 4556899-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/20/05ISR Number: 4556900-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00982
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Gastrooesophageal Reflux Disease					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556901-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00015
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		270 DAY
Initial or Prolonged	Headache		Propoxyphene					
	Hypertension		Napsylate	C				
UNKNOWN								

Date:01/20/05ISR Number: 4556902-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/20/05ISR Number: 4556903-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01781
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556905-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03271
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
	Ocular Vascular Disorder		Zocor	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								

Date:01/20/05ISR Number: 4556907-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01392
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:01/20/05ISR Number: 4556908-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular							

Date:01/20/05ISR Number: 4556909-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556910-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556911-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1083 DAY

Date:01/20/05ISR Number: 4556912-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556913-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01777
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556915-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556917-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01881
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556919-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556921-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01799
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/20/05ISR Number: 4556922-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556923-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556925-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01797
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
							1	YR

Date:01/20/05ISR Number: 4556926-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01830
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556927-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01880
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556930-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01796
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556931-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556932-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/20/05ISR Number: 4556934-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556938-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/20/05ISR Number: 4556940-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02295
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Renal Failure Thrombosis							

Date:01/20/05ISR Number: 4556942-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556943-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Cardiac Failure Congestive Myocardial Infarction							

Date:01/20/05ISR Number: 4556945-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02296
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556946-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/20/05ISR Number: 4556947-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02095
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Mobility Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Speech Disorder		Norvasc	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556952-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Thrombosis							

Date:01/20/05ISR Number: 4556954-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:01/20/05ISR Number: 4556955-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02321
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/20/05ISR Number: 4556956-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02297
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1137	DAY
	Thrombosis							

Date:01/20/05ISR Number: 4556958-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02362
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/20/05ISR Number: 4556960-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/20/05ISR Number: 4556961-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02327
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1029	DAY

Date:01/20/05ISR Number: 4556962-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	256	DAY
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4556963-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Pulmonary Embolism							

Date:01/20/05ISR Number: 4556965-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Hypothyroidism		Synthroid	C			UNKNOWN	
			Asacol	C			UNKNOWN	
			Premarin	C			UNKNOWN	

Date:01/20/05ISR Number: 4556967-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:01/20/05ISR Number: 4556971-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02394
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4556972-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive Death Renal Failure							

Date:01/20/05ISR Number: 4556974-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Other	Myocardial Infarction							

Date:01/20/05ISR Number: 4556975-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557069-3Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0351046A
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Deroxat	PS	Glaxosmithkline	ORAL	20MG Per day	
Initial or Prolonged	Blood Amylase Increased		Efferalgan	SS	Glaxosmithkline	ORAL	4UNIT per day	
	Gamma-Glutamyltransferase		Nexen	SS	Glaxosmithkline	ORAL		
	Increased		Vioxx	SS		ORAL	1UNIT Per day	
	Hepatic Steatosis		Topalgic (France)	SS		ORAL	2UNIT per day	
	Pancreatitis Acute		Art	SS		ORAL	50MG Per day	
	Pancreatitis Necrotising							

Date:01/20/05ISR Number: 4557554-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aortic Valve Incompetence
Initial or Prolonged	Aortic Valve Sclerosis
Disability	Autoimmune Thyroiditis
Other	Binocular Eye Movement Disorder
	Bronchitis Chronic
	Carpal Tunnel Syndrome
	Cataract
	Cerebrovascular Accident
	Chest Pain
	Cholelithiasis
	Chronic Fatigue Syndrome
	Coronary Artery Disease
	Depression
	Dizziness
	Drug Hypersensitivity
	Duodenitis
	Endocarditis
	Gallbladder Disorder
	Gastritis
	Gastrooesophageal Reflux Disease
	Generalised Anxiety

Disorder
Haematuria
Hemianopia Homonymous
Herpes Zoster
Hypertension
Hypertensive Crisis
Hypoacusis
Hypokalaemia
Hyponatraemia
Irritable Bowel Syndrome
Labile Hypertension
Lacunar Infarction
Laryngitis
Migraine With Aura
Mitral Valve
Calcification
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Panic Disorder
Rhinitis Seasonal
Sleep Apnoea Syndrome
Strabismus

		Tension Headache					
		Thalamus Haemorrhage					
		Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Upper Respiratory Tract		Hytrin	C		
UNKNOWN							
		Infection		Estratab	C		
UNKNOWN							
				Ranitidine	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				L-Thyroxin	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:01/20/05ISR Number: 4557557-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
Other		Back Pain		Lortab	C		ORAL
		Bladder Disorder		Excedrin			
		Buttock Pain		Extra-Strength	C		
UNKNOWN							
		Cerebrovascular Accident					
		Constipation					
		Csf Glucose Decreased					
		Csf White Blood Cell					
		Count Increased					
		Delusion					
		Diarrhoea					
		Headache					
		Herpes Zoster					
		Hypotonic Urinary Bladder					

Intervertebral Disc
Protrusion
Ligament Sprain
Meningitis Aseptic
Muscle Contractions
Involuntary
Muscle Spasticity
Nausea
Pain In Extremity
Paranoia
Psychotic Disorder
Pyrexia
Sinusitis
Stomach Discomfort
Tremor
Venous Thrombosis Limb

Date:01/20/05ISR Number: 4557558-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Cough
Disability	Dyspnoea
	Emotional Distress
	Fatigue
	Gastrooesophageal Reflux

		Disease					
		Hypersensitivity					
		Migraine					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Small Intestinal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Upper Respiratory Tract		Aspirin	C		
UNKNOWN							
		Infection		Echinacea	C		
UNKNOWN		1483 DAY					
		Viral Infection		Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Dicyclomine Hydrochloride	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							

Date:01/20/05ISR Number: 4557560-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00785
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adenoma Benign		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
		Amaurosis Fugax		Vioxx	SS	Merck & Co., Inc	ORAL
		Angina Pectoris		Digoxin	C		ORAL
		Angiopathy		Pravastatin Sodium	C		ORAL
		Bladder Cancer		Cartia Xt	C		ORAL
		Blood Pressure Increased		Pletal	C		ORAL
		Cardiomegaly		Vitamin E	C		ORAL
		Carotid Artery Occlusion		Ascorbic Acid	C		ORAL
		Convulsion		Minerals			
		Cystitis Noninfective		(Unspecified) And			
		Electrocardiogram St		Vitamins			
		Segment Abnormal		(Unspecified)	C		ORAL
		Femoral Pulse Decreased		Flomax			

	Myocardial Ischaemia Nodule Peripheral Vascular Disorder Prostatitis Pulmonary Granuloma Transient Ischaemic Attack	(Morniflumate)	C	ORAL

Date:01/20/05ISR Number: 4557561-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome Hospitalization - Initial or Prolonged	PT Abdominal Abscess Cyst Diarrhoea Diverticulum Duodenal Dyspepsia Emotional Distress Gastrooesophageal Reflux Disease Hiatus Hernia Ileal Ulcer Ileitis Intervertebral Disc

		Degeneration					
		Large Intestinal Obstruction					
		Large Intestinal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Large Intestine		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Metabolic Acidosis		Vasotec	C		ORAL
		Multi-Organ Failure		Vasotec	C		ORAL
		Necrotising Colitis		Lipitor	C		
UNKNOWN							
		Osteoarthritis		Ecotrin	C		ORAL
		Pleural Effusion		Hydrochlorothiazide	C		
UNKNOWN							
		Renal Cortical Necrosis		Prevacid	C		
UNKNOWN							
		Renal Cyst		Relafen	C		
UNKNOWN							
		Renal Failure Acute		Ziac	C		
UNKNOWN							
		Renal Tubular Necrosis		Zebeta	C		
UNKNOWN							
		Respiratory Failure					
		Septic Shock					
		Small Intestine Ulcer					
		Vasospasm					
		Wound Infection					

Date:01/20/05ISR Number: 4557562-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abscess Limb
Other	Adhesion
	Adrenal Insufficiency
	Adverse Event
	Ankle Fracture
	Axillary Mass
	Back Injury
	Blood Cholesterol Increased
	Breast Cancer

Cellulitis
Chest Discomfort
Chest Pain
Contusion
Coronary Artery Disease
Csf Shunt Removal
Cyst Aspiration
Depression
Diarrhoea
Discomfort
Dizziness
Dyspepsia
Dyspnoea
Eye Injury
Fall
Gastritis
Gastroenteritis
Haemorrhoids
Helicobacter Gastritis
Hyperlipidaemia
Increased Tendency To
Bruise
Intestinal Hypomotility
Iron Deficiency Anaemia

		Joint Injury					
		Limb Injury					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Normal Pressure		Vioxx	SS	Merck & Co., Inc	ORAL
		Hydrocephalus		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Valium	C		
UNKNOWN							
		Radicular Pain		Sk-Erythromycin	C		
UNKNOWN							
		Road Traffic Accident		Cyanocobalamin	C		
PARENTERAL							
		Shunt Infection		Nitrostat	C		
UNKNOWN							
		Transaminases Increased		Synthroid	C		
UNKNOWN							
		Wheezing		Paxil	C		
UNKNOWN							
		Wound Dehiscence		Lanoxin	C		
UNKNOWN							
				Salagen Tablets	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Zofran	C		
UNKNOWN							
				Miacalcin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Detrol La	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							

	Primidone	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		

Date:01/20/05ISR Number: 4557570-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00069
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Discomfort
Hospitalization - Initial or Prolonged	Aneurysm
	Asthma
Other	Atelectasis
	Basal Cell Carcinoma
	Blood Cholesterol Increased
	Bronchitis Acute
	Carotid Artery Stenosis
	Cerebral Haemorrhage
	Chest Wall Pain
	Coma
	Confusional State
	Deep Vein Thrombosis
	Depression
	Dyspepsia
	Eczema
	Emotional Distress
	Eye Haemorrhage
	Flatulence
	Gastrointestinal Disorder
	Heart Rate Increased
	Hyperlipidaemia
	Hypertension
	Hypokalaemia
	Mitral Valve Incompetence

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Osteoarthritis					
		Osteopenia					
		Respiratory Alkalosis					
		Respiratory Rate		Vioxx	PS	Merck & Co., Inc	ORAL
457	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Albuterol	C		
UNKNOWN							
		Sputum Abnormal		Singulair	C		
UNKNOWN							
		Transient Ischaemic		Amoxicillin	C		
UNKNOWN							
		Attack		Correctol			
		Tricuspid Valve		(Bisacodyl)	C		
UNKNOWN							
		Incompetence		Hydrochlorothiazide	C		
UNKNOWN							
		Wheezing		Aspirin	C		
UNKNOWN							
				Medrol	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Baycol	C		
UNKNOWN							
				Doxepin			
				Hydrochloride	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN		119 DAY					
				Calan	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN		1210 DAY					
				Tylenol	C		
UNKNOWN							

Date:01/20/05ISR Number: 4557571-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		573 DAY
Initial or Prolonged	Coagulopathy		Synthroid	C				UNKNOWN
Disability	Cough		Spironolactone	C				UNKNOWN
	Dehydration		Hydrocodone Hydrochloride	C				UNKNOWN
	Depression		Ibuprofen	C				UNKNOWN
	Haemorrhagic Stroke		Celebrex	C				UNKNOWN
	Nasal Congestion		Demadex	C				UNKNOWN
	Thrombocytopenia		Lasix (Furosemide)	C				UNKNOWN
	Visual Acuity Reduced		Lozol	C				UNKNOWN
			Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C				UNKNOWN

Date:01/20/05ISR Number: 4557572-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia							
Disability	Back Pain							
Other	Buttock Pain							
	Coronary Artery Disease							
	Hyperlipidaemia							
	Hypertension							
	Muscle Spasms							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557573-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01976
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		97 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		97 DAY
Disability	Infarction		Neurontin	C		ORAL		
Other	Aortic Dilatation		Ultram	C		ORAL		
	Back Pain		Doxepin Hydrochloride	C				UNKNOWN
	Cellulitis		Zanaflex	C				UNKNOWN
	Cerebral Atherosclerosis		Serzone	C		ORAL		
	Chest Pain		Acetaminophen And Oxycodone Hydrochloride	C		ORAL		
	Convulsion							
	Coronary Artery Disease							
	Dizziness							
	Drug Hypersensitivity							
	Drug Ineffective							
	Dyspepsia							
	Dysphagia							
	Dyspnoea							
	Ear Pain							
	Eructation							
	Fall							
	Fatigue							
	Generalised Anxiety Disorder							
	Haemorrhage Intracranial							
	Headache							
	Hiatus Hernia							
	Hypersensitivity							
	Hypertension							
	Hypoaesthesia							
	Insomnia							
	Joint Effusion							
	Joint Injury							
	Joint Sprain							
	Local Swelling							
	Oesophagitis							
	Pain							
	Panic Attack							
	Pharyngolaryngeal Pain							
	Psoriasis							

Pulmonary Congestion
Retinal Ischaemia
Rhinitis
Rhinitis Allergic
Sleep Apnoea Syndrome
Ventricular Extrasystoles
Visual Acuity Reduced
Visual Disturbance

Date:01/20/05ISR Number: 4557574-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery Disease

		Dementia Alzheimer'S Type					
		Depression					
		Diabetic Foot Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Glucophage	C		
UNKNOWN							
		Emotional Distress		Zocor	C		ORAL
		Eyelid Ptosis		Arthrotec	C		
UNKNOWN							
		Haematuria					
		Headache					
		Ingrowing Nail					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Musculoskeletal Stiffness					
		Myalgia					
		Psychomotor Hyperactivity					
		Rash					
		Sinobronchitis					
		Somnolence					
		Syncope					
		Upper Respiratory Tract Infection					
		Vision Blurred					

Date:01/20/05ISR Number: 4557576-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00094
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 922 DAY	Adams-Stokes Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrioventricular Block		Aspirin	C		ORAL
Disability	Second Degree		Levothyroxine Sodium	C		ORAL

Date:01/20/05ISR Number: 4557577-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00139
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Acute Sinusitis
Disability	Arthralgia

Other	Asthenia
	Atherosclerosis
	Benign Neoplasm
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis Acute
	Carotid Artery Stenosis
	Cerebral Artery Occlusion
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Conjunctivitis
	Cubital Tunnel Syndrome
	Dizziness
	Emotional Distress
	Epidermal Naevus
	Fatigue
	Hemianopia Homonymous
	High Density Lipoprotein Decreased

		Hypertension					
		Hypoacusis					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein		Vioxx	SS		ORAL
1	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Malaise					
		Pain In Extremity					
		Paraesthesia					
		Pharyngitis					
		Radial Tunnel Syndrome					
		Temperature Intolerance					
		Thermal Burn					
		Transient Ischaemic					
		Attack					
		Ulnar Tunnel Syndrome					
		Vascular Stenosis					
		X-Ray Limb Abnormal					

Date:01/20/05ISR Number: 4557591-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00391
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL
319	DAY					
Hospitalization -	Complete		Vioxx	SS	Merck & Co., Inc	ORAL
82	DAY					
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
156	DAY					
Disability	Cerebrovascular Accident		Xipamide	C		ORAL
	Hypertension		[Therapy Unspecified]	C		ORAL

Date:01/20/05ISR Number: 4557592-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01740
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Accident
Other	Acute Myocardial

Infarction
Anxiety
Arthralgia
Arthropathy
Atrial Fibrillation
Blood Alkaline
Phosphatase Increased
Blood Pressure Increased
Blood Triglycerides
Increased
Cardiomegaly
Coronary Artery Disease
Coronary Artery Stenosis
Cystitis
Depression
Dermatitis Contact
Diabetes Mellitus
Inadequate Control
Diabetic Nephropathy
Drug Hypersensitivity
Exercise Lack Of
Food Allergy

		Gastrooesophageal Reflux Disease					
		General Physical Health Deterioration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
26	MON						
		Hepatic Enzyme Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vicodin Tablets	C		
UNKNOWN							
		Hypercholesterolaemia		Clonidine	C		
UNKNOWN							
		Hypertension					
		Joint Sprain					
		Migraine					
		Myocardial Infarction					
		Osteoarthritis					
		Pain					
		Pernicious Anaemia					
		Productive Cough					
		Pulmonary Congestion					
		Sinusitis					
		Traumatic Arthritis					
		Upper Respiratory Tract Infection					
		Ventricular Fibrillation					
		Ventricular Tachycardia					
		Weight Increased					

Date:01/20/05ISR Number: 4557594-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
1128 DAY							
Initial or Prolonged		Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
1128 DAY							
Other		Acute Myocardial		Effexor	C		
UNKNOWN		247 DAY					
		Infarction		Nortriptyline	C		
UNKNOWN		233 DAY					
		Arthralgia		Trazodone			
		Chest Pain		Hydrochloride	C		
UNKNOWN							

	Corneal Ulcer	Vicodin Tablets	C
UNKNOWN			
	Coronary Artery Occlusion		
	Coronary Artery Restenosis		
	Cough		
	Diverticulum		
	Emotional Distress		
	Fatigue		
	Gastritis		
	Gastroduodenitis		
	Haematuria		
	Hyperlipidaemia		
	Hypertension		
	Myocardial Infarction		
	Nausea		
	Neck Pain		
	Nephrolithiasis		
	Pain		
	Vision Blurred		
	Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557599-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00047
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		5 MIN
Initial or Prolonged	Stevens-Johnson Syndrome		Celecoxib	SS		ORAL		14 DAY

Date:01/20/05ISR Number: 4557601-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01509
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Valium	C				UNKNOWN
			Effexor	C		ORAL		
			Motrin	C		ORAL		
			Tylenol With Codeine #3	C		ORAL		

Date:01/20/05ISR Number: 4557602-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01508
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Disability	Cardiac Failure		Lipitor	C				UNKNOWN
	Congestive		Prevacid	C				UNKNOWN
	Cardiac Murmur		Cefuroxime	C				UNKNOWN
	Dilatation Atrial		Clonazepam	C				UNKNOWN
	Lipids Increased							
	Mitral Valve Incompetence							

Myocardial Infarction
Oedema

Date:01/20/05ISR Number: 4557603-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03531
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Prempro	C				
UNKNOWN								

Date:01/20/05ISR Number: 4557604-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00654
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Anal Haemorrhage
	Anxiety
	Cerebrovascular Accident
	Coronary Artery Disease
	Decreased Appetite
	Diarrhoea
	Dyspepsia
	Fall
	Fatigue
	Hip Fracture

	Hyperlipidaemia						
	Hypertension						
	Intestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction		Toprol Xl Tablets	C			UNKNOWN	
	Rash		Clonidine	C			UNKNOWN	
	Renal Bruit		[Therapy					
	Sinus Disorder		Unspecified]	C			UNKNOWN	
	Urinary Retention							

Date:01/20/05ISR Number: 4557606-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02213
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blindness Unilateral							
	Blood Pressure Increased							
	Diverticulum							
	Eyelid Ptosis							
	Glaucoma							
	Haemorrhoids							
	Intraocular Pressure							
	Increased							
	Macular Oedema							
	Retinal Vein Occlusion							

Date:01/20/05ISR Number: 4557608-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00856
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557609-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02805
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Lasix (Furosemide)	C				
Initial or Prolonged	Limb Discomfort		Albuterol	C				
Disability			Lisinopril	C				
			Spironolactone	C				
			Aspirin	C				
			Digitora	C				
			Zocor	C				
			Karvedilol	C				

Date:01/20/05ISR Number: 4557610-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01990
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	92 DAY	
Hospitalization -	Hemianopia Homonymous		Calan Sr	C		ORAL		
Initial or Prolonged	Lacunar Infarction		Synthroid	C		ORAL		
Disability	Visual Disturbance		Fosamax	C		ORAL		
			Ambien	C		ORAL		
			Hyzaar	C		ORAL		

Date:01/20/05ISR Number: 4557611-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01937
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
	Headache		Singulair	C			UNKNOWN	
	Loss Of Consciousness		Lortab	C			UNKNOWN	
	Pain In Extremity		Soma	C			UNKNOWN	
	Renal Cyst		Claritin-D	C			UNKNOWN	
	Renal Impairment		Valium	C			UNKNOWN	
	Upper Respiratory Tract Infection		Zantac	C			UNKNOWN	
			Patanol	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	
			Hydrocortisone	C			UNKNOWN	
			Seroquel	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Albuterol	C			UNKNOWN	

Date:01/20/05ISR Number: 4557612-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00814
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Hepatic Neoplasm		Prilosec	C		ORAL		

Hospitalization -	Malignant		Nexium	C
UNKNOWN				
Initial or Prolonged	Neoplasm Malignant		Ativan	C
UNKNOWN				
Disability			Restrol	C
UNKNOWN				

Date:01/20/05ISR Number: 4557613-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00842
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557614-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01993
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -	Cardiac Disorder		[Therapy					
Initial or Prolonged	Cardiac Failure		Unspecified]	C				
UNKNOWN								
Disability	Congestive		[Therapy					
Other	Hepatomegaly		Unspecified]	C				
UNKNOWN								
	Limb Injury							

Date:01/20/05ISR Number: 4557615-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01017
Age:90 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:01/20/05ISR Number: 4557616-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03369
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atelectasis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		[Therapy					
Initial or Prolonged	Coronary Artery Disease		Unspecified]	C				
UNKNOWN								
Disability	Dyslipidaemia		[Therapy					
Other	Dyspepsia		Unspecified]	C				
UNKNOWN								
	Fibromyalgia		Singulair	C				
UNKNOWN								
	Fungal Infection		Singulair	C				
UNKNOWN								
	Gastrooesophageal Reflux Disease							
	Haematoma							
	Hypercholesterolaemia							
	Mitral Valve Disease							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Osteoporosis							

Date:01/20/05ISR Number: 4557617-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00011
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Methotrexate	C				
UNKNOWN								

	Cozaar	C		ORAL
	Metoprolol Succinate	C		
UNKNOWN				
	Aspirin	C		
UNKNOWN				
	Insulin Aspart	C		
UNKNOWN				
	Insulin Human, Isophane	C		
UNKNOWN				

Date:01/20/05ISR Number: 4557620-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00073
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							
	Sciatica							
	Thrombosis							

Date:01/20/05ISR Number: 4557622-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/20/05ISR Number: 4557623-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01894
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/20/05ISR Number: 4557624-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557625-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Quadruple Vessel Bypass Graft		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557626-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01750
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557627-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01812
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/20/05ISR Number: 4557629-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Thrombosis							

Date:01/20/05ISR Number: 4557631-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01791
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557632-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00892
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
	Renal Failure							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557633-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00016
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	1662 DAY	
Initial or Prolonged	Condition Aggravated		Atenolol	C			UNKNOWN	
			Isosorbide Mononitrate	C			UNKNOWN	
			Amiloride Hydrochloride And Hydrochlorothiazide	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	
			Omeprazole Magnesium	C			UNKNOWN	
			Acetaminophen And Propoxyphene Hydrochloride	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	

Date:01/20/05ISR Number: 4557634-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01807
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	
	Coma							
	Convulsion							

Date:01/20/05ISR Number: 4557636-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01565
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/20/05ISR Number: 4557637-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01811
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/20/05ISR Number: 4557638-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/20/05ISR Number: 4557640-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557642-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557643-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557644-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01865
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557646-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01898
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:01/20/05ISR Number: 4557647-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

Date:01/20/05ISR Number: 4557648-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557650-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02350
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polyneuropathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557651-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02243
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557653-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02348
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557654-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	758 DAY	
	Cardiac Failure Congestive							

Date:01/20/05ISR Number: 4557656-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
	Hypertension							

Date:01/20/05ISR Number: 4557657-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02238
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4557658-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02672
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
3 YR

Date:01/20/05ISR Number: 4557660-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01832
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
5 YR

Date:01/20/05ISR Number: 4557661-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01828
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
2 YR
Myocardial Infarction

Date:01/20/05ISR Number: 4557664-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02257
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Chest Pain Vioxx PS Merck & Co., Inc ORAL
Myocardial Infarction

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/20/05ISR Number: 4557666-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							
	Pulmonary Embolism							
	Thrombosis							

Date:01/20/05ISR Number: 4557677-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/20/05ISR Number: 4559974-0Report Type:Direct Company Report #CTU 237314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS				
25 MG 1 DAILY								
Initial or Prolonged	Chest Pain							
	Headache							
	Hypertension							
	Oedema Peripheral							
	Pain In Extremity							
	Renal Disorder							
	Vision Blurred							

Date:01/20/05ISR Number: 4559975-2Report Type:Direct Company Report #CTU 237515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Vioxx	PS				
25 MG 1 TIME								
Initial or Prolonged	Arthritis							
A DAY								

Cerebrovascular Accident
Chest Pain
Condition Aggravated
Hypertension
Pain
Renal Pain

Date:01/21/05ISR Number: 4558385-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:01/21/05ISR Number: 4558386-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01910
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558393-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01918
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558395-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02233
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:01/21/05ISR Number: 4558400-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02244
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Thrombosis							

Date:01/21/05ISR Number: 4558401-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558402-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558403-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02234
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558406-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02237
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558407-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02227
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558409-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/21/05ISR Number: 4558410-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558415-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02377
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/21/05ISR Number: 4558416-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558417-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558418-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558419-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02371
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558421-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558424-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558429-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02384
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/21/05ISR Number: 4558432-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02679
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558433-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:01/21/05ISR Number: 4558434-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02386
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558435-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/21/05ISR Number: 4558436-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/21/05ISR Number: 4558438-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558439-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558440-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02331
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558441-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	16 MON	
	Transient Ischaemic Attack							

Date:01/21/05ISR Number: 4558446-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

Date:01/21/05ISR Number: 4558452-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558455-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00705
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Mass
Disability	Abdominal Panniculectomy

Adverse Event
Back Pain
Breast Neoplasm
Bronchitis
Diverticulum Duodenal
Dyspepsia
Dyspnoea Exertional
Haemorrhoids
Hypertension
Hypoaesthesia
Hypoventilation
Incision Site
Complication
Intraductal Papilloma Of
Breast
Lobar Pneumonia
Lumbar Vertebral Fracture
Migraine
Muscle Spasms
Osteitis Deformans
Pain
Palpitations
Pancreatic Mass
Piriformis Syndrome
Polytraumatism

	Retrosternal Fluid Evacuation						
	Sleep Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Urinary Incontinence		Synthroid	C		ORAL	
	Urinary Tract Infection		Elavil	C		ORAL	
	Vaginitis Atrophic		Restoril	C		ORAL	
	Vision Blurred		Fiorinal	C			UNKNOWN
			Felodipine	C			UNKNOWN
			Maxzide	C			UNKNOWN
			Lotensin	C			UNKNOWN
			Premarin	C			UNKNOWN
			Labetalol Hydrochloride	C			UNKNOWN
			Fioricet Tablets	C			UNKNOWN
			Flexeril	C			UNKNOWN

Date:01/21/05ISR Number: 4558460-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1127 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	1127 DAY
	Arthropathy		Viagra	C			UNKNOWN
	Bursitis		Amoxicillin	C			UNKNOWN
	Coronary Artery Disease		Plavix	C			UNKNOWN

	Depression	Ambien	C
UNKNOWN			
	Erectile Dysfunction	Trazodone	
	Hypercholesterolaemia	Hydrochloride	C
UNKNOWN			
	Hypertension	Ibuprofen	C
UNKNOWN			
	Laceration	Zanaflex	C
UNKNOWN			
	Peroneal Nerve Palsy	Altace	C
UNKNOWN			
	Pleuritic Pain	Diazepam	C
UNKNOWN			
		Hydrocodone Bitartrate	C
UNKNOWN			
		Hydrocodone Bitartrate	C
UNKNOWN	14 MON		
		Oxycontin	C
UNKNOWN	14 MON		

Date:01/21/05ISR Number: 4558462-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acarodermatitis
Other	Anaemia
	Anorexia
	Blood Pressure Inadequately Controlled
	Blood Testosterone Decreased
	Cardiac Failure
	Cholecystitis
	Cholelithiasis
	Chronic Hepatitis
	Coma
	Decreased Appetite
	Emotional Distress

		Erectile Dysfunction					
		Eye Infection					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gallbladder Enlargement		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease					
		Haemodialysis					
		Headache					
		Hepatic Cirrhosis					
		Hepatic Failure					
		Hiatus Hernia					
		Hypertension					
		Impaired Gastric Emptying					
		Infection					
		Insomnia					
		Intervertebral Disc					
		Disorder					
		Myocardial Infarction					
		Nasal Septum Deviation					
		Platelet Count Decreased					
		Rash					
		Renal Cyst					
		Renal Disorder					
		Renal Failure Acute					
		Testicular Mass					
		Weight Decreased					
		Weight Increased					

Date:01/21/05ISR Number: 4558463-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY						
Initial or Prolonged		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
Disability		Blood Triglycerides		Tylenol With Codeine			
		Increased		#3	C		ORAL
		Hypertension		Vicodin Tablets	C		
UNKNOWN							
		Joint Swelling		Tylenol	C		
UNKNOWN							

	Myocardial Infarction	Ecotrin	C
UNKNOWN			
	Oxygen Saturation Decreased		
	Tendonitis		

Date:01/21/05ISR Number: 4558464-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthenia
	Benign Prostatic Hyperplasia
	Choking
	Cough
	Depression
	Diverticulum
	Dysuria
	Erosive Duodenitis
	Fatigue
	Gastritis Erosive

		Gastrooesophageal Reflux Disease					
		Heat Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Aspirin	C		
UNKNOWN							
		Hypoacusis		Restoril	C		
UNKNOWN							
		Muscle Atrophy					
		Oesophageal Rupture					
		Pancreatitis					
		Renal Cyst					
		Rhinorrhoea					
		Supraventricular Extrasystoles					
		Thromboembolic Stroke					
		Transient Ischaemic Attack					
		Upper Respiratory Tract Infection					
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:01/21/05ISR Number: 4558465-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02683
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/21/05ISR Number: 4558466-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Acute Sinusitis
	Angina Pectoris
	Asthenia
	Blood Cholesterol

Increased
Bone Pain
Cardiac Failure
Congestive
Carpal Tunnel Syndrome
Coronary Artery Disease
Depression
Dizziness
Emotional Distress
Glucose Tolerance
Impaired
Intervertebral Disc
Protrusion
Nasopharyngitis
Neck Pain
Nervousness
Otitis Media
Pain
Pain In Extremity
Peripheral Nerve

Decompression
Radiculitis
Swelling

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc		UNKNOWN	582 DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Pancof	C			UNKNOWN	
	Celexa	C			UNKNOWN	
	Ziac	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Pepcid	C		ORAL		
	Diovan	C			UNKNOWN	
	Marcof Expectorant	C			UNKNOWN	
	Atrovent	C			UNKNOWN	
	Nasacort	C			UNKNOWN	
	Folic Acid	C			UNKNOWN	
	Tequin	C			UNKNOWN	
	Allfen Dm	C			UNKNOWN	
	Avelox	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	
	Hyzaar	C		ORAL		
	Proventil	C			UNKNOWN	
	Serevent	C			UNKNOWN	
	Rhinocort	C			UNKNOWN	

Date:01/21/05ISR Number: 4558468-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Angina Pectoris
	Anxiety
	Arrhythmia
	Balance Disorder
	Bladder Pain
	Cardiac Disorder
	Cough
	Cystitis
	Cystitis Noninfective
	Dermatitis
	Dermatitis Allergic
	Dizziness
	Duodenal Ulcer
	Dyspepsia
	Faecal Incontinence
	Fall
	Gastric Disorder
	Gastric Ulcer
	Gastritis
	Haematuria
	Headache
	Helicobacter Gastritis
	Hyperkeratosis
	Hypertonic Bladder
	Intestinal Haemorrhage
	Intestinal Polyp
	Irritable Bowel Syndrome
	Knee Deformity
	Ligament Sprain
	Osteoarthritis

		Pain					
		Pain In Extremity					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Reflux Oesophagitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Tinea Pedis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Incontinence		Losartan Potassium			
		Ventricular Fibrillation		And			
				Hydrochlorothiazide	C		ORAL
				Piracetam	C		ORAL
				Flupirtine Maleate	C		ORAL

Date:01/21/05ISR Number: 4558473-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00299
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Disturbance In Attention		Captopril	C		
UNKNOWN							
		Headache		Levothyroxine Sodium	C		
UNKNOWN							
		Hypertension		Tamsulosin			
		Metabolic Disorder		Hydrochloride	C		
UNKNOWN							
		Oedema Peripheral		Benzthiazide And			
		Palpitations		Triamterene	C		
UNKNOWN							
		Renal Failure		Harpagophytum			
		Vision Blurred		Procumbens	C		
UNKNOWN							
		Weight Increased		Tramadol			
				Hydrochloride	C		
UNKNOWN							
				Buprenorphine			
				Hydrochloride	C		
UNKNOWN							
				Esomeprazole			

			Magnesium	C		
UNKNOWN						

Date:01/21/05ISR Number: 4558475-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01377
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Dyspnoea		Calan Sr	C		ORAL		
			Aciphex	C		ORAL		
			Lasix (Furosemide Sodium)	C		ORAL		
			Zyrtec	C		ORAL		
			Metoprolol	C		ORAL		

Date:01/21/05ISR Number: 4558476-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00671
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis
	Hip Arthroplasty
Disability	Post Procedural

Complication
Pulmonary Embolism

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Omeprazole	C		ORAL		

Date:01/21/05ISR Number: 4558477-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Artery Occlusion		Oxycodone Hydrochloride	C				
	Cerebrovascular Accident							
	Monoparesis		Tolperisone Hydrochloride	C				
	Myocardial Infarction							
	Overdose		Omeprazole	C				
	Paresis		Flupirtine Maleate	C				
			Amitriptyline Hydrochloride	C		ORAL		
			Fentanyl	C		ORAL		
			Ranitidine Hydrochloride	C		ORAL		
			Dipyrone	C		ORAL		
			Simvastatin	C		ORAL		

Date:01/21/05ISR Number: 4558478-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00234
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Artery Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vitamin E	C		ORAL		
			Ranitidine	C		ORAL		
			[Therapy Unspecified]	C		ORAL		

Date:01/21/05ISR Number: 4558479-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Back Pain
	Cough
	Depression
	Dupuytren'S Contracture
	Dyslipidaemia
	Dysphagia
	Dyspnoea
	Erectile Dysfunction
	Fatigue
	Hypoaesthesia
	Impulse-Control Disorder
	Myocardial Infarction
	Pain In Extremity

	Premature Ejaculation						
	Pulmonary Congestion						
	Purulent Discharge	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Restless Legs Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	106 DAY
	Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL	363 DAY
	Rhonchi		Vioxx	SS	Merck & Co., Inc	ORAL	106 DAY
	Self-Injurious Ideation		Vioxx	SS	Merck & Co., Inc	ORAL	363 DAY
	Sinus Disorder		Zantac	C			UNKNOWN
	Sleep Apnoea Syndrome		Celexa	C			UNKNOWN
	Spinal Column Stenosis		Albuterol	C			RESPIRATORY
	Upper Respiratory Tract						(INHALATION)
	Infection		Vicodin Tablets	C		ORAL	
	Weight Increased						
	Wheezing						

Date:01/21/05ISR Number: 4558482-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00308
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Blood Pressure Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	
	Cardiac Failure		Piretanide	C		ORAL	
	Cardiovascular Disorder		Hydrochlorothiazide				
	Chest Discomfort		And Triamterene	C		ORAL	
	Coronary Artery Disease		Metoprolol	C		ORAL	
	Electrocardiogram		Clopidogrel				
	Abnormal		Bisulfate	C		ORAL	
	Extrasystoles		Levothyroxine Sodium				
	Fluid Retention		And Potassium Iodide	C		ORAL	
	Gastric Haemorrhage		Magnesium Aspartate				
	Gastric Ulcer		And Potassium				
	Gastritis		Aspartate	C		ORAL	
	Hypertensive Heart		Esomeprazole				
	Disease		Magnesium	C		ORAL	
	Sinoatrial Block		Simvastatin	C		ORAL	

Syncope

Date:01/21/05ISR Number: 4558484-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00090
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Prerenal Failure
	Adverse Event
	Angina Pectoris
	Anxiety Disorder
	Asthenia
	Blood Cholesterol Increased
	Cardiac Failure Chronic
	Cardiac Failure Congestive
	Cardiomegaly
	Cataract Nuclear
	Chest Pain
	Coronary Artery Disease
	Dementia
	Dependent Personality Disorder

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Depression					
		Diabetes Mellitus Non-Insulin-Dependent					
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		[Therapy			
		Dysthymic Disorder		Unspecified]	C		
UNKNOWN							
		Emotional Distress		Nifedipine	C		
UNKNOWN							
		Eye Pain		Maxzide	C		
UNKNOWN							
		Fibromyalgia		[Therapy			
		Gastric Disorder		Unspecified]	C		
UNKNOWN							
		Gastrooesophageal Reflux		Celexa	C		ORAL
		Disease		Lopressor	C		ORAL
		Gout		Nasonex	C		
RESPIRATORY							
		Haemorrhage					
(INHALATION)							
		Headache		Lotrel	C		ORAL
		Hyperlipidaemia		Nitrostat	C		
UNKNOWN							
		Hypertension					
		Hypertensive Crisis					
		Hypertensive Heart Disease					
		Hypovolaemia					
		Local Swelling					
		Major Depression					
		Memory Impairment					
		Mitral Valve Incompetence					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Personality Disorder					
		Pseudodementia					
		Psychogenic Pain Disorder					
		Pulmonary Valve Incompetence					
		Pyelonephritis					
		Respiratory Failure					
		Rhinitis Allergic					
		Sepsis					
		Sinusitis					
		Sleep Disorder					

Soft Tissue Infection
Transient Ischaemic
Attack
Urinary Tract Infection

Date:01/21/05ISR Number: 4558486-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02705
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558487-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	

Date:01/21/05ISR Number: 4558489-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00887
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Motrin	C				
UNKNOWN								
Disability	Atherosclerosis		Tylenol	C				
UNKNOWN								
Other	Blood Cholesterol Increased		[Therapy Unspecified]	C				
UNKNOWN								
	Coronary Artery Occlusion		Ultram	C				
UNKNOWN								
	Depression		Vicodin Tablets	C				
UNKNOWN								
	Dyslipidaemia		Atenolol Msd	C				
UNKNOWN								
	Injury							
	Myocardial Infarction							
	Nausea							
	Obesity							
	Stress							
	Ventricular Extrasystoles							

Date:01/21/05ISR Number: 4558491-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00907
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Aortic Aneurysm
Disability	Asthenia
	Back Pain
	Benign Prostatic Hyperplasia
	Brain Natriuretic Peptide Increased
	Cardiac Arrest
	Cardiac Disorder
	Cardiac Failure Congestive
	Cardiogenic Shock

Chest Discomfort
Coronary Artery Disease
Delirium
Depression Postoperative
Gastrooesophageal Reflux
Disease
General Physical Health
Deterioration
Hypertension
Hypotension
Hypoxia
Myocardial Infarction
Non-Cardiac Chest Pain
Osteoarthritis
Post Procedural
Complication
Post Procedural Haematoma
Post Procedural
Haemorrhage
Prostate Cancer
Pruritus
Renal Failure Acute
Urinary Incontinence

Vascular Bypass Graft
Ventricular Fibrillation

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558493-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558494-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Cerebrovascular Accident							

Date:01/21/05ISR Number: 4558495-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03295
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Corticosteroids					
	Spinal Column Stenosis		(Unspecified)	C			UNKNOWN	
			Tylox	C			UNKNOWN	
			Ultracet	C			UNKNOWN	

Date:01/21/05ISR Number: 4558496-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00155
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		119 DAY

Date:01/21/05ISR Number: 4558497-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01457
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Splenic Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1064 DAY
Other			Vioxx	SS	Merck & Co., Inc	ORAL		1064 DAY
			Prednisone	C		ORAL		
			Levoxyl	C		ORAL		
			Norvasc	C		ORAL		
			Premarin	C		ORAL		
			Premarin	C		ORAL		

Date:01/21/05ISR Number: 4558498-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01205
Age:84 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural		Benicar	C				UNKNOWN
	Haemorrhage		A.S.A.	C				UNKNOWN

Date:01/21/05ISR Number: 4558499-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00115
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
			Hormonal Contraceptives (Unspecified)	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Warfarin	C				UNKNOWN

Date:01/21/05ISR Number: 4558500-XReport Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00003
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	180 DAY	
Hospitalization -	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	18 DAY	
Initial or Prolonged	Dilatation Ventricular		Budesonide And					
Disability	High Density Lipoprotein		Formoterol Fumarate	C				
RESPIRATORY								

Other	Increased					
(INHALATION)						
	Myocardial Infarction		Tiotropium Bromide	C		
RESPIRATORY						
	Pulmonary Bulla					
(INHALATION)						
			Proscar	C		ORAL

Date:01/21/05ISR Number: 4558501-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04271
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Silent Myocardial					
Other	Infarction					

Date:01/21/05ISR Number: 4558502-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01668
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
868 DAY						
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
868 DAY						
Other	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
			Tiazac	C		ORAL
			Synthroid	C		ORAL
			Methotrexate	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558503-5Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00013
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	76	DAY
Initial or Prolonged			Ramipril	C		ORAL		
			Simvastatin	C		ORAL		

Date:01/21/05ISR Number: 4558505-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							1	YR

Date:01/21/05ISR Number: 4558506-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03095
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Flutter							
	Atrioventricular Block							
	Second Degree							
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Chest Pain							
	Coronary Artery Disease							
	Cough							
	Diarrhoea							
	Discomfort							
	Dysphonia							
	Dyspnoea Exertional							
	Effusion							
	Feeling Abnormal							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux							

Disease
Heart Rate Increased
Hyperhidrosis
Ischaemic Cardiomyopathy
Memory Impairment
Mitral Valve Incompetence
Nausea
Oedema Peripheral
Pain In Extremity
Pneumonia
Productive Cough
Refusal Of Treatment By
Patient
Respiration Abnormal
Sputum Discoloured
Thrombosis
Treatment Noncompliance
Tricuspid Valve
Incompetence
Ventricular Hypokinesia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558507-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure							

Date:01/21/05ISR Number: 4558508-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01676
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Zoloft	C			UNKNOWN	
			Claritin	C			UNKNOWN	

Date:01/21/05ISR Number: 4558509-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/21/05ISR Number: 4558510-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blindness Unilateral							
Other	Eye Disorder							
	Haemorrhage							
	Ocular Vascular Disorder							
	Retinal Artery Occlusion							

Date:01/21/05ISR Number: 4558512-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00168
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease							
	Myocardial Infarction							

Date:01/21/05ISR Number: 4558513-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01701
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Bextra	C				
Initial or Prolonged UNKNOWN			Celebrex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558514-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558516-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01772
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558518-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01824
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia Cerebrovascular Accident Coma		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/21/05ISR Number: 4558519-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00157
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysarthria Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558520-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01773
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						

Date:01/21/05ISR Number: 4558521-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01866
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Heart Transplant					
	Myocardial Infarction					

Date:01/21/05ISR Number: 4558523-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
	Inadequately Controlled					
	Cerebrovascular Accident					
	Hypertension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558524-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01857
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558526-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01909
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558527-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01895
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/21/05ISR Number: 4558528-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01856
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/21/05ISR Number: 4558532-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01902
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558533-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/21/05ISR Number: 4558544-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02356
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558876-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Cholesterol Increased
Hospitalization - Initial or Prolonged	Bronchitis
Disability	Chest Pain
	Coronary Artery Atherosclerosis

		Coronary Artery Restenosis					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Methotrexate	C		ORAL
		Myocardial Infarction		Ibuprofen	C		
UNKNOWN							
		Psoriatic Arthropathy		Folic Acid	C		
UNKNOWN							
				Zocor	C		ORAL
				Nitroquick	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Leucovorin	C		
UNKNOWN							
				Darvocet-N	C		ORAL
				Plavix	C		ORAL
				Lopressor	C		ORAL

Date:01/21/05ISR Number: 4558885-4Report Type:Expedited (15-DaCompany Report #US-MERCK-00072405
Age:82 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
68	DAY						
Initial or Prolonged		Duodenal Ulcer					
Disability		Duodenal Ulcer Haemorrhage					
		Upper Gastrointestinal Haemorrhage					

Date:01/21/05ISR Number: 4558890-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age:47 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adnexa Uteri Mass		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event					
Disability		Atherosclerosis					

Other	Basedow'S Disease
	Cardiac Failure
	Congestive
	Cellulitis
	Colonic Polyp
	Diverticulum
	Dyspnoea
	Dyspnoea Exertional
	Dyspnoea Paroxysmal
	Nocturnal
	Endocrine Ophthalmopathy
	Haemorrhoids
	Hyperhidrosis
	Hypertension
	Incontinence
	Mass
	Myocardial Infarction
	Nausea
	Non-Cardiac Chest Pain
	Oedema Peripheral
	Ovarian Cyst
	Pyelonephritis
	Sleep Apnoea Syndrome
	Urinary Tract Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558891-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
	Basal Cell Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL	53 DAY	
Disability	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	53 DAY	
	Conjunctivitis		Fosamax	C		ORAL		
	Coronary Artery Disease		Hydrodiuril	C		ORAL		
	Cough							
	Depression							
	Ingrowing Nail							
	Pain In Extremity							
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							

Date:01/21/05ISR Number: 4558898-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Lower
Other	Abscess
	Abscess Intestinal
	Acute Abdomen
	Adverse Event
	Angina Pectoris
	Arthralgia
	Atelectasis
	Blood Cholesterol Increased
	Blood Glucose Decreased
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure Congestive
	Carotid Artery Stenosis
	Cerebral Artery Stenosis
	Cerebral Ventricle Dilatation
	Cervical Cyst

Chest Pain
Colitis
Convulsion
Demyelination
Diverticular Perforation
Diverticulitis
Diverticulum Intestinal
Dizziness
Dyspnoea
Facial Palsy
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hand Fracture
Headache
Hypertension
Hypoaesthesia
Hypokalaemia
Leukocytosis

		Nausea					
		Ovarian Cyst					
		Pain In Extremity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonitis		Effexor Xr	C		
UNKNOWN							
		Pyrexia					
		Rotator Cuff Syndrome					
		Transient Ischaemic					
		Attack					
		Trigger Finger					
		Tubo-Ovarian Abscess					
		Umbilical Hernia					
		Vomiting					

Date:01/21/05ISR Number: 4558906-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Bronchitis					
		Cerebral Infarction					
		Cerebrovascular Accident					
		Chronic Lymphocytic					
		Leukaemia					
		Confusional State					
		Dermatitis Contact					
		Diarrhoea					
		Dysphasia					
		Eructation					
		Fatigue					
		Hot Flush					
		Hypercalcaemia					
		Hypertension					
		Lymphadenopathy					
		Neurodermatitis					
		Pollakiuria					
		Polyp					
		Rectal Haemorrhage					
		Restless Legs Syndrome					
		Speech Disorder					
		Tension Headache					

Thyroid Neoplasm
Vomiting

Date:01/21/05ISR Number: 4558907-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Anxiety
	Asthenia
	Atherosclerosis
	Back Pain
	Blood Pressure
	Inadequately Controlled
	Cerebral Infarction
	Cerebrovascular Accident

		Chest Pain					
		Convulsion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
		Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphagia		Lotrel	C		
UNKNOWN							
		Dyspnoea		Plavix	C		
UNKNOWN							
		Epidermal Naevus		Paxil	C		
UNKNOWN							
		Eructation		Nexium	C		
UNKNOWN							
		Eye Irritation		Prilosec	C		
UNKNOWN							
		Eye Pruritus		Norvasc	C		
UNKNOWN		395 DAY					
		Fatigue		Lipitor	C		
UNKNOWN		831 DAY					
		Flatulence		Lipitor	C		
UNKNOWN							
		Insomnia		Lipitor	C		
UNKNOWN		831 DAY					
		Intention Tremor		Lipitor	C		
UNKNOWN							
		Irritability		Zocor	C		ORAL
		Lacrimation Increased		Zocor	C		ORAL
		Lacunar Infarction		Zocor	C		ORAL
		Muscle Spasms		Tricor	C		
UNKNOWN							
		Myalgia		Zetia	C		ORAL
		Nausea		Zetia	C		ORAL
		Ocular Hyperaemia		Toprol Xl Tablets	C		ORAL
		Pain In Extremity		Toprol Xl Tablets	C		ORAL
		Palpitations		Neurontin	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Robaxin	C		ORAL
		Upper Respiratory Tract		Aspirin	C		
UNKNOWN							
		Infection		Ibuprofen	C		
UNKNOWN							
		Vascular Dementia		Glucovance	C		
UNKNOWN							
		Wheezing		Clorazepate			

	Dipotassium	C	UNKNOWN
	Darvocet-N	C	UNKNOWN
	Allegra	C	UNKNOWN
	Hydrodiuril	C	ORAL

Date:01/21/05ISR Number: 4558908-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Adverse Event
	Amnesia
	Anaemia
	Anal Fistula
	Aneurysm Ruptured
	Angina Unstable
	Anxiety
	Appendicitis Perforated
	Arthralgia
	Atelectasis
	Back Pain
	Cardiac Failure
	Cerebral Artery Stenosis
	Colitis Ulcerative
	Contusion
	Convulsion
	Coronary Artery Disease
	Cough
	Defaecation Urgency
	Depression

		Dermatitis					
		Dizziness					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Faecal Incontinence		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Flatulence					
		Headache					
		Hernia					
		Hyperlipidaemia					
		Hypertension					
		Hypotension					
		Ileitis					
		Impaired Healing					
		Infection					
		Inflammatory Bowel					
		Disease					
		Intestinal Perforation					
		Intestinal Spasm					
		Intracranial Aneurysm					
		Joint Injury					
		Migraine					
		Musculoskeletal Chest					
		Pain					
		Pain					
		Pain In Extremity					
		Perianal Abscess					
		Perirectal Abscess					
		Pneumoperitoneum					
		Proctalgia					
		Proctitis Ulcerative					
		Pruritus Ani					
		Pyrexia					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Tachycardia					
		White Blood Cell Count					
		Increased					

Date:01/21/05ISR Number: 4558911-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder

Hospitalization - Initial or Prolonged	Anxiety Back Injury Back Pain Blood Cholesterol Increased Blood Triglycerides Increased Depression Drug Dependence Drug Detoxification Drug Withdrawal Syndrome Dyspepsia Facet Joint Syndrome Gastric Ulcer Haematocrit Abnormal Headache

		Helicobacter Pylori Identification Test Positive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		High Density Lipoprotein		Vioxx	PS	Merck & Co., Inc	ORAL
		Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Zoloft	C		
UNKNOWN							
		Degeneration		Zoloft	C		
UNKNOWN							
		Intervertebral Disc		Avalide	C		
UNKNOWN							
		Disorder		Claritin	C		
UNKNOWN							
		Intervertebral Disc		Prozac	C		
UNKNOWN							
		Protrusion					
		Mood Altered					
		Nervousness					
		Osteoarthritis					
		Peptic Ulcer					
		Rhinitis Allergic					
		Spondylolisthesis					
		Spondylolysis					

Date:01/21/05ISR Number: 4558913-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00967
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Articular Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
		Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Bone Cyst					
		Cataract					
		Eye Haemorrhage					
		Gout					
		Hyperlipidaemia					
		Ischaemic Stroke					

Low Density Lipoprotein
Increased
Macular Oedema
Myocardial Infarction
Post-Traumatic Stress
Disorder
Retinal Haemorrhage
Retinal Vein Occlusion
Road Traffic Accident
Synovitis
Thrombosis

Date:01/21/05ISR Number: 4558915-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04169
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Leg Amputation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Lotensin	C				
UNKNOWN								
Initial or Prolonged	Peripheral Vascular		Lotrel	C				
UNKNOWN								
Disability	Disorder		Meclizine					
Other			Hydrochloride	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								

	Lorazepam	C	
UNKNOWN			
	Avandia	C	
UNKNOWN			
	Insulin	C	
UNKNOWN			

Date:01/21/05ISR Number: 4558916-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	30	DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Depression							
	Headache							
	Hepatic Enzyme Increased							
	Palpitations							
	Pulmonary Embolism							
	Stress							
	Tachycardia							

Date:01/21/05ISR Number: 4558917-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03808
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Renal Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
Initial or Prolonged	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Vioxx	SS	Merck & Co., Inc	ORAL	2	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		

				[Composition Unspecified]	C		
UNKNOWN							

Date:01/21/05ISR Number: 4558918-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00441
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Retinal Artery Occlusion		Prednisolone	C				
UNKNOWN								
Disability			Acetaminophen	C				
UNKNOWN								
			Lactulose	C				
UNKNOWN								
			Omeprazole Magnesium	C				
UNKNOWN							2	WK

Date:01/21/05ISR Number: 4558919-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02890
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
191 DAY								
Hospitalization -	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
191 DAY								
Initial or Prolonged	Peripheral Vascular		Diovan	C				
UNKNOWN								
Disability	Disorder		Evista	C				
UNKNOWN								
Other			Nexium	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN							1	YR
			Dyazide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558920-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01954
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		599 DAY
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angiopathy		Accupril	C			UNKNOWN	418 DAY
	Bronchitis		Vasotec	C			UNKNOWN	725 DAY
	Cardiomegaly		Enalapril Maleate	C			UNKNOWN	323 DAY
	Cellulitis		Verapamil	C			UNKNOWN	418 DAY
	Diabetic Neuropathy		Glucovance	C			UNKNOWN	
	Gout		Glucophage	C			UNKNOWN	
	Joint Sprain		Glucotrol Xl	C			UNKNOWN	
	Osteoarthritis		Allopurinol	C			UNKNOWN	
	Skin Ulcer		Colchicine	C			UNKNOWN	
			Benzonatate	C			UNKNOWN	

Date:01/21/05ISR Number: 4558921-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01301
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Lisinopril	C			UNKNOWN	
Other	Labyrinthitis		Maxzide	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Proscar	C		ORAL		

	Flomax (Morniflumate)	C
UNKNOWN		
	Prevacid	C
UNKNOWN		
	Glucosamine Hydrochloride And Chondroitin Sulfate Sodium	C
UNKNOWN		
	Ascorbic Acid	C
UNKNOWN		
	Vitamin E	C
UNKNOWN		
	Thiamine	C
UNKNOWN		
	Pyridoxine	C
UNKNOWN		
	Zinc (Unspecified)	C
UNKNOWN		
	Folic Acid	C
UNKNOWN		
	Doxycycline	C
UNKNOWN		
	Cardura	C
UNKNOWN		

Date:01/21/05ISR Number: 4558922-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Disability Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558923-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02508
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Disability	Prescribed Overdose		Prevacid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558924-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00154
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Hot And Cold		Hypericin	C				UNKNOWN
	Hyperventilation		Glimepiride	C				UNKNOWN
	Hypotension		Amitriptyline Hydrochloride	C				UNKNOWN
	Paraesthesia							
	Syncope		Betaxolol Hydrochloride	C				UNKNOWN
	Vertigo							
			Hydrochlorothiazide And Valsartan	C				UNKNOWN
			Diclofenac	C				UNKNOWN

Date:01/21/05ISR Number: 4558925-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Myocardial Infarction							

Date:01/21/05ISR Number: 4558926-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00020
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	440 DAY	UNKNOWN
			Lansoprazole	C				UNKNOWN
			Amlodipine Besylate	C				UNKNOWN

			Formoterol Fumarate	C
UNKNOWN				
			Prednisolone	C
UNKNOWN				
			Aspirin And Magnesium Oxide	C
UNKNOWN				
			Clopidogrel Bisulfate	C
UNKNOWN	9	MON		
			Atorvastatin Calcium	C
UNKNOWN				
			Metoprolol Tartrate	C
UNKNOWN				
			Abciximab	C
UNKNOWN	12	HR		
			Aspirin Calcium	C
UNKNOWN				
			Verapamil Hydrochloride	C
UNKNOWN				
			Heparin	C
UNKNOWN				

Date:01/21/05ISR Number: 4558927-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01756
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558928-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01009
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Dysarthria
Disability	Feeling Abnormal
	Incoherent
	Logorrhoea

		Mental Disorder					
		Mood Swings					
		Panic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Topamax	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Activella	C		
UNKNOWN							
				Deconamine	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:01/21/05ISR Number: 4558929-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01751
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/21/05ISR Number: 4558930-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01451
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Cell Carcinoma		Coumadin	C		
UNKNOWN							
		Stage Unspecified		Darvocet-N	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:01/21/05ISR Number: 4558931-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558932-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01911
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558933-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01920
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/21/05ISR Number: 4558934-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01500
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

				Lipitor	C		
UNKNOWN							

Date:01/21/05ISR Number: 4558935-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02097
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebrovascular Accident Heart Rate Irregular Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558936-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01921
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558937-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558938-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558939-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02241
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558940-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01944
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558941-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02677
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558942-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02363
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558943-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02273
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558944-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02354
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558945-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02219
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/21/05ISR Number: 4558947-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558948-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02390
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558949-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02674
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558950-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558951-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558952-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558953-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1461 DAY	

Date:01/21/05ISR Number: 4558954-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558955-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02106
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Thrombosis		Altace	C				
Initial or Prolonged UNKNOWN			Lanoxin	C				
Disability								

Date:01/21/05ISR Number: 4558956-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/21/05ISR Number: 4558957-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02675
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558958-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558959-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02661
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	634 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/21/05ISR Number: 4558960-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02676
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558961-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558962-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02689
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/21/05ISR Number: 4558963-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02659
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1071	DAY

Date:01/21/05ISR Number: 4558965-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:01/21/05ISR Number: 4558966-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02383
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558967-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Myocarditis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4558971-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Atherosclerosis Attention Deficit/Hyperactivity Disorder Blood Cholesterol Increased

		Chest Pain Chronic Fatigue Syndrome Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						
		Disease Generalised Anxiety		[Therapy Unspecified]	C		
UNKNOWN							
		Disorder		Paxil	C		
UNKNOWN							
		Haemorrhoidal Haemorrhage		Ibuprofen	C		
UNKNOWN							
		Hypertension		Zoloft	C		
UNKNOWN							
		Insomnia Lower Gastrointestinal Haemorrhage Microcytic Anaemia Panic Disorder Phlebitis Superficial					

Date:01/21/05ISR Number: 4558972-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02292
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/21/05ISR Number: 4558973-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02268
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/21/05ISR Number: 4558974-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/21/05ISR Number: 4560640-6Report Type:Expedited (15-DaCompany Report #2005-01-0690
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage Hypotension	Foreign Health Professional	Peg-Interferon Alfa-2b Injectable Powder	PS			SUBCUTANEOUS	SEE IMAGE
		Company	Ribavirin Capsules	SS		ORAL	SEE IMAGE	
		Representative	Naproxen	SS		ORAL	ORAL	
			Vioxx (Rofecoxib)	SS				

Date:01/21/05ISR Number: 4561608-6Report Type:Expedited (15-DaCompany Report #2005008566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Dissection	Consumer	Celebrex (Celecoxib)	PS			200 MG	
			Rofecoxib (Rofecoxib)	SS				

Date:01/21/05ISR Number: 4562383-1Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00233
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Foreign	Tab Vioxx					
	Silent Myocardial	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
	Infarction	Health					PO	240 DAY
		Professional	Amlodipine Besylate	C				
		Other	Aspirin	C				
			Bendroflumethiazide	C				
			Chondoitin Sulfate					
			Sodium (+) Glucosami	C				
			Cod Liver Oil	C				

Date:01/21/05ISR Number: 4562427-7Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00075
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Fluctuation	Foreign	Tab Vioxx					
Initial or Prolonged	Cardiac Failure	Study	(Rofecoxib)	PS		ORAL	25MG DAILY,	
	Congestive	Health					PO	
	Cardiac Murmur	Professional	Aspirin	C				
	Crepitations	Other	Atorvastatin Calcium	C				
	Dilatation Atrial		Escitalopram Oxalate	C				
	Dilatation Ventricular		Furosemide	C				
	Dyspnoea Exertional		Insulin, Biphasic					
	Dyspnoea Paroxysmal		Isophane (Injection)	C				
	Nocturnal		Metformin	C				
	Hypokinesia		Orlistat	C				
	Mitral Valve Incompetence		Quinapril Hcl	C				
	Orthopnoea		Sildenafil Citrate	C				
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							

Date:01/21/05ISR Number: 4562428-9Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00504
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Coronary Artery Occlusion							
	Myocardial Infarction	Health Professional	Alfuzosin Hydrochloride	C				
			Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil Dihydrochloride	C				

Date:01/21/05ISR Number: 4562434-4Report Type:Expedited (15-DaCompany Report #A02200403489
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bradycardia
	Chills
	Chronic Respiratory Failure
	Csf White Blood Cell Count Positive

		Grand Mal Convulsion Hypertension Leukoencephalopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Meningeal Disorder Nodal Rhythm Procedural Complication Pyrexia	Health Professional	Stilnox - (Zolpidem) - Tablet - 10 Mg	PS		ORAL
1000 MG QID				Dafalgan - (Paracetamol) - Tablet - 500 Mg	SS		ORAL
INTRAVENOUS	3 DAY			Vancomycin "Dakota Pharm" (Vancomycin Hydrochloride) - Powder	SS	Dakota Pharm	
				Vioxx - (Rofecoxib) - Tablet	SS		
20 MG QD				Morphine Chlorhydrate - (Morphine) - Solution	SS		ORAL
INTRAVENOUS	2 G Q 4HR			Claforan - (Cefotaxime Sodium) - Powder - 1g	SS		
INTRAVENOUS	80 MG QD			Acupan - (Nefopam Hydrochloride)	SS		
				(Troxerutin) - Powder - 3.5 G	SS		ORAL
				Stresam - (Etifoxine) - Capsule - 50 Mg	SS		ORAL

Date:01/21/05ISR Number: 4563919-7Report Type:Expedited (15-DaCompany Report #2004053291
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Anorexia
Disability	Arthralgia
Other	Ascites
	Asthenia
	Cachexia

Coagulopathy
Cognitive Disorder
Drug Ineffective
Fatigue
Feeling Abnormal
Gastroduodenitis
Haemangioma
Hepatic Failure
Hepatitis Toxic
Hepatosplenomegaly
Inadequate Analgesia
Lymphadenopathy
Lymphoma
Malnutrition
Metastatic Neoplasm
Mobility Decreased
Muscle Atrophy
Nausea
Pain Of Skin
Portal Hypertension
Pruritus

		Renal Failure					
		Sleep Disorder					
		Splenic Neoplasm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Malignancy Unspecified	Foreign	Lipitor			
		Splenomegaly	Health	(Atorvastatin)	PS		ORAL
20 MG (20 MG,							
		Varices Oesophageal	Professional				
1 IN 1 D),							
			Other				
ORAL							
				Rofecoxib			
				(Rofecoxib)	SS		ORAL
25 MG (25 MG,							
1 IN 1 D),							
ORAL							
				Ibuprofen			
				(Ibuprofen)	C		
				Paracetamol			
				(Paracetamol)	C		

Date:01/24/05ISR Number: 4559230-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00804
Age:42 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorientation		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Ultram	C		
UNKNOWN							
		Injury		Diazepam	C		
UNKNOWN							
		Pain In Extremity		Vitamins			
		Sleep Disorder		(Unspecified)	C		
UNKNOWN							
		Speech Disorder					
		Uterine Disorder					
		Weight Decreased					

Date:01/24/05ISR Number: 4559232-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Blood Pressure Increased
	Cardiomegaly
	Chest Discomfort
	Convulsion
	Coronary Artery Disease
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Discomfort
	Epicondylitis
	Extrasystoles
	Hot Flush
	Hypertension
	Mitral Valve Incompetence
	Myocardial Infarction
	Pulmonary Hypertension
	Radial Tunnel Syndrome
	Rotator Cuff Syndrome
	Thrombosis
	Ventricular Hypertrophy

Ventricular Hypokinesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lortab	C			UNKNOWN	
	Soma	C			UNKNOWN	
	Viagra	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Temazepam	C			UNKNOWN	

Date:01/24/05ISR Number: 4559233-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00807
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	1151 DAY	
Hospitalization -	Adverse Event		Naprosyn	SS			UNKNOWN	
Initial or Prolonged	Anaemia							
Disability	Arrhythmia							
	Atrial Flutter							
	Azotaemia							
	Bronchial Carcinoma							
	Candidiasis							
	Cardio-Respiratory Arrest							
	Cardiomegaly							
	Carotid Bruit							
	Chest Discomfort							
	Cholelithiasis							
	Coronary Artery Atherosclerosis							
	Dysphagia							
	Dyspnoea							
	Epicondylitis							
	Gammopathy							
	Gastrooesophageal Reflux Disease							

Haematuria
Hypotension
Interstitial Lung Disease
Jaundice
Leukocytosis
Multi-Organ Failure
Nephropathy Toxic
Neuralgia
Pulmonary Oedema
Renal Failure
Respiratory Failure
Rheumatoid Arthritis
Sepsis
Sepsis Syndrome
Tachycardia
Upper Respiratory Tract
Infection
Urinary Tract Infection
Urosepsis
Venous Insufficiency
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559234-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0403FRA00120
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
Initial or Prolonged	Gastroenteritis		Ginkgo Biloba					
	Melaena		Extract	C		ORAL		

Date:01/24/05ISR Number: 4559236-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01752
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		51 DAY
Initial or Prolonged	Infarction		Tenormin	C				
UNKNOWN								
Disability	Anal Inflammation							
Other	Anxiety Disorder							
	Back Injury							
	Back Pain							
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Cervical Spasm							
	Colonic Polyp							
	Constipation							
	Convulsion							
	Coordination Abnormal							
	Coronary Artery Occlusion							
	Depression							
	Dermatitis							
	Haematochezia							
	Haemorrhoids							
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertension							
	Memory Impairment							
	Mental Status Changes							
	Muscle Spasms							
	Nasal Cyst							
	Nasal Mucosal Disorder							
	Obesity							
	Oedema Peripheral							

Paraesthesia
Pharyngitis
Rhinitis
Sensory Disturbance
Sinus Polyp
Sleep Apnoea Syndrome
Stomach Discomfort
Stress
Upper Respiratory Tract
Infection

Date:01/24/05ISR Number: 4559240-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Arthropathy
Other	Back Pain
	Bronchitis
	Cardiomegaly

	Cerebrovascular Accident					
	Chest Discomfort					
	Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Cholelithiasis		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY					
	Coordination Abnormal		Wellbutrin	C		
UNKNOWN						
	Drug Hypersensitivity		Aspirin	C		
UNKNOWN						
	Fall		Lipitor	C		
UNKNOWN						
	Gastrooesophageal Reflux		Metformin	C		
UNKNOWN						
	Disease		Prozac	C		
UNKNOWN						
	Headache		Prilosec	C		
UNKNOWN						
	Hiatus Hernia		Glucophage	C		
UNKNOWN						
	Hypertension					
	Hypotension					
	Intention Tremor					
	Intervertebral Disc					
	Degeneration					
	Laryngitis					
	Non-Cardiac Chest Pain					
	Pneumonia					
	Respiratory Failure					
	Shock					
	Sinus Disorder					
	Spinal Column Stenosis					
	Spinal Compression					
	Fracture					
	Transient Ischaemic					
	Attack					
	Urinary Tract Infection					
	Vertigo					

Date:01/24/05ISR Number: 4559246-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Anaemia

Disability	Angina Pectoris
Other	Arthralgia
	Atherosclerosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chondromalacia
	Convulsion
	Diabetes Mellitus
	Inadequate Control
	Diabetic Complication
	Diabetic Neuropathy
	Diverticulum
	Dizziness
	Eye Injury
	Fall
	Gastritis
	Haemorrhoidal Haemorrhage
	Hand Fracture
	Hypertension
	Hypotension
	Joint Dislocation
	Leukopenia
	Ligament Sprain
	Meniscus Lesion

		Myelodysplastic Syndrome					
		Pharyngitis					
		Subcutaneous Abscess	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombocytopenia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Upper Respiratory Tract		Plavix	SS		
UNKNOWN							
		Infection		Captopril Msd	C		ORAL
				Glucotrol Xl	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Evista	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Prilosec	C		ORAL
				Humulin	C		
UNKNOWN							

Date:01/24/05ISR Number: 4559250-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02061
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Hospitalization -	Death		Vioxx	SS	Merck & Co., Inc	ORAL
1 YR						
Initial or Prolonged	General Physical Health					
Other	Deterioration					
	General Symptom					
	Knee Arthroplasty					
	Sepsis					
	Thrombosis					

Date:01/24/05ISR Number: 4559251-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	984 DAY	
	Atherosclerosis		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Cardiovascular Disorder							
	Cystocele							
	Depression		Wellbutrin	C		ORAL		
	Hypertension		Valium	C		ORAL		
	Liver Disorder		Estradiol	C		ORAL		
	Osteoporosis		Remeron	C		ORAL		
	Pain In Extremity		Lotensin	C			UNKNOWN	
	Polyneuropathy		Effexor Xr	C		ORAL		
	Rectocele		Prilosec	C			UNKNOWN	
	Renal Failure		Atacand	C			UNKNOWN	
			Celexa	C			UNKNOWN	
			Iron (Unspecified)	C			UNKNOWN	
			Diazepam	C			UNKNOWN	

Date:01/24/05ISR Number: 4559252-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Angina Pectoris
	Angina Unstable
	Cerebrovascular Accident
	Cervical Cord Compression
	Colonic Polyp

		Diabetes Mellitus					
		Non-Insulin-Dependent					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysphonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Heart Rate Irregular		Ketoconazole	C		ORAL
		Insomnia		Prednisone	C		ORAL
		Intervertebral Disc		Aspirin	C		ORAL
		Disorder		Tylenol	C		ORAL
		Intervertebral Disc		Guaifenex	C		ORAL
		Protrusion		Skelaxin	C		ORAL
		Irritable Bowel Syndrome		Claritin-D	C		ORAL
		Middle Ear Disorder		Estropipate	C		ORAL
		Musculoskeletal		Clidinium Bromide	C		ORAL
		Discomfort		Butalbital	C		ORAL
		Non-Cardiac Chest Pain		Motrin	C		ORAL
		Palpitations		Biaxin	C		ORAL
		Paraesthesia		Diflucan	C		
UNKNOWN							
		Spinal Column Stenosis		Trimox	C		ORAL
		Swelling		Hydrocodone			
		Swelling Face		Bitartrate	C		ORAL
		Vocal Cord Thickening		Diovan	C		ORAL
		Weight Decreased					
		Weight Increased					

Date:01/24/05ISR Number: 4559253-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01742
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthralgia		Vaseretic	C		ORAL
		Chronic Obstructive					
		Pulmonary Disease					
		Coronary Artery Disease					
		Haemorrhage					
		Heart Rate Irregular					
		Oedema Peripheral					

Date:01/24/05ISR Number: 4559262-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00621
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Anal Fistula
Disability	Atrial Fibrillation
	Carotid Artery Stenosis
	Coronary Artery Disease
	Dehydration
	Extrasystoles
	Haemorrhoids
	Intervertebral Disc Degeneration
	Intracardiac Thrombus
	Left Ventricular Failure
	Mitral Valve Incompetence
	Myocardial Infarction
	Peripheral Occlusive

		Disease Postoperative Infection Reactive Psychosis Renal Failure Chronic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence Varicose Vein		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Diltiazem Hydrochloride	C		
UNKNOWN							
				Oxycodone Hydrochloride	C		
UNKNOWN							
				Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		
UNKNOWN							

Date:01/24/05ISR Number: 4559264-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00011
Age:77 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Myocardial Infarction Retinal Vascular Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Methotrexate	C		
UNKNOWN							
				Cozaar	C		ORAL
				Metoprolol Succinate	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Insulin Aspart	C		
UNKNOWN							
				Insulin Human, Isophane	C		
UNKNOWN							

Date:01/24/05ISR Number: 4559265-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00086
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559266-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00219
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Arthritis
Hospitalization - Initial or Prolonged	Back Disorder
Disability	Bradycardia
Other	Chest Pain
	Coronary Artery Disease
	Diabetes Mellitus Non-Insulin-Dependent
	Dilatation Atrial
	Drug Dependence
	Electrocardiogram Q Wave Abnormal
	Erectile Dysfunction
	Gastrooesophageal Reflux Disease
	Hypoglycaemia
	Hypotension
	Insulin-Requiring Type Ii Diabetes Mellitus
	Myocardial Infarction

	Myocardial Ischaemia						
	Pain In Extremity						
	Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sinus Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	
	Visual Disturbance		Novolin R	C			UNKNOWN
			Morphine	C			UNKNOWN
			Alprazolam	C			UNKNOWN
			Nexium	C			UNKNOWN

Date:01/24/05ISR Number: 4559267-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01787
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
Initial or Prolonged			Zoloft	C		ORAL	
			Zestoretic	C		ORAL	
			Aspirin	C		ORAL	

Date:01/24/05ISR Number: 4559272-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01677
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abnormal Dreams		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Activities Of Daily		Vioxx	SS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Living Impaired		Lexapro	C			UNKNOWN
Disability	Asthenia		Synthroid	C		ORAL	
Other	Balance Disorder		Vitamin E	C		ORAL	
	Brain Oedema		Centrum	C		ORAL	
	Cerebrovascular Accident		Calcium				
	Clumsiness		(Unspecified)	C			UNKNOWN
	Coordination Abnormal		Estrace	C		ORAL	
	Drug Ineffective		Fosamax	C		ORAL	

	Dry Mouth		Hydrochlorothiazide	C		ORAL
	Dysaesthesia					
	Feeling Abnormal					
	Hemiparesis					
	Hypertension					
	Hypoaesthesia					
	Labyrinthitis					
	Lacunar Infarction					
	Mobility Decreased					
	Muscle Spasticity					
	Neuralgia					
	Osteoarthritis					
	Paraesthesia					
	Sensory Disturbance					
	Thalamic Syndrome					
	Vertigo					

Date:01/24/05ISR Number: 4559273-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02796
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	119 DAY	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	119 DAY	
	Treatment Noncompliance		Navane	C			UNKNOWN	
			Trazodone					

				Hydrochloride	C		
UNKNOWN							

Date:01/24/05ISR Number: 4559281-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01003
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Insulin	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:01/24/05ISR Number: 4559282-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:01/24/05ISR Number: 4559283-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia							
Disability	Cardiac Failure							
	Congestive							
	Dyspnoea							
	Hypertension							
	Oedema							

Date:01/24/05ISR Number: 4559284-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559285-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01891
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559286-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559288-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00170
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Perforated Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559292-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559293-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01844
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559294-4Report Type:Expedited (15-DaCompany Report #DK-MERCK-0501DNK00014
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	742	DAY
			Lisinopril	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Mesalamine	C		ORAL		
			Oxazepam	C		ORAL		
			Dipyridamole	C		ORAL		

Date:01/24/05ISR Number: 4559315-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/24/05ISR Number: 4559316-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/24/05ISR Number: 4559317-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559318-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Disorder Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559319-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02285
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559321-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	44	MON

Date:01/24/05ISR Number: 4559322-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02251
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Disorder Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/24/05ISR Number: 4559323-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02239
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR						
	Myocardial Infarction					

Date:01/24/05ISR Number: 4559324-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02678
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Heart Rate Irregular					
	Renal Failure					

Date:01/24/05ISR Number: 4559325-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain					
	Myocardial Infarction					
	Palpitations					
	Procedural Complication					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559326-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01892
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:01/24/05ISR Number: 4559327-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02424
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559328-7Report Type:Expedited (15-DaCompany Report #AT-MERCK-0501AUT00006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Composition					
	Hypertension		Unspecified]	C				
UNKNOWN								
	Paralysis							

Date:01/24/05ISR Number: 4559329-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00204
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Ventricular Hypertrophy							

Date:01/24/05ISR Number: 4559330-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559331-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/24/05ISR Number: 4559332-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559333-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:01/24/05ISR Number: 4559335-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559350-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR

Date:01/24/05ISR Number: 4559388-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01851
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559772-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event Blood Cholesterol
Other	Abnormal

Bursitis
Cardiac Failure
Congestive
Cardiomegaly
Cardiovascular Disorder
Chest Wall Pain
Confusional State
Decreased Activity
Drug Hypersensitivity
Faecal Incontinence
Fatigue
Feeling Cold
Fibula Fracture
Head Injury
Headache
Hot Flush
Hypertension
Incontinence
Laryngitis
Libido Decreased
Mood Swings
Muscle Spasms
Musculoskeletal Chest
Pain
Myocardial Infarction

		Neck Injury					
		Oedema					
		Ovarian Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pelvic Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Effexor	SS		
UNKNOWN							
		Renal Failure		Osteo-Bi-Flex	C		
UNKNOWN							
		Rotator Cuff Syndrome		Estrace	C		
UNKNOWN							
		Sleep Disorder		Vitamins			
		Stress		(Unspecified)	C		
UNKNOWN							
		Stress Incontinence		Vitamin B			
		Tendonitis		(Unspecified)	C		
UNKNOWN							
		Tricuspid Valve		Flagyl	C		
UNKNOWN							
		Incompetence		Cipro	C		
UNKNOWN							
		Urinary Tract Infection		Lotensin	C		
UNKNOWN							
		Vaginal Erosion		Zyrtec	C		
UNKNOWN							
		Vaginal Infection		Detrol	C		
UNKNOWN							
		Vaginal Odour					
		Varicose Vein					
		Vein Disorder					
		Vertigo					
		Viral Upper Respiratory					
		Tract Infection					
		Visual Disturbance					
		Vulvovaginal Discomfort					
		Weight Increased					

Date:01/24/05ISR Number: 4559773-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01113
Age:40 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Chest Pain	Coumadin	SS
UNKNOWN			
Other	Dizziness	Plavix	SS
UNKNOWN			
	Dyspnoea	Vitamins	
	Dyspnoea Exertional	(Unspecified)	C
UNKNOWN			
	Hyperlipidaemia	Aspirin	C
UNKNOWN			
	Loss Of Consciousness		
	Pyrexia		
	Renal Failure		

Date:01/24/05ISR Number: 4559777-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00638
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
Other	Asthenia
	Asthma
	Back Injury
	Back Pain
	Cardiac Failure
	Congestive
	Cataract
	Chest Pain
	Coronary Artery Disease
	Diabetes Mellitus
	Non-Insulin-Dependent

	Dyspnoea						
	Fibromyalgia						
	Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Disease		Vioxx	PS	Merck & Co., Inc	ORAL	
	Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hallucination, Auditory		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Limb Injury		Norflex	C			UNKNOWN
	Musculoskeletal Pain		Polaramine	C			UNKNOWN
	Nausea		Alprazolam	C			UNKNOWN
	Oedema Peripheral		Nitroquick	C			UNKNOWN
	Paraesthesia		Pepcid	C			UNKNOWN
	Peripheral Vascular		Diovan Hct	C			UNKNOWN
	Disorder		K-Dur	C		ORAL	
	Syncope		Fosamax	C			UNKNOWN
	Venous Stasis		Pravachol	C			UNKNOWN
	Ventricular Extrasystoles		Volmax	C		ORAL	
	Viral Infection		Albuterol	C			UNKNOWN
			Prevacid	C		ORAL	
			Accolate	C		ORAL	

Date:01/24/05ISR Number: 4559785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00706
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Chest Pain		Darvocet-N	C			UNKNOWN
	Deep Vein Thrombosis						
	Diastolic Dysfunction						
	Dilatation Atrial						
	Ear Pain						

Flank Pain
Hypertension
Insomnia
International Normalised
Ratio Increased
Joint Injury
Limb Injury
Localised Infection
Musculoskeletal Chest
Pain
Musculoskeletal Pain
Osteoarthritis
Pain In Extremity
Pain Of Skin
Patellofemoral Pain
Syndrome
Post Thrombotic Syndrome
Pruritus
Pulmonary Embolism
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559791-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00127
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		80 DAY
Initial or Prolonged Disability	Cardiac Failure		Prinivil	C		ORAL		UNKNOWN
	Congestive		Lasix (Furosemide)	C				UNKNOWN
	Cardioactive Drug Level		Coumadin	C				UNKNOWN
	Increased		Premarin	C				UNKNOWN
	Congestive Cardiomyopathy		Ginkgo Biloba Extract	C				UNKNOWN
	Depression							
	Dyspepsia		Pamelor	C				UNKNOWN
	Fibroadenoma Of Breast		Magnesium (Unspecified)	C				UNKNOWN
	Gastrointestinal Tract							
	Adenoma		Calcium (Unspecified)	C				UNKNOWN
	Haemorrhoids							
	Hyperlipidaemia		Vitamin B (Unspecified)	C				UNKNOWN
	Hypertension							
	Mood Swings		Vitamin E	C				UNKNOWN
	Musculoskeletal Chest		Ascorbic Acid	C				UNKNOWN
	Pain		Levocarnitine	C				UNKNOWN
	Nightmare		Lanoxin	C				UNKNOWN
	Pain In Extremity		Coenzyme Q10	C				UNKNOWN
	Pleurisy		Wellbutrin	C				UNKNOWN
	Sinus Tachycardia		Nicotine	C				UNKNOWN
	Snoring							
	Somnolence							
	Spinal Osteoarthritis							
	Ventricular Dyskinesia							
	Ventricular Extrasystoles							

Weight Increased

Date:01/24/05ISR Number: 4559792-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00648
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Discomfort
Other	Abdominal Pain
	Abdominal Pain Upper
	Adhesion
	Adverse Event
	Aerophagia
	Anaphylactic Reaction
	Anxiety
	Arthralgia
	Arthritis
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Breast Pain
	Chest Discomfort
	Chills
	Constipation
	Coronary Artery Atherosclerosis
	Cystitis
	Decreased Appetite
	Depressed Level Of Consciousness

Depression
Diarrhoea
Disease Recurrence
Dizziness
Drug Hypersensitivity
Drug Ineffective
Drug Intolerance
Dry Eye
Dry Mouth
Dysphagia
Dyspnoea
Dysuria
Ear Pain
Electrocardiogram
Abnormal
Electrocardiogram St
Segment Depression
Family Stress
Feeling Abnormal
Gastric Disorder
Gastrointestinal Motility
Disorder
Glossodynia
Headache
Helicobacter Infection
Hot Flush
Hyperchlorhydria
Hyperhidrosis
Hyperlipidaemia
Hypersensitivity
Injury
Insomnia
Limb Injury
Lipids Abnormal
Lipomatosis
Low Density Lipoprotein
Increased
Lymphadenopathy
Malaise
Microcytic Anaemia
Migraine
Multiple Allergies
Musculoskeletal Stiffness
Myofascial Pain Syndrome
Nasal Congestion
Nasal Septum Deviation
Nasal Turbinate

Hypertrophy
Nausea
Neck Pain
Neuropathy Peripheral
Odynophagia
Oedema Peripheral
Oesophageal Candidiasis
Oesophagitis Ulcerative
Oral Candidiasis
Osteoarthritis
Pain
Pain In Extremity
Palpitations
Pancreatic Insufficiency

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Pancreatitis					
		Peripheral Sensory Neuropathy					
		Photosensitivity Reaction		Vioxx	PS	Merck & Co., Inc	ORAL
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
		Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sicca Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sjogren'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Promethazine	C		
UNKNOWN							
		Subcutaneous Nodule		Furosemide	C		
UNKNOWN							
		Syncope		Ambien	C		
UNKNOWN							
		Temporomandibular Joint		Alprazolam	C		
UNKNOWN							
		Syndrome		Aciphex	C		
UNKNOWN							
		Thirst		Prilosec	C		
UNKNOWN							
		Urethral Disorder		Bel-Phen-Ergot S Tabs	C		
		Urinary Tract Infection					
UNKNOWN							
		Urine Flow Decreased		Butalbital	C		
UNKNOWN							
		Vaginal Discharge		Acetaminophen And Caffeine	C		
		Vomiting					
UNKNOWN							
				Buspar	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Estratest	C		
UNKNOWN							
				Indapamide	C		
UNKNOWN							

			Dulcolax	C		
UNKNOWN						
			Diflucan	C		
UNKNOWN						

Date:01/24/05ISR Number: 4559803-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00653
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertonic Bladder		Claritin	C		
UNKNOWN						
	Insomnia		Analgesic Or			
	Intervertebral Disc		Anesthetic			
	Degeneration		(Unspecified)	C		
UNKNOWN						
	Intervertebral Disc					
	Protrusion					
	Prostatitis					
	Proteinuria					
	Suicidal Ideation					
	Tinea Infection					

Date:01/24/05ISR Number: 4559805-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Abscess Limb		Vioxx	SS	Merck & Co., Inc	ORAL		
Adhesion		Vioxx	SS	Merck & Co., Inc	ORAL		
Adrenal Insufficiency		Valium	C			UNKNOWN	
Adverse Event		Sk-Erythromycin	C			UNKNOWN	
Ankle Fracture		Cyanocobalamin	C			PARENTERAL	
Axillary Mass		Nitrostat	C			UNKNOWN	
Back Injury		Synthroid	C			UNKNOWN	
Blood Cholesterol		Paxil	C			UNKNOWN	
Increased		Lanoxin	C			UNKNOWN	
Breast Cancer		Salagen Tablets	C			UNKNOWN	
Bunion		Claritin	C			UNKNOWN	
Cellulitis		Zofran	C			UNKNOWN	
Chest Discomfort		Miacalcin	C			UNKNOWN	
Chest Pain		Neurontin	C			UNKNOWN	
Contusion		Vitamin E	C			UNKNOWN	
Coronary Artery Disease		Premarin	C			UNKNOWN	
Csf Shunt Removal		Aciphex	C			UNKNOWN	
Cyst Aspiration		Detrol La	C			UNKNOWN	
Depression		Lasix (Furosemide)	C			UNKNOWN	
Diarrhoea		K-Dur	C			UNKNOWN	
Discomfort		Lorazepam	C			UNKNOWN	

	Dizziness	Primidone	C
UNKNOWN			
	Dyspepsia	[Therapy	
	Dyspnoea	Unspecified]	C
UNKNOWN			
	Eye Injury		
	Fall		
	Gastritis		
	Gastroenteritis		
	Haemorrhoids		
	Helicobacter Gastritis		
	Hyperlipidaemia		
	Increased Tendency To Bruise		
	Intestinal Hypomotility		
	Iron Deficiency Anaemia		
	Joint Injury		
	Limb Injury		
	Morton'S Neuroma		
	Myocardial Infarction		
	Nausea		
	Normal Pressure Hydrocephalus		
	Oedema Peripheral		
	Pain In Extremity		
	Radicular Pain		
	Road Traffic Accident		
	Shunt Infection		
	Transaminases Increased		
	Wheezing		
	Wound Dehiscence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00786
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angioneurotic Oedema							
Other	Bronchitis							
	Chest Pain							
	Constipation							
	Deep Vein Thrombosis							
	Depression							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Diverticulum							
	Dyspnoea							
	Fatigue							
	Gastric Operation							
	Gastric Outlet							
	Obstruction							
	Hypertension							
	Neuropathy Peripheral							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Oesophageal Obstruction							
	Osteoarthritis							
	Peptic Ulcer							
	Restrictive Pulmonary							
	Disease							
	Stress Incontinence							
	Tendonitis							
	Urinary Tract Infection							
	Ventricular Dysfunction							

Date:01/24/05ISR Number: 4559811-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Valve Incompetence
	Arrhythmia
	Supraventricular
	Back Pain
	Blood Cholesterol

Increased
Bronchitis
Cardiac Failure
Congestive
Cerebrovascular Accident
Cerebrovascular Disorder
Coronary Artery Disease
Diverticulum Intestinal
Dyspnoea
Emotional Distress
Flank Pain
Haematuria
Heart Rate Irregular
Mitral Valve Incompetence
Myocardial Infarction
Overdose
Pneumonia

		Pruritus					
		Rash Papular					
		Sebaceous Gland Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Diazide	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Zocor	C		ORAL

Date:01/24/05ISR Number: 4559812-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00926
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Drug Reaction
Disability	Adverse Event
	Anxiety
	Arthralgia
	Balance Disorder
	Bronchitis
	Bursitis
	Cardiac Disorder
	Chest Pain
	Constipation
	Contusion
	Deafness
	Depression
	Diplopia
	Dysphagia
	Dyspnoea
	Extrasystoles
	Femur Fracture
	Gastritis
	Haematochezia
	Haemorrhoids
	Headache
	Hyperhidrosis
	Hypertension
	Insomnia
	Intervertebral Disc Degeneration

Intestinal Functional
Disorder
Meniscus Lesion
Muscle Spasms
Muscle Strain
Myalgia
Nervous System Disorder
Neuroma
Nocturia
Personality Change
Polyp
Radicular Syndrome
Rash
Renal Failure
Restless Legs Syndrome
Sleep Apnoea Syndrome
Snoring
Stress
Therapy Non-Responder

		Tinnitus					
		Vertigo Labyrinthine					
		Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/24/05ISR Number: 4559816-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00618
Age:78 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY							
Other		Congestive		Humulin N	C		
UNKNOWN							
		Cataract		Glyburide	C		
UNKNOWN							
		Hypertension					
		Macular Hole					
		Myocardial Infarction					
		Renal Disorder					
		Sleep Apnoea Syndrome					

Date:01/24/05ISR Number: 4559817-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03966
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Connective Tissue		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vitamins			
		Generalised Oedema		(Unspecified)	C		
UNKNOWN							
		Orbital Oedema		Macrobid	C		
UNKNOWN							
		Oropharyngeal Swelling		Maxzide	C		ORAL
		Swelling Face		Prednisone	C		
UNKNOWN							
		Vasculitis		Medrol	C		
UNKNOWN							

Date:01/24/05ISR Number: 4559818-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00949
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1186 DAY
Hospitalization -	Chest Pain		[Therapy					
Initial or Prolonged	Gastritis		Unspecified]	C				UNKNOWN
Disability	Hernia		Zestril	C				UNKNOWN
Other	Myocardial Infarction		Xanax	C				UNKNOWN
			Procardia	C				UNKNOWN
			Pravachol	C				UNKNOWN

Date:01/24/05ISR Number: 4559821-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02093
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
	Fatigue		Zocor	C				UNKNOWN
	Feeling Abnormal		Diovan	C		ORAL		
	Vein Pain		Amoxil	C		ORAL		
			Lescol	C		ORAL		
			Klor-Con	C		ORAL		
			Ibuprofen	C		ORAL		
			Tiazac	C		ORAL		
			Prevacid	C		ORAL		

			Aspirin	C		ORAL
			Hydrocodone Hydrochloride	C		
UNKNOWN						
			Carisoprodol	C		ORAL

Date:01/24/05ISR Number: 4559822-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02830
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Life-Threatening								

Date:01/24/05ISR Number: 4559823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00655
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	16 MON	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR	
Disability	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	16 MON	
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR	
	Coronary Artery Disease		Prilosec	C				
UNKNOWN								
	Hypercholesterolaemia							
	Hypertension							
	Pain							
	Rash							

Date:01/24/05ISR Number: 4559825-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 476 DAY	Abdominal Pain	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 128 DAY	Acute Myocardial	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Infarction	Prilosec	C		ORAL
	Angina Unstable	Tylenol	C		
UNKNOWN					
	Anxiety	Inderal	C		
UNKNOWN					
	Cardiac Failure	Lipitor	C		ORAL
	Congestive	Lipitor	C		
UNKNOWN					
	Carotid Artery Disease	Zithromax	C		
UNKNOWN					
	Coronary Artery Disease	Zantac	C		ORAL
	Diarrhoea	Nitrostat	C		
SUBLINGUAL					
	Ischaemic Cardiomyopathy				
	Mixed Hyperlipidaemia				

Date:01/24/05ISR Number: 4559826-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
	Crohn'S Disease
	Cyst
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Hiatus Hernia

	Ileal Ulcer						
	Ileitis						
	Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Large Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL	15 DAY
	Obstruction		Vasotec	C		ORAL	
	Large Intestinal Ulcer		Vasotec	C		ORAL	
	Large Intestine		Lipitor	C			UNKNOWN
	Perforation		Ecotrin	C		ORAL	
	Metabolic Acidosis		Hydrochlorothiazide	C			UNKNOWN
	Multi-Organ Failure		Prevacid	C			UNKNOWN
	Necrotising Colitis		Relafen	C			UNKNOWN
	Osteoarthritis		Ziac	C			UNKNOWN
	Pleural Effusion		Zebeta	C			UNKNOWN
	Renal Cortical Necrosis						
	Renal Cyst						
	Renal Failure Acute						
	Renal Tubular Necrosis						
	Respiratory Failure						
	Septic Shock						
	Small Intestine Ulcer						
	Vasospasm						
	Wound Infection						

Date:01/24/05ISR Number: 4559827-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
	Coronary Artery Disease						

Date:01/24/05ISR Number: 4559828-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00753
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Burning Sensation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Temazepam	C				
	Flushing							
	Hyperhidrosis							
	Paraesthesia							
	Vision Blurred							

Date:01/24/05ISR Number: 4559830-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03304
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	2100 DAY	
			Kerlone	C			UNKNOWN	

Date:01/24/05ISR Number: 4559834-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00182
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Microangiopathy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559835-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Zocor	C		ORAL		
Other	Depression		Methotrexate	C				UNKNOWN
	Fall		Prednisone	C				UNKNOWN
	Hyperlipidaemia		Folic Acid	C		ORAL		
	Loss Of Consciousness							

Date:01/24/05ISR Number: 4559837-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03988
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL		1609 DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		1609 DAY
	Fluid Retention		Neurontin	C		ORAL		
	Hypertension		Vicoprofen	C				UNKNOWN
	Oedema Peripheral							

Date:01/24/05ISR Number: 4559838-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02218
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		[Therapy					
	Myalgia		Unspecified]	C				UNKNOWN
	Myositis							

Date:01/24/05ISR Number: 4559839-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00045
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Actos	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

Date:01/24/05ISR Number: 4559841-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00176
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Wellbutrin	C			UNKNOWN	
Initial or Prolonged	Renal Failure							

Date:01/24/05ISR Number: 4559842-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00018
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	
Initial or Prolonged	Suicide Attempt		Hydrochlorothiazide	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559843-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00019
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Omeprazole Sodium	C				UNKNOWN
			Lansoprazole	C				UNKNOWN

Date:01/24/05ISR Number: 4559845-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02035
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Coumadin	C				UNKNOWN

Date:01/24/05ISR Number: 4559846-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02039
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Therapy Unspecified]	C				UNKNOWN
	Dizziness							
	Mental Impairment							

Date:01/24/05ISR Number: 4559847-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00017
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1711 DAY
Initial or Prolonged			Aspirin	C				UNKNOWN

Date:01/24/05ISR Number: 4559848-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00195
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction							

Date:01/24/05ISR Number: 4559849-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:01/24/05ISR Number: 4559850-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Chest Pain Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559851-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00020
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisolone	C				
Congenital Anomaly			Sulfasalazine	C				
			Acetaminophen	C				
			Tramadol Hydrochloride	C				

Date:01/24/05ISR Number: 4559852-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01216
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1371 DAY
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Erectile Dysfunction		Lipitor	C				
	Mental Impairment		Serevent	C				
			Hyzaar	C		ORAL		

Date:01/24/05ISR Number: 4559855-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02577
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Fosamax	C		ORAL		
	Paraesthesia		Aspirin	C				
Disability			Prednisone	C				

Date:01/24/05ISR Number: 4559857-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/24/05ISR Number: 4559859-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559860-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02045
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Dyspnoea		Glucophage	C				
Initial or Prolonged Disability	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559861-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Methotrexate	C		ORAL		
Disability	Back Pain		Ibuprofen	C				
UNKNOWN								
	Blood Cholesterol		Folic Acid	C				
UNKNOWN								
	Increased		Zocor	C		ORAL		
	Blood Triglycerides		Nitroquick	C				
UNKNOWN								
	Increased		Prilosec	C				
UNKNOWN								
	Bronchitis		Leucovorin	C				
UNKNOWN								
	Cardiovascular Disorder		Darvocet-N	C		ORAL		
	Chest Pain		Plavix	C		ORAL		
	Condition Aggravated		Lopressor	C		ORAL		
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery							
	Restenosis							
	Coronary Ostial Stenosis							
	Drug Ineffective							
	Emotional Distress							
	Hyperlipidaemia							
	Hypertension							
	Low Density Lipoprotein							
	Increased							
	Multiple Allergies							
	Muscle Spasms							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain In Extremity							
	Psoriatic Arthropathy							
	Renal Failure							

Date:01/24/05ISR Number: 4559863-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559864-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559865-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02664
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	384 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559866-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02671
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559867-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02686
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559868-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02687
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559869-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02697
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559870-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02685
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559871-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559872-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02700
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559873-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559874-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02692
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Thrombosis							

Date:01/24/05ISR Number: 4559875-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02696
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559876-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02711
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:01/24/05ISR Number: 4559877-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559878-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02703
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559879-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02691
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559880-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559881-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02704
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559882-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559883-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559884-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559885-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:01/24/05ISR Number: 4559886-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02702
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON

Date:01/24/05ISR Number: 4559887-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Occlusion Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559888-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vascular		Vioxx	PS	Merck & Co., Inc	ORAL	215 DAY	
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	227 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559889-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559890-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559891-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559892-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559893-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559894-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559895-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01376
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
Other	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Aneurysm Rupture		Cardura	C		ORAL		
			Lipitor	C				

UNKNOWN

Date:01/24/05ISR Number: 4559896-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559897-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559898-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559899-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559900-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559901-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559902-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02994
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559903-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:01/24/05ISR Number: 4559904-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559905-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559906-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559907-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559908-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Heart Rate Irregular Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559909-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03077
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
870 DAY								

Initial or Prolonged Insulin C
UNKNOWN

Date:01/24/05ISR Number: 4559910-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559911-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03025
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559912-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4559913-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559915-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559916-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559917-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559919-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4559921-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/24/05ISR Number: 4562622-7Report Type:Expedited (15-DaCompany Report #2004117950
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure	Foreign	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
	Fluctuation	Consumer						
	Chest Pain							
	Heart Rate Increased		Rofecoxib (Rofecoxib)	SS		ORAL	1 D, ORAL	
	Palpitations							
			Flupirtine Maleate (Flupirtine Maleate)	SS		ORAL	3 IN 1 D, ORAL	
			Diclofenac Sodium (Diclofenac Sodium)	C				
			Diazepam (Diazepam)	C				
			Esclerobin (Pyricarbate, Pyritinol,					

Tocopheryl Nicotinate)	C
Nandroloen Decanoate (Nandrolone Decanoate)	C
Tioscina (Escin, Thiocolchicoside)	C
Nimesulide (Nimesulide)	C
Diazepam (Diazepam)	C
Tramadol (Tramadol)	C
All Other Therapeutic Products (All Other Theapeutic Products)	C

Date:01/24/05ISR Number: 4562632-XReport Type:Expedited (15-DaCompany Report #2004099920
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dermatitis Eczema Skin Oedema	Foreign Health Professional	Atarax (Tablet) (Hydroxyzine Hydrochloride)	PS		ORAL	ORAL	
	Toxic Skin Eruption		Zoxan Lp (Doxazosin) (Doxazosin)	SS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Tramadol/Acetaminophen (Paracetamol, Tramadol)	SS		ORAL	ORAL	
			Amiodarone Hydrochloride (Amiodarone Hydrochloride)	SS		INTRAVENOUS	INTRAVENOUS	
			Betahistine Hydrochloride (Betahistine Hydrochloride)	SS		ORAL	ORAL	
			Clonidine					

(Clonidine)	C
Amlodipine Besilate (Amlodipine Besilate)	C
Loprazolam Mesilate (Loprazolam Mesilate)	C
Acenocoumarol (Acenocoumarol)	C
Potassium Chloride (Potassium Chloride)	C
Fosinopril (Fosinopril)	C
Pravastatin (Pravastatin)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560419-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560420-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560421-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03019
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560422-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560423-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560425-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560427-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560428-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560430-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Chest Wall Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560431-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560432-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560433-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560434-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560435-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560436-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560437-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560438-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560439-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00729
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Acne		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Vasotec	C		ORAL		
	Angina Pectoris		Lipitor	C				
Other UNKNOWN	Arthralgia		Aspirin	C				
	Atrial Flutter		Verelan	C				
	Basal Ganglion		Nitrostat	C				
	Degeneration							
	Benign Prostatic							
	Hyperplasia							
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Chest Discomfort							
	Convulsion							
	Coronary Artery							
	Atherosclerosis							
	Device Failure							
	Dyspepsia							
	Dyspnoea							
	Ear Disorder							
	Fall							
	Headache							
	Hiatus Hernia							
	Hypertension							
	Hypoaesthesia							
	Nocturia							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Palpitations							
	Paraesthesia							
	Rash							
	Renal Impairment							
	Scrotal Mass							
	Sinus Bradycardia							
	Ventricular Dysfunction							
	Vertigo							

Date:01/25/05ISR Number: 4560443-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03148
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560444-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03109
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged UNKNOWN Disability	Cardiac Valve Disease		Vioxx Levoxyl	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560445-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560446-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03379
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560447-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00775
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event Anger Angina Pectoris Angiopathy Anhedonia Anxiety Appendicectomy Appendix Disorder Arthropathy Asthenia Blood Pressure Inadequately Controlled Bunion Carotid Artery Atheroma Carotid Artery Stenosis Carpal Tunnel Syndrome Cerebral Atherosclerosis Cerebral Ischaemia Cerebrovascular Accident Cerebrovascular Disorder Chronic Obstructive Pulmonary Disease Complicated Migraine Contusion

Convulsion
Depression
Dizziness
Fall
Fatigue
Feeling Of Despair
Ganglion
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Hypoaesthesia
Lacunar Infarction
Major Depression
Microangiopathy
Migraine
Mitral Valve Incompetence

		Mood Swings					
		Neck Pain					
		Nerve Compression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neurological Symptom		Vioxx	PS	Merck & Co., Inc	ORAL
		Personality Disorder		Prempro	C		
UNKNOWN							
		Photopsia		Dyazide	C		
UNKNOWN							
		Skin Lesion		Aspirin	C		
UNKNOWN							
		Somnolence					
		Syncope					
		Tinel'S Sign					
		Tonsillar Disorder					
		Tonsillectomy					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Trigger Finger					
		Urge Incontinence					
		Vertigo					
		Wrist Fracture					

Date:01/25/05ISR Number: 4560450-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abnormal Dreams
Initial or Prolonged	Adverse Event
Disability	Angina Pectoris
Other	Aphthous Stomatitis
	Arthralgia
	Blood Pressure Increased
	Breast Pain
	Bronchitis Acute
	Bursitis
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Pain
	Conjunctival Haemorrhage
	Contusion
	Convulsion
	Cyst

Dizziness
Drug Dependence
Eczema
Epistaxis
Fall
Fatigue
Gastroenteritis Viral
Generalised Oedema
Headache
Hip Arthroplasty
Hypoaesthesia
Increased Tendency To
Bruise
Ingrowing Nail
Injury
Laryngitis
Localised Infection
Menorrhagia
Migraine

		Munchausen'S Syndrome					
		Muscle Atrophy					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal		Vioxx	PS	Merck & Co., Inc	ORAL
		Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nervousness					
		Osteoarthritis					
		Otitis Externa					
		Otitis Media					
		Pain					
		Pain In Jaw					
		Panic Attack					
		Paraesthesia					
		Patent Ductus Arteriosus					
		Pharyngitis					
		Pyrexia					
		Rash					
		Rhinitis Allergic					
		Sinus Disorder					
		Sinusitis					
		Thrombotic Stroke					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Viral Infection					

Date:01/25/05ISR Number: 4560453-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00821
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Atelectasis
	Back Pain
	Blood Sodium Decreased
	Buttock Pain
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Diabetes Mellitus Non-Insulin-Dependent

Dyspnoea
Hypokalaemia
Influenza Like Illness
Injury
Obesity
Pain
Pain In Extremity
Paranoid Personality
Disorder
Post Procedural
Complication
Post Procedural
Haemorrhage
Pyrexia
Spermatocele
Spinal Disorder

Ventricular Dysfunction
Ventricular Hypokinesia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560454-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00808
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
	Abdominal Pain Upper
	Adenomatous Polyposis Coli
	Anxiety
	Arthralgia
	Arthritis
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Diastolic Increased
	Bronchitis
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Airways Disease Exacerbated
	Chronic Obstructive Pulmonary Disease
	Conjunctivitis
	Constipation
	Coronary Artery Disease
	Defaecation Urgency
	Depression
	Diarrhoea
	Diverticulitis
	Dizziness
	Ejection Fraction Decreased
	Fatigue
	Flatulence
	Gastritis
	Haematoma

Hypertension
Injury
Insomnia
Lipoma
Lobar Pneumonia
Malaise
Musculoskeletal Pain
Myalgia
Nausea
Nephrolithiasis
Nodule
Osteopenia
Pain
Pain In Extremity
Pallor
Pollakiuria

		Postoperative Adhesion					
		Procedural Complication					
		Productive Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rash		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinusitis		Alprazolam	C		
UNKNOWN							
		Skin Lesion		Prilosec	C		
UNKNOWN							
		Skin Nodule		Estratest	C		
UNKNOWN							
		Syncope		Paxil	C		
UNKNOWN							
		Tremor					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Vomiting					
		Weight Increased					
		White Blood Cell Count Increased					

Date:01/25/05ISR Number: 4560456-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03136
Age:61 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Nexium	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:01/25/05ISR Number: 4560457-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00805
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Adverse Event
Other	Arthropathy
	Asthma
	Blindness Unilateral

Blood Creatinine
Increased
Blood Urea Increased
Bronchospasm
Bursitis
Candidiasis
Cardiac Failure
Congestive
Cervical Polyp
Chest Pain
Cough
Dizziness
Drug Ineffective
Dyspepsia
Face Oedema
Fall
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Head Discomfort
Headache
Hot Flush
Hypertension
International Normalised

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Ratio Increased					
		Microcytic Anaemia					
		Nodule					
		Oedema Peripheral					
		Oesophageal Obstruction		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Pneumonia Haemophilus		Vioxx	SS	Merck & Co., Inc	ORAL
		Postmenopausal		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash Generalised		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Sinusitis		Lotrel	C		ORAL
		Skin Lesion		Lotrel	C		ORAL
		Stomach Discomfort		Lotrel	C		ORAL
		Tachycardia		Lasix (Furosemide)	C		
UNKNOWN							
		Tinea Infection		Nolvadex	C		
UNKNOWN							
		Urinary Tract Infection		Benicar	C		ORAL
397	DAY						
		Uterine Leiomyoma		Lipitor	C		ORAL
		Uterine Polyp		Lipitor	C		ORAL
		Wrist Fracture		Toprol Xl Tablets	C		ORAL
				Singulair	C		ORAL
				Prevacid	C		
UNKNOWN							
				Prilosec	C		ORAL
				Proventil Inhaler	C		
UNKNOWN							
				Evista	C		ORAL
				Claritin	C		ORAL
				Vasoretic	C		ORAL
				Norvasc	C		ORAL
				Zoloft	C		ORAL
				Zocor	C		ORAL
				Lescol	C		ORAL

Coreg C ORAL

Date:01/25/05ISR Number: 4560461-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00798
Age:53 YR Gender:Female I/FU:F

Outcome PT
Disability Abdominal Pain Upper
Adverse Event
Arthralgia
Asthenia
Back Pain
Barrett'S Oesophagus
Breast Cyst
Breast Mass
Breast Pain
Bronchitis
Carpal Tunnel Syndrome
Cervicobrachial Syndrome
Chest Pain
Coordination Abnormal
Cystitis
Diabetes Mellitus
Diarrhoea
Dizziness
Dysphagia

		Electrocardiogram St Segment Depression					
		Epistaxis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erosive Oesophagitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Flatulence		Robaxin	C		
UNKNOWN							
		Gastrooesophageal Reflux		Lotrel	C		
UNKNOWN							
		Disease					
		Headache					
		Helicobacter Gastritis					
		Hiatus Hernia					
		Intervertebral Disc Degeneration					
		Irritable Bowel Syndrome					
		Loss Of Consciousness					
		Micturition Urgency					
		Muscle Spasms					
		Myocardial Ischaemia					
		Neck Injury					
		Neck Pain					
		Nerve Root Lesion					
		Oedema Peripheral					
		Pain In Extremity					
		Pharyngitis					
		Road Traffic Accident					
		Sinusitis					
		Spinal Osteoarthritis					
		Syncope					
		Vaginal Discharge					
		Vaginal Infection					
		Vaginal Mycosis					

Date:01/25/05ISR Number: 4560463-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00989
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Aortic Valve Sclerosis
Other	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Colon Adenoma
	Colonic Polyp

Delusion
Depression
Dizziness
Fatigue
Feeling Abnormal
Gastrointestinal
Dysplasia
Gastrointestinal
Haemorrhage
Glucose Tolerance
Impaired
Haemorrhoids
Hallucination
Hernia
Hyperlipidaemia
Hypertension
Insomnia
Male Sexual Dysfunction

		Mitral Valve Incompetence					
		Nocturia					
		Obesity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
585	DAY						
		Panic Attack		Vioxx	SS	Merck & Co., Inc	ORAL
585	DAY						
		Periarthritis		Lorcet 10/650	C		
UNKNOWN			283 DAY				
		Somnolence		Cozaar	C		
UNKNOWN							
		Varicose Vein		Hydrocodone			
		Ventricular Hypertrophy		Bitartrate	C		
UNKNOWN			201 DAY				
				Ibuprofen	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							

Date:01/25/05ISR Number: 4560464-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03373
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:01/25/05ISR Number: 4560465-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00866
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Wall Infection
Other	Adverse Event
	Anuria
	Arthralgia
	Asthenia
	Asthma
	Bronchitis Acute
	Cervical Vertebral
	Fracture
	Constipation
	Cough

Difficulty In Walking
Dyspnoea
Dysstasia
Eye Disorder
Herpes Zoster
Hypoaesthesia
Incontinence
Injury
Joint Injury
Keloid Scar
Nausea
Neck Pain
Nocturia
Oedema Peripheral
Paranasal Sinus
Hypersecretion
Peripheral Coldness
Personality Disorder
Rash
Road Traffic Accident
Scar
Senile Dementia
Sleep Apnoea Syndrome
Somnolence
Urinary Incontinence

Urinary Retention

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Risperdal	C			UNKNOWN	
	Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	

Date:01/25/05ISR Number: 4560466-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Diovan	C			UNKNOWN	
	Angina Pectoris		Zocor	C			UNKNOWN	
	Atrial Fibrillation		Dapsone	C			UNKNOWN	
	Atrioventricular Block		Toprol Xl Tablets	C			UNKNOWN	
	Body Tinea							
	Cardiovascular Disorder							
	Carotid Artery Stenosis							
	Chest Pain							
	Coronary Artery Occlusion							
	Dermatitis							
	Diverticulum							
	Eczema							
	Epidermal Necrosis							
	Erythema Multiforme							
	Granuloma Annulare							
	Leukocytoclastic							
	Vasculitis							
	Myocardial Ischaemia							
	Nail Bed Bleeding							
	Onycholysis							
	Polyp							
	Pruritus Ani							
	Psoriasis							

Renal Disorder
Renal Failure
Syncope
Vasculitis

Date:01/25/05ISR Number: 4560469-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eyelid Ptosis		Trandolapril And Verapamil Hydrochloride	C				
	Procedural Complication							
	Swelling							
UNKNOWN	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560471-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00923
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Abscess							
	Adverse Event							
	Angina Pectoris							
	Arthralgia							
	Arthritis							
	Back Pain							
	Blindness Transient							
	Blood Pressure Increased							
	Carpal Tunnel Syndrome							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Condition Aggravated							
	Conjunctivitis							
	Convulsion							
	Coronary Artery Disease							
	Drug Ineffective							
	Duodenal Ulcer							
	Ear Pain							
	Eye Pain							
	Fall							
	Furuncle							
	Gastrooesophageal Reflux Disease							
	Gingival Pain							
	Glaucoma							
	Headache							
	Herpes Zoster							
	Hiatus Hernia							
	Hyperhidrosis							
	Hypertension							
	Memory Impairment							
	Night Sweats							
	Osteoarthritis							
	Pain							
	Pain In Extremity							
	Papilloedema							
	Paralysis							
	Periarthritis							
	Rash							

Respiratory Tract
Congestion
Road Traffic Accident
Skin Papilloma
Subcutaneous Abscess
Tendonitis
Trigeminal Neuralgia
Viith Nerve Paralysis
Vision Blurred
Visual Acuity Reduced

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560473-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00304
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Pantoprazole Sodium	C		ORAL		
Disability			Pantoprazole Sodium	C		ORAL		

Date:01/25/05ISR Number: 4560474-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02359
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Initial or Prolonged	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL	7	MON
	Aphasia		Klor-Con	C			UNKNOWN	
	Blood Triglycerides		Advair	C			UNKNOWN	
	Increased		[Therapy					
	Catheter Site Phlebitis		Unspecified]	C			UNKNOWN	
	Cerebrovascular Accident		Albuterol	C			UNKNOWN	
	Coronary Artery Disease							
	Dizziness							
	Dyslipidaemia							
	Dysphemia							
	Feeling Abnormal							
	Headache							
	Low Density Lipoprotein							
	Increased							
	Memory Impairment							
	Oedema Peripheral							
	Phlebitis							
	Protein C Decreased							
	Syphilis Test Positive							
	Vision Blurred							

Date:01/25/05ISR Number: 4560476-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02287
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged Disability	Mitral Valve Prolapse Surgery							

Date:01/25/05ISR Number: 4560477-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03352
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bronchospasm Cardiac Disorder Myocardial Infarction Sinus Arrhythmia Ventricular Dysfunction Ventricular Fibrillation Ventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560478-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

Date:01/25/05ISR Number: 4560479-1Report Type:Expedited (15-DaCompany Report #AT-MERCK-0501AUT00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/25/05ISR Number: 4560480-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0501AUT00005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Infarction							

Date:01/25/05ISR Number: 4560481-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00869
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Other	Arthralgia		Celebrex	C		ORAL	20	MON
	Atrophy		Norco	C				
UNKNOWN								
	Back Pain		Flexeril	C				
UNKNOWN								

	Chronic Obstructive	Motrin	C
UNKNOWN			
	Pulmonary Disease		
	Decreased Appetite		
	Dyspnoea		
	Electrocardiogram		
	Abnormal		
	Electrocardiogram St		
	Segment Depression		
	Exostosis		
	Flatulence		
	General Symptom		
	Ischaemia		
	Lumbar Spinal Stenosis		
	Neck Pain		
	Oedema Peripheral		
	Pain In Extremity		
	Palpitations		
	Pharyngitis		
	Renal Cyst		
	Renal Failure Chronic		
	Seasonal Allergy		
	Sinus Bradycardia		
	Sinusitis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560483-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02357
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebral Ischaemia		Premarin	C				
UNKNOWN							11	YR
	Cerebrovascular Accident		Prozac	C				
UNKNOWN								
	Confusional State		Guaifenesin Dm	C				
UNKNOWN								
	Cough		Serevent	C				
UNKNOWN								
	Depression		Pulmicort	C				
UNKNOWN								
	Disturbance In Attention							
	Hypersensitivity							
	Hypertension							
	Memory Impairment							
	Nausea							
	Panic Attack							
	Pneumonia							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Transient Ischaemic							
	Attack							
	Vasculitis							
	Vomiting							

Date:01/25/05ISR Number: 4560484-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00534
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Aspirin	C				
UNKNOWN								
	Cardiovascular Disorder							
	Colonic Polyp							
	Constipation							
	Dizziness							
	Dyspepsia							

Intestinal Haemorrhage
Joint Effusion
Palpitations
Polyneuropathy Idiopathic
Progressive
Stomach Discomfort
Tachycardia
Tendonitis

Date:01/25/05ISR Number: 4560488-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C		ORAL		
			Insulin	C		PARENTERAL		
			Leflunomide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560489-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02872
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		474 MON
Hospitalization - Initial or Prolonged	Atrial Thrombosis		Lanoxin	C		ORAL		
	Coma		Aspirin	C		ORAL		
	Embolic Stroke		Viagra	C		ORAL		
	Myocardial Ischaemia		Lidex E	C		TOPICAL		
	Neck Pain		Diprosone	C		TOPICAL		
	Oedema Peripheral		Lamisil	C		ORAL		
	Pain In Extremity		Centrum Silver	C		ORAL		
	Pneumonia Aspiration							
	Polytraumatism							
	Road Traffic Accident							

Date:01/25/05ISR Number: 4560490-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:01/25/05ISR Number: 4560491-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03589
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Composition Unspecified]	C				
UNKNOWN								
Disability								
Other								

Date:01/25/05ISR Number: 4560492-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03026
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		791 DAY
Hospitalization - Initial or Prolonged			Prinivil [Therapy Unspecified]	C		ORAL		
Disability				C				
UNKNOWN								

Date:01/25/05ISR Number: 4560493-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02076
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged			Zoloft	C				
UNKNOWN								
Disability								

Date:01/25/05ISR Number: 4560495-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560496-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02047
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Plavix	C				
UNKNOWN								
Initial or Prolonged			Ranitidine	C				
UNKNOWN								

Date:01/25/05ISR Number: 4560497-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02555
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								

Date:01/25/05ISR Number: 4560498-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01601
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angioneurotic Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
7 YR								
Hospitalization -	Anti-Thyroid Antibody		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
7 YR								
Disability	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Singulair	C		ORAL		
	Dysphonia		Doxepin					
	Eye Swelling		Hydrochloride	C				
UNKNOWN								
	Idiopathic Urticaria		Allegra	C				
UNKNOWN								
	Muscle Mass		Zyrtec	C				
UNKNOWN								
	Orthopedic Examination		Accolate	C				
UNKNOWN								
	Abnormal		Hydroxyzine					

	Overdose		Hydrochloride	C
UNKNOWN				
	Therapeutic Response			
	Unexpected			
	Urticaria			
	Urticaria Chronic			

Date:01/25/05ISR Number: 4560500-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00030
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diclofenac Sodium And Misoprostol	SS		ORAL		

Date:01/25/05ISR Number: 4560501-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560502-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02680
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560503-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02698
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560504-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02286
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560505-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02113
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Visual Disturbance		Zetia	C		ORAL		

Date:01/25/05ISR Number: 4560506-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02699
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560508-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02879
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560509-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02728
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560510-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02789
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mitral Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL	161 DAY	
Hospitalization -			Asacol	C			UNKNOWN	
Initial or Prolonged			Claritin	C			UNKNOWN	
Disability			Cimetidine	C			UNKNOWN	
			Nasacort	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560511-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560512-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560513-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02880
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560516-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560593-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 117 DAY	Coagulation Factor Viii		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Level Decreased		Zocor	SS		ORAL		
	Coagulation Time Prolonged		Ginkgo Biloba Extract	SS		ORAL		
	Haematoma		Hydrochlorothiazide					

			And Lisinopril	SS		ORAL

Date:01/25/05ISR Number: 4560596-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00015
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Deafness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Inner Ear Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Disability						

Date:01/25/05ISR Number: 4560599-1Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00045
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Blood Iron Decreased
Initial or Prolonged	Diarrhoea
Disability	Faecal Incontinence
	Fluid Retention
	Gastrointestinal Disorder
	Generalised Oedema
	Intervertebral Disc
	Disorder
	Intervertebral Disc

	Protrusion						
	Intestinal Polyp						
	Oedema Peripheral						
	Polyp	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Tenesmus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Renal Failure		Fluoxetine Hydrochloride	C			UNKNOWN	
	Weight Increased		Flurazepam Hydrochloride	C			UNKNOWN	

Date:01/25/05ISR Number: 4560601-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00277
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastritis							
	Gastrointestinal Carcinoma							
	Hypertension							
	Insomnia							
	Muscle Spasms							
	Pain							
	Pneumonia							
	Renal Failure							

Date:01/25/05ISR Number: 4560602-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00130
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability							
Disability	Myocardial Infarction							

Date:01/25/05ISR Number: 4560603-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00142
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Digoxin	C				
			Aspirin	C			UNKNOWN	

Date:01/25/05ISR Number: 4560604-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00134
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560605-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02829
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability			Zelnorm	C				
			Nexium	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560606-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560607-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Cardiac Disorder Disability Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560608-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02987
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560609-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02848
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560610-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560611-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560612-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/25/05ISR Number: 4560613-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560614-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560615-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560616-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560617-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02988
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/25/05ISR Number: 4560618-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02832
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident Dyspnoea Thrombosis		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

UNKNOWN

Disability [Therapy Unspecified] C

UNKNOWN

Date:01/25/05ISR Number: 4560619-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1034 DAY
	Hypertension							
	Oedema Peripheral							

Date:01/25/05ISR Number: 4560620-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560621-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560622-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560623-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560624-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560625-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560626-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560627-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03268
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560628-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON
	Myocardial Infarction							

Date:01/25/05ISR Number: 4560630-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03269
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							
	Thrombosis							
	Urinary Bladder Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4560631-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Thrombosis							

Date:01/25/05ISR Number: 4560632-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/25/05ISR Number: 4560634-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560635-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/25/05ISR Number: 4560638-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	57	MON
	Transient Ischaemic							

Attack

Date:01/25/05ISR Number: 4563931-8Report Type:Direct Company Report #CTU 237800
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS			25 MG	

Date:01/25/05ISR Number: 4567755-7Report Type:Direct Company Report #CTU 237804
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS			TAKE 1 TABLET DAILY WITH FOOD	
	Fatigue							
	Haematochezia							
	Jaundice		Bextra	SS			TAKE 1 TABLET DAILY WITH FOOD	
	Ocular Icterus							
	Pruritus							
	Rash							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/25/05ISR Number: 4567763-6Report Type:Direct Company Report #CTU 237807
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	B-Cell Lymphoma Stage Iv		Vioxx 12.5 Mg	PS			AS NEEDED 1X/	
	Metastases To Liver						OVER 1 YEAR	
			Lovastatin 20 Mg	SS			NIGHT 1X/	
							LESS THAN A	
							YEAR	

Date:01/25/05ISR Number: 4567779-XReport Type:Direct Company Report #CTU 237832
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Embolism		Vioxx - 25 Mg	PS			1 OR 2 DAILY	
Initial or Prolonged	Fall						UNTIL SEPT.	
Required	Gait Disturbance						2004	
Intervention to			Hydrochlorothiazide	C				
Prevent Permanent			Atacand	C				
Impairment/Damage			Nexium	C				
			Zocor	C				
			Msd	C				

Date:01/25/05ISR Number: 4570020-5Report Type:Direct Company Report #CTU 237831
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Disability		Vioxx 25mg -					
Disability			2000-2002	PS				
Other			Celebrex - 200mg					
			Twice A Day I Think	SS				

Date:01/25/05ISR Number: 4570029-1Report Type:Direct Company Report #CTU 237821
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hyperventilation		Vioxx	PS			1 TABLET	6 MON
Initial or Prolonged	Palpitations							

Date:01/25/05ISR Number: 4570057-6Report Type:Direct Company Report #CTU 237861
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx 25 Mg	PS			25 MG 1X	
Initial or Prolonged	Attack							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:01/25/05ISR Number: 4570059-XReport Type:Direct Company Report #CTU 237862
Age:66 YR Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability Required Intervention to Prevent Permanent Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Abasia		Vioxx 25 Mg Merck + Co	PS	Merck + Co		1 A DAY	
	Activities Of Daily Living Impaired							
	Aphasia							
	Movement Disorder							
	Myocardial Infarction							

Date:01/25/05ISR Number: 4570064-3Report Type:Direct Company Report #CTU 237871
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS			25 MG	
Other	Chest Pain		Cellebrax	SS				
	Dyspnoea		Bextra	SS				
	Gastric Disorder		Celestone Pain					
	Gastrointestinal Disorder		Theopl Shuts	C				
	Lower Gastrointestinal Haemorrhage							
	Upper Gastrointestinal Haemorrhage							

Date:01/26/05ISR Number: 4561329-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	895 DAY	
	Cardiac Failure							
	Congestive Cerebrovascular Accident							
	Coronary Artery Disease							
	Hypertension							
	Myocardial Infarction							
	Pain							

Date:01/26/05ISR Number: 4561330-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561331-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561335-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561336-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02825
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561338-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561339-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02651
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Naproxen	C				
UNKNOWN								

Date:01/26/05ISR Number: 4561342-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561344-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02856
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561345-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561346-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03108
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON

Date:01/26/05ISR Number: 4561347-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561348-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1121 DAY

Date:01/26/05ISR Number: 4561350-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561351-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561352-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561353-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/26/05ISR Number: 4561354-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561355-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561356-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02975
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561357-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:01/26/05ISR Number: 4561358-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561361-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03295
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561406-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03342
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Activated Partial
Hospitalization -	Thromboplastin Time
Initial or Prolonged	Prolonged
Other	Acute Myocardial
	Infarction
	Amnesia
	Arrhythmia
	Atrioventricular Block
	Benign Prostatic
	Hyperplasia
	Blood Pressure Decreased
	Cardiac Failure
	Congestive
	Cardiac Murmur

Cerebellar Syndrome
Cerebral Haematoma
Cerebral Haemorrhage
Cerebrovascular Accident
Chondromalacia
Complex Partial Seizures
Confusional State
Convulsion
Coronary Artery Disease
Deafness Neurosensory
Dehydration
Diabetes Mellitus
Disseminated
Intravascular Coagulation
Drug Ineffective
Dysphagia
Dyspnoea
Ejection Fraction
Decreased
Embolic Cerebral
Infarction
Fall

		Fibrous Histiocytoma					
		Flatulence					
		Gastritis Haemorrhagic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemodialysis		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL
		Head Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypermetropia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Neurontin	C		
UNKNOWN							
		Inner Ear Disorder		Prilosec	C		
UNKNOWN							
		Leukocytosis		Glucosamine	C		
UNKNOWN							
		Loss Of Consciousness					
		Meniscus Lesion					
		Mitral Valve Incompetence					
		Multi-Organ Failure					
		Myocardial Infarction					
		Oedema					
		Osteonecrosis					
		Pain					
		Pneumonia Escherichia					
		Postoperative Infection					
		Presbyopia					
		Prothrombin Time					
		Prolonged					
		Pupillary Disorder					
		Renal Failure Acute					
		Respiratory Failure					
		Sepsis					
		Sleep Apnoea Syndrome					
		Subarachnoid Haemorrhage					
		Syncope					
		Transient Ischaemic					
		Attack					
		Tremor					
		Tricuspid Valve					
		Incompetence					
		Varicose Vein					
		Ventricle Rupture					
		Ventricular Septal Defect					
		Acquired					

Ventricular Tachycardia
Vertigo Positional

Date:01/26/05ISR Number: 4561413-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02846
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/26/05ISR Number: 4561847-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02968
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Cardiac Enzymes Increased
	Cerebrovascular Accident
Disability	Chest Pain

	Fatigue						
	Hyperlipidaemia						
	Hypokalaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL	
	Syncope		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Attack		Lasix (Furosemide)	C			UNKNOWN
			Pravachol	C			UNKNOWN
			Aggrenox	C			UNKNOWN
			Soma	C			UNKNOWN
			Zestril	C			UNKNOWN
			Demerol	C			UNKNOWN
			Flomax (Morniflumate)	C			UNKNOWN
			Nitroglycerin	C			UNKNOWN

Date:01/26/05ISR Number: 4561856-5Report Type:Expedited (15-DaCompany Report #PH-MERCK-0412PHL00003
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc		UNKNOWN
	Infarction						
	Treatment Noncompliance						

Date:01/26/05ISR Number: 4561859-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00891
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	

Initial or Prolonged	Aortic Dissection	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Asthenia	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Glucose Increased	Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain	Paxil	C		ORAL
	Drug Abuser	Norvasc	C		ORAL
	Dyspepsia	Labetalol			
	Hypertension	Hydrochloride	C		
UNKNOWN					
	Hypoaesthesia	Hyzaar	C		
UNKNOWN					
	Joint Stiffness	Humulin 70/30	C		
SUBCUTANEOUS	243 DAY				
	Lower Respiratory Tract	Humulin 70/30	C		
SUBCUTANEOUS	243 DAY				
	Infection				
	Obesity				
	Pain				
	Pain In Extremity				
	Palpitations				
	Paraesthesia				
	Penile Pain				
	Renal Cyst				
	Swelling				
	Vision Blurred				
	Weight Increased				

Date:01/26/05ISR Number: 4561864-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04266
Age: Gender:Female I/FU:F

Outcome	PT
Other	Adverse Event
	Anhedonia
	Emotional Distress

	Myocardial Infarction						
	Pain						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561865-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00329
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease		Tramadol					
	Coronary Artery Stenosis		Hydrochloride	C				
UNKNOWN								
	Dyspnoea		Esomeprazole					
	Hypertension		Magnesium	C				
UNKNOWN								
	Treatment Noncompliance		Sulfasalazine	C				
UNKNOWN								

Date:01/26/05ISR Number: 4561866-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01956
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
1478 DAY								
Hospitalization -	Myocardial Infarction		Altace	C				
UNKNOWN								
Initial or Prolonged			Toprol Xl Tablets	C				
UNKNOWN								
Other			Paxil	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								

Date:01/26/05ISR Number: 4561869-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01115
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	362 DAY	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	362 DAY	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Drug Ineffective		Adalat	C		ORAL		
	Dyspnoea		Klor-Con	C		ORAL		
	Emotional Distress		Zantac	C			UNKNOWN	
	Oedema Peripheral		Aspirin	C		ORAL		
	Palpitations		Pepcid	C			UNKNOWN	
	Renal Failure		Tylenol	C			UNKNOWN	
	Rotator Cuff Syndrome		Ibuprofen	C			UNKNOWN	
	Scoliosis		Algae (As Drug)	C			UNKNOWN	
	Sensory Loss							
	Sinus Bradycardia							
	Weight Increased							

Date:01/26/05ISR Number: 4561875-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00513
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Borrelia Infection		Vioxx	PS	Merck & Co., Inc	ORAL	459 DAY	
	Hypertension		Tramadol Hydrochloride	SS		ORAL	UNKNOWN	
Disability	Leukoencephalomyelitis		Chloroquine Phosphate	SS		ORAL		
	Meniere'S Disease		Ceftriaxone Sodium	SS				

	Hydroxychloroquine Sulfate	SS	ORAL
	Betahistine Mesylate	C	
UNKNOWN			
	Atorvastatin Calcium	C	ORAL
	Candesartan Cilexetil	C	ORAL
	Aspirin	C	ORAL

Date:01/26/05ISR Number: 4561881-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00518
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561883-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02881
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561884-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02670
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561886-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/26/05ISR Number: 4561888-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02397
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vitamins					
Initial or Prolonged	Myocardial Infarction		(Unspecified)	C				
UNKNOWN								
Disability								

Date:01/26/05ISR Number: 4561889-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561891-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561892-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03042
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/26/05ISR Number: 4561893-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561896-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00519
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561897-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03205
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Headache		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myalgia		Naproxen	C				
UNKNOWN								

Swelling

Date:01/26/05ISR Number: 4561898-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03332
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561901-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561907-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03128
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atacand	C				
UNKNOWN								
Initial or Prolonged			Effexor	C				
UNKNOWN								
Disability			Lasix (Furosemide)	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561908-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561909-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03237
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/26/05ISR Number: 4561910-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561911-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03294
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561913-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03293
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561915-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:01/26/05ISR Number: 4561916-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561917-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/05ISR Number: 4561919-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03298
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/26/05ISR Number: 4561920-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03330
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:01/26/05ISR Number: 4561928-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01749
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropod Bite		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Aspirin	C		ORAL		
	Cerebrovascular Accident		Motrin	C		ORAL		
	Cervical Cord Compression		Tylenol	C		ORAL		
	Colitis Viral		Butalbital	C		ORAL		
	Colonic Polyp		Guaifenex	C		ORAL		
	Diverticulitis		Clidinium Bromide	C		ORAL		
	Dizziness		Estropipate	C		ORAL		
	Dyspepsia		Claritin-D	C		ORAL		
	Dysphagia		Skelaxin	C		ORAL		
	Dysphonia		Ketoconazole	C		ORAL		
	Dyspnoea		Prednisone	C		ORAL		
	Emotional Distress		Biaxin	C		ORAL		
	Facet Joint Syndrome		Diflucan	C				
UNKNOWN								
	Fatigue		Trimox	C		ORAL		
	Flatulence		Hydrocodone					
	Headache		Bitartrate	C		ORAL		
	Hypoaesthesia		Diovan	C		ORAL		
	Insomnia							

Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Irritable Bowel Syndrome
Joint Stiffness
Nausea
Neck Pain
Pain In Extremity
Paraesthesia
Radiculopathy
Road Traffic Accident
Spinal Column Stenosis
Swelling
Swelling Face
Therapy Non-Responder
Tinnitus
Vertigo
Vocal Cord Thickening
Weight Decreased
Weight Increased

Date:01/26/05ISR Number: 4564556-0Report Type:Expedited (15-DaCompany Report #WAES 0501GBR00078
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	109 DAY
	Shortened	Health Professional Other	Fosamax	C				
	Asthenia		Proscar	C				
	Carotid Artery Stenosis		Prednisolone	C				
	Diplopia		Tamsulosin Hydrochloride	C				
	Dizziness							
	Hypercholesterolaemia							
	Lymphocyte Count Decreased							
	Platelet Count Decreased							
	Red Blood Cell Count Decreased							
	Red Blood Cell Sedimentation Rate Increased							
	Transient Ischaemic Attack							

Date:01/26/05ISR Number: 4565387-8Report Type:Expedited (15-DaCompany Report #WAES 0304USA02713
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Aortic Dilatation
	Aortic Dissection
	Atelectasis
	Blood Creatinine Increased
	Blood Pressure Decreased
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Stenosis
	Cough
	Diaphragmatic Disorder
	Diaphragmatic Hernia
	Diaphragmatic Paralysis
	Duodenitis

Dyspnoea
Electrocardiogram Qt
Shortened
Emphysema
Feeling Abnormal
Gastritis Erosive
Gastrointestinal Disorder
Haemothorax
Hypertension
Hypotension
Hypovolaemia
Lung Disorder
Mucosal Erosion
Mucosal Inflammation
Myocardial Infarction
Oesophageal Polyp
Oral Intake Reduced
Osteoarthritis

	Renal Artery Stenosis Scar Telangiectasia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Visual Disturbance	Study	Tab Vioxx 25 Mg	PS		ORAL	25
		Health					MG/DAILY/PO
		Professional	Tab Acetaminophen	SS		ORAL	325 MG/PRN/PO
			Dulcolax	C			
			Lipitor	C			
			Nifedical Xl	C			
			Paxil	C			
			Plavix	C			
			Premarin	C			
			Procardia	C			
			Tylenol	C			
			Aspirin	C			
			Cyanocobalamin	C			
			Metoprolol	C			
			Pyridoxine	C			
			Vitamins (Unspecified)	C			

Date:01/26/05ISR Number: 4566321-7Report Type:Direct Company Report #CTU 238130
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS			

Date:01/26/05ISR Number: 4566695-7Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Injury
	Abdominal Pain
Other	Accident
	Back Disorder
	Back Pain
	Blood Cholesterol

Increased
Body Temperature
Decreased
Cardiac Disorder
Chest Pain
Condition Aggravated
Contusion
Coordination Abnormal
Disorientation
Drug Ineffective
Drug Intolerance
Erectile Dysfunction
Facial Pain
Feeling Abnormal
Feeling Cold
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Gingival Pain
Glossodynia
Hostility

		Hypersomnia Hyporeflexia Impaired Healing	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury Irritability	Consumer Health	Neurontin (Gabapentin)	PS		ORAL
1800 MG (600							
MG, 3 IN 1		Limb Injury	Professional				
D), ORAL		Medication Error					
		Movement Disorder Myalgia		Lipitor (Atorvastatin)	SS		ORAL
20 MG (20 MG,							
1 IN 1		Neck Pain					
D),ORAL		Oesophageal Spasm					
		Overdose		Lithium (Lithium)	SS		
		Pain In Jaw		Naproxen (Naproxen)	SS		
		Post Procedural Pain Sedation		Amoxicillin (Amoxicillin)	SS		ORAL
1000 MG (1 IN							
2 D), ORAL		Sleep Disorder					
		Somnolence Tenderness		Rofecoxib (Rofecoxib)	SS		
		Tooth Abscess Tremor Vertigo		All Other Therapeutic Products (All Other Therapeutic Products)	C		
				Levothyroxine Sodium (Levothyroxine Sodium)	C		
				Vitamins (Vitamins)	C		
				Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C		

Date:01/27/05ISR Number: 4562200-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:01/27/05ISR Number: 4562547-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01120434
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Atrial Fibrillation
	Bronchitis
	Coagulation Factor Viii Level Increased
	Depression
	Emotional Distress
	Fatigue
	Headache
	Influenza
	Injury
	Insomnia
	International Normalised Ratio Increased
	Myocardial Infarction
	Pain

	Protein C Increased						
	Pulmonary Embolism						
	Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Cyst		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Suicidal Ideation		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	Upper Respiratory Tract		Ambien	C			UNKNOWN	
	Infection		Ma Huang Extract	C			UNKNOWN	1523 DAY

Date:01/27/05ISR Number: 4562551-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00701
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization -	Collagen Disorder		[Therapy					
Initial or Prolonged	Coronary Artery Disease		Unspecified]	C				
UNKNOWN								
	Dehydration							
	Diarrhoea							
	Dyspnoea							
	Hepatosplenomegaly							
	Hyperlipidaemia							
	Hypertensive							
	Cardiomyopathy							
	Iron Deficiency Anaemia							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain							
	Panniculitis							
	Renal Failure Acute							
	Renal Failure Chronic							
	Sudden Death							
	Vomiting							

Date:01/27/05ISR Number: 4562554-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00206
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Epigastric Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Exercise Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
Initial or Prolonged	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
	Haemoglobin Decreased		Celecoxib	C		ORAL		
	Myocardial Infarction		[Therapy					
	Renal Disorder		Unspecified]	C				UNKNOWN

Date:01/27/05ISR Number: 4562555-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Atherosclerosis
	Blood Cholesterol
	Increased
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Cardiogenic Shock

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain					
		Convulsion					
		Coronary Artery Disease					
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Atenolol	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Prozac	C		
UNKNOWN							
		Lung Infiltration		Prozac	C		
UNKNOWN							
		Myalgia		Tylenol	C		
UNKNOWN							
		Myocardial Infarction		Buspar	C		
UNKNOWN							
		Nausea		Atrovent	C		
UNKNOWN							
		Orthostatic Hypotension		Magnesium Sulfate	C		
UNKNOWN							
		Papilloma		Claforan	C		
UNKNOWN							
		Skin Laceration		Cordarone	C		
UNKNOWN							
		Ventricular Tachycardia		Pepcid	C		
UNKNOWN							
		Vomiting		Reopro	C		
UNKNOWN							
				Dopamine Hydrochloride	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Aspirin	C		ORAL
				Celexa	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Dalmane	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							

Date:01/27/05ISR Number: 4562564-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00739
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Amaurosis Fugax
Other	Amnesia
	Anaemia Haemolytic Autoimmune
	Anxiety
	Arthralgia
	Arthritis Bacterial
	Asthenia
	Atelectasis
	Azotaemia
	Blindness Transient
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Blood Pressure Increased
	Cardiac Flutter
	Cellulitis
	Cerebral Ventricle Dilatation
	Cerebrovascular Accident
	Chest Pain
	Cholecystitis
	Cholelithiasis
	Coagulation Factor Viii Level Increased
	Coagulopathy
	Condition Aggravated

Decreased Appetite
Disturbance In Attention
Drug Hypersensitivity
Drug Ineffective
Dysphagia
Dyspnoea
Emotional Distress
Endocrine Disorder
Eye Pain
Face Oedema
Fall
Gastric Polyps
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Haematochezia
Haemophilus Infection
Haemorrhage
Hiatus Hernia
High Density Lipoprotein
Decreased
Hypercalcaemia
Hyperglycaemia
Hypocalcaemia
Hypomagnesaemia
Increased Appetite
Injury
Insomnia
Iron Deficiency
Irritable Bowel Syndrome
Leukocytosis
Loss Of Consciousness
Low Density Lipoprotein
Increased
Lung Neoplasm
Mental Status Changes
Migraine
Muscle Spasms
Muscle Twitching
Musculoskeletal Stiffness
Neurogenic Bladder
Oesophageal Disorder
Operative Haemorrhage
Pharyngitis Streptococcal
Presbyoesophagus
Pruritus
Pulmonary Granuloma

Pyrexia
Red Blood Cell
Spherocytes Present
Renal Failure
Renal Failure Acute
Sinus Disorder
Sinusitis
Sputum Discoloured
Tachycardia
Tinnitus
Tooth Disorder
Toothache
Tracheobronchitis
Transient Ischaemic

		Attack Upper Respiratory Tract Infection Viral Infection	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON	
		Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	8 MON	
		Weight Increased		Os-Cal + D	C			UNKNOWN	
				Slow-Mag	C			UNKNOWN	
				Potassium Chloride	C			UNKNOWN	
				Rocaltrol	C		ORAL		
				Synthroid	C			UNKNOWN	
				Synthroid	C		ORAL		
				Prilosec	C			UNKNOWN	
				Reglan	C			UNKNOWN	
				Reglan	C			UNKNOWN	
				Ambien	C			UNKNOWN	
				Ditropan Xl	C			UNKNOWN	
				Amitriptyline Hydrochloride	C			UNKNOWN	
				Claritin	C			UNKNOWN	
				Claritin-D	C			UNKNOWN	
				Lasix (Furosemide)	C			UNKNOWN	
				Slow-K	C			UNKNOWN	
				Premarin	C			UNKNOWN	
				Quinine	C			UNKNOWN	
				Flonase	C			UNKNOWN	
				Tessalon Perles	C			UNKNOWN	

				Percocet	C		
UNKNOWN							

Date:01/27/05ISR Number: 4562567-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562568-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00232
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Disease		Piretanide	C				
UNKNOWN								
	Hearing Impaired		Atorvastatin Calcium	C		ORAL		
	Visual Disturbance		Nifedipine	C				
AURICULAR								
(OTIC)								
			Fenofibrate	C				
UNKNOWN								

Date:01/27/05ISR Number: 4562569-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00065
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
Initial or Prolonged	Myocardial Infarction		Atorvastatin Calcium	C		ORAL		
			Acetaminophen	C		ORAL		
			Pindolol	C		ORAL		
2 YR								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/05ISR Number: 4562570-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562571-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00527
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30 MON	
Hospitalization - Initial or Prolonged	Pain Transient Ischaemic		[Therapy Unspecified]	C			UNKNOWN	
Disability	Attack							

Date:01/27/05ISR Number: 4562573-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02561
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain Fatigue Hyperhidrosis White Blood Cell Count Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562574-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00513
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562575-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02935
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562590-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00229
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	852	DAY

Date:01/27/05ISR Number: 4562591-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02783
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562592-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/05ISR Number: 4562594-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02963
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Fatigue Myocardial Infarction Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562595-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562596-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562597-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03161
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:01/27/05ISR Number: 4562598-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562599-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hypertension							
	Paraplegia							
	Spinal Cord Infarction							
	Syncope							
	Transient Ischaemic Attack							

Date:01/27/05ISR Number: 4562605-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/27/05ISR Number: 4562607-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562609-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03329
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
Other	Myocardial Infarction							

Date:01/27/05ISR Number: 4562610-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562612-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03303
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/27/05ISR Number: 4562614-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:01/27/05ISR Number: 4565203-4Report Type:Direct Company Report #CTU 238427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS				
Hospitalization - Initial or Prolonged	Congestive Cardiomegaly							
Other	Myocardial Infarction							

Date:01/27/05ISR Number: 4567383-3Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00029
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Blood Urea Decreased
	Brain Oedema
	Cerebrovascular Accident
	Ischaemic Cerebral Infarction
	Mean Cell Haemoglobin Concentration Increased
	Mean Cell Haemoglobin Increased

Platelet Count Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG; DAILY;	
Health Professional					PO	103 DAY

Date:01/27/05ISR Number: 4570306-4Report Type:Direct Company Report #CTU 238324
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Abnormal Behaviour Blood Pressure Increased Disorientation Feeling Abnormal		Vioxx Mother Has Info	PS				

Date:01/27/05ISR Number: 4570359-3Report Type:Direct Company Report #CTU 238303
Age:26 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	No Adverse Effect		Vioxx 50 Mg Mercer	PS	Mercer	ORAL	25MG TWICE A DAY ORAL	

Date:01/27/05ISR Number: 4575286-3Report Type:Direct Company Report #CTU 238346
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS			1 TO 2 A DAY	
Hospitalization - Initial or Prolonged	Increased Gastrointestinal Disorder		Celebrex Bextra	SS SS				

Disability	Hypertension	Relafen	SS
Required	Myocardial Infarction		
Intervention to Prevent Permanent Impairment/Damage			

Date:01/28/05ISR Number: 4564061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00754
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Anaemia
	Angina Pectoris
	Asthenia
	Blood Pressure Increased
	Bronchopneumonia
	Confusional State
	Convulsion
	Coronary Artery Disease
	Duodenal Ulcer
	Fall
	Hallucination
	Leukocytosis

	Lung Infiltration						
	Myocardial Ischaemia						
	Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL	
	Spinal Fracture		Vioxx	SS	Merck & Co., Inc	ORAL	
	Urinary Tract Infection		Fosamax	C		ORAL	
	Vomiting		Aspirin	C			UNKNOWN

Date:01/28/05ISR Number: 4564067-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00020
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 440 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Lansoprazole	C			UNKNOWN
			Amlodipine Besylate	C			UNKNOWN
			Formoterol Fumarate	C			UNKNOWN
			Prednisolone	C			UNKNOWN
			Aspirin And Magnesium Oxide	C			UNKNOWN
			Clopidogrel Bisulfate	C			UNKNOWN
	9 MON		Atorvastatin Calcium	C			UNKNOWN
			Metoprolol Tartrate	C			UNKNOWN
			Prochlorperazine Maleate	C			UNKNOWN

Date:01/28/05ISR Number: 4564082-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01966
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Contusion		Atenolol	C				
UNKNOWN								
Initial or Prolonged	Haemorrhage		Lexapro	C				
UNKNOWN								
Disability	Memory Impairment							
	Platelet Destruction							
	Increased							

Date:01/28/05ISR Number: 4564085-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00130
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Omeprazole Magnesium	C		ORAL		

Date:01/28/05ISR Number: 4564087-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02261
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Withdrawal Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Injury		Valium	C				
UNKNOWN								
	Oedema Peripheral		Vicoprofen	C				
UNKNOWN								
	Skin Laceration							
	Torticollis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564095-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00100
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Celebrex	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564097-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01024
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
28 MON								
Hospitalization -	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
28 MON								
Initial or Prolonged	Mitral Valve Disease		Altace	C				
UNKNOWN								
Disability	Myocardial Infarction							
Other	Nephrolithiasis							
	Osteoarthritis							
	Plantar Fasciitis							
	Rotator Cuff Syndrome							
	Tendonitis							
	Urinary Tract Infection							

Date:01/28/05ISR Number: 4564099-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00510
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Leg Amputation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Musculoskeletal Disorder							
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564100-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01598
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Hospitalization -	Infarction		Glucotrol	C				UNKNOWN
Initial or Prolonged	Angina Unstable		Lasix (Furosemide)	C				UNKNOWN
Disability	Anorexia		Nitroglycerin	C				UNKNOWN
	Asthenia		Vicodin Tablets	C		ORAL		
	Bundle Branch Block Left		Norvasc	C				UNKNOWN
	Conduction Disorder		Cotazym	C				UNKNOWN
	Coronary Artery Disease							
	Electrocardiogram T Wave Inversion							
	Hypertension							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain							
	Renal Failure Chronic							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564102-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
Initial or Prolonged	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
Disability	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Dyspnoea		Aspirin	C			UNKNOWN	
	Emotional Distress		Echinacea	C			UNKNOWN	1483 DAY
	Fatigue		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Gastrointestinal Haemorrhage		Dicyclomine Hydrochloride	C			UNKNOWN	
	Gastrooesophageal Reflux Disease		Nexium	C			UNKNOWN	
	Headache							
	Hypersensitivity							
	Intervertebral Disc Degeneration							
	Intervertebral Disc Protrusion							
	Malaise							
	Melaena							
	Migraine							
	Mitral Valve Prolapse							
	Multiple Allergies							
	Muscle Spasms							
	Musculoskeletal Pain							
	Nasal Congestion							
	Nausea							
	Neck Pain							
	Pain							
	Pain In Extremity							
	Pallor							
	Pharyngolaryngeal Pain							
	Pyrexia							
	Rectal Haemorrhage							

Small Intestinal Ulcer
Haemorrhage
Small Intestine Ulcer
Upper Respiratory Tract
Infection
Viral Infection

Date:01/28/05ISR Number: 4564107-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564108-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension Abdominal Pain Dizziness Fatigue Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564110-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02632
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Non-Insulin-Dependent		Oxycontin	C		ORAL		
	Hypertension		Oxycontin	C		ORAL		
	Myocardial Infarction		Oxycontin	C				
UNKNOWN								
			Vicodin Tablets	C		ORAL		
			Vicodin Tablets	C		ORAL		
			Neurontin	C				
UNKNOWN							15	DAY
			Neurontin	C				
UNKNOWN							22	DAY
			Celebrex	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564115-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
1	YR							
Initial or Prolonged	Heart Injury							
Disability	Overdose							

Date:01/28/05ISR Number: 4564117-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
73	DAY							

Date:01/28/05ISR Number: 4564120-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564121-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Pacemaker Insertion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564122-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02202
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 18 MON Initial or Prolonged	Coagulopathy Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564124-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03229
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Death Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564126-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dissection Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564127-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:01/28/05ISR Number: 4564129-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00144
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Disability		Omeprazole	C			UNKNOWN	
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564131-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acoustic Stimulation
Disability	Tests Abnormal
	Amnesia
	Arthralgia
	Asthenia
	Chronic Fatigue Syndrome
	Clavicle Fracture
	Coccidioidomycosis
	Convulsion
	Dementia
	Drug Ineffective

Dry Eye
Dry Mouth
Eczema Asteatotic
Emotional Distress
Encephalitis
Endocarditis
Fall
Fibromyalgia
Fracture
Gastrooesophageal Reflux
Disease
Grand Mal Convulsion
Headache
Insomnia
Iritis
Joint Dislocation
Joint Injury
Lacrimation Increased
Lethargy
Limb Injury
Meningitis
Mitral Valve Prolapse
Myocarditis

	Nausea						
	Night Sweats						
	Photosensitivity Reaction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pruritus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Calcification		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stomatitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL		
	Viral Infection		Anaprox	C				UNKNOWN
	Vomiting		Femhrt	C				UNKNOWN
			Herbs (Unspecified)	C				UNKNOWN
			Celebrex	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Trazodone Hydrochloride	C		ORAL		
			Trazodone Hydrochloride	C		ORAL		
			Prozac	C				UNKNOWN
			Prozac	C		ORAL		

Date:01/28/05ISR Number: 4564136-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564139-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00141
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564140-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03388
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564141-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03334
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Pacemaker Insertion Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564145-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Difficulty In Walking		Percocet	C			UNKNOWN	
	Hypoaesthesia		Omega-3	C			UNKNOWN	
	Monoplegia		Ginkgo Biloba Extract	C			UNKNOWN	
	Pain In Extremity							
	Phlebitis							
	Road Traffic Accident							
	Sensory Loss							
	Thermal Burn							
	Thrombosis							

Date:01/28/05ISR Number: 4564147-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564148-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Hydrochlorothiazide And Irbesartan	C			UNKNOWN	

Date:01/28/05ISR Number: 4564158-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03333
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564160-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00613
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event
	Agitation
	Alcohol Withdrawal Syndrome
	Alcoholism
	Anaemia
	Angina Pectoris
	Anxiety
	Atelectasis
	Atrial Fibrillation
	Blood Pressure Increased
	Cardiac Procedure Complication

		Cardiomegaly					
		Convulsion					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Glimepiride	C		ORAL
		Coronary Artery Stenosis					
		Ejection Fraction					
		Decreased					
		Ischaemic Cardiomyopathy					
		Platelet Count Decreased					
		Post Procedural					
		Haemorrhage					
		Procedural Complication					
		Psychotic Disorder					
		Pulmonary Oedema					
		Respiratory Distress					
		Respiratory Failure					
		Vascular Injury					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:01/28/05ISR Number: 4564165-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
284 DAY						
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
284 DAY						
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Discomfort		Prevacid	C		
UNKNOWN						
	Chest Pain		Methylprednisolone	C		
UNKNOWN						
	Cholelithiasis		Estradiol	C		ORAL
	Coronary Artery		Clonazepam	C		
UNKNOWN						
	Atherosclerosis		Vantin	C		
UNKNOWN						
	Coronary Artery Stenosis		Meclizine	C		
UNKNOWN						
	Depression		Acetaminophen And			

	Dizziness	Hydrocodone Bitartrate	C	UNKNOWN
	Dyspnoea	Sulfamethoxazole And Trimethoprim	C	UNKNOWN
	Dyspnoea Paroxysmal Nocturnal	Serzone	C	ORAL
336 DAY	Gastrooesophageal Reflux	Serzone	C	ORAL
	Disease	Albuterol	C	UNKNOWN
	Hyperhidrosis	Zyrtec	C	UNKNOWN
	Hypertension	Prednisone	C	UNKNOWN
	Mitral Valve Prolapse	Cephalexin	C	UNKNOWN
	Myocardial Infarction	Augmentin	C	UNKNOWN
	Nausea	Allegra	C	UNKNOWN
	Orthopnoea	Flonase	C	UNKNOWN
	Pain	Cyanocobalamin	C	PARENTERAL
	Palpitations	Cyanocobalamin	C	PARENTERAL
	Panic Attack	Remeron	C	UNKNOWN
	Paraesthesia	Aciphex	C	UNKNOWN
	Uterine Leiomyoma	Tequin	C	UNKNOWN
	Vaginal Haemorrhage	Diovan	C	ORAL
	Vision Blurred	Verapamil Msd Lp	C	ORAL
		A.S.A.	C	ORAL
		A.S.A.	C	ORAL
		Prometrium	C	ORAL
		Mobic	C	ORAL

			Promethazine	C		ORAL

Date:01/28/05ISR Number: 4564182-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01542
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Premarin	C				
UNKNOWN								
Other	Gastric Haemorrhage		Tiazac	C				
UNKNOWN								
	Headache		Valium	C				
UNKNOWN								
	Heart Rate Increased							
	Oedema Peripheral							

Date:01/28/05ISR Number: 4564187-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
1	DAY							
Initial or Prolonged	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL		
1	DAY							
	Chest Pain							
	Diarrhoea							
	Emotional Distress							
	Erosive Oesophagitis							
	Gastritis Erosive							
	Gastrooesophageal Reflux							
	Disease							
	Hepatic Cyst							
	Hiatus Hernia							
	Hypercholesterolaemia							
	Hypersensitivity							
	Hypertriglyceridaemia							
	Intervertebral Disc							
	Degeneration							
	Panic Attack							

Date:01/28/05ISR Number: 4564192-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00832
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
Disability	Basal Cell Carcinoma
	Benign Vascular Neoplasm
	Bone Pain
	Bronchitis
	Burning Sensation
	Cerebrovascular Accident
	Conversion Disorder
	Coordination Abnormal
	Depression
	Dizziness
	Dry Skin
	Emotional Distress
	Fall
	Fatigue
	Ganglion
	Generalised Anxiety
	Disorder

		Haemorrhoids					
		Hallucination					
		Hemiparesis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Synthroid	C		
UNKNOWN							
		Hypoaesthesia		Aspirin	C		
UNKNOWN							
		Hypokalaemia		Celexa	C		
UNKNOWN							
		Hyporeflexia		Niacin	C		
UNKNOWN		14671DAY					
		Inflammation		Lexapro	C		
UNKNOWN							
		Insomnia		Claritin	C		
UNKNOWN							
		Lacunar Infarction		Ventolin (Albuterol)	C		
RESPIRATORY							
		Liver Function Test					
(INHALATION)							
		Abnormal		Aerobid	C		
UNKNOWN							
		Loss Of Consciousness					
		Menopausal Symptoms					
		Migraine With Aura					
		Movement Disorder					
		Oesophageal Spasm					
		Orthostatic Hypotension					
		Pain In Extremity					
		Palpitations					
		Post Procedural					
		Complication					
		Psychosomatic Disease					
		Stress					
		Suicidal Ideation					
		Syncope					
		Tinnitus					
		Torticollis					
		Tremor					

Date:01/28/05ISR Number: 4564193-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00094
Age:40 YR Gender:Male I/FU:F

Outcome PT

Death	Anoxic Encephalopathy
Hospitalization - Initial or Prolonged	Anxiety
	Apnoea
	Back Injury
	Back Pain
	Cardiac Disorder
	Cardio-Respiratory Arrest
	Chronic Obstructive Pulmonary Disease
	Convulsion
	Coronary Artery Disease
	Cough
	Dyslipidaemia
	Emotional Distress
	Epicondylitis
	Eye Pain
	Headache
	Influenza
	Insomnia
	Malaise
	Myocardial Infarction
	Obesity
	Pneumonia
	Pyrexia
	Respiratory Failure

		Upper Respiratory Tract Infection					
		Ventricular Fibrillation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
223	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Toprol Xl Tablets	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Claritin-D	C		ORAL
				Tylenol	C		
UNKNOWN							
				Wellbutrin Sr	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Norflex	C		
UNKNOWN							
				Norflex	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							

Date:01/28/05ISR Number: 4564203-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00777
Age:36 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						

Initial or Prolonged	Asthenia	Vioxx	SS	Merck & Co., Inc	ORAL
2 YR					
Disability	Cardiovascular Disorder	Tramadol			
	Chest Pain	Hydrochloride	C		
UNKNOWN					
	Deep Vein Thrombosis	Tramadol			
	Disturbance In Attention	Hydrochloride	C		
UNKNOWN					
	Dizziness	Dipyrone	C		
UNKNOWN					
	Intervertebral Disc	Dipyrone	C		
UNKNOWN					
	Protrusion	Dipyrone	C		
UNKNOWN					
	Memory Impairment	Cromolyn Sodium	C		
UNKNOWN					
	Pulmonary Embolism	Acetaminophen	C		
UNKNOWN					
		Aspirin	C		
UNKNOWN					
		Acetylcysteine	C		
UNKNOWN					
		Acetylcysteine	C		
UNKNOWN					

Date:01/28/05ISR Number: 4564206-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00707
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Cholesterol
Disability	Increased
	Blood Potassium Decreased
	Condition Aggravated
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent

		Erectile Dysfunction					
		Hypertension					
		Hypertriglyceridaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		International Normalised		Vioxx	PS	Merck & Co., Inc	ORAL
17	MON						
		Ratio Increased		Neurontin	C		ORAL
		Micturition Disorder		Flexeril	C		ORAL
		Myocardial Infarction		Viagra	C		ORAL
		Platelet Count Decreased		Lipitor	C		ORAL
		Prothrombin Time		Valtrex	C		ORAL
77	DAY						
		Shortened		Niaspan	C		ORAL
		Renal Failure Acute		Paxil	C		
UNKNOWN							
		White Blood Cell Count		Darvocet-N	C		ORAL
		Increased					

Date:01/28/05ISR Number: 4564212-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Neurontin	C		
UNKNOWN							
		Back Injury		Ibuprofen	C		
UNKNOWN							
		Cardiac Murmur		Claritin	C		
UNKNOWN							
		Carpal Tunnel Syndrome		Premarin	C		
UNKNOWN							
		Cerebrovascular Accident		Cephalexin	C		
UNKNOWN							
		Clumsiness		Skelaxin	C		
UNKNOWN							
		Contusion		Trazodone			
		Depression		Hydrochloride	C		
UNKNOWN							
		Drug Effect Decreased		Zovirax	C		
UNKNOWN							

	Dysthymic Disorder	Methylprednisolone	C	UNKNOWN
	Fall	Propoxyphene Hydrochloride	C	UNKNOWN
	Fatigue	Naproxen	C	UNKNOWN
	Gastrooesophageal Reflux	Baclofen	C	ORAL
	Disease			
	General Symptom			
	Headache			
	Hypertension			
	Intervertebral Disc Protrusion			
	Irritability			
	Mitral Valve Incompetence			
	Myofascial Pain Syndrome			
	Pain			
	Pain In Extremity			
	Thrombosis			
	Tinnitus			
	Transient Ischaemic Attack			
	Tricuspid Valve Incompetence			

Date:01/28/05ISR Number: 4564268-3Report Type:Expedited (15-DaCompany Report #PH-MERCK-0412PHL00004
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564269-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00936
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acarodermatitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Accidental Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Drug Reaction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bladder Pain		Diltiazem					
	Bradycardia		Hydrochloride	C			UNKNOWN	
	Cardiac Arrest		Lisinopril	C		ORAL		
	Dehydration		Atenolol	C			UNKNOWN	
	Dizziness Postural		Paxil	C			UNKNOWN	
	Dyspepsia		Ambien	C			UNKNOWN	
	Foot Fracture		Lorazepam	C			UNKNOWN	
	Heart Rate Decreased							
	Hypotension							
	Insomnia							
	Liver Function Test							
	Abnormal							
	Migraine							
	Skin Disorder							
	Skin Irritation							
	Staphylococcal Infection							
	Tension Headache							
	Tinea Pedis							

Date:01/28/05ISR Number: 4564272-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04149
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease							
Other	Dermatitis Allergic							
	Diabetes Mellitus							
	Groin Pain							
	Hypercholesterolaemia							

Hypertension
Laceration
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Pharyngitis
Renal Failure
Spinal Osteoarthritis
Viral Upper Respiratory
Tract Infection

Date:01/28/05ISR Number: 4564273-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00061
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Dilantin	C				
UNKNOWN								
Initial or Prolonged			Zocor	C				
UNKNOWN								
			Moexipril Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564275-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02525
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		[Therapy Unspecified]	C				
	Atrial Septal Defect							
	Blood Glucose Increased							
	Cardiac Disorder							
	Chest Pain							
	Dyspnoea							
	Fluid Retention							
	Infection							
	Upper Respiratory Tract Infection							
	White Blood Cell Count Increased							

Date:01/28/05ISR Number: 4564278-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00120
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Post Thrombotic Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	594 DAY	
	Thrombosis		Allopurinol	C		ORAL		
			Diclofenac	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:01/28/05ISR Number: 4564279-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00540
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alveolitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sarcoidosis		Fosamax	C		ORAL		
			Prednisone	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

[Therapy
Unspecified] C
UNKNOWN

Date:01/28/05ISR Number: 4564280-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01171
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
Hospitalization -	Aortic Valve Stenosis
Initial or Prolonged	Atrial Fibrillation
Disability	Cardiac Failure
	Congestive
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Dental Caries
	Diverticulum Intestinal
	Fall
	Hip Fracture
	Loss Of Consciousness
	Mitral Valve Incompetence
	Myeloproliferative
	Disorder

	Myocardial Infarction						
	Nasal Polyps						
	Nephrolithiasis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pain		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
	Refractory Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Renal Infarct		Propranolol					
	Restrictive Pulmonary Disease		Hydrochloride	C		ORAL		
	Sinusitis							
	Splenomegaly							
	Thrombocytopenia							
	Upper Limb Fracture							
	Urinary Tract Infection							

Date:01/28/05ISR Number: 4564283-XReport Type:Expedited (15-DaCompany Report #PL-MERCK-0501POL00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Coronary Artery Disease							
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564285-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01061
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Tylenol	C				

Date:01/28/05ISR Number: 4564296-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02110
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Pain	Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Pain In Extremity	Vioxx	SS	Merck & Co., Inc	ORAL
	Rash				
	Renal Failure Chronic				
	Thrombosis				

Date:01/28/05ISR Number: 4564297-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00138
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			[Composition Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide And Irbesartan	C		
UNKNOWN						

Date:01/28/05ISR Number: 4564299-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00110
Age: Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Theophylline	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564301-9Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00030
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
933 DAY								
	Dyspnoea		Venlafaxine					
	Fluid Retention		Hydrochloride	C		ORAL		
	Hyperhidrosis		Atenolol	C		ORAL		
	Paraesthesia		Chlorthalidone	C		ORAL		
	Tremor		Acetaminophen	C		ORAL		

Date:01/28/05ISR Number: 4564302-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02750
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Blister		Lipitor	C				
UNKNOWN								
	Haemorrhage		[Therapy					
	Pulmonary Embolism		Unspecified]	C				
UNKNOWN								
	Rash							

Date:01/28/05ISR Number: 4564305-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02773
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Cough	Zocor	C
UNKNOWN			
Disability	Dehydration	Meclizine	C
UNKNOWN			
	Dyspnoea	Premarin	C
UNKNOWN			
	Headache	[Therapy	
	Lacrimation Increased	Unspecified]	C
UNKNOWN			
	Sneezing		
	Spinal Osteoarthritis		
	Thyroid Neoplasm		
	Transient Ischaemic		
	Attack		
	Upper Respiratory Tract		
	Infection		
	Vertigo		

Date:01/28/05ISR Number: 4564307-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00026
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 367 DAY	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Atorvastatin Calcium	C		ORAL
	Myocardial Infarction		Benserazide Hydrochloride And			
	Oedema		Levodopa	C		ORAL
			Gabapentin	C		ORAL

			Darbepoetin Alfa	C		SUBCUTANEOUS

Date:01/28/05ISR Number: 4564309-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction Hemiplegia Psychomotor Agitation Respiratory Disorder		Vioxx Amlodipine Besylate Phenprocoumon Sotalol Hydrochloride Lorazepam	PS C C C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL ORAL		

Date:01/28/05ISR Number: 4564310-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00512
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Operation Chest Pain Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564311-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02242
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN Other	Cerebrovascular Accident Dialysis Renal Disorder		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564313-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564314-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564320-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564321-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02355
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Hypertension							

Date:01/28/05ISR Number: 4564322-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00514
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564323-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02805
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Subdural Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:01/28/05ISR Number: 4564325-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00526
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged	Heart Rate Increased							
	Ocular Vascular Disorder							
Disability								

Date:01/28/05ISR Number: 4564326-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02415
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564327-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564328-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02823
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564389-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02416
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564391-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564393-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02882
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564394-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03009
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cholecystitis Infective Gallbladder Enlargement							

Date:01/28/05ISR Number: 4564395-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564396-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02887
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564398-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02885
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		348 DAY

Date:01/28/05ISR Number: 4564399-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564402-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564437-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564439-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564445-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564446-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564448-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	665	DAY

Date:01/28/05ISR Number: 4564449-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease Death Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564450-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564451-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564461-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03322
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564463-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564464-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03250
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564465-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564466-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564468-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03284
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Operation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564469-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03281
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564470-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564472-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564473-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564474-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03249
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564476-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564477-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03304
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Withdrawal Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack							

Date:01/28/05ISR Number: 4564490-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03335
Age:63 YR Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Disorder
	Cardiac Pacemaker Insertion
	Implantable Defibrillator Insertion
	Transient Ischaemic

Attack

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564491-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564492-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03319
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564493-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564494-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03317
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564495-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03311
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564496-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness							
	Brain Stem Infarction							
	Paraesthesia							

Date:01/28/05ISR Number: 4564498-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564499-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03422
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Chest Pain		Prilosec	C				
UNKNOWN								
Hospitalization - Initial or Prolonged								
Disability								

Date:01/28/05ISR Number: 4564500-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03421
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564501-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03413
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN			Wellbutrin	C				
			Hormones (Unspecified)	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564502-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564503-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03362
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564504-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03327
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564505-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564506-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564507-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03328
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564508-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564509-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04362
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Coumadin	C				
	Vertigo		Coreg	C				
			Allopurinol	C				
			Lasix (Furosemide)	C				
			[Therapy Unspecified]	C				

Date:01/28/05ISR Number: 4564511-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03528
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Hospitalization -								

Initial or Prolonged
Disability

Date:01/28/05ISR Number: 4564512-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03430
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:01/28/05ISR Number: 4564513-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:01/28/05ISR Number: 4564514-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03368
Age: Gender:Female I/FU:I

Outcome	PT
Death	Death
	Hypertensive Heart

	Disease						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564515-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03363
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:01/28/05ISR Number: 4564516-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564518-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564532-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03361
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564798-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anxiety Disorder
Other	Back Injury
	Chest Discomfort
	Chest Pain
	Chromaturia
	Contusion
	Coronary Artery
	Restenosis
	Cough
	Decreased Appetite
	Dehydration
	Depressed Mood
	Diarrhoea
	Disturbance In Attention
	Diverticulum Intestinal
	Haemorrhagic
	Drug Ineffective
	Dyspnoea
	Fatigue
	Fluid Retention

		Haemorrhoids					
		Hypertension					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Iron Deficiency		Vioxx	SS	Merck & Co., Inc	ORAL
		Libido Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Lung Neoplasm		Norvasc	C		
UNKNOWN							
		Myocardial Infarction		Monopril	C		
UNKNOWN							
		Nausea		Indocin			
		Non-Cardiac Chest Pain		(Indomethacin)	C		
UNKNOWN							
		Oedema Peripheral		Naproxen	C		
UNKNOWN							
		Paraesthesia		Ecotrin	C		
UNKNOWN							
		Pneumonia		Lopressor	C		
UNKNOWN							
		Prostatic Specific		Toprol Xl Tablets	C		
UNKNOWN							
		Antigen Increased		Lipitor	C		
UNKNOWN							
		Proteinuria		Allopurinol	C		
UNKNOWN							
		Renal Cyst		Prilosec	C		
UNKNOWN							
		Rheumatoid Arthritis		Lasix (Furosemide)	C		
UNKNOWN							
		Rhinitis Allergic		K-Dur	C		
UNKNOWN							
		Stress					
		Tendon Rupture					
		Treatment Noncompliance					
		Umbilical Hernia					
		Ventricular Extrasystoles					

Date:01/28/05ISR Number: 4564800-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0212USA00230
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - 222 DAY	Angina Pectoris	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Arthralgia	Humulin	C		
Disability UNKNOWN	Chest Discomfort	Humulin	C		
	Coronary Artery Disease	Clotrimazole	C		
UNKNOWN					
	Drug Ineffective	Neurotonin Capsules	C		
UNKNOWN					
	Dyspepsia	Vicoprofen	C		
UNKNOWN					
	Dysphagia				
	Gastric Ulcer				
	Headache				
	Myocardial Infarction				
	Neuralgia				
	Oesophagitis				
	Pain				
	Pain In Extremity				
	Spinal Osteoarthritis				
	Stomach Discomfort				
	Vomiting				
	Weight Increased				

Date:01/28/05ISR Number: 4564801-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Hernia
Hospitalization -	Anaemia
Initial or Prolonged	Anorexia
Other	Anxiety
	Bacterial Sepsis
	Bipolar I Disorder

		Calculus Ureteric					
		Cervix Carcinoma					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diarrhoea		Avapro	C		
UNKNOWN							
		Fatigue		Paxil	C		
UNKNOWN							
		Flank Pain		Geodon	C		
UNKNOWN							
		Gastritis		Lipitor	C		
UNKNOWN							
		Hydronephrosis		Lipitor	C		
UNKNOWN							
		Hydroureter		Prilosec	C		
UNKNOWN							
		Hyperparathyroidism		Levoxyl	C		
UNKNOWN							
		Hypertension		Prevacid	C		
UNKNOWN							
		Incisional Hernia					
		Nephrolithiasis					
		Phlebolith					
		Renal Atrophy					
		Renal Failure					
		Renal Failure Acute					
		Schizoaffective Disorder					
		Sepsis					
		Staphylococcal Infection					
		Ureteric Stenosis					
		Urinary Retention					
		Urinary Tract Infection					
		Urine Output Decreased					
		Urosepsis					
		Weight Increased					

Date:01/28/05ISR Number: 4564804-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 10 DAY		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged 15 DAY	Back Injury	Vioxx	SS	Merck & Co., Inc	ORAL
Disability 10 DAY	Bladder Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
Other 15 DAY	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL
	Increased	Lortab	C		ORAL
	Cerebrovascular Accident	Excedrin			
	Constipation	Extra-Strength	C		
UNKNOWN					
	Delusion	Aspirin	C		
UNKNOWN					
	Diarrhoea				
	Emotional Distress				
	Ependymoma				
	Headache				
	Herpes Zoster				
	Intervertebral Disc				
	Protrusion				
	Meningitis				
	Muscle Contractions				
	Involuntary				
	Paranoia				
	Psychotic Disorder				
	Pyrexia				
	Stomach Discomfort				
	Tremor				
	Venous Thrombosis Limb				

Date:01/28/05ISR Number: 4564805-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		984 DAY
	Anaemia		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Atherosclerosis							
	Back Pain							
	Cystocele		Wellbutrin	C		ORAL		
	Depression		Valium	C		ORAL		
	Hepatitis		Estradiol	C		ORAL		
	Hypertension		Remeron	C		ORAL		
	Liver Disorder		Lotensin	C				UNKNOWN
	Osteoporosis		Effexor Xr	C		ORAL		
	Pain In Extremity		Prilosec	C				UNKNOWN
	Polymyalgia Rheumatica		Atacand	C				UNKNOWN
	Polyneuropathy		Celexa	C				UNKNOWN
	Rectocele		Iron (Unspecified)	C				UNKNOWN
	Renal Failure		Diazepam	C				UNKNOWN
	Rhinitis Seasonal							
	Tremor							
	Weight Increased							

Date:01/28/05ISR Number: 4564806-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00861
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
Other	Arrhythmia
	Arthralgia
	Atherosclerosis
	Atrial Fibrillation
	Blister
	Blood Parathyroid Hormone Increased

Cardiac Murmur
Chest Pain
Colonic Polyp
Conjunctival Haemorrhage
Coronary Artery Disease
Dermatitis Contact
Diarrhoea
Diastolic Dysfunction
Dilatation Atrial
Diverticulum Intestinal
Dysgeusia
Dyspepsia
Dyspnoea
Eye Haemorrhage
Fatigue
Furuncle
Gastritis
Gastroenteritis
Gastrooesophageal Reflux
Disease
Haemorrhoids
Headache
Hepatic Cyst
Hepatic Steatosis
Hiatus Hernia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypercalcaemia					
		Hypertension					
		Intermittent Claudication					
		Laryngitis		Vioxx	PS	Merck & Co., Inc	ORAL
213	DAY						
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Nephrosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Pancreatitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
213	DAY						
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
59	DAY						
		Pleural Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
81	DAY						
		Pleural Fibrosis		Vioxx	SS	Merck & Co., Inc	ORAL
60	DAY						
		Pulmonary Fibrosis		Vioxx	SS	Merck & Co., Inc	ORAL
17	DAY						
		Rash Macular		Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
		Renal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Imdur	C		
UNKNOWN							
		Renal Failure Chronic		Monopril	C		
UNKNOWN							
		Rhinitis Allergic		Lipitor	C		
UNKNOWN							
		Rotator Cuff Syndrome		Glucotrol	C		
UNKNOWN							
		Sinusitis		Hydrodiuril	C		ORAL
		Sleep Apnoea Syndrome		Hydrodiuril	C		ORAL
		Tricuspid Valve		Toprol Xl Tablets	C		ORAL
		Incompetence		Cardura	C		
UNKNOWN							
		Ventricular Hypertrophy					

Date:01/28/05ISR Number: 4564807-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass
Disability	Adverse Event
Other	Atherosclerosis
	Basedow'S Disease
	Cardiac Failure
	Congestive
	Cellulitis
	Colonic Polyp
	Diabetes Mellitus
	Disorder Of Orbit
	Diverticulum
	Dyspnoea
	Dyspnoea Exertional
	Dyspnoea Paroxysmal
	Nocturnal
	Endocrine Ophthalmopathy
	Episcleritis
	Haemorrhoids
	Hyperhidrosis
	Hypertension
	Incontinence
	Mass
	Myocardial Infarction
	Myopathy
	Nausea
	Non-Cardiac Chest Pain
	Oedema Peripheral
	Optic Neuropathy
	Ovarian Cyst

	Pyelonephritis					
	Rash					
	Sleep Apnoea Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Thrombophlebitis		Vioxx	PS	Merck & Co., Inc	ORAL
	Superficial					
	Urinary Tract Infection					

Date:01/28/05ISR Number: 4564808-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Blood Cholesterol
Other	Abnormal
	Bursitis
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cardiovascular Disorder
	Chest Wall Pain
	Chills
	Confusional State
	Decreased Activity
	Drug Hypersensitivity
	Faecal Incontinence
	Fatigue
	Feeling Cold
	Fibula Fracture
	Head Injury
	Headache
	Hot Flush
	Hypertension
	Incontinence
	Laryngitis
	Libido Decreased
	Mood Swings
	Muscle Spasms
	Musculoskeletal Chest
	Pain
	Myocardial Infarction
	Neck Injury
	Oedema
	Ovarian Cyst
	Pelvic Pain

Pharyngolaryngeal Pain
Pollakiuria
Pulmonary Oedema
Renal Failure
Rhinitis Allergic
Rotator Cuff Syndrome
Sleep Disorder
Stress
Stress Incontinence
Suprapubic Pain
Tricuspid Valve
Incompetence
Urethritis
Urinary Tract Infection
Vaginal Erosion
Vaginal Infection

	Vaginal Odour						
	Varicose Vein						
	Vein Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL	
	Viral Upper Respiratory		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tract Infection		Effexor	SS			UNKNOWN
	Vision Blurred		Osteo-Bi-Flex	C			UNKNOWN
	Visual Disturbance		Estrace	C			UNKNOWN
	Vulvovaginal Discomfort		Vitamins				
	Weight Increased		(Unspecified)	C			UNKNOWN
			Vitamin B (Unspecified)	C			UNKNOWN
			Flagyl	C			UNKNOWN
			Cipro	C			UNKNOWN
			Lotensin	C			UNKNOWN
			Zyrtec	C			UNKNOWN
			Detrol	C			UNKNOWN

Date:01/28/05ISR Number: 4564809-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 55 DAY	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged Disability	Blood Triglycerides Increased		Zocor	C		ORAL	
			Estrace	C			UNKNOWN
	Drug Hypersensitivity		Estrace	C			UNKNOWN
	Dyspepsia		Prilosec	C			UNKNOWN
	Dyspnoea		Lortab	C			UNKNOWN

Emotional Distress
Fall
Gout
Hypercholesterolaemia
Injury
Limb Discomfort
Pain In Extremity
Peptic Ulcer
Transient Ischaemic
Attack
Trigeminal Neuralgia
Vaginal Infection
Vulvovaginal Dryness

Date:01/28/05ISR Number: 4564810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00754
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Activated Partial Thromboplastin Time Prolonged
	Acute Myocardial Infarction
	Anaemia
	Angina Pectoris
	Anxiety
	Aortic Calcification
	Aspartate

		Aminotransferase Increased					
		Asthenia					
		Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Alkaline		Vioxx	SS	Merck & Co., Inc	ORAL
		Phosphatase Increased		Fosamax	C		ORAL
		Blood Calcium Decreased		Aspirin	C		ORAL
		Blood Creatine		Nitroglycerin	C		ORAL
		Phosphokinase Increased		Capoten	C		ORAL
		Blood Glucose Increased		Ambien	C		ORAL
		Blood Potassium Decreased		Caltrate Plus	C		ORAL
		Blood Pressure Increased		Caltrate Plus	C		ORAL
		Blood Sodium Decreased		Darvocet-N	C		ORAL
		Blood Urea Increased		Acetaminophen	C		ORAL
		Bronchopneumonia		Maalox	C		ORAL
		Bundle Branch Block		Phillips' Milk Of			
		Cardiac Failure		Magnesia	C		ORAL
		Congestive		Bisacodyl	C		ORAL
		Cardiomegaly		Glyburide	C		ORAL
		Confusional State		Ultram	C		ORAL
		Convulsion		Prozac	C		ORAL
		Coronary Artery Disease		Xanax	C		ORAL
		Culture Stool Positive		Fleet Enema	C		
UNKNOWN							
		Duodenal Ulcer					
		Electrocardiogram					
		Abnormal					
		Fall					
		Gastric Haemorrhage					
		Glycosuria					
		Haemorrhage					
		Hallucination					
		Leukocytosis					
		Lung Infiltration					
		Myocardial Ischaemia					
		Nausea					
		Osteoporosis					
		Pain					
		Pallor					
		Pancreatitis					
		Peptic Ulcer					
		Pleural Effusion					
		Pruritus					
		Spinal Compression					
		Fracture					
		Spinal Fracture					

Urinary Tract Infection
Urine Ketone Body Present
Vomiting

Date:01/28/05ISR Number: 4564811-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00920
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization - Initial or Prolonged	Affective Disorder
Other	Alopecia
	Angina Pectoris
	Blood Pressure Increased
	Bronchopneumonia
	Bronchospasm

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	240	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		

Bundle Branch Block Right
Chest Pain
Chronic Obstructive
Pulmonary Disease
Convulsion
Coronary Artery
Atherosclerosis
Cushing'S Syndrome
Deafness
Death
Depression
Dizziness
Dyskinesia
Emphysema
Epicondylitis
Erectile Dysfunction
Fall
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder
Head Injury
Hot Flush
Hyperlipidaemia
Hypersensitivity
Hypertension
Hyperventilation
Interstitial Lung Disease
Irritable Bowel Syndrome
Mental Impairment
Muscle Twitching
Myocardial Infarction
Nausea
Nodule
Pharyngolaryngeal Pain
Pneumonia
Spinal Column Stenosis
Syncope
Tunnel Vision
Visual Disturbance

Date:01/28/05ISR Number: 4564812-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		476 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		128 DAY
Other	Infarction		Prilosec	C		ORAL		
	Angina Unstable		Tylenol	C				UNKNOWN
	Anxiety		Inderal	C				UNKNOWN
	Cardiac Failure		Lipitor	C		ORAL		
	Congestive		Lipitor	C				UNKNOWN
	Carotid Artery Disease		Zithromax	C				UNKNOWN
	Coronary Artery Disease		Zantac	C		ORAL		
	Diarrhoea		Nitrostat	C				SUBLINGUAL
	Ischaemic Cardiomyopathy							
	Mixed Hyperlipidaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564813-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accident At Work		Vioxx	PS	Merck & Co., Inc	ORAL		536 DAY
Initial or Prolonged	Acquired Diaphragmatic		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Eventration		Vioxx	SS	Merck & Co., Inc	ORAL		214 DAY
Other	Acute Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		536 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		214 DAY
	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Buspar	C		ORAL		405 DAY
	Bundle Branch Block Right		Lortab	C		ORAL		573 DAY
	Cardiac Arrest		Lortab	C		ORAL		
	Cardiac Failure		Ziac	C		ORAL		322 DAY
	Congestive		Vicodin Tablets	C		ORAL		
	Chest Pain		Lipitor	C		ORAL		
	Convulsion		Valium	C		ORAL		214 DAY
	Coronary Artery Disease		Talwin	C		ORAL		24 DAY
	Coronary Artery Occlusion		Ultram	C		ORAL		9 DAY
	Electrocardiogram Change		Skelaxin	C		ORAL		14 DAY
	Electrocardiogram Qrs		Tenyl	C				
UNKNOWN	36 DAY							
	Complex Prolonged		Claritin	C				
UNKNOWN								
	Haemoptysis		Serzone	C				
UNKNOWN								
	Hypotension		Carisoprodol	C				
UNKNOWN								
	Hypoxic Encephalopathy		Acetaminophen And					
	Intervertebral Disc		Propoxyphene					
	Protrusion		Hydrochloride	C				
UNKNOWN								

	Myocardial Infarction	Mobic	C
UNKNOWN			
	Nodal Rhythm	Hydrocodone	
	Ventricular Fibrillation	Hydrochloride	C
UNKNOWN			
	Ventricular Hypertrophy	Altace	C
UNKNOWN			
	Weight Decreased	Toprol Xl Tablets	C
UNKNOWN			
		Aspirin	C
UNKNOWN			

Date:01/28/05ISR Number: 4564814-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alopecia
Initial or Prolonged	Anaemia
Disability	Anorexia
	Asthma
	Atelectasis
	Blood Lactate
	Dehydrogenase Increased
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Colitis Ulcerative
	Constipation
	Cough
	Deep Vein Thrombosis
	Depressed Mood

		Depression					
		Diarrhoea					
		Dilatation Atrial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache					
		Hypertonia					
		Insomnia					
		Iron Deficiency Anaemia					
		Joint Swelling					
		Lacunar Infarction					
		Muscle Spasms					
		Oedema Peripheral					
		Orthopnoea					
		Osteoarthritis					
		Pericardial Effusion					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Postmenopausal					
		Haemorrhage					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Rectal Ulcer					
		Reflux Oesophagitis					
		Renal Failure					
		Tremor					
		Upper Motor Neurone					
		Lesion					
		Weight Decreased					
		Wheezing					

Date:01/28/05ISR Number: 4564815-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00655
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
16	MON						
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						

Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
16 MON						
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
2 YR						
	Cardiac Murmur		Prilosec	C		
UNKNOWN						
	Coronary Artery Disease					
	Hypertension					
	Pain					
	Rash					
	Urticaria					

Date:01/28/05ISR Number: 4564816-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00071
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anaemia		Prednisone	SS		ORAL
	Duodenal Ulcer					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564817-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00097
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Infarction		Arginine Glutamate	C			UNKNOWN	
Disability	Angina Unstable		Tyrosine	C			UNKNOWN	
	Anxiety		Vitamin B					
	Arrhythmia		(Unspecified)	C		PARENTERAL		
	Arteriospasm Coronary		Vitamins					
	Atrial Septal Defect		(Unspecified)	C		UNKNOWN		
	Cardiac Failure		Garlic Extract	C		ORAL		
	Congestive							
	Coronary Artery Disease							
	Coronary Artery							
	Thrombosis							
	Dyslipidaemia							
	Emotional Distress							
	Ischaemic Cardiomyopathy							
	Joint Sprain							
	Mitral Valve Incompetence							
	Supraventricular							
	Tachycardia							
	Transaminases Increased							

Date:01/28/05ISR Number: 4564818-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00511
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1434	DAY
Hospitalization -	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Initial or Prolonged	Confusional State		Vioxx	SS	Merck & Co., Inc	ORAL	1434	DAY
	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Depressed Mood							

Disturbance In Attention
Fall
Hyponatraemia
Sleep Apnoea Syndrome
Thoracic Vertebral
Fracture
Urinary Tract Infection

Date:01/28/05ISR Number: 4564819-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00955
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Electrocardiogram		Vioxx	SS	Merck & Co., Inc	ORAL		
	Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Non-Cardiac Chest Pain		Proventil	C			UNKNOWN	
			Azmacort	C			UNKNOWN	

Date:01/28/05ISR Number: 4564820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Arthralgia
	Asthenia
	Atherosclerosis
	Blood Glucose Increased
	Blood Immunoglobulin A Increased
	Blood Immunoglobulin M Increased
	Blood Pressure Increased
	Cardiomegaly
	Cardiomyopathy
	Cerebrovascular Accident
	Chest Pain
	Connective Tissue Disorder
	Coronary Artery Disease
	Coronary Artery Stenosis
	Dementia Alzheimer'S Type
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Foot Infection
	Dilatation Atrial
	Diplopia
	Dizziness
	Drug Ineffective
	Emotional Distress
	Encephalitis
	Eyelid Ptosis
	Fall
	Haematuria
	Headache
	Ingrowing Nail
	Injury
	Insomnia
	Limb Injury
	Loss Of Consciousness
	Mitral Valve Incompetence
	Muscle Spasms
	Myalgia
	Nerve Injury

Osteoarthritis
Pseudodementia
Psychomotor Hyperactivity
Psychomotor Retardation
Rash
Sinobronchitis
Somnolence
Syncope
Systemic Lupus
Erythematosus
Tachyarrhythmia
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection

	Vasculitis						
	Vertigo						
	Vestibular Neuronitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL		
			Glucophage	C			UNKNOWN	
			Zocor	C		ORAL		
			Arthrotec	C			UNKNOWN	

Date:01/28/05ISR Number: 4564821-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00145
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Electrocardiogram T Wave Inversion							
	Exercise Test Abnormal							
	Medication Error							
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564822-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03580
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		65 DAY
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		103 DAY
Disability	Insulin Resistance		Vioxx	SS	Merck & Co., Inc	ORAL		103 DAY
	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL		103 DAY
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		103 DAY

	Vasoconstriction		Vioxx	SS	Merck & Co., Inc	ORAL
65 DAY						
			Actos	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Wellbutrin Sr	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Triamcinolone	C		
UNKNOWN						
			Tegretol	C		
UNKNOWN						
			Topamax	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Hydrocodone Hydrochloride	C		
UNKNOWN						
			Lortab	C		
UNKNOWN						

Date:01/28/05ISR Number: 4564823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04133
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Fear		Vioxx	SS	Merck & Co., Inc	ORAL
	Medication Error		Celebrex	C		
UNKNOWN						
	Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564824-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03698
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1289 DAY
Hospitalization -	Cardiac Failure		Lanoxin	C		ORAL		
Initial or Prolonged	Congestive		Lanoxin	C		ORAL		
Disability	Embolic Stroke		Prinivil	C		ORAL		
	Gastric Disorder		Tricor	C		ORAL		
	Heart Injury		K-Dur	C		ORAL		
	Hemiparesis		Neurontin	C		ORAL		
	Spinal Vascular Disorder		Coumadin	C				UNKNOWN
			Betapace	C				UNKNOWN

Date:01/28/05ISR Number: 4564825-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02875
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia							
	Chest Pain							
	Hypertension							
	Pitting Oedema							
	Pyrexia							
	Spondylitis							

Date:01/28/05ISR Number: 4564826-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03789
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective							
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564827-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00220
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	459 DAY	
	Cerebrovascular Accident		Synthroid	C			UNKNOWN	
	Renal Disorder							
	Stomach Discomfort							

Date:01/28/05ISR Number: 4564828-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00855
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Disease							
Initial or Prolonged	Renal Disorder							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564829-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01491
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypoaesthesia		[Therapy					
Disability	Loss Of Consciousness		Unspecified]	C				
UNKNOWN								
	Osteoarthritis		Estrogens					
			(Unspecified)	C				
UNKNOWN								
			Diuretic					
			(Unspecified)	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564830-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deafness Unilateral		[Therapy					
	Vestibular Disorder		Unspecified]	C				
UNKNOWN								
	Vestibular Neuronitis							

Date:01/28/05ISR Number: 4564831-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00014
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Emphysema		Celecoxib	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		[Therapy					
Other			Unspecified]	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564832-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00413
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								
Disability								
Other								

Date:01/28/05ISR Number: 4564833-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03743
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Drug Effect Decreased							
	Transient Ischaemic Attack							

Date:01/28/05ISR Number: 4564834-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00236
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Benazepril					

			Hydrochloride And Hydrochlorothiazide	C		ORAL

Date:01/28/05ISR Number: 4564835-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00023
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY

Date:01/28/05ISR Number: 4564836-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00138
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C		ORAL		
Disability								

Date:01/28/05ISR Number: 4564837-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01993
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization -	Cardiac Disorder		[Therapy Unspecified]	C				
Initial or Prolonged	Cardiac Failure							UNKNOWN
Disability	Congestive		[Therapy Unspecified]	C				
Other	Coronary Arterial Stent							UNKNOWN
	Insertion							
	Gastric Disorder							
	Hepatomegaly							
	Limb Injury							
	Renal Failure							

Date:01/28/05ISR Number: 4564838-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00022
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Meprednisone	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Citalopram Hydrobromide	C			UNKNOWN	

Date:01/28/05ISR Number: 4564839-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02847
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Coumadin	C			UNKNOWN	
	Oedema Peripheral		Lipitor	C			UNKNOWN	
			Fosamax	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564840-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00210
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular							
	Neck Pain							
	Thyroid Neoplasm							
	Ulnar Nerve Injury							
	Vertebral Artery Occlusion							

Date:01/28/05ISR Number: 4564841-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00252
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564842-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00027
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	127 DAY	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

Date:01/28/05ISR Number: 4564843-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00515
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Arterial Thrombosis Limb		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/28/05ISR Number: 4564844-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564845-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:01/28/05ISR Number: 4564846-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564847-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564848-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564849-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03264
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564850-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564851-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564852-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564853-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03265
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Dyspnoea Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564854-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03171
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564855-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03257
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1523 DAY	
	Myocardial Infarction							

Date:01/28/05ISR Number: 4564856-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564857-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03260
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564858-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Triple Vessel Bypass Graft							

Date:01/28/05ISR Number: 4564859-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Overdose

Date:01/28/05ISR Number: 4564861-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564862-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564863-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03364
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4564864-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03277
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564865-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564866-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03533
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Prozac	C			UNKNOWN	
	Anxiety		Clonidine	C			UNKNOWN	
	Bradycardia		Lotrel	C			UNKNOWN	
	Chest Pain		Aspirin	C			UNKNOWN	
	Chronic Obstructive		Proventil	C			UNKNOWN	
	Pulmonary Disease		Coreg	C			UNKNOWN	
	Colonic Polyp		Indomethacin	C			UNKNOWN	
	Diabetes Mellitus		Lasix (Furosemide					
	Diverticulum		Sodium)	C			UNKNOWN	
	Fall							
	Headache							
	Hypertension							
	Hypertensive Heart Disease							

Malignant Hypertension
Ovarian Mass
Pain In Extremity
Sleep Apnoea Syndrome
Umbilical Hernia

Date:01/28/05ISR Number: 4564867-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564868-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03331
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564869-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03424
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

				[Therapy Unspecified]	C		
UNKNOWN							

Date:01/28/05ISR Number: 4564870-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03408
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564872-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00375
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Restenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery		Levothyroxine Sodium	C				
UNKNOWN								
	Restenosis		Acetaminophen	C				
UNKNOWN								
	Myocardial Infarction		Aspirin	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								
			Simvastatin	C		ORAL		
			Ramipril	C				
UNKNOWN								
			Metformin	C				
UNKNOWN								

Date:01/28/05ISR Number: 4564874-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Heart Rate Decreased							

Date:01/28/05ISR Number: 4564877-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04223
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564879-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03409
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4564880-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00139
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident At Work
Disability	Acute Sinusitis
Other	Arthralgia
	Asthenia
	Benign Neoplasm
	Blood Cholesterol Increased
	Blood Triglycerides

		Increased					
		Bronchitis Acute					
		Carotid Artery Stenosis					
		Carpal Tunnel Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebral Infarction		Vioxx	SS		ORAL
1	DAY						
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Conjunctivitis					
		Cubital Tunnel Syndrome					
		Dizziness					
		Emotional Distress					
		Epidermal Naevus					
		Fatigue					
		Hemianopia Homonymous					
		High Density Lipoprotein					
		Decreased					
		Hypertension					
		Hypoacusis					
		Hypoaesthesia					
		Hypotension					
		Low Density Lipoprotein					
		Increased					
		Malaise					
		Muscle Disorder					
		Pain In Extremity					
		Paraesthesia					
		Pharyngitis					
		Radial Tunnel Syndrome					
		Temperature Intolerance					
		Thermal Burn					
		Transient Ischaemic					
		Attack					
		Ulnar Tunnel Syndrome					
		Vascular Stenosis					

Date:01/28/05ISR Number: 4564881-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04224
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis					

Date:01/28/05ISR Number: 4564882-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/28/05ISR Number: 4566341-2Report Type:Expedited (15-DaCompany Report #WAES 0410SWE00020
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Coronary Artery Atherosclerosis	Foreign Study Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	209 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/05ISR Number: 4575410-2Report Type:Direct Company Report #CTU 238636
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Fatigue Paraesthesia Speech Disorder Transient Ischaemic Attack		Vioxx 25mg Merck	PS	Merck		1 A DAY	

Date:01/28/05ISR Number: 4575439-4Report Type:Direct Company Report #CTU 238644
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Myocardial Infarction		Vioxx	PS	Merck		ONCE DAILY	

Date:01/28/05ISR Number: 4575611-3Report Type:Direct Company Report #CTU 238634
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx 50 Mg (Merc)	PS			1 TABLET A DAY	

Date:01/31/05ISR Number: 4565292-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00721
Age:35 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Adverse Event	Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Affective Disorder	Remeron	C		
Other	Aggression	Elavil	C		
UNKNOWN					
	Angina Pectoris	Vicodin Tablets	C		
UNKNOWN					
	Anxiety	Soma	C		
UNKNOWN					
	Bipolar Disorder				
	Blood Pressure Increased				
	Bronchitis				
	Convulsion				
	Delusion				
	Delusional Disorder, Persecutory Type				
	Depression				
	Fluid Retention				
	Hypertension				
	Intervertebral Disc Protrusion				
	Osteoarthritis				
	Pain				
	Road Traffic Accident				
	Sciatica				
	Spinal Osteoarthritis				
	Stress				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565306-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0207DEU00144
Age:7 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Colitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Off Label Use		Potassium Chloride	C			UNKNOWN	
			Sulfasalazine	C			UNKNOWN	
			Amlodipine Besylate	C		ORAL		

Date:01/31/05ISR Number: 4565316-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	195 DAY	
Initial or Prolonged	Anxiety							
Disability	Arthralgia							
	Balanitis							
	Coronary Artery Disease							
	Depression							
	Dislocation Of Vertebra							
	Dysarthria							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Joint Dislocation							
	Malaise							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Radiculopathy							
	Road Traffic Accident							
	Visual Disturbance							

Date:01/31/05ISR Number: 4565318-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00062833
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
Hospitalization - Initial or Prolonged	Cardiac Failure		Lipitor	C		ORAL	UNKNOWN	
	Congestive		Flomax (Niflumic Acid (Beta)-Morpholinoethyl Ester)	C		ORAL	UNKNOWN	
	Chest Wall Pain		Aspirin	C		ORAL	UNKNOWN	
	Costochondritis		Prilosec	C			UNKNOWN	
	Cough		Vitamin E	C			UNKNOWN	
	Fatigue							
	Hypertension							
	Lymphadenopathy							
	Myocardial Ischaemia							
	Nail Avulsion							
	Pharyngolaryngeal Pain							
	Renal Failure							
	Seborrhoeic Keratosis							
	Skin Laceration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565319-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anorexia		Premarin	C				
UNKNOWN								
Other	Atrial Fibrillation		Singulair	C				
UNKNOWN								
	Blood Albumin Decreased		Azmacort	C				
RESPIRATORY								
	Blood Cholesterol							
(INHALATION)								
	Increased							
	Bronchial Infection							
	Bronchiectasis							
	Bronchitis							
	Bronchitis Chronic							
	Candidiasis							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Cerebral Haematoma							
	Cerebrovascular Accident							
	Chills							
	Chronic Obstructive							
	Pulmonary Disease							
	Chronic Respiratory							
	Failure							
	Clostridium Colitis							
	Conjunctivitis							
	Corneal Disorder							
	Diarrhoea							
	Drug Hypersensitivity							
	Dry Mouth							
	Dyspepsia							
	Emphysema							
	Fatigue							
	Head Discomfort							
	Hiatus Hernia							
	Hyperkalaemia							
	Hypokalaemia							
	Hypoxia							
	Lobar Pneumonia							
	Mitral Valve Incompetence							
	Muscle Spasms							

Nausea
Oedema Peripheral
Oxygen Saturation
Decreased
Pain
Palpitations
Pneumonia
Pneumonia Pneumococcal
Pseudomonas Infection
Pulmonary Hypertension
Skin Laceration
Sputum Culture Positive
Tremor
Weight Decreased

Date:01/31/05ISR Number: 4565347-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Acute Myocardial Infarction
	Adverse Event
	Anaemia
	Angina Pectoris
	Angioneurotic Oedema
	Arthralgia
	Back Pain
	Barrett'S Oesophagus
	Blood Cholesterol Increased
	Bone Density Decreased
	Breast Cyst
	Burning Sensation
	Cataract Operation
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Discomfort
	Chest Pain
	Colonic Polyp
	Constipation
	Contusion
	Convulsion
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Diverticulum Intestinal
	Dyspepsia
	Dyspnoea
	Electrocardiogram St Segment Depression
	Erosive Oesophagitis
	Eructation
	Fall
	Fatigue
	Flatulence
	Gastrointestinal Disorder
	Gastrointestinal Haemorrhage

Gastrooesophageal Reflux
Disease
Granuloma
Haematemesis
Haemorrhoids
Hiatus Hernia
Hyperhidrosis
Hyperlipidaemia
Hypertension
Hypoaesthesia
Hypothyroidism
Low Density Lipoprotein
Increased
Lung Disorder
Lymphangitis

	Malaise						
	Medication Error						
	Meniscus Lesion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	319 DAY
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oesophageal Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL	319 DAY
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Peptic Ulcer		Aspirin	C			UNKNOWN
	Pruritus		Monopril	C			UNKNOWN
	Rash Erythematous		Hydrochlorothiazide	C			UNKNOWN
	Rectal Haemorrhage						
	Renal Failure						
	Urinary Tract Infection						

Date:01/31/05ISR Number: 4565349-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00813
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	232 DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL	232 DAY
Disability	Amnesia		Atenolol And				
	Anaemia		Chlorthalidone	C		ORAL	
	Arthralgia		Ferrous Sulfate	C		ORAL	
	Asthenia						
	Chest Pain						
	Chest Wall Pain						
	Constipation						
	Costochondritis						
	Dizziness						
	Ear Pain						
	Gastritis						
	Gastroenteritis Viral						
	Haematemesis						
	Haemoptysis						
	Headache						
	High Density Lipoprotein						

Decreased
Hypokalaemia
Hypomagnesaemia
Inflammation
Injury
Muscle Spasms
Musculoskeletal Chest
Pain
Nasal Congestion
Neck Pain
Pain
Pain In Extremity
Pain In Jaw
Pharyngitis
Pharyngolaryngeal Pain
Rash Pruritic
Rhinitis Allergic
Sinobronchitis
Sinusitis
Spinal Osteoarthritis
Spondylitis
Upper Respiratory Tract
Infection
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565353-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00808
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Abdominal Pain		Alprazolam	C			UNKNOWN	
	Abdominal Pain Upper		Prilosec	C			UNKNOWN	
	Arthralgia		Estratest	C			UNKNOWN	
	Blood Cholesterol Increased		Paxil	C			UNKNOWN	
	Bronchitis							
	Chest Discomfort							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Conjunctivitis							
	Constipation							
	Depression							
	Diarrhoea							
	Diverticulitis							
	Dizziness							
	Ejection Fraction Decreased							
	Haematoma							
	Hypertension							
	Insomnia							
	Lipoma							
	Lobar Pneumonia							
	Malaise							
	Musculoskeletal Pain							
	Myalgia							
	Nausea							
	Nephrolithiasis							
	Nodule							
	Osteopenia							
	Pain							
	Productive Cough							
	Rash							
	Sinusitis							
	Skin Lesion							
	Syncope							
	Upper Respiratory Tract							

Infection
Urinary Tract Infection
Vomiting
Weight Increased

Date:01/31/05ISR Number: 4565378-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00836
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
Other	Anastomotic Stenosis
	Anastomotic Ulcer
	Biliary Dilatation
	Blood Pressure Increased
	Bursitis
	Candidiasis
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome

		Colonic Polyp					
		Coronary Artery Disease					
		Dysphagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
493	DAY						
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
493	DAY						
		Impaired Gastric Emptying		Carafate	C		ORAL
		Injury		Atenolol	C		ORAL
		Myocardial Ischaemia		Reglan	C		ORAL
		Oedema		Theo-Dur	C		ORAL
		Orthostatic Hypotension		Aldactone	C		ORAL
		Osteoarthritis		Phenergan			
		Pain		Tablets/Suppositorie			
		Peptic Ulcer Haemorrhage		s	C		ORAL
		Prothrombin Level		Flovent	C		
RESPIRATORY							
		Increased					
(INHALATION)							
		Syncope		Combivent	C		
RESPIRATORY							
		Tenosynovitis					
(INHALATION)							
		Upper Respiratory Tract		Elavil	C		ORAL
		Infection		Nitrostat	C		
SUBLINGUAL							
		Vestibular Neuronitis		Buspar	C		ORAL
				Methadone			
				Hydrochloride	C		ORAL
				Serevent Diskhaler	C		
RESPIRATORY							
(INHALATION)							
				Flonase	C		
RESPIRATORY							
(INHALATION)							
				Zantac	C		
UNKNOWN							
				Iron (Unspecified)	C		ORAL
				Fosfree	C		
UNKNOWN							
				Ultram	C		ORAL

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Anxiety
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Discomfort
	Chest Pain
	Cholelithiasis
	Coronary Artery Atherosclerosis
	Depression
	Dizziness
	Dyspnoea
	Dyspnoea Paroxysmal Nocturnal
	Fibromyalgia
	Gastrooesophageal Reflux Disease
	Hyperhidrosis
	Hypertension
	Mitral Valve Prolapse
	Myocardial Infarction
	Nausea
	Neuropathy
	Orthopnoea

		Osteoporosis					
		Pain					
		Palpitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
284	DAY						
		Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Platybasia		Vioxx	SS	Merck & Co., Inc	ORAL
284	DAY						
		Uterine Leiomyoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Vaginal Haemorrhage		Prevacid	C		
UNKNOWN							
		Vertigo Positional		Methylprednisolone	C		
UNKNOWN							
		Vision Blurred		Estradiol	C		ORAL
				Clonazepam	C		
UNKNOWN							
				Vantin	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Sulfamethoxazole And Trimethoprim	C		
UNKNOWN							
				Serzone	C		ORAL
336	DAY						
				Serzone	C		ORAL
				Albuterol	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Cephalexin	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Cyanocobalamin	C		
PARENTERAL							

	Cyanocobalamin	C	
PARENTERAL			
	Remeron	C	
UNKNOWN			
	Aciphex	C	
UNKNOWN			
	Tequin	C	
UNKNOWN			
	Diovan	C	ORAL
	Verapamil Msd Lp	C	ORAL
	A.S.A.	C	ORAL
	A.S.A.	C	ORAL
	Prometrium	C	ORAL
	Mobic	C	ORAL
	Promethazine	C	ORAL

Date:01/31/05ISR Number: 4565391-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00848
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Amenorrhoea
	Anxiety Disorder
	Blood Pressure Increased
	Breast Lump Removal
	Breast Pain
	Carotid Artery Disease
	Cervical Spasm
	Chest Pain
	Depression
	Diarrhoea
	Dyslipidaemia
	Food Poisoning
	Gastritis
	Gastrooesophageal Reflux Disease

	Headache						
	Hypertension						
	Hypertensive Crisis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Injury		Vioxx	PS	Merck & Co., Inc	ORAL	
	Oedema		Vioxx	SS	Merck & Co., Inc	ORAL	
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL	980 DAY
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL	
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rash Erythematous		Hydrochlorothiazide	C			UNKNOWN
	Sedation		Norvasc	C			UNKNOWN
	Somnolence		Ec Naprosyn	C			UNKNOWN
	Transient Ischaemic		Ec Naprosyn	C			UNKNOWN
	Attack						
	Upper Respiratory Tract						
	Infection						

Date:01/31/05ISR Number: 4565394-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00892
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthritis						
Disability	Asthenia						
Other	Breathing-Related Sleep						
	Disorder						
	Burning Sensation						
	Cataract						
	Chest Pain						
	Constipation						
	Coronary Artery Disease						
	Cough						
	Eye Disorder						
	Femoral Arterial Stenosis						
	Hypercholesterolaemia						
	Hyperlipidaemia						
	Hypoaesthesia						
	Lung Neoplasm Malignant						
	Mass						

Myocardial Infarction
Neoplasm
Oedema Peripheral
Pain In Extremity
Palpitations
Paraesthesia
Peripheral Vascular
Disorder
Polytraumatism
Post Procedural Haematoma
Post Procedural Pain
Pyrexia
Stress Fracture
Umbilical Hernia
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565395-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01821
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Bowel Movement		Coumadin	C			UNKNOWN	
Disability	Irregularity		Cozaar	C			UNKNOWN	
	Myocardial Infarction		[Therapy					
	Stomach Discomfort		Unspecified]	C			UNKNOWN	

Date:01/31/05ISR Number: 4565397-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Wall Mass
Initial or Prolonged	Anorexia
Disability	Anxiety
Other	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp
	Back Pain
	Blister
	Bronchitis
	Bursitis
	Cardiac Disorder
	Caustic Injury
	Chest Pain
	Constipation
	Depression
	Diastolic Dysfunction
	Diverticulum Intestinal
	Dizziness
	Drug Eruption
	Dysphonia
	Dysuria
	Ecchymosis
	Epistaxis

Fall
Frequent Bowel Movements
Gastritis
Glucose Tolerance
Impaired
Gout
Haemorrhoids
Headache
Helicobacter Infection
Hypertension
Hypoaesthesia
Insomnia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Crepitation
Kidney Infection
Labyrinthitis
Muscle Strain
Nasopharyngeal Disorder
Nasopharyngitis

	Nausea						
	Oedema Peripheral						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Otitis Media		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
	Pharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Polyarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
	Rash		Prinivil	C				UNKNOWN
	Sinusitis		K-Dur	C				UNKNOWN
	Sleep Disorder		Lortab	C				UNKNOWN
	Stomach Discomfort		Coumadin	C				UNKNOWN
	Syncope		[Therapy					
	Tricuspid Valve		Unspecified]	C				UNKNOWN
	Incompetence		Lasix (Furosemide					
	Vertigo		Sodium)	C				UNKNOWN
	Vision Blurred							
	Vomiting							

Date:01/31/05ISR Number: 4565407-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00462
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:01/31/05ISR Number: 4565408-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00672
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Dizziness		Accupril	C		
Other	Dysstasia					
	Feeling Hot					
	Hyperhidrosis					
	Myocardial Infarction					
	Pallor					
	Tremor					

Date:01/31/05ISR Number: 4565409-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03558
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Chest Pain		Synthroid	C		
UNKNOWN						
	Dyspnoea		Zoloft	C		
UNKNOWN						
	Haemorrhoids		Xanax	C		
UNKNOWN						
	Headache		Aciphex	C		
UNKNOWN						
	Heart Rate Increased		Risperdal	C		ORAL
	Hypertension		Risperdal	C		ORAL
	Insomnia		Zanaflex	C		
UNKNOWN						
	Nausea					
	Overdose					
	Psychogenic Pain Disorder					
	Stress					
	Vomiting					

Date:01/31/05ISR Number: 4565414-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00391
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		319 DAY
Hospitalization -	Complete		Vioxx	SS	Merck & Co., Inc	ORAL		82 DAY
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		156 DAY
Disability	Cerebrovascular Accident		Xipamide	C		ORAL		
	Hypertension		[Therapy Unspecified]	C		ORAL		

Date:01/31/05ISR Number: 4565415-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02358
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		601 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		601 DAY
	Increased		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vicodin Tablets	C				UNKNOWN
	Coronary Artery Disease		Ibuprofen	C				UNKNOWN
	Depression		Zoloft	C				UNKNOWN
	Diabetes Mellitus		Hydrocodone					
	Dizziness		Hydrochloride	C				UNKNOWN
	Drug Ineffective		Quinine	C				UNKNOWN
	Erectile Dysfunction		Skelaxin	C				UNKNOWN
	Heart Disease Congenital		Elavil	C				UNKNOWN

Hyperlipidaemia
Hypertension
Increased Tendency To
Bruise
Myocardial Infarction
Myocardial Ischaemia
Restless Legs Syndrome
Sexual Dysfunction
Sleep Disorder
Sweat Gland Infection
Ventricular Hypertrophy
Weight Increased

Date:01/31/05ISR Number: 4565417-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00684
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Chronic Obstructive		Norco	C				
UNKNOWN								
	Pulmonary Disease		Zestril	C				
UNKNOWN								
	Hypertensive Heart		Indapamide	C				
UNKNOWN								
	Disease							

Date:01/31/05ISR Number: 4565419-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01877
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Death	Arthralgia
Disability	Blood Pressure
Other	Inadequately Controlled

		Burning Sensation					
		Cardiomegaly					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cyanosis		Oxycodone	C		ORAL
6	DAY						
		Death		Docusate Sodium	C		ORAL
		Depressed Mood		Ascorbic Acid	C		ORAL
		Depression		Ferrous Sulfate	C		ORAL
		Device Failure		Coumadin	C		
UNKNOWN							
		Fatigue					
		Femur Fracture					
		Gout					
		Hip Fracture					
		Injury					
		Insomnia					
		Intervertebral Disc					
		Protrusion					
		Joint Swelling					
		Limb Discomfort					
		Myocardial Fibrosis					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nephrolithiasis					
		Oedema Peripheral					
		Pain In Extremity					
		Pulmonary Congestion					
		Sleep Disorder					
		Spinal Osteoarthritis					
		Thermal Burn					
		Ventricular Hypertrophy					

Date:01/31/05ISR Number: 4565422-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00839
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
Disability	Adverse Event
	Angiomyolipoma

Appendicitis
Arrhythmia
Arthralgia
Back Pain
Breast Discharge
Breast Pain
Cervical Spasm
Chest Pain
Dehydration
Dependence
Diarrhoea
Diverticulitis
Drug Dependence
Duodenitis
Dysfunctional Uterine
Bleeding
Electrolyte Imbalance
Enteritis Infectious

		Gastritis Gastrointestinal Arteriovenous	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Malformation		Vioxx	PS	Merck & Co., Inc	ORAL
110	DAY						
		Gastrointestinal Haemorrhage Haemorrhoids Headache Hyperglycaemia Hyperhidrosis Hypersensitivity Hypertension Ileus Infection Injury Insomnia Iron Deficiency Anaemia Joint Stiffness Loss Of Consciousness Menometrorrhagia Migraine Muscle Spasms Muscle Twitching Musculoskeletal Discomfort Nausea Neck Pain Non-Cardiac Chest Pain Pain Pain In Extremity Panic Attack Pelvic Inflammatory Disease Pelvic Pain Peripheral Coldness Platelet Count Increased Pneumonia Postoperative Ileus Raynaud'S Phenomenon Rectal Haemorrhage Restless Legs Syndrome Syncope Tinnitus Urinary Tract Infection Vaginal Candidiasis					

Vaginal Infection
Vomiting

Date:01/31/05ISR Number: 4565429-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00001
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Clopidogrel Bisulfate	C			UNKNOWN	
			Ranitidine	C			UNKNOWN	
			Ramipril	C			UNKNOWN	
			Meloxicam	C			UNKNOWN	
			[Therapy					

Unspecified] C
UNKNOWN

Date:01/31/05ISR Number: 4565434-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00400
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Simple Partial Seizures		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Transient Ischaemic		Levothyroxine Sodium	C				
UNKNOWN								
	Attack		Fenofibrate	C				
UNKNOWN								
			Metformin	C		ORAL		

Date:01/31/05ISR Number: 4565435-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4565436-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02782
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Dependence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Facial Palsy							
	Hypertension							
	Hypoaesthesia							
	Muscle Disorder							

Date:01/31/05ISR Number: 4565439-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/31/05ISR Number: 4565441-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/31/05ISR Number: 4565442-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03382
Age:78 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure Bradycardia Cerebrovascular Accident Contusion Diarrhoea Fall Hypertension Hypothyroidism Major Depression Peptic Ulcer

	Refractory Anaemia Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Plavix	C			UNKNOWN	
			Tenormin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Zantac	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Tegretol	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

Date:01/31/05ISR Number: 4565444-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04219
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4565451-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03356
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Death Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4565452-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03357
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/31/05ISR Number: 4565454-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease Blood Pressure Increased Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:01/31/05ISR Number: 4565455-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00040
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Disorder Cerebrovascular Accident Gastric Disorder Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4565462-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
	Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Guaifenesin	C			UNKNOWN	
	Gastrooesophageal Reflux		Ceftin	C			UNKNOWN	
	Disease		Aspirin	C		ORAL		
	Meningioma		Probeta (Dipivefrin Hydrochloride (+) Levobunolol Hydrochloride)	C			OPHTHALMIC	
	Myocardial Infarction							
	Paraesthesia							
	Retinal Artery Occlusion							
	Tooth Disorder		Diamox	C		ORAL		
			Glucosamine	C		ORAL		
			Advil	C		ORAL		

Date:01/31/05ISR Number: 4565972-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4565974-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Arthralgia
Other	Arthropathy
	Breast Cyst
	Bursitis
	Chest Discomfort
	Closed Head Injury
	Complex Regional Pain

Syndrome
Concussion
Contusion
Depression
Dizziness
Emotional Distress
Epicondylitis
Extrasystoles
Fall
Fatigue
Gingival Disorder
Haematochezia
Haemorrhage
Headache
Heart Rate Irregular
Hypercholesterolaemia
Hypertension
Injury
Lumbar Spinal Stenosis
Nausea
Nerve Injury
Palpitations
Post-Traumatic Stress

	Disorder						
	Sleep Disorder						
	Syncope						
	Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Uterine Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	33 DAY
	Uterine Leiomyoma		Vioxx	SS	Merck & Co., Inc	ORAL	33 DAY
	Vaginal Haemorrhage		Vioxx	SS		ORAL	33 DAY
	Vasodilatation		Vioxx	SS		ORAL	33 DAY
	Vomiting		Vitamins (Unspecified)	C			UNKNOWN
			Bayer Aspirin	C		ORAL	
			Bayer Aspirin	C		ORAL	

Date:01/31/05ISR Number: 4565979-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00144
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Myocardial Infarction		Omeprazole	C			
UNKNOWN							
Disability							

Date:01/31/05ISR Number: 4565985-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00845
Age:26 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	437 DAY
Initial or Prolonged	Autoimmune Thyroiditis		Vioxx	SS	Merck & Co., Inc	ORAL	437 DAY
Disability	Contusion		Atenolol	SS			UNKNOWN
	Convulsion						
	Dyspepsia						
	Emotional Distress						
	Exostosis						

Hypertension
Joint Swelling
Migraine
Morton'S Neuroma
Nausea
Neuroma
Oedema Peripheral
Osteoarthritis
Sinus Congestion
Syncope
Tremor
Vomiting

Date:01/31/05ISR Number: 4565987-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00634
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Adverse Event
Disability	Decreased Appetite
Other	Depressive Symptom
	Dizziness
	Drug Ineffective
	Gastrooesophageal Reflux
	Disease
	Headache
	Hypertension

		Injury Iron Deficiency Anaemia Menopausal Symptoms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Menorrhagia Migraine		Vioxx Premarin	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Musculoskeletal Stiffness Nausea Polycystic Ovaries Uterine Leiomyoma Vomiting					

Date:01/31/05ISR Number: 4565988-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00648
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain
Other	Adhesion
	Adverse Event
	Aerophagia
	Anaphylactic Reaction
	Blood Cholesterol Increased
	Breast Pain
	Chest Discomfort
	Coronary Artery Atherosclerosis
	Decreased Appetite
	Depressed Level Of Consciousness
	Depression
	Drug Hypersensitivity
	Drug Ineffective
	Drug Intolerance
	Dysphagia
	Dysuria
	Fatigue
	Gastrointestinal Motility Disorder
	Generalised Oedema
	Glossodynia
	Headache
	Heart Rate Irregular
	Helicobacter Infection

Hot Flush
Hypersensitivity
Hypertension
Insomnia
Joint Injury
Limb Injury
Lipomatosis
Lymphadenopathy
Malaise
Menopausal Symptoms
Microcytic Anaemia
Migraine
Musculoskeletal Stiffness
Nasal Congestion
Nausea
Neuropathy Peripheral
Odynophagia

		Oedema Peripheral					
		Oesophageal Candidiasis					
		Oesophagitis Ulcerative	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oral Candidiasis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pancreatic Insufficiency		Vioxx	SS	Merck & Co., Inc	ORAL
		Photosensitivity Reaction		Vioxx	SS	Merck & Co., Inc	ORAL
		Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sjogren'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Promethazine	C		
UNKNOWN							
		Subcutaneous Nodule		Furosemide	C		
UNKNOWN							
		Syncope		Ambien	C		
UNKNOWN							
		Temporomandibular Joint		Alprazolam	C		
UNKNOWN							
		Syndrome		Aciphex	C		
UNKNOWN							
		Thirst		Prilosec	C		
UNKNOWN							
		Upper Respiratory Tract		Bel-Phen-Ergot S			
		Infection		Tabs	C		
UNKNOWN							
		Urethral Disorder		Butalbital	C		
UNKNOWN							
		Urinary Tract Infection		Acetaminophen And			
		Vaginal Discharge		Caffeine	C		
UNKNOWN							
		Vomiting		Buspar	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Estratest	C		
UNKNOWN							
				Indapamide	C		
UNKNOWN							

			Dulcolax	C		
UNKNOWN						
			Diflucan	C		
UNKNOWN						

Date:01/31/05ISR Number: 4566004-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00810
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Constipation		Zestril	C		ORAL
	Haematuria		Vicodin Tablets	C		
UNKNOWN						
	Humerus Fracture		Tiazac	C		
UNKNOWN						
	Normochromic Normocytic					
	Anaemia					
	Oedema Peripheral					
	Spinal Cord Injury Cauda					
	Equina					
	Urinary Tract Infection					

Date:01/31/05ISR Number: 4566005-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00832
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Adverse Event
Disability	Arthralgia
	Back Pain
	Buttock Pain
	Diarrhoea
	Difficulty In Walking

		Fall					
		Gastritis					
		Haematochezia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vicodin Tablets	C		ORAL
		Intervertebral Disc		Flexeril	C		ORAL
		Protrusion		Flexeril	C		ORAL
		Limb Discomfort					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Post Laminectomy Syndrome					
		Radiculitis Lumbosacral					
		Sacroiliitis					
		Vomiting					

Date:01/31/05ISR Number: 4566012-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 3 DAY		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		[Therapy			
		Atherosclerosis		Unspecified]	C		
UNKNOWN							
		Attention		Paxil	C		
UNKNOWN							
		Deficit/Hyperactivity		Ibuprofen	C		
UNKNOWN							
		Disorder		Zoloft	C		
UNKNOWN							
		Chest Pain					
		Chronic Fatigue Syndrome					
		Depression					
		Gastrooesophageal Reflux					
		Disease					
		Generalised Anxiety					
		Disorder					
		Haemorrhoidal Haemorrhage					
		Hypercholesterolaemia					
		Hypertension					
		Insomnia					

Lower Gastrointestinal
Haemorrhage
Microcytic Anaemia
Panic Disorder
Phlebitis Superficial

Date:01/31/05ISR Number: 4566013-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00815
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Distension
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abscess Limb
Other	Adhesion
	Adrenal Insufficiency
	Adverse Event
	Ankle Fracture
	Axillary Mass
	Back Injury
	Blood Cholesterol Increased

		Breast Cancer					
		Bunion					
		Cellulitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Csf Shunt Removal		Valium	C		
UNKNOWN							
		Cyst Aspiration		Sk-Erythromycin	C		
UNKNOWN							
		Depression		Cyanocobalamin	C		
PARENTERAL							
		Diarrhoea		Nitrostat	C		
UNKNOWN							
		Discomfort		Synthroid	C		
UNKNOWN							
		Dizziness		Paxil	C		
UNKNOWN							
		Dysarthria		Lanoxin	C		
UNKNOWN							
		Dyspepsia		Salagen Tablets	C		
UNKNOWN							
		Dyspnoea		Claritin	C		
UNKNOWN							
		Eye Injury		Zofran	C		
UNKNOWN							
		Fall		Miacalcin	C		
UNKNOWN							
		Fatigue		Neurontin	C		
UNKNOWN							
		Gait Disturbance		Vitamin E	C		
UNKNOWN							
		Gastritis		Premarin	C		
UNKNOWN							
		Gastroenteritis		Aciphex	C		
UNKNOWN							
		Haemorrhoids		Detrol La	C		
UNKNOWN							
		Helicobacter Gastritis		Lasix (Furosemide)	C		
UNKNOWN							
		Hyperlipidaemia		K-Dur	C		
UNKNOWN							
		Increased Tendency To		Lorazepam	C		
UNKNOWN							

	Bruise	Primidone	C
UNKNOWN			
	Intestinal Hypomotility	[Therapy	
	Iron Deficiency Anaemia	Unspecified]	C
UNKNOWN			
	Joint Injury		
	Limb Injury		
	Lumbar Spinal Stenosis		
	Morton'S Neuroma		
	Myocardial Infarction		
	Nausea		
	Neuropathy Peripheral		
	Normal Pressure		
	Hydrocephalus		
	Oedema Peripheral		
	Pain In Extremity		
	Radicular Pain		
	Road Traffic Accident		
	Shunt Infection		
	Spondylolisthesis		
	Transaminases Increased		
	Weight Decreased		
	Wheezing		
	Wound Dehiscence		

Date:01/31/05ISR Number: 4566014-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acarodermatitis
Initial or Prolonged	Anaemia
Other	Atrial Fibrillation
	Blood Testosterone
	Decreased
	Cardiac Failure
	Cholecystitis

		Cholelithiasis					
		Clostridium Colitis					
		Coma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Erectile Dysfunction					
		Eye Infection					
		Fatigue					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hepatic Cirrhosis					
		Hepatic Failure					
		Hiatus Hernia					
		Hypertension					
		Impaired Gastric Emptying					
		Insomnia					
		Intervertebral Disc					
		Disorder					
		Lethargy					
		Myocardial Infarction					
		Nasal Septum Deviation					
		Pneumonia					
		Rash					
		Renal Disorder					
		Renal Failure Acute					
		Respiratory Failure					
		Testicular Mass					
		Weight Decreased					
		Weight Increased					

Date:01/31/05ISR Number: 4566015-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00867
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anaemia Postoperative
	Aortic Valve Sclerosis
	Bradycardia
	Cardiac Failure
	Congestive
	Cardiac Murmur
	Cardiomegaly
	Chronic Obstructive

Pulmonary Disease
Coronary Artery Disease
Diabetic Retinopathy
Diastolic Dysfunction
Dyspnoea Exertional
Facial Palsy
Goitre
Hyperlipidaemia
Hypertension
Hypoxia
Interstitial Lung Disease
Ischaemic Cardiomyopathy
Macular Degeneration
Neuropathy Peripheral
Onychomycosis
Osteoarthritis

		Primary Hypothyroidism					
		Pulmonary Hypertension					
		Restrictive Pulmonary	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Right Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Skin Cancer		Zyrtec	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Prinivil	C		
UNKNOWN							
		Thyroid Neoplasm					
		Ventricular Hypertrophy					

Date:01/31/05ISR Number: 4566017-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00005
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension					
	Non-Cardiac Chest Pain					
	Tachycardia					

Date:01/31/05ISR Number: 4566018-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01900
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypertension		[Therapy			
Disability	Hypoaesthesia		Unspecified]	C		
UNKNOWN						
Other			Plavix	C		
UNKNOWN						

Date:01/31/05ISR Number: 4566019-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00810
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Gastrooesophageal Reflux Disease		Zantac	C		ORAL		
			Protonix	C			UNKNOWN	
	Stent Placement		Prozac	C			UNKNOWN	
			Aciphex	C		ORAL		
			Prevacid	C			OPHTHALMIC	
			Celebrex	C		ORAL		
			Colchicine	C		ORAL		
			Prandin	C			TOPICAL	
			Zetia	C		ORAL		
			Austyn	C			RESPIRATORY	
							(INHALATION)	
			Nasalcrom	C			RESPIRATORY	
							(INHALATION)	
			Claritin	C		ORAL		
			Claritin	C		ORAL		
			Tricor	C		ORAL		
			Zocor	C		ORAL		
			Imdur	C		ORAL		
			Folic Acid	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Toprol Xl Tablets	C		ORAL		
			Trental	C		ORAL		

	Procardia Xl	C	ORAL
	Prilosec	C	ORAL
	Aspirin	C	
UNKNOWN			
	Avelox	C	ORAL
	Erythromycin	C	ORAL
	Erythromycin	C	ORAL
	Dipyridamole	C	
UNKNOWN			
	Plavix	C	ORAL
	Tussionex (Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex)	C	ORAL
	Cefzil	C	ORAL
	Aldactone	C	ORAL
	K-Dur	C	ORAL
	Zaroxolyn	C	ORAL
	Dermadex	C	ORAL
	Wellbutrin Sr	C	ORAL
	Zovirax	C	ORAL
	Proventil	C	
RESPIRATORY (INHALATION)			
	Volmax	C	ORAL
	Lortab	C	ORAL
	Amitriptyline Hydrochloride	C	ORAL
	Humibid Dm	C	ORAL
	Levaquin	C	ORAL
	Levaquin	C	ORAL
	Flonase	C	
RESPIRATORY (INHALATION)			
	Diflucan	C	ORAL
	Skelaxin	C	ORAL
	Guaifenesin	C	ORAL
	Nexium	C	ORAL

Date:01/31/05ISR Number: 4566020-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00925
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Adhesions
Disability	Abdominal Haematoma
Other	Abdominal Pain
	Adverse Event
	Anaemia
	Angina Pectoris
	Anxiety
	Arthralgia
	Asthenia
	Blood Cholesterol Increased
	Carotid Arterial Embolus
	Carotid Artery Disease
	Carotid Artery Stenosis
	Carotid Bruit
	Cervical Spasm
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Convulsion

		Coronary Artery Disease					
		Diverticulum Intestinal					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphagia		Cozaar	C		ORAL
		Dyspnoea		Cardizem	C		
UNKNOWN							
		Ear Pain		Darvocet-N	C		
UNKNOWN							
		Electrocardiogram St		Ecotrin	C		ORAL
		Segment Abnormal		Ecotrin	C		ORAL
		Emphysema		Premarin	C		ORAL
		Essential Hypertension					
		Gastric Ulcer					
		Gastrointestinal					
		Candidiasis					
		Gastrointestinal					
		Haemorrhage					
		Headache					
		Heart Rate Increased					
		Hiatus Hernia					
		Hypertension					
		Hypochromic Anaemia					
		Iron Deficiency Anaemia					
		Lung Crepitation					
		Lymphadenopathy					
		Monarthritis					
		Myocardial Ischaemia					
		Neck Mass					
		Neck Pain					
		Neutrophil Count					
		Increased					
		Oral Candidiasis					
		Osteoporosis					
		Palpitations					
		Pelvic Peritoneal					
		Adhesions					
		Peptic Ulcer					
		Peripheral Vascular					
		Disorder					
		Pharyngitis					
		Pharyngolaryngeal Pain					
		Platelet Count Increased					
		Post Procedural					
		Complication					

Pruritus Generalised
Pulmonary Hypertension
Rash Pruritic
Renal Artery Stenosis
Rhonchi
Sensory Disturbance
Subcutaneous Haematoma
Transient Ischaemic
Attack
Ventricular Hypertrophy
Vertebral Artery Stenosis
Visual Disturbance
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4566023-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00140
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Hospitalization - Initial or Prolonged Disability	Headache Hypertension Lacunar Infarction Prescribed Overdose							

Date:01/31/05ISR Number: 4566025-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01637
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Atherosclerosis Hypertensive Cardiomyopathy Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:01/31/05ISR Number: 4566026-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00404
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL		426 DAY
Hospitalization -	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL		426 DAY
Initial or Prolonged Disability	Infection Myocardial Infarction Status Asthmaticus		Levothyroxine Sodium Theophylline Fenoterol Hydrobromide And Ipratropium Bromide	C C C		ORAL ORAL	RESPIRATORY (INHALATION)	
			Verapamil Amitriptyline	C		ORAL		

Hydrochloride	C	ORAL
Opipramol Hydrochloride	C	ORAL

Date:01/31/05ISR Number: 4566027-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03666
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Arachnoiditis
	Arterial Injury
	Arthropathy
	Back Pain
	Breast Cancer
	Cholelithiasis
	Colonic Stenosis
	Exostosis
	Foot Fracture
	Gastritis
	Hypoaesthesia
	Intermittent Claudication
	Lumbar Radiculopathy
	Lumbar Spinal Stenosis
	Myofascial Pain Syndrome
	Nausea

		Neuropathy Peripheral					
		Oedema Peripheral					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Vascular		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Sciatica					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Upper Gastrointestinal					
		Haemorrhage					
		Uterine Enlargement					
		Uterine Leiomyoma					
		Vomiting					

Date:01/31/05ISR Number: 4566029-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00142
Age:79 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Digoxin	C		ORAL
				Aspirin	C		ORAL

Date:01/31/05ISR Number: 4566030-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00451
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Cardiac Disorder		Plavix	C		ORAL
Initial or Prolonged		Cardiac Murmur		Nitroglycerin	C		
SUBLINGUAL							
Disability		Chest Pain		Nitroglycerin	C		
TOPICAL							
		Contusion		Zestril	C		ORAL
		Coronary Artery		Metoprolol	C		
UNKNOWN							
		Atherosclerosis		Aspirin	C		ORAL
		Dizziness		Pravacol	C		
UNKNOWN							
		Fatigue		[Therapy			

	Hypoaesthesia		Unspecified]	C		
UNKNOWN						
	Orthostatic Hypotension		Klor-Con	C		ORAL
	Sexual Dysfunction		Metoprolol	C		ORAL
			Tricor	C		
UNKNOWN						
			Spironolactone	C		ORAL
			Demadex	C		ORAL
			Zyrtec	C		ORAL

Date:01/31/05ISR Number: 4566031-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00928
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Joint Dislocation		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction					
	Osteoarthritis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4566033-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00026
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		367 DAY
Initial or Prolonged	Cardiac Failure		Atorvastatin Calcium	C		ORAL		
	Myocardial Infarction		Benserazide Hydrochloride And Levodopa	C		ORAL		
	Oedema		Gabapentin	C		ORAL		
			Darbepoetin Alfa	C		SUBCUTANEOUS		

Date:01/31/05ISR Number: 4566034-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02916
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Apnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blepharitis		Cardura	C		UNKNOWN		
	Breathing-Related Sleep		Elavil	C		ORAL		
	Disorder		Prilosec	C		UNKNOWN		
	Cerebral Artery Occlusion		Zantac	C		UNKNOWN		
	Cerebral Haemorrhage							
	Cerebrovascular Accident							
	Clumsiness							
	Diarrhoea							
	Dysarthria							
	Facial Palsy							
	Gastroenteritis							
	Grip Strength Decreased							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Intertrigo Candida							
	Malaise							
	Nausea							

Osteoarthritis
Prostatic Disorder
Pyrexia
Rash Pruritic
Reversible Ischaemic
Neurological Deficit
Snoring
White Blood Cell Count
Increased

Date:01/31/05ISR Number: 4566035-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03420
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4566036-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00032
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Acetylcysteine	C				
UNKNOWN								

Date:01/31/05ISR Number: 4566037-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03053
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	183 DAY	
Hospitalization - Initial or Prolonged	Drug Ineffective		Premarin	C				
UNKNOWN								
	Myocardial Infarction		Atenolol	C				
UNKNOWN								
			Elavil	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								

Date:01/31/05ISR Number: 4566038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00631
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
Other	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiovascular Disorder
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive

Pulmonary Disease
Convulsion
Costochondritis
Cough
Dry Mouth
Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Headache
Hemiparesis
Hypertension
Hypoaesthesia Oral
Hypotension
Increased Upper Airway
Secretion
Insomnia
Monoplegia
Multiple Sclerosis
Musculoskeletal Chest
Pain
Pain
Painful Respiration
Pleurisy
Renal Failure
Transient Ischaemic

		Attack Upper Respiratory Tract Infection Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Advil	C		
UNKNOWN							
				A.S.A.	C		
UNKNOWN							
				A.S.A.	C		ORAL
				A.S.A.	C		
UNKNOWN							
				Ulcerin (Cimetidine)	C		ORAL
				Ulcerin (Cimetidine)	C		ORAL
				Zestril	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Agyrax (Meclizine Hydrochloride)	C		
UNKNOWN							
				Agyrax (Meclizine Hydrochloride)	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Carafate	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							

	Hydrochlorothiazide	C
UNKNOWN		
	Ecotrin	C
UNKNOWN		
	Ecotrin	C
UNKNOWN		
	Nexium	C
UNKNOWN		
	Nexium	C
UNKNOWN		
	Aminophylline	C
UNKNOWN		

Date:01/31/05ISR Number: 4566039-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566040-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566041-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03353
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4566042-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03525
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Injury Organ Failure Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566043-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Darvocet-N	C				
Initial or Prolonged Disability			Motrin	C				

Date:01/31/05ISR Number: 4566044-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566046-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566047-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4566049-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03615
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Valve Replacement		[Therapy					
Initial or Prolonged	Cardiac Disorder		Unspecified]	C				
UNKNOWN								
Disability	Cardiac Failure							
	Congestive							

Date:01/31/05ISR Number: 4566050-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03535
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/31/05ISR Number: 4566053-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00245
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability								

Date:01/31/05ISR Number: 4566056-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04148
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:01/31/05ISR Number: 4569772-XReport Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Injury
	Abdominal Pain
Other	Accident
	Back Disorder
	Back Pain
	Blood Cholesterol Increased
	Chest Pain
	Contusion
	Coordination Abnormal
	Disorientation
	Drug Ineffective
	Drug Intolerance
	Erectile Dysfunction
	Facial Pain
	Feeling Cold
	Gastrooesophageal Reflux Disease
	Gingival Disorder
	Glossodynia
	Hostility
	Hypersomnia

Hyporeflexia
Impaired Healing
Injury
Irritability
Limb Injury
Medication Error
Mobility Decreased
Muscle Spasms
Myalgia
Neck Pain
Oesophageal Spasm
Pain In Extremity
Pain In Jaw
Sedation
Sleep Disorder
Somnolence
Tooth Abscess
Treatment Noncompliance
Tremor

Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (600 MG, 3 IN 1 D), ORAL	
Professional	Lipitor (Atorvastatin)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
	Lithium (Lithium) (Lithium)	SS				
	Naproxen (Naproxen) (Naproxen)	SS				
	Amoxicillin (Amoxicillin) (Amoxicillin)	SS		ORAL	1000 MG (1 IN 2 D), ORAL	
	Rofecoxib (Rofecoxib)	SS				
	Levothyroxine (Levothyroxine Sodium)	C				
	Vitamins (Vitamins)	C				
	Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C				

Date:02/01/05ISR Number: 4566588-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00084
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
	Renal Cell Carcinoma		Candesartan Cilexetil And Hydrochlorothiazide	C		
	Stage Unspecified					
	Tachycardia					
UNKNOWN						
			Candesartan Cilexetil And Hydrochlorothiazide	C		
UNKNOWN						
			Bisoprolol	C		
UNKNOWN						

Date:02/01/05ISR Number: 4566591-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01146
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Thrombosis		Neurontin	C		
UNKNOWN						
Initial or Prolonged						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4566611-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00022
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Meprednisone	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	
			Citalopram Hydrobromide	C			UNKNOWN	

Date:02/01/05ISR Number: 4566612-XReport Type:Expedited (15-DaCompany Report #IT-MERCK-0501ITA00026
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566614-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00059
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxia		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Life-Threatening	Arrhythmia		Pindolol	SS		ORAL		
Hospitalization - Initial or Prolonged	Cardiac Arrest		Tamsulosin Hydrochloride	SS		ORAL		
	Coma		Glimepiride	C		ORAL		
	General Physical Health Deterioration		Metformin	C		ORAL		
	Lung Infection Pseudomonal							
	Nosocomial Infection							
	Sepsis							

Date:02/01/05ISR Number: 4566625-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566627-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00717
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acrochordon
Other	Adhesion
	Angina Pectoris
	Arthralgia
	Autonomic Neuropathy
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Carotid Artery Stenosis
	Chest Pain
	Chest Wall Pain
	Chronic Sinusitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Convulsion					
		Cough					
		Decreased Activity					
		Diastolic Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum		Lipitor	C		
UNKNOWN							
		Dizziness		Levothyroxine Sodium	C		
UNKNOWN							
		Dyspnoea		Prevacid	C		
UNKNOWN							
		Dyspnoea Exertional		Estratest	C		
UNKNOWN							
		Essential Tremor		Vicodin Tablets	C		
UNKNOWN							
		Fall		Fluoxetine			
		Fibromyalgia		Hydrochloride	C		
UNKNOWN							
		Flank Pain					
		Folliculitis					
		Gastroenteritis					
		Headache					
		Hyperglycaemia					
		Joint Contracture					
		Libido Decreased					
		Memory Impairment					
		Muscle Spasms					
		Myalgia					
		Nausea					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Otitis Media Acute					
		Pain In Extremity					
		Pruritus					
		Pyrexia					
		Restless Legs Syndrome					
		Rhinitis Allergic					
		Sciatica					
		Skin Lesion					
		Syncope					
		Transient Ischaemic Attack					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Visual Acuity Reduced					

Date:02/01/05ISR Number: 4566637-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04097
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
Hospitalization -	Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL	21 DAY	
Initial or Prolonged			Lexapro	C			UNKNOWN	
Disability			Synthroid	C			UNKNOWN	
			Estratest	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Prinivil	C		ORAL		
			Zoloft	C			UNKNOWN	
			Clonazepam	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4566638-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00023
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Brain Stem Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		11 DAY
	Drug Ineffective							
	Heart Rate Increased							

Date:02/01/05ISR Number: 4566642-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Prevacid	C				UNKNOWN
	Arthralgia		Amitriptyline Hydrochloride	C		ORAL		
	Blood Pressure Increased		Atenolol	C		ORAL		
	Bundle Branch Block Left		Atenolol	C		ORAL		
	Carotid Artery Stenosis		Nitroquick	C				SUBLINGUAL
	Chest Pain		Aspirin	C				UNKNOWN
	Colon Cancer		Lipitor	C		ORAL		
	Convulsion		Zantac	C		ORAL		
	Coronary Artery Disease		Plavix	C				UNKNOWN
	Diverticulum		Amaryl	C				UNKNOWN
	Dysphagia		Baycol	C				UNKNOWN
	Dyspnoea		Pravachol	C				UNKNOWN
	Hiatus Hernia		Ambien	C				UNKNOWN
	Limb Discomfort		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Loss Of Consciousness							
	Oesophagitis							
	Polyp							

Post Procedural Haematoma
Prostatitis
Renal Cyst
Retrograde Ejaculation
Tinnitus
Urinary Retention

Date:02/01/05ISR Number: 4566644-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00866
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Wall Infection
Other	Abnormal Behaviour
	Adverse Event
	Asthenia
	Asthma
	Bronchitis Acute
	Cervical Vertebral
	Fracture
	Constipation
	Encephalopathy
	Eye Disorder
	Herpes Zoster
	Hypoaesthesia
	Incontinence
	Nausea
	Oedema Peripheral
	Paranasal Sinus

	Hypersecretion						
	Peripheral Coldness						
	Personality Disorder						
	Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Senile Dementia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	
	Somnolence		Risperdal	C			UNKNOWN
	Urinary Retention		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN

Date:02/01/05ISR Number: 4566646-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01401
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1 DAY
Initial or Prolonged							
Other							

Date:02/01/05ISR Number: 4566647-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00963
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	476 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY
Other	Infarction		Prilosec	C		ORAL	
	Angina Unstable		Tylenol	C			UNKNOWN
	Anxiety		Inderal	C			UNKNOWN
	Blood Triglycerides		Lipitor	C		ORAL	
	Increased		Lipitor	C			UNKNOWN
	Cardiac Failure		Zithromax	C			UNKNOWN

	Congestive		Zantac	C		ORAL
	Carotid Artery Disease		Nitrostat	C		
SUBLINGUAL						
	Carotid Artery Stenosis					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Diarrhoea					
	Dilatation Atrial					
	Dizziness					
	Fatigue					
	Ischaemic Cardiomyopathy					
	Mitral Valve Incompetence					
	Mixed Hyperlipidaemia					
	Palpitations					
	Supraventricular					
	Extrasystoles					
	Ventricular Extrasystoles					
	Ventricular Hypertrophy					
	Ventricular Hypokinesia					
	Weight Decreased					

Date:02/01/05ISR Number: 4566648-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00383
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Phlebitis							
	Skin Ulcer							

Date:02/01/05ISR Number: 4566656-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566658-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03901
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	2 WK	

Date:02/01/05ISR Number: 4566659-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566660-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566667-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02437
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Fatigue		[Therapy Unspecified]	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:02/01/05ISR Number: 4566668-4Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00066
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Leukocytoclastic		Vioxx	PS	Merck & Co., Inc	ORAL
763 DAY						
Initial or Prolonged	Vasculitis		Celecoxib	SS		ORAL
160 DAY						
	Varicose Ulceration					
	Vascular Purpura					

Date:02/01/05ISR Number: 4566671-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03290
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Unstable
	Angiodysplasia

		Cardiac Failure Congestive Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum Intestinal		Cardizem	C		
UNKNOWN							
		Encephalopathy		Epogen	C		
UNKNOWN							
		Haemorrhoids		Imdur	C		
UNKNOWN							
		Hypertension		Normodyne	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Zantac	C		
UNKNOWN							
		Myocardial Infarction		Zoloft	C		
UNKNOWN							
		Peripheral Vascular Disorder Upper Gastrointestinal Haemorrhage Ventricular Dysfunction					

Date:02/01/05ISR Number: 4566672-6Report Type:Expedited (15-DaCompany Report #AE-MERCK-0501USA03405
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/01/05ISR Number: 4566673-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03893
Age:62 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiac Failure		Celebrex	C		
UNKNOWN							
		Congestive Coronary Artery Disease Transient Ischaemic Attack					

Date:02/01/05ISR Number: 4566675-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00023
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemiplegia		Amlodipine Besylate	C		ORAL		
	Psychomotor Agitation		Phenprocoumon	C		ORAL		
	Respiratory Disorder		Sotalol Hydrochloride	C		ORAL		
			Lorazepam	C		ORAL		

Date:02/01/05ISR Number: 4566676-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02079
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Amnesia
	Anxiety
	Blood Cholesterol Increased
	Blood Pressure Inadequately Controlled
	Bradycardia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Carotid Artery Stenosis					
		Cellulitis					
		Chronic Obstructive Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL
		Contusion					
		Coronary Artery Disease					
		Decreased Activity					
		Depression					
		Dizziness					
		Drug Hypersensitivity					
		Emphysema					
		Excoriation					
		Fall					
		Fatigue					
		Fibrosis					
		Gastritis					
		Glucose Tolerance Impaired					
		Groin Pain					
		Hepatic Cirrhosis					
		Insomnia					
		Intervertebral Disc Protrusion					
		Ischaemic Cardiomyopathy					
		Lumbar Radiculopathy					
		Malnutrition					
		Muscle Spasms					
		Musculoskeletal Disorder					
		Myocardial Ischaemia					
		Nerve Root Compression					
		Nightmare					
		Onychogryphosis					
		Osteopenia					
		Pericarditis					
		Peripheral Vascular Disorder					
		Pneumonia					
		Portal Hypertension					
		Rectal Haemorrhage					
		Renal Cyst					
		Renal Failure					
		Rib Fracture					
		Rotator Cuff Syndrome					
		Sciatica					
		Shoulder Deformity					

Sinus Bradycardia
Sleep Apnoea Syndrome
Spinal Decompression
Tendonitis
Thrombosis
Tinea Cruris
Ventricular Hypokinesia
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4566679-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04123
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566680-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04140
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4566683-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00883
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
	Angina Pectoris
	Anxiety
	Arrhythmia
	Arthralgia
	Blister
	Blister Infected
	Blood Pressure Increased
	Breast Cancer In Situ
	Breast Pain
	Bronchitis
	Bursitis
	Cataract
	Chest Pain
	Colonic Polyp
	Congenital Eye Naevus
	Contusion
	Cough
	Deafness Neurosensory
	Diverticulum
	Dry Mouth
	Dyspnoea
	Endolymphatic Hydrops
	Exostosis

Fatigue
Fibrocystic Breast
Disease
Flatulence
Haemangioma
Haemorrhoids
Herpes Simplex
Hot Flush
Hyperhidrosis
Hypertension
Hypertensive Crisis
Hypertensive
Encephalopathy
Injury
Intermittent Claudication
Interstitial Lung Disease
Limb Discomfort
Limb Injury
Loss Of Consciousness

		Myocardial Infarction					
		Nausea					
		Night Sweats	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Spironolactone	C		
UNKNOWN							
		Palatal Disorder		Captopril Msd	C		ORAL
		Palpitations		Toprol Xl Tablets	C		ORAL
		Plantar Fasciitis					
		Pneumonitis					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pulmonary Fibrosis					
		Pulmonary Hypertension					
		Rash					
		Respiratory Failure					
		Rhinitis					
		Seasonal Allergy					
		Seroma					
		Sinus Congestion					
		Skin Disorder					
		Sleep Disorder					
		Sputum Retention					
		Syncope					
		Tendonitis					
		Tinnitus					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urine Ketone Body					
		Ventricular Hypertrophy					
		Vertebrobasilar					
		Insufficiency					
		Vertigo Positional					
		Vitreous Detachment					
		Vulval Ulceration					

Date:02/01/05ISR Number: 4566687-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00807
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Lower
Hospitalization -	Adverse Event

Initial or Prolonged Disability	Anaemia
	Anorexia
	Arrhythmia
	Arthralgia
	Asthenia
	Atelectasis
	Atrial Flutter
	Azotaemia
	Back Pain
	Bladder Disorder
	Bronchial Carcinoma
	Candidiasis
	Cardio-Respiratory Arrest
	Cardiomegaly
	Carotid Bruit
	Chest Discomfort
	Cholelithiasis

Collagen-Vascular Disease
Coronary Artery
Atherosclerosis
Dehydration
Disease Recurrence
Drug Ineffective
Dysphagia
Dyspnoea
Epicondylitis
Fatigue
Flank Pain
Gammopathy
Gastrooesophageal Reflux
Disease
Glomerulonephritis
Haematuria
Haemodialysis
Haemolytic Anaemia
Hyperhidrosis
Hypotension
Injury
Interstitial Lung Disease
Jaundice
Leukaemia
Leukocytosis
Liver Disorder
Lung Consolidation
Mitral Valve Incompetence
Mitral Valve Prolapse
Multi-Organ Failure
Muscle Spasms
Nausea
Nephropathy Toxic
Neuralgia
Oedema Peripheral
Oliguria
Pain In Extremity
Pancreatitis
Peptic Ulcer
Pleural Effusion
Pneumonia
Pneumothorax
Proteinuria
Pulmonary Congestion
Pulmonary Oedema
Renal Failure
Renal Tubular Necrosis

Respiratory Failure
Rheumatoid Arthritis
Scar
Sepsis
Sepsis Syndrome
Sinus Tachycardia
Tachycardia
Upper Respiratory Tract Infection
Urinary Tract Infection
Urosepsis
Vasculitis
Venous Insufficiency
Vocal Cord Paralysis

Vomiting
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1151 DAY	
	Naprosyn	SS			UNKNOWN	

Date:02/01/05ISR Number: 4566689-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Angina Pectoris
	Arrhythmia
	Benign Prostatic Hyperplasia
	Blood Pressure Increased
	Bradycardia
	Bronchitis Acute
	Cerebrovascular Accident
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Convulsion
	Coronary Artery Disease
	Cough
	Decreased Appetite
	Depression
	Dermatitis Atopic
	Diverticulum
	Dizziness
	Dysgeusia
	Dyspnoea
	Emphysema
	Fatigue
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Hiatus Hernia
	Inner Ear Disorder
	Intervertebral Disc Degeneration

Lumbar Radiculopathy
Lumbar Spinal Stenosis
Lung Neoplasm
Myocardial Infarction
Neuroma
Non-Hodgkin'S Lymphoma
Palpitations
Peptic Ulcer
Peripheral Vascular
Disorder
Pleural Effusion
Renal Abscess
Renal Cyst
Renal Mass
Rhinitis Allergic
Splenomegaly
Spondylolisthesis
Vertigo

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	586	DAY
	Claritin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Pravachol	C			UNKNOWN	
	Calcium (Unspecified)	C			UNKNOWN	
	Folic Acid	C			UNKNOWN	
	Digoxin	C			UNKNOWN	
	Naprosyn	C		ORAL		
	Keflex	C		ORAL		
	Allegra	C		ORAL		
	Elocon	C			UNKNOWN	
	Lopressor	C		ORAL		
	Darvocet-N	C		ORAL		
	Pravachol	C			UNKNOWN	
	Lanoxin	C		ORAL		
	Lortab	C		ORAL		
	Clarinex	C		ORAL		
	Zocor	C		ORAL		
	Nexium	C		ORAL		
	Paxil	C		ORAL		
	Vitamin E	C			UNKNOWN	

Date:02/01/05ISR Number: 4566692-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1128	DAY

Initial or Prolonged	Acute Coronary Syndrome	Vioxx	SS	Merck & Co., Inc	ORAL
1128 DAY					
Other	Acute Myocardial	Effexor	C		
UNKNOWN	247 DAY				
	Infarction	Nortriptyline	C		
UNKNOWN	233 DAY				
	Arthralgia	Trazodone Hydrochloride	C		
	Chest Pain				
UNKNOWN					
	Corneal Ulcer	Vicodin Tablets	C		
UNKNOWN					
	Coronary Artery Occlusion				
	Coronary Artery Restenosis				
	Cough				
	Diverticulum				
	Emotional Distress				
	Fatigue				
	Gastritis				
	Gastroduodenitis				
	Haematuria				
	Hyperlipidaemia				
	Hypertension				
	Myocardial Infarction				
	Nausea				
	Neck Pain				
	Nephrolithiasis				
	Pain				
	Vision Blurred				
	Vomiting				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4566701-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00862
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alanine Aminotransferase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Potassium Increased							
	Calcinosis							
	Carpal Tunnel Syndrome							
	Dysuria							
	Gallbladder Disorder							
	Hernia							
	Hypertension							
	Intervertebral Disc Protrusion							
	Lumbar Spinal Stenosis							
	Osteoarthritis							
	Pain							
	Post Laminectomy Syndrome							
	Renal Mass							
	Spinal Osteoarthritis							

Date:02/01/05ISR Number: 4567050-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567474-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00275
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fear							

Date:02/01/05ISR Number: 4567478-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00276
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gait Disturbance		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Lower Limb Fracture							
	Mobility Decreased							

Date:02/01/05ISR Number: 4567480-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00283
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567489-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
		Asthma		Diflunisal	C			UNKNOWN	
		Atherosclerosis		Ultram	C			UNKNOWN	
		Blood Cholesterol		Rebetol	C			UNKNOWN	
		Increased		Allegra	C			UNKNOWN	
		Cardiomegaly		Soma	C		ORAL		
		Carotid Artery Occlusion		Premarin	C			UNKNOWN	
		Cerebrovascular Accident		Darvocet-N	C			UNKNOWN	
		Chest Pain		Accupril	C			UNKNOWN	
		Concussion		Wellbutrin	C			UNKNOWN	
		Constipation		Estratest	C			UNKNOWN	
		Contusion		Rebetron	C			UNKNOWN	3 DAY
		Depression							
		Drug Abuser							
		Dry Mouth							
		Dysphonia							
		Excoriation							
		Fall							
		Gastrointestinal Haemorrhage							
		Gastrooesophageal Reflux Disease							
		Hyperlipidaemia							
		Laceration							
		Macrocytosis							
		Melaena							
		Microcytic Anaemia							
		Neurogenic Bladder							
		Oedema Peripheral							
		Orthostatic Hypotension							
		Pain							

Pain In Extremity
Pneumonia
Pulmonary Congestion
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation
Tibia Fracture
Urinary Tract Infection
Weight Increased

Date:02/01/05ISR Number: 4567505-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03556
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Lung Disorder		Zetia	C				
UNKNOWN								
Initial or Prolonged			Lisinopril	C				
UNKNOWN								
Disability			Lasix (Furosemide)	C				
UNKNOWN								
			Blood Thinner (Unspecified)	C				
UNKNOWN								
			Warfarin	C				
UNKNOWN								
			Digitek	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

			[Therapy Unspecified]	C			
UNKNOWN							

Date:02/01/05ISR Number: 4567506-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00284
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567509-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00274
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blister		[Therapy Unspecified]	C				
UNKNOWN	Bradycardia							
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN	Chest Pain		Celexa	C				
UNKNOWN	Confusional State							
	Fatigue							
	Neck Pain							
	Visual Disturbance							

Date:02/01/05ISR Number: 4567510-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00114
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Adverse Event
Other	Angina Unstable
	Anxiety
	Aortic Aneurysm
	Atherosclerosis
	Atrial Fibrillation

Back Pain
Blood Potassium Decreased
Blood Triglycerides
Increased
Cardiac Failure
Congestive
Cardiac Valve Disease
Cholelithiasis
Depression
Disseminated
Intravascular Coagulation
Diverticulum
Embolic Stroke
Encephalopathy
Endocarditis
Feeling Hot
Haematuria
Haemorrhage
Hepatic Cyst
High Density Lipoprotein
Decreased
Ischaemic Cardiomyopathy
Low Density Lipoprotein

		Increased Myocardial Infarction Nephrosclerosis Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Mass		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		Prinivil	C		ORAL
		Sinus Tachycardia		Atenolol	C		
UNKNOWN							
		Splenic Infarction		[Therapy			
		Stress		Unspecified]	C		
UNKNOWN							
		Ventricular Tachycardia		Aspirin	C		
UNKNOWN							
		Vision Blurred		Plavix	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:02/01/05ISR Number: 4567514-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00285
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Myocardial Infarction					

Date:02/01/05ISR Number: 4567516-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 3 DAY		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		[Therapy			
		Atherosclerosis		Unspecified]	C		
UNKNOWN							
		Attention		Paxil	C		
UNKNOWN							
		Deficit/Hyperactivity		Ibuprofen	C		
UNKNOWN							

	Disorder		Zoloft	C			
UNKNOWN							
	Chest Pain						
	Chronic Fatigue Syndrome						
	Depression						
	Eye Swelling						
	Gastrooesophageal Reflux						
	Disease						
	Generalised Anxiety						
	Disorder						
	Haemorrhoidal Haemorrhage						
	Hypercholesterolaemia						
	Hypertension						
	Insomnia						
	Joint Swelling						
	Lower Gastrointestinal						
	Haemorrhage						
	Microcytic Anaemia						
	Panic Disorder						
	Phlebitis Superficial						

Date:02/01/05ISR Number: 4567517-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01440
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations		Flexeril	C				
UNKNOWN								
			Zoloft	C		ORAL		

Date:02/01/05ISR Number: 4567519-4Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00042
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1647 DAY
Initial or Prolonged	Aortic Aneurysm		Acetaminophen And					
Disability	Arrhythmia		Codeine Phosphate	C				
UNKNOWN								
Other	Atrial Fibrillation		Metildigoxin	C		ORAL		
	Dyspnoea		Bisoprolol Fumarate	C		ORAL		
	General Physical Health Deterioration		Lisinopril	C		ORAL		
	Myocardial Infarction							
	Supraventricular Extrasystoles							

Date:02/01/05ISR Number: 4567520-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02728
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
	Congestive							

Date:02/01/05ISR Number: 4567521-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567522-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02640
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

Initial or Prolonged Cardiac Arrest
Myocardial Infarction

Date:02/01/05ISR Number: 4567523-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Epilepsy		Vioxx	PS	Merck & Co., Inc		UNKNOWN	5 DAY

Date:02/01/05ISR Number: 4567524-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567525-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00533
Age:64 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL		
	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arrhythmia		Diclofenac Sodium	C		ORAL		
	Blood Cholesterol Increased		Magnesium (Unspecified)	C				
	Blood Pressure Increased							
	Coagulopathy							
	Deep Vein Thrombosis							
	Low Density Lipoprotein Increased							
	Muscle Spasms							
	Pulmonary Embolism							
	Syncope							
	Thrombosis							

Date:02/01/05ISR Number: 4567528-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03691
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		[Therapy Unspecified]	C				
	Joint Swelling							
	Muscle Spasms							
	Oedema Peripheral							
	Pain In Extremity							

Date:02/01/05ISR Number: 4567529-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/01/05ISR Number: 4567530-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04021
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diazepam	C				UNKNOWN
			Percocet	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Allopurinol	C				UNKNOWN

Date:02/01/05ISR Number: 4567531-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4567532-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04115
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567533-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/01/05ISR Number: 4567535-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567536-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567537-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Initial or Prolonged	Blood Pressure Increased
	Chest Pain
	Gastrointestinal
	Haemorrhage
	Left Ventricular Failure
	Oedema Peripheral
	Visual Disturbance

Date:02/01/05ISR Number: 4567538-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03711
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4567539-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/05ISR Number: 4567541-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04154
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/01/05ISR Number: 4569311-3Report Type:Expedited (15-DaCompany Report #2005018474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury	Consumer	Neurontin					
	Overdose		(Gabapentin)	PS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:02/01/05ISR Number: 4576167-1Report Type:Direct Company Report #CTU 238803
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx 50 Mg	PS		ORAL	1 A DAY	
	Sudden Cardiac Death						ORALLY	
	Vascular Calcification		Diovan	C				
			Zocor	C				
			Prednisone	C				

Date:02/02/05ISR Number: 4568053-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/02/05ISR Number: 4568152-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization -	Aptyalism
Initial or Prolonged	Asthenia
Other	Atrial Flutter
	Back Disorder
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Chest Pain
	Contusion
	Coronary Artery Disease
	Decreased Activity
	Decreased Appetite
	Dyspepsia
	Fall
	Gastric Ulcer
	Gastrooesophageal Reflux
	Disease
	Haematoma
	Hypertensive Heart
	Disease

		Influenza					
		Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Sinus Drainage		Coumadin	SS		
UNKNOWN							
		Nausea		Coumadin	SS		
UNKNOWN							
		Oedema Peripheral					
		Osteoarthritis					
		Pain					
		Pneumonia					
		Pruritus					
		Renal Failure					
		Rotator Cuff Syndrome					
		Sinusitis					
		Stomach Discomfort					
		Subdural Haematoma					
		Urinary Retention					

Date:02/02/05ISR Number: 4568163-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 115 DAY		Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Angina Unstable		Haldol	C		
UNKNOWN							
Other		Back Pain		Hydrocodone Bitartrate	C		
		Coronary Artery Disease					
UNKNOWN							
		Depression					
		Gout					
		Intervertebral Disc Protrusion					
		Myocardial Infarction					
		Neck Pain					
		Pain In Extremity					
		Road Traffic Accident					
		Weight Increased					

Date:02/02/05ISR Number: 4568169-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00270
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Delusion		Morphine	C				
Initial or Prolonged	Feeling Abnormal		[Therapy					
	Lung Disorder		Unspecified]	C				
UNKNOWN								
	Myocardial Infarction							

Date:02/02/05ISR Number: 4568172-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								
	Myocardial Infarction							

Date:02/02/05ISR Number: 4568173-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01084
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Electroencephalogram Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fall							
	Loss Of Consciousness							
	Tongue Injury							
	Tooth Disorder							
	Transient Ischaemic Attack							

Date:02/02/05ISR Number: 4568174-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00259
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Phlebothrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	11	DAY

Date:02/02/05ISR Number: 4568176-3Report Type:Expedited (15-DaCompany Report #CN-MERCK-0501CHN00019
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	348	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	348	DAY
	Angina Pectoris		Alfacalcidol	C		ORAL		
	Atrioventricular Block Complete		Elcatonin	C		ORAL		
	Cardiogenic Shock							

Date:02/02/05ISR Number: 4568177-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00274
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other								

Date:02/02/05ISR Number: 4568179-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03555
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Joint Swelling		Norvasc	C				
UNKNOWN								
	Musculoskeletal Stiffness		Lipitor	C				
UNKNOWN								
	Uterine Disorder		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/02/05ISR Number: 4568182-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568190-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03908
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		23 MON
Hospitalization -	Cardiac Disorder		Lasix (Furosemide)	C				UNKNOWN
Initial or Prolonged	Cardiac Failure		Clonidine	C				UNKNOWN
Disability	Congestive		Cozaar	C		ORAL		
	Diarrhoea		Zantac	C				UNKNOWN
	Dizziness		Claritin	C				UNKNOWN
	Fatigue		Elavil	C		ORAL		
	Haematochezia							
	Haemorrhage							
	Hypertension							
	Movement Disorder							
	Swelling Face							

Date:02/02/05ISR Number: 4568191-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/02/05ISR Number: 4568192-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568198-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03556
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Attack		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability				C				
UNKNOWN								

Date:02/02/05ISR Number: 4568199-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/02/05ISR Number: 4568201-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00210
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
	Carotid Artery Stenosis
	Heart Rate Irregular
	Neck Pain
	Thyroid Neoplasm
	Ulnar Nerve Injury
	Vertebral Artery

Occlusion

			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/02/05ISR Number: 4568203-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03909
Age:51 YR Gender:Female I/FU:I

Outcome	PT		Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening	Dilatation Ventricular			Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Heart Rate Increased			[Therapy			
	Palpitations			Unspecified]	C		
UNKNOWN							

Date:02/02/05ISR Number: 4568215-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04334
Age: Gender:Male I/FU:I

Outcome	PT		Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other	Myocardial Infarction			Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/02/05ISR Number: 4568485-8Report Type:Expedited (15-DaCompany Report #DEWYE114518OCT04
Age: Gender:Male I/FU:F

Outcome	PT		Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening	Dehydration		Health	Enbrel	PS		
SUBCUTANEOUS		43 DAY					
Hospitalization -	Demyelination		Professional	Enbrel	SS		
43 DAY							
Initial or Prolonged	Depressed Level Of			Vioxx	SS		ORAL
827 DAY							
	Consciousness			Budesonide	C		ORAL
98 DAY							
	Diarrhoea						
	Korsakoff'S Psychosis						
	Non-Alcoholic						

Date:02/02/05ISR Number: 4568690-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00044
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chronic Lymphocytic		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Leukaemia		Valsartan	C		ORAL		17 DAY
	Idiopathic		Omeprazole	C		ORAL		17 DAY
	Thrombocytopenic Purpura		Tetrazepam	C		ORAL		17 DAY
	Thrombocytopenia Weight Decreased		Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL		17 DAY

Date:02/02/05ISR Number: 4568692-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04028
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Zocor	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery		Estrogel	SS				UNKNOWN
	Atherosclerosis		Atacand	SS				UNKNOWN
			[Therapy Unspecified]	SS				UNKNOWN
			Vioxx	SS		ORAL		
			Enbrel	SS				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568695-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02552
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis		Premarin	C				
	Cardiomyopathy		Effexor Xr	C				
	Cerebral Artery Stenosis		Remeron	C		ORAL		
	Cerebrovascular Accident		Vicodin Tablets	C				
	Constipation		Soma	C				
	Cough		Seroquel	C		ORAL		
	Cubital Tunnel Syndrome		Phenergan (Promethazine Hydrochloride)	C				
	Decreased Appetite							
	Diarrhoea							
	Emotional Distress		Klonopin	C				
	Feeling Hot And Cold		Klonopin	C				
	Headache		Risperdal	C		ORAL		
	Hyperlipidaemia		Zestril	C		ORAL		
	Injury		Zocor	C				
	Insomnia		Celebrex	C		ORAL	30	DAY
	Lower Respiratory Tract Infection		Lanoxin	C		ORAL		
			Plavix	C		ORAL		
	Nasopharyngitis		Aspirin	C		ORAL		
	Nervous System Disorder		Vistaril	C				
	Neuropathy		Geodon	C				
	Nocturia							
	Road Traffic Accident							
	Sexual Dysfunction							
	Sinusitis							
	Tension							
	Transient Ischaemic Attack							
	Urinary Incontinence							
	Visual Disturbance							

Date:02/02/05ISR Number: 4568697-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Cervicobrachial Syndrome
	Chest Discomfort
	Cough
	Dyspnoea
	Emotional Distress
	Fatigue
	Gastrointestinal Haemorrhage
	Gastrointestinal Ulcer
	Gastrooesophageal Reflux Disease
	Haemorrhage
	Hypersensitivity
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion
	Malaise
	Melaena
	Migraine
	Mitral Valve Prolapse

		Multiple Allergies					
		Muscle Spasms					
		Musculoskeletal Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
34	DAY						
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Pallor		Aspirin	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Echinacea	C		
UNKNOWN			1483 DAY				
		Rectal Haemorrhage		Cyclobenzaprine			
		Small Intestinal Ulcer		Hydrochloride	C		
UNKNOWN							
		Haemorrhage		Dicyclomine			
		Upper Respiratory Tract		Hydrochloride	C		
UNKNOWN							
		Infection		Nexium	C		
UNKNOWN							
		Viral Infection					

Date:02/02/05ISR Number: 4568698-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
984	DAY						
		Anaemia		Acetaminophen And			
		Atherosclerosis		Hydrocodone			
		Back Pain		Bitartrate	C		
UNKNOWN							
		Cystocele		Wellbutrin	C		ORAL
		Depression		Valium	C		ORAL
		Hepatitis		Estradiol	C		ORAL
		Hypertension		Remeron	C		ORAL
		Liver Disorder		Lotensin	C		
UNKNOWN							
		Osteoporosis		Effexor Xr	C		ORAL

	Pain In Extremity	Prilosec	C
UNKNOWN			
	Pelvic Prolapse	Atacand	C
UNKNOWN			
	Polymyalgia Rheumatica	Celexa	C
UNKNOWN			
	Polyneuropathy	Iron (Unspecified)	C
UNKNOWN			
	Rectocele	Diazepam	C
UNKNOWN			
	Renal Failure	Celebrex	C
UNKNOWN			
	Rhinitis Seasonal		
	Stress Incontinence		
	Tremor		
	Vaginitis Atrophic		
	Weight Increased		

Date:02/02/05ISR Number: 4568699-7Report Type:Expedited (15-DaCompany Report #US-MERCK-00072405
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	68	DAY
Initial or Prolonged	Duodenal Ulcer							
Disability	Upper Gastrointestinal							
	Haemorrhage							

Date:02/02/05ISR Number: 4568700-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Coronary Syndrome
Initial or Prolonged	Acute Myocardial
Other	Infarction

Adverse Event	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blood Cholesterol Increased							
Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Congestive Cardiomegaly							
Cerebrovascular Accident							
Cerebrovascular Disorder							
Confusional State							
Coronary Artery Atherosclerosis							
Coronary Artery Disease							
Depression							
Diabetes Mellitus Inadequate Control							
Diabetic Neuropathy							
Diarrhoea							
Escherichia Sepsis							
Essential Hypertension							
Intermittent Claudication							
Lipoprotein Deficiency							
Mitral Valve Disease							
Mitral Valve Incompetence							
Myocardial Infarction							
Oedema Peripheral							
Osteoarthritis							
Peripheral Occlusive Disease							
Pulmonary Oedema							
Renal Failure							
Renal Failure Acute							
Sciatica							
Spinal Column Stenosis							
Stress Incontinence							
Transient Ischaemic Attack							
Urinary Tract Infection							
Urosepsis							
Uterine Infection							

Date:02/02/05ISR Number: 4568720-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02542
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Ortho-Novum 7/7/7	C			UNKNOWN	
	Fibromyalgia		Zoloft	C			UNKNOWN	
	Gastrooesophageal Reflux		Paxil	C			UNKNOWN	
	Disease		Trazodone					
	Headache		Hydrochloride	C			UNKNOWN	
	Intervertebral Disc		Lithobid	C			UNKNOWN	
	Degeneration		Vitamin D					
	Osteomalacia		(Unspecified)	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Ultram	C			UNKNOWN	

			Oxycontin	C		
UNKNOWN						
			Methadone Hcl	C		
UNKNOWN						
			Advil	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

Date:02/02/05ISR Number: 4568721-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	
UNKNOWN	582 DAY					
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Acute Sinusitis		Pancof	C		
UNKNOWN						
	Angina Pectoris		Celexa	C		
UNKNOWN						
	Asthenia		Ziac	C		
UNKNOWN						
	Blood Cholesterol		Ultram	C		
UNKNOWN						
	Increased		Claritin	C		
UNKNOWN						
	Bone Pain		Pepcid	C		ORAL
	Cardiac Failure		Diovan	C		
UNKNOWN						
	Congestive		Marcof Expectorant	C		
UNKNOWN						
	Carpal Tunnel Syndrome		Atrovent	C		
UNKNOWN						
	Coronary Artery Disease		Nasacort	C		
UNKNOWN						
	Depression		Folic Acid	C		
UNKNOWN						
	Dizziness		Tequin	C		
UNKNOWN						
	Emotional Distress		Allfen Dm	C		
UNKNOWN						
	Glucose Tolerance		Avelox	C		
UNKNOWN						

	Impaired		Zyrtec	C		
UNKNOWN						
	Intervertebral Disc Protrusion		Hyzaar	C		ORAL
			Proventil	C		
UNKNOWN						
	Nasopharyngitis		Serevent	C		
UNKNOWN						
	Neck Pain		Rhinocort	C		
UNKNOWN						
	Nervousness					
	Otitis Media					
	Pain					
	Pain In Extremity					
	Peripheral Nerve Decompression					
	Radiculitis					
	Swelling					

Date:02/02/05ISR Number: 4568723-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 435 DAY	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Congestive		Darvocet-N	C		
UNKNOWN						
Disability	Diabetes Mellitus		Synthroid	C		
UNKNOWN						
Other	Emotional Disorder		Prevacid	C		
UNKNOWN						
	Injury		Accupril	C		
UNKNOWN						
	Ischaemic Cardiomyopathy		Norvasc	C		
UNKNOWN						
	Myocardial Infarction		Hydrodiuril	C		
UNKNOWN						
	Nasal Septum Deviation		Claritin	C		
UNKNOWN						
	Pneumonia		Ceftin	C		
UNKNOWN						
	Renal Failure		Combivent	C		
UNKNOWN						
	Respiratory Failure		Albuterol	C		
UNKNOWN						
	Sinus Congestion		Zestril	C		
UNKNOWN						
	Wheezing		Coreg	C		
UNKNOWN	581 DAY					
			Lasix (Furosemide)	C		
UNKNOWN						

	Aspirin	C
UNKNOWN		
	Prempro	C
UNKNOWN		

	Theophylline	C	
UNKNOWN			
	Metab-O-Lite	C	
UNKNOWN			

Date:02/02/05ISR Number: 4568727-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Blood Pressure Increased							
	Bronchitis							
	Chest Pain							
	Diarrhoea							
	Emotional Distress							
	Erosive Oesophagitis							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Hepatic Cyst							
	Hiatus Hernia							
	Hypercholesterolaemia							
	Hypersensitivity							
	Hypertriglyceridaemia							
	Joint Sprain							
	Metal Poisoning							
	Polycythaemia							
	Weight Decreased							

Date:02/02/05ISR Number: 4568732-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00329
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus							
	Hypertension							
	Hypertensive Crisis							

Hypertensive Heart
Disease
Lipid Metabolism Disorder

Date:02/02/05ISR Number: 4568733-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02952
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL	222	DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	264	DAY

Date:02/02/05ISR Number: 4568734-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04019
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Anxiety
	Back Pain

	Confusional State						
	Depression						
	Dyspepsia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON
	Prostate Infection		Prevacid	C			UNKNOWN

Date:02/02/05ISR Number: 4568736-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0501CHE00039
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/02/05ISR Number: 4568738-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00119
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	
	Erosive Duodenitis		Atenolol	C			UNKNOWN
Disability	Gastric Ulcer		Atenolol	C			UNKNOWN
	Myocardial Infarction		Zocor	C		ORAL	
	Upper Gastrointestinal		Metformin	C			UNKNOWN
	Haemorrhage		Isosorbide Dinitrate	C			UNKNOWN

Date:02/02/05ISR Number: 4568741-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03544
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	
Disability	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL	

	Dizziness	Naproxen	C
UNKNOWN			
	Ear Pain	Percocet	C
UNKNOWN			
	Epicondylitis	Tylenol	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	Haematochezia		
	Joint Swelling		
	Muscle Strain		
	Neuralgic Amyotrophy		
	Pain		
	Swelling Face		
	Tendonitis		
	Urinary Tract Infection		

Date:02/02/05ISR Number: 4568743-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00864
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myelodysplastic Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
			Hydrochlorothiazide	C		ORAL		
			Capoten	C		ORAL		
			Plaquenil	C		ORAL		
			Parafon Forte	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568745-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568746-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00892
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Vitamins (Unspecified)	C				
	Gynaecological							
	Examination Abnormal		Nexium	C				
	Helicobacter Infection		Aspirin	C				
	Lipids Increased		Ascorbic Acid	C				
	Muscle Spasms		Prempro	C				
	Musculoskeletal		Synthroid	C				
	Discomfort		Gastrointestinal Preparations (Unspecified)	C				
	Nasopharyngitis							
	Upper Gastrointestinal							
	Haemorrhage		Calcium (Unspecified)	C				

Date:02/02/05ISR Number: 4568747-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00092
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568748-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00019
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Omeprazole Sodium	C				
UNKNOWN								
			Lansoprazole	C				
UNKNOWN								

Date:02/02/05ISR Number: 4568749-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03077
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
870 DAY								
Initial or Prolonged	Cerebrovascular Accident		Insulin	C				
UNKNOWN								

Date:02/02/05ISR Number: 4568750-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00030
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder							
Other	Myocardial Infarction							
	Renal Failure							
	Respiratory Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568751-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03927
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Protonix	C				
UNKNOWN								
	Disease							

Date:02/02/05ISR Number: 4568753-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								

Date:02/02/05ISR Number: 4568754-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00260
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Optic Nerve Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568755-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Injury							

Date:02/02/05ISR Number: 4568757-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Coronary Artery Disease Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568758-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568759-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04262
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthropathy Asthenia Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568761-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568762-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568763-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03617
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Cozaar	C		ORAL		
	Hypoaesthesia		Atenolol	C				
UNKNOWN								
	Tachycardia		Baclofen	C				
UNKNOWN								

Date:02/02/05ISR Number: 4568764-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03966
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/02/05ISR Number: 4568766-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04151
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/02/05ISR Number: 4568767-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Left Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Muscle Fatigue		Methotrexate	C				UNKNOWN
	Ventricular Dysfunction		Prednisolone	C				UNKNOWN
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN

Date:02/02/05ISR Number: 4568768-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568770-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568771-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568772-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04528
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Palpitations		Zestril	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								

Date:02/02/05ISR Number: 4568773-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04313
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568774-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568775-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04515
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/02/05ISR Number: 4568776-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04314
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/02/05ISR Number: 4568777-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04529
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4568787-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/02/05ISR Number: 4570714-1Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Health Professional Distributor Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 367 DAY

Date:02/02/05ISR Number: 4578361-2Report Type:Direct Company Report #CTU 238889
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Rofecoxib	PS		ORAL	25 MG PO DAILY	6 MON
	Disease Progression		Lisinopril Atenolol	C C				

			Sertraline	C		
			Flomax	C		

Date:02/02/05ISR Number: 4578372-7Report Type:Direct Company Report #CTU 238946
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Balance Disorder		Vioxx-121/2 Mg-25 Mg	PS		
25 MG -1-2						
Required	Dizziness					
DAILY						
Intervention to	Muscle Tightness					
Prevent Permanent	Vision Blurred					
Impairment/Damage						

Date:02/03/05ISR Number: 4568982-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00829
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Disability	Adverse Event
	Back Pain
	Carpal Tunnel Syndrome
	Insomnia
	Muscle Spasms
	Muscle Strain
	Nausea

		Neck Pain Rotator Cuff Syndrome Tendon Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Darvocet-N	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							
				Fioricet Tablets	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN							

Date:02/03/05ISR Number: 4569227-2Report Type:Expedited (15-DaCompany Report #PHRM2005FR00683
Age:74 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anoxia		Visken (Pindolol)	PS	Novartis Sector: Pharma	ORAL
Life-Threatening		Arrhythmia					
Hospitalization - Initial or Prolonged		Bronchopneumonia		Omix	SS		ORAL
		Cardiac Arrest		Amarel	SS		ORAL
Other		Cerebral Disorder		Vioxx	SS		ORAL
		Coma		Metformine	SS		ORAL
		Electroencephalogram Abnormal					
		General Physical Health Deterioration					
		Lung Disorder					
		Lung Infection Pseudomonal					
		Neurological Examination Abnormal					
		Nosocomial Infection					
		Pseudomonal Sepsis					
		Pseudomonas Infection					
		Sepsis					
		Tracheostomy					

Date:02/03/05ISR Number: 4569236-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00453
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Myocardial Infarction							

Date:02/03/05ISR Number: 4569237-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00215
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569240-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03232
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Stress Test		Vicodin Tablets	C				
UNKNOWN								
Other	Abnormal							
	Chest Pain							
	Dehydration							
	Pancreatitis							
	Pneumonia							

Date:02/03/05ISR Number: 4569242-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03279
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Disability								

Date:02/03/05ISR Number: 4569245-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569247-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01075
Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Heart Rate Increased							
	Heart Rate Irregular							
	Myalgia							

Pain
Rheumatoid Arthritis
Rheumatoid Factor
Increased
Tremor

Date:02/03/05ISR Number: 4569249-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00164
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:02/03/05ISR Number: 4569250-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01782
Age:63 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Depression		Allopurinol	C				UNKNOWN
Dyslipidaemia							
Dyspnoea							
Emotional Distress							
Flatulence							
Gout							
Hemiparesis							
Hyperlipidaemia							
Local Swelling							
Myocardial Infarction							
Suicide Attempt							
Ventricular Dysfunction							

Date:02/03/05ISR Number: 4569252-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00826
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lacunar Infarction		Nexium	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Zyrtec	C				UNKNOWN
			Levothyroxine Sodium	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Lescol	C				UNKNOWN
			Fosamax	C		ORAL		

Date:02/03/05ISR Number: 4569253-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02729
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
9 DAY								
Initial or Prolonged	Congestive							
	Cor Pulmonale							
	Pulmonary Hypertension							
	Weight Increased							

Date:02/03/05ISR Number: 4569257-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:02/03/05ISR Number: 4569258-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04116
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569259-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569260-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02394
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		77 DAY
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		77 DAY
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
			Furosemide	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Diovan	C				UNKNOWN
			Verapamil	C				UNKNOWN
			Potassium (Unspecified)	C				UNKNOWN
			Alprazolam	C				UNKNOWN

Date:02/03/05ISR Number: 4569261-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				UNKNOWN

Date:02/03/05ISR Number: 4569262-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hallucination		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								

Date:02/03/05ISR Number: 4569281-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04045
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569282-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569283-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569285-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00142
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
116 DAY								
Initial or Prolonged	First Degree		Hydrochlorothiazide					
	Contusion		And Valsartan	C				
UNKNOWN								
	Fall		Valsartan	C				
UNKNOWN								
	Periorbital Haematoma		Aspirin	C				
UNKNOWN								
	Prescribed Overdose							
	Syncope							
	Vomiting							

Date:02/03/05ISR Number: 4569286-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02415
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis							
Disability								

Date:02/03/05ISR Number: 4569288-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03944
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

	Ocular Vascular Disorder		Zocor	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Plendil	C		
UNKNOWN						
			Prinivil	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:02/03/05ISR Number: 4569289-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569290-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569291-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569292-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04309
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569293-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Embolism Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569294-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569298-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569299-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569300-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00440
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	27	DAY

Date:02/03/05ISR Number: 4569301-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00090519
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Drug Ineffective
Initial or Prolonged	Myocardial Infarction

Oedema Peripheral
Treatment Noncompliance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Acupril	C			UNKNOWN	
	Metoprolol	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	
	Insulin	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	

Date:02/03/05ISR Number: 4569302-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00002
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celiprolol Hydrochloride	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		

Date:02/03/05ISR Number: 4569303-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Arthralgia
Disability	Aspergillosis

Bronchitis
Cerebrovascular Accident
Complicated Migraine
Conversion Disorder
Drug Dependence
Drug Ineffective
Hypercholesterolaemia
Hypertriglyceridaemia
Hypotension
Iris Disorder
Major Depression
Migraine
Migraine With Aura
Muscle Spasms
Neuropathic Pain
Night Sweats
Nystagmus
Oesophageal Spasm
Pain In Extremity
Pigmented Naevus
Rib Fracture
Road Traffic Accident
Skin Hypopigmentation
Skin Laceration
Syncope

Tremor

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569305-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01811
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		1330 DAY
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1330 DAY
Initial or Prolonged								
Other								

Date:02/03/05ISR Number: 4569357-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/03/05ISR Number: 4569358-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Infarct		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Retinal Infarction							

Date:02/03/05ISR Number: 4569743-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome PT

Hospitalization -
Initial or Prolonged
Disability
Other

Angina Pectoris
Anxiety
Cardiomegaly
Carpal Tunnel Syndrome
Cerebrovascular Accident
Chest Pain
Coronary Artery Disease
Coronary Artery Stenosis
Dementia Alzheimer'S Type
Depression
Diabetic Foot Infection
Diplopia
Dizziness
Emotional Distress
Eyelid Ptosis
Haematuria
Headache
Ingrowing Nail
Injury
Insomnia
Intervertebral Disc
Degeneration
Mitral Valve Incompetence
Muscle Spasms

		Musculoskeletal Stiffness					
		Myalgia					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Psychomotor Hyperactivity		Vioxx	PS	Merck & Co., Inc	ORAL
		Rash		Glucophage	C		
UNKNOWN							
		Sinobronchitis		Zocor	C		ORAL
		Somnolence		Arthrotec	C		
UNKNOWN							
		Syncope					
		Systemic Lupus					
		Erythematosus					
		Upper Respiratory Tract					
		Infection					
		Vertigo					
		Vision Blurred					

Date:02/03/05ISR Number: 4569745-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01104508
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Disability	Abnormal Behaviour
	Accidental Overdose
	Anxiety
	Arthralgia
	Arthropod Bite
	Asthenia
	Back Injury
	Back Pain
	Blood Glucose Increased
	Cardiovascular Disorder
	Carpal Tunnel Syndrome
	Cellulitis
	Closed Head Injury
	Concussion
	Constipation
	Convulsion
	Coronary Artery Disease
	Deafness Neurosensory
	Depression
	Diabetic Neuropathy
	Difficulty In Walking
	Dysphonia

Emotional Distress
Epididymitis
Facial Bones Fracture
Head Injury
Headache
Hiatus Hernia
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Hypoaesthesia
Inguinal Hernia
Injury
Joint Effusion
Laceration
Loss Of Consciousness
Memory Impairment
Multiple Allergies
Muscle Atrophy

	Nasal Congestion						
	Nasal Septum Deviation						
	Nasal Turbinate	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL	
	Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neuritis		Zocor	C			UNKNOWN
	Nodule						
	Nose Deformity						
	Obesity						
	Oedema						
	Oesophagitis						
	Osteoarthritis						
	Overdose						
	Pain						
	Paraesthesia						
	Renal Failure						
	Skin Nodule						
	Sleep Apnoea Syndrome						
	Snoring						
	Somnolence						
	Tendonitis						
	Upper Extremity Mass						
	Ventricular Hypokinesia						
	Victim Of Crime						
	Vocal Cord Disorder						

Date:02/03/05ISR Number: 4569751-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02381
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	
	Carpal Tunnel Syndrome		Protonix	C			UNKNOWN
	Chills		Oramorph	C			UNKNOWN
	Depression		Cannabis	C			UNKNOWN
	Dyspepsia		Ambien	C			UNKNOWN
	Dysphagia		Lorazepam	C			UNKNOWN

Emotional Distress
Feeling Hot And Cold
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Haematemesis
Joint Effusion
Leukocytosis
Ligament Injury
Lumbar Radiculopathy
Migraine
Nausea
Oedema Peripheral
Overdose
Pyrexia
Radiculopathy
Rectal Haemorrhage
Renal Pain
Road Traffic Accident
Sleep Disorder
Vomiting
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569765-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		89 DAY
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
Other	Gastrooesophageal Reflux		Humulin N	C				UNKNOWN
	Disease		Humulin R	C				UNKNOWN
	Hypoaesthesia		Naproxen	C		ORAL		
	Hypotension		Naproxen	C		ORAL		
	Insomnia		Livostin	C				OPHTHALMIC
	Intervertebral Disc		Prevacid	C		ORAL		
	Degeneration		Vasotec	C				UNKNOWN
	Ischaemic Stroke							
	Muscle Spasms							
	Nasopharyngitis							
	Nephropathy							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain In Extremity							
	Pollakiuria							
	Upper Respiratory Tract Infection							

Date:02/03/05ISR Number: 4569774-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Balance Disorder		[Therapy					
Other	Benign Prostatic		Unspecified]	C				
UNKNOWN								
	Hyperplasia		Tylenol With Codeine					
	Blood Triglycerides		#3	C				
UNKNOWN								
	Increased							
	Cerebrovascular Accident							

Depression
Facet Joint Syndrome
Gait Disturbance
Hypoaesthesia
Insomnia
Lumbar Radiculopathy
Nausea
Neck Pain
Oedema Peripheral
Post Laminectomy Syndrome
Skin Papilloma
Sleep Apnoea Syndrome
Spinal Cord Disorder
Tachycardia
Vomiting

Date:02/03/05ISR Number: 4569775-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01803
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Chest Discomfort
Disability	Coronary Artery Disease
	Intracranial Aneurysm

	Ischaemia Thromboembolic Stroke Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Attack		Vioxx	PS	Merck & Co., Inc	ORAL	596	DAY
			Plavix	C			UNKNOWN	
			Zetia	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:02/03/05ISR Number: 4569776-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02515
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	274	DAY
Hospitalization -	Infarction		Premarin	C			UNKNOWN	
Initial or Prolonged	Acute Respiratory Failure		Lipitor	C			UNKNOWN	
	Anxiety		Ativan	C			UNKNOWN	
	Aortic Valve Incompetence		Aleve	C			UNKNOWN	
	Arthritis		Ecotrin	C			UNKNOWN	
	Cardiac Arrest		Vitamins					

	Coma	(Unspecified)	C	
UNKNOWN				
	Ejection Fraction	Albuterol	C	
UNKNOWN				
	Decreased	Prozac	C	
UNKNOWN				
	Hypoxic Encephalopathy	Zocor	C	ORAL
	Injury			
	Mitral Valve Incompetence			
	Sinus Tachycardia			
	Tenosynovitis			
	Ventricular Fibrillation			

Date:02/03/05ISR Number: 4569778-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Disability	Accident At Work
Other	Adverse Event
	Anxiety
	Aortic Valve Incompetence
	Asthenia
	Back Injury
	Cardiac Murmur
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Clumsiness
	Contusion
	Depression
	Drug Effect Decreased
	Dysthymic Disorder
	Fall
	Fatigue
	Gastrooesophageal Reflux
	Disease

		General Symptom					
		Headache					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
		Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Irritability		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Myofascial Pain Syndrome		Neurontin	C		
UNKNOWN							
		Pain		Ibuprofen	C		
UNKNOWN							
		Pain In Extremity		Claritin	C		
UNKNOWN							
		Thrombosis		Premarin	C		
UNKNOWN							
		Tinnitus		Cephalexin	C		
UNKNOWN							
		Transient Ischaemic		Skelaxin	C		
UNKNOWN							
		Attack		Trazodone			
		Tricuspid Valve		Hydrochloride	C		
UNKNOWN							
		Incompetence		Zovirax	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Propoxyphene			
				Hydrochloride	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Baclofen	C		ORAL

Date:02/03/05ISR Number: 4569785-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
373 DAY							
Initial or Prolonged		Infarction		Lipitor	C		
UNKNOWN							
		Blood Pressure Increased		Tranxene	C		
UNKNOWN							

	Coronary Artery	Prozac	C
UNKNOWN			
	Atherosclerosis	Zantac	C
UNKNOWN			
	Emotional Distress		
	Obstructive Airways Disorder		

Date:02/03/05ISR Number: 4569786-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Alopecia
Hospitalization - Initial or Prolonged	Angina Pectoris
	Anxiety
	Arrhythmia
	Balance Disorder
	Bladder Pain
	Cardiac Disorder
	Cardiac Failure
	Cough
	Cystitis
	Cystitis Noninfective
	Dermatitis
	Dermatitis Allergic
	Dizziness
	Duodenal Ulcer
	Dyspepsia
	Faecal Incontinence
	Fall
	Gastric Disorder
	Gastric Haemorrhage

	Gastric Ulcer						
	Gastritis						
	Haematuria	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	
	Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL	930 DAY
	Hyperkeratosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL	930 DAY
	Intestinal Polyp		Vioxx	SS	Merck & Co., Inc	ORAL	
	Irritable Bowel Syndrome		Hyzaar	C		ORAL	
	Knee Deformity		Piracetam	C		ORAL	
	Ligament Sprain		Flupirtine Maleate	C		ORAL	
	Osteoarthritis		Indomethacin	C			UNKNOWN
	Pain						
	Pain In Extremity						
	Palpitations						
	Reflux Oesophagitis						
	Renal Pain						
	Sleep Disorder						
	Tinea Pedis						
	Tinnitus						
	Urinary Incontinence						
	Ventricular Fibrillation						

Date:02/03/05ISR Number: 4569794-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02771
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	42 DAY
Hospitalization -	Arthralgia		Ultracet	C			UNKNOWN
Initial or Prolonged	Bone Disorder		Piroxicam	C			UNKNOWN
Disability	Cerebrovascular Accident		[Therapy				
	Diabetes Mellitus		Unspecified]	C			UNKNOWN
	Dyspnoea		Hydrochlorothiazide	C			UNKNOWN

	Feeling Abnormal	Verapamil	C
UNKNOWN			
	Hypertension	Fluoxetine	C
UNKNOWN			
	Renal Failure	Insulin	C
UNKNOWN			
	Wheezing	[Therapy Unspecified]	C
UNKNOWN			
		Theophylline	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			
		Metformin	C
UNKNOWN			
		Skelaxin	C
UNKNOWN			
		Nabumetone	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Diclofenac Potassium	C
UNKNOWN			
		Flovent	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569795-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03031
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prozac	C				
UNKNOWN								

Date:02/03/05ISR Number: 4569796-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Epididymitis		Aspirin	C		ORAL		
Disability			Diclofenac	C				
UNKNOWN								
Other								

Date:02/03/05ISR Number: 4569799-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia							
Disability	Back Pain							
Other	Buttock Pain							
	Coronary Artery Disease							
	Dysphonia							
	Intervertebral Disc							
	Protrusion							
	Muscle Spasms							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Pain In Extremity							
	Rotator Cuff Syndrome							
	Tendonitis							

Date:02/03/05ISR Number: 4569803-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00984
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			Flovent	C			UNKNOWN	
			Serevent	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Centrum	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Metoclopramide Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569804-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03738
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL
	Escherichia Bacteraemia					
	Escherichia Urinary Tract					
	Infection					
	Medication Error					

Date:02/03/05ISR Number: 4569805-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00471
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY						
Initial or Prolonged	Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
	Staphylococcal Infection		Naloxone			
	Urinary Tract Infection		Hydrochloride And			
	Vertebral Artery		Tilidine			
	Occlusion		Hydrochloride	C		ORAL
			Amitriptyline			
			Hydrochloride	C		ORAL
			Diclofenac Sodium	C		
UNKNOWN						

Date:02/03/05ISR Number: 4569806-2Report Type:Expedited (15-DaCompany Report #BE-MERCK-0411BEL00042
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
1647 DAY						
Initial or Prolonged	Aortic Aneurysm		Acetaminophen And			
Disability	Atrial Fibrillation		Codeine Phosphate	C		
UNKNOWN						
Other	Dyspnoea		Metildigoxin	C		ORAL
	General Physical Health		Bisoprolol Fumarate	C		ORAL
	Deterioration		Lisinopril	C		ORAL

Myocardial Infarction
Supraventricular
Extrasystoles

Date:02/03/05ISR Number: 4569807-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Angiopathy		[Therapy					
	Cardiac Arrest		Unspecified]	C				
	Overdose							

Date:02/03/05ISR Number: 4569808-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00739
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Coronary Syndrome
Hospitalization -	Arthralgia
Initial or Prolonged	Back Pain
	Coronary Artery
	Atherosclerosis

	Hypercholesterolaemia Myocardial Infarction Sinus Bradycardia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Zoloft	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Coreg	C			UNKNOWN	
			Avapro	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Detrol La	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Ubidecarenone	C			UNKNOWN	
			Arimidex	C			UNKNOWN	
			Benadryl	C			UNKNOWN	

Date:02/03/05ISR Number: 4569809-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00400
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569810-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0501ESP00048
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Acute Myocardial	Vioxx	PS	Merck & Co., Inc	
UNKNOWN					
Other	Infarction				
	Death				

Date:02/03/05ISR Number: 4569811-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0501NLD00045
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Fluticasone					
Other	Hypertension		Propionate	C				
UNKNOWN								
	Myocardial Infarction							

Date:02/03/05ISR Number: 4569812-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00239
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569813-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01938
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Xanax	C				
UNKNOWN								
Initial or Prolonged			Zoloft	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569814-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00084
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Candesartan Cilexetil And Hydrochlorothiazide	C			UNKNOWN	
	Renal Cell Carcinoma							
	Stage Unspecified							
	Tachycardia		Candesartan Cilexetil And Hydrochlorothiazide	C			UNKNOWN	
			Bisoprolol	C			UNKNOWN	

Date:02/03/05ISR Number: 4569815-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04371
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Ziac	C			UNKNOWN	
Disability	Asthma		Potassium (Unspecified)	C			UNKNOWN	
	Back Pain							
	Bronchospasm		Allegra	C			UNKNOWN	
	Chest Pain		Zocor	C		ORAL		
	Depression		Nexium	C			UNKNOWN	
	Dermatosis							
	Dyspepsia							
	Eustachian Tube Dysfunction							
	Fatigue							
	Folliculitis							
	Gastroenteritis							
	Gravitational Oedema							

Groin Pain
Headache
Hyperlipidaemia
Hypertension
Myalgia
Nausea
Neck Mass
Otitis Media
Pain In Extremity
Pneumonia
Radiculopathy
Rectocele
Rhinitis Allergic
Sinusitis
Tuberculin Test Positive
Upper Respiratory Tract Infection
Urinary Tract Infection
Vision Blurred
Visual Acuity Reduced
Weight Increased

Date:02/03/05ISR Number: 4569824-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Overdose		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/03/05ISR Number: 4569825-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00053
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Ulcer Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Celecoxib	C				
UNKNOWN							325	DAY
			Celecoxib	C		ORAL		
			Candesartan Cilexetil	C				
UNKNOWN								
			Valdecoxib	C				
UNKNOWN								
			Hydrochlorothiazide And Triamterene	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								
			Atorvastatin Calcium	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Ginkgo Biloba Extract	C				
UNKNOWN								

Date:02/03/05ISR Number: 4569826-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02509
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	6	YR
Initial or Prolonged	Cerebrovascular Accident		Coumadin	C		ORAL		
Disability	Scotoma		Aspirin	C		ORAL		
Other	Transient Ischaemic		Heparin	C				
UNKNOWN								
	Attack		Vitamins					
	Vasculitis		(Unspecified)	C		ORAL		
	Visual Disturbance		Zocor	C		ORAL		

Date:02/03/05ISR Number: 4569827-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00065
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Prednisolone	C				
UNKNOWN								
	Ventricular Arrhythmia		Bisoprolol Fumarate	C				
UNKNOWN								
			Methotrexate	C				
PARENTERAL								
			Cilazapril And Hydrochlorothiazide	C				
UNKNOWN								

Date:02/03/05ISR Number: 4569828-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02414
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569829-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569830-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569831-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569832-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569833-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569834-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569835-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04298
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569836-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	354 DAY	
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4569837-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569838-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0501ESP00049
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Other	Death							

Date:02/03/05ISR Number: 4569839-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569840-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569841-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00001
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 18 DAY	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Facial Palsy		Irbesartan	C		ORAL
	Fall		Carvedilol	C		ORAL
	Visual Disturbance		Pravastatin Sodium	C		ORAL
			Aspirin And Magnesium Oxide	C		ORAL
			Acetaminophen And Codeine Phosphate	C		
UNKNOWN						

Date:02/03/05ISR Number: 4569842-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/03/05ISR Number: 4569843-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

Date:02/03/05ISR Number: 4569844-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0502ESP00002
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Dissection Hypersensitivity Phlebitis Subarachnoid Haemorrhage		Vioxx Nonsteroidal Anti-Inflammatory Drug (Unspecified) [Therapy Unspecified]	PS C C	Merck & Co., Inc	ORAL	UNKNOWN UNKNOWN	

Date:02/03/05ISR Number: 4569845-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569846-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04318
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/03/05ISR Number: 4569847-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	

Date:02/03/05ISR Number: 4569850-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00005
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Valdecoxib	C				
UNKNOWN								
	Myocardial Infarction							

Date:02/03/05ISR Number: 4569851-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04139
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death							

Date:02/03/05ISR Number: 4570544-0Report Type:Direct Company Report #CTU 239150
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx 25 Mg	PS				
SEE IMAGE								
Hospitalization -	Increased		Meclizine	C				
Initial or Prolonged	Chest Discomfort		Hydrochlorothiazide	C				
	Dyspnoea							
	Myocardial Infarction							
	Respiratory Tract							
	Congestion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/05ISR Number: 4571935-4Report Type:Direct Company Report #CTU 239204
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx 50 Mg	PS			1 QD	

Date:02/03/05ISR Number: 4571950-0Report Type:Direct Company Report #CTU 239203
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS			25 MG X 1 DAY	1 DAY
Initial or Prolonged	Myocardial Infarction							

Date:02/04/05ISR Number: 4570444-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		435 DAY
Initial or Prolonged	Arthralgia		Darvocet-N	C				UNKNOWN
Disability	Bundle Branch Block Left		Synthroid	C				UNKNOWN
Other	Cardiac Failure		Prevacid	C				UNKNOWN
	Congestive		Accupril	C				UNKNOWN
	Chest Discomfort		Norvasc	C				UNKNOWN
	Cough		Hydrodiuril	C				UNKNOWN
	Diabetes Mellitus		Claritin	C				UNKNOWN

	Dysfunctional Uterine	Ceftin	C
UNKNOWN			
	Bleeding	Combivent	C
UNKNOWN			
	Dyspnoea	Albuterol	C
UNKNOWN			
	Emotional Disorder	Zestril	C
UNKNOWN			
	Injury	Coreg	C
UNKNOWN	581 DAY		
	Ischaemic Cardiomyopathy	Lasix (Furosemide)	C
UNKNOWN			
	Joint Sprain	Aspirin	C
UNKNOWN			
	Muscle Spasms	Prempro	C
UNKNOWN			
	Myocardial Infarction	Theophylline	C
UNKNOWN			
	Nasal Septum Deviation	Metab-O-Lite	C
UNKNOWN			
	Oedema Peripheral		
	Pain In Extremity		
	Pharynx Discomfort		
	Pneumonia		
	Pulmonary Congestion		
	Renal Failure		
	Respiratory Failure		
	Rhinitis Allergic		
	Sinus Congestion		
	Uterine Haemorrhage		
	Wheezing		

Date:02/04/05ISR Number: 4570446-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01585
Age:59 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	153	DAY
			[Composition Unspecified]	C				

UNKNOWN

Date:02/04/05ISR Number: 4570447-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Lopressor	C				
UNKNOWN								
	Neuropathy Peripheral							

Date:02/04/05ISR Number: 4570448-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03788
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:02/04/05ISR Number: 4570449-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Injury Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/04/05ISR Number: 4570450-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00097
Age:31 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Alanine Aminotransferase Increased
	Angina Unstable
	Anxiety
	Arrhythmia
	Arteriospasm Coronary
	Aspartate Aminotransferase Increased
	Atrial Septal Defect
	Blood Alkaline Phosphatase Increased
	Cardiac Failure Congestive
	Coronary Artery Disease

	Coronary Artery Thrombosis						
	Dyslipidaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
	Ischaemic Cardiomyopathy		Arginine Glutamate	C			UNKNOWN
	Joint Sprain		Tyrosine	C			UNKNOWN
	Mitral Valve Incompetence		Vitamin B				
	Supraventricular		(Unspecified)	C			PARENTERAL
	Tachycardia		Vitamins				
	Transaminases Increased		(Unspecified)	C			UNKNOWN
			Garlic Extract	C		ORAL	

Date:02/04/05ISR Number: 4570451-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00770
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL	
	Congenital Eye Naevus		Vioxx	SS	Merck & Co., Inc	ORAL	
	Eye Haemorrhage		Atenolol	C			UNKNOWN
	Facial Palsy		Prinivil	C		ORAL	
	Vitreous Detachment		Lasix (Furosemide)	C			UNKNOWN
	Vitreous Haemorrhage		Aspirin	C			UNKNOWN

Date:02/04/05ISR Number: 4570452-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01647
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Dizziness		Norvasc	C			UNKNOWN
Initial or Prolonged	Nausea		[Therapy				

	Oedema Peripheral	Unspecified]	C
UNKNOWN			
	Paraesthesia	Vitamin E	C
UNKNOWN			
	Spinal Disorder	Ascorbic Acid	C
UNKNOWN			
	Stomach Discomfort	Vitamin B Complex	C
UNKNOWN			

Date:02/04/05ISR Number: 4570462-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00087
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebral Haematoma		Fluindione	SS		ORAL
Initial or Prolonged	Coma		Candesartan			
Other	Drug Interaction		Cilexetil	C		ORAL
	Fall		Cifenline Succinate	C		ORAL
	Hemiplegia		Metoprolol	C		ORAL
	Hypocoagulable State		Metoprolol	C		ORAL
	Hypothermia		Zocor	C		ORAL
	International Normalised		Allopurinol	C		ORAL
	Ratio Increased		Terbutaline Sulfate	C		
RESPIRATORY						
	Rhonchi					
(INHALATION)						
	Urinary Incontinence					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570464-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0411CAN00084
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Prinivil	C		ORAL		
			Betahistine Hydrochloride	C				
			Furosemide	C				
			Levothyroxine Sodium	C				

Date:02/04/05ISR Number: 4570465-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570466-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570469-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04293
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	184 DAY	

Date:02/04/05ISR Number: 4570470-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04272
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prilosec	C				

Date:02/04/05ISR Number: 4570471-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03955
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570472-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04082
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness		Zocor	C		ORAL		
	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570474-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthritis		Cardizem Cd	C				
UNKNOWN								
Disability	Blood Pressure Abnormal		K-Dur	C				
UNKNOWN								
Other	Cardiac Murmur		Accupril	C				
UNKNOWN							18	DAY
	Cardiac Valve Disease		Accupril	C				
UNKNOWN							38	DAY
	Chest Pain		Accupril	C				
UNKNOWN							152	DAY
	Chest Wall Pain		Paxil	C				
UNKNOWN								
	Chronic Obstructive		Paxil	C				
UNKNOWN							42	DAY
	Pulmonary Disease		Paxil	C				
UNKNOWN								
	Coronary Artery Occlusion		Paxil	C				
UNKNOWN							145	DAY
	Depression		Lasix (Furosemide)	C				
UNKNOWN								
	Dysphagia		Lasix (Furosemide)	C				
UNKNOWN								
	Emotional Distress		Lasix (Furosemide)	C				
UNKNOWN								
	Fatigue		Soma	C				
UNKNOWN								
	Gastrooesophageal Reflux		Aleve	C				
UNKNOWN								
	Disease		Nitroglycerin	C				
UNKNOWN								
	Haematoma		Aspirin	C				
UNKNOWN								
	Heart Rate Decreased		Percocet	C				
UNKNOWN								
	Herpes Zoster		Ferrous Sulfate	C				
UNKNOWN								
	Hypertension		Tylenol Extra					
	Hypotension		Strength	C				
UNKNOWN								
	Insomnia							

Irritable Bowel Syndrome
Myocardial Infarction
Oedema Peripheral
Oesophageal Spasm
Pain
Rash Pruritic
Restless Legs Syndrome
Somnolence
Syncope
Tremor

Date:02/04/05ISR Number: 4570478-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03520
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Amnesia
Disability	Anxiety
Other	Arthralgia
	Asthenia
	Back Pain
	Bronchitis
	Cerebrovascular Accident
	Constipation
	Cough
	Depression
	Diarrhoea
	Dysphagia
	Ear Pain
	Fall
	Fatigue
	Haematochezia
	Haemorrhoids
	Headache

	Hot Flush						
	Hypersensitivity						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Irritable Bowel Syndrome		Bextra	C				UNKNOWN
	Mouth Ulceration							
	Muscle Spasms							
	Muscle Strain							
	Myalgia							
	Nasal Sinus Drainage							
	Nausea							
	Neck Pain							
	Neuropathy							
	Panic Attack							
	Pharyngitis							
	Pharyngolaryngeal Pain							
	Rash Pustular							
	Systemic Lupus							
	Erythematosus							
	Upper Respiratory Tract							
	Infection							

Date:02/04/05ISR Number: 4570482-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03988
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Lasix (Furosemide)	C				UNKNOWN
Other	Parathyroid Tumour Benign		Diovan	C				UNKNOWN

Date:02/04/05ISR Number: 4570483-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04295
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570484-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00022
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570486-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570487-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04374
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Tuberculosis Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570488-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04296
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570489-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570490-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
			Vioxx	SS	Merck & Co., Inc	ORAL	4 YR	

Date:02/04/05ISR Number: 4570493-8Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased Diabetes Mellitus Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04367
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Sudden Death					

Date:02/04/05ISR Number: 4570923-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Atrial Fibrillation		Dilacor Xr	C		
Initial or Prolonged UNKNOWN	Atrial Flutter		Cozaar	C		
Other UNKNOWN	Cardiac Failure		Aspirin	C		
	Congestive		Furosemide	C		
UNKNOWN						
	Coronary Artery Disease		Cordarone	C		
UNKNOWN						
	Cough		Lipitor	C		
UNKNOWN						
	Injury					
	Mitral Valve Incompetence					
	Myocardial Infarction					
	Oedema Peripheral					
	Osteoarthritis					
	Rhinitis Allergic					
	Tricuspid Valve Incompetence					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570953-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02618
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bronchitis		Benicar	C		ORAL		
Initial or Prolonged	Cardiac Valve Disease		Clarinex	C		ORAL		
Disability	Chest Pain		Parafon Forte	C				
UNKNOWN								
	Dyspepsia		Klonopin	C				
UNKNOWN								
	Dyspnoea		Elavil	C				
UNKNOWN								
	Heart Rate Irregular		Darvocet-N	C				
UNKNOWN								
	Myocardial Infarction		Singulair	C				
UNKNOWN								
	Nephrolithiasis		Atrovent	C				
UNKNOWN								
			Tequin	C				
UNKNOWN								

Date:02/04/05ISR Number: 4570956-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02542
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cluster Headache		Ortho-Novum 7/7/7	C				
UNKNOWN								
	Depression		Zoloft	C				
UNKNOWN								
	Diplopia		Paxil	C				
UNKNOWN								
	Dizziness		Trazodone					
	Eyelid Retraction		Hydrochloride	C				
UNKNOWN								
	Fibromyalgia		Lithobid	C				
UNKNOWN								
	Gastrooesophageal Reflux		Vitamin D					

	Disease	(Unspecified)	C
UNKNOWN			
	Headache	Calcium	
	Hemianopia Homonymous	(Unspecified)	C
UNKNOWN			
	Intervertebral Disc	Vicodin Tablets	C
UNKNOWN			
	Degeneration	Ultram	C
UNKNOWN			
	Lid Lag	Oxycontin	C
UNKNOWN			
	Nausea	Methadone Hcl	C
UNKNOWN			
	Osteomalacia	Advil	C
UNKNOWN			
	Visual Disturbance	Tylenol	C
UNKNOWN			

Date:02/04/05ISR Number: 4570958-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Barrett'S Oesophagus
	Blood Pressure Increased
	Bronchitis
	Chest Pain
	Diarrhoea
	Emotional Distress
	Erosive Oesophagitis
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Hepatic Cyst
	Hiatus Hernia
	Hypercholesterolaemia
	Hypersensitivity
	Hypertriglyceridaemia

	Joint Sprain						
	Metal Poisoning						
	Polycythaemia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY

Date:02/04/05ISR Number: 4570962-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00277
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenocarcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia							
	Colon Cancer							
	Dizziness							
	Gastritis							
	Hypertension							
	Insomnia							
	Muscle Spasms							
	Pain							
	Pleurisy							
	Pneumonia							
	Renal Failure							
	Urinary Tract Infection							

Date:02/04/05ISR Number: 4570964-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acarodermatitis
	Aggression
Other	Anaemia
	Asthenia
	Atrial Fibrillation
	Blood Testosterone Decreased
	Cardiac Failure
	Cholecystitis
	Cholelithiasis
	Chronic Hepatitis

Clostridium Colitis
Coagulopathy
Coma
Confusional State
Cough
Decreased Appetite
Emotional Distress
Erectile Dysfunction
Eye Infection
Fatigue
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Haemodialysis
Headache
Hepatic Cirrhosis
Hepatic Failure
Hepatic Necrosis
Hiatus Hernia
Hyperkalaemia

		Hypertension					
		Hypotension					
		Hypoxia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Impaired Gastric Emptying		Vioxx	PS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc Disorder					
		Lethargy					
		Myocardial Infarction					
		Nasal Septum Deviation					
		Nausea					
		Platelet Count Decreased					
		Pleural Effusion					
		Pneumonia					
		Rash					
		Refractory Anaemia					
		Renal Cyst					
		Renal Disorder					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Respiratory Disorder					
		Respiratory Failure					
		Sepsis					
		Spinal Disorder					
		Tachycardia					
		Testicular Mass					
		Treatment Noncompliance					
		Vomiting					
		Weight Decreased					
		Weight Increased					

Date:02/04/05ISR Number: 4570969-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00705
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN		Chest Pain		Nexium	C		
Initial or Prolonged Disability UNKNOWN		Overdose		Vicodin Tablets	C		ORAL
				Naproxen	C		

Date:02/04/05ISR Number: 4570970-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00412
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	803 DAY	
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY	
	Angina Pectoris		Voltaren	C			UNKNOWN	
	Atrial Fibrillation		Prednisone	C			UNKNOWN	
	Brain Death		Dexamethasone	C			INTRAMUSCULAR	
	Conduction Disorder		Nicotrol	C			RESPIRATORY (INHALATION)	
	High Density Lipoprotein Decreased		Influenza Virus Vaccine (Unspecified)	C			UNKNOWN	
	Low Density Lipoprotein Increased							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570971-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00038
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Celecoxib	C				
UNKNOWN								

Date:02/04/05ISR Number: 4570973-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Depression							
	Disturbance In Attention							
	Dizziness							
	Ischaemic Cerebral Infarction							
	Lacunar Infarction							
	Tinnitus							

Date:02/04/05ISR Number: 4570974-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04089
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/04/05ISR Number: 4570976-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Injury
Thrombosis

Date:02/04/05ISR Number: 4570977-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00624
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Date:02/04/05ISR Number: 4570978-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04087
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nitroquick	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570980-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00511
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prednisone	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Prinivil	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:02/04/05ISR Number: 4570981-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00275
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blindness Blindness Unilateral Contusion Fall Febrile Convulsion Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570982-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04094
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Abdominal Pain Upper Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:02/04/05ISR Number: 4570984-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04368
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged			[Therapy Unspecified]	C				
Disability								
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:02/04/05ISR Number: 4570985-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04557
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Accolate	C				
UNKNOWN								
Initial or Prolonged			Potassium (Unspecified)	C				
Disability								
UNKNOWN								

Date:02/04/05ISR Number: 4570986-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04310
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570987-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Hypertension Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570988-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/04/05ISR Number: 4570989-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04312
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570990-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00004
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	329	DAY

Initial or Prolonged

Date:02/04/05ISR Number: 4570991-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04369
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy Unspecified]	C				
Disability								
UNKNOWN								

Date:02/04/05ISR Number: 4570992-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00002
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin And Magnesium Oxide	C		ORAL		
			Tolterodine Tartrate	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL		
			Trimeprazine Tartrate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4570993-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570994-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570995-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00082
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570996-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/04/05ISR Number: 4570997-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/04/05ISR Number: 4570998-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	595	DAY

Date:02/04/05ISR Number: 4570999-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00024
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Levothyroxine Sodium	C				
UNKNOWN								

Date:02/04/05ISR Number: 4571011-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04118
Age:63 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Digoxin	C			UNKNOWN	
		Synthroid	C			UNKNOWN	
		Warfarin	C			UNKNOWN	
		Lexapro	C			UNKNOWN	

Date:02/04/05ISR Number: 4571012-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00530
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc		UNKNOWN	383 DAY
Initial or Prolonged	Aortic Valve Sclerosis		Prinivil	C			UNKNOWN	
Other	Back Pain		Atenolol	C			UNKNOWN	
	Cardiac Disorder		Aspirin	C			UNKNOWN	
	Cardiac Failure		Crestor	C			UNKNOWN	
	Congestive		[Therapy					
	Chest Discomfort		Unspecified]	C			UNKNOWN	
	Chest Wall Pain							
	Coronary Artery Disease							
	Drug Ineffective							
	Fibromyalgia							
	Haematoma							
	Hyperlipidaemia							
	Intervertebral Disc Degeneration							

Muscle Spasms
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Pulmonary Hypertension
Ventricular Hypertrophy

Date:02/04/05ISR Number: 4571013-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Back Pain
Hospitalization - Initial or Prolonged	Bronchitis
Disability	Cardiomegaly
Other	Chronic Obstructive Pulmonary Disease
	Convulsion
	Drug Interaction
	Emphysema
	Facial Bones Fracture
	Gastrooesophageal Reflux Disease
	Hepatitis C
	Hiatus Hernia
	Hypercholesterolaemia
	Intervertebral Disc Protrusion

	Muscle Spasms						
	Musculoskeletal Discomfort	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
	Overdose		Neurontin	C		ORAL	
	Peptic Ulcer		Wellbutrin	C			UNKNOWN
	Radiculopathy						
	Road Traffic Accident						

Date:02/04/05ISR Number: 4571014-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/04/05ISR Number: 4571015-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00111
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	27 MON

Date:02/04/05ISR Number: 4571016-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Hypertension		Zocor	C			UNKNOWN
Disability	Renal Disorder						

Date:02/04/05ISR Number: 4574078-9Report Type:Expedited (15-DaCompany Report #2005021852
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Bextra (Valdecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:02/04/05ISR Number: 4574458-1Report Type:Expedited (15-DaCompany Report #2004118037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemarthrosis	Consumer	Bextra (Valdecoxib)	PS		ORAL	20 MG (20 MG, 1 IN 1 D),	ORAL
	Muscle Spasms							
			Rofecoxib (Rofecoxib)	SS		ORAL		ORAL
			Vitamins (Vitamins)	C				
			Glucosamine W/Chondroitin Sulfates (Ascorbic Acid, Chondroitin Sulfate, Glucosamine	C				
			Hyzaar (Hydrochlorothiazide, Losartan Potassium)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/05ISR Number: 4574466-0Report Type:Expedited (15-DaCompany Report #2004094260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety	Consumer	Celebrex (Celecoxib)	PS				
	Cerebrovascular Accident		Rofecoxib					
	Fear		(Rofecoxib)	SS				
	Pain							

Date:02/07/05ISR Number: 4571478-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		611 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		611 DAY
Initial or Prolonged	Bipolar Disorder		Ativan	C				UNKNOWN
Disability	Blood Cholesterol		Hydrochlorothiazide	C				UNKNOWN
	Increased Blood Triglycerides		Hydrocodone Hydrochloride	C				UNKNOWN
	Increased		Maxzide	C				UNKNOWN
	Cervicobrachial Syndrome		Neurontin	C				UNKNOWN
	Diarrhoea		Remeron	C				UNKNOWN
	Emotional Distress		Trazodone Hydrochloride	C				UNKNOWN
	Fatigue							
	Intervertebral Disc		Tricor	C				UNKNOWN
	Degeneration		Zanaflex	C				UNKNOWN
	Menstrual Disorder		Midrin	C				UNKNOWN
	Myofascial Pain Syndrome		Lidoderm	C				UNKNOWN
	Nerve Injury							
	Oedema Peripheral							

Pelvic Pain
Renal Failure
Renal Failure Acute
Tibia Fracture

Date:02/07/05ISR Number: 4571626-XReport Type:Expedited (15-DaCompany Report #200510328FR
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxia		Amarel	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Arrhythmia							
	Cardiac Arrest		Visken	SS		ORAL		
	Cerebral Disorder		Omix	SS		ORAL		
	Coma		Vioxx	SS		ORAL		
	Electroencephalogram Abnormal		Metformine	SS		ORAL		
	General Physical Health Deterioration							
	Nosocomial Infection							
	Pneumonia							
	Sepsis							
	Superinfection							

Date:02/07/05ISR Number: 4571759-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00966
Age:30 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Coronary Syndrome

		Anxiety Arterial Thrombosis Asthenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bronchitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
		Chest Discomfort		Ovcon	C		
UNKNOWN							
		Chest Pain		Ibuprofen	C		
UNKNOWN							
		Constipation Coronary Artery Occlusion		Amitriptyline Hydrochloride	C		
UNKNOWN							
		Diabetes Mellitus Diarrhoea Dizziness Electrocardiogram Change Fatigue Feeling Abnormal Gastrooesophageal Reflux Disease Helicobacter Infection Herpes Zoster Hyperhidrosis Hyperlipidaemia Hypersensitivity Limb Discomfort Myocardial Infarction Nausea Pain In Extremity Palpitations Panic Attack Paraesthesia Protein S Deficiency Rash Sinusitis Sweat Gland Infection Vomiting					

Date:02/07/05ISR Number: 4571771-9Report Type:Expedited (15-DaCompany Report #US-MERCK-00072278
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
Other	Bundle Branch Block		Amaryl	C			UNKNOWN
	Gastric Ulcer		Norvasc	C		ORAL	
	Hyperglycaemia						
	Laboratory Test Abnormal						
	Myocardial Infarction						
	Nausea						
	Pain In Extremity						
	Tachycardia						
	Vomiting						

Date:02/07/05ISR Number: 4571772-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02482
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Other	Cerebral Haemorrhage		Synthroid	C				UNKNOWN
	Cerebrovascular Accident		Plavix	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Lotrel	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4571783-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00926
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Drug Reaction Adverse Event Anxiety Arthralgia Back Pain Balance Disorder Bronchitis Bursitis Cardiac Disorder Chest Pain Concussion Constipation Contusion Deafness Depression Diplopia Dysphagia Dyspnoea Extrasystoles Femur Fracture Gastritis Haematochezia Haemorrhoids Headache Hyperhidrosis Hypertension Insomnia Intervertebral Disc Degeneration Intestinal Functional Disorder Meniscus Lesion Muscle Spasms Muscle Strain Myalgia Neck Pain Nervous System Disorder Neuroma Nocturia Personality Change Polyp Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Radicular Syndrome
Rash
Renal Failure
Restless Legs Syndrome
Road Traffic Accident
Sleep Apnoea Syndrome
Snoring
Stress
Therapy Non-Responder
Tinnitus
Vertigo Labyrinthine
Weight Increased

Date:02/07/05ISR Number: 4571789-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02498
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable Atrial Fibrillation Back Pain Bronchitis Chest Wall Pain Coronary Artery Atherosclerosis Coronary Artery Disease Dilatation Atrial Dilatation Ventricular Dyspnoea Exertional Hypercholesterolaemia Hyperhidrosis Ischaemic Cardiomyopathy Mitral Valve Incompetence Myocardial Infarction Nausea Oesophagitis Pleural Effusion Productive Cough Supraventricular Extrasystoles Tricuspid Valve Incompetence Ventricular Dysfunction Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4571806-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00517
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:02/07/05ISR Number: 4571810-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00268
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Cimetidine	C				
UNKNOWN								
Initial or Prolonged	Diabetes Mellitus		Skelaxin	C				
UNKNOWN								
	Drug Hypersensitivity		Zoloft	C				
UNKNOWN								
	Emphysema		Amitriptyline					
	Gastric Haemorrhage		Hydrochloride	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:02/07/05ISR Number: 4571813-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01120
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Areflexia
	Bursitis

		Cerebrovascular Accident					
		Confusional State					
		Diverticulum Intestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
15	MON						
		Eructation		Pravachol	C		
UNKNOWN							
		Increased Tendency To		Vitamins			
		Bruise		(Unspecified)	C		ORAL
		Localised Infection		Hydrochlorothiazide	C		ORAL
		Mitral Valve Incompetence		Methotrexate	C		ORAL
		Paronychia		Folic Acid	C		ORAL
		Pleural Fibrosis		Premphase	C		ORAL
804	DAY						
		Polyneuropathy		Calcium			
		Rheumatoid Arthritis		(Unspecified)	C		
UNKNOWN							
		Tricuspid Valve		Folic Acid	C		ORAL
		Incompetence		Plaquenil	C		
UNKNOWN							
		Ventricular Dysfunction		Lipitor	C		ORAL
366	DAY						
				Tylenol	C		ORAL

Date:02/07/05ISR Number: 4571814-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/07/05ISR Number: 4571816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00262
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Humalog	C		
UNKNOWN						
	Localised Infection		Cimetidine	C		
UNKNOWN						

	Pain In Extremity		Metformin	C		
UNKNOWN						
	Urinary Tract Infection		Verapamil	C		
UNKNOWN						
	Uterine Leiomyoma		Metoclopramide	C		
UNKNOWN						
			Benazepril Hydrochloride	C		
UNKNOWN						

Date:02/07/05ISR Number: 4571819-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04279
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		[Therapy Unspecified]	C				
	Dizziness							
	Fatigue							
	Hypotension							
	Syncope							

Date:02/07/05ISR Number: 4571820-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Aortic Stenosis
	Cardiac Disorder
	Cardiac Valve Disease
	Coronary Artery Disease

		Gastrointestinal Haemorrhage					
		Post Procedural Complication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
		Respiratory Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
225	DAY						
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
225	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						

Date:02/07/05ISR Number: 4571823-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:65 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Allopurinol	C		ORAL
		Diplopia		Nitrendipine	C		ORAL
		Visual Disturbance		Aspirin	C		ORAL

Date:02/07/05ISR Number: 4571825-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03171
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
13	MON						
Hospitalization - Initial or Prolonged							
Disability							

Date:02/07/05ISR Number: 4571827-0Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00087
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Hospitalization - Initial or Prolonged	Blood Glucose Decreased		Fluindione	SS		ORAL		
	Blood Pressure Systolic Increased		Candesartan Cilexetil	C		ORAL		
	Cerebral Haematoma		Cifenline Succinate	C		ORAL		
	Cerebrovascular Accident		Metoprolol	C		ORAL		
	Coma		Metoprolol	C		ORAL		
	Drug Interaction		Zocor	C		ORAL		
	Hypothermia		Allopurinol	C		ORAL		
	International Normalised Ratio Increased		Terbutaline Sulfate	C		RESPIRATORY (INHALATION)		
	Rhonchi							

Date:02/07/05ISR Number: 4571830-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01541
Age:65 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction Pulmonary Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4571832-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vitamins (Unspecified)	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Octreotide	C				
UNKNOWN								

Date:02/07/05ISR Number: 4571833-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01966
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Idiopathic Thrombocytopenic Purpura		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Atenolol	C				
Initial or Prolonged UNKNOWN	Memory Impairment		Lexapro	C				
Disability UNKNOWN			Zocor	C				

Date:02/07/05ISR Number: 4571835-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4571838-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00233
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		2 YR

Date:02/07/05ISR Number: 4571841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1111 DAY

Date:02/07/05ISR Number: 4571853-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4571898-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572469-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00574
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:02/07/05ISR Number: 4572470-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
Disability	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	10	DAY
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
	Increased		Lortab	C		ORAL		
	Cerebrovascular Accident		Excedrin					
	Constipation		Extra-Strength	C			UNKNOWN	
	Delusion		Aspirin	C			UNKNOWN	
	Diarrhoea							
	Emotional Distress							
	Ependymoma							
	Headache							
	Herpes Zoster							
	Intervertebral Disc							
	Protrusion							
	Meningitis							
	Muscle Contractions							

Involuntary
Paranoia
Psychotic Disorder
Pyrexia
Stomach Discomfort
Tremor
Venous Thrombosis Limb

Date:02/07/05ISR Number: 4572473-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder
Hospitalization - Initial or Prolonged	Anxiety
Other	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Depression
	Drug Dependence
	Drug Detoxification
	Drug Withdrawal Syndrome
	Dyspepsia
	Facet Joint Syndrome

		Gastric Ulcer					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematocrit Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Helicobacter Pylori		Vioxx	SS	Merck & Co., Inc	ORAL
		Identification Test		Zoloft	C		
UNKNOWN							
		Positive		Zoloft	C		
UNKNOWN							
		High Density Lipoprotein		Avalide	C		
UNKNOWN							
		Abnormal		Claritin	C		
UNKNOWN							
		Hypertension		Prozac	C		
UNKNOWN							
		Injury					
		Intervertebral Disc Degeneration					
		Intervertebral Disc Disorder					
		Intervertebral Disc Protrusion					
		Mood Altered					
		Nervousness					
		Osteoarthritis					
		Peptic Ulcer					
		Rhinitis Allergic					
		Sleep Apnoea Syndrome					
		Spondylolisthesis					
		Spondylolysis					

Date:02/07/05ISR Number: 4572474-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
984 DAY							
		Anaemia		Acetaminophen And			
		Atherosclerosis		Hydrocodone			
		Back Pain		Bitartrate	C		
UNKNOWN							
		Cystocele		Wellbutrin	C		ORAL

	Depression	Valium	C		ORAL
	Feeling Drunk	Estradiol	C		ORAL
	Headache	Remeron	C		ORAL
	Hepatitis	Lotensin	C		
UNKNOWN					
	Hypertension	Effexor Xr	C		ORAL
	Liver Disorder	Prilosec	C		
UNKNOWN					
	Nausea	Atacand	C		
UNKNOWN					
	Osteoporosis	Celexa	C		
UNKNOWN					
	Pain In Extremity	Iron (Unspecified)	C		
UNKNOWN					
	Pelvic Prolapse	Diazepam	C		
UNKNOWN					
	Polymyalgia Rheumatica	Celebrex	C		
UNKNOWN					
	Polyneuropathy	Paxil Cr	C		ORAL
	Rectocele	Paxil Cr	C		ORAL
	Renal Failure				
	Rhinitis Seasonal				
	Sinusitis				
	Somnolence				
	Stress Incontinence				
	Tongue Disorder				
	Tremor				
	Vaginitis Atrophic				
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572475-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00774
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Anaemia		Zestril	C		ORAL		
	Arthralgia		Glucophage	C		ORAL		
	Atrial Fibrillation		Methylprednisolone	C				
UNKNOWN								
	Atrial Flutter		Levaquin	C		ORAL		
	Blood Pressure Increased							
	Cardiac Failure Chronic							
	Cardiac Failure							
	Congestive							
	Carotid Bruit							
	Clostridium Colitis							
	Coma							
	Congestive Cardiomyopathy							
	Convulsion							
	Diabetes Mellitus							
	Inadequate Control							
	Diabetic Microangiopathy							
	Diabetic Neuropathy							
	Diarrhoea							
	Diverticulum							
	Dysphonia							
	Ear Infection							
	Fibrosis							
	Furuncle							
	Gastrointestinal							
	Haemorrhage							
	Graft Thrombosis							
	Hyperammonaemia							
	Hypercholesterolaemia							
	Hyperkalaemia							
	Hyponatraemia							
	Hypotension							
	Hypoxic Encephalopathy							
	Insomnia							
	Ischaemia							
	Ischaemic Hepatitis							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Pain In Extremity							
	Polyp							
	Pulmonary Hypertension							

Pyrexia
Renal Failure
Renal Failure Acute
Sinus Arrest
Sinus Bradycardia
Thrombocytopenia
Urinary Tract Infection
Vertigo
Vocal Cord Paralysis
Vomiting
Weight Decreased
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572476-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Asthma		Diflunisal	C			UNKNOWN	
	Atherosclerosis		Ultram	C			UNKNOWN	
	Back Injury		Rebetol	C			UNKNOWN	
	Blood Cholesterol		Allegra	C			UNKNOWN	
	Increased		Soma	C		ORAL		
	Brain Neoplasm		Premarin	C			UNKNOWN	
	Cardiomegaly		Darvocet-N	C			UNKNOWN	
	Carotid Artery Occlusion		Accupril	C			UNKNOWN	
	Cerebral Artery		Wellbutrin	C			UNKNOWN	
	Thrombosis		Estratest	C			UNKNOWN	
	Cerebral Infarction		Rebetron	C			UNKNOWN	3 DAY
	Cerebrovascular Accident							
	Chest Discomfort							
	Chest Pain							
	Concussion							
	Constipation							
	Contusion							
	Depression							
	Drug Abuser							
	Dry Mouth							
	Dysphonia							
	Excoriation							
	Fall							
	Fatigue							
	Gastrointestinal Haemorrhage							
	Gastrooesophageal Reflux Disease							
	Hyperlipidaemia							

Ischaemic Stroke
Laceration
Limb Injury
Macrocytosis
Melaena
Microcytic Anaemia
Myalgia
Neurogenic Bladder
Oedema Peripheral
Orthostatic Hypotension
Pain
Pain In Extremity
Pneumonia
Polydipsia
Polyuria
Pulmonary Congestion
Skin Striae
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation
Tibia Fracture
Urinary Incontinence
Urinary Tract Infection
Weight Increased

Date:02/07/05ISR Number: 4572477-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00819
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Biliary Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Amoxicillin	C			UNKNOWN	
	Blood Pressure Diastolic		Lortab	C			UNKNOWN	
	Increased							
	Bronchitis							
	Bronchitis Acute							
	Cardiomegaly							
	Chills							
	Diarrhoea							
	Haemarthrosis							
	Hand Fracture							
	Heart Rate Increased							
	Hyperkeratosis							
	Hypertension							
	Hypoaesthesia							
	Hypokalaemia							
	Influenza							
	Injury							
	Monarthritis							
	Muscle Spasms							
	Oedema Peripheral							
	Osteoarthritis							
	Pain In Extremity							
	Pharyngolaryngeal Pain							
	Postoperative Infection							
	Pyrexia							
	Sinusitis							
	Skin Ulcer							
	Tinea Pedis							
	Toe Deformity							
	White Blood Cell Count Increased							

Date:02/07/05ISR Number: 4572480-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01740
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Accident
	Acute Myocardial Infarction
	Anxiety
	Arthralgia
	Arthropathy
	Atrial Fibrillation
	Blood Alkaline Phosphatase Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Cardiac Arrest
	Cardiomegaly
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis

		Cystitis					
		Depression					
		Dermatitis Contact	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
26	MON						
		Inadequate Control		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetic Nephropathy		Vioxx	SS	Merck & Co., Inc	ORAL
26	MON						
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vicodin Tablets	C		
UNKNOWN							
		Disease		Clonidine	C		
UNKNOWN							
		General Physical Health					
		Deterioration					
		Hepatic Enzyme Increased					
		Hepatic Steatosis					
		Hypercholesterolaemia					
		Hypertension					
		Insomnia					
		Joint Sprain					
		Migraine					
		Musculoskeletal Disorder					
		Nausea					
		Pernicious Anaemia					
		Productive Cough					
		Pulmonary Congestion					
		Rash					
		Sinusitis					
		Therapy Non-Responder					
		Upper Respiratory Tract					
		Infection					
		Ventricular Fibrillation					
		Weight Increased					

Date:02/07/05ISR Number: 4572481-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Abscess
Initial or Prolonged	Bundle Branch Block Right
	Crohn'S Disease
	Cyst
	Diarrhoea

Diverticulum Duodenal
Dyspepsia
Emotional Distress
Gastrooesophageal Reflux
Disease
Hiatus Hernia
Ileal Ulcer
Ileitis
Intervertebral Disc
Degeneration
Large Intestinal
Obstruction
Large Intestinal Ulcer
Large Intestine
Perforation
Metabolic Acidosis
Multi-Organ Failure
Necrotising Colitis
Osteoarthritis
Pleural Effusion

	Renal Cortical Necrosis						
	Renal Cyst						
	Renal Failure Acute	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Tubular Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY
	Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL	15 DAY
	Septic Shock		Vasotec	C		ORAL	
	Small Intestine Ulcer		Vasotec	C		ORAL	
	Ureteral Disorder		Lipitor	C			UNKNOWN
	Vasospasm		Ecotrin	C		ORAL	
	Wound Infection		Hydrochlorothiazide	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Relafen	C			UNKNOWN
			Ziac	C			UNKNOWN
			Zebeta	C			UNKNOWN

Date:02/07/05ISR Number: 4572482-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA02691
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability							

Date:02/07/05ISR Number: 4572483-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Unstable
Other	Anxiety
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome

Chest Discomfort
Chest Pain
Cholelithiasis
Coronary Artery
Atherosclerosis
Depression
Dizziness
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Fibromyalgia
Gastrooesophageal Reflux
Disease
Hyperhidrosis
Hypertension
Mitral Valve Prolapse
Myocardial Infarction
Nausea
Neuropathy
Orthopnoea
Osteoporosis
Pain
Palpitations
Panic Attack
Paraesthesia
Platybasia

		Uterine Leiomyoma Vaginal Haemorrhage Vertigo Positional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL
284	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
284	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Prevacid	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Estradiol	C		ORAL
				Clonazepam	C		
UNKNOWN							
				Vantin	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Sulfamethoxazole And Trimethoprim	C		
UNKNOWN							
				Serzone	C		ORAL
336	DAY						
				Serzone	C		ORAL
				Albuterol	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Cephalexin	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Cyanocobalamin	C		
PARENTERAL							

	Cyanocobalamin	C	
PARENTERAL			
	Remeron	C	
UNKNOWN			
	Aciphex	C	
UNKNOWN			
	Tequin	C	
UNKNOWN			
	Diovan	C	ORAL
	Verapamil Msd Lp	C	ORAL
	A.S.A.	C	ORAL
	A.S.A.	C	ORAL
	Prometrium	C	ORAL
	Mobic	C	ORAL
	Promethazine	C	ORAL

Date:02/07/05ISR Number: 4572484-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Atelectasis
	Atrial Fibrillation
	Blood Pressure Increased
	Bronchitis
	Cardiac Failure
	Congestive
	Chest Pain
	Congestive Cardiomyopathy
	Convulsion
	Dizziness
	Hypercholesterolaemia
	Hyperlipidaemia
	Irritable Bowel Syndrome
	Nasopharyngitis

		Osteoarthritis Palpitations Squamous Cell Carcinoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia Viral Myocarditis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Estrace	C		
UNKNOWN				Aspirin	C		
UNKNOWN				Allegra	C		
UNKNOWN				Hyoscyamine	C		
UNKNOWN				Elavil	C		
UNKNOWN				Diovan	C		
UNKNOWN				[Therapy Unspecified]	C		
UNKNOWN				Robitussin-Dm	C		
UNKNOWN							

Date:02/07/05ISR Number: 4572485-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01731
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -	3 DAY	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	3 DAY	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Arthritis Asthenia Blood Glucose Abnormal Bursitis Cerebrovascular Accident Difficulty In Walking Drug Intolerance Hyperlipidaemia Hypertension Lumbar Spinal Stenosis Otorrhoea Rotator Cuff Syndrome Tremor		Tylenol Extra Strength	C		ORAL
				Robitussin	C		ORAL

Urinary Tract Infection
Viral Infection
Vitreous Floaters

Date:02/07/05ISR Number: 4572486-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00075
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness							
	Inflammation							
	Sudden Hearing Loss							
	Tinnitus							
	Tooth Disorder							

Date:02/07/05ISR Number: 4572487-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Abdominal Pain
Other	Acute Myocardial Infarction
	Adenomatous Polyposis Coli

Adverse Event
Anaemia
Angina Pectoris
Angioneurotic Oedema
Arthralgia
Barrett'S Oesophagus
Blood Cholesterol
Increased
Blood Creatine
Phosphokinase Mb
Increased
Bone Density Decreased
Breast Cyst
Burning Sensation
Cataract Operation
Cerebrovascular Accident
Cerebrovascular Disorder
Chest Discomfort
Chest Pain
Colonic Polyp
Constipation
Contusion
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery
Restenosis
Diverticulum Intestinal
Drug Effect Decreased
Drug Ineffective
Dyspepsia
Electrocardiogram St
Segment Depression
Erosive Oesophagitis
Eructation
Fall
Flatulence
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Haematemesis
Haemorrhoids
Hyperhidrosis
Hyperlipidaemia
Hypertension
Hypoaesthesia

Hypothyroidism
Injection Site Reaction
Low Density Lipoprotein
Increased
Lung Disorder
Lung Neoplasm
Lymphangitis
Medication Error
Meniscus Lesion
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oesophageal Ulcer
Osteoarthritis

	Peptic Ulcer					
	Pulmonary Granuloma					
	Rash Erythematous	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
319	DAY					
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
	Troponin Increased		Vioxx	SS	Merck & Co., Inc	ORAL
319	DAY					
	Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
	Ventricular Hypokinesia		Aspirin	C		
UNKNOWN						
			Monopril	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

Date:02/07/05ISR Number: 4572488-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain Upper
Disability	Activities Of Daily
Other	Living Impaired
	Anxiety
	Arthralgia
	Arthritis
	Asthenia
	Asthma
	Back Disorder
	Back Pain
	Bladder Disorder
	Calcinosis
	Cardiac Disorder
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Wall Pain
	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease
	Computerised Tomogram
	Abnormal
	Coronary Artery
	Atherosclerosis

Coronary Artery Disease
Decreased Appetite
Depression
Diarrhoea
Difficulty In Walking
Dizziness
Dyspnoea
Electrocardiogram St-T
Change
Emotional Distress
Enanthema
Excoriation
Face Injury
Feeling Drunk
Flatulence
Gastrooesophageal Reflux
Disease
Hemiparesis
Hepatomegaly
Hyperhomocysteinaemia
Hypertensive Heart

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hypothyroidism							
Injury							
Insomnia							
Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Memory Impairment		Vioxx	SS	Merck & Co., Inc	ORAL		
Movement Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Nausea		Plavix	C			UNKNOWN	
Nervous System Disorder		Flovent	C			RESPIRATORY (INHALATION)	
Nervousness							
Pain		Levoxyl	C			UNKNOWN	
Pruritus		Levoxyl	C			UNKNOWN	
Rash		Tylenol With Codeine #3	C			UNKNOWN	
Renal Failure Chronic							
Swelling Face		Prednisone	C			UNKNOWN	
Ulcer		Advair	C			UNKNOWN	
Upper Respiratory Tract		Monopril	C			UNKNOWN	
Infection		Azmacort	C			UNKNOWN	
Uterine Disorder		Aspirin	C			UNKNOWN	
		Nexium	C			UNKNOWN	
		Ventolin (Albuterol)	C			RESPIRATORY (INHALATION)	
		Ranitidine	C			UNKNOWN	
		Hydroxychloroquine Sulfate	C			UNKNOWN	
		Hydrochlorothiazide	C			UNKNOWN	
		Cozaar	C			UNKNOWN	

Date:02/07/05ISR Number: 4572489-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Arthralgia
Other	Bundle Branch Block Left
	Cardiac Failure Congestive
	Chest Discomfort
	Cough
	Diabetes Mellitus
	Dysfunctional Uterine Bleeding
	Dyspnoea
	Emotional Disorder
	Essential Hypertension
	Injury
	Ischaemic Cardiomyopathy
	Joint Sprain
	Muscle Spasms
	Myocardial Infarction
	Nasal Septum Deviation
	Oedema Peripheral
	Pain In Extremity
	Pharynx Discomfort
	Pneumonia
	Pulmonary Congestion
	Renal Disorder
	Renal Failure Acute
	Respiratory Failure
	Rhinitis Allergic

Dose	Duration	Sinus Congestion Uterine Haemorrhage Wheezing	Report Source	Product	Role	Manufacturer	Route
				Vioxx	PS	Merck & Co., Inc	ORAL
477	DAY						
				Darvocet-N	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Hydrodiuril	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Ceftin	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Coreg	C		
UNKNOWN		581	DAY				
				Lasix (Furosemide)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Theophylline	C		
UNKNOWN							
				Metab-O-Lite	C		
UNKNOWN							

Date:02/07/05ISR Number: 4572490-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00529
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Aspirin	C		ORAL
Disability	Atrial Fibrillation		Hypericin	C		
UNKNOWN						
	Coronary Artery Occlusion					
	Depression					
	Dyspnoea					
	Hot Flush					
	Myocardial Infarction					
	Panic Disorder					
	Restlessness					
	Ventricular Fibrillation					

Date:02/07/05ISR Number: 4572491-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00348
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache		Diclofenac Resinate	SS		ORAL
	Osteoarthritis		Atenolol	C		ORAL
			Chlordiazepoxide Hydrochloride	C		ORAL
			Cyclandelate	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Sumatriptan Succinate	C		ORAL
			Dalteparin Sodium	C		
UNKNOWN						
			Pantoprazole Sodium	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572492-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01683
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Nitrol (Nitroglycerin)	C		ORAL		
	Burning Sensation		Hydrochlorothiazide	C		ORAL		
	Cardiac Disorder		Enalapril Maleate	C		ORAL		
	Chest Pain		Lopressor	C		ORAL		
	Coronary Artery Disease		Ativan	C		ORAL		
	Dyspnoea		Isordil	C		ORAL		
	Faeces Discoloured		Lexapro	C		ORAL		
	Hyperhidrosis							
	Myocardial Infarction							
	Nausea							
	Pain							
	Stress							
	Ulcer Haemorrhage							
	Upper Gastrointestinal Haemorrhage							
	Vomiting							

Date:02/07/05ISR Number: 4572493-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Aspirin	C		ORAL		
Other	Nervous System Disorder		Glyburide	C		ORAL		
	Syncope		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/07/05ISR Number: 4572494-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00101
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Abdominal Pain Upper Diarrhoea Dizziness Faeces Discoloured Fall Fatigue Hepatic Cirrhosis Localised Infection Loss Of Consciousness Rash Renal Cyst	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/07/05ISR Number: 4572495-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00257
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
			Rebetol	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572496-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00847
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		335 DAY
Disability	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		121 DAY
	Cerumen Impaction		Vioxx	SS	Merck & Co., Inc	ORAL		183 DAY
	Facial Bones Fracture							
	Hyperlipidaemia							
	Joint Sprain							
	Liver Disorder							
	Myalgia							
	Renal Disorder							
	Rhinitis Allergic							
	Sinus Headache							
	Sinusitis							
	Stomach Discomfort							
	Syncope							
	Tooth Fracture							
	Upper Respiratory Tract Infection							

Date:02/07/05ISR Number: 4572497-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0410FRA00044
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chronic Lymphocytic		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Leukaemia		Valsartan	C		ORAL		17 DAY
	Petechiae		Omeprazole	C		ORAL		17 DAY
	Thrombocytopenia		Tetrazepam	C		ORAL		17 DAY
			Aspirin And Caffeine And Propoxyphene Hydrochloride	C		ORAL		17 DAY

Date:02/07/05ISR Number: 4572498-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03381
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572499-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01520
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adrenal Adenoma
Hospitalization -	Arteriospasm Coronary
Initial or Prolonged	Asthenia
Other	Atrial Flutter
	Atrioventricular Block
	Autoimmune Thyroiditis
	Back Pain
	Chest Pain
	Dizziness
	Dyspnoea
	Electrocardiogram St-T

		Segment Depression					
		Gallbladder Disorder					
		Headache					
		Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Infiltration		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Pain					
		Palpitations					
		Renal Mass					
		Supraventricular					
		Extrasystoles					
		Supraventricular					
		Tachycardia					
		Tricuspid Valve					
		Incompetence					
		Vertigo					

Date:02/07/05ISR Number: 4572500-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00009
Age:64 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
				Vasotec	C		
UNKNOWN							

Date:02/07/05ISR Number: 4572501-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04514
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:02/07/05ISR Number: 4572502-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04131
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Sudden Death					

Date:02/07/05ISR Number: 4572503-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572504-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00002
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		215 DAY
Initial or Prolonged	Transient Ischaemic Attack		Celiprolol Hydrochloride	C		ORAL		
			Chondroitin Sulfate Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572505-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04511
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diovan Hct	C				
Other			Lipitor	C				
			Toprol Xl Tablets	C				
			Aspirin	C				
			Prilosec	C				

Date:02/07/05ISR Number: 4572506-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04377
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572507-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572508-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	
2 YR							

Date:02/07/05ISR Number: 4572509-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00072
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:02/07/05ISR Number: 4572510-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572511-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572512-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572513-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572514-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00076
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572515-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04424
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening UNKNOWN	Sudden Death		Lipitor	C				
			Procardia	C				
UNKNOWN								

Date:02/07/05ISR Number: 4572516-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572517-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572518-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	943 DAY	

Date:02/07/05ISR Number: 4572520-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00158
Age:77 YR Gender:Female I/FU:I

Outcome
Death
Life-Threatening

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged								
Disability								
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572521-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00216
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572523-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00310
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:02/07/05ISR Number: 4572524-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00274
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	35	DAY
Initial or Prolonged	Overdose		Prevacid	C			UNKNOWN	
Disability								

Date:02/07/05ISR Number: 4572525-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00134
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Labile Blood Pressure		Oxycontin	C		
UNKNOWN	Palpitations		Roxicodone	C		
UNKNOWN			Ritalin	C		
UNKNOWN			Kristalose	C		
UNKNOWN			Tizanidine Hydrochloride	C		

Date:02/07/05ISR Number: 4572527-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00315
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Respiratory Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Swelling Face		[Therapy Unspecified]	C		
UNKNOWN						

Date:02/07/05ISR Number: 4572528-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00178
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Chest Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4572529-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572530-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572531-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00214
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain							
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:02/07/05ISR Number: 4572533-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/07/05ISR Number: 4572535-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00695
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Disability	Abnormal Faeces
	Acute Sinusitis

Adverse Event
Arthralgia
Barrett'S Oesophagus
Benign Duodenal Neoplasm
Blood Pressure Increased
Bronchospasm
Brunner'S Gland
Hyperplasia
Chest Discomfort
Chest Pain
Constipation
Costochondritis
Dermatitis Allergic
Diarrhoea
Duodenal Ulcer
Gastrointestinal Pain
Gastrooesophageal Reflux
Disease
Haematoma
Headache
Helicobacter Infection
Hyperglycaemia
Insomnia

		Lipids Increased					
		Liver Function Test Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Melaena		Vioxx	PS	Merck & Co., Inc	ORAL
		Neck Pain		Prevacid	C		
UNKNOWN							
		Otitis Media		Ultram	C		
UNKNOWN							
		Pain		Norvasc	C		
UNKNOWN							
		Pain In Extremity		Pulmicort	C		
UNKNOWN							
		Pharyngitis		Celebrex	C		
UNKNOWN							
		Pneumonia		Maxzide	C		
UNKNOWN							
		Polytraumatism		Estradiol	C		
UNKNOWN							
		Pyrexia		Singulair	C		
UNKNOWN							
		Rhinitis Allergic		Diovan	C		
UNKNOWN							
		Sensation Of Pressure					
		Sinus Congestion					
		Sinusitis					
		Tendonitis					
		Upper Respiratory Tract Infection					

Date:02/07/05ISR Number: 4572536-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00033
Age:44 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
21 MON							
Other		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
21 MON							

Date:02/07/05ISR Number: 4572537-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00161
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction							
Hospitalization - Initial or Prolonged	Pain							
Disability								

Date:02/07/05ISR Number: 4572538-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	514	DAY

Date:02/07/05ISR Number: 4576351-7Report Type:Expedited (15-DaCompany Report #2005-124819-NL
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism	Foreign	Mirtazapine	PS			15 MG QD NI	
	Thrombosis	Health Professional Other	Rofecoxib	SS		ORAL	1 DF BID ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4576453-5Report Type:Expedited (15-DaCompany Report #2004097552
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Celebrex (Celecoxib)	PS		ORAL	ORAL	
		Health Professional	Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Folic Acid	C				

Date:02/07/05ISR Number: 4578671-9Report Type:Direct Company Report #CTU 239422
Age:25 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS			25MG 2X A DAY	
	Heart Rate Increased							
			Elavil	SS			10MG 1X A DAY	

Date:02/07/05ISR Number: 4578792-0Report Type:Direct Company Report #CTU 239410
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Discomfort		Vioxx 25 Mg	PS			25 MG DAILY	
	Chest Pain							
	Dyspnoea							
	Pain In Extremity							

Date:02/08/05ISR Number: 4574963-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Accident At Work
Disability	Acquired Diaphragmatic Eventration
Other	Acute Respiratory Failure
	Adverse Event
	Angina Pectoris
	Atherosclerosis
	Atrial Fibrillation
	Bipolar Disorder
	Blood Pressure Increased
	Bundle Branch Block Right
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Electrocardiogram Change
	Electrocardiogram Qrs
	Complex Prolonged
	Haemoptysis
	Hypercholesterolaemia
	Hypotension
	Hypoxic Encephalopathy
	Intervertebral Disc
	Protrusion
	Loss Of Consciousness

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Myocardial Infarction Nodal Rhythm Sudden Death					
		Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
536 DAY							
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
536 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Buspar	C		ORAL
405 DAY							
				Lortab	C		ORAL
573 DAY							
				Lortab	C		ORAL
				Ziac	C		ORAL
322 DAY							
				Vicodin Tablets	C		ORAL
				Lipitor	C		ORAL
				Valium	C		ORAL
214 DAY							
				Talwin	C		ORAL
24 DAY							
				Ultram	C		ORAL
9 DAY							
				Skelaxin	C		ORAL
14 DAY							
				Tenyl	C		
UNKNOWN		36 DAY					
				Claritin	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				Carisoprodol	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Hydrochloride	C		
UNKNOWN							
				Mobic	C		
UNKNOWN							

	Hydrocodone Hydrochloride	C
UNKNOWN		
	Altace	C
UNKNOWN		
	Toprol Xl Tablets	C
UNKNOWN		
	Aspirin	C
UNKNOWN		

Date:02/08/05ISR Number: 4574964-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00831
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Anaemia
	Anxiety
	Asthenia
	Asthma
	Atelectasis
	Back Pain
	Breast Cancer Stage I
	Bronchitis Acute
	Chest Pain
	Chronic Sinusitis
	Colonic Polyp
	Crying
	Dehydration
	Depression
	Diarrhoea
	Diverticulum
	Dysphagia
	Erosive Oesophagitis
	Gastritis

		Haemorrhoids					
		Hepatic Steatosis					
		Hot Flush	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperglycaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperthyroidism		Os-Cal	C		ORAL
		Hypokalaemia		Centrum	C		ORAL
		Hypothyroidism		Hydrochlorothiazide			
		Irritable Bowel Syndrome		And Triamterene	C		ORAL
		Lung Neoplasm		Adalat	C		
UNKNOWN							
		Menopause		Zoloft	C		
UNKNOWN							
		Nasal Septum Deviation		Ativan	C		
UNKNOWN							
		Neuropathy		Elavil	C		
UNKNOWN							
		Oedema Peripheral					
		Orthostatic Hypotension					
		Osteoarthritis					
		Polydipsia					
		Polytraumatism					
		Rhinitis Allergic					
		Sciatica					
		Sinus Headache					
		Tachycardia					
		Upper Respiratory Tract					
		Infection					
		Vertigo Positional					
		Vestibular Neuronitis					
		Viral Upper Respiratory					
		Tract Infection					

Date:02/08/05ISR Number: 4574965-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acarodermatitis
Initial or Prolonged	Aggression
Other	Anaemia
	Anxiety
	Atrial Fibrillation
	Back Disorder
	Blood Pressure
	Inadequately Controlled

Blood Testosterone
Decreased
Cardiac Failure
Cholecystitis
Cholelithiasis
Chronic Hepatitis
Clostridium Colitis
Coagulopathy
Coma
Condition Aggravated
Confusional State
Contusion
Decreased Appetite
Depression
Dyspepsia
Emotional Distress
Erectile Dysfunction
Eye Infection
Fatigue
Flank Pain

		Gastrooesophageal Reflux Disease					
		Haemodialysis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Cirrhosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hepatic Failure					
		Hiatus Hernia					
		Hypertension					
		Hypotension					
		Impaired Gastric Emptying					
		Insomnia					
		Intentional Misuse					
		Intervertebral Disc Disorder					
		Lethargy					
		Myocardial Infarction					
		Nasal Septum Deviation					
		Nephropathy					
		Nervousness					
		Oedema Peripheral					
		Platelet Count Decreased					
		Pleural Effusion					
		Pneumonia					
		Rash					
		Rash Generalised					
		Refractory Anaemia					
		Renal Cyst					
		Renal Disorder					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Respiratory Failure					
		Sepsis					
		Suicide Attempt					
		Tachycardia					
		Testicular Mass					
		Weight Decreased					
		Weight Increased					
		White Blood Cell Count Increased					

Date:02/08/05ISR Number: 4574966-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02777
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Darvocet-N	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	

Date:02/08/05ISR Number: 4574968-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00037
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Meningioma							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4574969-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00212
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1385 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1385 DAY
Initial or Prolonged	Atrioventricular Block							
Disability	Complete							

Date:02/08/05ISR Number: 4574970-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03654
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Rectal Haemorrhage							
Initial or Prolonged	Ulcer Haemorrhage							

Date:02/08/05ISR Number: 4574971-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00033
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4574972-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00087
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								

Date:02/08/05ISR Number: 4574973-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Disability							
Other	Myocardial Infarction							

Date:02/08/05ISR Number: 4574974-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00026
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Mirtazapine	C				
UNKNOWN								

Date:02/08/05ISR Number: 4574975-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00126
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Pantoprazole Sodium	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Perindopril Erbumine	C		ORAL		

Silibinin	C		ORAL
Ademetionine Sulfate Tosylate	C		ORAL
Lormetazepam	C		ORAL
Tamsulosin Hydrochloride	C		ORAL
Amylase And Bromelains And Chymotrypsin And Lipase And Pancreatin And	C		ORAL
Aspirin	C		ORAL
Sildenafil Citrate	C		ORAL

Date:02/08/05ISR Number: 4574977-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00006
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		458 DAY

Date:02/08/05ISR Number: 4574979-1Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00261
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Atorvastatin Calcium	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Perindopril Erbumine	C				UNKNOWN
			Metoprolol Tartrate	C				UNKNOWN
			Bendroflumethiazide And Potassium Chloride	C				UNKNOWN

Date:02/08/05ISR Number: 4574980-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00258
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C				
	Arterial Restenosis		Lithium Acetate	C			UNKNOWN	
	Coronary Artery		Lorazepam	C			UNKNOWN	
	Atherosclerosis		Lexapro	C			UNKNOWN	
	Coronary Artery Disease		Doxazosin Mesylate	C			UNKNOWN	
	Dilatation Ventricular		Advair	C			UNKNOWN	
	Hyperlipidaemia		[Therapy Unspecified]	C			UNKNOWN	
	Hypertensive Heart Disease		Prevacid	C			UNKNOWN	
	Ischaemic Cardiomyopathy		Glucotrol	C			UNKNOWN	
	Peripheral Vascular Disorder							
	Renal Impairment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4574981-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00228
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4574982-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00007
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL	807 DAY	
	Complete		Etidronate Disodium	C		ORAL		
	Coronary Artery Stenosis		Methotrexate	C			UNKNOWN	
	Hypotension		Folic Acid	C			UNKNOWN	
	Lung Infiltration		Cyanocobalamin	C			UNKNOWN	
	Myocardial Infarction		Esomeprazole					
			Magnesium	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Zopiclone	C			UNKNOWN	
			Bumetanide	C		ORAL		

Date:02/08/05ISR Number: 4574984-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4574987-0Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00005
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged			Furosemide	C		
UNKNOWN						
			Acetaminophen	C		
UNKNOWN						
			Carbidopa And Levodopa	C		
UNKNOWN						
			Amlodipine Besylate	C		
UNKNOWN						
			Pantoprazole Sodium	C		
UNKNOWN						
			Aminopicoline Camsylate	C		
UNKNOWN						

Date:02/08/05ISR Number: 4574988-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/08/05ISR Number: 4574990-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00148
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4574991-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575135-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00627
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:02/08/05ISR Number: 4575139-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02679
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Norvasc	C		ORAL		
	Constipation		Celebrex	C		ORAL		
	Depression							
	Diarrhoea							
	Eating Disorder							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Halitosis							
	Hiatus Hernia							
	Hypertension							
	Irritable Bowel Syndrome							
	Oesophageal Stenosis							
	Weight Increased							

Date:02/08/05ISR Number: 4575140-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Zoloft	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:02/08/05ISR Number: 4575141-9Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00009
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575143-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4575146-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00045
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575147-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02100
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575149-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502DEU00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Thrombosis Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575151-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575152-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:02/08/05ISR Number: 4575153-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575154-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/08/05ISR Number: 4575155-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4575156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575157-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575159-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575160-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00362
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575161-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00388
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575162-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00398
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lithium Carbonate	C			UNKNOWN	
			Effexor	C			UNKNOWN	

Date:02/08/05ISR Number: 4575163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00609
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Blood Pressure Increased
Other	Bursitis
	Carbuncle
	Cervical Root Pain
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Flatulence
	Hyperlipidaemia
	Hypertension
	Joint Stiffness
	Muscle Spasms

		Myalgia					
		Myocardial Infarction					
		Neuropathy Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Tension Headache		Monopril	C		
UNKNOWN							
		Tinel'S Sign		Estrace	C		
UNKNOWN							
		Ventricular Tachycardia					
		Weight Increased					

Date:02/08/05ISR Number: 4575165-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00532
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/08/05ISR Number: 4575166-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00487
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/08/05ISR Number: 4575167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00458
Age:59 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Chest Pain		Glucotrol	C		
UNKNOWN							
Initial or Prolonged		Dyspnoea					
Disability		Musculoskeletal Disorder					
		Pain In Extremity					

Date:02/08/05ISR Number: 4575168-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575170-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00431
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Effexor	C				
UNKNOWN								

Date:02/08/05ISR Number: 4575171-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00756
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Aortic Valve Sclerosis
Disability	Arthralgia
Other	Autoimmune Thyroiditis
	Binocular Eye Movement Disorder
	Blood Pressure

		Inadequately Controlled Bronchitis Chronic Carpal Tunnel Syndrome Cataract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL
401	DAY						
		Cerebrovascular Accident		Hytrin	C		
UNKNOWN							
		Chest Pain		Estratab	C		
UNKNOWN							
		Cholelithiasis		Ranitidine	C		
UNKNOWN							
		Chronic Fatigue Syndrome		Aspirin	C		
UNKNOWN							
		Cognitive Disorder		Aspirin	C		
UNKNOWN							
		Colonic Polyp		L-Thyroxin	C		
UNKNOWN							
		Coronary Artery Disease		Tagamet	C		
UNKNOWN							
		Depression		Premarin	C		
UNKNOWN							
		Dilatation Atrial Diplopia Diverticulum Dizziness Drug Hypersensitivity Duodenitis Endocarditis Fatigue Gallbladder Disorder Gastritis Gastrooesophageal Reflux Disease Generalised Anxiety Disorder Haematuria Hemianopia Homonymous Herpes Zoster Heterophoria Hypertension Hypertensive Crisis Hypoacusis Hypokalaemia Hyponatraemia Injury Irritable Bowel Syndrome					

Labile Hypertension
Lacunar Infarction
Laryngitis
Microangiopathy
Migraine With Aura
Mitral Valve
Calcification
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Pain In Extremity
Pain In Jaw
Panic Disorder
Rectal Haemorrhage
Retinopathy Hypertensive
Rhinitis Seasonal
Sleep Apnoea Syndrome
Strabismus
Tension Headache
Thalamus Haemorrhage
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Ventricular Hypertrophy

Date:02/08/05ISR Number: 4575173-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00389
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575174-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575176-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00381
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575177-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00070
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged UNKNOWN Disability	Tachycardia Transient Ischaemic Attack		Vioxx Toprol Xl Tablets	PS C	Merck & Co., Inc	ORAL		

Date:02/08/05ISR Number: 4575178-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Bronchitis	Methotrexate	C	ORAL
Disability	Chest Pain	Ibuprofen	C	
UNKNOWN				
	Coronary Artery	Folic Acid	C	
UNKNOWN				
	Atherosclerosis	Zocor	C	ORAL
	Coronary Artery	Nitroquick	C	
UNKNOWN				
	Restenosis	Prilosec	C	
UNKNOWN				
	Emotional Distress	Leucovorin	C	
UNKNOWN				
	Hyperlipidaemia	Darvocet-N	C	ORAL
	Hypertension	Plavix	C	ORAL
	Muscle Spasms	Lopressor	C	ORAL
	Myocardial Infarction			
	Psoriatic Arthropathy			

Date:02/08/05ISR Number: 4575181-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abscess Intestinal
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Arteriospasm Coronary
	Atherosclerosis
	Bundle Branch Block Right
	Cardiac Disorder

	Cardiomyopathy Cervicobrachial Syndrome Chronic Obstructive Pulmonary Disease Congestive Cardiomyopathy Coronary Artery Occlusion Diverticular Perforation Drug Hypersensitivity Fatigue Heart Sounds Abnormal Hyperlipidaemia Leukocytosis Muscle Spasms Myeloproliferative Disorder Myocardial Ischaemia Prostatic Specific Antigen Increased Scar Viral Infection Viral Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY					

Date:02/08/05ISR Number: 4575182-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anal Haemorrhage
Other	Angina Pectoris
	Arthralgia
	Arthropathy
	Breast Cyst
	Breast Haemorrhage
	Bursitis
	Cardiac Disorder
	Chest Discomfort
	Closed Head Injury
	Complex Regional Pain
	Syndrome
	Concussion
	Contusion
	Cubital Tunnel Syndrome
	Depression

Dizziness
Dyspnoea
Dyspnoea Paroxysmal
Nocturnal
Emotional Distress
Epicondylitis
Extrasystoles
Fall
Fatigue
Gingival Disorder
Haematochezia
Haemorrhage
Headache
Heart Rate Irregular
Hypercholesterolaemia
Hypertension
Hypoaesthesia

		Lumbar Spinal Stenosis					
		Mental Disorder					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Pain In Extremity		Vioxx	SS		ORAL
33	DAY						
		Palpitations		Vioxx	SS		ORAL
33	DAY						
		Post-Traumatic Stress		Vitamins			
		Disorder		(Unspecified)	C		
UNKNOWN							
		Relationship Breakdown		Bayer Aspirin	C		ORAL
		Sexual Dysfunction		Bayer Aspirin	C		ORAL
		Sleep Disorder					
		Syncope					
		Synovitis					
		Tachycardia					
		Uterine Cyst					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					
		Vasodilatation					
		Vomiting					

Date:02/08/05ISR Number: 4575185-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Acute Prerenal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Acute Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Acute Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vasotec	C		
UNKNOWN							
		Asthma		Actos	C		
UNKNOWN							
		Atelectasis		Brethine	C		
UNKNOWN							

	Blood Glucose Increased	Lasix (Furosemide)	C
UNKNOWN			
	Cardiac Failure	K-Dur	C
UNKNOWN			
	Congestive	Flexeril	C
UNKNOWN			
	Depression	Altace	C
UNKNOWN			
	Fatigue	Glipizide	C
UNKNOWN			
	Heart Rate Increased		
	Heart Rate Irregular		
	Hypothyroidism		
	Injury		
	Mitral Valve Incompetence		
	Osteoarthritis		
	Pain In Extremity		
	Pericardial Effusion		
	Pneumonia		
	Pulmonary Oedema		
	Respiratory Disorder		
	Respiratory Failure		
	Sinus Tachycardia		
	Sleep Apnoea Syndrome		
	Tachycardia		
	Tricuspid Valve Incompetence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4575187-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01232
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Anxiety Disorder		Lotrel	C			UNKNOWN	
	Arthralgia		Norvasc	C			UNKNOWN	
	Asthenia		Celebrex	C			UNKNOWN	
	Cardiac Disorder		Lorazepam	C			UNKNOWN	
	Carotid Artery Stenosis		Venlafaxine Hydrochloride	C			UNKNOWN	
	Carpal Tunnel Syndrome							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Atherosclerosis							
	Deafness							
	Dementia							
	Dyskinesia							
	Gastrooesophageal Reflux Disease							
	Hepatitis B							
	Hypertension							
	Joint Sprain							
	Myocardial Ischaemia							
	Neuropathy Peripheral							
	Osteoporosis							
	Otitis Media							
	Palpitations							
	Panic Disorder							
	Pelvic Pain							
	Peripheral Vascular Disorder							
	Prescribed Overdose							
	Rheumatoid Arthritis							
	Schizophrenia, Paranoid Type							
	Toe Deformity							

Date:02/08/05ISR Number: 4575188-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Myocardial Infarction
	Anxiety
	Aortic Dilatation
	Aortic Valve Incompetence
	Azotaemia
	Blood Bilirubin Increased
	Cardiac Valve Disease
	Change Of Bowel Habit
	Chest Pain
	Coronary Artery Atherosclerosis
	Coronary Artery Occlusion
	Dilatation Atrial
	Dyspnoea
	Haemorrhoids
	Hand Fracture
	Heart Valve Calcification

		Mitral Valve Incompetence					
		Myocardial Infarction					
		Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
66	DAY						
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
66	DAY						
		Incompetence					
		Vascular Calcification					
		Ventricular Arrhythmia					
		Ventricular Hypertrophy					

Date:02/08/05ISR Number: 4575189-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00607
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Dizziness					
	Hyperhidrosis					
	Hypertension					
	Musculoskeletal Chest					
	Pain					
	Neck Pain					
	Pallor					
	Supraventricular					
	Tachycardia					
	Visual Disturbance					

Date:02/08/05ISR Number: 4575190-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01736
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Chronic Obstructive		Humulin U Ultralente	C		
UNKNOWN						
	Pulmonary Disease		Humalog	C		
UNKNOWN						

	Diabetes Mellitus	Premarin	C
UNKNOWN			
	Inadequate Control	Prevacid	C
UNKNOWN			
	Emotional Distress	Vitamins	
	Gastrooesophageal Reflux	(Unspecified)	C
UNKNOWN			
	Disease	Darvocet-N	C
UNKNOWN			
	Mitral Valve Incompetence	Tenormin	C
UNKNOWN			
	Myocardial Infarction		
	Tricuspid Valve Incompetence		

Date:02/08/05ISR Number: 4575191-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amaurosis Fugax
Other	Aortic Dilatation
	Asthenia
	Blood Cholesterol Increased
	Blood Creatine Phosphokinase Increased
	Blood Creatinine

		Increased					
		Blood Glucose Increased					
		Blood Potassium Increased					
		Blood Pressure Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
89	DAY						
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Dyspnoea Exertional		Humulin N	C		
UNKNOWN							
		Emotional Distress		Humulin R	C		
UNKNOWN							
		Fatigue		Naproxen	C		ORAL
		Gastrooesophageal Reflux		Naproxen	C		ORAL
		Disease		Livostin	C		
OPHTHALMIC							
		Hyperhidrosis		Prevacid	C		ORAL
		Hypoaesthesia		Vasotec	C		
UNKNOWN							
		Hypotension					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Ischaemic Stroke					
		Low Density Lipoprotein					
		Increased					
		Muscle Spasms					
		Nasopharyngitis					
		Nephropathy					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Pain In Extremity					
		Pollakiuria					
		Sinus Congestion					
		Sleep Apnoea Syndrome					
		Somnolence					
		Spinal Column Stenosis					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypertrophy					

Date:02/08/05ISR Number: 4575194-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Stenosis		Aspirin	C		ORAL
Other	Nervous System Disorder		Glyburide	C		ORAL
	Syncope		[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:02/08/05ISR Number: 4575195-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00560
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Other	Alanine Aminotransferase
	Increased
	Antithrombin Iii
	Decreased
	Anxiety
	Arrhythmia
	Aspartate
	Aminotransferase
	Increased

		Blood Creatine Phosphokinase Increased					
		Blood Creatinine Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
30	DAY			Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY	Blood Lactate		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY	Dehydrogenase Increased		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY	Blood Urea Increased		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY	Bundle Branch Block Right		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Valve Disease					
		Carotid Bruit					
		Chest Pain					
		Coagulopathy					
		Coronary Artery Atherosclerosis					
		Depression					
		Dyspnoea					
		Electrocardiogram Repolarisation Abnormality					
		Electrocardiogram T Wave Peaked					
		Granulocyte Count Increased					
		Headache					
		Hepatic Enzyme Increased					
		Hypoaesthesia					
		Lymphocyte Count Increased					
		Mitral Valve Incompetence					
		Mitral Valve Stenosis					
		Muscle Spasms					
		Palpitations					
		Pleuritic Pain					
		Prothrombin Time Prolonged					
		Pulmonary Embolism					
		Sinus Bradycardia					
		Sinus Tachycardia					
		Stress					

Tachycardia
Tricuspid Valve
Incompetence
White Blood Cell Count
Increased

Date:02/08/05ISR Number: 4575198-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01989
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alcoholism
Hospitalization - Initial or Prolonged	Anaemia Macrocytic
	Aortic Stenosis
	Aortic Valve Sclerosis
	Bifascicular Block
	Blood Magnesium Decreased
	Bundle Branch Block Left
	Bundle Branch Block Right
	Cardiac Failure
	Congestive

		Cerebrovascular Accident					
		Chronic Obstructive Airways Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Exacerbated		Vioxx	PS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
1093	DAY						
		Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Colonic Polyp					
		Confusional State					
		Congestive Cardiomyopathy					
		Contusion					
		Deficiency Anaemia					
		Depression					
		Electrocardiogram St					
		Segment Depression					
		Faecal Occult Blood					
		Positive					
		Fall					
		Haemorrhoids					
		Headache					
		Hypertension					
		Hypotension					
		Insomnia					
		Lipoma					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Peptic Ulcer					
		Pleural Effusion					
		Renal Failure					
		Sick Sinus Syndrome					
		Somnolence					
		Supraventricular					
		Extrasystoles					
		Syncope					
		Transient Ischaemic					
		Attack					
		Ventricular Extrasystoles					

Date:02/08/05ISR Number: 4575200-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00064
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cranial Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Microangiopathy		[Therapy					
	Musculoskeletal		Unspecified]	C				
UNKNOWN							1 DAY	
	Discomfort							

Date:02/08/05ISR Number: 4575201-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01017
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Lipitor	C				
UNKNOWN								
	Blood Cholesterol		Atenolol	C				
UNKNOWN								
	Increased		Lisinopril	C				
UNKNOWN								
	Cardiac Disorder							
	Cerebral Infarction							
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4575203-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00410
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Chest Pain		[Therapy Unspecified]	C				UNKNOWN
	Depression		Tramadol Hydrochloride	C				UNKNOWN
	Discomfort		Dipyrone	C				UNKNOWN
	Drug Ineffective		Atorvastatin Calcium	C				UNKNOWN
	Duodenitis		Tetrazepam	C				UNKNOWN
	Gastritis		Clorazepate Dipotassium	C				UNKNOWN
	Hyperhidrosis							
	Neuralgia							
	Pain							
	Palpitations							
	Reflux Oesophagitis							
	Spinal Disorder							
	Supraventricular Extrasystoles							
	Tachycardia							
	Tremor							
	Visual Field Defect							

Date:02/08/05ISR Number: 4575205-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		535 DAY
	Infarction							

Date:02/08/05ISR Number: 4575207-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA01159
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder		Zestril	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	

Date:02/08/05ISR Number: 4576953-8Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Accident
	Back Disorder
	Blood Cholesterol Increased
	Chest Pain
	Condition Aggravated
	Contusion
	Disorientation
	Drug Effect Decreased
	Erectile Dysfunction
	Facial Pain
	Feeling Cold

	Gastrooesophageal Reflux Disease						
	Gingival Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Glossodynia	Consumer	Neurontin				
	Hostility	Health	(Gabapentin)	PS		ORAL	1800 MG (600
	Hypersomnia	Professional					MG, 3 IN 1
	Hyporeflexia						D), ORAL
	Impaired Healing		Lipitor				
	Injury		9atorvastatin)	SS		ORAL	20 MG (20 MG,
	Movement Disorder						1 IN 1 D),
	Muscle Spasms						ORAL
	Myalgia		Lithium (Lithium)	SS			
	Oesophageal Spasm		Naproxen (Naproxen)	SS			
	Overdose		Amoxicillin				
	Pain In Extremity		(Amoxicillin)	SS		ORAL	1000 MG (1 IN
	Pain In Jaw						2 D), ORAL
	Sedation		Rofecoxib				
	Skeletal Injury		(Rofecoxib)	SS			
	Sleep Disorder		All Other				
	Somnolence		Therapeutic				
	Tenderness		Products(All Other				
	Tooth Abscess		Therapeutic				
	Tremor		Products0	C			
	Vertigo		Levothyroxine Sodium				
			(Levothyroxine				
			Sodium)	C			
			Vitamins (Vitamins0	C			
			Diltiazem				
			Hydrochloride				
			(Dialtiazem				
			Hydrochloride)	C			

Date:02/08/05ISR Number: 4577441-5Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00233
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO								240 DAY
			Amlodipine Besylate	C				
			Aspirin	C				
			Bendroflumethiazide	C				
			Chondroitin Sulfate Sodium (+) Glucosami	C				
			Cod Liver Oil	C				

Date:02/08/05ISR Number: 4577442-7Report Type:Expedited (15-DaCompany Report #WAES 0410SWE00020
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Atherosclerosis	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Chest Pain							
PO								209 DAY
	Coronary Artery Disease							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/05ISR Number: 4577486-5Report Type:Expedited (15-DaCompany Report #2004098177
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign Health Professional	Celebrex (Celecoxib)	PS		ORAL	100 MG (100 MG, 1 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D), ORAL	
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
			Lansoprazole (Lansoprazole)	C				
			Arthrotec (Diclofenac Sodium, Misoprostol)	C				

Date:02/08/05ISR Number: 4577511-1Report Type:Expedited (15-DaCompany Report #2005020325
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Glomerulonephritis	Foreign Health Professional	Artrotec	PS		ORAL	ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:02/08/05ISR Number: 4579162-1Report Type:Direct Company Report #CTU 239733
Age:24 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Hypoaesthesia		Vioxx	PS		ORAL
1PILL 2						
	Paraesthesia					
TWICE A DAY						
ORAL						

Date:02/08/05ISR Number: 4579171-2Report Type:Direct Company Report #CTU 239728
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardio-Respiratory Arrest		Celebrex 200 Mg			
Hospitalization -	Circulatory Collapse		G.D.Searle	PS	G.D.Searle	ORAL
TWO CAPSULES						
Initial or Prolonged	Coma					
DAILY ORAL						
Disability			Vioxx 100 Mg	SS		ORAL
1 CAPSULE AS						
NEEDED ORAL						

Date:02/09/05ISR Number: 4575719-2Report Type:Expedited (15-DaCompany Report #FR-JNJFOC-20050101306
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hepatic Steatosis		Topalgic	PS		
OROPHARINGEAL						
Initial or Prolonged	Pancreatic Necrosis		Efferalgan	SS		
OROPHARINGEAL						
	Pancreatitis Acute		Deroxat	SS		
OROPHARINGEAL						
			Nexen	SS		
UNKNOWN						
			Vioxx	SS		
OROPHARINGEAL						
			Art 50	SS		
OROPHARINGEAL						

Date:02/09/05ISR Number: 4575825-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00719
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abscess
	Adverse Event
	Anaemia
	Angina Unstable
	Anxiety
	Arrhythmia
	Arthropathy
	Atelectasis
	Back Pain
	Bacterial Infection
	Barrett'S Oesophagus
	Blood Creatinine Increased
	Breast Pain
	Cataract
	Cervicobrachial Syndrome
	Chest Pain
	Chest Wall Pain
	Chills
	Cholelithiasis
	Contusion
	Convulsion
	Corneal Scar
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dermatitis Contact
	Disease Recurrence
	Dizziness
	Dysaesthesia
	Dysuria
	Eosinophil Count Increased
	Fluid Retention
	Gastritis
	Hepatic Enzyme Increased
	Hypercholesterolaemia
	Hyperhidrosis
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Hypertriglyceridaemia

Intervertebral Discitis
Lethargy
Lipase Increased
Lipoma
Lymphadenopathy
Lymphangitis
Medical Device Removal
Migraine
Monocyte Count Increased
Myocardial Infarction
Neuralgia
Neuropathy Peripheral
Nuclear Magnetic
Resonance Imaging
Abnormal

		Oedema Peripheral					
		Oesophagitis					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteomyelitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Hydrodiuril	C		ORAL
		Pleural Fibrosis		Norvasc	C		
UNKNOWN							
		Polyneuropathy		Vicodin Es Tablets	C		
UNKNOWN							
		Pyrexia					
		Rectal Haemorrhage					
		Red Blood Cell					
		Sedimentation Rate					
		Increased					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Rotator Cuff Syndrome					
		Sepsis					
		Seroma					
		Spondylolisthesis					
		Staphylococcal Infection					
		Suicidal Ideation					
		Therapeutic Response					
		Decreased					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Venous Stenosis					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Vomiting					
		Weight Decreased					
		White Blood Cell Count					
		Increased					
		Wound Infection					
		Wound Infection					
		Staphylococcal					

Date:02/09/05ISR Number: 4575833-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:57 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Abdominal Bruit
Disability	Abdominal Pain
Other	Abdominal Pain Upper
	Acute Coronary Syndrome
	Angina Pectoris
	Angina Unstable
	Aortic Bruit
	Aortic Valve Calcification
	Aortic Valve Incompetence
	Appendix Disorder
	Arteriosclerosis
	Arthralgia
	Atherosclerosis
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Carotid Artery Occlusion

Carotid Artery Stenosis
Carpal Tunnel Syndrome
Cataract
Cerebrovascular Accident
Cerumen Impaction
Chest Discomfort
Constipation
Convulsion
Coronary Artery Disease
Cough
Cystitis Haemorrhagic
Depressed Mood
Diastolic Dysfunction
Dilatation Atrial
Diverticulum
Diverticulum Intestinal
Drug Hypersensitivity
Dyslipidaemia
Ear Pain
Emotional Distress
Fatigue
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux
Disease
Granuloma
Haematuria
Headache
Hepatic Cyst
Hernia
Hypercholesterolaemia
Hyperhomocysteinaemia
Hyperkalaemia
Hypoacusis
Hypokalaemia
Infection
Kidney Small
Localised Infection
Lung Disorder
Metaplasia
Mitral Valve
Calcification
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Nausea

Neck Injury
Nervous System Disorder
Osteoarthritis
Osteoporosis
Pharyngolaryngeal Pain
Pulmonary Congestion
Rash Erythematous
Renal Artery Stenosis
Renal Failure
Road Traffic Accident
Rotator Cuff Syndrome
Sciatica
Scoliosis
Shoulder Operation

		Skin Lesion					
		Spinal Osteoarthritis					
		Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tearfulness		Vioxx	PS	Merck & Co., Inc	ORAL
		Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Tonsillar Disorder					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Uterine Disorder					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Vertigo					
		Visual Disturbance					

Date:02/09/05ISR Number: 4575838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
Disability	Anaemia
	Angina Pectoris
	Arthralgia
	Chest Discomfort
	Condition Aggravated
	Confusional State
	Connective Tissue Disorder
	Depression
	Diabetes Mellitus
	Diabetes Mellitus Non-Insulin-Dependent
	Diverticulum Duodenal
	Dizziness
	Drug Ineffective
	Dysphoria
	Fall
	Gastritis
	Generalised Anxiety Disorder

Haemorrhoids
Hypertension
Idiopathic
Thrombocytopenic Purpura
Inflammation
Injury
Intestinal Obstruction
Joint Lock
Malaise
Melaena
Nervousness
Pain
Sjogren'S Syndrome
Stomach Discomfort
Systemic Lupus
Erythematosus

		Tremor Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Ms Contin	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Hydro-Chlor	C		
UNKNOWN							
				Elavil	C		ORAL
				Heparin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Hydroxychloroquine Sulfate	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							

Date:02/09/05ISR Number: 4575842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00746
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Lower
Disability	Back Injury
Other	Back Pain
	Cardiac Disorder
	Cardiac Murmur
	Chest Pain
	Chest Wall Pain
	Constipation
	Diarrhoea
	Dry Skin
	Dyspnoea Exertional
	Emotional Distress
	Flank Pain
	Frequent Bowel Movements
	Gastrooesophageal Reflux
	Disease
	Haematuria
	Haemochromatosis
	Headache
	Hirsutism
	Hyperlipidaemia
	Injury
	Intervertebral Disc
	Protrusion
	Lactose Intolerance
	Migraine
	Musculoskeletal Pain
	Myocardial Infarction
	Nausea

		Neck Injury					
		Neck Pain					
		Nephrolithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neuropathy Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Non-Cardiac Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Antimicrobial			
		Pyelonephritis		(Unspecified)	C		
UNKNOWN							
		Pyrexia		Analgesic Or			
		Rectal Haemorrhage		Anesthetic			
		Sinusitis		(Unspecified)	C		
UNKNOWN							
		Skin Discolouration		Butalbital	C		
UNKNOWN							
		Skin Striae					
		Spinal Osteoarthritis					
		Thyroid Neoplasm					
		Vision Blurred					
		Vomiting					
		Weight Increased					
		Weight Loss Poor					

Date:02/09/05ISR Number: 4575845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00790
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Soma	C		ORAL
		Congestive		Levbid	C		
UNKNOWN							
		Cardio-Respiratory Arrest		Dilantin	C		
UNKNOWN							
		Chronic Obstructive		Paxil Cr	C		
UNKNOWN							
		Pulmonary Disease		Elavil	C		
UNKNOWN							
		Convulsion		Claritin	C		
UNKNOWN							
		Drug Ineffective		Phenergan			
		Ear Pain		(Promethazine			

	Fall	Hydrochloride)	C
UNKNOWN			
	Fractured Coccyx	Protonix	C
UNKNOWN			
	Gastrooesophageal Reflux	Carafate	C
UNKNOWN			
	Disease	Aciphex	C
UNKNOWN			
	Headache	Lomotil	C
UNKNOWN			
	Hepatitis C	Questran	C
UNKNOWN			
	Hyperlipidaemia	Atenolol	C
UNKNOWN			
	Hypertension	Lasix (Furosemide)	C
UNKNOWN			
	Insomnia	Potassium	
	Joint Injury	(Unspecified)	C
UNKNOWN			
	Lacunar Infarction	Premarin	C
UNKNOWN			
	Liver Function Test	Paxil	C
UNKNOWN			
	Abnormal	Synthroid	C
UNKNOWN			
	Malaise	Darvocet-N	C
UNKNOWN			
	Meralgia Paraesthetica	Melatonina	C
UNKNOWN			
	Monarthritis		
	Naevus Cell Naevus		
	Nervousness		
	Osteoarthritis		
	Palpitations		
	Pulmonary Fibrosis		
	Pyrexia		
	Syncope		
	Vision Blurred		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575850-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01171
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization -	Aortic Valve Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged Disability	Atrial Fibrillation Cardiac Failure Congestive Coronary Artery Atherosclerosis Coronary Artery Disease Dental Caries Diverticulum Intestinal Fall Hip Fracture Loss Of Consciousness Mitral Valve Incompetence Myeloproliferative Disorder Myocardial Infarction Nasal Polyps Nephrolithiasis Pain Refractory Anaemia Renal Infarct Restrictive Pulmonary Disease Sinusitis Splenomegaly Thrombocytopenia Upper Limb Fracture Urinary Tract Infection		Propranolol Hydrochloride	C		ORAL		

Date:02/09/05ISR Number: 4575852-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00685
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		840 DAY

Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
840 DAY						
	Non-Insulin-Dependent		Hydrochlorothiazide And Metoprolol Succinate	C		
UNKNOWN	906 DAY					

Date:02/09/05ISR Number: 4575854-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01627
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
830 DAY						
Hospitalization -	Congestive		Furosemide	C		
UNKNOWN						
Initial or Prolonged			Tarka	C		
UNKNOWN						
Disability			Proventil	C		
UNKNOWN						
			Pulmicort	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575855-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Myocardial Infarction Thyroid Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4575858-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Disability	Accident At Home
Other	Accident At Work
	Adverse Event
	Anxiety
	Aortic Valve Incompetence
	Asthenia
	Cardiac Murmur
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Pain
	Clumsiness
	Cognitive Disorder
	Contusion
	Depression
	Disturbance In Attention
	Drug Effect Decreased
	Dyspepsia
	Dyspnoea
	Dysthymic Disorder
	Face Injury
	Fall
	Fatigue
	Gastrooesophageal Reflux
	Disease
	General Symptom
	Headache
	Hypertension
	Increased Tendency To
	Bruise
	Injury
	Intervertebral Disc
	Protrusion

Irritability
Joint Injury
Memory Impairment
Mitral Valve Incompetence
Myofascial Pain Syndrome
Pain
Pain In Extremity
Pruritus
Sleep Disorder
Stress
Stress Fracture
Thrombosis
Tinnitus
Transient Ischaemic
Attack
Tremor
Tricuspid Valve

Incompetence
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Neurontin	C			UNKNOWN	
	Ibuprofen	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Cephalexin	C			UNKNOWN	
	Skelaxin	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Zovirax	C			UNKNOWN	
	Methylprednisolone	C			UNKNOWN	
	Propoxyphene Hydrochloride	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Baclofen	C		ORAL		

Date:02/09/05ISR Number: 4575876-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00135
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Lower
	Aneurysm
	Angina Unstable
	Anorexia
	Anxiety
	Anxiety Disorder

Aortic Aneurysm
Asthenia
Cardiac Disorder
Carotid Artery Occlusion
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Colonic Polyp
Decubitus Ulcer
Depression
Diabetes Mellitus
Duodenal Ulcer
Duodenal Ulcer
Haemorrhage
Eating Disorder
Emotional Distress
Emphysema
Facial Palsy
Fall
Foot Fracture
Gastric Ulcer
Gastroenteritis
Haemorrhage
Hemiparesis
Hypertension
Intestinal Functional
Disorder

		Leg Amputation					
		Micturition Urgency					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Cyanocobalamin	C		
UNKNOWN							
		Peripheral Ischaemia		Reglan	C		
UNKNOWN							
		Peripheral Vascular		Norvasc	C		
UNKNOWN							
		Disorder		Lorazepam	C		
UNKNOWN							
		Pyrexia		Aggrenox	C		
UNKNOWN							
		Thrombosis		Zocor	C		
UNKNOWN							
		Toe Amputation					
		Toe Deformity					
		Transient Ischaemic					
		Attack					
		Upper Gastrointestinal					
		Haemorrhage					
		Ventricular Hypertrophy					
		Vomiting					
		Wound Dehiscence					

Date:02/09/05ISR Number: 4575896-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00220
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:02/09/05ISR Number: 4575897-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00039
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Malaise					

Date:02/09/05ISR Number: 4575901-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00012
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Metoprolol Tartrate	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Simvastatin	C		ORAL		

Date:02/09/05ISR Number: 4575908-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575910-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4575912-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	354 DAY	
Other	Death							
	Hyperlipidaemia							
	Hypertension							

Date:02/09/05ISR Number: 4575913-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00057
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL	345 DAY	
Disability	Difficulty In Walking		Paxil	C				
UNKNOWN								
	Dizziness							
	Emotional Distress							
	Fatigue							
	Feeling Abnormal							
	Nervousness							
	Palpitations							
	Thrombosis							

Date:02/09/05ISR Number: 4575917-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Emotional Disorder Injury Pulmonary Embolism					

Date:02/09/05ISR Number: 4575920-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00024
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Carotid Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Paroxetine	SS		ORAL
			Diacerein	SS		ORAL
			Estradiol	SS		
TOPICAL						

Date:02/09/05ISR Number: 4575921-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris Angiopathy Cardiac Disorder Coronary Artery Disease Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575926-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00003
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	International Normalised		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Ratio Increased		Warfarin Sodium	SS		ORAL		
	Vasculitis		Acetaminophen	C			UNKNOWN	
			Furosemide Sodium	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	
			Vasotec	C			UNKNOWN	
			Sotalol Hydrochloride	C			UNKNOWN	

Date:02/09/05ISR Number: 4575927-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01070
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		277 YR
	Erectile Dysfunction		Lipitor	C			UNKNOWN	
	Transient Ischaemic		Axid	C			UNKNOWN	
	Attack		Vitamins (Unspecified)	C			UNKNOWN	
			Viagra	C			UNKNOWN	

Date:02/09/05ISR Number: 4575946-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00423
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
17 MON							
Initial or Prolonged							
Disability							

Date:02/09/05ISR Number: 4575949-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00246
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bradycardia		Altace	C				
UNKNOWN								
Initial or Prolonged	Dizziness							
	Tachycardia							

Date:02/09/05ISR Number: 4575950-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00366
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4575951-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00485
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dysphagia		[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4575958-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4575959-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/09/05ISR Number: 4575961-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Embolism							

Date:02/09/05ISR Number: 4576442-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Ceftin	C		ORAL		
	Emotional Distress		Percocet	C		ORAL		
	Hyperlipidaemia		Vicodin Es Tablets	C		ORAL		
	Hypertension		Ambien	C		ORAL		
	Mitral Valve Prolapse		Zoloft	C		ORAL		
	Sleep Apnoea Syndrome		Zoloft	C		ORAL		
	Thrombosis							
	Trigger Finger							

Date:02/09/05ISR Number: 4576446-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthrodesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Carotid Artery Stenosis		Baclofen	C		ORAL		
Other	Cerebrovascular Accident		Ativan	C		ORAL		
	Cervicobrachial Syndrome		Soma	C		ORAL		
	Death		Wellbutrin	C		ORAL		
	Depression		Dulcolax	C			UNKNOWN	
	Oedema		Tegretol	C		ORAL		
			Ms Contin	C		ORAL		
			Colace	C		ORAL		
			Vistaril	C		ORAL		
			Vistaril	C		ORAL		
			Seroquel	C			UNKNOWN	
			Seroquel	C		ORAL		
			Mexiletine Hydrochloride	C		ORAL		
			Coumadin	C		ORAL		
			Percocet	C		ORAL		

				Fleet Enema	C		
UNKNOWN							
				Magnesia [Milk Of]	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							
				Neurontin	C		ORAL
				Elavil	C		ORAL

Date:02/09/05ISR Number: 4576450-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00900
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	723	DAY
Life-Threatening			Pravachol	C				
UNKNOWN								
Disability			Lopressor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Vitamin E	C				
UNKNOWN								

Date:02/09/05ISR Number: 4576451-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		A.S.A.	C		ORAL		
	Cardiac Disorder		Zyrtec	C				
UNKNOWN								
	Carpal Tunnel Syndrome		Celexa	C				
UNKNOWN								
	Coronary Artery		Atenolol	C				
UNKNOWN								

	Atherosclerosis	Hydrocodone		
	Drug Ineffective	Bitartrate	C	
UNKNOWN				
	Dyslipidaemia	Levsin	C	
UNKNOWN				
	Facet Joint Syndrome	Oxycontin	C	
UNKNOWN				
	Fall	Aciphex	C	
UNKNOWN				
	Headache	Prilosec	C	
UNKNOWN				
	Muscular Weakness	Indocin		
	Night Sweats	(Indomethacin)	C	ORAL
	Peripheral Coldness	Plavix	C	ORAL
196 DAY				
	Pyrexia	Naproxen	C	
UNKNOWN				
	Road Traffic Accident	Flonase	C	
UNKNOWN				
	Rotator Cuff Syndrome			
	Scapula Fracture			
	Skin Laceration			
	Trigger Finger			
	Umbilical Hernia			

Date:02/09/05ISR Number: 4576455-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00798
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Abdominal Pain Upper
	Adverse Event
	Asthenia
	Back Pain
	Barrett'S Oesophagus
	Breast Cyst
	Breast Pain
	Bronchitis

		Carpal Tunnel Syndrome					
		Cervicobrachial Syndrome					
		Coordination Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Robaxin	C		
UNKNOWN							
		Diarrhoea		Lotrel	C		
UNKNOWN							
		Dizziness					
		Dysphagia					
		Epistaxis					
		Erosive Oesophagitis					
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Helicobacter Gastritis					
		Hiatus Hernia					
		Intervertebral Disc					
		Degeneration					
		Irritable Bowel Syndrome					
		Loss Of Consciousness					
		Myocardial Ischaemia					
		Neck Injury					
		Neck Pain					
		Oedema Peripheral					
		Pain In Extremity					
		Pharyngitis					
		Polytraumatism					
		Road Traffic Accident					
		Sinusitis					
		Syncope					
		Vaginal Infection					

Date:02/09/05ISR Number: 4576456-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00769
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abscess
Other	Adverse Event
	Angina Pectoris
	Atelectasis
	Blood Cholesterol
	Increased

Blood Glucose Decreased
Bronchitis
Cardiac Failure
Congestive
Cervical Cyst
Chest Pain
Colitis
Convulsion
Diastolic Dysfunction
Diverticulum
Dyspnoea
Facial Palsy
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hand Fracture
Headache
Hypertension

		Hypoaesthesia					
		Hypokalaemia					
		Leukocytosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Prolapse		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Effexor Xr	C		
UNKNOWN							
		Pain In Extremity					
		Palpitations					
		Pneumonitis					
		Pulmonary Hypertension					
		Rotator Cuff Syndrome					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Trigger Finger					
		Tubo-Ovarian Abscess					
		Umbilical Hernia					
		Vomiting					

Date:02/09/05ISR Number: 4576464-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
34 DAY						
Initial or Prolonged	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY						
Disability	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
34 DAY						
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY						
	Dyspnoea		Aspirin	C		
UNKNOWN						
	Emotional Distress		Echinacea	C		
UNKNOWN	1483 DAY					
	Fatigue		Cyclobenzaprine			
	Gastrooesophageal Reflux		Hydrochloride	C		
UNKNOWN						
	Disease		Dicyclomine			
	Hypersensitivity		Hydrochloride	C		
UNKNOWN						

	Jejunal Ulcer	Nexium	C
UNKNOWN			
	Migraine		
	Mitral Valve Prolapse		
	Multiple Allergies		
	Muscle Spasms		
	Musculoskeletal Pain		
	Nausea		
	Pharyngitis		
	Rectal Haemorrhage		
	Small Intestinal Ulcer		
	Haemorrhage		
	Upper Respiratory Tract		
	Infection		
	Viral Infection		

Date:02/09/05ISR Number: 4576465-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Back Pain
Initial or Prolonged	Bipolar I Disorder
Disability	Bladder Disorder
Other	Body Tinea
	Cerebral Artery Occlusion
	Chest Pain
	Chronic Fatigue Syndrome

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Depression Dyspnoea Fall					
		Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL
38 DAY							
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
38 DAY							
		Hypotension Insomnia		Hydrocodone Bitartrate	C		
UNKNOWN		663 DAY					
		Loss Of Consciousness Migraine Myocardial Infarction		Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN		840 DAY					
		Neuropathic Pain		Estraderm	C		
UNKNOWN		409 DAY					
		Rash		Duradrin	C		
UNKNOWN							
		Renal Failure Acute		Methotrexate	C		
UNKNOWN							
		Temperature Intolerance		Klonopin	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN		976 DAY					
				Alprazolam	C		
UNKNOWN							
				Prochlorperazine	C		
UNKNOWN							
				Avonex	C		
INTRAMUSCULAR							
				Zanaflex	C		
UNKNOWN		473 DAY					
				Zocor	C		
UNKNOWN							
				Zocor	C		ORAL
809 DAY							
				Propranolol Hydrochloride	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							

			Nizatidine	C		
UNKNOWN						
			Indomethacin	C		
UNKNOWN						
			Klor-Con	C		
UNKNOWN						
			Benadryl	C		
UNKNOWN						
			Zyprexa	C		ORAL
			Vitamin E	C		ORAL

Date:02/09/05ISR Number: 4576475-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02403
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspnoea		Zoloft	C		
UNKNOWN						
	Muscular Weakness		Prinzide	C		
UNKNOWN						
			Flexeril	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

Date:02/09/05ISR Number: 4576476-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00173
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/09/05ISR Number: 4576478-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/09/05ISR Number: 4576479-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02383
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fluid Retention		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		12 MON
Initial or Prolonged Disability	Weight Increased							

Date:02/09/05ISR Number: 4576481-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00456
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Fosinopril Sodium	C				
UNKNOWN								
			Fosinopril Sodium	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Metoprolol Succinate	C				
UNKNOWN								
			Simethicone	C				
UNKNOWN								
			Metoclopramide	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Zopiclone	C				
UNKNOWN								

Date:02/09/05ISR Number: 4576483-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00011
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Melaena		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged

Date:02/09/05ISR Number: 4576484-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Hospitalization -	Pulmonary Oedema		Atacand	C				
Initial or Prolonged			Norvasc	C				
Disability			Lasix (Furosemide)	C				
			Provera	C				
			Estradiol	C				

Date:02/09/05ISR Number: 4576485-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02612
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4576487-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	605	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4576489-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00531
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other								

Date:02/09/05ISR Number: 4576490-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01532
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	33	DAY
Initial or Prolonged	Congestive		Synthroid	C		ORAL		
Disability	Cardiomegaly		Lasix (Furosemide					
Other	Cerebrovascular Accident		Sodium)	C		ORAL		
	Coronary Artery		Premarin	C		ORAL		
	Atherosclerosis							
	Hypertension							
	Sinusitis							
	Ventricular Hypertrophy							

Date:02/09/05ISR Number: 4576492-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00146
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	725	DAY
Initial or Prolonged	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	725	DAY
	Chest Pain		Aspirin	C		ORAL		
	Disorientation		Ranitidine					
	Dysphagia		Hydrochloride	C		ORAL		
	Fall		Levothyroxine Sodium	C		ORAL		
	Fatigue		Diclofenac	C		ORAL	757	DAY
	Forearm Fracture		Amoxicillin	C		ORAL		

	Mandibulofacial		Amoxicillin	C			ORAL
	Dysostosis		Amoxicillin	C			ORAL
	Nausea						
	Pharyngitis						
	Tonsillitis						

Date:02/09/05ISR Number: 4576496-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01024
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Onychomycosis							
	Skin Exfoliation							
	Skin Fissures							

Date:02/09/05ISR Number: 4576498-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03411
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4576499-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00172
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:02/09/05ISR Number: 4576501-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Death							
Other	Myocardial Infarction							

Date:02/09/05ISR Number: 4576502-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	44	MON

Date:02/09/05ISR Number: 4576504-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0502CHE00011
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4576505-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00505
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

	Cerebrovascular Accident		Diazepam	C			
UNKNOWN							
	Diarrhoea		Prozac	C			
UNKNOWN							
	Vomiting		Protonix	C			
UNKNOWN							
			Testosterone	C			
UNKNOWN							
			Crestor	C			
UNKNOWN							

Date:02/09/05ISR Number: 4576506-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00625
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/09/05ISR Number: 4576508-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00609
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4576509-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00586
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Clarinex	C				UNKNOWN
			Pravachol	C				UNKNOWN
			Hydrochlorothiazide And Lisinopril	C				UNKNOWN

Date:02/09/05ISR Number: 4576510-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00671
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vasotec	C		ORAL		UNKNOWN
Disability	Dilatation Atrial Mitral Valve Incompetence		Lasix (Furosemide Sodium)	C		ORAL		UNKNOWN
Other	Treatment Noncompliance		Zocor	C		ORAL		UNKNOWN
			Digoxin	C		ORAL		UNKNOWN
			Aspirin	C		ORAL		UNKNOWN
			Nitroglycerin	C				UNKNOWN

Date:02/09/05ISR Number: 4576511-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	819 DAY	

Date:02/09/05ISR Number: 4576512-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY

Date:02/09/05ISR Number: 4576513-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1071 DAY

Date:02/09/05ISR Number: 4576515-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00060
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sciatica		Furosemide	C				UNKNOWN
			Doxazosin Mesylate	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Valsartan	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Calcium Carbonate	C				UNKNOWN

Date:02/09/05ISR Number: 4577828-0Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00029
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Blood Urea Decreased Cerebral Infarction Confusional State Ischaemic Stroke Mean Cell Haemoglobin Concentration Increased Mean Cell Haemoglobin Increased Platelet Count Decreased	Foreign Study Health Professional	Tab Vioxx (Rofecoxib) Acetaminophen Aspirin Karaya Gum Pravastatin Na	PS C C C C		ORAL	25 MG/DAILY	103 DAY

Date:02/09/05ISR Number: 4577829-2Report Type:Expedited (15-DaCompany Report #WAES 0501GBR00078
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Shortened Asthenia C-Reactive Protein Increased Carotid Artery Stenosis Diplopia Dizziness Hypercholesterolaemia Lymphocyte Count Decreased Platelet Count Decreased Red Blood Cell Count Decreased Red Blood Cell Sedimentation Rate Increased Transient Ischaemic Attack	Foreign Study Health Professional	Tab Vioxx (Rofecoxib) Fosamax Proscar Prednisolone Tamsulosin Hydrochloride	PS C C C C		ORAL	25 MG/DAILY	104 DAY

Date:02/09/05ISR Number: 4577830-9Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	367 DAY

Date:02/09/05ISR Number: 4578243-6Report Type:Expedited (15-DaCompany Report #2005023596
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Consumer	Celebrex (Celecoxib)	PS			(200 MG,)	
Other			Rofecoxib (Rofecoxib)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/09/05ISR Number: 4578491-5Report Type:Expedited (15-DaCompany Report #2005019506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Celebrex (Celecoxib)	PS			(200 MG)	
			Rofecoxib (Rofecoxib)	SS				

Date:02/09/05ISR Number: 4578583-0Report Type:Expedited (15-DaCompany Report #2005-124866-NL
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Delirium		Mirtazapine	PS			8 MG	
	Drug Interaction		Quetiapine Fumarate	SS			75 MG	1 MON
	Hallucinations, Mixed		Pipamperone Hydrochloride	SS			100 MG	1 MON
	Refusal Of Treatment By Patient		Rofecoxib	SS			25 MG	1 MON
	Restlessness							

Date:02/10/05ISR Number: 4577058-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02079
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Acute Myocardial Infarction
	Anaemia
	Angina Pectoris
	Arterial Disorder
	Arthralgia
	Atherosclerosis
	Back Disorder
	Cardiac Failure
	Congestive
	Chest Pain
	Coronary Artery

Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Dehydration
Dermatitis Allergic
Diabetes Mellitus
Non-Insulin-Dependent
Dyspepsia
Dyspnoea
Ear Infection
Ejection Fraction
Decreased
Emotional Distress
Gastroenteritis
Gastrooesophageal Reflux
Disease
Glaucoma
Haematoma
Hiatus Hernia
Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Injury
Myocardial Infarction

	Osteoarthritis						
	Osteoporosis						
	Renal Failure	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sciatica		Vioxx	PS	Merck & Co., Inc	ORAL	276	DAY
	Spondylolisthesis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stress		Fosamax	C		ORAL	328	DAY
			Baycol	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Betimol	C			OPHTHALMIC	
			Vicodin Tablets	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Evista	C			UNKNOWN	
			Benadryl	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Prinivil	C		ORAL		
			Pravachol	C			UNKNOWN	
			Celebrex	C			UNKNOWN	

Date:02/10/05ISR Number: 4577063-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Lortab	C			UNKNOWN	
	Chest Discomfort		Soma	C			UNKNOWN	
	Convulsion		Viagra	C			UNKNOWN	

	Coronary Artery Disease	Vicodin Tablets	C
UNKNOWN			
	Coronary Artery	Temazepam	C
UNKNOWN			
	Restenosis		
	Epicondylitis		
	Hot Flush		
	Myocardial Infarction		
	Pulmonary Hypertension		
	Radial Tunnel Syndrome		
	Rotator Cuff Syndrome		
	Thrombosis		

Date:02/10/05ISR Number: 4577064-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01753
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Acute Sinusitis
	Angina Pectoris
	Asthenia
	Back Injury
	Back Pain
	Blood Cholesterol Increased
	Bone Pain
	Cardiac Failure Congestive
	Carpal Tunnel Syndrome
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression

		Dilatation Atrial					
		Dizziness					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Glucose Tolerance		Vioxx	PS	Merck & Co., Inc	
UNKNOWN		582 DAY					
		Impaired		Vioxx	SS	Merck & Co., Inc	ORAL
		High Density Lipoprotein		Pancof	C		
UNKNOWN							
		Decreased		Celexa	C		
UNKNOWN							
		Intervertebral Disc		Ziac	C		
UNKNOWN							
		Degeneration		Ultram	C		
UNKNOWN							
		Intervertebral Disc		Claritin	C		
UNKNOWN							
		Protrusion		Pepcid	C		ORAL
		Mitral Valve Incompetence		Diovan	C		
UNKNOWN							
		Nasopharyngitis		Marcof Expectorant	C		
UNKNOWN							
		Neck Injury		Atrovent	C		
UNKNOWN							
		Neck Pain		Nasacort	C		
UNKNOWN							
		Nervousness		Folic Acid	C		
UNKNOWN							
		Otitis Media		Tequin	C		
UNKNOWN							
		Pain		Allfen Dm	C		
UNKNOWN							
		Pain In Extremity		Avelox	C		
UNKNOWN							
		Peripheral Nerve		Zyrtec	C		
UNKNOWN							
		Decompression		Hyzaar	C		ORAL
		Radiculitis		Proventil	C		
UNKNOWN							
		Radiculitis Cervical		Serevent	C		
UNKNOWN							
		Spinal Column Stenosis		Rhinocort	C		
UNKNOWN							
		Spinal Osteoarthritis					
		Swelling					
		Tricuspid Valve					
		Incompetence					

Ventricular Extrasystoles

Date:02/10/05ISR Number: 4577065-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00936
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							
	Dysplasia							
	Dyspnoea							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							

Date:02/10/05ISR Number: 4577066-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00412
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Phenprocoumon	C				
UNKNOWN								
	Atrial Fibrillation		Losartan Potassium	C				
UNKNOWN								
	Blood Pressure Increased							
	Chest Discomfort							
	Dysphagia							
	Dyspnoea							
	Ecg Signs Of Myocardial							
	Ischaemia							
	Gastritis							
	Palpitations							
	Reflux Oesophagitis							
	Tachyarrhythmia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577067-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00085
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Exanthem		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Pravastatin Sodium	SS				
UNKNOWN								
	Myocardial Infarction							

Date:02/10/05ISR Number: 4577070-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:02/10/05ISR Number: 4577071-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00017
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Celecoxib	SS		ORAL		
			Aspirin And Magnesium Oxide	C		ORAL		
			Hydrochlorothiazide And Losartan Potassium	C		ORAL		

Date:02/10/05ISR Number: 4577072-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02409
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
1526 DAY								
	Arthralgia							
	Back Pain							
	Chest Pain							

Cough
Deafness
Gastrooesophageal Reflux
Disease
Nasal Congestion
Postnasal Drip
Tinnitus
Visual Disturbance
Wheezing

Date:02/10/05ISR Number: 4577073-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577074-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00285
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577075-2Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00008
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident							

Date:02/10/05ISR Number: 4577076-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Insufficiency							
Other	Coronary Artery Occlusion							
	Feeling Abnormal							
	Gastrointestinal							
	Haemorrhage							
	Haemorrhage							
	Headache							
	Hypersensitivity							
	Hypertension							
	Urinary Tract Infection							
	Bacterial							

Date:02/10/05ISR Number: 4577078-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
883 DAY								

Initial or Prolonged	Valium	C	
UNKNOWN			
Disability	Trazodone Hydrochloride	C	
UNKNOWN			
	Premarin	C	
UNKNOWN			

Date:02/10/05ISR Number: 4577079-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/10/05ISR Number: 4577080-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00513
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577082-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00016
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Esomeprazole					
Initial or Prolonged Disability			Magnesium	C		ORAL		

Date:02/10/05ISR Number: 4577083-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00549
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Basilar Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
							2	YR
Other	Cerebrovascular Accident Death							

Date:02/10/05ISR Number: 4577084-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00474
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Premarin	C				
UNKNOWN								
Initial or Prolonged			Synthroid	C				
UNKNOWN								

Date:02/10/05ISR Number: 4577085-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
							600	DAY

Date:02/10/05ISR Number: 4577086-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00554
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1166 DAY

Date:02/10/05ISR Number: 4577088-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00275
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hepatic Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pain							

Date:02/10/05ISR Number: 4577089-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00774
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1563 DAY

Date:02/10/05ISR Number: 4577090-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00386
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577091-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577092-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00676
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Arthralgia Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/10/05ISR Number: 4577093-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00571
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Feeling Cold		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Sudden Death Tremor		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/10/05ISR Number: 4577095-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			Hydrochlorothiazide And Irbesartan	C			UNKNOWN	

Date:02/10/05ISR Number: 4577574-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
	Adverse Event
Disability	Angina Pectoris
Other	Angina Unstable
	Aphagia
	Arthritis
	Asthenia
	Astigmatism
	Back Pain
	Bloody Discharge
	Carpal Tunnel Syndrome
	Cataract

Cervical Spinal Stenosis
Cervicobrachial Syndrome
Chest Pain
Corneal Disorder
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery Stenosis
Cystitis
Deep Vein Thrombosis
Depression
Dizziness
Duodenal Ulcer
Dysaesthesia
Dyspepsia
Dyspnoea
Electrocardiogram Q Waves
Electrocardiogram St
Segment Elevation
Electrocardiogram T Wave
Inversion
Emotional Distress
Erectile Dysfunction
Exostosis
Fatigue
Fluid Overload
Gastritis
Gastroenteritis
Helicobacter
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Haematemesis
Haemorrhage
Haemorrhoids
Hypercalcaemia
Hyperparathyroidism
Hypertension
Injury
Insomnia
Intervertebral Disc
Degeneration
Irritability
Large Intestinal Ulcer
Localised Infection
Mediastinitis

Mental Disorder Due To A
General Medical Condition
Nausea
Night Sweats
Oedema Peripheral
Pain In Extremity
Peptic Ulcer
Pericarditis
Peripheral Nerve
Transposition
Plantar Fasciitis
Pleural Effusion
Pleuritic Pain
Postoperative Infection

		Postpericardiotomy Syndrome					
		Pseudophakia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scan Myocardial Perfusion		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Ulnar Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Vascular Graft Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Venous Thrombosis Limb		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Zoloft	C		
UNKNOWN							
		Weight Decreased		Tenormin	C		
UNKNOWN							
		Weight Increased		Tenormin	C		
UNKNOWN							
				Temazepam	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Zocor	C		ORAL
				Motrin	C		ORAL
				Plavix	C		ORAL
				Relafen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							
				Ultram	C		ORAL
				Ultracet	C		
UNKNOWN							
				Ultracet	C		
UNKNOWN							

	Celebrex	C
UNKNOWN		
	Celebrex	C
UNKNOWN		
	Trazodone Hydrochloride	C
UNKNOWN		
	Trazodone Hydrochloride	C
UNKNOWN		
	Trazodone Hydrochloride	C
UNKNOWN		
	Bextra	C
UNKNOWN		
	Bextra	C
UNKNOWN		
	Flexeril	C
UNKNOWN		
	Flexeril	C
UNKNOWN		
	Paxil	C
UNKNOWN		

Date:02/10/05ISR Number: 4577577-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01792
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Cardiac Failure
	Cardiomyopathy
	Coronary Artery Thrombosis
	Drug Effect Decreased
	Gastrooesophageal Reflux Disease
	Nerve Stimulation Test Abnormal
	Neuralgia

Neuropathy Peripheral

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lopressor	C			UNKNOWN	

Date:02/10/05ISR Number: 4577579-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00802
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Global Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		109 DAY
Initial or Prolonged	Hypertension		Synthroid	C			UNKNOWN	
Other	Injury		Estrace	C			UNKNOWN	
	Ischaemic Stroke		Accupril	C			UNKNOWN	
	Lacunar Infarction		Lasix (Furosemide)	C			UNKNOWN	
	Transient Ischaemic Attack		Potassium (Unspecified)	C			UNKNOWN	
	Urinary Tract Infection		Tylenol	C			UNKNOWN	5141 DAY

Date:02/10/05ISR Number: 4577598-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00302
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cervicobrachial Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Migraine		Vioxx	SS	Merck & Co., Inc	ORAL		

	Syncope	Fentanyl	C
TOPICAL			
	Tachycardia		
	Ventricular Extrasystoles		
	Vomiting		

Date:02/10/05ISR Number: 4577600-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Anaemia
	Angina Pectoris
	Atrial Fibrillation
	Atrioventricular Block
	Body Tinea
	Cardiovascular Disorder
	Carotid Artery Stenosis
	Chest Pain
	Coronary Artery Occlusion
	Dermatitis
	Diverticulum
	Eczema
	Epidermal Necrosis
	Erythema Multiforme
	Granuloma Annulare
	Leukocytoclastic

	Vasculitis						
	Myocardial Ischaemia						
	Nail Bed Bleeding						
	Onycholysis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pruritus Ani		Diovan	C			UNKNOWN	
	Psoriasis		Zocor	C			UNKNOWN	
	Renal Failure		Dapsone	C			UNKNOWN	
	Syncope		Toprol Xl Tablets	C			UNKNOWN	
	Vasculitis							

Date:02/10/05ISR Number: 4577609-8Report Type:Expedited (15-DaCompany Report #BE-MERCK-0410BEL00007
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:02/10/05ISR Number: 4577610-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00626
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adnexa Uteri Mass
Disability	Adverse Event
Other	Agitation
	Arteriovenous Malformation
	Atherosclerosis
	Basedow'S Disease
	Cardiac Disorder
	Cardiac Failure Congestive
	Cardiac Murmur
	Cellulitis
	Chest Injury
	Chest Pain

Chronic Obstructive
Pulmonary Disease
Colonic Polyp
Cough
Diabetes Mellitus
Diabetes Mellitus
Non-Insulin-Dependent
Diplopia
Disorder Of Orbit
Diverticulum
Diverticulum Intestinal
Dizziness
Drug Hypersensitivity
Dyspnoea
Dyspnoea Exertional
Dyspnoea Paroxysmal
Nocturnal
Endocrine Ophthalmopathy
Episcleritis
Eye Disorder
Eye Pain
Fatigue

		Flank Pain					
		Flushing					
		Haemorrhoids	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperhidrosis					
		Hypertension					
		Incontinence					
		Influenza Like Illness					
		Injury					
		Insomnia					
		Limb Discomfort					
		Mass					
		Metastatic Neoplasm					
		Muscle Spasms					
		Myocardial Infarction					
		Myopathy					
		Myositis					
		Nasal Cyst					
		Nausea					
		Nephrolithiasis					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Oedema					
		Oedema Peripheral					
		Optic Atrophy					
		Optic Neuritis					
		Optic Neuropathy					
		Orthopnoea					
		Ovarian Cyst					
		Ovarian Neoplasm					
		Pain In Extremity					
		Palpitations					
		Panic Disorder					
		Panic Reaction					
		Pneumonia					
		Pyelonephritis					
		Rash					
		Road Traffic Accident					
		Sleep Apnoea Syndrome					
		Swelling Face					
		Systemic Lupus					
		Erythematosus					
		Thrombophlebitis					
		Superficial					
		Treatment Noncompliance					
		Urinary Tract Infection					

Venous Stasis
Weight Increased
White Blood Cell Count
Increased

Date:02/10/05ISR Number: 4577617-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01754
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bursitis
	Chest Pain
Disability	Coronary Artery Disease
	Coronary Artery Occlusion
	Ejection Fraction

Decreased
Hypertension
Myocardial Infarction
Tendonitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Combipatch	C			UNKNOWN	
	Minocycline	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Ibuprofen	C			UNKNOWN	
	Advil	C			UNKNOWN	
	Motrin	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Diazepam	C			UNKNOWN	
	Diazepam	C			UNKNOWN	
	Estrogens (Unspecified)	C			UNKNOWN	

Date:02/10/05ISR Number: 4577618-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00717
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Acrochordon
	Adhesion
	Angina Pectoris
	Arthralgia
	Autonomic Neuropathy
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Carotid Artery Stenosis
	Carpal Tunnel
	Decompression

Chest Pain
Chest Wall Pain
Chronic Sinusitis
Convulsion
Cough
Decreased Activity
Diastolic Dysfunction
Diverticulum
Dizziness
Dyspnoea
Dyspnoea Exertional
Essential Tremor
Fall
Fibromyalgia
Flank Pain
Folliculitis
Gastroenteritis
Headache
Hyperglycaemia
Joint Contracture
Kidney Infection
Libido Decreased
Memory Impairment
Muscle Spasms
Myalgia
Nausea

		Nephrolithiasis					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Orthostatic Hypotension		Lipitor	C		
UNKNOWN							
		Otitis Media Acute		Levothyroxine Sodium	C		
UNKNOWN							
		Pain In Extremity		Prevacid	C		
UNKNOWN							
		Pruritus		Estratest	C		
UNKNOWN							
		Pyrexia		Vicodin Tablets	C		
UNKNOWN							
		Restless Legs Syndrome		Fluoxetine			
		Rhinitis Allergic		Hydrochloride	C		
UNKNOWN							
		Sciatica					
		Skin Lesion					
		Syncope					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Visual Acuity Reduced					

Date:02/10/05ISR Number: 4577640-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00605
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
428 DAY						
Hospitalization -	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
504 DAY						
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
13 DAY						
	Stent Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
754 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
428 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
504 DAY						

	Vioxx	SS	Merck & Co., Inc	ORAL	13 DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	754 DAY
	Metoprolol Succinate	C		ORAL	
	Magnesium (Unspecified)	C			UNKNOWN

Date:02/10/05ISR Number: 4577642-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01562
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577646-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02536
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Prerenal Failure
	Anxiety
	Aortic Valve Calcification
	Arthritis
	Atherosclerosis
	Blood Cholesterol Increased
	Blood Pressure Systolic

		Increased					
		Cardiac Murmur					
		Cerebrovascular Accident					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diastolic Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Exostosis		Darvocet-N	C		
UNKNOWN							
		Eye Pain		Avalide	C		
UNKNOWN							
		Gastrooesophageal Reflux		Avalide	C		
UNKNOWN							
		Disease		Avalide	C		
UNKNOWN							
		Gout		Zestril	C		
UNKNOWN							
		Headache		Tiazac	C		
UNKNOWN							
		High Density Lipoprotein		Clonidine	C		ORAL
		Decreased					
		Hypoacusis					
		Hypoaesthesia					
		Ingrowing Nail					
		Injury					
		Irritability					
		Lipids Increased					
		Low Density Lipoprotein					
		Increased					
		Memory Impairment					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Nail Infection					
		Nephrolithiasis					
		Osteoarthritis					
		Pain In Extremity					
		Renal Failure					
		Renal Function Test					
		Abnormal					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					
		Vision Blurred					

Date:02/10/05ISR Number: 4577648-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00122
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ocular Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Oedema Peripheral		Diclofenac Sodium	C				
UNKNOWN								
	Papilloedema							
	Vision Blurred							

Date:02/10/05ISR Number: 4577649-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00035
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Atrial Fibrillation
	Atrioventricular Block Complete
	Blood Creatinine Increased

	Bradyarrhythmia Hypertension Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/10/05ISR Number: 4577650-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01108
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/10/05ISR Number: 4577651-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00329
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Coronary Artery Stenosis Diabetes Mellitus Hypertension Hypertensive Crisis Hypertensive Heart Disease Lipid Metabolism Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/10/05ISR Number: 4577652-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03403
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - UNKNOWN	Epistaxis		Altace	C			
Initial or Prolonged UNKNOWN	Haematuria		Nitroglycerin	C			
Other UNKNOWN	Hiccups		Alprazolam	C			
	Myocardial Infarction		Allopurinol	C			
UNKNOWN							

	Pulmonary Mass		Trazodone Hydrochloride	C		
UNKNOWN						
			Pentoxifylline	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Cymbalta	C		
UNKNOWN						

Date:02/10/05ISR Number: 4577654-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03935
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
	Coronary Artery Disease					

Date:02/10/05ISR Number: 4577655-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03543
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Electrocardiogram T Wave		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Inversion		Synthroid	C		
UNKNOWN						
Initial or Prolonged	Ventricular Extrasystoles		Zyrtec	C		
UNKNOWN						
Disability			Estratest	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577656-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00163
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		149 DAY
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eating Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		149 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stress		Nexium	C				UNKNOWN
	Weight Decreased		Aspirin	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Calcium (Unspecified)	C				UNKNOWN

Date:02/10/05ISR Number: 4577658-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02296
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Motrin	C		ORAL		
	Drug Ineffective							
	Palpitations							

Date:02/10/05ISR Number: 4577659-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03187
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Renal Failure		Vistaril	C				UNKNOWN
Initial or Prolonged			Flomax					

Disability		(Morniflumate)	C
UNKNOWN			
Other		Aspirin	C
UNKNOWN			
		Toprol Xl Tablets	C
UNKNOWN			
		Lopid	C
UNKNOWN			
		Seroquel	C
UNKNOWN			
		Alloprinol	C
UNKNOWN			
		Lisinopril	C
UNKNOWN			
		Imdur	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			
		Nitroglycerin	C
SUBLINGUAL			
		Motrin	C
UNKNOWN			
		Demadex	C
UNKNOWN			

Date:02/10/05ISR Number: 4577660-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00471
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
Disability	Depression
	Dyspnoea Exertional
	Embolism
	Enuresis
	Helicobacter Gastritis
	Osteoarthritis
	Sleep Disorder
	Staphylococcal Infection

	Treatment Noncompliance Urinary Tract Infection Vertebral Artery	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
	Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL	
			Amitriptyline Hydrochloride	C		ORAL	
			Diclofenac Sodium	C			UNKNOWN

Date:02/10/05ISR Number: 4577661-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Chest Discomfort Coronary Artery Disease Electrocardiogram St Segment Depression Heart Rate Irregular Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	

Date:02/10/05ISR Number: 4577663-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00013
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Cardiovascular Disorder Cerebrovascular Accident Deafness Unilateral		Vioxx	PS	Merck & Co., Inc		UNKNOWN

Date:02/10/05ISR Number: 4577664-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00062
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Stenosis Cardiac Valve Disease Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577665-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00082
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
	Varicose Vein		Vioxx	SS	Merck & Co., Inc	ORAL		
	Venous Occlusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577667-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00149
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Palpitations		Flupirtine Maleate	C			UNKNOWN	
	Restlessness		Levothyroxine Sodium	C			UNKNOWN	
	Tachyarrhythmia		Ascorbic Acid And					
	Ventricular Fibrillation		Aspirin	C			UNKNOWN	

Date:02/10/05ISR Number: 4577668-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00779
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Ulcer Haemorrhage							
Hospitalization - Initial or Prolonged								
Disability								

Date:02/10/05ISR Number: 4577669-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00004
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Metoprolol Tartrate	C			UNKNOWN	
			Lansoprazole	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	

Date:02/10/05ISR Number: 4577670-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/10/05ISR Number: 4577671-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00039
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:02/10/05ISR Number: 4577673-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577674-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00043
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		[Therapy					
	Renal Disorder		Unspecified]	C				
UNKNOWN								

Date:02/10/05ISR Number: 4577675-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		[Therapy					
Initial or Prolonged	Myocardial Infarction		Unspecified]	C		ORAL		
Disability	Sensory Loss		[Therapy					
			Unspecified]	C		ORAL		

Date:02/10/05ISR Number: 4577676-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:02/10/05ISR Number: 4577678-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:02/10/05ISR Number: 4577679-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		1334 DAY

Date:02/10/05ISR Number: 4577680-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00170
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Duodenal Ulcer Perforation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lercanidipine	C				UNKNOWN
Initial or Prolonged			Atorvastatin Calcium	C				UNKNOWN
Other			Propranolol Hydrochloride	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4577681-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00019
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Aspirin Calcium	C				UNKNOWN
	Coronary Artery Disease		Fosamax	C		ORAL		
	Neck Pain		Insulin Aspart	C				UNKNOWN
	Neuropathy		Insulin Human, Isophane	C				UNKNOWN
	Osteoarthritis		[Composition Unspecified]	C				UNKNOWN

Date:02/10/05ISR Number: 4577685-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00822
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Drug Toxicity		Vioxx	PS	Merck & Co., Inc			UNKNOWN
	Hepatic Steatosis		Clozaril	SS				UNKNOWN
	Portal Triaditis		Lorazepam	C				UNKNOWN
	Uterine Leiomyoma		Paxil	C				UNKNOWN

Date:02/10/05ISR Number: 4577689-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02729
Age:93 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Congestive Cor Pulmonale							
	Pulmonary Hypertension							
	Weight Increased							

Date:02/10/05ISR Number: 4577694-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03615
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1614 DAY
Hospitalization - Initial or Prolonged	Aortic Valve Replacement		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder			C				
UNKNOWN	Cardiac Failure							
	Congestive							
	Coronary Artery Surgery							

Date:02/10/05ISR Number: 4577696-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								1260 DAY
	Hyperlipidaemia							
	Myocardial Infarction							

Date:02/10/05ISR Number: 4579615-6Report Type:Expedited (15-DaCompany Report #2005-BP-01574YA
Age:74 YR Gender:Male I/FU:I

Outcome	PT
Death	Anoxia
	Arrhythmia

		Cardiac Arrest Coma Electroencephalogram	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Abnormal General Physical Health Deterioration	Health Professional Other	Omix (Tamsulosin Hydrochloride) (Tamsulosin)	PS		
0.4 MG							
		Lung Disorder Lung Infiltration Nosocomial Infection Sepsis Sudden Death Superinfection Lung		Visken (Pindolol) Amarel (Glimepiride) Vioxx (Rofecoxib) Metformin (Metformin)	SS SS SS SS		

Date:02/10/05ISR Number: 4579623-5Report Type:Expedited (15-DaCompany Report #WAES 0311GBR00154
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Malignant Neoplasm Progression	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY,							
		Myocardial Infarction	Health				
PO	420 DAY						
		Oesophageal Carcinoma	Professional				

Date:02/10/05ISR Number: 4579653-3Report Type:Expedited (15-DaCompany Report #WAES 0501USA50184
Age:64 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Electrocardiogram St-T	Study	Tab Vioxx 25mg	PS		ORAL
25							
		Change	Health				
MG/DAILY/PO							
			Professional	Cosopt	C		
				Brimonidine Tartrate	C		
				Latanoprost	C		
				Vitamins	C		

Date:02/10/05ISR Number: 4579805-2Report Type:Expedited (15-DaCompany Report #2004098177
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Celebrex (Celecoxib)	PS		ORAL	100 MG (100 MG 1 IN 1 D)	
Hospitalization - Initial or Prolonged		Health Professional						
Other			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG 1 IN 1 D)	
			Acetylsalicylic Acid(Acetylsalicylic Acid)	C				
			Lansoprazole (Lansoprazole)	C				
			Arthrotec (Diclofenac Sodium, Misoprostol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578328-4Report Type:Expedited (15-DaCompany Report #200511227GDDC
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Melaena		Clexane	PS	Aventis Pharmaceuticals Inc.	SUBCUTANEOUS		
			Vioxx	SS		ORAL		
			Calcium With Vitamin D	C		ORAL		
			Actonel	C		ORAL		
			Ascorbic Acid	C		ORAL		
			Amitriptyline	C		ORAL		
			Folic Acid	C		ORAL		

Date:02/11/05ISR Number: 4578601-XReport Type:Expedited (15-DaCompany Report #US-MERCK-00051950
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Blood Creatine		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Disability	Phosphokinase Increased		Zocor	SS		ORAL	83	DAY
	Cerebellar Infarction		Hydrodiuril	C		ORAL		
	Cerebrovascular Accident		Acetaminophen	C		UNKNOWN		
	Dermatitis		Claritin	C		UNKNOWN		
	Dermatomyositis		Vitamins (Unspecified)	C		UNKNOWN		
	Diabetes Mellitus		Calcium (Unspecified)	C		UNKNOWN		
	Fall							
	Fatigue							
	Headache							
	Hyperhidrosis							
	Hyperplasia							
	Hypertension							
	Insomnia							
	Labyrinthitis							
	Lipoma							

Liver Function Test
Abnormal
Mitochondrial Myopathy
Myalgia
Myopathy
Nystagmus
Pain In Extremity
Paraesthesia
Pharyngitis
Restless Legs Syndrome
Skin Lesion

Date:02/11/05ISR Number: 4578615-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00078
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578616-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01796
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
Initial or Prolonged	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		18 MON
Disability	Arthralgia		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Arthropod Bite							
	Back Pain							
	Blood Glucose Increased							
	Cardiac Failure							
	Congestive							
	Cerumen Impaction							
	Chest Pain							
	Dizziness							
	Drug Hypersensitivity							
	Dyspnoea							
	Dysuria							
	Fall							
	Headache							
	Hodgkin'S Disease							
	Hyperhidrosis							
	Hypertension							
	Injury							
	Intervertebral Disc Degeneration							
	Joint Swelling							
	Labile Hypertension							
	Labyrinthitis							
	Myocardial Infarction							
	Non-Hodgkin'S Lymphoma							
	Oedema Peripheral							
	Osteopenia							
	Skin Cancer							
	Thrombophlebitis							
	Vertigo							
	Weight Increased							

Date:02/11/05ISR Number: 4578627-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02837
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Medication Error		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Pain		Norvasc	C				
UNKNOWN								
	Procedural Complication		Metoprolol	C				
UNKNOWN								

Date:02/11/05ISR Number: 4578632-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578635-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Accident At Home		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Accident At Work		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Neurontin	C			UNKNOWN	
	Asthenia		Ibuprofen	C			UNKNOWN	
	Cardiac Murmur		Claritin	C			UNKNOWN	
	Carpal Tunnel Syndrome		Premarin	C			UNKNOWN	
	Cerebrovascular Accident		Cephalexin	C			UNKNOWN	
	Chest Pain		Skelaxin	C			UNKNOWN	
	Clumsiness		Trazodone Hydrochloride	C			UNKNOWN	
	Cognitive Disorder							
	Contusion		Zovirax	C			UNKNOWN	
	Depression		Methylprednisolone	C			UNKNOWN	
	Disturbance In Attention		Propoxyphene Hydrochloride	C			UNKNOWN	
	Drug Effect Decreased							
	Dyspepsia		Naproxen	C			UNKNOWN	
	Dyspnoea		Baclofen	C		ORAL		
	Dysthymic Disorder							
	Face Injury							
	Fall							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	General Symptom							
	Headache							
	Hypertension							
	Increased Tendency To Bruise							
	Injury							
	Intervertebral Disc							

Protrusion
Irritability
Joint Injury
Memory Impairment
Mitral Valve Incompetence
Myofascial Pain Syndrome
Pain
Pain In Extremity
Pruritus
Sleep Disorder
Stress
Stress Fracture
Thrombosis
Tinnitus
Transient Ischaemic
Attack
Tremor
Tricuspid Valve
Incompetence
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578651-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00214
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiac Valve Disease							
	Fluid Retention							
	Intestinal Haemorrhage							

Date:02/11/05ISR Number: 4578652-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00083
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Circulatory Collapse							
Hospitalization -	Gastric Disorder							
Initial or Prolonged	Gastric Haemorrhage							
Disability	Myocardial Infarction							

Date:02/11/05ISR Number: 4578658-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00126
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Pantoprazole Sodium	C		ORAL		
	Dyspnoea Exertional		Atorvastatin Calcium	C		ORAL		
			Perindopril Erbumine	C		ORAL		
			Silibinin	C		ORAL		
			Ademetionine Sulfate Tosylate	C		ORAL		
			Lormetazepam	C		ORAL		
			Tamsulosin Hydrochloride	C		ORAL		
			Amylase And Bromelains And Chymotrypsin And Lipase And Pancreatin And	C		ORAL		
			Aspirin	C		ORAL		

			Sildenafil Citrate	C		ORAL

Date:02/11/05ISR Number: 4578663-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00533
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4578665-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00158
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578666-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1653 DAY

Date:02/11/05ISR Number: 4578753-1Report Type:Expedited (15-DaCompany Report #PHHO2004US11369
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Femara	PS	Novartis Sector: Pharma	ORAL	2.5 mg, QD	604 DAY
	Asthenia							
	Cerebrovascular Accident		Zoledronate	SS				
	Confusional State							
	Drug Interaction							
	Dysarthria		Vioxx	SS				
	Facial Paresis		Levoxyl	C		ORAL	1 mg, QD	
	Hypoaesthesia		Prilosec	C		ORAL	QD	
	Mitral Valve		Calcium	C			600 mg, BID	
	Calcification		Vicodin	C				
	Mitral Valve Incompetence		Duragesic	C				
	Nausea		Vitamin D	C			400 mg, QD	
	Thrombosis		Lexapro	C		ORAL	10 mg, QD	
	Transient Ischaemic		Advair	C				
	Attack		Flexeril	C			10 mg	
	Tricuspid Valve		Ultram	C			50 mg	
	Incompetence							
	Ventricular Hypertrophy							

Date:02/11/05ISR Number: 4578947-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
	Asthenia
	Benign Prostatic Hyperplasia
	Choking
	Cognitive Disorder
	Cough
	Depression
	Diverticulum
	Dyspnoea
	Dysuria
	Erosive Duodenitis
	Erosive Oesophagitis
	Fatigue
	Gastric Disorder
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Heat Stroke
	Hiatus Hernia
	Hypertension
	Hypoacusis
	Intestinal Functional Disorder
	Lung Disorder
	Malaise

		Muscle Atrophy					
		Nasopharyngitis					
		Oesophageal Rupture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pancreatitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Cyst		Aspirin	C		
UNKNOWN							
		Rhinorrhoea		Restoril	C		
UNKNOWN							
		Stomach Discomfort					
		Stress					
		Supraventricular					
		Extrasystoles					
		Thromboembolic Stroke					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:02/11/05ISR Number: 4578956-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 55 DAY		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability		Drug Hypersensitivity		Zocor	C		ORAL
		Dyspnoea		Estrace	C		
UNKNOWN							
		Emotional Distress		Estrace	C		
UNKNOWN							
		Fall		Prilosec	C		
UNKNOWN							
		Gout		Lortab	C		
UNKNOWN							
		Hypoaesthesia					
		Injury					
		Limb Discomfort					
		Pain In Extremity					
		Sinus Headache					
		Transient Ischaemic					

Attack
Trigeminal Neuralgia
Vaginal Infection

Date:02/11/05ISR Number: 4578959-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00437
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Atrial Fibrillation
	Azotaemia
	Cellulitis
	Cerebrovascular Accident
	Cholelithiasis
	Chronic Sinusitis
	Complex Partial Seizures
	Contusion
	Convulsion
	Dehydration
	Dementia
	Drug Level Fluctuating
	Epistaxis
	Exostosis

		Fall					
		Femoral Neck Fracture					
		Gastritis Atrophic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
1	MON						
		Disease		Tylenol	C		
UNKNOWN							
		Goitre		Atenolol	C		
UNKNOWN							
		Grand Mal Convulsion		Prempro	C		
UNKNOWN							
		Haemorrhoids		Salsalate	C		
UNKNOWN							
		Hypokalaemia		Sulfasalazine	C		
UNKNOWN							
		Hyponatraemia		Claritin	C		
UNKNOWN							
		Injury		Hydrodiuril	C		ORAL
		Malnutrition		Captopril	C		
UNKNOWN							
		Oesophagitis		Hydroxychloroquine			
		Pleural Effusion		Sulfate	C		
UNKNOWN							
		Pneumonia Aspiration		Potassium			
		Pyelonephritis		(Unspecified)	C		
UNKNOWN							
		Rectal Ulcer					
		Reflux Gastritis					
		Staphylococcal Infection					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:02/11/05ISR Number: 4578964-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acanthosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Infarction		Reopro	C		
UNKNOWN						
	Atherosclerosis		Dopamine			
	Blood Cholesterol		Hydrochloride	C		
UNKNOWN						

	Increased	Restoril	C	
UNKNOWN				
	Cardiac Arrest	Aspirin	C	ORAL
	Cardiac Failure	Prozac	C	
UNKNOWN				
	Congestive	Tylenol	C	
UNKNOWN				
	Cardio-Respiratory Arrest	Atrovent	C	
UNKNOWN				
	Cardiogenic Shock	Pepcid	C	
UNKNOWN				
	Chest Pain	Cordarone	C	
UNKNOWN				
	Convulsion	Claforan	C	
UNKNOWN				
	Coronary Artery Disease	Magnesium Sulfate	C	
UNKNOWN				
	Dizziness	Buspar	C	
UNKNOWN				
	Haematuria	Prozac	C	
UNKNOWN				
	Hyperkeratosis	Atenolol	C	
UNKNOWN				
	Hypertension	Celexa	C	
UNKNOWN				
	Ischaemic Cardiomyopathy	Neurontin	C	
UNKNOWN				
	Lung Infiltration	Dalmane	C	
UNKNOWN				
	Myalgia	Vasotec	C	
UNKNOWN				
	Myocardial Infarction			
	Nausea			
	Orthostatic Hypotension			
	Papilloma			
	Skin Laceration			
	Ventricular Fibrillation			
	Ventricular Hypokinesia			
	Ventricular Tachycardia			
	Vomiting			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578965-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03698
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1289 DAY
Hospitalization -	Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1289 DAY
Initial or Prolonged	Asthenia		Lanoxin	C		ORAL		
Disability	Atrial Fibrillation		Lanoxin	C		ORAL		
Other	Cardiac Failure		Prinivil	C		ORAL		
	Congestive		Prinivil	C		ORAL		
	Chest Pain		Tricor	C		ORAL		
	Embolic Stroke		K-Dur	C		ORAL		
	Flank Pain		Neurontin	C		ORAL		
	Gastric Disorder		Coumadin	C				UNKNOWN
	Heart Injury		Betapace	C				UNKNOWN
	Hemiparesis		Arava	C		ORAL		89 DAY
	Hypoaesthesia		Nitrostat	C				SUBLINGUAL
	Spinal Vascular Disorder		A.S.A.	C				UNKNOWN

Date:02/11/05ISR Number: 4578968-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00812
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Respiratory Failure
Hospitalization -	Anorexia
Initial or Prolonged	Atrial Fibrillation
Other	Blood Albumin Decreased
	Blood Cholesterol Increased
	Bronchial Infection
	Bronchiectasis
	Bronchitis
	Bronchitis Chronic
	Candidiasis
	Cardiac Disorder
	Cardiac Failure
	Congestive

Cerebral Haematoma
Cerebrovascular Accident
Chills
Chronic Obstructive
Pulmonary Disease
Chronic Respiratory
Failure
Clostridium Colitis
Conjunctivitis
Corneal Disorder
Death
Diarrhoea
Drug Hypersensitivity
Dry Mouth
Dyspepsia
Emphysema
Fatigue
Head Discomfort
Hiatus Hernia
Hyperkalaemia
Hypokalaemia
Hypoxia
Injury
Lobar Pneumonia

		Mitral Valve Incompetence					
		Muscle Spasms					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Oxygen Saturation		Premarin	C		
UNKNOWN							
		Decreased		Singulair	C		
UNKNOWN							
		Pain		Azmacort	C		
RESPIRATORY							
		Palpitations					
(INHALATION)							
		Pneumonia					
		Pneumonia Pneumococcal					
		Pseudomonas Infection					
		Pulmonary Hypertension					
		Skin Laceration					
		Sputum Culture Positive					
		Tremor					
		Weight Decreased					

Date:02/11/05ISR Number: 4578970-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00081270
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
2 MON						
	Myocardial Infarction		Prinivil	C		
UNKNOWN						
	Polytraumatism					
	Renal Disorder					

Date:02/11/05ISR Number: 4578971-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
10 DAY						
Initial or Prolonged	Infarction		Griseofulvin	C		
UNKNOWN						

	Anhedonia		[Therapy	
	Anxiety		Unspecified]	C
UNKNOWN				
	Coronary Artery Occlusion		Isoptin	C
UNKNOWN				
	Drug Ineffective		Beconase Aq	C
UNKNOWN				
	Emotional Distress			
	Haematoma			
	Hyperkeratosis			
	Hyperlipidaemia			
	Hyperplasia			
	Injury			
	Pain			
	Pelvic Haematoma			
	Stress			
	Tinea Infection			

Date:02/11/05ISR Number: 4578972-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00391
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		319 DAY
Hospitalization -	Complete		Vioxx	SS	Merck & Co., Inc	ORAL		82 DAY
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		156 DAY
Disability	Cerebrovascular Accident		[Therapy					
Other	Hypertension		Unspecified]	C		ORAL		
	Hypertensive Crisis		Xipamide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578973-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Abdominal Distension		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
	Abdominal Sepsis		Vasotec	C		ORAL		
	Blood Pressure Systolic Decreased		Vasotec	C		ORAL		
			Lipitor	C				UNKNOWN
	Bowel Sounds Abnormal		Ecotrin	C		ORAL		
	Breath Sounds Decreased		Hydrochlorothiazide	C				UNKNOWN
	Constipation		Prevacid	C				UNKNOWN
	Crohn'S Disease		Relafen	C				UNKNOWN
	Cyst		Ziac	C				UNKNOWN
	Diarrhoea		Zebeta	C				UNKNOWN
	Diverticulum Duodenal							
	Dyspepsia							
	Emotional Distress							
	Extravasation							
	Gastrooesophageal Reflux Disease							
	Hiatus Hernia							
	Ileal Ulcer							
	Ileitis							
	Intervertebral Disc Degeneration							
	Lactose Intolerance							
	Large Intestinal Obstruction							
	Large Intestinal Ulcer							
	Large Intestine Perforation							
	Livedo Reticularis							
	Lung Infiltration							
	Metabolic Acidosis							
	Miosis							
	Multi-Organ Failure							
	Necrotising Colitis							

Osteoarthritis
Peripheral Ischaemia
Pleural Effusion
Postoperative Ileus
Purulent Discharge
Renal Cortical Necrosis
Renal Cyst
Renal Failure Acute
Renal Tubular Necrosis
Respiratory Failure
Septic Shock
Sinus Tachycardia
Small Intestine Ulcer
Ureteral Disorder
Vasospasm
Wound Infection

Date:02/11/05ISR Number: 4578974-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA02515
Age:60 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	274	DAY
Infarction		Premarin	C			UNKNOWN	
Acute Respiratory Failure		Lipitor	C			UNKNOWN	
Anxiety		Ativan	C			UNKNOWN	
Arthritis		Aleve	C			UNKNOWN	
Cardiac Arrest		Ecotrin	C			UNKNOWN	
Hypoxic Encephalopathy		Vitamins					
Injury		(Unspecified)	C			UNKNOWN	
Tenosynovitis		Albuterol	C			UNKNOWN	
Ventricular Fibrillation		Prozac	C			UNKNOWN	
		Zocor	C		ORAL		

Date:02/11/05ISR Number: 4578975-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arterial Stenosis		Premarin	C				
UNKNOWN								
Disability	Arthralgia		Zocor	C				
UNKNOWN								
Other	Back Pain		Voltaren	C				
UNKNOWN								
	Buttock Pain		Flexeril	C				
UNKNOWN								
	Coronary Artery Disease		Guaifenesin And					
	Depression		Pseudoephedrine					
	Dysphonia		Hydrochloride	C				
UNKNOWN								
	Intervertebral Disc							
	Protrusion							

Muscle Spasms
Myocardial Infarction
Myocardial Ischaemia
Neck Injury
Neck Pain
Pain In Extremity
Rotator Cuff Syndrome
Tendonitis

Date:02/11/05ISR Number: 4578976-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Coronary Syndrome
	Acute Myocardial Infarction
	Arthralgia
	Blindness
	Chest Pain
	Corneal Ulcer
	Coronary Artery Occlusion
	Coronary Artery Restenosis
	Cough
	Diverticulum
	Emotional Distress
	Fatigue
	Gastritis
	Gastroduodenitis

	Glaucoma						
	Haematuria						
	Hyperlipidaemia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	1128 DAY	
	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	1128 DAY	
	Myocardial Infarction		Nortriptyline	C			UNKNOWN	233 DAY
	Nausea		Trazodone Hydrochloride	C			UNKNOWN	
	Neck Pain							
	Nephrolithiasis		Vicodin Tablets	C			UNKNOWN	
	Osteoarthritis							
	Pain							
	Platelet Count Decreased							
	Ventricular Hypertrophy							
	Vomiting							

Date:02/11/05ISR Number: 4578977-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	115 DAY	
Initial or Prolonged	Angina Unstable		Haldol	C			UNKNOWN	
Other	Back Injury		Hydrocodone Bitartrate	C			UNKNOWN	
	Back Pain							
	Cervicobrachial Syndrome							
	Coronary Artery Disease							
	Depression							
	Gout							
	Hypertension							
	Intervertebral Disc Protrusion							
	Lumbar Radiculopathy							
	Myocardial Infarction							
	Neck Injury							
	Post Concussion Syndrome							
	Post-Traumatic Headache							

Road Traffic Accident
Weight Increased

Date:02/11/05ISR Number: 4578979-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA00704
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Atherosclerosis
	Attention Deficit/Hyperactivity Disorder
	Chest Pain
	Chronic Fatigue Syndrome
	Depression
	Dizziness
	Eye Swelling
	Gastrooesophageal Reflux Disease
	Generalised Anxiety Disorder
	Haemorrhoidal Haemorrhage
	Hypercholesterolaemia

	Hypertension						
	Insomnia						
	Joint Swelling	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Lower Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
	Haemorrhage		[Therapy				
	Microcytic Anaemia		Unspecified]	C			UNKNOWN
	Oedema Peripheral		Paxil	C			UNKNOWN
	Panic Disorder		Ibuprofen	C			UNKNOWN
	Phlebitis Superficial		Zoloft	C			UNKNOWN

Date:02/11/05ISR Number: 4578980-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03341
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Hospitalization -	Blood Albumin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Blood Alkaline		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Blood Lactate		Ortho-Cyclen	C			UNKNOWN
	Dehydrogenase Increased		Iron (Unspecified)	C			UNKNOWN
	Cardio-Respiratory Arrest		Darvocet-N	C			UNKNOWN
	Convulsion						
	Cyanosis						
	Deep Vein Thrombosis						
	Dizziness						
	Dyspnoea Exertional						
	Fatigue						
	Headache						
	Hyperhidrosis						
	Hypoxia						
	Pulmonary Embolism						
	Thrombosis						

Date:02/11/05ISR Number: 4578981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Abnormal Dreams
Other	Acute Sinusitis
	Adverse Event
	Amenorrhoea
	Angina Pectoris
	Aphthous Stomatitis
	Arthralgia
	Atelectasis
	Blood Pressure Increased
	Breast Pain
	Breast Tenderness
	Bronchitis Acute
	Bursitis
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Pain
	Coagulopathy
	Condition Aggravated
	Conjunctival Haemorrhage
	Contusion
	Convulsion

Cyst
Diarrhoea
Difficulty In Walking
Disease Recurrence
Dizziness
Drug Dependence
Drug Hypersensitivity
Drug Ineffective
Drug Tolerance Decreased
Dysstasia
Eczema
Endometriosis
Epistaxis
Fall
Fatigue
Feeling Cold
Flushing
Gastroenteritis Viral
Generalised Oedema
Headache
Hip Arthroplasty
Hyperglycaemia
Hypoaesthesia
Hypoglycaemia
Hypothyroidism
Increased Tendency To
Bruise
Influenza
Ingrowing Nail
Inguinal Hernia
Injury
International Normalised
Ratio Increased
Laryngitis
Localised Infection
Loss Of Libido
Mastitis
Menorrhagia
Migraine
Munchausen'S Syndrome
Muscle Atrophy
Muscle Spasms
Musculoskeletal
Discomfort
Nausea
Neck Mass
Nervousness

Non-Hodgkin'S Lymphoma
Oligomenorrhoea
Osteoarthritis
Otitis Externa
Otitis Media
Ovarian Cyst
Pain
Pain In Extremity
Pain In Jaw
Panic Attack
Panic Disorder
Paraesthesia
Patent Ductus Arteriosus
Pelvic Inflammatory

		Disease					
		Pharyngitis					
		Photosensitivity Reaction					
		Postoperative Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
		Scar					
		Sinus Disorder					
		Sinusitis					
		Splenic Cyst					
		Stress					
		Systemic Lupus Erythematosus					
		Thrombotic Stroke					
		Tooth Disorder					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Urine Abnormality					
		Vaginal Mycosis					
		Vaginitis Bacterial					
		Viral Infection					
		Vomiting					
		Weight Decreased					

Date:02/11/05ISR Number: 4578989-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03743
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Feeling Hot		Fosamax	C		ORAL
		Transient Ischaemic Attack		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C		ORAL
				Calcium (Unspecified) And Vitamin D (Unspecified)	C		
UNKNOWN							

Date:02/11/05ISR Number: 4578990-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03128
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atacand	C				
UNKNOWN								
Initial or Prolonged			Effexor	C				
UNKNOWN								
Disability			Lasix (Furosemide)	C				
UNKNOWN								

Date:02/11/05ISR Number: 4578991-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00611
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cerebellar Infarction
Initial or Prolonged	Chest Pain
Disability	Dyspnoea Exertional
	Vertebral Artery

Occlusion
Wallenberg Syndrome

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Phenprocoumon	C			UNKNOWN	
	Levetiracetam	C			UNKNOWN	
	Tizanidine Hydrochloride	C			UNKNOWN	

Date:02/11/05ISR Number: 4578992-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00049
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	30	DAY
	Peripheral Occlusive Disease							

Date:02/11/05ISR Number: 4578993-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00087
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion							
	Myocardial Infarction							

Date:02/11/05ISR Number: 4578994-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00683
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization -	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Haemorrhage		Vicodin Tablets	C			
UNKNOWN							
Disability	Heart Injury						
	Myocardial Infarction						
	Thrombosis						

Date:02/11/05ISR Number: 4578995-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00022
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4578996-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								
			Hydrochlorothiazide And Irbesartan	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4578998-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03533
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cauda Equina Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Prozac	C			UNKNOWN	
	Colonic Polyp		Clonidine	C			UNKNOWN	
	Diabetes Mellitus		Lotrel	C			UNKNOWN	
	Diverticulum		Aspirin	C			UNKNOWN	
	Diverticulum Intestinal		Proventil	C			UNKNOWN	
	Fall		Coreg	C			UNKNOWN	
	Ligament Sprain		Indomethacin	C			UNKNOWN	
	Malignant Hypertension		Lasix (Furosemide					
	Myocardial Ischaemia		Sodium)	C			UNKNOWN	
	Neck Injury							
	Osteoarthritis							
	Pain In Extremity							

Date:02/11/05ISR Number: 4578999-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01205
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Lower Gastrointestinal		Benicar	C		ORAL		
	Haemorrhage		A.S.A.	C			UNKNOWN	
Other	Procedural Site Reaction		Prozac	C		ORAL		
			Tranxene	C		ORAL		

Date:02/11/05ISR Number: 4579000-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03413
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Wellbutrin	C				
Other			Hormones (Unspecified)	C			UNKNOWN	

Date:02/11/05ISR Number: 4579002-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03257
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Cardiac Disorder		Metformin Hydrochloride	C				
Other	Coronary Artery Disease		Metformin Hydrochloride	C			UNKNOWN	
	Coronary Artery Restenosis		Tramadol Hydrochloride	C			UNKNOWN	
	Coronary Artery Stenosis		Piroxicam	C			UNKNOWN	
	Hypertension		Metoprolol Succinate	C			UNKNOWN	
	Medication Error		Isosorbide Mononitrate	C			UNKNOWN	
	Myocardial Infarction		Sertraline Hydrochloride	C			UNKNOWN	
	Refusal Of Treatment By Patient		Trazodone Hydrochloride	C			UNKNOWN	
	Ventricular Hypokinesia		Lisinopril	C			UNKNOWN	

			Zocor	C	ORAL
			Morphine	C	
UNKNOWN					
			Omeprazole	C	
UNKNOWN					
			Atenolol	C	ORAL
			Aspirin	C	
UNKNOWN					

Date:02/11/05ISR Number: 4579004-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00023
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/11/05ISR Number: 4579005-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02933
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
768 DAY						
Disability	Arthropod Bite		Vioxx	SS	Merck & Co., Inc	ORAL
768 DAY						
	Cataract		Plavix	C		
UNKNOWN						
	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						
	Diarrhoea					
	Headache					
	Hemianopia Homonymous					
	Localised Infection					
	Nausea					
	Pain In Extremity					
	Temperature Intolerance					
	Transient Ischaemic					
	Attack					

Date:02/11/05ISR Number: 4579006-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03933
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579007-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Atenolol	C			UNKNOWN	
	Coronary Artery Stenosis		Norvasc	C			UNKNOWN	
	Hypertension Myocardial Infarction Ventricular Hypokinesia							

Date:02/11/05ISR Number: 4579008-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03366
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Tricor	C			UNKNOWN	
Initial or Prolonged	Dizziness		Crestor	C			UNKNOWN	
Disability	Myocardial Infarction		Plavix	C			UNKNOWN	

			Prinivil	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			Imdur	C		
UNKNOWN						
			Metoprolol	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						

Date:02/11/05ISR Number: 4579009-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04373
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Lisinopril	C				
UNKNOWN								
	Cerebrovascular Accident		Premarin	C				
UNKNOWN								
	Formication		[Therapy					
	Headache		Unspecified]	C				
UNKNOWN								
	Hyperhidrosis		Xanax	C		ORAL		
	Hypertension		Hydrochlorothiazide					
	Hypoaesthesia		And Lisinopril	C		ORAL		
	Joint Range Of Motion		Aspirin	C		ORAL		
	Decreased		Wellbutrin Sr	C		ORAL		
	Movement Disorder		Dynacirc Cr	C		ORAL		
	Pain		Norvasc	C				
UNKNOWN								
	Pain In Extremity		Toprol Xl Tablets	C				
UNKNOWN								
	Refusal Of Treatment By Patient							
	Road Traffic Accident							

Date:02/11/05ISR Number: 4579016-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:02/11/05ISR Number: 4579020-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00085
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:02/11/05ISR Number: 4579021-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00057
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579022-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579023-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:02/11/05ISR Number: 4579024-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00081
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastritis Erosive		Ketoprofen	SS		ORAL		
	Haematemesis		Ketoprofen	SS		ORAL		
			Lisinopril	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Pravastatin Sodium	C		ORAL		

Date:02/11/05ISR Number: 4579025-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00078
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	869	DAY
Hospitalization - Initial or Prolonged			Celecoxib	SS		ORAL	92	DAY
			Risedronate Sodium	C		ORAL		
			Quinine	C		ORAL		
			Methotrexate	C		ORAL		

			Prednisolone	C		ORAL
			Furosemide	C		ORAL
			Ranitidine	C		ORAL
			Acetaminophen And Propoxyphene Hydrochloride	C		ORAL

Date:02/11/05ISR Number: 4579026-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00082
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Melaena		Enoxaparin Sodium	SS		SUBCUTANEOUS	38	DAY
			Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
			Risedronate Sodium	C		ORAL		
			Ascorbic Acid	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Folic Acid	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4579027-5Report Type:Expedited (15-DaCompany Report #DK-MERCK-0502DNK00012
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		30 MON
Initial or Prolonged			Levothyroxine Sodium	C		ORAL		

Date:02/11/05ISR Number: 4579028-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00058
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma Hepatic		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Life-Threatening	Jaundice Cholestatic							
Hospitalization - Initial or Prolonged								

Date:02/11/05ISR Number: 4579030-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00543
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579031-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00424
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dehydration Difficulty In Walking Dizziness Dry Mouth Ejection Fraction Decreased Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		

Heart Rate Decreased
Hypotension
Palpitations

Date:02/11/05ISR Number: 4579032-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00425
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Choking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea							
	Pain							

Date:02/11/05ISR Number: 4579033-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00290
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Other	Anxiety
	Arthropathy
	Balance Disorder
	Blood Cholesterol Increased
	Bradycardia

	Cerebral Atrophy						
	Chest Pain						
	Costochondritis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Epidermal Naevus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Menest	C		ORAL		
	Foot Fracture		Fosamax	C		ORAL		
	Gastrointestinal		A.S.A.	C		ORAL		
	Haemorrhage		Tylenol Pm	C		ORAL		
	Headache							
	Hypertension							
	Lacunar Infarction							
	Myocardial Infarction							
	Sleep Disorder							
	Stress							
	Transient Ischaemic							
	Attack							
	Ulcer							

Date:02/11/05ISR Number: 4579034-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00555
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1095 DAY	

Date:02/11/05ISR Number: 4579036-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	967 DAY	

Date:02/11/05ISR Number: 4579037-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability Other	Cardiac Disorder Cardiac Failure Congestive Disability Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/11/05ISR Number: 4579042-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00437
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579043-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00340
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Myocardial Infarction		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL		

Unspecified] C
UNKNOWN

Date:02/11/05ISR Number: 4579045-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00018
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		1335 DAY
Initial or Prolonged	Atherosclerosis		Metoprolol Tartrate	C				UNKNOWN
			Amlodipine Besylate	C				UNKNOWN
			Aspirin And Magnesium Oxide	C				UNKNOWN
			Celecoxib	C		ORAL		
			Isosorbide Mononitrate	C				UNKNOWN

Date:02/11/05ISR Number: 4579046-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00913
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579047-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ovarian Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Atenolol	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Levoxyl	C				UNKNOWN

Date:02/11/05ISR Number: 4579049-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579050-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abortion Spontaneous Drug Exposure During Pregnancy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579051-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00790
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Trazodone Hydrochloride	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Hydroxyzine Hydrochloride	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			[Therapy					

Unspecified] C
UNKNOWN

Date:02/11/05ISR Number: 4579052-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579053-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00806
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prozac	C				
UNKNOWN								
Initial or Prolonged	Thrombosis		Celebrex	C				
UNKNOWN								
Disability								

Date:02/11/05ISR Number: 4579055-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579057-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00911
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579058-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579059-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579061-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/11/05ISR Number: 4579062-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579064-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00912
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/11/05ISR Number: 4579067-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00180
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alcohol Detoxification
Other	Amaurosis Fugax
	Amnesia
	Anaemia
	Aortic Aneurysm
	Aortic Stenosis
	Aortic Valve Incompetence
	Aortic Valve Stenosis
	Appendicectomy
	Arterial Occlusive Disease
	Asthenia
	Atrial Fibrillation
	Atrioventricular Block First Degree
	Atrioventricular Block Second Degree
	Blindness Transient
	Blood Pressure Increased
	Cardiac Disorder
	Cardiomegaly
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Confusional State
	Contusion

Coronary Artery
Atherosclerosis
Coronary Artery Disease
Dementia
Diverticulum Intestinal
Dyspnoea Exertional
Electrocardiogram St-T
Change
Fall
Gait Disturbance
Haematoma
Headache
Hypertension
Insomnia
Irritable Bowel Syndrome
Mitral Valve Incompetence
Nervousness
Osteitis Deformans
Pain

		Procedural Complication Qrs Axis Abnormal Retinal Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Upper Limb Fracture		Coreg	C		
UNKNOWN							
		Vascular Calcification		Enalapril Maleate	C		
UNKNOWN							
		Ventricular Hypertrophy		Ambien	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							

Date:02/11/05ISR Number: 4579071-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00917
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:02/11/05ISR Number: 4582528-7Report Type:Direct Company Report #CTU 240194
Age:49 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx 50 Mg	PS		
3 X DAILY							
Hospitalization - Initial or Prolonged							

Date:02/11/05ISR Number: 4582531-7Report Type:Direct Company Report #CTU 240190
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS			DAILY	-3 YRS
Required Intervention to Prevent Permanent Impairment/Damage	Dyspnoea		Rofecoxib	C				
	Syncope							

Date:02/11/05ISR Number: 4582594-9Report Type:Direct Company Report #CTU 240232
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx 50 Mg	PS		ORAL	1 A DAY	
	Myocardial Calcification						ORALLY	
	Sudden Cardiac Death		Diovan	C				
			Zocor	C				
			Prednisone	C				

Date:02/14/05ISR Number: 4580031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Aptyalism
Other	Arthralgia
	Asthenia

		Atrial Flutter					
		Back Pain					
		Blood Cholesterol	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure Diastolic		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Coumadin	SS		
UNKNOWN							
		Bursitis		Coumadin	SS		
UNKNOWN							
		Cardiac Flutter					
		Cerebral Haemorrhage					
		Chest Pain					
		Condition Aggravated					
		Contusion					
		Coronary Artery Disease					
		Decreased Activity					
		Decreased Appetite					
		Disease Recurrence					
		Dyspepsia					
		Dysphagia					
		Fall					
		Gastric Ulcer					
		Gastrooesophageal Reflux					
		Disease					
		Haematoma					
		Headache					
		Hypertensive Heart					
		Disease					
		Influenza					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Injury					
		Laceration					
		Lacunar Infarction					
		Limb Injury					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasal Sinus Drainage					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					

Pain
Pneumonia
Pruritus
Pulmonary Hypertension
Radiculopathy
Renal Failure
Rotator Cuff Syndrome
Sinus Disorder
Sinusitis
Spinal Osteoarthritis
Stomach Discomfort
Subdural Haematoma
Tricuspid Valve
Incompetence
Urinary Retention

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580046-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03988
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		K-Dur	C		ORAL		1308 DAY
Other	Back Injury		K-Dur	C		ORAL		
	Back Pain		Minipress	C		ORAL		646 DAY
	Blood Calcium Increased		Lopressor	C		ORAL		48 DAY
	Cervical Polyp		Lopressor	C		ORAL		593 DAY
	Cholecystitis		Lozol	C		ORAL		594 DAY
	Fatigue							
	Heart Rate Decreased							
	Hyperparathyroidism							
	Intestinal Cyst							
	Migraine							
	Myocardial Infarction							
	Nausea							
	Parathyroid Tumour Benign							
	Tenosynovitis							
	Thrombophlebitis Superficial							

Date:02/14/05ISR Number: 4580050-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03030
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		443 DAY
Hospitalization - UNKNOWN	Chest Pain		Enbrel	C				
Initial or Prolonged UNKNOWN	Palpitations		Synthroid	C				
Disability								

Date:02/14/05ISR Number: 4580054-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00901
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		584 DAY
Disability	Pneumonia		Lovenox	C				UNKNOWN
	Pulmonary Embolism		Coumadin	C				UNKNOWN

Date:02/14/05ISR Number: 4580059-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02769
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pain							

Date:02/14/05ISR Number: 4580060-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00111
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Death	Agitation
Hospitalization - Initial or Prolonged	Arteriosclerosis
	Cerebral Infarction
	Cerebrovascular Accident
	Coma
	Crying

		Decreased Appetite					
		Delirium					
		Dysuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
		Encephalopathy		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Fatigue		Norvasc	C		ORAL
		Feeling Hot And Cold		Prevacid	C		
UNKNOWN							
		Gastrooesophageal Reflux		Tylenol	C		
UNKNOWN							
		Disease		Aspirin	C		
UNKNOWN							
		Injury		Prilosec	C		
UNKNOWN							
		Insomnia		Univasc	C		
UNKNOWN							
		Intracranial Aneurysm					
		Nerve Degeneration					
		Restlessness					
		Stress					
		Thyroid Disorder					
		Vasculitis					

Date:02/14/05ISR Number: 4580062-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00715
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Adverse Event
	Alanine Aminotransferase
	Increased
	Anaemia
	Angina Pectoris
	Angina Unstable
	Aspartate
	Aminotransferase
	Increased
	Biliary Tract Disorder
	Blood Alkaline
	Phosphatase Increased

Blood Ph Increased
Blood Pressure Diastolic
Decreased
Cardiac Failure
Cardiomegaly
Cerebrovascular Accident
Chest Pain
Convulsion
Coronary Artery Disease
Diarrhoea
Dilatation Atrial
Drug Ineffective
Dyspepsia
Fibromyalgia
Gamma-Glutamyltransferase
Increased
Gastritis
Gastritis Erosive
Haemodialysis
Haemoglobin Increased
Haemorrhoids
Hypertension
Hypoalbuminaemia

		Hypoxia					
		Infectious Mononucleosis					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL
		Left Ventricular		Vioxx	SS	Merck & Co., Inc	ORAL
		End-Diastolic Pressure		Serzone	C		
UNKNOWN							
		Increased		Fiorinal	C		
UNKNOWN							
		Liver Disorder					
		Lung Infiltration					
		Migraine					
		Mitral Valve Incompetence					
		Multi-Organ Disorder					
		Muscle Spasms					
		Pancreatitis					
		Platelet Count Decreased					
		Pneumonia					
		Pneumonitis					
		Pulmonary Fibrosis					
		Pulmonary Oedema					
		Pyoderma Gangrenosum					
		Renal Failure					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Respiratory Disorder					
		Respiratory Distress					
		Respiratory Failure					
		Skin Ulcer					
		Spondylolisthesis					
		Therapeutic Response					
		Decreased					
		Vasculitis					
		White Blood Cell Count					
		Increased					

Date:02/14/05ISR Number: 4580067-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00492
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Hypercoagulation		Vioxx	SS	Merck & Co., Inc	ORAL

Initial or Prolonged	Intestinal Haemorrhage	Metformin	C
UNKNOWN			
	Intestinal Infarction	Acarbose	C
UNKNOWN			
	Intestinal Ischaemia	Pantoprazole Sodium	C
UNKNOWN			
	Mesenteric Vein	Silibinin	C
UNKNOWN			
	Thrombosis	Magnesium Aspartate And Potassium Aspartate	C
UNKNOWN			
		Tetrazepam	C
UNKNOWN			

Date:02/14/05ISR Number: 4580068-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00575
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anaemia		[Therapy			
Initial or Prolonged	Asthenia		Unspecified]	C		
UNKNOWN						
Disability	Dyspnoea					
	Haemorrhage					

Date:02/14/05ISR Number: 4580071-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01637
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Hypertensive		[Therapy					
UNKNOWN	Cardiomyopathy		Unspecified]	C				
Other	Transient Ischaemic Attack							

Date:02/14/05ISR Number: 4580072-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00426
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Disorder							

Date:02/14/05ISR Number: 4580074-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01821
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Initial or Prolonged	Bowel Movement		Coumadin	C				
UNKNOWN								
Disability	Irregularity		Cozaar	C				
UNKNOWN								
	Faecal Volume Increased		[Therapy					
	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
	Stomach Discomfort		Zocor	C		ORAL		
			Atenolol	C		ORAL		
			Atenolol	C		ORAL		
			Lasix (Furosemide Sodium)	C		ORAL		
			Lasix (Furosemide					

Sodium)	C			ORAL
Lanoxin	C			ORAL
K-Dur	C			ORAL

Date:02/14/05ISR Number: 4580075-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03936
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580082-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00012
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580085-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580087-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00036
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Convulsion Haemorrhage Hyponatraemia Skin Laceration		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580088-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00015
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580089-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00174
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
	Labile Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx Naloxone Hydrochloride And Tilidine	SS	Merck & Co., Inc	ORAL		

				Hydrochloride	C		
UNKNOWN	22	DAY					
				Nadroparin Calcium	C		
SUBCUTANEOUS	6	DAY					

Date:02/14/05ISR Number: 4580090-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00646
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Prevacid	C				
UNKNOWN								
Initial or Prolonged	Cardiac Murmur		Plavix	C				
UNKNOWN								
	Myocardial Infarction		Aspirin	C				
UNKNOWN								

Date:02/14/05ISR Number: 4580091-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00014
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580093-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00625
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization - Initial or Prolonged	Aortic Valve Calcification		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
Disability	Atrioventricular Block		Plavix	C				
UNKNOWN								
Other	First Degree		Aspirin	C				
UNKNOWN								
	Blood Pressure Inadequately Controlled		Labetalol Hydrochloride	C				
UNKNOWN								
	Cardiac Failure		Lipitor	C				
UNKNOWN								
	Congestive		Xanax	C				
UNKNOWN								
	Cardiovascular Disorder Electrocardiogram St-T		[Therapy Unspecified]	C				
UNKNOWN								
	Change							
	Hot Flush							
	Hypertension							
	Mitral Valve Incompetence							
	Pulmonary Oedema							
	Rash							
	Tricuspid Valve Incompetence							

Date:02/14/05ISR Number: 4580095-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00197
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Heart Rate Increased		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/14/05ISR Number: 4580096-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00183
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Peripheral Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580098-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	95	DAY

Date:02/14/05ISR Number: 4580099-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580100-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00562
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prevacid	C				
UNKNOWN								
Initial or Prolonged			Metoclopramide	C				
UNKNOWN								

Date:02/14/05ISR Number: 4580103-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00561
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580104-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00420
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580105-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
1797 DAY								

Date:02/14/05ISR Number: 4580106-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00559
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
447 DAY

Date:02/14/05ISR Number: 4580110-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580114-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebral Infarction Ischaemic Stroke Retinal Artery Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580119-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580120-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Supraventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580121-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580122-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580123-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580125-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01049
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Cholesterol Increased Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Chest Pain
Hepatic Enzyme Increased
Thrombosis

Date:02/14/05ISR Number: 4580126-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580128-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4580129-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580130-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580131-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased Cerebrovascular Accident Chest Pain Hepatic Enzyme Increased Hypertension Renal Disorder Thrombosis Transient Ischaemic Attack Visual Acuity Reduced		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4580146-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	66	DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	66	DAY

Blood Bilirubin Increased
Cardiac Valve Disease
Change Of Bowel Habit
Chest Pain
Coronary Artery
Atherosclerosis
Dyspnoea
Hand Fracture
Myocardial Infarction
Rectal Haemorrhage
Renal Failure

Date:02/14/05ISR Number: 4580257-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369493A
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dissection		Deroxat	PS	Glaxosmithkline	ORAL	20MG Per day	
Initial or Prolonged	Carotid Artery Dissection		Art	SS		ORAL	50MG Twice per day	
	Cerebrovascular Accident							
			Oesclim	SS				
			Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582003-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Arthralgia		Aspirin	C				
Disability	Asthenia		Restoril	C				UNKNOWN
	Benign Prostatic Hyperplasia							
	Choking							
	Cough							
	Depression							
	Diverticulum							
	Dysgeusia							
	Dyspnoea							
	Dysuria							
	Erosive Duodenitis							
	Erosive Oesophagitis							
	Fatigue							
	Gastric Disorder							
	Gastritis Erosive							
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Heat Stroke							
	Hiatus Hernia							
	Hypertension							
	Hypoacusis							
	Intestinal Functional Disorder							
	Lung Disorder							
	Malaise							
	Muscle Atrophy							
	Nasopharyngitis							
	Oesophageal Rupture							
	Pancreatitis							
	Renal Cyst							
	Rhinorrhoea							
	Stomach Discomfort							
	Stress							
	Supraventricular Extrasystoles							
	Thromboembolic Stroke							
	Transient Ischaemic							

Attack
Upper Respiratory Tract
Infection
Urinary Retention
Urinary Tract Disorder
Urinary Tract Infection
Weight Decreased

Date:02/14/05ISR Number: 4582004-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
	Anaemia
	Atherosclerosis
	Back Pain
	Cardiovascular Disorder

		Cystocele					
		Depression					
		Feeling Drunk	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
984	DAY						
		Hepatitis		Acetaminophen And			
		Hypertension		Hydrocodone			
		Liver Disorder		Bitartrate	C		
UNKNOWN							
		Nausea		Wellbutrin	C		ORAL
		Osteoporosis		Valium	C		ORAL
		Pain In Extremity		Estradiol	C		ORAL
		Pelvic Prolapse		Remeron	C		ORAL
		Polymyalgia Rheumatica		Lotensin	C		
UNKNOWN							
		Polyneuropathy		Effexor Xr	C		ORAL
		Rectocele		Prilosec	C		
UNKNOWN							
		Renal Failure		Atacand	C		
UNKNOWN							
		Rhinitis Seasonal		Celexa	C		
UNKNOWN							
		Sinusitis		Iron (Unspecified)	C		
UNKNOWN							
		Somnolence		Diazepam	C		
UNKNOWN							
		Stress Incontinence		Celebrex	C		
UNKNOWN							
		Tongue Disorder		Paxil Cr	C		ORAL
		Tremor		Paxil Cr	C		ORAL
		Urinary Hesitation					
		Vaginitis Atrophic					
		Weight Increased					

Date:02/14/05ISR Number: 4582005-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00873
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
Other	Arterial Injury
	Arthritis
	Blood Cholesterol

Increased
Cardiomyopathy
Cardiovascular Disorder
Chest Pain
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Device Failure
Diarrhoea
Dizziness Postural
Dyslipidaemia
Dyspepsia
Ejection Fraction
Decreased
Fatigue
Gastric Disorder
Gastrooesophageal Reflux
Disease
Hypertension
Hypotension
Injury
Insomnia
Joint Swelling
Liver Disorder
Oesophagitis

	Post Procedural Complication Pyelonephritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL	255 DAY
	Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL	255 DAY
	Vision Blurred		Tylenol	C			UNKNOWN
			Aspirin	C			UNKNOWN

Date:02/14/05ISR Number: 4582011-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01968
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN
	Cartilage Injury		Altace	C			UNKNOWN
	Contusion		Amitriptyline Hydrochloride	C			UNKNOWN
	Coronary Artery Disease						
	Dizziness		Pravachol	C			UNKNOWN
	Drug Abuser		Aspirin	C			UNKNOWN
	Emotional Distress						
	Fall						
	Fatigue						
	Ligament Injury						
	Road Traffic Accident						
	Therapeutic Response Decreased						
	Upper Respiratory Tract Infection						

Date:02/14/05ISR Number: 4582012-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Amaurosis Fugax
Other	Asthenia
	Blood Cholesterol Increased
	Diabetic Retinopathy
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Hypertension
	Hypoaesthesia
	Hypotension
	Insomnia
	Intervertebral Disc Degeneration
	Ischaemic Stroke
	Low Density Lipoprotein Increased
	Muscle Spasms
	Nasopharyngitis
	Nephropathy
	Neuropathy Peripheral
	Oedema Peripheral
	Pain In Extremity
	Pollakiuria
	Upper Respiratory Tract Infection

Ventricular Hypertrophy
Vitreous Haemorrhage

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	89 DAY	
	Humulin N	C			UNKNOWN	
	Humulin R	C			UNKNOWN	
	Naproxen	C		ORAL		
	Naproxen	C		ORAL		
	Livostin	C			OPHTHALMIC	
	Prevacid	C		ORAL		
	Vasotec	C			UNKNOWN	

Date:02/14/05ISR Number: 4582017-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00020
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Cerebrovascular Accident							
	Injury							

Date:02/14/05ISR Number: 4582018-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Arthralgia
	Balance Disorder
	Complex Partial Seizures
	Constipation
	Contusion
	Depressed Level Of Consciousness
	Depressed Mood

Diarrhoea
Dizziness
Drug Hypersensitivity
Drug Ineffective
Drug Level Decreased
Emotional Distress
Fall
Fatigue
Folliculitis
Gingival Hyperplasia
Headache
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypernatraemia
Hypertension
Hypoacusis
Injury
Laceration
Myocardial Infarction
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Otitis Media

	Overdose						
	Periarthritis						
	Psoriasis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	
	Respiratory Failure		Ms Contin	SS			UNKNOWN
	Scab		Ms Contin	SS			UNKNOWN
	Sepsis		Depakote	C			UNKNOWN
	Spinal Osteoarthritis		Tegretol	C			UNKNOWN
	Synovitis		Aspirin	C			UNKNOWN
	Tinnitus		Vitamins				
	Vaginal Infection		(Unspecified)	C			UNKNOWN
	Weight Decreased		Msir	C		ORAL	
	Weight Increased						
	Wrist Fracture						

Date:02/14/05ISR Number: 4582021-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	
	Cerebral Ischaemia						
	Depression						
	Disturbance In Attention						
	Dizziness						
	Lacunar Infarction						
	Tinnitus						
	Vertigo						

Date:02/14/05ISR Number: 4582022-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03927
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	6 YR

Drug Effect Decreased
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Pain

Date:02/14/05ISR Number: 4582023-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Anxiety
	Asthenia
	Back Pain
	Blood Pressure
	Inadequately Controlled
	Body Temperature
	Decreased
	Carotid Artery Disease
	Cerebral Infarction
	Chest Pain
	Confusional State
	Convulsion
	Depression

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Diabetes Mellitus Non-Insulin-Dependent					
		Difficulty In Walking					
		Disorientation		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysarthria		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyslipidaemia		Lotrel	C		
UNKNOWN							
		Dyspepsia		Plavix	C		
UNKNOWN							
		Dysphagia		Paxil	C		
UNKNOWN							
		Dysphemia		Nexium	C		
UNKNOWN							
		Dyspnoea		Prilosec	C		
UNKNOWN							
		Epidermal Naevus		Norvasc	C		
UNKNOWN		395 DAY					
		Eructation		Lipitor	C		
UNKNOWN		831 DAY					
		Expressive Language		Lipitor	C		
UNKNOWN							
		Disorder		Lipitor	C		
UNKNOWN		831 DAY					
		Eye Irritation		Lipitor	C		
UNKNOWN							
		Eye Pruritus		Zocor	C		ORAL
		Fatigue		Zocor	C		ORAL
		Feeling Abnormal		Zocor	C		ORAL
		Flatulence		Tricor	C		
UNKNOWN							
		Gait Disturbance		Zetia	C		ORAL
		Hypercholesterolaemia		Zetia	C		ORAL
		Hypertriglyceridaemia		Toprol Xl Tablets	C		ORAL
		Insomnia		Toprol Xl Tablets	C		ORAL
		Irritability		Neurontin	C		
UNKNOWN							
		Lacrimation Increased		Robaxin	C		ORAL
		Memory Impairment		Aspirin	C		
UNKNOWN							
		Muscle Spasms		Ibuprofen	C		
UNKNOWN							
		Myalgia		Glucovance	C		
UNKNOWN							
		Nausea		Clorazepate			

	Night Sweats	Dipotassium	C	UNKNOWN
	Nuclear Magnetic	Darvocet-N	C	UNKNOWN
	Resonance Imaging Brain	Allegra	C	UNKNOWN
	Abnormal	Hydrodiuril	C	ORAL
	Ocular Hyperaemia	Albuterol	C	RESPIRATORY (INHALATION)
	Oedema Peripheral			
	Onychomycosis			
	Pain In Extremity			
	Palpitations			
	Paraesthesia			
	Sleep Apnoea Syndrome			
	Tinea Pedis			
	Toe Deformity			
	Tremor			
	Upper Respiratory Tract Infection			
	Vascular Dementia			
	Wheezing			

Date:02/14/05ISR Number: 4582025-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
Disability	Anorexia
Other	Anxiety
	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp

		Back Pain					
		Blister					
		Bronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Caustic Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Constipation		Prinivil	C		
UNKNOWN							
		Depression		K-Dur	C		
UNKNOWN							
		Diastolic Dysfunction		Lortab	C		
UNKNOWN							
		Diverticulum Intestinal		Coumadin	C		
UNKNOWN							
		Dizziness		[Therapy			
		Drug Eruption		Unspecified]	C		
UNKNOWN							
		Dysphonia		Lasix (Furosemide			
		Dysuria		Sodium)	C		
UNKNOWN							
		Ecchymosis					
		Epistaxis					
		Fall					
		Frequent Bowel Movements					
		Gastritis					
		Glucose Tolerance					
		Impaired					
		Gout					
		Haemorrhoids					
		Headache					
		Helicobacter Infection					
		Hypertension					
		Hypoaesthesia					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Crepitation					
		Kidney Infection					
		Labyrinthitis					
		Muscle Strain					
		Nasopharyngeal Disorder					

Nasopharyngitis
Nausea
Oedema Peripheral
Osteoarthritis
Otitis Media
Pain
Pharyngitis
Polyarthritis
Rash
Sinusitis
Sleep Disorder
Stomach Discomfort
Syncope
Tricuspid Valve
Incompetence
Vertigo
Vision Blurred
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582031-4Report Type:Expedited (15-DaCompany Report #ES-MERCK-0502ESP00023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Initial or Prolonged	Ischaemic Cardiomyopathy							
Disability	Myocardial Infarction							

Date:02/14/05ISR Number: 4582033-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00078
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Hypertension							
Disability								

Date:02/14/05ISR Number: 4582034-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:02/14/05ISR Number: 4582035-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01058
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:02/14/05ISR Number: 4582036-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582037-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1660 DAY	

Date:02/14/05ISR Number: 4582038-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582039-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582040-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582041-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01052
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582042-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00661
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	

Date:02/14/05ISR Number: 4582043-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582044-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01061
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertensive Heart Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582045-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01063
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Pulmonary Embolism Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582046-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01067
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cardiovascular Disorder Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582047-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582048-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582049-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582050-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction

Date:02/14/05ISR Number: 4582051-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582052-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582053-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582054-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582055-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582056-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cerebrovascular Accident Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582057-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582058-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Thrombosis

Date:02/14/05ISR Number: 4582059-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/14/05ISR Number: 4582060-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	18 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582062-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:02/14/05ISR Number: 4582063-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Heart Injury							
	Stent Placement							

Date:02/14/05ISR Number: 4582064-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Other	Death							

Date:02/14/05ISR Number: 4582065-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Coronary Artery Disease							

Date:02/14/05ISR Number: 4582066-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:02/14/05ISR Number: 4582067-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:02/14/05ISR Number: 4582068-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Cardiac Disorder							

Date:02/14/05ISR Number: 4582069-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/14/05ISR Number: 4582070-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						

Date:02/14/05ISR Number: 4582087-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Other	Myocardial Infarction					

Date:02/14/05ISR Number: 4582088-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
	Thrombosis					

Date:02/14/05ISR Number: 4585205-1Report Type:Expedited (15-DaCompany Report #2005024677
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Atrial Fibrillation	Consumer	Celebrex (Celecoxib)	PS		
	Cerebrovascular Accident		Bextra (Valdecoxib)	SS		
10 MG						
			Rofecoxib (Rofecoxib)	SS		
			Enalapril (Enalapril)	C		
			Warfarin Sodium (Warfarin Sodium)	C		
			Metropolol Succinate (Metropolol			

				Succinate)	C		
				Amlodipine Besilate (Amlodipine Besilate)	C		
				Rosiglitazone Maleate (Rosiglitazone Maleate)	C		
				Bimatoprost (Bimatoprost)	C		

Date:02/14/05ISR Number: 4585290-7Report Type:Expedited (15-DaCompany Report #2005022892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose	Consumer	Celebrex (Celecoxib)	PS		ORAL		
	Drug Ineffective		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D),	
	Feeling Abnormal							
	Medication Error					ORAL		
			Rofecoxib (Rofecoxib)	SS				
			Warfarin (Warfarin)	C				
			Acetylsalicylic Acid (Acetylsalicylic					

Acid)	C
Pantoprazole (Pantoprazole)	C
Metoprolol (Metoprolol)	C
Atorvastatin (Atorvastatin)	C
Isosorbide Dinitrate (Isosorbide Dinitrate)	C

Date:02/14/05ISR Number: 4585302-0Report Type:Expedited (15-DaCompany Report #2005024963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Vioxx (Rofecoxib)	SS				

Date:02/14/05ISR Number: 4587703-3Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	367 DAY
		Health Professional						

Date:02/14/05ISR Number: 4587705-7Report Type:Expedited (15-DaCompany Report #WAES 0409SWE00006
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Dyspnoea	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	22 DAY
		Health Professional	Alfuzosin Hydrochloride	C				
			Atenolol	C				

Date:02/15/05ISR Number: 4582647-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction Arrhythmia Arteriospasm Coronary Back Injury Back Pain Blood Cholesterol Increased Blood Pressure Decreased Blood Triglycerides Increased Bone Pain Chondromalacia Dyspepsia Gait Disturbance Impaired Work Ability Intervertebral Disc

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Displacement					
		Low Density Lipoprotein Increased					
		Meniscus Lesion					
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
487 DAY							
		Neuralgia		Vioxx	SS	Merck & Co., Inc	ORAL
487 DAY							
		Oedema		Inderal La	C		
UNKNOWN							
		Osteoarthritis		Inderal La	C		
UNKNOWN							
		Palpitations		Claritin-D	C		
UNKNOWN							
	1758 DAY						
		Pleuritic Pain		Humibid	C		
UNKNOWN							
		Radicular Pain		Prevacid	C		
UNKNOWN							
		Sacroiliitis		Nasonex	C		
UNKNOWN							
	764 DAY						
		Tachyarrhythmia		Darvocet-N	C		
UNKNOWN							
		Tachycardia		Bactrim	C		
UNKNOWN							
		Traumatic Arthritis		Pseudoephedrine	C		
UNKNOWN							
		Tricuspid Valve		Maxzide	C		
UNKNOWN							
		Incompetence		Naprosyn	C		
UNKNOWN							
		Ventricular Hypokinesia		Entex La	C		
UNKNOWN							
		Weight Decreased		Voltaren	C		
UNKNOWN							
		Weight Increased		Voltaren	C		ORAL
				Evening Primrose Oil	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Chondroitin	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Sudafed	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

				Norco	C		
UNKNOWN							

Date:02/15/05ISR Number: 4582648-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03909
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dilatation Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL	116 DAY	
Disability	Heart Rate Increased		Valium	C			UNKNOWN	
	Palpitations		Allegra-D	C			UNKNOWN	
			Claritin-D	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Guaifenex G	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Zithromax	C			UNKNOWN	
			Levaquin	C			UNKNOWN	

Date:02/15/05ISR Number: 4582649-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00016
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	2 MON	
	Ventricular Extrasystoles							

Date:02/15/05ISR Number: 4582650-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00045
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident At Work
Other	Aortic Aneurysm
	Aortic Dilatation
	Arthralgia
	Asthenia

		Back Pain					
		Blood Albumin Increased					
		Blood Chloride Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
751	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
341	DAY						
		Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Naproxen	C		
UNKNOWN							
		Carotid Artery Occlusion		Desyrel	C		
UNKNOWN							
		Carotid Artery Stenosis		Desyrel	C		
UNKNOWN							
		Cerebral Haemorrhage		Viagra	C		ORAL
		Cerebral Infarction		Zocor	C		ORAL
		Cerebral Ischaemia		Aggrenox	C		ORAL
		Cerebrovascular Accident		Klonopin	C		ORAL
		Cerebrovascular Disorder					
		Confusional State					
		Coronary Artery					
		Atherosclerosis					
		Depression					
		Dilatation Atrial					
		Dizziness					
		Drug Screen Positive					
		Ejection Fraction					
		Decreased					
		Fall					
		Full Blood Count Abnormal					
		Gait Disturbance					
		Haematocrit Decreased					
		Hemiparesis					
		Hyperlipidaemia					
		Hypoaesthesia					
		Intermittent Claudication					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Swelling					
		Low Density Lipoprotein					
		Increased					
		Mitral Valve Incompetence					
		Nausea					
		Neck Pain					

Paraesthesia
Peroneal Nerve Palsy
Restless Legs Syndrome
Sinusitis
Spinal Osteoarthritis
Total Cholesterol/Hdl
Ratio Decreased
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Date:02/15/05ISR Number: 4582652-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02993
Age:77 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
		Premarin	C				
Cerebrovascular Accident		Glipizide	C				
Diabetes Mellitus Hypertension		[Therapy Unspecified]	C				
Treatment Noncompliance		[Therapy Unspecified]	C				

Date:02/15/05ISR Number: 4582654-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582655-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00186
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582656-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582657-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582658-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	651	DAY

Date:02/15/05ISR Number: 4582659-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582661-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Asthenia Cerebrovascular Accident Impaired Work Ability		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582662-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00575
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
			Neurontin	C			UNKNOWN	UNKNOWN
			Detrol	C			UNKNOWN	UNKNOWN
			Valium	C			UNKNOWN	UNKNOWN
			Celexa	C			UNKNOWN	UNKNOWN
			Soma	C			UNKNOWN	UNKNOWN
			Clarinex	C			UNKNOWN	UNKNOWN
			Bentyl	C			UNKNOWN	UNKNOWN
			Lorcet 10/650	C			UNKNOWN	UNKNOWN
			Albuterol	C			UNKNOWN	UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN	UNKNOWN

Date:02/15/05ISR Number: 4582663-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582664-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01248
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582665-7Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00024
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fluoxetine Hydrochloride	C		ORAL		

Date:02/15/05ISR Number: 4582666-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582667-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582669-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00056
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
	Coma		[Therapy Unspecified]	C			UNKNOWN	

Date:02/15/05ISR Number: 4582670-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coma							

Date:02/15/05ISR Number: 4582671-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582672-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582673-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction							

Date:02/15/05ISR Number: 4582675-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01146
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/05ISR Number: 4582677-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582678-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582680-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01434
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582681-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4582696-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01433
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	1727 DAY	
Hospitalization - Initial or Prolonged	Hypoaesthesia Paraesthesia							
Disability								

Date:02/15/05ISR Number: 4582697-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	625	DAY

Date:02/15/05ISR Number: 4582811-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00185
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583199-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Cardiomegaly
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Pain

		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Dementia Alzheimer'S Type	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Diabetic Foot Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Diplopia		Glucophage	C		
UNKNOWN							
		Dizziness		Zocor	C		ORAL
		Emotional Distress		Arthrotec	C		
UNKNOWN							
		Eyelid Ptosis		Avandia	C		
UNKNOWN							
		Haematuria		Glynase Prestab			
		Headache		Tablets	C		
UNKNOWN							
		Ingrowing Nail		Darvocet-N	C		
UNKNOWN							
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Musculoskeletal Stiffness					
		Myalgia					
		Osteoarthritis					
		Psychomotor Hyperactivity					
		Rash					
		Sinobronchitis					
		Somnolence					
		Syncope					
		Systemic Lupus					
		Erythematosus					
		Upper Respiratory Tract					
		Infection					
		Vertigo					
		Vision Blurred					

Date:02/15/05ISR Number: 4583205-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00008
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anal Haemorrhage
	Anxiety
Disability	Arrhythmia

Other	Arthralgia
	Arthropathy
	Breast Cyst
	Breast Haemorrhage
	Bursitis
	Cardiac Disorder
	Chest Discomfort
	Chest Pain
	Closed Head Injury
	Complex Regional Pain Syndrome
	Concussion
	Confusional State
	Contusion
	Cubital Tunnel Syndrome
	Depression
	Diarrhoea
	Dizziness
	Drug Effect Decreased
	Dyspareunia
	Dyspnoea Paroxysmal

		Nocturnal					
		Emotional Distress					
		Epicondylitis					
		Extrasystoles	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
33	DAY						
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
33	DAY						
		Gingival Disorder		Vioxx	SS		ORAL
33	DAY						
		Haematochezia		Vioxx	SS		ORAL
33	DAY						
		Haemorrhage		Vitamins			
		Headache		(Unspecified)	C		
UNKNOWN							
		Heart Rate Irregular		Bayer Aspirin	C		ORAL
		Hypercholesterolaemia		Bayer Aspirin	C		ORAL
		Hyperlipidaemia					
		Hypertension					
		Hypoaesthesia					
		Injury					
		Insomnia					
		Lumbar Spinal Stenosis					
		Menorrhagia					
		Migraine					
		Mitral Valve Prolapse					
		Muscle Tightness					
		Nausea					
		Nerve Injury					
		Pain In Extremity					
		Palpitations					
		Pelvic Pain					
		Post-Traumatic Stress Disorder					
		Radial Nerve Lesion					
		Sensation Of Pressure					
		Sinus Bradycardia					
		Sleep Disorder					
		Supraventricular Tachycardia					
		Syncope					
		Tachycardia					
		Thrombosis					
		Uterine Cyst					
		Uterine Haemorrhage					
		Uterine Leiomyoma					
		Vaginal Haemorrhage					

Vasodilatation
Ventricular Extrasystoles
Vomiting

Date:02/15/05ISR Number: 4583217-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00107
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Eprosartan	C			UNKNOWN	
			Valsartan	C			UNKNOWN	
			Hydrochlorothiazide And Triamterene	C			UNKNOWN	
			Homeopathic Medications (Unspecified)	C			UNKNOWN	
			Tibolone	C			UNKNOWN	
			Omeprazole Magnesium	C			UNKNOWN	

				Diclofenac Sodium	C		
UNKNOWN							
				Fluticasone Propionate	C		
UNKNOWN							
				Fenoterol Hydrobromide And Ipratropium Bromide	C		
UNKNOWN							

Date:02/15/05ISR Number: 4583220-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00381
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						

Date:02/15/05ISR Number: 4583222-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00065
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 YR	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Stenosis		Atorvastatin Calcium	C		ORAL
	Hypertension		Acetaminophen	C		ORAL
	Myocardial Infarction		Pindolol	C		ORAL
2 YR						

Date:02/15/05ISR Number: 4583223-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02224
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Increased					
Initial or Prolonged	Cardiac Failure					
Disability	Congestive					

Headache
Transient Ischaemic
Attack

Date:02/15/05ISR Number: 4583225-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00011
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583226-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00010
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C				
UNKNOWN								

Date:02/15/05ISR Number: 4583227-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Disorder Intestinal Functional Disorder Renal Disorder Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583229-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00036
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Convulsion Encephalopathy Haematuria Haemorrhage Hyponatraemia Skin Laceration		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583230-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00009
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	696 DAY	UNKNOWN
			Atenolol	C				

Date:02/15/05ISR Number: 4583234-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01081
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Disorder Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/15/05ISR Number: 4583235-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
Disability	Anxiety
Other	Arthralgia
	Arthritis
	Asthma
	Back Disorder
	Back Pain
	Cerebral Infarction
	Chest Wall Pain
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Depression
	Diabetes Mellitus Inadequate Control

		Dizziness					
		Emotional Distress					
		Enanthema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL
		Face Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Plavix	C		
UNKNOWN							
		Hypertensive Heart		Flovent	C		
RESPIRATORY							
		Disease					
(INHALATION)							
		Hypothyroidism		Levoxyl	C		
UNKNOWN							
		Idiosyncratic Drug		Levoxyl	C		
UNKNOWN							
		Reaction		Tylenol With Codeine			
		Insomnia		#3	C		
UNKNOWN							
		Lobar Pneumonia		Prednisone	C		
UNKNOWN							
		Lung Disorder		Advair	C		
UNKNOWN							
		Nausea		Monopril	C		
UNKNOWN							
		Nervousness		Azmacort	C		
UNKNOWN							
		Post Procedural Nausea		Aspirin	C		
UNKNOWN							
		Pruritus		Nexium	C		
UNKNOWN							
		Renal Failure Chronic		Ventolin (Albuterol)	C		
RESPIRATORY							
		Swelling Face					
(INHALATION)							
		Ulcer		Ranitidine	C		
UNKNOWN							
		Upper Respiratory Tract		Hydroxychloroquine			
		Infection		Sulfate	C		
UNKNOWN							
		Urinary Tract Infection		Hydrochlorothiazide	C		
UNKNOWN							
		Uterine Disorder		Cozaar	C		
UNKNOWN							

Date:02/15/05ISR Number: 4583237-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01076
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583238-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583240-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583241-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01079
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/05ISR Number: 4583243-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01072
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583244-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583245-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583254-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx Celebrex	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:02/15/05ISR Number: 4583255-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Celebrex	C		
UNKNOWN						
	Myocardial Infarction					

Date:02/15/05ISR Number: 4583256-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Celebrex	C		
UNKNOWN						
	Myocardial Infarction					

Date:02/15/05ISR Number: 4583258-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Celebrex	C		
UNKNOWN						
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/15/05ISR Number: 4583259-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01083
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583260-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
	Myocardial Infarction							

Date:02/15/05ISR Number: 4583262-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01077
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Extraocular Muscle							
	Paresis							

Date:02/15/05ISR Number: 4583273-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/15/05ISR Number: 4583274-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01525
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Disorder Multi-Organ Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4583276-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/15/05ISR Number: 4587491-0Report Type:Expedited (15-DaCompany Report #2005025731
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Chest Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, 1 IN 2 D), ORAL	

			Rofecoxib (Rofecoxib)	SS		
			All Other Therapeutic Products (All Other Therapeutic Products)	C		

Date:02/15/05ISR Number: 4588004-XReport Type:Expedited (15-DaCompany Report #2005024954
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
	Arthropathy							
	Back Disorder							
	Diabetes Mellitus		Rofecoxib (Rofecoxib)	SS				
	Drug Effect Decreased		Atorvastatin (Atorvastatin)	C				
	Fall		Quinine Sulfate (Quinine Sulfate)	C				
	Irritable Bowel Syndrome							
	Medical Device Complication							
	Oedema Peripheral							
	Peripheral Vascular Disorder							
	Skin Discolouration							
	Walking Aid User							

Date:02/15/05ISR Number: 4603034-7Report Type:Direct Company Report #CTU 240413
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG PER DAY ORAL	
	Dizziness							
	Fatigue		Vioxx	C				
	Headache							
	Pain In Extremity							

Date:02/16/05ISR Number: 4584002-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00179
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Aspirin	SS		ORAL		
	Haemoglobin Abnormal		Clopidogrel Bisulfate	SS		ORAL		
	Haemoglobin Decreased		Amitriptyline Hydrochloride	C		ORAL		
	Melaena		Senna	C		ORAL		
	Oesophagitis		Lactulose	C		ORAL		
			Alfuzosin Hydrochloride	C		ORAL		
			Bendroflumethiazide	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584003-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Accident At Home		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Accident At Work		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Neurontin	C			UNKNOWN	
	Asthenia		Ibuprofen	C			UNKNOWN	
	Cardiac Murmur		Claritin	C			UNKNOWN	
	Carpal Tunnel Syndrome		Premarin	C			UNKNOWN	
	Cerebrovascular Accident		Cephalexin	C			UNKNOWN	
	Chest Pain		Skelaxin	C			UNKNOWN	
	Clumsiness		Trazodone Hydrochloride	C			UNKNOWN	
	Cognitive Disorder							
	Contusion		Zovirax	C			UNKNOWN	
	Deafness Bilateral		Methylprednisolone	C			UNKNOWN	
	Depression		Propoxyphene Hydrochloride	C			UNKNOWN	
	Disturbance In Attention							
	Drug Effect Decreased		Naproxen	C			UNKNOWN	
	Dyspepsia		Baclofen	C		ORAL		
	Dyspnoea							
	Dysthymic Disorder							
	Face Injury							
	Fall							
	Fatigue							
	Gastrooesophageal Reflux Disease							
	General Symptom							
	Headache							
	Hypertension							
	Increased Tendency To Bruise							
	Intervertebral Disc							

Protrusion
Irritability
Joint Injury
Memory Impairment
Mitral Valve Incompetence
Myofascial Pain Syndrome
Nasal Congestion
Osteoma
Pain
Pain In Extremity
Pruritus
Sleep Disorder
Stress
Stress Fracture
Temporomandibular Joint
Syndrome
Thrombosis
Tinnitus
Transient Ischaemic
Attack
Tremor
Tricuspid Valve
Incompetence
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584024-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00440
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		27 DAY

Date:02/16/05ISR Number: 4584025-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00304
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Basedow'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Weight Decreased		Diuretic (Unspecified)	C				

UNKNOWN

Date:02/16/05ISR Number: 4584026-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Bruit
Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Acute Coronary Syndrome
	Angina Pectoris
	Aortic Bruit
	Aortic Valve Incompetence
	Appendix Disorder
	Arthralgia
	Atherosclerosis
	Blood Pressure Increased
	Bronchitis
	Carotid Artery Occlusion
	Carpal Tunnel Syndrome
	Cataract
	Cerebrovascular Accident
	Cerumen Impaction
	Constipation
	Convulsion

Coronary Artery Disease
Cough
Cystitis Haemorrhagic
Depressed Mood
Dilatation Atrial
Diverticulum
Drug Hypersensitivity
Dyslipidaemia
Ear Pain
Emotional Distress
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux
Disease
Granuloma
Haematuria
Headache
Hepatic Cyst
Hernia
Hypercholesterolaemia
Hyperhomocysteinaemia
Hyperkalaemia

		Hypokalaemia					
		Infection					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Kidney Small		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Metaplasia					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Neck Injury					
		Nervous System Disorder					
		Osteoarthritis					
		Osteoporosis					
		Pharyngolaryngeal Pain					
		Pulmonary Congestion					
		Renal Artery Stenosis					
		Renal Failure					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sciatica					
		Shoulder Operation					
		Skin Lesion					
		Spinal Osteoarthritis					
		Tachycardia					
		Tinnitus					
		Tonsillar Disorder					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Uterine Disorder					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:02/16/05ISR Number: 4584036-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-00125597
Age:35 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Agitation		Vioxx	PS	Merck & Co., Inc	ORAL
		Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL

Blood Pressure Increased Leflunomide C
UNKNOWN

Cardiac Disorder
Chest Discomfort
Dizziness
Fear
Hyperhidrosis
Tachycardia
Visual Disturbance
Weight Increased

Date:02/16/05ISR Number: 4584037-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00074
Age:83 YR Gender:Female I/FU:F

Outcome PT
Death Adverse Event
Alopecia
Anaemia

		Anorexia					
		Aphasia					
		Arthralgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Creatinine		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Diastolic		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased		Azopt Drops	C		
UNKNOWN							
		Blood Urea Increased		Levoxyl	C		
UNKNOWN							
		Bundle Branch Block Left		Ocupress	C		
UNKNOWN							
		Cardiac Failure		Prempro	C		
UNKNOWN							
		Congestive		Maxzide	C		
UNKNOWN							
		Cardiac Murmur					
		Chromaturia					
		Chronic Obstructive					
		Pulmonary Disease					
		Confusional State					
		Contusion					
		Cough					
		Death					
		Decreased Appetite					
		Difficulty In Walking					
		Dizziness					
		Dizziness Postural					
		Dyspnoea Exacerbated					
		Dysuria					
		Extrasystoles					
		Eye Pain					
		Failure To Thrive					
		Fall					
		Fatigue					
		Feeling Hot					
		Gait Disturbance					
		Head Injury					
		Heart Sounds Abnormal					
		Joint Injury					
		Laceration					
		Lymphocyte Percentage					
		Decreased					
		Metabolic Disorder					
		Mouth Breathing					

Myalgia
Neutrophil Percentage
Increased
Normochromic Normocytic
Anaemia
Oral Intake Reduced
Pneumonia
Rales
Respiratory Rate
Increased
Salivary Gland Neoplasm
Skin Laceration
Tachycardia
Thyroid Neoplasm
Treatment Noncompliance
Urinary Retention
Urinary Tract Infection
Urine Odour Abnormal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584039-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00015
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		485 DAY
Initial or Prolonged			Acetaminophen	C				UNKNOWN
			Ranitidine Hydrochloride	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:02/16/05ISR Number: 4584046-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00046
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriospasm Coronary		Vioxx	PS	Merck & Co., Inc	ORAL		552 DAY
Initial or Prolonged	Chest Pain		Folic Acid	C		ORAL		
	Myocardial Ischaemia		Methotrexate	C		ORAL		

Date:02/16/05ISR Number: 4584047-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00101
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety							
	Chronic Obstructive Pulmonary Disease							
	Diarrhoea							
	Diverticulitis							
	Dizziness							
	Faeces Discoloured							
	Fall							
	Fatigue							
	Hepatic Cirrhosis							
	Hypothyroidism							
	Localised Infection							

Loss Of Consciousness
Rash
Renal Cyst
Spinal Column Stenosis

Date:02/16/05ISR Number: 4584049-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Coronary Artery Disease		Aspirin	C				UNKNOWN
	General Physical Health		Atorvastatin Calcium	C				UNKNOWN
	Deterioration		Metoprolol	C				UNKNOWN
	Ventricular Hypertrophy		Clopidogrel Bisulfate	C				UNKNOWN

Date:02/16/05ISR Number: 4584050-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0411SWE00033
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		1425 DAY
Initial or Prolonged	Cerebrovascular Accident		Methotrexate	C				UNKNOWN
Other			Omega-3 Marine					

				Triglycerides	C		
UNKNOWN							

Date:02/16/05ISR Number: 4584053-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00055
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:02/16/05ISR Number: 4584055-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00007
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Acetaminophen	C				
UNKNOWN								
	Attack		Glucosamine	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Tramadol Hydrochloride	C				
UNKNOWN								

Date:02/16/05ISR Number: 4584056-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Output Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584058-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00020
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 440 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Lansoprazole	C				
UNKNOWN								
	Coronary Artery Occlusion		Amlodipine Besylate	C				
UNKNOWN								
	Coronary Artery Stenosis		Formoterol Fumarate	C				
UNKNOWN								
	Dyspepsia		Prednisolone	C				
UNKNOWN								
	Myocardial Infarction		Aspirin And Magnesium Oxide	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN							9	MON
			Atorvastatin Calcium	C				
UNKNOWN								
			Metoprolol Tartrate	C				
UNKNOWN								
			Prochlorperazine Maleate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584059-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00014
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Omeprazole	C				
UNKNOWN								
Initial or Prolonged								

Date:02/16/05ISR Number: 4584065-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01548
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Bextra	C				
UNKNOWN								
	Myocardial Infarction							

Date:02/16/05ISR Number: 4584066-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00082
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
Initial or Prolonged			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:02/16/05ISR Number: 4584068-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Emotional Distress							
	Myocardial Infarction							
	Polytraumatism							

Date:02/16/05ISR Number: 4584069-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584070-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01131
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584071-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584072-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01263
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion Tooth Loss		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584073-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01255
Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			Valium	C				
UNKNOWN								

Date:02/16/05ISR Number: 4584074-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00018
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:02/16/05ISR Number: 4584079-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584086-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01583
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Chest Pain		Inderal	C				
	Hypoaesthesia							

Date:02/16/05ISR Number: 4584129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01262
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Xanax	C				

Date:02/16/05ISR Number: 4584207-9Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369493A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Dissection		Deroxat	PS	Glaxosmithkline	ORAL	20MG Per day	
	Cerebrovascular Accident		Art	SS		ORAL	50MG Twice per day	
			Oesclim	SS				
			Vioxx	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584519-9Report Type:Expedited (15-DaCompany Report #DE-ABBOTT-04P-062-0261391-00
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe	PS		SUBCUTANEOUS		3 MON
	Drug Ineffective							
	Suicide Attempt		Clomipramine	SS		ORAL	1 MON	
			Rofecoxib	SS		ORAL	1 MON	
			Rofecoxib	SS			1 MON	
			Methotrexate Sodium	C			11 MON	
			Sulfasalazine	C			1 MON	
			Hydroxychloroquine	C			8 MON	
			Leflunomide	C			2 MON	
			Methylprednisolone	C				
			Etanercept	C				
			Celecoxib	C				

Date:02/16/05ISR Number: 4584597-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04256
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack							

Date:02/16/05ISR Number: 4584598-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00689
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage		Mobic	SS		ORAL		
	Musculoskeletal Stiffness		Coumadin	C				
UNKNOWN								

Prothrombin Level
Increased

Date:02/16/05ISR Number: 4584599-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00757
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Sotalol Hydrochloride	C			UNKNOWN	
	Embolic Cerebral Infarction		Quinapril Hydrochloride	C			UNKNOWN	
	Embolism		Molsidomine	C			UNKNOWN	
	Hypertensive Heart Disease		Xipamide	C			UNKNOWN	
	Melaena							
	Palpitations							

Date:02/16/05ISR Number: 4584602-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00187
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
	Cardiac Failure
Disability	Fall
Other	Heart Rate Irregular

		Hip Fracture Mitral Valve Incompetence Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Shock		Vioxx	PS	Merck & Co., Inc	ORAL
61	DAY						
				Fluoxetine	C		
UNKNOWN							
				Acetaminophen And Dihydrocodeine Bitartrate	C		
UNKNOWN							
				Ramipril	C		
UNKNOWN							

Date:02/16/05ISR Number: 4584603-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00534
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Arthropathy Cardiovascular Disorder		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Colonic Polyp Dizziness Gastritis Haemorrhoids Intestinal Haemorrhage Joint Effusion Palpitations Polyneuropathy Idiopathic Progressive Rectal Prolapse Reflux Oesophagitis Tachycardia Tendonitis					

Date:02/16/05ISR Number: 4584611-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02385
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1 MON
Other	Gastric Ulcer						
	Haemoptysis						
	Haemorrhage						
	Helicobacter Infection						
	Pain						

Date:02/16/05ISR Number: 4584613-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01981
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	54	MON

Date:02/16/05ISR Number: 4584615-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02437
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Lipitor C
UNKNOWN

Date:02/16/05ISR Number: 4584618-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01804
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	54	MON

Date:02/16/05ISR Number: 4584620-XReport Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00026
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:02/16/05ISR Number: 4584622-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01801
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584624-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00018
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584625-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584626-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00065
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Prednisolone	C				
UNKNOWN								
Initial or Prolonged			Bisoprolol Fumarate	C				
UNKNOWN								
			Methotrexate	C				
PARENTERAL								
			Cilazapril And Hydrochlorothiazide	C				
UNKNOWN								

Date:02/16/05ISR Number: 4584627-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00984
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mouth Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:02/16/05ISR Number: 4584628-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584629-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01002
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584630-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584639-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00903
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/16/05ISR Number: 4584641-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01616
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584642-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01032
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584644-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/16/05ISR Number: 4584646-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01617
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4584648-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/16/05ISR Number: 4588343-2Report Type:Direct Company Report #CTU 240610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subarachnoid Haemorrhage		Vioxx	PS			25 MG , DAILY	TABLET

Date:02/16/05ISR Number: 4588345-6Report Type:Direct Company Report #CTU 240605
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Disorder Liver Disorder		Vioxx 50 Mg Tabs 10 Day	PS			1 TIME A DAY	50 MG

Date:02/16/05ISR Number: 4589343-9Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Foreign	Rofecoxib	PS		ORAL	25 MG/DAILY	35 DAY
	Blood Cholesterol Increased	Study	Omeprazole	C				
	Blood Triglycerides Increased	Health Professional						
	Haematocrit Decreased	Other						
	Haemoglobin Decreased							
	Joint Swelling							
	Low Density Lipoprotein Increased							
	Memory Impairment							
	Myocardial Ischaemia							

Date:02/16/05ISR Number: 4589446-9Report Type:Expedited (15-DaCompany Report #2005014116
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulitis	Foreign	Relpax (Eletriptan)	PS		ORAL	ORAL	
Hospitalization - Initial or Prolonged	Drug Interaction	Health Professional	Celebrex (Celecoxib)	SS				
	Sigmoiditis		Rofecoxib					
Other		Company	(Rofecoxib)	SS		ORAL	ORAL	
		Representative	Naratriptan Hydrochloride (Naratriptan					

			Hydrochloride)	SS		
ORAL						
			Atenolol (Atenolol)	C		

Date:02/17/05ISR Number: 4585586-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02150
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
3 WK								
Initial or Prolonged	Upper Gastrointestinal Haemorrhage		[Therapy Unspecified]	C				
UNKNOWN								
			Ibuprofen	C				
UNKNOWN								

Date:02/17/05ISR Number: 4585590-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Pressure Increased Carpal Tunnel Syndrome Convulsion Intervertebral Disc Protrusion Lumbar Radiculopathy Lumbar Spinal Stenosis Radiculitis Radiculopathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4585592-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
81 DAY								
Initial or Prolonged	Antiphospholipid Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Advil	C		ORAL		

	Asthenia	Prempro	C	
UNKNOWN				
	Back Disorder	Prilosec	C	
UNKNOWN				
	Balance Disorder	Synthroid	C	
UNKNOWN				
	Blood Pressure Increased	Diovan	C	
UNKNOWN				
	Cerebrovascular Accident	Dimethyl Sulfone	C	
UNKNOWN				
	Convulsion	Gaviscon Antacid		
	Diabetes Mellitus	Tablets	C	
UNKNOWN				
	Non-Insulin-Dependent	Hydrocodone		
	Dizziness	Hydrochloride	C	
UNKNOWN				
	Drug Hypersensitivity	[Therapy		
	Gastrooesophageal Reflux	Unspecified]	C	ORAL
	Disease			
	Hemiparesis			
	Ischaemia			
	Labyrinthitis			
	Muscle Spasms			
	Neck Injury			
	Tinnitus			
	Tongue Ulceration			
	Urticaria Generalised			
	Vasculitis			

Date:02/17/05ISR Number: 4585599-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
	Coronary Artery Stenosis		Plavix	C			UNKNOWN	
	Diaphragmatic Hernia		Prilosec	C			UNKNOWN	
	Diverticulum		Lipitor	C			UNKNOWN	
	Gastrooesophageal Reflux		Zocor	C		ORAL		
	Disease		Zocor	C		ORAL		
	Headache		Aspirin	C			UNKNOWN	
	Hypercholesterolaemia							
	Hypotension							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Post Procedural Haematoma							

Date:02/17/05ISR Number: 4585604-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA01675
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	103	DAY
Hospitalization -	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	103	DAY
Initial or Prolonged	Chest Pain		Oxycontin	C			UNKNOWN	637 DAY
	Depression		Endocet	C			UNKNOWN	530 DAY
	Headache		Percocet	C			UNKNOWN	

	Hypertension	Nitroquick	C
UNKNOWN			
	Myocardial Infarction	Neurontin	C
UNKNOWN			
	Neuropathy	Topamax	C
UNKNOWN			
	Pain	Duragesic	C
UNKNOWN	42 DAY		
	Pain In Extremity	Amitriptylin	C
UNKNOWN			
		Norvasc	C
UNKNOWN			
		Effexor	C
UNKNOWN			
		Allegra	C
UNKNOWN			
		Elavil	C
UNKNOWN			

Date:02/17/05ISR Number: 4585608-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Atrial Fibrillation
Disability	Basal Cell Carcinoma
Other	Blood Creatinine
	Increased
	Breast Cyst
	Cardiolipin Antibody
	Positive
	Cerebrovascular Accident
	Chronic Sinusitis
	Coagulopathy
	Colonic Polyp
	Coronary Artery Disease
	Depression
	Dyspepsia

		Ear Pain					
		Ecchymosis					
		Episcleritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Felty'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Disease		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Haemorrhoidal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Herpes Zoster Ophthalmic		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Hypertension		Methotrexate	SS		
UNKNOWN							
		Hypertonic Bladder		Methotrexate	SS		
UNKNOWN							
		Immunoglobulins Decreased		Remicade	SS		
INTRAVENOUS							
		Insomnia		Remicade	SS		
INTRAVENOUS							
		Keratitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Keratitis Herpetic		Vioxx	SS	Merck & Co., Inc	ORAL
		Laryngitis Viral		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukopenia		Triamterene	C		
UNKNOWN							
		Lymphoma		Tylenol	C		
UNKNOWN							
		Mental Impairment		Tegretol	C		
UNKNOWN							
		Migraine		Tegretol	C		
UNKNOWN							
		Mitral Valve Incompetence		Tegretol	C		
UNKNOWN							
		Mouth Injury		Carbamazepine	C		
UNKNOWN							
		Nausea		Acyclovir	C		
INTRAVENOUS							
		Nocturia		Hydroxychloroquine			
		Orthostatic Hypotension		Sulfate	C		
UNKNOWN							

	Overdose	Azathioprine	C	
UNKNOWN				
	Pain	Prilosec	C	
UNKNOWN				
	Pancytopenia	Allopurinol	C	
UNKNOWN				
	Platelet Disorder	Zyrtec	C	
UNKNOWN				
	Prostatitis	K-Dur	C	
UNKNOWN				
	Pyrexia	Proventil	C	ORAL
	Rash	Fiorinal With		
	Renal Disorder	Codeine	C	
UNKNOWN				
	Renal Pain	Prednisone	C	
UNKNOWN				
	Rheumatoid Arthritis	Elavil	C	ORAL
	Rib Fracture	Purinethol	C	
UNKNOWN				
	Sinusitis	[Therapy		
	Thrombocytopenia	Unspecified]	C	
UNKNOWN				
	Transient Ischaemic	Advil	C	
UNKNOWN				
	Attack			
	Trigger Finger			
	Viral Pharyngitis			

Date:02/17/05ISR Number: 4585627-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00638
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Wall Mass
Other	Acquired Oesophageal Web
	Antibody Test Abnormal
	Asthma
	Atrial Fibrillation
	Blood Pressure Increased
	Bursitis
	Cardiac Disorder
	Cardiac Failure

		Congestive Cardiomegaly Cataract Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL
22	DAY						
		Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL
884	DAY						
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Deafness		Vioxx	SS	Merck & Co., Inc	ORAL
123	DAY						
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
884	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Emphysema		Vioxx	SS	Merck & Co., Inc	ORAL
		Eructation		Vioxx	SS	Merck & Co., Inc	ORAL
		Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
123	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY						
		Headache		Aspirin	C		
UNKNOWN							
		Hypercalcaemia		Prempro	C		
UNKNOWN							
		Hyperparathyroidism		Flovent	C		
UNKNOWN							
		Hyperproteinaemia		Nexium	C		
UNKNOWN							
		Hypertension		Lopid	C		
UNKNOWN							
		Hypoglycaemia		Lipitor	C		
UNKNOWN							
		Insomnia		Accolate	C		
UNKNOWN							
		Lipoma		Serevent	C		
UNKNOWN							
		Lung Consolidation		Combivent	C		
UNKNOWN							
		Lung Neoplasm		Claritin	C		
UNKNOWN							
		Memory Impairment Muscle Spasms Musculoskeletal Discomfort Non-Cardiac Chest Pain					

Oedema
Oedema Peripheral
Osteopenia
Pain In Extremity
Palpitations
Pericardial Effusion
Postnasal Drip
Pruritus
Rash Pruritic
Renal Cyst
Rhinorrhoea
Sciatica
Sinus Congestion
Sinus Disorder
Stress Incontinence
Supraventricular
Extrasystoles
Venous Insufficiency
Ventricular Extrasystoles
Wrist Fracture

Date:02/17/05ISR Number: 4585631-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03932
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585632-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02806
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Lipitor	C				
UNKNOWN								
	Pain							
	Weight Increased							

Date:02/17/05ISR Number: 4585635-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03334
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Synthroid	C				
UNKNOWN								
Initial or Prolonged	Swelling		Norvasc	C				
UNKNOWN								
Disability	Swelling Face		Ativan	C				
UNKNOWN								
	Transient Ischaemic							
	Attack							

Date:02/17/05ISR Number: 4585636-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00086
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease							
Initial or Prolonged	Escherichia Sepsis							
	Myocardial Infarction							
	Peripheral Occlusive							
	Disease							
	Sudden Death							
	Toe Amputation							

Date:02/17/05ISR Number: 4585638-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00040
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Fluvastatin Sodium	C			UNKNOWN	
			Moxonidine	C			UNKNOWN	
			Nitrendipine	C			UNKNOWN	1559 DAY
			Aspirin	C			UNKNOWN	3990 DAY

Date:02/17/05ISR Number: 4585639-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01573
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Prozac	C			UNKNOWN	
Disability	Transient Ischaemic Attack		Xanax	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585641-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01171
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization -	Aortic Valve Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Initial or Prolonged Disability	Atrial Fibrillation Cardiac Failure Congestive Coronary Artery Atherosclerosis Coronary Artery Disease Dental Caries Diverticulum Intestinal Dizziness Dyspnoea Paroxysmal Nocturnal Fall Hip Fracture Loss Of Consciousness Mitral Valve Incompetence Myeloproliferative Disorder Myocardial Infarction Myocardial Ischaemia Nasal Polyps Nephrolithiasis Pain Refractory Anaemia Renal Infarct Restrictive Pulmonary Disease Sinusitis Splenomegaly Thrombocytopenia Upper Limb Fracture Urinary Tract Infection		Propranolol Hydrochloride	C		ORAL		

Date:02/17/05ISR Number: 4585647-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00614
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vitamins					
Other	Coronary Artery Stenosis		(Unspecified)	C				
UNKNOWN								
	Headache		Potassium					
	Hyperlipidaemia		(Unspecified)	C				
UNKNOWN								
	Muscle Injury							
	Myocardial Ischaemia							
	Thrombosis							

Date:02/17/05ISR Number: 4585658-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03590
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
Hospitalization -	Amnesia
Initial or Prolonged	Cardiac Arrest
Disability	Cardiac Disorder

	Emotional Distress Medication Error Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Stomach Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	
			Influenza Virus Vaccine (Unspecified)	C			UNKNOWN
			Zyrtec	C			UNKNOWN

Date:02/17/05ISR Number: 4585659-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00142
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 579 DAY	Behcet'S Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Eyelid Ptosis		Oxytetracycline	C			UNKNOWN
Disability	Hemiparesis		Propranolol Hydrochloride	C		ORAL	
			Prochlorperazine	C		ORAL	
			Folic Acid	C		ORAL	
			Cyanocobalamin	C			INTRAMUSCULAR

Date:02/17/05ISR Number: 4585661-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01797
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/17/05ISR Number: 4585662-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02746
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Plaquenil	C		

UNKNOWN

Date:02/17/05ISR Number: 4585665-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Ischaemia					

Date:02/17/05ISR Number: 4585666-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01452
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness		[Therapy			
Disability	Visual Acuity Reduced		Unspecified]	C		

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4585667-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00024
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	25	MON
	Myocardial Infarction							

Date:02/17/05ISR Number: 4585669-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00663
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Headache		Depakote	C				
UNKNOWN								
	Insomnia		Protonix	C				
UNKNOWN								
	Oedema Peripheral		Ms Contin	C				
UNKNOWN								
	Thrombosis		Avapro	C				
UNKNOWN								
	Vein Disorder		Synthroid	C				
UNKNOWN								
			Ativan	C				
UNKNOWN								
			Effexor	C				
UNKNOWN								
			Trazodone Hydrochloride	C				
UNKNOWN								

Date:02/17/05ISR Number: 4585671-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4585672-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4585674-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01207
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Disability	Bronchitis Chronic
Other	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cataract
	Coronary Artery Disease
	Depression
	Eating Disorder
	Gastrooesophageal Reflux
	Disease
	Hypotrichosis
	Insomnia
	Ischaemic Cardiomyopathy
	Mitral Valve Incompetence
	Myocardial Infarction
	Night Cramps
	Oesophageal Candidiasis
	Palpitations
	Pulmonary Hypertension
	Silent Myocardial

		Infarction					
		Tricuspid Valve Incompetence					
		Vertigo Positional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vulval Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Synthroid	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Flurazepam	C		
UNKNOWN							
				Estrace	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Dalmane	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:02/17/05ISR Number: 4585677-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death					

Date:02/17/05ISR Number: 4585678-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01495
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged Pantoprazole C
UNKNOWN

Date:02/17/05ISR Number: 4585679-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Disorder					
	Cardiovascular Disorder					
	Multi-Organ Disorder					
	Myocardial Infarction					
	Pain					

Date:02/17/05ISR Number: 4585685-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder					
	Cerebrovascular Accident					
	Multi-Organ Disorder					
	Pain					

Date:02/17/05ISR Number: 4585686-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4585690-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01503
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Captopril	C		ORAL		
Initial or Prolonged	Attack		Tegretol	C		ORAL		
Disability								

Date:02/17/05ISR Number: 4585692-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety							
	Cardiac Disorder							
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Multi-Organ Disorder							
	Pain							

Date:02/17/05ISR Number: 4585694-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4585695-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Antineoplastic (Unspecified)	C				
UNKNOWN								

Date:02/17/05ISR Number: 4585696-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586240-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0202USA01241
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour
	Adverse Event
Disability	Anorexia
	Antisocial Behaviour
	Chest Discomfort

Convulsion
Depression
Disturbance In Attention

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Headache
Insomnia
Sensation Of Pressure
Social Avoidant Behaviour
Suicidal Ideation
Tinnitus

Date:02/17/05ISR Number: 4586241-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00002
Age:73 YR Gender:Female I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability
Other

PT
Arthralgia
Asthenia
Atelectasis
Bursitis
Carotid Artery Stenosis
Chronic Obstructive Pulmonary Disease
Decreased Appetite
Deep Vein Thrombosis
Depression
Diabetes Mellitus
Drug Ineffective
Dyspnoea
Epicondylitis
Faeces Discoloured
Fatigue
Hypercholesterolaemia
Hypertension
Inflammation
Injury
Intervertebral Disc Degeneration
Low Density Lipoprotein Increased
Malignant Melanoma
Meniscus Lesion
Menopausal Symptoms
Mitral Valve Incompetence
Mixed Incontinence

Monocyte Count Decreased
Muscle Spasms
Myalgia
Myositis
Neutrophil Count
Increased
Normochromic Normocytic
Anaemia
Oedema Peripheral
Osteoarthritis
Osteomyelitis
Pain
Post Thrombotic Syndrome
Skin Discolouration
Skin Lesion
Syncope
Tendonitis

	Tricuspid Valve Incompetence Weight Decreased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Accupril	C			UNKNOWN	535 DAY
			Premarin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	366 DAY
			Ultram	C			UNKNOWN	
			Ultram	C		ORAL		
			Plaquenil	C		ORAL		
			Plaquenil	C		ORAL		
			Allegra	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:02/17/05ISR Number: 4586244-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00155
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586245-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00709
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Other	Adverse Event Blood Glucose Increased Blood Pressure Increased Convulsion Coronary Artery Disease Coronary Artery Stenosis Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/17/05ISR Number: 4586246-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00806
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Other	Abdominal Distension Abdominal Pain Abdominal Pain Lower Acute Myocardial Infarction Adverse Event Angina Unstable Aortic Valve Calcification Aortic Valve Incompetence Aortic Valve Sclerosis Arthralgia

Asthenia
Autonomic Neuropathy
Back Injury
Back Pain
Bile Duct Stone
Biliary Dilatation
Blood Pressure Increased
Bundle Branch Block
Bundle Branch Block Left
Bundle Branch Block Right
Cardiac Failure
Congestive
Cataract
Cataract Operation
Chest Pain
Cholelithiasis
Cholelithiasis
Obstructive
Compression Fracture
Constipation
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery
Restenosis
Coronary Artery Stenosis
Costochondritis
Cough
Dehydration
Depression
Diabetes Mellitus
Inadequate Control
Diabetes Mellitus
Insulin-Dependent
Diabetic Retinopathy
Dizziness
Dyspnoea
Ear Discomfort
Ear Disorder
Faecaloma
Fall
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Haematoma

Headache
Hepatic Steatosis
Hypertension
Hypoaesthesia
Hypotension
Hypovolaemia
Impaired Gastric Emptying
Insomnia
Intervertebral Disc
Degeneration
Joint Injury
Ketosis
Ligament Injury
Lumbar Radiculopathy

		Migraine					
		Muscle Spasms					
		Musculoskeletal Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Myositis		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nocturia		Nitroglycerin	C		
RESPIRATORY							
		Oedema Peripheral					
(INHALATION)							
		Osteoporosis		Imdur	C		ORAL
		Pain In Extremity		Humulin N	C		
SUBCUTANEOUS							
		Paraesthesia		Humulin N	C		
SUBCUTANEOUS							
		Pleural Fibrosis		Cardizem	C		ORAL
		Pulmonary Hypertension		Potassium			
		Pulmonary Oedema		(Unspecified)	C		ORAL
		Retinal Detachment		Pepcid	C		ORAL
		Rotator Cuff Syndrome		Ambien	C		ORAL
		Spinal Column Stenosis		Propulsid	C		ORAL
		Stent Occlusion		Aspirin	C		ORAL
		Tibia Fracture		Lipitor	C		ORAL
		Tinnitus		Glucophage	C		ORAL
		Vascular Calcification		Lasix (Furosemide)	C		ORAL
		Vomiting		Prozac	C		ORAL
				Surfak	C		ORAL
				Triple Tannate			
				Pediatric Suspension	C		
UNKNOWN							
				Celebrex	C		ORAL

Date:02/17/05ISR Number: 4586253-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Wall Abscess
Other	Adverse Event
	Anaemia
	Angina Pectoris
	Anxiety
	Back Pain
	Blood Glucose Increased

Blood Pressure Increased
Cardiomegaly
Carotid Artery Stenosis
Cellulitis
Cerebrovascular Accident
Claustrophobia
Conjunctivitis Allergic
Convulsion
Deep Vein Thrombosis
Depressed Mood
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Dyspnoea
Ear Pain
Fatigue
Fear
Goitre
Hallucination
Headache
Hepatic Steatosis

		Herpes Zoster					
		Hypoglycaemia					
		Impaired Gastric Emptying	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injection Site Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
		Injection Site		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Irritability		Coumadin	C		
UNKNOWN							
		Lipomatosis		Risperdal	C		
UNKNOWN							
		Mastoiditis		Prozac	C		
UNKNOWN							
		Migraine		Elavil	C		ORAL
		Mood Swings		Effexor	C		
UNKNOWN							
		Pain In Extremity		Effexor	C		
UNKNOWN							
		Peripheral Sensory		Glucophage	C		
UNKNOWN							
		Neuropathy					
		Phlebitis					
		Rash					
		Retinopathy					
		Seasonal Allergy					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					
		Suicidal Ideation					
		Syncope					
		Thinking Abnormal					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vaginal Haemorrhage					

Date:02/17/05ISR Number: 4586269-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
	Adverse Event
Disability	Agitation

Other	Angina Pectoris
	Angina Unstable
	Anxiety
	Arthralgia
	Astigmatism
	Back Pain
	Blood Glucose Increased
	Blood Ph Increased
	Carpal Tunnel Syndrome
	Cataract
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Corneal Disorder
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Coronary Ostial Stenosis
	Cystitis
	Depression

		Diastolic Dysfunction					
		Dizziness					
		Duodenal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dysaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Electrocardiogram T Wave		Vioxx	SS	Merck & Co., Inc	ORAL
		Inversion		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Erectile Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Exostosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Fluid Overload		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Helicobacter		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal Disorder		Zoloft	C		
UNKNOWN							
		Gastrooesophageal Reflux		Tenormin	C		
UNKNOWN							
		Disease		Tenormin	C		
UNKNOWN							
		Haematemesis		Temazepam	C		
UNKNOWN							
		Haemorrhage		Tagamet	C		
UNKNOWN							
		Haemorrhoids		Aspirin	C		
UNKNOWN							
		Hypercalcaemia		Augmentin	C		
UNKNOWN							
		Hyperlipidaemia		Zocor	C		ORAL
		Hyperparathyroidism		Motrin	C		ORAL
		Hypertension		Plavix	C		ORAL
		Injury		Relafen	C		
UNKNOWN							
		Insomnia		Nitrostat	C		
UNKNOWN							
		Intervertebral Disc		Ultram	C		ORAL
		Degeneration		Ultracet	C		
UNKNOWN							
		Irritability		Ultracet	C		
UNKNOWN							

	Localised Infection	Celebrex	C
UNKNOWN			
	Mediastinitis	Celebrex	C
UNKNOWN			
	Nausea	Trazodone	
	Neck Pain	Hydrochloride	C
UNKNOWN			
	Night Sweats	Trazodone	
	Oedema Peripheral	Hydrochloride	C
UNKNOWN			
	Pain In Extremity	Trazodone	
	Pericardial Effusion	Hydrochloride	C
UNKNOWN			
	Pericarditis	Bextra	C
UNKNOWN			
	Phlebothrombosis	Bextra	C
UNKNOWN			
	Plantar Fasciitis	Flexeril	C
UNKNOWN			
	Pleural Effusion	Flexeril	C
UNKNOWN			
	Postoperative Infection	Paxil	C
UNKNOWN			
	Postpericardiotomy Syndrome		
	Pseudophakia		
	Sinus Bradycardia		
	Spinal Column Stenosis		
	Spinal Osteoarthritis		
	Stress		
	Tricuspid Valve Incompetence		
	Ulnar Nerve Injury		
	Venous Thrombosis Limb		
	Ventricular Hypertrophy		
	Vomiting		
	Weight Decreased		
	Weight Increased		
	Wound Secretion		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4586275-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00694
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Quinine	C				
UNKNOWN								
Disability	Amnesia		Calcium (Unspecified)	C				
Other	Aneurysm							
UNKNOWN								
	Angina Pectoris		Vitamins (Unspecified)	C				
	Anxiety							
UNKNOWN								
	Aortic Valve Sclerosis		Amitriptyline Hydrochloride	C		ORAL		
	Arthralgia							
	Asthenia		Axocet (Acetaminophen (+) Butalbital)	C				
	Bursitis							
	Cardiomegaly							
UNKNOWN								
	Carotid Artery Stenosis		Paxil	C				
UNKNOWN								
	Carpal Tunnel Syndrome							
	Cerebrovascular Accident							
	Chest Wall Pain							
	Convulsion							
	Diabetes Mellitus Non-Insulin-Dependent							
	Diabetic Neuropathy							
	Dysarthria							
	Dyspepsia							
	Dysphonia							
	Encephalomalacia							
	Facial Palsy							
	Fall							
	Haemoglobin Decreased							
	Haemorrhagic Infarction							
	Haemorrhagic Stroke							
	Hand Fracture							
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertriglyceridaemia							
	Hypoaesthesia							
	Ileus							
	Intracranial Aneurysm							
	Malnutrition							
	Muscle Spasms							

Nasopharyngitis
Night Cramps
Ocular Discomfort
Oedema
Pain
Pain In Extremity
Paraesthesia
Periarthritis
Pitting Oedema
Postoperative Ileus
Pruritus
Rhinitis Allergic
Small Intestinal
Obstruction
Throat Irritation
Upper Respiratory Tract
Infection
Vision Blurred
Wound

Date:02/17/05ISR Number: 4586291-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00609
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Monopril	C				
UNKNOWN								
Other	Bursitis		Estrace	C				
UNKNOWN								
	Carbuncle							
	Cervical Root Pain							
	Chest Pain							
	Chest Wall Pain							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Flatulence							
	Hyperlipidaemia							
	Hypertension							
	Joint Stiffness							
	Muscle Spasms							
	Musculoskeletal Pain							
	Myalgia							
	Myocardial Infarction							
	Neuropathy Peripheral							
	Pleurisy Viral							
	Sinusitis							
	Tension Headache							
	Tinel'S Sign							
	Tricuspid Valve Incompetence							
	Ventricular Tachycardia							
	Weight Increased							

Date:02/17/05ISR Number: 4586292-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Zoloft	C				
UNKNOWN								
	Blood Pressure Increased		Lopressor	C				
UNKNOWN								

	Cerebrovascular Accident	Prilosec	C
UNKNOWN			
	Chest Discomfort	Aspirin	C
UNKNOWN			
	Chest Pain	Hytrin	C
UNKNOWN			
	Coronary Artery	Librium	C
UNKNOWN			
	Atherosclerosis	Lipitor	C
UNKNOWN			
	Coronary Artery Stenosis	Nitrostat	C
UNKNOWN			
	Dyspnoea	Altace	C
UNKNOWN			
	Fatigue		
	Hyperlipidaemia		
	Hypertension		
	Myocardial Infarction		
	Nystagmus		
	Oedema Peripheral		
	Palpitations		

Date:02/17/05ISR Number: 4586294-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00492
Age:57 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Hypercoagulation		Vioxx	SS	Merck & Co., Inc	ORAL		
Intestinal Haemorrhage		Metformin	C				
Intestinal Infarction		Pantoprazole Sodium	C				
Intestinal Ischaemia		Silibinin	C				
Mesenteric Vein Thrombosis		Magnesium Aspartate And Potassium Aspartate	C				
Oedema Peripheral		Tetrazepam	C				
		Tolperisone Hydrochloride	C				
		Tamsulosin Hydrochloride	C				
		Xipamide	C				
		Acarbose	C				

Date:02/17/05ISR Number: 4586295-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Activities Of Daily Living Impaired
Other	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Atherosclerosis
	Biliary Neoplasm
	Blood Cholesterol Increased
	Cardiomegaly

Carotid Artery Occlusion
Cerebrovascular Accident
Chest Pain
Chromaturia
Concussion
Constipation
Contusion
Decreased Appetite
Depression
Drug Abuser
Dry Mouth
Dysgeusia
Dysphonia
Dyspnoea
Excoriation
Fall
Fatigue
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Headache
Hepatic Steatosis
Hot Flush
Hyperhidrosis

		Hyperlipidaemia					
		Insomnia					
		Ischaemic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Laceration		Vioxx	PS	Merck & Co., Inc	ORAL
		Macrocytosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Malaise		Vioxx	SS	Merck & Co., Inc	ORAL
		Melaena		Diflunisal	C		
UNKNOWN							
		Microcytic Anaemia		Ultram	C		
UNKNOWN							
		Mitral Valve Incompetence		Rebetol	C		
UNKNOWN							
		Muscle Spasms		Allegra	C		
UNKNOWN							
		Myalgia		Soma	C		ORAL
		Nausea		Premarin	C		
UNKNOWN							
		Neurogenic Bladder		Darvocet-N	C		
UNKNOWN							
		Oedema Peripheral		Accupril	C		
UNKNOWN							
		Orthostatic Hypotension		Wellbutrin	C		
UNKNOWN							
		Pain		Estratest	C		
UNKNOWN							
		Pain In Extremity		Rebetron	C		
UNKNOWN		3 DAY					
		Pneumonia					
		Pulmonary Congestion					
		Skin Ulcer					
		Spinal Compression					
		Fracture					
		Suicidal Ideation					
		Tibia Fracture					
		Urinary Tract Infection					
		Urine Odour Abnormal					
		Weight Increased					

Date:02/17/05ISR Number: 4586300-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03649
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Ankle Fracture

Other	Asthma
	Atrial Fibrillation
	Bronchitis
	Bronchospasm
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Cervicobrachial Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Diabetes Mellitus
	Non-Insulin-Dependent
	Dyspnoea
	Fatigue
	Gastrooesophageal Reflux
	Disease
	Hyperhidrosis
	Hypertension
	Migraine
	Mitral Valve Incompetence
	Myocardial Infarction
	Neck Pain
	Nerve Injury
	Non-Cardiac Chest Pain
	Palpitations

		Sinus Arrhythmia Sinus Disorder Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence Ventricular Dysfunction Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/17/05ISR Number: 4586301-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02420
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident Fatigue Heart Rate Increased Hyperhidrosis Tendon Disorder Tremor		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/17/05ISR Number: 4586304-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
				Adalimumab	SS		
PARENTERAL							
				Methotrexate	SS		
UNKNOWN							
				Estrogens, Conjugated	SS		
UNKNOWN							
				Fluoxetine	SS		
UNKNOWN							
				Amoxicillin And Clavulanate Potassium	SS		
UNKNOWN							
				Acetaminophen And Dihydrocodeine			

			Bitartrate	SS			
UNKNOWN							

Date:02/17/05ISR Number: 4586306-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00348
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bone Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Diclofenac Resinate	SS		ORAL		
	Headache		Atenolol	C		ORAL		
	Inguinal Hernia		Chlordiazepoxide Hydrochloride	C		ORAL		
	Neck Pain		Cyclandelate	C		ORAL		
	Osteoarthritis		Levothyroxine Sodium	C		ORAL		
	Paraesthesia		Sumatriptan Succinate	C		ORAL		
			Dalteparin Sodium	C				
UNKNOWN								
			Pantoprazole Sodium	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4586311-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage Urinary Tract							
	Transient Ischaemic Attack							

Date:02/17/05ISR Number: 4586312-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00022
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586313-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00803
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Death							

Date:02/17/05ISR Number: 4586314-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03128
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atacand	C				
UNKNOWN								
Initial or Prolonged			Effexor	C				
UNKNOWN								
Disability			Lasix (Furosemide)	C				
UNKNOWN								

Date:02/17/05ISR Number: 4586316-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00017
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Escitalopram Oxalate	C				
UNKNOWN								
Initial or Prolonged			Buclizine Hydrochloride	C				
UNKNOWN								
			Acetaminophen	C				
UNKNOWN								
			Meprednisone	C				
UNKNOWN								
			Metoclopramide Hydrochloride	C				
UNKNOWN								
			Estradiol	C				
UNKNOWN								
			Metoclopramide Hydrochloride	C				
UNKNOWN								
			Lactulose	C				
UNKNOWN								
			Lansoprazole	C				
UNKNOWN								
			Dimethicone	C				
UNKNOWN								
			Zolpidem Tartrate	C				
UNKNOWN								
			Sodium Picosulfate	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4586317-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01088
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blister							
Initial or Prolonged	Blood Pressure Increased							
Disability	Cardiac Disorder							
	Chest Discomfort							
	Drug Ineffective							
	Glaucoma							
	Rotator Cuff Syndrome							
	Thermal Burn							
	Visual Acuity Reduced							

Date:02/17/05ISR Number: 4586318-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00033
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Candesartan Cilexetil	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Cyanocobalamin And Folic Acid And Pyridoxine Hydrochloride	C			UNKNOWN	

Date:02/17/05ISR Number: 4586319-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02620
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586320-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00146
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		725 DAY
Initial or Prolonged	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		725 DAY
	Chest Pain		Aspirin	C		ORAL		
	Coronary Artery Atherosclerosis		Ranitidine Hydrochloride	C		ORAL		
	Coronary Artery Disease		Levothyroxine Sodium	C		ORAL		
	Disorientation		Diclofenac	C		ORAL		757 DAY
	Dysphagia		Amoxicillin	C		ORAL		
	Fall		Amoxicillin	C		ORAL		
	Fatigue		Amoxicillin	C		ORAL		
	Forearm Fracture							
	Headache							
	Hypertension							
	Mandibulofacial Dysostosis							
	Nausea							
	Paraesthesia							
	Tonsillitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/17/05ISR Number: 4586321-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03873
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL	4	MON
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
Disability	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	4	MON
	Dyspnoea		Lorazepam	C			UNKNOWN	
	Fatigue		Vicodin Tablets	C			UNKNOWN	
	Feeling Abnormal		Celebrex	C			UNKNOWN	
	Renal Cell Carcinoma		Elavil	C			UNKNOWN	
	Stage Unspecified							
	Ureteric Cancer							

Date:02/17/05ISR Number: 4586322-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00261
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Wall Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Dizziness		Methotrexate	C			UNKNOWN	
	Hot Flush		Nexium	C			UNKNOWN	
	Palpitations		Salagen Tablets	C			UNKNOWN	
	Pollakiuria							

Date:02/17/05ISR Number: 4586324-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01922
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Back Pain	Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain	Vioxx	SS	Merck & Co., Inc	ORAL
	Pain In Extremity	Flexeril	C		ORAL
		Flexeril	C		ORAL

Date:02/17/05ISR Number: 4586325-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0502CHE00011
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586326-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00152
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Death	Asthenia
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree
	Blood Albumin Decreased
	Blood Chloride Decreased
	Blood Osmolarity Decreased
	Blood Pressure Increased
	Brain Natriuretic Peptide Increased
	Cardiac Arrest
	Cardiac Failure Congestive
	Coma

		Computerised Tomogram					
		Abnormal					
		Cyanosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Electrocardiogram T Wave		Vioxx	SS	Merck & Co., Inc	
UNKNOWN		107 DAY					
		Abnormal		Vioxx	SS	Merck & Co., Inc	
UNKNOWN		28 DAY					
		Fluid Overload		Zoloft	C		
UNKNOWN							
		Fluid Retention		Xanax	C		
UNKNOWN							
		Haematocrit Decreased		Quinine	C		
UNKNOWN							
		Haemoglobin Decreased		Humulin 70/30	C		
UNKNOWN							
		Hypervolaemia					
		Hyponatraemia					
		Myocardial Infarction					
		Nausea					
		Rales					
		Respiratory Failure					
		Vomiting					

Date:02/17/05ISR Number: 4586331-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00808
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			[Therapy			
			Unspecified]	C		
UNKNOWN						

Date:02/17/05ISR Number: 4586332-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01360
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/17/05ISR Number: 4586333-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:02/17/05ISR Number: 4586334-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01611
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Acute Myocardial Infarction Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586336-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01323
Age: Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged	Cardiac Disorder Cardiac Valve Disease Chest Pain Dyspnoea Gastrooesophageal Reflux Disease

Heart Rate Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586341-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death		Bextra	C				
UNKNOWN								

Date:02/17/05ISR Number: 4586342-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01619
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
39 MON								

Date:02/17/05ISR Number: 4586343-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01328
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/17/05ISR Number: 4586345-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01346
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:02/17/05ISR Number: 4589715-2Report Type:Expedited (15-DaCompany Report #WAES 0410DEU00504
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort	Foreign	Tab Vioxx					
Hospitalization -	Coronary Artery Occlusion	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Myocardial Infarction	Other						
PO								93 DAY
Disability	Scar		Alfuzosin Hydrochloride	C				
			Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil Dihydrochloride	C				

Date:02/17/05ISR Number: 4589717-6Report Type:Expedited (15-DaCompany Report #WAES 0501GBR00078
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Activated Partial
Initial or Prolonged	Thromboplastin Time
	Shortened
	Asthenia
	C-Reactive Protein

		Increased					
		Carotid Artery Stenosis					
		Diplopia					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypercholesterolaemia	Foreign	Tab Vioxx			
		Lymphocyte Count	Study	(Rofecoxib)	PS		ORAL
25 MG/DAILY							
		Decreased	Other				
PO	104 DAY						
		Platelet Count Decreased		Fosamax	C		
		Red Blood Cell Count		Proscar	C		
		Decreased		Prednisolone	C		
		Red Blood Cell		Tamsulosin			
		Sedimentation Rate		Hydrochloride	C		
		Increased					
		Transient Ischaemic					
		Attack					

Date:02/17/05ISR Number: 4590313-5Report Type:Expedited (15-DaCompany Report #2004118129
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Drug Ineffective	Consumer	Celebrex (Celecoxib)	PS		
		Pain		Rofecoxib			
		Renal Failure		(Rofecoxib)	SS		
				Non Steroidal Anti			
				Inflammatory Drug			
				(Antiinflammatory/An			
				tirheumatic			
				Non-Steroids	SS		
				Gabapentin			
				(Gabapantin)	C		
				Sertraline			
				Hydrochloride			
				(Sertraline			
				Hydrochloride)	C		

Date:02/18/05ISR Number: 4586968-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104492
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthralgia

Initial or Prolonged	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Pressure Fluctuation
	Blood Triglycerides Increased
	Bursitis
	Calcinosis
	Cardiovascular Disorder
	Carotid Artery Stenosis
	Cellulitis
	Cerebrovascular Accident
	Chondrocalcinosis
	Dizziness
	Extrasystoles
	Granuloma
	Hyperlipidaemia
	Hypertension
	Joint Effusion

		Low Density Lipoprotein Increased					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Tendon Calcification					
		Tendon Injury					
		Tendonitis					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					

Date:02/18/05ISR Number: 4586997-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03706
Age:41 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Premarin	C		
UNKNOWN							
		Dysphagia					

Date:02/18/05ISR Number: 4586998-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02525
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -				Centrum Silver	C		
UNKNOWN							
Initial or Prolonged				Cephalexin	C		
UNKNOWN							
Disability				Vicodin Tablets	C		
UNKNOWN							

Date:02/18/05ISR Number: 4586999-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02635
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Duodenitis		Micronase	C				
UNKNOWN								
	Extrasystoles							
	Faecal Occult Blood							
	Positive							
	Gastric Ulcer Haemorrhage							
	Gastritis							
	Haemorrhoids							
	Hiatus Hernia							
	Rectal Haemorrhage							

Date:02/18/05ISR Number: 4587000-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00216
Age:86 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Blister
Disability	Difficulty In Walking
Other	Hemiplegia
	Hypoaesthesia

Physical Disability
Pigmentation Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Potassium (Unspecified)	C			UNKNOWN	
	Norvasc	C			UNKNOWN	

Date:02/18/05ISR Number: 4587001-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00889
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL	44	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	44	DAY
			Norvasc	C			UNKNOWN	
			Hydrocortisone	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	

Date:02/18/05ISR Number: 4587002-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02507
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Alopecia
	Anaemia
	Anorexia
	Arthralgia
	Arthropathy
	Asthenia
	Asthma
	Atelectasis

Blood Lactate
Dehydrogenase Increased
Breath Sounds Decreased
Cardiac Failure
Congestive
Cardiomegaly
Cerebral Atrophy
Cerebral Infarction
Cerebrovascular Accident
Chest Pain
Chronic Obstructive
Pulmonary Disease
Colitis
Colitis Ulcerative
Constipation
Cough
Crackles Lung
Deep Vein Thrombosis
Depressed Mood
Depression
Diarrhoea
Dilatation Atrial
Drug Interaction
Dysarthria
Dyspnoea
Fall
Fibrin D Dimer Increased

		Headache					
		Hemiparesis					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL
		Iron Deficiency Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Joint Swelling		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacunar Infarction					
		Lobar Pneumonia					
		Muscle Spasms					
		Oedema Peripheral					
		Osteoarthritis					
		Paraesthesia					
		Pericardial Effusion					
		Pharyngolaryngeal Pain					
		Postmenopausal					
		Haemorrhage					
		Pulmonary Congestion					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Reading Disorder					
		Rectal Ulcer					
		Reflux Oesophagitis					
		Renal Failure					
		Thrombosis					
		Tremor					
		Upper Motor Neurone					
		Lesion					
		Vision Blurred					
		Weight Decreased					

Date:02/18/05ISR Number: 4587007-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00716
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Emotional Disorder		Dilantin	C		
UNKNOWN							
Disability		Fatigue					

Date:02/18/05ISR Number: 4587008-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587009-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
			Blood Thinner (Unspecified)	C				

UNKNOWN

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587010-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:02/18/05ISR Number: 4587012-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587024-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00862
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Tenoret	C				
UNKNOWN								
Initial or Prolonged	Gastric Haemorrhage							
Disability								

Date:02/18/05ISR Number: 4587026-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0501SWE00015
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
270 DAY								
Initial or Prolonged	Headache		Propoxyphene					
	Hypertension		Napsylate	C				
UNKNOWN								

Date:02/18/05ISR Number: 4587027-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03315
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Original Formula					
Disability	Cerebrovascular Accident		Sensodyne-Sc	SS				
UNKNOWN								
	Feeling Abnormal							
	Walking Aid User							

Date:02/18/05ISR Number: 4587028-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00672
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion							
	Headache							
	Malaise							
	Nausea							
	Palpitations							
	Tremor							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587030-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02045
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cerebrovascular Accident		Glucophage	C				
Initial or Prolonged Disability	Chest Pain Dyspnoea Polytraumatism Transient Ischaemic Attack							

Date:02/18/05ISR Number: 4587036-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01358
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthritis Infective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Gastric Disorder							

Date:02/18/05ISR Number: 4587037-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03555
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	568	DAY

Other	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
568 DAY						
	Joint Swelling		Norvasc	C		
UNKNOWN						
	Musculoskeletal Stiffness		Lipitor	C		
UNKNOWN						
	Uterine Disorder		[Therapy Unspecified]	C		
UNKNOWN						

Date:02/18/05ISR Number: 4587041-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00016
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
24 MON						
	Injury					

Date:02/18/05ISR Number: 4587043-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hypertension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587045-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01497
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								

Date:02/18/05ISR Number: 4587046-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive							

Date:02/18/05ISR Number: 4587047-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/18/05ISR Number: 4587049-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02231
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:02/18/05ISR Number: 4587054-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/18/05ISR Number: 4587055-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587059-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587060-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587061-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							
	Polytraumatism							

Date:02/18/05ISR Number: 4587098-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Bilirubin Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Ceftin	C		ORAL		
	Increased		Percocet	C		ORAL		
	Carpal Tunnel Syndrome		Vicodin Es Tablets	C		ORAL		
	Coronary Artery Disease		Ambien	C		ORAL		
	Ejection Fraction		Zoloft	C		ORAL		
	Decreased		Zoloft	C		ORAL		
	Emotional Distress							
	Hyperlipidaemia							
	Hypertension							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Sleep Apnoea Syndrome							
	Thrombosis							
	Trigger Finger							

Date:02/18/05ISR Number: 4587110-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00795
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Nicotine	SS				
UNKNOWN								
			Albuterol	C				
UNKNOWN								

			Fluticasone Propionate	C		
UNKNOWN						
			Ipratropium Bromide	C		
UNKNOWN						

Date:02/18/05ISR Number: 4587635-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		153 DAY
Initial or Prolonged	Decreased Appetite		Methotrexate	SS		ORAL		YR
	Fatigue		Sertraline Hydrochloride	SS		ORAL		
	Hepatic Cirrhosis		Sertraline Hydrochloride	SS		ORAL		
	Hepatic Fibrosis		Omeprazole Magnesium	SS		ORAL		153 DAY
	Hepatic Steatosis		Omeprazole Magnesium	SS		ORAL		153 DAY
	Hepatitis		Infliximab	SS		INTRAVENOUS		122 DAY
	Hepatocellular Damage		Glyburide	C		UNKNOWN		
	Liver Disorder		Folic Acid	C		UNKNOWN		
	Muscle Atrophy							
	Nausea							
	Vasculitis							

Date:02/18/05ISR Number: 4587653-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Accident At Home
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Angina Pectoris
	Anxiety
	Atrial Septal Defect
	Balance Disorder
	Bipolar Disorder
	Borderline Personality
	Disorder
	Bradycardia
	Breast Pain
	Bursitis
	Cardiac Aneurysm
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cellulitis
	Cerebral Infarction
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Death
	Diverticulum
	Drug Abuser
	Drug Dependence
	Dyspnoea
	Emotional Distress
	Fibromyalgia
	Haemorrhoids
	Headache
	Hyperkalaemia
	Hypertrophy Breast
	Hyponatraemia
	Injury
	Intermittent Claudication
	Intracranial Aneurysm
	Lacunar Infarction
	Leukocytosis
	Limb Discomfort

Major Depression
Mania
Mitral Valve Incompetence
Myocardial Infarction
Obsessive-Compulsive
Disorder
Oedema Peripheral
Overdose
Pain
Pain In Extremity
Pollakiuria
Pulmonary Hypertension
Spinal Osteoarthritis
Suicidal Ideation
Transient Ischaemic

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Attack Tricuspid Valve Incompetence Upper Respiratory Tract					
		Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Varices Oesophageal		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN	668 DAY						
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN	96 DAY						
				Neurontin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Monopril	C		ORAL
				Norvasc	C		
UNKNOWN							
				Lithium Carbonate	C		ORAL
				Lithium Carbonate	C		ORAL
				Zyprexa	C		ORAL
				Zyprexa	C		ORAL
				Zithromax	C		ORAL
4 DAY							
				Navane	C		ORAL
				Cogentin	C		ORAL
				Tegretol-Xr	C		ORAL
				Claritin-D	C		
UNKNOWN							

Date:02/18/05ISR Number: 4587678-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
Disability	Increased		Tylenol With Codeine					
	Blood Pressure Decreased		#3	C		ORAL		
	Blood Triglycerides		Vicodin Tablets	C				UNKNOWN
	Increased		Tylenol	C				UNKNOWN
	Coronary Artery Disease		Ecotrin	C				UNKNOWN
	Dizziness							
	Dyspnoea							
	Fatigue							
	Hyperhidrosis							
	Hypertension							
	Insomnia							
	Joint Swelling							
	Myocardial Infarction							
	Oxygen Saturation							
	Decreased							
	Weight Increased							

Date:02/18/05ISR Number: 4587684-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01113
Age:40 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Blood Homocysteine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
		Coumadin	SS				UNKNOWN
Cardiovascular Disorder		Plavix	SS				UNKNOWN
Cerebral Infarction		Vitamins (Unspecified)	C				UNKNOWN
Cerebrovascular Accident							
Chest Pain		Aspirin	C				UNKNOWN
Circulatory Collapse							
Dizziness							
Dyspnoea							
Dyspnoea Exertional							
Feeling Of Body Temperature Change							
Hyperlipidaemia							
Hypoaesthesia							
Lipoprotein (A) Increased							
Loss Of Consciousness							
Pyrexia							
Renal Disorder							
Renal Failure							
Speech Disorder							
Ventricular Extrasystoles							

Date:02/18/05ISR Number: 4587688-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00610
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
Other	Angina Pectoris
	Arterial Stenosis
	Arthralgia
	Asthenia
	Atelectasis
	Back Pain
	Blood Pressure Increased
	Bundle Branch Block Right
	Cardiac Failure
	Congestive

Cardiomyopathy
Cervicobrachial Syndrome
Chest Discomfort
Chest Pain
Coccydynia
Convulsion
Coronary Artery Stenosis
Dizziness
Drug Ineffective
Dyspepsia
Ejection Fraction
Decreased
Fall
Gait Disturbance
Headache
Hypercholesterolaemia
Hypoaesthesia
Left Ventricular Failure
Lumbar Radiculopathy
Lumbar Spinal Stenosis

		Muscle Spasms					
		Myocardial Infarction					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Zocor	C		
UNKNOWN							
		Plantar Fasciitis		Skelaxin	C		
UNKNOWN							
		Pneumonia		Ultram	C		
UNKNOWN							
		Productive Cough		Furosemide	C		
UNKNOWN							
		Pulmonary Hypertension		Zestril	C		
UNKNOWN							
		Spinal Osteoarthritis		Hydrocodone/Apap	C		
UNKNOWN							
		Upper Respiratory Tract		Lopressor	C		
UNKNOWN							
		Infection		Imdur	C		
UNKNOWN							
		Ventricular Dysfunction		Digoxin	C		
UNKNOWN							
		Weight Decreased		Aspirin	C		
UNKNOWN							
		Wheezing		Aerobid	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Ipratropium Bromide	C		
UNKNOWN							

Date:02/18/05ISR Number: 4587700-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00534
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Bronchitis Acute		Prilosec	C		
UNKNOWN						
Initial or Prolonged	Cardiac Failure		Methadone Hcl	C		ORAL
Other	Congestive					
	Deep Vein Thrombosis					

Diabetes Mellitus
Hypoaesthesia
International Normalised
Ratio Increased
Pain
Peripheral Vascular
Disorder
Pulmonary Embolism
Weight Decreased

Date:02/18/05ISR Number: 4587702-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00146
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		725 DAY
Initial or Prolonged	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		725 DAY
	Chest Pain		Aspirin	C		ORAL		
	Coronary Artery Disease		Ranitidine Hydrochloride	C		ORAL		
	Disorientation		Levothyroxine Sodium	C		ORAL		
	Dysphagia		Diclofenac	C		ORAL		757 DAY
	Fall		Amoxicillin	C		ORAL		
	Fatigue		Amoxicillin	C		ORAL		
	Forearm Fracture		Amoxicillin	C		ORAL		
	Headache							
	Hypertension							
	Mandibulofacial Dysostosis							
	Nausea							
	Paraesthesia							
	Tonsillitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587706-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01338
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Life-Threatening	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
Hospitalization -	Sudden Cardiac Death		Synthroid	C				UNKNOWN
Initial or Prolonged			Zocor	C		ORAL		
Disability			Aspirin	C				UNKNOWN

Date:02/18/05ISR Number: 4587707-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01469
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cystitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dehydration		Premarin	C				UNKNOWN
	Renal Failure		Atenolol	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:02/18/05ISR Number: 4587709-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02433
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Disorder		Oxycodone	C				UNKNOWN
	Irritable Bowel Syndrome		Zoloft	C				UNKNOWN
	Monarthritis							
	Musculoskeletal Chest							

Pain

Date:02/18/05ISR Number: 4587710-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		373 DAY
Initial or Prolonged	Infarction		Lipitor	C				UNKNOWN
	Coronary Artery		Tranxene	C				UNKNOWN
	Atherosclerosis		Prozac	C				UNKNOWN
	Emotional Distress		Zantac	C				UNKNOWN
	Exostosis							
	Fall							
	Obstructive Airways							
	Disorder							
	Ulna Fracture							

Date:02/18/05ISR Number: 4587711-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Actinic Keratosis
Initial or Prolonged	Anaemia
	Angina Pectoris
	Atrial Fibrillation
	Atrioventricular Block
	Blood Pressure
	Fluctuation

		Body Tinea					
		Carotid Artery Stenosis					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Dermatitis		Diovan	C		
UNKNOWN							
		Diverticulum		Zocor	C		
UNKNOWN							
		Eczema		Dapsone	C		
UNKNOWN							
		Epidermal Necrosis		Toprol Xl Tablets	C		
UNKNOWN							
		Erythema Multiforme		Viagra	C		
UNKNOWN							
		Granuloma Annulare					
		Leukocytoclastic					
		Vasculitis					
		Myocardial Ischaemia					
		Nail Bed Bleeding					
		Onycholysis					
		Polyp					
		Pruritus Ani					
		Psoriasis					
		Syncope					
		Vasculitis					

Date:02/18/05ISR Number: 4587715-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01986
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Ischaemia		Vitamins			
Initial or Prolonged	Ventricular Tachycardia		(Unspecified)	C		
UNKNOWN						
Disability			Protonix	C		ORAL
			Lipitor	C		ORAL
			Zoloft	C		ORAL
			Lorazepam	C		ORAL
			Atenolol	C		ORAL
			Fiorinal	C		
UNKNOWN						

Date:02/18/05ISR Number: 4587716-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00707
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON
Initial or Prolonged	Coronary Artery Disease		Darvocet-N	C		ORAL		
Disability	Depression		Neurontin	C		ORAL		
	Diabetes Mellitus		Flexeril	C		ORAL		
	Non-Insulin-Dependent		Viagra	C		ORAL		
	Erectile Dysfunction		Lipitor	C		ORAL		
	Gastrooesophageal Reflux		Valtrex	C		ORAL		77 DAY
	Disease		Niaspan	C		ORAL		
	Hypertension		Paxil	C				UNKNOWN
	Hypertriglyceridaemia							
	Intervertebral Disc							
	Protrusion							
	Joint Effusion							
	Micturition Disorder							
	Myocardial Infarction							
	Renal Failure Acute							
	Rotator Cuff Syndrome							
	Tendonitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587717-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00152
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Hospitalization - UNKNOWN	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc			107 DAY
Initial or Prolonged UNKNOWN	First Degree		Vioxx	SS	Merck & Co., Inc			28 DAY
	Blood Calcium Decreased		Zoloft	C				
	Blood Chloride Decreased		Xanax	C				
	Blood Glucose Increased		Quinine	C				
	Cardiac Arrest		Humulin 70/30	C				
	Cardiac Failure							
	Congestive							
	Coma							
	Cyanosis							
	Fluid Retention							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Hypervolaemia							
	Hyponatraemia							
	Loss Of Consciousness							
	Myocardial Infarction							
	Nausea							
	Respiratory Failure							
	Vomiting							

Date:02/18/05ISR Number: 4587718-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01997
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Life-Threatening	Decubitus Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
Hospitalization - Initial or Prolonged	Urosepsis							

Disability

Date:02/18/05ISR Number: 4587719-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01934
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587720-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01373
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	26 MON	
Hospitalization -	Disease		Paxil	C			UNKNOWN	
Initial or Prolonged	Coronary Artery Occlusion		Amitriptyline					
Disability	Dyspnoea		Hydrochloride	C			UNKNOWN	
			Cyclobenzaprine Hydrochloride	C			UNKNOWN	
			Esclim	C			UNKNOWN	
			Fosamax	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587722-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01994
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		72 DAY
Initial or Prolonged	Hypertension							
	Myocardial Infarction							

Date:02/18/05ISR Number: 4587723-9Report Type:Expedited (15-DaCompany Report #CN-MERCK-0501CHN00019
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		348 DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		348 DAY
	Angina Pectoris		Alfacalcidol	C		ORAL		
	Atrioventricular Block Complete		Elcatonin	C		ORAL		
	Cardiogenic Shock							

Date:02/18/05ISR Number: 4587724-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00041
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Atenolol	C		ORAL		
Disability	Attack							

Date:02/18/05ISR Number: 4587725-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Hospitalization -								

Initial or Prolonged

Date:02/18/05ISR Number: 4587726-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02355
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Hospitalization - Initial or Prolonged	Cardiovascular Disorder		Hydrochlorothiazide And Triamterene	C				
	Cerebrovascular Accident							
UNKNOWN								
Other	Colonic Polyp							
	Constipation							
	Diverticulum							
	Dysuria							
	Erythema							
	Gastrointestinal Tract Adenoma							
	Genital Pruritus Female							
	Hypertension							
	Hypokalaemia							
	Insomnia							
	Oesophageal Stenosis							
	Osteoarthritis							
	Urinary Tract Infection							
	Urticaria							
	Vaginitis Atrophic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587729-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587730-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01038
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Celebrex	C				
UNKNOWN								
Initial or Prolonged			Bextra	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:02/18/05ISR Number: 4587732-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00999
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization -			Vicodin Tablets	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:02/18/05ISR Number: 4587733-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00024
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	701	DAY
	Myocardial Infarction		Hydrochlorothiazide					

				And Irbesartan	C		
UNKNOWN							
				Levomepromazine	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Metformin Hydrochloride	C		
UNKNOWN							

Date:02/18/05ISR Number: 4587734-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00013
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Initial or Prolonged	Cardiac Failure		Carvedilol	C		
UNKNOWN						
	Myocardial Infarction					

Date:02/18/05ISR Number: 4587735-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00128
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Disability			Clopidogrel Bisulfate	C		ORAL
			Ramipril	C		ORAL
			Simvastatin	C		ORAL
			Isosorbide Mononitrate	C		ORAL
			Atenolol	C		
UNKNOWN						

	Aspirin	C	UNKNOWN
	Nicorandil	C	UNKNOWN
	Acetaminophen	C	UNKNOWN
	Codeine Phosphate	C	UNKNOWN

Date:02/18/05ISR Number: 4587738-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Coronary Artery Thrombosis Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587739-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587740-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587743-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00012
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	240 DAY	

Date:02/18/05ISR Number: 4587744-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01251
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	386 DAY	
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C			UNKNOWN	
			Glucophage	C			UNKNOWN	

Date:02/18/05ISR Number: 4587745-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01769
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Full Blood Count Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4587746-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01100
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587747-1Report Type:Expedited (15-DaCompany Report #AT-MERCK-0502AUT00010
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587748-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01099
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4587753-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01262
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization - Initial or Prolonged			Xanax	C			UNKNOWN	

Date:02/18/05ISR Number: 4587754-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01263
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Convulsion
Hypoaesthesia
Tooth Loss

Date:02/18/05ISR Number: 4587768-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/18/05ISR Number: 4590022-2Report Type:Direct Company Report #CTU 240818
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pain		Vioxx	PS	Merck & Co	ORAL	1 ORAL	

Date:02/18/05ISR Number: 4591295-2Report Type:Expedited (15-DaCompany Report #2005024693
Age:84 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Coma
	Hemiplegia

		Loss Of Consciousness Myocardial Infarction Respiratory Arrest	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Foreign Health Professional Company Representative	Celebrex (Celecoxib) Rofecoxib (Rofecoxib) Beta Blocking Agents (Beta Blocknig Agents)	PS SS C		

Date:02/18/05ISR Number: 4591627-5Report Type:Expedited (15-DaCompany Report #2005025469
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective Knee Operation Macular Degeneration	Consumer	Celebrex (Celecoxib) Arthrotec (Diclofenac Sodium, Misoprostol) Rofecoxib (Rofecoxib) Salsalate Provella -14 (Estrogens Conjugated, Medroxyprogesterone Acetate)	PS SS SS C C		

Date:02/18/05ISR Number: 4591647-0Report Type:Expedited (15-DaCompany Report #2005020279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Chest Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL
ORAL						
	Difficulty In Walking		Bextra (Valdecoxib)	SS		ORAL
20 MG (20 MG,						
	Drug Ineffective					
1 IN 1 D),						
	Dyspnoea					
ORAL						
	Fluid Retention		Rofecoxib			

	Gastric Disorder	(Rofecoxib)	SS	ORAL
ORAL				
	Oral Mucosal Blistering	Furosemide (Furosemide)	C	
	Post Procedural Pain	Acetylsalicylic Acid (Acetylsalicylic Acid)	C	
	Pyrexia	Escitalopram (Escitalopram)	C	
	Stomatitis	Atorvastatin (Atorvastatin)	C	
	Weight Increased	Tramadol (Tramadol)	C	
		Potassium Chloride (Potassium Chloride)	C	
		Alprazolam (Alprazolam)	C	
		Estrogens Conjugated (Estrogens Conjugated)	C	
		Vicodin (Hydrocodone Bitartrate, Paracetamol)	C	
		Irbesartan (Irbesartan)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/18/05ISR Number: 4591653-6Report Type:Expedited (15-DaCompany Report #2004118543
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Constipation	Consumer	Celebrex (Celecoxib)	PS				
	Drug Ineffective		Vioxx (Rofecoxib)	SS				
	Haematochezia							
	Haemorrhage							

Date:02/18/05ISR Number: 4591657-3Report Type:Expedited (15-DaCompany Report #2005026476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abnormal Faeces	Consumer	Celebrex (Celecoxib)	PS			200 MG (200 MG,1 IN 1 D)	
	Drug Ineffective							
	Flatulence		Bextra (Valdecoxib)	SS			(1 IN 1 D)	
	Haemorrhage		Rofecoxib (Rofecoxib)	SS			(1 IN 1 D)	
	Hip Arthroplasty							
	Osteoarthritis							
	Osteoporosis							

Date:02/18/05ISR Number: 4591667-6Report Type:Expedited (15-DaCompany Report #2005025375
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
	Condition Aggravated							
Other	Diarrhoea							
	Fibromyalgia		Rofecoxib (Rofecoxib)	SS				
	Gastric Haemorrhage							
	Gastric Ulcer		Pantoprazole (Pantoprazole)	C				
	Gastritis							
	Gastrointestinal		Metoprolol					

	Haemorrhage		(Metoprolol)	C
	Nausea		Irbesartan	
	Oesophageal Haemorrhage		(Irbesartan)	C
	Transient Ischaemic Attack			

Date:02/21/05ISR Number: 4588131-7Report Type:Expedited (15-DaCompany Report #PHEH2005US02041
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Failure		Lamisil	PS	Novartis Sector: Pharma	ORAL	UNK, UNK	
			Vioxx	SS		ORAL	UNK, UNK	

Date:02/22/05ISR Number: 4588668-0Report Type:Expedited (15-DaCompany Report #US-MERCK-00070003
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Asthenia		Atenolol	C				
	Cerebrovascular Accident		Diuretic Preparation (Composition Unspecified)	C			UNKNOWN	
	General Symptom							
	Myocardial Infarction							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4588672-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00730
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Prilosec	C				
UNKNOWN								
	Convulsion							
	Costochondritis							
	Orthopnoea							
	Pyrexia							

Date:02/22/05ISR Number: 4588674-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00319
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
93 DAY								
Initial or Prolonged	Increased		Prilosec	C				
UNKNOWN								
Disability	Blood Pressure		Flonase	C				
UNKNOWN								
	Fluctuation		Baclofen	C				
UNKNOWN								
	Cerebral Infarction							
	Cerebrovascular Accident							
	Chest Pain							
	Drug Ineffective							
	Peroneal Nerve Palsy							
	Prostatic Specific							
	Antigen Increased							
	Ventricular Hypertrophy							

Date:02/22/05ISR Number: 4588675-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia
Disability	Asthenia
	Benign Prostatic

Hyperplasia
Choking
Cough
Depression
Diverticulum
Dysgeusia
Dyspepsia
Dyspnoea
Dysuria
Early Satiety
Erosive Duodenitis
Erosive Oesophagitis
Fatigue
Gastric Disorder
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Heat Stroke
Hiatus Hernia
Hypertension
Hypoacusis
Intestinal Functional
Disorder
Lung Disorder

Malaise
Muscle Atrophy
Nasopharyngitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oesophageal Rupture					
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Pancreatitis					
	Aspirin	C			UNKNOWN	
	Renal Cyst					
	Restoril	C			UNKNOWN	

Rhinorrhoea
Stomach Discomfort
Stress
Supraventricular
Extrasystoles
Thromboembolic Stroke
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Urinary Retention
Urinary Tract Disorder
Urinary Tract Infection
Weight Decreased

Date:02/22/05ISR Number: 4588676-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Alopecia
Other	Benign Neoplasm
	Chest Pain
	Colonic Polyp
	Constipation
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Dermatitis
	Diarrhoea
	Drug Intolerance
	Dyspepsia
	Dysuria
	Early Morning Awakening
	Epicondylitis

Exostosis
Food Intolerance
Gastroenteritis Viral
Generalised Anxiety
Disorder
Gout
Haematoma
Hair Texture Abnormal
Hearing Impaired
Hypercholesterolaemia
Hypertension
Increased Tendency To
Bruise
Insomnia
Intervertebral Disc
Degeneration
Lung Neoplasm
Myocardial Infarction

		Myositis					
		Nasal Congestion					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nervousness		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteochondrosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Pollakiuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Postnasal Drip		Librax Capsules	C		
UNKNOWN							
		Productive Cough		Zantac	C		
UNKNOWN							
		Pruritus		Cyclobenzaprine			
		Radiculitis Cervical		Hydrochloride	C		
UNKNOWN							
		Rectal Haemorrhage		Acetaminophen And			
		Rhinorrhoea		Propoxyphene			
		Rotator Cuff Syndrome		Napsylate	C		
UNKNOWN							
		Sinus Disorder		Allegra	C		
UNKNOWN							
		Sleep Disorder		Prilosec	C		
UNKNOWN							
		Sneezing		Xanax	C		
UNKNOWN							
		Spinal Osteoarthritis		Aspirin	C		
UNKNOWN							
		Stomach Discomfort		Tylenol	C		
UNKNOWN							
		Tendonitis					
		Tinnitus					
		Urinary Tract Infection					

Date:02/22/05ISR Number: 4588678-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00993
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
7 DAY						
Initial or Prolonged	Infarction		Advil	C		
UNKNOWN						
Disability	Back Injury		Advil	C		
UNKNOWN						

	Back Pain	Tylenol	C
UNKNOWN			
	Blood Pressure Increased	Tylenol	C
UNKNOWN			
	Bradycardia	Imitrex	C
UNKNOWN			
	Coronary Artery Stenosis	Percocet	C
UNKNOWN			
	Depression	Medrol	C
UNKNOWN			
	Emotional Distress	Maalox	C
UNKNOWN			
	Enthesopathy		
	Exostosis		
	Fatigue		
	Gastritis		
	Gastrooesophageal Reflux Disease		
	Hypercholesterolaemia		
	Hypotension		
	Intervertebral Disc Degeneration		
	Intervertebral Disc Protrusion		
	Neck Injury		
	Psoriasis		
	Seborrhoeic Dermatitis		
	Urinary Retention		
	Ventricular Tachycardia		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4588680-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00630
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - UNKNOWN	Angina Pectoris 2 MON		Vioxx	PS	Merck & Co., Inc	
Initial or Prolonged UNKNOWN	Atelectasis		Diclofenac Sodium	C		
	Atherosclerosis		Cyclobenzaprine Hydrochloride	C		
	Back Pain					
	Blood Cholesterol		Premarin	C		
	Increased		Zocor	C		
	Cardiac Disorder		Sudafed	C		
	Chest Pain		Guaifenesin	C		
	Corneal Abrasion		Amoxicillin	C		
	Coronary Artery Disease		Pravachol	C		
	Coronary Artery Occlusion		Lipitor	C		
	Hypertension					
	Myocardial Infarction					
	Pyrexia					

Date:02/22/05ISR Number: 4588681-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 MON	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 2 MON	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Arterial Stenosis		Premarin	C		ORAL
Other UNKNOWN	Arthralgia		Zocor	C		
	Atelectasis		Voltaren	C		ORAL
	Atherosclerosis		Flexeril	C		ORAL
	Back Pain		Guaifenesin And			

	Buttock Pain		Pseudoephedrine		
	Cardiac Disorder		Hydrochloride	C	ORAL
	Chest Pain		Amoxicillin	C	
UNKNOWN					
	Corneal Abrasion		Pravachol	C	
UNKNOWN					
	Coronary Artery Disease		Lopid	C	ORAL
	Depression				
	Dysphonia				
	Headache				
	Intervertebral Disc				
	Protrusion				
	Muscle Spasms				
	Myocardial Infarction				
	Myocardial Ischaemia				
	Neck Injury				
	Neck Pain				
	Pain In Extremity				
	Pyrexia				
	Rotator Cuff Syndrome				
	Tendonitis				
	Ventricular Extrasystoles				

Date:02/22/05ISR Number: 4588682-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4588683-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4588684-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01126
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4588685-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01999
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prednisone	C				
			Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	

Date:02/22/05ISR Number: 4588686-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01964
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Haemorrhage Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Gemfibrozil	C				
			Vitamins (Unspecified)	C			UNKNOWN	

Date:02/22/05ISR Number: 4588687-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01483
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrophy		Aspirin	C				
Disability	Bulbar Palsy		Meperidine Hydrochloride And Promethazine Hydrochloride	C				
	Cardiovascular Disorder							
	Carotid Artery Stenosis							
	Coronary Artery Atherosclerosis		Prednisone	C				
	Coronary Artery Disease							
	Disturbance In Attention							
	Dyspnoea							
	Ischaemia							
	Mitral Valve Incompetence							
	Myalgia							
	Pain							
	Peripheral Nerve Decompression							
	Pulmonary Calcification							
	Transient Ischaemic Attack							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4588691-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Paxil	C				
			Coumadin	C			UNKNOWN	

Date:02/22/05ISR Number: 4588693-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4588694-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4588695-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00059
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1226 DAY	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				
Disability			[Therapy Unspecified]	C			UNKNOWN	

			Aspirin	C			
UNKNOWN							

Date:02/22/05ISR Number: 4588716-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00747
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Initial or Prolonged	Blindness		Tylenol	C				
UNKNOWN								
Disability	Cerebrovascular Accident		Naprosyn	C		ORAL		
Other	Chest Pain		Ibuprofen	C		ORAL		
	Deafness							
	Emotional Distress							
	Gastrointestinal Disorder							
	Headache							
	Injury							
	Liver Disorder							

Date:02/22/05ISR Number: 4589032-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00141
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:02/22/05ISR Number: 4589033-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-00087270
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cholangitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		153 DAY
Initial or Prolonged	Decreased Appetite		Methotrexate	SS		ORAL		YR
	Hepatic Fibrosis		Sertraline					
	Hepatic Steatosis		Hydrochloride	SS		ORAL		
	Hepatitis		Sertraline					
	Hepatocellular Damage		Hydrochloride	SS		ORAL		
	Liver Disorder		Omeprazole Magnesium	SS		ORAL		153 DAY
	Muscle Atrophy		Omeprazole Magnesium	SS		ORAL		153 DAY
	Psoriatic Arthropathy		Infliximab	SS			INTRAVENOUS	122 DAY
	Vasculitis		Glyburide	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	

Date:02/22/05ISR Number: 4589035-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Arthralgia
Other	Balance Disorder
	Complex Partial Seizures
	Constipation
	Contusion
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Decreased
	Emotional Distress
	Fall
	Fatigue

Gingival Hyperplasia
Headache
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypernatraemia
Hypertension
Hypoacusis
Laceration
Myocardial Infarction
Nail Pitting
Nasal Polyps
Neck Pain
Osteoporosis
Otitis Media
Periarthritis
Psoriasis
Rash
Sepsis
Spinal Osteoarthritis
Synovitis
Tinnitus
Vaginal Infection
Weight Decreased

		Weight Increased Wrist Fracture					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Ms Contin	SS		
UNKNOWN							
				Ms Contin	SS		
UNKNOWN							
				Depakote	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Msir	C		ORAL

Date:02/22/05ISR Number: 4589038-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00655
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Gastric Ulcer Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/22/05ISR Number: 4589039-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastric Ulcer		Ranitidine	C		
UNKNOWN						
	Hypertension		Enalapril Maleate	C		
UNKNOWN						
	Migraine		Diclofenac	C		
UNKNOWN						
	Visual Disturbance					

Date:02/22/05ISR Number: 4589042-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Other	Anal Fissure
	Bronchitis
	Cerebrovascular Accident
	Chronic Lymphocytic
	Leukaemia
	Dermatitis Contact
	Diarrhoea
	Eructation
	Fatigue
	Hot Flush
	Hypercalcaemia
	Hypertension
	Lacunar Infarction
	Lymphadenopathy
	Neurodermatitis
	Pollakiuria
	Polyp
	Prurigo
	Rectal Haemorrhage
	Restless Legs Syndrome
	Tension Headache
	Thyroid Neoplasm

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4589043-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 106 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged 363 DAY	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
106 DAY	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
363 DAY	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
UNKNOWN	Asthenia		Zantac	C				
UNKNOWN	Asthma		Celexa	C				
RESPIRATORY (INHALATION)	Back Pain		Albuterol	C				
	Chest Pain							
	Coronary Artery Atherosclerosis		Vicodin Tablets	C		ORAL		
	Cough							
	Depression							
	Dupuytren'S Contracture							
	Dyslipidaemia							
	Dysphagia							
	Dyspnoea							
	Erectile Dysfunction							
	Fatigue							
	Hypoaesthesia							
	Impulse-Control Disorder							
	Pain In Extremity							
	Premature Ejaculation							
	Pulmonary Congestion							
	Purulent Discharge							
	Restless Legs Syndrome							

Rhinitis Allergic
Rhonchi
Self-Injurious Ideation
Sinus Disorder
Sleep Apnoea Syndrome
Spinal Column Stenosis
Upper Respiratory Tract
Infection
Weight Increased
Wheezing

Date:02/22/05ISR Number: 4589048-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Arthralgia
Other	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine Increased
	Breast Cyst
	Cardiolipin Antibody Positive

		Cerebrovascular Accident					
		Chronic Sinusitis					
		Coagulopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Ear Pain		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Ecchymosis		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Episcleritis		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Faeces Discoloured		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Felty'S Syndrome		Methotrexate	SS		
UNKNOWN							
		Gastrooesophageal Reflux		Methotrexate	SS		
UNKNOWN							
		Disease		Remicade	SS		
INTRAVENOUS							
		Haemorrhoidal Haemorrhage		Remicade	SS		
INTRAVENOUS							
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Zoster Ophthalmic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Triamterene	C		
UNKNOWN							
		Hypertonic Bladder		Tylenol	C		
UNKNOWN							
		Immunoglobulins Decreased		Tegretol	C		
UNKNOWN							
		Injury		Tegretol	C		
UNKNOWN							
		Insomnia		Tegretol	C		
UNKNOWN							
		Keratitis		Carbamazepine	C		
UNKNOWN							
		Keratitis Herpetic		Acyclovir	C		
INTRAVENOUS							
		Laryngitis Viral		Hydroxychloroquine			
		Leukopenia		Sulfate	C		
UNKNOWN							

	Lymphoma	Azathioprine	C	
UNKNOWN				
	Mental Impairment	Prilosec	C	
UNKNOWN				
	Migraine	Allopurinol	C	
UNKNOWN				
	Mitral Valve Incompetence	Zyrtec	C	
UNKNOWN				
	Mouth Injury	K-Dur	C	
UNKNOWN				
	Nausea	Proventil	C	ORAL
	Nocturia	Fiorinal With		
	Orthostatic Hypotension	Codeine	C	
UNKNOWN				
	Overdose	Prednisone	C	
UNKNOWN				
	Pain	Elavil	C	ORAL
	Pancytopenia	Purinethol	C	
UNKNOWN				
	Platelet Disorder	[Therapy		
	Prostatitis	Unspecified]	C	
UNKNOWN				
	Pyrexia	Advil	C	
UNKNOWN				
	Rash			
	Renal Disorder			
	Renal Pain			
	Rheumatoid Arthritis			
	Rib Fracture			
	Sinusitis			
	Thrombocytopenia			
	Transient Ischaemic			
	Attack			
	Trigger Finger			
	Viral Pharyngitis			

Date:02/22/05ISR Number: 4589056-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00531
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Coronary Artery Disease

	Coronary Artery Restenosis Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Intracardiac Thrombus		Vioxx	PS	Merck & Co., Inc	ORAL	
	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Peripheral Occlusive Disease						
	Stent Occlusion						

Date:02/22/05ISR Number: 4589059-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0502DNK00018
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Spinal Cord Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
Initial or Prolonged			Tolbutamide	C		ORAL	
Disability			Enalapril Maleate	C		ORAL	
			Simvastatin	C		ORAL	

Date:02/22/05ISR Number: 4589060-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0410CAN00273
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C			
UNKNOWN							

Date:02/22/05ISR Number: 4589061-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Initial or Prolonged	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide And Irbesartan	C		
UNKNOWN						

Date:02/22/05ISR Number: 4589063-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00024
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
701 DAY						
	Cardiac Arrest		Hydrochlorothiazide And Irbesartan	C		
	Fall					
UNKNOWN						
	Myocardial Infarction		Levomepromazine	C		
UNKNOWN						
	Rib Fracture		Atenolol	C		
UNKNOWN						
			Metformin Hydrochloride	C		
UNKNOWN						

Date:02/22/05ISR Number: 4589064-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00077
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Fibrillation							
	Feeling Abnormal							
	Myocardial Infarction							

Date:02/22/05ISR Number: 4589065-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00040
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Lisinopril	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Fluvastatin Sodium	C			UNKNOWN	
			Moxonidine	C			UNKNOWN	
			Nitrendipine	C			UNKNOWN	1559 DAY
			Aspirin	C			UNKNOWN	3990 DAY

Date:02/22/05ISR Number: 4589067-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02847
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	6 DAY	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Coumadin	C			UNKNOWN	
	Palpitations		Lipitor	C			UNKNOWN	

			Fosamax	C		ORAL

Date:02/22/05ISR Number: 4589068-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00138
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			[Composition Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide And Irbesartan	C		
UNKNOWN						

Date:02/22/05ISR Number: 4589069-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00067
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/22/05ISR Number: 4589070-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Unstable		Aspirin	C		
UNKNOWN						
	Coronary Artery Disease		Atorvastatin Calcium	C		
UNKNOWN						

				Metoprolol	C	
UNKNOWN						
				Clopidogrel Bisulfate	C	
UNKNOWN						

Date:02/22/05ISR Number: 4589071-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00772
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
	Atherosclerosis		Neurontin	C		
UNKNOWN						
	Complex Regional Pain Syndrome		Amitriptyline Hydrochloride	C		
UNKNOWN						
	Coronary Artery Disease					
	Dilatation Ventricular					
	Dyspnoea					
	Myocardial Ischaemia					
	Sensation Of Heaviness					
	Ventricular Dysfunction					
	Ventricular Hypertrophy					

Date:02/22/05ISR Number: 4589072-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Myocardial Infarction					

Date:02/22/05ISR Number: 4589073-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
200 DAY						

Date:02/22/05ISR Number: 4589074-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01503
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dizziness		Captopril	C		ORAL
Initial or Prolonged	Head Injury		Tegretol	C		ORAL
Disability	Loss Of Consciousness					
	Transient Ischaemic					
	Attack					

Date:02/22/05ISR Number: 4589075-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Death					
	Polytraumatism					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4589076-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/22/05ISR Number: 4589077-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:02/22/05ISR Number: 4589078-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:02/22/05ISR Number: 4589079-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4589080-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/22/05ISR Number: 4589081-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01882
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Injury		Vioxx	PS	Merck & Co., Inc		UNKNOWN	5 YR
	Thrombosis							

Date:02/22/05ISR Number: 4590945-4Report Type:Direct Company Report #CTU 240927
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg	PS			2 X DAY	
Hospitalization -			Celebrex 200 Mg	SS			1 X DAY	
Initial or Prolonged								

Date:02/22/05ISR Number: 4591091-6Report Type:Direct Company Report #CTU 241029
Age:30 DY Gender:Female I/FU:I

Outcome	PT
Other	Contusion
	Foot Deformity
	Impaired Healing
	Insomnia

Muscle Spasms

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Dcb - Merck		1 TABLET	TWICE A DAY

Date:02/22/05ISR Number: 4592694-5Report Type:Expedited (15-DaCompany Report #2005-02-0877
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness	Foreign Health	Imdur Extended Release	PS		ORAL	ORAL	
		Professional Other	Vioxx (Rofecoxib)	SS		ORAL	12.5 MG QD	ORAL
			Lipitor (Atorvastatin)	C				
			Metoprolol Tartrate	C				
			Plavix (Clopidogrel)	C				
			Rivotril	C				
			Tegretol	C				
			Telmisartan	C				

Date:02/22/05ISR Number: 4592750-1Report Type:Expedited (15-DaCompany Report #2005024726
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm	Foreign	Celebrex (Celecoxib)	PS		ORAL	400 MG (400 MG, 1 IN 1 D), ORAL	
	Breast Pain	Consumer						
	Breast Tenderness							
	Chest Pain		Naproxen (Naproxen)	SS				
Other								

	Drug Ineffective Paraesthesia Rheumatoid Arthritis Vomiting	Rofecoxic (Rofecoxib) Folic Acid (Folic Acid) Amlodipine (Amlodipine) Hyzaar (Hydrochlorothiazide, Losartan Potassium) Methotrexate (Methotrexate)	SS C C C C

Date:02/22/05ISR Number: 4592760-4Report Type:Expedited (15-DaCompany Report #WAES 0502GBR00025
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/22/05ISR Number: 4594056-3Report Type:Expedited (15-DaCompany Report #S04-GER-03331-01
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign Health	Cipralex (Escitalopram)	PS		ORAL	10 MG QD PO	
		Professional Other	Vioxx (Rofecoxib)	SS				
			Propecia (Finasteride)	C				

Date:02/23/05ISR Number: 4589606-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00027
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angiogram Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Aspirin	C				
UNKNOWN								
Disability			Lisinopril	C				
UNKNOWN								

Date:02/23/05ISR Number: 4589607-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03070
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accidental Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589608-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
	Activities Of Daily
Disability	Living Impaired
Other	Anorexia

Anxiety
Arthralgia
Arthritis
Asthenia
Atherosclerosis
Aural Polyp
Back Pain
Blister
Blood Pressure
Inadequately Controlled
Blood Pressure Increased
Bronchitis
Bursitis
Cardiac Disorder
Cardiac Failure
Congestive
Caustic Injury
Chest Pain
Constipation
Depression
Diastolic Dysfunction
Diverticulum Intestinal
Dizziness
Drug Eruption

		Dysphonia					
		Dysuria					
		Ecchymosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL
		Exostosis		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Frequent Bowel Movements		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Gastritis		Prinivil	C		
UNKNOWN							
		Glucose Tolerance		K-Dur	C		
UNKNOWN							
		Impaired		Lortab	C		
UNKNOWN							
		Gout		Coumadin	C		
UNKNOWN							
		Haemorrhoids		[Therapy			
		Headache		Unspecified]	C		
UNKNOWN							
		Helicobacter Infection		Lasix (Furosemide			
		Hepatic Cirrhosis		Sodium)	C		
UNKNOWN							
		Hypertension					
		Hyperuricaemia					
		Hypoaesthesia					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Crepitation					
		Kidney Infection					
		Labyrinthitis					
		Muscle Strain					
		Myalgia					
		Nasopharyngeal Disorder					
		Nasopharyngitis					
		Nausea					
		Oedema					
		Oedema Peripheral					
		Osteoarthritis					
		Otitis Media					
		Pain					
		Pharyngitis					
		Phlebolith					

Polyarthritis
Rash
Rhinitis
Sinusitis
Sleep Disorder
Spinal Osteoarthritis
Stomach Discomfort
Syncope
Tricuspid Valve
Incompetence
Urinary Incontinence
Vertigo
Vision Blurred
Vomiting
Weight Decreased

Date:02/23/05ISR Number: 4589614-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00080
Age:57 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Chest Pain							

Date:02/23/05ISR Number: 4589615-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00968
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 115 DAY	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Haldol	C				
UNKNOWN								
Other	Back Injury		Hydrocodone					
	Back Pain		Bitartrate	C				
UNKNOWN								
	Cardiomegaly							
	Cartilage Injury							
	Cervicobrachial Syndrome							
	Coronary Artery Disease							
	Depression							
	Gout							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Lumbar Radiculopathy							
	Myocardial Infarction							
	Neck Injury							
	Neck Pain							
	Pain In Extremity							
	Post Concussion Syndrome							
	Post-Traumatic Headache							
	Road Traffic Accident							
	Weight Increased							

Date:02/23/05ISR Number: 4589620-1Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00046
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal Disorder Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589625-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00001
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Carotid Artery Stenosis Cerebral Haemorrhage Chest Injury Fall Hypertension		Vioxx Irbesartan Carvedilol Pravastatin Sodium Aspirin And Magnesium Oxide Acetaminophen And Codeine Phosphate	PS C C C C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL ORAL	18 DAY	

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589626-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00048
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Impaired Work Ability							

Date:02/23/05ISR Number: 4589628-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00021
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C				
Disability			Cyanocobalamin	C				
			Calcium Pantothenate	C				

Date:02/23/05ISR Number: 4589629-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00019
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:02/23/05ISR Number: 4589631-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01785
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Duoneb	C				

Initial or Prolonged Premarin C
UNKNOWN
Disability Nexium C
UNKNOWN
Accolate C
UNKNOWN
Advair C
UNKNOWN
Clonazepam C
UNKNOWN

Date:02/23/05ISR Number: 4589632-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
	Injury							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589634-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
	Injury							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589639-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589640-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00270
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Delusion		Morphine	C			UNKNOWN	
	Feeling Abnormal		Ramipril	C			UNKNOWN	
	Loss Of Consciousness		Aspirin	C			UNKNOWN	
	Pleural Effusion		Gabapentin	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Furosemide And Spironolactone	C			UNKNOWN	
			Omeprazole	C			UNKNOWN	
			Dipyrone	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Buprenorphine Hydrochloride	C			TOPICAL	

Date:02/23/05ISR Number: 4589642-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celebrex	C			UNKNOWN	
	Injury							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589644-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Bextra	C			UNKNOWN	
	Myocardial Infarction		Celebrex	C			UNKNOWN	
	Polytraumatism							

Date:02/23/05ISR Number: 4589692-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Antiphospholipid Syndrome
Other	Back Disorder
	Blood Cholesterol Increased
	Blood Immunoglobulin M Increased
	Cardiolipin Antibody

		Positive					
		Cerebrovascular Accident					
		Cholecystitis					
		Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coagulation Time		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Prolonged		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Coagulopathy		Allegra	C		
UNKNOWN							
		Colonic Polyp					
		Confusional State					
		Contusion					
		Diarrhoea					
		Diverticulum					
		Dyspepsia					
		Emotional Distress					
		Epistaxis					
		Fatigue					
		Gallbladder Disorder					
		Gastroenteritis Viral					
		Haemorrhoids					
		Hypoaesthesia					
		Injury					
		International Normalised					
		Ratio Decreased					
		International Normalised					
		Ratio Increased					
		Irritability					
		Lumbar Radiculopathy					
		Menorrhagia					
		Migraine					
		Migraine With Aura					
		Mitral Valve Incompetence					
		Nervousness					
		Neurogenic Bladder					
		Ovarian Cyst					
		Protein S Increased					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					
		Vaginal Pain					
		Vision Blurred					

Date:02/23/05ISR Number: 4589862-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arthritis
Disability	Blood Pressure Abnormal
Other	Bone Pain
	Cardiac Murmur
	Cardiac Valve Disease
	Chest Pain
	Chest Wall Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Occlusion
	Depression
	Dysphagia

		Dyspnoea					
		Emotional Distress					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematoma		Cardizem Cd	C		
UNKNOWN							
		Headache		K-Dur	C		
UNKNOWN							
		Heart Rate Decreased		Accupril	C		
UNKNOWN		18 DAY					
		Herpes Zoster		Accupril	C		
UNKNOWN		38 DAY					
		Hypertension		Accupril	C		
UNKNOWN		152 DAY					
		Hypotension		Paxil	C		
UNKNOWN							
		Insomnia		Paxil	C		
UNKNOWN		42 DAY					
		Irritable Bowel Syndrome		Paxil	C		
UNKNOWN							
		Myocardial Infarction		Paxil	C		
UNKNOWN		145 DAY					
		Oedema Peripheral		Lasix (Furosemide)	C		
UNKNOWN							
		Oesophageal Spasm		Lasix (Furosemide)	C		
UNKNOWN							
		Pain		Lasix (Furosemide)	C		
UNKNOWN							
		Rash Pruritic		Soma	C		
UNKNOWN							
		Restless Legs Syndrome		Aleve	C		
UNKNOWN							
		Somnolence		Nitroglycerin	C		
UNKNOWN							
		Syncope		Aspirin	C		
UNKNOWN							
		Tremor		Percocet	C		
UNKNOWN							
		Upper Respiratory Tract		Ferrous Sulfate	C		
UNKNOWN							
		Infection		Tylenol Extra			
				Strength	C		
UNKNOWN							

Date:02/23/05ISR Number: 4589863-7Report Type:Expedited (15-DaCompany Report #US-MERCK-01052039
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Dizziness							
	Feeling Abnormal							
	Headache							
	Nausea							
	Syncope							
	Vertigo							
	Vomiting							

Date:02/23/05ISR Number: 4589865-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
Other	Arthralgia
	Autotransfusion
	Back Injury
	Back Pain
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Blood Urine Present
	Buttock Pain
	Chronic Fatigue Syndrome
	Coronary Artery Disease
	Cyst

		Depression					
		Drug Dependence					
		Drug Detoxification	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Withdrawal Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Facet Joint Syndrome		Zoloft	C		
UNKNOWN							
		Gastric Ulcer		Zoloft	C		
UNKNOWN							
		Gastrooesophageal Reflux		Avalide	C		
UNKNOWN							
		Disease		Claritin	C		
UNKNOWN							
		Haematochezia		Prozac	C		
UNKNOWN							
		Haematocrit Abnormal					
		Headache					
		Helicobacter Pylori					
		Identification Test					
		Positive					
		High Density Lipoprotein					
		Abnormal					
		Hyperlipidaemia					
		Hypertension					
		Injury					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Disorder					
		Intervertebral Disc					
		Protrusion					
		Mood Altered					
		Myelopathy					
		Nervousness					
		Osteoarthritis					
		Paraesthesia					
		Peptic Ulcer					
		Protein Urine Present					
		Radicular Pain					
		Renal Failure					
		Rhinitis Allergic					
		Sleep Apnoea Syndrome					
		Spinal Osteoarthritis					
		Spondylolisthesis					

Spondylolysis
Urobilin Urine Present

Date:02/23/05ISR Number: 4589867-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02528
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
	Aortic Valve Incompetence
	Aspartate Aminotransferase Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Coronary Artery Disease
	Depression

		Emotional Distress					
		Fatigue					
		Fear	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Prostata	C		
UNKNOWN							
		Thrombosis		Herbs (Unspecified)	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Advil	C		
UNKNOWN							
				Mylanta & Mylanta Ds	C		
UNKNOWN							

Date:02/23/05ISR Number: 4589868-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02526
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Unstable
	Anxiety
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Discomfort
	Chest Pain
	Cholelithiasis
	Coronary Artery Atherosclerosis
	Cough
	Depression
	Dizziness
	Dysphagia
	Dyspnoea
	Dyspnoea Paroxysmal Nocturnal
	Fibromyalgia
	Ganglion
	Gastrooesophageal Reflux Disease
	Headache

Hyperhidrosis
Hypertension
Intervertebral Disc
Degeneration
Mastoiditis
Mental Disorder
Mitral Valve Prolapse
Myocardial Infarction
Nausea
Neuropathy
Orthopnoea
Osteoporosis
Pain
Palpitations
Panic Attack
Paraesthesia
Peptic Ulcer
Platybasia
Sinusitis
Spinal Column Stenosis
Tension
Uterine Leiomyoma

		Vaginal Haemorrhage Vertigo Positional Vision Blurred	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
284	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
284	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Prevacid	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Estradiol	C		ORAL
				Clonazepam	C		
UNKNOWN							
				Vantin	C		
UNKNOWN							
				Meclizine	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Sulfamethoxazole And Trimethoprim	C		
UNKNOWN							
				Serzone	C		ORAL
336	DAY						
				Serzone	C		ORAL
				Albuterol	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Cephalexin	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Cyanocobalamin	C		
PARENTERAL							

	Cyanocobalamin	C	
PARENTERAL			
	Remeron	C	
UNKNOWN			
	Aciphex	C	
UNKNOWN			
	Tequin	C	
UNKNOWN			
	Diovan	C	ORAL
	Verapamil Msd Lp	C	ORAL
	A.S.A.	C	ORAL
	A.S.A.	C	ORAL
	Prometrium	C	ORAL
	Mobic	C	ORAL
	Promethazine	C	ORAL

Date:02/23/05ISR Number: 4589878-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Cough
	Dyspnoea
	Emotional Distress
	Fatigue
	Gastrooesophageal Reflux Disease
	Hypersensitivity
	Migraine
	Mitral Valve Prolapse
	Musculoskeletal Pain
	Nausea
	Small Intestinal Ulcer Haemorrhage
	Upper Respiratory Tract Infection

Viral Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	34 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Aspirin	C			UNKNOWN	
	Echinacea	C			UNKNOWN	1483 DAY
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Dicyclomine Hydrochloride	C			UNKNOWN	
	Nexium	C			UNKNOWN	

Date:02/23/05ISR Number: 4589880-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03554
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Hospitalization -	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	6 MON	
Initial or Prolonged	Malaise		[Therapy					
Disability	Neck Pain		Unspecified]	C			UNKNOWN	
	Stomach Discomfort		Glyburide	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

Date:02/23/05ISR Number: 4589881-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		83 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Calculus Ureteric		Advil	C				
UNKNOWN								
Other	Calculus Urinary		Advil	C				
UNKNOWN								
	Coronary Artery Occlusion		Vicodin Tablets	C				
UNKNOWN								
	Diverticulitis		Aspirin	C				
UNKNOWN								
	Impaired Work Ability		Ultram	C				
UNKNOWN								
	Injury		Ultram	C				
UNKNOWN								
	Mitral Valve Incompetence							
	Osteoarthritis							
	Pneumonia Influenzal							
	Pulmonary Arterial							
	Pressure Increased							
	Tricuspid Valve							
	Incompetence							

Date:02/23/05ISR Number: 4589884-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02475
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Aspirin	C				
UNKNOWN								
Disability			Plavix	C				
UNKNOWN								
			Zocor	C		ORAL		
			Actos	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589885-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00121
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589886-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03420
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
Other	Asthenia
	Atelectasis
	Back Pain
	Blood Cholesterol Increased
	Bronchospasm
	Bursitis
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Decreased Appetite
	Depression
	Diarrhoea
	Diplopia
	Dizziness
	Dysarthria
	Dyspepsia
	Dysphagia
	Dysphemia
	Dysphoria
	Ear Pain
	Electrocardiogram St-T Segment Depression
	Epigastric Discomfort
	Epistaxis
	Extrasystoles
	Fatigue
	Hot Flush
	Hyperhidrosis
	Hypertension

Insomnia
Irritable Bowel Syndrome
Muscle Spasms
Nausea
Neck Pain
Night Sweats
Osteoarthritis
Pain
Pulmonary Fibrosis
Spinal Column Stenosis
Spinal Osteoarthritis
Stress
Transient Ischaemic
Attack
Viral Infection
Vision Blurred
Vomiting

		Weight Decreased White Blood Cell Count Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Neurontin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Maxair	C		
UNKNOWN							
				Vivelle	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							

Date:02/23/05ISR Number: 4589889-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01783
Age:65 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Hydrochlorothiazide	C		
UNKNOWN							
		Attack		Nexium	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:02/23/05ISR Number: 4589891-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00122
Age:40 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/23/05ISR Number: 4589892-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04237
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589893-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01864
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589895-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00036
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	280	DAY
	Palpitations		Calcium (Unspecified)	C			UNKNOWN	

Date:02/23/05ISR Number: 4589896-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02746
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Plaquenil	C			UNKNOWN	
	Feeling Abnormal							
	Hypothyroidism							
	Pallor							
	Pneumonia							

Date:02/23/05ISR Number: 4589899-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Injury							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589900-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02047
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589902-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01789
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Altace	C				
Initial or Prolonged Disability								

Date:02/23/05ISR Number: 4589903-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01890
Age: Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event
	Amnesia
	Cerebrovascular Accident
	Pulmonary Embolism
	Speech Disorder
	Transient Ischaemic

Attack

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589904-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01931
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589905-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589906-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:02/23/05ISR Number: 4589907-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							

Multi-Organ Disorder
Pain
Transient Ischaemic
Attack

Date:02/23/05ISR Number: 4589909-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02049
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON

Date:02/23/05ISR Number: 4589910-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589913-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Injury Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589914-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589915-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02327
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1204 DAY	

Date:02/23/05ISR Number: 4589917-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02106
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Hospitalization - UNKNOWN	Renal Failure		Glyburide	C				
Initial or Prolonged Disability			Metformin	C				

Date:02/23/05ISR Number: 4589918-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589919-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589920-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02217
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Peripheral Coldness		Vitamins (Unspecified)	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589922-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02326
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589923-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02203
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspergillosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bronchopulmonary		Coumadin	C				
UNKNOWN								
Initial or Prolonged	Aspergillosis		Prednisone	C				
UNKNOWN								
	Deep Vein Thrombosis		Entocort	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								

Date:02/23/05ISR Number: 4589924-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								

Date:02/23/05ISR Number: 4589926-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02328
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589927-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02330
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiovascular Disorder							
	Injury							
	Multi-Organ Disorder							
	Myocardial Infarction							
	Pain							

Date:02/23/05ISR Number: 4589928-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02355
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Fatigue							
	Myocardial Infarction							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4589930-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589931-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589932-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02333
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589933-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02470
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589934-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		240 DAY

Date:02/23/05ISR Number: 4589937-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02353
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/23/05ISR Number: 4589938-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03848
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	22	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Digoxin	C		ORAL		
			Lotrel	C			UNKNOWN	
			Ultram	C		ORAL		
			Lasix (Furosemide)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4591684-6Report Type:Direct Company Report #CTU 241112
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Contrast Media Reaction Diverticulum Intestinal Haemorrhagic Hypersensitivity Rectal Haemorrhage		Vioxx	PS				

Date:02/23/05ISR Number: 4595023-6Report Type:Expedited (15-DaCompany Report #WAES0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	367 DAY

Date:02/23/05ISR Number: 4595025-XReport Type:Expedited (15-DaCompany Report #WAES0502GBR00025
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension	Foreign Study Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	196 DAY

Date:02/23/05ISR Number: 4595029-7Report Type:Expedited (15-DaCompany Report #WAES0410DEU00504
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion Myocardial Infarction	Foreign Study	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAIL, PO	93 DAY
Disability		Health Professional Other	Alfuzosin Hydrochloride	C				
			Aspirin	C				
			Irbesartan	C				
			Piretanide	C				
			Vardenafil Dihydrochloride	C				

Date:02/23/05ISR Number: 4595031-5Report Type:Expedited (15-DaCompany Report #WAES0311GBR00154
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY, PO	
	Oesophageal Carcinoma	Study						
		Health Professional Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/23/05ISR Number: 4595168-0Report Type:Expedited (15-DaCompany Report #2005024963
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Vioxx (Rofecoxib)	SS				

Date:02/23/05ISR Number: 4595178-3Report Type:Expedited (15-DaCompany Report #2005031962
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Consumer	Bextra (Valdecoxib)	PS		ORAL	20 MG (20 MG, 1 IN 1 D),	ORAL
	Cardiomegaly							
	Condition Aggravated							
	Pneumonia		Celebrex (Celecoxib)	SS		ORAL	600 MG (200 MG, 3 IN 1 D),	ORAL
	Pollakiuria							
	Renal Failure							
	Renal Pain		Rofecoxib (Rofecoxib)	SS		ORAL	1 IN 1 D,	ORAL
			Naproxen (Naproxen)	SS		ORAL		ORAL
			Insulin (Insulin)	C				
			Carvedilol (Carvedilol)	C				

Date:02/23/05ISR Number: 4606539-8Report Type:Periodic Company Report #WAES 0409USA00565
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rhabdomyolysis	Health	Tab Zocor 80 Mg	PS		ORAL	80	

Hospitalization - Professional
MG/DAILY/PO
Initial or Prolonged Company Tab Vioxx 25 Mg SS ORAL
25
Other Representative
MG/DAILY/PO

Clarinex	C
Fosamax	C
Prevpac	C
Protonix	C
Synthroid	C

Date:02/24/05ISR Number: 4590370-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02269
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Premarin	C		
UNKNOWN						

Date:02/24/05ISR Number: 4590371-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00690
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Alopecia
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anxiety
	Aortic Disorder
	Arrhythmia
	Arthropathy
	Balance Disorder

		Bladder Pain					
		Cardiac Disorder					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
930	DAY						
		Cystitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cystitis Noninfective		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
930	DAY						
		Dermatitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
		Dermatophytosis		Hyzaar	C		ORAL
		Disease Recurrence		Piracetam	C		ORAL
		Dizziness		Flupirtine Maleate	C		ORAL
		Duodenal Ulcer		Indomethacin	C		
UNKNOWN							
		Dyspepsia					
		Faecal Incontinence					
		Fall					
		Gastric Disorder					
		Gastric Haemorrhage					
		Gastric Ph Decreased					
		Gastric Ulcer					
		Gastritis					
		Haematuria					
		Headache					
		Helicobacter Gastritis					
		Hyperkeratosis					
		Hypersensitivity					
		Hypertension					
		Hypertonic Bladder					
		Intestinal Polyp					
		Irritable Bowel Syndrome					
		Knee Deformity					
		Ligament Sprain					
		Osteoarthritis					
		Pain					
		Pain In Extremity					
		Palpitations					
		Reflux Oesophagitis					
		Renal Pain					
		Sleep Disorder					
		Stress Incontinence					
		Tinea Pedis					
		Tinnitus					
		Urge Incontinence					

Urinary Incontinence
Urinary Tract Infection
Ventricular Fibrillation

Date:02/24/05ISR Number: 4590379-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03560
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590380-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00214
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Sotalol Hydrochloride	SS				
	Cardiac Disorder							
	Fluid Retention		Ibuprofen	C				
	Hypotension		Trimipramine	C				
	Intestinal Haemorrhage		Indomethacin	C				
	Respiratory Tract Infection							
	Sleep Apnoea Syndrome							
	Supraventricular Extrasystoles							
	Weight Increased							

Date:02/24/05ISR Number: 4590385-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00685
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		840 DAY
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		840 DAY
	Diabetes Mellitus Non-Insulin-Dependent Hypertension		Hydrochlorothiazide And Metoprolol Succinate	C				
UNKNOWN								906 DAY

Date:02/24/05ISR Number: 4590387-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00444
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Hospitalization -	Chest Pain
Initial or Prolonged	Feeling Abnormal
Disability	Hypertension

Date:02/24/05ISR Number: 4590389-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00038
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lumbar Vertebral Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Skin Ulcer		Pantoprazole Sodium	C		ORAL		
	Thrombophlebitis		Pravastatin Sodium	C		ORAL		
	Varicose Vein		Oxazepam	C		ORAL		

Date:02/24/05ISR Number: 4590390-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00624
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590391-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590392-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03585
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Asthenia		Plavix	C				
UNKNOWN								
Initial or Prolonged	Back Pain		Colchicine	C				
UNKNOWN								
	Constipation		Xalatan	C				
UNKNOWN								
	Death		Alphagan	C				
UNKNOWN								
	Decreased Appetite		Betoptic	C				
UNKNOWN								
	Decubitus Ulcer							
	Depression							
	Malignant Hypertension							
	Malnutrition							
	Metabolic Acidosis							
	Muscle Atrophy							
	Myalgia							
	Osteoporosis							
	Pneumonia							
	Pneumonitis							
	Pulmonary Mass							
	Renal Failure							
	Renal Failure Chronic							

Date:02/24/05ISR Number: 4590393-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00020
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 246 DAY	Angina Pectoris	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Coronary Artery Stenosis	Metoprolol Tartrate	C		
UNKNOWN		Ramipril	C		
UNKNOWN		Atorvastatin Calcium	C		
UNKNOWN		Aspirin	C		
UNKNOWN		Repaglinide	C		

Date:02/24/05ISR Number: 4590394-9Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00062
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Ischaemia Difficulty In Walking Dysarthria Facial Palsy Malaise Motor Dysfunction Tongue Paralysis Ultrasound Doppler Abnormal		Hydrochlorothiazide And Lisinopril	SS		ORAL		

Date:02/24/05ISR Number: 4590395-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01251
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		386 DAY
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
			Glucophage	C				UNKNOWN

Date:02/24/05ISR Number: 4590397-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00119
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590398-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590399-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590410-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01814
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:02/24/05ISR Number: 4590411-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01883
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590413-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01807
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590415-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590416-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590418-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590419-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02042
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	623 DAY	

Date:02/24/05ISR Number: 4590429-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01850
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Tricor	C	
UNKNOWN			
Disability	Nortriptyline	C	
UNKNOWN			

Date:02/24/05ISR Number: 4590431-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590432-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590433-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590434-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:02/24/05ISR Number: 4590435-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00009
Age:93 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradyarrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	75	DAY
Hospitalization - Initial or Prolonged	Cardiac Failure		Verapamil Hydrochloride	C			UNKNOWN	
	Skin Ulcer							
	Tachyarrhythmia		Candesartan Cilexetil	C			UNKNOWN	
	Venous Insufficiency							
	Visual Acuity Reduced		Allopurinol	C			UNKNOWN	
			Bezafibrate	C			UNKNOWN	

Date:02/24/05ISR Number: 4590437-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00154
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability							
Disability	Myocardial Infarction							

Date:02/24/05ISR Number: 4590438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR

Date:02/24/05ISR Number: 4590439-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02671
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590440-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590441-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590442-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00137
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				
UNKNOWN								

Date:02/24/05ISR Number: 4590443-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Deafness							
	Hypoaesthesia							
	Transient Ischaemic Attack							

Date:02/24/05ISR Number: 4590444-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02613
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Coumadin	C				
UNKNOWN								
Disability								
Other								

Date:02/24/05ISR Number: 4590706-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Drug Reaction
	Anxiety
Disability	Arrhythmia

Other	Arthralgia
	Arthropod Bite
	Asthenia
	Blindness Transient
	Blood Albumin Increased
	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Immunoglobulin A Increased
	Blood Immunoglobulin G Increased
	Blood Triglycerides Increased
	Bone Pain
	Bradyarrhythmia
	Cardiomegaly
	Cardiomyopathy
	Carpal Tunnel Syndrome
	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Complex Partial Seizures

Confusional State
Connective Tissue
Disorder
Coronary Artery Disease
Coronary Artery Stenosis
Cranial Neuropathy
Csf Glucose Increased
Csf Protein Increased
Csf Test Abnormal
Dementia Alzheimer'S Type
Depressed Mood
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Foot Infection
Diabetic Neuropathy
Difficulty In Walking
Dilatation Atrial
Diplopia
Dizziness
Dyspnoea
Ear Pain
Emotional Distress
Encephalitis
Eyelid Ptosis
Fall
Glycosylated Haemoglobin
Increased
Haematuria
Headache
High Density Lipoprotein
Decreased
Hot Flush
Hyperhidrosis
Hyperlipidaemia
Hypertension
Hypoaesthesia
Hypotonia
Ingrowing Nail
Injury
Insomnia
Intervertebral Disc
Degeneration
Limb Discomfort
Limb Injury
Localised Infection
Loss Of Consciousness

Mitral Valve Incompetence
Muscle Spasms
Musculoskeletal Stiffness
Myalgia
Myocardial Infarction
Myocardial Ischaemia
Nerve Compression
Nerve Injury
Neuropathy
Orthostatic Hypotension
Osteoarthritis
Pain
Pain In Extremity
Paraesthesia

		Peripheral Sensory Neuropathy Polyneuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pseudodementia		Vioxx	PS	Merck & Co., Inc	ORAL
		Psychomotor Hyperactivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Psychomotor Retardation		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash		Glucophage	C		
UNKNOWN							
		Sensation Of Pressure		Zocor	C		ORAL
		Sinobronchitis		Arthrotec	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Avandia	C		
UNKNOWN							
		Somnolence		Glynase Prestab			
		Supraventricular		Tablets	C		
UNKNOWN							
		Extrasystoles		Darvocet-N	C		
UNKNOWN							
		Syncope					
		Systemic Lupus					
		Erythematosus					
		Tachyarrhythmia					
		Thermal Burn					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Vasculitis					
		Venous Angioma Of Brain					
		Vertigo					
		Vision Blurred					

Date:02/24/05ISR Number: 4590711-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00700
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
Other	Acute Myocardial Infarction
	Adenomatous Polyposis Coli
	Adverse Event
	Anaemia
	Angina Pectoris

Arthralgia
Back Pain
Barrett'S Oesophagus
Blood Cholesterol
Increased
Bone Density Decreased
Breast Cyst
Cataract
Catheter Site Related
Reaction
Cerebrovascular Accident
Cerebrovascular Disorder
Chest Pain
Colonic Polyp
Constipation
Contusion
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery

		Restenosis					
		Coronary Artery Stenosis					
		Diverticulum Intestinal					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
319	DAY						
		Electrocardiogram St		Vioxx	SS	Merck & Co., Inc	ORAL
		Segment Depression		Vioxx	SS	Merck & Co., Inc	ORAL
319	DAY						
		Erosive Oesophagitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Eructation		Aspirin	C		
UNKNOWN							
		Fall		Monopril	C		
UNKNOWN							
		Fatigue		Hydrochlorothiazide	C		
UNKNOWN							
		Flatulence					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Haematemesis					
		Haemorrhoids					
		Hyperlipidaemia					
		Hypertension					
		Hypoaesthesia					
		Hypothyroidism					
		Lung Disorder					
		Lung Neoplasm					
		Lymphangitis					
		Malaise					
		Medication Error					
		Meniscus Lesion					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Oesophageal Ulcer					
		Osteoarthritis					
		Pinguecula					
		Pulmonary Granuloma					
		Rash Erythematous					
		Rash Macular					
		Rectal Haemorrhage					
		Renal Failure					
		Retinal Disorder					
		Retinal Naevus					
		Urinary Tract Infection					

Date:02/24/05ISR Number: 4590712-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Arthralgia
	Balance Disorder
	Complex Partial Seizures
	Constipation
	Contusion
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Decreased
	Emotional Distress

		Fall					
		Fatigue					
		Gingival Hyperplasia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Enzyme Increased		Ms Contin	SS		
UNKNOWN							
		Hepatic Steatosis		Ms Contin	SS		
UNKNOWN							
		Hyperlipidaemia		Depakote	C		
UNKNOWN							
		Hypernatraemia		Tegretol	C		
UNKNOWN							
		Hypertension		Aspirin	C		
UNKNOWN							
		Hypoacusis		Vitamins			
		Laceration		(Unspecified)	C		
UNKNOWN							
		Myocardial Infarction		Msir	C		ORAL
		Nail Pitting					
		Nasal Polyps					
		Neck Pain					
		Osteoporosis					
		Otitis Media					
		Periarthritis					
		Psoriasis					
		Rash					
		Sepsis					
		Spinal Osteoarthritis					
		Synovitis					
		Tinnitus					
		Vaginal Infection					
		Weight Decreased					
		Weight Increased					
		Wrist Fracture					

Date:02/24/05ISR Number: 4590713-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
81 DAY							
Initial or Prolonged		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Antiphospholipid Syndrome		Advil	C		ORAL

	Asthenia	Prempro	C	
UNKNOWN				
	Back Disorder	Prilosec	C	
UNKNOWN				
	Balance Disorder	Synthroid	C	
UNKNOWN				
	Blood Pressure Increased	Diovan	C	
UNKNOWN				
	Cerebrovascular Accident	Dimethyl Sulfone	C	
UNKNOWN				
	Convulsion	Gaviscon Antacid		
	Diabetes Mellitus	Tablets	C	
UNKNOWN				
	Non-Insulin-Dependent	Hydrocodone		
	Dizziness	Hydrochloride	C	
UNKNOWN				
	Drug Hypersensitivity	[Therapy		
	Gastrooesophageal Reflux	Unspecified]	C	ORAL
	Disease			
	Hemiparesis			
	Ischaemia			
	Labyrinthitis			
	Muscle Spasms			
	Neck Injury			
	Tinnitus			
	Tongue Ulceration			
	Urticaria Generalised			
	Vasculitis			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590714-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adenomatous Polyposis Coli		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc			
Other	Adverse Event		Levothyroxine Sodium	C			UNKNOWN	
	Angina Pectoris		Cardizem	C			UNKNOWN	
	Arteriosclerosis		Prilosec	C			UNKNOWN	
	Arthralgia		Lipitor	C			UNKNOWN	
	Benign Prostatic Hyperplasia		Triamterene	C			UNKNOWN	
			Plavix	C			UNKNOWN	
	Blood Cholesterol Increased		Aspirin	C			UNKNOWN	
	Blood Potassium Decreased							
	Cataract							
	Cerebrovascular Accident							
	Claustrophobia							
	Colonic Polyp							
	Conjunctival Haemorrhage							
	Convulsion							
	Drug Eruption							
	Dyspnoea							
	Electrocardiogram St-T Change							
	Encephalomalacia							
	Eye Pain							
	Gastrooesophageal Reflux Disease							
	Haematuria							
	Haemorrhoids							
	Hydronephrosis							
	Hypertension							
	Hypertonic Bladder							
	Neurodermatitis							
	Nocturia							
	Nodule							
	Pain In Extremity							

Paralysis
Penile Vein Thrombosis
Pneumonia
Post Procedural Pain
Proteinuria
Rash
Rectal Haemorrhage
Vertigo
Vitreous Detachment

Date:02/24/05ISR Number: 4590715-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Arrhythmia
	Arteriospasm Coronary
	Arthralgia
	Arthropathy
	Back Injury
	Blood Cholesterol Increased

		Blood Pressure Decreased					
		Bone Pain					
		Coronary Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
487	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
487	DAY						
		Endometriosis		Inderal La	C		
UNKNOWN							
		Gait Disturbance		Inderal La	C		
UNKNOWN							
		Intermittent Claudication		Claritin-D	C		
UNKNOWN		1758 DAY					
		Intervertebral Disc		Humibid	C		
UNKNOWN							
		Displacement		Prevacid	C		
UNKNOWN							
		Low Density Lipoprotein		Nasonex	C		
UNKNOWN		764 DAY					
		Increased		Darvocet-N	C		
UNKNOWN							
		Meniscus Lesion		Bactrim	C		
UNKNOWN							
		Mitral Valve Incompetence		Pseudoephedrine	C		
UNKNOWN							
		Mobility Decreased		Maxzide	C		
UNKNOWN							
		Musculoskeletal		Naprosyn	C		
UNKNOWN							
		Discomfort		Entex La	C		
UNKNOWN							
		Neuralgia		Voltaren	C		
UNKNOWN							
		Oedema		Voltaren	C		ORAL
		Palpitations		Evening Primrose Oil	C		
UNKNOWN							
		Pleuritic Pain		Glucosamine	C		
UNKNOWN							
		Sacroiliitis		Chondroitin	C		
UNKNOWN							
		Sinusitis		Zantac	C		
UNKNOWN							
		Tachyarrhythmia		Sudafed	C		
UNKNOWN							
		Tricuspid Valve		Aspirin	C		
UNKNOWN							

		Incompetence		Norco	C		
UNKNOWN							
		Uterine Leiomyoma					
		Ventricular Hypokinesia					
		Weight Increased					

Date:02/24/05ISR Number: 4590716-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02542
Age:32 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Cluster Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diplopia		Ortho-Novum 7/7/7	C		
UNKNOWN							
		Dizziness		Zoloft	C		
UNKNOWN							
		Eyelid Retraction		Paxil	C		
UNKNOWN							
		Fibromyalgia		Trazodone			
		Gastrooesophageal Reflux		Hydrochloride	C		
UNKNOWN							
		Disease		Lithobid	C		
UNKNOWN							
		Headache		Vitamin D			
		Hemianopia Homonymous		(Unspecified)	C		
UNKNOWN							
		Intervertebral Disc		Calcium			
		Degeneration		(Unspecified)	C		
UNKNOWN							
		Lid Lag		Vicodin Tablets	C		
UNKNOWN							
		Nausea		Ultram	C		
UNKNOWN							
		Osteomalacia		Oxycontin	C		
UNKNOWN							
		Vision Blurred		Methadone Hcl	C		
UNKNOWN							
		Vitamin D Deficiency		Advil	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590717-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01227
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Diovan	C				
UNKNOWN								
	Angina Pectoris		Zocor	C				
UNKNOWN								
	Atrial Fibrillation		Dapsone	C				
UNKNOWN								
	Atrioventricular Block		Toprol Xl Tablets	C				
UNKNOWN								
	Blood Pressure		Viagra	C				
UNKNOWN								
	Fluctuation							
	Body Tinea							
	Cardiovascular Disorder							
	Carotid Artery Stenosis							
	Chest Pain							
	Coronary Artery Occlusion							
	Dermatitis							
	Diverticulum							
	Eczema							
	Epidermal Necrosis							
	Erythema Multiforme							
	Granuloma Annulare							
	Leukocytoclastic							
	Vasculitis							
	Myocardial Ischaemia							
	Nail Bed Bleeding							
	Onycholysis							
	Polyp							
	Pruritus Ani							
	Psoriasis							
	Renal Failure							
	Syncope							
	Vasculitis							

Date:02/24/05ISR Number: 4590718-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Acquired Immunodeficiency Syndrome	Vioxx	PS	Merck & Co., Inc	ORAL
		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY					
Disability	Aortic Dilatation	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Aortic Valve Incompetence	Vioxx	SS	Merck & Co., Inc	ORAL
	Arthralgia	Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY					
	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
	Convulsion	Vioxx	SS	Merck & Co., Inc	ORAL
	Depression	Dilantin	C		
UNKNOWN					
	Drug Level Below Therapeutic				
	Ejection Fraction Decreased				
	Hypertension				
	Nuclear Magnetic Resonance Imaging Brain Abnormal				
	Pain In Extremity				
	Spinal Osteoarthritis				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590719-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01838
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		907 DAY
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Right		Vioxx	SS	Merck & Co., Inc	ORAL		424 DAY
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		8 DAY
	Chondrocalcinosis		Potassium Chloride	C		ORAL		
	Pyrophosphate		Aldomet (Methyldopa)	C		ORAL		
	Erythema		Colchicine	C		ORAL		
	Hypertension		Clorpres	C		ORAL		
	Hypomagnesaemia		Synthroid	C		ORAL		
	Myocardial Infarction		Slow-Mag	C		ORAL		
	Oedema Peripheral		Premarin	C		ORAL		
	Osteoporosis		Allegra	C				UNKNOWN
	Swelling Face		Acetaminophen And					
	Ventricular Fibrillation		Codeine	C				UNKNOWN
			Lotrel	C				UNKNOWN

Date:02/24/05ISR Number: 4590720-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00022
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590721-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01342
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		

Disability	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cough	Vioxx	SS	Merck & Co., Inc	ORAL
2 DAY					
	Dilatation Atrial	Vioxx	SS	Merck & Co., Inc	ORAL
	Ear Infection	Guaifenesin	C		
UNKNOWN					
	Emotional Distress	Ceftin	C		
UNKNOWN					
	Gastrooesophageal Reflux	Aspirin	C		ORAL
	Disease	Probeta (Dipivefrin			
	Meningioma	Hydrochloride (+)			
	Myocardial Infarction	Levobunolol			
	Paraesthesia	Hydrochloride)	C		
OPHTHALMIC					
	Retinal Artery Occlusion	Diamox	C		ORAL
	Tooth Disorder	Glucosamine	C		ORAL
		Advil	C		ORAL

Date:02/24/05ISR Number: 4590722-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00887
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Angina Unstable
Disability	Anxiety
	Arthralgia
	Atherosclerosis
	Back Pain
	Blood Cholesterol

		Increased Chest Pain Coronary Artery Occlusion Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyslipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Motrin	C		
UNKNOWN							
		Epicondylitis		Tylenol	C		
UNKNOWN							
		Gastrooesophageal Reflux Disease		[Therapy Unspecified]	C		
UNKNOWN							
		Hand Fracture		Ultram	C		
UNKNOWN							
		Headache		Vicodin Tablets	C		
UNKNOWN							
		Helicobacter Pylori		Viagra	C		
UNKNOWN							
		Identification Test Positive Hiatus Hernia Injury Joint Stiffness Mitral Valve Incompetence Myocardial Infarction Nausea Pharyngolaryngeal Pain Productive Cough Pulmonary Hypertension Rectal Haemorrhage Stress Tricuspid Valve Incompetence Ventricular Extrasystoles Visual Acuity Reduced Visual Disturbance Vomiting					

Date:02/24/05ISR Number: 4590724-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Activated Partial Thromboplastin Time

Prolonged
Anxiety
Back Pain
Blood Cholesterol
Increased
Bronchitis
Bronchitis Acute
Carotid Artery Stenosis
Cerebral Infarction
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Constipation
Dermatitis
Drug Eruption
Dyspepsia
Dyspnoea
Eczema Infected
Emotional Distress
Fall
Fractured Coccyx
Gastric Disorder

		Gastritis					
		Goitre					
		Hemiparesis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperthyroidism		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Motrin	C		
UNKNOWN							
		International Normalised		Paxil	C		
UNKNOWN							
		Ratio Increased		Paxil	C		
UNKNOWN							
		Low Density Lipoprotein		Benadryl	C		
UNKNOWN							
		Increased		Correctol (Docusate			
		Muscle Spasms		Sodium (+)			
		Myocardial Infarction		Phenolphthalein)	C		
UNKNOWN							
		Nasopharyngitis					
		Nicotine Dependence					
		Oedema Peripheral					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pneumonia					
		Prothrombin Time					
		Prolonged					
		Sinus Congestion					
		Sinusitis					
		Syncope					
		Thyroid Mass					
		Thyroid Pain					
		Transient Ischaemic					
		Attack					
		Vision Blurred					

Date:02/24/05ISR Number: 4590725-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00862
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain		Tenoret	C		
UNKNOWN						
Initial or Prolonged	Gastric Haemorrhage					
Disability						

Date:02/24/05ISR Number: 4590726-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00929
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris Blood Pressure Increased Bradycardia Carotid Artery Occlusion Carotid Artery Stenosis Cerebrovascular Accident Convulsion Drug Hypersensitivity Hemianopia Homonymous Sedation Sensory Loss		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590727-3Report Type:Expedited (15-DaCompany Report #AT-MERCK-0502AUT00010
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis Coronary Artery Atherosclerosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01610
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Loss Of Consciousness		Premarin	C				UNKNOWN
Disability			Alprazolam	C				UNKNOWN
			Nitro	C				UNKNOWN

Date:02/24/05ISR Number: 4590729-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00006
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		421 DAY
	Chest Pain Fall Pain In Extremity							

Date:02/24/05ISR Number: 4590730-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02621
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		

	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Norvasc	C		
UNKNOWN						
			Lisinopril	C		ORAL

Date:02/24/05ISR Number: 4590731-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00080
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							

Date:02/24/05ISR Number: 4590732-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03862
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Asthenia
Disability	Cerebrovascular Accident
Other	Hyperhidrosis

		Hypotension					
		Pallor					
		Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/24/05ISR Number: 4590733-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00130
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL

Date:02/24/05ISR Number: 4590734-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/24/05ISR Number: 4590735-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00137
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Hypertension					
		Pulmonary Embolism					
		Thrombosis					

Date:02/24/05ISR Number: 4590736-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02009
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/24/05ISR Number: 4590737-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01769
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Red Blood Cell Count		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Abnormal Ulcer Haemorrhage							

Date:02/24/05ISR Number: 4590738-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02771
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Dizziness		Glyburide	C			UNKNOWN	
	Sick Sinus Syndrome		Toprol Xl Tablets	C			UNKNOWN	
	Syncope		[Therapy Unspecified]	C			UNKNOWN	
	Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590739-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590740-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00423
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dilatation Ventricular		Lovastatin	C				
UNKNOWN								
	Drug Ineffective		Atenolol	C				
UNKNOWN								
	Dyspepsia		Lisinopril	C				
UNKNOWN								
	Erectile Dysfunction		Hydrochlorothiazide	C				
UNKNOWN								
	Fibromyalgia		Levothyroxine Sodium	C				
UNKNOWN								
	Hypertension		Ranitidine	C				
UNKNOWN								
	Insomnia		Cyanocobalamin	C				
UNKNOWN								
	Mitral Valve Incompetence							
	Pain							
	Pernicious Anaemia							
	Tendonitis							
	Transient Ischaemic							
	Attack							
	Weight Increased							

Date:02/24/05ISR Number: 4590741-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00161
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive							

Hospitalization - Initial or Prolonged Disability	Gastrointestinal Haemorrhage Hypotension Myocardial Infarction Pain Pneumonia

Date:02/24/05ISR Number: 4590742-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01893
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:02/24/05ISR Number: 4590743-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01895
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590744-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON
	Amnesia							
	Cerebrovascular Accident							
	Mitral Valve Replacement							

Date:02/24/05ISR Number: 4590745-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590746-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00009
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vasotec	C				
UNKNOWN								

Date:02/24/05ISR Number: 4590747-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00025
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1729	DAY

Date:02/24/05ISR Number: 4590748-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00022
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1639 DAY
Initial or Prolonged			Methotrexate	C				UNKNOWN
			Cortisone	C				UNKNOWN
			Estrogens (Unspecified)	C				UNKNOWN
			Omeprazole Magnesium	C				UNKNOWN
			Propoxyphene Hydrochloride	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Folic Acid	C				UNKNOWN

Date:02/24/05ISR Number: 4590749-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590750-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02038
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590751-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
	Renal Failure							

Date:02/24/05ISR Number: 4590752-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00186
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bone Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Transient Ischaemic Attack							

Date:02/24/05ISR Number: 4590753-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02116
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								

Date:02/24/05ISR Number: 4590754-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590755-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02230
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C			UNKNOWN	
			Ultracet	C			UNKNOWN	

Date:02/24/05ISR Number: 4590756-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02279
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
2 DAY								
Initial or Prolonged			Furosemide	C			UNKNOWN	
Disability			Hyzaar	C			UNKNOWN	
			Crestor	C			UNKNOWN	
			Biaxin	C			UNKNOWN	

Date:02/24/05ISR Number: 4590757-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02165
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Hospitalization - Initial or Prolonged Disability			Vioxx	SS	Merck & Co., Inc	ORAL		7 MON

Date:02/24/05ISR Number: 4590758-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02118
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			[Therapy Unspecified]	C				

Date:02/24/05ISR Number: 4590759-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02208
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Tylenol	C				UNKNOWN
			Benadon	C				UNKNOWN
			Prevacid	C				UNKNOWN

Date:02/24/05ISR Number: 4590760-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590761-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02226
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590762-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia Cerebrovascular Accident Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590763-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02027
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Imuran (Azathioprine)	C				
UNKNOWN								
Disability			Prednisone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590764-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01915
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590765-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02281
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Stiffness		Prednisone	C			UNKNOWN	
	Musculoskeletal Stiffness		Advair	C			UNKNOWN	
	Overdose		Calcium (Unspecified)	C			UNKNOWN	
			Ascorbic Acid	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Nexium	C			UNKNOWN	

Date:02/24/05ISR Number: 4590766-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02444
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590767-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02313
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
			Vitamins (Unspecified)	C		

UNKNOWN

Date:02/24/05ISR Number: 4590768-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02417
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:02/24/05ISR Number: 4590769-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590770-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02315
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Renal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Renal Impairment							

Date:02/24/05ISR Number: 4590772-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590773-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02400
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/24/05ISR Number: 4590774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02641
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590775-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590776-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590777-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590778-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02458
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590779-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590780-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590781-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14 MON	

Date:02/24/05ISR Number: 4590782-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590783-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590784-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/24/05ISR Number: 4590785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590786-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590788-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590789-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02656
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590790-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590791-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02708
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Nausea
Tremor

Date:02/24/05ISR Number: 4590792-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590793-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590795-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590796-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:02/24/05ISR Number: 4590797-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4590799-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03027
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Initial or Prolonged	Cardiac Failure Congestive Hypertension							

Date:02/24/05ISR Number: 4590800-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02889
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:02/24/05ISR Number: 4590801-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00260
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Eye Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
	Eye Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache					
	Optic Atrophy					
	Optic Disc Haemorrhage					
	Optic Nerve Infarction					
	Papillitis					
	Papilloedema					
	Visual Acuity Reduced					
	Visual Disturbance					

Date:02/24/05ISR Number: 4590802-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4590803-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02127
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/24/05ISR Number: 4595374-5Report Type:Expedited (15-DaCompany Report #WAES0411USA03928
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation	Study	Etoricoxib	PS		ORAL	30	
Initial or Prolonged		Health					MG/DAILY/PO	
		Professional	Acetaminophen	SS		ORAL	325 MG/PRN/PO	
			Placebo	SS		ORAL	PO	
			Vioxx	SS		ORAL	25	
							MG/DAILY/PO	
			Effexor	C				
			Tylenol Arthritis					
			Extended Relie	C				
			Tyneol Sinus	C				

Date:02/24/05ISR Number: 4595615-4Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest	Foreign	Tab Vioxx					
Hospitalization -	Infection	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Pneumonia	Health	Allopurinol	C				
	Post Procedural	Professional						
	Complication							
	Therapy Non-Responder							

Date:02/24/05ISR Number: 4595618-XReport Type:Expedited (15-DaCompany Report #WAES 0411DEU00393
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization -	Alanine Aminotransferase Decreased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	827 DAY
Initial or Prolonged	Aspartate Aminotransferase Decreased Blood Creatine Phosphokinase Mb Increased C-Reactive Protein Increased Dehydration Demyelination Depressed Level Of Consciousness Diarrhoea Korsakoff'S Psychosis Non-Alcoholic Myoglobin Blood Increased White Blood Cell Count Increased	Health Professional Other	Inj Etanercept	SS		SUBCUTANEOUS	25 MG/2XW	43 DAY
			Budesonide	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/24/05ISR Number: 4595765-2Report Type:Direct Company Report #CTU 241320
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse		Voltaren Xr	PS		ORAL	1 DAILY ORAL	
Hospitalization -	Gastric Ulcer		Vioxx	SS		ORAL	1 DAILY ORAL	
Initial or Prolonged	Incision Site		Celebrex	SS		ORAL	1 DAILY ORAL	
Disability	Complication		Aspirin	C				
Required	Incoherent							
Intervention to	Myocardial Infarction							
Prevent Permanent	Open Wound							
Impairment/Damage	Surgery							

Date:02/24/05ISR Number: 4595923-7Report Type:Direct Company Report #CTU 241300
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Subcutaneous		Vioxx 20 Mg					
	Skin Discolouration		Merek	PS	Merek			
1 PER DAY								

Date:02/25/05ISR Number: 4591184-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00121
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Faeces Discoloured		Fosamax	PS	Merck & Co., Inc	ORAL	402 DAY	
Initial or Prolonged	Gastric Ulcer Haemorrhage		Rofecoxib	SS		ORAL		
	Haematemesis		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
	Haemoglobin Decreased		Acetaminophen And Dihydrocodeine Bitartrate	C		ORAL		
			Beclomethasone Dipropionate	C				
RESPIRATORY								

(INHALATION)

	Calcium Carbonate And Cholecalciferol	C	ORAL
	Albuterol	C	RESPIRATORY (INHALATION)
	Lisinopril	C	ORAL
	Lansoprazole	C	ORAL

Date:02/25/05ISR Number: 4591198-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02738
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1522 DAY
Initial or Prolonged	Coronary Artery Disease		[Therapy Unspecified]	C		UNKNOWN		
Other	Heart Rate Irregular		[Therapy Unspecified]	C		UNKNOWN		
			[Therapy Unspecified]	C		UNKNOWN		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591207-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00502
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		587 DAY
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		587 DAY
Other	Non-Insulin-Dependent		Aspirin	C				UNKNOWN
	Gastritis		Bisoprolol Fumarate					
	Hypertensive		And					
	Cardiomyopathy		Hydrochlorothiazide	C				UNKNOWN
	Myocardial Infarction		Atorvastatin Calcium	C				UNKNOWN

Date:02/25/05ISR Number: 4591208-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00984
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haematemesis		Prevacid	C				UNKNOWN
Initial or Prolonged	Headache							
Disability	Nausea							

Date:02/25/05ISR Number: 4591209-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03882
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thyroid Function Test		Vioxx	SS	Merck & Co., Inc	ORAL		
	Abnormal		[Therapy					
			Unspecified]	C				UNKNOWN

Date:02/25/05ISR Number: 4591210-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01727
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Scar		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591211-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02837
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc			
							UNKNOWN	
Other	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Self-Medication		Vioxx	SS	Merck & Co., Inc			
							UNKNOWN	
			Norvasc	C				
							UNKNOWN	
			Metoprolol	C				
							UNKNOWN	
			[Therapy Unspecified]	C				
							UNKNOWN	

Date:02/25/05ISR Number: 4591213-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Arrhythmia
Other	Carotid Artery Stenosis

	Demyelination						
	Dizziness						
	Nervous System Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL	
	Transient Ischaemic Attack		Aspirin	C		ORAL	
			Glyburide	C		ORAL	
			Magnesium Aspartate And Magnesium Citrate And Magnesium Glutamate And Magnesium	C			UNKNOWN
			Glyburide	C			UNKNOWN

Date:02/25/05ISR Number: 4591214-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00736
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL	1 DAY
Life-Threatening	Drug Exposure During Pregnancy						
Hospitalization - Initial or Prolonged							

Date:02/25/05ISR Number: 4591222-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/25/05ISR Number: 4591223-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02213
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	

Hospitalization - UNKNOWN	Cardiac Disorder	Synthroid	C
Initial or Prolonged UNKNOWN	Chest Pain	Lipitor	C
	Coronary Arterial Stent Insertion		

Date:02/25/05ISR Number: 4591227-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

Date:02/25/05ISR Number: 4591229-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02413
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591230-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02185
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Unevaluable Event		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
			Prozac	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Ambien	C			UNKNOWN	

Date:02/25/05ISR Number: 4591236-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00087
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Hospitalization -	Cerebral Haematoma		Fluindione	SS		ORAL		
Initial or Prolonged	Cerebrovascular Accident		Candesartan					
	Coma		Cilexetil	C		ORAL		
	Drug Interaction		Cifenline Succinate	C		ORAL		
	Hypothermia		Metoprolol	C		ORAL		
	International Normalised		Metoprolol	C		ORAL		
	Ratio Increased		Zocor	C		ORAL		
	Mixed Incontinence		Allopurinol	C		ORAL		
			Terbutaline Sulfate	C				
RESPIRATORY								
(INHALATION)								

Date:02/25/05ISR Number: 4591242-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591243-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02221
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Surgery		Zocor	C		ORAL		
			Toprol Xl Tablets	C				
UNKNOWN								
Disability								

Date:02/25/05ISR Number: 4591245-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02447
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							
Disability	Tension							

Date:02/25/05ISR Number: 4591246-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02418
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
							18	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591247-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00152
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591253-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591254-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02897
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591255-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/25/05ISR Number: 4591257-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02092
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591260-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02568
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591264-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1463 DAY

Date:02/25/05ISR Number: 4591878-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02553
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Lortab	C				
UNKNOWN								
	Dyspnoea		Tylenol	C				
UNKNOWN								
			Skelaxin	C				
UNKNOWN								

Date:02/25/05ISR Number: 4591880-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591882-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02301
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Chest Pain		[Therapy Unspecified]	C				
	Heart Rate Irregular							
UNKNOWN								
	Hypoaesthesia							
	Oedema Peripheral							

Date:02/25/05ISR Number: 4591883-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Test Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

Initial or Prolonged		Chest Pain Heart Rate Irregular					

Date:02/25/05ISR Number: 4591885-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591886-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Sudden Death							

Date:02/25/05ISR Number: 4591888-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02296
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Irregular							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591890-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02288
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Limb Injury		Prozac	C				
UNKNOWN								
Other			Darvocet-N	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:02/25/05ISR Number: 4591891-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591901-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Other	Abdominal Pain Upper
	Anaemia
	Anaemia Of Chronic Disease
	Angina Pectoris
	Anxiety
	Arthralgia
	Arthritis
	Asthenia
	Asthma
	Atherosclerosis
	Back Pain
	Bladder Disorder
	Blood Erythropoietin Decreased
	Breast Disorder
	Breath Sounds Decreased
	Bronchitis

Bursitis
Cardiac Failure
Cardiac Failure
Congestive
Cardiomegaly
Cerebral Infarction
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Cholecystitis
Computerised Tomogram
Abnormal
Confusional State
Congestive Cardiomyopathy
Constipation
Cough
Crepitations
Cyst
Cystitis
Diabetes Mellitus
Inadequate Control
Diabetic Retinopathy

Diarrhoea
Disease Recurrence
Dizziness
Drug Hypersensitivity
Drug Ineffective
Duodenitis
Dyslipidaemia
Dyspnoea Exertional
Dysstasia
Ecchymosis
Electrocardiogram St
Segment Depression
Electrocardiogram T Wave
Inversion
Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Flatulence
Fluid Retention
Gastritis
Glycosylated Haemoglobin
Increased
Gout
Haematoma
Haemorrhage
Headache
Heart Valve Stenosis
Hemianopia Homonymous
Hyperglycaemia
Hypertensive Crisis
Hypertrophic
Cardiomyopathy
Hyperuricaemia
Injury
Insomnia
Iron Deficiency Anaemia
Irritable Bowel Syndrome
Joint Effusion
Joint Swelling
Lactose Intolerance
Low Density Lipoprotein
Increased
Macular Degeneration
Malaise
Mitral Valve
Calcification

Mitral Valve Incompetence
Mouth Haemorrhage
Myalgia
Myocardial Infarction
Nausea
Oedema Peripheral
Orthopnoea
Pain
Pain In Extremity
Pelvic Prolapse
Pharyngolaryngeal Pain
Pitting Oedema
Pulmonary Oedema
Renal Failure Chronic

	Restless Legs Syndrome						
	Rheumatoid Arthritis						
	Salivary Gland Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
	Skin Discolouration		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR
	Skin Nodule		Diovan	C			UNKNOWN
	Spinal Osteoarthritis		Methotrexate	C			UNKNOWN
	Swelling		Prednisone	C			UNKNOWN
	Synovitis		Cozaar	C		ORAL	
	Treatment Noncompliance						
	Urinary Incontinence						
	Urinary Tract Infection						
	Ventricular Dysfunction						
	Vision Blurred						
	Weight Decreased						
	Wheezing						
	White Blood Cell Count Increased						

Date:02/25/05ISR Number: 4591909-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02896
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/25/05ISR Number: 4591911-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:02/25/05ISR Number: 4591912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591913-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02661
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591915-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03511
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gangrene		Zestril	C				
UNKNOWN								
Initial or Prolonged	Leg Amputation		Verapamil	C				
UNKNOWN								
Disability	Peripheral Embolism		Lipitor	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00657
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Injury							
Disability								

Date:02/25/05ISR Number: 4591918-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00989
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Actonel	C				
UNKNOWN								
	Back Pain		Motrin	C				
UNKNOWN								
	Cerebrovascular Accident		[Therapy					
	Chest Pain		Unspecified]	C				
UNKNOWN								
	Difficulty In Walking		Antimicrobial					
	Hyperhidrosis		(Unspecified)	C				
UNKNOWN								
	Pain In Extremity							
	Weight Decreased							

Date:02/25/05ISR Number: 4591919-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
83 DAY								
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Calculus Ureteric		Advil	C				
UNKNOWN								
Other	Calculus Urinary		Advil	C				
UNKNOWN								

	Chest Discomfort		Vicodin Tablets	C		
UNKNOWN						
	Coronary Artery Occlusion		Aspirin	C		
UNKNOWN						
	Cough		Ultram	C		
UNKNOWN						
	Diverticulitis		Ultram	C		
UNKNOWN						
	Fatigue					
	Osteoarthritis					
	Palpitations					
	Pneumonia Influenzal					
	Weight Fluctuation					

Date:02/25/05ISR Number: 4591921-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03524
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL
38 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
4 MON						
			Vioxx	SS	Merck & Co., Inc	ORAL
38 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
4 MON						
			Aspirin	C		
UNKNOWN						
			Coumadin	C		
UNKNOWN						
			Lasix (Furosemide Sodium)	C		
UNKNOWN						
			Zocor	C		ORAL
			Isordil	C		
UNKNOWN						
			Captopril	C		
UNKNOWN						
			Coreg	C		
UNKNOWN						
			Digoxin	C		
UNKNOWN						

			Potassium Chloride	C		
UNKNOWN						

Date:02/25/05ISR Number: 4591924-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00214
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
	Aortic Valve Incompetence		Sotalol Hydrochloride	SS		
	Cardiac Disorder					
UNKNOWN						
	Chest Pain		Ibuprofen	C		
UNKNOWN						
	Fluid Retention		Trimipramine	C		
UNKNOWN						
	Gastrointestinal		Indomethacin	C		
UNKNOWN						
	Haemorrhage					
	Heart Rate Irregular					
	Hypotension					
	Intestinal Haemorrhage					
	Oedema Peripheral					
	Refusal Of Treatment By Patient					
	Respiratory Tract Infection					
	Sleep Apnoea Syndrome					
	Supraventricular Extrasystoles					
	Weight Increased					

Date:02/25/05ISR Number: 4591929-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00119
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cerebral Haemorrhage		Aspirin	C		ORAL
	Speech Disorder		Ramipril	C		ORAL
			Magnesium Oxide	C		ORAL

			Simvastatin	C		ORAL

Date:02/25/05ISR Number: 4591933-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0412SWE00013
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Stress		Nitroglycerin	C		
UNKNOWN						
Disability						

Date:02/25/05ISR Number: 4591935-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00184
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
	Chest Pain					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/25/05ISR Number: 4591940-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
	Arterial Thrombosis			C				
UNKNOWN	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Low Density Lipoprotein Increased							

Date:02/25/05ISR Number: 4591941-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00090
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Inadequately Controlled							
	Cardiac Disorder							
	Cerebral Ischaemia							
	Transient Ischaemic Attack							

Date:02/25/05ISR Number: 4591945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04262
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Aspirin	C				
UNKNOWN								
Disability	Overdose							

Date:02/25/05ISR Number: 4591946-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591972-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02310
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/25/05ISR Number: 4591989-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00104
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence Colitis Ulcerative Congestive Cardiomyopathy

	Coronary Artery Disease						
	Coronary Artery Stenosis						
	Diarrhoea Haemorrhagic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Sulfasalazine	C			UNKNOWN
	Tachycardia		Prednisolone	C			UNKNOWN
	Ventricular Hypertrophy		Mesalamine	C			UNKNOWN
	Visual Disturbance		Metoprolol	C			UNKNOWN

Date:02/25/05ISR Number: 4593970-2Report Type:Expedited (15-DaCompany Report #GXKR2005GB00593
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus	Foreign	Ketoprofen (Ketoprofen)	PS		ORAL	200 MG, QD, ORAL
	Gastric Ulcer	Health					
	Gastritis Erosive	Professional					
	Haematemesis	Other	Rofecoxib (Rofecoxib)	SS		ORAL	12.5 MG, ORAL
			Lisinopril (Lisinopril)	C			
			Bendrofluazide (Bendroflumethiazide)	C			
			Pravastatin (Pravastatin)	C			

Date:02/25/05ISR Number: 4595209-0Report Type:Expedited (15-DaCompany Report #2005022759
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL

Hospitalization - Initial or Prolonged	Circulatory Collapse Diabetes Mellitus Heart Rate Increased Myocardial Infarction Nausea	Rofecoxib (Rofecoxib) Atenolol (Atenolol) Isosorbide Dinitrate (Isosorbide Dinitrate)	SS C C

Date:02/25/05ISR Number: 4595264-8Report Type:Expedited (15-DaCompany Report #2004116207
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)	PS			UNKNOWN	UNKNOWN
	Chest Pain Dyspnoea		Rofecoxib (Rofecoxib)	SS			UNKNOWN	UNKNOWN
	Neoplasm Malignant Surgery Ulcer							

Date:02/25/05ISR Number: 4596127-4Report Type:Expedited (15-DaCompany Report #2005-BP-02238RO
Age:41 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive Arthropathy

		Blood Albumin Decreased Blood Calcium Decreased Blood Chloride Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
20 MG/WEEK - DIVIDED DOSE	6 YR	Bone Marrow Depression Chest X-Ray Abnormal Chills Deformity Drug Clearance Decreased	Literature Health Professional	Methotrexate (Methotrexate) Rofecoxib (Rofecoxib)	PS SS		
3 WK		Drug Interaction Drug Toxicity Epstein-Barr Virus Infection Erythema Multiforme Hepatosplenomegaly Immunosuppression Laboratory Test Abnormal Leukocytoclastic Vasculitis Lymphadenopathy Lymphoproliferative Disorder Oedema Peripheral Pancytopenia Pyrexia Rales Red Blood Cell Sedimentation Rate Increased Synovitis Therapy Non-Responder Thrombin Time Prolonged		Medroxyprogesterone (Medroxyprogesterone) Levofloxacin (Levofloxacin) Pirbuterol (Pirbuterol) Vitamin B12 (Cyanocobalamin)	 C C C C		

Date:02/26/05ISR Number: 4592150-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00703
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL

Gastric Disorder

Date:02/26/05ISR Number: 4592152-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization - Initial or Prolonged	Back Disorder
Disability	Cerebrovascular Accident
Other	Chest Discomfort
	Depression
	Dizziness
	Drug Ineffective
	Hypertension
	Loss Of Consciousness
	Myocardial Infarction
	Pain In Extremity
	Paraesthesia
	Postoperative Infection

		Staphylococcal Infection					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vitreous Floaters		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Premarin	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							

Date:02/26/05ISR Number: 4592153-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03228
Age:41 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
1372 DAY							
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
		Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
1372 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
				Prilosec	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Levaquin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

			Codeine	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:02/26/05ISR Number: 4592154-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
225 DAY						
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL
41 DAY						
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
225 DAY						
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
41 DAY						
	Respiratory Disorder		Fenoterol Hydrobromide And Ipratropium Bromide	C		
UNKNOWN						
			Formoterol Fumarate	C		
UNKNOWN						
			Bisoprolol Fumarate	C		
UNKNOWN						
			Enalapril Maleate	C		
UNKNOWN						
			Atorvastatin Calcium	C		
UNKNOWN						
			Tamsulosin Hydrochloride	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Beclomethasone Dipropionate	C		
UNKNOWN						

Date:02/26/05ISR Number: 4592155-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02287
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Cough							
Disability	Dyspnoea							
	Lipids Increased							
	Mitral Valve Prolapse							
	Myalgia							
	Oedema Peripheral							
	Tendonitis							

Date:02/26/05ISR Number: 4592156-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Distension
Other	Abdominal Pain
	Angiopathy
	Anxiety
	Asthenia
	Atherosclerosis
	Back Pain
	Balance Disorder
	Blood Pressure Increased
	Body Temperature
	Decreased
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Convulsion
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent
	Diabetic Neuropathy
	Difficulty In Walking
	Disorientation
	Dizziness
	Dyskinesia
	Dyspepsia
	Dysphagia
	Dyspnoea

Epidermal Naevus
Eructation
Eye Irritation
Eye Pruritus
Fatigue
Feeling Abnormal
Gait Disturbance
Hypercholesterolaemia
Hypertriglyceridaemia
Hypoaesthesia
Hypotension
Insomnia
Irritability
Lacunar Infarction
Memory Impairment
Muscle Spasms
Muscle Twitching
Myalgia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Nausea					
		Night Sweats					
		Ocular Hyperaemia					
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophageal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Onychomycosis		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Pain		Lotrel	C		
UNKNOWN		Pain In Extremity		Plavix	C		
UNKNOWN		Palpitations		Paxil	C		
UNKNOWN		Paraesthesia		Nexium	C		
UNKNOWN		Productive Cough		Prilosec	C		
UNKNOWN		Sleep Apnoea Syndrome		Norvasc	C		
	395 DAY						
UNKNOWN		Sputum Discoloured		Lipitor	C		
	831 DAY						
UNKNOWN		Suicidal Ideation		Lipitor	C		
UNKNOWN		Tinea Pedis		Lipitor	C		
	831 DAY						
UNKNOWN		Toe Deformity		Lipitor	C		
		Tremor		Zocor	C		ORAL
		Upper Respiratory Tract		Zocor	C		ORAL
		Infection		Zocor	C		ORAL
UNKNOWN		Vascular Dementia		Tricor	C		
		Wheezing		Zetia	C		ORAL
				Zetia	C		ORAL
				Toprol Xl Tablets	C		ORAL
				Toprol Xl Tablets	C		ORAL
UNKNOWN				Neurontin	C		
				Robaxin	C		ORAL
UNKNOWN				Aspirin	C		
UNKNOWN				Ibuprofen	C		
UNKNOWN				Glucovance	C		
				Clorazepate			

				Dipotassium	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Albuterol	C		
RESPIRATORY							
(INHALATION)							

Date:02/26/05ISR Number: 4592157-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02397
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Vitamins			
Initial or Prolonged	Myocardial Infarction		(Unspecified)	C		
UNKNOWN						
Disability						

Date:02/26/05ISR Number: 4592158-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01226
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Chest Pain					
	Tachycardia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/05ISR Number: 4592159-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592160-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01727
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Scar		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592161-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Hypersensitivity Iliac Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592162-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02442
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592163-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02187
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Tachycardia		[Therapy					

Initial or Prolonged Unspecified] C
UNKNOWN

Date:02/26/05ISR Number: 4592164-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02441
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Dyspnoea							

Date:02/26/05ISR Number: 4592165-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02496
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Coumadin	C				
UNKNOWN								
	Difficulty In Walking		Toprol Xl Tablets	C				
UNKNOWN								
	Dyspnoea		Prednisone	C				
UNKNOWN								
	Heart Rate Increased		Hydrodiuril	C				
UNKNOWN								
			Amiodarone	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/05ISR Number: 4592166-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02459
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592167-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00024
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	701 DAY	
	Fall		Hydrochlorothiazide And Irbesartan	C			UNKNOWN	
	Myocardial Infarction							
	Rib Fracture		Levomepromazine	C			UNKNOWN	
	Treatment Noncompliance		Atenolol	C			UNKNOWN	
			Metformin Hydrochloride	C			UNKNOWN	

Date:02/26/05ISR Number: 4592168-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02423
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592169-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00174
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	98 MON	

Initial or Prolonged	Cardiac Failure	Vioxx	SS	Merck & Co., Inc	ORAL
	Pelvic Fracture	Fosamax	C		ORAL
	Tachycardia	Dipyrone	C		ORAL

Date:02/26/05ISR Number: 4592170-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00079
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Pain
Disability	Acquired Diaphragmatic
	Eventration
	Adverse Event
	Anorexia
	Aortic Occlusion
	Arthralgia
	Asthenia
	Back Pain
	Blood Disorder
	Bronchitis
	Cerebral Atrophy
	Cervical Myelopathy
	Chest Pain
	Constipation
	Contusion
	Difficulty In Walking
	Disability

		Emotional Distress					
		Excoriation					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gait Spastic		Vioxx	PS	Merck & Co., Inc	ORAL
		Gout		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Tylenol	C		
UNKNOWN							
		Hyperlipidaemia					
		Insomnia					
		Intermittent Claudication					
		Laceration					
		Livedo Reticularis					
		Low Density Lipoprotein					
		Increased					
		Lung Infiltration					
		Malaise					
		Nasopharyngitis					
		Obstruction					
		Painful Respiration					
		Peripheral Circulatory					
		Failure					
		Peroneal Nerve Palsy					
		Pleural Disorder					
		Poor Peripheral					
		Circulation					
		Road Traffic Accident					
		Scar					
		Skin Laceration					
		Weight Decreased					

Date:02/26/05ISR Number: 4592171-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00164
Age:48 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
15 DAY							

Date:02/26/05ISR Number: 4592172-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02539
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Heart Rate Irregular		Glyburide	C				
UNKNOWN								
	Thrombosis		Glucophage	C				
UNKNOWN								

Date:02/26/05ISR Number: 4592173-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
6 YR								

Date:02/26/05ISR Number: 4592174-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								

Date:02/26/05ISR Number: 4592175-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02530
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Dyspnoea Pain In Extremity							

Date:02/26/05ISR Number: 4592176-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Emotional Distress Haemorrhage Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592177-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592178-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	27	MON

Date:02/26/05ISR Number: 4592179-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592181-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592182-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/26/05ISR Number: 4592183-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592185-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592186-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	YR

Date:02/26/05ISR Number: 4592188-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/26/05ISR Number: 4592189-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:02/26/05ISR Number: 4592191-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acquired Oesophageal Web
Hospitalization - Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Aptyalism
	Asthenia
	Atrial Flutter
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bursitis
	Cerebral Haemorrhage
	Chest Pain
	Contusion
	Coronary Artery Disease
	Decreased Activity
	Decreased Appetite
	Dyspepsia
	Fall
	Gastric Ulcer

		Gastrooesophageal Reflux Disease					
		Haematoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertensive Heart		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Influenza		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Coumadin	SS		
UNKNOWN							
		Degeneration		Coumadin	SS		
UNKNOWN							
		Intervertebral Disc Protrusion					
		Joint Injury					
		Lacunar Infarction					
		Mitral Valve Prolapse					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasal Sinus Drainage					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Pain					
		Pneumonia					
		Pruritus					
		Pulmonary Hypertension					
		Renal Failure					
		Rotator Cuff Syndrome					
		Sinusitis					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Subdural Haematoma					
		Tricuspid Valve Incompetence					
		Urinary Retention					

Date:02/28/05ISR Number: 4592541-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02233
Age:74 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Ischaemic Stroke		Lotrel	C		
UNKNOWN							

Hydrochlorothiazide C
UNKNOWN

Date:02/28/05ISR Number: 4592768-9Report Type:Expedited (15-DaCompany Report #PHBS2005NO02892
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Trileptal	PS	Novartis Sector:			
	Dyskinesia				Pharma	ORAL	300 mg, BID	
	Feeling Abnormal		Aerius	SS		ORAL	5 mg/d	
	Nausea		Vioxx	SS		ORAL	25 mg/d	10080MIN
	Reaction To Medical Agent		Azitromax	SS		ORAL	500 mg/d	4320 MIN
	Preservatives							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/05ISR Number: 4592837-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ocular Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:02/28/05ISR Number: 4596491-6Report Type:Expedited (15-DaCompany Report #8578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Methotrexate	PS		ORAL	10 MG WEEKLY,	
Hospitalization -	Balance Disorder						PO	5 YR
Initial or Prolonged	Dizziness		Rofecoxib	SS		ORAL	12.5 MG PO	1 YR
Disability	Drug Interaction		Folic Acid	C				
	Drug Toxicity							
	Epistaxis							
	Malaise							
	Syncope							

Date:02/28/05ISR Number: 4596585-5Report Type:Expedited (15-DaCompany Report #2004116207
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)	PS				
	Chest Pain		Rofecoxib					
	Gastrointestinal Ulcer		(Rofecoxib)	SS				
	Nocturnal Dyspnoea							
	Pain							
	Spinal Operation							

Date:02/28/05ISR Number: 4596639-3Report Type:Expedited (15-DaCompany Report #2004107519
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Musculoskeletal Disorder	Consumer	Lipitor	
Other	Myocardial Infarction		(Atorvastatin)	PS
			Rofecoxib	
			(Rofecoxib)	SS

Date:02/28/05ISR Number: 4596670-8Report Type:Expedited (15-DaCompany Report #2005030666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Breast Induration	Consumer	Celebrex (Celecoxib)	PS		ORAL
ORAL						
	Breast Swelling		Rofecoxib			
	Conjunctivitis		(Rofecoxib)	SS		
	Eczema		Diclofenac Sodium			
	Herpes Simplex		(Diclofenac Sodium)	C		
	Rotator Cuff Syndrome					
	Scar					

Date:02/28/05ISR Number: 4596924-5Report Type:Expedited (15-DaCompany Report #2004103390
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired

Drug Ineffective Memory Impairment Migration Of Implant	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Osteoarthritis Post Procedural Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL	(1 IN 1 D), ORAL	
		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	
		Morphine Injection (Morphine Sulfate)	SS				
		Rofecoxib (Rofecoxib)	SS				
		Oxycocet (Oxycodone Hydrochloride, Paracetamol)	SS			(6 IN 1 AS NECESSARY),	
		Metoprolol Tartrate (Metoprolol Tartrate)	C				
		Triamterene (Triamterene)	C				
		Atorvastatin (Atorvastatin)	C				
		Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C				
		All Other Therapeutic Products (All Other Therapeutic Products)	C				

Date:02/28/05ISR Number: 4596933-6Report Type:Expedited (15-DaCompany Report #2004116587
Age:87 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alcohol Use	Consumer	Celebrex (Celecoxib)	PS		ORAL	(100 MG), ORAL	
	Arrhythmia							
	Blood Pressure Increased		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG, ORAL	
	Hiccups							
	Medication Error		Atenolol (Atenolol)	C				
	Self-Medication		Bellaspon Retard (Belladonna Alkaloids, Ergotamine Tartrate, Phenobarbital)	C				
			Prazosin (Prazosin)	C				
			Dyazide (Hydrochlorothiazide, Triamterene)	C				
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
			Finasteride (Finasteride)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/05ISR Number: 4596942-7Report Type:Expedited (15-DaCompany Report #2004088892
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, W IN 1 D), ORAL	
	Arthralgia							
	Cardiac Disorder							
	Condition Aggravated		Rofecoxib (Rofecoxib)	SS				
	Dehydration		Tocopherol (Tocopherol)	C				
	Drug Effect Decreased		Retinol (Retinol)	C				
	Extrasystoles		B-Komplex "Leciva" (Calcium Pantothenate, Nicotinamide, Pyridoxine	C				
	Musculoskeletal Stiffness		Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide, Glucosamine Sulfate/Minerals/Multivitamins (Glucosamine Sulfate, Minerals	C				
	Pain		Ergocalciferol (Ergocalciferol)	C				
			Ascorbic Acid (Ascorbic Acid)	C				
			Digoxin (Digoxin)	C				
			Vitamins (Vitamins)	C				

Date:02/28/05ISR Number: 4596965-8Report Type:Expedited (15-DaCompany Report #2005023694
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased	Consumer	Celebrex (Celecoxib)	PS				

	Drug Ineffective		Bextra (Valdecoxib)	SS			ORAL 10 MG, ORAL
	Dyspepsia Mobility Decreased Pollakiuria		Rofecoxib (Rofecoxib)	SS			

Date:02/28/05ISR Number: 4597027-6Report Type:Expedited (15-DaCompany Report #GXKR2005GB00593
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus Gastric Ulcer	Foreign Health	Ketoprofen (Ngx)(Ketoprofen)	PS		ORAL	200 MG, QD, ORAL	
	Gastritis Erosive	Professional						
	Haematemesis	Other	Rofecoxib (Rofecoxib)	SS		ORAL	12.5 MG, ORAL	
			Lisinopril (Lisinopril)	C				
			Bendrofluazide (Bendrofluazide)	C				
			Pravastatin (Pravastatin)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/05ISR Number: 4597585-1Report Type:Direct Company Report #CTU 241604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Eyelid Margin Crusting		Vioxx 25-50 Mg Daily	PS		ORAL	DAILY ORAL	
Hospitalization -	Hordeolum		Bextra	SS		ORAL	DAILY ORAL	
Initial or Prolonged	Impetigo							
Required Intervention to Prevent Permanent Impairment/Damage	Pulmonary Embolism							

Date:03/01/05ISR Number: 4593949-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY	
Hospitalization -	Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY	
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY	
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY	
	Disturbance In Attention		Lorazepam	C			UNKNOWN	
	Diverticulitis		Amoxicillin	C			UNKNOWN	
	Dizziness		Hydrocodone Bitartrate	C			UNKNOWN	
	Emotional Distress							
	Gastrooesophageal Reflux		Viagra	C			UNKNOWN	
	Disease		Chlorhexidine Hydrochloride	C			UNKNOWN	
	General Physical							
	Condition Abnormal							
	Hypertension							
	Iliac Artery Thrombosis							
	Impaired Healing							
	Irritability							

Keloid Scar
Myocardial Infarction
Pain
Pneumonia
Rash Pruritic
Self Esteem Decreased
Sexual Dysfunction
Vascular Injury

Date:03/01/05ISR Number: 4593957-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00024
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiac Arrest
	Cardio-Respiratory Arrest
	Coma
	Dilatation Atrial
	Face Oedema
	Gastrooesophageal Reflux
	Disease
	Hypertension
	Mitral Valve Incompetence
	Otitis Media Chronic
	Pulmonary Hypertension
	Sleep Apnoea Syndrome
	Sudden Death
	Tendonitis
	Tricuspid Valve

Incompetence
Ventricular Hypertrophy
Vomiting
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Atacand	C			UNKNOWN	
	Ziac	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Tums	C			UNKNOWN	

Date:03/01/05ISR Number: 4593961-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00050869
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Hydrodiuril	C			UNKNOWN	

Date:03/01/05ISR Number: 4593962-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrial Fibrillation		Dilacor Xr	C			UNKNOWN	
Initial or Prolonged	Atrial Flutter		Cozaar	C			UNKNOWN	
Other	Cardiac Failure		Aspirin	C			UNKNOWN	

	Congestive		Furosemide	C		
UNKNOWN						
	Coronary Artery Disease		Cordarone	C		
UNKNOWN						
	Cough		Lipitor	C		
UNKNOWN						
	Hypokalaemia					
	Myocardial Infarction					
	Oedema Peripheral					
	Osteoarthritis					
	Pain In Extremity					
	Pleural Effusion					
	Rhinitis Allergic					
	Thyroid Mass					

Date:03/01/05ISR Number: 4593966-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA01159
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Cardiac Disorder		Zestril	C		
UNKNOWN						
			Furosemide	C		
UNKNOWN						
			Lanoxin	C		
UNKNOWN						

Date:03/01/05ISR Number: 4593968-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA03139
Age:41 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT
Abdominal Pain Upper
Anxiety
Arthralgia
Asthenia
Asthma
Atherosclerosis
Biliary Neoplasm
Blood Cholesterol
Increased
Cardiomegaly
Carotid Artery Occlusion
Cerebrovascular Accident
Chest Pain
Concussion
Constipation
Contusion
Decreased Appetite
Depression
Drug Abuser
Dry Mouth
Dysgeusia
Dyslipidaemia
Dysphonia
Dyspnoea
Excoriation
Fall
Fatigue
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Headache
Hepatic Steatosis
Hot Flush
Hyperhidrosis
Hyperlipidaemia
Insomnia
Laceration
Macrocytosis
Malaise
Melaena
Microcytic Anaemia
Mitral Valve Incompetence
Muscle Spasms

Nausea
Neurogenic Bladder
Oedema Peripheral
Orthostatic Hypotension
Osteoporosis
Pain
Pain In Extremity
Pneumonia
Pulmonary Congestion
Skin Ulcer
Spinal Compression
Fracture
Suicidal Ideation
Tibia Fracture

Urinary Tract Infection
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Diflunisal	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Rebetol	C			UNKNOWN	
	Allegra	C			UNKNOWN	
	Soma	C		ORAL		
	Premarin	C			UNKNOWN	
	Darvocet-N	C			UNKNOWN	
	Accupril	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Estratest	C			UNKNOWN	
	Rebetron	C			UNKNOWN	3 DAY

Date:03/01/05ISR Number: 4593988-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Respiratory Failure
	Amnesia
	Angina Unstable
	Arthralgia
	Arthropod Bite
	Asthma
	Blood Pressure Increased
	Bronchitis
	Cardiomegaly
	Chronic Obstructive Pulmonary Disease

Clumsiness
Convulsion
Coronary Artery Disease
Coronary Artery Occlusion
Difficulty In Walking
Dizziness
Dysarthria
Dysphagia
Dysphonia
Dysuria
Encephalopathy
Fall
Foot Fracture
Fractured Coccyx
Gastrooesophageal Reflux
Disease
Haematuria
Head Injury
Headache
Hypertension
Hypertensive Crisis
Hypoaesthesia
Hypokalaemia
Hyponatraemia
Hypotension
Insomnia

		Joint Sprain					
		Malaise					
		Mental Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
		Mouth Cyst					
		Muscle Spasms					
		Muscle Twitching					
		Myalgia					
		Myocardial Infarction					
		Myoclonus					
		Nausea					
		Neck Pain					
		Neuropathy					
		Neuropathy Peripheral					
		Night Sweats					
		Orthostatic Hypotension					
		Osteoarthritis					
		Pain In Extremity					
		Palpitations					
		Paraesthesia					
		Renal Impairment					
		Respiratory Distress					
		Road Traffic Accident					
		Seborrhoeic Keratosis					
		Skeletal Injury					
		Skin Papilloma					
		Sleep Walking					
		Upper Respiratory Tract Infection					
		Urinary Incontinence					
		Urinary Tract Infection					
		Urticaria					

Date:03/01/05ISR Number: 4593994-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cerebrovascular Accident					
		Chronic Lymphocytic Leukaemia					

Dermatitis Contact
Diarrhoea
Eructation
Fatigue
Hot Flush
Hypercalcaemia
Lymphadenopathy
Neurodermatitis
Pollakiuria
Polyp
Rectal Haemorrhage
Restless Legs Syndrome
Tension Headache
Thyroid Neoplasm
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4593995-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03598
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Premarin	C		ORAL		
Disability	Arthropathy		Celexa	C		ORAL		
	Bronchitis		Lasix (Furosemide)	C		ORAL		
	Cataract		Lasix (Furosemide)	C		ORAL		
	Coronary Artery		Lotensin	C		ORAL		
	Atherosclerosis		Lotensin	C		ORAL		
	Dehydration		Norvasc	C		ORAL		
	Gastric Ulcer Haemorrhage		Norvasc	C		ORAL		
	Haematemesis		Xanax	C		ORAL		
	Joint Effusion		Vicoprofen	C			UNKNOWN	
	Myalgia		Quinine Sulfate	C			UNKNOWN	
	Myositis		Aspirin	C			UNKNOWN	
	Neck Pain							
	Oedema Peripheral							
	Osteoarthritis							
	Rotator Cuff Syndrome							

Date:03/01/05ISR Number: 4593996-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04096
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Liver Disorder		Premarin	C			UNKNOWN	
	Total Lung Capacity		Paroxetine	C			UNKNOWN	
	Decreased		Cyproheptadine Hydrochloride	C		ORAL		
			Famotidine	C		ORAL		
			Meclofenamate Sodium	C			UNKNOWN	

Date:03/01/05ISR Number: 4593998-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00392
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		925 DAY
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus		Alprazolam	C		ORAL		
	Dizziness		Potassium Bicarbonate And Potassium Citrate	C		ORAL		
	Fatigue		Spironolactone	C		ORAL		
	Feeling Abnormal		Zocor	C		ORAL		
	Hospitalisation							
	Hyperhidrosis							
	Hypertension							
	Oedema Peripheral							
	Syncope							

Date:03/01/05ISR Number: 4593999-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00891
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Disability	Accident At Home
Other	Accident At Work
	Adverse Event
	Anxiety

		Aortic Valve Incompetence					
		Asthenia					
		Cardiac Murmur	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Clumsiness		Vioxx	SS	Merck & Co., Inc	ORAL
		Cognitive Disorder		Neurontin	C		
UNKNOWN							
		Contusion		Ibuprofen	C		
UNKNOWN							
		Deafness Bilateral		Claritin	C		
UNKNOWN							
		Depression		Premarin	C		
UNKNOWN							
		Disturbance In Attention		Cephalexin	C		
UNKNOWN							
		Drug Effect Decreased		Skelaxin	C		
UNKNOWN							
		Dyspepsia		Trazodone			
		Dyspnoea		Hydrochloride	C		
UNKNOWN							
		Dysthymic Disorder		Zovirax	C		
UNKNOWN							
		Face Injury		Methylprednisolone	C		
UNKNOWN							
		Fall		Propoxyphene			
		Fatigue		Hydrochloride	C		
UNKNOWN							
		Foot Fracture		Naproxen	C		
UNKNOWN							
		Gastrooesophageal Reflux		Baclofen	C		ORAL
		Disease					
		General Symptom					
		Headache					
		Hypertension					
		Hypoaesthesia					
		Increased Tendency To					
		Bruise					
		Injury					
		Intervertebral Disc					
		Protrusion					
		Irritability					
		Joint Injury					
		Memory Impairment					
		Mitral Valve Incompetence					

Myofascial Pain Syndrome
Nasal Congestion
Neck Pain
Osteoma
Pain
Pain In Extremity
Paraesthesia
Peripheral Nerve Injury
Pruritus
Sleep Disorder
Spinal Column Stenosis
Stress
Temporomandibular Joint
Syndrome
Thrombosis
Tinnitus
Transient Ischaemic
Attack
Tremor
Tricuspid Valve
Incompetence
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594018-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03789
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective							
	Silent Myocardial							
	Infarction							
	Stomach Discomfort							

Date:03/01/05ISR Number: 4594019-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03557
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Chronic Granulomatous		Promethazine	C				
UNKNOWN								
Disability	Disease		Estratest	C				
UNKNOWN								
	Chronic Obstructive		Nystatin	C				
UNKNOWN								
	Pulmonary Disease		Endocet	C				
UNKNOWN								
	Gastrooesophageal Reflux		Zocor	C				
UNKNOWN								
	Disease							

Date:03/01/05ISR Number: 4594021-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00539
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594022-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02746
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Plaquenil	C				
UNKNOWN								
	Dizziness							
	Feeling Abnormal							
	Hypothyroidism							
	Malaise							
	Pallor							
	Pneumonia							

Date:03/01/05ISR Number: 4594029-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Alanine Aminotransferase Increased
	Alcohol Use
	Angina Unstable
	Blood Cholesterol

		Increased Blood Pressure Increased Burning Sensation Chest Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Conjunctival Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Atenolol	C		
UNKNOWN							
		Coronary Artery Stenosis		Norvasc	C		
UNKNOWN							
		Dilatation Ventricular Drug Intolerance Ejection Fraction Decreased Fatigue Hyperlipidaemia Iliac Artery Stenosis Intermittent Claudication Low Density Lipoprotein Increased Memory Impairment Mitral Valve Incompetence Myocardial Infarction Neuropathy Paraesthesia Peripheral Vascular Disorder Pharyngitis Polydipsia Refusal Of Treatment By Patient Shock Spinal Disorder Upper Respiratory Tract Infection Ventricular Hypokinesia Weight Increased					

Date:03/01/05ISR Number: 4594030-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03382
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure Anaemia Aortic Valve Sclerosis

Bradycardia
Carotid Artery Stenosis
Cerebral Ischaemia
Cerebrovascular Accident
Contusion
Depression
Diarrhoea
Echocardiogram Abnormal
Fall
Haemorrhoidal Haemorrhage
Hyperlipidaemia
Hypertension
Hypothyroidism
Major Depression
Melaena
Mitral Valve Incompetence
Oedema Peripheral
Peptic Ulcer

		Rectal Haemorrhage					
		Refractory Anaemia					
		Subclavian Steal Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
67	DAY						
		Tremor		Plavix	C		
UNKNOWN							
		Tricuspid Valve		Tenormin	C		
UNKNOWN							
		Incompetence		Norvasc	C		
UNKNOWN							
		Upper Gastrointestinal		Zantac	C		
UNKNOWN							
		Haemorrhage		Lexapro	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:03/01/05ISR Number: 4594032-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02004
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure					
	Osteoarthritis					

Date:03/01/05ISR Number: 4594034-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03265
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Furosemide	C		
UNKNOWN						
Disability			Hydroxyzine			
			Hydrochloride	C		
UNKNOWN						
			Meclizine			

	Hydrochloride	C		
UNKNOWN				
	Lescol	C		
UNKNOWN				
	Cosopt	C		
OPHTHALMIC				
	Norvasc	C		ORAL
	Aspirin	C		ORAL
	Plavix	C		
UNKNOWN				
	Alphagan	C		
UNKNOWN				

Date:03/01/05ISR Number: 4594035-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00059
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	
UNKNOWN 2 YR						
Life-Threatening	Brain Hypoxia		Pindolol	SS		ORAL
Hospitalization -	Cardiac Arrest		Tamsulosin			
Initial or Prolonged	Coma		Hydrochloride	SS		ORAL
	Electroencephalogram		Glimepiride	C		ORAL
	Abnormal		Metformin	C		ORAL
	General Physical Health					
	Deterioration					
	Lung Infection					
	Pseudomonal					
	Neurological Examination					
	Abnormal					
	Nosocomial Infection					
	Sepsis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594036-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Unstable		Zoloft	C			UNKNOWN	
	Arthropathy		Lopressor	C			UNKNOWN	
	Atherosclerosis		Prilosec	C			UNKNOWN	
	Blood Pressure Increased		Aspirin	C			UNKNOWN	
	Cardiac Stress Test		Hytrin	C			UNKNOWN	
	Abnormal		Librium	C			UNKNOWN	
	Cerebral Ischaemia		Lipitor	C			UNKNOWN	
	Cerebrovascular Accident		Nitrostat	C			UNKNOWN	
	Chest Discomfort		Altace	C			UNKNOWN	
	Chest Pain							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Dizziness							
	Dyspnoea							
	Fatigue							
	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nausea							
	Nystagmus							
	Oedema Peripheral							
	Osteoarthritis							
	Palpitations							
	Procedural Complication							
	Vertigo							

Date:03/01/05ISR Number: 4594039-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0502CHE00024
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594040-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00068
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Erysipelas		Fendiline Hydrochloride	C				
Disability	Headache							
UNKNOWN	Macular Degeneration		Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C				
	Necrotising Fasciitis							
	Retinal Tear							
	Retinal Vascular							
UNKNOWN	Thrombosis							
	Retinal Vein Occlusion							
	Retinal Vein Thrombosis							
	Skin Graft							
	Thrombosis							
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594043-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02508
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	5	YR
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C			UNKNOWN	

Date:03/01/05ISR Number: 4594044-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04380
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Aortic Stenosis
	Aortic Valve Incompetence
	Arthralgia
	Back Injury
	Back Pain
	Blood Calcium Increased
	Blood Pressure Increased
	Cerebrovascular Accident
	Contusion
	Depression
	Dilatation Atrial
	Diverticulum
	Dyspepsia
	Gastrointestinal
	Haemorrhage
	Headache
	Herpes Zoster
	Hiatus Hernia
	Hypocoagulable State
	Insomnia
	Intervertebral Disc
	Degeneration
	Intervertebral Disc
	Protrusion

Iron Deficiency Anaemia
Kyphosis
Ligament Sprain
Mental Status Changes
Mitral Valve Incompetence
Mitral Valve Stenosis
Muscle Spasms
Muscle Strain
Myofascial Pain Syndrome
Neuralgia
Osteitis
Osteoarthritis
Osteopenia
Pathological Fracture
Post Herpetic Neuralgia
Sciatica
Sedation
Spinal Osteoarthritis
Spondylolisthesis
Transient Ischaemic

	Attack Tricuspid Valve Incompetence Vaginal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	

Date:03/01/05ISR Number: 4594052-6Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00053
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			Aspirin	C		ORAL	
			Folic Acid	C		ORAL	
			Glimepiride	C		ORAL	
			Aspirin Calcium	C		ORAL	
			Atenolol	C		ORAL	
			Acenocoumarol	C		ORAL	
			Pantoprazole Sodium	C		ORAL	

Date:03/01/05ISR Number: 4594053-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02403
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON
Initial or Prolonged	Arterial Occlusive		Glucophage	C			UNKNOWN
	Disease		Glucotrol Xl	C			UNKNOWN
	Band Neutrophil		Actos	C			UNKNOWN
	Percentage Increased		Precose	C			UNKNOWN

	Blood Culture Positive	Cozaar	C
UNKNOWN			
	Blood Glucose Increased	Lipitor	C
UNKNOWN			
	Chest Discomfort	Ecotrin	C
UNKNOWN			
	Chest Pain	Lopressor	C
UNKNOWN			
	Crepitations	Humulin 70/30	C
UNKNOWN			
	Dyspnoea	Xanax	C
UNKNOWN			
	Escherichia Infection	Pepcid Ac	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	Haematocrit Decreased		
	Haemoglobin Decreased		
	Lymphocyte Percentage Decreased		
	Nausea		
	Pitting Oedema		
	Pyelonephritis		

Date:03/01/05ISR Number: 4594055-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594057-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Operation Discomfort Stress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594058-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02412
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594059-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Blood Potassium Decreased Blood Sodium Decreased Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

Date:03/01/05ISR Number: 4594060-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02409
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Cardiac Disorder Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594066-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594067-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02426
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594068-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02540
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability			Amaryl	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594069-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01358
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - Initial or Prolonged Disability	Arthritis Infective Arthropathy Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON

Date:03/01/05ISR Number: 4594072-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lovastatin	SS				
UNKNOWN								

Date:03/01/05ISR Number: 4594073-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02454
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Operation Feeling Abnormal Heart Valve Replacement		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594074-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03171
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/01/05ISR Number: 4594075-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594081-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Celebrex	C				
UNKNOWN								

Date:03/01/05ISR Number: 4594083-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594084-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	38	MON

Date:03/01/05ISR Number: 4594086-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02471
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594087-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02450
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		[Therapy					
Disability	Arthralgia		Unspecified]	C				
UNKNOWN								
Other	Back Pain							
	Blood Cholesterol							
	Abnormal							
	Bronchitis Chronic							
	Cardiac Disorder							
	Cholecystectomy							
	Depression							
	Diabetes Mellitus							
	Disability							
	Drug Ineffective							
	Dyskinesia							
	Foot Fracture							
	Gallbladder Disorder							
	Hypertension							
	Lower Limb Fracture							
	Muscle Spasms							
	Myocardial Infarction							
	Neck Pain							
	Pain							

Parkinson'S Disease
Poor Peripheral
Circulation
Restless Legs Syndrome
Sleep Apnoea Syndrome
Stress Fracture
Thyroid Disorder
Thyroidectomy Partial
Transient Ischaemic
Attack
Tremor

Date:03/01/05ISR Number: 4594090-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594095-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594099-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03172
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594101-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:03/01/05ISR Number: 4594109-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02820
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Relafen	C				
UNKNOWN								

Date:03/01/05ISR Number: 4594111-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/01/05ISR Number: 4594112-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02757
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Plavix	C				
UNKNOWN								
			Altace	C				
UNKNOWN								
			Vytorin	C		ORAL		
			Toprol Xl Tablets	C				
UNKNOWN								
			Zocor	C		ORAL		

Date:03/01/05ISR Number: 4594115-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594120-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03189
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Obstructive Airways Disorder		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
				C				
UNKNOWN								
			Nexium	C				
UNKNOWN								

Date:03/01/05ISR Number: 4594121-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02778
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nephrolithiasis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:03/01/05ISR Number: 4594122-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	36	MON
	Arrhythmia							
	Bacteraemia							
	Coronary Artery Thrombosis							
	Fistula							
	International Normalised Ratio Abnormal							
	Staphylococcal Bacteraemia							
	Staphylococcal Infection							

Date:03/01/05ISR Number: 4594124-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03186
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction							

Date:03/01/05ISR Number: 4594125-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594127-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03243
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4594129-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4594130-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03229
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Other								

Date:03/01/05ISR Number: 4595073-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		
89 DAY								
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
DAY								
	Dysphagia		Humulin N	C				
UNKNOWN								
	Dyspnoea Exertional		Humulin R	C				
UNKNOWN								
	Emotional Distress		Naproxen	C		ORAL		
	Gastrooesophageal Reflux		Naproxen	C		ORAL		
	Disease		Livostin	C				
OPHTHALMIC								
	Hypoaesthesia		Prevacid	C		ORAL		
	Hypotension		Vasotec	C				
UNKNOWN								
	Insomnia							
	Ischaemic Stroke							
	Muscle Spasms							
	Nasopharyngitis							
	Nephropathy							

Neuropathy Peripheral
Oedema Peripheral
Pain In Extremity
Pollakiuria
Spinal Column Stenosis
Upper Respiratory Tract
Infection
Vitreous Haemorrhage

Date:03/01/05ISR Number: 4595085-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00636
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		479 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Condition Aggravated		Isosorbide Dinitrate	C				UNKNOWN
	Meniscus Lesion		Allopurinol	C				UNKNOWN
	Thrombosis		Furosemide	C				UNKNOWN
			Magnesium Aspartate	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Atorvastatin Calcium	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4595086-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00392
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		925 DAY
Disability	Arrhythmia		Alprazolam	C		ORAL		
	Diabetes Mellitus		Potassium Bicarbonate And Potassium Citrate	C		ORAL		
	Dizziness		Spironolactone	C		ORAL		
	Fatigue		Zocor	C		ORAL		
	Feeling Abnormal							
	Hyperhidrosis							
	Hypertension							
	Oedema Peripheral							
	Polyarthritis							
	Syncope							

Date:03/01/05ISR Number: 4595088-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02895
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		33 DAY
	Gastric Infection		Trazodone Hydrochloride	C				UNKNOWN
	Myocardial Infarction		Ibuprofen	C		ORAL		1140 DAY
	Skin Discolouration		Paxil	C		ORAL		219 DAY
			Xanax	C		ORAL		376 DAY
			Albuterol	C				RESPIRATORY (INHALATION) 1499 DAY

Date:03/01/05ISR Number: 4595089-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00052
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bacteriuria		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Alkaline Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Lactate Dehydrogenase Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Body Temperature Decreased		Fosamax	C		ORAL		
	Calcinosis		Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
	Carotid Artery Atheroma							
	Cerebral Infarction							
	Kyphosis							
	Osteoporosis							
	Patella Fracture							
	Pyuria							
	Supraventricular Extrasystoles							
	Supraventricular Tachycardia							
	Treatment Noncompliance							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4595090-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02748
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dyspnoea Exertional		Celebrex	C				
UNKNOWN								
Initial or Prolonged	Feeling Hot And Cold		[Therapy					
Disability	Mass		Unspecified]	C				
UNKNOWN								
	Myocardial Infarction		Lipitor	C				
UNKNOWN								
	Overdose							
	Rash							

Date:03/01/05ISR Number: 4595093-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00154
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								
Disability								

Date:03/01/05ISR Number: 4595094-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	225	DAY
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL	41	DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	225	DAY

	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
41 DAY						
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
	Pyrexia		Formoterol Fumarate	C		
UNKNOWN						
	Respiratory Disorder		Bisoprolol Fumarate	C		
UNKNOWN						
			Fenoterol Hydrobromide And Ipratropium Bromide	C		
UNKNOWN						
			Enalapril Maleate	C		
UNKNOWN						
			Atorvastatin Calcium	C		
UNKNOWN						
			Tamsulosin Hydrochloride	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Beclomethasone Dipropionate	C		
UNKNOWN						

Date:03/01/05ISR Number: 4595102-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03253
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Peripheral Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
			Norvasc	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/01/05ISR Number: 4595104-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00185
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident Epilepsy Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4595108-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02753
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/01/05ISR Number: 4595154-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01583
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Chest Pain Hypoaesthesia		Vioxx Inderal	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:03/01/05ISR Number: 4598830-9Report Type:Expedited (15-DaCompany Report #2005022892
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Accidental Overdose Drug Ineffective Feeling Abnormal Quadruple Vessel Bypass	Consumer	Celebrex (Celecoxib) Bextra (Valdecoxib)	PS SS		ORAL ORAL	10 MG (10 MG,	

Graft
1 IN 1 D),

ORAL

Rofecoxib	SS
Warfarin (Warfarin)	C
Acetylsalicylic Acid(Acetylsalicylic Acid)	C
Pantoprazole (Pantoprazole)	C
Metoprolol (Metoprolol)	C
Atorvastatin (Atorvastatin)	C
Isosorbide Dinitrate (Isosorbide Dinitrate)	C

Date:03/02/05ISR Number: 4596283-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00645
Age:56 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angiopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Synthroid	C		ORAL		
	Atelectasis		Methotrexate	C		ORAL		
	Back Pain		Prednisone	C		ORAL		
	Carotid Artery Stenosis		Nexium	C		ORAL		
	Cerebrovascular Accident		Aspirin	C		ORAL		
	Compression Fracture							
	Constipation							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Emotional Distress							
	Fatigue							
	Hypertension							
	Intervertebral Disc							
	Degeneration							
	Left Ventricular							
	End-Diastolic Pressure							
	Increased							
	Myocardial Infarction							
	Osteoarthritis							
	Pain In Extremity							
	Sleep Disorder							
	Subclavian Artery							
	Stenosis							
	Therapy Non-Responder							
	Urinary Tract Infection							
	Ventricular Dysfunction							
	Ventricular Hypokinesia							

Date:03/02/05ISR Number: 4596291-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00174
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		98 MON
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		

	Pelvic Fracture		Fosamax	C			ORAL
	Prescribed Overdose		Dipyrone	C			ORAL
	Tachycardia						

Date:03/02/05ISR Number: 4596301-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00094
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/05ISR Number: 4596302-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4596306-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/02/05ISR Number: 4596308-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00003
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL	199	DAY
Hospitalization -	Muscle Spasms		[Therapy Unspecified]	C				
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
UNKNOWN								

Date:03/02/05ISR Number: 4596312-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02827
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged			Lenoxin	C				
UNKNOWN								
UNKNOWN			Synthroid	C				

Lipitor	C	UNKNOWN
Avandamet	C	UNKNOWN
Prevacid	C	UNKNOWN
Coumadin	C	UNKNOWN
Avapro	C	UNKNOWN

Date:03/02/05ISR Number: 4596313-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4596318-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4596319-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/05ISR Number: 4596553-3Report Type:Expedited (15-DaCompany Report #PHRM2005FR00683
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Arrhythmia		Visken (Pindolol)	PS	Novartis Sector:	
Life-Threatening	Bronchopneumonia				Pharma	ORAL
Hospitalization -	Cardiac Arrest		Omix	SS		ORAL
Initial or Prolonged	Cerebral Disorder		Amarel	SS		ORAL
Other	Coma		Vioxx	SS		ORAL
	General Physical Health		Metformine	SS		ORAL
	Deterioration					
	Lung Disorder					
	Neurological Examination					
	Abnormal					
	Nosocomial Infection					
	Pseudomonal Sepsis					
	Pseudomonas Infection					
	Tracheostomy					

Date:03/02/05ISR Number: 4597068-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia
	Arthropathy
	Back Pain
	Benign Prostatic
	Hyperplasia
	Bundle Branch Block Right
	Cardiac Failure
	Congestive
	Chest Pain
	Conduction Disorder
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery
	Restenosis
	Depression
	Diabetes Mellitus
	Inadequate Control

Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinopathy
Drug Ineffective
Dyspepsia
Fall
Hepatitis
Herpes Zoster
Hypercholesterolaemia
Hypotension
Infection
Injury
Intervertebral Disc
Disorder
Ischaemic Cardiomyopathy

		Myocardial Infarction					
		Oedema Peripheral					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Sepsis		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Sexual Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Ventricular Extrasystoles		Zestril	C		
UNKNOWN		2170 DAY					
		Ventricular Tachycardia		Zestril	C		
UNKNOWN		2170 DAY					
		Weight Increased		Tenormin	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Micronase	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN		1051 DAY					
				[Therapy Unspecified]	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							

Date:03/02/05ISR Number: 4597077-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Angina Pectoris
	Anxiety
	Aspiration
	Atherosclerosis
	Atrial Fibrillation
	Back Pain

Blood Cholesterol
Increased
Blood Triglycerides
Increased
Bradycardia
Cardio-Respiratory Arrest
Chest Pain
Coma
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Dysthymic Disorder
Emotional Distress
Feeling Of Despair
Gastritis
Haematemesis
Headache
Hypertension
Intervertebral Disc
Protrusion
Lethargy
Low Density Lipoprotein
Decreased
Lumbar Radiculopathy
Mental Impairment
Myocardial Infarction
Prothrombin Time
Shortened
Stress

		Tricuspid Valve Incompetence					
		Upper Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
297	DAY						
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
297	DAY						
		Ventricular Hypertrophy		Aspirin	SS		
UNKNOWN							
				Plavix	SS		
UNKNOWN		1	YR				
				Heparin	SS		
INTRAVENOUS							
				Monopril	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN		339	DAY				
				Celebrex	C		
UNKNOWN							

Date:03/02/05ISR Number: 4597085-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Alanine Aminotransferase		Atenolol	C		
UNKNOWN						
	Increased		Norvasc	C		
UNKNOWN						
	Angina Pectoris					

Bradycardia
Conjunctival Haemorrhage
Coronary Artery Disease
Coronary Artery Stenosis
Dilatation Ventricular
Fatigue
Hyperlipidaemia
Hypotension
Iliac Artery Stenosis
Intermittent Claudication
Memory Impairment
Myocardial Infarction
Myocardial Ischaemia
Neuropathy
Peripheral Vascular
Disorder
Pharyngitis
Polydipsia
Rhythm Idioventricular
Shock
Upper Respiratory Tract
Infection
Ventricular Tachycardia
Weight Increased

Date:03/02/05ISR Number: 4597087-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02571
Age:71 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	145	DAY
Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	145	DAY
		Acupril	C			UNKNOWN	
		Hydrochlorothiazide	C			UNKNOWN	
		Potassium (Unspecified)	C			UNKNOWN	
		Allegra	C			UNKNOWN	
		Celebrex	C			UNKNOWN	

Date:03/02/05ISR Number: 4597089-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -			Synthroid	C			UNKNOWN	
Initial or Prolonged Disability			[Therapy Unspecified]	C			UNKNOWN	
			Keppra	C			UNKNOWN	
			Depakote	C			UNKNOWN	
			Aricept	C			UNKNOWN	
			Zyprexa	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Diuretic (Unspecified)	C			UNKNOWN	

Date:03/02/05ISR Number: 4597091-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02789
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							

Date:03/02/05ISR Number: 4597093-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Oxybutynin Chloride	C		ORAL		
	Myocardial Infarction		Amantadine Sulfate	C		ORAL		
			Levocarnitine Tartrate	C				
			Sodium Lauryl Sulfoacetate	C				

Date:03/02/05ISR Number: 4597094-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00730
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Complete		Lipitor	C				
Initial or Prolonged	Cardiac Disorder		Proscar	C				
Other	Heart Rate Decreased		Hytrin	C				
	Loss Of Consciousness		Plavix	C				

			Prevacid	C			
UNKNOWN							

Date:03/02/05ISR Number: 4597095-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00027
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Cerebral Infarction		Mirtazapine	C				
UNKNOWN								
			Budesonide	C				
UNKNOWN								

Date:03/02/05ISR Number: 4597097-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00014
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Second Degree		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Blood Creatinine Decreased		Fluoxetine Hydrochloride	C				
UNKNOWN								
	Myocardial Infarction		Pravastatin Sodium	C				
UNKNOWN								
	Sensation Of Heaviness							

Date:03/02/05ISR Number: 4597101-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Epididymitis		Aspirin	C		ORAL		
Disability	Vertigo		Diclofenac	C				
UNKNOWN								
Other								

Date:03/02/05ISR Number: 4597110-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03355
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Lisinopril	C		ORAL		

Date:03/02/05ISR Number: 4597111-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4597113-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/05ISR Number: 4597114-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02795
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Balance Disorder		Mobic	C				
Initial or Prolonged UNKNOWN	Haemorrhage		Glucophage	C				
Disability								

Date:03/02/05ISR Number: 4597116-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03285
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:03/02/05ISR Number: 4597117-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03485
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Systemic Lupus Erythematosus		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4597119-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00088
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4597120-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4597121-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/02/05ISR Number: 4597123-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00085
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/05ISR Number: 4597158-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0412CAN00137
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death		Metformin	C				UNKNOWN
Initial or Prolonged	Myocardial Infarction		Aspirin	C				UNKNOWN
	Osteoarthritis		Metoprolol	C				UNKNOWN
	Thrombocytopenia		Nifedipine	C				UNKNOWN
			Nitroglycerin	C				UNKNOWN
			Acetaminophen	C				UNKNOWN
			Gliclazide	C				UNKNOWN

Date:03/03/05ISR Number: 4597445-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00062
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:03/03/05ISR Number: 4597446-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00131
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Omeprazole	C				UNKNOWN

Date:03/03/05ISR Number: 4597447-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00138
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597448-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02741
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Ejection Fraction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Coumadin	C				
UNKNOWN								
	Nausea		Neurontin	C				
UNKNOWN								
	Silent Myocardial Infarction		Zocor	C		ORAL		
	Ventricular Extrasystoles		Fish Oil (Unspecified)	C				
UNKNOWN								

Date:03/03/05ISR Number: 4597449-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00646
Age: Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	357	DAY
Cardiac Disorder		Prevacid	C			UNKNOWN	
Cardiac Murmur		Plavix	C			UNKNOWN	
Coronary Artery Occlusion		Aspirin	C			UNKNOWN	
Myocardial Infarction							

Date:03/03/05ISR Number: 4597450-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00648
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Actinic Keratosis
	Acute Myocardial Infarction
	Anxiety
	Aortic Valve Sclerosis
	Arthralgia
	Aspartate Aminotransferase Increased
	Atherosclerosis
	Basal Cell Carcinoma
	Blood Creatine Phosphokinase Increased
	Blood Creatine Phosphokinase Mb Increased
	Blood Lactate Dehydrogenase Increased
	Blood Pressure Increased
	Cardiac Failure
	Chest Discomfort
	Chest Pain
	Conjunctivitis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis

Dermatitis
Dyspepsia
Ejection Fraction
Decreased
Electrocardiogram St
Segment Elevation
Electrocardiogram T Wave
Amplitude Increased
Eustachian Tube
Dysfunction
Excoriation
Fibrous Histiocytoma
Foreign Body Trauma
Gastritis
Gastrooesophageal Reflux
Disease
Hydrocele
Intracardiac Thrombus
Lacrimation Increased
Muscle Spasms

		Myocardial Ischaemia					
		Oedema Peripheral					
		Pigmented Naevus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polycythaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Prostatic Specific		Vioxx	SS	Merck & Co., Inc	ORAL
		Antigen Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Qrs Axis Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Red Blood Cell Count		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Scrotal Disorder					
		Skin Laceration					
		Sleep Apnoea Syndrome					
		Squamous Cell Carcinoma					
		Of Skin					
		Stent Placement					
		Swelling					
		Thrombocytopenia					
		Tinnitus					
		Tricuspid Valve					
		Incompetence					
		Troponin Increased					
		Ventricular Dysfunction					
		Ventricular Dyskinesia					
		Ventricular Hypertrophy					
		Weight Decreased					

Date:03/03/05ISR Number: 4597451-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03492
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/03/05ISR Number: 4597453-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03176
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/03/05ISR Number: 4597454-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02987
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Lipitor	C				
UNKNOWN								
Initial or Prolonged			Atenolol	C				
UNKNOWN								
			Protonix	C				
UNKNOWN								
			Celexa	C				
UNKNOWN								

Date:03/03/05ISR Number: 4597455-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02602
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Multiple Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		[Therapy					
	Attack		Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597457-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03310
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prednisone	C				
			Synthroid	C			UNKNOWN	

Date:03/03/05ISR Number: 4597458-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Ejection Fraction Decreased							
	Myocardial Infarction							

Date:03/03/05ISR Number: 4597460-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Intracranial Aneurysm		Insulin Lispro	C				
Other			Levothyroxine Sodium	C			UNKNOWN	
			Escitalopram Oxalate	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	
			Diazepam	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Glimepiride	C			UNKNOWN	
			Amitriptyline					

	Hydrochloride	C	UNKNOWN
	Insulin Glargine	C	UNKNOWN
	Clopidogrel Bisulfate	C	UNKNOWN
	Lisinopril	C	UNKNOWN
	Aspirin	C	UNKNOWN
	Dextroamphetamine Sulfate	C	UNKNOWN

Date:03/03/05ISR Number: 4597461-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03488
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597462-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597463-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03244
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bowel Movement Irregularity							
	Chest Pain							
	Constipation							
	Dyspnoea							
	Oedema							
	Oedema Peripheral							
	Swelling							

Date:03/03/05ISR Number: 4597464-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03496
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597465-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/03/05ISR Number: 4597466-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/03/05ISR Number: 4597467-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597472-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597473-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597474-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03497
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597476-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction Renal Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597478-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03174
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597479-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00002
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	540 DAY	
Hospitalization - Initial or Prolonged	Myocardial Infarction		Diazepam	C		ORAL		
			Zopiclone	C		ORAL		
			Acetaminophen	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:03/03/05ISR Number: 4597539-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03494
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597745-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02543
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Cardiomegaly
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis
	Dementia Alzheimer'S Type
	Depression
	Diabetic Foot Infection
	Diplopia
	Dizziness

		Emotional Distress					
		Eyelid Ptosis					
		Haematuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Ingrowing Nail		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Glucophage	C		
UNKNOWN							
		Intervertebral Disc		Zocor	C		ORAL
		Degeneration		Arthrotec	C		
UNKNOWN							
		Limb Discomfort		Avandia	C		
UNKNOWN							
		Mitral Valve Incompetence		Glynase Prestab			
		Muscle Spasms		Tablets	C		
UNKNOWN							
		Musculoskeletal Stiffness		Darvocet-N	C		
UNKNOWN							
		Myalgia					
		Neuropathy					
		Osteoarthritis					
		Psychomotor Hyperactivity					
		Rash					
		Sinobronchitis					
		Somnolence					
		Syncope					
		Systemic Lupus					
		Erythematosus					
		Upper Respiratory Tract					
		Infection					
		Vertigo					
		Vision Blurred					

Date:03/03/05ISR Number: 4597757-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02378
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anorexia
	Anxiety
	Atrioventricular Block
	First Degree
	Bradycardia
	Cardiac Failure

Congestive
Chest Pain
Coronary Artery
Atherosclerosis
Cystitis
Diarrhoea
Dilatation Atrial
Dysarthria
Dyspepsia
Dyspnoea
Emotional Distress
Erosive Oesophagitis
Faeces Discoloured
Gastritis
Gastrointestinal Ulcer
Haematochezia
Haemorrhoids
Headache
Hemiparesis
Hyperlipidaemia
Hypertension

		Nasopharyngitis					
		Nausea					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Otitis Media		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		[Therapy			
		Urinary Tract Infection		Unspecified]	C		
UNKNOWN							
		Vomiting		Valium	C		
UNKNOWN							
		Weight Decreased		Paxil	C		
UNKNOWN							
		Weight Increased		Nexium	C		
UNKNOWN							

Date:03/03/05ISR Number: 4597766-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:87 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Bruit
Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Acute Coronary Syndrome
	Angina Pectoris
	Aortic Bruit
	Aortic Valve Incompetence
	Appendix Disorder
	Arthralgia
	Atherosclerosis
	Blood Pressure Increased
	Bronchitis
	Carotid Artery Occlusion
	Carpal Tunnel Syndrome
	Cataract
	Cerebrovascular Accident
	Cerumen Impaction
	Constipation
	Convulsion
	Coronary Artery Disease
	Cough
	Cystitis Haemorrhagic
	Depressed Mood
	Dilatation Atrial
	Diverticulum

Drug Hypersensitivity
Dyslipidaemia
Ear Pain
Emotional Distress
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux
Disease
Granuloma
Haematuria
Headache
Hepatic Cyst
Hernia
Hypercholesterolaemia
Hyperhomocysteinaemia
Hyperkalaemia
Hypokalaemia
Infection
Injury
Intervertebral Disc

		Degeneration					
		Kidney Small					
		Lung Disorder					
		Metaplasia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia					
		Neck Injury					
		Nervous System Disorder					
		Osteoarthritis					
		Osteoporosis					
		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pulmonary Congestion					
		Renal Artery Stenosis					
		Renal Failure					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sciatica					
		Shoulder Operation					
		Skin Lesion					
		Spinal Osteoarthritis					
		Tachycardia					
		Tinnitus					
		Toe Deformity					
		Tonsillar Disorder					
		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					
		Uterine Disorder					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:03/03/05ISR Number: 4597774-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00655
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
		Helicobacter Gastritis					

Date:03/03/05ISR Number: 4597775-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01406
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Hyperplasia							
Other	Blood Cholesterol Increased							
	Cerebrovascular Accident							
	Hepatic Cyst							
	Hypertension							
	Pulmonary Granuloma							
	Transient Ischaemic Attack							
	Ureteric Stenosis							
	Urinary Retention							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597777-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	112 DAY	
	Angina Pectoris		Propranolol Hydrochloride	C			UNKNOWN	
	Anxiety							
	Aortic Stenosis		Darvocet-N	C			UNKNOWN	
	Appetite Disorder							
	Arthralgia							
	Cardiac Disorder							
	Cardiac Murmur							
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Disease							
	Depression							
	Dyspepsia							
	Dyspnoea							
	Fatigue							
	Femoral Arterial Stenosis							
	Gastric Disorder							
	Gastrooesophageal Reflux Disease							
	Insomnia							
	Intermittent Claudication							
	Liver Function Test Abnormal							
	Mitral Valve Stenosis							
	Myocardial Infarction							
	Paralysis							
	Peripheral Vascular Disorder							
	Rectal Haemorrhage							
	Thrombosis							
	Weight Fluctuation							

Date:03/03/05ISR Number: 4597780-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial

Initial or Prolonged	Infarction
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Back Pain
	Chest Pain
	Coronary Artery
	Atherosclerosis
	Cough
	Depression
	Dupuytren'S Contracture
	Dyslipidaemia
	Dysphagia
	Dyspnoea
	Erectile Dysfunction
	Fatigue
	Hypoaesthesia
	Impulse-Control Disorder
	Pain In Extremity

	Premature Ejaculation						
	Pulmonary Congestion						
	Purulent Discharge	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	106 DAY
	Restless Legs Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	363 DAY
	Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL	106 DAY
	Rhonchi		Vioxx	SS	Merck & Co., Inc	ORAL	363 DAY
	Self-Injurious Ideation		Zantac	C			UNKNOWN
	Sinus Disorder		Celexa	C			UNKNOWN
	Sleep Apnoea Syndrome		Albuterol	C			RESPIRATORY
	Spinal Column Stenosis						(INHALATION)
	Spinal Osteoarthritis		Vicodin Tablets	C		ORAL	
	Upper Respiratory Tract Infection						
	Weight Increased						
	Wheezing						

Date:03/03/05ISR Number: 4597788-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03617
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Back Pain		Cozaar	C		ORAL	
	Hypoaesthesia		Atenolol	C			UNKNOWN
	Tachycardia		Baclofen	C			UNKNOWN

Date:03/03/05ISR Number: 4597789-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03654
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
			Vioxx	SS	Merck & Co., Inc	ORAL
1 YR						

Date:03/03/05ISR Number: 4597791-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02833
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Eyelid Sensory Disorder		Synthroid	C		
UNKNOWN						
	Palpitations					

Date:03/03/05ISR Number: 4597793-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00145
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatic Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL
	Hepatic Failure					

Date:03/03/05ISR Number: 4597794-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01434
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Disability	Blindness
Other	Blood Pressure Abnormal
	Cerebrovascular Accident
	Eye Disorder

		Eye Haemorrhage Vitreous Floaters					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/03/05ISR Number: 4597795-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02824
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Feeling Abnormal		Theo-Dur	C		
UNKNOWN						
	Headache		Lasix (Furosemide)	C		
UNKNOWN						
	Prescribed Overdose		Potassium Chloride	C		
UNKNOWN						
	Vomiting		Zoloft	C		
UNKNOWN						
			Estrogens (Unspecified)	C		
UNKNOWN						

Date:03/03/05ISR Number: 4597797-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00214
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
	Aortic Valve Incompetence		Sotalol Hydrochloride	SS		
	Cardiac Disorder					
UNKNOWN						
	Fluid Retention		Ibuprofen	C		
UNKNOWN						
	Hypotension		Trimipramine	C		
UNKNOWN						
	Intestinal Haemorrhage		Indomethacin	C		
UNKNOWN						
	Refusal Of Treatment By Patient					
	Respiratory Tract					

Infection
Sleep Apnoea Syndrome
Supraventricular
Extrasystoles
Weight Increased

Date:03/03/05ISR Number: 4597801-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03573
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Diovan	C			UNKNOWN	

Date:03/03/05ISR Number: 4597803-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02952
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Other	Arthritis
	Cardiomegaly
	Condition Aggravated
	Dyspnoea
	Electrocardiogram T Wave Abnormal

		Gastrointestinal Haemorrhage Myocardial Ischaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
222	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
264	DAY						

Date:03/03/05ISR Number: 4597804-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00458
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Chest Pain		Glucotrol	C		
Initial or Prolonged Disability	Dyspnoea Musculoskeletal Disorder Pain In Extremity					

Date:03/03/05ISR Number: 4597805-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00048
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident Death Of Spouse Impaired Work Ability					

Date:03/03/05ISR Number: 4597806-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02599
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Death		[Therapy			
Hospitalization -			Unspecified]	C		
UNKNOWN						
Initial or Prolonged						
Disability						

Date:03/03/05ISR Number: 4597808-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Pulmonary Embolism		Metoprolol Tartrate	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						

Date:03/03/05ISR Number: 4597810-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03094
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			[Therapy			
Disability			Unspecified]	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597811-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02821
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Cardiac Valve Disease Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597812-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03602
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Nexium	C				
UNKNOWN								
Initial or Prolonged	Nausea		Allegra	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Hyzaar	C		ORAL		
			Lipitor	C				
UNKNOWN								

Date:03/03/05ISR Number: 4597813-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03099
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage							

Date:03/03/05ISR Number: 4597814-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597815-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Coumadin	C				
UNKNOWN								

Date:03/03/05ISR Number: 4597817-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00277
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Cerebrovascular Accident							

Date:03/03/05ISR Number: 4597818-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/03/05ISR Number: 4597820-XReport Type:Expedited (15-DaCompany Report #CZ-MERCK-0503CZE00001
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597822-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597824-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597826-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4597829-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00134
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/03/05ISR Number: 4599935-9Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00444
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased	Foreign Study	Vioxx	PS		ORAL	50 MG/DAILY/PO	
Disability	Cardiac Failure Congestive	Health Professional Other	Acetaminophen	C				
			Amitriptyline Hydrochloride	C				
			Bromazepam	C				
			Captopril	C				
			Celecoxib	C				
			Hydrochlorothiazide	C				
			Leflunomide	C				
			Omeprazole	C				

Date:03/03/05ISR Number: 4600002-6Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00095
Age:72 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Colon Cancer	Foreign	Vioxx					
	Myocardial Ischaemia	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
		Health						
		Professional	Aspirin	C			PO	337 DAY
		Other	Atenolol	C				
			Gliclazide	C				
			Nitroglycerin	C				
			Simvastatin	C				

Date:03/03/05ISR Number: 4600122-6Report Type:Expedited (15-DaCompany Report #2005CG00384
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia	Foreign	Zestoretic	PS			20 + 12.5 MG	
Initial or Prolonged	Atherosclerosis	Health					QD	
	Carotid Artery Stenosis	Professional	Vioxx	SS				
	Cerebral Atherosclerosis	Other	Kardegic	C				
	Cerebral Ischaemia							
	Difficulty In Walking							
	Dysarthria							
	Essential Hypertension							
	Facial Palsy							
	Malaise							
	Motor Dysfunction							
	Tongue Paralysis							
	Vertebrobasilar Insufficiency							

Date:03/04/05ISR Number: 4598545-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01094
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adjustment Disorder
	Adverse Event

Anaemia
Anxiety
Atherosclerosis
Back Pain
Barrett'S Oesophagus
Cardiovascular Disorder
Cystocele
Cystourethrocele
Depression
Fatigue
Feeling Drunk
Haemangioma
Headache
Hepatitis
Hypertension
Incontinence
Liver Disorder
Nausea
Osteoporosis
Pain In Extremity
Pelvic Prolapse
Polymyalgia Rheumatica

		Polyneuropathy					
		Rectocele					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis Seasonal		Vioxx	PS	Merck & Co., Inc	ORAL
984	DAY						
		Sinusitis		Acetaminophen And			
		Somnolence		Hydrocodone			
		Stress Incontinence		Bitartrate	C		
UNKNOWN							
		Tongue Disorder		Wellbutrin	C		ORAL
		Tremor		Valium	C		ORAL
		Ultrasound Abdomen		Estradiol	C		ORAL
		Abnormal		Remeron	C		ORAL
		Vaginitis Atrophic		Lotensin	C		
UNKNOWN							
		Weight Increased		Effexor Xr	C		ORAL
				Prilosec	C		
UNKNOWN							
				Atacand	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Diazepam	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Paxil Cr	C		ORAL
				Paxil Cr	C		ORAL

Date:03/04/05ISR Number: 4598552-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00096
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
1127	DAY						
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
1127	DAY						
Disability		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
1127	DAY						
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
1127	DAY						

	Arthropathy	Viagra	C
UNKNOWN			
	Blood Cholesterol	Amoxicillin	C
UNKNOWN			
	Increased	Plavix	C
UNKNOWN			
	Bursitis	Ambien	C
UNKNOWN			
	Chest Discomfort	Trazodone Hydrochloride	C
	Coronary Artery Disease		
UNKNOWN			
	Coronary Artery Stenosis	Ibuprofen	C
UNKNOWN			
	Depression	Zanaflex	C
UNKNOWN			
	Dizziness	Altace	C
UNKNOWN			
	Dyspepsia	Diazepam	C
UNKNOWN			
	Erectile Dysfunction	Hydrocodone Bitartrate	C
	Hypercholesterolaemia		
UNKNOWN			
	Hypertension	Hydrocodone Bitartrate	C
	Laceration		
UNKNOWN	14 MON		
	Mitral Valve Incompetence	Oxycontin	C
UNKNOWN	14 MON		
	Musculoskeletal Chest Pain		
	Peroneal Nerve Palsy		
	Pleuritic Pain		
	Sinus Bradycardia		
	Syncope		
	Tricuspid Valve Incompetence		
	Ventricular Dysfunction		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598558-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02029
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Anaemia		Lorcet Plus	C		ORAL		
Other	Anxiety		Ambien	C		ORAL		
	Arrhythmia							
	Arthralgia							
	Back Injury							
	Back Pain							
	Blood Urea Increased							
	Cardiac Murmur							
	Cerebrovascular Accident							
	Chest Pain							
	Cholesterol Granuloma							
	Chronic Fatigue Syndrome							
	Depression							
	Drug Dependence							
	Dyspnoea							
	Erythema							
	Haemolysis							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Hypoacusis							
	Hypoaesthesia							
	Insomnia							
	Intervertebral Disc Protrusion							
	Labile Hypertension							
	Mixed Hyperlipidaemia							
	Muscle Spasms							
	Nail Disorder							
	Nail Growth Cessation							
	Nausea							
	Neuritis							
	Oedema							
	Osteoarthritis							
	Pain							
	Post Procedural Complication							
	Pruritus							
	Radiculitis							
	Rhinitis Allergic							
	Rhinorrhoea							
	Spherocytic Anaemia							

Swelling
Tachycardia
Weight Increased

Date:03/04/05ISR Number: 4598565-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01745
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension Adenoidal Hypertrophy Angina Pectoris Blood Glucose Increased Blood Triglycerides Increased Chronic Sinusitis

		Depression					
		General Physical Health Deterioration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Otitis Media Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Disorder		Zyrtec	C		
UNKNOWN							
				Lotrel	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Clarinex	C		
UNKNOWN							
				Foltx	C		
UNKNOWN							
				Levaquin	C		
UNKNOWN							

Date:03/04/05ISR Number: 4598567-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00380
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other			Acetaminophen And Codeine Phosphate	C		ORAL
			Tramadol Hydrochloride	C		ORAL

Date:03/04/05ISR Number: 4598584-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00747
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chronic Obstructive		Lotrel	C				
UNKNOWN								
	Pulmonary Disease							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Stenosis							
	Dyspnoea							
	Electrocardiogram St							
	Segment Elevation							
	Hyperhidrosis							
	Troponin Increased							
	Ventricular Extrasystoles							

Date:03/04/05ISR Number: 4598600-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00889
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety Disorder
Initial or Prolonged	Cerebrovascular Accident
Disability	Depression
	Disorientation
	Fatigue
	Generalised Anxiety
	Disorder
	Injury

Memory Impairment

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Aspirin	C			UNKNOWN	
	Darvocet-N	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Ibuprofen	C			UNKNOWN	

Date:03/04/05ISR Number: 4598606-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00410
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
	Depression		[Therapy Unspecified]	C			UNKNOWN	
	Discomfort							
	Drug Ineffective		Tramadol Hydrochloride	C			UNKNOWN	
	Duodenitis							
	Gastritis		Dipyrone	C			UNKNOWN	
	Hyperhidrosis		Atorvastatin Calcium	C			UNKNOWN	
	Pain		Tetrazepam	C			UNKNOWN	
	Palpitations		Clorazepate Dipotassium	C			UNKNOWN	
	Reflux Oesophagitis							
	Tachycardia							
	Tremor							
	Visual Field Defect							

Date:03/04/05ISR Number: 4598610-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00212
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1385 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1385 DAY
Initial or Prolonged	Atrioventricular Block							
Disability	Complete							
	Coronary Artery Occlusion							
	Drug Ineffective							

Date:03/04/05ISR Number: 4598614-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03698
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization -	Asthenia
Initial or Prolonged	Atrial Fibrillation
Disability	Cardiac Failure
Other	Congestive
	Chest Pain
	Embolic Stroke
	Flank Pain
	Gastric Disorder
	Haemangioma
	Heart Injury
	Hemiparesis

		Hypoaesthesia Intervertebral Disc Protrusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Spinal Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
1289 DAY							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
1289 DAY							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Lanoxin	C		ORAL
				Lanoxin	C		ORAL
				Prinivil	C		ORAL
				Prinivil	C		ORAL
				Tricor	C		ORAL
				K-Dur	C		ORAL
				Neurontin	C		ORAL
				Coumadin	C		
UNKNOWN							
				Betapace	C		
UNKNOWN							
				Arava	C		ORAL
89 DAY							
				Nitrostat	C		
SUBLINGUAL							
				A.S.A.	C		
UNKNOWN							

Date:03/04/05ISR Number: 4598616-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00035
Age:80 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged		Atrial Fibrillation		Eprosartan	C		ORAL
		Atrioventricular Block Complete					
		Blood Creatinine Increased					
		Bradyarrhythmia					
		Hypertension					
		Myocardial Infarction					

Nausea

Date:03/04/05ISR Number: 4598619-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00172
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Oxycodone Hydrochloride	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:03/04/05ISR Number: 4598620-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00647
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amenorrhoea
	Anxiety
Other	Arrhythmia

		Arthropathy					
		Back Pain					
		Blood Glucose Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Breast Pain		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
5	YR						
		Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Bayer Enteric			
		Creatinine Renal		Aspirin	C		
UNKNOWN							
		Clearance Decreased		Tenormin	C		
UNKNOWN							
		Crying					
		Decreased Interest					
		Depression					
		Drug Ineffective					
		Drug Tolerance Decreased					
		Dysgraphia					
		Dyspepsia					
		Dyspnoea					
		Dyspnoea Exertional					
		Emotional Distress					
		Facial Paresis					
		Fatigue					
		Gastritis					
		Gastrooesophageal Reflux					
		Disease					
		Glucose Tolerance					
		Impaired					
		Hip Dysplasia					
		Hot Flush					
		Hyperparathyroidism					
		Hyperparathyroidism					
		Primary					
		Hypertension					
		Hypoaesthesia					
		Increased Appetite					
		Irritability					
		Mass					
		Menstruation Irregular					
		Metabolic Syndrome					
		Muscle Spasms					
		Muscular Weakness					
		Myoclonus					

Nausea
Neck Pain
Neoplasm
Nerve Compression
Obesity
Osteoarthritis
Pain In Extremity
Parathyroid Tumour Benign
Snoring
Stress
Tenderness
Thyroxine Free Increased
Transient Ischaemic
Attack
Treatment Noncompliance
Varicose Vein
Vertebrobasilar
Insufficiency
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598630-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON
Hospitalization - Initial or Prolonged	Haemorrhage		Hyzaar	C		ORAL	RESPIRATORY	
	Rectal Polyp		Combivent	C			(INHALATION)	
	Urinary Tract Infection							
			Coumadin	C			UNKNOWN	

Date:03/04/05ISR Number: 4598638-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02633
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged			Synthroid	C			UNKNOWN	
Disability			Furosemide	C			UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Protonix	C			UNKNOWN	

Date:03/04/05ISR Number: 4598639-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01109
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Disability		Vioxx	PS	Merck & Co., Inc	ORAL
6 YR						
Hospitalization -	Fall		Celebrex	C		
UNKNOWN						
Initial or Prolonged	Hypertension		Zestril	C		
UNKNOWN						
Disability			Zocor	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:03/04/05ISR Number: 4598641-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00407
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Lisinopril	C		ORAL
	Sleep Apnoea Syndrome		Carvedilol	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Isosorbide Dinitrate	C		ORAL
			Aspirin	C		ORAL
			Molsidomine	C		ORAL
			Phenprocoumon	C		
UNKNOWN						

Date:03/04/05ISR Number: 4598642-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged	Blood Sodium Decreased							
Disability	Dehydration							

Date:03/04/05ISR Number: 4598643-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02627
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Triglycerides Increased							
Disability	Cerebrovascular Accident							
Other	High Density Lipoprotein Increased							
	Low Density Lipoprotein Increased							

Date:03/04/05ISR Number: 4598644-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:03/04/05ISR Number: 4598645-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02841
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - Myocardial Infarction Lotrel C
UNKNOWN
Initial or Prolonged
Disability

Date:03/04/05ISR Number: 4598646-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03337
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598647-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598648-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598649-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598650-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00056
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
	Coma		[Therapy Unspecified]	C			UNKNOWN	

Date:03/04/05ISR Number: 4598651-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03460
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/04/05ISR Number: 4598652-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/04/05ISR Number: 4598653-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598654-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:03/04/05ISR Number: 4598655-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Disability	Myocardial Infarction							

Date:03/04/05ISR Number: 4598656-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							
	Ulcer Haemorrhage							

Date:03/04/05ISR Number: 4598658-XReport Type:Expedited (15-DaCompany Report #NL-MERCK-0503NLD00001
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		1185 DAY
Initial or Prolonged			Tramadol Hydrochloride	C		ORAL		

Date:03/04/05ISR Number: 4598659-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00022
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								
Other								

Date:03/04/05ISR Number: 4598661-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598662-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00007
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Electrocardiogram		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY
	Abnormal		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
			Acetaminophen	C		ORAL	8	DAY
			Hyzaar	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Acetaminophen And Codeine Phosphate	C		ORAL	8	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4598664-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00004
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Mesalamine	C				
			Acetaminophen	C			UNKNOWN	

Date:03/04/05ISR Number: 4598665-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00005
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Dyskinesia		Desloratadine	SS		ORAL	150	DAY
	Feeling Abnormal		Azithromycin	SS		ORAL	3	DAY
	Nausea		Oxcarbazepine	SS		ORAL	90	DAY

Date:03/04/05ISR Number: 4598667-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00194
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization -			Synthroid	C			UNKNOWN	
Initial or Prolonged			[Therapy					
Disability			Unspecified]	C			UNKNOWN	

Date:03/04/05ISR Number: 4598669-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00224
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Nitroglycerin	C				
UNKNOWN								
Disability			Synthroid	C				
UNKNOWN								

Date:03/04/05ISR Number: 4598670-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00147
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Hypertension							
Other								

Date:03/04/05ISR Number: 4598672-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4598673-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Anxiety
Disability	Arterial Restenosis

		Barrett'S Oesophagus					
		Blood Cholesterol Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Coagulopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Ulcer		Acetaminophen And Oxycodone Hydrochloride	C		
		Heart Rate Irregular					
		Hypotension					
UNKNOWN							
		International Normalised Ratio Increased		Avapro	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
		Myocardial Infarction					
		Pain					
		Palpitations					
		Prostatic Disorder					
		Thrombosis					
		Tongue Haemorrhage					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:03/04/05ISR Number: 4598687-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01328
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/04/05ISR Number: 4598985-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00005
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Pressure Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
			Candesartan			

	Dyspnoea Exertional	Cilexetil	C
UNKNOWN			
	Hypertension	[Therapy	
	Mitral Valve Incompetence	Unspecified]	C
UNKNOWN			
	Spinal Osteoarthritis	[Therapy	
		Unspecified]	C
UNKNOWN			
		[Therapy	
		Unspecified]	C
UNKNOWN			

Date:03/04/05ISR Number: 4598988-1Report Type:Expedited (15-DaCompany Report #US-MERCK-00010882
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Deafness Neurosensory		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY						
Disability	Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
	Tinnitus		Vioxx	SS	Merck & Co., Inc	ORAL
8 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
			Premarin	C		
UNKNOWN						

Date:03/04/05ISR Number: 4598991-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0206USA02437
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Abscess
Other	Abdominal Pain
	Abdominal Pain Upper
	Adenomyosis
	Amnesia
	Angina Pectoris
	Arthralgia
	Arthritis
	Asthenia
	Atrioventricular Block
	Back Pain
	Bronchitis
	Cardiac Valve Disease
	Cardiomyopathy
	Cellulitis
	Chest Pain
	Complex Regional Pain Syndrome
	Constipation
	Convulsion
	Costochondritis
	Dental Caries
	Dermatitis
	Diverticulitis
	Duodenal Ulcer
	Duodenitis
	Dyspnoea Exertional
	Encephalopathy
	Fatigue
	Gastritis
	Grand Mal Convulsion
	Haematoma Infection
	Haemorrhoids
	Helicobacter Gastritis
	Hypertension
	Hypertensive Crisis
	Hypokalaemia
	Hypotension
	Irritable Bowel Syndrome
	Joint Contracture
	Laceration
	Malignant Hypertension
	Melaena

Memory Impairment
Micturition Urgency
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema
Oedema Peripheral
Oesophagitis
Orthopnoea
Osteoarthritis
Pain In Extremity
Palpitations
Pelvic Inflammatory
Disease
Peptic Ulcer

		Pyrexia					
		Renal Failure					
		Salpingitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sensory Loss		Vioxx	PS	Merck & Co., Inc	ORAL
		Supraventricular		Vioxx	SS	Merck & Co., Inc	ORAL
		Tachycardia		Normodyne	C		
UNKNOWN							
		Upper Respiratory Tract		Prevacid	C		
UNKNOWN							
		Infection		Flagyl	C		
UNKNOWN							
		Vaginal Discharge		Minoxidil	C		
UNKNOWN							
		Vaginal Haemorrhage		Procardia Xl	C		
UNKNOWN							
		Vulvovaginal Discomfort		Cardura	C		
UNKNOWN							

Date:03/04/05ISR Number: 4599035-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Other	Anaemia
	Angle Closure Glaucoma
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Arthralgia
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cardiovascular Disorder
	Catheter Related
	Infection
	Cholelithiasis
	Dehydration
	Faeces Discoloured
	Haemodialysis
	Headache
	Hypertension
	Hypertensive Nephropathy
	Hypoaesthesia
	Injury
	Joint Effusion

Mitral Valve
Calcification
Mitral Valve Incompetence
Muscle Spasms
Myocardial Infarction
Nephrolithiasis
Nephrosclerosis
Oedema
Oedema Peripheral
Osteoarthritis
Pharyngolaryngeal Pain
Renal Artery
Atherosclerosis
Renal Artery Stenosis
Renal Failure Acute
Renal Failure Chronic
Renal Tubular Disorder
Staphylococcal Infection
Steal Syndrome
Transplant
Tricuspid Valve
Incompetence

		Ventricular Hypertrophy					
		Wound Infection					
		Staphylococcal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Tiazac	C		
UNKNOWN							
				Advil	C		
UNKNOWN							

Date:03/04/05ISR Number: 4599038-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00470
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acquired Oesophageal Web		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Angina Pectoris		Aspirin	C		
UNKNOWN							
		Anxiety		Pravachol	C		
UNKNOWN							
		Aortic Atherosclerosis		Ziac	C		
UNKNOWN							
		Blood Cholesterol		Nexium	C		
UNKNOWN							
		Increased		Claritin-D	C		
UNKNOWN							
		Blood Pressure Increased		Flonase	C		
UNKNOWN							
		Blood Triglycerides		Trazodone			
		Increased		Hydrochloride	C		
UNKNOWN							
		Cerebrovascular Accident		Vitamins			
		Chest Pain		(Unspecified)	C		
UNKNOWN							
		Chronic Fatigue Syndrome					

Coronary Artery
Atherosclerosis
Depression
Difficulty In Walking
Disturbance In Attention
Dyspnoea
Emotional Distress
Eye Haemorrhage
Fatigue
Gastric Disorder
Headache
Hiatus Hernia
Hypertension
Insomnia
Low Density Lipoprotein
Increased
Migraine
Myocardial Infarction
Nausea
Panic Disorder
Pneumonia
Sinus Disorder
Spinal Column Stenosis
Transient Ischaemic
Attack
Vertigo
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4599039-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00213
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Sulfasalazine	C		ORAL		
Initial or Prolonged	Prescribed Overdose							

Date:03/04/05ISR Number: 4599040-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00407
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Lisinopril	C		ORAL		
	Sleep Apnoea Syndrome		Carvedilol	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Isosorbide Dinitrate	C		ORAL		
			Aspirin	C		ORAL		
			Molsidomine	C		ORAL		
			Phenprocoumon	C				
UNKNOWN								

Date:03/04/05ISR Number: 4599041-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00274
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
							2	YR
Other	Increased							
	Alcoholism							
	Aspartate							
	Aminotransferase							
	Increased							
	Autoimmune Thyroiditis							
	Blood Alkaline							
	Phosphatase Increased							
	Cerebrovascular Accident							
	Depression							
	Gamma-Glutamyltransferase							

Increased
Hepatic Enzyme Increased
Hypothyroidism
Iron Deficiency
Psoriasis
Renal Failure

Date:03/04/05ISR Number: 4599042-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00447
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization -	Cardiac Disorder		Detrol La	C				
Initial or Prolonged	Dizziness		Aspirin	C				
	Dyspnoea		Prozac	C				
	Palpitations		Zonegran	C				
			Limbitrol Tablets	C				
			Protonix	C				
			[Therapy Unspecified]	C				
			Vicodin Tablets	C				

UNKNOWN	Benadryl	C
UNKNOWN	Phenergan (Promethazine Hydrochloride)	C
UNKNOWN	Lomotil	C
UNKNOWN	Oxycontin	C
UNKNOWN	Midrin	C

Date:03/04/05ISR Number: 4599043-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Lower
Hospitalization - Initial or Prolonged	Agitation
Other	Anaemia
	Anxiety
	Aortic Aneurysm
	Aortic Calcification
	Aortic Stenosis
	Arcus Lipoides
	Arthralgia
	Asthenia
	Asthma
	Atelectasis
	Atherosclerosis
	Atrial Fibrillation
	Atrial Pressure Increased
	Back Pain
	Blindness
	Blood Bicarbonate Increased
	Blood Blister
	Blood Potassium Increased
	Blood Pressure Systolic Increased
	Bradycardia
	Bronchitis
	Bronchospasm
	Calcinosis
	Cardiac Failure

Congestive
Cardiac Murmur
Cardiomegaly
Cardiomyopathy
Carpal Tunnel Syndrome
Chest Pain
Chronic Obstructive
Pulmonary Disease
Confusional State
Conjunctivitis Allergic
Constipation
Crepitations
Death
Difficulty In Walking
Disease Recurrence
Disorientation
Dizziness
Drug Hypersensitivity
Dyspepsia
Emotional Distress

		Glaucoma					
		Herpes Simplex					
		Herpes Virus Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Herpes Zoster		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Interstitial Lung Disease		Fosamax	C		
UNKNOWN							
		Intracardiac Thrombus		Percocet	C		
UNKNOWN							
		Labile Hypertension		Zestril	C		
UNKNOWN							
		Laryngitis		Zestril	C		
UNKNOWN							
		Loss Of Consciousness		Diltiazem			
		Mental Status Changes		Hydrochloride	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Musculoskeletal Disorder					
		Myocardial Infarction					
		Nasopharyngitis					
		Nausea					
		Neuropathy					
		Osteoarthritis					
		Osteoporosis					
		Overdose					
		Pain In Extremity					
		Paraesthesia					
		Pneumonia					
		Productive Cough					
		Pulmonary Fibrosis					
		Pulmonary Hypertension					
		Radiculopathy					
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Sputum Discoloured					
		Syncope					
		Tracheal Obstruction					
		Tricuspid Valve					
		Incompetence					
		Urinary Retention					
		Ventricular Hypertrophy					

Vomiting

Date:03/04/05ISR Number: 4599046-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/04/05ISR Number: 4599047-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01788
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/04/05ISR Number: 4599048-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0502CHE00024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599049-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	46	MON

Date:03/04/05ISR Number: 4599050-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/04/05ISR Number: 4599052-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599053-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03606
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Arterial Occlusive Disease Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599054-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599055-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Increased							
	Brain Damage							
	Myocardial Infarction							

Date:03/04/05ISR Number: 4599056-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4599058-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00003
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Sudden Death		Azathioprine	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	

Date:03/04/05ISR Number: 4599059-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03576
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diabetic Complication		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Head Injury		Vicodin Tablets	C			UNKNOWN	
Initial or Prolonged	Syncope		Glipizide	C			UNKNOWN	

Date:03/04/05ISR Number: 4599060-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03552
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	136	DAY
Hospitalization -			Lotrel	C			UNKNOWN	
Initial or Prolonged			Fluconazole	C			UNKNOWN	

Date:03/04/05ISR Number: 4599062-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02100
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599065-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03343
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599066-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03473
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/04/05ISR Number: 4599067-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03422
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening UNKNOWN Hospitalization - Initial or Prolonged Disability Other	Cardiac Arrest Chest Pain Coronary Artery Occlusion Myocardial Infarction		Vioxx Prilosec	PS C	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4599068-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599069-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00263
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599072-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00135
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1681 DAY	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Procardia	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								
			Ditropan	C				
UNKNOWN								

Date:03/04/05ISR Number: 4599073-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599074-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599075-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4599076-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599078-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/04/05ISR Number: 4599079-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00010
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1054	DAY

Date:03/04/05ISR Number: 4599080-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599081-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:03/04/05ISR Number: 4599084-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599085-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00375
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599086-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599087-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00369
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/04/05ISR Number: 4599088-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599089-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00372
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599090-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599093-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599094-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/04/05ISR Number: 4599647-1Report Type:Direct Company Report #CTU 242043
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Muscle Spasms Myocardial Infarction		Vioxx	PS				

Date:03/04/05ISR Number: 4599648-3Report Type:Direct Company Report #CTU 242047
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Inadequately Controlled Gastric Haemorrhage Stent Placement		Vioxx Tabs 12.5mg	PS			1 TAB TWICE DAILY/5 1/2 YERAS DIALYSIS	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/04/05ISR Number: 4600495-4Report Type:Expedited (15-DaCompany Report #2004110678
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)	PS			200 MG (100 MG, 2 IN 1 D)	
	Amnesia							
Other	Coronary Artery Occlusion		Rofecoxib (Rofecoxib)	SS				
	Cough							
	Fatigue							
	Foot Fracture							
	Incision Site Complication							
	Myocardial Infarction							
	Oedema Peripheral							
	Post Procedural Complication							

Date:03/04/05ISR Number: 4600515-7Report Type:Expedited (15-DaCompany Report #2004118129
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Ineffective	Consumer	Celebrex (Celecoxib)	PS				
	Inadequate Analgesia		Rofecoxib (Rofecoxib)	SS				
	Pain		Nsaid'S (Nsaid'S)	SS				
	Renal Failure		Gabapentin (Gabapentin)	C				
	Renal Impairment		Sertraline Hydrochloride (Sertraline Hydrochloride)	C				

Date:03/04/05ISR Number: 4601196-9Report Type:Expedited (15-DaCompany Report #2005024963
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib					

(Rofecoxib) SS

Date:03/07/05ISR Number: 4599888-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02106
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Adverse Event
	Angina Pectoris
	Angina Unstable
	Anxiety Disorder
	Arthralgia
	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Pressure Inadequately Controlled
	Cerebrovascular Accident
	Chronic Fatigue Syndrome
	Coronary Artery Disease

		Deep Vein Thrombosis					
		Depression					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea Exertional		Soma	C		
UNKNOWN							
		Emotional Distress		Atenolol	C		
UNKNOWN							
		Gout					
		High Density Lipoprotein					
		Decreased					
		Hypertension					
		Hypoaesthesia					
		Injection Site Induration					
		Injury					
		Insomnia					
		Joint Swelling					
		Lung Disorder					
		Lymphadenopathy					
		Mastoiditis					
		Myocardial Infarction					
		Pain In Extremity					
		Palpitations					
		Personality Disorder					
		Rectal Haemorrhage					
		Social Phobia					
		Varicose Vein					
		Vascular Pseudoaneurysm					

Date:03/07/05ISR Number: 4599898-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Back Pain
Initial or Prolonged	Bronchitis
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Constipation
	Dermatitis
	Dyspepsia
	Dyspnoea
	Eczema Infected
	Emotional Distress

Gastric Disorder
Gastritis
Goitre
Hemiparesis
Hyperlipidaemia
Hyperthyroidism
Nasopharyngitis
Nicotine Dependence
Oedema Peripheral
Pain In Extremity
Pharyngolaryngeal Pain
Pneumonia
Sinus Congestion
Sinusitis
Syncope
Thyroid Pain
Transient Ischaemic
Attack

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Motrin	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Benadryl	C			UNKNOWN	
	Correctol (Docusate Sodium (+) Phenolphthalein)	C			UNKNOWN	

Date:03/07/05ISR Number: 4599909-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acquired Oesophageal Web
Hospitalization - Initial or Prolonged	Anxiety
Other	Aptyalism
	Asthenia
	Atrial Flutter
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cerebral Haemorrhage
	Chest Pain
	Constipation
	Contusion
	Coronary Artery Disease
	Decreased Activity
	Decreased Appetite
	Dyspepsia
	Fall
	Gastric Ulcer
	Gastrooesophageal Reflux Disease
	Haematoma

Headache
Hiatus Hernia
Hypertensive Heart
Disease
Influenza
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Joint Injury
Lacunar Infarction
Myocardial Infarction
Myocardial Ischaemia
Nasal Sinus Drainage
Nausea
Neck Pain
Oedema Peripheral
Osteoarthritis
Pain

	Pneumonia						
	Pruritus						
	Renal Failure	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Subdural Haematoma		Coumadin	SS				UNKNOWN
	Tendonitis		Coumadin	SS				UNKNOWN
	Urinary Retention							

Date:03/07/05ISR Number: 4599925-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00045
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Artery Occlusion		Hyaluronic Acid	C				PARENTERAL
	Cerebral Infarction		Bisoprolol	C				UNKNOWN
	Coma							
	Monoparesis							
	Restlessness							
	Supraventricular							
	Tachycardia							

Date:03/07/05ISR Number: 4599928-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Pain							

Date:03/07/05ISR Number: 4599930-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
	Arterial Thrombosis			C				
UNKNOWN								
	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Femoral Arterial Stenosis							
	Intermittent Claudication							
	Low Density Lipoprotein Increased							
	Peripheral Embolism							

Date:03/07/05ISR Number: 4599932-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01728
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Convulsion
Disability	Depression
	Dizziness

	Headache						
	Hyperhidrosis						
	Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY
	Sleep Apnoea Syndrome		Ativan	C			UNKNOWN	
	Sleep Disorder		Aspirin	C			UNKNOWN	
	Spinal Osteoarthritis							
	Transient Ischaemic Attack							
	Urinary Incontinence							
	Vertigo Positional							
	Vomiting							

Date:03/07/05ISR Number: 4599934-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00536
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Altace	C			UNKNOWN	
Disability	Ejection Fraction		Bayer Aspirin	C			UNKNOWN	
	Decreased							
	Fatigue							
	Flank Pain							
	Gout							
	Haematuria							
	Haemorrhoids							
	Hyperlipidaemia							
	Myocardial Infarction							
	Nausea							
	Nephrolithiasis							
	Pain In Extremity							
	Pharyngitis							
	Pollakiuria							
	Upper Respiratory Tract Infection							

Date:03/07/05ISR Number: 4599936-0Report Type:Expedited (15-DaCompany Report #IL-MERCK-0503ISR00007
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hydrocephalus		Aspirin	C		ORAL		
Initial or Prolonged	Subarachnoid Haemorrhage		Aspirin	C		ORAL		
Disability								

Date:03/07/05ISR Number: 4599937-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00104
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Aortic Valve Incompetence
Hospitalization -	Cardiomyopathy
Initial or Prolonged	Colitis Ulcerative
Disability	Congestive Cardiomyopathy
	Coronary Artery Disease
	Coronary Artery Stenosis
	Diarrhoea Haemorrhagic
	Dizziness
	Dyspepsia

		Fatigue					
		Haemorrhoids					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Palpitations		Sulfasalazine	C		
UNKNOWN							
		Peripheral Coldness		Prednisolone	C		
UNKNOWN							
		Refusal Of Treatment By		Mesalamine	C		
UNKNOWN							
		Patient		Vitamin E	C		
UNKNOWN							
		Sinus Tachycardia					
		Tachycardia					
		Ventricular Hypertrophy					
		Vision Blurred					

Date:03/07/05ISR Number: 4599938-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01108
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Colitis Ulcerative		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/07/05ISR Number: 4599940-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01314
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Electrocardiogram		Vioxx	PS	Merck & Co., Inc	ORAL
		Abnormal		Tylenol	C		
UNKNOWN							
		Myocardial Infarction		Wellbutrin Sr	C		
UNKNOWN							

Date:03/07/05ISR Number: 4599946-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00779
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Circulatory Collapse							
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability	Ulcer Haemorrhage							
Other								

Date:03/07/05ISR Number: 4599952-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01945
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Conjunctivitis Infective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Diazepam	C			UNKNOWN	
			Telenzepine	C			UNKNOWN	
			Citalopram	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4599954-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00479
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4599955-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4599959-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00477
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Difficulty In Walking Hypotension		[Therapy Unspecified]	C				
UNKNOWN								
Disability	Lung Infection Myocardial Infarction		Analgesic Or Anesthetic (Unspecified)	C				
UNKNOWN								
			Darvocet-N	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

				[Therapy Unspecified]	C		
UNKNOWN							

Date:03/07/05ISR Number: 4599960-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00031
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	548	DAY
	Infarction		Celecoxib	SS		ORAL	84	DAY
			Doxazosin Mesylate	C		ORAL		
			Felodipine	C		ORAL		
			Folic Acid	C		ORAL		
			Methotrexate	C		ORAL		

Date:03/07/05ISR Number: 4600075-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00378
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Multi-Organ Disorder							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4600258-XReport Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0346839A
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain		Lamictal	PS	Glaxosmithkline	ORAL		
	Alanine Aminotransferase		Vioxx	SS		ORAL	1TAB per day	19 DAY
	Increased		Pariet	SS		ORAL	20MG per day	40 DAY
	Aspartate Aminotransferase		Paracetamol + Tramadol	SS		ORAL	1TAB Four times per day	31 DAY
	Increased							
	Asthenia		Art 50	SS		ORAL	50MG per day	
	Chromaturia		Zyprexa	C		ORAL	10MG per day	7 DAY
	Diarrhoea		Rivotril	C		ORAL	10DROP Per day	
	Lipase Increased							
	Nausea							
	Oedema							
	Pancreatitis Acute							
	Weight Decreased							
	Weight Increased							

Date:03/07/05ISR Number: 4600714-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1128 DAY
Initial or Prolonged	Acute Coronary Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		1128 DAY
Other	Acute Myocardial Infarction		Nortriptyline	C				UNKNOWN 233 DAY
	Arthralgia		Trazodone Hydrochloride	C				UNKNOWN
	Blindness		Vicodin Tablets	C				UNKNOWN

Blindness Unilateral
Chest Pain
Chest Wall Pain
Corneal Ulcer
Coronary Artery Occlusion
Coronary Artery
Restenosis
Cough
Diverticulum
Dyspepsia
Emotional Distress
Fatigue
Gastritis
Gastroduodenitis
Haematuria
Hyperlipidaemia
Hypertension
Myocardial Infarction
Nausea
Neck Pain
Nephrolithiasis
Pain
Vomiting

Date:03/07/05ISR Number: 4600723-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Anger					
		Angina Pectoris					
		Anxiety					
		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
106 DAY							
		Aspartate		Vioxx	SS	Merck & Co., Inc	ORAL
363 DAY							
		Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL
106 DAY							
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
363 DAY							
		Asthenia		Zantac	C		
UNKNOWN							
		Asthma		Celexa	C		
UNKNOWN							
		Atelectasis		Albuterol	C		
RESPIRATORY							
		Back Disorder					
(INHALATION)							
		Back Pain		Vicodin Tablets	C		ORAL
		Blood Urea Increased					
		Chest Pain					
		Coronary Artery					
		Atherosclerosis					
		Coronary Artery Stenosis					
		Cough					
		Depression					
		Difficulty In Walking					
		Dupuytren'S Contracture					
		Dyslipidaemia					
		Dyspepsia					
		Dysphagia					
		Dyspnoea					
		Erectile Dysfunction					
		Fatigue					
		Haemolysis					
		Hypoaesthesia					
		Impulse-Control Disorder					
		Myocardial Ischaemia					
		Pain In Extremity					
		Pleural Effusion					
		Premature Ejaculation					
		Productive Cough					
		Pulmonary Congestion					
		Purulent Discharge					
		Reperfusion Arrhythmia					

Respiratory Tract
Congestion
Restless Legs Syndrome
Rhinitis Allergic
Rhonchi
Self-Injurious Ideation
Sinus Disorder
Sleep Apnoea Syndrome
Sleep Disorder
Spinal Column Stenosis
Spinal Osteoarthritis
Tongue Disorder
Upper Respiratory Tract
Infection
Weight Increased
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4600730-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600732-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00556
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600737-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600740-5Report Type:Expedited (15-DaCompany Report #CZ-MERCK-0503CZE00001
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600743-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00275
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600745-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00307
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Belligerence		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diabetes Mellitus		Levoxyl	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Lexapro	C				
UNKNOWN								
Disability			Actonel	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Glucotrol	C				
UNKNOWN								

Date:03/07/05ISR Number: 4600746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4600748-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00308
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amitriptylin	C				
			Nexium	C				
			Flexeril	C				
			Pepcid	C				
			Claritin	C				
			Nasonex	C				
			Darvocet-N	C				

Date:03/07/05ISR Number: 4600749-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00568
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600751-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00567
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	662 DAY	

Date:03/07/05ISR Number: 4600752-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:03/07/05ISR Number: 4600753-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600755-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	610	DAY

Date:03/07/05ISR Number: 4600756-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00563
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	730	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4600758-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00565
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY

Date:03/07/05ISR Number: 4600760-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600762-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600763-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00648
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600765-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00646
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600767-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600768-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00644
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600770-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00572
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/07/05ISR Number: 4600771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600772-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600773-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00659
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600774-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600775-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00560
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600779-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4600799-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00559
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/07/05ISR Number: 4602551-3Report Type:Expedited (15-DaCompany Report #2005036480
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Bextra (Valdecoxib)	PS		ORAL	ORAL	
			Rofecoxib					

				(Rofecoxib)	SS		ORAL
ORAL							

Date:03/07/05ISR Number: 4603069-4Report Type:Expedited (15-DaCompany Report #2005-02-1687
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness	Foreign	Aerius					
	Dyskinesia	Health	(Desloratadine)	PS		ORAL	5 MG QD ORAL	
	Feeling Abnormal	Professional	Vioxx (Rofecoxib)	SS		ORAL	25 MG QD ORAL	
	Nausea	Other	Azithromycin	SS		ORAL	500 MG QD ORAL	
			Trileptal	SS		ORAL	300 MG BID ORAL	

Date:03/08/05ISR Number: 4601506-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03664
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4601507-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00001
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen	C			UNKNOWN	

Date:03/08/05ISR Number: 4601509-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04133
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Intervertebral Disc Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	C			UNKNOWN	
	Neck Injury							
	Nodule							
	Road Traffic Accident							

Date:03/08/05ISR Number: 4601510-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00003
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	221 MON	
	Sudden Death		Azathioprine	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	

Date:03/08/05ISR Number: 4601513-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00037
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4601514-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY

Date:03/08/05ISR Number: 4601515-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Anaemia Of Chronic
	Disease
	Angina Pectoris
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Atherosclerosis
	Back Pain
	Blood Erythropoietin
	Decreased
	Blood Pressure
	Inadequately Controlled
	Bronchitis
	Bursitis
	Cardiac Failure
	Congestive
	Cataract
	Cerebrovascular Accident
	Chest Pain
	Cholecystitis
	Condition Aggravated
	Confusional State
	Congestive Cardiomyopathy
	Constipation
	Cough
	Cyst
	Cystitis

Diabetes Mellitus
Inadequate Control
Diabetic Retinopathy
Diarrhoea
Diastolic Dysfunction
Dizziness
Drug Hypersensitivity
Drug Ineffective
Duodenitis
Dyslipidaemia
Dyspnoea Exertional
Dysstasia
Ecchymosis
Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Flatulence
Gastritis

		Glaucoma					
		Gout					
		Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hallucination, Visual		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Hypertensive Crisis		Diovan	C		
UNKNOWN							
		Hypertrophic		Methotrexate	C		
UNKNOWN							
		Cardiomyopathy		Prednisone	C		
UNKNOWN							
		Injury		Cozaar	C		ORAL
		Insomnia					
		Iron Deficiency Anaemia					
		Irritable Bowel Syndrome					
		Joint Effusion					
		Lactose Intolerance					
		Low Density Lipoprotein					
		Increased					
		Macular Degeneration					
		Malaise					
		Marrow Hyperplasia					
		Mitral Valve					
		Calcification					
		Mitral Valve Incompetence					
		Mouth Haemorrhage					
		Myalgia					
		Myocardial Infarction					
		Optic Disc Drusen					
		Pain					
		Pain In Extremity					
		Pelvic Prolapse					
		Pharyngolaryngeal Pain					
		Pitting Oedema					
		Pulmonary Oedema					
		Renal Failure					
		Renal Failure Chronic					
		Restless Legs Syndrome					
		Retinal Degeneration					
		Rheumatoid Arthritis					
		Salivary Gland Disorder					
		Spinal Osteoarthritis					
		Synovitis					
		Treatment Noncompliance					

Urinary Incontinence
Urinary Tract Infection
Ventricular Dysfunction
Vision Blurred
Weight Decreased
White Blood Cell Count
Increased

Date:03/08/05ISR Number: 4601521-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00258
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coma							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4601523-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00553
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4601524-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	913 DAY	
	Myocardial Infarction							
	Thrombosis							

Date:03/08/05ISR Number: 4601525-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/08/05ISR Number: 4601528-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00535
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	4 YR	
			Crestor	C			UNKNOWN	
			Glyburide	C			UNKNOWN	

Date:03/08/05ISR Number: 4601529-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4601531-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00058
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma Hepatic		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Jaundice Cholestatic		Vioxx	SS	Merck & Co., Inc	ORAL	7	DAY
			Dipyrone	C		ORAL		

Date:03/08/05ISR Number: 4601532-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4601533-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4601540-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00624
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602039-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00507
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Angina Pectoris Arrhythmia Bronchitis Acute		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident Coronary Artery Atherosclerosis Diabetes Mellitus Diabetic Neuropathy Diverticulum Eye Disorder Hyperuricaemia Influenza Like Illness Osteoarthritis Osteoporosis Post Thrombotic Syndrome Pulmonary Embolism Skin Ulcer Spinal Fracture Thrombophlebitis Superficial Toe Deformity							

Date:03/08/05ISR Number: 4602042-XReport Type:Expedited (15-DaCompany Report #US-MERCK-00090519
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acupril	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:03/08/05ISR Number: 4602050-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eyelid Ptosis		Trandolapril And Verapamil Hydrochloride	C				
	Procedural Complication							
	Swelling							
	Temporal Arteritis							
	Viith Nerve Injury							
	Visual Disturbance							

Date:03/08/05ISR Number: 4602052-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blue Toe Syndrome		[Therapy Unspecified]	C				

Date:03/08/05ISR Number: 4602054-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00764
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							
	Myocardial Infarction							

Date:03/08/05ISR Number: 4602055-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02920
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - UNKNOWN	Hypercalcaemia		Glucophage	C		
Initial or Prolonged	Hypertension		Lexapro	C		ORAL
Disability UNKNOWN	Rheumatoid Arthritis		Lexapro	C		
UNKNOWN	Vaginal Haemorrhage		Lexapro	C		
UNKNOWN			Alprazolam	C		
UNKNOWN			Premarin	C		
UNKNOWN			Ambien	C		
UNKNOWN			Nifedical Xl	C		
UNKNOWN			Lisinopril	C		
UNKNOWN			Lasix (Furosemide)	C		
UNKNOWN			Calcium (Unspecified)	C		

Date:03/08/05ISR Number: 4602064-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00027
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		448 DAY
Hospitalization -	Heart Rate Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		448 DAY
Initial or Prolonged			Allopurinol	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4602073-XReport Type:Expedited (15-DaCompany Report #DK-MERCK-0503DNK00004
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL		398 DAY
Initial or Prolonged Disability	Visual Acuity Reduced							

Date:03/08/05ISR Number: 4602074-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602075-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00025
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602076-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Cardiac Failure Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602079-0Report Type:Expedited (15-DaCompany Report #DK-MERCK-0503DNK00005
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								866 DAY
Initial or Prolonged	Difficulty In Walking		Acetaminophen	C				
UNKNOWN								1415 DAY
Disability	Dysphonia		Aspirin	C				
UNKNOWN								1601 DAY
	Gait Disturbance		Estradiol	C				
UNKNOWN								3333 DAY
	Headache		Ketobemidone	C				
UNKNOWN								241 DAY
	Vertigo		Flunitrazepam	C				
UNKNOWN								1453 DAY

Date:03/08/05ISR Number: 4602080-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:87 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Bruit
Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Lower
Other	Abdominal Pain Upper
	Acute Coronary Syndrome
	Angina Pectoris
	Aortic Valve
	Calcification
	Aortic Valve Incompetence
	Appendix Disorder
	Arthralgia
	Atelectasis

Atherosclerosis
Blood Pressure Increased
Bronchitis
Carotid Artery Occlusion
Carotid Artery Stenosis
Carpal Tunnel Syndrome
Cataract
Cerebrovascular Accident
Cerumen Impaction
Constipation
Convulsion
Coronary Artery Disease
Cough
Cystitis Haemorrhagic
Depressed Mood
Dilatation Atrial
Diverticulum
Drug Hypersensitivity
Dyslipidaemia
Ear Pain
Emotional Distress
Epigastric Discomfort
Fatigue
Feeling Abnormal
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux
Disease
Granuloma
Haematuria
Headache
Hepatic Cyst
Hernia
Hypercholesterolaemia
Hyperhomocysteinaemia
Hyperkalaemia
Hypertension
Hypertensive Heart
Disease
Hypoacusis
Hypoaesthesia Oral
Hypokalaemia
Infection
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc

Disorder
Kidney Small
Lipids Increased
Lung Disorder
Metaplasia
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Nausea
Neck Injury
Neck Pain
Nervous System Disorder
Osteoarthritis
Osteoporosis

		Pain In Extremity					
		Pharyngolaryngeal Pain					
		Pulmonary Congestion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Pain					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Scar					
		Sciatica					
		Scoliosis					
		Shoulder Operation					
		Skin Lesion					
		Spinal Osteoarthritis					
		Tachycardia					
		Tearfulness					
		Tinnitus					
		Toe Deformity					
		Tonsillar Disorder					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					
		Uterine Disorder					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Visual Disturbance					

Date:03/08/05ISR Number: 4602088-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00033
Age:38 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
609 DAY							

Date:03/08/05ISR Number: 4602090-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00043
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602091-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00130
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Enalapril Maleate	C		ORAL		
	Thrombosis		Glyburide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4602092-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00195
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602094-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00337
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		[Therapy					
Disability	Headache		Unspecified]	C				
UNKNOWN								
Other	Syncope							

Date:03/08/05ISR Number: 4602096-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00234
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602098-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602099-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00336
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
2 YR						
Disability	Difficulty In Walking		Prevacid	C		
UNKNOWN						
	Vertigo		Atenolol Msd	C		
UNKNOWN						
			Miacalcin	C		
UNKNOWN						
			Fosamax	C		
UNKNOWN						
			Celexa	C		
UNKNOWN						

Date:03/08/05ISR Number: 4602100-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
	Polytraumatism					

Date:03/08/05ISR Number: 4602101-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					
	Polytraumatism					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4602102-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602106-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00233
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602114-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Myocardial Infarction Peripheral Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602116-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00653
Age:52 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602118-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00514
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Lopressor	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								

Date:03/08/05ISR Number: 4602119-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602121-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4602123-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00393
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602124-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00385
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602127-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Murmur Echocardiogram Abnormal Heart Rate Irregular Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602129-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Other	Death		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR	

Date:03/08/05ISR Number: 4602130-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00389
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON

Date:03/08/05ISR Number: 4602131-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602134-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00605
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602135-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00671
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602137-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	121	DAY

Date:03/08/05ISR Number: 4602139-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602140-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00670
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602142-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602144-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602145-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00674
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1130 DAY
	Myocardial Infarction							
	Thrombosis							

Date:03/08/05ISR Number: 4602160-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602162-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00665
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/05ISR Number: 4602163-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00797
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/08/05ISR Number: 4602165-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4602185-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00034
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Interaction		Carbamazepine	SS		ORAL		
Other	Hypertensive Crisis							

Date:03/08/05ISR Number: 4602208-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00663
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/08/05ISR Number: 4603383-2Report Type:Expedited (15-DaCompany Report #2005-124819-NL
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy	Health	Mirtazapine	PS			15 MG QD	

	Back Disorder	Professional	Rofecoxib	SS	ORAL
1 DF BID					
	Back Pain				
	Circulatory Collapse				
	General Physical Health Deterioration				
	Insomnia				
	Pain In Extremity				
	Pneumonia				
	Pulmonary Embolism				
	Pulmonary Infarction				

Date:03/08/05ISR Number: 4603651-4Report Type:Direct Company Report #CTU 242286
Age:79 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx -25 Mg	PS		
1 TABLET						
Disability						
DAILY						

Date:03/08/05ISR Number: 4603665-4Report Type:Direct Company Report #CTU 242253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS		ORAL
25 MG PO QD 5 YR						
Initial or Prolonged	Hiatus Hernia		Tricor	C		

Welcol	C
Zantac	C
Hydrocodone/Apap	C
Alprazolam	C

Date:03/08/05ISR Number: 4603670-8Report Type:Direct Company Report #CTU 242280
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx, 25mg	PS		ORAL	25 MG, DAILY,	
Hospitalization -	Convulsion							
Initial or Prolonged	Myocardial Infarction							
Disability	Scar							

Date:03/08/05ISR Number: 4603787-8Report Type:Expedited (15-DaCompany Report #2005037997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol	Consumer	Celebrex (Celecoxib)	PS		ORAL		
Initial or Prolonged	Increased Malaise		Rofecoxib (Rofecoxib)	SS				

Date:03/08/05ISR Number: 4603841-0Report Type:Expedited (15-DaCompany Report #2005008465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Celebrex (Celecoxib)	PS			400 MG (200	
	Arthritis						MG, 2 IN 1 D)	
	Pain In Extremity		Rofecoxib (Rofecoxib)	SS				

Date:03/08/05ISR Number: 4611904-9Report Type:Periodic Company Report #2004UW25606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder	Consumer	Crestor	PS		
	Hypoaesthesia		Lipitor	SS		
	Myalgia		Pravachol	SS		
	Renal Cyst		Naprosyn	SS		
			Bextra	SS		
			Celebrex	SS		
			Vioxx	SS		
			Aleve	SS		

Date:03/09/05ISR Number: 4602743-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00751
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4602746-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00472
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deafness Neurosensory		Metoprolol	C		ORAL		
	Depression		Allopurinol	C		ORAL		
	Dizziness							
	Encephalopathy							
	Lacunar Infarction							
	Polyneuropathy							
	Retinopathy Hypertensive							
	Spinal Osteoarthritis							
	Tinnitus							

Date:03/09/05ISR Number: 4602747-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00087
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Infarction		Nitrendipine	C				
UNKNOWN								
Disability	Acute Prerenal Failure		Magnesium Aspartate					
	Cardiogenic Shock		And Magnesium					
	Cerebrovascular Accident		Citrate And					
	Intestinal Infarction		Magnesium Glutamate					
	Multi-Organ Failure		And Magnesium	C				
UNKNOWN								
	Peripheral Embolism		Amitriptyline					
	Tachyarrhythmia		Hydrochloride	C				
UNKNOWN								
			Tramadol					
			Hydrochloride	C				
UNKNOWN								
			Metoclopramide	C				
UNKNOWN								

Date:03/09/05ISR Number: 4602748-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01062655
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL		91 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetes Mellitus							
	Drug Ineffective							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Ischaemic Cardiomyopathy							
	Joint Range Of Motion Decreased							
	Musculoskeletal Stiffness							
	Myocardial Infarction							

Date:03/09/05ISR Number: 4602749-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00385
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Sudden Hearing Loss		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C		PARENTERAL		
			Hydrochlorothiazide And Ramipril Hydrochlorothiazide	C		ORAL		

				And Ramipril	C		ORAL
				Clonidine	C		
UNKNOWN							
				Aspirin	C		ORAL
				Metoprolol Succinate	C		ORAL
				Metoprolol Succinate	C		ORAL
				Atorvastatin Calcium	C		ORAL
				Clopidogrel Bisulfate	C		
UNKNOWN							
				Clopidogrel Bisulfate	C		ORAL

Date:03/09/05ISR Number: 4602750-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00938
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Amitriptyline Hydrochloride	C				
UNKNOWN	Angina Pectoris							
	Blood Pressure Increased							
	Convulsion							
	Coronary Artery Disease							
	Drug Ineffective							
	Gastrooesophageal Reflux Disease							
	Hypercholesterolaemia							
	Sleep Apnoea Syndrome							
	Somnolence							

Date:03/09/05ISR Number: 4602751-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04245
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							

Date:03/09/05ISR Number: 4602752-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0407DEU00163
Age:14 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Convulsion		Magnesium Aspartate	C		ORAL		
Other	Electrocardiogram Qt Prolonged		Potassium Chloride	C		ORAL		
	Hypoxia							
	Loss Of Consciousness							
	Nasopharyngitis							
	Prescribed Overdose							
	Shock							

Date:03/09/05ISR Number: 4602753-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00606
Age:72 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	95	DAY
	Atrial Flutter		Vioxx	SS	Merck & Co., Inc	ORAL	95	DAY
	Atrial Thrombosis							
	Cardiac Failure							
	Mitral Valve Prolapse							
	Pulmonary Oedema							

Date:03/09/05ISR Number: 4602757-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic							
	Attack							

Date:03/09/05ISR Number: 4602760-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia
Disability	Asthenia
	Benign Prostatic
	Hyperplasia
	Choking
	Cough
	Depression
	Diverticulum
	Dysgeusia
	Dyspepsia
	Dyspnoea
	Dysuria
	Early Satiety
	Erosive Duodenitis
	Erosive Oesophagitis
	Fatigue

Gastric Disorder
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Heat Stroke
Hiatus Hernia
Hypertension
Hypoacusis
Intestinal Functional
Disorder
Lung Disorder
Malaise
Muscle Atrophy
Nasopharyngitis
Oesophageal Rupture
Pancreatitis
Renal Cyst
Rhinorrhoea
Stomach Discomfort
Stress

		Supraventricular Extrasystoles					
		Thromboembolic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
		Upper Respiratory Tract Infection		Restoril	C		
UNKNOWN							
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:03/09/05ISR Number: 4602761-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03651
Age:65 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
Initial or Prolonged		Cerebrovascular Accident		Verapamil	SS		
UNKNOWN							
		Heart Rate Decreased		Atenolol	SS		
UNKNOWN							
		Hypotension		[Therapy			
		Myocardial Infarction		Unspecified]	SS		
UNKNOWN							
				Listerine Antiseptic	C		
UNKNOWN							

Date:03/09/05ISR Number: 4602762-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00604
Age:60 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged							

Date:03/09/05ISR Number: 4602763-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/09/05ISR Number: 4602766-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01612
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:03/09/05ISR Number: 4602769-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00595
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4602775-5Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908829
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Completed Suicide	Health	Ultracet	PS		OROPHARINGEAL	30g/3 g	
Hospitalization - Initial or Prolonged		Professional	Cyclobenzaprine	SS		OROPHARINGEAL		
			Amitriptyline	SS				
			Tizanidine	SS				
			Rofecoxib	SS				
			Omeprazole	SS				

Date:03/09/05ISR Number: 4602783-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602785-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00801
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/09/05ISR Number: 4602786-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		597 DAY

Date:03/09/05ISR Number: 4602787-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00798
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602788-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00573
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602789-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00596
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602790-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00851
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		454 DAY
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4602791-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00468
Age:90 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive		Monopril	C				
UNKNOWN								
Hospitalization -	Haemorrhage		[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								

Date:03/09/05ISR Number: 4602793-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
1174 DAY								
	Myocardial Infarction							
	Polytraumatism							

Date:03/09/05ISR Number: 4602794-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00852
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
	Myocardial Infarction							
	Polytraumatism							

Date:03/09/05ISR Number: 4602795-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
16 MON								
	Cerebrovascular Accident							

Date:03/09/05ISR Number: 4602796-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00856
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/09/05ISR Number: 4602797-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00855
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602798-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4602801-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4602804-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Myocardial Infarction							

Date:03/09/05ISR Number: 4602805-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00857
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	953	DAY
	Cerebrovascular Accident							
	Myocardial Infarction							
	Polytraumatism							

Date:03/09/05ISR Number: 4602842-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							
	Vertigo							

Date:03/09/05ISR Number: 4603338-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident At Work
Disability	Acquired Diaphragmatic Eventration
Other	Acute Respiratory Failure
	Angina Pectoris
	Atrial Fibrillation
	Basal Cell Carcinoma
	Bipolar Disorder
	Blood Pressure Increased
	Bundle Branch Block Right
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Electrocardiogram Change
	Electrocardiogram Qrs
	Complex Prolonged
	Haemoptysis
	Hypotension
	Hypoxic Encephalopathy
	Intervertebral Disc

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Protrusion Myocardial Infarction Nodal Rhythm Squamous Cell Carcinoma Of Skin		Vioxx	PS	Merck & Co., Inc	ORAL
536 DAY							
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
		Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
536 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Buspar	C		ORAL
405 DAY							
				Lortab	C		ORAL
573 DAY							
				Lortab	C		ORAL
				Ziac	C		ORAL
322 DAY							
				Vicodin Tablets	C		ORAL
				Lipitor	C		ORAL
				Valium	C		ORAL
214 DAY							
				Talwin	C		ORAL
24 DAY							
				Ultram	C		ORAL
9 DAY							
				Skelaxin	C		ORAL
14 DAY							
				Tenyl	C		
UNKNOWN		36 DAY					
				Claritin	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				Carisoprodol	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Hydrochloride	C		
UNKNOWN							
				Mobic	C		
UNKNOWN							

	Hydrocodone Hydrochloride	C
UNKNOWN		
	Altace	C
UNKNOWN		
	Toprol Xl Tablets	C
UNKNOWN		
	Aspirin	C
UNKNOWN		

Date:03/09/05ISR Number: 4603349-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00614
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Anaemia Vitamin B12 Deficiency
	Angina Pectoris
	Arthritis
	Asthenia
	Blood Potassium Decreased
	Blood Pressure Increased
	Bronchitis Acute
	Carotid Bruit
	Cerebrovascular Accident
	Claustrophobia
	Conjunctivitis
	Convulsion
	Coronary Artery Stenosis
	Dental Caries
	Diarrhoea
	Dizziness
	Dry Eye
	Dyspnoea Exertional
	Foot Fracture

		Gastrointestinal Haemorrhage					
		Goitre	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hydrocephalus		Prevacid	C		ORAL
		Hyperkeratosis		Premarin	C		ORAL
		Hypoaesthesia		Trental	C		ORAL
		Intermittent Claudication		Prednisone	C		ORAL
		Lobar Pneumonia		Aquaphor Ointment	C		
TOPICAL							
		Mammogram Abnormal					
		Mucosal Ulceration					
		Myocardial Infarction					
		Normal Pressure Hydrocephalus					
		Orthopnoea					
		Peptic Ulcer					
		Peripheral Vascular Disorder					
		Rash Macular					
		Skin Lesion					
		Urinary Tract Infection					
		Ventricular Dysfunction					
		Vision Blurred					
		Vulvovaginitis					
		Trichomonal					

Date:03/09/05ISR Number: 4603360-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Ceftin	C		ORAL
		Emotional Distress		Percocet	C		ORAL
		Hyperlipidaemia		Vicodin Es Tablets	C		ORAL
		Hypertension		Ambien	C		ORAL
		Mitral Valve Prolapse		Zoloft	C		ORAL
		Sleep Apnoea Syndrome		Zoloft	C		ORAL
		Thrombosis					
		Trigger Finger					

Date:03/09/05ISR Number: 4603369-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00348
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Diclofenac Resinate	SS		ORAL		
	Inguinal Hernia		Atenolol	C		ORAL		
	Neck Pain		Chlordiazepoxide Hydrochloride	C		ORAL		
	Osteoarthritis		Cyclandelate	C		ORAL		
	Paraesthesia		Levothyroxine Sodium	C		ORAL		
			Sumatriptan Succinate	C		ORAL		
			Dalteparin Sodium	C				

UNKNOWN

Pantoprazole Sodium C
UNKNOWN

Date:03/09/05ISR Number: 4603376-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00617
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Endocet	C				
Disability	Costochondritis		Smz-Tmp	C			UNKNOWN	
	Diabetes Mellitus		Augmentin	C			UNKNOWN	
	Inadequate Control		Hydrocodone/Apap	C			UNKNOWN	
	Dilatation Ventricular		Diazepam	C			UNKNOWN	
	Gastrooesophageal Reflux		Diflucan	C			UNKNOWN	
	Disease							
	Hyperlipidaemia							
	Hypertension							
	Injury							
	Insomnia							
	Left Ventricular Failure							
	Myocardial Infarction							
	Pleural Effusion							
	Respiratory Failure							

Date:03/09/05ISR Number: 4603380-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01953
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Wall Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess Neck		Vioxx	SS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Coronary Artery Disease							
	Dermal Cyst							

Gas Poisoning
Gastrooesophageal Reflux
Disease
Herpes Simplex
Hypercholesterolaemia
Hypertension
Intervertebral Disc
Degeneration
Muscle Injury
Palpitations
Periarthritis
Seborrhoeic Keratosis
Squamous Cell Carcinoma
Telangiectasia
Tenosynovitis
Ventricular Tachycardia

Date:03/09/05ISR Number: 4603381-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Arthropathy
	Back Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Bronchitis					
		Cardiomegaly					
		Cerebrovascular Accident					
		Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Chest Pain		Aspirin	C		
UNKNOWN							
		Cholelithiasis		Lipitor	C		
UNKNOWN							
		Coordination Abnormal		Metformin	C		
UNKNOWN							
		Drug Hypersensitivity		Prozac	C		
UNKNOWN							
		Fall		Prilosec	C		
UNKNOWN							
		Gastrooesophageal Reflux		Glucophage	C		
UNKNOWN							
		Disease		Wellbutrin	C		
UNKNOWN							
		Headache					
		Hiatus Hernia					
		Hypertension					
		Hypotension					
		Intention Tremor					
		Intervertebral Disc					
		Degeneration					
		Laryngitis					
		Non-Cardiac Chest Pain					
		Pneumonia					
		Respiratory Failure					
		Shock					
		Sinus Disorder					
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Vertigo					

Date:03/09/05ISR Number: 4603392-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603393-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03261
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Lipitor	C				
UNKNOWN								
Initial or Prolonged			Prevacid	C				
UNKNOWN								
Disability			Elavil	C				
UNKNOWN								
			Darvocet-N	C				
UNKNOWN								

Date:03/09/05ISR Number: 4603395-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00534
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthropathy
Initial or Prolonged	Cardiovascular Disorder
	Colonic Polyp
	Dizziness
	Gastritis
	Haemorrhoids

	Intestinal Haemorrhage						
	Joint Effusion						
	Palpitations	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Polyneuropathy Idiopathic		Vioxx	PS	Merck & Co., Inc	ORAL	
	Progressive		Aspirin	C			UNKNOWN
	Rectal Prolapse						
	Reflux Oesophagitis						
	Tachycardia						
	Tendonitis						

Date:03/09/05ISR Number: 4603400-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00045
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Congestive		Alendronate Sodium	C		ORAL	
	Hepatocellular Damage		Aluminum Hydroxide And Magnesium Carbonate	C		ORAL	
	Pyrexia		Acetaminophen And Propoxyphene Hydrochloride	C		ORAL	
			Omeprazole	C		ORAL	

Date:03/09/05ISR Number: 4603401-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/09/05ISR Number: 4603403-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00080
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	

Hospitalization - Initial or Prolonged Disability Other	Infarction Chest Pain Mallory-Weiss Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL

Date:03/09/05ISR Number: 4603404-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00584
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
Life-Threatening	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Hospitalization - Initial or Prolonged	Coma		Ramipril	C		ORAL		
	Fall		Pantoprazole Sodium	C				UNKNOWN
	Loss Of Consciousness		Furosemide Sodium	C				UNKNOWN
	Ventricular Fibrillation		Xipamide	C		ORAL		

Date:03/09/05ISR Number: 4603405-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Detrol	C		ORAL		
Other	Arthralgia		Sinemet	C		ORAL		
	Asthenia		Temazepam	C				
UNKNOWN								
	Cerebrovascular Accident		Alphagan	C				
OPHTHALMIC								
	Contusion		Nystatin	C		ORAL		
	Cough							
	Fall							
	Fungal Infection							
	Gastric Disorder							
	Gastrostomy Closure							
	Glaucoma							
	Oedema Peripheral							
	Orthostatic Hypotension							
	Pain In Extremity							
	Parkinson'S Disease							
	Pneumonia Klebsiella							
	Psoriasis							
	Rotator Cuff Syndrome							
	Seasonal Allergy							

Date:03/09/05ISR Number: 4603406-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							
	Polytraumatism							

Date:03/09/05ISR Number: 4603407-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Polytraumatism

Date:03/09/05ISR Number: 4603408-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00254
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603409-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00412
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Angina Pectoris Arrhythmia Atrial Fibrillation Chest Discomfort Dysphagia Dyspnoea

		Gastritis					
		Lymphoedema					
		Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nocturia		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema		Phenprocoumon	C		
UNKNOWN							
		Oedema Peripheral		Losartan Potassium	C		
UNKNOWN							
		Palpitations					
		Reflux Oesophagitis					
		Tachyarrhythmia					

Date:03/09/05ISR Number: 4603424-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00379
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Injury					
Disability		Myocardial Infarction					

Date:03/09/05ISR Number: 4603425-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00067
Age:49 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
22 MON							
Initial or Prolonged				[Therapy			
Disability				Unspecified]	C		
UNKNOWN							
Other							

Date:03/09/05ISR Number: 4603427-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03070
Age:46 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Accidental Death		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					

Myocardial Infarction
Thermal Burn

Date:03/09/05ISR Number: 4603428-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603429-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603434-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00588
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4603435-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00591
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603437-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00405
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603438-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	291	DAY

Date:03/09/05ISR Number: 4603439-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603440-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00622
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603441-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603442-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603443-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Limb Injury Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4603445-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00792
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603446-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00631
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603447-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603448-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00803
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	509 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	116 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	99 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	27 DAY	

Date:03/09/05ISR Number: 4603450-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00804
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603451-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/09/05ISR Number: 4603452-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603454-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4603455-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00807
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603456-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603457-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00813
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON

Date:03/09/05ISR Number: 4603458-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603459-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/09/05ISR Number: 4603460-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00850
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/09/05ISR Number: 4603461-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/09/05ISR Number: 4603463-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/09/05ISR Number: 4603467-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/09/05ISR Number: 4603468-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00808
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/09/05ISR Number: 4608783-2Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00020
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse	Foreign	Tab Vioxx					
	Diverticulum	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	309 DAY
	Haemoglobin Decreased	Health	Tab Aspirin	SS		ORAL	75 MG	
	Rectal Haemorrhage	Professional	Lansoprazole	C				
			Lisinopril	C				
			Prazosin	C				
			Simvastatin	C				

Date:03/10/05ISR Number: 4603793-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
	Anorexia
Disability	Anxiety
Other	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp
	Back Pain
	Blister
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Cardiac Disorder
	Caustic Injury
	Chest Pain
	Constipation

Depression
Diastolic Dysfunction
Diverticulum Intestinal
Dizziness
Drug Eruption
Dysphonia
Dysuria
Ecchymosis
Epistaxis
Fall
Frequent Bowel Movements
Gastritis
Glucose Tolerance
Impaired
Gout
Haemorrhoids
Headache
Helicobacter Infection
Hypertension
Hypoaesthesia
Insomnia
Intervertebral Disc

		Degeneration Intervertebral Disc Protrusion					
		Joint Crepitation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Kidney Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Labyrinthitis		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasopharyngeal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Nasopharyngitis		Prinivil	C		
UNKNOWN							
		Nausea		K-Dur	C		
UNKNOWN							
		Oedema Peripheral		Lortab	C		
UNKNOWN							
		Osteoarthritis		Coumadin	C		
UNKNOWN							
		Otitis Media		[Therapy			
		Pain		Unspecified]	C		
UNKNOWN							
		Pharyngitis		Lasix (Furosemide			
		Polyarthritis		Sodium)	C		
UNKNOWN							
		Rash					
		Rhinitis					
		Sinusitis					
		Sleep Disorder					
		Stomach Discomfort					
		Syncope					
		Tricuspid Valve Incompetence					
		Vertigo					
		Vision Blurred					
		Vomiting					

Date:03/10/05ISR Number: 4603798-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00010
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 665 DAY	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident Hemiparesis					

Date:03/10/05ISR Number: 4603800-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		869 DAY

Date:03/10/05ISR Number: 4603801-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acquired Immunodeficiency Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Kidney Infection		Dilantin	C				UNKNOWN
	Pain In Extremity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4603802-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4603803-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0503ESP00017
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4603805-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00551
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization - Initial or Prolonged			Premarin	C			UNKNOWN	
Disability			[Therapy Unspecified]	C			UNKNOWN	

Date:03/10/05ISR Number: 4603806-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00144
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4603807-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00404
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4603808-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1260 DAY

Date:03/10/05ISR Number: 4603809-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4603811-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00838
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		581 DAY
	Physical Disability							
	Speech Disorder							

Date:03/10/05ISR Number: 4603812-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00136
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Insulin	C				
UNKNOWN								
			Metformin Hydrochloride	C				
UNKNOWN								

Date:03/10/05ISR Number: 4603813-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00063
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Quinine Sulfate	C				
UNKNOWN								
Disability			Fluvastatin Sodium	C				
UNKNOWN								
			Isosorbide Mononitrate	C				
UNKNOWN								
			Amlodipine Besylate	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN								

				Esomeprazole Magnesium	C		
UNKNOWN							
				Nicorandil	C		
UNKNOWN							

Date:03/10/05ISR Number: 4603815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4603816-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00911
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Joint Injury Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/10/05ISR Number: 4603817-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00929
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Congestive		Synthroid	C				
UNKNOWN								
Initial or Prolonged			Avapro	C				
UNKNOWN								

			Coreg	C		
UNKNOWN						
			Guaifenesin	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						
			Furosemide	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			Klor-Con	C		
UNKNOWN						

Date:03/10/05ISR Number: 4603818-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00140
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	General Symptom		Fluticasone Propionate And Salmeterol Xinafoate	C				
UNKNOWN								
			Fosinopril Sodium	C				
UNKNOWN								

Date:03/10/05ISR Number: 4603819-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00142
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Myocardial Infarction							

Date:03/10/05ISR Number: 4603825-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00147
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/10/05ISR Number: 4604527-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01060285
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C			UNKNOWN	
			Percocet	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:03/10/05ISR Number: 4604534-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02074
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Angina Unstable Aortic Dilatation Aortic Valve Incompetence Bone Cyst Bronchitis Coronary Artery Stenosis Depression Dry Skin

	Emotional Distress						
	Hyperlipidaemia						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Initial Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Nocturia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pericarditis		Methotrexate	C			UNKNOWN
	Pleurisy		Wellbutrin	C			UNKNOWN
	Refusal Of Treatment By		Glucosamine	C			UNKNOWN
	Patient		Enbrel	C			SUBCUTANEOUS
	Rheumatoid Arthritis		Plaquenil	C			UNKNOWN
	Rotator Cuff Syndrome		Folic Acid	C			UNKNOWN
	Sinus Tachycardia		Pepcid	C		ORAL	
	Upper Respiratory Tract		Flexeril	C		ORAL	
	Infection		Ambien	C			UNKNOWN
			Viagra	C			UNKNOWN

Date:03/10/05ISR Number: 4604546-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00655
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Amnesia		Amaryl	C		ORAL	
Other	Angina Pectoris		Lipitor	C			UNKNOWN
	Angle Closure Glaucoma		Toprol Xl Tablets	C		ORAL	
	Anxiety		Tylenol Sinus	C			UNKNOWN
	Arthropathy		Flexeril	C		ORAL	
	Back Pain		Diazepam	C		ORAL	
	Blood Pressure Increased		Prevacid	C		ORAL	
	Cartilage Hypertrophy						

Cerebrovascular Accident
Chest Pain
Convulsion
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Dizziness
Faeces Discoloured
Gait Disturbance
Gastric Ulcer Haemorrhage
Headache
Hypercholesterolaemia
Hyperhidrosis
Hypertension
Intervertebral Disc
Disorder
Joint Sprain
Memory Impairment
Myocardial Infarction
Nausea
Posture Abnormal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604548-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00785
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adenoma Benign		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		
	Amaurosis Fugax		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Digoxin	C		ORAL		
	Angiopathy		Pravastatin Sodium	C		ORAL		
	Bladder Cancer		Cartia Xt	C		ORAL		
	Blood Pressure Increased		Pletal	C		ORAL		
	Cardiac Failure		Vitamin E	C		ORAL		
	Cardiomegaly		Ascorbic Acid	C		ORAL		
	Chest Discomfort		Minerals (Unspecified) And Vitamins (Unspecified)	C		ORAL		
	Convulsion							
	Cystitis Noninfective							
	Dyspnoea Exertional							
	Femoral Pulse Decreased		Flomax (Morniflumate)	C		ORAL		
	Influenza Like Illness							
	Ischaemia							
	Myocardial Ischaemia							
	Nodule							
	Peripheral Vascular Disorder							
	Prostatitis							
	Transient Ischaemic Attack							
	Ventricular Dysfunction							

Date:03/10/05ISR Number: 4604549-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Estrace	C				UNKNOWN
Other	Atelectasis		Aspirin	C				UNKNOWN
	Atrial Fibrillation		Allegra	C				UNKNOWN
	Blood Pressure Increased		Hyoscyamine	C				UNKNOWN

	Bronchitis	Elavil	C
UNKNOWN			
	Cardiac Failure	Diovan	C
UNKNOWN			
	Congestive Chest Pain	[Therapy Unspecified]	C
UNKNOWN			
	Congestive Cardiomyopathy	Robitussin-Dm	C
UNKNOWN			
	Convulsion		
	Dizziness		
	Hypercholesterolaemia		
	Hyperlipidaemia		
	Irritable Bowel Syndrome		
	Nasopharyngitis		
	Osteoarthritis		
	Palpitations		
	Squamous Cell Carcinoma		
	Tachycardia		
	Viral Myocarditis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604555-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Lasix (Furosemide Sodium)	C				
	Bradycardia							
Other	Cardiac Failure		Lasix (Furosemide Sodium)	C				
	Cerebrovascular Accident							
	Chest Pain		Aspirin	C				
	Feeling Abnormal		Avalide	C				
	Hypertensive Crisis		Motrin	C				
	Myocardial Infarction		Premarin	C				
			Naproxen	C				
			Tylenol	C				

Date:03/10/05ISR Number: 4604558-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00671
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Post Procedural Complication		Vioxx	SS	Merck & Co., Inc	ORAL		
			Omeprazole	C		ORAL		
	Pulmonary Embolism							

Date:03/10/05ISR Number: 4604561-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02547
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aggression
	Anaemia
Other	Aneurysm
	Anticonvulsant Drug Level

Below Therapeutic
Anxiety
Atrial Fibrillation
Calculus Ureteric
Cerebral Haemorrhage
Cerebrovascular Accident
Convulsion
Depressed Level Of
Consciousness
Depression
Dyspepsia
Dyspnoea
Electrocardiogram St
Segment Depression
Fatigue
Fibrin D Dimer Increased
Gait Disturbance
Gout
Haematuria
Hypersomnia
Hypertension
Hypokalaemia
Memory Impairment
Mental Status Changes
Nephrolithiasis
Renal Colic
Stress

		Subarachnoid Haemorrhage					
		Supraventricular Extrasystoles	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Supraventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles		Lasix (Furosemide)	C		
UNKNOWN							
		Ventricular Tachycardia		Lasix (Furosemide)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Dilantin	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Magnesium (Unspecified)	C		
UNKNOWN							
				Propafenone Hydrochloride	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							

Date:03/10/05ISR Number: 4604562-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00530
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Angina Pectoris Cardiac Disorder Electrocardiogram St Segment Elevation Pulmonary Bulla Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604565-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00706
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Effusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Insulin, Biphasic Isophane [Injection]	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Glimepiride	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604566-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00155
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased		Synthroid	C				
UNKNOWN								
	Cerebrovascular Accident		Fiorinal	C				
UNKNOWN								
	Depression		Zantac	C				
UNKNOWN								
	Fibromyalgia							
	Insomnia							
	Labyrinthitis							
	Malaise							
	Sinusitis							
	Upper Respiratory Tract Infection							

Date:03/10/05ISR Number: 4604571-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00182
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebellar Infarction		Insulin Human	C				
UNKNOWN								
	Tremor		Insulin Human, Isophane	C				
UNKNOWN								
			Domperidone	C		ORAL		

Date:03/10/05ISR Number: 4604573-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00040
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Burns Third Degree		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cataract		Escin	C				
UNKNOWN								

Other	Cerebellar Infarction	Melilot And Rutin	C
UNKNOWN			
	Cerebral Atrophy	Ginkgo Biloba	
	Cerebral Disorder	Extract	C
UNKNOWN			
	Cholestasis	Vitamins	
	Confusional State	(Unspecified)	C
UNKNOWN			
	Culture Positive	Calcium	
	Diarrhoea	(Unspecified)	C
UNKNOWN			
	Fall	Acetaminophen	C
UNKNOWN			
	Large Intestinal Ulcer	Amoxicillin And	
	Melaena	Clavulanate	
	Pyrexia	Potassium	C
UNKNOWN			
	Skin Graft		

Date:03/10/05ISR Number: 4604575-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00204
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Myocardial Ischaemia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604577-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03955
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Bronchitis							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Epigastric Discomfort							
	Myocardial Infarction							
	Peripheral Artery Aneurysm							
	Renal Cyst							

Date:03/10/05ISR Number: 4604591-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00284
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematuria		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Hyperhidrosis		Piroxicam Betadex	C				
UNKNOWN								
	Hypertension		Celecoxib	C				
UNKNOWN								
	Hypertensive Crisis		Tilidine Hydrochloride	C				
	Nausea							
UNKNOWN								
	Nephrosclerosis		Fosamax	C				
UNKNOWN								
	Pain							
	Renal Failure Acute							
	Renal Infarct							
	Retinal Infarction							
	Visual Disturbance							

Date:03/10/05ISR Number: 4604592-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00425
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Choking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nausea							
	Pain							
	Pain In Extremity							

Date:03/10/05ISR Number: 4604594-2Report Type:Expedited (15-DaCompany Report #CN-MERCK-0503CHN00003
Age:16 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope							

Date:03/10/05ISR Number: 4604596-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00739
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Coronary Syndrome
Hospitalization - Initial or Prolonged	Anxiety
	Apathy

		Arthralgia					
		Atrioventricular Block					
		Back Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyslipidaemia		Zoloft	C		
UNKNOWN							
		Fatigue		Pravachol	C		
UNKNOWN							
		Hypercholesterolaemia		Synthroid	C		
UNKNOWN							
		Hypertension		Coreg	C		
UNKNOWN							
		Myocardial Infarction		Avapro	C		
UNKNOWN							
		Sinus Bradycardia		Plavix	C		
UNKNOWN							
				Detrol La	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Ubidecarenone	C		
UNKNOWN							
				Arimidex	C		
UNKNOWN							
				Benadryl	C		
UNKNOWN							

Date:03/10/05ISR Number: 4604597-8Report Type:Expedited (15-DaCompany Report #NL-MERCK-0502NLD00009
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
				Ethinyl Estradiol And Norgestrel	C		
UNKNOWN							
				Diclofenac Sodium And Misoprostol	C		
UNKNOWN							

Date:03/10/05ISR Number: 4604600-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604602-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01263
Age:30 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion							
	Hypoaesthesia							

Date:03/10/05ISR Number: 4604603-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00245
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Goitre		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disorder							
Disability	Pulmonary Embolism							
	Spinal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604614-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00121
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
Disability								
UNKNOWN								
			Blood Thinner (Unspecified)	C				
UNKNOWN								

Date:03/10/05ISR Number: 4604620-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00026
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Mirtazapine	SS				
UNKNOWN								

Date:03/10/05ISR Number: 4604623-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00030
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Esomeprazole Magnesium	C		ORAL		
1097 DAY								

Date:03/10/05ISR Number: 4604627-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00396
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604628-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00072
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604634-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00027
Age:96 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Thromboembolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	212 DAY	
Initial or Prolonged			Valdecoxib	SS		ORAL	123 DAY	

Date:03/10/05ISR Number: 4604635-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00581
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Operation Cerebrovascular Accident Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604638-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604639-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00025
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	40	DAY
Initial or Prolonged	Dyspnoea							
	Hypertension							

Date:03/10/05ISR Number: 4604640-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00749
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pulmonary Infarction		Duragesic	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								
			Hyzaar	C				
UNKNOWN								

Date:03/10/05ISR Number: 4604643-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00628
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Myocardial Infarction							

Date:03/10/05ISR Number: 4604644-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Cerebrovascular Accident							
	Embolic Stroke							

Date:03/10/05ISR Number: 4604645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604646-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00816
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604647-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00584
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604649-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00003
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 241 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Tramadol Hydrochloride	C			UNKNOWN	
			Acetaminophen	C			UNKNOWN	
			Cortisone	C			UNKNOWN	

Date:03/10/05ISR Number: 4604650-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604652-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00764
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Increased Transient Ischaemic Attack							

Date:03/10/05ISR Number: 4604654-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00029
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1107 DAY	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Budesonide And Formoterol Fumarate	C				
RESPIRATORY								
(INHALATION)								
			Terbutaline Sulfate	C				
UNKNOWN								
			Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		

Date:03/10/05ISR Number: 4604656-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00825
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4604664-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01015
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604666-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Musculoskeletal Stiffness		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Pain		Dynacirc Cr	C			UNKNOWN	

Date:03/10/05ISR Number: 4604709-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604714-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00629
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/10/05ISR Number: 4604999-XReport Type:Direct Company Report #CTU 242598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS			12.5 MG DAILY	

Date:03/10/05ISR Number: 4607898-2Report Type:Expedited (15-DaCompany Report #2005038063
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness Dyskinesia Feeling Abnormal Nausea	Foreign Health Professional Other	Azithromax (Azithromycin)	PS		ORAL	500 MG(500 MG, 1 IN 1 D), ORAL	
			Desloratadine (Desloratadine)	SS		ORAL	5 MG (5 MG, 1 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG(25 MG, 1 IN 1 D), ORAL	
			Oxcarbazepine (Oxcarbazepine)	SS		ORAL	600 MG (300 MG, 2 IN1 D), ORAL	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4605761-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01501
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	69	DAY
	Myocardial Infarction		Oxycontin	C		ORAL		
	Renal Failure		Prednisone	C		ORAL		
			Dilantin	C		ORAL		
			Ativan	C		ORAL		

Date:03/11/05ISR Number: 4605762-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00781
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605763-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02544
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Discomfort
	Arthralgia
	Asthma
Other	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Chest Discomfort
	Cough
	Diabetes Mellitus
	Dizziness
	Dysfunctional Uterine
	Bleeding
	Dyspnoea
	Emotional Disorder
	Essential Hypertension
	Exercise Tolerance
	Decreased

Fatigue
Gouty Arthritis
Hepatic Function Abnormal
Hyperglycaemia
Injury
Ischaemic Cardiomyopathy
Joint Sprain
Lymphocytosis
Malaise
Multiple Allergies
Muscle Spasms
Muscle Strain
Myocardial Infarction
Nasal Septum Deviation
Oedema Peripheral
Pain In Extremity
Palpitations
Pharyngolaryngeal Pain
Pharynx Discomfort
Pneumonia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Pulmonary Congestion					
		Pulmonary Oedema					
		Renal Failure Acute					
		Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL
477	DAY						
		Respiratory Tract		Darvocet-N	C		
UNKNOWN							
		Congestion		Synthroid	C		
UNKNOWN							
		Rhinitis Allergic		Prevacid	C		
UNKNOWN							
		Sinus Congestion		Accupril	C		
UNKNOWN							
		Stress		Norvasc	C		
UNKNOWN							
		Uterine Haemorrhage		Hydrodiuril	C		
UNKNOWN							
		Ventricular Hypokinesia		Claritin	C		
UNKNOWN							
		Wheezing		Ceftin	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Coreg	C		
UNKNOWN		581	DAY				
				Lasix (Furosemide)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Prempro	C		
UNKNOWN							
				Theophylline	C		
UNKNOWN							
				Metab-O-Lite	C		
UNKNOWN							

Date:03/11/05ISR Number: 4605766-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01966
Age:57 YR Gender:Female I/FU:F

Outcome PT

Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Anxiety
Disability	Back Pain
	Breast Mass
	Chest Wall Pain
	Cold Sweat
	Contusion
	Cough
	Depression
	Diarrhoea
	Difficulty In Walking
	Drug Ineffective
	Dyskinesia
	Dyspepsia
	Fatigue
	Gastrooesophageal Reflux Disease
	Haemorrhage
	Hyperlipidaemia
	Hypotension
	Idiopathic Thrombocytopenic Purpura
	Infection
	Insomnia
	Leukopenia
	Localised Infection
	Memory Impairment
	Nasal Congestion
	Nausea
	Night Cramps
	Pharyngolaryngeal Pain
	Productive Cough
	Sputum Discoloured
	Stress

		Suicidal Ideation					
		Vomiting					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Atenolol	C		ORAL
				Lexapro	C		ORAL
				Zocor	C		ORAL

Date:03/11/05ISR Number: 4605775-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00511
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
281 DAY						
Hospitalization -	Myocardial Infarction		Almotriptan Malate	SS		ORAL
308 DAY						
Initial or Prolonged	Normochromic Normocytic		Oxycodone	C		
UNKNOWN						
	Anaemia					
	Renal Failure Chronic					
	Ventricular Dysfunction					

Date:03/11/05ISR Number: 4605786-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01379
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain					
	Chest Wall Pain					
	Cough					
	Dysphagia					
	Dyspnoea					
	Dyspnoea Exertional					
	Hypoaesthesia					
	Vision Blurred					
	Wheezing					

Date:03/11/05ISR Number: 4605796-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00599
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605797-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605798-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dementia Alzheimer'S Type							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4605799-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605800-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00457
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocarditis							

Date:03/11/05ISR Number: 4605801-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00068
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Tachycardia							

Date:03/11/05ISR Number: 4605803-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00891
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Blood Potassium Decreased		Prilosec	C		ORAL		
Disability	Blood Pressure Increased		Diazide	C				
UNKNOWN								
Other	Cardiac Failure		Premarin	C				
UNKNOWN								
	Congestive		Lasix (Furosemide)	C				
UNKNOWN								
	Cataract		Detrol	C				
UNKNOWN								

	Chest Discomfort	Antivert	C
UNKNOWN			
	Drug Ineffective	Tenormin	C
UNKNOWN			
	Dyspnoea Exertional		
	Early Satiety		
	Gastritis		
	Gastrooesophageal Reflux		
	Disease		
	Injury		
	Insomnia		
	Migraine		
	Mitral Valve Incompetence		
	Muscle Spasms		
	Myocardial Infarction		
	Oedema		
	Oedema Peripheral		
	Pain In Extremity		
	Upper Respiratory Tract		
	Infection		
	Vertigo		
	Vomiting		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4605806-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605810-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00601
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605812-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00616
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605816-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00840
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL	454 DAY	

Date:03/11/05ISR Number: 4605818-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4605819-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	710	DAY
	Injury							

Date:03/11/05ISR Number: 4605821-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							

Date:03/11/05ISR Number: 4606385-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	10	DAY
Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
Increased Cerebrovascular Accident		Lortab Excedrin	C		ORAL		
Constipation		Extra-Strength	C			UNKNOWN	
Delusion		Aspirin	C			UNKNOWN	
Diarrhoea							
Emotional Distress							
Ependymoma							
Headache							
Herpes Zoster							
Intervertebral Disc Protrusion							
Meningitis							
Muscle Contractions Involuntary							
Paranoia							
Psychotic Disorder							
Pyrexia							
Stomach Discomfort							
Tremor							
Venous Thrombosis Limb							

Date:03/11/05ISR Number: 4606414-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Discomfort		Premarin	C				
UNKNOWN								

Other	Depression	Percocet	C
UNKNOWN			
	Dizziness		
	Drug Ineffective		
	Hypertension		
	Loss Of Consciousness		
	Myocardial Infarction		
	Pain In Extremity		
	Paraesthesia		
	Postoperative Infection		
	Staphylococcal Infection		
	Vitreous Floaters		

Date:03/11/05ISR Number: 4606415-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00703
Age:95 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
Other	Atelectasis
	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Convulsion

		Depressed Level Of Consciousness					
		Eating Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Haemoglobin Decreased					
		Haemoptysis					
		Lung Infiltration					
		Pneumonia Aspiration					
		Pulmonary Embolism					
		Staphylococcal Infection					
		Urinary Tract Infection					
		Urinary Tract Infection Staphylococcal					

Date:03/11/05ISR Number: 4606417-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00729
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acne		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Adverse Event		Vasotec	C		ORAL
Disability	Angina Pectoris		Lipitor	C		
UNKNOWN						
Other	Anxiety		Aspirin	C		
UNKNOWN						
	Arthralgia		Verelan	C		
UNKNOWN						
	Atrial Flutter		Nitrostat	C		
UNKNOWN						
	Basal Ganglion Degeneration					
	Benign Prostatic Hyperplasia					
	Cardiac Failure Congestive					
	Cerebrovascular Accident					
	Chest Discomfort					
	Confusional State					
	Convulsion					
	Coronary Artery Atherosclerosis					
	Depression					
	Device Failure					
	Dyspepsia					

Dyspnoea
Ear Disorder
Fall
Headache
Hiatus Hernia
Hypertension
Hypoaesthesia
Nocturia
Non-Cardiac Chest Pain
Pain In Extremity
Palpitations
Paraesthesia
Rash
Renal Impairment
Scrotal Mass
Suicidal Ideation
Ventricular Dysfunction
Vertigo

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606418-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0310CHE00016
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Hospitalization -	Complete		Lithium Carbonate	SS		ORAL		12 YR
Initial or Prolonged	Blood Creatinine		Lithium Carbonate	SS		ORAL		
	Increased		Carbamazepine	SS		ORAL		
	Blood Pressure Increased		Carbamazepine	SS		ORAL		12 YR
	Bradycardia		Pipamperone					
	Drug Interaction		Hydrochloride	C		ORAL		6 YR
	Drug Level Increased		Mirtazapine	C		ORAL		3 MON
	Drug Toxicity		Zopiclone	C		ORAL		
	Dysarthria							
	Electrocardiogram							
	Abnormal							
	Electrocardiogram T Wave							
	Inversion							
	Extrapyramidal Disorder							
	Feeling Abnormal							
	Headache							
	Hypotension							
	Kyphosis							
	Lordosis							
	Malaise							
	Osteochondrosis							
	Pancytopenia							
	Renal Impairment							
	Sinus Arrest							
	Sinus Bradycardia							
	Somnolence							
	Spinal Osteoarthritis							
	Therapeutic Agent							
	Toxicity							
	Tremor							
	Vomiting							

Date:03/11/05ISR Number: 4606421-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00611
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dysphagia		Phenprocoumon	C				
UNKNOWN								
	Dyspnoea Exertional		Levetiracetam	C				
UNKNOWN								
	Impaired Work Ability		Tizanidine Hydrochloride	C				
	Nystagmus							
UNKNOWN								
	Pupils Unequal							
	Vertebral Artery Occlusion							
	Wallenberg Syndrome							

Date:03/11/05ISR Number: 4606422-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Activities Of Daily
Disability	Living Impaired
Other	Anaemia

		Aortic Aneurysm					
		Atelectasis					
		Bacterial Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL
		Fluctuation		Aspirin	SS		ORAL
		Bronchiectasis		Dyazide	C		
UNKNOWN							
		Bronchitis		Oxybutynin	C		ORAL
		Cardiomegaly		Propranolol			
		Cataract		Hydrochloride	C		
UNKNOWN							
		Chest Pain		Isosorbide	C		
UNKNOWN							
		Chronic Obstructive		Hyzaar	C		ORAL
		Pulmonary Disease		Ciprofloxacin	C		
UNKNOWN							
		Chronic Sinusitis		Ciprofloxacin	C		
UNKNOWN							
		Colon Cancer		Albuterol	C		
RESPIRATORY							
		Coronary Artery Disease					
(INHALATION)							
		Deep Vein Thrombosis		Nitroglycerin	C		
UNKNOWN							
		Difficulty In Walking		Ativan	C		ORAL
		Dyspepsia		Quinine	C		
UNKNOWN							
		Dysphagia					
		Dyspnoea					
		Ecchymosis					
		Emotional Distress					
		Essential Tremor					
		Faeces Discoloured					
		Fibromyalgia					
		Fluid Overload					
		Fluid Retention					
		Gastric Ulcer Haemorrhage					
		Gastritis					
		Gastroenteritis Viral					
		Gastrointestinal					
		Haemorrhage					
		Gastrooesophageal Reflux					
		Disease					
		Hypertension					
		Iron Deficiency Anaemia					

Macular Degeneration
Myocardial Infarction
Oesophageal Pain
Osteoarthritis
Osteoporosis
Peptic Ulcer
Pseudoexfoliation Of Lens
Capsule
Pyrexia
Renal Cyst
Rheumatic Fever
Rhinitis Allergic
Stress Incontinence
Supraventricular
Extrasystoles
Venous Stasis
Vertigo
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606431-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:03/11/05ISR Number: 4606432-0Report Type:Expedited (15-DaCompany Report #PL-MERCK-0410POL00004
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Alopecia		Carvedilol	C		ORAL		
Initial or Prolonged	Anaemia Haemolytic		Perindopril Erbumine	C		ORAL		
Disability	Autoimmune		Atorvastatin Calcium	C		ORAL		
Other	Asthenia		Diosmin And					
	Dyspnoea		Hesperidin	C		ORAL		
	Hepatic Pain		Trimetazidine	C		ORAL		
	Malaise		Metoprolol Tartrate	C		ORAL		
	Oedema Peripheral		[Therapy					
	Vomiting		Unspecified]	C		ORAL		

Date:03/11/05ISR Number: 4606433-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01943
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/11/05ISR Number: 4606434-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00456
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastritis Erosive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy					

Disability	Stress	Unspecified]	C
UNKNOWN			
		Metoprolol Succinate	C
UNKNOWN			
		Simethicone	C
UNKNOWN			
		Metoclopramide	C
UNKNOWN			
		Simvastatin	C
UNKNOWN			
		Zopiclone	C
UNKNOWN			
		Citalopram Hydrobromide	C
UNKNOWN			
		Piretanide	C
UNKNOWN			
		Lercanidipine	C
UNKNOWN			
		Fosinopril Sodium	C
UNKNOWN			

Date:03/11/05ISR Number: 4606436-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Anaemia
	Angina Pectoris
	Arthralgia
	Basal Cell Carcinoma
	Blood Pressure Increased

		Bundle Branch Block Left					
		Carotid Artery Stenosis					
		Carpal Tunnel Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Colon Cancer		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Prevacid	C		
UNKNOWN							
		Coronary Artery Disease		Amitriptyline			
		Diverticulum		Hydrochloride	C		ORAL
		Dysphagia		Atenolol	C		ORAL
		Dyspnoea		Atenolol	C		ORAL
		Hiatus Hernia		Nitroquick	C		
SUBLINGUAL							
		Limb Discomfort		Aspirin	C		
UNKNOWN							
		Loss Of Consciousness		Lipitor	C		ORAL
		Oesophagitis		Zantac	C		ORAL
		Osteoarthritis		Plavix	C		
UNKNOWN							
		Polyp		Amaryl	C		
UNKNOWN							
		Post Procedural Haematoma		Baycol	C		
UNKNOWN							
		Prostatitis		Pravachol	C		
UNKNOWN							
		Renal Cyst		Ambien	C		
UNKNOWN							
		Retrograde Ejaculation		Acetaminophen And			
		Rotator Cuff Syndrome		Hydrocodone			
		Seborrhoeic Keratosis		Bitartrate	C		
UNKNOWN							
		Tinnitus					
		Urinary Retention					

Date:03/11/05ISR Number: 4606442-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00526
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Hospitalization -	Blindness Unilateral					
Initial or Prolonged	Heart Rate Increased					
Disability	Ocular Vascular Disorder					

Retinal Ischaemia

Date:03/11/05ISR Number: 4606443-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00210
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Depression		Zocor	C		ORAL		
Other			Methotrexate	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								
			Folic Acid	C		ORAL		

Date:03/11/05ISR Number: 4606446-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01177
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anterior Spinal Artery		Vioxx	PS	Merck & Co., Inc	ORAL		647 DAY
Hospitalization -	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		647 DAY
Initial or Prolonged	Gastrooesophageal Reflux		Lipitor	C		ORAL		
Disability	Disease		Diovan	C		ORAL		
	Osteoporosis		Aspirin	C				
UNKNOWN								
	Paraplegia		Tenormin	C		ORAL		

Date:03/11/05ISR Number: 4606447-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00424
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
	Chest Pain		Lotensin	C		ORAL		
	Difficulty In Walking		Hydrochlorothiazide	C				UNKNOWN
	Dizziness		Hydrochlorothiazide	C				UNKNOWN
	Ejection Fraction Decreased		Aspirin	C		ORAL		
			Niacin	C				UNKNOWN
	Extrasystoles		Vitamins (Unspecified)	C		ORAL		
	Hypotension		Glucophage Xr	C		ORAL		
	Hypovolaemia		Lopid	C				UNKNOWN
	Palpitations		Ascorbic Acid	C				UNKNOWN
			Vitamin E	C				UNKNOWN
			Fish Oil (Unspecified)	C				UNKNOWN
			Grape Seeds	C				UNKNOWN
			Camellia Sinensis	C				UNKNOWN
			Clonazepam	C		ORAL		
			Buspirone Hydrochloride	C				UNKNOWN
			Flaxseed	C				UNKNOWN
			Garlic Extract	C				UNKNOWN
			Tizanidine Hydrochloride	C				UNKNOWN

Date:03/11/05ISR Number: 4606448-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02089
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Hypertension		Synthroid	C				UNKNOWN
	Hypothyroidism		Asacol	C				UNKNOWN
			Premarin	C				UNKNOWN

Date:03/11/05ISR Number: 4606449-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00005
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1241 YR
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1241 YR
Other			Tamsulosin Hydrochloride	C				UNKNOWN

Date:03/11/05ISR Number: 4606451-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03093
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Loss Of Consciousness							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606452-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
	Blue Toe Syndrome			C				
	Chest Pain							

Date:03/11/05ISR Number: 4606454-XReport Type:Expedited (15-DaCompany Report #BE-MERCK-0503BEL00023
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR

Date:03/11/05ISR Number: 4606455-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01964
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Gemfibrozil	C				
			Vitamins (Unspecified)	C				

Date:03/11/05ISR Number: 4606456-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00061
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606457-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00576
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606458-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00579
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	656	DAY

Date:03/11/05ISR Number: 4606459-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00580
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606460-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00026
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	850 DAY	
			Celecoxib	C		ORAL	918 DAY	
			Valdecoxib	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

Date:03/11/05ISR Number: 4606461-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00744
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606463-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606464-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00748
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Congestive		Oxycontin	C			UNKNOWN	
Initial or Prolonged	Heart Rate Decreased		Prevacid	C			UNKNOWN	
Disability			Isorbid	C			UNKNOWN	

			Cardizem	C		
UNKNOWN						

Date:03/11/05ISR Number: 4606466-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606467-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00577
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606468-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			[Therapy					
Hospitalization -			Unspecified]	C				
UNKNOWN								
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606469-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00469
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective Myocardial Infarction Stomach Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606471-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00811
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/11/05ISR Number: 4606475-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	91	DAY

Date:03/11/05ISR Number: 4606476-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:03/11/05ISR Number: 4606477-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00849
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

31 DAY

Date:03/11/05ISR Number: 4606478-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00835
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606479-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00818
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606480-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00836
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4606482-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00976
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:03/11/05ISR Number: 4606483-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiopulmonary Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/11/05ISR Number: 4606484-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	505	DAY

Date:03/11/05ISR Number: 4606487-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	651	DAY

Date:03/11/05ISR Number: 4607182-7Report Type:Direct Company Report #CTU 242903
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Humulin 70/30	PS			30	UNITS

Initial or Prolonged	Hemiplegia		Celebrex	SS
2X DAY				
Disability			Vioxx	SS
3 OR 4 TIMES				
DAY				

Date:03/11/05ISR Number: 4607281-XReport Type:Direct Company Report #CTU 242858
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx Tabs -25 Mg			
Hospitalization -			-Merck And Co	PS	Merck And Co	
1 TAB DAILY						
Initial or Prolonged						
Other						

Date:03/11/05ISR Number: 4607315-2Report Type:Direct Company Report #CTU 242764
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Myocardial Infarction		Vioxx	PS		
1 A DAY						
Hospitalization -			Stent Placement	C		
Initial or Prolonged						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/11/05ISR Number: 4608206-3Report Type:Expedited (15-DaCompany Report #2005039948
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction	Foreign Health Professional	Celecoxib (Celecoxib)	PS		ORAL	100 MG (100 MG, 1 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	50 MG (50 MG, 1 IN 1 D) , ORAL	
			Doxazosin (Doxazosin)	C				
			Felodipine (Felodipine)	C				
			Folic Acid (Folic Acid)	C				
			Methotrexate (Methotrexate)	C				

Date:03/11/05ISR Number: 4608450-5Report Type:Expedited (15-DaCompany Report #WAES 01058101
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertensive Crisis Treatment Noncompliance	Foreign Study Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	89 MON
			Amlodipine Besylate	C				
			Atenolol	C				
			Lisinopril	C				

Date:03/11/05ISR Number: 4608976-4Report Type:Expedited (15-DaCompany Report #2005040366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Foreign Health Professional	Celebra (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D), ORAL	
			Levothyroxine Sodium (Levothyroxine Sodium)	C				
			Warfarin (Warfarin)	C				

Date:03/11/05ISR Number: 4609025-4Report Type:Expedited (15-DaCompany Report #2005021014
Age: Gender:Male I/FU:F

Outcome	PT
Other	Cataract Operation
	Cough
	Dizziness
	Feeling Abnormal
	Gastrointestinal Disorder
	Glaucoma
	Knee Operation

Post Procedural Pain
Sinusitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Consumer	Celebrex (Celecoxib)	PS			200 MG(200	
Health						
Professional	Vicodin (Hydrocodone Bitartrate, Paracetamol)	SS		ORAL	MG, 1 IN 1 D)	
	Rofecoxib (Rofecoxib)	SS			ORAL	
	Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Warfarin (Warfarin)	C				

Date:03/11/05ISR Number: 4609149-1Report Type:Expedited (15-DaCompany Report #2005040524
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Colonic Haemorrhage	Consumer	Celebrex (Celecoxib)	PS				
	Gastric Disorder		Rofecoxib (Rofecoxib)	SS				
	Gastric Ulcer Haemorrhage		Acetylsalicylic Acid (Acetylsalicylic Acid)	C				

Date:03/11/05ISR Number: 4615866-XReport Type:Periodic Company Report #2004-BP-11394BP
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia	Consumer	Spiriva Handihaler (Tiotropium Bromide)	PS		RESPIRATORY		
	Headache							
	Hypoaesthesia Oral							
	Nausea							

(INHALATION) 18 MCG (18 MCG), IH

	Paraesthesia Oral	Celebrex (Celecoxib)	SS
	Transient Ischaemic	Vioxx (Rofecoxib)	SS
	Attack	Avalide (Karvea Hct)	C
		Asa (Acetylsalicylic Acid)	C
		Prednisone (Prednisone)	C
		Betopic S	C
		Florazepam	C
		Asecol	C

Date:03/14/05ISR Number: 4607263-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00157
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysarthria		Lisinopril	C		ORAL		
	Hyperlipidaemia		Hydrochlorothiazide	C		ORAL		
	Hypertension		Aspirin	C		ORAL		
	Nuclear Magnetic Resonance Imaging Brain Abnormal		Pravastatin Sodium	C		ORAL		
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4607264-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00043
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL		
	Positive		Lansoprazole	SS		ORAL		
	Autoimmune Thyroiditis		Fluvastatin Sodium	SS		ORAL		
	Haemoglobin Decreased		Fluvastatin Sodium	SS		ORAL		
	Hepatic Cirrhosis		Acetaminophen And Propoxyphene Hydrochloride	SS		ORAL		
	Hepatitis							
	Hepatomegaly							
	Rhabdomyolysis		Acebutolol Hydrochloride	SS		ORAL		
	Serum Ferritin Increased							
			Domperidone	SS		ORAL		

Date:03/14/05ISR Number: 4607266-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00063
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607268-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00027
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Arterial Stent Insertion							

Date:03/14/05ISR Number: 4607269-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01332
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Death	Anaemia
Life-Threatening	Asthenia
Hospitalization - Initial or Prolonged	Bezoar
	Bronchitis

Disability	Cardiac Failure
Other	Congestive
	Cerebrovascular Accident
	Collapse Of Lung
	Coronary Artery
	Atherosclerosis
	Dysphagia
	Dyspnoea
	Erosive Oesophagitis
	Gastritis
	Gastrointestinal
	Haemorrhage
	Hypertension
	Immunosuppression
	Lung Infiltration
	Malnutrition
	Mitral Valve Incompetence
	Mitral Valve Stenosis
	Oesophageal Candidiasis
	Parkinson'S Disease
	Pleural Effusion

		Pneumonia					
		Pulmonary Hypertension					
		Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
628 DAY							
				Paxil	C		ORAL
				Potassium Chloride	C		ORAL
				Prednisone	C		ORAL
				Xanax	C		ORAL
				Cordarone	C		ORAL
				Aspirin	C		ORAL
				Lasix (Furosemide)	C		ORAL
				Prevacid	C		ORAL
				Synthroid	C		ORAL
				Reglan	C		ORAL
				Singulair	C		ORAL
				[Therapy Unspecified]	C		ORAL

Date:03/14/05ISR Number: 4607275-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00076
Age:50 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Alopecia Totalis		Vioxx	PS	Merck & Co., Inc	ORAL
				[Therapy Unspecified]	SS		ORAL
				Propecia	C		ORAL

Date:03/14/05ISR Number: 4607277-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00008
Age:62 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
170 DAY							
Hospitalization - Initial or Prolonged Disability				Norethindrone Acetate And Estradiol	C		
UNKNOWN							
				Plendil	C		ORAL

Hydrochlorothiazide And Valsartan	C	ORAL

Date:03/14/05ISR Number: 4607280-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
	Acute Myocardial Infarction
	Anger
	Anxiety
	Arthralgia
	Aspartate Aminotransferase Increased
	Asthenia
	Asthma
	Atelectasis
	Back Pain
	Blood Potassium Increased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Urea Increased					
		Chest Pain					
		Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
106	DAY						
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
363	DAY						
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
106	DAY						
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
363	DAY						
		Depression		Zantac	C		
UNKNOWN							
		Difficulty In Walking		Celexa	C		
UNKNOWN							
		Dupuytren'S Contracture		Albuterol	C		
RESPIRATORY							
		Dyslipidaemia					
(INHALATION)							
		Dyspepsia		Vicodin Tablets	C		ORAL
		Dysphagia					
		Dyspnoea					
		Erectile Dysfunction					
		Fatigue					
		Haemolysis					
		Haemorrhoids					
		Hypoaesthesia					
		Impulse-Control Disorder					
		Inadequate Analgesia					
		Pain In Extremity					
		Pleural Effusion					
		Premature Ejaculation					
		Pulmonary Congestion					
		Purulent Discharge					
		Reperfusion Arrhythmia					
		Restless Legs Syndrome					
		Rhinitis Allergic					
		Rhonchi					
		Self-Injurious Ideation					
		Sinus Disorder					
		Sleep Apnoea Syndrome					
		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Tongue Disorder					
		Upper Respiratory Tract Infection					

Weight Increased
Wheezing

Date:03/14/05ISR Number: 4607293-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00154
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Disorder		Hypericin	C		ORAL
	Depression		Glimepiride	C		ORAL
	Fall		Amitriptyline Hydrochloride	C		ORAL
	Feeling Hot And Cold		Betaxolol Hydrochloride	C		ORAL
	Hyperventilation		Hydrochlorothiazide And Valsartan	C		ORAL
	Hypotension		Diclofenac	C		ORAL
	Polyneuropathy					
	Somatisation Disorder					
	Syncope					
	Tinnitus					
	Vertigo					
	Vision Blurred					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4607294-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/14/05ISR Number: 4607297-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00847
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Injury							

Date:03/14/05ISR Number: 4607299-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Injury							

Date:03/14/05ISR Number: 4607300-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00666
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/14/05ISR Number: 4607301-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01235
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
1001 DAY

Date:03/14/05ISR Number: 4607302-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00930
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
1456 DAY

Date:03/14/05ISR Number: 4607304-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01233
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
290 DAY

Date:03/14/05ISR Number: 4607305-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00132
Age: Gender:Female I/FU:F

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4607306-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607309-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607311-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01237
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	724	DAY

Date:03/14/05ISR Number: 4607312-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01238
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	661	DAY

Date:03/14/05ISR Number: 4607314-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01241
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607316-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00144
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Omeprazole	C			UNKNOWN	
Disability			Naproxen	C			UNKNOWN	
			Zolpidem Tartrate	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Moclobemide	C			UNKNOWN	
			Insulin Lispro	C			UNKNOWN	

Date:03/14/05ISR Number: 4607317-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00143
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4607319-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01242
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607325-5Report Type:Expedited (15-DaCompany Report #US-AMGEN-US017239
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchiectasis		Kineret	PS				
SUBCUTANEOUS								
Initial or Prolonged	Dehydration		Prednisone	SS		ORAL		
	Escherichia Infection		Vioxx	SS				
	Escherichia Urinary Tract		Plaquenil	SS				
	Infection		Tamoxifen Citrate	C				
	Hepatic Cyst		Nexium	C				
	Lung Neoplasm		Fosamax	C				
	Pulmonary Fibrosis		Zoloft	C				
	Pyelonephritis		Fentanyl	C				
TOPICAL								
			Ativan	C				

Date:03/14/05ISR Number: 4607338-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00164
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Silent Myocardial							
	Infarction							

Date:03/14/05ISR Number: 4607356-5Report Type:Expedited (15-DaCompany Report #SG-MERCK-0503SGP00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastrooesophageal Reflux							

Disease
Stomach Discomfort
Tendonitis

Date:03/14/05ISR Number: 4607358-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00146
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607359-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00018
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Mental Disorder Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc		UNKNOWN UNKNOWN	

Date:03/14/05ISR Number: 4607382-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00151
Age:33 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4607534-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00149
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Trandolapril	C			UNKNOWN	
Disability	Myocardial Infarction		Omeprazole	C		ORAL		
			Aspirin	C		ORAL		

Date:03/14/05ISR Number: 4607817-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547915A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Ecotrin Adult Low Strength Tablets	PS	Glaxosmithkline	ORAL		6 YR
	Faeces Discoloured							
	Gastric Ulcer Haemorrhage		Celebrex	SS		ORAL		
	Haemoglobin Decreased		Vioxx	SS		ORAL		
	Rectal Haemorrhage		Avandia	C	Glaxosmithkline	ORAL	8MG per day	
			Lipitor	C		ORAL	40MG per day	
			Multiple Vitamin	C		ORAL		
			Fluconazole	C		ORAL	200MG cumulative dose	
			Altace	C		ORAL	2.5MG per day	

				(Trimethoprim + Sulfamethoxazol)	C	Glaxosmithkline	ORAL
1 YR							

Date:03/14/05ISR Number: 4608056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02039
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acrochordon		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
	Alopecia		Diovan	C			UNKNOWN	
	Blood Pressure Increased		Premarin	C			UNKNOWN	
	Cystocele		Aspirin	C			UNKNOWN	
	Dermatitis Contact							
	Fungal Skin Infection							
	Headache							
	Lichen Planus							
	Lung Neoplasm							
	Ovarian Mass							
	Rectocele							
	Seborrhoeic Dermatitis							
	Seborrhoeic Keratosis							
	Skin Lesion							
	Vaginal Prolapse							
	Wrist Deformity							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608059-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 482 DAY	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Coronary Artery Disease		Celebrex	C		
Other	Coronary Artery Reocclusion					
	Haematocrit Decreased					
	Haematoma					
	Hypercholesterolaemia					
	Myocardial Infarction					
	Post Procedural Complication					

Date:03/14/05ISR Number: 4608067-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00179
Age:90 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastric Ulcer		Aspirin	SS		ORAL
	Haematemesis		Clopidogrel Bisulfate	SS		ORAL
	Haemoglobin Abnormal		Amitriptyline Hydrochloride	C		ORAL
	Melaena		Senna	C		ORAL
	Oesophagitis		Lactulose	C		ORAL
			Alfuzosin Hydrochloride	C		ORAL
			Bendroflumethiazide	C		ORAL
			Tramadol Hydrochloride	C		ORAL

Date:03/14/05ISR Number: 4608074-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00873
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

Disability	Angina Unstable
Other	Anxiety
	Arterial Injury
	Arthritis
	Blood Cholesterol
	Increased
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Device Failure
	Diarrhoea
	Dizziness Postural
	Dyslipidaemia
	Dyspepsia
	Ejection Fraction
	Decreased
	Fatigue

		Gastric Disorder Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
255	DAY						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
255	DAY						
		Insomnia		Tylenol	C		
UNKNOWN							
		Joint Swelling		Aspirin	C		
UNKNOWN							
		Liver Disorder Myocardial Ischaemia Oesophagitis Post Procedural Complication Pyelonephritis Pyrexia Urinary Tract Infection Vision Blurred					

Date:03/14/05ISR Number: 4608082-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bipolar I Disorder		Avapro	C		
UNKNOWN						
Other	Chest Pain		Paxil	C		
UNKNOWN						
	Cystitis		Geodon	C		
UNKNOWN						
	Deep Vein Thrombosis		Lipitor	C		
UNKNOWN						
	Diarrhoea		Lipitor	C		
UNKNOWN						
	Fatigue		Prilosec	C		
UNKNOWN						
	Flank Pain		Levoxyl	C		
UNKNOWN						
	Gastritis		Prevacid	C		
UNKNOWN						

Hydronephrosis
Incisional Hernia
Kidney Infection
Nephrolithiasis
Pseudomonas Infection
Renal Failure
Schizoaffective Disorder
Sepsis
Staphylococcal Infection
Ureteric Stenosis
Urinary Retention
Urinary Tract Infection
Urosepsis
Weight Increased

Date:03/14/05ISR Number: 4608104-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00149
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acanthoma
Hospitalization - Initial or Prolonged	Angina Pectoris
	Basal Cell Carcinoma
	Chest Pain
	Dizziness
	Eczema
	Hypertension
	Migraine
	Nausea

		Palpitations					
		Restlessness					
		Tachyarrhythmia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
		Ventricular Hypertrophy		Flupirtine Maleate	C		
UNKNOWN							
				Levothyroxine Sodium	C		ORAL
				Ascorbic Acid And Aspirin	C		
UNKNOWN							
				Risedronate Sodium	C		ORAL
				Acetyldigoxin	C		ORAL
				Verapamil Hydrochloride	C		ORAL
				Atorvastatin Calcium	C		ORAL

Date:03/14/05ISR Number: 4608111-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00058
Age:75 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
Initial or Prolonged		Increased		Trimetazidine			
		Body Temperature		Hydrochloride	SS		ORAL
		Increased		Clopidogrel			
		Diarrhoea		Bisulfate	SS		ORAL
				Sotalol Hydrochloride	SS		ORAL
				Ginkgo Biloba Extract	SS		ORAL
				Pravastatin Sodium	SS		ORAL

Date:03/14/05ISR Number: 4608113-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03767
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastrooesophageal Reflux		Prilosec	C		
UNKNOWN						
	Disease		Pravachol	C		
UNKNOWN						
	Hypoacusis					
	Middle Ear Effusion					
	Synovitis					
	Tinnitus					

Date:03/14/05ISR Number: 4608114-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Adalimumab	SS		
PARENTERAL						
			Methotrexate	SS		
UNKNOWN						
			Estrogens, Conjugated	SS		
UNKNOWN						
			Fluoxetine	SS		
UNKNOWN						
			Amoxicillin And Clavulanate Potassium	SS		
UNKNOWN						
			Acetaminophen And Dihydrocodeine			

Bitartrate SS

UNKNOWN

Date:03/14/05ISR Number: 4608116-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01516
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Acute Myocardial Infarction
	Aortic Valve Calcification
	Aortic Valve Sclerosis
	Atelectasis
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Coma
	Confusional State
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Cough
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Neuropathy
	Diarrhoea
	Dilatation Atrial
	Dry Skin
	Dyspepsia
	Dysphagia
	Escherichia Sepsis
	Essential Hypertension
	Fall
	Femoral Artery Occlusion
	Gallop Rhythm Present
	Generalised Oedema
	Hyperlipidaemia

Iliac Artery Stenosis
Intermittent Claudication
Lipoprotein Deficiency
Mitral Valve
Calcification
Mitral Valve Disease
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Oedema Peripheral
Onychomycosis
Orthopnoea
Osteoarthritis
Pallor
Peripheral Occlusive
Disease

		Pleural Effusion					
		Pulmonary Oedema					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL
		Respiratory Distress					
		Sciatica					
		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Stress Incontinence					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					
		Urosepsis					
		Uterine Infection					
		Ventricular Hypertrophy					
		White Blood Cell Count					
		Increased					

Date:03/14/05ISR Number: 4608127-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00015
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Deafness Unilateral		Iodine	C		
UNKNOWN							
		Demyelination					
		Inner Ear Disorder					
		Osteochondrosis					
		Treatment Noncompliance					
		Vertigo					
		Vestibular Disorder					

Date:03/14/05ISR Number: 4608129-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Back Pain

Disability	Balance Disorder
Other	Bipolar I Disorder
	Bladder Disorder
	Body Tinea
	Cerebral Artery Occlusion
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome
	Circulatory Collapse
	Constipation
	Depression
	Dizziness
	Dyspnoea
	Electrocardiogram Qt
	Prolonged
	Fall
	Fatigue
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Head Injury							
Headache							
Hemiparesis							
Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	38	DAY
Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL	38	DAY
Insomnia		Lasix (Furosemide)	C			UNKNOWN	976 DAY
Ischaemic Stroke		Nizatidine	C			UNKNOWN	
Loss Of Consciousness		Trazodone Hydrochloride	C			UNKNOWN	
Migraine							
Myocardial Infarction		Prozac	C			UNKNOWN	
Neuropathic Pain		Zocor	C		ORAL	809	DAY
Nuclear Magnetic Resonance Imaging Brain		Zanaflex	C			UNKNOWN	473 DAY
Abnormal		Prochlorperazine	C			UNKNOWN	
Oedema Peripheral		Vitamin E	C		ORAL		
Paraesthesia		Zyprexa	C		ORAL		
Pupillary Disorder		Benadryl	C			UNKNOWN	
Rash		Klor-Con	C			UNKNOWN	
Relapsing-Remitting Multiple Sclerosis		Indomethacin	C			UNKNOWN	
Renal Failure Acute		Methotrexate	C			UNKNOWN	
Temperature Intolerance		Duradrin	C			UNKNOWN	
Tenderness		Estraderm	C			UNKNOWN	409 DAY
Vision Blurred		Alprazolam	C			UNKNOWN	
		Avonex	C		INTRAMUSCULAR		
		Zocor	C			UNKNOWN	
		Propranolol Hydrochloride	C			UNKNOWN	

				Seroquel	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							
				Hydrocodone Bitartrate	C		
UNKNOWN	663	DAY					
				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN	840	DAY					

Date:03/14/05ISR Number: 4608134-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04115
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Auricular Swelling		Valium	C				
UNKNOWN								
	Cardiac Disorder							
	Dizziness							
	Palpitations							
	Syncope							
	Vomiting							

Date:03/14/05ISR Number: 4608135-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01312
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		
			Cyanocobalamin	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								
			Levothyroxine Sodium	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Colchicine	C				
UNKNOWN								

			Zocor	C		ORAL
			Lisinopril	C		
UNKNOWN						

Date:03/14/05ISR Number: 4608136-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00646
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Hyzaar	C		ORAL
Disability	Cerebral Infarction		Glucophage	C		
UNKNOWN						
Other	Cerebrovascular Accident		Glipizide	C		
UNKNOWN						
	Depression		Cozaar	C		
UNKNOWN						
	Diabetes Mellitus		Aspirin	C		
UNKNOWN						
	Inadequate Control		Ferrous Sulfate	C		
UNKNOWN						
	Hyperlipidaemia		Celexa	C		
UNKNOWN						
	Nasal Congestion		Lipitor	C		
UNKNOWN						

Date:03/14/05ISR Number: 4608137-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00074
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Dysuria		Flomax (Tamsulosin			
Initial or Prolonged			Hydrochloride)	C		
UNKNOWN						
Disability			Darvocet-N	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

Date:03/14/05ISR Number: 4608138-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00088
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608140-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608141-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02599
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Congestive Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Coronary Artery Disease		[Therapy					
Hospitalization - UNKNOWN	Diabetes Mellitus		Unspecified]	C				
Initial or Prolonged	Insulin-Dependent							
Disability	Pneumonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608142-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00357
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/14/05ISR Number: 4608143-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608144-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00858
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608146-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Emotional Disorder							
	Injury							
	Mental Disorder							

Date:03/14/05ISR Number: 4608147-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00741
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Dyspnoea Hypertension Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608148-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00977
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608149-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608151-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01234
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:03/14/05ISR Number: 4608152-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608153-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00724
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death		Percocet	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								
			Oxycodone	C				
UNKNOWN								

Date:03/14/05ISR Number: 4608154-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01262
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Hospitalization - UNKNOWN Initial or Prolonged			Xanax	C				

Date:03/14/05ISR Number: 4608155-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02578
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1030 DAY
	Thrombosis							

Date:03/14/05ISR Number: 4608156-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		25 MON

Date:03/14/05ISR Number: 4608157-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608158-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01373
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Cardiomegaly		Estrogens (Unspecified)	C		ORAL		
	Myocardial Infarction							

Date:03/14/05ISR Number: 4608160-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01371
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:03/14/05ISR Number: 4608161-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/14/05ISR Number: 4608162-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608163-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/14/05ISR Number: 4608164-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01384
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

Date:03/14/05ISR Number: 4608165-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608167-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01750
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608168-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Other								

Date:03/14/05ISR Number: 4608170-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608172-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/14/05ISR Number: 4608173-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Damage Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/14/05ISR Number: 4608174-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
3 YR							

Date:03/14/05ISR Number: 4608175-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								

Date:03/14/05ISR Number: 4608177-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00632
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:03/14/05ISR Number: 4608183-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01377
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4608200-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00148
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		303 DAY
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:03/14/05ISR Number: 4608207-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00163
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							

Date:03/14/05ISR Number: 4608209-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00165
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	General Symptom		Prednisone	C				
UNKNOWN								
			Olsalazine Sodium	C				
UNKNOWN								

Date:03/14/05ISR Number: 4608220-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00166
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							
Disability	Hypertension							

Date:03/14/05ISR Number: 4608226-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00156
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability		Methotrexate	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Sulfasalazine	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:03/14/05ISR Number: 4608238-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00167
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Venlafaxine Hydrochloride	C		ORAL		
			Prazosin Hydrochloride	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/05ISR Number: 4609770-0Report Type:Direct Company Report #CTU 243135
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Occlusive		Vioxx 25 Mg	PS			ONE TABLET	
Hospitalization -	Disease						ONCE DAILY	
Initial or Prolonged	Myocardial Infarction							
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:03/14/05ISR Number: 4609775-XReport Type:Direct Company Report #CTU 243131
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Activities Of Daily		Vioxx	PS			25 MG/BID, 50	
Hospitalization -	Living Impaired						MG BID	30 DAY
Initial or Prolonged	Cerebrovascular Accident							
Disability								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:03/14/05ISR Number: 4609915-2Report Type:Direct Company Report #CTU 243132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx 25mg & 50 Mg	PS		ORAL	ONE TABLET BY	
Initial or Prolonged	Hemiplegia						MOUTH ONCE	
Disability	Hypertension						DAILY	
	Hypoaesthesia							

Nausea

Date:03/14/05ISR Number: 4609919-XReport Type:Direct Company Report #CTU 243133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS				

Date:03/14/05ISR Number: 4610215-5Report Type:Expedited (15-DaCompany Report #2005-BP-01574YA
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Anoxia
	Arrhythmia
	Cardiac Arrest
	Coma
	Electroencephalogram Abnormal
	General Physical Health Deterioration
	Lung Disorder
	Nervous System Disorder
	Nosocomial Infection
	Sepsis
	Sudden Death

	Superinfection						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Health Professional	Omix (Tamsulosin Hydrochloride) (Tamsulosin)	PS		ORAL	0.4 MG	
			Visken (Pindolol)	SS		ORAL		
			Amarel (Glimepiride)	SS		ORAL		
			Vioxx (Rofecoxib)	SS		ORAL	2 YR	
			Metformin (Metformin)	SS		ORAL		

Date:03/14/05ISR Number: 4610443-9Report Type:Expedited (15-DaCompany Report #2005041617
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:03/15/05ISR Number: 4608667-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01728
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Hospitalization -	Chest Pain		Lopressor	C			UNKNOWN	
Initial or Prolonged	Coronary Artery Disease		Coumadin	C			UNKNOWN	
Disability	Myocardial Infarction		Vitamins (Unspecified)	C			UNKNOWN	
Other			Amiodarone	C			UNKNOWN	
			Niaspan	C			UNKNOWN	

			Zocor	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

Date:03/15/05ISR Number: 4608670-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01061
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged	Myocardial Infarction		Tylenol	C				
UNKNOWN								

Date:03/15/05ISR Number: 4608672-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00122
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ocular Vascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	200	DAY
Other	Oedema Peripheral		Diclofenac Sodium	C				
UNKNOWN								
	Papilloedema							
	Scotoma							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608675-9Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00260
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Dyspnoea		Ibuprofen	SS		ORAL		
	Gastrointestinal Ulcer		Ibuprofen	SS		ORAL		
	Haemoglobin Decreased		Atorvastatin Calcium	C		ORAL		
	Oesophagitis		Acetaminophen	C		ORAL		
	Syncope							

Date:03/15/05ISR Number: 4608676-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Benign Prostatic		[Therapy					
	Hyperplasia		Unspecified]	C				
UNKNOWN								
	Blood Triglycerides		Tylenol With Codeine					
	Increased		#3	C				
UNKNOWN								
	Blood Urine Present							
	Cataract Operation							
	Cerebrovascular Accident							
	Depression							
	Facet Joint Syndrome							
	Gait Disturbance							
	Hypoaesthesia							
	Insomnia							
	Lumbar Radiculopathy							
	Musculoskeletal							
	Discomfort							
	Nausea							
	Neck Pain							
	Oedema Peripheral							
	Post Laminectomy Syndrome							
	Post Procedural							
	Complication							
	Skin Papilloma							
	Sleep Apnoea Syndrome							

Spinal Cord Disorder
Tachycardia
Vertebrobasilar
Insufficiency
Vomiting

Date:03/15/05ISR Number: 4608681-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608685-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00028
Age:89 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Hospitalization - Initial or Prolonged	Death Myocardial Infarction							

Date:03/15/05ISR Number: 4608686-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01187
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	41 MON	

Date:03/15/05ISR Number: 4608687-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01748
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:03/15/05ISR Number: 4608688-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

Date:03/15/05ISR Number: 4608689-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4608693-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	267	DAY

Date:03/15/05ISR Number: 4608694-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01041
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4608695-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01382
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Zoloft	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4608696-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/15/05ISR Number: 4609168-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00908
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	556	DAY
	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	556	DAY
	Cognitive Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	556	DAY
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL	556	DAY
	Fatigue		Gabapentin	C		ORAL	UNKNOWN	
	Myalgia		Effexor Xr	C		ORAL		
	Neuropathy		Topamax	C		ORAL		
	Urinary Incontinence		Skelaxin	C		ORAL		
			Provigil	C				
			Oxycontin	C		ORAL		

Date:03/15/05ISR Number: 4609169-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02533
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Initial or Prolonged	Back Injury							
Other	Cerebrovascular Accident							
	Convulsion							
	Emotional Distress							
	Hypertension							
	Injury							
	Intervertebral Disc							

Protrusion
Intestinal Functional
Disorder
Myocardial Infarction
Neck Pain
Neuropathy
Radiculitis
Radiculitis Brachial
Spinal Osteoarthritis
Stress
Tendonitis
Urinary Tract Disorder

Date:03/15/05ISR Number: 4609171-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00074
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
	Alopecia
	Anorexia
	Anuria
	Aphasia
	Arthralgia
	Asthenia
	Blood Creatinine Increased

		Blood Pressure Diastolic Decreased					
		Blood Urea Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL
		Buttock Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL
		Chromaturia		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Azopt Drops	C		
UNKNOWN							
		Pulmonary Disease		Levoxyl	C		
UNKNOWN							
		Confusional State		Ocupress	C		
UNKNOWN							
		Contusion		Prempro	C		
UNKNOWN							
		Death		Maxzide	C		
UNKNOWN							
		Decreased Appetite					
		Dizziness					
		Dizziness Postural					
		Dry Mouth					
		Dysphagia					
		Dyspnoea					
		Extrasystoles					
		Eye Pain					
		Failure To Thrive					
		Fall					
		Fatigue					
		Feeling Hot					
		Gait Disturbance					
		Head Injury					
		Interstitial Lung Disease					
		Limb Injury					
		Lymphocyte Percentage Decreased					
		Metabolic Disorder					
		Myalgia					
		Normochromic Normocytic Anaemia					
		Oedema Peripheral					
		Oral Intake Reduced					
		Pitting Oedema					
		Pneumonia					
		Productive Cough					
		Rales					
		Red Blood Cell Count					

Decreased
Refusal Of Treatment By Patient
Respiratory Rate Increased
Salivary Gland Neoplasm
Salivary Gland Pain
Skin Laceration
Supraventricular Extrasystoles
Treatment Noncompliance
Urinary Retention
Urinary Tract Infection
Urine Odour Abnormal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609173-9Report Type:Expedited (15-DaCompany Report #NZ-MERCK-0410NZL00062
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Fibrillation		Chondroitin Sulfate Sodium And Dimethyl Sulfone And Glucosamine	C		ORAL		
	Cerebrovascular Accident		Aspirin	C		ORAL		
	Eye Disorder							
	Eye Injury							

Date:03/15/05ISR Number: 4609174-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01131
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder With Depressed Mood
Disability	Affective Disorder
Other	Alopecia
	Anaemia
	Angina Unstable
	Ankylosing Spondylitis
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Concussion
	Constipation
	Depression
	Drug Ineffective
	Dysphagia
	Dysphoria
	Facet Joint Syndrome
	Facial Bones Fracture
	Fall
	Gastrooesophageal Reflux Disease
	Hypothyroidism
	Insomnia
	Intervertebral Disc Degeneration
	Intervertebral Disc Displacement

Intervertebral Disc
Protrusion
Jaw Disorder
Limb Injury
Myofascial Pain Syndrome
Neck Pain
Nephritis Interstitial
Oesophageal Stenosis
Osteoporosis
Palpitations
Peripheral Sensory
Neuropathy
Polyarthritis
Psoriatic Arthropathy
Raynaud'S Phenomenon
Reflux Oesophagitis
Reiter'S Syndrome

Dose	Duration	Renal Failure Sacroiliitis Spondyloarthropathy Urinary Tract Pain Weight Increased	Report Source	Product	Role	Manufacturer	Route
5	DAY			Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Microzide	SS		
UNKNOWN				Microzide	SS		
24	DAY			Vioxx	SS	Merck & Co., Inc	ORAL
179	DAY			Vioxx	SS	Merck & Co., Inc	ORAL
22	DAY			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		27 DAY		Zestoretic	SS		
99	DAY			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN				Vicodin Es Tablets	C		
UNKNOWN				Celebrex	C		
PARENTERAL		1 DAY		Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN				Estratest	C		
UNKNOWN				Claritin	C		
UNKNOWN				Effexor	C		
UNKNOWN				Trazodone Hydrochloride	C		
UNKNOWN				Imitrex	C		
UNKNOWN				Trazodone Hydrochloride	C		
UNKNOWN				Claritin	C		
UNKNOWN				Estratest	C		

			Beconase	C			
UNKNOWN							
			Valium	C			
UNKNOWN							
			Prevacid	C			
UNKNOWN							
			Prevacid	C			
UNKNOWN							

Date:03/15/05ISR Number: 4609180-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01729
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609183-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00736
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Life-Threatening Hospitalization - Initial or Prolonged	Blighted Ovum Drug Exposure During Pregnancy		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609190-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00156
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C				
UNKNOWN								
Disability			Prednisone	C				
UNKNOWN								
			Sulfasalazine	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

[Therapy
Unspecified] C
UNKNOWN

Date:03/15/05ISR Number: 4609191-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebral Infarction Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609193-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Ranitidine	C				
UNKNOWN								
	Hypertension		Vasotec	C				
UNKNOWN								
	Migraine		Diclofenac	C				
UNKNOWN								
	Visual Disturbance							

Date:03/15/05ISR Number: 4609197-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebral Infarction Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609199-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02192
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm Ruptured		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Oxycontin	C		ORAL		
			Ambien	C		ORAL		
			Lexxel	C		ORAL		
			Diovan	C		ORAL		
			Clonidine	C		ORAL		

Date:03/15/05ISR Number: 4609200-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0503DNK00012
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 331 DAY Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609201-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609202-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00097
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	341 DAY	
Hospitalization - Initial or Prolonged			Celecoxib	SS		ORAL		
			Bumetanide	C		ORAL		
			Potassium (Unspecified)	C		ORAL		
			Digoxin	C		ORAL		
			Verapamil	C		ORAL		

Date:03/15/05ISR Number: 4609203-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03243
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609205-8Report Type:Expedited (15-DaCompany Report #IL-MERCK-0503ISR00008
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL	40 DAY	
Disability	Poor Peripheral Circulation		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609207-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00903
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		1 DAY
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Urine Present		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Bundle Branch Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	Confusional State		Flexeril	C			UNKNOWN	
	Cough		Imipramine Hydrochloride	C			UNKNOWN	
	Headache							
	Oedema							
	Prescribed Overdose							
	Vomiting							

Date:03/15/05ISR Number: 4609209-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609210-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609211-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609212-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	253 DAY	
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL	106 DAY	
	Congestive Coronary Artery Disease Myocardial Infarction							

Date:03/15/05ISR Number: 4609214-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Disease Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609215-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON

Date:03/15/05ISR Number: 4609216-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609218-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain Diarrhoea Gastric Disorder Liver Disorder Nausea Urinary Tract Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609219-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Convulsion Heart Rate Increased Heart Rate Irregular Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609220-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01313
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cerebral Haemorrhage Cerebrovascular Accident Gastrooesophageal Reflux Disease Headache Hemiparesis Hypertension Micturition Disorder Nausea Pollakiuria Vision Blurred Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609221-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609222-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609223-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01360
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Nerve Injury		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:03/15/05ISR Number: 4609224-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609225-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609226-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:03/15/05ISR Number: 4609227-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609228-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Other	Pain							

Date:03/15/05ISR Number: 4609232-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/15/05ISR Number: 4609233-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/15/05ISR Number: 4609234-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01679
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609235-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01730
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Deep Vein Thrombosis Emotional Distress Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609236-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/15/05ISR Number: 4609238-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609239-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01759
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Transient Ischaemic Attack							

Date:03/15/05ISR Number: 4609240-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Other	Cerebrovascular Accident Pain							

Date:03/15/05ISR Number: 4609242-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609243-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/15/05ISR Number: 4609244-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/15/05ISR Number: 4609245-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/15/05ISR Number: 4609250-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01798
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx [Therapy Unspecified]	SS	Merck & Co., Inc	ORAL		
Disability				C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

Date:03/15/05ISR Number: 4609251-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609252-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	454 DAY	

Date:03/15/05ISR Number: 4609253-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609255-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other	Cerebrovascular Accident Pain							

Date:03/15/05ISR Number: 4609256-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Life Expectancy Shortened Myocardial Infarction Pain							

Date:03/15/05ISR Number: 4609257-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609259-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609260-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609261-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01777
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609262-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Emotional Distress Pain Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609263-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01778
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609264-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01788
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1722 DAY

Date:03/15/05ISR Number: 4609265-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609266-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01785
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609267-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	979	DAY

Date:03/15/05ISR Number: 4609268-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609269-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01772
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609271-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	795	DAY

Date:03/15/05ISR Number: 4609272-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01800
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Metformin	C				
UNKNOWN								

Initial or Prolonged Enalapril Maleate C
UNKNOWN

Glucophage C
UNKNOWN

Date:03/15/05ISR Number: 4609280-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609281-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:03/15/05ISR Number: 4609282-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01955
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609283-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02081
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/15/05ISR Number: 4609285-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609287-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	376 DAY	
	Polytraumatism							

Date:03/15/05ISR Number: 4609288-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609289-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609293-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02699
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Calculus Ureteric							
	Phlebolith							
	Pyelonephritis Chronic							
	Renal Failure							
	Wound Infection							

Date:03/15/05ISR Number: 4609295-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4609298-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02084
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4609332-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02082
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/15/05ISR Number: 4611063-2Report Type:Direct Company Report #CTU 243231
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx 12.5 , 25mg	PS		ORAL	12.5	1-2X
Hospitalization -	Coronary Artery Surgery						DAILY BY	
Initial or Prolonged	Dyspnoea						MOUTH	
Required	Fatigue							
Intervention to	Hyperhidrosis							
Prevent Permanent								
Impairment/Damage								

Date:03/15/05ISR Number: 4611174-1Report Type:Direct Company Report #CTU 243270
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Difficulty In Walking		Vioxx 25 Mg	PS			1 PR DAY	
Initial or Prolonged								

Date:03/15/05ISR Number: 4611175-3Report Type:Direct Company Report #CTU 243271
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx 50 Mg	PS		ORAL	1 TAB MY	
Hospitalization -	Myocardial Infarction						MOUTH DAILY	

Initial or Prolonged	Pulmonary Embolism		Celebrex	SS		ORAL
1 TAB BY MOUTH DAILY	Thrombosis					

Date:03/15/05ISR Number: 4611176-5Report Type:Direct Company Report #CTU 243272
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx - 25 Mg.	PS		
1 DAILY						
Initial or Prolonged	Memory Impairment					

Date:03/15/05ISR Number: 4611177-7Report Type:Direct Company Report #CTU 243273
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Joint Swelling		Vioxx 25 Mg 1			
Hospitalization -	Myocardial Infarction		Daily	PS		
25 MG DAILY						
Initial or Prolonged						
Required Intervention to Prevent Permanent Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4611228-XReport Type:Direct Company Report #CTU 243277
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Celebrex 200 Mg - Searle	PS	Searle		200 MG 1 DAILY	Required
Intervention to Prevent Permanent Impairment/Damage			Vioxx Merck	SS	Merck		1 DAILY	

Date:03/15/05ISR Number: 4611247-3Report Type:Direct Company Report #CTU 243265
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardio-Respiratory Arrest		Vioxx 25mg	PS			SEE IMAGE	
Hospitalization - Initial or Prolonged	Dyspnoea							
Disability								

Date:03/15/05ISR Number: 4611249-7Report Type:Direct Company Report #CTU 243267
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx 20 Mg	PS			1 PER DAY	2 YR
			Bextra 20 Mg	SS			1 PER DAY	2 YR
Other								

Date:03/15/05ISR Number: 4613327-5Report Type:Expedited (15-DaCompany Report #2005019442
Age:92 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Pressure Systolic Increased Condition Aggravated	Foreign Health Professional	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
		Company Representative	Rofecoxib (Rofecoxib)	SS				
			Losartan Potassium (Losartan Potassium)	C				
			Oxazepam (Oxazepam)	C				
			Di-Gesic (Dextropropoxyphene, Paracetamol)	C				

Date:03/15/05ISR Number: 4613863-1Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00140
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Headache Hypertension	Foreign Study Other	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY PO	367 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/15/05ISR Number: 4613864-3Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00095
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome	Foreign	Tab Vioxx					
Hospitalization -	Alanine Aminotransferase	Study	(Rofecoxib)	PS		ORAL	25 MG/ DAILY	
Initial or Prolonged	Increased	Other					PO	
	Atrial Fibrillation		Digoxin	C				
	Blood Alkaline		Ferrousso4	C				
	Phosphatase Increased		Omeprazole	C				
	Blood Calcium Decreased							
	Bundle Branch Block Left							
	Endocarditis							
	Haemoglobin Decreased							
	Left Ventricular Failure							
	Loss Of Consciousness							
	Pulmonary Oedema							
	Troponin Increased							

Date:03/15/05ISR Number: 4614128-4Report Type:Expedited (15-DaCompany Report #WAES 0502USA02963
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Study	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Atrial Fibrillation	Health						
	Pneumonia	Professional						
	Renal Failure Acute							
	Upper Gastrointestinal							
	Haemorrhage							

Date:03/15/05ISR Number: 4614193-4Report Type:Expedited (15-DaCompany Report #WAES 0308GBR00095
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome	Foreign	Tab Vioxx					
Hospitalization -	Alanine Aminotransferase	Study	(Rofecoxib)	PS		ORAL	25 MG DAILY;	

Initial or Prolonged Increased Other
PO 331 DAY

Atrial Fibrillation	Digoxin	C
Blood Alkaline	Ferrousso4	C
Phosphatase Increased	Omeprazole	C
Blood Calcium Decreased		
Bundle Branch Block Left		
Confusional State		
Cyanosis		
Left Ventricular Failure		
Loss Of Consciousness		
Pulmonary Oedema		

Date:03/15/05ISR Number: 4615087-0Report Type:Expedited (15-DaCompany Report #2005040366
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Health Professional	Celebra (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D), ORAL	

				Levothyroxine Sodium (Levothyroxine Sodium)	C		

Date:03/16/05ISR Number: 4609868-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00182
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tremor		Insulin Human	C				
UNKNOWN								
			Insulin Human, Isophane	C				
UNKNOWN								
			Domperidone	C		ORAL		

Date:03/16/05ISR Number: 4609869-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04082
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Zocor	C		ORAL		
	Balance Disorder		[Therapy					
	Blindness		Unspecified]	C				
UNKNOWN								
	Blindness Unilateral		[Therapy					
	Bronchitis		Unspecified]	C				
UNKNOWN								
	Bronchitis Acute							
	Cellulitis							
	Cerebrovascular Accident							
	Constipation							
	Drug Ineffective							
	Dysphagia							
	Dyspnoea							
	Dysuria							
	Emphysema							
	Fatigue							
	Genital Pruritus Female							
	Glossodynia							

Hypothyroidism
Lymphoma
Muscle Spasms
Oedema Peripheral
Onychomycosis
Oral Candidiasis
Pain In Extremity
Pelvic Pain
Peripheral Vascular
Disorder
Sinusitis
Stomatitis
Upper Respiratory Tract
Infection
Weight Decreased

Date:03/16/05ISR Number: 4609877-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00008
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		170 DAY
Hospitalization - Initial or Prolonged			Estradiol And Norethindrone Acetate	SS				
Disability			Plendil	C		ORAL		
UNKNOWN			Hydrochlorothiazide And Valsartan	C		ORAL		

Date:03/16/05ISR Number: 4609879-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00165
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C				
UNKNOWN								
Disability			Olsalazine Sodium	C				
UNKNOWN								

Date:03/16/05ISR Number: 4609881-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609882-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609883-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Ceftin	C		ORAL		
	Cough		Percocet	C		ORAL		
	Emotional Distress		Vicodin Es Tablets	C		ORAL		
	Headache		Ambien	C		ORAL		
	Hyperhidrosis		Zoloft	C		ORAL		
	Hyperlipidaemia		Zoloft	C		ORAL		
	Hypertension							
	Mitral Valve Prolapse							
	Pharyngolaryngeal Pain							
	Sinusitis							
	Sleep Apnoea Syndrome							
	Stomach Discomfort							
	Thrombosis							
	Trigger Finger							
	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609885-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebral Infarction Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609888-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01224
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Hospitalization -			Ambien	C			UNKNOWN	
Initial or Prolonged			Talwin	C			UNKNOWN	

Date:03/16/05ISR Number: 4609889-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00026
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	850	DAY
			Celecoxib	SS		ORAL	918	DAY

Date:03/16/05ISR Number: 4609892-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00163
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:03/16/05ISR Number: 4609893-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609894-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/16/05ISR Number: 4609907-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609908-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609910-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609911-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01409
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01404
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/16/05ISR Number: 4609914-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609916-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	58	MON

Date:03/16/05ISR Number: 4609917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Initial or Prolonged	Myocardial Infarction							
	Pain							

Date:03/16/05ISR Number: 4609918-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01733
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	53	MON
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609928-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01983
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Polytraumatism							

Date:03/16/05ISR Number: 4609929-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:03/16/05ISR Number: 4609930-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:03/16/05ISR Number: 4609932-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:03/16/05ISR Number: 4609933-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01737
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
25 MON						
	Cardiovascular Disorder					
	Myocardial Infarction					
	Pain					

Date:03/16/05ISR Number: 4609934-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01987
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/16/05ISR Number: 4609937-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01894
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/16/05ISR Number: 4609940-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01897
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609941-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	498	DAY
	Myocardial Infarction							
	Thrombosis							

Date:03/16/05ISR Number: 4609942-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01984
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	196	DAY
	Polytraumatism							

Date:03/16/05ISR Number: 4609943-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609944-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609948-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609949-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609950-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Sinus Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609951-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01735
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	53	MON
	Myocardial Infarction							
	Pain							

Date:03/16/05ISR Number: 4609952-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Polytraumatism							

Date:03/16/05ISR Number: 4609953-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01916
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1457	DAY

Date:03/16/05ISR Number: 4609954-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:03/16/05ISR Number: 4609959-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
	Polytraumatism							

Date:03/16/05ISR Number: 4609961-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609962-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609963-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4609964-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4609967-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2223 DAY

Date:03/16/05ISR Number: 4609980-2Report Type:Expedited (15-DaCompany Report #PHBS2005NO02892
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness Dyskinesia		Trileptal	PS	Novartis Sector: Pharma	ORAL	300 mg, BID	
	Feeling Abnormal		Aerius	SS		ORAL	5 mg/d	
	Hypersensitivity		Vioxx	SS		ORAL	25 mg/d	10080MIN
	Nausea		Azitromax	SS		ORAL	500 mg/d	4320 MIN

Date:03/16/05ISR Number: 4610026-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc		UNKNOWN	8 MON

Date:03/16/05ISR Number: 4610502-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01336
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		194 DAY
Hospitalization - UNKNOWN	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc			
Initial or Prolonged Disability	Loss Of Consciousness		Metformin	C		ORAL		
	Prescribed Overdose		Lisinopril	C		ORAL		
Other	Urinary Tract Infection		Atenol	C		ORAL		
			Ultram	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		

Date:03/16/05ISR Number: 4610510-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability Other	Abdominal Pain Upper
	Back Pain
	Blood Triglycerides Increased
	Chromaturia
	Chronic Fatigue Syndrome
	Constipation
	Convulsion
	Costochondritis

		Depression					
		Diabetes Mellitus					
		Inadequate Control	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disturbance In Attention		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL
		General Physical Health		Vioxx	SS	Merck & Co., Inc	ORAL
		Deterioration		Baycol	C		
UNKNOWN							
		Headache		Actos	C		
UNKNOWN							
		Hypertension		[Composition			
		Insomnia		Unspecified]	C		
UNKNOWN							
		Macular Oedema					
		Muscle Spasms					
		Myalgia					
		Myocardial Infarction					
		Neck Injury					
		Neuritis					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Pain					
		Peripheral Vascular					
		Disorder					
		Restless Legs Syndrome					
		Retinopathy					
		Road Traffic Accident					
		Serum Ferritin Decreased					
		Tachycardia					

Date:03/16/05ISR Number: 4610526-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03070
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
Hospitalization -		Disease		[Therapy			

Initial or Prolonged	Chest Pain	Unspecified]	C
UNKNOWN			
	Coronary Artery Disease	Toprol Xl Tablets	C
UNKNOWN			
		Altace	C
UNKNOWN			
		Plavix	C
UNKNOWN			
		Zocor	C
UNKNOWN			
		Aspirin	C
UNKNOWN			

Date:03/16/05ISR Number: 4610531-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02602
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Dysarthria		Vioxx	SS	Merck & Co., Inc	ORAL
	Multiple Sclerosis		[Therapy			
	Muscle Spasticity		Unspecified]	C		
UNKNOWN						
			Oxycontin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610533-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01745
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adenoidal Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL		3 DAY
Other	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		3 DAY
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Chronic Sinusitis		Zyrtec	C				
	Depression		Lotrel	C				UNKNOWN
	General Physical Health		Lipitor	C				UNKNOWN
	Deterioration		Furosemide	C				UNKNOWN
	Hernia		Potassium (Unspecified)	C				UNKNOWN
	Mitral Valve Incompetence							
	Myocardial Infarction		Aspirin	C				UNKNOWN
	Oedema Peripheral		Clarinex	C				UNKNOWN
	Otitis Media Chronic		Foltx	C				UNKNOWN
	Pain		Levaquin	C				UNKNOWN
	Sinus Disorder							
	Tricuspid Valve Incompetence							

Date:03/16/05ISR Number: 4610543-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610544-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02468
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON
Initial or Prolonged	Adverse Event		Tylenol	C				UNKNOWN
Other	Blood Urea Increased		Lipitor	C				UNKNOWN
	Bundle Branch Block Left		Triamterene	C				UNKNOWN
	Dilatation Atrial		Hydrodiuril	C				UNKNOWN
	Duodenal Ulcer		Atenolol	C		ORAL		
	Emotional Distress		Clorazepate					
	Gastrooesophageal Reflux		Monopotassium	C				UNKNOWN
	Disease		Roxicet	C				UNKNOWN
	Pain		Fosamax	C		ORAL		
	Upper Gastrointestinal Haemorrhage							
	Ventricular Hypertrophy							
	White Blood Cell Count Increased							

Date:03/16/05ISR Number: 4610545-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia

		Arthropathy					
		Back Pain					
		Benign Prostatic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
10	DAY						
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
146	DAY						
		Restenosis		Zestril	C		
UNKNOWN		2170 DAY					
		Depression		Zestril	C		
UNKNOWN		2170 DAY					
		Diabetes Mellitus		Tenormin	C		
UNKNOWN							
		Non-Insulin-Dependent		Tenormin	C		
UNKNOWN							
		Diabetic Nephropathy		Glucophage	C		
UNKNOWN							
		Diabetic Neuropathy		Micronase	C		
UNKNOWN							
		Diabetic Retinopathy		Lanoxin	C		
UNKNOWN		1051 DAY					
		Dilatation Ventricular		[Therapy			
		Drug Ineffective		Unspecified]	C		
UNKNOWN							
		Fall		Aciphex	C		
UNKNOWN							
		Hepatitis					
		Herpes Zoster					
		Hypercholesterolaemia					
		Hypoglycaemia					
		Hypotension					
		Infection					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Disorder					
		Ischaemic Cardiomyopathy					
		Oedema Peripheral					
		Pneumonia					
		Renal Cyst					

Sepsis
Sexual Dysfunction
Ventricular Tachycardia
Weight Increased

Date:03/16/05ISR Number: 4610555-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/16/05ISR Number: 4610557-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610558-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01005
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Hiatus Hernia		Tricor	C				
UNKNOWN								
Other			Welchol	C				
UNKNOWN								
			Zantac	C				
UNKNOWN								

	Acetaminophen And Hydrocodone Bitartrate	C	UNKNOWN
	Alprazolam	C	UNKNOWN

Date:03/16/05ISR Number: 4610559-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Aortic Aneurysm							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive Cardiomyopathy							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Kidney Small							
	Metabolic Disorder							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Myoclonus							
	Renal Failure							

Date:03/16/05ISR Number: 4610561-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:03/16/05ISR Number: 4610562-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00064
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610563-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01597
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Insulin	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

Date:03/16/05ISR Number: 4610565-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01602
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Levothroid	C			UNKNOWN	
Disability								

Date:03/16/05ISR Number: 4610566-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON
	Cerebrovascular Accident							
	Pain							

Date:03/16/05ISR Number: 4610567-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00033
Age:86 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Valpromide	C		ORAL		
	Purpura		Triptorelin Acetate	C		ORAL		
			Sertraline Hydrochloride	C			UNKNOWN	
			Bicalutamide	C			UNKNOWN	
			Rabeprazole Sodium	C			UNKNOWN	
			Oxazepam	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	

Date:03/16/05ISR Number: 4610568-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/16/05ISR Number: 4610570-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Bayer Aspirin	C				
UNKNOWN								
	Chest Pain		Lisinopril	C				
UNKNOWN								
	Dizziness							
	Heat Stroke							
	Loss Of Consciousness							
	Nausea							
	Vomiting							

Date:03/16/05ISR Number: 4610572-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01661
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610573-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01672
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610574-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01716
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Disability	Myocardial Infarction							
	Pain							

Date:03/16/05ISR Number: 4610576-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01718
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/16/05ISR Number: 4610577-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Surgery							
	Myocardial Infarction							

Date:03/16/05ISR Number: 4610578-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610580-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01739
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
34 MON

Date:03/16/05ISR Number: 4610581-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/16/05ISR Number: 4610582-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01818
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610583-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01741
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	54	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610585-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01709
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610590-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01898
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610591-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:03/16/05ISR Number: 4610594-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610596-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610598-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	731 DAY	
	Polytraumatism							

Date:03/16/05ISR Number: 4610599-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610601-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610602-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Disability	Pain							

Date:03/16/05ISR Number: 4610604-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:03/16/05ISR Number: 4610605-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01892
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610607-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01879
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Potassium Decreased		Glucophage	C				
UNKNOWN								
Initial or Prolonged	Cerebrovascular Accident		Buspar	C				
UNKNOWN								
Disability	Myocardial Infarction		Amaryl	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								
			Caduet	C				
UNKNOWN								

	Plavix	C	UNKNOWN
	Ultram	C	UNKNOWN
	Prinivil	C	UNKNOWN
	Prempro	C	UNKNOWN

Date:03/16/05ISR Number: 4610608-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01896
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610609-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610610-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610617-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Polytraumatism							

Date:03/16/05ISR Number: 4610618-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Polytraumatism							

Date:03/16/05ISR Number: 4610620-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/16/05ISR Number: 4610622-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/16/05ISR Number: 4610624-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/16/05ISR Number: 4610625-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/16/05ISR Number: 4610626-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610627-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610629-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610630-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610633-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	1125 DAY	

Date:03/16/05ISR Number: 4610634-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:03/16/05ISR Number: 4610635-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
578 DAY

Date:03/16/05ISR Number: 4610636-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01981
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
3 YR

Date:03/16/05ISR Number: 4610637-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01997
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
205 DAY

Date:03/16/05ISR Number: 4610638-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02000
Age: Gender:Male I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610639-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610640-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610641-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610642-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/16/05ISR Number: 4610643-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610644-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	393	DAY
	Polytraumatism							

Date:03/16/05ISR Number: 4610645-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:03/16/05ISR Number: 4610646-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610647-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610648-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	689	DAY
	Cerebrovascular Accident							

Date:03/16/05ISR Number: 4610649-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/16/05ISR Number: 4610650-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01961
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610651-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:03/16/05ISR Number: 4610655-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610658-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02018
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/16/05ISR Number: 4610659-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other	Death Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610660-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610662-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/16/05ISR Number: 4610663-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/16/05ISR Number: 4610665-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/16/05ISR Number: 4610666-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02057
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1111	DAY

Date:03/16/05ISR Number: 4610667-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Polytraumatism							

Date:03/16/05ISR Number: 4610669-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610670-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610671-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610674-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	322	DAY
	Polytraumatism							

Date:03/16/05ISR Number: 4610678-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610679-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610681-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610683-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610684-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610686-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610687-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610688-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610690-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610691-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02204
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/16/05ISR Number: 4610692-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610695-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		466 DAY

Date:03/16/05ISR Number: 4610696-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610697-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02213
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/16/05ISR Number: 4610699-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0503ZAF00005
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610701-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc			
	Emotional Distress							
	Myocardial Infarction							
	Pain							

Date:03/16/05ISR Number: 4610710-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4610722-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/16/05ISR Number: 4612493-5Report Type:Direct Company Report #CTU 243339
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Dyspnoea	Vioxx 25 Mg	
Congenital Anomaly	Fatigue	(Refills)	PS
25 MG DAILY			
Required	Mitral Valve Incompetence		
Intervention to			
Prevent Permanent			
Impairment/Damage			

Date:03/16/05ISR Number: 4613180-XReport Type:Expedited (15-DaCompany Report #2005022759
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Hospitalization -	Circulatory Collapse		Rofecoxib					
Initial or Prolonged	Convulsion		(Rofecoxib)	SS				
Other	Diabetes Mellitus		Atenolol (Atenolol)	C				
	Heart Rate Increased		Isosorbide Dinitrate					
	Intervertebral Disc		(Isosorbide					
	Disorder		Dinitrate)	C				
	Localised Oedema							
	Nausea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611200-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		726 DAY
Initial or Prolonged	Aortic Valve Disease		Levoxyl	C				UNKNOWN
Other	Atherosclerosis		Hydrochlorothiazide	C				UNKNOWN
	Blood Cholesterol		Cardizem	C				UNKNOWN
	Increased		Lovastatin	C				UNKNOWN
	Cardiac Failure		Premarin	C				UNKNOWN
	Congestive							
	Coronary Artery Disease							
	Drug Hypersensitivity							
	Gallbladder Disorder							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							

Date:03/17/05ISR Number: 4611202-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00111
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability		Ultram	C				UNKNOWN
	Oedema Peripheral		Lasix (Furosemide					
	Rash Generalised		Sodium)	C				UNKNOWN
	Renal Pain		Prilosec	C				UNKNOWN
	Swelling Face		Clonidine	C				UNKNOWN
	Thrombosis		Acetaminophen And					
	Transient Ischaemic		Hydrocodone					
	Attack		Bitartrate	C				UNKNOWN

	Urinary Tract Infection		Tizanidine	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						

Date:03/17/05ISR Number: 4611204-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00132
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Premarin	C		
UNKNOWN						
	Rotator Cuff Syndrome		Pravachol	C		
UNKNOWN						

Date:03/17/05ISR Number: 4611206-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:F

Outcome	PT
Death	Aggression
Hospitalization - Initial or Prolonged	Aspiration
	Completed Suicide
Other	Depressed Level Of Consciousness
	Drug Interaction
	Drug Screen Positive
	Drug Toxicity
	Foreign Body Aspiration
	Intentional Misuse
	Lung Crepitation

	Lung Disorder						
	Sedation						
	Self-Medication	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		
			Flexeril	SS		ORAL		
			Ultracet	SS				UNKNOWN
			Omeprazole	SS		ORAL		
			Elavil	SS		ORAL		
			Tizanidine Hydrochloride	SS		ORAL		

Date:03/17/05ISR Number: 4611207-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0501GBR00033
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	123 DAY	
	Hemiplegia		Tramadol Hydrochloride	C				UNKNOWN
			Clonazepam	C				UNKNOWN
			Nortriptyline	C				UNKNOWN
			Clonidine	C				UNKNOWN
			Mebeverine Hydrochloride	C				UNKNOWN

Date:03/17/05ISR Number: 4611209-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebral Atrophy		Allopurinol	C		ORAL		
	Cerebrovascular Accident		Nitrendipine	C		ORAL		
	Diplopia		Aspirin	C		ORAL		
	Transient Ischaemic		Cetirizine					

Attack	Hydrochloride	C		ORAL
Visual Disturbance	Methotrexate	C		ORAL
	Prednisolone	C		ORAL

Date:03/17/05ISR Number: 4611220-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00031
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		MON
Initial or Prolonged	Myocardial Ischaemia							
Other								

Date:03/17/05ISR Number: 4611221-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611222-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03128
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Myocardial Infarction		Atacand	C				
Initial or Prolonged UNKNOWN			Effexor	C				
Disability UNKNOWN			Lasix (Furosemide)	C				

Date:03/17/05ISR Number: 4611226-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01683
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Injury							

Date:03/17/05ISR Number: 4611227-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00458
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cardiac Murmur		Glucotrol	C				
Initial or Prolonged	Cardiomyopathy							
Disability	Chest Pain							
Other	Cholecystectomy							
	Diabetes Mellitus							
	Inadequate Control							
	Dyspnoea							
	Fall							
	Flank Pain							
	Gallbladder Disorder							
	Hyperlipidaemia							
	Hypertension							
	Injury							
	Intervertebral Disc							

Disorder
Intervertebral Disc
Operation
Muscle Strain
Musculoskeletal Disorder
Night Sweats
Pain In Extremity
Pancreatitis
Renal Failure
Skin Hyperpigmentation
Staphylococcal Infection
Toxic Shock Syndrome
Streptococcal

Date:03/17/05ISR Number: 4611229-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01342
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611230-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611231-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00177
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Diverticulitis Intestinal Haemorrhagic Diverticulum Polycythaemia Vera Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611233-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01401
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611234-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01899
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611235-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01414
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611236-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01681
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/17/05ISR Number: 4611237-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Global Amnesia Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611238-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611239-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01901
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1216 DAY	

Date:03/17/05ISR Number: 4611240-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01935
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	

Date:03/17/05ISR Number: 4611241-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	26 MON	

Date:03/17/05ISR Number: 4611242-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:03/17/05ISR Number: 4611243-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611244-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	505	DAY

Date:03/17/05ISR Number: 4611245-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611246-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611250-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Injury							

Date:03/17/05ISR Number: 4611251-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	975	DAY

Date:03/17/05ISR Number: 4611252-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1738	DAY

Date:03/17/05ISR Number: 4611253-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01965
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/17/05ISR Number: 4611254-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01966
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
7 MON

Date:03/17/05ISR Number: 4611256-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01974
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611257-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1606 DAY	
	Injury							

Date:03/17/05ISR Number: 4611258-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611259-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

Date:03/17/05ISR Number: 4611260-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/17/05ISR Number: 4611261-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01963
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1660	DAY

Date:03/17/05ISR Number: 4611262-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:03/17/05ISR Number: 4611263-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611264-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/17/05ISR Number: 4611265-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611270-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611272-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02041
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1226 DAY	
	Injury							

Date:03/17/05ISR Number: 4611275-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/17/05ISR Number: 4611276-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/17/05ISR Number: 4611277-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Injury							

Date:03/17/05ISR Number: 4611278-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/17/05ISR Number: 4611280-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	463	DAY

Date:03/17/05ISR Number: 4611281-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02218
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	875	DAY

Date:03/17/05ISR Number: 4611283-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	160	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611284-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611286-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1096 DAY	

Date:03/17/05ISR Number: 4611287-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611289-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02016
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL	678 DAY	

Date:03/17/05ISR Number: 4611298-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1169 DAY	

Date:03/17/05ISR Number: 4611299-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611301-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/17/05ISR Number: 4611302-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611305-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02284
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Myocardial Infarction							

Date:03/17/05ISR Number: 4611306-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	658	DAY

Date:03/17/05ISR Number: 4611307-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:03/17/05ISR Number: 4611314-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	421	DAY

Date:03/17/05ISR Number: 4611316-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02275
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
5 MON

Date:03/17/05ISR Number: 4611317-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02281
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
13 MON

Date:03/17/05ISR Number: 4611318-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02277
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Cerebrovascular Accident Vioxx PS Merck & Co., Inc ORAL
1628 DAY

Date:03/17/05ISR Number: 4611319-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02283
Age: Gender:Female I/FU:I

Outcome PT Report Source Product Role Manufacturer Route
Dose Duration
Other Myocardial Infarction Vioxx PS Merck & Co., Inc ORAL
3 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611323-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Thrombosis							

Date:03/17/05ISR Number: 4611325-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02285
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	723	DAY

Date:03/17/05ISR Number: 4611331-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02286
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1265	DAY

Date:03/17/05ISR Number: 4611341-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611355-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611363-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Multi-Organ Disorder							
	Pain							
	Vascular Injury							

Date:03/17/05ISR Number: 4611365-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:03/17/05ISR Number: 4611967-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT
Aortic Atherosclerosis
Aortic Stenosis
Blood Cholesterol
Increased
Blood Pressure Systolic
Increased
Blood Triglycerides
Increased
Cardiac Disorder
Cardiac Failure
Congestive
Cardiac Murmur
Cardiomyopathy
Connective Tissue
Inflammation
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Dilatation Atrial
Drug Ineffective
Dyspnoea
Dyspnoea Exertional
Dysuria
Emotional Distress
Endocarditis
Fatigue
Fibromyalgia
Fluid Overload
Heart Rate Increased
Heart Rate Irregular
High Density Lipoprotein
Decreased
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Hyperextension
Libido Disorder
Low Density Lipoprotein
Increased
Metabolic Syndrome

Micturition Disorder
Mitral Valve Incompetence
Mitral Valve Prolapse
Myocardial Infarction
Normochromic Normocytic
Anaemia
Pulmonary Hypertension
Pulmonary Valve Stenosis
Radiculitis
Respiratory Disorder
Sleep Apnoea Syndrome
Spinal Compression
Fracture
Spinal Osteoarthritis

Treatment Noncompliance
Type Iia Hyperlipidaemia
Ventricular Dysfunction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vicodin Tablets	C				

Ventricular Extrasystoles
Weight Increased

UNKNOWN

Date:03/17/05ISR Number: 4611973-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Abscess Limb
	Agitation
	Anxiety
	Aortic Aneurysm
	Aortic Atherosclerosis
	Aortic Calcification
	Arcus Lipoides
	Arthralgia
	Asthenia
	Asthma
	Atelectasis
	Atherosclerosis
	Atrial Fibrillation
	Back Pain
	Blood Blister
	Blood Potassium Increased
	Blood Pressure Inadequately Controlled
	Blood Sodium Decreased
	Bradycardia
	Bronchitis
	Bronchospasm
	Cardiac Discomfort
	Cardiac Failure Congestive
	Cardiomegaly
	Cardiomyopathy
	Carpal Tunnel Syndrome
	Cellulitis

Chest Pain
Chronic Obstructive
Pulmonary Disease
Condition Aggravated
Confusional State
Conjunctivitis Allergic
Constipation
Crackles Lung
Death
Disorientation
Dizziness
Drug Hypersensitivity
Dyspepsia
Emotional Distress
Foreign Body Trauma
Herpes Simplex
Herpes Zoster

		Hypotension					
		Injury					
		Interstitial Lung Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Labile Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Laryngitis		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
		Mental Status Changes		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Mitral Valve Incompetence		Fosamax	C		
UNKNOWN							
		Myocardial Calcification		Percocet	C		
UNKNOWN							
		Myocardial Infarction		Zestril	C		
UNKNOWN							
		Nasopharyngitis		Zestril	C		
UNKNOWN							
		Nausea		Diltiazem			
		Neuropathy		Hydrochloride	C		
UNKNOWN							
		Osteoporosis					
		Pneumonia					
		Pulmonary Fibrosis					
		Renal Artery Stenosis					
		Restlessness					
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Sputum Discoloured					
		Syncope					
		Tracheal Obstruction					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Retention					
		Vomiting					

Date:03/17/05ISR Number: 4611983-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 11 DAY	Asthenia	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 2 DAY	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Increased	Tylenol With Codeine			
	Blood Pressure Decreased	#3	C		ORAL
	Blood Triglycerides	Vicodin Tablets	C		
UNKNOWN					
	Increased	Tylenol	C		
UNKNOWN					
	Bronchitis	Ecotrin	C		
UNKNOWN					
	Bronchospasm				
	Coronary Artery Disease				
	Fatigue				
	Hypertension				
	Insomnia				
	Joint Swelling				
	Myocardial Infarction				
	Oxygen Saturation Decreased				
	Pharyngitis				
	Pharyngitis Streptococcal				
	Sinusitis				
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4611988-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00058
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cholangitis		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Hospitalization -	Coma Hepatic		Vioxx	SS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged	Hepatic Failure		Esomeprazole					
	Jaundice		Magnesium	C				UNKNOWN
	Malignant Neoplasm Of		Acetyldigoxin	C				UNKNOWN
	Ampulla Of Vater		Hydrochlorothiazide And Ramipril	C				UNKNOWN
			Dipyrone	C		ORAL		
			Verapamil Hydrochloride	C				UNKNOWN

Date:03/17/05ISR Number: 4611998-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4611999-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01009
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL		987 DAY
Initial or Prolonged	Incoherent		Vioxx	SS	Merck & Co., Inc	ORAL		987 DAY
Disability	Mental Disorder		Topamax	C				UNKNOWN
	Mood Swings		Ditropan	C				UNKNOWN

	Panic Attack	Lotensin	C
UNKNOWN			
	Weight Decreased	Activella	C
UNKNOWN			
		Deconamine	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			

Date:03/17/05ISR Number: 4612003-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction							

Date:03/17/05ISR Number: 4612004-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612005-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00084
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Asthenia
	Cardiac Failure
	Chest Pain

		Dizziness Renal Cell Carcinoma Stage Iii	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
		Stage Unspecified		Vioxx	SS	Merck & Co., Inc	ORAL
		Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Candesartan Cilexetil And Hydrochlorothiazide	C		
UNKNOWN							
				Candesartan Cilexetil And Hydrochlorothiazide	C		
UNKNOWN							
				Bisoprolol	C		
UNKNOWN							

Date:03/17/05ISR Number: 4612006-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01305
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/17/05ISR Number: 4612007-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00127
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/17/05ISR Number: 4612008-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02480
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
	Benign Prostatic Hyperplasia
	Carotid Artery Stenosis
	Cerebellar Infarction
	Cerebral Infarction
	Cerebrovascular Disorder
	Cervicobrachial Syndrome
	Chronic Obstructive Pulmonary Disease
	Circumcision
	Coronary Artery Disease
	Depression
	Fatigue
	Feeling Abnormal
	Glucose Tolerance Impaired
	Headache
	Hypokalaemia
	Influenza
	Intervertebral Disc Degeneration
	Intervertebral Disc Protrusion

	Neuralgia						
	Pitting Oedema						
	Radiculitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sinus Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stress		Corgard	C				UNKNOWN
	Tinnitus		Hydrodiuril	C		ORAL		
	Weight Increased		Altace	C				UNKNOWN
			Nexium	C				UNKNOWN
			Glipizide	C				UNKNOWN

Date:03/17/05ISR Number: 4612010-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01580
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		35 DAY
Initial or Prolonged								

Date:03/17/05ISR Number: 4612011-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04306
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		161 DAY
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1298 DAY
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		59 DAY
Disability	Chest Pain		Synthroid	C				UNKNOWN
Other	Coronary Artery Disease		Synthroid	C				UNKNOWN
	Depression		Ogen	C				UNKNOWN
	Dermal Cyst		Zyrtec	C				UNKNOWN

	Diabetes Mellitus	Doxycycline	C
UNKNOWN	7 DAY		
	Non-Insulin-Dependent		
	Eustachian Tube		
	Dysfunction		
	Exostosis		
	Fibrocystic Breast		
	Disease		
	Fibromyalgia		
	Gastrooesophageal Reflux		
	Disease		
	Hypertension		
	Intervertebral Disc		
	Degeneration		
	Intervertebral Disc		
	Protrusion		
	Joint Sprain		
	Lumbar Spinal Stenosis		
	Medication Error		
	Muscle Spasms		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Oedema Peripheral		
	Osteoarthritis		
	Pulmonary Oedema		
	Seborrhoeic Keratosis		
	Sinusitis		
	Tendonitis		
	Vertigo Positional		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612014-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
	Emotional Distress							
	Pain							

Date:03/17/05ISR Number: 4612016-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01999
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Attack		Prednisone	C				
UNKNOWN								
			Analgesic Or Anesthetic (Unspecified)	C				
UNKNOWN								

Date:03/17/05ISR Number: 4612018-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01585
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		
42 MON								
	Dyspnoea		Synthroid	C				
UNKNOWN								

Date:03/17/05ISR Number: 4612019-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612021-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:03/17/05ISR Number: 4612023-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612024-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01787
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612026-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612028-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612030-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612031-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612033-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON
	Polytraumatism							

Date:03/17/05ISR Number: 4612034-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:03/17/05ISR Number: 4612035-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/17/05ISR Number: 4612037-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1250	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612039-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:03/17/05ISR Number: 4612041-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01731
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Cardiac Disorder							
Disability	Emotional Distress							

Date:03/17/05ISR Number: 4612042-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01727
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Emotional Distress							
Disability	Myocardial Infarction							

Date:03/17/05ISR Number: 4612051-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	463	DAY

Date:03/17/05ISR Number: 4612052-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612054-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612057-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON

Date:03/17/05ISR Number: 4612058-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	538	DAY

Date:03/17/05ISR Number: 4612061-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612063-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	117	DAY

Date:03/17/05ISR Number: 4612064-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	291	DAY

Date:03/17/05ISR Number: 4612078-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612079-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02063
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		376 DAY
	Myocardial Infarction							

Date:03/17/05ISR Number: 4612080-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02065
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:03/17/05ISR Number: 4612082-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612084-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02079
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612086-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02090
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612090-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612095-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612103-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612104-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612106-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1671 DAY	

Date:03/17/05ISR Number: 4612108-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612109-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:03/17/05ISR Number: 4612110-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Polytraumatism							

Date:03/17/05ISR Number: 4612112-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	60	MON
	Polytraumatism							

Date:03/17/05ISR Number: 4612113-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	576	DAY

Date:03/17/05ISR Number: 4612114-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/17/05ISR Number: 4612116-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612117-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1594 DAY	

Date:03/17/05ISR Number: 4612118-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	49 MON	
	Pulmonary Embolism							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612119-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612120-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612121-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02304
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	810	DAY

Date:03/17/05ISR Number: 4612122-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	1036	DAY

Date:03/17/05ISR Number: 4612123-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612124-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02343
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612125-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY

Date:03/17/05ISR Number: 4612126-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	997	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612130-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	101	DAY

Date:03/17/05ISR Number: 4612132-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1339	DAY

Date:03/17/05ISR Number: 4612133-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:03/17/05ISR Number: 4612134-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	822	DAY

Date:03/17/05ISR Number: 4612136-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02348
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612137-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02351
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612138-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612139-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612140-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612142-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612144-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612145-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612146-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612149-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612151-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02361
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612153-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02366
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/17/05ISR Number: 4612154-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	900	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612156-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612157-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1487 DAY	

Date:03/17/05ISR Number: 4612158-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aneurysm Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612159-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/17/05ISR Number: 4612161-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Other	Emotional Distress		Bextra	SS		ORAL
232 DAY						
	Heart Injury					
	Injury					
	Myocardial Infarction					
	Pain					
	Thrombosis					

Date:03/17/05ISR Number: 4612162-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
1108 DAY						
	Pulmonary Embolism					

Date:03/17/05ISR Number: 4612163-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02379
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612164-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	807	DAY

Date:03/17/05ISR Number: 4612165-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY

Date:03/17/05ISR Number: 4612166-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02381
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	130	DAY

Date:03/17/05ISR Number: 4612168-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02677
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612169-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612170-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02377
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1096 DAY

Date:03/17/05ISR Number: 4612174-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612175-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02382
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/05ISR Number: 4612176-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02681
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/17/05ISR Number: 4612178-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02683
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1188	DAY

Date:03/17/05ISR Number: 4612180-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612184-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02711
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/17/05ISR Number: 4612185-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02684
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	761	DAY

Date:03/17/05ISR Number: 4612792-7Report Type:Direct Company Report #CTU 243482
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS		ORAL	DOSE, ONCE	
							DAILY, PO	5 DAY
			Lanoxin	C				
			Norpace	C				
			Metoprolol	C				
			Lisinopril	C				

Date:03/17/05ISR Number: 4615628-3Report Type:Expedited (15-DaCompany Report #L04-USA-07403-02
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy	Literature	Levothyroxine	PS				
	Cerebral Infarction	Health	Ethylene Glycol					
	Coma	Professional	(Polyethylene					
	Completed Suicide		Glycol)	SS				
	Dizziness		Gabapentin	SS				
	Intentional Misuse		Paroxetine	SS				
	Loss Of Consciousness		Rofecoxib	SS				
	Metabolic Acidosis		Trazodone	SS				
	Mydriasis		Lovastatin	SS				
			Clonazepam	SS				
			Lorazepam	SS				

Benazepril	SS	
Lansoprazole	SS	
Medroxyprogesterone	SS	
Aspirin	SS	

Date:03/17/05ISR Number: 4619027-XReport Type:Direct Company Report #CTU 243515
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	25 Mg	PS			25 MG	
Initial or Prolonged	Complicated Migraine							QD-BID PRN	
Disability	Confusional State								
	Dysarthria								
	Fall								
	Headache								

Date:03/17/05ISR Number: 4619683-6Report Type:Direct Company Report #CTU 243519
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product		Role	Manufacturer	Route	Dose	Duration
Other	Dyspnoea		Vioxx	Unknown					
	Gastrointestinal Disorder		Merck		PS	Merck			
	Hypertension								
	Oedema Peripheral								
	Oliguria								

Date:03/18/05ISR Number: 4612428-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:03/18/05ISR Number: 4612742-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anuria
	Arthralgia
	Back Injury
	Back Pain
	Cerebrovascular Accident
	Chest Pain
	Dizziness
	Drug Ineffective
	Emotional Distress
	Facial Pain
	Fall
	Feeling Hot
	Hypertension
	Hypoaesthesia
	Injury
	Intervertebral Disc
	Disorder
	Ligament Sprain
	Monoparesis
	Oedema Peripheral
	Pain In Extremity

		Prostatitis					
		Pyrexia					
		Rheumatoid Arthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sciatic Nerve Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Testicular Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL
		Testicular Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Coumadin	C		
UNKNOWN							

Date:03/18/05ISR Number: 4612748-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00822
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Acute Myocardial Infarction
Other	Adrenal Mass
	Angina Unstable
	Asthenia
	Bacteriuria
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Cataract
	Conjunctivitis
	Coronary Artery Disease
	Cystitis
	Depression
	Dermatitis
	Diabetic Nephropathy
	Diabetic Neuropathy
	Diabetic Retinal Oedema
	Diabetic Retinopathy
	Escherichia Urinary Tract Infection
	Fall
	Fatigue
	Gastrooesophageal Reflux Disease
	Headache
	Hearing Impaired

Hypertension
Hypoglycaemia
Lacunar Infarction
Lipids Increased
Lung Neoplasm
Maculopathy
Mass
Metabolic Alkalosis
Nocturia
Pleural Effusion
Proteinuria
Pulmonary Hypertension
Radius Fracture
Rectal Haemorrhage
Renal Cyst
Renal Failure Chronic
Road Traffic Accident

		Scoliosis					
		Seasonal Allergy					
		Sinusitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Lesion		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Hydrodiuril	C		
UNKNOWN							
		Stasis Dermatitis		Lasix (Furosemide)	C		
UNKNOWN							
		Vaginal Infection		Synthroid	C		
UNKNOWN							
		Ventricular Hypertrophy		Insulin, Biphasic			
		Weight Increased		Isophane [Injection]	C		
UNKNOWN							
		Wrist Fracture		Pepcid	C		
UNKNOWN							
				Dyrenium	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Alupent	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							

Date:03/18/05ISR Number: 4612758-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01487
Age:71 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Prinivil	C		ORAL
	Coronary Artery		Aspirin	C		ORAL
	Restenosis		Plavix	C		ORAL
41 DAY						
	Hypertension		Plavix	C		ORAL
	Hypotension		Plavix	C		ORAL
41 DAY						
	Injury		Plavix	C		ORAL
	Ischaemic Cardiomyopathy		Lipitor	C		ORAL
	Mitral Valve Incompetence		Synthroid	C		
UNKNOWN						
	Musculoskeletal		Flomax (Tamsulosin			
	Discomfort		Hydrochloride)	C		
UNKNOWN						
	Myocardial Infarction		Colace	C		
UNKNOWN						
	Prostatic Atrophy		Vicodin Tablets	C		
UNKNOWN						
	Prostatic Disorder		Prevacid	C		
UNKNOWN						
	Prostatitis		Zestril	C		
UNKNOWN						
	Rash					
	Sick Sinus Syndrome					

Date:03/18/05ISR Number: 4612760-5Report Type:Expedited (15-DaCompany Report #NL-MERCK-0411NLD00001
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Transient Ischaemic		Acetylcysteine	C		ORAL
	Attack		Prednisolone	C		
UNKNOWN						
			Doxycycline	C		
UNKNOWN						
			Cromolyn Sodium	C		
UNKNOWN						
			Lisinopril	C		
UNKNOWN						
			Fluticasone			
			Propionate And			

	Salmeterol Xinafoate	C
UNKNOWN		
	Albuterol Sulfate	C
UNKNOWN		
	Felodipine	C
UNKNOWN		
	Sotalol Hydrochloride	C
UNKNOWN		
	Levocetirizine Hydrochloride	C
UNKNOWN		
	Amoxicillin And Clavulanate Potassium	C
UNKNOWN		
	Azithromycin	C
UNKNOWN		

Date:03/18/05ISR Number: 4612761-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Oesophageal Web
Other	Anaemia
	Anxiety
	Bile Duct Stone
	Blood Culture Positive
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Choledochal Cyst
	Chronic Fatigue Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Coagulopathy
	Coronary Artery Disease
	Depression
	Diabetes Mellitus
	Inadequate Control
	Diverticulum
	Dyspepsia
	Dysphagia
	Dyspnoea

Emotional Distress
Fluid Retention
Gastric Disorder
Gastric Haemorrhage
Gastritis
Gastritis Haemorrhagic
Gastrointestinal
Arteriovenous
Malformation
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Haematochezia
Hepatic Failure
Hypercholesterolaemia
Injury
Iron Deficiency Anaemia
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Joint Swelling

		Myocardial Infarction					
		Oedema Peripheral					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pancreatitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pleural Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Coumadin	SS		
UNKNOWN							
		Pulmonary Oedema		Atorvastatin Calcium	SS		
UNKNOWN							
		Respiratory Failure		Prednisone	SS		
UNKNOWN							
		Troponin Increased		Infliximab	SS		
UNKNOWN							
		Urinary Tract Infection					
		Enterococcal					

Date:03/18/05ISR Number: 4612767-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04059
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						

Date:03/18/05ISR Number: 4612768-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00024
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
			Dipyrone	C		ORAL
			Hydrochlorothiazide	C		ORAL
			Enalapril Maleate	C		ORAL
			Levothyroxine Sodium	C		ORAL

Date:03/18/05ISR Number: 4612769-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02635
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - UNKNOWN	Pulmonary Embolism		Prilosec	C			
Initial or Prolonged	Thrombosis						
	Ulcer						

Date:03/18/05ISR Number: 4612770-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03884
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	488	DAY
Initial or Prolonged			Prevacid	C				
UNKNOWN								
Disability			Viagra	C				
UNKNOWN								

Date:03/18/05ISR Number: 4612772-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02155
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Glioblastoma		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization -			Verapamil	C				
UNKNOWN								
Initial or Prolonged			Singulair	C		ORAL		
Disability			Advair	C				
UNKNOWN								
Other			Maxalt (Rizatriptan Benzoate)	C				
UNKNOWN								
			Imitrex Nasal Spray	C				
RESPIRATORY								

(INHALATION)

Date:03/18/05ISR Number: 4612773-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02703
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1504 DAY
Hospitalization - Initial or Prolonged								

Date:03/18/05ISR Number: 4612774-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00386
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Carbinoxamine Maleate And Phenylephrine Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C				
UNKNOWN								

Date:03/18/05ISR Number: 4612775-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00380
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Acetaminophen And Codeine Phosphate	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:03/18/05ISR Number: 4612777-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612778-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00804
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Adverse Event
Other	Anaemia
	Atrioventricular Block First Degree
	Bradycardia
	Carotid Artery Disease
	Cellulitis
	Chest Pain
	Chills
	Diabetic Neuropathy
	Diplopia
	Exostosis
	Gastritis

		Groin Pain					
		Hyperlipidaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intermittent Claudication		Vioxx	PS	Merck & Co., Inc	ORAL
		Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Mitral Valve Incompetence		Oxycontin	C		
UNKNOWN							
		Myalgia		Neurontin	C		
UNKNOWN							
		Nausea		Neurontin	C		
UNKNOWN							
		Neuropathy		Aspirin	C		
UNKNOWN							
		Pain In Extremity		Vitamins			
		Peripheral Vascular		(Unspecified)	C		
UNKNOWN							
		Disorder		Vitamin E	C		
UNKNOWN							
		Pyrexia		Prilosec	C		ORAL
		Renal Failure		Prilosec	C		ORAL
		Seroma		Elavil	C		ORAL
		Tricuspid Valve		Cardura	C		ORAL
		Incompetence		Pravachol	C		
UNKNOWN							
		Vascular Graft Occlusion		Micardis	C		ORAL
		Ventricular Hypertrophy		Phytonadione	C		
UNKNOWN							
		Vomiting		Glucophage	C		
UNKNOWN							
		Weight Decreased		Glucovance	C		
UNKNOWN							
		Wound Abscess					

Date:03/18/05ISR Number: 4612779-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01397
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:03/18/05ISR Number: 4612780-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612781-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612782-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01422
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612783-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01687
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	232 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612784-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612785-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01337
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612786-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612793-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	34 MON	

Date:03/18/05ISR Number: 4612794-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Cardiovascular Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612795-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612796-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	235	DAY

Date:03/18/05ISR Number: 4612797-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON

Date:03/18/05ISR Number: 4612798-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:03/18/05ISR Number: 4612799-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01918
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612803-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

Date:03/18/05ISR Number: 4612804-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/18/05ISR Number: 4612805-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612807-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	366	DAY

Date:03/18/05ISR Number: 4612808-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	53	DAY

Date:03/18/05ISR Number: 4612809-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Congestive Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612810-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Renal Injury							

Date:03/18/05ISR Number: 4612811-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/18/05ISR Number: 4612812-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612813-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01854
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Prilosec	C				
UNKNOWN								
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:03/18/05ISR Number: 4612821-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/18/05ISR Number: 4612822-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612823-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1360	DAY

Date:03/18/05ISR Number: 4612825-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612826-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02145
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness Muscle Spasms Nausea Speech Disorder Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612827-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612828-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612829-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02043
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:03/18/05ISR Number: 4612830-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02155
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -
Initial or Prolonged

Date:03/18/05ISR Number: 4612832-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612833-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612846-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612848-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02405
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612849-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02390
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Sotalol Hydrochloride	C				UNKNOWN
			Bumetanide	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Warfarin	C				UNKNOWN
			Protonix	C				UNKNOWN
			Benicar	C				UNKNOWN

Date:03/18/05ISR Number: 4612851-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612861-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02431
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Disability Detrol La C
UNKNOWN

Date:03/18/05ISR Number: 4612862-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02482
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Hospitalization -	Anaemia		Synthroid	C				
UNKNOWN								
Initial or Prolonged	Blood Cholesterol		Plavix	C				
UNKNOWN								
Other	Increased		Prevacid	C				
UNKNOWN								
	Cerebrovascular Accident		Lotrel	C				
UNKNOWN								
	Haemorrhagic Stroke							
	Hemianopia							
	Muscle Spasms							
	Oedema Peripheral							
	Pollakiuria							

Date:03/18/05ISR Number: 4612863-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	914	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612864-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02300
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612865-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00204
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue							
	Myocardial Infarction							

Date:03/18/05ISR Number: 4612866-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612867-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02660
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612868-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612869-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/18/05ISR Number: 4612870-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02146
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Mental Disorder							
	Pain							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4612871-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02407
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612872-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4612875-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	68	DAY

Date:03/18/05ISR Number: 4612882-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/18/05ISR Number: 4613012-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00456
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastritis Erosive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy					

Disability	Unspecified]	C
UNKNOWN		
	Metoprolol Succinate	C
UNKNOWN		
	Simethicone	C
UNKNOWN		
	Metoclopramide	C
UNKNOWN		
	Zocor	C
UNKNOWN		
	Zopiclone	C
UNKNOWN		
	Citalopram Hydrobromide	C
UNKNOWN		
	Piretanide	C
UNKNOWN		
	Lercanidipine	C
UNKNOWN		
	Fosinopril Sodium	C
UNKNOWN		

Date:03/18/05ISR Number: 4613019-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02001
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthrodesis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Carotid Artery Stenosis		Baclofen	C		ORAL		
Other	Cerebrovascular Accident		Ativan	C		ORAL		
	Death		Soma	C		ORAL		
	Injury		Wellbutrin	C		ORAL		
	Neck Pain		Dulcolax	C				
UNKNOWN								
	Oedema		Tegretol	C		ORAL		
	Pain		Ms Contin	C		ORAL		
	Thermal Burn		Colace	C		ORAL		

				Vistaril	C		ORAL
				Vistaril	C		ORAL
				Seroquel	C		
UNKNOWN							
				Seroquel	C		ORAL
				Mexiletine Hydrochloride	C		ORAL
				Coumadin	C		ORAL
				Percocet	C		ORAL
				Fleet Enema	C		
UNKNOWN							
				Magnesia [Milk Of]	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							
				Neurontin	C		ORAL
				Elavil	C		ORAL

Date:03/18/05ISR Number: 4613020-9Report Type:Expedited (15-DaCompany Report #TW-MERCK-0410TWN00018
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bladder Cancer		Celecoxib	C		ORAL		
Other	Epilepsy		Celecoxib	C		ORAL		
	Gastric Ulcer		Valproate Sodium	C		ORAL		
	Headache		Valproate Sodium	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:03/18/05ISR Number: 4613021-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00510
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery		Theophylline	C				
UNKNOWN								
	Atherosclerosis		Albuterol	C				
UNKNOWN								

	Headache		Budesonide And	
	Hypertension		Formoterol Fumarate	C
UNKNOWN				
			Moxonidine	C
UNKNOWN				
			Indapamide	C
UNKNOWN				
			Aspirin	C
UNKNOWN				
			Nitrendipine	C
UNKNOWN				

Date:03/18/05ISR Number: 4613022-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acquired Immunodeficiency		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY						
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY						
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Kidney Infection		Dilantin	C		
UNKNOWN						
	Pain In Extremity					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613023-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00046
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis Hypertrophic Cardiomyopathy Myocardial Infarction Thrombosis							

Date:03/18/05ISR Number: 4613024-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	39 DAY	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	39 DAY	
Disability	Angina Unstable		Zocor	C		ORAL		
	Aortic Aneurysm		Cardura	C		ORAL		
	Aortic Dilatation		Tylenol Pm	C			UNKNOWN	
	Arthralgia		Tagamet	C			UNKNOWN	
	Barrett'S Oesophagus		Tagamet	C			UNKNOWN	
	Blood Pressure Increased		Plavix	C			UNKNOWN	
	Cardiac Failure Congestive Chest Pain Chronic Fatigue Syndrome Contusion Coronary Artery Disease Cyst Depression Dilatation Ventricular Duodenitis Dyspepsia Emotional Distress							

Gastritis Erosive
Gastrooesophageal Reflux
Disease
Haemoglobin Decreased
Headache
Hyperhidrosis
Hypogonadism
Ischaemic Cardiomyopathy
Mitral Valve Incompetence
Mood Altered
Peptic Ulcer
Reflux Oesophagitis
Sinus Tachycardia
Sleep Apnoea Syndrome
Tendonitis
Ventricular Extrasystoles
Weight Increased

Date:03/18/05ISR Number: 4613025-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:54 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability	Other	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
		Arthritis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Blindness		Vioxx	SS	Merck & Co., Inc	ORAL		
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Catheter Site Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	58	DAY
		Cholecystitis Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
		Duodenal Scarring		Vioxx	SS	Merck & Co., Inc	ORAL		
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
		Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL	58	DAY
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
		Disease		Aspirin	C			UNKNOWN	
		Haematuria		Wellbutrin	C			UNKNOWN	
		Herpes Simplex		Lovastatin	C			UNKNOWN	
		Hiatus Hernia		Lovastatin	C			UNKNOWN	
		Hypermetropia		Codeine	C			UNKNOWN	
		Hyperreflexia		[Therapy					
		Hypersensitivity		Unspecified]	C			UNKNOWN	
		Inguinal Hernia		Naproxen	C			UNKNOWN	
		Irritable Bowel Syndrome		Flexeril	C			UNKNOWN	
		Joint Contracture		Flexeril	C			UNKNOWN	
		Mental Disorder		Trazodone					
		Morton'S Neuroma		Hydrochloride	C			UNKNOWN	
		Muscle Contractions		Zoloft	C			UNKNOWN	

	Involuntary	Sulfasalazine	C
UNKNOWN			
	Myocardial Infarction	Acetaminophen	C
UNKNOWN			
	Nasopharyngitis	Gabapentin	C
UNKNOWN			
	Nausea	Compazine	C
UNKNOWN			
	Neck Pain	Seroquel	C
UNKNOWN			
	Nephrolithiasis	Seroquel	C
UNKNOWN			
	Overdose	Baclofen	C
UNKNOWN			
	Polycythaemia	Baclofen	C
UNKNOWN			
	Presbyopia	Medrol	C
UNKNOWN			
	Pterygium		
	Road Traffic Accident		
	Skin Discolouration		
	Skin Laceration		
	Tympanic Membrane Perforation		
	Upper Respiratory Tract Infection		
	Vertigo Positional		
	Vision Blurred		
	Vitreous Floaters		
	Vomiting		
	Whiplash Injury		
	Wound Infection		

Date:03/18/05ISR Number: 4613026-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02255
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Angina Unstable

		Anxiety					
		Chest Discomfort					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Lipitor	C		
UNKNOWN							
		Dyspnoea		Clarinex	C		
UNKNOWN							
		Fatigue		Nexium	C		
UNKNOWN							
		Gastrooesophageal Reflux		Xanax	C		
UNKNOWN							
		Disease		Estrogens			
		Hypertension		(Unspecified)	C		
UNKNOWN							
		Insomnia					
		Lung Neoplasm					
		Myocardial Infarction					
		Orthostatic Hypotension					
		Pollakiuria					

Date:03/18/05ISR Number: 4613027-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03988
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthropathy		K-Dur	C		ORAL
1308 DAY							
Other		Back Injury		K-Dur	C		ORAL
		Back Pain		Minipress	C		ORAL
646 DAY							
		Blood Potassium Decreased		Lopressor	C		ORAL
48 DAY							
		Blood Pressure Increased		Lopressor	C		ORAL
593 DAY							
		Cardiomegaly		Lozol	C		ORAL
594 DAY							
		Cervical Polyp					
		Cholecystitis					
		Cholelithiasis					
		Colonic Polyp					
		Fatigue					
		Heart Rate Decreased					

Hypercalcaemia
Hyperparathyroidism
Intestinal Cyst
Joint Effusion
Migraine
Muscle Strain
Myocardial Infarction
Nausea
Palpitations
Parathyroid Tumour Benign
Scoliosis
Tenosynovitis
Thrombophlebitis
Superficial

Date:03/18/05ISR Number: 4613028-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01614
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		[Therapy Unspecified]	C				
	Hypertension							
	Myocardial Infarction		Aspirin	C				
	Pain In Extremity		[Therapy Unspecified]	C				

		[Therapy Unspecified]	C
UNKNOWN			
		Herbs (Unspecified)	C
UNKNOWN			

Date:03/18/05ISR Number: 4613029-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00920
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613030-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bifascicular Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache							
	Hypertension							
	Jaw Fracture							
	Joint Sprain							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Periodontal Disease							
	Prescribed Overdose							
	Renal Impairment							
	Rib Fracture							
	Tooth Loss							
	Ventricular Extrasystoles							
	Vital Capacity Decreased							

Date:03/18/05ISR Number: 4613031-3Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00112
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diplopia Fluid Retention Hypertension Intracranial Pressure Increased Retinal Haemorrhage Vith Nerve Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613032-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00111
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613033-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00036
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL
	Back Disorder		Candesartan			
	Blood Pressure Decreased		Cilexetil	C		ORAL
	Coronary Artery Stenosis					
	Gastroenteritis					
	Myalgia					
	Myocardial Infarction					
	Oral Pain					
	Post Procedural Pain					
	Sinus Bradycardia					

Date:03/18/05ISR Number: 4613034-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00032
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
683 DAY						
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirin And Magnesium Oxide	C		
UNKNOWN						
			Esomeprazole Magnesium	C		
UNKNOWN						
			Metoprolol Tartrate	C		
UNKNOWN						
			Pravastatin Sodium	C		
UNKNOWN						
			Nitroglycerin	C		
UNKNOWN						
			Aluminum Hydroxide And Magnesium Carbonate And Magnesium Hydroxide	C		
UNKNOWN						

Date:03/18/05ISR Number: 4613035-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01725
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pain							

Date:03/18/05ISR Number: 4613036-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01735
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:03/18/05ISR Number: 4613037-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01610
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Norvasc	C				
UNKNOWN								
	Attack		Plavix	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

Cosopt C
OPHTHALMIC

Date:03/18/05ISR Number: 4613038-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	55	MON
Disability	Pain							

Date:03/18/05ISR Number: 4613039-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613040-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01749
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Other	Cerebrovascular Accident Nervous System Disorder Pain							

Date:03/18/05ISR Number: 4613041-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613042-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01162
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Life-Threatening Hospitalization - Initial or Prolonged Disability	Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613043-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613044-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01770
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Cardiovascular Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613045-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01758
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Myocardial Infarction							
	Pain							

Date:03/18/05ISR Number: 4613046-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00016
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1712 DAY
Initial or Prolonged			Aspergillus Oryzae Extract And Pancreatin	C				UNKNOWN
			Levothyroxine Sodium	C				UNKNOWN
			Ibuprofen	C				UNKNOWN
			Methotrexate	C				UNKNOWN
			Zopiclone	C				UNKNOWN
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN

Date:03/18/05ISR Number: 4613047-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01762
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Other	Cerebrovascular Accident							
	Pain							

Date:03/18/05ISR Number: 4613048-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01766
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Myocardial Infarction							
	Pain							

Date:03/18/05ISR Number: 4613049-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613050-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	287	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613051-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Pain							

Date:03/18/05ISR Number: 4613052-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613053-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613054-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01991
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613055-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613056-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01994
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:03/18/05ISR Number: 4613057-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	961	DAY

Date:03/18/05ISR Number: 4613058-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613059-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613060-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613061-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613062-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01943
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613063-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	58	MON

Date:03/18/05ISR Number: 4613064-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613065-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:03/18/05ISR Number: 4613066-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/18/05ISR Number: 4613067-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613068-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02018
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/18/05ISR Number: 4613069-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02093
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613070-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613071-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON

Date:03/18/05ISR Number: 4613072-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/18/05ISR Number: 4613073-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON

Date:03/18/05ISR Number: 4613074-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/18/05ISR Number: 4613075-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613076-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02310
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613077-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Thrombosis							

Date:03/18/05ISR Number: 4613078-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/18/05ISR Number: 4613079-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02225
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	57	MON

Date:03/18/05ISR Number: 4613080-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Myocardial Infarction							

Date:03/18/05ISR Number: 4613081-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
61 MON						
Other						

Date:03/18/05ISR Number: 4613082-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02315
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
30 MON						

Date:03/18/05ISR Number: 4613083-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/18/05ISR Number: 4613084-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder					
	Myocardial Infarction					
	Organ Failure					
	Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613085-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02517
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/18/05ISR Number: 4613086-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02346
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613087-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02327
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613088-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02330
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613089-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02166
Age:91 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613090-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02531
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613091-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613092-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02622
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1949 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613093-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02695
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1004 DAY

Date:03/18/05ISR Number: 4613094-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613095-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02630
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613096-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02691
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613097-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02525
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/18/05ISR Number: 4613098-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02693
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		627 DAY

Date:03/18/05ISR Number: 4613099-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613100-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613101-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613102-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613103-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:03/18/05ISR Number: 4613104-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02708
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613105-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:03/18/05ISR Number: 4613106-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02701
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1465	DAY
	Myocardial Infarction							

Date:03/18/05ISR Number: 4613107-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02697
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:03/18/05ISR Number: 4613108-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613109-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02696
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:03/18/05ISR Number: 4613110-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	34	MON

Date:03/18/05ISR Number: 4613111-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02705
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	263	DAY

Date:03/18/05ISR Number: 4613112-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613113-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01605
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebellar Infarction Cerebrovascular Accident Dizziness Injury Asphyxiation Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613114-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/18/05ISR Number: 4613115-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/18/05ISR Number: 4613116-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613117-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613118-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02791
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:03/18/05ISR Number: 4613119-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613120-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON

Date:03/18/05ISR Number: 4613121-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:03/18/05ISR Number: 4613122-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02699
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613123-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02700
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON

Date:03/18/05ISR Number: 4613124-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02707
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/18/05ISR Number: 4613125-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02790
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:03/18/05ISR Number: 4613129-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4613131-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/18/05ISR Number: 4613667-XReport Type:Direct Company Report #CTU 243778
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS			1-25MG	A DAY

Date:03/18/05ISR Number: 4613669-3Report Type:Direct Company Report #CTU 243756
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Vioxx	PS			1 DAILY	
Hospitalization - Initial or Prolonged	Dyspnoea							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:03/18/05ISR Number: 4614916-4Report Type:Direct Company Report #CTU 243707
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS				

Date:03/18/05ISR Number: 4614919-XReport Type:Direct Company Report #CTU 243709
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg	PS			1-BY MOUTH	
Hospitalization -							PER DAY	
Initial or Prolonged								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:03/18/05ISR Number: 4614920-6Report Type:Direct Company Report #CTU 243711
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx 25 Mg Merck					
Initial or Prolonged	Transient Ischaemic		And Co , Inc	PS	Merck And Co , Inc		25 MG 1 DAILY	
Disability	Attack							

Date:03/18/05ISR Number: 4614933-4Report Type:Direct Company Report #CTU 243716
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg	PS		ORAL	DAILY /	
Hospitalization -								
ORALLY								
Initial or Prolonged								
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:03/18/05ISR Number: 4614963-2Report Type:Direct Company Report #CTU 243729
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 12.5 Mg	PS			ONE PER DAY	
Hospitalization -	Myocardial Infarction							
Initial or Prolonged								
Disability								

Date:03/18/05ISR Number: 4614990-5Report Type:Direct Company Report #CTU 243765
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx 25 Mg	PS			1 TABLET BY	
Hospitalization -	Increased						MOUTH DAILY	
Initial or Prolonged	Chest Pain							
Disability	Hypertension							
Congenital Anomaly	Myocardial Infarction							
Required								
Intervention to								
Prevent Permanent								
Impairment/Damage								

Date:03/18/05ISR Number: 4614998-XReport Type:Direct Company Report #CTU 243769
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Myocardial Infarction		Vioxx	PS			1 X DAILY	

Date:03/18/05ISR Number: 4615032-8Report Type:Direct Company Report #CTU 243780
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Ankle Fracture Cerebrovascular Accident Fall Foot Fracture Lower Limb Fracture Pulse Abnormal Vascular Occlusion		Vioxx 25 Mg Once Daily	PS			25 MG 1 DAILY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/05ISR Number: 4616433-4Report Type:Expedited (15-DaCompany Report #L04-USA-07403-28
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abnormal Behaviour	Literature	Celexa (Citalopram					
Hospitalization -	Cardiac Arrest	Health	Hydrobromide)	PS				
Initial or Prolonged	Completed Suicide	Professional	Risperidone					
	Confusional State		(Risperidone)	SS				
	Convulsion		Methylphenidate	SS				
	Hypotension		Rofecoxib	SS				
	Intentional Misuse		Hydrochlorothiazide	SS				
	Respiratory Arrest		Aspirin					
	Stupor		(Acetylsalicylic					
	Ventricular Tachycardia		Acid)	SS				

Date:03/18/05ISR Number: 4617447-0Report Type:Expedited (15-DaCompany Report #WAES 0411DEU00393
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Foreign	Tab Vioxx					
Hospitalization -	Abnormal	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	
Initial or Prolonged	Aspartate	Other						
PO							827	DAY
Other	Aminotransferase Abnormal		Inj Etanercept	SS				
SUBCUTANEOUS							25 MG/2XW SC	43 DAY
	Blood Creatine		Isoniazid	SS				
	Phosphokinase Increased		Budesonide	C				
	Blood Creatine							
	Phosphokinase Mb							
	Increased							
	C-Reactive Protein							
	Increased							
	Csf Test Abnormal							
	Dehydration							
	Demyelination							
	Depressed Level Of							
	Consciousness							
	Diarrhoea							
	Korsakoff'S Psychosis							
	Non-Alcoholic							
	Myoglobin Blood Increased							
	Pancreatitis							

Psychotic Disorder
Somnolence
Syncope
White Blood Cell Count
Increased

Date:03/21/05ISR Number: 4613737-6Report Type:Expedited (15-DaCompany Report #FR-BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.-2005-BAge:74 YR Gender:Male I/FU:F

Outcome	PT
Death	Anoxia
	Arrhythmia
	Cardiac Arrest
	Coma
	Electroencephalogram Abnormal
	General Physical Health Deterioration
	Nosocomial Infection
	Overweight

		Pseudomonas Infection					
		Sepsis					
		Sudden Cardiac Death	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sudden Death		Omix (Tamsulosin			
		Superinfection Lung		Hydrochloride)	PS	B.I.	
		Therapy Non-Responder				Pharmaceuticals,Inc.	
						/Ridgefield	ORAL
				Visken	SS		ORAL
				Amarel	SS		ORAL
				Vioxx	SS		ORAL
2	YR						
				Metformin	SS		ORAL

Date:03/21/05ISR Number: 4613755-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02420
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Depression					
	Fatigue					
	Heart Rate Increased					
	Hyperhidrosis					
	Lumbar Spinal Stenosis					
	Sleep Disorder					
	Tendon Disorder					
	Tremor					

Date:03/21/05ISR Number: 4613758-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02523
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
233 DAY						
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
233 DAY						
Disability	Blood Triglycerides		Toprol Xl Tablets	C		
UNKNOWN						
	Increased		Zocor	C		ORAL
439 DAY						

	Bundle Branch Block	Viagra	C
UNKNOWN			
	Coronary Artery Disease	Diovan	C
UNKNOWN	79 DAY		
	Coronary Artery Stenosis		
	Depression		
	Dyspepsia		
	Fear		
	Headache		
	Incision Site Abscess		
	Injury		
	Low Density Lipoprotein		
	Increased		
	Myocardial Infarction		
	Neck Pain		
	Pleural Effusion		
	Rectal Haemorrhage		
	Road Traffic Accident		
	Sleep Disorder		
	Supraventricular		
	Extrasystoles		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613759-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		209 DAY
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		209 DAY
Disability	Bradycardia		Lasix (Furosemide					
Other	Cardiac Failure		Sodium)	C				
UNKNOWN								
	Cerebrovascular Accident		Lasix (Furosemide					
	Chest Pain		Sodium)	C				
UNKNOWN								
	Feeling Abnormal		Aspirin	C				
UNKNOWN								
	Hypertensive Crisis		Avalide	C				
UNKNOWN								
	Injury		Motrin	C				
UNKNOWN								
	Joint Dislocation		Premarin	C				
UNKNOWN								
	Myocardial Infarction		Naproxen	C				
UNKNOWN								
	Transient Ischaemic		Tylenol	C				
UNKNOWN								
	Attack							

Date:03/21/05ISR Number: 4613760-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		7 DAY
Hospitalization -	Aortic Dissection		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Disturbance In Attention		Lorazepam	C				
UNKNOWN								

	Diverticulitis		Amoxicillin	C		
UNKNOWN						
	Dizziness		Hydrocodone			
	Emotional Distress		Bitartrate	C		
UNKNOWN						
	Gastrooesophageal Reflux		Viagra	C		
UNKNOWN						
	Disease		Chlorhexidine			
	General Physical		Hydrochloride	C		
UNKNOWN						
	Condition Abnormal					
	Hypertension					
	Iliac Artery Thrombosis					
	Impaired Healing					
	Intermittent Claudication					
	Irritability					
	Keloid Scar					
	Myocardial Infarction					
	Pain					
	Pneumonia					
	Rash Pruritic					
	Self Esteem Decreased					
	Sexual Dysfunction					
	Vascular Injury					

Date:03/21/05ISR Number: 4613763-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00190
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cellulitis Staphylococcal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Deep Vein Thrombosis		Vitamins			
Other	Drug Hypersensitivity		(Unspecified)	C		
UNKNOWN						
	Gangrene		Synthroid	C		
UNKNOWN						
	Hypertension		Inderal	C		
UNKNOWN						
	Osteomyelitis		Zantac	C		
UNKNOWN						
			Cenestin	C		
UNKNOWN						
			[Therapy			

	Unspecified]	C
UNKNOWN		
	Levbid	C
UNKNOWN		
	Valium	C
UNKNOWN		
	Valtrex	C
UNKNOWN		
	Imitrex	C
UNKNOWN		
	Vicodin Tablets	C
UNKNOWN		
	Prozac	C
UNKNOWN		

Date:03/21/05ISR Number: 4613766-2Report Type:Expedited (15-DaCompany Report #PHRM2005FR00683
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Visken (Pindolol)	PS	Novartis Sector: Pharma	ORAL		
Life-Threatening	Bronchopneumonia							
Hospitalization - Initial or Prolonged	Cardiac Arrest		Omix	SS		ORAL		
	Cerebral Disorder		Amarel	SS		ORAL		
Other	Coma		Vioxx	SS		ORAL		
	General Physical Health Deterioration		Metformine	SS		ORAL		
	Lung Disorder							
	Neurological Examination Abnormal							
	Nosocomial Infection							
	Pseudomonal Sepsis							
	Pseudomonas Infection							
	Tracheostomy							

Date:03/21/05ISR Number: 4613767-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613768-6Report Type:Expedited (15-DaCompany Report #IL-MERCK-0503ISR00014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613769-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613770-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01726
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON

Date:03/21/05ISR Number: 4613772-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00139
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Discomfort							
	Mitral Valve Incompetence							

Date:03/21/05ISR Number: 4613773-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00090
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
	Polytraumatism							

Date:03/21/05ISR Number: 4613775-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/21/05ISR Number: 4613776-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613779-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02190
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1607 DAY	

Date:03/21/05ISR Number: 4613780-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613781-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613782-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02005
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613783-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613784-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	38 MON	

Date:03/21/05ISR Number: 4613785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02430
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Tylenol	C			UNKNOWN	
			Vitamins					

(Unspecified) C
UNKNOWN

Date:03/21/05ISR Number: 4613786-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/21/05ISR Number: 4613788-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613789-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613790-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON
	Thrombosis							

Date:03/21/05ISR Number: 4613791-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/21/05ISR Number: 4613792-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02608
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:03/21/05ISR Number: 4613793-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613794-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613795-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613796-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613797-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02813
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613798-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:03/21/05ISR Number: 4613799-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02334
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	

Date:03/21/05ISR Number: 4613802-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1024 DAY	
	Thrombosis							

Date:03/21/05ISR Number: 4613803-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	118 DAY	

Date:03/21/05ISR Number: 4613804-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								1326 DAY

Date:03/21/05ISR Number: 4613805-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								8 MON

Date:03/21/05ISR Number: 4613806-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613808-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	31 MON

Date:03/21/05ISR Number: 4613810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613814-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613816-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	429 DAY	

Date:03/21/05ISR Number: 4613819-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02978
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613821-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	281 DAY	

Date:03/21/05ISR Number: 4613823-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03352
Age:17 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4613824-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03355
Age:24 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613826-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02975
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613827-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	13 MON

Date:03/21/05ISR Number: 4613829-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02945
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	274 DAY

Date:03/21/05ISR Number: 4613866-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4613893-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Disability							
	Emotional Distress							
	Heart Injury							
	Myocardial Infarction							
	Pain							

Date:03/21/05ISR Number: 4614404-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:03/21/05ISR Number: 4614406-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01653
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614407-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03413
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Wellbutrin	C				
	Aspartate		Necon	C			UNKNOWN	
	Aminotransferase		Paxil	C			UNKNOWN	
	Increased		Paxil	C			UNKNOWN	
	Blood Chloride Decreased		Robaxin	C			UNKNOWN	
	Blood Glucose Increased		Mevacor	C			UNKNOWN	
	Blood Potassium Decreased							
	Blood Sodium Decreased							
	Chest Wall Pain							
	Chills							
	Diarrhoea							
	Dyspnoea							
	Hyperhidrosis							
	Mental Status Changes							
	Myocardial Infarction							
	Nausea							
	Pco2 Increased							
	Retching							
	Vomiting							

Date:03/21/05ISR Number: 4614418-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00086
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Azathioprine Sodium	C		ORAL		
	Escherichia Sepsis		Cloprednol	C		ORAL		
	Myocardial Infarction		Pantoprazole Sodium	C		ORAL		
	Oedema Peripheral		Bisoprolol Fumarate	C		ORAL		
	Peripheral Occlusive		Nafronyl Oxalate	C		ORAL		
	Disease		Ramipril	C		ORAL		
	Skin Ulcer							

Sudden Death
Toe Amputation

Date:03/21/05ISR Number: 4614419-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hepatitis C							
	Hypertension							
	Intervertebral Disc Displacement							
	Joint Injury							
	Myocardial Infarction							

Date:03/21/05ISR Number: 4614421-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01652
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614423-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:03/21/05ISR Number: 4614424-0Report Type:Expedited (15-DaCompany Report #PT-MERCK-0503PRT00005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue							
	Generalised Oedema							

Date:03/21/05ISR Number: 4614427-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614428-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	120	DAY

Date:03/21/05ISR Number: 4614431-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/21/05ISR Number: 4614432-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614434-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02573
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614435-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02572
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614437-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02570
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/21/05ISR Number: 4614439-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614440-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614441-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614442-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02541
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:03/21/05ISR Number: 4614444-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02577
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614445-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02586
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614446-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02580
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	158	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614448-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02576
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614449-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614451-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614452-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02579
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614454-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02581
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614455-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1298 DAY

Date:03/21/05ISR Number: 4614458-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614459-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02590
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:03/21/05ISR Number: 4614460-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614462-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	91	DAY

Date:03/21/05ISR Number: 4614464-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614465-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	161	DAY

Date:03/21/05ISR Number: 4614467-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614468-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614471-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614472-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	48	MON

Date:03/21/05ISR Number: 4614473-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614475-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Emotional Distress Fatigue General Symptom Myocardial Infarction Pain Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614478-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614479-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614480-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02599
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614481-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614483-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Emotional Distress Fatigue Myocardial Infarction Pain Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614484-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	630	DAY

Date:03/21/05ISR Number: 4614485-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:03/21/05ISR Number: 4614486-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/21/05ISR Number: 4614487-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

Date:03/21/05ISR Number: 4614488-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	700	DAY

Date:03/21/05ISR Number: 4614489-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Emotional Distress Fatigue Myocardial Infarction Pain Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614490-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/21/05ISR Number: 4614492-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02621
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614493-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614495-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON

Date:03/21/05ISR Number: 4614496-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02641
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:03/21/05ISR Number: 4614497-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Emotional Distress Fatigue Myocardial Infarction Pain Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614500-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614501-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:03/21/05ISR Number: 4614502-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:03/21/05ISR Number: 4614504-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614505-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614506-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:03/21/05ISR Number: 4614508-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02656
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614513-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02727
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614514-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/21/05ISR Number: 4614515-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:03/21/05ISR Number: 4614516-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	57	MON

Date:03/21/05ISR Number: 4614517-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02725
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614519-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614520-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02868
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614522-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02787
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/21/05ISR Number: 4614523-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02731
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614524-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614525-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614526-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614527-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02726
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614528-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02667
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:03/21/05ISR Number: 4614529-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	55	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614530-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02653
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614531-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02881
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:03/21/05ISR Number: 4614532-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614533-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON

Date:03/21/05ISR Number: 4614534-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614535-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614536-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other								

Date:03/21/05ISR Number: 4614538-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02795
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614539-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614541-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614542-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02882
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	41	MON

Date:03/21/05ISR Number: 4614543-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/21/05ISR Number: 4614545-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614546-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614547-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02966
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614553-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/21/05ISR Number: 4614554-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614556-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/21/05ISR Number: 4614557-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Other	Myocardial Infarction							

Date:03/21/05ISR Number: 4614558-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL	3	MON
	Transient Ischaemic Attack							

Date:03/21/05ISR Number: 4614560-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614561-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	564	DAY

Date:03/21/05ISR Number: 4614562-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03248
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/21/05ISR Number: 4614563-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03496
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Coronary Artery Disease
	Coronary Artery Occlusion

	Cough						
	Faecal Occult Blood Positive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertensive		Vioxx	PS	Merck & Co., Inc	ORAL	
	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL	225 DAY
	Prescribed Overdose		Betaseron	C			UNKNOWN
	Pulmonary Congestion		Coreg	C			UNKNOWN
			Vitamins (Unspecified)	C			UNKNOWN
			Baclofen	C			UNKNOWN

Date:03/21/05ISR Number: 4614565-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/21/05ISR Number: 4614566-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/21/05ISR Number: 4614567-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON

Date:03/21/05ISR Number: 4614569-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02974
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614570-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	15	DAY

Date:03/21/05ISR Number: 4614571-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1350	DAY

Date:03/21/05ISR Number: 4614572-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614574-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:03/21/05ISR Number: 4614575-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614576-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02901
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02953
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	509	DAY

Date:03/21/05ISR Number: 4614583-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614584-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/21/05ISR Number: 4614585-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/21/05ISR Number: 4614586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614587-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614588-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:03/21/05ISR Number: 4614589-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614591-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

Date:03/21/05ISR Number: 4614592-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02888
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614595-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02959
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Constipation							
	Dizziness							
	Embolism							
	Peripheral Vascular Disorder							
	Stomach Discomfort							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614604-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25	MON
	Transient Ischaemic Attack							

Date:03/21/05ISR Number: 4614605-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1102	DAY

Date:03/21/05ISR Number: 4614607-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02892
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614608-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02952
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614609-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death Other	Acute Myocardial Infarction Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/21/05ISR Number: 4614610-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614611-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4614612-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614613-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614615-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614619-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Cardiovascular Disorder Constipation Dizziness Embolism Peripheral Vascular Disorder Stomach Discomfort Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614620-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/21/05ISR Number: 4614635-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1553 DAY	

Date:03/21/05ISR Number: 4616201-3Report Type:Expedited (15-DaCompany Report #2005024954
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Arrhythmia
	Arthralgia
	Back Pain
	Diabetes Mellitus
	Fall
	Irritable Bowel Syndrome
	Medical Device Change
	Oedema Peripheral

		Pharmaceutical Product Complaint Skin Discolouration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Surgical Procedure Repeated	Consumer Health	Celebrex (Celecoxib_)	PS		ORAL
200 MG (200 MG, 1 IN 1 D),ORAL							
		Vascular Rupture	Professional				
				Rofecoxib (Rofecoxib)	SS		
				Atorvastatin (Atorvastatin)	C		
				Quinine Sulfate (Quinine Sulfate)	C		
				..	C		

Date:03/21/05ISR Number: 4616403-6Report Type:Expedited (15-DaCompany Report #2005041938
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Other		Abdominal Pain Upper Constipation Dry Mouth Hypertonic Bladder	Consumer	Detrol La Capsule, Prolonged Release (Tolterodine L-Tartrate)	PS		ORAL
4 MG (4 MG, 1 IN 1 D), ORAL							
		Lymphoma					
		Memory Impairment		Celebrex (Celecoxib)	SS		
		Nausea		Chemotherapy Nos (Chemotherapy Nos)	SS		
		Spinal Column Stenosis		Rofecoxib (Rofecoxib)	SS		
		Stomach Discomfort		Naproxen Sodium (Naproxen Sodium)	SS		
		Therapy Non-Responder		Ibuprofen (Ibuprofen)	SS		
				Acetylsalicylic Acid (Acetylsalicylic Acid)	C		
				Fluticasone Propionate			

(Fluticasone Propionate)	C
Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C
Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C
Tocopherol (Tocopherol)	C
Temazepam (Temazepam)	C
Tamsulosin (Tamsulosin)	C
Quinine (Quinine)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/05ISR Number: 4616649-7Report Type:Expedited (15-DaCompany Report #8738
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Methotrexate	PS		ORAL	20 MG WEEKLY	
Hospitalization -	Hyperhidrosis							
PO								49 MON
Initial or Prolonged	Myalgia		Rofecoxib	SS		ORAL	25 MG PO	1 MON
	Pneumonitis		Folic Acid	C				
			Co-Proxamol	C				
			Omeprazole	C				
			Atorvastatin	C				
			Co-Amilofruse	C				
			Iron Sulphate	C				
			Aspirin	C				

Date:03/21/05ISR Number: 4617111-8Report Type:Expedited (15-DaCompany Report #2005-124819-NL
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Circulatory Collapse	Foreign	Mirtazapine	PS			15 MG QD	
	Pain In Extremity	Health	Rofecoxib	SS		ORAL	1 DF BID ORAL	
	Pulmonary Embolism	Professional						
	Pulmonary Infarction	Other						

Date:03/21/05ISR Number: 4619900-2Report Type:Direct Company Report #CTU 243839
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx-Merck	PS	Merck		ONE A DAY	
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged								
Other								

Date:03/21/05ISR Number: 4620179-6Report Type:Direct Company Report #CTU 243858
Age:46 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 25mg Merck	PS	Merck	ORAL	50MG DAILY	
	Medication Error							
ORAL								

Date:03/21/05ISR Number: 4620202-9Report Type:Direct Company Report #CTU 243879
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 25 Mg Merck	PS	Merck	ORAL	25 MG DAILY	
	Ventricular Tachycardia							
ORAL								
			Norvasc	C				
			Lithium	C				
			Neurontin	C				

Date:03/21/05ISR Number: 4620229-7Report Type:Direct Company Report #CTU 243866
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx 50 Merck	PS	Merck	ORAL	50MG DAILY	
Hospitalization -								
ORAL								
Initial or Prolonged			Vioxx 25					

			Merck	SS	Merck	ORAL
25G DAILY						
ORAL						
			Persantine	C		
			Prilosec	C		
			Restoril	C		
			Estrace	C		
			Cardizem Cd	C		
			Oxycontin	C		

Date:03/21/05ISR Number: 4621222-0Report Type:Direct Company Report #CTU 243906
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Voixx 25 Mg			
Initial or Prolonged			Merck	PS	Merck	ORAL
1 TAB						
ORAL						

Date:03/22/05ISR Number: 4614801-8Report Type:Expedited (15-DaCompany Report #200510328FR
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Anoxia		Amarel	PS	Aventis	
Life-Threatening	Arrhythmia				Pharmaceuticals Inc.	ORAL
	Cardiac Arrest		Visken	SS		ORAL
	Coma		Omix	SS		ORAL
	Electroencephalogram		Vioxx	SS		ORAL
	Abnormal		Metformine	SS		ORAL
	General Physical Health					
	Deterioration					
	Grimacing					
	Nosocomial Infection					
	Overweight					
	Pneumonia					
	Sepsis					
	Superinfection Lung					

Date:03/22/05ISR Number: 4614917-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614918-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01570
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Coronary Syndrome
	Acute Myocardial Infarction
	Angina Pectoris
	Arthralgia
	Blindness
	Chest Pain
	Chest Wall Pain
	Corneal Ulcer
	Coronary Artery Occlusion
	Coronary Artery

	Restenosis						
	Cough						
	Diverticulum						
	Emotional Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL	1128 DAY
	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL	1128 DAY
	Gastroduodenitis		Nortriptyline	C			UNKNOWN 233 DAY
	Haematuria		Trazodone Hydrochloride	C			UNKNOWN
	Hyperlipidaemia						
	Hypertension		Vicodin Tablets	C			UNKNOWN
	Myocardial Infarction						
	Nausea						
	Neck Pain						
	Nephrolithiasis						
	Pain						
	Vomiting						

Date:03/22/05ISR Number: 4614923-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02417
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/22/05ISR Number: 4614926-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	112 DAY
Disability	Angina Pectoris		Propranolol Hydrochloride	C			UNKNOWN
	Anxiety						
	Aortic Stenosis		Darvocet-N	C			UNKNOWN
	Appetite Disorder						

Cardiac Disorder
Cardiac Murmur
Chest Discomfort
Chest Pain
Coronary Artery Disease
Depression
Dyspepsia
Dyspnoea
Fatigue
Femoral Arterial Stenosis
Gastric Disorder
Gastrooesophageal Reflux
Disease
Insomnia
Intermittent Claudication
Liver Function Test
Abnormal
Mitral Valve Stenosis
Myocardial Infarction
Pain
Paralysis
Peripheral Vascular
Disorder
Rectal Haemorrhage
Thrombosis
Weight Fluctuation

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4614927-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00755
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	950	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	126	DAY
			Imuran (Azathioprine)	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Cytotec	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Zoloft	C			UNKNOWN	

Date:03/22/05ISR Number: 4614928-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00259
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Phlebothrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	11	DAY
			Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL		
			Populus And Serenoa Repens And Urtica	C		ORAL		

Date:03/22/05ISR Number: 4614929-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00032
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		683 DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin And Magnesium Oxide	C				UNKNOWN
			Esomeprazole Magnesium	C				UNKNOWN
			Metoprolol Tartrate	C				UNKNOWN
			Pravastatin Sodium	C				UNKNOWN
			Nitroglycerin	C				UNKNOWN
			Aluminum Hydroxide And Magnesium Carbonate And Magnesium Hydroxide	C				UNKNOWN

Date:03/22/05ISR Number: 4614940-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02585
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614942-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02582
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4614943-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614964-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1187 MON	

Date:03/22/05ISR Number: 4614968-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	46 MON	

Date:03/22/05ISR Number: 4614970-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614971-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA00829
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL		943 DAY

Date:03/22/05ISR Number: 4614972-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614974-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		56 MON
Disability	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4614981-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02432
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614983-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	49	MON

Date:03/22/05ISR Number: 4614985-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02565
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON

Date:03/22/05ISR Number: 4614986-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02502
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hydro-Chlor	C				
UNKNOWN								

Date:03/22/05ISR Number: 4614988-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02504
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Disturbance		[Therapy					

				Unspecified]	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							

Date:03/22/05ISR Number: 4614989-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614991-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4614992-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4614994-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
	Myocardial Infarction							

Date:03/22/05ISR Number: 4615002-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615004-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02634
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	64	MON

Date:03/22/05ISR Number: 4615008-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02686
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/22/05ISR Number: 4615010-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON

Date:03/22/05ISR Number: 4615012-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	714	DAY

Date:03/22/05ISR Number: 4615013-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/22/05ISR Number: 4615014-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02687
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615016-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/22/05ISR Number: 4615017-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02685
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/22/05ISR Number: 4615018-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503USA02659
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:03/22/05ISR Number: 4615019-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02639
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:03/22/05ISR Number: 4615020-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02689
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2314	DAY

Date:03/22/05ISR Number: 4615025-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02690
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:03/22/05ISR Number: 4615027-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02748
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	37	MON

Date:03/22/05ISR Number: 4615028-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:03/22/05ISR Number: 4615030-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615031-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02714
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615034-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02718
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615035-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02749
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	

Date:03/22/05ISR Number: 4615036-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615037-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1863 DAY	

Date:03/22/05ISR Number: 4615038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/22/05ISR Number: 4615039-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02768
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615040-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615056-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615058-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02898
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615059-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02799
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	65	MON

Date:03/22/05ISR Number: 4615060-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615061-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Renal Disorder
Thrombosis
Ulcer

Date:03/22/05ISR Number: 4615063-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615066-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02797
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615068-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615077-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615078-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615079-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615080-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03151
Age: Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event
	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615082-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure					
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Disorder					
	Thrombosis					
	Ulcer					

Date:03/22/05ISR Number: 4615083-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03229
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure					
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Disorder					
	Thrombosis					
	Ulcer					

Date:03/22/05ISR Number: 4615085-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1217 DAY	

Date:03/22/05ISR Number: 4615086-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615089-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03154
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615090-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615091-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02829
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615093-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03232
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615097-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03239
Age: Gender: I/FU:I

Outcome	PT
Other	Adverse Event
	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain

		Hepatocellular Damage					
		Myocardial Infarction					
		Polytraumatism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615099-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03265
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure					
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Polytraumatism					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615100-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03270
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure					
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615102-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615103-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03268
Age: Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event
	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615105-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03244
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure					
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615106-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03235
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure					
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/22/05ISR Number: 4615107-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:03/22/05ISR Number: 4615109-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03236
Age: Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event
	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Renal Disorder
	Thrombosis

Ulcer

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615113-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615543-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03101
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Zoloft	C				
UNKNOWN								
	Blood Pressure Increased		Lopressor	C				
UNKNOWN								
	Cerebrovascular Accident		Prilosec	C				
UNKNOWN								
	Chest Discomfort		Aspirin	C				
UNKNOWN								
	Chest Pain		Hytrin	C				
UNKNOWN								
	Coronary Artery		Librium	C				
UNKNOWN								
	Atherosclerosis		Lipitor	C				
UNKNOWN								
	Dyspnoea		Nitrostat	C				
UNKNOWN								

	Fatigue		Altace	C		
UNKNOWN						
	Myocardial Infarction					
	Oedema Peripheral					
	Palpitations					

Date:03/22/05ISR Number: 4615552-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Constipation					
	Dizziness					
	Embolism					
	Peripheral Vascular Disorder					
	Stomach Discomfort					
	Vomiting					

Date:03/22/05ISR Number: 4615555-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00067
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Myocardial Infarction
	Palpitations

Panic Attack

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:03/22/05ISR Number: 4615558-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615559-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00036
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastroenteritis		Candesartan					
	Myalgia		Cilexetil	C		ORAL		
	Myocardial Infarction							

Date:03/22/05ISR Number: 4615560-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00206
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615561-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00535
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL
4 YR						
Initial or Prolonged			Crestor	C		
UNKNOWN						
Other			Glyburide	C		
UNKNOWN						

Date:03/22/05ISR Number: 4615562-9Report Type:Expedited (15-DaCompany Report #SG-MERCK-0503SGP00008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrooesophageal Reflux Disease					
	Stomach Discomfort					
	Tendonitis					

Date:03/22/05ISR Number: 4615563-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0501NOR00003
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Blood Creatinine Increased

		Blood Urea Increased Coronary Artery Occlusion Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
		Venous Thrombosis Limb		Hydrochlorothiazide And Losartan Potassium	C		
UNKNOWN		9 YR					
				Lansoprazole	C		
UNKNOWN		11 YR					
				Atorvastatin Calcium	C		
UNKNOWN		7 YR					
				Allopurinol	C		
UNKNOWN		6 YR					
				Atenolol	C		
UNKNOWN		7 YR					
				Levothyroxine Sodium	C		
UNKNOWN		5 YR					
				Aspirin And Magnesium Oxide	C		ORAL
				Levothyroxine Sodium	C		
UNKNOWN							

Date:03/22/05ISR Number: 4615564-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00146
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain		Aspirin	C		ORAL
	Coronary Artery Atherosclerosis		Ranitidine Hydrochloride	C		ORAL
	Coronary Artery Disease		Levothyroxine Sodium	C		ORAL
	Disorientation		Diclofenac	C		ORAL
757 DAY						
	Dysphagia		Amoxicillin	C		ORAL
	Fall		Amoxicillin	C		ORAL
	Fatigue		Amoxicillin	C		ORAL
	Forearm Fracture		Pridinol	C		ORAL
	Headache					
	Hypertension					
	Mandibulofacial					

Dysostosis
Memory Impairment
Nausea
Paraesthesia
Syncope
Tonsillitis

Date:03/22/05ISR Number: 4615570-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00283
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL		
	Left Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
			Methotrexate	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	
			Calcium Carbonate And Cholecalciferol	C			UNKNOWN	
			Celecoxib	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615572-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00040
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prednisolone	C				
			Fosamax	C			UNKNOWN	

Date:03/22/05ISR Number: 4615575-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1499 DAY	

Date:03/22/05ISR Number: 4615576-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615578-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615579-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02750
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1667 DAY						

Date:03/22/05ISR Number: 4615581-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02751
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Dyspnoea Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/22/05ISR Number: 4615582-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/22/05ISR Number: 4615583-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02908
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615585-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02910
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615586-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Constipation							
	Dizziness							
	Embolism							
	Peripheral Vascular Disorder							
	Stomach Discomfort							
	Vomiting							

Date:03/22/05ISR Number: 4615587-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02918
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615589-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	60	MON

Date:03/22/05ISR Number: 4615590-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1391 DAY

Date:03/22/05ISR Number: 4615591-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615593-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615595-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615596-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615597-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Drug Interaction		Coumadin	SS			UNKNOWN	
	Myocardial Infarction							

Date:03/22/05ISR Number: 4615599-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02903
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615603-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Chest Pain
Hepatocellular Damage
Myocardial Infarction
Renal Disorder
Thrombosis
Ulcer

Date:03/22/05ISR Number: 4615604-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615605-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615606-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03207
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615608-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615609-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03211
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615610-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc

UNKNOWN 46 MON

Date:03/22/05ISR Number: 4615621-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03196
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiac Failure					
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Polytraumatism					
	Renal Injury					
	Thrombosis					
	Ulcer					

Dose Duration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4615624-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY

Date:03/22/05ISR Number: 4615625-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615626-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615629-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03243
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							

Ulcer

Date:03/22/05ISR Number: 4615630-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03149
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/22/05ISR Number: 4615631-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03251
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615632-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615633-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/22/05ISR Number: 4615634-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	12	MON

Date:03/22/05ISR Number: 4615637-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03255
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON
	Anxiety							
	Balance Disorder							
	Bedridden							
	Cerebral Infarction							
	Depression							
	Dysgraphia							
	Sensory Loss							

Date:03/22/05ISR Number: 4615649-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00039
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		YR
	Infarction		Aspirin And Magnesium Oxide	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Zocor	C		ORAL		
			Vasotec	C		ORAL		
			Metoprolol Tartrate	C		ORAL		
			Nitroglycerin	C		ORAL		

Date:03/22/05ISR Number: 4615677-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03209
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/22/05ISR Number: 4617976-XReport Type:Expedited (15-DaCompany Report #2005AP01576
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased	Foreign	Lisinopril	PS		ORAL	20 MG DAILY	
Initial or Prolonged	Haemodialysis	Health					PO	
	Lactic Acidosis	Professional	Amlodipine	SS		ORAL	10 MG DAILY	
	Renal Failure	Other					PO	
			Contrast Medium	SS			1 UNK ONCE	
			Diaformin	SS		ORAL	2.5 G DAILY	
							PO	
			Vioxx	SS			25 MG DAILY	

Date:03/22/05ISR Number: 4620210-8Report Type:Direct Company Report #CTU 243914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Bowel Movement		Vioxx	PS	Merck		3	DAY
	Irregularity							
	Change Of Bowel Habit							
	Drug Ineffective							
	Haemorrhage							

Date:03/23/05ISR Number: 4617093-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02063
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Arthritis
Disability	Blindness
Other	Bronchitis
	Catheter Site Haemorrhage

Cholecystitis Chronic
Cholelithiasis
Coronary Artery Disease
Drug Ineffective
Duodenal Scarring
Emotional Distress
Fibromyalgia
Gastritis
Gastrooesophageal Reflux
Disease
Haematuria
Herpes Simplex
Hiatus Hernia
Hypermetropia
Hyperreflexia
Hypersensitivity
Inguinal Hernia
Irritable Bowel Syndrome
Joint Contracture
Mental Disorder
Morton'S Neuroma
Muscle Contractions
Involuntary
Myocardial Infarction
Nasopharyngitis
Nausea
Neck Pain
Nephrolithiasis

		Overdose					
		Polycythaemia					
		Presbyopia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pterygium		Vioxx	PS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Skin Discolouration		Vioxx	SS	Merck & Co., Inc	ORAL
		Skin Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Tympanic Membrane		Vioxx	SS	Merck & Co., Inc	ORAL
58	DAY						
		Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Vertigo Positional		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL
		Vitreous Floaters		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
58	DAY						
		Whiplash Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Wound Infection		Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Lovastatin	C		
UNKNOWN							
				Lovastatin	C		
UNKNOWN							
				Codeine	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							

			Sulfasalazine	C		
UNKNOWN						
			Acetaminophen	C		
UNKNOWN						
			Gabapentin	C		
UNKNOWN						
			Compazine	C		
UNKNOWN						
			Seroquel	C		
UNKNOWN						
			Seroquel	C		
UNKNOWN						
			Baclofen	C		
UNKNOWN						
			Baclofen	C		
UNKNOWN						
			Medrol	C		
UNKNOWN						

Date:03/23/05ISR Number: 4617095-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00502
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 587 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 587 DAY	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
Other UNKNOWN	Non-Insulin-Dependent		Aspirin	C		
	Gastritis		Bisoprolol Fumarate			
	Hypertensive		And			
	Cardiomyopathy		Hydrochlorothiazide	C		
UNKNOWN						
	Myocardial Infarction		Atorvastatin Calcium	C		
UNKNOWN						
			Celecoxib	C		ORAL
			Dexketoprofen	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617098-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00639
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Pepcid	C			UNKNOWN	
	Chest Pain		Albuterol	C			UNKNOWN	
	Coronary Artery Disease		Atrovent	C			UNKNOWN	
	Diabetes Mellitus		Lisinopril	C			UNKNOWN	
	Non-Insulin-Dependent		Aspirin	C			UNKNOWN	
	Disorientation							
	Drug Hypersensitivity							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Hyperventilation							
	Hypoxia							
	Injury							
	Neurodermatitis							
	Osteoarthritis							
	Stress							
	Thrombosis							
	Transient Ischaemic Attack							
	Vertebral Artery Stenosis							
	Vertigo							

Date:03/23/05ISR Number: 4617099-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
Other	Aortic Disorder
	Asthenia
	Back Pain
	Blood Pressure Increased

Chest Discomfort
Chest Pain
Chronic Obstructive
Pulmonary Disease
Colonic Polyp
Convulsion
Coronary Artery Stenosis
Dehydration
Diaphragmatic Disorder
Diaphragmatic Hernia
Diverticulum
Drug Effect Decreased
Foot Fracture
Gastrooesophageal Reflux
Disease
Haematoma
Headache
Hypercholesterolaemia
Hyperhidrosis
Hyperlipidaemia
Hypoaesthesia
Hypotension

		Induration					
		Intervertebral Disc Degeneration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lethargy		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Nerve Compression		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Osteoporosis		Plavix	C		
UNKNOWN							
		Paraesthesia		Prilosec	C		
UNKNOWN							
		Polyp		Lipitor	C		
UNKNOWN							
		Post Procedural Haematoma		Zocor	C		ORAL
		Radiculopathy		Zocor	C		ORAL
		Spinal Osteoarthritis		Aspirin	C		
UNKNOWN							
		Spondylolisthesis					
		Treatment Noncompliance					

Date:03/23/05ISR Number: 4617108-8Report Type:Expedited (15-DaCompany Report #US-MERCK-00061211
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cardiac Failure					
	Cerebrovascular Accident					
	Chest Pain					
	Gastric Ulcer					
	Hepatocellular Damage					
	Hyperhidrosis					
	Injury					
	Myocardial Infarction					
	Rectal Haemorrhage					
	Renal Disorder					
	Thrombosis					
	Ulcer					

Date:03/23/05ISR Number: 4617109-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:03/23/05ISR Number: 4617110-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01768
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Nifedipine	C				
UNKNOWN								
	Drug Effect Decreased		Fosinopril Sodium	C				
UNKNOWN								
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617112-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00949
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	1186 DAY	
Hospitalization - Initial or Prolonged	Cardiac Arrest		[Therapy Unspecified]	C			UNKNOWN	
	Chest Pain							
Disability	Gastritis		Zestril	C			UNKNOWN	
Other	Hernia		Xanax	C			UNKNOWN	
	Myocardial Infarction		Procardia	C			UNKNOWN	
			Pravachol	C			UNKNOWN	

Date:03/23/05ISR Number: 4617113-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617116-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00928
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Device Failure							
	Hip Arthroplasty							
	Joint Dislocation							
	Migration Of Implant							
	Myocardial Infarction							
	Osteoarthritis							

Date:03/23/05ISR Number: 4617119-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00164
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617120-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617127-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00308
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Amitriptylin	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Flexeril	C			UNKNOWN	
			Pepcid	C			UNKNOWN	
			Claritin	C			UNKNOWN	
			Nasonex	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:03/23/05ISR Number: 4617129-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00018
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Transient Ischaemic Attack							

Date:03/23/05ISR Number: 4617131-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00093
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia Cardiovascular Disorder Life Expectancy Shortened Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617132-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:03/23/05ISR Number: 4617134-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02457
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617135-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617136-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03173
Age: Gender: I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Renal Injury
	Thrombosis

	Ulcer						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617138-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:03/23/05ISR Number: 4617139-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	41	MON

Date:03/23/05ISR Number: 4617141-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03192
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617143-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617144-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617145-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Coumadin	C				
UNKNOWN								
	Renal Disorder							

Date:03/23/05ISR Number: 4617267-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/23/05ISR Number: 4617270-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:03/23/05ISR Number: 4617273-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02050
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Neoplasm Malignant		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Life-Threatening	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Gastric Cancer		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL	5	YR
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lung Neoplasm Malignant		Vioxx	SS	Merck & Co., Inc	ORAL		
	Therapeutic Response		Lortab	C				
UNKNOWN								

	Decreased	Duragesic	C
UNKNOWN			
		Celebrex	C
UNKNOWN			
		Depakote	C
UNKNOWN			
		Trazodone Hydrochloride	C
UNKNOWN			
		Advil	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Elavil	C
UNKNOWN			
		Prevacid	C
UNKNOWN			
		Flexeril	C
UNKNOWN			
		Verapamil Hydrochloride	C
UNKNOWN			
		Xanax	C
UNKNOWN			
		Oxycodone	C
UNKNOWN			
		Calcium (Unspecified)	C
UNKNOWN			
		Vitamins (Unspecified)	C
UNKNOWN			
		Zantac	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617274-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01978
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Initial or Prolonged	Asthenia		Xanax	C				UNKNOWN
Other	Back Injury		Prilosec	C				UNKNOWN
	Breast Pain		[Therapy Unspecified]	C				UNKNOWN
	Carpal Tunnel Syndrome							
	Cellulitis							
	Cervical Spinal Stenosis							
	Cervicobrachial Syndrome							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Colitis							
	Contusion							
	Decreased Activity							
	Depression							
	Drug Dependence							
	Emotional Distress							
	Exostosis							
	Fall							
	Feeling Abnormal							
	Gastritis							
	Gastrooesophageal Reflux Disease							
	Haemorrhoids							
	Head Injury							
	Helicobacter Infection							
	Hypercholesterolaemia							
	Hypertension							
	Hypoaesthesia							
	Incision Site Complication							
	Insomnia							
	Intervertebral Disc Protrusion							
	Ligament Sprain							
	Loss Of Consciousness							
	Lumbar Spinal Stenosis							
	Malaise							
	Migraine							

Muscle Spasms
Myofascial Pain Syndrome
Nausea
Oesophagitis
Osteoarthritis
Panic Attack
Panic Disorder
Pelvic Pain
Radiculitis Cervical
Road Traffic Accident
Swelling Face
Therapeutic Response
Decreased
Trigger Finger
Visual Acuity Reduced

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617276-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01070
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	277	YR
Other	Erectile Dysfunction		Lipitor	C			UNKNOWN	
	Transient Ischaemic		Axid	C			UNKNOWN	
	Attack		Vitamins (Unspecified)	C			UNKNOWN	
			Viagra	C			UNKNOWN	

Date:03/23/05ISR Number: 4617278-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00019
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Injury		Zocor	C		ORAL		
Disability	Nervous System Disorder							

Date:03/23/05ISR Number: 4617279-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01877
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
	Burning Sensation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Oxycodone	C		ORAL	6	DAY
	Coronary Artery		Docusate Sodium	C		ORAL		
	Atherosclerosis		Ascorbic Acid	C		ORAL		
	Coronary Artery		Ferrous Sulfate	C		ORAL		
	Thrombosis		Coumadin	C			UNKNOWN	

Death
Depressed Mood
Fatigue
Femur Fracture
Gout
Hip Fracture
Hypoaesthesia
Joint Swelling
Limb Discomfort
Myocardial Fibrosis
Myocardial Infarction
Nephrolithiasis
Oedema Peripheral
Pain In Extremity
Pulmonary Congestion
Sensory Disturbance
Sleep Disorder

Date:03/23/05ISR Number: 4617280-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coagulation Factor Viii		Vioxx	PS	Merck & Co., Inc	ORAL		117 DAY
Initial or Prolonged	Level Decreased		Zocor	SS		ORAL		
	Coagulation Time Prolonged		Ginkgo Biloba Extract	SS		ORAL		
	Haematoma		Hydrochlorothiazide					

Date:03/23/05ISR Number: 4617281-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00825
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain Lower
Hospitalization - Initial or Prolonged	Abscess Limb
Other	Agitation
	Anaemia
	Anxiety
	Aortic Aneurysm
	Aortic Atherosclerosis
	Aortic Calcification
	Aortic Valve Sclerosis
	Arcus Lipoides
	Arthralgia
	Asthenia
	Asthma
	Atelectasis
	Atherosclerosis
	Atrial Fibrillation
	Atrial Pressure Increased
	Back Pain
	Blood Bicarbonate Increased
	Blood Blister
	Blood Potassium Decreased
	Blood Sodium Decreased
	Bradycardia
	Bronchitis
	Bronchospasm
	Calcinosis
	Cardiac Failure Congestive
	Cardiomegaly
	Cardiomyopathy
	Carpal Tunnel Syndrome
	Cellulitis
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Confusional State
	Conjunctivitis Allergic
	Constipation
	Crepitations

Death
Depressed Level Of
Consciousness
Difficulty In Walking
Dilatation Ventricular
Disorientation
Dizziness
Drug Hypersensitivity
Dysarthria
Dyspepsia
Dyspnoea
Emotional Distress
Foreign Body Trauma
Heart Valve Calcification
Herpes Virus Infection

		Herpes Zoster					
		Hyperhidrosis					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Interstitial Lung Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Labile Hypertension		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Laryngitis		Fosamax	C		
UNKNOWN							
		Lethargy		Percocet	C		
UNKNOWN							
		Loss Of Consciousness		Zestril	C		
UNKNOWN							
		Medication Error		Zestril	C		
UNKNOWN							
		Mental Status Changes		Diltiazem			
		Mitral Valve		Hydrochloride	C		
UNKNOWN							
		Calcification					
		Mitral Valve Incompetence					
		Multiple Fractures					
		Myocardial Infarction					
		Nasopharyngitis					
		Nausea					
		Neuropathy					
		Osteoporosis					
		Overdose					
		Pneumonia					
		Productive Cough					
		Pulmonary Fibrosis					
		Renal Artery Stenosis					
		Skin Lesion					
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Sputum Discoloured					
		Syncope					
		Tracheal Obstruction					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Retention					
		Ventricular Hypertrophy					

Vomiting

Date:03/23/05ISR Number: 4617284-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00524
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							
	Renal Atrophy							

Date:03/23/05ISR Number: 4617285-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00617
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure
	Congestive
Disability	Cardiomegaly
Other	Coronary Artery Disease
	Costochondritis
	Diabetes Mellitus

		Inadequate Control					
		Dilatation Ventricular					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Endocet	C		
UNKNOWN							
		Injury		Smz-Tmp	C		
UNKNOWN							
		Insomnia		Augmentin	C		
UNKNOWN							
		Left Ventricular Failure		Hydrocodone/Apap	C		
UNKNOWN							
		Loss Of Consciousness		Diazepam	C		
UNKNOWN							
		Myocardial Infarction		Diflucan	C		
UNKNOWN							
		Pleural Effusion					
		Pulmonary Hypertension					
		Pulmonary Valve Incompetence					
		Respiratory Failure					
		Tricuspid Valve Incompetence					

Date:03/23/05ISR Number: 4617286-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01951
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 424 DAY		Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Coronary Artery Disease		Prednisone	C		
UNKNOWN							
Other		Cough		Minocycline	C		
UNKNOWN							
		Dermatitis		Respaire	C		
UNKNOWN							
		Diabetes Mellitus		Piroxicam	C		
UNKNOWN							
		Insulin-Dependent		Zantac	C		
UNKNOWN							
		Diastolic Dysfunction		Flonase	C		
UNKNOWN							
		Foot Deformity					

Hyperlipidaemia
Hypertension
Myocardial Infarction
Oedema Peripheral
Pulmonary Oedema
Rheumatoid Arthritis
Rhinitis Allergic
Rotator Cuff Syndrome
Seborrhoeic Keratosis
Skin Ulcer
Syncope

Date:03/23/05ISR Number: 4617287-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00507
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Arrhythmia
Other	Bronchitis Acute
	Cerebrovascular Accident
	Coronary Artery Atherosclerosis
	Diabetes Mellitus
	Diabetic Neuropathy
	Diverticulum
	Eye Disorder
	Hyperuricaemia
	Influenza Like Illness
	Osteoarthritis

	Osteoporosis Post Thrombotic Syndrome Pulmonary Embolism	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Skin Ulcer Spinal Fracture Thrombophlebitis Superficial Toe Deformity		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN

Date:03/23/05ISR Number: 4617288-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00169
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Positive		Vioxx	SS	Merck & Co., Inc	ORAL	
	Arthralgia		Celebrex	C			UNKNOWN
Other	Cardiomegaly Coronary Artery Atherosclerosis Coronary Artery Disease Coronary Artery Occlusion Hepatic Steatosis Hepatomegaly Hypertrophy Initial Insomnia Insomnia Intracardiac Thrombus Myocardial Infarction No Therapeutic Response Ovarian Cyst Pain In Extremity Pulmonary Haemorrhage Pulmonary Oedema Pyrexia Renal Cyst Sinusitis Subcutaneous Abscess Upper Respiratory Tract Infection						

Date:03/23/05ISR Number: 4617289-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00157
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL		25 DAY
Initial or Prolonged	Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL		42 DAY
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		31 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lisinopril	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Aspirin	C		ORAL		
			Pravastatin Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617290-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00068
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Erysipelas		Fendiline Hydrochloride	C				
	Headache							
	Macular Degeneration		Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C				
	Necrotising Fasciitis							
	Pseudomonas Infection							
	Retinal Tear							
	Retinal Vascular Thrombosis							
	Retinal Vein Occlusion							
	Skin Graft Thrombosis							

Date:03/23/05ISR Number: 4617291-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03944
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ocular Vascular Disorder		Zocor	C				
			Lipitor	C				
			Plendil	C				
			Prinivil	C				
			Hydrochlorothiazide	C				
			Toprol Xl Tablets	C				
			Aspirin	C				

Date:03/23/05ISR Number: 4617292-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02315
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Disability	Hypertension Renal Artery Occlusion Renal Impairment Weight Decreased							

Date:03/23/05ISR Number: 4617294-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deafness Unilateral		Phenprocoumon	C		ORAL		
	Diabetes Mellitus Inadequate Control Gastritis Hepatomegaly Vestibular Neuronitis							

Date:03/23/05ISR Number: 4617295-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02757
Age:84 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
		Vioxx	SS	Merck & Co., Inc	ORAL		
		Plavix	C				UNKNOWN
		Altace	C				UNKNOWN
		Vytorin	C		ORAL		
		Toprol Xl Tablets	C				UNKNOWN
		Zocor	C		ORAL		

Date:03/23/05ISR Number: 4617296-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Aspirin	C				UNKNOWN
	Coronary Artery Stenosis		Atorvastatin Calcium	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Clopidogrel Bisulfate	C				UNKNOWN

Date:03/23/05ISR Number: 4617297-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:03/23/05ISR Number: 4617298-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0503BRA00043
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiogenic Shock							
	Pleural Effusion							
	Pseudomonas Infection							
	Rectal Neoplasm							
	Respiratory Failure							

Date:03/23/05ISR Number: 4617300-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00206
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617301-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Coronary Artery Disease							

Date:03/23/05ISR Number: 4617302-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	288	DAY

Date:03/23/05ISR Number: 4617303-8Report Type:Expedited (15-DaCompany Report #NL-MERCK-0503NLD00032
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617305-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00134
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Simvastatin	C		ORAL		
	Attack		Omeprazole Magnesium	C		ORAL		
			Aspirin	C		ORAL		

Date:03/23/05ISR Number: 4617307-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02871
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:03/23/05ISR Number: 4617308-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03019
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/23/05ISR Number: 4617309-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
	Constipation					
	Dizziness					
	Embolism					
	Peripheral Vascular Disorder					
	Stomach Discomfort					
	Vomiting					

Date:03/23/05ISR Number: 4617310-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00133
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Anxiety
Other	Arthralgia
	Asthenia
	Blood Pressure Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

		Catheter Related Infection					
		Cerebral Atrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Detrol	C		ORAL
		Chest X-Ray Abnormal		Sinemet	C		ORAL
		Condition Aggravated		Temazepam	C		
UNKNOWN							
		Contusion		Alphagan	C		
OPHTHALMIC							
		Cough		Nystatin	C		ORAL
		Electrocardiogram St-T Change					
		Erythema					
		Fall					
		Fungal Infection					
		Gastric Disorder					
		Gastritis					
		Gastrostomy Closure					
		Glaucoma					
		Haematoma					
		Headache					
		Hiatus Hernia					
		Klebsiella Infection					
		Ligament Laxity					
		Lung Disorder					
		Meningioma					
		Multiple Allergies					
		Nausea					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Pain In Extremity					
		Parkinson'S Disease					
		Pleural Fibrosis					
		Pneumonia Klebsiella					
		Psoriasis					
		Pulmonary Granuloma					
		Rotator Cuff Syndrome					
		Seasonal Allergy					
		Skin Discolouration					
		Skin Laceration					
		Upper Gastrointestinal Haemorrhage					

Date:03/23/05ISR Number: 4617311-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL TOPICAL		

Date:03/23/05ISR Number: 4617312-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617313-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/23/05ISR Number: 4617314-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02886
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Other								

Date:03/23/05ISR Number: 4617315-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/23/05ISR Number: 4617316-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617317-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56	DAY

Date:03/23/05ISR Number: 4617318-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617319-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03104
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617320-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02933
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617321-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617322-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617323-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617324-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617325-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03119
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617326-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03116
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617327-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617328-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617329-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617330-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617331-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Injury Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617332-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617333-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03102
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617334-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03132
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617335-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Disorder					
	Thrombosis					
	Ulcer					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617336-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617337-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617338-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617339-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03138
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617340-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03158
Age: Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event
	Cardiac Failure

		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617342-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03141
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617343-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03168
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Injury					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617344-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03175
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617345-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03172
Age: Gender: I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage

		Myocardial Infarction					
		Polytraumatism					
		Renal Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Ulcer					

Date:03/23/05ISR Number: 4617346-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03176
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617347-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03174
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617348-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03150
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Cerebrovascular Accident
Chest Pain
Hepatocellular Damage
Myocardial Infarction
Renal Disorder
Thrombosis
Ulcer

Date:03/23/05ISR Number: 4617349-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617350-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617351-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03178
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:03/23/05ISR Number: 4617352-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617353-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1733 DAY

Date:03/23/05ISR Number: 4617354-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03180
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617355-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03182
Age: Gender: I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Polytraumatism

	Renal Injury						
	Thrombosis						
	Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617356-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617357-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03179
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617358-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617359-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1643 DAY
	Thrombosis							

Date:03/23/05ISR Number: 4617360-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03194
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617362-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617363-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:03/23/05ISR Number: 4617364-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	47	MON

Date:03/23/05ISR Number: 4617365-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							

Polytraumatism
Renal Injury
Thrombosis
Ulcer

Date:03/23/05ISR Number: 4617366-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03225
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617367-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03234
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617368-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617369-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03220
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617370-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		586 DAY

Date:03/23/05ISR Number: 4617371-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617372-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03264
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617373-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617374-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Cerebrovascular Accident							
	Limb Injury							
	Polytraumatism							

Date:03/23/05ISR Number: 4617375-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03428
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Glipizide	C		ORAL
Initial or Prolonged	Hyperglycaemia		Hydrocodone			
	Respiratory Failure		Bitartrate	C		ORAL
			Soma	C		ORAL
			Darvon	C		
UNKNOWN						
			Estradiol	C		ORAL
			Zocor	C		ORAL
			Celebrex	C		ORAL
			Celexa	C		ORAL

Date:03/23/05ISR Number: 4617376-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03269
Age: Gender: I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617377-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03238
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617393-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03215
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:03/23/05ISR Number: 4617394-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617395-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617396-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03573
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Other	Death							

Date:03/23/05ISR Number: 4617397-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617398-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617400-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON
	Infarction							

Date:03/23/05ISR Number: 4617401-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03456
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON

Date:03/23/05ISR Number: 4617403-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03548
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction							

Date:03/23/05ISR Number: 4617404-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4617406-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03140
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617407-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03212
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/23/05ISR Number: 4617408-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/23/05ISR Number: 4617409-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03233
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/23/05ISR Number: 4618257-0Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00273
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Silent Myocardial Infarction	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL
25 MG/DAILY						
		Other				
PO 15 DAY						
			Acetaminophen	C		
			Aspirin	C		
			Lansoprazole	C		

Date:03/23/05ISR Number: 4618259-4Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00273
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 15 DAY
			Acetaminophen	C				
			Aspirin	C				
			Lansoprazole	C				

Date:03/23/05ISR Number: 4618264-8Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Blood Cholesterol Increased Haematocrit Decreased Haemoglobin Decreased Low Density Lipoprotein Increased	Foreign Study Health Professional	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 35 DAY
			Omeprazole	C				

Date:03/23/05ISR Number: 4620305-9Report Type:Direct Company Report #CTU 244088
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Feeling Abnormal Myocardial Infarction Nausea		Vioxx	PS	Merck			

Date:03/23/05ISR Number: 4621312-2Report Type:Direct Company Report #CTU 244000
Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx 50mg 2x Day	PS			50 MG 2X DAY	1 MON
Hospitalization - Initial or Prolonged								
Disability								
Other								

Date:03/24/05ISR Number: 4617623-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02865
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/24/05ISR Number: 4617624-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02281
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Joint Stiffness		Prednisone	C			UNKNOWN	
	Musculoskeletal Stiffness		Advair	C			UNKNOWN	
	Overdose		Calcium (Unspecified)	C			UNKNOWN	

				Ascorbic Acid	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							

Date:03/24/05ISR Number: 4617626-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03281
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Bone Pain					
	Headache					
	Myocardial Infarction					

Date:03/24/05ISR Number: 4617628-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02374
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Vitamins			
Initial or Prolonged			(Unspecified)	C		
UNKNOWN						
Disability			Minerals			
			(Unspecified)	C		
UNKNOWN						

Date:03/24/05ISR Number: 4617629-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02877
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4617630-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02866
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4617631-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02484
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:03/24/05ISR Number: 4617633-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02895
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4617634-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03169
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4617635-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03052
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability			Prilosec	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Protonix	C			UNKNOWN	

Date:03/24/05ISR Number: 4617636-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4617637-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 10 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Beclomethasone Dipropionate	C				
RESPIRATORY (INHALATION)	Anhedonia							
	Anxiety							
UNKNOWN	Aortic Valve Incompetence		Verapamil Hydrochloride	C				729 DAY
	Coronary Artery Occlusion							
UNKNOWN	Diarrhoea		[Therapy Unspecified]	C				382 DAY
	Disorientation							
UNKNOWN	Drug Ineffective		Griseofulvin	C				25 DAY
	Emotional Distress							
	Fatigue							
	Feeling Abnormal							
	Hyperhidrosis							
	Hyperkeratosis							
	Hyperlipidaemia							
	Injury							
	Nausea							
	Pain							
	Pelvic Haematoma							
	Skin Hypertrophy							
	Stress							
	Tinea Infection							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4617639-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00214
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain							
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:03/24/05ISR Number: 4617640-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0301USA02188
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged	Infarction		Griseofulvin	C			UNKNOWN	
	Anhedonia		[Therapy					
	Anxiety		Unspecified]	C			UNKNOWN	
	Aortic Valve Incompetence		Isoptin	C			UNKNOWN	
	Coronary Artery Occlusion		Beconase Aq	C			UNKNOWN	
	Drug Ineffective							
	Emotional Distress							
	Fatigue							
	Hyperkeratosis							
	Hyperlipidaemia							
	Injury							
	Pain							
	Pelvic Haematoma							
	Skin Hypertrophy							
	Stress							
	Tinea Infection							

Date:03/24/05ISR Number: 4617643-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
29 MON						

Date:03/24/05ISR Number: 4617645-6Report Type:Expedited (15-DaCompany Report #CZ-MERCK-0503CZE00010
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	General Symptom		Vioxx	PS	Merck & Co., Inc	ORAL
774 DAY						
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL
774 DAY						
			Celecoxib	C		ORAL
			Celecoxib	C		ORAL

Date:03/24/05ISR Number: 4617646-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4617648-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4617649-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02894
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4617650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03163
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4617651-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL
59 MON					

Date:03/24/05ISR Number: 4617653-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Barrett'S Oesophagus
	Bifascicular Block
	Colon Adenoma
	Congestive Cardiomyopathy
	Coronary Artery Disease
	Dilatation Ventricular
	Dyspnoea
	Extrasystoles
	Gastrointestinal
	Haemorrhage
	Headache
	Hypertension
	Jaw Fracture
	Joint Sprain
	Left Ventricular Failure

		Mitral Valve Incompetence					
		Prescribed Overdose					
		Renal Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rib Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Tooth Abscess		Vioxx	SS	Merck & Co., Inc	ORAL
		Tooth Loss		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
		Vital Capacity Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4617659-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03450
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4618343-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00099
Age:87 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Bruit
	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Acute Coronary Syndrome
	Angina Pectoris
	Aortic Bruit
	Aortic Valve Incompetence
	Appendix Disorder
	Arthralgia
	Atherosclerosis
	Blood Pressure Increased
	Bronchitis
	Carotid Artery Occlusion
	Carpal Tunnel Syndrome
	Cataract
	Cerebrovascular Accident

Cerumen Impaction
Constipation
Convulsion
Coronary Artery Disease
Cough
Cystitis Haemorrhagic
Depressed Mood
Dilatation Atrial
Diverticulum
Drug Hypersensitivity
Dyslipidaemia
Dysuria
Ear Pain
Emotional Distress
Flank Pain
Food Allergy
Gastritis Atrophic
Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Granuloma							
Haematuria							
Headache							
Hepatic Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
Hernia		Vioxx	SS	Merck & Co., Inc	ORAL		
Hypercholesterolaemia							
Hyperhomocysteinaemia							
Hyperkalaemia							
Hypokalaemia							
Infection							
Injury							
Intervertebral Disc Degeneration							
Kidney Small							
Lipids Increased							
Lumbar Spinal Stenosis							
Lung Disorder							
Metaplasia							
Mitral Valve Incompetence							
Myocardial Infarction							
Myocardial Ischaemia							
Neck Injury							
Nervous System Disorder							
Osteoarthritis							
Osteoporosis							
Pain In Extremity							
Pharyngolaryngeal Pain							
Pulmonary Congestion							
Renal Artery Stenosis							
Renal Failure							
Renal Pain							
Road Traffic Accident							
Rotator Cuff Syndrome							
Sciatica							
Shoulder Operation							
Skin Lesion							
Spinal Osteoarthritis							
Tachycardia							
Tinnitus							
Toe Deformity							
Tricuspid Valve Incompetence							
Upper Respiratory Tract Infection							
Urinary Tract Infection							
Uterine Disorder							

Ventricular Dysfunction
Ventricular Hypertrophy
Visual Disturbance

Date:03/24/05ISR Number: 4618352-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00234
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	PARENTERAL	UNKNOWN
			Diclofenac Sodium	C		ORAL		
			Insulin, Biphasic Isophane [Injection]	C				
			Repaglinide	C				
			Tetrazepam	C				

Metformin Hydrochloride	C		ORAL
Magnesium (Unspecified)	C		ORAL
Tolperisone Hydrochloride	C		
Thioctic Acid	C		ORAL

UNKNOWN

Date:03/24/05ISR Number: 4618361-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00611
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Abdominal Pain Lower Adverse Event Angina Pectoris Arthralgia Atelectasis Back Pain Blood Pressure Increased Cerebrovascular Accident Convulsion Deep Vein Thrombosis Hepatic Steatosis Pain In Extremity Pulmonary Embolism White Blood Cell Count Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618362-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02085
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Other	Adverse Event Blood Cholesterol Abnormal Bursitis Cardiac Failure Congestive Cardiomegaly Cardiovascular Disorder Chest Wall Pain

Chills
Confusional State
Decreased Activity
Drug Hypersensitivity
Faecal Incontinence
Fatigue
Feeling Cold
Fibula Fracture
Head Injury
Headache
Hot Flush
Hypertension
Incontinence
Laryngitis
Libido Decreased
Mood Swings
Muscle Spasms
Musculoskeletal Chest

		Pain					
		Myocardial Infarction					
		Neck Injury					
		Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ovarian Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
		Pelvic Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pharyngolaryngeal Pain		Effexor	SS		
UNKNOWN							
		Pollakiuria		Osteo-Bi-Flex	C		
UNKNOWN							
		Pulmonary Oedema		Estrace	C		
UNKNOWN							
		Renal Failure		Vitamins			
		Rotator Cuff Syndrome		(Unspecified)	C		
UNKNOWN							
		Sleep Disorder		Vitamin B			
		Stress		(Unspecified)	C		
UNKNOWN							
		Stress Incontinence		Flagyl	C		
UNKNOWN							
		Suprapubic Pain		Cipro	C		
UNKNOWN							
		Tricuspid Valve		Lotensin	C		
UNKNOWN							
		Incompetence		Zyrtec	C		
UNKNOWN							
		Urinary Tract Infection		Detrol	C		
UNKNOWN							
		Vaginal Erosion					
		Vaginal Infection					
		Vaginal Odour					
		Varicose Vein					
		Vein Disorder					
		Vertigo					
		Viral Upper Respiratory					
		Tract Infection					
		Vision Blurred					
		Visual Disturbance					
		Vulvovaginal Discomfort					
		Weight Increased					

Date:03/24/05ISR Number: 4618369-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04071
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Influenza		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							
	Pneumonia							
	Renal Disorder							

Date:03/24/05ISR Number: 4618370-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00741
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Disability	Adverse Event
Other	Angina Pectoris
	Arrhythmia
	B-Cell Lymphoma
	Benign Prostatic Hyperplasia
	Blood Pressure Increased
	Bradycardia
	Bronchitis Acute
	Cerebrovascular Accident
	Cervicobrachial Syndrome
	Cholelithiasis
	Chronic Obstructive

		Pulmonary Disease					
		Convulsion					
		Coronary Artery Disease					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL
586	DAY						
		Depression		Claritin	C		
UNKNOWN							
		Dermatitis Atopic		Aspirin	C		
UNKNOWN							
		Diverticulum		Pravachol	C		
UNKNOWN							
		Dizziness		Calcium			
		Dysgeusia		(Unspecified)	C		
UNKNOWN							
		Dyspnoea		Folic Acid	C		
UNKNOWN							
		Emphysema		Digoxin	C		
UNKNOWN							
		Fatigue		Naprosyn	C		ORAL
		Gastrooesophageal Reflux		Keflex	C		ORAL
		Disease		Allegra	C		ORAL
		Haemorrhoids		Elocon	C		
UNKNOWN							
		Hiatus Hernia		Lopressor	C		ORAL
		Inner Ear Disorder		Darvocet-N	C		ORAL
		Intervertebral Disc		Pravachol	C		
UNKNOWN							
		Degeneration		Lanoxin	C		ORAL
		Lumbar Radiculopathy		Lortab	C		ORAL
		Lumbar Spinal Stenosis		Clarinex	C		ORAL
		Lung Neoplasm		Zocor	C		ORAL
		Myocardial Infarction		Nexium	C		ORAL
		Neck Pain		Paxil	C		ORAL
		Neuroma		Vitamin E	C		
UNKNOWN							
		Non-Hodgkin'S Lymphoma					
		Oesophageal Disorder					
		Pain In Extremity					
		Palpitations					
		Peptic Ulcer					
		Peripheral Vascular					
		Disorder					
		Pleural Effusion					
		Post Procedural Pain					
		Renal Abscess					
		Renal Cyst					

Renal Mass
Rhinitis Allergic
Splenomegaly
Spondylolisthesis
Vertigo
Weight Decreased

Date:03/24/05ISR Number: 4618373-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Epididymitis		Aspirin	C		ORAL		
UNKNOWN			Diclofenac	C				
Other			Dipyridamole And Aspirin	C		ORAL		
			Clopidogrel Bisulfate	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Uva Ursi	C		ORAL		
			Escin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618385-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Adverse Event							
	Angina Pectoris							
	Blood Pressure Increased							
	Carpal Tunnel Syndrome							
	Chronic Sinusitis							
	Convulsion							
	Cyst							
	Intervertebral Disc Protrusion							
	Lumbar Radiculopathy							
	Lumbar Spinal Stenosis							
	Nasal Polyps							
	Nasal Septum Deviation							
	Nasal Turbinate Hypertrophy							
	Radiculitis							
	Radiculopathy							
	Sinusitis							

Date:03/24/05ISR Number: 4618386-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03743
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Medication Error		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Fosamax	C		ORAL		
			Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C		ORAL		
			Calcium (Unspecified) And Vitamin D (Unspecified)	C				
UNKNOWN								

Date:03/24/05ISR Number: 4618388-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00654
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Anal Haemorrhage
Initial or Prolonged	Anxiety
	Arthralgia
	Arthritis
	Back Pain
	Cardiac Murmur
	Cerebral Atrophy
	Cerebral Infarction
	Cerebrovascular Accident
	Coronary Artery Disease
	Decreased Appetite
	Dehydration
	Depression
	Diarrhoea
	Dyspepsia

		Electrocardiogram St-T Change					
		Excoriation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Fatigue		Toprol Xl Tablets	C		
UNKNOWN							
		Gastrointestinal		Clonidine	C		
UNKNOWN							
		Haemorrhage		[Therapy			
		Haemoglobin Decreased		Unspecified]	C		
UNKNOWN							
		Hip Fracture					
		Hyperlipidaemia					
		Hypertension					
		Hypokalaemia					
		Intestinal Haemorrhage					
		Lacunar Infarction					
		Lethargy					
		Major Depression					
		Myocardial Infarction					
		Nervousness					
		Pain In Extremity					
		Purulence					
		Purulent Discharge					
		Rash					
		Renal Artery Stenosis					
		Renal Bruit					
		Sinus Disorder					
		Urinary Retention					

Date:03/24/05ISR Number: 4618393-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02958
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Oedema Peripheral					

Date:03/24/05ISR Number: 4618394-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03029
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618398-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03031
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618399-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03051
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618400-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01945
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Conjunctivitis Infective		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Diazepam	C			UNKNOWN	
			Telenzepine	C			UNKNOWN	
			Citalopram	C			UNKNOWN	

Date:03/24/05ISR Number: 4618402-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03033
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/24/05ISR Number: 4618405-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03555
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	568 DAY	
Other	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	568 DAY	
	Joint Swelling		Norvasc	C			UNKNOWN	
	Musculoskeletal Stiffness		Lipitor	C			UNKNOWN	
	Uterine Disorder		[Therapy Unspecified]	C			UNKNOWN	

Date:03/24/05ISR Number: 4618406-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00057
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
Disability	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metoprolol Succinate	C		ORAL		16 DAY
			Torsemide	C		ORAL		15 DAY
			Atorvastatin Calcium	C		ORAL		17 DAY
			Aspirin	C		ORAL		17 DAY

Date:03/24/05ISR Number: 4618407-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02552
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Chest Discomfort		Toprol Xl Tablets	C				UNKNOWN
	Dysgeusia							
	Hypoaesthesia							
	Hypoaesthesia Oral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618412-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00041
Age:32 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Sick Sinus Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/24/05ISR Number: 4618413-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00038
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aspartate		Tramadol					
	Aminotransferase		Hydrochloride	C		ORAL		
	Increased		Tramadol					
	Blood Albumin Increased		Hydrochloride	C		ORAL		
	Blood Lactate		Estradiol And					
	Dehydrogenase Increased		Norethindrone					
	Dialysis		Acetate	C				
UNKNOWN								
	Embolism		Amitriptyline					
	Extremity Necrosis		Hydrochloride	C				
UNKNOWN								
	Hypercholesterolaemia							
	Influenza Like Illness							
	Interventricular Septum							
	Rupture							
	Myocardial Infarction							
	Pain							
	Post Procedural							
	Complication							
	Prothrombin Time Abnormal							
	Renal Failure							
	Toe Amputation							

Date:03/24/05ISR Number: 4618414-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02309
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Coumadin	C				
UNKNOWN								
Initial or Prolonged	Attack		Lipitor	C				
UNKNOWN								
Disability								

Date:03/24/05ISR Number: 4618416-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03005
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic							
	Attack							

Date:03/24/05ISR Number: 4618417-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00036
Age:55 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Arthritis
	Chest Pain

	Coronary Artery Stenosis						
	Diarrhoea						
	Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Glossodynia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myalgia		Candesartan					
	Myocardial Infarction		Cilexetil	C		ORAL		
	Palpitations							
	Pulse Pressure Decreased							
	Ventricular Extrasystoles							

Date:03/24/05ISR Number: 4618420-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02135
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hormones (Unspecified)	C				
UNKNOWN								

Date:03/24/05ISR Number: 4618421-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618422-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618424-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618425-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:03/24/05ISR Number: 4618426-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Atenolol Msd	C				
Disability			Cardura	C				
			Zocor	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618427-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618428-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618429-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618430-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02915
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618432-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02913
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618433-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03261
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618435-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02446
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	
Disability	Headache		Dolobid	C		ORAL	UNKNOWN	
	Hypertension		Ultracet	C				
	Vision Blurred		Lorcet 10/650	C			UNKNOWN	

Date:03/24/05ISR Number: 4618436-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618437-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618439-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03166
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Injury
	Myocardial Infarction

	Renal Disorder						
	Thrombosis						
	Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618440-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618441-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03005
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Singulair	C		ORAL		
	Attack		Ativan	C				
UNKNOWN								

Date:03/24/05ISR Number: 4618444-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03146
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4618445-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03387
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618446-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618447-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1276 DAY

Date:03/24/05ISR Number: 4618448-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03384
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618449-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618450-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618451-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		21 MON

Date:03/24/05ISR Number: 4618452-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618453-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03461
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Cerebrovascular Accident Emotional Distress Injury Mental Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	

Date:03/24/05ISR Number: 4618454-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03469
Age: Gender:Male I/FU:I

Outcome	PT
Disability	Adverse Event Anhedonia

		Cardiac Disorder Chest Pain Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress Fear Of Disease Injury Mental Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4618455-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03452
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
32 MON						
	Myocardial Infarction					

Date:03/24/05ISR Number: 4618456-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4618457-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4618458-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03713
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/24/05ISR Number: 4618459-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03635
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618460-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618461-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03575
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618462-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618463-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03890
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618464-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618465-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03440
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Lotensin	C				
Disability			Aspirin	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Verapamil Hydrochloride	C			UNKNOWN	

Date:03/24/05ISR Number: 4618466-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON

Date:03/24/05ISR Number: 4618467-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618468-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03897
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618469-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03018
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/24/05ISR Number: 4618472-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618474-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03630
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618475-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03899
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/24/05ISR Number: 4618476-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/24/05ISR Number: 4620384-9Report Type:Expedited (15-DaCompany Report #2005044028
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coagulopathy	Health	Bextra (Valdecoxib)	PS			40 MG (20 MG, 2 IN 1 D)	
	Multi-Organ Failure	Professional						
	Post Procedural Nausea	Company Representative	Rofecoxib (Rofecoxib)	SS				
	Renal Failure		Hydromorphone Hydrochloride (Hydromorphone Hydrochloride)	SS				
	Renal Tubular Necrosis		Diclofenac (Diclofenac Sodium)	C				
	Shoulder Operation							
	Vascular Occlusion							

Date:03/25/05ISR Number: 4619287-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Accident At Home
	Activated Partial Thromboplastin Time Prolonged
Disability	
Other	Angina Pectoris

		Anxiety					
		Atrial Septal Defect					
		Balance Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bipolar Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Borderline Personality		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Breast Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Aneurysm		Aspirin	C		
UNKNOWN		668 DAY					
		Cardiac Failure		Coumadin	C		
UNKNOWN							
		Congestive		Coumadin	C		
UNKNOWN							
		Cardiomegaly		Coumadin	C		
UNKNOWN		96 DAY					
		Cellulitis		Neurontin	C		
UNKNOWN							
		Cerebral Infarction		Vicodin Tablets	C		
UNKNOWN							
		Chest Pain		Seroquel	C		
UNKNOWN							
		Coronary Artery Disease		Ativan	C		
UNKNOWN							
		Coronary Artery		Ativan	C		
UNKNOWN							
		Restenosis		Monopril	C		ORAL
		Death		Norvasc	C		
UNKNOWN							
		Diverticulum		Lithium Carbonate	C		ORAL
		Drug Abuser		Lithium Carbonate	C		ORAL
		Drug Dependence		Zyprexa	C		ORAL
		Dyspnoea		Zyprexa	C		ORAL
		Emotional Distress		Zithromax	C		ORAL
4	DAY						
		Fibromyalgia		Navane	C		ORAL
		Haemorrhoids		Cogentin	C		ORAL
		Headache		Tegretol-Xr	C		ORAL
		Hyperkalaemia		Claritin-D	C		
UNKNOWN							
		Hypertrophy Breast					
		Hyponatraemia					
		Injury					
		Intermittent Claudication					
		Intracranial Aneurysm					

Lacunar Infarction
Leukocytosis
Limb Discomfort
Major Depression
Mitral Valve Incompetence
Myocardial Infarction
Obsessive-Compulsive
Disorder
Oedema Peripheral
Overdose
Pain
Pain In Extremity
Pollakiuria
Pulmonary Hypertension
Spinal Osteoarthritis
Suicidal Ideation
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Upper Respiratory Tract
Infection
Varices Oesophageal
Ventricular Dysfunction
Weight Increased

Date:03/25/05ISR Number: 4619306-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00005
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Candesartan Cilexetil	C		ORAL		
	Mitral Valve Incompetence		[Therapy Unspecified]	C		UNKNOWN		
	Spinal Osteoarthritis		[Therapy Unspecified]	C		UNKNOWN		
			[Therapy Unspecified]	C		UNKNOWN		
			Rizatriptan Benzoate	C		ORAL		
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL		
			Levothyroxine Sodium	C		ORAL		
			Estradiol	C		TOPICAL	81	DAY

Date:03/25/05ISR Number: 4619308-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Oesophageal Web
	Anaemia
Other	Anaemia Vitamin B12 Deficiency
	Angina Pectoris
	Angina Unstable
	Anorexia
	Anxiety
	Asthenia
	Bile Duct Stone

Blood Culture Positive
Body Temperature
Increased
Cardiac Failure
Congestive
Cardiomegaly
Carotid Artery Atheroma
Carotid Artery Stenosis
Catheter Related
Infection
Cerebrovascular Accident
Chest Pain
Choledochal Cyst
Cholelithiasis
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coagulopathy
Coronary Artery Disease
Cyanosis
Depression

Diabetes Mellitus
Inadequate Control
Diverticulum
Dizziness
Dyspepsia
Dysphagia
Dyspnoea
Dyspnoea Exertional
Ejection Fraction
Decreased
Emotional Distress
Enterobacter Bacteraemia
Enterococcal Bacteraemia
Enterococcal Sepsis
Epigastric Discomfort
Escherichia Urinary Tract
Infection
Fatigue
Feeling Cold
Femur Fracture
Fluid Overload
Fluid Retention
Gastric Disorder
Gastric Haemorrhage
Gastritis
Gastritis Erosive
Gastritis Haemorrhagic
Gastrointestinal
Arteriovenous
Malformation
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Haematochezia
Haemorrhage
Hepatic Failure
Hypercholesterolaemia
Hyperhidrosis
Hyperkalaemia
Hypertension
Hypoaesthesia
Hypokalaemia
Hypotension
Iron Deficiency Anaemia
Ischaemic Cardiomyopathy

Ischaemic Hepatitis
Joint Swelling
Myocardial Infarction
Myocardial Ischaemia
Nasopharyngitis
Oedema Peripheral
Osteoarthritis
Pancreatitis
Pleural Effusion
Pneumonia
Pneumonia Aspiration
Pulmonary Embolism
Pulmonary Hypertension
Pulmonary Oedema

		Renal Failure Acute					
		Respiratory Distress					
		Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
		Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL
		Staphylococcal Infection		Coumadin	SS		
UNKNOWN							
		Supraventricular		Lipitor	SS		ORAL
		Extrasystoles		Lipitor	SS		ORAL
		Syncope		Prednisone	SS		
UNKNOWN							
		Tachypnoea		Infliximab	SS		
UNKNOWN							
		Thirst		Prinivil	SS		ORAL
		Thrombotic Stroke		Methotrexate	SS		ORAL
		Troponin I Increased		Methotrexate	SS		
UNKNOWN							
		Troponin Increased					
		Upper Gastrointestinal					
		Haemorrhage					
		Urinary Tract Infection					
		Enterococcal					
		Urinary Tract Infection					
		Staphylococcal					
		Ventricular Extrasystoles					
		Weight Decreased					

Date:03/25/05ISR Number: 4619333-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02601
Age:37 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL
680 DAY							
Hospitalization -		Artery Dissection		Ultram	C		
UNKNOWN							
Initial or Prolonged		Blood Glucose Increased		Flexeril	C		
UNKNOWN							
		Brain Herniation		Ultracet	C		
UNKNOWN							
		Cerebrovascular Accident		Cyclobenzaprine			
		Coma		Hydrochloride	C		
UNKNOWN							
		Contrast Media Reaction		Penicillin			

	Hydrocephalus	(Unspecified)	C
UNKNOWN			
	Hypertension	Lortab	C
UNKNOWN			
	Pneumonia	Tramadol Msd	C
UNKNOWN			
	Respiratory Arrest		
	Thrombotic Stroke		

Date:03/25/05ISR Number: 4619335-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Acquired Diaphragmatic
Disability	Eventration
Other	Acute Respiratory Failure
	Adverse Event
	Alcohol Use
	Angina Pectoris
	Aortic Atherosclerosis
	Atelectasis
	Atrial Fibrillation
	Back Injury
	Back Pain
	Basal Cell Carcinoma
	Bipolar Disorder
	Blood Pressure Increased

		Bundle Branch Block Right					
		Cardiac Arrest					
		Cardiac Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Congestive		Vioxx	PS	Merck & Co., Inc	ORAL
536	DAY						
		Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
214	DAY						
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
536	DAY						
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased Activity		Vioxx	SS	Merck & Co., Inc	ORAL
214	DAY						
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Hypertension		Buspar	C		ORAL
405	DAY						
		Dyspnoea		Lortab	C		ORAL
573	DAY						
		Electrocardiogram Change		Lortab	C		ORAL
		Electrocardiogram Qrs		Ziac	C		ORAL
322	DAY						
		Complex Prolonged		Vicodin Tablets	C		ORAL
		Fatigue		Lipitor	C		ORAL
		Feeling Abnormal		Valium	C		ORAL
214	DAY						
		Haemoptysis		Talwin	C		ORAL
24	DAY						
		Hypercholesterolaemia		Ultram	C		ORAL
9	DAY						
		Hypotension		Skelaxin	C		ORAL
14	DAY						
		Hypoxic Encephalopathy		Tenyl	C		
UNKNOWN		36 DAY					
		Intervertebral Disc		Claritin	C		
UNKNOWN							
		Degeneration		Serzone	C		
UNKNOWN							
		Intervertebral Disc		Carisoprodol	C		
UNKNOWN							
		Protrusion		Acetaminophen And			
		Loss Of Consciousness		Propoxyphene			
		Myocardial Infarction		Hydrochloride	C		
UNKNOWN							
		Nodal Rhythm		Mobic	C		
UNKNOWN							

	Pain	Hydrocodone	
	Pulmonary Congestion	Hydrochloride	C
UNKNOWN			
	Road Traffic Accident	Altace	C
UNKNOWN			
	Sinus Disorder	Toprol Xl Tablets	C
UNKNOWN			
	Squamous Cell Carcinoma	Aspirin	C
UNKNOWN			
	Squamous Cell Carcinoma		
	Of Skin		
	Stress		
	Sudden Death		
	Ventricular Extrasystoles		
	Ventricular Fibrillation		
	Ventricular Hypertrophy		
	Weight Decreased		
	Weight Increased		

Date:03/25/05ISR Number: 4619339-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00205
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Insufficiency		Ramipril	C		ORAL		
Initial or Prolonged			Ramipril	C		ORAL		
Disability			Zocor	C		ORAL		

Date:03/25/05ISR Number: 4619340-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02983
Age: Gender:Male I/FU:F

Outcome	PT
Other	Cardiac Arrest
	Myocardial Infarction

	Thrombosis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619341-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02980
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Palpitations							

Date:03/25/05ISR Number: 4619343-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00307
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Belligerence		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diabetes Mellitus		Levoxyl	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Lexapro	C				
UNKNOWN								
Disability			Actonel	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Glucotrol	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619344-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00137
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deep Vein Thrombosis							
Disability	Hypertension							
	Pulmonary Embolism							

Date:03/25/05ISR Number: 4619345-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02438
Age:48 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Acute Chest Syndrome
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Blood Testosterone
	Decreased
	Cervicobrachial Syndrome
	Deafness
	Depression
	Erectile Dysfunction
	Flight Of Ideas
	Insomnia
	Laryngitis
	Lipids Increased
	Loss Of Libido
	Nephrolithiasis
	Prostate Infection
	Rhinitis Allergic
	Sexual Dysfunction
	Skin Lesion
	Spinal Osteoarthritis
	Upper Respiratory Tract

	Infection Viral Pharyngitis Viral Tonsillitis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619346-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02717
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:03/25/05ISR Number: 4619348-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02388
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619349-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00237
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged UNKNOWN	Abdominal Pain Arterial Stenosis		Vioxx Aspirin	PS C	Merck & Co., Inc	ORAL		
Other	Blood Pressure Increased Coronary Artery Disease Coronary Artery Insufficiency							

Coronary Artery Stenosis
Diarrhoea
Diverticulum
Dizziness
Dyspnoea Exertional
Feeling Abnormal
Gastritis Erosive
Gastrointestinal
Haemorrhage
Haemorrhage
Haemorrhoids
Headache
Hot Flush
Hypersensitivity
Hypertension
Nausea
Oesophageal Ulcer
Urinary Tract Infection
Bacterial

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619355-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00179
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619357-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03027
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619358-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01157
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619359-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03003
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619360-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02994
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619362-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619363-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03201
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1509 DAY
	Myocardial Infarction							

Date:03/25/05ISR Number: 4619380-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		932 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619381-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619383-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03164
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619384-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03204
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619386-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:03/25/05ISR Number: 4619387-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619389-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02884
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:03/25/05ISR Number: 4619392-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619393-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	863	DAY

Date:03/25/05ISR Number: 4619395-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03206
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							

Renal Injury
Thrombosis
Ulcer

Date:03/25/05ISR Number: 4619396-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619397-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619398-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disability							
	Economic Problem							
	Myocardial Infarction							
	Pain							

Date:03/25/05ISR Number: 4619402-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03259
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56	MON

Date:03/25/05ISR Number: 4619403-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							

Hepatocellular Damage
Myocardial Infarction
Renal Injury
Thrombosis
Ulcer

Date:03/25/05ISR Number: 4619405-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03036
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Tenormin	C				
UNKNOWN								
Initial or Prolonged			Coumadin	C				
UNKNOWN								
			Vicodin Tablets	C				
UNKNOWN								
			Zyrtec	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619409-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619411-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:03/25/05ISR Number: 4619413-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Renal Failure							

Date:03/25/05ISR Number: 4619414-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury		Vioxx	PS	Merck & Co., Inc	UNKNOWN		10 MON
	Pain							
	Transient Ischaemic							

Attack

Date:03/25/05ISR Number: 4619416-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03285
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Thrombosis							

Date:03/25/05ISR Number: 4619417-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:03/25/05ISR Number: 4619419-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03287
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN	30	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619420-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Anxiety							
	Cerebrovascular Accident							
	Pain							

Date:03/25/05ISR Number: 4619422-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							

Date:03/25/05ISR Number: 4619424-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Disorder		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Myocardial Infarction							

Date:03/25/05ISR Number: 4619425-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03284
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							5	MIN

Date:03/25/05ISR Number: 4619426-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619427-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03297
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619429-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619430-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:03/25/05ISR Number: 4619431-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03551
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619432-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03554
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619433-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03552
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619434-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03597
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:03/25/05ISR Number: 4619435-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03561
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619437-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03604
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619439-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03553
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619440-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619441-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619444-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619447-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619449-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619451-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619452-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03756
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619453-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03784
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619456-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619457-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Initial or Prolonged Disability	Cerebrovascular Accident							

Date:03/25/05ISR Number: 4619458-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Initial or Prolonged								

Date:03/25/05ISR Number: 4619461-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619462-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619463-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03557
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619465-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03558
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:03/25/05ISR Number: 4619466-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619468-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03647
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619469-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619492-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619493-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03836
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619495-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619496-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619497-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Injury Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619498-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619501-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619502-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619503-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619512-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619513-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:03/25/05ISR Number: 4619515-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MIN

Date:03/25/05ISR Number: 4619518-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04147
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619519-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619525-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/25/05ISR Number: 4619569-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619745-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03185
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Norvasc	C		ORAL		
	Cellulitis		Prevacid	C				
UNKNOWN								
	Chest Wall Pain		Tylenol	C				
UNKNOWN								
	Coronary Artery Disease		Dicyclomine					
	Dressler'S Syndrome		Hydrochloride	C				
UNKNOWN								
	Dyspnoea		Saw Palmetto	C				
UNKNOWN								
	Erectile Dysfunction		Ambien	C				
UNKNOWN								
	Glaucoma		Aspirin	C		ORAL		
	Haemorrhoids							
	Hyperglycaemia							
	Hyperlipidaemia							
	Injury							
	Libido Decreased							
	Myocardial Infarction							

Pericarditis
Prostatitis
Sleep Apnoea Syndrome

Date:03/25/05ISR Number: 4619748-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02133
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619751-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02398
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1172 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1172 DAY
Other	Myocardial Infarction		Ranitidine	C				UNKNOWN
	Oedema Peripheral		Hytrin	C				UNKNOWN
			Plendil	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Plavix	C				UNKNOWN
			Metoprolol	C				UNKNOWN
			Nitroquick	C				UNKNOWN
			Diovan	C				UNKNOWN
			Zyrtec	C				UNKNOWN
			Diurex (Hydrochlorothiazide)	C				UNKNOWN

Date:03/25/05ISR Number: 4619753-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia
	Arthropathy
	Back Pain

Benign Prostatic
Hyperplasia
Cardiac Failure
Congestive
Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diabetic Nephropathy
Diabetic Neuropathy
Diabetic Retinopathy
Drug Hypersensitivity
Drug Ineffective
Fall
Hepatitis
Herpes Zoster
Hypercholesterolaemia
Infection
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Ischaemic Cardiomyopathy
Oedema Peripheral
Pneumonia
Renal Cyst

Sepsis
Sexual Dysfunction
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Zyban	SS			UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY	
	Zestril	C			UNKNOWN	2170 DAY
	Zestril	C			UNKNOWN	2170 DAY
	Tenormin	C			UNKNOWN	
	Tenormin	C			UNKNOWN	
	Glucophage	C			UNKNOWN	
	Micronase	C			UNKNOWN	
	Lanoxin	C			UNKNOWN	1051 DAY
	[Therapy Unspecified]	C			UNKNOWN	
	Aciphex	C			UNKNOWN	

Date:03/25/05ISR Number: 4619754-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Adverse Event
Other	Anaemia
	Angina Pectoris
	Arthralgia

Arthritis
Asthenia
Atherosclerosis
Blood Pressure Increased
Bursitis
Cardiovascular Disorder
Carotid Artery Stenosis
Cerebral Artery Stenosis
Cerebral Infarction
Cerebrovascular Accident
Cerebrovascular Disorder
Chest Discomfort
Chest Pain
Chondromalacia
Constipation
Convulsion
Coronary Artery Disease
Diabetes Mellitus
Inadequate Control
Diabetic Complication
Diabetic Neuropathy
Diverticulum
Dizziness
Dysarthria
Dyspnoea Exertional
Eye Injury
Fall
Gastritis
Glycosuria
Haemorrhoidal Haemorrhage

		Hand Fracture					
		Hypertension					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Dislocation		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Swelling		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Lacunar Infarction		Plavix	SS		
UNKNOWN							
		Leukopenia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Ligament Sprain		Captopril Msd	C		ORAL
		Meniscus Lesion		Evista	C		
UNKNOWN							
		Mental Status Changes		Amitriptyline			
		Myelodysplastic Syndrome		Hydrochloride	C		
UNKNOWN							
		Nocturia		Glucotrol Xl	C		
UNKNOWN							
		Pain		Synthroid	C		
UNKNOWN							
		Peroneal Nerve Injury		Prilosec	C		ORAL
		Pharyngitis		Humulin	C		
UNKNOWN							
		Prothrombin Time					
		Prolonged					
		Radiculopathy					
		Rotator Cuff Syndrome					
		Sensation Of Pressure					
		Subcutaneous Abscess					
		Syncope					
		Tendonitis					
		Thrombocytopenia					
		Upper Respiratory Tract					
		Infection					
		Visual Acuity Reduced					

Date:03/25/05ISR Number: 4619756-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Arthralgia
Disability	Asthenia
	Benign Prostatic

Hyperplasia
Choking
Cough
Dehydration
Depression
Diverticulum
Dysgeusia
Dyspepsia
Dyspnoea
Dysuria
Early Satiety
Erosive Duodenitis
Erosive Oesophagitis
Fatigue
Gastric Disorder
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Heat Stroke
Hiatus Hernia
Hydronephrosis
Hypertension
Hypoacusis
Intestinal Functional

		Disorder					
		Lung Disorder					
		Malaise					
		Muscle Atrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasopharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Oesophageal Rupture		Aspirin	C		
UNKNOWN							
		Pancreatitis		Restoril	C		
UNKNOWN							
		Renal Cyst					
		Rhinorrhoea					
		Stomach Discomfort					
		Stress					
		Supraventricular					
		Extrasystoles					
		Thromboembolic Stroke					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:03/25/05ISR Number: 4619757-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02915
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea					
		Fatigue					

Date:03/25/05ISR Number: 4619758-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Deafness Unilateral		Phenprocoumon	C		ORAL
Disability		Diabetes Mellitus		Verapamil	C		ORAL
		Inadequate Control		Atorvastatin Calcium	C		ORAL

Gastritis	Propafenone		
Hepatomegaly	Hydrochloride	C	ORAL
Nausea	Digitoxin	C	ORAL
Vestibular Disorder	Theophylline	C	ORAL
Vestibular Neuronitis	Omeprazole	C	ORAL
Vomiting	Citalopram	C	ORAL
	Prednisolone	C	ORAL

Date:03/25/05ISR Number: 4619759-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00939
Age:40 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Wall Abscess
	Anaemia
	Angina Pectoris
	Anxiety
	Back Pain
	Blood Glucose Increased
	Blood Pressure Increased

		Cardiomegaly					
		Cellulitis					
		Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Conjunctivitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depressed Mood		Coumadin	C		
UNKNOWN							
		Diabetes Mellitus		Risperdal	C		
UNKNOWN							
		Non-Insulin-Dependent		Prozac	C		
UNKNOWN							
		Dizziness		Elavil	C		ORAL
		Dyspnoea		Effexor	C		
UNKNOWN							
		Ear Pain		Effexor	C		
UNKNOWN							
		Fall		Glucophage	C		
UNKNOWN							
		Fatigue					
		Fear					
		Goitre					
		Hallucination					
		Headache					
		Hepatic Steatosis					
		Herpes Zoster					
		Hypoglycaemia					
		Impaired Gastric Emptying					
		Injection Site					
		Haemorrhage					
		Irritability					
		Lipomatosis					
		Mastoiditis					
		Migraine					
		Mood Swings					
		Oedema Peripheral					
		Osteoarthritis					
		Pain In Extremity					
		Peripheral Sensory					
		Neuropathy					
		Phlebitis					
		Rash					
		Retinopathy					
		Sinusitis					
		Strabismus					
		Subcutaneous Abscess					

Suicidal Ideation
Syncope
Thinking Abnormal
Thrombophlebitis
Superficial
Transient Ischaemic
Attack
Urinary Tract Infection
Vaginal Haemorrhage

Date:03/25/05ISR Number: 4619760-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02941
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619761-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03019
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619762-3Report Type:Expedited (15-DaCompany Report #BE-MERCK-0503BEL00062
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619763-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03189
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Obstructive Airways		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Disorder		[Therapy Unspecified]	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619764-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00086
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Peptic Ulcer		Prilosec	C				
UNKNOWN								
	Upper Gastrointestinal		Teveten (Eprosartan)	C				
UNKNOWN								
	Haemorrhage		Vicodin Tablets	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619765-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01162
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Myocardial Infarction							

Date:03/25/05ISR Number: 4619766-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00019
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Acetaminophen	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619767-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02957
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Wall Pain							
	Post Procedural Complication							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619768-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Rofecoxib	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619769-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02917
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619770-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03110
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619771-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Thrombosis
Ulcer

Date:03/25/05ISR Number: 4619772-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03082
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Constipation		Vicodin Tablets	C				
UNKNOWN								
	Sexual Dysfunction		Uristat	C				
UNKNOWN								
	Urinary Tract Infection		Celexa	C				
UNKNOWN								
			Baclofen	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619773-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03100
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain

	Hepatocellular Damage Myocardial Infarction Renal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/25/05ISR Number: 4619774-XReport Type:Expedited (15-DaCompany Report #IS-MERCK-0503DNK00027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/25/05ISR Number: 4619775-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Injury Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:03/25/05ISR Number: 4619776-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02779
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 1 YR	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Renal Disorder		[Therapy Unspecified]	C			

UNKNOWN

Date:03/25/05ISR Number: 4619777-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03147
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619778-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02857
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619779-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619780-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619782-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03113
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619783-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619784-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03188
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619785-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619786-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	12	MON

Date:03/25/05ISR Number: 4619787-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619788-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619789-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03131
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619790-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619791-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03579
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619792-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619793-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619794-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619795-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619796-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619797-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03242
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:03/25/05ISR Number: 4619798-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/25/05ISR Number: 4619799-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619800-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619801-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03661
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619802-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619803-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03711
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Cardiovascular Disorder							
	Chest Pain							

Date:03/25/05ISR Number: 4619804-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619805-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619806-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619807-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/25/05ISR Number: 4619808-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619809-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619810-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Valve Disease Mitral Valve Disease Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619811-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03883
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619814-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03068
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02399
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Valve Incompetence		Quinine Sulfate	C				
UNKNOWN								
Initial or Prolonged	Cardiac Arrest		Renagel	C				
UNKNOWN								
Other	Chest Wall Pain		Glyburide	C				
UNKNOWN								
	Deep Vein Thrombosis		[Therapy					
	Endocarditis		Unspecified]	C				
UNKNOWN								
	Fall		Toprol Xl Tablets	C				
UNKNOWN								
	Gastritis		Lamisil	C				
UNKNOWN								
	Gastrointestinal							

Haemorrhage
Mitral Valve Incompetence
Myocardial Infarction
Pulmonary Hypertension
Sepsis
Sepsis Syndrome
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Date:03/25/05ISR Number: 4619816-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02094
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cataract		[Therapy					
	Myocardial Infarction		Unspecified]	C				
UNKNOWN								
	Pain In Extremity		[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619817-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03922
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619818-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619819-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03849
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Celexa	C				
UNKNOWN								
Initial or Prolonged	Attack		Levothyroxine Sodium	C				
UNKNOWN								
Disability			Nexium	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03878
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619821-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/25/05ISR Number: 4619822-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/25/05ISR Number: 4619823-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03761
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619824-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03885
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619825-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619826-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619827-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:03/25/05ISR Number: 4619828-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Thrombosis

Date:03/25/05ISR Number: 4619829-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1227 DAY

Date:03/25/05ISR Number: 4619830-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619831-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02927
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dissection Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4619832-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619833-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619834-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03846
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1682 DAY

Date:03/25/05ISR Number: 4619835-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619836-7Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0503ZAF00005
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619837-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	490	DAY

Date:03/25/05ISR Number: 4619839-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03962
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619840-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03958
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:03/25/05ISR Number: 4619841-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00020
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	28	DAY
Initial or Prolonged	Myocardial Infarction		Metformin Hydrochloride	C				
UNKNOWN								
			Glyburide	C				
UNKNOWN								

Date:03/25/05ISR Number: 4619842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/25/05ISR Number: 4619843-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA01725
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Benign Prostatic Hyperplasia		[Therapy Unspecified]	C				
UNKNOWN								
	Blood Triglycerides Increased		Tylenol With Codeine #3	C				
UNKNOWN								

Cerebrovascular Accident
Depression
Facet Joint Syndrome
Fibromyalgia
Gait Disturbance
Hypoaesthesia
Insomnia
Intervertebral Disc
Protrusion
Joint Dislocation
Lumbar Radiculopathy
Nausea
Neck Pain
Oedema Peripheral
Post Laminectomy Syndrome
Skin Papilloma
Sleep Apnoea Syndrome
Sleep Disorder
Spinal Cord Disorder
Tachycardia
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/25/05ISR Number: 4621377-8Report Type:Expedited (15-DaCompany Report #2005-BP-01574YA
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia Cardiac Arrest Electroencephalogram	Foreign Health Professional	Omix (Tamsulosin Hydrochloride) (Tamsulosin)	PS		ORAL	0.4 MG (, 0.4 MG) PO	
	Abnormal	Other						
	General Physical Health Deterioration		Visken (Pindolol) (Nr)	SS		ORAL	PO	
	Lung Disorder Nosocomial Infection		Amarel (Glimepiride) (Nr)	SS		ORAL	PO	
	Overweight Pseudomonas Infection		Vioxx (Rofecoxib) (Nr)	SS		ORAL	PO	2 YR
	Sepsis Sudden Death		Metformin (Metformin) (Nr)	SS		ORAL	PO	
	Superinfection Lung Tracheostomy							

Date:03/25/05ISR Number: 4622397-XReport Type:Direct Company Report #CTU 244296
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS			25 MG ONCE DAILY	
Other								

Date:03/25/05ISR Number: 4622416-0Report Type:Direct Company Report #CTU 244287
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS				

	Chest Pain		Celebrex	SS
	Dizziness		Bextra	SS
	Muscle Spasms			
	Pain In Extremity			
	Pruritus			
	Vomiting			

Date:03/28/05ISR Number: 4620372-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00862
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Costochondritis		Tenoret	C				
UNKNOWN								
Disability	Gastric Haemorrhage							
	Gastritis							
	Gastrooesophageal Reflux							
	Disease							
	Hyperlipidaemia							
	Hypertension							
	Obesity							
	Overdose							
	Vision Blurred							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4620380-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00777
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Lotensin	C				
UNKNOWN								
Other	Arthritis		[Therapy Unspecified]	C				
	Asthma							
UNKNOWN								
	Biliary Dyskinesia							
	Blood Cholesterol Increased							
	Blood Pressure Increased							
	Chest Pain							
	Colon Adenoma							
	Colonic Polyp							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Diverticulum							
	Dizziness							
	Dyspepsia							
	Dysphagia							
	Gastritis							
	Headache							
	Hypertension							
	Low Density Lipoprotein Increased							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nerve Compression							
	Palpitations							
	Polyarthritis							
	Tricuspid Valve Incompetence							
	Urinary Tract Infection							
	Ventricular Extrasystoles							

Date:03/28/05ISR Number: 4620390-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01517
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Other	Alopecia

Angina Pectoris
Back Pain
Blindness
Cerebrovascular Accident
Chest Discomfort
Chest Pain
Confusional State
Dyspnoea
Hypoaesthesia
Hypotrichosis
Limb Discomfort
Loss Of Consciousness
Nausea
Oedema Peripheral
Pain
Pain In Extremity
Palpitations
Road Traffic Accident
Teeth Brittle

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	388 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	388 DAY	
	Valium	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	[Therapy Unspecified]	C			RESPIRATORY (INHALATION)	

Date:03/28/05ISR Number: 4620391-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	487 DAY	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	487 DAY	
Disability	Arrhythmia		Inderal La	C			UNKNOWN	
	Arteriospasm Coronary		Inderal La	C			UNKNOWN	
	Back Injury		Claritin-D	C			UNKNOWN	1758 DAY
	Bone Pain		Humibid	C			UNKNOWN	
	Dyspepsia		Prevacid	C			UNKNOWN	
	Endometriosis		Nasonex	C			UNKNOWN	764 DAY
	Intervertebral Disc		Darvocet-N	C			UNKNOWN	
	Displacement		Bactrim	C			UNKNOWN	
	Meniscus Lesion		Pseudoephedrine	C			UNKNOWN	

	Mitral Valve Incompetence		Maxzide	C			
UNKNOWN							
	Neuralgia		Naprosyn	C			
UNKNOWN							
	Pleuritic Pain		Entex La	C			
UNKNOWN							
	Sacroiliitis		Voltaren	C			
UNKNOWN							
	Sinusitis		Voltaren	C			ORAL
	Tachyarrhythmia		Evening Primrose Oil	C			
UNKNOWN							
	Tricuspid Valve		Glucosamine	C			
UNKNOWN							
	Incompetence		Chondroitin	C			
UNKNOWN							
	Uterine Leiomyoma		Zantac	C			
UNKNOWN							
	Weight Increased		Sudafed	C			
UNKNOWN							
			Aspirin	C			
UNKNOWN							
			Norco	C			
UNKNOWN							

Date:03/28/05ISR Number: 4620392-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01026
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Colon Operation		[Therapy					
Initial or Prolonged	Gastrointestinal Disorder		Unspecified]	C				
UNKNOWN								
Disability	Retinal Vascular							
Other	Thrombosis							

Date:03/28/05ISR Number: 4620405-3Report Type:Expedited (15-DaCompany Report #IT-MERCK-0412ITA00008
Age:88 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
			Furosemide	C		ORAL		
			Salmeterol	C				
UNKNOWN								
			Methylprednisolone	C		ORAL		
			Rutin	C				
UNKNOWN								

				Melilot	C		
UNKNOWN							

Date:03/28/05ISR Number: 4620407-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01145
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Diarrhoea							
	Gastric Disorder							
	Liver Disorder							
	Liver Function Test Abnormal							
	Nausea							
	Urinary Tract Disorder							

Date:03/28/05ISR Number: 4620408-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03356
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/28/05ISR Number: 4620410-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00021
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1675 DAY	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Methotrexate	C				
UNKNOWN								
			Carbamazepine	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								

Date:03/28/05ISR Number: 4620411-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02424
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Loss Of Control Of Legs		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/28/05ISR Number: 4620412-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0503ESP00065
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		19 DAY
Initial or Prolonged	Melaena							

Date:03/28/05ISR Number: 4620413-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03343
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4620414-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00024
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiovascular Disorder Myocardial Infarction		Vioxx Acetaminophen	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:03/28/05ISR Number: 4620431-4Report Type:Expedited (15-DaCompany Report #NL-MERCK-0503NLD00035
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1227 DAY
Initial or Prolonged			Atenolol	C		ORAL		1982 DAY
			Irbesartan	C		ORAL		391 DAY
			Triamcinolone	C		PARENTERAL		

Date:03/28/05ISR Number: 4620432-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00022
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Omeprazole Sodium	C				
UNKNOWN								

Date:03/28/05ISR Number: 4620433-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03562
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4620434-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4620435-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03084
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	250	DAY
Initial or Prolonged			Effexor	C			UNKNOWN	
Other			Miacalcin	C			UNKNOWN	

Date:03/28/05ISR Number: 4620436-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03280
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4620438-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03085
Age:81 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer Haemorrhage		Verapamil	C				UNKNOWN
			Lescol	C				UNKNOWN
			Isosorbide	C				UNKNOWN

Date:03/28/05ISR Number: 4620447-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02830
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vitamins (Unspecified)	C				UNKNOWN
Disability								

Date:03/28/05ISR Number: 4621036-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00350
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abscess Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Darvocet-N	C				UNKNOWN
	Cerebrovascular Accident		Zantac	C				UNKNOWN
	Chest Discomfort		Metformin	C				UNKNOWN
	Cold Sweat		Lipitor	C				UNKNOWN
	Diverticulitis		Aspirin	C				UNKNOWN
	Drug Hypersensitivity							
	Dyspnoea							
	Fall							

Gastritis
Hiatus Hernia
Hypercholesterolaemia
Hypertension
Injury
Joint Injury
Liver Disorder
Myocardial Infarction
Non-Cardiac Chest Pain
Non-Hodgkin'S Lymphoma
Pharyngolaryngeal Pain
Post Laminectomy Syndrome
Pyrexia
Simple Partial Seizures
Transient Ischaemic
Attack
Tuberculosis
Vertigo Positional
Vomiting

Date:03/28/05ISR Number: 4621039-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
Other	Arthralgia
	Bursitis

		Chest Pain Coronary Artery Disease Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Reocclusion		Vioxx	PS	Merck & Co., Inc	ORAL
482	DAY						
		Coronary Artery		Celebrex	C		
UNKNOWN							
		Restenosis Haematocrit Decreased Haematoma Hypercholesterolaemia Injury Mitral Valve Incompetence Myocardial Infarction Post Procedural Complication Post Procedural Haematoma Sinus Bradycardia Tricuspid Valve Incompetence					

Date:03/28/05ISR Number: 4621050-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02979
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased Cerebrovascular Accident Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/28/05ISR Number: 4621051-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Anxiety
Other	Arthralgia Back Pain Benign Prostatic Hyperplasia Cholecystitis Cholelithiasis

Chronic Sinusitis
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Cyst
Deafness
Depression
Gout
Hodgkin'S Disease
Inguinal Hernia
Myalgia
Myopathy
Nasal Cyst
Prostatic Specific
Antigen Increased
Rectal Examination
Abnormal
Renal Failure
Renal Failure Acute

Renal Tubular Necrosis
Tension Headache

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Claritin-D	C			UNKNOWN	
	Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Diazepam	C			UNKNOWN	
	Plendil	C			UNKNOWN	
	Pravachol	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	

Date:03/28/05ISR Number: 4621053-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		254 DAY
Other	Bronchitis							
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cardiogenic Shock							
	Cardiomyopathy							
	Coronary Artery Disease							
	Irritable Bowel Syndrome							
	Mitral Valve Incompetence							
	Myocardial Infarction							

Oedema Peripheral
Pericarditis
Pneumonia
Sinusitis
Tricuspid Valve
Incompetence

Date:03/28/05ISR Number: 4621056-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01929
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	21 DAY	
			Lipitor	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

Date:03/28/05ISR Number: 4621057-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00900
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Death	Bronchitis
Life-Threatening	Cough
Disability	Hyperkeratosis

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
	Myocardial Infarction Pharyngolaryngeal Pain Pulmonary Congestion					
723 DAY	Sinus Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Sinus Congestion		Pravachol	C		
UNKNOWN	Sudden Death		Lopressor	C		
UNKNOWN			Aspirin	C		
UNKNOWN			Vitamin E	C		
UNKNOWN			Lotensin	C		
UNKNOWN			Diurex (Hydrochlorothiazide)	C		
UNKNOWN			Prolex Pd	C		
UNKNOWN			Prolex Pd	C		
UNKNOWN	6 DAY		Robitussin	C		
UNKNOWN			Medent Dm	C		
UNKNOWN			Biaxin Xl	C		
UNKNOWN	10 DAY		Norel Dm	C		
UNKNOWN			Bidex	C		
UNKNOWN			Tessalon Perles	C		
UNKNOWN			Tessalon Perles	C		
UNKNOWN			Claritin	C		
UNKNOWN			Tavist	C		
UNKNOWN			Medent Ld	C		
UNKNOWN			Medent Ld	C		

Doxyclin C

UNKNOWN 7 DAY

Doxyclin C

UNKNOWN

Date:03/28/05ISR Number: 4621058-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Acute Myocardial Infarction
	Arthralgia
	Blood Glucose Increased
	Bronchitis
	Cardiac Failure Congestive
	Cardiac Valve Disease
	Chest Pain
	Confusional State
	Coordination Abnormal
	Coronary Artery Disease
	Cough
	Depressed Level Of Consciousness
	Dysarthria
	Dyspnoea
	Hepatic Fibrosis
	Hepatitis C
	Hepatosplenomegaly
	Hypertension
	Hypokalaemia
	Hypoxia
	Injury
	Insomnia
	Intervertebral Disc Displacement

		Intervertebral Disc Protrusion					
		Joint Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Claritin	C		
UNKNOWN							
		Oedema Peripheral		Hyzaar	C		
UNKNOWN							
		Pulmonary Embolism		Hyzaar	C		
UNKNOWN							
		Somnolence		Interferon			
		Weight Increased		(Unspecified)	C		
UNKNOWN							
				Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Ascriptin	C		ORAL
				Altace	C		ORAL
				Atenolol	C		ORAL
				Zocor	C		ORAL
				Lortab	C		ORAL
				Nexium	C		
UNKNOWN							

Date:03/28/05ISR Number: 4621062-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03683
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/28/05ISR Number: 4621063-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02829
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Disability	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sensory Loss		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Zelnorm	C			UNKNOWN	
	Attack		Nexium	C			UNKNOWN	

Date:03/28/05ISR Number: 4621064-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
	Acute Myocardial Infarction
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Back Pain
	Bronchitis
	Cellulitis
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Atherosclerosis
	Cough

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Depression					
		Dermal Cyst					
		Drug Hypersensitivity					
		Dupuytren'S Contracture		Vioxx	PS	Merck & Co., Inc	ORAL
106	DAY						
		Dyslipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
363	DAY						
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
106	DAY						
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
363	DAY						
		Dyspnoea		Zantac	C		
UNKNOWN							
		Erectile Dysfunction		Celexa	C		
UNKNOWN							
		Fatigue		Albuterol	C		
RESPIRATORY							
		Haemorrhoids					
(INHALATION)							
		Hyperlipidaemia		Vicodin Tablets	C		ORAL
		Hypertension					
		Hypoaesthesia					
		Impulse-Control Disorder					
		Otitis Media					
		Pain In Extremity					
		Pharyngitis					
		Premature Ejaculation					
		Pulmonary Congestion					
		Purulent Discharge					
		Restless Legs Syndrome					
		Rhinitis Allergic					
		Rhonchi					
		Self-Injurious Ideation					
		Sinus Disorder					
		Sleep Apnoea Syndrome					
		Spinal Column Stenosis					
		Spinal Osteoarthritis					
		Upper Respiratory Tract Infection					
		Weight Increased					
		Wheezing					

Date:03/28/05ISR Number: 4621065-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00984
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Gastrooesophageal Reflux		Prevacid	C				
UNKNOWN								
	Disease							
	Haematemesis							
	Haemorrhoids							
	Headache							
	Microcytic Anaemia							
	Nausea							
	Oesophagitis							
	Upper Gastrointestinal							
	Haemorrhage							

Date:03/28/05ISR Number: 4621066-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00694
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Anxiety
	Aphonia

	Arrhythmia						
	Arthralgia						
	Atrial Fibrillation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	579 DAY
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	579 DAY
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL	
	Condition Aggravated						
	Coronary Artery Disease						
	Dizziness						
	Dyspnoea						
	Fluid Retention						
	Headache						
	Hearing Impaired						
	Hyperhidrosis						
	Hypertension						
	Insomnia						
	Maculopathy						
	Muscle Spasms						
	Oedema						
	Pain In Extremity						
	Palpitations						
	Retinal Vascular						
	Occlusion						
	Syncope						
	Vertigo						
	Visual Disturbance						

Date:03/28/05ISR Number: 4621067-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03651
Age:93 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged							
Disability							

Date:03/28/05ISR Number: 4621068-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621069-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02946
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621070-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01602
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Levothroid	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4621071-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621072-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03818
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621073-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03669
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621074-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03672
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621075-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621076-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621077-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03808
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cerebrovascular Accident Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621078-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4621079-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03809
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:03/28/05ISR Number: 4621081-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03777
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Coumadin	C				
UNKNOWN								
Initial or Prolonged			[Therapy					
Other			Unspecified]	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:03/28/05ISR Number: 4621082-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03810
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621083-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Emotional Disorder							
	Injury							
	Pain							

Date:03/28/05ISR Number: 4621084-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03840
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621085-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621100-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4621101-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Haemorrhage							
	Myocardial Infarction							

Date:03/28/05ISR Number: 4621102-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/28/05ISR Number: 4621103-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	226	DAY

Date:03/28/05ISR Number: 4621104-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621105-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/28/05ISR Number: 4621107-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621108-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/28/05ISR Number: 4621115-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/28/05ISR Number: 4621486-3Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00095
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Colon Cancer	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	337 DAY
Other	Myocardial Ischaemia Nausea	Health Professional Other	Aspirin	C				
			Atenolol	C				
			Gliclazide	C				
			Nitroglycerin	C				
			Simvastatin	C				

Date:03/28/05ISR Number: 4622788-7Report Type:Direct Company Report #CTU 244440
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hip Arthroplasty		Vioxx	PS			ONE	
	Myocardial Infarction						ONCE A DAY	
			Celebrex	SS			ONE	ONCE A DAY
			Bextra	SS				

Date:03/29/05ISR Number: 4621569-8Report Type:Expedited (15-DaCompany Report #2005041938
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Other	Constipation Dry Mouth Hypertonic Bladder Lymphoma	Consumer	Detrol La Capsule, Prolonged Release (Tolterodine L-Tartrate)	PS		ORAL	4 MG (4 MG, 1 IN 1 D), ORAL	
	Memory Impairment Micturition Urgency Nausea		Celebrex (Celecoxib)	SS				
			Chemotherapy Nos					

Procedural Complication	(Chemotherapy Nos)	SS
Spinal Column Stenosis	Rofecoxib (Rofecoxib)	SS
Stomach Discomfort	Naproxen Sodium (Naproxen Sodium)	SS
	Ibuprofen (Ibuprofen)	SS
	Acetylsalicylic Acid (Acetylsalicylic Acid)	C
	Fluticasone Propionate (Fluticasone Propionate)	C
	Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C
	Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C
	Tocopherol (Tocopherol)	C
	Temazepam (Temazepam)	C

	Tamsulosin (Tamsulosin)	C
	Quinine (Quinine)	C

Date:03/29/05ISR Number: 4621735-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00639
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Pepcid	C			UNKNOWN	
	Chest Pain		Albuterol	C			UNKNOWN	
	Coronary Artery Disease		Atrovent	C			UNKNOWN	
	Diabetes Mellitus		Lisinopril	C			UNKNOWN	
	Non-Insulin-Dependent		Aspirin	C			UNKNOWN	
	Disorientation							
	Drug Hypersensitivity							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Hyperventilation							
	Hypoxia							
	Neurodermatitis							
	Osteoarthritis							
	Stress							
	Thrombosis							
	Transient Ischaemic Attack							
	Vertebral Artery Stenosis							
	Vertigo							

Date:03/29/05ISR Number: 4621738-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03650
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Colon Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Lotensin	C		
			Hydrochlorothiazide	C		
UNKNOWN						

Date:03/29/05ISR Number: 4621739-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/29/05ISR Number: 4621740-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03160
Age: Gender: I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Renal Injury
	Thrombosis

Ulcer

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:03/29/05ISR Number: 4621741-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03367
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621742-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621743-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00045
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Actos	C			UNKNOWN	
	Palpitations		Lisinopril	C			UNKNOWN	

Date:03/29/05ISR Number: 4621744-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02855
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/29/05ISR Number: 4621745-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening Hospitalization - Initial or Prolonged Disability	Adverse Event Epistaxis Insomnia Myalgia Myocardial Infarction Nasopharyngitis Pericardial Effusion Pharyngolaryngeal Pain Pleural Effusion Pneumonia Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621747-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00062
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Atherosclerosis		Hydrochlorothiazide And Lisinopril	SS		ORAL		
	Cerebral Ischaemia							
	Difficulty In Walking							
	Dysarthria							
	Facial Palsy							
	Malaise							
	Motor Dysfunction							
	Tongue Paralysis							

Date:03/29/05ISR Number: 4621752-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/29/05ISR Number: 4621753-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03819
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:03/29/05ISR Number: 4621754-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621755-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621756-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621757-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03812
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621758-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621759-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621760-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621761-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03945
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621762-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621763-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621764-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621769-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621770-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04098
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Protonix	C				
UNKNOWN								
Initial or Prolonged			Plavix	C				
UNKNOWN								
Disability			[Therapy Unspecified]	C				
UNKNOWN								

Date:03/29/05ISR Number: 4621771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/29/05ISR Number: 4621772-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:03/29/05ISR Number: 4621773-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621774-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04555
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia Emotional Distress Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621799-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03700
Age:65 YR Gender:Male I/FU:F

Outcome	PT
	Abnormal Faeces Asthma Blood Pressure Abnormal Dental Operation Dysgraphia

	Faeces Discoloured						
	Local Swelling						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL	
	Tooth Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C			UNKNOWN

Date:03/29/05ISR Number: 4621847-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00058
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 15 DAY	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Increased Body Temperature		Trimetazidine Hydrochloride	SS		ORAL	
	Increased Diarrhoea		Clopidogrel Bisulfate	SS		ORAL	
			Sotalol Hydrochloride	SS		ORAL	
			Ginkgo Biloba Extract	SS		ORAL	
			Pravastatin Sodium	SS		ORAL	

Date:03/29/05ISR Number: 4621871-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
	Deep Vein Thrombosis						

Date:03/29/05ISR Number: 4621962-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00783
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Postoperative
Disability	Arthralgia
Other	Aseptic Necrosis Bone
	Atelectasis
	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Contusion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Diabetes Mellitus
	Diabetes Mellitus Insulin-Dependent
	Dyspnoea
	Ejection Fraction Decreased
	Hypercholesterolaemia
	Hyperlipidaemia
	Mitral Valve Incompetence
	Muscle Spasms

		Myocardial Infarction					
		Osteoarthritis					
		Post Procedural	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complication		Vioxx	PS	Merck & Co., Inc	ORAL
		Postoperative		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Percocet	C		
UNKNOWN							
		Radiculopathy		Vicodin Tablets	C		
UNKNOWN							
		Sciatica					
		Silent Myocardial					
		Infarction					
		Staphylococcal Infection					
		Urinary Retention					
		Ventricular Extrasystoles					

Date:03/29/05ISR Number: 4621964-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03590
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/29/05ISR Number: 4621965-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
373 DAY							
Initial or Prolonged		Infarction		Lipitor	C		
UNKNOWN							
		Coronary Artery		Tranxene	C		
UNKNOWN							
		Atherosclerosis		Prozac	C		
UNKNOWN							
		Emotional Distress		Zantac	C		
UNKNOWN							
		Fall					
		Obstructive Airways					
		Disorder					
		Ulna Fracture					

Ulnar Nerve Injury

Date:03/29/05ISR Number: 4621966-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00169
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1066 DAY
Initial or Prolonged	Infarction		Pravachol	C				UNKNOWN
	Akinesia		Zocor	C				UNKNOWN
	Bradycardia		Ambien	C				UNKNOWN
	Hypotension		Tylenol	C				UNKNOWN
	Insomnia							
	Mitral Valve Incompetence							
	Tricuspid Valve Incompetence							
	Ventricular Arrhythmia							
	Ventricular Dysfunction							

Date:03/29/05ISR Number: 4621967-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03098
Age:57 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL	117 DAY	
	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL	1642 DAY	
	Asthenia							
	Balance Disorder							
	Cerebrovascular Accident							
	Dysarthria							
	Dysphagia							
	Eating Disorder							
	Eye Disorder							
	Facial Palsy							
	Fall							
	Hemiplegia							
	Hypoaesthesia							
	Impaired Driving Ability							
	Impaired Work Ability							
	Micturition Urgency							
	Sweat Gland Disorder							
	Visual Acuity Reduced							
	Visual Disturbance							

Date:03/29/05ISR Number: 4621969-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03017
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621970-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01897
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:03/29/05ISR Number: 4621971-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00912
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort							
	Chest Pain							
	Headache							

Date:03/29/05ISR Number: 4621972-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0406FRA00038
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Erysipelas		Gentamicin	SS				
INTRAVENOUS								
	Hyperphosphataemia		Lisinopril	SS		ORAL		
	Hyponatraemia		Furosemide	SS		ORAL		
	Renal Failure Acute		Amiodarone	C		ORAL		
	Sepsis		Lansoprazole	C		ORAL		
	Staphylococcal Sepsis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621977-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04076
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Synthroid	C				
	Hypoaesthesia		[Therapy Unspecified]	C				
	Nausea		Toprol Xl Tablets	C				

Date:03/29/05ISR Number: 4621978-7Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00023
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	50	DAY
	Cerebrovascular Accident							
	Muscle Disorder							

Date:03/29/05ISR Number: 4621979-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01788
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
Other	Arthralgia		Plendil	C				
	Back Pain		Calcium (Unspecified) And Vitamin D (Unspecified)	C				
	Bundle Branch Block Left							
	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident		Aspirin	C				
	Ear Pain		Potassium					

	Ejection Fraction	(Unspecified)	C
UNKNOWN			
	Decreased		
	Exostosis		
	Foot Deformity		
	Headache		
	Hypertension		
	Intervertebral Disc		
	Degeneration		
	Intervertebral Disc		
	Protrusion		
	Lumbar Hernia		
	Mitral Valve Disease		
	Mitral Valve Incompetence		
	Muscle Strain		
	Myocardial Ischaemia		
	Nausea		
	Neck Pain		
	Obesity		
	Oedema		
	Pharyngolaryngeal Pain		
	Respiratory Tract		
	Infection		
	Road Traffic Accident		
	Sinusitis		
	Sleep Apnoea Syndrome		
	Spinal Column Stenosis		
	Tricuspid Valve		
	Incompetence		
	Vision Blurred		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621980-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621981-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Operation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621982-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621983-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04174
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Date:03/29/05ISR Number: 4621984-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		

Infarction
Myocardial Rupture

Date:03/29/05ISR Number: 4621985-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04129
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Zantac	C				
UNKNOWN								
	Chest Pain		Ranitidine	C				
UNKNOWN								
	Palpitations		Maxalt (Rizatriptan Benzoate)	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Acular	C				
UNKNOWN								

Date:03/29/05ISR Number: 4621986-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621987-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621989-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04182
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:03/29/05ISR Number: 4621990-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia Cardiovascular Deconditioning Life Expectancy Shortened Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621991-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Nervous System Disorder Pain Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621992-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coma							
	Deep Vein Thrombosis							
	Intracranial Aneurysm							
	Life Expectancy Shortened							
	Myocardial Infarction							
	Nervous System Disorder							
	Pain							

Date:03/29/05ISR Number: 4621993-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Apallic Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4621994-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:03/29/05ISR Number: 4621995-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
	Myocardial Infarction							

Date:03/29/05ISR Number: 4621996-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621997-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04814
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621998-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4621999-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04544
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4622000-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia Cerebrovascular Accident Life Expectancy Shortened Nervous System Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4622001-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04201
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4622002-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Life Expectancy Shortened							
	Myocardial Infarction							
	Nervous System Disorder							
	Pain							

Date:03/29/05ISR Number: 4622003-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04551
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder							
	Cardiovascular Disorder							
	Life Expectancy Shortened							
	Myocardial Infarction							
	Pain							

Date:03/29/05ISR Number: 4622004-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
Other	Death							
	Thrombosis							

Date:03/29/05ISR Number: 4622005-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04812
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4622006-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/29/05ISR Number: 4622048-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		121 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/29/05ISR Number: 4622106-4Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Injury	Consumer Health	Neurontin (Gabapentin)	PS		ORAL	1800 MG (600 MG, 3 IN 1 D), ORAL	
Other	Abdominal Pain	Professional						
	Back Disorder							
	Blood Cholesterol Increased		Lipitor (Atorvastatin)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
	Chest Pain							
	Contusion							
	Coordination Abnormal							
	Difficulty In Walking		Lithium (Lithium)					
	Disorientation		(Lithium)	SS				
	Drug Ineffective		Naproxen (Naproxen)	SS				
	Erectile Dysfunction		Amoxicillin (Amoxicillin)					
	Facial Pain							
	Feeling Cold		(Amoxicillin)	SS		ORAL	1000 MG (1 IN 2 D), ORAL	
	Gastrooesophageal Reflux Disease		Rofecoxib (Rofecoxib)	SS				
	General Physical Health Deterioration		Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Glossodynia							
	Hostility							
	Hyporeflexia		Vitamins (Vitamins)	C				
	Impaired Healing		Diltiazem Hydrochloride (Diltiazem Hydrochloride)	C				
	Injury							
	Irritability							
	Limb Injury							
	Movement Disorder							
	Muscle Spasms							
	Myalgia							
	Neck Pain							
	Oesophageal Spasm							
	Pain In Extremity							
	Pain In Jaw							
	Road Traffic Accident							
	Sedation							

Sleep Disorder
Somnolence
Tenderness
Tooth Abscess
Tremor
Vertigo

Date:03/29/05ISR Number: 4623003-0Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00273
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial Infarction	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
PO		Health Professional	Acetaminophen	C				15 DAY
			Aspirin	C				
			Lansoprazole	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4622601-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01498
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Prerenal Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable							
	Atrial Fibrillation							
	Bradycardia							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Haemoglobin Decreased							
	Hypoperfusion							
	Myocardial Infarction							
	Parathyroid Tumour Benign							

Date:03/30/05ISR Number: 4622602-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02926
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Myocardial Infarction							

Date:03/30/05ISR Number: 4622604-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01964
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Gemfibrozil	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN

Date:03/30/05ISR Number: 4622605-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02923
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622606-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02950
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622615-8Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0550173A
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 75 YR	Cerebrovascular Accident		Sensodyne	PS	Glaxosmithkline			
Initial or Prolonged	Feeling Abnormal		Vioxx	SS		ORAL		
			Calcium	C				
			Multivitamin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4622621-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622624-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03771
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622625-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03641
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ear Pain		Lipitor	C				
UNKNOWN								
	Heart Rate Decreased		Zoloft	C				
UNKNOWN								
	Tinnitus		Atenolol	C				
UNKNOWN								
			Codeine	C				
UNKNOWN								

Date:03/30/05ISR Number: 4622626-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02757
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Plavix	C				
UNKNOWN								
			Altace	C				
UNKNOWN								
			Vytorin	C		ORAL		

			Toprol Xl Tablets	C		
UNKNOWN						
			Zocor	C		ORAL

Date:03/30/05ISR Number: 4622627-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622628-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03751
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Disability								

Date:03/30/05ISR Number: 4622629-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00105
Age:69 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Convulsion
	Diarrhoea
	Hypocalcaemia
	Hypomagnesaemia

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Spironolactone	C		ORAL		
	Carvedilol	C		ORAL		
	Digoxin	C		ORAL		
	Omeprazole	C		ORAL		
	Acenocoumarol	C		ORAL		
	Acenocoumarol	C		ORAL		

Date:03/30/05ISR Number: 4622642-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622643-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03862
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622644-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622645-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622646-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03857
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Extrasystoles		Synthroid	C				
UNKNOWN								
Initial or Prolonged			Aspirin	C				
UNKNOWN								

Date:03/30/05ISR Number: 4622647-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02778
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Stomach Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Vioxx	SS	Merck & Co., Inc	ORAL	
Vioxx	SS	Merck & Co., Inc	ORAL	
Vioxx	SS	Merck & Co., Inc	ORAL	
Vioxx	SS	Merck & Co., Inc	ORAL	
Atenolol	SS			

UNKNOWN

Date:03/30/05ISR Number: 4622648-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04518
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622649-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622651-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04438
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	

Date:03/30/05ISR Number: 4622655-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622656-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622658-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04557
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Pain							
	Spinal Cord Injury							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4622659-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622689-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622717-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04374
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Tuberculosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4622735-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623314-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02213
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blindness Unilateral Blood Pressure Increased Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL		

Diverticulum Intestinal
Eyelid Ptosis
Glaucoma
Haemorrhoids
Macular Oedema
Retinal Haemorrhage
Retinal Vein Occlusion

Date:03/30/05ISR Number: 4623315-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 643 DAY	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Valsartan	C		ORAL		
	Cerebrovascular Accident		Furosemide	C		ORAL		
	Hypersensitivity		Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
	Hypertension		Allopurinol	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623317-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02484
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					
Initial or Prolonged			Unspecified]	C				
UNKNOWN								
Disability								

Date:03/30/05ISR Number: 4623318-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00043
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Microangiopathy		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623327-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00639
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthropod Bite		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blindness Transient		Pepcid	C				
UNKNOWN								
	Blood Pressure		Albuterol	C				
UNKNOWN								
	Inadequately Controlled		Atrovent	C				
UNKNOWN								
	Carpal Tunnel Syndrome		Lisinopril	C				
UNKNOWN								
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Chest Pain		Ginkgo Biloba Forte	C				
UNKNOWN								
	Coronary Artery Disease							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Disorientation							
	Drug Hypersensitivity							

Gastrooesophageal Reflux
Disease
Headache
Hypertension
Hyperventilation
Hypoxia
Injury
Myocardial Infarction
Neurodermatitis
Osteoarthritis
Stress
Thrombosis
Transient Ischaemic
Attack
Vertebral Artery Stenosis
Vertigo

Date:03/30/05ISR Number: 4623329-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03701
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623330-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03694
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623332-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA00213
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 195 DAY	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Anxiety							
	Arthralgia							
	Arthropathy							
	Balanitis							
	Coronary Artery Disease							
	Depression							
	Dislocation Of Vertebra							
	Dysarthria							
	Foot Fracture							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Joint Dislocation							
	Malaise							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Pain							
	Pain In Extremity							
	Radiculopathy							
	Road Traffic Accident							
	Visual Disturbance							

Date:03/30/05ISR Number: 4623336-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00357
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Dyspnoea	Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Fatigue	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction				
Disability					

Date:03/30/05ISR Number: 4623337-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization -	Abnormal Faeces
Initial or Prolonged	Acquired Oesophageal Web
Other	Anaemia
	Anaemia Of Chronic
	Disease
	Anaemia Vitamin B12
	Deficiency
	Angina Pectoris
	Anorexia
	Anticoagulation Drug

Level Below Therapeutic
Anxiety
Asthenia
Atrial Fibrillation
Bile Duct Stone
Blood Creatinine
Increased
Blood Culture Positive
Blood Urea Increased
Cardiac Failure
Congestive
Cardiomegaly
Carotid Artery Atheroma
Carotid Artery Stenosis
Chest Pain
Chills
Choledochal Cyst
Cholelithiasis
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coagulopathy
Constipation
Coronary Artery Disease
Depression
Diabetes Mellitus
Inadequate Control
Diarrhoea
Diverticulum
Dizziness
Drug Toxicity
Dyskinesia
Dyspepsia
Dysphagia
Dyspnoea
Dyspnoea Exertional
Ejection Fraction
Decreased
Emotional Distress
Enterobacter Bacteraemia
Enterococcal Bacteraemia
Enterococcal Sepsis
Epigastric Discomfort
Escherichia Urinary Tract
Infection
Fall
Feeling Abnormal
Feeling Cold

Femur Fracture
Fluid Overload
Fluid Retention
Gastric Disorder
Gastric Haemorrhage
Gastritis
Gastritis Erosive
Gastritis Haemorrhagic
Gastrointestinal
Arteriovenous
Malformation
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Glaucoma							
Haematemesis							
Haematochezia							
Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hepatic Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Hypercholesterolaemia		Coumadin	SS			UNKNOWN	
Hyperkalaemia		Lipitor	SS		ORAL		
Hypertension		Lipitor	SS		ORAL		
Hypoaesthesia		Prednisone	SS			UNKNOWN	
Hypokalaemia		Infliximab	SS			UNKNOWN	
Hypotension		Prinivil	SS		ORAL		
Influenza Like Illness		Methotrexate	SS		ORAL		
Iron Deficiency Anaemia		Methotrexate	SS			UNKNOWN	
Ischaemic Cardiomyopathy							
Ischaemic Hepatitis							
Joint Injury							
Joint Swelling							
Melaena							
Mental Status Changes							
Myocardial Infarction							
Nasopharyngitis							
Nausea							
Obesity							
Oedema Peripheral							
Oesophageal Disorder							
Osteoarthritis							
Pancreatitis							
Pleural Effusion							
Pneumonia							
Pneumonia Aspiration							
Pneumonitis							
Pulmonary Hypertension							
Pulmonary Oedema							
Pyrexia							
Renal Failure Acute							
Respiratory Distress							
Respiratory Failure							
Sinus Tachycardia							
Somnolence							
Staphylococcal Infection							
Streptococcal Infection							
Syncope							

Tachypnoea
Thrombotic Stroke
Troponin Increased
Upper Gastrointestinal
Haemorrhage
Urinary Tract Infection
Enterococcal
Vomiting
Weight Decreased
Whole Blood Transfusion

Date:03/30/05ISR Number: 4623338-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00161
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623339-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00128
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Deafness Unilateral		Phenprocoumon	C		ORAL		
	Diabetes Mellitus		Verapamil	C		ORAL		
	Inadequate Control		Atorvastatin Calcium	C		ORAL		
	Gastritis		Propafenone Hydrochloride	C		ORAL		
	Hepatomegaly		Digitoxin	C		ORAL		
	Vestibular Neuronitis		Theophylline	C		ORAL		
			Omeprazole	C		ORAL		
			Citalopram	C		ORAL		
			Prednisolone	C		ORAL		

Date:03/30/05ISR Number: 4623347-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01234
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:03/30/05ISR Number: 4623348-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:03/30/05ISR Number: 4623349-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00147
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prazosin					

Hydrochloride C
UNKNOWN

Date:03/30/05ISR Number: 4623350-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623351-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03674
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623352-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03895
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
Disability								
UNKNOWN								

Date:03/30/05ISR Number: 4623353-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Pain							

Date:03/30/05ISR Number: 4623354-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00036
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Candesartan Cilexetil	C		ORAL		
	Coronary Artery Stenosis							
	Diarrhoea							
	Fatigue							
	Gastroenteritis							
	Glossodynia							
	Myalgia							
	Myocardial Infarction							
	Palpitations							
	Pulse Pressure Decreased							
	Ventricular Extrasystoles							

Date:03/30/05ISR Number: 4623355-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00038
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dialysis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Embolism		Tramadol					
Other	Extremity Necrosis		Hydrochloride	C		ORAL		
	Hypercholesterolaemia		Tramadol					
	Interventricular Septum		Hydrochloride	C		ORAL		
	Rupture		Estradiol And					
	Myocardial Infarction		Norethindrone					
	Necrosis		Acetate	C				
UNKNOWN								
	Pain In Extremity		Amitriptyline					
	Renal Failure		Hydrochloride	C				
UNKNOWN								
	Toe Amputation							

Date:03/30/05ISR Number: 4623356-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623357-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623358-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623369-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623370-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623372-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623373-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Lower Respiratory Tract Infection							
	Myocardial Infarction							

Date:03/30/05ISR Number: 4623374-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04783
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623375-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04602
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623376-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03038
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623377-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03587
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623378-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03894
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Poor Peripheral		Zyprexa	C				
Initial or Prolonged UNKNOWN	Circulation		Seroquel	C				
Disability	Respiratory Failure Skin Discolouration Vein Disorder							

Date:03/30/05ISR Number: 4623379-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623380-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04426
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Effexor	C				
UNKNOWN								
Initial or Prolonged			Zyprexa	C				
UNKNOWN								
Disability			Trazodone Hydrochloride	C				
UNKNOWN								

Date:03/30/05ISR Number: 4623382-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623383-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03637
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Femoral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623384-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623385-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	32 MON	
Other	Emotional Distress Life Expectancy Shortened Myocardial Infarction Pain							

Date:03/30/05ISR Number: 4623386-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623387-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623388-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04961
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Thrombosis

Date:03/30/05ISR Number: 4623389-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623390-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:03/30/05ISR Number: 4623391-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623392-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Pulmonary Embolism Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623393-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623394-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623404-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04613
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623405-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04605
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623406-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04625
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623407-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623413-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623414-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623415-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623417-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction Thrombosis Transient Ischaemic Attack							

Date:03/30/05ISR Number: 4623424-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623425-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623426-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623427-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4623428-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04960
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623437-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02046
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Lipitor	C			UNKNOWN	
	Asthenia		Duragesic	C			UNKNOWN	
	Atrial Fibrillation		Prevacid	C			UNKNOWN	
	Axillary Pain		Peri-Colace	C			UNKNOWN	
	Blood Creatinine Increased		Senokot (Senna)	C			UNKNOWN	
	Blood Pressure Fluctuation							
	Blood Urea Increased							
	Brain Natriuretic Peptide Increased							
	Cardiac Failure Congestive							
	Cerebrovascular Accident							
	Constipation							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Dehydration							
	Depression							
	Ejection Fraction Decreased							
	Emotional Distress							
	Gastric Ulcer							
	Haemodynamic Instability							
	Hyperlipidaemia							
	Hypotension							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Panic Attack							
	Pleural Effusion							
	Post Procedural Complication							

Respiratory Failure
Throat Tightness
Ulcer
Ventricular Extrasystoles
Vomiting
Weight Decreased

Date:03/30/05ISR Number: 4623438-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03388
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Other	Acute Myocardial Infarction Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4623439-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02254
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Abnormal		Norvasc	C				
	Blood Thyroid Stimulating Hormone Decreased							
	Cardiac Murmur							
	Cerebral Artery Occlusion							
	Cerebral Artery Stenosis							
	Cerebrovascular Accident							
	Computerised Tomogram Abnormal							
	Emotional Distress							
	Fall							
	Fibula Fracture							
	Gastric Disorder							
	Hyperglycaemia							
	Hypertension							
	Neutrophil Count Increased							
	Oedema Peripheral							

Date:03/30/05ISR Number: 4623446-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05008
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/30/05ISR Number: 4625937-XReport Type:Expedited (15-DaCompany Report #2004115699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS			400 MG (200 MG, 2 IN 1 D)	
	Coronary Artery Occlusion							

	Drug Ineffective Ventricular Wall Thickening		Rofecoxib (Rofecoxib)	SS		
25 MG (25 MG, 1 IN 1 D)						

Date:03/30/05ISR Number: 4625957-5Report Type:Expedited (15-DaCompany Report #2005025469
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Ineffective Knee Operation Macular Degeneration Unevaluable Event	Consumer	Celebrex (Celecoxib) Arthrotec (Diclofenac Sodium, Misoprostol) Rofecoxib (Rofecoxib) Salsalate (Salsalate) Provella-14	PS SS SS C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/05ISR Number: 4626194-0Report Type:Expedited (15-DaCompany Report #2005035612
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism	Foreign	Celebrex (Celecoxib)	PS		ORAL	ORAL	
		Health Professional Company Representative	Rofecoxib (Rofecoxib)	SS				
			Etoricoxib (Etoricoxib)	SS				

Date:03/31/05ISR Number: 4623848-7Report Type:Expedited (15-DaCompany Report #200512465US
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Lantus	PS	Aventis Pharmaceuticals Inc.	SUBCUTANEOUS	Dose unit: units	
	Blood Glucose Increased							
	Cardiac Valve Disease							
	Cerebrovascular Accident		Opticlik (Insulin Injection Pen)	SS			dose: UNK	
	Disease Recurrence							
	Infection		Vioxx	SS			dose: UNK	
	Medical Device Complication		Some Type Of Insulin Nos	C			dose: UNK	
	Pyrexia		Proventil	C			dose: UNK	
	Tongue Disorder		Zocor	C				
	Viral Infection		Synthroid	C				
	Visual Disturbance		Actos	C			dose: 10-12.5	
	Vomiting		Zestril	C			dose: UNK	
			Plavix	C				
			Amaryl	C				
			Levaquin	C			dose: UNK	
			Namenda	C			dose: UNK	

Date:03/31/05ISR Number: 4623915-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Atherosclerosis
	Blood Cholesterol Increased
	Bradycardia
	Cardiac Failure Congestive
	Cardio-Respiratory Arrest
	Cardiogenic Shock
	Cardiomyopathy
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Dizziness
	Dyspnoea
	Haematuria
	Hypertension
	Ischaemic Cardiomyopathy
	Limb Discomfort
	Lung Infiltration
	Myalgia
	Myocardial Infarction
	Nausea

		Orthostatic Hypotension					
		Papilloma					
		Skin Laceration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Dalmane	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Claforan	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Dopamine Hydrochloride	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Aspirin	C		ORAL
				Restoril	C		
UNKNOWN							
				Reopro	C		
UNKNOWN							
				Cordarone	C		
UNKNOWN							
				Magnesium Sulfate	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							

Date:03/31/05ISR Number: 4623920-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Disability	Anuria
	Anxiety
	Arthralgia
	Arthroscopy
	Asthenia
	Back Injury
	Back Pain
	Chest Pain
	Diverticulum
	Dizziness
	Drug Hypersensitivity
	Emotional Distress
	Facial Pain
	Fall
	Hypertension
	Hypoaesthesia
	Inflammation
	Injury
	Intervertebral Disc
	Disorder
	Intervertebral Disc
	Protrusion
	Ligament Sprain
	Loose Body In Joint
	Monoparesis
	Muscle Strain
	Non-Cardiac Chest Pain
	Oedema Peripheral
	Pain
	Pain In Extremity
	Peripheral Embolism

	Prostatitis						
	Pyrexia						
	Renal Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Sciatic Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL	
	Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Testicular Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Testicular Swelling		Vioxx	SS	Merck & Co., Inc	ORAL	
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Urethritis		Coumadin	C			UNKNOWN

Date:03/31/05ISR Number: 4623921-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03366
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Life-Threatening	Cerebrovascular Accident						
Hospitalization -	Death						
Initial or Prolonged	Dizziness						
Disability	Dyspepsia						
	Fatigue						
	Headache						
	Pain						
	Respiratory Disorder						
	Urinary Tract Infection						
	Volvulus Of Bowel						

Date:03/31/05ISR Number: 4623922-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04045
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatine		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Phosphokinase Mb		Vioxx	SS	Merck & Co., Inc	ORAL	
	Increased		Serzone	C		ORAL	
	Blood Urea Increased		Serzone	C		ORAL	
	Cardiac Murmur		Wellbutrin	C			UNKNOWN
	Dyspepsia		Wellbutrin	C			UNKNOWN

	Dyspnoea	Clonazepam	C	ORAL
	Electrocardiogram T Wave	Doxycycline	C	
UNKNOWN				
	Inversion			
	Emotional Distress			
	Feeling Abnormal			
	Hordeolum			
	Myoglobin Blood Increased			
	Pulmonary Hypertension			
	Upper Respiratory Tract			
	Infection			

Date:03/31/05ISR Number: 4623923-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00109
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Valve Incompetence
	Arrhythmia
	Supraventricular
	Arthralgia
	Back Pain

		Blood Cholesterol Increased					
		Bronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Diazide	C		
UNKNOWN							
		Cerebrovascular Disorder		Lopressor	C		
UNKNOWN							
		Coronary Artery Disease		Lopressor	C		
UNKNOWN							
		Diverticulum Intestinal		Zocor	C		ORAL
		Dyspnoea					
		Emotional Distress					
		Flank Pain					
		Haematuria					
		Heart Rate Irregular					
		Injury					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Overdose					
		Pneumonia					
		Pruritus					
		Rash Papular					
		Sebaceous Gland Disorder					
		Thrombosis					
		Upper Respiratory Tract Infection					

Date:03/31/05ISR Number: 4623924-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Epididymitis		Aspirin	C		ORAL
Disability		Vascular Encephalopathy		Diclofenac	C		
UNKNOWN							
Other				Metformin Hydrochloride	C		ORAL
				Uva Ursi	C		ORAL

Date:03/31/05ISR Number: 4623925-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04062
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Other			[Therapy Unspecified]	C				
UNKNOWN								

Date:03/31/05ISR Number: 4623936-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:03/31/05ISR Number: 4623937-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04639
Age: Gender:Male I/FU:I

Outcome	PT
Death	Adverse Event
	Death

	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623938-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623939-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder							
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:03/31/05ISR Number: 4623940-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04087
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623941-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623942-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623943-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01265
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Bayer Aspirin	C				
UNKNOWN								
	Chest Pain		Lisinopril	C				
UNKNOWN								
	Dizziness							
	Heat Stroke							
	Loss Of Consciousness							
	Malaise							
	Nausea							
	Urinary Tract Disorder							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4623944-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04467
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Accident Femur Fracture Pain		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:03/31/05ISR Number: 4623945-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00163
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Cerebrovascular Disorder Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623952-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623954-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623956-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623961-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04209
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623962-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4623963-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623964-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623981-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623982-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04991
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4623983-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624443-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lymphoedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Phlebothrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Ibuprofen	C				
UNKNOWN								
	Varicose Vein							

Date:03/31/05ISR Number: 4624445-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
	Ageusia
Disability	Carpal Tunnel Syndrome
Other	Cerebrovascular Accident
	Cholecystitis Chronic
	Cholelithiasis
	Colon Adenoma
	Constipation
	Dizziness
	Dry Mouth
	Dysplasia
	Fatigue

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Headache					
		Hypertension					
		Insomnia					
		Joint Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
		Prostate Cancer		Vioxx	SS	Merck & Co., Inc	ORAL
		Psoriasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash Erythematous		Vioxx	SS	Merck & Co., Inc	ORAL
46	DAY						
		Urge Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
5	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Zocor	SS		ORAL
2099	DAY						
				Prevacid	SS		
UNKNOWN							
				Prevacid	SS		
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
46	DAY						
				Monopril	C		
UNKNOWN		1183 DAY					
				Monopril	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN		4268 DAY					
				Naprosyn	C		
UNKNOWN		4268 DAY					
				Levaquin	C		
UNKNOWN							
				Levaquin	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							

Date:03/31/05ISR Number: 4624449-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00679
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL	280	DAY
	Myalgia		Darvocet-N	C			UNKNOWN	
	Myocardial Infarction		Celebrex	C			UNKNOWN	
	Rhinitis Allergic							
	Road Traffic Accident							
	Spinal Osteoarthritis							

Date:03/31/05ISR Number: 4624471-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00780
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL	247	DAY
Initial or Prolonged	Depression		Ultram	C			UNKNOWN	
Disability	Emotional Distress		Ultram	C			UNKNOWN	
	Ischaemic Stroke		Hydrocodone/Apap	C			UNKNOWN	
	Protein S Deficiency		Hydrocodone/Apap	C			UNKNOWN	
	Psychomotor Hyperactivity							
	Renal Disorder							
	Tendonitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4624472-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0502AUT00010
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis Coronary Artery Atherosclerosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624473-4Report Type:Expedited (15-DaCompany Report #IT-MERCK-0503ITA00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Acute Myocardial Infarction Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624474-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:03/31/05ISR Number: 4624475-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00764
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Memory Impairment							
	Transient Ischaemic Attack							

Date:03/31/05ISR Number: 4624476-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04084
Age:43 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:03/31/05ISR Number: 4624477-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02647
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Monopril	C				
UNKNOWN								
	Coronary Artery Disease		Motrin	C				
UNKNOWN								
	Emotional Distress		Norvasc	C				
UNKNOWN								
	Hyperlipidaemia		Aciphex	C				
UNKNOWN								
	Hypertension		Tylenol	C				
UNKNOWN								
	Oedema Peripheral							
	Sinus Bradycardia							

Date:03/31/05ISR Number: 4624478-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0503SWE00020
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		28 DAY
Initial or Prolonged	Myocardial Infarction		Metformin Hydrochloride	C				UNKNOWN
			Glyburide	C				UNKNOWN

Date:03/31/05ISR Number: 4624479-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03882
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thyroid Function Test Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				UNKNOWN

Date:03/31/05ISR Number: 4624480-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02523
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Activated Partial
Initial or Prolonged	Thromboplastin Time
Disability	Prolonged
	Asthenia
	Blood Albumin Decreased
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Bundle Branch Block
	Bundle Branch Block Right
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression

Dilatation Ventricular
Dyspepsia
Exercise Tolerance
Decreased
Fatigue
Fear
Haematocrit Decreased
Haemoglobin Decreased
Headache
Hypertension
Incision Site Abscess
Injury
Low Density Lipoprotein
Increased
Myalgia
Myocardial Infarction
Neck Pain
Pallor
Pleural Effusion
Rectal Haemorrhage
Road Traffic Accident
Sleep Disorder
Stitch Abscess

		Supraventricular Extrasystoles Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
233	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
233	DAY						
				Toprol Xl Tablets	C		
UNKNOWN							
				Zocor	C		ORAL
439	DAY						
				Viagra	C		
UNKNOWN							
				Diovan	C		
UNKNOWN		79 DAY					

Date:03/31/05ISR Number: 4624498-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Arrest Cardiac Disorder Heart Injury Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/31/05ISR Number: 4624499-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death Hospitalization - Initial or Prolonged Other	Adverse Event Cardiac Disorder Chest Pain Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/31/05ISR Number: 4624500-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04951
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624501-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04851
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624502-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624503-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04755
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation Irritable Bowel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4624504-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624505-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04326
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Angina Pectoris Aortic Valve Incompetence Arthritis Atrioventricular Block Second Degree Burning Sensation Cardiac Failure Congestive Cardiomegaly Chest Discomfort Coronary Artery Atherosclerosis Coronary Artery Disease Depression Dermatitis Allergic Diabetes Mellitus Hyperlipidaemia Hypertension Hypotension Ischaemic Cardiomyopathy Mitral Valve Incompetence Neuropathy Peripheral Non-Cardiac Chest Pain Subclavian Artery Stenosis Tricuspid Valve Incompetence Wound Complication		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624506-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624519-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4624520-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04953
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Cerebrovascular Accident Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624523-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624525-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624526-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:03/31/05ISR Number: 4624527-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04956
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:03/31/05ISR Number: 4624528-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624529-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624531-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05011
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/31/05ISR Number: 4624553-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Myocardial Infarction Polytraumatism Respiratory Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624554-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05070
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624555-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624556-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624557-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04957
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624572-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:03/31/05ISR Number: 4624617-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04236
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Disorder		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:03/31/05ISR Number: 4632638-0Report Type:Periodic Company Report #200414184BCC
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaphylactic Reaction Dyspnoea Throat Irritation	Consumer Other	Aleve Tablets (Naproxen Sodium)	PS		ORAL	220 MG, ONCE, ORAL	
			Vioxx (Rofecoxib)	SS				

			Allergy Shots (Nos)	C
			Epinephrine	C

Date:03/31/05ISR Number: 4647044-2Report Type:Periodic Company Report #04P-163-0265813-00
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
	Abdominal Pain	Consumer	Humira 40 Mg / 0.8			
	Diarrhoea		Ml Pre-Filled			
	Dyspepsia		Syringe (Humira)			
	Influenza Like Illness		(Adalimumab)			
	Paranasal Sinus		(Adalimumab)	PS		
SUBCUTANEOUS 40 MG,	1 IN 2					
	Hypersecretion					
WK,						
	Somnolence					
SUBCUTANEOUS;						
40 MG, 1 IN						
2 WK						
			Meloxicam	SS		
			Rofecoxib	SS		
			Risedronate Sodium	C		
			Prednisone	C		

Date:04/01/05ISR Number: 4624807-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04637
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/01/05ISR Number: 4625219-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01985
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL

Initial or Prolonged	Death	Motrin	C	
UNKNOWN				
Other	Depression	Mylanta & Mylanta Ds	C	
UNKNOWN				
	Dyspnoea	[Therapy Unspecified]	C	
	Epigastric Discomfort			
UNKNOWN				
	Injury	Cytotec	C	
UNKNOWN				
	Myocardial Infarction	Celebrex	C	
UNKNOWN				
	Stomach Discomfort	Tylenol	C	
UNKNOWN				
	Vomiting	Catapres	C	
UNKNOWN				
		Procardia	C	
UNKNOWN				
		Orudis	C	
UNKNOWN				
		Actifed	C	
UNKNOWN				
		Zestril	C	
UNKNOWN				
		Zestril	C	
UNKNOWN				
		Dyazide	C	
UNKNOWN				
		Naproxen	C	
UNKNOWN				
		Meridia	C	
UNKNOWN				
		Xenical	C	
UNKNOWN				
		Ventolin (Albuterol)	C	
UNKNOWN				
		Azmacort	C	
UNKNOWN				
		Pepcid	C	ORAL

Date:04/01/05ISR Number: 4625222-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00805
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Agitation
	Alanine Aminotransferase Increased
	Alcoholism
	Anticonvulsant Drug Level Decreased
	Arthralgia
	Aspartate Aminotransferase Increased
	Balance Disorder
	Belligerence
	Blood Cholesterol Increased
	Blood Potassium Decreased
	Blood Thyroid Stimulating Hormone Increased
	Body Temperature Decreased
	Cholelithiasis
	Complex Partial Seizures
	Confusional State
	Constipation
	Contusion
	Deafness Neurosensory
	Depressed Level Of Consciousness
	Depressed Mood
	Diarrhoea
	Dizziness
	Drug Eruption
	Drug Hypersensitivity
	Drug Ineffective
	Drug Level Below Therapeutic
	Drug Level Decreased
	Drug Screen Positive
	Ear Discomfort
	Emotional Distress
	Erythema
	Factitious Disorder
	Fall

Fatigue
Feeling Abnormal
Folliculitis
Gingival Hyperplasia
Grand Mal Convulsion
Headache
Hepatic Enzyme Increased
Hepatic Steatosis
Hyperlipidaemia
Hypernatraemia
Hypertension
Hypoacusis
Injury
Laceration
Low Density Lipoprotein

		Increased Meningitis Mental Status Changes Middle Ear Effusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Musculoskeletal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Ms Contin	SS		
UNKNOWN							
		Nail Pitting		Ms Contin	SS		
UNKNOWN							
		Nasal Cavity Cancer		Depakote	C		
UNKNOWN							
		Nasal Polyps		Tegretol	C		
UNKNOWN							
		Neck Pain		Aspirin	C		
UNKNOWN							
		Obstructive Airways Disorder		Vitamins (Unspecified)	C		
UNKNOWN							
		Osteopenia		Msir	C		ORAL
		Osteoporosis					
		Otitis Media					
		Overdose					
		Periarthritis					
		Psoriasis					
		Pyrexia					
		Radius Fracture					
		Rash					
		Respiratory Failure					
		Scab					
		Sepsis					
		Spinal Osteoarthritis					
		Stupor					
		Synovitis					
		Tinnitus					
		Treatment Noncompliance					
		Tremor					
		Tympanic Membrane Disorder					
		Urinary Incontinence					
		Urine Ketone Body Present					
		Vaginal Infection					
		Vertigo					
		Weight Decreased					
		Weight Increased					
		Wrist Fracture					

Date:04/01/05ISR Number: 4625223-8Report Type:Expedited (15-DaCompany Report #US-MERCK-01104508
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abnormal Behaviour
Initial or Prolonged	Accidental Overdose
Disability	Anxiety
	Arthralgia
	Asthenia
	Back Injury
	Back Pain
	Carpal Tunnel Syndrome
	Cellulitis
	Closed Head Injury
	Concussion
	Constipation
	Depression
	Diabetic Neuropathy
	Emotional Distress
	Epididymitis
	Facial Bones Fracture

	Head Injury					
	Headache					
	Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypercholesterolaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Zocor	C		
UNKNOWN						
	Inguinal Hernia					
	Laceration					
	Muscle Atrophy					
	Nasal Congestion					
	Nasal Septum Deviation					
	Neuritis					
	Nocturia					
	Nodule					
	Nose Deformity					
	Obesity					
	Pain					
	Sleep Apnoea Syndrome					
	Somnolence					
	Tendonitis					
	Upper Extremity Mass					
	Vision Blurred					

Date:04/01/05ISR Number: 4625226-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial Infarction
Disability	Acute Respiratory Failure
	Angina Unstable
	Arthralgia
	Cardiac Arrest
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cerebrovascular Accident
	Chest Pain
	Congestive Cardiomyopathy
	Coronary Artery Disease
	Dilatation Ventricular
	Dizziness

Emotional Distress
Encephalopathy
Fatigue
Folliculitis
Gastrooesophageal Reflux
Disease
Headache
Heart Rate Increased
Hypercholesterolaemia
Hypertension
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Lumbar Radiculopathy
Lung Infiltration
Migraine

		Multi-Organ Failure					
		Muscle Spasms					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
14	MON						
		Renal Failure Acute		Diovan	C		
UNKNOWN							
		Tendonitis		Ultram	C		
UNKNOWN							
		Thyroid Neoplasm		Oxycodone	C		
UNKNOWN							
		Ulcer Haemorrhage		Zantac	C		ORAL
		Urinary Tract Infection		Prozac	C		
UNKNOWN							
		Ventricular Fibrillation		Maxalt (Rizatriptan			
		Ventricular Tachycardia		Benzoate)	C		ORAL
		Visual Disturbance		Zoloft	C		
UNKNOWN							

Date:04/01/05ISR Number: 4625238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02627
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged						
Disability						
Other						

Date:04/01/05ISR Number: 4625244-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
			Adalimumab	SS		
SUBCUTANEOUS						
			Methotrexate	SS		
UNKNOWN						
			Estrogens,			

	Conjugated	SS
UNKNOWN		
	Fluoxetine	SS
UNKNOWN		
	Amoxicillin And Clavulanate Potassium	SS
UNKNOWN		
	Acetaminophen And Dihydrocodeine Bitartrate	SS
UNKNOWN		

Date:04/01/05ISR Number: 4625245-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00613
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event
	Aggression
	Agitation
	Alcohol Withdrawal Syndrome
	Alcoholism
	Amnesia
	Anaemia
	Anaphylactic Reaction
	Angina Pectoris
	Angina Unstable
	Anxiety

Aortic Valve Sclerosis
Arteriosclerosis
Arthralgia
Atelectasis
Atrial Fibrillation
Back Pain
Blood Glucose Increased
Blood Pressure Increased
Bone Pain
Calcinosis
Cardiac Aneurysm
Cardiac Failure
Congestive
Chills
Chronic Obstructive
Airways Disease
Exacerbated
Convulsion
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Cough
Dilatation Atrial
Dilatation Ventricular
Ejection Fraction
Decreased
Faecal Occult Blood
Positive
Fall
Fear
Global Amnesia
Ischaemic Cardiomyopathy
Mental Disorder Due To A
General Medical Condition
Mitral Valve Incompetence
Myocardial Infarction
Platelet Count Decreased
Post Procedural
Haemorrhage
Procedural Complication
Psychotic Disorder
Pulmonary Embolism
Pulmonary Oedema
Red Blood Cells Urine
Positive
Refusal Of Treatment By

Patient
Respiratory Distress
Respiratory Failure
Sinus Arrhythmia
Supraventricular
Extrasystoles
Tricuspid Valve
Incompetence
Vascular Injury
Ventricular Dyskinesia
Ventricular Fibrillation
Ventricular Hyperkinesia
Ventricular Tachycardia
Vitamin B12 Decreased

Vitamin B12 Deficiency

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Glimepiride	C		ORAL		

Date:04/01/05ISR Number: 4625246-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03708
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Stenosis							
	Bladder Disorder							
	Blood Creatinine Increased							
	Blood Potassium Increased							
	Blood Pressure Systolic Increased							
	Blood Sodium Decreased							
	Blood Urea Increased							
	Coronary Artery Disease							
	Deep Vein Thrombosis							
	Mitral Valve Prolapse							
	Myocardial Infarction							
	Oedema Peripheral							
	Renal Failure Chronic							

Date:04/01/05ISR Number: 4625247-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04311
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased		[Therapy Unspecified]	C				
UNKNOWN								
Disability	Blood Creatine		Patanol	C				
UNKNOWN								
	Phosphokinase Mb Increased		[Therapy Unspecified]	C				
UNKNOWN								

Cerebral Atrophy
Cerebrovascular Accident
Cerebrovascular Disorder
Difficulty In Walking
Dizziness
Fatigue
Headache
Pain In Extremity

Date:04/01/05ISR Number: 4625248-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02420
Age:78 YR Gender:Female I/FU:F

Outcome PT
Other Cerebrovascular Accident
Depression
Drug Ineffective
Fatigue
Heart Rate Increased
Hyperhidrosis
Hypoaesthesia
Lumbar Spinal Stenosis

	Sleep Disorder Tendon Disorder Tremor	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625249-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00263
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:04/01/05ISR Number: 4625250-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02100
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Stenosis		Lasix (Furosemide)	C				
UNKNOWN								
Initial or Prolonged	Blood Cholesterol		Lipitor	C				
UNKNOWN								
	Increased		Neurontin	C				
UNKNOWN								
	Blood Creatinine		A.S.A.	C				
UNKNOWN								
	Increased Blood Homocysteine Increased Blood Urea Increased Cardiac Failure Congestive Cardiac Murmur Cardiovascular Disorder Carotid Artery Stenosis Cataract Cerebral Ischaemia Cerebrovascular Accident Cervical Spinal Stenosis Diabetes Mellitus Discomfort							

Heart Rate Irregular
High Density Lipoprotein
Decreased
Hypoaesthesia
Infection
Intervertebral Disc
Protrusion
Low Density Lipoprotein
Increased
Musculoskeletal Stiffness
Nervous System Disorder
Orthopnoea
Pain
Paraesthesia
Skin Haemorrhage
Sleep Apnoea Syndrome
Sleep Disorder
Snoring
Somnolence
Speech Disorder
Spinal Osteoarthritis
Total Cholesterol/Hdl
Ratio Decreased
Treatment Noncompliance

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625251-2Report Type:Expedited (15-DaCompany Report #PL-MERCK-0503POL00023
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625271-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04137
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Ageusia Asthenia Cerebrovascular Accident Grip Strength Decreased Hypoaesthesia Jaw Disorder Sensory Loss Speech Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625279-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05092
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625280-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625281-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:04/01/05ISR Number: 4625283-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03589
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colitis Ulcerative							
	Gastrointestinal Disorder							
	Heart Rate Increased							
	Hypertension							
	Hypotension							
	Infection							
	Intestinal Perforation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625288-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03705
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625289-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia Blood Pressure Increased Cerebrovascular Accident Dizziness Life Expectancy Shortened Polytraumatism Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625290-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04196
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Lipitor	C				UNKNOWN
	Loss Of Consciousness		Paxil	C				UNKNOWN

Date:04/01/05ISR Number: 4625537-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00611
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Abscess Abdominal Pain Abdominal Pain Lower Accidental Overdose Angina Pectoris

Anxiety
Appetite Disorder
Arthralgia
Asthenia
Atelectasis
Back Pain
Blood Pressure Increased
Brain Oedema
Bronchitis
Bronchitis Acute
Bronchitis Chronic
Cerebrovascular Accident
Complex Partial Seizures
Constipation
Convulsion
Dermatitis
Diabetes Mellitus
Diarrhoea
Dizziness
Dyspepsia
Dyspnoea
Dysuria
Ear Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Eczema					
		Electrocardiogram Qt Prolonged					
		Encephalopathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Depakote	C		
UNKNOWN							
		Fatigue		Folic Acid	C		
UNKNOWN							
		Femoral Neck Fracture		Ambien	C		
UNKNOWN							
		Haematochezia		Lasix (Furosemide)	C		
UNKNOWN							
		Hepatic Steatosis		Coumadin	C		
UNKNOWN							
		Hypothyroidism		Zoloft	C		
UNKNOWN							
		Increased Tendency To Bruise					
		Insomnia					
		Irritable Bowel Syndrome					
		Muscle Spasms					
		Myofascitis					
		Nasal Congestion					
		Night Sweats					
		Oedema					
		Oedema Peripheral					
		Osteoporosis					
		Pain					
		Pain In Extremity					
		Peripheral Vascular Disorder					
		Phantom Pain					
		Phlebitis					
		Pneumonia					
		Respiratory Tract Infection					
		Seasonal Allergy					
		Sinusitis					
		Skin Lesion					
		Stress					
		Subdural Haematoma					
		Transient Ischaemic Attack					
		Upper Respiratory Tract Infection					
		Urinary Tract Infection					

Vertigo
White Blood Cell Count
Increased

Date:04/01/05ISR Number: 4625540-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01101
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Angiopathy
Hospitalization - Initial or Prolonged	Blood Glucose Decreased
	Blood Ph Decreased
Other	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiovascular Disorder
	Cellulitis
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Circulatory Collapse

		Coma					
		Coronary Artery Disease					
		Cushing'S Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cushingoid		Vioxx	PS	Merck & Co., Inc	ORAL
323	DAY						
		Dermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness Postural		Vioxx	SS	Merck & Co., Inc	ORAL
323	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Ear Infection		Altace	C		
UNKNOWN							
		Gastric Ulcer		Altace	C		
UNKNOWN							
		Gastroenteritis Viral		Inderal	C		
UNKNOWN							
		Generalised Oedema		Inderal	C		
UNKNOWN							
		Hyperkalaemia		Lopressor	C		ORAL
		Hypotension		Lopressor	C		ORAL
		Influenza		Toprol Xl Tablets	C		
UNKNOWN							
		Metabolic Acidosis		Toprol Xl Tablets	C		
UNKNOWN							
		Myocardial Infarction		Hytrin	C		
UNKNOWN							
		Oedema Peripheral		Lasix (Furosemide)	C		
UNKNOWN							
		Pain In Extremity		Demadex	C		
UNKNOWN							
		Pruritus		Aldactazide	C		
UNKNOWN							
		Pulse Absent		Aspirin	C		
UNKNOWN							
		Renal Failure		Lipitor	C		ORAL
		Sinus Tachycardia		Zocor	C		
UNKNOWN							
		Sudden Death		Advil	C		
UNKNOWN							
				Theophylline	C		ORAL
				Wellbutrin	C		ORAL
				Wellbutrin	C		ORAL
				Klonopin	C		ORAL
				Klonopin	C		ORAL
				Singulair	C		ORAL
				Prozac	C		ORAL

	Pulmicort	C	
RESPIRATORY			
(INHALATION)			
	Allegra	C	ORAL
	Albuterol And Ipratropium Bromide	C	
RESPIRATORY			
(INHALATION)			
	Nitroglycerin	C	
TOPICAL			
	Serevent	C	
RESPIRATORY			
(INHALATION)			
	Plavix	C	
UNKNOWN			
	Potassium Chloride	C	ORAL
	Beconase	C	
UNKNOWN			
	Prilosec	C	ORAL
	Naproxen	C	
UNKNOWN			
	Spironolactone	C	ORAL
	Temazepam	C	ORAL
	Humibid L.A.	C	ORAL
	Vitamins (Unspecified)	C	ORAL
	Ascorbic Acid	C	ORAL

Date:04/01/05ISR Number: 4625541-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01396
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Coronary Artery Disease
Other	Dermatitis
	Hypertension
	Injury

		Myocardial Infarction Myocardial Ischaemia Nervousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Streptococcal Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Celebrex	C		
UNKNOWN							
		Enterococcal		Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Fosamax	C		ORAL
				Duragesic	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Verapamil Msd Lp	C		ORAL

Date:04/01/05ISR Number: 4625542-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01740
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Accident
	Acute Myocardial Infarction
	Anxiety
	Arthralgia
	Arthropathy
	Atrial Fibrillation
	Blood Alkaline Phosphatase Increased
	Blood Creatine Phosphokinase Increased
	Blood Creatine Phosphokinase Mb Increased
	Blood Triglycerides Increased

Cardiac Arrest
Cardiomegaly
Chest Pain
Coronary Artery Disease
Coronary Artery Stenosis
Cystitis
Depression
Dermatitis Contact
Diabetes Mellitus
Inadequate Control
Diabetic Nephropathy
Drug Effect Decreased
Emotional Distress
Fall
Gastrooesophageal Reflux
Disease
General Physical Health
Deterioration
Hepatic Enzyme Increased
Hepatic Steatosis
Hypercholesterolaemia
Insomnia
Joint Arthroplasty
Joint Sprain

		Osteoarthritis					
		Pernicious Anaemia					
		Productive Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Congestion		Vioxx	PS	Merck & Co., Inc	ORAL
26	MON						
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
26	MON						
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vicodin Tablets	C		
UNKNOWN							
		Ventricular Fibrillation		Clonidine	C		
UNKNOWN							
		Weight Increased					

Date:04/01/05ISR Number: 4625544-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00770
Age:73 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris		Baycol	C		ORAL
		Arthritis		Glynase Prestab			
		Blood Pressure Increased		Tablets	C		ORAL
		Cerebrovascular Accident		Levothroid	C		ORAL
		Colonic Polyp		Imdur	C		
UNKNOWN							
		Convulsion		Procardia Xl	C		ORAL
		Gastrooesophageal Reflux		Metoprolol	C		
UNKNOWN							
		Disease		Lasix (Furosemide)	C		ORAL
				Aspirin	C		
UNKNOWN							
				Glucophage	C		ORAL
				Synthroid	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							

Date:04/01/05ISR Number: 4625545-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02548
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	High Density Lipoprotein		Tagamet	C		ORAL		
	Decreased		Tylenol	C				
UNKNOWN								
	Myocardial Infarction		Dilacor Xr	C		ORAL		
	Osteoarthritis		Maxzide	C		ORAL		
			Pepcid	C		ORAL		
			Allopurinol Msd	C		ORAL		

Date:04/01/05ISR Number: 4625546-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Aortic Valve Disease
	Arterial Occlusive Disease
	Atherosclerosis
	Atrial Fibrillation
	Bleeding Time Prolonged
	Blood Cholesterol Increased
	Cardiac Failure Congestive

		Cardiac Valve Disease Coronary Artery Atherosclerosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
726	DAY						
		Coronary Artery Stenosis		Levoxyl	C		
UNKNOWN							
		Gallbladder Disorder		Hydrochlorothiazide	C		
UNKNOWN							
		Heart Rate Irregular		Cardizem	C		
UNKNOWN							
		Hypersensitivity		Lovastatin	C		
UNKNOWN							
		Hypertension		Premarin	C		
UNKNOWN							
		Injury Muscle Spasms Myocardial Infarction Nausea Nerve Injury Post Procedural Complication Pseudomonas Infection Urinary Tract Infection Vomiting					

Date:04/01/05ISR Number: 4625547-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01954
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
599	DAY					
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Angiopathy		Accupril	C		
UNKNOWN	418 DAY					
	Bronchitis		Vasotec	C		
UNKNOWN	725 DAY					
	Cardiomegaly		Enalapril Maleate	C		
UNKNOWN	323 DAY					
	Cellulitis		Verapamil	C		
UNKNOWN	418 DAY					
	Diabetic Neuropathy		Glucovance	C		
UNKNOWN						

	Gout	Glucophage	C
UNKNOWN			
	Joint Sprain	Glucotrol Xl	C
UNKNOWN			
	Skin Ulcer	Allopurinol	C
UNKNOWN			
		Colchicine	C
UNKNOWN			
		Benzonatate	C
UNKNOWN			

Date:04/01/05ISR Number: 4625550-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00753
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Disability	Atrial Fibrillation
Other	Blood Pressure Increased
	Brain Stem Infarction
	Chest Discomfort
	Convulsion
	Death
	Depressed Level Of
	Consciousness
	Depression
	Fall
	Gastrointestinal
	Haemorrhage
	Normal Pressure
	Hydrocephalus
	Respiratory Failure

Sinus Bradycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Plavix	C		ORAL		
	Ginkgo Biloba Forte	C		ORAL		
	Imdur	C		ORAL		
	Imdur	C		ORAL		
	Norvasc	C		ORAL		
	Trazodone Hydrochloride	C		ORAL		
	Metoprolol	C		ORAL		
	Lysine	C		ORAL		
	Lanoxin	C		ORAL		
	Lasix (Furosemide)	C		ORAL		
	Xanax	C		ORAL		
	Ultram	C		ORAL		
	Humulin 70/30	C		SUBCUTANEOUS		
	Humulin 70/30	C		SUBCUTANEOUS		
	Avandia	C		ORAL		
	Aspirin	C		ORAL		
	Pravachol	C		ORAL		
	Sonata	C		ORAL		
	Paxil	C		ORAL		
	Prevacid	C		ORAL		

Date:04/01/05ISR Number: 4625551-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Abnormal Dreams
Other	Activated Partial Thromboplastin Time Prolonged
	Acute Sinusitis
	Adverse Event
	Amenorrhoea
	Amnesia
	Angina Pectoris
	Antithrombin Iii Increased

Aphthous Stomatitis
Arthralgia
Asthenia
Atelectasis
Atrial Septal Defect
Blood Pressure Abnormal
Blood Pressure Increased
Breast Pain
Breast Tenderness
Bronchitis Acute
Bursitis
Cardiac Disorder
Cerebrovascular Accident
Chest Pain
Coagulopathy
Computerised Tomogram
Abnormal
Condition Aggravated

Conjunctival Haemorrhage
Contusion
Convulsion
Cyst
Deep Vein Thrombosis
Diarrhoea
Difficulty In Walking
Disease Recurrence
Dizziness
Drug Abuser
Drug Dependence
Dry Throat
Dyshidrosis
Dysmenorrhoea
Dyspnoea
Dysstasia
Eczema
Embolic Stroke
Emotional Distress
Endometriosis
Epistaxis
Fall
Fatigue
Feeling Cold
Feeling Hot And Cold
Flushing
Fungal Infection
Gastroenteritis Viral
Generalised Oedema
Headache
Hearing Impaired
Hemiparesis
Hip Arthroplasty
Hip Fracture
Hodgkin'S Disease
Hypercoagulation
Hyperhidrosis
Hypoaesthesia
Hypothyroidism
Increased Tendency To
Bruise
Infarction
Ingrowing Nail
Inguinal Hernia
Injury
Laryngitis
Localised Infection

Loss Of Libido
Lung Infiltration
Mastitis
Memory Impairment
Menorrhagia
Migraine
Mobility Decreased
Mucous Membrane Disorder
Munchausen'S Syndrome
Muscle Atrophy
Muscle Spasms
Musculoskeletal
Discomfort
Nausea

		Neck Mass					
		Nervousness					
		Oligomenorrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Otitis Externa		Vioxx	SS	Merck & Co., Inc	ORAL
		Otitis Media		Vioxx	SS	Merck & Co., Inc	ORAL
		Ovarian Cyst					
		Ovarian Enlargement					
		Pain					
		Pain In Extremity					
		Pain In Jaw					
		Palpitations					
		Panic Attack					
		Panic Disorder					
		Paraesthesia					
		Patent Ductus Arteriosus					
		Pelvic Pain					
		Peripheral Embolism					
		Pharyngitis					
		Photophobia					
		Post Procedural Complication					
		Protein C Decreased					
		Protein S Decreased					
		Prothrombin Level Increased					
		Pyrexia					
		Rash					
		Renal Disorder					
		Rhinitis Allergic					
		Scar					
		Sinus Disorder					
		Sinus Operation					
		Sinusitis					
		Skin Nodule					
		Splenic Cyst					
		Swelling					
		Systemic Lupus Erythematosus					
		Thinking Abnormal					
		Thrombotic Stroke					
		Tinnitus					
		Tooth Disorder					
		Tooth Extraction					
		Transient Ischaemic Attack					

Upper Respiratory Tract
Infection
Urinary Tract Infection
Urine Abnormality
Vaginal Mycosis
Vaginitis Bacterial
Viral Infection
Viral Upper Respiratory
Tract Infection
Vision Blurred
Visual Acuity Reduced
Visual Field Defect
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625552-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02579
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
Hospitalization - RESPIRATORY	Cardio-Respiratory Arrest		Albuterol	C		
Initial or Prolonged (INHALATION)	Chronic Obstructive					
Disability UNKNOWN	Pulmonary Disease		Verapamil	C		
	Decreased Appetite					
	Gastritis					
	Hyponatraemia					
	Myocardial Infarction					
	Pneumonia Aspiration					
	Pulmonary Oedema					
	Weight Decreased					

Date:04/01/05ISR Number: 4625553-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00781
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 3 MON	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abdominal Pain					
Other	Acute Myocardial					
	Infarction					
	Angina Unstable					
	Blood Pressure Increased					
	Chest Pain					
	Chronic Obstructive					
	Pulmonary Disease					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Diverticulitis					
	Ejection Fraction					
	Decreased					
	Fatigue					
	Hypertensive Heart					
	Disease					
	Hypothyroidism					

Ischaemic Stroke
Left Ventricular
End-Diastolic Pressure
Increased
Lower Respiratory Tract
Infection
Mitral Valve
Calcification
Mitral Valve Incompetence
Myocardial Infarction
Nasopharyngitis
Pericardial Effusion
Pulmonary Congestion
Pulmonary Hypertension
Renal Failure
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Dysfunction
Ventricular Hypokinesia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625554-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03891
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Tofranil	C				
UNKNOWN								
	Cerebrovascular Accident		Plavix	C				
UNKNOWN								
	Chest Pain		Synthroid	C				
UNKNOWN								
	Dizziness		Norvasc	C				
UNKNOWN								
	Dyspnoea		Prempro	C				
UNKNOWN								
	Fatigue		Strovite	C				
UNKNOWN								
	Gastrointestinal Motility		Aspirin	C		ORAL		
	Disorder		Librium	C				
UNKNOWN								
	Headache							
	Hypercholesterolaemia							
	Hypertriglyceridaemia							
	Insomnia							
	Lacunar Infarction							
	Memory Impairment							
	Mitral Valve Incompetence							
	Morbid Thoughts							
	Presbyacusis							
	Tricuspid Valve							
	Incompetence							
	Upper Respiratory Tract							
	Infection							
	Vertigo							
	Vertigo Positional							

Date:04/01/05ISR Number: 4625555-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625556-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625557-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Speech Disorder		Prednisone	C		ORAL		
1083 DAY								
Disability	Thalamic Syndrome		Amitriptyline Hydrochloride	C		ORAL		
30 DAY								

Date:04/01/05ISR Number: 4625558-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625559-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hemiplegia							
	Impaired Work Ability							

Date:04/01/05ISR Number: 4625560-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03094
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	19	DAY
	Aortic Valve Replacement		Vioxx	SS	Merck & Co., Inc	ORAL	19	DAY
	Carotid Artery Disease		Insulin Human,					
	Coronary Artery Disease		Isophane	C			SUBCUTANEOUS	
			Enalapril Maleate	C		ORAL		
			Lipitor	C		ORAL		
			Atenolol	C		ORAL		

Date:04/01/05ISR Number: 4625561-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625562-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00176
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lactic Acidosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Renal Failure		Lisinopril	SS		ORAL		
			Amlodipine Besylate	SS		ORAL		
			Radiographic					

		Contrast Medium (Unspecified)	SS	
UNKNOWN				
		Metformin Hydrochloride	SS	ORAL

Date:04/01/05ISR Number: 4625563-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/01/05ISR Number: 4625564-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625565-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625567-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05106
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Dehydration Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625568-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05057
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chronic Obstructive		Advair	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Disease		Singulair	C				
UNKNOWN								
	Emphysema		Buspar	C				
UNKNOWN								

Date:04/01/05ISR Number: 4625569-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
12 MON								
	Myocardial Infarction							

Date:04/01/05ISR Number: 4625571-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	748	DAY

Date:04/01/05ISR Number: 4625572-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/01/05ISR Number: 4625573-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05166
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Hypertension		Metoprolol	C			UNKNOWN	
	Renal Disorder		Coreg	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/01/05ISR Number: 4625574-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	23 MON	

Date:04/01/05ISR Number: 4626929-7Report Type:Direct Company Report #CTU 245058
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx 25 Mg	PS		ORAL	25 MG X 2 ORAL	

Date:04/04/05ISR Number: 4626058-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02539
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Distension
Hospitalization -	Acidosis
Initial or Prolonged	Aortic Aneurysm
Disability	Aortic Valve Incompetence
	Atrioventricular Block
	Complete
	Back Disorder
	Basilar Artery Stenosis
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diplopia

Embolism
Heart Rate Irregular
Hepatic Congestion
Hepatic Necrosis
Hypercalciuria
Hypoaesthesia
Hypoaesthesia Oral
Hypotension
Injury
Intestinal Infarction
Mitral Valve Incompetence
Myocardial Infarction
Nephritis Interstitial
Pain
Palpitations
Pleural Effusion
Renal Tubular Necrosis
Sinus Bradycardia
Splenic Infarction
Thromboembolic Stroke
Transient Ischaemic
Attack

Tricuspid Valve
Incompetence
Ventricular Dysfunction
Ventricular Fibrillation
Ventricular Hypertrophy

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Prilosec	C			UNKNOWN	
	Hydrochlorothiazide	C			UNKNOWN	

Date:04/04/05ISR Number: 4626059-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00723
Age:60 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Other

PT
Abdominal Pain
Angina Pectoris
Aortic Valve Sclerosis
Asthenia
Atelectasis
Blood Lactate Dehydrogenase Decreased
Blood Triglycerides Increased
Carotid Artery Disease
Cerebellar Infarction
Cerebrovascular Accident
Chest Wall Pain
Colonic Polyp
Convulsion
Drug Ineffective
Dysarthria
Ejection Fraction Decreased
Exostosis
Facial Palsy
Fall
Fatigue
Haematocrit Decreased
Haemoptysis
Haemorrhoids
Hemiparesis
High Density Lipoprotein Decreased
Hypercholesterolaemia

Hyperlipidaemia
Hypertension
Hypoaesthesia
Hyponatraemia
Intermittent Claudication
Intervertebral Disc Space
Narrowing
Leukocytosis
Low Density Lipoprotein
Increased
Lung Consolidation
Lung Infiltration
Malaise
Mitral Valve Incompetence
Muscle Spasms
Pain In Extremity
Paraesthesia
Pleurisy

	Pneumonia						
	Polyp Colorectal						
	Renal Cyst	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sensory Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL	
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tricuspid Valve		Wygesic Tablets	C			UNKNOWN
	Incompetence		Ultram	C			UNKNOWN
			Blood Thinner (Unspecified)	C			UNKNOWN

Date:04/04/05ISR Number: 4626066-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04020
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
	Carotid Artery Stenosis		Ecotrin	C		ORAL	
	Cerebrovascular Accident		Glucotrol Xl	C		ORAL	
	Chest Pain		Avandia	C		ORAL	
	Coronary Artery Disease		Lipitor	C		ORAL	
	Coronary Artery Occlusion		Lipitor	C		ORAL	
	Diabetic Nephropathy		Atenolol	C		ORAL	
	Dyspnoea		Folic Acid	C		ORAL	
	Mitral Valve Incompetence		Glyburide	C		ORAL	
	Myocardial Ischaemia		Nexium	C		ORAL	
	Ventricular Dysfunction		Isosorbide				
	Ventricular Tachycardia		Mononitrate	C		ORAL	
	Viral Upper Respiratory Tract Infection						

Date:04/04/05ISR Number: 4626068-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02901
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL	

			Unspecified]	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Nexium	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						

Date:04/04/05ISR Number: 4626069-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02100
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Lasix (Furosemide)	C				
UNKNOWN								
Initial or Prolonged	Blood Urea Increased		Lipitor	C				
UNKNOWN								
	Cardiac Murmur		Neurontin	C				
UNKNOWN								
	Cerebrovascular Accident		A.S.A.	C				
UNKNOWN								
	Heart Rate Irregular							
	Nervous System Disorder							
	Sleep Apnoea Syndrome							
	Spinal Column Stenosis							
	Spinal Osteoarthritis							
	Weight Decreased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4626070-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		2 MON
Disability	Arterial Stenosis		Premarin	C		ORAL		
Other	Arthralgia		Zocor	C				UNKNOWN
	Atelectasis		Voltaren	C		ORAL		
	Atherosclerosis		Flexeril	C		ORAL		
	Back Pain		Guaifenesin And Pseudoephedrine Hydrochloride	C		ORAL		
	Buttock Pain							
	Cardiac Disorder							
	Chest Pain		Amoxicillin	C				UNKNOWN
	Corneal Abrasion		Pravachol	C				UNKNOWN
	Coronary Artery Disease		Lopid	C		ORAL		
	Depression							
	Dysphonia							
	Headache							
	Intervertebral Disc Protrusion							
	Muscle Spasms							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Neck Injury							
	Neck Pain							
	Pain In Extremity							
	Pyrexia							
	Rotator Cuff Syndrome							
	Tendonitis							
	Ventricular Extrasystoles							

Date:04/04/05ISR Number: 4626076-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02468
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		40 DAY

Initial or Prolonged	Adverse Event	Tylenol	C	
UNKNOWN				
Other	Blood Urea Increased	Lipitor	C	
UNKNOWN				
	Bundle Branch Block Left	Triamterene	C	
UNKNOWN				
	Dilatation Atrial	Hydrodiuril	C	
UNKNOWN				
	Disease Recurrence	Atenolol	C	ORAL
	Duodenal Ulcer	Clorazepate		
	Emotional Distress	Monopotassium	C	
UNKNOWN				
	Gastrooesophageal Reflux	Roxicet	C	
UNKNOWN				
	Disease	Fosamax	C	ORAL
	Pain			
	Peptic Ulcer			
	Upper Gastrointestinal			
	Haemorrhage			
	Ventricular Hypertrophy			
	White Blood Cell Count			
	Increased			

Date:04/04/05ISR Number: 4626078-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04749
Age:21 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Exposure During Pregnancy		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626079-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03027
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 2 YR	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure Congestive							
	Chest Pain							
	Diabetes Mellitus Inadequate Control							
	Fatigue							
	Hypertension							
	Musculoskeletal Discomfort							
	Pericardial Effusion							
	Pharyngeal Oedema							
	Pharyngolaryngeal Pain							

Date:04/04/05ISR Number: 4626082-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04748
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cervical Vertebra Injury		[Therapy Unspecified]	C				
	Dizziness							
UNKNOWN	Essential Tremor							
	Head Deformity							
	Head Injury							

Date:04/04/05ISR Number: 4626084-3Report Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626085-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03909
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	116 DAY	
Disability	Dilatation Ventricular		Valium	C			UNKNOWN	
	Extrasystoles		Allegra-D	C			UNKNOWN	
	Heart Rate Increased		Claritin-D	C			UNKNOWN	
	Pain		Prevacid	C			UNKNOWN	
	Palpitations		Acetaminophen	C			UNKNOWN	
			Guaifenex G	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Zithromax	C			UNKNOWN	
			Levaquin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4626088-0Report Type:Expedited (15-DaCompany Report #NL-MERCK-0503NLD00040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/04/05ISR Number: 4626089-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02101
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bruxism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Acupril	C			UNKNOWN	
	Diabetic Neuropathy		Insulin	C			UNKNOWN	
	Headache		Pepcid	C			UNKNOWN	
	Hepatitis C		Tylenol With Codeine #3	C		ORAL	6	HR
	Intervertebral Disc		Amoxicillin	C		ORAL	10	DAY
	Protrusion							
	Muscle Spasms							
	Musculoskeletal Disorder							
	Radiculopathy							
	Rotator Cuff Syndrome							
	Tendonitis							
	Transient Ischaemic Attack							

Date:04/04/05ISR Number: 4626495-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Angina Pectoris
Disability	Anxiety
	Aortic Stenosis
	Appetite Disorder

Arterial Occlusive
Disease
Arthralgia
Atherosclerosis
Atrioventricular Block
First Degree
Blood Pressure Decreased
Cardiac Disorder
Cardiac Murmur
Carotid Bruit
Chest Discomfort
Chest Pain
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Dizziness
Dyspepsia
Dyspnoea
Electrocardiogram T Wave
Abnormal
Fatigue
Femoral Arterial Stenosis
Femoral Bruit
Gastric Disorder

		Gastrooesophageal Reflux Disease					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
112	DAY						
		Iliac Artery Stenosis		Propranolol Hydrochloride	C		
		Insomnia					
UNKNOWN							
		Intermittent Claudication		Darvocet-N	C		
UNKNOWN							
		Liver Function Test Abnormal					
		Mitral Valve Stenosis					
		Myocardial Infarction					
		Pain					
		Paralysis					
		Peripheral Vascular Disorder					
		Rectal Haemorrhage					
		Soft Tissue Haemorrhage					
		Thrombosis					
		Weight Fluctuation					

Date:04/04/05ISR Number: 4626498-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00533
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Coagulopathy		Diclofenac Sodium	SS		ORAL
Disability		Muscle Spasms		Valdecoxib	SS		
UNKNOWN							
Other		Pulmonary Embolism		Magnesium (Unspecified)	C		
		Syncope					
UNKNOWN							
		Thrombosis		Nebivolol Hydrochloride	C		
UNKNOWN							
				Budesonide And Formoterol Fumarate	C		
RESPIRATORY							
(INHALATION)							

Date:04/04/05ISR Number: 4626500-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02696
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Depression							
	Disability							
	Myocardial Infarction							
	Pericarditis							
	Stent Occlusion							
	Ventricular Dysfunction							

Date:04/04/05ISR Number: 4626501-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00035
Age:80 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Atrioventricular Block
Hospitalization - Initial or Prolonged	Complete
	Blood Creatinine Increased
	Bradyarrhythmia

		Hypertension Myocardial Infarction					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Eprosartan	C		ORAL

Date:04/04/05ISR Number: 4626502-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acute Myocardial		Hyzaar	C		
UNKNOWN							
Disability		Infarction		Interferon			
		Arthralgia		(Unspecified)	C		
UNKNOWN							
		Biliary Colic		Phenergan			
		Blood Glucose Increased		(Promethazine			
		Bronchitis		Hydrochloride)	C		
UNKNOWN							
		Cardiac Failure		Oxycontin	C		
UNKNOWN							
		Congestive		Percocet	C		
UNKNOWN							
		Cardiac Valve Disease		Valium	C		
UNKNOWN							
		Chest Pain		Claritin	C		
UNKNOWN							
		Confusional State		Hyzaar	C		
UNKNOWN							
		Coordination Abnormal		Ascriptin	C		ORAL
		Coronary Artery Disease		Altace	C		ORAL
		Depressed Level Of		Atenolol	C		ORAL
		Consciousness		Zocor	C		ORAL
		Dysarthria		Lortab	C		ORAL
		Dyspnoea		Nexium	C		
UNKNOWN							
		Generalised Oedema					
		Hepatic Fibrosis					
		Hepatitis C					
		Hepatosplenomegaly					
		Hypertension					
		Hypokalaemia					

Hypoxia
Injury
Insomnia
Intervertebral Disc
Displacement
Intervertebral Disc
Protrusion
Joint Injury
Myocardial Infarction
Myocardial Ischaemia
Somnolence
Therapy Non-Responder
Weight Increased

Date:04/04/05ISR Number: 4626504-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00346
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Rash		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ventricular Tachycardia		Interferon Alfa-2a	C				
PARENTERAL								1641 DAY
Disability			Levothyroxine Sodium	C		ORAL		
Other			Glyburide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4626507-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626508-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02399
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Hearing Disability							
	Myocardial Infarction							

Date:04/04/05ISR Number: 4626509-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00415
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Clostridial Infection		Atenolol Msd	C				
UNKNOWN								
Disability	Colitis							
	Depression							
	Fall							
	Loss Of Consciousness							

Date:04/04/05ISR Number: 4626510-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04934
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Chronic Obstructive		Zantac	C				
UNKNOWN								
Hospitalization -	Pulmonary Disease		[Therapy					
Initial or Prolonged	Gastrointestinal		Unspecified]	C				
UNKNOWN								

Disability Haemorrhage

Date:04/04/05ISR Number: 4626511-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05241
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Myocardial Infarction		Altace	C				
UNKNOWN								
Initial or Prolonged			Lanoxin	C				
UNKNOWN								
Disability			Furosemide	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:04/04/05ISR Number: 4626512-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02035
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Epistaxis		Lipitor	C				
UNKNOWN								
	Prothrombin Time Prolonged		[Therapy Unspecified]	C				
UNKNOWN								
	Pruritus		Coumadin	C				
UNKNOWN								
			Warfarin	C				
UNKNOWN								

				Bumex	C		ORAL
				Potassium Chloride	C		ORAL
				Doxazosin Mesylate	C		ORAL
				Lanoxin	C		
UNKNOWN							
				Erythromycin Stearate	C		
UNKNOWN							

Date:04/04/05ISR Number: 4626513-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		821 DAY
Initial or Prolonged	Speech Disorder		Amitriptyline Hydrochloride	C		ORAL		30 DAY
Disability	Thalamic Syndrome							
			Prednisone	C		ORAL		1083 DAY

Date:04/04/05ISR Number: 4626514-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident							
	Difficulty In Walking							
	Dizziness							
	Hypoaesthesia							
	Myocardial Infarction							

Date:04/04/05ISR Number: 4626515-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05269
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Embolism							

Date:04/04/05ISR Number: 4626516-0Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0503ZAF00005
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626517-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:04/04/05ISR Number: 4626518-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00274
Age:61 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Aspartate Aminotransferase Increased							
	Autoimmune Thyroiditis							
	Blood Alkaline Phosphatase Increased							
	Cerebrovascular Accident							
	Depression							
	Hepatic Enzyme Increased							
	Hypothyroidism							
	Iron Deficiency							
	Psoriasis							
	Renal Failure							
	Syncope							

Date:04/04/05ISR Number: 4626519-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Embolism							

Date:04/04/05ISR Number: 4626520-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626521-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Cardiac Disorder					
	Cardiovascular Disorder					
	Death					
	Organ Failure					
	Pain					

Date:04/04/05ISR Number: 4626522-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00146
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626523-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00148
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1188 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4626524-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05274
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626525-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00015
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Haemorrhage		Feldene	SS				
UNKNOWN								
Initial or Prolonged			Verapamil	C				
UNKNOWN								
Disability			Lisinopril-Bc	C				
UNKNOWN								
			Theophylline	C				
UNKNOWN								

Date:04/04/05ISR Number: 4626526-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4626528-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00149
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/04/05ISR Number: 4628293-6Report Type:Expedited (15-DaCompany Report #2004223216FR
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Pulmonary Oedema	Foreign	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
	Hypertension	Health Professional						
			Rofecoxib (Rofecoxib)	SS			(200 MG)	
			Aldactazine (Altizide, Spironolactone)	C				
			Gliclazide (Glicazide)	C				

Date:04/04/05ISR Number: 4628646-6Report Type:Expedited (15-DaCompany Report #WAES 0406GBR00245
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Electrocardiogram St Segment Depression
	Haemoglobin Decreased
	Low Density Lipoprotein

Increased
Myocardial Ischaemia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Other						
					PO	35 DAY
	Omeprazole	C				

Date:04/04/05ISR Number: 4628653-3Report Type:Expedited (15-DaCompany Report #WAES 0503USAO3318
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged	Congestive	Health					MG/DAILY/PO	
	Hypoxia	Professional	Infusion (Form)					
	Pleural Effusion		Cisplatin 60 Mg/M[2]	SS			INTRAVENOUS	60
	Pneumonia						MG/M[2]/Q3W/I	
							V	
			Infusion (Form) Etoposide 120 Mg/M[2]	SS			INTRAVENOUS	120
							MG/M[2]/IV	
			Lanoxi	C				

Date:04/04/05ISR Number: 4628654-5Report Type:Expedited (15-DaCompany Report #WAES 0503USA03318
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure	Study	Tab Vioxx 25 Mg	PS		ORAL	25	

Initial or Prolonged		Congestive	Health			
MG/DAILY/PO						
		Hypoxia	Professional	Infusion(Form)		
		Pleural Effusion		Cisplatin 60 Mg/M[2]	SS	
INTRAVENOUS	60					
		Pneumonia				
MG/M[2]/Q3W/I						
V						
				Infusion (Form)		
				Etoposide 120		
				Mg/M[2]	SS	
INTRAVENOUS	120					
MG/M[2]/IV						
				Lanoxin	C	

Date:04/04/05ISR Number: 4629047-7Report Type:Direct Company Report #CTU 245147
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Impaired Work Ability		Vioxx - Merck	PS	Merck	
25MG 2						
Hospitalization -	Myocardial Infarction					
TIMES/DAY						
Initial or Prolonged						
Disability						
Required						
Intervention to						
Prevent Permanent						
Impairment/Damage						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4629062-3Report Type:Direct Company Report #CTU 245197
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS			25MG & 12.5MG	
Hospitalization - Initial or Prolonged	Dyspnoea							
Required Intervention to Prevent Permanent Impairment/Damage	Mitral Valve Repair							
	Respiratory Distress							
	Triple Vessel Bypass Graft							

Date:04/04/05ISR Number: 4629066-0Report Type:Direct Company Report #CTU 245187
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS			1 X DAILY	
Hospitalization - Initial or Prolonged								
Disability								
Required Intervention to Prevent Permanent Impairment/Damage								

Date:04/04/05ISR Number: 4629188-4Report Type:Direct Company Report #CTU 245170
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriogram Abnormal		Vioxx	PS			AS DIRECTED	
Hospitalization -	Cardiac Stress Test						BY DOCTOR	
Initial or Prolonged	Abnormal		Bextra	SS				
Disability	Computerised Tomogram		Femine Pads	C				
Other	Abnormal		Syringes For Insulin	C				
Required Intervention to	Coronary Artery Disease							
	Dialysis							

Prevent Permanent Impairment/Damage	Gastrooesophageal Reflux Disease Goitre Hypertension Impaired Healing Insulin-Requiring Type Ii Diabetes Mellitus Ischaemia Myocardial Infarction Neck Mass Peripheral Vascular Disorder Renal Failure Chronic Salivary Gland Neoplasm Thyroid Cyst Thyroid Mass Thyroid Neoplasm Vascular Graft Occlusion

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/04/05ISR Number: 4629240-3Report Type:Direct Company Report #CTU 245127
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS			.25 MG ONCE A	Initial or Prolonged

DAY

Date:04/05/05ISR Number: 4626901-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthroscopy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum		Coumadin	C				
UNKNOWN								
	Dizziness							
	Ecchymosis							
	Emotional Distress							
	Facial Pain							
	Hypertension							
	Hypoaesthesia							
	Inflammation							
	Injury							
	Intervertebral Disc							
	Disorder							
	Ligament Sprain							
	Limb Injury							
	Loose Body In Joint							
	Monoparesis							
	Musculoskeletal Chest							
	Pain							
	Non-Cardiac Chest Pain							
	Oedema Peripheral							
	Pain							
	Pain In Extremity							
	Peripheral Embolism							
	Pyrexia							

Renal Failure
Rheumatoid Arthritis
Sciatic Nerve Injury
Testicular Cyst

Date:04/05/05ISR Number: 4626903-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02824
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL		
			Theo-Dur	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Potassium Chloride	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Estrogens					

	(Unspecified)	C	UNKNOWN
	Avapro	C	UNKNOWN
	Zonegran	C	UNKNOWN
	Magnesium (Unspecified)	C	UNKNOWN

Date:04/05/05ISR Number: 4626904-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00715
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Serzone	C				UNKNOWN
	Anaemia		Fiorinal	C				UNKNOWN
	Angina Pectoris		Prevacid	C				UNKNOWN
	Chest Discomfort		Lipitor	C				UNKNOWN
	Chest Pain		Zanaflex	C				UNKNOWN
	Convulsion		Depoestradiol	C				UNKNOWN
	Coronary Artery Disease		Ecotrin	C				UNKNOWN
	Drug Ineffective		Colace	C				UNKNOWN
	Dysphagia		Cardizem	C				UNKNOWN
	Fibromyalgia		Serzone	C				UNKNOWN
	Gastritis		Neurontin	C				UNKNOWN
	Gastrooesophageal Reflux		Elavil	C				UNKNOWN
	Disease		Ativan	C				UNKNOWN
	Haemorrhoids		Aggrenox	C				UNKNOWN
	Hypertension		Deptran (Doxepin					

	Hypoaesthesia	Hydrochloride)	C
UNKNOWN			
	Infectious Mononucleosis	Estrace	C
UNKNOWN			
	Intervertebral Disc	Vicodin Tablets	C
UNKNOWN			
	Degeneration		
	Left Ventricular		
	End-Diastolic Pressure		
	Increased		
	Liver Disorder		
	Lymphadenopathy		
	Memory Impairment		
	Migraine		
	Mitral Valve Incompetence		
	Multi-Organ Disorder		
	Muscle Spasms		
	Night Sweats		
	Pain		
	Pancreatitis		
	Platelet Count Decreased		
	Pneumonia		
	Pulmonary Oedema		
	Pyoderma Gangrenosum		
	Pyrexia		
	Renal Failure		
	Renal Tubular Necrosis		
	Respiratory Disorder		
	Respiratory Failure		
	Vasculitis		
	Vision Blurred		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4626905-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00043
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriosclerosis Cerebral Infarction Hypertension Macroangiopathy Refusal Of Treatment By Patient		Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

Date:04/05/05ISR Number: 4626906-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00218
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx Nebivolol Hydrochloride Hypericin Risedronate Sodium	PS C C C	Merck & Co., Inc	ORAL ORAL ORAL ORAL		

Date:04/05/05ISR Number: 4626908-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0503GBR00202
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Headache Memory Impairment Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4626912-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4626913-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04900
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:04/05/05ISR Number: 4626914-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4626915-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4626916-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	929	DAY

Date:04/05/05ISR Number: 4626917-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00005
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Dyskinesia		Desloratadine	SS		ORAL	150	DAY
	Feeling Abnormal		Azithromycin	SS		ORAL	3	DAY
	Nausea		Oxcarbazepine	SS		ORAL	90	DAY

Date:04/05/05ISR Number: 4626918-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02716
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Abscess Limb Alopecia Angina Pectoris Arthritis Bacterial Benign Prostatic Hyperplasia Cardiac Murmur Chronic Obstructive Pulmonary Disease Diabetes Mellitus Diabetic Foot Diabetic Neuropathy Diarrhoea Diastolic Dysfunction Dry Throat		Vioxx	PS	Merck & Co., Inc	ORAL		

Electrocardiogram St-T
Change
Erectile Dysfunction
Exostosis
Fatigue
Hypertension
Microalbuminuria
Necrotising Fasciitis
Oedema Peripheral
Osteomyelitis
Osteopenia
Phimosis
Testicular Atrophy
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Ventricular Hypertrophy
Visual Disturbance

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4626919-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4626920-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:04/05/05ISR Number: 4626933-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	11	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	11	MON

Date:04/05/05ISR Number: 4626934-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4626935-2Report Type:Expedited (15-DaCompany Report #DK-MERCK-0504DNK00001
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Initial or Prolonged	Vioxx	SS	Merck & Co., Inc	ORAL	3 YR
	Vioxx	SS	Merck & Co., Inc	ORAL	1 YR
	Vioxx	SS	Merck & Co., Inc	ORAL	3 YR
	Glimepiride	C		ORAL	
	Sulfasalazine	C		ORAL	

Date:04/05/05ISR Number: 4626937-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00211
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4627433-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adjustment Disorder
Disability	Angina Pectoris
	Angina Unstable
	Anxiety
	Aspiration
	Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased

	Cardiac Arrest Chest Pain Coronary Artery	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	297 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	297 DAY
	Depression		Aspirin	SS			UNKNOWN
	Dysthymic Disorder		Plavix	SS			UNKNOWN 1 YR
	Emotional Distress		Heparin	SS			INTRAVENOUS
	Gastritis		Monopril	C			UNKNOWN
	Haematoma		Metoprolol	C			UNKNOWN
	Hypertension		Lipitor	C			UNKNOWN
	Intervertebral Disc		Niacin	C			UNKNOWN
	Protrusion Lethargy Lumbar Radiculopathy		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN
	Myocardial Infarction		Zoloft	C			UNKNOWN
	Upper Gastrointestinal		Vicodin Tablets	C			UNKNOWN 339 DAY
	Haemorrhage		Celebrex	C			UNKNOWN
	Ventricular Fibrillation						

Date:04/05/05ISR Number: 4627434-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00264
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN
			Prevacid	C			
Disability			Ranitidine	C			UNKNOWN

				Nexium	C		
UNKNOWN							

Date:04/05/05ISR Number: 4627435-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4627436-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4627437-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00003
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1010 DAY	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Sotalol Hydrochloride	C		ORAL		
			Aspirin And Magnesium Oxide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4627439-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00026
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
	Feeling Abnormal		Protonix	C				
UNKNOWN								

Date:04/05/05ISR Number: 4627449-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00116
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/05/05ISR Number: 4627456-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00245
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Aortic Dilatation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Cyanocobalamin And Folic Acid And Pyridoxine Hydrochloride	C				
Disability	Goitre							
	Headache							
	Hepatic Steatosis							
UNKNOWN								
	Intervertebral Disc		Piretanide	C				
UNKNOWN								
	Disorder		Pravastatin Sodium	C				
UNKNOWN								
	Intervertebral Disc							
	Operation							
	Pancreas Lipomatosis							
	Pulmonary Embolism							
	Renal Lipomatosis							
	Spinal Disorder							

Date:04/05/05ISR Number: 4627457-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00456
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Hospitalization - Initial or Prolonged	Gastric Neoplasm		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Gastritis Erosive		[Therapy Unspecified]	C			UNKNOWN	
	Myocardial Infarction		Metoprolol Succinate	C			UNKNOWN	
			Simethicone	C			UNKNOWN	
			Metoclopramide	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	
			Citalopram Hydrobromide	C			UNKNOWN	
			Piretanide	C			UNKNOWN	
			Lercanidipine	C			UNKNOWN	
			Fosinopril Sodium	C			UNKNOWN	

Date:04/05/05ISR Number: 4629474-8Report Type:Expedited (15-DaCompany Report #2005048095
Age:51 YR Gender:Female I/FU:I

Outcome	PT
Disability	Dizziness
	Dyskinesia
	Feeling Abnormal

Nausea

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Foreign Health Professional	Azitromax (Azithromycin)	PS		ORAL	500 MG (1 IN 1 D), ORAL	
	Desloratadine (Desloratadine)	SS		ORAL	5 MG (1 IN 1 D), ORAL	
	Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (1 IN 1 D), ORAL	
	Oxcarbazepine (Oxcarbazepine)	SS		ORAL	300 MG (1 IN 2 D), ORAL	

Date:04/06/05ISR Number: 4628031-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00213
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON	
Hospitalization - Initial or Prolonged	Myocardial Infarction Polytraumatism							
Disability								

Date:04/06/05ISR Number: 4628034-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628035-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02633
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		[Therapy					
Initial or Prolonged	Congestive		Unspecified]	C				
UNKNOWN								
Disability	Dyspnoea		[Therapy					
Other	Heart Rate Decreased		Unspecified]	C				
UNKNOWN								
	Vomiting		Celebrex	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

Date:04/06/05ISR Number: 4628037-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01535
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure
Hospitalization -	Fluctuation
Initial or Prolonged	Blood Pressure
Disability	Inadequately Controlled
	Cardiac Failure
	Epistaxis
	Hypersensitivity
	Influenza Like Illness
	Myocardial Infarction
	Pharyngolaryngeal Pain

		Pneumonia					
		Rash Erythematous					
		Rash Pruritic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
18	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
18	DAY						
				Diltiazem Msd	C		
UNKNOWN							

Date:04/06/05ISR Number: 4628038-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00221
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/06/05ISR Number: 4628607-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00801
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Adverse Event
	Angina Pectoris
	Anxiety
	Aortic Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis
	Bundle Branch Block
	Cardiac Failure Congestive
	Cardiomyopathy
	Carotid Artery Stenosis
	Cervicobrachial Syndrome
	Cholecystitis Acute
	Conjunctivitis Allergic
	Coronary Artery Disease
	Depression
	Dermatitis Allergic

Dermatitis Atopic
Diarrhoea
Femoral Artery Occlusion
Gastritis
Gastrooesophageal Reflux
Disease
Hypertension
Hypokinesia
Intervertebral Disc
Degeneration
Irritable Bowel Syndrome
Lung Neoplasm
Metabolic Encephalopathy
Mitral Valve Incompetence
Myocardial Infarction
Peripheral Vascular
Disorder
Pulmonary Hypertension
Rash
Rhinitis Allergic
Sexual Dysfunction

	Sleep Disorder						
	Staphylococcal Infection						
	Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	
	Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Celebrex	C			UNKNOWN
			Nexium	C			UNKNOWN

Date:04/06/05ISR Number: 4628612-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 81 DAY	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Antiphospholipid Syndrome		Advil	C		ORAL	
	Asthenia		Prempro	C			UNKNOWN
	Back Disorder		Prilosec	C			UNKNOWN
	Balance Disorder		Synthroid	C			UNKNOWN
	Blood Pressure Increased		Diovan	C			UNKNOWN
	Cerebrovascular Accident		Dimethyl Sulfone	C			UNKNOWN
	Convulsion		Gaviscon Antacid				
	Diabetes Mellitus		Tablets	C			UNKNOWN
	Non-Insulin-Dependent		Hydrocodone				
	Dizziness		Hydrochloride	C			UNKNOWN
	Drug Hypersensitivity		[Therapy				
	Gastrooesophageal Reflux		Unspecified]	C		ORAL	
	Disease						
	Hemiparesis						
	Ischaemia						
	Labyrinthitis						
	Muscle Spasms						

Neck Injury
Tinnitus
Tongue Ulceration
Transient Ischaemic
Attack
Urticaria Generalised
Vasculitis

Date:04/06/05ISR Number: 4628614-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02613
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Coumadin	C				
UNKNOWN								
Disability								
Other								

Date:04/06/05ISR Number: 4628615-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00730
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arthralgia
Other	Blood Pressure Increased

	Clavicle Fracture						
	Contusion						
	Convulsion	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Costochondritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Interaction		Prilosec	C				UNKNOWN
	Headache		[Therapy					
	Intervertebral Disc		Unspecified]	C				UNKNOWN
	Disorder							
	Migraine With Aura							
	Muscle Spasms							
	Musculoskeletal Pain							
	Neck Injury							
	Orthopnoea							
	Pyrexia							
	Radicular Syndrome							
	Road Traffic Accident							
	Scintillating Scotoma							
	Visual Disturbance							

Date:04/06/05ISR Number: 4628616-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03446
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Norvasc	C				UNKNOWN
Disability	Polytraumatism							

Date:04/06/05ISR Number: 4628617-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00905
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Celebrex	C				UNKNOWN
Disability	Coronary Artery Disease		Ativan	C				UNKNOWN

UNKNOWN	Fatigue	Cardizem	C
UNKNOWN	Fibromyalgia	Premarin	C
UNKNOWN	Hypertension	Propulsid	C
UNKNOWN	Joint Crepitation	Phenobarbital	C
UNKNOWN	Joint Stiffness	Prevacid	C
UNKNOWN	Muscle Spasms	Fibro Malic	C
UNKNOWN	Muscle Tightness	Minipress	C
UNKNOWN	Myocardial Infarction	Dimethyl Sulfone	C
UNKNOWN	Night Sweats	Prozac	C
UNKNOWN	Peptic Ulcer	Salagen Tablets	C
UNKNOWN	Sleep Disorder	Ascorbic Acid	C
UNKNOWN	Ulcer	Vitamin E	C
UNKNOWN	Vomiting	Darvocet-N	C
UNKNOWN		Restoril	C
UNKNOWN		Estratest	C
UNKNOWN		Evoxac	C
UNKNOWN		Monopril	C
UNKNOWN		Nitro-Bid	C
UNKNOWN		Ambien	C
UNKNOWN		Reglan	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/05ISR Number: 4628620-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00035
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Eprosartan	C		ORAL		
Initial or Prolonged	Atrioventricular Block							
	Complete							
	Blood Creatinine							
	Increased							
	Bradyarrhythmia							
	Hypertension							
	Myocardial Infarction							

Date:04/06/05ISR Number: 4628622-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00007
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypoaesthesia		Metoprolol Tartrate	C		ORAL		
	Muscular Weakness		Insulin, Neutral	C				
RESPIRATORY								
	Myocardial Infarction							
(INHALATION)								
	Pupillary Light Reflex		Insulin, Biphasic					
	Tests Abnormal		Isophane [Injection]	C				
UNKNOWN								
			Insulin, Biphasic					
			Isophane [Injection]	C				
UNKNOWN								
			Prednisolone	C				
UNKNOWN								
			Leflunomide	C				
UNKNOWN								
			Mevacor	C				
UNKNOWN								
			Omega-3 Marine					
			Triglycerides	C		ORAL		
			Aspirin And					
			Magnesium Oxide	C				
UNKNOWN								
			Nitroglycerin	C				
UNKNOWN								

Date:04/06/05ISR Number: 4628627-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02528
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anxiety
	Aortic Valve Incompetence
	Aspartate Aminotransferase Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Coronary Artery Disease
	Depression
	Fatigue
	Fear
	Hypertension
	Joint Injury
	Low Density Lipoprotein Increased
	Mitral Valve Incompetence
	Muscle Spasms
	Oedema Peripheral

Osteoarthritis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Prostata	C			UNKNOWN	
	Herbs (Unspecified)	C			UNKNOWN	
	Protonix	C			UNKNOWN	
	Motrin	C			UNKNOWN	
	Advil	C			UNKNOWN	
	Mylanta & Mylanta Ds	C			UNKNOWN	

Date:04/06/05ISR Number: 4628628-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628629-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04147
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628630-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628631-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628636-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1919 DAY
	Myocardial Infarction							
	Thrombosis							

Date:04/06/05ISR Number: 4628637-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/05ISR Number: 4628638-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628640-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03807
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Heart Rate Irregular		Lotrel	C				
Initial or Prolonged UNKNOWN	Sensation Of Heaviness		Hydrochlorothiazide	C				

Date:04/06/05ISR Number: 4628641-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628642-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05208
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia Gait Disturbance Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/06/05ISR Number: 4628668-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03738
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
	Escherichia Infection							
	Hypertension							
	Medication Error							
	Urosepsis							

Date:04/06/05ISR Number: 4630719-9Report Type:Expedited (15-DaCompany Report #WAES 0503DEU00208
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia	Foreign	Tab Vioxx Unk	PS		ORAL	25 MG DAILY	
Initial or Prolonged	Hemiparesis	Study					PO	
	Psychotic Disorder	Health	Tab 0663-Blinded					
	Transient Ischaemic	Professional	Therapy	SS		ORAL	PO	
	Attack		Tab Blinded Therapy	SS		ORAL	PO	
			Prednisolone	C				
			Sulfasalazine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/06/05ISR Number: 4631109-5Report Type:Direct Company Report #CTU 245431
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arterial Occlusive Disease Cardiovascular Disorder		Vioxx	PS				

Date:04/07/05ISR Number: 4629295-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00161
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Ischaemic Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1749 DAY	

Date:04/07/05ISR Number: 4631245-3Report Type:Direct Company Report #CTU 245609
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS			25 MG OVER A YEAR OR SO	

Date:04/07/05ISR Number: 4631457-9Report Type:Expedited (15-DaCompany Report #2005050275
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness Faeces Discoloured	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Other	Haematochezia Haemoglobin Decreased		Acetylsalicylic Acid (Acetylsalicylic Acid0	SS		ORAL	ORAL	

	Haemorrhage		Rofecoxib			
	Ulcer		(Rogecoxib)	SS		ORAL
ORAL						
			Atorvastatin (Atorvastatin)	C		
			Multiple Vitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Retinol, Tocopherol, Vitamin	C		
			Fluconazole (Fluconazole)	C		
			Ramipril (Ramipril)	C		
			Bactrim (Sulfamethoxazole, Trimethoprim)	C		

Date:04/08/05ISR Number: 4629903-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00005
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Paralysis		Hyaluronic Acid	C		
UNKNOWN			Warfarin Sodium	C		
UNKNOWN			Cyanocobalamin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4629904-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01727
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Gastrooesophageal Reflux Disease Irritable Bowel Syndrome Mitral Valve Incompetence Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4629905-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4629906-5Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00004
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1202 DAY	
Initial or Prolonged	Loss Of Consciousness		Acetaminophen	C			UNKNOWN	
			Bisoprolol Fumarate	C			UNKNOWN	
			Verapamil Hydrochloride	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Fluticasone Propionate And Salmeterol Xinafoate	C			UNKNOWN	
			Singulair	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	

				Adalimumab	C		
UNKNOWN							

Date:04/08/05ISR Number: 4629907-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:04/08/05ISR Number: 4629908-9Report Type:Expedited (15-DaCompany Report #IS-MERCK-0503DNK00027
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Testosterone Propionate	C				
PARENTERAL								

Date:04/08/05ISR Number: 4629909-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00162
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Glucose Increased Blood Pressure Increased Cerebral Atrophy Cerebrovascular Accident Hemiparesis Microangiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4629910-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00477
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Difficulty In Walking Hypotension		[Therapy Unspecified]	C				UNKNOWN
Disability	Lung Infection Malaise Myocardial Infarction		Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
			Darvocet-N	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:04/08/05ISR Number: 4629911-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05077
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		[Therapy Unspecified]	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:04/08/05ISR Number: 4629912-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		821 DAY
Initial or Prolonged	Overdose		Amitriptyline					
Disability	Speech Disorder		Hydrochloride	C		ORAL		30 DAY
	Thalamic Syndrome		Prednisone	C		ORAL		1083 DAY

Date:04/08/05ISR Number: 4629914-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation

		Cerebral Infarction					
		Hypersensitivity					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lacunar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
643	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Valsartan	C		ORAL
				Furosemide	C		ORAL
				Equilin Sodium			
				Sulfate And Estrone			
				Sodium Sulfate	C		ORAL
				Allopurinol	C		ORAL

Date:04/08/05ISR Number: 4629916-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00482
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/08/05ISR Number: 4629963-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02632
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomegaly		Oxycontin	C		ORAL
Disability	Coronary Artery Stenosis		Oxycontin	C		ORAL
Other	Diabetes Mellitus		Oxycontin	C		
UNKNOWN						
	Non-Insulin-Dependent		Vicodin Tablets	C		ORAL
	Hypertension		Vicodin Tablets	C		ORAL
	Myocardial Infarction		Neurontin	C		
UNKNOWN	15 DAY					
	Road Traffic Accident		Neurontin	C		
UNKNOWN	22 DAY					
	Visual Disturbance		Celebrex	C		
UNKNOWN						

Date:04/08/05ISR Number: 4629974-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00005
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1241 YR
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		1241 YR
Other			Tamsulosin Hydrochloride	C				
UNKNOWN								

Date:04/08/05ISR Number: 4629977-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00047
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		605 DAY
	Coronary Artery Disease							
	Dyspnoea Exertional							
	Hypertension							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4629978-8Report Type:Expedited (15-DaCompany Report #US-MERCK-00072405
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Duodenal Ulcer							
	Gastritis							
	Upper Gastrointestinal Haemorrhage							

Date:04/08/05ISR Number: 4629979-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00245
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Dilatation		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Constipation		Cyanocobalamin And Folic Acid And Pyridoxine Hydrochloride	C				UNKNOWN
	Depression							
	Disease Recurrence							
	Goitre							
	Headache		Piretanide	C				UNKNOWN
	Hepatic Steatosis		Pravastatin Sodium	C				UNKNOWN
	Intervertebral Disc Disorder							
	Intervertebral Disc Operation							
	Intervertebral Disc Protrusion							
	Pancreas Lipomatosis							
	Pulmonary Embolism							
	Renal Lipomatosis							
	Spinal Disorder							

Date:04/08/05ISR Number: 4629980-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00233
Age:43 YR Gender:Male I/FU:F

Outcome PT

Life-Threatening Hospitalization - Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Glucose Increased Carotid Artery Stenosis Chest Pain Deep Vein Thrombosis Dyspnoea Electrocardiogram P Wave Abnormal Fibrin D Dimer Decreased Gastrooesophageal Reflux Disease Hepatic Steatosis Hypercoagulation Hyperhidrosis Hypertension International Normalised Ratio Increased Muscle Spasms Nausea Non-Cardiac Chest Pain Palpitations Pulmonary Embolism

		Restlessness Sinus Tachycardia Supraventricular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Vomiting		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Niaspan	C		
UNKNOWN							

Date:04/08/05ISR Number: 4629984-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02313
Age:36 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
3	WK						
Other		Macular Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
4	WK						
		Prescribed Overdose Retinal Vein Occlusion		Vitamins (Unspecified)	C		
UNKNOWN							

Date:04/08/05ISR Number: 4629989-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02753
Age:48 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening Hospitalization - Initial or Prolonged Disability		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/08/05ISR Number: 4629996-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00499
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:04/08/05ISR Number: 4629997-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	666	DAY

Date:04/08/05ISR Number: 4630011-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00692
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630012-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00693
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630088-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00401
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		190 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Tagamet	C				UNKNOWN
	Chest Pain		Zantac	C		ORAL		
	Coronary Artery Restenosis							
	Coronary Artery Stenosis							
	Dyspnoea							
	Hypokinesia							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Sleep Apnoea Syndrome							
	Tachycardia							
	Tricuspid Valve Incompetence							
	Ventricular Extrasystoles							

Date:04/08/05ISR Number: 4630089-6Report Type:Expedited (15-DaCompany Report #CH-MERCK-0504CHE00006
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm Ruptured		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Tamponade		Tamsulosin Hydrochloride	C		ORAL		
Initial or Prolonged	Myocardial Infarction		Flupentixol Hydrochloride And Melitracen Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		

Date:04/08/05ISR Number: 4630090-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00548
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630091-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630092-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4630093-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00694
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630094-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01597
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Wall Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetic Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
	Displacement		Insulin	C				
UNKNOWN								
	Myocardial Ischaemia		Lisinopril	C				
UNKNOWN								
	Peroneal Nerve Palsy							
	Radiculopathy							
	Retinopathy							

Date:04/08/05ISR Number: 4630095-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00691
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630096-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Adverse Event Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/08/05ISR Number: 4630099-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630163-4Report Type:Expedited (15-DaCompany Report #IT-MERCK-0503ITA00021
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Acute Myocardial Infarction Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4630507-3Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547915A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Ecotrin Adult Low Strength Tablets	PS	Glaxosmithkline	ORAL	81MG Per day	6 YR
	First Degree							
	Azotaemia		Celebrex	SS		ORAL		
	Chest Pain		Vioxx	SS		ORAL		
	Dizziness		Bextra	SS				
	Dyspepsia		Avandia	C	Glaxosmithkline	ORAL	8MG Per day	
	Faeces Discoloured		Lipitor	C		ORAL	40MG Per day	
	Gastric Ulcer Haemorrhage		Multiple Vitamin	C		ORAL		
	Haemoglobin Decreased		Fluconazole	C		ORAL	200MG cumulative dose	
	Headache							
	Hyperhidrosis							
	Rectal Haemorrhage		Altace	C		ORAL	2.5MG Per day	
	Volume Blood Decreased		(Trimethoprim + Sulfamethoxazol)	C	Glaxosmithkline	ORAL	1 YR	
			Atenolol	C			50MG Per day	
			Vitamin E	C			400UD Per day	
			Trazodone	C			400MG At night	
			Tylenol Arthritis	C	Glaxosmithkline			
			Levitra	C				

Date:04/08/05ISR Number: 4630564-4Report Type:Expedited (15-DaCompany Report #PHNU2005DE00547
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Co-Diovan	PS	Novartis Sector:			

Initial or Prolonged	Increased					Pharma	ORAL
1 DF, QD							
	Infection		Vioxx	SS			
UNK, UNK							
	Nephritis Interstitial		Prednisolon	SS			ORAL
1 DF, QD							
	Pyrexia		Acetylsalicylic Acid	C			ORAL
1 DF, QD							
			Diovan	C			ORAL
0.5 DF, QD							
			Allopurinol	C			ORAL
			Sortis	C			ORAL
1 DF, QD							
			Concor	C			ORAL
1 DF, QD							

Date:04/08/05ISR Number: 4630574-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01506
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Gastrointestinal Disorder		Ultram	C		
UNKNOWN						
	Gastrooesophageal Reflux		Tarka	C		
UNKNOWN						
	Disease		Xanax	C		
UNKNOWN						
	Haemorrhage		Trazodone			
	Hypertension		Hydrochloride	C		
UNKNOWN						
	Hypoaesthesia		Evista	C		
UNKNOWN						
	Incontinence		Oxytrol	C		
UNKNOWN						
	Nerve Compression					
	Paraesthesia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4630580-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00565
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630583-8Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00087
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Hospitalization - Initial or Prolonged	Coma		Fluindione	SS		ORAL		
	Drug Interaction		Candesartan Cilexetil	C		ORAL		
	Fall		Cifenline Succinate	C		ORAL		
			Metoprolol	C		ORAL		
			Metoprolol	C		ORAL		
			Zocor	C		ORAL		
			Allopurinol	C		ORAL		
			Terbutaline Sulfate	C		RESPIRATORY (INHALATION)		

Date:04/08/05ISR Number: 4630590-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630592-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00701
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630593-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4630599-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00720
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							

Date:04/08/05ISR Number: 4630693-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00630
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL		
361 DAY								
Initial or Prolonged	Chest Pain		Nitroglycerin	C				
UNKNOWN								
Other	Deep Vein Thrombosis		Coumadin	C				
UNKNOWN								
	Pulmonary Embolism							

Date:04/08/05ISR Number: 4631239-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		482 DAY
Initial or Prolonged	Chest Pain		Celebrex	C				UNKNOWN
Other	Coronary Artery Disease							
	Coronary Artery Reocclusion							
	Haematocrit Decreased							
	Haematoma							
	Hypercholesterolaemia							
	Injury							
	Myocardial Infarction							
	Post Procedural Complication							

Date:04/08/05ISR Number: 4631242-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Accident At Home
Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
Disability	Angina Pectoris
Other	Anxiety
	Atrial Septal Defect
	Balance Disorder
	Bipolar Disorder
	Borderline Personality Disorder
	Bradycardia
	Breast Pain
	Bursitis
	Cardiac Aneurysm
	Cardiac Failure Congestive
	Cardiomegaly
	Cellulitis
	Cerebral Infarction

Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Death
Diverticulum
Drug Abuser
Drug Dependence
Dyspnoea
Emotional Distress
Fibromyalgia
Haemorrhoids
Headache
Hyperkalaemia
Hypertrophy Breast
Hyponatraemia
Injury
Intermittent Claudication
Intracranial Aneurysm

		Lacunar Infarction					
		Leukocytosis					
		Limb Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Major Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Obsessive-Compulsive		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Overdose		Aspirin	C		
UNKNOWN		668 DAY					
		Pain		Coumadin	C		
UNKNOWN							
		Pain In Extremity		Coumadin	C		
UNKNOWN							
		Pollakiuria		Coumadin	C		
UNKNOWN		96 DAY					
		Pulmonary Hypertension		Neurontin	C		
UNKNOWN							
		Spinal Osteoarthritis		Vicodin Tablets	C		
UNKNOWN							
		Suicidal Ideation		Seroquel	C		
UNKNOWN							
		Transient Ischaemic		Ativan	C		
UNKNOWN							
		Attack		Ativan	C		
UNKNOWN							
		Tricuspid Valve		Monopril	C		ORAL
		Incompetence		Norvasc	C		
UNKNOWN							
		Upper Respiratory Tract		Lithium Carbonate	C		ORAL
		Infection		Lithium Carbonate	C		ORAL
		Varices Oesophageal		Zyprexa	C		ORAL
		Ventricular Dysfunction		Zyprexa	C		ORAL
		Weight Increased		Zithromax	C		ORAL
4	DAY						
				Navane	C		ORAL
				Cogentin	C		ORAL
				Tegretol-Xr	C		ORAL
				Claritin-D	C		
UNKNOWN							

Date:04/08/05ISR Number: 4631255-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02789
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							

Date:04/08/05ISR Number: 4631256-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01585
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	1598 DAY	
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL	1598 DAY	
	Disease		Synthroid	C			UNKNOWN	

Date:04/08/05ISR Number: 4631257-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00009
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4631258-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00070
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiovascular Disorder		Thalidomide	SS				
	Cough		Dexamethasone	C			UNKNOWN	
	Hypersensitivity		Zoledronate Disodium	C			UNKNOWN	
	Oedema Peripheral		Morphine Sulfate	C			UNKNOWN	
	Pain In Extremity							
	Phlebitis							
	Plasmacytoma							
	Polyneuropathy							
	Urticaria							

Date:04/08/05ISR Number: 4631259-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00005
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
			Etoricoxib	C		ORAL	3 MON	
			Ipratropium Bromide	C			RESPIRATORY (INHALATION)	
			Albuterol Sulfate	C			RESPIRATORY (INHALATION)	
			Salmeterol Xinafoate And Fluticasone Propionate	C			RESPIRATORY (INHALATION)	

Date:04/08/05ISR Number: 4631260-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00818
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Naproxen	C			UNKNOWN	
	Depression		Skelaxin	C			UNKNOWN	
	Disturbance In Attention		Flexeril	C			UNKNOWN	
	Emotional Distress		Theragesic	C			TOPICAL	
	Hypertension							
	Stress							

Date:04/08/05ISR Number: 4631268-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04529
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Asthenia
	Back Pain
	Cardiac Murmur
	Chest Discomfort
	Chest Pain
	Chest Wall Pain
	Dyspnoea
	Headache
	Hyperhidrosis
	Hypoaesthesia
	Migraine
	Mitral Valve Prolapse

	Musculoskeletal Discomfort						
	Myocardial Ischaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pleuritic Pain		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/08/05ISR Number: 4631270-2Report Type:Expedited (15-DaCompany Report #DK-MERCK-0504DNK00004
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	86 DAY
Hospitalization - UNKNOWN			Hydroxyurea	C			
Initial or Prolonged Disability							

Date:04/08/05ISR Number: 4631280-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00023
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Thrombocythaemia		Acetaminophen	SS		ORAL	
			Irbesartan	SS		ORAL	
			Fondaparinux Sodium	SS		SUBCUTANEOUS	
			Omeprazole	SS		ORAL	
			Iron (Unspecified)	SS		ORAL	

Date:04/08/05ISR Number: 4631281-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/08/05ISR Number: 4631282-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00195
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4631283-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00001
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Stem Ischaemia		Omeprazole	C		ORAL		
	Hypertension		Aspirin	C		ORAL		
	Microangiopathy							

Date:04/08/05ISR Number: 4631285-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4631286-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00412
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:04/08/05ISR Number: 4631287-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism		Celebrex	C		ORAL		

Date:04/08/05ISR Number: 4631288-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00567
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:04/08/05ISR Number: 4631289-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12 MON	
	Polytraumatism							

Date:04/08/05ISR Number: 4631290-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4631291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00595
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Initial or Prolonged	Hypertension Limb Injury Malaise							

Date:04/08/05ISR Number: 4631292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19 MON	

Date:04/08/05ISR Number: 4631304-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00696
Age: Gender:Male I/FU:I

Outcome	PT
Other	Arterial Occlusive Disease

Chest Pain

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4631305-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00700
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:04/08/05ISR Number: 4631306-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	171 DAY	

Date:04/08/05ISR Number: 4631307-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4631308-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON	
	Polytraumatism							

Date:04/08/05ISR Number: 4631309-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00762
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	16 MON	
Life-Threatening Hospitalization - UNKNOWN Initial or Prolonged Disability			[Therapy Unspecified]	C				

Date:04/08/05ISR Number: 4631311-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/08/05ISR Number: 4631332-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/08/05ISR Number: 4631356-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		254 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		254 DAY
Other	Bronchitis							
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cardiogenic Shock							
	Cardiomyopathy							
	Coronary Artery Disease							
	Hyperlipidaemia							
	Injury							
	Irritable Bowel Syndrome							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Oedema Peripheral							
	Pericarditis							
	Pneumonia							
	Sinusitis							
	Tricuspid Valve Incompetence							

Date:04/08/05ISR Number: 4633427-3Report Type:Expedited (15-DaCompany Report #2004118129
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Condition Aggravated	Consumer	Celebrex (Celecoxib)	PS				
Other	Drug Ineffective	Health	Rofecoxib					
	Nephropathy Toxic	Professional	(Rofecoxib)	SS				
	Pain		Nsaid'S (Nsaid'S)	SS				
	Renal Failure Chronic		Gabapentin (Gabapentin)	C				
			Sertraline Hydrochloride (Sertraline Hydrochloride)	C				

Date:04/08/05ISR Number: 4633428-5Report Type:Expedited (15-DaCompany Report #2005008465
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Celebrex (Celecoxib)	PS			400 MG (200 MG, 2 IN 1 D)	
	Knee Operation	Health Professional						
	Pain In Extremity		Rofecoxib (Rofecoxib)	SS				

Date:04/11/05ISR Number: 4632303-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Arthralgia
	Cerebrovascular Accident
	Drug Hypersensitivity
	Dyspnoea
	Emotional Distress
	Fall

	Gout						
	Hypoaesthesia						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Limb Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	55 DAY
	Meniscus Lesion		Zocor	C		ORAL	
	Pain In Extremity		Estrace	C			UNKNOWN
	Tendon Injury		Estrace	C			UNKNOWN
	Transient Ischaemic		Prilosec	C			UNKNOWN
	Attack		Lortab	C			UNKNOWN
	Trigeminal Neuralgia						
	Vaginal Infection						

Date:04/11/05ISR Number: 4632304-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02546
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	63 DAY
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL	
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL	63 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
	Electrocardiogram T Wave		Paxil	C			UNKNOWN
	Inversion		Motrin	C			UNKNOWN
	Emotional Distress		Aleve	C			UNKNOWN
	Hypertension		Tylenol	C			UNKNOWN
	Hypoaesthesia		Glyburide	C			UNKNOWN
	Hypokalaemia		Aspirin	C			UNKNOWN
	Injury		[Therapy				

	Mitral Valve Incompetence		Unspecified]	C		
UNKNOWN						
	Myocardial Ischaemia		Celebrex	C		
UNKNOWN						
	Nocturia					
	Pain In Extremity					
	Pulmonary Valve Incompetence					
	Renal Disorder					
	Rhabdomyolysis					
	Tricuspid Valve Incompetence					
	Varicose Vein					

Date:04/11/05ISR Number: 4632315-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00472
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Metoprolol	C		ORAL		
	Dizziness		Allopurinol	C		ORAL		
	Encephalopathy		Ibuprofen	C				
UNKNOWN								
	Lacunar Infarction							
	Polyneuropathy							
	Retinopathy Hypertensive							
	Spinal Osteoarthritis							
	Tinnitus							
	Visual Field Defect							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632319-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00828
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Chest Pain Chronic Obstructive Pulmonary Disease Cognitive Disorder Feeling Cold Gastric Disorder Heart Rate Increased Peptic Ulcer Haemorrhage Pulmonary Embolism Traumatic Brain Injury Viral Infection		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632320-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01010
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zestril	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Detrol La	C			UNKNOWN	

Date:04/11/05ISR Number: 4632324-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00065
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Stenosis		Prednisolone	C			UNKNOWN	
Initial or Prolonged	Haematoma		Bisoprolol Fumarate	C			UNKNOWN	

	Haemoglobin Decreased		Methotrexate	C		
PARENTERAL						
	Myocardial Infarction		Cilazapril And			
	Ventricular Arrhythmia		Hydrochlorothiazide	C		
UNKNOWN						

Date:04/11/05ISR Number: 4632325-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01434
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Blood Pressure Abnormal					
	Cerebrovascular Accident					
	Eye Disorder					
	Retinal Haemorrhage					

Date:04/11/05ISR Number: 4632326-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00871
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Norvasc	C		
UNKNOWN						
Initial or Prolonged			Atenolol	C		
UNKNOWN						
Disability						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632327-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632328-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02315
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Hospitalization -	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Renal Artery Occlusion		Lisinopril	C				UNKNOWN
Disability	Renal Impairment		Aciphex	C				UNKNOWN
Other	Weight Decreased							

Date:04/11/05ISR Number: 4632337-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00686
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				UNKNOWN
			Zoloft	C				UNKNOWN
			Premarin	C				UNKNOWN

Date:04/11/05ISR Number: 4632539-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
30 DAY						
Hospitalization -	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Epigastric Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
30 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Heparin	C		
PARENTERAL	24 DAY					
			Gabapentin	C		ORAL
			Esomeprazole			
			Magnesium	C		ORAL
882 DAY						

Date:04/11/05ISR Number: 4632549-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03573
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache		Aspirin	C		
UNKNOWN						
	Hypertension		Levoxyl	C		
UNKNOWN						
	Nail Infection		Diovan	C		
UNKNOWN						
	Pain In Extremity		Flexeril	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632550-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02587
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		661 DAY
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Toprol Xl Tablets	C				UNKNOWN
	Cardiac Enzymes Increased		Lipitor	C				UNKNOWN
	Dehydration		Ecotrin	C				UNKNOWN
	Dizziness							
	Fatigue							
	Gait Disturbance							
	Haematoma							
	Myocardial Infarction							
	Vertigo							

Date:04/11/05ISR Number: 4632552-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00283
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
	Left Ventricular Failure		Methotrexate	C		ORAL		
			Prednisolone	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C				UNKNOWN
			Celecoxib	C		ORAL		
			Fosamax	C		ORAL		
			Folic Acid	C		ORAL		

Date:04/11/05ISR Number: 4632553-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01785
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Duoneb	C
Initial or Prolonged UNKNOWN	Premarin	C
Disability UNKNOWN	Nexium	C
	Accolate	C
UNKNOWN		
	Advair	C
UNKNOWN		
	Clonazepam	C
UNKNOWN		

Date:04/11/05ISR Number: 4632556-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Polytraumatism Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632557-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03355
Age:24 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632558-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00336
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	7	MON
Initial or Prolonged	Arthritis Bacterial		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL	7	MON
	Back Pain		Prevacid	C		ORAL		
	Blood Pressure Increased		Atenolol	C		ORAL		
	Cardiac Failure		Miacalcin	C			UNKNOWN	
	Congestive		Fosamax	C		ORAL		
	Chest Pain		Celexa	C		ORAL		
	Chest Wall Pain		Levsin	C			UNKNOWN	
	Diarrhoea		Hydrodiuril	C		ORAL	19	DAY
	Difficulty In Walking		Vitamin D					
	Dizziness		(Unspecified)	C			UNKNOWN	
	Dyspnoea Exertional		Vitamins					
	Ear Infection		(Unspecified)	C			UNKNOWN	
	Ear Pruritus		Calcium					
	Fall		(Unspecified)	C			UNKNOWN	
	Fatigue		Percocet	C		ORAL		
	Haemorrhoids		Prinivil	C		ORAL		
	Headache		Lasix (Furosemide)	C		ORAL		
	Leukoplakia Oral		Lasix (Furosemide)	C			UNKNOWN	
	Oedema Peripheral		Norvasc	C		ORAL		
	Otorrhoea							
	Panic Attack							
	Renal Failure							
	Rib Fracture							
	Sinusitis							
	Skin Laceration							
	Urinary Tract Infection							
	Vertigo							
	Vision Blurred							

Date:04/11/05ISR Number: 4632559-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02145
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
	Feeling Abnormal							
	Heart Rate Increased							
	Muscle Spasms							
	Nausea							
	Speech Disorder							
	Tachycardia							

Date:04/11/05ISR Number: 4632563-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00162
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632564-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00968
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632565-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	34	MON

Date:04/11/05ISR Number: 4632566-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632567-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632568-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00487
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632569-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	44	MON

Date:04/11/05ISR Number: 4632573-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00006
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	3	MON

Date:04/11/05ISR Number: 4632574-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632579-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON
	Deep Vein Thrombosis							
	Myocardial Infarction							

Date:04/11/05ISR Number: 4632580-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Liver Disorder							

Date:04/11/05ISR Number: 4632581-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01061
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632582-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01091
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4632584-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	883	DAY

Date:04/11/05ISR Number: 4632585-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01099
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - OPHTHALMIC	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc			33 MON
Initial or Prolonged Other	Myocardial Infarction							

Date:04/11/05ISR Number: 4632586-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00978
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	WK

Date:04/11/05ISR Number: 4632588-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/11/05ISR Number: 4632603-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01049
Age:15 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/11/05ISR Number: 4634376-7Report Type:Expedited (15-DaCompany Report #2005051546
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	General Physical Condition Abnormal Renal Failure Acute Tubulointerstitial Nephritis	Foreign Literature Health Professional	Celecoxib (Celecoxib) Rofecoxib (Rofecoxib)	 PS SS				

Date:04/11/05ISR Number: 4635010-2Report Type:Expedited (15-DaCompany Report #2005053592
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Bextra (Valdecoxib) Rofecoxib (Rofecoxib)	PS SS				

Date:04/11/05ISR Number: 4635276-9Report Type:Expedited (15-DaCompany Report #2005025375
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200	
Initial or Prolonged	Abdominal Pain	Health					MG, 1 IN 1 D)	
Other	Anxiety	Professional					, ORAL	
	Condition Aggravated Diarrhoea		Rofecoxib (Rofecoxib)	 SS				

	Fibromyalgia	Pantoprazole (Pantoprazole)	C
	Gastric Disorder	Metoprolol (Metoprolol)	C
	Gastric Haemorrhage	Irbesartan (Irbasrtan)	C
	Gastric Ulcer	Hydrochlorothiazide (Hydrochlorothiazide)	C
	Gastritis	Loratadine (Loratadine)	C
	Gastrointestinal Haemorrhage		
	Malaise		
	Muscle Spasms		
	Nausea		
	Oesophageal Haemorrhage		
	Transient Ischaemic Attack		

Date:04/12/05ISR Number: 4632966-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04071
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
	Influenza		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Pain							
	Pneumonia							
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4632967-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00262
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Fall		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Hospitalization - Initial or Prolonged	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Imdur	C				
Disability			[Therapy Unspecified]	C			UNKNOWN	

Date:04/12/05ISR Number: 4632968-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04528
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Palpitations		Zestril	C				
			Atenolol	C			UNKNOWN	
			Zoloft	C			UNKNOWN	

Date:04/12/05ISR Number: 4632969-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00016
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Dizziness		Atenolol	C				
	Hallucination		Amlodipine Besylate	C			UNKNOWN	
	Nausea							

Date:04/12/05ISR Number: 4632970-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00031
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thyroid Disorder							

Date:04/12/05ISR Number: 4632971-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00048
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia							
	Cerebrovascular Accident							
	Dyspnoea							
	Headache							
	Hyperhidrosis							
	Immune System Disorder							
	Impaired Work Ability							
	Muscle Tightness							
	Oedema Peripheral							
	Oropharyngeal Swelling							
	Pain							
	Paraesthesia							
	Suffocation Feeling							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4632972-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00743
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Asthenia		Atenolol	C				
	Cerebrovascular Accident		A.S.A.	C			UNKNOWN	
	Ear Pain		Risperdal	C			UNKNOWN	
	Gait Disturbance		Risperdal	C			UNKNOWN	
	Oedema Peripheral		Triamcinolone	C			UNKNOWN	
	Pelvic Mass		Nitrolingual Spray	C			UNKNOWN	
	Squamous Cell Carcinoma		Synthroid	C			UNKNOWN	
	Of The Cervix		Synthroid	C			UNKNOWN	
	Tension Headache		Os-Cal D	C			UNKNOWN	
			Levothroid	C			UNKNOWN	
			Garlic-Active	C			UNKNOWN	
			Remeron	C			UNKNOWN	
			Remeron	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	
			Robitussin	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Fosamax	C		ORAL		

Fosamax	C		ORAL
Lipitor	C		
UNKNOWN			
Niacin	C		
UNKNOWN			
Rite Aid Therapeutic M	C		
UNKNOWN			
Levaquin	C		
UNKNOWN			
Advair	C		
UNKNOWN			
Ultram	C		
UNKNOWN			
Vitamins (Unspecified)	C		
UNKNOWN			

Date:04/12/05ISR Number: 4632974-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0504CHE00012
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc		UNKNOWN	3 YR
	Coronary Artery Thrombosis							

Date:04/12/05ISR Number: 4632975-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632977-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4632978-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632979-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632980-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632982-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4632988-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01013
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4633055-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01189
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Asthenia Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4633060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cor Pulmonale		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							
	Thrombosis							

Date:04/12/05ISR Number: 4633310-3Report Type:Expedited (15-DaCompany Report #2005020853
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract Operation	Consumer	Celebrex (Celecoxib)	PS				
	Drug Ineffective		Bextra (Valdecoxib)	SS				
	Throat Irritation		Rofecoxib (Rofecoxib)	SS				
			Alendronate Sodium (Alendronate Sodium)	C				

Date:04/12/05ISR Number: 4633378-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0212USA02514
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	11	DAY
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	11	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY

			Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						

Date:04/12/05ISR Number: 4633381-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02132
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction					

Date:04/12/05ISR Number: 4633382-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00416
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
			Ancillin	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						
			Insulin	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						

Date:04/12/05ISR Number: 4633383-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00130
Age:69 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	776	DAY
	Myocardial Infarction							
	Ventricular Fibrillation							

Date:04/12/05ISR Number: 4633384-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0503CHE00011
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction							
	Hemiplegia							

Date:04/12/05ISR Number: 4633385-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00496
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/12/05ISR Number: 4633405-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Peripheral Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged								

Date:04/12/05ISR Number: 4633406-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
4 YR							

Date:04/12/05ISR Number: 4633407-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
34 MON								
Initial or Prolonged	Cardiac Failure							

Date:04/12/05ISR Number: 4633408-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Coronary Ostial Stenosis							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4633409-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4633410-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4633411-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4633418-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:04/12/05ISR Number: 4633419-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Peripheral Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:04/12/05ISR Number: 4633421-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/12/05ISR Number: 4633422-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:04/12/05ISR Number: 4633423-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/05ISR Number: 4633424-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	General Symptom		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Malaise							
	Myocardial Infarction							
	Renal Disorder							

Date:04/12/05ISR Number: 4633432-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	45 MON	

Date:04/12/05ISR Number: 4633584-9Report Type:Direct Company Report #CTU 245893
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diverticulum Intestinal		Naproxen	PS			25 MG, 25 MG Required	
	Haemorrhagic		Rofecoxib	SS		ORAL	QD ORAL Intervention to Prevent Permanent Impairment/Damage	

Date:04/12/05ISR Number: 4634748-0Report Type:Direct Company Report #CTU 245889
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrointestinal		Vioxx 25 Mg	PS		ORAL	25 MG DAILY ORAL	
	Haemorrhage							

Required			Plavix 75 Mg	SS		ORAL
75 MG DAILY						
Intervention to						
ORAL						
Prevent Permanent			Maxide	C		
Impairment/Damage			Calcium	C		

Date:04/13/05ISR Number: 4634118-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0376952A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Deep Vein Thrombosis		Arixtra	PS	Glaxosmithkline	
SUBCUTANEOUS	2.5MG Per day					
Initial or Prolonged			Doliprane	SS	Glaxosmithkline	ORAL
1G Three						
times per day						
			Aprovel	SS		ORAL
150MG Per day						
			Vioxx	SS		ORAL
25MG Per day						
			Mopral	SS	Glaxosmithkline	ORAL
20MG Per day						
			Fumafer	SS	Glaxosmithkline	ORAL
1UNIT Three						
times per day						

Date:04/13/05ISR Number: 4634133-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00053
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Atrial Fibrillation
Hospitalization -	Gastric Ulcer
Initial or Prolonged	Gastric Ulcer Haemorrhage

Gastritis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Celecoxib	C			UNKNOWN	325 DAY
	Celecoxib	C		ORAL		
	Candesartan Cilexetil	C			UNKNOWN	
	Valdecoxib	C			UNKNOWN	
	Hydrochlorothiazide And Triamterene	C			UNKNOWN	
	Allopurinol	C			UNKNOWN	
	Atorvastatin Calcium	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Ginkgo Biloba Extract	C			UNKNOWN	

Date:04/13/05ISR Number: 4634138-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00017
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	SS		ORAL		
			Aspirin And Caffeine And Codeine Phosphate	C			UNKNOWN	
			Elavil	C			UNKNOWN	

Date:04/13/05ISR Number: 4634139-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05166
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Hypertension		Metoprolol	C			UNKNOWN	
	Renal Disorder		Coreg	C			UNKNOWN	
	Renal Failure Acute							

Date:04/13/05ISR Number: 4634141-0Report Type:Expedited (15-DaCompany Report #SE-MERCK-0502SWE00021
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction		Aspirin	C			UNKNOWN	
Disability	Cerebrovascular Accident		Cyanocobalamin	C			UNKNOWN	
			Calcium Pantothenate	C			UNKNOWN	
			Felodipine	C			UNKNOWN	

Date:04/13/05ISR Number: 4634142-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arrhythmia
	Arterial Restenosis
	Cardiac Failure

	Carotid Artery Stenosis						
	Demyelination						
	Dizziness	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Syncope		Aspirin	C		ORAL		
	Transient Ischaemic		Glyburide	C		ORAL		
	Attack		Magnesium Aspartate And Magnesium Citrate And Magnesium Glutamate And Magnesium	C				UNKNOWN
			Glyburide	C				UNKNOWN

Date:04/13/05ISR Number: 4634149-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01234
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arteriosclerotic		Glucotrol	C				UNKNOWN
	Retinopathy							
	Cerebrovascular Accident							

Date:04/13/05ISR Number: 4634150-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Myocardial Infarction							

Date:04/13/05ISR Number: 4634152-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03811
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged 2 MON	Amnesia	Vioxx	PS	Merck & Co., Inc	ORAL
	Arthralgia	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Arthropathy	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Asthenia	Vioxx	SS	Merck & Co., Inc	ORAL
	Blindness	Vioxx	SS	Merck & Co., Inc	ORAL
2 MON					
	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness				
	Dysgraphia				
	Hemiparesis				
	Hypertension				
	Knee Arthroplasty				
	Macular Degeneration				
	Mental Impairment				
	Prescribed Overdose				
	Transient Ischaemic Attack				
	Walking Disability				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634153-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	980	DAY

Date:04/13/05ISR Number: 4634154-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01071
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634160-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01043
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634163-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01044
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634198-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634490-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00487
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Atenolol	C		ORAL		
	Cerebrovascular Accident		Captopril	C		ORAL		
	Hemianopia Homonymous		Magnesium					
	Hypertensive Crisis		Pyridoxal-5'-Phosphate Glutamate	C				
	Ischaemic Stroke							
UNKNOWN								

Date:04/13/05ISR Number: 4634494-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Myocardial
Disability	Infarction
	Arthralgia
	Bronchitis
	Cardiac Failure
	Congestive
	Cardiac Valve Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain					
		Confusional State					
		Coordination Abnormal					
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery		Valium	SS		
UNKNOWN							
		Reocclusion		Claritin	C		
UNKNOWN							
		Dilatation Atrial		Hyzaar	C		
UNKNOWN							
		Dyspnoea		Hyzaar	C		
UNKNOWN							
		Fall		Ascriptin	C		ORAL
		Fibromyalgia		Atenolol	C		ORAL
		Hepatitis C		Lortab	C		ORAL
		Hepatosplenomegaly		Nexium	C		
UNKNOWN							
		Hypertension		Zocor	C		ORAL
		Hypokalaemia		Altace	C		ORAL
		Hypoxia		Interferon			
		Injury		(Unspecified)	C		
UNKNOWN							
		Intervertebral Disc		Phenergan			
		Displacement		(Promethazine			
		Joint Injury		Hydrochloride)	C		
UNKNOWN							
		Joint Range Of Motion		Oxycontin	C		
UNKNOWN							
		Decreased		Percocet	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Pulmonary Hypertension					
		Somnolence					
		Synovitis					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					

Date:04/13/05ISR Number: 4634498-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00265
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Dyspnoea Liver Disorder Tachyarrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634502-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01109
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diplegia		Vioxx	PS	Merck & Co., Inc	ORAL	6 YR	
Hospitalization -	Disability		Celebrex	C			UNKNOWN	
Initial or Prolonged	Fall		Zestril	C			UNKNOWN	
Disability	Hypertension		Zocor	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634503-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00632
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ibuprofen	C		ORAL	6	DAY
			Ibuprofen	C		ORAL	6	DAY

Date:04/13/05ISR Number: 4634504-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00236
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blue Toe Syndrome		[Therapy Unspecified]	C			UNKNOWN	
	Prescribed Overdose							

Date:04/13/05ISR Number: 4634514-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00497
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							

Date:04/13/05ISR Number: 4634515-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0502CHE00024
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						

Date:04/13/05ISR Number: 4634516-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00414
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		[Therapy			
Initial or Prolonged			Unspecified]	C		
UNKNOWN						
Disability						

Date:04/13/05ISR Number: 4634518-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00274
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased
Disability	Alcoholism
Other	Aspartate
	Aminotransferase
	Increased
	Autoimmune Thyroiditis
	Blood Alkaline
	Phosphatase Increased

Cerebrovascular Accident
Depression
Drug Abuser

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gamma-Glutamyltransferase					
	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Increased
Hepatic Enzyme Increased
Hypothyroidism
Iron Deficiency
Psoriasis
Renal Failure
Syncope
Syncope Vasovagal

Date:04/13/05ISR Number: 4634528-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01298
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON
Other	Optic Nerve Infarction							

Date:04/13/05ISR Number: 4634529-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Heart Injury		Celebrex	SS				
UNKNOWN							4	YR

Date:04/13/05ISR Number: 4634530-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04374
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tuberculosis							

Date:04/13/05ISR Number: 4634531-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01234
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Arteriosclerotic		Glucotrol	C				
UNKNOWN								
	Retinopathy		[Therapy					
	Cerebrovascular Accident		Unspecified]	C				
UNKNOWN								

Date:04/13/05ISR Number: 4634532-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease							
	Myocardial Infarction							
	Pain							
	Transient Ischaemic							
	Attack							

Date:04/13/05ISR Number: 4634533-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00964
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634534-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00014
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1570 DAY	
Initial or Prolonged	Syncope		Simvastatin	C			UNKNOWN	
			Cholecalciferol And Calcium Carbonate	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Warfarin Sodium	C			UNKNOWN	

Date:04/13/05ISR Number: 4634535-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	549 DAY	

Date:04/13/05ISR Number: 4634536-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03352
Age:17 YR Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634537-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:04/13/05ISR Number: 4634538-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02131
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Death	Anxiety
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Failure Congestive
	Cerebrovascular Accident
	Depression
	Diabetes Mellitus
	Heart Rate Irregular

	Hernia						
	Hypertension						
	Low Density Lipoprotein	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vasotec	C			UNKNOWN	
			Prozac	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	42 DAY
			Xanax	C			UNKNOWN	
			Pravachol	C			UNKNOWN	641 DAY
			Coumadin	C			UNKNOWN	75 DAY
			Lasix (Furosemide)	C			UNKNOWN	
			Avandia	C			UNKNOWN	
			Roxicodone	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

Date:04/13/05ISR Number: 4634539-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Myocardial Infarction							

Date:04/13/05ISR Number: 4634540-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00061
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Arrhythmia	Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder	Ibuprofen	C		ORAL
	Hypertension	Diclofenac	C		ORAL
	Myocardial Infarction	Diclofenac	C		
TOPICAL					
		Nitroglycerin	C		
UNKNOWN					
		Glimepiride	C		ORAL
		Metoprolol	C		ORAL
		Atorvastatin Calcium	C		ORAL

Date:04/13/05ISR Number: 4634541-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01302
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634543-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01308
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:04/13/05ISR Number: 4634552-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634553-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00966
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634554-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:04/13/05ISR Number: 4634555-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01299
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:04/13/05ISR Number: 4634556-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:04/13/05ISR Number: 4634558-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01306
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Other								

Date:04/13/05ISR Number: 4634559-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01311
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON

Date:04/13/05ISR Number: 4634568-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01301
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634569-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01310
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634570-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634571-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634572-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Coma Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25	MON

Date:04/13/05ISR Number: 4634574-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634575-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01585
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/13/05ISR Number: 4634587-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00925
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Feeling Abnormal Hypoaesthesia Oral Memory Impairment Pain In Extremity Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/13/05ISR Number: 4634588-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01614
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Fosinopril Sodium	C				
	Myocardial Infarction		Aspirin	C				
	Pain In Extremity		Zocor	C		ORAL		
			Plavix	C				

Date:04/13/05ISR Number: 4634700-5Report Type:Direct Company Report #CTU 246025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS				
Hospitalization -	Gastric Disorder							
Initial or Prolonged	Gastrointestinal Disorder							
Disability	Oesophageal Disorder							
Required Intervention to Prevent Permanent Impairment/Damage								

Date:04/13/05ISR Number: 4635782-7Report Type:Expedited (15-DaCompany Report #WAES 0503GBR00214
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris	Foreign	Tab Vioxx Unk	PS		ORAL		
Initial or Prolonged	Blood Potassium Decreased	Study	Acetaminophen (+)					
	Condition Aggravated	Health	Codeine Phosph	C				
	Haematocrit Decreased	Professional	Amlodipine Besylate	C				
	Haemoglobin Decreased		Aspirin	C				

	Mean Cell Haemoglobin Increased	Atenolol	C
		Atorvastatin Calcium	C
	Mean Cell Volume Increased	Bendroflumethiazide	C
		Cyanocobalamin	C
	Myocardial Ischaemia	Diazepam	C
	Pharmaceutical Product Complaint	Nitroglcyerin	C
		Potassium Chloride	C
	Red Blood Cell Count Decreased	Prednisolone	C
		Quinine	C
	Vascular Graft Occlusion	Sulfasalazine	C
	Vitamin B12 Deficiency	Trazodone Hydrochloride	C

Date:04/14/05ISR Number: 4634995-8Report Type:Expedited (15-DaCompany Report #200512465US
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Glucose Increased
	Cardiac Valve Disease
	Cerebrovascular Accident
	Infection
	Medication Error
	Pharmaceutical Product Complaint
	Pyrexia
	Viral Infection

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Lantus	PS	Aventis Pharmaceuticals Inc.	SUBCUTANEOUS	Dose unit: units	
	Opticlik (Insulin Injection Pen)	SS			dose: UNK	
	Vioxx	SS			dose: UNK	
	Some Type Of Insulin Nos	C			dose: UNK	
	Proventil	C			dose: UNK	
	Zocor	C				
	Synthroid	C				
	Actos	C			dose: 10-12.5	
	Zestril	C			dose: UNK	
	Plavix	C				
	Amaryl	C				
	Levaquin	C			dose: UNK	
	Namenda	C			dose: UNK	

Date:04/14/05ISR Number: 4635093-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01863
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Aortic Valve Incompetence		Paxil	C				
Other	Aortic Valve Sclerosis		Vitamins (Unspecified)	C			UNKNOWN	
	Blood Cholesterol							
	Increased Cardiac Disorder		Analgesic Or Anesthetic					

	Cardiac Murmur		(Unspecified)	C		
UNKNOWN						
	Cardiac Valve Disease		Pletal	C		
UNKNOWN						
	Chest Pain		Pravachol	C		ORAL
	Congestive Cardiomyopathy					
	Convulsion					
	Coronary Artery Disease					
	Deep Vein Thrombosis					
	Hypertension					
	Mitral Valve					
	Calcification					
	Mitral Valve Incompetence					
	Mitral Valve Sclerosis					
	Myocardial Infarction					
	Neck Pain					
	Peripheral Vascular					
	Disorder					
	Tooth Disorder					
	Tricuspid Valve					
	Incompetence					
	Ventricular Hypertrophy					
	Ventricular Hypokinesia					

Date:04/14/05ISR Number: 4635095-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Death					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635097-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02098
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Acute Myocardial Infarction		Prevacid	C			UNKNOWN	
			Ditropan	C			UNKNOWN	
	Asthenia		Triamterene	C			UNKNOWN	
	Back Injury		Quinine Sulfate	C			UNKNOWN	
	Benign Breast Neoplasm		Diuretic (Unspecified)	C			UNKNOWN	
	Blood Potassium Increased		Advil	C			UNKNOWN	
	Bronchitis		Naproxen	C			UNKNOWN	
	Carcinoma In Situ Of Skin		Tylenol	C			UNKNOWN	
	Chest Pain		Dyazide	C			UNKNOWN	
	Coronary Artery Disease		Asacol	C			UNKNOWN	
	Deep Vein Thrombosis		Quinidine	C			UNKNOWN	
	Diarrhoea		Z-Pak	C			UNKNOWN	
	Dizziness		Cipro	C			UNKNOWN	
	Drug Hypersensitivity							
	Emotional Distress							
	Enterocele							
	Fall							
	Gastrointestinal Infection							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hiatus Hernia							
	Hypoaesthesia							
	Osteoarthritis							
	Pulmonary Embolism							
	Radius Fracture							

Renal Failure Acute
Rotator Cuff Syndrome
Ulna Fracture
Urinary Tract Infection
Visual Disturbance

Date:04/14/05ISR Number: 4635109-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03077
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		870 DAY
Initial or Prolonged	Cerebrovascular Accident		Insulin	C				UNKNOWN
	Gastrointestinal		Synthroid	C				UNKNOWN
	Haemorrhage		Slow-Mag	C				UNKNOWN
	Transient Ischaemic		Humulin	C				UNKNOWN
	Attack		Pravachol	C				UNKNOWN
			Glucovance	C				UNKNOWN
			Climara	C				UNKNOWN
			Slow Fe	C				UNKNOWN
			Tums	C				UNKNOWN
			Ecotrin	C				UNKNOWN
			Ecotrin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635110-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03036
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tenormin	C			UNKNOWN	
			Coumadin	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	

Date:04/14/05ISR Number: 4635111-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635112-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635113-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01590
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635114-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635115-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	54	MON

Date:04/14/05ISR Number: 4635116-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01591
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635117-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01000
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	360	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635118-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635135-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635136-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635137-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635138-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01641
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635140-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635141-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635178-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01592
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635371-4Report Type:Expedited (15-DaCompany Report #2005055371
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Lipitor					
	Blood Cholesterol		(Atorvastatin)	PS		ORAL	10 MG (10 MG,	
	Increased						1 INI 1 D),	
	Blood Test Abnormal						ORAL	
	Contusion		Vioxx (Rofecoxib)	SS				
	Drug Effect Decreased		Irbesartan	C				
	Hypersensitivity		Amlodipine Besilate	C				
	Knee Arthroplasty		Nadolol	C				
	Limb Injury		Estrogens Conjugated	C				
	Muscle Atrophy		Levothyroxine Sodium	C				
	Tenderness		Furosemide	C				
			Tolterodine L-Tartrate	C				
			All Other Therapeutic Products	C				
			Glimepiride	C				
			Calcium Carbonate	C				
			Actylsalicylic Acid	C				

Date:04/14/05ISR Number: 4635526-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Acute Sinusitis
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Asthenia
	Barrett'S Oesophagus
	Benign Prostatic Hyperplasia
	Blood Pressure Increased
	Brain Oedema
	Bronchitis Acute
	Calculus Ureteric
	Central Nervous System Infection

Cerebellar Ataxia
Cerebellar Infarction
Cerebrovascular Accident
Coma
Constipation
Cough
Defaecation Urgency
Diplopia
Diverticulitis
Dizziness
Dysstasia
Dysuria
Epidermal Naevus
Erythema
Eye Irritation
Fall
Flank Pain
Gait Disturbance
Haematochezia
Haematospermia

		Haemorrhoidal Haemorrhage					
		Headache					
		Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Inflammation		Vioxx	PS	Merck & Co., Inc	ORAL
		Labyrinthitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Micturition Urgency		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Congestion		Prevacid	C		
UNKNOWN							
		Nausea		Allopurinol	C		
UNKNOWN							
		Nephrolithiasis					
		Nervous System Disorder					
		Nocturia					
		Nystagmus					
		Pallor					
		Phlebolith					
		Prostatism					
		Pyrexia					
		Reflexes Abnormal					
		Renal Colic					
		Renal Cyst					
		Renal Failure					
		Respiratory Rate					
		Increased					
		Sensation Of Pressure					
		Sinusitis					
		Terminal Dribbling					
		Tricuspid Valve					
		Incompetence					
		Vascular Calcification					
		Vertigo					
		Vomiting					

Date:04/14/05ISR Number: 4635536-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02139
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -				Aspirin	C		ORAL
6749 DAY							
Initial or Prolonged				[Therapy			

			Unspecified]	C		
UNKNOWN						
			Zocor	C		ORAL
2397 DAY						
			Ibuprofen	C		
UNKNOWN	3613 DAY					
			Naprosyn	C		
UNKNOWN	3613 DAY					

Date:04/14/05ISR Number: 4635537-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00364
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthenia		Metformin	C		
UNKNOWN						
	Blood Cholesterol		Humulin	C		
UNKNOWN						
	Increased		Levoxyl	C		
UNKNOWN						
	Cerebrovascular Accident					
	Chest Pain					
	Hypercholesterolaemia					
	Hypertension					
	Hypoaesthesia					

Date:04/14/05ISR Number: 4635547-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02081
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acquired Oesophageal Web
Hospitalization - Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Aptyalism
	Asthenia
	Atrial Flutter
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Chest Pain
	Constipation
	Contusion
	Coronary Artery Disease
	Decreased Activity
	Decreased Appetite
	Dyspepsia
	Fall
	Gastric Ulcer
	Gastritis
	Gastrooesophageal Reflux Disease
	Haematoma
	Haemorrhage Intracranial
	Headache
	Hiatus Hernia
	Hypertension
	Hypertensive Heart Disease
	Influenza
	Intervertebral Disc Degeneration
	Intervertebral Disc Disorder
	Intervertebral Disc Protrusion
	Joint Injury
	Lacunar Infarction
	Laxative Abuse
	Melanosis Coli
	Myocardial Infarction
	Myoclonus
	Nasal Sinus Drainage

Nausea
Neck Pain
Neuropathy Peripheral
Oedema Peripheral
Osteoarthritis
Pain
Pneumonia
Pruritus
Renal Failure
Rotator Cuff Syndrome
Sinusitis
Sleep Disorder
Spinal Osteoarthritis
Stomach Discomfort
Subdural Haematoma

	Tendonitis						
	Urinary Retention						
	Vasculitis Cerebral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Coumadin	SS				UNKNOWN
			Coumadin	SS				UNKNOWN

Date:04/14/05ISR Number: 4635559-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01174
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		50 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1253 DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		52 DAY
	Increased		Aspirin	C				UNKNOWN
	Blood Pressure Increased		Premarin	C				UNKNOWN
	Cerebrovascular Accident		Flexeril	C				UNKNOWN
	Chest Discomfort		Lovastatin	C				UNKNOWN
	Chest Pain		Lipitor	C				UNKNOWN
	Depression		Hydrochlorothiazide	C				UNKNOWN
	Dyspepsia		Prinivil	C				UNKNOWN
	Feeling Abnormal		Atenolol	C				UNKNOWN
	Hyperlipidaemia		Carbidopa	C				UNKNOWN
	Insomnia		Aggrenox	C				UNKNOWN

	Intestinal Polyp	Ambien	C
UNKNOWN			
	Mitral Valve Incompetence	Clonidine	C
UNKNOWN			
	Myalgia	Naproxen	C
UNKNOWN			
	Nausea	Potassium Chloride	C
UNKNOWN			
	Neck Pain	Trazodone	
	Pain In Extremity	Hydrochloride	C
UNKNOWN			
	Palpitations	Lorazepam	C
UNKNOWN			
	Panic Disorder	Cephalexin	C
UNKNOWN			
	Psoriasis	Diazepam	C
UNKNOWN			
	Renal Failure	Catapres	C
UNKNOWN			
	Restless Legs Syndrome		
	Sinus Bradycardia		
	Stress		
	Tachycardia		
	Transient Ischaemic		
	Attack		
	Tricuspid Valve		
	Incompetence		

Date:04/14/05ISR Number: 4635560-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02027
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Acute Prerenal Failure
	Acute Respiratory Failure
	Anxiety
	Arthritis
	Asthma
	Depression
	Heart Rate Increased

		Heart Rate Irregular					
		Hypothyroidism					
		Ingrowing Nail	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Nail Discolouration		Vioxx	SS	Merck & Co., Inc	ORAL
		Nodule		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pericardial Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Raynaud'S Phenomenon		Vasotec	C		
UNKNOWN							
		Respiratory Disorder		Glipizide	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Actos	C		
UNKNOWN							
		Tachycardia		Brethine	C		
UNKNOWN							
		Toe Deformity		Lasix (Furosemide)	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Altace	C		
UNKNOWN							

Date:04/14/05ISR Number: 4635562-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00549
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Death					

Date:04/14/05ISR Number: 4635563-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04467
Age:57 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Femur Fracture		[Therapy			

Pain Unspecified] C
UNKNOWN

Date:04/14/05ISR Number: 4635564-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02430
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged	Blood Sodium Decreased Dehydration							
Disability								

Date:04/14/05ISR Number: 4635565-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04062
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Rash		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Other			[Therapy Unspecified]	C				
UNKNOWN								

Date:04/14/05ISR Number: 4635566-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635568-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03337
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635578-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635579-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	1007 DAY	
Other								

Date:04/14/05ISR Number: 4635580-4Report Type:Expedited (15-DaCompany Report #DK-MERCK-0504DNK00010
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dementia		Vioxx	PS	Merck & Co., Inc	ORAL	576 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	165 DAY	
			Fosamax	C		ORAL		
			Tolterodine Tartrate	C		ORAL		
			Methotrexate	C		ORAL		

Date:04/14/05ISR Number: 4635581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	532	DAY
	Congestive Myocardial Infarction Pulmonary Oedema							

Date:04/14/05ISR Number: 4635582-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01538
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Haemorrhagic Stroke		Ibuprofen	C		ORAL		
	Hypertension		Ibuprofen	C		ORAL		
	Self-Medication		Aleve	C		ORAL		

Date:04/14/05ISR Number: 4635583-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01293
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635584-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01269
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:04/14/05ISR Number: 4635586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:04/14/05ISR Number: 4635587-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00701
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635588-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635589-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01374
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Glucophage	C				
Initial or Prolonged Disability								

Date:04/14/05ISR Number: 4635590-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635591-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635592-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01640
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635595-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635596-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635598-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01282
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:04/14/05ISR Number: 4635599-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635612-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	380	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4635627-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01656
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635628-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01655
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/14/05ISR Number: 4635629-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635630-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/14/05ISR Number: 4635631-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01615
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/14/05ISR Number: 4636514-9Report Type:Direct Company Report #CTU 246217
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS		ORAL	CAPSULE	
	Feeling Abnormal						DAILY ORAL	

Date:04/14/05ISR Number: 4636862-2Report Type:Expedited (15-DaCompany Report #2005CG00675
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis	Foreign	Mopral	PS		ORAL	20 MG QD PO	
Initial or Prolonged	Post Procedural	Health	Doliprane	SS		ORAL	1 G TID PO	
	Complication	Professional	Aprovel	SS		ORAL	150 MG QD PO	
		Other	Vioxx	SS		ORAL	25 MG QD PO	
			Arixtra	SS			SUBCUTANEOUS	1 DF QD SQ
			Fumafer	SS		ORAL	1 DF TID PO	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4635995-4Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12921656
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Aprovel Tabs 150 Mg	PS	Bristol-Myers Squibb Company	ORAL	SUBCUTANEOUS	
			Doliprane	SS				
			Vioxx	SS				
			Arixtra	SS				
			Mopral	SS				
			Fumafer	SS				

Date:04/15/05ISR Number: 4636109-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00790
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Joint Swelling		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Oedema Peripheral		[Therapy Unspecified]	C				
			Premarin	C			UNKNOWN	
			Provera	C			UNKNOWN	

Date:04/15/05ISR Number: 4636113-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636114-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0407CAN00027
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 97 DAY	Blood Magnesium Decreased	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Potassium Decreased Myalgia Myocardial Infarction				

Date:04/15/05ISR Number: 4636115-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01506
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Disability	Bladder Disorder
Other	Blood Pressure Abnormal Diarrhoea Dizziness Eating Disorder Gastrointestinal Disorder Gastrooesophageal Reflux Disease Haemorrhage Hypertension Hypoaesthesia Incontinence Nerve Compression Pain Paraesthesia Sleep Disorder Thyroid Disorder

Vomiting

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Ultram	C			UNKNOWN	
	Tarka	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Evista	C			UNKNOWN	
	Oxytrol	C			UNKNOWN	

Date:04/15/05ISR Number: 4636116-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acoustic Stimulation Tests Abnormal
Disability	Amnesia
Other	Arthralgia
	Asthenia
	Blindness Unilateral
	Chronic Fatigue Syndrome
	Clavicle Fracture
	Coccidioidomycosis
	Convulsion
	Dementia
	Drug Ineffective
	Dry Eye
	Dry Mouth
	Eczema Asteatotic
	Emotional Distress
	Encephalitis
	Endocarditis
	Fall
	Fibromyalgia
	Fracture

Gastrooesophageal Reflux
Disease
Grand Mal Convulsion
Headache
Hypoaesthesia
Incontinence
Insomnia
Iritis
Joint Dislocation
Joint Injury
Lacrimation Increased
Lethargy
Limb Injury
Meningitis
Mitral Valve Prolapse
Myocarditis
Nausea
Night Sweats
Photosensitivity Reaction
Pruritus
Pulmonary Calcification
Pyrexia
Rash

		Stomatitis					
		Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vertigo		Vioxx	PS	Merck & Co., Inc	ORAL
		Viral Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Anaprox	C		
UNKNOWN							
				Femhrt	C		
UNKNOWN							
				Herbs (Unspecified)	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Trazodone Hydrochloride	C		ORAL
				Trazodone Hydrochloride	C		ORAL
				Prozac	C		
UNKNOWN							
				Prozac	C		ORAL

Date:04/15/05ISR Number: 4636119-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00012
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Occlusion		Metoprolol Tartrate	C		ORAL
	Cerebral Infarction		Aspirin And Magnesium Oxide	C		ORAL
	Facial Paresis		Zocor	C		ORAL
	Hypoaesthesia		Irbesartan And Hydrochlorothiazide	C		ORAL
	Speech Disorder					

Date:04/15/05ISR Number: 4636120-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00494
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636121-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00124
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia Blood Pressure Increased Chest Pain Fluid Retention Intervertebral Disc Protrusion Pain Pancreatitis Renal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636122-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01513
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Cerebrovascular Accident Hip Arthroplasty Joint Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636123-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03946
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	128 DAY	
Hospitalization - Initial or Prolonged Disability	Convulsion		Protonix	C			UNKNOWN	
	Myocardial Infarction		Rite Aid Col-Rite Stool Softener	C			UNKNOWN	
	Renal Disorder		Clonidine	C			UNKNOWN	
	Transient Ischaemic		Diovan	C			UNKNOWN	
	Attack		Norvasc	C			UNKNOWN	
			Hydrodiuril	C			UNKNOWN	
			Wellbutrin Sr	C			UNKNOWN	
			Combivent	C			UNKNOWN	
			Advair	C			UNKNOWN	
			Theophylline	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Bisacodyl	C			UNKNOWN	
			Metoclopramide	C			UNKNOWN	

Date:04/15/05ISR Number: 4636130-9Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00018
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cerebrovascular Accident Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636131-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01855
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636132-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0504GBR00069
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dyspepsia Headache Weight Increased Wheezing		Vioxx Simvastatin	PS C	Merck & Co., Inc	ORAL ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636133-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01865
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Convulsion Myocardial Infarction Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636134-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01540
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636135-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01778
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN Disability	Myocardial Infarction		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	6 MON	

Date:04/15/05ISR Number: 4636138-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL	91 DAY	

Date:04/15/05ISR Number: 4636139-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01742
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636887-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03085
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Difficulty In Walking		Verapamil	C				
Disability	Duodenal Ulcer		Lescol	C				
	Haemorrhage		Isosorbide	C				

Date:04/15/05ISR Number: 4636889-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00678
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Cerebrovascular Accident
Disability	Emotional Distress
Other	General Physical Health

	Deterioration						
	Kidney Infection						
	Neuropathy						
	Onychomycosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
	Toe Deformity		Vioxx	SS	Merck & Co., Inc	ORAL	
	Traumatic Haematoma		Glucophage	C			UNKNOWN
	Weight Decreased		Glucotrol	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Neurontin	C			UNKNOWN
			Novolin 70/30	C			UNKNOWN

Date:04/15/05ISR Number: 4636890-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Anxiety						
Other	Arrhythmia						
	Cardiac Failure						
	Congestive						
	Cardiomyopathy						
	Chest Pain						
	Congestive Cardiomyopathy						
	Depression						
	Dilatation Atrial						
	Dilatation Ventricular						
	Extrasystoles						
	Feeling Abnormal						
	Generalised Anxiety						
	Disorder						
	Haematochezia						
	Hypertension						
	Injury						
	Mitral Valve Incompetence						
	Myocardial Infarction						
	Nocturia						

	Palpitations
	Tachycardia
	Treatment Noncompliance
	Tricuspid Valve Incompetence
	Ventricular Dysfunction
	Ventricular Hypokinesia

Date:04/15/05ISR Number: 4636891-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01195
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Aortic Dilatation
	Aortic Valve Sclerosis
	Asthenia
	Blood Pressure Increased
	Cardiac Murmur
	Coronary Artery Occlusion
	Dizziness
	Dizziness Postural

		Emotional Distress					
		Hernia					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Stiffness		Claritin	C		
UNKNOWN							
		Mitral Valve Incompetence		Metoprolol	C		
UNKNOWN							
		Mitral Valve Sclerosis		Relafen	C		
UNKNOWN							
		Myocardial Infarction		Nitroglycerin	C		
UNKNOWN							
		Nasopharyngitis		Imdur	C		
UNKNOWN							
		Peripheral Artery		Dipyridamole	C		
UNKNOWN							
		Aneurysm		Xanax	C		
UNKNOWN							
		Plantar Fasciitis		Cartia Xt	C		
UNKNOWN							
		Post Procedural		Cartia Xt	C		
UNKNOWN							
		Complication		Paxil	C		
UNKNOWN							
		Radiculopathy		Lipitor	C		
UNKNOWN							
		Renal Cyst		Tylenol With Codeine			
		Skin Lesion		#3	C		
UNKNOWN							
		Supraventricular		Dyazide	C		
UNKNOWN							
		Tachycardia		Aspirin	C		
UNKNOWN							
		Ventricular Dysfunction		Cardizem Cd	C		
UNKNOWN							
		Ventricular Hypertrophy		Plavix	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Hydrocodone/Apap	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:04/15/05ISR Number: 4636892-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
							225	DAY
Disability	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
							1	DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
							41	DAY
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
							225	DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
							1	DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
							41	DAY
	Gastrointestinal		Fenoterol					
	Haemorrhage		Hydrobromide And					
	Hypertensive Crisis		Ipratropium Bromide	C				
							UNKNOWN	
	Pulmonary Infarction		Formoterol Fumarate	C				
							UNKNOWN	
	Pyrexia		Bisoprolol Fumarate	C				
							UNKNOWN	
	Respiratory Disorder		Enalapril Maleate	C				
							UNKNOWN	
			Atorvastatin Calcium	C				
							UNKNOWN	
			Tamsulosin Hydrochloride	C				
							UNKNOWN	
			Spironolactone	C				
							UNKNOWN	
			Beclomethasone Dipropionate	C				
							UNKNOWN	
			Theophylline	C		ORAL		
			Prednisolone	C		ORAL		
			Captopril	C		ORAL		
			Aspirin	C		ORAL		
			Acetylcysteine	C		ORAL		
			Calcium					

			(Unspecified)	C		ORAL

Date:04/15/05ISR Number: 4636893-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00057
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	6 DAY	
			Metoprolol Succinate	C		ORAL	16 DAY	
			Torsemide	C		ORAL	15 DAY	
			Atorvastatin Calcium	C		ORAL	17 DAY	
			Aspirin	C		ORAL	17 DAY	

Date:04/15/05ISR Number: 4636894-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02530
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Disability	Dyspnoea							
	Pain In Extremity							

Date:04/15/05ISR Number: 4636895-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00112
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Heart Rate Irregular		Celecoxib	SS		ORAL		
Disability	Loss Of Consciousness		Atenolol	C				
UNKNOWN								
	Migraine		Propranolol					
	Muscle Spasms		Hydrochloride	C				
UNKNOWN								
	Pain In Extremity							
	Paraesthesia							
	Photophobia							
	Spinal Disorder							
	Tachycardia							
	Ventricular Tachycardia							

Date:04/15/05ISR Number: 4636896-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01800
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Enalapril Maleate	C				
UNKNOWN								
Other	Hypertensive Heart		Glucophage	C				
UNKNOWN								
	Disease		Micronase	C				
UNKNOWN								
	Mitral Valve Sclerosis		Mevacor	C		ORAL		
	Ventricular Arrhythmia							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636897-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00827
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
	Injury							

Date:04/15/05ISR Number: 4636898-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01045
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	662	DAY
	Thrombosis							

Date:04/15/05ISR Number: 4636899-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON
	Atherosclerosis							
	Coronary Artery Stenosis							

Date:04/15/05ISR Number: 4636901-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00056
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	1595	DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	1595	DAY
	Dizziness		Clopidogrel Bisulfate	C		ORAL		

Metoprolol	C			ORAL
Atorvastatin Calcium	C			ORAL
Ramipril	C			ORAL
Aspirin	C			ORAL

Date:04/15/05ISR Number: 4636902-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636903-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00070
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Retinal Vascular Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Fenoterol Hydrobromide And Ipratropium Bromide	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Fluticasone Propionate And Salmeterol Xinafoate	C			UNKNOWN	
			Diclofenac	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636904-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636907-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON

Date:04/15/05ISR Number: 4636908-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636909-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636910-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01243
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636911-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/15/05ISR Number: 4636912-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01624
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/15/05ISR Number: 4636913-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636914-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	27	MON

Date:04/15/05ISR Number: 4636915-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01827
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636916-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	700	DAY

Date:04/15/05ISR Number: 4636917-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01581
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1183	DAY

Date:04/15/05ISR Number: 4636918-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	65	MON

Date:04/15/05ISR Number: 4636919-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/15/05ISR Number: 4636920-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01605
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/15/05ISR Number: 4636921-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636922-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636923-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01632
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636924-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								

Date:04/15/05ISR Number: 4636925-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636928-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01833
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:04/15/05ISR Number: 4636929-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636930-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01628
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636931-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01847
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636932-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	531 DAY	
	Ischaemic Stroke							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636933-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01840
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1124 DAY	
	Cerebrovascular Accident							
	Injury							
	Myocardial Infarction							

Date:04/15/05ISR Number: 4636934-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01837
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Other	Cardiac Disorder							
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Injury							
	Pain							

Date:04/15/05ISR Number: 4636937-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01835
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage Intracranial							

Date:04/15/05ISR Number: 4636938-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:04/15/05ISR Number: 4636939-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01852
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636941-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	80 DAY	
Other	Death							

Date:04/15/05ISR Number: 4636943-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/15/05ISR Number: 4636947-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Abnormal Dreams
Other	Adverse Event
	Amenorrhoea
	Angina Pectoris
	Aphthous Stomatitis
	Arthralgia
	Atrial Septal Defect
	Blood Pressure Abnormal
	Blood Pressure Increased
	Breast Pain
	Breast Tenderness
	Bronchitis Acute
	Bursitis
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Pain
	Conjunctival Haemorrhage
	Contusion
	Convulsion
	Cyst
	Deep Vein Thrombosis
	Dizziness
	Drug Abuser
	Drug Dependence
	Eczema
	Embolic Stroke
	Endometriosis
	Epistaxis
	Fall
	Fatigue
	Gastroenteritis Viral
	Generalised Oedema
	Headache
	Hip Arthroplasty
	Hypercoagulation
	Hypoaesthesia
	Increased Tendency To Bruise
	Ingrowing Nail
	Inguinal Hernia
	Injury
	Laryngitis

Localised Infection
Loss Of Libido
Mastitis
Menorrhagia
Migraine
Munchausen'S Syndrome
Muscle Atrophy
Muscle Spasms
Musculoskeletal
Discomfort
Nausea
Neck Mass
Nervousness
Oligomenorrhoea
Osteoarthritis

	Otitis Externa						
	Otitis Media						
	Ovarian Cyst	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ovarian Enlargement		Vioxx	PS	Merck & Co., Inc	ORAL	
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pain In Jaw		Vioxx	SS	Merck & Co., Inc	ORAL	
	Panic Attack						
	Paraesthesia						
	Patent Ductus Arteriosus						
	Pelvic Pain						
	Pharyngitis						
	Pyrexia						
	Rash						
	Rhinitis Allergic						
	Sinus Disorder						
	Sinusitis						
	Splenic Cyst						
	Systemic Lupus Erythematosus						
	Thrombotic Stroke						
	Transient Ischaemic Attack						
	Upper Respiratory Tract Infection						
	Urinary Tract Infection						
	Urine Abnormality						
	Vaginal Mycosis						
	Vaginitis Bacterial						
	Viral Infection						

Date:04/15/05ISR Number: 4636950-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/15/05ISR Number: 4636960-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01608
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/15/05ISR Number: 4636961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:04/15/05ISR Number: 4636962-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01839
Age: Gender:Male I/FU:I

Outcome	PT
Disability	Cardiac Disorder
	Cardiac Failure
	Cerebrovascular Accident
	Multi-Organ Disorder

	Pain						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4636967-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/15/05ISR Number: 4638249-5Report Type:Expedited (15-DaCompany Report #2004088892
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia	Consumer	Celebrex (Celecoxib)	PS		ORAL	SEE IMAGE	
	Atrial Tachycardia	Health Professional	Rofecoxib (Rofecoxib)	SS			UNKNOWN	UNKNOWN
	Cardiac Disorder							
	Dehydration		Tocopherol (Tocopherol)	C				
	Extrasystoles		Retinol (Retinol)	C				
			B-Komplex (Calcium Pantothenate, Nicotinamide, Pyridoxine Hydrochloride,	C				
			Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C				
			Glucosamine Sulfate/Minerals/Multivitamins (Glucosamine Sulfate, Minerals	C				
			Ergocalciferol (Ergocalciferol)	C				

Ascorbic Acid (Ascorbic Acid)	C
Digoxin (Digoxin)	C
Vitamins (Vitamins)	C
Acetylsalicylic Acid (Acetylsalicylic Acid)	C

Date:04/18/05ISR Number: 4637427-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637709-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00613
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	52	DAY
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	52	DAY
	Chest Pain							
	Drug Ineffective							

Date:04/18/05ISR Number: 4637731-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01798
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C			UNKNOWN	
			Zocor	C			UNKNOWN	

Date:04/18/05ISR Number: 4637733-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00014
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Second Degree		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
	Blood Creatinine Decreased		Fluoxetine Hydrochloride	C			UNKNOWN	
	Myocardial Infarction		Pravastatin Sodium	C			UNKNOWN	

Date:04/18/05ISR Number: 4637734-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637735-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01214
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Allergic Sinusitis Cartilage Injury Cerebrovascular Accident Cerumen Impaction Coronary Artery Disease Cyst Dyspnoea Emotional Distress Eye Haemorrhage Fall Gastrooesophageal Reflux Disease Glaucoma Intestinal Functional Disorder Lumbar Radiculopathy Mitral Valve Incompetence

	Oedema						
	Oedema Peripheral						
	Pleural Effusion	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Seborrhoeic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR
	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL	4 YR
	Tinea Pedis		Aspirin	C			UNKNOWN
	Tricuspid Valve		Atenolol	C			UNKNOWN
	Incompetence		Nexium	C			UNKNOWN
	Ventricular Hypertrophy		Lasix (Furosemide)	C			UNKNOWN
			Prevacid	C			UNKNOWN 90 DAY
			Glucosamine	C			UNKNOWN
			Klor-Con	C			UNKNOWN

Date:04/18/05ISR Number: 4637737-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02137
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	330 DAY
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL	152 DAY
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	
	Gastrooesophageal Reflux		Celexa	C			UNKNOWN
	Disease		Celebrex	C		ORAL	
	Injury		Plavix	C			UNKNOWN
	Nausea		Darvocet-N	C			UNKNOWN
	Sleep Apnoea Syndrome						
	Weight Decreased						

Date:04/18/05ISR Number: 4637739-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00010
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Retinal Vascular Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Warfarin Sodium	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Metoprolol Tartrate	C			UNKNOWN	
			Zocor	C			UNKNOWN	

Date:04/18/05ISR Number: 4637742-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02417
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Thrombosis Fall Gait Disturbance Headache Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637743-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03191
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Cerebrovascular Accident
Hospitalization - Initial or Prolonged	Diabetes Mellitus
	Emotional Distress
Other	Hypercholesterolaemia
	Hypertension

Myocardial Infarction

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
772 DAY			Vioxx	PS	Merck & Co., Inc	ORAL
772 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN			Atuss Ex	C		
UNKNOWN			Neurontin	C		
UNKNOWN			Dilantin	C		
UNKNOWN			Dilantin	C		
UNKNOWN			Vitamin B (Unspecified)	C		
UNKNOWN			Diovan	C		
UNKNOWN			Darvocet-N	C		
UNKNOWN	1 DAY		Naprosyn	C		
UNKNOWN	DAY		Naprosyn	C		
UNKNOWN	1 DAY		Allegra	C		
UNKNOWN			Clemastine	C		
UNKNOWN						

Date:04/18/05ISR Number: 4637746-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01376
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/18/05ISR Number: 4637747-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00625
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Hospitalization - Initial or Prolonged	Aortic Valve Calcification		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atrioventricular Block		Zocor	C		ORAL		
UNKNOWN			Plavix	C				
Other	First Degree		Aspirin	C				
UNKNOWN								
	Cardiac Failure Congestive		Labetalol Hydrochloride	C				
UNKNOWN								
	Cardiovascular Disorder		Lipitor	C				
UNKNOWN								
	Hypertension		Xanax	C				
UNKNOWN								
	Mitral Valve Incompetence Pulmonary Oedema		[Therapy Unspecified]	C				
UNKNOWN								
	Pulmonary Valve Incompetence Rash Tricuspid Valve Incompetence							

Date:04/18/05ISR Number: 4637748-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01159
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety Disorder
	Arthropathy
	Cardiac Flutter
	Cardiomegaly
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis

		Hyperhomocysteinaemia					
		Insomnia					
		Joint Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Periarthritis		Actos	C		ORAL
		Pulmonary Congestion		Tricor	C		ORAL
		Stress		Glucovance	C		ORAL

Date:04/18/05ISR Number: 4637749-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01229
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL
18 MON						
Hospitalization -	Heart Rate Irregular		Glucophage	C		
UNKNOWN						
Initial or Prolonged	Myocardial Infarction		Insulin	C		
UNKNOWN						
Other						

Date:04/18/05ISR Number: 4637761-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01477
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Pulmonary Embolism					
Initial or Prolonged						

Date:04/18/05ISR Number: 4637762-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01370
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Heart Rate Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
	Heart Rate Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Libido Decreased		Vioxx	SS	Merck & Co., Inc	ORAL

	Palpitations		Hydrochlorothiazide			
	Respiratory Arrest		Tablets (Usp 23)	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Oxycontin	C		
UNKNOWN						
			Percocet	C		
UNKNOWN						
			Benadryl	C		
UNKNOWN						
			Claritin	C		
UNKNOWN						
			Flonase	C		
UNKNOWN						
			Afrin	C		
UNKNOWN						
			Peg-Intron	C		
UNKNOWN						
			Rebetol	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:04/18/05ISR Number: 4637763-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01160
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrioventricular Block		Accupril	C				
UNKNOWN								
Other	Cardiac Disorder							
	Chest Pain							
	Emotional Distress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637766-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637767-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637768-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637769-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637770-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637771-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01661
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637772-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637783-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Life Expectancy Shortened							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637784-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637785-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637786-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	69	MON
	Life Expectancy Shortened							
	Myocardial Infarction							
	Neuropathy							
	Pain							
	Paralysis							
	Spinal Cord Injury							

Date:04/18/05ISR Number: 4637788-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637797-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:04/18/05ISR Number: 4637798-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637799-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01824
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Original Formula Sensodyne-Sc	SS			UNKNOWN	
	Hypertension		Calcium (Unspecified)	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637800-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637801-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:04/18/05ISR Number: 4637802-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637803-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637804-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01594
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637815-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1730 DAY

Date:04/18/05ISR Number: 4637816-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637817-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637818-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637819-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01830
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	731 DAY	

Date:04/18/05ISR Number: 4637820-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637821-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01992
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C			UNKNOWN	
			Ranitidine	C			UNKNOWN	
			Sertraline Hydrochloride	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

	Potassium Chloride	C
UNKNOWN		
	Hydrochlorothiazide	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		
	Vitamins (Unspecified)	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		

Date:04/18/05ISR Number: 4637822-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637823-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4637824-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637825-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637831-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02151
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637832-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4637875-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1003 DAY

Date:04/18/05ISR Number: 4638333-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00426
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nervous System Disorder							
	Scar							
	Sleep Disorder							

Date:04/18/05ISR Number: 4638339-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0412ESP00045
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Iron Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fluid Retention		Fluoxetine					
	Generalised Oedema		Hydrochloride	C				
UNKNOWN								
	Intervertebral Disc		Flurazepam					
	Disorder		Hydrochloride	C				
UNKNOWN								
	Intestinal Polyp							
	Oedema Peripheral							
	Rectal Tenesmus							
	Renal Disorder							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638340-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638341-5Report Type:Expedited (15-DaCompany Report #BR-MERCK-0504BRA00015
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Hospitalization - Initial or Prolonged			Ascorbic Acid And Ferrous Sulfate And Folic Acid	C				
UNKNOWN			Manidipine Hydrochloride	C		ORAL		
			Omeprazole	C		ORAL		
			Nizatidine	C		ORAL		
			Vitamins (Unspecified) And Minerals (Unspecified)	C		ORAL		
			Isosorbide Dinitrate	C				
SUBLINGUAL								

Date:04/18/05ISR Number: 4638344-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00089
Age:28 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638345-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00015
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Discomfort		Amlodipine Besylate	C		ORAL		
	Hypertension		Lercanidipine Hydrochloride	C				
	Oedema							
UNKNOWN								
	Pain In Extremity		Bendroflumethiazide	C				
UNKNOWN								
			Atorvastatin Calcium	C				
UNKNOWN								

Date:04/18/05ISR Number: 4638346-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01202
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Arthritis Infective
	Blood Glucose Increased
	Cardiac Failure
	Congestive
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Dizziness
	Dysphagia
	Emotional Distress
	Knee Arthroplasty

		Neuralgia					
		Platelet Count Increased					
		Sleep Apnoea Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		White Blood Cell Count		Vioxx	PS	Merck & Co., Inc	ORAL
1059 DAY							
		Increased		Vioxx	C		ORAL
				Vioxx	C		ORAL
				Diovan	C		ORAL
				Diovan	C		ORAL
				Diovan	C		ORAL
				Zyrtec	C		ORAL

Date:04/18/05ISR Number: 4638347-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00088
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Procedural Complication		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/18/05ISR Number: 4638348-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00090
Age:26 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/18/05ISR Number: 4638349-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00085
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Brain Damage					
		Cerebrovascular Accident					
		Pain					

Date:04/18/05ISR Number: 4638350-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00085
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Celecoxib	SS		ORAL		

Date:04/18/05ISR Number: 4638359-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638360-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01546
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638361-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638362-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638363-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638364-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01580
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638365-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01228
Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	1 YR	
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	1 YR	

	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL
1 YR						
	Pain In Extremity					
	Panic Attack					
	Paraesthesia					
	Sensory Disturbance					

Date:04/18/05ISR Number: 4638366-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638367-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01622
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638368-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638369-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638370-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01621
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638371-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638372-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01623
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638373-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01649
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638374-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638375-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638376-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638385-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638386-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638397-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction							

Date:04/18/05ISR Number: 4638398-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01670
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638399-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01664
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638400-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638401-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01635
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638402-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638403-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638404-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638405-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01625
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638414-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02040
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Myocardial Infarction							

Date:04/18/05ISR Number: 4638415-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638416-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638417-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638418-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638419-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638420-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02048
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638421-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638422-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638423-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638432-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638433-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638437-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/18/05ISR Number: 4638438-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4638451-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02045
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/18/05ISR Number: 4639341-1Report Type:Expedited (15-DaCompany Report #2005055371
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Lipitor					
	Blood Cholesterol		(Atorvastatin)	PS		ORAL	10 MG (10 MG	
	Increased						1 IN 1 D),	
	Blood Test Abnormal						ORAL	
	Contusion		Vioxx (Rofecoxib)	SS				
	Knee Arthroplasty		Irbesartan					
	Liver Disorder		(Irbesartan)	C				
	Muscle Atrophy		Amlodipine Besilate					
	Pain In Extremity		(Amlodipine					
	Renal Disorder		Besilate)	C				
			Nadolol (Nadolol)	C				
			Estrogens Conjugated					
			(Estrogens					
			Conjugated)	C				
			Levothyroxine Sodium					
			(Levothyroxine					
			Sodium)	C				
			Furosemide					
			(Furosemide)	C				
			Tolterodine					
			L-Tartrate					

(Tolterodine L-Tartrate)	C
Glimepiride (Glimepiride)	C
Calcium Carbonate (Calcium Carbonate)	C
Acetylsalicylic Acid (Acetysalicylic Acid)	C

Date:04/19/05ISR Number: 4638969-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02009
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
Other	Carpal Tunnel Syndrome
	Chest Pain
	Chest Wall Pain
	Dizziness
	Fall
	Hypotension
	Myocardial Infarction

		Transient Ischaemic Attack					
		Ventricular Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL
		Vestibular Disorder		Coreg	C		
UNKNOWN							
				Imdur	C		ORAL
				Lasix (Furosemide)	C		
UNKNOWN							
				Levoxan	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zetia	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Isosorbide	C		
UNKNOWN							
				Evista	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:04/19/05ISR Number: 4638974-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01865
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 77 DAY	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL	32 DAY
Other	Increased	Vioxx	SS	Merck & Co., Inc	ORAL	19 DAY
	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL	1440 DAY
	Chronic Fatigue Syndrome	Humulin	C			UNKNOWN
	Constipation	Avandia	C			UNKNOWN
	Diverticulitis	Vasotec	C			UNKNOWN
	Gastroenteritis	Aceon	C			UNKNOWN
	Intestinal Obstruction	Actos	C			UNKNOWN
	Oedema Peripheral	Lantus	C			UNKNOWN
	Peripheral Vascular Disorder					
	Thrombosis					
	Thyroid Disorder					

Date:04/19/05ISR Number: 4638975-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638976-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4638977-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	46	MON
	Pain							

Date:04/19/05ISR Number: 4638978-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04298
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Brain Damage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Tylenol	C				
UNKNOWN								
	Attack		Advil	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Accupril	C				
UNKNOWN								
			Metoprolol	C				
UNKNOWN								

Date:04/19/05ISR Number: 4638979-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638980-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01665
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638981-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01676
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638982-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638983-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4638984-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04748
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Cervical Vertebra Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		[Therapy					
	Essential Tremor		Unspecified]	C				
UNKNOWN								
	Head Deformity							
	Head Injury							

Date:04/19/05ISR Number: 4638985-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4638989-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
52 MON								
	Thrombosis							

Date:04/19/05ISR Number: 4638999-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639000-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	433	DAY

Date:04/19/05ISR Number: 4639001-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1273	DAY

Date:04/19/05ISR Number: 4639004-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Pain							

Date:04/19/05ISR Number: 4639009-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639010-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02136
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1050	DAY

Date:04/19/05ISR Number: 4639012-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	180	DAY

Date:04/19/05ISR Number: 4639013-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:04/19/05ISR Number: 4639014-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02065
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Potassium Chloride	C				
	Dyspnoea		Plavix	C				
	Emotional Distress		Lasix (Furosemide)	C				
	Hypertension		Aciphex	C				
	Myocardial Infarction		Toprol Xl Tablets	C		ORAL		
	Oedema Peripheral		Allopurinol	C				

	Sleep Apnoea Syndrome		Isosorbide Mononitrate	C		
UNKNOWN						
			Zocor	C		ORAL
			Cozaar	C		ORAL
			Nifedipine	C		
UNKNOWN						
			Hydralazine	C		
UNKNOWN						

Date:04/19/05ISR Number: 4639031-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639032-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639033-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639034-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639035-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02332
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639036-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00552
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Bisoprolol	C		ORAL		
	Dyspepsia		Zocor	C		ORAL		
	Goitre		Aspirin	C		ORAL		
	Helicobacter Pylori		Isosorbide					
	Identification Test		Mononitrate	C		ORAL		
	Positive		Torsemide	C		ORAL		
	Hyperthyroidism		Betaxolol					
	Nausea		Hydrochloride	C		ORAL		
	Nervousness		Aspirin	C		ORAL		
	Palpitations							
	Tachyarrhythmia							

Date:04/19/05ISR Number: 4639037-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639038-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639039-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639120-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prolonged		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Motrin	C			UNKNOWN	
	Blood Cholesterol		Paxil	C			UNKNOWN	
	Increased		Paxil	C			UNKNOWN	
	Bronchitis		Benadryl	C			UNKNOWN	
	Carotid Artery Stenosis Cerebral Infarction Cerebrovascular Accident		Correctol (Docusate Sodium (+) Phenolphthalein)	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease Constipation Cough Dermatitis Drug Eruption Dyspepsia Dyspnoea Eczema Infected Emotional Distress Fall Gastric Disorder Gastritis Goitre Hemiparesis Hyperlipidaemia Hyperthyroidism Hypoaesthesia Injury International Normalised Ratio Increased Low Density Lipoprotein Increased Nasopharyngitis Nicotine Dependence Oedema Peripheral							

Pain In Extremity
Paraesthesia
Pharyngolaryngeal Pain
Pneumonia
Prothrombin Time
Prolonged
Sinus Congestion
Sinusitis
Syncope
Thyroid Mass
Thyroid Pain
Transient Ischaemic
Attack
Vision Blurred

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639125-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0547915A
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Ecotrin Adult Low Strength Tablets	PS	Glaxosmithkline	ORAL	81MG Per day	6 YR
	Azotaemia		Celebrex	SS		ORAL		
	Chest Pain		Vioxx	SS		ORAL		
	Dizziness		Bextra	SS				
	Dyspepsia		Avandia	C	Glaxosmithkline	ORAL	8MG Per day	
	Faeces Discoloured		Lipitor	C		ORAL	40MG Per day	
	Gastric Ulcer Haemorrhage		Multiple Vitamin	C		ORAL		
	Haemoglobin Decreased		Fluconazole	C		ORAL	200MG	
	Headache						cumulative	
	Hyperhidrosis						dose	
	Rectal Haemorrhage		Altace	C		ORAL	2.5MG Per day	
	Volume Blood Decreased		(Trimethoprim + Sulfamethoxazol)	C	Glaxosmithkline	ORAL	1 YR	
	White Blood Cell Count Decreased		Atenolol	C			50MG Per day	
			Vitamin E	C			400UD Per day	
			Trazodone	C			400MG At night	
			Tylenol Arthritis	C	Glaxosmithkline			
			Levitra	C				

Date:04/19/05ISR Number: 4639397-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03894
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization -	Feeling Abnormal	Zyprexa	C
UNKNOWN			
Initial or Prolonged	Poor Peripheral	Seroquel	C
UNKNOWN			
Disability	Circulation		
	Respiratory Failure		
	Skin Discolouration		
	Vein Disorder		

Date:04/19/05ISR Number: 4639401-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00234
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Diclofenac Sodium	C		ORAL
			Insulin, Biphasic Isophane [Injection]	C		
PARENTERAL						
			Repaglinide	C		
UNKNOWN						
			Tetrazepam	C		
UNKNOWN						
			Metformin Hydrochloride	C		ORAL
			Magnesium (Unspecified)	C		ORAL
			Tolperisone Hydrochloride	C		
UNKNOWN						
			Thioctic Acid	C		ORAL

Date:04/19/05ISR Number: 4639403-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00551
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Premarin	C		
UNKNOWN						
Initial or Prolonged	Dizziness		[Therapy			
Disability	Inner Ear Disorder		Unspecified]	C		
UNKNOWN						
	Paraesthesia					
	Vertigo					

Date:04/19/05ISR Number: 4639404-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Alanine Aminotransferase
Disability	Increased
Other	Alopecia
	Anxiety
	Arthralgia
	Aspartate
	Aminotransferase
	Increased
	Back Pain
	Benign Prostatic
	Hyperplasia
	Blood Alkaline
	Phosphatase Increased
	Blood Bilirubin Increased
	Bone Marrow Depression
	Cholecystitis
	Cholelithiasis
	Chronic Sinusitis
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Cyst
	Deafness
	Deafness Unilateral
	Dehydration

Depression
Discomfort
Erythema
Fatigue
Flatulence
Gout
Herpes Simplex
Hodgkin'S Disease
Inguinal Hernia
Lipase Increased
Lymphadenopathy
Murphy'S Sign Positive
Myalgia
Myopathy
Nasal Cyst
Nausea
Neutrophil Percentage
Increased
Pain In Extremity

	Pneumonia						
	Poor Peripheral Circulation	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Prostatic Specific		Vioxx	PS	Merck & Co., Inc	ORAL	
	Antigen Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rectal Examination		Vioxx	SS	Merck & Co., Inc	ORAL	
	Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	
	Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL	
	Renal Failure Acute		Claritin-D	C			UNKNOWN
	Renal Impairment		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN
	Renal Tubular Necrosis						
	Soft Tissue Disorder		Flonase	C			UNKNOWN
	Swelling		Valium	C			UNKNOWN
	Synovial Cyst		Plendil	C			UNKNOWN
	Tension Headache		Pravachol	C			UNKNOWN
	White Blood Cell Count		Wellbutrin	C			UNKNOWN
	Increased		Paxil	C			UNKNOWN

Date:04/19/05ISR Number: 4639405-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00024
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged			Amitriptyline Hydrochloride	C		ORAL	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN

Date:04/19/05ISR Number: 4639407-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	211 DAY	

Date:04/19/05ISR Number: 4639408-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639409-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	369 DAY	

Date:04/19/05ISR Number: 4639419-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01834
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639420-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02068
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639421-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639422-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639423-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639424-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639426-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639427-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639428-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639437-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639438-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02073
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639439-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639440-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	28	DAY
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:04/19/05ISR Number: 4639441-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02203
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639443-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639444-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639445-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02217
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639446-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639458-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02224
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639459-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639460-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02204
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639461-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02234
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON

Date:04/19/05ISR Number: 4639462-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON
	Myocardial Infarction							

Date:04/19/05ISR Number: 4639469-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02230
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
	Heart Injury							

Date:04/19/05ISR Number: 4639471-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639472-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639473-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02343
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639474-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639475-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639486-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639487-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639488-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Thrombosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	35 MON	

Date:04/19/05ISR Number: 4639489-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639490-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639491-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02421
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639492-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639493-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02472
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639494-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Cerebrovascular Accident
Myocardial Infarction
Polytraumatism

Date:04/19/05ISR Number: 4639495-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639496-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639497-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/19/05ISR Number: 4639498-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:04/19/05ISR Number: 4639499-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:04/19/05ISR Number: 4639500-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:04/19/05ISR Number: 4639501-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639502-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639503-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02989
Age: Gender:Female I/FU:I

Outcome	PT
Death	Adverse Event Death

	Injury						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639504-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639514-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639515-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639516-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639517-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03002
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4639518-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/19/05ISR Number: 4639543-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/19/05ISR Number: 4640472-0Report Type:Expedited (15-DaCompany Report #2005020279
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
	Drug Ineffective	Health Professional						
	Dyspnoea							
	Fluid Retention		Bextra (Valdecoxib)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
	Gastric Disorder							
	Glossodynia							
	Herpes Simplex		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Oral Pain							
	Post Procedural Pain		Furosemide (Furosemide)	C				
	Skin Exfoliation							
	Weight Increased		Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
			Escitalopram (Escitalopram)	C				
			Atorvastatin (Atorvastatin)	C				
			Tramadol (Tramadol)	C				
			Potassium Chloride (Potassium Chloride)	C				
			Alprazolam (Alprazolam)	C				
			Estrogens Conjugated (Estrogens Conjugated)	C				
			Vicodin (Hydrocodone					

			Bitartrate, Paracetamol)	C		
			Irbesartan (Irbesartan)	C		

Date:04/19/05ISR Number: 4641039-0Report Type:Direct Company Report #CTU 246571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arterial Occlusive		Vioxx 50 Mg	PS		
25-50 MG						
Hospitalization - Initial or Prolonged Disability	Disease					
	Basal Cell Carcinoma					
	Cerebrovascular Accident					
	Deep Vein Thrombosis					
	Pulmonary Embolism					
	Skin Graft					
	Toe Amputation					
	Transient Ischaemic Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4639973-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02064
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640142-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640143-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640144-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02546
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
63 DAY								
	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
63 DAY								
	Gout		Paxil	C				
UNKNOWN								
	Hepatitis C		Motrin	C				
UNKNOWN								
	Hypoaesthesia		Aleve	C				
UNKNOWN								

	Hypokalaemia	Tylenol	C
UNKNOWN			
	Injury	Glyburide	C
UNKNOWN			
	Mitral Valve Incompetence	Aspirin	C
UNKNOWN			
	Myocardial Ischaemia	[Therapy	
	Nocturia	Unspecified]	C
UNKNOWN			
	Oedema Peripheral	Celebrex	C
UNKNOWN			
	Pain In Extremity		
	Pulmonary Valve		
	Incompetence		
	Renal Disorder		
	Rhabdomyolysis		
	Scar		
	Tricuspid Valve		
	Incompetence		
	Varicose Vein		

Date:04/20/05ISR Number: 4640145-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01203
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aspiration
	Back Injury
	Bronchitis
	Chest Pain
	Chest Wall Pain
	Chondrosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Contusion					
		Coronary Artery Atherosclerosis					
59 MON		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
14 DAY		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	
59 MON		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
14 DAY		Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	
UNKNOWN		Joint Sprain		Daypro	C		
UNKNOWN		Lung Neoplasm		Daypro	C		
UNKNOWN		Muscle Strain		Flexeril	C		
UNKNOWN		Myocardial Infarction		Flexeril	C		
		Osteoarthritis		Corticosteroids (Unspecified)			
UNKNOWN		Pain In Extremity			C		
UNKNOWN		Rash		Celebrex	C		
UNKNOWN		Road Traffic Accident		Celebrex	C		
UNKNOWN		Sarcoidosis		Ultram	C		
UNKNOWN		Spinal Osteoarthritis		Ultram	C		
UNKNOWN				Ultram	C		
UNKNOWN				Ultram	C		
UNKNOWN				Flexeril	C		
UNKNOWN				Zithromax	C		
UNKNOWN				Levaquin	C		
UNKNOWN				Claritin-D	C		
UNKNOWN							

Betoptic C
UNKNOWN

Date:04/20/05ISR Number: 4640146-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640147-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640153-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640155-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640156-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640166-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02083
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
	Myocardial Infarction							

Date:04/20/05ISR Number: 4640167-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640168-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640169-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640170-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640171-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640173-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02102
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640174-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02085
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640186-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640187-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640188-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02321
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640189-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640190-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	37	MON

Date:04/20/05ISR Number: 4640191-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640192-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640193-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640194-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640195-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03029
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640196-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640197-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640199-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640200-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640201-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640202-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640203-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640213-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:04/20/05ISR Number: 4640214-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02971
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640217-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03091
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640218-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03089
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640231-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640233-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Coronary Artery Disease Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640234-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03094
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640384-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640385-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02258
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
Disability			[Therapy					

				Unspecified]	C		
UNKNOWN							

Date:04/20/05ISR Number: 4640779-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03746
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	First Degree		Ecotrin	SS		ORAL		
6 YR								
	Azotaemia		Bextra	SS				
UNKNOWN								
	Gastrointestinal Haemorrhage		Celebrex	SS		ORAL		
			Avandia	C				
UNKNOWN								
	Headache		Lipitor	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Fluconazole	C				
UNKNOWN								
			Altace	C				
UNKNOWN								
			Sulfamethoxazole And Trimethoprim	C				
UNKNOWN							1	YR
			Atenolol	C				
UNKNOWN								
			Vitamin E	C				
UNKNOWN								
			Trazodone Hydrochloride	C				
UNKNOWN								
			Tylenol Arthritis					

			Extended Relief	C		
UNKNOWN						
			Levitra	C		
UNKNOWN						

Date:04/20/05ISR Number: 4640789-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640791-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01857
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640792-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	841 DAY	

Date:04/20/05ISR Number: 4640797-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640798-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640799-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640801-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	476 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640815-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640816-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640817-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/20/05ISR Number: 4640818-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00015
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Damage		Amlodipine Besylate	C		ORAL		
	Deep Vein Thrombosis		Lercanidipine Hydrochloride	C				
	Discomfort							
UNKNOWN								
	Dizziness		Bendroflumethiazide	C				
UNKNOWN								
	Hypertension		Atorvastatin Calcium	C				
UNKNOWN								
	Hypoaesthesia Oral		Metoprolol	C				
UNKNOWN								
	Memory Impairment							
	Oedema							
	Pain In Extremity							

Ventricular Hypertrophy

Date:04/20/05ISR Number: 4640820-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction						27	MON

Date:04/20/05ISR Number: 4640821-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640822-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02090
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640823-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/20/05ISR Number: 4640824-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02086
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640825-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/20/05ISR Number: 4640826-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02091
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640837-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640838-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640839-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640840-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640852-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640854-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640856-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640857-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640858-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640859-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02110
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640860-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640861-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640862-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640863-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02111
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640864-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02095
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640865-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02263
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Premarin	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	

Date:04/20/05ISR Number: 4640866-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02698
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640867-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/20/05ISR Number: 4640868-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640869-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640879-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02713
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640880-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02114
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640881-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02706
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640882-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640883-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640884-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02704
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640885-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Injury Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640886-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640887-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02703
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640888-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02710
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640901-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03013
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640902-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02866
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640903-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02718
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640914-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640915-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640916-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03033
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640918-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03018
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Injury
	Myocardial Infarction
	Renal Injury

		Thrombosis					
		Ulcer					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/20/05ISR Number: 4640919-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03031
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/20/05ISR Number: 4640920-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03036
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:04/20/05ISR Number: 4640921-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03028
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/20/05ISR Number: 4640922-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03032
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640923-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03025
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury

Thrombosis
Ulcer

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640924-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640925-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03035
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640926-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Failure	Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident				
	Chest Pain				
	Hepatocellular Damage				
	Injury				
	Myocardial Infarction				
	Renal Injury				
	Thrombosis				
	Ulcer				

Date:04/20/05ISR Number: 4640927-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03024
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Injury
	Myocardial Infarction

	Renal Injury Thrombosis Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/20/05ISR Number: 4640933-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/20/05ISR Number: 4640934-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/20/05ISR Number: 4640935-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/20/05ISR Number: 4640936-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Disorder Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640937-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640938-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640939-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640940-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640942-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00085
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cough							
	Erectile Dysfunction							
	Gastric Disorder							
	Myocardial Infarction							
	Rash							
	Seasonal Allergy							

Date:04/20/05ISR Number: 4640943-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640944-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03360
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	179 DAY	

Date:04/20/05ISR Number: 4640945-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640946-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03121
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder							

Date:04/20/05ISR Number: 4640947-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03038
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/20/05ISR Number: 4640948-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03119
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640949-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
	Atherosclerosis
Disability	Atrioventricular Block
Other	First Degree
	Benign Prostatic Hyperplasia

Blood Pressure
Inadequately Controlled
Bundle Branch Block Right
Cataract
Cellulitis
Cerebellar Infarction
Cerebrovascular Accident
Chalazion
Chest Pain
Coronary Artery Disease
Dizziness
Dyslipidaemia
Gastric Disorder
Gastrooesophageal Reflux
Disease
Hypertension
Injury
Lacunar Infarction
Sinus Arrhythmia
Sinus Bradycardia
Sinus Tachycardia

		Supraventricular Tachycardia Vestibular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
8	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol	C		
UNKNOWN							

Date:04/20/05ISR Number: 4640950-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/20/05ISR Number: 4640951-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00111
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Adverse Event Carotid Artery Aneurysm Cerebral Haemorrhage Cerebrovascular Accident General Physical Health Deterioration Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/20/05ISR Number: 4640952-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction					

Date:04/20/05ISR Number: 4640953-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01433
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Pain
	Anxiety
	Arteriospasm Coronary
	Atrial Fibrillation
	Back Pain
	Biliary Colic
	Blood Cholesterol Increased
	Blood Homocysteine Decreased
	Blood Pressure Increased
	Bronchial Irritation
	Cardiac Failure Congestive
	Cardioactive Drug Level Above Therapeutic
	Cardioactive Drug Level Increased
	Chills

Condition Aggravated	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Cholelithiasis							
Colitis							
Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	157	DAY
Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL	157	DAY
Dysphagia		Hyzaar	C		ORAL		
Dyspnoea		Klor-Con	C			UNKNOWN	
Fatigue		Vitamins (Unspecified)	C			UNKNOWN	
Flatulence							
Gastric Disorder		Tamoxifen Citrate	C			UNKNOWN	
Gastritis							
Gastroenteritis Viral							
Glaucoma							
Glycosylated Haemoglobin Increased							
Hepatic Steatosis							
Hepatomegaly							
Hormone Level Abnormal							
Hydronephrosis							
Hypercalcaemia							
Injury							
Mitral Valve Incompetence							
Myocardial Infarction							
Myofascial Pain Syndrome							
Nausea							
Nephrolithiasis							
Oedema Peripheral							
Oesophageal Spasm							
Oesophagitis							
Otitis Media Acute							
Overdose							
Pain							
Pain In Extremity							
Palpitations							
Pharyngitis							
Prinzmetal Angina							
Pyrexia							
Road Traffic Accident							
Seasonal Allergy							
Sinus Congestion							
Stress							

Temporomandibular Joint
Syndrome
Venous Insufficiency
Ventricular Hypokinesia
Vomiting
Whiplash Injury

Date:04/20/05ISR Number: 4640954-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03118
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640955-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00779
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Aortic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
15 DAY								
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		
15 DAY								
	Pulmonary Disease		Plavix	C				
UNKNOWN								
	Colonic Polyp		Prilosec	C				
UNKNOWN								
	Convulsion		Lipitor	C				
UNKNOWN								
	Coronary Artery Stenosis		Zocor	C		ORAL		
	Diaphragmatic Disorder		Zocor	C		ORAL		
	Diaphragmatic Hernia		Aspirin	C				
UNKNOWN								
	Diverticulum							
	Foot Fracture							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hypercholesterolaemia							
	Hypotension							
	Intervertebral Disc							
	Degeneration							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Osteoporosis							
	Post Procedural Haematoma							
	Spinal Osteoarthritis							
	Treatment Noncompliance							

Date:04/20/05ISR Number: 4640956-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/20/05ISR Number: 4640957-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00966
Age:30 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Coronary Syndrome
	Anxiety
	Arterial Thrombosis
	Asthenia
	Balance Disorder
	Blood Pressure Diastolic Increased
	Bronchitis Acute
	Chest Discomfort
	Chest Pain
	Constipation
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diabetes Mellitus
	Diarrhoea
	Discomfort
	Dizziness

		Dyspepsia					
		Electrocardiogram Change					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
6	DAY						
		Fibrin D Dimer Increased		Ovcon	C		
UNKNOWN							
		Gallbladder Disorder		Ibuprofen	C		
UNKNOWN							
		Gastrooesophageal Reflux		Amitriptyline			
		Disease		Hydrochloride	C		
UNKNOWN							
		Head Injury					
		Helicobacter Infection					
		Herpes Zoster					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hypersensitivity					
		Lethargy					
		Limb Discomfort					
		Myocardial Infarction					
		Nausea					
		Oesophageal Spasm					
		Pain In Extremity					
		Palpitations					
		Panic Attack					
		Paraesthesia					
		Protein S Deficiency					
		Pulmonary Oedema					
		Rash					
		Sinusitis					
		Sweat Gland Infection					
		Vomiting					

Date:04/20/05ISR Number: 4640958-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00084
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						

	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Renal Cell Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL
7 DAY						
	Stage Iii		Candesartan Cilexetil And Hydrochlorothiazide	C		
	Tachycardia					
UNKNOWN						
			Candesartan Cilexetil And Hydrochlorothiazide	C		
UNKNOWN						
			Bisoprolol	C		
UNKNOWN						
			Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL

Date:04/20/05ISR Number: 4640959-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Disability Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/20/05ISR Number: 4640960-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00179
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Nolvadex	C				
UNKNOWN								
Other	Chest Pain		Synthroid	C				
UNKNOWN								
	Constipation		Ecotrin	C				
UNKNOWN								
	Coronary Artery Disease		Lopressor	C				
UNKNOWN								
	Dementia		Zestril	C				
UNKNOWN								
	Dizziness		Rocaltrol	C				
UNKNOWN								
	Dyspnoea		Lipitor	C				
UNKNOWN								
	Hip Fracture							
	Hyperhidrosis							
	Myocardial Infarction							
	Nausea							
	Transient Ischaemic Attack							
	Weight Decreased							

Date:04/20/05ISR Number: 4640961-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00777
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Keflex	C				
UNKNOWN								
	Depression		Roxicet	C				
UNKNOWN								
	Disorientation							
	Dry Mouth							
	Dysgraphia							
	Erectile Dysfunction							
	Gastritis							
	Hypertensive Crisis							

	Hypoacusis
	Insomnia
	Nausea
	Neurological Symptom
	Oedema
	Reading Disorder
	Renal Failure
	Speech Disorder

Date:04/20/05ISR Number: 4640962-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04529
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Asthenia
	Back Pain
	Blood Pressure Systolic Increased
	Body Temperature Decreased
	Bone Pain
	Cardiac Murmur
	Chest Discomfort
	Chest Pain
	Chest Wall Pain
	Dyspnoea

		Headache					
		Hyperhidrosis					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Left Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL
		End-Diastolic Pressure					
		Increased					
		Migraine					
		Mitral Valve Prolapse					
		Muscle Strain					
		Musculoskeletal					
		Discomfort					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Pleuritic Pain					

Date:04/20/05ISR Number: 4640964-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02850
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 1034 DAY		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Synthroid	C		
UNKNOWN							
		Increased		Maxzide	C		
UNKNOWN							
		Cardiomegaly					
		Carpal Tunnel Syndrome					
		Cerebrovascular Accident					
		Chest Pain					
		Decreased Appetite					
		Deep Vein Thrombosis					
		Depression					
		Dizziness					
		Dyspepsia					
		Dyspnoea Exertional					
		Electrocardiogram					
		Abnormal					
		Fatigue					
		Gastritis					
		Hypertension					
		Liver Function Test					
		Abnormal					

Migraine With Aura
Oedema Peripheral
Oesophagitis
Osteoarthritis
Palpitations
Stomach Discomfort
Stress
Transient Ischaemic
Attack
Urge Incontinence
Wound Dehiscence

Date:04/20/05ISR Number: 4640966-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03022
Age: Gender:Female I/FU:I

Outcome PT
Other Cardiac Failure
Cerebrovascular Accident
Chest Pain

		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Ulcer					

Date:04/20/05ISR Number: 4640967-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03040
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/21/05ISR Number: 4640996-6Report Type:Expedited (15-DaCompany Report #AU-BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.-2005-
BAge: 29AU Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Angioplasty		Mobic	PS	B.I.	
		Cerebrovascular Accident				Pharmaceuticals,Inc.	
		Myocardial Infarction				/Ridgefield	ORAL
		Pulmonary Infarction		Celebrex	SS		
		Stent Placement		Vioxx	SS		

Date:04/21/05ISR Number: 4641316-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00781
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Angina Unstable
	Cardiac Failure

Congestive
Chest Pain
Chronic Obstructive
Pulmonary Disease
Coronary Artery Occlusion
Hypertensive Heart
Disease
Hypothyroidism
Ischaemic Stroke
Lower Respiratory Tract
Infection
Mitral Valve Incompetence
Myocardial Infarction
Nasopharyngitis
Pulmonary Congestion
Renal Failure
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence

Ventricular Dysfunction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:04/21/05ISR Number: 4641319-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02539
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrioventricular Block		Prilosec	C			UNKNOWN	
Disability	Complete		Hydrochlorothiazide	C			UNKNOWN	
	Back Disorder							
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiogenic Shock							
	Carotid Artery Stenosis							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Occlusion							
	Injury							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Pleural Effusion							
	Thromboembolic Stroke							
	Tricuspid Valve							
	Incompetence							
	Ventricular Fibrillation							

Date:04/21/05ISR Number: 4641320-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03239
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		[Therapy					

Other	Diplopia		Unspecified]	C		
UNKNOWN						
	Emotional Distress		Ecotrin	C		ORAL
	Gastrooesophageal Reflux		Accupril	C		
UNKNOWN						
	Disease		Hyzaar	C		
UNKNOWN						
	Hypertension		Advil	C		
UNKNOWN						
	Renal Artery Stenosis					

Date:04/21/05ISR Number: 4641321-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02202
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Initial or Prolonged	Chest Pain		Mobic	C		
UNKNOWN						
	Coagulopathy		Neurontin	C		ORAL
	Deep Vein Thrombosis		Allegra	C		ORAL
	Pulmonary Infarction		Cardizem La	C		ORAL
			Maxzide	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641324-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00082
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							
	Hypertensive Crisis							
	Mucous Membrane Disorder							
	Reflux Oesophagitis							
	Sinoatrial Block							

Date:04/21/05ISR Number: 4641338-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	76	DAY

Date:04/21/05ISR Number: 4641340-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00438
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Connective Tissue		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Inflammation		Vicodin Tablets	C				
UNKNOWN								
	Coronary Artery Disease							
	Depression							
	Dyspnoea							
	Emotional Distress							
	Fatigue							
	Heart Rate Irregular							
	Injury							
	Intervertebral Disc							
	Degeneration							
	Intervertebral Disc							
	Protrusion							
	Libido Disorder							
	Micturition Disorder							

Mitral Valve Prolapse
Myocardial Infarction
Normochromic Normocytic
Anaemia
Sleep Apnoea Syndrome
Spinal Compression
Fracture
Spinal Osteoarthritis
Weight Increased

Date:04/21/05ISR Number: 4641341-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641342-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00381
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Coronary Artery Disease							
	Hepatocellular Damage							
	Hypertension							
	Myocardial Infarction							
	Renal Impairment							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641343-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON
	Myocardial Infarction							

Date:04/21/05ISR Number: 4641344-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02867
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641347-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02865
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Disorder					
	Thrombosis					
	Ulcer					

Date:04/21/05ISR Number: 4641348-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02843
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Renal Disorder

		Thrombosis					
		Ulcer					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/21/05ISR Number: 4641349-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02846
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:04/21/05ISR Number: 4641360-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01686
Age:76 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension					
		Muscle Atrophy					
		Palpitations					

Date:04/21/05ISR Number: 4641361-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02167
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/21/05ISR Number: 4641362-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00819
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641364-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641365-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01794
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Gastric Disorder		Accupril	C				UNKNOWN
	Joint Swelling		Prevacid	C				UNKNOWN
	Rash		Synthroid	C				UNKNOWN
			Premarin	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN

Date:04/21/05ISR Number: 4641366-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641367-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641368-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02434
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/21/05ISR Number: 4641369-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1626 DAY

Date:04/21/05ISR Number: 4641370-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:04/21/05ISR Number: 4641377-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641384-9Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0553303A
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Tums E-X Tablets,			
Initial or Prolonged	Arthritis		Sugar Free Orange	PS	Glaxosmithkline	ORAL
	Chest Pain		Vioxx	SS		ORAL
	Coronary Artery Stenosis		Celebrex	SS		ORAL
	Myocardial Infarction		Bextra	SS		ORAL
	Renal Failure Acute		Synthroid	C	Glaxosmithkline	ORAL
	Tooth Infection		Toprol Xl	C		ORAL
			Zantac	C	Glaxosmithkline	ORAL
			Baby Aspirin	C	Glaxosmithkline	ORAL
			Avandia	C	Glaxosmithkline	ORAL
			Norvasc	C		ORAL
			Imdur	C		ORAL
			Altace	C		ORAL
			Plavix	C		ORAL
			Catapres Tts	C		
			Lipitor	C		ORAL

Date:04/21/05ISR Number: 4641392-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02897
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Injury					
	Thrombosis					
	Ulcer					

Date:04/21/05ISR Number: 4641393-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					

Chest Pain
Hepatocellular Damage
Myocardial Infarction
Renal Disorder
Thrombosis
Ulcer

Date:04/21/05ISR Number: 4641394-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02869
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641395-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641396-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02881
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641397-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02871
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641399-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641400-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02206
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641401-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02890
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis					
		Ulcer					

Date:04/21/05ISR Number: 4641402-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02895
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:04/21/05ISR Number: 4641403-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02883
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Renal Disorder					
		Thrombosis					
		Ulcer					

Date:04/21/05ISR Number: 4641412-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02898
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Cardiac Failure	Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident				
	Chest Pain				
	Hepatocellular Damage				
	Myocardial Infarction				
	Renal Injury				
	Thrombosis				
	Ulcer				

Date:04/21/05ISR Number: 4641413-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02902
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Renal Injury
	Thrombosis

Ulcer

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641414-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641415-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641416-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03042
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641417-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02900
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Renal Injury					
	Thrombosis					
	Ulcer					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641418-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641419-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641420-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641425-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Cerebrovascular Accident
Chest Pain
Hepatocellular Damage
Myocardial Infarction
Renal Injury
Thrombosis
Ulcer

Date:04/21/05ISR Number: 4641426-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03049
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641427-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641428-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03051
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641429-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641430-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03053
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641431-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641432-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641433-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03050
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641434-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641435-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641440-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641441-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03359
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641442-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03356
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641443-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641444-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON
	Arterial Thrombosis							
	Atherosclerosis							
	Myocardial Infarction							
	Thrombosis							

Date:04/21/05ISR Number: 4641445-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03059
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Hepatocellular Damage
	Myocardial Infarction
	Polytraumatism

	Renal Injury Thrombosis Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/21/05ISR Number: 4641454-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03361
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/21/05ISR Number: 4641455-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03098
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/21/05ISR Number: 4641456-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03362
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/21/05ISR Number: 4641464-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury		Vioxx	PS	Merck & Co., Inc	ORAL	

Thrombosis
Ulcer

Date:04/21/05ISR Number: 4641465-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03100
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641516-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641752-5Report Type:Expedited (15-DaCompany Report #2005056765
Age:31 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged (1 IN 1 D),	Dyspnoea	Consumer	Celebrex (Celecoxib)	PS				
	Pruritus Generalised		Bextra (Valdecoxib)	SS		ORAL		
Other	Surgery							
	Weight Fluctuation		Rofecoxib (Rofecoxib)	SS				
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	C				
			Oxycocet (Oxycodone Hydrochloride , Paracetamol)	C				

Date:04/21/05ISR Number: 4641783-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA02212
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	447 DAY	
	Retinal Vein Occlusion							

Date:04/21/05ISR Number: 4641785-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00921
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Avalide	C			UNKNOWN	
	Angina Pectoris		Cardura	C			UNKNOWN	
	Aortic Valve Sclerosis		Plavix	C			UNKNOWN	
	Atrial Fibrillation		Ecotrin	C			UNKNOWN	
	Blood Pressure Increased							

Cardiac Murmur
Cerebrovascular Accident
Colonic Polyp
Convulsion
Cough
Depression
Diarrhoea
Dilatation Atrial
Diverticulum Intestinal
Dizziness
Fatigue
Feeling Abnormal
Frequent Bowel Movements
Gastritis Erosive
Haemorrhoids
Hypoaesthesia
Mitral Valve Incompetence
Mitral Valve Sclerosis
Oesophageal Disorder
Pyrexia
Sick Sinus Syndrome
Tricuspid Valve
Incompetence
Upper Gastrointestinal
Haemorrhage
Ventricular Hypertrophy
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641788-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00068
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Atelectasis		Zocor	SS		ORAL		
Other	Atrial Fibrillation		Zocor	SS		ORAL		
UNKNOWN	Blood Cholesterol		Methotrexate	C				
	Increased		Prednisone	C		ORAL		
UNKNOWN	Blood Creatinine		Atenolol	C				
	Increased		Motrin	C				
UNKNOWN	Bradycardia		Vitamins					
	Coronary Artery		(Unspecified)	C				
UNKNOWN	Atherosclerosis		Zantac	C		ORAL		
	Coronary Artery Disease		Claritin Reditabs	C				
UNKNOWN	Coronary Artery		Temazepam	C				
UNKNOWN	Reocclusion		Percocet	C				
UNKNOWN	Coronary Bypass		Folic Acid	C				
UNKNOWN	Thrombosis		Ambien	C				
UNKNOWN	Deep Vein Thrombosis		Ismo	C				
UNKNOWN	Diverticulitis Intestinal		Oxycodone					
	Haemorrhagic		Hydrochloride	C				
UNKNOWN	Diverticulum							
	Dizziness							
	Fatigue							
	Haemorrhoids							
	Hyperlipidaemia							
	Hypertension							
	Intervertebral Disc							
	Degeneration							
	Medical Device							
	Complication							
	Myalgia							
	Myocardial Infarction							
	Nausea							

Polyp
Pyrexia
Renal Failure Chronic
Respiratory Distress
Sigmoiditis
Vascular Graft Occlusion
Visual Acuity Reduced
Weight Decreased
Wound Dehiscence

Date:04/21/05ISR Number: 4641803-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anaemia
Other	Angina Pectoris
	Arthralgia
	Atherosclerosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chondromalacia
	Convulsion
	Diabetes Mellitus
	Inadequate Control
	Diabetic Complication

		Diabetic Neuropathy					
		Diverticulum					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Eye Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Gastritis		Plavix	SS		
UNKNOWN							
		Haemorrhoidal Haemorrhage		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hand Fracture		Captopril Msd	C		ORAL
		Hypertension		Evista	C		
UNKNOWN							
		Hypotension		Amitriptyline			
		Joint Dislocation		Hydrochloride	C		
UNKNOWN							
		Leukopenia		Glucotrol Xl	C		
UNKNOWN							
		Ligament Sprain		Synthroid	C		
UNKNOWN							
		Meniscus Lesion		Prilosec	C		ORAL
		Muscle Spasms		Humulin	C		
UNKNOWN							
		Myelodysplastic Syndrome					
		Orthostatic Hypotension					
		Pain In Extremity					
		Pharyngitis					
		Subcutaneous Abscess					
		Surgery					
		Syncope					
		Thrombocytopenia					
		Upper Respiratory Tract					
		Infection					
		Urinary Tract Infection					

Date:04/21/05ISR Number: 4641805-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00146
Age:51 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged Disability		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:04/21/05ISR Number: 4641806-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01597
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Increased
Disability	Cardiac Disorder
Other	Cerebrovascular Accident
	Chest Pain
	Chest Wall Pain
	Diabetic Neuropathy
	Ejection Fraction Decreased
	Intervertebral Disc Disorder
	Intervertebral Disc Displacement
	Intervertebral Disc Protrusion
	Lacunar Infarction
	Myocardial Ischaemia
	Osteoarthritis
	Peroneal Nerve Palsy
	Radiculopathy
	Retinopathy

Spondylolisthesis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Insulin	C			UNKNOWN	
	Lisinopril	C			UNKNOWN	

Date:04/21/05ISR Number: 4641807-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00164
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	84	DAY
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	84	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	21	DAY
			Esomeprazole Magnesium	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		

Date:04/21/05ISR Number: 4641808-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03399
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Disorder		Vicodin Tablets	C				
UNKNOWN								

Initial or Prolonged Disability	Ulcer		[Therapy Unspecified]	C		
UNKNOWN						

Date:04/21/05ISR Number: 4641809-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00657
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641810-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03255
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641811-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02663
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atherosclerosis		Glucophage	C				UNKNOWN
	Atrial Fibrillation		Aspirin	C				UNKNOWN
	Blood Cholesterol		Plavix	C				UNKNOWN
	Increased		Lipitor	C				UNKNOWN
	Brain Stem Infarction		Altace	C				UNKNOWN
	Cerebrovascular Accident		Zocor	C				UNKNOWN
	Constipation		Glucotrol	C				UNKNOWN
	Coronary Artery Disease							
	Diabetes Mellitus							
	Inadequate Control							
	Heart Rate Irregular							
	Hypertension							
	Mitral Valve Incompetence							
	Neuropathy Peripheral							

Date:04/21/05ISR Number: 4641812-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03953
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Diovan	C				UNKNOWN
	Fatigue		Prilosec	C		ORAL		
	Myocardial Infarction		Lexapro	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		

Date:04/21/05ISR Number: 4641813-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641814-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00121
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641815-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02207
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641817-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01207
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Bronchitis Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Synthroid	C			UNKNOWN	
	Congestive		Lorazepam	C			UNKNOWN	
	Cardiac Stress Test		Flurazepam	C			UNKNOWN	
	Abnormal		Estrace	C			UNKNOWN	
	Cataract		Xanax	C			UNKNOWN	
	Congestive Cardiomyopathy		Flonase	C			UNKNOWN	
	Coronary Artery Disease		Claritin	C			UNKNOWN	
	Depression		Dalmane	C			UNKNOWN	
	Diarrhoea		Aspirin	C			UNKNOWN	
	Eating Disorder		Vitamins (Unspecified)	C			UNKNOWN	
	Ejection Fraction Decreased							
	Gastrooesophageal Reflux Disease							
	Hypotrichosis							
	Insomnia							
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Night Cramps							
	Oesophageal Candidiasis							
	Palpitations							
	Pulmonary Hypertension							
	Silent Myocardial Infarction							
	Tricuspid Valve Incompetence							
	Ventricular Hypokinesia							
	Vertigo Positional							
	Vulval Haemorrhage							

Weight Decreased

Date:04/21/05ISR Number: 4641818-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641819-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02211
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641820-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Circulatory Collapse Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641821-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641822-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641823-3Report Type:Expedited (15-DaCompany Report #IT-MERCK-0504ITA00019
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL		21 MON
	Myocardial Ischaemia							

Date:04/21/05ISR Number: 4641824-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641825-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02209
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641826-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641827-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641828-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02436
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641829-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641830-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02107
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641831-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641832-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02354
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641833-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02450
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641834-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641835-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02466
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641836-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02455
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641837-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641838-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641839-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02452
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641840-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02468
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641842-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641843-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641844-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641845-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641846-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641847-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641848-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641849-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02633
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641850-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641851-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02684
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641852-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641853-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02956
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641854-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	49	MON

Date:04/21/05ISR Number: 4641855-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/21/05ISR Number: 4641856-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02469
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641857-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02680
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	2	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641858-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03063
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641859-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641860-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4641861-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	OPHTHALMIC		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641862-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03060
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641863-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Insufficiency Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641864-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641865-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Renal Injury
Thrombosis
Ulcer

Date:04/21/05ISR Number: 4641866-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641867-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Disorder Fall Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641868-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641869-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641870-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03126
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/21/05ISR Number: 4641871-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

	Injury		Vioxx	SS	Merck & Co., Inc	ORAL

1 YR

Date:04/21/05ISR Number: 4641872-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641873-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03132
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
Other	Myocardial Infarction							

Date:04/21/05ISR Number: 4641874-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03138
Age:51 YR Gender:Male I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:04/21/05ISR Number: 4641875-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03131
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder							
	Myocardial Infarction							

Date:04/21/05ISR Number: 4641876-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/21/05ISR Number: 4641877-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Disability	Injury							

Date:04/21/05ISR Number: 4641879-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03293
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Cardiac Disorder Heart Injury						

Date:04/21/05ISR Number: 4641880-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641881-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:04/21/05ISR Number: 4641882-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03264
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641883-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03320
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641884-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641885-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03265
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
			Vioxx	SS	Merck & Co., Inc	ORAL	5	YR

Date:04/21/05ISR Number: 4641886-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641888-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03134
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641889-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/21/05ISR Number: 4641892-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/05ISR Number: 4641893-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Injury							
	Myocardial Infarction							

Date:04/21/05ISR Number: 4641894-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Injury							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/21/05ISR Number: 4642919-2Report Type:Expedited (15-DaCompany Report #WAES 0503NOR00042
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 90	Coronary Artery Occlusion	Foreign	Tab Etoricoxib 90 Mg	PS		ORAL		
Initial or Prolonged	Myocardial Infarction	Health						
MG/DAILY/PO								
		Professional	Tab Vioxx 25 Mg	SS		ORAL		
25 MG/BID/PO								
			Vasoretic	C				
			Amlodipine Besylate	C				
			Metoprolol Tartrate	C				

Date:04/21/05ISR Number: 4642935-0Report Type:Expedited (15-DaCompany Report #2004105304
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Leukocytoclastic Vasculitis	Foreign Health	Celebrex (Celecoxib)	PS		ORAL	(200 MG, 1 IN 1 D), ORAL	
	Skin Ulcer Vascular Purpura	Professional	Rofecoxib (Rofecoxib)	SS		ORAL	(1 IN 1 D), ORAL	

Date:04/21/05ISR Number: 4643372-5Report Type:Expedited (15-DaCompany Report #2005057665
Age:88 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Height Decreased	Health	Feldene (Piroxicam)	PS			(1 IN 1 D)	
	Gastrointestinal Haemorrhage	Professional	Motrin (Ibuprofen) (Ibuprofen)	SS		ORAL	3200 MG (800 MG, 4 IN 1 D), ORAL	
	Thrombosis							
			Rofecoxib (Rofecoxib)	SS				
			Oxycodone (Oxycodone)	C				
			Verapamil					

		Hydrochloride (Verapamil Hydrochloride)	C	
		Verapamil (Verapamil)	C	

Date:04/22/05ISR Number: 4642055-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemorrhage							
	Myocardial Infarction							
	Thrombosis							

Date:04/22/05ISR Number: 4642198-6Report Type:Expedited (15-DaCompany Report #200414349FR
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Claforan	PS	Aventis Pharmaceuticals Inc.		INTRAVENOUS	
	Chronic Respiratory Failure		Vancomycine	SS			INTRAVENOUS	
	Encephalopathy		Dafalgan	SS		ORAL		
	Grand Mal Convulsion		Vioxx	SS		ORAL		
	Hypertension		Morphine					
	Iatrogenic Injury		Chlorhydrate	SS		ORAL		
	Nodal Rhythm		Acupan	SS			INTRAVENOUS	
	Reversible Posterior Leukoencephalopathy Syndrome		Troxerutin	C				
			Stresam	C				
			Stilnox	C				

Date:04/22/05ISR Number: 4642250-5Report Type:Expedited (15-DaCompany Report #AU-BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.-2005-BAge: 29AU Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Mobic	PS	B.I.			

	Cerebrovascular Accident		Pharmaceuticals,Inc.	
	Myocardial Infarction		/Ridgefield	ORAL
	Pulmonary Infarction	Celebrex	SS	
		Vioxx	SS	

Date:04/22/05ISR Number: 4642476-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00113
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
	Aortic Atherosclerosis
	Asthenia
	Blood Glucose Increased
	Carotid Artery Atheroma
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Confusional State
	Convulsion
	Dilatation Atrial
	Dizziness
	Facial Neuralgia

Gait Disturbance
Headache
Hemianopia Homonymous
Nephropathy
Scar
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Zocor	C		ORAL		
	Glucophage Xr	C		ORAL		
	Ecotrin	C		ORAL		
	Trental	C		ORAL		
	Humalog	C		SUBCUTANEOUS		
	Synthroid	C		ORAL		
	Lipitor	C		UNKNOWN		

Date:04/22/05ISR Number: 4642478-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01752
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Acute Myocardial Infarction
Other	Anal Inflammation
	Anxiety Disorder
	Back Injury
	Back Pain
	Blood Alkaline Phosphatase Increased
	Blood Amylase Decreased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Cervical Spasm
	Chest Pain
	Colonic Polyp
	Constipation
	Convulsion
	Coordination Abnormal
	Coronary Artery Occlusion
	Depression
	Dermatitis
	Haematochezia
	Haemorrhoidal Haemorrhage
	Haemorrhoids

Hypercholesterolaemia
Hyperlipidaemia
Hypertension
Memory Impairment
Mental Status Changes
Muscle Spasms
Nasal Cyst
Nasal Mucosal Disorder
Obesity
Oedema Peripheral
Paraesthesia
Pharyngitis
Rhinitis
Sensory Disturbance
Sinus Polyp
Sleep Apnoea Syndrome
Stomach Discomfort
Stress

	Upper Respiratory Tract Infection						
	Ventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	51	DAY
			Tenormin	C			UNKNOWN	

Date:04/22/05ISR Number: 4642479-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05057
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chronic Obstructive		Advair	C			UNKNOWN	
Initial or Prolonged	Pulmonary Disease		Singulair	C			UNKNOWN	
	Emphysema		Buspar	C			UNKNOWN	

Date:04/22/05ISR Number: 4642480-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03136
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642481-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00098
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/05ISR Number: 4642483-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00130
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Disability Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642484-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00165
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:04/22/05ISR Number: 4642486-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00024
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiac Arrest Cardio-Respiratory Arrest Face Oedema

		Gastrooesophageal Reflux Disease					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Otitis Media Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Sudden Death		Atacand	C		
UNKNOWN							
		Tendonitis		Ziac	C		
UNKNOWN							
		Weight Increased		Zyrtec	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tums	C		
UNKNOWN							

Date:04/22/05ISR Number: 4642487-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00094
Age:73 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Avalide	C		
UNKNOWN							
		Chest Pain		Ambien	C		
UNKNOWN							
		Lacunar Infarction		Aspirin	C		
UNKNOWN							
		Myocardial Infarction		Lescol	C		
UNKNOWN							
		Transient Ischaemic Attack					

Date:04/22/05ISR Number: 4642489-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00956
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Respiratory Failure

Life-Threatening	Angina Pectoris
Hospitalization -	Anxiety Disorder
Initial or Prolonged	Aortic Stenosis
	Aortic Valve Incompetence
	Atrioventricular Block
	First Degree
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Catheter Sepsis
	Cerebral Haemorrhage
	Cerebrovascular Accident
	Chest Pain
	Coma
	Convulsion
	Coronary Artery Disease
	Eye Pain
	Haemoglobin Decreased
	Haemophilus Infection
	Headache
	Klebsiella Sepsis
	Mitral Valve
	Calcification

		Oral Candidiasis Pneumonia Aspiration Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scar		Vioxx	PS	Merck & Co., Inc	ORAL
1186 DAY							
		Sepsis		Monopril	C		ORAL
		Sinus Bradycardia		Toprol Xl Tablets	C		ORAL
		Sputum Culture Positive		Nasonex	C		
RESPIRATORY							
		Staphylococcal Sepsis					
(INHALATION)							
		Ventricular Extrasystoles		Zithromax	C		
UNKNOWN							
		Ventricular Hypertrophy		Allegra	C		ORAL
		White Blood Cell Count		Imdur	C		
UNKNOWN							
		Increased		Imdur	C		
UNKNOWN							
				Enulose	C		
UNKNOWN							
				Nitroquick	C		
UNKNOWN							
				Acular	C		
UNKNOWN							
				Lotemax	C		
UNKNOWN							
				Ocuflox	C		
UNKNOWN							
				Cefzil	C		
UNKNOWN							
				Promethazine	C		
UNKNOWN							
				Alrex	C		
UNKNOWN							
				Alocril	C		
UNKNOWN							
				Biaxin	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Zocor	C		ORAL
				Diazepam	C		
UNKNOWN							
				Rhinocort Aqua	C		
UNKNOWN							

			Patanol	C	
UNKNOWN					
			Flomax (Morniflumate)	C	
UNKNOWN					
			Levaquin	C	
UNKNOWN					
			Aspirin	C	ORAL
			Zestril	C	
UNKNOWN					

Date:04/22/05ISR Number: 4642496-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642497-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02182
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642498-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01690
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642499-1Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00023
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1290 DAY	
Initial or Prolonged	Transient Ischaemic Attack							

Date:04/22/05ISR Number: 4642501-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02177
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Celebrex	C				

Date:04/22/05ISR Number: 4642502-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	42 MON	

Date:04/22/05ISR Number: 4642503-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02180
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Myocardial Infarction							

Date:04/22/05ISR Number: 4642504-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642505-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01618
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Epstein-Barr Virus Infection		Methotrexate	SS		ORAL	UNKNOWN	
			Levofloxacin	C				
	Lymphoproliferative Disorder		Pirbuterol Acetate	C			RESPIRATORY (INHALATION)	
			Cyanocobalamin	C			UNKNOWN	
			Medroxyprogesterone Acetate	C			UNKNOWN	

Date:04/22/05ISR Number: 4642508-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642511-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642512-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642516-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02186
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON

Date:04/22/05ISR Number: 4642517-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02914
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642518-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02188
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642519-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642520-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642521-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642524-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642531-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642532-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642534-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02950
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Diarrhoea Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	11 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642535-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642536-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642537-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642538-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Cerebrovascular Accident
Chest Pain
Hepatocellular Damage
Myocardial Infarction
Polytraumatism
Renal Injury
Thrombosis
Ulcer

Date:04/22/05ISR Number: 4642539-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02960
Age: Gender:Female I/FU:I

Outcome PT
Other Cardiac Failure
Cerebrovascular Accident
Chest Pain
Hepatocellular Damage
Myocardial Infarction
Polytraumatism
Renal Injury
Thrombosis

	Ulcer					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/05ISR Number: 4642540-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Polytraumatism					
	Renal Injury					
	Thrombosis					
	Ulcer					

Date:04/22/05ISR Number: 4642541-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Polytraumatism					
	Renal Injury					
	Thrombosis					
	Ulcer					

Date:04/22/05ISR Number: 4642542-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/05ISR Number: 4642546-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642547-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03065
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642550-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642551-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03056
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642552-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642553-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03067
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/22/05ISR Number: 4642556-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03066
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Polytraumatism					
	Renal Injury					
	Thrombosis					
	Ulcer					

Date:04/22/05ISR Number: 4642557-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Chest Pain					
	Hepatocellular Damage					
	Myocardial Infarction					
	Polytraumatism					
	Renal Injury					
	Thrombosis					
	Ulcer					

Date:04/22/05ISR Number: 4642563-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged Disability	Coronary Artery Occlusion							

Date:04/22/05ISR Number: 4642565-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03072
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642566-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03061
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642567-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03080
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642568-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03073
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642569-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/22/05ISR Number: 4642570-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03077
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Failure
	Cerebrovascular Accident

		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis					
		Ulcer					

Date:04/22/05ISR Number: 4642571-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03101
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/05ISR Number: 4642572-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03108
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
12 MON							
		Emotional Distress		Celebrex	C		
UNKNOWN							
		Pain					

Date:04/22/05ISR Number: 4642573-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03083
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Polytraumatism					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/22/05ISR Number: 4642575-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03145
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642576-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03137
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Embolism Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642577-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642578-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642579-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642580-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642581-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Renal Injury
Thrombosis
Ulcer

Date:04/22/05ISR Number: 4642582-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03074
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Hepatocellular Damage							
	Myocardial Infarction							
	Polytraumatism							
	Renal Injury							
	Thrombosis							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642583-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03147
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642590-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03149
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress Myocardial Infarction Pain Self Esteem Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642600-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03139
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642601-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03148
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia Emotional Distress Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642602-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03174
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death					
	Thrombosis					

Date:04/22/05ISR Number: 4642603-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:04/22/05ISR Number: 4642604-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03178
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642605-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642606-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642607-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03154
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Eye Operation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642608-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642609-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642613-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642614-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642615-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642616-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642617-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642618-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642619-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03195
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642620-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642621-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642639-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642640-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03272
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4642641-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03271
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642642-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642643-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642644-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642645-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642646-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642647-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642648-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642666-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	882	DAY

Date:04/22/05ISR Number: 4642667-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642669-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642670-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642671-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4642672-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0504ZAF00022
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Celecoxib	C		ORAL		

Date:04/22/05ISR Number: 4642673-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03514
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
8	MON							

Date:04/22/05ISR Number: 4642691-6Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050404847
Age: Gender:Male I/FU:I

Outcome	PT
Other	Body Height Decreased
	Colon Cancer
	Diverticulum
	Gastric Haemorrhage
	Haematemesis

		Haematochezia Thrombosis					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Motrin 800 Mg	PS		
OROPHARINGEAL							
				Feldene	SS		
				Vioxx	SS		
				Oxycodone	C		
OROPHARINGEAL							
				Calan	C		
OROPHARINGEAL							
				Verapamil	C		
OROPHARINGEAL							

Date:04/22/05ISR Number: 4642715-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03140
Age:51 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Coronary Artery Disease					
		Myocardial Infarction					
		Thrombosis					
		Transient Ischaemic					
		Attack					

Date:04/22/05ISR Number: 4642717-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03084
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Chest Pain					
		Hepatocellular Damage					
		Myocardial Infarction					
		Polytraumatism					
		Renal Injury					
		Thrombosis					
		Ulcer					

Date:04/22/05ISR Number: 4643154-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0204USA02151
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Percocet	C			UNKNOWN	
	Hypoaesthesia		Omega-3	C			UNKNOWN	
	Monoplegia		Ginkgo Biloba Extract	C			UNKNOWN	
	Myocardial Infarction							
	Pain In Extremity							
	Phlebitis							
	Sensory Loss							
	Thermal Burn							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643158-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104514
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Affect Lability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia		Azulfidine	C			UNKNOWN	
	Atherosclerosis		Prilosec	C			UNKNOWN	
	Back Pain		Enbrel	C			UNKNOWN	
	Blood Cholesterol		Enbrel	C			UNKNOWN	
	Increased		Prednisone	C			UNKNOWN	
	Blood Creatine		Prozac	C			UNKNOWN	
	Phosphokinase Mb		Prozac	C			UNKNOWN	
	Increased		Prozac	C			UNKNOWN	
	Blood Pressure Abnormal		Trazodone Hydrochloride	C			UNKNOWN	
	Cellulitis							
	Cerebrovascular Accident							
	Chest Pain							
	Coronary Artery Restenosis							
	Coronary Artery Stenosis							
	Dizziness Postural							
	Feeling Abnormal							
	Fluid Retention							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux Disease							
	Groin Pain							
	Gynaecomastia							
	Hiatus Hernia							
	Hypertension							
	Hypokalaemia							
	Myocardial Infarction							
	Nephrolithiasis							
	Post Procedural Complication							
	Psoriatic Arthropathy							

Rhinitis Seasonal
Therapeutic Response
Decreased

Date:04/22/05ISR Number: 4643159-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00927
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Asthma
	Back Pain
	Cardiac Failure
	Congestive
	Chronic Obstructive
	Pulmonary Disease
	Congestive Cardiomyopathy
	Convulsion
	Diverticulum Intestinal
	Haemorrhagic
	Gastrooesophageal Reflux
	Disease
	Hyperlipidaemia
	Hypertension

	Hypertensive Heart Disease					
	Lipoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
584	DAY					
	Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain In Extremity		Celebrex	C		
UNKNOWN						
	Spinal Osteoarthritis		Clonidine	C		
UNKNOWN						
	Tendonitis		Demadex	C		
UNKNOWN						
			Digitek	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Accupril	C		
UNKNOWN						

Date:04/22/05ISR Number: 4643162-3Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Anxiety
	Arthralgia
	Asthenia
	Benign Prostatic Hyperplasia
	Choking
	Cough
	Depression
	Diverticulum
	Dysgeusia
	Dyspepsia
	Dyspnoea
	Dysuria
	Early Satiety
	Erosive Duodenitis
	Erosive Oesophagitis
	Fatigue
	Gastric Disorder
	Gastritis Erosive
	Gastrooesophageal Reflux Disease

Heat Stroke
Hiatus Hernia
Hypertension
Hypoacusis
Intestinal Functional
Disorder
Lung Disorder
Malaise
Muscle Atrophy
Nasopharyngitis
Oesophageal Rupture
Pancreatitis
Renal Cyst
Rhinorrhoea
Stomach Discomfort
Stress
Supraventricular
Extrasystoles
Thromboembolic Stroke
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection

	Urinary Retention						
	Urinary Tract Disorder						
	Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C				UNKNOWN
			Restoril	C				UNKNOWN

Date:04/22/05ISR Number: 4643164-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00394
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Aspirin	C		ORAL		
	Osteoarthritis		Metoprolol Succinate	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Candesartan Cilexetil	C		ORAL		
			Doxazosin Mesylate	C		ORAL		
			Ranitidine Hydrochloride	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Magnesium Aspartate And Potassium Aspartate	C		ORAL		

Date:04/22/05ISR Number: 4643165-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00348
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Diclofenac Resinate	SS		ORAL		
	Inguinal Hernia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Neck Pain		Atenolol	C		ORAL		
	Osteoarthritis		Chlordiazepoxide Hydrochloride	C		ORAL		
	Paraesthesia							

Cyclandelate	C	ORAL
Levothyroxine Sodium	C	ORAL
Sumatriptan Succinate	C	ORAL
Dalteparin Sodium	C	

UNKNOWN

Pantoprazole Sodium	C	

UNKNOWN

Date:04/22/05ISR Number: 4643172-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00017
Age:66 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Blood Albumin Increased Blood Bilirubin Increased Blood Calcium Decreased Blood Phosphorus Decreased Blood Pressure Increased Cerebral Atrophy Dysarthria

	Gait Disturbance						
	Haematocrit Decreased						
	Laboratory Test Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	570	DAY
	Mitral Valve Prolapse		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Atorvastatin Calcium	C			UNKNOWN	
	Attack		Prednisolone	C			UNKNOWN	
			Citalopram Hydrobromide	C			UNKNOWN	
			Mianserin Hydrochloride	C			UNKNOWN	

Date:04/22/05ISR Number: 4643173-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00084
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Brain Scan Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction							
	Cerebrovascular Disorder							
	Dyspnoea							
	Hyperhidrosis							
	Intervertebral Disc Degeneration							
	Microangiopathy							
	Monoparesis							
	Sick Sinus Syndrome							
	Syncope							
	Treatment Noncompliance							

Date:04/22/05ISR Number: 4643174-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02845
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Death	Agitation
Hospitalization -	Atherosclerosis

Initial or Prolonged	Body Temperature
Other	Increased
	Cardiac Failure
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Coagulopathy
	Coma
	Hypertension
	Incoherent
	Intracardiac Thrombus
	Leukocytosis
	Loss Of Consciousness
	Multi-Organ Failure
	Myocardial Infarction
	Post Procedural
	Haemorrhage
	Rhonchi
	Sepsis
	Tooth Extraction
	Ventricular Dysfunction
	Ventricular Hypertrophy
	Ventricular Tachycardia

Wrist Fracture

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	DAY	
	Levoxyl	C			UNKNOWN	
	Zydone	C			UNKNOWN	
	Citracal	C		ORAL		
	Skelaxin	C			UNKNOWN	
	Skelaxin	C		ORAL		
	Lorcet 10/650	C			UNKNOWN	

Date:04/22/05ISR Number: 4643175-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02877
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Triglycerides		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	9	MON
Other	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Coronary Artery Disease							
	Hypertension							
	Lipids Increased							
	Myocardial Infarction							

Date:04/22/05ISR Number: 4643185-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02849
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
			Ultram	C		ORAL		
			Elavil	C		ORAL		
			Zoloft	C		ORAL		
			Nexium	C		ORAL		
			Zelnorm	C		ORAL		
			Coumadin	C				
			Accupril	C		ORAL		
			Neurontin	C		ORAL		
			Detrol	C		ORAL		
			Prempro	C		ORAL		
			Calcium (Unspecified)	C		ORAL		
			Calcitriol	C		ORAL		

Date:04/22/05ISR Number: 4643186-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02884
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Deep Vein Thrombosis
	Dizziness
	Dyspnoea

		Groin Pain					
		Pain In Extremity					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Traumatic Haematoma		Aspirin	C		
UNKNOWN							
		Varicose Vein		Visken	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Lactulose	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Didrex	C		
UNKNOWN							
				Epogen	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Florinef	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:04/22/05ISR Number: 4643188-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03525
Age:54 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
Other		Cardiac Arrest		Zocor	C		ORAL
1	YR						
		Cardiac Disorder		Zocor	C		ORAL
		Cardiovascular Disorder		Levaquin	C		
UNKNOWN							

	Chills	Plavix	C	
UNKNOWN				
	Cough	Toprol Xl Tablets	C	ORAL
	Fall	Aspirin	C	ORAL
	Headache	Aspirin	C	ORAL
	Increased Upper Airway Secretion	Vitamins (Unspecified)	C	
UNKNOWN				
	Joint Sprain			
	Myocardial Infarction			
	Nausea			
	Organ Failure			
	Pain			
	Pollakiuria			
	Pyrexia			
	Vomiting			

Date:04/22/05ISR Number: 4643189-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02214
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643190-8Report Type:Expedited (15-DaCompany Report #CH-MERCK-0504CHE00028
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643191-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00080
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Insufficiency		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysarthria		Hydrocodone Bitartrate	C			UNKNOWN	
	Gastric Disorder		Zocor	C			UNKNOWN	
	Hypersensitivity		Hydrocodone Bitartrate	C			UNKNOWN	
	Hypertension							
	Mental Impairment							
	Refusal Of Treatment By Patient							
	Transient Ischaemic Attack							

Date:04/22/05ISR Number: 4643193-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00182
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tremor		Insulin Human	C			UNKNOWN	
			Insulin Human, Isophane	C			UNKNOWN	
			Domperidone	C		ORAL		
			Metoprolol Succinate	C		ORAL		

Date:04/22/05ISR Number: 4643194-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01532
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	37	DAY

Hospitalization - 6 DAY	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Congestive Cerebrovascular Accident		Synthroid	C		ORAL
Other	Coronary Artery Atherosclerosis Hypertension Sinusitis Ventricular Hypertrophy		Lasix (Furosemide Sodium)	C		ORAL
			Premarin	C		ORAL

Date:04/22/05ISR Number: 4643195-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03262
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vasotec	C		ORAL		
	Cerebrovascular Accident		Diovan	C				UNKNOWN
	Depression		Norvasc	C				UNKNOWN
	Pain		Premarin	C				UNKNOWN

Date:04/22/05ISR Number: 4643196-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643197-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02212
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643198-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02213
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/22/05ISR Number: 4643200-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00386
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Ischaemic Cardiomyopathy		Benadryl	C				
UNKNOWN								
Other	Myocardial Infarction		Advil	C				
UNKNOWN								
	Pulmonary Hypertension		Tylenol	C				
UNKNOWN								
	Pulmonary Oedema							
	Respiratory Distress							
	Sinus Bradycardia							
	Stomach Discomfort							

Date:04/22/05ISR Number: 4643210-0Report Type:Expedited (15-DaCompany Report #2005026476
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy	Consumer	Celebrex (Celecoxib)	PS				
UNKNOWN							200 MG (200	

		Drug Effect Decreased				
MG, 1 IN 1						
		Drug Ineffective				
D), UNKNOWN						
		Faeces Discoloured		Bextra (Valdecoxib)	SS	
UNKNOWN	1 IN 1	D,				
		Flatulence				
UNKNOWN						
		Haemorrhage		Rofecoxib	SS	
		Osteoarthritis				
		Osteoporosis				

Date:04/22/05ISR Number: 4643217-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00022
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
226 DAY						
Initial or Prolonged	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
226 DAY						
	Chest Pain		Metoprolol Tartrate	C		ORAL
	Dyspnoea		Aspirin And			
	Myocardial Infarction		Magnesium Oxide	C		ORAL
			Isosorbide			
			Mononitrate	C		ORAL
			Ranitidine			
			Hydrochloride	C		ORAL
			Amlodipine Besylate	C		ORAL
			Nitroglycerin	C		ORAL
			Lactose	C		ORAL

Date:04/22/05ISR Number: 4643218-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643219-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02377
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643220-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00019
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 15 DAY	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Acetaminophen And Codeine Phosphate	C		ORAL		

Date:04/22/05ISR Number: 4643221-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643222-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02393
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Polytraumatism

Date:04/22/05ISR Number: 4643223-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643224-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643225-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02668
Age:60 YR Gender:Female I/FU:I

Outcome	PT
Disability	Adverse Event
	Asthenia
	Pain

Weight Increased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643226-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643227-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643235-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643236-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643237-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02689
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643238-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02735
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643239-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02740
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643240-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643241-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643242-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643243-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02733
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643244-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643245-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643246-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02747
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643247-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02682
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643248-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02671
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643250-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643253-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Cerebrovascular Accident
Myocardial Infarction
Polytraumatism

Date:04/22/05ISR Number: 4643254-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02676
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643255-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02688
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643256-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

Date:04/22/05ISR Number: 4643257-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02726
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643259-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643260-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03075
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident Chest Pain Hepatocellular Damage Myocardial Infarction Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643261-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:04/22/05ISR Number: 4643262-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03510
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643263-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643264-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643265-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction Polytraumatism							

Date:04/22/05ISR Number: 4643266-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03513
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643267-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03414
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Neoplasm Malignant		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:04/22/05ISR Number: 4643268-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/22/05ISR Number: 4643269-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643270-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03085
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643271-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643272-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643273-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643274-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643275-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03162
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/22/05ISR Number: 4643276-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03078
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Chest Pain
Hepatic Failure
Myocardial Infarction
Polytraumatism
Renal Injury
Thrombosis
Ulcer

Date:04/22/05ISR Number: 4643278-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03219
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Hospitalization -	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
Initial or Prolonged			Aspirin	C			UNKNOWN	
			Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/22/05ISR Number: 4643280-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00091
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertensive Heart		Vioxx	SS	Merck & Co., Inc	ORAL
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
			Clomipramine Hydrochloride	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL
			Nebivolol Hydrochloride	C		ORAL
			Lisinopril	C		ORAL

Date:04/22/05ISR Number: 4643281-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:04/22/05ISR Number: 4644952-3Report Type:Expedited (15-DaCompany Report #2005057597
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Blood Pressure Increased	Consumer	Celebrex (Celecoxib)	PS		ORAL
1 IN 1 D),						
	Dyspepsia					
ORAL						
	Feeling Abnormal		Bextra (Valdecoxib)	SS		
	Haematochezia		Rofecoxib			
	Headache		(Rofecoxib)	SS		
			Cetirizine			

	Hydrohcloride (Cetirizine Hydrochloride)	C

Date:04/22/05ISR Number: 4646370-0Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Death	Blood Bicarbonate Decreased
Hospitalization - Initial or Prolonged	Blood Ph Increased
	Carcinoembryonic Antigen Increased
	Cardiac Failure
	Cardio-Respiratory Arrest
	Dyspnoea
	Haematocrit Decreased
	Haemoglobin Decreased
	Infection
	Laboratory Test Abnormal
	Mean Cell Haemoglobin

	Concentration Decreased Mean Cell Haemoglobin Decreased Monocyte Count Increased	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neutrophil Count Increased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Oxygen Saturation Decreased Pco2 Decreased Pleural Effusion Pneumonia Post Procedural Complication Prothrombin Time Prolonged Red Cell Distribution Width Increased Therapy Non-Responder White Blood Cell Count Increased	Health Professional	Allopurinol	C		PO	293	DAY

Date:04/25/05ISR Number: 4643824-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00651
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anticoagulation Drug Level Above Therapeutic		Vioxx Tums	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
Other	Blood Urea Increased		Pepcid	C			UNKNOWN	
	Cerebrovascular Accident		Coumadin	C			UNKNOWN	
	Heart Rate Irregular Upper Gastrointestinal Haemorrhage							

Date:04/25/05ISR Number: 4643828-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthenia
Other	Atherosclerosis
	Atrial Fibrillation
	Blood Glucose Increased
	Blood Potassium Decreased
	Blood Pressure Increased
	Bradycardia
	Cardiac Failure
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Coronary Artery Disease
	Depression
	Dyspnoea
	Emotional Distress
	Fatigue
	Feeling Abnormal
	Headache
	Hypertensive Crisis
	Hypoxia
	Injury
	Joint Dislocation

	Metabolic Alkalosis Mitral Valve Incompetence Muscle Spasms	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	209 DAY
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL	209 DAY
	Neck Pain Nervousness		Lasix (Furosemide Sodium)	C			UNKNOWN
	Pain In Extremity Respiratory Alkalosis		Lasix (Furosemide Sodium)	C			UNKNOWN
	Shoulder Pain		Aspirin	C			UNKNOWN
	Sinus Bradycardia		Avalide	C			UNKNOWN
	Transient Ischaemic		Motrin	C			UNKNOWN
	Attack		Premarin	C			UNKNOWN
	Tricuspid Valve		Naproxen	C			UNKNOWN
	Incompetence		Tylenol	C			UNKNOWN
	Ventricular Hypertrophy						

Date:04/25/05ISR Number: 4643829-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adnexa Uteri Mass		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Anxiety		Zestril	C			UNKNOWN
	Cardiac Murmur		Prilosec	C			UNKNOWN
	Cellulitis		Xanax	C			UNKNOWN
	Coronary Artery Disease		Zyrtec	C			UNKNOWN
	Coronary Artery Stenosis		Aspirin	C			UNKNOWN

	Coronary Artery	Celebrex	C
UNKNOWN			
	Thrombosis	Prozac	C
UNKNOWN			
	Depression	Naproxen	C
UNKNOWN			
	Drug Hypersensitivity		
	Dyspnoea		
	Emotional Distress		
	Eyelid Ptosis		
	Fatigue		
	Fungal Infection		
	Haemangioma		
	Insomnia		
	Macular Degeneration		
	Myocardial Infarction		
	Nervousness		
	Oedema		
	Oedema Peripheral		
	Osteoporosis		
	Palpitations		
	Pollakiuria		
	Postnasal Drip		
	Radiculopathy		
	Rash		
	Renal Failure		
	Sinus Disorder		
	Sinusitis		
	Snoring		
	Spinal Column Stenosis		
	Spinal Osteoarthritis		
	Urethritis		
	Visual Disturbance		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4643830-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01689
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident							
Initial or Prolonged	Chest Pain							
Disability	Hepatocellular Damage							
Other	Myocardial Infarction							
	Renal Injury							
	Thrombosis							
	Ulcer							

Date:04/25/05ISR Number: 4643831-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02880
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis							
	Blood Cholesterol							
	Increased							
	Cardiac Disorder							
	Coronary Artery Disease							
	Dyspnoea							
	Emotional Distress							
	Hypertension							
	Myocardial Infarction							

Date:04/25/05ISR Number: 4643832-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02862
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		1577 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1577 DAY
Other			Prevacid	C		ORAL		
			Plavix	C		ORAL		
			Alprazolam	C		ORAL		

	[Therapy Unspecified]	C	ORAL

Date:04/25/05ISR Number: 4643833-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01517
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Other	Alopecia
	Angina Pectoris
	Back Pain
	Blindness
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Confusional State
	Dyspnoea
	Hypoaesthesia
	Hypokinesia
	Hypotrichosis
	Limb Discomfort
	Loss Of Consciousness

		Nausea Oedema Peripheral Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
427	DAY						
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
427	DAY						
		Respiratory Failure		Valium	C		
UNKNOWN							
		Road Traffic Accident		Ambien	C		
UNKNOWN							
		Teeth Brittle Vision Blurred		[Therapy Unspecified]	C		
RESPIRATORY							
(INHALATION)							

Date:04/25/05ISR Number: 4643835-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02237
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL
1193	DAY						
Other		Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
1193	DAY						
		Coronary Artery Occlusion		Methylprednisolone	C		
UNKNOWN							
		Diarrhoea		Bextra	C		
UNKNOWN							
		Gout		Colchicine	C		
UNKNOWN							
		Hypertension		Norvasc	C		
UNKNOWN							
		Myocardial Infarction		Triamterene	C		
UNKNOWN							
		Treatment Noncompliance		Allopurinol	C		
UNKNOWN							
				Methocarbamol	C		
UNKNOWN							
				Indomethacin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							

Protonix	C	UNKNOWN
Hydrocodone Bitartrate	C	UNKNOWN
Altace	C	UNKNOWN
Toprol Xl Tablets	C	UNKNOWN
Nitroquick	C	UNKNOWN

Date:04/25/05ISR Number: 4643836-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01555
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthma Bronchitis Cardiac Failure Cerebrovascular Accident Chest Pain Chronic Obstructive Pulmonary Disease Hepatocellular Damage Myocardial Infarction Polytraumatism Renal Injury Thrombosis Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643838-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03261
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Other	Blood Cholesterol Increased Confusional State

		Myocardial Infarction					
		Oedema Peripheral					
		Papilloedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
				Cozaar	C		ORAL
				Cozaar	C		ORAL
				Theophylline	C		
UNKNOWN							
				Xopenex	C		
UNKNOWN							
				Ipratropium Bromide	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Levothyroxine Sodium	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Pacerone	C		
UNKNOWN							
				Nitroquick	C		
UNKNOWN							

Date:04/25/05ISR Number: 4643839-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03302
Age:62 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris					
		Cardiac Murmur					
		Cardiac Valve Disease					
		Dementia					
		Emotional Distress					
		Gastrooesophageal Reflux					
		Disease					
		Hernia					

Hypertension
Hypoaesthesia
Myocardial Infarction

Date:04/25/05ISR Number: 4643840-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03252
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Aortic Stenosis
	Aortic Valve Incompetence
	Bicuspid Aortic Valve
	Breast Cancer
	Cardiac Valve Disease
	Chest Pain
	Dyspnoea
	Emotional Distress
	Faeces Discoloured
	Gastrooesophageal Reflux Disease
	Haematochezia
	Hernia
	Intestinal Obstruction
	Mitral Valve Incompetence
	Mitral Valve Prolapse
	Mitral Valve Stenosis
	Myocardial Infarction

Osteoarthritis
Pulmonary Hypertension

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Pepcid	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Bextra	C			UNKNOWN	
	Toprol Xl Tablets	C			UNKNOWN	
	St. Joseph Adult Chewable Aspirin	C			UNKNOWN	
	Tamoxifen Citrate	C			UNKNOWN	
	Actonel	C			UNKNOWN	
	Inderal	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Neurontin	C			UNKNOWN	
	Nexium	C			UNKNOWN	
	Coumadin	C			UNKNOWN	

Date:04/25/05ISR Number: 4643842-XReport Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00009
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643843-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00364
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anxiety
	Asthenia
	Bereavement Reaction
	Calculus Ureteric
	Cerebrovascular Accident
	Chest Pain
	Colitis
	Concussion
	Constipation
	Contusion
	Costovertebral Angle
	Tenderness
	Cough
	Depression
	Diarrhoea
	Dizziness Postural
	Fall
	Fatigue
	Fear
	Fear Of Disease
	Feeling Cold
	Haematoma
	Haemorrhoids
	Hemiparesis
	Herpes Zoster
	Human Bite
	Hyperglycaemia

	Hyperlipidaemia						
	Hypertension						
	Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Intentional Self-Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL		
	Jaundice		Metformin	C			UNKNOWN	
	Limb Injury		Humulin	C			UNKNOWN	
	Lung Neoplasm		Levoxyl	C			UNKNOWN	
	Muscle Spasms		Zocor	C			UNKNOWN	
	Pain							
	Pallor							
	Paraesthesia							
	Rheumatoid Arthritis							
	Self Injurious Behaviour							
	Transient Ischaemic							
	Attack							
	Urinary Tract Infection							

Date:04/25/05ISR Number: 4643845-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04262
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Aspirin	C			UNKNOWN	
Disability	Hip Arthroplasty							
	Overdose							

Date:04/25/05ISR Number: 4643846-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:04/25/05ISR Number: 4643847-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00078
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		902 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Ogen	C				UNKNOWN
	Cataract		Progesterone	C				UNKNOWN
	Cerebral Artery Occlusion		Antimicrobial					
	Cerebral Artery Stenosis		(Unspecified)	C				UNKNOWN
	Cerebrovascular Accident		Lipitor	C				UNKNOWN
	Confusional State		Toprol Xl Tablets	C				UNKNOWN
	Disturbance In Attention		Norvasc	C				UNKNOWN
	Drug Ineffective		Aspirin	C				UNKNOWN
	Emotional Distress		Naprosyn	C				UNKNOWN
	Knee Arthroplasty		Daypro	C				UNKNOWN
	Lacunar Infarction		Aleve	C				UNKNOWN
			Percocet	C				UNKNOWN
			Ortho-Est	C				UNKNOWN
			Lopressor	C				UNKNOWN
			Evista	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4643848-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02877
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Cholesterol		Tenormin	C				
Disability	Increased		Premarin	C			UNKNOWN	7508 DAY
	Blood Triglycerides		Protonix	C			UNKNOWN	
	Increased							
	Dyspnoea							
	Emotional Distress							
	Hip Arthroplasty							
	Myocardial Infarction							
	Pain							
	Rheumatoid Arthritis							

Date:04/25/05ISR Number: 4643849-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02014
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:04/25/05ISR Number: 4643850-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01973
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Plavix	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:04/25/05ISR Number: 4643856-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03303
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Amlodipine Besylate	C				
UNKNOWN								
	Convulsion		Prinivil	C				
UNKNOWN								
	Diabetes Mellitus		Rabeprazole Sodium	C				
UNKNOWN								
	Emotional Distress		Ranitidine	C				
UNKNOWN								
	Glaucoma		Tylenol	C				
UNKNOWN								
	Knee Operation		Norvasc	C				
UNKNOWN								
	Low Density Lipoprotein Increased							

Date:04/25/05ISR Number: 4643857-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4643860-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643861-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643862-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction Polytraumatism							

Date:04/25/05ISR Number: 4643863-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643864-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02642
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/25/05ISR Number: 4643865-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643866-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02632
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Groin Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Hydrochlorothiazide [Therapy Unspecified]	C C		ORAL		
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4643867-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643889-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643890-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643891-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643892-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction							

Polytraumatism

Date:04/25/05ISR Number: 4643894-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02734
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643896-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02665
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4643898-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02659
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							
	Polytraumatism							

Date:04/25/05ISR Number: 4643914-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02661
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:04/25/05ISR Number: 4643931-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/25/05ISR Number: 4643932-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02660
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/25/05ISR Number: 4643933-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03165
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4643934-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03218
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644004-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644236-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03496
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644237-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644238-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644243-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644244-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644245-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644246-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644248-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03772
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644249-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	OPHTHALMIC		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644250-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644251-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644252-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03478
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644253-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644254-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644266-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02970
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Disorder
Other	Blood Potassium Decreased
	Cerebrovascular Accident
	Chest Pain
	Diplopia
	Dysphagia
	Dyspnoea
	Eating Disorder
	Gastric Disorder
	Gastrointestinal Disorder
	Headache
	Hypersensitivity
	Hypokalaemia
	Nephrolithiasis
	Oedema
	Paraesthesia
	Pelvic Mass
	Sinusitis
	Tachycardia
	Temperature Intolerance
	Transient Ischaemic Attack

		Tremor Urinary Tract Infection Weight Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Cozaar	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Lexapro	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Estrogens (Unspecified)	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							

Date:04/25/05ISR Number: 4644267-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03343
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/25/05ISR Number: 4644268-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02987
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Anxiety					
	Atrial Fibrillation					
	Atrial Tachycardia					
	Breast Pain					
	Cerebrovascular Accident					
	Chest Discomfort					
	Chest Pain					
	Cholelithiasis					
	Coronary Artery Disease					
	Cough					
	Dizziness					
	Drug Toxicity					
	Heart Rate Irregular					
	Hyperhidrosis					
	Hypertension					
	Myocardial Infarction					
	Nausea					
	Palpitations					
	Supraventricular					
	Tachycardia					

Date:04/25/05ISR Number: 4644269-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644270-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00027
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pravastatin Sodium	C		ORAL		
			Hydrochlorothiazide And Irbesartan	C		ORAL		
			Loratadine	C		ORAL		

Date:04/25/05ISR Number: 4644271-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644272-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03217
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Nexium	C				
UNKNOWN								

Date:04/25/05ISR Number: 4644273-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644274-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644275-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00023
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction Cyanosis Extremity Necrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	
	Pain In Extremity		Ferrous Sulfate	C			UNKNOWN	
			Iron Dextran	C			UNKNOWN	
			Clopidogrel Bisulfate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644284-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00153
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Comminuted Fracture Feeling Abnormal Headache Herpes Zoster Major Depression Suicidal Ideation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644285-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03894
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Poor Peripheral		Zyprexa	C				
Initial or Prolonged UNKNOWN	Circulation		Seroquel	C				
Disability	Respiratory Failure Vein Disorder							

Date:04/25/05ISR Number: 4644286-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644287-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03345
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644288-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644289-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644304-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644305-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03452
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644306-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03457
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644307-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03349
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644320-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644321-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03459
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hyperhidrosis Pyrexia		Vioxx Premarin	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Disability	Renal Disorder		Synthroid	C

UNKNOWN

Date:04/25/05ISR Number: 4644322-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644324-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03468
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644325-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03464
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/05ISR Number: 4644326-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644327-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03346
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644350-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/25/05ISR Number: 4644479-9Report Type:Direct Company Report #CTU 247071
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Celebrex	PS				
TWICE A DAY								
Initial or Prolonged			Vioxx	SS				

Date:04/25/05ISR Number: 4645728-3Report Type:Expedited (15-DaCompany Report #2005057705
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib					
			(Rofecoxib)	SS				

Date:04/25/05ISR Number: 4645730-1Report Type:Expedited (15-DaCompany Report #2005058431
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Burning Sensation	Consumer	Bextra (Valdecoxib)	PS				
	Chest Pain		Celebrex (Celecoxib)	SS			200 MG	
	Diarrhoea		Rofecoxib (Rofecoxib)	SS			50 MG (25 MG, 2 IN 1 D)	
	Dizziness							
	Drug Effect Decreased							
	Drug Tolerance		Indometacin (Indometacin)	SS			2 IN 1 D)	
	Left Ventricular Failure							
	Stomach Discomfort		Losartan Potassium (Losartan Potassium)	C				
			Lotrel (Amlodipine, Benazepril Hydrochloride)	C				

Date:04/26/05ISR Number: 4644563-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4644823-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02201
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gangrene		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Leg Amputation							
Initial or Prolonged	Thrombosis							
Disability								

Date:04/26/05ISR Number: 4644826-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Advil	C				
UNKNOWN								
Other	Atherosclerosis		Advil	C				
UNKNOWN								
	Calculus Ureteric		Vicodin Tablets	C				
UNKNOWN								
	Calculus Urinary		Aspirin	C				
UNKNOWN								
	Chest Discomfort		Ultram	C				
UNKNOWN								
	Coronary Artery Occlusion		Ultram	C				
UNKNOWN								
	Cough							
	Diverticulitis							
	Emotional Distress							
	Fatigue							
	Headache							
	Mitral Valve Incompetence							
	Osteoarthritis							
	Palpitations							
	Pharyngolaryngeal Pain							
	Pneumonia Influenzal							
	Ventricular Hypokinesia							
	Weight Decreased							
	Weight Fluctuation							
	Weight Increased							

Date:04/26/05ISR Number: 4644828-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01232
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Unstable
	Anxiety
	Anxiety Disorder
	Arthralgia
	Asthenia
	Cardiac Disorder
	Cardiac Murmur
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Deafness
	Dementia
	Depression
	Dyskinesia
	Emotional Distress
	Foot Deformity
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hepatitis B							
Hypertension							
Joint Sprain							
Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Neuropathy Peripheral		Lotrel	C			UNKNOWN	
Osteoporosis		Norvasc	C			UNKNOWN	
Otitis Media		Celebrex	C			UNKNOWN	
Palpitations		Lorazepam	C			UNKNOWN	
Panic Disorder		Venlafaxine Hydrochloride	C			UNKNOWN	
Pelvic Pain							
Peripheral Vascular Disorder							
Prescribed Overdose							
Rheumatoid Arthritis							
Schizophrenia, Paranoid Type							
Toe Deformity							
Venous Insufficiency							

Date:04/26/05ISR Number: 4644829-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00357
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Ear Pain		Aspirin	C			UNKNOWN	
	Myocardial Infarction		Bextra	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

Date:04/26/05ISR Number: 4644838-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03128
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Apnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiomegaly		Atacand	C				
UNKNOWN								
Disability	Chest Pain		Effexor	C				
UNKNOWN								
Other	Dyspnoea		Lasix (Furosemide)	C				
UNKNOWN								
	Eye Injury							
	Eye Swelling							
	Fall							
	Fatigue							
	Hunger							
	Hyperlipidaemia							
	Influenza							
	Insomnia							
	Joint Sprain							
	Lymphoedema							
	Myocardial Infarction							
	Oedema Peripheral							
	Weight Increased							

Date:04/26/05ISR Number: 4644840-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00647
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4644841-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0504SWE00025
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1492 DAY
Initial or Prolonged	Cerebrovascular Accident		Auranofin	C				UNKNOWN
	Myocardial Infarction		Propoxyphene Napsylate	C				UNKNOWN
			Acetaminophen	C				UNKNOWN
			Prednisolone	C				UNKNOWN

Date:04/26/05ISR Number: 4644842-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00080
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Synthroid	C				UNKNOWN
	Cardiac Murmur							
	Cardiac Valve Disease							
	Coronary Artery Disease							
	Dyspepsia							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							
	Prescribed Overdose							
	Thyroid Disorder							

Date:04/26/05ISR Number: 4644844-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03491
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644845-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644846-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02882
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia Carotid Artery Occlusion
Disability	Cerebral Infarction
Other	Cerebrovascular Accident Constipation Fall Gastrooesophageal Reflux Disease

		Memory Impairment					
		Sinusitis					
		Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vision Blurred		Vioxx	PS	Merck & Co., Inc	ORAL
626	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
626	DAY						
				Zocor	C		ORAL
				Accupril	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Robaxin	C		ORAL

Date:04/26/05ISR Number: 4644847-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03488
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/26/05ISR Number: 4644854-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03486
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Economic Problem		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress					
		Injury					
		Myocardial Infarction					

Date:04/26/05ISR Number: 4644855-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03495
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/26/05ISR Number: 4644856-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644857-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03705
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644858-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4644866-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644867-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03709
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:04/26/05ISR Number: 4644869-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03521
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644870-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644872-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03765
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:04/26/05ISR Number: 4644873-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644874-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03750
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644875-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644876-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4644877-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03748
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644878-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	163 DAY	
Other	Death							

Date:04/26/05ISR Number: 4644879-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03680
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Naproxen	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Levothyroxine Sodium	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Zocor	C		ORAL		
			Amaryl	C			UNKNOWN	
			Quinine	C			UNKNOWN	

Lisinopril C
UNKNOWN

Date:04/26/05ISR Number: 4644880-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644881-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/26/05ISR Number: 4644890-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4644891-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644933-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03707
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON

Date:04/26/05ISR Number: 4644934-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03706
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4644963-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645455-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00005
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dilatation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		

	Condition Aggravated	Vioxx	SS	Merck & Co., Inc	ORAL
	Dizziness	Candesartan Cilexetil	C		ORAL
	Dyspnoea Exertional	[Therapy Unspecified]	C		
	Mitral Valve Incompetence	[Therapy Unspecified]	C		
	Spinal Osteoarthritis	[Therapy Unspecified]	C		
	Tricuspid Valve Incompetence	Rizatriptan Benzoate	C		ORAL
		Naloxone Hydrochloride And Tilidine Hydrochloride	C		ORAL
		Levothyroxine Sodium	C		ORAL
		Estradiol	C		
UNKNOWN					
UNKNOWN					
UNKNOWN					
TOPICAL	81 DAY				

Date:04/26/05ISR Number: 4645469-2Report Type:Expedited (15-DaCompany Report #AT-MERCK-0410AUT00009
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Emotional Distress

Polytraumatism

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645473-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03073
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
Initial or Prolonged	Angina Pectoris		Aspirin	C				
UNKNOWN								
Other	Asthenia		Lasix (Furosemide					
	Blood Cholesterol		Sodium)	C				
UNKNOWN								
	Increased		[Therapy					
	Cardiac Failure		Unspecified]	C				
UNKNOWN								
	Congestive		Toprol Xl Tablets	C				
UNKNOWN	9712 DAY							
	Cardiac Murmur		Procardia	C				
UNKNOWN								
	Cerebrovascular Accident		Capoten	C		ORAL		
	Coagulopathy		[Therapy					
	Deep Vein Thrombosis		Unspecified]	C				
UNKNOWN								
	Depression							
	Dyspnoea							
	Hand Deformity							
	Heart Disease Congenital							
	Heart Rate Abnormal							
	High Density Lipoprotein							
	Decreased							
	Hypoxia							
	Low Density Lipoprotein							
	Increased							
	Obesity							
	Oedema Peripheral							
	Pain In Extremity							
	Rheumatoid Arthritis							
	Sleep Disorder							

Thrombosis

Date:04/26/05ISR Number: 4645474-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00826
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
Other	Anxiety
	Asthenia
	Cataract
	Cerebrovascular Accident
	Chronic Fatigue Syndrome
	Confusional State
	Coronary Artery Disease
	Depression
	Diastolic Dysfunction
	Disturbance In Attention
	Dizziness
	Dyspnoea
	Fungal Infection
	Headache
	Herpes Zoster
	Hypertension

Dose	Duration	Injury	Report Source	Product	Role	Manufacturer	Route
		Hyperventilation					
		Hypoacusis					
		Loss Of Libido		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Macular Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Glyburide	C		
UNKNOWN							
		Nephrolithiasis		Zocor	C		ORAL
		Oedema Peripheral		Neurontin	C		
UNKNOWN							
		Palpitations		Temazepam	C		
UNKNOWN							
		Panic Attack		Naprosyn	C		
UNKNOWN							
		Personality Disorder		Naprosyn	C		
UNKNOWN							
		Post-Traumatic Stress		Maxzide	C		
UNKNOWN							
		Disorder		Beta Carotene	C		
UNKNOWN							
		Psychiatric Symptom		Verapamil	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Ginkgo Biloba			
		Sleep Disorder		Extract	C		
UNKNOWN							
		Suicidal Ideation		Garlic Extract	C		
UNKNOWN							
		Syncope		Vitamin E	C		
UNKNOWN							
		Tremor		Pyridoxine	C		
UNKNOWN							
		Tricuspid Valve		Vitamins			
		Incompetence		(Unspecified)	C		
UNKNOWN							
		Vision Blurred		Atrovent	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							

			Flonase	C			
UNKNOWN							
			Altace	C			
UNKNOWN							
			Calan	C			
UNKNOWN							
			Ocuvite	C			
UNKNOWN							

Date:04/26/05ISR Number: 4645476-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02960
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Atenolol	C				
UNKNOWN								
	Back Injury		Cholestyramine Resin	C				
UNKNOWN								
	Cardiac Failure		Clonidine	C				
UNKNOWN								
	Congestive		Hydrochlorothiazide	C				
UNKNOWN								
	Chest Pain		Lasix (Furosemide)	C				
UNKNOWN								
	Chronic Fatigue Syndrome		Lipitor	C				
UNKNOWN								
	Depression		Paxil	C				
UNKNOWN								
	Dysphagia		Paxil	C				
UNKNOWN								
	Heart Rate Irregular		Xanax	C				
UNKNOWN								
	Myocardial Infarction		Xanax	C				
UNKNOWN								
	Oedema Peripheral		Zetia	C				
UNKNOWN								
	Panic Disorder		Zyprexa	C				
UNKNOWN								
	Sexual Dysfunction		Zyprexa	C				
UNKNOWN								
	Tension		Aspirin	C				
UNKNOWN								
			Advil	C				
UNKNOWN								
			Motrin	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4645488-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00174
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zocor	C		ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

Date:04/26/05ISR Number: 4645489-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01159
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Actos	C		ORAL		
	Anxiety Disorder		Tricor	C		ORAL		
	Arthropathy		Glucovance	C		ORAL		
	Cardiac Flutter							
	Cardiomegaly							
	Cold Sweat							
	Coronary Artery Disease							
	Hyperhomocysteinaemia							
	Insomnia							
	Joint Swelling							
	Periarthritis							
	Pulmonary Congestion							

Date:04/26/05ISR Number: 4645490-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03712
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
							42 MON	

Date:04/26/05ISR Number: 4645491-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00140
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:04/26/05ISR Number: 4645493-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02400
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Neoplasm Malignant							
	Sudden Death							

Date:04/26/05ISR Number: 4645494-1Report Type:Expedited (15-DaCompany Report #NL-MERCK-0504NLD00025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	UNKNOWN		
	Hypertonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4645495-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03715
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25	MON

Date:04/26/05ISR Number: 4645496-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00802
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Blood Pressure Diastolic Decreased Coronary Artery Disease Coronary Artery Occlusion Hepatic Cyst Myocardial Infarction Procedural Complication Sleep Apnoea Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645497-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03415
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645507-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645508-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY

Date:04/26/05ISR Number: 4645509-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03742
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON

Date:04/26/05ISR Number: 4645510-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03716
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	992	DAY

Date:04/26/05ISR Number: 4645511-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/26/05ISR Number: 4645512-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645513-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:04/26/05ISR Number: 4645514-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03713
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Polytraumatism							

Date:04/26/05ISR Number: 4645515-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:04/26/05ISR Number: 4645516-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645517-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645518-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645519-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	88	DAY

Date:04/26/05ISR Number: 4645520-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03759
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645521-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03758
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645522-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645530-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paralysis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645536-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645537-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645538-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	933 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4645539-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645540-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03761
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:04/26/05ISR Number: 4645541-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03791
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645542-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645543-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:04/26/05ISR Number: 4645544-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645545-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03780
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645546-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03783
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cerebrovascular Accident Injury

Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645547-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645555-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645556-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645557-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645558-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645559-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645560-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/26/05ISR Number: 4645578-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03747
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/26/05ISR Number: 4645583-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03754
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder							

Date:04/26/05ISR Number: 4647163-0Report Type:Direct Company Report #CTU 247134
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Generalised Oedema		Celebrex	PS				
	Vaginal Haemorrhage		Vioxx	SS				

Date:04/26/05ISR Number: 4647314-8Report Type:Expedited (15-DaCompany Report #2005061884
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis Infective	Consumer	Celebrex (Celecoxib)	PS		ORAL		
ORAL								
Initial or Prolonged	Cerebrovascular Accident		Bextra (Valdecoxib)	SS		ORAL		
20 MG (20 MG,								
	Diabetes Mellitus							
1 IN 1 D),								
	Inadequate Control							
ORAL								
	Staphylococcal Infection		Rofecoxib					
			(Rofecoxib)	SS		ORAL		
25 MG (25 MG,								
1 IN 1 D),								

ORAL

Levothyroxine Sodium (Levothyroxine Sodium)	C
Tamoxifen (Tamoxifen)	C
Anastrozole (Anastrozole)	C
Glibenclamide (Glibenclamide)	C
Metformin Hydrochloride (Metformin Hydrochloride)	C
Pioglitazone (Pioglitazone)	C
Insulin Zinc Suspension(Insulin Zinc Suspension)	C
Insulin Aspart (Insulin Aspart)	C
Insulin Glargine (Insulin Glargine)	C
Acetylsalicylic Acid (Acetylsalicylic Acid)	C
Vitamins (Vitamins)	C
Tocopherol	

(Tocoperol)	C
Asasantin (Acetylsalicylic Acid, Dipyridamole)	C
Folic Acid (Folic Acid)	C
Chondroitin/Glucosamine (Chondroitin, Glucosamine)	C
Omeprazole(Omeprazole)	C
Sucralfate (Sucralfate)	C

Date:04/26/05ISR Number: 4647737-7Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00172
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Myocardial Ischaemia	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	148 DAY
		Health Professional Other	Nifedipine	C				

Date:04/26/05ISR Number: 4647739-0Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00095
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Colon Cancer	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	337 DAY
Other	Myocardial Ischaemia Nausea	Health Professional	Aspirin	C				
			Atenolol	C				
			Gliclazide	C				
			Nitroglycerin	C				
			Simvastatin	C				

Date:04/26/05ISR Number: 4648285-0Report Type:Expedited (15-DaCompany Report #2005062475
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Ineffective Knee Arthroplasty Pulmonary Embolism	Consumer	Daypro Caplet (Oxaprozin)	PS				
			Celebrex (Celecoxib)	SS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
			Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS				

Date:04/27/05ISR Number: 4646278-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01744
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Back Pain
Other	Blood Creatinine

Increased
Bronchitis
Cardiac Failure
Congestive

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cardiac Murmur					
	Vioxx	PS	Merck & Co., Inc	ORAL	254	DAY
	Cardiogenic Shock					
	Vioxx	SS	Merck & Co., Inc	ORAL	254	DAY

Cardiomyopathy
Carpal Tunnel Syndrome
Coronary Artery Disease
Coronary Artery Occlusion
Decreased Activity
Depression
Diabetes Mellitus
Non-Insulin-Dependent
Diarrhoea
Dilatation Atrial
Dilatation Ventricular
Hyperlipidaemia
Hypersensitivity
Influenza
Insomnia
Irritable Bowel Syndrome
Mitral Valve Incompetence
Musculoskeletal Pain
Myocardial Infarction
Oedema Peripheral
Osteoarthritis
Pericarditis
Pneumonia
Post Procedural Oedema
Pulmonary Oedema
Sinusitis
Treatment Noncompliance
Tricuspid Valve
Incompetence
Wound Secretion

Date:04/27/05ISR Number: 4646292-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02848
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Aortic Valve Disease

Disability	Appendicitis
	Asthma
	Cerebrovascular Accident
	Depression
	Dizziness
	Dyspepsia
	Dyspnoea Exertional
	Fall
	Gastrooesophageal Reflux
	Disease
	Hyperlipidaemia
	Hypertension
	Mitral Valve Disease
	Myocardial Ischaemia
	Oedema Peripheral
	Sensation Of Heaviness
	Syncope
	Transient Ischaemic

Attack
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Chronulac	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Albuterol	C			UNKNOWN	
	Methylprednisolone	C			UNKNOWN	
	Evista	C			UNKNOWN	
	Effexor Xr	C			UNKNOWN	
	Atacand	C			UNKNOWN	
	Foradil	C			UNKNOWN	
	Deltasone	C			UNKNOWN	
	Singulair	C			UNKNOWN	
	Clarinex	C			UNKNOWN	
	Astelin	C			UNKNOWN	
	Combivent	C			UNKNOWN	
	Avelox	C			UNKNOWN	
	Tequin	C			UNKNOWN	
	Levaquin	C			UNKNOWN	
	Tamoxifen Citrate	C			UNKNOWN	

Date:04/27/05ISR Number: 4646293-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00038
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Lumbar Vertebral Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Skin Ulcer		Pantoprazole Sodium	C		ORAL		
	Thrombophlebitis		Pravastatin Sodium	C		ORAL		
	Varicose Vein		Oxazepam	C		ORAL		
	Venous Insufficiency							

Date:04/27/05ISR Number: 4646294-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00141
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:04/27/05ISR Number: 4646296-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arterial Thrombosis
Initial or Prolonged	Cerebral Infarction
Disability	Dizziness
Other	Eyelid Ptosis
	Hypoacusis
	Iatrogenic Injury
	Procedural Complication
	Swelling
	Temporal Arteritis
	Viith Nerve Injury

	Visual Disturbance Visual Field Defect						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Trandolapril And Verapamil Hydrochloride	C			UNKNOWN	

Date:04/27/05ISR Number: 4646297-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00111
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	28 MON	
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Flomax (Morniflumate)	C			UNKNOWN	
	Myocardial Infarction		Furosemide	C			UNKNOWN	
	Oedema Peripheral		Toprol Xl Tablets	C			UNKNOWN	
	Pneumonia		Zocor	C			UNKNOWN	
	Prostate Cancer		Digoxin	C			UNKNOWN	
			Potassium Chloride	C			UNKNOWN	
			Amiodarone Msd	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Cozaar	C			UNKNOWN	
			Phenazopyridine Hydrochloride	C			UNKNOWN	
			Levaquin	C			UNKNOWN	

Date:04/27/05ISR Number: 4646298-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02969
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		376 DAY
Initial or Prolonged	Anxiety Disorder		Cantil	C				UNKNOWN
Other	Haematochezia		Biaxin	C				UNKNOWN
	Pain		Flexeril	C				UNKNOWN
	Pulmonary Embolism		Buspar	C				UNKNOWN
	Renal Cell Carcinoma		Elavil	C				UNKNOWN
	Stage Unspecified		Robaxin	C				UNKNOWN
	Renal Surgery		Motrin	C				UNKNOWN
	Thrombosis		Vicodin Tablets	C				UNKNOWN
			Viagra	C				UNKNOWN
			Talwin	C				UNKNOWN
			Ibuprofen	C				UNKNOWN
			Percocet	C				UNKNOWN
			Advil	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Zyprexa	C				UNKNOWN

Date:04/27/05ISR Number: 4646300-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00055
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lorazepam	C				UNKNOWN
			Olanzapine	C				UNKNOWN
			Clarithromycin	C				UNKNOWN
			Homatropine				10 DAY	

				Methylbromide And Hydrocodone Bitartrate	C		
UNKNOWN							
				Acetaminophen And Codeine Phosphate	C		
UNKNOWN							
				Acetaminophen And Oxycodone Hydrochloride	C		
UNKNOWN							
				Albuterol	C		
RESPIRATORY							
(INHALATION)							

Date:04/27/05ISR Number: 4646301-3Report Type:Expedited (15-DaCompany Report #NL-MERCK-0504NLD00025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
	Hypertonia							

Date:04/27/05ISR Number: 4646302-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01824
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Original Formula Sensodyne-Sc	SS				
	Hypertension							
UNKNOWN								
			Calcium (Unspecified)	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:04/27/05ISR Number: 4646303-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03701
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646304-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646305-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03718
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	DAY

Date:04/27/05ISR Number: 4646306-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646307-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	4	MON

Date:04/27/05ISR Number: 4646308-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646309-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646310-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646320-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03703
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646339-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646340-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0504ZAF00022
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Celecoxib	C		ORAL		

Date:04/27/05ISR Number: 4646647-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646898-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00905
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Increased		Celebrex	C				
UNKNOWN								
Disability	Candidiasis		Ativan	C				
UNKNOWN								
	Coronary Artery Disease		Cardizem	C				
UNKNOWN								
	Coronary Artery Occlusion		Premarin	C				
UNKNOWN								
	Coronary Artery Stenosis		Propulsid	C				
UNKNOWN								
	Cough		Phenobarbital	C				
UNKNOWN								
	Difficulty In Walking		Prevacid	C				
UNKNOWN								
	Dry Skin		Fibro Malic	C				
UNKNOWN								
	Electrocardiogram T Wave		Minipress	C				
UNKNOWN								
	Abnormal		Dimethyl Sulfone	C				
UNKNOWN								
	Fatigue		Prozac	C				
UNKNOWN								
	Fibromyalgia		Salagen Tablets	C				
UNKNOWN								
	Fluid Retention		Ascorbic Acid	C				
UNKNOWN								
	Fungal Infection		Vitamin E	C				
UNKNOWN								
	Gastrooesophageal Reflux		Darvocet-N	C				
UNKNOWN								
	Disease		Restoril	C				
UNKNOWN								
	Headache		Estratest	C				
UNKNOWN								
	Hiatus Hernia		Evoxac	C				
UNKNOWN								
	Insomnia		Monopril	C				
UNKNOWN								
	Joint Crepitation		Nitro-Bid	C				
UNKNOWN								

	Joint Sprain		Ambien	C		
UNKNOWN						
	Joint Stiffness		Reglan	C		
UNKNOWN						
	Ligament Sprain		Diflucan	C		ORAL
	Muscle Spasms		Diflucan	C		
UNKNOWN						
	Musculoskeletal Discomfort		Vitamins (Unspecified)	C		
UNKNOWN						
	Myocardial Infarction		Esgic-Plus Tablets	C		
UNKNOWN						
	Night Sweats		Mylanta & Mylanta Ds	C		
UNKNOWN						
	Peptic Ulcer					
	Pharyngeal Candidiasis					
	Pleural Effusion					
	Post Procedural Complication					
	Pruritus					
	Rash					
	Sleep Disorder					
	Tremor					
	Ulcer					
	Ventricular Tachycardia					
	Vomiting					
	Weight Increased					

Date:04/27/05ISR Number: 4646902-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00231
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Enalapril Maleate And Hydrochlorothiazide	C		ORAL
	Chest Pain					
	Emotional Distress					
	Fluid Retention					
	General Symptom					
	Nausea					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646903-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02424
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Loss Of Control Of Legs		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Lasix (Furosemide)	C				
UNKNOWN								
Disability	Surgery		Zocor	C				
UNKNOWN								
Other			Accupril	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Imdur	C				
UNKNOWN								

Date:04/27/05ISR Number: 4646904-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00359
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		[Therapy Unspecified]	C				
UNKNOWN								
	Coronary Artery Disease		Orphenadrine	C				
UNKNOWN								
	Myocardial Infarction		Furosemide	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			Nitroquick	C				
UNKNOWN								
			Lanoxin	C				
UNKNOWN								
			Uniphyl	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:04/27/05ISR Number: 4646905-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Aortic Valve Incompetence
	Arthralgia
	Bursitis
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Reocclusion
	Coronary Artery Restenosis
	Diarrhoea
	Dyspnoea
	Electrocardiogram St-T Change
	Haematochezia
	Haematocrit Decreased
	Haematoma
	Hypercholesterolaemia
	Hyperhidrosis
	Injury
	Mitral Valve Incompetence
	Myocardial Infarction
	Post Procedural Complication
	Sinus Bradycardia
	Tricuspid Valve

	Incompetence Vascular Graft Complication Ventricular Hypokinesia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	482	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Celebrex	C				

Date:04/27/05ISR Number: 4646906-XReport Type:Expedited (15-DaCompany Report #ES-MERCK-0410ESP00036
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
Other	Lower Limb Deformity		Insulin, Isophane	C				
	Myocardial Infarction		Aspirin	C				
	Osteomyelitis		Enalapril Maleate	C				
			Nitroglycerin	C				

Date:04/27/05ISR Number: 4646907-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0502FRA00024
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL	TOPICAL	
	Cerebrovascular Accident		Paroxetine	SS		ORAL		
	Infarction		Diacerein	SS		ORAL		
			Estradiol	SS				

Date:04/27/05ISR Number: 4646908-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00142
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Peripheral Paralysis		Bisoprolol Fumarate And Hydrochlorothiazide	C		ORAL	222 DAY	
			Amlodipine Besylate	C		ORAL		

Date:04/27/05ISR Number: 4646915-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03596
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Diovan	C				
UNKNOWN								
	Hypertension		Coumadin	C				
UNKNOWN								
	Interstitial Lung Disease		Aspirin	C				
UNKNOWN								
	Lung Infiltration		Plavix	C				
UNKNOWN								
	Myocardial Infarction		Lipitor	C				
UNKNOWN								
	Shoulder Arthroplasty		Zocor	C				
UNKNOWN							181 DAY	
			Tylenol	C				
UNKNOWN								
			Lisinopril	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646916-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02541
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Soma	C			UNKNOWN	
	Asthenia		Soma	C			UNKNOWN	
	Blood Cholesterol Increased		Amitriptyline Hydrochloride	C			UNKNOWN	
	Cardiac Disorder		Flexeril	C			UNKNOWN	
	Cerebrovascular Accident		Flexeril	C			UNKNOWN	
	Chest Discomfort		Apap	C			UNKNOWN	
	Chest Pain		Codeine	C			UNKNOWN	
	Coronary Artery Disease							
	Dyspepsia							
	Dyspnoea							
	Fear							
	Generalised Anxiety Disorder							
	Injury							
	Nausea							
	Non-Cardiac Chest Pain							
	Sinus Tachycardia							
	Sleep Disorder							
	Stress							
	Syncope							
	Vomiting							

Date:04/27/05ISR Number: 4646917-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03642
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:04/27/05ISR Number: 4646918-6Report Type:Expedited (15-DaCompany Report #DK-MERCK-0504DNK00024
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1086 DAY

Date:04/27/05ISR Number: 4646919-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03741
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Unstable
	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Conjunctival Haemorrhage
	Dyspnoea
	Dyspnoea Paroxysmal
	Nocturnal
	Gastritis Haemorrhagic
	Headache

		Hyperkalaemia					
		Hypovolaemia					
		Mitral Valve Incompetence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
4	MON						
		Orthopnoea		Vasotec	C		ORAL
		Orthostatic Hypotension		Aspirin	C		ORAL
		Pain In Extremity		Lasix (Furosemide)	C		ORAL
		Renal Failure Chronic		Prilosec	C		ORAL
				Lipitor	C		ORAL
				Allopurinol	C		ORAL
				Tylenol	C		ORAL

Date:04/27/05ISR Number: 4646920-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03714
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
20 MON						
	Polytraumatism					

Date:04/27/05ISR Number: 4646921-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00160
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Surgery		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Mitral Valve Replacement					
	Pulmonary Embolism					
	Pulmonary Oedema					
	Thrombosis					

Date:04/27/05ISR Number: 4646922-8Report Type:Expedited (15-DaCompany Report #ES-MERCK-0504ESP00035
Age:68 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Duodenal Ulcer		Piroxicam	SS		
36 DAY						
	Gastric Ulcer		Eprosartan	C		ORAL
	Gastrointestinal Haemorrhage					

Date:04/27/05ISR Number: 4646928-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04236
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		[Therapy Unspecified]	C		
UNKNOWN						

Date:04/27/05ISR Number: 4646929-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
366 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646931-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03726
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646937-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03725
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646938-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03248
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1960 DAY	
Hospitalization -			Lisinopril	C			UNKNOWN	
Initial or Prolonged			Prilosec	C			UNKNOWN	
Disability			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	

Date:04/27/05ISR Number: 4646939-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03724
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	

Date:04/27/05ISR Number: 4646940-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03779
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:04/27/05ISR Number: 4646941-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646942-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03776
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646943-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646944-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03778
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:04/27/05ISR Number: 4646945-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03777
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646952-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646953-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646954-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646955-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646956-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03971
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646957-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646958-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646959-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03889
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	38	MON

Date:04/27/05ISR Number: 4646960-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:04/27/05ISR Number: 4646961-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/27/05ISR Number: 4646962-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/27/05ISR Number: 4646963-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646964-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646965-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646966-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646968-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03891
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:04/27/05ISR Number: 4646969-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Polytraumatism

Date:04/27/05ISR Number: 4646970-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646971-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04246
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4646977-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04292
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646978-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646979-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/27/05ISR Number: 4646986-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04406
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vicodin Tablets	C				
UNKNOWN								
	Pain In Extremity		Methadone Hydrochloride	C				
UNKNOWN								

Date:04/27/05ISR Number: 4646988-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04324
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56	MON

Date:04/27/05ISR Number: 4646991-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03722
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	79	DAY

Date:04/27/05ISR Number: 4648542-8Report Type:Expedited (15-DaCompany Report #2005061375
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia	Foreign	Bextra (Valdecoxib)	PS		ORAL	(40 MG,	
	Diarrhoea	Consumer					UNKNOWN),	
	Liver Disorder						ORAL	
	Skin Exfoliation		Rofecoxib (Rofecoxib)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/27/05ISR Number: 4649186-4Report Type:Expedited (15-DaCompany Report #2005059717
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Exostosis		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	
	Joint Range Of Motion Decreased							
	Rectal Haemorrhage		Ibuprofen (Ibuprofen)	SS		ORAL	4000 MG (800 MG, 5 IN 1 D), ORAL	
	Self-Medication							
	Treatment Noncompliance							
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	SS			(750 MG)	
			Cortisone (Cortisone)	SS			INTRASYNOVIAL	INTRASYNOVIAL
			Pantoprazole (Pantoprazole)	C				
			Vitamins (Vitamins)	C				

Date:04/27/05ISR Number: 4649187-6Report Type:Expedited (15-DaCompany Report #2005059746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Celebrex (Celecoxib)	PS				
Other			Rofecoxib (Rofecoxib)	SS				

Date:04/27/05ISR Number: 4649380-2Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00095
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain	Foreign Study Health Professional Other	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	PO 337 DAY
	Angina Pectoris							
	Blood Sodium Decreased							
	Colon Cancer							
	Gamma-Glutamyltransferase Increased		Aspirin	C				
			Atenolol	C				
	Haemoglobin Decreased		Gliclazide	C				
	Monocyte Count Increased		Lansoprazole	C				
	Myocardial Ischaemia		Nitroglycerin	C				
	Nausea		Simvastatin	C				
	Platelet Count Decreased							

Date:04/27/05ISR Number: 4649404-2Report Type:Expedited (15-DaCompany Report #2005060545
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Consumer	Celebrex (Celecoxib)	PS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	ORAL
	Cough		Bextra (Valdecoxib)	SS		ORAL		
	Nasopharyngitis							
	Stress							
			Rofecoxib (Rofecoxib)	SS				
			Levothyroxine Sodium (Levothyroxine					

Sodium)	C
Acetylsalicylic Acid (Acetylsalicylic Acid)	C

Date:04/27/05ISR Number: 4649447-9Report Type:Expedited (15-DaCompany Report #2005059832
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Chest Pain		Bextra (Valdecoxib)	SS		ORAL	ORAL	
	Perforated Ulcer Surgery		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	

Date:04/27/05ISR Number: 4649452-2Report Type:Expedited (15-DaCompany Report #2005060572
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Celebrex (Celecoxib)	PS				
			Bextra (Valdecoxib)	SS				
			Rofecoxib (Rofecoxib)	SS				

Date:04/28/05ISR Number: 4647535-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Ageusia
Other	Anosmia
	Arthropathy
	Cardiomegaly
	Chronic Obstructive Pulmonary Disease
	Colon Adenoma
	Decreased Appetite
	Deep Vein Thrombosis

Emotional Distress
Essential Hypertension
Faecal Incontinence
Fatigue
Fibromyalgia
Haemangioma
Haematochezia
Hypercoagulation
Hypertension
Injury
Lumbar Spinal Stenosis
Macular Degeneration
Nausea
Nephrolithiasis
Osteopenia
Osteoporosis
Pulmonary Embolism
Pulmonary Hypertension
Rectal Haemorrhage
Renal Disorder
Skeletal Injury
Urinary Incontinence

		Weight Decreased					
		Weight Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Atenolol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Niaspan	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Acetaminophen	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Herbs (Unspecified)	C		
UNKNOWN							

Date:04/28/05ISR Number: 4647555-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00077
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
				Furosemide	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							

Date:04/28/05ISR Number: 4647556-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01602
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Headache		Progesterone	C				
UNKNOWN								
Disability	Hypertension							
Other	Neck Pain							
	Pain In Extremity							
	Pulmonary Embolism							
	Sleep Disorder							

Date:04/28/05ISR Number: 4647558-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02804
Age:80 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
	Anxiety
	Arteriospasm Coronary
	Back Pain
	Bronchitis Viral
	Cardiomyopathy
	Chest Pain
	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease
	Dizziness
	Fatigue
	Headache
	Hypercholesterolaemia

		Hypertension					
		Hypotension					
		Influenza	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Hydrodiuril	C		ORAL
		Pulmonary Hypertension					
		Renal Cyst					
		Upper Respiratory Tract Infection					
		Ventricular Dysfunction					
		Viral Upper Respiratory Tract Infection					

Date:04/28/05ISR Number: 4647559-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00274
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
Initial or Prolonged		Autoimmune Thyroiditis					
Disability		Cerebrovascular Accident					
Other		Depression					
		Drug Abuser					
		Hepatic Enzyme Increased					
		Hypothyroidism					
		Iron Deficiency					
		Psoriasis					
		Renal Failure					
		Syncope					
		Treatment Noncompliance					

Date:04/28/05ISR Number: 4647561-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03108
Age:51 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
31	MON						

Date:04/28/05ISR Number: 4647562-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00694
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Anxiety
	Aphonia
	Arthralgia
	Atrial Fibrillation
	Balance Disorder
	Blindness Unilateral
	Cerebrovascular Accident
	Cervical Spinal Stenosis
	Chest Discomfort
	Coronary Artery Disease
	Dizziness
	Dyspnoea
	Fluid Retention
	Headache
	Hyperhidrosis
	Hypertension

	Hypoacusis						
	Insomnia						
	Muscle Spasms	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	579 DAY
	Osteochondrosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL	579 DAY
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL	
	Retinal Vascular		Aspirin	C			UNKNOWN
	Occlusion		Calcium Dobesilate	C			UNKNOWN
	Syncope		Oxazepam	C			UNKNOWN
	Vascular Encephalopathy		Vitamin E Acetate				
	Vertigo		D-Form	C			UNKNOWN
	Visual Disturbance		Magnesium (Unspecified)	C			UNKNOWN
			Nifedipine	C			UNKNOWN
			Calcium Citrate And Cholecalciferol	C			UNKNOWN
			Nitroglycerin	C			UNKNOWN

Date:04/28/05ISR Number: 4647574-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:04/28/05ISR Number: 4647590-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
51 MON						

Date:04/28/05ISR Number: 4647591-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Cardiovascular Disorder					
	Cerebrovascular Accident					
	Injury					
	Myocardial Infarction					
	Organ Failure					
	Pain					

Date:04/28/05ISR Number: 4647592-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03435
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
	Transient Ischaemic Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4647593-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	606	DAY

Date:04/28/05ISR Number: 4647594-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647595-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00017
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alcohol Induced		Vioxx	PS	Merck & Co., Inc	ORAL	570	DAY
Initial or Prolonged	Persisting Dementia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Atorvastatin Calcium	C				
	Brain Damage		Prednisolone	C				
	Cerebral Atrophy		Citalopram Hydrobromide	C				
	Dysarthria							
	Gait Disturbance		Mianserin Hydrochloride	C				

Date:04/28/05ISR Number: 4647597-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647598-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03450
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647599-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03455
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647600-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00232
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Congestive		[Therapy					
Hospitalization - UNKNOWN	Cerebrovascular Accident		Unspecified]	C				
Initial or Prolonged			[Therapy					
Disability UNKNOWN			Unspecified]	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4647601-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02973
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Increased							
Other	Bronchitis Acute							
	Cardiac Failure							
	Cardiac Failure							
	Congestive							
	Chronic Obstructive							
	Pulmonary Disease							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Mitral Valve Incompetence							
	Obesity							
	Perineal Abscess							
	Pneumonia							
	Renal Failure Chronic							
	Rhinitis							
	Sleep Apnoea Syndrome							
	Swelling							
	Tricuspid Valve Incompetence							
	Venous Stasis							

Date:04/28/05ISR Number: 4647603-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00022
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		226 DAY
Initial or Prolonged	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		226 DAY
	Chest Pain		Metoprolol Tartrate	C		ORAL		
	Dyspnoea		Aspirin And Magnesium Oxide	C		ORAL		
	Myocardial Infarction		Isosorbide Mononitrate	C		ORAL		
			Ranitidine Hydrochloride	C		ORAL		
			Amlodipine Besylate	C		ORAL		

			Nitroglycerin	C	ORAL
			Lactose	C	ORAL

Date:04/28/05ISR Number: 4647604-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647605-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03798
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4647606-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03880
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Zocor	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Levothroid	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

Date:04/28/05ISR Number: 4647607-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03731
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:04/28/05ISR Number: 4647608-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:04/28/05ISR Number: 4647609-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647610-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03797
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647611-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647623-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03885
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:04/28/05ISR Number: 4647624-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03952
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647625-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03730
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1157 DAY

Date:04/28/05ISR Number: 4647626-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647629-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04420
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647630-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647632-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		54 DAY

Date:04/28/05ISR Number: 4647633-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647641-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04409
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4647642-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04467
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4647661-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648014-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00120
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Compartment Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		594 DAY
Initial or Prolonged	Muscle Rupture		Allopurinol	C		ORAL		
Disability	Post Thrombotic Syndrome		Diclofenac	C		ORAL		
	Thrombosis		Tramadol					
	Varicose Vein		Hydrochloride	C		ORAL		

Date:04/28/05ISR Number: 4648018-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02598
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		44 MON
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		44 MON
	Coronary Artery Disease		Mobic	C				UNKNOWN
	Ecchymosis		Skelaxin	C				UNKNOWN
	Emotional Distress		Percocet	C				UNKNOWN
	Fall		Zantac	C				UNKNOWN
	Groin Pain							
	Myocardial Infarction							
	Pain In Extremity							
	Urticaria							

Date:04/28/05ISR Number: 4648019-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00392
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		17 DAY
Initial or Prolonged	Bacterial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		925 DAY
Disability	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		233 DAY
	Diabetes Mellitus		Alprazolam	C		ORAL		
	Non-Insulin-Dependent		Potassium Citrate					
	Dizziness		And Potassium					
	Fatigue		Bicarbonate	C		ORAL		
	Gastrointestinal Disorder		Spironolactone	C		ORAL		
	Hyperhidrosis		Zocor	C		ORAL		
	Malaise		Diclofenac					
	Oedema Peripheral		Diethylamine	C		TOPICAL		
	Polyarthritis		Globulin, Immune	C		INTRAMUSCULAR		
	Supraventricular		Antimicrobial					
	Extrasystoles		(Unspecified)	C		UNKNOWN		
	Syncope		Acetaminophen	C		UNKNOWN		

Date:04/28/05ISR Number: 4648026-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01784
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Blood Lactate
Initial or Prolonged	Dehydrogenase Increased
Other	Cerebrovascular Accident

		Chills					
		Nausea					
		Platelet Count Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pollakiuria		Vioxx	PS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage					
		Thrombotic					
		Thrombocytopenic Purpura					
		Vision Blurred					

Date:04/28/05ISR Number: 4648027-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03746
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	First Degree		Ecotrin	C		ORAL
6 YR						
	Azotaemia		Celebrex	C		ORAL
	Benign Prostatic		Avandia	C		ORAL
	Hyperplasia		Lipitor	C		ORAL
	Faeces Discoloured		Vitamins			
	Gastric Ulcer Haemorrhage		(Unspecified)	C		ORAL
	Haemoglobin Decreased		Fluconazole	C		ORAL
	Headache		Altace	C		ORAL
			Sulfamethoxazole And			
			Trimethoprim	C		ORAL
1 YR						
			Atenolol	C		
UNKNOWN						
			Vitamin E	C		
UNKNOWN						
			Trazodone			
			Hydrochloride	C		
UNKNOWN						
			Tylenol Arthritis			
			Extended Relief	C		
UNKNOWN						
			Levitra	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						

Date:04/28/05ISR Number: 4648029-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00999
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Balance Disorder		Amitriptyline Hydrochloride	C			UNKNOWN	
	Carotid Artery Aneurysm		Lasix (Furosemide)	C			UNKNOWN	
	Cerebral Haemangioma		Oxycontin	C			UNKNOWN	
	Cerebrovascular Accident		Nitrostat	C			UNKNOWN	
	Fall		Mobic	C			UNKNOWN	
	Heart Rate Increased		[Therapy Unspecified]	C			UNKNOWN	
	Loss Of Consciousness		Neurontin	C			UNKNOWN	
	Myocardial Infarction							
	Neck Pain							
	Pain							
	Syncope							

Date:04/28/05ISR Number: 4648031-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00060
Age:73 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Acute Myocardial		Diabinese	C				
Infarction		Celebrex	C				
Anaemia		Celebrex	C				
Angina Unstable		Aspirin	C				
Angiodysplasia		Imdur	C				
Arthralgia		Glucophage	C				
Blood Disorder							
Chest Pain							
Congestive Cardiomyopathy							
Dyspnoea							
Electrocardiogram Abnormal							
Gastric Haemorrhage							
Gastritis							
Gastrointestinal Haemorrhage							
Haematochezia							
Hypochromic Anaemia							
Hypomagnesaemia							
Ischaemic Cardiomyopathy							
Musculoskeletal Chest Pain							
Myocardial Infarction							
Palpitations							
Panic Disorder							
Peptic Ulcer							
Respiratory Tract Infection							
Sinus Bradycardia							
Staphylococcal Bacteraemia							
Urosepsis							
Ventricular Dysfunction							

Date:04/28/05ISR Number: 4648032-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01768
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Nifedipine	C				
UNKNOWN								
	Dizziness		Fosinopril Sodium	C				
UNKNOWN								
	Drug Effect Decreased							
	Dyspnoea							

Date:04/28/05ISR Number: 4648033-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03074
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Other	Atherosclerosis
	Blood Cholesterol Increased
	Cardiac Disorder
	Cardiac Failure Congestive
	Carotid Artery Stenosis

	Hypertension Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	43 MON
			Vioxx	SS	Merck & Co., Inc	ORAL	43 MON
			Aspirin	C			UNKNOWN

Date:04/28/05ISR Number: 4648038-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00081
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	44 MON
Initial or Prolonged	Cerebrovascular Accident		Hyzaar	C			UNKNOWN 2 YR
Other	Chest Pain Incorrect Dose Administered Loss Of Consciousness Transient Ischaemic Attack						

Date:04/28/05ISR Number: 4648046-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00105
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Asthma		Theophylline	C			UNKNOWN
	Breast Pain		Singulair	C			UNKNOWN
	Cardiac Disorder Chest Pain		Fluticasone Propionate And Salmeterol Xinafoate	C			RESPIRATORY (INHALATION)

Date:04/28/05ISR Number: 4648048-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1189 DAY	
	Injury							
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:04/28/05ISR Number: 4648049-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29 MON	

Date:04/28/05ISR Number: 4648050-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03427
Age:72 YR Gender:Female I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Difficulty In Walking
	Malaise

Muscle Abscess

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648051-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03251
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	
Hospitalization -	Chest Pain		Hydrodiuril	C				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Prinivil	C				
UNKNOWN								

Date:04/28/05ISR Number: 4648052-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02065
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anal Fissure
Other	Angina Unstable
	Anorectal Disorder
	Anxiety
	Arteriosclerosis
	Atherosclerosis
	Bradycardia
	Bronchitis Acute
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Chest Pain
	Cholelithiasis
	Chronic Obstructive
	Pulmonary Disease
	Colitis Ischaemic
	Congenital Anaemia
	Coronary Artery Disease
	Coronary Artery Embolism
	Coronary Artery Stenosis

Diabetes Mellitus
Diverticulum
Dizziness
Dyslipidaemia
Emotional Distress
Gastrointestinal
Haemorrhage
Haemorrhoids
Hypertension
Large Intestinal Ulcer
Left Ventricular
End-Diastolic Pressure
Increased
Myocardial Infarction
Platelet Count Increased
Pneumonia
Pulmonary Hypertension
Renal Cyst
Sleep Apnoea Syndrome
Staphylococcal
Bacteraemia

		Staphylococcal Infection Vascular Pseudoaneurysm White Blood Cell Count	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Wound Infection		K-Dur	C		
UNKNOWN							
		Staphylococcal		Plavix	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Toprol Xl Tablets	C		ORAL
				Allopurinol	C		
UNKNOWN							
				Isosorbide Mononitrate	C		
UNKNOWN							
				Zocor	C		ORAL
				Cozaar	C		ORAL
				Nifedipine	C		
UNKNOWN							
				Hydralazine	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:04/28/05ISR Number: 4648053-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00007
Age:67 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Glycosylated Haemoglobin		Metoprolol Tartrate	C		ORAL
		Increased		Insulin, Neutral	C		
RESPIRATORY							
		Hypoaesthesia					
(INHALATION)							
		Muscular Weakness		Insulin, Biphasic			
		Platelet Count Increased		Isophane [Injection]	C		
UNKNOWN							
				Insulin, Biphasic Isophane [Injection]	C		
UNKNOWN							

Prednisolone	C		
UNKNOWN			
Leflunomide	C		
UNKNOWN			
Mevacor	C		
UNKNOWN			
Omega-3 Marine Triglycerides	C		ORAL
Magnesium Oxide And Aspirin	C		
UNKNOWN			
Nitroglycerin	C		
UNKNOWN			

Date:04/28/05ISR Number: 4648054-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON	

Date:04/28/05ISR Number: 4648055-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03695
Age:55 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Anxiety
	Asthenia
	Asthma
	Blood Testosterone Decreased
	Cardiac Failure Congestive
	Chest Pain

	Deafness						
	Drug Ineffective						
	Dyspnoea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL	
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	
	Femoral Nerve Injury		Lisinopril	C			UNKNOWN
	Fluid Retention		Plavix	C			UNKNOWN
	Gastrooesophageal Reflux		Zocor	C			UNKNOWN
	Disease		Advair	C			UNKNOWN
	Granuloma		Toprol Xl Tablets	C			UNKNOWN
	Hyperhidrosis		Flonase	C			UNKNOWN
	Hypertension		Liquibid	C			UNKNOWN
	Myocardial Infarction		Singulair	C			UNKNOWN
	Nocturia		Furosemide	C			UNKNOWN
	Oedema Peripheral						
	Sexual Dysfunction						
	Sleep Apnoea Syndrome						
	Synovial Cyst						
	Thyroid Neoplasm						
	Tremor						

Date:04/28/05ISR Number: 4648065-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00032
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 15 DAY	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged							

Date:04/28/05ISR Number: 4648066-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00031
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		570 DAY
	Cerebral Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Dexchlorpheniramine Maleate	C		ORAL		

Date:04/28/05ISR Number: 4648067-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03858
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:04/28/05ISR Number: 4648068-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03727
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:04/28/05ISR Number: 4648071-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03812
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648072-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03792
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648073-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03794
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648084-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04206
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648085-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiovascular Disorder							
	Organ Failure							
	Pain							

Date:04/28/05ISR Number: 4648086-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04204
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648087-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL	407	DAY

Date:04/28/05ISR Number: 4648088-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648089-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648090-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04013
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648091-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04428
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648092-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648093-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648094-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04225
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648095-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648105-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648106-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04455
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648107-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648108-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648109-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04000
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648110-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648111-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648117-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04460
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648118-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:04/28/05ISR Number: 4648119-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04469
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648120-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04456
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648121-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04464
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/28/05ISR Number: 4648122-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:04/28/05ISR Number: 4648123-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648124-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04470
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648130-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648132-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04466
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:04/28/05ISR Number: 4648133-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00781
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
3 MON								
Initial or Prolonged	Acute Myocardial							
Other	Infarction							
	Angina Pectoris							
	Angina Unstable							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery Disease							
	Coronary Artery Occlusion							

Dizziness
Dyspnoea Exertional
Hypertension
Hypothyroidism
Ischaemic Stroke
Lower Respiratory Tract
Infection
Mitral Valve Incompetence
Myocardial Infarction
Nasopharyngitis
Pulmonary Congestion
Renal Failure
Sleep Apnoea Syndrome
Somnolence
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Dysfunction

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4648134-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00105
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Blood Cholesterol		Synthroid	C			UNKNOWN	
	Increased		Diovan Hct	C			UNKNOWN	
	Blood Potassium Decreased		Toprol Xl Tablets	C			UNKNOWN	
	Chest Pain		Cozaar	C			UNKNOWN	
	Emotional Distress							
	Nasopharyngitis							
	Pain							
	Sciatica							

Date:04/28/05ISR Number: 4648140-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:04/28/05ISR Number: 4648141-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/28/05ISR Number: 4648146-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04224
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648151-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03953
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/28/05ISR Number: 4648152-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/28/05ISR Number: 4649796-4Report Type:Direct Company Report #CTU 247329
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx 50 Mg	PS				

Date:04/28/05ISR Number: 4650256-5Report Type:Expedited (15-DaCompany Report #2005060819
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Back Pain		Bextra (Valdecoxib)	SS		ORAL	ORAL	
	Cardiac Disorder		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Chest Pain							
	Dizziness		Etanercept (Etanercept)	C				
	Dyspepsia		Oxycocet (Oxycodone Hydrochloride, Paracetamol)	C				
	Feeling Abnormal		Tizanidine Hydrochloride (Tizanidine Hydrochloride)	C				
	Fibromyalgia		Venlafaxine Hydrochloride (Venlafaxine Hydrochloride)	C				
	Heart Rate Increased		Estrogens Conjugated (Estrogens Conjugated)	C				
	Hypertension		Hydroxychloroquine Phosphate (Hydroxychloroquine Phosphate)	C				
			Alprazolam (Alprazolam)	C				
			Folic Acid (Folic Acid)	C				
			Methotrexate					

(Methotrexate)	C
Omeprazole (Omeprazole)	C
Ibuprofen (Ibuprofen)	C
Methadone (Methadone)	C

Date:04/29/05ISR Number: 4648438-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00137
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		76 DAY
Hospitalization - Initial or Prolonged Disability	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Rabeprazole Sodium	C		ORAL		
	Pulmonary Embolism		Rabeprazole Sodium	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648781-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anal Fistula							
	Aneurysm Ruptured							
	Angina Unstable							
	Anxiety							
	Appendicitis Perforated							
	Arthralgia							
	Atelectasis							
	Back Pain							
	Cardiac Failure							
	Cerebral Artery Stenosis							
	Colitis Ulcerative							
	Contusion							
	Convulsion							
	Coronary Artery Disease							
	Cough							
	Defaecation Urgency							
	Depression							
	Dermatitis							
	Dizziness							
	Drug Ineffective							
	Faecal Incontinence							
	Fall							
	Flatulence							
	Headache							
	Hernia							
	Hyperlipidaemia							
	Hypertension							
	Hypotension							
	Ileitis							
	Impaired Healing							
	Infection							
	Inflammatory Bowel Disease							
	Intestinal Perforation							
	Intestinal Spasm							
	Intracranial Aneurysm							
	Joint Injury							
	Migraine							
	Musculoskeletal Chest Pain							

Pain
Pain In Extremity
Perianal Abscess
Perirectal Abscess
Pneumoperitoneum
Proctalgia
Proctitis Ulcerative
Pruritus Ani
Pyrexia
Sepsis
Subarachnoid Haemorrhage
Syncope
Tachycardia
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648791-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA00889
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Chronic Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Depression		Aspirin	C			UNKNOWN	
	Disorientation		Darvocet-N	C			UNKNOWN	
	Fatigue		Naproxen	C			UNKNOWN	
	Generalised Anxiety Disorder		Ibuprofen	C			UNKNOWN	
	Herpes Zoster							
	Memory Impairment							
	Transient Ischaemic Attack							

Date:04/29/05ISR Number: 4648792-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anorexia		Aspirin	C			UNKNOWN	
Other	Atherosclerosis							
	Chest Discomfort							
	Chloasma							
	Chronic Sinusitis							
	Constipation							
	Coronary Artery Disease							
	Cough							
	Depression							
	Dizziness							
	Drug Dependence							
	Dysuria							
	Eustachian Tube Disorder							
	Feeling Abnormal							
	Gastric Ulcer							
	Gastrooesophageal Reflux							

Disease
Headache
Hypertension
Iliac Artery Stenosis
Injury
Intermittent Claudication
Malaise
Muscle Spasms
Myocardial Infarction
Nicotine Dependence
Paraesthesia
Peripheral Vascular
Disorder
Pleurisy
Pulmonary Calcification
Sinus Bradycardia
Stomatitis
Stress

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648797-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01732
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Initial or Prolonged	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL		2 DAY
Disability	First Degree		Tylenol With Codeine #3	C		ORAL		
	Blood Cholesterol Increased		Vicodin Tablets	C				UNKNOWN
	Blood Pressure Decreased		Tylenol	C				UNKNOWN
	Blood Triglycerides Increased		Ecotrin	C				UNKNOWN
	Bradycardia							
	Bronchitis							
	Bronchospasm							
	Chest Pain							
	Coronary Artery Disease							
	Fatigue							
	Hypertension							
	Hypoxia							
	Insomnia							
	Joint Swelling							
	Myocardial Infarction							
	Oxygen Saturation Decreased							
	Pharyngitis							
	Pharyngitis Streptococcal							
	Sinusitis							
	Weight Increased							

Date:04/29/05ISR Number: 4648798-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accelerated Hypertension
Initial or Prolonged	Alanine Aminotransferase Increased
Disability	Blood Cholesterol Increased

Bradycardia
Conjunctival Haemorrhage
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery Stenosis
Dilatation Atrial
Drug Intolerance
Fatigue
Hyperlipidaemia
Hypotension
Intermittent Claudication
Low Density Lipoprotein
Increased
Memory Impairment
Mitral Valve Incompetence
Myocardial Infarction
Neuropathy
Peripheral Vascular
Disorder
Pharyngitis

	Polydipsia						
	Shock						
	Spinal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Upper Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL	
	Infection		Vioxx	SS	Merck & Co., Inc	ORAL	
	Ventricular Tachycardia		Atenolol	C			UNKNOWN
	Weight Increased		Norvasc	C			UNKNOWN

Date:04/29/05ISR Number: 4648800-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02535
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	67 DAY
Initial or Prolonged	Cerebral Haemorrhage		Excedrin				
Disability	Cyclic Vomiting Syndrome		(Acetaminophen (+)				
	Headache		Aspirin (+)				
	Injury		Caffeine)	C			UNKNOWN
	Insomnia		Midrin	C			UNKNOWN
	Migraine		Grape Seeds	C			UNKNOWN
	Migraine Without Aura		Linseed Oil	C			UNKNOWN
	Nausea		Ascorbic Acid	C			UNKNOWN
	Stress						

Date:04/29/05ISR Number: 4648815-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02879
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Pectoris
	Angina Unstable
	Anxiety
	Asthenia

Back Injury
Back Pain
Balance Disorder
Bone Pain
Cerebellar Ataxia
Cerebellar Atrophy
Cerebrovascular Accident
Chest Pain
Chills
Convulsion
Coordination Abnormal
Coronary Artery
Thrombosis
Depression
Discomfort
Dizziness
Dyslipidaemia
Dyspnoea
Ecchymosis
Emotional Distress
Fatigue
Gastrooesophageal Reflux
Disease
Haematoma
Headache
Hyperhidrosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypoaesthesia					
		Ischaemic Cardiomyopathy					
		Lumbar Radiculopathy					
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis		Plavix	C		
UNKNOWN							
		Oedema Peripheral		Lipitor	C		
UNKNOWN							
		Otitis Media		Indocin			
		Pain		(Indomethacin)	C		
UNKNOWN							
		Paraesthesia		Paxil	C		
UNKNOWN							
		Pharyngolaryngeal Pain		Tenormin	C		
UNKNOWN							
		Radiculopathy		Aspirin	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Lisinopril	C		
UNKNOWN							
		Snoring		Nitroglycerin	C		
UNKNOWN							
		Somnolence		Ativan	C		
UNKNOWN							
		Speech Disorder		Ativan	C		
UNKNOWN							
		Stress		Ativan	C		
UNKNOWN							
		Vertigo		Garlic Extract	C		
UNKNOWN							
		Vestibular Neuronitis		Ascorbic Acid	C		
UNKNOWN							
		Vision Blurred		Advair	C		
UNKNOWN							
		Vitamin B12 Deficiency		Prinivil	C		
UNKNOWN							
		Weight Decreased		Flexeril	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							

Date:04/29/05ISR Number: 4648817-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02877
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anaemia Postoperative		Tenormin	C				
Disability	Angina Unstable		Premarin	C			UNKNOWN	7508 DAY
	Blood Triglycerides Increased		Protonix	C			UNKNOWN	
	Carotid Artery Stenosis							
	Coronary Artery Disease							
	Diabetes Mellitus							
	Dyspnoea							
	Emotional Distress							
	Hip Arthroplasty							
	Hyperlipidaemia							
	Hypertriglyceridaemia							
	Insulin Resistance Syndrome							
	Leukocytosis							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Pain							
	Paraesthesia							
	Refusal Of Treatment By Patient							
	Rheumatoid Arthritis							
	Sleep Apnoea Syndrome							

Date:04/29/05ISR Number: 4648818-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02858
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

		Anxiety					
		Arthralgia					
		Blood Pressure Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Calculus Urinary		Vioxx	SS	Merck & Co., Inc	ORAL
5	YR						
		Cyst		Gastrointestinal			
		Drug Hypersensitivity		Preparations			
		Goitre		(Unspecified)	C		
UNKNOWN							
		Herpes Virus Infection		Hydrochlorothiazide	C		
UNKNOWN							
		Joint Lock		Levothyroxine Sodium	C		
UNKNOWN							
		Nephrolithiasis		Atacand	C		
UNKNOWN							
		Sinusitis		Premarin	C		
UNKNOWN							
		Sleep Apnoea Syndrome					
		Supraventricular					
		Extrasystoles					
		Thermal Burn					
		Ventricular Extrasystoles					
		Ventricular Tachycardia					

Date:04/29/05ISR Number: 4648820-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03303
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Cholesterol		Amlodipine Besylate	C		
UNKNOWN							
		Increased		Prinivil	C		
UNKNOWN							
		Cerebrovascular Accident		Rabeprazole Sodium	C		
UNKNOWN							
		Convulsion		Ranitidine	C		
UNKNOWN							
		Diabetes Mellitus		Tylenol	C		
UNKNOWN							

	Emotional Distress	Norvasc	C
UNKNOWN			
	Gait Disturbance		
	Glaucoma		
	Low Density Lipoprotein		
	Increased		
	Post Procedural		
	Complication		

Date:04/29/05ISR Number: 4648821-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03298
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accelerated Hypertension
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Chest Pain
	Coronary Artery Occlusion
	Diverticulitis
	Diverticulum
	Dizziness
	Epigastric Discomfort
	Gastroenteritis
	Gastrointestinal
	Haemorrhage
	Headache
	Hiatus Hernia
	Hypercholesterolaemia
	Intervertebral Disc
	Protrusion

		Lumbar Radiculopathy					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Coumadin	C		
UNKNOWN							
		Platelet Disorder		Tenormin	C		
UNKNOWN							
		Rectal Polyp		Pravachol	C		
UNKNOWN							
		Urinary Retention		Aspirin	C		
UNKNOWN							
		Vertigo					

Date:04/29/05ISR Number: 4648822-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04326
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris					
		Aortic Valve Incompetence					
		Arthritis					
		Atrioventricular Block Second Degree					
		Burning Sensation					
		Cardiac Failure Congestive					
		Cardiomegaly					
		Chest Discomfort					
		Coronary Artery Atherosclerosis					
		Coronary Artery Disease					
		Depression					
		Dermatitis Allergic					
		Diabetes Mellitus					
		Hyperlipidaemia					
		Hypertension					
		Hypotension					
		Ischaemic Cardiomyopathy					
		Mitral Valve Incompetence					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					

Subclavian Artery
Stenosis
Tricuspid Valve
Incompetence
White Blood Cell Count
Increased
Wound Complication

Date:04/29/05ISR Number: 4648823-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03261
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Angina Unstable
	Aortic Valve Incompetence
	Atrial Flutter
	Blindness
	Blood Cholesterol

		Increased Cardiac Failure Congestive Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Confusional State		Cozaar	C		ORAL
		Constipation		Cozaar	C		ORAL
		Coronary Artery Stenosis		Theophylline	C		
UNKNOWN							
		Dementia		Xopenex	C		
UNKNOWN							
		Diverticulum Intestinal		Ipratropium Bromide	C		
UNKNOWN							
		Haemorrhagic		Glyburide	C		
UNKNOWN							
		Metabolic Disorder		Levothyroxine Sodium	C		
UNKNOWN							
		Myocardial Infarction		Potassium Chloride	C		
UNKNOWN							
		Nephrolithiasis		Lanoxin	C		
UNKNOWN							
		Oedema Peripheral		Lipitor	C		
UNKNOWN							
		Papilloedema		Plavix	C		
UNKNOWN							
		Pelvic Congestion		Pacerone	C		
UNKNOWN							
		Psychotic Disorder		Nitroquick	C		
UNKNOWN							
		Pulmonary Valve Incompetence Renal Failure Sinus Tachycardia Transient Ischaemic Attack Tricuspid Valve Incompetence Ventricular Extrasystoles Ventricular Hypertrophy					

Date:04/29/05ISR Number: 4648824-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00102
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Azmacort	C			UNKNOWN	
	Congestive		Albuterol	C			UNKNOWN	
	Constipation		Ambien	C			UNKNOWN	
	Depression		Amitriptyline Hydrochloride	C			UNKNOWN	
	Dyspepsia							
	Faeces Hard		Aspirin	C			UNKNOWN	
	Fungal Infection		Aspirin	C			UNKNOWN	
	Hyperlipidaemia		Atrovent	C			UNKNOWN	
	Hypersensitivity		Bextra	C			UNKNOWN	
	Hypertension		Biaxin	C			UNKNOWN	
	Hypokalaemia		Bidex	C			UNKNOWN	
	Insomnia		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Iron Deficiency Anaemia							
	Muscle Contractions		Docusate Calcium	C			UNKNOWN	
	Involuntary		Docusate Calcium	C			UNKNOWN	
	Muscle Spasms		Duragesic	C			UNKNOWN	
	Myocardial Infarction		Ferrous Sulfate	C			UNKNOWN	
	Oedema		Flovent	C			UNKNOWN	
	Sudden Cardiac Death		Fluoxetine	C			UNKNOWN	
	Thyroid Disorder		Fosamax	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Acetaminophen And Hydrocodone					

	Bitartrate	C
UNKNOWN		
	Hydroxychloroquine Sulfate	C
UNKNOWN		
	Lanoxin	C
UNKNOWN		
	Levoxyl	C
UNKNOWN		
	Maxair	C
UNKNOWN		
	Miacalcin	C
UNKNOWN		
	Nystatin	C
UNKNOWN		
	Percocet	C
UNKNOWN		
	Phenergan Tablets/Suppositories	C
UNKNOWN		
	Potassium (Unspecified)	C
UNKNOWN		
	Prednisone	C
UNKNOWN		
	Premarin	C
UNKNOWN		
	Prilosec	C
UNKNOWN		
	Promethazine	C
UNKNOWN		
	Prozac	C
UNKNOWN		
	Synthroid	C
UNKNOWN		
	Tequin	C
UNKNOWN		
	Tizanidine Hydrochloride	C
UNKNOWN		
	Z-Pak	C
UNKNOWN		
	Zanaflex	C
UNKNOWN		
	Zanaflex	C
UNKNOWN		

	Zocor	C
UNKNOWN		
	Zyrtec	C
UNKNOWN		
	Prevacid	C
UNKNOWN		

Date:04/29/05ISR Number: 4648827-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03302
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Aortic Valve Incompetence							
	Basal Cell Carcinoma							
	Cardiac Murmur							
	Coronary Artery Disease							
	Dementia							
	Dizziness							
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hernia							
	Hypertension							
	Lipoma							
	Marfan'S Syndrome							
	Memory Impairment							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nail Discolouration							
	Onychomycosis							
	Sinusitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648828-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02989
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Cerebral Venous		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Thrombosis		Synthroid	C				
UNKNOWN								
	Cerebrovascular Accident		Lipitor	C				
UNKNOWN								
	Cerebrovascular Disorder		Prempro	C				
UNKNOWN								
	Migraine		Labetalol					
	Osteoarthritis		Hydrochloride	C				
UNKNOWN								
	Palpitations		Glucotrol	C				
UNKNOWN								
	Renal Cyst							
	Transverse Sinus							
	Thrombosis							

Date:04/29/05ISR Number: 4648836-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03931
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:04/29/05ISR Number: 4648837-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00556
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		600 DAY
Initial or Prolonged	Dyspepsia		Diovan	C				
UNKNOWN								
	Myocardial Infarction		Zocor	C		ORAL		
	Ulcer							

Date:04/29/05ISR Number: 4648838-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00146
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Ineffective							
	Fatigue							
	Myocardial Infarction							
	Weight Decreased							

Date:04/29/05ISR Number: 4648839-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03262
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vasotec	C		ORAL		
	Blood Pressure Increased		Diovan	C				
UNKNOWN								
	Carpal Tunnel Syndrome		Norvasc	C				
UNKNOWN								
	Cerebrovascular Accident		Premarin	C				
UNKNOWN								
	Depression		Zyrtec	C				
UNKNOWN								
	Headache		Prozac	C				
UNKNOWN								
	Pain		Protonix	C				
UNKNOWN								
	Ventricular Hypertrophy		Fioricet Tablets	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648850-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00034
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebral Infarction		Atenolol	C		ORAL		
Disability	Cerebrovascular Accident		Atorvastatin Calcium	C		ORAL		
	Disturbance In Attention		Formoterol Fumarate	C		RESPIRATORY (INHALATION)		
	Performance Status							
	Decreased		Nifedipine	C		ORAL		
	Sinus Bradycardia		Nitroglycerin	C		SUBLINGUAL		
			Budesonide	C		RESPIRATORY (INHALATION)		

Date:04/29/05ISR Number: 4648851-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03437
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Diovan	C				
UNKNOWN								

Date:04/29/05ISR Number: 4648852-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:04/29/05ISR Number: 4648853-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03932
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648863-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648864-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648865-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04136
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648866-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03935
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648868-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04189
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Adverse Event Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648869-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:04/29/05ISR Number: 4648870-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648871-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/29/05ISR Number: 4648872-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4648873-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648874-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04191
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
Other	Cardiac Disorder Economic Problem Myocardial Infarction							

Date:04/29/05ISR Number: 4648880-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648881-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648882-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648883-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:04/29/05ISR Number: 4648884-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:04/29/05ISR Number: 4648885-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04430
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648886-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04436
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4648887-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4648890-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04393
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Crohn'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Gastric Ulcer		Coumadin	C				
UNKNOWN								
Hospitalization - Initial or Prolonged								
Disability								

Date:04/29/05ISR Number: 4648891-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4648892-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4648901-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04443
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:04/29/05ISR Number: 4648911-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04442
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4648912-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04441
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Death							
	Injury							

Date:04/29/05ISR Number: 4649138-4Report Type:Expedited (15-DaCompany Report #B0379470A
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Quilonorm Retard	PS	Glaxosmithkline	ORAL	12.5MMOL	Unknown
	Drug Interaction							
	Drug Level Increased		Rofecoxib	SS		ORAL	50MG	Unknown
	Therapeutic Agent		Diclofenac	SS		ORAL	50MG	Unknown
	Toxicity		Hydrochlorothiazide + Losartan Potassium	SS		ORAL		
	Tremor		Clomipramine	C		ORAL	75MG per day	
			Maprotilin	C		ORAL	75MG per day	
			Bisoprolol	C		ORAL	10MG per day	
			Amlodipine	C		ORAL	10MG per day	
			Phenprocoumon	C		ORAL		
			Nadroparin	C	Glaxosmithkline	SUBCUTANEOUS	.6ML per day	DAY
			Esomeprazole	C		ORAL	10MG per day	
			Losartan	C		ORAL	50MG per day	

Date:04/29/05ISR Number: 4649264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02237
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		1193 DAY
Initial or Prolonged	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		1193 DAY
Disability	Condyloma Acuminatum		Methylprednisolone	C				UNKNOWN
Other	Coronary Artery Occlusion		Bextra	C				UNKNOWN
	Diarrhoea		Colchicine	C				UNKNOWN
	Gout		Norvasc	C				UNKNOWN
	Hypertension		Triamterene	C				UNKNOWN
	Myocardial Infarction		Allopurinol	C				UNKNOWN
			Methocarbamol	C				UNKNOWN
			Indomethacin	C				UNKNOWN
			Plavix	C				UNKNOWN
			Protonix	C				UNKNOWN
			Hydrocodone Bitartrate	C				UNKNOWN
			Altace	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Nitroquick	C				UNKNOWN

Date:04/29/05ISR Number: 4649265-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00826
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Arthralgia
	Asthenia
	Back Pain

Blood Bicarbonate
Decreased
Blood Creatine
Phosphokinase Mb
Increased
Blood Glucose Increased
Blood Magnesium Increased
Blood Ph Increased
Blood Pressure Systolic
Increased
Body Temperature
Decreased
Cataract
Cerebrovascular Accident
Chronic Fatigue Syndrome
Confusional State
Coronary Artery Disease
Crying
Depression
Diastolic Dysfunction
Disturbance In Attention
Dizziness
Drug Ineffective
Dyspnoea
Dyspnoea Exertional
Fungal Infection
Fungal Skin Infection
Glossitis
Headache
Heart Rate Increased
Herpes Zoster
Hypertension
Hyperventilation
Hypoacusis
Hypoaesthesia
Impaired Driving Ability
Libido Decreased
Loss Of Libido
Macular Degeneration
Mitral Valve Incompetence
Nausea
Nephrolithiasis
Oedema Peripheral
Palpitations
Panic Attack
Pco2 Decreased
Personality Disorder

Post-Traumatic Stress
Disorder
Psychiatric Symptom
Rash Vesicular
Respiratory Rate
Increased
Sinus Bradycardia
Sleep Apnoea Syndrome
Sleep Disorder
Suicidal Ideation
Syncope
Tremor
Tricuspid Valve
Incompetence

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	15 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vicodin Tablets	C			UNKNOWN	
	Lorazepam	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	
	Zocor	C		ORAL		
	Temazepam	C			UNKNOWN	
	Naprosyn	C			UNKNOWN	
	Atrovent	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Pyridoxine	C			UNKNOWN	
	Vitamin E	C			UNKNOWN	
	Garlic Extract	C			UNKNOWN	
	Ginkgo Biloba Extract	C			UNKNOWN	
	Verapamil	C			UNKNOWN	
	Beta Carotene	C			UNKNOWN	
	Maxzide	C			UNKNOWN	
	Naprosyn	C			UNKNOWN	
	Neurontin	C			UNKNOWN	
	Glyburide	C			UNKNOWN	

			Flonase	C		
UNKNOWN						
			Altace	C		
UNKNOWN						
			Calan	C		
UNKNOWN						
			Ocuvite	C		
UNKNOWN						

Date:04/29/05ISR Number: 4649266-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00721
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event Cerebrovascular Accident Refusal Of Treatment By Patient		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649267-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00440
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Blood Pressure Systolic Increased Coronary Artery Disease Myocardial Infarction Panic Attack Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL	27	DAY

Date:04/29/05ISR Number: 4649268-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	225	DAY
Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	41	DAY
Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		
Airways Disease		Vioxx	SS	Merck & Co., Inc	ORAL	225	DAY
Exacerbated		Vioxx	SS	Merck & Co., Inc	ORAL		
Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	41	DAY
Dyspnoea		Fenoterol					
Gastrointestinal		Hydrobromide And					
Haemorrhage		Ipratropium Bromide	C			UNKNOWN	
Hypertensive Crisis		Formoterol Fumarate	C			UNKNOWN	
Hypoxia		Bisoprolol Fumarate	C			UNKNOWN	
Infection		Enalapril Maleate	C			UNKNOWN	
Ischaemia		Atorvastatin Calcium	C			UNKNOWN	
Osteitis		Tamsulosin					
Osteoarthritis		Hydrochloride	C			UNKNOWN	
Pyrexia		Spironolactone	C			UNKNOWN	
Radicular Syndrome		Beclomethasone					
Respiratory Disorder		Dipropionate	C			UNKNOWN	
Respiratory Tract		Theophylline	C		ORAL		
Infection		Prednisolone	C		ORAL		
Tachycardia		Captopril	C		ORAL		
Tendon Disorder		Aspirin	C		ORAL		
Ventricular Dysfunction		Acetylcysteine	C		ORAL		

			Calcium (Unspecified)	C		ORAL

Date:04/29/05ISR Number: 4649269-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00161
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1749 DAY	
	Embolism		Aspirin	C			UNKNOWN	
	Vascular Encephalopathy		Hydrochlorothiazide	C			UNKNOWN	
			Amlodipine Mesylate	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	

Date:04/29/05ISR Number: 4649270-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02525
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anger
	Back Pain
Disability	Bipolar I Disorder
Other	Bladder Disorder
	Blood Pressure Decreased
	Body Tinea
	Cerebral Artery Occlusion
	Cerebral Artery Stenosis
	Cerebral Infarction

		Cerebrovascular Accident					
		Chest Pain					
		Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL
38	DAY						
		Condition Aggravated		Vioxx	SS	Merck & Co., Inc	ORAL
38	DAY						
		Constipation		Nizatidine	C		
UNKNOWN							
		Depression		Klonopin	C		
UNKNOWN							
		Dyspnoea		Trazodone			
		Electrocardiogram Qt		Hydrochloride	C		
UNKNOWN							
		Prolonged		Seroquel	C		
UNKNOWN							
		Embolic Stroke		Prozac	C		
UNKNOWN							
		Fall		Propranolol			
		Gastrooesophageal Reflux		Hydrochloride	C		
UNKNOWN							
		Disease		Zocor	C		ORAL
809	DAY						
		Head Injury		Zocor	C		
UNKNOWN							
		Headache		Zanaflex	C		
UNKNOWN		473 DAY					
		Hemiparesis		Avonex	C		
INTRAMUSCULAR							
		Hypoaesthesia		Prochlorperazine	C		
UNKNOWN							
		Hypotension		Alprazolam	C		
UNKNOWN							
		Incontinence		Lasix (Furosemide)	C		
UNKNOWN		976 DAY					
		Insomnia		Hydrocodone			
		Ischaemic Stroke		Bitartrate	C		
UNKNOWN		663 DAY					
		Left Ventricular Failure		Acetaminophen And			
		Loss Of Consciousness		Propoxyphene			
		Migraine		Napsylate	C		
UNKNOWN		840 DAY					
		Migraine With Aura		Estraderm	C		
UNKNOWN		409 DAY					
		Myocardial Infarction		Duradrin	C		
UNKNOWN							

	Neuropathic Pain		Methotrexate	C		
UNKNOWN						
	Nocturia		Indomethacin	C		
UNKNOWN						
	Rash		Klor-Con	C		
UNKNOWN						
	Relapsing-Remitting		Benadryl	C		
UNKNOWN						
	Multiple Sclerosis		Zyprexa	C		ORAL
	Renal Failure Acute		Vitamin E	C		ORAL
	Sensory Disturbance					
	Temperature Intolerance					

Date:04/29/05ISR Number: 4649271-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00120
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 594 DAY	Compartment Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Deep Vein Thrombosis		Allopurinol	C		ORAL
	Muscle Rupture		Diclofenac	C		ORAL
	Post Thrombotic Syndrome		Tramadol Hydrochloride	C		ORAL
	Thrombosis					
	Varicose Vein					

Date:04/29/05ISR Number: 4649272-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00073
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Hypertension					
	Hypertensive Crisis					

Date:04/29/05ISR Number: 4649273-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04299
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	354 DAY	
Hospitalization -	Myocardial Infarction		Tylenol	C			UNKNOWN	
Initial or Prolonged			[Therapy Unspecified]	C			UNKNOWN	

Date:04/29/05ISR Number: 4649274-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00076
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Maxzide	C			UNKNOWN	
	Blood Alkaline		Maxzide	C			UNKNOWN	
	Phosphatase Increased		Accupril	C			UNKNOWN	
	Cardiomegaly		Toprol Xl Tablets	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Depression		Lipitor	C			UNKNOWN	
	Dyspepsia							
	Heart Rate Irregular							
	Leukocytosis							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649275-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00677
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Arthropathy	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Carotid Artery Occlusion	Prozac	C		ORAL
Other	Cerebrovascular Accident	Lipitor	C		ORAL
	Coronary Artery Disease	Glucophage	C		ORAL
	Depression	Ambien	C		ORAL
	Dyspepsia	Coumadin	C		ORAL
	Dysuria	Coumadin	C		ORAL
	Gastrooesophageal Reflux	Atenolol	C		ORAL
	Disease	Allegra	C		
UNKNOWN					
	Headache	Amaryl	C		
UNKNOWN					
	Hypoacusis	Aspirin	C		
UNKNOWN					
	Ischaemic Cerebral	Paxil	C		
UNKNOWN					
	Infarction				
	Lymphadenopathy				
	Musculoskeletal				
	Discomfort				
	Sciatica				
	Ventricular Hypokinesia				

Date:04/29/05ISR Number: 4649276-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00261
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Dysphonia		Vioxx	PS	Merck & Co., Inc	ORAL
	Eczema Impetiginous		Vioxx	SS	Merck & Co., Inc	ORAL
	Eczema Infected		Esomeprazole			
	Lichenification		Magnesium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4649277-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00646
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		819 DAY
	Gastric Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		819 DAY
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649278-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00738
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Blood Glucose Increased		Lantus	SS				UNKNOWN
	Cardiac Valve Disease		Insulin	SS				UNKNOWN
	Cerebrovascular Accident		Proventil	C				UNKNOWN
	Disease Recurrence		Zocor	C				UNKNOWN
	Infection		Synthroid	C				UNKNOWN
	Medical Device		Actos	C				UNKNOWN
	Complication		Zestril	C				UNKNOWN
	Pyrexia		Plavix	C				UNKNOWN
	Tongue Disorder		Amaryl	C				UNKNOWN
	Viral Infection		Levaquin	C				UNKNOWN
	Visual Disturbance		Namenda	C				UNKNOWN
	Vomiting		Insulin	C				UNKNOWN

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Acute Myocardial Infarction
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Confusional State
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Depression
	Diabetes Mellitus Inadequate Control
	Diabetic Neuropathy
	Diarrhoea
	Escherichia Sepsis
	Essential Hypertension
	Fall
	Intermittent Claudication
	Lipoprotein Deficiency
	Mitral Valve Disease
	Mitral Valve Incompetence
	Myocardial Infarction
	Oedema Peripheral
	Onychomycosis
	Osteoarthritis

	Peripheral Occlusive Disease						
	Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Failure Acute							
	Sciatica							
	Spinal Column Stenosis							
	Stress Incontinence							
	Transient Ischaemic Attack							
	Urinary Tract Infection							
	Uterine Infection							

Date:04/29/05ISR Number: 4649280-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03704
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	910	DAY

Date:04/29/05ISR Number: 4649281-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00005
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
	Dyskinesia		Desloratadine	SS		ORAL	150	DAY
	Feeling Abnormal		Azithromycin	SS		ORAL	3	DAY
	Nausea		Oxcarbazepine	SS		ORAL	90	DAY

Date:04/29/05ISR Number: 4649282-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01722
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx Tylenol	PS C	Merck & Co., Inc	ORAL	UNKNOWN

Date:04/29/05ISR Number: 4649284-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00109
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Prednisone	C				UNKNOWN
	Dyspnoea		Enalapril Maleate	C				UNKNOWN
	Gastric Disorder		Glipizide	C				UNKNOWN

Date:04/29/05ISR Number: 4649285-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00053
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Lotrel	C				UNKNOWN
	Hypercholesterolaemia		Trazodone Hydrochloride	C				UNKNOWN
	Overdose							
	Sleep Apnoea Syndrome		Xanax	C				UNKNOWN
			Folic Acid	C				UNKNOWN
			Hydroxyzine Hydrochloride	C				UNKNOWN

			Seroquel	C		UNKNOWN
			Avandia	C		UNKNOWN
			Requip	C		UNKNOWN
			Norvasc	C		UNKNOWN
			Indocin (Indomethacin Sodium)	C		UNKNOWN
			Celexa	C		UNKNOWN
			Methotrexate	C		UNKNOWN
			Methotrexate	C		UNKNOWN
			Acetaminophen And Codeine	C		UNKNOWN
			Enbrel	C		UNKNOWN

Date:04/29/05ISR Number: 4649286-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00505
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Diazepam	C				UNKNOWN
	Diarrhoea		Prozac	C				UNKNOWN
	Vomiting		Protonix	C				UNKNOWN
			Testosterone	C				UNKNOWN
			Crestor	C				UNKNOWN

Date:04/29/05ISR Number: 4649287-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02769
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain							
	Polyp							

Date:04/29/05ISR Number: 4649288-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00114
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1111 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		1111 DAY
	Dyspepsia		Tylenol	C		ORAL		
	Emotional Distress		Aspirin	C		ORAL		
	High Density Lipoprotein		Ibuprofen	C		ORAL		
	Decreased		Saw Palmetto					
	Hyperlipidaemia		Standardized Extract	C				UNKNOWN
	Hypertension		Viagra	C				UNKNOWN
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Prostatitis							
	Upper Respiratory Tract Infection							
	Ventricular Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4649289-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03702
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649290-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0504ESP00047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastric Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	51 DAY

Date:04/29/05ISR Number: 4649291-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03785
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649292-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03698
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649293-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00029
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 1320 DAY	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation Blood Pressure Increased Dyspnoea International Normalised Ratio Increased Mitral Valve Incompetence Myocardial Ischaemia Supraventricular Extrasystoles Tricuspid Valve Incompetence Ventricular Extrasystoles		Aspirin And Magnesium Oxide	C		ORAL

Date:04/29/05ISR Number: 4649294-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiovascular Disorder Chronic Obstructive Pulmonary Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4649295-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03253
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peripheral Vascular Disorder		Vioxx Norvasc	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:04/29/05ISR Number: 4649296-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03787
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649297-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03819
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649298-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649299-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649300-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03821
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649301-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649302-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03788
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649303-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649304-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649305-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649306-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03913
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649307-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03822
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:04/29/05ISR Number: 4649308-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03944
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		42 MON
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649309-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649310-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	472	DAY

Date:04/29/05ISR Number: 4649311-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1429	DAY
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:04/29/05ISR Number: 4649312-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03818
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649313-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649317-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649318-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04453
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:04/29/05ISR Number: 4649319-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04250
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4649321-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649322-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649323-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04421
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649324-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4649325-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:04/29/05ISR Number: 4651023-9Report Type:Expedited (15-DaCompany Report #2005062926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200	
Initial or Prolonged	Knee Operation						MG, 1 IN 1	
Other	Myocardial Infarction						D), ORAL	
	Post Procedural Pain		Bextra (Valdecoxib)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
			Rofecoxib (Rofecoxib)	SS				
			Galenic/Paracetamol/ Codeine/ (Codeine, Paracematol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/29/05ISR Number: 4651047-1Report Type:Expedited (15-DaCompany Report #2005061415
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation	Consumer	Bextra (Valdecoxib)	PS		ORAL	ORAL	
	Crohn'S Disease		Celebrex (Celecoxib)	SS		ORAL	ORAL	
	Eating Disorder		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Fluid Retention		Sertraline Hydrochloride (Sertraline Hydrochloride)	C				
	Hypertension		Olanzapine (Olanzapine)	C				
	Myocardial Infarction		Alprazolam (Alprazolam)	C				
	Nausea		Mirtazapine (Mirtazapine)	C				
	Pain							
	Palpitations							
	Stomach Discomfort							

Date:04/29/05ISR Number: 4651049-5Report Type:Expedited (15-DaCompany Report #2005061419
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hypertension	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG, 1 IN 1 D),	
	Pain Of Skin							
	Psoriasis						ORAL	
	Rash		Rofecoxib (Rofecoxib)	SS			UNKNOWN	UNKNOWN
	Rash Macular		Meloxicam (Meloxicam)	C				
	Rash Scaly		Fluoxetine (Fluoxetine)	C				
	Rotator Cuff Repair		Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	C				
	Scab							
	Skin Disorder							
	Skin Reaction							

				Propacet (Dextropropoxyphene Napsilate, Paracetamol)	C		

Date:04/30/05ISR Number: 4649360-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649873-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -			Synthroid	C				
Initial or Prolonged			Keppra	C				
Disability			Aricept	C				
			Zyprexa	C				
			Allegra	C				
			Prevacid	C				
			Norvasc	C				

			Hydrochlorothiazide	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Depakote	C		
UNKNOWN						
			Lotensin	C		
UNKNOWN						
			Detrol	C		
UNKNOWN						

Date:05/02/05ISR Number: 4649874-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03252
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Initial or Prolonged	Adhesion		Pepcid	C			UNKNOWN	
Other	Angina Pectoris		Celebrex	C			UNKNOWN	
	Back Pain		Bextra	C			UNKNOWN	
	Breast Cancer		Toprol Xl Tablets	C			UNKNOWN	
	Bronchitis		St. Joseph Adult Chewable Aspirin	C			UNKNOWN	
	Cardiac Valve Disease							
	Chest Pain		Tamoxifen Citrate	C			UNKNOWN	
	Coronary Artery Disease		Actonel	C			UNKNOWN	
	Diarrhoea		Inderal	C			UNKNOWN	
	Dyspnoea		Lipitor	C			UNKNOWN	
	Emotional Distress		Wellbutrin	C			UNKNOWN	
	Faeces Discoloured		Xanax	C			UNKNOWN	
	Gastrooesophageal Reflux		Neurontin	C			UNKNOWN	

	Disease		Nexium	C	
UNKNOWN					
	Hernia		Coumadin	C	
UNKNOWN					
	Intestinal Obstruction		Darvocet-N	C	
UNKNOWN					
	Melaena		Prilosec	C	
UNKNOWN					
	Myocardial Infarction				
	Nausea				
	Osteoarthritis				
	Peptic Ulcer				

Date:05/02/05ISR Number: 4649875-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03233
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
1 DAY						
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL
1 DAY						
	Blood Cholesterol		Naproxen	C		
UNKNOWN	5 YR					
	Increased					
	Cardiac Disorder					
	Carotid Artery Stenosis					
	Chest Pain					
	Coronary Artery Disease					
	Dizziness					
	Electrocardiogram St					
	Segment Depression					
	Electrocardiogram T Wave					
	Inversion					
	Hernia					
	Hyperglycaemia					
	Hypertension					
	Hypertriglyceridaemia					
	Intervertebral Disc					
	Disorder					
	Myocardial Infarction					
	Vertigo					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4649876-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00119
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		3 WK
Initial or Prolonged	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Vascular Graft		Atorvastatin Calcium	C		ORAL		
	Complication		Aspirin	C		ORAL		
	Venous Stenosis		Bisoprolol Fumarate	C		ORAL		
			Pantoprazole Sodium	C		ORAL		

Date:05/02/05ISR Number: 4649877-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02069
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Azotaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Accupril	SS				
UNKNOWN								
	Congestive		Levaquin	SS				
UNKNOWN								
	Cholecystitis		[Therapy					
	Cholelithiasis		Unspecified]	C				
UNKNOWN								
	Emotional Distress							
	Gastrooesophageal Reflux							
	Disease							
	Hydronephrosis							
	Liver Function Test							
	Abnormal							
	Lobar Pneumonia							
	Metabolic Acidosis							
	Myocardial Infarction							
	Nephritis Interstitial							
	Nephrolithiasis							
	Platelet Count Increased							
	Renal Failure Acute							
	Swelling							
	Urinary Tract Infection							

Date:05/02/05ISR Number: 4649886-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04029
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Adverse Event
	Aneurysm
	Angina Unstable
	Asthma
	Coronary Artery Disease
	Cough
	Dyspepsia
	Fatigue
	Hyperlipidaemia
	Hypertension
	Lung Disorder
	Nocturia
	Pain In Extremity
	Post Procedural Complication
	Sinobronchitis
	Sinus Bradycardia
	Sinusitis

Tinnitus

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	286	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Zoloft	C			UNKNOWN	
	Zyrtec	C			UNKNOWN	
	Zantac	C			UNKNOWN	
	Advair	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Nasonex	C			UNKNOWN	
	Combivent	C			UNKNOWN	
	Zestril	C			UNKNOWN	

Date:05/02/05ISR Number: 4649888-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00216
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649889-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00106
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1432	DAY
Initial or Prolonged	Infarction		Pravachol	C			UNKNOWN	
Other	Anxiety		Zocor	C		ORAL		
	Chest Pain		Lopid	C			UNKNOWN	

	Coronary Artery Stenosis		Motrin	C		
UNKNOWN						
			Flexeril	C		ORAL
			Ambien	C		
UNKNOWN						

Date:05/02/05ISR Number: 4649890-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02447
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Duodenal Ulcer		Allegra	C		
UNKNOWN						
Disability	Perforation		Hytrin	C		
UNKNOWN						
	Hyperkalaemia					
	Hypoxia					
	Pain					
	Pneumonia Aspiration					
	Urinary Retention					
	Postoperative					

Date:05/02/05ISR Number: 4649891-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00115
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Aneurysm
Initial or Prolonged	Angina Pectoris
Other	Aortic Aneurysm
	Blood Cholesterol
	Increased
	Blood Triglycerides
	Increased

		Cardiac Disorder Cardiac Failure Congestive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Carotid Artery Stenosis		Ventolin (Albuterol)	C		
UNKNOWN							
		Drug Hypersensitivity		Tricor	C		
UNKNOWN							
		Dyspnoea		Cartia Xt	C		
UNKNOWN							
		Emotional Distress		Furosemide	C		
UNKNOWN							
		Gallbladder Disorder		Ambien	C		
UNKNOWN							
		Gastric Ulcer		Paxil	C		
UNKNOWN							
		Gastrooesophageal Reflux		Aspirin	C		
UNKNOWN							
		Disease		Isosorbide	C		
UNKNOWN							
		Heart Rate Irregular		Nitroglycerin	C		
UNKNOWN							
		Myocardial Infarction		Aciphex	C		
UNKNOWN							
		Oedema		Elavil	C		
UNKNOWN							
		Renal Disorder Transient Ischaemic Attack					

Date:05/02/05ISR Number: 4649892-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00694
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL

Date:05/02/05ISR Number: 4649893-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00667
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		71 DAY
Initial or Prolonged	Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		71 DAY
	Myocardial Infarction		Hydrochlorothiazide	C				UNKNOWN
			Accupril	C				UNKNOWN
			Inderal La	C				UNKNOWN
			Actonel	C				UNKNOWN
			Ecotrin	C				UNKNOWN

Date:05/02/05ISR Number: 4649894-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0504ESP00043
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Diplopia Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649895-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03733
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Polytraumatism Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4649896-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00661
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Infarction		Vioxx	SS		ORAL		
Disability	Anxiety		Vioxx	SS		ORAL		
	Aortic Aneurysm		Aspirin	C				UNKNOWN
	Bronchitis		Meclizine	C				UNKNOWN
	Cardiac Disorder							
	Carotid Artery Stenosis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Diverticulum							
	Diverticulum Intestinal							
	Dyspnoea							
	Emotional Distress							
	Erectile Dysfunction							
	Fear							
	Gastrooesophageal Reflux							
	Disease							
	Haematuria							
	Hypercholesterolaemia							
	Oedema Peripheral							

Date:05/02/05ISR Number: 4649900-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649901-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02789
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain
Hospitalization -	Aortic Disorder

Initial or Prolonged	Arthralgia
Other	Aspiration
	Basal Cell Carcinoma
	Blood Pressure
	Inadequately Controlled
	Cardiac Failure
	Congestive
	Cerebral Atherosclerosis
	Cerebral Haemorrhage
	Coma
	Diarrhoea
	Dysphasia
	Dyspnoea
	Gastrointestinal
	Haemorrhage
	Haemorrhagic Stroke
	Hypertension
	Hypotension
	Ischaemic Cardiomyopathy
	Loss Of Consciousness
	Myocardial Infarction
	Pain In Extremity

	Pollakiuria						
	Rash						
	Sinus Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Spinal Column Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Subarachnoid Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	
	Upper Gastrointestinal		Evista	C		ORAL	
	Haemorrhage		Vasotec	C		ORAL	
	Vision Blurred		Hydrodiuril	C		ORAL	
	Vomiting		Lomotil	C			UNKNOWN

Date:05/02/05ISR Number: 4649902-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01584
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/02/05ISR Number: 4649903-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	472 DAY

Date:05/02/05ISR Number: 4649904-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/02/05ISR Number: 4649905-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03732
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/02/05ISR Number: 4649906-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:05/02/05ISR Number: 4649907-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03735
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Polytraumatism							

Date:05/02/05ISR Number: 4649909-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03734
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Polytraumatism							

Date:05/02/05ISR Number: 4649914-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649917-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:05/02/05ISR Number: 4649918-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04178
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Chest Pain Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649919-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649920-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649921-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04222
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649922-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04223
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649923-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04238
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4649925-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04221
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649926-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04237
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649933-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649934-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649935-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04736
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Chest Pain
Dyspnoea

Date:05/02/05ISR Number: 4649936-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649937-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03948
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649938-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4649939-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649940-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04734
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649941-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649948-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04403
Age:36 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Convulsion Dizziness Loss Of Consciousness Migraine Tremor		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649966-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04763
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Bypass Operation Cardiovascular Disorder Stent Placement Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649968-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04772
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4649970-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4649971-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04762
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650049-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650476-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02112
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL	2	WK
Disability	Lung Disorder							
	Weight Decreased							

Date:05/02/05ISR Number: 4650477-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anosmia		Atenolol	C				
UNKNOWN								
Disability	Arthropathy		Aspirin	C				
UNKNOWN								
	Cardiomegaly		Zoloft	C				
UNKNOWN								
	Colon Adenoma		Lipitor	C				
UNKNOWN								

	Decreased Appetite	Niaspan	C
UNKNOWN			
	Deep Vein Thrombosis	Iron (Unspecified)	C
UNKNOWN			
	Emotional Distress	Acetaminophen	C
UNKNOWN			
	Essential Hypertension	Lopressor	C
UNKNOWN			
	Faecal Incontinence	Herbs (Unspecified)	C
UNKNOWN			
	Fatigue		
	Fibromyalgia		
	Haemangioma		
	Haematochezia		
	Hypercoagulation		
	Hypertension		
	Injury		
	Lumbar Spinal Stenosis		
	Macular Degeneration		
	Meniscus Lesion		
	Nausea		
	Nephrolithiasis		
	Osteopenia		
	Osteoporosis		
	Pancreatitis		
	Pulmonary Embolism		
	Pulmonary Hypertension		
	Rectal Haemorrhage		
	Renal Disorder		
	Skeletal Injury		
	Thrombophlebitis		
	Urinary Incontinence		
	Weight Decreased		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4650480-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00669
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1247 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		85 DAY
	Barrett'S Oesophagus		Enbrel	C			SUBCUTANEOUS	
	Coronary Artery Disease		Methotrexate	C			UNKNOWN	
	Disturbance In Attention		Prednisone	C			UNKNOWN	
	Dyslipidaemia		Prevacid	C			UNKNOWN	
	Emotional Distress		Plendil	C		ORAL		
	Fatigue		Folic Acid	C			UNKNOWN	
	Libido Decreased		Vitamin B Complex	C			UNKNOWN	
	Pain		Aciphex	C			UNKNOWN	
	Sleep Disorder		Elavil	C		ORAL		
			Etidronate Disodium	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Diflucan	C			UNKNOWN	
			Avelox	C			UNKNOWN	
			Vitamin D (Unspecified)	C			UNKNOWN	
			Phenergan Vc	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	

Date:05/02/05ISR Number: 4650481-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01693
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY	
Disability	Back Injury		Protonix	C			UNKNOWN	
	Blindness		Triamcinolone	C			UNKNOWN	
	Dry Skin		Sunscreen					
	Dyspnoea		(Unspecified)	C			UNKNOWN	
	Fatigue		Corticosteroids					
	Loss Of Consciousness		(Unspecified)	C			UNKNOWN	
	Nightmare							
	Photosensitivity Reaction							
	Polyp							
	Pruritus							
	Road Traffic Accident							
	Skin Depigmentation							
	Skin Discolouration							
	Suicidal Ideation							
	Swelling							

Date:05/02/05ISR Number: 4650482-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00042
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Refusal Of Treatment By		Vioxx	PS	Merck & Co., Inc	ORAL		
	Patient		Darvocet-N	C		ORAL		
	Road Traffic Accident		Atenolol	C		ORAL		
	Transient Ischaemic		Hydrodiuril	C		ORAL		
	Attack		Lexapro	C		ORAL		
			Glucophage	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4650488-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00035
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Retinal Vascular Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		YR

Date:05/02/05ISR Number: 4650489-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650490-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:05/02/05ISR Number: 4650491-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650492-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/02/05ISR Number: 4650493-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03134
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:05/02/05ISR Number: 4650494-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02880
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Angina Pectoris
	Aortic Stenosis
	Arteriosclerosis
	Carotid Bruit
	Coronary Artery Disease
	Dermal Cyst
	Emotional Distress
	Haemorrhoids
	Hyperlipidaemia

		Intermittent Claudication					
		Leukocytosis					
		Occult Blood Positive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Paronychia		Vioxx	PS	Merck & Co., Inc	ORAL
		Peripheral Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Cozaar	C		
UNKNOWN							
		Renal Impairment		Atenolol	C		
UNKNOWN							
		Upper Respiratory Tract		Prilosec	C		
UNKNOWN							
		Congestion					
		Upper Respiratory Tract					
		Infection					
		Ventricular Hypokinesia					

Date:05/02/05ISR Number: 4650495-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04434
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Polytraumatism					

Date:05/02/05ISR Number: 4650496-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04424
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension					
		Myocardial Infarction					

Date:05/02/05ISR Number: 4650502-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04776
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/02/05ISR Number: 4650503-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650504-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02468
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650505-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00774
Age: Gender:Male I/FU:F

Outcome	PT
Other	Appendix Disorder
	Back Disorder
	Cardiac Disorder
	Carotid Artery Stenosis

	Depression						
	Dyspepsia						
	Gastric Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hepatitis B		Vioxx	PS	Merck & Co., Inc	ORAL	1564 DAY	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1564 DAY	
	Swelling		Vioxx	SS	Merck & Co., Inc	ORAL		
			Accupril	C		ORAL		
			Ventolin (Albuterol)	C			UNKNOWN	
			Aspirin	C		ORAL		

Date:05/02/05ISR Number: 4650506-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650507-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04774
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650508-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650509-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04778
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650510-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease Death Thrombosis							

Date:05/02/05ISR Number: 4650512-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04732
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/02/05ISR Number: 4650513-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04769
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4650514-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/02/05ISR Number: 4651484-5Report Type:Expedited (15-DaCompany Report #2005063174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hip Arthroplasty	Consumer	Bextra (Valdecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:05/02/05ISR Number: 4651507-3Report Type:Expedited (15-DaCompany Report #2005063723
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness	Consumer	Bextra (Valdecoxib)	PS		ORAL	20 MG (20 MG, 1 IN 1 D),	ORAL
	Drug Intolerance							
	Dyspnoea							
	Feeling Abnormal		Rofecoxib (Rofecoxib)	SS		ORAL		ORAL
	Heart Rate Decreased							
	Heart Rate Increased		Muscle Relaxants (Muscle Relaxants)	SS		ORAL		ORAL
	Hypoaesthesia							
	Malaise		Clonazepam					

	Muscle Spasms		(Clonazepam)	C		
	Nausea		Lansoprazole			
	Pain In Extremity		(Lansoprazole)	C		
	Paraesthesia					
	Somnolence					

Date:05/02/05ISR Number: 4651563-2Report Type:Expedited (15-DaCompany Report #2005062374
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Other	Hypersensitivity		Rofecoxib					
	Procedural Complication		(Rofecoxib)	SS		ORAL	ORAL	
	Rash							
	Transient Ischaemic							
	Attack							

Date:05/02/05ISR Number: 4652199-XReport Type:Expedited (15-DaCompany Report #2005065412
Age:49 YR Gender:Female I/FU:I

Outcome	PT
Other	Alcohol Intolerance
	Dyspnoea
	Erythema
	Feeling Hot

	Headache						
	Paraesthesia Oral						
	Pruritus	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash	Foreign	Celebra (Celecoxib)	PS		ORAL	200 MG (200
	Skin Disorder	Consumer					MG, 1 IN 1 D)
	Skin Exfoliation						ORAL
	Swelling		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D) ORAL

Date:05/03/05ISR Number: 4650932-4Report Type:Expedited (15-DaCompany Report #US-GLAXOSMITHKLINE-A0554927A
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Activities Of Daily Living Impaired		Phazyme Ultra Strength Softgels	PS	Glaxosmithkline	ORAL	
	Amnesia		Vioxx	SS		ORAL	
	Cerebrovascular Accident		Lithium	SS	Glaxosmithkline	ORAL	2200MG Per day
	Coma						
	Dialysis		Ibuprofen	SS	Glaxosmithkline	ORAL	
	Difficulty In Walking		Bextra	SS		ORAL	
	Hallucination		Multi Vitamin	C		ORAL	
	Hemiplegia		Vitamin C	C	Glaxosmithkline	ORAL	
	Influenza		Acidophilus	C		ORAL	
	Malaise		Garlic	C		ORAL	
	Renal Failure		Vitamin E	C		ORAL	
	Speech Disorder		Neurontin	C		ORAL	2400MG Per day
			Celebrex	C		ORAL	400MG Per day
			Prilosec	C	Glaxosmithkline	ORAL	

				Singular	C		ORAL
10MG Per day							
				Claritin	C		ORAL
				Imitrex	C	Glaxosmithkline	ORAL
				Buspar	C		ORAL
				Sleeping Tablets (Unspecified)	C		ORAL
				Colace	C		ORAL
				Effexor	C		ORAL
				Pulmicort	C		
RESPIRATORY (INHALATION)							
				Albuterol	C	Glaxosmithkline	
RESPIRATORY (INHALATION)							
				Serevent	C	Glaxosmithkline	
RESPIRATORY (INHALATION)							
				Atrovent	C	Glaxosmithkline	
RESPIRATORY (INHALATION)							
				Aspirin	C	Glaxosmithkline	ORAL

Date:05/03/05ISR Number: 4650951-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01096
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cholecystitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease Recurrence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infection		Protonix	C		ORAL		
			Geodon	C		ORAL		
			Lexapro	C		ORAL		
			Clonazepam	C		ORAL		

		Trazodone Hydrochloride	C	ORAL
		Remeron	C	ORAL

Date:05/03/05ISR Number: 4650952-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00110
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc			
	Biopsy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Aspirin	C				
	Carotid Artery Stenosis		Lipitor	C				
	Coronary Artery Disease		Prilosec	C				
	Oedema Peripheral		Armour Thyroid Tablets	C				
	Transient Ischaemic Attack		Ambien	C				
	Ventricular Tachycardia		Diazepam	C				
			Folic Acid	C				
			Timoptic	C			OPHTHALMIC	
			Viagra	C				
			Verapamil	C				

Date:05/03/05ISR Number: 4650953-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01540
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged
	Back Pain

Bronchitis
Cerebrovascular Accident
Constipation
Dermatitis
Dyspepsia
Dyspnoea
Eczema Infected
Emotional Distress
Fall
Gastric Disorder
Gastritis
Goitre
Hemiparesis
Hyperlipidaemia
Hyperthyroidism
Hypoaesthesia
Nasopharyngitis
Nicotine Dependence
Oedema Peripheral
Pain In Extremity
Paraesthesia
Pharyngolaryngeal Pain
Pneumonia
Polytraumatism
Sinus Congestion
Sinusitis
Syncope
Thyroid Pain

	Transient Ischaemic Attack						
	Vision Blurred	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Correctol (Docusate Sodium (+) Phenolphthalein)	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Benadryl	C			UNKNOWN	

Date:05/03/05ISR Number: 4650960-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0504CHE00039
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4650961-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00221
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	666 DAY	
	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL	307 DAY	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Renal Neoplasm		Klor-Con	C			UNKNOWN	
	Chest Discomfort		Pravachol	C			UNKNOWN	

	Colitis Ischaemic	Neurontin	C
UNKNOWN			
	Contusion	Vicodin Tablets	C
UNKNOWN			
	Deep Vein Thrombosis	Fosamax	C
UNKNOWN			
	Delirium	Calcium	
	Dizziness	(Unspecified)	C
UNKNOWN			
	Dyspnoea	Nexium	C
UNKNOWN			
	Fall	Cardizem	C
UNKNOWN			
	Fatigue	Lasix (Furosemide)	C
UNKNOWN	5 YR		
	Gastrointestinal	Zocor	C
UNKNOWN			
	Haemorrhage	Estrogens	
	Herpes Zoster	(Unspecified)	C
UNKNOWN			
	Mitral Valve Incompetence	Ibuprofen	C
UNKNOWN	5 YR		
	Myocardial Infarction	Zestril	C
UNKNOWN			
	Pain		
	Renal Failure		
	Rotator Cuff Syndrome		
	Sacroiliitis		
	Sleep Apnoea Syndrome		
	Staphylococcal Infection		
	Subclavian Vein Thrombosis		
	Treatment Noncompliance		
	Tricuspid Valve Incompetence		
	Urinary Tract Infection		
	Ventricular Hypertrophy		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/05ISR Number: 4650962-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4650963-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00078
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 902 DAY	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Ogen	C				
UNKNOWN								
	Cerebral Artery Stenosis		Progesterone	C				
UNKNOWN								
	Cerebrovascular Accident		Antimicrobial					
	Confusional State		(Unspecified)	C				
UNKNOWN								
	Disturbance In Attention		Lipitor	C				
UNKNOWN								
	Drug Ineffective		Toprol Xl Tablets	C				
UNKNOWN								
	Embolism		Norvasc	C				
UNKNOWN								
	Emotional Distress		Aspirin	C				
UNKNOWN								
	Knee Arthroplasty		Lopressor	C				
UNKNOWN								
	Lacunar Infarction							

Date:05/03/05ISR Number: 4650972-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4650974-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04626
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4650975-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04625
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4650977-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03483
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Singulair	C			RESPIRATORY	(INHALATION)
	Cerebrovascular Accident							
	Hypertension		Combivent	C			RESPIRATORY	(INHALATION)
	Transient Ischaemic Attack		Azmacort	C			UNKNOWN	
			Advair	C			RESPIRATORY	(INHALATION)

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/05ISR Number: 4650988-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
Disability	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
	Increased		Lortab	C		ORAL		
	Cardiovascular Disorder		Excedrin					
	Cerebrovascular Accident		Extra-Strength	C				UNKNOWN
	Constipation		Aspirin	C				UNKNOWN
	Delusion							
	Diarrhoea							
	Emotional Distress							
	Headache							
	Herpes Zoster							
	Intervertebral Disc							
	Protrusion							
	Meningitis							
	Muscle Contractions							
	Involuntary							
	Paranoia							
	Psychotic Disorder							
	Pyrexia							
	Renal Disorder							
	Renal Failure							
	Stomach Discomfort							
	Tremor							
	Venous Thrombosis Limb							

Date:05/03/05ISR Number: 4651001-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04476
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4651002-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00665
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Atrioventricular Block
Other	First Degree
	Benign Prostatic
	Hyperplasia
	Blood Cholesterol
	Increased
	Blood Potassium Decreased
	Blood Pressure
	Orthostatic Decreased
	Blood Triglycerides
	Increased
	Cardiac Murmur
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Coronary Artery Disease
	Crackles Lung
	Dehydration

		Dizziness					
		Dyspnoea					
		Gait Disturbance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Steatosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Mass		Doxazosin Mesylate	C		
UNKNOWN							
		Myocardial Infarction		Lasix (Furosemide)	C		
UNKNOWN							
		Nerve Compression		Lanoxin	C		
UNKNOWN							
		Neuropathy Peripheral		Hyzaar	C		ORAL
		Orthostatic Hypotension		Allopurinol	C		ORAL
		Pancreatic Cyst		Zaroxolyn	C		ORAL
		Syncope					
		Transient Ischaemic					
		Attack					
		Vertigo					
		Wheezing					

Date:05/03/05ISR Number: 4651008-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04330
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
665 DAY							
Initial or Prolonged		Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL
		Blindness Unilateral		Oxycontin	C		ORAL
		Cardiac Failure		Hyzaar	C		ORAL
		Cardio-Respiratory Arrest		Ibuprofen	C		ORAL
		Coma		Duragesic	C		
TOPICAL							
		Dementia		Ativan	C		ORAL
		Hemiplegia		Ativan	C		ORAL
		Hypertension					
		Overdose					
		Palpitations					
		Renal Failure Acute					
		Renal Failure Chronic					

Date:05/03/05ISR Number: 4651016-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Myocardial Infarction							

Date:05/03/05ISR Number: 4651029-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00033
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autoimmune Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Erythema		Valpromide	C		ORAL		
	Granuloma		Triptorelin Acetate	C		ORAL		
	Leukocytoclastic		Sertraline					
	Vasculitis		Hydrochloride	C				
							UNKNOWN	
	Oedema Peripheral		Bicalutamide	C				
							UNKNOWN	
	Purpura		Rabeprazole Sodium	C				
							UNKNOWN	
			Oxazepam	C				
							UNKNOWN	
			Zopiclone	C				
							UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/05ISR Number: 4651030-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02527
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		1452 DAY
Disability	Anxiety		Allegra	C				UNKNOWN
Other	Atrial Fibrillation		Tylenol With Codeine #3	C				UNKNOWN
	Carotid Artery Stenosis							
	Cerebral Infarction		Atenolol	C				UNKNOWN
	Cerebrovascular Accident		Vasotec	C				UNKNOWN
	Depression							
	Dizziness							
	Eye Disorder							
	Gallbladder Disorder							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Injury							
	Intestinal Gangrene							
	Knee Arthroplasty							
	Neuralgia							
	Oedema Peripheral							
	Osteoarthritis							
	Road Traffic Accident							
	Stomach Discomfort							

Date:05/03/05ISR Number: 4651490-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder
Hospitalization - Initial or Prolonged	Anxiety
	Back Injury
Other	Back Pain
	Blood Triglycerides Increased
	Depression

Drug Dependence
Drug Detoxification
Drug Withdrawal Syndrome
Dyspepsia
Facet Joint Syndrome
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Haematocrit Abnormal
Headache
Helicobacter Pylori
Identification Test
Positive
High Density Lipoprotein
Abnormal
Hypertension
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Intervertebral Disc

		Protrusion					
		Mood Altered					
		Nervousness					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peptic Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Zoloft	C		
UNKNOWN							
		Spondylolisthesis		Zoloft	C		
UNKNOWN							
		Spondylolysis		Avalide	C		
UNKNOWN							
				Claritin	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							

Date:05/03/05ISR Number: 4651499-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00166
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Herpes Zoster		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension					

Date:05/03/05ISR Number: 4651501-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00104
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Colitis Ulcerative		Sulfasalazine	C		
UNKNOWN							
Disability		Congestive Cardiomyopathy		Prednisolone	C		
UNKNOWN							
		Coronary Artery Disease		Mesalamine	C		
UNKNOWN							
		Dizziness		Vitamin E	C		
UNKNOWN							
		Fatigue					
		Haemorrhoids					

Hypertension
Myocardial Infarction
Nausea
Palpitations
Peripheral Coldness
Sinus Tachycardia
Tachycardia
Ventricular Hypertrophy
Vision Blurred

Date:05/03/05ISR Number: 4651502-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02046
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Anaemia
	Atrial Fibrillation
	Brain Natriuretic Peptide Increased
	Cardiac Failure Congestive
	Cerebrovascular Accident
	Coronary Artery Disease
	Dehydration
	Depression
	Diverticulum

		Emotional Distress					
		Faecaloma					
		Gastric Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Irritable Bowel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Ischaemic Cardiomyopathy		Lipitor	C		
UNKNOWN							
		Mitral Valve Incompetence		Duragesic	C		
UNKNOWN							
		Panic Attack		Prevacid	C		
UNKNOWN							
		Respiratory Failure		Peri-Colace	C		
UNKNOWN							
		Ventricular Extrasystoles		Senokot (Senna)	C		
UNKNOWN							
		Weight Decreased					

Date:05/03/05ISR Number: 4651503-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00947
Age:64 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Ogen	C		ORAL
		Anxiety		Lasix (Furosemide)	C		
UNKNOWN							
		Blood Cholesterol		Norvasc	C		ORAL
		Increased		Cipro	C		
UNKNOWN							
		Blood Homocysteine		Hydroxyzine			
		Increased		Hydrochloride	C		
UNKNOWN							
		Cardiomegaly		Levaquin	C		
UNKNOWN							
		Coronary Artery		[Therapy			
		Atherosclerosis		Unspecified]	C		
UNKNOWN							
		Diabetes Mellitus		Vicodin Tablets	C		ORAL
		Electrocardiogram St		Klor-Con	C		
UNKNOWN							
		Segment Abnormal		Zithromax	C		
UNKNOWN							

	Fear	Zofran	C	
UNKNOWN				
	Hot Flush	Synthroid	C	ORAL
	Hyperphagia	Phentermine	C	
UNKNOWN				
	Libido Decreased	Ativan	C	ORAL
	Myocardial Ischaemia			
	Oedema Peripheral			
	Social Problem			
	Tricuspid Valve Incompetence			
	Ventricular Dysfunction			
	Ventricular Hypokinesia			

Date:05/03/05ISR Number: 4651513-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Other	Angina Pectoris
	Atelectasis
	Blood Pressure Increased
	Carpal Tunnel Syndrome
	Chronic Sinusitis
	Convulsion
	Coronary Artery Disease
	Cyst
	Hyperlipidaemia
	Intervertebral Disc Protrusion

		Lumbar Radiculopathy					
		Lumbar Spinal Stenosis					
		Nasal Polyps	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Septum Deviation		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasal Turbinate Hypertrophy					
		Pain In Extremity					
		Radiculitis					
		Radiculopathy					
		Sinusitis					

Date:05/03/05ISR Number: 4651514-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03554
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Hospitalization -	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Malaise		[Therapy			
Disability	Neck Pain		Unspecified]	C		
UNKNOWN						
	Stomach Discomfort		Glyburide	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:05/03/05ISR Number: 4651515-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Lymphoedema		Vioxx	SS	Merck & Co., Inc	ORAL
	Phlebothrombosis		Hormones			
	Thrombosis		(Unspecified)	SS		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						
			Hypericin	C		
UNKNOWN						

Date:05/03/05ISR Number: 4651516-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00928
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Zydone	C			UNKNOWN	
	Convulsion		Prozac	C		ORAL		
	Coronary Artery Disease		Prilosec	C		ORAL		
	Depression		Elavil	C			UNKNOWN	
	Hypertension		Zanaflex	C		ORAL		
	Joint Dislocation		Aleve	C			UNKNOWN	
	Lumbar Radiculopathy							
	Myocardial Infarction							
	Narcotic Intoxication							
	Overdose							
	Pulmonary Oedema							
	Renal Failure Chronic							
	Stent Occlusion							
	Urinary Tract Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/03/05ISR Number: 4651517-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00037
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc			UNKNOWN
	Fall		Metoprolol Tartrate	C				UNKNOWN
	Pain In Jaw							
	Pharyngolaryngeal Pain							
	Sudden Death							

Date:05/03/05ISR Number: 4651518-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00647
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1071 DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		1071 DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1071 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1071 DAY
	Coronary Artery Disease		Zithromax	C				UNKNOWN
	Deep Vein Thrombosis		Claritin-D	C				UNKNOWN
	Diabetes Mellitus		Hydroxyzine Hydrochloride	C				UNKNOWN
	Hip Arthroplasty							
	Joint Injury		Zyrtec	C				UNKNOWN
	Limb Injury		Monodox	C				UNKNOWN
	Limb Operation		Ultravate	C				UNKNOWN
	Myocardial Infarction		Temovate	C				UNKNOWN
	Sleep Apnoea Syndrome		Zonalon Cream	C				UNKNOWN
			Tazorac	C				UNKNOWN

Date:05/03/05ISR Number: 4651519-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4651521-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00655
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Norvasc	C				
UNKNOWN								
	Fall		Lipitor	C				
UNKNOWN								
	Ischaemic Stroke		Hyoscyamine	C				
UNKNOWN								
	Laceration		Atacand	C				
UNKNOWN								
	Limb Injury		Vitamin E	C				
UNKNOWN								
	Low Tension Glaucoma		Aspirin	C				
UNKNOWN								
	Optic Ischaemic		Aspirin	C				
UNKNOWN								
	Neuropathy		Toprol Xl Tablets	C				
UNKNOWN								
			Celebrex	C				
UNKNOWN								
			Ascorbic Acid	C				
UNKNOWN								
			Detrol La	C				
UNKNOWN								

Date:05/03/05ISR Number: 4651523-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00012
Age:57 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Carotid Artery Stenosis

		Cerebral Infarction					
		Cerebrovascular Disorder					
		Facial Palsy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Facial Paresis		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Metoprolol Tartrate	C		ORAL
		Hypokinesia		Aspirin And			
		Speech Disorder		Magnesium Oxide	C		ORAL
				Zocor	C		ORAL
				Hydrochlorothiazide			
				And Irbesartan	C		ORAL

Date:05/03/05ISR Number: 4651534-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00359
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Orphenadrine	C		
UNKNOWN							
		Cardiac Disorder		Furosemide	C		
UNKNOWN							
		Cardiovascular Disorder		Isosorbide	C		
UNKNOWN							
		Condition Aggravated		Lorazepam	C		
UNKNOWN							
		Coronary Artery Disease		Nitroquick	C		
UNKNOWN							
		Haemorrhage		Lanoxin	C		
UNKNOWN							
		Myocardial Infarction		Uniphyl	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		
UNKNOWN							

Date:05/03/05ISR Number: 4651536-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03355
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Disability			Lisinopril	C		ORAL		

Date:05/03/05ISR Number: 4651538-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/03/05ISR Number: 4651541-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00749
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Arteriosclerosis
	Arthralgia
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Cataract
	Cerebrovascular Accident
	Colonic Polyp

		Conjunctival Haemorrhage					
		Convulsion					
		Eye Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Haematuria		Levothyroxine Sodium	C		
UNKNOWN							
		Haemorrhoids		Cardizem	C		
UNKNOWN							
		Hydronephrosis		Prilosec	C		
UNKNOWN							
		Hypertension		Lipitor	C		
UNKNOWN							
		Hypertonic Bladder		Triamterene	C		
UNKNOWN							
		Neurodermatitis		Plavix	C		
UNKNOWN							
		Nodule		Aspirin	C		
UNKNOWN							
		Pain In Extremity					
		Pneumonia					
		Proteinuria					
		Rash					
		Vitreous Detachment					

Date:05/03/05ISR Number: 4651544-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05010
Age:63 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Arthritis		Tums	SS		
UNKNOWN							
Other		Catheter Related		Bextra	SS		ORAL
		Complication		Celebrex	SS		ORAL
		Chest Pain		Synthroid	C		
UNKNOWN							
		Coronary Artery Stenosis		Toprol Xl Tablets	C		
UNKNOWN							
		Myocardial Infarction		Zantac	C		
UNKNOWN							
		Post Procedural		Aspirin	C		
UNKNOWN							

	Complication		Avandia	C		
UNKNOWN						
	Procedural Complication		Norvasc	C		
UNKNOWN						
	Renal Failure Acute		Imdur	C		
UNKNOWN						
	Stent Occlusion		Altace	C		
UNKNOWN						
	Tooth Infection		Plavix	C		
UNKNOWN						
	Vascular Injury		Catapres	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:05/03/05ISR Number: 4651567-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Occlusion		Allopurinol	C		ORAL
Other	Cerebral Atrophy		Nitrendipine	C		ORAL
	Cerebrovascular Accident		Aspirin	C		ORAL
	Diplopia		Cetirizine			
	Transient Ischaemic		Hydrochloride	C		ORAL
	Attack		Methotrexate	C		ORAL
	Visual Disturbance		Prednisolone	C		ORAL

Date:05/03/05ISR Number: 4651583-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02105
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Difficulty In Walking		[Therapy			
	Headache		Unspecified]	C		
UNKNOWN						

			Hydrochlorothiazide	C		
UNKNOWN						
			Clonidine	C		
UNKNOWN						

Date:05/03/05ISR Number: 4651584-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00067
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		22 MON
Initial or Prolonged	Cerebral Infarction		[Therapy					
Disability			Unspecified]	C				
UNKNOWN								

Date:05/03/05ISR Number: 4651608-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		40 MON
	Myocardial Infarction							

Date:05/03/05ISR Number: 4653145-5Report Type:Expedited (15-DaCompany Report #2005062966
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Azotaemia	Health	Bextra (Valdecoxib)	PS				
Initial or Prolonged	Dizziness	Professional	Celebrex (Celecoxib)	SS				
	Faeces Discoloured		Rofecoxib					
	Haemoglobin Decreased		(Rofecoxib)	SS				
	Headache		Acetylsalicylic Aicd					
	Ulcer Haemorrhage		(Acetylsalicylic					
	Volume Blood Decreased		Acid)	SS				
81 MG (81 MG,								
1 IN 1 D)								
			Rosiglitazone					

Maleate (Rosiglitazone Maleate)	C
Atorvastatin (Atorvastatin)	C
Multivit (Vitamins Nos)	C
Fluconazole (Fluconazole)	C
Ramipril (Ramipril)	C
Bactm (Sulfamethoxazole, Trimethoprim)	C
Trazodone (Trazodone)	C
Paracetamol (Paracetamol)	C
Vardenafil (Vardenafil)	C

Date:05/03/05ISR Number: 4653294-1Report Type:Direct Company Report #CTU 247649
Age:70 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability
Other
Required
Dose Duration
Intervention to Prevent Permanent Impairment/Damage

PT	Report Source	Product	Role	Manufacturer	Route
Abdominal Distension		Vioxx	PS		
Burning Sensation		Celebrex	SS		
Change Of Bowel Habit		Aciphex	SS		
Diarrhoea		Flagyl	SS		
Dry Throat					
Gastric Disorder					
Gastrooesophageal Reflux Disease					
Hiccups					
Lip Dry					
Nasal Dryness					
Oedema Peripheral					
Rash Generalised					
Rectal Haemorrhage					
Sensory Disturbance					
Sensory Loss					
Stomach Discomfort					
Vitamin B12 Deficiency					

Date:05/03/05ISR Number: 4653331-4Report Type:Direct Company Report #CTU 247664
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 - 50 MG Initial or Prolonged	Cardiac Disorder		Vioxx	PS		

Date:05/04/05ISR Number: 4651986-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/04/05ISR Number: 4652364-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04449
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1075 DAY	

Date:05/04/05ISR Number: 4652365-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	19 MON	
	Myocardial Infarction							

Date:05/04/05ISR Number: 4652372-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0406USA01553
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Alopecia
Disability	Anxiety
Other	Arthralgia

		Back Pain					
		Benign Prostatic Hyperplasia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cholecystitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Claritin-D	C		
UNKNOWN							
		Cyst		Flomax (Tamsulosin Hydrochloride)	C		
		Deafness					
UNKNOWN							
		Dehydration		Flonase	C		
UNKNOWN							
		Depression		Valium	C		
UNKNOWN							
		Erythema		Plendil	C		
UNKNOWN							
		Fatigue		Pravachol	C		
UNKNOWN							
		Gout		Wellbutrin	C		
UNKNOWN							
		Hodgkin'S Disease		Paxil	C		
UNKNOWN							
		Inguinal Hernia					
		Myalgia					
		Myopathy					
		Nasal Cyst					
		Pain In Extremity					
		Pneumonia					
		Prostatic Specific Antigen Increased					
		Rectal Examination Abnormal					
		Renal Failure					
		Renal Failure Acute					
		Renal Tubular Necrosis					
		Tension Headache					

Date:05/04/05ISR Number: 4652373-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00415
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Atenolol Msd	C				
UNKNOWN								
Disability	Blindness							
	Cerebrovascular Accident							
	Clostridial Infection							
	Colitis							
	Deafness							
	Depression							
	Fall							
	Hypertension							
	Impaired Work Ability							
	Loss Of Consciousness							
	Paralysis							
	Traumatic Brain Injury							
	Treatment Noncompliance							

Date:05/04/05ISR Number: 4652374-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00665
Age:84 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration	Other
Anorectal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL			
Asthenia		Doxazosin Mesylate	C					UNKNOWN
Benign Prostatic Hyperplasia		Lasix (Furosemide)	C					UNKNOWN
		Lanoxin	C					UNKNOWN
Blindness		Hyzaar	C		ORAL			
Blood Cholesterol Increased		Allopurinol	C		ORAL			
		Zaroxolyn	C		ORAL			
Blood Potassium Decreased		Cyclocort	C					UNKNOWN
Blood Triglycerides Increased		Tenormin	C					UNKNOWN
		Lotrisone	C					UNKNOWN
Cardiac Murmur		Nizoral	C					UNKNOWN
Carpal Tunnel Syndrome		Bacitracin	C					UNKNOWN
Cerebrovascular Accident		Ocuflox	C					UNKNOWN
Coronary Artery Disease		Altace	C					UNKNOWN
Crackles Lung Dehydration		[Therapy Unspecified]	C					UNKNOWN
Dizziness		Digitek	C					UNKNOWN
Dyspnoea		Cyanocobalamin	C					UNKNOWN
Hepatic Steatosis		Diamox	C					UNKNOWN
Mass		Coreg	C					UNKNOWN
Myocardial Infarction Nerve Compression		[Therapy Unspecified]	C					UNKNOWN
Neuropathy Peripheral		Augmentin	C					UNKNOWN
Orthostatic Hypotension		Alprazolam	C					UNKNOWN

	Pain		Doxycycline	C			
UNKNOWN							
	Syncope		Levaquin	C			
UNKNOWN							
	Transient Ischaemic		Plavix	C			
UNKNOWN							
	Attack		Cozaar	C			
UNKNOWN							
	Vomiting		Colchicine Injection	C			
UNKNOWN							
	Wheezing		Norvasc	C			
UNKNOWN							

Date:05/04/05ISR Number: 4652377-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04342
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:05/04/05ISR Number: 4652378-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
10 DAY								
Initial or Prolonged	Infarction		Beclomethasone					
	Anhedonia		Dipropionate	C				
RESPIRATORY								
	Anxiety							
(INHALATION)	729 DAY							
	Blood Pressure Decreased		Verapamil					
	Drug Ineffective		Hydrochloride	C				
UNKNOWN	382 DAY							
	Emotional Distress		[Therapy					
	Fatigue		Unspecified]	C				
UNKNOWN								
	Hyperkeratosis		Griseofulvin	C				
UNKNOWN	25 DAY							
	Hyperlipidaemia							
	Injury							
	Pain							
	Pelvic Haematoma							
	Tinea Infection							

Date:05/04/05ISR Number: 4652379-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02661
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		634 DAY
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Non-Insulin-Dependent		Norvasc	C				UNKNOWN
	Hypercholesterolaemia		Atenolol	C				UNKNOWN
	Myocardial Infarction							417 DAY
	Palpitations							

Date:05/04/05ISR Number: 4652380-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0305USA00547
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
	Atrial Fibrillation		Dilacor Xr	C				UNKNOWN
	Atrial Flutter		Furosemide	C				UNKNOWN
	Benign Prostatic		Cozaar	C				UNKNOWN
	Hyperplasia		Aspirin	C				UNKNOWN
	Brain Oedema		Cordarone	C				UNKNOWN
	Cardiac Failure		Lipitor	C				UNKNOWN
	Congestive							
	Cerebral Atherosclerosis							
	Contusion							
	Coronary Artery Disease							
	Cough							
	Ejection Fraction							
	Decreased							

Emphysema
Hypokalaemia
Mitral Valve Incompetence
Myocardial Infarction
Nephrosclerosis
Oedema Peripheral
Osteoarthritis
Osteoporosis
Pain In Extremity
Pleural Effusion
Rhinitis Allergic
Seborrhoeic Keratosis
Thyroid Mass
Tricuspid Valve
Incompetence

Date:05/04/05ISR Number: 4652386-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03026
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Angina Unstable
Hospitalization - Initial or Prolonged	Atherosclerosis
	Coronary Artery Disease
Disability	Diabetes Mellitus
	Dyslipidaemia
	Mass
	Myocardial Infarction
	Peripheral Vascular

	Disorder					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
791 DAY						
			Aspirin	C		ORAL
			Bumetanide	C		ORAL
			Serevent	C		
UNKNOWN						
			Quinine Sulfate	C		
UNKNOWN						

Date:05/04/05ISR Number: 4652388-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04451
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
1648 DAY						
	Infarction					
	Palpitations					

Date:05/04/05ISR Number: 4652389-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04781
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/04/05ISR Number: 4652390-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Heart Injury					
	Hypertension					

Date:05/04/05ISR Number: 4652391-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652392-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:05/04/05ISR Number: 4652393-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04783
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	642 DAY	
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/05ISR Number: 4652394-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:05/04/05ISR Number: 4652395-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04723
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:05/04/05ISR Number: 4652396-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04785
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652403-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04724
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	56	MON

Date:05/04/05ISR Number: 4652404-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04807
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:05/04/05ISR Number: 4652413-0Report Type:Expedited (15-DaCompany Report #DK-MERCK-0505DNK00001
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Visual Disturbance		Etodolac	SS		ORAL		

Date:05/04/05ISR Number: 4652417-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00194
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652418-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00092
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	580 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/04/05ISR Number: 4652419-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652421-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00093
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652422-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00184
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/04/05ISR Number: 4652481-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Celebrex	SS				
UNKNOWN								

Date:05/04/05ISR Number: 4653776-2Report Type:Expedited (15-DaCompany Report #2005063258
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200	
Other	Chest Pain						MG, 2 IN 1	

	Drug Hypersensitivity			
D), ORAL				
	Drug Ineffective	Bextra (Valdecoxib)	SS	ORAL
10 MG (10				
	Dyspnoea			
MG,1 IN 1 D),				
	Dysstasia			
ORAL				
	Laboratory Test Abnormal	Rofecoxib		
	Pain	(Rofecoxib)	SS	ORAL
ORAL				
	Pericarditis	Telmisartan		
		(Telmisartan)	SS	ORAL
ORAL				
		Provella-14 (Estrogens Conjugated, Medroxyprogesterone Acetate)	C	
		Metformin Hydrochloride (Metformin Hydrochloride)	C	
		Cetirizine Hydrochloride (Cetirizine Hydrochloride)	C	
		Alprazolam (Alprazolam)	C	
		Propacet (Dextropropoxyphene Napsilate, Paracetamol)	C	

				Metoprolol (Metoprolol)	C		

Date:05/04/05ISR Number: 4653778-6Report Type:Expedited (15-DaCompany Report #2005059717
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Drug Ineffective		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG,	
	Exostosis						1 IN 1 D),	
	Movement Disorder						ORAL	
	Pain		Ibuprofen (Ibuprofen)	SS		ORAL	4000 MG (800	
	Pharmaceutical Product						MG, 5 IN 1	
	Complaint						D), ORAL	
	Rectal Haemorrhage							
			Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	SS			750 MG	
			Cortisone (Cortisone)	SS		INTRASYNOVIAL	INTRASYNOVIAL	
			Pantoprazole (Pantoprazole)	C				
			Vitamins (Vitamins)	C				

Date:05/04/05ISR Number: 4654191-8Report Type:Expedited (15-DaCompany Report #2005062475
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Daypro Caplet					

Initial or Prolonged	Drug Ineffective	(Oxaprozin)	PS	
	Dyspnoea	Celebrex (Celecoxib)	SS	ORAL 200 MG (200 MG, 1 IN 1 D) ORAL
	Knee Arthroplasty			
	Pulmonary Embolism			
		Bextra (Valdecoxib)	SS	ORAL 10 MG (10 MG, 1 IN 1 D) ORAL
		Rofecoxib (Rofecoxib)	SS	

Date:05/04/05ISR Number: 4655040-4Report Type:Expedited (15-DaCompany Report #2005063446
Age:72 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree
	Azotaemia
	Benign Prostatic Hyperplasia
	Blood Pressure Diastolic Decreased
	Chest Pain
	Dizziness
	Epigastric Discomfort
	Feeling Hot
	Gastrointestinal Haemorrhage

		Haematocrit Decreased Haemoglobin Decreased Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperhidrosis	Consumer	Celebrex (Celecoxib)	PS		ORAL
ORAL							
		Ulcer Haemorrhage		Bextra (Valdecoxib)	SS		
				Acetylsalicylic Acid (Acetylsalicylic Acid)	SS		ORAL
81 MG (81 MG,							
1 IN 1 D),							
ORAL							
				Rofecoxib (Rofecoxib)	SS		ORAL
ORAL							
				Atorvastatin Calcium (Atorvastatin Calcium)	C		
				Rosiglitazone Maleate (Rosiglitazone Maleate)	C		
				Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide,	C		
				Fluconaolze (Fluconazole)	C		
				Ramipril (Ramipril)	C		
				Bactrim (Sulfamethoxazole, Trimethoprim)	C		
				Atenolol (Atenolol)	C		
				Tocopherol (Tocopherol)	C		
				Trazodone (Trazodone)	C		
				Paracetamol (Paracetamol)	C		
				Vardenafil (Vardenafil)	C		

Date:05/04/05ISR Number: 4656394-5Report Type:Expedited (15-DaCompany Report #WAES 0503DEU00208
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia	Foreign	Tab Vioxx	PS		ORAL	25 MG/DAILY/PO	
	Cerebral Artery Stenosis	Study						
	Dyspepsia	Health Professional	Tab 0663-Blinded Therapy	SS		ORAL	PO	
	Electrocardiogram Abnormal		Tab Blinded Therapy	SS		ORAL	PO	
	Hemiparesis		Hypericin	C				
	Nuclear Magnetic Resonance Imaging Abnormal		Lisinopril	C				
			Piretanide	C				
			Prednisolone	C				
	Psychotic Disorder		Sulfasalazine	C				
	Speech Disorder		Theophylline	C				
	Transient Ischaemic Attack							

Date:05/04/05ISR Number: 4656485-9Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Increased	Foreign	Tab Vioxx					
Hospitalization -	Carcinoembryonic Antigen	Study	(Rofecoxib)	PS		ORAL	25 MG DAILY	293 DAY
Initial or Prolonged	Increased	Health	Allopurinol	C				
	Cardiac Failure	Professional						
	Cardio-Respiratory Arrest							
	Cardiomegaly							
	Drug Ineffective							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Mean Cell Haemoglobin							
	Concentration Decreased							
	Mean Cell Haemoglobin							
	Decreased							
	Pleural Effusion							
	Pneumonia							
	Post Procedural							
	Complication							
	Prothrombin Time							
	Prolonged							
	Red Cell Distribution							
	Width Increased							

Date:05/05/05ISR Number: 4653049-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00217
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Brain Stem Ischaemia		Dipyrone	C		ORAL		
	Cerebral Ischaemia		Vitamin A	C				
UNKNOWN								
	Difficulty In Walking		Estradiol And					
	Dysphagia		Norethindrone					
	Dysphonia		Acetate	C				
UNKNOWN								
	Foot Fracture							
	Headache							
	Tachycardia							

Date:05/05/05ISR Number: 4653050-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02633
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Congestive Dyspnoea		[Therapy Unspecified]	C				UNKNOWN
Disability	Heart Rate Decreased		[Therapy Unspecified]	C				UNKNOWN
Other	Vomiting							
			Celebrex	C				UNKNOWN
			Celebrex	C				UNKNOWN

Date:05/05/05ISR Number: 4653051-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01997
Age:71 YR Gender:Female I/FU:F

Outcome
Death
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY
	Decubitus Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL	30	DAY
	Urosepsis							

Date:05/05/05ISR Number: 4653053-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02541
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Soma	C			UNKNOWN	
	Asthenia		Soma	C			UNKNOWN	
	Blood Cholesterol Increased		Amitriptyline Hydrochloride	C			UNKNOWN	
	Bone Pain		Flexeril	C			UNKNOWN	
	Cardiac Disorder		Flexeril	C			UNKNOWN	
	Cerebrovascular Accident		Apap	C			UNKNOWN	
	Dyspepsia		Codeine	C			UNKNOWN	
	Dyspnoea							
	Fear							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							
	Haemorrhoids							
	Injury							
	Nausea							
	Non-Cardiac Chest Pain							
	Rectal Prolapse							
	Sinus Tachycardia							
	Stress							

Syncope
Vomiting

Date:05/05/05ISR Number: 4653055-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02976
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		1121 DAY
Initial or Prolonged	Increased		Zoloft	C				UNKNOWN
Disability	Cardiac Disorder		Nefazodone					
Other	Emotional Distress		Hydrochloride	C				UNKNOWN
	Hypertension							
	Myocardial Infarction							

Date:05/05/05ISR Number: 4653056-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Other	Anal Fistula
	Aneurysm Ruptured
	Angina Unstable
	Anxiety

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Appendicitis Perforated Arthralgia Atelectasis Back Pain Cardiac Failure Cerebral Artery Stenosis Colitis Ulcerative Contusion Convulsion Coronary Artery Disease Cough Defaecation Urgency Depression Dermatitis Dizziness Drug Ineffective Faecal Incontinence Fall Flatulence Headache Hernia Hyperlipidaemia Hypertension Hypotension Ileitis Impaired Healing Infection Inflammatory Bowel Disease Intestinal Perforation Intestinal Spasm Intracranial Aneurysm Joint Injury Migraine Musculoskeletal Chest Pain Pain Pain In Extremity Perianal Abscess Perirectal Abscess Pneumoperitoneum Proctalgia Proctitis Ulcerative Pruritus Ani Pyrexia Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL

Subarachnoid Haemorrhage
Syncope
Tachycardia
White Blood Cell Count
Increased

Date:05/05/05ISR Number: 4653058-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00018
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation Carotid Artery Stenosis Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653060-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00480
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Humulin	C			SUBCUTANEOUS	
	Coronary Artery Disease		Glucophage	C		ORAL		
	Coronary Artery Occlusion		Lopressor	C		ORAL		
	Coronary Artery Stenosis		Acupril	C		ORAL		
	Depression		Zocor	C		ORAL		
	Diabetic Retinopathy		Hydrochlorothiazide	C		ORAL		
	Dizziness		Nexium	C		ORAL		
	Dysphagia		Estradiol	C		ORAL		
	Dyspnoea Exertional		Ultram	C		ORAL		
	Electrocardiogram		Aspirin	C		ORAL		
	Abnormal		Nitroglycerin	C			UNKNOWN	
	Electrocardiogram St-T Segment Abnormal		[Therapy Unspecified]	C		ORAL		
	Gastroenteritis		Bextra	C		ORAL		
	Impingement Syndrome		Lipitor	C		ORAL		
	Injury		Gemfibrozil	C		ORAL		
	Myocardial Ischaemia		Flexeril	C		ORAL		
	No Therapeutic Response		Glucosamine	C			UNKNOWN	
	Nocturia		Prevacid	C			UNKNOWN	
	Non-Cardiac Chest Pain		Nitroglycerin	C			UNKNOWN	
	Post-Traumatic Stress Disorder							
	Renal Disorder							
	Renal Impairment							
	Rotator Cuff Syndrome							
	Sleep Apnoea Syndrome							
	Stomach Discomfort							
	Temperature Intolerance							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Weight Increased							

Date:05/05/05ISR Number: 4653061-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01342
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		10 MON
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		10 MON
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		10 MON
	Coronary Artery		Tricor	C				UNKNOWN
	Thrombosis		Gemfibrozil	C				UNKNOWN
	Injury		Viagra	C				UNKNOWN
			Accupril	C				UNKNOWN

Date:05/05/05ISR Number: 4653062-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00002
Age:39 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Dyspnoea
	Muscle Spasms
	Muscular Weakness

	Myalgia Overdose	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	12	DAY
			Piroxicam Betadex	C			UNKNOWN	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	1 DAY

Date:05/05/05ISR Number: 4653063-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00068
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Extrasystoles Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653064-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00066
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fosinopril Sodium	C		ORAL		
	Anxiety		Fosinopril Sodium	C			UNKNOWN	
	Blood Chloride Increased		Atorvastatin Calcium [Therapy Unspecified]	C		ORAL		
	Depression							
	Electrocardiogram			C			UNKNOWN	
	Abnormal Myocardial Ischaemia		Codeine Phosphate And Acetaminophen	C			UNKNOWN	
	Spinal Column Stenosis Ventricular Dysfunction		Fluoxetine Hydrochloride	C			UNKNOWN	
			Fluoxetine Hydrochloride	C			UNKNOWN	

Date:05/05/05ISR Number: 4653065-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653066-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01428
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653067-XReport Type:Expedited (15-DaCompany Report #DK-MERCK-0504DNK00023
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Inner Ear Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	413 DAY	
	Meniere'S Disease		Vioxx	SS	Merck & Co., Inc	ORAL	413 DAY	
	Thrombosis		Acetaminophen	C			UNKNOWN	

Date:05/05/05ISR Number: 4653068-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00097
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Pacemaker Insertion		Vioxx	SS	Merck & Co., Inc	ORAL		
			Prevacid	C			UNKNOWN	
	Cerebrovascular Accident		Naproxen	C			UNKNOWN	
	Dizziness		Amlodipine Besylate	C			UNKNOWN	
	Dyspepsia		Felodipine	C			UNKNOWN	
	Nausea		Aspirin	C			UNKNOWN	
	Osteoporosis		Actonel	C			UNKNOWN	
	Vomiting		Herbs (Unspecified)	C			UNKNOWN	
	Weight Decreased							

Date:05/05/05ISR Number: 4653069-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04605
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		1302 DAY

Date:05/05/05ISR Number: 4653071-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653072-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure Congestive Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653073-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653074-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653075-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04636
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653076-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653077-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04634
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23 MON	

Date:05/05/05ISR Number: 4653078-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00239
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653079-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00116
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653080-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653081-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00113
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653083-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00235
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	93	DAY

Date:05/05/05ISR Number: 4653084-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:05/05/05ISR Number: 4653085-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653087-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:05/05/05ISR Number: 4653090-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Atenolol	C				
UNKNOWN								

Other	High Density Lipoprotein		Norvasc	C
UNKNOWN				
	Decreased			
	Hypertension			
	Hypoaesthesia			
	Myocardial Infarction			
	Sinus Bradycardia			
	Stent Occlusion			
	Swelling			

Date:05/05/05ISR Number: 4653503-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00055
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
			Lorazepam	C		
UNKNOWN						
			Olanzapine	C		
UNKNOWN						
			Clarithromycin	C		
UNKNOWN	10 DAY					
			Homatropine Methylbromide And Hydrocodone Bitartrate	C		
UNKNOWN						
			Acetaminophen And Codeine Phosphate	C		
UNKNOWN						
			Acetaminophen And Oxycodone Hydrochloride	C		
UNKNOWN						

Albuterol C
RESPIRATORY

(INHALATION)

Date:05/05/05ISR Number: 4653505-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00034
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		943 DAY
Hospitalization -	Hypertensive Heart		Lipitor	C				UNKNOWN
Initial or Prolonged	Disease		Verapamil	C				UNKNOWN
			Flovent	C				UNKNOWN
			Combivent	C				UNKNOWN

Date:05/05/05ISR Number: 4653509-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00630
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL		361 DAY
Initial or Prolonged	Atelectasis		Nitroglycerin	C				UNKNOWN
	Chest Pain		Coumadin	C				UNKNOWN
	Deep Vein Thrombosis							
	Haemochromatosis							
	Phlebotomy							
	Polycythaemia							
	Pulmonary Embolism							

Date:05/05/05ISR Number: 4653510-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Back Pain
Other	Blood Triglycerides Increased
	Chromaturia
	Chronic Fatigue Syndrome
	Constipation
	Convulsion
	Costochondritis
	Depression
	Diabetes Mellitus Inadequate Control
	Dizziness
	Drug Hypersensitivity
	Drug Ineffective
	Emotional Distress
	Fatigue
	General Physical Health Deterioration
	Hypertension
	Insomnia
	Macular Oedema
	Myalgia
	Myocardial Infarction
	Neuritis
	Neuropathy Peripheral
	Oedema Peripheral
	Pain

	Peripheral Vascular Disorder						
	Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Retinopathy		Vioxx	PS	Merck & Co., Inc	ORAL	
	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
	Serum Ferritin Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
	Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Baycol	C			UNKNOWN
			Actos	C			UNKNOWN
			[Composition Unspecified]	C			UNKNOWN

Date:05/05/05ISR Number: 4653511-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00089
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Joint Dislocation		Vioxx	PS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Osteoarthritis						

Date:05/05/05ISR Number: 4653518-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 373 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Infarction		Lipitor	C			UNKNOWN
	Blood Pressure Increased		Tranxene	C			UNKNOWN
	Coronary Artery		Prozac	C			UNKNOWN

	Atherosclerosis		Zantac	C	
UNKNOWN					
	Ejection Fraction Decreased				
	Emotional Distress				
	Exostosis				
	Fall				
	Hyperlipidaemia				
	Obstructive Airways Disorder				
	Ulna Fracture				
	Ulnar Nerve Injury				

Date:05/05/05ISR Number: 4653521-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04638
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653531-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	32 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4653532-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00241
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653533-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
	Death							
	Organ Failure							
	Pain							

Date:05/05/05ISR Number: 4653534-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00036
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							222	DAY
Initial or Prolonged	Infarction		Acitretin	C				
UNKNOWN								
	Chest Pain		Estradiol Valerate	C				
UNKNOWN								
	Overdose		Atorvastatin Calcium	C				
UNKNOWN								
	Urinary Tract Infection							

Date:05/05/05ISR Number: 4653535-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
5	MON							

Date:05/05/05ISR Number: 4653537-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653548-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00115
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4653549-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00238
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1906 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4654121-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00837
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebrovascular Accident		Zocor	C		ORAL		
Disability	Depression		Vasotec	C				
UNKNOWN								
	Polytraumatism							

Date:05/05/05ISR Number: 4654122-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00056
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Omeprazole	C				
UNKNOWN								
Initial or Prolonged	Coma		Hydrochlorothiazide	C				
UNKNOWN								
Disability			Atenolol	C				
UNKNOWN								
			Pravastatin Sodium	C				
UNKNOWN								

Date:05/05/05ISR Number: 4654123-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03255
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -								
Initial or Prolonged								
Disability								

Date:05/05/05ISR Number: 4654124-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02340
Age:80 YR Gender:Female I/FU:F

Outcome	PT

Hospitalization - Initial or Prolonged	Anaemia Aortic Atherosclerosis Aortic Stenosis Arthropathy Cardiac Failure Congestive Compression Fracture Coronary Artery Disease Depression Drug Ineffective Duodenal Ulcer Fall Gastrooesophageal Reflux Disease Hiatus Hernia Hyperglycaemia Insomnia Mitral Valve Incompetence Myocardial Infarction Osteoarthritis Peptic Ulcer Pericardial Effusion Pulmonary Hypertension Scoliosis Skeletal Injury Small Intestinal Obstruction

		Tricuspid Valve Incompetence					
		Upper Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Lotrel	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							

Date:05/05/05ISR Number: 4654127-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00666
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Pain					
		Mitral Valve Incompetence					
		Retinal Artery Embolism					
		Sleep Disorder					
		Spondylolysis					
		Transient Ischaemic Attack					
		Tricuspid Valve Incompetence					

Date:05/05/05ISR Number: 4654128-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04615
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/05/05ISR Number: 4654129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04383
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Diovan	C				
UNKNOWN								
Initial or Prolonged			Cardizem	C				
UNKNOWN								
Disability			Crestor	C				
UNKNOWN								

Date:05/05/05ISR Number: 4654131-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104508
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abnormal Behaviour
Initial or Prolonged	Accidental Overdose
Disability	Anxiety
Other	Arthralgia
	Asthenia
	Back Injury
	Back Pain
	Blood Glucose Increased
	Carpal Tunnel Syndrome

		Cellulitis					
		Chest Pain					
		Closed Head Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Concussion		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Zocor	C		
UNKNOWN							
		Depression					
		Diabetic Neuropathy					
		Emotional Distress					
		Epididymitis					
		Facial Bones Fracture					
		Head Injury					
		Headache					
		Hiatus Hernia					
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Hypertension					
		Inguinal Hernia					
		Laceration					
		Muscle Atrophy					
		Nasal Congestion					
		Nasal Septum Deviation					
		Neuritis					
		Nocturia					
		Nodule					
		Nose Deformity					
		Obesity					
		Pain					
		Sleep Apnoea Syndrome					
		Somnolence					
		Tendonitis					
		Upper Extremity Mass					
		Vision Blurred					

Date:05/05/05ISR Number: 4654133-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03577
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Cardiac Flutter		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Rectal Haemorrhage		Atenolol Msd	C		ORAL

	Stomach Discomfort	Premarin	C
UNKNOWN			
		Potassium (Unspecified)	C
UNKNOWN			
		Lasix (Furosemide Sodium)	C
UNKNOWN			

Date:05/05/05ISR Number: 4654134-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00113
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
	Carotid Artery Disease
	Cerebrovascular Accident
	Convulsion
	Dilatation Atrial
	Dyspepsia
	Emotional Distress
	Headache
	Hemianopia Homonymous

	Nephropathy						
	Scar						
	Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventricular Hypertrophy		Zocor	C		ORAL		
			Glucophage Xr	C		ORAL		
			Ecotrin	C		ORAL		
			Trental	C		ORAL		
			Humalog	C			SUBCUTANEOUS	
			Synthroid	C		ORAL		
			Lipitor	C			UNKNOWN	

Date:05/05/05ISR Number: 4654144-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00611
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Dyspnoea Exertional		Phenprocoumon	C			UNKNOWN	
	Phlebothrombosis		Levetiracetam	C			UNKNOWN	
	Syncope		Tizanidine					
	Vertebral Artery		Hydrochloride	C			UNKNOWN	
	Occlusion							

Date:05/05/05ISR Number: 4654145-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02664
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	379 DAY	
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	379 DAY	
Other			Claritin	C			UNKNOWN	

		Adalat	C	
UNKNOWN				
		Oxycontin	C	
UNKNOWN				
		Percodan	C	
UNKNOWN				
		Nortriptyline	C	
UNKNOWN				
		Amoxicillin	C	
UNKNOWN				
		Zestril	C	
UNKNOWN				
		Indocin (Indomethacin Sodium)	C	ORAL
		Humalog	C	
UNKNOWN				
		Lantus	C	
UNKNOWN				
		Erythromycin	C	
UNKNOWN				
		Phenergan (Promethazine Hydrochloride)	C	
UNKNOWN				

Date:05/05/05ISR Number: 4654147-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04447
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/05/05ISR Number: 4654148-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00099
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		28 DAY
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion							

Date:05/05/05ISR Number: 4654149-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04445
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		66 MON

Date:05/05/05ISR Number: 4654150-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00041
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		295 DAY
Initial or Prolonged	Cerebral Infarction		Estradiol And Norethindrone Acetate	C				
Disability								
UNKNOWN								

Date:05/05/05ISR Number: 4654151-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04400
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			[Therapy					

Initial or Prolonged Unspecified] C
UNKNOWN
Disability

Date:05/05/05ISR Number: 4654169-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04619
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654170-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02339
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	200 DAY	
Hospitalization - Initial or Prolonged	Congestive Cardiopulmonary Failure Coronary Artery Disease							

Date:05/05/05ISR Number: 4654171-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04666
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4654172-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04747
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654173-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05024
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654174-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04729
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	57 MON	

Date:05/05/05ISR Number: 4654175-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654176-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654177-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04748
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654178-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		882 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		882 DAY

Date:05/05/05ISR Number: 4654180-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05195
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Bereavement Reaction
Other	Chest Pain
	Cough
	Dizziness

		Dyspepsia					
		Fatigue					
		Haematochezia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhoids		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL
		High Density Lipoprotein		Aspirin	C		
UNKNOWN							
		Decreased		Chondroitin Sulfate			
		Hypertensive Heart		Sodium And			
		Disease		Glucosamine			
		Oedema Peripheral		Hydrochloride	C		
UNKNOWN							
		Osteoarthritis		Allegra	C		
UNKNOWN							
		Pulmonary Hypertension					
		Rectal Haemorrhage					
		Silent Myocardial					
		Infarction					
		Sleep Apnoea Syndrome					
		Snoring					
		Weight Increased					

Date:05/05/05ISR Number: 4654192-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/05/05ISR Number: 4654193-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00138
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiogenic Shock		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction					

Date:05/05/05ISR Number: 4654194-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654195-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:05/05/05ISR Number: 4654196-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4654197-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00226
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Myocardial Infarction							

Date:05/05/05ISR Number: 4654198-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	36	MON

Date:05/05/05ISR Number: 4654199-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654200-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00139
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:05/05/05ISR Number: 4654201-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:05/05/05ISR Number: 4654212-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00161
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654213-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00154
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654214-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:05/05/05ISR Number: 4654215-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Date:05/05/05ISR Number: 4654216-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00162
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654217-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00218
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	60	DAY

Date:05/05/05ISR Number: 4654218-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00160
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	38	MON
Initial or Prolonged	Supraventricular							
Disability	Cerebrovascular Accident							
	Sick Sinus Syndrome							

Date:05/05/05ISR Number: 4654219-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1299 DAY						

Date:05/05/05ISR Number: 4654220-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/05/05ISR Number: 4654232-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
2 YR						

Date:05/05/05ISR Number: 4654233-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1160 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4654234-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00269
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	48	DAY
	Sudden Death							

Date:05/05/05ISR Number: 4654235-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00279
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654246-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00254
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4654247-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	733	DAY

Date:05/05/05ISR Number: 4654251-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00497
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	24	MON

Date:05/05/05ISR Number: 4654260-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:05/05/05ISR Number: 4654266-3Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00023
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Acetaminophen	SS		ORAL		
			Irbesartan	SS		ORAL		
			Fondaparinux Sodium	SS		SUBCUTANEOUS		
			Omeprazole	SS		ORAL		
			Iron (Unspecified)	SS		ORAL		
			Tinzaparin Sodium	SS		SUBCUTANEOUS	4	DAY

Date:05/05/05ISR Number: 4654272-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00148
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/05ISR Number: 4654282-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/05/05ISR Number: 4655873-4Report Type:Direct Company Report #CTU 247910
Age:85 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Pressure Increased		Vioxx - 12.5 Mg.	PS			1 TABLET ONCE	
	Brain Stem Haemorrhage						A DAY AFTER	
	Cerebrovascular Accident						DINNER	
	Coma							
	Fall							

Date:05/06/05ISR Number: 4654925-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00075
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	1482 DAY	
Initial or Prolonged	Cerebral Atrophy		Vioxx	SS	Merck & Co., Inc	ORAL	1482 DAY	
Disability	Cerebral Ischaemia		Toprol Xl Tablets	C		ORAL		
	Cerebrovascular Accident		Darvocet-N	C			UNKNOWN	
	Depression		Calcium (Unspecified)	C			UNKNOWN	
	Headache							
	Insomnia		Premarin	C			UNKNOWN	
	Migraine		Lortab	C			UNKNOWN	
	Neuropathy Peripheral		Norvasc	C			UNKNOWN	

	Pharyngitis	Neurontin	C
UNKNOWN			
	Seborrhoeic Keratosis	Lotrel	C
UNKNOWN			
	Transient Ischaemic	Cephalexin	C
UNKNOWN			
	Attack	Levaquin	C
UNKNOWN			
		Amitriptylin	C
UNKNOWN			

Date:05/06/05ISR Number: 4654926-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02846
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
	Infarction							
	Ventricular Arrhythmia							

Date:05/06/05ISR Number: 4654927-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00957
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anxiety
Disability	Arteriosclerosis
	Atrial Fibrillation
	Cerebrovascular Accident
	Cholelithiasis
	Closed Head Injury
	Confusional State
	Decreased Interest
	Dehydration
	Drug Intolerance

		Emotional Distress					
		Fall					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fear		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Impatience		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Zestril	SS		
UNKNOWN							
		Irritability		Lipitor	C		
UNKNOWN							
		Memory Impairment		Amiodarone	C		
UNKNOWN							
		Mitral Valve Incompetence		Triamcinolone	C		
TOPICAL							
		Pulmonary Valve		Hydrodiuril	C		
UNKNOWN							
		Incompetence		Cipro	C		
UNKNOWN							
		Renal Cyst		Metoprolol	C		
UNKNOWN							
		Renal Failure		Levoxyl	C		
UNKNOWN							
		Sick Sinus Syndrome		Nitroglycerin	C		
UNKNOWN							
		Transaminases Increased		Warfarin Sodium	C		
UNKNOWN							
		Transient Ischaemic		Microzide	C		
UNKNOWN							
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					

Date:05/06/05ISR Number: 4654928-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04245
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Anxiety					
Initial or Prolonged	Aortic Atherosclerosis					
	Atrial Fibrillation					
	Candida Sepsis					

Cerebrovascular Accident
Depression
Hiatus Hernia
Hydrocephalus
Intracranial Aneurysm
Pneumonia
Pneumonia Klebsiella
Respiratory Failure
Staphylococcal Infection
Stress
Subarachnoid Haemorrhage
Urinary Tract Infection
Wound

Date:05/06/05ISR Number: 4654930-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00554
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		70 DAY
Initial or Prolonged	Blood Cholesterol		Zestril	C				UNKNOWN
	Increased		Allegra	C				UNKNOWN
	Blood Triglycerides		Zyrtec	C				UNKNOWN
	Increased		Lipitor	C				UNKNOWN
	Coronary Artery Occlusion							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4654931-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02347
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety							
	Cerebrovascular Accident							
	Chronic Fatigue Syndrome							
	Depression							
	Dizziness							
	Emotional Distress							
	Flatulence							
	Glaucoma							
	Haemorrhoids							
	Headache							
	Lumbar Radiculopathy							
	Nausea							
	Panic Attack							

Date:05/06/05ISR Number: 4654932-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02343
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Plavix	C				
UNKNOWN								
	Chest Pain		Prilosec	C				
UNKNOWN								
	Circulatory Collapse		Celebrex	C				
UNKNOWN								
	Depression		Tylenol	C				
UNKNOWN								
	Dyspepsia		Advil	C				
UNKNOWN								
	Dyspnoea							
	Ear Discomfort							
	Gastrooesophageal Reflux Disease							
	Heart Rate Increased							
	Muscle Strain							
	Myocardial Infarction							
	Syncope							

Tachycardia
Transient Ischaemic
Attack

Date:05/06/05ISR Number: 4654940-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01506
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anaemia
Other	Application Site
	Dermatitis
	Bladder Disorder
	Blood Cholesterol
	Increased
	Blood Pressure Abnormal
	Blood Pressure Increased
	Cough
	Diarrhoea
	Dizziness
	Dyspepsia
	Dysuria
	Eating Disorder

		Gastroenteritis					
		Gastroenteritis Viral					
		Gastrointestinal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertensive Heart		Ultram	C		
UNKNOWN							
		Disease		Tarka	C		
UNKNOWN							
		Hypoaesthesia		Xanax	C		
UNKNOWN							
		Hypothyroidism		Trazodone			
		Incontinence		Hydrochloride	C		
UNKNOWN							
		Infection		Evista	C		
UNKNOWN							
		Insomnia		Oxytrol	C		
UNKNOWN							
		Nerve Compression					
		Pain					
		Paraesthesia					
		Pollakiuria					
		Rash					
		Sleep Disorder					
		Thyroid Disorder					
		Vaginitis Atrophic					

Date:05/06/05ISR Number: 4654942-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00955
Age:84 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
28	DAY						
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Anger		Vioxx	SS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
28	DAY						

	Bacteriuria	Vioxx	SS	Merck & Co., Inc	ORAL
	Cataract	Vioxx	SS	Merck & Co., Inc	ORAL
	Confusional State	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion	Diabeta	C		ORAL
	Depression	Vitamins			
	Ejection Fraction	(Unspecified)	C		
UNKNOWN					
	Decreased	Travatan	C		
AURICULAR					
	Emotional Distress				
(OTIC)					
	Fear	Alphagan	C		
AURICULAR					
	Gastrointestinal				
(OTIC)					
	Haemorrhage	Tears Naturale	C		
AURICULAR					
	Glaucoma				
(OTIC)					
	Hypertension	Levobunolol			
	Injury	Hydrochloride	C		
AURICULAR					
	Tenosynovitis				
(OTIC)					
		Joint Advantage	C		
UNKNOWN					
		Cyanocobalamin And			
		Pyridoxine	C		
UNKNOWN					
		Prednisone	C		
UNKNOWN					
		Allopurinol	C		
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4654945-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654946-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01620
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Cerebrovascular Accident							

Date:05/06/05ISR Number: 4654947-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00478
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Arterial Occlusive		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Disease		Prilosec	C				
UNKNOWN								
	Blood Glucose Increased		Amitriptyline					
	Bradycardia		Hydrochloride	C				
UNKNOWN								
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Chest Pain		Pentoxifylline	C				
UNKNOWN								
	Coronary Artery Disease							
	Depression							
	Dyspnoea							
	Gastritis							
	Gastrointestinal Disorder							
	Hypotension							
	Iliac Artery Thrombosis							
	Injury							
	Myocardial Infarction							
	Neuropathy Peripheral							

Pericarditis
Peripheral Vascular
Disorder
Post-Traumatic Stress
Disorder
Pulmonary Hypertension
White Blood Cell Count
Increased

Date:05/06/05ISR Number: 4654948-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654949-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	129	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4654950-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:05/06/05ISR Number: 4654951-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04752
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654952-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04599
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654953-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04958
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654955-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654956-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654957-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04672
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Urinary Tract Infection		Aspirin	C		ORAL		
			Premarin	C				
UNKNOWN								
			Nadolol	C				
UNKNOWN								

Date:05/06/05ISR Number: 4654958-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4654959-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654960-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654961-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654972-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00245
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654973-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05082
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654990-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00262
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4654992-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00313
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		[Therapy Unspecified]	C				
UNKNOWN								
Disability								

Date:05/06/05ISR Number: 4654994-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4654995-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04754
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655262-2Report Type:Expedited (15-DaCompany Report #GB-JNJFOC-20050405882
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Tramadol Hydrochloride	PS		OROPHARINGEAL	50-100 qds.	
			Tramadol Hydrochloride	SS		OROPHARINGEAL		
			Valdecoxib	SS		OROPHARINGEAL		
			Valdecoxib	SS		OROPHARINGEAL	took for over 5 years	
			Rofecoxib	SS		OROPHARINGEAL	1-2 daily.	
			Paracetamol	C		OROPHARINGEAL	500mg-1g qds.	
			Glucosamine	C		OPHTHALMIC		
			Glucosamine	C		OPHTHALMIC		

Date:05/06/05ISR Number: 4655484-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00145
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655485-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00163
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Atenolol	SS		ORAL		
	Drug Dispensing Error		Atenolol	SS		ORAL		
	Dyspnoea		Atenolol	SS		ORAL		
	Heart Rate Decreased							
	Incorrect Dose Administered							
	Insomnia							
	Myocardial Infarction							
	Neck Pain							
	Polytraumatism							

Date:05/06/05ISR Number: 4655486-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00165
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655495-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4655496-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00178
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Body Height Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Colon Cancer		Motrin	SS		ORAL		
	Diverticulum		Feldene	SS				
UNKNOWN							1	WK
	Gastrointestinal		Oxycodone	C		ORAL		
	Haemorrhage		Calan	C		ORAL		
	Haematemesis		Verapamil	C		ORAL		
	Haematochezia							
	Thrombosis							

Date:05/06/05ISR Number: 4655497-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00164
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655499-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655500-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00232
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/06/05ISR Number: 4655501-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00229
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:05/06/05ISR Number: 4655502-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655503-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00227
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:05/06/05ISR Number: 4655509-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1058	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4655510-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Myocardial Infarction							

Date:05/06/05ISR Number: 4655511-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00230
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON
	Myocardial Infarction							

Date:05/06/05ISR Number: 4655512-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00176
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation							
	Cardiomyopathy							
	Cardiovascular Disorder							
	Cataract Subcapsular							
	Heart Rate Irregular							
	Palpitations							
	Supraventricular							
	Tachycardia							
	Tachycardia							

Date:05/06/05ISR Number: 4655513-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655514-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		691 DAY

Date:05/06/05ISR Number: 4655515-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655516-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		283 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4655517-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655518-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00216
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:05/06/05ISR Number: 4655519-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655520-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655534-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00391
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655536-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00257
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:05/06/05ISR Number: 4655537-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Cerebrovascular Accident							

Date:05/06/05ISR Number: 4655538-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4655539-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	57	MON
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL	110	DAY
	Attack							

Date:05/06/05ISR Number: 4655540-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655541-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Cerebrovascular Accident							

Date:05/06/05ISR Number: 4655542-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00396
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
	Cerebrovascular Accident							

Date:05/06/05ISR Number: 4655550-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4655564-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/06/05ISR Number: 4656564-6Report Type:Expedited (15-DaCompany Report #2005063846
Age:68 YR Gender:Unknown I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction	Foreign	Feldene (Piroxicam)	PS		ORAL	40 MG (20 MG,	
Initial or Prolonged	Duodenal Ulcer	Health					2 IN 1 D),	
	Gastric Ulcer	Professional					ORAL	
	Gastrointestinal Haemorrhage		Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG,	
							1 IN 1 D),	
							ORAL	
			Eprosartan (Eprosartan)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/06/05ISR Number: 4657099-7Report Type:Expedited (15-DaCompany Report #2005064598
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Body Height Decreased	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Initial or Prolonged	Dyspnoea		Bextra (Valdecoxib)	SS		ORAL	ORAL	
Other	Pain		Rofecoxib					
	Rash		(Rofecoxib)	SS		ORAL	ORAL	
	Transient Ischaemic Attack		Calcium (Calcium)	C				

Date:05/07/05ISR Number: 4655743-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04020
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Carotid Artery Stenosis		Ecotrin	C		ORAL		
	Cerebrovascular Accident		Glucotrol Xl	C		ORAL		
	Chest Pain		Avandia	C		ORAL		
	Coronary Artery Disease		Lipitor	C		ORAL		
	Coronary Artery Occlusion		Lipitor	C		ORAL		
	Diabetic Nephropathy		Atenolol	C		ORAL		
	Dyspnoea		Folic Acid	C		ORAL		
	Mitral Valve Incompetence		Glyburide	C		ORAL		
	Myocardial Ischaemia		Nexium	C		ORAL		
	Ventricular Dysfunction		Isosorbide					
	Ventricular Tachycardia		Mononitrate	C		ORAL		
	Viral Upper Respiratory Tract Infection							

Date:05/07/05ISR Number: 4655744-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03057
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acquired Porphyria		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blister		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655745-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02379
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Aortic Stenosis
	Arthralgia
	Brain Stem Infarction
	Carotid Artery Stenosis
	Cerebral Haemorrhage
	Cerebral Infarction
	Cerebrovascular Accident
	Constipation
	Dyspepsia
	Embolism
	Gastrooesophageal Reflux Disease
	Hyperlipidaemia
	Limb Injury
	Localised Infection
	Myalgia
	Nasal Congestion
	Neuromyopathy

	Rash Erythematous						
	Skin Laceration						
	Speech Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	710	DAY
	Traumatic Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	710	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	

Date:05/07/05ISR Number: 4655746-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01988
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Aspergillosis							
Initial or Prolonged	Back Pain							
Other	Blood Glucose Increased							
	Bronchitis							
	Cardio-Respiratory Arrest							
	Carotid Artery Disease							
	Cerebrovascular Accident							
	Chronic Obstructive							
	Pulmonary Disease							
	Compression Fracture							
	Diabetes Mellitus							
	Diabetic Neuropathy							
	Dizziness							
	Epistaxis							
	General Physical Health							
	Deterioration							
	Haematochezia							
	Haemoptysis							
	Hyperglycaemia							
	Hypotension							
	Injury Corneal							
	Leukopenia							
	Metastases To Bone							
	Metastases To Liver							
	Metastases To Lymph Nodes							
	Muscle Spasms							

Neutropenia
Pleuritic Pain
Pneumonia
Pneumonia Bacterial
Pneumonia Staphylococcal
Polytraumatism
Weight Decreased

Date:05/07/05ISR Number: 4655747-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02399
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Bundle Branch Block Right
	Cardiac Arrest
	Catheter Sepsis
	Chest Wall Pain

		Deep Vein Thrombosis					
		Electrocardiogram St Segment Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Endocarditis		Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
		Fall		Quinine Sulfate	C		
UNKNOWN							
		Gastritis		Renagel	C		
UNKNOWN							
		Gastrointestinal		Glyburide	C		
UNKNOWN							
		Haemorrhage		[Therapy Unspecified]	C		
		Mitral Valve Incompetence					
UNKNOWN							
		Myocardial Infarction		Toprol Xl Tablets	C		
UNKNOWN							
		Pulmonary Hypertension		Lamisil	C		
UNKNOWN							
		Sepsis					
		Sepsis Syndrome					
		Tricuspid Valve Incompetence					
		Ventricular Hypertrophy					

Date:05/07/05ISR Number: 4655748-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02881
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
33	MON						
Initial or Prolonged		Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
		Infarction		Biaxin	C		
UNKNOWN							
		Anger		Prilosec	C		
UNKNOWN							
		Anxiety		Nexium	C		
UNKNOWN							
		Atherosclerosis		Skelaxin	C		
UNKNOWN							
		Back Injury		Flexeril	C		ORAL
		Blood Cholesterol		Hydrocodone			

	Increased	Bitartrate	C
UNKNOWN			
	Blood Pressure Increased	Ultracet	C
UNKNOWN			
	Coronary Artery Disease	Acetaminophen And Propoxyphene Napsylate	C
	Decreased Interest		
	Depression		
UNKNOWN			
	Dizziness Postural	Folic Acid	C
UNKNOWN			
	Dyspepsia	Famvir	C
UNKNOWN			
	Ecchymosis	Vytorin	C
UNKNOWN			
	Emotional Distress		
	Fear		
	Gastrooesophageal Reflux Disease		
	Headache		
	Insomnia		
	Intervertebral Disc Protrusion		
	Ischaemic Cardiomyopathy		
	Migraine		
	Mitral Valve Incompetence		
	Platelet Aggregation Increased		
	Renal Disorder		
	Sinus Disorder		
	Social Avoidant Behaviour		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/05ISR Number: 4655749-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00116
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Aspirin	C		ORAL		
	Arterial Restenosis		Glyburide	C		ORAL		
	Arteriosclerosis		Magnesium Aspartate And Magnesium Citrate And Magnesium Glutamate And Magnesium	C				
	Cardiac Failure							
	Carotid Artery Stenosis							
	Dizziness							
	Nervous System Disorder							
	Peripheral Occlusive		Glyburide	C				
	Disease							
	Syncope							
	Transient Ischaemic Attack							

Date:05/07/05ISR Number: 4655750-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03308
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
								5 DAY
Disability	Angina Pectoris		Dyazide	C				
	Aortic Aneurysm		Lortab	C				
	Cardiac Disorder							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Atherosclerosis							
	Emotional Distress							
	Mental Status Changes							
	Pain							

Date:05/07/05ISR Number: 4655751-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02856
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		521 DAY
Initial or Prolonged	Coronary Artery Disease		Synthroid	C				UNKNOWN
Disability	Depression		Synthroid	C				UNKNOWN
Other	Fatigue		Phenobarbital	C				UNKNOWN
	Hypercholesterolaemia							
	Hypertension							
	Hypertensive Crisis							
	Myocardial Infarction							
	Retroperitoneal Haematoma							

Date:05/07/05ISR Number: 4655752-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00114
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Glyburide	C				UNKNOWN
			Furosemide	C				UNKNOWN

Amlodipine Besylate	C	UNKNOWN
Metoprolol	C	UNKNOWN
Amitriptyline Hydrochloride	C	UNKNOWN
Amitriptyline Hydrochloride	C	UNKNOWN
Fosinopril Sodium	C	UNKNOWN
Allopurinol	C	UNKNOWN
Indapamide	C	UNKNOWN
Metformin	C	UNKNOWN

Date:05/07/05ISR Number: 4655753-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01203
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		59 MON
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		14 DAY
Disability	Anhedonia		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Aspiration		Vioxx	SS	Merck & Co., Inc	ORAL		59 MON
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		14 DAY
	Bronchitis		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Chest Pain		Daypro	C				UNKNOWN
	Chest Wall Pain		Daypro	C				UNKNOWN
	Chondrosis		Flexeril	C				UNKNOWN
	Contusion		Flexeril	C				UNKNOWN
	Coronary Artery		Corticosteroids					

	Atherosclerosis		(Unspecified)	C		
UNKNOWN						
	Coronary Artery Embolism		Celebrex	C		
UNKNOWN						
	Dyspnoea		Celebrex	C		
UNKNOWN						
	Emotional Distress		Ultram	C		
UNKNOWN						
	Gastrooesophageal Reflux		Ultram	C		
UNKNOWN						
	Disease		Ultram	C		
UNKNOWN						
	Glaucoma		Ultram	C		
UNKNOWN						
	Hypercholesterolaemia		Flexeril	C		
UNKNOWN						
	Joint Sprain		Zithromax	C		
UNKNOWN						
	Lung Neoplasm		Levaquin	C		
UNKNOWN						
	Muscle Strain		Claritin-D	C		
UNKNOWN						
	Myocardial Infarction		Betoptic	C		
UNKNOWN						
	Osteoarthritis					
	Pain In Extremity					
	Rash					
	Road Traffic Accident					
	Sarcoidosis					
	Spinal Osteoarthritis					

Date:05/07/05ISR Number: 4655754-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01132
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Triglycerides		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cerebrovascular Accident		Allopurinol	C		ORAL
Other	Coronary Artery Disease		Zyrtec	C		
UNKNOWN						
	Diabetes Mellitus		Lorazepam	C		
UNKNOWN						
	Emotional Distress		Oxycocet	C		
UNKNOWN						
	Haematochezia		Tylenol	C		
UNKNOWN						
	Hypertension		Celexa	C		
UNKNOWN						
	Myocardial Infarction					
	Renal Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/05ISR Number: 4655755-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02885
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		321 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		27 DAY
	Increased		Oxycontin	C				UNKNOWN
	Coronary Artery Disease		Klonopin	C				UNKNOWN
	Depression		Isoniazid	C				UNKNOWN
	Diverticulum Intestinal		Pyridoxine	C				UNKNOWN
	Erectile Dysfunction		Effexor	C				UNKNOWN
	Gastric Disorder							
	Hypertension							
	Memory Impairment							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain In Extremity							
	Pulmonary Valve Incompetence							
	Tricuspid Valve Incompetence							

Date:05/07/05ISR Number: 4655756-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02323
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiomegaly		Glipizide	C				UNKNOWN
	Coronary Artery		Insulin	C				UNKNOWN
	Restenosis		Cozaar	C				UNKNOWN

	Dehydration	Norvasc	C
UNKNOWN			
	Ejection Fraction	Atenolol	C
UNKNOWN			
	Decreased	Niacin	C
UNKNOWN			
	Pleural Effusion	Lipitor	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			
		Plavix	C
UNKNOWN			

Date:05/07/05ISR Number: 4655757-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Back Pain
Hospitalization - Initial or Prolonged	Bronchitis
Disability	Cardiomegaly
Other	Chronic Obstructive Pulmonary Disease
	Convulsion
	Drug Interaction
	Emphysema
	Facial Bones Fracture
	Gastrooesophageal Reflux Disease
	Hepatitis C
	Hiatus Hernia
	Hypercholesterolaemia
	Intervertebral Disc Protrusion

		Muscle Spasms					
		Musculoskeletal Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Overdose		Neurontin	C		ORAL
		Peptic Ulcer		Wellbutrin	C		
UNKNOWN							
		Radiculopathy		Bextra	C		
UNKNOWN							
		Road Traffic Accident					

Date:05/07/05ISR Number: 4655758-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00715
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event
	Anaemia
	Angina Pectoris
	Chest Discomfort
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Diarrhoea
	Drug Ineffective
	Dysphagia
	Fibromyalgia
	Gastritis
	Gastrooesophageal Reflux Disease
	Haemorrhoids
	Hypertension
	Hypoaesthesia
	Hypoalbuminaemia
	Infectious Mononucleosis
	Intervertebral Disc Degeneration
	Left Ventricular End-Diastolic Pressure Increased
	Liver Disorder
	Lymphadenopathy
	Memory Impairment

Migraine
Mitral Valve Incompetence
Multi-Organ Disorder
Muscle Spasms
Night Sweats
Normochromic Normocytic
Anaemia
Pain
Pancreatitis
Platelet Count Decreased
Pneumonia
Pulmonary Oedema
Pyoderma Gangrenosum
Pyrexia
Renal Failure
Renal Tubular Necrosis
Respiratory Disorder
Respiratory Failure

Vasculitis
Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Serzone	C			UNKNOWN	
	Fiorinal	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Zanaflex	C			UNKNOWN	
	Depoestradiol	C			UNKNOWN	
	Ecotrin	C			UNKNOWN	
	Colace	C			UNKNOWN	
	Cardizem	C			UNKNOWN	
	Serzone	C			UNKNOWN	
	Neurontin	C			UNKNOWN	
	Elavil	C			UNKNOWN	
	Ativan	C			UNKNOWN	
	Aggrenox	C			UNKNOWN	
	Deptran (Doxepin Hydrochloride)	C			UNKNOWN	
	Estrace	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	

Date:05/07/05ISR Number: 4655759-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655760-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02843
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	215 DAY	
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY	
	Retinal Vascular		Vioxx	SS	Merck & Co., Inc	ORAL	227 DAY	
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	215 DAY	
	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	227 DAY	
			Aspirin	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Bextra	C			UNKNOWN	2 WK
			Acyclovir	C			UNKNOWN	

Date:05/07/05ISR Number: 4655761-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0504ESP00043
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diplopia							

Date:05/07/05ISR Number: 4655762-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00041
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		295 DAY
Initial or Prolonged Disability	Cerebral Infarction		Estradiol And Norethindrone Acetate	C				UNKNOWN

Date:05/07/05ISR Number: 4655763-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Infarction		Beclomethasone Dipropionate	C				RESPIRATORY
	Anhedonia							(INHALATION)
	Anxiety							
	Aortic Valve Incompetence		Verapamil Hydrochloride	C				UNKNOWN
	Blood Pressure Decreased							729 DAY
	Coronary Artery Occlusion		[Therapy Unspecified]	C				UNKNOWN
	Dizziness							382 DAY
	Drug Ineffective		Griseofulvin	C				UNKNOWN
	Emotional Distress							25 DAY
	Fatigue							
	Hyperkeratosis							
	Hyperlipidaemia							
	Injury							
	Pain							
	Pelvic Haematoma							
	Stress							
	Tinea Infection							

Date:05/07/05ISR Number: 4655764-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02659
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL		1071 MON
Initial or Prolonged	Gastrooesophageal Reflux		Altace	C				UNKNOWN
Disability	Disease		Altace	C				UNKNOWN
Other	Myocardial Infarction		Glucophage	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Verapamil Msd Lp	C				UNKNOWN
			Verapamil Msd Lp	C				UNKNOWN
			Hydrochlorothiazide Tablets (Usp 23)	C				UNKNOWN
			Hydrochlorothiazide Tablets (Usp 23)	C				UNKNOWN
			K-Dur	C				UNKNOWN
			K-Dur	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Nexium	C				UNKNOWN
			Nexium	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Plavix	C				UNKNOWN
			Plavix	C				UNKNOWN
			Norvasc	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/05ISR Number: 4655765-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02334
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Infarction		Reglan	C				
Initial or Prolonged	Cardiac Valve Disease		Procardia Xl	C				
Other	Cardio-Respiratory Arrest		Procardia Xl	C				
	Eye Haemorrhage		Tegretol	C				
	General Physical Health		Ultram	C				
	Deterioration		Zantac	C				
	Loss Of Consciousness		Lasix (Furosemide)	C				
	Myocardial Ischaemia		Lasix (Furosemide)	C				
	Oedema		Lipitor	C				
	Rhinorrhoea		Elavil	C		ORAL		
	Tachyarrhythmia		Paxil	C				
	Ventricular Fibrillation		Tums	C				

Date:05/07/05ISR Number: 4655766-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04611
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655767-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02988
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Bronchitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Cerebrovascular Accident		Prednisone	C		
Other	Chest Pain		Naproxen	C		
UNKNOWN						
	Dandruff		Ultram	C		
UNKNOWN						
	Dehydration		Flexeril	C		
UNKNOWN						
	Depression		Plaquenil	C		
UNKNOWN						
	Migraine		Acetaminophen And			
	Otitis Externa		Codeine	C		
UNKNOWN						
	Photophobia					
	Pleurisy					
	Pneumonia					
	Post-Traumatic Stress Disorder					

Date:05/07/05ISR Number: 4655768-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/07/05ISR Number: 4655769-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02424
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Loss Of Control Of Legs		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN	Myocardial Infarction		Lasix (Furosemide)	C		
Disability			Zocor	C		
UNKNOWN						
Other			Accupril	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						

Imdur C
UNKNOWN

Date:05/07/05ISR Number: 4655770-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655772-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04653
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655773-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655775-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04463
Age:83 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
Disability	Bereavement Reaction
Other	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Carotid Bruit
	Chest Discomfort
	Coronary Artery Disease
	Hypertension
	Hypoaesthesia
	Hypoaesthesia Teeth
	Ischaemic Cardiomyopathy
	Joint Dislocation
	Lacunar Infarction
	Lymphadenopathy

		Nasal Sinus Drainage Oedema Peripheral Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL
				Coreg	C		
UNKNOWN							
				Flomax (Morniflumate)	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Imdur	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:05/07/05ISR Number: 4655776-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04669
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:05/07/05ISR Number: 4655777-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04655
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Transient Ischaemic Attack Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/07/05ISR Number: 4655778-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655779-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655780-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04678
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aciphex	C		ORAL		

Date:05/07/05ISR Number: 4655781-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00001
Age:43 YR Gender:Female I/FU:I

Outcome	PT
Death	Back Pain Cardio-Respiratory Arrest Chest Pain

	Dyspnoea Headache Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL	863	DAY

Date:05/07/05ISR Number: 4655782-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04793
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:05/07/05ISR Number: 4655783-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:05/07/05ISR Number: 4655784-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:05/07/05ISR Number: 4655785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655786-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00107
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:05/07/05ISR Number: 4655787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Hypertension							
	Mitral Valve Prolapse							
	Multi-Organ Disorder							
	Pain							

Date:05/07/05ISR Number: 4655788-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00123
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Heart Injury

	Myocardial Infarction						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:05/07/05ISR Number: 4655789-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	860	DAY

Date:05/07/05ISR Number: 4655791-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00141
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655792-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00142
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655793-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04791
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	38	MON

Date:05/07/05ISR Number: 4655794-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04790
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655795-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00007
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Irregular		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:05/07/05ISR Number: 4655796-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/07/05ISR Number: 4655797-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655799-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655800-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655801-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/07/05ISR Number: 4655802-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00106
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656350-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA02027
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	100 DAY	
Other	Aphasia		Vioxx	SS	Merck & Co., Inc	ORAL	50 DAY	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	50 DAY	
	Drug Administration Error		Vioxx	SS	Merck & Co., Inc	ORAL	100 DAY	
	Emotional Distress		Premarin	C			UNKNOWN	
	Hypoaesthesia		Progesterone	C			UNKNOWN	
	Injury		Motrin	C			UNKNOWN	
	Optic Atrophy							
	Optic Ischaemic							
	Neuropathy							
	Optic Neuritis							
	Spondylitis							
	Urinary Tract Infection							

Date:05/09/05ISR Number: 4656351-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02069
Age:62 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON	
Azotaemia		Accupril	SS			UNKNOWN	
Cardiac Failure		Accupril	SS			UNKNOWN	
Congestive		Accupril	SS			UNKNOWN	
Cholecystitis		Accupril	SS			UNKNOWN	
Cholelithiasis		Accupril	SS			UNKNOWN	
Chronic Obstructive		Levaquin	SS			UNKNOWN	
Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	7 MON	
Condition Aggravated		Protonix	C			UNKNOWN	
Cystitis		Protonix	C			UNKNOWN	
Diplopia		Protonix	C			UNKNOWN	
Dizziness		Protonix	C			UNKNOWN	
Dyspnoea		Protonix	C			UNKNOWN	
Emotional Distress							
Femur Fracture							
Gastritis							
Gastrooesophageal Reflux Disease							
Glomerulonephritis							
Hydronephrosis							
Injury							
Liver Function Test Abnormal							
Lobar Pneumonia							
Metabolic Acidosis							
Myocardial Infarction							
Nephritis Interstitial							
Nephrolithiasis							
Oedema Peripheral							
Pancreatitis							

Platelet Count Increased
Pneumonia
Pyelonephritis Acute
Renal Failure Acute
Urinary Tract Infection
White Blood Cell Count
Increased

Date:05/09/05ISR Number: 4656354-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00751
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Aortic Atherosclerosis
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Blood Cholesterol Increased
	Blood Glucose Increased
	Cardiac Flutter
	Cardiac Murmur
	Carpal Tunnel Syndrome
	Chest Discomfort
	Coronary Artery Disease
	Cough

		Electrocardiogram T Wave Abnormal					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Gallop Rhythm Present		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Ceftin	C		ORAL
		Hypertension		Percocet	C		ORAL
		Hypertensive Heart		Vicodin Es Tablets	C		ORAL
		Disease		Ambien	C		ORAL
		Incision Site		Zoloft	C		ORAL
		Complication		Zoloft	C		ORAL
		Insomnia					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse					
		Mitral Valve Sclerosis					
		Myocardial Ischaemia					
		Nasal Turbinate					
		Hypertrophy					
		Oxygen Saturation					
		Decreased					
		Pharyngolaryngeal Pain					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Stomach Discomfort					
		Thrombosis					
		Trigger Finger					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					
		Viral Infection					

Date:05/09/05ISR Number: 4656375-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00074
Age:50 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR						
		Cardiac Valve Disease		Celebrex	C		
UNKNOWN							

	Coronary Artery Disease	Celebrex	C
UNKNOWN			
	Emotional Distress		
	Heart Rate Irregular		
	Myocardial Infarction		
	Oedema Peripheral		

Date:05/09/05ISR Number: 4656379-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Acute Myocardial Infarction
	Arthralgia
	Blood Glucose Increased
	Blood Triglycerides Increased
	Bronchitis
	Cardiac Failure

		Congestive Cardiac Valve Disease					
		Chest Pain					
		Confusional State	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coordination Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Valium	SS		
UNKNOWN							
		Coronary Artery		Claritin	C		
UNKNOWN							
		Reocclusion		Hyzaar	C		
UNKNOWN							
		Depressed Level Of		Hyzaar	C		
UNKNOWN							
		Consciousness		Ascriptin	C		ORAL
		Dilatation Atrial		Atenolol	C		ORAL
		Dysarthria		Lortab	C		ORAL
		Dyspnoea		Nexium	C		
UNKNOWN							
		Fall		Zocor	C		ORAL
		Fibromyalgia		Altace	C		ORAL
		Generalised Oedema		Interferon			
		Hepatic Steatosis		(Unspecified)	C		
UNKNOWN							
		Hepatitis C		Phenergan			
		Hepatosplenomegaly		(Promethazine			
		Hypertension		Hydrochloride)	C		
UNKNOWN							
		Hypokalaemia		Oxycontin	C		
UNKNOWN							
		Hypoxia		Percocet	C		
UNKNOWN							
		Insomnia					
		Intervertebral Disc Displacement					
		Intervertebral Disc Protrusion					
		Joint Injury					
		Joint Range Of Motion Decreased					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Oedema Peripheral					
		Pulmonary Hypertension					
		Sinus Bradycardia					
		Somnolence					
		Synovitis					

Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Weight Increased

Date:05/09/05ISR Number: 4656380-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthropathy
	Asthenia
	Barrett'S Oesophagus
	Bifascicular Block
	Colon Adenoma
	Congestive Cardiomyopathy
	Coronary Artery Disease
	Dyspnoea
	Gastrointestinal
	Haemorrhage
	Headache
	Hypertension
	Influenza Like Illness
	Jaw Fracture

		Left Ventricular Failure					
		Mitral Valve Incompetence					
		Muscle Strain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Failure Chronic		Vioxx	SS	Merck & Co., Inc	ORAL
		Rib Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Tooth Abscess		Vioxx	SS	Merck & Co., Inc	ORAL
		Tooth Loss		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Vital Capacity Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:05/09/05ISR Number: 4656381-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01159
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
40 MON						
Initial or Prolonged	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anxiety Disorder		Actos	C		ORAL
	Arthropathy		Tricor	C		ORAL
	Cardiac Flutter		Glucovance	C		ORAL
	Cardiomegaly					
	Coronary Artery Disease					
	Coronary Artery Occlusion					
	Coronary Artery Stenosis					
	Emotional Distress					
	Hyperhomocysteinaemia					
	Insomnia					
	Joint Swelling					
	Myocardial Infarction					
	Oedema Peripheral					
	Pain					
	Periarthritis					
	Pulmonary Congestion					
	Stress At Work					

Date:05/09/05ISR Number: 4656383-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02331
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		[Therapy			
	Coronary Artery Disease		Unspecified]	C		
UNKNOWN						
	Depression					
	Herpes Zoster					
	Myocardial Infarction					
	Nausea					

Date:05/09/05ISR Number: 4656384-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03473
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardiac Disorder
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Death

		Depression					
		Emotional Distress					
		Leg Amputation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Poor Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Circulation		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR						
				Atenolol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Prinivil	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:05/09/05ISR Number: 4656386-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04098
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Hip Fracture		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Myocardial Infarction		Naprosyn	C		
UNKNOWN						
Initial or Prolonged			Plavix	C		
UNKNOWN						
Disability			Tiazac	C		ORAL
Other			Protonix	C		
UNKNOWN						

Date:05/09/05ISR Number: 4656387-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00101
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		108 DAY
Hospitalization - Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		108 DAY
	Anaemia		Hydrochlorothiazide	C				UNKNOWN
	Arrhythmia		Plavix	C				UNKNOWN
	Cardiac Failure		Codeine	C				UNKNOWN
	Congestive		Naproxen	C				UNKNOWN
	Cerebrovascular Accident		Detrol	C				UNKNOWN
	Coronary Artery		Meclizine	C				UNKNOWN
	Atherosclerosis		Phenazopyridine Hydrochloride	C				UNKNOWN
	Coronary Artery Disease		Diltiazem Malate	C				UNKNOWN
	Cystitis							
	Decubitus Ulcer							
	Dementia Alzheimer'S Type							
	Duodenal Ulcer							
	Ecchymosis							
	Headache							
	Myocardial Infarction							
	Oedema Peripheral							
	Pneumonia							
	Transient Ischaemic Attack							
	Ventricular Tachycardia							

Date:05/09/05ISR Number: 4656388-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02662
Age:66 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Anaphylactic Shock		Vioxx	PS	Merck & Co., Inc	ORAL		
Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Blood Thyroid Stimulating		Vioxx	SS	Merck & Co., Inc	ORAL	2	DAY
Hormone Abnormal		Neurontin	C			UNKNOWN	
Cerebrovascular Accident		Synthroid	C			UNKNOWN	
Dysphagia		Hydrodiuril	C		ORAL		
Fall		Arava	C			UNKNOWN	
Gait Disturbance		Methotrexate	C			UNKNOWN	
Headache		Premarin	C			UNKNOWN	
Hypertension							
Hypoaesthesia							
Hypoxia							
Liver Function Test Abnormal							
Loss Of Consciousness							
Multiple Sclerosis							
Myocardial Infarction							
Pain In Extremity							
Pleural Effusion							
Pneumonia							
Renal Disorder							
Syncope							
Transient Ischaemic Attack							
Visual Disturbance							

Date:05/09/05ISR Number: 4656391-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03474
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Initial or Prolonged	Heart Rate Increased	Lupron	C
UNKNOWN			
	Hypersensitivity	Doxazosin Mesylate	C
UNKNOWN			
	Mediastinal Disorder	Casodex	C
UNKNOWN			
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Prostate Cancer		
	Metastatic		
	Pulmonary Embolism		
	Pulmonary Valve Incompetence		
	Syncope Vasovagal		
	Thrombosis		
	Tricuspid Valve Incompetence		

Date:05/09/05ISR Number: 4656392-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04743
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/05ISR Number: 4656395-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest Cardiovascular Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656396-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656397-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:05/09/05ISR Number: 4656398-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04654
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656399-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04682
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Asthenia Cataract

Cerebrovascular Accident
Crying
Diarrhoea
Difficulty In Walking
Drooling
Eating Disorder
Fatigue
Gastroenteritis Viral
Hypertension
Insomnia
Major Depression
Migraine
Nausea
Panic Disorder
Photopsia
Pruritus
Pseudoexfoliation Of Lens
Capsule
Speech Disorder
Stress
Suicidal Ideation
Transient Ischaemic
Attack
Urticaria

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	49	MON
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	49	MON
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Premarin	C			UNKNOWN	
	Prilosec	C			UNKNOWN	
	Tylenol	C		ORAL		
	Calcium (Unspecified) And Vitamin D (Unspecified)	C		ORAL		
	Ascorbic Acid	C		ORAL		
	Vitamin E	C		ORAL		

Date:05/09/05ISR Number: 4656400-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04670
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastric Ulcer		Aspirin	SS			UNKNOWN	

Date:05/09/05ISR Number: 4656401-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	469	DAY

Date:05/09/05ISR Number: 4656430-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656431-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00167
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/09/05ISR Number: 4656432-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00006
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin And Magnesium Oxide	C			UNKNOWN	
			Amlodipine Besylate	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/05ISR Number: 4656433-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656434-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00170
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656435-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656436-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656438-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00243
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656440-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris Chest Pain Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656441-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00004
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 392 DAY	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Hydrochlorothiazide And Losartan Potassium	C		ORAL		

Date:05/09/05ISR Number: 4656442-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00168
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656443-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
	Death							
Other								

Date:05/09/05ISR Number: 4656444-6Report Type:Expedited (15-DaCompany Report #AT-MERCK-0505AUT00001
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Stem Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	945	DAY
	Dysphagia							
Disability	Paresis							

Date:05/09/05ISR Number: 4656445-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656460-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656513-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04728
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656514-2Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505USA00274
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	195 DAY	
	Chest Pain							

Date:05/09/05ISR Number: 4656964-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acquired Oesophageal Web
Hospitalization -	Anaemia
Initial or Prolonged	Anaemia Vitamin B12
Other	Deficiency
	Angina Pectoris
	Angina Unstable
	Anxiety
	Arteriovenous
	Malformation
	Bile Duct Stone

Blood Culture Positive
Cardiac Failure
Congestive
Cardiomegaly
Chest Pain
Choledochal Cyst
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coagulopathy
Constipation
Coronary Artery Disease
Depression
Diabetes Mellitus
Inadequate Control
Diarrhoea
Diverticulum
Dyspepsia
Dysphagia
Dyspnoea
Emotional Distress
Endocarditis Bacterial
Enterobacter Bacteraemia
Enterococcal Bacteraemia
Epigastric Discomfort
Fall
Femur Fracture
Fluid Retention
Gastric Disorder
Gastric Haemorrhage
Gastritis
Gastritis Haemorrhagic
Gastrointestinal
Arteriovenous
Malformation
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Glaucoma
Haematochezia
Hepatic Failure
Hypercholesterolaemia
Hyperkalaemia
Influenza Like Illness
Iron Deficiency Anaemia
Ischaemic Cardiomyopathy

Ischaemic Hepatitis
Joint Swelling
Malaise
Mental Status Changes
Myocardial Infarction
Nasopharyngitis
Nausea
Oedema Peripheral
Osteoarthritis
Pancreatitis
Pleural Effusion
Pneumonia
Pneumonitis
Pulmonary Hypertension

		Pulmonary Oedema					
		Renal Failure Acute					
		Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Staphylococcal Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Syncope		Vioxx	SS	Merck & Co., Inc	ORAL
		Thrombotic Stroke		Coumadin	SS		
UNKNOWN							
		Troponin Increased		Lipitor	SS		ORAL
		Urinary Tract Infection		Lipitor	SS		ORAL
		Enterococcal		Prednisone	SS		
UNKNOWN							
		Vomiting		Infliximab	SS		
UNKNOWN							
		Weight Decreased		Prinivil	SS		ORAL
				Methotrexate	SS		ORAL
				Methotrexate	SS		
UNKNOWN							

Date:05/09/05ISR Number: 4656973-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00401
Age:70 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
190 DAY							
Initial or Prolonged		Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Tagamet	C		
UNKNOWN							
		Carbon Dioxide Decreased		Zantac	C		ORAL
		Chest Pain					
		Condition Aggravated					
		Coronary Artery Stenosis					
		Coronary Artery					
		Thrombosis					
		Dyspnoea					
		Foot Deformity					
		Heart Rate Increased					
		Hydrocele					
		Hypokinesia					
		International Normalised					
		Ratio Increased					
		Mitral Valve Incompetence					
		Myocardial Infarction					

Oedema Peripheral
Osteoarthritis
Prothrombin Time
Prolonged
Sleep Apnoea Syndrome
Spinal Column Stenosis
Stent Occlusion
Tachycardia
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
White Blood Cell Count
Increased

Date:05/09/05ISR Number: 4656974-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00783
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Postoperative
Disability	Aseptic Necrosis Bone
Other	Atelectasis
	Atrial Fibrillation

		Benign Prostatic Hyperplasia					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Percocet	C		
UNKNOWN							
		Diabetes Mellitus		Vicodin Tablets	C		
UNKNOWN							
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Muscle Spasms					
		Myocardial Infarction					
		Osteoarthritis					
		Postoperative					
		Constipation					
		Radiculopathy					
		Sciatica					
		Staphylococcal Infection					
		Urinary Retention					

Date:05/09/05ISR Number: 4656975-9Report Type:Expedited (15-DaCompany Report #US-MERCK-01104511
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Sinusitis
	Anaemia
	Angiopathy
	Angle Closure Glaucoma
	Aortic Valve Incompetence
	Aortic Valve Sclerosis
	Arthralgia
	Asthenia
	Atrial Pressure Increased
	Azotaemia
	Blood Calcium Decreased
	Calcinosis
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cardiovascular Disorder
	Catheter Related
	Infection

Cholelithiasis
Dehydration
Dyspnoea
Ejection Fraction
Decreased
Faeces Discoloured
Fatigue
Flatulence
Gallbladder Disorder
Glomerulonephritis
Haemodialysis
Headache
Hypertension
Hypertensive Nephropathy
Hypokalaemia
Hypomagnesaemia
Incision Site
Complication

	Injury					
	Joint Swelling					
	Jugular Vein Distension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Lymphadenopathy		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY					
	Malaise		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY					
	Mitral Valve		Vioxx	SS	Merck & Co., Inc	ORAL
	Calcification		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY					
	Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY					
	Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Tiazac	C		
UNKNOWN						
	Nephrolithiasis		Advil	C		
UNKNOWN						
	Nephropathy Toxic					
	Oedema					
	Oedema Peripheral					
	Osteoarthritis					
	Pain In Extremity					
	Pharyngolaryngeal Pain					
	Renal Artery					
	Atherosclerosis					
	Renal Artery Stenosis					
	Renal Failure Chronic					
	Renal Tubular Disorder					
	Tricuspid Valve					
	Incompetence					
	Ventricular Dysfunction					
	Ventricular Hypertrophy					
	Weight Decreased					
	Wound Infection					
	Staphylococcal					

Date:05/09/05ISR Number: 4656976-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Ageusia
Initial or Prolonged	Anosmia
Disability	Arthropathy
Other	Cardiomegaly

Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Colon Adenoma
Decreased Appetite
Deep Vein Thrombosis
Emotional Distress
Essential Hypertension
Faecal Incontinence
Fatigue
Fibromyalgia
Haemangioma
Haematochezia
Hypercoagulation
Hypertension
Lumbar Spinal Stenosis
Macular Degeneration
Meniscus Lesion
Nausea
Nephrolithiasis
Osteopenia
Osteoporosis

		Pancreatitis					
		Pulmonary Embolism					
		Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Disorder		Atenolol	C		
UNKNOWN							
		Thrombophlebitis		Aspirin	C		
UNKNOWN							
		Urinary Incontinence		Zoloft	C		
UNKNOWN							
		Weight Decreased		Lipitor	C		
UNKNOWN							
		Weight Increased		Niaspan	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Acetaminophen	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Herbs (Unspecified)	C		
UNKNOWN							

Date:05/09/05ISR Number: 4656985-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Angina Pectoris
	Anxiety
	Aortic Stenosis
	Appetite Disorder
	Arterial Occlusive Disease
	Arthralgia
	Atherosclerosis
	Atrioventricular Block First Degree
	Blood Pressure Decreased
	Cardiac Disorder
	Cardiac Murmur
	Carotid Artery Atheroma
	Carotid Bruit
	Chest Discomfort

Chest Pain
Coronary Artery Disease
Coronary Artery Stenosis
Depression
Dizziness
Dyspepsia
Dyspnoea
Electrocardiogram T Wave
Abnormal
Fatigue
Femoral Arterial Stenosis
Femoral Bruit
Gastric Disorder
Gastrooesophageal Reflux
Disease
Haematoma
Headache
Heart Rate Increased
Hypertension
Iliac Artery Stenosis
Injury
Insomnia
Intermittent Claudication
Liver Function Test
Abnormal

	Mitral Valve Stenosis Myocardial Infarction Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	112 DAY
	Peripheral Vascular Disorder		Propranolol Hydrochloride	C			UNKNOWN
	Rectal Haemorrhage		Darvocet-N	C			UNKNOWN
	Soft Tissue Haemorrhage Thrombosis Weight Fluctuation						

Date:05/09/05ISR Number: 4656993-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02332
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Pressure Inadequately Controlled Coronary Artery Disease Coronary Artery Stenosis Depression Dizziness Dyspnoea Ejection Fraction Decreased Electrocardiogram T Wave Inversion Hydronephrosis Hypercholesterolaemia Muscle Spasms Myocardial Infarction Myocardial Ischaemia Oedema Peripheral Refusal Of Treatment By Patient Rotator Cuff Syndrome Stress Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/09/05ISR Number: 4656994-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00585
Age:37 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4656996-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00558
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		967 DAY
Other	Congestive Cardio-Respiratory Arrest Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/05ISR Number: 4656997-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C				UNKNOWN
	Anxiety		Norvasc	C				UNKNOWN
	Blood Glucose Increased		Zestril	C				UNKNOWN
	Coronary Artery Disease							
	Coronary Artery Restenosis							
	Coronary Ostial Stenosis							
	High Density Lipoprotein Decreased							
	Hypertension							
	Hypoaesthesia							
	Sinus Bradycardia							
	Stent Occlusion							
	Swelling							

Date:05/09/05ISR Number: 4656998-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00001
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		863 DAY
	Hypertension							
	Myocardial Infarction							
	Renal Arteriosclerosis							

Date:05/09/05ISR Number: 4656999-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00383
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion							

Hypoaesthesia
Myocardial Ischaemia
Pain In Extremity
Somnolence

Date:05/09/05ISR Number: 4657000-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/09/05ISR Number: 4657008-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00002
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 12 DAY	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dyspnoea		Acetaminophen And Codeine Phosphate	SS				
UNKNOWN	Muscle Spasms						1	DAY
UNKNOWN	Myalgia		Piroxicam Betadex	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/05ISR Number: 4657034-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00646
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		819 DAY
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		819 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Lipitor	C		ORAL		
	Chest Pain		Plavix	C		ORAL		
	Coronary Artery Disease		Lopressor	C		ORAL		
	Dyspnoea		Vasotec	C		ORAL		
	Erectile Dysfunction		Aspirin	C		ORAL		
	Gastric Ulcer							
	Hyperhidrosis							
	Hypertension							
	Insomnia							
	Mitral Valve Incompetence							
	Mixed Hyperlipidaemia							
	Myocardial Ischaemia							

Date:05/09/05ISR Number: 4657036-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
	Myocardial Infarction							

Date:05/09/05ISR Number: 4658391-2Report Type:Expedited (15-DaCompany Report #2005066770
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG,	
Initial or Prolonged	Dyspepsia						1 IN 1 D),	

Other		Flatulence					
ORAL							
		Gastric Disorder		Celebrex (Celecoxib)	SS		ORAL
ORAL							
		Meniscus Lesion		Nifedipine			
		Retching		(Nifedipine)	SS		ORAL
60 MG, ORAL							
		Stomach Discomfort		Lipitor			
				(Atorvastatin)	SS		ORAL
10 MG, ORAL							
				Rofecoxib			
				(Rofecoxib)	SS		

Date:05/09/05ISR Number: 4658405-XReport Type:Expedited (15-DaCompany Report #2005068169
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident	Consumer	Bextra (Valdecoxib)	PS		
		Emotional Distress		Rofecoxib			
		Injury		(Rofecoxib)	SS		
		Pain					

Date:05/09/05ISR Number: 4658414-0Report Type:Expedited (15-DaCompany Report #2005065948
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident	Consumer	Celebrex (Celecoxib)	PS		
				Refecoxib			

(Rofecoxib) SS

Date:05/09/05ISR Number: 4658433-4Report Type:Expedited (15-DaCompany Report #2005066604
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Crohn'S Disease	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:05/09/05ISR Number: 4658565-0Report Type:Expedited (15-DaCompany Report #2005060545
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Drug Ineffective		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	
	Nasopharyngitis							
	Stress							
			Rofecoxib (Rofecoxib)	SS				
			Levothyroxine Sodium (Levothyroxine Sodium)	C				
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C				

Date:05/09/05ISR Number: 4658880-0Report Type:Expedited (15-DaCompany Report #WAES 00064210
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer	Study	Tab 0966-Blinded					
	Melaena	Health	Therapy	PS		ORAL	DAILY/PO	

		Professional	Tab Blinded Therapy	SS			ORAL
BID/PO							
			Aricept	C			
			Vitamin E	C			
			Vitamins	C			

Date:05/09/05ISR Number: 4658884-8Report Type:Expedited (15-DaCompany Report #WAES 01071534
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain	Study	Vioxx	PS		ORAL	25	
	Gastritis Erosive	Health					MG/DAILY/PO	
	Haematochezia	Professional	Placebo	SS		ORAL	PO	

Date:05/09/05ISR Number: 4658888-5Report Type:Expedited (15-DaCompany Report #WAES 00111635
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anal Haemorrhage	Study	Vioxx	PS		ORAL	25 MG/DAILY/	
Hospitalization -	Flatulence	Health					PO	
Initial or Prolonged	Haematocrit Decreased	Professional	Placebo					
	Haemoglobin Decreased	Other	(Unspecified)	SS		ORAL	PO	
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/09/05ISR Number: 4658890-3Report Type:Expedited (15-DaCompany Report #WAES 00101457
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Study	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
	Blood Creatinine Increased	Health Professional	Placebo (Unspecified)	C				
	Duodenal Ulcer							
	Faecal Occult Blood							

Date:05/10/05ISR Number: 4657436-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04750
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657497-1Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050104205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Ultracet	PS				
			Vioxx	SS				

Date:05/10/05ISR Number: 4657798-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Aggression
Other	Anger
	Anorexia
	Anxiety
	Appendicitis
	Arthralgia
	Bone Disorder

Bursitis
Cardiac Disorder
Carpal Tunnel Syndrome
Cellulitis
Chest Pain
Constipation
Depression
Diarrhoea
Difficulty In Walking
Discomfort
Dysstasia
Fatigue
Groin Pain
Heart Injury
Heart Rate Irregular
Hypervigilance
Hypoaesthesia
Hypoglycaemia
Inguinal Hernia
Injury
Irritability
Joint Dislocation
Joint Swelling

		Knee Operation					
		Mobility Decreased					
		Mood Swings	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Atrophy		Vioxx	PS	Merck & Co., Inc	ORAL
29	DAY						
		Musculoskeletal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
29	DAY						
		Nightmare		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Onychomycosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis		Lithium Carbonate	C		
UNKNOWN							
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Paranoia					
		Pharyngolaryngeal Pain					
		Post Procedural					
		Complication					
		Post-Traumatic Stress					
		Disorder					
		Pyrexia					
		Rash					
		Rotator Cuff Syndrome					
		Sacroiliitis					
		Sensory Disturbance					
		Sputum Abnormal					
		Squamous Cell Carcinoma					
		Stomach Discomfort					
		Suicidal Ideation					
		Vomiting					

Date:05/10/05ISR Number: 4657805-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01301
Age:42 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adrenal Insufficiency
	Angina Unstable
	Anxiety
	Asthenia
	Bronchitis

Cardiomegaly
Catheter Site Haematoma
Cellulitis
Contusion
Coronary Artery Disease
Coronary Artery Stenosis
Costochondritis
Diarrhoea
Diastolic Dysfunction
Drug Withdrawal Syndrome
Dysphagia
Dyspnoea
Facial Palsy
Gastrooesophageal Reflux
Disease
Haemarthrosis
Headache
Hyperparathyroidism
Hypothyroidism
Increased Tendency To
Bruise

		Intervertebral Disc Protrusion					
		Intestinal Functional Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Libido Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Chest Pain		Ultram	C		
UNKNOWN							
				Levaquin	C		
UNKNOWN							
		Myocardial Infarction		Sudal	C		
UNKNOWN							
		Neck Injury		Zantac	C		
UNKNOWN							
		Neuralgia		Aspirin	C		
UNKNOWN							
		Oedema		Synthroid	C		
UNKNOWN							
		Oedema Peripheral		Celebrex	C		
UNKNOWN							
		Pain					
		Panic Attack					
		Pneumonia					
		Raynaud'S Phenomenon					
		Road Traffic Accident					
		Spinal Osteoarthritis					
		Weight Increased					

Date:05/10/05ISR Number: 4657806-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01451
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
1	DAY						
Initial or Prolonged		Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Blood Pressure Increased					
		Bronchitis					
		Chest Pain					
		Diarrhoea					
		Drug Hypersensitivity					
		Emotional Distress					
		Erosive Oesophagitis					
		Fear					

Gastritis Erosive
Gastrointestinal Motility
Disorder
Gastrooesophageal Reflux
Disease
Hepatic Cyst
Hiatus Hernia
High Density Lipoprotein
Decreased
Hypersensitivity
Joint Sprain
Metal Poisoning
Mineral Metabolism
Disorder
Myocardial Infarction
Panic Attack
Polycythaemia
Tachycardia
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4657808-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04403
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Convulsion							
Initial or Prolonged	Dizziness							
Disability	Loss Of Consciousness							
	Migraine							
	Tremor							

Date:05/10/05ISR Number: 4657809-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01132
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Triglycerides		Allopurinol	C		ORAL		
Other	Increased		Zyrtec	C				
UNKNOWN								
	Cardiac Disorder		Lorazepam	C				
UNKNOWN								
	Cerebrovascular Accident		Oxycocet	C				
UNKNOWN								
	Chest Pain		Tylenol	C				
UNKNOWN								
	Coronary Artery Disease		Celexa	C				
UNKNOWN								
	Diabetes Mellitus							
	Dizziness							
	Emotional Distress							
	Haematochezia							
	Hypertension							
	Myocardial Infarction							
	Renal Disorder							
	Weight Decreased							

Date:05/10/05ISR Number: 4657810-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00017
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Atorvastatin Calcium	SS				
UNKNOWN							3	MON
	Ascites		Ibuprofen	C				
UNKNOWN								
	Chromaturia		Acetaminophen	C				
UNKNOWN								
	Coagulopathy							
	Cognitive Disorder							
	Fatigue							
	Hepatic Failure							
	Hepatitis							
	Jaundice							
	Muscle Atrophy							
	Nausea							
	Pruritus							
	Renal Failure							
	Sleep Disorder							
	Varices Oesophageal							

Date:05/10/05ISR Number: 4657815-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
2	MON							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4657816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02602
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		64 DAY
Other	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL		426 DAY
	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		666 DAY
	Blister		Clindamycin	C				UNKNOWN
	Cardiac Arrest		Lamisil	C				UNKNOWN
	Cardiac Failure		Naproxen	C				UNKNOWN
	Cough		Hydrocodone Hydrochloride	C				732 DAY
	Cyanosis							UNKNOWN
	Diarrhoea		Cephalexin	C				UNKNOWN
	Dyspnoea		Cyclobenzaprine Hydrochloride	C				UNKNOWN
	Dyspnoea Exertional							
	Ear Infection		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
	Exostosis							
	Flatulence							
	Hyperhidrosis		Penicillin (Unspecified)	C				UNKNOWN
	Hypertension							
	Oedema Peripheral		Prilosec	C				UNKNOWN
	Osteoarthritis		Ranitidine	C				UNKNOWN
	Pulmonary Oedema		Protonix	C				UNKNOWN
	Respiratory Distress		Amoxicillin	C				UNKNOWN
			Diovan	C				UNKNOWN
			Amitriptyline Hydrochloride	C				UNKNOWN
			Ammonium Lactate	C				UNKNOWN

Didronel	C	UNKNOWN
Indomethacin	C	UNKNOWN
Relafen	C	UNKNOWN

Date:05/10/05ISR Number: 4657822-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:05/10/05ISR Number: 4657826-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00223
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia Angina Pectoris Confusional State Constipation Dehydration Fall Flatulence Hypercholesterolaemia Hyperlipidaemia Monarthritis Myocardial Infarction Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4657827-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657828-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00352
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657839-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00280
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657840-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00746
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00553
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4657853-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00025
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiovascular Disorder		Zocor	C				
UNKNOWN								
Initial or Prolonged	Infection		Mevacor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:05/10/05ISR Number: 4657854-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02333
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Atherosclerosis
Disability	Carotid Artery Stenosis
Other	Carotid Bruit
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Lumbar Spinal Stenosis

	Prescribed Overdose						
	Sinusitis						
	Spinal Column Stenosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Spinal Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL	17 MON
	Staphylococcal Infection		Vioxx	SS	Merck & Co., Inc	ORAL	17 MON
	Transient Ischaemic		Claritin	C		ORAL	
	Attack		Ventilan (Albuterol)	C			
RESPIRATORY							
(INHALATION)							
			Ultram	C		ORAL	
			Naprosyn	C		ORAL	

Date:05/10/05ISR Number: 4657855-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02654
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	25 MON
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	25 MON
	Compression Fracture		Vioxx	SS	Merck & Co., Inc	ORAL	3 MON
	Diarrhoea		Evista	C			UNKNOWN
	Hypertension		Amitriptyline				
	Joint Swelling		Hydrochloride	C			UNKNOWN
			Tylenol With Codeine	C			UNKNOWN
			Ultracet	C			UNKNOWN

Date:05/10/05ISR Number: 4657861-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00255
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	37	MON

Date:05/10/05ISR Number: 4657862-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00742
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY

Date:05/10/05ISR Number: 4657863-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:05/10/05ISR Number: 4657868-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	298	DAY

Date:05/10/05ISR Number: 4657872-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4657956-1Report Type:Expedited (15-DaCompany Report #2005CG00675
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Mopral	PS		ORAL		
	Drug Effect Decreased		Innohep	SS			SUBCUTANEOUS	4 DAY
			Aprovel	SS		ORAL		
			Vioxx	SS		ORAL		
			Arixtra	SS			SUBCUTANEOUS	7 DAY
			Fumafer	SS		ORAL		

Date:05/10/05ISR Number: 4658038-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02339
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	200 DAY	
Hospitalization - Initial or Prolonged	Anxiety		Motrin	C			UNKNOWN	
	Cardiac Failure		Tylenol	C			UNKNOWN	
Other	Congestive Cardiopulmonary Failure		[Therapy Unspecified]	C			UNKNOWN	
	Chest Pain Coronary Artery Disease		[Therapy Unspecified]	C			UNKNOWN	
	Depression Disturbance In Attention		[Therapy Unspecified]	C			UNKNOWN	
	Heart Rate Irregular Hernia Irritability		Gastrointestinal Preparations (Unspecified)	C			UNKNOWN	
	Mood Swings Panic Attack Respiratory Arrest Sleep Disorder							

Date:05/10/05ISR Number: 4658039-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00701
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension							
Initial or Prolonged	Labile Blood Pressure							
Disability	Silent Myocardial							
Other	Infarction							
	Ventricular Dysfunction							

Date:05/10/05ISR Number: 4658041-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03474
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
339 YR								
Initial or Prolonged	Cardiac Arrest		Lupron	C				
UNKNOWN								
	Hypersensitivity		Doxazosin Mesylate	C				
UNKNOWN								
	Myocardial Infarction		Casodex	C				
UNKNOWN								
	Prostate Cancer		Cipro	C				
UNKNOWN								
	Metastatic		Toprol Xl Tablets	C				
UNKNOWN								
	Pulmonary Embolism							
	Syncope Vasovagal							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4658043-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00761
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Candidiasis		Fluticasone					
	Depression		Propionate	C				
UNKNOWN								
	Dizziness		Albuterol	C				
UNKNOWN								
	Duodenitis							
	Gastritis Erosive							
	Nausea							
	Reflux Oesophagitis							
	Syncope							
	Vomiting							

Date:05/10/05ISR Number: 4658044-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03235
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
665 DAY								
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
665 DAY								
	Increased		Cytotec	C				
UNKNOWN								
	Coronary Artery Disease		Diclofenac	C				
UNKNOWN								
	Coronary Artery Stenosis							
	Hypertension							
	Intestinal Perforation							
	Myocardial Infarction							
	Osteoarthritis							
	Post Procedural							
	Complication							

Date:05/10/05ISR Number: 4658045-2Report Type:Expedited (15-DaCompany Report #GB-MERCK-0408GBR00154
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematemesis		Etidronate Disodium	SS		ORAL		
	Haemoglobin Decreased		Lansoprazole	C		ORAL		
	Hiatus Hernia		Lansoprazole	C		ORAL		
	Oesophagitis		Calcium Carbonate And Cholecalciferol	C		ORAL		
	Portal Hypertensive Gastropathy		Hydroxyzine Hydrochloride	C		ORAL		
			Thiamine	C		ORAL		
			Atenolol	C			UNKNOWN	
			Acetaminophen And Codeine Phosphate	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Amlodipine Besylate	C			UNKNOWN	

Date:05/10/05ISR Number: 4658046-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00109
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	SS				
	Myocardial Infarction						UNKNOWN	
	Myocardial Rupture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4658052-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658053-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							

Date:05/10/05ISR Number: 4658055-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658056-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00666
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658057-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00062
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	
			Metoprolol Tartrate	C			UNKNOWN	
			Irbesartan	C			UNKNOWN	
			Aspirin And Dipyridamole	C			UNKNOWN	
			Zocor	C			UNKNOWN	

Date:05/10/05ISR Number: 4658063-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04670
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastric Ulcer		Aspirin	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4658064-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02492
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658065-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Acute Respiratory Failure
Other	Anxiety
	Arthralgia
	Arthritis
	Ascites
	Asthenia
	Asthma
	Back Disorder
	Back Pain
	Cardiac Disorder
	Cerebral Infarction
	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Wall Pain
	Cholecystitis Acute
	Cholelithiasis
	Chronic Obstructive
	Airways Disease
	Exacerbated
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Cough
	Decreased Appetite
	Depression
	Diabetes Mellitus
	Inadequate Control
	Diarrhoea
	Difficulty In Walking

Dizziness
Dyspnoea Exertional
Emotional Distress
Enanthema
Epistaxis
Excoriation
Face Injury
Gallbladder Disorder
Gastrooesophageal Reflux
Disease
Hepatomegaly
Hyperhomocysteinaemia
Hypertensive Heart
Disease
Hypothyroidism
Idiosyncratic Drug
Reaction

Dose	Duration	Injury Insomnia Lacunar Infarction	Report Source	Product	Role	Manufacturer	Route
		Lobar Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Nervousness		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Plavix	C		
UNKNOWN							
		Pneumonia		Flovent	C		
RESPIRATORY (INHALATION)							
		Post Procedural Nausea					
		Pruritus		Levoxyl	C		
UNKNOWN							
		Rash Pruritic		Levoxyl	C		
UNKNOWN							
		Renal Cyst		Tylenol With Codeine #3	C		
		Renal Failure Chronic					
UNKNOWN							
		Swelling Face		Prednisone	C		
UNKNOWN							
		Therapy Non-Responder		Advair	C		
UNKNOWN							
		Ulcer		Monopril	C		
UNKNOWN							
		Upper Respiratory Tract		Azmacort	C		
UNKNOWN							
		Infection		Aspirin	C		
UNKNOWN							
		Urinary Tract Infection		Nexium	C		
UNKNOWN							
		Uterine Disorder		Ventolin (Albuterol)	C		
RESPIRATORY (INHALATION)							
				Ranitidine	C		
UNKNOWN							
				Hydroxychloroquine Sulfate	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Cozaar	C		
UNKNOWN							

Date:05/10/05ISR Number: 4658068-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02416
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658069-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00870
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658070-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00093
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Death Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome Cardio-Respiratory Arrest Dyspepsia Gastric Haemorrhage Gastric Perforation Gastric Ulcer Gastrooesophageal Reflux Disease Haematochezia Loss Of Consciousness Myocardial Infarction

		Oedema Peripheral Pancreatitis Acute Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Lipitor	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Prednisolon	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Diltiazem Hydrochloride	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Ketoconazole	C		
UNKNOWN							

Date:05/10/05ISR Number: 4658071-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/10/05ISR Number: 4658072-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00874
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/10/05ISR Number: 4658073-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658074-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658075-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658078-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4658079-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658080-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00929
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658081-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00894
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658082-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658083-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/10/05ISR Number: 4658697-7Report Type:Direct Company Report #CTU 248087
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Decreased Activity Diarrhoea Erosive Duodenitis Erythema Gastrointestinal Mucosal Disorder Malaise		Vioxx 25 Mg	PS		ORAL	25 MG ONCE A DAY ORAL	

Date:05/10/05ISR Number: 4659914-XReport Type:Expedited (15-DaCompany Report #2005066827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cerebrovascular Accident Myocardial Infarction	Consumer	Bextra (Valdecoxib) Rofecoxib (Rofecoxib)	PS SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/10/05ISR Number: 4659919-9Report Type:Expedited (15-DaCompany Report #2005066770
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG, 1 IN 1 D),	
Other	Drug Ineffective							
	Dyspepsia						ORAL	
	Flatulence		Celebrex (Celecoxib)	SS		ORAL	ORAL	
	Gastric Disorder							
	Hypertension		Nifedipine (Nifedipine)	SS		ORAL	60 MG, ORAL	
	Meniscus Lesion							
	Retching		Lipitor (Atorvastatin)	SS		ORAL	10 MG, ORAL	
			Rofecoxib (Rofecoxib)	SS				

Date:05/11/05ISR Number: 4658620-5Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0369493A
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Dissection		Deroxat	PS	Glaxosmithkline	ORAL	20MG Per day	
Initial or Prolonged	Cerebral Infarction		Art	SS		ORAL	50MG Twice	
	Cerebrovascular Accident						per day	
	Hemiplegia		Oesclim	SS				
			Vioxx	SS		ORAL		

Date:05/11/05ISR Number: 4658621-7Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0376952A
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Deep Vein Thrombosis		Arixtra	PS	Glaxosmithkline	
SUBCUTANEOUS 2.5MG Per day 7 DAY						
Initial or Prolonged	Pain In Extremity		Innohep	SS		
SUBCUTANEOUS 4500IU Per day 5 DAY						
	Therapeutic Response Decreased		Doliprane	SS	Glaxosmithkline	ORAL
1G Three times per day						
			Aprovel	SS		ORAL
150MG Per day						
			Vioxx	SS		ORAL
25MG Per day						
			Mopral	SS	Glaxosmithkline	ORAL
20MG Per day						
			Fumafer	SS	Glaxosmithkline	ORAL
1UNIT Three times per day						

Date:05/11/05ISR Number: 4658838-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00929
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Hospitalization -	Congestive		Synthroid	C				UNKNOWN
Initial or Prolonged	Cardiomyopathy		Avapro	C				UNKNOWN
Other	Dyspnoea		Coreg	C				UNKNOWN
	Ejection Fraction		Guaifenesin	C				UNKNOWN
	Decreased		Protonix	C				UNKNOWN
			Furosemide	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Klor-Con	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4658839-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01992
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
			Zantac	C			UNKNOWN	
			Sertraline Hydrochloride	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Potassium Chloride	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Ascorbic Acid	C			UNKNOWN	
			Percocet	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Vasotec	C			UNKNOWN	

Date:05/11/05ISR Number: 4658843-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01339
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Coronary Artery Atherosclerosis Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	659 DAY UNKNOWN	
			Zocor	C		ORAL		
			Aspirin	C				

	Myocardial Infarction		Zyrtec	C		
UNKNOWN						
	Osteoarthritis		Viagra	C		
UNKNOWN						
	Palpitations					
	Rheumatoid Arthritis					
	Sciatica					

Date:05/11/05ISR Number: 4658844-7Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00005
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 7 DAY	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arterial Disorder		Spironolactone	SS		
UNKNOWN						
	Dehydration		Statin (Unspecified)	C		
UNKNOWN						
	Drug Interaction		Iron (Unspecified)	C		ORAL
	Fatigue					
	General Physical Health Deterioration					
	Haemoglobin Decreased					
	Pallor					
	Pyrexia					
	Red Blood Cell Sedimentation Rate Increased					
	Renal Artery Stenosis					
	Renal Failure					
	Renal Interstitial Fibrosis					
	Renal Tubular Atrophy					
	Tubulointerstitial Nephritis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4658854-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00764
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	932	DAY

Date:05/11/05ISR Number: 4658856-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01616
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anxiety		Hytrin	C			UNKNOWN	
	Arthralgia		Ecotrin	C			UNKNOWN	
	Carotid Artery Atheroma		Trazodone Hydrochloride	C			UNKNOWN	
	Cerebrovascular Accident		Zocor	C			UNKNOWN	
	Colonic Polyp		Toprol Xl Tablets	C			UNKNOWN	
	Dehydration		Norvasc	C			UNKNOWN	
	Depression		Trusopt	C			UNKNOWN	
	Diarrhoea		Pilocarpine	C			UNKNOWN	
	Diastolic Dysfunction		Captopril	C			UNKNOWN	
	Dizziness		Hydrochlorothiazide	C			UNKNOWN	
	Fatigue		Lexapro	C			UNKNOWN	
	Haemorrhoids							
	Hepatic Cyst							
	Hypovolaemia							
	Inguinal Hernia							
	Nausea							
	Syncope Vasovagal							
	Vision Blurred							
	Vomiting							
	Weight Decreased							

Date:05/11/05ISR Number: 4658857-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00686
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658858-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658859-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00769
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4658860-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00304
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Bone Pain		Prolixin	C			UNKNOWN	
	Musculoskeletal Discomfort		Cogentin	C		ORAL		
	Sensory Disturbance							

Date:05/11/05ISR Number: 4658862-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00773
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	77	DAY

Date:05/11/05ISR Number: 4658865-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00695
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Increased		Synthroid	C			UNKNOWN	
	Hepatic Function Abnormal							
	Hepatomegaly							

Date:05/11/05ISR Number: 4658878-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00771
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	768	DAY

Date:05/11/05ISR Number: 4658879-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	328	DAY

Date:05/11/05ISR Number: 4658895-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658896-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4658899-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658900-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Emotional Distress Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658901-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20	DAY

Date:05/11/05ISR Number: 4658902-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658903-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658905-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658906-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00961
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4658964-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00270
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Death	Death
Hospitalization - Initial or Prolonged	Delusion Feeling Abnormal Loss Of Consciousness Metastasis

Pleural Effusion

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Morphine	C			UNKNOWN	
	Ramipril	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Gabapentin	C			UNKNOWN	
	Allopurinol	C			UNKNOWN	
	Metoprolol	C			UNKNOWN	
	Amitriptyline Hydrochloride	C			UNKNOWN	
	Furosemide And Spironolactone	C			UNKNOWN	
	Omeprazole	C			UNKNOWN	
	Dipyrone	C			UNKNOWN	
	Fosamax	C			UNKNOWN	
	Buprenorphine Hydrochloride	C			TOPICAL	

Date:05/11/05ISR Number: 4658976-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00766
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	593 DAY	

Date:05/11/05ISR Number: 4659518-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00655
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		16 MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
Disability	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		16 MON
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
	Cardiac Murmur		Prilosec	C				UNKNOWN
	Coronary Artery Disease							
	Drug Toxicity							
	Hypertension							
	Pain							
	Rash							
	Urticaria							

Date:05/11/05ISR Number: 4659523-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Bladder Spasm
	Bronchial Infection
	Cervicobrachial Syndrome
	Cholelithiasis
	Contusion
	Dysuria
	Embolic Stroke
	Emotional Distress
	Fall
	Hypertension
	Joint Injury

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Migraine Myofascial Pain Syndrome Nerve Compression					
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Pollakiuria		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
		Shoulder Pain		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
9	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
13	DAY						
				Parafon Forte	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lioresal	C		
UNKNOWN							
				Inderal	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Demerol	C		
UNKNOWN							
				Serevent	C		
RESPIRATORY							
(INHALATION)							
				Proventil	C		
RESPIRATORY							
(INHALATION)							

Date:05/11/05ISR Number: 4659524-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01984
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Vasotec	C			UNKNOWN	
	Cerebrovascular Accident		Tegretol	C			UNKNOWN	
	Emotional Distress		Zantac	C			UNKNOWN	
	Gout		Insulin	C			UNKNOWN	
	Haematochezia							
	Haemorrhage Urinary Tract							
	Qrs Axis Abnormal							
	Ventricular Hypertrophy							

Date:05/11/05ISR Number: 4659526-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00669
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	
Other	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Zocor	C			UNKNOWN	
	Cerebrovascular Accident		Insulin	C			UNKNOWN	
	Chest Pain		Toprol Xl Tablets	C			UNKNOWN	
	Deep Vein Thrombosis		Nexium	C			UNKNOWN	
	Dyspnoea							
	Glaucoma							
	Gout							
	Haematochezia							
	Myocardial Infarction							
	Oedema Peripheral							
	Paralysis							
	Renal Disorder							
	Road Traffic Accident							
	Thrombosis							
	Vascular Injury							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659527-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bronchitis		Neurontin	C		ORAL		
Initial or Prolonged	Cardiomegaly		Wellbutrin	C				
UNKNOWN								
Disability	Chronic Obstructive		Bextra	C				
UNKNOWN								
Other	Pulmonary Disease							
	Convulsion							
	Drug Interaction							
	Emphysema							
	Facial Bones Fracture							
	Gastrooesophageal Reflux							
	Disease							
	Hepatitis C							
	Hiatus Hernia							
	Hypercholesterolaemia							
	Intervertebral Disc							
	Protrusion							
	Muscle Spasms							
	Musculoskeletal							
	Discomfort							
	Neck Pain							
	Overdose							
	Peptic Ulcer							
	Radiculopathy							
	Road Traffic Accident							

Date:05/11/05ISR Number: 4659528-1Report Type:Expedited (15-DaCompany Report #GB-MERCK-0407GBR00288
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Balance Disorder		Methotrexate	SS		ORAL		
Initial or Prolonged	Dizziness		Folic Acid	C		ORAL		
Disability	Drug Interaction							
Other	Drug Toxicity							
	Epistaxis							
	Malaise							
	Syncope							

Date:05/11/05ISR Number: 4659535-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00374
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	750 DAY	

Date:05/11/05ISR Number: 4659536-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intra-Abdominal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659537-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659538-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659539-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00624
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death General Physical Health Deterioration		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659540-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00896
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659541-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:05/11/05ISR Number: 4659542-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659543-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:05/11/05ISR Number: 4659544-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659545-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659546-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02734
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659547-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	

Date:05/11/05ISR Number: 4659548-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02423
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659549-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00003
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Hydroxychloroquine Sulfate	C				

UNKNOWN

Methotrexate	C		
UNKNOWN			
Sulfasalazine	C		
UNKNOWN			
Prednisolone	C		
UNKNOWN			
Folic Acid	C		
UNKNOWN			

Date:05/11/05ISR Number: 4659550-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03415
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659551-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00390
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659557-8Report Type:Expedited (15-DaCompany Report #AT-MERCK-0505AUT00002
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		157 DAY
			Tramadol Hydrochloride	C			UNKNOWN	
			Lornoxicam	C			UNKNOWN	
			Pantoprazole Sodium	C			UNKNOWN	

Date:05/11/05ISR Number: 4659558-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03746
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	First Degree		Ecotrin	SS		ORAL		6 YR
	Azotaemia		Bextra	SS			UNKNOWN	
	Benign Prostatic Hyperplasia		Celebrex	SS		ORAL		
			Avandia	C		ORAL		
	Blood Glucose Increased		Lipitor	C		ORAL		
	Gastric Ulcer Haemorrhage		Vitamins (Unspecified)	C		ORAL		
	Headache		Fluconazole	C		ORAL		
	Helicobacter Infection		Altace	C		ORAL		
	Platelet Count Decreased		Sulfamethoxazole And Trimethoprim	C		ORAL		1 YR
	Volume Blood Decreased							
	White Blood Cell Count							
	Decreased		Atenolol	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Tylenol Arthritis					

			Extended Relief	C		
UNKNOWN						
			Levitra	C		
UNKNOWN						

Date:05/11/05ISR Number: 4659560-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659561-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659568-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/11/05ISR Number: 4659569-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	41	DAY

Date:05/11/05ISR Number: 4659570-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00916
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659571-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659572-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659573-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659575-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/11/05ISR Number: 4659588-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	213	DAY

Date:05/11/05ISR Number: 4660947-8Report Type:Expedited (15-DaCompany Report #200511248GDS
Age:63 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Drug Ineffective
Other	Dyspepsia
	Flatulence
	Gastric Disorder
	Gastrointestinal Disorder
	Knee Arthroplasty
	Meniscus Lesion
	Osteoarthritis
	Pain

		Retching Stomach Discomfort Treatment Noncompliance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
			Consumer	Nifedipine	PS		ORAL
60 MG, TOTAL							
			Health				
DAILY, ORAL							
			Professional	Nifedipine	SS		ORAL
60 MG, BIW,							
			Other				
ORAL							
				Bextra (Valdecoxib)	SS		
30 MG, TOTAL							
DAILY							
				Celebrex (Celecoxib)	SS		ORAL
ORAL							
				Lipitor (Atorvastatin)	SS		ORAL
19 MG, TOTAL							
DAILY, ORAL							
				Rofecoxib	SS		

Date:05/11/05ISR Number: 4660989-2Report Type:Expedited (15-DaCompany Report #2005050275
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrioventricular Block	Consumer	Celebrex (Celecoxib)	PS		ORAL
ORAL							
Initial or Prolonged		First Degree		Bextra (Valdecoxib)	SS		
Other		Azotaemia Benign Prostatic Hyperplasia		Acetylsalicylic Acid (Acetylsalicylic Acid)	SS		ORAL
ORAL							
		Blood Pressure Diastolic Decreased		Rofecoxib (Rofecoxib)	SS		ORAL
ORAL							
		Blood Urea Increased Chest Pain Dizziness Epigastric Discomfort		Rosiglitazone Maleate (Rosiglitazone Maleate)	C		

Faecal Occult Blood Positive	Atorvastatin (Atorvastatin)	C
Faeces Discoloured	Multivitamins (Ascorbic Acid/Ergocalciferol/ Folic Acid/Nicotinamide/Pa	C
Feeling Hot	Fluconazole (Fluconazole)	C
Gastric Ulcer	Ramipril (Ramipril)	C
Gastrointestinal Ulcer	Bactrim (Sulfamethoxazole, Trimethoprim)	C
Haemorrhage	Trazodone (Trazodone)	C
Headache	Paracetamol (Paracetamol)	C
Helicobacter Pylori Identification Test Positive	Vardenafil (Vardenafil)	C
Hyperhidrosis	Atenolol (Atenolol)	C
White Blood Cell Count Decreased	Tocopherol (Tocopherol)	C

Date:05/12/05ISR Number: 4660307-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02351
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		20 DAY
Other	Depression		Motrin	C				UNKNOWN
	Migraine		Tylenol	C				UNKNOWN
	Muscle Spasms		Analgesic Or Anesthetic (Unspecified)	C				UNKNOWN
	Myocardial Infarction							
	Stress							
	Vision Blurred							

Date:05/12/05ISR Number: 4660309-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00200
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		457 DAY
Initial or Prolonged	Overdose		Ramipril	SS		ORAL		
Other	Pancytopenia		Mirtazapine	SS		ORAL		61 DAY
	Suicide Attempt		Azathioprine	SS		ORAL		72 DAY
			Risedronate Sodium	C		ORAL		
			Calcium Carbonate And Cholecalciferol	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Prednisolone	C		ORAL		

Date:05/12/05ISR Number: 4660311-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00062
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Aspirin	C
UNKNOWN		
Disability	Metoprolol Tartrate	C
UNKNOWN		
	Irbesartan	C
UNKNOWN		
	Aspirin And Dipyridamole	C
UNKNOWN		
	Zocor	C
UNKNOWN		

Date:05/12/05ISR Number: 4660312-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03633
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Motrin	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:05/12/05ISR Number: 4660315-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00640
Age:35 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Blood Magnesium Decreased
Disability	Blood Potassium Decreased
	Chest Pain
	Dizziness
	Dyspnoea

	Ventricular Extrasystoles						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

Date:05/12/05ISR Number: 4660330-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660331-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660332-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1000	DAY

Date:05/12/05ISR Number: 4660546-8Report Type:Expedited (15-DaCompany Report #FR-BRISTOL-MYERS SQUIBB COMPANY-12921656
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Aprovel Tabs 150 Mg	PS	Bristol-Myers Squibb Company	ORAL	4	DAY
	Therapeutic Response Decreased		Innohep	SS				

Vioxx	SS
Mopral	SS
Fumafer	SS

Date:05/12/05ISR Number: 4660701-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alcoholism
Disability	Angina Pectoris
Other	Anorexia
	Anxiety
	Chest Discomfort
	Chloasma
	Chronic Sinusitis
	Constipation
	Coronary Artery Disease
	Cough
	Depression
	Drug Dependence
	Dry Mouth
	Dysuria
	Eustachian Tube Disorder
	Gastric Ulcer
	Gastrooesophageal Reflux

		Disease					
		Hypertension					
		Iliac Artery Stenosis					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intermittent Claudication		Vioxx	PS	Merck & Co., Inc	ORAL
		Malaise		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Aspirin	C		
UNKNOWN							
		Myocardial Infarction					
		Paraesthesia					
		Peripheral Vascular					
		Disorder					
		Pleurisy					
		Sinus Headache					
		Stomatitis					

Date:05/12/05ISR Number: 4660703-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00038
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain					

Date:05/12/05ISR Number: 4660704-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00049
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
11 DAY							
Initial or Prolonged		Renal Failure Acute		Lansoprazole	SS		ORAL
11 DAY							
		Urticaria		Acetaminophen And Propoxyphene Hydrochloride	SS		ORAL
11 DAY							
				[Therapy Unspecified]	SS		
TOPICAL		11 DAY					

Date:05/12/05ISR Number: 4660705-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00912
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disturbance In Attention		Nadolol	C		ORAL		
	Dizziness		Nexium	C		ORAL		
	Dysarthria		Aspirin	C		ORAL		
	Headache		Estrace	C				
VAGINAL								
	Hypoaesthesia							
	Palpitations							
	Paraesthesia							
	Sensory Loss							
	Visual Field Defect							

Date:05/12/05ISR Number: 4660708-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00647
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Arthropathy
Other	Atherosclerosis
	Cardiac Disorder
	Chest Pain

		Coronary Artery Disease Deep Vein Thrombosis Diabetes Mellitus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Limb Injury		Vioxx	PS	Merck & Co., Inc	ORAL
1071 DAY							
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
1071 DAY							
		Paraesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
1071 DAY							
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
1071 DAY							
		Transient Ischaemic		Zithromax	C		
UNKNOWN							
		Attack		Claritin-D	C		
UNKNOWN							
		Ventricular Dysfunction		Hydroxyzine Hydrochloride	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Monodox	C		
UNKNOWN							
				Ultravate	C		
UNKNOWN							
				Temovate	C		
UNKNOWN							
				Zonalon Cream	C		
UNKNOWN							
				Tazorac	C		
UNKNOWN							

Date:05/12/05ISR Number: 4660710-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02728
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/12/05ISR Number: 4660711-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02670
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Cerebral Infarction		Ecotrin	C				
Other	Colonic Polyp		Zocor	C				UNKNOWN
	Deafness		Benicar	C				UNKNOWN
	Hypoaesthesia		Hydrochlorothiazide	C				UNKNOWN
	Memory Impairment		Aleve	C				UNKNOWN
	Transient Ischaemic Attack							

Date:05/12/05ISR Number: 4660713-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00965
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		651 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		651 DAY
	Difficulty In Walking		Estrace	C				UNKNOWN
	Dyspnoea		Nexium	C				UNKNOWN
	Dysstasia		Calcium (Unspecified)	C				UNKNOWN
	Hypertension							
	Infection							
	Neuropathy							
	Oedema Peripheral							
	Palpitations							
	Ulcer							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/05ISR Number: 4660714-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04294
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemic Stroke		Flonase	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Nasacort	C				
UNKNOWN								
			Zyrtec	C				
UNKNOWN								

Date:05/12/05ISR Number: 4660715-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505USA00274
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
195 DAY								

Date:05/12/05ISR Number: 4660716-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00103
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
1165 DAY								
Hospitalization -	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
1165 DAY								
	Blood Urea Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Premarin	C				
UNKNOWN								
	Dizziness		Accupril	C		ORAL		
	Osteoporosis		Procardia Xl	C		ORAL		
	Pneumonia		Methotrexate	C		ORAL		
	Tachycardia		Folic Acid	C				
UNKNOWN								
			Os-Cal	C				
UNKNOWN								

			Diclofenac	C		
UNKNOWN						
			Xanax	C		ORAL
			Reglan	C		
UNKNOWN						

Date:05/12/05ISR Number: 4660717-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02119
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		1012 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		1012 DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		1012 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1012 DAY
	Myocardial Ischaemia		Colchicine	C				UNKNOWN
			Advil	C				UNKNOWN
			Advil	C				UNKNOWN

Date:05/12/05ISR Number: 4660718-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02896
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Aneurysm
Other	Angina Unstable
	Aortic Valve Incompetence
	Blood Potassium Increased
	Cardiomyopathy
	Carotid Artery Stenosis
	Diabetes Mellitus

		Diplopia					
		Emotional Distress					
		Fear	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal		Corzide Tablets	C		
UNKNOWN							
		Haemorrhage		Cozaar	C		
UNKNOWN							
		Gastrooesophageal Reflux		Arthrotec	C		
UNKNOWN							
		Disease		Terazosin			
		Ischaemic Stroke		Hydrochloride	C		
UNKNOWN							
		Mitral Valve Incompetence		Detrol La	C		
UNKNOWN							
		Myocardial Ischaemia		Nexium	C		
UNKNOWN							
		Nephrolithiasis		Protonix	C		
UNKNOWN							
		Pleural Effusion		Plavix	C		
UNKNOWN		182 DAY					
		Renal Cyst		Ultracet	C		
UNKNOWN							
		Renal Failure Chronic		Toprol Xl Tablets	C		
UNKNOWN							
		Sick Sinus Syndrome		Lescol	C		
UNKNOWN							
		Sinus Bradycardia		Aspirin	C		
UNKNOWN							
				Saw Palmetto	C		
UNKNOWN							

Date:05/12/05ISR Number: 4660722-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03680
Age:78 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
				Naproxen	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		
UNKNOWN							
				[Therapy			

	Unspecified]	C	
UNKNOWN			
	[Therapy Unspecified]	C	
UNKNOWN			
	Levothyroxine Sodium	C	
UNKNOWN			
	Plavix	C	
UNKNOWN			
	Zocor	C	ORAL
	Amaryl	C	
UNKNOWN			
	Quinine	C	
UNKNOWN			
	Lisinopril	C	
UNKNOWN			

Date:05/12/05ISR Number: 4660723-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660724-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00887
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	62	MON

Date:05/12/05ISR Number: 4660725-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00573
Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/05ISR Number: 4660726-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660727-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA04280
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchopneumonia Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660729-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02717
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest Death		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	

Date:05/12/05ISR Number: 4660730-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03698
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1289 DAY	

Hospitalization - UNKNOWN	Asthenia		Vioxx	SS	Merck & Co., Inc	
Initial or Prolonged 1289 DAY	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	
Other	Congestive		Lanoxin	C		ORAL
	Chest Pain		Lanoxin	C		ORAL
	Embolic Stroke		Prinivil	C		ORAL
	Flank Pain		Prinivil	C		ORAL
	Gastric Disorder		Tricor	C		ORAL
	Haemangioma		K-Dur	C		ORAL
	Heart Injury		Neurontin	C		ORAL
	Hemiparesis		Coumadin	C		
UNKNOWN						
	Hypoaesthesia		Betapace	C		
UNKNOWN						
	Intervertebral Disc		Arava	C		ORAL
89 DAY						
	Protrusion		Nitrostat	C		
SUBLINGUAL						
	Spinal Vascular Disorder		A.S.A.	C		
UNKNOWN						

Date:05/12/05ISR Number: 4660732-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00971
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/12/05ISR Number: 4660733-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00888
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/12/05ISR Number: 4660740-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0504AUS00165
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/13/05ISR Number: 4661586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00840
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Infarction		Serzone	C			UNKNOWN	
	Electromechanical Dissociation		Vitamins (Unspecified)	C			UNKNOWN	
	Loss Of Consciousness		Flonase	C			UNKNOWN	
	Malaise		Motrin	C			UNKNOWN	
	Pulse Absent		Vicodin Tablets	C			UNKNOWN	
	Pupil Fixed Sleep Apnoea Syndrome		Tylenol With Codeine #3	C		ORAL	3	DAY

Date:05/13/05ISR Number: 4661589-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalimumab	SS			SUBCUTANEOUS	
			Methotrexate	SS			UNKNOWN	
			Estrogens, Conjugated	SS			UNKNOWN	
			Fluoxetine	SS			UNKNOWN	
			Amoxicillin And Clavulanate Potassium	SS			UNKNOWN	
			Acetaminophen And Dihydrocodeine Bitartrate	SS			UNKNOWN	

Date:05/13/05ISR Number: 4661590-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01604
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	C		ORAL		
	Cerebrovascular Accident		Norvasc	C			UNKNOWN	
	Emotional Distress		Diovan	C			UNKNOWN	
	Multi-Organ Disorder		Synthroid	C			UNKNOWN	
	Pain		Lopressor	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661592-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01340
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		625 DAY
Initial or Prolonged	Increased		Diovan	C				UNKNOWN
Disability	Cerebrovascular Accident		Cozaar	C				UNKNOWN
	Chest Pain		Zestril	C				UNKNOWN
			Avapro	C				UNKNOWN

Date:05/13/05ISR Number: 4661593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		143 DAY
Initial or Prolonged	Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		143 DAY
Disability	Aneurysm		Amitriptyline Hydrochloride	C				UNKNOWN
	Cerebrovascular Accident		Meclizine	C				UNKNOWN
	Chronic Obstructive Pulmonary Disease		Darvocet-N	C				UNKNOWN
	Colonic Polyp							
	Complex Regional Pain Syndrome							
	Depression							
	Diverticulum							
	Dizziness							
	Emotional Distress							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Joint Dislocation							
	Large Cell Carcinoma Of The Respiratory Tract							

Stage Unspecified
Pneumothorax
Stress
Stress Incontinence
Ventricular Extrasystoles

Date:05/13/05ISR Number: 4661594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01920
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661595-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Angina Unstable
Other	Anxiety
	Atrioventricular Block
	Blood Glucose Increased
	Cataract
	Chest Pain
	Conjunctivitis Infective
	Contusion
	Diplopia

		Dyspnoea					
		Emotional Distress					
		Feeling Cold	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hot Flush		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasopharyngitis		Lipitor	C		
UNKNOWN	1304 DAY						
		Nausea		Motrin	C		
UNKNOWN							
		Pain		Naproxen	C		
UNKNOWN							
		Palpitations		Tylenol	C		
UNKNOWN							
		Pinguecula		Premarin	C		
UNKNOWN							
		Somnolence		Aspirin	C		
UNKNOWN							
		Upper Respiratory Tract		Aspirin	C		
UNKNOWN							
		Infection		Synthroid	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Micronase	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Refresh	C		
OPHTHALMIC							
				[Therapy Unspecified]	C		
OPHTHALMIC							

Date:05/13/05ISR Number: 4661596-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02850
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
1034 DAY						
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
399 DAY						

	Increased	Synthroid	C
UNKNOWN			
	Cardiomegaly	Maxzide	C
UNKNOWN			
	Carpal Tunnel Syndrome		
	Cerebrovascular Accident		
	Chest Pain		
	Decreased Appetite		
	Deep Vein Thrombosis		
	Depression		
	Dizziness		
	Dyspepsia		
	Dyspnoea Exertional		
	Electrocardiogram		
	Abnormal		
	Fatigue		
	Gastritis		
	Hypertension		
	Liver Function Test		
	Abnormal		
	Migraine With Aura		
	Oedema Peripheral		
	Oesophagitis		
	Osteoarthritis		
	Palpitations		
	Spondylolysis		
	Stomach Discomfort		
	Stress		
	Transient Ischaemic		
	Attack		
	Urge Incontinence		
	Wound Dehiscence		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661602-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00091
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Advair	C			UNKNOWN	
	Dyspnoea		Dilantin	C			UNKNOWN	
			Singulair	C			UNKNOWN	
			Vitamin B Complex	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Lortab	C			UNKNOWN	
			Metformin	C			UNKNOWN	
			Prozac	C			UNKNOWN	
			Allegra	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Zonegran	C			UNKNOWN	
			Ditropan Xl	C			UNKNOWN	

Date:05/13/05ISR Number: 4661604-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01605
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		869 DAY
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		869 DAY
Disability	Arteriosclerosis		Norvasc	C				UNKNOWN
	Atrial Bigeminy		Zocor	C		ORAL		
	Bursitis		Prinivil	C		ORAL		
	Cardiac Disorder		Lipitor	C				UNKNOWN
	Cardiovascular Disorder		Relafen	C				UNKNOWN
	Cerebrovascular Accident		Tylenol	C				UNKNOWN
	Chronic Sinusitis		Vasotec	C		ORAL		
	Depression							
	Goitre							
	Hypertension							
	Multi-Organ Disorder							
	Pain							
	Syncope							
	Ventricular Hypertrophy							
	Visual Disturbance							

Date:05/13/05ISR Number: 4661605-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02795
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Arthritis
Disability	Balance Disorder
	Blood Creatine
	Phosphokinase Increased
	Drug Ineffective
	Fistula
	Flatulence
	Fungal Skin Infection

	Gastritis						
	Haematochezia						
	Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Headache		Vioxx	PS	Merck & Co., Inc	ORAL	
	Myalgia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neuropathy Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rash		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rotator Cuff Repair		Zocor	SS		ORAL	
	Rotator Cuff Syndrome		Mobic	C			UNKNOWN
	Shoulder Pain		Tylenol	C			UNKNOWN
			Elavil	C		ORAL	
			Glucophage	C			UNKNOWN
			Neurontin	C			UNKNOWN
			Monopril	C		ORAL	
			Hyzaar	C		ORAL	

Date:05/13/05ISR Number: 4661606-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00502
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON

Date:05/13/05ISR Number: 4661607-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00428
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN
			[Therapy				

			Unspecified]	C			
UNKNOWN							
			Aspirin	C			
UNKNOWN							

Date:05/13/05ISR Number: 4661608-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03459
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	No Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pyrexia		Premarin	C				
UNKNOWN								
	Renal Disorder		Synthroid	C				
UNKNOWN								
	Urinary Tract Infection							

Date:05/13/05ISR Number: 4661610-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04129
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Zantac	C				
UNKNOWN								
	Chest Pain		Ranitidine	C				
UNKNOWN								
	Palpitations		Maxalt (Rizatriptan Benzoate)	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Acular	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661634-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02325
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death		Aspirin	C				
UNKNOWN								
	Hypertension		Insulin	C				
UNKNOWN								

Date:05/13/05ISR Number: 4661635-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00102
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Cozaar	C		ORAL		
	Cardiac Failure		Cozaar	C		ORAL		
	Cardiac Failure		Lopressor	C				
UNKNOWN								
	Congestive		Coumadin	C				
UNKNOWN								
	Cardiomegaly		Coumadin	C				
UNKNOWN								
	Diabetes Mellitus		Tylenol	C				
UNKNOWN								
	Dizziness		Prochlorperazine	C				
UNKNOWN								
	Dyspepsia		Prochlorperazine	C				
UNKNOWN								
	Dyspnoea		Levoxyl	C				
UNKNOWN								
	Foot Fracture		Glyburide	C				
UNKNOWN								
	Gastrooesophageal Reflux		Singulair	C				
UNKNOWN								
	Disease		Pepcid Ac	C		ORAL		
	Malaise		Meclizine	C				
UNKNOWN								
	Nausea		Celebrex	C				
UNKNOWN								
	Oedema		Nitrostat	C				
UNKNOWN								

	Pain	Plavix	C
UNKNOWN			
	Renal Disorder	Aspirin	C
UNKNOWN			
	Stomach Discomfort	Aspirin	C
UNKNOWN			
	Thyroid Disorder		
	Transient Ischaemic Attack		

Date:05/13/05ISR Number: 4661641-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00523
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661642-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661655-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00920
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661656-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00495
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction							
Disability								

Date:05/13/05ISR Number: 4661658-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00886
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	46	MON

Date:05/13/05ISR Number: 4661659-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00795
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	306	DAY

Date:05/13/05ISR Number: 4661660-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Injury							

Date:05/13/05ISR Number: 4661661-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00504
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661662-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661663-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00713
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661664-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00778
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY

Date:05/13/05ISR Number: 4661665-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661666-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		151 DAY
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:05/13/05ISR Number: 4661667-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00588
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		220 DAY
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:05/13/05ISR Number: 4661668-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661669-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661674-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01445
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661705-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Organ Failure							
	Polytraumatism							
	Pulmonary Embolism							
	Thrombosis							

Date:05/13/05ISR Number: 4661881-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104513
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Barrett'S Oesophagus		Synthroid	C				
							UNKNOWN	
	Blood Cholesterol		Synthroid	C		ORAL		
	Increased		Premarin	C				
							UNKNOWN	
	Cardiac Murmur		Allegra	C		ORAL		
	Cystitis		Detrol	C		ORAL		
	Depression		Aciphex	C		ORAL		
	Diarrhoea		Azithromycin	C		ORAL		
							25 DAY	
	Diverticulum		Celexa	C				
							UNKNOWN	
	Drug Ineffective		Nortriptyline	C				
							UNKNOWN	
	Dyspepsia		Fosamax	C		ORAL		
	Emotional Distress		Tussionex					
	Gastritis		(Hydrocodone					
	Headache		Polistirex (+)					
	Herpes Zoster		Phenyltoloxamine					
	Hiatus Hernia		Polistirex)	C		ORAL		
	Hypertension		Atenolol	C		ORAL		
	Hypothyroidism		Aspirin	C		ORAL		
	Limb Injury		Calcium					
	Mitral Valve Prolapse		(Unspecified)	C				
							UNKNOWN	
	Muscle Spasms		Vitamin D					

	Neck Pain	(Unspecified)	C
UNKNOWN			
	Palpitations	Questran	C
UNKNOWN			
	Pneumonia	Ibuprofen	C
UNKNOWN			
	Rhinitis Allergic	Aleve	C
UNKNOWN			
	Road Traffic Accident		
	Rotator Cuff Syndrome		
	Seasonal Allergy		
	Shoulder Pain		
	Sleep Disorder		
	Urethritis		
	Viral Infection		
	Xanthelasma		

Date:05/13/05ISR Number: 4661888-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Drug Reaction
	Anxiety
Disability	Coronary Artery Atherosclerosis
	Depression
	Drug Hypersensitivity

	Haematoma Mitral Valve Incompetence Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Panic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
	Patellofemoral Pain		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Syndrome		Celebrex	C			UNKNOWN 4 DAY
	Tendonitis		Aspirin	C			UNKNOWN
	Traumatic Arthropathy		Lipitor	C			UNKNOWN
	Tricuspid Valve		Toprol Xl Tablets	C			UNKNOWN
	Incompetence		Plavix	C			UNKNOWN
			Pyridoxine	C			UNKNOWN
			Folic Acid	C			UNKNOWN
			Xanax	C			UNKNOWN
			Wellbutrin	C			UNKNOWN
			Lopressor	C			UNKNOWN

Date:05/13/05ISR Number: 4661889-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	487 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	487 DAY
Disability	Anxiety		Inderal La	C			UNKNOWN
	Arrhythmia		Inderal La	C			UNKNOWN
	Arteriospasm Coronary		Claritin-D	C			UNKNOWN 1758 DAY

	Bone Pain	Humibid	C	
UNKNOWN				
	Dyspepsia	Prevacid	C	
UNKNOWN				
	Endometriosis	Nasonex	C	
UNKNOWN	764 DAY			
	Headache	Darvocet-N	C	
UNKNOWN				
	Insomnia	Bactrim	C	
UNKNOWN				
	Intervertebral Disc	Pseudoephedrine	C	
UNKNOWN				
	Displacement	Maxzide	C	
UNKNOWN				
	Meniscus Lesion	Naprosyn	C	
UNKNOWN				
	Mitral Valve Incompetence	Entex La	C	
UNKNOWN				
	Neuralgia	Voltaren	C	
UNKNOWN				
	Pleuritic Pain	Voltaren	C	ORAL
	Sacroiliitis	Evening Primrose Oil	C	
UNKNOWN				
	Sinusitis	Glucosamine	C	
UNKNOWN				
	Stress	Chondroitin	C	
UNKNOWN				
	Tachyarrhythmia	Zantac	C	
UNKNOWN				
	Tension	Sudafed	C	
UNKNOWN				
	Tricuspid Valve	Aspirin	C	
UNKNOWN				
	Incompetence	Norco	C	
UNKNOWN				
	Uterine Leiomyoma			
	Weight Increased			

Date:05/13/05ISR Number: 4661890-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Abnormal Dreams
Disability	Activated Partial
Other	Thromboplastin Time
	Prolonged
	Adverse Event
	Amenorrhoea
	Angina Pectoris
	Aphthous Stomatitis

Arthralgia
Asthenia
Atelectasis
Atrial Septal Defect
Blood Pressure Abnormal
Blood Pressure Increased
Breast Pain
Breast Tenderness
Bronchitis Acute
Bursitis
Cardiac Disorder
Cerebral Infarction
Cerebrovascular Accident
Chest Pain
Condition Aggravated
Conjunctival Haemorrhage
Contusion
Convulsion
Cyst
Deep Vein Thrombosis
Difficulty In Walking
Disease Recurrence
Dizziness
Drug Abuser
Drug Dependence
Drug Hypersensitivity
Dry Throat
Dyspnoea
Dysstasia
Eczema
Embolic Stroke
Emotional Distress
Endometriosis
Epistaxis
Fall
Fatigue
Feeling Hot And Cold
Fungal Infection
Gastroenteritis Viral
Gastrointestinal Disorder
Generalised Oedema
Haemorrhage
Headache
Hearing Impaired
Hip Arthroplasty
Hip Fracture
Hodgkin'S Disease

Hypercoagulation
Hyperhidrosis
Hypoaesthesia
Hypothyroidism
Increased Tendency To
Bruise
Ingrowing Nail
Inguinal Hernia
Inguinal Hernia Repair
Injury
Laboratory Test Abnormal
Laryngitis
Localised Infection
Loss Of Libido

		Lung Infiltration					
		Mastitis					
		Menorrhagia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Migraine		Vioxx	PS	Merck & Co., Inc	ORAL
		Mucous Membrane Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Munchausen'S Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Atrophy					
		Muscle Spasms					
		Musculoskeletal					
		Discomfort					
		Nausea					
		Neck Mass					
		Neoplasm Recurrence					
		Nervous System Disorder					
		Nervousness					
		Oligomenorrhoea					
		Osteoarthritis					
		Otitis Externa					
		Otitis Media					
		Ovarian Cyst					
		Ovarian Enlargement					
		Pain					
		Pain In Jaw					
		Palpitations					
		Panic Attack					
		Paraesthesia					
		Patent Ductus Arteriosus					
		Pelvic Pain					
		Peripheral Embolism					
		Pharyngitis					
		Pyrexia					
		Rash					
		Renal Disorder					
		Rhinitis Allergic					
		Scar					
		Sinus Disorder					
		Sinusitis					
		Splenic Cyst					
		Systemic Lupus					
		Erythematosus					
		Tinnitus					
		Tooth Extraction					
		Transient Ischaemic					
		Attack					
		Upper Respiratory Tract					
		Infection					

Urinary Tract Infection
Urine Abnormality
Vaginal Mycosis
Vaginitis Bacterial
Viral Infection
Viral Upper Respiratory
Tract Infection
Vision Blurred
Visual Field Defect
Vomiting
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661891-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Adverse Event		Zestril	SS				UNKNOWN
Other	Alopecia		Isosorbide	C				UNKNOWN
	Anaemia		Cardura	C				UNKNOWN
	Angina Pectoris		Zocor	C		ORAL		
	Asthenia		Aspirin	C				UNKNOWN
	Atrial Fibrillation							
	Atrial Flutter							
	Blood Pressure Increased							
	Bradycardia							
	Chest Pain							
	Coccydynia							
	Colon Adenoma							
	Colonic Polyp							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Insufficiency							
	Dizziness							
	Drug Ineffective							
	Duodenal Ulcer							
	Dyspnoea							
	Dyspnoea Exertional							
	Eczema							
	Gastritis							
	Gastrointestinal Arteriovenous Malformation							
	Hyperhidrosis							
	Hypotension							
	International Normalised Ratio Increased							
	Joint Sprain							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nasal Congestion							
	Nasal Polyps							

Neck Pain
Oedema Peripheral
Osteoarthritis
Postnasal Drip
Prothrombin Time
Prolonged
Pulmonary Congestion
Reflux Oesophagitis
Rhinitis
Rhinitis Allergic
Rhinorrhoea
Sinusitis
Skin Exfoliation
Skin Lesion
Sleep Disorder
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661892-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA01321
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:05/13/05ISR Number: 4661894-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00159
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661895-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia Of Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Lipitor	C				
UNKNOWN								
	Diverticular Perforation		Lopressor	C				
UNKNOWN								
	Dyspnoea		Dyazide	C				
UNKNOWN								
	Gastritis		Prilosec	C				
UNKNOWN								
	Gastrointestinal		Duragesic	C				
TOPICAL								
	Haemorrhage		Voltaren	C				
UNKNOWN								
	Gastrooesophageal Reflux		Zoloft	C				
UNKNOWN								
	Disease		Celebrex	C				
UNKNOWN								

	Muscle Spasms		Triamterene	C
UNKNOWN				
	Osteoarthritis		Denavir	C
UNKNOWN				
	Polyp Colorectal		Metoprolol	C
UNKNOWN				
	Rectal Haemorrhage			
	Small Intestinal			
	Haemorrhage			

Date:05/13/05ISR Number: 4661896-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00129
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
	Left Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY						
	Oedema		Amlodipine Besylate	SS		ORAL
			Carvedilol	C		ORAL
			Ramipril	C		ORAL

Date:05/13/05ISR Number: 4661897-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03891
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Other	Anxiety Disorder
	Asthenia
	Blood Pressure Increased
	Bronchitis
	Cerebrovascular Accident

		Chest Pain					
		Dizziness					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal Motility		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Tofranil	C		
UNKNOWN							
		Headache		Plavix	C		
UNKNOWN							
		Hypercholesterolaemia		Synthroid	C		
UNKNOWN							
		Hypertriglyceridaemia		Norvasc	C		
UNKNOWN							
		Insomnia		Prempro	C		
UNKNOWN							
		Memory Impairment		Strovite	C		
UNKNOWN							
		Mitral Valve Incompetence		Aspirin	C		ORAL
		Morbid Thoughts		Librium	C		
UNKNOWN							
		Platelet Aggregation					
		Increased					
		Presbyacusis					
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Vertigo					
		Vertigo Positional					

Date:05/13/05ISR Number: 4661898-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00284
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Exanthem		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Flatulence		Piroxicam Betadex	C		
UNKNOWN						
	Hypertension		Tilidine			
	Hypertensive Crisis		Hydrochloride	C		
UNKNOWN						
	Iritis					
	Nephrosclerosis					

Renal Failure Acute
Sleep Disorder
Visual Field Defect

Date:05/13/05ISR Number: 4661899-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00431
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cerebrovascular Accident		Effexor	C				
Initial or Prolonged								
Disability								
Other								

Date:05/13/05ISR Number: 4661900-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00043
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Back Pain
	Cerebral Infarction
	Coronary Artery Disease
	Depression
	Diverticulum

		Epistaxis					
		Gait Disturbance					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertensive Heart		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease					
		Myalgia					
		Nasal Septum Disorder					
		Nerve Root Compression					
		Peripheral Occlusive					
		Disease					
		Polyneuropathy					
		Renal Failure					
		Ventricular Extrasystoles					

Date:05/13/05ISR Number: 4661901-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00062
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	First Degree					
	Cholelithiasis					
	Coronary Artery Disease					
	Hyperlipidaemia					
	Hypertension					

Date:05/13/05ISR Number: 4661902-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00038
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Lumbar Vertebral Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
22 DAY						
	Road Traffic Accident		Pantoprazole Sodium	C		ORAL
	Skin Ulcer		Pravastatin Sodium	C		ORAL
	Thrombophlebitis		Lormetazepam	C		ORAL
	Venous Insufficiency		Dipyrone	C		ORAL
			Tramadol			

Hydrochloride	C	ORAL
Acetaminophen And Codeine	C	ORAL
Buprenorphine Hydrochloride	C	

UNKNOWN

Date:05/13/05ISR Number: 4661903-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain
Other	Cerebrovascular Accident
	Dysaesthesia
	Faecal Incontinence
	Failure Of Implant
	Gastric Disorder
	Gastric Ulcer
	Hypertension
	Lumbar Spinal Stenosis

		Migraine					
		Myelopathy					
		Nephrolithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Ranitidine	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Diclofenac	C		
UNKNOWN							

Date:05/13/05ISR Number: 4661904-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00105
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Theophylline	C		
UNKNOWN						
	Asthma		Singulair	C		
UNKNOWN						
	Chest Pain		Fluticasone Propionate And Salmeterol Xinafoate	C		
RESPIRATORY						
(INHALATION)						

Date:05/13/05ISR Number: 4661905-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00779
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Hospitalization -	Ulcer Haemorrhage					
Initial or Prolonged						
Disability						

Date:05/13/05ISR Number: 4661906-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00773
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	50 MON	
Other	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	1657 DAY	
	Cardiac Disorder		Zestril	C			UNKNOWN	
	Cardiac Failure		Zestril	C			UNKNOWN	
	Congestive							
	Diabetes Mellitus							
	Epistaxis							
	Gastrooesophageal Reflux Disease							
	Myocardial Infarction							
	Osteoporosis							
	Pelvic Fracture							
	Upper Limb Fracture							

Date:05/13/05ISR Number: 4661907-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04334
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Atrial Flutter
Disability	Colonic Polyp
Other	Diverticulum Intestinal

		Haemorrhoids					
		Hypercholesterolaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
49	MON						
		Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Non-Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Cardiomyopathy		Bextra	C		
UNKNOWN							
		Palpitations		Oxycodone	C		
UNKNOWN							
		Tendonitis		Hydrocodone Hydrochloride	C		
UNKNOWN							

Date:05/13/05ISR Number: 4661908-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02987
Age:73 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Atrial Fibrillation					
		Atrial Tachycardia					
		Blood Glucose Increased					
		Blood Urea Increased					
		Breast Pain					
		Cardiac Flutter					
		Cerebrovascular Accident					
		Chest Discomfort					
		Chest Pain					
		Cholelithiasis					
		Coronary Artery Disease					
		Cough					
		Dizziness					
		Drug Intolerance					
		Drug Toxicity					
		Dyspnoea					
		Fatigue					
		Heart Rate Irregular					

Hyperhidrosis
Hypertension
Low Density Lipoprotein
Increased
Mitral Valve Incompetence
Myocardial Infarction
Nausea
Pain
Palpitations
Prescribed Overdose
Prothrombin Time
Prolonged
Right Ventricular
Systolic Pressure
Increased
Sinus Bradycardia
Supraventricular
Extrasystoles
Supraventricular
Tachycardia
Tricuspid Valve
Incompetence
Ventricular Extrasystoles

Date:05/13/05ISR Number: 4661909-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00050
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661910-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661911-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02830
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vitamins (Unspecified)	C				
UNKNOWN								
Disability								

Date:05/13/05ISR Number: 4661912-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04136
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	9	DAY
	Gastrooesophageal Reflux Disease							

Date:05/13/05ISR Number: 4661913-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00545
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Disorder		Hydrodiuril	C				
UNKNOWN								
			Potassium (Unspecified)	C				
UNKNOWN								

Date:05/13/05ISR Number: 4661914-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00352
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661915-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1354 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661916-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661917-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00015
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Gastric Haemorrhage		Feldene	SS				
UNKNOWN								
Initial or Prolonged			Verapamil	C				
UNKNOWN								
Disability			Lisinopril-Bc	C				
UNKNOWN								
			Theophylline	C				
UNKNOWN								

Date:05/13/05ISR Number: 4661918-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
1675 DAY								

Date:05/13/05ISR Number: 4661919-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00704
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
51 MON								
			Effexor	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								

Neurontin	C	UNKNOWN
Nasonex	C	UNKNOWN
Protopic	C	UNKNOWN
Allopurinol	C	UNKNOWN
Lisinopril	C	UNKNOWN
Triamcinolone	C	UNKNOWN
Albuterol	C	UNKNOWN
Hydroxychloroquine Sulfate	C	UNKNOWN
Fluocinonide	C	UNKNOWN
Alprazolam	C	UNKNOWN

Date:05/13/05ISR Number: 4661920-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00060
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Simvastatin	C		ORAL		
			Atenolol	C		ORAL		
			Aspirin Calcium	C		ORAL		

Date:05/13/05ISR Number: 4661921-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Cerebrovascular Accident Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661922-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00751
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661923-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00748
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	DAY

Date:05/13/05ISR Number: 4661924-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00664
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Silent Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1533	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1533	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1533	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1533	DAY
			Prednisolone Acetate	C			UNKNOWN	
			Sodium Sulfate	C			UNKNOWN	

Date:05/13/05ISR Number: 4661925-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00749
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661926-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00785
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:05/13/05ISR Number: 4661927-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661928-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00891
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:05/13/05ISR Number: 4661929-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661930-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	27	MON

Date:05/13/05ISR Number: 4661931-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661932-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	43	DAY

Date:05/13/05ISR Number: 4661933-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia Chest Pain Cold Sweat Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661937-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00890
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661938-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661939-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00925
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661940-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00759
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	560	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/13/05ISR Number: 4661941-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01104
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1086 DAY

Date:05/13/05ISR Number: 4661942-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661943-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661944-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661946-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661947-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00952
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661948-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/13/05ISR Number: 4661949-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01343
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Angiopathy Arterial Stenosis Cardiac Disorder Chest Pain

	Depression						
	Diarrhoea						
	Headache	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON
	Post-Traumatic Stress		Aspirin	C		ORAL	5 MON
	Disorder		Tylenol	C		ORAL	

Date:05/13/05ISR Number: 4661950-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00149
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Acanthoma		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR
Initial or Prolonged	Basal Cell Carcinoma		Flupirtine Maleate	C			UNKNOWN
	Chest Pain		Levothyroxine Sodium	C		ORAL	
	Dizziness		Ascorbic Acid And				
	Eczema		Aspirin	C			UNKNOWN
	Hypertension		Risedronate Sodium	C		ORAL	
	Migraine		Acetyldigoxin	C		ORAL	
	Nausea		Verapamil				
	Palpitations		Hydrochloride	C		ORAL	
	Restlessness		Atorvastatin Calcium	C		ORAL	
	Tachyarrhythmia						
	Tinnitus						
	Ventricular Fibrillation						
	Ventricular Hypertrophy						

Date:05/13/05ISR Number: 4661951-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
	Death						
	Polytraumatism						

Date:05/13/05ISR Number: 4663051-8Report Type:Expedited (15-DaCompany Report #TNZFR200500039
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis Platelet Count Increased	Foreign Health Professional	Innohep (Tinzaparin Sodium Injection)	PS		SUBCUTANEOUS	4500 IU (4500 IU, ONCE DAILY), SUBCUTANEOUS	
			Approvel (Irbesartan)	SS		ORAL	150 MG, ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	25 MG, ORAL	
			Arixtra (Fondaparinux Sodium)	SS		SUBCUTANEOUS	1 DOSAGE FORMS, SUBCUTANEOUS	
			Mopral (Omeprazole) (20 Milligram, Capsules)	SS		ORAL	20 MG, ORAL	
			Fumafer (Ferrous Fumarate) (Tablets)	SS		ORAL	3 DOSAGE FORMS (1	

DOSAGE FORMS,

THREE TIMES

DAILY); ORAL

Date:05/13/05ISR Number: 4663364-XReport Type:Expedited (15-DaCompany Report #2005066739
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthenia	Foreign	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, BID INTERVAL: EVERY DAY), ORAL	
	Cardio-Respiratory Arrest	Health						
	Electrocardiogram	Professional						
	Repolarisation	Company						
	Abnormality	Representative						
	Electrocardiogram St		Vioxx (Rofecoxib)	SS		ORAL	50 MG (25 MG, BID INTERVAL: EVERY DAY),ORAL	
	Segment Abnormal							
	Heart Rate Increased							
	Mitral Valve Incompetence							
			Calcort (Deflazacort)	C				
			Condrosulf (Chondroitin Sulfate Sodium)	C				
			Blopress (Candesartan Cilexetil)	C				
			Dafalgan (Paracetamol)	C				
			Lexotanil (Bromazepam)	C				
			Tramadolor	C				
			Duspatalin Retard	C				
			Ibuprofen (Ibuprofen)	C				

			Neurontin (Gabapentin)	C		

Date:05/13/05ISR Number: 4663460-7Report Type:Expedited (15-DaCompany Report #2005069201
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Initial or Prolonged	Arthritis		Bextra (Valdecoxib)	SS		ORAL	ORAL	
Other	Cardiac Procedure Complication		Rofecoxib (Rofecoxib)	SS		ORAL	ORAL	
	Catheter Related Complication		Calcium Carbonate (Calcium Carbonate)	SS		ORAL	ORAL	
	Dyspepsia		Amlodipine Besilate (Amlodipine Besilate)	C				
	Myocardial Infarction		Atorvastatin (Atorvastatin)	C				
	Renal Failure Acute		Levothyroxine Sodium (Levothyroxine Sodium)	C				
	Tooth Infection		Metoprolol Succinate (Metoprolol Succinate)	C				
			Ranitidine Hydrochloride (Ranitidine					

Hydrochloride)	C
Acetylsalicylic Acid (Acetylsalicylic Acid)	C
Rosiglitazone Maleate (Rosiglitazone Maleate)	C
Isosorbide Mononitrate (Isosorbide Mononitrate)	C
Ramipril (Ramipril)	C
Clopidogrel Sulfate (Clopidogrel Sulfate)	C
Clonidine (Clonidine)	C

Date:05/16/05ISR Number: 4662125-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4662408-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00412
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	803	DAY
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Angina Pectoris		Voltaren	C			UNKNOWN	
	High Density Lipoprotein		Prednisone	C			UNKNOWN	
	Decreased		Dexamethasone	C			INTRAMUSCULAR	
	Low Density Lipoprotein		Nicotrol	C			RESPIRATORY	

Increased
(INHALATION)
Influenza Virus
Vaccine
(Unspecified) C
UNKNOWN

Date:05/16/05ISR Number: 4662409-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00533
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Asacol	C				
UNKNOWN								
Other	Diarrhoea Haemorrhagic		Bentyl	C				
UNKNOWN								
	Gastrooesophageal Reflux		Prednisone	C				
UNKNOWN								
	Disease		Corticosteroids					
	Heart Rate Irregular		(Unspecified)	C				
UNKNOWN								
	Hypertension							
	Myocardial Infarction							
	Pericarditis							
	Pneumonia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662419-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00558
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		967 DAY
Other	Cardiac Failure		Premarin	C				UNKNOWN
	Congestive		Atrovent	C				RESPIRATORY
	Cardio-Respiratory Arrest							(INHALATION)
	Chest Pain		Prilosec	C		ORAL		
	Chronic Obstructive		Paxil	C		ORAL		
	Pulmonary Disease		Serevent	C				RESPIRATORY
	Diabetes Mellitus							(INHALATION)
	Dyspepsia		Xanax	C		ORAL		
	Myocardial Infarction		Vicodin Tablets	C		ORAL		
			Lasix (Furosemide)	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Albuterol	C				RESPIRATORY (INHALATION)
			Ferrous Sulfate	C				UNKNOWN

Date:05/16/05ISR Number: 4662420-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:05/16/05ISR Number: 4662421-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4662422-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00579
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Valve Disease							
	Myocardial Infarction							
Disability	Pericardial Effusion							

Date:05/16/05ISR Number: 4662423-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00774
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Polytraumatism							

Date:05/16/05ISR Number: 4662425-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00665
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662435-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00650
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Congestive		Zanaflex	C			UNKNOWN	
Other	Cerebrovascular Accident							

Date:05/16/05ISR Number: 4662436-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4662437-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00796
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	966	DAY
Initial or Prolonged	Infarction							
Disability	Angina Pectoris							
	Anxiety							
	Bladder Cancer							
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cerebrovascular Accident							
	Cervical Root Pain							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery Disease							
	Depression							
	Dyspnoea Exertional							
	Ejection Fraction							
	Decreased							
	Epigastric Discomfort							

Hyperlipidaemia
Hypertension

Date:05/16/05ISR Number: 4662450-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01514
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cardiac Arrest							
	Cardiac Disorder							
	Cerebrovascular Accident							
	Death							
	Multi-Organ Disorder							
	Pain							

Date:05/16/05ISR Number: 4662451-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01929
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Culture Positive
	Cellulitis

	Haematuria Hyperlipidaemia Leukocytoclastic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Vasculitis		Vioxx	PS	Merck & Co., Inc	ORAL	21 DAY
	Necrosis		Vioxx	SS	Merck & Co., Inc	ORAL	21 DAY
	Skin Ulcer		Lipitor	C			UNKNOWN
	Staphylococcal Infection		Furosemide	C			UNKNOWN
			Synthroid	C			UNKNOWN

Date:05/16/05ISR Number: 4662452-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01452
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON
	Rash						

Date:05/16/05ISR Number: 4662453-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/16/05ISR Number: 4662455-7Report Type:Expedited (15-DaCompany Report #NL-MERCK-0505NLD00009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	

Date:05/16/05ISR Number: 4662966-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Other	Angina Unstable
	Anxiety
	Anxiety Disorder
	Azotaemia
	Benign Neoplasm
	Benign Prostatic Hyperplasia
	Bundle Branch Block Right
	Chest Pain
	Chondromalacia
	Colonic Polyp
	Condition Aggravated
	Constipation
	Coronary Artery Disease
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Dehydration
	Depression
	Dermatitis
	Diarrhoea
	Drug Intolerance
	Dyspepsia

		Dysuria					
		Early Morning Awakening					
		Epicondylitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Exostosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Food Intolerance		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis Viral		Vioxx	SS	Merck & Co., Inc	ORAL
		Generalised Anxiety		Librax Capsules	C		
UNKNOWN							
		Disorder		Zantac	C		
UNKNOWN							
		Gout		Cyclobenzaprine			
		Haematoma		Hydrochloride	C		
UNKNOWN							
		Hair Texture Abnormal		Acetaminophen And			
		Headache		Propoxyphene			
		Hearing Impaired		Napsylate	C		
UNKNOWN							
		Hypercholesterolaemia		Allegra	C		
UNKNOWN							
		Hypertension		Prilosec	C		
UNKNOWN							
		Hypoaesthesia		Xanax	C		
UNKNOWN							
		Increased Tendency To		Aspirin	C		
UNKNOWN							
		Bruise		Tylenol	C		
UNKNOWN							
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Ischaemic Cardiomyopathy					
		Lipoprotein (A) Abnormal					
		Low Density Lipoprotein					
		Increased					
		Lung Neoplasm					
		Micturition Urgency					
		Myocardial Infarction					
		Myositis					
		Nasal Congestion					
		Neck Pain					
		Nerve Root Compression					
		Nervousness					
		Oesophageal Spasm					

Osteochondrosis
Pain In Extremity
Pollakiuria
Postnasal Drip
Productive Cough
Prostatitis
Pruritus
Radiculitis
Radiculitis Cervical
Rectal Haemorrhage
Rhinorrhoea
Rotator Cuff Syndrome
Sinus Disorder
Sleep Disorder
Sneezing
Spinal Column Stenosis
Spinal Osteoarthritis
Stomach Discomfort
Stress
Tendonitis
Tinnitus
Urinary Tract Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662974-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0408DEU00191
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		1 WK
Hospitalization -	Gout		Vioxx	SS	Merck & Co., Inc	ORAL		1 WK
Initial or Prolonged	Hypertension							
	Myocardial Ischaemia							
	Renal Failure							

Date:05/16/05ISR Number: 4662975-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Initial or Prolonged	Acute Myocardial		Diovan	C				UNKNOWN
Disability	Infarction		Ultram	C				UNKNOWN
	Acute Respiratory Failure		Oxycodone	C				UNKNOWN
	Angina Unstable		Zantac	C		ORAL		
	Arthralgia		Prozac	C				UNKNOWN
	Cardiac Failure		Maxalt (Rizatriptan					
	Congestive		Benzoate)	C		ORAL		
	Cardiogenic Shock		Zoloft	C				UNKNOWN
	Cerebrovascular Accident							
	Chest Pain							
	Congestive Cardiomyopathy							
	Coronary Artery Disease							
	Depression							
	Dizziness							
	Emotional Distress							
	Encephalopathy							
	Fatigue							
	Folliculitis							
	Gastrooesophageal Reflux							
	Disease							

Headache
Heart Rate Increased
Hypercholesterolaemia
Hypertension
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Ischaemic Hepatitis
Lumbar Radiculopathy
Lung Infiltration
Migraine
Multi-Organ Failure
Muscle Spasms
Oedema Peripheral
Panic Disorder
Renal Failure Acute
Tendonitis
Thyroid Neoplasm
Ulcer Haemorrhage
Urinary Tract Infection
Ventricular Fibrillation
Ventricular Tachycardia
Visual Disturbance

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662984-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01341
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ziac	C			UNKNOWN	
	Cardiac Murmur		Bisoprolol	C			UNKNOWN	
	Chest Pain		Naproxen	C			UNKNOWN	
	Chronic Fatigue Syndrome		Verapamil	C			UNKNOWN	
	Colonic Polyp		Tiazac	C			UNKNOWN	
	Coronary Artery Disease							
	Depression							
	Dyspepsia							
	Dyspnoea							
	Ear Canal Injury							
	Extrasystoles							
	Haemorrhoids							
	Hypertension							
	Joint Swelling							
	Labyrinthitis							
	Myocardial Infarction							
	Post-Traumatic Stress Disorder							
	Vertigo							

Date:05/16/05ISR Number: 4662986-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	89	DAY
	Prescribed Overdose		Vioxx	C		ORAL	89	DAY
			Vioxx	C		ORAL	89	DAY

			Vioxx	C		ORAL
89 DAY						
			Vioxx	C		ORAL
89 DAY						

Date:05/16/05ISR Number: 4662987-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
40 MON						

Date:05/16/05ISR Number: 4662988-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00063
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Disorder		Valdecoxib	SS		ORAL
	Myocardial Infarction					

Date:05/16/05ISR Number: 4662989-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01359
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
699 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4662990-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00959
Age:26 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4662991-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4662992-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalimumab	SS			SUBCUTANEOUS	
			Methotrexate	SS			UNKNOWN	
			Estrogens, Conjugated	SS			UNKNOWN	
			Fluoxetine	SS			UNKNOWN	
			Amoxicillin And Clavulanate Potassium	SS			UNKNOWN	
			Acetaminophen And Dihydrocodeine Bitartrate	SS			UNKNOWN	

Date:05/16/05ISR Number: 4663002-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00601
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Diclofenac Resinate	C		ORAL		
	Psoriatic Arthropathy		Flecainide Acetate	C		ORAL		
	Tenosynovitis		Verapamil Hydrochloride	C				
	Transient Ischaemic Attack		Vitamin E	C				
			Aesculus	C				
			Zolpidem Tartrate	C		ORAL		
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		

Date:05/16/05ISR Number: 4663003-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02845
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Death	Atherosclerosis
Hospitalization - Initial or Prolonged	Body Temperature Increased
Other	Cardiac Failure
	Cardiac Failure Congestive

		Cardiogenic Shock					
		Coagulopathy					
		Coma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Intracardiac Thrombus		Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Multi-Organ Failure		Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
1	YR						
		Sepsis		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Tooth Extraction		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Ventricular Dysfunction		Citracal	C		ORAL
		Ventricular Tachycardia		Skelaxin	C		
UNKNOWN							
		Wrist Fracture		Lorcet 10/650	C		
UNKNOWN							
				Zydone	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							
				Skelaxin	C		ORAL

Date:05/16/05ISR Number: 4663007-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01505
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
40	MON						

Date:05/16/05ISR Number: 4663008-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01673
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
806	DAY						
		Transient Ischaemic					

Attack

Date:05/16/05ISR Number: 4663009-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01651
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4663010-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/16/05ISR Number: 4663713-2Report Type:Expedited (15-DaCompany Report #2005071457
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia	Consumer	Celebrex (Celecoxib)	PS		ORAL		
ORAL								
Initial or Prolonged	Iatrogenic Injury		Bextra (Valdecoxib)	SS		ORAL		
ORAL								
Other	Myocardial Infarction Post Procedural Complication Procedural Complication		Rofecoxib (Rofecoxib) Calcium Carbonate (Calcium Carbonate)	SS SS		ORAL		
(AS								
NECESSARY),	Renal Failure Acute							
ORAL	Tooth Infection							

Levothyroxine Sodium (Levothyroxine Sodium)	C
Metoprolol Succinate (Metoprolol Succinate)	C
Ranitidine Hydrochloride (Ranitidine Hydrochloride)	C
Acetylsalicylic Acid (Acetylsalicylic Acid)	C
Rosiglitazone Maleate (Rosiglitazone Maleate)	C
Amlodipine Besilate (Amlodipine Besilate)	C
Isosorbide Mononitrate (Isosorbide Mononitrate)	C
Ramipril (Ramipril)	C
Clopidogrel Sulfate (Clopidogrel Sulfate)	C
Clonidine (Clonidine)	C
Atorvastatin (Atorvastatin)	C

Date:05/16/05ISR Number: 4664063-0Report Type:Direct Company Report #CTU 248677
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Mitral Valve Incompetence		Vioxx 25 Mg	PS			1 X A DAY	
Other			Cardura	C				
			Norvasc	C				
			Hctz	C				
			Cholestgramine	C				

Date:05/16/05ISR Number: 4664469-XReport Type:Direct Company Report #CTU 248699
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Haemorrhage		Vioxx 25mg	PS			1-2 TABLETS DAILY AS NEEDED	

Date:05/16/05ISR Number: 4664470-6Report Type:Direct Company Report #CTU 248700
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS			2 TABLETS DAILY	
Other	Dizziness							
	Heart Rate Increased		.	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/16/05ISR Number: 4664505-0Report Type:Direct Company Report #CTU 248703
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS			25 MG 1 X A	
Hospitalization -	Impaired Driving Ability							DAY
Initial or Prolonged Disability Required Intervention to Prevent Permanent Impairment/Damage	Transient Ischaemic Attack		Blood Pressure And Prostate Drugs	C				
	Visual Disturbance							

Date:05/17/05ISR Number: 4663626-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03456
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adnexa Uteri Mass		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Zestril	C				
UNKNOWN								
	Cardiac Murmur		Prilosec	C				
UNKNOWN								
	Cellulitis		Xanax	C				
UNKNOWN								
	Coronary Artery Disease		Zyrtec	C				
UNKNOWN								
	Depression		Aspirin	C				
UNKNOWN								
	Dyspnoea		Celebrex	C				
UNKNOWN								
	Eyelid Ptosis		Prozac	C				
UNKNOWN								
	Fatigue		Naproxen	C				
UNKNOWN								
	Fungal Infection							
	Haemangioma							
	Insomnia							
	Macular Degeneration							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema							

Oedema Peripheral
Osteoporosis
Palpitations
Panic Attack
Pollakiuria
Postnasal Drip
Radiculopathy
Rash
Renal Failure
Sinus Bradycardia
Sinus Disorder
Sinusitis
Sleep Disorder
Snoring
Spinal Column Stenosis
Spinal Osteoarthritis
Urethritis
Visual Disturbance
Weight Increased

Date:05/17/05ISR Number: 4663635-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00707
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
Other	Atelectasis

		Atrial Fibrillation Blood Pressure Increased Bronchitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure Congestive		Vioxx Estrace	PS C	Merck & Co., Inc	ORAL
UNKNOWN							
		Carpal Tunnel Syndrome		Aspirin	C		
UNKNOWN							
		Chest Pain		Allegra	C		
UNKNOWN							
		Congestive Cardiomyopathy		Hyoscyamine	C		
UNKNOWN							
		Convulsion		Elavil	C		
UNKNOWN							
		Dizziness		Diovan	C		
UNKNOWN							
		Hypercholesterolaemia Hyperlipidaemia		[Therapy Unspecified]	C		
UNKNOWN							
		Irritable Bowel Syndrome		Robitussin-Dm	C		
UNKNOWN							
		Nasopharyngitis Osteoarthritis Palpitations Squamous Cell Carcinoma Tachycardia Viral Myocarditis					

Date:05/17/05ISR Number: 4663637-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00179
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/17/05ISR Number: 4663638-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04335
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Depression	Synthroid	C
UNKNOWN			
Other	Myocardial Infarction	Prempro	C
UNKNOWN			

Date:05/17/05ISR Number: 4663639-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02550
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Asthenia
Disability	Atherosclerosis
Other	Atrial Fibrillation
	Blood Pressure Increased
	Bradycardia
	Cardiac Failure
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery Disease
	Depression
	Dyspnoea
	Fatigue
	Feeling Abnormal
	Hypertensive Crisis
	Joint Dislocation
	Myocardial Infarction
	Pain In Extremity
	Sinus Bradycardia
	Transient Ischaemic

Attack

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	209	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	209	DAY
	Lasix (Furosemide Sodium)	C			UNKNOWN	
	Lasix (Furosemide Sodium)	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Avalide	C			UNKNOWN	
	Motrin	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Tylenol	C			UNKNOWN	

Date:05/17/05ISR Number: 4663640-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure							
	Congestive							
	Congestive Cardiomyopathy							
	Depression							
	Generalised Anxiety							
	Disorder							
	Haematochezia							
	Hypertension							
	Myocardial Infarction							
	Nocturia							
	Palpitations							

Date:05/17/05ISR Number: 4663643-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00521
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Acetyldigoxin	C		ORAL		
	Cardiac Failure Congestive		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL		
	Heart Rate Increased		Captopril	C		ORAL		
	Pulmonary Congestion							
	Refusal Of Treatment By Patient							

Date:05/17/05ISR Number: 4663644-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00398
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization - UNKNOWN	Catheterisation Cardiac		Lithium Carbonate	C				
Initial or Prolonged UNKNOWN	Cerebrovascular Accident		Effexor	C				
Disability								
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/17/05ISR Number: 4663645-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02670
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Ecotrin	C				UNKNOWN
Other	Cerebral Infarction		Zocor	C				UNKNOWN
	Deafness		Benicar	C				UNKNOWN
	Hypoaesthesia		Hydrochlorothiazide	C				UNKNOWN
	Memory Impairment		Aleve	C				UNKNOWN
	Transient Ischaemic Attack							

Date:05/17/05ISR Number: 4663646-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02533
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY
Initial or Prolonged	Back Injury							
Other	Cerebrovascular Accident							
	Convulsion							
	Emotional Distress							
	Hypertension							
	Intervertebral Disc Protrusion							
	Intestinal Functional Disorder							
	Myocardial Infarction							
	Neck Pain							
	Neuropathy							
	Radiculitis							
	Radiculitis Brachial							
	Spinal Osteoarthritis							
	Stress							
	Tendonitis							
	Transient Ischaemic Attack							

Urinary Tract Disorder

Date:05/17/05ISR Number: 4663647-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03607
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abdominal Tenderness		Vioxx	SS	Merck & Co., Inc	ORAL
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	General Physical Health		Vioxx	SS	Merck & Co., Inc	ORAL
	Deterioration		Vioxx	SS	Merck & Co., Inc	ORAL
	No Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain		K-Dur	C		ORAL
	Pain In Extremity		Cardura	C		ORAL
	Pernicious Anaemia		Diazepam	C		ORAL
	Wheelchair User		Slow-Mag	C		ORAL
			Cardizem	C		ORAL
			Nitropatch	C		
TOPICAL						
			Fiorinal-C 14	C		ORAL
			Maxzide	C		ORAL
			Blephamide	C		
OPHTHALMIC						
			Guaifenesin Dm	C		ORAL
			Prilosec	C		ORAL

Vitamins (Unspecified)	C		ORAL
Ferrous Sulfate	C		UNKNOWN
Actonel	C		ORAL
Calcium (Unspecified)	C		ORAL
Anusol-Hc 25 Mg Suppositories	C		RECTAL

Date:05/18/05ISR Number: 4664293-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00090
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arteriosclerosis		Zocor	C				
UNKNOWN							38	DAY
Initial or Prolonged	Atherosclerosis		Toprol Xl Tablets	C				
UNKNOWN							143	DAY
	Blood Cholesterol		Adalat	C				
UNKNOWN								
	Increased Blood Triglycerides		Edetate Sodium And Ginkgo Biloba Extract	C				
UNKNOWN								
	Increased Cataract		Lasix (Furosemide Sodium)	C				
UNKNOWN								
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Atherosclerosis							
	Dyspepsia							
	Dyspnoea							
	Hypertension							
	Myocardial Infarction							
	Oedema Peripheral							
	Osteoarthritis							
	Skin Cancer							
	Thyroid Disorder							
	Ulcer							

Date:05/18/05ISR Number: 4664295-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01513
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Multi-Organ Disorder							
	Organ Failure							
	Pain							
	Polytraumatism							

Date:05/18/05ISR Number: 4664297-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00218
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arteriosclerosis		Nebivolol Hydrochloride	C		ORAL		
	Encephalopathy		Hypericin	C		ORAL		
	Fall		Risedronate Sodium	C		ORAL		
	Transient Ischaemic Attack							
	Ventricular Hypertrophy							

Date:05/18/05ISR Number: 4664298-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04129
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abdominal Pain Upper		Zantac	C			UNKNOWN	
	Anxiety		Ranitidine	C			UNKNOWN	
	Apnoea		Maxalt (Rizatriptan Benzoate)	C			UNKNOWN	
	Back Pain							
	Chest Pain		Allegra	C			UNKNOWN	
	Diarrhoea		Acular	C			UNKNOWN	
	Dizziness							
	Dyspnoea							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux Disease							
	Headache							
	Influenza Like Illness							
	Nausea							
	Palpitations							
	Vomiting							

Date:05/18/05ISR Number: 4664299-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00087
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Percocet	C			UNKNOWN	
	Emotional Distress		Ativan	C			UNKNOWN	
	Loss Of Consciousness							

Date:05/18/05ISR Number: 4664300-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00967
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664301-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664302-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664305-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664306-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664325-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03068
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	First Degree		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysphonia		Insulin	C				
UNKNOWN								
	Erectile Dysfunction							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Muscle Injury							
	Muscle Strain							
	Myocardial Infarction							
	Osteoarthritis							
	Plantar Fasciitis							
	Rotator Cuff Syndrome							
	Tendonitis							

Date:05/18/05ISR Number: 4664354-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00553
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebral Haemorrhage		Fluocortolone					
Initial or Prolonged	Constipation		Caproate	C		ORAL		
Disability	Dizziness		Sitosterols	C		ORAL		
Other	Facial Paresis		Beclomethasone					
	Fatigue		Dipropionate	C				
RESPIRATORY								

Grand Mal Convulsion
(INHALATION)
Hemiparesis Salmeterol Xinafoate C
RESPIRATORY

(INHALATION)
Ipratropium Bromide C
RESPIRATORY

(INHALATION)
Pantoprazole Sodium C ORAL
Prednisolone C
UNKNOWN

Date:05/18/05ISR Number: 4664373-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00512
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Meniere'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Venlafaxine Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664377-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03763
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Zyrtec	C				
Disability	Bronchitis		Atenolol	C				
	Bronchopneumonia		Prevacid	C				
	Gastrooesophageal Reflux Disease		[Therapy Unspecified]	C				
	Hiatus Hernia							
	Hypertension							
	Myocardial Infarction							
	Sinusitis							
	Weight Increased							

Date:05/18/05ISR Number: 4664378-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Affective Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Pain		Zoloft	C				
	Colonic Polyp		Zoloft	C				
	Depression		Avalide	C				
	Drug Dependence		Claritin	C				
	Drug Detoxification		Prozac	C				
	Drug Withdrawal Syndrome							
	Dyspepsia							
	Facet Joint Syndrome							
	Gastric Ulcer							
	Gastrooesophageal Reflux Disease							

Haematocrit Abnormal
Headache
Helicobacter Pylori
Identification Test
Positive
High Density Lipoprotein
Abnormal
Hypertension
Injury
Intervertebral Disc
Degeneration
Intervertebral Disc
Disorder
Intervertebral Disc
Protrusion
Mood Altered
Nervousness
Osteoarthritis
Peptic Ulcer
Rectal Haemorrhage
Rhinitis Allergic
Sleep Apnoea Syndrome
Spondylolisthesis
Spondylolysis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664379-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL		29 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		62 DAY
Disability	Appendicitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		29 DAY
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		62 DAY
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cellulitis		Lithium Carbonate	C				UNKNOWN
	Chest Pain							
	Constipation							
	Depression							
	Diarrhoea							
	Dizziness							
	Fatigue							
	Heart Injury							
	Heart Rate Irregular							
	Inguinal Hernia							
	Injury							
	Joint Dislocation							
	Myocardial Infarction							
	Nerve Compression							
	Nerve Injury							
	Onychomycosis							
	Osteoarthritis							
	Pain In Extremity							
	Paranoia							
	Penis Carcinoma							
	Pharyngolaryngeal Pain							
	Post-Traumatic Stress Disorder							
	Rash							
	Rotator Cuff Syndrome							
	Sacroiliitis							
	Sputum Abnormal							
	Squamous Cell Carcinoma							
	Stomach Discomfort							
	Suicidal Ideation							

Date:05/18/05ISR Number: 4664382-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03777
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Coumadin	C				
UNKNOWN								
Other			[Therapy Unspecified]	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:05/18/05ISR Number: 4664383-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age:60 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diverticulum Intestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Epididymitis		Aspirin	C		ORAL		
	Mental Disorder Due To A General Medical Condition							
	Vascular Encephalopathy							

Date:05/18/05ISR Number: 4664384-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00678
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 3 YR	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	General Physical Health		Glucophage	C				
UNKNOWN								
Other	Deterioration		Glucotrol	C				
UNKNOWN								
	Kidney Infection		Aspirin	C				
UNKNOWN								
	Neuropathy Peripheral		Neurontin	C				
UNKNOWN								
	Onychomycosis		Novolin 70/30	C				
UNKNOWN								
	Pain In Extremity							
	Post-Traumatic Stress Disorder							
	Toe Deformity							
	Traumatic Haematoma							
	Treatment Noncompliance							
	Ventricular Hypertrophy							
	Weight Decreased							

Date:05/18/05ISR Number: 4664385-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02201
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged Disability	Activities Of Daily Living Impaired Arterial Thrombosis Limb Back Pain Bundle Branch Block Left Cellulitis Coronary Artery Disease Femoral Arterial Stenosis Gangrene Hypertension Impaired Healing Ischaemic Ulcer Leg Amputation Osteoarthritis Pain Pain In Extremity Peripheral Vascular Disorder Pulmonary Hypertension Traumatic Ulcer	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664386-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01104484
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acoustic Stimulation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Tests Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Clavicle Fracture		Anaprox	C				
UNKNOWN								
	Coccidioidomycosis		Femhrt	C				
UNKNOWN								
	Convulsion		Herbs (Unspecified)	C				
UNKNOWN								
	Dacryocystitis Infective		Celebrex	C				
UNKNOWN								
	Dacryostenosis Acquired		Trazodone Hydrochloride	C				
	Dementia							
UNKNOWN								
	Drug Ineffective		Trazodone Hydrochloride	C		ORAL		
	Dry Eye							
	Dry Mouth		Trazodone Hydrochloride	C		ORAL		
	Eczema Asteatotic							
	Emotional Distress		Prozac	C				
UNKNOWN								
	Encephalitis		Prozac	C		ORAL		
	Endocarditis							
	Fall							
	Fibromyalgia							
	Fracture							
	Gastrooesophageal Reflux Disease							
	Grand Mal Convulsion							
	Headache							
	Hypoaesthesia							
	Incontinence							
	Insomnia							
	Iritis							
	Joint Dislocation							
	Joint Injury							
	Lacrimation Increased							
	Lethargy							

Limb Injury
Meningitis
Mitral Valve Prolapse
Myocarditis
Nausea
Night Sweats
Photosensitivity Reaction
Pruritus
Pulmonary Calcification
Pyrexia
Rash
Renal Failure
Stomatitis
Upper Respiratory Tract
Infection
Vertigo
Viral Infection
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664387-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00501
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	28 DAY	
	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL	197 DAY	
	Hepatitis		Vioxx	SS	Merck & Co., Inc	ORAL	DAY	
	Hypertensive Heart Disease		Ativan	C		ORAL		
			Paxil	C		ORAL		
	Nephrosclerosis							
	Sudden Death							

Date:05/18/05ISR Number: 4664388-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00161
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1749 DAY	
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1749 DAY	
	Cerebrovascular Accident		Tramadol Hydrochloride	C		ORAL	1729 DAY	
	Diarrhoea							
	Diastolic Dysfunction		Hydrochlorothiazide	C		ORAL		
	Electrocardiogram Abnormal		Amlodipine Mesylate	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
	Embolism		Enalapril Maleate	C		ORAL		
	Hypertension							
	Ultrasound Doppler Abnormal							
	Vascular Encephalopathy							
	Wrong Technique In Drug Usage Process							

Date:05/18/05ISR Number: 4664389-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Infarction		Beclomethasone					
	Anxiety		Dipropionate	C				
RESPIRATORY								
	Aortic Valve Incompetence							
(INHALATION)								729 DAY
	Coronary Artery Occlusion		[Therapy					
	Diarrhoea		Unspecified]	C				
UNKNOWN								
	Disorientation		Griseofulvin	C				
UNKNOWN								25 DAY
	Drug Ineffective		Verapamil					
	Electrocardiogram Poor		Hydrochloride	C		ORAL		
382 DAY								
	R-Wave Progression							
	Emotional Distress							
	Haematoma							
	Hyperkeratosis							
	Hyperlipidaemia							
	Hyperplasia							
	Pain							
	Pelvic Haematoma							
	Skin Disorder							
	Stress							
	Tinea Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664390-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00218
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arteriosclerosis		Nebivolol					
Initial or Prolonged	Cerebrovascular Accident		Hydrochloride	C		ORAL		
	Encephalopathy		Hypericin	C		ORAL		
	Fall		Risedronate Sodium	C		ORAL		
	Ventricular Hypertrophy							

Date:05/18/05ISR Number: 4664391-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Organ Failure							
	Polytraumatism							
	Pulmonary Embolism							
	Thrombosis							

Date:05/18/05ISR Number: 4664392-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00010
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	885 DAY	
Initial or Prolonged			Metoprolol Tartrate	C			UNKNOWN	
			Aspirin And Magnesium Oxide	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Isosorbide Mononitrate	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	

			Omega-3 Marine Triglycerides	C			
UNKNOWN							
			Clindamycin Hydrochloride	C			
UNKNOWN							

Date:05/18/05ISR Number: 4664393-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00135
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		1681 DAY
Initial or Prolonged	Cardiac Disorder		Procardia	C				
UNKNOWN								
			Zoloft	C				
UNKNOWN								
			Ditropan	C				
UNKNOWN								

Date:05/18/05ISR Number: 4664394-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01348
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664395-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01160
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Accupril	C				
UNKNOWN								
	Depression							
	Myocardial Infarction							

Date:05/18/05ISR Number: 4664396-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664397-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02973
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								
Initial or Prolonged	Increased							
Other	Cardiac Failure							
	Cardiac Failure							
	Congestive							
	Chest Discomfort							
	Chronic Obstructive							
	Pulmonary Disease							
	Diabetes Mellitus							
	Inadequate Control							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Hypertension							
	Mitral Valve Incompetence							
	Obesity							
	Perineal Abscess							
	Pneumonia							
	Post-Traumatic Stress							

Disorder
Renal Failure Chronic
Rhinitis
Sleep Apnoea Syndrome
Swelling
Tricuspid Valve
Incompetence
Venous Stasis

Date:05/18/05ISR Number: 4664398-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664399-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664401-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00227
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		
RESPIRATORY Disability (INHALATION)			Formoterol Fumarate	C				
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		

Date:05/18/05ISR Number: 4664404-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01661
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Cerebrovascular Accident Organ Failure Pain Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664405-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01781
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	107	DAY

Date:05/18/05ISR Number: 4664406-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01789
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

Date:05/18/05ISR Number: 4664407-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01785
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/18/05ISR Number: 4664408-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01787
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664409-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01788
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:05/18/05ISR Number: 4664410-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01501
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664411-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01543
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Anaemia Postoperative Atrial Fibrillation Azotaemia Cardiac Failure Congestive Coagulopathy Dehydration Diarrhoea Dilatation Atrial Emotional Distress Escherichia Urinary Tract Infection Heart Rate Increased Hiatus Hernia Hypertension Hypertensive Heart Disease Hypokalaemia Hypomagnesaemia Hyponatraemia Hypovolaemia		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Influenza Like Illness
International Normalised
Ratio Abnormal
Metabolic Acidosis
Mitral Valve Incompetence
Osteoarthritis
Osteoporosis
Postmenopausal
Renal Disorder
Renal Failure Chronic
Respiratory Failure
Thrombosis
Tricuspid Valve
Incompetence
Urinary Tract Infection
Ventricular Hypertrophy
Ventricular Hypokinesia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664412-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664413-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/18/05ISR Number: 4664414-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664416-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01782
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664417-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01790
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:05/18/05ISR Number: 4664656-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02339
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		33 MON
	Hyperkeratosis		Protonix	C				UNKNOWN
	Myocardial Infarction							
	Rotator Cuff Repair							

Date:05/18/05ISR Number: 4664657-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01530
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664658-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664659-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664670-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664671-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01658
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4664673-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01354
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN								

Date:05/18/05ISR Number: 4664674-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00129
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		

	Left Ventricular Failure		Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY						
	Oedema		Amlodipine Besylate	SS		ORAL
			Carvedilol	C		ORAL
			Ramipril	C		ORAL

Date:05/18/05ISR Number: 4664676-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01660
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/18/05ISR Number: 4664677-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01780
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
4 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4664686-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665214-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Glucophage Xr	C		ORAL		
	Gastric Disorder		Glucophage Xr	C				
UNKNOWN								
	Headache		Glucophage Xr	C		ORAL		
	Hypertension		Lidocaine And					
	Injury		Triamcinolone					
	Joint Dislocation		Acetonide	C				
PARENTERAL							1	DAY
	Labyrinthitis							
	Lower Limb Fracture							
	Overdose							
	Pain							
	Pharyngolaryngeal Pain							
	Pilonidal Cyst							
	Sinus Disorder							
	Sinusitis							

Date:05/18/05ISR Number: 4665229-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00533
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Diclofenac Sodium	SS		ORAL		
Disability	Blood Pressure Increased		Valdecoxib	SS				
UNKNOWN								

Other	Coagulopathy	Magnesium	
	Deep Vein Thrombosis	(Unspecified)	C
UNKNOWN			
	Lymphadenitis	Nebivolol	
	Muscle Spasms	Hydrochloride	C
UNKNOWN			
	Pulmonary Embolism	Budesonide And	
	Syncope	Formoterol Fumarate	C
RESPIRATORY			
	Thrombosis		
(INHALATION)			

Date:05/18/05ISR Number: 4665230-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01998
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	WK
	Diarrhoea		Indocin					
	Drug Ineffective		(Indomethacin)	C				
UNKNOWN								
	Gastric Disorder		Colchicine	C				
UNKNOWN								
	Myocardial Infarction		Prednisone	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								

Date:05/18/05ISR Number: 4665231-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02024
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL		28 MON
Other	Blood Pressure Increased		[Therapy Unspecified]	C				
UNKNOWN	Cerebrovascular Accident							
	Chest Pain							
	Diabetic Retinopathy							
	Dyspnoea							
	Macular Oedema							
	Oedema Peripheral							
	Post-Traumatic Stress Disorder							
	Renal Failure							
	Tricuspid Valve Incompetence							
	Vitreous Haemorrhage							

Date:05/18/05ISR Number: 4665244-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00781
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Myocardial Infarction
	Angina Pectoris
	Angina Unstable
	Cardiac Failure Congestive
	Cardiomegaly
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Restenosis
	Diverticulum
	Dizziness
	Dyspnoea Exertional
	Hypertension

Hypertensive Heart
Disease
Hypothyroidism
Ischaemic Stroke
Lower Respiratory Tract
Infection
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Nasopharyngitis
Pulmonary Congestion
Renal Failure
Sleep Apnoea Syndrome
Somnolence
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Dysfunction

Visual Disturbance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Hydrocodone Bitartrate	C			UNKNOWN	
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	

Date:05/18/05ISR Number: 4665245-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00078
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	902	DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Ogen	C			UNKNOWN	
	Cerebrovascular Accident		Progesterone	C			UNKNOWN	
	Confusional State		Antimicrobial (Unspecified)	C			UNKNOWN	
	Disturbance In Attention							
	Drug Ineffective		Lipitor	C			UNKNOWN	
	Emotional Distress		Toprol Xl Tablets	C			UNKNOWN	
	Knee Arthroplasty		Norvasc	C			UNKNOWN	
	Lacunar Infarction		Aspirin	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Naproxen	C			UNKNOWN	3 YR
			Daypro	C			UNKNOWN	6 MON

Date:05/18/05ISR Number: 4665246-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02632
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Stenosis		Spironolactone	C			UNKNOWN	
	Bundle Branch Block Right		Norvasc	C			UNKNOWN	
	Cardiac Disorder		Aspirin	C			UNKNOWN	
	Coronary Artery Disease		Hydrochlorothiazide	C			UNKNOWN	
	Dilatation Atrial		Xenical	C			UNKNOWN	
	Electrocardiogram Q Waves		Actos	C			UNKNOWN	
	Electrocardiogram St-T		Metformin	C			UNKNOWN	
	Change		Naproxen	C			UNKNOWN	
	Emotional Distress							
	Fatigue							
	Headache							
	Liver Function Test							
	Abnormal							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain In Extremity							
	Prothrombin Time							
	Prolonged							
	Rotator Cuff Syndrome							
	Throat Irritation							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665248-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01126
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adhesion		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain							
Disability	Heart Rate Irregular							
Other	Hypertrophy							
	Limb Injury							
	Myocardial Infarction							
	Rotator Cuff Syndrome							

Date:05/18/05ISR Number: 4665249-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00052
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Morphine Sulfate	C		ORAL		
	Nystagmus		Levomepromazine					
	Therapeutic Response		Maleate	C				
UNKNOWN								
	Decreased		Mepivacaine					
	Tinnitus		Hydrochloride	C				
SUBCUTANEOUS								
	Vertigo							
	Vomiting							

Date:05/18/05ISR Number: 4665250-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
61 YR								
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
146 DAY								
Other	Anxiety		Atenolol	C				
UNKNOWN								

	Blood Calcium Decreased	Aspirin	C	
UNKNOWN				
	Bradycardia	Pravachol	C	
UNKNOWN				
	Brain Neoplasm Malignant	Zocor	C	ORAL
	Colon Cancer Stage Iii	Tylenol	C	
UNKNOWN				
	Colonic Polyp	Ibuprofen	C	
UNKNOWN				
	Decreased Appetite	Piroxicam	C	ORAL
	Emotional Distress			
	Fear			
	Gastritis			
	Gastrointestinal			
	Haemorrhage			
	Hypoparathyroidism			
	Hypotension			
	Iron Deficiency Anaemia			
	Lung Neoplasm			
	Myocardial Infarction			
	Performance Status			
	Decreased			
	Pulmonary Embolism			
	Pulmonary Thrombosis			
	Reflux Oesophagitis			
	Thyroid Cancer Metastatic			
	Upper Respiratory Tract			
	Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665257-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00039
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		969 DAY
Initial or Prolonged	Enzyme Abnormality		Vioxx	SS	Merck & Co., Inc	ORAL		969 DAY
Disability	Heart Injury		Vioxx	SS	Merck & Co., Inc	ORAL		969 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		969 DAY
			Lipitor	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Zoloft	C				UNKNOWN
			Lisinopril	C				UNKNOWN
			Plavix	C				UNKNOWN
			Tricor	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:05/18/05ISR Number: 4665258-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01801
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665259-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01504
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Optic Ischaemic Neuropathy							

Date:05/18/05ISR Number: 4665260-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00124
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Diclofenac	SS			UNKNOWN	
	Chest Pain		Levothyroxine Sodium	C			UNKNOWN	
	Fluid Retention		Flupirtine Maleate	C			UNKNOWN	
	Intervertebral Disc		Bisoprolol	C			UNKNOWN	
	Protrusion		Bisoprolol	C			UNKNOWN	
	Pain		Heparin Sodium	C			UNKNOWN	
	Pancreatitis		Ranitidine	C			UNKNOWN	
	Renal Pain		Telmisartan	C			UNKNOWN	
			Telmisartan	C			UNKNOWN	

Date:05/18/05ISR Number: 4665261-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01803
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/18/05ISR Number: 4665262-4Report Type:Expedited (15-DaCompany Report #SE-MERCK-0505SWE00010
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celecoxib	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665263-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665264-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01319
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	34 MON	
Initial or Prolonged	Bladder Disorder		Monopril	C			UNKNOWN	
	Chest Pain		Toprol Xl Tablets	C		ORAL		
	Coronary Artery		Aspirin	C			UNKNOWN	
	Atherosclerosis		Zocor	C		ORAL		
	Dyspepsia		Tylenol	C			UNKNOWN	
	Emotional Distress		Celebrex	C		ORAL	3 MON	
	Gastric Ulcer		Prempro	C			UNKNOWN	
	Hypertension		Glucosamine	C			UNKNOWN	
	Left Ventricular Failure		Prozac	C		ORAL		
	Mitral Valve Incompetence		Librax Capsules	C			UNKNOWN	
	Myocardial Infarction		Wellbutrin	C			UNKNOWN	26 MON
	Normochromic Normocytic		Nexium	C			UNKNOWN	
	Anaemia		Synthroid	C			UNKNOWN	
	Pericardial Effusion		Prevacid	C			UNKNOWN	
	Tricuspid Valve		Ditropan	C		ORAL		
	Incompetence		Zyrtec	C		ORAL		
			Levaquin	C			UNKNOWN	
			Cefzil	C			UNKNOWN	

				Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Ecotrin	C		ORAL
				Folic Acid	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:05/18/05ISR Number: 4665271-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01221
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Wellbutrin Sr	SS		ORAL	4	YR
	Hypotension		Wellbutrin Sr	SS		ORAL		
			Norvasc	C				
UNKNOWN								
			Dyrenium	C				
UNKNOWN								
			Clonazepam	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								
			Macrobid	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

Date:05/18/05ISR Number: 4665272-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665273-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01804
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665274-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665275-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON

Date:05/18/05ISR Number: 4665276-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665277-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665278-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01806
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:05/18/05ISR Number: 4665279-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665281-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01955
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/05ISR Number: 4665282-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665286-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:05/18/05ISR Number: 4665287-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665303-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/18/05ISR Number: 4665323-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anxiety Cardiac Failure Condition Aggravated General Symptom Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Pain

Date:05/18/05ISR Number: 4665324-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:05/19/05ISR Number: 4666138-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0203USA00374
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Carotid Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Diltiazem Hydrochloride	C		UNKNOWN		
	Heart Rate Decreased							
	Hypertension							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666148-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02116
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Arthralgia		Celebrex	C		
UNKNOWN						
	Bursitis					
	Chest Pain					
	Coronary Artery Disease					
	Coronary Artery Reocclusion					
	Diarrhoea					
	Dyspnoea					
	Erectile Dysfunction					
	Haematochezia					
	Haematocrit Decreased					
	Haematoma					
	Hydrocele					
	Hypercholesterolaemia					
	Injury					
	Mitral Valve Incompetence					
	Myocardial Infarction					
	Nocturia					
	Post Procedural Complication					
	Sinus Bradycardia					
	Tricuspid Valve Incompetence					

Date:05/19/05ISR Number: 4666150-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03884
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 488 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Depression		Prevacid	C		
Disability UNKNOWN	Fatigue		Viagra	C		
	Post-Traumatic Stress Disorder					

Date:05/19/05ISR Number: 4666151-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03708
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bladder Disorder							
	Blood Potassium Increased							
	Blood Pressure Inadequately Controlled							
	Blood Sodium Decreased							
	Coronary Artery Disease							
	Myocardial Infarction							
	Oedema Peripheral							
	Renal Failure Chronic							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666152-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00144
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666153-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02027
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Imuran (Azathioprine)	C				
Disability			Prednisone	C				

Date:05/19/05ISR Number: 4666154-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00023
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Fondaparinux Sodium	SS			SUBCUTANEOUS	
			Acetaminophen	C		ORAL		
			Iron (Unspecified)	C		ORAL		
			Tinzaparin Sodium	C			SUBCUTANEOUS	4 DAY
			Omeprazole	C		ORAL		
			Irbesartan	C		ORAL		

Date:05/19/05ISR Number: 4666155-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0404USA00099
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis Bladder Spasm

Disability
Other

Cardiomegaly
Cellulitis
Cerebral Haemorrhage
Cerebrovascular Accident
Convulsion
Depression
Emotional Distress
Facial Pain
Fracture Malunion
Generalised Anxiety
Disorder
Haemorrhage
Hypertension
Hypertriglyceridaemia
Hypotension
Nasal Congestion
Post-Traumatic Stress
Disorder
Skin Laceration
Sleep Disorder
Transient Ischaemic
Attack
Vaginal Mycosis
Ventricular Hypertrophy
White Blood Cell Count

Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Keflex	C			UNKNOWN	
	Adenosine	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	

Date:05/19/05ISR Number: 4666156-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00060
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	C			UNKNOWN	
Other	Anaemia		Celebrex	C			UNKNOWN	
	Angina Unstable		Aspirin	C			UNKNOWN	
	Angiodysplasia		Aspirin	C			UNKNOWN	
	Blood Disorder		Imdur	C			UNKNOWN	
	Chest Pain		Imdur	C			UNKNOWN	
	Congestive Cardiomyopathy		Glucophage	C			UNKNOWN	
	Dyspnoea		Diabinese	C			UNKNOWN	
	Gastric Haemorrhage		Cozaar	C			UNKNOWN	
	Gastritis		Plendil	C			UNKNOWN	
	Gastrointestinal		Diovan	C			UNKNOWN	
	Haemorrhage		Lopressor	C			UNKNOWN	

		Haematochezia		Toprol Xl Tablets	C		
UNKNOWN		901 DAY					
		Hypochromic Anaemia		Norvasc	C		
UNKNOWN							
		Hypomagnesaemia		Lanoxin	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Heparin	C		
UNKNOWN							
		Myocardial Infarction		Plavix	C		
UNKNOWN							
		Palpitations		Zocor	C		
UNKNOWN							
		Panic Disorder					
		Peptic Ulcer					
		Respiratory Tract Infection					
		Shoulder Pain					
		Sinus Bradycardia					
		Staphylococcal Bacteraemia					
		Urosepsis					
		Ventricular Dysfunction					

Date:05/19/05ISR Number: 4666157-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02980
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Zestril	C				
UNKNOWN								
	Coronary Artery Disease		Aspirin	C				
UNKNOWN								
	Groin Abscess		Hydrodiuril	C				
UNKNOWN								
	Hyperlipidaemia		Toprol Xl Tablets	C				
UNKNOWN								
	Lymphocele		Lipitor	C				
UNKNOWN								
	Meniere'S Disease		Synthroid	C				
UNKNOWN								
	Myocardial Infarction							
	Renal Disorder							
	Sinus Bradycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666158-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00122
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	200	DAY
	Oedema Peripheral		Diclofenac Sodium	C			UNKNOWN	
	Optic Ischaemic Neuropathy Scotoma Vision Blurred							

Date:05/19/05ISR Number: 4666163-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666164-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01672
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666165-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666166-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Date:05/19/05ISR Number: 4666167-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	24	MON

Date:05/19/05ISR Number: 4666168-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666169-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01671
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1187	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666170-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01670
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666175-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01357
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:05/19/05ISR Number: 4666176-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	WK

Date:05/19/05ISR Number: 4666177-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01675
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666180-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01363
Age:27 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666183-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505USA01815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	130 DAY	

Date:05/19/05ISR Number: 4666807-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
Disability	Barrett'S Oesophagus
Other	Benign Prostatic Hyperplasia
	Bladder Obstruction
	Cardiac Failure Congestive
	Cellulitis
	Chronic Obstructive Pulmonary Disease
	Constipation
	Coronary Artery Disease
	Cough
	Duodenal Ulcer

		Emotional Distress					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hiatus Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
		Injury		Zocor	SS		ORAL
		Interstitial Lung Disease		[Therapy			
		Leukocytosis		Unspecified]	C		
UNKNOWN							
		Meniscus Lesion		Tylenol Arthritis			
		Metabolic Acidosis		Extended Relief	C		
UNKNOWN							
		Monarthritis		Hydrocodone			
		Myocardial Infarction		Bitartrate	C		
UNKNOWN							
		Oesophageal Ulcer		Aspirin	C		
UNKNOWN							
		Pain In Extremity		Diltiazem Msd	C		
UNKNOWN							
		Pleural Disorder		Glucophage	C		
UNKNOWN							
		Renal Failure		Glyburide	C		
UNKNOWN							
		Renal Tubular Necrosis					
		Rhabdomyolysis					
		Rib Fracture					
		Rotator Cuff Syndrome					

Date:05/19/05ISR Number: 4666811-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Ageusia
Disability	Anosmia
Other	Arthropathy
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Chronic Obstructive Pulmonary Disease
	Colon Adenoma
	Decreased Appetite
	Deep Vein Thrombosis
	Diverticulum
	Emotional Distress

Essential Hypertension
Faecal Incontinence
Fatigue
Fibromyalgia
Haemangioma
Haematochezia
Hypercoagulation
Hypertension
Injury
Lumbar Spinal Stenosis
Macular Degeneration
Meniscus Lesion
Nausea
Nephrolithiasis
Osteopenia
Osteoporosis
Pancreatitis
Pulmonary Embolism
Pulmonary Hypertension
Rectal Haemorrhage
Renal Cyst
Renal Disorder
Thrombophlebitis

		Toe Deformity					
		Urinary Incontinence					
		Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Atenolol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Niaspan	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Acetaminophen	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Herbs (Unspecified)	C		
UNKNOWN							

Date:05/19/05ISR Number: 4666814-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00162
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Glucose Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
25	DAY						
Disability		Cerebral Atrophy		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
25	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Celecoxib	C		ORAL
281	DAY						
				Celecoxib	C		ORAL
281	DAY						
				Pantoprazole Sodium	C		ORAL
				Ramipril	C		ORAL
				Heparin	C		
UNKNOWN							

Ramipril	C	ORAL
Flunarizine Hydrochloride	C	ORAL

Date:05/19/05ISR Number: 4666815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0303USA00626
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Strangulated Hernia
	Acute Prerenal Failure
	Anaemia
	Benign Prostatic Hyperplasia
	Cardiac Failure Congestive
	Carotid Bruit
	Carpal Tunnel Syndrome
	Colonic Polyp
	Deafness Neurosensory
	Emotional Distress
	Gastric Ulcer Haemorrhage
	Gastritis
	Gastritis Erosive
	Gastroenteritis
	Gastrointestinal Disorder
	Haemorrhoids
	Hiatus Hernia
	Intervertebral Disc

		Degeneration					
		Melaena					
		Mitral Valve Incompetence					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rotator Cuff Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
244	DAY						
		Small Intestinal		Ultram	C		
UNKNOWN							
		Obstruction		Centrum	C		
UNKNOWN							
		Spinal Column Stenosis		Carisoprodol	C		
UNKNOWN							
		Spinal Osteoarthritis		Vicodin Tablets	C		
UNKNOWN							
		Sudden Hearing Loss		Micronase	C		
UNKNOWN							
		Thrombocytopenia		Vasotec	C		
UNKNOWN							
		Tricuspid Valve		Zyloprim	C		
UNKNOWN							
		Incompetence		Lipitor	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Ecotrin	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:05/19/05ISR Number: 4666816-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00529
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Colitis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Depression		Aspirin	C		ORAL
Disability	Diarrhoea		Hypericin	C		
UNKNOWN						
	Dizziness		Carvedilol	C		ORAL
1254 DAY						

	Dyspepsia	Salvia	C		ORAL
	Fungal Infection	Tramadol Hydrochloride	C	39 DAY	ORAL
	Gastroenteritis	Metoclopramide Hydrochloride	C	6 DAY	ORAL
	Gastrointestinal Disorder	Amphotericin B	C	10 DAY	ORAL
	Herpes Zoster	Ciprofloxacin Hydrochloride	C	11 DAY	ORAL
	Hypertension	Tramadol Hydrochloride	C	158 DAY	ORAL
	Myocardial Infarction	Lactobacillus Helveticus (As Drug)	C	16 DAY	ORAL
	Nausea	Lactobacillus Acidophilus (As Drug)	C	16 DAY	ORAL
	Panic Disorder	Saccharomyces Boulardii (As Drug)	C	7 DAY	ORAL
	Ventricular Fibrillation	Escherichia Coli (As Drug)	C	31 DAY	ORAL
		[Therapy Unspecified]	C	UNKNOWN	

Date:05/19/05ISR Number: 4666820-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00113
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Chest Pain
	Full Blood Count Abnormal
Other	Gastric Ulcer
	Hypertension
	Muscle Spasms
	Nausea

		Oedema Peripheral					
		Rash					
		Silent Myocardial	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
				Liotrix	C		
UNKNOWN							
				Metoclopramide	C		
UNKNOWN							
				Calcium Carbonate And Cholecalciferol	C		
UNKNOWN							

Date:05/19/05ISR Number: 4666821-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02692
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:05/19/05ISR Number: 4666824-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03298
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Coumadin	C		
UNKNOWN						
Disability	Anxiety		Tenormin	C		
UNKNOWN						
Other	Chest Pain		Pravachol	C		
UNKNOWN						
	Coronary Artery Occlusion		Aspirin	C		
UNKNOWN						
	Diverticulitis					
	Diverticulum					
	Dizziness					
	Epigastric Discomfort					
	Gastroenteritis					
	Gastrointestinal					
	Haemorrhage					

Headache
Hiatus Hernia
Hypercholesterolaemia
Intervertebral Disc
Protrusion
Lumbar Radiculopathy
Mitral Valve Incompetence
Mitral Valve Prolapse
Myocardial Infarction
Osteoarthritis
Pain
Platelet Disorder
Rectal Polyp
Urinary Retention

Date:05/19/05ISR Number: 4666825-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03238
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1093 DAY	
	Emotional Distress		Zocor	C		ORAL	1827 DAY	
	Gout		Zocor	C		ORAL	1827 DAY	
	Haematochezia		Tylenol	C			UNKNOWN	3653 DAY
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666826-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01886
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666827-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00183
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666828-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02131
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Triglycerides Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vasotec	C			UNKNOWN	
	Cardiac Failure		Prozac	C			UNKNOWN	
	Congestive		Aspirin	C			UNKNOWN	3616 DAY
	Cerebrovascular Accident		Norvasc	C			UNKNOWN	42 DAY
	Depression		Xanax	C			UNKNOWN	
	Diabetes Mellitus		Tylenol With Codeine #3	C			UNKNOWN	
	Hernia		Coumadin	C			UNKNOWN	75 DAY
	Hypertension		Lasix (Furosemide)	C			UNKNOWN	
	Low Density Lipoprotein Increased		Avandia	C			UNKNOWN	
	Myocardial Infarction		Roxicodone	C			UNKNOWN	390 DAY

			Ibuprofen	C
UNKNOWN	390	DAY		
			Pravachol	C
UNKNOWN	641	DAY		
			Pravachol	C
UNKNOWN	641	DAY		

Date:05/19/05ISR Number: 4666830-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00127
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL		878 DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		878 DAY
	Aspartate		Zoloft	C				UNKNOWN
	Aminotransferase		Prevacid	C				UNKNOWN
	Increased		Coumadin	C				UNKNOWN
	Atherosclerosis							
	Blood Lactate Dehydrogenase Increased							
	Cardiac Arrest							
	Foot Fracture							
	Osteonecrosis							
	Peripheral Vascular Disorder							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666837-9Report Type:Expedited (15-DaCompany Report #NL-MERCK-0505NLD00009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00852
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Diovan	C			UNKNOWN	
	Myocardial Infarction		Pravachol	C		ORAL		
	Polytraumatism		Niaspan	C		ORAL		
			Lasix (Furosemide)	C		ORAL		
			Norvasc	C			UNKNOWN	

Date:05/19/05ISR Number: 4666839-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01496
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666840-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0505DNK00008
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	1565 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	1565 DAY	
			Amlodipine Besylate	C		ORAL		

Furosemide	C	ORAL
Esomeprazole		
Magnesium	C	ORAL
Bromazepam	C	ORAL

Date:05/19/05ISR Number: 4666841-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02890
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Aortic Valve Incompetence
	Arterial Thrombosis
	Atherosclerosis
	Bladder Disorder
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cardiac Valve Disease
	Cardiovascular Disorder
	Coronary Artery Disease
	Deep Vein Thrombosis
	Emotional Distress
	Hypertension
	Intracardiac Thrombus
	Mitral Valve Prolapse

		Myocardial Infarction					
		Pain					
		Postoperative Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
		Attack		Protonix	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		
UNKNOWN							
				Micardis	C		
UNKNOWN							
				Zetia	C		ORAL
				Lipitor	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Imdur	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:05/19/05ISR Number: 4666842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01362
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/19/05ISR Number: 4666843-4Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00010
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 DAY

Date:05/19/05ISR Number: 4666844-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01419
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01499
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Myocardial Infarction Polytraumatism Pulmonary Embolism Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666852-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01512
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Multi-Organ Disorder							
	Pain							
	Polytraumatism							

Date:05/19/05ISR Number: 4666853-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02979
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
902 YR								
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
902 YR								
Disability	Depression		Prempro	C		ORAL		
	Hypertension		Advil	C				
UNKNOWN								
	Idiopathic		Neurontin	C		ORAL		
	Thrombocytopenic Purpura		Tylenol	C		ORAL		
	Ischaemia		Klonopin	C				
UNKNOWN								
	Memory Impairment		Aspirin	C				
UNKNOWN								
	Urinary Tract Infection							

Date:05/19/05ISR Number: 4666854-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01784
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Multi-Organ Disorder							
	Myocardial Infarction							

Date:05/19/05ISR Number: 4666855-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01802
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON

Date:05/19/05ISR Number: 4666856-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

Date:05/19/05ISR Number: 4666857-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:05/19/05ISR Number: 4666858-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01510
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666860-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666870-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02022
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:05/19/05ISR Number: 4666872-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02083
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666873-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01511
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4666874-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						

Date:05/19/05ISR Number: 4666885-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure Congestive Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/19/05ISR Number: 4666886-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01786
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death Multi-Organ Disorder Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/19/05ISR Number: 4666908-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03074
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	43 MON	
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	43 MON	
	Increased		Aspirin	C			UNKNOWN	
	Cardiac Disorder		[Therapy					
	Cardiac Failure		Unspecified]	C			UNKNOWN	
	Congestive							
	Carotid Artery Stenosis							
	Chest Pain							
	Depression							
	Dyspnoea							
	Hypertension							
	Muscle Fatigue							
	Myocardial Infarction							
	Post-Traumatic Stress Disorder							

Date:05/19/05ISR Number: 4666912-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01798
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/19/05ISR Number: 4668613-XReport Type:Expedited (15-DaCompany Report #2005072203
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG,	
Initial or Prolonged	Blood Disorder						1 IN 1 D),	
Other	Body Temperature						ORAL	

	Increased	Celebrex (Celecoxib)	SS	ORAL (ONCE DAILY),
	Chest Wall Pain			ORAL
	Dehydration	Vioxx (Rofecoxib)	SS	
	Diarrhoea	Lopressor (Metoprolol Tartrate)	C	
	Drug Ineffective	Isosorbide (Isosorbide)	C	
	Fall	Metoprolol (Metoprolol)	C	
	Malaise	Pravachol (Pravastatin Sodium)	C	
	Pain	Triamterene (Triamterene)	C	
	Pneumonia	Paxil (Paroxetine Hydrochloride)	C	
	Skin Discolouration	Xanax (Alprazolam)	C	
	Vomiting	Vitamin E (Vitamin E)	C	

Date:05/19/05ISR Number: 4668842-5Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Base Excess Increased Blood Bicarbonate Decreased Blood Ph Increased Carcinoembryonic Antigen Increased Cardiac Failure Cardio-Respiratory Arrest Cardiomegaly Colorectal Cancer Recurrent Dyspnoea Haematocrit Decreased Haemoglobin Decreased Infection Laboratory Test Abnormal Lung Consolidation Mean Cell Haemoglobin Concentration Decreased Mean Cell Haemoglobin Decreased Monocyte Count Increased Neutrophil Count Increased Oxygen Saturation Decreased Pco2 Decreased Pleural Effusion Pneumonia Post Procedural Complication Prothrombin Time Prolonged Red Cell Distribution Width Increased Therapy Non-Responder White Blood Cell Count Increased	Foreign Study Health Professional Other	Tab Vioxx (Rofecoxib)	PS C		ORAL	25 MG/DAILY, PO	293 DAY

Date:05/19/05ISR Number: 4668845-0Report Type:Expedited (15-DaCompany Report #WAES 0505GBR00076
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Increased	Foreign	Tab Vioxx					
Hospitalization -	Blood Sodium Decreased	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Cardiac Arrest	Health						
PO							676	DAY
	Chills	Professional	Clomipramine Hcl	C				
	Pco2 Decreased	Other	Lactulose	C				
	Pleural Effusion		Oxybutynin	C				

Date:05/19/05ISR Number: 4669085-1Report Type:Expedited (15-DaCompany Report #2005066739
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Death	Asthenia
Other	Cardio-Respiratory Arrest

		Electrocardiogram Repolarisation Abnormality	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
		Heart Rate Increased	Foreign	Celebrex (Celecoxib)	PS		ORAL	400 MG (200 MG, 2 IN 1 D), ORAL	
		Mitral Valve Incompetence	Health Professional						
			Company Representative	Vioxx (Rofecoxib)	SS		ORAL	50 MG (25 MG, 2 IN 1 D), ORAL	
			Other						
				Calcort (Deflazacort)	C				
				Condrosulf (Chondroitin Sulfate Sodium)	C				
				Blopress (Andesartan Cilexetil)	C				
				Dafalgan (Paracetamol)	C				
				Lexotanil (Bromazepam)	C				
				Tramadolor (Tramadol Hydrochloride)	C	Hexal			
				Duspatalin "Duphar" (Mebeverine Hydrochloride)	C				
				Ibuprofen (Ibuprofen)	C				
				Neurontin (Gabapentin)	C				

Date:05/20/05ISR Number: 4667799-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02970
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Chest Pain	Cozaar	C		
UNKNOWN					
	Diplopia	Aspirin	C		
UNKNOWN					
	Dyspnoea	Vitamins			
	Gastrointestinal Disorder	(Unspecified)	C		
UNKNOWN					
	Headache	Lexapro	C		
UNKNOWN					
	Hypersensitivity	Skelaxin	C		
UNKNOWN					
	Hypokalaemia	Maxzide	C		
UNKNOWN					
	Multiple Allergies	Prilosec	C		
UNKNOWN					
	Nephrolithiasis	[Therapy			
	Paraesthesia	Unspecified]	C		
UNKNOWN					
	Pelvic Mass	Estrogens			
	Sinusitis	(Unspecified)	C		
UNKNOWN					
	Tachycardia	Iron (Unspecified)	C		
UNKNOWN					
	Transient Ischaemic Attack				
	Urinary Tract Infection				
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4667806-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03637
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Increased		Betoptic	C				
UNKNOWN								
	Death		Darvocet-N	C				
UNKNOWN								
	Emotional Distress		Atenolol	C		ORAL		
	Myocardial Infarction		Saw Palmetto					
	Pain In Extremity		Standardized Extract	C				
UNKNOWN							3	YR

Date:05/20/05ISR Number: 4667807-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02541
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Soma	C				
UNKNOWN								
	Asthenia		Soma	C				
UNKNOWN								
	Blood Cholesterol		Amitriptyline					
	Increased		Hydrochloride	C				
UNKNOWN								
	Cerebrovascular Accident		Flexeril	C				
UNKNOWN								
	Dyspepsia		Flexeril	C				
UNKNOWN								
	Dyspnoea		Apap	C				
UNKNOWN								
	Gastrooesophageal Reflux		Codeine	C				
UNKNOWN								
	Disease							
	Generalised Anxiety							
	Disorder							
	Haemorrhoids							
	Nausea							
	Non-Cardiac Chest Pain							
	Rectal Prolapse							
	Syncope							

Vomiting

Date:05/20/05ISR Number: 4667810-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01521
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Acute Myocardial Infarction Anxiety Aortic Valve Incompetence Atrial Hypertrophy Blood Bilirubin Increased Cardiac Valve Disease Change Of Bowel Habit Chest Pain Coronary Artery Atherosclerosis Dyspnoea Hand Fracture Mitral Valve Incompetence Myocardial Infarction Rectal Haemorrhage Renal Failure Tricuspid Valve Incompetence Vascular Calcification

Ventricular Hypertrophy

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	66	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	66	DAY

Date:05/20/05ISR Number: 4667811-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00923
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Xenical	C			UNKNOWN	
	Carotid Bruit							
	Chest Pain							
	Erectile Dysfunction							
	Intermittent Claudication							
	Skin Laceration							
	Ventricular Hypokinesia							
	Weight Increased							

Date:05/20/05ISR Number: 4667820-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00695
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Increased		Synthroid	C			UNKNOWN	
	Hepatic Function Abnormal							
	Hepatomegaly							

Date:05/20/05ISR Number: 4667822-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00529
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4667823-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00231
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Myocardial Infarction		Tylenol	C				UNKNOWN
								10 YR
	Prostate Cancer		Advair	C				UNKNOWN
			Flomax (Morniflumate)	C				UNKNOWN
			Serevent	C				UNKNOWN
			Ventilan (Albuterol)	C				UNKNOWN
			Zithromax	C				UNKNOWN
			Fenamin (Promethazine)	C				UNKNOWN
			Cipro	C				UNKNOWN
			Hydrocodone/Apap	C				UNKNOWN
			Motrin	C				UNKNOWN
								7 YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4667824-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:05/20/05ISR Number: 4667825-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03470
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		1340 MON
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Lexapro	C		ORAL		326 DAY
	Cerebrovascular Accident		Lexapro	C		ORAL		326 DAY
	Chest Pain		Kemadrin	C		ORAL		
	Chronic Obstructive		Depakote	C		ORAL		1188 DAY
	Pulmonary Disease		Aspirin	C		ORAL		
	Costochondritis		Atenolol	C		ORAL		2952 DAY
	Dependent Personality		Albuterol	C				RESPIRATORY
	Disorder							(INHALATION)
	Dyslipidaemia		Micro K	C		ORAL		
	Emotional Distress		Seroquel	C		ORAL		1029 DAY
	Emphysema		Gemfibrozil	C		ORAL		2419 DAY
	Extrapyramidal Disorder		Persantine	C		ORAL		
	Gout		Nexium	C		ORAL		
	Haemorrhoids		Nph Insulin	C				SUBCUTANEOUS
	Herpes Virus Infection		Nicoderm Patch	C				UNKNOWN
	Hypertension		Zyprexa	C				UNKNOWN
	Major Depression							

Meniscus Lesion
Musculoskeletal
Discomfort
Myalgia
Nephrolithiasis
Obsessive-Compulsive
Personality Disorder
Oedema Peripheral
Pain
Personality Disorder
Renal Cyst
Rhinitis Allergic
Schizoaffective Disorder
Transient Ischaemic
Attack

Date:05/20/05ISR Number: 4667826-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00553
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Abdominal Pain Drug Hypersensitivity Drug Ineffective Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4667828-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02977
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		26 MON
Initial or Prolonged	Blood Cholesterol		Aspirin	C				UNKNOWN
	Increased		Lipitor	C				UNKNOWN
	Myocardial Infarction		Prednisone	C				UNKNOWN
	Spinal Column Stenosis		Lisinopril-Bc	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN

Date:05/20/05ISR Number: 4667829-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00099
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		1060 DAY
Hospitalization -	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		1060 DAY
Initial or Prolonged	Blood Glucose Decreased		Coumadin	C				UNKNOWN
	Cardiac Failure		Theophylline	C			725 DAY	UNKNOWN
	Congestive		Theophylline	C				UNKNOWN
	Coronary Artery		Combivent	C				UNKNOWN
	Atherosclerosis		Prilosec	C				UNKNOWN
	Coronary Artery Thrombosis							
	Diabetes Mellitus Non-Insulin-Dependent							
	Hypertension							
	Pneumonia							

Date:05/20/05ISR Number: 4667830-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01811
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4667839-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4667840-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01959
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:05/20/05ISR Number: 4667841-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	31	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4667842-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON

Date:05/20/05ISR Number: 4667843-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0505BRA00064
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Haemorrhage Muscle Spasms Shock		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4667844-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668027-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01355
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668028-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00428
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Life-Threatening Hospitalization - Initial or Prolonged UNKNOWN	Dyspnoea Gout Myocardial Infarction		Vioxx [Therapy Unspecified] [Therapy Unspecified] [Therapy Unspecified] Aspirin	PS C C C C	Merck & Co., Inc	ORAL

Date:05/20/05ISR Number: 4668029-6Report Type:Expedited (15-DaCompany Report #BR-MERCK-0505BRA00064
Age: Gender: I/FU:I

Outcome Dose Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	Anaemia Gastrointestinal Haemorrhage Muscle Spasms Shock		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668033-8Report Type:Expedited (15-DaCompany Report #BR-MERCK-0505BRA00056
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cholecalciferol	C		ORAL		
			Riboflavin	C		ORAL		
			Benserazide Hydrochloride And Levodopa	C		ORAL		
			Benserazide Hydrochloride And Levodopa	C		ORAL		

Date:05/20/05ISR Number: 4668034-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00009
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	122 DAY	
	Infarction		Cyanocobalamin	C			UNKNOWN	
	Myocardial Infarction							
	Sudden Death							

Date:05/20/05ISR Number: 4668035-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01667
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668037-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01597
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	

Initial or Prolonged [Therapy
Disability Unspecified] C
UNKNOWN

Xanax C
UNKNOWN

Date:05/20/05ISR Number: 4668038-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:05/20/05ISR Number: 4668039-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01791
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668040-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01692
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	11	MON

Date:05/20/05ISR Number: 4668041-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01679
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:05/20/05ISR Number: 4668042-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01793
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	52	MON
	Myocardial Infarction							

Date:05/20/05ISR Number: 4668043-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01794
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Other	Cardiovascular Disorder							
	Death							
	Myocardial Infarction							
	Organ Failure							

Date:05/20/05ISR Number: 4668044-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01684
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx Prempro	PS C	Merck & Co., Inc	ORAL		UNKNOWN

Date:05/20/05ISR Number: 4668045-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01743
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Anxiety
Disability	Arterial Stenosis
Other	Arthralgia
	Atelectasis
	Atherosclerosis
	Back Pain
	Breast Disorder Female
	Buttock Pain
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Chest Pain
	Corneal Abrasion
	Coronary Artery Disease
	Depression

		Dysphonia					
		Headache					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL
2	MON						
		Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
2	MON						
		Muscle Spasms		Premarin	C		ORAL
		Myocardial Infarction		Zocor	C		
UNKNOWN							
		Myocardial Ischaemia		Voltaren	C		ORAL
		Neck Injury		Flexeril	C		ORAL
		Neck Pain		Guaifenesin And			
		Neuropathy Peripheral		Pseudoephedrine			
		Pain In Extremity		Hydrochloride	C		ORAL
		Pyrexia		Amoxicillin	C		
UNKNOWN							
		Rotator Cuff Syndrome		Pravachol	C		
UNKNOWN							
		Skin Irritation		Lopid	C		ORAL
		Tendonitis					
		Ventricular Extrasystoles					

Date:05/20/05ISR Number: 4668046-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01952
Age:19 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/20/05ISR Number: 4668047-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01799
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
50	MON						
		Polytraumatism					
		Thrombosis					

Date:05/20/05ISR Number: 4668048-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668049-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:05/20/05ISR Number: 4668050-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01953
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Amnesia Aphasia Cerebrovascular Accident Hemiplegia Post Procedural Complication		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668051-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02135
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668052-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03184
Age:94 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aortic Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Aspirin	SS		ORAL		
Other	Atelectasis		Dyazide	C				
UNKNOWN								
	Blood Pressure		Oxybutynin	C		ORAL		
	Fluctuation		Propranolol					
	Bronchitis		Hydrochloride	C				
UNKNOWN								
	Cardiomegaly		Isosorbide	C				
UNKNOWN								
	Cataract		Hyzaar	C		ORAL		
	Chest Pain		Ciprofloxacin	C				
UNKNOWN								
	Chronic Obstructive		Ciprofloxacin	C				
UNKNOWN								
	Pulmonary Disease		Albuterol	C				
RESPIRATORY								
	Chronic Sinusitis							
(INHALATION)								
	Colon Cancer		Nitroglycerin	C				
UNKNOWN								
	Coronary Artery Disease		Ativan	C		ORAL		
	Deep Vein Thrombosis		Quinine	C				
UNKNOWN								
	Dizziness							
	Dyspepsia							
	Dysphagia							
	Dyspnoea							
	Ecchymosis							
	Emotional Distress							
	Essential Tremor							
	Faeces Discoloured							

Fibromyalgia
Fluid Overload
Gastric Ulcer Haemorrhage
Gastritis
Gastroenteritis Viral
Gastrointestinal
Haemorrhage
Headache
Hypertension
Injury
Iron Deficiency Anaemia
Macular Degeneration
Myocardial Infarction
Neoplasm
Oesophageal Pain
Osteoarthritis
Osteoporosis
Pseudoexfoliation Of Lens
Capsule
Pyrexia
Renal Cyst
Rheumatic Fever
Rhinitis Allergic
Stress Incontinence
Venous Stasis
Vertigo
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668053-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02107
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	220 DAY	
	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL	220 DAY	
			Glucosamine	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:05/20/05ISR Number: 4668054-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Oxybutynin Chloride	C		ORAL		
	Myocardial Infarction		Amantadine Sulfate	C		ORAL		
			Levocarnitine Tartrate	C			UNKNOWN	
			Sodium Lauryl Sulfoacetate	C			RECTAL	

Date:05/20/05ISR Number: 4668055-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00061
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1260 DAY	
Hospitalization - Initial or Prolonged	Myocardial Infarction		Oxybutynin	C		ORAL	RECTAL	
			Sodium Bicarbonate	C				
Disability			[Therapy Unspecified]	C			RECTAL	

Date:05/20/05ISR Number: 4668056-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01798
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:05/20/05ISR Number: 4668057-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:05/20/05ISR Number: 4668058-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1125	DAY

Date:05/20/05ISR Number: 4668059-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01950
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668060-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668061-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668062-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable Chest Pain Coronary Artery Disease Dyspnoea Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	47	MON

Date:05/20/05ISR Number: 4668063-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668064-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00201
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness Postural							
	Gastrointestinal Ulcer							
	Haemorrhage							
	Haematemesis							
	Intestinal Perforation							
	Joint Swelling							
	Malaise							
	Oedema Peripheral							

Date:05/20/05ISR Number: 4668065-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00265
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Death	Arthritis Bacterial
Hospitalization - Initial or Prolonged	Autoimmune Disorder
	Bursitis
	Cardiac Disorder
	Diabetes Mellitus
	Insulin-Dependent
	Dyspnoea
	Gastroenteritis
	Salmonella

		Hepatic Cirrhosis					
		Hepatitis B					
		Liver Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Necrotising Fasciitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia Legionella					
		Rheumatoid Arthritis					
		Systemic Inflammatory					
		Response Syndrome					
		Tachyarrhythmia					

Date:05/20/05ISR Number: 4668066-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00529
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Colitis		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Occlusion		Aspirin	C		ORAL
Disability	Depression		Hypericin	C		
UNKNOWN						
Other	Diarrhoea		Carvedilol	C		ORAL
1254 DAY						
	Dizziness		Salvia	C		ORAL
	Dyspepsia		Tramadol			
	Fungal Infection		Hydrochloride	C		ORAL
39 DAY						
	Gastroenteritis		Metoclopramide			
	Gastrointestinal Disorder		Hydrochloride	C		ORAL
6 DAY						
	Herpes Zoster		Amphotericin B	C		ORAL
10 DAY						
	Hypertension		Ciprofloxacin			
	Myocardial Infarction		Hydrochloride	C		ORAL
11 DAY						
	Nausea		Tramadol			
	Panic Disorder		Hydrochloride	C		ORAL
158 DAY						
	Ventricular Fibrillation		Lactobacillus			
			Helveticus (As Drug)	C		ORAL
16 DAY						
			Lactobacillus			
			Acidophilus (As			
			Drug)	C		ORAL
16 DAY						

Saccharomyces Boulardii (As Drug)	C	ORAL	7 DAY
Escherichia Coli (As Drug)	C	ORAL	31 DAY
[Therapy Unspecified]	C		UNKNOWN

Date:05/20/05ISR Number: 4668067-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02858
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Anxiety
	Blood Pressure Increased
	Bursitis
	Calculus Urinary
	Coronary Artery Occlusion
	Cyst
	Drug Hypersensitivity
	Ejection Fraction Decreased
	Goitre
	Herpes Virus Infection
	Joint Lock

	Nephrolithiasis						
	Pain						
	Shoulder Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR
	Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	5 YR
	Supraventricular Extrasystoles		Gastrointestinal Preparations (Unspecified)	C			UNKNOWN
	Thermal Burn		Hydrochlorothiazide	C			UNKNOWN
	Ventricular Extrasystoles		Levothyroxine Sodium	C			UNKNOWN
	Ventricular Tachycardia		Atacand	C			UNKNOWN
			Premarin	C			UNKNOWN

Date:05/20/05ISR Number: 4668068-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03239
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	
Other	Cerebral Atrophy		[Therapy Unspecified]	C			UNKNOWN
	Cerebral Ischaemia		Ecotrin	C		ORAL	
	Cerebrovascular Accident		Accupril	C			UNKNOWN
	Diplopia		Hyzaar	C			UNKNOWN
	Emotional Distress		Advil	C			UNKNOWN
	Gastrooesophageal Reflux						
	Disease						
	Procedural Hypotension						

Date:05/20/05ISR Number: 4668069-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00359
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	783 DAY	
Hospitalization - Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiovascular Disorder		Orphenadrine	C			UNKNOWN	
	Chest Pain		Furosemide	C			UNKNOWN	
	Coronary Artery Disease		Isosorbide	C			UNKNOWN	
	Dyspnoea		Isosorbide	C			UNKNOWN	
	Myocardial Infarction		Lorazepam	C			UNKNOWN	
	Oedema Peripheral		Lorazepam	C		ORAL		
			Nitroquick	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	
			Spironolactone	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Uniphyl	C		ORAL		
			Uniphyl	C		ORAL		
			Uniphyl	C		ORAL		
			Uniphyl	C		ORAL		

Date:05/20/05ISR Number: 4668070-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03525
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Myocardial Infarction
	Adverse Event

		Cardiac Arrest					
		Cardiac Disorder					
		Cardiovascular Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chills		Vioxx	PS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
3	YR						
		Dyspnoea		Toprol Xl Tablets	C		ORAL
		Fall		Aspirin	C		ORAL
		Headache		Aspirin	C		ORAL
		Increased Upper Airway		Zocor	C		ORAL
1	YR						
		Secretion		Levaquin	C		
UNKNOWN							
		Joint Sprain		Plavix	C		
UNKNOWN							
		Myocardial Infarction		Zocor	C		ORAL
		Nausea		Vitamins			
		Organ Failure		(Unspecified)	C		
UNKNOWN							
		Pain		Saw Palmetto	C		
UNKNOWN							
		Pollakiuria		Ubidecarenone	C		
UNKNOWN							
		Pyrexia		Ginkgo Biloba			
		Vomiting		Extract	C		
UNKNOWN							

Date:05/20/05ISR Number: 4668071-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00115
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR					
Initial or Prolonged	Angina Pectoris		Ventolin (Albuterol)	C		
UNKNOWN						
Other	Aortic Aneurysm		Tricor	C		
UNKNOWN						
	Blood Cholesterol		Cartia Xt	C		
UNKNOWN						
	Increased		Furosemide	C		
UNKNOWN						
	Blood Triglycerides		Ambien	C		
UNKNOWN						

	Increased	Paxil	C
UNKNOWN			
	Cardiac Disorder	Aspirin	C
UNKNOWN			
	Cardiac Failure	Isosorbide	C
UNKNOWN			
	Congestive	Nitroglycerin	C
UNKNOWN			
	Carotid Artery Occlusion	Aciphex	C
UNKNOWN			
	Carotid Artery Stenosis	Elavil	C
UNKNOWN			
	Drug Hypersensitivity		
	Dyspnoea		
	Emotional Distress		
	Gallbladder Disorder		
	Gastric Ulcer		
	Gastrooesophageal Reflux		
	Disease		
	Heart Rate Irregular		
	Myocardial Infarction		
	Oedema		
	Renal Disorder		
	Transient Ischaemic		
	Attack		

Date:05/20/05ISR Number: 4668072-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02662
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaphylactic Shock
Initial or Prolonged	Angina Unstable
Other	Arthropathy
	Blood Alkaline
	Phosphatase Increased
	Cardiac Enzymes Increased

		Diplopia					
		Dysphagia					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gait Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Liver Function Test		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal		Neurontin	C		
UNKNOWN							
		Loss Of Consciousness		Synthroid	C		
UNKNOWN							
		Multiple Sclerosis		Hydrodiuril	C		ORAL
		Myocardial Infarction		Arava	C		
UNKNOWN							
		Pain In Extremity		Methotrexate	C		
UNKNOWN							
		Pleural Effusion		Premarin	C		
UNKNOWN							
		Pneumonia					
		Renal Disorder					
		Syncope					
		Transient Ischaemic					
		Attack					
		Visual Disturbance					

Date:05/20/05ISR Number: 4668073-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00111
Age:79 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
28	MON						
Hospitalization -		Cardiac Failure		Amiodarone Msd	C		
UNKNOWN							
Initial or Prolonged		Congestive		Plavix	C		
UNKNOWN							
		Myocardial Infarction		Cozaar	C		
UNKNOWN							
		Oedema Peripheral		Phenazopyridine			

	Pneumonia		Hydrochloride	C
UNKNOWN				
	Prostate Cancer		Flomax (Morniflumate)	C
UNKNOWN				
			Toprol Xl Tablets	C
UNKNOWN				
			Digoxin	C
UNKNOWN				
			Potassium Chloride	C
UNKNOWN				
			Zocor	C
UNKNOWN				
			Furosemide	C
UNKNOWN				
			Levaquin	C
UNKNOWN				
			Lipitor	C
UNKNOWN				
			Advil	C
UNKNOWN				
			Tylenol	C
UNKNOWN				

Date:05/20/05ISR Number: 4668074-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00410
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/20/05ISR Number: 4668075-2Report Type:Expedited (15-DaCompany Report #VI-MERCK-0502USA00218
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Procardia	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668076-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03487
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aspartate		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aminotransferase		Synthroid	C				
UNKNOWN								
	Increased							
	Colitis Ischaemic							
	Deep Vein Thrombosis							
	Depression							
	Diverticulum							
	Dyspnoea							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Hiatus Hernia							
	High Density Lipoprotein							
	Decreased							
	Hypertension							
	Influenza							
	Insomnia							
	Leukocytosis							
	Migraine							
	Neck Pain							
	Pulmonary Embolism							

Date:05/20/05ISR Number: 4668077-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01888
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperlipidaemia		Atacand	C		ORAL		
	Hypertension		Hydrochlorothiazide					
	Panic Attack		And Metoprolol					
	Post-Traumatic Stress		Tartrate	C		ORAL		

	Disorder Supraventricular Tachycardia Upper Respiratory Tract Infection Wolff-Parkinson-White Syndrome

Date:05/20/05ISR Number: 4668078-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01893
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Emotional Distress Infection
Disability	Intervertebral Disc Degeneration Intervertebral Discitis Pulmonary Embolism

Spinal Column Stenosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
	Flexeril	C		ORAL		
	Motrin	C		ORAL		

Date:05/20/05ISR Number: 4668079-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01603
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diplopia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Nexium	C				
UNKNOWN								
	Erectile Dysfunction							
	Hepatic Enzyme Increased							
	Hip Arthroplasty							
	Hypertension							
	Hypoaesthesia Oral							
	Multi-Organ Disorder							
	Myocardial Infarction							
	Pain							

Date:05/20/05ISR Number: 4668080-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02696
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
5 YR								
Initial or Prolonged	Increased		Darvocet-N	C				
UNKNOWN								
Disability	Cerebral Atrophy		Premarin	C				
UNKNOWN								

	Cerebrovascular Accident	Atenolol	C
UNKNOWN			
	Diabetes Mellitus Drug Hypersensitivity Emotional Distress Flank Pain Haematochezia Hypertension Mental Impairment Neck Pain Nephrolithiasis Pain Pelvic Mass Rotator Cuff Syndrome Sinus Disorder Synovitis Thrombosed Varicose Vein Transient Ischaemic Attack		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/20/05ISR Number: 4668081-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02695
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Ultram	C		ORAL		
	Blood Cholesterol		Zoloft	C			UNKNOWN	
	Increased		Estraderm	C			UNKNOWN	3506 DAY
	Blood Creatinine Increased							
	Blood Glucose Increased							
	Blood Urea Increased							
	Cellulitis							
	Chest Pain							
	Constipation							
	Coronary Artery Disease							
	Drug Ineffective							
	Emotional Distress							
	Fatigue							
	Gastritis							
	Haematochezia							
	Hypertension							
	Hypotension							
	Meniscus Lesion							
	Pain							

Date:05/20/05ISR Number: 4668082-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Hospitalization - Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
	Coronary Artery Disease							
	Deep Vein Thrombosis							
	Myocardial Infarction							
	Thrombosis							

Date:05/20/05ISR Number: 4668084-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00088
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Zoloft	C				
UNKNOWN							10	YR
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Emotional Distress							
	Myocardial Infarction							
	Obesity							

Date:05/20/05ISR Number: 4668085-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03480
Age:58 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS		ORAL		
	Angina Unstable							
	Bladder Neoplasm							
	Cardiac Disorder							
	Cardiomegaly							
	Cerebrovascular Accident							
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Disease							
	Cystitis							
	Depression							
	Haematuria							
	Haemorrhoids							
	Metabolic Syndrome							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Post-Traumatic Stress Disorder							
	Pulmonary Oedema							
	Rectal Haemorrhage							
	Sinusitis							

Date:05/20/05ISR Number: 4668086-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02328
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:05/20/05ISR Number: 4668087-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02390
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris Non-Cardiac Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
			Sotalol Hydrochloride	C			UNKNOWN	
			Bumetanide	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Warfarin	C			UNKNOWN	
			Protonix	C			UNKNOWN	
			Benicar	C			UNKNOWN	

Date:05/20/05ISR Number: 4668088-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03217
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization - Initial or Prolonged	Headache Heart Rate Increased
Disability	Pulmonary Embolism

	Thrombophlebitis White Blood Cell Count Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Nexium	C			UNKNOWN

Date:05/20/05ISR Number: 4668091-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01687
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 232 DAY	Bronchopneumonia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cardiac Failure		Prednisone	C			UNKNOWN
	Congestive		Guaifenesin	C			UNKNOWN
	Carotid Artery Occlusion		Nicoderm Patch	C			UNKNOWN
	Cerebrovascular Accident		Zantac	C			UNKNOWN
	Chronic Obstructive		Atenolol	C			UNKNOWN
	Pulmonary Disease		Claritin	C			UNKNOWN
	Coronary Artery Disease		Effexor Xr	C			UNKNOWN
	Depression		Bactrim Ds Tablets	C			UNKNOWN
	Dyslipidaemia		Adalat Cc	C			UNKNOWN
	Dyspnoea Headache Hypoxia Joint Swelling Lobar Pneumonia Lung Infiltration Mitral Valve Incompetence						

Oedema Peripheral
Polytraumatism
Pulmonary Hilum Mass
Pulmonary Hypertension

Date:05/20/05ISR Number: 4668092-2Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:05/20/05ISR Number: 4668094-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02136
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON

Date:05/23/05ISR Number: 4668848-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00758
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abasia
	Angina Pectoris
Disability	Anxiety
Other	Arthralgia

		Aspiration					
		Asthma					
		Back Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Glucophage	C		
UNKNOWN							
		Diplopia		Evista	C		
UNKNOWN							
		Dizziness		Vasotec	C		
UNKNOWN							
		Drug Ineffective		Glucotrol Xl	C		
UNKNOWN							
		Dysphonia		Claritin	C		
UNKNOWN							
		Dyspnoea		Hydrochlorothiazide			
		Erythema		And Triamterene	C		
UNKNOWN							
		Excoriation		Aspirin	C		
UNKNOWN							
		Eye Swelling		Aspirin	C		
UNKNOWN							
		Facial Pain		Flovent	C		
UNKNOWN							
		Fall		[Therapy			
		Headache		Unspecified]	C		
UNKNOWN							
		Hypoaesthesia		Calcium			
		Myocardial Infarction		(Unspecified)	C		
UNKNOWN							
		Neck Injury		Tranxene	C		
UNKNOWN							
		Oedema Peripheral		Zoloft	C		
UNKNOWN							
		Pneumonia		Univasc	C		
UNKNOWN							
		Sinusitis		Avandia	C		
UNKNOWN							
		Somnolence		Propacet	C		
UNKNOWN							
		Swelling Face		Wellbutrin Xl	C		
UNKNOWN							
		Tremor		Allegra	C		
UNKNOWN							

			Toprol Xl Tablets	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						
			Glucovance	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Naproxen	C		
UNKNOWN						
			Chlorazepate	C		
UNKNOWN						
			Vanceril	C		
UNKNOWN						
			Advair	C		
UNKNOWN						
			Darvocet-N	C		
UNKNOWN						
			Kenalog	C		
INTRAMUSCULAR						
			Vicodin Tablets	C		
UNKNOWN						
			Avelox	C		
UNKNOWN						
			Nasonex	C		
UNKNOWN						
			Spironolactone	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						

Date:05/23/05ISR Number: 4668850-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00089
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cytomegalovirus Infection		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Gastritis Erosive		Cyclosporine	C				
UNKNOWN								
	Graft Versus Host Disease		[Therapy					
	Hypertension		Unspecified]	C				
UNKNOWN								
	Renal Failure		Defibrotide	C				
INTRAVENOUS							22	DAY

	Renal Tubular Necrosis Tachyarrhythmia	Antimicrobial (Unspecified)	C

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4668852-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00723
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Sodium Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebellar Infarction		Wygesic Tablets	C			UNKNOWN	
	Cerebrovascular Accident		Ultram	C			UNKNOWN	
	Chest Wall Pain		Plavix	C			UNKNOWN	
	Convulsion							
	Death							
	Drug Effect Decreased							
	Drug Ineffective							
	Fatigue							
	Haemoptysis							
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Hyponatraemia							
	Intermittent Claudication							
	Malaise							
	Mitral Valve Incompetence							
	Nausea							
	Pain In Extremity							
	Polyp Colorectal							
	Renal Cyst							
	Respiratory Failure							
	Sepsis							
	Thrombocytopenia							
	Transient Ischaemic Attack							
	Tricuspid Valve Incompetence							

Date:05/23/05ISR Number: 4668856-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00762
Age: Gender:Male I/FU:F

Outcome	PT

Death	Angina Pectoris
Hospitalization - Initial or Prolonged	Aortic Stenosis
Disability	Blood Glucose Decreased
Other	Blood Pressure Increased
	Cachexia
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Death
	Decubitus Ulcer
	Dehydration
	Fall
	Hospitalisation
	Hypoglycaemia
	Multiple System Atrophy
	Myocardial Ischaemia
	Pulmonary Oedema

		Red Blood Cell Count Decreased					
		Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Staphylococcal Sepsis		Vioxx	PS	Merck & Co., Inc	ORAL
		Syncope		Allopurinol	C		
UNKNOWN							
		Tooth Fracture		Pepcid	C		
UNKNOWN							
		Urinary Tract Infection		Flonase	C		
UNKNOWN							
		Wound Infection		Micronase	C		
UNKNOWN							
		Staphylococcal		Lactulose	C		
UNKNOWN							
				Carbidopa And Levodopa	C		
UNKNOWN							
				Probenecid	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							
				Selegiline	C		
UNKNOWN							
				Tramadol Hydrochloride	C		
UNKNOWN							
				Bisacodyl	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							
				Mylanta & Mylanta Ds	C		
UNKNOWN							

Date:05/23/05ISR Number: 4668857-7Report Type:Expedited (15-DaCompany Report #BR-MERCK-0410BRA00043
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
	Gastrointestinal Haemorrhage					
	Shock					

Date:05/23/05ISR Number: 4668858-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bifascicular Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis							
	Hypertension							
	Inflammation							
	Influenza Like Illness							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Prescribed Overdose							
	Renal Failure Chronic							
	Rib Fracture							
	Ventricular Arrhythmia							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4668859-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01070
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		277 YR
Other	Costochondritis		Lipitor	C				UNKNOWN
	Disease Recurrence		Axid	C				UNKNOWN
	Emotional Distress		Vitamins (Unspecified)	C				UNKNOWN
	Erectile Dysfunction							
	Gastrooesophageal Reflux		Viagra	C				UNKNOWN
	Disease							
	Stress							

Date:05/23/05ISR Number: 4668860-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01038
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:05/23/05ISR Number: 4668861-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00457
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dyspnoea							
	Hypertension							
	Insomnia							
	Lymphadenopathy							
	Mammogram Abnormal							
	Migraine With Aura							
	Myocardial Infarction							

Myocarditis
Rectal Tenesmus
Restless Legs Syndrome
Retinal Haemorrhage

Date:05/23/05ISR Number: 4668862-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00783
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Postoperative
Disability	Aseptic Necrosis Bone
Other	Atelectasis
	Atrial Fibrillation
	Benign Prostatic Hyperplasia
	Chronic Obstructive Pulmonary Disease
	Contusion
	Coronary Artery Disease
	Diabetes Mellitus
	Hypercholesterolaemia
	Hyperlipidaemia
	Muscle Spasms
	Myocardial Infarction

	Osteoarthritis						
	Postoperative						
	Constipation	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Radiculopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Sciatica		Vioxx	SS	Merck & Co., Inc	ORAL		
	Staphylococcal Infection		Percocet	C			UNKNOWN	
	Urinary Retention		Vicodin Tablets	C			UNKNOWN	

Date:05/23/05ISR Number: 4668863-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03191
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	775	DAY
Life-Threatening	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	775	DAY
Hospitalization -	Brain Stem Infarction		Atuss Ex	C			UNKNOWN	
Initial or Prolonged	Cardiac Arrest		Neurontin	C			UNKNOWN	
	Cardiac Failure		Dilantin	C			UNKNOWN	
	Congestive		Dilantin	C			UNKNOWN	
	Cerebrovascular Accident		Vitamin B					
	Coma		(Unspecified)	C			UNKNOWN	
	Decubitus Ulcer		Diovan	C			UNKNOWN	
	Diabetes Mellitus		Darvocet-N	C			UNKNOWN	1 DAY
	Dyspnoea		Naprosyn	C			UNKNOWN	DAY
	Emotional Distress		Naprosyn	C			UNKNOWN	1 DAY
	Facial Palsy		Allegra	C			UNKNOWN	
	Gastrointestinal Disorder		Clemastine	C			UNKNOWN	
	Glucose Tolerance		Metoclopramide	C			UNKNOWN	

Impaired
Haematuria
Hypercholesterolaemia
Hypernatraemia
Hypertension
Hyponatraemia
Hypotension
Increased Bronchial
Secretion
Influenza
Ischaemic Cardiomyopathy
Leukocytosis
Locked-In Syndrome
Mitral Valve Incompetence
Obstructive Airways
Disorder
Pneumonia Aspiration
Respiratory Failure
Respiratory Tract
Infection
Shock
Staphylococcal
Bacteraemia
Tracheitis
Tricuspid Valve
Incompetence
Ventricular Tachycardia
Vertebral Artery
Thrombosis
Vith Nerve Paralysis

Date:05/23/05ISR Number: 4668864-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01883
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Darvocet-N	C				
UNKNOWN								
	Myocardial Infarction							

Date:05/23/05ISR Number: 4668865-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02652
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
1 MON								
Other	Angina Pectoris		Lortab	C				
UNKNOWN								
	Anxiety		Covera	C				
UNKNOWN								
	Blood Cholesterol		Ambien	C				
UNKNOWN								
	Increased							
	Blood Testosterone							
	Decreased							
	Cardiac Failure							
	Congestive							
	Cellulitis							
	Cerebrovascular Accident							
	Cervicobrachial Syndrome							
	Confusional State							
	Contusion							
	Coronary Artery Disease							
	Crush Syndrome							
	Dehydration							
	Depression							
	Dyspnoea							
	Dysuria							
	Emotional Distress							
	Epicondylitis							
	Erectile Dysfunction							
	Fatigue							

Gastric Ulcer
Gastritis Erosive
Gastrooesophageal Reflux
Disease
Hypertension
Hyperventilation
Ischaemic Cardiomyopathy
Laceration
Leukocytosis
Localised Infection
Multiple Sclerosis
Relapse
Pancreatitis
Pleural Effusion
Pneumonia
Renal Cyst
Respiratory Distress
Sinus Bradycardia
Supraventricular
Extrasystoles
Ventricular Extrasystoles

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4668866-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00679
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		14 MON
Disability	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		7 MON
Other	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		14 MON
	Depression		Zestril	C				
UNKNOWN								3 MON
	Diabetes Mellitus		Zocor	C		ORAL		
	Disability		Lipitor	C				
UNKNOWN								
	Emotional Distress		Paxil	C				
UNKNOWN								
	Fear		Paxil	C				
UNKNOWN								
	Foot Fracture		Xanax	C				
UNKNOWN								
	Gallbladder Disorder		Xanax	C				
UNKNOWN								
	Hypertension		Risperdal	C				
UNKNOWN								
	Myocardial Infarction							
	Pain							
	Renal Disorder							
	Thrombosis							
	Ulcer							

Date:05/23/05ISR Number: 4668867-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02976
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1211 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
Disability	Increased		Lipitor	C				
UNKNOWN								92 DAY

	Blood Triglycerides Increased	Potassium (Unspecified)	C	
UNKNOWN	63 DAY			
	Bradycardia Bronchopneumonia	Potassium (Unspecified)	C	
UNKNOWN				
	Carotid Artery Disease	Plavix	C	
UNKNOWN				
	Chronic Obstructive	Atarax	C	
UNKNOWN				
	Pulmonary Disease	Ery-Tab	C	
UNKNOWN				
	Coronary Artery Disease	Codal Dh	C	
UNKNOWN				
	Gastroenteritis	Tessalon	C	
UNKNOWN				
	Myocardial Infarction	Spironolactone	C	
UNKNOWN				
	Obesity	Zyrtec	C	
UNKNOWN				
	Osteoarthritis	Levaquin	C	
UNKNOWN				
	Pain	Combivent	C	
UNKNOWN				
	Renal Cyst	Aldactone	C	
UNKNOWN				
	Renal Impairment	Aldactone	C	
UNKNOWN				
	Respiratory Disorder	Vitamin E	C	
UNKNOWN				
	Vertigo	Garlic Extract	C	
UNKNOWN				
		Adalat	C	
UNKNOWN				
		Pepcid	C	ORAL
		Aspirin Tablets	C	
UNKNOWN				
		Calcium (Unspecified)	C	
UNKNOWN				

Date:05/23/05ISR Number: 4668868-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01889
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
	Anxiety
Other	Benign Lung Neoplasm
	Blood Pressure Increased

		Cerebrovascular Accident					
		Cerebrovascular Disorder					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Head Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoacusis		Darvocet-N	C		
UNKNOWN							
		Hypoaesthesia		Procardia Xl	C		
UNKNOWN		7 MON					
		Joint Injury		Minocin	C		ORAL
		Lacunar Infarction		Restoril	C		
UNKNOWN							
		Lung Neoplasm		Fosamax	C		
UNKNOWN							
		Lymphadenopathy		Os-Cal	C		
UNKNOWN							
		Mediastinal		Vitamins			
		Obliterative		(Unspecified)	C		
UNKNOWN							
		Bronchiolitis		Zinc (Unspecified)	C		
UNKNOWN							
		Pulmonary Embolism		Folic Acid	C		
UNKNOWN							
		Raynaud'S Phenomenon		Thyroid	C		
UNKNOWN							
		Rheumatoid Arthritis		Prevacid	C		
UNKNOWN							
		Sleep Disorder		Motrin	C		
UNKNOWN							
		Subarachnoid Haemorrhage		Doxycycline	C		
UNKNOWN							
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Venous Angioma Of Brain					
		Venous Stenosis					
		Visual Disturbance					

Date:05/23/05ISR Number: 4668870-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02981
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 608 DAY	Anxiety	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Asthenia	Aspirin	C		
Disability	Atrial Fibrillation				
Other	Cardiomegaly				
	Chest Pain				
	Coronary Artery Disease				
	Dizziness				
	Drug Hypersensitivity				
	Emotional Distress				
	Flushing				
	Headache				
	Left Ventricular Failure				
	Mitral Valve Incompetence				
	Myocardial Infarction				
	Pulmonary Valve Incompetence				
	Tricuspid Valve Incompetence				

Date:05/23/05ISR Number: 4668871-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03229
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Transient Ischaemic		Zestril	C		ORAL		
Initial or Prolonged	Attack		Zocor	C		ORAL		
Other			Celebrex	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4668873-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00100
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		79 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		79 DAY
	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Cardiac Failure		Nexium	C				UNKNOWN
	Congestive		Darvocet-N	C				UNKNOWN
	Carpal Tunnel Syndrome		Psorcon	C				UNKNOWN
	Catheter Site Haemorrhage		Atenolol	C				UNKNOWN
	Coronary Artery Disease							1463 DAY
	Depression							
	Drug Ineffective							
	Gastric Haemorrhage							
	Gastrooesophageal Reflux Disease							
	Haematochezia							
	Haematocrit Decreased							
	Hypercholesterolaemia							
	Hypotension							
	International Normalised Ratio Increased							
	Myocardial Infarction							
	Post Procedural Complication							
	Vertigo							
	Wrist Fracture							

Date:05/23/05ISR Number: 4668874-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/23/05ISR Number: 4668875-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01709
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension							
	Myocardial Infarction							
	Syncope							

Date:05/23/05ISR Number: 4668876-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03490
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Failure
Hospitalization -	Congestive
Initial or Prolonged	Death
	Dementia Alzheimer'S Type
	Emotional Distress
	Grand Mal Convulsion
	Lethargy
	Mental Status Changes
	Pulmonary Oedema

		Shift To The Left					
		Sinus Tachycardia					
		Upper Limb Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		White Blood Cell Count		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Tylenol	C		
UNKNOWN							
				Exelon	C		
UNKNOWN							
				Exelon	C		
UNKNOWN							
				Ditropan Xl	C		
UNKNOWN							

Date:05/23/05ISR Number: 4668877-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03904
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
65	MON						

Date:05/23/05ISR Number: 4668878-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03191
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Brain Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Cardiac Arrest		Prilosec	C		
UNKNOWN							
		Diplopia		Atenolol	C		ORAL
		Emotional Distress		Diovan	C		
UNKNOWN							
		Eye Injury		Ziac	C		
UNKNOWN							
		Myocardial Infarction		Hyzaar	C		ORAL
		Psychomotor Skills		Lopid	C		
UNKNOWN							
		Impaired		Betapace	C		
UNKNOWN							

	Speech Disorder	Plavix	C
UNKNOWN			
	Traumatic Brain Injury	Plavix	C
UNKNOWN			
		Nexium	C
UNKNOWN			
		Tricor	C
UNKNOWN			
		Foltx	C
UNKNOWN			

Date:05/23/05ISR Number: 4668880-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00096
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glaucoma							
	Myocardial Infarction							
	Overdose							
	Pyoderma Gangrenosum							
	Rheumatoid Arthritis							

Date:05/23/05ISR Number: 4668889-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01711
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Pectoris
	Back Pain
	Blood Triglycerides Increased

		Chronic Obstructive Pulmonary Disease Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
67	MON						
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
67	MON						
		Hyperlipidaemia Hypertension Intervertebral Disc Protrusion Peripheral Vascular Disorder Rotator Cuff Syndrome Sleep Apnoea Syndrome					

Date:05/23/05ISR Number: 4670440-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01890
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
6	YR					
Hospitalization -	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
6	YR					
Initial or Prolonged						

Date:05/23/05ISR Number: 4670444-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01842
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
43	MON					
	Feeling Guilty		Effexor Xr	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Pepcid	C		ORAL

Date:05/23/05ISR Number: 4670486-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00849
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL	31 DAY	
	Myocardial Infarction							

Date:05/23/05ISR Number: 4670495-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00060
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Anaemia
	Angina Unstable
	Angiodysplasia
	Blood Disorder
	Chest Pain
	Congestive Cardiomyopathy
	Dyspnoea
	Gastric Haemorrhage
	Gastritis
	Gastrointestinal Haemorrhage
	Haematochezia

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypochromic Anaemia					
		Hypomagnesaemia					
		Ischaemic Cardiomyopathy					
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL
		Panic Disorder		Celebrex	C		
UNKNOWN							
		Peptic Ulcer		Celebrex	C		
UNKNOWN							
		Respiratory Tract		Aspirin	C		
UNKNOWN							
		Infection		Aspirin	C		
UNKNOWN							
		Shoulder Pain		Imdur	C		
UNKNOWN							
		Sinus Bradycardia		Imdur	C		
UNKNOWN							
		Staphylococcal		Glucophage	C		
UNKNOWN							
		Bacteraemia		Diabinese	C		
UNKNOWN							
		Urosepsis		Cozaar	C		
UNKNOWN							
		Ventricular Dysfunction		Plendil	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN		901 DAY					
				Norvasc	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Heparin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							

Date:05/23/05ISR Number: 4670498-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00648
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acrochordon
Other	Actinic Keratosis
	Acute Myocardial Infarction
	Anxiety
	Aortic Valve Sclerosis
	Arthralgia
	Aspartate Aminotransferase Increased
	Atherosclerosis
	Basal Cell Carcinoma
	Blood Lactate Dehydrogenase Increased
	Blood Pressure Increased
	Chest Discomfort
	Chest Pain
	Conjunctivitis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Dermatitis
	Dyspepsia
	Ejection Fraction Decreased
	Eustachian Tube Disorder
	Eustachian Tube Dysfunction
	Excoriation
	Fibrous Histiocytoma
	Foreign Body In Eye
	Gastritis

		Gastrooesophageal Reflux Disease					
		Hydrocele	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intracardiac Thrombus		Vioxx	PS	Merck & Co., Inc	ORAL
		Laceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacrimation Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Pigmented Naevus					
		Polycythaemia					
		Prostatic Specific					
		Antigen Increased					
		Pyrexia					
		Right Ventricular Failure					
		Scrotal Disorder					
		Skin Laceration					
		Skin Lesion					
		Sleep Apnoea Syndrome					
		Squamous Cell Carcinoma					
		Of Skin					
		Swelling					
		Thrombocytopenia					
		Tinnitus					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Dyskinesia					
		Ventricular Hypertrophy					

Date:05/23/05ISR Number: 4670499-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03179
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
421 DAY							
Hospitalization -		Infarction		Toprol Xl Tablets	C		
UNKNOWN		1113 DAY					
Initial or Prolonged		Anoxic Encephalopathy		Accupril	C		
UNKNOWN		612 DAY					
		Atrioventricular Block		Aspirin	C		
UNKNOWN							
		Complete		[Therapy			

Coronary Artery Disease Unspecified] C
UNKNOWN
Electromechanical
Dissociation
Hypercholesterolaemia
Sudden Cardiac Death
Ventricular Fibrillation

Date:05/23/05ISR Number: 4670501-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00212
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/23/05ISR Number: 4670502-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00105
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Acute Myocardial

		Infarction					
		Arthralgia					
		Atelectasis					
		Blood Cholesterol	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Blood Potassium Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
		Calculus Urethral		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Chest Pain		Synthroid	C		
UNKNOWN							
		Emotional Distress		Diovan Hct	C		
UNKNOWN							
		Left Ventricular		Toprol Xl Tablets	C		
UNKNOWN							
		End-Diastolic Pressure		Cozaar	C		
UNKNOWN							
		Increased					
		Myocardial Ischaemia					
		Nasopharyngitis					
		Pain					
		Sciatica					

Date:05/23/05ISR Number: 4670504-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00146
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR					
	Cerebrovascular Accident					

Date:05/23/05ISR Number: 4670509-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01559
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
627	DAY					
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
627	DAY					
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
627	DAY					

	Chest Pain	Vioxx	SS	Merck & Co., Inc	ORAL	627 DAY
	Coronary Artery Disease	Levaquin	C			UNKNOWN
	Deep Vein Thrombosis	Glucotrol	C			UNKNOWN
	Diabetes Mellitus	Zestril	C			UNKNOWN
	Emotional Distress	Lipitor	C			UNKNOWN
	Faecal Occult Blood Positive	Cyclobenzaprine Hydrochloride	C			UNKNOWN
	Fear	Metoprolol	C			UNKNOWN
	Gastrooesophageal Reflux	Naproxen Sodium	C			UNKNOWN
	Disease	Naproxen Sodium	C			UNKNOWN
	Hyperlipidaemia Hypertension	Hydrocodone Bitartrate	C			UNKNOWN
	Neck Pain	Neurontin	C			UNKNOWN
	Obesity	Maxair	C			UNKNOWN
	Osteoarthritis	Lopressor	C			UNKNOWN
	Spinal Column Stenosis	Ciloxan	C			UNKNOWN
	Spinal Disorder	Allegra	C			UNKNOWN
		Nasonex	C			UNKNOWN
		Smz-Tmp	C			UNKNOWN
		Imdur	C			UNKNOWN
		Humibid	C			UNKNOWN
		Vicodin Tablets	C			UNKNOWN
		Flexeril	C			UNKNOWN
		Motrin	C			UNKNOWN
		Aspirin	C			UNKNOWN
		Ranitidine	C			UNKNOWN

Date:05/23/05ISR Number: 4670518-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01796
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	41	MON
	Myocardial Infarction							

Date:05/23/05ISR Number: 4670817-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01922
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Bronchospasm							
Other	Cerebrovascular Accident							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Intervertebral Disc Disorder							
	Upper Respiratory Tract Infection							

Date:05/23/05ISR Number: 4670819-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:05/23/05ISR Number: 4670823-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03194
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		

Other	Atrial Fibrillation	Zestril	SS
UNKNOWN			
	Bradycardia		
	Cardiac Failure		
	Congestive		
	Chronic Obstructive		
	Pulmonary Disease		
	Coronary Artery Disease		
	Depression		
	Drug Ineffective		
	Dyspnoea		
	Fall		
	Hyperlipidaemia		
	Hypertension		
	Inguinal Hernia		
	Myocardial Infarction		
	Pleural Effusion		
	Pulmonary Fibrosis		
	Pulmonary Hypertension		
	Thrombosis		
	Tricuspid Valve		
	Incompetence		
	Urinary Retention		

Date:05/23/05ISR Number: 4670824-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00137
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	76 DAY	
Hospitalization -	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	76 DAY	
Disability	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
			Rabeprazole Sodium	C		ORAL		
			Rabeprazole Sodium	C		ORAL		

Date:05/23/05ISR Number: 4670825-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00097
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Abdominal Pain Lower
Other	Anhedonia
	Anxiety
	Arthralgia
	Back Pain
	Blood Cholesterol
	Increased
	Bronchitis Acute
	Bursitis
	Chest Discomfort
	Chest Pain
	Colitis Ulcerative
	Concussion
	Constipation
	Convulsion
	Costochondritis
	Depression
	Diarrhoea
	Disturbance In Attention
	Dizziness
	Drug Ineffective
	Duodenal Ulcer
	Dysuria
	Enterocolitis
	Haemorrhagic
	Erectile Dysfunction

Eye Disorder
Fall
Flatulence
Gastric Ulcer
Gastritis
Gastrooesophageal Reflux
Disease
Haematochezia
Haemorrhage
Haemorrhoids
Head Injury
Hypertension
Hypertriglyceridaemia
Hypogonadism
Kidney Infection
Loss Of Consciousness
Major Depression
Migraine
Multiple Drug Overdose

	Muscle Spasms						
	Myoclonus						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	
	Oesophageal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	
	Palpitations		Vioxx	SS	Merck & Co., Inc	ORAL	
	Refusal Of Examination		Zocor	C		ORAL	
	Renal Disorder		Prevacid	C			UNKNOWN
	Suicide Attempt						
	Syncope						
	Ulcer						
	Ulna Fracture						
	Vomiting						

Date:05/23/05ISR Number: 4670826-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00155
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Blood Pressure Increased		Synthroid	C			UNKNOWN
	Cerebrovascular Accident		Fiorinal	C			UNKNOWN
	Depression		Zantac	C			UNKNOWN
	Fibromyalgia						
	Insomnia						
	Labyrinthitis						
	Malaise						
	Sinusitis						
	Upper Respiratory Tract Infection						

Date:05/23/05ISR Number: 4670827-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01450
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Life-Threatening	Abdominal Pain	Vioxx	PS	Merck & Co., Inc	ORAL
611 DAY					
Hospitalization -	Abdominal Pain Lower	Vioxx	SS	Merck & Co., Inc	ORAL
611 DAY					
Initial or Prolonged	Anxiety	Ativan	C		
UNKNOWN					
Disability	Arthralgia	Hydrochlorothiazide	C		
UNKNOWN					
	Bipolar Disorder	Hydrocodone			
	Diarrhoea	Hydrochloride	C		
UNKNOWN					
	Emotional Distress	Maxzide	C		
UNKNOWN					
	Fatigue	Neurontin	C		
UNKNOWN					
	Headache	Remeron	C		
UNKNOWN					
	Menstrual Disorder	Trazodone			
	Nerve Injury	Hydrochloride	C		
UNKNOWN					
	Oedema Peripheral	Tricor	C		
UNKNOWN					
	Pelvic Pain	Zanaflex	C		
UNKNOWN					
	Pyrexia	Midrin	C		
UNKNOWN					
	Renal Failure	Lidoderm	C		
UNKNOWN					
	Tibia Fracture				

Date:05/23/05ISR Number: 4670829-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Arthralgia
Other	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine Increased
	Bone Marrow Disorder
	Breast Cyst
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Chronic Sinusitis
	Coagulopathy
	Colonic Polyp
	Coronary Artery Disease
	Depression
	Dyspepsia
	Ear Pain
	Ecchymosis
	Episcleritis
	Faeces Discoloured
	Fall
	Felty'S Syndrome
	Gastrooesophageal Reflux Disease
	Haemorrhoidal Haemorrhage
	Herpes Zoster
	Herpes Zoster Ophthalmic
	Hiatus Hernia
	Hypertension
	Hypertonic Bladder
	Immunoglobulins Decreased
	Injury
	Insomnia
	Keratitis
	Keratitis Herpetic
	Laryngitis Viral
	Leukopenia
	Lymphoma
	Mental Impairment
	Migraine
	Mitral Valve Incompetence
	Mouth Injury

Nausea
Nocturia
Orthostatic Hypotension
Overdose
Pain
Pancytopenia
Platelet Disorder
Prostatitis
Pyrexia
Rash
Renal Disorder
Renal Pain
Rheumatoid Arthritis
Rib Fracture
Sinusitis

Dose	Duration	Thrombocytopenia Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
		Trigger Finger		Vioxx	PS	Merck & Co., Inc	ORAL
		Viral Pharyngitis		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
				Methotrexate	SS		
UNKNOWN							
				Methotrexate	SS		
UNKNOWN							
				Remicade	SS		
INTRAVENOUS							
				Remicade	SS		
INTRAVENOUS							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Carbamazepine	C		
UNKNOWN							
				Acyclovir	C		
INTRAVENOUS							
				Hydroxychloroquine Sulfate	C		
UNKNOWN							

	Advil	C		
UNKNOWN				
	[Therapy Unspecified]	C		
UNKNOWN				
	Purinethol	C		
UNKNOWN				
	Elavil	C		ORAL
	Prednisone	C		
UNKNOWN				
	Fiorinal With Codeine	C		
UNKNOWN				
	Proventil	C		ORAL
	K-Dur	C		
UNKNOWN				
	Zyrtec	C		
UNKNOWN				
	Allopurinol	C		
UNKNOWN				
	Prilosec	C		
UNKNOWN				
	Azathioprine	C		
UNKNOWN				
	Tegretol	C		
UNKNOWN				

Date:05/23/05ISR Number: 4670831-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02357
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bronchiectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Premarin	C				
UNKNOWN							11	YR
	Depression		Prozac	C				
UNKNOWN								
	Hypersensitivity		Guaifenesin Dm	C				
UNKNOWN								
	Hypertension		Serevent	C				
UNKNOWN								
	Migraine With Aura		Pulmicort	C				
UNKNOWN								
	Nausea							
	Pneumonia							
	Transient Ischaemic Attack							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4670853-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04409
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/23/05ISR Number: 4670854-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03596
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Diovan	C				
UNKNOWN								
	Coronary Artery Stenosis		Coumadin	C				
UNKNOWN								
	Emotional Distress		Aspirin	C				
UNKNOWN								
	Hypertension		Plavix	C				
UNKNOWN								
	Interstitial Lung Disease		Lipitor	C				
UNKNOWN								
	Lung Infiltration		Zocor	C				
UNKNOWN	181 DAY							
	Myocardial Infarction		Tylenol	C				
UNKNOWN								
	Shoulder Arthroplasty		Lisinopril	C				
UNKNOWN								

Date:05/23/05ISR Number: 4670879-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03343
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

Date:05/23/05ISR Number: 4670881-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00007
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		[Therapy Unspecified]	C				
UNKNOWN								

Date:05/23/05ISR Number: 4670882-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00132
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebral Artery Stenosis		Carvedilol	C		ORAL		
	Scotoma		Ramipril	C		ORAL		
	Transient Ischaemic Attack							

Date:05/23/05ISR Number: 4670884-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							976	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/23/05ISR Number: 4670885-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01721
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Hospitalization - UNKNOWN	Heart Rate Increased		Celebrex	C				
Initial or Prolonged Disability	Myocardial Infarction							
Other								

Date:05/23/05ISR Number: 4672886-7Report Type:Expedited (15-DaCompany Report #2005072753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Rofecoxib (Rofecoxib)	SS				

Date:05/24/05ISR Number: 4672653-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02528
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/05ISR Number: 4672654-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01738
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/05ISR Number: 4672655-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02080
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/24/05ISR Number: 4672656-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01776
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
Disability			Vioxx	SS	Merck & Co., Inc	ORAL	1	MON

Date:05/24/05ISR Number: 4672659-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01863
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Aortic Valve Incompetence
Other	Aortic Valve Sclerosis
	Blood Cholesterol Increased
	Cardiac Disorder
	Cardiac Murmur

		Cardiac Valve Disease					
		Chest Pain					
		Congestive Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Paxil	C		ORAL
		Deep Vein Thrombosis		Vitamins			
		Ejection Fraction		(Unspecified)	C		
UNKNOWN							
		Decreased		Analgesic Or			
		Erectile Dysfunction		Anesthetic			
		Hypertension		(Unspecified)	C		
UNKNOWN							
		Migration Of Implant					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Neck Pain					
		Pain					
		Peripheral Vascular					
		Disorder					
		Tooth Disorder					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					

Date:05/24/05ISR Number: 4672660-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Abnormal Dreams
Disability	Amenorrhoea
Other	Angina Pectoris
	Aphthous Stomatitis
	Arthralgia
	Atrial Septal Defect
	Blood Pressure Abnormal
	Blood Pressure Increased
	Breast Pain
	Breast Tenderness
	Bronchitis Acute
	Bursitis
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Pain

Conjunctival Haemorrhage
Contusion
Convulsion
Cyst
Deep Vein Thrombosis
Dizziness
Drug Abuser
Drug Dependence
Eczema
Embolic Stroke
Endometriosis
Epistaxis
Fall
Fatigue
Gastroenteritis Viral
Generalised Oedema
Haemorrhage
Headache

		Hip Arthroplasty					
		Hypercoagulation					
		Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased Tendency To		Vioxx	PS	Merck & Co., Inc	ORAL
		Bruise		Vioxx	SS	Merck & Co., Inc	ORAL
		Ingrowing Nail		Vioxx	SS	Merck & Co., Inc	ORAL
		Inguinal Hernia		Vicodin Tablets	C		
UNKNOWN							
		Injury		Aspirin	C		
UNKNOWN							
		Laryngitis		Zantac	C		
UNKNOWN							
		Localised Infection		Restoril	C		
UNKNOWN							
		Loss Of Libido		Flexeril	C		
UNKNOWN							
		Mastitis		Ascriptin	C		
UNKNOWN							
		Menorrhagia					
		Migraine					
		Munchausen'S Syndrome					
		Muscle Atrophy					
		Muscle Spasms					
		Musculoskeletal					
		Discomfort					
		Nausea					
		Neck Mass					
		Nervousness					
		Oligomenorrhoea					
		Osteoarthritis					
		Otitis Externa					
		Otitis Media					
		Ovarian Cyst					
		Ovarian Enlargement					
		Pain					
		Pain In Jaw					
		Panic Attack					
		Paraesthesia					
		Patent Ductus Arteriosus					
		Pelvic Pain					
		Pharyngitis					
		Pyrexia					
		Rash					
		Rhinitis Allergic					
		Sinus Disorder					
		Sinusitis					

Splenic Cyst
Systemic Lupus
Erythematosus
Transient Ischaemic
Attack
Upper Respiratory Tract
Infection
Urinary Tract Infection
Urine Abnormality
Vaginal Mycosis
Vaginitis Bacterial
Viral Infection

Date:05/24/05ISR Number: 4672663-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00856
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Cerebrovascular Accident
Other	Emotional Distress

		Injury Spina Bifida Wheelchair User	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Diovan	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Tegretol	C		
UNKNOWN							
				Robaxin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Reglan	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:05/24/05ISR Number: 4672664-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00852
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Initial or Prolonged	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Impaired Work Ability		Diovan	C		
UNKNOWN						
	Injury		Pravachol	C		ORAL
	Myocardial Infarction		Niaspan	C		ORAL
	Pain		Lasix (Furosemide)	C		ORAL
			Norvasc	C		
UNKNOWN						

Aspirin	C	ORAL

Date:05/24/05ISR Number: 4672666-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02696
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angiopathy
Disability	Blood Cholesterol Increased
	Cerebrovascular Accident
	Diabetes Mellitus Non-Insulin-Dependent
	Drug Hypersensitivity
	Emotional Distress
	Flank Pain
	Haematochezia
	Hypertension
	Hypokalaemia
	Ischaemic Stroke
	Lacunar Infarction
	Mental Impairment
	Neck Pain
	Nephrolithiasis
	Pain
	Pelvic Mass
	Rotator Cuff Syndrome
	Sinus Disorder
	Synovitis
	Thrombosed Varicose Vein
	Transient Ischaemic

Attack

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Darvocet-N	C			UNKNOWN	
	Premarin	C			UNKNOWN	
	Atenolol	C			UNKNOWN	

Date:05/24/05ISR Number: 4672939-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03174
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Nexium	C			UNKNOWN	
	Increased		Tegretol	C			UNKNOWN	
	Congestive Cardiomyopathy		Lorazepam	C			UNKNOWN	
	Coronary Artery Disease		Prozac	C			UNKNOWN	
	Coronary Artery		Zoloft	C			UNKNOWN	
	Thrombosis							
	Gastrooesophageal Reflux Disease							

Date:05/24/05ISR Number: 4672940-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00810
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abnormal Clotting Factor		Vioxx	PS	Merck & Co., Inc	ORAL		

	Emotional Distress	Norvasc	C
UNKNOWN			
	Fibromyalgia	Omeprazole	C
UNKNOWN	178 DAY		
	Gastrooesophageal Reflux	Foltx	C
UNKNOWN			
	Disease	Trazodone Hydrochloride	C
	Pulmonary Embolism		
UNKNOWN			
	Road Traffic Accident	Nasonex	C
UNKNOWN			
		Lexapro	C
UNKNOWN			
		Gemfibrozil	C
UNKNOWN			
		Baclofen	C
UNKNOWN			
		Warfarin Sodium	C
UNKNOWN			
		Hydroxychloroquine Sulfate	C
UNKNOWN			
		Ranitidine	C
UNKNOWN			
		Lipitor	C
UNKNOWN			
		Cephalexin	C
UNKNOWN			
		Depakote	C
UNKNOWN			
		Allegra	C
UNKNOWN			
		Alprazolam	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Zyrtec	C
UNKNOWN			
		Astelin	C
UNKNOWN			
		Folbee	C
UNKNOWN			
		Elocon	C
UNKNOWN			
		Epi-Pen	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/05ISR Number: 4672941-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00106
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1432 DAY
Initial or Prolonged	Infarction		Pravachol	C				UNKNOWN
Other	Anxiety		Zocor	C		ORAL		
	Chest Pain		Lopid	C				UNKNOWN
	Coronary Artery Stenosis		Motrin	C				UNKNOWN
			Flexeril	C		ORAL		
			Ambien	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:05/24/05ISR Number: 4672943-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00837
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Economic Problem		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
	Myocardial Infarction							
	Pain							

Date:05/24/05ISR Number: 4672944-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00061
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1260 DAY
Hospitalization -	Infarction		Oxybutynin	C		ORAL		
Initial or Prolonged	Coronary Artery Disease		Sodium Bicarbonate	C				RECTAL
Disability	Myocardial Infarction		[Therapy					
	Removal Of Internal		Unspecified]	C				RECTAL

Fixation

Date:05/24/05ISR Number: 4672948-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01015
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celexa	C				
UNKNOWN								
	Myocardial Infarction		Aspirin	C				
UNKNOWN								
	Pulmonary Embolism		[Therapy					
	Sudden Death		Unspecified]	C				
UNKNOWN								
			Coumadin	C				
UNKNOWN								
			[Therapy					
			Unspecified]	C				
UNKNOWN								

Date:05/24/05ISR Number: 4672951-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00530
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
30 DAY								
Hospitalization -	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
32 DAY								
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
20 DAY								
	Muscle Spasms		Atorvastatin Calcium	SS		ORAL		
	Myalgia		Ramipril	SS		ORAL		
			Atorvastatin Calcium	SS		ORAL		
			Nateglinide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/05ISR Number: 4672956-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/05ISR Number: 4672957-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02340
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/24/05ISR Number: 4672958-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON

Date:05/24/05ISR Number: 4672959-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02278
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:05/24/05ISR Number: 4672969-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:05/24/05ISR Number: 4672970-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00014
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Etoricoxib	SS		ORAL		
			Zopiclone	C		ORAL		
			Amlodipine Besylate	C		ORAL		
			Zuclopenthixol Hydrochloride	C		ORAL		
			Atenolol	C		ORAL		
			Acetaminophen	C		ORAL		

Date:05/24/05ISR Number: 4672971-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/24/05ISR Number: 4672972-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02258
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON

Date:05/24/05ISR Number: 4672987-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00063
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Occlusion		Valdecoxib	SS		ORAL		
	Intervertebral Disc Disorder							
	Myocardial Infarction							

Date:05/24/05ISR Number: 4674186-8Report Type:Expedited (15-DaCompany Report #WAES 0505USA01702
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Headache	Study	Tab Vioxx Unk	PS		ORAL	PO	
Initial or Prolonged		Health Professional	Tamoxifen Citrate 20 Mg	SS		ORAL	20	MG/DAILY/PO
			Asacol	C				
			Azmacort	C				
			Diovan	C				
			Prilosec	C				
			Singulair	C				
			Xalatan	C				
			Albuterol	C				
			Hydrochorothiazide	C				

Date:05/24/05ISR Number: 4674211-4Report Type:Expedited (15-DaCompany Report #2005075323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Bextra (Valdecoxib)	SS				
			Vioxx (Rofecoxib)	SS				

Date:05/25/05ISR Number: 4673251-9Report Type:Expedited (15-DaCompany Report #200514476GDDC
Age:82 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hyponatraemia		Metronidazole	PS	Aventis Pharmaceuticals Inc.			
			Ramipril	SS		ORAL		
			Cephalexin	SS				
			Vioxx	SS				
			Aspirin	C				
			Heparin	C				

SUBCUTANEOUS

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673328-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1105 DAY
Other	Death							

Date:05/25/05ISR Number: 4673329-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02350
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Date:05/25/05ISR Number: 4673332-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02254
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Thyroid Stimulating		Norvasc	C				UNKNOWN
	Hormone Decreased		Darvocet-N	C				UNKNOWN
	Cardiac Murmur							
	Cerebrovascular Accident							
	Emotional Distress							
	Fall							
	Fibula Fracture							
	Gastric Disorder							
	Hyperglycaemia							
	Hypertension							

Date:05/25/05ISR Number: 4673333-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02077
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atrial Fibrillation		Aspirin	C				
Disability	Depression		Paxil	C			UNKNOWN	
Other	Dyspnoea		Valium	C			UNKNOWN	
	Emotional Distress							
	Guillain-Barre Syndrome							
	Heart Rate Irregular							
	Hyperlipidaemia							
	Myocardial Infarction							
	Non-Cardiac Chest Pain							
	Obesity							
	Pneumonia							
	Sleep Apnoea Syndrome							

Date:05/25/05ISR Number: 4673334-3Report Type:Expedited (15-DaCompany Report #SE-MERCK-0505SWE00012
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1768 DAY	
			Simvastatin	C			UNKNOWN	
			Propiomazine Maleate	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

			Aspirin And Dipyridamole	C		
UNKNOWN						

Date:05/25/05ISR Number: 4673865-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02875
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL
	Anaemia					
	Arthritis					
	Blood Cholesterol Increased					
	Blood Triglycerides Increased					
	Chest Pain					
	Hemiparesis					
	Hypertension					
	Joint Range Of Motion Decreased					
	Low Density Lipoprotein Increased					
	Muscle Spasms					
	Neck Pain					
	Pain In Extremity					
	Pitting Oedema					
	Pleural Effusion					
	Polytraumatism					
	Pyrexia					
	Shoulder Pain					
	Spondylitis					
	Treatment Noncompliance					
	Ventricular Hypertrophy					

Date:05/25/05ISR Number: 4673870-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00029
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL

Initial or Prolonged	Gastrointestinal	Premarin	C
UNKNOWN			
Disability	Haemorrhage	Prevacid	C
UNKNOWN			
	Myocardial Infarction	Pravastatin Sodium	C
UNKNOWN			
	Pneumonia	Aygestin	C
UNKNOWN			

Date:05/25/05ISR Number: 4673874-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00659
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Gastric Ulcer Haemorrhage		Metoprolol Tartrate	C		ORAL
	Gastritis		Tolperisone Hydrochloride	C		ORAL
	Sinus Tachycardia		Amitriptyline Hydrochloride	C		ORAL
	Therapeutic Response Decreased		Pantoprazole Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673889-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0505BRA00056
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cholecalciferol	C		ORAL		
			Riboflavin	C		ORAL		
			Benserazide Hydrochloride And Levodopa	C		ORAL		
			Benserazide Hydrochloride And Levodopa	C		ORAL		

Date:05/25/05ISR Number: 4673890-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00035
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Ischaemic Stroke		Celecoxib	SS		ORAL	89 DAY	

Date:05/25/05ISR Number: 4673891-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02287
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673892-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	458 DAY	

Date:05/25/05ISR Number: 4673893-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
	Lacunar Infarction							

Date:05/25/05ISR Number: 4673894-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02131
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673895-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00218
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anxiety
Hospitalization - Initial or Prolonged	Anxiety Disorder
Disability	Arteriosclerosis
	Asthenia
	Atherosclerosis

		Balance Disorder					
		Cerebrovascular Accident					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysphagia		Nebivolol			
		Encephalopathy		Hydrochloride	C		ORAL
		Facial Paresis		Hypericin	C		ORAL
		Fall		Risedronate Sodium	C		ORAL
		Hypertension		Valsartan	C		
UNKNOWN							
		Paraesthesia					
		Transient Ischaemic					
		Attack					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					

Date:05/25/05ISR Number: 4673896-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01618
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bone Marrow Depression		Vioxx	PS	Merck & Co., Inc	ORAL
2 WK						
Initial or Prolonged	Drug Interaction		Methotrexate	SS		ORAL
	Drug Toxicity		Levofloxacin	C		
UNKNOWN						
	Epstein-Barr Virus		Pirbuterol Acetate	C		
RESPIRATORY						
	Antibody Positive					
(INHALATION)						
	Epstein-Barr Virus		Cyanocobalamin	C		
UNKNOWN						
	Antigen Positive		Medroxyprogesterone			
	Epstein-Barr Virus		Acetate	C		
UNKNOWN						
	Infection					
	Erythema Multiforme					
	Immunosuppression					
	Leukocytoclastic					
	Vasculitis					
	Lymphoproliferative					
	Disorder					
	Pancytopenia					
	Rales					

Renal Failure Acute
Therapy Non-Responder

Date:05/25/05ISR Number: 4673897-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01687
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Bronchopneumonia
	Cardiac Failure
	Congestive
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebral Infarction
	Cerebrovascular Accident
	Chronic Obstructive
	Airways Disease
	Exacerbated
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Depression
	Dyslipidaemia

		Dyspnoea					
		Emotional Distress					
		Gastric Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematemesis		Vioxx	PS	Merck & Co., Inc	ORAL
232	DAY						
		Headache		Claritin	C		
UNKNOWN							
		Hypoxia		Effexor Xr	C		
UNKNOWN							
		Joint Swelling		Bactrim Ds Tablets	C		
UNKNOWN							
		Lobar Pneumonia		Guaifenesin	C		
UNKNOWN							
		Lung Infiltration		Zantac	C		
UNKNOWN							
		Mitral Valve Incompetence		Tenormin	C		
UNKNOWN							
		Oedema Peripheral		Nicoderm Patch	C		
UNKNOWN							
		Pneumonia		Prednisone	C		
UNKNOWN							
		Pulmonary Hilum Mass		Adalat Cc	C		
UNKNOWN							
		Pulmonary Hypertension		Tylenol	C		
UNKNOWN							
		Transient Ischaemic Attack					

Date:05/25/05ISR Number: 4673898-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01240
Age:49 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Arthralgia		Lipitor	C		ORAL
		Aspartate		Lopid	C		ORAL
		Aminotransferase					
		Increased					
		Blood Cholesterol					
		Increased					
		Blood Creatine					
		Phosphokinase Increased					
		Blood Pressure Increased					

Blood Triglycerides
Increased
Difficulty In Walking
Dilatation Atrial
Dilatation Ventricular
Haemorrhoidal Haemorrhage
High Density Lipoprotein
Decreased
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Tricuspid Valve
Incompetence

Date:05/25/05ISR Number: 4673909-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00660
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Actinic Keratosis
	Angina Pectoris
	Anxiety
	Benign Prostatic Hyperplasia
	Blood Creatine Phosphokinase Increased
	Cardiac Failure Congestive

		Carotid Artery Stenosis					
		Carpal Tunnel Syndrome					
		Cellulitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
2	WK						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Ziac	C		
UNKNOWN							
		Joint Sprain		Prilosec	C		ORAL
		Memory Impairment		Catapres	C		
UNKNOWN							
		Meniscus Lesion		Simethicone	C		
UNKNOWN							
		Myocardial Infarction		Norvasc	C		
UNKNOWN							
		Nerve Injury		Aspirin	C		
UNKNOWN		999 DAY					
		Otitis Externa		Tylenol	C		
UNKNOWN							
		Pain		[Therapy			
		Renal Artery Stenosis		Unspecified]	C		
UNKNOWN							
		Shoulder Pain		Ibuprofen	C		
UNKNOWN							
		Stomach Discomfort		Xanax	C		
UNKNOWN							
		Tinnitus					

Date:05/25/05ISR Number: 4673910-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00818
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease					
Disability	Emotional Distress					
	Gastrooesophageal Reflux					
	Disease					
	Myocardial Infarction					

Date:05/25/05ISR Number: 4673911-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
	Anxiety		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)		
	Drug Ineffective							729 DAY
	Emotional Distress		[Therapy Unspecified]	C		UNKNOWN		
	Hyperlipidaemia							
	Pain		Griseofulvin	C		UNKNOWN		25 DAY
	Pelvic Haematoma							
	Stress		Verapamil Hydrochloride	C		ORAL		382 DAY
	Tinea Infection							

Date:05/25/05ISR Number: 4673912-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00028
Age:89 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL		11 DAY
Hospitalization - Initial or Prolonged	Death							
	Myocardial Infarction							
	Pneumonia							
	Renal Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673913-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00196
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Diarrhoea		Certoparin Sodium	C		PARENTERAL		
Disability	Fatigue							
	Intestinal Infarction							
	Nausea							
	Osteomyelitis							
	Pulmonary Embolism							

Date:05/25/05ISR Number: 4673914-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04013
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Bruit		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Cerebrovascular Accident		Aspirin	C				
Initial or Prolonged	Transient Ischaemic Attack		Prilosec	C		ORAL		
			Wellbutrin Sr	C		ORAL		
			Antivert	C		ORAL		
			Claritin	C		ORAL		
			Synthroid	C		ORAL		
			Desyrel	C		ORAL		
			Ultram	C		ORAL		
			Oxycontin	C		ORAL		
			Zocor	C		ORAL		
			Darvocet-N	C		ORAL		

Date:05/25/05ISR Number: 4673916-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02255
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673917-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	41 MON	
	Cerebrovascular Disorder							
	Embolism							
	Pulmonary Embolism							

Date:05/25/05ISR Number: 4673926-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02384
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	
Hospitalization - Initial or Prolonged	Syncope		Trazodone Hydrochloride	C				
UNKNOWN								
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673927-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal Pain		Atorvastatin Calcium	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Perindopril Erbumine	C			UNKNOWN	
			Pantoprazole Sodium	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lactulose	C			UNKNOWN	
			Psyllium Husk	C			UNKNOWN	
			Codeine	C			UNKNOWN	

Date:05/25/05ISR Number: 4673928-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02338
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON

Date:05/25/05ISR Number: 4673929-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02567
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673930-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02291
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673931-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02479
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673932-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673933-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673934-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02565
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		YR

Date:05/25/05ISR Number: 4673936-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02552
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673937-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	DAY

Date:05/25/05ISR Number: 4673945-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	917	DAY

Date:05/25/05ISR Number: 4673947-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673948-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02721
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON
	Myocardial Infarction							

Date:05/25/05ISR Number: 4673950-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673951-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02570
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/25/05ISR Number: 4673953-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02571
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Date:05/25/05ISR Number: 4673981-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/25/05ISR Number: 4673986-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02712
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder							

Date:05/25/05ISR Number: 4675616-8Report Type:Expedited (15-DaCompany Report #WAES 0503GBR00214
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Decreased	Foreign	Vioxx	PS		ORAL	25 MG/DAILY/	
Initial or Prolonged	Condition Aggravated	Study					PO	
	Coronary Artery Occlusion	Health	Acetaminophen (+)					
	Haematocrit Decreased	Professional	Codeine Phosph	C				
	Haemoglobin Decreased	Other	Amlodipine Besilate	C				
	Mean Cell Haemoglobin		Aspirin	C				
	Increased		Atenolol	C				
	Mean Cell Volume		Atorvastatin Calcium	C				
	Increased		Bendroflumethiazide	C				
	Myocardial Ischaemia		Cyanocobalamin	C				
	Red Blood Cell Count		Diazepam	C				

	Decreased	Nitroglycerin	C
	Vascular Graft Occlusion	Potassium Chloride	C
	Vitamin B12 Deficiency	Prednisolone	C
		Quinine	C
		Sulfasalazine	C
		Trazodone Hydrochloride	C

Date:05/25/05ISR Number: 4677122-3Report Type:Direct Company Report #CTU 249585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx 25mg Merck	PS	Merck	BUCCAL	1 TABLET TWICE A DAY	

BUCCAL

Date:05/26/05ISR Number: 4674521-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00076
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction

		Angina Unstable					
		Depression					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL
514	DAY						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
514	DAY						
				Maxzide	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Diuretic (Unspecified)	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Metoprolol	C		
UNKNOWN		1829 DAY					

Date:05/26/05ISR Number: 4674522-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02848
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Appendicitis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Asthma		Chronulac	C		
UNKNOWN						
Other	Cerebrovascular Accident		Paxil	C		
UNKNOWN						
	Chest Pain		Prevacid	C		
UNKNOWN						
	Depression		Albuterol	C		
UNKNOWN						
	Dyspnoea Exertional		Methylprednisolone	C		
UNKNOWN						

	Gastrooesophageal Reflux		Evista	C		
UNKNOWN						
	Disease		Effexor Xr	C		
UNKNOWN						
	Hyperlipidaemia		Atacand	C		
UNKNOWN						
	Hypertension		Foradil	C		
UNKNOWN						
	Myocardial Ischaemia		Deltasone	C		
UNKNOWN						
	Oedema Peripheral		Singulair	C		
UNKNOWN						
	Transient Ischaemic		Clarinex	C		
UNKNOWN						
	Attack		Astelin	C		
UNKNOWN						
	Vertigo		Combivent	C		
UNKNOWN						
			Avelox	C		
UNKNOWN						
			Tequin	C		
UNKNOWN						
			Levaquin	C		
UNKNOWN						
			Tamoxifen Citrate	C		
UNKNOWN						
			Cozaar	C		ORAL

Date:05/26/05ISR Number: 4674543-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON

Date:05/26/05ISR Number: 4674544-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02191
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4674546-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02680
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	2	MON

Date:05/26/05ISR Number: 4674550-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00156
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1362	DAY
	Ear Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1362	DAY
	Hysterectomy		Vioxx	SS	Merck & Co., Inc	ORAL	1362	DAY
	Uterine Disorder		Bellamine S	C			UNKNOWN	

Date:05/26/05ISR Number: 4674551-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	35	MON
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							
	Thrombosis							

Date:05/26/05ISR Number: 4674553-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02262
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
45 MON						

Date:05/26/05ISR Number: 4674554-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00040
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
	Blindness Unilateral		Crestor	C		ORAL
	Cough		Clobetasol			
	Dizziness		Propionate	C		
UNKNOWN						
	Fatigue		Vitamin E	C		ORAL
	Hypoaesthesia		Magnesium			
	Insomnia		(Unspecified) And			
	Muscle Contractions		Calcium			
	Involuntary		(Unspecified)	C		
UNKNOWN						
	Myalgia		Aspirin	C		ORAL
	Neck Pain		Cyanocobalamin	C		ORAL
	Neuralgia		Ascorbic Acid	C		ORAL
	Pain In Extremity		Acetic Acid	C		
UNKNOWN						
	Shoulder Pain		Triamcinolone	C		
UNKNOWN						
	Upper Respiratory Tract		Diovan Hct	C		ORAL
	Infection		Flonase	C		
RESPIRATORY						
	Vitreous Haemorrhage					
(INHALATION)						
	Weight Increased		Zyrtec	C		ORAL
			Estradiol	C		ORAL
			Humulin 70/30	C		
SUBCUTANEOUS						
			Humulin N	C		
SUBCUTANEOUS						
			Benadryl	C		ORAL

			Ultracet	C		ORAL
			Bextra	C		ORAL
			Lescol	C		ORAL
			Advair	C		
RESPIRATORY						
(INHALATION)						
			Provera	C		ORAL

Date:05/26/05ISR Number: 4674555-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	41	MON

Date:05/26/05ISR Number: 4674556-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02706
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
	Polytraumatism							
	Thrombosis							

Date:05/26/05ISR Number: 4674557-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02485
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1858	DAY
Initial or Prolonged			Coumadin	C			UNKNOWN	
			Atacand Hct	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Singulair	C		ORAL		

Mucinex	C		UNKNOWN
Fosamax	C	ORAL	
Restoril	C		UNKNOWN
Citracal	C		UNKNOWN
Protonix	C		UNKNOWN
Advair	C		UNKNOWN
Sotalol Hydrochloride	C		UNKNOWN
Vitamins (Unspecified)	C		UNKNOWN

Date:05/26/05ISR Number: 4674558-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02725
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4674560-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02266
Age: Gender:Female I/FU:I

Outcome	PT
Death	Cerebrovascular Accident
Other	Transient Ischaemic

Attack

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc		UNKNOWN	510 DAY

Date:05/26/05ISR Number: 4674561-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4674562-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02120
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Anxiety Cardiac Failure Congestive Depression Motor Dysfunction Myocardial Infarction Neuropathic Pain Neuropathy Paraesthesia Sensory Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4674563-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	44 MON	

Date:05/26/05ISR Number: 4674564-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00018
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Levothyroxine Sodium	C		ORAL		
Initial or Prolonged	Cardiac Failure		Nifedipine	C				
UNKNOWN								
	Myocardial Infarction							
	Peripheral Ischaemia							

Date:05/26/05ISR Number: 4674565-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02707
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
54 DAY								
Disability	Pulmonary Oedema							
	Respiratory Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4674569-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Carotid Artery Occlusion Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4674582-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02131
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	60 DAY
			Cardizem	C				
	Anxiety		Lipitor	C			UNKNOWN	
	Arteriosclerosis Azotaemia Blood Cholesterol		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Increased		Ultram	C			UNKNOWN	902 DAY
	Chronic Obstructive Pulmonary Disease Coronary Artery Disease Coronary Artery Stenosis Gingival Bleeding Hot Flush Mitral Valve Incompetence Myocardial Infarction Obstructive Airways Disorder Palpitations Tricuspid Valve Incompetence Venous Insufficiency Ventricular Dysfunction Ventricular Fibrillation Ventricular Hypertrophy							

Date:05/26/05ISR Number: 4674588-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01943
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4674972-4Report Type:Expedited (15-DaCompany Report #2005075392
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Iron Abnormal Contusion Oedema Peripheral Pain In Extremity Rotator Cuff Syndrome Skin Discolouration Weight Increased	Consumer	Bextra (Valdecoxib) Vioxx (Rofecoxib) Darvocet (Dextropropoxyphene Napsilate, Paracetamol) Prempro (Estrogens Conjugated, Medroxyprogesterone	PS SS C		ORAL ORAL	20 MG, (20 MG, 1 IN 1 D), ORAL	

	Acetate)	C
	Vicodin (Hydrocodone Bitartrate, Paracetamol)	C

Date:05/26/05ISR Number: 4675021-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	277	DAY

Date:05/26/05ISR Number: 4675022-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02026
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Flank Pain		Premarin	C				
UNKNOWN								
	Headache		Calcium (Unspecified)	C				
	Hypertension							
UNKNOWN								
	Hypoaesthesia							
	Musculoskeletal Stiffness							
	Neck Pain							
	Varicose Vein							

Date:05/26/05ISR Number: 4675024-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:05/26/05ISR Number: 4675025-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:05/26/05ISR Number: 4675026-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02223
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Disability	Chest Pain		Ultram	C			UNKNOWN	
	Ventricular Hypertrophy							

Date:05/26/05ISR Number: 4675027-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675043-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02133
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675051-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	794	DAY
	Myocardial Infarction							
	Pulmonary Embolism							

Date:05/26/05ISR Number: 4675052-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02564
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675053-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02753
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Injury							
	Pain							
	Visual Disturbance							

Date:05/26/05ISR Number: 4675054-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	12 MON	
	Polytraumatism							

Date:05/26/05ISR Number: 4675055-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Organ Failure							
	Polytraumatism							
	Pulmonary Embolism							
	Thrombosis							

Date:05/26/05ISR Number: 4675056-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02312
Age:47 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Pectoris
	Anxiety

Coronary Artery Disease
Coronary Artery Occlusion
Fear
Gastritis
Reflux Oesophagitis
Stress

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675058-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675059-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02530
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675061-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	52 MON	

Date:05/26/05ISR Number: 4675062-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02284
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	424	DAY

Date:05/26/05ISR Number: 4675063-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675064-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	47	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675065-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02285
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1492 DAY

Date:05/26/05ISR Number: 4675066-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675076-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00169
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiomegaly		Celebrex	C				
UNKNOWN								
Other	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Hepatomegaly							
	Hypertrophy							
	Insomnia							
	Intracardiac Thrombus							
	Myocardial Infarction							
	No Therapeutic Response							
	Ovarian Cyst							
	Pain In Extremity							
	Pulmonary Haemorrhage							
	Renal Cyst							
	Sinusitis							
	Subcutaneous Abscess							
	Upper Respiratory Tract Infection							

Date:05/26/05ISR Number: 4675077-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02327
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675078-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02599
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Back Pain
	Cardiac Failure
	Congestive
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Dizziness

	Drug Intolerance Ejection Fraction Decreased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	857 DAY
	Neuropathy Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	14 DAY
	Pain Polytraumatism Skin Lesion Ventricular Hypertrophy						

Date:05/26/05ISR Number: 4675079-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03955
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Other	Aortic Dilatation Aortic Thrombosis Blood Pressure Increased Bronchitis Cerebrovascular Accident Chest Pain Chronic Obstructive Pulmonary Disease Coronary Artery Disease Epigastric Discomfort Myocardial Infarction Peripheral Artery Aneurysm Renal Cyst Respiratory Depression Sinus Tachycardia Transient Ischaemic Attack Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/26/05ISR Number: 4675080-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Acute Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/26/05ISR Number: 4675081-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02546
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Aortic Valve Incompetence
	Cellulitis
	Cerebrovascular Accident
	Emotional Distress
	Gout
	Hepatitis C
	Hypertension
	Hypoaesthesia
	Hypokalaemia
	Injury
	Mitral Valve Incompetence

		Myocardial Ischaemia					
		Nocturia					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
63	DAY						
		Renal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Rhabdomyolysis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
63	DAY						
		Incompetence		Paxil	C		
UNKNOWN							
		Varicose Vein		Motrin	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:05/26/05ISR Number: 4675083-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00634
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acquired Oesophageal Web
Hospitalization -	Anaemia
Initial or Prolonged	Anaemia Vitamin B12
Other	Deficiency
	Angina Pectoris
	Angina Unstable
	Anxiety
	Arteriovenous
	Malformation
	Bile Duct Stone
	Blood Culture Positive

Cardiac Failure
Congestive
Cardiomegaly
Catheter Bacteraemia
Chest Pain
Choledochal Cyst
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coagulopathy
Constipation
Coronary Artery Disease
Depression
Diabetes Mellitus
Inadequate Control
Diarrhoea
Diverticulum
Dyspepsia
Dysphagia
Dyspnoea
Emotional Distress
Endocarditis Bacterial
Enterobacter Bacteraemia
Enterococcal Bacteraemia
Epigastric Discomfort
Fall

		Femur Fracture					
		Fluid Retention					
		Gastric Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Methotrexate	SS		
UNKNOWN							
		Gastritis Haemorrhagic		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Coumadin	SS		
UNKNOWN							
		Arteriovenous		Lipitor	SS		ORAL
		Malformation		Lipitor	SS		ORAL
		Gastrointestinal		Prednisone	SS		
UNKNOWN							
		Haemorrhage		Infliximab	SS		
UNKNOWN							
		Gastrooesophageal Reflux		Prinivil	SS		ORAL
		Disease		Methotrexate	SS		ORAL
		Glaucoma					
		Haematochezia					
		Hepatic Failure					
		Hypercholesterolaemia					
		Hyperkalaemia					
		Influenza Like Illness					
		Iron Deficiency Anaemia					
		Ischaemic Cardiomyopathy					
		Ischaemic Hepatitis					
		Joint Swelling					
		Malaise					
		Mental Status Changes					
		Myocardial Infarction					
		Nasopharyngitis					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Pancreatitis					
		Pleural Effusion					
		Pneumonia					
		Pneumonitis					
		Pulmonary Hypertension					
		Pulmonary Oedema					
		Renal Failure Acute					
		Respiratory Failure					
		Staphylococcal Infection					
		Syncope					
		Thrombotic Stroke					
		Troponin Increased					

Urinary Tract Infection
Enterococcal
Vomiting
Weight Decreased

Date:05/26/05ISR Number: 4675085-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02719
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:05/26/05ISR Number: 4675086-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02557
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper Acute Coronary Syndrome

		Arrhythmia					
		Carotid Artery Stenosis					
		Chest Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL
43	DAY						
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
154	DAY						
		Drug Intolerance		Vioxx	SS	Merck & Co., Inc	ORAL
43	DAY						
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
154	DAY						
		Exostosis		Lipitor	C		ORAL
		Fall		Lorazepam	C		
UNKNOWN							
		Fibromyalgia		Seroquel	C		
UNKNOWN							
		Head Injury		Norvasc	C		ORAL
46	DAY						
		Mitral Valve Incompetence		Motrin	C		
UNKNOWN							
		Myofascial Pain Syndrome		Naprosyn	C		
UNKNOWN							
		Nausea		Tiazac	C		ORAL
		Neck Pain		Flexeril	C		ORAL
		Oedema Peripheral		Prilosec	C		ORAL
		Pain In Extremity					
		Palpitations					
		Rosacea					
		Syncope					

Date:05/26/05ISR Number: 4675087-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
373	DAY						
Initial or Prolonged		Infarction		Lipitor	C		
UNKNOWN							

	Anxiety		Tranxene	C			
UNKNOWN							
	Asthenia		Prozac	C			
UNKNOWN							
	Blood Pressure Increased		Zantac	C			
UNKNOWN							
	Coronary Artery Atherosclerosis						
	Fall						
	Fear						
	Hyperhidrosis						
	Nausea						
	Obstructive Airways Disorder						
	Ulna Fracture						
	Ulnar Nerve Injury						
	Vomiting						

Date:05/26/05ISR Number: 4675088-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02781
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/26/05ISR Number: 4675089-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02645
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Occlusion		Toprol Xl Tablets	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Norvasc	C				
UNKNOWN								
			Foltx	C				
UNKNOWN								

			Pravachol	C		
UNKNOWN						
			Meperidine Hydrochloride	C		
UNKNOWN						

Date:05/26/05ISR Number: 4675090-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00045
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 751 DAY	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 341 DAY	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Chronic Obstructive		Naproxen	C		
UNKNOWN						
	Pulmonary Disease		Desyrel	C		ORAL
	Confusional State		Desyrel	C		ORAL
	Depression		Viagra	C		ORAL
	Dizziness		Zocor	C		ORAL
	Fall		Aggrenox	C		ORAL
	Hyperlipidaemia		Klonopin	C		ORAL
	Hypoaesthesia		Chondroitin	C		
UNKNOWN						
	Intervertebral Disc		Glucosamine	C		
UNKNOWN						
	Degeneration		Tylenol Sinus	C		
UNKNOWN						
	Intervertebral Disc Protrusion		Trazodone Hydrochloride	C		
UNKNOWN						
	Joint Swelling					
	Mitral Valve Incompetence					
	Nausea					
	Restless Legs Syndrome					
	Sinusitis					
	Transient Ischaemic Attack					
	Tricuspid Valve Incompetence					

Date:05/26/05ISR Number: 4675107-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00793
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amaurosis Fugax
Initial or Prolonged	Asthma
Other	Balance Disorder
	Blindness Unilateral
	Blood Amylase Increased
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chronic Obstructive
	Pulmonary Disease
	Dizziness
	Duodenal Ulcer
	Duodenal Ulcer
	Haemorrhage
	Emotional Distress
	Fatigue
	Gait Disturbance
	Gastrooesophageal Reflux
	Disease
	Hypertension
	Insomnia
	Metabolic Acidosis

		Osteitis Deformans					
		Osteoporosis					
		Retinal Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
		Attack		Zantac	C		
UNKNOWN							
		Vertigo Positional		Tylenol	C		
UNKNOWN							
		Wrist Fracture		Percocet	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Norco	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							

Date:05/26/05ISR Number: 4675108-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00791
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
7 MON							
		Blindness		Vioxx	SS	Merck & Co., Inc	ORAL
		Cataract		Vitamins			
		Dizziness		(Unspecified)	C		ORAL
		Headache		Fish Oil			
		Nausea		(Unspecified)	C		ORAL
		Syncope		Atenolol	C		ORAL
		Vision Blurred					

Date:05/26/05ISR Number: 4675109-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00398
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Lithium Carbonate	C				
UNKNOWN								
Initial or Prolonged			Effexor	C				
UNKNOWN								
Disability			Androgel	C				
UNKNOWN								
Other								

Date:05/26/05ISR Number: 4675110-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03172
Age:25 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety							
	Atherosclerosis							
	Coronary Artery Disease							
	Pain							

Date:05/26/05ISR Number: 4675111-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01900
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Back Disorder
Disability	Cerebral Thrombosis

		Cerebrovascular Accident					
		Dyspepsia					
		Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gout		Vioxx	PS	Merck & Co., Inc	ORAL
12	DAY						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL
12	DAY						
		Obesity		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Thrombosis		Allopurinol Msd	C		ORAL
				Accupril	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Glucovance	C		
UNKNOWN							
				Actos	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							

Date:05/26/05ISR Number: 4675112-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00940
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased		Soma	C		
UNKNOWN							
		Convulsion		Medrol	C		
UNKNOWN							
		Neck Pain		Vicodin Tablets	C		
UNKNOWN							
		Phlebothrombosis		Aciphex	C		
UNKNOWN							
		Rotator Cuff Syndrome		Coumadin	C		
UNKNOWN							

Date:05/26/05ISR Number: 4675113-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03171
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON	
Hospitalization - Initial or Prolonged	Arthralgia							
Disability	Asthenia							
	Cerebrovascular Accident							
	Coordination Abnormal							
	Depression							
	Fall							
	Gait Disturbance							
	Limb Discomfort							
	Tremor							
	Vision Blurred							

Date:05/26/05ISR Number: 4675114-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01807
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR	

Date:05/26/05ISR Number: 4675115-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675123-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01685
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Initial or Prolonged	Arteriovenous Fistula		Vioxx	SS	Merck & Co., Inc	ORAL		13 MON
Disability	Thrombosis		Famvir	C				UNKNOWN
Other	Cardiac Failure		Cozaar	C		ORAL		
	Congestive		Diatx	C				UNKNOWN
	Faeces Discoloured		Duricef	C				UNKNOWN
	Haematochezia		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Hernia							
	Pain							
	Pulmonary Infarction		Nephro-Vite Rx	C				UNKNOWN
	Red Blood Cell Count Decreased		Prednisone	C		ORAL		
	Thrombosis		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
			Amitriptyline Hydrochloride	C		ORAL		
			Zoloft	C				UNKNOWN
			Lopressor	C				UNKNOWN
			Avandia	C				UNKNOWN
			Norvasc	C				UNKNOWN
		1333 DAY	Lipitor	C				UNKNOWN
		1093 DAY	Docusate Sodium	C				UNKNOWN
			Allopurinol	C		ORAL		
			Diphenhydramine Hydrochloride	C				UNKNOWN
			Pravachol	C				UNKNOWN

			Aspirin	C	ORAL
			Heparin	C	
UNKNOWN					
			Carbidopa And Levodopa	C	ORAL
			Methylprednisolone	C	
UNKNOWN					
			Colchicine	C	
UNKNOWN					
			Calcitriol	C	
UNKNOWN					
			Bextra	C	
UNKNOWN	15	DAY			
			Tylenol	C	
UNKNOWN					
			Clonidine	C	
UNKNOWN					
			Levaquin	C	
UNKNOWN					
			Hydralazine	C	
UNKNOWN					
			Triamcinolone Acetonide	C	
UNKNOWN					
			Clindamycin	C	
UNKNOWN					
			Zithromax	C	
UNKNOWN					
			Nifedipine	C	ORAL
			Phoslo	C	
UNKNOWN					
			Temazepam	C	
UNKNOWN					
			Amoxicillin And Clavulanate Potassium	C	
UNKNOWN					
			Minoxidil 2%	C	
UNKNOWN					
			Metronidazole	C	
UNKNOWN					
			Endocet	C	
UNKNOWN					
			Labetalol Hydrochloride	C	
UNKNOWN					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675125-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00830
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1892 DAY
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Adjustment Disorder		Nexium	C		ORAL		
Other	Adrenal Adenoma		Effexor Xr	C		ORAL		
	Anxiety		Zestoretic	C		ORAL		
	Arthralgia		Plaquenil	C		ORAL		
	Back Disorder		Prednisone	C		ORAL		
	Biliary Tract Disorder		Prednisone	C		ORAL		
	Cervical Vertebra Injury		Prednisone	C		ORAL		
	Coronary Artery Occlusion		Prednisone	C		ORAL		
	Depressed Mood							
	Drug Ineffective							
	Exostosis							
	Fibromyalgia							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hypercholesterolaemia							
	Hypoaesthesia							
	Insomnia							
	Myocardial Infarction							
	Nerve Compression							
	Panic Disorder							
	Polymyalgia Rheumatica							
	Rotator Cuff Syndrome							
	Shoulder Pain							

Date:05/26/05ISR Number: 4675126-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02884
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Aspirin	C				UNKNOWN
	Dizziness		Visken	C				UNKNOWN

	Dyspnoea	Ambien	C
UNKNOWN			
	Groin Pain	Nexium	C
UNKNOWN			
	Pain In Extremity	Lactulose	C
UNKNOWN			
	Rotator Cuff Syndrome	Synthroid	C
UNKNOWN			
	Sinus Bradycardia	Didrex	C
UNKNOWN			
	Thrombosis	Epogen	C
UNKNOWN			
	Traumatic Haematoma	Ativan	C
UNKNOWN			
	Varicose Vein	Restoril	C
UNKNOWN			
		Florinef	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			

Date:05/26/05ISR Number: 4675127-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00011
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Prednisolone	C		ORAL		
			Fluticasone Propionate And Salmeterol Xinafoate	C				

RESPIRATORY

(INHALATION)

Theophylline	C		ORAL
Levothyroxine Sodium	C		ORAL
Estradiol And Norethindrone Acetate	C		ORAL

Date:05/26/05ISR Number: 4675128-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01683
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		4 MON
	Coma							
	Convulsion							
	Depression							
	Diarrhoea							
	Face Oedema							
	Faeces Discoloured							
	Fatigue							
	Headache							
	Hypertension							
	Oedema							
	Oedema Peripheral							
	Oral Soft Tissue Disorder							
	Pain							
	Upper Respiratory Tract Infection							
	Vomiting							

Date:05/26/05ISR Number: 4675129-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0504NOR00010
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vascular		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Warfarin Sodium	C				
UNKNOWN								

	Levothyroxine Sodium	C
UNKNOWN		
	Metoprolol Tartrate	C
UNKNOWN		
	Zocor	C
UNKNOWN		

Date:05/26/05ISR Number: 4675131-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02607
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Atrioventricular Block
	Carotid Artery Stenosis
	Cognitive Disorder
	Coronary Artery Disease
	Delirium
	Dizziness
	Dysuria
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Haematocrit Decreased
	Hypertension

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Iron Deficiency Anaemia Mass Excision Myocardial Infarction						
Nephrolithiasis	Vioxx	PS	Merck & Co., Inc	ORAL		
Oesophagitis	Vioxx	SS	Merck & Co., Inc	ORAL		
Rash	Clonidine	C			UNKNOWN	
Transient Ischaemic Attack Vestibular Disorder Vomiting	Zetia	C		ORAL		
	Acetaminophen And Propoxyphene Hydrochloride	C			UNKNOWN	
Weight Decreased	Acetaminophen And Propoxyphene Hydrochloride	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Warfarin	C			UNKNOWN	
	Quinine	C			UNKNOWN	
	Acetaminophen And Butalbital And Caffeine	C			UNKNOWN	
	Butalbital And Caffeine And Acetaminophen	C			UNKNOWN	
	Touro La	C			UNKNOWN	
	Altace	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Sucralfate	C			UNKNOWN	
	Coumadin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	

			Hydrochlorothiazide	C	
UNKNOWN					
			Alprazolam	C	
UNKNOWN					
			Travatan	C	
UNKNOWN					
			Lorazepam	C	
UNKNOWN					
			Nasonex	C	
UNKNOWN					
			Fluoxetine	C	
UNKNOWN					
			Levothyroxine Sodium	C	
UNKNOWN					
			Toprol Xl Tablets	C	
UNKNOWN					
			Omeprazole	C	
UNKNOWN					
			Zocor	C	ORAL
			Inderal	C	
UNKNOWN					
			Synthroid	C	
UNKNOWN					
			Norvasc	C	
UNKNOWN					
			Clonazepam	C	
UNKNOWN					
			Lexapro	C	
UNKNOWN	32	DAY			
			Alphagan	C	
UNKNOWN					
			Oxycodone	C	
UNKNOWN					
			Ibuprofen	C	
UNKNOWN					
			Hydrocodone Bitartrate	C	
UNKNOWN					
			Diphenhydramine Hydrochloride	C	
UNKNOWN					
			Meclizine	C	
UNKNOWN					

Date:05/26/05ISR Number: 4675132-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00115
Age:77 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Angina Pectoris		Ventolin (Albuterol)	C			UNKNOWN	
Aortic Aneurysm		Tricor	C			UNKNOWN	
Blood Cholesterol		Cartia Xt	C			UNKNOWN	
Increased		Furosemide	C			UNKNOWN	
Blood Triglycerides		Ambien	C			UNKNOWN	
Increased		Paxil	C			UNKNOWN	
Cardiac Disorder		Aspirin	C			UNKNOWN	
Cardiac Failure		Isosorbide	C			UNKNOWN	
Congestive		Nitroglycerin	C			UNKNOWN	
Carotid Artery Occlusion		Aciphex	C			UNKNOWN	
Carotid Artery Stenosis		Elavil	C			UNKNOWN	
Drug Hypersensitivity							
Dyspnoea							
Emotional Distress							
Gallbladder Disorder							
Gastric Ulcer							
Gastrooesophageal Reflux Disease							
Heart Rate Irregular							
Myocardial Infarction							
Oedema							
Renal Disorder							
Transient Ischaemic Attack							

Date:05/26/05ISR Number: 4675133-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0505FRA00096
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		9 MON
Initial or Prolonged	Myocardial Infarction		Fosamax	C		ORAL		
			Furosemide And Spironolactone	C		ORAL		
			Acetaminophen	C		ORAL		

Date:05/26/05ISR Number: 4675134-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00025
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Aneurysm		Zocor	C				
UNKNOWN								
Initial or Prolonged	Cardiac Disorder		Mevacor	C				
UNKNOWN								
	Cardiovascular Disorder		Aspirin	C				
UNKNOWN								
	Infection		Vitamins					
	Pain		(Unspecified)	C				
UNKNOWN								

Date:05/26/05ISR Number: 4675137-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00168
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675138-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05010
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis		Tums	SS				
UNKNOWN								
Other	Catheter Related Complication		Bextra	SS		ORAL		
			Celebrex	SS		ORAL		
	Chest Pain		Synthroid	C				
UNKNOWN								
	Coronary Artery Stenosis		Toprol Xl Tablets	C				
UNKNOWN								
	Myocardial Infarction		Zantac	C				
UNKNOWN								
	Renal Failure Acute		Aspirin	C				
UNKNOWN								
	Tooth Infection		Avandia	C				
UNKNOWN								
	Vascular Injury		Norvasc	C				
UNKNOWN								
	Vessel Puncture Site		Imdur	C				
UNKNOWN								
	Reaction		Altace	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Catapres	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								

Date:05/26/05ISR Number: 4675140-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01926
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Actos	C				
UNKNOWN								
	Cardiomegaly		Glucovance	C				
UNKNOWN								
	Chest Pain							
	Dermal Cyst							

Electrocardiogram
Abnormal
Lipoma
Muscle Spasms
Nasopharyngitis

Date:05/26/05ISR Number: 4675158-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02563
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:05/26/05ISR Number: 4675167-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Constipation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal Disorder		Fentanyl	SS			UNKNOWN	
	Palpitations		Diclofenac	SS		ORAL	10	DAY
	Stomach Discomfort							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4675173-6Report Type:Expedited (15-DaCompany Report #2005075386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension	Consumer	Bextra (Valdecoxib)	PS		ORAL	ORAL	
Initial or Prolonged	Chest Wall Pain		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Diarrhoea		Verapamil (Verapamil)	C				
	Drug Ineffective		Irbesartan (Irbesartan)	C				
	Inadequate Analgesia							
	Increased Tendency To Bruise							
	Inflammation							
	Skin Lesion							
	Stomach Discomfort							
	Vomiting							
	Weight Decreased							

Date:05/26/05ISR Number: 4675205-5Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00020
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis	Foreign	Tab Vioxx					
Initial or Prolonged	Fall	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	309 DAY
	Haemoglobin Decreased	Health	Tab Aspirin	SS		ORAL	75 MG/DAILY	
	Rectal Haemorrhage	Professional	Lansoprazole	C				
		Other	Lisinopril	C				
			Prazosin	C				
			Simvastatin	C				

Date:05/26/05ISR Number: 4675206-7Report Type:Expedited (15-DaCompany Report #WAES 0411GBR00095
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain	Foreign	Tab Vioxx					
Initial or Prolonged	Angina Pectoris	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	337 DAY

Other	Blood Albumin Decreased	Health	Aspirin	C
	Blood Sodium Decreased	Professional	Atenolol	C
	C-Reactive Protein	Other	Gliclazide	C
	Increased		Lansoprazole	C
	Carcinoembryonic Antigen		Nitroglycerin	C
	Increased		Simvastatin	C
	Colon Cancer			
	Gamma-Glutamyltransferase			
	Increased			
	Haemoglobin Decreased			
	Monocyte Count Increased			
	Myocardial Ischaemia			
	Nausea			
	Platelet Count Increased			

Date:05/26/05ISR Number: 4677116-8Report Type:Direct Company Report #CTU 249737
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/05ISR Number: 4677208-3Report Type:Direct Company Report #CTU 249616
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphonia		50 Mb Vioxx 50 Tabs	PS			ONCE A DAY AS	
Hospitalization -	Heart Rate Abnormal						NEEDED	
Initial or Prolonged	Hypertension		Celebrex 200 Mg 20					
Required	Inflammation		Tabs	SS				
Intervention to	Vocal Cord Inflammation							
Prevent Permanent								
Impairment/Damage								

Date:05/26/05ISR Number: 4677725-6Report Type:Direct Company Report #CTU 249621
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Activities Of Daily		Vioxx	PS			? DOSE/1-2	
	Living Impaired						TABLETS /DAY	
	Back Disorder		Actos	C				
	Dyspnoea		Amaryl	C				
	Localised Oedema		Atarax	C				
	Oedema Peripheral		Synthroid	C				
	Sleep Apnoea Syndrome		Neutontin	C				
	Weight Increased		Gemfibrozil	C				
	Weight Loss Poor		Doxepin	C				

Date:05/27/05ISR Number: 4675678-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03185
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Accelerated Hypertension
Initial or Prolonged	Anaemia
Other	Anxiety
	Blood Glucose Fluctuation
	Cardiac Failure
	Congestive
	Cardiomegaly

Carotid Artery Atheroma
Cerebrovascular Accident
Chest Discomfort
Confusional State
Convulsion
Depression
Diverticulum
Dyspnoea
Essential Hypertension
Gastroenteritis Viral
Gastrooesophageal Reflux
Disease
Hallucination
Hallucination, Visual
Heart Rate Increased
Hyperhidrosis
Hyponatraemia
Iron Deficiency Anaemia
Labile Blood Pressure
Mental Status Changes
Muscle Spasms
Pain In Jaw
Palpitations

	Paraesthesia					
	Poor Peripheral Circulation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
512	DAY					
	Attack		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Urinary Tract Infection		Aspirin	C		
UNKNOWN						
	Viral Pharyngitis		Procardia	C		
UNKNOWN						
			Lasix (Furosemide)	C		
UNKNOWN						
			Catapres	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						

Date:05/27/05ISR Number: 4676423-2Report Type:Expedited (15-DaCompany Report #BE-MERCK-0503BEL00062
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged Disability			Tramadol Hydrochloride	C		ORAL

Date:05/27/05ISR Number: 4676424-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00816
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR					
	Myocardial Infarction					

Date:05/27/05ISR Number: 4676425-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00150
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		504 DAY
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		504 DAY
	Anxiety		Aspirin	C				UNKNOWN
	Chest Pain							
	Generalised Anxiety Disorder							
	Hypercholesterolaemia							
	Hypertension							
	Myocardial Infarction							

Date:05/27/05ISR Number: 4676426-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00034
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		943 DAY
Hospitalization -	Fall		Lipitor	C				UNKNOWN
Initial or Prolonged	Hypertensive Heart		Verapamil	C				UNKNOWN
	Disease		Flovent	C				UNKNOWN
			Combivent	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676427-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02139
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Aspirin	C		ORAL		
6749 DAY								
Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								
			Zocor	C		ORAL		
2397 DAY								
			Ibuprofen	C				
UNKNOWN							3613 DAY	
			Naprosyn	C				
UNKNOWN							3613 DAY	

Date:05/27/05ISR Number: 4676428-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00771
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acoustic Neuroma
Initial or Prolonged	Acute Sinusitis
Other	Adverse Event
	Alopecia Scarring
	Angina Pectoris
	Antiphospholipid
	Antibodies Positive
	Antiphospholipid Syndrome
	Anxiety
	Arthralgia
	Asthenia
	Atelectasis
	Back Disorder
	Balance Disorder
	Blood Pressure Increased
	Blood Thyroid Stimulating
	Hormone Decreased
	Brain Stem Syndrome
	Cerebral Artery Stenosis
	Cerebrovascular Accident
	Convulsion
	Coordination Abnormal
	Cow'S Milk Intolerance

Demyelination
Diabetes Mellitus
Non-Insulin-Dependent
Diarrhoea
Dilatation Intrahepatic
Duct Acquired
Dizziness
Drug Hypersensitivity
Dysstasia
Embolism
Encephalitis
Fatigue
Gait Disturbance
Gastrooesophageal Reflux
Disease
Glomus Tumour
Haemorrhage
Hemiparesis
Hepatic Lesion
Hypoaesthesia
Hypothyroidism
Inner Ear Disorder

		Ischaemia Labyrinthitis Lymphadenopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Meniere'S Disease		Vioxx	PS	Merck & Co., Inc	ORAL
81	DAY						
		Mouth Ulceration		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Advil	C		ORAL
		Musculoskeletal Stiffness		Prempro	C		
UNKNOWN							
		Nausea		Prilosec	C		
UNKNOWN							
		Neck Injury		Synthroid	C		
UNKNOWN							
		Nystagmus		Diovan	C		
UNKNOWN							
		Paraesthesia		Dimethyl Sulfone	C		
UNKNOWN							
		Pleural Effusion		Gaviscon Antacid			
		Sensation Of Heaviness		Tablets	C		
UNKNOWN							
		Surgery		Hydrocodone			
		Tinnitus		Hydrochloride	C		
UNKNOWN							
		Tongue Ulceration		[Therapy			
		Transient Ischaemic		Unspecified]	C		ORAL
		Attack					
		Urticaria Generalised					
		Vasculitis					
		Vertigo					
		Vomiting					

Date:05/27/05ISR Number: 4676429-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Other	Anal Fistula
	Anastomotic Complication
	Aneurysm Ruptured
	Angina Unstable
	Anxiety
	Appendicitis Perforated
	Arthralgia

Atelectasis
Back Pain
Cardiac Failure
Cerebral Artery Stenosis
Colitis Ulcerative
Contusion
Convulsion
Coronary Artery Disease
Cough
Crohn'S Disease
Defaecation Urgency
Depression
Dermatitis
Dizziness
Drug Ineffective
Faecal Incontinence
Fall
Flatulence
Headache
Hernia
Hyperlipidaemia
Hypertension
Hypotension
Ileitis

		Impaired Healing					
		Infection					
		Inflammatory Bowel	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Intestinal Perforation					
		Intestinal Spasm					
		Intracranial Aneurysm					
		Joint Injury					
		Migraine					
		Musculoskeletal Chest					
		Pain					
		Pain					
		Pain In Extremity					
		Perianal Abscess					
		Perirectal Abscess					
		Pneumoperitoneum					
		Pouchitis					
		Proctalgia					
		Proctitis Ulcerative					
		Pruritus Ani					
		Pyrexia					
		Sepsis					
		Subarachnoid Haemorrhage					
		Syncope					
		Tachycardia					
		White Blood Cell Count					
		Increased					

Date:05/27/05ISR Number: 4676430-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00001
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
		Brain Stem Ischaemia		Omeprazole	C		ORAL
		Facial Pain		Aspirin	C		ORAL
		Feeling Cold					
		Hypertension					
		Microangiopathy					
		Paraesthesia Oral					
		Vertigo					
		Visual Disturbance					

Date:05/27/05ISR Number: 4676431-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02960
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Fatigue Syndrome
	Depression
	Dysphagia
	Dyspnoea
	Emotional Distress
	Heart Rate Irregular
	Myocardial Infarction

		Non-Consummation					
		Oedema Peripheral					
		Oesophageal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Panic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Sexual Dysfunction		Lipitor	C		
UNKNOWN							
		Tension		Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Zyprexa	C		
UNKNOWN							
				Zyprexa	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:05/27/05ISR Number: 4676432-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00119
Age:55 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
3	WK						
Initial or Prolonged		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Effect Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
3	WK						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Venous Stenosis		Atorvastatin Calcium	C		ORAL
				Aspirin	C		ORAL
				Bisoprolol Fumarate	C		ORAL
				Pantoprazole Sodium	C		ORAL
				Dipyrone	C		ORAL

Date:05/27/05ISR Number: 4676433-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02137
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		330 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		152 DAY
Disability	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celexa	C				UNKNOWN
	Dyspepsia		Celebrex	C		ORAL		
	Emotional Distress		Plavix	C				UNKNOWN
	Facial Palsy		Darvocet-N	C				UNKNOWN
	Gastrooesophageal Reflux Disease							
	Headache							
	Injury							
	Nausea							
	Obesity							
	Sleep Apnoea Syndrome							
	Weight Decreased							

Date:05/27/05ISR Number: 4676434-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03184
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abnormal Sensation In Eye
Initial or Prolonged	Anxiety
	Arachnoid Cyst
	Back Pain
	Blindness Unilateral
	Blood Pressure Increased

Cerebrovascular Accident
Depression
Drug Ineffective

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Vioxx	SS	Merck & Co., Inc	ORAL		

Emotional Distress
Erythema
Eye Irritation
Eye Pain
Fibromyalgia
Headache
Hemianopia
Hypoaesthesia
Intervertebral Disc
Protrusion
Leukocytosis
Macular Scar
Oedema Peripheral
Optic Ischaemic
Neuropathy
Optic Nerve Disorder
Osteoarthritis
Pain In Extremity
Papillitis
Papilloedema
Paraesthesia
Pigmentation Disorder
Retinal Artery Occlusion
Retinal Ischaemia
Rheumatoid Arthritis
Sciatica
Shoulder Pain
Vasculitis
Vision Blurred
Visual Acuity Reduced
Visual Field Defect

Date:05/27/05ISR Number: 4676435-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03491
Age:64 YR Gender:Male I/FU:F

Outcome
Death

PT
Alanine Aminotransferase
Increased
Aspartate
Aminotransferase

Increased
Blood Alkaline
Phosphatase Increased
Blood Cholesterol
Increased
Coronary Artery
Atherosclerosis
Coronary Artery
Thrombosis
Diverticulum
Diverticulum Intestinal
Drug Screen Positive
Gout
Hypertensive Heart
Disease
Myocardial Infarction
Nodule

		Pain Prescribed Overdose Skin Nodule	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Spinal Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
154	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
154	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
687	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
715	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
154	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
154	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
687	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
715	DAY						
				Allopurinol	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							

Date:05/27/05ISR Number: 4676436-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03169
Age:43 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL
		Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL

	Pain	Percocet	C
UNKNOWN			
	Parathyroid Disorder	Toradol	C
UNKNOWN			
	Pulmonary Embolism	Warfarin	C
UNKNOWN			
	Swelling	Alesse	C
UNKNOWN			
		Hydrocodone Bitartrate	C
UNKNOWN			
		Methylprednisolone	C
UNKNOWN			
		Bextra	C
UNKNOWN			

Date:05/27/05ISR Number: 4676437-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00228
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Depression		Zantac	C		
UNKNOWN						
Disability	Emotional Distress		Estrogens			
	Uterine Polyp		(Unspecified)	C		
UNKNOWN						

Date:05/27/05ISR Number: 4676438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00431
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Effexor	C		
UNKNOWN						
Initial or Prolonged	Vascular Bypass Graft					
Disability						
Other						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676450-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00849
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL	31	DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Congestion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Renal Cell Carcinoma		Ambien	C			UNKNOWN	
	Stage Unspecified							
	Small Cell Carcinoma							
	Upper Respiratory Tract Infection							

Date:05/27/05ISR Number: 4676451-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02279
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/27/05ISR Number: 4676452-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	825	DAY
	Lacunar Infarction							

Date:05/27/05ISR Number: 4676456-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02280
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

59 DAY

Date:05/27/05ISR Number: 4676457-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Dose Duration
722 DAY

Date:05/27/05ISR Number: 4676458-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Dose Duration

Date:05/27/05ISR Number: 4676459-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01678
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
Disability	Acute Myocardial Infarction
	Adjustment Disorder

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Alcoholism					
		Bronchitis Acute					
		Change Of Bowel Habit					
		Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Ostial Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Cyclobenzaprine			
		Eye Pain		Hydrochloride	C		
UNKNOWN							
		Gastritis		Foltx	C		
UNKNOWN							
		Haematoma		Frova	C		
UNKNOWN							
		Headache		Nadolol	C		
UNKNOWN							
		Hyperlipidaemia		Nexium	C		
UNKNOWN							
		Infusion Site Reaction		Pepcid Ac	C		
UNKNOWN							
		Insomnia		Prochlorperazine	C		
UNKNOWN							
		Migraine		Tetracycline	C		
UNKNOWN							
		Muscle Spasms		Cyanocobalamin	C		
UNKNOWN							
		Myocardial Ischaemia		Ascorbic Acid	C		
UNKNOWN							
		Nausea		Saw Palmetto	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Ocuvite Lutein	C		
UNKNOWN							
		Oesophageal Spasm		Advil	C		
UNKNOWN							
		Osteoarthritis		Tylenol	C		
UNKNOWN							
		Peptic Ulcer		Ambien	C		
UNKNOWN							
		Rhinitis					
		Sinusitis					
		Vein Disorder					

Date:05/27/05ISR Number: 4676461-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
	Coronary Artery Disease							
	Myocardial Infarction							

Date:05/27/05ISR Number: 4676462-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury		Celebrex	C				
UNKNOWN								

Date:05/27/05ISR Number: 4676463-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02603
Age:57 YR Gender:Female I/FU:I

Outcome	PT
Disability	Abdominal Pain Lower
	Abdominal Pain Upper
	Anxiety
	Arthralgia
	Back Pain
	Bronchitis
	Cerebrovascular Accident
	Dysphagia

		Emotional Distress Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hemiparesis		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR						
		Intervertebral Disc		Estratest	C		
UNKNOWN							
		Degeneration		Diovan	C		
UNKNOWN							
		Lacunar Infarction		Hydrochlorothiazide			
		Mental Disorder		Tablets (Usp 23)	C		
UNKNOWN							
		Multiple Sclerosis		Bextra	C		
UNKNOWN		2 MON					
		Oedema Peripheral					
		Pain					
		Pain In Extremity					
		Paraesthesia					
		Transient Ischaemic Attack					
		Vision Blurred					
		Visual Acuity Reduced					

Date:05/27/05ISR Number: 4676464-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02281
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
8 MON						
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:05/27/05ISR Number: 4676465-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03487
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Lower
	Anaemia
	Anxiety

Aspartate
Aminotransferase
Increased
Asthenia
Atelectasis
Back Pain
Blood Alkaline
Phosphatase Increased
Blood Urea Increased
Breath Sounds Decreased
Chest Pain
Colitis Ischaemic
Constipation
Deep Vein Thrombosis
Dehydration
Depression
Diarrhoea
Diverticulum
Dizziness
Dyspnoea
Dysstasia
Emotional Distress
Faecal Occult Blood
Positive
Faeces Discoloured

		Gastric Ulcer Haemorrhage Gastrointestinal Disorder Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Synthroid	C		
UNKNOWN							
		Haematocrit Decreased Haemoglobin Decreased Haemorrhoids Hiatus Hernia High Density Lipoprotein Decreased Hypercoagulation Hyperhidrosis Hypertension Hypothyroidism Hypoventilation Infection Influenza Insomnia International Normalised Ratio Increased Leukocytosis Lipase Increased Lung Infiltration Melaena Migraine Muscle Spasms Nausea Neck Pain Osteoarthritis Pco2 Decreased Peptic Ulcer Pleuritic Pain Pneumonia Po2 Decreased Prothrombin Time Prolonged Pulmonary Embolism Sinus Tachycardia Ulcer Haemorrhage Vomiting					

Date:05/27/05ISR Number: 4676487-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/27/05ISR Number: 4676491-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02852
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	12 MON	
Disability	Dyspnoea Paraesthesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676545-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02989
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthroscopic Surgery		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Venous		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Other	Thrombosis		Synthroid	C			UNKNOWN	
	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Cerebrovascular Disorder		Prempro	C			UNKNOWN	
	Depression		Labetalol Hydrochloride	C			UNKNOWN	
	Fear							
	Migraine		Glucotrol	C			UNKNOWN	
	Osteoarthritis							
	Palpitations							
	Post-Traumatic Stress Disorder							
	Renal Cyst							
	Tachycardia							
	Transverse Sinus Thrombosis							

Date:05/27/05ISR Number: 4676768-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00005
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Anaemia
Disability	Angina Pectoris
	Arthralgia
	Arthritis
	Blood Pressure Systolic Increased
	Chest Discomfort
	Condition Aggravated
	Confusional State
	Connective Tissue Disorder
	Depression

Diabetes Mellitus
Diverticulum Duodenal
Dizziness
Drug Ineffective
Dysphoria
Fall
Gastritis
Generalised Anxiety
Disorder
Haemorrhoids
Hypertension
Idiopathic
Thrombocytopenic Purpura
Injury
Intestinal Obstruction
Joint Lock
Malaise
Melaena
Nervousness
Osteoarthritis
Pain
Stomach Discomfort
Tremor

		Upper Gastrointestinal Haemorrhage Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Ms Contin	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Lotensin	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Hydro-Chlor	C		
UNKNOWN							
				Elavil	C		ORAL
				Heparin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Hydroxychloroquine Sulfate	C		
UNKNOWN							
				Compazine	C		
UNKNOWN							

Outcome	PT
Other	Adverse Event
	Anger
	Angina Pectoris
	Angiopathy
	Anhedonia
	Anxiety
	Appendicectomy
	Appendix Disorder
	Arthropathy
	Blood Pressure
	Inadequately Controlled
	Brain Stem Ischaemia
	Bunion
	Carotid Artery Atheroma
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebral Atherosclerosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chronic Obstructive
	Pulmonary Disease
	Complicated Migraine
	Contusion
	Convulsion
	Depressed Mood
	Depression
	Diastolic Dysfunction
	Dizziness
	Fall
	Fatigue

		Feeling Of Despair					
		Ganglion					
		Gastrointestinal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Prempro	C		
UNKNOWN							
		Hyperlipidaemia		Dyazide	C		
UNKNOWN							
		Hypertension		Aspirin	C		
UNKNOWN							
		Hypoaesthesia					
		Lacunar Infarction					
		Microangiopathy					
		Migraine					
		Mitral Valve Incompetence					
		Monarthritis					
		Mood Swings					
		Neck Pain					
		Nerve Compression					
		Neuropathy Peripheral					
		Pain In Extremity					
		Periarthritis					
		Personality Change					
		Sinus Tarsi Syndrome					
		Skin Lesion					
		Somnolence					
		Stress					
		Syncope					
		Therapy Non-Responder					
		Tinel'S Sign					
		Toe Deformity					
		Tonsillar Disorder					
		Tonsillectomy					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Trigger Finger					
		Urge Incontinence					
		Ventricular Hypertrophy					
		Vertigo					
		Wrist Fracture					

Date:05/27/05ISR Number: 4676770-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00814
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Anaemia Postoperative
Hospitalization -	Aneurysm
Initial or Prolonged	Antinuclear Antibody
Disability	Positive
	Aortic Dissection
	Aortic Valve Incompetence
	Asthenia
	Chronic Obstructive
	Pulmonary Disease
	Coagulopathy
	Depression
	Disturbance In Attention
	Diverticulitis
	Dizziness
	Emotional Distress

		Gastrooesophageal Reflux Disease					
		General Physical Condition Abnormal	Report Source	Product Vioxx	Role PS	Manufacturer Merck & Co., Inc	Route ORAL
Dose	Duration						
7	DAY						
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Iliac Artery Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Impaired Healing		Lorazepam	C		
UNKNOWN							
		Injury		Amoxicillin	C		
UNKNOWN							
		Intermittent Claudication		Hydrocodone Bitartrate	C		
		Irritability					
UNKNOWN							
		Keloid Scar		Viagra	C		
UNKNOWN							
		Mitral Valve Incompetence		Chlorhexidine Hydrochloride	C		
		Myocardial Infarction					
UNKNOWN							
		Pain					
		Pneumonia					
		Rash Pruritic					
		Self Esteem Decreased					
		Sexual Dysfunction					
		Sinus Bradycardia					
		Tricuspid Valve Incompetence					
		Vascular Injury					

Date:05/27/05ISR Number: 4676771-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01437
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
Disability	Anxiety
	Arrhythmia
	Blood Cholesterol Increased
	Bradycardia

Bronchitis
Cardiac Failure
Congestive
Carotid Artery Disease
Chronic Obstructive
Pulmonary Disease
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Dermatitis
Diverticulum Intestinal
Emotional Disorder
Gastritis
Gastrointestinal
Haemorrhage
Haematuria
Haemorrhoids
Hyperlipidaemia
Hypertension
Hypotension
Myocardial Infarction
Pain
Pain In Extremity
Palpitations
Proctitis

		Rash Pruritic Sinusitis Stress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
532	DAY						
		Upper Gastrointestinal		Tylenol	C		
UNKNOWN							
		Haemorrhage		Motrin	C		
UNKNOWN							
		Upper Respiratory Tract		Ultram	C		
UNKNOWN							
		Infection		Nasonex	C		
UNKNOWN							
		Urinary Tract Infection		Elocon	C		
UNKNOWN							
		Weight Decreased		Hydroxyzine Pamoate	C		
UNKNOWN							
				Tranxene	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Loperamide Hydrochloride	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Proventil	C		
UNKNOWN							
				Duratuss	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Epi-Pen	C		
UNKNOWN							
				Diphenhydramine Citrate	C		
UNKNOWN							

Date:05/27/05ISR Number: 4676772-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00762
Age: Gender:Male I/FU:F

Outcome	PT
Death	Angina Pectoris
Hospitalization -	Aortic Stenosis
Initial or Prolonged	Atrioventricular Block
Disability	First Degree
Other	Blood Glucose Decreased
	Blood Pressure Increased
	Cachexia
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chest Discomfort
	Chest Pain
	Convulsion
	Coronary Artery Disease
	Death
	Decubitus Ulcer
	Dehydration
	Electrocardiogram
	Abnormal
	Fall
	Hospitalisation
	Hypoglycaemia
	Mental Status Changes
	Multiple System Atrophy
	Myocardial Ischaemia
	Orthostatic Hypotension
	Pulmonary Embolism
	Pulmonary Oedema
	Red Blood Cell Count
	Decreased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Renal Failure Staphylococcal Infection Staphylococcal Sepsis					
99	DAY	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL
38	DAY	Tooth Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
296	DAY	Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Urosepsis		Allopurinol	C		
UNKNOWN		Wound Infection		Pepcid	C		
UNKNOWN		Staphylococcal		Flonase	C		
UNKNOWN				Micronase	C		
UNKNOWN				Lactulose	C		
UNKNOWN				Carbidopa And Levodopa	C		
UNKNOWN				Probenecid	C		
UNKNOWN				Quinine Sulfate	C		
UNKNOWN				Selegiline	C		
UNKNOWN				Tramadol Hydrochloride	C		
UNKNOWN				Bisacodyl	C		
UNKNOWN				Compazine	C		
UNKNOWN				Mylanta & Mylanta Ds	C		
UNKNOWN				Atenolol	C		
UNKNOWN				Chlorthalidone	C		
UNKNOWN				Darvocet-N	C		

Date:05/27/05ISR Number: 4676773-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00806
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Adverse Event
	Angina Unstable
	Arthralgia
	Asthenia
	Autonomic Neuropathy
	Back Pain
	Biliary Dilatation
	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cataract
	Chest Pain
	Cholelithiasis
	Obstructive
	Constipation
	Convulsion
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Diabetes Mellitus
	Insulin-Dependent
	Diabetic Retinopathy
	Dyspnoea
	Ear Disorder
	Faecaloma
	Fall
	Gastroenteritis Viral

		Gastrooesophageal Reflux Disease					
		Haematoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatic Steatosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
		Impaired Gastric Emptying		Nitroglycerin	C		
RESPIRATORY							
		Insomnia					
(INHALATION)							
		Intervertebral Disc		Imdur	C		ORAL
		Degeneration		Humulin N	C		
SUBCUTANEOUS							
		Ligament Injury		Humulin N	C		
SUBCUTANEOUS							
		Lumbar Radiculopathy		Cardizem	C		ORAL
		Muscle Spasms		Potassium			
		Musculoskeletal Pain		(Unspecified)	C		ORAL
		Myocardial Ischaemia		Pepcid	C		ORAL
		Myositis		Ambien	C		ORAL
		Nausea		Propulsid	C		ORAL
		Oedema Peripheral		Aspirin	C		ORAL
		Pain In Extremity		Lipitor	C		ORAL
		Paraesthesia		Glucophage	C		ORAL
		Pulmonary Oedema		Lasix (Furosemide)	C		ORAL
		Retinal Detachment		Prozac	C		ORAL
		Rotator Cuff Syndrome		Surfak	C		ORAL
		Vomiting		Triple Tannate			
				Pediatric Suspension	C		
UNKNOWN							
				Celebrex	C		ORAL

Date:05/27/05ISR Number: 4676774-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
83	DAY						
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Calculus Ureteric		Advil	C		
UNKNOWN							
Other		Calculus Urinary		Advil	C		
UNKNOWN							

	Chest Discomfort	Vicodin Tablets	C
UNKNOWN			
	Coronary Artery Occlusion	Aspirin	C
UNKNOWN			
	Cough	Ultram	C
UNKNOWN			
	Diverticulitis	Ultram	C
UNKNOWN			
	Emotional Distress		
	Fatigue		
	Osteoarthritis		
	Palpitations		
	Pneumonia Influenzal		
	Weight Fluctuation		

Date:05/27/05ISR Number: 4676777-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Abdominal Pain Upper
Disability	Acquired Claw Toe
Other	Angina Pectoris
	Back Injury
	Back Pain
	Blood Triglycerides Increased
	Chest Pain

Chest Wall Pain
Chromaturia
Chronic Fatigue Syndrome
Constipation
Convulsion
Coordination Abnormal
Costochondritis
Cyanosis
Depression
Diabetes Mellitus
Inadequate Control
Diabetic Neuropathy
Diabetic Retinopathy
Difficulty In Walking
Disturbance In Attention
Dizziness
Drug Hypersensitivity
Drug Ineffective
Drug Intolerance
Emotional Distress
Exostosis
Fatigue
Fear
Feeling Cold
Flatulence
General Physical Health
Deterioration
Headache
Hot Flush
Hyperkeratosis
Hypertension
Injury
Insomnia
Macular Oedema
Mental Status Changes
Microalbuminuria
Mood Altered
Muscle Mass
Muscle Spasms
Myalgia
Myocardial Infarction
Neck Injury
Neuralgia
Neuritis
Neuropathy Peripheral
Non-Cardiac Chest Pain
Oedema

Oedema Peripheral
Pain
Pain In Extremity
Peripheral Vascular
Disorder
Pollakiuria
Restless Legs Syndrome
Retinal Exudates
Retinal Oedema
Retinopathy
Road Traffic Accident
Serum Ferritin Decreased
Sinus Congestion
Sinus Tachycardia

	Tachycardia						
	Toe Deformity						
	Traumatic Haematoma	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Treatment Noncompliance		Vioxx	PS	Merck & Co., Inc	ORAL	
	Weight Decreased		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Baycol	C			UNKNOWN
			Actos	C			UNKNOWN
			[Composition Unspecified]	C			UNKNOWN

Date:05/27/05ISR Number: 4676778-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA02375
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	7 DAY
Initial or Prolonged	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL	7 DAY
Disability	Antiphospholipid Syndrome		Allegra	C			UNKNOWN
Other	Back Disorder						
	Blood Cholesterol Increased						
	Cerebrovascular Accident						
	Cholecystitis						
	Chronic Fatigue Syndrome						
	Coagulopathy						
	Colonic Polyp						
	Contusion						
	Diarrhoea						
	Diverticulum						
	Dyspepsia						
	Emotional Distress						
	Epistaxis						

Gallbladder Disorder
Gastroenteritis Viral
Haemorrhoids
Headache
Hypoaesthesia
International Normalised
Ratio Increased
Menometrorrhagia
Migraine
Migraine With Aura
Mitral Valve Disease
Nervousness
Neurogenic Bladder
Ovarian Cyst
Peridiverticular Abscess
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Urinary Tract Infection

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676780-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02079
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		276 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anaemia		Fosamax	C		ORAL		328 DAY
	Angina Pectoris		Baycol	C				UNKNOWN
	Arterial Disorder		Folic Acid	C				UNKNOWN
	Arthralgia		Betimol	C				OPHTHALMIC
	Atherosclerosis		Vicodin Tablets	C				UNKNOWN
	Back Disorder		Norvasc	C				UNKNOWN
	Cardiac Failure		Evista	C				UNKNOWN
	Congestive		Benadryl	C				UNKNOWN
	Chest Pain		[Therapy					
	Coronary Artery Disease		Unspecified]	C				UNKNOWN
	Dehydration		Prinivil	C		ORAL		
	Dermatitis Allergic		Pravachol	C				UNKNOWN
	Diabetes Mellitus		Celebrex	C				UNKNOWN
	Non-Insulin-Dependent		Soma	C				UNKNOWN
	Dyspepsia							
	Dyspnoea							
	Ear Infection							
	Emotional Distress							
	Gastroenteritis							
	Haematoma							
	Hiatus Hernia							
	Hypertension							
	Injury							
	Myocardial Infarction							
	Osteoarthritis							
	Osteoporosis							
	Renal Failure							

	Sciatica Spondylolisthesis Stress Supraventricular Extrasystoles

Date:05/27/05ISR Number: 4676781-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04293
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Death	Acidosis
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged Arterial Occlusive Disease Arterial Spasm Atherosclerosis Bradycardia Cardiac Arrest Cardio-Respiratory Arrest Catheter Related Complication Deep Vein Thrombosis Disseminated Intravascular Coagulation Fractured Sacrum Haematocrit Decreased

	Haemoglobin Decreased					
	Hyperkalaemia					
	Hypoaesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
188 DAY						
	Intermittent Claudication		Vioxx	SS	Merck & Co., Inc	ORAL
188 DAY						
	International Normalised		Diovan	C		
UNKNOWN						
	Ratio Increased		Os-Cal	C		
UNKNOWN						
	Limb Injury		Xanax	C		
UNKNOWN						
	Neuropathy		Synthroid	C		
UNKNOWN						
	Peripheral Ischaemia		Darvocet-N	C		
UNKNOWN						
	Platelet Count Decreased		Fosamax	C		
UNKNOWN						
	Pulse Absent		Levoxyl	C		
UNKNOWN						
	Raynaud'S Phenomenon		Neurontin	C		
UNKNOWN						
	Renal Tubular Necrosis		Oxycodone	C		
UNKNOWN						
	Reperfusion Injury		Alprazolam	C		
UNKNOWN						
	White Blood Cell Count		Norvasc	C		
UNKNOWN						
	Increased					

Date:05/27/05ISR Number: 4676785-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00814
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anal Fissure
	Anxiety
	Aortic Aneurysm
	Aortic Dilatation
	Aortic Valve Incompetence
	Arrhythmia
	Back Pain
	Benign Prostatic Hyperplasia

Cellulitis
Chest Discomfort
Chest Pain
Chromaturia
Claustrophobia
Coronary Artery Occlusion
Diverticulum
Dizziness
Dyspnoea
Eczema
Exostosis
Flank Pain
Haemorrhoids
Headache
Hyperhidrosis
Hypertension
Hypoaesthesia
Influenza
Lipids Increased
Nausea
Nephrolithiasis
Panic Disorder
Peripheral Artery
Aneurysm
Pharyngolaryngeal Pain
Polyp
Pyrexia
Renal Artery Stenosis
Retrograde Ejaculation

		Right Ventricular Systolic Pressure Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Scoliosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Infection					
		Ventricular Extrasystoles					

Date:05/27/05ISR Number: 4676786-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03096
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Allegra	C		
UNKNOWN							
		Depression		Methylprednisolone	C		
UNKNOWN							
		Diverticulum					
		Emotional Distress					
		Eye Disorder					
		Gastrooesophageal Reflux Disease					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hypertension					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Renal Disorder					
		Sinusitis					
		Thrombosis					
		Upper Respiratory Tract Infection					

Date:05/27/05ISR Number: 4676787-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02723
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Aspirin	C			UNKNOWN	
	Atherosclerosis		Zocor	C			UNKNOWN	
	Cardiac Disorder		Toprol Xl Tablets	C			UNKNOWN	
	Coronary Artery Occlusion		Lasix (Furosemide)	C			UNKNOWN	
	Decubitus Ulcer		Enalapril Comp	C			UNKNOWN	
	Depression		Meclizine	C			UNKNOWN	
	Diabetes Mellitus							
	Dizziness							
	Fear							
	Herpes Simplex							
	Upper Respiratory Tract Infection							
	Urinary Tract Obstruction							
	Venous Insufficiency							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676789-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02743
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bladder Disorder		Procardia	C			UNKNOWN	
Other	Blindness		Prevacid	C			UNKNOWN	
	Cerebrovascular Accident		Cardura	C			UNKNOWN	
	Chest Pain		Detrol	C			UNKNOWN	
	Chest Wall Pain		Ambien	C			UNKNOWN	
	Cough		Colace	C			UNKNOWN	
	Depression		Gemfibrozil	C			UNKNOWN	
	Drooling		Xalatan	C			UNKNOWN	
	Dysphagia		Aspirin	C			UNKNOWN	
	Gastrooesophageal Reflux		Doxazosin Mesylate	C			UNKNOWN	
	Disease		Allegra	C			UNKNOWN	
	Hiatus Hernia		Nasonex	C			UNKNOWN	
	Oedema		Tylenol	C			UNKNOWN	
	Speech Disorder		Gaviscon Antacid Tablets	C			UNKNOWN	
	Thrombosis							
	Vocal Cord Disorder		Augmentin	C			UNKNOWN	
			Humibid	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Dyazide	C			UNKNOWN	

Date:05/27/05ISR Number: 4676790-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02655
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arterial Occlusive Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bursitis		Synthroid	C			UNKNOWN	
	Coronary Artery Disease		Nasacort Aq	C			UNKNOWN	
	Depressed Mood		Methylprednisolone	C			UNKNOWN	
	Diarrhoea		Avalide	C			UNKNOWN	
	Drug Ineffective		Premarin	C			UNKNOWN	
	Dysfunctional Uterine Bleeding		Medroxyprogesterone Acetate	C			UNKNOWN	
	Emotional Distress		Sulfamethoxazole	C			UNKNOWN	
	Gastrooesophageal Reflux Disease		Combivent	C			UNKNOWN	
	Influenza Like Illness		Atropine Sulfate And Diphenoxylate Hydrochloride	C			UNKNOWN	
	Leukocytosis		Cipro	C			UNKNOWN	
	Myocardial Infarction		Ambien	C			UNKNOWN	
	Paraesthesia		Wellbutrin	C			UNKNOWN	
	Pharyngolaryngeal Pain		Isosorbide	C			UNKNOWN	
	Prescribed Overdose		Avelox	C			UNKNOWN	
	Stress Incontinence		Clindamycin	C			UNKNOWN	
	Trigger Finger		Flonase	C			UNKNOWN	
	Urinary Tract Infection		Aciphex	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Pravachol	C			UNKNOWN	

UNKNOWN

UNKNOWN

UNKNOWN

Bextra	C
Microzide	C
Celebrex	C

			Nitroglycerin	C			
UNKNOWN							

Date:05/27/05ISR Number: 4676791-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00832
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		869 DAY
Other	Cataract							
	Cerebrovascular Accident							
	Pain							
	Polytraumatism							
	Retinal Vein Occlusion							

Date:05/27/05ISR Number: 4676792-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00798
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx [Therapy Unspecified]	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease			C				
UNKNOWN								
	Dyspnoea		Geneva Calcium Plus Soy	C				
	Ejection Fraction							
UNKNOWN								
	Decreased		Crestor	C				
UNKNOWN								
	Emotional Distress							
	Heart Injury							
	Hyperhidrosis							

Date:05/27/05ISR Number: 4676793-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00800
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		223 DAY

Initial or Prolonged	Bundle Branch Block Right	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
223 DAY					
	Chest Pain	Beconase	C		
UNKNOWN					
	Cough	Hydrochlorothiazide	C		
UNKNOWN					
	Depression				
	Dyspnoea				
	Dysuria				
	Gastrooesophageal Reflux				
	Disease				
	Hyperhidrosis				
	Hypokalaemia				
	Lacunar Infarction				
	Syncope				
	Transient Ischaemic				
	Attack				
	Vomiting				

Date:05/27/05ISR Number: 4676794-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00809
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Dizziness
Disability	Emotional Distress
	Epigastric Discomfort

	Polytraumatism						
	Sinus Disorder						
	Sinusitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Attack		Zyrtec	C				UNKNOWN
	Ventricular Hypertrophy							

Date:05/27/05ISR Number: 4676795-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00806
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
613 DAY								
Other	Muscle Spasms		Aceon	C				
UNKNOWN	1166 DAY							
	Myocardial Infarction		Actos	C				
UNKNOWN								
	Pain		Glyburide	C				
UNKNOWN								
	Silent Myocardial		Lozol	C				
UNKNOWN								
	Infarction		Glucophage	C				
UNKNOWN								
	Urinary Tract Infection		Acetaminophen	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Alprazolam	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								
			Verelan Pm	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Clonidine	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Cipro	C				
UNKNOWN								

		Covera	C	
UNKNOWN				
		Tramadol Msd	C	
UNKNOWN				
		Sulfamethoxazole And Trimethoprim	C	
UNKNOWN				
		Celebrex	C	
UNKNOWN				
		Premarin	C	
UNKNOWN				

Date:05/27/05ISR Number: 4676800-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02651
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Lotrel	C				
UNKNOWN								
	Dyspnoea		Allopurinol	C				
UNKNOWN								
	Emotional Distress		Terazosin Hydrochloride	C				
	Fatigue							
UNKNOWN								
	Lower Gastrointestinal		Niferex	C				
UNKNOWN								
	Haemorrhage		Lipitor	C				
UNKNOWN								
	Myocardial Infarction		Ambien	C				
UNKNOWN								
	Thrombosis		Xanax	C				
UNKNOWN								

Date:05/27/05ISR Number: 4676801-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00808
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
Disability	Blood Cholesterol Increased
	Blood Triglycerides

		Increased Cardiac Disorder					
		Cerebrovascular Accident					
		Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Disturbance In Sexual		Vioxx	SS	Merck & Co., Inc	ORAL
		Arousal		Lopressor	C		ORAL
		Dizziness		Toprol Xl Tablets	C		ORAL
		Ear Pain		Prevacid	C		ORAL
		Insomnia		Tagamet	C		
UNKNOWN							
		Pain		Elavil	C		ORAL
		Pharyngitis		Elavil	C		ORAL
		Shoulder Pain		Remeron	C		ORAL
		Suicidal Ideation		Aspirin	C		ORAL
		Transient Ischaemic Attack					

Date:05/27/05ISR Number: 4676802-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03194
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Prerenal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
42 MON						
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL
42 MON						
Disability	Arthritis Infective		Diovan	C		ORAL
	Blood Pressure		Coumadin	C		
UNKNOWN						
	Inadequately Controlled		Vitamins			
	Cardiomegaly		(Unspecified)	C		
UNKNOWN						
	Cataract		Ambien	C		
UNKNOWN						
	Coronary Artery Disease		Lortab	C		
UNKNOWN						
	Cyst					
	Drug Ineffective					
	Emotional Distress					
	Erectile Dysfunction					
	Fatigue					
	Gastrooesophageal Reflux Disease					
	Inguinal Hernia					

Ischaemic Cardiomyopathy
Joint Dislocation
Myocardial Infarction
Normochromic Normocytic
Anaemia
Orthostatic Hypotension
Osteomyelitis
Pain
Rectal Haemorrhage
Renal Failure
Urinary Tract Infection

Date:05/27/05ISR Number: 4676803-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02897
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
	Acute Myocardial Infarction
	Asthenia
	Blood Cholesterol Increased

	Coronary Artery Atherosclerosis						
	Depression	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	
	Impaired Work Ability		Ery-Tab	C			UNKNOWN
	Non-Consummation		Ventolin (Albuterol)	C			UNKNOWN
	Osteoarthritis		Hydrocodone Bitartrate	C			UNKNOWN
			Lamisil	C			UNKNOWN

Date:05/27/05ISR Number: 4676804-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00144
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	
	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Confusional State		Metoprolol Succinate	SS		ORAL	
	Delirium		Metoprolol Succinate	SS		ORAL	
	Depression		Ramipril	C		ORAL	
	Disorientation		Aspirin	C		ORAL	
	Dizziness		Zocor	C		ORAL	
	Fatigue						
	Intracranial Venous Sinus Thrombosis						
	Lumbar Radiculopathy						
	Sleep Disorder						
	Somnolence						
	Tension Headache						

Date:05/27/05ISR Number: 4676805-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Respiratory
Other	Distress Syndrome

Acute Respiratory Failure
Aggression
Arthralgia
Arthropathy
Atelectasis
Back Pain
Blood Pressure Systolic
Abnormal
Bronchitis
Cardiomegaly
Cerebrovascular Accident
Cerebrovascular Accident
Prophylaxis
Chest Discomfort
Chest Pain
Cholecystitis
Cholecystitis Chronic
Cholelithiasis
Coordination Abnormal
Drug Hypersensitivity
Fall
Gastrooesophageal Reflux

		Disease					
		Headache					
		Hiatus Hernia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Hypoxia		Aspirin	C		
UNKNOWN							
		Intention Tremor		Lipitor	C		
UNKNOWN							
		Intervertebral Disc		Metformin	C		
UNKNOWN							
		Degeneration		Prozac	C		
UNKNOWN							
		Laryngitis		Prilosec	C		
UNKNOWN							
		Lung Infiltration		Glucophage	C		
UNKNOWN							
		Mitral Valve Incompetence		Wellbutrin	C		
UNKNOWN							
		Non-Cardiac Chest Pain					
		Pericardial Effusion					
		Ph Body Fluid Abnormal					
		Pneumonia					
		Pulmonary Embolism					
		Shock					
		Sinus Disorder					
		Spinal Column Stenosis					
		Spinal Compression					
		Fracture					
		Transient Ischaemic					
		Attack					
		Treatment Noncompliance					
		Urinary Tract Infection					
		Ventricular Hypokinesia					
		Vertigo					

Date:05/27/05ISR Number: 4676806-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04295
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
48	MON						

Initial or Prolonged	Hypertension	Vioxx	SS	Merck & Co., Inc	ORAL
48 MON					
Disability		Claritin	C		
UNKNOWN					
		Flovent	C		
UNKNOWN					
		Advair	C		
UNKNOWN					
		Allegra-D	C		
UNKNOWN					
		Singulair	C		
UNKNOWN					

Date:05/27/05ISR Number: 4676807-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00102
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Death	Asthma
Other	Cardiac Arrest
	Cardiac Failure
	Congestive
	Constipation
	Depression
	Dyspepsia
	Faeces Hard
	Fungal Infection
	Hyperlipidaemia
	Hypersensitivity
	Hypertension
	Hypokalaemia
	Insomnia
	Iron Deficiency Anaemia

		Muscle Contractions Involuntary Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Respiratory Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
				Azmacort	C		
UNKNOWN							
		Sudden Cardiac Death		Albuterol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Atrovent	C		
UNKNOWN							
				Biaxin	C		
UNKNOWN							
				Bidex	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Docusate Calcium	C		
UNKNOWN							
				Docusate Calcium	C		
UNKNOWN							
				Duragesic	C		
UNKNOWN							
				Ferrous Sulfate	C		
UNKNOWN							
				Flovent	C		
UNKNOWN							
				Fluoxetine	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN		610 DAY					
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN		603 DAY					
				Hydroxychloroquine			

			Sulfate	C
UNKNOWN	381	DAY		
			Levoxyl	C
UNKNOWN				
			Maxair	C
UNKNOWN				
			Miacalcin	C
UNKNOWN				
			Nystatin	C
UNKNOWN				
			Phenergan Tablets/Suppositories	C
UNKNOWN				
			Potassium (Unspecified)	C
UNKNOWN				
			Prednisone	C
UNKNOWN				
			Premarin	C
UNKNOWN	568	DAY		
			Prilosec	C
UNKNOWN				
			Promethazine	C
UNKNOWN				
			Prozac	C
UNKNOWN				
			Synthroid	C
UNKNOWN				
			Tequin	C
UNKNOWN				
			Tizanidine Hydrochloride	C
UNKNOWN	52	DAY		
			Z-Pak	C
UNKNOWN				
			Zocor	C
UNKNOWN	602	DAY		
			Zyrtec	C
UNKNOWN				
			Prevacid	C
UNKNOWN				

Date:05/27/05ISR Number: 4676808-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Disorder
	Cerebrovascular Accident
Disability	Diplopia

		Diverticulum					
		Dyspepsia					
		Haemorrhoids	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL
		Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
		Myasthenia Gravis		Acupril	C		
UNKNOWN							
		Nausea		Premarin	C		ORAL
		Osteopenia		Lipitor	C		ORAL
		Osteoporosis		Hydrochlorothiazide	C		ORAL
		Pain		Aspirin	C		ORAL
		Pain In Extremity		Premarin	C		
VAGINAL							
		Plantar Fasciitis		Prilosec	C		ORAL
		Rectocele		Claritin	C		ORAL
		Rhinitis Allergic		Vitamin E	C		ORAL
		Spinal Column Stenosis		Miacalcin	C		
UNKNOWN							
		Spinal Compression					
		Fracture					
		Spondylolisthesis					
		Transient Ischaemic					
		Attack					
		Vaginal Prolapse					
		Vomiting					

Date:05/27/05ISR Number: 4676810-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02601
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL
680 DAY						
Hospitalization -	Artery Dissection		Ultram	C		
UNKNOWN						
Initial or Prolonged	Blood Glucose Increased		Flexeril	C		
UNKNOWN						
	Blood Pressure Increased		Ultracet	C		
UNKNOWN						
	Brain Death		Cyclobenzaprine			
	Brain Herniation		Hydrochloride	C		
UNKNOWN						
	Cerebral Infarction		Penicillin			

	Cerebrovascular Accident	(Unspecified)	C
UNKNOWN			
	Coma	Lortab	C
UNKNOWN			
	Contrast Media Reaction	Tramadol Msd	C
UNKNOWN			
	Dizziness	Zoloft	C
UNKNOWN			
	Drug Screen Positive		
	Headache		
	Loss Of Consciousness		
	Pneumonia		
	Quadriparesis		
	Respiratory Arrest		
	Thrombotic Stroke		

Date:05/27/05ISR Number: 4676811-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02969
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adrenal Disorder
Initial or Prolonged	Anxiety
	Anxiety Disorder
	Depression
	Dizziness
	Haematochezia
	Loss Of Consciousness
	Musculoskeletal Pain
	Pain

		Post-Traumatic Stress Disorder					
		Pulmonary Embolism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL
376	DAY						
		Stage Unspecified		Cantil	C		
UNKNOWN							
		Renal Surgery		Biaxin	C		
UNKNOWN							
		Thrombosis		Flexeril	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				Elavil	C		
UNKNOWN							
				Robaxin	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Viagra	C		
UNKNOWN							
				Talwin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Advil	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Zyprexa	C		
UNKNOWN							

Date:05/27/05ISR Number: 4676812-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00579
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
656	DAY						

Initial or Prolonged	Infarction	Vioxx	SS	Merck & Co., Inc	ORAL
656 DAY					
Disability	Coronary Artery Disease	Bisoprolol Fumarate			
Other	Emotional Distress	And			
	Hypertensive Crisis	Hydrochlorothiazide	C		
UNKNOWN					
	Hypoaesthesia				
	Lower Gastrointestinal				
	Haemorrhage				
	Productive Cough				
	Spinal Disorder				

Date:05/27/05ISR Number: 4676813-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03193
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abasia
Initial or Prolonged	Abdominal Discomfort
	Abdominal Pain
	Abdominal Pain Upper
	Activities Of Daily
	Living Impaired
	Anhedonia
	Anorexia
	Anxiety
	Back Pain
	Blood Pressure
	Inadequately Controlled
	Cardiac Valve Disease
	Chest Pain
	Condition Aggravated
	Coronary Artery Disease
	Decreased Appetite
	Depression
	Dizziness
	Emotional Distress

		Eye Infection Viral					
		Eye Pain					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fibromyalgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
6	DAY						
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercalcaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacrimation Increased		Cyclobenzaprine			
		Lumbar Spinal Stenosis		Hydrochloride	C		
UNKNOWN							
		Malaise		Tylenol	C		
UNKNOWN							
		Musculoskeletal Pain		Mevacor	C		
UNKNOWN							
		Myocardial Infarction		Nasonex	C		
UNKNOWN							
		Non-Cardiac Chest Pain		Chlorothiazide	C		
UNKNOWN							
		Osteoarthritis		Norvasc	C		
UNKNOWN							
		Pain In Extremity		Biaxin	C		
UNKNOWN							
		Pruritus					
		Rectal Haemorrhage					
		Rhinorrhoea					
		Stress					
		Vertigo					
		Weight Decreased					

Date:05/27/05ISR Number: 4676814-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00059
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
	Prescribed Overdose					

Date:05/27/05ISR Number: 4676815-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00017
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	258 MON	
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	258 MON	
	Cardiac Tamponade		Lisinopril	C		ORAL		
	Cardiomegaly		Esomeprazole	C		ORAL	1102 DAY	
	Cold Sweat							
	Coronary Artery Disease							
	Diarrhoea							
	Myocardial Infarction							
	Nausea							
	Paresis							
	Pneumonia							
	Post Procedural Complication							
	Pyrexia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676816-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02629
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Anoxic Encephalopathy		Vioxx	SS	Merck & Co., Inc	ORAL		8 MON
Disability	Blood Cholesterol							
Other	Increased							
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Clostridium Colitis							
	Coronary Artery Disease							
	Depression							
	Emotional Distress							
	Haemophilus Infection							
	Myocardial Infarction							
	Nausea							
	Overdose							
	Pain In Extremity							
	Platelet Aggregation Increased							
	Staphylococcal Infection							

Date:05/27/05ISR Number: 4676819-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03086
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/27/05ISR Number: 4676820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							
	Organ Failure							
	Pulmonary Embolism							

Thrombosis

Date:05/27/05ISR Number: 4676822-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02560
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:05/27/05ISR Number: 4676825-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	62	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676828-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:05/27/05ISR Number: 4676829-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02561
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/27/05ISR Number: 4676830-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02697
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:05/27/05ISR Number: 4676831-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02715
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	736	DAY

Date:05/27/05ISR Number: 4676833-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR						

Date:05/27/05ISR Number: 4676834-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03006
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
			Neurontin	C		ORAL
			Neurontin	C		ORAL
			Vaseretic	C		ORAL
			Lipitor	C		ORAL
			Alprazolam	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Soma	C		ORAL
			Darvocet-N	C		ORAL
			Daypro	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						
			Vasotec	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/27/05ISR Number: 4676835-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02744
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Celebrex	SS				
UNKNOWN								
	Myocardial Infarction							
	Pain							
	Polytraumatism							

Date:05/27/05ISR Number: 4676836-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
674 DAY								

Date:05/27/05ISR Number: 4676837-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04026
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atelectasis		Zoloft	C				
UNKNOWN								
Other	Back Pain		Nitroglycerin	C				
UNKNOWN								
	Blood Pressure Abnormal							
	Bronchitis Acute							
	Chest Pain							
	Conversion Disorder							
	Convulsion							
	Dysfunctional Uterine							
	Bleeding							
	Fall							
	Gastric Ulcer							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Gastrooesophageal Reflux							

Disease
Headache
Hypertension
Iron Deficiency Anaemia
Myocardial Infarction
Sinusitis
Syncope
Vitamin B12 Deficiency

Date:05/27/05ISR Number: 4676838-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02324
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/27/05ISR Number: 4676839-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01686
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Disability	Antinuclear Antibody Positive
	Emotional Distress

Haemorrhagic Stroke
Headache
Injury | Report Source | Product | Role | Manufacturer | Route | Dose | Duration
Tourette'S Disorder | Vioxx | PS | Merck & Co., Inc | ORAL | 14 DAY
White Blood Cell Count | Naproxen | C | UNKNOWN
Increased

Date:05/27/05ISR Number: 4676840-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02315
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	65 MON	
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	65 MON	
Disability	Thrombosis		Prozac	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

Date:05/27/05ISR Number: 4676841-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02701
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:05/27/05ISR Number: 4676851-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02874
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:05/27/05ISR Number: 4678232-7Report Type:Expedited (15-DaCompany Report #2005075840
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activities Of Daily	Consumer	Lithium (Lithium)	PS		ORAL	2200 MG, ORAL	
Initial or Prolonged	Living Impaired		Bextra (Valdecoxib)	SS		ORAL	ORAL	
Disability	Amnesia		Ibuprofen	SS		ORAL	ORAL	
	Cerebrovascular Accident		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Coma Dialysis Difficulty In Walking		Phazyme (Diastase, Pancreatin, Pepsin, Simeticone)	SS		ORAL	ORAL	
	Hallucination Hemiplegia Influenza Renal Failure Speech Disorder		Multivitamins	C				
			Ascorbic Acid	C				
			Acidophilus (Lactobacillus Adicophilus)	C				
			Garlic	C				
			Vitamin E	C				
			Neurontin (Gabapentin)	C				
			Celebrex (Celecoxib)	C				
			Prilosec (Omeprazole)	C				
			Montelukast Sodium	C				
			Claritin (Loratadine)	C				

Imitrex (Sumatriptan Succinate)	C
Buspar (Buspirone Hydrochloride)	C
All Other Therapeutic Products	C
Colace (Docusate Sodium)	C
Effexor (Venlafaxine Hydrochloride)	C
Pulmicort (Budenoside)	C
Albuterol (Salbutamol)	C
Serevent (Salmeterol Xinafoate)	C
Atrovent (Ipratropium Bromide)	C
Aspirin (Acetylsalicylic Acid)	C

Date:05/31/05ISR Number: 4677653-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00745
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Cardizem	C			UNKNOWN	
	Cardiac Disorder		Zyloprim	C			UNKNOWN	
	Cardiac Failure		Altace	C			UNKNOWN	
	Congestive		Pravachol	C			UNKNOWN	
	Carotid Artery Occlusion		Aspirin	C			UNKNOWN	
	Cellulitis		Glucophage	C			UNKNOWN	
	Chest Pain		Vitamin E	C			UNKNOWN	

	Convulsion	Ascorbic Acid	C
UNKNOWN			
	Coronary Artery Disease	Omega-3	C
UNKNOWN			
	Dyspnoea	Centrum	C
UNKNOWN			
	Gastric Ulcer	Vitamin B Complex	C
UNKNOWN			
	Gastrointestinal	Avandia	C
UNKNOWN			
	Haemorrhage	Viagra	C
UNKNOWN			
	Glycosylated Haemoglobin	Imdur	C
UNKNOWN			
	Increased		
	Haemorrhage		
	Herpes Zoster		
	Hypertension		
	Hyperventilation		
	Hypothyroidism		
	Melaena		
	Monarthritis		
	Myocardial Infarction		
	Oedema		
	Pneumothorax		
	Renal Failure Acute		
	Renal Failure Chronic		
	Respiratory Failure		
	Tachycardia		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4677654-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03192
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bundle Branch Block Left		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Indapamide	C				
UNKNOWN								
	Chest Pain		Protonix	C				
UNKNOWN								
	Congestive Cardiomyopathy		Zoloft	C				
UNKNOWN								
	Diplopia		Xanax	C				
UNKNOWN								
	Dizziness		Hydrochlorothiazide	C				
UNKNOWN								
	Drug Ineffective		Prilosec	C		ORAL		
	Emotional Distress		Vitamin E	C				
UNKNOWN								
	Insomnia		Ascorbic Acid	C				
UNKNOWN								
	Pain		Vitamins					
	Sinus Disorder		(Unspecified)	C				
UNKNOWN								
	Spinal Osteoarthritis		Vitamins					
			(Unspecified)	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								

Date:05/31/05ISR Number: 4677655-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bronchitis		Neurontin	C		ORAL		
Initial or Prolonged	Cardiomegaly		Wellbutrin	C				
UNKNOWN								
Disability	Chronic Obstructive		Bextra	C				
UNKNOWN								
Other	Pulmonary Disease							

Convulsion
Drug Interaction
Drug Screen Positive
Emphysema
Facial Bones Fracture
Gastrooesophageal Reflux
Disease
Hepatitis C
Hiatus Hernia
Hypercholesterolaemia
Intervertebral Disc
Protrusion
Joint Injury
Muscle Spasms
Musculoskeletal
Discomfort
Neck Pain
Overdose
Peptic Ulcer
Radiculopathy
Road Traffic Accident

Date:05/31/05ISR Number: 4677661-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00815
Age:61 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Cardiac Failure		Novolin R	C			SUBCUTANEOUS	
Congestive		Novolin R	C			SUBCUTANEOUS	
Cardiomegaly		Novolin R	C			SUBCUTANEOUS	
Cerebral Atrophy		Novolin N	C			SUBCUTANEOUS	
Chest Discomfort		Coumadin	C		ORAL		
Chest Pain		Sodium Chloride	C		ORAL		
Coronary Artery Disease		Piroxicam	C		ORAL		
Cough		Novolin N	C			SUBCUTANEOUS	
Decreased Appetite		Lasix (Furosemide)	C			UNKNOWN	
Dyspnoea		Lasix (Furosemide)	C		ORAL		
Emotional Distress		Potassium Chloride	C		ORAL		
Fluid Overload							
Gastritis							
Haematochezia							
Hallucination							
Hepatic Steatosis							
Hernia							
Insomnia							
Ischaemic Cardiomyopathy							
Joint Dislocation							
Lung Disorder							
Metabolic Syndrome							
Mitral Valve Incompetence							
Musculoskeletal Discomfort							
Myalgia							
Myocardial Infarction							
Obesity							
Oedema Peripheral							
Renal Failure							
Rheumatoid Arthritis							
Rib Fracture							
Sleep Apnoea Syndrome							
Tenosynovitis							
Upper Gastrointestinal							

Haemorrhage
Urinary Tract Disorder
Wound Infection
Staphylococcal

Date:05/31/05ISR Number: 4677665-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03337
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4677666-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03176
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Coronary Artery Stenosis
	Myocardial Infarction

Post Procedural Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	11	MON
	Norvasc	C			UNKNOWN	
	Hydrodiuril	C			UNKNOWN	
	Aspirin	C			UNKNOWN	

Date:05/31/05ISR Number: 4677667-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03183
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON
Initial or Prolonged	Emotional Distress		Aspirin	C			UNKNOWN	
Disability	Myocardial Infarction							

Date:05/31/05ISR Number: 4677668-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01505
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anal Fissure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bronchitis							
	Cerebrovascular Accident							
	Chronic Lymphocytic Leukaemia							
	Colonic Polyp							
	Dermatitis Contact							
	Diarrhoea							
	Eructation							
	Eye Movement Disorder							
	Fatigue							
	Hot Flush							
	Hypercalcaemia							

Lung Disorder
Lymphadenopathy
Neurodermatitis
Pollakiuria
Rectal Haemorrhage
Restless Legs Syndrome
Tension Headache
Thyroid Neoplasm
Vomiting

Date:05/31/05ISR Number: 4677672-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00062
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree Cholelithiasis Coronary Artery Disease Hyperlipidaemia Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4677683-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00837
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Initial or Prolonged	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Diabetes Mellitus		Aspirin	C		ORAL		
Other	Dyspnoea		Isosorbide					
	Fatigue		Mononitrate	C		ORAL		
	Gastrooesophageal Reflux		Zocor	C		ORAL		
	Disease		Sular	C		ORAL		
	Homocystinaemia		Hydrochlorothiazide	C		ORAL		
	Hypokalaemia		Micro K	C		ORAL		
	Left Ventricular Failure		Pepcid	C		ORAL		
	Myocardial Infarction							
	Nodal Arrhythmia							
	Pain							

Date:05/31/05ISR Number: 4677684-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02439
Age:35 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Living Impaired		Simethicone	SS		ORAL		
Disability	Amnesia		Lithium Sulfate	SS		ORAL		
	Arthritis		Bextra	SS		ORAL		
	Cerebrovascular Accident		Ibuprofen	SS		ORAL		
	Coma		Vitamins					
	Dialysis		(Unspecified)	C				
UNKNOWN								
	Difficulty In Walking		Ascorbic Acid	C				
UNKNOWN								
	Hallucination		Acidophilus	C				
UNKNOWN								
	Hemiplegia		Garlic Extract	C				
UNKNOWN								
	Influenza		Vitamin E	C				
UNKNOWN								
	Malaise		Gabapentin	C				
UNKNOWN								
	Renal Failure		Celebrex	C				
UNKNOWN								

	Speech Disorder	Omeprazole	C
UNKNOWN			
		Singulair	C
UNKNOWN			
		Loratadine	C
UNKNOWN			
		Sumatriptan Succinate	C
UNKNOWN			
		Buspirone Hydrochloride	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Aspirin	C
UNKNOWN			
		Ipratropium Bromide	C
UNKNOWN			
		Docusate Sodium	C
UNKNOWN			
		Venlafaxine Hydrochloride	C
UNKNOWN			
		Budesonide	C
UNKNOWN			
		Albuterol Sulfate	C
UNKNOWN			
		Salmeterol Xinafoate	C
UNKNOWN			

Date:05/31/05ISR Number: 4677686-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02296
Age:52 YR Gender:Male I/FU:I

Outcome	PT
Death	Blood Pressure Increased
	Dyspnoea Exertional
	Facial Palsy

		Insomnia					
		Mitral Valve Incompetence					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Apnoea Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
24	MON						
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
24	MON						
		Ventricular Hypertrophy					

Date:05/31/05ISR Number: 4677687-1Report Type:Expedited (15-DaCompany Report #CO-MERCK-0505COL00016
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Hypertension					

Date:05/31/05ISR Number: 4677688-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02341
Age:74 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Detrol La	C		ORAL
				Timoptic	C		
OPHTHALMIC							

Date:05/31/05ISR Number: 4677689-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02738
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:05/31/05ISR Number: 4677690-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4677693-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4677694-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02559
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4677959-0Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050507184
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired
Disability	Amnesia

		Cerebrovascular Accident					
		Coma					
		Dialysis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Difficulty In Walking		Ibuprofen	PS		
OROPHARINGEAL							
		Drug Interaction		Phazyme	SS		
OROPHARINGEAL							
		Hallucination		Phazyme	SS		
OROPHARINGEAL							
		Hemiplegia		Phazyme	SS		
OROPHARINGEAL							
		Influenza		Vioxx	SS		
OROPHARINGEAL							
		Malaise		Phazyme	SS		
OROPHARINGEAL							
		Renal Failure		Multivitamins	C		
		Speech Disorder		Multivitamins	C		
				Multivitamins	C		
				Imitrex	C		
				Claritin	C		
				Prilosec	C		
				Celebrex	C		
				Neurontin	C		
				Vitamin E	C		
				Garlic	C		
				Acidophilus	C		
				Ascorbic Acid	C		
				Singulair	C		
				Aspirin	C		
				Atrovent	C		
				Serevent	C		
				Albuterol	C		
				Pulmicort	C		
				Effexor	C		
				Colace	C		
				Sleeping Tablets	C		
				Buspar	C		
				Multivitamins	C		
				Multivitamins	C		
				Multivitamins	C		
				Multivitamins	C		
				Multivitamins	C		
				Lithium	I		
OROPHARINGEAL							
				-Bextra	I		
OROPHARINGEAL							

Date:05/31/05ISR Number: 4678027-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02856
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		521 DAY
Initial or Prolonged	Coronary Artery Disease		Synthroid	C				UNKNOWN
Disability	Depression		Synthroid	C				UNKNOWN
Other	Fatigue		Phenobarbital	C				UNKNOWN
	Hypercholesterolaemia							
	Hypertension							
	Hypertensive Crisis							
	Myocardial Infarction							
	Retroperitoneal Haematoma							

Date:05/31/05ISR Number: 4678028-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:62 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability							
Other							
		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Diplopia		Allopurinol	C		ORAL
		Transient Ischaemic		Nitrendipine	C		ORAL
		Attack		Aspirin	C		ORAL
		Visual Disturbance		Cetirizine Hydrochloride	C		ORAL
				Methotrexate	C		ORAL
				Prednisolone	C		
UNKNOWN							
				Cholecalciferol	C		
UNKNOWN							
				Cholecalciferol	C		
UNKNOWN							

Date:05/31/05ISR Number: 4678029-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02077
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Aspirin	C		
UNKNOWN							
Disability		Depression		Paxil	C		
UNKNOWN							
Other		Dyspnoea		Valium	C		
UNKNOWN							
		Emotional Distress					
		Guillain-Barre Syndrome					
		Heart Rate Irregular					
		Hyperlipidaemia					
		Myocardial Infarction					
		Non-Cardiac Chest Pain					
		Obesity					
		Pneumonia					
		Sleep Apnoea Syndrome					

Date:05/31/05ISR Number: 4678030-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00382
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Eyelid Ptosis		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Hypertension		Trandolapril And			
Other	Hypoacusis		Verapamil			
	Injury		Hydrochloride	C		ORAL
	Procedural Complication					
	Temporal Arteritis					
	Thrombosis					

Date:05/31/05ISR Number: 4678031-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00147
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Alanine Aminotransferase
Initial or Prolonged	Increased
Disability	Bradycardia
	Conjunctival Haemorrhage
	Coronary Artery Disease
	Dilatation Ventricular
	Emotional Distress
	Hypotension

		Intermittent Claudication					
		Low Density Lipoprotein Increased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy		Atenolol	C		
UNKNOWN							
		Peripheral Vascular		Norvasc	C		
UNKNOWN							
		Disorder					
		Pharyngitis					
		Polydipsia					
		Upper Respiratory Tract Infection					
		Ventricular Tachycardia					
		Weight Increased					

Date:05/31/05ISR Number: 4678032-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00984
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acarodermatitis
	Acute Prerenal Failure
	Agitation
	Angina Unstable
	Azotaemia
	Benign Prostatic Hyperplasia
	Bladder Obstruction
	Bronchitis
	Cardiac Failure Congestive
	Carotid Artery Stenosis
	Central Line Infection
	Cerebral Artery Occlusion
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Clavicle Fracture
	Confusional State
	Constipation
	Contusion
	Coronary Artery

Restenosis
Decreased Appetite
Dermatitis Contact
Diarrhoea
Dressler'S Syndrome
Duodenal Ulcer
Faecal Occult Blood
Positive
Faeces Discoloured
Gastritis
Gastrointestinal
Haemorrhage
Hyperbilirubinaemia
Hyperkalaemia
Hyperlipidaemia
Hypertension
Lobar Pneumonia
Major Depression

		Myocardial Infarction					
		Oesophageal Candidiasis					
		Oesophageal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peripheral Vascular		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		Aricept	C		
UNKNOWN							
		Radiculopathy		Aspirin	C		
UNKNOWN							
		Renal Failure		Allopurinol	C		
UNKNOWN							
		Renal Failure Acute		Vitamin E	C		
UNKNOWN							
		Renal Failure Chronic		Ascorbic Acid	C		
UNKNOWN							
		Respiratory Failure					
		Skin Candida					
		Subclavian Artery					
		Stenosis					
		Urinary Tract Infection					
		Weight Decreased					

Date:05/31/05ISR Number: 4678033-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01104513
Age:86 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Barrett'S Oesophagus		Synthroid	C		
UNKNOWN							
		Blood Cholesterol		Synthroid	C		ORAL
		Increased		Premarin	C		
UNKNOWN							
		Cardiac Murmur		Allegra	C		ORAL
		Cardiovascular Disorder		Detrol	C		ORAL
		Cystitis		Aciphex	C		ORAL
		Depression		Azithromycin	C		ORAL
25	DAY						
		Diarrhoea		Celexa	C		
UNKNOWN							
		Diverticulum		Nortriptyline	C		
UNKNOWN							
		Drug Ineffective		Fosamax	C		ORAL

	Dyspepsia	Tussionex		
	Emotional Distress	(Hydrocodone		
	Gastritis	Polistirex (+)		
	Headache	Phenyltoloxamine		
	Herpes Zoster	Polistirex)	C	ORAL
	Hiatus Hernia	Atenolol	C	ORAL
	Hypertension	Aspirin	C	ORAL
	Hypothyroidism	Calcium		
	Limb Injury	(Unspecified)	C	
UNKNOWN				
	Mitral Valve Prolapse	Vitamin D		
	Muscle Spasms	(Unspecified)	C	
UNKNOWN				
	Neck Pain	Questran	C	
UNKNOWN				
	Oedema Peripheral	Ibuprofen	C	
UNKNOWN				
	Palpitations	Aleve	C	
UNKNOWN				
	Pneumonia			
	Renal Failure			
	Rhinitis Allergic			
	Road Traffic Accident			
	Rotator Cuff Syndrome			
	Seasonal Allergy			
	Shoulder Pain			
	Sleep Disorder			
	Urethritis			
	Varicose Vein			
	Viral Infection			
	Xanthelasma			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4678035-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03891
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Tofranil	C				
UNKNOWN								
	Bronchitis		Plavix	C				
UNKNOWN								
	Cerebrovascular Accident		Synthroid	C				
UNKNOWN								
	Chest Pain		Norvasc	C				
UNKNOWN								
	Dizziness		Prempro	C				
UNKNOWN								
	Dyspnoea		Strovite	C				
UNKNOWN								
	Fatigue		Aspirin	C		ORAL		
	Gastrointestinal Motility		Librium	C				
UNKNOWN								
	Disorder							
	Headache							
	Hypercholesterolaemia							
	Hypertriglyceridaemia							
	Hypoaesthesia							
	Insomnia							
	Memory Impairment							
	Mitral Valve Incompetence							
	Morbid Thoughts							
	Platelet Aggregation							
	Increased							
	Presbyacusis							
	Tricuspid Valve							
	Incompetence							
	Upper Respiratory Tract							
	Infection							
	Vertigo							
	Vertigo Positional							

Date:05/31/05ISR Number: 4678037-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02953
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:05/31/05ISR Number: 4678038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678039-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02731
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678040-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02065
Age:72 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Anal Fissure		Vioxx	SS	Merck & Co., Inc	ORAL		
Angina Unstable		K-Dur	C			UNKNOWN	
Anorectal Disorder		Plavix	C			UNKNOWN	
Arteriosclerosis		Lasix (Furosemide)	C			UNKNOWN	
Atherosclerosis		Aciphex	C			UNKNOWN	
Bradycardia		Toprol Xl Tablets	C		ORAL		
Bronchitis Acute		Allopurinol	C			UNKNOWN	
Cardiac Disorder		Isosorbide					
Cardiac Failure		Mononitrate	C			UNKNOWN	
Congestive		Zocor	C		ORAL		
Chest Pain		Cozaar	C		ORAL		
Cholelithiasis		Nifedipine	C			UNKNOWN	
Chronic Obstructive		Hydralazine	C			UNKNOWN	
Pulmonary Disease		Prilosec	C			UNKNOWN	
Colitis Ischaemic							
Congenital Anaemia							
Coronary Artery Disease							
Coronary Artery Embolism							
Coronary Artery Stenosis							
Diabetes Mellitus							
Diverticulum							
Dizziness							
Dyslipidaemia							
Emotional Distress							
Gastrointestinal							
Haemorrhage							
Large Intestinal Ulcer							
Left Ventricular							
End-Diastolic Pressure							
Increased							
Myocardial Infarction							
Platelet Count Increased							
Pneumonia							

Pulmonary Hypertension
Renal Cyst
Sleep Apnoea Syndrome
Staphylococcal
Bacteraemia
Staphylococcal Infection
Vascular Pseudoaneurysm
Wound Infection
Staphylococcal

Date:05/31/05ISR Number: 4678041-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03089
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678042-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02944
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4678043-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		412 DAY

Date:05/31/05ISR Number: 4678044-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
	Stent Placement							

Date:05/31/05ISR Number: 4678045-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678046-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00047
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		1097 DAY
Hospitalization -	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		514 DAY
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		1097 DAY
	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		514 DAY
	Hypertension		Tramadol					
	Myocardial Infarction		Hydrochloride	C				UNKNOWN
	Oedema Peripheral		Cimicifuga And					

Hypericin	C	UNKNOWN
Celandine	C	UNKNOWN
Tibolone	C	UNKNOWN

Date:05/31/05ISR Number: 4678047-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02916
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

Date:05/31/05ISR Number: 4678048-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Emotional Distress							
	General Symptom							
	Pain							

Date:05/31/05ISR Number: 4678049-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01919
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Angina Unstable

	Bronchitis						
	Cholelithiasis						
	Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	
	Gastroenteritis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Haematoma		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hyperlipidaemia		Atenolol	C			UNKNOWN
	Myocardial Infarction		Skelaxin	C		ORAL	
	Palpitations		Prilosec	C		ORAL	
	Stress Fracture		Celebrex	C			UNKNOWN
			Nicotrol	C			UNKNOWN
			Nexium	C			UNKNOWN
			Aspirin	C			UNKNOWN

Date:05/31/05ISR Number: 4678050-XReport Type:Expedited (15-DaCompany Report #IR-MERCK-0505USA02754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:05/31/05ISR Number: 4678051-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03732
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	
	Blood Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery Disease		Coreg	C		ORAL	
	Polyp		Niaspan	C			UNKNOWN
			Lortab	C			UNKNOWN
			Amaryl	C			UNKNOWN

Altace C
UNKNOWN

Date:05/31/05ISR Number: 4678052-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678053-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:05/31/05ISR Number: 4678054-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiovascular Disorder Cerebrovascular Accident Injury Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4678055-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:05/31/05ISR Number: 4678056-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03092
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:05/31/05ISR Number: 4678057-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678058-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03091
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Cerebrovascular Accident Injury Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:05/31/05ISR Number: 4678059-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Cardiac Disorder							
	Myocardial Infarction							
	Nausea							
	Tremor							

Date:05/31/05ISR Number: 4679001-4Report Type:Expedited (15-DaCompany Report #WAES 0505GBR00076
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Ph Increased	Foreign	Tab Vioxx					
Hospitalization -	Blood Sodium Decreased	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	676 DAY
Initial or Prolonged	Cardiac Arrest	Health	Clomipramine Hcl	C				
	Chills	Professional	Lactulose	C				
	Pco2 Decreased		Oxybutynin	C				
	Pleural Effusion							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/31/05ISR Number: 4679002-6Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00020
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Condition Aggravated Diverticulitis Intestinal	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	309 DAY
	Haemorrhagic	Health	Tab Aspirin	SS		ORAL	75 MG/DAILY	
	Fall	Professional	Lansoprazole	C				
			Lisinopril	C				
			Prazosin	C				
			Simvastatin	C				

Date:05/31/05ISR Number: 4679822-8Report Type:Expedited (15-DaCompany Report #WAES 0505NOR00015
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase	Foreign	Tab Vioxx 25 Mg	PS		ORAL	25 MG/DAILY/PO	
Hospitalization - Initial or Prolonged	Increased	Study						
	Aspartate Aminotransferase	Health Professional	Tab 0663-Blinded Therapy	SS		ORAL	PO	
	Increased		Tab Blinded Therapy	SS		ORAL	PO	
	Blood Albumin Decreased		Acetaminophen	C				
	Blood Creatinine Increased		Bendroflumethiazide	C				
	Blood Glucose Increased		Ciprofloxacin	C				
	Blood Sodium Decreased		Folic Acid	C				
	Blood Thyroid Stimulating Hormone Increased		Metoprolol	C				
	C-Reactive Protein Increased		Metoprolol Tartrate	C				
	Cardiomegaly		Metronidazole	C				
	Diarrhoea		Prednisone	C				
	Electrocardiogram Q Wave Abnormal		Risedronate Sodium	C				
	Electrocardiogram St Segment Elevation							
	Haemoglobin Increased							

Hypotension
Myocardial Infarction
Red Blood Cell
Sedimentation Rate
Increased
Vomiting
White Blood Cell Count
Increased

Date:06/01/05ISR Number: 4678516-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02039
Age:19 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Cardiac Failure
Other	Congestive
	Cerebrovascular Accident
	Chest Pain
	Emotional Distress
	Fluid Retention
	Gallbladder Disorder
	Malaise
	Mitral Valve Prolapse

		Nasopharyngitis Pneumonia Systemic Lupus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erythematosus		Vioxx	PS	Merck & Co., Inc	ORAL
39	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
39	MON						
				Lasix (Furosemide)	C		
UNKNOWN							

Date:06/01/05ISR Number: 4678517-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
486 DAY						

Date:06/01/05ISR Number: 4678523-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00270
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Circulatory Collapse		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Convulsion		Morphine	C		
UNKNOWN						
Initial or Prolonged	Delusion		Ramipril	C		
UNKNOWN						
	Feeling Abnormal		Aspirin	C		
UNKNOWN						
	Hypertension		Gabapentin	C		
UNKNOWN						
	Pleural Effusion		Allopurinol	C		
UNKNOWN						
			Metoprolol	C		
UNKNOWN						
			Amitriptyline Hydrochloride	C		
UNKNOWN						
			Furosemide And Spironolactone	C		
UNKNOWN						

				Omeprazole	C		
UNKNOWN							
				Dipyrone	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				Buprenorphine Hydrochloride	C		
TOPICAL							

Date:06/01/05ISR Number: 4678524-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Heart Transplant							
	Myocardial Infarction							

Date:06/01/05ISR Number: 4678525-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Initial or Prolonged	Infarction		Beclomethasone Dipropionate	C		RESPIRATORY (INHALATION)	729	DAY
	Anxiety		[Therapy Unspecified]	C		UNKNOWN		
	Drug Ineffective		Griseofulvin	C		UNKNOWN	25	DAY
	Emotional Distress		Verapamil Hydrochloride	C		ORAL	382	DAY
	Hyperlipidaemia							
	Pain							
	Pelvic Haematoma							
	Stress							
	Tinea Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/05ISR Number: 4678526-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/01/05ISR Number: 4678527-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/01/05ISR Number: 4678528-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02947
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/01/05ISR Number: 4678529-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
Disability	Acute Respiratory Failure
Other	Adjustment Disorder With Depressed Mood
	Alcoholism
	Anaemia
	Anxiety
	Arthralgia
	Asthenia
	Atrioventricular Block Complete
	Blood Urea Increased
	Bradycardia
	Bundle Branch Block
	Cardiac Failure Congestive

Cardiomyopathy
Catheter Related
Complication
Cellulitis
Cervicobrachial Syndrome
Condition Aggravated
Constipation
Coronary Artery Disease
Dehydration
Depression
Difficulty In Walking
Dizziness
Drug Hypersensitivity
Drug Ineffective
Epicondylitis
Fall
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Hyperlipidaemia
Hypersensitivity

		Hypotension					
		Hypoxic Encephalopathy					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Joint Contracture		Vioxx	PS	Merck & Co., Inc	ORAL
		Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Laceration					
		Lung Infiltration					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Neck Pain					
		Neurogenic Bladder					
		Neurogenic Bowel					
		Oedema Peripheral					
		Paraplegia					
		Peripheral Vascular					
		Disorder					
		Post-Traumatic Stress					
		Disorder					
		Pulmonary Oedema					
		Quadriplegia					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Shoulder Pain					
		Sinus Bradycardia					
		Somnolence					
		Spinal Cord Injury					
		Transfusion Reaction					
		Ulcer					
		Urinary Incontinence					
		Urinary Tract Infection					
		Urosepsis					
		Wound Infection					

Date:06/01/05ISR Number: 4678559-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02971
Age:60 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Hypoventilation					
		Lethargy					
		Pulmonary Thrombosis					
		Tachycardia					

Thrombosis

Date:06/01/05ISR Number: 4678562-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03215
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebral Haemorrhage							
	Cerebrovascular Accident							
	Emotional Distress							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/05ISR Number: 4678563-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03248
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON
	Pain							

Date:06/01/05ISR Number: 4678577-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1077	DAY

Date:06/01/05ISR Number: 4678578-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							

Date:06/01/05ISR Number: 4678579-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1154	DAY

Date:06/01/05ISR Number: 4678580-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00017
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
483 DAY						
Life-Threatening	Cardiac Tamponade		Vioxx	SS	Merck & Co., Inc	ORAL
258 DAY						
Hospitalization -	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL
483 DAY						
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
258 DAY						
	Myocardial Infarction		Lisinopril	C		ORAL
	Myocardial Ischaemia		Esomeprazole	C		ORAL
1102 DAY						
	Pneumonia					

Date:06/01/05ISR Number: 4678582-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					
	Life Expectancy Shortened					
	Nervous System Disorder					
	Pain					

Date:06/01/05ISR Number: 4678584-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
122 DAY						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/01/05ISR Number: 4680874-XReport Type:Direct Company Report #CTU 250033
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS				
Congenital Anomaly								

Date:06/01/05ISR Number: 4681000-3Report Type:Expedited (15-DaCompany Report #2005077110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Disorder	Consumer	Bextra (Valdecoxib)	PS		ORAL		
ORAL								
	Mobility Decreased		Rofecoxib					
	Oedema Mouth		(Rofecoxib)	SS				
	Oedema Peripheral							
	Swelling							
	Visual Acuity Reduced							

Date:06/01/05ISR Number: 4681049-0Report Type:Expedited (15-DaCompany Report #2005079674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction	Consumer	Lipitor					
			(Atorvastatin)	PS				
UNKNOWN	UNKNOWN							
			Vioxx (Rofecoxib)	SS				
UNKNOWN	UNKNOWN							

Date:06/01/05ISR Number: 4681801-1Report Type:Expedited (15-DaCompany Report #2005056765
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspnoea	Consumer	Celebrex (Celecoxib)	PS				
Initial or Prolonged	Haematochezia		Bextra (Valdecoxib)	SS		ORAL		
(1 IN 1 D)								

Other	Pruritus Generalised			
ORAL				
	Weight Decreased		Vioxx (Rofecoxib)	SS
	Weight Increased		Vidodin (Hydrocodone Bitartrate, Paracetamol)	C
			Percocet (Oxycodone Hydrochloride, Paracetamol)	C

Date:06/01/05ISR Number: 4681803-5Report Type:Expedited (15-DaCompany Report #2005077009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death	Consumer	Celebrex (Celecoxib)	PS		
			Vioxx (Rofecoxib)	SS		

Date:06/02/05ISR Number: 4679439-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00039
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Hepatitis		Vioxx	PS	Merck & Co., Inc	
UNKNOWN	32 DAY					
	Hepatocellular Damage		Diclofenac	SS		
UNKNOWN	62 DAY					
	Jaundice		Erythromycin	SS		
UNKNOWN	32 DAY					
			Moxifloxacin Hydrochloride	SS		
UNKNOWN	32 DAY					

					Carbamazepine	SS	
UNKNOWN							
					Clarithromycin	C	
UNKNOWN		32	DAY				
					Azithromycin	C	
UNKNOWN		32	DAY				

Date:06/02/05ISR Number: 4679444-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04129
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Zantac	C				
UNKNOWN								
	Back Pain		Ranitidine	C				
UNKNOWN								
	Chest Pain		Maxalt (Rizatriptan					
	Diarrhoea		Benzoate)	C				
UNKNOWN								
	Dizziness		Allegra	C				
UNKNOWN								
	Dyspnoea		Acular	C				
UNKNOWN								
	Gastritis							
	Gastrointestinal Pain							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Influenza Like Illness							
	Nausea							
	Palpitations							
	Vomiting							

Date:06/02/05ISR Number: 4679445-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03244
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
43	MON							
	Pulmonary Embolism							

Date:06/02/05ISR Number: 4679447-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03746
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		6 YR
	First Degree		Ecotrin	SS		ORAL		
	Azotaemia		Bextra	SS				UNKNOWN
	Benign Prostatic Hyperplasia		Celebrex	SS		ORAL		
			Avandia	C		ORAL		
	Chest Pain		Lipitor	C		ORAL		
	Dizziness		Vitamins (Unspecified)	C		ORAL		
	Faecal Occult Blood Positive		Fluconazole	C		ORAL		
	Faeces Discoloured		Altace	C		ORAL		
	Gastric Ulcer Haemorrhage		Trimethoprim And Sulfamethoxazole	C		ORAL		1 YR
	Haemoglobin Decreased							
	Headache		Atenolol	C				UNKNOWN
	Hyperhidrosis		Vitamin E	C				UNKNOWN
	Orthostatic Hypotension		Trazodone Hydrochloride	C				UNKNOWN
	Platelet Count Decreased							
	Rectal Haemorrhage		Tylenol Arthritis Extended Relief	C				UNKNOWN
	Volume Blood Decreased							
	White Blood Cell Count Decreased		Levitra	C				UNKNOWN

Date:06/02/05ISR Number: 4679448-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00825
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	5	YR
	Emotional Distress							
	Myocardial Infarction							
	Polytraumatism							

Date:06/02/05ISR Number: 4679449-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cerebrovascular Accident							
	Multi-Organ Disorder							
	Pain							

Date:06/02/05ISR Number: 4679450-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
	Cardiovascular Disorder							
	Myocardial Infarction							
	Pain							

Date:06/02/05ISR Number: 4679451-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03405
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Cardiac Arrest
Cardiac Disorder
Cardiovascular Disorder
Lung Disorder
Multi-Organ Disorder
Pain

Date:06/02/05ISR Number: 4679452-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03295
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Difficulty In Walking		Neurontin	C				
UNKNOWN								
Initial or Prolonged	Myocardial Infarction		Amitriptylin	C				
UNKNOWN								
Disability			Topamax	C				
UNKNOWN								

Date:06/02/05ISR Number: 4679453-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03403
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4679454-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03257
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		32 MON
	Nervous System Disorder							
	Pain							

Date:06/02/05ISR Number: 4679456-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679457-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03355
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		28 MON
Other	Death							

Date:06/02/05ISR Number: 4679458-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03404
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiovascular Disorder							
	Lung Disorder							
	Multi-Organ Disorder							
	Pain							

Date:06/02/05ISR Number: 4679459-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679461-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Lung Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679462-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03407
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Arrest Cardiac Disorder

Cardiovascular Disorder
Lung Disorder
Multi-Organ Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Pain

Date:06/02/05ISR Number: 4679463-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03409
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679464-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03410
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679465-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679490-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00041
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gynaecomastia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:06/02/05ISR Number: 4679491-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679492-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679493-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00626
Age:89 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Cataract
	Cerebrovascular Accident
	Concussion
	Contusion
	Emotional Distress
	Excoriation
	Gastritis

	Gastrooesophageal Reflux Disease						
	Hiatus Hernia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL	1365 DAY	
	Hypertension		Plavix	C			UNKNOWN	
	Laceration		Aspirin	C			UNKNOWN	
	Polytraumatism		Ibuprofen	C			UNKNOWN	
	Road Traffic Accident							
	Transient Ischaemic Attack							

Date:06/02/05ISR Number: 4679494-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02375
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Homocysteine		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bradyarrhythmia		Atenolol	C			UNKNOWN	
	Cardiac Failure		Lortab	C			UNKNOWN	
	Congestive							
	Chest Pain							
	Emotional Distress							
	Hypertension							
	Hypothyroidism							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Oedema Peripheral							
	Renal Failure Chronic							

Date:06/02/05ISR Number: 4679495-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00853
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
450 MON						
	Cerebrovascular Accident		Lexxel	C		
UNKNOWN						
	Depression		Toprol Xl Tablets	C		
UNKNOWN						
	Dyspepsia		Norvasc	C		
UNKNOWN						
	Emotional Distress		Dyazide	C		
UNKNOWN						
	Rotator Cuff Syndrome		Dyazide	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						

Date:06/02/05ISR Number: 4679496-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00797
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Potassium			
	Myocardial Infarction		(Unspecified)	C		
UNKNOWN						
	Obesity		Celexa	C		
UNKNOWN						
	Sleep Apnoea Syndrome		Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Wellbutrin	C		
UNKNOWN						

		Furosemide	C
UNKNOWN			
		Colchicine	C
UNKNOWN			
		Oxycontin	C
UNKNOWN			
		Chlorzoxazone	C
UNKNOWN			
		Trazodone Hydrochloride	C
UNKNOWN			
		Cephalexin	C
UNKNOWN			
		Zanaflex	C
UNKNOWN			
		Endocet	C
UNKNOWN			
		Zaroxolyn	C
UNKNOWN			
		Percocet	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Warfarin	C
UNKNOWN			
		Clindamycin	C
UNKNOWN			
		Ultracet	C
UNKNOWN			
		[Therapy Unspecified]	C
UNKNOWN			
		Penicillin (Unspecified)	C
UNKNOWN			
		Deltasone	C
UNKNOWN			
		Levaquin	C
UNKNOWN			
		Acetaminophen And Propoxyphene Napsylate	C
UNKNOWN			
		K-Dur	C
UNKNOWN			
		Indomethacin	C
UNKNOWN			

				Ultram	C		
UNKNOWN							
				Biaxin Xl	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Methylprednisolone	C		
UNKNOWN							
				Ery-Tab	C		
UNKNOWN							
				Roxicet	C		
UNKNOWN							
				Chlorine	C		
UNKNOWN							
				Duragesic	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Clarinex	C		
UNKNOWN							
				Omeprazole	C		
UNKNOWN							
				Tizanidine Hydrochloride	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/02/05ISR Number: 4679499-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Organ Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679505-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03406
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4679506-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03356
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:06/02/05ISR Number: 4679507-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03408
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Cardiovascular Disorder							
	Lung Disorder							
	Multi-Organ Disorder							
	Pain							

Date:06/02/05ISR Number: 4679508-XReport Type:Expedited (15-DaCompany Report #SE-MERCK-0505SWE00020
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Alfuzosin Hydrochloride	C				
	Chronic Obstructive Pulmonary Disease		Zolpidem Tartrate	C				
	Palpitations		Lymecycline	C				
	Supraventricular Extrasystoles		Acetaminophen And Caffeine And Carisoprodol	C				
	Tachyarrhythmia		Bromhexine Hydrochloride And Ephedrine Hydrochloride	C				
	Transient Ischaemic Attack							
	Ventricular Extrasystoles							

			Cyanocobalamin	C		
UNKNOWN						
			Acetylcysteine	C		
UNKNOWN						
			Sildenafil Citrate	C		
UNKNOWN						

Date:06/02/05ISR Number: 4679791-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00563
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 730 DAY	Aspartate		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aminotransferase		Plaquenil	C		
UNKNOWN						
	Increased		Prednisone	C		
UNKNOWN	3 MON					
	Coronary Artery Stenosis		Nexium	C		
UNKNOWN						
	Dyspnoea		Hydrochlorothiazide	C		
UNKNOWN						
	Haematocrit Decreased		Prinivil	C		
UNKNOWN						
	Haematoma					
	Haemoglobin Decreased					
	Hyperhidrosis					
	Myocardial Infarction					
	Post Procedural Complication					
	Red Blood Cell Count Decreased					

Date:06/02/05ISR Number: 4679802-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01925
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Elavil	C		ORAL		
	Blood Pressure Immeasurable		Prilosec	C		ORAL		
	Blood Sodium Decreased		Potassium Chloride	C		ORAL		
	Brain Death		Coumadin	C				
	Brain Hypoxia		Lanoxin	C		ORAL		
	Cardiac Murmur		Lasix (Furosemide)	C		ORAL		
	Cardio-Respiratory Arrest		Coreg	C		ORAL		
	Cerebral Atrophy		Tegretol	C		ORAL		
	Cerebrovascular Accident		Baclofen	C		ORAL		
	Convulsion		Zoloft	C		ORAL		
	Cyanosis		Avapro	C		ORAL		
	Dilatation Atrial							
	Electroencephalogram Abnormal							
	Encephalopathy							
	Fall							
	Heart Rate Irregular							
	Hyperglycaemia							
	Loss Of Consciousness							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Pneumonia Aspiration							
	Pulmonary Valve Incompetence							
	Pulse Absent							
	Pupil Fixed							
	Pyrexia							
	Tricuspid Valve Incompetence							
	Urinary Incontinence							
	Ventricular Hypertrophy							

Date:06/02/05ISR Number: 4679805-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00013
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Disability	Palpitations		Verapamil	C			UNKNOWN	
			Valium	C			UNKNOWN	

Date:06/02/05ISR Number: 4679806-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679807-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03383
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cerebrovascular Accident Myocardial Infarction

	Thrombosis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679808-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03276
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	116	DAY

Date:06/02/05ISR Number: 4679811-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4679812-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/02/05ISR Number: 4680104-9Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050600380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Body Height Decreased		Motrin	PS				
Initial or Prolonged	Constipation		Motrin	SS				
	Dizziness		-Bextra	SS				
	Drug Ineffective		-Bextra	SS				
	Gastritis		Vioxx	SS				

	Muscle Spasms	Vioxx	SS
	Nausea	Advil	SS
	Paralysis	Advil	SS
	Pruritus	Aleve	SS
	Somnolence	Aleve	SS
		Levoxyl	C
OROPHARINGEAL			
		Thyroid Medication	C
OROPHARINGEAL			

Date:06/02/05ISR Number: 4680432-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02977
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence
	Bladder Disorder
	Cerebrovascular Accident
	Chest Discomfort
	Dilatation Atrial
	Diplopia
	Dyspepsia
	Hiatus Hernia
	Hypertension
	Mitral Valve Incompetence
	Nausea

		Pulmonary Hypertension Skin Cancer Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Attack		Vioxx	PS	Merck & Co., Inc	ORAL
69	MON						
		Tricuspid Valve Incompetence Vascular Calcification Ventricular Hypertrophy		Zocor	C		ORAL

Date:06/02/05ISR Number: 4680433-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01927
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Infarction		Plavix	C		
UNKNOWN						
Initial or Prolonged	Coronary Artery Occlusion		Mavik	C		
UNKNOWN						
	Coronary Artery Stenosis		Inderal	C		
UNKNOWN						
	Depression Myocardial Infarction Myocardial Ischaemia Neoplasm Malignant Sinus Bradycardia Ventricular Tachycardia					

Date:06/02/05ISR Number: 4680434-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00086
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Bundle Branch Block Left		Orlistat	C		
UNKNOWN						
	Dyspnoea		[Therapy Unspecified]	C		
UNKNOWN						

Date:06/02/05ISR Number: 4680435-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04115
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthritis		Valium	C				
UNKNOWN								
	Auricular Swelling							
	Cardiac Disorder							
	Dizziness							
	Palpitations							
	Syncope							
	Vomiting							

Date:06/02/05ISR Number: 4680436-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00701
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Blood Pressure
Hospitalization -	Fluctuation
Initial or Prolonged	Bradycardia
Disability	Cardiac Disorder
Other	Hypertension
	Labile Blood Pressure
	Silent Myocardial

Infarction
Ventricular Dysfunction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680437-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00171
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		75 DAY
Initial or Prolonged	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		139 DAY
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Ranitidine	C				UNKNOWN
	Coronary Artery Occlusion		Celecoxib	C				UNKNOWN 20 DAY
	Emotional Distress		Celecoxib	C				UNKNOWN 20 DAY
	Gastrooesophageal Reflux Disease		Diclofenac Sodium And Misoprostol	C				UNKNOWN
	Hernia		Acetaminophen And Methocarbamol	C				UNKNOWN
	Myocardial Infarction							
	Pain In Extremity							
	Platelet Aggregation Increased							
	Sinus Bradycardia							
	Sinusitis							

Date:06/02/05ISR Number: 4680451-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01133
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Acute Myocardial Infarction
Disability	Anorectal Disorder
	Aphthous Stomatitis

Apnoea
Arthritis
Cardiac Valve Disease
Coronary Artery Disease
Coronary Artery
Restenosis
Coronary Artery Stenosis
Diabetes Mellitus
Diabetes Mellitus
Non-Insulin-Dependent
Diverticulitis
Dysphonia
Dyspnoea
Emotional Distress
Erectile Dysfunction
Facet Joint Syndrome
Hand Fracture
Hyperlipidaemia
Hypertension
Insomnia
Intervertebral Disc
Protrusion
Lumbar Spinal Stenosis
Muscle Strain
Nervousness

		Osteoarthritis Pain Pneumothorax	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
350	DAY	Raynaud'S Phenomenon		Vioxx	PS	Merck & Co., Inc	ORAL
		Respiratory Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		27	DAY	Vioxx	SS	Merck & Co., Inc	
350	DAY			Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		27	DAY	Vioxx	SS	Merck & Co., Inc	
UNKNOWN				Diovan	C		
UNKNOWN				Propecia	C		
UNKNOWN				Atenolol	C		
UNKNOWN				Norco	C		
UNKNOWN				Chlorthalidone	C		
UNKNOWN				Celebrex	C		
UNKNOWN				Celebrex	C		
UNKNOWN				Cyclobenzaprine Hydrochloride	C		
UNKNOWN				Ultram	C		
UNKNOWN				Hydrocodone Hydrochloride	C		
UNKNOWN				[Therapy Unspecified]	C		
UNKNOWN				Tenormin	C		
UNKNOWN				Avandia	C		
UNKNOWN				Glucovance	C		

			Hygroton	C		
UNKNOWN						
			Cardizem	C		
UNKNOWN						
			Altace	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:06/02/05ISR Number: 4680453-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02884
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
1 YR								
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Constipation		Aspirin	C				
UNKNOWN								
	Deep Vein Thrombosis		Visken	C				
UNKNOWN								
	Dizziness		Ambien	C				
UNKNOWN								
	Dyspnoea		Nexium	C				
UNKNOWN								
	Groin Pain		Lactulose	C				
UNKNOWN								
	Haematoma		Synthroid	C				
UNKNOWN								
	Mitral Valve Incompetence		Didrex	C				
UNKNOWN								
	Orthostatic Hypotension		Epogen	C				
UNKNOWN								
	Pain In Extremity		Ativan	C				
UNKNOWN								
	Rotator Cuff Syndrome		Restoril	C				
UNKNOWN								
	Sinus Bradycardia		Florinef	C				
UNKNOWN								
	Thrombosis		Ibuprofen	C				
UNKNOWN								
	Traumatic Haematoma							
	Tricuspid Valve Incompetence							
	Varicose Vein							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680465-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01891
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Zocor	C		ORAL		
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Emotional Distress							
	Hypertension							
	Myocardial Infarction							
	Oedema							
	Polytraumatism							
	Swelling							

Date:06/02/05ISR Number: 4680466-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Angina Pectoris
	Apnoea
Disability	Arthritis
Other	Blood Pressure Abnormal
	Bone Pain
	Cardiac Murmur
	Cardiac Septal Defect
	Cardiac Valve Disease
	Catheter Site Haematoma
	Chest Pain
	Chest Wall Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Dysphagia
	Dyspnoea
	Emotional Distress
	Fall
	Fatigue
	Gastrooesophageal Reflux Disease

Haematoma
Headache
Heart Rate Decreased
Herpes Zoster
Hypertension
Hypotension
Insomnia
Irritable Bowel Syndrome
Myocardial Infarction
Oedema Peripheral
Oesophageal Spasm
Pain
Paraesthesia
Pneumonia
Rash Pruritic
Restless Legs Syndrome
Sinusitis

		Somnolence Syncope Tremor	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
120 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
120 DAY				Vioxx	SS	Merck & Co., Inc	ORAL
				Cardizem Cd	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Accupril	C		
UNKNOWN		18 DAY					
				Accupril	C		
UNKNOWN		38 DAY					
				Accupril	C		
UNKNOWN		152 DAY					
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		42 DAY					
				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN		145 DAY					
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Aleve	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							

			Ferrous Sulfate	C		
UNKNOWN						
			Tylenol Extra Strength	C		
UNKNOWN						

Date:06/02/05ISR Number: 4680473-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02086
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Failure		Inderal	C		
UNKNOWN						
Other	Congestive					
	Coronary Artery Disease					
	Dyspepsia					
	Emotional Distress					
	Gastric Cancer					
	Hypoaesthesia					
	Myocardial Infarction					
	Pulmonary Valve Incompetence					
	Renal Artery Stenosis					
	Renal Failure					
	Tricuspid Valve Incompetence					

Date:06/02/05ISR Number: 4680475-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02233
Age:74 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
Hospitalization - Initial or Prolonged	Cardiac Arrest
	Emotional Distress
	Heart Rate Decreased

		Hypoxic Encephalopathy Loss Of Consciousness Pupil Fixed	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhonchi		Vioxx	PS	Merck & Co., Inc	ORAL
221	DAY						
		Ventricular Arrhythmia		Altace	C		
UNKNOWN							
		Ventricular Tachycardia		Covera	C		
UNKNOWN							
				Covera	C		
UNKNOWN							
				A.S.A.	C		
UNKNOWN							
				Alprazolam	C		
UNKNOWN							
				K-Dur	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Phenazopyridine Hydrochloride	C		
UNKNOWN							
				Sulfatrim	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							

Date:06/02/05ISR Number: 4680476-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00018
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Blood Pressure Increased					
		Carotid Artery Disease					
		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Heart Rate Decreased					
		Sinus Arrhythmia					

Date:06/02/05ISR Number: 4680477-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02518
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	1020 MON	
	Increased		Lexapro	C			UNKNOWN	
	Cardio-Respiratory Arrest		Prevacid	C			UNKNOWN	
	Convulsion		Neurontin	C			UNKNOWN	
	Emotional Distress							
	Myocardial Infarction							
	Ventricular Fibrillation							

Date:06/02/05ISR Number: 4680478-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02192
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Arrhythmia
Hospitalization - Initial or Prolonged	Cardiac Arrest
	Cold Sweat
	Coronary Artery Atherosclerosis
	Dyspepsia
	Emotional Distress
	Gastric Disorder
	Hyperhidrosis
	Hypotension
	Loss Of Consciousness

		Myocardial Infarction Nausea Syncope	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
133	DAY						
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
133	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Methotrexate	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Cardura	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Axid	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							

Date:06/02/05ISR Number: 4680479-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00416
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
				Ancillin	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							

			Diovan	C			
UNKNOWN							

Date:06/02/05ISR Number: 4680480-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02310
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		397 YR
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		397 YR
Disability	Chest Pain		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
	Depression							
	Duodenitis							
	Dyspnoea		Panmist Dm	C				UNKNOWN
	Enteritis		Alprazolam	C				UNKNOWN
	Gastric Ulcer		Ambien	C				UNKNOWN
	Gastritis Erosive		Prednisone	C				UNKNOWN
	Haemorrhoids		Prevacid	C				UNKNOWN
	Hypertensive Crisis		Levaquin	C				UNKNOWN
	Hypoaesthesia		Celexa	C				UNKNOWN
	Migraine With Aura		Cyclobenzaprine Hydrochloride	C				UNKNOWN
	Oesophagitis							
	Pain In Extremity		Avelox	C				UNKNOWN
	Sinusitis		Prozac	C				UNKNOWN
	Swelling		Furosemide	C				UNKNOWN
	Ulcer		Furosemide	C				UNKNOWN
	Vision Blurred		Serzone	C				UNKNOWN
			Serzone	C				UNKNOWN
			Estrogens (Unspecified)	C			3 MON	UNKNOWN
			Atenolol	C				UNKNOWN

Atenolol C

UNKNOWN

22-Aug-2005 10:31 AM
Page: 12396

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680481-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00076
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Pressure Systolic Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Amiodarone Hydrochloride	C			UNKNOWN	
	Cardiac Failure							
	Dilatation Atrial		Bisoprolol	C		ORAL		
	Dyspnoea							
	Mitral Valve Incompetence							
	Mitral Valve Sclerosis							
	Tachyarrhythmia							
	Ventricular Dysfunction							
	Vital Capacity Decreased							

Date:06/02/05ISR Number: 4680482-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00097
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Prevacid	C			UNKNOWN	
	Osteoporosis		Naproxen	C			UNKNOWN	
	Weight Decreased		Amlodipine Besylate	C			UNKNOWN	
			Felodipine	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Actonel	C			UNKNOWN	
			Herbs (Unspecified)	C			UNKNOWN	

Date:06/02/05ISR Number: 4680483-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00089
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Joint Dislocation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Altace	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Plavix	C			UNKNOWN	

Date:06/02/05ISR Number: 4680490-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01319
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Bladder Disorder
	Chest Pain
	Coronary Artery Atherosclerosis
	Dyspepsia
	Emotional Distress
	Gastric Ulcer
	Hypertension
	Left Ventricular Failure
	Mitral Valve Incompetence
	Myocardial Infarction
	Normochromic Normocytic Anaemia
	Pericardial Effusion

Tricuspid Valve Incompetence

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
34 MON			Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Vioxx	SS	Merck & Co., Inc	
UNKNOWN			Vioxx	SS	Merck & Co., Inc	
UNKNOWN			Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C		
UNKNOWN			Zithromax	C		
			Toprol Xl Tablets	C		ORAL
			Zocor	C		ORAL
			Celebrex	C		ORAL
3 MON			Glucosamine	C		
UNKNOWN			Levaquin	C		
UNKNOWN			Zyrtec	C		ORAL
			Ditropan	C		ORAL
			Prevacid	C		
UNKNOWN			Synthroid	C		
UNKNOWN			Nexium	C		
UNKNOWN			Wellbutrin	C		
UNKNOWN	26 MON		Librax Capsules	C		
UNKNOWN			Prozac	C		ORAL
			Cefzil	C		
UNKNOWN			Prempro	C		
UNKNOWN			Tylenol	C		
UNKNOWN			Aspirin	C		
UNKNOWN						

				Monopril	C		
UNKNOWN							
				Ecotrin	C		ORAL
				Folic Acid	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:06/02/05ISR Number: 4680492-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00874
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					
	Oedema Peripheral					

Date:06/02/05ISR Number: 4680493-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03041
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Dyspepsia		Amitriptylin	C		
UNKNOWN						
Other	Gout		Maxzide	C		ORAL
	Hypothyroidism		Aspirin	C		ORAL
	Intervertebral Disc		Colchicine	C		ORAL
	Degeneration		Synthroid	C		ORAL
	Lumbar Spinal Stenosis		Lovenox	C		
UNKNOWN						
	Spinal Osteoarthritis		Indomethacin	C		
UNKNOWN						
	Urinary Tract Infection		Gastrointestinal Preparations (Unspecified)	C		
UNKNOWN						
			Neurontin	C		ORAL
			Hydrochlorothiazide	C		
UNKNOWN						

			Triamterene	C			
UNKNOWN							

Date:06/02/05ISR Number: 4680494-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03093
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680495-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03259
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Emotional Distress							
	Pain							

Date:06/02/05ISR Number: 4680496-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00101
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	108	DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	108	DAY
Initial or Prolonged	Anaemia		Plavix	C				
UNKNOWN								
	Arrhythmia		Meclizine	C				
UNKNOWN								
	Cardiac Failure		Codeine	C				
UNKNOWN								
	Congestive		Detrol	C				
UNKNOWN								
	Cerebrovascular Accident		Naproxen	C				
UNKNOWN								
	Coronary Artery		Hydrochlorothiazide	C				
UNKNOWN								

	Atherosclerosis	Phenazopyridine Hydrochloride	C
UNKNOWN	Coronary Artery Disease		
	Cystitis	Diltiazem Malate	C
UNKNOWN	Decubitus Ulcer	Cardizem	C
UNKNOWN	Dementia Alzheimer'S Type	Lasix (Furosemide)	C
UNKNOWN	Disorientation	Aspirin	C
UNKNOWN	Duodenal Ulcer	Zocor	C
UNKNOWN	Ecchymosis Headache Myocardial Infarction Oedema Peripheral Pneumonia Pulse Absent Transient Ischaemic Attack Ventricular Tachycardia		

Date:06/02/05ISR Number: 4680497-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02928
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680498-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness							
	Emotional Distress							
	Headache							
	Nervous System Disorder							

Date:06/02/05ISR Number: 4680506-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:06/02/05ISR Number: 4680507-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680517-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680518-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00087
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		

Disability Hypertension Hydrocodone
Loss Of Consciousness Bitartrate C
UNKNOWN

Date:06/02/05ISR Number: 4680519-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03437
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680520-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680521-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680522-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680523-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03434
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680524-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680525-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680526-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03397
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anoxic Encephalopathy Myocardial Infarction Ventricular Fibrillation Ventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680527-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680528-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03353
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Pain							

Date:06/02/05ISR Number: 4680529-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680530-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03261
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680531-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Other	Cardiac Arrest Cerebrovascular Accident Death Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680532-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00647
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:06/02/05ISR Number: 4680533-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03223
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:06/02/05ISR Number: 4680534-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680535-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03398
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680536-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4680550-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00114
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability UNKNOWN	Cerebrovascular Accident		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680553-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4680556-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00067
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 22 MON Initial or Prolonged Disability UNKNOWN	Aphasia Cerebral Artery Occlusion Headache Hemiparesis Hypertension Infarction Labile Hypertension Memory Impairment Speech Disorder Tinnitus		Vioxx [Therapy Unspecified]	PS C	Merck & Co., Inc	ORAL		

Date:06/02/05ISR Number: 4681565-1Report Type:Expedited (15-DaCompany Report #2005077695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain	Consumer	Neurontin					

Initial or Prolonged	Body Height Decreased	(Gabapentin)	PS
100 MG (100			
Other	Constipation		
MG 1 IN 1D)			
	Delayed Recovery From	Bextra(Valdecoxib)	SS
	Anaesthesia	Motrin (Ibuprofen)	SS
	Dizziness	Fentanyl (Fentanyl)	SS
TRANSDERMAL (25 MCG)			
	Drug Ineffective		
TRANSDERMAL			
	Emotional Disorder	Vioxx (Rofecoxib)	SS
	Feeling Abnormal	Advil (Ibuprofen)	SS
	Gastritis	Aleve (Naproxen	
	Impaired Driving Ability	Sodium)	C
	Muscle Spasms	Levoxyl	
	Nausea	(Levothyroxine	
	Paralysis	Sodium)	C
	Pruritus		
	Somnolence		

Date:06/02/05ISR Number: 4681772-8Report Type:Expedited (15-DaCompany Report #2005050275
Age:72 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atrioventricular Block
Initial or Prolonged	First Degree
Other	Azotaemia
	Blood Glucose Increased

	Blood Pressure Orthostatic Decreased						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Feeling Hot	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL
	Gastric Ulcer Haemorrhage	Health Professional	Bextra (Valdecoxib)	SS			
	Haematocrit Decreased		Ecotrin (Acetylsalicylic Acid)	SS		ORAL	81 MG (81 MG 1 IN 1 D)
	Haemoglobin Decreased						
	Headache						
	Helicobacter Infection						
	Hyperhidrosis						ORAL
	Volume Blood Decreased		Vioxx (Rofecoxib)	SS		ORAL	ORAL
	White Blood Cell Count Decreased		Avandia (Rosglitazone)	C			
			Lipitor (Atorvastatin)	C			
			Multivitamins(Multivitamins)	C			
			Fluconazole (Fluconazole)	C			
			Altace (Ramipril)	C			
			Sulfamethoxazole W/Trimethoprim (Sulfamethoxazole, Trimethoprim)	C			
			Trazodone (Trazodone)	C			
			Paracetamol (Paracetamol)	C			
			Vardenafil (Vardenafil)	C			
			Atenolol (Atenolol)	C			
			Vitamin E (Vitamin E)	C			

Date:06/02/05ISR Number: 4682360-XReport Type:Direct Company Report #CTU 250157
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization -	Colonic Polyp		Vioxx	PS
1 TABLET PER				
Initial or Prolonged	Gastric Disorder			
DAY				
	Gastrointestinal Haemorrhage			

Date:06/03/05ISR Number: 4681116-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00667
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	71 DAY	
Initial or Prolonged	Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	71 DAY	
	Myocardial Infarction		Hydrochlorothiazide	C			UNKNOWN	
			Accupril	C			UNKNOWN	
			Inderal La	C			UNKNOWN	
			Actonel	C			UNKNOWN	
			Ecotrin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681117-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02523
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Activated Partial		Vioxx	PS	Merck & Co., Inc	ORAL		233 DAY
Initial or Prolonged	Thromboplastin Time		Vioxx	SS	Merck & Co., Inc	ORAL		233 DAY
Disability	Prolonged		Toprol Xl Tablets	C				UNKNOWN
	Blood Cholesterol		Zocor	C		ORAL		439 DAY
	Increased		Viagra	C				UNKNOWN
	Blood Triglycerides		Diovan	C				UNKNOWN
	79 DAY							
	Increased							
	Bundle Branch Block							
	Bundle Branch Block Left							
	Bundle Branch Block Right							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Depression							
	Dizziness							
	Dyspepsia							
	Fear							
	Haematocrit Decreased							
	Haemoglobin Decreased							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Incision Site Abscess							
	Low Density Lipoprotein Increased							
	Myocardial Infarction							
	Neck Pain							
	Pleural Effusion							
	Post Procedural Complication							
	Rectal Haemorrhage							
	Road Traffic Accident							
	Sinus Disorder							
	Sleep Disorder							
	Stitch Abscess							
	Supraventricular							

Extrasystoles
Weight Increased

Date:06/03/05ISR Number: 4681119-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Asthenia
	Blood Cholesterol Increased
	Blood Lactate Dehydrogenase Increased
	Cardiovascular Disorder
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Dizziness
	Embolism
	General Physical Health Deterioration
	Infarction

		Infection					
		Malaise					
		Monoparesis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Oxycodone Hydrochloride	C		
UNKNOWN		Sleep Disorder					
		Speech Disorder		Tolperisone Hydrochloride	C		
UNKNOWN							
				Omeprazole	C		
UNKNOWN							
				Flupirtine Maleate	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		ORAL
				Fentanyl	C		ORAL
				Ranitidine Hydrochloride	C		ORAL
				Dipyrone	C		ORAL
				Simvastatin	C		ORAL
				Naloxone Hydrochloride And Tilidine Hydrochloride	C		
UNKNOWN							
				Naloxone Hydrochloride And Tilidine Hydrochloride	C		
UNKNOWN							
				Naloxone Hydrochloride And Tilidine Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		
UNKNOWN							
				Buprenorphine Hydrochloride	C		
UNKNOWN							
				Buprenorphine Hydrochloride	C		
UNKNOWN							

	Hydromorphone Hydrochloride	C
UNKNOWN		
	Procaine Hydrochloride	C
UNKNOWN		
	Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C
UNKNOWN		
	Amitriptyline Hydrochloride	C
UNKNOWN		

Date:06/03/05ISR Number: 4681123-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00900
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Adverse Event
Hospitalization - Initial or Prolonged	Aneurysm
	Cerebrovascular Accident
Disability	Cholecystitis
Other	Haematocrit Decreased
	Haemoglobin Decreased
	Headache
	Hypertensive Crisis

		Laryngospasm Palpitations Sialoadenitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic Attack		Atenol	C		ORAL

Date:06/03/05ISR Number: 4681131-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681132-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681133-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Arrest Cardiovascular Disorder Lung Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681134-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03386
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4681135-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01342
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	10 MON	
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	10 MON	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	10 MON	
	Coronary Artery		Tricor	C			UNKNOWN	
	Thrombosis		Gemfibrozil	C			UNKNOWN	
			Viagra	C			UNKNOWN	
			Accupril	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681136-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02043
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
Initial or Prolonged	Infarction		Capoten	C				UNKNOWN
Disability	Anxiety Disorder		Zestril	C				UNKNOWN
	Atelectasis		Toprol Xl Tablets	C				UNKNOWN
	Atrioventricular Block		Cardizem	C				UNKNOWN
	Atrioventricular Block		Aspirin	C				UNKNOWN
	Complete							
	Blood Cholesterol							
	Increased							
	Borderline Glaucoma							
	Bradycardia							
	Chest Pain							
	Coronary Artery Disease							
	Depression							
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Emotional Distress							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Glaucoma							
	Insomnia							
	Leukocytosis							
	Osteoarthritis							
	Pain							
	Rheumatoid Arthritis							

Date:06/03/05ISR Number: 4681138-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03214
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							

Cardiovascular Disorder
Organ Failure
Pain

Date:06/03/05ISR Number: 4681140-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01132
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Anxiety
Other	Atherosclerosis
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery Disease
	Diabetes Mellitus
	Emotional Distress
	Hypertension
	Hypoaesthesia
	Myocardial Infarction
	Renal Disorder
	Shock

Weight Decreased

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Allopurinol	C		ORAL		
			Zyrtec	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

Date:06/03/05ISR Number: 4681141-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	52	MON

Date:06/03/05ISR Number: 4681144-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02681
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4681145-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02448
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:06/03/05ISR Number: 4681212-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01070
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	277 YR	
Other	Colonic Polyp		Lipitor	C			UNKNOWN	
	Emotional Distress		Axid	C			UNKNOWN	
	Erectile Dysfunction		Vitamins					
	Haematospermia		(Unspecified)	C			UNKNOWN	
	Haemorrhoids		Viagra	C			UNKNOWN	
	Headache							

Date:06/03/05ISR Number: 4681664-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4681675-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00077
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Furosemide	C			UNKNOWN	
	Myocardial Infarction		Furosemide	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Plavix	C			UNKNOWN	

	Nexium	C	UNKNOWN
	Insulin	C	UNKNOWN
	Lipitor	C	UNKNOWN
	Lopressor	C	UNKNOWN
	Lopressor	C	UNKNOWN

Date:06/03/05ISR Number: 4681676-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00825
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Dizziness Postural		Vioxx	SS	Merck & Co., Inc	ORAL		6 DAY
	Emotional Distress							
	Hypercholesterolaemia							
	Shoulder Pain							
	Ventricular Dysfunction							

Date:06/03/05ISR Number: 4681677-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00824
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Infection		Evista	C				UNKNOWN

Disability	Hernia		Lipitor	C		
UNKNOWN						
	Intracardiac Thrombus		Levothyroxine Sodium	C		
UNKNOWN						
	Pain					
	Thyroid Disorder					

Date:06/03/05ISR Number: 4681678-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01890
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
23 MON						
Initial or Prolonged	Anxiety		Synthroid	C		
UNKNOWN						
Disability	Cerebrovascular Accident		Lotensin	C		
UNKNOWN						
Other	Cholecystectomy		Prempro	C		
UNKNOWN						
	Deep Vein Thrombosis		Sarafem	C		
UNKNOWN						
	Depression		Detrol	C		
UNKNOWN						
	Diabetes Mellitus		Tiazac	C		
UNKNOWN						
	Dyspepsia		Hydrochlorothiazide			
	Dyspnoea		And Triamterene	C		
UNKNOWN						
	Gastrooesophageal Reflux		Hydroxyzine			
	Disease		Hydrochloride	C		
UNKNOWN						
	Nausea		Lorazepam	C		
UNKNOWN						
	Oedema Peripheral		Ambien	C		
UNKNOWN						
	Pain		Toprol Xl Tablets	C		
UNKNOWN						
	Pulmonary Embolism					
	Sleep Apnoea Syndrome					
	Speech Disorder					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681685-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00669
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1247 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		85 DAY
	Anxiety		Enbrel	C			SUBCUTANEOUS	
	Barrett'S Oesophagus		Methotrexate	C			UNKNOWN	
	Coronary Artery Disease		Prednisone	C			UNKNOWN	
	Disturbance In Attention		Prevacid	C			UNKNOWN	
	Dyslipidaemia		Plendil	C		ORAL		
	Emotional Distress		Folic Acid	C			UNKNOWN	
	Fatigue		Vitamin B Complex	C			UNKNOWN	
	High Density Lipoprotein		Aciphex	C			UNKNOWN	
	Decreased		Elavil	C		ORAL		
	Hyperhidrosis		Etidronate Disodium	C			UNKNOWN	
	Libido Decreased		Diflucan	C			UNKNOWN	
	Mitral Valve Incompetence		Avelox	C			UNKNOWN	
	Pain		Vitamin D					
	Pallor		(Unspecified)	C			UNKNOWN	
	Raynaud'S Phenomenon		Phenergan Vc	C			UNKNOWN	
	Sleep Disorder		Amoxicillin	C			UNKNOWN	
	Tricuspid Valve Incompetence							
	Ventricular Hypokinesia							

Date:06/03/05ISR Number: 4681687-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00560
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1797 DAY
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		1797 DAY
	Increased		Acetaminophen	C		ORAL		
	Cardiovascular Disorder		Aspirin	C		ORAL		
	Chest Pain		Aspirin	C		ORAL		
	Depression		Ibuprofen	C		ORAL		
	Disturbance In Attention							
	Dyspnoea							
	Myocardial Infarction							
	Overdose							
	Sleep Disorder							
	Thyroid Disorder							

Date:06/03/05ISR Number: 4681688-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00677
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Arthropathy
	Asthenia
	Atherosclerosis
	Atrophy
	Balance Disorder
	Bundle Branch Block Left
	Bursa Removal
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebrovascular Accident

		Cerebrovascular Disorder					
		Chest Discomfort					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Ostial Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Prozac	C		ORAL
		Dyspepsia		Lipitor	C		ORAL
		Dysuria		Glucophage	C		ORAL
		Ejection Fraction		Ambien	C		ORAL
		Decreased		Coumadin	C		ORAL
		Electrocardiogram St-T		Coumadin	C		ORAL
		Segment Abnormal		Atenolol	C		ORAL
		Emotional Distress		Allegra	C		
UNKNOWN							
		Fatigue		Amaryl	C		
UNKNOWN							
		Gastrooesophageal Reflux		Aspirin	C		
UNKNOWN							
		Disease		Paxil	C		
UNKNOWN							
		Headache					
		Hypoacusis					
		Hypoaesthesia Oral					
		Ischaemic Cerebral					
		Infarction					
		Joint Injury					
		Lymphadenopathy					
		Microangiopathy					
		Musculoskeletal					
		Discomfort					
		Myocardial Ischaemia					
		Sciatica					
		Subdural Haematoma					
		Thrombosis					
		Vascular Graft Occlusion					
		Ventricular Hypokinesia					

Date:06/03/05ISR Number: 4681689-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01617
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Blood Cholesterol	Vicodin Tablets	C
UNKNOWN			
	Increased	Pepcid	C
UNKNOWN			
	Cardiac Murmur	Aspirin	C
UNKNOWN			
	Cardiac Valve Disease	[Therapy	
	Cerebrovascular Accident	Unspecified]	C
UNKNOWN			
	Hepatitis C		
	Hypertrophic Obstructive		
	Cardiomyopathy		

Date:06/03/05ISR Number: 4681690-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00025
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681692-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02976
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1121 DAY
Initial or Prolonged	Blood Cholesterol		Zoloft	C				UNKNOWN
Disability	Increased		Nefazodone					
Other	Cardiac Disorder		Hydrochloride	C				UNKNOWN
	Chest Pain							
	Emotional Disorder							
	Hypertension							
	Mental Disorder							
	Myocardial Infarction							
	Post Concussion Syndrome							

Date:06/03/05ISR Number: 4681693-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00934
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
	Asthma		[Therapy					
	Back Disorder		Unspecified]	C				UNKNOWN
	Chest Pain							
	Dysphagia							
	Dyspnoea							
	Heart Rate Increased							
	Hypertension							
	Stomach Discomfort							

Date:06/03/05ISR Number: 4681695-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Brain Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON

Initial or Prolonged

Date:06/03/05ISR Number: 4681700-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Arthralgia
Other	Asthenia
	Atherosclerosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chondromalacia
	Convulsion
	Diabetes Mellitus
	Inadequate Control
	Diabetic Complication
	Diabetic Neuropathy
	Diverticulum
	Dizziness
	Eye Injury
	Fall
	Fatigue
	Gastritis
	Gastrointestinal

	Haemorrhage						
	Haemorrhoidal Haemorrhage						
	Hand Fracture						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL	
	Joint Dislocation		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Ligament Sprain		Plavix	SS			UNKNOWN
	Meniscus Lesion		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Muscle Spasms		Captopril Msd	C		ORAL	
	Myelodysplastic Syndrome		Evista	C			UNKNOWN
	Orthostatic Hypotension		Amitriptyline				
	Pain In Extremity		Hydrochloride	C			UNKNOWN
	Pancytopenia		Glucotrol Xl	C			UNKNOWN
	Pharyngitis		Synthroid	C			UNKNOWN
	Subcutaneous Abscess		Prilosec	C		ORAL	
	Surgery		Humulin	C			UNKNOWN
	Syncope						
	Upper Respiratory Tract Infection						
	Urinary Tract Infection						

Date:06/03/05ISR Number: 4681701-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/03/05ISR Number: 4681702-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00074
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 2 YR	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	

Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
2 YR						
	Cardiac Valve Disease		Advil	C		
UNKNOWN						
	Coronary Artery Disease					
	Emotional Distress					
	Heart Rate Irregular					
	Myocardial Infarction					
	Oedema Peripheral					

Date:06/03/05ISR Number: 4681703-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0402NOR00011
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vomiting							

Date:06/03/05ISR Number: 4681704-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01484
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Back Pain
Disability	Blood Triglycerides
Other	Increased
	Chest Pain
	Chromaturia
	Chronic Fatigue Syndrome

		Constipation					
		Convulsion					
		Costochondritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cyanosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Inadequate Control		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Baycol	C		
UNKNOWN							
		General Physical Health		Actos	C		
UNKNOWN							
		Deterioration		[Composition			
		Hypertension		Unspecified]	C		
UNKNOWN							
		Insomnia					
		Macular Oedema					
		Muscle Spasms					
		Myalgia					
		Myocardial Infarction					
		Neuritis					
		Neuropathy Peripheral					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Pain					
		Peripheral Vascular					
		Disorder					
		Restless Legs Syndrome					
		Retinopathy					
		Road Traffic Accident					
		Serum Ferritin Decreased					
		Tachycardia					

Date:06/03/05ISR Number: 4681706-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02685
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 914 DAY		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Hypercholesterolaemia					

Disability Hypertension
Myocardial Infarction

Date:06/03/05ISR Number: 4681707-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00149
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Diazepam	C			UNKNOWN	
			Gemfibrozil	C			UNKNOWN	
			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
			Glipizide	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681708-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00842
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		16 MON
Hospitalization -	Anxiety		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Arthropathy		Allegra-D	C				UNKNOWN
Disability	Asthenia		[Therapy Unspecified]	C				UNKNOWN
	Atrial Fibrillation		Naproxen	C				UNKNOWN
	Back Pain		Relafen	C				UNKNOWN
	Benign Prostatic Hyperplasia		Prinivil	C				UNKNOWN
	Bezoar		Atenolol Msd	C				UNKNOWN
	Blood Potassium Decreased		Prilosec	C				UNKNOWN
	Blood Pressure Diastolic Decreased							
	Cardiac Disorder							
	Cardiomyopathy							
	Chest Pain							
	Cholecystitis Acute							
	Cholelithiasis							
	Contusion							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Diabetes Mellitus Non-Insulin-Dependent							
	Dizziness							
	Dysphagia							
	Dyspnoea							
	Emotional Distress							
	Feeling Abnormal							
	Gastritis							
	Heart Rate Increased							
	Hyperhidrosis							
	Hyperlipidaemia							

Hypertension
Injury
Insulin Resistance
Intestinal Polyp
Low Density Lipoprotein
Increased
Muscle Spasms
Myocardial Infarction
Nausea
Oesophageal Disorder
Pain
Palpitations
Peripheral Vascular
Disorder
Renal Cyst
Sacroiliitis
Sinus Bradycardia
Stent Placement
White Blood Cell Count
Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681711-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4681712-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03233
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4681713-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03420
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	110	DAY

Date:06/03/05ISR Number: 4681714-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03255
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON

Date:06/03/05ISR Number: 4681715-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03418
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Cardiac Disorder
Cardiovascular Disorder
Injury
Lung Disorder
Multi-Organ Disorder
Pain

Date:06/03/05ISR Number: 4681716-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON
	Nervous System Disorder							
	Pain							

Date:06/03/05ISR Number: 4681717-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02106
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Other	Cerebrovascular Accident
	Depression
	Emotional Distress
	Haematuria
	Intervertebral Disc

	Degeneration Pain Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
			Zoloft	C			UNKNOWN	

Date:06/03/05ISR Number: 4681718-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02044
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
Initial or Prolonged	Cardiac Failure		Altace	C			UNKNOWN	
Disability	Congestive		Nexium	C			UNKNOWN	
Other	Chest Pain		Nexium	C			UNKNOWN	
	Dyspnoea		Dyazide	C			UNKNOWN	
	Emotional Distress		Iron (Unspecified)	C			UNKNOWN	
	Herpes Zoster		Macrodantin	C			UNKNOWN	
	Hyperkalaemia							
	Mental Disorder							
	Myocardial Infarction							
	Sleep Apnoea Syndrome							
	Sleep Disorder							
	Supraventricular Extrasystoles							
	Urinary Tract Infection							

Date:06/03/05ISR Number: 4681720-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02045
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angiopathy

Initial or Prolonged	Arthralgia
	Arthropathy
	Aspartate
	Aminotransferase
	Increased
	Back Pain
	Blood Thyroid Stimulating
	Hormone Decreased
	Cardiac Disorder
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Emotional Distress
	Exostosis
	Haemoglobin Decreased
	Hypertension
	Intervertebral Disc
	Protrusion
	Lymphocyte Percentage
	Decreased
	Mean Cell Haemoglobin
	Decreased
	Mean Cell Volume
	Decreased
	Monocyte Percentage
	Decreased
	Myocardial Infarction
	Neutrophil Percentage

	Increased Oedema Peripheral Osteoarthritis Pain In Extremity	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Tendon Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1154 MON	
			Lipitor	C			UNKNOWN	
			Levoxyl	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Ranitidine	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

Date:06/03/05ISR Number: 4681724-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01890
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Aspirin	C			UNKNOWN	
Disability	Emotional Distress		Lasix (Furosemide)	C			UNKNOWN	
Other	Nephrolithiasis		Lasix (Furosemide)	C			UNKNOWN	
	Overdose		Plavix	C			UNKNOWN	
	Transient Ischaemic		Lipitor	C			UNKNOWN	
	Attack		[Therapy Unspecified]	C			UNKNOWN	

Date:06/03/05ISR Number: 4681725-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01922
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		28 MON
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Equate	C				
UNKNOWN								
	Carotid Artery Stenosis		Cardizem	C				
UNKNOWN								
	Cerebrovascular Accident		Coumadin	C				
UNKNOWN								
	Constipation		Tylenol	C				
UNKNOWN								
	Dyspnoea		Xanax	C				
UNKNOWN								
	Hypercholesterolaemia		Furosemide	C		ORAL		
			Coreg	C				
UNKNOWN								

Date:06/03/05ISR Number: 4681726-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01892
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		35 MON
Initial or Prolonged	Emotional Distress		Ziac	C				
UNKNOWN		9 YR						
Disability	Gastritis		Aspirin	C				
UNKNOWN								
	Myocardial Infarction		Tylenol	C				
UNKNOWN								
			Pamelor	C				
UNKNOWN								
			Buspar	C				
UNKNOWN								
			Skelaxin	C				
UNKNOWN								
			Zanaflex	C				
UNKNOWN								
			Hydrochlorothiazide And Bisoprolol Fumarate	C				
UNKNOWN								
			Dexamethasone	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00853
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		450 MON
Initial or Prolonged	Carotid Artery Stenosis		Lexxel	C				UNKNOWN
	Cerebrovascular Accident		Toprol Xl Tablets	C		ORAL		
	Depression		Norvasc	C		ORAL		
	Dyspepsia		Dyazide	C				UNKNOWN
	Emotional Distress		Dyazide	C				UNKNOWN
	Hypertension		Aspirin	C		ORAL		
	Osteoarthritis		Aspirin	C		ORAL		
	Rotator Cuff Syndrome		Premarin	C				UNKNOWN

Date:06/03/05ISR Number: 4681729-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01911
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Lasix (Furosemide)	C				UNKNOWN
Other	Atrial Fibrillation		Digoxin	C				UNKNOWN
	Bursitis		Zocor	C		ORAL		
	Cardiac Failure		Pacerone	C				UNKNOWN
	Congestive		Lorazepam	C				UNKNOWN
	Cardiac Murmur		Neurontin	C				UNKNOWN
	Cataract		Meclizine	C				UNKNOWN
	Chronic Fatigue Syndrome		Salmeterol	C				UNKNOWN
	Depression		Baclofen	C				UNKNOWN
	Dyspnoea		Temazepam	C				UNKNOWN

	Emotional Distress	Centrum	C
UNKNOWN			
	Eye Injury	Potassium	
	Fall	(Unspecified)	C
UNKNOWN			
	Gastritis	Potassium	
	Hiatus Hernia	(Unspecified)	C
UNKNOWN			
	Hypercholesterolaemia		
	Hypertension		
	Insomnia		
	Ischaemic Stroke		
	Lower Limb Fracture		
	Meningioma		
	Myocardial Infarction		
	Oedema Peripheral		
	Palpitations		
	Rash		
	Scleral Haemorrhage		
	Sick Sinus Syndrome		
	Sleep Apnoea Syndrome		
	Tri-Iodothyronine Uptake Increased		

Date:06/03/05ISR Number: 4681730-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02060
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthropathy
	Back Pain
	Blood Pressure Increased
	Blood Pressure Systolic

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Increased Cardiovascular Disorder Chest Discomfort Chest Pain					
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR	Diastolic Dysfunction		Premarin	C		
UNKNOWN		Drug Administration Error		Synthroid	C		
UNKNOWN		Dyspnoea		Prozac	C		
UNKNOWN		Emotional Distress		Zyrtec	C		
UNKNOWN		Gastric Disorder		Prevacid	C		
UNKNOWN		Hernia		Norvasc	C		
UNKNOWN		Hernia Repair		Zomax	C		
UNKNOWN		Hypertension		Aciphex	C		
UNKNOWN		Intervertebral Disc		Tagamet	C		
UNKNOWN		Protrusion		Paxil	C		
UNKNOWN		Ischaemia		Zantac	C		
UNKNOWN		Mitral Valve Incompetence		Belladonna	C		
UNKNOWN		Myocardial Infarction		Skelaxin	C		
UNKNOWN		Myocardial Ischaemia		Hydrocodone/Apap	C		
UNKNOWN		Night Sweats		Promethazine	C		
UNKNOWN				Ibuprofen	C		
UNKNOWN				Avapro	C		
UNKNOWN				Xanax	C		
UNKNOWN				Xanax	C		
UNKNOWN							

			Nexium	C		
UNKNOWN						

Date:06/03/05ISR Number: 4681731-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02210
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 160 DAY	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
160 DAY						
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Distress		Vasotec	C		ORAL
	Fatigue		Claritin	C		
UNKNOWN						
	Hepatic Enzyme Increased		Asacol	C		
UNKNOWN						
	Hyperhidrosis		Sulfasalazine	C		
UNKNOWN						
	Hyperlipidaemia					
	Hypertension					
	Mental Disorder					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Nausea					
	Rhinitis Allergic					
	Weight Decreased					

Date:06/03/05ISR Number: 4681732-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03181
Age:48 YR Gender:Male I/FU:I

Outcome	PT
Other	Angina Unstable
	Blood Triglycerides Increased
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Hypercholesterolaemia
	Hyperlipidaemia

	Hypertension						
	Myocardial Ischaemia						
	Ventricular Dyskinesia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Hypokinesia		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON
			Cortisone	C			UNKNOWN

Date:06/03/05ISR Number: 4681733-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/03/05ISR Number: 4681734-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02288
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Biliary Dilatation		Klonopin	C		ORAL	
	Carotid Artery Stenosis		Premarin	C		ORAL	
	Cerebrovascular Accident		Trileptal	C		ORAL	
	Convulsion		Plavix	C		ORAL	
	Depression		Aspirin	C		ORAL	
	Emotional Distress		Antivert	C		ORAL	
	Fall		Topamax	C		ORAL	
	Gallbladder Disorder		Synthroid	C		ORAL	
	Headache		Verapamil	C		ORAL	
	Hypertension		Fosamax	C			
							UNKNOWN
	Ischaemic Stroke						
	Liver Function Test Abnormal						
	Nervous System Disorder						
	Oedema						
	Osteoarthritis						
	Pulmonary Granuloma						
	Renal Failure Acute						
	Renal Failure Chronic						

Rib Fracture
Skeletal Injury

Date:06/03/05ISR Number: 4681736-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02112
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Triamterene	C		ORAL		
	Cardiac Arrest		Claritin-D	C		ORAL		
	Carpal Tunnel Syndrome		Flonase	C				
RESPIRATORY								
	Depression							
(INHALATION)								
	Diabetes Mellitus		Valtrex	C		ORAL		
	Emotional Distress		Premarin	C				
UNKNOWN								
	Loss Of Consciousness							
	Myocardial Infarction							
	Neoplasm Malignant							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681737-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02288
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	458	DAY
	Infarction							
	Injury							

Date:06/03/05ISR Number: 4681738-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01916
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	1457	DAY
Initial or Prolonged	Infarction							
	Emotional Distress							
	Hyperlipidaemia							

Date:06/03/05ISR Number: 4681739-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03185
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	5	MON
Other	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	8	DAY
	Fall							
	Haemoglobin Decreased							
	Oedema Peripheral							
	Pain							
	Staphylococcal Infection							
	Transient Ischaemic							
	Attack							

Date:06/03/05ISR Number: 4681740-6Report Type:Expedited (15-DaCompany Report #SE-MERCK-0505SWE00024
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Folic Acid	C				
UNKNOWN								
Initial or Prolonged			Methotrexate	C				
UNKNOWN								

Date:06/03/05ISR Number: 4681741-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03231
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased							
	Cerebrovascular Accident							
	Myocardial Infarction							
	Nausea							
	Tremor							

Date:06/03/05ISR Number: 4681748-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03424
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cardiac Arrest
	Cardiac Disorder

		Multi-Organ Disorder Pain					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681749-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03419
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Arrest Cardiac Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681750-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03417
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder Coronary Artery Surgery Gangrene Myocardial Infarction Paralysis Peripheral Vascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL

Date:06/03/05ISR Number: 4681751-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03432
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Injury Lung Disorder Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Pain

Date:06/03/05ISR Number: 4681752-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03289
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Cerebrovascular Accident							
	Fall							
	Retinal Artery Thrombosis							
	Visual Field Defect							

Date:06/03/05ISR Number: 4681753-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4681755-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01925
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Calculus Bladder		Lotensin	C		ORAL		
Initial or Prolonged	Cerebrovascular Accident		Hydrochlorothiazide	C		ORAL		
Other	Chest Pain		Zocor	C		ORAL		
	Coronary Artery		Metoprolol-Bc	C		ORAL		
	Restenosis		Prilosec	C		ORAL		
	Depression		Lexapro	C		ORAL		
	Diabetes Mellitus		Plavix	C		ORAL		
	Inadequate Control		Glucophage	C		ORAL		
	Dyspnoea		Humalog Mix 75/25	C		PARENTERAL		
	Foot Fracture		Humalog Mix 75/25	C		PARENTERAL		
	Gastritis Erosive		Aspirin	C		ORAL		
	Helicobacter Gastritis		Nitroglycerin	C		UNKNOWN		
	Hypertension		Actos	C		ORAL		
	Hypoglycaemia		Meclizine	C		ORAL		
	Impaired Gastric Emptying		Trileptal	C		ORAL		
	Intervertebral Disc Degeneration		[Therapy Unspecified]	C		UNKNOWN		
	Myocardial Infarction		Zanaflex	C		ORAL		
	Oedema Peripheral							
	Oral Candidiasis							
	Pain In Extremity							
	Rheumatoid Arthritis							
	Spinal Osteoarthritis							
	Urinary Tract Infection							
	Vertigo							

Date:06/03/05ISR Number: 4681756-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00062
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	First Degree Cholelithiasis							
	Coronary Artery Disease							

Hyperlipidaemia

Date:06/03/05ISR Number: 4681757-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02935
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/03/05ISR Number: 4684756-9Report Type:Expedited (15-DaCompany Report #2005059072
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Foreign	Bextra (Valdecoxib)	PS		ORAL	40 MG (40 MG, 1 IN 1 D), ORAL	
	Hypersensitivity	Consumer						
	Mass							
	Pruritus		Vioxx (Rofecoxib)	SS				
	Skin Discolouration							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/03/05ISR Number: 4684946-5Report Type:Expedited (15-DaCompany Report #WAES 99117015
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase Increased	Foreign Study	Tab Vioxx (Rofecoxib)	PS		ORAL	50 MG/DAILY	
Hospitalization - Initial or Prolonged	Aspartate Aminotransferase Increased	Other	Tab Placebo (Unspecified)	SS			PO	288 DAY
	Myocardial Infarction Ventricular Hypertrophy		Estradiol/Norethindrone Acetate	C				288 DAY
			Lisinopril-Hctz	C				
			Methotrexate	C				
			Metoprolol	C				

Date:06/06/05ISR Number: 4682504-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY	
	Hepatic Enzyme Increased		Tizanidine Hydrochloride	SS		ORAL	1 DAY	
			Tizanidine Hydrochloride	SS		ORAL	1 DAY	
			Tizanidine Hydrochloride	SS		ORAL	1 DAY	
			Diclofenac Sodium	SS		ORAL		
			Herbs (Unspecified)	C		ORAL		

Date:06/06/05ISR Number: 4682519-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02663
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angina Pectoris	Vioxx	PS	Merck & Co., Inc	ORAL
	Aortic Valve Incompetence	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Atherosclerosis	Glucophage	C		
UNKNOWN					
	Atrial Fibrillation	Aspirin	C		
UNKNOWN					
	Blood Cholesterol	Plavix	C		
UNKNOWN					
	Increased	Lipitor	C		
UNKNOWN					
	Brain Stem Infarction	Altace	C		
UNKNOWN					
	Cerebrovascular Accident	Zocor	C		
UNKNOWN					
	Constipation	Glucotrol	C		
UNKNOWN					
	Coronary Artery Disease	Ibuprofen	C		
UNKNOWN					
	Dilatation Atrial	Celebrex	C		
UNKNOWN					
	Disturbance In Attention				
	Heart Rate Irregular				
	Hypertension				
	Mitral Valve Incompetence				
	Neuropathy Peripheral				
	Ventricular Hypertrophy				

Date:06/06/05ISR Number: 4682521-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02927
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Back Injury
	Bradycardia

		Chest Pain					
		Coronary Artery Disease					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram St		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY						
		Segment Elevation		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Advil	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:06/06/05ISR Number: 4682522-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02356
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
Initial or Prolonged		Infarction		Aricept	C		
UNKNOWN							
Other		Blood Cholesterol		Lovastatin	C		
UNKNOWN							
		Increased		Advil	C		
UNKNOWN							
		Cardiac Disorder		Tylenol	C		
UNKNOWN							
		Cerebral Infarction		Ginkgo Biloba			
		Cerebrovascular Accident		Extract	C		
UNKNOWN							
		Dementia Alzheimer'S Type					
		Emotional Distress					
		Joint Injury					
		Sinusitis					

Date:06/06/05ISR Number: 4682523-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02315
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Bradyarrhythmia		Vioxx	SS	Merck & Co., Inc			UNKNOWN
Other	Cardiac Disorder		Hydroxychloroquine Sulfate	C				UNKNOWN
	Coronary Artery Disease		Atenolol	C				UNKNOWN
	Dyspnoea		Omeprazole	C				UNKNOWN
	Headache		Fluocinonide	C				UNKNOWN
	Hyperaemia		Triamcinolone	C				UNKNOWN
	Irritable Bowel Syndrome		Sulfamethoxazole	C				UNKNOWN
	Myocardial Infarction		Methylprednisolone	C				UNKNOWN
	Oesophageal Disorder		Metronidazole	C				UNKNOWN
	Pneumothorax		Rabeprazole Sodium	C				UNKNOWN
	Sick Sinus Syndrome		Zantac	C				UNKNOWN
	Ulcer		Sildenafil Citrate	C				UNKNOWN
			Albuterol	C				UNKNOWN
			Capsaicin	C				UNKNOWN
			Ferrous Sulfate	C				UNKNOWN
			Ipratropium Bromide	C				UNKNOWN
			Nifedipine	C				UNKNOWN
			Ramipril	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4682524-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02023
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		498 DAY
Initial or Prolonged	Atherosclerosis		Lipitor	C				UNKNOWN
Other	Cardiac Disorder		Synthroid	C				UNKNOWN
	Cardiac Enzymes Increased		Coumadin	C				UNKNOWN
	Cerebrovascular Accident		Tenormin	C				UNKNOWN
	Coronary Artery Disease		Celebrex	C				UNKNOWN
	Dyspnoea							
	Emotional Distress							
	Myocardial Infarction							
	Thrombosis							

Date:06/06/05ISR Number: 4682525-7Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00021
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		6 DAY
Initial or Prolonged	C-Reactive Protein Increased							
	Colitis Ischaemic							
	Erythema							
	Gastrointestinal Necrosis							
	Large Intestinal Ulcer							
	Leukocytosis							
	Oedema Mucosal							
	Rectal Haemorrhage							
	Thrombosis							

Date:06/06/05ISR Number: 4682538-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02843
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypercholesterolaemia		Vioxx	PS	Merck & Co., Inc	ORAL	215 DAY	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY	
	Retinal Vascular		Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY	
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	227 DAY	
	Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL	215 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	128 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	227 DAY	
			Aspirin	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Bextra	C			UNKNOWN	2 WK
			Acyclovir	C			UNKNOWN	

Date:06/06/05ISR Number: 4682539-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02378
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Bronchospasm
	Cholelithiasis
	Coronary Artery Disease
	Emotional Distress
	Hyperkalaemia
	Hyperlipidaemia
	Hyperthyroidism

	Hyponatraemia Hypoxia Lobar Pneumonia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	944	DAY
			Synthroid	C			UNKNOWN	
			Hydroxyurea	C			UNKNOWN	

Date:06/06/05ISR Number: 4682542-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01931
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Emotional Distress		Neurontin	C			UNKNOWN	
	Monarthritis		Zyprexa	C			UNKNOWN	
	Pain		Celexa	C			UNKNOWN	
	Periodontitis		Ambien	C			UNKNOWN	
	Pulmonary Embolism		Norvasc	C			UNKNOWN	
	Tendon Rupture		Serevent	C			UNKNOWN	
			Atrovent	C			UNKNOWN	
			Tylenol With Codeine #4	C			UNKNOWN	
			Tylenol With Codeine #4	C			UNKNOWN	

Date:06/06/05ISR Number: 4682543-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00611
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 5 YR	Abdominal Pain	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aspartate Aminotransferase Increased Blood Albumin Decreased Blood Alkaline Phosphatase Increased Blood Glucose Increased Constipation Coronary Artery Disease Coronary Artery Stenosis Depression Duodenal Stenosis Gastrointestinal Haemorrhage Myalgia Myocardial Infarction Pancreatitis Peptic Ulcer Protein Total Decreased Pulmonary Embolism Thoracic Cavity Drainage Ventricular Hypertrophy	Zocor	SS		ORAL

Date:06/06/05ISR Number: 4682544-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01920
Age:63 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL	720	DAY
Aortic Valve Sclerosis		Pravachol	C			UNKNOWN	
Back Pain		Aspirin	C			UNKNOWN	
Cerebrovascular Accident Emotional Distress Fall		Glyburide And Metformin Hydrochloride	C			UNKNOWN	
Hypersensitivity Intracranial Aneurysm Lacunar Infarction		Glyburide And Metformin Hydrochloride	C			UNKNOWN	
Ventricular Hypertrophy		Prilosec	C		ORAL		
		Omeprazole	C		ORAL		

Date:06/06/05ISR Number: 4682547-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00011
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Paroxetine Hydrochloride	C		ORAL		
			Cimetidine	C			UNKNOWN	

Date:06/06/05ISR Number: 4682549-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00806
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL	613	DAY

Other	Blood Pressure Increased	Aceon	C
UNKNOWN	1166 DAY		
	Emotional Distress	Actos	C
UNKNOWN			
	Gastric Disorder	Glyburide	C
UNKNOWN			
	Muscle Spasms	Lozol	C
UNKNOWN			
	Pain	Glucophage	C
UNKNOWN			
	Silent Myocardial	Acetaminophen	C
UNKNOWN			
	Infarction	Lipitor	C
UNKNOWN			
	Urinary Tract Infection	Alprazolam	C
UNKNOWN			
		Paxil	C
UNKNOWN			
		Verelan Pm	C
UNKNOWN			
		Ambien	C
UNKNOWN			
		Clonidine	C
UNKNOWN			
		Prevacid	C
UNKNOWN			
		Cipro	C
UNKNOWN			
		Covera	C
UNKNOWN			
		Tramadol Msd	C
UNKNOWN			
		Sulfamethoxazole And Trimethoprim	C
UNKNOWN			
		Celebrex	C
UNKNOWN			
		Premarin	C
UNKNOWN			
		Hydroquinone	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4682550-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02030
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aspiration		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fluid Retention		Tetracycline	C			UNKNOWN	
	Myocardial Infarction		Glyburide	C			UNKNOWN	
	Prescribed Overdose		Prandin	C			UNKNOWN	
			Avandia	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Captopril	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Amaryl	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	

Date:06/06/05ISR Number: 4682552-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01517
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL	427 DAY	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	427 DAY	
	Back Pain		Valium	C			UNKNOWN	
	Blindness		Ambien	C			UNKNOWN	
	Cerebrovascular Accident		[Therapy					

Chest Discomfort Unspecified] C
RESPIRATORY
Chest Pain
(INHALATION)
Confusional State
Dyspnoea
Hypoaesthesia
Hypokinesia
Hypotrichosis
Limb Discomfort
Loss Of Consciousness
Nausea
Oedema Peripheral
Pain
Pain In Extremity
Palpitations
Respiratory Failure
Road Traffic Accident
Teeth Brittle
Vision Blurred

Date:06/06/05ISR Number: 4682553-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03695
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Disability	Anxiety
	Asthenia
	Asthma
	Blood Testosterone Decreased
	Cardiac Failure Congestive
	Chest Pain

		Deafness					
		Drug Ineffective					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Femoral Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Lisinopril	C		
UNKNOWN							
		Disease		Plavix	C		
UNKNOWN							
		Granuloma		Zocor	C		
UNKNOWN							
		Hyperhidrosis		Advair	C		
UNKNOWN							
		Hypertension		Toprol Xl Tablets	C		
UNKNOWN							
		Myocardial Infarction		Flonase	C		
UNKNOWN							
		Nocturia		Liquibid	C		
UNKNOWN							
		Oedema Peripheral		Singulair	C		
UNKNOWN							
		Sexual Dysfunction		Furosemide	C		
UNKNOWN							
		Sleep Apnoea Syndrome					
		Stomach Discomfort					
		Synovial Cyst					
		Thyroid Neoplasm					
		Tremor					

Date:06/06/05ISR Number: 4682554-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02085
Age:35 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Ventricular					
		Emotional Distress					
		Hypoaesthesia					
		Joint Injury					
		Ligament Injury					
		Mitral Valve Incompetence					

Myocardial Infarction
Tricuspid Valve
Incompetence
Weight Increased

Date:06/06/05ISR Number: 4682555-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02231
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Infarction		Lovenox	C				UNKNOWN
Other	Emotional Distress		Nitrol					
	Pulmonary Granuloma		(Nitroglycerin)	C				UNKNOWN
	Transient Ischaemic		Nexium	C				UNKNOWN
	Attack		Zoloft	C				UNKNOWN
			Zelnorm	C				UNKNOWN
			Citrucel	C				UNKNOWN
			Carafate	C				UNKNOWN
			Advair	C				UNKNOWN
			Flonase	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4682556-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02977
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		429 DAY
Initial or Prolonged	Cerebral Artery Occlusion		Zoloft	C				
UNKNOWN								265 DAY
	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
	Dysarthria		Metoprolol	C				
UNKNOWN								
	Emotional Distress		Tenex	C				
UNKNOWN								
	Fall		Propranolol Hydrochloride	C				
	Granulocytopenia							
UNKNOWN								
	Heart Rate Irregular		Coumadin	C				
UNKNOWN								
	Hepatic Neoplasm							
	Hypertension							
	Hyperthyroidism							
	Hypothyroidism							
	Lung Infiltration							
	Rash Pruritic							
	Respiratory Failure							
	Sepsis							
	Urinary Tract Infection							
	Fungal							

Date:06/06/05ISR Number: 4682573-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03252
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR

Date:06/06/05ISR Number: 4682575-0Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00022
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Cyclosporine	C		ORAL		
			Corticosteroids (Unspecified)	C				
UNKNOWN								
			Ramipril	C		ORAL		

Date:06/06/05ISR Number: 4682576-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4682577-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03253
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Cerebrovascular Accident							
	Nervous System Disorder							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4682578-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:06/06/05ISR Number: 4682580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1971	DAY
	Myocardial Infarction							

Date:06/06/05ISR Number: 4682581-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03251
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Cerebrovascular Accident							
	Myocardial Infarction							
	Nervous System Disorder							

Date:06/06/05ISR Number: 4682582-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03002
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Zantac	C				
UNKNOWN								
Initial or Prolonged			Tagamet	C				
UNKNOWN								

Date:06/06/05ISR Number: 4682583-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01358
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		40 MON
Initial or Prolonged Disability	Atherosclerosis Cognitive Disorder Depression Emotional Distress Gastrooesophageal Reflux Disease Lower Limb Fracture Memory Impairment Myocardial Infarction Ulcer Haemorrhage		Aspirin	C		ORAL		

Date:06/06/05ISR Number: 4682593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03515
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anaemia Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Procrit	SS		SUBCUTANEOUS	25 WK	
			Vitamin B (Unspecified)	C		UNKNOWN		
			Diuretic (Unspecified)	C		UNKNOWN		
			[Therapy					

Unspecified] C
UNKNOWN

Date:06/06/05ISR Number: 4682598-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03400
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Lung Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4682600-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00558
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4682601-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03120
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Upper Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4682608-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4682628-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00978
Age:56 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Acute Respiratory Failure Bundle Branch Block Left Cardiac Failure Congestive Chest Pain Chronic Obstructive Pulmonary Disease Coronary Artery Occlusion Dyspnoea Gout Herpes Zoster Hypertension Ischaemic Cardiomyopathy Joint Swelling Mental Status Changes Mitral Valve Incompetence Myocardial Infarction Obstructive Airways Disorder Peptic Ulcer Pneumothorax Pulmonary Oedema Renal Impairment Respiratory Failure

	Sepsis Ventricular Extrasystoles Ventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	45 DAY
			Zocor	C			UNKNOWN
			Glucophage	C			UNKNOWN
			Lasix (Furosemide)	C			UNKNOWN
			Cardizem	C			UNKNOWN

Date:06/06/05ISR Number: 4682808-0Report Type:Expedited (15-DaCompany Report #2005CG00675
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Deep Vein Thrombosis		Mopral	PS		ORAL	
Initial or Prolonged	Drug Effect Decreased		Innohep	SS			SUBCUTANEOUS 4 DAY
			Aprovel	SS		ORAL	
			Vioxx	SS		ORAL	
			Arixtra	SS			SUBCUTANEOUS 7 DAY
			Fumafer	SS		ORAL	

Date:06/06/05ISR Number: 4683012-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00115
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR
Initial or Prolonged	Angina Pectoris		Ventolin (Albuterol)	C			UNKNOWN
Other	Aortic Aneurysm		Tricor	C			UNKNOWN
	Blood Cholesterol		Cartia Xt	C			UNKNOWN

	Increased	Furosemide	C
UNKNOWN			
	Blood Triglycerides	Ambien	C
UNKNOWN			
	Increased	Paxil	C
UNKNOWN			
	Cardiac Disorder	Aspirin	C
UNKNOWN			
	Cardiac Failure	Isosorbide	C
UNKNOWN			
	Congestive	Nitroglycerin	C
UNKNOWN			
	Carotid Artery Occlusion	Aciphex	C
UNKNOWN			
	Carotid Artery Stenosis	Elavil	C
UNKNOWN			
	Drug Hypersensitivity Dyspnoea Emotional Distress Gallbladder Disorder Gastric Ulcer Gastrooesophageal Reflux Disease Heart Rate Irregular Myocardial Infarction Oedema Renal Disorder Transient Ischaemic Attack Ulcer		

Date:06/06/05ISR Number: 4683013-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00955
Age:84 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Anaemia

		Anger					
		Anxiety					
		Bacteriuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cataract		Vioxx	PS	Merck & Co., Inc	ORAL
28	DAY						
		Confusional State		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
28	DAY						
		Fear		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Tenosynovitis		Joint Advantage	C		
UNKNOWN							
				Cyanocobalamin And Pyridoxine	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Alphagan	C		
AURICULAR							
(OTIC)							
				Levobunolol Hydrochloride	C		
AURICULAR							
(OTIC)							
				Tears Naturale	C		
AURICULAR							
(OTIC)							
				Travatan	C		
AURICULAR							
(OTIC)							
				Diabeta	C		ORAL
				Prednisone	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							

Date:06/06/05ISR Number: 4683014-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acute Respiratory Distress Syndrome
	Acute Respiratory Failure
	Angina Pectoris
	Arthropathy
	Atelectasis
	Back Pain
	Balance Disorder
	Blood Pressure Systolic Abnormal
	Bone Pain
	Bronchitis
	Cardiac Failure Congestive
	Cardiomegaly
	Cerebrovascular Accident
	Cerebrovascular Accident Prophylaxis
	Chest Discomfort
	Chest Pain
	Cholecystitis
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Confusional State Coordination Abnormal Costochondritis					
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Drug Hypersensitivity		Aspirin	C		
UNKNOWN							
		Essential Tremor		Lipitor	C		
UNKNOWN							
		Fall		Metformin	C		
UNKNOWN							
		Gastrooesophageal Reflux		Prozac	C		
UNKNOWN							
		Disease		Prilosec	C		
UNKNOWN							
		Headache		Glucophage	C		
UNKNOWN							
		Hernia Hiatus Repair		Wellbutrin	C		
UNKNOWN							
		Hiatus Hernia Hypertension Hypokinesia Hypotension Hypoxia Intention Tremor Intervertebral Disc Degeneration Laryngitis Mitral Valve Incompetence Non-Cardiac Chest Pain Pericardial Effusion Ph Body Fluid Abnormal Pneumonia Pulmonary Embolism Shock Shoulder Operation Sinus Disorder Spinal Column Stenosis Spinal Compression Fracture Transient Ischaemic Attack Tremor Urinary Tract Infection Vertigo Vomiting					

Date:06/06/05ISR Number: 4683015-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00655
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Norvasc	C				
UNKNOWN								
	Fall		Lipitor	C				
UNKNOWN								
	Ischaemic Stroke		Hyoscyamine	C				
UNKNOWN								
	Laceration		Atacand	C				
UNKNOWN								
	Limb Injury		Vitamin E	C				
UNKNOWN								
	Low Tension Glaucoma		Aspirin	C				
UNKNOWN								
	Optic Ischaemic		Aspirin	C				
UNKNOWN								
	Neuropathy		Toprol Xl Tablets	C				
UNKNOWN								
	Pain		Celebrex	C				
UNKNOWN								
			Ascorbic Acid	C				
UNKNOWN								
			Detrol La	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683016-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00824
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cellulitis		Evista	C				UNKNOWN
Disability	Coronary Artery Disease		Lipitor	C				UNKNOWN
	Diverticulitis		Levothyroxine Sodium	C				UNKNOWN
	Hernia							
	Intracardiac Thrombus							
	Pain							
	Urinary Tract Infection							

Date:06/06/05ISR Number: 4683019-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02376
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		21 DAY
Initial or Prolonged	Blood Cholesterol Increased		Vitamins (Unspecified)	C				UNKNOWN
	Cerebrovascular Accident		Tricor	C				UNKNOWN
	Dizziness		Coumadin	C				UNKNOWN
	Dyspnoea							
	Emotional Distress							
	Eye Swelling							
	Face Oedema							
	Headache							
	Nausea							
	Sinus Bradycardia							
	Swelling Face							
	Transient Ischaemic Attack							
	Vomiting							

Date:06/06/05ISR Number: 4683020-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05166
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Disability	Hypertension		Metoprolol	C				
UNKNOWN	Renal Disorder		Coreg	C				
UNKNOWN	Renal Failure							

Date:06/06/05ISR Number: 4683021-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02298
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Allergic Sinusitis
	Arrhythmia
	Asthenia
	Back Pain
	Benign Neoplasm Of Thyroid Gland
	Blood Cholesterol Increased
	Blood Glucose Increased
	Blood Triglycerides Increased
	Cataract Operation

		Cerebrovascular Accident Chest Pain Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
49	MON						
		Difficulty In Walking		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
49	MON						
		Dyspnoea		Prevacid	C		
UNKNOWN							
		Emotional Distress		Atacand	C		
UNKNOWN							
		Fatigue		Allegra	C		
UNKNOWN							
		Glycosylated Haemoglobin		Allegra	C		
UNKNOWN							
		Increased Hepatic Steatosis Hepatomegaly		Lasix (Furosemide Sodium) Potassium Chloride	C C		ORAL
UNKNOWN							
		Hypertension		Nitroglycerin	C		
SUBLINGUAL							
		Infarction		Vitamin E	C		
UNKNOWN							
		Intervertebral Disc		Ecotrin	C		
UNKNOWN							
		Protrusion		Darvocet-N	C		
UNKNOWN							
		Oedema Peripheral Pancreas Lipomatosis		Potassium (Unspecified)	C		
UNKNOWN							
		Pulmonary Embolism		Lortab	C		
UNKNOWN							
		Rotator Cuff Repair Scoliosis		Calcium (Unspecified)	C		
UNKNOWN							
		Spondylitis		Motrin	C		
UNKNOWN							
		Stress		Aspirin	C		
UNKNOWN							
		Thrombosis		Coumadin	C		
UNKNOWN							

	Upper Respiratory Tract	Celebrex	C
UNKNOWN			
	Infection	Lipitor	C
UNKNOWN			
	Weight Decreased	Vitamins (Unspecified)	C
UNKNOWN			
		Tums	C
UNKNOWN			
		Bextra	C
UNKNOWN			
		Protonix	C
UNKNOWN			
		Serevent	C
UNKNOWN			
		Epa Capsules	C
UNKNOWN			
		Magnesium (Unspecified)	C
UNKNOWN			
		Vitamin B Complex	C
UNKNOWN			

Date:06/06/05ISR Number: 4683023-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02195
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adrenal Mass
	Aortic Aneurysm
	Arterial Occlusive Disease
	Blood Homocysteine Increased
	Cardiac Failure Congestive
	Coronary Artery Disease
	Diarrhoea
	Diverticulum
	Duodenal Ulcer
	Emotional Distress
	Fatigue
	Gastrointestinal Haemorrhage
	Gastrooesophageal Reflux

		Disease					
		Hyperlipidaemia					
		Hypoxia					
		Intervertebral Disc	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Lotrel	C		
UNKNOWN							
		Peripheral Vascular					
		Disorder					
		Urinary Tract Infection					

Date:06/06/05ISR Number: 4683024-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02075
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Amnesia
	Angina Pectoris
	Aortic Stenosis
	Atrial Tachycardia
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Confusional State
	Dementia
	Diabetes Mellitus
	Diverticulitis
	Duodenal Ulcer
	Dyspnoea
	Emotional Distress
	Gait Disturbance
	Gastric Disorder
	Gastrointestinal
	Haemorrhage
	Gastrointestinal Ulcer
	Haematochezia
	Incontinence
	Irritable Bowel Syndrome
	Lactose Intolerance
	Major Depression
	Mental Disorder Due To A
	General Medical Condition

Migraine
Mitral Valve Incompetence
Myocardial Infarction
Normal Pressure
Hydrocephalus
Oedema
Panic Disorder
Pulmonary Valve
Incompetence
Seasonal Allergy
Sinus Bradycardia
Sinus Disorder
Swelling
Tricuspid Valve
Incompetence
Upper Gastrointestinal
Haemorrhage

Venous Insufficiency
Ventricular Hypertrophy
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Altace	C		ORAL		
	Aspirin	C			UNKNOWN	
	Aricept	C		ORAL		
	Synthroid	C		ORAL		
	Synthroid	C		ORAL		
	Prozac	C		ORAL		
	Claritin-D	C		ORAL		
	Ursodiol	C			UNKNOWN	
	Hydrochlorothiazide And Triamterene	C			UNKNOWN	
	Zestril	C			UNKNOWN	
	Humulin Nph	C			UNKNOWN	
	Humalog	C			SUBCUTANEOUS	
	Premarin	C			UNKNOWN	
	Remeron	C			UNKNOWN	
	Risperdal	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Prozac	C		ORAL		
	Prozac	C		ORAL		
	Synthroid	C		ORAL		
	Synthroid	C		ORAL		
	Aricept	C		ORAL		
	Altace	C		ORAL		
	Lipitor	C			UNKNOWN	

Date:06/06/05ISR Number: 4683025-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01929
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		474 DAY
Initial or Prolonged	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		474 DAY
Other	Pulmonary Disease		Premarin	C				UNKNOWN
	Coronary Artery Disease		Diabeta	C				UNKNOWN
	Coronary Artery Occlusion		Motrin	C				UNKNOWN
	Dyspepsia		Premarin	C				UNKNOWN
	Dyspnoea							
	Emotional Distress							
	Hypertension							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							

Date:06/06/05ISR Number: 4683026-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01906
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Chest Discomfort
Initial or Prolonged	Chest Pain
	Disorientation
	Electrocardiogram
	Abnormal
	Electrocardiogram T Wave
	Abnormal

		Emotional Distress					
		Hypertension					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Hydrocodone			
				Bitartrate	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:06/06/05ISR Number: 4683027-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01913
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 797 DAY		Abscess		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Anaemia		Prilosec	C		ORAL
		Angina Unstable		Norvasc	C		
UNKNOWN							
		Atherosclerosis		Norvasc	C		
UNKNOWN							
		Blood Pressure Decreased					
		Bone Infection					
		Cardiac Failure					
		Cardiac Failure					
		Congestive					
		Cardiovascular Disorder					
		Cellulitis					
		Coronary Artery Disease					
		Depression					
		Drug Tolerance Increased					
		Emotional Distress					
		Heart Rate Irregular					
		Hyperlipidaemia					
		Increased Tendency To					
		Bruise					
		Ischaemic Cardiomyopathy					
		Leg Amputation					
		Myocardial Infarction					
		Poor Peripheral					

Circulation
Psoriasis
Rash
Rash Generalised
Renal Disorder
Renal Impairment
Sinusitis
Skin Disorder
Supraventricular
Extrasystoles
Weight Decreased

Date:06/06/05ISR Number: 4683028-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01195
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
	Aortic Atherosclerosis
	Asthenia
	Cardiac Disorder
	Cardiac Murmur

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain					
		Coronary Artery Occlusion					
		Dizziness					
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress		Claritin	C		
UNKNOWN							
		Hernia		Metoprolol	C		
UNKNOWN							
		Intervertebral Disc		Relafen	C		
UNKNOWN							
		Protrusion		Nitroglycerin	C		
UNKNOWN							
		Mitral Valve Sclerosis		Imdur	C		
UNKNOWN							
		Myocardial Infarction		Dipyridamole	C		
UNKNOWN							
		Peripheral Artery		Xanax	C		
UNKNOWN							
		Aneurysm		Cartia Xt	C		
UNKNOWN							
		Plantar Fasciitis		Cartia Xt	C		
UNKNOWN							
		Radiculopathy		Paxil	C		
UNKNOWN							
		Renal Cyst		Lipitor	C		
UNKNOWN							
		Rheumatoid Arthritis		Tylenol With Codeine			
		Skin Cancer		#3	C		
UNKNOWN							
		Skin Lesion		Dyazide	C		
UNKNOWN							
		Ventricular Hypertrophy		Aspirin	C		
UNKNOWN							
				Cardizem Cd	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Hydrocodone/Apap	C		
UNKNOWN							
				Potassium Chloride	C		
UNKNOWN							

Date:06/06/05ISR Number: 4683029-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03104
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ischaemic Cardiomyopathy		Plavix	C			UNKNOWN	
	Pneumonia		Coreg	C			UNKNOWN	
			Cyanocobalamin	C			INTRAMUSCULAR	
			Monopril	C			UNKNOWN	

Date:06/06/05ISR Number: 4683034-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1409 DAY	

Date:06/06/05ISR Number: 4683035-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	40 MON	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	40 MON	

Date:06/06/05ISR Number: 4683036-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00695
Age:55 YR Gender:Female I/FU:F

Outcome	PT
	Blood Cholesterol Increased
	Hepatomegaly
	Liver Function Test

Abnormal

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
			Synthroid	C			UNKNOWN	

Date:06/06/05ISR Number: 4683037-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03372
Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Chest Pain							
Disability	Dyspnoea							
	Overdose							

Date:06/06/05ISR Number: 4683038-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4683039-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02112
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Sphincter Atony		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atherosclerosis		Triamterene	C		ORAL		
Other	Bursitis		Claritin-D	C		ORAL		
	Cardiac Arrest		Flonase	C				
RESPIRATORY								
	Carpal Tunnel Syndrome							
(INHALATION)								
	Depression		Valtrex	C		ORAL		

	Diabetes Mellitus	Premarin	C
UNKNOWN			
	Intervertebral Disc Protrusion	Vitamins (Unspecified)	C
UNKNOWN			
	Loss Of Consciousness		
	Myocardial Infarction		
	Neoplasm Malignant		
	Pain		
	Radiculopathy		
	Rectal Prolapse		
	Spinal Column Stenosis		
	Syncope Vasovagal		
	Tendonitis		
	Tenosynovitis		

Date:06/06/05ISR Number: 4683040-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00686
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	5 MON	
			Lipitor	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Premarin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683041-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00025
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	6 YR	
Hospitalization -	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	6 YR	
Initial or Prolonged	Infection		Vioxx	SS	Merck & Co., Inc	ORAL	6 YR	
			Vioxx	SS	Merck & Co., Inc	ORAL	6 YR	
			Zocor	C			UNKNOWN	
			Mevacor	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	

Date:06/06/05ISR Number: 4683042-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02033
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	291 DAY	
Initial or Prolonged	Atelectasis		Elavil	SS			UNKNOWN	
Disability	Blood Glucose Increased		Vioxx	C		ORAL		
	Bone Neoplasm Malignant		Dilaudid	C			UNKNOWN	
	Bronchitis		Duragesic	C			UNKNOWN	
	Bursitis		Lortab	C			UNKNOWN	
	Cardio-Respiratory Arrest							
	Chronic Obstructive Pulmonary Disease							
	Confusional State							
	Coronary Artery Stenosis							
	Cyst							

Depression
Drug Hypersensitivity
Emotional Distress
Gastrooesophageal Reflux
Disease
Hallucination
Hypotension
Joint Sprain
Mental Status Changes
Metastasis
Mitral Valve Incompetence
Myocardial Infarction
Overdose
Pain
Pneumonia Aspiration
Psychotic Disorder
Respiratory Distress
Respiratory Failure
Sinus Tachycardia
Torsade De Pointes
Tremor
Tricuspid Valve
Incompetence

Date:06/06/05ISR Number: 4683049-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00399
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683050-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00397
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4683051-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00396
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4683052-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00368
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Arrhythmia Atrial Fibrillation Back Pain Blood Pressure Inadequately Controlled Cardiac Failure Congestive Cardiac Murmur Cardiomegaly Chest Pain Chondromalacia Chronic Obstructive Pulmonary Disease Coronary Artery Atherosclerosis Coronary Artery Occlusion Coronary Artery Stenosis Diabetes Mellitus Non-Insulin-Dependent		Vioxx	PS	Merck & Co., Inc	ORAL		

Dyspnoea
Ejection Fraction
Decreased
Emotional Distress
Exostosis
Gravitational Oedema
Haemorrhage
Hypertension
Meniscus Lesion
Myocardial Infarction
Nerve Root Compression
Paraesthesia
Pitting Oedema
Pulmonary Congestion
Rotator Cuff Syndrome
Spinal Column Stenosis
Synovitis
Ventricular Tachycardia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683053-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03396
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bacterial Sepsis							
	Cyst							
	Emotional Distress							
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Renal Failure Acute							
	Skin Ulcer							
	Thrombosis							

Date:06/06/05ISR Number: 4683054-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00340
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		57 MON
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		57 MON
Disability	Aortic Valve Incompetence		Trazodone Hydrochloride	C				UNKNOWN
Other	Asthma							
	Back Disorder		Pravachol	C				UNKNOWN
	Back Pain		Ranitidine	C		ORAL		
	Blood Cholesterol		Levothroid	C				UNKNOWN
	Increased		Plavix	C				UNKNOWN
	Bradycardia		Depoestradiol	C				UNKNOWN
	Chest Pain		Lisinopril	C		ORAL		
	Convulsion							
	Dermatitis Atopic							
	Dyspnoea							
	Ear Pain							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							

Heart Rate Irregular
Hypertension
Insomnia
Myocardial Infarction
Oedema Peripheral
Otitis Media
Urinary Tract Infection
Ventricular Hypertrophy

Date:06/06/05ISR Number: 4683055-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	62	MON

Date:06/06/05ISR Number: 4683056-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00364
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	53	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683057-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Lung Disorder							
	Multi-Organ Disorder							
	Pain							

Date:06/06/05ISR Number: 4683058-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							

Date:06/06/05ISR Number: 4683059-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05195
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anti-Hbc Igg Antibody		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Positive		Aspirin	C				
UNKNOWN								
	Arthralgia		Chondroitin Sulfate					
	Bereavement Reaction		Sodium And					
	Chest Pain		Glucosamine					
	Cough		Hydrochloride	C				
UNKNOWN								
	Dilatation Ventricular		Allegra	C				
UNKNOWN								
	Dizziness							
	Dyspepsia							
	Fatigue							
	Haematochezia							
	Haemorrhoids							
	Hepatic Steatosis							
	High Density Lipoprotein							
	Decreased							

Hypertensive Heart
Disease
Liver Disorder
Mitral Valve Incompetence
Myocardial Infarction
Non-High-Density
Lipoprotein Cholesterol
Decreased
Oedema Peripheral
Osteoarthritis
Pulmonary Hypertension
Rectal Haemorrhage
Silent Myocardial
Infarction
Sleep Apnoea Syndrome
Snoring
Ventricular Dysfunction
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683060-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03642
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Pain		Ambien	C				
UNKNOWN								
Initial or Prolonged	Deep Vein Thrombosis		Colace	C				
UNKNOWN								
	Fall		Bextra	C				
UNKNOWN								

Date:06/06/05ISR Number: 4683061-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00009
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ranitidine Hydrochloride	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								
			Oxazepam	C				
UNKNOWN								

Date:06/06/05ISR Number: 4683062-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00365
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							1465 MON	

Date:06/06/05ISR Number: 4683067-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00395
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Injury Lung Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/06/05ISR Number: 4683068-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder Lung Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/06/05ISR Number: 4683069-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiac Arrest Cardiac Disorder Multi-Organ Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683070-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00366
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:06/06/05ISR Number: 4683081-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/06/05ISR Number: 4683082-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00392
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Lung Disorder							
	Multi-Organ Disorder							
	Pain							

Date:06/06/05ISR Number: 4683093-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02881
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL	4	MON
	Infarction		Prilosec	C			UNKNOWN	
	Anger		Nexium	C			UNKNOWN	
	Anxiety		Skelaxin	C			UNKNOWN	

	Atherosclerosis	Ultracet	C	
UNKNOWN				
	Back Injury	Hydrocodone		
	Blood Cholesterol	Bitartrate	C	
UNKNOWN				
	Increased	Biaxin	C	
UNKNOWN				
	Blood Pressure Increased	Soma	C	
UNKNOWN				
	Coronary Artery Disease	Flexeril	C	ORAL
	Decreased Interest	Acetaminophen And		
	Depression	Propoxyphene		
	Dizziness Postural	Napsylate	C	
UNKNOWN				
	Emotional Distress	Folic Acid	C	
UNKNOWN				
	Fear	Famvir	C	
UNKNOWN				
	Gastrooesophageal Reflux	Vytorin	C	
UNKNOWN				
	Disease			
	Headache			
	Insomnia			
	Intervertebral Disc			
	Protrusion			
	Ischaemic Cardiomyopathy			
	Migraine			
	Mitral Valve Incompetence			
	Platelet Aggregation			
	Increased			
	Renal Disorder			
	Sinus Disorder			
	Social Avoidant Behaviour			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/06/05ISR Number: 4683109-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04292
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Infarction							
	Injury							

Date:06/06/05ISR Number: 4684927-1Report Type:Direct Company Report #CTU 250461
Age:28 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Alanine Aminotransferase		Vioxx	PS		ORAL	25 MG PO ONCE	
Hospitalization -	Increased							
Initial or Prolonged	Syncope		Celebrex	SS		ORAL	200 MG PO	
	Ventricular Tachycardia							
			Vicodin	C				
			Protonix	C				
			Vicodin	C				
			Flexeril	C				
			Lexapro	C				

Date:06/07/05ISR Number: 4683903-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Other	Anal Fistula
	Anastomotic Complication
	Aneurysm Ruptured
	Angina Unstable
	Anxiety
	Appendicitis Perforated
	Arthralgia
	Atelectasis

Back Pain
Breast Mass
Cardiac Failure
Cerebral Artery Stenosis
Chest Pain
Colitis Ulcerative
Contusion
Convulsion
Coronary Artery Disease
Cough
Crohn'S Disease
Defaecation Urgency
Depression
Dermatitis
Dizziness
Drug Ineffective
Dyspepsia
Faecal Incontinence
Fall
Flatulence
Gastrooesophageal Reflux
Disease
Headache
Hernia

		Hyperlipidaemia					
		Hypertension					
		Hypotension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ileitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Impaired Healing					
		Infection					
		Inflammatory Bowel Disease					
		Intestinal Perforation					
		Intestinal Spasm					
		Intracranial Aneurysm					
		Joint Injury					
		Migraine					
		Musculoskeletal Chest Pain					
		Pain					
		Pain In Extremity					
		Palpitations					
		Perianal Abscess					
		Perirectal Abscess					
		Pneumoperitoneum					
		Pouchitis					
		Proctalgia					
		Proctitis Ulcerative					
		Pruritus Ani					
		Pyrexia					
		Sepsis					
		Sleep Disorder					
		Subarachnoid Haemorrhage					
		Syncope					
		Tachycardia					
		White Blood Cell Count Increased					

Date:06/07/05ISR Number: 4683921-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01936
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 22 MON		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN		Myocardial Infarction		Clarinex	C		

Skelaxin C
UNKNOWN

Date:06/07/05ISR Number: 4683922-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02058
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Coronary Syndrome
Hospitalization -	Arthropathy
Initial or Prolonged	Benign Prostatic
Other	Hyperplasia
	Dyschezia
	Dysphagia
	Dyspnoea
	Extrasystoles
	Flushing
	Gastrooesophageal Reflux
	Disease
	Headache
	Heart Rate Increased

		Hypertriglyceridaemia					
		Influenza					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage		Lisinopril-Bc	C		
UNKNOWN							
				Atenolol Msd	C		ORAL

Date:06/07/05ISR Number: 4683927-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02230
Age:66 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
62	MON						
Hospitalization -		Infarction		Mevacor	C		ORAL
82	MON						
Initial or Prolonged		Anoxic Encephalopathy		Lasix (Furosemide)	C		ORAL
14	YR						
		Cardiac Failure		Synthroid	C		
UNKNOWN							
		Congestive					
		Cardio-Respiratory Arrest					
		Cataract					
		Cerebrovascular Accident					
		Death					
		Depression					
		Emotional Distress					
		Glaucoma					
		Leukopenia					
		Myelodysplastic Syndrome					
		Palpitations					
		Pneumonia					
		Pulmonary Oedema					
		Respiratory Failure					
		Tachycardia					

Date:06/07/05ISR Number: 4683928-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02078
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Death	Abdominal Pain

Hospitalization - Initial or Prolonged	Acute Respiratory Distress Syndrome Aortic Valve Incompetence Bronchitis Cardiac Failure Congestive Cardio-Respiratory Arrest Cardiomegaly Cerebral Infarction Collapse Of Lung Dyspepsia Dyspnoea Dyspnoea Exertional Emotional Distress Gastric Disorder Hypotension Hypoxia Mycobacterium Avium Complex Infection Myocardial Infarction Peptic Ulcer Pericardial Effusion Pneumonia

		Pulmonary Fibrosis Pulmonary Hypertension Right Ventricular Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Rifampin	C		
UNKNOWN				Sodium Chloride	C		
UNKNOWN				Oxycontin	C		
UNKNOWN				Zithromax	C		
UNKNOWN				Biaxin	C		
UNKNOWN				Ultravate	C		
UNKNOWN				Hydrocodone Bitartrate	C		
UNKNOWN				Bactroban	C		
UNKNOWN				Erythromycin	C		
UNKNOWN				Levaquin	C		
UNKNOWN				Ethambutol Hydrochloride	C		
UNKNOWN				Protopic	C		
UNKNOWN				Potassium Chloride	C		
UNKNOWN				Furosemide	C		
UNKNOWN				Gentamicin	C		
UNKNOWN				Enulose	C		
UNKNOWN				Prednisone	C		
UNKNOWN				Ventilan (Albuterol)	C		
UNKNOWN				Prilosec	C		
UNKNOWN				Amitriptyline			

UNKNOWN	Hydrochloride	C
UNKNOWN	Oxycodone	C
UNKNOWN	Amoxicillin	C
UNKNOWN	Cipro	C
UNKNOWN	Cephalexin	C
UNKNOWN	Norco	C
UNKNOWN	Celebrex	C
UNKNOWN	Metaproterenol Sulfate	C
UNKNOWN	Pentoxifylline	C
UNKNOWN	Ambien	C
UNKNOWN	Hydrochlorothiazide	C
UNKNOWN	Coumadin	C
UNKNOWN		

Date:06/07/05ISR Number: 4683930-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03473
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Anxiety
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Cardiac Disorder
	Cerebrovascular Accident
	Death
	Depression
	Disturbance In Attention
	Emotional Distress
	Fluid Retention
	Hypertension
	Leg Amputation
	Panic Attack
	Poor Peripheral Circulation
	Sleep Disorder

		Stress Suicidal Ideation Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
				Vioxx	SS	Merck & Co., Inc	ORAL
4	YR						
				Ambien	C		
UNKNOWN							
				Prinivil	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							

Date:06/07/05ISR Number: 4683931-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02227
Age:83 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
30	DAY						
Hospitalization -		Infarction		Triazolam	C		
UNKNOWN							
Initial or Prolonged		Anaemia		Aleve	C		
UNKNOWN							
		Anxiety		Ibuprofen	C		
UNKNOWN							
		Aspiration		Aspirin	C		
UNKNOWN							
		Azotaemia		Aspirin	C		
UNKNOWN							
		Bundle Branch Block Left		Tylenol	C		
UNKNOWN							
		Cachexia Candidiasis Cardiac Failure Congestive Cardiomyopathy Death Dehydration					

Diabetes Mellitus
Dysphagia
Hypoxia
Nephrolithiasis
Pain
Pancytopenia
Pneumonia
Pulmonary Fibrosis
Renal Failure
Renal Failure Acute
Respiratory Failure
Rheumatoid Lung
Urinary Tract Infection

Date:06/07/05ISR Number: 4683932-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01003
Age:86 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Cardiomyopathy
Hospitalization - Initial or Prolonged	Confusional State
	Coronary Artery Disease
	Ejection Fraction Decreased
	Gastrointestinal Disorder
	Glycosylated Haemoglobin Increased
	Hyponatraemia
	Memory Impairment
	Mitral Valve Incompetence
	Sensory Disturbance

	Transient Ischaemic Attack						
	Tricuspid Valve Incompetence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Humalog	C			UNKNOWN
			Humalog	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN
			Lantus	C			UNKNOWN
			Zocor	C		ORAL	
			Norvasc	C		ORAL	
			Vasotec	C		ORAL	
			Coreg	C			UNKNOWN
			Diazide	C			UNKNOWN
			Xanax	C			UNKNOWN
			Desyrel	C			UNKNOWN

Date:06/07/05ISR Number: 4683933-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 61 YR	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged 146 DAY	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Blood Calcium Decreased		Atenolol	C			UNKNOWN
	Bradycardia		Aspirin	C			UNKNOWN
	Brain Neoplasm Malignant		Pravachol	C			UNKNOWN
	Colon Cancer Stage Iii		Zocor	C		ORAL	

	Colonic Polyp		Tylenol	C		
UNKNOWN						
	Decreased Appetite		Ibuprofen	C		
UNKNOWN						
	Deep Vein Thrombosis		Piroxicam	C		ORAL
	Gastritis					
	Gastrointestinal					
	Haemorrhage					
	Hypoparathyroidism					
	Iron Deficiency Anaemia					
	Lung Neoplasm					
	Myocardial Infarction					
	Pulmonary Embolism					
	Thyroid Cancer Metastatic					
	Upper Respiratory Tract					
	Infection					

Date:06/07/05ISR Number: 4683934-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02073
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Electrocardiogram St		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Segment Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastric Ulcer		Tylenol	C		
UNKNOWN						
	Gastrointestinal					
	Haemorrhage					
	Hypomagnesaemia					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4683936-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02897
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Living Impaired		Vioxx	SS	Merck & Co., Inc	ORAL
	Acute Myocardial		Ery-Tab	C		
UNKNOWN						
	Infarction		Ventolin (Albuterol)	C		
UNKNOWN						
	Angina Unstable		Hydrocodone			
	Asthenia		Bitartrate	C		
UNKNOWN						
	Blood Cholesterol		Lamisil	C		
UNKNOWN						
	Increased					
	Chest Pain					
	Coronary Artery					
	Atherosclerosis					
	Coronary Artery Disease					
	Depression					
	Emotional Distress					
	Hyperlipidaemia					
	Hypertension					
	Impaired Work Ability					
	Non-Consummation					
	Osteoarthritis					

Date:06/07/05ISR Number: 4683943-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02361
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
3 YR						
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
3 YR						
Other	Blood Cholesterol		Metformin	C		
UNKNOWN						
	Increased		Glipizide	C		
UNKNOWN						
	Chest Pain		Lisinopril	C		
UNKNOWN						
	Chronic Fatigue Syndrome		Amitriptyline			

	Coronary Artery Disease		Hydrochloride	C		
UNKNOWN						
	Diabetes Mellitus		Paxil	C		
UNKNOWN						
	Dyspnoea		Ipratropium Bromide	C		
UNKNOWN						
	Emotional Distress					
	Hypertension					
	Influenza					
	Myocardial Infarction					
	Pain					

Date:06/07/05ISR Number: 4683944-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00360
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
394 DAY								
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Tamoxifen Citrate	C				
UNKNOWN								
	Dizziness		Hydrea	C				
UNKNOWN								
	Dyspnoea		Aspirin	C		ORAL		
	Emotional Distress							
	Phlebitis Superficial							
	Renal Impairment							
	Tendonitis							
	Venous Insufficiency							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4683947-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00736
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	

Date:06/07/05ISR Number: 4683951-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02382
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acne
Disability	Adrenal Mass
Other	Alcoholism
	Alpha Haemolytic Streptococcal Infection
	Angina Pectoris
	Anorexia
	Anxiety
	Bacteraemia
	Bacteroides Infection
	Blood Cholesterol Increased
	Blood Sodium Increased
	Cardiac Failure
	Cardiac Failure Congestive
	Chest Pain
	Chills
	Congestive Cardiomyopathy
	Cough
	Dehydration
	Diabetes Mellitus Inadequate Control
	Diabetic Coma
	Diarrhoea
	Dizziness
	Dyspepsia
	Emotional Distress
	Eye Pain
	Gastrooesophageal Reflux Disease
	Heart Rate Irregular
	Hyperhidrosis

Hyperlipidaemia
Hypertension
Hypomagnesaemia
Insomnia
Liver Abscess
Muscle Spasms
Myocardial Infarction
Nasal Congestion
Obesity
Osteoarthritis
Panic Disorder
Platelet Count Decreased
Pyrexia
Restless Legs Syndrome
Sinus Tachycardia
Sleep Apnoea Syndrome
Supraventricular
Tachycardia

	Sweat Gland Infection						
	Syncope						
	Upper Limb Fracture	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Glucophage	C				
UNKNOWN								

Date:06/07/05ISR Number: 4683952-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00694
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
1221 DAY								

Date:06/07/05ISR Number: 4683958-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02307
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
17 MON								
Initial or Prolonged	Infarction		Aspirin	C				
UNKNOWN								
	Chest Discomfort		Prevacid	C				
UNKNOWN								
	Coronary Artery Disease							
	Dyspepsia							
	Emotional Distress							
	Fatigue							
	Hypercholesterolaemia							
	Hypertension							
	Ulcer Haemorrhage							

Date:06/07/05ISR Number: 4683959-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02672
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1832 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1832 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		1832 DAY
	Coronary Artery Disease							
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Essential Hypertension							
	Gastrooesophageal Reflux Disease							
	Musculoskeletal Discomfort							
	Oral Fungal Infection							
	Palpitations							
	Pleurisy							
	Pruritus							
	Sleep Apnoea Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4683960-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02313
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure		Hydrocodone Bitartrate	C				
	Congestive							
UNKNOWN	Chronic Obstructive		Lisinopril	C				
UNKNOWN	Pulmonary Disease		Lisinopril	C				
UNKNOWN	Convulsion		Aspirin	C		ORAL		
	Dyspepsia		Zocor	C		ORAL		
	Dyspnoea		Naproxen	C				
UNKNOWN	Emotional Distress		Cefcapene Pivoxil Hydrochloride	C				
	Gastrooesophageal Reflux							
UNKNOWN	Disease		Famotidine	C				
UNKNOWN	Hypoglycaemia							
	Loss Of Consciousness							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Pulmonary Embolism							
	Renal Cell Carcinoma							
	Stage Unspecified							
	Renal Failure							
	Renal Mass							
	Syncope							
	Tricuspid Valve Incompetence							

Date:06/07/05ISR Number: 4683961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03358
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/07/05ISR Number: 4683962-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02229
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Other	Blood Homocysteine Increased
	Cardiac Failure Congestive
	Cardiogenic Shock
	Cardiomegaly
	Cardiomyopathy
	Coronary Artery Disease
	Ejection Fraction Decreased
	Emotional Distress
	Hypertension
	Leukocytosis
	Mitral Valve Incompetence
	Myocardial Infarction
	Orthopnoea
	Palpitations
	Pulmonary Hypertension
	Rash
	Tricuspid Valve

	Incompetence						
	Weight Increased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	3	WK
			Flexeril	C		ORAL		
			Naproxen	C		ORAL		

Date:06/07/05ISR Number: 4683963-9Report Type:Expedited (15-DaCompany Report #BR-MERCK-0506BRA00010
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiomegaly							
	Fatigue							

Date:06/07/05ISR Number: 4683964-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02232
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL	1024	DAY
	Second Degree		Zyrtec	C			UNKNOWN	
	Cardiac Disorder		Estrace	C			UNKNOWN	
	Cardiomegaly							
	Cholelithiasis							
	Dizziness							
	Emotional Distress							
	Oedema Peripheral							
	Pulmonary Granuloma							
	Subclavian Artery							
	Thrombosis							
	Thrombosis							

Date:06/07/05ISR Number: 4683966-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02948
Age:32 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Back Pain
	Balance Disorder
	Chest Pain
	Chronic Fatigue Syndrome
	Dizziness
	Dyspnoea
	Fibromyalgia
	Gastric Disorder
	Haematochezia
	Insomnia
	Mitral Valve Incompetence
	Myocardial Infarction
	Nausea
	Nervous System Disorder
	Nervousness
	Nocturia
	Osteoarthritis
	Pain
	Pericarditis
	Rash

	Road Traffic Accident						
	Sleep Apnoea Syndrome						
	Swelling	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Oxycontin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Bextra	C			UNKNOWN	
			Elavil	C			UNKNOWN	
			Mobic	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

Date:06/07/05ISR Number: 4683976-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00847
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Cerebrovascular Accident		Nitroglycerin	C			UNKNOWN	
	Chronic Obstructive		Zocor	C		ORAL		
	Pulmonary Disease		Plavix	C		ORAL		
	Coronary Artery Disease		Prinivil	C		ORAL		
	Cough		Amitriptyline					
	Depression		Hydrochloride	C			UNKNOWN	
	Excoriation		Pentoxifylline	C		ORAL		
	Heart Rate Increased		Metoclopramide	C		ORAL		
	Memory Impairment		Metoclopramide	C		ORAL		
	Polytraumatism		Bextra	C		ORAL		
	Renal Failure Chronic		Tizanidine					
	Transient Ischaemic		Hydrochloride	C		ORAL		

Attack
Ventricular Tachycardia

Date:06/07/05ISR Number: 4683977-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02896
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Blood Pressure Inadequately Controlled
	Bundle Branch Block Right
	Chest Discomfort
	Chest Pain
	Constipation
	Dizziness
	Drug Intolerance
	Dyslipidaemia
	Dyspepsia
	Dysphagia
	Emotional Distress
	Enzyme Abnormality
	Fatigue
	Hiatus Hernia
	Hyperlipidaemia
	Hypertension
	Hypertensive Heart

		Disease					
		Hypothyroidism					
		Joint Swelling					
		Musculoskeletal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
5	YR						
		Myocardial Ischaemia		Norvasc	SS		
UNKNOWN							
		Nausea		Zocor	SS		
UNKNOWN							
		Oedema Peripheral		Clonidine	SS		
UNKNOWN							
		Pruritus		Tenex	C		
UNKNOWN							
		Ventricular Dysfunction		Tenex	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Aciphex	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							

Date:06/07/05ISR Number: 4684019-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02287
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR					
Initial or Prolonged	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR					
	Atrophy		Cardizem	C		
UNKNOWN						
	Cardiomegaly		Cozaar	C		
UNKNOWN						
	Carotid Artery Stenosis		Aspirin	C		
UNKNOWN						
	Cerebral Infarction					
	Cerebrovascular Accident					
	Chronic Obstructive					
	Pulmonary Disease					
	Coronary Artery Disease					

Emotional Distress
Gout
Myocardial Infarction
Pain
Paraesthesia
Sinusitis
Syncope
Thrombosis

Date:06/07/05ISR Number: 4684687-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02567
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		1044 DAY
Initial or Prolonged	Fall		Norvasc	C				UNKNOWN
	Fracture		Prempro	C			50 MON	UNKNOWN
	Joint Injury		Fosamax	C				UNKNOWN
	Joint Sprain		Valium	C				UNKNOWN
	Myocardial Infarction		A.S.A.	C		ORAL		
	Treatment Noncompliance							

Date:06/07/05ISR Number: 4684688-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00072
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		63 DAY
Hospitalization -	Haemorrhage		Lipitor	C				UNKNOWN
Initial or Prolonged	Loss Of Consciousness							
	Mouth Haemorrhage							
	Rectal Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4684689-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00596
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				
UNKNOWN								

Date:06/07/05ISR Number: 4684691-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02400
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Lung Cancer Metastatic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Metastases To Central		Prilosec	C				
UNKNOWN								
	Nervous System		Synthroid	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Lisinopril	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Combivent	C				
UNKNOWN								

Date:06/07/05ISR Number: 4684692-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00592
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/07/05ISR Number: 4684694-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00033
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Erythema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Leukocytoclastic Vasculitis		Valpromide	C		ORAL		
	Oedema Peripheral		Triptorelin Acetate	C		ORAL		
	Purpura		Sertraline Hydrochloride	C			UNKNOWN	
			Bicalutamide	C			UNKNOWN	
			Rabeprazole Sodium	C			UNKNOWN	
			Oxazepam	C			UNKNOWN	
			Zopiclone	C			UNKNOWN	

Date:06/07/05ISR Number: 4684705-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/07/05ISR Number: 4684706-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00875
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4684707-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0506FRA00007
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Osteoarthritis		Fenofibrate	C		ORAL		
	Paroxysmal Arrhythmia							

Date:06/07/05ISR Number: 4684710-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00877
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/07/05ISR Number: 4684711-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01923
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		16 MON
Initial or Prolonged	Cerebral Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							
	Emotional Distress							
	Headache							
	Hypercholesterolaemia							
	Intracranial Aneurysm							
	Joint Injury							
	Knee Operation							
	Myocardial Infarction							
	Pharyngolaryngeal Pain							

Date:06/07/05ISR Number: 4684712-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/07/05ISR Number: 4684713-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00749
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:06/07/05ISR Number: 4684714-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00748
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:06/07/05ISR Number: 4684715-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/07/05ISR Number: 4685777-2Report Type:Direct Company Report #CTU 250595
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abasia		Vioxx (Merck)	PS	Merck		25-50 MG 1-2X	
Initial or Prolonged	Ischaemic Stroke						DAILY	

Date:06/07/05ISR Number: 4687030-XReport Type:Expedited (15-DaCompany Report #WAES 0402GBR00183
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation	Foreign	Tab Vioxx					
Hospitalization -	Malaise	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY,	
Initial or Prolonged	Ventricular Dysfunction	Health					PO	152 DAY
		Professional	Amlodipine Besylate	C				

Date:06/08/05ISR Number: 4685343-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02703
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		767 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		767 DAY
Initial or Prolonged	Anorexia		Vioxx	SS		ORAL		767 DAY
	Asthenia		Vioxx	SS		ORAL		767 DAY
	Blood Glucose Increased		Vaseretic	C		ORAL		
	Carotid Artery Stenosis		Tylenol	C				UNKNOWN
	Chest X-Ray Abnormal		Advil	C				UNKNOWN
	Chills		Toprol Xl Tablets	C				UNKNOWN
	Constipation		Methadone					

Coronary Artery Stenosis Hydrochloride C
UNKNOWN

Dizziness
Emotional Distress
Hyperhidrosis
Hyperlipidaemia
Inflammation
Leukocytosis
Metabolic Syndrome
Oedema Peripheral
Osteoarthritis
Pain
Pyrexia
Renal Failure
Respiratory Distress
Sinus Tachycardia
Tachycardia

Date:06/08/05ISR Number: 4685347-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01776
Age:74 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

PT
Anxiety
Atrioventricular Block
First Degree
Blood Cholesterol
Increased
Chest Pain
Constipation
Dyspnoea Exertional
Gastric Disorder

	Hypertension Intestinal Obstruction Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Supraventricular		Vioxx	PS	Merck & Co., Inc	ORAL	979	DAY
	Extrasystoles		Vioxx	SS	Merck & Co., Inc	ORAL	979	DAY
	Ventricular Extrasystoles		Norvasc	C			UNKNOWN	
			Hydrodiuril	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Advil	C			UNKNOWN	

Date:06/08/05ISR Number: 4685356-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685416-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00610
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:06/08/05ISR Number: 4685417-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00745
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
79 DAY						
	Gastric Ulcer					
	Polytraumatism					

Date:06/08/05ISR Number: 4685418-4Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00021
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
6 DAY						
Initial or Prolonged						

Date:06/08/05ISR Number: 4685419-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02565
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Prerenal Failure
Initial or Prolonged	Angina Pectoris
Other	Angina Unstable
	Aortic Stenosis
	Aortic Valve Incompetence
	Bacteria Urine Identified
	Blood Cholesterol Increased
	Blood Pressure Increased
	Blood Pressure Systolic Increased
	Blood Triglycerides

		Increased Cardiac Murmur Cellulitis Chest Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
22	MON						
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Dementia		Prempro	C		
UNKNOWN							
		Depression		Questran	C		
UNKNOWN							
		Dilatation Atrial		Mylanta & Mylanta Ds	C		
UNKNOWN							
		Electrocardiogram St		Protonix	C		
UNKNOWN							
		Segment Elevation Hyponatraemia Hypotension Inappropriate Antidiuretic Hormone Secretion Mitral Valve Calcification Mitral Valve Incompetence Myocardial Infarction Myocardial Ischaemia Platelet Aggregation Increased Pleural Effusion Tachycardia Tricuspid Valve Incompetence Urine Output Decreased Weight Increased					

Date:06/08/05ISR Number: 4685420-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00602
Age:71 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Renal Injury		Estrogens (Unspecified)	C		
UNKNOWN							

Date:06/08/05ISR Number: 4685421-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00723
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685422-6Report Type:Expedited (15-DaCompany Report #IT-MERCK-0505ITA00022
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Colitis Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged			Cyclosporine	C		ORAL		UNKNOWN
			Corticosteroids (Unspecified)	C				
			Ramipril	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685423-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02236
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1096 DAY
	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		1096 DAY
	Atherosclerosis							
	Emotional Distress							

Date:06/08/05ISR Number: 4685427-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00841
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		479 DAY

Date:06/08/05ISR Number: 4685433-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00843
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		344 DAY
Other	Death							

Date:06/08/05ISR Number: 4685434-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00756
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Fatigue		Zoloft	C				UNKNOWN
	Hypersomnia		Levoxyl	C				UNKNOWN
	Hypertension		Analgesic Or					

Anesthetic
(Unspecified) C
UNKNOWN

Date:06/08/05ISR Number: 4685435-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00837
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	28	MON

Date:06/08/05ISR Number: 4685436-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00746
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685456-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00720
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685629-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0412GBR00086
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bundle Branch Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Orlistat	C				
			[Therapy Unspecified]	C				

Date:06/08/05ISR Number: 4685630-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00045
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		751 DAY
Initial or Prolonged	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL		341 DAY
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides		Naproxen	C				
	Increased		Desyrel	C		ORAL		
	Bronchitis		Desyrel	C		ORAL		
	Carotid Artery Occlusion		Viagra	C		ORAL		
	Carotid Artery Stenosis		Zocor	C		ORAL		
	Cerebral Infarction		Aggrenox	C		ORAL		
	Cerebral Ischaemia		Klonopin	C		ORAL		
	Cerebrovascular Accident		Chondroitin	C				
	Chronic Obstructive		Glucosamine	C				
	Pulmonary Disease		Tylenol Sinus	C				
	Confusional State		Trazodone					
	Depression		Hydrochloride	C				
	Dilatation Atrial							
	Dizziness							
	Drug Screen Positive							
	Fall							
	Full Blood Count							

Increased
Hyperlipidaemia
Hypoaesthesia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Swelling
Low Density Lipoprotein
Increased
Mitral Valve Incompetence
Nausea
Restless Legs Syndrome
Sinusitis
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence
Ventricular Hypertrophy

Date:06/08/05ISR Number: 4685631-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age:65 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	726	DAY
Aortic Valve Disease		Levoxyl	C			UNKNOWN	
Atherosclerosis		Hydrochlorothiazide	C			UNKNOWN	
Atrial Fibrillation		Cardizem	C			UNKNOWN	
Blood Cholesterol		Lovastatin	C			UNKNOWN	
Increased		Premarin	C			UNKNOWN	
Cardiac Failure							
Congestive							
Cardiac Valve Disease							
Coronary Artery							
Atherosclerosis							
Coronary Artery Disease							
Gallbladder Disorder							
Heart Rate Irregular							
Hypertension							
Injury							
Myocardial Infarction							
Nausea							
Urinary Tract Infection							
Vomiting							

Date:06/08/05ISR Number: 4685633-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00611
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Phenprocoumon	C			UNKNOWN	
	Dysphagia		Levetiracetam	C			UNKNOWN	
	Dyspnoea Exertional		Tizanidine					
	Epilepsy		Hydrochloride	C			UNKNOWN	

	Nystagmus	Tizanidine		
	Pupils Unequal	Hydrochloride	C	ORAL
	Syncope	Atorvastatin Calcium	C	
UNKNOWN				
	Transient Ischaemic Attack			
	Venous Thrombosis Limb			
	Vertebral Artery Occlusion			

Date:06/08/05ISR Number: 4685637-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00093
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Death	Acute Respiratory Distress Syndrome
Hospitalization - Initial or Prolonged	Cardio-Respiratory Arrest
	Dyspepsia
	Gastric Haemorrhage
	Gastric Perforation
	Gastric Ulcer
	Gastrooesophageal Reflux Disease
	Haematochezia
	Loss Of Consciousness
	Myocardial Infarction

		Oedema Peripheral Pancreatitis Acute Renal Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Lipitor	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Prednisolon	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Folic Acid	C		
UNKNOWN							
				Diltiazem Hydrochloride	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Ketoconazole	C		
UNKNOWN							

Date:06/08/05ISR Number: 4685641-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00838
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL
				Norvasc	C		
UNKNOWN	2823 DAY						
		Cerebrovascular Accident		Lipitor	C		
UNKNOWN							
		Diabetes Mellitus		Zocor	C		
UNKNOWN							
		Emotional Distress		Zoloft	C		
UNKNOWN							
		Multiple Sclerosis Physical Disability					

Pneumonia
Polytraumatism
Speech Disorder

Date:06/08/05ISR Number: 4685642-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01747
Age:47 YR Gender:Female I/FU:F

Outcome PT
Other Abdominal Pain Upper
Anorexia
Anxiety
Arrhythmia
Atherosclerosis
Blood Cholesterol
Increased
Cardiac Disorder
Cardiac Murmur
Cardiac Valve Disease
Cerebrovascular Accident
Chest Pain
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coronary Artery Disease
Depression
Diarrhoea
Gastrooesophageal Reflux
Disease
Glaucoma
Haematochezia
Insomnia

		Intestinal Mass					
		Myocardial Infarction					
		Nausea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
		Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Suicidal Ideation		Atenolol	C		
UNKNOWN							
		Syncope		Vicodin Tablets	C		
UNKNOWN							
		Weight Decreased		Oxycontin	C		
UNKNOWN							
		Weight Increased					

Date:06/08/05ISR Number: 4685643-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00563
Age:45 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Blindness		Vioxx	PS	Merck & Co., Inc	ORAL
574 DAY							
		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
574 DAY							
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
574 DAY							
		Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL
574 DAY							
				Motrin	C		
UNKNOWN		16 DAY					

Date:06/08/05ISR Number: 4685644-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00705
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
5 MON							
		Myocardial Infarction					
		Organ Failure					
		Pulmonary Embolism					
		Thrombosis					

Date:06/08/05ISR Number: 4685645-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685646-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00740
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685647-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00137
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Arrest							
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Depression							
	Lethargy							
	Life Expectancy Shortened							
	Mental Disorder							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685648-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02001
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cardiac Murmur		Lipitor	C		ORAL
	Carotid Artery Occlusion		Aspirin	C		ORAL
	Carotid Artery Stenosis		Aggrenox	C		ORAL
	Carotid Bruit		Fosamax	C		ORAL
	Cerebrovascular Accident		Zantac	C		ORAL
	Cervical Myelopathy		Tylenol	C		ORAL
	Confusional State		Glucosamine Sulfate	C		ORAL
	Dizziness		Calcium Citrate And			
	Emotional Distress		Cholecalciferol	C		ORAL
	Erectile Dysfunction		Hydrodiuril	C		ORAL
	Exostosis		[Therapy			
	Fall		Unspecified]	C		
UNKNOWN						
	Haemorrhoids					
	Hypertension					
	Mediastinal Mass					
	Myocardial Infarction					
	Paraesthesia					
	Polymyalgia					
	Renal Failure					
	Thrombosis					
	Transient Ischaemic					
	Attack					
	Viral Infection					

Date:06/08/05ISR Number: 4685649-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blood Cholesterol		Oxybutynin Chloride	C		ORAL
Initial or Prolonged	Increased		Amantadine Sulfate	C		ORAL
Disability	Chest Discomfort		Levocarnitine			
	Condition Aggravated		Tartrate	C		
UNKNOWN						
	Coronary Artery Disease		Sodium Lauryl			

Depression Sulfoacetate C
RECTAL
Dyspepsia
Dysphagia
Dyspnoea
Hypertension
Multiple Sclerosis
Myocardial Infarction

Date:06/08/05ISR Number: 4685650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01894
Age:46 YR Gender:Male I/FU:F

Outcome PT
Disability Angina Pectoris
Cardiac Failure
Congestive
Cardiac Valve Disease
Deep Vein Thrombosis
Dyspnoea
Emotional Distress
Heart Injury

	Heart Rate Irregular						
	Hypertension						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	5 DAY
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	

Date:06/08/05ISR Number: 4685651-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02856
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	521 DAY	
Initial or Prolonged	Chest Pain		Synthroid	C			UNKNOWN	
Disability	Coronary Artery Disease		Synthroid	C			UNKNOWN	
Other	Depression		Phenobarbital	C			UNKNOWN	
	Emotional Distress							
	Fatigue							
	Hypercholesterolaemia							
	Hypertension							
	Hypertensive Crisis							
	Myocardial Infarction							
	Retroperitoneal Haematoma							
	Ventricular Hypertrophy							

Date:06/08/05ISR Number: 4685653-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA03352
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Adjustment Disorder
	Angina Pectoris
	Angina Unstable

Anxiety
Aspiration
Asthenia
Atherosclerosis
Atrial Fibrillation
Back Pain
Blood Cholesterol
Increased
Blood Triglycerides
Increased
Bradycardia
Cardiac Arrest
Cardio-Respiratory Arrest
Chest Pain
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Stenosis
Crying
Depressed Level Of
Consciousness
Depression
Dysthymic Disorder
Ejection Fraction
Decreased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Emotional Distress					
		Gastritis					
		Haematemesis					
		Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL
297 DAY							
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
297 DAY							
		Hypertension		Aspirin	SS		
UNKNOWN							
		Impaired Work Ability		Plavix	SS		
UNKNOWN							
	1 YR						
		Intervertebral Disc		Heparin	SS		
INTRAVENOUS							
		Protrusion		Monopril	C		
UNKNOWN							
		Lethargy		Metoprolol	C		
UNKNOWN							
		Low Density Lipoprotein		Lipitor	C		
UNKNOWN							
		Decreased		Niacin	C		
UNKNOWN							
		Lumbar Radiculopathy		Analgesic Or Anesthetic (Unspecified)	C		
		Myocardial Infarction					
		Nerve Root Injury					
UNKNOWN							
		Nervous System Disorder		Zoloft	C		
UNKNOWN							
		Pericardial Effusion		Vicodin Tablets	C		
UNKNOWN							
	339 DAY						
		Prothrombin Time		Celebrex	C		
UNKNOWN							
		Shortened					
		Refusal Of Treatment By Patient					
		Sexual Dysfunction					
		Stress					
		Thrombosis					
		Tricuspid Valve Incompetence					
		Upper Gastrointestinal Haemorrhage					
		Ventricular Fibrillation					
		Ventricular Hypertrophy					

Date:06/08/05ISR Number: 4685654-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02380
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	145 MON	
Other	Cardiac Enzymes Increased		Lisinopril	C			UNKNOWN	
	Chest Pain		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Chronic Fatigue Syndrome							
	Death							
	Depression							
	Fluid Retention							
	Haemoglobin Decreased							
	Hypertension							
	Liver Function Test Abnormal							
	Mitral Valve Incompetence							
	Muscle Spasms							
	Pain							
	Panic Disorder							
	Pulmonary Hypertension							
	Renal Failure Acute							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685655-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02279
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		163 MON
Initial or Prolonged	Anxiety		Serevent	C				UNKNOWN
Other	Cerebrovascular Accident		Albuterol	C				UNKNOWN
	Chest Pain		Atrovent	C				UNKNOWN
	Complicated Migraine							
	Depression							
	Drug Hypersensitivity							
	Dyspnoea							
	Emotional Distress							
	Myocardial Infarction							
	Status Migrainosus							
	Transient Ischaemic Attack							

Date:06/08/05ISR Number: 4685656-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03919
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
	Road Traffic Accident							

Date:06/08/05ISR Number: 4685657-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00495
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Hospitalization -	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:06/08/05ISR Number: 4685658-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00735
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685659-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685660-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00099
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Acute Myocardial Infarction Angina Unstable Coronary Artery Occlusion

Depression
Mitral Valve Incompetence
Pulmonary Hypertension

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		1140 DAY

Date:06/08/05ISR Number: 4685661-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02398
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1172 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1172 DAY
Other	Cerebrovascular Accident		Ranitidine	C				UNKNOWN
	Depression		Hytrin	C				UNKNOWN
	Myocardial Infarction		Plendil	C				UNKNOWN
	Oedema Peripheral		Lipitor	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Plavix	C				UNKNOWN
			Metoprolol	C			415 DAY	UNKNOWN
			Nitroquick	C				UNKNOWN
			Diovan	C				UNKNOWN
			Zyrtec	C				UNKNOWN
			Diurex (Hydrochlorothiazide)	C				UNKNOWN

Date:06/08/05ISR Number: 4685662-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:06/08/05ISR Number: 4685663-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00857
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:06/08/05ISR Number: 4685666-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00847
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685667-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:06/08/05ISR Number: 4685668-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/05ISR Number: 4685670-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00863
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685684-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01773
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/08/05ISR Number: 4685686-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03516
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Ultracet	SS		ORAL		

Date:06/08/05ISR Number: 4686818-9Report Type:Expedited (15-DaCompany Report #WAES 0505USA01702
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Ischaemia	Study	Tab Vioxx	PS		ORAL	PO	
Initial or Prolonged	Headache	Health	Nolvadex 20 Mg	SS		ORAL	20	
		Professional					MG/DAILY/PO	
			Asacol	C				

			Azmacort	C		
			Diovan	C		
			Prilosec	C		
			Singulair	C		
			Xalatan	C		
			Albuterol	C		
			Hydrochlorothiazide	C		

Date:06/08/05ISR Number: 4687063-3Report Type:Expedited (15-DaCompany Report #2005077695
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Body Height Decreased	Consumer	Neurontin (Gabapentin)	PS			100 MG (100 MG, 1 IN 1 D)	
	Constipation							
Other	Dizziness							
	Drug Ineffective		Bextra (Valdecoxib)	SS				
	Feeling Abnormal		Motrin (Ibuprofen)	SS				
	Gastritis		Fentanyl (Fentanyl)	SS				
	Impaired Driving Ability		Vioxx (Rofecoxib)	SS				
	Muscle Spasms		Advil (Ibuprofen)	SS				
	Nausea		Aleve (Naproxen Sodium)	C				
	Paralysis							
	Pruritus		Levoxyl (Levothyroxine					
	Somnolence							

TRANSDERMAL BACK PAIN

			Sodium)	C		
			All Other Therapetuic Rpdoucts (All Other Therapeutic Products)	C		

Date:06/08/05ISR Number: 4687145-6Report Type:Expedited (15-DaCompany Report #2005079681
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bacterial Infection	Consumer	Celebrex (Celecoxib)	PS		ORAL	1 IN 1 D),	
	Drug Ineffective					ORAL		
	Gastric Infection		Vioxx (Refecoxib)	SS		ORAL	ORAL	
	Joint Arthroplasty		Calcium (Calcium)	C				
	Osteoporosis							

Date:06/08/05ISR Number: 4687366-2Report Type:Expedited (15-DaCompany Report #2005080946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal	Consumer	Celebrex (Celecoxib)	PS				
	Drug Ineffective		Bextra (Valdecoxib)	SS				
Other	Erectile Dysfunction		Viagra (Sildenafil)	SS				
	Loose Body In Joint		Vioxx (Rofecoxib)	SS				
	Neuropathy Peripheral		Mobic (Meloxicam)	SS				
	Renal Cell Carcinoma		Thyroid Hormones (Thyroid Hormones)	C				
	Stage Unspecified		Antihypertensives (Antihypertensives)	C				
			Lipitor (Atorvastatin)	C				

Date:06/08/05ISR Number: 4688023-9Report Type:Expedited (15-DaCompany Report #2004116207
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)	PS				
	Chest Pain		Vioxx (Rofecoxib)	SS				
	Neoplasm Malignant							
	Nocturnal Dyspnoea							
	Pain							
	Spinal Disorder							
	Surgery							
	Ulcer							

Date:06/09/05ISR Number: 4686132-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00275
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL	1634 DAY	
	Anxiety		Methimazole	C		ORAL		
	Arrhythmia							
	Cold Sweat							
	Gastritis							
	Hyperthyroidism							
	Palpitations							
	Reflux Oesophagitis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4686135-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0305USA01814
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Oedema		Vioxx	PS	Merck & Co., Inc	ORAL	24	DAY
Other	Cardio-Respiratory Arrest		Vicoprofen	C			UNKNOWN	
	Cardiomegaly		Methocarbamol	C			UNKNOWN	
	Coronary Artery Atherosclerosis							
	Coronary Artery Thrombosis							
	Myocardial Infarction							
	Pulmonary Oedema							
	Splenomegaly							
	Sudden Death							
	Ventricular Fibrillation							

Date:06/09/05ISR Number: 4686144-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02517
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrioventricular Block First Degree		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vasotec	C			UNKNOWN	
Other	Bronchitis		Ticlid	C			UNKNOWN	
	Cardiac Failure		Norvasc	C			UNKNOWN	
	Cardiac Failure		Atrovent	C			UNKNOWN	
	Congestive		K-Dur	C			UNKNOWN	
	Cardiac Valve Disease		Aspirin	C			UNKNOWN	
	Cardiogenic Shock		Lasix (Furosemide)	C			UNKNOWN	
	Cardioversion		Celebrex	C			UNKNOWN	

	Cerebrovascular Accident	Lopressor	C
UNKNOWN			
	Chronic Fatigue Syndrome		
	Chronic Obstructive		
	Pulmonary Disease		
	Coronary Artery Disease		
	Depression		
	Dilatation Atrial		
	Dilatation Ventricular		
	Dyspnoea		
	Emotional Distress		
	Epistaxis		
	Fatigue		
	Hypercholesterolaemia		
	Hypersensitivity		
	Hypokinesia		
	Insomnia		
	Ischaemic Cardiomyopathy		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Pulmonary Hypertension		
	Sinus Bradycardia		
	Sleep Apnoea Syndrome		
	Tricuspid Valve		
	Incompetence		
	Ventricular Dysfunction		
	Ventricular Hypertrophy		
	Weight Decreased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4686145-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02035
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Zocor	C				
UNKNOWN								
	Emotional Distress							

Date:06/09/05ISR Number: 4686146-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00744
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686147-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02690
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Aspirin	C				
UNKNOWN								
	Infarction		Avapro	C				
UNKNOWN								
	Anxiety		Lopressor	C				
UNKNOWN								
	Cardiac Arrest		Lipitor	C				
UNKNOWN								
	Depression		Zocor	C		ORAL		
	Dizziness		Saw Palmetto					
	Gastritis		Standardized Extract	C				
UNKNOWN								
	Hiatus Hernia							
	Hypertension							
	Oedema							
	Postpericardiotomy							
	Syndrome							
	Weight Decreased							

Date:06/09/05ISR Number: 4686148-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02318
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Cardura	C				UNKNOWN
Other	Hernia		Proscar	C		ORAL		
	Stomach Discomfort		Zantac	C				UNKNOWN
	Transient Ischaemic Attack							

Date:06/09/05ISR Number: 4686149-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02358
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
	Cerebrovascular Accident
Other	Dizziness
	Emotional Distress
	Hyperhidrosis
	Hypertension
	Loss Of Consciousness
	Mental Disorder
	Nephrolithiasis
	Oesophageal Disorder

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Ultram	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Tylenol	C				UNKNOWN

Date:06/09/05ISR Number: 4686150-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00874
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686151-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00818
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686152-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02018
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1415 YR	Apraxia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Breast Microcalcification		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebellar Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Fluoxetine	C				UNKNOWN
	Colitis		Prevacid	C				UNKNOWN

UNKNOWN	Coordination Abnormal	Plavix	C
UNKNOWN	Diarrhoea Haemorrhagic	Albuterol	C
UNKNOWN	Disinhibition	Temazepam	C
UNKNOWN	Emotional Distress	Temazepam	C
UNKNOWN	Fall	Allegra	C
UNKNOWN	Fibrocystic Breast	Detrol	C
UNKNOWN	Disease	Asacol	C
UNKNOWN	Generalised Anxiety	Klor-Con	C
UNKNOWN	Disorder	Cozaar	C
UNKNOWN	Hypertension	Advair	C
UNKNOWN	Injury	Lasix (Furosemide)	C
UNKNOWN	Intestinal Haemorrhage	Lasix (Furosemide)	C
UNKNOWN	Lymphadenopathy	Wellbutrin	C
UNKNOWN	Mood Altered	Cardizem	C
UNKNOWN	Oedema Peripheral	Bupropion Hydrochloride	C
UNKNOWN	Sleep Disorder	Relafen	C
UNKNOWN	Wound	Prozac	C
UNKNOWN		Prempro	C
UNKNOWN		Claritin	C
UNKNOWN		Armour Thyroid Tablets	C
UNKNOWN		Potassium Chloride	C
UNKNOWN		K-Dur	C
UNKNOWN		Cartia Xt	C
UNKNOWN		Medroxyprogesterone Acetate	C
UNKNOWN			

			Theophylline	C		
UNKNOWN						
			Levothroid	C		
UNKNOWN						
			Uniphyl	C		
UNKNOWN						
			Prinivil	C		ORAL
			Tylenol	C		
UNKNOWN						

Date:06/09/05ISR Number: 4686153-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02020
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
919 DAY						
Hospitalization -	Cerebrovascular Disorder		Premarin	C		
UNKNOWN						
Initial or Prolonged	Coronary Artery Disease		Daypro	C		
UNKNOWN						
	Emotional Distress		Advil	C		
UNKNOWN	3 YR					
	Hepatomegaly		Tylenol	C		
UNKNOWN	3 YR					
	Hypertension		Zestril	C		
UNKNOWN	4 YR					
	Inflammation		Toprol Xl Tablets	C		
UNKNOWN	4 YR					
	Lymphadenopathy		[Therapy			
	Mediastinal		Unspecified]	C		
UNKNOWN						
	Myocardial Infarction					
	Pulmonary Embolism					
	Transient Ischaemic					
	Attack					

Date:06/09/05ISR Number: 4686158-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01030
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/09/05ISR Number: 4686169-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686841-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02659
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bundle Branch Block Right		Vioxx	PS	Merck & Co., Inc	ORAL	1071 MON	
Initial or Prolonged	Coronary Artery		Altace	C			UNKNOWN	
Disability	Atherosclerosis		Altace	C			UNKNOWN	
Other	Gastrooesophageal Reflux		Glucophage	C			UNKNOWN	
	Disease		Glucophage	C			UNKNOWN	
	Myocardial Infarction		Verapamil Msd Lp	C			UNKNOWN	
			Verapamil Msd Lp	C			UNKNOWN	
			Hydrochlorothiazide Tablets (Usp 23)	C			UNKNOWN	
			Hydrochlorothiazide Tablets (Usp 23)	C			UNKNOWN	
			K-Dur	C			UNKNOWN	
			K-Dur	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Nexium	C			UNKNOWN	

			Lipitor	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						

Date:06/09/05ISR Number: 4686845-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00998
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Bronchitis Acute		Prevacid	C		
UNKNOWN						
	Cerebellar Infarction		Allopurinol	C		
UNKNOWN						
	Dysuria					
	Epidermal Naevus					
	Haematospermia					
	Haemorrhoidal Haemorrhage					
	Micturition Urgency					
	Nephrolithiasis					
	Prostatism					
	Sinusitis					
	Vomiting					

Date:06/09/05ISR Number: 4686859-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02028
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
109 DAY						
Initial or Prolonged	Chest Pain		Paxil	C		
UNKNOWN						

Depression
Infection
Mental Status Changes
Myocardial Infarction
Oedema Peripheral
Staphylococcal Infection

Date:06/09/05ISR Number: 4686861-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01930
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx Cardura	SS C	Merck & Co., Inc	ORAL		
UNKNOWN								
Disability	Brain Stem Infarction Cerebral Infarction Emotional Distress Hepatic Steatosis Leukocytosis Liver Function Test Abnormal Neurological Symptom Neuropathy Peripheral Overdose Subclavian Artery Stenosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4686862-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02077
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Fosamax	C			UNKNOWN	2 WK
	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN	1462 DAY
	Nephrolithiasis							
	Peptic Ulcer							
	Skeletal Injury							

Date:06/09/05ISR Number: 4686863-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01755
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	242 YR	
Initial or Prolonged	Atrioventricular Block		Procardia	C			UNKNOWN	
	Second Degree		Hytrin	C			UNKNOWN	
	Cerebrovascular Accident		Prevacid	C			UNKNOWN	
	Coronary Artery Disease		Dipyridamole	C			UNKNOWN	
	Emotional Distress		Nifedipine	C			UNKNOWN	
	Fall		Tylenol	C			UNKNOWN	
	Gait Disturbance		Aspirin	C			UNKNOWN	

Date:06/09/05ISR Number: 4686865-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00847
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Anorexia	Vioxx	PS	Merck & Co., Inc	ORAL
45 MON					
Initial or Prolonged	Chronic Obstructive	Nitroglycerin	C		
UNKNOWN					
Disability	Pulmonary Disease	Zocor	C		ORAL
	Coronary Artery Disease	Plavix	C		ORAL
	Cough	Prinivil	C		ORAL
	Depression	Amitril	C		
UNKNOWN					
	Emotional Distress	Pentoxifylline	C		ORAL
	Excoriation	Metoclopramide	C		ORAL
	Heart Rate Increased	Metoclopramide	C		ORAL
	Memory Impairment	Bextra	C		ORAL
	Oedema Peripheral	Tizanidine			
	Renal Failure Chronic	Hydrochloride	C		ORAL
	Transient Ischaemic				
	Attack				
	Ventricular Tachycardia				

Date:06/09/05ISR Number: 4686880-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02070
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Benign Prostatic
Other	Hyperplasia
	Blood Cholesterol
	Increased
	Cerebrovascular Accident
	Chest Pain
	Convulsion
	Dysphagia
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Haematuria							
Hypoacusis							
Intervertebral Disc Degeneration		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON
Panic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	42	MON
Polyneuropathy		Amaryl	C			UNKNOWN	
Salivary Gland Calculus		Glucophage	C			UNKNOWN	
Transient Ischaemic Attack		Avandia	C			UNKNOWN	
		Allopurinol	C			UNKNOWN	
Urinary Tract Infection		Pravachol	C			UNKNOWN	
Ventricular Hypertrophy		Propoxyphene Hydrochloride	C			UNKNOWN	
Vertigo Positional		Vitamin E	C			UNKNOWN	
		Centrum Silver	C			UNKNOWN	
		Glucosamine	C			UNKNOWN	
		Chondroitin	C			UNKNOWN	
		Lipitor	C			UNKNOWN	
		Neurotonin Capsules	C			UNKNOWN	
		Lantus	C			UNKNOWN	

Date:06/09/05ISR Number: 4686881-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02447
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anaemia Postoperative		Allegra	C			UNKNOWN	

	Blood Glucose Increased		Hytrin	C		
UNKNOWN						
	Diarrhoea					
	Duodenal Ulcer					
	Perforation					
	Electrocardiogram St-T					
	Change					
	Fat Necrosis					
	Gastric Disorder					
	Hyperkalaemia					
	Hypoventilation					
	Hypoxia					
	Medication Error					
	Pain					
	Peritonitis					
	Pneumonia Aspiration					
	Sinus Tachycardia					
	Tension					
	Urinary Retention					
	Postoperative					
	Wound Dehiscence					

Date:06/09/05ISR Number: 4686883-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00067
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON
Initial or Prolonged	Hypertension		Atorvastatin Calcium	C		ORAL		
Disability			Omeprazole	C				
UNKNOWN								
			Allopurinol And Benzbromarone	C				
UNKNOWN								

Date:06/09/05ISR Number: 4686884-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02356
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		240 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		240 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		240 DAY
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		240 DAY
	Cough		Tylenol	C				UNKNOWN
	Depression		Tylenol Sinus	C				UNKNOWN
	Fear		Ibuprofen	C				UNKNOWN
	Hyperaemia							
	Mitral Valve Incompetence							
	Pneumothorax							
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							

Date:06/09/05ISR Number: 4686903-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00572
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fatigue							
Initial or Prolonged	Peritonitis							
Disability								

Date:06/09/05ISR Number: 4686904-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00085
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686905-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03340
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Adverse Event Cardiac Failure Congestive Epistaxis Myalgia Myocardial Infarction Pericardial Effusion Pharyngolaryngeal Pain Pleural Effusion Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686906-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00589
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Arterial Occlusive Disease Vascular Calcification		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4686907-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02966
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Nexium	C				
UNKNOWN								
Other	Emotional Distress							
	Fall							
	Haemorrhage							
	Hypertension							
	Loss Of Consciousness							
	Myocardial Infarction							
	Pulmonary Embolism							
	Transient Ischaemic Attack							

Date:06/09/05ISR Number: 4686908-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02369
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		1487 DAY
Initial or Prolonged	Acute Myocardial		Zestril	C				
UNKNOWN								
	Infarction		Hydrochlorothiazide	C				
UNKNOWN								
	Cardiogenic Shock		Cozaar	C		ORAL		
	Emotional Distress		Ibuprofen	C				
UNKNOWN								
	Ischaemic Hepatitis		Zoloft	C				
UNKNOWN								
	Metabolic Acidosis							
	Pneumonia							
	Renal Failure Acute							
	Respiratory Failure							
	Skin Papilloma							
	Thoracic Cavity Drainage							

Date:06/09/05ISR Number: 4686909-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02300
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Anxiety Bradycardia Cerebrovascular Accident Emotional Distress Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686910-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02213
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Arthropathy Balance Disorder Benign Neoplasm Of Thyroid Gland Breast Mass Breast Pain Cerebrovascular Accident Coordination Abnormal Deafness Deafness Neurosensory Deep Vein Thrombosis Diverticulum

		Dizziness					
		Emotional Distress					
		Goitre	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gynaecomastia		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Tenex	C		
UNKNOWN							
		Post Thrombotic Syndrome					
		Salivary Gland Adenoma					
		Thrombosis					
		Thyroid Disorder					
		Thyroid Neoplasm					
		Transient Ischaemic					
		Attack					
		Vertigo					

Date:06/09/05ISR Number: 4686911-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00661
Age:62 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -				Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Clarinex	C		
UNKNOWN							
				[Therapy			
				Unspecified]	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							

Date:06/09/05ISR Number: 4686912-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01893
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Abscess
	Activities Of Daily
	Living Impaired

Atherosclerosis
Blood Bicarbonate
Increased
Blood Cholesterol
Increased
Blood Glucose Increased
Blood Thyroid Stimulating
Hormone Increased
Cardiac Flutter
Cellulitis
Chest Pain
Coronary Artery Disease
Coronary Artery Occlusion
Dilatation Atrial
Dizziness
Dyspepsia
Dyspnoea
Dyspnoea Exertional
Dyspnoea Paroxysmal
Nocturnal
Electrocardiogram T Wave
Abnormal
Emotional Distress

		Gastrooesophageal Reflux Disease					
		Haemoglobin Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Low Density Lipoprotein		Humulin	C		
UNKNOWN							
		Increased		Synthroid	C		
UNKNOWN							
		Musculoskeletal		Lasix (Furosemide)	C		
UNKNOWN							
		Discomfort		Slow-K	C		
UNKNOWN							
		Myocardial Infarction		Valium	C		
UNKNOWN							
		Oedema Peripheral		Cyclobenzaprine			
		Orthopnoea		Hydrochloride	C		
UNKNOWN							
		Palpitations		Diphenhydramine			
		Panic Attack		Citrate	C		
UNKNOWN							
		Pyoderma		Betamethasone	C		
UNKNOWN							
		Subcutaneous Abscess					
		Ventricular Hypertrophy					
		Weight Increased					

Date:06/09/05ISR Number: 4686913-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02092
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
39 MON						
Initial or Prolonged	Cardiac Disorder		Nexium	C		
UNKNOWN						
	Chest Pain		Synthroid	C		
UNKNOWN						
	Chronic Obstructive Pulmonary Disease					
	Emotional Distress					
	Sleep Apnoea Syndrome					

Date:06/09/05ISR Number: 4686939-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00734
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		1282 DAY
	Congestive Myocardial Infarction							

Date:06/09/05ISR Number: 4686940-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4686943-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00824
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4686944-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00708
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/09/05ISR Number: 4688228-7Report Type:Expedited (15-DaCompany Report #TPA2005A00625
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Bladder Disorder Cerebrovascular Accident Diabetic Coma Loss Of Consciousness Myocardial Infarction	Consumer	Actos (Pioglitazone Hydrochloride) (Tablets)	PS		ORAL	PER ORAL	
			Humalog 75/25 (Insulin Lispro)	SS				
			Humalog (Insulin Lispro)	SS				
			Metformin (Metformin)	SS				
			Vioxx (Rofecoxib)	SS				
			Plavix Clopidogrel Sulfate)	C				
			Potassium Chloride (Potassium Chloride)	C				
			Lasix (Furosemide)	C				

Date:06/10/05ISR Number: 4687728-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00660
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL	2 WK	
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Benign Prostatic		Ziac	C			UNKNOWN	

	Hyperplasia	Prilosec	C	ORAL
	Blood Creatine	Catapres	C	
UNKNOWN				
	Phosphokinase Increased	Simethicone	C	
UNKNOWN				
	Cardiac Failure	Norvasc	C	
UNKNOWN				
	Congestive	Aspirin	C	
UNKNOWN	999 DAY			
	Carotid Artery Stenosis	Tylenol	C	
UNKNOWN				
	Carpal Tunnel Syndrome	[Therapy		
	Cellulitis	Unspecified]	C	
UNKNOWN				
	Cerebrovascular Accident	Ibuprofen	C	
UNKNOWN				
	Fatigue	Xanax	C	
UNKNOWN				
	Headache			
	Hypertension			
	Joint Sprain			
	Memory Impairment			
	Meniscus Lesion			
	Myocardial Infarction			
	Nerve Injury			
	Otitis Externa			
	Pain			
	Renal Artery Stenosis			
	Shoulder Pain			
	Stomach Discomfort			
	Tinnitus			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687730-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Synthroid	C				
			Keppra	C				
			Aricept	C				
			Zyprexa	C				
			Allegra	C				
			Prevacid	C				
			Norvasc	C				
			Hydrochlorothiazide	C				
			Lipitor	C				
			Ambien	C				
			Depakote	C				
			Lotensin	C				
			Detrol	C				

Date:06/10/05ISR Number: 4687743-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01697
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Premarin	C				
Disability	Chest Pain							
	Cyst							
	Dyspnoea							
	Emotional Distress							

Gallbladder Disorder
Pain
Polytraumatism
Post-Traumatic Stress
Disorder
Syncope
Ulcer

Date:06/10/05ISR Number: 4687748-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02102
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		52 MON
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		52 MON
Other	Cerebrovascular Accident							
	Constipation							
	Coronary Artery Disease							
	Demyelination							
	Diverticulitis							
	Diverticulum							
	Dyslipidaemia							
	Emotional Distress							
	Fibromyalgia							
	Hypertension							
	Intestinal Polyp							
	Myocardial Infarction							
	Pelvic Pain							
	Synovial Cyst							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687749-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01698
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Musculoskeletal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricle Rupture		Glucophage	C				
			Avandia	C				

Date:06/10/05ISR Number: 4687751-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00093
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687754-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02373
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Accupril	C				
	Anaemia		Glyburide	C				
	Aortic Valve Incompetence		Insulin	C				
	Blood Pressure Systolic Decreased							
	Blood Urea Increased							
	Cardiac Aneurysm							
	Cardiac Failure							
	Congestive							
	Coronary Artery Disease							
	Dyspepsia							
	Emotional Distress							
	Eye Disorder							
	Hepatic Enzyme Increased							

Hyperlipidaemia
Hypertension
Hypotension
Mitral Valve Incompetence
Pericardial Effusion
Pneumonia
Post Procedural
Complication
Tricuspid Valve
Incompetence
Ventricular Dysfunction
Ventricular Hypertrophy
Wound Complication

Date:06/10/05ISR Number: 4687755-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00092
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687756-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02584
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		1251 DAY
Initial or Prolonged	Carotid Artery Stenosis		Prevacid	C				UNKNOWN
	Cerebrovascular Accident		Nexium	C				UNKNOWN
	Chronic Obstructive Pulmonary Disease							
	Emotional Distress							
	Haemorrhagic Stroke							
	Multiple Sclerosis							
	Transient Ischaemic Attack							

Date:06/10/05ISR Number: 4687757-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02336
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
	Emotional Distress		Insulin	C				UNKNOWN
	Flatulence		Lipitor	C				UNKNOWN
	Thermal Burn		Altace	C				UNKNOWN
			Tricor	C				UNKNOWN
			Diovan	C				UNKNOWN

Date:06/10/05ISR Number: 4687758-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00091
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687759-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00094
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687760-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02224
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Affective Disorder
	Anger
	Carotid Artery Occlusion
	Cerebral Artery Occlusion
	Cerebral Atrophy
	Cerebrovascular Accident
	Depression
	Dizziness
	Drug Ineffective
	Fall
	Headache
	Mitral Valve Incompetence
	Neuropathic Pain
	Peripheral Occlusive

		Disease					
		Pulmonary Valve Incompetence					
		Respiratory Failure	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve		Vioxx	PS	Merck & Co., Inc	ORAL
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Decreased		Plavix	C		ORAL
				Aspirin	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							
				Baycol	C		
UNKNOWN							

Date:06/10/05ISR Number: 4687761-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02226
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 1594 DAY		Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Glucose Increased		Prinivil	C		ORAL
Other		Carotid Artery Stenosis		Metoprolol	C		
UNKNOWN							
		Cerebrovascular Accident		Aspirin	C		
UNKNOWN							
		Coronary Artery Disease		Vytorin	C		ORAL
		Diabetes Mellitus		Glyburide	C		
UNKNOWN							
		Inadequate Control		Plavix	C		
UNKNOWN							
		Dyspnoea		Viagra	C		
UNKNOWN							
		Emotional Distress					
		Hyperlipidaemia					
		Myocardial Infarction					
		Neuropathy					
		Transient Ischaemic Attack					

Date:06/10/05ISR Number: 4687762-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01696
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		505 DAY
Initial or Prolonged	Aortic Valve Incompetence		Zestril	C				UNKNOWN
	Atherosclerosis		Toprol Xl Tablets	C				UNKNOWN
	Blood Triglycerides		Cardizem	C				UNKNOWN
	Increased		Tylenol	C				UNKNOWN
	Chest Pain							
	Coronary Artery Disease							
	Electrocardiogram							
	Abnormal							
	Emotional Distress							
	Ischaemia							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Sinus Bradycardia							

Date:06/10/05ISR Number: 4687763-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02050
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Carotid Artery Stenosis
Disability	Cerebrovascular Accident
	Emotional Distress

	Hypercholesterolaemia						
	Hypertension						
	Muscle Spasms	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	9	MON
			Aspirin	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

Date:06/10/05ISR Number: 4687764-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01894
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulum		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysarthria		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Premarin	C		ORAL		
	Facial Palsy		Inderal	C			UNKNOWN	
	Gastrooesophageal Reflux		Neurontin	C		ORAL		
	Disease		Neurontin	C		ORAL		
	Grand Mal Convulsion		Prevacid	C		ORAL		
	Headache		Vicodin Tablets	C			UNKNOWN	
	Hot Flush		Tylenol	C		ORAL		
	Insomnia		Aspirin	C		ORAL		
	Intestinal Ischaemia		Relafen	C		ORAL		
	Lipoma							
	Mental Status Changes							
	Myocardial Infarction							
	Neck Pain							
	Neurological Symptom							
	Oesophageal Stenosis							
	Skin Lesion							
	Syncope							

Date:06/10/05ISR Number: 4687765-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01901
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Hydrocodone Bitartrate	C			UNKNOWN	
	Contusion		Naprosyn	C			UNKNOWN	
	Emotional Distress							
	Headache							
	Hypertension							
	Joint Sprain							
	Macular Degeneration							
	Polycythaemia							
	Retinal Artery Occlusion							
	Rotator Cuff Syndrome							
	Skin Cancer							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687767-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02977
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		69 MON
Initial or Prolonged	Bladder Disorder		Zocor	C		ORAL		
Other	Blood Disorder							
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Chest Discomfort							
	Dilatation Atrial							
	Diplopia							
	Dyspepsia							
	Hiatus Hernia							
	Hypertension							
	Mitral Valve Incompetence							
	Nausea							
	Pulmonary Hypertension							
	Skin Cancer							
	Tricuspid Valve Incompetence							
	Vascular Calcification							
	Ventricular Hypertrophy							

Date:06/10/05ISR Number: 4687774-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02065
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Atrial Septal Defect		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Disability	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Cerebrovascular Accident		Zoloft	C				UNKNOWN
	Disturbance In Attention		Dilacor Xr	C				UNKNOWN
	Electrocardiogram Poor		Oxycontin	C				UNKNOWN

	R-Wave Progression	Reglan	C
UNKNOWN			
	Emotional Distress	Amantadine	
	Hyperhomocysteinaemia	Hydrochloride	C
UNKNOWN			
	Intermittent Claudication	Zoladex	C
UNKNOWN			
	Intervertebral Disc	Levbid	C
UNKNOWN			
	Disorder	Coenzyme Q10	C
UNKNOWN			
	Leukocytosis		

Date:06/10/05ISR Number: 4687775-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01918
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Concussion
	Deafness
	Dizziness
	Gastrooesophageal Reflux
	Prophylaxis
	Headache
	Hypoaesthesia
	Myocardial Infarction
	Road Traffic Accident
	Rotator Cuff Syndrome
	Simple Partial Seizures

Dose	Duration	Swelling Tinnitus Vision Blurred	Report Source	Product	Role	Manufacturer	Route
45 MON				Vioxx	PS	Merck & Co., Inc	ORAL
45 MON				Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		2 MIN		Prozac	C		
UNKNOWN				Norvasc	C		
UNKNOWN				Zestoretic	C		
UNKNOWN				Phentermine	C		
UNKNOWN				Nortriptyline	C		
UNKNOWN				Grifulvin	C		
UNKNOWN				Diazepam	C		
UNKNOWN				Atenolol	C		
UNKNOWN				Carbamazepine	C		
UNKNOWN				Protonix	C		
UNKNOWN				Levaquin	C		
UNKNOWN				Epitol	C		
UNKNOWN				Prinivil	C		
UNKNOWN				Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C		
UNKNOWN				Lisino	C		
UNKNOWN				Prevacid	C		
UNKNOWN							

Date:06/10/05ISR Number: 4687776-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02354
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Amnesia
Other	Blood Pressure Increased
	Blood Triglycerides Increased
	Cerebrovascular Accident
	Constipation
	Coronary Artery Disease
	Depression
	Drug Hypersensitivity
	Drug Intolerance
	Emotional Distress
	Fatigue
	Hilar Lymphadenopathy
	Hyperlipidaemia
	Hypertension
	Infection
	Inflammation
	Lymphadenopathy
	Lymphadenopathy Mediastinal
	Neck Pain
	Otitis Media
	Overdose
	Pain In Extremity
	Pneumonia
	Proteinuria
	Pulmonary Embolism
	Tendon Calcification
	Tendonitis

Urinary Incontinence
Urine Analysis Abnormal

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	326	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lotrel	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Prempro	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Fluoxetine	C			UNKNOWN	
	Temazepam	C			UNKNOWN	

UNKNOWN	Flurazepam	C
UNKNOWN	Nexium	C
UNKNOWN	Lantus	C
UNKNOWN	Glucovance	C
UNKNOWN	Detrol	C
UNKNOWN	Lithium Carbonate	C
UNKNOWN	Advair	C
UNKNOWN	Albuterol	C
UNKNOWN		

Date:06/10/05ISR Number: 4687780-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00054
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anosmia		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Chest Pain							
	Skin Irritation							

Date:06/10/05ISR Number: 4687781-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00103
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687782-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00100
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687783-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00035
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Emotional Distress							
	Hypertension							
	Myocardial Infarction							

Date:06/10/05ISR Number: 4687784-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00101
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687785-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00099
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687787-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01010
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:06/10/05ISR Number: 4687788-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00743
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:06/10/05ISR Number: 4687789-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00742
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Injury Myocardial Infarction							

Date:06/10/05ISR Number: 4687790-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00894
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687791-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00568
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Animal Bite		Vioxx	PS	Merck & Co., Inc	ORAL		939 DAY
Initial or Prolonged	Atherosclerosis		Aspirin	SS				UNKNOWN
	Cardiac Disorder		Aspirin	SS				UNKNOWN
	Cardiac Murmur		Protonix	SS				UNKNOWN
	Cardiac Valve Disease		Lipitor	SS				UNKNOWN
	Dyspnoea		Glucotrol	SS				UNKNOWN
	Emotional Distress		Zestoretic	SS		ORAL		
	Gastric Haemorrhage		Avapro	C				UNKNOWN
	Haematochezia		Avapro	C				UNKNOWN
	Hernia							
	Myocardial Infarction							
	Road Traffic Accident							
	Thrombosis							
	Whole Blood Transfusion							

Date:06/10/05ISR Number: 4687793-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00819
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687794-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00104
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687795-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00095
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687796-9Report Type:Expedited (15-DaCompany Report #QA-MERCK-0506USA00367
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemoglobin Decreased		Enoxaparin Sodium	SS				UNKNOWN
	Haemorrhage		Digoxin	C				UNKNOWN
	Hypotension							
	Retroperitoneal Haematoma							

Date:06/10/05ISR Number: 4687797-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00102
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4687800-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly Coronary Artery Atherosclerosis Death Ventricular Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687801-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00813
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4687820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01904
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	53 DAY	
	Cerebrovascular Accident		Metformin	C			UNKNOWN	
	Emotional Distress		Accupril	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Chloridin	C			UNKNOWN	

Date:06/10/05ISR Number: 4687867-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00062
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
			[Therapy Unspecified]	C				

UNKNOWN

Date:06/10/05ISR Number: 4688259-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00833
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
	Emotional Distress							
	Myocardial Infarction							

Date:06/10/05ISR Number: 4688260-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00813
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Benign Prostatic Hyperplasia
	Blood Pressure Systolic Increased
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery

	Thrombosis						
	Discomfort						
	Dizziness						
	Emotional Distress	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Faeces Discoloured		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haemodynamic Instability		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperkalaemia		Flomax (Tamsulosin					
	Hyperlipidaemia		Hydrochloride)	C				
UNKNOWN								
	Hypertension							
	Hypotension							
	Melaena							
	Myocardial Infarction							
	Sinus Arrhythmia							
	Sinus Bradycardia							
	Ventricular Hypokinesia							
	Vertigo							

Date:06/10/05ISR Number: 4688261-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00930
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
1456 DAY								
Initial or Prolonged	Arrhythmia		Lotrel	C				
UNKNOWN								
Other	Blood Cholesterol		Prednisone	C				
UNKNOWN								
	Increased		Imipramine					
	Blood Triglycerides		Hydrochloride	C				
UNKNOWN								
	Increased		Celebrex	C				
UNKNOWN								
	Cardiac Failure		Aspirin	C				
UNKNOWN								
	Congestive		Bextra	C				
UNKNOWN								
	Chest Pain							
	Chronic Fatigue Syndrome							
	Dizziness							
	Dyspepsia							
	Dyspnoea							
	Emotional Distress							
	Headache							

Heart Rate Irregular
Myocardial Infarction
Sleep Apnoea Syndrome

Date:06/10/05ISR Number: 4688262-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01194
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Arthralgia
	Atelectasis
	Back Pain
	Blood Alkaline Phosphatase Increased
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Body Temperature Increased
	Breath Sounds Decreased
	Bronchitis
	Bronchitis Acute
	Chest Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chronic Obstructive Pulmonary Disease					
		Coagulopathy					
		Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN				Vioxx	SS	Merck & Co., Inc	
		Crying		Buspar	C		
UNKNOWN							
		Deep Vein Thrombosis		Zoloft	C		
UNKNOWN							
		Depression		Claritin	C		
UNKNOWN							
		Diaphragmatic Disorder					
		Dyslipidaemia					
		Dyspnoea					
		Empyema					
		Haematocrit Decreased					
		Haemoptysis					
		Haemothorax					
		Heart Rate Increased					
		Hyperhidrosis					
		Hypertension					
		International Normalised Ratio Decreased					
		International Normalised Ratio Increased					
		Lobar Pneumonia					
		Muscle Spasms					
		Nasopharyngitis					
		Night Sweats					
		Platelet Count Increased					
		Pleural Effusion					
		Pleural Fibrosis					
		Pleurisy					
		Pleuritic Pain					
		Productive Cough					
		Pulmonary Artery Thrombosis					
		Pulmonary Embolism					
		Pulmonary Haematoma					
		Pulmonary Infarction					
		Pulmonary Thrombosis					
		Pyrexia					
		Red Blood Cell Sedimentation Rate Increased					

Respiratory Rate
Increased
Rheumatoid Arthritis
Sputum Discoloured
Thrombocytopenic Purpura
Vasculitis
Viral Infection
Weight Decreased
Weight Increased
Wheezing

Date:06/10/05ISR Number: 4688264-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00774
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Disability	Appendix Disorder
Other	Back Disorder
	Cardiac Disorder

	Carotid Artery Stenosis						
	Depression						
	Dyspepsia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1564 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neoplasm Malignant		Vioxx	SS	Merck & Co., Inc	ORAL	1564 DAY
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL	
	Panic Disorder		Accupril	C		ORAL	
	Stress		Ventolin (Albuterol)	C			UNKNOWN
			Aspirin	C		ORAL	

Date:06/10/05ISR Number: 4688266-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00611
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 5 YR	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	
	Bacterial Infection		Zocor	SS		ORAL	
	Constipation		Hydrocodone Bitartrate	C			UNKNOWN
	Coronary Artery Disease						
	Depression		Aspirin	C			UNKNOWN
	Duodenal Stenosis		Levothyroxine Sodium	C			UNKNOWN
	Emotional Distress		Estrogens (Unspecified)	C			UNKNOWN
	Gallbladder Disorder						
	Gastrointestinal Haemorrhage						
	Myalgia						
	Myocardial Infarction						
	Nausea						
	Pancreatitis						
	Peptic Ulcer						
	Thoracic Cavity Drainage						

Date:06/10/05ISR Number: 4688268-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00546
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Heart Rate Irregular							
	Renal Disorder							

Date:06/10/05ISR Number: 4688269-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00038
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		22 DAY
Initial or Prolonged	Lumbar Vertebral Fracture		Vioxx	SS	Merck & Co., Inc	ORAL		
	Road Traffic Accident		Pantoprazole Sodium	C		ORAL		
	Skin Ulcer		Pravastatin Sodium	C		ORAL		
	Thrombophlebitis		Lormetazepam	C		ORAL		
	Venous Insufficiency		Dipyrone	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Acetaminophen And Codeine	C		ORAL		
			Buprenorphine Hydrochloride	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4688282-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01777
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		348 DAY
Initial or Prolonged	Chronic Obstructive		Celebrex	SS				UNKNOWN
Other	Pulmonary Disease		Celebrex	SS				UNKNOWN
	Convulsion		Calan	C				UNKNOWN
	Gastrooesophageal Reflux		Bextra	C				UNKNOWN
	Disease		Bextra	C				UNKNOWN
	Haematochezia		Lopid	C				UNKNOWN
	Myocardial Infarction		Aspirin	C			366 DAY	UNKNOWN
	Rheumatoid Arthritis		Ventilan (Albuterol)	C				UNKNOWN
	Sleep Apnoea Syndrome							

Date:06/10/05ISR Number: 4688283-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02076
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Bigeminy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervical Dysplasia		Tenormin	C				UNKNOWN
	Chest Pain							
	Electrocardiogram T Wave Inversion							
	Emotional Distress							
	Fibrocystic Breast Disease							
	Hypertension							
	Mitral Valve Incompetence							
	Pollakiuria							
	Stress							
	Temperature Intolerance							

Tricuspid Valve Disease
Tricuspid Valve
Incompetence
Umbilical Hernia
Ventricular Extrasystoles

Date:06/10/05ISR Number: 4688284-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02082
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Emotional Distress		Atenolol	C				
UNKNOWN								
Initial or Prolonged	Malignant Hypertension							

Date:06/10/05ISR Number: 4688285-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01937
Age:79 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Amnesia
Initial or Prolonged	Anaemia
Other	Atrial Fibrillation
	Bundle Branch Block Left
	Cardiomegaly
	Dyspepsia
	Emotional Distress
	Gastric Disorder

		Haemorrhage Intracranial Haemorrhagic Stroke Heart Rate Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hernia		Vioxx	PS	Merck & Co., Inc	ORAL
22	MON						
		Infection		Metoprolol	C		
UNKNOWN							
		Mitral Valve Incompetence		Triamterene	C		
UNKNOWN							
		Myocardial Infarction		Lisinopril	C		
UNKNOWN							
		Skin Cancer		Maxzide	C		
UNKNOWN							
		Tricuspid Valve		Gemfibrozil	C		
UNKNOWN							
		Incompetence		Casodex	C		
UNKNOWN							
		Visual Field Defect		Protonix	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Cardura	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:06/10/05ISR Number: 4688286-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02031
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR					
Initial or Prolonged	Infarction Chest Pain Chronic Obstructive Pulmonary Disease Coronary Artery Disease Depression Emotional Distress Gamma-Glutamyltransferase					

	Increased
	Gastrooesophageal Reflux
	Disease
	Headache
	Joint Swelling
	Laceration
	Nocturia
	Retching

Date:06/10/05ISR Number: 4688287-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02372
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Aortic Stenosis
	Asthma
	Atrial Fibrillation
	Atrioventricular Block
	First Degree
	Chest Injury
	Coronary Artery Disease
	Dyspepsia
	Dyspnoea
	Emotional Distress
	Fall
	Gastritis
	Gout
	Hypertension
	Low Density Lipoprotein

		Increased Muscle Spasms Musculoskeletal Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Productive Cough		Paxil	C		
UNKNOWN							
		Skin Exfoliation		Buspar	C		
UNKNOWN							
		Sternal Injury		Mevacor	C		ORAL
		Supraventricular		Synthroid	C		
UNKNOWN							
		Extrasystoles		Neurontin	C		
UNKNOWN							
		Thrombosis		Trazodone			
		Ventricular Extrasystoles		Hydrochloride	C		
UNKNOWN							
		Weight Increased		Isosorbide	C		
UNKNOWN							
				Cartia Xt	C		
UNKNOWN							
				Nitro	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Prilosec	C		ORAL
				Lipitor	C		
UNKNOWN							
				Amoxicillin	C		
UNKNOWN							
				Tamiflu	C		
UNKNOWN							
				Dicyclomine Hydrochloride	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							

Date:06/10/05ISR Number: 4688288-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00997
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Affective Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Initial or Prolonged	Amnesia		Trazodone					
Disability	Atherosclerosis		Hydrochloride	C				
UNKNOWN								
Other	Blood Cholesterol		Augmentin	C				
UNKNOWN								
	Increased		Aspirine	C				
UNKNOWN								
	Blood Triglycerides							
	Increased							
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Cognitive Disorder							
	Convulsion							
	Depression							
	Diabetes Mellitus							
	Hypertension							
	Transient Ischaemic							
	Attack							

Date:06/10/05ISR Number: 4688289-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00640
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Magnesium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY
Disability	Blood Potassium Decreased							
	Bradycardia							
	Chest Pain							
	Dizziness							
	Dyspnoea							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4688290-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02366
Age:83 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Infarction		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
			Vioxx	SS	Merck & Co., Inc		UNKNOWN	
			Detrol	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

Date:06/10/05ISR Number: 4688291-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02221
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	1339 DAY	
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	1339 DAY	
Other	Increased		Aleve	C			UNKNOWN	3362 DAY
	Cerebrovascular Accident		Darvocet-N	C			UNKNOWN	
	Emotional Distress		Novolog	C			UNKNOWN	
	Myocardial Infarction		Glyburide	C			UNKNOWN	
	Sleep Apnoea Syndrome		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN	
			Ritalin	C			UNKNOWN	
			Focalin	C			UNKNOWN	
			Norvasc	C			UNKNOWN	

			Avalide	C		
UNKNOWN						
			Actos	C		
UNKNOWN						
			Provigil	C		
UNKNOWN						
			Effexor	C		
UNKNOWN						
			Mobic	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						

Date:06/10/05ISR Number: 4688292-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02363
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Depression		Glucovance	C				
UNKNOWN								
	Myocardial Infarction		Avandia	C				
UNKNOWN								
	Personality Disorder		Tricor	C				
UNKNOWN								
	Post-Traumatic Stress		Zoloft	C				
UNKNOWN								
	Disorder		Aspirin	C				
UNKNOWN								
	Suicidal Ideation		Lotrel	C				
UNKNOWN								
	Tension Headache							

Date:06/10/05ISR Number: 4688293-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02340
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Agitation
Disability	Anaemia
	Aortic Valve Incompetence
	Bacteraemia
	Cardiac Failure
	Congestive

Cardiac Murmur
Cardiovascular Disorder
Cellulitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	35	MON

Dementia
Diverticulum
Encephalopathy
Gastrointestinal
Arteriovenous
Malformation
Gastrointestinal
Haemorrhage
Haematochezia
Hepatomegaly
Hypothyroidism
Iron Deficiency Anaemia
Lower Gastrointestinal
Haemorrhage
Mental Status Changes
Metabolic Alkalosis
Mitral Valve Incompetence
Multi-Organ Disorder
Myocardial Infarction
Pain
Speech Disorder
Tricuspid Valve
Incompetence

Date:06/10/05ISR Number: 4688294-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02214
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrioventricular Block First Degree
Other	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Cerebral Disorder
	Cerebral Ischaemia
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Dilatation Atrial
	Dizziness

Dyspnoea
Electroencephalogram
Abnormal
Emotional Distress
Facial Palsy
Fluid Overload
Haematocrit Decreased
Haematoma Evacuation
Haemoglobin Decreased
Hyperlipidaemia
Hypertension
Laryngeal Oedema
Myocardial Infarction
Myocardial Ischaemia
Oedema Peripheral
Peripheral Vascular
Disorder

	Post Procedural Haemorrhage						
	Spinal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	136 DAY
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL	
	Attack		Glyburide	C		ORAL	UNKNOWN
	Ventricular Dysfunction		Ventolin (Albuterol)	C			
	Ventricular Hypokinesia						
	Wheezing						
	White Blood Cell Count Increased						

Date:06/10/05ISR Number: 4688295-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01837
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON
Initial or Prolonged	Aortic Stenosis		Metformin	C			UNKNOWN
Disability	Aortic Valve		Labetalol				
Other	Calcification		Hydrochloride	C			UNKNOWN
	Aortic Valve Incompetence		Lipitor	C			UNKNOWN
	Cardiac Disorder		Meclizine	C			UNKNOWN
	Cardiovascular Disorder		Aleve	C			UNKNOWN
	Carotid Artery Stenosis		Diovan	C			UNKNOWN
	Cerebrovascular Accident						
	Chest Discomfort						
	Chest Pain						
	Colon Adenoma						
	Coronary Artery Disease						
	Cough						
	Depression						
	Diastolic Dysfunction						
	Dizziness						
	Dyspepsia						

Emotional Distress
Eructation
Gastrointestinal Disorder
Hepatic Function Abnormal
Hypotension
Lacunar Infarction
Left Ventricular
End-Diastolic Pressure
Increased
Mitral Valve Incompetence
Multi-Organ Disorder
Myocardial Infarction
Pain
Sinus Bradycardia
Supraventricular
Extrasystoles
Tricuspid Valve
Incompetence
Ventricular Extrasystoles

Date:06/10/05ISR Number: 4688296-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02204
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		66 DAY
Initial or Prolonged	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Viagra	C				UNKNOWN
	Cerebellar Infarction		Aspirin	C				UNKNOWN
	Cerebrovascular Accident		Lescol	C				UNKNOWN
	Difficulty In Walking		Tylenol Arthritis Extended Relief	C				UNKNOWN
	Dilatation Atrial							
	Disorientation		Aleve	C				UNKNOWN
	Dizziness		Glucosamine	C				UNKNOWN
	Drug Ineffective		Mobic	C				UNKNOWN
	Dysgraphia		Darvocet-N	C				UNKNOWN
	Hemiparesis		Celebrex	C				UNKNOWN
	Mitral Valve Incompetence		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Muscle Atrophy							
	Nausea							
	Osteoarthritis		Tylenol	C				UNKNOWN
	Patellofemoral Pain Syndrome							
	Ventricular Hypertrophy							
	Vomiting							

Date:06/10/05ISR Number: 4688297-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01232
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		1005 DAY

	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL
1005 DAY					
	Increased	Methotrexate	C		
UNKNOWN					
	Colonic Polyp	Prednisone	C		
UNKNOWN					
	Hypertension	Prednisone	C		
UNKNOWN					
	Myopathy	Prevacid	C		
UNKNOWN					
	Neuropathy	Diflunisal	C		
UNKNOWN					
	Retinal Artery Embolism				
	Retinal Artery Occlusion				
	Thrombosis				

Date:06/10/05ISR Number: 4688298-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02282
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aneurysm
Disability	Artery Dissection
	Back Pain
	Basilar Artery Thrombosis
	Blood Cholesterol Increased
	Brain Stem Infarction
	Cerebellar Artery Occlusion
	Cerebral Atrophy
	Cerebrovascular Accident
	Constipation
	Difficulty In Walking
	Disturbance In Attention
	Dizziness
	Dysarthria

	Emotional Distress						
	Facial Palsy						
	Fibromyalgia	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Groin Pain		Vioxx	PS	Merck & Co., Inc	ORAL	658	DAY
	Haemangioma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemangioma Of Liver		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Antivert	C			UNKNOWN	
	Hepatic Lesion		Estrogens					
	Hyperlipidaemia		(Unspecified)	C			UNKNOWN	
	Hypoaesthesia		Aspirin	C			UNKNOWN	
	Hypoaesthesia Oral		Darvocet-N	C			UNKNOWN	
	Increased Tendency To Bruise							
	Intervertebral Disc Protrusion							
	Intracranial Aneurysm							
	Ischaemia							
	Memory Impairment							
	Migraine							
	Neuralgia							
	Osteoarthritis							
	Palpitations							
	Paraesthesia							
	Retroperitoneal Haematoma							
	Retroperitoneal Haemorrhage							
	Speech Disorder							
	Tongue Paralysis							
	Tremor							
	Urinary Tract Infection							
	Vertigo							
	Visual Disturbance							
	Vomiting							

Date:06/10/05ISR Number: 4688299-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02052
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cardiac Disorder	Vioxx	PS	Merck & Co., Inc	ORAL
1729 DAY					
Initial or Prolonged	Dyspepsia	Zantac	C		
UNKNOWN					
Disability	Emotional Distress	Prevacid	C		
UNKNOWN					
	Haemorrhoids	Lipitor	C		
UNKNOWN					
	Lung Disorder	[Therapy			
	Myocardial Infarction	Unspecified]	C		
UNKNOWN					
		[Therapy			
		Unspecified]	C		
UNKNOWN					
		Vasotec	C		
UNKNOWN					
		Tenormin	C		
UNKNOWN					
		Probenecid	C		
UNKNOWN					

Date:06/10/05ISR Number: 4688300-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01238
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Blood Cholesterol
Initial or Prolonged	Increased
Other	Cerebrovascular Accident
	Chest Pain
	Depression

		Diabetes Mellitus					
		Generalised Anxiety Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prescribed Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Estrace	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Accupril	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							

Date:06/10/05ISR Number: 4688301-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02003
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Arrest		Norvasc	C		ORAL
		Emotional Distress		Norvasc	C		ORAL
		Gastric Disorder		Lodine	C		ORAL
		Hypertensive		Vicoprofen	C		ORAL
		Cardiomyopathy		Ambien	C		
UNKNOWN							
		Hypertensive Heart		Prednisone	C		
UNKNOWN							
		Disease		Mylanta & Mylanta Ds	C		
UNKNOWN							
		Musculoskeletal Stiffness		Darvon	C		
UNKNOWN							
		Myocardial Infarction		Lipitor	C		
UNKNOWN							
		Nasopharyngitis		Sulfasalazine	C		
UNKNOWN							
		Pain		Aciphex	C		
UNKNOWN							

Date:06/10/05ISR Number: 4688309-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688310-4Report Type:Expedited (15-DaCompany Report #IL-MERCK-0506ISR00001
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lidocaine And Tribenoside	C				
UNKNOWN								
			Lidocaine And Tribenoside	C				
UNKNOWN								
			Diclofenac Diethylamine	C				
UNKNOWN								
			Nutritional Supplements	C				
UNKNOWN								

Date:06/10/05ISR Number: 4688311-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00126
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4688312-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00090
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688313-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01597
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL	198 MON	
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	433 DAY	
Initial or Prolonged	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	198 MON	
Disability	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL	433 DAY	
	Pain In Extremity		Xanax	C			UNKNOWN	
	Pyrexia		Lexapro	C			UNKNOWN	
	Urinary Tract Infection		Claritin	C			UNKNOWN	
			Colace	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Valium	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:06/10/05ISR Number: 4688315-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00097
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688316-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00087
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688317-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00096
Age:76 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688318-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02277
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balance Disorder
	Brain Stem Ischaemia
	Brain Stem Syndrome
	Cardiac Murmur
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Difficulty In Walking
	Diplopia

		Dizziness Dyspnoea Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Epilepsy		Vioxx	PS	Merck & Co., Inc	ORAL
31	DAY						
		Eye Movement Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
306	DAY						
		Gingival Bleeding		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Lotensin	C		
UNKNOWN							
		Iiird Nerve Paralysis		Lotensin	C		
UNKNOWN							
		Insomnia		Aspirin	C		
UNKNOWN							
		International Normalised Ratio Increased Intracranial Pressure Increased Muscle Spasms Nuclear Magnetic Resonance Imaging Brain Abnormal Nystagmus Pain Palpitations Pharyngeal Haemorrhage Photophobia Reflexes Abnormal Stomach Discomfort Stomatitis Systemic Lupus Erythematosus Tinnitus Transient Ischaemic Attack Vertigo Vision Blurred Vith Nerve Paralysis					

Date:06/10/05ISR Number: 4688319-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00114
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/10/05ISR Number: 4688320-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688321-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00098
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4688322-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00004
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	General Physical Health		Metoprolol Tartrate	C				UNKNOWN
	Deterioration		Nifedipine	C				UNKNOWN
	Heart Rate Increased							

Date:06/10/05ISR Number: 4688323-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00713
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Initial or Prolonged	Cardiac Failure Congestive							
	Heart Rate Irregular							

Date:06/10/05ISR Number: 4688324-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00128
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688325-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00089
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688329-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00115
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688330-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00133
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688336-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00130
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:06/10/05ISR Number: 4688337-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00739
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/10/05ISR Number: 4688338-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00116
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688339-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00446
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abortion Spontaneous		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Drug Exposure During		Robaxin	C				
UNKNOWN								
Initial or Prolonged	Pregnancy		Flexeril	C				
UNKNOWN								
	Haemorrhage							
	Pregnancy							

Date:06/10/05ISR Number: 4688341-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Pain							

Date:06/10/05ISR Number: 4688342-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00117
Age:77 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688343-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00889
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	116 DAY	
	Cyanosis		Provera	C			UNKNOWN	17 MON
	Depressed Level Of		Provera	C			UNKNOWN	17 MON
	Consciousness							
	Electromechanical							
	Dissociation							
	Myocardial Infarction							
	Ventricular Fibrillation							

Date:06/10/05ISR Number: 4688347-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688348-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01054
Age:79 YR Gender:Female I/FU:I

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
Lethargy							
Myocardial Infarction							
Pneumonia							

Date:06/10/05ISR Number: 4688349-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00934
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - 1549 DAY			Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Lipitor	C				
UNKNOWN								
Disability			Insulin	C				
UNKNOWN								
			Insulin	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								

Date:06/10/05ISR Number: 4688350-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00732
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				
UNKNOWN								

Date:06/10/05ISR Number: 4688351-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	944	DAY

Date:06/10/05ISR Number: 4688352-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00637
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis		[Therapy Unspecified]	C				
UNKNOWN								

Date:06/10/05ISR Number: 4688360-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00512
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688361-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00931
Age:90 YR Gender:Female I/FU:I

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged
Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
		Aricept	C			UNKNOWN	
		Sucralfin	C			UNKNOWN	
		[Therapy Unspecified]	C			UNKNOWN	

Date:06/10/05ISR Number: 4688362-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00513
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:06/10/05ISR Number: 4688363-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00729
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4688364-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/10/05ISR Number: 4691160-6Report Type:Expedited (15-DaCompany Report #2005081800
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident	Consumer	Bextra (Valdecoxib)	PS				
			Vioxx (Rofecoxib)	SS				

Date:06/10/05ISR Number: 4691303-4Report Type:Expedited (15-DaCompany Report #2005061419
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG,	
Initial or Prolonged	Pain	Health					1 IN 1 D),	
	Psoriasis	Professional					ORAL	
	Rash Scaly		Vioxx (Rofecoxib)	SS				
	Scab		Mobic (Meloxicam)	C				
			Fluoxetine (Fluoxetine)	C				
			Allegra (Fexofenadine Hydrochloride)	C				
			Darvocet (Dextropropoxyphene Napsilate, Paracetamol)	C				
			Aciphex (Rabeprazole Sodium)	C				

			Prozac (Fluoxetine Hydrochloride)	C
			Benicar Hct (Hydrochlorothiazide, Olmesartan)	C

Date:06/13/05ISR Number: 4688949-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02881
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		4 MON
	Infarction		Biaxin	C				UNKNOWN
	Anger		Prilosec	C				UNKNOWN
	Anxiety		Nexium	C				UNKNOWN
	Atherosclerosis		Ultracet	C				UNKNOWN
	Back Injury		Hydrocodone Bitartrate	C				UNKNOWN
	Back Pain		Soma	C				UNKNOWN
	Blood Cholesterol		Flexeril	C		ORAL		
	Increased		Skelaxin	C				UNKNOWN
	Blood Pressure Increased		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
	Coronary Artery Disease		Folic Acid	C				UNKNOWN
	Coronary Artery Stenosis		Famvir	C				UNKNOWN
	Cough							
	Decreased Interest							
	Depression							
	Dizziness Postural							
	Drug Effect Decreased							
	Ecchymosis							
	Ejection Fraction Decreased							
	Emotional Distress							

Fear
Gastrooesophageal Reflux
Disease
Headache
Insomnia
Intervertebral Disc
Protrusion
Ischaemic Cardiomyopathy
Migraine
Mitral Valve Incompetence
Musculoskeletal
Discomfort
Platelet Aggregation
Increased
Renal Disorder
Sinus Disorder
Social Avoidant Behaviour
Treatment Noncompliance
Ventricular Hypokinesia
Weight Decreased

Date:06/13/05ISR Number: 4688952-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0401FRA00075
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cytolytic Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL		3 DAY
Initial or Prolonged	Hepatitis Cholestatic		Acetaminophen	C		ORAL		11 DAY

			Acetaminophen	C		ORAL
			Irbesartan	C		ORAL
			Zopiclone	C		ORAL

Date:06/13/05ISR Number: 4688963-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01775
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cough		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
			Zetia	C		ORAL
			Prevacid	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Meclizine	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

Date:06/13/05ISR Number: 4688964-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01924
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
1250 DAY						
	Back Injury		Daypro	C		
UNKNOWN						
	Bipolar Disorder		Naproxen	C		
UNKNOWN						
	Blood Cholesterol		Aspirin	C		
UNKNOWN						
	Increased		Famvir	C		
UNKNOWN						
	Cardiac Failure		Zocor	C		
UNKNOWN						
	Congestive		Ridaura	C		
UNKNOWN						
	Cardiac Valve Disease		Singulair	C		
UNKNOWN						

	Cellulitis	Depakote	C
UNKNOWN			
	Chronic Obstructive	Nexium	C
UNKNOWN			
	Pulmonary Disease	Valtrex	C
UNKNOWN			
	Constipation	Zoloft	C
UNKNOWN			
	Depression	Advair	C
UNKNOWN			
	Dyspepsia	Celebrex	C
UNKNOWN	2 YR		
	Heart Rate Irregular	Toprol Xl Tablets	C
UNKNOWN			
	Herpes Virus Infection	Zyprexa	C
UNKNOWN			
	Hypertension	Spiriva	C
UNKNOWN			
	Myocardial Infarction	Coumadin	C
UNKNOWN			
	Overdose	Abilify	C
UNKNOWN			
	Rheumatoid Arthritis		
	Sleep Apnoea Syndrome		

Date:06/13/05ISR Number: 4688965-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02222
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Cardiac Failure Congestive
	Carpal Tunnel Syndrome
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Dizziness
	Dyspnoea
	Dyspnoea Paroxysmal

		Nocturnal					
		Emotional Distress					
		Limb Discomfort					
		Orthopnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteopenia		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
		Prostate Cancer Recurrent		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Swelling		Simvastatin	C		
UNKNOWN							
		Weight Increased		Risperidone	C		
UNKNOWN							
				Trazodone Hydrochloride	C		
UNKNOWN							
				Testred	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							
				Celexa	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Lisinopril	C		
UNKNOWN							
				Lisinopril	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Klonopin	C		
UNKNOWN							
				Quetiapine Fumarate	C		
UNKNOWN							
				Mevacor	C		ORAL
				Imdur	C		
UNKNOWN							

Aciphex C
UNKNOWN

Date:06/13/05ISR Number: 4688966-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02101
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Anxiety
	Blood Cholesterol Increased
	Cervical Stricture
	Cholecystitis
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Costochondritis
	Depression
	Dyspnoea Exertional
	Emotional Distress
	Essential Hypertension
	Fatigue
	Ganglion
	Hiatus Hernia
	Hyperlipidaemia
	Ileus
	Ingrowing Nail
	Intervertebral Disc Degeneration
	Lumbar Radiculopathy
	Muscle Spasms

		Myocardial Infarction					
		Oedema Peripheral					
		Ovarian Cyst	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
		Panic Attack		Vioxx	SS	Merck & Co., Inc	ORAL
		Postmenopausal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Column Stenosis		Nexium	C		
UNKNOWN							
		Spondylolisthesis		Toprol Xl Tablets	C		
UNKNOWN							
		Uterine Leiomyoma		Vitamins (Unspecified)	C		
UNKNOWN							

Date:06/13/05ISR Number: 4688967-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02272
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
444 DAY						
Hospitalization -	Arteriosclerosis		Altace	C		ORAL
701 DAY						
Initial or Prolonged	Arthralgia					
Other	Blood Cholesterol Increased					
	Blood Triglycerides Increased					
	Bronchitis					
	Cataract					
	Chest Pain					
	Dermatitis					
	Hypertension					
	Pulmonary Congestion					
	Rash Generalised					
	Skin Papilloma					
	Sudden Death					

Date:06/13/05ISR Number: 4688968-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02377
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Acute Coronary Syndrome Atrial Fibrillation Blood Potassium Increased C-Reactive Protein Increased Cardiac Valve Disease Coronary Artery Disease Dysuria Emotional Distress Feeling Hot And Cold Gastrooesophageal Reflux Disease Haematuria Headache Heart Rate Increased Hot Flush Hypertension Irritable Bowel Syndrome Myocardial Infarction Onychomycosis Ovarian Cyst

	Panic Disorder						
	Renal Atrophy						
	Renal Failure	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rheumatic Fever		Vioxx	PS	Merck & Co., Inc	ORAL	1096 DAY
	Tremor		Vioxx	SS	Merck & Co., Inc	ORAL	1096 DAY
	Tuberculosis		Aleve	C			UNKNOWN
	Urinary Hesitation		Premarin	C			UNKNOWN
	Urinary Tract Infection		Effexor	C			UNKNOWN
			Effexor	C			UNKNOWN

Date:06/13/05ISR Number: 4688969-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02365
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL	900 DAY
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL	900 DAY
	Depression Suicidal		Lipitor	C			UNKNOWN
	Helicobacter Pylori		Zoloft	C			UNKNOWN
	Identification Test		Propecia	C			UNKNOWN
	Positive		Biaxin	C			UNKNOWN
	Myocardial Infarction		Niaspan	C			UNKNOWN
	Oesophageal Spasm		Aspirin	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Allegra	C			UNKNOWN
			Carisoprodol	C			UNKNOWN
			Trazodone				

	Hydrochloride	C	
UNKNOWN			
	Neomycin	C	
UNKNOWN			
	Folic Acid	C	
UNKNOWN			
	Wellbutrin	C	
UNKNOWN			
	Metronidazole	C	
UNKNOWN			
	Nexium	C	
UNKNOWN			
	Zyrtec	C	
UNKNOWN			

Date:06/13/05ISR Number: 4688970-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02337
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ascites		Effexor	C				
UNKNOWN								
Disability	Cerebrovascular Accident		Ativan	C				
UNKNOWN								
	Chest Pain							
	Depression							
	Diabetes Mellitus							
	Emotional Distress							
	Myocardial Infarction							
	Strabismus							

Date:06/13/05ISR Number: 4688972-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01898
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Anterior Spinal Artery Syndrome
	Anxiety Disorder

		Arthralgia					
		Arthropathy					
		Asthenia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Contusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
		Atherosclerosis		Zestril	C		ORAL
		Coronary Artery Disease		Zestril	C		ORAL
		Coronary Artery Occlusion					
		Depression					
		Diabetes Mellitus					
		Dyspepsia					
		Emotional Distress					
		Fatigue					
		Hypotension					
		Lethargy					
		Motor Dysfunction					
		Musculoskeletal Chest					
		Pain					
		Myocardial Infarction					
		Oedema Peripheral					
		Pneumonia					
		Spinal Osteoarthritis					

Date:06/13/05ISR Number: 4688973-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01936
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 649 DAY		Alanine Aminotransferase		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN		Increased		Clarinex	C		
		Blood Cholesterol		Skelaxin	C		
UNKNOWN							
		Increased		Claritin-D	C		
UNKNOWN							
		Chest Pain					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Dermatitis Contact					
		Dizziness					
		Epigastric Discomfort					

High Density Lipoprotein
Decreased
Hypertension
Hypoglycaemia
Low Density Lipoprotein
Increased
Myocardial Infarction
Renal Disorder

Date:06/13/05ISR Number: 4688974-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02284
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
Other	Arthralgia
	Back Disorder
	Back Pain
	Blindness
	Cerebrovascular Accident
	Depression

		Dizziness					
		Emotional Distress					
		Fibromyalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Ultram	C		
UNKNOWN							
		Hypertensive Heart		Synthroid	C		
UNKNOWN							
		Disease					
		Intervertebral Disc					
		Protrusion					
		Myocardial Infarction					
		Rheumatoid Arthritis					
		Sleep Disorder					
		Synovitis					

Date:06/13/05ISR Number: 4688975-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01917
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Aleve	C		
UNKNOWN							
		Atherosclerosis		Prilosec	C		
UNKNOWN							
		Carpal Tunnel Syndrome					
		Coronary Artery Disease					
		Ejection Fraction					
		Decreased					
		Emotional Distress					
		Joint Injury					
		Musculoskeletal Stiffness					
		Pelvic Discomfort					
		Renal Disorder					
		Rotator Cuff Syndrome					
		Shoulder Pain					
		Sleep Apnoea Syndrome					

Date:06/13/05ISR Number: 4688976-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02011
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Captopril	C				
	Angina Unstable		Lasix (Furosemide Sodium)	C			UNKNOWN	
	Asthenia		Metoprolol	C			UNKNOWN	
	Atelectasis		Isosorbide	C			UNKNOWN	
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Emotional Distress		Plavix	C			UNKNOWN	
	Graft Complication		Zoloft	C			UNKNOWN	
	Hypertension		Glucotrol	C			UNKNOWN	
	Pleural Effusion		Synthroid	C			UNKNOWN	
	Pneumonia		Synalar	C			UNKNOWN	
	Pulmonary Oedema		Hydrocortisone Ointment	C			UNKNOWN	
			Kenalog	C			UNKNOWN	

Date:06/13/05ISR Number: 4688978-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03909
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		116 DAY
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased							
Disability	Blood Urine Present							
	Cardiomegaly							
	Chest Pain							
	Colon Adenoma							
	Constipation							
	Dry Socket							
	Dysplasia							
	Extrasystoles							
	Heart Rate Increased							
	Hypertension							
	Intervertebral Disc Protrusion							
	Neck Injury							
	Otitis Media							
	Pain							
	Pain In Jaw							
	Palpitations							
	Road Traffic Accident							
	Upper Respiratory Tract Infection							
	Urinary Tract Infection							
	Vaginal Prolapse							
	Ventricular Extrasystoles							
	Wrist Fracture							

Date:06/13/05ISR Number: 4688981-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01896
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
Other	Blood Pressure Decreased
	Chest Discomfort
	Depression
	Dizziness
	Drug Ineffective

Emotional Distress
Gastrooesophageal Reflux
Disease
Haemorrhage
Haemorrhoids
Headache
Hypercholesterolaemia
Hypertension
Insomnia
Joint Injury
Myocardial Infarction
Reflux Oesophagitis
Rib Fracture
Sinusitis
Syncope
Transient Ischaemic
Attack
Ventricular Tachycardia

Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Benicar	C			UNKNOWN	
	Cardizem	C			UNKNOWN	
	Coreg	C			UNKNOWN	
	Lofibra	C			UNKNOWN	
	Plavix	C			UNKNOWN	
	Pletal	C			UNKNOWN	
	Protonix	C			UNKNOWN	
	Mobic	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	

Date:06/13/05ISR Number: 4688982-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02219
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Cardizem	C			UNKNOWN	
Other	Convulsion		Cardizem	C			UNKNOWN	
	Gastrooesophageal Reflux		Motrin	C			UNKNOWN	
	Disease		Vicodin Tablets	C			UNKNOWN	
	Haematochezia		Morphine	C			UNKNOWN	
	Intestinal Obstruction		Carisoprodol	C			UNKNOWN	
	Myocardial Infarction		Carisoprodol	C			UNKNOWN	

	Nervous System Disorder		Lithium Acetate	C		
UNKNOWN						
	Oedema		Dilantin	C		
UNKNOWN						
	Peptic Ulcer					
	Peripheral Vascular Disorder					
	Renal Disorder					
	Sleep Apnoea Syndrome					

Date:06/13/05ISR Number: 4688984-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02063
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 376 DAY	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 376 DAY	Cerebrovascular Accident		Vioxx	SS		ORAL
Disability UNKNOWN	Depression		Plendil	C		
Other UNKNOWN	Dizziness		Glucotrol	C		
	Emotional Distress		[Therapy			
	Gallbladder Disorder		Unspecified]	C		
UNKNOWN						
	Inner Ear Disorder		Aspirin	C		
UNKNOWN						
	Myocardial Infarction		Baycol	C		
UNKNOWN						
	Spinal Disorder		Plavix	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Zestril	C		
UNKNOWN						

Date:06/13/05ISR Number: 4688985-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00103
Age:85 YR Gender:Female I/FU:F

Outcome	PT
Death	Arthralgia
Hospitalization -	Aspiration
Initial or Prolonged	Atrial Fibrillation
	Back Pain

	Blood Urea Increased						
	Cerebrovascular Accident						
	Dizziness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemoglobin Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	1165 DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	1165 DAY
	Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Spinal Osteoarthritis		Premarin	C			UNKNOWN
			Accupril	C		ORAL	
			Procardia Xl	C		ORAL	
			Methotrexate	C		ORAL	
			Folic Acid	C			UNKNOWN
			Os-Cal	C			UNKNOWN
			Diclofenac	C			UNKNOWN
			Xanax	C		ORAL	
			Reglan	C			UNKNOWN

Date:06/13/05ISR Number: 4688991-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03459
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	121 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	121 DAY
Disability	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	No Therapeutic Response		Vioxx	SS	Merck & Co., Inc	ORAL	121 DAY
	Pyrexia		Premarin	C			UNKNOWN
	Renal Disorder		Synthroid	C			UNKNOWN
	Urinary Tract Infection						

Date:06/13/05ISR Number: 4688992-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00108
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4688993-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03291
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Anxiety		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Emotional Distress							
	Myocardial Infarction							
	Polytraumatism							

Date:06/13/05ISR Number: 4688994-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00105
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4688995-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00107
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4688996-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03889
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	38 MON	
			Lipitor	C			UNKNOWN	
			Ketoconazole	C			UNKNOWN	
			Viagra	C			UNKNOWN	
			Casodex	C			UNKNOWN	

Date:06/13/05ISR Number: 4688997-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00109
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4688998-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02602
Age:18 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30 DAY	
Initial or Prolonged	Coagulopathy		Vioxx	SS	Merck & Co., Inc	ORAL	30 DAY	
Disability	Convulsion							
	Deep Vein Thrombosis							
	Depression							
	Rash							
	Stress							
	Systemic Lupus							
	Erythematosus							
	Tooth Disorder							

Date:06/13/05ISR Number: 4688999-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02274
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Occlusion		Diovan	C				UNKNOWN
	Coronary Artery Stenosis		Micardis	C				UNKNOWN
	Emotional Distress		Micardis	C				UNKNOWN
	Intervertebral Disc Disorder		Toprol Xl Tablets	C		ORAL		
			Norvasc	C				UNKNOWN
	Myocardial Infarction		Aspirin	C				UNKNOWN
	Pancreatic Cyst		Plavix	C				UNKNOWN
	Renal Pain		Plavix	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Zocor	C		ORAL		
			Zoloft	C				UNKNOWN

Date:06/13/05ISR Number: 4689001-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00106
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689002-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03002
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Hospitalization -			Zantac	C			UNKNOWN	
Initial or Prolonged			Tagamet	C			UNKNOWN	

Date:06/13/05ISR Number: 4689004-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00122
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1735	DAY

Date:06/13/05ISR Number: 4689006-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00121
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689007-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00124
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689008-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00127
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/13/05ISR Number: 4689009-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00111
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689011-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00129
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689012-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00113
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689013-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00123
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689015-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00118
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689017-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00110
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689018-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00135
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:06/13/05ISR Number: 4689019-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00137
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689020-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00738
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689023-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00141
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	366 DAY	

Date:06/13/05ISR Number: 4689024-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00566
Age:47 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Amnesia
	Anxiety
	Arthritis
	Asthma
	Atherosclerosis
	Cardiac Failure
	Congestive
	Cardiac Valve Disease

		Cerebrovascular Accident					
		Chest Pain					
		Chronic Obstructive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Bumetanide	C		
UNKNOWN							
		Deep Vein Thrombosis		Ultram	C		
UNKNOWN							
		Depression		Naproxen	C		
UNKNOWN							
		Dermatitis		Norvasc	C		
UNKNOWN							
		Diabetes Mellitus		Amitriptyline			
		Dizziness		Hydrochloride	C		
UNKNOWN							
		Fall		Elavil	C		
UNKNOWN							
		Fibromyalgia		Cardizem	C		
UNKNOWN							
		Gastrooesophageal Reflux		Cozaar	C		
UNKNOWN							
		Disease		Lisinopril	C		
UNKNOWN							
		Haematochezia		Clonazepam	C		
UNKNOWN							
		Heart Rate Increased		Ultracet	C		
UNKNOWN							
		Hemiparesis		Serevent	C		
RESPIRATORY							
		Herpes Simplex					
(INHALATION)							
		Hypertension		Neurontin	C		
UNKNOWN							
		Hypoaesthesia		Vicodin Tablets	C		
UNKNOWN							
		Inflammation					
		Liver Disorder					
		Microcytic Anaemia					
		Myocardial Infarction					
		Nausea					
		Oedema Peripheral					
		Panic Attack					
		Pharyngolaryngeal Pain					
		Post-Traumatic Stress					

Disorder
Rheumatoid Arthritis
Suicide Attempt
Ulcer
Vision Blurred
Weight Increased

Date:06/13/05ISR Number: 4689027-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00850
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:06/13/05ISR Number: 4689028-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00134
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:06/13/05ISR Number: 4689029-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00822
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689030-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00131
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

Date:06/13/05ISR Number: 4689033-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00503
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Pain		Metoprolol	C				
UNKNOWN								
Initial or Prolonged	Bronchitis		[Therapy					
Disability	Headache		Unspecified]	C				
UNKNOWN								
	Heart Rate Irregular		Insulin	C				
UNKNOWN								
	Muscular Weakness							
	Vertigo							

Date:06/13/05ISR Number: 4689034-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01005
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
992 DAY								
	Emotional Distress		Zocor	C		ORAL		
3 YR								
	Haemorrhoids		Zestril	C		ORAL		
43 MON								
	Intervertebral Disc Disorder							
	Myocardial Infarction							
	Rectal Polyp							

Date:06/13/05ISR Number: 4689035-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02190
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acrochordon Excision		Vioxx	PS	Merck & Co., Inc	ORAL		1607 DAY
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		1612 DAY
Other	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		1612 DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1607 DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1612 DAY
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		1612 DAY
	Emotional Distress		Tiazac	C				UNKNOWN
	Gastrooesophageal Reflux		Nexium	C				UNKNOWN
	Disease							
	Hypertension							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nail Operation							
	Scar							
	Supraventricular Extrasystoles							
	Tricuspid Valve Incompetence							
	Trigger Finger							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689083-1Report Type:Expedited (15-DaCompany Report #200512465US
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Glucose Increased		Lantus	PS	Aventis Pharmaceuticals Inc.	SUBCUTANEOUS	Dose unit: units	
	Cerebrovascular Accident							
	Infection		Opticlik (Insulin Injection Pen)	SS			dose: UNK	
	Pharmaceutical Product							
	Complaint		Vioxx	SS			dose: UNK	
	Pyrexia		Some Type Of Insulin Nos	C			dose: UNK	
	Viral Infection							
	Vomiting		Proventil	C			dose: UNK	
			Zocor	C				
			Synthroid	C				
			Actos	C			dose: 10-12.5	
			Zestril	C			dose: UNK	
			Plavix	C				
			Amaryl	C				
			Levaquin	C			dose: UNK	
			Namenda	C			dose: UNK	

Date:06/13/05ISR Number: 4689237-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00753
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Anaemia		Plavix	C		ORAL		
	Angina Pectoris		Ginkgo Biloba Forte	C		ORAL		
Disability	Atrial Fibrillation		Imdur	C		ORAL		
Other	Blood Pressure Increased		Imdur	C		ORAL		
	Brain Stem Infarction		Norvasc	C		ORAL		
	Cerebrovascular Accident		Trazodone					

	Chest Discomfort	Hydrochloride	C	ORAL
	Colonic Polyp	Metoprolol	C	ORAL
	Convulsion	Lysine	C	ORAL
	Death	Lanoxin	C	ORAL
	Depressed Level Of	Lasix (Furosemide)	C	ORAL
	Consciousness	Xanax	C	ORAL
	Depression	Ultram	C	ORAL
	Diverticulum	Humulin 70/30	C	
SUBCUTANEOUS				
	Fall	Humulin 70/30	C	
SUBCUTANEOUS				
	Gastrointestinal	Avandia	C	ORAL
	Haemorrhage	Aspirin	C	ORAL
	General Physical Health	Pravachol	C	ORAL
	Deterioration	Sonata	C	ORAL
	Hiatus Hernia	Paxil	C	ORAL
	Memory Impairment	Prevacid	C	ORAL
	Normal Pressure			
	Hydrocephalus			
	Oesophagitis			
	Respiratory Failure			
	Sinus Bradycardia			

Date:06/13/05ISR Number: 4689239-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02021
Age:53 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
39 MON		Atrial Flutter		Vioxx	SS	Merck & Co., Inc	ORAL
39 MON		Blood Glucose Decreased		Amaryl	C		
UNKNOWN		Blood Glucose Increased		Lexapro	C		
UNKNOWN		Body Temperature		Aspirin	C		
UNKNOWN		Increased		Glucophage	C		
UNKNOWN		Cardiac Failure		Glucophage	C		
UNKNOWN		Congestive		Celebrex	C		
UNKNOWN		Carotid Artery Atheroma		Vicodin Tablets	C		
UNKNOWN		Chest Discomfort		Ventilan (Albuterol)	C		
UNKNOWN		Chest Pain		Vitamins (Unspecified)	C		
UNKNOWN		Coronary Artery Disease					
UNKNOWN		Dyspnoea		Chondroitin Sulfate Sodium And Glucosamine Sulfate	C		
UNKNOWN		Effusion					
UNKNOWN		Emotional Distress					
UNKNOWN		Fluid Overload		Nitroglycerin	C		
UNKNOWN		Fluid Retention		Imdur	C		
UNKNOWN		Implant Site Infection		Alupent	C		
UNKNOWN		Incision Site		Alupent	C		
UNKNOWN		Complication		Lorcet 10/650	C		
UNKNOWN		Myocardial Infarction					
		Oedema Peripheral					
		Parotitis					
		Pleural Effusion					
		Sleep Apnoea Syndrome					
		Throat Tightness					

Ventricular Dysfunction

Date:06/13/05ISR Number: 4689240-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01927
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
	Chest Pain							
	Coronary Artery Disease							
	Dyspnoea							
	Hypertrophic Anal Papilla							
	Pupil Fixed							

Date:06/13/05ISR Number: 4689241-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01928
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Blood Cholesterol Increased
	Bradycardia
	Cardiac Disorder
	Chest Pain
	Chest Wall Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Perforation
	Coronary Artery Stenosis

		Dizziness					
		Emotional Distress					
		Fatigue	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
1	YR						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Allegra	C		
UNKNOWN							
		Gout		Vitamins			
		Hyperlipidaemia		(Unspecified)	C		
UNKNOWN							
		Hypotension		Biaxin	C		
UNKNOWN							
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Nasal Disorder					
		Nasal Operation					
		Procedural Complication					
		Tricuspid Valve					
		Incompetence					
		Ventricular Hypertrophy					

Date:06/13/05ISR Number: 4689242-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01903
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
433	YR						
Initial or Prolonged		Back Pain		Zocor	C		ORAL
693	DAY						
		Blood Pressure Decreased		Synthroid	C		
UNKNOWN							
		Cellulitis					
		Coronary Artery Disease					
		Diverticulum					
		Haemorrhoids					
		Intervertebral Disc					
		Protrusion					
		Myocardial Infarction					

Date:06/13/05ISR Number: 4689244-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00759
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Acquired Diaphragmatic
Disability	Eventration
Other	Acute Respiratory Failure
	Alcohol Use
	Angina Pectoris
	Arrhythmia
	Atelectasis
	Atrial Fibrillation
	Back Pain
	Basal Cell Carcinoma
	Bipolar Disorder
	Blood Pressure Increased
	Bundle Branch Block Right
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cerebral Ischaemia
	Chest Discomfort
	Chest Pain
	Convulsion

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Coronary Artery Atherosclerosis Coronary Artery Disease					
		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
536 DAY							
		Decreased Activity		Vioxx	SS	Merck & Co., Inc	ORAL
		Diaphragmatic Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
		Diaphragmatic Paralysis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
536 DAY							
		Disease Recurrence		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Abuser		Vioxx	SS	Merck & Co., Inc	ORAL
214 DAY							
		Dyskinesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Buspar	C		ORAL
405 DAY							
		Dyspnoea Exertional		Lortab	C		ORAL
573 DAY							
		Ejection Fraction		Lortab	C		ORAL
		Decreased		Ziac	C		ORAL
322 DAY							
		Electrocardiogram Change		Vicodin Tablets	C		ORAL
		Electrocardiogram P Wave		Lipitor	C		ORAL
		Abnormal		Valium	C		ORAL
214 DAY							
		Electrocardiogram Qrs		Talwin	C		ORAL
24 DAY							
		Complex Prolonged		Ultram	C		ORAL
9 DAY							
		Fatigue		Skelaxin	C		ORAL
14 DAY							
		Feeling Abnormal		Tenyl	C		
UNKNOWN		36 DAY					
		Haemoptysis		Claritin	C		
UNKNOWN							
		Hypercholesterolaemia		Serzone	C		
UNKNOWN							
		Hypotension		Carisoprodol	C		
UNKNOWN							
		Hypoxic Encephalopathy		Acetaminophen And			
		Implant Site Erythema		Propoxyphene			
		Implant Site Swelling		Hydrochloride	C		
UNKNOWN							
		Intervertebral Disc		Mobic	C		
UNKNOWN							

	Degeneration	Hydrocodone	
	Intervertebral Disc	Hydrochloride	C
UNKNOWN			
	Protrusion	Altace	C
UNKNOWN			
	Jaw Disorder	Toprol Xl Tablets	C
UNKNOWN			
	Loss Of Consciousness	Aspirin	C
UNKNOWN			
	Lumbar Spinal Stenosis		
	Lung Consolidation		
	Musculoskeletal		
	Discomfort		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Nodal Rhythm		
	Pulmonary Congestion		
	Radicular Pain		
	Respiratory Rate		
	Increased		
	Road Traffic Accident		
	Sinus Disorder		
	Squamous Cell Carcinoma		
	Of Skin		
	Stress		
	Sudden Death		
	Tremor		
	Ventricular Extrasystoles		
	Ventricular Fibrillation		
	Ventricular Hypertrophy		
	Ventricular Hypokinesia		
	Weight Decreased		
	Weight Increased		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689246-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01897
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Glucophage	C			UNKNOWN	
	Cardiac Arrest		Flovent	C			UNKNOWN	
	Cardiac Failure		Serevent	C			UNKNOWN	
	Congestive		Amaryl	C			UNKNOWN	
	Cardiogenic Shock							
	Cerebrovascular Accident							
	Chest Wall Pain							
	Coronary Artery Disease							
	Depressed Level Of Consciousness							
	Diabetic Gastroparesis							
	Dressler'S Syndrome							
	Drug Ineffective							
	Emotional Distress							
	Hypertension							
	Myocardial Ischaemia							
	Nausea							
	Oral Intake Reduced							
	Pleural Effusion							
	Pyrexia							
	Renal Failure Acute							
	Renal Failure Chronic							
	Respiratory Failure							
	Sedation							
	Ventricular Dysfunction							
	Vomiting							
	White Blood Cell Count Increased							

Date:06/13/05ISR Number: 4689252-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02506
Age:75 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Abdominal Abscess
	Abdominal Pain Lower
	Anal Inflammation
	Arthritis
	Barrett'S Oesophagus
	Body Temperature Decreased
	Bowel Sounds Abnormal
	Breath Sounds Decreased
	Carbon Dioxide Decreased
	Colitis
	Constipation
	Crohn'S Disease
	Cyst
	Diarrhoea
	Diverticulum Duodenal
	Dyspepsia
	Electrocardiogram Abnormal
	Emotional Distress
	Enterocolitis

		Enterocolitis Infectious					
		Extravasation					
		Gastrointestinal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
28	DAY						
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
28	DAY						
		Disease		Vasotec	C		ORAL
		Haematochezia		Vasotec	C		ORAL
		Haemorrhoids		Lipitor	C		
UNKNOWN							
		Hiatus Hernia		Ecotrin	C		ORAL
		Hypercholesterolaemia		Hydrochlorothiazide	C		
UNKNOWN							
		Hypertension		Prevacid	C		
UNKNOWN							
		Ileal Ulcer		Relafen	C		
UNKNOWN							
		Ileitis		Ziac	C		
UNKNOWN							
		Injury		Zebeta	C		
UNKNOWN							
		Intervertebral Disc					
		Degeneration					
		Lactose Intolerance					
		Large Intestinal					
		Obstruction					
		Large Intestinal Ulcer					
		Large Intestine					
		Perforation					
		Livedo Reticularis					
		Lung Infiltration					
		Malabsorption					
		Metabolic Acidosis					
		Miosis					
		Mucosal Erosion					
		Multi-Organ Failure					
		Nausea					
		Necrotising Colitis					
		Osteoarthritis					
		Pleural Effusion					
		Purulence					
		Renal Cortical Necrosis					
		Renal Failure Acute					
		Renal Impairment					
		Renal Necrosis					

Renal Tubular Necrosis
Respiratory Failure
Septic Shock
Sinus Tachycardia
Small Intestine Ulcer
Spinal Osteoarthritis
Spleen Disorder
Ureteral Disorder
Vasospasm
Vomiting
White Blood Cell Count
Increased
Wound Infection

Date:06/13/05ISR Number: 4689253-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02215
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Akinesia
	Angina Pectoris

		Arterial Disorder					
		Blood Calcium Increased					
		Blood Phosphorus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Increased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Chest Wall Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion					
		Coronary Artery Stenosis					
		Costochondritis					
		Dilatation Atrial					
		Emotional Distress					
		Gastrooesophageal Reflux					
		Disease					
		Haemoglobin Decreased					
		Hypertension					
		Iliac Artery Stenosis					
		Iliac Artery Thrombosis					
		Intermittent Claudication					
		Lipoma					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Prostate Cancer					
		Rales					
		Scrotal Haematoma					
		Ventricular Dysfunction					

Date:06/13/05ISR Number: 4689254-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01932
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
12 MON						
Initial or Prolonged	Arthralgia		Diovan	C		
UNKNOWN						
Other	Asthenia					
	Cerebral Atherosclerosis					
	Cerebrovascular Accident					
	Diabetes Mellitus					
	Dysphagia					

Emotional Distress
Gastroenteritis
Gastrooesophageal Reflux
Disease
Hypertension
Hypoaesthesia
Hypoaesthesia Oral
Increased Tendency To
Bruise
Neuropathy Peripheral
Paraesthesia
Pharyngolaryngeal Pain
Refusal Of Treatment By
Patient
Temperature Intolerance
Transient Ischaemic
Attack

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689255-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02051
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		58 MON
Initial or Prolonged	Increased		Cardizem	C				UNKNOWN
Other	Blood Triglycerides		Premarin	C				UNKNOWN
	10 YR							
	Increased							
	Breast Microcalcification							
	Carotid Artery Stenosis							
	Cerebral Ischaemia							
	Cerebrovascular Accident							
	Cholecystitis							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Emotional Distress							
	Hyperlipidaemia							
	Lacunar Infarction							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Pain							
	Polyp							
	Sleep Disorder							
	Spinal Column Stenosis							
	Vulvovaginitis							
	Trichomonal							

Date:06/13/05ISR Number: 4689256-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02132
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Akinesia		Vioxx	PS	Merck & Co., Inc	ORAL		67 MON
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		67 MON
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		67 MON

	Blindness Transient	Zanaflex	C
UNKNOWN			
	Blood Pressure Increased	Senokot (Senna)	C
UNKNOWN			
	Cerebral Infarction	Ms Contin	C
UNKNOWN			
	Cerebrovascular Accident	Neurontin	C
UNKNOWN			
	Coronary Artery Disease	Effexor	C
UNKNOWN			
	Dilatation Atrial	Zanaflex	C
UNKNOWN			
	Drug Ineffective		
	Dyslipidaemia		
	Embolic Stroke		
	Hemianopia		
	Hepatic Failure		
	Hepatic Function Abnormal		
	Hypertension		
	Muscle Spasms		
	Visual Field Defect		

Date:06/13/05ISR Number: 4689257-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02223
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Coronary Artery Disease
	Coronary Artery Stenosis

		Diverticulitis					
		Ejection Fraction Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Glucotrol	C		
UNKNOWN							
		Ventricular Hypokinesia		Metformin	C		ORAL
				Lipitor	C		ORAL
				Metoprolol	C		ORAL
				Zyrtec	C		ORAL
				Tegretol	C		ORAL
				Tegretol	C		ORAL
				Aspirin	C		
UNKNOWN							

Date:06/13/05ISR Number: 4689258-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02280
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 5 YR	Anaemia Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Pain		Vicodin Tablets	C		
UNKNOWN						
Other	Chest Pain		Phentermine	C		
UNKNOWN						
	Chronic Obstructive		Zocor	C		
UNKNOWN						
	Pulmonary Disease		Nexium	C		
UNKNOWN						
	Coronary Artery		Lamisil	C		
UNKNOWN						
	Atherosclerosis		Nystatin	C		
UNKNOWN						
	Coronary Artery Disease		Lotrel	C		
UNKNOWN						
	Diabetes Mellitus		Fioricet Tablets	C		
UNKNOWN						
	Dizziness		Arthrotec	C		
UNKNOWN						
	Dyspnoea					
	Emotional Distress					
	Hypersensitivity					
	Hypoaesthesia					

Hypoperfusion
Intervertebral Disc
Protrusion
Lumbar Radiculopathy
Mental Disorder
Myocardial Infarction
Myocardial Ischaemia
Nausea
Paraesthesia
Peptic Ulcer
Pulmonary Embolism
Thrombosis
Transient Ischaemic
Attack
Venous Thrombosis Limb

Date:06/13/05ISR Number: 4689259-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02275
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
Disability	Blood Cholesterol Increased
	Blood Pressure Increased
	Blood Triglycerides Increased
	Bradycardia
	Cerebrovascular Accident

		Chest Pain					
		Cough					
		Crepitations	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL
5	MON						
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
5	MON						
		Dyspepsia		Singulair	C		ORAL
		Dyspnoea		Prednisone	C		
UNKNOWN							
		Emotional Distress		Alupent	C		
UNKNOWN							
		Eye Pain		Naproxen	C		
UNKNOWN		1	YR				
		Flatulence		Advair	C		
UNKNOWN							
		High Density Lipoprotein		Albuterol	C		
UNKNOWN							
		Increased		Alesse	C		
UNKNOWN							
		Hordeolum					
		Hypertension					
		Hypotension					
		Loss Of Consciousness					
		Low Density Lipoprotein					
		Increased					
		Ocular Hyperaemia					
		Syncope					
		Syncope Vasovagal					
		Tachycardia					
		Wheezing					

Date:06/13/05ISR Number: 4689260-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02098
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Anxiety
	Arrhythmia
	Atelectasis
	Blood Pressure Increased
	Blood Triglycerides

Increased
Burning Sensation
Cardiomegaly
Chest Pain
Chronic Obstructive
Pulmonary Disease
Contusion
Coronary Artery Disease
Coronary Artery Occlusion
Depression
Dizziness
Dyspepsia
Ejection Fraction
Decreased
Electrocardiogram St-T
Change
Emotional Distress
Eye Injury
Ganglion
Haematoma
Headache
Heart Rate Abnormal
Hyperlipidaemia
Hypertension

		Hypoaesthesia					
		Hypoxia					
		Incision Site	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Complication		Vioxx	PS	Merck & Co., Inc	ORAL
		Liver Function Test		Vioxx	SS	Merck & Co., Inc	ORAL
		Abnormal					
		Mental Disorder					
		Mitral Valve Disease					
		Nerve Compression					
		Pulmonary Embolism					
		Radiculopathy					
		Rash Pruritic					
		Sleep Apnoea Syndrome					
		Sleep Disorder					
		Syncope					
		Thrombophlebitis					
		Superficial					
		Ventricular Dysfunction					
		Ventricular Hypokinesia					

Date:06/13/05ISR Number: 4689261-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00873
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Fosamax	C		ORAL
	Cystitis		Singulair	C		ORAL
	Ear Pain		Pamelor	C		
UNKNOWN						
	Electrocardiogram		Valium	C		
UNKNOWN						
	Abnormal		Percocet	C		
UNKNOWN						
	Groin Pain		Flonase	C		
UNKNOWN						
	Headache		Premarin	C		
UNKNOWN						
	Neck Pain		Allegra	C		
UNKNOWN						
	Somnolence		Plavix	C		
UNKNOWN						
	Urine Odour Abnormal					

Date:06/13/05ISR Number: 4689262-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02088
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Vicodin Tablets	C			UNKNOWN	
	Reocclusion		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Coronary Artery Stenosis							
	Diastolic Dysfunction							
	Dyspepsia		Flexeril	C		ORAL		
	Emotional Distress		Metoprolol	C			UNKNOWN	
	Feeling Hot		Plavix	C		ORAL		
	Hyperlipidaemia		Zocor	C		ORAL		
	Hypotension							
	Myocardial Infarction							
	Nausea							
	Pleuritic Pain							
	Tricuspid Valve Incompetence							
	Urinary Tract Infection							
	Ventricular Dysfunction							
	Ventricular Hypokinesia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02228
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Atherosclerosis		Lozol	C				
UNKNOWN								
Other	Blood Cholesterol		Zocor	C				
UNKNOWN								
	Increased		Cardizem	C				
UNKNOWN							1493	DAY
	Cardiomegaly		Bayer Aspirin	C				
UNKNOWN								
	Coronary Artery		Prinivil	C				
UNKNOWN								
	Atherosclerosis							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Emotional Distress							
	Hernia Repair							
	Hip Arthroplasty							
	Myocardial Calcification							
	Myocardial Infarction							
	Oedema Peripheral							

Date:06/13/05ISR Number: 4689264-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02083
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Cartia (Diltiazem Hydrochloride)	C		ORAL		
			Cartia (Diltiazem Hydrochloride)	C		ORAL		
			Bayer Aspirin	C				
UNKNOWN								
			Lorazepam	C				
UNKNOWN								
			Viagra	C				
UNKNOWN								
			Toprol Xl Tablets	C		ORAL		

Levitra C
UNKNOWN

Date:06/13/05ISR Number: 4689267-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02787
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acquired Cardiac Septal Defect
	Arthralgia
	Arthroscopy
	Blood Cholesterol Increased
	Bronchitis Acute
	Bronchospasm
	Cardiac Murmur
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Depression
	Hypertension
	Knee Operation
	Lobar Pneumonia
	Meniscus Lesion
	Myocardial Infarction
	Oedema Peripheral
	Pain In Extremity

	Pneumonia Weight Increased	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	5 YR
			Vioxx	SS	Merck & Co., Inc	ORAL	5 YR
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	5 YR
			Vioxx	SS	Merck & Co., Inc	ORAL	5 YR
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Prozac	C		ORAL	
			Tenormin	C		ORAL	

Date:06/13/05ISR Number: 4689269-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03082
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/13/05ISR Number: 4689270-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00008
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 1505 DAY	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Cerebral Infarction		Prednisolone	C		ORAL	
	Dizziness						
	Fall						
	Humerus Fracture						
	Infection						
	Nausea						
	Neurological Symptom						
	Sensory Loss						

Date:06/13/05ISR Number: 4689271-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00827
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689272-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02538
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Apnoea		Vioxx	PS	Merck & Co., Inc	ORAL	132 DAY	
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	132 DAY	
	Coma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depressed Level Of		Aspirin	C			UNKNOWN	
	Consciousness							
	Diarrhoea							
	Fall							
	Fatigue							
	Hypertension							
	Pain							
	Pulse Absent							
	Pupil Fixed							
	Ventricular Fibrillation							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689273-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02362
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	11 DAY	
Initial or Prolonged	Infarction		Imitrex Tablets	C			UNKNOWN	
Disability	Anxiety							
	Arthralgia							
	Blood Glucose Increased							
	Blood Pressure Increased							
	Coronary Artery Disease							
	Depression							
	Feeling Abnormal							
	Homocystinuria							
	Insomnia							
	Irritable Bowel Syndrome							
	Meniscus Lesion							
	Migraine							
	Neuropathy Peripheral							
	Pain							
	Panic Disorder							
	Self-Medication							
	Toothache							
	Vasospasm							
	Ventricular Hypokinesia							

Date:06/13/05ISR Number: 4689274-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02663
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Angina Pectoris
Disability	Angina Unstable
	Anxiety
	Arthropathy
	Bradycardia
	Cellulitis
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis

Emotional Distress
Gastric Disorder
Gastritis
Gastrooesophageal Reflux
Disease
Hypertension
Intervertebral Disc Space
Narrowing
Intracardiac Thrombus
Lipoma
Mass
Musculoskeletal Pain
Myalgia
Myelopathy
Myocardial Infarction
Myocardial Ischaemia
Pain In Extremity
Shoulder Pain
Sleep Apnoea Syndrome

		Spinal Osteoarthritis					
		Tachycardia					
		Thrombosis In Device	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Upper Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Isosorbide	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Wellbutrin Sr	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Nitroquick	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/13/05ISR Number: 4689275-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02381
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
130 DAY							
Initial or Prolonged		Arteriospasm Coronary		Aspirin	C		ORAL
Disability		Bradyarrhythmia		Synthroid	C		
UNKNOWN							
		Cardiovascular Disorder					
		Coronary Artery					
		Atherosclerosis					
		Coronary Artery Disease					
		Coronary Artery Stenosis					
		Depression					
		Disturbance In Attention					
		Ejection Fraction					

Decreased
Hyperlipidaemia
Mitral Valve Incompetence
Mitral Valve Prolapse
Myocardial Infarction
Palpitations
Panic Disorder
Sinus Bradycardia
Stress
Ventricular Dysfunction
Ventricular Extrasystoles
Ventricular Hypertrophy
Ventricular Hypokinesia

Date:06/13/05ISR Number: 4689281-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689282-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00976
Age: Gender:Female I/FU:I

Outcome	PT
Disability	Blood Cholesterol
Other	Increased
	Blood Pressure Increased

		Cardiac Disorder Cerebrovascular Accident Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Ambien	C		
UNKNOWN							
		Overdose		Wellbutrin	C		
UNKNOWN							
		Surgery		Hydrocodone			
		Transient Ischaemic		Bitartrate	C		
UNKNOWN							
		Attack		Clonazepam	C		
UNKNOWN							
				Diflucan	C		
UNKNOWN							
				Lexapro	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							
				Carisoprodol	C		
UNKNOWN							
				Naprosyn	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Clonazepam	C		
UNKNOWN							

Date:06/13/05ISR Number: 4689283-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00973
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/13/05ISR Number: 4689284-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689285-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689286-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00831
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689287-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689288-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:06/13/05ISR Number: 4689289-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00970
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abnormal Behaviour		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Asthma		Levoxyl	C			UNKNOWN	
	Atherosclerosis		Wellbutrin	C			UNKNOWN	
	Blood Cholesterol		Detrol	C			UNKNOWN	
	Increased		Imitrex Tablets	C			UNKNOWN	
	Bronchospasm		Neurontin	C			UNKNOWN	
	Carotid Artery Stenosis		Neurontin	C			UNKNOWN	
	Carotid Bruit		Flexeril	C			UNKNOWN	
	Cerebral Infarction		Flexeril	C			UNKNOWN	
	Cerebrovascular Accident		Diclofenac	C			UNKNOWN	
	Confusional State		Xalatan	C			UNKNOWN	
	Disorientation		Ventolin (Albuterol)	C			UNKNOWN	
	Dizziness		Nicotrol	C			UNKNOWN	
	Emotional Distress							
	Fall							
	Gait Disturbance							
	Gastrooesophageal Reflux Disease							
	Headache							

Hypertension
Hypothyroidism
Lacunar Infarction
Lethargy
Migraine
Nausea
Osteoarthritis
Pneumonia
Syncope
Transient Ischaemic
Attack
Vertebral Artery Stenosis
Visual Field Defect

Date:06/13/05ISR Number: 4689291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02568
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00928
Age:45 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Adrenal Mass
	Chest Pain
Disability	Cholecystitis Acute
	Coronary Artery Disease

		Depression					
		Emotional Distress					
		Fistula	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL
3	YR						
		Hypercholesterolaemia		Paxil	C		
UNKNOWN							
		Hypertension					
		Hypoxia					
		Incision Site Cellulitis					
		Liver Function Test					
		Abnormal					
		Myocardial Infarction					
		Oedema Peripheral					
		Osteoarthritis					
		Tachycardia					

Date:06/13/05ISR Number: 4689293-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02914
Age:58 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Angina Pectoris					
		Arteriosclerosis					
		Blood Pressure					
		Immeasurable					
		Cardio-Respiratory Arrest					
		Cerebrovascular Accident					
		Depressed Level Of					
		Consciousness					
		Depression					
		Emotional Distress					
		Gastrooesophageal Reflux					
		Disease					
		Haematochezia					
		Myocardial Infarction					
		Peptic Ulcer					
		Renal Failure Chronic					
		Skin Ulcer					
		Sleep Apnoea Syndrome					

Date:06/13/05ISR Number: 4689294-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02895
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Arrhythmia
	Asthenia
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Electrocardiogram Q Waves
	Emotional Distress
	Fatigue
	Heart Rate Irregular
	Mental Disorder
	Myocardial Infarction
	Pain In Jaw
	Stress At Work

Ventricular Hypokinesia

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Detrol La	C			UNKNOWN	

Date:06/13/05ISR Number: 4689300-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	92	DAY

Date:06/13/05ISR Number: 4689301-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01036
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	448	DAY

Date:06/13/05ISR Number: 4689302-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:06/13/05ISR Number: 4689303-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689304-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689305-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689306-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01029
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689311-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01046
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689312-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689313-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689314-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689315-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01134
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689316-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01431
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Organ Failure Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689317-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01442
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/13/05ISR Number: 4689320-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/13/05ISR Number: 4689321-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01243
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -			Atenolol	C				
UNKNOWN								
Initial or Prolonged			Cozaar	C				
UNKNOWN								
Disability			Insulin	C				
UNKNOWN								

Date:06/13/05ISR Number: 4690206-9Report Type:Expedited (15-DaCompany Report #2005062475
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain	Consumer	Daypro					
Initial or Prolonged	Drug Ineffective	Health	(Oxaprozin)	PS				
UNKNOWN	UNKNOWN							
	Knee Arthroplasty	Professional	Celebrex					
	Pulmonary Embolism		(Celecoxib)	SS		ORAL	200 MG (200 MG, 1 IN 1 D), ORAL	
			Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D), ORAL	
			Vioxx (Rofecoxib)	SS				
UNKNOWN	UNKNOWN							

Date:06/14/05ISR Number: 4692110-9Report Type:Expedited (15-DaCompany Report #2005085296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Therapy Responder	Consumer	Celebrex (Celecoxib)	PS				

Vioxx (Rofecoxib) SS

Date:06/15/05ISR Number: 4690239-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01909
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Occlusion		Ibuprofen	C			UNKNOWN	
	Depression		Loestrin	C			UNKNOWN	
	Generalised Anxiety		Loestrin	C			UNKNOWN	
	Disorder		Toprol Xl Tablets	C			UNKNOWN	
	Impaired Fasting Glucose		Atenolol	C			UNKNOWN	
	Myocardial Infarction		Ecotrin	C			UNKNOWN	
	Myocardial Ischaemia		Pravachol	C			UNKNOWN	
	Palpitations		Lipitor	C			UNKNOWN	
			Mobic	C			UNKNOWN	
			Estratest	C			UNKNOWN	
			Medroxyprogesterone Acetate	C			UNKNOWN	
			Alprazolam	C			UNKNOWN	
			Hydrocodone Hydrochloride	C			UNKNOWN	
			Hydrocodone Hydrochloride	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690241-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03891
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Tofranil	C			UNKNOWN	
	Bronchitis		Plavix	C			UNKNOWN	
	Cerebrovascular Accident		Synthroid	C			UNKNOWN	
	Chest Pain		Norvasc	C			UNKNOWN	
	Dizziness		Prempro	C			UNKNOWN	
	Dyspnoea		Strovite	C			UNKNOWN	
	Fatigue		Aspirin	C		ORAL		
	Gastrointestinal Motility		Librium	C			UNKNOWN	
	Disorder		Zocor	C		ORAL	4	MON
	Headache		Zocor	C		ORAL	4	MON
	Hypercholesterolaemia							
	Hypertriglyceridaemia							
	Hypoaesthesia							
	Insomnia							
	Memory Impairment							
	Mitral Valve Incompetence							
	Morbid Thoughts							
	Platelet Aggregation							
	Increased							
	Presbyacusis							
	Tricuspid Valve							
	Incompetence							
	Upper Respiratory Tract							
	Infection							
	Vertigo							
	Vertigo Positional							

Date:06/15/05ISR Number: 4690242-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
Other	Anaemia
	Anal Fistula
	Anastomotic Complication
	Aneurysm Ruptured
	Angina Unstable
	Anxiety
	Appendicitis Perforated
	Arthralgia
	Atelectasis
	Back Pain
	Breast Mass
	Cardiac Failure
	Cerebral Artery Stenosis
	Chest Pain
	Colitis Ulcerative
	Contusion
	Convulsion
	Coronary Artery Disease
	Cough
	Crohn'S Disease
	Defaecation Urgency
	Depression
	Dermatitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dizziness Drug Ineffective Dyspepsia Faecal Incontinence Fall Flatulence Gastrooesophageal Reflux Disease Headache Hernia Hyperlipidaemia Hypertension Hypotension Ileitis Impaired Healing Infection Inflammatory Bowel Disease Intestinal Perforation Intestinal Spasm Intracranial Aneurysm Joint Injury Migraine Musculoskeletal Chest Pain Pain Pain In Extremity Palpitations Perianal Abscess Perirectal Abscess Pneumoperitoneum Pouchitis Proctalgia Proctitis Ulcerative Pruritus Ani Pyrexia Sepsis Sleep Disorder Subarachnoid Haemorrhage Syncope Tachycardia White Blood Cell Count Increased		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/15/05ISR Number: 4690243-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Arterial Occlusive Disease
	Aseptic Necrosis Bone
	Bursitis
	Carotid Artery Stenosis
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Cognitive Disorder
	Colonic Polyp
	Depression
	Diverticulum

	Drug Ineffective						
	Dyspepsia						
	Feeling Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Gait Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	92	DAY
	Haematochezia		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ischaemic Stroke		Duragesic	C			UNKNOWN	
	Joint Swelling		Prevacid	C			UNKNOWN	
	Nephrolithiasis		Effexor	C			UNKNOWN	
	Oesophageal Disorder							
	Pain							
	Seborrhoeic Keratosis							
	Skin Lesion							
	Spinal Disorder							
	Spinal Osteoarthritis							

Date:06/15/05ISR Number: 4690250-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01782
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis							
	Blood Triglycerides							
	Increased							
	Cardiac Failure							
	Congestive							
	Chronic Fatigue Syndrome							
	Chronic Obstructive							
	Pulmonary Disease							
	Coagulopathy							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Deep Vein Thrombosis							
	Drug Hypersensitivity							
	Emotional Distress							
	Haemoptysis							
	Hypertension							

Hypovolaemia
Lower Gastrointestinal
Haemorrhage
Myocardial Infarction
Nausea
Pulmonary Embolism
Scar
Thrombocytopenia
Thrombosis In Device

Date:06/15/05ISR Number: 4690251-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01908
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome Acute Myocardial Infarction Atherosclerosis Coronary Artery Disease Emotional Distress Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690252-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01784
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Advil	C		
UNKNOWN						
Disability	Chest Pain		Aspirin	C		
UNKNOWN						
	Dizziness					
	Emotional Distress					
	Headache					
	Hypertension					
	Myocardial Infarction					
	Road Traffic Accident					
	Thyroid Disorder					
	Vision Blurred					

Date:06/15/05ISR Number: 4690253-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02286
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
1265 DAY						
Initial or Prolonged	Adenoma Benign		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Adenomyosis		Toprol Xl Tablets	C		ORAL
598 DAY						
	Anaemia		Aspirin	C		ORAL
	Angina Pectoris		Premarin	C		ORAL
	Aortic Atherosclerosis		Darvocet-N	C		ORAL
	Appendix Disorder					
	Arrhythmia					
	Cervical Cyst					
	Cervicitis					
	Chest Pain					
	Coronary Artery Disease					
	Emotional Distress					
	Endometrial Disorder					
	Faeces Discoloured					
	Fluid Retention					
	Gastroenteritis					
	Headache					
	Hypertension					

Intervertebral Disc
Degeneration
Irritable Bowel Syndrome
Meniscus Lesion
Migraine
Myocardial Infarction
Ovarian Cyst
Pancreatitis
Pigmented Naevus
Reflux Oesophagitis
Scoliosis
Supraventricular
Tachycardia
Upper Respiratory Tract
Infection
Uterine Infection
Uterine Leiomyoma
Uterine Prolapse
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690254-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00010
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		665 DAY
Initial or Prolonged	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Epilepsy							
	Extrasystoles							
	Hemiparesis							
	Supraventricular							
	Tachycardia							

Date:06/15/05ISR Number: 4690255-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01921
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Prilosec	C				UNKNOWN
Disability	Increased		Zocor	C				UNKNOWN
	Carpal Tunnel Syndrome		Atenolol	C				UNKNOWN
	Chest Discomfort		Tylenol Extra					
	Chest Pain		Strength	C				UNKNOWN
	Convulsion							
	Coronary Artery Disease							
	Dilatation Atrial							
	Dyspnoea Exertional							
	Electrocardiogram St							
	Segment Depression							
	Emotional Distress							
	Gastritis Erosive							
	Gastrooesophageal Reflux							
	Disease							
	Hypertension							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Palpitations							
	Pulmonary Valve							

Incompetence
Rotator Cuff Syndrome
Sinus Bradycardia
Sleep Apnoea Syndrome
Spinal Disorder
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Ventricular Hypertrophy
Ventricular Hypokinesia

Date:06/15/05ISR Number: 4690256-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01905
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Biliary Colic
	Bronchospasm
Disability	Constipation
	Deep Vein Thrombosis
	Diarrhoea
	Emotional Distress
	Epistaxis

		Gastrooesophageal Reflux Disease					
		Hypothyroidism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Peptic Ulcer		Ginkgo Biloba			
		Peripheral Vascular		Extract	C		
UNKNOWN							
		Disorder					
		Pleural Effusion					
		Pulmonary Embolism					
		Rectal Haemorrhage					

Date:06/15/05ISR Number: 4690257-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01739
Age:53 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Anxiety		Prednisone	C		
UNKNOWN							
Other		Atherosclerosis		Immunotherapy			
		Back Pain		(Unspecified)	C		
UNKNOWN							
		Blood Cholesterol		Colazal	C		
UNKNOWN							
		Increased		Imuran			
		Chest Discomfort		(Azathioprine)	C		
UNKNOWN							
		Coronary Artery Occlusion		Celexa	C		
UNKNOWN							
		Crohn'S Disease		Rowasa	C		
UNKNOWN							
		Deafness					
		Discomfort					
		Electrocardiogram Poor					
		R-Wave Progression					
		Enzyme Abnormality					
		Hypertension					
		Movement Disorder					
		Nausea					
		Pulmonary Congestion					
		Qrs Axis Abnormal					

Sleep Apnoea Syndrome
Vomiting

Date:06/15/05ISR Number: 4690259-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02091
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Anxiety Disorder
	Aortic Atherosclerosis
	Atrial Fibrillation
	Atrial Septal Defect
	Bronchitis
	Cardiac Disorder
	Cellulitis
	Cerebral Infarction
	Cerebrovascular Accident
	Coronary Artery Disease
	Cystitis
	Deep Vein Thrombosis
	Depression
	Emotional Distress

	Emphysema						
	Hiatus Hernia						
	Hypertriglyceridaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL	4 MON
	Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL	4 MON
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL	
	Protrusion		Naprosyn	C			UNKNOWN
	Labyrinthitis		Paxil	C			UNKNOWN
	Oesophagitis		Synthroid	C			UNKNOWN
	Osteoporosis						
	Pruritus Generalised						
	Pulmonary Congestion						
	Rash Erythematous						
	Sinus Tachycardia						
	Sinusitis						
	Thoracic Outlet Syndrome						
	Upper Respiratory Tract Infection						
	Urinary Tract Infection						
	Vaginitis Gardnerella						

Date:06/15/05ISR Number: 4690311-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0503FRA00033
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Antibody Test Positive		Vioxx	PS	Merck & Co., Inc	ORAL	
	Erythema		Valpromide	C		ORAL	
	Oedema Peripheral		Triptorelin Acetate	C		ORAL	
	Purpura		Sertraline Hydrochloride	C			UNKNOWN
	Skin Lesion		Bicalutamide	C			UNKNOWN
			Rabeprazole Sodium	C			UNKNOWN
			Oxazepam	C			UNKNOWN

			Zopiclone	C		
UNKNOWN						

Date:06/15/05ISR Number: 4690312-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02079
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Pectoris		Aspirin	C		
UNKNOWN						
Disability	Angina Unstable					
	Blood Cholesterol Increased					
	Condition Aggravated					
	Coronary Artery Disease					
	Emotional Distress					
	Erectile Dysfunction					
	Hilar Lymphadenopathy					
	Hyperlipidaemia					
	Myocardial Infarction					
	Osteoarthritis					
	Spinal Osteoarthritis					
	Upper Respiratory Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690313-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02080
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Coronary Syndrome		Acetaminophen	C				
	Adverse Drug Reaction		Ambien	C				
	Anaemia		Amox	C				
	Angina Unstable		Androderm	C				
	Arthralgia		Augmentin	C				
	Chest Wall Pain		Bextra	C				
	Diarrhoea		Carisoprodol	C				
	Emotional Distress		Cefadroxil	C				
	Gastric Haemorrhage		Cipro	C				
	Gastrooesophageal Reflux Disease		Cyclobenzaprine(West Point Pharma)	C				
	Hepatitis Acute		Prednisona Sod. Fos	C				
	Hydronephrosis		Demerol	C				
	Myocardial Infarction		Detrol	C				
	Nephrolithiasis		Diazepam	C				
	Renal Failure Acute		Diflucan	C				
	Retroperitoneal Haematoma		Estazolam	C				
	Systemic Inflammatory Response Syndrome		Flurazepam Hydrochloride	C				
	Thrombocytopenia		Fosamax	C				
	Urinary Tract Infection Urosepsis		Hydrocodone Bitartrate	C				

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN

Isosorbide	C
Levaquin	C
Macrobid	C
Mercaptopurine	C
Metronidazole	C
Nystatin	C
Oxycodone	C
Plavix	C
Prevacid	C
Purinethol	C
Remicade	C
Sulfamethoxazole	C
Urispas	C
Ursodiol	C
Viagra	C
Vicodin Tablets	C
Zyvox	C
Celebrex	C

Date:06/15/05ISR Number: 4690315-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02081
Age:38 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
Other	Chest Pain
	Dizziness
	Dyspnoea Exertional
	Emotional Distress
	Headache
	Hemiplegia Transient
	Hypoaesthesia
	Myocardial Infarction
	Myopia

Nausea

	Palpitations						
	Paraesthesia						
	Renal Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Speech Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
	Vision Blurred		Cardizem	C			UNKNOWN

Date:06/15/05ISR Number: 4690316-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02304
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	886 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Alanine Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL	
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	886 DAY
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	
	Blood Alkaline		Vioxx	SS	Merck & Co., Inc	ORAL	
	Phosphatase Increased		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	
	Increased		Tylenol Arthritis				
	Blood Glucose Increased		Extended Relief	C			UNKNOWN
	Blood Pressure Increased		Advil	C			UNKNOWN
	Bundle Branch Block Right		Extra Strength Bayer				
	Carotid Artery Stenosis		Plus	C			UNKNOWN
	Chest Discomfort		Aleve	C			UNKNOWN
	Concussion		Aspirin	C			UNKNOWN
	Coronary Artery Disease		Celebrex	C			UNKNOWN
	Coronary Artery Occlusion						
	Cough						
	Diarrhoea						
	Diverticulitis						

Drug Hypersensitivity
Dyspepsia
Emotional Distress
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Hernia
Hyperphagia
Musculoskeletal
Discomfort
Myocardial Infarction
Myringoplasty
Oesophageal Disorder
Pneumonia
Polyuria
Sinus Bradycardia
Stress
Tympanic Membrane
Perforation
Ventricular Hypertrophy
Ventricular Tachycardia
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690317-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02055
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anger		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Cardiac Disorder		Metoprolol	C		ORAL
	Chest Pain		Imdur	C		ORAL
	Coronary Artery Disease		Nitrostat	C		ORAL
	Coronary Artery Stenosis		Promethazine	C		
UNKNOWN						
	Depression		Amiloride	C		
UNKNOWN						
	Dermatitis Contact		Prednisone	C		
UNKNOWN						
	Ejection Fraction		Ambien	C		
UNKNOWN						
	Decreased		Furosemide	C		
UNKNOWN						
	Insomnia		Nitroquick	C		
UNKNOWN						
	Irritability		Lipitor	C		ORAL
	Laceration		Plavix	C		ORAL
	Mitral Valve Prolapse		Acetaminophen And			
	Myalgia		Propoxyphene			
	Myocardial Infarction		Napsylate	C		ORAL
	Peptic Ulcer		Toprol Xl Tablets	C		ORAL
	Vascular Graft Occlusion		Atarax	C		ORAL
	Ventricular Dysfunction		Aspirin	C		ORAL
			Crataegus	C		ORAL
			Mevacor	C		ORAL

Date:06/15/05ISR Number: 4690318-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02090
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Asthma		Zyprexa	C		
UNKNOWN						
Other	Cardiac Murmur		Lithonate	C		
UNKNOWN						
	Cardiovascular Disorder		Cogentin	C		
UNKNOWN						

	Diabetes Mellitus	Accupril	C
UNKNOWN			
	Dyspnoea	Ibuprofen	C
UNKNOWN			
	Emotional Distress	Tylenol	C
UNKNOWN			
	Exophthalmos	Haloperidol	
	Grand Mal Convulsion	Decanoate	C
UNKNOWN			
	Hypercholesterolaemia	Isosorbide	
	Hypertension	Mononitrate	C
UNKNOWN			
	Mitral Valve Incompetence	Isosorbide	
	Myocardial Infarction	Mononitrate	C
UNKNOWN			
	Osteoarthritis	Medroxyprogesterone	
		Acetate	C
UNKNOWN			
		Depakote	C
UNKNOWN			
		Ferrous Sulfate	C
UNKNOWN			
		Hydrochlorothiazide	C
UNKNOWN			
		Amantadine	
		Hydrochloride	C
UNKNOWN			
		Aspirin	C
UNKNOWN			
		Zocor	C
UNKNOWN			

Date:06/15/05ISR Number: 4690324-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02283
Age:46 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Atherosclerosis
	Cholecystectomy

		Congestive Cardiomyopathy Coronary Artery Disease Coronary Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
983	DAY						
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
983	DAY						
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
983	DAY						
		Ejection Fraction		Vioxx	SS	Merck & Co., Inc	ORAL
983	DAY						
		Decreased		Zocor	C		ORAL
983	DAY						
		Emotional Distress		Levoxyl	C		
UNKNOWN							
		Gastrointestinal Disorder		Tylenol	C		
UNKNOWN							
		Gastrooesophageal Reflux Disease Ischaemic Cardiomyopathy Myocardial Infarction Sudden Death Tachyarrhythmia Ventricular Tachycardia					

Date:06/15/05ISR Number: 4690327-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00012
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
453	DAY					
Initial or Prolonged			Citalopram Hydrobromide	C		ORAL
			Clonazepam	C		ORAL
			Amitriptyline Hydrochloride	C		ORAL
			Acetaminophen	C		ORAL

Date:06/15/05ISR Number: 4690328-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00848
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		[Therapy					
	Hypertension		Unspecified]	C				
UNKNOWN								

Date:06/15/05ISR Number: 4690329-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00856
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								
Disability								

Date:06/15/05ISR Number: 4690330-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02320
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Neurontin	C				
UNKNOWN								
Disability	Increased		Vicodin Tablets	C				
UNKNOWN								
	Coronary Artery Disease		Methadone Hcl	C				
UNKNOWN								
	Emotional Distress		Synthroid	C				
UNKNOWN								
	Post Polio Syndrome							

Date:06/15/05ISR Number: 4690331-2Report Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00099
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		1140 DAY
Initial or Prolonged	Acute Myocardial Infarction Angina Unstable Coronary Artery Occlusion Depression							

Date:06/15/05ISR Number: 4690332-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02940
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc		UNKNOWN	13 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc		UNKNOWN	13 MON
Disability	Cerebrovascular Accident Deep Vein Thrombosis Hypertension							

Date:06/15/05ISR Number: 4690333-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00833
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690336-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00926
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		848 DAY

Initial or Prolonged Disability	Cardiac Disorder	Motrin	C	ORAL
	Cardiac Failure	Flexen (Naproxen)	C	ORAL
	Congestive	Samarin 70	C	ORAL
	Cardiac Murmur	Procardia	C	ORAL
	Cardiovascular Disorder	Bayer Aspirin	C	ORAL
	Chronic Fatigue Syndrome	Celebrex	C	ORAL
	Confusional State	Norvasc	C	
UNKNOWN				
	Deep Vein Thrombosis	Cardizem	C	
UNKNOWN				
	Depression	Hepathrombin		
	Gastric Disorder	(Heparin)	C	
UNKNOWN				
	Gastroenteritis	Premarin	C	
UNKNOWN				
	Gastrooesophageal Reflux	Triam-A	C	
UNKNOWN				
	Disease	Correctol (Docusate		
	Glaucoma	Sodium)	C	
UNKNOWN				
	Gout	Cataflam (Diclofenac		
	Haematochezia	Potassium)	C	
UNKNOWN				
	Haemorrhage	Vicodin Tablets	C	ORAL
	Heart Disease Congenital	Lasix (Furosemide		
	Heart Rate Irregular	Sodium)	C	
UNKNOWN				
	Hypertension	Catapres	C	
UNKNOWN				
	Irritable Bowel Syndrome	Hormones		
	Panic Disorder	(Unspecified)	C	
UNKNOWN				
	Sinusitis			
	Sleep Apnoea Syndrome			
	Viral Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690385-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00146
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Condition Aggravated		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Duodenitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Metformin Hydrochloride	C		ORAL		
	Ventricular Hypertrophy		Indomethacin	C		ORAL		
			Indomethacin	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Enalapril Maleate	C				
UNKNOWN								
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Hydrochlorothiazide And Triamterene	C				
UNKNOWN								
			Captopril	C				
UNKNOWN								

Date:06/15/05ISR Number: 4690387-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/15/05ISR Number: 4690388-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690390-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690391-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00992
Age:50 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Angina Unstable

		Appendicitis					
		Chest Pain					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
		Restenosis		Aciphex	C		
UNKNOWN							
		Diabetes Mellitus		Zetia	C		
UNKNOWN							
		Emotional Distress		Bentyl	C		
UNKNOWN							
		Hypertensive Heart					
		Disease					
		Sick Sinus Syndrome					
		Sleep Apnoea Syndrome					
		Urinary Retention					
		Postoperative					

Date:06/15/05ISR Number: 4690394-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02367
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
1108 DAY							
Initial or Prolonged		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
773 DAY							
		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
1108 DAY							
		Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
773 DAY							
		Deep Vein Thrombosis		Xenical	C		
UNKNOWN							
		Depression		Levoxyl	C		
UNKNOWN							
		Diarrhoea					
		Diverticulum Intestinal					
		Dizziness					
		Dysphagia					
		Dyspnoea Exertional					
		Emotional Distress					
		Erectile Dysfunction					
		Eyelid Ptosis					
		Gastritis					
		Gastrointestinal					

Haemorrhage
Haematoma
Haematuria
Herpes Simplex
Hypoalbuminaemia
Intervertebral Disc
Protrusion
Melaena
Mitral Valve Incompetence
Normochromic Normocytic
Anaemia
Pulmonary Embolism
Pulmonary Valve
Incompetence
Scrotal Swelling
Sinus Bradycardia
Sinus Congestion
Spinal Osteoarthritis
Thrombocytopenia
Tinnitus
Tricuspid Valve
Incompetence
Urticaria
Vascular Pseudoaneurysm
Ventricular Dysfunction

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690395-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1408 DAY	

Date:06/15/05ISR Number: 4690396-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02891
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety							
	Atrial Fibrillation							
	Blood Pressure Increased							
	Chest Pain							
	Diarrhoea							
	Dizziness							
	Herpes Simplex							
	Hypoacusis							
	Leukocytosis							
	Nausea							
	Sinus Disorder							
	Sleep Apnoea Syndrome							

Date:06/15/05ISR Number: 4690397-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01000
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Pressure Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zyrtec	C			UNKNOWN	
	Cerebrovascular Accident		Bactrim	C			UNKNOWN	
	Deep Vein Thrombosis		Dilantin	C			UNKNOWN	

	Dehydration	Tylenol	C
UNKNOWN			
	Emotional Distress	Advil	C
UNKNOWN			
	Feeling Of Body	Hydrocortisone	C
UNKNOWN			
	Temperature Change	Motrin	C
UNKNOWN			
	Headache	Premarin	C
UNKNOWN			
	Hyperhidrosis	Insulin	C
UNKNOWN			
	Photophobia	Vicodin Tablets	C
UNKNOWN			
	Spinal Osteoarthritis	Amitriptyline	
	Vision Blurred	Hydrochloride	C
UNKNOWN			
	Vitreous Floaters		
	Vomiting		

Date:06/15/05ISR Number: 4690398-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00927
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		120 DAY
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		147 DAY
	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		120 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

	Vioxx	SS	Merck & Co., Inc	ORAL
147 DAY				
	Vioxx	SS	Merck & Co., Inc	ORAL
396 DAY				
	Vioxx	SS	Merck & Co., Inc	ORAL
396 DAY				
	Vioxx	SS	Merck & Co., Inc	ORAL
	Vicodin Tablets	C		
UNKNOWN				
	Ativan	C		
UNKNOWN				
	Vitamin E	C		
UNKNOWN				
	Vitamins (Unspecified)	C		
UNKNOWN				
	Zantac	C		
UNKNOWN				
	Tylenol	C		
UNKNOWN				
	Tylenol	C		
UNKNOWN				
	Advil	C		
UNKNOWN				
	Zocor	C		ORAL
	Glucosamine	C		
UNKNOWN				

Date:06/15/05ISR Number: 4690410-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01954
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
274 DAY						
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
69 DAY						
Disability	Coronary Artery Disease		Furosemide	C		
UNKNOWN						
Other	Emotional Distress		Singulair	C		ORAL
	Goitre		Premarin	C		
UNKNOWN	1218 DAY					
	Hypermagnesaemia		Ditropan	C		
UNKNOWN						

	Hypotension	Klor-Con	C
UNKNOWN			
	Myocardial Infarction	Captopril	C
UNKNOWN	1455 DAY		
	Neutropenia	Albuterol	C
UNKNOWN			
	Renal Failure Acute		
	Sleep Apnoea Syndrome		
	Thrombocytopenia		
	Venous Insufficiency		

Date:06/15/05ISR Number: 4690435-4Report Type:Expedited (15-DaCompany Report #PHBS2004CH11775
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Other	Aspartate Aminotransferase Increased
	Brain Natriuretic Peptide Increased
	Chest Discomfort
	Chest Pain
	Diarrhoea
	Drug Interaction
	Dyspnoea
	Fibrin D Dimer Increased
	Gamma-Glutamyltransferase Increased
	Haemangioma Of Liver
	Hepatic Enzyme Increased
	Hepatic Lesion
	Hepatotoxicity
	Hyperhidrosis

	Nausea						
	Pleural Effusion						
	Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Right Ventricular Failure		Voltaren	PS	Novartis Sector: Pharma			
	Sinus Bradycardia							
UNKNOWN							50 mg/d	4320 MIN
	Vomiting		Sirdalud	SS		ORAL	6 mg/day	4320 MIN
			Vioxx	SS				
UNKNOWN							25 mg/d	4320 MIN
			Herbal Extracts Nos	SS				

Date:06/15/05ISR Number: 4690489-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690490-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01444
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1338 DAY	

Date:06/15/05ISR Number: 4690494-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01427
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	588 DAY	

Date:06/15/05ISR Number: 4690495-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:06/15/05ISR Number: 4690496-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01428
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690497-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690498-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02680
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia Back Pain Balance Disorder Blood Cholesterol Increased

		Cerebrovascular Accident					
		Chest Pain					
		Cholelithiasis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Difficulty In Walking		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea					
		Dysuria					
		Emotional Distress					
		Emphysema					
		Gout					
		Headache					
		Hypertension					
		Hypoaesthesia					
		Micturition Disorder					
		Nasopharyngitis					
		Neck Pain					
		Oedema Peripheral					
		Pain					
		Post Concussion Syndrome					
		Road Traffic Accident					
		Syncope					
		Visual Disturbance					

Date:06/15/05ISR Number: 4690499-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02981
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
147	DAY						
		Infarction		Norvasc	C		
UNKNOWN							
		Anhedonia		Allegra	C		
UNKNOWN							
		Anxiety		Wellbutrin	C		
UNKNOWN							
		Emotional Distress		Trazodone			
		Pain		Hydrochloride	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690500-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	650	DAY

Date:06/15/05ISR Number: 4690501-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01423
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690503-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02130
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthralgia
	Arthropathy
Other	Blood Cholesterol Increased
	Emotional Distress
	Myocardial Infarction

Thyroid Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1360 DAY	
	Premarin	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	

Date:06/15/05ISR Number: 4690504-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02566
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL	58 MON	
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	58 MON	
	Depression		Atenolol	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Cozaar	C			UNKNOWN	

Date:06/15/05ISR Number: 4690505-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02126
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anorectal Disorder
Other	Bladder Disorder
	Blood Triglycerides Increased
	Brain Stem Infarction
	Brain Stem Ischaemia
	Cardiac Disorder

Cerebral Ischaemia
Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Confusional State
Constipation
Coronary Arterial Stent
Insertion
Coronary Artery Disease
Cough
Deafness
Dehydration
Depression
Dizziness
Dysphagia
Dyspnoea
Dyspnoea Exertional
Eyelid Ptosis
Haemorrhoids
Headache
Hyperlipidaemia
Hypertension
Insomnia
Migraine
Oedema Peripheral
Pain In Extremity
Palpitations
Paraesthesia

		Peripheral Vascular Disorder					
		Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinus Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Sleep Apnoea Syndrome		Vicodin Tablets	C		
UNKNOWN							
		Tinnitus		Hydrocodone Hydrochloride	C		
		Transient Ischaemic Attack					
UNKNOWN		389 DAY					
		Vascular Pseudoaneurysm		Hydrocodone Hydrochloride	C		
UNKNOWN							
		Ruptured		Tylenol With Codeine #3	C		
		Wheezing					
UNKNOWN							
				Calcium (Unspecified)	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN		213 DAY					
				Vitamin B Complex	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Amoxicillin	C		
UNKNOWN							
				Zyban	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Dilor	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690506-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02034
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	463 DAY	
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atrial Septal Defect		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	463 DAY	
	Cardiac Murmur		Ambien	C			UNKNOWN	
	Cerebrovascular Accident		Hydrocodone Bitartrate	C			UNKNOWN	
	Emotional Distress		Lovastatin	C			UNKNOWN	
	Generalised Anxiety		Advil	C			UNKNOWN	
	Disorder		Ativan	C			UNKNOWN	
	Heart Rate Irregular		Plavix	C			UNKNOWN	
	Lung Disorder		Lisinopril	C			UNKNOWN	
	Mental Status Changes							
	Mitral Valve Incompetence							
	Nervous System Disorder							
	Pulmonary Valve Incompetence							
	Sleep Apnoea Syndrome							
	Ventricular Hypertrophy							

Date:06/15/05ISR Number: 4690509-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690510-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690511-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01317
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis							

Date:06/15/05ISR Number: 4690512-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Multi-Organ Disorder Myocardial Infarction Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690513-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01207
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690514-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01968
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Anxiety	Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Triglycerides	Zocor	C		ORAL
	Increased	Lotrel	C		
UNKNOWN					
	Chest Pain	Pravachol	C		
UNKNOWN					
	Depression				
	Emotional Distress				
	Hernia				
	Myocardial Infarction				
	Panic Disorder				

Date:06/15/05ISR Number: 4690516-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02586
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Pain
	Adverse Event
	Anxiety
	Blood Cholesterol
	Increased
	Coronary Artery Disease
	Emotional Distress
	Myocardial Infarction
	Pain

Tendon Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Cephalexin	C			UNKNOWN	
	Promethazine	C			UNKNOWN	
	Meperidine Hydrochloride	C			UNKNOWN	
	Prevacid	C			UNKNOWN	
	Lipitor	C			UNKNOWN	

Date:06/15/05ISR Number: 4690517-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01899
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
509 DAY								
Initial or Prolonged	Anxiety		Dilantin	SS				
UNKNOWN								
Disability	Aspiration		Duac	C				
UNKNOWN								
	Blood Cholesterol		Viagra	C				
UNKNOWN								
	Increased		Nifedical Xl	C				
UNKNOWN								
	Cardiac Arrest		Phenobarbital	C				
UNKNOWN								
	Cardiomyopathy		Nexium	C				
UNKNOWN								
	Carotid Artery Occlusion		Cialis	C				
UNKNOWN								
	Cerebral Infarction		Plexion	C				
UNKNOWN								
	Cerebrovascular Accident		Ranitidine	C				
UNKNOWN								
	Cognitive Disorder		Mometasone Furoate	C				
UNKNOWN								

	Coronary Artery Disease	Methylprednisolone	C
UNKNOWN			
	Depression	Minocycline	C
UNKNOWN			
	Drug Screen Positive	Procardia	C
UNKNOWN			
	Encephalopathy	Zocor	C
UNKNOWN			
	Fall	Plavix	C
UNKNOWN			
	Fluid Intake Reduced	Tylenol	C
UNKNOWN			
	Gastrooesophageal Reflux	Keppra	C
UNKNOWN			
	Disease Grand Mal Convulsion Haematuria Hydrocephalus Injury Loss Of Consciousness Mental Status Changes Myocardial Infarction Post-Traumatic Stress Disorder Pulse Absent Renal Failure Acute Respiratory Disorder Torsade De Pointes Urinary Tract Infection Ventricular Fibrillation		

Date:06/15/05ISR Number: 4690518-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01998
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Anxiety Cholelithiasis Coronary Artery Disease

		Fall					
		Gait Disturbance					
		Hip Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ileus		Vioxx	PS	Merck & Co., Inc	ORAL
		Phimosis		Bacitracin	C		
OPHTHALMIC							
		Renal Atrophy		Micronase	C		
UNKNOWN							
		Renal Mass		Betamethasone	C		
UNKNOWN							
				Ciloxan	C		
OPHTHALMIC							
				Erythromycin	C		
UNKNOWN							
				Tobradex	C		
OPHTHALMIC							
				Prednisolone	C		
OPHTHALMIC							
				Ocuflox	C		
OPHTHALMIC							
				Synthroid	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Ferrex	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690519-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01948
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Lotrel	C		
UNKNOWN							
		Cerebral Infarction		Plavix	C		
UNKNOWN							
		Chest Pain		Paxil	C		
UNKNOWN							
		Convulsion		Nexium	C		
UNKNOWN							

	Depression	Prilosec	C		
UNKNOWN					
	Diabetes Mellitus	Norvasc	C		
UNKNOWN	395 DAY				
	Non-Insulin-Dependent	Lipitor	C		
UNKNOWN	831 DAY				
	Diabetic Neuropathy	Lipitor	C		
UNKNOWN					
	Difficulty In Walking	Lipitor	C		
UNKNOWN	831 DAY				
	Dizziness	Lipitor	C		
UNKNOWN					
	Dysphagia	Zocor	C		ORAL
	Dyspnoea	Zocor	C		ORAL
	Epidermal Naevus	Zocor	C		ORAL
	Eructation	Tricor	C		
UNKNOWN					
	Eye Irritation	Zetia	C		ORAL
	Fatigue	Zetia	C		ORAL
	Insomnia	Toprol Xl Tablets	C		ORAL
	Memory Impairment	Toprol Xl Tablets	C		ORAL
	Muscle Spasms	Neurontin	C		
UNKNOWN					
	Myalgia	Robaxin	C		ORAL
	Onychomycosis	Aspirin	C		
UNKNOWN					
	Pain In Extremity	Ibuprofen	C		
UNKNOWN					
	Palpitations	Glucovance	C		
UNKNOWN					
	Sleep Apnoea Syndrome	Clorazepate			
	Suicidal Ideation	Dipotassium	C		
UNKNOWN					
	Tinea Pedis	Darvocet-N	C		
UNKNOWN					
	Toe Deformity	Allegra	C		
UNKNOWN					
	Upper Respiratory Tract	Hydrodiuril	C		ORAL
	Infection	Albuterol	C		
RESPIRATORY					
	Wheezing				
(INHALATION)					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690520-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00766
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Ischaemia Hypercholesterolaemia Ischaemia Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690521-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02485
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1858 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
			Coumadin	C				UNKNOWN
			Atacand Hct	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Singulair	C		ORAL		
			Mucinex	C				UNKNOWN
			Fosamax	C		ORAL		
			Restoril	C				UNKNOWN
			Citracal	C				UNKNOWN
			Protonix	C				UNKNOWN
			Advair	C				UNKNOWN
			Sotalol Hydrochloride	C				UNKNOWN

				Vitamins (Unspecified)	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690522-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690523-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02722
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arteriovenous Malformation		Vioxx	PS	Merck & Co., Inc	ORAL		
			Valtrex	C				
UNKNOWN								
Other	Blood Creatinine Increased		Vitamins (Unspecified)	C				
UNKNOWN								
	Chest Wall Pain							
	Coronary Artery Atherosclerosis							
	Labile Hypertension							
	Myocardial Infarction							
	Panic Attack							
	Viral Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690524-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00006
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		1545 DAY
Initial or Prolonged	Renal Artery Stenosis		Prednisolone	C		ORAL		
			Metoprolol Tartrate	C				UNKNOWN
			Aspirin And Magnesium Oxide	C		ORAL		
			Felodipine	C				UNKNOWN
			Atorvastatin Calcium	C		ORAL		
			Furosemide	C		ORAL		
			Doxazosin Mesylate	C		ORAL		
			Acetaminophen	C				UNKNOWN
			Acetaminophen And Codeine Phosphate	C				UNKNOWN

Date:06/15/05ISR Number: 4690525-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00090
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690526-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02930
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anxiety
	Atrioventricular Block First Degree
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Condition Aggravated

Conjunctival Haemorrhage
Constipation
Contusion
Corneal Abrasion
Coronary Artery Disease
Diarrhoea
Dyspepsia
Electrocardiogram Qrs
Complex Prolonged
Emotional Distress
Epididymal Enlargement
Epididymitis
Essential Hypertension
Ganglion
Gastritis
Gastrooesophageal Reflux
Disease
Gout
Haematoma
Hypertension
Intestinal Polyp
Myocardial Infarction
Night Cramps
Osteoarthritis

		Rectal Polyp					
		Rotator Cuff Syndrome					
		Sinus Bradycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Hypertrophy		Vioxx	PS	Merck & Co., Inc	ORAL
1217 DAY							
				Aspirin	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690527-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04216
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR						
Initial or Prolonged	Myocardial Infarction					
	Pain					

Date:06/15/05ISR Number: 4690528-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02359
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
7 MON						
Initial or Prolonged	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
7 MON						
	Coronary Artery Disease		Klor-Con	C		
UNKNOWN						
	Dyslipidaemia		Advair	C		
UNKNOWN						
	Headache		[Therapy			

	Memory Impairment	Unspecified]	C
UNKNOWN			
	Phlebitis	Albuterol	C
UNKNOWN			

Date:06/15/05ISR Number: 4690529-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00905
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Angina Unstable
Disability	Arthralgia
	Blood Pressure Increased
	Candidiasis
	Coronary Artery Disease
	Difficulty In Walking
	Dry Skin
	Fatigue
	Fibromyalgia
	Fluid Retention
	Fungal Infection
	Headache
	Hiatus Hernia
	Joint Crepitation
	Joint Sprain
	Joint Stiffness
	Ligament Sprain
	Muscle Spasms
	Night Sweats
	Oral Candidiasis
	Peptic Ulcer

		Pharyngeal Candidiasis Pruritus Sleep Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tremor		Vioxx	PS	Merck & Co., Inc	ORAL
		Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
104	DAY						
		Vomiting		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
104	DAY						
				Celebrex	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Propulsid	C		
UNKNOWN							
				Phenobarbital	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Fibro Malic	C		
UNKNOWN							
				Minipress	C		
UNKNOWN							
				Dimethyl Sulfone	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Salagen Tablets	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Estratest	C		
UNKNOWN							
				Evoxac	C		
UNKNOWN							

			Monopril	C		
UNKNOWN						
			Nitro-Bid	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Reglan	C		
UNKNOWN						
			Diflucan	C		ORAL
			Diflucan	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						
			Esgic-Plus Tablets	C		
UNKNOWN						
			Mylanta & Mylanta Ds	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Lasix (Furosemide Sodium)	C		
UNKNOWN						
			K-Dur	C		
UNKNOWN						
			Lopressor	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						

Date:06/15/05ISR Number: 4690532-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01891
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Aldactone	C				
UNKNOWN								
	Emotional Distress		Celexa	C				
UNKNOWN								
	Insomnia		Remeron	C				
UNKNOWN								
	Myocardial Infarction		Wellbutrin	C				
UNKNOWN								
	Transient Ischaemic		Glyburide	C				
UNKNOWN								

Attack Avandia C

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690533-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03946
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		128 DAY
Hospitalization -	Anaemia		Protonix	C				UNKNOWN
Initial or Prolonged	Anorexia		Rite Aid Col-Rite					
Disability	Anxiety Disorder		Stool Softener	C				UNKNOWN
	Cerebrovascular Accident		Clonidine	C				UNKNOWN
	Constipation		Diovan	C				UNKNOWN
	Convulsion		Norvasc	C				UNKNOWN
	Cough		Hydrodiuril	C				UNKNOWN
	Diverticulum		Wellbutrin Sr	C				UNKNOWN
	Fatigue		Combivent	C				UNKNOWN
	Gastric Ulcer		Advair	C				UNKNOWN
	Gastrooesophageal Reflux		Theophylline	C				UNKNOWN
	Disease		Aspirin	C				UNKNOWN
	Helicobacter Infection		Bisacodyl	C				UNKNOWN
	Hypertension		Metoclopramide	C				UNKNOWN
	Hypotension							
	Impaired Gastric Emptying							
	Iron Deficiency							
	Major Depression							
	Myocardial Infarction							
	Nephrosclerosis							
	Proteinuria							
	Rectal Polyp							
	Renal Artery Occlusion							
	Renal Artery Stenosis							
	Renal Atrophy							
	Renal Cyst							
	Renal Disorder							

Renal Failure Chronic
Vertigo

Date:06/15/05ISR Number: 4690535-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00234
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Diclofenac Sodium	C		ORAL		
			Insulin, Biphasic Isophane [Injection]	C			PARENTERAL	
			Repaglinide	C			UNKNOWN	
			Tetrazepam	C			UNKNOWN	
			Metformin Hydrochloride	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Tolperisone Hydrochloride	C			UNKNOWN	
			Thioctic Acid	C		ORAL		

Date:06/15/05ISR Number: 4690536-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA02595
Age:56 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Calculus Ureteric		Advil	C			UNKNOWN	
Calculus Urinary		Advil	C			UNKNOWN	
Chest Discomfort		Vicodin Tablets	C			UNKNOWN	
Coronary Artery Occlusion		Aspirin	C			UNKNOWN	
Cough		Ultram	C			UNKNOWN	
Diverticulitis		Ultram	C			UNKNOWN	
Emotional Distress							
Fatigue							
Injury							
Mitral Valve Incompetence							
Morbid Thoughts							
Osteoarthritis							
Palpitations							
Pneumonia Influenzal							
Tricuspid Valve							
Incompetence							
Weight Fluctuation							

Date:06/15/05ISR Number: 4690538-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01299
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Anxiety
	Arterial Restenosis
	Barrett'S Oesophagus
	Blood Cholesterol Increased
	Bradycardia
	Carpal Tunnel Syndrome
	Coagulopathy
	Coronary Artery Disease

Coronary Artery
Restenosis
Depression
Dilatation Atrial
Dizziness
Emotional Distress
Gastric Disorder
Gastric Ulcer
Haematocrit Decreased
Heart Rate Irregular
Hypotension
International Normalised
Ratio Increased
Mitral Valve Incompetence
Myocardial Infarction
Pain
Palpitations
Prostatic Disorder
Pulmonary Valve
Incompetence
Thrombosis
Tongue Biting
Tongue Haemorrhage

		Tricuspid Valve Incompetence					
		Ventricular Dysfunction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Tachycardia		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Acetaminophen And Oxycodone Hydrochloride	C		
UNKNOWN							
				Avapro	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							

Date:06/15/05ISR Number: 4690539-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0212USA02514
Age:33 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
11	DAY						
		Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Lymphoedema		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
		Sudden Death		Vioxx	SS	Merck & Co., Inc	ORAL
11	DAY						
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						

Date:06/15/05ISR Number: 4690541-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00646
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		357 DAY
Hospitalization - UNKNOWN	Acute Myocardial		Prevacid	C				
Initial or Prolonged UNKNOWN	Infarction		Plavix	C				
	Angina Pectoris		Aspirin	C				
UNKNOWN	Angina Unstable		Prevacid	C				
UNKNOWN	Anxiety		Synthroid	C				
UNKNOWN	Anxiety Disorder		Estrogens (Unspecified)	C				
UNKNOWN	Back Pain							
	Cardiac Murmur							
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Occlusion							
	Dyspnoea Exertional							
	Fatigue							
	Hypertensive Heart Disease							
	Major Depression							
	Myalgia							
	Nausea							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690551-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0407FRA00013
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Haemophilia		Vioxx	PS	Merck & Co., Inc	ORAL		117 DAY
Initial or Prolonged	Coagulation Factor Viii Level Decreased		Zocor	SS		ORAL		
	Coagulation Time Prolonged		Ginkgo Biloba Extract	SS		ORAL		
	Haematoma		Hydrochlorothiazide And Lisinopril	SS		ORAL		

Date:06/15/05ISR Number: 4690552-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03901
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		2 WK
Hospitalization - Initial or Prolonged								
Disability								

Date:06/15/05ISR Number: 4690553-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02654
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		26 MON
Initial or Prolonged	Blood Pressure		Vioxx	SS	Merck & Co., Inc	ORAL		26 MON
Disability	Inadequately Controlled		Flomax					
	Depression		(Morniflumate)	C				UNKNOWN
	Haemorrhagic Stroke		Glucovance	C		ORAL		
	Hypotension		Zantac	C				UNKNOWN
	Unresponsive To Pain		Micronase	C				UNKNOWN
	Stimuli		Glucophage	C				UNKNOWN

Date:06/15/05ISR Number: 4690554-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01915
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dressler'S Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Hypercholesterolaemia		Methadone Hydrochloride	C				UNKNOWN
	Left Ventricular Failure							
	Myocardial Infarction		Oxycodone	C				UNKNOWN
	Pneumonia		Oxycontin	C				UNKNOWN
			Verapamil Hydrochloride	C				UNKNOWN
			Verapamil Hydrochloride	C				UNKNOWN
			Flexeril	C		ORAL		
			Effexor Xr	C				UNKNOWN
			Maxalt (Rizatriptan Benzoate)	C				UNKNOWN
			Nexium	C				UNKNOWN

Date:06/15/05ISR Number: 4690555-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690556-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00129
Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690557-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Acute Myocardial Infarction Cardiac Disorder Fear		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690719-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00232
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690723-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00122
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Epistaxis		Vioxx	PS	Merck & Co., Inc	ORAL	200 DAY	
	Oedema Peripheral		Diclofenac Sodium	C			UNKNOWN	
	Optic Ischaemic Neuropathy Scotoma Vision Blurred							

Date:06/15/05ISR Number: 4690724-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02918
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Ischaemia Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690753-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00850
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Atrioventricular Block First Degree Cardiomyopathy Chest Discomfort Coronary Artery Disease Emotional Distress Gastroenteritis Hyperlipidaemia Myocardial Ischaemia Pain Pericardial Effusion Syncope

Ventricular Tachycardia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1663 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	1663 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	1663 DAY	
	Cardura	C			UNKNOWN	155 DAY
	Zoloft	C			UNKNOWN	1660 DAY
	Lorazepam	C			UNKNOWN	
	Claritin	C			UNKNOWN	
	Hydrocodone Bitartrate	C			UNKNOWN	67 DAY

Date:06/15/05ISR Number: 4690754-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03483
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL	RESPIRATORY	
			Singulair	C			(INHALATION)	
	Cerebrovascular Accident							
	Hypertension		Combivent	C			RESPIRATORY	
	Pain						(INHALATION)	
	Transient Ischaemic		Azmacort	C			UNKNOWN	
	Attack		Advair	C			RESPIRATORY	
							(INHALATION)	

Date:06/15/05ISR Number: 4690755-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00621
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anaemia Postoperative		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anal Fistula		Diltiazem					
Disability	Atrial Fibrillation		Hydrochloride	C				
UNKNOWN								
	Bundle Branch Block Right		Oxycodone					
	Carotid Artery Stenosis		Hydrochloride	C				
UNKNOWN								
	Constipation		Polyethylene Glycol					
	Coronary Artery Disease		3350 And Potassium					
	Dehydration		Chloride And Sodium					
	Extrasystoles		Bicarbonate And					
	Haemorrhoids		Sodium Chloride	C				
UNKNOWN								
	Hypersensitivity							
	Intervertebral Disc Degeneration							
	Intracardiac Thrombus							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Peripheral Occlusive Disease							
	Postoperative Infection							
	Reactive Psychosis							
	Renal Failure Chronic							
	Tricuspid Valve Incompetence							
	Varicose Vein							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690756-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02946
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Aleve	C				
UNKNOWN								
	Diverticulum Intestinal							
	Dyspnoea							
	Headache							
	Hernia							
	Hypertension							
	Myocardial Infarction							

Date:06/15/05ISR Number: 4690757-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00014
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL		
837 DAY								
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
434 DAY								
			Budesonide	C				
RESPIRATORY								
(INHALATION)								
			Terbutaline Sulfate	C				
RESPIRATORY								
(INHALATION)								
			Meloxicam	C		ORAL		
			Orlistat	C				
UNKNOWN								

Date:06/15/05ISR Number: 4690758-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02326
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Death

Date:06/15/05ISR Number: 4690759-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02313
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							
	Injury							

Date:06/15/05ISR Number: 4690761-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00096
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	993	DAY
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	993	DAY
	Emotional Distress		Celebrex	C			UNKNOWN	
	Glaucoma		Celebrex	C			UNKNOWN	
	Myocardial Infarction							
	Overdose							
	Pyoderma Gangrenosum							
	Rheumatoid Arthritis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690762-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02894
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Emotional Distress							
	Fall							
	Ligament Injury							
	Pain							
	Speech Disorder							
	Walking Aid User							

Date:06/15/05ISR Number: 4690768-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690769-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690770-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690771-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01917
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged Disability	Pain		[Therapy Unspecified]	C				
UNKNOWN								

Date:06/15/05ISR Number: 4690772-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01550
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690773-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01885
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690774-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01878
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4690775-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	66	MON

Date:06/15/05ISR Number: 4690776-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02952
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	General Symptom		Lopressor	C			UNKNOWN	
	Myocardial Infarction		Allopurinol	C			UNKNOWN	
	Sleep Apnoea Syndrome							

Date:06/15/05ISR Number: 4690777-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01556
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1605	DAY

Date:06/15/05ISR Number: 4690778-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01860
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1772 DAY

Date:06/15/05ISR Number: 4690779-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01473
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		973 DAY

Date:06/15/05ISR Number: 4690780-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		125 DAY

Date:06/15/05ISR Number: 4690781-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01576
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690782-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01871
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	10	WK
	Rash							

Date:06/15/05ISR Number: 4690810-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00124
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Abdominal Pain		Diclofenac	SS				
	Abdominal Pain Upper		Levothyroxine Sodium	C			UNKNOWN	
	Alopecia		Flupirtine Maleate	C			UNKNOWN	
	Bile Duct Obstruction		Bisoprolol	C			UNKNOWN	
	Biliary Dilatation		Bisoprolol	C			UNKNOWN	
	Blood Pressure		Heparin Sodium	C			UNKNOWN	
	Inadequately Controlled		Ranitidine	C			UNKNOWN	
	Blood Pressure Increased		Telmisartan	C			UNKNOWN	
	Cardiac Failure		Telmisartan	C			UNKNOWN	
	Congestive							
	Chest Pain							
	Dyspnoea							
	Gastritis							
	Gastrooesophageal Reflux							
	Disease							
	Intervertebral Disc							
	Protrusion							
	Oedema Peripheral							
	Pancreatitis Acute							
	Renal Pain							

Date:06/15/05ISR Number: 4691332-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03197
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		55 DAY
Initial or Prolonged	Cerebrovascular Accident		Zocor	C		ORAL		
Disability	Drug Hypersensitivity		Estrace	C				
UNKNOWN								
Other	Dyspnoea		Estrace	C				
UNKNOWN								
	Emotional Distress		Prilosec	C				
UNKNOWN								
	Fall		Lortab	C				
UNKNOWN								
	Fungal Infection							
	Gout							
	Incontinence							
	Injury							
	Limb Discomfort							
	Pain In Extremity							
	Tendon Injury							
	Transient Ischaemic Attack							
	Trigeminal Neuralgia							
	Vaginal Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4691333-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00070
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Aspirin	C			UNKNOWN	
	Coronary Artery Stenosis		Atorvastatin Calcium	C			UNKNOWN	
	Ventricular Hypertrophy		Metoprolol	C			UNKNOWN	
			Clopidogrel Bisulfate	C			UNKNOWN	

Date:06/15/05ISR Number: 4691334-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03252
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Adhesion		Pepcid	C			UNKNOWN	
Disability	Angina Pectoris		Celebrex	C			UNKNOWN	
Other	Back Pain		Bextra	C			UNKNOWN	
	Breast Cancer		Toprol Xl Tablets	C			UNKNOWN	
	Bronchitis		St. Joseph Adult Chewable Aspirin	C			UNKNOWN	
	Cardiac Valve Disease		Tamoxifen Citrate	C			UNKNOWN	
	Chest Pain		Actonel	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Inderal	C			UNKNOWN	
	Coronary Artery Disease		Lipitor	C			UNKNOWN	
	Diarrhoea		Wellbutrin	C			UNKNOWN	

	Dyspnoea	Xanax	C
UNKNOWN			
	Faeces Discoloured	Neurontin	C
UNKNOWN			
	Gastrooesophageal Reflux	Nexium	C
UNKNOWN			
	Disease	Coumadin	C
UNKNOWN			
	Hernia	Darvocet-N	C
UNKNOWN			
	Intestinal Obstruction	Prilosec	C
UNKNOWN			
	Melaena		
	Myocardial Infarction		
	Nausea		
	Osteoarthritis		
	Pain		
	Peptic Ulcer		

Date:06/15/05ISR Number: 4691335-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0410GBR00187
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		61 DAY
Initial or Prolonged	Cardiac Failure		Fluoxetine	C				
UNKNOWN								245 DAY
Disability	Fall		Acetaminophen And					
Other	Heart Rate Irregular		Dihydrocodeine					
	Hip Fracture		Bitartrate	C				
UNKNOWN								
	Mitral Valve Incompetence							
	Myocardial Infarction							

Date:06/15/05ISR Number: 4691336-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA00752
Age:39 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
Agitation		Vioxx	SS	Merck & Co., Inc	ORAL	4	DAY
Anxiety		Celebrex	C			UNKNOWN	4 DAY
Coronary Artery Aneurysm		Aspirin	C			UNKNOWN	
Coronary Artery		Lipitor	C			UNKNOWN	
Atherosclerosis		Toprol Xl Tablets	C			UNKNOWN	
Depression		Plavix	C			UNKNOWN	
Drug Hypersensitivity		Pyridoxine	C			UNKNOWN	
Embolism		Folic Acid	C			UNKNOWN	
Haematoma		Xanax	C			UNKNOWN	
Mitral Valve Incompetence		Wellbutrin	C			UNKNOWN	
Muscle Necrosis		Lopressor	C			UNKNOWN	
Myocardial Infarction							
Panic Disorder							
Patellofemoral Pain Syndrome							
Refusal Of Treatment By Patient							
Tendonitis							
Traumatic Arthropathy							
Tricuspid Valve Incompetence							

Date:06/15/05ISR Number: 4691337-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00561
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Vioxx	SS	Merck & Co., Inc	ORAL
Vioxx	SS	Merck & Co., Inc	ORAL
Vioxx	SS	Merck & Co., Inc	ORAL
[Therapy Unspecified]	C		

UNKNOWN

Date:06/15/05ISR Number: 4691341-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Ageusia
Disability	Anosmia
Other	Aortic Valve Calcification
	Arthropathy
	Atelectasis
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Chest Pain
	Cholelithiasis
	Chronic Obstructive Pulmonary Disease
	Colon Adenoma
	Condition Aggravated
	Confusional State
	Decreased Appetite
	Deep Vein Thrombosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Defaecation Urgency					
		Diverticulum					
		Drug Hypersensitivity					
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Emotional Distress		Atenolol	C		
UNKNOWN		Essential Hypertension		Aspirin	C		
UNKNOWN		Exostosis		Zoloft	C		
UNKNOWN		Faecal Incontinence		Lipitor	C		
UNKNOWN		Fatigue		Niaspan	C		
UNKNOWN		Fibromyalgia		Iron (Unspecified)	C		
UNKNOWN		Haemangioma		Acetaminophen	C		
UNKNOWN		Haematochezia		Lopressor	C		
UNKNOWN		Haemorrhoids		Herbs (Unspecified)	C		
UNKNOWN		Hypercoagulation					
		Hypertension					
		Injury					
		Lumbar Spinal Stenosis					
		Lung Disorder					
		Macular Degeneration					
		Malaise					
		Meniscus Lesion					
		Micturition Urgency					
		Nausea					
		Neck Pain					
		Nephrolithiasis					
		Osteopenia					
		Osteoporosis					
		Pain In Extremity					
		Pancreatitis					
		Phlebothrombosis					
		Pulmonary Embolism					
		Pulmonary Hypertension					
		Rectal Haemorrhage					
		Renal Cyst					
		Renal Disorder					
		Rhinitis					
		Scar					

Spinal Osteoarthritis
Spondylolisthesis
Thrombophlebitis
Toe Deformity
Urinary Incontinence
Weight Decreased
Weight Increased

Date:06/15/05ISR Number: 4691350-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02941
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		31 MON
Initial or Prolonged	Blood Potassium Increased		Monopril	C		ORAL		
	Hyperkalaemia		Avandia	C		ORAL		
	Transient Ischaemic		Amaryl	C				UNKNOWN
	Attack		Norvasc	C		ORAL		
			Maxzide	C				UNKNOWN
			Lipitor	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4691351-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03440
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Ulcer Haemorrhage		Lotensin	C				
Disability			Aspirin	C				
			Premarin	C				
			Verapamil Hydrochloride	C				
			Fosamax	C		ORAL		

Date:06/15/05ISR Number: 4691352-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02956
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	475	MON
	Emotional Distress		Aspirin	C				
Disability	Myocardial Infarction		Oxycodone	C				
	Neck Injury		Hydrocodone Hydrochloride	C				
	Pain		Claritin	C				
			Lamisil	C				
			Indomethacin	C				

Date:06/15/05ISR Number: 4691353-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00969
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acrochordon

Initial or Prolonged	Acute Myocardial Infarction
	Anxiety
	Arthralgia
	Asthenia
	Asthma
	Back Pain
	Bronchitis
	Cellulitis
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Atherosclerosis
	Cough
	Depression
	Dermal Cyst
	Drug Hypersensitivity
	Dupuytren'S Contracture
	Dyslipidaemia
	Dyspepsia
	Dysphagia
	Dyspnoea
	Erectile Dysfunction
	Fatigue
	Haemorrhoids
	Hyperlipidaemia
	Hypertension
	Hypoaesthesia
	Impulse-Control Disorder

	Otitis Media						
	Pain In Extremity						
	Pharyngitis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Premature Ejaculation		Vioxx	PS	Merck & Co., Inc	ORAL	106	DAY
	Pulmonary Congestion		Vioxx	SS	Merck & Co., Inc	ORAL	363	DAY
	Purulent Discharge		Vioxx	SS	Merck & Co., Inc	ORAL	106	DAY
	Restless Legs Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	363	DAY
	Rhinitis Allergic		Zantac	C			UNKNOWN	
	Rhonchi		Celexa	C			UNKNOWN	
	Self-Injurious Ideation		Albuterol	C			RESPIRATORY	
	Sinus Disorder						(INHALATION)	
	Sleep Apnoea Syndrome		Vicodin Tablets	C		ORAL		
	Spinal Column Stenosis							
	Spinal Osteoarthritis							
	Upper Respiratory Tract Infection							
	Weight Increased							
	Wheezing							

Date:06/15/05ISR Number: 4691354-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02540
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Injury		Amaryl	C		ORAL		
Disability								

Date:06/15/05ISR Number: 4691355-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02934
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Neurontin	C		
UNKNOWN						
			Effexor Xr	C		
UNKNOWN						
			Indocid (Indomethacin)	C		
UNKNOWN						
			Pravachol	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						
			Lisinopril	C		
UNKNOWN						

Date:06/15/05ISR Number: 4691356-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02701
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Congestive		Flonase	C		
UNKNOWN						
	Death		Maxair Autohaler	C		
UNKNOWN						
	Myocardial Infarction		Indapamide	C		
UNKNOWN						
			Patanol	C		
UNKNOWN						
			Singulair	C		
UNKNOWN						
			Potassium Chloride	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Serevent	C		
UNKNOWN						
			Tramadol			

	Hydrochloride	C	UNKNOWN
	Prednisone	C	UNKNOWN
	Hydroxyzine Hydrochloride	C	UNKNOWN
	Vanceril	C	UNKNOWN
	Deltasone	C	UNKNOWN
	Potassium (Unspecified)	C	UNKNOWN
	Demadex	C	UNKNOWN
	Analgesic Or Anesthetic (Unspecified)	C	UNKNOWN
	Qvar	C	UNKNOWN

Date:06/15/05ISR Number: 4691357-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02916
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Avalide	C				UNKNOWN

Date:06/15/05ISR Number: 4691358-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02915
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anhedonia		Lipitor	C				UNKNOWN
	Anxiety							
	Coronary Artery Occlusion							
	Emotional Distress							

Joint Injury
Myocardial Infarction
Oedema Peripheral

Date:06/15/05ISR Number: 4691359-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02960
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Glucophage	C				UNKNOWN
Disability	Emotional Distress		Adalat	C				UNKNOWN
	Myocardial Infarction							

Date:06/15/05ISR Number: 4691360-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02684
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Barrett'S Oesophagus
Other	Coronary Artery Disease
	Depression
	Gastritis Erosive
	Hiatus Hernia
	Hyperlipidaemia
	Myocardial Infarction
	Oesophagitis Ulcerative
	Upper Gastrointestinal

Haemorrhage

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	761	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	761	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	761	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	761	DAY

Date:06/15/05ISR Number: 4691375-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01493
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:06/15/05ISR Number: 4691376-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691377-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691378-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01489
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691379-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01052
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691380-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01055
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691381-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:06/15/05ISR Number: 4691389-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01045
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691390-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/15/05ISR Number: 4691391-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	1781 DAY	

Date:06/15/05ISR Number: 4691393-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01548
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	40 MON	

Date:06/15/05ISR Number: 4693751-5Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Activated Partial Thromboplastin Time	Foreign Study	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -								

Initial or Prolonged	Prolonged	Health		
PO 293 DAY				
	Adenocarcinoma	Professional	Allopurinol	C
	Bronchopneumonia	Other		
	Carcinoembryonic Antigen Increased			
	Cardiac Failure			
	Cardio-Respiratory Arrest			
	Cardiomegaly			
	Haematocrit Decreased			
	Haemoglobin Decreased			
	Lung Consolidation			
	Mean Cell Haemoglobin Concentration Decreased			
	Mean Cell Haemoglobin Decreased			
	Neutrophil Count Increased			
	Pleural Effusion			
	Post Procedural Complication			
	Prothrombin Time Prolonged			
	Recurrent Cancer			
	Red Cell Distribution Width Increased			
	Therapy Non-Responder			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/16/05ISR Number: 4691722-6Report Type:Expedited (15-DaCompany Report #200515495GDDC
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bradycardia		Frusemide	PS	Aventis Pharmaceuticals Inc.	ORAL		
	Hypoxia							
	Nausea		Indapamide Hemihydrate	SS		ORAL		
	Orthostatic Hypotension		Prazosin Hydrochloride	SS		ORAL		
	Pallor		Amiodarone	SS		ORAL		
	Pulmonary Fibrosis		Rofecoxib	SS		ORAL		
	Syncope		Glipizide	C		ORAL		
			Pantoprazole	C		ORAL		
			Ramipril	C		ORAL		

Date:06/16/05ISR Number: 4694014-4Report Type:Expedited (15-DaCompany Report #US014950
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Intentional Misuse	Study	Actiq	PS			BUCCAL	800 UG ONCE
	Lethargy	Health Professional	Dilantin /Aus/	SS			BUCCAL	
	Somnolence		Prozac	SS				
	Suicide Attempt		Depakote	SS				
			Vioxx	SS				

Date:06/16/05ISR Number: 4694061-2Report Type:Expedited (15-DaCompany Report #2005086379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Celebrex (Celecoxib)	PS				
			Vioxx (Rofecoxib)	SS				
			.	SS				

Date:06/16/05ISR Number: 4695745-2Report Type:Direct Company Report #CTU 251302
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx 12.5 Mg	PS	Merck And Co, Inc	ORAL	25 MG PO Q DAILY; 50 MG QD X 2 WKS	
	Dysphonia							
	Dyspnoea							
	Excoriation		Vioxx 12.5 Mg Merck And Co , Inc	SS				
	Fatigue							
	Headache							
	Hypoaesthesia							
	Loss Of Consciousness							
	Migraine							
	Myocardial Infarction							
	Nervous System Disorder							
	Pain In Extremity							
	Parosmia							
	Syncope							
	Thrombosis							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692528-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01524
Age:69 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
			[Therapy Unspecified]	C				
UNKNOWN								

Date:06/17/05ISR Number: 4692529-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	DAY

Date:06/17/05ISR Number: 4692530-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01501
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1020	DAY

Date:06/17/05ISR Number: 4692531-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02054
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Diabetes Mellitus Non-Insulin-Dependent		Vioxx	SS	Merck & Co., Inc	ORAL		
			Levoxyl	C				
UNKNOWN								
	Gastric Disorder		Coumadin	C				
UNKNOWN								
	Knee Arthroplasty		Glipizide Xl	C				
UNKNOWN								

UNKNOWN	Oedema Peripheral	Zoloft	C
UNKNOWN	Polyp	Aspirin	C
UNKNOWN	Pulmonary Embolism	Zocor	C
UNKNOWN	Rectal Haemorrhage	Metformin	C
UNKNOWN	Thrombosis	Hydrocodone/Apap	C
UNKNOWN		Lasix (Furosemide)	C
UNKNOWN		Trazodone Hydrochloride	C
UNKNOWN		Vicodin Tablets	C
UNKNOWN		Plaquenil	C
UNKNOWN		Potassium (Unspecified)	C
UNKNOWN		Levaquin	C
UNKNOWN		Ambien	C
UNKNOWN		Prevacid	C
UNKNOWN		Prednisone	C
UNKNOWN		Glucotrol Xl	C
UNKNOWN		Avandia	C
UNKNOWN		Darvocet-N	C
UNKNOWN		Pepcid	C
UNKNOWN		Ecotrin	C
UNKNOWN		Demerol	C
UNKNOWN		Arthrotec	C
UNKNOWN		Reglan	C
UNKNOWN		Ancef	C
UNKNOWN		Heparin Sodium Injection (Lilly)	C
UNKNOWN		Maalox	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692532-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02347
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692533-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00965
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antinuclear Antibody		Vioxx	PS	Merck & Co., Inc	ORAL		651 DAY
Initial or Prolonged	Positive		Vioxx	SS	Merck & Co., Inc	ORAL		651 DAY
Disability	Arthralgia		Estrace	C				UNKNOWN
	Asthenia		Nexium	C				UNKNOWN
	Cerebrovascular Accident		Calcium (Unspecified)	C				UNKNOWN
	Difficulty In Walking							
	Dizziness							
	Dyspnoea							
	Dysstasia							
	Gastrooesophageal Reflux Disease							
	Headache							
	Hypertension							
	Infection							
	Ischaemic Stroke							
	Lower Limb Fracture							
	Musculoskeletal Stiffness							
	Nausea							
	Neuropathy							
	Oedema Peripheral							
	Palpitations							
	Postnasal Drip							
	Productive Cough							
	Pulmonary Embolism							
	Rash Erythematous							
	Rheumatoid Factor							
	Snoring							

Somnolence
Sputum Discoloured
Ulcer

Date:06/17/05ISR Number: 4692534-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02773
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 375 DAY	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Nexium	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								
			Remicade	C				
INTRAVENOUS								
						DRIP		
			Folic Acid	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692535-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04207
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Provigil	C			UNKNOWN	
	Chest Pain		Methylphenidate	C			UNKNOWN	
	Diabetes Mellitus		Prevacid	C			UNKNOWN	
	Hypersensitivity		Hyoscyamine	C			UNKNOWN	
	Musculoskeletal Disorder		Acetaminophen	C			UNKNOWN	
			Alendronate Sodium	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	

Date:06/17/05ISR Number: 4692536-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00414
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN	
Disability								

Date:06/17/05ISR Number: 4692538-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692539-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02342
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692540-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01069
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692541-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Injury Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692545-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01006
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692546-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01011
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:06/17/05ISR Number: 4692547-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02344
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692553-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01411
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56	DAY

Date:06/17/05ISR Number: 4692557-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01410
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692563-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00460
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hypertensive Heart Disease		Hydrochlorothiazide And Valsartan	C			UNKNOWN	
Other	Myocardial Infarction		Nitrendipine	C			UNKNOWN	
	Tachyarrhythmia		Diltiazem Hydrochloride	C			UNKNOWN	
			Benazepril Hydrochloride And Hydrochlorothiazide	C			UNKNOWN	
			Magnesium (Unspecified)	C			UNKNOWN	
			Torsemide	C			UNKNOWN	
			Esomeprazole Magnesium	C			UNKNOWN	
			Insulin Human, Isophane	C			UNKNOWN	
			Indomethacin	C			UNKNOWN	
			Dexibuprofen	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692571-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	48	DAY
	Contusion		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Dysthymic Disorder		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Fall							
	Fibromyalgia							
	Gravitational Oedema		Premarin	C			UNKNOWN	
	Hypertension		[Therapy Unspecified]	C			UNKNOWN	
	Increased Tendency To							
	Bruise		Neurontin	C			UNKNOWN	
	Lacunar Infarction		Lasix (Furosemide)	C			UNKNOWN	
	Lower Respiratory Tract		Actonel	C			UNKNOWN	
	Infection		Vitamin E	C			UNKNOWN	
	Migraine		Calcium Carbonate	C			UNKNOWN	
	Neuralgia		Aspirin	C		ORAL		
	Oedema Peripheral		Paxil	C		ORAL		
	Osteopenia		Elavil	C		ORAL		
	Osteoporosis		Oxycontin	C			UNKNOWN	
	Pain In Extremity		Vicodin Tablets	C			UNKNOWN	

	Radius Fracture		Vitamins			
	Renal Disorder		(Unspecified)	C		
UNKNOWN						
	Rotator Cuff Syndrome					
	Sinusitis					
	Spinal Osteoarthritis					
	Stress					
	Tendonitis					
	Urinary Tract Infection					

Date:06/17/05ISR Number: 4692574-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01912
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL
21 DAY						
Initial or Prolonged	Blood Cholesterol		Warfarin	C		
UNKNOWN						
Disability	Increased		Warfarin	C		
UNKNOWN						
Other	Cerebrovascular Accident					
	Emotional Distress					
	Migraine					
	Pain					

Date:06/17/05ISR Number: 4692575-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00728
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Respiratory Failure
Other	Aggression

Amnesia
Angina Unstable
Arthralgia
Arthropod Bite
Asthma
Blood Pressure Increased
Bronchitis
Cardiomegaly
Chronic Obstructive
Pulmonary Disease
Clumsiness
Confusional State
Contusion
Convulsion
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Artery Stenosis
Depression
Difficulty In Walking
Dissociation
Dizziness
Dysarthria
Dysphagia
Dysphonia
Dysuria
Encephalopathy
Eye Disorder
Fall
Foot Fracture
Fractured Coccyx
Gastrooesophageal Reflux
Disease
Haematuria
Head Injury
Headache
Hypercholesterolaemia
Hypertension
Hypertensive Crisis
Hypoaesthesia
Hypokalaemia
Hyponatraemia
Hypotension
Incisional Hernia
Insomnia
Intervertebral Disc
Degeneration
Joint Sprain

Loss Of Consciousness
Malaise
Mental Impairment
Mental Status Changes
Micturition Urgency
Migraine
Mitral Valve Incompetence
Mitral Valve Prolapse
Mouth Cyst
Muscle Spasms
Muscle Twitching
Myalgia
Myocardial Infarction
Myocardial Ischaemia

		Myoclonus					
		Nausea					
		Neck Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nephrectomy		Vioxx	PS	Merck & Co., Inc	ORAL
		Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuropathy Peripheral					
		Night Sweats					
		Orthostatic Hypotension					
		Osteoarthritis					
		Pain In Extremity					
		Palpitations					
		Paraesthesia					
		Peptic Ulcer					
		Pollakiuria					
		Pupil Fixed					
		Pyelonephritis Chronic					
		Renal Atrophy					
		Renal Impairment					
		Respiratory Distress					
		Road Traffic Accident					
		Seborrhoeic Keratosis					
		Skeletal Injury					
		Skin Papilloma					
		Sleep Walking					
		Spinal Fracture					
		Stress Incontinence					
		Toxicologic Test Abnormal					
		Upper Respiratory Tract Infection					
		Urinary Incontinence					
		Urinary Tract Infection					
		Urticaria					
		Ventricular Hypertrophy					

Date:06/17/05ISR Number: 4692577-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01419
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
591	DAY						

Date:06/17/05ISR Number: 4692578-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Alopecia
Other	Anaemia
	Angina Pectoris
	Arrhythmia
	Supraventricular
	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Benign Prostatic
	Hyperplasia
	Blood Pressure Increased
	Bone Pain
	Bradycardia
	Bronchospasm

		Chest Pain					
		Coccydynia					
		Colon Adenoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Convulsion		Zestril	SS		
UNKNOWN							
		Coronary Artery Disease		Isosorbide	C		
UNKNOWN							
		Coronary Artery		Cardura	C		
UNKNOWN							
		Insufficiency		Zocor	C		ORAL
		Coronary Artery Occlusion		Aspirin	C		
UNKNOWN							
		Coronary Artery Stenosis					
		Dizziness					
		Drug Ineffective					
		Duodenal Ulcer					
		Dyspnoea					
		Dyspnoea Exertional					
		Eczema					
		Fluid Overload					
		Gastritis					
		Gastrointestinal					
		Arteriovenous					
		Malformation					
		Hyperhidrosis					
		Hypotension					
		International Normalised					
		Ratio Increased					
		Joint Sprain					
		Limb Injury					
		Muscle Strain					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasal Congestion					
		Nasal Polyps					
		Neck Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Postnasal Drip					
		Prothrombin Time					
		Prolonged					
		Pulmonary Congestion					
		Reflux Oesophagitis					
		Rhinitis					

Rhinitis Allergic
Rhinorrhoea
Sinusitis
Skin Exfoliation
Skin Lesion
Sleep Disorder
Upper Respiratory Tract
Congestion
Urinary Retention
Weight Decreased

Date:06/17/05ISR Number: 4692580-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01408
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Multi-Organ Disorder							
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692586-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01933
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		879 MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		879 MON
Disability	Akinesia		Motrin	C				UNKNOWN
	Aortic Valve Incompetence		Testosterone	C				UNKNOWN
	Blood Triglycerides		Nexium	C				UNKNOWN
	Increased							
	Cardiac Disorder							
	Cardiac Flutter							
	Cardiac Murmur							
	Chest Pain							
	Coronary Artery Disease							
	Heart Disease Congenital							
	Hypokinesia							
	Myocardial Infarction							
	Sinus Tachycardia							
	Ventricular Dysfunction							
	Ventricular Hypokinesia							

Date:06/17/05ISR Number: 4692591-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01613
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS		ORAL		
Other	Nerve Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Vioxx	SS		ORAL		
	Attack		Lantus	C				UNKNOWN
	Traumatic Brain Injury		Toprol Xl Tablets	C				UNKNOWN
			Diovan	C				UNKNOWN
			Ultracet	C				UNKNOWN

Date:06/17/05ISR Number: 4692592-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01120
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Areflexia
	Bursitis
	Cerebrovascular Accident
	Confusional State
	Conjunctivitis Viral
	Diverticulum Intestinal
	Dyspepsia
	Epicondylitis
	Eructation
	Hypertension
	Increased Tendency To Bruise
	Liver Function Test Abnormal
	Mitral Valve Incompetence
	Nasal Septum Perforation
	Nasal Ulcer
	Paronychia
	Pleural Fibrosis
	Polyneuropathy

		Rheumatoid Arthritis Sjogren'S Syndrome Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
15	MON						
		Ventricular Dysfunction		Plaquenil	C		
UNKNOWN							
				Methotrexate	C		ORAL
				Folic Acid	C		ORAL
				Folic Acid	C		ORAL
				Calcium (Unspecified)	C		
UNKNOWN							
				Premphase	C		ORAL
804	DAY						
				Pravachol	C		
UNKNOWN							
				Vitamins (Unspecified)	C		ORAL
				Hydrochlorothiazide	C		ORAL
				Lipitor	C		ORAL
366	DAY						
				Tylenol	C		ORAL

Date:06/17/05ISR Number: 4692593-4Report Type:Expedited (15-DaCompany Report #NL-MERCK-0412NLD00004
Age:39 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL
10	DAY						
		Vertigo		[Composition Unspecified]	C		
UNKNOWN							

Date:06/17/05ISR Number: 4692596-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02331
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL

	Increased		[Therapy			
	Coronary Artery Disease		Unspecified]	C		
UNKNOWN						
	Depression					
	Herpes Zoster					
	Myocardial Infarction					
	Nausea					

Date:06/17/05ISR Number: 4692597-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00157
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 25 DAY	Dysarthria		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 42 DAY	Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL
Disability 31 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Hydrochlorothiazide	C		ORAL
			Lisinopril	C		ORAL
			Aspirin	C		ORAL
			Pravastatin Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692598-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01914
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
Hospitalization - UNKNOWN	Cerebrovascular Accident		Lipitor	C				1294 DAY
Initial or Prolonged UNKNOWN	Death		Prevacid	C				
Other	Oedema Peripheral		Zocor	C		ORAL		
			Levothyroxine Sodium	C				
UNKNOWN								1323 DAY
			Synthroid	C				
UNKNOWN								2863 DAY

Date:06/17/05ISR Number: 4692599-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04781
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	

Date:06/17/05ISR Number: 4692600-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00010
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	877 DAY	
Hospitalization - UNKNOWN	Dyspnoea		Nitroglycerin	C				
Initial or Prolonged UNKNOWN	Flatulence		Metoprolol Tartrate	C				
	Regurgitation Of Food		Enalaprilat	C				
UNKNOWN								
	Sudden Death		Zocor	C				
UNKNOWN								
			Diazepam	C				
UNKNOWN								
			Aspirin And					

Magnesium Oxide C
UNKNOWN

Date:06/17/05ISR Number: 4692601-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01783
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Ibuprofen	C				UNKNOWN
	Blood Cholesterol Increased		Aspirin	C		ORAL		
	Coronary Artery Disease							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							
	Overdose							
	Palpitations							

Date:06/17/05ISR Number: 4692602-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02978
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Adverse Event
Other	Bone Pain
	Cerebrovascular Accident
	Convulsion
	Dysphagia
	Dyspnoea
	Fatigue
	Fibromyalgia
	Gastrointestinal Disorder

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Gastrointestinal Haemorrhage					
		Gastrooesophageal Reflux Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Haematochezia		Asacol	C		
UNKNOWN							
		Hernia		Claritin	C		
UNKNOWN							
		Hypertension		Prevacid	C		
UNKNOWN							
		Myalgia		Singulair	C		
UNKNOWN							
		Nausea		Arthotec	C		
UNKNOWN							
		Oesophageal Disorder		Neurontin	C		
UNKNOWN							
		Pain		Celebrex	C		
UNKNOWN							
		Panic Attack		Plavix	C		
UNKNOWN							
		Urinary Tract Infection		Nasarel	C		
UNKNOWN							
		Vomiting		Amitriptyline Hydrochloride	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Lexapro	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Zelnorm	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Pepcid	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Z-Pak	C		
UNKNOWN							

Aspirin C
UNKNOWN

Date:06/17/05ISR Number: 4692603-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01597
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia
Disability	Cardiac Disorder
Other	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Pain
	Chest Wall Pain
	Collagen-Vascular Disease
	Diabetic Neuropathy
	Diabetic Retinopathy
	Ejection Fraction Decreased
	Erectile Dysfunction
	Essential Hypertension
	Folliculitis
	Gastrooesophageal Reflux Disease
	Glaucoma
	Glycosylated Haemoglobin Increased
	Hypercholesterolaemia
	Hypoaesthesia
	Intervertebral Disc Disorder
	Intervertebral Disc Displacement
	Lacunar Infarction
	Microalbuminuria

		Myocardial Ischaemia					
		Oedema Peripheral					
		Paraesthesia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Peroneal Nerve Palsy		Vioxx	PS	Merck & Co., Inc	ORAL
		Radiculopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Red Blood Cell		Vioxx	SS	Merck & Co., Inc	ORAL
		Sedimentation Rate		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Vasculitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Vitreous Haemorrhage		Insulin	C		
UNKNOWN							
				Lisinopril	C		
UNKNOWN							

Date:06/17/05ISR Number: 4692608-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Abnormal Dreams
Disability	Activated Partial
Other	Thromboplastin Time
	Prolonged
	Amenorrhoea
	Angina Pectoris
	Aphthous Stomatitis
	Arthralgia
	Asthenia
	Atelectasis
	Atrial Septal Defect
	Blood Pressure Abnormal
	Blood Pressure Increased
	Breast Pain
	Breast Tenderness
	Bronchitis Acute
	Bursitis
	Cardiac Disorder
	Cerebral Infarction
	Cerebrovascular Accident
	Chest Pain
	Chondropathy
	Coagulopathy

Conjunctival Haemorrhage
Contusion
Convulsion
Cyst
Deep Vein Thrombosis
Diarrhoea
Disease Recurrence
Dizziness
Drug Abuser
Drug Dependence
Drug Hypersensitivity
Dry Throat
Dysmenorrhoea
Dyspnoea
Eczema
Embolic Stroke
Emotional Disorder
Endometriosis

Epistaxis
Fall
Fatigue
Feeling Cold
Feeling Hot And Cold
Fungal Infection
Gastroenteritis Viral
Generalised Oedema
Haemorrhage
Headache
Hearing Impaired
Heparin-Induced
Thrombocytopenia
Hip Arthroplasty
Hip Fracture
Hypercoagulation
Hyperhidrosis
Hypoaesthesia
Hypothyroidism
Increased Tendency To
Bruise
Ingrowing Nail
Inguinal Hernia
Inguinal Hernia Repair
Injury
Laryngitis
Localised Infection
Loss Of Libido
Lung Infiltration
Mastitis
Menorrhagia
Migraine
Munchausen'S Syndrome
Muscle Atrophy
Muscle Spasms
Musculoskeletal
Discomfort
Nausea
Neck Mass
Nervousness
Nuclear Magnetic
Resonance Imaging Brain
Abnormal
Oligomenorrhoea
Osteoarthritis
Otitis Externa
Otitis Media

Ovarian Cyst
Ovarian Enlargement
Pain
Pain In Extremity
Pain In Jaw
Palpitations
Panic Attack
Paraesthesia
Patent Ductus Arteriosus
Pelvic Pain
Peripheral Embolism
Pharyngitis
Photosensitivity Reaction
Post Procedural

		Complication Protein C Decreased Protein S Decreased Prothrombin Time	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL
		Pyrexia		Vioxx	SS	Merck & Co., Inc	ORAL
		Rash		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Vicodin Tablets	C		
UNKNOWN							
		Rhinitis Allergic		Aspirin	C		
UNKNOWN							
		Scar		Zantac	C		
UNKNOWN							
		Sinus Disorder		Restoril	C		
UNKNOWN							
		Sinusitis		Flexeril	C		
UNKNOWN							
		Splenic Cyst		Ascriptin	C		
UNKNOWN							
		Systemic Lupus Erythematosus Tinnitus Tooth Disorder Transient Ischaemic Attack Upper Respiratory Tract Infection Urinary Tract Infection Urine Abnormality Uterine Enlargement Vaginal Mycosis Vaginitis Bacterial Viral Infection Viral Upper Respiratory Tract Infection Vision Blurred Visual Field Defect Vomiting Weight Decreased					

Date:06/17/05ISR Number: 4692611-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA04107
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Death	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON
Other	Cerebrovascular Accident		Acupril	C			UNKNOWN
	Death Gastrointestinal Obstruction Vomiting						

Date:06/17/05ISR Number: 4692612-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00081
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	44 MON
Initial or Prolonged	Cerebrovascular Accident		Hyzaar	C			UNKNOWN 2 YR
Other	Chest Pain Transient Ischaemic Attack						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692615-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00284
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Exanthem		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Flatulence		Piroxicam Betadex	C				
UNKNOWN								
Disability	Hypertension		Tilidine					
	Hypertensive Crisis		Hydrochloride	C				
UNKNOWN								
	Iritis		Tramadol					
	Nephrosclerosis		Hydrochloride	C		ORAL		
	Psoriasis		Cholecalciferol	C		ORAL		
	Renal Failure Acute		Amlodipine Besylate	C		ORAL		
	Sleep Disorder		Enalapril Maleate	C		ORAL		
	Visual Field Defect		Bisoprolol Fumarate	C		ORAL		
			Pimecrolimus	C				
TOPICAL								

Date:06/17/05ISR Number: 4692622-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01764
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Inadequately Controlled		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Celebrex	C				
UNKNOWN								
	Diabetes Mellitus		Zocor	C				
UNKNOWN								
	Malnutrition-Related		Singulair	C				
UNKNOWN								
	Excoriation		Albuterol	C				
UNKNOWN								
	Fall		Actos	C				
UNKNOWN								
	Stomach Discomfort		Glucophage	C				
UNKNOWN								
			Glipizide Xl	C				
UNKNOWN								
			Lopressor	C				
UNKNOWN								

	Metoprolol	C
UNKNOWN		
	Quinapril Hydrochloride	C
UNKNOWN		
	Accupril	C
UNKNOWN		
	Duragesic	C
UNKNOWN		
	Pletal	C
UNKNOWN		
	Metoclopramide	C
UNKNOWN		
	Vitamins (Unspecified)	C
UNKNOWN		
	Ascorbic Acid	C
UNKNOWN		
	Calcium (Unspecified)	C
UNKNOWN		

Date:06/17/05ISR Number: 4692625-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02976
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
	Chronic Fatigue Syndrome
	Deep Vein Thrombosis
	Disturbance In Attention
	Emotional Distress
	Gastric Disorder
	Gastrointestinal Disorder
	Hypertension
	Irritable Bowel Syndrome
	Myocardial Infarction
	Nausea

Pain
Pulmonary Embolism

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Prednisone	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	
	Tylenol With Codeine #3	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	
	Potassium (Unspecified)	C			UNKNOWN	
	Azulfidine	C			UNKNOWN	
	Ultram	C			UNKNOWN	

Date:06/17/05ISR Number: 4692626-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00894
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692627-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00819
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692628-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00912
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastric Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Effexor	C		ORAL		
			Aleve	C		ORAL		

Date:06/17/05ISR Number: 4692629-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00103
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692630-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01096
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	870 DAY	
Other	Cerebrovascular Accident		Pepcid	C			UNKNOWN	
	Fall		Metoclopramide Hydrochloride	C			UNKNOWN	
	Myocardial Infarction		Diclofenac	C			UNKNOWN	
			Doxycycline	C			UNKNOWN	
			Paxil	C			UNKNOWN	
			Lipitor	C			UNKNOWN	

				Allegra	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Aricept	C		
UNKNOWN							
				Diflucan	C		
UNKNOWN							
				Chlorazepate	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							

Date:06/17/05ISR Number: 4692631-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01075
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Transient Ischaemic		Levoxyl	C			UNKNOWN	
	Attack		Synthroid	C			UNKNOWN	
			Chibro B12	C			UNKNOWN	

Date:06/17/05ISR Number: 4692632-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692633-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00012
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		453 DAY
			Citalopram Hydrobromide	C		ORAL		
			Clonazepam	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Acetaminophen	C		ORAL		

Date:06/17/05ISR Number: 4692634-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00014
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bundle Branch Block Left		Vioxx	PS	Merck & Co., Inc	ORAL		837 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		434 DAY
			Budesonide	C			RESPIRATORY (INHALATION)	
			Terbutaline Sulfate	C			RESPIRATORY (INHALATION)	
			Meloxicam	C		ORAL		
			Orlistat	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692635-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01076
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	6	MON

Date:06/17/05ISR Number: 4692636-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692637-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00086
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	120	DAY
Life-Threatening	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN	Depression		Prednisolone	C				
Initial or Prolonged	Inguinal Hernia							
	Pleural Effusion							
	Pneumonia							
	Sepsis							
	Transient Ischaemic Attack							
	Vasculitis							

Date:06/17/05ISR Number: 4692638-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01077
Age:60 YR Gender:Male I/FU:I

Outcome	PT
Death	Alopecia
Hospitalization -	Anxiety Disorder

Initial or Prolonged	Arthritis Bacterial
	Arthritis Infective
	Atrial Fibrillation
	Bacterial Sepsis
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Cholelithiasis
	Coagulopathy
	Depression
	Dermatitis
	Dilatation Atrial
	Emotional Distress
	Fall
	Hyperglycaemia
	Joint Dislocation
	Meniscus Lesion
	Myocardial Infarction
	Plantar Fasciitis
	Pneumonia
	Quadriparesis
	Renal Failure
	Respiratory Failure
	Sleep Apnoea Syndrome
	Staphylococcal Infection

	Vertigo						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Xenical	C		ORAL		
			Prilosec	C		ORAL		
			Zocor	C		ORAL		

Date:06/17/05ISR Number: 4692639-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01305
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692640-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692641-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01476
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	529 DAY	

Date:06/17/05ISR Number: 4692642-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01104
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
			Claritin	C			UNKNOWN	
			Hydroxyzine Hydrochloride	C			UNKNOWN	

Date:06/17/05ISR Number: 4692643-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01412
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:06/17/05ISR Number: 4692644-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	451	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692645-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00578
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Triglycerides		Vioxx	PS	Merck & Co., Inc	ORAL		423 DAY
Initial or Prolonged	Increased		Maxzide	C				UNKNOWN
	Deep Vein Thrombosis		Coumadin	C				UNKNOWN
	Gastrooesophageal Reflux		Synthroid	C				UNKNOWN
	Disease							
	Shoulder Pain							

Date:06/17/05ISR Number: 4692646-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02128
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastric Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Pulmonary Embolism		Atenolol	C				UNKNOWN
Disability	Thrombosis		Lasix (Furosemide)	C				UNKNOWN
			Coumadin	C				UNKNOWN
			Timoptic	C				UNKNOWN

Date:06/17/05ISR Number: 4692649-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02315
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Hospitalization -	Aortic Dilatation		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Barrett'S Oesophagus		Lisinopril	C				UNKNOWN

Disability	Bursitis	Aciphex	C
UNKNOWN			
Other	Cholelithiasis		
	Colonic Polyp		
	Coronary Artery Disease		
	Hepatic Cyst		
	Hypertension		
	Iron Deficiency		
	Kyphosis		
	Rectal Adenoma		
	Renal Aneurysm		
	Renal Artery		
	Atherosclerosis		
	Renal Artery Occlusion		
	Renal Atrophy		
	Renal Cyst		
	Renal Impairment		
	Renal Lipomatosis		
	Sexual Dysfunction		
	Testicular Atrophy		
	Tinnitus		
	Weight Decreased		

Date:06/17/05ISR Number: 4692650-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02405
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
							18	MON
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Overdose		Prinzide	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692653-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00478
Age:59 YR Gender:Male I/FU:U

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Prilosec	C			UNKNOWN	
	Coronary Artery Disease		Amitriptyline Hydrochloride	C			UNKNOWN	
	Depression							
	Dyspnoea		Aspirin	C			UNKNOWN	
	Gastritis		Pentoxifylline	C			UNKNOWN	
	Iliac Artery Thrombosis							
	Joint Sprain							
	Myocardial Infarction							
	Pericarditis							
	Peripheral Vascular Disorder							
	Post-Traumatic Stress Disorder							
	Pulmonary Hypertension							

Date:06/17/05ISR Number: 4692654-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02665
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia Postoperative		Avandia	C			UNKNOWN	
Other	Cellulitis		Glucophage	C			UNKNOWN	
	Cerebral Atrophy		Glucotrol	C			UNKNOWN	
	Cerebral Infarction		Crestor	C			UNKNOWN	
	Dementia		Neurontin	C			UNKNOWN	
	Depression		Ambien	C			UNKNOWN	

	Essential Hypertension	Effexor	C
UNKNOWN			
	Fall	Zyprexa	C
UNKNOWN			
	Gastrointestinal Haemorrhage	Diltiazem Hydrochloride	C
UNKNOWN			
	Hemiparesis	Wellbutrin	C
UNKNOWN			
	Hip Fracture	Celexa	C
UNKNOWN			
	Ileus Paralytic	Lipitor	C
UNKNOWN			
	Insomnia	Avapro	C
UNKNOWN			
	Intermittent Claudication	Plavix	C
UNKNOWN			
	Ischaemic Cerebral	Pravachol	C
UNKNOWN			
	Infarction		
	Lacunar Infarction		
	Mental Status Changes		
	Oesophagitis Ulcerative		
	Peripheral Vascular Disorder		
	Sinusitis		
	Tension Headache		
	Transient Ischaemic Attack		

Date:06/17/05ISR Number: 4692656-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01836
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cardiac Disorder
	Cardiac Failure

Congestive

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692657-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01368
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692658-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692659-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01414
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14 MON	

Date:06/17/05ISR Number: 4692660-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	1032 DAY	

Date:06/17/05ISR Number: 4692661-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	625	DAY

Date:06/17/05ISR Number: 4692662-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01316
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692663-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01853
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692664-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01858
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON

Date:06/17/05ISR Number: 4692665-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692666-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Haemorrhage Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692667-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01870
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692668-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02213
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Hernia
Joint Injury
Myocardial Infarction

Date:06/17/05ISR Number: 4692669-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01857
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692670-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692671-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01845
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692672-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02610
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
Initial or Prolonged	Blood Cholesterol		Femhrt	C				UNKNOWN 12 MON
Disability	Increased		Femhrt	C				UNKNOWN 12 MON
	Blood Pressure Increased		Aleve	C				UNKNOWN
	Cerebrovascular Accident		Zoloft	C				UNKNOWN 1 MON
	Dyspnoea		Vitamins					
	Ischaemic Stroke		(Unspecified)	C				UNKNOWN
	Sleep Disorder		Calcium (Unspecified)	C				UNKNOWN

Date:06/17/05ISR Number: 4692673-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02472
Age:68 YR Gender:Female I/FU:F

Outcome	PT
Other	Activated Partial Thromboplastin Time Prolonged
	Angina Pectoris
	Aortic Valve Incompetence
	Arterial Stenosis
	Arthralgia
	Asthenia
	Cardiomegaly
	Chest Discomfort
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Restenosis
	Coronary Artery Stenosis
	Cough
	Cyanosis

Deep Vein Thrombosis
Difficulty In Walking
Dizziness
Dyspnoea
Exercise Tolerance
Decreased
Fatigue
Hyperlipidaemia
Hypotension
Injury
Intermittent Claudication
International Normalised
Ratio Increased
Leriche Syndrome
Myocardial Infarction
Oedema Peripheral
Pain In Extremity
Prothrombin Time
Prolonged
Pulse Absent
Renal Artery Stenosis
Scar
Sinus Bradycardia
Skin Discolouration

	Stent Occlusion Syncope Tricuspid Valve	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Incompetence Vascular Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692676-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01523
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	40	MON

Date:06/17/05ISR Number: 4692678-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03395
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692680-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01422
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	934	DAY

Date:06/17/05ISR Number: 4692681-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01420
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	373	DAY

Date:06/17/05ISR Number: 4692682-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01421
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		218 DAY

Date:06/17/05ISR Number: 4692683-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01436
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692684-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01440
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692685-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01435
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692686-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01424
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	62	DAY

Date:06/17/05ISR Number: 4692687-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0307NOR00011
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Factitious Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	29	DAY
Initial or Prolonged	Haematemesis		Warfarin Sodium	C			UNKNOWN	
	Ulcer		Risperidone	C		ORAL		
			Sertraline Hydrochloride	C		ORAL		
			Insulin Human, Isophane	C		SUBCUTANEOUS		
			Folic Acid	C		ORAL		

Date:06/17/05ISR Number: 4692688-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03761
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692689-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01558
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692690-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02125
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Atherosclerosis
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Fatigue Syndrome
	Depression
	Dyspnoea
	Emotional Distress
	Gastric Disorder
	Headache
	Hypertension
	Insomnia
	Myocardial Infarction
	Overdose

Sleep Apnoea Syndrome

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Ranitidine	C			UNKNOWN	
	Avandia	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Glucophage	C			UNKNOWN	
	Insulin	C			UNKNOWN	
	Tylenol Pm Extra Strength	C			UNKNOWN	
	Glyburide	C			UNKNOWN	

Date:06/17/05ISR Number: 4692691-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02787
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Bronchospasm		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery		Prozac	C		ORAL		
	Atherosclerosis		Tenormin	C		ORAL		
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Restenosis							
	Coronary Artery Stenosis							
	Depression							

Hypercholesterolaemia
Hypertension
Knee Operation
Meniscus Lesion
Myocardial Infarction
Oedema Peripheral
Pain In Extremity
Pneumonia
Weight Increased

Date:06/17/05ISR Number: 4692695-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02340
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692698-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02750
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Coronary Artery Disease Deformity Dyspepsia Flatulence Gastrooesophageal Reflux

		Disease					
		Hypertension					
		Major Depression					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Neuropathy Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
55	MON						
		Urinary Tract Infection		Zocor	C		ORAL
				Tenormin	C		ORAL
				Maxzide	C		ORAL

Date:06/17/05ISR Number: 4692699-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02791
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
65 MON						
Initial or Prolonged	Condition Aggravated		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
65 MON						
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion		Bextra	C		ORAL
	Depression		Cozaar	C		ORAL
	Dyspepsia		Levitra	C		ORAL
	Epicondylitis		Allopurinol	C		ORAL
	Hyperglycaemia		Lorcet 10/650	C		ORAL
	Hypokalaemia		Lipitor	C		ORAL
	Injury		Colchicine	C		
UNKNOWN						
	Myocardial Infarction		Lotrel	C		ORAL
	Peptic Ulcer					
	Sleep Apnoea Syndrome					
	Upper Respiratory Tract Infection					

Date:06/17/05ISR Number: 4692701-5Report Type:Expedited (15-DaCompany Report #TR-MERCK-0506USA02102
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL

Vioxx	SS	Merck & Co., Inc	ORAL	
Vioxx	SS	Merck & Co., Inc	ORAL	

Date:06/17/05ISR Number: 4692702-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00640
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Insulin Human, Isophane	C			SUBCUTANEOUS	
	Convulsion		Prednisone	C			UNKNOWN	
	Leukocytosis		Zaroxolyn	C			UNKNOWN	
	Rash		Lipitor	C			UNKNOWN	
	Respiratory Failure		Spironolactone	C			UNKNOWN	
	Spleen Disorder		Wellbutrin Sr	C			UNKNOWN	
			Premphase	C			UNKNOWN	
			Actonel	C			UNKNOWN	
			Plaquenil	C			UNKNOWN	
			Colace	C			UNKNOWN	
			K-Dur	C			UNKNOWN	
			Ultram	C		ORAL		

				Lasix (Furosemide)	C		
UNKNOWN							
				Azathioprine	C		ORAL
				Diflucan	C		
UNKNOWN							
				Zyban	C		
UNKNOWN							
				Actigall	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:06/17/05ISR Number: 4692703-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00017
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ventricular Tachycardia		Montelukast Sodium	C				
UNKNOWN								
			Pentaerythritol Tetranitrate	C				
UNKNOWN								
			Budesonide And Formoterol Fumarate	C				
UNKNOWN								
			Simvastatin	C				
UNKNOWN								
			Fenoterol Hydrobromide And Ipratropium Bromide	C				
UNKNOWN								

Date:06/17/05ISR Number: 4692704-0Report Type:Expedited (15-DaCompany Report #TR-MERCK-0506USA02150
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vein Disorder							

Date:06/17/05ISR Number: 4692705-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00103
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		1165 DAY
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		1165 DAY
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		UNKNOWN
	Dizziness		Premarin	C				
	Hypertension		Accupril	C		ORAL		UNKNOWN
	Osteoporosis		Procardia Xl	C		ORAL		UNKNOWN
	Pneumonia		Methotrexate	C		ORAL		UNKNOWN
			Folic Acid	C				UNKNOWN
			Os-Cal	C				UNKNOWN
			Diclofenac	C				UNKNOWN
			Xanax	C		ORAL		UNKNOWN
			Reglan	C				UNKNOWN

Date:06/17/05ISR Number: 4692706-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00101
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
	Atherosclerosis
Disability	Barrett'S Oesophagus
Other	Benign Prostatic

Hyperplasia
Bladder Obstruction
Blood Pressure Systolic
Increased
Cardiac Failure
Congestive
Cardiomegaly
Cellulitis
Chronic Obstructive
Pulmonary Disease
Constipation
Coronary Artery Disease
Cough
Depressed Level Of
Consciousness
Diabetes Mellitus
Inadequate Control
Duodenal Ulcer
Emotional Distress
Fluid Overload
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Haemodialysis
Hiatus Hernia
Hilar Lymphadenopathy
Hyperlipidaemia
Hypocalcaemia
Hypoxia
Infection
Injury
Interstitial Lung Disease
Leukocytosis
Limb Injury
Meniscus Lesion
Metabolic Acidosis
Monarthritis
Myocardial Infarction
Nephropathy Toxic
Oesophageal Ulcer
Osteoarthritis
Osteochondrosis
Pain In Extremity
Pleural Disorder
Pneumonia
Pulmonary Oedema
Pulmonary Vascular
Disorder

Rash Erythematous
Rash Generalised
Rash Maculo-Papular
Renal Failure
Renal Failure Acute
Renal Tubular Necrosis
Rhabdomyolysis
Rib Fracture
Rotator Cuff Syndrome
Skin Hyperpigmentation
Tachycardia
Tricuspid Valve
Incompetence
Urinary Tract Obstruction

Vascular Calcification
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Zocor	SS		ORAL		
	[Therapy Unspecified]	C			UNKNOWN	
	Tylenol Arthritis Extended Relief	C			UNKNOWN	
	Hydrocodone Bitartrate	C			UNKNOWN	
	Accupril	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Diltiazem Msd	C			UNKNOWN	
	Glucophage	C			UNKNOWN	
	Glyburide	C			UNKNOWN	

Date:06/17/05ISR Number: 4692707-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02687
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Lipitor	C			UNKNOWN	
	Delirium Tremens		Vitamins (Unspecified)	C			UNKNOWN	
	Depression							
	Dyspnoea		Celebrex	C			UNKNOWN	
	Gastrooesophageal Reflux		Wellbutrin	C			UNKNOWN	

	Disease	Flexeril	C
UNKNOWN			
	Hepatitis Alcoholic Hypertension Ligament Injury Nasal Disorder Oesophageal Disorder Rectal Haemorrhage		

Date:06/17/05ISR Number: 4692708-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00947
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Anxiety Blood Cholesterol Increased Blood Homocysteine Increased Cardiomegaly Coronary Artery Atherosclerosis Diabetes Mellitus Electrocardiogram St Segment Abnormal Emotional Distress Fear Hot Flush Hyperphagia

		Libido Decreased Oedema Peripheral Social Problem	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
				Ogen	C		ORAL
				Lasix (Furosemide)	C		
UNKNOWN							
				Phentermine	C		
UNKNOWN							
				Ativan	C		ORAL
				Norvasc	C		ORAL
				Synthroid	C		ORAL
				Cipro	C		
UNKNOWN							
				Zofran	C		
UNKNOWN							
				Hydroxyzine Hydrochloride	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Levaquin	C		
UNKNOWN							
				Klor-Con	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Vicodin Tablets	C		ORAL

Date:06/17/05ISR Number: 4692709-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00129
Age:81 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Arrhythmia Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4692710-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02127
Age:43 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Disability	Abnormal Sensation In Eye Amaurosis Asthenia Blindness Transient Blood Cholesterol Increased Carpal Tunnel Syndrome Cerebrovascular Accident Cervicobrachial Syndrome Embolic Cerebral Infarction Facial Palsy Headache Hernia Hypercholesterolaemia Hypertension Hypoaesthesia Laboratory Test Abnormal Mass Neck Pain Osteoarthritis Pain In Extremity Paraesthesia Partial Seizures Speech Disorder Spinal Osteoarthritis Tunnel Vision

Vision Blurred
Visual Disturbance

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	1010 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Hyzaar	C			UNKNOWN	
	Vicodin Tablets	C			UNKNOWN	
	Hydrocodone/Apap	C			UNKNOWN	
	Motrin	C			UNKNOWN	3 MON
	Tylenol	C			UNKNOWN	11 DAY
	Crestor	C			UNKNOWN	
	Aspirin	C			UNKNOWN	

Date:06/17/05ISR Number: 4692711-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01900
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	899 DAY	
Other	Atrioventricular Block		Coumadin	C			UNKNOWN	
	Second Degree		Skelaxin	C			UNKNOWN	
	Bradycardia		Propacet	C			UNKNOWN	
	Cardiac Pacemaker		Valium	C			UNKNOWN	
	Insertion		Tenormin	C			UNKNOWN	7429 DAY
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Delusion							
	Difficulty In Walking							

Emotional Distress
Hypersomnia
Memory Impairment
Myocardial Infarction
Palpitations
Sinus Arrest
Sleep Apnoea Syndrome
Speech Disorder
Transient Ischaemic
Attack

Date:06/17/05ISR Number: 4692712-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure							
Other	Congestive							
	Congestive Cardiomyopathy							
	Depression							
	Generalised Anxiety							
	Disorder							
	Haematochezia							
	Hypertension							
	Myocardial Infarction							
	Nocturia							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4692713-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03889
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Nexium	C				
UNKNOWN								
	Colonic Polyp		Nexium	C				
UNKNOWN								
	Emotional Distress							
	Hypertension							
	Limb Injury							

Date:06/17/05ISR Number: 4692714-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02081
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bundle Branch Block Right		Cardizem	C				
UNKNOWN								
Other	Cerebrovascular Accident							
	Chest Pain							
	Dilatation Ventricular							
	Dizziness							
	Dyspnoea Exertional							
	Emotional Distress							
	Headache							
	Hemiplegia Transient							
	Hypoaesthesia							
	Migraine							
	Myocardial Infarction							
	Myopia							
	Nausea							
	Palpitations							
	Paraesthesia							
	Renal Disorder							
	Speech Disorder							
	Vision Blurred							

Date:06/17/05ISR Number: 4692715-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02698
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Adverse Event
	Angina Pectoris
	Anorectal Disorder
	Arthropod Sting
	Blood Urine Present
	Bronchitis
	Cellulitis
	Contusion
	Coronary Artery Disease
	Diabetes Mellitus
	Drug Administration Error
	Dyspepsia
	Dysuria
	Emotional Distress
	Fall
	Hypertension
	Ischaemic Cardiomyopathy

		Lobar Pneumonia Rectal Haemorrhage Treatment Noncompliance	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
1617 MON							
				Viagra	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							
				Bextra	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN		4 MON					

Date:06/17/05ISR Number: 4692716-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00874
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
5 MON							
		Infarction		Celebrex	C		ORAL
2 YR							
		Blood Pressure Increased Coronary Artery Disease Oedema Peripheral Pain In Extremity					

Date:06/17/05ISR Number: 4692718-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01122
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4692719-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01128
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		79 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692720-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01073
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		1691 DAY
Initial or Prolonged	Colonic Polyp		Vioxx	SS	Merck & Co., Inc	ORAL		1691 DAY
	Diverticulum		Advil	C				UNKNOWN
	Emotional Distress		Prinzide	C		ORAL		
	Hyperlipidaemia		Advair Diskus	C				UNKNOWN
	Hypertension							
	Myocardial Infarction							

Date:06/17/05ISR Number: 4692721-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00674
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Cerebrovascular Accident
	Coronary Artery

		Atherosclerosis Coronary Artery Occlusion Coronary Artery Stenosis Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
1130 DAY							
		Deep Vein Thrombosis		Neurontin	C		
UNKNOWN							
		Jugular Vein Distension		Prinivil	C		ORAL
		Myocardial Infarction		Renagel	C		
UNKNOWN							
		Nausea		Calcium Carbonate	C		
UNKNOWN							
		Oedema Peripheral		Docusate Sodium	C		
UNKNOWN							
		Rales		Endocet	C		
UNKNOWN							
		Thrombosis		Zestril	C		
UNKNOWN		45 DAY					
		Vomiting		Lasix (Furosemide)	C		
UNKNOWN		1060 DAY					
				Ranitidine	C		
UNKNOWN							
				Labetalol Hydrochloride	C		
UNKNOWN							
				Humalog	C		
UNKNOWN							

Date:06/17/05ISR Number: 4692722-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4692757-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01735
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Emotional Distress	Gengraf	C
UNKNOWN			
Disability	Myocardial Infarction	Lopressor	C
UNKNOWN			
	Pain	Lipitor	C
UNKNOWN			
	Weight Increased	Colchicine	C
UNKNOWN			
		Advil	C
UNKNOWN			
		Tylenol	C
UNKNOWN			

Date:06/17/05ISR Number: 4692759-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00144
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY

Date:06/17/05ISR Number: 4692777-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04652
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Herpes Zoster Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692778-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02624
Age:46 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL	54	MON
Other	Blood Cholesterol		Aspirin	SS			UNKNOWN	
	Increased		Aspirin	SS			UNKNOWN	
	Cerebrovascular Accident		Advil	SS			UNKNOWN	
	Chest Pain		Hydrochlorothiazide	C			UNKNOWN	
	Emotional Distress							
	Fall							
	Gastrointestinal Disorder							
	Hypertension							
	Meniscus Lesion							
	Myocardial Infarction							
	Pain							
	Paraesthesia							
	Skin Discolouration							
	Transient Ischaemic Attack							

Date:06/17/05ISR Number: 4692779-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02686
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Depression Postoperative		Vioxx	SS	Merck & Co., Inc	ORAL	1	YR
	Mental Disorder		Prednisone	C			UNKNOWN	
	Myocardial Infarction		Singulair	C			UNKNOWN	
			Flonase	C			UNKNOWN	

Date:06/17/05ISR Number: 4692780-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02621
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atrial Fibrillation		Pepcid	C		ORAL		
	Blood Cholesterol Increased		Darvocet-N	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
	Diarrhoea		Xanax	C			UNKNOWN	
	Diverticulitis		Acetaminophen	C			UNKNOWN	
	Gastritis							
	Hypertension							
	Lobar Pneumonia							
	Nausea							
	Oedema							
	Pericarditis							
	Pleurisy							
	Vomiting							

Date:06/17/05ISR Number: 4692792-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00665
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Back Disorder
	Blood Cholesterol Increased

Laryngitis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4692793-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03180
Age:83 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Amnesia		Advil	C				
UNKNOWN								
Disability	Angina Pectoris		Tylenol	C				
UNKNOWN								
Other	Blood Sodium Decreased		Levothyroxine Sodium	C				
UNKNOWN								
	Cardiac Failure		Spironolactone	C				
UNKNOWN								
	Congestive		Furosemide	C				
UNKNOWN								
	Cerebrovascular Accident		Nabumetone	C				
UNKNOWN								
	Confusional State		Lisinopril	C		ORAL		
	Coronary Artery Disease		Atenolol	C				
UNKNOWN								
	Depression		Quinine	C				
UNKNOWN								
	Fall		Temazepam	C				
UNKNOWN								
	Gastrointestinal Disorder							
	Haematoma							
	Heart Injury							
	Hyperlipidaemia							
	Hypertension							
	Hypotension							
	Hypothyroidism							
	Loss Of Consciousness							
	Osteoporosis							
	Radiculopathy							
	Renal Failure Chronic							
	Transient Ischaemic							
	Attack							

Date:06/17/05ISR Number: 4693156-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693317-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00669
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Angina Pectoris
Other	Asthenia
	Atherosclerosis
	Back Injury
	Blood Creatine Phosphokinase Increased
	Burning Sensation
	Carotid Artery Stenosis
	Cellulitis
	Cerebrovascular Accident
	Constipation
	Cough
	Deep Vein Thrombosis

		Difficulty In Walking Dyspnoea Exertional Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Flank Pain		Vioxx	PS	Merck & Co., Inc	ORAL
31	MON						
		Gammopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Zocor	C		
UNKNOWN							
		Disease		Insulin	C		
UNKNOWN							
		Glaucoma		Toprol Xl Tablets	C		
UNKNOWN							
		Gout		Nexium	C		
UNKNOWN							
		Haematochezia Haematuria Hepatomegaly Leukopenia Lichen Planus Loss Of Consciousness Micturition Disorder Micturition Urgency Monocyte Count Increased Myalgia Mycetoma Mycotic Myocardial Infarction Nail Tinea Neuropathic Pain Neuropathy Peripheral Oedema Peripheral Onychomycosis Paralysis Polyneuropathy Postnasal Drip Renal Disorder Road Traffic Accident Skin Disorder Syncope Thrombosis Urinary Bladder Polyp Vascular Injury Weight Decreased					

Date:06/17/05ISR Number: 4693320-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01582
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		228 DAY
Initial or Prolonged	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Dementia Alzheimer'S Type							
	Dyspnoea							
	Headache							
	Vision Blurred							

Date:06/17/05ISR Number: 4693322-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00146
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization -	Back Pain
Initial or Prolonged	Drug Hypersensitivity
Other	Drug Ineffective
	Duodenitis

	Dyspnoea Exertional						
	Fibromyalgia						
	Helicobacter Gastritis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metformin Hydrochloride	C		ORAL		
			Indomethacin	C		ORAL		
			Indomethacin	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Enalapril Maleate	C				
UNKNOWN								
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Hydrochlorothiazide And Triamterene	C				
UNKNOWN								
			Captopril	C				
UNKNOWN								

Date:06/17/05ISR Number: 4693326-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00119
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Inadequate Control		Aspirin	C		ORAL		
Other	Diverticulum Intestinal							
	Epididymitis							
	Fatigue							

Mental Disorder Due To A
General Medical Condition
Vascular Encephalopathy
Vertigo

Date:06/17/05ISR Number: 4693329-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA02077
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Arrhythmia
Hospitalization - Initial or Prolonged	Atherosclerosis
Disability	Atrial Fibrillation
Other	Coronary Artery Stenosis
	Depression
	Diarrhoea
	Dilatation Atrial
	Dizziness
	Dysphagia
	Dyspnoea

		Dyspnoea Exertional Ejection Fraction Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Fatigue		Aspirin	C		
UNKNOWN							
		Flushing		Paxil	C		
UNKNOWN							
		Guillain-Barre Syndrome		Valium	C		
UNKNOWN							
		Heart Rate Irregular					
		Hot Flush					
		Hypercholesterolaemia					
		Hyperhidrosis					
		Hyperlipidaemia					
		Hypoaesthesia					
		Memory Impairment					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Negative Thoughts					
		Non-Cardiac Chest Pain					
		Obesity					
		Pain In Extremity					
		Panic Attack					
		Paralysis					
		Pneumonia					
		Pyrexia					
		Renal Failure					
		Renal Failure Acute					
		Sexual Dysfunction					
		Shoulder Pain					
		Sleep Apnoea Syndrome					
		Sleep Disorder					
		Suicidal Ideation					
		Ventricular Hypertrophy					
		Ventricular Hypokinesia					

Date:06/17/05ISR Number: 4693330-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00045
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Aneurysm Bronchitis
Other	Carotid Artery Stenosis

Cerebrovascular Accident
Chronic Obstructive
Pulmonary Disease
Confusional State
Depression
Dizziness
Fall
Hyperlipidaemia
Hypoaesthesia
Intervertebral Disc
Degeneration
Intervertebral Disc
Protrusion
Joint Swelling
Mitral Valve Incompetence
Nausea
Restless Legs Syndrome
Sinusitis
Transient Ischaemic

Attack
Tricuspid Valve
Incompetence

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	751	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	341	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Naproxen	C			UNKNOWN	
	Desyrel	C		ORAL		
	Desyrel	C		ORAL		
	Viagra	C		ORAL		
	Zocor	C		ORAL		
	Aggrenox	C		ORAL		
	Klonopin	C		ORAL		
	Chondroitin	C			UNKNOWN	
	Glucosamine	C			UNKNOWN	
	Tylenol Sinus	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	

Date:06/17/05ISR Number: 4693335-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01988
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	567	DAY
	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL	567	DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	567	DAY
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	567	DAY
	Hypoaesthesia		Prednisone	C			UNKNOWN	
	Osteoporosis		Plaquenil	C			UNKNOWN	

	Pancreatic Carcinoma		Axid	C		
UNKNOWN						
	Rectal Polyp		Levsin	C		
UNKNOWN						
	Sinus Disorder		Bextra	C		
UNKNOWN						
	Transient Ischaemic Attack					

Date:06/17/05ISR Number: 4693336-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01946
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Abdominal Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
Other	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
	Cerebrovascular Accident		Zoloft	C				
UNKNOWN								
	Chest Wall Pain		Toprol Xl Tablets	C				
UNKNOWN								
	Deep Vein Thrombosis		Celebrex	C				
UNKNOWN								
	Dyspepsia		Premarin	C				
UNKNOWN								
	Gastrooesophageal Reflux Disease							
	Haemorrhagic Stroke							
	Oedema Peripheral							
	Pain In Extremity							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693337-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02470
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Asthma		Vioxx	C		ORAL		
Other	Blood Creatine							
	Phosphokinase Increased							
	Burning Sensation							
	Cerebrovascular Accident							
	Convulsion							
	Diverticulum							
	Dizziness							
	Drug Ineffective							
	Faecal Occult Blood							
	Positive							
	Groin Pain							
	Haematochezia							
	Haemorrhage Intracranial							
	Haemorrhoids							
	Headache							
	Hepatic Enzyme Increased							
	High Density Lipoprotein							
	Decreased							
	Hypertension							
	Hypoaesthesia							
	Injury							
	Musculoskeletal Stiffness							
	Pain							
	Paraesthesia							
	Sciatica							
	Syncope							

Date:06/17/05ISR Number: 4693338-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02595
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Affect Lability
Other	Agitation
	Amnesia
	Aneurysm
	Anxiety

Aortic Valve Incompetence
Cerebellar Infarction
Chest Pain
Convulsion
Depression
Diarrhoea
Expressive Language
Disorder
Hallucination
Mitral Valve Incompetence
Pulmonary Hypertension
Restless Legs Syndrome
Sinus Bradycardia
Sleep Disorder
Transient Ischaemic
Attack
Tricuspid Valve
Incompetence

	Vertebral Artery Occlusion Vertigo Positional	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	C			UNKNOWN	193 DAY
			Lipitor	C			UNKNOWN	260 DAY
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	

Date:06/17/05ISR Number: 4693339-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02885
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 2 YR Initial or Prolonged Disability	Anxiety Disorder Bladder Disorder Blood Cholesterol Increased Cardiac Murmur Cerebrovascular Accident Depression Fistula Insomnia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693340-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02720
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Aphasia	Vioxx	PS	Merck & Co., Inc	ORAL
	Arthralgia	Vioxx	SS	Merck & Co., Inc	
UNKNOWN					
	Blood Cholesterol	Tylenol	C		
UNKNOWN					
	Increased	Effexor	C		
UNKNOWN	5 MON				
	Cerebrovascular Accident	Bextra	C		
UNKNOWN					
	Chest Pain	Aspirin	C		
UNKNOWN					
	Dyspepsia				
	Feeling Abnormal				
	Hypersensitivity				
	Myocardial Infarction				
	Thrombosis				

Date:06/17/05ISR Number: 4693341-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02640
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Other	Alopecia
	Amnesia
	Autoimmune Thyroiditis
	Bundle Branch Block Left
	Cardiac Disorder
	Chest Discomfort
	Closed Head Injury
	Congestive Cardiomyopathy

		Diplopia					
		Ejection Fraction Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Goitre		Vioxx	PS	Merck & Co., Inc	ORAL
1229 DAY							
		Influenza Like Illness		Ultram	C		
UNKNOWN							
		Intestinal Resection		Copaxone	C		
UNKNOWN							
		Myocardial Infarction		Symmetrel	C		
UNKNOWN							
		Oedema Peripheral		Zanaflex	C		
UNKNOWN							
		Road Traffic Accident		Neurontin	C		
UNKNOWN							
		Thyroid Disorder		Detrol La	C		
UNKNOWN							
		Thyroid Neoplasm		Elavil	C		
UNKNOWN							
		Ventricular Dysfunction					
		Ventricular Hypokinesia					
		Viral Infection					

Date:06/17/05ISR Number: 4693342-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02344
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Mass		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Cholesterol		Diovan	C		
UNKNOWN							
		Increased		Metoprolol	C		
UNKNOWN							
		Cerebrovascular Accident					
		Chest Wall Pain					
		Depression					
		Diverticulum Intestinal					
		Fall					
		Gout					
		Gouty Arthritis					
		Haemorrhoids					
		High Density Lipoprotein Decreased					

Hypercholesterolaemia
Hypertension
Hypertriglyceridaemia
Joint Sprain
Lacunar Infarction
Low Density Lipoprotein
Increased
Mass
Mental Disorder
Musculoskeletal Chest
Pain
Pain In Extremity
Shoulder Pain

Date:06/17/05ISR Number: 4693343-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01098
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Synthroid	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Claritin-D	C			UNKNOWN	
			Tranxene	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693344-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03455
Age:16 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adenoidectomy		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Adenoiditis		Tylenol With Codeine					
Initial or Prolonged	Cardiac Failure		#4	C				
UNKNOWN								
Disability	Cardiac Valve Disease		Folic Acid	C				
UNKNOWN								
	Cor Pulmonale Chronic		Dilaudid	C				
UNKNOWN								
	Deep Vein Thrombosis		Hydroxyurea	C				
UNKNOWN								
	Depression		[Therapy					
	Drug Hypersensitivity		Unspecified]	C				
UNKNOWN								
	Emotional Distress		Paxil	C				
UNKNOWN								
	Gastric Disorder		Prevacid	C				
UNKNOWN								
	Injury		Prilosec	C				
UNKNOWN								
	Pulmonary Embolism		Morphine	C				
UNKNOWN								
	Pulmonary Hypertension		Demerol	C				
UNKNOWN								
	Sickle Cell Anaemia							
	Sleep Apnoea Syndrome							
	Tonsillectomy							
	Tonsillitis							

Date:06/17/05ISR Number: 4693345-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00141
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693346-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01056
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		26 MON
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		26 MON
	Increased		Prilosec	C		ORAL		
	Depression		Aspirin	C				UNKNOWN
	Hypercholesterolaemia							
	Myocardial Infarction							
	Osteoporosis							
	Pain							

Date:06/17/05ISR Number: 4693354-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01875
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693355-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01068
Age:40 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
	Angina Pectoris
	Bradyarrhythmia
	Chest Discomfort
	Cold Sweat
	Coronary Artery Disease

		Coronary Artery Stenosis Flatulence Hyperhidrosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Warm Stent Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693356-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01839
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693357-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01415
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						

Date:06/17/05ISR Number: 4693358-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01872
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693359-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01874
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder Liver Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693360-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693361-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02936
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Aspirin	C				
UNKNOWN								
	Pain							

Date:06/17/05ISR Number: 4693367-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01020
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693368-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	568	DAY
Other	Myocardial Infarction							

Date:06/17/05ISR Number: 4693369-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	122	DAY

Date:06/17/05ISR Number: 4693370-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03545
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Anaemia		Zocor	C				
	Angina Unstable		Cardura	C			UNKNOWN	
	Aortic Stenosis		Aspirin	C			UNKNOWN	
	Back Pain		Glucovance	C			UNKNOWN	
	Buttock Pain		Glucophage	C			UNKNOWN	
	Cardiac Murmur							
	Chest Pain							
	Colonic Polyp							
	Coronary Artery Disease							
	Diastolic Dysfunction							
	Diverticulum							
	Duodenitis							
	Dyspepsia							
	Dyspnoea							
	Encephalopathy							

Eructation
Flatulence
Gastritis
Hypertension
Hypokinesia
Intestinal Functional
Disorder
Nausea
Peripheral Vascular
Disorder
Ventricular Hypertrophy

Date:06/17/05ISR Number: 4693375-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05195
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Arthralgia
	Bereavement Reaction
	Chest Pain
	Cough
	Dizziness
	Dyspepsia
	Fatigue
	Haematochezia
	Haemorrhoids

		Hepatic Steatosis					
		High Density Lipoprotein Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertensive Heart Disease		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
		Liver Disorder		Aspirin	C		
UNKNOWN							
		Oedema Peripheral		Glucosamine Hydrochloride And Chondroitin Sulfate Sodium	C		
		Osteoarthritis					
		Pulmonary Hypertension					
		Rectal Haemorrhage					
UNKNOWN							
		Silent Myocardial Infarction		Allegra	C		
UNKNOWN							
		Sleep Apnoea Syndrome					
		Snoring					
		Weight Increased					

Date:06/17/05ISR Number: 4693398-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01418
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Multi-Organ Disorder					
	Myocardial Infarction					
	Pain					

Date:06/17/05ISR Number: 4693399-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01120
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Depression		Vioxx	PS	Merck & Co., Inc	ORAL
	Pulmonary Embolism		Wellbutrin	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693402-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02021
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693436-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02910
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Verapamil	C				
UNKNOWN								
	Cardiac Disorder		Aspirin	C				
UNKNOWN								
	Liver Function Test Abnormal							
	Myocardial Infarction							

Date:06/17/05ISR Number: 4693437-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02933
Age:71 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability
Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Actinic Keratosis		Vioxx	SS	Merck & Co., Inc	ORAL	15	DAY
Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Back Injury							
Back Pain							
Bronchitis							
Carpal Tunnel Syndrome							
Cerebrovascular Accident							
Chest Pain							
Depression							
Dizziness							
Dizziness Postural							
Dyspnoea							
Dysuria							
Essential Tremor							
Eye Pain							
Eye Pruritus							
Fall							
Gastrooesophageal Reflux Disease							
Headache							
Hypersensitivity							
Hypertonic Bladder							
Incontinence							
Intervertebral Disc Protrusion							
Lacrimation Increased							
Muscle Spasms							
Muscular Weakness							
Myalgia							
Nasal Discomfort							
Oedema Peripheral							
Pain In Extremity							
Panic Attack							
Perineal Pain							
Pharyngeal Oedema							
Polyneuropathy							
Prostatitis							
Renal Disorder							
Road Traffic Accident							

Sinusitis
Skin Lesion
Testicular Pain
Thermal Burn
Transient Ischaemic
Attack
Venous Insufficiency
Vision Blurred

Date:06/17/05ISR Number: 4693438-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02538
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Cardio-Respiratory Arrest
	Diarrhoea

		Fatigue					
		Hypertension					
		Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vomiting		Vioxx	PS	Merck & Co., Inc	ORAL
132	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
132	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							

Date:06/17/05ISR Number: 4693882-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01579
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack					

Date:06/17/05ISR Number: 4693884-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01469
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
Other		Myocardial Infarction					

Date:06/17/05ISR Number: 4693885-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01862
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
13	MON						
		Myocardial Infarction					

Date:06/17/05ISR Number: 4693886-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	34	MON

Date:06/17/05ISR Number: 4693894-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01864
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693895-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01861
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693896-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01687
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chondropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Amaryl	C				
UNKNOWN								
	Coronary Artery Thrombosis							

Date:06/17/05ISR Number: 4693897-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01863
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693898-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693900-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
42 MON								
	Infarction							

Date:06/17/05ISR Number: 4693905-8Report Type:Expedited (15-DaCompany Report #NL-MERCK-0506NLD00022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - UNKNOWN Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc

Date:06/17/05ISR Number: 4693912-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01580
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693913-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01413
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	49 MON	

Date:06/17/05ISR Number: 4693915-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00600
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Emotional Distress Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693916-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	906	DAY

Date:06/17/05ISR Number: 4693921-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02025
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693922-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02091
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased Chest Pain Migraine Stomach Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693923-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02027
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693924-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

			Vioxx	SS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693925-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02005
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:06/17/05ISR Number: 4693926-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01865
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693927-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01855
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693928-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01951
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Hospitalization -			Vasotec	C				UNKNOWN
Initial or Prolonged			Lipitor	C				UNKNOWN
Disability								

Date:06/17/05ISR Number: 4693929-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/17/05ISR Number: 4693930-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01939
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Dialysis							
Initial or Prolonged	Haemorrhage							
	Myocardial Infarction							
	Renal Disorder							

Date:06/17/05ISR Number: 4693931-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693932-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693933-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03190
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Disability	Arthralgia
Other	Basal Cell Carcinoma
	Bradycardia
	Breast Tenderness
	Compartment Syndrome
	Constipation
	Cough
	Dermatophytosis
	Diabetes Mellitus
	Diabetes Mellitus
	Insulin-Dependent
	Dialysis
	Emotional Distress
	External Ear Lesion

	Excision						
	Haematoma						
	Hot Flush						
	Hyperglycaemia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	37 DAY
	Impaired Work Ability		Goserelin	C			PARENTERAL
	Influenza		Goserelin	C			PARENTERAL
	Injury		Casodex	C		ORAL	
	Limb Traumatic Amputation		Casodex	C		ORAL	
	Musculoskeletal		Ecotrin	C		ORAL	
	Discomfort		Felodipine	C		ORAL	
	Myocardial Infarction		Fluticasone				
	Nail Tinea		Propionate	C			RESPIRATORY
	Neuropathy						(INHALATION)
	Oedema Peripheral		Metoprolol	C			UNKNOWN
	Renal Failure		Ranitidine				
	Renal Failure Acute		Hydrochloride	C			UNKNOWN
	Sleep Apnoea Syndrome		Zocor	C			UNKNOWN
	Urinary Tract Infection		Warfarin	C		ORAL	
			Phillips' Milk Of Magnesia	C			UNKNOWN
			Docusate Sodium	C		ORAL	
			Hydrocodone Bitartrate	C		ORAL	

Date:06/17/05ISR Number: 4693934-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00131
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	
			Omeprazole	C			UNKNOWN

Date:06/17/05ISR Number: 4693935-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00139
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693936-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00131
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C		ORAL		
			Insulin	C		PARENTERAL		
			Leflunomide	C		ORAL		

Date:06/17/05ISR Number: 4693937-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00143
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693938-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00697
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Unstable		Tenormin	C			UNKNOWN	
	Blood Pressure Increased		Tenormin	C			UNKNOWN	
	Blood Urea Increased		Baycol	C			UNKNOWN	
	Convulsion		Ogen	C			UNKNOWN	
	Coronary Artery Disease		Lipitor	C			UNKNOWN	
	Electrocardiogram		Atenolol	C			UNKNOWN	
	Repolarisation Abnormality							
	Haemoptysis							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Syncope							
	Ventricular Hypertrophy							

Date:06/17/05ISR Number: 4693940-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02009
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Other	Asthenia
	Basophil Count Increased
	Blood Creatinine Increased
	Blood Glucose Increased
	Blood Pressure Systolic Increased
	Blood Urea Increased
	Bradycardia
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain

Chest Wall Pain
Coronary Artery Disease
Dehydration
Diarrhoea
Diplopia
Dizziness
Ejection Fraction
Decreased
Eosinophil Count
Increased
Feeling Abnormal
Headache
Hypotension
Lymphocyte Count
Increased
Monocyte Count Increased
Myocardial Infarction
Pain In Extremity
Red Cell Distribution
Width Increased
Respiratory Rate
Increased
Sinus Bradycardia

		Syncope					
		Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Coreg	C		
UNKNOWN							
		Ventricular Hypokinesia		Imdur	C		ORAL
		Vestibular Disorder		Lasix (Furosemide)	C		
UNKNOWN							
		Vision Blurred		Levoxan	C		
UNKNOWN							
				Prilosec	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zetia	C		
UNKNOWN							
				Zocor	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Isosorbide	C		
UNKNOWN							
				Evista	C		
UNKNOWN							
				Levoxyl	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:06/17/05ISR Number: 4693941-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01156
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/17/05ISR Number: 4693942-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00137
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Insulin	C				

Date:06/17/05ISR Number: 4693949-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03554
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cough		[Therapy Unspecified]	C				
	Diabetes Mellitus							
	Inadequate Control		Glyburide	C				
	Dizziness		Lipitor	C				
	Dyspnoea							
	Headache							
	Insomnia							
	Malaise							
	Neck Pain							
	Pain							
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693955-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02654
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON
Hospitalization -	Compression Fracture		Vioxx	SS	Merck & Co., Inc	ORAL		25 MON
Initial or Prolonged	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		25 MON
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		3 MON
	Joint Swelling		Evista	C				UNKNOWN
			Tenormin	C				UNKNOWN
			Amitriptyline Hydrochloride	C				UNKNOWN
			Tylenol With Codeine	C				UNKNOWN
			Ultracet	C				UNKNOWN

Date:06/17/05ISR Number: 4693956-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00138
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:06/17/05ISR Number: 4693957-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00058
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coma Hepatic		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
Hospitalization -	Jaundice		Vioxx	SS	Merck & Co., Inc	ORAL		9 DAY

Initial or Prolonged	Malignant Neoplasm Of Ampulla Of Vater		Dipyrone	C		ORAL
			Acetyldigoxin	C		
UNKNOWN						
			Hydrochlorothiazide And Ramipril	C		
UNKNOWN						
			Esomeprazole Magnesium	C		
UNKNOWN						
			Verapamil Hydrochloride	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693958-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00062
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 4 YR	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					
Disability						

Date:06/17/05ISR Number: 4693959-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide And Irbesartan	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693960-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00163
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693961-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00061
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693962-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00059
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1226 DAY	
Disability	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:06/17/05ISR Number: 4693963-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00132
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/17/05ISR Number: 4693964-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00148
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		303 DAY
Initial or Prolonged Disability	Myocardial Infarction							

Date:06/17/05ISR Number: 4693965-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02334
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Accelerated Hypertension
Initial or Prolonged	Angina Pectoris
Other	Arteriospasm Coronary
	Asthenia
	Atherosclerosis
	Back Pain
	Chest Pain
	Coronary Artery Stenosis
	Deep Vein Thrombosis
	Depression
	Dyspnoea
	Emotional Disorder
	Emotional Distress
	Fatigue

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Foot Fracture					
		Gastrooesophageal Reflux Disease					
		Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL
5	YR						
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
5	YR						
		Myocardial Infarction		Levaquin	C		
UNKNOWN							
		Nausea		Premarin	C		
UNKNOWN							
		Neck Pain		Tricor	C		
UNKNOWN							
		Oedema Peripheral		Diltiazem Er	C		
UNKNOWN							
		Pulmonary Embolism		Fosamax	C		
UNKNOWN							
		Scan Myocardial Perfusion Abnormal		Acetaminophen And Hydrocodone Bitartrate	C		
		Sleep Apnoea Syndrome					
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Gentamicin	C		
UNKNOWN							
				Imdur	C		
UNKNOWN							
				Nitroquick	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Tenormin	C		
UNKNOWN							
				Penlac	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							

			Zoloft	C		
UNKNOWN						
			Triamterene	C		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN						
			Sulfamethoxazole And Trimethoprim	C		
UNKNOWN						
			Flonase	C		
UNKNOWN						
			Zyrtec	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Rhinocort Aqua	C		
UNKNOWN						
			Protonix	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693967-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00062
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Aspirin	C		
UNKNOWN						
Disability			Metoprolol Tartrate	C		
UNKNOWN						
			Irbesartan	C		
UNKNOWN						
			Aspirin And Dipyridamole	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693968-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03295
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Acute Chest Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Chest Pain		Neurontin	C		ORAL
Initial or Prolonged	Difficulty In Walking		Amitriptylin	C		
UNKNOWN						

Disability	Myocardial Infarction	Topamax	C	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693969-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00144
Age:10 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Fall							
	Inflammation							
	Respiratory Disorder							
	Swelling Face							
	Swollen Tongue							

Date:06/17/05ISR Number: 4693973-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02861
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	288	DAY
Initial or Prolonged	Back Injury							
Disability	Blood Cholesterol							
Other	Increased							
	Cardiac Failure							
	Congestive							
	Constipation							
	Dizziness							
	Hernia							
	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							

Date:06/17/05ISR Number: 4693974-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02866
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Idioventricular Rhythm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Morphine	C		INTRAVENOUS		
	Coronary Artery Disease					DRIP		

	Coronary Artery Stenosis		Lorcet 10/650	C		
UNKNOWN						
	Ejection Fraction		Soma	C		
UNKNOWN						
	Decreased		Restoril	C		
UNKNOWN						
	Emotional Distress Hypotension Malignant Melanoma		Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN						
	Myocardial Infarction		Prozac	C		
UNKNOWN						
	Thrombolysis		Zantac	C		
UNKNOWN						
	Ventricular Hypokinesia		Testosterone	C		
PARENTERAL						

Date:06/17/05ISR Number: 4693975-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02792
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 371 YR	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 371 YR	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Ischaemia		Zocor	C		
UNKNOWN						
	Myocardial Infarction		Zyprexa	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693976-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02573
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Aspirin	C			UNKNOWN	
	Cognitive Disorder		Excedrin					
	Coronary Artery Disease		(Acetaminophen (+)					
	Dehydration		Aspirin (+)					
	Delirium		Caffeine)	C			UNKNOWN	
	Depression		Xanax	C			UNKNOWN	
	Dizziness		Valium	C			UNKNOWN	
	Dyspnoea		Effexor	C			UNKNOWN	
	Epistaxis							
	Gastrointestinal Disorder							
	Generalised Anxiety Disorder							
	Gout							
	Headache							
	Hyperhidrosis							
	Hypertension							
	Hypertensive Heart Disease							
	Hypoaesthesia							
	International Normalised Ratio Increased							
	Loss Of Consciousness							
	Muscle Spasms							
	Nausea							
	Neck Pain							
	Non-Cardiac Chest Pain							
	Pain In Extremity							
	Panic Disorder							
	Rhinorrhoea							
	Sinusitis							
	Syncope							

Thrombosis
Transient Ischaemic
Attack

Date:06/17/05ISR Number: 4693977-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00991
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		845 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		845 DAY
	Back Pain		Aspirin	C				UNKNOWN
	Nerve Compression		Aspirin	C				UNKNOWN
	Osteoarthritis		Aleve	C				UNKNOWN
			Advil	C				UNKNOWN
			Mobic	C				UNKNOWN
			Accupril	C				UNKNOWN
			Atacand	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Lopressor	C				UNKNOWN
			Tylenol	C				UNKNOWN

				Lipitor	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Motrin	C		
UNKNOWN							

Date:06/17/05ISR Number: 4693978-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01735
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Gengraf	C				
UNKNOWN								
Disability	Depression		Lopressor	C				
UNKNOWN								
	Emotional Distress		Lipitor	C				
UNKNOWN								
	Myocardial Infarction		Colchicine	C				
UNKNOWN								
	Pain		Advil	C				
UNKNOWN								
	Weight Increased		Tylenol	C				
UNKNOWN								

Date:06/17/05ISR Number: 4693979-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02022
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Tamponade		Prempro	C				
UNKNOWN								
	Myocardial Infarction		Hydrochlorothiazide	C				
UNKNOWN								
	Pericardial Haemorrhage		Tricor	C				
UNKNOWN								
			Cardizem	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								

			Toprol Xl Tablets	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						
			Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C		
UNKNOWN						

Date:06/17/05ISR Number: 4693983-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02673
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Aspirin	C		
UNKNOWN						
	Myocardial Infarction		Desyrel	C		
UNKNOWN						
	Myocardial Ischaemia		Viagra	C		
UNKNOWN						
	Overdose		Lortab	C		
UNKNOWN						
	Pain		Flexeril	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/05ISR Number: 4693984-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02632
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Constipation		Lisinopril	C		ORAL		
	Dehydration		Lexapro	C				UNKNOWN
	Depression		Lotrel	C		ORAL		
	Fall		Oxybutynin	C		ORAL		
	Muscle Spasms		Norvasc	C				UNKNOWN
	Renal Failure		Aggrenox	C				UNKNOWN
	Urinary Tract Infection		Bextra	C				UNKNOWN
	Vaginal Candidiasis		Exelon	C		ORAL		
	Venous Insufficiency		Detrol	C				UNKNOWN

Date:06/17/05ISR Number: 4694844-9Report Type:Expedited (15-DaCompany Report #2004118811
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Health	Celebrex (Celecoxib)	PS		ORAL	200 MG 1 IN 1	
	Exostosis	Professional						D, ORAL
	Surgery		Vioxx (Rofecoxib)	SS				
			Hydrochlorothiazide (Hydrochlorothiazide)	C				
			Atenolol (Atenolol)	C				
			Aricept (Donepezil)	C				
			Aciphex (Rabeprazole Sodium)	C				
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	C				
			Atacand (Candesartan Cilexetil)	C				

Date:06/17/05ISR Number: 4695028-0Report Type:Expedited (15-DaCompany Report #ACO_0167_2005
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Right Ventricular	Foreign	Sirdalud	PS		ORAL	VAR QDAY PO	3 DAY
Initial or Prolonged	Failure	Literature	Vioxx	SS		ORAL	25 MG QDAY PO	
Required	Alanine Aminotransferase	Health	Voltaren	C				
Intervention to	Increased	Professional	Phytotherapeutics	C				
Prevent Permanent	Angiopathy	Other						
Impairment/Damage	Aspartate							
	Aminotransferase							
	Increased							
	Blood Pressure Systolic							
	Increased							
	Bradycardia							
	Drug Interaction							
	Gamma-Glutamyltransferase							
	Increased							
	Haemangioma Of Liver							
	Hepatic Cyst							
	Liver Function Test							
	Abnormal							
	Pulmonary Hypertension							
	Tachycardia							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694525-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atenolol	C				UNKNOWN
	Anxiety		Norvasc	C				UNKNOWN
	Blood Glucose Increased		Zestril	C				UNKNOWN
	Coronary Artery Atherosclerosis							
	Dyslipidaemia							
	High Density Lipoprotein Decreased							
	Hypertension							
	Hypoaesthesia							
	Sinus Bradycardia							
	Stent Occlusion							
	Swelling							

Date:06/20/05ISR Number: 4694531-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00143
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction							

Date:06/20/05ISR Number: 4694539-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	General Symptom		Fluticasone Propionate And Salmeterol Xinafoate	C				UNKNOWN

	Fosinopril Sodium	C
UNKNOWN		
	[Therapy Unspecified]	C
RESPIRATORY		
(INHALATION)		

Date:06/20/05ISR Number: 4694541-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02046
Age:37 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Accidental Overdose
	Coronary Artery Atherosclerosis
	Dyspepsia
	Gastric Ulcer
	Hypoaesthesia
	Joint Effusion
	Joint Swelling
	Lipoma
	Lymphoedema
	Myocardial Infarction
	Rash
	Rheumatoid Arthritis
	Tooth Abscess

		Upper Gastrointestinal Haemorrhage					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Methotrexate	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Methotrexate	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:06/20/05ISR Number: 4694542-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 2 DAY	Abscess Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Acute Myocardial					
Other	Infarction					
	Angina Pectoris					
	Aortic Valve Incompetence					
	Atherosclerosis					
	Bundle Branch Block Right					
	Cardiac Murmur					
	Cardiomyopathy					
	Cervicobrachial Syndrome					
	Chronic Obstructive					
	Pulmonary Disease					
	Congestive Cardiomyopathy					
	Coronary Artery Disease					
	Diverticular Perforation					
	Diverticulitis					
	Drug Hypersensitivity					

Hyperlipidaemia
Leukocytosis
Muscle Spasms
Myeloproliferative
Disorder
Polycythaemia Vera
Prostatic Specific
Antigen Increased
Therapeutic Response
Decreased
Upper Respiratory Tract
Infection
Viral Infection

Date:06/20/05ISR Number: 4694543-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01948
Age: Gender:Female I/FU:F

Outcome PT
Other Angle Closure Glaucoma
Back Pain
Cerebrovascular Accident
Pain In Extremity
Polymyalgia Rheumatica
Transient Ischaemic

Attack

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	178	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Norvasc	C			UNKNOWN	
	Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN	
	Prednisone	C			UNKNOWN	
	Lorazepam	C			UNKNOWN	
	Hydrochlorothiazide	C			UNKNOWN	
	Dicyclomine Hydrochloride	C			UNKNOWN	

Date:06/20/05ISR Number: 4694544-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02040
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Astrocytoma		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - UNKNOWN	Cardio-Respiratory Arrest		Levothroid	C				
Initial or Prolonged UNKNOWN	Cerebrovascular Accident		Fosamax	C				
Other	Cerebrovascular Disorder							
	Coronary Artery Disease							
	Decreased Appetite							
	Dehydration							
	Dyspnoea							
	Hypercalcaemia							
	Hyperlipidaemia							
	Hypertension							
	Lacunar Infarction							
	Lethargy							
	Metastasis							

	Myocardial Infarction
	Non-Hodgkin'S Lymphoma
	Transient Ischaemic
	Attack

Date:06/20/05ISR Number: 4694545-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00134
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Zocor	C		ORAL		
	Attack		Omeprazole Magnesium	C		ORAL		
			Aspirin	C		ORAL		

Date:06/20/05ISR Number: 4694546-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00146
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Angina Pectoris
Hospitalization -	Back Pain
Initial or Prolonged	Drug Hypersensitivity
Other	Drug Ineffective
	Duodenitis
	Dyspnoea Exertional
	Fibromyalgia

		Helicobacter Gastritis					
		Hyperhidrosis					
		Hypertensive Crisis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Ventricular Hypertrophy		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Metformin Hydrochloride	C		ORAL
				Indomethacin	C		ORAL
				Indomethacin	C		ORAL
				Sotalol Hydrochloride	C		ORAL
				Atorvastatin Calcium	C		ORAL
				Amitriptyline Hydrochloride	C		ORAL
				Enalapril Maleate	C		
UNKNOWN							
				Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL
				Hydrochlorothiazide And Triamterene	C		
UNKNOWN							
				Captopril	C		
UNKNOWN							

Date:06/20/05ISR Number: 4694547-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00142
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - 4 YR	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					

Date:06/20/05ISR Number: 4694548-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01737
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		25 MON
Initial or Prolonged	Infarction		Pravachol	C				UNKNOWN
Disability	Anhedonia		Pravachol	C				UNKNOWN
Other	Arthritis							
	Cardiovascular Disorder							
	Carpal Tunnel Syndrome							
	Coronary Artery Disease							
	Hypertension							
	Life Expectancy Shortened							
	Myalgia							
	Pain							
	Trigger Finger							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694552-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01551
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bacterial Infection		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Photosensitivity Reaction		Verapamil	C				
UNKNOWN								
Initial or Prolonged								
Disability								

Date:06/20/05ISR Number: 4694553-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01276
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Appendix Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
25 MON								
Initial or Prolonged	Cardiac Disorder		Neurontin	C				
UNKNOWN								
	Cardiac Failure		Premarin	C				
UNKNOWN								
	Congestive		Norvasc	C				
UNKNOWN								
	Carpal Tunnel Syndrome							
	Cataract							
	Cervicobrachial Syndrome							
	Cholelithiasis							
	Confusional State							
	Coronary Artery Disease							
	Gastroenteritis							
	Haemorrhoids							
	Haemothorax							
	Herpes Simplex							
	Hyperglycaemia							
	Hyperlipidaemia							
	Intermittent Claudication							
	Myocardial Infarction							
	Skin Lesion							
	Spinal Osteoarthritis							

Date:06/20/05ISR Number: 4694555-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00118
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		DAY

Date:06/20/05ISR Number: 4694556-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00111
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694557-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00749
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694558-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694559-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	970	DAY

Date:06/20/05ISR Number: 4694564-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00167
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Venlafaxine Hydrochloride	C		ORAL		
			Prazosin Hydrochloride	C		ORAL		

Date:06/20/05ISR Number: 4694565-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02971
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
Other	Cardiac Disorder		Ritalin	C			UNKNOWN	
	Dyspepsia		Singulair	C		ORAL		
	Dyspnoea		Pravachol	C			UNKNOWN	

UNKNOWN	Fatigue	Flexeril	C
UNKNOWN	Gastrooesophageal Reflux	Darvocet-N	C
UNKNOWN	Disease	Advair	C
UNKNOWN	Hypertension	Wellbutrin	C
UNKNOWN	Mobility Decreased	Prozac	C
UNKNOWN	Myocardial Infarction	Nitro-Dur	C
UNKNOWN	Oedema Peripheral	Flonase	C
UNKNOWN	Panic Disorder	Toprol Xl Tablets	C
UNKNOWN	Paralysis	Klonopin	C
UNKNOWN	Sleep Apnoea Syndrome	Albuterol Sulfate	C
UNKNOWN		Vicodin Tablets	C
UNKNOWN		Nitroglycerin	C
UNKNOWN		Norvasc	C
UNKNOWN		Protonix	C
UNKNOWN		Hydrochlorothiazide Tablets (Usp 23)	C
UNKNOWN		Carbatrol	C
UNKNOWN		Provigil	C
UNKNOWN		Celebrex	C
UNKNOWN	366 DAY	Aspirin	C
UNKNOWN		Ibuprofen	C
UNKNOWN		Zanaflex	C
UNKNOWN		Diovan	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694566-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01405
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694567-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01407
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694568-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02024
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694569-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694571-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02023
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694574-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01989
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Urine Present		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	
Hospitalization - Initial or Prolonged	Cardiac Failure		[Composition Unspecified]	C			UNKNOWN	
	Congestive							
Disability	Cerebrovascular Accident		[Therapy Unspecified]	C			UNKNOWN	
	Dementia							
	Renal Haemorrhage							

Date:06/20/05ISR Number: 4694579-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02429
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4694617-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02451
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4694618-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695079-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00818
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Naproxen	C			UNKNOWN	
	Depression		Skelaxin	C			UNKNOWN	
	Disturbance In Attention		Flexeril	C			UNKNOWN	
	Emotional Distress		Theragesic	C			TOPICAL	
	Hypertension							
	Oral Soft Tissue Disorder							
	Stress							

Date:06/20/05ISR Number: 4695084-XReport Type:Expedited (15-DaCompany Report #US-MERCK-01082564
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
Disability	Arthralgia
Other	Back Pain
	Blindness
	Bronchitis
	Cataract
	Cerebrovascular Accident
	Depression
	Diverticulum
	Endometrial Hyperplasia
	Epistaxis
	Flushing
	Gastrooesophageal Reflux Disease

Gout
Haemorrhage Intracranial
Headache
Hemianopia Homonymous
Herpes Zoster
Hyperhidrosis
Hypersensitivity
Hypertension
Joint Injury
Musculoskeletal
Discomfort
Nasal Congestion
Nausea
Pain
Pallor
Paraesthesia
Pneumonia
Postmenopausal
Haemorrhage
Rash
Rift Valley Fever
Sciatica
Tachycardia

		Thyroid Mass Uterine Polyp Vaginal Haemorrhage	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
676	DAY						
				Provera	SS		
UNKNOWN							
				Heparin	SS		
UNKNOWN							
				Captopril	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Cisapride	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							
				Capozide	C		
UNKNOWN							

Date:06/20/05ISR Number: 4695086-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
144	MON						
Initial or Prolonged		Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL
144	MON						
Disability		Aneurysm Cerebrovascular Accident		Amitriptyline Hydrochloride	C		
UNKNOWN							
		Chronic Obstructive		Meclizine	C		
UNKNOWN							
		Pulmonary Disease		Darvocet-N	C		
UNKNOWN							
		Colonic Polyp Complex Regional Pain Syndrome Depression					

Diverticulum
Dizziness
Emotional Distress
Hyperlipidaemia
Hypertension
Hypoaesthesia
Joint Dislocation
Large Cell Carcinoma Of
The Respiratory Tract
Stage Unspecified
Pneumothorax
Stress
Stress Incontinence
Ventricular Extrasystoles

Date:06/20/05ISR Number: 4695087-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02551
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Back Pain
Other	Blood Glucose Increased
	Cardiac Arrest
	Chest Pain
	Depression
	Dysuria
	Fungal Infection
	Hypercholesterolaemia
	Hypertension
	Injury
	Low Density Lipoprotein

	Increased Myalgia Myocardial Infarction Penile Swelling	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Tendonitis		Vioxx	PS	Merck & Co., Inc	ORAL	129 DAY
			Zestril	C			UNKNOWN
			Zestril	C			UNKNOWN
			Aspirin	C			UNKNOWN
			Zocor	C		ORAL	
			Combivent	C			RESPIRATORY (INHALATION)
			Naprosyn	C			UNKNOWN
			Zantac	C			UNKNOWN
			Hytrin	C			UNKNOWN

Date:06/20/05ISR Number: 4695088-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0112USA01793
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY
Initial or Prolonged			Vitamins (Unspecified)	C			Other UNKNOWN
			Estrogens (Unspecified)	C			UNKNOWN
			Guaifenesin	C			UNKNOWN

Date:06/20/05ISR Number: 4695098-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02870
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Heart Rate Decreased		Metoprolol	C			UNKNOWN	
			Cardura	C			UNKNOWN	
			Synthroid	C			UNKNOWN	

Date:06/20/05ISR Number: 4695099-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02604
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiac Failure Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Insulin	C			UNKNOWN	
	Cardiac Murmur		Ibuprofen	C			UNKNOWN	
	Cerebrovascular Accident		Actos	C			UNKNOWN	
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain							

Date:06/20/05ISR Number: 4695100-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02606
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Other	Blood Cholesterol Increased

		Cerebrovascular Accident Hypertension					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Paxil	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Dicyclomine Hydrochloride	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Ditropan	C		
UNKNOWN							

Date:06/20/05ISR Number: 4695101-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02590
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
6 MON						
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Feeling Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
	Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Centrum	C		
UNKNOWN						
	Loss Of Consciousness					
	Myocardial Infarction					
	Neoplasm Malignant					

Date:06/20/05ISR Number: 4695102-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02328
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL

Disability	Gallbladder Disorder		Paxil	C
UNKNOWN				
	Irritable Bowel Syndrome		Nexium	C
UNKNOWN				
	Oedema Peripheral			

Date:06/20/05ISR Number: 4695103-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00137
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder					
	Cerebrovascular Accident					
	Depression					
	Lethargy					
	Life Expectancy Shortened					
	Mental Disorder					
	Myocardial Infarction					

Date:06/20/05ISR Number: 4695104-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00460
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Death	Atrial Fibrillation
Life-Threatening	Hypertensive Crisis
Hospitalization - Initial or Prolonged	Hypertensive Heart Disease
Other	Myocardial Infarction

Tachyarrhythmia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hydrochlorothiazide And Valsartan	C			UNKNOWN	
	Nitrendipine	C			UNKNOWN	
	Diltiazem Hydrochloride	C			UNKNOWN	
	Benazepril Hydrochloride And Hydrochlorothiazide	C			UNKNOWN	
	Magnesium (Unspecified)	C			UNKNOWN	
	Torsemide	C			UNKNOWN	
	Esomeprazole Magnesium	C			UNKNOWN	
	Insulin Human, Isophane	C			UNKNOWN	
	Indomethacin	C			UNKNOWN	
	Dexibuprofen	C			UNKNOWN	

Date:06/20/05ISR Number: 4695105-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		17 MON

	Cerebral Infarction		Hydrodiuril	SS	ORAL
	Dermatitis Contact		Methotrexate	C	
UNKNOWN		2219 DAY			
	Dizziness		Folic Acid	C	ORAL
	Hypertension		Toprol Xl Tablets	C	ORAL
	Non-Cardiac Chest Pain		Aspirin	C	
UNKNOWN					
	Peripheral Coldness				
	Sinusitis				
	Stomach Discomfort				
	Transient Ischaemic Attack				

Date:06/20/05ISR Number: 4695106-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00130
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Omeprazole Magnesium	C		ORAL		

Date:06/20/05ISR Number: 4695109-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02929
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Atherosclerosis
	Blood Cholesterol Increased
	Dental Discomfort

		Hypertension Myocardial Infarction Narcolepsy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Seasonal Allergy		Duragesic	C		
TOPICAL							
				Oxycodone	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Hydrocodone Hydrochloride	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Oxycodone	C		
UNKNOWN							

Date:06/20/05ISR Number: 4695110-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01746
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - 373 DAY		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Lipitor	C		
UNKNOWN							
		Anxiety		Tranxene	C		
UNKNOWN							
		Asthenia		Prozac	C		
UNKNOWN							
		Coronary Artery		Zantac	C		
UNKNOWN							
		Atherosclerosis Coronary Artery Occlusion Ejection Fraction					

Decreased
Emotional Distress
Fall
Fatigue
Hyperlipidaemia
Obstructive Airways
Disorder
Ulna Fracture
Ulnar Nerve Injury
Ventricular Hyperkinesia

Date:06/20/05ISR Number: 4695118-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02017
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695119-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02656
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased Chest Pain		Vioxx Vasopril (Fosinopril Sodium)	PS C	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Mega Men	C			UNKNOWN	
	Dyspepsia		Celebrex	C			UNKNOWN	
	Hypertension Myocardial Infarction Sleep Apnoea Syndrome							

Date:06/20/05ISR Number: 4695121-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03804
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Goitre		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhagic Stroke		Aspirin	C				
UNKNOWN								
	Nephrolithiasis							

Date:06/20/05ISR Number: 4695122-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02897
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Aspirin	C				
UNKNOWN								
Other	Increased		Vasotec	C				
UNKNOWN								
	Cardiac Disorder		Synthroid	C				
UNKNOWN								
	Chronic Fatigue Syndrome		Metformin	C				
UNKNOWN								
	Deep Vein Thrombosis		Plavix	C				
UNKNOWN								
	Diabetes Mellitus		Tylenol With Codeine					
	Dyspnoea		#3	C				
UNKNOWN								
	Muscle Spasms		Hydrochlorothiazide	C				
UNKNOWN								
	Oedema Peripheral							
	Pain In Extremity							
	Panic Disorder							

Date:06/20/05ISR Number: 4695123-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00128
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Polytraumatism		Rizatriptan Benzoate	C		ORAL		

Other Road Traffic Accident

Date:06/20/05ISR Number: 4695124-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02649
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Zanaflex	C			UNKNOWN	
	Cerebrovascular Accident		Klonopin	C			UNKNOWN	
	Gallbladder Disorder		Remeron	C			UNKNOWN	
	Myocardial Infarction		Elavil	C			UNKNOWN	
			Elavil	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Imdur	C			UNKNOWN	
			Imdur	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Proventil	C			UNKNOWN	
			Flovent	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	
			Potassium Chloride	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			Theophylline	C			UNKNOWN	

	Diazepam	C	
UNKNOWN			
	Ambien	C	
UNKNOWN			
	Tylenol With Codeine #3	C	ORAL
	Wellbutrin	C	
UNKNOWN			
	Teveten (Eprosartan Mesylate)	C	
UNKNOWN			
	Bumex	C	
UNKNOWN			
	K-Dur	C	
UNKNOWN			
	Theo-Dur	C	
UNKNOWN			
	Lipitor	C	
UNKNOWN			
	Niaspan	C	
UNKNOWN			
	Ecotrin	C	
UNKNOWN			
	Ismo	C	
UNKNOWN			
	Lotrel	C	
UNKNOWN			

Date:06/20/05ISR Number: 4695125-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05153
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695126-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04403
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Confusional State							

Disability	Convulsion Dizziness Hypoaesthesia Loss Of Consciousness Migraine Tremor						

Date:06/20/05ISR Number: 4695127-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03373
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adjustment Disorder With Anxiety		Vioxx Lipitor	PS C	Merck & Co., Inc	ORAL		UNKNOWN
Disability	Cerebrovascular Accident Cognitive Disorder Haemorrhage Intracranial Weight Decreased		Trazodone Hydrochloride	C				UNKNOWN

Date:06/20/05ISR Number: 4695128-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02413
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4695129-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695130-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02033
Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695132-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01489
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695138-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02031
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695139-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02002
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		

Hospitalization - UNKNOWN	Appendicitis		Synthroid	C		
Initial or Prolonged UNKNOWN			[Therapy Unspecified]	C		

Date:06/20/05ISR Number: 4695140-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00008
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1505 DAY
Initial or Prolonged	Fall Humerus Fracture Infection		Prednisolone	C		ORAL		

Date:06/20/05ISR Number: 4695141-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4695143-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02000
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:06/20/05ISR Number: 4695144-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695155-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02126
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695156-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02699
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695157-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02710
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	UNKNOWN		

Date:06/20/05ISR Number: 4695158-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02713
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695159-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	868 DAY	
Other	Sudden Cardiac Death							

Date:06/20/05ISR Number: 4695160-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02149
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/05ISR Number: 4695161-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/20/05ISR Number: 4695162-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02143
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Ischaemic Cardiomyopathy							
	Myocardial Infarction							

Date:06/20/05ISR Number: 4696318-8Report Type:Expedited (15-DaCompany Report #2005087341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Abnormal	Consumer	Bextra (Valdecoxib)	PS				
Other	Chest Pain		Celebrex (Celecoxib)	SS				
	Drug Ineffective		Baclofen (Baclofen)	SS				
	Heart Rate Irregular		Vioxx (Rofecoxib)	SS				
	Hepatic Cyst		Rebif (Interferon Beta)	SS				
	Mobility Decreased		Biaxin (Clarithromycin)	SS				
	Multiple Sclerosis		Skelaxin (Metaxalone)	SS				
	Nausea							
	Spinal Cord Injury							

Date:06/20/05ISR Number: 4697131-8Report Type:Expedited (15-DaCompany Report #2005087429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure	Consumer	Bextra (Valdecoxib)	PS				

Congestive	Celebrex (Celecoxib)	SS	
Osteoarthritis	Vioxx (Rofecoxib)	SS	

Date:06/21/05ISR Number: 4695918-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01831
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness							
	Gait Disturbance							
	Headache							
	Nausea							
	Paraesthesia							
	Vomiting							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4695920-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03281
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Initial or Prolonged	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		13 MON
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Ibuprofen	C				UNKNOWN
	Musculoskeletal Pain		Nexium	C				UNKNOWN
	Myocardial Infarction		Albuterol	C				UNKNOWN
	Oedema Peripheral							

Date:06/21/05ISR Number: 4695924-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01914
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aspartate		Vioxx	PS	Merck & Co., Inc	ORAL		974 DAY
Initial or Prolonged	Aminotransferase		Vioxx	SS	Merck & Co., Inc	ORAL		974 DAY
Other	Increased		Prinivil	C		ORAL		
	Blood Albumin Increased		Glucophage	C				UNKNOWN
	Blood Glucose Increased		Glyburide	C				UNKNOWN
	Blood Pressure Diastolic		Avandia	C				UNKNOWN
	Decreased		Diltiazem					
	Carotid Artery Dissection		Hydrochloride And					
	Chronic Obstructive		Enalapril Maleate	C				UNKNOWN
	Pulmonary Disease		Zocor	C		ORAL		
	Decreased Appetite		Aspirin	C				UNKNOWN
	Diarrhoea		Ibuprofen	C				UNKNOWN
	Duodenal Ulcer							

Gastrointestinal
Haemorrhage
Lung Infiltration
Melaena
Microcytic Anaemia
Myocardial Infarction
Oedema
Peripheral Vascular
Disorder
Protein Total Decreased
Pyrexia
Upper Gastrointestinal
Haemorrhage
Ventricular Hypokinesia
White Blood Cell Count
Increased

Date:06/21/05ISR Number: 4695927-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02022
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	7 MON	
			Coumadin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4695930-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01964
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4695933-5Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4696468-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02871
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
Initial or Prolonged	Atherosclerosis		Glucotrol	C				UNKNOWN
	Chest Pain		Plavix	C				UNKNOWN
	Coronary Artery Disease		Prevacid	C				UNKNOWN
	Diabetes Mellitus		Zoloft	C				UNKNOWN
	Dyspepsia		Prinivil	C		ORAL		
	Dyspnoea		Flomax					
	Heart Rate Irregular		(Morniflumate)	C				UNKNOWN
	Hernia		Lovastatin	C				UNKNOWN
	Myocardial Infarction		Temazepam	C				UNKNOWN
	Oedema Peripheral		Arthrotec	C				UNKNOWN

		Overdose		Pangestyme Ec	C		
UNKNOWN							
		Stent Placement		Neurontin	C		
UNKNOWN							

Date:06/21/05ISR Number: 4696469-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02972
Age:56 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Carotid Artery Stenosis		Aspirin	C		
UNKNOWN							
		Chest Pain		Xanax	C		
UNKNOWN							
		Coronary Artery Disease		Prempro	C		
UNKNOWN							
		Gastric Ulcer		Nitroglycerin	C		
UNKNOWN							
		Hypertension		Plavix	C		
UNKNOWN							
		Myocardial Infarction		Celebrex	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Bextra	C		
UNKNOWN							
		Stress					
		Swelling					

Date:06/21/05ISR Number: 4696470-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01020
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4696471-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02423
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bradycardia		Digoxin	SS				
UNKNOWN								
Other	Therapeutic Agent Toxicity							

Date:06/21/05ISR Number: 4696473-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00710
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								
			Keppra	C				
UNKNOWN								
			Aricept	C				
UNKNOWN								
			Zyprexa	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Depakote	C				
UNKNOWN								
			Lotensin	C				
UNKNOWN								
			Detrol	C				
UNKNOWN								

Date:06/21/05ISR Number: 4696476-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00027
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	90 DAY	

Date:06/21/05ISR Number: 4696487-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder Death Renal Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4696496-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Hospitalization - UNKNOWN	Dizziness		Acetaminophen	C				
Initial or Prolonged	Feeling Abnormal General Physical Health Deterioration Hepatic Failure Hepatocellular Damage Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4696497-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00017
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Aspirin And Magnesium Oxide	C				
	Chest Pain							
	Headache		Levothyroxine Sodium	C				
	Nervousness		Zuclopenthixol Hydrochloride	C				

Date:06/21/05ISR Number: 4696498-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02642
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arrhythmia		Neurontin	C				
	Chest Pain		Neurontin	C				
	Depression		Valium	C				
	Gallbladder Disorder		Valium	C				
	Gastrooesophageal Reflux		Percocet	C				
	Disease		Tylox	C				
	Hand Deformity		Xanax	C				
	Heart Rate Irregular		Xanax	C				
	Myocardial Infarction		Tylenol	C				
			Ranitidine	C				
			Darvocet-N	C				
			Relafen	C				

Ultram	C	UNKNOWN
Soma	C	UNKNOWN
Oxycontin	C	UNKNOWN
Flexeril	C	UNKNOWN
Ativan	C	UNKNOWN
Ativan	C	UNKNOWN
Benzonatate	C	UNKNOWN
Vicodin Tablets	C	UNKNOWN
Celebrex	C	UNKNOWN
Celebrex	C	UNKNOWN

Date:06/21/05ISR Number: 4696499-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02296
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Valve Disease		Altace	C				
Initial or Prolonged	Intervertebral Disc		Crestor	C				
Disability	Protrusion		Lortab	C				
	Myalgia		Soma	C				
	Renal Failure							
	Vascular Occlusion							
	Ventricular Hypertrophy							

Date:06/21/05ISR Number: 4696501-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01834
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Chest Pain
	Coronary Artery Disease

	Hypoaesthesia						
	Muscle Spasms						
	Neck Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Sensation Of Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							
	Ventricular Hypertrophy							
	Ventricular Hypokinesia							

Date:06/21/05ISR Number: 4696502-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03219
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
Hospitalization - Initial or Prolonged	Congestive Congestive Cardiomyopathy		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
			Synthroid	C		ORAL		
			Aspirin	C		ORAL		
			Nitroglycerin	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:06/21/05ISR Number: 4696503-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02321
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Fibromyalgia							

Date:06/21/05ISR Number: 4696504-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03834
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Congestive		Ibuprofen	C		
UNKNOWN	Cardiac Murmur		Clonidine	C		
UNKNOWN	Chest Pain		Aleve	C		
UNKNOWN	Knee Arthroplasty		Icy Hot Cream	C		
UNKNOWN	Myocardial Infarction		Lisinopril	C		
	Osteoarthritis					
	Road Traffic Accident					
	Swelling					

Date:06/21/05ISR Number: 4696505-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02166
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:06/21/05ISR Number: 4696506-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01672
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Cardiac Disorder

		Chest Wall Pain					
		Coronary Artery Disease					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastroenteritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Pleural Effusion		Ambien	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/21/05ISR Number: 4696514-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02718
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/21/05ISR Number: 4696515-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02625
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/21/05ISR Number: 4696516-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02683
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/21/05ISR Number: 4696517-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02705
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic					

Attack

Date:06/21/05ISR Number: 4696518-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02702
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4696519-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02717
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4696520-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02694
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain Overdose Stent Placement		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4696521-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02476
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1759 DAY

Date:06/21/05ISR Number: 4696522-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02477
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:06/21/05ISR Number: 4696523-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02703
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/21/05ISR Number: 4696524-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01840
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Chest Sound		Vioxx	PS	Merck & Co., Inc	ORAL		1124 DAY
Initial or Prolonged	Anxiety		Zocor	C		ORAL		
Other	Asthma		Zantac	C				UNKNOWN
	Cardiac Disorder		Monopril	C				UNKNOWN
	Cardiac Failure		Furosemide	C				UNKNOWN
	Congestive		Azmacort	C				UNKNOWN
	Cataract							

Coronary Artery Disease
Cough
Dilatation Atrial
Dyspnoea
Essential Hypertension
Gastrooesophageal Reflux
Disease
Gout
Groin Pain
Haemorrhoids
Herpes Simplex
Hypercholesterolaemia
Mitral Valve Incompetence
Myocardial Infarction
Myocardial Ischaemia
Rash
Tricuspid Valve
Incompetence

Date:06/21/05ISR Number: 4696534-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02722
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/21/05ISR Number: 4696552-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00502
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		587 DAY
Initial or Prolonged	Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		587 DAY
Other	Cognitive Disorder		Aspirin	C				UNKNOWN
	Depression		Bisoprolol Fumarate And Hydrochlorothiazide	C				UNKNOWN
	Diabetes Mellitus Non-Insulin-Dependent							
	Gastritis		Atorvastatin Calcium	C				UNKNOWN
	Hypertensive		Celecoxib	C		ORAL		
	Cardiomyopathy		Dexketoprofen	C		ORAL		
	Myocardial Infarction							

Date:06/21/05ISR Number: 4696562-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00478
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression							
Disability	Disturbance In Attention							
	Dizziness							
	Lacunar Infarction							
	Tinnitus							

Date:06/21/05ISR Number: 4698229-0Report Type:Expedited (15-DaCompany Report #2005080946
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Abnormal	Consumer	Celebrex (Celecoxib)	PS				
Initial or Prolonged	Drug Ineffective		Bextra (Valdecoxib)	SS				
Other	Erectile Dysfunction		Viagra (Sildenafil)	SS				
	Neuropathy Peripheral		Vioxx (Rofecoxib)	SS				
	Renal Cell Carcinoma		Mobic (Meloxicam)	SS				

	Stage Unspecified		Thyroid Hormones	C
			Antihypertensives	C
			Lipitor (Atorvastatin)	C

Date:06/21/05ISR Number: 4698288-5Report Type:Expedited (15-DaCompany Report #WAES 0506NLD00013
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris	Foreign	Tab Etoricoxib	PS		ORAL	90 MG/DAILY	
Hospitalization -	Myocardial Infarction	Other						
PO								154 DAY
Initial or Prolonged			Tab Vioxx (Rofecoxib)	SS		ORAL	25 MG/DAILY	
							PO	
			Formoterol Fumarate	C				
			Methotrexate	C				
			Pilocarpine	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697075-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00082
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Mucous Membrane Disorder							
	Reflux Oesophagitis							
	Sinoatrial Block							

Date:06/22/05ISR Number: 4697077-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02896
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Corzide Tablets	C			UNKNOWN	
Other	Aneurysm		Cozaar	C			UNKNOWN	
	Angina Unstable		Arthrotec	C			UNKNOWN	
	Aortic Valve Incompetence		Terazosin Hydrochloride	C			UNKNOWN	
	Blood Potassium Increased		Detrol La	C			UNKNOWN	
	Cardiomyopathy		Nexium	C			UNKNOWN	
	Coronary Artery Disease		Protonix	C			UNKNOWN	
	Diabetes Mellitus		Plavix	C			UNKNOWN	
	Diplopia		Ultracet	C			UNKNOWN	182 DAY
	Embolic Stroke		Toprol Xl Tablets	C			UNKNOWN	
	Emotional Distress		Lescol	C			UNKNOWN	
	Fear		Aspirin	C			UNKNOWN	
	Gastritis		Saw Palmetto	C			UNKNOWN	
	Gastritis Erosive							

Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Hypertension
Ischaemic Stroke
Mitral Valve Incompetence
Myocardial Ischaemia
Nephrolithiasis
Pleural Effusion
Renal Cyst
Renal Failure Chronic
Sick Sinus Syndrome
Sinus Bradycardia

Date:06/22/05ISR Number: 4697079-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02576
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Vasotec	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Nexium	C			UNKNOWN	
			Prednisona Sod. Fos	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697093-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04185
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Obstructive		Spironolactone	C			UNKNOWN	
	Pulmonary Disease		Pacerone	C			UNKNOWN	
	Retinal Artery Embolism		Prevacid	C			UNKNOWN	
	Retinal Artery Occlusion		Coumadin	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Amiodarone	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:06/22/05ISR Number: 4697094-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02154
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	57 MON	
Initial or Prolonged	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Vioxx	SS	Merck & Co., Inc	ORAL	57 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697095-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02691
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697096-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02706
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Hernia		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Plavix	C				
			Aspirin	C				

Date:06/22/05ISR Number: 4697097-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02627
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastrooesophageal Reflux Disease		Tylenol With Codeine #3	C				
	Headache		Pepcid Complete	C				
	Hypertension							
	Monarthritis							
	Myocardial Infarction							
	Oedema							
	Pain							
	Silent Myocardial Infarction							

Date:06/22/05ISR Number: 4697098-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02693
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	42	MON

Date:06/22/05ISR Number: 4697099-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02348
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	20	MON
Initial or Prolonged	Myocardial Infarction		Tylenol	C				
UNKNOWN								

Date:06/22/05ISR Number: 4697100-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03504
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Fosamax	C				
UNKNOWN								
	Fall							
	Lacunar Infarction							
	Lumbar Spinal Stenosis							
	Mobility Decreased							
	Myocardial Infarction							
	Pain							
	Polyneuropathy							
	Transient Ischaemic Attack							

Date:06/22/05ISR Number: 4697101-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00062
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - Initial or Prolonged	Angina Pectoris	Vioxx	PS	Merck & Co., Inc	ORAL
	Atrioventricular Block	Torsemide	C		ORAL
	First Degree	Methotrexate	C		ORAL
	Cholelithiasis	Levothyroxine Sodium	C		ORAL
	Coronary Artery Disease	[Therapy			
	Hypertension	Unspecified]	C		ORAL

Date:06/22/05ISR Number: 4697117-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697121-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc		UNKNOWN	9 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697123-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02013
Age:84 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	General Physical Health		Valium	C				UNKNOWN
Initial or Prolonged	Deterioration		[Therapy Unspecified]	C				UNKNOWN
			Alphagan	C				UNKNOWN
			Timolol	C				UNKNOWN

Date:06/22/05ISR Number: 4697124-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00558
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1018 DAY

Date:06/22/05ISR Number: 4697132-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00115
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hemianopia Homonymous		Vioxx	PS	Merck & Co., Inc	ORAL		453 DAY
Initial or Prolonged	Pulmonary Embolism		Celecoxib	SS		ORAL		99 DAY
			Clopidogrel Bisulfate	C				UNKNOWN
			Levothyroxine Sodium	C				UNKNOWN
			Methotrexate	C				UNKNOWN
			Folic Acid	C				UNKNOWN

			Prednisolone	C		
UNKNOWN						

Date:06/22/05ISR Number: 4697133-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02707
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:06/22/05ISR Number: 4697134-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02808
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Sudden Death					

Date:06/22/05ISR Number: 4697147-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02922
Age:67 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accelerated Hypertension
	Asthma
	Cardiac Disorder
	Cardiac Failure
	Congestive
	Coronary Artery Disease
	Dyspnoea
	Hypoxia

		Limb Injury Lobar Pneumonia Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Prevacid	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							
				Toprol Xl Tablets	C		ORAL
				Tricor	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							
				Zestril	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Cefuroxime	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Cardizem	C		
UNKNOWN							

Date:06/22/05ISR Number: 4697168-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							

Date:06/22/05ISR Number: 4697521-3Report Type:Expedited (15-DaCompany Report #ES-MERCK-0411ESP00031
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
246 DAY								
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
246 DAY								
	Chest Pain		Insulin	C				
SUBCUTANEOUS								
	Coronary Artery Disease		Atorvastatin Calcium	C		ORAL		
	Coronary Artery Stenosis		Aspirin	C		ORAL		
	Electrocardiogram		Nitroglycerin	C				
UNKNOWN								
	Abnormal		Omeprazole	C		ORAL		
	Ischaemic Cardiomyopathy		Caffeine, Citrated					
	Stent Occlusion		And Nitroglycerin	C				
SUBLINGUAL								

Date:06/22/05ISR Number: 4697523-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02354
Age: Gender:Male I/FU:F

Outcome	PT
Death	Blood Cholesterol
Hospitalization -	Increased
Initial or Prolonged	Blood Triglycerides
	Increased
	Cardiac Failure
	Congestive
	Dyspnoea
	Heart Rate Irregular

		Myocardial Infarction					
		Oedema Peripheral					
		Overdose	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Triple Vessel Bypass		Vioxx	SS	Merck & Co., Inc	ORAL
		Graft		Vioxx	SS	Merck & Co., Inc	ORAL
				Xanax	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/22/05ISR Number: 4697525-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00120
Age:57 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
594 DAY							
Initial or Prolonged		Bursitis		Allopurinol	C		ORAL
Disability		Compartment Syndrome		Diclofenac	C		ORAL
		Muscle Rupture		Tramadol Hydrochloride	C		ORAL
		Post Thrombotic Syndrome					
		Thrombosis					
		Varicose Vein					

Date:06/22/05ISR Number: 4697536-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02323
Age:72 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Aortic Valve Sclerosis		Glipizide	C		
UNKNOWN							

	Aphagia		Insulin	C			
UNKNOWN							
	Asthenia		Cozaar	C			
UNKNOWN							
	Blood Chloride Increased		Norvasc	C			
UNKNOWN							
	Cardiomegaly		Atenolol	C			
UNKNOWN							
	Coronary Artery Occlusion		Niacin	C			
UNKNOWN							
	Coronary Artery		Lipitor	C			ORAL
	Restenosis		Ibuprofen	C			
UNKNOWN							
	Dehydration		Darvocet-N	C			
UNKNOWN							
	Dilatation Atrial		Avapro	C			
UNKNOWN							
	Haematocrit Decreased						
	Haemoglobin Decreased						
	Mitral Valve Incompetence						
	Oedema Peripheral						
	Pleural Effusion						
	Tricuspid Valve Incompetence						

Date:06/22/05ISR Number: 4697544-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01955
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Xanax	C				
UNKNOWN								
	Dyspepsia							
	Hypertension							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697545-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02334
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Other	Arteriospasm Coronary		Premarin	C				UNKNOWN
	Atherosclerosis		Lipitor	C				UNKNOWN
	Back Pain		Tricor	C				UNKNOWN
	Chest Pain		Prevacid	C				UNKNOWN
	Deep Vein Thrombosis		Zyrtec	C				UNKNOWN
	Depression		Fosamax	C				UNKNOWN
	Dyspnoea		Flonase	C				UNKNOWN
	Emotional Distress		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Fatigue							
	Foot Fracture							
	Gastrooesophageal Reflux Disease		Sulfamethoxazole And Trimethoprim	C				UNKNOWN
	Insomnia		Allegra	C				UNKNOWN
	Mitral Valve Incompetence		Penlac	C				UNKNOWN
	Myocardial Infarction		Tenormin	C				UNKNOWN
	Nausea		Zestril	C				UNKNOWN
	Neck Pain		Nitroquick	C				UNKNOWN
	Oedema Peripheral		Imdur	C				UNKNOWN
	Pulmonary Embolism		Gentamicin	C				UNKNOWN
	Restless Legs Syndrome		Norvasc	C				UNKNOWN

	Skin Discolouration	Diltiazem Er	C	
UNKNOWN				
	Sleep Apnoea Syndrome	Protonix	C	
UNKNOWN				
		Rhinocort Aqua	C	
UNKNOWN				
		Levaquin	C	
UNKNOWN				
		Neurontin	C	
UNKNOWN				
		Effexor	C	
UNKNOWN				
		Zoloft	C	
UNKNOWN				
		Triamterene	C	
UNKNOWN				
		Methylprednisolone	C	
UNKNOWN				
		Naproxen	C	
UNKNOWN				
		Hydrochlorothiazide	C	
UNKNOWN				

Date:06/22/05ISR Number: 4697546-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02575
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebellar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Confusional State		Ecotrin	C		ORAL		
	Deafness Neurosensory		Hydralazine	C		ORAL		
	Depression		Norvasc	C		ORAL		
	Diarrhoea							
	Disorientation							
	Dizziness							
	Gastrooesophageal Reflux							
	Disease							
	Ischaemic Stroke							
	Oedema Peripheral							
	Pseudophakia							
	Retinal Vein Occlusion							
	Transient Ischaemic							
	Attack							
	Urinary Tract Infection							
	Vertigo							
	Vitreous Detachment							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697547-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01667
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Benign Prostatic		Lipitor	C		
UNKNOWN						
	Hyperplasia					
	Bladder Obstruction					
	Drug Abuser					
	Hernia					
	Hypotension					
	Metabolic Acidosis					
	Obstructive Uropathy					
	Pneumonia					
	Renal Failure Acute					
	Urinary Retention					

Date:06/22/05ISR Number: 4697548-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02541
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Increased		Lopid	C		
UNKNOWN	299 DAY					
Initial or Prolonged	Cardiac Arrest		Insulin	C		
UNKNOWN						
Other	Cardiac Disorder		Plavix	C		
UNKNOWN	299 DAY					
	Cardiac Failure		Aspirin	C		
UNKNOWN	4 YR					
	Congestive		Furosemide	C		
UNKNOWN	635 DAY					
	Cardiogenic Shock		Actos	C		
UNKNOWN						
	Cerebrovascular Accident		Ambien	C		
UNKNOWN	662 DAY					
	Chest Pain		Humulin	C		
UNKNOWN						
	Chronic Obstructive		Lipitor	C		
UNKNOWN	635 DAY					
	Pulmonary Disease		Fluoxetine	C		
UNKNOWN	635 DAY					

	Depression	Lisinopril	C
UNKNOWN	474 DAY		
	Dyspnoea	Zyrtec	C
UNKNOWN			
	Eye Disorder	Klor-Con	C
UNKNOWN			
	Hypersensitivity	Ferrous Sulfate	C
UNKNOWN			
	Hypertension	Serevent	C
UNKNOWN			
	Myocardial Infarction	Combivent	C
UNKNOWN			
	Renal Failure	Glucophage Xr	C
UNKNOWN			
	Sleep Apnoea Syndrome	Glucotrol Xl	C
UNKNOWN			
		Novolog	C
UNKNOWN			
		Acetaminophen And Hydrocodone Bitartrate	C
UNKNOWN	97 DAY		
		Tobradex	C
UNKNOWN			
		Patanol	C
UNKNOWN			
		Lidocaine	C
UNKNOWN			
		Zaroxolyn	C
UNKNOWN	601 DAY		
		Altace	C
UNKNOWN	96 DAY		
		Zestril	C
UNKNOWN			

Date:06/22/05ISR Number: 4697550-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02159
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		57 MON
Initial or Prolonged	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		57 MON
Disability	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697551-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03428
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Hyperglycaemia		Glipizide	C		ORAL		
	Hypoaesthesia		Hydrocodone Bitartrate	C		ORAL		
	Pain		Soma	C		ORAL		
	Respiratory Failure		Darvon	C				
			Estradiol	C		ORAL		
			Zocor	C		ORAL		
			Celebrex	C		ORAL		
			Celexa	C		ORAL		

Date:06/22/05ISR Number: 4697552-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01833
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Altace	C				
	Cardiac Failure		Ambien	C				
	Congestive		Glyburide	C				
	Chest Pain		Avandamet	C				
	Coronary Artery Disease							
	Dyslipidaemia							
	Headache							
	Hot Flush							
	Hypertension							
	Ischaemia							
	Nausea							
	Pulmonary Fibrosis							
	Urinary Tract Infection							

Date:06/22/05ISR Number: 4697553-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01051
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	650 DAY	
Hospitalization - Initial or Prolonged								

Date:06/22/05ISR Number: 4697554-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02681
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Cerebrovascular Accident
	Depression
	Disorientation
	Fall
	Hypertension
	Knee Operation
	Nausea

	Osteoarthritis						
	Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Insulin	C				UNKNOWN

Date:06/22/05ISR Number: 4697555-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05106
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Renal Failure							

Date:06/22/05ISR Number: 4697556-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02731
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Aspirin	C				UNKNOWN
	Heart Rate Irregular		Plavix	C				UNKNOWN
	Myocardial Infarction		Pravachol	C				UNKNOWN
	Oedema Peripheral		Benicar	C				UNKNOWN
	Pain							
	Swelling							

Date:06/22/05ISR Number: 4697557-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02721
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hernia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Prevacid	C			UNKNOWN	
	Myocardial Infarction		Xanax	C			UNKNOWN	
	Panic Attack		Paxil	C			UNKNOWN	

Date:06/22/05ISR Number: 4697568-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697569-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697570-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02964
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697571-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697572-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02713
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/22/05ISR Number: 4697580-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697581-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	61	MON
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697582-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:06/22/05ISR Number: 4697583-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02162
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
2 YR								
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
2 YR								
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697584-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/22/05ISR Number: 4697585-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1651 DAY

Date:06/22/05ISR Number: 4697593-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/22/05ISR Number: 4697696-6Report Type:Expedited (15-DaCompany Report #2005077110
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Agraphia	Consumer	Bextra (Valdecoxib)	PS		ORAL	ORAL	
	Gastrooesophageal Reflux Disease		Vioxx (Refecoxib)	SS				
	Mobility Decreased							
	Oedema Mouth							
	Oedema Peripheral							
	Renal Disorder							
	Swelling							
	Visual Acuity Reduced							

Date:06/22/05ISR Number: 4698441-0Report Type:Expedited (15-DaCompany Report #2005087952
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident	Consumer	Bextra (Valdecoxib)	PS				(UNK, 1 D)
			Vioxx (Rofecoxib)	SS				

Date:06/22/05ISR Number: 4698542-7Report Type:Expedited (15-DaCompany Report #2005060819
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
	Arthralgia	Health	Bextra (Valdecoxib)	SS		ORAL	ORAL	
	Back Pain	Professional	Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Blood Count Abnormal		Enbrel "Immunex" (Etanercept)	C				
	Chest Pain		Percocet (Oxycodone Hydrochloride, Paracetamol)	C				
	Depressed Level Of Consciousness		Zanaflex (Tizandine Hydrochloride)	C				
	Dyspepsia		Effexor (Venlafaxine Hydrochloride)	C				
	Feeling Abnormal		Cenestin (Estrogens Conjugated)	C				
	Fibromyalgia		Plaquenil (Hydroxychloroquine Phosphate)	C				
	Heart Rate Increased		Xanax (Alprazolam)	C				
	Hypertension		Folic Acid	C				
	Palpitations		Methotrexate	C				
			Prilosec					

			(Omeprazole)	C
			Ibuprofen	C
			Methadone	C

Date:06/22/05ISR Number: 4698842-0Report Type:Expedited (15-DaCompany Report #WAES 0506USA01903
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diverticulitis	Study	Tab Vioxx 25 Mg	PS		ORAL	25	
Initial or Prolonged		Health					MG/DAILY/PO	
		Professional	Prevacid	C				
			Prilosec	C				
			Singulair	C				
			Tylenol	C				
			Ascorbic Acid	C				
			Aspirin	C				
			Atenolol	C				
			Blinded Therapy	C				
			Calcium (Unspecified)	C				
			Fish Oil (Unspecified)	C				
			Lecithin	C				
			Vitamin D (Unspecified)	C				
			Vitamin E	C				
			Vitamins	C				

Date:06/22/05ISR Number: 4698843-2Report Type:Expedited (15-DaCompany Report #WAES 0503USA02686
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased	Consumer	Tab Vioxx 25mg	PS		ORAL	25	
Initial or Prolonged	Coronary Artery	Health					MG/DAILY/PO	
	Thrombosis	Professional	Flonase	C				
	Depression Postoperative		Singulair	C				
	Fatigue		Prednisone	C				
	Haematocrit Decreased							

Myocardial Infarction
Ulcer

Date:06/22/05ISR Number: 4698844-4Report Type:Expedited (15-DaCompany Report #WAES 0506USA01077
Age:60 YR Gender:Male I/FU:I

Outcome	PT
Death	Agitation
Hospitalization -	Alopecia
Initial or Prolonged	Anxiety
	Arthritis Bacterial
	Atrial Fibrillation
	Atrial Flutter
	Bacterial Sepsis
	Blood Thyroid Stimulating
	Hormone Increased
	Cardiac Failure
	Congestive
	Choking
	Cholelithiasis
	Coagulopathy

		Cor Pulmonale					
		Crying					
		Decreased Activity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression	Consumer	Tab Vioxx 12.5 Mg	PS		ORAL
12.5 & 25							
		Dermatitis					
MG/DAILY/PO							
		Dialysis		Prilosec	C		
		Dyspnoea		Xenical	C		
		Emotional Distress		Zocor	C		
		Encephalopathy					
		Haemoglobin Decreased					
		Hyperglycaemia					
		Hyperkinesia					
		Insomnia					
		Joint Dislocation					
		Meniscus Lesion					
		Myocardial Ischaemia					
		Panic Attack					
		Plantar Fasciitis					
		Platelet Count Decreased					
		Pneumonia					
		Quadriparesis					
		Renal Failure					
		Respiratory Failure					
		Sleep Apnoea Syndrome					
		Snoring					
		Spinal Cord Infarction					
		Staphylococcal Infection					
		Stenotrophomonas Sepsis					
		Stress					
		Transient Ischaemic					
		Attack					
		Ventricular Dysfunction					
		Vertigo					
		Weight Increased					

Date:06/23/05ISR Number: 4698185-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01892
Age:48 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

	Road Traffic Accident		Zocor	C		
UNKNOWN						
			Vasotec	C		
UNKNOWN						
			Warfarin	C		
UNKNOWN						

Date:06/23/05ISR Number: 4698187-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01397
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
	Stress		Voltaren	SS		
UNKNOWN						
			Prevacid	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/05ISR Number: 4698188-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02971
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Life-Threatening			Methotrexate	C		ORAL		
Disability			Amitriptyline Hydrochloride	C		ORAL		
			Flexeril	C		ORAL		
			Zoloft	C		ORAL		
			Premarin	C		ORAL		

Date:06/23/05ISR Number: 4698189-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01948
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angle Closure Glaucoma		Vioxx	PS	Merck & Co., Inc	ORAL	178	YR
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Norvasc	C			UNKNOWN	
	Cerebrovascular Accident		Propoxyphene Napsylate And Acetaminophen	C			UNKNOWN	
	Cystitis							
	Depression							
	Intervertebral Disc		Prednisone	C			UNKNOWN	
	Protrusion		Lorazepam	C			UNKNOWN	
	Irritable Bowel Syndrome		Hydrochlorothiazide	C			UNKNOWN	
	Liver Function Test Abnormal		Dicyclomine Hydrochloride	C			UNKNOWN	
	Neuropathy							
	Pain In Extremity							
	Polymyalgia Rheumatica							
	Polyneuropathy							
	Tarsal Tunnel Syndrome							
	Transient Ischaemic Attack							

Date:06/23/05ISR Number: 4698196-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04182
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blindness Unilateral
Initial or Prolonged	Blood Pressure
Other	Inadequately Controlled
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Chest Pain
	Drug Tolerance Decreased
	Hyperlipidaemia
	Lacunar Infarction
	Muscle Spasms
	Pleural Effusion
	Pseudophakia
	Renal Impairment
	Retinal Artery Occlusion
	Treatment Noncompliance
	Viral Upper Respiratory
	Tract Infection

	Weight Decreased						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	38	MON
			Trental	C		ORAL		
			Isordil	C			UNKNOWN	

Date:06/23/05ISR Number: 4698199-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/23/05ISR Number: 4698201-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Gastrooesophageal Reflux							
	Disease							
	Lipids Increased							
	Myocardial Infarction							

Date:06/23/05ISR Number: 4698202-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/23/05ISR Number: 4698203-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Celebrex	C				
	Ischaemia							

Date:06/23/05ISR Number: 4698206-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/23/05ISR Number: 4698217-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02191
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Digitek	C				
			Ambien	C				
			Premarin	C				
			Plavix	C				
			Magnesium (Unspecified)	C				

UNKNOWN	Aspirin	C
UNKNOWN	Vitamin E	C
UNKNOWN	Ascorbic Acid	C
UNKNOWN	Clonazepam	C
UNKNOWN	Nexium	C
UNKNOWN	Centrum	C
UNKNOWN	Amitriptyline Hydrochloride	C
UNKNOWN	Singulair	C
UNKNOWN	Allegra	C
UNKNOWN	Ultracet	C
UNKNOWN	Neurontin	C
UNKNOWN	Pancrease (Pancreatin)	C
UNKNOWN	[Therapy Unspecified]	C
UNKNOWN	[Therapy Unspecified]	C
UNKNOWN	[Therapy Unspecified]	C

Date:06/23/05ISR Number: 4698264-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acrochordon
	Aggression
	Alcoholic Seizure
	Anaemia

Anion Gap Increased
Ascites
Barrett'S Oesophagus
Blood Pressure
Fluctuation
Cardiovascular Disorder
Cerebral Atrophy
Change Of Bowel Habit
Cholecystitis
Drug Hypersensitivity
Duodenitis
Emphysema
Encephalopathy
Gastritis
Grand Mal Convulsion
Haematemesis
Haematoma
Headache
Hepatic Cyst
Hepatic Steatosis
Hiatus Hernia
Hordeolum
Hydrocholecystis
Hypokalaemia
Influenza
Intestinal Dilatation
Laceration
Limb Injury
Mean Cell Volume
Increased

		Oedema					
		Postictal State					
		Pruritus	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL
34	DAY						
		Tachycardia					
		Tenosynovitis Stenosans					
		Vision Blurred					
		Weight Decreased					

Date:06/23/05ISR Number: 4699797-5Report Type:Expedited (15-DaCompany Report #2005063723
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Dizziness	Consumer	Bextra (Valdecoxib)	PS		ORAL
20 MG (20 MG,						
	Dyspnoea	Health				
1 IN 1 D),						
	Feeling Abnormal	Professional				
ORAL						
	Heart Rate Increased		Vioxx (Rofecoxib)	SS		ORAL
ORAL						
	Heart Rate Irregular		Muscle Relaxants			
	Hypoaesthesia		(Muscle Relaxants)	SS		ORAL
ORAL						
	Malaise		Klonopin			
	Muscle Spasms		(Clonazepam)	C		
	Nausea		Prevacid			
	Pain In Extremity		(Lansoprazole)	C		
	Paraesthesia					
	Somnolence					

Date:06/23/05ISR Number: 4699801-4Report Type:Expedited (15-DaCompany Report #2003158731US
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arrhythmia	Consumer	Celebrex (Celecoxib)	PS		ORAL
(200 MG),ORAL						
	Blood Pressure Increased		Vioxx (Rofecoxib)	SS		ORAL
(25 MG),ORAL						

Large Intestinal Ulcer
Haemorrhage
Oedema
Oesophageal Ulcer
Haemorrhage

Date:06/23/05ISR Number: 4699806-3Report Type:Expedited (15-DaCompany Report #2005056765
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged (1 IN 1	Dyspnoea	Consumer	Celebrex (Celecoxib)	PS				
	Haematochezia		Bextra (Valdecoxib)	SS		ORAL		
Other D),ORAL	Pruritus Generalised							
	Weight Fluctuation		Vioxx (Rofecoxib)	SS				
			Vicodin (Hydrocodone Bitartrate, Paracetamol)	C				
			Percocet (Hydrocodone Bitartrate, Paracetamol)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/23/05ISR Number: 4701074-0Report Type:Expedited (15-DaCompany Report #2005062475
Age:75 YR Gender:Not SpecifiI/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain	Consumer	Daypro Caplet					
	Drug Ineffective	Health	(Oxaprozin)	PS				
	Dyspnoea	Professional	Celebrex (Celecoxib)	SS		ORAL	200 MG (200 MG 1 IN 1 D)	
	Knee Arthroplasty							
	Pulmonary Embolism							
			Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG 1 IN 1 D)	
			Vioxx (Rofecoxib)	SS				

Date:06/24/05ISR Number: 4699209-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02542
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Basedow'S Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cluster Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vitamin D					
	Diplopia		(Unspecified)	C				UNKNOWN
	Dizziness		Calcium					
	Eyelid Retraction		(Unspecified)	C				UNKNOWN
	Fibromyalgia		Zoloft	C				UNKNOWN
	Gastrooesophageal Reflux		Lithobid	C				UNKNOWN
	Disease		Trazodone					
	Headache		Hydrochloride	C				UNKNOWN

	Hemianopia Homonymous	Paxil	C
UNKNOWN			
	Intervertebral Disc	Ortho-Novum 7/7/7	C
UNKNOWN			
	Degeneration	Vicodin Tablets	C
UNKNOWN			
	Lid Lag	Ultram	C
UNKNOWN			
	Nausea	Oxycontin	C
UNKNOWN			
	Osteomalacia	Methadone Hcl	C
UNKNOWN			
	Vision Blurred	Advil	C
UNKNOWN			
	Vitamin D Deficiency	Tylenol	C
UNKNOWN			

Date:06/24/05ISR Number: 4699218-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01739
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Adverse Event
	Anxiety
	Asbestosis
	Blood Glucose Increased
	Blood Pressure Diastolic Decreased
	Bronchitis
	Burning Sensation
	Cardiac Arrest
	Cardiac Failure Congestive
	Chest Pain
	Chronic Sinusitis

		Coronary Artery Atherosclerosis					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dermatitis Contact		Vioxx	PS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Exostosis		Pepcid	C		
UNKNOWN							
		Eye Pruritus		Aspirin	C		
UNKNOWN							
		Heart Rate Decreased		Flexeril	C		ORAL
		Hepatic Steatosis		Zocor	C		ORAL
		Hyperhidrosis		[Therapy			
		Joint Ankylosis		Unspecified]	C		
UNKNOWN							
		Lacrimation Increased					
		Loss Of Consciousness					
		Lower Respiratory Tract Infection					
		Memory Impairment					
		Mitral Valve Prolapse					
		Neck Pain					
		Papilloedema					
		Pleural Fibrosis					
		Pneumonia					
		Pruritus					
		Respiratory Tract Infection					
		Road Traffic Accident					
		Sensation Of Pressure					
		Sinusitis					
		Sputum Discoloured					
		Stomach Discomfort					
		Upper Respiratory Tract Infection					
		Urinary Incontinence					
		Ventricular Fibrillation					
		Viral Infection					

Date:06/24/05ISR Number: 4699219-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02357
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Adverse Drug Reaction

Disability	Bronchiectasis
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Cough
	Depression
	Hypersensitivity
	Hypertension
	Migraine With Aura
	Mitral Valve Incompetence
	Nausea
	Pneumonia
	Pneumonitis
	Red Blood Cell
	Sedimentation Rate
	Increased
	Respiratory Tract
	Infection
	Transient Ischaemic
	Attack

	Tricuspid Valve Incompetence Vomiting	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Premarin	C		
UNKNOWN	11 YR					
			Prozac	C		
UNKNOWN						
			Guaifenesin Dm	C		
UNKNOWN						
			Serevent	C		
UNKNOWN						
			Pulmicort	C		
UNKNOWN						

Date:06/24/05ISR Number: 4699220-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00839
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
383 YR						
Initial or Prolonged	Arthropathy		Uniretic	C		
UNKNOWN						
	Asthenia		Oxaprozin	C		
UNKNOWN						
	Blood Cholesterol		Zocor	C		
UNKNOWN						
	Increased Chest Pain		Moexipril Hydrochloride	C		
UNKNOWN						
	Difficulty In Walking		Toprol Xl Tablets	C		
UNKNOWN						
	Dizziness Dyspnoea		Meclizine Hydrochloride	C		
UNKNOWN						
	Headache		Warfarin Sodium	C		
UNKNOWN						
	Hypertension		Lovenox	C		
UNKNOWN						
	Thrombosis					

Date:06/24/05ISR Number: 4699222-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00127
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Acetaminophen And Codeine Phosphate	C				
	Basal Cell Carcinoma		Ramipril	C				
	Blood Triglycerides Increased							
	Chest Pain							
	High Density Lipoprotein Decreased							
	Mitral Valve Incompetence							
	Sleep Apnoea Syndrome							
	Tricuspid Valve Incompetence							
	Upper Respiratory Tract Infection							
	Ventricular Dysfunction							

Date:06/24/05ISR Number: 4699223-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00957
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Anxiety
Disability	Arteriosclerosis
	Atrial Fibrillation
	Cerebrovascular Accident

		Cholelithiasis					
		Closed Head Injury					
		Confusional State	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased Interest		Vioxx	PS	Merck & Co., Inc	ORAL
		Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Intolerance		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Zestril	SS		
UNKNOWN							
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Fear		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrointestinal Disorder		Microzide	C		
UNKNOWN							
		Hypokalaemia		Levoxyl	C		
UNKNOWN							
		Impatience		Nitroglycerin	C		
UNKNOWN							
		Insomnia		Warfarin Sodium	C		
UNKNOWN							
		Irritability		Metoprolol	C		
UNKNOWN							
		Memory Impairment		Amiodarone	C		
UNKNOWN							
		Mitral Valve Incompetence		Cipro	C		
UNKNOWN							
		Pulmonary Valve		Triamcinolone	C		
TOPICAL							
		Incompetence		Hydrodiuril	C		
UNKNOWN							
		Renal Cyst		Lipitor	C		
UNKNOWN							
		Renal Failure					
		Sick Sinus Syndrome					
		Transaminases Increased					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Urinary Tract Infection					

Date:06/24/05ISR Number: 4699224-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00075
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		1482 DAY
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		1482 DAY
Disability	Cerebrovascular Accident		Toprol Xl Tablets	C		ORAL		
	Depression		Darvocet-N	C				UNKNOWN
	Headache		Calcium (Unspecified)	C				UNKNOWN
	Hepatic Enzyme Increased		Premarin	C				UNKNOWN
	Insomnia		Lortab	C				UNKNOWN
	Migraine		Norvasc	C				UNKNOWN
	Pharyngitis		Neurontin	C				UNKNOWN
	Seborrhoeic Keratosis		Lotrel	C				UNKNOWN
			Cephalexin	C				UNKNOWN
			Levaquin	C				UNKNOWN
			Amitriptylin	C				UNKNOWN

Date:06/24/05ISR Number: 4699225-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01343
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angiopathy
Initial or Prolonged	Arterial Occlusive
Disability	Disease
	Arterial Stenosis
	Cardiac Disorder
	Chest Pain
	Depression

		Diarrhoea					
		Dyspnoea					
		Femoral Artery Aneurysm	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Hypersensitivity		Aspirin	C		
UNKNOWN							
		Hysterectomy		Aspirin	C		ORAL
		Muscle Spasms		Tylenol	C		ORAL
		Post-Traumatic Stress					
		Disorder					
		Surgery					

Date:06/24/05ISR Number: 4699227-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02528
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Atrioventricular Block		[Therapy			
Initial or Prolonged	Blood Pressure		Unspecified]	C		
UNKNOWN						
Disability	Inadequately Controlled					
	Chest Pain					
	Dyspnoea					
	Heart Rate Decreased					

Date:06/24/05ISR Number: 4699236-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00244
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Activities Of Daily		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Living Impaired		Aspirin	C		ORAL
	Acute Myocardial		Plavix	C		ORAL
	Infarction		Lovenox	C		
SUBCUTANEOUS						
	Asthenia		Lasix (Furosemide)	C		ORAL
	Bundle Branch Block Left		Prinivil	C		ORAL
	Cardiac Murmur		Lopressor	C		ORAL
	Cardiovascular		Oxycontin	C		ORAL
	Deconditioning		Potassium			

	Chest Pain	(Unspecified)	C	ORAL
	Coronary Artery	Senokot (Senna)	C	
UNKNOWN				
	Atherosclerosis	Flomax		
	Coronary Artery Disease	(Morniflumate)	C	ORAL
	Coronary Artery Occlusion	Hydrochlorothiazide	C	
UNKNOWN				
	Decreased Activity	Zestril	C	ORAL
	Dizziness	Toprol Xl Tablets	C	
UNKNOWN				
	Drug Intolerance	Glucosamine	C	
UNKNOWN				
	Dyspnoea	Zocor	C	ORAL
	Haemorrhoids	Lorazepam	C	
UNKNOWN				
	Hyperlipidaemia	Vitamins		
	Intervertebral Disc	(Unspecified)	C	
UNKNOWN				
	Degeneration			
	Lumbar Spinal Stenosis			
	Oedema			
	Oedema Peripheral			
	Osteoarthritis			
	Pain In Extremity			
	Ventricular Tachycardia			

Date:06/24/05ISR Number: 4699242-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02711
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthma		[Therapy Unspecified]	C				
Other	Cerebrovascular Accident							
UNKNOWN								
	Colonic Polyp		Theophylline	C				
UNKNOWN								
	Headache		Plavix	C				
UNKNOWN								
	Myocardial Infarction		Lipitor	C				
UNKNOWN								
	Pneumonia		Prempro	C				
UNKNOWN								
			Catapres	C				
UNKNOWN								
			Tenex	C				
UNKNOWN								
			Aldomet (Methyldopate Hydrochloride)	C				
UNKNOWN								
			Wytensin	C				
UNKNOWN								
			Cozaar	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Avapro	C				
UNKNOWN								
			Micardis	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

Date:06/24/05ISR Number: 4699244-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02714
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		

	Angina Pectoris		Celebrex	C		ORAL
	Blood Cholesterol Increased		Bextra	C		ORAL
	Coronary Artery Occlusion					
	Hypertension					
	Nausea					
	Oedema Peripheral					

Date:06/24/05ISR Number: 4699245-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01995
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Disability	Basilar Migraine		Celebrex	C				UNKNOWN
	Cerebrovascular Accident							
	Depression							
	Hypertension							
	Panic Disorder							
	Sleep Disorder							
	Vertebral Artery Occlusion							
	Vertigo							
	Visual Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699246-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02583
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Pepcid	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Cipro	C			UNKNOWN	
			Doxycycline	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Celebrex	C			UNKNOWN	

Date:06/24/05ISR Number: 4699247-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02038
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiac Disorder		[Therapy Unspecified]	C				
	Depression							
	Dizziness							
	Drug Ineffective							
	Dyspepsia							
	Flatulence							
	Loss Of Consciousness							
	Myocardial Infarction							
	Oedema Peripheral							
	Post-Traumatic Stress Disorder							

Date:06/24/05ISR Number: 4699248-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02700
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Arthropathy
	Bacterial Infection
	Bundle Branch Block Right
	Cardiac Arrest
	Cardiac Murmur
	Cardio-Respiratory Arrest
	Chest Pain
	Constipation
	Contusion
	Convulsion
	Depression
	Dizziness
	Drug Abuser
	Dyskinesia
	Dyspnoea
	Fatigue
	Heart Rate Irregular
	Hypertension
	Hypoaesthesia
	Loss Of Consciousness
	Muscle Twitching
	Myocardial Infarction
	Oedema Peripheral
	Panic Attack
	Post Procedural

Dose	Duration	Complication	Report Source	Product	Role	Manufacturer	Route
		Respiratory Arrest					
		Somnolence					
		Sputum Culture Positive					
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
316	DAY						
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
316	DAY						
		Urinary Tract Disorder		Methadone			
		Wound Infection		Hydrochloride	C		ORAL
		Staphylococcal		Avinza	C		ORAL
				Toprol Xl Tablets	C		ORAL
6	MON						
				Zocor	C		ORAL
				Prozac	C		ORAL
4	YR						
				Trazodone			
				Hydrochloride	C		ORAL
				Lithobid	C		ORAL
4	YR						
				Paxil	C		ORAL
				Risperdal	C		ORAL
2	YR						
				Zantac	C		
UNKNOWN							
				Zanaflex	C		
UNKNOWN							
				Topamax	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Synthroid	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699250-9Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00007
Age:65 YR Gender:Female I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening			Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL
	807	DAY						
			Coronary Artery Stenosis		Etidronate Disodium	C		ORAL
			Hypotension		Methotrexate	C		
	UNKNOWN							

	Lung Infiltration		Folic Acid	C		
UNKNOWN						
	Myocardial Infarction		Cyanocobalamin	C		
UNKNOWN						
			Esomeprazole Magnesium	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Zopiclone	C		
UNKNOWN						
			Bumetanide	C		ORAL

Date:06/24/05ISR Number: 4699251-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02791
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 65 MON	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL
Disability 65 MON	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
	Depression		Bextra	C		ORAL
	Dyspepsia		Cozaar	C		ORAL
	Epicondylitis		Levitra	C		ORAL
	Hyperglycaemia		Allopurinol	C		ORAL
	Hypokalaemia		Lorcet 10/650	C		ORAL
	Myocardial Infarction		Lipitor	C		ORAL
	Peptic Ulcer		Colchicine	C		
UNKNOWN						
	Sleep Apnoea Syndrome		Lotrel	C		ORAL
	Upper Respiratory Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699252-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02684
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		761 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		761 DAY
Other	Barrett'S Oesophagus		Vioxx	SS	Merck & Co., Inc	ORAL		761 DAY
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		761 DAY
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Depression							
	Diarrhoea							
	Dyspnoea							
	Fatigue							
	Gastritis Erosive							
	Hiatus Hernia							
	Hyperlipidaemia							
	Melaena							
	Myocardial Infarction							
	Oesophageal Ulcer							
	Oesophagitis Ulcerative							
	Pain In Jaw							
	Upper Gastrointestinal Haemorrhage							

Date:06/24/05ISR Number: 4699258-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01830
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		633 DAY
Initial or Prolonged	Atherosclerosis		Monopril	C				UNKNOWN
Other	Cardiac Failure		Dilacor Xr	C				UNKNOWN
	Congestive		Zantac	C				UNKNOWN

	Coronary Artery		Hydrochlorothiazide	C		
UNKNOWN						
	Atherosclerosis					
	Cough					
	Dyspepsia					
	Dyspnoea					
	Epidermal Naevus					
	Essential Hypertension					
	Headache					
	Limb Injury					
	Myalgia					
	Myocardial Infarction					
	Rectal Haemorrhage					
	Rhinitis Allergic					

Date:06/24/05ISR Number: 4699259-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00334
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Facial Palsy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrooesophageal Reflux		Avapro	C		
UNKNOWN						
	Disease					
	Hypertension					
	Lacunar Infarction					
	Speech Disorder					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699260-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal Pain		Atorvastatin Calcium	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Perindopril Erbumine	C			UNKNOWN	
			Pantoprazole Sodium	C			UNKNOWN	
			Oxycodone Hydrochloride	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lactulose	C			UNKNOWN	
			Psyllium Husk	C			UNKNOWN	
			Codeine	C			UNKNOWN	

Date:06/24/05ISR Number: 4699261-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02564
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Electrocardiogram Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
			Viagra	C			UNKNOWN	
	Glucose Tolerance Impaired		Vitamins (Unspecified)	C			UNKNOWN	
	Hypertension		Tagamet	C			UNKNOWN	

Date:06/24/05ISR Number: 4699262-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00070
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Retinal Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Fenoterol Hydrobromide And Ipratropium Bromide	C			UNKNOWN	
			Alendronate Sodium	C			UNKNOWN	
			Fluticasone Propionate And Salmeterol Xinafoate	C			UNKNOWN	
			Diclofenac	C			UNKNOWN	

Date:06/24/05ISR Number: 4699264-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03842
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Contusion		Vioxx	PS	Merck & Co., Inc	ORAL	38 MON	
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL	38 MON	
Disability	Haematochezia		Xanax	C			UNKNOWN	
	Myocardial Infarction		Prozac	C			UNKNOWN	
	Upper Limb Fracture		Lipitor	C			UNKNOWN	
			Tricor	C			UNKNOWN	
			Plavix	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699265-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04187
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699266-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04201
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Basilar Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Brain Stem Infarction		Claritin-D	C				
UNKNOWN								
	Cerebrovascular Accident							
	Chest Pain							
	Diplopia							
	Electrolyte Imbalance							
	Facial Palsy							
	Haemorrhagic Stroke							
	Hypertension							
	Infection In An							
	Immunocompromised Host							
	Leukocytosis							
	Locked-In Syndrome							
	Pneumonia							
	Pyrexia							
	Respiratory Failure							
	Sepsis							
	Sinusitis Bacterial							
	Staphylococcal Infection							
	Tracheobronchitis							

Date:06/24/05ISR Number: 4699267-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02932
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Cozaar	C				
UNKNOWN								

	Increased	Lipitor	C
UNKNOWN			
	Dyspnoea	Flomax	
	Hypertension	(Morniflumate)	C
UNKNOWN			
	Myocardial Infarction	Buspar	C
UNKNOWN			
	Pneumoconiosis	Claritin	C
UNKNOWN			
		Cipro	C
UNKNOWN			
		Apap	C
UNKNOWN			
		Tylenol With Codeine	
		#3	C
UNKNOWN			
		Atenolol Msd	C
UNKNOWN			
		Cephalexin	
		Hydrochloride	C
UNKNOWN			
		Ultracet	C
UNKNOWN			
		Macrobid	C
UNKNOWN			

Date:06/24/05ISR Number: 4699268-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02837
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Other	Cardiac Disorder
	Fluid Retention

	Hypertension Myocardial Infarction Swelling	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	72	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	72	MON
			Naproxen Sodium	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:06/24/05ISR Number: 4699269-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03809
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON
Initial or Prolonged	Asthma							
Other	Atherosclerosis							
	Blood Cholesterol Increased							
	Bone Disorder							
	Cerebrovascular Accident							
	Chest Pain							
	Dyspepsia							
	Embolism							
	Flatulence							
	Haematochezia							
	Haemoptysis							
	Haemorrhage							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Muscle Spasms							
	Overdose							
	Pain							
	Palpitations							
	Pancreatitis							
	Peptic Ulcer							
	Shoulder Arthroplasty							
	Skin Infection							
	Sleep Apnoea Syndrome							

Swelling
Thrombosis
Tremor

Date:06/24/05ISR Number: 4699270-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02876
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Lisinopril	C		ORAL		
	Cerebrovascular Accident		Aspirin	C		ORAL		
	Chest Pain		Tylenol	C		ORAL		
	Eye Disorder		Plavix	C		ORAL		
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699271-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02095
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	28 MON	
	Increased		Tricor	C			UNKNOWN	
	Gastric Disorder		Lipitor	C			UNKNOWN	
	Gastrooesophageal Reflux		Celexa	C			UNKNOWN	
	Disease		Pepcid	C		ORAL		
	Myocardial Infarction		Carbidopa And Levodopa	C		ORAL		
	Pallor		Aggrenox	C			UNKNOWN	

Date:06/24/05ISR Number: 4699272-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02891
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Adrenal Disorder							
	Anxiety							
	Aortic Valve Incompetence							
	Atrial Fibrillation							
	Blood Pressure Increased							
	Blood Testosterone Decreased							
	Chest Pain							
	Diarrhoea							
	Dizziness							
	Endocrine Test Abnormal							
	Epistaxis							
	Headache							
	Herpes Simplex							
	Hyperlipidaemia							
	Hypertension							
	Hypoacusis							
	Leukocytosis							

Mitral Valve Incompetence
Myocarditis
Nausea
Sinus Disorder
Sleep Apnoea Syndrome
Tricuspid Valve
Incompetence
Vasospasm
Ventricular Hypertrophy

Date:06/24/05ISR Number: 4699273-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03279
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Furosemide	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			Potassium Chloride	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Diuretic (Unspecified)	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699275-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02917
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	60	MON
	Intestinal Functional		Vioxx	SS	Merck & Co., Inc	ORAL	60	MON
	Disorder		Darvocet-N	C			UNKNOWN	
	Myocardial Infarction		Cimetidine	C			UNKNOWN	
	Renal Disorder		Allegra	C			UNKNOWN	
			Doxepin Hydrochloride	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Skelaxin	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	

Date:06/24/05ISR Number: 4699276-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03807
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699277-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03836
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthropathy		Folic Acid	C			UNKNOWN	
	Asthenia		Prilosec	C		ORAL		
	Blood Pressure Increased		[Therapy					

	Cardiac Disorder		Unspecified]	C		
UNKNOWN						
	Chest Pain					
	Chronic Fatigue Syndrome					
	Difficulty In Walking					
	Disturbance In Attention					
	Dyspepsia					
	Dyspnoea					
	Gastric Ulcer					
	Gastrointestinal Disorder					
	Myocardial Infarction					
	Nausea					
	Peptic Ulcer					
	Renal Disorder					
	Sickle Cell Anaemia					

Date:06/24/05ISR Number: 4699278-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04220
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		1644 DAY
	Blood Cholesterol		Vasotec	C				
UNKNOWN								
	Increased		Atenolol	C				
UNKNOWN								
	Blood Triglycerides		Motrin	C				
UNKNOWN								
	Increased		Imitrex Tablets	C				
UNKNOWN								
	Cerebrovascular Accident		Imitrex Tablets	C				
UNKNOWN								
	Chest Pain		Nitrostat	C				
UNKNOWN								
	Chronic Fatigue Syndrome		Loratadine	C				
UNKNOWN								
	Hypertension		Paxil	C				
UNKNOWN								
			Buspar	C				
UNKNOWN								

				Calcium (Unspecified)	C	
UNKNOWN						
				Seroquel	C	
UNKNOWN						

Date:06/24/05ISR Number: 4699306-0Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0358933A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Exposure During		Seretide	PS	Glaxosmithkline			1 MON
	Pregnancy		Vioxx	SS				11 DAY
	Pilonidal Cyst Congenital		Fucidine	SS			500MG Per day	8 DAY
	Talipes		Pantoprazole	SS			40MG Per day	15 DAY
			Prednisolone	C	Glaxosmithkline		3UNIT per day	5 DAY
			Cefuroxim	C	Glaxosmithkline			
			Necyrane	C				
			Biclotymol	C				
			Ambroxol	C	Glaxosmithkline			
			Propofan	C				

Date:06/24/05ISR Number: 4699307-2Report Type:Expedited (15-DaCompany Report #FR-GLAXOSMITHKLINE-B0358933B
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Drug Exposure During		Seretide	PS	Glaxosmithkline			32 DAY
Congenital Anomaly	Pregnancy		Vioxx	SS				11 DAY
	Pilonidal Cyst Congenital		Fucidine	SS			500MG Per day	8 DAY
	Talipes		Pantoprazole	SS			40MG Per day	15 DAY
			Prednisolone	C	Glaxosmithkline		3UNIT per day	5 DAY
			Cefuroxim	C	Glaxosmithkline			

Necyrane	C		
Biclotymol	C		
Ambroxol	C	Glaxosmithkline	
Propofan	C		

Date:06/24/05ISR Number: 4699337-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02949
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Cyanocobalamin	C			UNKNOWN	
	Hypertension		Vitamin E	C			UNKNOWN	
	Pain							

Date:06/24/05ISR Number: 4699339-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03880
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Aortic Valve Incompetence
	Blood Alkaline Phosphatase Increased
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Airways Disease

		Exacerbated Chronic Obstructive Pulmonary Disease					
		Dermatitis Atopic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypothyroidism		Vioxx	SS	Merck & Co., Inc	ORAL
11	DAY						
		Insomnia		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
11	DAY						
		Degeneration		Spironolactone	C		
UNKNOWN							
		Lacunar Infarction		Benicar	C		
UNKNOWN							
		Musculoskeletal		Lipitor	C		
UNKNOWN							
		Discomfort		Aspirin	C		
UNKNOWN							
		Oedema		Synthroid	C		
UNKNOWN							
		Oedema Peripheral		Estrace	C		
UNKNOWN							
		Rhinitis Allergic		Zetia	C		
UNKNOWN							
		Spinal Osteoarthritis		Norvasc	C		
UNKNOWN							
		Supraventricular		Darvocet-N	C		
UNKNOWN							
		Extrasystoles		Singulair	C		
UNKNOWN							
		Swelling		Doxepin			
		Upper Respiratory Tract		Hydrochloride	C		
UNKNOWN							
		Infection					
		Urinary Tract Infection					
		Urticaria					
		White Blood Cell Count Decreased					

Date:06/24/05ISR Number: 4699352-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00128
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1338 DAY						

Date:06/24/05ISR Number: 4699353-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02138
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
37 MON						
Initial or Prolonged	Cardiac Failure		Hyzaar	C		
UNKNOWN						
	Congestive		Lipitor	C		
UNKNOWN						
	Cardiomegaly		Theophylline	C		
UNKNOWN						
	Cardiomyopathy		Prednisone	C		
UNKNOWN						
	Coronary Artery		Flovent	C		
UNKNOWN						
	Atherosclerosis		Singulair	C		
UNKNOWN						
	Dyspepsia					
	Hypoprothrombinaemia					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Ventricular Hypertrophy					

Date:06/24/05ISR Number: 4699354-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01326
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/05ISR Number: 4699355-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02946
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699358-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	64	MON
	Cardiac Disorder							
	Muscle Spasms							

Date:06/24/05ISR Number: 4699359-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02697
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699360-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00006
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	1545	DAY
Initial or Prolonged	Hypertension		Prednisolone	C		ORAL	UNKNOWN	
	Renal Artery Stenosis		Metoprolol Tartrate	C				
			Aspirin And Magnesium Oxide	C		ORAL	UNKNOWN	
			Felodipine	C				
			Atorvastatin Calcium	C		ORAL		
			Furosemide	C		ORAL		
			Doxazosin Mesylate	C		ORAL		

			Acetaminophen	C		
UNKNOWN						
			Acetaminophen And Codeine Phosphate	C		
UNKNOWN						

Date:06/24/05ISR Number: 4699361-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00125
Age:80 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699362-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02158
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699363-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02148
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Percocet	C				
Disability	Chronic Fatigue Syndrome		Loratadine	C				
	Chronic Obstructive Pulmonary Disease		Zoloft	C				
			Bextra	C				
	Gastric Disorder		Synthroid	C				
	Lung Disorder							
	Myocardial Infarction							
	Nasopharyngeal Disorder							
	Oesophageal Disorder							
	Tremor							

Date:06/24/05ISR Number: 4699367-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699373-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02810
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc			
	Cardiac Disorder							
	Lung Disorder							
	Multi-Organ Disorder							
	Pain							

Date:06/24/05ISR Number: 4699374-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699376-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699377-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Anxiety
Other	Blood Calcium Decreased
	Bradycardia
	Brain Cancer Metastatic
	Colon Cancer Stage Iii
	Colonic Polyp
	Decreased Appetite
	Deep Vein Thrombosis

	Gastritis						
	Gastrointestinal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypoparathyroidism		Vioxx	PS	Merck & Co., Inc	ORAL	61 YR
	Iron Deficiency Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY
	Lung Neoplasm		Atenolol	C			UNKNOWN
	Myocardial Infarction		Aspirin	C			UNKNOWN
	Nasopharyngitis		Pravachol	C			UNKNOWN
	Pulmonary Embolism		Zocor	C		ORAL	
	Thyroid Cancer Metastatic		Tylenol	C			UNKNOWN
	Upper Respiratory Tract		Ibuprofen	C			UNKNOWN
	Infection		Piroxicam	C		ORAL	

Date:06/24/05ISR Number: 4699379-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02165
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR
Initial or Prolonged	Renal Failure		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR

Date:06/24/05ISR Number: 4699385-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02937
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:06/24/05ISR Number: 4699386-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02938
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Failure							
	Cerebrovascular Accident							

Date:06/24/05ISR Number: 4699387-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02951
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699388-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01525
Age:76 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Asthma
	Back Pain
	Balance Disorder
	Blood Homocysteine Increased
	Cardiac Disorder
	Cardiac Failure
	Cardiac Failure Congestive

		Cardiovascular Disorder					
		Chest Pain					
		Concussion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Celebrex	C		ORAL
		Dilatation Atrial		Celebrex	C		ORAL
		Disease Recurrence		Metoprolol	C		ORAL
		Fall		Lasix (Furosemide)	C		ORAL
		Fracture		Nexium	C		ORAL
		Gait Disturbance		Alprazolam	C		
UNKNOWN							
		Gastrooesophageal Reflux					
		Disease					
		Gout					
		Hypertension					
		Hypotension					
		Injury					
		Inner Ear Disorder					
		Ischaemic Cardiomyopathy					
		Joint Dislocation					
		Joint Injury					
		Meniscus Lesion					
		Mitral Valve Incompetence					
		Multi-Organ Disorder					
		Neck Pain					
		Osteochondrosis					
		Pain					
		Post Concussion Syndrome					
		Pulmonary Hypertension					
		Radiculopathy					
		Squamous Cell Carcinoma					
		Ventricular Hypertrophy					
		Vertigo					

Date:06/24/05ISR Number: 4699390-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02811
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Death					

Date:06/24/05ISR Number: 4699391-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03517
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Coronary Syndrome
	Angina Unstable
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Thrombosis
	Coronary Ostial Stenosis
	Cough
	Diabetes Mellitus Non-Insulin-Dependent
	Diarrhoea
	Dizziness
	Dysphonia

		Fatigue					
		Hypertension					
		Microalbuminuria	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage		Claritin	C		
UNKNOWN							
		Stasis Dermatitis		Prempro	C		
UNKNOWN							
		Umbilical Hernia					
		Urinary Tract Infection					
		Venous Insufficiency					
		Weight Decreased					

Date:06/24/05ISR Number: 4699392-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02967
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/05ISR Number: 4699393-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02958
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/05ISR Number: 4699394-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00088
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atherosclerosis		Zoloft	C		
UNKNOWN		10 YR					
Other		Blood Cholesterol					
		Increased					
		Blood Triglycerides					
		Increased					
		Emotional Distress					

Myocardial Infarction
Obesity
Renal Disorder

Date:06/24/05ISR Number: 4699395-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699396-5Report Type:Expedited (15-DaCompany Report #US-MERCK-01060285
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Aortic Valve Disease
	Blood Cholesterol Increased
	Convulsion
	Depression
	Drug Ineffective
	Dyspnoea

		Gastrooesophageal Reflux Disease					
		Glaucoma	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema		Tylenol	C		
UNKNOWN							
		Overdose		Percocet	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699397-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02843
Age:64 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Hypercholesterolaemia		Vioxx	PS	Merck & Co., Inc	ORAL
215 DAY							
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
128 DAY							
		Meniscus Lesion		Vioxx	SS	Merck & Co., Inc	ORAL
62 DAY							
		Retinal Vascular		Vioxx	SS	Merck & Co., Inc	ORAL
227 DAY							
		Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tendon Rupture		Vioxx	SS	Merck & Co., Inc	ORAL
227 DAY							
		Urticaria		Vioxx	SS	Merck & Co., Inc	ORAL
215 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
128 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
62 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
227 DAY							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
227 DAY							
				Aspirin	C		
UNKNOWN							

			Aspirin	C	
UNKNOWN					
			Bextra	C	
UNKNOWN	2	WK			
			Acyclovir	C	
UNKNOWN					

Date:06/24/05ISR Number: 4699407-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02685
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Acute Myocardial Infarction Angina Pectoris Anxiety Aortic Valve Sclerosis Arthralgia Blood Cholesterol Increased Chest Pain Chest Wall Pain Chronic Fatigue Syndrome Coronary Artery Disease Depression Hypertrophy Joint Injury Mitral Valve Incompetence Myocardial Infarction Suicidal Ideation Suicide Attempt Syncope Tricuspid Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699409-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02676
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Peripheral Vascular		Procardia	C				UNKNOWN
	Disorder		Hydrochlorothiazide	C				UNKNOWN
			Plavix	C				UNKNOWN
			Premarin	C				UNKNOWN

Date:06/24/05ISR Number: 4699410-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02668
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Premarin	C				UNKNOWN
Disability	Blood Cholesterol		Prozac	C				UNKNOWN
	Increased		Nitroglycerin	C				UNKNOWN
	Blood Pressure Abnormal		Nitroglycerin	C				UNKNOWN
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cerebrovascular Accident							
	Dyspepsia							
	Gastric Disorder							
	Haematochezia							
	Myocardial Infarction							
	Oedema							
	Thrombosis							
	Thyroid Disorder							

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Anaemia
	Anorexia
	Anxiety
	Atrial Fibrillation
	Atrial Flutter
	Bladder Disorder
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchospasm
	Cardiac Failure Congestive
	Cardiomyopathy
	Carotid Artery Stenosis
	Cellulitis
	Cerebral Artery Occlusion
	Cerebrovascular Accident
	Chest Pain
	Coagulopathy
	Compression Fracture
	Congestive Cardiomyopathy
	Constipation
	Diarrhoea

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dyspepsia Ejection Fraction Decreased					
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
		Fluid Retention Gastric Polyps Gastric Ulcer Gastritis Erosive Glucose Tolerance Impaired Hallucination Hypertension Hyperthyroidism Hypokalaemia Incontinence Intervertebral Disc Degeneration Libido Decreased Lipodystrophy Acquired Lobar Pneumonia Lymphopenia Nausea Nephrolithiasis Neuropathy Osteoarthritis Pain Panic Attack Peripheral Vascular Disorder Pneumonia Pulmonary Oedema Spinal Compression Fracture Supraventricular Tachycardia Transient Ischaemic Attack Urethral Stricture Urinary Tract Infection Vitamin B12 Deficiency Weight Increased					

Date:06/24/05ISR Number: 4699412-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01996
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased
Other	Anxiety
	Atrial Fibrillation
	Atrioventricular Block First Degree
	Back Pain
	Basal Cell Carcinoma
	Blindness
	Blindness Transient
	Blood Cholesterol Increased
	Blood Glucose Increased
	Bradycardia

	Coronary Artery Disease						
	Dizziness						
	Drug Ineffective	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Drug Intolerance		Vioxx	PS	Merck & Co., Inc	ORAL	58	MON
	Dysphonia		Allegra	C			UNKNOWN	
	Epigastric Discomfort		Wellbutrin	C			UNKNOWN	
	Gastritis		Pravachol	C			UNKNOWN	
	Gastrooesophageal Reflux Disease							
	Headache							
	Hyperlipidaemia							
	Myocardial Infarction							
	Nipple Pain							
	Pleurisy							
	Salivary Hypersecretion							
	Supraventricular Tachycardia							
	Tendon Rupture							
	Thrombosis							
	Tinnitus							
	Tremor							

Date:06/24/05ISR Number: 4699413-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02657
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged	Cardiac Disorder		Lortab	C			UNKNOWN	
Disability	Cardiac Failure		Zonegran	C			UNKNOWN	
Other	Congestive Cerebrovascular Accident							
	Gastrooesophageal Reflux Disease							
	Haematochezia							
	Hypertension							
	Myocardial Infarction							

Oedema Peripheral
Palpitations

Date:06/24/05ISR Number: 4699414-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02666
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	12 MON		Lorcet 10/650	C		
Other	Cardiac Disorder		Percocet	C		
UNKNOWN	12 MON					
	Dyspnoea		[Therapy			
	Hernia		Unspecified]	C		
UNKNOWN						
	Myocardial Infarction					
	Overdose					
	Surgery					

Date:06/24/05ISR Number: 4699415-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02036
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Disability	Actinic Keratosis
Other	Anaemia

	Azotaemia						
	Carotid Artery Stenosis						
	Carpal Tunnel Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Dermal Cyst		Lipitor	C			UNKNOWN	
	Diabetic Retinopathy		Aspirin	C			UNKNOWN	
	Dupuytren'S Contracture							
	Hypertension							
	Kyphosis							
	Pain In Extremity							
	Renal Failure							
	Renal Failure Chronic							
	Renal Osteodystrophy							
	Shoulder Pain							
	Skin Lesion							
	Spinal Osteoarthritis							

Date:06/24/05ISR Number: 4699416-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02589
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Neurontin	C			UNKNOWN	
	Pain		Neurontin	C			UNKNOWN	
			Bextra	C			UNKNOWN	
			Hydrocodone Bitartrate	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Ultram	C			UNKNOWN	

Date:06/24/05ISR Number: 4699417-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02042
Age:31 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Angina Unstable
	Blood Pressure Increased
	Chest Pain
	Depression
	Diabetes Mellitus
	Headache
	Homicidal Ideation
	Hypokalaemia
	Major Depression
	Obesity
	Oophorectomy
	Post-Traumatic Stress Disorder
	Pruritus
	Psychotic Disorder
	Pyuria
	Schizoaffective Disorder
	Schizophrenia
	Sleep Apnoea Syndrome
	Suicidal Ideation
	Thrombosis

	Urticaria						
	Uterine Leiomyoma						
	Vomiting	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Zoloft	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Ambien	C			UNKNOWN	
			Celexa	C			UNKNOWN	

Date:06/24/05ISR Number: 4699418-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01388
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
28 MON								
Initial or Prolonged	Infarction		Toprol Xl Tablets	C				
UNKNOWN								
	Arterial Occlusive		Neurontin	C				
UNKNOWN								
	Disease		Hyzaar	C				
UNKNOWN								
	Asthma		Singulair	C				
UNKNOWN								
	Chest Pain		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease		Ibuprofen	C				
UNKNOWN								
	Coronary Artery		Insulin	C				
UNKNOWN								
	Restenosis							
	Diabetic Foot							
	Erectile Dysfunction							
	Hypercholesterolaemia							
	Myocardial Infarction							
	Neuropathy Peripheral							
	Onychomycosis							
	Pharyngitis							

Date:06/24/05ISR Number: 4699419-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02114
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	865	DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	865	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	865	DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	865	DAY
	Myocardial Infarction							

Date:06/24/05ISR Number: 4699420-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04198
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	301	DAY
	Infarction		Zyrtec	C			UNKNOWN	
	Myocardial Rupture		Carisoprodol	C			UNKNOWN	

Date:06/24/05ISR Number: 4699421-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02600
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiac Disorder		Insulin	C			UNKNOWN	
Other	Myocardial Infarction		Glucophage	C			UNKNOWN	
	Overdose		Lipitor	C			UNKNOWN	

			Actos	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						
			Synthroid	C		
UNKNOWN						

Date:06/24/05ISR Number: 4699432-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02595
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Affect Lability		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Agitation		Vioxx	SS	Merck & Co., Inc	ORAL
	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL
	Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
	Aortic Valve Incompetence		Celebrex	C		
UNKNOWN	193 DAY					
	Cerebellar Infarction		Lipitor	C		
UNKNOWN	260 DAY					
	Chest Pain		Amitriptyline			
	Constipation		Hydrochloride	C		
UNKNOWN						
	Convulsion		Skelaxin	C		
UNKNOWN						
	Depression		Atenolol	C		
UNKNOWN						
	Diarrhoea					
	Expressive Language Disorder					
	Haematuria					
	Hallucination					
	Hypertension					
	Mitral Valve Incompetence					
	Pulmonary Hypertension					
	Restless Legs Syndrome					
	Sinus Bradycardia					
	Sleep Disorder					
	Transient Ischaemic Attack					
	Tricuspid Valve Incompetence					
	Urinary Hesitation					

Urinary Tract Infection
Vertebral Artery
Occlusion
Vertigo Positional
Vomiting
Weight Decreased

Date:06/24/05ISR Number: 4699435-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02933
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Actinic Keratosis
Other	Amnesia
	Anaemia
	Anxiety
	Back Injury
	Back Pain
	Balance Disorder
	Bronchitis
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebrovascular Accident

		Chest Pain					
		Contusion					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness Postural		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
15	DAY						
		Dysuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Essential Tremor		Vioxx	SS	Merck & Co., Inc	ORAL
		Eye Pain					
		Eye Pruritus					
		Fall					
		Gastrooesophageal Reflux					
		Disease					
		Haemorrhage					
		Headache					
		Hypersensitivity					
		Hypertonic Bladder					
		Incontinence					
		Intervertebral Disc					
		Protrusion					
		Lacrimation Increased					
		Muscle Spasms					
		Muscular Weakness					
		Myalgia					
		Nasal Discomfort					
		Oedema Peripheral					
		Pain In Extremity					
		Panic Attack					
		Perineal Pain					
		Peripheral Sensory					
		Neuropathy					
		Pharyngeal Oedema					
		Polyneuropathy					
		Prostatitis					
		Renal Disorder					
		Road Traffic Accident					
		Sinusitis					
		Skin Lesion					
		Testicular Pain					
		Thermal Burn					
		Transient Ischaemic					
		Attack					
		Venous Insufficiency					
		Vision Blurred					

Date:06/24/05ISR Number: 4699443-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00416
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Ancillin	C				
UNKNOWN								
	Nausea		Synthroid	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Lasix (Furosemide)	C				
UNKNOWN								
			Humulin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699445-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02893
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		59 MON
Initial or Prolonged	Increased		Isosorbide	C				UNKNOWN
Disability	Cardiac Disorder		Atenolol	C				UNKNOWN
Other	Carpal Tunnel Syndrome		Zocor	C				UNKNOWN
	Chest Pain							
	Heart Rate Abnormal							
	Hypertension							
	Myocardial Infarction							

Date:06/24/05ISR Number: 4699446-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
	Angina Pectoris
	Anxiety
	Arthralgia
	Back Pain
	Blood Pressure Increased
	Carotid Artery Stenosis
	Chronic Obstructive
	Pulmonary Disease
	Constipation
	Contusion
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Dizziness
	Drug Effect Decreased
	Drug Hypersensitivity
	Drug Ineffective
	Dry Eye
	Dry Skin
	Dyslipidaemia
	Dyspepsia

Dysuria
Ear Disorder
Electrocardiogram St-T
Segment Abnormal
Eructation
Fatigue
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Hearing Impaired
Hypoacusis
Increased Tendency To
Bruise
Injury
Insomnia
Medication Error
Memory Impairment
Musculoskeletal Stiffness
Myocardial Ischaemia
Nausea
Neck Pain

		Nocturia					
		Oedema Peripheral					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
		Polyuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Congestion		Flexeril	SS		ORAL
		Tension		Advil	C		
UNKNOWN							
		Vertigo		Aleve	C		
UNKNOWN							
		Vomiting		Naproxen	C		
UNKNOWN							
		Xanthelasma		Mobic	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699447-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03478
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
984 DAY							
Hospitalization -		Infarction		Indocin			
Initial or Prolonged		Blood Urea Increased		(Indomethacin)	C		
UNKNOWN							
		Cardio-Respiratory Arrest		Glipizide Xl	C		ORAL
		Chest Pain		Hydrodiuril	C		ORAL
		Cough		Glucophage	C		ORAL
		Death		Zestril	C		ORAL
		Dehydration		Lopressor	C		ORAL
		Hypokalaemia		Glyburide	C		
UNKNOWN							
		Osteopenia		Timoptic	C		
UNKNOWN							
		Pericardial Effusion					
		Ventricular Hypokinesia					

Date:06/24/05ISR Number: 4699448-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02745
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Disorder							
Other	Carotid Artery Occlusion							
	Dyspepsia							
	Myocardial Infarction							
	Renal Artery Occlusion							

Date:06/24/05ISR Number: 4699450-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY

Date:06/24/05ISR Number: 4699453-3Report Type:Expedited (15-DaCompany Report #BR-MERCK-0506BRA00046
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Haemorrhage Urinary Tract		Rivastigmine	SS		ORAL		
	Hepatic Encephalopathy		Rivastigmine	SS		ORAL		
			Rivastigmine	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699455-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699456-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02667
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 693 DAY	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Celebrex	C				
UNKNOWN	1189 DAY							
	Dyspepsia							
	Effusion							
	Hypertension							
	Myocardial Infarction							

Date:06/24/05ISR Number: 4699457-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02685
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Transient Ischaemic Attack							

Date:06/24/05ISR Number: 4699458-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02686
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
3 YR								
	Myocardial Infarction							

Date:06/24/05ISR Number: 4699459-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02170
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain							
	Transient Ischaemic Attack							

Date:06/24/05ISR Number: 4699460-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00063
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Intervertebral Disc Protrusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Valdecoxib	SS		ORAL		

Date:06/24/05ISR Number: 4699461-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	534	DAY

Date:06/24/05ISR Number: 4699462-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02152
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699463-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699470-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01831
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	144	DAY
	Injury							
	Myocardial Infarction							

Date:06/24/05ISR Number: 4699482-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699493-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699525-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02163
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON

Date:06/24/05ISR Number: 4699533-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02734
Age:80 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Unstable
	Asthenia
	Blood Creatinine Increased
	Blood Triglycerides

	Increased Blood Urea Increased Cardiac Failure Congestive	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cerumen Impaction		Vioxx	PS	Merck & Co., Inc	ORAL	739 DAY
	Contusion		Aspirin	C			UNKNOWN
	Dehydration		Captopril Msd	C		ORAL	
	Dyspepsia		Iron (Unspecified)	C			UNKNOWN
	Gastrooesophageal Reflux		Metoprolol	C			UNKNOWN
	Disease		Ventolin (Albuterol)	C			UNKNOWN
	Hypertension		Temazepam	C			UNKNOWN
	Hypertensive Heart Disease Myocardial Ischaemia Pain In Extremity Pharyngolaryngeal Pain Syncope Urinary Tract Infection Ventricular Extrasystoles						

Date:06/24/05ISR Number: 4699852-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00130
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Omeprazole Magnesium	C		ORAL	

Date:06/24/05ISR Number: 4699872-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03454
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	738 MON
Initial or Prolonged	Atherosclerosis		Pravachol	C		ORAL	
Disability	Benign Oesophageal		Amaryl	C		ORAL	

Other	Neoplasm	Aggrenox	C
UNKNOWN			
	Cerebrovascular Accident	Combivent	C
UNKNOWN			
	Chest Pain		
	Dyspnoea		
	Fall		
	Hypoxia		
	Oedema Peripheral		
	Pain In Extremity		
	Rotator Cuff Syndrome		
	Visual Disturbance		

Date:06/24/05ISR Number: 4699873-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03210
Age:75 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident
Initial or Prolonged	Arthropathy
Other	Coronary Artery Disease
	Flank Pain
	Lower Gastrointestinal
	Haemorrhage
	Meniscus Lesion
	Myocardial Infarction
	Osteoarthritis
	Spinal Osteoarthritis

	Ventricular Dysfunction Whiplash Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	863 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	863 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Flomax (Morniflumate)	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Proscar	C		ORAL	

Date:06/24/05ISR Number: 4699874-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02423
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
	Bradycardia		Digoxin	SS			
Other	Therapeutic Agent Toxicity						

Date:06/24/05ISR Number: 4699875-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02624
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Life-Threatening	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	54 MON
Hospitalization - Initial or Prolonged	Back Injury		Aspirin	SS			UNKNOWN
	Blood Cholesterol		Aspirin	SS			UNKNOWN
Disability	Increased Cerebrovascular Accident		Dexatrim (Old Formula)	SS			UNKNOWN

	Chest Pain	Advil	SS
UNKNOWN			
	Emotional Distress	Hydrochlorothiazide	C
UNKNOWN			
	Fall		
	Gastrointestinal Disorder		
	Hot Flush		
	Hypertension		
	Meniscus Lesion		
	Nausea		
	Pain		
	Paraesthesia		
	Refusal Of Treatment By		
	Patient		
	Sciatica		
	Skin Discolouration		
	Transient Ischaemic		
	Attack		

Date:06/24/05ISR Number: 4699876-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02960
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Other	Angina Pectoris
	Anxiety
	Back Injury
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Fatigue Syndrome

		Depression					
		Dysphagia					
		Heart Rate Irregular	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Lipitor	C		
UNKNOWN							
		Panic Disorder		Paxil	C		
UNKNOWN							
		Sexual Dysfunction		Paxil	C		
UNKNOWN							
		Tension		Xanax	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Zyprexa	C		
UNKNOWN							
				Zyprexa	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699878-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00072
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Stenosis					
	Nephrosclerosis					
	Pancytopenia					
	Renal Failure Chronic					

Date:06/24/05ISR Number: 4699879-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00143
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					

Disability

Date:06/24/05ISR Number: 4699880-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02332
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Pressure Inadequately Controlled Blood Pressure Increased Blood Triglycerides Increased Coronary Artery Disease Coronary Artery Stenosis Depression Dizziness Dyspnoea Electrocardiogram T Wave Inversion Hydronephrosis Hypercholesterolaemia Influenza Muscle Spasms Myocardial Infarction Oedema Peripheral Rotator Cuff Syndrome Weight Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699881-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03483
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C				
	Cerebrovascular Accident		Singulair	C			RESPIRATORY (INHALATION)	
	Hypertension							
	Pain		Azmacort	C			UNKNOWN	
	Productive Cough		Atrovent	C			UNKNOWN	
	Transient Ischaemic Attack		Levaquin	C			UNKNOWN	
			Disalcid	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Aggrenox	C			UNKNOWN	
			Dulcolax	C			UNKNOWN	
			Fosamax	C			UNKNOWN	
			Proventil	C			UNKNOWN	
			Monopril	C			UNKNOWN	
			Advair	C			RESPIRATORY (INHALATION)	
			Combivent	C			RESPIRATORY (INHALATION)	
			Albuterol	C			UNKNOWN	

Date:06/24/05ISR Number: 4699882-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00453
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Coronary Artery Disease Gastritis Ischaemic Cardiomyopathy Left Ventricular Failure Mitral Valve Incompetence Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699883-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02343
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Plavix	C			UNKNOWN	
	Chest Pain		Prilosec	C			UNKNOWN	
	Depression		Celebrex	C			UNKNOWN	
	Dyspepsia		Tylenol	C			UNKNOWN	
	Dyspnoea		Advil	C			UNKNOWN	
	Ear Discomfort Gastrooesophageal Reflux Disease Muscle Strain Myocardial Infarction Syncope Tachycardia Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699886-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bifascicular Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis							
	Hypertension							
	Influenza Like Illness							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Pain In Extremity							
	Prescribed Overdose							
	Renal Colic							
	Renal Failure Chronic							
	Ventricular Extrasystoles							

Date:06/24/05ISR Number: 4699887-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03455
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
							2	DAY
Initial or Prolonged	Bladder Spasm		Vioxx	SS	Merck & Co., Inc	ORAL		
							9	DAY
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
							13	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
							2	DAY
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
							9	DAY
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
							13	DAY
	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		

	Dysuria	Parafon Forte	C
UNKNOWN			
	Embolic Stroke	Aspirin	C
UNKNOWN			
	Emotional Distress	Lioresal	C
UNKNOWN			
	Fall	Inderal	C
UNKNOWN			
	Glucose Tolerance	Ditropan	C
UNKNOWN			
	Impaired	Valium	C
UNKNOWN			
	Hypertension	Tylenol	C
UNKNOWN			
	Joint Injury	Demerol	C
UNKNOWN			
	Migraine	Serevent	C
RESPIRATORY			
	Myofascial Pain Syndrome		
(INHALATION)			
	Nerve Compression	Proventil	C
RESPIRATORY			
	Oedema Peripheral		
(INHALATION)			
	Pollakiuria		
	Rotator Cuff Syndrome		
	Shoulder Pain		
	Urinary Tract Infection		

Date:06/24/05ISR Number: 4699888-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01888
Age:34 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Arthralgia

		Blood Pressure Inadequately Controlled Coronary Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Atacand	C		ORAL
		Hypertension		Hydrochlorothiazide			
		Palpitations		And Metoprolol			
		Panic Attack		Tartrate	C		ORAL
		Polyp					
		Post-Traumatic Stress Disorder					
		Sleep Apnoea Syndrome					
		Supraventricular Extrasystoles					
		Supraventricular Tachycardia					
		Upper Respiratory Tract Infection					
		Ventricular Extrasystoles					
		Ventricular Hypertrophy					
		Wolff-Parkinson-White Syndrome					

Date:06/24/05ISR Number: 4699889-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02008
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
52	MON						
Initial or Prolonged		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
52	MON						
Other		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
52	MON						
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
52	MON						
		Erectile Dysfunction		Allegra	C		
UNKNOWN							

	Intervertebral Disc	Aspirin	C UNKNOWN
	Protrusion	Vitamins (Unspecified)	C UNKNOWN
	Libido Decreased		
	Myocardial Infarction	Cough, Cold, And Flu Therapies (Unspecified)	C UNKNOWN

Date:06/24/05ISR Number: 4699890-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00090
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Death	Anxiety
Hospitalization - Initial or Prolonged	Arteriosclerosis
	Atherosclerosis
	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Cataract
	Cataract Operation
	Chronic Obstructive Pulmonary Disease

		Coronary Artery Atherosclerosis					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Zocor	C		
UNKNOWN	38 DAY						
		Myocardial Infarction		Toprol Xl Tablets	C		
UNKNOWN	143 DAY						
		Oedema Peripheral		Adalat	C		
UNKNOWN							
		Osteoarthritis		Edetate Sodium And			
		Pulmonary Oedema		Ginkgo Biloba			
		Skin Cancer		Extract	C		
UNKNOWN							
		Thyroid Disorder		Lasix (Furosemide			
		Ulcer		Sodium)	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699891-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02103
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation		Plavix	C		
UNKNOWN						
Disability	Cardiac Failure		Cordarone	C		ORAL
	Congestive		Lasix (Furosemide)	C		
UNKNOWN						
	Cardiomyopathy		Tenormin	C		
UNKNOWN						
	Intermittent Claudication		Lipitor	C		
UNKNOWN						
	Mitral Valve Incompetence		Zyrtec	C		
UNKNOWN						
	Transient Ischaemic		Prilosec	C		
UNKNOWN						
	Attack		Viagra	C		
UNKNOWN						

Date:06/24/05ISR Number: 4699892-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03387
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Activated Partial Thromboplastin Time Prolonged		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Blood Calcium Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Chloride Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Urea Increased		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Cerebrovascular Accident							
	Chest Pain							
	Depression							
	Diarrhoea							
	Hyperlipidaemia							
	Hypertension							
	International Normalised Ratio Decreased							
	Lobar Pneumonia							
	Post-Traumatic Stress Disorder							

Date:06/24/05ISR Number: 4699893-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00669
Age:60 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
Disability	Asthenia
Other	Atherosclerosis
	Back Injury

		Blood Creatine Phosphokinase Increased					
		Burning Sensation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
31	MON						
		Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Zocor	C		
UNKNOWN							
		Constipation		Insulin	C		
UNKNOWN							
		Cough		Toprol Xl Tablets	C		
UNKNOWN							
		Deep Vein Thrombosis		Nexium	C		
UNKNOWN							
		Difficulty In Walking					
		Dyspnoea					
		Dyspnoea Exertional					
		Fall					
		Flank Pain					
		Gammopathy					
		Gastrooesophageal Reflux					
		Disease					
		Glaucoma					
		Gout					
		Haematochezia					
		Haematuria					
		Hepatomegaly					
		Leukopenia					
		Lichen Planus					
		Loss Of Consciousness					
		Micturition Disorder					
		Micturition Urgency					
		Monocyte Count Increased					
		Myalgia					
		Mycetoma Mycotic					
		Myocardial Infarction					
		Nail Tinea					
		Neuropathic Pain					
		Neuropathy Peripheral					
		Oedema Peripheral					
		Onychomycosis					
		Paralysis					
		Polyneuropathy					
		Postnasal Drip					
		Renal Disorder					
		Road Traffic Accident					

Skin Disorder
Syncope
Thrombosis
Urinary Bladder Polyp
Vascular Injury
Weight Decreased

Date:06/24/05ISR Number: 4699897-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/24/05ISR Number: 4699898-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02973
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699899-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03010
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Lipitor	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:06/24/05ISR Number: 4699900-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02803
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	23 DAY	

Date:06/24/05ISR Number: 4699901-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02178
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Thrombosis Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699902-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03847
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Norvasc	C				
	Chest Pain		Paxil	C				
	Fall		Plavix	C				
	Haematuria		Prinivil	C				
	Polyp		Hydrochlorothiazide	C				
	Spinal Column Stenosis		Cardura	C				
	Syncope		Buspirone Hydrochloride	C				
	Urinary Retention							

Date:06/24/05ISR Number: 4699903-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02689
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	OPHTHALMIC	14	MON

Date:06/24/05ISR Number: 4699904-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03811
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
	Cholelithiasis

		Coronary Artery Atherosclerosis Coronary Artery Thrombosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Oedema		Hydrocodone Bitartrate	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Topamax	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Lorazepam	C		
UNKNOWN							
				Tizanidine Hydrochloride	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Endocet	C		
UNKNOWN							
				Serzone	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Methadone Hydrochloride	C		
UNKNOWN							
				Lexapro	C		
UNKNOWN							

Date:06/24/05ISR Number: 4699910-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02151
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/24/05ISR Number: 4699911-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03456
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Joint Injury							
	Myocardial Infarction							
	Testicular Disorder							

Date:06/24/05ISR Number: 4699912-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04179
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization - Initial or Prolonged	Infarction
	Blood Cholesterol
Other	Increased
	Cardiac Failure
	Cardiogenic Shock
	Cerebrovascular Accident
	Convulsion
	Coronary Artery Disease
	Coronary Artery Occlusion
	Death
	Device Failure
	Gastrointestinal

	Haemorrhage						
	Graft Complication						
	Haematocrit Decreased						
	Haematoma	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON
	Pericarditis		Prinivil	C		ORAL	18 MON
	Pericarditis Adhesive		Zocor	C			UNKNOWN 18 MON
	Post Procedural Complication		Indocin (Indomethacin)	C		ORAL	
	Pulmonary Oedema						
	Renal Failure						
	Respiratory Failure						
	Sepsis						
	Stent Occlusion						
	Thrombosis						

Date:06/24/05ISR Number: 4699913-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON
Initial or Prolonged	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL	
Other							

Date:06/24/05ISR Number: 4699914-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02804
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5 MON

Date:06/24/05ISR Number: 4699915-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02341
Age:51 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Angina Pectoris Blood Creatinine Increased Blood Pressure Decreased Blood Urea Increased Cardiac Arrest Cardiac Failure Cardiac Valve Disease Cardio-Respiratory Arrest Cardiomegaly Cardiovascular Disorder Chronic Fatigue Syndrome Coronary Artery Disease Coronary Artery Occlusion Difficulty In Walking Dilatation Atrial Drug Interaction Drug Toxicity Dyspnoea Fall Gastrointestinal Disorder Gastrooesophageal Reflux Disease Haematocrit Decreased Haemoglobin Decreased

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Heart Rate Irregular					
		Hyperchlorhydria					
		Hyperplasia					
		Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL
		Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Consciousness		Amiodarone Hydrochloride	SS		
UNKNOWN		Low Density Lipoprotein					
		Increased		Zoloft	C		
UNKNOWN		Multi-Organ Disorder		Procardia	C		
UNKNOWN		Myocardial Infarction		Fiorinal	C		
UNKNOWN		Nausea		Ambien	C		
UNKNOWN		Nocturia		Erythromycin	C		
UNKNOWN		Obesity		Volmax	C		
UNKNOWN		Obstructive Airways Disorder		Cyclobenzaprine Hydrochloride	C		
UNKNOWN	1125 DAY	Oedema		Endocet	C		
UNKNOWN	1527 DAY	Pain		Valium	C		
UNKNOWN		Panic Disorder		Digoxin	C		
UNKNOWN		Pneumonia					
		Post-Traumatic Stress Disorder					
		Prostatic Specific Antigen Increased					
		Respiratory Failure					
		Rhonchi					
		Tricuspid Valve Incompetence					
		Upper Respiratory Tract Infection					
		Vascular Injury					
		Ventricular Dysfunction					
		Ventricular Fibrillation					
		Ventricular Hypertrophy					
		Vomiting					

Date:06/24/05ISR Number: 4699916-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02146
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Zocor	C			UNKNOWN	
Disability	Pain		Humulin	C			UNKNOWN	
	Renal Disorder		Prozac	C			UNKNOWN	
	Thrombosis		Humalog	C			UNKNOWN	
			Lantus	C			UNKNOWN	

Date:06/24/05ISR Number: 4699917-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04203
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Chest Pain
	Depression
	Haematochezia
	Hypertension
	Insomnia

Myocardial Infarction
Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Allopurinol	C			UNKNOWN	
	Colchicine	C			UNKNOWN	
	Cozaar	C			UNKNOWN	
	Roxicet	C			UNKNOWN	
	Ciprofloxacin	C			UNKNOWN	
	Urocit-K	C			UNKNOWN	

Date:06/24/05ISR Number: 4699919-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01047
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Darvocet-N	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:06/24/05ISR Number: 4699920-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25 MON	

Date:06/24/05ISR Number: 4699921-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/24/05ISR Number: 4699922-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03899
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Dilantin	C				UNKNOWN
			Lorazepam	C				UNKNOWN
			Effexor	C				UNKNOWN
			Lortab	C				UNKNOWN
			Diovan	C				UNKNOWN

Date:06/24/05ISR Number: 4699923-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01834
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Angina Unstable
Disability	Blood Cholesterol Increased
	Bone Pain
	Chest Pain
	Coronary Artery Disease
	Drug Hypersensitivity
	Dyspnoea

	Hypersensitivity						
	Hypoaesthesia						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neck Pain							
	Oedema Peripheral							
	Pain In Extremity							
	Sensation Of Pressure							
	Thrombosis							
	Ventricular Hypertrophy							
	Ventricular Hypokinesia							

Date:06/24/05ISR Number: 4699931-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03154
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Tylenol	C		ORAL		
	Chest Pain		Tylenol	C		ORAL		
	Depression		Motrin	C		ORAL		
	Dyspnoea		Motrin	C		ORAL		
	Headache							
	Hypertension							
	Muscle Spasms							
	Myocardial Infarction							
	Renal Disorder							

Date:06/24/05ISR Number: 4699932-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02814
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged			Tiazac	C			UNKNOWN	

Date:06/24/05ISR Number: 4699934-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03200
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Injury							

Date:06/24/05ISR Number: 4699935-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03199
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Myocardial Infarction							
	Stress							

Date:06/24/05ISR Number: 4700249-4Report Type:Direct Company Report #CTU 251928
Age: Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Activities Of Daily Living Impaired

Myocardial Infarction
Weight Decreased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx 25 Mg Merck	PS	Merck	ORAL	1 TABLET BY MOUTH DAILY	
	Humulin N	C				
	Atenolol	C				
	Zyprexa	C				
	Diazepam	C				
	Prozac	C				
	Lortab	C				

Date:06/27/05ISR Number: 4700299-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02653
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Other			Zoloft	C				
	Agitation		Prednisone	C				
	Atherosclerosis		Prevacid	C				
	Blood Pressure Increased		A.S.A.	C				
	Bradycardia		Coumadin	C				
	Cardiogenic Shock		Lopressor	C				
	Cardiomegaly							
	Confusional State							
	Coronary Artery Atherosclerosis							
	Coronary Artery Occlusion							
	Coronary Artery Stenosis							
	Electromechanical Dissociation							
	Gastric Haemorrhage							
	Gastric Ulcer							
	Gastrointestinal Ischaemia							

Haematemesis
Hepatic Congestion
Hydrocele
Hypotension
Lobar Pneumonia
Metabolic Acidosis
Nephrosclerosis
Pulmonary Congestion
Pulmonary Oedema
Renal Atrophy
Restlessness
Sudden Cardiac Death
Upper Gastrointestinal
Haemorrhage
Ventricular Fibrillation
Ventricular Tachycardia

Date:06/27/05ISR Number: 4700302-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02596
Age:43 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Behaviour Acute Myocardial Infarction

	Anxiety						
	Back Pain						
	Chest Discomfort	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON
	Coronary Artery Disease		Tramadol				
	Coronary Artery		Hydrochloride	C			UNKNOWN
	Restenosis						
	Disturbance In Attention						
	Dyslipidaemia						
	Fatigue						
	Headache						
	Hyperhidrosis						
	Hypertension						
	Impaired Work Ability						
	Initial Insomnia						
	Myocardial Infarction						
	Palpitations						
	Post Laminectomy Syndrome						
	Radiculopathy						
	Restlessness						

Date:06/27/05ISR Number: 4700303-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02848
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Appendicitis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Asthma		Chronulac	C			UNKNOWN
	Cerebrovascular Accident		Paxil	C			UNKNOWN
	Chest Pain		Prevacid	C			UNKNOWN
	Depression		Albuterol	C			UNKNOWN
	Dyspnoea Exertional		Methylprednisolone	C			UNKNOWN
	Gastrooesophageal Reflux		Evista	C			UNKNOWN
	Disease		Effexor Xr	C			UNKNOWN

	Hyperlipidaemia	Atacand	C	
UNKNOWN				
	Hypertension	Foradil	C	
UNKNOWN				
	Myocardial Ischaemia	Deltasone	C	
UNKNOWN				
	Oedema Peripheral	Singulair	C	
UNKNOWN				
	Transient Ischaemic	Clarinex	C	
UNKNOWN				
	Attack	Astelin	C	
UNKNOWN				
	Vertigo	Combivent	C	
UNKNOWN				
		Avelox	C	
UNKNOWN				
		Tequin	C	
UNKNOWN				
		Levaquin	C	
UNKNOWN				
		Tamoxifen Citrate	C	
UNKNOWN				
		Cozaar	C	ORAL

Date:06/27/05ISR Number: 4700304-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00558
Age:72 YR Gender:Female I/FU:F

Outcome	PT
Death	Cardiac Disorder
Other	Cardiac Failure
	Congestive
	Cardio-Respiratory Arrest
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Diabetes Mellitus

Diabetes Mellitus
Non-Insulin-Dependent
Dyspepsia

Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	967	DAY
	Premarin	C			UNKNOWN	
	Atrovent	C			RESPIRATORY (INHALATION)	
	Paxil	C		ORAL		
	Serevent	C			RESPIRATORY (INHALATION)	
	Xanax	C		ORAL		
	Vicodin Tablets	C		ORAL		
	Prednisone	C			UNKNOWN	
	Albuterol	C			RESPIRATORY (INHALATION)	
	Ferrous Sulfate	C			UNKNOWN	
	Hydrocodone/Apap	C			UNKNOWN	
	Didronel	C			UNKNOWN	
	Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Azathioprine	C			UNKNOWN	
	Methotrexate	C			UNKNOWN	
	Glipizide	C			UNKNOWN	

Date:06/27/05ISR Number: 4700305-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Blood Cholesterol		Oxybutynin Chloride	C		ORAL		
Initial or Prolonged	Increased		Amantadine Sulfate	C		ORAL		
Disability	Chest Discomfort		Levocarnitine					
	Condition Aggravated		Tartrate	C				
UNKNOWN								
	Coronary Artery Disease		Sodium Lauryl					
	Depression		Sulfoacetate	C				
RECTAL								
	Dyspepsia							
	Dysphagia							
	Dyspnoea							
	Headache							
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Multiple Sclerosis							
	Myocardial Infarction							
	Neck Pain							

Date:06/27/05ISR Number: 4700307-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02664
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
379 DAY								
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
379 DAY								
Other			Claritin	C				
UNKNOWN								
			Adalat	C				
UNKNOWN								
			Oxycontin	C				
UNKNOWN								
			Percodan	C				
UNKNOWN								
			Nortriptyline	C				
UNKNOWN								
			Amoxicillin	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								

				Indocin (Indomethacin Sodium)	C		ORAL
				Humalog	C		
UNKNOWN							
				Lantus	C		
UNKNOWN							
				Erythromycin	C		
UNKNOWN							
				Phenergan (Promethazine Hydrochloride)	C		
UNKNOWN							

Date:06/27/05ISR Number: 4700310-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00766
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Rhinitis		Advil	C		
UNKNOWN						
	Snoring					

Date:06/27/05ISR Number: 4700311-6Report Type:Expedited (15-DaCompany Report #GB-MERCK-0303GBR00053
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Intraocular Pressure		Prednisolone	C		
UNKNOWN						
	Increased		Bendroflumethiazide	C		
UNKNOWN						
	Iritis		Atorvastatin Calcium	C		
UNKNOWN						
			Mycophenolate Mofetil	C		
UNKNOWN						

Date:06/27/05ISR Number: 4700317-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03452
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vicodin Tablets	C				
UNKNOWN								
Disability	Blood Cholesterol Increased		Tylenol With Codeine #3	C				
UNKNOWN								
	Blood Glucose Abnormal		Tylenol	C				
UNKNOWN								
	Cardiac Murmur		[Therapy Unspecified]	C				
	Chest Pain							
UNKNOWN								
	Coronary Artery Disease							
	Diarrhoea							
	Dyspepsia							
	Flatulence							
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Hypertension							
	Insomnia							
	Major Depression							
	Myocardial Infarction							
	Stomach Discomfort							
	Stress							
	Ventricular Extrasystoles							
	Vomiting							

Date:06/27/05ISR Number: 4700326-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700328-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700329-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700331-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease Prostatic Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	

Date:06/27/05ISR Number: 4700333-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04211
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

	Vioxx	SS	ORAL
	Vioxx	SS	ORAL
	Cimetidine	C	
UNKNOWN			
	Calcium Carbonate	C	
UNKNOWN			
	Premarin	C	
UNKNOWN			
	Hydrodiuril	C	
UNKNOWN			
	Norvasc	C	
UNKNOWN			
	Norvasc	C	
UNKNOWN			
	Prilosec	C	
UNKNOWN			
	Ultram	C	
UNKNOWN			
	Nitrofurantoin	C	
UNKNOWN			
	Prochlorperazine	C	
UNKNOWN			
	Lipitor	C	
UNKNOWN			
	Perphenazine	C	
UNKNOWN			
	Ferrous Sulfate	C	
UNKNOWN			
	Aspirin	C	
UNKNOWN			

Date:06/27/05ISR Number: 4700334-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02941
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Anxiety
	Blood Potassium Increased

		Diabetic Retinopathy					
		Macular Oedema					
		Renal Impairment	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Monopril	C		ORAL
				Avandia	C		ORAL
				Amaryl	C		
UNKNOWN							
				Norvasc	C		ORAL
				Maxzide	C		
UNKNOWN							
				Lipitor	C		ORAL

Date:06/27/05ISR Number: 4700335-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04200
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
860 DAY						
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
860 DAY						
Disability	Myocardial Infarction		Zocor	C		
UNKNOWN	709 DAY					
Other	Vertigo Positional		Actos	C		
UNKNOWN						
			Gemfibrozil	C		
UNKNOWN	780 DAY					
			Neurontin	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN	794 DAY					
			Meclizine	C		
UNKNOWN						
			Glucotrol	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN	1282 DAY					
			Butalbital	C		
UNKNOWN						

			Acetaminophen	C
UNKNOWN				
			Monopril	C
UNKNOWN	733	DAY		
			Enalapril Maleate	C
UNKNOWN	33	DAY		
			Zithromax	C
UNKNOWN				

Date:06/27/05ISR Number: 4700336-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03845
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Acute Sinusitis
	Alveolitis
	Arachnoid Cyst
	Cellulitis
	Chest Pain
	Condition Aggravated
	Confusional State
	Constipation
	Deep Vein Thrombosis
	Dermatitis Contact
	Diastolic Dysfunction
	Dyspepsia
	Dyspnoea
	Electrocardiogram Qrs Complex Abnormal
	Electrocardiogram T Wave Inversion
	Gastrooesophageal Reflux Disease
	Hypocoagulable State
	Impetigo

		International Normalised Ratio Increased					
		Interstitial Lung Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Limb Traumatic Amputation		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Infiltration		Coumadin	C		
UNKNOWN							
		Lung Injury		[Therapy			
		Lupus-Like Syndrome		Unspecified]	C		
UNKNOWN							
		Mental Status Changes		Aspirin	C		
UNKNOWN							
		Obstructive Airways		Wellbutrin	C		
UNKNOWN							
		Disorder		Prednisone	C		
UNKNOWN							
		Oedema Peripheral		Compazine	C		
UNKNOWN							
		Pleuritic Pain		Oxycontin	C		
UNKNOWN							
		Pneumonia		Aciphex	C		
UNKNOWN							
		Pulmonary Embolism					
		Pulmonary Fibrosis					
		Pulmonary Infarction					
		Rash Pruritic					
		Reiter'S Syndrome					
		Systemic Lupus					
		Erythematosus					
		Vasculitis					

Date:06/27/05ISR Number: 4700338-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02169
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
MON							
				Vioxx	SS	Merck & Co., Inc	ORAL
57	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
MON							
				Vioxx	SS	Merck & Co., Inc	ORAL
57	MON						

Date:06/27/05ISR Number: 4700339-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02686
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		169 DAY
Disability	Myocardial Infarction		Prednisone	C				UNKNOWN
			Singulair	C				UNKNOWN
			Flonase	C				UNKNOWN

Date:06/27/05ISR Number: 4700340-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02939
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700341-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00185
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700342-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:06/27/05ISR Number: 4700622-4Report Type:Expedited (15-DaCompany Report #2005089425
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Hemianopia Homonymous	Foreign	Celecoxib					
	Pulmonary Embolism	Health	(Celecoxib)	PS		ORAL	200 MG (100 MG, 2 IN 1 D), ORAL	
		Professional						
			Rofecoxib (Rofecoxib)	SS		ORAL	25 MG (25 MG, 1 IN 1 D), ORAL	
			Clopidogrel (Clopidogrel)	C				
			Levothyroxine (Levothyroxine)	C				
			Methotrexate (Methotrexate)	C				
			Folic Acid (Folic Acid)	C				
			Prednisolone (Prednisolone)	C				

Date:06/27/05ISR Number: 4700642-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03300
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700643-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03303
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700644-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03301
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700645-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03296
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Pravachol	C				
			Diovan	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700646-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03082
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Pulmonary Thrombosis Thrombosis		Vioxx Synthroid Vitamins (Unspecified)	PS C C	Merck & Co., Inc	ORAL	UNKNOWN	UNKNOWN

Date:06/27/05ISR Number: 4700647-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03302
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700648-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02949
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700650-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03064
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acne Cystic		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL	15 MON	
Other	Alopecia Drug Hypersensitivity Irritable Bowel Syndrome Menorrhagia Photosensitivity Reaction Pulmonary Embolism							

Date:06/27/05ISR Number: 4700651-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700655-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Bronchitis
Other	Bursitis
	Carpal Tunnel Syndrome
	Cervicobrachial Syndrome
	Chronic Obstructive Pulmonary Disease
	Contusion
	Cough
	Depression
	Drug Ineffective
	Dyspepsia

		Dysthymic Disorder					
		Fall					
		Fibromyalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gravitational Oedema		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Increased Tendency To		Vioxx	SS	Merck & Co., Inc	ORAL
		Bruise		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Lower Respiratory Tract		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Migraine		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteopenia		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Radius Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Analgesic Or			
		Rotator Cuff Syndrome		Anesthetic			
		Sinusitis		(Unspecified)	C		
UNKNOWN							
		Spinal Osteoarthritis		Premarin	C		
UNKNOWN							
		Stress		[Therapy			
		Tendonitis		Unspecified]	C		
UNKNOWN							
		Urinary Tract Infection		Neurontin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Calcium Carbonate	C		
UNKNOWN							
				Aspirin	C		ORAL
				Paxil	C		ORAL
				Elavil	C		ORAL
				Oxycontin	C		
UNKNOWN							

			Vicodin Tablets	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						

Date:06/27/05ISR Number: 4700656-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02333
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		17 MON
Disability	Cerebrovascular Accident		Claritin	C		ORAL		
Other	Chronic Obstructive		Ventilan (Albuterol)	C				
RESPIRATORY								
	Pulmonary Disease							
(INHALATION)								
	Lumbar Spinal Stenosis							
	Prescribed Overdose							
	Staphylococcal Infection							
	Transient Ischaemic							
	Attack							

Date:06/27/05ISR Number: 4700657-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03233
Age:41 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Back Injury
	Blood Cholesterol
	Increased

Cardiac Disorder
Carotid Artery Stenosis
Chest Pain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Disease					
	Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
	Dizziness					
	Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Electrocardiogram St					
	Naproxen	C			UNKNOWN	32 YR
	Segment Depression					
	Naproxen	C			UNKNOWN	31 DAY
	Electrocardiogram T Wave					
	Naproxen	C			UNKNOWN	32 DAY

Inversion
Hernia
Hyperglycaemia
Hypertension
Hypertriglyceridaemia
Intervertebral Disc
Disorder
Myocardial Infarction
Vertigo

Date:06/27/05ISR Number: 4700658-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01018
Age:61 YR Gender:Male I/FU:F

Outcome
Hospitalization - Initial or Prolonged
Disability

PT
Abscess Jaw
Angina Pectoris
Anxiety
Blood Cholesterol Increased
Blood Creatine Phosphokinase Increased
Cardiac Murmur
Carotid Artery Stenosis
Chest Discomfort
Coronary Artery Disease
Depression
Dizziness
Drug Hypersensitivity
Duodenal Ulcer
Duodenal Ulcer
Haemorrhage

Duodenitis
Food Poisoning
Gastroenteritis
Gastrointestinal
Haemorrhage
Gout
Gouty Arthritis
Haematocrit Decreased
Haemoglobin Decreased
Hypertension
Hypovolaemia
Joint Swelling
Loss Of Consciousness
Musculoskeletal Stiffness
Myocardial Infarction
Nervousness
Oedema Peripheral
Oesophageal Disorder
Osteoarthritis
Otitis Media
Overdose

		Pain In Extremity Peptic Ulcer Haemorrhage Sinus Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Somnolence		Vioxx	PS	Merck & Co., Inc	ORAL
846	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
846	DAY						
				Vicodin Tablets	C		
UNKNOWN							
				Covera	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Trimox	C		
UNKNOWN							
				Relafen	C		
UNKNOWN		2	MON				
				[Therapy Unspecified]	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							

Date:06/27/05ISR Number: 4700659-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02351
Age:35 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
20	DAY						
Initial or Prolonged		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
20	DAY						
Other		Cardiovascular Disorder		Motrin	C		
UNKNOWN							
		Cerebrovascular Accident		Tylenol	C		
UNKNOWN							
		Depression Dyspnoea Hypertension		Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							
		Migraine Muscle Spasms					

Myocardial Infarction
Renal Disorder
Stress
Vision Blurred

Date:06/27/05ISR Number: 4700660-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700661-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01156
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Zestril	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Norvasc	C			UNKNOWN	

Date:06/27/05ISR Number: 4700662-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00659
Age:56 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Abdominal Pain Upper
Hospitalization - Initial or Prolonged	Cardiac Disorder
	Depressed Mood
Disability	Gastric Ulcer
	Gastric Ulcer Haemorrhage

		Gastritis					
		Helicobacter Pylori Identification Test	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Positive		Vioxx	PS	Merck & Co., Inc	ORAL
		Inadequate Analgesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Metoprolol Tartrate	C		ORAL
		Reflux Oesophagitis		Tolperisone Hydrochloride	C		ORAL
		Sinus Tachycardia		Amitriptyline Hydrochloride	C		ORAL
		Syncope		Pantoprazole Sodium	C		ORAL
		Therapeutic Response Decreased		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C		
		Therapy Non-Responder		Citalopram Hydrobromide	C		
UNKNOWN							
UNKNOWN							

Date:06/27/05ISR Number: 4700663-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03399
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/27/05ISR Number: 4700664-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00773
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 50 MON	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 1657 DAY	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Cardiac Disorder		Zestril	C		
UNKNOWN	Cardiac Failure		Zestril	C		
	Congestive Coronary Artery Disease Diabetes Mellitus					

Epistaxis
Febrile Infection
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Myocardial Infarction
Osteoporosis
Pelvic Fracture
Upper Limb Fracture

Date:06/27/05ISR Number: 4700665-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01713
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anoxic Encephalopathy
Disability	Cerebrovascular Accident
	Convulsion
	Deep Vein Thrombosis
	Depression
	Dyspepsia
	Heart Rate Decreased
	Heart Rate Irregular
	Neck Pain

		Pain Syncope					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Rebetol	C		
UNKNOWN							
				Rebetol	C		
UNKNOWN							
				Mobic	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							
				Rebetron	C		
UNKNOWN							
				Rebetron	C		
UNKNOWN							
				Interferon (Unspecified)	C		
UNKNOWN							
				Interferon (Unspecified)	C		
UNKNOWN							

Date:06/27/05ISR Number: 4700666-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04210
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Unstable		Tylenol	C		
UNKNOWN						
	Brain Stem Infarction		Metformin Hydrochloride	C		
	Coronary Artery Disease					
UNKNOWN						
	Headache		Atenolol Msd	C		ORAL
3 YR						
	Hypertension		Plavix	C		ORAL
	Myocardial Infarction		Zocor	C		ORAL
	Myocardial Ischaemia		Naprosyn	C		
UNKNOWN						
	Nausea		Prempro	C		
UNKNOWN						

	Oedema Peripheral	Lupron	C
UNKNOWN	3 YR		
	Rhinorrhoea	Ginseng	C
UNKNOWN			
		Ginkgo Biloba Extract	C
UNKNOWN			
		Hypericin	C
UNKNOWN			
		Glucotrol	C
UNKNOWN			

Date:06/27/05ISR Number: 4700667-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03479
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Asthenia
	Asthma
	Calcinosis
	Cataract
	Cerebrovascular Accident
	Confusional State
	Dizziness
	Dysarthria
	Dyspnoea
	Dyspnoea Exertional
	Ear Discomfort
	Ear Pain
	Electrocardiogram T Wave Inversion
	Haemorrhage Intracranial
	Headache
	Hot Flush
	Hyperhidrosis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Hypertension Hypoacusis Hypoaesthesia					
		Inner Ear Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Labyrinthitis		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Memory Impairment		Buspar	C		
UNKNOWN		Mitral Valve Prolapse		Desyrel	C		
UNKNOWN		Muscle Spasms		Celexa	C		
UNKNOWN		Nasal Congestion		Celexa	C		
UNKNOWN		Palpitations		Lexapro	C		
UNKNOWN		Paralysis		Lexapro	C		
UNKNOWN		Sensory Disturbance		Ogen	C		
UNKNOWN		Transient Ischaemic		Prevacid	C		
UNKNOWN		Attack		Prevacid	C		
UNKNOWN		Vaginal Infection		Protonix	C		
UNKNOWN		Vaginal Mycosis		Protonix	C		
UNKNOWN		Vertigo Positional		Nexium	C		
UNKNOWN				Nexium	C		
UNKNOWN				Allegra	C		
UNKNOWN				Dyazide	C		
UNKNOWN				Dyazide	C		
UNKNOWN				Midamor	C		
UNKNOWN				Atenolol Msd	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Lipitor	C		
UNKNOWN							

			Zelnorm	C		
UNKNOWN						
			Lotensin	C		
UNKNOWN		63 DAY				
			Estradiol	C		
UNKNOWN		1828 DAY				
			Inderal	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

Date:06/27/05ISR Number: 4700668-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00995
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cor Pulmonale		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
Initial or Prolonged	Diarrhoea		Verapamil	C				
UNKNOWN								
	Faecal Occult Blood		Roxicet	C				
UNKNOWN								
	Positive		Dexamethasone	C				
UNKNOWN								
	Infarction		Anzemet	C				
UNKNOWN								
	Prostate Cancer Recurrent		Emcyt	C				
UNKNOWN								
	Pulmonary Embolism		Prochlorperazine	C				
UNKNOWN								
	Thrombosis		Norvasc	C				
UNKNOWN								
			Flutamide	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								
			Oxycodone	C				
UNKNOWN								
			Duragesic	C				
UNKNOWN								
			Iron (Unspecified)	C				
UNKNOWN								
			Promethazine	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Msir	C				
UNKNOWN								
			Antineoplastic					

(Unspecified) C

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700669-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01731
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Protonix	C				
UNKNOWN								
Disability	Cardiac Disorder		[Therapy Unspecified]	C				
	Chest Pain							
SUBLINGUAL								
	Coronary Artery Disease							
	Myocardial Infarction							
	Platelet Count Decreased							
	Post Procedural Pain							

Date:06/27/05ISR Number: 4700670-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02610
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
Initial or Prolonged	Blood Cholesterol		Femhrt	C				
UNKNOWN							12 MON	
Disability	Increased		Femhrt	C				
UNKNOWN							12 MON	
	Cerebrovascular Accident		Aleve	C				
UNKNOWN								
	Dyspnoea		Zoloft	C				
UNKNOWN							1 MON	
	Gastrooesophageal Reflux Disease		Vitamins (Unspecified)	C				
UNKNOWN								
			Calcium (Unspecified)	C				
UNKNOWN								

Date:06/27/05ISR Number: 4700671-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00114
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/27/05ISR Number: 4700672-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01685
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
Other	Anxiety
	Arteriovenous Fistula Thrombosis
	Cardiac Failure Congestive
	Chest Pain
	Clostridium Colitis
	Dialysis
	Drug Hypersensitivity
	Faeces Discoloured
	Fluid Overload
	Gastrointestinal Haemorrhage
	Graft Thrombosis
	Gynaecomastia
	Hernia
	Hypertensive Crisis
	Hypertensive Emergency
	Latex Allergy
	Medical Device Complication

		Non-Cardiac Chest Pain Peritoneal Disorder Pleuritic Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pneumonia		Vioxx	PS	Merck & Co., Inc	ORAL
13	MON						
		Pulmonary Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
13	MON						
		Pulmonary Oedema		Avandia	C		
UNKNOWN							
		Thrombosis		Lopressor	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Famvir	C		
UNKNOWN							
				Cozaar	C		ORAL
				Diatx	C		
UNKNOWN							
				Duricef	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Nephro-Vite Rx	C		
UNKNOWN							
				Temazepam	C		
UNKNOWN							
				Amoxicillin And Clavulanate Potassium	C		
UNKNOWN							
				Minoxidil 2%	C		
UNKNOWN							
				Metronidazole	C		
UNKNOWN							
				Endocet	C		
UNKNOWN							
				Labetalol Hydrochloride	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		ORAL
				Acetaminophen And Propoxyphene			

		Napsylate	C	
UNKNOWN				
		Diphenhydramine Hydrochloride	C	
UNKNOWN				
		Pravachol	C	
UNKNOWN				
		Aspirin	C	ORAL
		Heparin	C	
UNKNOWN				
		Carbidopa And Levodopa	C	ORAL
		Colchicine	C	
UNKNOWN				
		Calcitriol	C	
UNKNOWN				
		Bextra	C	
UNKNOWN	15 DAY			
		Tylenol	C	
UNKNOWN				
		Levaquin	C	
UNKNOWN				
		Norvasc	C	
UNKNOWN	1333 DAY			
		Lipitor	C	
UNKNOWN	1093 DAY			
		Docusate Sodium	C	
UNKNOWN				
		Allopurinol	C	ORAL
		Prednisone	C	ORAL
		Phoslo	C	
UNKNOWN				
		Nifedipine	C	ORAL
		Zithromax	C	
UNKNOWN				
		Clindamycin	C	
UNKNOWN				
		Triamcinolone Acetonide	C	
UNKNOWN				

Date:06/27/05ISR Number: 4700673-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00666
Age:43 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Joint Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/27/05ISR Number: 4700674-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00087
Age:86 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Emotional Distress		Percocet	C				
UNKNOWN								
	Loss Of Consciousness		Ativan	C				
UNKNOWN								

Date:06/27/05ISR Number: 4700678-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00567
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
662 DAY								
Initial or Prolonged	Gastrooesophageal Reflux		Simvastatin	C		ORAL		
Other	Disease							
	Hypertension							
	Myocardial Infarction							
	Oedema Peripheral							

Date:06/27/05ISR Number: 4700679-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03806
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	20 MON	
	Migraine		Verapamil	C			UNKNOWN	
	Myocardial Infarction		Fosamax	C			UNKNOWN	
	Pain		Hyoscyamine	C			UNKNOWN	
	Pain In Extremity							

Date:06/27/05ISR Number: 4700680-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02696
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR	
Initial or Prolonged	Diplopia		Zyrtec	C			UNKNOWN	
	Hemiparesis		Nasacort	C			UNKNOWN	
	Hypertension		[Therapy					
	Hypoaesthesia Oral		Unspecified]	C			UNKNOWN	
	Nausea		Motrin	C		ORAL		
	Sialoadenitis		Cipro	C			UNKNOWN	
	Vertigo		Diflucan	C			UNKNOWN	
	Vomiting		Naproxen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700681-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02936
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	17 MON	
			Aspirin	C			UNKNOWN	
			Diovan	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Plavix	C			UNKNOWN	

Date:06/27/05ISR Number: 4700682-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02750
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	55 MON	
Initial or Prolonged	Infarction		Zocor	C		ORAL		
	Angina Pectoris		Tenormin	C		ORAL		
	Aortic Stenosis		Maxzide	C		ORAL		
	Arthralgia							
	Atrioventricular Block First Degree							
	Carpal Tunnel Syndrome							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Deformity							
	Depression							
	Dyspepsia							
	Electrocardiogram St-T Change							
	Flatulence							
	Gastrooesophageal Reflux Disease							
	Haematoma Infection							
	Herpes Simplex							
	Hypertension							

Major Depression
Neuropathy
Neuropathy Peripheral
Sinus Bradycardia
Tricuspid Valve Sclerosis
Urinary Tract Infection

Date:06/27/05ISR Number: 4700683-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00100
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Discomfort
	Acute Myocardial Infarction
	Anaemia
	Angina Pectoris
	Anhedonia
	Anxiety
	Arteriovenous Malformation
	Cardiac Failure Congestive
	Carpal Tunnel Syndrome
	Catheter Site Haemorrhage

		Coronary Artery Disease					
		Depression					
		Drug Effect Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Ineffective		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
79	DAY						
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
79	DAY						
		Gastrooesophageal Reflux		Nexium	C		
UNKNOWN							
		Disease		Darvocet-N	C		
UNKNOWN							
		Haematochezia		Psorcon	C		
UNKNOWN							
		Haematocrit Decreased		Atenolol	C		
UNKNOWN		1463 DAY					
		Haemorrhage					
		Hypercholesterolaemia					
		Hypoaesthesia					
		Hypotension					
		International Normalised					
		Ratio Increased					
		Intracardiac Thrombus					
		Labyrinthitis					
		Myocardial Infarction					
		Pain					
		Pericardial Effusion					
		Post Procedural					
		Complication					
		Procedural Hypotension					
		Ventricular Hypertrophy					
		Vertigo					
		Wrist Fracture					

Date:06/27/05ISR Number: 4700684-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02885
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Antimicrobial		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR						
Initial or Prolonged		Susceptibility Test					
Disability		Resistant					

Anxiety Disorder
Bladder Disorder
Blood Cholesterol
Increased
Blood Pressure
Fluctuation
Cardiac Murmur
Cerebrovascular Accident
Depression
Fistula
Insomnia
Renal Mass

Date:06/27/05ISR Number: 4700687-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02797
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700688-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02715
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		736 DAY
Hospitalization - Initial or Prolonged	Bacterial Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Morphine	C			UNKNOWN	6 MON
	Congestive		Duragesic	C			UNKNOWN	4 MON
	Cerebrovascular Accident		Furosemide	C			UNKNOWN	
	Coronary Artery Disease		Altace	C			UNKNOWN	1074 DAY
	Diabetes Mellitus		Nortriptyline	C			UNKNOWN	
	Ear Infection		Sulfatrim	C			UNKNOWN	
	Lower Respiratory Tract		Cephalexin	C			UNKNOWN	
	Infection		Triamcinolone	C			UNKNOWN	
	Psoriasis		Lidoderm	C			UNKNOWN	28 MON
			Trimox	C			UNKNOWN	
			Zithromax	C			UNKNOWN	
			Xenical	C			UNKNOWN	
			Cipro	C			UNKNOWN	
			Zaroxolyn	C			UNKNOWN	
			Clobetasol Propionate	C			UNKNOWN	
			Serzone	C			UNKNOWN	111 DAY
			Neurontin	C			UNKNOWN	4 MON
			Lipitor	C			UNKNOWN	156 DAY
			Ambien	C			UNKNOWN	

			Effexor Xr	C
UNKNOWN	300	DAY		
			Dovonex	C
UNKNOWN				
			Vanceril	C
UNKNOWN				
			Metoprolol	C
UNKNOWN	1068	DAY		
			Potassium (Unspecified)	C
UNKNOWN				
			Methadone Hydrochloride	C
UNKNOWN	4	MON		
			Premarin	C
UNKNOWN				
			Temazepam	C
UNKNOWN	6	DAY		

Date:06/27/05ISR Number: 4700690-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00063
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Reocclusion		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL		
	Protrusion		Valdecoxib	SS		ORAL		
	Ligament Disorder		Clopidogrel					
	Myocardial Infarction		Bisulfate	C				
UNKNOWN								
			Magnesium (Unspecified)	C				
UNKNOWN								
			Spironolactone	C				
UNKNOWN								
			Saw Palmetto	C				
UNKNOWN								
			Fosinopril Sodium And Hydrochlorothiazide	C				
UNKNOWN								
			Mesalamine	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4700691-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01840
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Chest Sound		Vioxx	PS	Merck & Co., Inc	ORAL		1124 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1124 DAY
Other	Asthma		Zocor	C		ORAL		
	Cardiac Failure		Zantac	C				UNKNOWN
	Congestive		Monopril	C		ORAL		
	Cataract		Furosemide	C				UNKNOWN
	Coronary Artery Disease		Azmacort	C				UNKNOWN
	Coronary Artery Occlusion		Zyrtec	C				UNKNOWN
	Coronary Artery Stenosis							
	Cough							
	Dilatation Atrial							
	Dyspnoea							
	Dyspnoea Exertional							
	Essential Hypertension							
	Genital Lesion							
	Genital Rash							
	Gout							
	Groin Pain							
	Haemorrhoids							
	Herpes Simplex							
	Hypercholesterolaemia							
	Injury							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Oedema Peripheral							
	Rash							
	Tricuspid Valve Incompetence							
	Triple Vessel Bypass Graft							
	Ventricular Dysfunction							

Date:06/27/05ISR Number: 4700692-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04209
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bacterial Infection		Vioxx	PS	Merck & Co., Inc	ORAL		882 DAY
Initial or Prolonged	Cerebrovascular Accident		Norvasc	C				UNKNOWN
Other	Chest Pain		Hydrocodone/Apap	C				UNKNOWN
	Hypersensitivity		Cyclobenzaprine Hydrochloride	C		ORAL		
	Transient Ischaemic Attack		Celebrex	C				UNKNOWN
			Metoprolol	C				UNKNOWN

Date:06/27/05ISR Number: 4700693-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01836
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Disorder
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chronic Obstructive
	Pulmonary Disease
	Fall

		Food Poisoning					
		Haemorrhage Intracranial					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteopenia		Persantine	C		
UNKNOWN							
		Spinal Compression		Folic Acid	C		
UNKNOWN							
		Fracture		Vitamins (Unspecified)	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN		7563 DAY					
				Darvocet-N	C		
UNKNOWN							

Date:06/27/05ISR Number: 4700694-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03450
Age:46 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
2 YR							
		Acute Myocardial		Loestrin	C		
UNKNOWN							
		Infarction		Tenormin	C		
UNKNOWN							
		Arteriosclerosis		Protonix	C		
UNKNOWN							
		Back Pain		Tums	C		
UNKNOWN							
		Dyspnoea		Aspirin	C		
UNKNOWN							
		Gastrooesophageal Reflux		Mylanta & Mylanta Ds	C		
UNKNOWN							
		Disease		Toprol Xl Tablets	C		
UNKNOWN							
		Interstitial Lung Disease					
		Pulmonary Congestion					
		Pulmonary Oedema					

Date:06/27/05ISR Number: 4700695-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03512
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiomyopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Lipitor	C				
Disability	Coronary Artery Disease		Excedrin (Acetaminophen (+) Caffeine)	C				
	Myocardial Infarction		Premarin	C				
			Avalide	C				

Date:06/27/05ISR Number: 4700702-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02725
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Aspirin	C				
Other	Drug Hypersensitivity		Aleve	C				
	Dyspnoea		Motrin	C				
	Gastrointestinal Disorder							
	Gout							
	Haematochezia							
	Hypertension							
	Myocardial Infarction							
	Nephrolithiasis							
	Oedema Peripheral							
	Overdose							

Date:06/28/05ISR Number: 4701243-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01886
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Celebrex	C			UNKNOWN	
	Increased		Celebrex	C			UNKNOWN	
	Blood Triglycerides Increased							
	Cardiac Disorder							
	Cardiac Failure Congestive							
	Coronary Artery Disease							
	Depression							
	Post-Traumatic Stress Disorder							

Date:06/28/05ISR Number: 4701246-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01726
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	17 MON	
	Head Injury							
	Overdose							

Date:06/28/05ISR Number: 4701247-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01737
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	25 MON	
Initial or Prolonged	Infarction		Pravachol	C			UNKNOWN	
Disability	Angina Pectoris		Pravachol	C			UNKNOWN	
Other	Anhedonia							
	Arthritis							

	Blood Cholesterol Increased
	Carpal Tunnel Syndrome
	Coronary Artery Disease
	Hypertension
	Myalgia
	Pain
	Trigger Finger

Date:06/28/05ISR Number: 4701248-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02334
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial Infarction
Hospitalization - Initial or Prolonged	Cardiac Valve Disease
Other	Cardio-Respiratory Arrest
	Eye Haemorrhage
	Loss Of Consciousness
	Myocardial Ischaemia
	Neuropathy
	Oedema
	Rhinorrhoea
	Skin Fissures
	Tachyarrhythmia

Ventricular Fibrillation

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Reglan	C			UNKNOWN	
	Procardia Xl	C			UNKNOWN	
	Procardia Xl	C			UNKNOWN	
	Tegretol	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Zantac	C			UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Lasix (Furosemide)	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Elavil	C		ORAL		
	Paxil	C			UNKNOWN	
	Tums	C			UNKNOWN	

Date:06/28/05ISR Number: 4701251-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00478
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Alopecia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Prilosec	C			UNKNOWN	
	Coronary Artery Disease		Amitriptyline Hydrochloride	C			UNKNOWN	
	Depression							
	Dyspnoea		Aspirin	C			UNKNOWN	

	Gastritis		Pentoxifylline	C		
UNKNOWN						
	Iliac Artery Thrombosis					
	Joint Sprain					
	Myocardial Infarction					
	Pericarditis					
	Peripheral Vascular Disorder					
	Post-Traumatic Stress Disorder					
	Pulmonary Hypertension					

Date:06/28/05ISR Number: 4701253-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0502NOR00007
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		807 DAY
			Etidronate Disodium	C		ORAL		
			Methotrexate	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								
			Cyanocobalamin	C				
UNKNOWN								
			Esomeprazole Magnesium	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Zopiclone	C				
UNKNOWN								
			Bumetanide	C		ORAL		

Date:06/28/05ISR Number: 4701255-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00402
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adjustment Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		144 MON
Initial or Prolonged	Adrenal Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		144 MON
Disability	Aneurysm		Amitriptyline Hydrochloride	C				UNKNOWN
	Cerebrovascular Accident		Meclizine	C				UNKNOWN
	Chronic Obstructive Pulmonary Disease		Darvocet-N	C				UNKNOWN
	Colonic Polyp							
	Complex Regional Pain Syndrome							
	Depression							
	Diverticulum							
	Dizziness							
	Emotional Distress							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Joint Dislocation							
	Large Cell Carcinoma Of The Respiratory Tract Stage Unspecified							
	Myocardial Infarction							
	Pneumothorax							
	Stress							
	Stress Incontinence							
	Ventricular Extrasystoles							

Date:06/28/05ISR Number: 4701257-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00110
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Biopsy		Vioxx	SS	Merck & Co., Inc	ORAL		

	Cardiac Disorder	Aspirin	C
UNKNOWN			
	Carotid Artery Stenosis	Aspirin	C
UNKNOWN			
	Coronary Artery Disease	Lipitor	C
UNKNOWN			
	Oedema Peripheral	Prilosec	C
UNKNOWN			
	Transient Ischaemic Attack	Armour Thyroid Tablets	C
UNKNOWN			
	Ventricular Tachycardia	Ambien	C
UNKNOWN			
		Diazepam	C
UNKNOWN			
		Folic Acid	C
UNKNOWN			
		Timoptic	C
OPHTHALMIC			
		Viagra	C
UNKNOWN			
		Verapamil	C
UNKNOWN			

Date:06/28/05ISR Number: 4701259-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02866
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Coronary Artery Disease Emotional Distress Gout Hypertension Malignant Melanoma Myocardial Infarction

Thrombolysis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Morphine	C			INTRAVENOUS	
				DRIP		
	Lorcet 10/650	C			UNKNOWN	
	Soma	C			UNKNOWN	
	Restoril	C			UNKNOWN	
	Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Zantac	C			UNKNOWN	
	Testosterone	C			PARENTERAL	

Date:06/28/05ISR Number: 4701260-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02048
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 597 DAY	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Toprol Xl Tablets	C			UNKNOWN	
Other	Cardiac Disorder		Metoprolol	C			UNKNOWN	
	Cardiac Failure		Cardura	C			UNKNOWN	939 DAY
	Congestive		Aspirin	C			UNKNOWN	
	Chest Pain		Prevacid	C			UNKNOWN	
	Coronary Artery Disease		Quinine Sulfate	C			UNKNOWN	

	Coronary Artery Occlusion		Cyclobenzaprine			
	Depression		Hydrochloride	C		
UNKNOWN						
	Dyslipidaemia		Hydrocodone			
	Feeling Abnormal		Bitartrate	C		
UNKNOWN						
	Gastric Ulcer		Levaquin	C		
UNKNOWN						
	Gastrooesophageal Reflux		Prilosec	C		
UNKNOWN						
	Disease		Zithromax	C		
UNKNOWN						
	Gout		Flonase	C		
UNKNOWN						
	High Density Lipoprotein		Oxycodone	C		
UNKNOWN						
	Decreased		Diazepam	C		
UNKNOWN						
	Hypertension		Pacerone	C		
UNKNOWN						
	Infection		Zocor	C		
UNKNOWN	149 DAY					
	Insomnia					
	Ischaemia					
	Malaria					
	Myocardial Infarction					
	Pneumonia					
	Transient Ischaemic Attack					

Date:06/28/05ISR Number: 4701261-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04199
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 10 MON	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Increased		Synthroid	C		
UNKNOWN						
	Dyspepsia		Tylenol	C		
UNKNOWN						
	Haemorrhage					
	Myocardial Infarction					
	Sleep Apnoea Syndrome					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701262-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02344
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Mass		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Metoprolol	C				
UNKNOWN								
	Cerebrovascular Accident		Diovan	C				
UNKNOWN								
	Depression							
	Diverticulum Intestinal							
	Facial Palsy							
	Fall							
	Gout							
	Gouty Arthritis							
	Haemorrhoids							
	Hypercholesterolaemia							
	Hyperglycaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypertriglyceridaemia							
	Joint Sprain							
	Lacunar Infarction							
	Mental Disorder							
	Musculoskeletal Chest							
	Pain							
	Shoulder Pain							

Date:06/28/05ISR Number: 4701263-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01788
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
1722 DAY								
Initial or Prolonged	Cerebrovascular Accident		Percocet	C				
UNKNOWN								
	Chest Pain							
	Depression							
	Gastric Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Oesophageal Disorder							

Panic Disorder

Date:06/28/05ISR Number: 4701264-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02573
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Antinuclear Antibody Positive
Disability	Aortic Aneurysm
Other	Aortic Dilatation
	Aortic Stenosis
	Aortic Thrombosis
	Aortic Valve Calcification
	Aortic Valve Incompetence
	Cardiac Disorder
	Carotid Artery Stenosis
	Cerebral Ischaemia
	Cerebrovascular Accident
	Chest Pain
	Chronic Fatigue Syndrome

		Cognitive Disorder					
		Coronary Artery Disease					
		Dehydration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Delirium		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Toxicity		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Epistaxis		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Coumadin	SS		
UNKNOWN							
		Gastrointestinal Disorder		Aspirin	C		
UNKNOWN							
		Generalised Anxiety		Xanax	C		
UNKNOWN							
		Disorder		Valium	C		
UNKNOWN							
		Gout		Effexor	C		
UNKNOWN							
		Haemodynamic Instability					
		Hyperhidrosis					
		Hypertensive Heart					
		Disease					
		Hypoaesthesia					
		Loss Of Consciousness					
		Migraine					
		Migraine Without Aura					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Myocardial Ischaemia					
		Nausea					
		Neck Pain					
		Non-Cardiac Chest Pain					
		Pain In Extremity					
		Panic Disorder					
		Pulmonary Valve					
		Incompetence					
		Rhinorrhoea					
		Sinusitis					
		Somnolence					
		Syncope					
		Thrombosis					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					

Ventricular Extrasystoles
Ventricular Hypertrophy
Vision Blurred
Visual Acuity Reduced

Date:06/28/05ISR Number: 4701265-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01709
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
	Anxiety
	Asthma
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Cellulitis
	Chest Pain
	Coronary Artery

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Atherosclerosis					
		Dehydration					
		Depression					
		Diabetes Mellitus					
		Haematuria		Vioxx	PS	Merck & Co., Inc	ORAL
		Hand Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Darvocet-N	C		
UNKNOWN							
		Hypertriglyceridaemia		Bumex	C		
UNKNOWN							
		Leukocytosis		Proventil	C		
RESPIRATORY							
		Lung Neoplasm					
(INHALATION)							
		Myocardial Infarction		Flovent	C		
RESPIRATORY							
		Non-Cardiac Chest Pain					
(INHALATION)							
		Pulmonary Embolism		Xanax	C		
UNKNOWN							
		Ventricular Arrhythmia		Valium	C		
UNKNOWN							
		Wound		Valium	C		
UNKNOWN							
				Valium	C		
UNKNOWN							
				Fluticasone Propionate	C		
RESPIRATORY							
(INHALATION)							
				Flomax (Morniflumate)	C		
UNKNOWN							
				Ventolin (Albuterol Sulfate)	C		
UNKNOWN							
				Beconase	C		
UNKNOWN							
				Prinivil	C		ORAL
				Verapamil Msd Lp	C		ORAL
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							

			Tylenol	C		
UNKNOWN						
			Propoxyphene Hydrochloride	C		
UNKNOWN						
			Imdur	C		
UNKNOWN	547 DAY					
			Nitrostat	C		
UNKNOWN						
			Warfarin Sodium	C		
UNKNOWN						

Date:06/28/05ISR Number: 4701266-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04383
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cardiac Disorder		Diovan	C		
UNKNOWN						
Initial or Prolonged			Cardizem	C		
UNKNOWN						
Disability			Crestor	C		
UNKNOWN						

Date:06/28/05ISR Number: 4701267-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03344
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fibula Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Pain In Extremity		Aspirin	C		ORAL
	Thrombosis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701268-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03846
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		46 MON
Initial or Prolonged	Aortic Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		46 MON
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Lipitor	C				UNKNOWN
	Fall		Vitamins					
	Haemorrhoids		(Unspecified)	C				UNKNOWN
	Oedema Peripheral		Detrol	C				UNKNOWN
	Rash Maculo-Papular		Lasix (Furosemide)	C				UNKNOWN
	Renal Failure							
	Retinopathy Hypertensive							
	Road Traffic Accident							
	Spinal Laminectomy							

Date:06/28/05ISR Number: 4701269-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04218
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		406 DAY
Initial or Prolonged	Cerebrovascular Accident		Vasotec	C				UNKNOWN
Disability	Eye Haemorrhage		Prempro	C				UNKNOWN
	Hypertension		Prempro	C				UNKNOWN
	Myocardial Infarction		Prempro	C				UNKNOWN
			Prempro	C				UNKNOWN
			Apap	C				UNKNOWN

			Tylenol	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

Date:06/28/05ISR Number: 4701270-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05000
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 769 DAY	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 769 DAY	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Chronic Obstructive		Protonix	C		
UNKNOWN						
	Airways Disease		Protonix	C		
UNKNOWN						
	Exacerbated		Norvasc	C		
UNKNOWN						
	Chronic Obstructive		Micardis	C		
UNKNOWN						
	Pulmonary Disease		Actonel	C		
UNKNOWN						
	Epistaxis		Mirtazapine	C		
UNKNOWN						
	Haemorrhage					
	Hypoxia					

Date:06/28/05ISR Number: 4701271-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02024
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					

Date:06/28/05ISR Number: 4701272-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00380
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701273-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00384
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701275-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03327
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:06/28/05ISR Number: 4701276-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03328
Age:87 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:06/28/05ISR Number: 4701277-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Lung Disorder Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Pain

Date:06/28/05ISR Number: 4701278-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03183
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Polytraumatism Unevaluable Event		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701279-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01831
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		144 DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		144 DAY
Disability			Valium	C				UNKNOWN
Other			[Therapy Unspecified]	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701280-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04222
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		885 DAY
Initial or Prolonged	Increased		Acetaminophen And					
Disability	Cardiac Failure		Propoxyphene					
	Congestive		Napsylate	C				UNKNOWN
	Dyspepsia							
	Gastrooesophageal Reflux							
	Disease							
	Haemorrhage							
	Hypertension							
	Myocardial Infarction							
	Ulcer							

Date:06/28/05ISR Number: 4701281-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701282-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02997
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Sclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Initial or Prolonged	Blood Creatinine		Toprol Xl Tablets	C				UNKNOWN
Disability	Increased		Coreg	C				UNKNOWN
Other	Blood Pressure Increased		Aspirin	C		ORAL		
	Blood Urea Increased		Zocor	C				UNKNOWN
	Carotid Artery Occlusion		Lipitor	C				UNKNOWN
	Carotid Artery Thrombosis							

Cerebral Artery Occlusion
Cerebral Infarction
Cerebrovascular Accident
Cough
Dilatation Atrial
Intervertebral Disc
Protrusion
Lacunar Infarction
Mitral Valve Incompetence
Nerve Root Compression
Nerve Root Lesion
Pulmonary Mass
Pulmonary Valve
Incompetence
Spinal Cord Compression
Tricuspid Valve
Incompetence
Ventricular Hypokinesia

Date:06/28/05ISR Number: 4701283-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03056
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Eye Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON
			[Therapy Unspecified]	C				

UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701284-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02136
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Lescol	C				
Other	Malaise		Verapamil Msd Lp	C				
	Myocardial Infarction		Flomax (Morniflumate)	C				
			Bextra	C				
			[Therapy Unspecified]	C				

Date:06/28/05ISR Number: 4701286-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02800
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:06/28/05ISR Number: 4701291-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03456
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701292-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03403
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Death		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						
Other	Myocardial Infarction					

Date:06/28/05ISR Number: 4701293-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03065
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Discomfort					
	Chest Pain					
	Coronary Artery Occlusion					
	Dyspnoea					
	Extrasystoles					
	Mood Altered					
	Nervousness					
	Oedema Peripheral					
	Pain					
	Swelling Face					

Date:06/28/05ISR Number: 4701295-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03408
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701298-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03330
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:06/28/05ISR Number: 4701299-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03572
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Other	Myocardial Infarction							

Date:06/28/05ISR Number: 4701300-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03402
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:06/28/05ISR Number: 4701319-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00381
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701936-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00148
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Disability

Date:06/28/05ISR Number: 4701937-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03491
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Death	Alanine Aminotransferase Increased
	Aspartate Aminotransferase Increased
	Blood Alkaline Phosphatase Increased
	Blood Cholesterol Increased
	Coronary Artery Atherosclerosis
	Coronary Artery Thrombosis
	Diverticulum Intestinal
	Gout
	Hypertensive Heart Disease
	Myocardial Infarction
	Nodule
	Prescribed Overdose

Spinal Osteoarthritis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	154 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	154 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	687 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	154 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	687 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	154 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	687 DAY	
	Vioxx	SS	Merck & Co., Inc	ORAL	687 DAY	
	Prednisone	C			UNKNOWN	
	Tylenol With Codeine #3	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Naproxen	C			UNKNOWN	
	Percocet	C			UNKNOWN	
	Percocet	C			UNKNOWN	
	Prednisone	C			UNKNOWN	
	Prednisone	C			UNKNOWN	
	Allopurinol	C			UNKNOWN	
	Allopurinol	C			UNKNOWN	
	Oxycodone Hydrochloride	C			UNKNOWN	
	Oxycodone Hydrochloride	C			UNKNOWN	

			Tylenol With Codeine #3	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						

Date:06/28/05ISR Number: 4701938-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01235
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		742 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		249 DAY

Date:06/28/05ISR Number: 4701939-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00228
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Estrogens (Unspecified)	C				
Disability	Uterine Polyp							
UNKNOWN								
	Uterine Polypectomy		Zantac	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Lozol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701940-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00487
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea							

Date:06/28/05ISR Number: 4701942-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03026
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		791 DAY
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Aspirin	C		ORAL		
	Mass		Bumetanide	C		ORAL		
Disability	Myocardial Infarction		Serevent	C				UNKNOWN
	Peripheral Vascular Disorder		Quinine Sulfate	C				UNKNOWN

Date:06/28/05ISR Number: 4701951-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01939
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701952-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04335
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Depression	Synthroid	C
UNKNOWN			
Other	Myocardial Infarction	Prempro	C
UNKNOWN			

Date:06/28/05ISR Number: 4701953-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00834
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
Other	Anxiety
	Arthralgia
	Arthropathy
	Back Pain
	Benign Prostatic
	Hyperplasia
	Cardiac Failure
	Congestive
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Depression
	Diabetes Mellitus
	Non-Insulin-Dependent

		Diabetic Nephropathy					
		Diabetic Neuropathy					
		Diabetic Retinopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY							
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY							
		Hepatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Zoster		Zyban	SS		
UNKNOWN							
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
10 DAY							
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
146 DAY							
		Injury		Zestril	C		
UNKNOWN		2170 DAY					
		Intervertebral Disc		Zestril	C		
UNKNOWN		2170 DAY					
		Degeneration		Tenormin	C		
UNKNOWN							
		Intervertebral Disc		Tenormin	C		
UNKNOWN							
		Disorder		Glucophage	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Micronase	C		
UNKNOWN							
		Oedema Peripheral		Lanoxin	C		
UNKNOWN		1051 DAY					
		Pneumonia		[Therapy			
		Renal Cyst		Unspecified]	C		
UNKNOWN							
		Sepsis		Aciphex	C		
UNKNOWN							
		Sexual Dysfunction					
		Weight Increased					

Date:06/28/05ISR Number: 4701956-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04226
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Other	Patella Fracture	Glyburide	C
UNKNOWN			
	Polyp Colorectal	Metformin	C
UNKNOWN			
	Pulmonary Embolism	Lipitor	C
UNKNOWN			
	Thrombosis	Allopurinol	C
UNKNOWN			
	Transient Ischaemic	Allopurinol	C
UNKNOWN			
	Attack		

Date:06/28/05ISR Number: 4701957-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00641
Age:21 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea					
	Thrombosis					

Date:06/28/05ISR Number: 4701962-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
			[Therapy			
			Unspecified]	C		
UNKNOWN						
			Hydrochlorothiazide			
			And Irbesartan	C		
UNKNOWN						

Date:06/28/05ISR Number: 4701974-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03178
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		41 MON
Initial or Prolonged	Blindness		Vioxx	SS	Merck & Co., Inc	ORAL		41 MON
Disability	Blood Cholesterol Increased		Flexeril [Therapy Unspecified]	C		ORAL		
	Cerebral Haemorrhage			C				UNKNOWN
	Cerebral Venous Thrombosis							
	Cerebrovascular Accident							
	Cholecystectomy							
	Coagulopathy							
	Cystitis							
	Deep Vein Thrombosis							
	Depression							
	Disturbance In Attention							
	Dizziness							
	Dyspepsia							
	Eye Haemorrhage							
	Fibromyalgia							
	Gallbladder Disorder							
	Generalised Anxiety Disorder							
	Haemorrhage							
	Headache							
	Hypertension							
	Kidney Infection							
	Nerve Injury							
	Oedema Peripheral							
	Panic Disorder							
	Thrombosis							
	Transient Ischaemic Attack							

Date:06/28/05ISR Number: 4701975-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02629
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain

Initial or Prolonged Disability	Acute Respiratory Failure
Other	Anoxic Encephalopathy
	Aspiration
	Atelectasis
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiac Arrest
	Cardio-Respiratory Arrest
	Cardiogenic Shock
	Cerebrovascular Accident
	Clostridium Colitis
	Coma
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Ostial Stenosis
	Depression
	Emotional Distress
	Haemophilus Infection
	Hypotension

		Incontinence					
		Loss Of Consciousness					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nausea		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Nystagmus		Vioxx	SS	Merck & Co., Inc	ORAL
8	MON						
		Overdose					
		Pain In Extremity					
		Peripheral Vascular					
		Disorder					
		Platelet Aggregation					
		Increased					
		Pneumonia					
		Pneumothorax					
		Postnasal Drip					
		Pulse Absent					
		Pyrexia					
		Staphylococcal Infection					
		Status Epilepticus					
		Tearfulness					
		Therapy Non-Responder					
		Ventricular Extrasystoles					
		Ventricular Fibrillation					
		Ventricular Tachycardia					

Date:06/28/05ISR Number: 4701976-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01772
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Anhedonia
	Blood Calcium Decreased
	Blood Chloride Decreased
	Blood Glucose Increased
	Blood Sodium Decreased
	Cardiac Failure
	Congestive
	Cardiovascular Disorder
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Disability

Dyslipidaemia
Dyspnoea Exertional
Escherichia Urinary Tract
Infection
Glycosylated Haemoglobin
Increased
Hepatic Enzyme Increased
Hypokalaemia
Infection
Leukocytosis
Lower Respiratory Tract
Infection
Myocardial Infarction
Orthopnoea
Pain
Panic Attack
Pco2 Decreased
Productive Cough

		Pulmonary Hypertension					
		Renal Failure Acute					
		Renal Failure Chronic	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Respiratory Tract		Vioxx	PS	Merck & Co., Inc	ORAL
1450	DAY						
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
1450	DAY						
		Sputum Discoloured		Accupril	C		
UNKNOWN							
		Urosepsis		Tylenol	C		
UNKNOWN							
		Ventricular Tachycardia		Humalog	C		
UNKNOWN							
				Humalog	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Colchicine	C		
UNKNOWN							
				Keflex	C		
UNKNOWN							
				Indocin (Indomethacin)	C		
UNKNOWN							

Date:06/28/05ISR Number: 4701978-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01990
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
7	DAY					
Initial or Prolonged	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY					
Disability	Foot Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
7	DAY					
	Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
30	DAY					
	Myocardial Infarction					
	Neck Pain					
	Pain In Extremity					
	Pain In Jaw					
	Sexual Dysfunction					
	Stomach Discomfort					

Vomiting

Date:06/28/05ISR Number: 4701979-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01688
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		34 MON
Hospitalization - UNKNOWN	Coronary Artery		Ultram	C				
Initial or Prolonged UNKNOWN	Atherosclerosis		Allegra	C				
	Emotional Disorder		Chlordiazepoxide	C				
UNKNOWN	Gastrooesophageal Reflux		Perphenazine	C				
UNKNOWN	Disease		Prevacid	C				
UNKNOWN	Heart Disease Congenital		Restoril	C				
UNKNOWN	Hypersensitivity		Sucralfate	C				
UNKNOWN	Hypertension		Temazepam	C				
UNKNOWN	Insomnia		Phenergan (Promethazine Hydrochloride)	C				
	Iron Deficiency							
	Oedema							
UNKNOWN	Oral Intake Reduced		Zithromax	C				
UNKNOWN	Peptic Ulcer		Celebrex	C				
UNKNOWN	Respiratory Failure						414	DAY
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701981-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02943
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701982-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02941
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701983-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00594
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701984-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701985-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02942
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701986-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01428
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Ulcer		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:06/28/05ISR Number: 4701987-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00377
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4701988-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03245
Age:27 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coagulopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Prevacid	C				
UNKNOWN								
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Dyspepsia							
	Gastrooesophageal Reflux							
	Disease							
	Peptic Ulcer							
	Pulmonary Embolism							
	Renal Impairment							
	Stomach Discomfort							
	Testis Cancer							
	Thrombosis							
	Vomiting							

Date:06/28/05ISR Number: 4701989-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03883
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Zocor	C				
UNKNOWN								
Other	Hypertension		Evista	C				
UNKNOWN								
	Myocardial Infarction							

Date:06/28/05ISR Number: 4701990-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00593
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4701991-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04655
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged Disability	Transient Ischaemic Attack Ulcer Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702005-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702006-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03217
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4702007-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1032 DAY	

Date:06/28/05ISR Number: 4702008-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03219
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:06/28/05ISR Number: 4702009-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	93	DAY

Date:06/28/05ISR Number: 4702010-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03194
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx Bextra	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

Date:06/28/05ISR Number: 4702022-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03211
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Date:06/28/05ISR Number: 4702023-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702024-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03195
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702025-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03210
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4702026-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702027-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	295	DAY

Date:06/28/05ISR Number: 4702043-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702044-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	38	MON

Date:06/28/05ISR Number: 4702046-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03312
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702047-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON

Date:06/28/05ISR Number: 4702048-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	874	DAY

Date:06/28/05ISR Number: 4702049-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03314
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4702050-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	536 DAY	

Date:06/28/05ISR Number: 4702051-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702052-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702053-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03324
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702054-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03468
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Hydrochlorothiazide	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								

Date:06/28/05ISR Number: 4702055-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	23 MON	
	Hypertension							

Date:06/28/05ISR Number: 4702057-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702058-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/05ISR Number: 4702062-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/28/05ISR Number: 4702065-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		275 DAY

Date:06/28/05ISR Number: 4703007-XReport Type:Direct Company Report #CTU 252101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx 25	PS				1 TIMES A DA
Other	Drug Hypersensitivity							Y
Required Intervention to Prevent Permanent Impairment/Damage	Hypertension Kidney Infection Micturition Disorder Myocardial Infarction Renal Disorder Respiratory Tract Infection Urinary Incontinence		Claritin Drugstore (Great)	SS				

Date:06/28/05ISR Number: 4703091-3Report Type:Direct Company Report #CTU 252102
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Cerebrovascular Accident		Vioxx 25 Mg Tab (Merc) Nocp	PS	Merc Nocp	ORAL	TAKE 1 TAB	

Other Gastric Ulcer
EVERY DAY
Required
ORAL
Intervention to
Prevent Permanent
Impairment/Damage

Date:06/28/05ISR Number: 4703534-5Report Type:Expedited (15-DaCompany Report #2005079681
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Ineffective	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200	
	Gastritis Bacterial						MG, 1 IN 1	
	Osteoporosis						D), ORAL	
			Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Calcium (Calcium)	C				

Date:06/28/05ISR Number: 4703755-1Report Type:Expedited (15-DaCompany Report #2005081860
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Bypass Operation	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200	
	Atrial Flutter	Health					MG, 2 IN 1	
	Peripheral Occlusive	Professional					D), ORAL	
	Disease		Bextra (Valdecoxib)	SS		ORAL	(10 MG,),	

ORAL

	Vioxx (Rofecoxib)	SS	ORAL

(25 MG,),

ORAL

Allopurinol (Allopurinol)	C
Aspirin "Bayer" (Acetylsalicylic Acid)	C
Prilosec (Omeprazole)	C
Lanoxin (Digoxin)	C
Plavix (Clopidogrel Sulfate)	C
Norvasc (Amlodipine)	C
Lisinopril (Lisinopril)	C
Lipitor (Atorvastatin)	C

Date:06/29/05ISR Number: 4702778-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4702780-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03188
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4702782-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00749
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Disability	Hypertension	Duragesic	C
UNKNOWN			
	Myocardial Infarction	Paxil	C
UNKNOWN			
	Pulmonary Infarction	Hyzaar	C
UNKNOWN			

Date:06/29/05ISR Number: 4702784-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02430
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Potassium Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
Hospitalization - Initial or Prolonged	Blood Sodium Decreased							
Disability	Dehydration							

Date:06/29/05ISR Number: 4702785-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02084
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Bladder Disorder
Other	Bundle Branch Block Right
	Cerebrovascular Accident

	Colonic Polyp						
	Convulsion						
	Coronary Artery	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	1046 DAY	
	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	1046 DAY	
	Difficulty In Walking		Depakote	C			UNKNOWN	
	Gastrointestinal Disorder		Keppra	C			UNKNOWN	
	Heart Injury		Tylenol With Codeine #3	C			UNKNOWN	
	Hypercholesterolaemia							
	Hyperlipidaemia		Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	
	Hypertension							
	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN	
	Nasal Congestion							
	Sedation							
	Sialoadenitis							
	Sinus Bradycardia							
	Transient Ischaemic Attack							

Date:06/29/05ISR Number: 4702794-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03337
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/29/05ISR Number: 4702795-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01769
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Disability	Asthma	Vioxx	SS	Merck & Co., Inc	ORAL
	Back Pain	Singulair	C		ORAL
	Blood Cholesterol	Prozac	C		
UNKNOWN					
	Increased	Ibuprofen	C		
UNKNOWN					
	Blood Creatinine Increased	[Therapy Unspecified]	C		
UNKNOWN					
	Cerebrovascular Accident	Norvasc	C		
UNKNOWN					
	Crohn'S Disease	Norvasc	C		
UNKNOWN					
	Depression				
	Ear Infection				
	Epistaxis				
	Gastric Disorder				
	Hernia				
	Hypertension				
	Nervous System Disorder				
	Obesity				
	Oesophageal Disorder				
	Pain				
	Respiratory Failure				
	Sinusitis				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4702816-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Hospitalization -	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Epigastric Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Heparin	C			PARENTERAL	24 DAY
			Gabapentin	C		ORAL		
			Esomeprazole					
			Magnesium	C		ORAL		882 DAY

Date:06/29/05ISR Number: 4702825-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00806
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anorexia		Aspirin	C				
UNKNOWN								
Other	Anxiety							
	Atherosclerosis							
	Cardiac Disorder							
	Chest Discomfort							
	Chloasma							
	Chronic Sinusitis							
	Constipation							
	Coronary Artery Disease							
	Cough							
	Depression							
	Drug Dependence							
	Dry Mouth							
	Dysuria							
	Eustachian Tube Disorder							

Gastric Ulcer
Gastrooesophageal Reflux
Disease
Hypertension
Iliac Artery Stenosis
Intermittent Claudication
Malaise
Muscle Spasms
Myocardial Infarction
Paraesthesia
Peripheral Vascular
Disorder
Pleurisy
Sinus Headache
Stomatitis

Date:06/29/05ISR Number: 4702826-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05004
Age:48 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Carotid Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL	23	MON
Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	23	MON
Depression		Fiorinal	C			UNKNOWN	
Hypertension		Darvocet-N	C			UNKNOWN	
Otitis Media		Amoxicillin	C			UNKNOWN	
		Tylenol	C			UNKNOWN	
		Flexeril	C			UNKNOWN	

Date:06/29/05ISR Number: 4702827-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03187
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4702831-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02723
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Aspirin	C			UNKNOWN	
	Atherosclerosis		Zocor	C			UNKNOWN	
	Cardiac Disorder		Toprol Xl Tablets	C			UNKNOWN	
	Decubitus Ulcer		Lasix (Furosemide)	C			UNKNOWN	
	Depression		Enalapril Comp	C			UNKNOWN	

	Dizziness	Meclizine	C
UNKNOWN			
	Fear		
	Herpes Simplex		
	Oedema Peripheral		
	Upper Respiratory Tract Infection		
	Urinary Tract Obstruction		
	Venous Insufficiency		
	Vertigo		

Date:06/29/05ISR Number: 4702843-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05026
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Arterial Stenosis
	Arthropathy
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis
	Gastroenteritis Radiation
	Haemangioma
	Headache
	Hiatus Hernia
	Irritable Bowel Syndrome
	Myocardial Infarction
	Nausea
	Prostate Cancer
	Scrotal Pain
	Stomach Discomfort

Vocal Cord Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		1603 DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		1603 DAY
	Cozaar	C				UNKNOWN
	Protonix	C				UNKNOWN
	Zocor	C				UNKNOWN
	Dyazide	C				UNKNOWN
	Valium	C				UNKNOWN
	Tenoretic	C				UNKNOWN

Date:06/29/05ISR Number: 4703262-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01482
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Lipitor	C				UNKNOWN
								1304 DAY
Disability	Anxiety		Motrin	C				UNKNOWN
Other	Atrioventricular Block		Naproxen	C				UNKNOWN
	Blood Glucose Increased		Tylenol	C				UNKNOWN
	Cataract		Premarin	C				UNKNOWN
	Chest Pain		Aspirin	C				UNKNOWN
	Conjunctivitis Infective		Aspirin	C				UNKNOWN
	Contusion		Synthroid	C				UNKNOWN

	Diplopia		Synthroid	C		
UNKNOWN						
	Dyspnoea		Micronase	C		
UNKNOWN						
	Emotional Distress		Glucophage	C		
UNKNOWN						
	Feeling Cold		Nitroglycerin	C		
UNKNOWN						
	Hot Flush		Refresh	C		
OPHTHALMIC						
	Nasopharyngitis		[Therapy			
	Nausea		Unspecified]	C		
OPHTHALMIC						
	Pain					
	Palpitations					
	Pinguecula					
	Somnolence					
	Upper Respiratory Tract					
	Infection					

Date:06/29/05ISR Number: 4703264-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acquired Immunodeficiency		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY						
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
6 DAY						
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Kidney Infection		Dilantin	C		
UNKNOWN						
	Pain In Extremity					

Date:06/29/05ISR Number: 4703265-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00632
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Depo-Provera	SS				
	Fracture		Percocet	C				
	Hypercoagulation		Penicillin (Unspecified)	C				
	Lymphadenopathy							
	Myocardial Infarction							

Date:06/29/05ISR Number: 4703270-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02087
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chondromalacia		Flomax (Morniflumate)	C				
	Colonic Polyp							
	Coronary Artery Disease		Androderm	C				
	Diverticulum		Cedax	C				
	Dyslipidaemia		Claritin	C				
	Intervertebral Disc		Diprolene	C				
	Protrusion		Muco-Fen La	C				
	Ligament Injury		Plavix	C				
	Meniscus Lesion							
	Myocardial Infarction							
	Rotator Cuff Syndrome							
	Sinusitis							
	Toe Deformity							

Date:06/29/05ISR Number: 4703271-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01719
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Aphasia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Injury		Wellbutrin	C				
UNKNOWN								
Disability	Back Pain		Avandia	C				
UNKNOWN								
	Basal Cell Carcinoma		Combivent	C				
UNKNOWN								
	Blood Cholesterol		Rhinocort	C				
UNKNOWN								
	Increased		Astelin	C				
UNKNOWN								
	Cauda Equina Syndrome		Glucotrol	C				
UNKNOWN								
	Cerebrovascular Accident		Augmentin	C				
UNKNOWN								
	Diabetes Mellitus		Zithromax	C				
UNKNOWN								
	Inadequate Control		Hydrocodone/Apap	C				
UNKNOWN								
	Facial Pain		Hydrocodone/Apap	C				
UNKNOWN								
	Fracture		Relafen	C				
UNKNOWN								
	Hemiparesis		Vicodin Tablets	C				
UNKNOWN								
	Hyperkeratosis							
	Hypertension							
	Injury							
	Melanocytic Naevus							
	Nasal Congestion							
	Oedema Peripheral							
	Toe Deformity							
	Upper Respiratory Tract Infection							
	Varicose Vein							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703272-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01770
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Appendix Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Benign Intracranial Hypertension		Capoten	C		ORAL		
	Bronchitis Acute		Lasix (Furosemide Sodium)	C		ORAL		
	Bundle Branch Block Left		Procardia Xl	C		ORAL		
	Cardiac Failure		Claritin-D	C				
	Congestive		Lipitor	C		ORAL		
	Cataract		Glucophage	C		ORAL		
	Dyspnoea		Evista	C		ORAL		
	Gastric Disorder		Humulin	C				
	Hyperhidrosis		Humalog	C				
	Hypertension		Neurontin	C		ORAL		
	Joint Swelling		Minocycline Hydrochloride	C		ORAL		
	Lower Limb Fracture		Avandia	C		ORAL		
	Myocardial Infarction		Fesofor	C		ORAL		
	Neuropathic Arthropathy		Nifedical Xl	C				
	Obesity		Lantus	C				
	Osteomyelitis		Allegra-D	C				
	Pain		Claritin	C		ORAL		
	Rosacea		Atenolol	C				
	Sleep Apnoea Syndrome		Lisinopril	C				
	Tonsillar Disorder		Nitrostat	C				
			Actos	C				
			Clarinex	C				
			Tramadol Hydrochloride	C				

Date:06/29/05ISR Number: 4703273-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00150
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		504 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		504 DAY
	Increased		Aspirin	C				UNKNOWN
	Generalised Anxiety Disorder							
	Hypertension							
	Myocardial Infarction							

Date:06/29/05ISR Number: 4703274-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02579
Age:58 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Arthralgia
	Blood Cholesterol Increased
	Cardiac Failure Congestive
	Chest Pain
	Constipation
	Coronary Artery Atherosclerosis
	Electrolyte Imbalance

		Haematuria					
		Hypertension					
		Hyponatraemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoxia		Vioxx	PS	Merck & Co., Inc	ORAL
		Ischaemic Cardiomyopathy		Melatonin	C		
UNKNOWN							
		Liver Function Test		Elavil	C		
UNKNOWN							
		Abnormal		Biaxin	C		
UNKNOWN							
		Metabolic Acidosis		Flonase	C		
UNKNOWN							
		Mitral Valve Incompetence		Flovent	C		
UNKNOWN							
		Myocardial Infarction		Hydrocodone			
		Oedema		Hydrochloride	C		
UNKNOWN							
		Pneumonia		Vicodin Tablets	C		
UNKNOWN							
		Protein Total Increased		Ativan	C		
UNKNOWN							
		Pyrexia		Neurontin	C		
UNKNOWN							
		Renal Failure		Paxil	C		
UNKNOWN							
		Urinary Tract Obstruction		Tradon	C		
UNKNOWN							
				Proscar	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							

Date:06/29/05ISR Number: 4703276-6Report Type:Expedited (15-DaCompany Report #US-MERCK-01104510
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia Of Chronic		Vioxx	PS	Merck & Co., Inc	ORAL
27 DAY						
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Blood Calcium Increased		Prevacid	C		
UNKNOWN						
	Carotid Artery Disease		Lipitor	C		
UNKNOWN						

	Colitis		Vasoretic	C		ORAL
	Coronary Artery Disease		Vasoretic	C		ORAL
	Eczema		Neurontin	C		
UNKNOWN						
	Gastric Ulcer Haemorrhage		Inderal	C		
UNKNOWN						
	Gastritis		Aspirin	C		
UNKNOWN						
	Helicobacter Pylori		Centrum	C		
UNKNOWN						
	Identification Test		Chondroitin Sulfate			
	Positive		Sodium And			
	Impaired Fasting Glucose		Glucosamine			
	Infection		Hydrochloride	C		
UNKNOWN						
	Intermittent Claudication		[Therapy			
	Joint Sprain		Unspecified]	C		
UNKNOWN						
	Myocardial Infarction		[Therapy			
	Oesophagitis		Unspecified]	C		
UNKNOWN						
	Peripheral Vascular		Pepto-Bismol	C		
UNKNOWN						
	Disorder		Vitamin E	C		
UNKNOWN						
	Renal Failure Chronic		Vitamin B			
	Stress		(Unspecified)	C		
UNKNOWN						
	Tachycardia					
	Ventricular Arrhythmia					

Date:06/29/05ISR Number: 4703277-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01715
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	60	MON
Disability	Dyspnoea							
	Hypertension							
	Myocardial Infarction							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703278-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	61 YR	
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	146 DAY	
Other	Asthenia		Atenolol	C			UNKNOWN	
	Blood Calcium Decreased		Aspirin	C			UNKNOWN	
	Bradycardia		Pravachol	C			UNKNOWN	
	Brain Cancer Metastatic		Zocor	C		ORAL		
	Brain Oedema		Tylenol	C			UNKNOWN	
	Colon Cancer Stage Iii		Ibuprofen	C			UNKNOWN	
	Colonic Polyp		Piroxicam	C		ORAL		
	Confusional State							
	Decreased Appetite							
	Deep Vein Thrombosis							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Headache							
	Hypoparathyroidism							
	Iron Deficiency Anaemia							
	Lung Neoplasm							
	Myocardial Infarction							
	Nasopharyngitis							
	Pulmonary Embolism							
	Thyroid Cancer Metastatic							
	Upper Respiratory Tract Infection							

Date:06/29/05ISR Number: 4703279-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02652
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial Infarction
Initial or Prolonged	
Other	Angina Pectoris

Anxiety
Atherosclerosis
Blood Cholesterol
Increased
Blood Testosterone
Decreased
Cardiac Failure
Congestive
Cellulitis
Cerebrovascular Accident
Cervicobrachial Syndrome
Confusional State
Contusion
Coronary Artery Disease
Crush Syndrome
Dehydration
Depression
Dyspnoea
Dysuria
Emotional Distress
Epicondylitis
Erectile Dysfunction
Fatigue
Gastric Ulcer

		Gastritis Erosive Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
1345 DAY							
		Hyperventilation		Vioxx	SS	Merck & Co., Inc	ORAL
1	MON						
		Ischaemic Cardiomyopathy		Lortab	C		
UNKNOWN							
		Laceration		Covera	C		
UNKNOWN							
		Leukocytosis		Ambien	C		
UNKNOWN							
		Localised Infection Multiple Sclerosis Relapse Pancreatitis Pleural Effusion Pneumonia Renal Cyst Respiratory Distress Sinus Bradycardia Supraventricular Extrasystoles Ventricular Extrasystoles					

Date:06/29/05ISR Number: 4703280-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03769
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cardiac Arrest Cardiac Disorder Lung Disorder Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/29/05ISR Number: 4703281-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03695
Age:58 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 96 DAY	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Liver Function Test Abnormal		Vioxx Toprol Xl Tablets	SS C	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:06/29/05ISR Number: 4703282-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03193
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL

Date:06/29/05ISR Number: 4703283-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01939
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged UNKNOWN	Myocardial Infarction		[Therapy Unspecified]	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703284-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		34 MON
Other	Death Myocardial Infarction							

Date:06/29/05ISR Number: 4703285-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03214
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703286-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04196
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Lipitor	C				UNKNOWN
			Paxil	C				UNKNOWN
	Chest Pain Dizziness Dyspnoea Hypothyroidism Loss Of Consciousness Neck Pain Palpitations							

Date:06/29/05ISR Number: 4703287-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03384
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Cerebrovascular Accident		Ibuprofen	C		
UNKNOWN						
	Diabetes Mellitus		Actos	C		
UNKNOWN						
	Gout					
	Hypertension					
	Pancreatic Carcinoma					
	Sleep Apnoea Syndrome					
	Swelling					

Date:06/29/05ISR Number: 4703288-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03957
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Plavix	C		
UNKNOWN						
Other	Chest Pain		Imdur	C		
UNKNOWN						
	Myocardial Infarction		Toprol Xl Tablets	C		
UNKNOWN						
	Oedema Peripheral					
	Renal Failure					
	Thrombosis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703289-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03487
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aspartate		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Aminotransferase		Synthroid	C				
UNKNOWN								
	Increased							
	Back Disorder							
	Colitis Ischaemic							
	Deep Vein Thrombosis							
	Depression							
	Diverticulum							
	Dyspnoea							
	Gastric Ulcer Haemorrhage							
	Gastrointestinal Disorder							
	Gastrooesophageal Reflux Disease							
	Hiatus Hernia							
	High Density Lipoprotein Decreased							
	Hypertension							
	Influenza							
	Insomnia							
	Leukocytosis							
	Migraine							
	Neck Pain							
	Post-Traumatic Stress Disorder							
	Pulmonary Embolism							

Date:06/29/05ISR Number: 4703290-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01940
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Back Pain		Tylenol	C				
UNKNOWN								
	Cardiac Arrest		Zestril	C				
UNKNOWN								

	Cardiac Failure	Zestoretic	C
UNKNOWN			
	Congestive	Celebrex	C
UNKNOWN			
	Coronary Artery Disease		
	Dizziness		
	Dyspepsia		
	Dyspnoea		
	Flatulence		
	Gastric Disorder		
	Hernia		
	Hypertension		
	Myocardial Infarction		
	Palpitations		
	Shoulder Pain		
	Sudden Cardiac Death		
	Supraventricular		
	Tachycardia		
	Ventricular Arrhythmia		
	Ventricular Fibrillation		
	Ventricular Tachycardia		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703291-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703292-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05082
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Diarrhoea							
Initial or Prolonged	Menorrhagia							
	Oedema Peripheral							
	Thrombosis							

Date:06/29/05ISR Number: 4703293-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
	Myocardial Infarction							

Date:06/29/05ISR Number: 4703294-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03304
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703295-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03599
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:06/29/05ISR Number: 4703296-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03396
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703297-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03575
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:06/29/05ISR Number: 4703298-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03591
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/05ISR Number: 4703299-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03576
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703301-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03593
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703302-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03770
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Thromboembolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4703303-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03598
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/29/05ISR Number: 4705995-4Report Type:Expedited (15-DaCompany Report #2005091678
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident	Consumer	Bextra (Valdecoxib)	PS				
Other			Vioxx (Rofecoxib)	SS				

Date:06/29/05ISR Number: 4706272-8Report Type:Expedited (15-DaCompany Report #02/02158-USE
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blindness Unilateral
Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Breath Sounds Decreased
	Deep Vein Thrombosis
	Depression
	Diabetes Mellitus Non-Insulin-Dependent
	Diplopia
	Electrocardiogram St Segment Abnormal
	Electrocardiogram T Wave Abnormal
	Fall
	Fibromyalgia
	Haemorrhagic Stroke
	Heart Rate Irregular
	Hydrocephalus
	International Normalised Ratio Decreased

	Joint Effusion						
	Lung Disorder						
	Memory Impairment	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Muscle Disorder	Consumer	Yasmin				
	Optic Nerve Disorder	Health	(Drospirenone,				
	Pain	Professional	Ethinylestradiol)				
	Papilloedema	Company	Film Tablet	PS		ORAL	1 TAB(S),
	Photophobia	Representative					1X/DAY, ORAL
	Rash	Other	Vioxx (Rofecoxib)				
	Sex Hormone Binding		Liquid	SS		ORAL	SEE IMAGE,
	Globulin Decreased						ORAL
	Sinus Tachycardia		Sandimmune				
	Sneezing		(Ciclosporin) Liquid	C			
	Subarachnoid Haemorrhage		Prelone Liquid	C			
	Superior Sagittal Sinus		Prednisone	C			
	Thrombosis						
	Tinnitus						
	Tunnel Vision						
	Uterine Enlargement						
	Uterine Leiomyoma						
	Vaginal Haemorrhage						
	Vision Blurred						
	Visual Field Defect						

Date:06/30/05ISR Number: 4703928-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01745
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	58 MON
Initial or Prolonged	Infarction		Neurontin	C			UNKNOWN
	Angina Pectoris		Neurontin	C			UNKNOWN
	Anxiety		Penicillin Vk	C			UNKNOWN
	Bronchospasm		Restoril	C			UNKNOWN

	Cardiac Failure	Seroquel	C
UNKNOWN			
	Cardiac Failure	Effexor Xr	C
UNKNOWN			
	Congestive	Abilify	C
UNKNOWN			
	Coronary Artery	Aspirin	C
UNKNOWN			
	Atherosclerosis	Plavix	C
UNKNOWN			
	Depression	Xanax	C
UNKNOWN			
	Eczema	Prinivil	C
UNKNOWN			
	Gastrooesophageal Reflux	Imdur	C
UNKNOWN			
	Disease	Catapres	C
UNKNOWN			
	Hyperkalaemia	Ambien	C
UNKNOWN			
	Hyperlipidaemia	Remeron	C
UNKNOWN			
	Hypertension	Metformin	C
UNKNOWN			
	Hypothyroidism	Vicodin Tablets	C
UNKNOWN			
	Influenza	Vicodin Tablets	C
UNKNOWN			
	Panic Disorder	Zyprexa	C
UNKNOWN			
	Pneumonia	Buspar	C
UNKNOWN			
	Refractory Anaemia	Prozac	C
UNKNOWN			
	Renal Failure Acute	Amoxicillin	C
UNKNOWN			
		Flonase	C
UNKNOWN			
		Colestid	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4703930-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01893
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Infection		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Intervertebral Disc		Flexeril	C		ORAL		
Disability	Degeneration		Motrin	C		ORAL		
	Intervertebral Discitis							
	Postoperative Infection							
	Pulmonary Embolism							
	Spinal Column Stenosis							

Date:06/30/05ISR Number: 4703941-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00156
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1362 DAY
	Ear Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1362 DAY
	Uterine Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1362 DAY
			Bellamine S	C				UNKNOWN

Date:06/30/05ISR Number: 4703942-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03253
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Peripheral Vascular		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disorder		Norvasc	C				UNKNOWN

Date:06/30/05ISR Number: 4703943-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00099
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		1060 DAY
Hospitalization -	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL		1060 DAY
Initial or Prolonged	Blood Glucose Decreased		Coumadin	C				UNKNOWN
	725 DAY							
Other	Cardiac Failure		Theophylline	C				UNKNOWN
	Congestive		Theophylline	C				UNKNOWN
	Coronary Artery		Combivent	C				UNKNOWN
	Atherosclerosis		Prilosec	C				UNKNOWN
	Coronary Artery Thrombosis							
	Diabetes Mellitus Non-Insulin-Dependent							
	Hypertension							
	Myocardial Infarction							
	Oedema Peripheral							
	Pneumonia							

Date:06/30/05ISR Number: 4703944-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00480
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Bladder Disorder
	Chest Pain
	Coronary Artery Disease
	Depression
	Diabetic Retinopathy

		Dizziness					
		Dysphagia					
		Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram		Vioxx	PS	Merck & Co., Inc	ORAL
		Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastroenteritis		Humulin	C		
SUBCUTANEOUS							
		No Therapeutic Response		Glucophage	C		ORAL
		Non-Cardiac Chest Pain		Lopressor	C		ORAL
		Post-Traumatic Stress		Acupril	C		ORAL
		Disorder		Zocor	C		ORAL
		Renal Disorder		Hydrochlorothiazide	C		ORAL
		Retinal Disorder		Nexium	C		ORAL
		Rotator Cuff Syndrome		Estradiol	C		ORAL
		Stomach Discomfort		Ultram	C		ORAL
		Temperature Intolerance		Aspirin	C		ORAL
		Upper Respiratory Tract		Nitroglycerin	C		
UNKNOWN							
		Infection		[Therapy			
		Urinary Tract Infection		Unspecified]	C		ORAL
		Weight Increased		Bextra	C		ORAL
				Lipitor	C		ORAL
				Gemfibrozil	C		ORAL
				Flexeril	C		ORAL
				Glucosamine	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:06/30/05ISR Number: 4703955-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02103
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
37 MON						
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
37 MON						
Disability	Cardiac Failure		Plavix	C		
UNKNOWN						
	Congestive		Cordarone	C		ORAL

	Cardiomyopathy	Lasix (Furosemide)	C
UNKNOWN			
	Hypoxia	Lipitor	C
UNKNOWN			
	Intermittent Claudication	Zyrtec	C
UNKNOWN			
	Mitral Valve Incompetence	Prilosec	C
UNKNOWN			
	Polytraumatism	Coumadin	C
UNKNOWN			
		Amoxil	C
UNKNOWN			
		Aldactone	C
UNKNOWN			
		Toprol Xl Tablets	C
UNKNOWN			
		Hyzaar	C
UNKNOWN			

Date:06/30/05ISR Number: 4703956-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02728
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		638 DAY
Initial or Prolonged	Disease		Tylenol	C				
UNKNOWN								
	Haematochezia		Acetaminophen	C				
UNKNOWN								
	Limb Injury		Tylenol	C				
UNKNOWN								
	Pulmonary Embolism							
	Stomach Discomfort							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4703957-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00604
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							
	Injury							

Date:06/30/05ISR Number: 4703958-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00503
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Pain		Metoprolol	C				
UNKNOWN								
Initial or Prolonged	Bronchitis		[Therapy					
Disability	Headache		Unspecified]	C				
UNKNOWN								
	Heart Rate Irregular		Insulin	C				
UNKNOWN								
	Movement Disorder							
	Vertigo							

Date:06/30/05ISR Number: 4703959-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01749
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain		Folic Acid	C				
UNKNOWN								
Disability	Cerebrovascular Accident		Plaquenil	C				
UNKNOWN								
	Depression		Catapres	C				
UNKNOWN								
	Dizziness		Prednisone	C				
UNKNOWN								
	Flatulence		Tylenol	C				
UNKNOWN								
	Gastrointestinal Motility		Ambien	C				
UNKNOWN								

	Disorder		Enbrel	C		
UNKNOWN						
	Gastrooesophageal Reflux		Methotrexate	C		
UNKNOWN						
	Disease					
	Headache					
	Hypertension					
	Oedema					
	Pain					
	Pollakiuria					
	Sinus Disorder					
	Visual Acuity Reduced					
	Weight Increased					

Date:06/30/05ISR Number: 4703960-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02612
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anal Tinea		Nexium	C		ORAL
Other	Cerebrovascular Accident		Novantrone	C		
UNKNOWN						
	Lobar Pneumonia		Metaglip	C		
UNKNOWN						
	Neutropenia		Zoloft	C		
UNKNOWN						
	Oedema Peripheral		Prevacid	C		
UNKNOWN						
	Paraesthesia		Lipitor	C		
UNKNOWN						
	Rhinitis Allergic		Neurontin	C		
UNKNOWN						
	Tinea Cruris		Flexeril	C		
UNKNOWN						
	Tinea Pedis		Aspirin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Avonex	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4703963-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01758
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
	Chest Pain		Premarin	C				UNKNOWN
	Coronary Artery Disease		Dyazide	C				UNKNOWN
	Heart Rate Irregular		Synthroid	C				UNKNOWN
	Hypertension		Aspirin	C				UNKNOWN
	Myocardial Infarction		Cytomel	C				UNKNOWN
	Pain							
	Rotator Cuff Syndrome							

Date:06/30/05ISR Number: 4703964-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02691
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Arava	C				UNKNOWN
	Blood Triglycerides Increased		Calcium (Unspecified)	C				UNKNOWN
	Carotid Artery Disease		Clarinex	C				UNKNOWN
	Coronary Artery Disease		Daypro	C				UNKNOWN
	Dizziness		Daypro	C				UNKNOWN
	Dysphagia		Enbrel	C				UNKNOWN

	Dyspnoea	Folic Acid	C
UNKNOWN			
	Fungal Infection	Methotrexate	C
UNKNOWN			
	Gastrooesophageal Reflux	Naprosyn	C
UNKNOWN			
	Disease	Plaquenil	C
UNKNOWN			
	Hypertension	Prednisone	C
UNKNOWN			
	Impaired Healing	Relafen	C
UNKNOWN			
	Infection		
	Ischaemic Cardiomyopathy		
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Myocardial Ischaemia		
	Obesity		
	Oedema Peripheral		
	Osteoporosis		
	Post Procedural		
	Complication		
	Rheumatoid Arthritis		
	Sleep Apnoea Syndrome		
	Tachycardia		
	Tricuspid Valve		
	Incompetence		
	Ventricular Dysfunction		
	Vertigo		

Date:06/30/05ISR Number: 4703978-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03316
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4703979-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02648
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		908 DAY
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Glucosamine Hydrochloride And Chondroitin Sulfate Sodium	C				UNKNOWN
Disability	Depression		Diazepam	C				UNKNOWN
	Hypertension		Baclofen	C				UNKNOWN
	Hypothyroidism		Furosemide	C				UNKNOWN
	Transient Ischaemic		Macrobid	C				UNKNOWN
	Attack		Vitamins (Unspecified)	C				UNKNOWN
	Ulcer							

Date:06/30/05ISR Number: 4703980-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		53 MON

Date:06/30/05ISR Number: 4703981-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4703982-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03317
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:06/30/05ISR Number: 4703983-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02531
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Unstable Arteriopathic Disease Chest Pain Coronary Artery Atherosclerosis Dyspepsia Dyspnoea Gallbladder Disorder Gastrooesophageal Reflux Disease Hyperlipidaemia Hypertension Insomnia Myocardial Infarction Oedema Vomiting		Vioxx Vicodin Tablets	PS C	Merck & Co., Inc	ORAL	UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4703984-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	99	DAY

Date:06/30/05ISR Number: 4703985-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Emotional Distress Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4703986-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03318
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4703987-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03310
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704000-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03319
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704001-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704002-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03567
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704003-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Electrolyte Imbalance							
	Hepatic Failure							
	Respiratory Failure							
	Ventricular Fibrillation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4704004-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03573
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Stenosis Cardiovascular Disorder Coronary Artery Disease Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704005-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03568
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704011-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03823
Age:86 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Hospitalization - Initial or Prolonged								

Date:06/30/05ISR Number: 4704637-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00231
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction		Advair	C			UNKNOWN	
Disability	Prostate Cancer		Flomax (Morniflumate)	C			UNKNOWN	
			Serevent	C			UNKNOWN	

			Ventilan (Albuterol)	C
UNKNOWN				
			Zithromax	C
UNKNOWN				
			Fenamin (Promethazine)	C
UNKNOWN				
			Cipro	C
UNKNOWN				
			Hydrocodone/Apap	C
UNKNOWN				
			Motrin	C
UNKNOWN	7	YR		
			Tylenol	C
UNKNOWN	10	YR		

Date:06/30/05ISR Number: 4704639-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
Other	Angina Pectoris
	Atelectasis
	Blood Pressure Increased
	Cardiac Disorder
	Carpal Tunnel Syndrome
	Chronic Sinusitis
	Convulsion
	Coronary Artery Disease
	Cyst
	Hyperlipidaemia
	Intervertebral Disc Protrusion

		Lumbar Radiculopathy					
		Lumbar Spinal Stenosis					
		Nasal Polyps	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Septum Deviation		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity					
		Radiculitis					
		Radiculopathy					
		Sinusitis					

Date:06/30/05ISR Number: 4704667-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02561
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Animal Bite		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anxiety		Ultram	C		
UNKNOWN						
	Back Injury		Persantine	C		
UNKNOWN						
	Back Pain		Neurontin	C		
UNKNOWN						
	Bronchitis		Stadol	C		
UNKNOWN						
	Carotid Artery Occlusion		Methadone			
	Cerebral Infarction		Hydrochloride	C		
UNKNOWN						
	Cerebrovascular Accident		Ibuprofen	C		
UNKNOWN						
	Chills					
	Diabetes Mellitus					
	Inadequate Control					
	Diabetes Mellitus					
	Non-Insulin-Dependent					
	Drug Hypersensitivity					
	Fluid Retention					
	Haemorrhoids					
	Hidradenitis					
	Hypercholesterolaemia					
	Hypertension					
	Lice Infestation					
	Lipids Abnormal					
	Menopausal Symptoms					
	Metastatic Neoplasm					

Mild Mental Retardation
Pilonidal Cyst
Pyrexia
Respiratory Tract
Infection
Retinal Disorder
Shoulder Pain
Viral Myocarditis
Viral Pharyngitis
Viral Upper Respiratory
Tract Infection
Vomiting

Date:06/30/05ISR Number: 4704668-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02577
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alcohol Use
	Aphasia
	Blood Cholesterol Increased
	Blood Triglycerides

		Increased					
		Bone Pain					
		Carotid Artery Occlusion					
		Carotid Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Hydrochlorothiazide	C		
UNKNOWN							
		Paraesthesia		Lipitor	C		
UNKNOWN							
		Transient Ischaemic		Allegra	C		
UNKNOWN							
		Attack					

Date:06/30/05ISR Number: 4704669-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02943
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
167 DAY							
Initial or Prolonged		Increased					
		Cardiac Disorder					
		Chronic Fatigue Syndrome					
		Deep Vein Thrombosis					
		Panic Disorder					
		Stress					

Date:06/30/05ISR Number: 4704670-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02859
Age:67 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cerebrovascular Accident		Synthroid	C		
UNKNOWN							
		Disturbance In Attention		Lipitor	C		
UNKNOWN							
		Pain In Extremity					
		Spinal Operation					
		Thyroid Disorder					

Date:06/30/05ISR Number: 4704671-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01883
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
Initial or Prolonged	Myocardial Infarction		Darvocet-N	C				UNKNOWN
Disability	Overdose							
	Post-Traumatic Stress Disorder							

Date:06/30/05ISR Number: 4704672-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00067
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		22 MON
Initial or Prolonged	Cerebral Artery Occlusion		Atorvastatin Calcium	C		ORAL		
Disability	Chest Pain		Omeprazole	C				UNKNOWN
	Headache		Allopurinol And Benzbromarone	C				UNKNOWN
	Hypertension							
	Tinnitus							
	Vertigo							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4704673-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00091
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Advair	C				
UNKNOWN								
	Fall		Dilantin	C				
UNKNOWN								
			Singulair	C				
UNKNOWN								
			Vitamin B Complex	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								
			Levoxyl	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Albuterol	C				
UNKNOWN								
			Lortab	C				
UNKNOWN								
			Lortab	C				
UNKNOWN								
			Metformin	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								
			Zonegran	C				
UNKNOWN								
			Ditropan Xl	C				
UNKNOWN								

Date:06/30/05ISR Number: 4704674-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03474
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		339 YR
Initial or Prolonged	Cardiac Arrest		Lupron	C				UNKNOWN
	Hypersensitivity		Doxazosin Mesylate	C				UNKNOWN
	Myocardial Infarction		Doxazosin Mesylate	C				UNKNOWN
	Prostate Cancer		Casodex	C				UNKNOWN
	Metastatic		Cipro	C				UNKNOWN
	Pulmonary Embolism		Toprol Xl Tablets	C				UNKNOWN
	Syncope Vasovagal							

Date:06/30/05ISR Number: 4704675-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01720
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Decompression		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Zocor	C		ORAL		
	Hypertriglyceridaemia		Zocor	C		ORAL		
	Myocardial Infarction		Lasix (Furosemide)	C		ORAL		
	Road Traffic Accident		Welchol	C		ORAL		
	Shoulder Operation		Aspirin	C				UNKNOWN

Date:06/30/05ISR Number: 4704686-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03309
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:06/30/05ISR Number: 4704687-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:06/30/05ISR Number: 4704688-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01317
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Thrombosis							

Date:06/30/05ISR Number: 4704689-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02699
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704690-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03306
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704692-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01766
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Initial or Prolonged	Hepatitis B	Premarin	C
UNKNOWN			
	Hypertension	Avapro	C
UNKNOWN			
	Limb Injury	[Therapy	
	Myocardial Infarction	Unspecified]	C
UNKNOWN			
	Nephrolithiasis	Buspar	C
UNKNOWN			
	Pain	Prilosec	C
UNKNOWN			
		Ambien	C
UNKNOWN			
		Prevacid	C
UNKNOWN			
		Pravachol	C
UNKNOWN			
		Propulsid	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			

Date:06/30/05ISR Number: 4704693-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0506BRA00077
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Subarachnoid Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704694-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02565
Age:45 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia
Disability	Blood Cholesterol

	Increased						
	Cardiac Disorder						
	Diabetes Mellitus						
	Hypertension	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Major Depression		Vioxx	PS	Merck & Co., Inc	ORAL	
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
	Pain In Extremity		Flexeril	C		ORAL	
	Respiratory Disorder		Talwin Nx	C			UNKNOWN
	Stress						

Date:06/30/05ISR Number: 4704695-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03088
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Nausea		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Syncope		Vioxx	SS	Merck & Co., Inc	ORAL	

Date:06/30/05ISR Number: 4704696-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04797
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	52 MON
Initial or Prolonged	Atherosclerosis		Norvasc	C			UNKNOWN
Other	Cardiac Disorder		Vasotec	C			UNKNOWN 558 DAY
	Cardiac Failure		Neurontin	C			UNKNOWN
	Congestive		Tenormin	C			UNKNOWN 470 DAY
	Cardiac Pacemaker Battery		Furosemide	C			UNKNOWN
	Replacement		Digitek	C			UNKNOWN
	Cardiovascular Disorder		Coumadin	C			UNKNOWN
	Cerebrovascular Accident		Atenolol	C			UNKNOWN

	Chest Pain	Amoxil	C
UNKNOWN			
	Coagulopathy	Novolin	C
UNKNOWN			
	Coronary Artery Disease	[Therapy	
	Deep Vein Thrombosis	Unspecified]	C
UNKNOWN			
	Gastric Ulcer	Zoloft	C
UNKNOWN	1 YR		
	Glaucoma	Enalapril Maleate	C
UNKNOWN			
	Heart Disease Congenital	Paxil	C
UNKNOWN	1 YR		
	Heart Rate Irregular	Plavix	C
UNKNOWN			
	Hypertension	Paroxetine	C
UNKNOWN			
	Infarction		
	Mitral Valve Incompetence		
	Myocardial Infarction		
	Oedema Peripheral		
	Scar		
	Transient Ischaemic		
	Attack		
	Tricuspid Valve		
	Incompetence		
	Ventricular Dysfunction		
	Ventricular Extrasystoles		

Date:06/30/05ISR Number: 4704698-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04798
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Anaemia
Disability	Cardiac Failure
	Congestive

		Cerebrovascular Accident					
		Chronic Obstructive Pulmonary Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Diverticulum		Glyburide	C		ORAL
		Gastritis Erosive		Calan	C		
UNKNOWN							
		Gastrointestinal		Lasix (Furosemide)	C		
UNKNOWN							
		Haemorrhage		Aspirin	C		
UNKNOWN							
		Haemorrhoids		Hydroxychloroquine Sulfate	C		
		Hypotension					
UNKNOWN							
		Ischaemic Cardiomyopathy		Altace	C		
UNKNOWN							
		Leukocytosis		Isosorbide Dinitrate	C		
UNKNOWN							
		Mitral Valve Incompetence		Pletal	C		
UNKNOWN							
		Myocardial Infarction		Protonix	C		
UNKNOWN							
		Peripheral Vascular		Lantus	C		
UNKNOWN							
		Disorder		Augmentin	C		
UNKNOWN							
		Pneumonia					
		Pulmonary Oedema					
		Renal Failure Acute					
		Therapeutic Agent Toxicity					
		Transient Ischaemic Attack					
		Urinary Tract Infection					

Date:06/30/05ISR Number: 4704705-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03808
Age:78 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Colonic Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Retinal Vein Occlusion		Atenolol	C		
UNKNOWN							

				Zoloft	C		
UNKNOWN							
				Buspar	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:06/30/05ISR Number: 4704707-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704708-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	49	MON

Date:06/30/05ISR Number: 4704718-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4704719-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03593
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704720-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704721-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03562
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704722-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03785
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Cerebrovascular Accident							

Date:06/30/05ISR Number: 4704723-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03341
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:06/30/05ISR Number: 4704724-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:06/30/05ISR Number: 4704725-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Myocardial Infarction							

Date:06/30/05ISR Number: 4704726-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03548
Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Malaise		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
Initial or Prolonged	Pain		Celebrex	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/30/05ISR Number: 4704727-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704728-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02663
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Atrial Fibrillation		Glucophage	C				
UNKNOWN								
	Blood Cholesterol		Aspirin	C				
UNKNOWN								
	Increased		Plavix	C				
UNKNOWN								
	Brain Stem Infarction		Lipitor	C				
UNKNOWN								
	Constipation		Altace	C				
UNKNOWN								
	Coronary Artery Disease		Zocor	C				
UNKNOWN								
	Heart Rate Irregular		Glucotrol	C				
UNKNOWN								
	Hypertension		Ibuprofen	C				
UNKNOWN								
	Mitral Valve Incompetence		Celebrex	C				
UNKNOWN								
	Neuropathy Peripheral							
	Overdose							

Date:06/30/05ISR Number: 4704729-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Abdominal Pain
Other	Anaemia
	Angina Unstable

Asthenia
Asthma
Bronchitis
Cardiomegaly
Carotid Artery Stenosis
Cerebrovascular Accident
Constipation
Contusion
Dehydration
Dementia Alzheimer'S Type
Dizziness
Gastritis
Glaucoma
Goitre
Headache
Hepatocellular Damage
Hypoglycaemia
Insomnia
Osteoporosis
Parkinson'S Disease
Renal Failure
Rheumatoid Arthritis
Thyroid Neoplasm
Transient Ischaemic
Attack
Urinary Incontinence
Urinary Tract Infection
Vertigo

	Vomiting						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:06/30/05ISR Number: 4704837-0Report Type:Direct Company Report #CTU 252324
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx				25 Mg	
Hospitalization -			Merke	PS	Merke			
Initial or Prolonged			Celebrex	SS				
Required Intervention to Prevent Permanent Impairment/Damage								

Date:07/01/05ISR Number: 4705166-1Report Type:Expedited (15-DaCompany Report #IE-MERCK-0410GBR00156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705172-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		17 MON
	Blood Creatinine		Vioxx	SS	Merck & Co., Inc	ORAL		8 WK
	Increased		Hydrodiuril	SS		ORAL		
	Blood Pressure Increased		Methotrexate	C				
UNKNOWN								2219 DAY

	Cerebral Infarction		Folic Acid	C		ORAL
	Dermatitis Contact		Toprol Xl Tablets	C		ORAL
	Dizziness		Aspirin	C		
UNKNOWN						
	Hyperlipidaemia					
	Hypertension					
	Non-Cardiac Chest Pain					
	Peripheral Coldness					
	Sinusitis					
	Stomach Discomfort					
	Transient Ischaemic					
	Attack					

Date:07/01/05ISR Number: 4705174-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03171
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
22 MON						
Hospitalization -	Blood Cholesterol		Glucophage	C		
UNKNOWN						
Initial or Prolonged	Increased		Glucotrol	C		
UNKNOWN						
	Cardiac Failure		Imdur	C		
UNKNOWN						
	Congestive		Cozaar	C		
UNKNOWN						
	Gastrointestinal		Demadex	C		
UNKNOWN						
	Haemorrhage		Prosom	C		
UNKNOWN						
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705177-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03584
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705181-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705182-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02645
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1769 DAY
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1769 DAY
Initial or Prolonged	Coronary Artery Occlusion		Toprol Xl Tablets	C		ORAL		UNKNOWN
	Myocardial Infarction		Toprol Xl Tablets	C		ORAL		UNKNOWN
			Norvasc	C				
			Foltx	C				
			Pravachol	C		ORAL		
			Meperidine Hydrochloride	C				UNKNOWN
			Altace	C		ORAL		
			Metaglip	C		ORAL		
			Ecotrin	C		ORAL		

Date:07/01/05ISR Number: 4705184-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02712
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
	Drug Administration Error		Diovan	C				
UNKNOWN								
	Hyperlipidaemia		Tenormin	C				
UNKNOWN								
	Hypertension		Restoril	C				
UNKNOWN								
	Insomnia		Hydrodiuril	C				
UNKNOWN								
	Ischaemic Cerebral		Lisinopril	C				
UNKNOWN								
	Infarction							
	Lobar Pneumonia							
	Palpitations							
	Rotator Cuff Syndrome							
	Sacroiliitis							

Date:07/01/05ISR Number: 4705185-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01524
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705186-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00523
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrial Flutter		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Arrest		Tylenol	C				
UNKNOWN								
	Chronic Obstructive		Elavil	C				
UNKNOWN								
	Pulmonary Disease		Fosamax	C		ORAL		
	Confusional State		Premarin	C				
UNKNOWN								
	Depression							
	Dizziness							
	Flank Pain							
	Headache							
	Leukocytosis							
	Myocardial Infarction							
	Nausea							
	Pneumonia							
	Renal Infarct							
	Respiratory Distress							
	Respiratory Failure							
	Staphylococcal Infection							
	Supraventricular							
	Tachycardia							
	Vomiting							
	Weight Decreased							

Date:07/01/05ISR Number: 4705187-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01653
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Aspirin	C				
UNKNOWN								
	Blood Cholesterol		Sulfasalazine	C				
UNKNOWN								
	Increased		Pravachol	C				
UNKNOWN								

	Chronic Obstructive	Plavix	C
UNKNOWN			
	Pulmonary Disease	Metoprolol	C
UNKNOWN			
	Coronary Artery Disease	Acetaminophen And	
	Depression	Hydrocodone	
	Hypertension	Bitartrate	C
UNKNOWN			
	Hyponatraemia	Combivent	C
UNKNOWN			
	Myocardial Infarction	Pepcid	C
UNKNOWN			
	Pain	Norvasc	C
UNKNOWN			
	Respiratory Failure	Actonel	C
UNKNOWN			
	Transient Ischaemic		
	Attack		

Date:07/01/05ISR Number: 4705188-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00125
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Exanthem		Vioxx	SS	Merck & Co., Inc	ORAL
	Headache		Calcium Gluconate			
			And Calcium			
			Phosphate Tribasic			
			And Cholecalciferol	C		
UNKNOWN						
			Rabeprazole Sodium	C		
UNKNOWN						
			Methotrexate Sodium	C		
UNKNOWN						

			Methotrexate Sodium	C		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN						
			Minocycline	C		
UNKNOWN						

Date:07/01/05ISR Number: 4705190-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03187
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
							4	YR
	Anxiety Disorder		Motrin	C				
UNKNOWN								
	Blood Cholesterol		Motrin	C				
UNKNOWN								
	Increased							
	Cerebrovascular Accident							
	Chronic Fatigue Syndrome							
	Convulsion							
	Hernia							
	Pain In Extremity							
	Sleep Apnoea Syndrome							

Date:07/01/05ISR Number: 4705260-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03866
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
							5	WK
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
							5	WK

	Coronary Artery Stenosis	Cozaar	C	ORAL
		Lasix (Furosemide)	C	ORAL
		Aspirin	C	ORAL
		Pravachol	C	ORAL
		Vicodin Tablets	C	ORAL
		Soma	C	ORAL
		Nitrostat	C	
UNKNOWN				
		Potassium Chloride	C	ORAL
		Vitamins (Unspecified)	C	
UNKNOWN				

Date:07/01/05ISR Number: 4705734-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00843
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Psychosis
Other	Basal Cell Carcinoma
	Cerumen Impaction
	Chest Pain
	Coronary Artery Disease
	Depression
	Fall
	Gastric Disorder
	Hiatus Hernia
	Hypertension
	Injury
	Irritable Bowel Syndrome

		Joint Sprain					
		Macular Degeneration					
		Myalgia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nasal Septum Deviation		Vioxx	PS	Merck & Co., Inc	ORAL
		Nasal Ulcer		Aspirin	C		
UNKNOWN							
		Nasopharyngeal Reflux		Zocor	C		ORAL
		Night Sweats		Zocor	C		ORAL
		Osteoarthritis		Tylenol	C		
UNKNOWN							
		Pain		Vicodin Tablets	C		
UNKNOWN							
		Pelvic Pain					
		Pneumonitis					
		Pyrexia					
		Reflux Oesophagitis					
		Rhinitis					
		Sleep Disorder					
		Tetany					
		Tinnitus					
		Urethral Stricture					
		Urinary Tract Infection					
		Vertigo					

Date:07/01/05ISR Number: 4705735-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Acute Pulmonary Oedema
Disability	Anxiety
Other	Aortic Valve Incompetence
	Asthenia
	Blood Cholesterol
	Increased
	Bundle Branch Block
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Convulsion
	Coronary Artery Disease
	Cystocele

Depression
Diabetes Mellitus
Inadequate Control
Diabetic Ketoacidosis
Emotional Distress
Emphysema
Hypertension
Hypokalaemia
Intervertebral Disc
Degeneration
Mitral Valve Incompetence
Myocardial Infarction
Nasopharyngitis
Palpitations
Rotator Cuff Syndrome
Supraventricular
Extrasystoles
Supraventricular
Tachycardia

	Transient Ischaemic Attack						
	Urinary Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL		
	Vision Blurred		Vioxx	SS	Merck & Co., Inc	ORAL		
			Lasix (Furosemide)	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Orphenadrine	C			UNKNOWN	
			Ativan	C			UNKNOWN	
			Lopressor	C			UNKNOWN	
			Glyburide	C			UNKNOWN	
			Glucotrol Xl	C			UNKNOWN	

Date:07/01/05ISR Number: 4705736-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00469
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Atenolol	C			UNKNOWN	
	Back Pain		Prozac	C			UNKNOWN	
	Blood Cholesterol		Prozac	C			UNKNOWN	
	Increased		Tylenol	C			UNKNOWN	
	Bradycardia		Buspar	C			UNKNOWN	
	Cardiac Failure		Atrovent	C			UNKNOWN	
	Congestive		Magnesium Sulfate	C			UNKNOWN	
	Cardio-Respiratory Arrest		Claforan	C			UNKNOWN	

	Cardiogenic Shock	Cordarone	C	
UNKNOWN				
	Cardiomyopathy	Pepcid	C	
UNKNOWN				
	Chest Pain	Reopro	C	
UNKNOWN				
	Convulsion	Dopamine Hydrochloride	C	
	Coronary Artery Disease			
UNKNOWN				
	Dizziness	Restoril	C	
UNKNOWN				
	Dyspnoea	Aspirin	C	ORAL
	Fall	Celexa	C	
UNKNOWN				
	Haematuria	Neurontin	C	
UNKNOWN				
	Hypertension	Dalmane	C	
UNKNOWN				
	Ischaemic Cardiomyopathy	Vasotec	C	
UNKNOWN				
	Limb Discomfort			
	Loss Of Consciousness			
	Lung Infiltration			
	Myalgia			
	Myocardial Infarction			
	Nasopharyngitis			
	Nausea			
	Neck Pain			
	Orthostatic Hypotension			
	Papilloma			
	Skin Laceration			
	Skin Lesion			
	Syncope			
	Upper Respiratory Tract Infection			
	Ventricular Tachycardia			
	Vomiting			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705741-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Ibuprofen	C				
UNKNOWN								
	Hiatus Hernia		Feosol	C				
UNKNOWN								
	Hypertension		Atenolol	C				
UNKNOWN								
	Inflammation		Prevacid	C				
UNKNOWN								
	Joint Injury		Relafen	C				
UNKNOWN								
	Peptic Ulcer Haemorrhage							

Date:07/01/05ISR Number: 4705743-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00111
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
4 YR								
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Ultram	C				
UNKNOWN								
	Drug Effect Decreased		Lasix (Furosemide					
	Dyspepsia		Sodium)	C				
UNKNOWN								
	Fungal Infection		Prilosec	C				
UNKNOWN								
	Gastric Disorder		Clonidine	C				
UNKNOWN								
	Haematuria		Acetaminophen And					
	Knee Arthroplasty		Hydrocodone					
	Malignant Hypertension		Bitartrate	C				
UNKNOWN								
	Nephrolithiasis		Tizanidine	C				
UNKNOWN								
	Nerve Injury		Premarin	C				
UNKNOWN								
	Oedema Peripheral							
	Osteoarthritis							

Rash Generalised
Renal Cyst
Renal Pain
Swelling Face
Thrombosis
Transient Ischaemic
Attack
Urinary Tract Infection
Vaginal Haemorrhage

Date:07/01/05ISR Number: 4705745-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01794
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Disability	Abdominal Pain Upper
Other	Adnexa Uteri Mass
	Anxiety
	Azotaemia
	Back Pain
	Blepharitis
	Candidiasis
	Cardiac Failure
	Congestive
	Cellulitis
	Cervicitis
	Cough
	Cystitis
	Diarrhoea
	Dyspnoea

		Emotional Distress					
		Endometrial Hyperplasia					
		Epistaxis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fallopian Tube Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
401 DAY							
		Fistula		Vioxx	SS	Merck & Co., Inc	ORAL
3 MON							
		Fluid Retention		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastritis		Ultram	C		
UNKNOWN							
		Helicobacter Pylori Identification Test		Ventolin (Albuterol Sulfate)	C		
UNKNOWN							
		Positive		Tenormin	C		
UNKNOWN							
		Hypertension		Vasotec	C		ORAL
		Infection		Cenestin	C		
UNKNOWN							
		Irritable Bowel Syndrome		Lodine Xl	C		
UNKNOWN							
		Lower Extremity Mass		Quinine Sulfate	C		
UNKNOWN							
		Melaena		K-Dur	C		
UNKNOWN							
		Meniscus Lesion		Ditropan	C		
UNKNOWN							
		Mobility Decreased		Lasix (Furosemide)	C		
UNKNOWN							
		Mood Swings		Lasix (Furosemide)	C		
UNKNOWN							
		Myocardial Infarction					
		Nausea					
		Nervousness					
		Neuropathic Pain					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Ovarian Fibrosis					
		Pain In Extremity					
		Palpitations					
		Peau D'Orange					
		Pharyngolaryngeal Pain					
		Pickwickian Syndrome					
		Pneumonia					
		Post Procedural Haemorrhage					

Pulmonary Oedema
Retching
Supraventricular
Tachycardia
Upper Respiratory Tract
Infection
Urinary Tract Infection
Weight Increased

Date:07/01/05ISR Number: 4705751-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0504CHE00006
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Tonsillitis		Vioxx	PS	Merck & Co., Inc	ORAL		985 DAY
Hospitalization -	Aneurysm Ruptured		Vioxx	SS	Merck & Co., Inc	ORAL		459 DAY
Initial or Prolonged	Cardiac Tamponade Myocardial Infarction		Tamsulosin Hydrochloride	C		ORAL		
			Flupentixol Hydrochloride And Melitracen Hydrochloride	C		ORAL		
			Zolpidem Tartrate	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705759-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03120
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vicodin Tablets	SS				
	Fall							
	Fatigue							
	Gastritis Haemorrhagic							
	Gastrooesophageal Reflux Disease							
	Oesophageal Ulcer							
	Upper Gastrointestinal Haemorrhage							

Date:07/01/05ISR Number: 4705760-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03197
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Triglycerides		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Aspirin	C				
	Fibromyalgia		Premarin	C				
	Gastrooesophageal Reflux		Nexium	C				
	Disease		Paxil	C				
	Haematochezia							
	Hypertension							
	Pulmonary Embolism							

Date:07/01/05ISR Number: 4705761-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0506CAN00200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:07/01/05ISR Number: 4705762-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02888
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rectal Haemorrhage		Plavix	C			UNKNOWN	
	Sinus Disorder		Toprol Xl Tablets	C			UNKNOWN	
	Transient Ischaemic		Folic Acid	C			UNKNOWN	
	Attack		Celexa	C			UNKNOWN	
			Zocor	C		ORAL		
			Lisinopril	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

Date:07/01/05ISR Number: 4705763-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01751
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Sinusitis
	Angina Unstable
Other	Blood Cholesterol Increased
	Bone Pain

		Cardiac Failure Congestive					
		Constipation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR						
		Fibromyalgia		Arava	C		
UNKNOWN		1573 DAY					
		Generalised Anxiety		Remicade	C		
UNKNOWN							
		Disorder		Prevacid	C		
UNKNOWN							
		Haemorrhoids		Levaquin	C		
UNKNOWN		11 DAY					
		Headache		Norco	C		
UNKNOWN							
		Hypertension		Valium	C		
UNKNOWN							
		Myocardial Infarction		Delestrogen	C		
UNKNOWN							
		Nausea		Vicodin Tablets	C		
UNKNOWN							
		Oedema					
		Pneumonia					
		Rash					
		Sinus Tachycardia					
		Stomatitis					
		Tearfulness					
		Tendon Sheath Incision					
		Tooth Abscess					
		Upper Respiratory Tract Infection					

Date:07/01/05ISR Number: 4705764-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01517
Age:43 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
427	DAY						
		Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL
427	DAY						

	Back Pain	Valium	C
UNKNOWN			
	Blindness	Ambien	C
UNKNOWN			
	Cerebrovascular Accident	[Therapy	
	Chest Discomfort	Unspecified]	C
RESPIRATORY			
	Chest Pain		
(INHALATION)			
	Confusional State		
	Dyspnoea		
	Hypoaesthesia		
	Hypokinesia		
	Hypotrichosis		
	Limb Discomfort		
	Loss Of Consciousness		
	Memory Impairment		
	Muscle Spasms		
	Nausea		
	Oedema Peripheral		
	Pain		
	Pain In Extremity		
	Palpitations		
	Respiratory Failure		
	Road Traffic Accident		
	Teeth Brittle		
	Vision Blurred		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705765-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00562
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		616 DAY
Initial or Prolonged	Knee Arthroplasty		Hytrin	C		ORAL		
	Renal Disorder		Tylenol	C		ORAL		
	Renal Failure		Premarin	C		ORAL		

Date:07/01/05ISR Number: 4705766-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00146
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Drug Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Duodenitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Crisis		Metformin Hydrochloride	C		ORAL		
	Myocardial Infarction		Indomethacin	C		ORAL		
	Ventricular Hypertrophy		Indomethacin	C		ORAL		
			Sotalol Hydrochloride	C		ORAL		
			Atorvastatin Calcium	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Enalapril Maleate	C				UNKNOWN
			Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Hydrochlorothiazide And Triamterene	C				UNKNOWN
			Captopril	C				UNKNOWN

Date:07/01/05ISR Number: 4705767-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00087
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening			Nitrendipine	C				
UNKNOWN								
Hospitalization - Initial or Prolonged	Acute Prerenal Failure		Magnesium Aspartate And Magnesium Citrate And Magnesium Glutamate And Magnesium	C				
Disability	Cardiogenic Shock							
	Cerebrovascular Accident							
	Crest Syndrome							
	Intestinal Infarction							
UNKNOWN								
	Multi-Organ Failure		Amitriptyline Hydrochloride	C				
	Peripheral Embolism							
UNKNOWN								
	Tachyarrhythmia		Tramadol Hydrochloride	C				
UNKNOWN								
			Metoclopramide	C				
UNKNOWN								

Date:07/01/05ISR Number: 4705770-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Accident At Home
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Angina Pectoris
	Anxiety
	Atrial Septal Defect
	Balance Disorder
	Bipolar Disorder
	Borderline Personality
	Disorder
	Bradycardia
	Breast Pain
	Bursitis
	Cardiac Aneurysm
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cellulitis
	Cerebral Infarction
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Death
	Diverticulum
	Drug Abuser
	Drug Dependence
	Dyspnoea
	Emotional Distress
	Fibromyalgia
	Haemorrhoids
	Headache
	Hyperkalaemia
	Hypertrophy Breast
	Hyponatraemia
	Injury
	Intermittent Claudication
	Intracranial Aneurysm
	Lacunar Infarction
	Leukocytosis
	Limb Discomfort

Major Depression
Mitral Valve Incompetence
Myocardial Infarction
Obsessive-Compulsive
Disorder
Oedema Peripheral
Overdose
Pain
Pain In Extremity
Pollakiuria
Pulmonary Hypertension
Skin Cancer
Spinal Osteoarthritis
Suicidal Ideation
Transient Ischaemic

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Attack Tricuspid Valve Incompetence Upper Respiratory Tract					
		Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Varices Oesophageal		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN	668 DAY						
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN	96 DAY						
				Neurontin	C		
UNKNOWN							
				Vicodin Tablets	C		
UNKNOWN							
				Seroquel	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Ativan	C		
UNKNOWN							
				Monopril	C		ORAL
				Norvasc	C		
UNKNOWN							
				Lithium Carbonate	C		ORAL
				Lithium Carbonate	C		ORAL
				Zyprexa	C		ORAL
				Zyprexa	C		ORAL
				Zithromax	C		ORAL
4 DAY							
				Navane	C		ORAL
				Cogentin	C		ORAL
				Tegretol-Xr	C		ORAL
				Claritin-D	C		
UNKNOWN							

Date:07/01/05ISR Number: 4705771-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00629
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Exercise Tolerance Decreased Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705772-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00673
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		121 DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		121 DAY
			Lipitor	C				UNKNOWN
			Zocor	C		ORAL		
			Saw Palmetto	C				UNKNOWN

Date:07/01/05ISR Number: 4705773-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02485
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		1858 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
Other			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		1858 DAY
			Coumadin	C				UNKNOWN
			Atacand Hct	C				UNKNOWN

		Lasix (Furosemide)	C	
UNKNOWN				
		Singulair	C	ORAL
		Mucinex	C	
UNKNOWN				
		Fosamax	C	ORAL
		Restoril	C	
UNKNOWN				
		Citracal	C	
UNKNOWN				
		Protonix	C	
UNKNOWN				
		Advair	C	
UNKNOWN				
		Sotalol Hydrochloride	C	
UNKNOWN				
		Vitamins (Unspecified)	C	
UNKNOWN				

Date:07/01/05ISR Number: 4705774-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01266
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Allergic Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	1211 DAY	
	Coronary Artery Disease		Diovan	C				
UNKNOWN							124 DAY	
	Drug Ineffective		Bisoprolol Fumarate	C				
UNKNOWN							882 DAY	
	Liver Function Test		Lipitor	C				
UNKNOWN								
	Abnormal		Zocor	C		ORAL	999 DAY	
	Muscle Atrophy		Pravachol	C				
UNKNOWN							938 DAY	
	Myocardial Infarction		Flomax (Morniflumate)	C				
	Onychomycosis							
UNKNOWN								
	Peripheral Vascular		Prilosec	C				
UNKNOWN								
	Disorder		Guaifenesin	C				
UNKNOWN								

Metoclopramide C
UNKNOWN

Omeprazole C
UNKNOWN

Date:07/01/05ISR Number: 4705775-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04380
Age:75 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Aortic Stenosis
	Aortic Valve Incompetence
	Arthralgia
	Back Injury
	Back Pain
	Blood Calcium Increased
	Blood Pressure Increased
	Cerebral Infarction
	Cerebrovascular Accident
	Contusion
	Depression
	Dilatation Atrial
	Diverticulum
	Dyspepsia
	Gastrointestinal
	Haemorrhage
	Headache
	Herpes Zoster
	Hiatus Hernia
	Hypocoagulable State
	Insomnia
	Intervertebral Disc
	Degeneration
	Intervertebral Disc

		Protrusion					
		Iron Deficiency Anaemia					
		Kyphosis					
		Ligament Sprain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mental Status Changes		Vioxx	PS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Strain		Vioxx	SS	Merck & Co., Inc	ORAL
		Myofascial Pain Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Neuralgia		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoarthritis					
		Osteopenia					
		Pathological Fracture					
		Post Herpetic Neuralgia					
		Sciatica					
		Sedation					
		Spinal Osteoarthritis					
		Spondylolisthesis					
		Transient Ischaemic					
		Attack					
		Tricuspid Valve					
		Incompetence					
		Vaginal Haemorrhage					
		Ventricular Hypertrophy					

Date:07/01/05ISR Number: 4705776-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04638
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
39 MON						
Initial or Prolonged	Depression		Zetia	C		
UNKNOWN						
	Transient Ischaemic		Allegra-D	C		
UNKNOWN						
	Attack		Levoxyl	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Os-Cal 500 + D	C		
UNKNOWN						
			Chondroitin Sulfate			

			Sodium And Glucosamine Hydrochloride	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			Fosamax	C		
UNKNOWN						
			Trazodone Hydrochloride	C		
UNKNOWN						
			Celebrex	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						
			Prempro	C		
UNKNOWN						
			Prozac	C		
UNKNOWN						
			Fluoxetine	C		
UNKNOWN						

Date:07/01/05ISR Number: 4705781-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04637
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Mysoline	C				
UNKNOWN								
	Myocardial Infarction		Lipitor	C				
UNKNOWN								
	Overdose		Paxil	C				
UNKNOWN								

	Doxepin Hydrochloride	C	UNKNOWN
	Acetaminophen And Hydrocodone Bitartrate	C	UNKNOWN
	Premarin	C	UNKNOWN
	Aspirin	C	UNKNOWN
	Nortriptyline	C	UNKNOWN
	Carisoprodol	C	UNKNOWN
	Prevacid	C	UNKNOWN

Date:07/01/05ISR Number: 4705786-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03569
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705787-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03574
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	1232 DAY	

Date:07/01/05ISR Number: 4705789-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	34 MON	

Date:07/01/05ISR Number: 4705790-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03974
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705791-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0506GBR00109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705792-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03595
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705793-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705794-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03594
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705795-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00023
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1261 DAY	
			Simvastatin	C			UNKNOWN	
			Metoprolol Tartrate	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Prednisolone	C			UNKNOWN	
			Magnesium Oxide And Aspirin	C			UNKNOWN	

Date:07/01/05ISR Number: 4705796-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705797-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03251
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Glucovance	C			UNKNOWN	

Disability	Diabetes Mellitus	Nph Insulin	C	
UNKNOWN				
	Non-Insulin-Dependent			
	Hypertension			

Date:07/01/05ISR Number: 4705798-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00572
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Fatigue							
Initial or Prolonged	Gastrointestinal							
Disability	Perforation							
	Peritonitis							

Date:07/01/05ISR Number: 4705799-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03878
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Appendix Disorder
	Atrial Fibrillation
	Atrioventricular Block
	First Degree
	Carpal Tunnel
	Decompression
	Cataract

		Colitis Ischaemic					
		Coronary Artery Disease					
		Coronary Artery	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Perforation		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Stenosis		Norvasc	C		
UNKNOWN							
		Drug Hypersensitivity					
		Fibromuscular Dysplasia					
		Gallbladder Disorder					
		Gastroenteritis					
		Hyperlipidaemia					
		Hysterectomy					
		Irritable Bowel Syndrome					
		Legionella Infection					
		Pneumoperitoneum					
		Renal Artery					
		Fibromuscular Dysplasia					
		Renal Artery Stenosis					
		Renovascular Hypertension					
		Rotator Cuff Syndrome					
		Small Intestinal					
		Obstruction					
		Thyroid Neoplasm					
		Ventricular Extrasystoles					

Date:07/01/05ISR Number: 4705800-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03777
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/01/05ISR Number: 4705801-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03970
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL

Date:07/01/05ISR Number: 4705802-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03606
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705803-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03514
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Dysuria		Vioxx	PS	Merck & Co., Inc	ORAL		
	Gastrointestinal Motility Disorder		Prozac	C				
	Haemorrhoids		[Therapy Unspecified]	C				
	Intestinal Obstruction							
	Myocardial Infarction							
	Polyp							
	Road Traffic Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705804-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Dementia Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705805-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03940
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705806-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03813
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	

Date:07/01/05ISR Number: 4705807-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03776
Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/01/05ISR Number: 4705808-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03909
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/01/05ISR Number: 4705809-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03955
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
	Disease		Lisinopril	C		
UNKNOWN						
	Ulcer					
	Ulcer Haemorrhage					

Date:07/01/05ISR Number: 4705810-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705814-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02545
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		112 DAY
Initial or Prolonged	Angina Pectoris		Propranolol					
Disability	Anxiety		Hydrochloride	C				
UNKNOWN								
	Aortic Stenosis		Darvocet-N	C				
UNKNOWN								
	Appetite Disorder							
	Atrioventricular Block							
	First Degree							
	Cardiac Disorder							
	Cardiac Murmur							
	Carotid Artery Disease							
	Carotid Bruit							
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Disease							
	Depression							
	Dyspepsia							
	Dyspnoea							
	Electrocardiogram T Wave							
	Abnormal							
	Fatigue							
	Femoral Arterial Stenosis							
	Gastric Disorder							
	Gastrooesophageal Reflux							
	Disease							
	Haematoma							
	Headache							
	Heart Rate Decreased							
	Hypertension							
	Iliac Artery Stenosis							
	Insomnia							
	Intermittent Claudication							
	Liver Function Test							
	Abnormal							
	Mitral Valve Stenosis							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Pain							
	Paralysis							
	Peripheral Occlusive							

Disease
Peripheral Vascular
Disorder
Rectal Haemorrhage
Soft Tissue Haemorrhage
Thrombosis
Ulnar Nerve Palsy
Weight Fluctuation

Date:07/01/05ISR Number: 4705815-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04061
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Hypertension		Synthroid	C				UNKNOWN
			Estrogens (Unspecified)	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/05ISR Number: 4705816-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03777
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diarrhoea		Lisinopril-Bc	C		TOPICAL		
Other	Gastrooesophageal Reflux		Nitroglycerin	C		UNKNOWN		
	Disease		Oxycontin	C		UNKNOWN		
			Codeine	C		UNKNOWN		
			Lisinopril-Bc	C		UNKNOWN		

Date:07/01/05ISR Number: 4707035-XReport Type:Expedited (15-DaCompany Report #S05-USA-03276-01
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder	Consumer	Lexapro					
Initial or Prolonged	Feeling Abnormal		(Escitalopram)	PS		ORAL	10 MG QD PO	
	Heart Rate Decreased		Vioxx (Rofecoxib)	SS		ORAL	25 MG QD PO	
	Loss Of Consciousness		Fosamax (Alendronate					
	Sensory Disturbance		Sodium)	SS		ORAL	70 MG QW PO	

Date:07/01/05ISR Number: 4707306-7Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arterial Catheterisation	Foreign	Tab Vioxx 50 Mg	PS		ORAL	1 MG/DAILY/PO	
Hospitalization -	Abnormal	Study						
Initial or Prolonged	Coronary Artery	Health						
	Insufficiency	Professional						
	Ventricular Hypokinesia							

Date:07/05/05ISR Number: 4706543-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON
	Transient Ischaemic Attack							

Date:07/05/05ISR Number: 4706544-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02710
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:07/05/05ISR Number: 4706546-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0505NOR00017
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Tamponade		Vioxx	PS	Merck & Co., Inc	ORAL	483	DAY
Life-Threatening	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	258	DAY
Hospitalization -			Vioxx	SS	Merck & Co., Inc	ORAL	483	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	258	DAY
			Lisinopril	C		ORAL		
			Esomeprazole	C		ORAL	1102	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/05ISR Number: 4706547-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:07/05/05ISR Number: 4706549-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706551-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706552-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	314	DAY

Date:07/05/05ISR Number: 4706553-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706554-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706555-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04320
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		38 MON
Initial or Prolonged	Atrial Thrombosis							
	Cardiac Disorder							
	Cardiac Failure							
	Congestive							
	Injury							

Date:07/05/05ISR Number: 4706557-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03455
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Aldactone	C				UNKNOWN
			Detrol	C				UNKNOWN
			Zantac	C				UNKNOWN

			[Therapy Unspecified]	C		UNKNOWN
			Minerals (Unspecified) And Vitamins (Unspecified)	C		UNKNOWN

Date:07/05/05ISR Number: 4706558-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03957
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Heart Injury							
	Ischaemia							

Date:07/05/05ISR Number: 4706559-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706560-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03944
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706561-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03992
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706562-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04315
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		26 MON
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		26 MON
Disability	Cardiac Valve Disease							
	Muscle Spasms							

Date:07/05/05ISR Number: 4706563-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/05/05ISR Number: 4706564-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03945
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706565-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/05/05ISR Number: 4706567-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03588
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	275 DAY	

Date:07/05/05ISR Number: 4708968-0Report Type:Expedited (15-DaCompany Report #2005086301
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain	Foreign	Tahor (Atorvastatin)	PS			10 MG 1 IN 1	
Hospitalization - D	Atrial Fibrillation	Health						
Initial or Prolonged	Blood Pressure Decreased	Professional	Omeprazole					
	Cardiogenic Shock	Company	(Omeprazole)	SS				
	Diarrhoea	Representative	Efferalgan Codeine					
	Gastroenteritis Viral		(Codeine Phosphate,					
	Hypercholesterolaemia		Paracetamol)	SS				
	Hypokalaemia		Celebrex (Celecoxib)	SS				
	Iatrogenic Injury		Diclofenac					
	Lung Disorder		(Diclofenac Sodium)	SS				
	Malaise		Vioxx (Rofecoxib)	SS				
	Renal Disorder							

Renal Tubular Acidosis
Syncope
Torsade De Pointes
Ventricular Extrasystoles
Ventricular Fibrillation
Ventricular Tachycardia
Vomiting

Date:07/06/05ISR Number: 4706841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	15	MON

Date:07/06/05ISR Number: 4706842-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04313
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4706843-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
	Cardiovascular Disorder							
	Multi-Organ Disorder							
	Myocardial Infarction							
	Pain							

Date:07/06/05ISR Number: 4706844-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706845-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04382
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706846-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Disorder							

Date:07/06/05ISR Number: 4706847-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00367
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/06/05ISR Number: 4706848-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00369
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706849-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706850-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00361
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4706852-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00373
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706853-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00376
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706854-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00374
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease Coronary Artery Stenosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706856-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00377
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706857-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03989
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	79	DAY

Date:07/06/05ISR Number: 4706858-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04378
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Prescribed Overdose		Vioxx	PS	Merck & Co., Inc			UNKNOWN
Initial or Prolonged	Renal Disorder		Vioxx	SS	Merck & Co., Inc			UNKNOWN
			Vioxx	SS	Merck & Co., Inc			UNKNOWN
			Vioxx	SS	Merck & Co., Inc			UNKNOWN
			Bextra	C				UNKNOWN

Date:07/06/05ISR Number: 4706859-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03966
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4706860-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706861-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01100
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706862-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12 MON	

Date:07/06/05ISR Number: 4706863-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03779
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706864-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02708
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706865-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01029
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4706866-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00175
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Aortic Calcification
	Arteriosclerosis
	Blood Cholesterol Increased
	Blood Homocysteine Increased
	Cardiac Murmur
	Chest Pain
	Coronary Artery Disease

		Coronary Artery Occlusion					
		Diabetes Mellitus					
		Inadequate Control	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Electrocardiogram T Wave		Vioxx	PS	Merck & Co., Inc	ORAL
		Abnormal		Elavil	C		ORAL
		Gastrooesophageal Reflux		Glyburide	C		
UNKNOWN							
		Disease		Cardizem	C		
UNKNOWN							
		Hypercholesterolaemia		Vasotec	C		ORAL
		Sinusitis		Allegra	C		
UNKNOWN							
		Somnolence		Serevent	C		
RESPIRATORY							
(INHALATION)							
				Azmacort	C		
RESPIRATORY							
(INHALATION)							
				Premarin	C		
UNKNOWN							
				Prilosec	C		ORAL

Date:07/06/05ISR Number: 4706867-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02046
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Brain Natriuretic Peptide		Lipitor	C		
UNKNOWN							
		Increased		Duragesic	C		
UNKNOWN							
		Cardiac Failure		Prevacid	C		
UNKNOWN							
		Congestive		Peri-Colace	C		
UNKNOWN							
		Cerebrovascular Accident		Senokot (Senna)	C		
UNKNOWN							
		Constipation					

Coronary Artery Disease
Decreased Appetite
Dehydration
Depression
Diverticulum
Emotional Distress
Faecaloma
Gastric Ulcer
Gastrooesophageal Reflux
Disease
Haemorrhoids
Hypertension
Irritable Bowel Syndrome
Ischaemic Cardiomyopathy
Lung Neoplasm
Mitral Valve Incompetence
Nausea
Panic Attack
Peptic Ulcer
Respiratory Failure
Ventricular Extrasystoles
Weight Decreased

Date:07/06/05ISR Number: 4706868-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02717
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4706869-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02384
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Hospitalization -	Dyslipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL		10 MON
Initial or Prolonged	Ear Pain		Trazodone					
Disability	Halitosis		Hydrochloride	C				
UNKNOWN								
	Hyperglycaemia							
	Ototoxicity							
	Postnasal Drip							
	Somnolence							
	Syncope							
	Varicose Vein							
	Weight Increased							

Date:07/06/05ISR Number: 4706870-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00640
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Brain Stem Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive		Insulin Human,					
	Convulsion		Isophane	C				
SUBCUTANEOUS								
	Leukocytosis		Prednisone	C				
UNKNOWN								
	Rash		Zaroxolyn	C				
UNKNOWN								
	Respiratory Failure		Lipitor	C				
UNKNOWN								
	Spleen Disorder		Spironolactone	C				
UNKNOWN								
			Wellbutrin Sr	C				
UNKNOWN								
			Premphase	C				
UNKNOWN								
			Actonel	C				
UNKNOWN								

	Plaquenil	C	
UNKNOWN			
	Colace	C	
UNKNOWN			
	K-Dur	C	
UNKNOWN			
	Ultram	C	ORAL
	Lasix (Furosemide)	C	
UNKNOWN			
	Azathioprine	C	ORAL
	Diflucan	C	
UNKNOWN			
	Zyban	C	
UNKNOWN			
	Actigall	C	
UNKNOWN			
	Methotrexate	C	
UNKNOWN			
	Celebrex	C	
UNKNOWN			

Date:07/06/05ISR Number: 4706871-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00845
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Valve Sclerosis
	Atelectasis
	Bronchitis
	Cerebrovascular Accident
	Dizziness
	Hypertension
	Injury
	Lacunar Infarction
	Mitral Valve Incompetence
	Otitis Media
	Plantar Fasciitis
	Sinusitis
	Therapy Non-Responder

	Tricuspid Valve Incompetence					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
17	MON					
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
17	MON					
			Vioxx	SS	Merck & Co., Inc	ORAL
			Tagamet	C		
UNKNOWN						
			Vitamins (Unspecified)	C		
UNKNOWN						
			Calcium (Unspecified)	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:07/06/05ISR Number: 4706872-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00763
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Angina Pectoris					
	Atelectasis					
	Blood Pressure Increased					
	Cardiac Disorder					
	Carpal Tunnel Syndrome					
	Chronic Sinusitis					
	Convulsion					
	Coronary Artery Disease					
	Cyst					
	Formication					
	Hyperlipidaemia					
	Intervertebral Disc Protrusion					
	Lumbar Radiculopathy					
	Lumbar Spinal Stenosis					
	Myocardial Infarction					
	Nasal Polyps					

Nasal Septum Deviation
Pain In Extremity
Radiculitis
Radiculopathy
Sinusitis
Spinal Osteoarthritis

Date:07/06/05ISR Number: 4706873-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00091
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Heart Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
			Clomipramine Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium					

Bicarbonate And Sodium Chloride	C		ORAL
Nebivolol Hydrochloride	C		ORAL
Lisinopril	C		ORAL

Date:07/06/05ISR Number: 4706874-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00472
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deafness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Metoprolol	C		ORAL		
	Disturbance In Attention		Allopurinol	C		ORAL		
	Encephalopathy		Ibuprofen	C				
UNKNOWN								
	Headache		Antipyrine	C				
UNKNOWN								
	Lacunar Infarction							
	Memory Impairment							
	Polyneuropathy							
	Retinopathy Hypertensive							
	Spinal Osteoarthritis							
	Tinnitus							
	Vertigo							
	Visual Field Defect							

Date:07/06/05ISR Number: 4706875-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00017
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Montelukast Sodium	C				
UNKNOWN								
	Coronary Artery Stenosis		Pentaerythritol Tetranitrate	C				
	Spinal Disorder							
UNKNOWN								
	Ventricular Tachycardia		Budesonide And Formoterol Fumarate	C				
UNKNOWN								

	Simvastatin	C
UNKNOWN		
	Fenoterol Hydrobromide And Ipratropium Bromide	C
UNKNOWN		

Date:07/06/05ISR Number: 4706876-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Pain
	Arthroscopy
	Asthenia
	Back Injury
	Back Pain
	Chest Pain
	Constipation
	Diverticulum
	Dizziness
	Ecchymosis
	Emotional Distress
	Facial Pain
	Hypertension
	Hypoaesthesia

		Inflammation					
		Intervertebral Disc Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ligament Sprain		Vioxx	PS	Merck & Co., Inc	ORAL
		Limb Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Loose Body In Joint		Vioxx	SS	Merck & Co., Inc	ORAL
		Monoparesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Chest		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Coumadin	C		
UNKNOWN							
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Pain					
		Pain In Extremity					
		Peripheral Embolism					
		Pyrexia					
		Renal Failure					
		Rheumatoid Arthritis					
		Sciatic Nerve Injury					
		Stress					
		Testicular Cyst					
		Urinary Tract Infection					

Date:07/06/05ISR Number: 4706881-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00697
Age:71 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Convulsion		Tenormin	C		
UNKNOWN							
		Coronary Artery Disease		Tenormin	C		
UNKNOWN							
		Deafness		Baycol	C		
UNKNOWN							
		Dystonia		Ogen	C		
UNKNOWN							
		Incontinence		Ogen	C		
UNKNOWN							
		Memory Impairment		Lipitor	C		
UNKNOWN							

	Mood Swings		Atenolol	C		
UNKNOWN						
	Myocardial Infarction		Flonase	C		
UNKNOWN						
	Respiratory Disorder		Bufferin	C		
UNKNOWN						
	Tinnitus					
	Torticollis					
	Tremor					
	Weight Increased					

Date:07/06/05ISR Number: 4706884-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02071
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Coronary Artery Disease							
	Haemorrhoids							
	Lumbar Radiculopathy							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707294-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL		2 DAY
Initial or Prolonged	Acute Myocardial							
Other	Infarction							
	Atherosclerosis							
	Cardiac Murmur							
	Cardiomyopathy							
	Cervicobrachial Syndrome							
	Chronic Obstructive							
	Pulmonary Disease							
	Diverticular Perforation							
	Diverticulitis							
	Drug Hypersensitivity							
	Hyperlipidaemia							
	Injury							
	Leukocytosis							
	Muscle Spasms							
	Prostatic Specific							
	Antigen Increased							
	Viral Infection							

Date:07/06/05ISR Number: 4707295-5Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00114
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Quinapril					
	Colon Adenoma		Hydrochloride	C				
UNKNOWN								
	Diverticulitis		Quinapril					
	Hiatus Hernia		Hydrochloride	C				
UNKNOWN								
	Left Ventricular Failure		Amitriptyline					
	Myocardial Ischaemia		Hydrochloride	C				
UNKNOWN								
	Papillary Thyroid Cancer		Amitriptyline					
	Thrombophlebitis		Hydrochloride	C				
UNKNOWN								

	Superficial	Aspirin	C
UNKNOWN			
	Varices Oesophageal	Piroxicam Betadex	C
UNKNOWN			
		Cholestyramine Resin	C
UNKNOWN			
		Methylprednisolone Acetate	C
UNKNOWN			
		Gliclazide	C
UNKNOWN			
		Doxepin Hydrochloride	C
UNKNOWN			
		Doxepin Hydrochloride	C
UNKNOWN			
		Venlafaxine Hydrochloride	C
UNKNOWN			
		Venlafaxine Hydrochloride	C
UNKNOWN			
		Acetaminophen And Codeine Phosphate	C
UNKNOWN			
		Zopiclone	C
UNKNOWN			
		Zopiclone	C
UNKNOWN			
		Ketorolac Tromethamine	C
UNKNOWN			
		Atropine Sulfate And Diphenoxylate Hydrochloride	C
UNKNOWN			

			Atropine Sulfate And Diphenoxylate Hydrochloride	C
UNKNOWN				
			Metformin Hydrochloride	C
UNKNOWN				
			Metronidazole	C
UNKNOWN				
			Morphine Sulfate	C
UNKNOWN				
			Naproxen	C
UNKNOWN				
			Lansoprazole	C
UNKNOWN	2	YR		
			Lansoprazole	C
UNKNOWN	2	YR		
			Lisinopril	C
UNKNOWN				
			Azithromycin	C
UNKNOWN				
			Zopiclone	C
UNKNOWN				
			Esomeprazole Magnesium	C
UNKNOWN				
			Temazepam	C
UNKNOWN				
			Nystatin	C
UNKNOWN				
			Paroxetine Hydrochloride	C
UNKNOWN				
			Paroxetine Hydrochloride	C
UNKNOWN				
			Acetaminophen And Codeine Phosphate	C
UNKNOWN				
			Gabapentin	C
UNKNOWN				
			Gabapentin	C
UNKNOWN				
			Orlistat	C
UNKNOWN				
			Acetaminophen And	

			Codeine Phosphate	C		
UNKNOWN						
			Celecoxib	C		
UNKNOWN						

Date:07/06/05ISR Number: 4707301-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00082
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastrointestinal Mucosal		Vioxx	SS	Merck & Co., Inc	ORAL
	Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertensive Crisis		Telmisartan	C		
UNKNOWN						
	Inguinal Hernia					
	Osteoarthritis					
	Reflux Oesophagitis					
	Renal Cyst					
	Sinoatrial Block					

Date:07/06/05ISR Number: 4707309-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/06/05ISR Number: 4707310-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707312-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Immunodeficiency		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
							6	DAY
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
							6	DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Kidney Infection		Dilantin	C				
							UNKNOWN	
	Pain In Extremity		Soma	C				
							UNKNOWN	

Date:07/06/05ISR Number: 4707313-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00108
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707314-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00045
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc			
							UNKNOWN	
Initial or Prolonged	Dyspnoea		Irbesartan	C				
							UNKNOWN	
	Myocardial Infarction		Metoprolol Tartrate	C				
							UNKNOWN	
	Pleural Effusion		Aspirin And Magnesium Oxide	C				
							UNKNOWN	
			Aspirin And					

			Magnesium Oxide	C		
UNKNOWN						
			Verapamil Hydrochloride	C		
UNKNOWN						

Date:07/06/05ISR Number: 4707315-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707316-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00175
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707317-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707318-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02952
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707319-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03403
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707340-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA03150
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Premarin	C				
UNKNOWN								
Other	Chest Discomfort		Percocet	C				
UNKNOWN								
	Depression							
	Dizziness							
	Drug Ineffective							
	Headache							
	Hypertension							
	Loss Of Consciousness							
	Myocardial Infarction							
	Pain In Extremity							
	Paraesthesia							
	Postoperative Infection							
	Road Traffic Accident							
	Staphylococcal Infection							
	Transient Ischaemic							
	Attack							
	Vitreous Floaters							

Date:07/06/05ISR Number: 4707342-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		501 DAY

Date:07/06/05ISR Number: 4707344-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00191
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		41 DAY

Date:07/06/05ISR Number: 4707345-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00187
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707346-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707347-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00307
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707348-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00188
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	936	DAY

Date:07/06/05ISR Number: 4707349-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	661	DAY

Date:07/06/05ISR Number: 4707350-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00202
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1011	DAY
	Pulmonary Embolism							

Date:07/06/05ISR Number: 4707358-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00283
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707386-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00147
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707614-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00158
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		821 DAY
Initial or Prolonged	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Sicca Syndrome		Amitriptyline					
	Speech Disorder		Hydrochloride	C		ORAL		30 DAY
	Thalamic Syndrome		Prednisone	C		ORAL		1083 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707616-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00113
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cauda Equina Syndrome		Metoclopramide	C			UNKNOWN	
	Cerebrovascular		Xipamide	C			UNKNOWN	
	Insufficiency		Clotrimazole And Hydrocortisone	C			TOPICAL	
	Cholelithiasis							
	Coronary Artery Disease		Calcium Citrate And Magnesium Citrate And Potassium Citrate	C			UNKNOWN	
	Depression							
	Dermatophytosis							
	Eczema							
	Erysipelas		Aspirin	C			UNKNOWN	
	Full Blood Count Abnormal		Celecoxib	C			UNKNOWN	
	Gastric Ulcer		Carbamazepine	C			UNKNOWN	
	Gastritis		Diclofenac	C			UNKNOWN	
	Goitre		Omeprazole	C			UNKNOWN	
	Gouty Arthritis		Ciprofloxacin Hydrochloride	C			UNKNOWN	
	Haemorrhoids							
	Herpes Zoster		Fluocinolone Acetonide And Lidocaine Hydrochloride	C			UNKNOWN	
	Hypercholesterolaemia							
	Hypertension							
	Idiopathic Urticaria							
	Inflammation		Valacyclovir Hydrochloride	C			UNKNOWN	
	Muscle Spasms							
	Mycosis Fungoides		Dipyrone	C			UNKNOWN	
	Myocardial Infarction		Acetylcysteine	C			UNKNOWN	
	Nausea		Ranitidine Hydrochloride	C			UNKNOWN	
	Oesophagitis							

	Pain	Lactulose	C	
UNKNOWN				
	Parotitis	Levothyroxine Sodium	C	
UNKNOWN				
	Periarthritis	Hydrochlorothiazide	C	
UNKNOWN				
	Pollakiuria	Amitriptyline Hydrochloride	C	
	Polyneuropathy			
UNKNOWN				
	Proctitis	Tetrazepam	C	
UNKNOWN				
	Pulmonary Embolism	Enalapril Maleate	C	
UNKNOWN				
	Silent Myocardial Infarction	Fosamax	C	ORAL
		Prednisolone	C	
UNKNOWN				
	Skin Ulcer	Metoprolol Tartrate	C	
UNKNOWN				
	Spinal Osteoarthritis	Sodium Perchlorate	C	
UNKNOWN				
	Tenosynovitis			
	Thrombosis			
	Urinary Incontinence			
	Urticaria			
	Venous Insufficiency			

Date:07/06/05ISR Number: 4707618-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02351
Age:35 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive
Other	Cardiovascular Disorder
	Cerebrovascular Accident
	Depression
	Dyspnoea
	Emotional Distress
	Hypertension
	Migraine

	Muscle Spasms						
	Myocardial Infarction						
	Post Thrombotic Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY
	Stress		Vioxx	SS	Merck & Co., Inc	ORAL	20 DAY
	Vision Blurred		Motrin	C			UNKNOWN
			Tylenol	C			UNKNOWN
			Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN

Date:07/06/05ISR Number: 4707619-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00685
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL	840 DAY
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	840 DAY
	Diabetes Mellitus		Hydrochlorothiazide And Metoprolol Succinate	C			UNKNOWN 906 DAY
	Non-Insulin-Dependent						
	Hypertension						
	Post Thrombotic Syndrome		Ramipril	C			UNKNOWN
	Venous Insufficiency						

Date:07/06/05ISR Number: 4707623-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	54 MON
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	54 MON

Cerebrovascular Accident
Myocardial Infarction

Date:07/06/05ISR Number: 4707624-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03966
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707626-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707630-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03154
Age: Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive Chest Pain Depression Dyspnoea Headache Hypertension

		Muscle Spasms					
		Myocardial Infarction					
		Renal Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Tylenol	C		ORAL
				Tylenol	C		ORAL
				Motrin	C		ORAL
				Motrin	C		ORAL

Date:07/06/05ISR Number: 4707631-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:07/06/05ISR Number: 4707633-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/06/05ISR Number: 4707634-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00374
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
750 DAY						

Date:07/06/05ISR Number: 4707635-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00125
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Exanthem	Vioxx	SS	Merck & Co., Inc	ORAL
	Headache	Methotrexate Sodium	C		
UNKNOWN					
		Methotrexate Sodium	C		
UNKNOWN					
		Methylprednisolone	C		
UNKNOWN					
		Methylprednisolone	C		
UNKNOWN					
		Methylprednisolone	C		
UNKNOWN					
		Rabeprazole Sodium	C		
UNKNOWN					
		Minocycline	C		
UNKNOWN					
		Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C		
UNKNOWN					

Date:07/06/05ISR Number: 4707636-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02087
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Distension
	Eructation
	Gastrooesophageal Reflux Disease
	Hypoaesthesia
	Joint Swelling

Oedema Mouth
Oedema Peripheral
Palatal Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Dilantin	C			UNKNOWN	
	Phenobarbital	C			UNKNOWN	
	Synthroid	C			UNKNOWN	

Date:07/06/05ISR Number: 4707640-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707641-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00165
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707642-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00164
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707643-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707644-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00167
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707645-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00148
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707646-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00144
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707647-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00135
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707648-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00161
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707649-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00145
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:07/06/05ISR Number: 4707650-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00143
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707652-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00296
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Thrombotic Stroke							

Date:07/06/05ISR Number: 4707653-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707654-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00201
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	40	MON

Date:07/06/05ISR Number: 4707655-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00284
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707658-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/06/05ISR Number: 4707659-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY
	Polytraumatism		Bextra	C		ORAL	697	DAY

Date:07/06/05ISR Number: 4707660-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03959
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707661-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00209
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1174	DAY

Date:07/06/05ISR Number: 4707662-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
1189 DAY						

Date:07/06/05ISR Number: 4707663-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
428 DAY						
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain					
	Choroidal Rupture					
	Pain In Extremity					
	Transient Ischaemic Attack					

Date:07/06/05ISR Number: 4707664-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00198
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
26 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4707665-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707666-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707667-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00185
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707668-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00184
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	49	MON

Date:07/06/05ISR Number: 4707669-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707670-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00173
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707671-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00199
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:07/06/05ISR Number: 4707672-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/06/05ISR Number: 4707676-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/06/05ISR Number: 4708495-0Report Type:Expedited (15-DaCompany Report #S05-USA-03147-01
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Cyst	Consumer	Celexa (Citalopram Hydrobromide)	PS				
	Deep Vein Thrombosis		Celebrex(Celecoxib)	SS				
	Dyspnoea		Vioxx(Rofecoxib)	SS				
	Head Injury		Aspirin	C				
	Memory Impairment		Vitamins	C				
	Myocardial Infarction		Calcium	C				
	Pallor							
	Paraesthesia							
	Paraesthesia Oral							
	Scar							

Date:07/07/05ISR Number: 4708280-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0504FRA00099
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	1140 DAY	
	Acute Myocardial Infarction							
	Angina Unstable							
	Coronary Artery Occlusion							
	Depression							

Date:07/07/05ISR Number: 4708281-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02096
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	7 MON	UNKNOWN
	Arthropathy		Humulin	C				
	Bradycardia		Lasix (Furosemide)	C				
	Cardiac Failure		Aldactone	C				

	Congestive	Diovan	C
UNKNOWN			
	Cardiogenic Shock	Prilosec	C
UNKNOWN			
	Diabetic Foot Infection	Zyloprim	C
UNKNOWN			
	Diarrhoea	Trental	C
UNKNOWN			
	Drug Intolerance	Aspirin	C
UNKNOWN			
	Fall	Norpramin	C
UNKNOWN			
	Gastritis	Avandia	C
UNKNOWN			
	Gastrointestinal	Lipitor	C
UNKNOWN			
	Haemorrhage	Sinequan	C
UNKNOWN			
	Hyperkalaemia	Neurontin	C
UNKNOWN			
	Myocardial Infarction	Premarin	C
UNKNOWN			
	Oesophagitis	Progesterone	C
UNKNOWN			
	Pain	Serevent	C
UNKNOWN			
	Renal Failure Acute	Albuterol	C
UNKNOWN			
	Shock Haemorrhagic		
	Sleep Apnoea Syndrome		

Date:07/07/05ISR Number: 4708283-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01341
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atherosclerosis
Initial or Prolonged	Blood Cholesterol
Disability	Increased
	Cardiac Failure

		Congestive					
		Cardiac Murmur					
		Chest Pain					
		Chronic Fatigue Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Colonic Polyp		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
21	MON						
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
21	MON						
		Dyspnoea		Ziac	C		
UNKNOWN							
		Ear Canal Injury		Bisoprolol	C		
UNKNOWN							
		Extrasystoles		Naproxen	C		
UNKNOWN							
		Haemorrhoids		Verapamil	C		
UNKNOWN							
		Hypertension		Tiazac	C		
UNKNOWN							
		Joint Swelling					
		Labyrinthitis					
		Myocardial Infarction					
		Post-Traumatic Stress					
		Disorder					
		Vertigo					

Date:07/07/05ISR Number: 4708284-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00921
Age:81 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Anaemia		Avalide	C		
UNKNOWN							
		Angina Pectoris		Cardura	C		
UNKNOWN							
		Aortic Valve Sclerosis		Plavix	C		
UNKNOWN							
		Atrial Fibrillation		Ecotrin	C		
UNKNOWN							
		Blood Pressure Increased					
		Cardiac Murmur					
		Cerebrovascular Accident					
		Colonic Polyp					

Convulsion
Cough
Depression
Diarrhoea
Dilatation Atrial
Diverticulum Intestinal
Dizziness
Fatigue
Frequent Bowel Movements
Gastritis Erosive
Haemorrhoids
Insomnia
Malaise
Mitral Valve Incompetence
Mitral Valve Sclerosis
Oesophageal Disorder
Pyrexia
Sick Sinus Syndrome
Tricuspid Valve
Incompetence
Ventricular Hypertrophy
Weight Decreased
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708286-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA00400
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia Of Chronic		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angiodysplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Lipitor	C			UNKNOWN	
	Diverticular Perforation		Lopressor	C			UNKNOWN	
	Dyspnoea		Dyazide	C			UNKNOWN	
	Gastritis		Prilosec	C			UNKNOWN	
	Gastrointestinal		Duragesic	C			TOPICAL	
	Haemorrhage		Voltaren	C			UNKNOWN	
	Gastrooesophageal Reflux		Zoloft	C			UNKNOWN	
	Disease		Celebrex	C			UNKNOWN	
	Muscle Spasms		Triamterene	C			UNKNOWN	
	Osteoarthritis		Denavir	C			UNKNOWN	
	Polyp Colorectal		Metoprolol	C			UNKNOWN	
	Rectal Haemorrhage							
	Small Intestinal Haemorrhage							

Date:07/07/05ISR Number: 4708287-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00329
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arrhythmia		Aspirin	C			UNKNOWN	

Other	Coronary Artery Disease		Tramadol			
	Dyspnoea		Hydrochloride	C		
UNKNOWN						
	Hypertension		Esomeprazole			
	Myocardial Infarction		Magnesium	C		
UNKNOWN						
			Sulfasalazine	C		
UNKNOWN						

Date:07/07/05ISR Number: 4708289-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00018
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Candesartan			
	Flushing		Cilexetil And			
	Hypertensive Heart		Hydrochlorothiazide	C		ORAL
	Disease		Nebivolol			
	Sinus Bradycardia		Hydrochloride	C		
UNKNOWN						
	Supraventricular		Beclomethasone			
	Tachycardia		Dipropionate	C		
RESPIRATORY						
(INHALATION)						
			Salmeterol Xinafoate	C		
RESPIRATORY						
(INHALATION)						
			Levothyroxine Sodium	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708290-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01959
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Glucophage Xr	C		ORAL		
	Gastric Disorder		Glucophage Xr	C			UNKNOWN	
	Headache		Glucophage Xr	C		ORAL		
	Hypertension		Lidocaine And Triamcinolone Acetonide	C		PARENTERAL	1	DAY
	Injury							
	Intracranial Aneurysm							
	Joint Dislocation							
	Labyrinthitis							
	Lower Limb Fracture							
	Overdose							
	Pain							
	Pharyngolaryngeal Pain							
	Pilonidal Cyst							
	Sinus Disorder							
	Sinusitis							

Date:07/07/05ISR Number: 4708307-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708308-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							

Date:07/07/05ISR Number: 4708309-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04277
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708310-5Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00039
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL		32 DAY
Initial or Prolonged	Hepatocellular Damage		Diclofenac Sodium	SS		ORAL		62 DAY
	Jaundice		Erythromycin	SS		ORAL		32 DAY
			Moxifloxacin Hydrochloride	SS		ORAL		32 DAY
			Carbamazepine	SS				UNKNOWN
			Clarithromycin	C		ORAL		8 DAY
			Azithromycin	C		ORAL		4 DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708312-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00170
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708313-0Report Type:Expedited (15-DaCompany Report #ES-MERCK-0505ESP00041
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gynaecomastia		Vioxx	PS	Merck & Co., Inc	ORAL	7	DAY

Date:07/07/05ISR Number: 4708320-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01922
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Bronchitis Bronchospasm Cerebrovascular Accident Chest Pain Dyspnoea Dyspnoea Paroxysmal Nocturnal Fatigue Gastrooesophageal Reflux Disease Headache Hyperhidrosis Hypertension Intervertebral Disc Disorder Nausea Oedema Peripheral Upper Respiratory Tract Infection		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708321-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708322-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON

Date:07/07/05ISR Number: 4708323-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00207
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708324-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00378
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Potassium (Unspecified)	C				
			Glucotrol	C				

UNKNOWN

UNKNOWN

Date:07/07/05ISR Number: 4708325-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708326-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00455
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708327-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00465
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708328-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00486
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/07/05ISR Number: 4708455-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/07/05ISR Number: 4708859-5Report Type:Expedited (15-DaCompany Report #2005087341
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation	Consumer Health	Bextra (Valdecoxib) Celebrex	PS		
Other	Chest Pain	Professional				
	Drug Ineffective		(Celecoxib)	SS		
	Heart Rate Irregular		Baclofen			
	Hepatic Cyst		(Baclofen)	SS		
	Multiple Sclerosis		Vioxx			
	Nausea		(Rofecoxib)	SS		
			Rebif			
			(Interferon Beta)	SS		

Biaxin (Clarithromycin)	SS	
Skelaxin (Metaxalone)	SS	

Date:07/07/05ISR Number: 4708909-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03303
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Amlodipine Besylate	C			UNKNOWN	
	Carotid Artery Stenosis		Prinivil	C			UNKNOWN	
	Cerebrovascular Accident		Rabeprazole Sodium	C			UNKNOWN	
	Colonic Polyp		Ranitidine	C			UNKNOWN	
	Convulsion		Tylenol	C			UNKNOWN	
	Diabetes Mellitus		Norvasc	C			UNKNOWN	
	Diverticulum							
	Dysphagia							
	Emotional Distress							
	Glaucoma							
	Haemorrhoids							
	Hiatus Hernia							
	Hypertriglyceridaemia							
	Ingrowing Nail							
	Lacrimation Increased							
	Low Density Lipoprotein Increased							
	Metaplasia							
	Partial Seizures							
	Vision Blurred							

Date:07/07/05ISR Number: 4708910-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00480
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Bladder Disorder
	Cardiac Stress Test Abnormal
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis
	Depression
	Diabetic Retinopathy
	Diarrhoea
	Dizziness
	Dysphagia
	Dyspnoea Exertional
	Electrocardiogram Abnormal
	Fatigue
	Gastroenteritis
	Hiatus Hernia
	Loss Of Consciousness
	Myocardial Ischaemia
	No Therapeutic Response
	Non-Cardiac Chest Pain

		Post-Traumatic Stress Disorder					
		Refusal Of Examination	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Retinal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Humulin	C		
SUBCUTANEOUS							
		Stomach Discomfort		Glucophage	C		ORAL
		Temperature Intolerance		Lopressor	C		ORAL
		Tenosynovitis		Acupril	C		ORAL
		Upper Respiratory Tract		Zocor	C		ORAL
		Infection		Hydrochlorothiazide	C		ORAL
		Urinary Tract Infection		Nexium	C		ORAL
		Vomiting		Estradiol	C		ORAL
		Weight Increased		Ultram	C		ORAL
				Aspirin	C		ORAL
				Nitroglycerin	C		
UNKNOWN							
				[Therapy Unspecified]	C		ORAL
				Bextra	C		ORAL
				Lipitor	C		ORAL
				Gemfibrozil	C		ORAL
				Flexeril	C		ORAL
				Glucosamine	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Nitroglycerin	C		
UNKNOWN							

Date:07/07/05ISR Number: 4708911-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00036
Age:80 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Circulatory Collapse		Amiloride Hydrochloride And Hydrochlorothiazide	C		ORAL
		Convulsion		Candesartan Cilexetil And Hydrochlorothiazide	C		ORAL
		Encephalopathy					
		Fall					
		Grand Mal Convulsion					
		Haematuria					
		Haemoglobin Decreased					

Haemorrhage
Head Injury
Hyponatraemia
Orthostatic Hypotension
Skin Laceration

Date:07/07/05ISR Number: 4708912-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dysaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Failure Of Implant		Ranitidine	C				
UNKNOWN								
	Gastric Disorder		Enalapril Maleate	C				
UNKNOWN								
	Gastric Ulcer		Diclofenac	C				
UNKNOWN								
	Lumbar Spinal Stenosis		Aspirin	C				
UNKNOWN								
	Myelopathy		Omeprazole	C				
UNKNOWN								
	Nephrolithiasis							
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708914-XReport Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00114
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebral Infarction		Quinapril Hydrochloride	C				
	Chest Pain							
	Colon Adenoma		Quinapril Hydrochloride	C				
	Diverticulitis							
	Hiatus Hernia		Amitriptyline Hydrochloride	C				
	Left Ventricular Failure							
	Myocardial Ischaemia		Amitriptyline Hydrochloride	C				
	Papillary Thyroid Cancer							
	Thrombophlebitis		Aspirin	C				
	Superficial		Piroxicam Betadex	C				
	Varices Oesophageal		Cholestyramine Resin	C				
			Methylprednisolone Acetate	C				
			Gliclazide	C				
			Doxepin Hydrochloride	C				
			Doxepin Hydrochloride	C				
			Venlafaxine Hydrochloride	C				
			Venlafaxine Hydrochloride	C				
			Acetaminophen And Codeine Phosphate	C				
			Zopiclone	C				

UNKNOWN			Zopiclone	C
UNKNOWN			Ketorolac Tromethamine	C
UNKNOWN			Atropine Sulfate And Diphenoxylate Hydrochloride	C
UNKNOWN			Atropine Sulfate And Diphenoxylate Hydrochloride	C
UNKNOWN			Metformin Hydrochloride	C
UNKNOWN			Metronidazole	C
UNKNOWN			Morphine Sulfate	C
UNKNOWN			Naproxen	C
UNKNOWN			Lansoprazole	C
UNKNOWN	2	YR	Lansoprazole	C
UNKNOWN	2	YR	Lisinopril	C
UNKNOWN			Azithromycin	C
UNKNOWN			Zopiclone	C
UNKNOWN			Esomeprazole Magnesium	C
UNKNOWN			Temazepam	C
UNKNOWN			Nystatin	C
UNKNOWN			Paroxetine Hydrochloride	C
UNKNOWN			Paroxetine Hydrochloride	C
UNKNOWN			Acetaminophen And Codeine Phosphate	C
UNKNOWN			Gabapentin	C
UNKNOWN			Gabapentin	C

				Orlistat	C		
UNKNOWN							
				Acetaminophen And Codeine Phosphate	C		
UNKNOWN							
				Celecoxib	C		
UNKNOWN							

Date:07/07/05ISR Number: 4708916-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00468
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL		30 DAY
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Circulatory Collapse		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Epigastric Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		30 DAY
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Heparin	C		PARENTERAL		24 DAY
			Gabapentin	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		882 DAY

Date:07/07/05ISR Number: 4708922-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04384
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stent Placement							

Date:07/07/05ISR Number: 4708923-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Pain In Extremity Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708924-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00178
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Pulmonary Embolism Pulmonary Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708925-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00179
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708926-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04334
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708927-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00173
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia							
	Cardiovascular Disorder							
	Chest Discomfort							
	Chest Pain							
	Coronary Artery Disease							
	Diarrhoea							
	Dyspnoea							
	Dyspnoea Paroxysmal							
	Nocturnal							
	Gastrooesophageal Reflux							
	Disease							
	Headache							
	Hyperlipidaemia							
	Myocardial Ischaemia							
	Neck Pain							
	Osteoarthritis							

Date:07/07/05ISR Number: 4708928-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03974
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708929-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04310
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4708930-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00174
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Other	Cerebrovascular Accident
	Coronary Artery Disease
	Deep Vein Thrombosis
	Depression
	Dyslipidaemia
	Gastrooesophageal Reflux Disease
	Hepatic Steatosis
	High Density Lipoprotein Increased
	Hypotension

		Idiopathic					
		Thrombocytopenic Purpura					
		Irritable Bowel Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ischaemic Cerebral		Vioxx	PS	Merck & Co., Inc	ORAL
		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Lacunar Infarction		Synthroid	C		
UNKNOWN							
		Liver Function Test		Prempro	C		
UNKNOWN							
		Abnormal		Prozac	C		
UNKNOWN							
		Mitral Valve Incompetence		Pepcid	C		
UNKNOWN							
		Pulmonary Embolism		Synvisc	C		
PARENTERAL							
		Pulmonary Hypertension		Celebrex	C		
UNKNOWN							
		Rhinitis Allergic					
		Simple Partial Seizures					
		Sinus Disorder					

Date:07/07/05ISR Number: 4708932-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/07/05ISR Number: 4708933-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02688
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 15 DAY	Catheter Site Infection		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Wall Abscess					
Disability	Emotional Distress					
Other	Encephalitis Brain Stem					
	Herpes Ophthalmic					
	Herpes Zoster					
	Hodgkin'S Disease Nodular					
	Sclerosis Stage					

Unspecified
Injury
Intervertebral Disc
Displacement
Lacunar Infarction
Meningitis Aseptic
Meningitis Herpes
Pruritus
Staphylococcal Sepsis

Date:07/07/05ISR Number: 4708934-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02101
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Pulmonary Oedema
	Adverse Event
	Angina Pectoris
	Arthralgia
	Breast Microcalcification
	Cardiac Failure
	Congestive
	Drug Hypersensitivity
	Drug Ineffective
	Dysphoria
	Dysuria

		Emotional Distress					
		Exostosis					
		Fall	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypernatraemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertensive Crisis		Vioxx	SS	Merck & Co., Inc	ORAL
		Iliac Artery Stenosis		Diuretic			
		Musculoskeletal Pain		(Unspecified)	SS		
UNKNOWN							
		Myocardial Infarction		Allopurinol	C		
UNKNOWN							
		Nausea		Vitamins			
		Pollakiuria		(Unspecified)	C		
UNKNOWN							
		Postnasal Drip		Atenolol	C		
UNKNOWN							
		Pulmonary Embolism		Atenolol	C		
UNKNOWN							
		Pyuria		Acetaminophen	C		
UNKNOWN							
		Renal Artery Stenosis					
		Renal Cyst					
		Renal Failure					
		Sinusitis					
		Skin Lesion					
		Urinary Tract Infection					

Date:07/07/05ISR Number: 4708935-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00027
Age:72 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
3	DAY						

Date:07/07/05ISR Number: 4708942-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00180
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
449	DAY						

Date:07/07/05ISR Number: 4708943-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00182
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/07/05ISR Number: 4709519-7Report Type:Expedited (15-DaCompany Report #2005087341
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Fluctuation	Consumer Health	Bextra (Valdecoxib)	PS				
Other	Chest Pain	Professional	Celebrex (Celecoxib)	SS				
	Drug Ineffective		Baclofen (Baclofen)	SS				
	Heart Rate Irregular		Vioxx (Rofecoxib)	SS				
	Hepatic Cyst		Rebif (Interferon Beta)	SS				
	Multiple Sclerosis		Biaxin (Clarithromycin)	SS				
	Nausea		Skelaxin (Metaxolone)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/05ISR Number: 4709817-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00290
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4709818-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	29	MON

Date:07/08/05ISR Number: 4709819-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01543
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia Postoperative		[Therapy Unspecified]	C				
	Anxiety							
	Atrial Fibrillation		Pravachol	C				
	Azotaemia		Prozac	C				
	Cardiac Failure		Xanax	C				
	Congestive		Digitek	C				
	Coagulopathy		Coumadin	C				
	Dehydration		Lopressor	C				
	Depression		Cardizem	C				
	Diarrhoea		Lipitor	C				
	Difficulty In Walking		Elavil	C				
	Dizziness							

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN

Dyspnoea
Fatigue
Hiatus Hernia
Hypertensive Heart
Disease
Hypokalaemia
Hypomagnesaemia
Hyponatraemia
Influenza Like Illness
Metabolic Acidosis
Mitral Valve Incompetence
Osteoarthritis
Osteoporosis
Postmenopausal
Overdose
Post-Traumatic Stress
Disorder
Renal Failure Chronic
Thrombosis
Urinary Tract Infection

Date:07/08/05ISR Number: 4709821-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01709
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension							
	Myocardial Infarction							
	Syncope							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/05ISR Number: 4709822-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00899
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4709826-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03972
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4709827-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00433
Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:07/08/05ISR Number: 4709828-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0401FRA00075
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cytolytic Hepatitis		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY	
Initial or Prolonged	Hepatitis Cholestatic		Zopiclone	C		ORAL		
			Acetaminophen	C		ORAL	11 DAY	
			Acetaminophen	C		ORAL		
			Irbesartan	C		ORAL		

Date:07/08/05ISR Number: 4709829-3Report Type:Expedited (15-DaCompany Report #VI-MERCK-0502USA00218
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Procardia	C				
UNKNOWN								
	Hypertension							
	Myocardial Infarction							
	Syncope							

Date:07/08/05ISR Number: 4709833-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00579
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/08/05ISR Number: 4709834-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03987
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4709835-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00581
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4709851-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/08/05ISR Number: 4710122-3Report Type:Direct Company Report #CTU 252805
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS			1 TABLET	
Hospitalization -	Chest Pain						DAILY	
Initial or Prolonged	Hypoaesthesia		Bextra	SS			1 TABLET	
Disability	Muscle Spasms						DAILY	
Other	Neck Pain		Accupril	C				
Required	Pain In Extremity		Dectrol La	C				
Intervention to			Bextra	C				
Prevent Permanent			Lipitor	C				
Impairment/Damage								

Date:07/08/05ISR Number: 4710184-3Report Type:Direct Company Report #CTU 252789
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Injury		Neurontin	PS			600 MG	
Hospitalization -	Convulsion		Bextra	SS			300 MG	
Initial or Prolonged	Joint Injury		Vioxx	SS				
Disability	Limb Injury		Theraphyin	C				
Other	Road Traffic Accident							

Date:07/08/05ISR Number: 4710964-4Report Type:Expedited (15-DaCompany Report #WAES 0503GBR00214
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Blood Potassium Decreased
	Condition Aggravated
	Coronary Artery Occlusion
	Exercise Tolerance
	Decreased
	Haemoglobin Decreased
	Laboratory Test Abnormal
	Mean Cell Volume
	Increased

		Myocardial Ischaemia Red Blood Cell Count Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vitamin B12 Deficiency	Foreign Study	Tab Vioxx Unk	PS		ORAL
25 MG DAILY							
PO							
			Health Professional	Acetaminophen (+)			
				Codeine Phosph	C		
				Amlodipine Besylate	C		
				Atenolol	C		
				Atorvastatin Calcium	C		
				Bendroflumethiazide	C		
				Cyancobalamin	C		
				Diazepam	C		
				Nitroglycerin	C		
				Potassium Chloride	C		
				Prednisolone	C		
				Quinine	C		
				Sulfasalazine	C		
				Trazodone Hydrochloride	C		

Date:07/08/05ISR Number: 4711260-1Report Type:Expedited (15-DaCompany Report #2004009355
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Injury
Other	Abdominal Pain
	Accident
	Agitation
	Back Disorder
	Blood Cholesterol Increased
	Cardiac Disorder
	Contusion
	Difficulty In Walking
	Disorientation
	Drug Intolerance
	Erectile Dysfunction
	Facial Pain
	Feeling Abnormal
	Feeling Cold
	Gastrooesophageal Reflux

Disease
Gingival Disorder
Glossodynia
Hostility
Hypersomnia
Hypokinesia
Hyporeflexia
Impaired Healing
Injury
Irritability
Limb Injury
Muscle Spasms
Myalgia
Neck Pain
Oesophageal Spasm
Overdose
Pain In Extremity
Pain In Jaw

		Sedation Sleep Disorder Somnolence	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tenderness Therapy Non-Responder	Consumer Health	Neurontin (Gabapentin)	PS		ORAL
1800 MG (600 MG, 3 IN 1 D); ORAL		Tooth Abscess Treatment Noncompliance	Professional				
		Tremor Vertigo		Lipitor (Atorvastatin)	SS		ORAL
20 (20MG, 1 IN 1 D); ORAL							
				Lithium (Lithium)	SS		
				Naproxen (Naproxen)	SS		
				Amoxicillin (Amoxicillin)	SS		ORAL
1000 MG (1 IN 2 D); ORAL							
				Rofecoxib (Rofecoxib)	SS		
				All Other Therapeutic Products	C		
				Levothyroxine Sodium	C		
				Vitamins (Vitamins)	C		
				Diltiazem Hydrochloride	C		

Date:07/09/05ISR Number: 4710195-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03394
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
40 MON							
				Vioxx	SS	Merck & Co., Inc	ORAL
40 MON							

Date:07/09/05ISR Number: 4710196-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02470
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prempro	C				

UNKNOWN

Date:07/09/05ISR Number: 4710197-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03480
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Angina Pectoris
	Angina Unstable
	Bladder Neoplasm
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Discomfort
	Coronary Artery Disease
	Cystitis
	Depression
	Haematuria
	Haemorrhoids
	Metabolic Syndrome
	Myocardial Infarction
	Non-Cardiac Chest Pain

	Post-Traumatic Stress Disorder						
	Rectal Haemorrhage	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS		ORAL	

Date:07/09/05ISR Number: 4710198-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/09/05ISR Number: 4710199-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03194
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Prerenal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	42 MON
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	42 MON
Disability	Arthritis Infective		Diovan	C		ORAL	
	Blood Pressure		Coumadin	C			UNKNOWN
	Inadequately Controlled		Vitamins				
	Cataract		(Unspecified)	C			UNKNOWN
	Coronary Artery Disease		Ambien	C			UNKNOWN
	Cyst		Lortab	C			UNKNOWN
	Drug Ineffective						
	Emotional Distress						
	Erectile Dysfunction						
	Fatigue						
	Gastrooesophageal Reflux Disease						
	Inguinal Hernia						
	Ischaemic Cardiomyopathy						
	Joint Dislocation						
	Myocardial Infarction						

Normochromic Normocytic
Anaemia
Orthostatic Hypotension
Osteomyelitis
Pain
Rectal Haemorrhage
Renal Failure
Urinary Tract Infection

Date:07/09/05ISR Number: 4710201-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02628
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Lortab	C				
UNKNOWN								
	Myocardial Infarction		Tylenol	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/05ISR Number: 4710202-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00195
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							

Date:07/09/05ISR Number: 4710203-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00070
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glucose Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypersensitivity		Thalidomide	SS				
UNKNOWN								
	Micturition Disorder		Dexamethasone	C				
UNKNOWN								
	Muscle Spasms		Zoledronate Disodium	C				
UNKNOWN								
	Oedema Peripheral		Morphine Sulfate	C				
UNKNOWN								
	Pain In Extremity		Piretanide	C				
UNKNOWN								
	Phlebitis		Magnesium					
	Plasmacytoma		(Unspecified)	C				
UNKNOWN								
	Polyneuropathy		Furosemide	C				
UNKNOWN								
	Seborrhoeic Dermatitis		Pamidronate Disodium	C				
UNKNOWN								
	Tinnitus		Zoledronic Acid	C				
UNKNOWN								
	Urticaria		Clemastine Fumarate	C				
UNKNOWN								
			Prednisolone Sodium					

			Succinate	C		
UNKNOWN						
			Moxifloxacin Hydrochloride	C		
UNKNOWN						
			Trifluprom azine Hydrochloride	C		
UNKNOWN						
			Biperiden Hydrochloride	C		
UNKNOWN						

Date:07/09/05ISR Number: 4710206-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01614
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Fosinopril Sodium	C		
UNKNOWN						
	Myocardial Infarction		Aspirin	C		
UNKNOWN						
	Pain In Extremity		Zocor	C		ORAL
			Plavix	C		
UNKNOWN						

Date:07/09/05ISR Number: 4710207-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02140
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Cerebrovascular Accident
Disability	Electrocardiogram Qt Prolonged

		Heart Rate Irregular Hypertensive Crisis Hypokalaemia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
31	DAY						
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
31	DAY						
				Klonopin	C		
UNKNOWN							
				Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Prempro	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		ORAL
				Cyclobenzaprine Hydrochloride	C		ORAL
				Relafen	C		ORAL
				Clonidine	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Trinalin	C		
UNKNOWN							

Date:07/09/05ISR Number: 4710208-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01998
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
23	MON						
		Diarrhoea Gastric Disorder		Indocin (Indomethacin)	C		
UNKNOWN							
		Myocardial Infarction		Colchicine	C		
UNKNOWN							
				Prednisone	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							

			Insulin	C		
UNKNOWN						

Date:07/09/05ISR Number: 4710212-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00766
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Intracardiac Thrombus		Advil	C		
UNKNOWN						
	Rhinitis					

Date:07/09/05ISR Number: 4710214-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00292
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/09/05ISR Number: 4710215-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00513
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
33 MON						
Other	Death					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/05ISR Number: 4710216-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00480
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12	MON

Date:07/09/05ISR Number: 4710217-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00393
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Emotional Disorder Hypertension Insomnia Mental Disorder Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710218-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00464
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710219-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00181
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1514	DAY

Date:07/09/05ISR Number: 4710220-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710221-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04294
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Flonase	C				
UNKNOWN								
Disability	Emotional Distress		Allegra	C				
UNKNOWN								
	Ischaemic Stroke		Nasacort	C				
UNKNOWN								
			Zyrtec	C				
UNKNOWN								

Date:07/09/05ISR Number: 4710222-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00004
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								
Initial or Prolonged	Headache		Levothyroxine Sodium	C				
UNKNOWN								
	Hypertension		Leflunomide	C				
UNKNOWN								
			Zopiclone	C				
UNKNOWN								
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								

				Prednisolone	C		
UNKNOWN							
				Estradiol And Norethindrone Acetate	C		
UNKNOWN							

Date:07/09/05ISR Number: 4710223-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710224-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04334
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710225-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710226-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710227-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710228-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00585
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710229-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/05ISR Number: 4710230-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00564
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710231-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00580
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710232-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00592
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710233-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00634
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	738	DAY

Date:07/09/05ISR Number: 4710234-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00588
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710235-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00540
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710237-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00612
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710239-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00609
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710240-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00607
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/09/05ISR Number: 4710241-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710242-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00611
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710243-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	11	MON

Date:07/09/05ISR Number: 4710244-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710245-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710246-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710247-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00619
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/09/05ISR Number: 4710248-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710674-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00601
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiovascular Disorder Coronary Artery Disease Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710685-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00603
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710686-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04313
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710687-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03185
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Accelerated Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	736 DAY	
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
Other	Anxiety		Aspirin	C			UNKNOWN	
	Blood Glucose Fluctuation		Procardia	C			UNKNOWN	
	Cerebrovascular Accident		Lasix (Furosemide)	C			UNKNOWN	
	Chest Discomfort		Catapres	C			UNKNOWN	

	Convulsion	Plavix	C
UNKNOWN			
	Depression Diverticulum Dyspnoea Essential Hypertension Gastroenteritis Viral Gastrooesophageal Reflux Disease Hallucination Hyperhidrosis Hyponatraemia Iron Deficiency Anaemia Labile Blood Pressure Muscle Spasms Pain In Jaw Palpitations Paraesthesia Poor Peripheral Circulation Transient Ischaemic Attack Urinary Tract Infection Viral Pharyngitis		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710688-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00287
Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
Other								

Date:07/11/05ISR Number: 4710689-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00447
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							

Date:07/11/05ISR Number: 4710690-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01113
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Plavix	SS				
UNKNOWN								
Other	Chest Pain		Coumadin	SS				
UNKNOWN								
	Dizziness		Vitamins					
	Dyspnoea		(Unspecified)	C				
UNKNOWN								
	Dyspnoea Exertional		Aspirin	C				
UNKNOWN								
	Exostosis							
	Hyperlipidaemia							
	Loss Of Consciousness							
	Pyrexia							
	Renal Failure							
	Varicose Vein							

Date:07/11/05ISR Number: 4710691-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00596
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	C				

UNKNOWN

Date:07/11/05ISR Number: 4710692-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00458
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomegaly							
	Hypertension							
	Insomnia							
	Pain In Extremity							

Date:07/11/05ISR Number: 4710696-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01510
Age:84 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Atrial Fibrillation
	Blood Cholesterol

		Increased Cholelithiasis					
		Chronic Fatigue Syndrome					
		Dehydration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Coumadin	C		
UNKNOWN							
		Macular Degeneration		Premarin	C		
UNKNOWN							
		Pain		Exelon	C		
UNKNOWN							
		Renal Failure Acute		Exelon	C		
UNKNOWN							
		Sleep Apnoea Syndrome		Os-Cal	C		
UNKNOWN							
		Spinal Osteoarthritis					
		Syncope					
		Transient Ischaemic Attack					
		Urinary Tract Infection					

Date:07/11/05ISR Number: 4710697-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01156
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
7 MON							
Other		Apnoea		Zestril	C		
UNKNOWN							
		Cardiac Arrest		Lipitor	C		
UNKNOWN							
		Coronary Artery		Norvasc	C		
UNKNOWN							
		Atherosclerosis		Acetaminophen And Hydrocodone Bitartrate	C		
		Loss Of Consciousness					
		Pulmonary Congestion					
UNKNOWN							
		Pulmonary Oedema		Bactroban	C		
UNKNOWN							
		Shoulder Pain					
		Snoring					
		Ventricular Fibrillation					

Date:07/11/05ISR Number: 4710700-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02648
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		61 YR
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		146 DAY
Other	Blood Calcium Decreased		Atenolol	C				UNKNOWN
	Bradycardia		Aspirin	C				UNKNOWN
	Brain Cancer Metastatic		Pravachol	C				UNKNOWN
	Brain Oedema		Zocor	C		ORAL		
	Colon Cancer Stage Iii		Tylenol	C				UNKNOWN
	Colonic Polyp		Ibuprofen	C				UNKNOWN
	Decreased Appetite		Piroxicam	C		ORAL		
	Deep Vein Thrombosis							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Hypoparathyroidism							
	Iron Deficiency Anaemia							
	Lung Neoplasm							
	Myocardial Infarction							
	Nasopharyngitis							
	Pulmonary Embolism							
	Thyroid Cancer Metastatic							
	Upper Respiratory Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710701-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		120 DAY
Initial or Prolonged	Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Pressure Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bone Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		120 DAY
	Cardiac Valve Disease		Cardizem Cd	C				UNKNOWN
	Chest Pain		Paxil	C				UNKNOWN
	Chest Wall Pain		Lasix (Furosemide)	C				UNKNOWN
	Chronic Obstructive Pulmonary Disease		Tylenol Extra Strength	C				UNKNOWN
	Coronary Artery Occlusion		Ferrous Sulfate	C				UNKNOWN
	Depression		Percocet	C				UNKNOWN
	Dysphagia		Aspirin	C				UNKNOWN
	Dyspnoea		Nitroglycerin	C				UNKNOWN
	Emotional Distress		Aleve	C				UNKNOWN
	Fall		Soma	C				UNKNOWN
	Fatigue		Lasix (Furosemide)	C				UNKNOWN
	Gastrooesophageal Reflux		Lasix (Furosemide)	C				UNKNOWN
	Disease		Paxil	C			145 DAY	UNKNOWN
	Haematoma		Paxil	C			42 DAY	UNKNOWN
	Headache		K-Dur	C				UNKNOWN
	Heart Rate Decreased		Accupril	C			18 DAY	UNKNOWN

	Herpes Zoster		Accupril	C		
UNKNOWN		38 DAY				
	Hypertension		Accupril	C		
UNKNOWN		152 DAY				
	Hypotension		Paxil	C		
UNKNOWN						
	Insomnia					
	Irritable Bowel Syndrome					
	Myocardial Infarction					
	Oedema Peripheral					
	Oesophageal Spasm					
	Pain					
	Paraesthesia					
	Rash Pruritic					
	Restless Legs Syndrome					
	Sinusitis					
	Somnolence					
	Syncope					
	Tremor					
	Upper Respiratory Tract Infection					

Date:07/11/05ISR Number: 4710703-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00511
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12 MON	

Date:07/11/05ISR Number: 4710704-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00118
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Autonomic Nervous System Imbalance		Vioxx	PS	Merck & Co., Inc	ORAL		
	Circulatory Collapse		[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4710723-2Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0507ZAF00005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710730-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00640
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710745-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		31 MON

Date:07/11/05ISR Number: 4710746-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00605
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON

Date:07/11/05ISR Number: 4710747-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00590
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4710748-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00675
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/11/05ISR Number: 4711325-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00528
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711326-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Acute Pulmonary Oedema
Disability	Anxiety
Other	Aortic Valve Incompetence
	Asthenia
	Blood Cholesterol Increased

		Bundle Branch Block					
		Cerebrovascular Accident					
		Chest Discomfort	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Cognitive Disorder		Lasix (Furosemide)	C		
UNKNOWN							
		Convulsion		Aspirin	C		
UNKNOWN							
		Coronary Artery Disease		Orphenadrine	C		
UNKNOWN							
		Cystocele		Ativan	C		
UNKNOWN							
		Depression		Lopressor	C		
UNKNOWN							
		Diabetes Mellitus		Glyburide	C		
UNKNOWN							
		Inadequate Control		Glucotrol Xl	C		
UNKNOWN							
		Diabetic Ketoacidosis					
		Emotional Distress					
		Emphysema					
		Hypertension					
		Hypokalaemia					
		Intervertebral Disc					
		Degeneration					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Nasopharyngitis					
		Palpitations					
		Rotator Cuff Syndrome					
		Supraventricular					
		Extrasystoles					
		Supraventricular					
		Tachycardia					
		Transient Ischaemic					
		Attack					
		Urinary Tract Infection					
		Ventricular Extrasystoles					
		Vision Blurred					

Date:07/11/05ISR Number: 4711329-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lymphoedema		Vioxx	SS	Merck & Co., Inc	ORAL		
	Phlebothrombosis		Hormones (Unspecified)	SS				
	Thrombosis							
			Ibuprofen	C				
			Hypericin	C				

Date:07/11/05ISR Number: 4711331-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02614
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL		
46 MON								
Initial or Prolonged	Dizziness		Prempro	C				
UNKNOWN								
	Gastrointestinal Disorder							
	Myocardial Infarction							
	Thyroid Disorder							

Date:07/11/05ISR Number: 4711335-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Accident At Home
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged
	Angina Pectoris
	Anxiety
	Atrial Septal Defect
	Balance Disorder
	Bipolar Disorder
	Borderline Personality
	Disorder
	Bradycardia
	Breast Pain
	Bursitis
	Cardiac Aneurysm
	Cardiac Failure
	Congestive
	Cardiomegaly
	Cellulitis
	Cerebral Infarction
	Chest Pain
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Death
	Diverticulum
	Drug Abuser
	Drug Dependence
	Dyspnoea
	Dysthymic Disorder
	Emotional Distress
	Fibromyalgia
	Haemorrhoids
	Headache
	Hyperkalaemia
	Hypertrophy Breast
	Hyponatraemia
	Injury
	Intermittent Claudication
	Intracranial Aneurysm
	Lacunar Infarction
	Leukocytosis

Limb Discomfort
Lung Disorder
Major Depression
Mitral Valve Incompetence
Myocardial Infarction
Obsessive-Compulsive
Disorder
Oedema Peripheral
Overdose
Pain
Pain In Extremity
Panic Disorder With
Agoraphobia
Pneumonia
Pollakiuria

		Post-Traumatic Stress Disorder					
		Pulmonary Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Cancer		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Suicidal Ideation		Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
		Attack		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
		Incompetence		Seroquel	C		
UNKNOWN							
		Upper Respiratory Tract		Ativan	C		
UNKNOWN							
		Infection		Ativan	C		
UNKNOWN							
		Varices Oesophageal		Monopril	C		ORAL
		Ventricular Dysfunction		Norvasc	C		
UNKNOWN							
		Weight Increased		Lithium Carbonate	C		ORAL
				Lithium Carbonate	C		ORAL
				Aspirin	C		
UNKNOWN		668 DAY					
				Vicodin Tablets	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN		96 DAY					
				Coumadin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Zyprexa	C		ORAL
				Zyprexa	C		ORAL
				Zithromax	C		ORAL
4	DAY						
				Navane	C		ORAL
				Cogentin	C		ORAL
				Tegretol-Xr	C		ORAL
				Claritin-D	C		
UNKNOWN							

Date:07/11/05ISR Number: 4711346-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00567
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/11/05ISR Number: 4711348-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00577
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711349-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1600 DAY	

Date:07/11/05ISR Number: 4711350-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00569
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4711351-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Sular	C				
UNKNOWN								
			Oxycontin	C				
UNKNOWN								

Date:07/11/05ISR Number: 4711352-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01005
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
992 DAY								
Initial or Prolonged	Acute Myocardial		Zocor	C		ORAL		
3 YR								
Disability	Infarction		Zestril	C		ORAL		
43 MON								
	Haemorrhoids							
	Intervertebral Disc							
	Disorder							
	Rectal Polyp							

Date:07/11/05ISR Number: 4711353-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00565
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711354-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03205
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

Chest Pain
Hepatocellular Damage
Injury
Myocardial Infarction
Renal Injury
Thrombosis
Ulcer

Date:07/11/05ISR Number: 4711355-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00578
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711356-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02177
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Infarction		Celebrex	C				
UNKNOWN								
	Cardiogenic Shock							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4711368-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00092
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							
	Overdose							

Date:07/11/05ISR Number: 4711369-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02169
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebellar Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebral Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711370-9Report Type:Expedited (15-DaCompany Report #CA-MERCK-0501CAN00114
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Electrocardiogram St		Vioxx	SS	Merck & Co., Inc	ORAL		
	Segment Elevation		Glyburide	C				
UNKNOWN								
	Insomnia		Furosemide	C				
UNKNOWN								
	Transient Ischaemic		Amlodipine Besylate	C				
UNKNOWN								
	Attack		Metoprolol	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								

			Fosinopril Sodium	C		
UNKNOWN						
			Allopurinol	C		
UNKNOWN						
			Indapamide	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						
			Diclofenac	C		
UNKNOWN						
			Ketorolac Tromethamine	C		
UNKNOWN						

Date:07/11/05ISR Number: 4711371-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00566
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711372-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02191
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Digitek	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Magnesium (Unspecified)	C				
UNKNOWN								

Aspirin	C	UNKNOWN
Vitamin E	C	UNKNOWN
Ascorbic Acid	C	UNKNOWN
Clonazepam	C	UNKNOWN
Nexium	C	UNKNOWN
Centrum	C	UNKNOWN
Amitriptyline Hydrochloride	C	UNKNOWN
Singulair	C	UNKNOWN
Allegra	C	UNKNOWN
Ultracet	C	UNKNOWN
Neurontin	C	UNKNOWN
Pancrease (Pancreatin)	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN

Date:07/11/05ISR Number: 4711373-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00562
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711374-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00400
Age:84 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness		Fosamax	C		ORAL		
	Fall		Norvasc	C				
	Femur Fracture							
	Loss Of Consciousness							

Date:07/11/05ISR Number: 4711375-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00007
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Phlebothrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Pulmonary Embolism		Acetaminophen	C		ORAL		37 DAY
	Vaginal Haematoma		Levothyroxine Sodium	C		ORAL		UNKNOWN
			Omega-3 Marine Triglycerides	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN
			Nutritional Supplements	C				UNKNOWN
			Dexchlorpheniramine Maleate	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/11/05ISR Number: 4711376-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711377-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00677
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	394 DAY	

Date:07/11/05ISR Number: 4711386-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00688
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/11/05ISR Number: 4711390-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00576
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/12/05ISR Number: 4711817-8Report Type:Expedited (15-DaCompany Report #2005SE03849
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Nexium	PS	Astrazeneca Pharmaceuticals	ORAL		
			Vioxx	SS		ORAL		

Date:07/12/05ISR Number: 4712079-8Report Type:Expedited (15-DaCompany Report #CA-MERCK-0502CAN00066
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Fluoxetine Hydrochloride	C				
UNKNOWN								
	Depression		Fosinopril Sodium	C		ORAL		
	Myocardial Ischaemia		Fosinopril Sodium	C				
UNKNOWN								
	Spinal Column Stenosis		Atorvastatin Calcium	C		ORAL		
	Ventricular Dysfunction		[Therapy Unspecified]	C				
UNKNOWN								
			Acetaminophen And Codeine Phosphate	C				
UNKNOWN								
			Fluoxetine Hydrochloride	C				
UNKNOWN								
			Fluoxetine Hydrochloride	C				
UNKNOWN								
			Fluoxetine Hydrochloride	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712081-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01839
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amputation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthenia		Zestril	SS				
UNKNOWN								
Other	Asthma		Humalog	C				
UNKNOWN								
	Autonomic Neuropathy		Prilosec	C				
UNKNOWN								
	Basilar Artery Occlusion		Aspirin	C				
UNKNOWN								
	Blood Glucose Increased		Insulin	C				
UNKNOWN								
	Cardiac Disorder							
	Cardiac Failure							
	Cardiac Failure							
	Congestive							
	Cardiomegaly							
	Carotid Artery Occlusion							
	Carotid Artery Stenosis							
	Cerebral Infarction							
	Cerebrovascular Accident							
	Chest Pain							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Drug Hypersensitivity							
	Ear Infection							
	Emotional Disorder							
	Emotional Distress							
	Fall							
	Foot Fracture							
	Fracture Nonunion							
	Gastrooesophageal Reflux							
	Disease							
	Hemianopia Homonymous							
	Hyperlipidaemia							
	Hypertension							
	Impaired Healing							
	Implant Site Infection							
	Infection							
	Laceration							
	Localised Infection							
	Loss Of Consciousness							

Multi-Organ Disorder
Myopathy
Orthostatic Hypotension
Osteomyelitis
Pain
Pain In Extremity
Sinus Tachycardia
Skin Laceration
Spondylolisthesis
Stomach Discomfort
Syncope
Tenosynovitis
Transient Ischaemic
Attack
Ulcer
Vascular Calcification

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712082-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02187
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		42 MON
Initial or Prolonged	Disease		Aciphex	C				UNKNOWN
	Hypertension		Bextra	C				UNKNOWN
	Myocardial Infarction							

Date:07/12/05ISR Number: 4712083-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04337
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Prescribed Overdose		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/12/05ISR Number: 4712084-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00555
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:07/12/05ISR Number: 4712085-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04367
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Death	Anxiety
Life-Threatening	Back Pain
	Benign Prostatic Hyperplasia
	Blood Cholesterol Increased
	Blood Triglycerides

Increased
Bronchitis
Cardio-Respiratory Arrest
Chest Discomfort
Chest Pain
Coronary Artery Disease
Dyspnoea
Fall
Feeling Abnormal
Gastrooesophageal Reflux
Disease
Hyperlipidaemia
Hypoaesthesia
Infusion Related Reaction
Intervertebral Disc
Protrusion
Joint Effusion
Muscle Spasms
Myocardial Infarction
Nail Infection
Night Cramps
Onychomycosis
Otitis Media Chronic
Pain

		Pain In Extremity					
		Polyarthritis					
		Postnasal Drip	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Skin Lesion		Vioxx	PS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Ventricular Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
		Vertigo Positional		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Ibuprofen	C		
UNKNOWN							

Date:07/12/05ISR Number: 4712086-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02651
Age:47 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Lotrel	C		
UNKNOWN							
		Chest Pain		Allopurinol	C		
UNKNOWN							
		Dyspnoea		Terazosin			
		Fatigue		Hydrochloride	C		
UNKNOWN							
		Insomnia		Niferex	C		
UNKNOWN							
		Lower Gastrointestinal		Lipitor	C		
UNKNOWN							
		Haemorrhage		Ambien	C		
UNKNOWN							
		Myocardial Infarction		Xanax	C		
UNKNOWN							

Date:07/12/05ISR Number: 4712087-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03176
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		11 MON
Initial or Prolonged	Myocardial Infarction		Norvasc	C				UNKNOWN
			Hydrodiuril	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:07/12/05ISR Number: 4712096-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03183
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL		649 DAY
Disability	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		7 DAY
	Coronary Artery Disease		Aspirin	C				UNKNOWN
	Hyperlipidaemia							
	Hypertension							
	Intermittent Claudication							
	Lumbar Spinal Stenosis							
	Myocardial Infarction							
	Oedema Peripheral							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712368-7Report Type:Expedited (15-DaCompany Report #WAES 0410BRA00332
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Coronary Artery	Foreign	Tab Vioxx 50 Mg	PS		ORAL	50	
Hospitalization -	Insufficiency	Study					MG/DAILY/PO	
Initial or Prolonged	Ventricular Hypokinesia	Health Professional	Post-Trial Therapy	C				

Date:07/12/05ISR Number: 4712574-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01721
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Adverse Event		Celebrex	SS				
	Arrhythmia							
	Blood Pressure Increased							
	Depression							
	Large Intestinal Ulcer							
	Haemorrhage							
	Myocardial Infarction							
	Oedema							
	Oesophageal Ulcer							
	Haemorrhage							
	Sleep Apnoea Syndrome							

Date:07/12/05ISR Number: 4712577-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspepsia		Ibuprofen	C				
	Hiatus Hernia		Feosol	C				
	Hypertension		Atenolol	C				

	Inflammation	Prevacid	C
UNKNOWN			
	Injury	Relafen	C
UNKNOWN			
	Joint Injury	Tylenol	C
UNKNOWN			
	Pain In Extremity		
	Peptic Ulcer Haemorrhage		

Date:07/12/05ISR Number: 4712579-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00080
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Intervertebral Disc		Vioxx	PS	Merck & Co., Inc	ORAL		43 DAY
Initial or Prolonged	Protrusion		Vioxx	SS	Merck & Co., Inc	ORAL		3 WK
	Mastitis		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		43 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		3 WK
			Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY

Date:07/12/05ISR Number: 4712600-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02194
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Intervertebral Disc
Disability	Protrusion

	Limb Injury Pain					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
27	MON					
			Vioxx	SS	Merck & Co., Inc	ORAL
27	MON					
			Novolog	C		
UNKNOWN						
			Glucotrol	C		
UNKNOWN						
			Glyburide	C		
UNKNOWN						
			Humulin	C		
UNKNOWN						
			Crestor	C		
UNKNOWN						
			Avandamet	C		
UNKNOWN						
			Viagra	C		
UNKNOWN						
			Hydrocodone/Apap	C		
UNKNOWN						
			Loratadine	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						
			Vasotec	C		ORAL

Date:07/12/05ISR Number: 4712601-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00070
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blindness		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Hyperthyroidism		Fenoterol			
	Osteoporosis		Hydrobromide And			
	Retinal Vein Thrombosis		Ipratropium Bromide	C		
UNKNOWN						
	Splenomegaly		Alendronate Sodium	C		
UNKNOWN						
			Fluticasone			
			Propionate And			

			Salmeterol Xinafoate	C		
UNKNOWN						
			Diclofenac	C		
UNKNOWN						

Date:07/12/05ISR Number: 4712602-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02530
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Arthralgia		Wellbutrin	C		
UNKNOWN						
Disability	Asthenia		Wellbutrin	C		
UNKNOWN						
	Chest Pain		Nitroglycerin	C		
UNKNOWN						
	Cholecystitis Chronic		Ultram	C		
UNKNOWN						
	Cholelithiasis		Ultracet	C		
UNKNOWN						
	Cystitis		Butalbital	C		
UNKNOWN						
	Emotional Distress		Aspirin	C		
UNKNOWN						
	Hypothyroidism					
	Ingrowing Nail					
	Migraine					
	Migraine Without Aura					
	Myocardial Infarction					
	Neuropathy Peripheral					
	Obesity					
	Pain					
	Rhinitis					
	Upper Respiratory Tract Infection					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712603-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA02524
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acquired Immunodeficiency		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
							6	DAY
Disability	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
							6	DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hiv Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Dilantin	C				
							UNKNOWN	
	Kidney Infection		Soma	C				
							UNKNOWN	
	Pain In Extremity							

Date:07/12/05ISR Number: 4712605-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02022
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		
							433	DAY
Initial or Prolonged	Diabetes Mellitus		Pravachol	C		ORAL		
	Dyspepsia		Prempro	C		ORAL		
							10	YR
	Gastrooesophageal Reflux		Glucotrol	C		ORAL		
	Disease							
	Infection							
	Myocardial Infarction							
	Renal Disorder							
	Vaginal Mycosis							

Date:07/12/05ISR Number: 4712606-0Report Type:Expedited (15-DaCompany Report #NO-MERCK-0412NOR00034
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 3 YR	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Dysarthria		Levothyroxine Sodium	C		
Disability UNKNOWN	Movement Disorder		Estradiol And Norethindrone Acetate	C		
			Budesonide And Formoterol Fumarate	C		
UNKNOWN						

Date:07/12/05ISR Number: 4712610-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03200
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1276 DAY	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged UNKNOWN	Myocardial Infarction		Oxycontin	C				
UNKNOWN			Alocril	C				
UNKNOWN			Prednisone	C				
UNKNOWN			Cyclobenzaprine Hydrochloride	C				
UNKNOWN			[Therapy Unspecified]	C				
UNKNOWN			Enbrel	C				
UNKNOWN			Methotrexate	C				
UNKNOWN			Levaquin	C				
			Neomycin Sulfate And Polymyxin B Sulfate					

And Hydrocortisone C
UNKNOWN

Zyban C
UNKNOWN

Tussionex (Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex) C
UNKNOWN

Guaifenesin C
UNKNOWN

Guaifenesin And Pseudoephedrine Hydrochloride C
UNKNOWN

Clindamycin C
UNKNOWN

Fluocinonide C
UNKNOWN

Zithromax C
UNKNOWN

Date:07/12/05ISR Number: 4712612-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03184
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1643 DAY
Initial or Prolonged	Hernia		Lortab	C		ORAL		
Other	Oedema Peripheral		Insulin	C				UNKNOWN
	Thrombosis		Levothyroxine Sodium	C		ORAL		

Date:07/12/05ISR Number: 4712613-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00563
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthralgia		Plaquenil	C				
UNKNOWN								

	Diarrhoea	Prednisone	C
UNKNOWN	3 MON		
	Dyspnoea	Nexium	C
UNKNOWN			
	Flatulence	Hydrochlorothiazide	C
UNKNOWN			
	Haematoma	Prinivil	C
UNKNOWN			
	Head Injury		
	Hyperhidrosis		
	Insomnia		
	Jaw Disorder		
	Myocardial Infarction		
	Neck Mass		
	Oedema Peripheral		
	Pain		
	Pain In Extremity		
	Upper Respiratory Tract Infection		

Date:07/12/05ISR Number: 4712614-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02355
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
	Asthenia
	Bradycardia
	Cardiac Disorder
	Chest Discomfort
	Chest Pain
	Coronary Artery Disease
	Dizziness

	Dyspepsia						
	Dyspnoea						
	Fatigue	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL	
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL	
	Muscle Spasms		Glucophage	C			UNKNOWN
	Myocardial Infarction		Glyburide	C			UNKNOWN
	Nasopharyngitis						
	Oedema						
	Oedema Peripheral						
	Pain In Extremity						
	Palpitations						
	Rhinitis Allergic						
	Skin Ulcer						
	Urinary Tract Infection						
	Vertigo						
	Visual Disturbance						

Date:07/12/05ISR Number: 4712615-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01344
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL	
	Glucose Tolerance		Xalatan	C			UNKNOWN
	Impaired		Timoptic	C			UNKNOWN
	Hyperlipidaemia		Toprol Xl Tablets	C		ORAL	
	Myocardial Infarction						

Date:07/12/05ISR Number: 4712616-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02280
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - 5 YR	Anaemia Postoperative	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Chest Pain	Vicodin Tablets	C		
Other UNKNOWN	Chronic Obstructive	Phentermine	C		
UNKNOWN	Pulmonary Disease	Zocor	C		
UNKNOWN	Coronary Artery	Nexium	C		
UNKNOWN	Atherosclerosis	Lamisil	C		
UNKNOWN	Coronary Artery Disease	Nystatin	C		
UNKNOWN	Diabetes Mellitus	Lotrel	C		
UNKNOWN	Emotional Distress	Fioricet Tablets	C		
UNKNOWN	Hypersensitivity	Arthrotec	C		
UNKNOWN	Hypoaesthesia				
	Lumbar Radiculopathy				
	Myocardial Infarction				
	Nausea				
	Peptic Ulcer				
	Thrombosis				
	Venous Thrombosis Limb				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712618-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02221
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		1339 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		1339 DAY
Other	Increased		Aleve	C				
UNKNOWN								3362 DAY
	Blood Glucose Increased		Darvocet-N	C				
UNKNOWN								
	Cerebrovascular Accident		Novolog	C				
UNKNOWN								
	Disturbance In Attention		Glyburide	C				
UNKNOWN								
	Emotional Distress		Acetaminophen And Propoxyphene Napsylate	C				
	Fatigue							
	Memory Impairment							
UNKNOWN								
	Myocardial Infarction		Ritalin	C				
UNKNOWN								
	Sleep Apnoea Syndrome		Focalin	C				
UNKNOWN								
	Transient Ischaemic		Norvasc	C				
UNKNOWN								
	Attack		Avalide	C				
UNKNOWN								
			Actos	C				
UNKNOWN								
			Provigil	C				
UNKNOWN								
			Effexor	C				
UNKNOWN								
			Mobic	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			Claritin	C				
UNKNOWN								
			Mirapex	C				
UNKNOWN								

Date:07/12/05ISR Number: 4712627-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00981
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	C				
			Celebrex	C			UNKNOWN	

Date:07/12/05ISR Number: 4712628-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	C				
			Celebrex	C			UNKNOWN	

Date:07/12/05ISR Number: 4712629-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS				
			Celebrex	SS			UNKNOWN	

Date:07/12/05ISR Number: 4712630-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00575
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712631-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00915
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				
UNKNOWN								
			Bextra	SS				
UNKNOWN								

Date:07/12/05ISR Number: 4712641-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00125
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acne		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Methotrexate Sodium	C				
UNKNOWN								
	Exanthem		Methotrexate Sodium	C				
UNKNOWN								
	Headache		Methotrexate Sodium	C				
UNKNOWN							153	DAY
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Rabeprazole Sodium	C				
UNKNOWN								
			Minocycline	C				
UNKNOWN								
			Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C				
UNKNOWN								
			Meloxicam	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								

Date:07/12/05ISR Number: 4712642-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00977
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS			UNKNOWN	
			Celebrex	SS			UNKNOWN	

Date:07/12/05ISR Number: 4712643-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03408
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	
			Sotalol Hydrochloride	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	
			Gemfibrozil	C			UNKNOWN	
			Imdur	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Accupril	C			UNKNOWN	
			Colace	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Plavix	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/12/05ISR Number: 4712644-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				UNKNOWN
			Bextra	SS				UNKNOWN

Date:07/12/05ISR Number: 4712656-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				UNKNOWN
			Celebrex	SS				UNKNOWN

Date:07/12/05ISR Number: 4713813-3Report Type:Expedited (15-DaCompany Report #2005094600
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia	Health Professional	Dilantin Kapseals (Phenytoin Sodium)	PS		ORAL	300 MG (100 MG,1 IN 1 D),ORAL	
	Convulsion							
Other	Drug Exposure During Pregnancy							
	Dyskinesia		Celebrex (Celecoxib)	SS		ORAL	ORAL	
	Dyspepsia		Phenobarbital (Phenobarbital)	SS			30 MG (1 IN 1 D)	
	Extrapyramidal Disorder							
	Fall							
	Food Allergy		Vioxx (Rofecoxib)	SS				
	Food Interaction		Prempro (Estrogens					

	Heart Rate Increased Hormone Level Abnormal Incoherent Intervertebral Disc Degeneration Muscle Twitching Neck Injury Neck Pain Palpitations Pregnancy Rash Generalised Stress Therapeutic Response Unexpected Treatment Noncompliance Trigger Finger Urticaria	Conjugated, Medroxyprogesterone Acetate)	C

Date:07/12/05ISR Number: 4713865-0Report Type:Expedited (15-DaCompany Report #2005096030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death	Consumer	Celebrex (Celecoxib)	PS				
			Bextra (Valdecoxib)	SS				
			Vioxx (Rofecoxib)	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713193-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01900
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		12 DAY
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
Initial or Prolonged	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		12 DAY
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
	Gout		Allopurinol Msd	C		ORAL		
	Headache		Accupril	C				UNKNOWN
	Impaired Work Ability		Coumadin	C				UNKNOWN
	Loss Of Consciousness		Glucovance	C				UNKNOWN
	Thrombosis		Actos	C				UNKNOWN
			Zithromax	C				UNKNOWN

Date:07/13/05ISR Number: 4713194-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01160
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Atenolol	C		ORAL		
			Prilosec	C		ORAL		
			Aspirin	C				UNKNOWN
			Diuretic (Unspecified)	C				UNKNOWN

Date:07/13/05ISR Number: 4713195-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02020
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL	180	MON
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	118	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY
	Cardiac Valve Disease		Vioxx	SS	Merck & Co., Inc	ORAL	1033	DAY
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	436	MON
	Eye Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1	MON
	Gout		Chlorzoxazone	C		ORAL	1116	DAY
	Hypertension		Parlodel	C		ORAL	2010	DAY
	Infection		Synthroid	C		ORAL		
	Migraine		Methotrexate	C		ORAL	10	YR
	Sleep Disorder		Folic Acid	C		ORAL		
			Amitriptyline Hydrochloride	C		ORAL		
			Darvocet-N	C		ORAL		

Date:07/13/05ISR Number: 4713196-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01404
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	219	DAY
Initial or Prolonged	Anaemia		Avapro	C			UNKNOWN	
Other	Cataract		Lipitor	C			UNKNOWN	
	Coronary Artery Disease							
	Dyspepsia							
	Epistaxis							
	Lipoma							
	Myocardial Infarction							
	Spinal Column Stenosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713197-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02572
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides		Aspirin	C		
UNKNOWN						
	Increased		Prilosec	C		
UNKNOWN						
	Breast Tenderness					
	Coronary Artery Disease					
	Dermal Cyst					
	Dyslipidaemia					
	Hepatic Enzyme Increased					
	Hypercholesterolaemia					
	Myocardial Infarction					
	Toe Deformity					

Date:07/13/05ISR Number: 4713199-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00773
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
50 MON						
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
1657 DAY						
Disability	Blood Immunoglobulin A		Zestril	C		
UNKNOWN						
	Increased		Zestril	C		
UNKNOWN						
	Blood Immunoglobulin G					
	Increased					
	Cardiac Disorder					
	Cardiac Failure					
	Congestive					
	Coronary Artery Disease					
	Diabetes Mellitus					
	Epistaxis					
	Febrile Infection					
	Gastrointestinal					
	Haemorrhage					
	Gastrooesophageal Reflux					

Disease
Iron Deficiency Anaemia
Myocardial Infarction
Osteoporosis
Pelvic Fracture
Upper Limb Fracture

Date:07/13/05ISR Number: 4713200-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00477
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1677 DAY
Hospitalization -	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1677 DAY
Initial or Prolonged	Cardiac Failure		[Therapy					
Disability	Cardiac Failure		Unspecified]	C				UNKNOWN
	Congestive		Analgesic Or					
	Difficulty In Walking		Anesthetic					
	Hypotension		(Unspecified)	C				UNKNOWN
	Lung Infection		Darvocet-N	C				UNKNOWN
	Myocardial Infarction		[Therapy					
			Unspecified]	C				UNKNOWN
			[Therapy					
			Unspecified]	C				UNKNOWN

			[Therapy Unspecified]	C		UNKNOWN
			[Therapy Unspecified]	C		UNKNOWN
			[Therapy Unspecified]	C		UNKNOWN

Date:07/13/05ISR Number: 4713202-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01493
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anosmia		Atenolol	C				
Disability	Arthropathy		Aspirin	C				
Other	Cardiomegaly		Zoloft	C				
	Cerebrovascular Accident		Lipitor	C				
	Chest Pain		Niaspan	C				
	Chronic Obstructive		Iron (Unspecified)	C				
	Pulmonary Disease		Acetaminophen	C				
	Colon Adenoma		Lopressor	C				
	Confusional State		Herbs (Unspecified)	C				
	Decreased Appetite							
	Deep Vein Thrombosis							
	Drug Hypersensitivity							
	Emotional Distress							
	Essential Hypertension							
	Faecal Incontinence							
	Fatigue							
	Haemangioma							
	Haematochezia							
	Hypercoagulation							
	Hypertension							

Lumbar Spinal Stenosis
Meniscus Lesion
Nausea
Nephrolithiasis
Osteopenia
Osteoporosis
Pancreatitis
Pulmonary Embolism
Pulmonary Hypertension
Rectal Haemorrhage
Renal Disorder
Thrombophlebitis
Toe Deformity
Urinary Incontinence
Weight Decreased
Weight Increased

Date:07/13/05ISR Number: 4713204-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0405DEU00009
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization - Initial or Prolonged	Cardiac Failure							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713206-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Basal Cell Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
Disability	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		53 DAY
	Cerebrovascular Accident		Fosamax	C		ORAL		
	Conjunctivitis		Hydrodiuril	C		ORAL		
	Coronary Artery Disease							
	Cough							
	Depression							
	Embolic Stroke							
	Ingrowing Nail							
	Injury							
	Pain In Extremity							
	Sexual Dysfunction							
	Sleep Apnoea Syndrome							

Date:07/13/05ISR Number: 4713208-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0501DEU00076
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		694 DAY
Hospitalization -	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		694 DAY
Initial or Prolonged	Cardiac Failure		Amiodarone					
	Dyspnoea		Hydrochloride	C				UNKNOWN
	Mitral Valve Disease		Bisoprolol	C		ORAL		
	Mixed							
	Tachyarrhythmia							
	Vital Capacity Decreased							

Date:07/13/05ISR Number: 4713212-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713214-8Report Type:Expedited (15-DaCompany Report #SE-MERCK-0507SWE00002
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 16 DAY	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Omeprazole Sodium	C				
UNKNOWN								

Date:07/13/05ISR Number: 4713215-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04329
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713217-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03251
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		10 MON
Initial or Prolonged	Dizziness		Prinivil	C		ORAL		
Other	Dyspnoea		Hydrodiuril	C		ORAL		

Date:07/13/05ISR Number: 4713218-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0507FRA00031
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Atheroma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic Attack		Flecainide Acetate	C		ORAL		

Date:07/13/05ISR Number: 4713219-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00486
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713220-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03454
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Prilosec	C		ORAL		
Initial or Prolonged	Exostosis		Norvasc	C		ORAL		
	Sleep Apnoea Syndrome		Accupril	C		ORAL		
	Spinal Osteoarthritis							

Date:07/13/05ISR Number: 4713221-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00663
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/13/05ISR Number: 4713223-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00527
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	64	MON

Date:07/13/05ISR Number: 4713224-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03169
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Parathyroid Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism		Percocet	C			UNKNOWN	
			Toradol	C			UNKNOWN	

			Warfarin	C		
UNKNOWN						
			Alesse	C		
UNKNOWN						
			Hydrocodone Bitartrate	C		
UNKNOWN						
			Methylprednisolone	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						

Date:07/13/05ISR Number: 4713225-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713226-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00961
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713227-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Bextra C
UNKNOWN

Celebrex C
UNKNOWN

Date:07/13/05ISR Number: 4713228-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00978
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Celebrex	SS			UNKNOWN	
			Bextra	SS			UNKNOWN	

Date:07/13/05ISR Number: 4713229-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS			UNKNOWN	
			Celebrex	SS			UNKNOWN	

Date:07/13/05ISR Number: 4713230-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS			UNKNOWN	
			Celebrex	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713231-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713232-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713234-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00765
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				
UNKNOWN								
			Bextra	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713236-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00680
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713237-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS				
			Celebrex	SS			UNKNOWN	

Date:07/13/05ISR Number: 4713238-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	C				
			Celebrex	C			UNKNOWN	

Date:07/13/05ISR Number: 4713240-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00952
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713242-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00919
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS			UNKNOWN	
			Celebrex	SS				

Date:07/13/05ISR Number: 4713243-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00572
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713244-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713245-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00903
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Celebrex	C				
			Bextra	C			UNKNOWN	

Date:07/13/05ISR Number: 4713246-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00954
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713248-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713249-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00904
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	C				
UNKNOWN								
			Bextra	C				
UNKNOWN								

Date:07/13/05ISR Number: 4713253-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Obstruction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713255-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01026
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
	Myocardial Infarction							

Date:07/13/05ISR Number: 4713256-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713257-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713258-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01109
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713259-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1285	DAY

Date:07/13/05ISR Number: 4713260-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01017
Age: Gender:Female I/FU:I

Outcome	PT
Death	Aortic Atherosclerosis
	Arteriosclerosis
	Arthritis
	Blood Creatine
	Phosphokinase Mb
	Increased
	Cerebrovascular Accident
	Cholelithiasis
	Constipation
	Death
	Dementia
	Dementia Alzheimer'S Type
	Depression
	Diverticulum Oesophageal
	Electrocardiogram St-T
	Change
	Encephalopathy
	Haemoglobin Decreased
	Hallucination
	Hypertension

		Reflux Oesophagitis Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vascular Dementia		Vioxx	PS	Merck & Co., Inc	ORAL
				Bextra	SS		
UNKNOWN							
				Celebrex	SS		
UNKNOWN							

Date:07/13/05ISR Number: 4713261-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01014
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
				Bextra	SS		
UNKNOWN							
				Celebrex	SS		
UNKNOWN							

Date:07/13/05ISR Number: 4713262-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00960
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
				Bextra	SS		
UNKNOWN							
				Celebrex	SS		
UNKNOWN							

Date:07/13/05ISR Number: 4713263-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01016
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/13/05ISR Number: 4713268-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01015
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS				
			Celebrex	SS			UNKNOWN	

Date:07/13/05ISR Number: 4713763-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00845
Age:78 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Ageusia
	Aortic Valve Sclerosis
	Atelectasis
	Bronchitis
	Burning Sensation
	Cerebrovascular Accident
	Dizziness
	Facial Pain
	Hypertension
	Hypoaesthesia
	Mitral Valve Incompetence
	Otitis Media
	Plantar Fasciitis
	Sinusitis
	Therapy Non-Responder

	Tricuspid Valve Incompetence						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	17	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	17	MON
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tagamet	C			UNKNOWN	
			Vitamins (Unspecified)	C			UNKNOWN	
			Calcium (Unspecified)	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Codeine	C			UNKNOWN	

Date:07/13/05ISR Number: 4713764-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00673
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	121	DAY
Initial or Prolonged	Adverse Event		Vioxx	SS	Merck & Co., Inc	ORAL	121	DAY
	Angina Pectoris		Lipitor	C			UNKNOWN	
	Bradycardia		Zocor	C		ORAL		
	Coronary Artery Disease		Saw Palmetto	C			UNKNOWN	
	Myocardial Infarction		Motrin	C			UNKNOWN	
	Ventricular Tachycardia							

Date:07/13/05ISR Number: 4713765-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02632
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Stenosis		Actos	C			UNKNOWN	
	Bundle Branch Block Right		Spironolactone	C			UNKNOWN	
	Cardiac Disorder		Aspirin	C			UNKNOWN	
	Carotid Artery Stenosis		Xenical	C			UNKNOWN	
	Coronary Artery Disease		Hydrochlorothiazide	C			UNKNOWN	
	Dilatation Atrial		Norvasc	C			UNKNOWN	
	Electrocardiogram Q Waves		Metformin	C			UNKNOWN	
	Electrocardiogram St-T		Naproxen	C			UNKNOWN	
	Change							
	Emotional Distress							
	Fatigue							
	Headache							
	Liver Function Test							
	Abnormal							
	Myocardial Infarction							
	Oedema Peripheral							
	Pain In Extremity							
	Prothrombin Time							
	Prolonged							
	Rotator Cuff Syndrome							
	Throat Irritation							
	Weight Increased							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713766-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00797
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Gastrointestinal Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Potassium (Unspecified)	C			UNKNOWN	
	Obesity		Celexa	C			UNKNOWN	
	Sleep Apnoea Syndrome		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Wellbutrin	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Colchicine	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	
			Chlorzoxazone	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	
			Cephalexin	C			UNKNOWN	
			Zanaflex	C			UNKNOWN	
			Endocet	C			UNKNOWN	
			Zaroxolyn	C			UNKNOWN	
			Percocet	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Warfarin	C			UNKNOWN	

UNKNOWN	Clindamycin	C
UNKNOWN	Ultracet	C
UNKNOWN	[Therapy Unspecified]	C
UNKNOWN	Penicillin (Unspecified)	C
UNKNOWN	Deltasone	C
UNKNOWN	Levaquin	C
UNKNOWN	Acetaminophen And Propoxyphene Napsylate	C
UNKNOWN	K-Dur	C
UNKNOWN	Indomethacin	C
UNKNOWN	Ultram	C
UNKNOWN	Biaxin Xl	C
UNKNOWN	Albuterol	C
UNKNOWN	Methylprednisolone	C
UNKNOWN	Ery-Tab	C
UNKNOWN	Roxicet	C
UNKNOWN	Chlorine	C
UNKNOWN	Duragesic	C
UNKNOWN	Zoloft	C
UNKNOWN	Clarinex	C
UNKNOWN	Omeprazole	C
UNKNOWN	Tizanidine Hydrochloride	C
UNKNOWN	[Therapy Unspecified]	C
UNKNOWN	Lasix (Furosemide)	C
UNKNOWN		

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

Coumadin	C
Aspirin	C
Advil	C
Motrin	C
Naproxen	C

				Aleve	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Indocin (Indomethacin)	C		
UNKNOWN							

Date:07/13/05ISR Number: 4713767-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00480
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Humulin	C				
SUBCUTANEOUS								
	Chest Wall Pain		Glucophage	C		ORAL		
	Coronary Artery Disease		Lopressor	C		ORAL		
	Depression		Acupril	C		ORAL		
	Diabetic Retinopathy		Zocor	C		ORAL		
	Diarrhoea		Hydrochlorothiazide	C		ORAL		
	Dizziness		Nexium	C		ORAL		
	Dysphagia		Estradiol	C		ORAL		
	Dyspnoea Exertional		Ultram	C		ORAL		
	Electrocardiogram		Aspirin	C		ORAL		
	Abnormal		Nitroglycerin	C				
UNKNOWN								
	Flushing		[Therapy					
	Gastroenteritis		Unspecified]	C		ORAL		
	Infected Insect Bite		Bextra	C		ORAL		
	Loss Of Consciousness		Lipitor	C		ORAL		
	Myocardial Ischaemia		Gemfibrozil	C		ORAL		
	Nausea		Flexeril	C		ORAL		
	No Therapeutic Response		Glucosamine	C				
UNKNOWN								
	Non-Cardiac Chest Pain		Prevacid	C				
UNKNOWN								
	Otitis Media		Nitroglycerin	C				
UNKNOWN								
	Pollakiuria							
	Post-Traumatic Stress Disorder							

Renal Disorder
Retinal Disorder
Rotator Cuff Syndrome
Sleep Disorder
Stomach Discomfort
Temperature Intolerance
Tenosynovitis
Upper Respiratory Tract Infection
Urinary Tract Infection
Vomiting
Weight Increased

Date:07/13/05ISR Number: 4713770-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00840
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		902 DAY
Hospitalization -	Injury		Wellbutrin	C				UNKNOWN
Initial or Prolonged			Seroquel	C				UNKNOWN
Disability			Aciphex	C				UNKNOWN
			Zocor	C				UNKNOWN
			Niaspan	C				UNKNOWN

			Vicodin Tablets	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

Date:07/13/05ISR Number: 4713773-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01341
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
21 MON								
Disability	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
21 MON								
	Cardiac Failure		Ziac	C				
UNKNOWN								
	Congestive		Bisoprolol	C				
UNKNOWN								
	Cardiac Murmur		Naproxen	C				
UNKNOWN								
	Chest Pain		Verapamil	C				
UNKNOWN								
	Colonic Polyp		Tiazac	C				
UNKNOWN								
	Coronary Artery Disease							
	Depression							
	Dyspnoea							
	Ear Canal Injury							
	Extrasystoles							
	Gastrooesophageal Reflux							
	Disease							
	Haemorrhoids							
	Hypertension							
	Labyrinthitis							
	Myocardial Infarction							
	Post-Traumatic Stress							
	Disorder							
	Shoulder Pain							
	Vertigo							

Date:07/13/05ISR Number: 4713775-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01084
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		10 DAY
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
Disability	Bladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		10 DAY
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		15 DAY
	Increased		Lortab	C		ORAL		
	Cerebrovascular Accident		Excedrin					
	Constipation		Extra-Strength	C				UNKNOWN
	Delusion		Aspirin	C				UNKNOWN
	Diarrhoea							
	Emotional Distress							
	Headache							
	Herpes Zoster							
	Intervertebral Disc							
	Protrusion							
	Meningitis							
	Muscle Contractions							
	Involuntary							
	Paranoia							
	Psychotic Disorder							
	Pyrexia							
	Stomach Discomfort							
	Tremor							
	Venous Thrombosis Limb							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713785-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01012
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713786-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713787-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713788-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00990
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								

Celebrex SS
UNKNOWN

Date:07/13/05ISR Number: 4713789-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00987
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713790-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/13/05ISR Number: 4713791-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00989
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713792-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02644
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Aortic Valve Sclerosis		Aspirin	C		ORAL		
	Blood Triglycerides Increased		Univasc	C		ORAL		
	Chest Pain							
	Chest Wall Pain							
	Hypertriglyceridaemia							
	Mitral Valve Incompetence							
	Musculoskeletal Pain							
	Myocardial Infarction							
	Ventricular Hypertrophy							

Date:07/13/05ISR Number: 4713793-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02006
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Nasacort	C				
UNKNOWN								
	Congestive		Altace	C				
UNKNOWN								
	Chest Discomfort							
	Cholelithiasis							
	Coronary Artery Disease							
	Diastolic Dysfunction							
	Dyspnoea							
	Dyspnoea Exertional							
	Fatigue							
	Fluid Overload							
	Hyperlipidaemia							
	Myocardial Infarction							
	Ventricular Extrasystoles							

Date:07/13/05ISR Number: 4713794-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02188
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Norvasc	C				
	Hypertension		[Therapy Unspecified]	C				
			Folic Acid	C				
			Toprol Xl Tablets	C				
			Ascorbic Acid	C				
			Cyanocobalamin	C				
			Plavix	C				
			Vitamin E	C				
			Atacand	C				
			Aspirin	C				
			Zocor	C				
			Thyroxin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713795-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02055
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anger		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Metoprolol	C		ORAL		
	Chest Pain		Imdur	C		ORAL		
	Coronary Artery Disease		Nitrostat	C		ORAL		
	Coronary Artery Stenosis		Promethazine	C				
	Depression		Amiloride	C				
	Dermatitis Contact		Prednisone	C				
	Drug Abuser		Ambien	C				
	Insomnia		Furosemide	C				
	Irritability		Nitroquick	C				
	Laceration		Lipitor	C		ORAL		
	Mitral Valve Incompetence		Plavix	C		ORAL		
	Myalgia		Acetaminophen And Propoxyphene Napsylate	C		ORAL		
	Peptic Ulcer		Toprol Xl Tablets	C		ORAL		
	Vascular Graft Occlusion		Atarax	C		ORAL		
			Aspirin	C		ORAL		
			Crataegus	C		ORAL		
			Mevacor	C		ORAL		

Date:07/13/05ISR Number: 4713806-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02321
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Disability	Fibromyalgia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713807-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02353
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Brain Neoplasm		Vasotec	C				
	Cerebral Artery Stenosis		Pepcid	C				
	Cerebrovascular Accident		Prozac	C				
	Cholecystitis		Oxycontin	C				
	Cholelithiasis		Norvasc	C				
	Fall		Zanaflex	C				
	Haematemesis		Flagyl	C				
	Pain Of Skin		Levaquin	C				
	Pneumonia		Toprol Xl Tablets	C				
	Renal Mass		[Therapy Unspecified]	C				
	Sensory Disturbance							
	Shoulder Pain		Zantac	C				
	Tinnitus							

Date:07/13/05ISR Number: 4713808-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01924
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety
	Back Injury
	Bipolar Disorder

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Blood Cholesterol Increased					
		Cardiac Valve Disease					
1250 DAY		Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Constipation		Daypro	C		
UNKNOWN		Depression		Naproxen	C		
UNKNOWN		Dyspepsia		Aspirin	C		
UNKNOWN		Headache		Famvir	C		
UNKNOWN		Herpes Virus Infection		Zocor	C		
UNKNOWN		Myocardial Infarction		Ridaura	C		
UNKNOWN		Overdose		Singulair	C		
UNKNOWN		Rheumatoid Arthritis		Depakote	C		
UNKNOWN		Sleep Apnoea Syndrome		Nexium	C		
UNKNOWN				Valtrex	C		
UNKNOWN				Zoloft	C		
UNKNOWN				Advair	C		
UNKNOWN				Celebrex	C		
UNKNOWN	2 YR			Toprol Xl Tablets	C		
UNKNOWN				Zyprexa	C		
UNKNOWN				Spiriva	C		
UNKNOWN				Coumadin	C		
UNKNOWN				Abilify	C		
UNKNOWN							

Date:07/13/05ISR Number: 4713809-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00979
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
			Celebrex	SS				

Date:07/13/05ISR Number: 4713810-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03725
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Nortriptyline	C				
			Nortriptyline	C				
			Trazodone Hydrochloride	C				
			Trazodone Hydrochloride	C				
			Meloxicam	C				
			Ibuprofen	C				
			Tylenol	C				

Date:07/13/05ISR Number: 4713811-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00988
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
			Celebrex	SS				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713812-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03187
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
	Blood Cholesterol		Motrin	C			UNKNOWN	
	Increased		Motrin	C			UNKNOWN	
	Cerebrovascular Accident		Dilantin	C			UNKNOWN	
	Chronic Fatigue Syndrome							
	Convulsion							
	Headache							
	Hernia							
	Overdose							
	Pain In Extremity							
	Shoulder Pain							
	Sleep Apnoea Syndrome							

Date:07/13/05ISR Number: 4713814-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02528
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	75	DAY
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	75	DAY
	Cerebrovascular Accident							
	Hypertension							

Date:07/13/05ISR Number: 4713815-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Angina Pectoris
	Arthralgia

Back Pain
Blood Pressure Increased
Carotid Artery Occlusion
Carotid Artery Stenosis
Carpal Tunnel Syndrome
Chronic Obstructive
Pulmonary Disease
Constipation
Coronary Artery Disease
Depression
Dizziness
Drug Ineffective
Dry Eye
Dry Skin
Dyslipidaemia
Dyspepsia
Dysuria
Ear Disorder
Electrocardiogram St-T
Segment Abnormal
Eructation
Fatigue
Gastrooesophageal Reflux
Disease
Hypoacusis

		Increased Tendency To Bruise					
		Insomnia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Medication Error		Vioxx	PS	Merck & Co., Inc	ORAL
		Memory Impairment		Vioxx	SS	Merck & Co., Inc	ORAL
		Musculoskeletal Stiffness		Flexeril	SS		ORAL
		Myocardial Ischaemia		Advil	C		
UNKNOWN							
		Nausea		Aleve	C		
UNKNOWN							
		Neck Pain		Naproxen	C		
UNKNOWN							
		Nocturia		Mobic	C		
UNKNOWN							
		Oedema Peripheral		Tylenol	C		
UNKNOWN							
		Pain In Extremity		Lortab	C		
UNKNOWN							
		Polyuria					
		Sinus Congestion					
		Tension					
		Transient Ischaemic					
		Attack					
		Vertigo					
		Vomiting					
		Xanthelasma					

Date:07/13/05ISR Number: 4713816-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00597
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Injury					

Date:07/13/05ISR Number: 4713822-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01223
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/13/05ISR Number: 4713825-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01222
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/13/05ISR Number: 4713826-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01267
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				
UNKNOWN								

Date:07/13/05ISR Number: 4713827-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01221
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Renal Injury							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4713881-9Report Type:Expedited (15-DaCompany Report #S05-USA-03147-01
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Cyst	Health Professional	Celexa (Citalopram Hydrobromide)	PS		ORAL	20 MG QD PO	
	Deep Vein Thrombosis							
	Dyspnoea		Celebrex (Celecoxib)	SS				
	Erythema		Vioxx (Rofecoxib)	SS		ORAL	25 MG QD PO	
	Feeling Abnormal		Aspirin	C				
	Head Injury		Vitamins	C				
	Headache		Calcium	C				
	Memory Impairment		Norvasc (Amlodipine Besilate)	C				
	Myocardial Infarction		Flexeril (Cyclobenzaprine Hydrochloride)	C				
	Non-Cardiac Chest Pain		Prednisone	C				
	Oedema Peripheral		Trazodone	C				
	Pallor		Ibuprofen	C				
	Paraesthesia		Vitamin B12	C				
	Pulmonary Embolism		Actonel (Risedronate Sodium)	C				
	Scar		Prilosec (Omeprazole)	C				
			Zantac (Ranitidine Hydrochloride)	C				
			Vicodin	C				
			Nitroglycerin	C				
			Claritin (Loratadine)	C				
			Allegra (Fexofenadine Hydrochloride)	C				
			Fluconazole	C				
			Nasonex (Mometasone Furoate)	C				
			Premarin (Estrogens Conjugated)	C				
			Neurontin (Gabapentin)	C				
			Doxycycline	C				
			Flonase (Fluticasone Propionate)	C				
			Reglan					

(Metoclopramide)	C		
Midrin	C		

Date:07/13/05ISR Number: 4714975-4Report Type:Expedited (15-DaCompany Report #2005098040
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Asthenia	Foreign	Relpax (Eletriptan)	PS		ORAL	ORAL	
	Balance Disorder	Health	Progynova (Estradiol					
	Cerebral Ischaemia	Professional	Valerate0	SS		ORAL	ORAL	
	Headache		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Paraesthesia							
	Paraesthesia Oral							
	Speech Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/13/05ISR Number: 4715553-3Report Type:Expedited (15-DaCompany Report #2005063258
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris	Consumer	Celebrex (Celecoxib)	PS		ORAL	400 MG (200	
Other	Chest Pain	Health					MG, 2 IN 1	
	Drug Hypersensitivity	Professional					D), ORAL	
	Drug Ineffective		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG,	
	Dyspnoea						1 IN 1 D),	
	Dysstasia						ORAL	
	Laboratory Test Abnormal		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Pain		Micardis					
	Pericarditis		(Telmisartna)	SS		ORAL	ORAL	
	Rash		Prempro(Estrogens Conjugated, Medroxyprogesterone Acetate)	C				
			Glucophage	C				
			Zyrtec	C				
			Alprazolam (Alprazolam)	C				
			Darvocet (Dextropropoxyphene Napsilate, Paracetamol)	C				
			Toprol (Metoprolol)	C				

Date:07/13/05ISR Number: 4715691-5Report Type:Expedited (15-DaCompany Report #WAES 0505GBR00076
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Back Pain	Foreign	Tab Vioxx					
Hospitalization -	Blood Alkaline	Study	(Rofecoxib)	PS		ORAL	25 MG/DAILY	

Initial or Prolonged	Phosphatase Increased	Health		
PO 676 DAY				
	Blood Ph Increased	Professional	Clomipramine Hcl	C
	Blood Pressure Increased		Lactulose	C
	Blood Sodium Decreased		Oxybutynin	C
	Cardiac Arrest			
	Chills			
	Colorectal Cancer			
	Recurrent			
	General Physical Health			
	Deterioration			
	Lung Neoplasm Malignant			
	Malignant Pleural			
	Effusion			
	Penile Pain			
	Pleural Effusion			
	Pneumonia			
	Proteus Infection			
	Suprapubic Pain			
	Urosepsis			

Date:07/14/05ISR Number: 4714293-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01238
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthropod Bite
Initial or Prolonged	Blood Cholesterol
Other	Increased

		Cerebrovascular Accident					
		Chest Pain					
		Chronic Obstructive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Estrace	C		
UNKNOWN							
		Disease		Captopril	C		
UNKNOWN							
		Generalised Anxiety		Accupril	C		
UNKNOWN							
		Disorder		Flexeril	C		
UNKNOWN							
		Hyperlipidaemia					
		Insomnia					
		Myalgia					
		Prescribed Overdose					
		Sleep Apnoea Syndrome					

Date:07/14/05ISR Number: 4714298-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03500
Age:69 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
		Attack		Atenolol	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Lisinopril	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							

Date:07/14/05ISR Number: 4714299-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02599
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
	Acute Myocardial Infarction		Maalox	C				
			Zantac	C		ORAL		
	Chest Pain		Aspirin	C		ORAL		
	Coronary Artery Disease		Acetaminophen And Hydrocodone Bitartrate	C		ORAL		
	Dyslipidaemia		Methocarbamol	C		ORAL		
	Hypertension							
	Muscle Spasms							
	Orthostatic Hypotension							
	Pain In Extremity							
	Pain In Jaw							
	Sleep Apnoea Syndrome							

UNKNOWN

Date:07/14/05ISR Number: 4714300-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02056
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Asthma
	Blood Cholesterol Increased
	Cough
	Dyspepsia
	Eye Allergy
	Eye Disorder

	Fungal Infection						
	Gastric Disorder						
	Migraine	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1290 DAY
	Skin Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	1290 DAY
	Sleep Disorder		Aleve	C			UNKNOWN
			Hydrocodone/Apap	C			UNKNOWN
			Hydrocodone/Apap	C			UNKNOWN
			Synthroid	C			UNKNOWN

Date:07/14/05ISR Number: 4714301-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00600
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN
			Celebrex	C		ORAL	
			Celebrex	C		ORAL	

Date:07/14/05ISR Number: 4714302-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02236
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1096 DAY
Other	Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL	1096 DAY
	Atherosclerosis						
	Cough						

Emotional Distress
Gastrooesophageal Reflux
Disease
Hepatic Steatosis

Date:07/14/05ISR Number: 4714303-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04155
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9 MON	
			Furosemide	C			UNKNOWN	
			Lotrel	C			UNKNOWN	
			Diflucan	C			UNKNOWN	
			Glucophage Xr	C			UNKNOWN	
			Actos	C			UNKNOWN	
			Lantus	C			UNKNOWN	
			Mevacor	C			UNKNOWN	
			Meclizine	C			UNKNOWN	

Date:07/14/05ISR Number: 4714304-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02958
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Drug Hypersensitivity
Other	Gun Shot Wound
	Hypotension

Vein Disorder

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Xanax	C			UNKNOWN	
	Xanax	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Prozac	C			UNKNOWN	
	Zoloft	C			UNKNOWN	
	Zoloft	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Wellbutrin	C			UNKNOWN	
	Klonopin	C			UNKNOWN	
	Klonopin	C			UNKNOWN	
	Inderal	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	

Date:07/14/05ISR Number: 4714305-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00947
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gangrene		[Therapy Unspecified]	C				
	Prescribed Overdose						UNKNOWN	

				[Therapy Unspecified]	C		
UNKNOWN							

Date:07/14/05ISR Number: 4714311-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02131
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Initial or Prolonged	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		1 WK
	Pulmonary Embolism		Lipitor	C			UNKNOWN	
	Sleep Apnoea Syndrome		Synthroid	C			UNKNOWN	
			Prevacid	C			UNKNOWN	
			Hormonal Contraceptives (Unspecified)	C			UNKNOWN	

Date:07/14/05ISR Number: 4714324-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01010
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS			UNKNOWN	
			Celebrex	SS			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714325-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04998
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		12 MON
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		12 MON
Disability	Back Disorder							
Other	Blood Cholesterol Increased							
	Cerebrovascular Accident							
	Chest Pain							
	Dyspepsia							
	Dyspnoea							
	Gastric Ulcer							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							
	Osteoarthritis							
	Rheumatoid Arthritis							

Date:07/14/05ISR Number: 4714326-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01009
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/14/05ISR Number: 4714327-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00091
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Advair	C				
UNKNOWN								

	Fall	Dilantin	C
UNKNOWN			
		Singulair	C
UNKNOWN			
		Vitamin B Complex	C
UNKNOWN			
		Amitriptyline Hydrochloride	C
UNKNOWN			
		Levoxyl	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Plavix	C
UNKNOWN			
		Albuterol	C
UNKNOWN			
		Lortab	C
UNKNOWN			
		Lortab	C
UNKNOWN			
		Metformin	C
UNKNOWN			
		Prozac	C
UNKNOWN			
		Allegra	C
UNKNOWN			
		Vitamins (Unspecified)	C
UNKNOWN			
		Zonegran	C
UNKNOWN			
		Ditropan Xl	C
UNKNOWN			
		Aspirin	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714328-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01227
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON
	Thrombosis							

Date:07/14/05ISR Number: 4714532-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02283
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	983	DAY
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	983	DAY
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL	983	DAY
	Cholecystitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL	983	DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea		Zocor	C		ORAL	983	DAY
	Emotional Distress		Diabeta	C			UNKNOWN	
	Headache		Glucophage	C			UNKNOWN	
	Myocardial Infarction		Benadryl	C			UNKNOWN	
	Tachyarrhythmia		Levoxyl	C			UNKNOWN	
	Ventricular Tachycardia		Depakote	C			UNKNOWN	
			Risperdal	C			UNKNOWN	
			Klonopin	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

Date:07/14/05ISR Number: 4714533-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02611
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		29 MON
Initial or Prolonged	Arthropathy		Famvir	C				UNKNOWN
Disability	Blindness		Aciphex	C				UNKNOWN
	Cerebrovascular Accident		Glucovance	C				UNKNOWN
	Chest Pain		Xalatan	C				UNKNOWN
	Gastritis		Cipro	C				UNKNOWN
	Hypercholesterolaemia		Zestril	C				UNKNOWN
	Insomnia		Novolin	C				UNKNOWN
	Retinopathy		Meridia	C				UNKNOWN
			Lantus	C				UNKNOWN
			Diflucan	C				UNKNOWN
			Zyrtec	C				UNKNOWN
			Avelox	C				UNKNOWN
			Clarinex	C				UNKNOWN
			Albuterol	C				RESPIRATORY (INHALATION)
			Zithromax	C				UNKNOWN
			Lescol	C				UNKNOWN
			Cosopt	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Alprazolam	C				UNKNOWN
			Diazide	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714534-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02096
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Arthropathy		Humulin	C				UNKNOWN
	Bradycardia		Lasix (Furosemide)	C		ORAL		
	Cardiac Failure		Aldactone	C				UNKNOWN
	Congestive		Diovan	C		ORAL		
	Cardiogenic Shock		Prilosec	C				UNKNOWN
	Diabetic Foot Infection		Zyloprim	C				UNKNOWN
	Diarrhoea		Trental	C				UNKNOWN
	Drug Intolerance		Ecotrin	C		ORAL		
	Fall		Norpramin	C		ORAL		
	Gastritis		Avandia	C				UNKNOWN
	Gastrointestinal		Lipitor	C				UNKNOWN
	Haemorrhage		Sinequan	C		ORAL		
	Hyperkalaemia		Neurontin	C				UNKNOWN
	Myocardial Infarction		Premarin	C				UNKNOWN
	Oesophagitis		Progesterone	C				UNKNOWN
	Pain		Serevent	C				UNKNOWN
	Renal Failure Acute		Albuterol	C				UNKNOWN
	Shock Haemorrhagic							
	Sleep Apnoea Syndrome							

Date:07/14/05ISR Number: 4714535-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00457
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
Other	Dyspnoea				
	Hypertension				
	Insomnia				
	Laboratory Test				
	Interference				
	Lymphadenopathy				
	Migraine With Aura				
	Myocardial Infarction				
	Myocarditis				
	Rectal Tenesmus				
	Restless Legs Syndrome				
	Retinal Haemorrhage				
	Visual Disturbance				

Date:07/14/05ISR Number: 4714536-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01897
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Anxiety Disorder
	Atrial Fibrillation
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Cerebrovascular Accident
	Chest Wall Pain
	Cholelithiasis

		Coronary Artery Disease					
		Diabetic Gastroparesis					
		Dressler'S Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Drug Intolerance		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Ileus Paralytic		Glucophage	C		
UNKNOWN							
		Lung Infiltration		Flovent	C		
UNKNOWN							
		Musculoskeletal Chest		Serevent	C		
UNKNOWN							
		Pain		Amaryl	C		
UNKNOWN							
		Myocardial Ischaemia					
		Nausea					
		Postoperative Thoracic					
		Procedure Complication					
		Renal Failure Acute					
		Renal Failure Chronic					
		Respiratory Failure					
		Sedation					
		Staphylococcal Infection					
		Ventricular Dysfunction					
		White Blood Cell Count					
		Increased					
		Wound Infection					

Date:07/14/05ISR Number: 4714537-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00753
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
Other	Aortic Valve Incompetence
	Arthralgia
	Asthenia
	Cardiac Disorder
	Cardiomegaly
	Carpal Tunnel Syndrome
	Chest Discomfort
	Chest Pain
	Complex Regional Pain

Syndrome
Coronary Artery
Atherosclerosis
Coronary Artery Stenosis
Depression
Disease Recurrence
Drug Ineffective
Dyslipidaemia
Facet Joint Syndrome
Fall
Gastrooesophageal Reflux
Disease
Head Injury
Headache
Intervertebral Disc
Disorder
Mitral Valve
Calcification
Mitral Valve Incompetence
Muscular Weakness

		Night Sweats					
		Pain In Jaw					
		Peripheral Coldness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pyrexia		Vioxx	PS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Scapula Fracture		Vioxx	SS	Merck & Co., Inc	ORAL
		Shoulder Pain		Naproxen	C		
UNKNOWN							
		Sinus Bradycardia		Indocin			
		Skin Laceration		(Indomethacin)	C		ORAL
		Spinal Osteoarthritis		Zyrtec	C		
UNKNOWN							
		Stress		Prilosec	C		
UNKNOWN							
		Supraventricular		Celexa	C		
UNKNOWN							
		Extrasystoles		Aciphex	C		
UNKNOWN							
		Therapy Non-Responder		Atenolol	C		
UNKNOWN							
		Trigger Finger		Oxycontin	C		
UNKNOWN							
		Umbilical Hernia		Hydrocodone			
		Ventricular Dysfunction		Bitartrate	C		
UNKNOWN							
				Levsin	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Plavix	C		ORAL
196 DAY							
				A.S.A.	C		ORAL

Date:07/14/05ISR Number: 4714538-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02080
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acute Coronary Syndrome		Acetaminophen	C		
UNKNOWN							
		Adenoma Benign		Ambien	C		
UNKNOWN							

	Adverse Drug Reaction	Amox	C
UNKNOWN			
	Anaemia	Androderm	C
UNKNOWN			
	Angina Unstable	Augmentin	C
UNKNOWN			
	Arthralgia	Bextra	C
UNKNOWN			
	Chest Wall Pain	Carisoprodol	C
UNKNOWN			
	Cholecystitis Chronic	Cefadroxil	C
UNKNOWN			
	Diarrhoea	Cipro	C
UNKNOWN			
	Emotional Distress	Cyclobenzaprine(West	
	Gastric Haemorrhage	Point Pharma)	C
UNKNOWN			
	Gastrooesophageal Reflux	Prednisona Sod. Fos	C
UNKNOWN			
	Disease	Demerol	C
UNKNOWN			
	Hepatitis Acute	Detrol	C
UNKNOWN			
	Hydronephrosis	Diazepam	C
UNKNOWN			
	Jaundice Cholestatic	Diflucan	C
UNKNOWN			
	Myocardial Infarction	Estazolam	C
UNKNOWN			
	Nephrolithiasis	Flurazepam	
	Renal Failure Acute	Hydrochloride	C
UNKNOWN			
	Retroperitoneal Haematoma	Fosamax	C
UNKNOWN			
	Systemic Inflammatory	Hydrocodone	
	Response Syndrome	Bitartrate	C
UNKNOWN			
	Thrombocytopenia	Isosorbide	C
UNKNOWN			
	Urinary Tract Infection	Levaquin	C
UNKNOWN			
	Urosepsis	Macrobid	C
UNKNOWN			
		Mercaptopurine	C
UNKNOWN			
		Metronidazole	C
UNKNOWN			
		Nystatin	C
UNKNOWN			
		Oxycodone	C
UNKNOWN			
		Plavix	C
UNKNOWN			

UNKNOWN

UNKNOWN

Prevacid	C
Purinethol	C

	Remicade	C	UNKNOWN
	Sulfamethoxazole	C	UNKNOWN
	Urispas	C	UNKNOWN
	Ursodiol	C	UNKNOWN
	Viagra	C	UNKNOWN
	Vicodin Tablets	C	UNKNOWN
	Zyvox	C	UNKNOWN
	Celebrex	C	UNKNOWN

Date:07/14/05ISR Number: 4714542-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA00111
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	4 YR	
	Drug Effect Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Ultram	C			UNKNOWN	
	Fungal Infection		Lasix (Furosemide Sodium)	C			UNKNOWN	
	Gastric Disorder							
	Haematuria		Prilosec	C			UNKNOWN	
	Knee Arthroplasty		Clonidine	C			UNKNOWN	
	Malignant Hypertension		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
	Nephrolithiasis							
	Nerve Injury							
	Oedema Peripheral		Tizanidine	C			UNKNOWN	
	Osteoarthritis		Premarin	C			UNKNOWN	

	Rash Generalised					
	Renal Cyst					
	Renal Disorder					
	Renal Pain					
	Swelling Face					
	Thrombosis					
	Transient Ischaemic Attack					
	Urinary Tract Infection					
	Vaginal Haemorrhage					

Date:07/14/05ISR Number: 4714544-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02025
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		52 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		52 MON
Other	Cardiac Disorder		Folic Acid	C		ORAL		
	Cardiac Failure		Glucosamine	C		ORAL		
	Congestive		Procardia	C		ORAL		
	Hypoxia		Synthroid	C		ORAL		
	Myocardial Infarction							
	Peripheral Vascular Disorder							
	Thrombosis							

Date:07/14/05ISR Number: 4714545-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01080
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		32 MON
Initial or Prolonged	Bacteraemia		Vioxx	SS	Merck & Co., Inc	ORAL		32 MON
Disability	Bacteria Blood Identified		Premarin	C		ORAL		
	Blood Pressure Increased		Amitriptyline Hydrochloride	C		ORAL		
	Bundle Branch Block Right		Amitriptyline Hydrochloride	C		ORAL		
	Cardiac Failure		Levothyroxine Sodium	C		ORAL		
	Congestive		Vitamins (Unspecified)	C		ORAL		
	Condition Aggravated		Calcium (Unspecified)	C		ORAL		
	Coronary Artery Disease		Vitamin D (Unspecified)	C		ORAL		
	Coronary Artery Restenosis		Vitamin E	C		ORAL		
	Coronary Artery Stenosis		Garlic Extract	C		ORAL		
	Depression		Chondroitin Sulfate Sodium And Glucosamine Hydrochloride	C		ORAL		
	Escherichia Urinary Tract Infection							
	Gastroenteritis							
	Hepatic Enzyme Increased							
	Hyperlipidaemia							
	Impaired Healing							
	Myocardial Infarction							
	Oedema Peripheral							
	Pleural Effusion							
	Postoperative Thoracic Procedure Complication							
	Pulmonary Oedema							
	Sinusitis							
	Toe Deformity							
	Urine Analysis Abnormal							
	Ventricular Dysfunction							
	Weight Increased							
	Wound Dehiscence							

Date:07/14/05ISR Number: 4714546-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04991
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anal Fissure		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Bladder Disorder	Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Cholesterol	Tegretol	C		
UNKNOWN					
	Increased	Darvocet-N	C		
UNKNOWN					
	Chest Discomfort	Lexapro	C		
UNKNOWN					
	Myocardial Infarction				
	Myocardial Ischaemia				
	Panic Disorder				
	Pigmented Naevus				

Date:07/14/05ISR Number: 4714547-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02027
Age:81 YR Gender:Female I/FU:F

Outcome	PT
Death	Arthropathy
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Gastrooesophageal Reflux
	Disease
	Hypertension
	Polycystic Ovaries

	Thrombosis Upper Limb Fracture Urinary Incontinence	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	874 DAY

Date:07/14/05ISR Number: 4714548-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02790
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL	842 MON
Initial or Prolonged	Cardiomegaly Coronary Artery Atherosclerosis Coronary Artery Disease Crepitations Diabetes Mellitus Non-Insulin-Dependent Dizziness Dyspnoea Electrocardiogram St Segment Depression Fatigue Hepatic Enzyme Increased Hyperlipidaemia Hypertension Insulin-Requiring Type Ii Diabetes Mellitus Myocardial Infarction Rotator Cuff Syndrome Shoulder Pain		Vioxx	SS	Merck & Co., Inc	ORAL	

Date:07/14/05ISR Number: 4714549-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02693
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	428 DAY

Initial or Prolonged	Low Density Lipoprotein		Vioxx	SS	Merck & Co., Inc	ORAL
143 DAY						
	Increased					
	Myocardial Infarction					

Date:07/14/05ISR Number: 4714550-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02675
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
898 DAY						
Initial or Prolonged	Cardiac Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
898 DAY						
Other	Cerebrovascular Accident					
	Dyspnoea					
	Mitral Valve					
	Calcification					
	Mitral Valve Incompetence					
	Mitral Valve Prolapse					
	Myocardial Infarction					
	Ventricular Hypertrophy					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714551-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03280
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Creatinine Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Vicodin Tablets	C		ORAL		
	Blood Magnesium Decreased		Aspirin	C		ORAL		
	Blood Potassium Decreased		Isosorbide Dinitrate	C		ORAL		
	Blood Pressure Inadequately Controlled		Valsartan	C		ORAL		
			Metoprolol Succinate	C		ORAL		
	Blood Sodium Decreased		Clonidine	C		ORAL		
	Cardiac Failure		Bumetanide	C		ORAL		
	Congestive Cardiomegaly		Bumetanide	C		ORAL		
			Spironolactone	C		ORAL		
	Cardiomyopathy		Rosuvastatin Calcium	C		ORAL		
	Cellulitis		Pantoprazole	C		ORAL		
	Cerebrovascular Accident		Gabapentin	C		ORAL		
	Chest Wall Pain		Cyclobenzaprine Hydrochloride	C		ORAL		
	Congestive Cardiomyopathy							
	Crepitations		Temazepam	C		ORAL		
	Diabetes Mellitus Non-Insulin-Dependent							
	Dyspnoea							
	Fall							
	Fatigue							
	Headache							
	Hyperglycaemia							
	Hyperlipidaemia							
	Hypoaesthesia							
	Incorrect Dose Administered							
	Lacunar Infarction							
	Medication Error							
	Mitral Valve Incompetence							
	Nausea							
	Pulmonary Oedema							
	Rales							
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							

Date:07/14/05ISR Number: 4714552-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03249
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation		Aspirin	C		ORAL
Other	Chest Pain		Glyburide	C		ORAL
	Coronary Artery Disease		Atenolol	C		ORAL
	Graft Thrombosis		Candesartan	C		ORAL
	Myocardial Infarction		Glucophage	C		ORAL

Date:07/14/05ISR Number: 4714553-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02662
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Chest Pain
Initial or Prolonged	Chronic Fatigue Syndrome
Other	Coronary Artery Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dizziness					
		Facial Palsy					
		Feeling Abnormal					
		Haematochezia		Vioxx	PS	Merck & Co., Inc	ORAL
58 MON							
		Hemiparesis		Nitroglycerin	C		
TOPICAL							
		Hypoaesthesia		Elavil	C		ORAL
15 YR							
		Impaired Healing		Elavil	C		ORAL
15 YR							
		Intestinal Obstruction		Xanax	C		
UNKNOWN		9 YR					
		Myocardial Infarction		Singulair	C		ORAL
				Prozac	C		
UNKNOWN		9 YR					
				Prozac	C		
UNKNOWN		9 YR					
				Prozac	C		
UNKNOWN		9 YR					
				Prozac	C		
UNKNOWN		9 YR					
				Lanoxin	C		
UNKNOWN		7 YR					
				Capoten	C		
UNKNOWN							
				Flexeril	C		ORAL
				Flexeril	C		ORAL
				Tricor	C		
UNKNOWN							
				Donnatal	C		
UNKNOWN							
				Lortab	C		
UNKNOWN							
				Advair	C		
RESPIRATORY							
(INHALATION)							
				Neurontin	C		
UNKNOWN							
				Gemfibrozil	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Valtrex	C		
UNKNOWN							

Date:07/14/05ISR Number: 4714554-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714555-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714556-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714557-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714558-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01241
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714559-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714560-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00995
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/14/05ISR Number: 4714561-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/14/05ISR Number: 4714562-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01117
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714563-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/14/05ISR Number: 4714564-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00539
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		
	Intestinal Haemorrhage		Indocin					
	Small Intestinal		(Indomethacin)	SS		ORAL		
	Obstruction							
	Small Intestinal Stenosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714565-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00991
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714566-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02185
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
Initial or Prolonged	Arthropathy		Terazosin					
	Benign Prostatic		Hydrochloride	C			UNKNOWN	
	Hyperplasia		Tylenol	C			UNKNOWN	
	Blood Disorder		Hydrochlorothiazide	C			UNKNOWN	
	Cardiac Disorder							
	Gallbladder Disorder							
	Gallbladder Operation							
	Hernia							
	Hernia Repair							
	Herpes Zoster							
	Infection							
	Joint Crepitation							
	Prostatic Disorder							
	Sleep Disorder							
	Transient Ischaemic Attack							

Date:07/14/05ISR Number: 4714567-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00001
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	471 DAY	
Initial or Prolonged	Increased		Candesartan	C		ORAL		
Disability	Carotid Artery Stenosis		Metoprolol	C		ORAL		

		Cerebral Infarction		Felodipine	C	ORAL
		Epilepsy		Felodipine	C	ORAL
		Hypertensive Heart		Furosemide	C	ORAL
		Disease		Doxycycline	C	ORAL
7	DAY					
		Nasopharyngitis		Doxycycline	C	ORAL
7	DAY					
		Ventricular Hypertrophy		Allopurinol	C	ORAL

Date:07/14/05ISR Number: 4714568-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00613
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Infarction					
		Adverse Event					
		Anhedonia					
		Injury					
		Pain					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4714569-0Report Type:Expedited (15-DaCompany Report #BR-MERCK-0507BRA00017
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cataract		Oxcarbazepine	C		ORAL		
	Glaucoma							

Date:07/14/05ISR Number: 4714570-7Report Type:Expedited (15-DaCompany Report #FR-MERCK-0507FRA00018
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arteriospasm Coronary		Vioxx	PS	Merck & Co., Inc	ORAL		
71 DAY								
Initial or Prolonged	Coronary Artery		Trimetazidine					
	Atherosclerosis		Hydrochloride	C		ORAL		
	Hypertension		Ginkgo Biloba					
	Myocardial Ischaemia		Extract	C		ORAL		

Date:07/14/05ISR Number: 4714571-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02031
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
841 DAY								
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
841 DAY								
	Increased		Lotensin	C		ORAL		
	Coronary Artery Disease		Advil	C		ORAL		
	Myocardial Infarction							
	Pain In Extremity							

Date:07/14/05ISR Number: 4714572-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02036
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 476 DAY	Blood Cholesterol	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 476 DAY	Increased	Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident Transient Ischaemic Attack	Cyclobenzaprine Hydrochloride	C		ORAL
21 MON		Hydrochlorothiazide	C		ORAL
		Toprol Xl Tablets	C		ORAL
11 YR		Estratest	C		ORAL
11 YR		Medroxyprogesterone Acetate	C		ORAL
		[Therapy Unspecified]	C		
UNKNOWN	11 YR				

Date:07/14/05ISR Number: 4714573-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03450
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cardiomegaly
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Occlusion
	Coronary Artery Stenosis
	Cough
	Dyspnoea

	Myocardial Infarction						
	Nasopharyngitis						
	Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Weight Decreased		Captopril	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Furosemide	C				UNKNOWN

Date:07/14/05ISR Number: 4714575-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/14/05ISR Number: 4714576-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02101
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Nexium	C				UNKNOWN
	Increased		Toprol Xl Tablets	C				UNKNOWN
	Cervical Stricture		Vitamins					
	Cervicitis		(Unspecified)	C				UNKNOWN
	Cholecystitis							
	Coronary Artery							
	Atherosclerosis							
	Coronary Artery Disease							
	Costochondritis							
	Depression							
	Dyspnoea Exertional							
	Emotional Distress							

Essential Hypertension
Fatigue
Ganglion
Hiatus Hernia
Hyperlipidaemia
Hypovolaemia
Ileus
Ingrowing Nail
Intervertebral Disc
Degeneration
Lumbar Radiculopathy
Muscle Spasms
Myocardial Infarction
Neuralgia
Neuritis
Oedema Peripheral
Ovarian Cyst
Pain In Extremity
Panic Attack
Postmenopausal
Haemorrhage
Respiratory Failure
Spinal Column Stenosis
Spondylolisthesis
Uterine Leiomyoma

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/14/05ISR Number: 4715612-5Report Type:Expedited (15-DaCompany Report #2005-DE-02549GD
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Delirium	Foreign	Morphine (Morphine)	PS			EPIDURAL	4MG/HOUR IN THE EMERGENCY ROOM, 1 OR 2 MG FOR SURGERY (SEE
	Pneumonia	Study						
	Post Procedural Complication	Literature						
	Respiratory Failure							
			Paracetamol (Paracetamol)	SS			4 G (NR, 6 HOURLY), NR	
			Bupivacaine (Bupivacaine)	SS			EPIDURAL	EMERGENCY ROOM: 0.25%, BOLUS OF 25 MG, FOLLOWED BY A
			Propofol (Propofol)	SS			10 - 40 MCG/KM/MIN (NR), NR	
			Rofecoxib (Rofecoxib)	SS			25 MG (NR, ONCE DAILY), NR	
			Cefuroxime (Cefuroxime)	SS			1.5 G (NR,	

ONCE

(INTRAOPERATI

VELY)), NR

Enoxaprin
(Enoxaparin) SS

40 MG (NR),

NR

Date:07/14/05ISR Number: 4715615-0Report Type:Expedited (15-DaCompany Report #2005-DE-02547GD
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure Acute	Foreign	Morphine (Morphine)	PS		
EPIDURAL	4 MG/HOUR IN					
		Study				
THE EMERGENCY						
		Literature				
ROOM, 1 OR 2						
MG FOR						
SURGERY; THE						
			Paracetamol (Paracetamol)	SS		
4 G (NR, 6						
HOURLY), NR						
			Bupivacaine (Bupivacaine)	SS		
EPIDURAL	EMERGENCY					
ROOM: 0.25%,						
BOLUS OF 25						
MG, FOLLOWED						
BY A						
			Propofol (Propofol)	SS		
10 - 40						
MCG/KG/MIN						
(NR), NR						
			Rofecoxib			

(Rofecoxib) SS

25 MG (NR,

ONCE DAILY),

NR

Cefuroxime
(Cefuroxime) SS

1.5 G (NR,

ONCE

(INTRAOPERATI

VELY)), NR

			Enoxaparin (Enoxaparin)	SS		

40 MG (NR),

NR

Date:07/14/05ISR Number: 4716643-1Report Type:Expedited (15-DaCompany Report #2005094600
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia Convulsion	Health Professional	Dilantin Kapseals (Phenytoin Sodium)	PS		ORAL	330 MG (2 IN 1 D), ORAL	
Other	Drug Dose Omission Drug Exposure During Pregnancy Drug Interaction Dyskinesia Dyspepsia Extrapyramidal Disorder Fall Heart Rate Increased Hormone Level Abnormal Hypersensitivity Impaired Driving Ability Intervertebral Disc Degeneration Muscle Twitching Myocardial Infarction Neck Injury Neck Pain Pain Pregnancy Rash Trigger Finger		Celebrex (Celecoxib) Phenobarbital (Phenobarbital) Vioxx (Rofecoxib) Prempro (Estrogens Conjugated, Medroxyprogesterone Acetate)	SS SS SS C		ORAL	ORAL 30 MG (1 IN 1 D)	

Urticaria

Date:07/14/05ISR Number: 4716699-6Report Type:Expedited (15-DaCompany Report #2005058468
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Myocardial Infarction	Consumer Health Professional	Bextra (Valdecoxib)	PS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
Other			Vioxx (Rofecoxib)	SS		ORAL	20 MG (20 MG, 1 IN 1 D), ORAL	
			Advair (Fluticasone Priopionate, Salmeterol Xinafoate)	C				
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C				
			Zocor (Simvastatin)	C				
			Plavix (Clopidogrel Sulfate)	C				
			Fosamax (Alendroante Sodium)	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715056-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01626
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Emotional Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypotension		Celebrex	SS				
UNKNOWN								
Disability	Myocardial Infarction		Bextra	SS				
UNKNOWN								
			Plavix	C				
UNKNOWN								
			Altace	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

Date:07/15/05ISR Number: 4715058-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acarodermatitis
Initial or Prolonged	Anaemia
Other	Atrial Fibrillation
	Blood Testosterone
	Decreased
	Cardiac Failure
	Cholecystitis
	Cholelithiasis
	Clostridium Colitis
	Coma
	Contusion
	Decreased Appetite
	Depression
	Emotional Distress
	Erectile Dysfunction
	Eye Infection
	Fatigue
	Flank Pain
	Gastrooesophageal Reflux
	Disease
	Headache
	Hepatic Cirrhosis
	Hepatic Failure

Hiatus Hernia
Hypertension
Impaired Gastric Emptying
Insomnia
Intentional Misuse
Intervertebral Disc
Disorder
Lethargy
Myocardial Infarction
Nasal Septum Deviation
Nervousness
Oedema Peripheral
Platelet Count Decreased
Pneumonia
Rash
Rash Generalised
Renal Disorder
Renal Failure Acute
Renal Tubular Necrosis
Respiratory Failure
Rhinitis
Sepsis

		Testicular Mass					
		Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Weight Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:07/15/05ISR Number: 4715061-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01709
Age:50 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Emotional Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Plavix	C		
UNKNOWN						
Disability			Aspirin	C		
UNKNOWN						
			Altace	C		
UNKNOWN						

Date:07/15/05ISR Number: 4715062-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00408
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Lymphoedema		Vioxx	SS	Merck & Co., Inc	ORAL
	Phlebothrombosis		Hormones (Unspecified)	SS		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						
			Hypericin	C		
UNKNOWN						

Date:07/15/05ISR Number: 4715085-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03287
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Cancer In Situ		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		RESPIRATORY (INHALATION)
	Coronary Artery Disease		Atrovent	C				UNKNOWN
	Diverticulum							
	Gastrooesophageal Reflux Disease		Sinutab Regular Strength Tablets	C				5 YR
	Hiatus Hernia		Vitamin Source Glucosamine Chondroitin Msm	C		ORAL		1 YR
	Major Depression							
	Myocardial Infarction		Vicodin Tablets	C		ORAL		9 YR
	Sinusitis		Premarin	C		ORAL		4 YR
			Prilosec	C		ORAL		RESPIRATORY (INHALATION)
			Provera	C		ORAL		UNKNOWN
			Pulmicort	C				1 MON
			Synthroid	C		ORAL		UNKNOWN
			Vitamins (Unspecified)	C				1661 DAY
			Celebrex	C		ORAL		
			Dilaudid	C		ORAL		
			Singulair	C		ORAL		
			Ventolin (Albuterol Sulfate)	C				
			Ibuprofen	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715086-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02591
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Fioricet Tablets	C				UNKNOWN
	Hyperlipidaemia		Advil	C				UNKNOWN
	Menopausal Symptoms		Tylenol	C				UNKNOWN
	Myocardial Infarction							
	Oedema Peripheral							
	Systolic Hypertension							
	Tooth Disorder							

Date:07/15/05ISR Number: 4715087-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02747
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cataract		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vitamin D (Unspecified) And					
	Haematochezia		Calcium					
	Hypersensitivity		(Unspecified)	C		ORAL		
	Myocardial Infarction							
	Ventricular Tachycardia							

Date:07/15/05ISR Number: 4715088-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02327
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prilosec	C				UNKNOWN

Disability	Anxiety	Tenormin	C
UNKNOWN			
	Cardiac Valve Disease	Aspirin	C
UNKNOWN			
	Chest Pain	Paxil	C
UNKNOWN			
	Chest Wall Pain	Norvasc	C
UNKNOWN			
	Coronary Artery Disease	Tobradex	C
UNKNOWN			
	Fluid Retention	Clarinex	C
UNKNOWN			
	Gastrooesophageal Reflux Disease		
	Headache		
	Hyperlipidaemia		
	Infection		
	Musculoskeletal Chest Pain		

Date:07/15/05ISR Number: 4715090-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00818
Age:28 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Emotional Distress		Darvocet-N	C				
UNKNOWN								
	Gastrooesophageal Reflux		Ibuprofen	C				
UNKNOWN								
	Disease							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715091-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA01454
Age:25 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	34 DAY	
Hospitalization -	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
Initial or Prolonged	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	34 DAY	
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
	Fatigue		Aspirin	C			UNKNOWN	
	Gastrooesophageal Reflux		Echinacea	C			UNKNOWN	1483 DAY
	Disease		Cyclobenzaprine Hydrochloride	C			UNKNOWN	
	Hypersensitivity							
	Migraine		Dicyclomine Hydrochloride	C			UNKNOWN	
	Mitral Valve Prolapse							
	Musculoskeletal Pain		Nexium	C			UNKNOWN	
	Nausea							
	Small Intestinal Ulcer							
	Haemorrhage							
	Upper Respiratory Tract Infection							
	Viral Infection							

Date:07/15/05ISR Number: 4715092-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00986
Age:27 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Naproxen	C			UNKNOWN	
	Hypoaesthesia		Ibuprofen	C			UNKNOWN	
	Palpitations		Zoloft	C			UNKNOWN	

	Rheumatoid Arthritis		Zoloft	C		
UNKNOWN						
	Sinusitis					
	Transient Ischaemic Attack					
	Viral Upper Respiratory Tract Infection					

Date:07/15/05ISR Number: 4715093-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02953
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 541 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL
541 DAY						
	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
			Allegra	C		ORAL
	Coronary Artery Disease		Claritin	C		
UNKNOWN						
	Dyspepsia		Tequin	C		
UNKNOWN						
	Hallucination		Nasonex	C		
UNKNOWN						
	Herpes Zoster		Advair	C		
UNKNOWN						
	Hypertension		Methylprednisolone	C		
UNKNOWN						
	Oedema Peripheral		Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN						
			Motrin	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715098-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715099-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01033
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715100-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury Pharmaceutical Product Complaint		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715101-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00605
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	33 MON	

Date:07/15/05ISR Number: 4715108-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715109-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715110-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01122
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1396 DAY

Date:07/15/05ISR Number: 4715112-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00980
Age:54 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event Blood Cholesterol Increased Bronchitis

		Drug Ineffective Dyspnoea Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Topamax	C		
UNKNOWN							
				Senna-C Plus	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN							

Date:07/15/05ISR Number: 4715113-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00603
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/15/05ISR Number: 4715114-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00984
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
	Pulmonary Disease		Lipitor	SS		
UNKNOWN						
	Depression		Vioxx	SS	Merck & Co., Inc	
UNKNOWN						
	Hepatic Steatosis		Prozac	C		ORAL
	Hypercholesterolaemia		Ativan	C		
UNKNOWN						
	Hypomagnesaemia		Advil	C		
UNKNOWN						
	Hypothyroidism		Advil	C		
UNKNOWN						

	Non-Cardiac Chest Pain		Zestril	C		
UNKNOWN						
	Post-Traumatic Stress Disorder		Synthroid	C		ORAL
	Tachycardia					
	Transient Ischaemic Attack					
	Ventricular Hypertrophy					
	Weight Increased					

Date:07/15/05ISR Number: 4715115-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0506NOR00044
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Duodenitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Pulmonary Embolism		Trimipramine Maleate	C		ORAL
	Thrombophlebitis					

Date:07/15/05ISR Number: 4715116-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02060
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Bacterial Infection
	Cardiac Valve Disease
	Cerebrovascular Accident
	Gastric Disorder

Hypersensitivity
Nasopharyngitis
Pain
Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	180	DAY
	Glucophage	C			UNKNOWN	
	Glipizide	C			UNKNOWN	
	Guaifenesin	C			UNKNOWN	
	Folic Acid	C			UNKNOWN	
	Celebrex	C			UNKNOWN	
	Atenolol	C			UNKNOWN	2263 DAY
	Haloperidol	C			UNKNOWN	
	Temazepam	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Furosemide	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	
	Alprazolam	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Prevacid	C			UNKNOWN	

Date:07/15/05ISR Number: 4715117-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00814
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anal Fissure
	Anxiety
	Aortic Aneurysm
	Aortic Dilatation

Aortic Valve Incompetence
Arrhythmia
Back Pain
Benign Prostatic
Hyperplasia
Cellulitis
Chest Discomfort
Chest Pain
Chromaturia
Claustrophobia
Coronary Artery Occlusion
Diverticulum
Dizziness
Dyspnoea
Eczema
Exostosis
Flank Pain
Haemorrhoids
Headache
Hyperhidrosis
Hypertension
Hypoaesthesia
Influenza
Lipids Increased
Nausea
Nephrolithiasis
Panic Disorder
Peripheral Artery
Aneurysm
Pharyngolaryngeal Pain
Polyp

		Pyrexia					
		Renal Artery Stenosis					
		Retrograde Ejaculation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Right Ventricular		Vioxx	PS	Merck & Co., Inc	ORAL
		Systolic Pressure		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Scoliosis		Vioxx	SS	Merck & Co., Inc	ORAL
4	DAY						
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Ventricular Extrasystoles					

Date:07/15/05ISR Number: 4715118-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03449
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hyperplasia		Celebrex	C		
UNKNOWN							
		Blood Cholesterol		Lotensin	C		
UNKNOWN							
		Increased		Cephalexin	C		
UNKNOWN							
		Blood Erythropoietin		Methocarbamol	C		
UNKNOWN							
		Decreased		Acetaminophen And			
		Cerebrovascular Accident		Hydrocodone			
		Dyspnoea		Bitartrate	C		
UNKNOWN							
		Erectile Dysfunction					
		Gravitational Oedema					
		Haematuria					
		Haemorrhage					
		Hypertension					
		Normochromic Normocytic					
		Anaemia					
		Osteoarthritis					
		Pneumonia					
		Renal Impairment					

Urinary Incontinence

Date:07/15/05ISR Number: 4715119-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00546
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Heart Rate Irregular		Norvasc	C				UNKNOWN
	Renal Disorder							

Date:07/15/05ISR Number: 4715120-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02028
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Respiratory Failure
	Adjustment Disorder With Mixed Disturbance Of Emotion And Conduct
	Anaemia
	Anoxic Encephalopathy
	Chest Pain

		Chondromatosis					
		Depression					
		Essential Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
109	DAY						
		Disease		Paxil	C		
UNKNOWN							
		Hypoxia					
		Infection					
		Mental Status Changes					
		Myocardial Infarction					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Pancreatitis Acute					
		Pneumonia					
		Renal Failure Acute					
		Renal Failure Chronic					
		Rhabdomyolysis					
		Seborrhoeic Dermatitis					
		Septic Shock					
		Staphylococcal Infection					
		Thrombophlebitis					
		Superficial					

Date:07/15/05ISR Number: 4715121-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02731
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Acute Pulmonary Oedema		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Acute Respiratory Failure		Biaxin	C		
UNKNOWN							
		Aggression		Zinc (Unspecified)	C		
UNKNOWN							
		Agitation		Atrovent	C		
UNKNOWN							
		Atrial Fibrillation					
		Breath Sounds Decreased					
		Cardiac Failure					
		Congestive					
		Chest Pain					
		Chest Wall Pain					
		Coronary Artery Disease					

Drug Ineffective
Dyspnoea
Epistaxis
Exercise Tolerance
Decreased
Fatigue
Hypertension
Hypertensive
Cardiomyopathy
Hypertensive Emergency
Hypokalaemia
Localised Infection
Myocardial Infarction
Onychomycosis
Phlebitis
Post Herpetic Neuralgia
Pyrexia
Renal Artery Stenosis
Respiratory Tract
Congestion
Thrombocytopenia
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715174-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02161
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		76 DAY
Initial or Prolonged	Blood Cholesterol		Lopressor	C		ORAL		
Disability	Increased		Dyazide	C		ORAL		
	Cerebrovascular Accident		Tylenol	C		ORAL		
	Diabetes Mellitus							
	Hypertension							
	Osteoporosis							
	Pneumonia							

Date:07/15/05ISR Number: 4715187-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00116
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715189-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01041
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715190-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01200
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/15/05ISR Number: 4715191-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715192-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01201
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/15/05ISR Number: 4715193-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01125
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715194-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01008
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS			UNKNOWN	
			Celebrex	SS			UNKNOWN	

Date:07/15/05ISR Number: 4715197-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							
	Loss Of Employment							
	Myocardial Infarction							
	Scar							

Date:07/15/05ISR Number: 4715220-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01203
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/15/05ISR Number: 4715237-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02043
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	387 DAY	
Other	Cardiac Disorder		Warfarin	C		ORAL	7 MON	
	Cerebrovascular Accident		Isosorbide	C		ORAL	16 MON	

	Hypertensive Heart		Accupril	C		ORAL
16 MON						
	Disease		Prevacid	C		
UNKNOWN						
	Myocardial Infarction		Digoxin	C		ORAL
1 YR						
			Zocor	C		ORAL
3 YR						
			Furosemide	C		ORAL
11 MON						
			Vitamins (Unspecified)	C		ORAL
4 MON						
			Captopril	C		ORAL
3 YR						
			Senokot (Senna)	C		ORAL
21 MON						
			Famotidine	C		ORAL
15 MON						
			Acetaminophen	C		ORAL
3 YR						
			Aspirin	C		ORAL
7 MON						
			Docusate Sodium	C		ORAL
3 YR						

Date:07/15/05ISR Number: 4715269-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02679
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
14 MON						
Initial or Prolonged	Back Pain		Glipizide	C		
UNKNOWN						
Disability	Bipolar Disorder		Lipitor	C		
UNKNOWN						
	Emotional Distress		Hydrocodone/Apap	C		
UNKNOWN						
	Hot Flush		Zoloft	C		
UNKNOWN						
	Myocardial Infarction		Tizanidine Hydrochloride	C		
	Osteoarthritis					
UNKNOWN						
	Panic Disorder		[Therapy Unspecified]	C		
UNKNOWN						

			Duragesic	C		
UNKNOWN						
			Paxil	C		
UNKNOWN						
			Accupril	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						

Date:07/15/05ISR Number: 4715271-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident					

Date:07/15/05ISR Number: 4715331-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01054
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
	Diabetic Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyslipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea		Coreg	C		
UNKNOWN						
	Gastrooesophageal Reflux		Imdur	C		
UNKNOWN						

	Disease	Ibuprofen	C
UNKNOWN			
	Insomnia	Darvocet-N	C
UNKNOWN			
	Loss Of Consciousness	Motrin	C
UNKNOWN			
	Myocardial Infarction	Acetaminophen And	
	Nervousness	Hydrocodone	
	Oedema Peripheral	Bitartrate	C
UNKNOWN			
	Post Procedural	Accupril	C
UNKNOWN			
	Complication		
	Renal Failure		
	Renal Failure Acute		
	Renal Failure Chronic		
	Vertigo		
	Wound Dehiscence		
	Wound Infection		

Date:07/15/05ISR Number: 4715332-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01231
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715333-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01219
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Celebrex	C				
UNKNOWN								
	Thrombosis							

Date:07/15/05ISR Number: 4715335-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02288
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
458 DAY								
Initial or Prolonged	Infarction		Norvasc	C				
UNKNOWN								
Disability	Angina Pectoris		Viagra	C				
UNKNOWN								
	Atherosclerosis		Acetaminophen And					
	Blood Cholesterol		Butalbital	C				
UNKNOWN								
	Increased		Ambien	C				
UNKNOWN								
	Blood Triglycerides		Lipitor	C				
UNKNOWN								
	Increased							
	Coronary Artery Disease							
	Electrocardiogram							
	Abnormal							
	Erectile Dysfunction							
	Ventricular Fibrillation							
	Ventricular Tachycardia							

Date:07/15/05ISR Number: 4715339-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01233
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
1 MON								

Coma

Date:07/15/05ISR Number: 4715344-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02369
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Actinic Keratosis		Vioxx	PS	Merck & Co., Inc	ORAL		1487 DAY
Initial or Prolonged	Acute Myocardial		Zestril	C				UNKNOWN
Other	Infarction		Hydrochlorothiazide	C				UNKNOWN
	Cardiac Arrest		Cozaar	C		ORAL		
	Cardiac Failure		Ibuprofen	C				UNKNOWN
	Congestive		Zoloft	C				UNKNOWN
	Cardiogenic Shock							
	Emotional Distress							
	Ischaemic Hepatitis							
	Metabolic Acidosis							
	Pneumonia							
	Renal Failure Acute							
	Respiratory Failure							
	Skin Papilloma							
	Thoracic Cavity Drainage							
	Ventricular Tachycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715345-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01754
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebrovascular Accident		Verapamil Msd Lp	C		ORAL		
Other	Chest Discomfort							
	Chest Pain							
	Cholelithiasis							
	Constipation							
	Depression							
	Gastrooesophageal Reflux Disease							
	Hallucination							
	Neuropathy							
	Parkinson'S Disease							
	Transient Ischaemic Attack							
	Vascular Dementia							

Date:07/15/05ISR Number: 4715346-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02619
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Pectoris		Bisoprolol	C				
UNKNOWN								
	Anxiety Disorder		Monopril	C				
UNKNOWN								
	Aortic Aneurysm		Lipitor	C				
UNKNOWN								
	Arthralgia		Premarin	C				
UNKNOWN								
	Atherosclerosis		Actonel	C				
UNKNOWN								
	Back Pain		Hydrocodone Hydrochloride	C				
	Blood Pressure Increased							
UNKNOWN								
	Cardiac Disorder		Aspirin	C				
UNKNOWN								
	Carotid Artery Occlusion		Norvasc	C				
UNKNOWN								

Carotid Artery Stenosis
Carotid Bruit
Cerebrovascular Accident
Chest Pain
Contusion
Coronary Artery Disease
Depression
Drug Ineffective
Fall
Headache
Hypertension
Joint Injury
Lacunar Infarction
Osteoporosis
Sinus Bradycardia

Date:07/15/05ISR Number: 4715347-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Coronary Artery Disease		Furosemide	C		ORAL		394 DAY
	Deep Vein Thrombosis		Plavix	C		ORAL		1117 DAY
	Myocardial Infarction							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715348-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02587
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1856 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Angina Pectoris		Avapro	C		ORAL		361 DAY
	Aortic Aneurysm		Avalide	C				UNKNOWN
	Arthritis		Lipitor	C				UNKNOWN
	Blood Cholesterol Increased		Hydrodiuril	C		ORAL		
	Blood Triglycerides Increased							
	Cardiac Murmur							
	Chest Pain							
	Coronary Artery Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Dizziness							
	Headache							
	Hyperhidrosis							
	Hypertension							
	Otorrhoea							
	Sinus Bradycardia							
	Ventricular Hypertrophy							

Date:07/15/05ISR Number: 4715349-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01532
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		38 DAY
Hospitalization -	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		38 DAY
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		5 DAY

Other	Coronary Artery		Synthroid	C	ORAL
	Atherosclerosis		Lasix (Furosemide		
	Drug Hypersensitivity		Sodium)	C	ORAL
	Hypertension		Premarin	C	ORAL
	Low Density Lipoprotein				
	Increased				
	Sinusitis				
	Ventricular Hypertrophy				

Date:07/15/05ISR Number: 4715350-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01386
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 375 DAY	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Pressure Increased					
	Catheter Site Haematoma					
	Haematoma					
	Myocardial Infarction					
	Sinus Tachycardia					
	Vascular Pseudoaneurysm					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715351-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Barrett'S Oesophagus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bifascicular Block		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Colon Adenoma		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Helicobacter Gastritis							
	Hypertension							
	Influenza Like Illness							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Pain In Extremity							
	Prescribed Overdose							
	Renal Colic							
	Renal Failure Chronic							
	Ventricular Extrasystoles							

Date:07/15/05ISR Number: 4715352-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00388
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Fatigue							
	Fluid Retention							
	Lymphoedema							
	Neck Pain							
	Pruritus							

Date:07/15/05ISR Number: 4715353-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA02099
Age:44 YR Gender:Female I/FU:F

Outcome	PT

Hospitalization - Initial or Prolonged Disability	Acute Coronary Syndrome Acute Myocardial Infarction Acute Respiratory Failure Angina Unstable Arthralgia Cardiac Failure Congestive Cardiogenic Shock Cerebrovascular Accident Chest Pain Congestive Cardiomyopathy Coronary Artery Disease Depression Dizziness Emotional Distress Encephalopathy Fatigue Folliculitis

		Gastrooesophageal Reflux Disease					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL
11	MON						
		Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
		Hypertension		Diovan	C		
UNKNOWN							
		Intervertebral Disc		Ultram	C		
UNKNOWN							
		Protrusion		Oxycodone	C		
UNKNOWN							
		Ischaemic Cardiomyopathy		Zantac	C		ORAL
		Ischaemic Hepatitis		Prozac	C		
UNKNOWN							
		Lumbar Radiculopathy		Maxalt (Rizatriptan			
		Lung Infiltration		Benzoate)	C		ORAL
		Migraine		Zoloft	C		
UNKNOWN							
		Multi-Organ Failure					
		Muscle Spasms					
		Oedema Peripheral					
		Panic Disorder					
		Renal Failure Acute					
		Tendonitis					
		Thyroid Neoplasm					
		Ulcer Haemorrhage					
		Urinary Tract Infection					
		Ventricular Fibrillation					
		Ventricular Tachycardia					
		Visual Disturbance					

Date:07/15/05ISR Number: 4715354-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01235
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
46	MON						

Date:07/15/05ISR Number: 4715355-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00632
Age:26 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
			Depo-Provera	SS				
	Fracture		Percocet	C				
	Hypercoagulation		Penicillin (Unspecified)	C				
	Hypertension							
	Lymphadenopathy							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Sweat Gland Infection							

Date:07/15/05ISR Number: 4715356-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00629
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise Tolerance Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Goitre		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Valdecoxib	C		ORAL		
	Osteoarthritis		Valdecoxib	C		ORAL		

			Insulin Glargine	C		
UNKNOWN						
			Metformin	C		
UNKNOWN						
			Glyburide	C		ORAL
			Simvastatin	C		ORAL
			Acarbose	C		ORAL
			Acarbose	C		ORAL
			Aspirin	C		ORAL
			Ramipril	C		
UNKNOWN						

Date:07/15/05ISR Number: 4715357-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00206
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:07/15/05ISR Number: 4715358-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02625
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Bronchitis Viral		Furosemide	C		
UNKNOWN						
	Carotid Artery Stenosis		Tylenol	C		
UNKNOWN						
	Cerebrovascular Accident		Potassium			
	Chest Discomfort		(Unspecified)	C		
UNKNOWN						
	Dental Caries		Humulin	C		
UNKNOWN						
	Diabetes Mellitus		Detrol La	C		
UNKNOWN						
	Inadequate Control		Premarin	C		
UNKNOWN						
	Encephalopathy		Meclizine	C		
UNKNOWN						

	Pyrexia	Prilosec	C
UNKNOWN			
	Tendonitis	Theragran-M	C
UNKNOWN			
	Toothache	Aspirin	C
UNKNOWN			
	Urinary Tract Infection		

Date:07/15/05ISR Number: 4715359-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02608
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthritis
Other	Arthropathy
	Asthenia
	Back Pain
	Blood Cholesterol Increased
	Blood Pressure Increased
	Cardiac Aneurysm
	Chest Discomfort
	Chest Pain
	Constipation
	Dyspnoea
	Dyspnoea Exertional
	Headache
	Hepatitis C
	Hypersensitivity
	Hypoglycaemia
	Insomnia

	Ischaemic Stroke Muscle Spasms Osteoporosis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Pancytopenia		Vioxx	PS	Merck & Co., Inc	ORAL	8 MON
	Tension Headache Weight Decreased		Prilosec	C		ORAL	
			Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN
			Humulin N	C			UNKNOWN
			Premarin	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN
			Lorazepam	C			UNKNOWN

Date:07/15/05ISR Number: 4715360-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02335
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON
Initial or Prolonged			Acetaminophen	C			UNKNOWN
Disability			Glipizide	C			UNKNOWN
			Zestoretic	C			UNKNOWN
			Celebrex	C			UNKNOWN 9 MON

Date:07/15/05ISR Number: 4715361-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02021
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	

Initial or Prolonged Disability UNKNOWN	Arthropathy	Vioxx	SS	Merck & Co., Inc	ORAL
	Atherosclerosis	Amaryl	C		
Other UNKNOWN	Cardiac Failure	Lexapro	C		
	Congestive	Aspirin	C		
UNKNOWN	Cellulitis Chest Discomfort Chest Pain Chondromalacia Chronic Obstructive Pulmonary Disease Coronary Artery Disease Erectile Dysfunction Haematoma Hyperlipidaemia Hypertension Infection Joint Effusion Left Ventricular Failure Ligament Injury Meniscus Lesion Myocardial Infarction Oedema Peripheral Parotitis Patellofemoral Pain Syndrome Sleep Apnoea Syndrome Synovitis Throat Tightness Tracheobronchitis				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715362-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01954
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		274 DAY
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		69 DAY
Disability	Coronary Artery Disease		Furosemide	C				UNKNOWN
Other	Emotional Distress		Singulair	C		ORAL		
	Goitre		Premarin	C				UNKNOWN
	Hypermagnesaemia		Ditropan	C				UNKNOWN
	Hypotension		Klor-Con	C				UNKNOWN
	Myocardial Infarction		Captopril	C				UNKNOWN
	Neutropenia		Albuterol	C				UNKNOWN
	Renal Failure Acute							
	Sleep Apnoea Syndrome							
	Thrombocytopenia							
	Venous Insufficiency							

Date:07/15/05ISR Number: 4715363-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02341
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Cardio-Respiratory Arrest
	Chest Wall Pain
	Cholelithiasis
	Chronic Fatigue Syndrome
	Coronary Artery Occlusion
	Difficulty In Walking
	Drug Interaction

Dyspnoea
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Headache
Heart Rate Irregular
Hyperplasia
Hypoxia
Intermittent Claudication
Ischaemic Cardiomyopathy
Leukocytosis
Multi-Organ Disorder
Myocardial Infarction
Nausea
Nephrolithiasis
Obesity
Oedema
Pain
Panic Disorder
Peptic Ulcer
Pneumonia
Post-Traumatic Stress
Disorder
Prostatic Specific
Antigen Increased

		Pulmonary Hypertension Respiratory Failure Upper Respiratory Tract	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Vascular Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Vomiting		Amiodarone Hydrochloride	SS		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Procardia	C		
UNKNOWN							
				Fiorinal	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Erythromycin	C		
UNKNOWN							
				Volmax	C		
UNKNOWN							
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN		1125 DAY					
				Endocet	C		
UNKNOWN		1527 DAY					
				Valium	C		
UNKNOWN							
				Digoxin	C		
UNKNOWN							

Date:07/15/05ISR Number: 4715364-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02017
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Diovan	C		
UNKNOWN							
				Selegiline	C		
UNKNOWN							
				Indapamide	C		
UNKNOWN							

		Indapamide	C	
UNKNOWN				
		Lescol	C	
UNKNOWN				
		Glucotrol	C	
UNKNOWN				
		Niaspan	C	
UNKNOWN				

Date:07/15/05ISR Number: 4715365-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03452
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Paxil	C		ORAL		
	Back Pain		Aspirin	C		ORAL		
	Chest Pain		Plavix	C		ORAL		
	Depression		Lipitor	C		ORAL		
	Diverticulitis		Zocor	C		ORAL		
	Dyspnoea Exertional		Lescol	C		ORAL		
	Gout		Advil	C		ORAL		
	Hypertension		Advil	C		ORAL		
	Hyperthyroidism		Naproxen	C		ORAL		
	Ischaemic Cardiomyopathy		Naproxen	C		ORAL		
	Myocardial Infarction		Mobic	C		ORAL		
	Myocardial Ischaemia		Mobic	C		ORAL		
	Pain In Extremity		Celebrex	C		ORAL		
	Platelet Aggregation		Celebrex	C		ORAL		
	Increased		Arthrotec	C		ORAL		
	Renal Failure		Arthrotec	C		ORAL		
	Sleep Apnoea Syndrome		Roxicet	C		ORAL		
	Thyroid Disorder		Roxicet	C		ORAL		
	Ventricular Fibrillation		Lodine	C		ORAL		
			Lodine	C		ORAL		

Hydrodiuril	C		ORAL
Irbesartan	C		ORAL
Potassium Chloride	C		ORAL
Lisinopril	C		ORAL
Toprol Xl Tablets	C		ORAL
Coreg	C		ORAL
Metoprolol	C		ORAL
Lasix (Furosemide)	C		ORAL
Furosemide	C		ORAL
Accupril	C		ORAL
Cozaar	C		ORAL
Avapro	C		ORAL
Avapro	C		ORAL
Ambien	C		
UNKNOWN			
Tessalon	C		
UNKNOWN			
Synthroid	C		
UNKNOWN			
Flovent	C		
UNKNOWN			
Serevent	C		
UNKNOWN			
Ceftin	C		
UNKNOWN			

Date:07/15/05ISR Number: 4715366-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03183
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1733 DAY
Initial or Prolonged Disability	Atherosclerosis Coronary Artery Disease Depression Hypertension Kidney Infection Myocardial Infarction							

Date:07/15/05ISR Number: 4715367-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03189
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL	6 MON	
	Brain Damage		Carbatrol	C			UNKNOWN	
	Cerebrovascular Accident		Fentanyl Oralet	C			UNKNOWN	
	Chronic Obstructive		Motrin	C			UNKNOWN	
	Pulmonary Disease		Midrin	C			UNKNOWN	
	Dizziness		Midrin	C			UNKNOWN	
	Nausea		Tylenol	C			UNKNOWN	
	Overdose		Dilaudid	C			UNKNOWN	
	Tonsillar Disorder							

Date:07/15/05ISR Number: 4715368-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02636
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Injury
Disability	Blood Creatinine Increased
Other	Cardiac Failure Congestive
	Cardiogenic Shock
	Chronic Obstructive

	Pulmonary Disease Confusional State Coronary Artery Disease Faeces Discoloured	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Groin Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	988	DAY
	Haemorrhoids Hypercholesterolaemia		Injectable Gold (Unspecified)	C			UNKNOWN	
	Hypoalbuminaemia		Methotrexate	C			UNKNOWN	
	Hypotension		Prednisone	C			UNKNOWN	
	Hypoxia		Zoloft	C			UNKNOWN	
	Joint Sprain		Solganal	C			UNKNOWN	
	Lobar Pneumonia		Xanax	C			UNKNOWN	
	Mitral Valve Incompetence		Paxil	C			UNKNOWN	
	Mycoplasma Serology Positive Myocardial Infarction Otitis Externa Overdose Pleural Effusion Pneumonia Pyothorax Seborrhoeic Dermatitis Subclavian Artery Thrombosis Toe Deformity Upper Gastrointestinal Haemorrhage Viraemia Vomiting							

Date:07/15/05ISR Number: 4715369-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02958
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	1350	DAY

Initial or Prolonged	Anxiety	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
Disability	Benign Prostatic	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
Other	Hyperplasia	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
	Diabetes Mellitus	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
	Non-Insulin-Dependent	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
	Dyspepsia	Vioxx	SS	Merck & Co., Inc	ORAL
1350 DAY					
	Gastrooesophageal Reflux	Vicodin Tablets	C		
UNKNOWN					
	Disease	Zetia	C		
UNKNOWN					
	Hypercholesterolaemia	Lovenox	C		
UNKNOWN					
	Hypertension				
	Joint Injury				
	Limb Injury				
	Myocardial Infarction				
	Overdose				

Date:07/15/05ISR Number: 4715371-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03211
Age:81 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adjustment Disorder With
Initial or Prolonged	Depressed Mood
Other	Anaemia
	Aortic Valve Incompetence
	Blood Culture Positive

	Bursitis						
	Cellulitis						
	Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	
	Hearing Impaired		Cardizem Cd	C		ORAL	
	Hyperlipidaemia		Cartia Xt	C		ORAL	
	Hypokalaemia		Cartia Xt	C		ORAL	
	Hypophosphataemia		Detrol La	C			UNKNOWN
	Macular Degeneration		Flomax (Tamsulosin				
	Osteoarthritis		Hydrochloride)	C			UNKNOWN
	Transient Ischaemic		Protonix	C			UNKNOWN
	Attack		Xenical	C			UNKNOWN
	Ventricular Hypertrophy		Zantac	C			UNKNOWN
	Visual Acuity Reduced		Aspirin	C		ORAL	

Date:07/15/05ISR Number: 4715372-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02694
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Chronic Fatigue Syndrome		Premarin	C			UNKNOWN
Other	Coronary Artery Disease		Norvasc	C			UNKNOWN
	Depression		Atenolol	C			UNKNOWN
	Disturbance In Attention						
	Gastric Disorder						
	Heart Rate Irregular						
	Myocardial Infarction						
	Sleep Apnoea Syndrome						

Date:07/15/05ISR Number: 4715373-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02912
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		56 DAY
Initial or Prolonged	Infarction		Tylenol	C				UNKNOWN
	Aortic Valve Incompetence		Ibuprofen	C				UNKNOWN
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Depression							
	Hypertension							
	Mitral Valve Incompetence							
	Pharyngolaryngeal Pain							
	Tricuspid Valve Incompetence							
	Ventricular Dysfunction							
	Ventricular Hypertrophy							

Date:07/15/05ISR Number: 4715374-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02645
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Other	Arthralgia
	Back Injury
	Bronchitis
	Cataract
	Cerebrovascular Accident
	Cervicobrachial Syndrome

		Chest Pain					
		Depression					
		Eye Swelling	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fatigue		Vioxx	PS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Injury		Ultracet	C		
UNKNOWN							
		Lacunar Infarction		Ultracet	C		
UNKNOWN							
		Myositis		Ortho Tri-Cyclen	C		
UNKNOWN							
		Neck Pain		Lexapro	C		
UNKNOWN							
		Photopsia		Claritin	C		
UNKNOWN							
		Sinusitis					
		Spinal Osteoarthritis					
		Syncope					
		Tracheobronchitis					
		Ulnar Nerve Injury					
		Vision Blurred					

Date:07/15/05ISR Number: 4715375-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03514
Age:61 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR							
Initial or Prolonged		Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
4 YR							
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Fibromyalgia		Prednisone	C		
UNKNOWN							
		Hyperlipidaemia					
		Hypertension					
		Hypoacusis					
		Insomnia					
		Joint Sprain					
		Macular Hole					
		Myocardial Infarction					
		Pain					
		Photosensitivity Reaction					

Psoriasis
Retinal Tear
Selective Iga
Immunodeficiency
Sinus Disorder
Tenosynovitis

Date:07/15/05ISR Number: 4715377-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02205
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ambien	C				
Disability	Cardiac Failure		Elavil	C				
	Congestive		Sterapred	C				
	Coronary Artery Disease		Ultram	C				
	Hypertension		Motrin	C				
	Injury		Methotrexate	C				
	Lung Disorder		Zoloft	C				
	Myocardial Infarction		Zoloft	C				
	Pleural Effusion		Flexeril	C				
	Pneumothorax		Restoril	C				
			Ciclopirox	C				
UNKNOWN								
Other								
UNKNOWN								
UNKNOWN								
UNKNOWN								
UNKNOWN								
UNKNOWN							45	DAY
UNKNOWN								
UNKNOWN								
UNKNOWN								
UNKNOWN								

				Paxil	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:07/15/05ISR Number: 4715378-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00693
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Angina Unstable		Aspirin	C				
UNKNOWN								
	Coronary Artery Disease		Actos	C				
UNKNOWN								
	Depression		Micronase	C				
UNKNOWN								
	Myocardial Infarction		Potassium					
	Nasal Congestion		(Unspecified)	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Glyburide	C				
UNKNOWN								
			Axid	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								
			Claritin	C				
UNKNOWN								
			Furosemide	C				
UNKNOWN								
			Potassium Chloride	C				
UNKNOWN								

Date:07/15/05ISR Number: 4715379-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01000
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		
360 DAY								

	Cardiomyopathy	Coreg	C
UNKNOWN			
	Hyperlipidaemia	Coreg	C
UNKNOWN			
	Myocardial Infarction	Tricor	C
UNKNOWN			
	Rotator Cuff Syndrome	Diazepam	C
UNKNOWN			
		Zestril	C
UNKNOWN			
		Glucophage	C
UNKNOWN			
		Glucotrol	C
UNKNOWN			
		Depo-Medrol	C
UNKNOWN			
		Norvasc	C
UNKNOWN			

Date:07/15/05ISR Number: 4715380-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02197
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		1717 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		1717 DAY
Disability	Blood Triglycerides Increased Coronary Artery Disease Hypertension Myocardial Infarction Overdose							

Date:07/15/05ISR Number: 4715381-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02651
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Other	Blindness Blood Cholesterol Increased

		Cerebrovascular Accident					
		Congenital Eye Naevus					
		Cutis Laxa	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Eyelid Ptosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Fat Embolism		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastric Disorder		Oxycodone	C		
UNKNOWN							
		Headache		Lamotrigine	C		
UNKNOWN							
		Inflammation					
		Muscle Spasms					
		Retinal Artery Embolism					
		Retinal Artery Occlusion					

Date:07/15/05ISR Number: 4715382-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00702
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Prevacid	C		
UNKNOWN							
		Aneurysm					
		Bradycardia					
		Cardiac Arrest					
		Cardiac Failure					
		Cardiac Function					
		Disturbance Postoperative					
		Complications Of					
		Transplant Surgery					
		Coronary Artery Disease					
		Coronary Artery Occlusion					
		Coronary Artery Stenosis					
		Gastritis					
		Haemorrhage					
		Heart Transplant					
		Hypotension					
		Lung Abscess					
		Mediastinal Haemorrhage					
		Osteomyelitis					
		Pericardial Haemorrhage					
		Pneumonia					
		Pulmonary Oedema					
		Urinary Tract Infection					

Date:07/15/05ISR Number: 4715383-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02184
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1626 DAY
Other	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Ineffective		Paxil	C				UNKNOWN
	Mitral Valve Repair		Nexium	C				UNKNOWN
	Myocardial Infarction		Advair	C				UNKNOWN
	Therapy Non-Responder		Clarinex	C				UNKNOWN
			Viagra	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715384-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02195
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Disability	Bronchitis		Diovan	C			UNKNOWN	
	Cardiac Failure		Coreg	C			UNKNOWN	
	Congestive		Furosemide	C			UNKNOWN	
	Chest Pain		Pravachol	C			UNKNOWN	
	Coronary Artery Disease		Folic Acid	C			UNKNOWN	
	Coronary Artery		Protonix	C			UNKNOWN	
	Restenosis		Clarinex	C			UNKNOWN	
	Hypotension		Zoloft	C			UNKNOWN	
	Ischaemic Cardiomyopathy		Potassium (Unspecified)	C			UNKNOWN	
	Myocardial Infarction		Centrum	C			UNKNOWN	
	Neoplasm Malignant		Calcium (Unspecified)	C			UNKNOWN	
	Peritonitis		Insulin	C			UNKNOWN	
	Postoperative Ileus		Nexium	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	

Date:07/15/05ISR Number: 4715385-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02705
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	263	DAY

Initial or Prolonged	Acute Coronary Syndrome	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
Other	Acute Myocardial	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Infarction	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Increased	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Bradycardia	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL	263 DAY
	Chest Pain	Plavix	C			UNKNOWN
	Coronary Artery Disease	Protonix	C			UNKNOWN
	Diabetes Mellitus	Aspirin	C			UNKNOWN
	Non-Insulin-Dependent					
	Drug Hypersensitivity					
	Duodenal Ulcer					
	Gastrointestinal					
	Haemorrhage					
	Headache					
	Hypotension					
	Myocardial Ischaemia					
	Pruritus					
	Psoriasis					
	Sinusitis					
	Urticaria					

Date:07/15/05ISR Number: 4715386-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02467
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Damage							
	Cerebrovascular Accident							
	Pain							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/15/05ISR Number: 4715563-6Report Type:Direct Company Report #CTU 253375
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx 12.5 Mg	PS			12.5 MG TWICE DAILY	
	Cerebrovascular Accident							
	Confusional State							
	Drug Ineffective							
	Headache							
	Shoulder Pain							

Date:07/15/05ISR Number: 4717320-3Report Type:Expedited (15-DaCompany Report #2005097969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage	Consumer	Celebrex (Celecoxib)	PS				
			Vioxx (Rofecoxib)	SS				

Date:07/15/05ISR Number: 4717383-5Report Type:Expedited (15-DaCompany Report #2005098264
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Required Intervention to Prevent Permanent Impairment/Damage	Coronary Artery Occlusion		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Emotional Distress							
	Injury							
	Pain							

Date:07/15/05ISR Number: 4717392-6Report Type:Expedited (15-DaCompany Report #2005097232
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest	Consumer	Celebrex (Celecoxib)	PS				

			Valdecoxib (Valdecoxib)	SS		
			Vioxx (Rofecoxib)	SS		

Date:07/18/05ISR Number: 4715879-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00910
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/18/05ISR Number: 4715880-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00909
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
UNKNOWN								
			Celebrex	SS				
UNKNOWN								

Date:07/18/05ISR Number: 4715882-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00948
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Blood Culture Positive		Lipitor	C				
	Cardiac Failure		Prilosec	C				
	Congestive		Enalapril Maleate	C				
	Cerebrovascular Accident		Norvasc	C				
	Coronary Artery Disease		Metformin	C				
	Coronary Artery Occlusion		Avandia	C				
	Emotional Distress		Glucotrol	C				
	Injection Site Phlebitis		Vitamins (Unspecified)	C				
	Ischaemic Cardiomyopathy							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Oedema Peripheral							
	Pulmonary Oedema							
	Pulmonary Valve Incompetence							
	Tricuspid Valve Incompetence							

Date:07/18/05ISR Number: 4715883-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00911
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Bextra	SS				
			Celebrex	SS				

Date:07/18/05ISR Number: 4715884-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01028
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715891-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01174
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715892-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01213
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715893-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01177
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715894-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01212
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715895-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01175
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715896-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715897-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01211
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715899-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01141
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	1	WK
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	1	WK

	Increased	Vioxx	SS	Merck & Co., Inc	ORAL
	Bronchitis Acute	Cozaar	C		ORAL
	Coronary Artery Stenosis	Cozaar	C		ORAL
	Hepatocellular Damage	Darvocet-N	C		
UNKNOWN					
	Iron Deficiency Anaemia	Maxzide	C		
UNKNOWN					
	Myocardial Infarction				
	Renal Failure				
	Rhinitis Allergic				

Date:07/18/05ISR Number: 4715900-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01139
Age:32 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Angina Unstable
	Anxiety
	Arteriosclerosis
	Arthralgia
	Asthenia
	Chest Pain
	Coronary Artery Disease
	Culture Urine Positive
	Depression
	Dyspepsia
	Gastrooesophageal Reflux

		Disease					
		Headache					
		Hypersensitivity					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypotension		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
		Influenza		Lortab	C		
UNKNOWN							
		Insomnia					
		Metabolic Encephalopathy					
		Mixed Hyperlipidaemia					
		Myocardial Infarction					
		Palpitations					
		Pericarditis					
		Pharyngolaryngeal Pain					
		Pulmonary Embolism					
		Thrombophlebitis					
		Superficial					
		Transient Ischaemic					
		Attack					
		Ventricular Tachycardia					

Date:07/18/05ISR Number: 4715901-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01106
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/18/05ISR Number: 4715902-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00908
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
				Bextra	SS		
UNKNOWN							
				Celebrex	SS		
UNKNOWN							

Date:07/18/05ISR Number: 4715903-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01029
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:07/18/05ISR Number: 4715904-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:07/18/05ISR Number: 4715905-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715906-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715907-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01169
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715908-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01171
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715909-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01173
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715913-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01735
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	36	MON

Date:07/18/05ISR Number: 4715914-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715915-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715916-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715917-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Angina Pectoris		Prevacid	C			UNKNOWN	
Arthralgia		Amitriptyline Hydrochloride	C		ORAL		
Basal Cell Carcinoma		Atenolol	C		ORAL		
Blood Pressure Increased		Atenolol	C		ORAL		
Bundle Branch Block Left		Nitroquick	C			SUBLINGUAL	
Carotid Artery Stenosis		Aspirin	C			UNKNOWN	
Carpal Tunnel Syndrome		Lipitor	C		ORAL		
Chest Pain		Zantac	C		ORAL		
Colon Cancer		Plavix	C			UNKNOWN	
Convulsion		Amaryl	C			UNKNOWN	
Coronary Artery Disease		Baycol	C			UNKNOWN	
Diverticulum		Pravachol	C			UNKNOWN	
Dysphagia		Ambien	C			UNKNOWN	
Dyspnoea		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	
Hiatus Hernia							
Limb Discomfort							
Loss Of Consciousness							
Oesophagitis							
Osteoarthritis							
Polyp							
Post Procedural Haematoma							
Prostatitis							
Renal Cyst							
Retrograde Ejaculation							
Rotator Cuff Syndrome							
Seborrhoeic Keratosis							
Tinnitus							
Urinary Retention							

Date:07/18/05ISR Number: 4715918-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715919-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01176
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715920-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01256
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715921-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715922-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01172
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715923-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02338
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
	Aortic Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arteriosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bundle Branch Block Right		Prinzide	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Atenolol	C			UNKNOWN	
			Combivent	C			UNKNOWN	
	Coronary Artery Atherosclerosis		Garlic Extract	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
	Dilatation Atrial Diverticulum		Omega-3 Marine Triglycerides	C			UNKNOWN	
	Erectile Dysfunction		Ascorbic Acid	C			UNKNOWN	
	Haemorrhoids		Theragran Tablets					
	Headache		Advanced Formula	C			UNKNOWN	
	Hip Arthroplasty		Lipitor	C			UNKNOWN	

	Hip Surgery		Aciphex	C		
UNKNOWN						
	Hypertension		Dihydroergotamine			
	Libido Decreased		Mesylate	C		
UNKNOWN						
	Panic Attack		Glucosamine	C		
UNKNOWN						
	Sleep Apnoea Syndrome		[Therapy			
	Sleep Disorder		Unspecified]	C		
UNKNOWN						
	Ventricular Hypertrophy		Hydroxychloroquine			
	Weight Increased		Sulfate	C		
UNKNOWN						

Date:07/18/05ISR Number: 4715924-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02339
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
38 MON						
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
38 MON						
	Hyperkeratosis		Protonix	C		
UNKNOWN						
	Myocardial Infarction					
	Rotator Cuff Repair					

Date:07/18/05ISR Number: 4715925-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02351
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arrhythmia
Initial or Prolonged	Cardiac Disorder
Disability	Chest Pain
	Chronic Obstructive

	Pulmonary Disease						
	Constipation						
	Convulsion						
	Depression	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Fall		Vioxx	PS	Merck & Co., Inc	ORAL	734 DAY
	Feeling Abnormal		Dilantin	SS			UNKNOWN
	Gastric Ulcer		Dilantin	SS			UNKNOWN 1 DAY
	Gastrooesophageal Reflux		Premarin	C			UNKNOWN
	Disease		Tylenol	C			UNKNOWN
	Headache		Celebrex	C			UNKNOWN
	Intentional Misuse						
	Ischaemic Stroke						
	Limb Injury						
	Mental Status Changes						
	Nausea						
	Neck Pain						
	Oesophageal Disorder						
	Overdose						
	Pain						
	Road Traffic Accident						
	Sleep Apnoea Syndrome						
	Spinal Disorder						
	Suicide Attempt						
	Transient Ischaemic						
	Attack						
	Tremor						
	Ventricular Dysfunction						
	Vomiting						

Date:07/18/05ISR Number: 4715926-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02363
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR
Initial or Prolonged	Cardiac Stress Test		Vioxx	SS	Merck & Co., Inc	ORAL	4 YR

	Abnormal	Glucovance	C
UNKNOWN			
	Coronary Artery Disease	Avandia	C
UNKNOWN			
	Coronary Artery Occlusion	Tricor	C
UNKNOWN			
	Depression	Zoloft	C
UNKNOWN			
	Diabetic Gastroparesis	Aspirin	C
UNKNOWN			
	Diarrhoea	Lotrel	C
UNKNOWN			
	Dysphagia		
	Gastritis		
	Haemorrhoids		
	Myocardial Infarction		
	Personality Disorder		
	Post-Traumatic Stress Disorder		
	Reflux Oesophagitis		
	Stomach Discomfort		
	Suicidal Ideation		
	Tension Headache		

Date:07/18/05ISR Number: 4715927-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02332
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Alopecia
	Cardiac Failure Congestive

		Cerebrovascular Accident Coronary Artery Disease Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
836	DAY						
		Musculoskeletal Pain		Tylenol	C		
UNKNOWN							
		Myocardial Infarction		Prevacid	C		
UNKNOWN							
		Oedema Peripheral		Hydrodiuril	C		
UNKNOWN							
		Paraesthesia		Diovan	C		
UNKNOWN							
		Pruritus		Effexor	C		
UNKNOWN							
		Rash		Flexeril	C		
UNKNOWN							
		Thrombocytopenia Urinary Tract Infection		Calcium (Unspecified)	C		
UNKNOWN							

Date:07/18/05ISR Number: 4715928-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02287
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
Initial or Prolonged		Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
4	YR						
		Atrophy		Cardizem	C		
UNKNOWN							
		Cardiomegaly		Cozaar	C		
UNKNOWN							
		Carotid Artery Stenosis		Aspirin	C		
UNKNOWN							
		Cerebral Infarction		Methotrexate	C		
UNKNOWN		1566 DAY					
		Chronic Obstructive Pulmonary Disease Emotional Distress Hypertension Myocardial Infarction Pain					

Paraesthesia
Syncope
Thrombosis

Date:07/18/05ISR Number: 4715929-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02235
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Azotaemia
	Blood Pressure Orthostatic
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Pain
	Coronary Artery Disease
	Diarrhoea
	Drug Interaction
	Dyspnoea
	Facial Palsy
	Hyperhidrosis
	Hyperlipidaemia
	Hypertension
	Nausea
	Palpitations
	Renal Failure Acute
	Syncope
	Transient Ischaemic Attack
	Urinary Tract Infection

	Vomiting					
	Weight Increased					
		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
30	MON					
			Cozaar	SS		
UNKNOWN						
			Prevacid	C		ORAL
			Effexor Xr	C		
UNKNOWN						
			Bumex	C		
UNKNOWN						
			Hyzaar	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Klonopin	C		
UNKNOWN						
			Neurontin	C		
UNKNOWN						

Date:07/18/05ISR Number: 4715930-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03191
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Brain Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Cardiac Arrest		Prilosec	C		
UNKNOWN						
	Depression		Atenolol	C		ORAL
	Diplopia		Diovan	C		
UNKNOWN						
	Eye Injury		Ziac	C		
UNKNOWN						
	Myocardial Infarction		Hyzaar	C		ORAL
	Psychomotor Skills		Lopid	C		
UNKNOWN						
	Impaired		Betapace	C		
UNKNOWN						
	Speech Disorder		Betapace	C		
UNKNOWN						
	Traumatic Brain Injury		Plavix	C		
UNKNOWN						

		Plavix	C	
UNKNOWN				
		Nexium	C	
UNKNOWN				
		Tricor	C	
UNKNOWN				
		Foltx	C	
UNKNOWN				

Date:07/18/05ISR Number: 4715931-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02071
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
505 YR						
Initial or Prolonged	Anxiety		Aspirin	C		ORAL
Disability	Coronary Artery Disease		Lipitor	C		ORAL
	Haemorrhoids		Zocor	C		ORAL
	Injury					
	Lumbar Radiculopathy					
	Myocardial Infarction					
	Neck Injury					
	Smoker					

Date:07/18/05ISR Number: 4715932-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Angina Unstable
	Aortic Aneurysm
	Barrett'S Oesophagus
	Blood Pressure Increased
	Cardiac Failure

		Congestive					
		Chest Pain					
		Chronic Fatigue Syndrome					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
39	DAY						
		Cyst		Vioxx	SS	Merck & Co., Inc	ORAL
39	DAY						
		Depression		Zocor	C		ORAL
		Disability		Cardura	C		ORAL
		Duodenitis		Tylenol Pm	C		
UNKNOWN							
		Dyspepsia		Tagamet	C		
UNKNOWN							
		Fatigue		Tagamet	C		
UNKNOWN							
		Gastritis Erosive		Plavix	C		
UNKNOWN							
		Gastrooesophageal Reflux					
		Disease					
		Headache					
		Hyperhidrosis					
		Hypogonadism					
		Ischaemic Cardiomyopathy					
		Mood Altered					
		Paraesthesia					
		Peptic Ulcer					
		Reflux Oesophagitis					
		Sleep Apnoea Syndrome					
		Tendonitis					
		Ventricular Extrasystoles					

Date:07/18/05ISR Number: 4715933-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00679
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
7	MON						
Initial or Prolonged		Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
14	MON						
Disability		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
7	MON						
Other		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
14	MON						

	Depression		Zestril	C	
UNKNOWN	3 MON				
	Diabetes Mellitus		Zocor	C	ORAL
	Disability		Lipitor	C	
UNKNOWN					
	Fear		Paxil	C	
UNKNOWN					
	Foot Fracture		Paxil	C	
UNKNOWN					
	Gallbladder Disorder		Xanax	C	
UNKNOWN					
	Hypertension		Xanax	C	
UNKNOWN					
	Myocardial Infarction		Avandia	C	
UNKNOWN					
	Pain		Premarin	C	
UNKNOWN					
	Renal Disorder				
	Thrombosis				
	Ulcer				

Date:07/18/05ISR Number: 4715934-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01806
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/18/05ISR Number: 4715935-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01394
Age: Gender:Male I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Injury

Myocardial Infarction

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715936-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01163
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Dermatitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haemarthrosis		Avalide	C				
UNKNOWN								
	Hypercoagulation		Fluoxetine	C				
UNKNOWN								
	Hypertension		Coumadin	C				
UNKNOWN								
	Laboratory Test Abnormal		Tarka	C				
UNKNOWN								
	Peripheral Coldness		Lovenox	C				
SUBCUTANEOUS								
	Peroneal Nerve Palsy							
	Rash							
	Rash Pustular							
	Skin Discolouration							
	Thermal Burn							
	Thrombophlebitis							
	Superficial							

Date:07/18/05ISR Number: 4715937-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01090
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Drug Ineffective		Depakote	C				
UNKNOWN								
	Emotional Distress		Nexium	C				
UNKNOWN								

	Haemorrhoids	Effexor	C	
UNKNOWN				
	Hyperglycaemia	Zestril	C	
UNKNOWN				
	Lumbar Radiculopathy	Lithium Carbonate	C	
UNKNOWN				
	Myocardial Infarction	[Therapy		
	Upper Respiratory Tract	Unspecified]	C	
UNKNOWN				
	Infection	Robaxin	C	
UNKNOWN				

Date:07/18/05ISR Number: 4715938-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00082
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension							
	Myocardial Infarction							

Date:07/18/05ISR Number: 4715939-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00562
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Knee Arthroplasty		Vioxx	PS	Merck & Co., Inc	ORAL		
616 DAY								
Initial or Prolonged	Renal Disorder		Hytrin	C		ORAL		
	Renal Failure		Tylenol	C		ORAL		
	Syncope		Premarin	C		ORAL		

Date:07/18/05ISR Number: 4715940-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Coumadin	C				
UNKNOWN								
Other	Carotid Artery Stenosis		Celebrex	C				
UNKNOWN								
	Cerebrovascular Accident							
	Drug Ineffective							
	Haemorrhoids							
	Hemianopia							
	Hypoaesthesia							
	International Normalised Ratio Increased							
	Intracranial Aneurysm							

Date:07/18/05ISR Number: 4715941-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02011
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Angina Unstable		Captopril	C				
UNKNOWN								
	Asthenia Atelectasis		Lasix (Furosemide Sodium)	C				
UNKNOWN								
	Coronary Artery Disease		Metoprolol	C				
UNKNOWN								
	Emotional Distress		Isosorbide	C				
UNKNOWN								
	Graft Complication		Aspirin	C				
UNKNOWN								
	Hypertension		Plavix	C				
UNKNOWN								
	Pleural Effusion		Zoloft	C				
UNKNOWN								
	Pneumonia		Glucotrol	C				
UNKNOWN								

	Polytraumatism	Synthroid	C
UNKNOWN			
	Pulmonary Oedema	Synalar	C
UNKNOWN			
	Staphylococcal Osteomyelitis	Hydrocortisone Ointment	C
UNKNOWN			
		Kenalog	C
UNKNOWN			

Date:07/18/05ISR Number: 4715942-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01958
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia
Disability	Arthralgia
Other	Atrial Fibrillation
	Basal Cell Carcinoma
	Blood Creatinine Increased
	Breast Cyst
	Cardiolipin Antibody Positive
	Cerebrovascular Accident
	Chronic Sinusitis
	Coagulopathy
	Colonic Polyp
	Coronary Artery Disease
	Depression
	Dyspepsia
	Ear Pain
	Ecchymosis
	Episcleritis

		Faeces Discoloured					
		Fall					
		Felty'S Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhoidal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Herpes Zoster		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Herpes Zoster Ophthalmic		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Hiatus Hernia		Vioxx	SS	Merck & Co., Inc	ORAL
3	DAY						
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Hypertonic Bladder		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Immunoglobulins Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
70	DAY						
		Insomnia		Methotrexate	SS		
UNKNOWN							
		Keratitis		Methotrexate	SS		
UNKNOWN							
		Keratitis Herpetic		Remicade	SS		
INTRAVENOUS							
		Laryngitis		Remicade	SS		
INTRAVENOUS							
		Laryngitis Viral		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukopenia		Vioxx	SS	Merck & Co., Inc	ORAL
		Lymphoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Mental Impairment		Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
		Migraine		Triamterene	C		
UNKNOWN							
		Mitral Valve Incompetence		Tylenol	C		
UNKNOWN							
		Mouth Injury		Tegretol	C		
UNKNOWN							
		Nasal Cyst		Tegretol	C		
UNKNOWN							
		Nausea		Carbamazepine	C		
UNKNOWN							
		Nocturia		Acyclovir	C		
INTRAVENOUS							
		Orthostatic Hypotension		Hydroxychloroquine			
		Overdose		Sulfate	C		
UNKNOWN							

	Pain	Advil	C	
UNKNOWN				
	Pancytopenia	[Therapy		
	Platelet Disorder	Unspecified]	C	
UNKNOWN				
	Prostatitis	Purinethol	C	
UNKNOWN				
	Pyrexia	Elavil	C	ORAL
	Rash	Prednisone	C	
UNKNOWN				
	Renal Disorder	Fiorinal With		
	Renal Pain	Codeine	C	
UNKNOWN				
	Rheumatoid Arthritis	Proventil	C	ORAL
	Rib Fracture	K-Dur	C	
UNKNOWN				
	Sinus Polyp	Zyrtec	C	
UNKNOWN				
	Sinusitis	Allopurinol	C	
UNKNOWN				
	Temporomandibular Joint	Prilosec	C	
UNKNOWN				
	Syndrome	Azathioprine	C	
UNKNOWN				
	Thrombocytopenia	Tegretol	C	
UNKNOWN				
	Transient Ischaemic Attack			
	Trigger Finger			
	Viral Pharyngitis			

Date:07/18/05ISR Number: 4715943-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01343
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angiopathy
	Arterial Stenosis
Disability	Cardiac Disorder
	Chest Pain
	Depression
	Diarrhoea
	Dyspnoea
	Femoral Artery Aneurysm

		Headache					
		Hypersensitivity					
		Hysterectomy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Muscle Spasms		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Post-Traumatic Stress		Aspirin	C		ORAL
		Disorder		Aspirin	C		
UNKNOWN							
		Surgery		Tylenol	C		ORAL

Date:07/18/05ISR Number: 4715944-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02877
Age:63 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
2	DAY						
		Myocardial Infarction		Lasix (Furosemide)	C		
UNKNOWN							
		Obesity		Lipitor	C		
UNKNOWN							
		Oedema Peripheral		Celebrex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							

Date:07/18/05ISR Number: 4715945-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02653
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive		[Therapy			
		Cerebrovascular Accident		Unspecified]	C		
UNKNOWN							
		Chronic Fatigue Syndrome		[Therapy			
		Dementia		Unspecified]	C		
UNKNOWN							

Depression
Diabetes Mellitus
Dyspnoea
Gastrooesophageal Reflux
Disease
Myalgia
Myocardial Infarction
Prostate Cancer

Date:07/18/05ISR Number: 4715948-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05003
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		950 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		950 DAY
	Cerebellar Infarction		Synthroid	C				UNKNOWN
	Fall		Fosamax	C				UNKNOWN
	Fractured Coccyx		Provera	C				UNKNOWN
	Haemorrhoidal Haemorrhage							
	Hypertension							
	Joint Swelling							
	Mass							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715949-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02669
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acrochordon		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Infarction		Vioxx	SS	Merck & Co., Inc			
UNKNOWN								
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Contusion		Atenolol	C				
UNKNOWN								
	Coronary Artery Disease		Lorcet 10/650	C				
UNKNOWN								
	Drug Administration Error		Celebrex	C				
UNKNOWN								
	Epistaxis							
	Fall							
	Hypercholesterolaemia							
	Nephrolithiasis							
	Non-Cardiac Chest Pain							
	Osteoarthritis							
	Vomiting							
	Wound Infection							

Date:07/18/05ISR Number: 4715950-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02594
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
868 DAY								
Initial or Prolonged	Cardiac Aneurysm		Vioxx	SS	Merck & Co., Inc	ORAL		
868 DAY								
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
868 DAY								
Other	Coronary Artery Disease		Aspirin	C				
UNKNOWN								
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Nervous System Disorder							

Date:07/18/05ISR Number: 4715951-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02688
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL	2	WK
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	584	YR
	Coronary Artery		Tenoretic	C			UNKNOWN	
	Atherosclerosis							
	Coronary Artery Disease							
	Coronary Artery Occlusion							
	Dyslipidaemia							
	Hypercholesterolaemia							
	Myocardial Infarction							
	Otitis Externa							

Date:07/18/05ISR Number: 4715952-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02867
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Back Injury
Initial or Prolonged	Back Pain
Disability	Blood Pressure Abnormal
	Carotid Artery Stenosis
	Cerebral Artery Occlusion
	Escherichia Urinary Tract Infection

Hypercholesterolaemia

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hydrodiuril	C		ORAL		
	Zestoretic	C		ORAL		
	Flexeril	C		ORAL	1042	DAY
	Hydrocodone Hydrochloride	C		ORAL	90	DAY
	Propacet	C		ORAL		
	Acetaminophen And Propoxyphene Hydrochloride	C		ORAL	40	DAY
	Roxicet	C		ORAL		
	Tylenol With Codeine	C		ORAL	2915	DAY
	Nexium	C		ORAL		
	Prevacid	C		ORAL		
	Ramipril	C		ORAL		
	Tylenol	C			UNKNOWN	
	Flonase	C			RESPIRATORY (INHALATION)	
	Protonix	C		ORAL		
	Darvocet-N	C			UNKNOWN	
	Ambien	C			UNKNOWN	
	Oxycontin	C		ORAL		
	Antivert	C		ORAL		
	Colace	C		ORAL		
	Lactulose	C			UNKNOWN	
	Darvon	C			UNKNOWN	
	Aciphex	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Zoloft	C		ORAL		

			Bisacodyl	C		ORAL

Date:07/18/05ISR Number: 4715963-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02618
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Aspirin	C		ORAL
Disability	Myocardial Infarction		Aleve	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						
			Advil	C		
UNKNOWN						
			Motrin	C		
UNKNOWN						

Date:07/18/05ISR Number: 4715964-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02517
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable
Disability	Atrioventricular Block
Other	First Degree
	Atrioventricular Block
	Second Degree
	Blood Homocysteine
	Increased
	Bronchitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cardiac Failure					
		Cardiac Failure					
		Congestive					
		Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiogenic Shock		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiomegaly		Vasotec	C		
UNKNOWN							
		Cardioversion		Ticlid	C		
UNKNOWN							
		Cerebrovascular Accident		Norvasc	C		
UNKNOWN							
		Chronic Fatigue Syndrome		Atrovent	C		
UNKNOWN							
		Chronic Obstructive		K-Dur	C		
UNKNOWN							
		Pulmonary Disease		Aspirin	C		
UNKNOWN							
		Coronary Artery Disease		Lasix (Furosemide)	C		
UNKNOWN							
		Depression		Celebrex	C		
UNKNOWN							
		Dilatation Atrial		Lopressor	C		
UNKNOWN							
		Dilatation Ventricular					
		Dyspnoea					
		Emotional Distress					
		Epistaxis					
		Fatigue					
		Haemoglobin Decreased					
		Hypercholesterolaemia					
		Hypersensitivity					
		Hypokinesia					
		Insomnia					
		Ischaemic Cardiomyopathy					
		Ischaemic Stroke					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nausea					
		Pulmonary Hypertension					
		Sinus Bradycardia					
		Sleep Apnoea Syndrome					
		Tricuspid Valve					
		Incompetence					
		Ventricular Dysfunction					
		Ventricular Hypertrophy					
		Ventricular Tachycardia					

Vomiting
Weight Decreased

Date:07/18/05ISR Number: 4715965-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02605
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Breast Cancer		Hyzaar	SS		ORAL		
	Coronary Artery Disease		Synthroid	C		ORAL		
	Drug Ineffective		Desyrel	C		ORAL		
	Gastrointestinal Mucosal Disorder		Premarin	C		ORAL		
	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							
	Normochromic Normocytic Anaemia							
	Radiculopathy							
	Stress							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715966-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02569
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		65 MON
Initial or Prolonged	Atrial Septal Defect		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Homocysteine		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		65 MON
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Aspirin	C				UNKNOWN
	Dyspepsia		Aspirin	C				UNKNOWN
	Heart Rate Irregular		Atenolol	C				UNKNOWN
	Hyperlipidaemia		Hytrin	C				UNKNOWN
	Hypertensive Crisis		Provigil	C				UNKNOWN
	Lacunar Infarction		Cozaar	C		ORAL		
	Nephrolithiasis		Norvasc	C				UNKNOWN
	Optic Neuropathy		Lasix (Furosemide)	C				UNKNOWN
	Palpitations		Potassium (Unspecified)	C				UNKNOWN
	Pneumonia							
	Transient Ischaemic		Robaxin	C				UNKNOWN
	Attack		Robaxin	C				UNKNOWN
	Viral Infection		Advil	C				UNKNOWN
	Vitamin B12 Deficiency		Advil	C				UNKNOWN
			Motrin	C				UNKNOWN
			Motrin	C				UNKNOWN
			Aleve	C				UNKNOWN
			Aleve	C				UNKNOWN

				Tylenol	C	
UNKNOWN						
				Tylenol	C	
UNKNOWN						
				Ativan	C	
UNKNOWN	6	YR				
				Effexor	C	
UNKNOWN						
				Naproxen	C	
UNKNOWN						
				Tricor	C	
UNKNOWN						

Date:07/18/05ISR Number: 4715967-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01776
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 979 DAY	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 979 DAY	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL
	First Degree		Norvasc	C		
UNKNOWN						
	Blood Cholesterol		Hydrodiuril	C		
UNKNOWN						
	Increased		Motrin	C		
UNKNOWN						
	Chest Pain		Motrin	C		
UNKNOWN						
	Constipation		Advil	C		
UNKNOWN						
	Dyspnoea Exertional		Advil	C		
UNKNOWN						
	Gastric Disorder					
	Hypertension					
	Intestinal Obstruction					
	Myocardial Infarction					
	Supraventricular Extrasystoles					
	Ventricular Extrasystoles					

Date:07/18/05ISR Number: 4715968-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03190
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Motrin	C				
UNKNOWN								
			Motrin	C				
UNKNOWN								

Date:07/18/05ISR Number: 4715969-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03198
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
62 DAY								
	Gastrointestinal Disorder		Vioxx	SS	Merck & Co., Inc			
UNKNOWN							35 DAY	
	Transient Ischaemic		Duragesic	C				
UNKNOWN								
	Attack		Msir	C				
UNKNOWN								
			Senokot (Senna)	C				
UNKNOWN								
			Colace	C				
UNKNOWN								

Date:07/18/05ISR Number: 4715970-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01082
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
549 DAY								
Initial or Prolonged	Infarction		Naproxen	C				
UNKNOWN								
	Anxiety		Premarin	C				
UNKNOWN								
	Aortic Aneurysm		Premarin	C				
UNKNOWN								

	Blue Toe Syndrome	Paxil	C	
UNKNOWN				
	Bradycardia	Celexa	C	
UNKNOWN				
	Chest Pain	Effexor	C	
UNKNOWN				
	Coronary Artery Disease	Ativan	C	
UNKNOWN				
	Coronary Artery Occlusion	Ativan	C	
UNKNOWN				
	Coronary Artery	Xanax	C	
UNKNOWN				
	Thrombosis	Xanax	C	
UNKNOWN				
	Emotional Distress	Metoprolol	C	
UNKNOWN				
	Gastric Ulcer			
	Hyperlipidaemia			
	Hypertension			
	Hypotension			
	Libido Decreased			
	Myocardial Infarction			
	Rash Erythematous			
	Rash Macular			
	Tachycardia			
	Thrombosis			

Date:07/18/05ISR Number: 4715971-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02921
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Gastric Disorder		Zocor	C				
UNKNOWN								
	Gastrooesophageal Reflux		Ranitidine	C				
UNKNOWN								
	Disease		Naproxen	C				
UNKNOWN								
	Hiatus Hernia		Flonase	C				
UNKNOWN								
	Hyperhidrosis							
	Myocardial Infarction							
	Ulcer Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715972-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03181
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy					
	Thyroid Disorder		Unspecified]	C				
UNKNOWN								

Date:07/18/05ISR Number: 4715973-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03208
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Mavik	C		ORAL		
Disability	Cardiac Murmur		Zestril	C		ORAL		
	Cardiac Valve Disease		Lopressor	C		ORAL		
	Chest Pain		Procardia	C		ORAL		
	Coronary Artery Disease		Hydrodiuril	C		ORAL		
	Diabetes Mellitus		Aspirin	C		ORAL		
	Non-Insulin-Dependent		Aspirin	C		ORAL		
	Dyspnoea		Plavix	C		ORAL		
	Gait Disturbance		Lipitor	C		ORAL		
	Gastrooesophageal Reflux		Lortab	C		ORAL		
	Disease		Hydrocodone/Apap	C		ORAL		
	Headache		Premarin	C				
UNKNOWN								
	Heart Rate Irregular		Albuterol	C				
UNKNOWN								
	Lacunar Infarction		Keflex	C				
UNKNOWN								
	Malignant Hypertension		Meclizine	C				
UNKNOWN								
	Nerve Compression		Metformin	C				
UNKNOWN								
	Pain In Extremity		Mytussin Ac	C		ORAL		
	Peripheral Vascular		Nexium	C				
UNKNOWN								
	Disorder		Provera	C				
UNKNOWN								
	Sinus Disorder		Prilosec	C				
UNKNOWN								

	Subclavian Artery	Prevacid	C
UNKNOWN			
	Stenosis	Valium	C
UNKNOWN			
	Vertigo	Paxil	C
UNKNOWN			

Date:07/18/05ISR Number: 4715974-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02180
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		1499 YR
Initial or Prolonged	Infarction							
	Anaemia							
	Aortic Aneurysm							
	Colonic Polyp							
	Coronary Artery Disease							
	Femoral Artery Occlusion							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Hypertriglyceridaemia							
	Ischaemic Stroke							
	Oesophagitis							
	Peripheral Vascular							
	Disorder							
	Renal Cyst							
	Renal Failure							
	Sleep Apnoea Syndrome							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715975-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01078
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Aphthous Stomatitis		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Arthralgia		Xanax	C				UNKNOWN
	Asthenia		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Bronchitis							
	Bronchitis Acute							
	Bursitis		Ultram	C				UNKNOWN
	Cataract Operation		Carisoprodol	C				UNKNOWN
	Cerebrovascular Disorder		Darvocet-N	C				UNKNOWN
	Coronary Artery		Premarin	C				UNKNOWN
	Atherosclerosis		Cycrin	C				UNKNOWN
	Coronary Artery Disease		Meclizine	C				UNKNOWN
	Depression		Zithromax	C				UNKNOWN
	Dysgeusia							
	Dyspepsia							
	Dyspnoea							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							
	Headache							
	Hypertonic Bladder							
	Increased Upper Airway Secretion							
	Insomnia							
	Myocardial Infarction							
	Pneumonitis							
	Pulmonary Oedema							
	Respiratory Disorder							
	Rhinitis Allergic							
	Sinusitis							

Transient Ischaemic
Attack
Urinary Incontinence
Urinary Tract Infection
Vaginal Mycosis
Vertigo Positional

Date:07/18/05ISR Number: 4715976-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02186
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		557 MON
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Diltiazem Hydrochloride	C		ORAL		
	Intervertebral Disc Protrusion		Lipitor	C				UNKNOWN
	Lumbar Radiculopathy		Lipitor	C				UNKNOWN
			Prevacid	C				UNKNOWN
			Aspirin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715977-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04191
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adrenal Mass		Vioxx	PS	Merck & Co., Inc	ORAL		1269 MON
Initial or Prolonged	Adverse Event		Ambien	C				UNKNOWN
Disability	Asthenia		Viagra	C				UNKNOWN
	Blood Pressure Increased		Monopril	C		ORAL		
	Carpal Tunnel Syndrome		Calan Sr	C				UNKNOWN
	Coronary Artery		Celexa	C				UNKNOWN
	Restenosis		Lortab	C				UNKNOWN
	Depression		Plaquenil	C				UNKNOWN
	Dizziness		Darvocet-N	C				UNKNOWN
	Erythema		Remicade	C				UNKNOWN
	Fatigue		Xanax	C				UNKNOWN
	Gastrooesophageal Reflux		Nexium	C				UNKNOWN
	Disease		Procardia Xl	C		ORAL		
	Hyponatraemia		Diuretic					
	Joint Swelling		(Unspecified)	C		ORAL		
	Localised Infection		Aspirin	C		ORAL		
	Myocardial Infarction		Aspirin	C		ORAL		
	Nasal Congestion		Methotrexate	C		ORAL		
	Oedema Peripheral		Prednisone	C				UNKNOWN
	Rash							
	Renal Failure							
	Sinus Bradycardia							
	Vision Blurred							
	Vomiting							

Date:07/18/05ISR Number: 4715978-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/18/05ISR Number: 4715979-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715980-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00566
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Amnesia
	Anaemia
	Angina Unstable
	Anxiety
	Arthritis
	Asthma
	Atherosclerosis
	Blood Pressure Increased
	Bundle Branch Block
	Bundle Branch Block Right
	Cardiac Failure
	Congestive

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cardiac Valve Disease					
		Cardiomegaly					
		Carotid Artery Disease					
		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR						
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Serevent	C		
RESPIRATORY							
		Pulmonary Disease					
(INHALATION)							
		Condition Aggravated		Naproxen	C		
UNKNOWN							
		Constipation		Ultracet	C		
UNKNOWN							
		Coronary Artery Disease		Norvasc	C		
UNKNOWN							
		Deep Vein Thrombosis		Clonazepam	C		
UNKNOWN							
		Depression		Amitriptyline			
		Dermatitis		Hydrochloride	C		
UNKNOWN							
		Dizziness		Lisinopril	C		
UNKNOWN							
		Drug Dependence		Elavil	C		
UNKNOWN							
		Fall		Cozaar	C		
UNKNOWN							
		Fibromyalgia		Cardizem	C		
UNKNOWN							
		Gastrointestinal		Bumetanide	C		
UNKNOWN							
		Haemorrhage		Ultram	C		
UNKNOWN							
		Haematochezia		Neurontin	C		
UNKNOWN							
		Haemoptysis		Vicodin Tablets	C		
UNKNOWN							
		Haemorrhoids					
		Heart Rate Increased					
		Hemiparesis					
		Herpes Simplex					
		Hyperglycaemia					
		Hypertension					
		Hypoaesthesia					
		Inflammation					
		Iron Deficiency Anaemia					

Liver Disorder
Lobar Pneumonia
Loss Of Consciousness
Microcytic Anaemia
Musculoskeletal Pain
Myocardial Infarction
Myocardial Ischaemia
Nausea
Oedema Peripheral
Pain
Panic Attack
Pharyngolaryngeal Pain
Pneumonia
Post-Traumatic Stress
Disorder
Refractory Anaemia
Renal Failure
Renal Failure Acute
Respiratory Acidosis
Rheumatoid Arthritis
Road Traffic Accident
Sciatica
Sinusitis
Staphylococcal Infection
Status Asthmaticus
Stress Incontinence
Suicide Attempt
Ulcer
Ventricular Extrasystoles
Vision Blurred
Weight Increased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4715981-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00583
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4715982-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01851
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	50 MON	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	50 MON	
Other	Blood Cholesterol Increased							
	Diabetes Mellitus							
	Hernia							
	Myocardial Infarction							
	Oesophageal Disorder							

Date:07/18/05ISR Number: 4716023-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00927
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	120 DAY	
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	147 DAY	
	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	396 DAY	
	Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	396 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	120 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	147 DAY	

	Vioxx	SS	Merck & Co., Inc	ORAL
396 DAY				
	Vioxx	SS	Merck & Co., Inc	ORAL
396 DAY				
	Vioxx	SS	Merck & Co., Inc	ORAL
	Vicodin Tablets	C		
UNKNOWN				
	Ativan	C		
UNKNOWN				
	Vitamin E	C		
UNKNOWN				
	Vitamins (Unspecified)	C		
UNKNOWN				
	Zantac	C		
UNKNOWN				
	Tylenol	C		
UNKNOWN				
	Tylenol	C		
UNKNOWN				
	Advil	C		
UNKNOWN				
	Zocor	C		ORAL
	Glucosamine	C		
UNKNOWN				

Date:07/18/05ISR Number: 4716024-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01876
Age: Gender:Male I/FU:F

Outcome	PT
Other	Arrhythmia
	Atrial Fibrillation
	Gastrointestinal Mucosal Disorder
	Haemorrhoids
	Intestinal Polyp
	Myocardial Infarction
	Nephrolithiasis

	Rectal Haemorrhage						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	1	WK

Date:07/18/05ISR Number: 4716025-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02912
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	63	MON
Initial or Prolonged	Atherosclerosis							
Disability	Myocardial Infarction							
	Rotator Cuff Repair							

Date:07/18/05ISR Number: 4716026-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01166
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716027-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03457
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Aspirin	C				UNKNOWN
	Bronchitis Acute		Hytrin	C				UNKNOWN
	Cerumen Impaction		Serevent	C				UNKNOWN
	Colon Adenoma		Flovent	C				UNKNOWN
	Colonic Polyp							

Coronary Artery Disease
Cough
Diverticulum
Dizziness
Dyspnoea Exertional
Erectile Dysfunction
Fatigue
Gastrointestinal Disorder
Hypercholesterolaemia
Hypoacusis
Hypoaesthesia
Hypotension
Ingrowing Nail
Interstitial Lung Disease
Lyme Disease
Nasal Congestion
Orthostatic Hypotension
Postnasal Drip
Prostate Cancer
Throat Irritation
Viral Infection
Wheezing

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716028-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02399
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Hospitalization -	Anxiety		Quinine Sulfate	C				
Initial or Prolonged	Aortic Valve Incompetence		Renagel	C				
Other	Candidiasis		Glyburide	C				
	Cardiac Arrest		[Therapy Unspecified]	C				
	Chest Wall Pain		Toprol Xl Tablets	C				
	Deep Vein Thrombosis		Lamisil	C				
	Endocarditis							
	Fall							
	Gastric Polyps							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Pulmonary Hypertension							
	Sepsis							
	Sepsis Syndrome							
	Tricuspid Valve Incompetence							
	Ventricular Hypertrophy							

Date:07/18/05ISR Number: 4716043-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				
			Celebrex	SS				

Date:07/18/05ISR Number: 4716045-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00584
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716128-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00019
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Coronary Syndrome
Hospitalization - Initial or Prolonged	Aortic Stenosis
Disability	Arrhythmia
	Arthropathy
	Atrial Fibrillation
	Cardiac Disorder
	Cardiac Valve Disease
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery Stenosis
	Dyspnoea
	Gastrointestinal Haemorrhage
	Hypertensive Crisis

		Osteitis					
		Osteoarthritis					
		Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Radicular Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Respiratory Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
225	DAY						
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Vascular Pseudoaneurysm		Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
225	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
1	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
41	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Fenoterol Hydrobromide And Ipratropium Bromide	C		
UNKNOWN							
				Formoterol Fumarate	C		
UNKNOWN							
				Bisoprolol Fumarate	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Atorvastatin Calcium	C		
UNKNOWN							
				Tamsulosin Hydrochloride	C		
UNKNOWN							
				Spironolactone	C		
UNKNOWN							
				Beclomethasone Dipropionate	C		
UNKNOWN							
				Theophylline	C		ORAL
				Prednisolone	C		ORAL
				Captopril	C		ORAL

				Aspirin	C		ORAL
				Acetylcysteine	C		ORAL
				Calcium (Unspecified)	C		ORAL
				Methylprednisolone	C		
UNKNOWN	23	DAY					

Date:07/18/05ISR Number: 4716129-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01612
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident							
Other	Chest Pain							
	Dyspnoea							
	Feeling Cold							
	Feeling Hot							
	Hypoaesthesia							
	Liver Disorder							
	Oedema Peripheral							
	Pruritus							
	Skin Exfoliation							
	Skin Ulcer							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716130-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01165
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chronic Sinusitis		Synthroid	C				
	Diverticulitis		Toprol Xl Tablets	C				
	Eye Injury		Zocor	C				
	Haemorrhoids		Pravachol	C				
	Headache							
	Intraocular Pressure Increased							
	Myocardial Infarction							
	Visual Disturbance							

Date:07/18/05ISR Number: 4716131-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00075
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dizziness							
Disability	Granuloma							
Other	Inflammation							
	Sudden Hearing Loss							
	Tinnitus							

Date:07/18/05ISR Number: 4716134-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00390
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope							

Date:07/18/05ISR Number: 4716135-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00669
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Acute Myocardial
Disability	Infarction
Other	Arthralgia
	Arthropathy
	Back Pain
	Bronchitis
	Cardiac Failure
	Congestive
	Cardiac Valve Disease
	Chest Pain
	Confusional State
	Coordination Abnormal
	Coronary Artery Disease
	Coronary Artery
	Reocclusion
	Dilatation Atrial
	Dyspnoea
	Exostosis
	Fall
	Fibromyalgia

		Hepatitis C					
		Hepatosplenomegaly					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypokalaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypoxia		Valium	SS		
UNKNOWN							
		Injury		Claritin	C		
UNKNOWN							
		Intervertebral Disc		Hyzaar	C		
UNKNOWN							
		Displacement		Hyzaar	C		
UNKNOWN							
		Joint Injury		Ascriptin	C		ORAL
		Joint Range Of Motion		Atenolol	C		ORAL
		Decreased		Lortab	C		ORAL
		Meniscus Lesion		Nexium	C		
UNKNOWN							
		Mitral Valve Incompetence		Zocor	C		ORAL
		Myocardial Infarction		Altace	C		ORAL
		Myocardial Ischaemia		Interferon			
		Osteoarthritis		(Unspecified)	C		
UNKNOWN							
		Pulmonary Hypertension		Phenergan			
		Somnolence		(Promethazine			
		Synovitis		Hydrochloride)	C		
UNKNOWN							
		Tricuspid Valve		Oxycontin	C		
UNKNOWN							
		Incompetence		Percocet	C		
UNKNOWN							
		Ventricular Hypertrophy					

Date:07/18/05ISR Number: 4716140-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00090
Age:60 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Ageusia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Amnesia		Glyburide	C		
UNKNOWN							
		Atherosclerosis		Ramipril	C		
UNKNOWN							
		Blood Glucose Decreased		Acarbose	C		
UNKNOWN							

	Bundle Branch Block Right	Pravastatin Sodium	C
UNKNOWN			
	Cerebral Infarction	Rosiglitazone	
	Cerebrovascular Accident	Maleate	C
UNKNOWN			
	Depression	Rosiglitazone	
	Dizziness	Maleate	C
UNKNOWN			
	Erectile Dysfunction	Pioglitazone	
	Facial Palsy	Hydrochloride	C
UNKNOWN			
	Mitral Valve Incompetence	Insulin Human,	
	Pulmonary Hypertension	Isophane	C
UNKNOWN			
	Spinal Column Stenosis	Insulin Human	C
UNKNOWN			
	Ventricular Dysfunction	Ranitidine	
	Ventricular Hypertrophy	Hydrochloride	C
UNKNOWN			
		Clopidogrel	
		Bisulfate	C
UNKNOWN			
		Nifedipine	C
UNKNOWN			
		Amitriptyline	
		Hydrochloride	C
UNKNOWN			
		Amitriptyline	
		Hydrochloride	C
UNKNOWN			
		Amitriptyline	
		Hydrochloride	C
UNKNOWN			
		Amitriptyline	
		Hydrochloride	C
UNKNOWN			
		Alprazolam	C
UNKNOWN			
		Alprazolam	C
UNKNOWN			
		Sulfamethoxazole	C
UNKNOWN			
		Sulfamethoxazole	C
UNKNOWN			
		Ofloxacin	C
UNKNOWN			
		Ofloxacin	C
UNKNOWN			

			Norfloxacin	C
UNKNOWN				
			Norfloxacin	C
UNKNOWN				
			Doxycycline	C
UNKNOWN				
			Acetaminophen And Codeine Phosphate	C
UNKNOWN				
			Acetaminophen And Codeine Phosphate	C
UNKNOWN				
			Celecoxib	C
UNKNOWN	431	DAY		
			Celecoxib	C
UNKNOWN	431	DAY		
			Meloxicam	C
UNKNOWN				
			Meloxicam	C
UNKNOWN				
			Naproxen	C
UNKNOWN				
			Naproxen	C
UNKNOWN				
			Acetaminophen	C
UNKNOWN				
			Indomethacin	C
UNKNOWN	1	MON		
			Metformin Hydrochloride	C
UNKNOWN				
			Ibuprofen	C
UNKNOWN				
			Cefuroxime	C
UNKNOWN				
			Fusidic Acid	C
UNKNOWN				
			Sulfamethoxazole And Trimethoprim	C
UNKNOWN				

Date:07/18/05ISR Number: 4716146-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0507CAN00088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716147-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02913
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON
Initial or Prolonged	Back Pain		Ambien	C			UNKNOWN	
Disability	Cardiac Disorder							
	Depression							
	Disturbance In Attention							
	Myocardial Infarction							
	Panic Attack							
	Sleep Disorder							
	Stress							
	Suicidal Ideation							
	Thyroid Disorder							

Date:07/18/05ISR Number: 4716148-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA05153
Age:70 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable
Other	Blood Triglycerides
	Increased
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease

		Coronary Artery Stenosis					
		Cyanosis					
		Dizziness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Essential Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Fat Embolism		Tagamet	C		ORAL
		Gastrooesophageal Reflux		Lopid	C		ORAL
		Disease		Vitamins			
		Headache		(Unspecified)	C		
UNKNOWN							
		High Density Lipoprotein					
		Decreased					
		Myocardial Infarction					
		Peripheral Vascular					
		Disorder					
		Renal Failure					
		Thrombosis					
		Treatment Noncompliance					
		Vascular Occlusion					

Date:07/18/05ISR Number: 4716149-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01170
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/18/05ISR Number: 4716150-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01178
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/18/05ISR Number: 4716151-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01291
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc		
UNKNOWN							
Disability	Hemianopia						
	Visual Acuity Reduced						

Date:07/18/05ISR Number: 4716152-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04409
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716153-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00222
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		
	Infarction		Ramipril	C				
UNKNOWN								
	Blood Cholesterol		Leflunomide	C				
UNKNOWN								
	Increased		Citalopram					
	Hypertension		Hydrobromide	C				
UNKNOWN								
	Obesity		Citalopram					

Hydrobromide	C	UNKNOWN
Isosorbide Dinitrate	C	UNKNOWN
Lorazepam	C	UNKNOWN
Prednisone	C	UNKNOWN
Acetaminophen And Codeine Phosphate	C	UNKNOWN
Azithromycin	C	UNKNOWN
Bupropion Hydrochloride	C	UNKNOWN
Aspirin	C	UNKNOWN
Acetaminophen And Codeine Phosphate	C	UNKNOWN
Folic Acid	C	UNKNOWN
Cyclobenzaprine Hydrochloride	C	UNKNOWN

Date:07/18/05ISR Number: 4716154-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02650
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL	6	DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulitis		Wellbutrin	C				
	Hernia		Xanax	C				
	Hypercholesterolaemia							
	Hypertension							

		Myocardial Infarction					
		Pulmonary Embolism					
		Thrombosis					

Date:07/18/05ISR Number: 4716155-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01183
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716156-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00120
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Faecal Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL		
	Failure Of Implant		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Haemorrhage		Ranitidine	C			UNKNOWN	
	Gastric Ulcer		Enalapril Maleate	C			UNKNOWN	
	Gastritis		Diclofenac	C			UNKNOWN	
	Lumbar Spinal Stenosis		Aspirin	C			UNKNOWN	
	Myelopathy		Omeprazole	C			UNKNOWN	
	Nephrolithiasis							
	Overdose							
	Visual Acuity Reduced							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716157-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01189
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716158-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01205
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716159-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716160-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01188
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716161-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01197
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716162-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01182
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/18/05ISR Number: 4716163-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716164-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01190
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716165-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716166-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716167-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01179
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716168-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01184
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716169-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01180
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716170-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716171-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01187
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/18/05ISR Number: 4716172-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716173-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01204
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716175-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01217
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716176-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01216
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716177-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01249
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716178-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716179-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01194
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716180-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01214
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716181-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01218
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716182-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716184-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01240
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716185-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01491
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716186-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01504
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716187-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716188-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01259
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716189-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716190-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Renal Vein Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716191-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716192-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01250
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716193-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01246
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716194-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	24	MON

Date:07/18/05ISR Number: 4716195-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716196-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716197-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	71	DAY

Date:07/18/05ISR Number: 4716198-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716199-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01364
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Impaired Work Ability		Vioxx	PS	Merck & Co., Inc	ORAL	580	DAY
	Infection		[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716200-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01498
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716201-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716202-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716203-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01495
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716204-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01501
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716205-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01496
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716206-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01505
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716207-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01508
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716208-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01512
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716209-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716210-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716211-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01659
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716212-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716213-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716214-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01511
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716215-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01557
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716216-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01500
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716219-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01777
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716220-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716221-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716222-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01831
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716223-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01779
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716224-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01829
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716230-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02004
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1779 DAY	

Date:07/18/05ISR Number: 4716231-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01666
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716232-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01696
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury		Celebrex	SS				
UNKNOWN								

Date:07/18/05ISR Number: 4716234-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01660
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/18/05ISR Number: 4716235-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01741
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716236-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01513
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716237-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01776
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01663
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716239-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716240-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01667
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/05ISR Number: 4716244-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01781
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716246-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01832
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716247-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01778
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716250-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01828
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716255-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01192
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/18/05ISR Number: 4716256-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01771
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716805-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01166
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	606	DAY
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL	3	DAY
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	606	DAY
	Pulmonary Hypertension		Lipitor	C			UNKNOWN	
	Sinusitis		Aspirin	C			UNKNOWN	
	Vertigo							

Date:07/19/05ISR Number: 4716807-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02094
Age:76 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Disability

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
Anaemia		Synthroid	C			UNKNOWN	
Arthropathy		Nitro-Dur	C			UNKNOWN	
Atrial Fibrillation		Naprosyn	C			UNKNOWN	
Cardiac Murmur		Xalatan	C			UNKNOWN	
Cardiomegaly		Cosopt	C			UNKNOWN	
Cholecystitis Acute		Cozaar	C			UNKNOWN	
Cholelithiasis		Aspirin	C			UNKNOWN	
Feeling Cold		Prilosec	C			UNKNOWN	
Gastric Haemorrhage							
Gastritis							
Headache							
Hepatic Cyst							
Hot Flush							
Hypertension							
Melaena							
Myocardial Infarction							
Nephrolithiasis							
Renal Cyst							

Date:07/19/05ISR Number: 4716809-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02728
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort							

Date:07/19/05ISR Number: 4716810-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00730
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN	Arthralgia		Prilosec	C		
Other	Blood Pressure Increased		[Therapy Unspecified]	C		
UNKNOWN	Clavicle Fracture					
	Contusion					
	Convulsion					
	Costochondritis					
	Drug Interaction					
	Headache					
	Intervertebral Disc Disorder					
	Migraine With Aura					
	Muscle Spasms					
	Musculoskeletal Pain					
	Neck Injury					
	Orthopnoea					
	Pyrexia					
	Radicular Syndrome					
	Road Traffic Accident					
	Scintillating Scotoma					
	Visual Disturbance					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716828-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716829-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02540
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 768 DAY	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Cardiac Failure		Biaxin	C		ORAL		
	Congestive		Hyoscyamine	C		ORAL		
	Coronary Artery Disease		Prevacid	C		ORAL		
	Fatigue		Cipro	C		ORAL		
	Myocardial Infarction		Zydone	C		ORAL		
	Sick Sinus Syndrome		Anaspaz	C		ORAL		
	Thrombocythaemia		Elocon	C		TOPICAL		
	Upper Gastrointestinal Haemorrhage							

Date:07/19/05ISR Number: 4716830-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716838-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01226
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716839-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01230
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716840-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02914
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Death	Angina Pectoris
Hospitalization - Initial or Prolonged	Arteriosclerosis
	Calciphylaxis
	Depression
	Emotional Distress
	Gastrooesophageal Reflux Disease
	Haematochezia
	Hyperparathyroidism
	Lethargy
	Pyrexia
	Renal Failure Chronic
	Skin Ulcer
	Sleep Apnoea Syndrome

Wound Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Calcium Acetate	C			UNKNOWN	
	Epoetin	C			UNKNOWN	
	Iron Sucrose	C			UNKNOWN	
	Imdur	C			UNKNOWN	
	Lisinopril	C			UNKNOWN	
	Metoprolol	C			UNKNOWN	
	Nephrocaps	C			UNKNOWN	
	Protonix	C			UNKNOWN	
	Ms Contin	C			UNKNOWN	
	Sertraline Hydrochloride	C			UNKNOWN	
	Trazodone Hydrochloride	C			UNKNOWN	
	Albuterol	C			UNKNOWN	
	Combivent	C			UNKNOWN	
	Heparin	C			UNKNOWN	
	Pantoprazole	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Insulin Lispro	C			UNKNOWN	
	Diflucan	C			UNKNOWN	
	Toprol Xl Tablets	C			UNKNOWN	

			Desyrel	C		
UNKNOWN						
			Pepcid	C		
UNKNOWN						
			Bextra	C		
UNKNOWN						
			Regranex	C		
UNKNOWN						
			Phoslo	C		
UNKNOWN						
			Phoslo	C		
UNKNOWN						
			Epogen	C		
UNKNOWN						
			Zemplar	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Niferex	C		
UNKNOWN						
			Hectorol	C		
UNKNOWN						
			Anusol Suppositories/Ointment	C		
UNKNOWN						
			Lactinex	C		ORAL

Date:07/19/05ISR Number: 4716845-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02603
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 48 MON	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 48 MON	Post Concussion Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
	Retinal Infarction		Procardia	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						
			Xalatan	C		
OPHTHALMIC						
			Cipro	C		
UNKNOWN						
			Iron (Unspecified)	C		
UNKNOWN						
			Hydrocodone			

			Bitartrate	C
UNKNOWN	161	DAY		
			Vitamins (Unspecified)	C
UNKNOWN				

Date:07/19/05ISR Number: 4716859-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00969
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 3 YR	Arterial Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atrial Fibrillation							
	Cardiac Failure							
	Congestive							
	Cardiovascular Disorder							
	Coronary Artery Disease							
	Deep Vein Thrombosis							
	Dysphagia							
	Dysphonia							
	Fatigue							
	Gastrointestinal Disorder							
	Headache							
	Myasthenia Gravis							
	Respiratory Failure							
	Rhinitis Allergic							
	Sepsis							
	Ventricular Extrasystoles							
	Ventricular Tachycardia							
	Wound Infection							

Date:07/19/05ISR Number: 4716860-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01238
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716861-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01272
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716863-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02331
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Coronary Artery Disease							
	Exostosis							
	Gastric Disorder							
	Headache							
	Knee Arthroplasty							
	Monarthritis							
	Myocardial Infarction							
	Osteoarthritis							
	Rash							
	Shoulder Arthroplasty							
	Thrombosis Prophylaxis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716865-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01232
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716867-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02924
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		740 DAY
Initial or Prolonged	Glucose Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		740 DAY
Other	Impaired Hyperlipidaemia Insulin Resistance Syndrome Lumbar Radiculopathy Metabolic Syndrome Neck Injury Pollakiuria Sinus Bradycardia							

Date:07/19/05ISR Number: 4716868-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01236
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716869-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01402
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716870-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01260
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	50 MON	
Initial or Prolonged	Arteriospasm Coronary							
Other	Cardiac Disorder							
	Stent Occlusion							
	Syncope							

Date:07/19/05ISR Number: 4716871-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01398
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716872-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Paralysis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716882-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01519
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716884-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716885-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716886-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01920
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716887-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01923
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716888-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01921
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/19/05ISR Number: 4716890-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01915
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716899-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716900-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716901-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716902-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01273
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716903-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01521
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716905-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01520
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716906-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01492
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716907-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01912
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716908-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01522
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716909-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01465
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716910-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01463
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716912-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01275
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716913-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02228
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716928-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01922
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716930-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01927
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/19/05ISR Number: 4716931-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01925
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4716932-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716934-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716935-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01929
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716936-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716937-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01924
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716938-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4716961-7Report Type:Expedited (15-DaCompany Report #DEWYE114518OCT04
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Dehydration		Enbrel	PS				
SUBCUTANEOUS								
Hospitalization -	Demyelination		Enbrel	SS				
Initial or Prolonged	Depressed Level Of		Vioxx	SS		ORAL		
	Consciousness		Budesonide	C		ORAL		
	Diarrhoea							
	Korsakoff'S Psychosis							
	Non-Alcoholic							

Date:07/19/05ISR Number: 4716968-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717000-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01919
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717431-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01369
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:07/19/05ISR Number: 4717432-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00087
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	General Physical		Aspirin	C		ORAL		
	Condition Abnormal		Sotalol					
	Haemoptysis		Hydrochloride	C		ORAL		
	Heart Rate Irregular		Fluvastatin Sodium	C		ORAL		
	Hypertension		Methimazole	C				
UNKNOWN								
	Lobar Pneumonia		Magnesium					
	Pulmonary Embolism		(Unspecified)	C		ORAL		
	Pulmonary Hypertension		Coumarin And					
	Respiratory Failure		Troxerutin	C		ORAL		
	Sick Sinus Syndrome		Vitamin E Acetate					
	Sinus Arrhythmia		D-Form	C		ORAL		
	Vital Capacity Decreased		Timolol Maleate	C				
OPHTHALMIC								
			Aminophylline And					
			Quinine Sulfate	C		ORAL		

Date:07/19/05ISR Number: 4717434-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00813
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Flomax (Tamsulosin Hydrochloride)	C				
UNKNOWN	Emotional Distress							
	Faeces Discoloured							
	Haemodynamic Instability							
	Hyperkalaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypotension							
	Injury							
	Myocardial Infarction							
	Sinus Arrhythmia							
	Sinus Bradycardia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717435-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00108
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Metoprolol Succinate	C		ORAL		
			Metoprolol Succinate [Therapy Unspecified]	C		ORAL		
			Pravastatin Sodium	C		ORAL		
			Insulin, Neutral	C		PARENTERAL		
			Insulin Human, Isophane	C		PARENTERAL		
			Allopurinol	C		ORAL		
			Piretanide	C		ORAL		
			Omeprazole	C		ORAL		
			Metformin Hydrochloride	C		ORAL		
			Xipamide	C		ORAL		
			Aspirin	C		ORAL		
			Potassium Bicarbonate And Potassium Citrate	C		ORAL		

Date:07/19/05ISR Number: 4717436-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00762
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		99 DAY
Life-Threatening	Aortic Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		38 DAY
Hospitalization -	Blood Glucose Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		296 DAY
Initial or Prolonged	Blood Pressure Increased		Allopurinol	C				UNKNOWN
Disability	Cachexia		Pepcid	C				UNKNOWN
Other	Cardiac Failure		Flonase	C				UNKNOWN

	Congestive	Micronase	C
UNKNOWN			
	Cerebrovascular Accident	Lactulose	C
UNKNOWN			
	Chest Discomfort	Carbidopa And	
	Chest Pain	Levodopa	C
UNKNOWN			
	Convulsion	Probenecid	C
UNKNOWN			
	Coronary Artery Disease	Quinine Sulfate	C
UNKNOWN			
	Death	Selegiline	C
UNKNOWN			
	Decubitus Ulcer	Tramadol	
	Dehydration	Hydrochloride	C
UNKNOWN			
	Fall	Bisacodyl	C
UNKNOWN			
	Gastroenteritis Viral	Compazine	C
UNKNOWN			
	Hospitalisation	Mylanta & Mylanta Ds	C
UNKNOWN			
	Hypoglycaemia	Atenolol	C
UNKNOWN			
	Multiple System Atrophy	Chlorthalidone	C
UNKNOWN			
	Myocardial Ischaemia	Darvocet-N	C
UNKNOWN			
	Pulmonary Oedema		
	Red Blood Cell Count		
	Decreased		
	Renal Failure		
	Staphylococcal Sepsis		
	Syncope		
	Tooth Fracture		
	Urinary Tract Infection		
	Wound Infection		
	Staphylococcal		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717450-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01383
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:07/19/05ISR Number: 4717458-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01445
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:07/19/05ISR Number: 4717459-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01373
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:07/19/05ISR Number: 4717460-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00149
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
10 DAY								
Initial or Prolonged	Infarction		Beclomethasone					
	Anhedonia		Dipropionate	C				
RESPIRATORY								
	Anxiety							
(INHALATION)	729 DAY							
	Aortic Valve Incompetence		[Therapy					
	Coronary Artery Occlusion		Unspecified]	C				
UNKNOWN								

	Drug Ineffective		Griseofulvin	C		
UNKNOWN		25 DAY				
	Emotional Distress		Verapamil			
	Hyperkeratosis		Hydrochloride	C		ORAL
382 DAY						
	Hyperlipidaemia					
	Hyperplasia					
	Injury					
	Pain					
	Pelvic Haematoma					
	Stress					
	Tinea Infection					

Date:07/19/05ISR Number: 4717461-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:07/19/05ISR Number: 4717462-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717463-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717464-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02107
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		237 DAY
Other	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		237 DAY
			Glucosamine	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN
			Xalatan	C		OPHTHALMIC		

Date:07/19/05ISR Number: 4717465-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01406
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717466-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01407
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Myocardial Infarction
Polytraumatism

Date:07/19/05ISR Number: 4717467-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01404
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717468-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717469-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717471-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717479-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01448
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717480-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01475
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717481-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01462
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717482-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01461
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717483-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01442
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717484-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717485-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717486-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01532
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717487-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Myocardial Infarction							

Date:07/19/05ISR Number: 4717488-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717490-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717491-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717492-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01528
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717493-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01525
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717494-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717495-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01526
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717496-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717504-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01524
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717515-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717516-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01840
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular		Prednisone	C				UNKNOWN
			Methadone Hydrochloride	C				UNKNOWN

Date:07/19/05ISR Number: 4717517-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717518-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717519-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01908
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717520-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717521-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01843
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/19/05ISR Number: 4717522-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01631
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717524-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01850
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717525-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01841
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717526-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01638
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717527-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01822
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717528-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01527
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717529-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717530-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717531-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01791
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Cardiac Disorder Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717532-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01818
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717533-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01819
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717534-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01823
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717543-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02047
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN							788 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	788 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717544-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717546-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02114
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717547-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02117
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14	MON

Date:07/19/05ISR Number: 4717548-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717549-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02115
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Ischaemia
Myocardial Infarction

Date:07/19/05ISR Number: 4717550-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02046
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident							

Date:07/19/05ISR Number: 4717551-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02113
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717552-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/19/05ISR Number: 4717559-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02054
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4717566-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/19/05ISR Number: 4720805-7Report Type:Expedited (15-DaCompany Report #2005086379
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction	Consumer	Celebrex (Celecoxib)	PS				
			Vioxx (Rofecoxib)	SS				

Date:07/20/05ISR Number: 4718395-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02662
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaphylactic Shock		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
Other	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL	1	DAY
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gait Disturbance		Neurontin	C			UNKNOWN	
	Headache		Synthroid	C			UNKNOWN	
	Hypoaesthesia		Hydrodiuril	C		ORAL		

	Hypoxia		Arava	C		
UNKNOWN						
	Multiple Sclerosis		Methotrexate	C		
UNKNOWN						
	Pain In Extremity		Premarin	C		
UNKNOWN						
	Pleural Effusion					
	Pneumonia					
	Renal Disorder					
	Syncope					
	Transient Ischaemic Attack					
	Visual Disturbance					

Date:07/20/05ISR Number: 4718396-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00013
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	
UNKNOWN	13 DAY					
Initial or Prolonged			Insulin, Isophane	C		
UNKNOWN						
			Amlodipine Besylate	C		
UNKNOWN						
			Testosterone Enanthate	C		
UNKNOWN						
			Diazepam	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718397-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00588
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718398-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00592
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718400-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Abdominal Pain		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Acute Right Ventricular Failure		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Bradycardia		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Diarrhoea		Tizanidine Hydrochloride	SS		ORAL		
	Hepatic Cyst		Diclofenac Sodium	SS		ORAL		
	Hepatic Enzyme Increased		Herbs (Unspecified)	C		ORAL		
	Hyperhidrosis							
	Nausea							
	Pulmonary Hypertension							
	Sinus Bradycardia							
	Vomiting							

Date:07/20/05ISR Number: 4718410-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA01377
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Norvasc	C				
UNKNOWN								
	Coronary Artery Disease		Lorazepam	C				
UNKNOWN								
	Hepatitis Acute		Premarin	C				
UNKNOWN								
	Myocardial Infarction		Aspirin	C				
UNKNOWN								
	Sinus Tachycardia		Levoxyl	C				
UNKNOWN								
			Cholestin (Policosanol)	C				
UNKNOWN								
			Atenolol	C				
UNKNOWN								

Date:07/20/05ISR Number: 4718424-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03186
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Disability	Adverse Event
Other	Back Pain
	Cholelithiasis
	Depression
	Gallbladder Disorder
	Gastric Disorder
	Injury
	Intervertebral Disc
	Protrusion
	Nervousness

Ulcer Haemorrhage
Weight Gain Poor

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718425-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00085
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exanthem		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Postinfarction Angina		Pravastatin Sodium	SS				
			Candesartan Cilexetil	C				
			Diltiazem Hydrochloride	C				
			Clopidogrel Bisulfate	C				
			Roxithromycin	C				
			Codeine Sulfate	C				
			Metoprolol Succinate	C				
			Hydrochlorothiazide And Triamterene	C				
			Diclofenac Sodium	C				
			Tetrazepam	C				

821 DAY

821 DAY

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

Date:07/20/05ISR Number: 4718426-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
Disability	Anorexia
Other	Anxiety
	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp
	Back Pain
	Blister
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Cardiac Disorder
	Caustic Injury
	Chest Pain
	Constipation
	Depression
	Diastolic Dysfunction
	Diverticulum Intestinal
	Dizziness
	Drug Eruption
	Dysphonia
	Dysuria
	Ecchymosis

		Epistaxis					
		Fall					
		Frequent Bowel Movements	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastritis		Vioxx	PS	Merck & Co., Inc	ORAL
		Glucose Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Impaired		Vioxx	SS	Merck & Co., Inc	ORAL
		Gout		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Haemorrhoids		Prinivil	C		
UNKNOWN							
		Headache		K-Dur	C		
UNKNOWN							
		Helicobacter Infection		Lortab	C		
UNKNOWN							
		Hypertension		Coumadin	C		
UNKNOWN							
		Hypoaesthesia		[Therapy			
		Insomnia		Unspecified]	C		
UNKNOWN							
		Intervertebral Disc		Lasix (Furosemide			
		Degeneration		Sodium)	C		
UNKNOWN							
		Intervertebral Disc					
		Protrusion					
		Joint Crepitation					
		Kidney Infection					
		Labyrinthitis					
		Muscle Strain					
		Nasopharyngeal Disorder					
		Nasopharyngitis					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Otitis Media					
		Pain					
		Pharyngitis					
		Polyarthritis					
		Rash					
		Rhinitis					
		Sinusitis					
		Sleep Disorder					
		Stomach Discomfort					
		Syncope					
		Tricuspid Valve					
		Incompetence					

Vertigo
Vision Blurred
Vomiting

Date:07/20/05ISR Number: 4718427-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00585
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718428-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01907
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718430-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01415
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718431-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718432-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01395
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 253 DAY	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Lasix (Furosemide Sodium)	C				
UNKNOWN								

Date:07/20/05ISR Number: 4718433-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01414
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Syncope		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718434-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718435-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01473
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718443-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718444-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01656
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718445-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01643
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718446-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718448-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718450-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01469
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718451-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718452-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718453-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01380
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718454-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Myocardial Infarction							

Date:07/20/05ISR Number: 4718455-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718456-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01478
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:07/20/05ISR Number: 4718464-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718465-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718466-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718471-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01782
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718472-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01815
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718473-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718474-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718476-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01755
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718482-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01794
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718978-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01588
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
	Eye Pain		Benadryl	C			UNKNOWN	
	Hypoaesthesia		Azmacort	C			UNKNOWN	

Monoplegia
Paralysis

Date:07/20/05ISR Number: 4718981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01627
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	35	MON

Date:07/20/05ISR Number: 4718990-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718991-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01682
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4718992-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/20/05ISR Number: 4718993-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01686
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718994-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718995-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01720
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718996-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01758
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease Quadruple Vessel Bypass Graft		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718997-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01678
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4718998-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01740
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719000-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01650
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719009-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01863
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719019-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01896
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719020-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01684
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719022-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01859
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/20/05ISR Number: 4719023-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719024-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01866
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719032-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01862
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719033-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02172
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Life-Threatening			Mellaril	C				
UNKNOWN								
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719034-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02191
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719035-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02056
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719036-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02176
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	44 MON	

Date:07/20/05ISR Number: 4719037-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02104
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719038-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01907
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719039-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01864
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719041-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719042-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02058
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719043-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719044-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02111
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719045-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719046-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01906
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719053-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00099
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Tolerance Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyslipidaemia		Zocor	C		ORAL		

	Fatigue	Procardia	C
UNKNOWN			
	Gastric Ulcer	Norvasc	C
UNKNOWN			
	Haemorrhoids	Lotensin	C
UNKNOWN			
	Hypokalaemia	Atenolol	C
UNKNOWN			
	Labile Hypertension	Bumetanide	C
UNKNOWN			
	Mass	K-Tab	C
UNKNOWN			
	Mitral Valve Incompetence	Prempro	C
UNKNOWN			
	Oedema	Celebrex	C
UNKNOWN			
	Palpitations	Coumadin	C
UNKNOWN			
	Phlebitis	Coumadin	C
UNKNOWN			
	Thrombosis	Coumadin	C
UNKNOWN			
	Tricuspid Valve	Coumadin	C
UNKNOWN			
	Incompetence	Aspirin	C
UNKNOWN			
	Umbilical Hernia	Tylenol	C
UNKNOWN			
	Weight Increased	Hydralazine	C
UNKNOWN			

Date:07/20/05ISR Number: 4719054-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00259
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Arterial Occlusive Disease
Disability	

Bursitis
Cerebral Artery Occlusion
Colonic Polyp

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Depression					
	Vioxx	PS	Merck & Co., Inc	ORAL	92	DAY
	Diverticulum					
	Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Drug Ineffective					
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia					
	Duragesic	C			UNKNOWN	
	Feeling Abnormal					
	Prevacid	C			UNKNOWN	
	Haematochezia					
	Effexor	C			UNKNOWN	

Hiatus Hernia
Nephrolithiasis
Oesophageal Disorder
Seborrhoeic Keratosis
Spinal Disorder

Date:07/20/05ISR Number: 4719056-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
Other	Anxiety
	Asthenia
	Asthma
	Bronchitis
	Bursitis
	Cardiac Failure
	Congestive
	Cataract
	Chest Pain
	Cholecystitis
	Cystitis
	Diabetes Mellitus
	Inadequate Control
	Drug Hypersensitivity
	Duodenitis
	Dyslipidaemia
	Dyspnoea Exertional
	Dysstasia

Embolic Cerebral
Infarction
Emotional Distress
Fatigue
Foot Fracture
Gastritis
Glaucoma
Gout
Haemorrhage
Hypertensive Crisis
Hypertrophic
Cardiomyopathy
Insomnia
Iron Deficiency Anaemia
Irritable Bowel Syndrome
Lactose Intolerance
Macular Degeneration
Malaise
Myocardial Infarction
Optic Disc Drusen
Pain

	Pharyngolaryngeal Pain						
	Renal Failure Chronic						
	Restless Legs Syndrome	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	2 YR
	Salivary Gland Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	2 YR
	Spinal Osteoarthritis		Diovan	C			UNKNOWN
	Urinary Incontinence		Methotrexate	C			UNKNOWN
	Urinary Tract Infection		Prednisone	C			UNKNOWN
	Ventricular Dysfunction		Cozaar	C		ORAL	
	Weight Decreased						

Date:07/20/05ISR Number: 4719057-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00766
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Intracardiac Thrombus		Advil	C			UNKNOWN
	Rhinitis						

Date:07/20/05ISR Number: 4719058-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Aggression		Vioxx	PS	Merck & Co., Inc	ORAL	29 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY
Disability	Appendicitis		Vioxx	SS	Merck & Co., Inc	ORAL	
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL	29 DAY
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL	62 DAY
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	

	Cellulitis	Lithium Carbonate	C
UNKNOWN			
	Chest Pain Constipation Depression Diarrhoea Dizziness Fatigue Heart Injury Heart Rate Irregular Inguinal Hernia Joint Dislocation Myocardial Infarction Nerve Compression Nerve Injury Onychomycosis Osteoarthritis Pain In Extremity Paranoia Penis Carcinoma Pharyngolaryngeal Pain Post-Traumatic Stress Disorder Rash Rotator Cuff Syndrome Sacroiliitis Sputum Abnormal Squamous Cell Carcinoma Stomach Discomfort Suicidal Ideation		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719059-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0210USA01489
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Atrial Tachycardia		Metformin	C				UNKNOWN
	Blood Cholesterol		Amaryl	C				UNKNOWN
	Abnormal							
	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Cardiac Valve Disease							
	Cardiomyopathy							
	Cataract							
	Chest Discomfort							
	Constipation							
	Convulsion							
	Coronary Artery Disease							
	Dizziness							
	Emotional Distress							
	Excoriation							
	Hepatitis B							
	Hypertension							
	Hypoaesthesia							
	Muscle Tightness							
	Myocardial Infarction							
	Nausea							
	Paraesthesia							
	Sarcoidosis							
	Sick Sinus Syndrome							
	Sinus Bradycardia							
	Sleep Apnoea Syndrome							
	Syncope							
	Throat Tightness							

Date:07/20/05ISR Number: 4719060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02059
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719061-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02357
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719062-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719063-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719069-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02334
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719070-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719072-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02325
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719073-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02335
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719074-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02330
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719075-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02044
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Disability	Abdominal Pain
	Asthenia
	Back Injury
	Back Pain
	Benign Prostatic Hyperplasia
	Chest Pain
	Constipation
	Contusion
	Diverticulum
	Dizziness
	Dysuria
	Ecchymosis
	Emotional Distress
	Facial Pain
	Hypersensitivity

		Hypertension					
		Hypoaesthesia					
		Inflammation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Injury		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Ligament Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Limb Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Loose Body In Joint		Coumadin	C		
UNKNOWN							
		Monoparesis					
		Musculoskeletal Chest					
		Pain					
		Nausea					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Pain					
		Pain In Extremity					
		Peripheral Embolism					
		Pyrexia					
		Renal Failure					
		Rheumatoid Arthritis					
		Sciatic Nerve Injury					
		Sinus Bradycardia					
		Stress					
		Testicular Cyst					
		Urinary Tract Infection					

Date:07/20/05ISR Number: 4719076-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02064
Age:36 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Aspergillosis
Disability	Bronchitis
	Cerebrovascular Accident
	Complicated Migraine
	Conversion Disorder
	Drug Dependence
	Drug Ineffective
	Hypercholesterolaemia
	Hypertriglyceridaemia
	Hypotension

Iris Disorder
Major Depression
Melas Syndrome
Migraine
Migraine With Aura
Muscle Spasms
Neuropathic Pain
Night Sweats
Nystagmus
Oesophageal Spasm
Pain In Extremity
Pigmented Naevus
Rib Fracture
Road Traffic Accident
Shoulder Pain
Skin Hypopigmentation
Skin Laceration

		Syncope Tremor Weight Decreased	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/20/05ISR Number: 4719077-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02355
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/20/05ISR Number: 4719078-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02333
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/20/05ISR Number: 4719090-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01384
Age:48 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Cyclobenzaprine Hydrochloride	C		
UNKNOWN							
				Percocet	C		
UNKNOWN							

Date:07/20/05ISR Number: 4719091-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04748
Age:70 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening		Cervical Vertebra Injury		Vioxx	SS	Merck & Co., Inc	ORAL

		Dizziness		[Therapy			
		Essential Tremor		Unspecified]	C		
UNKNOWN							
		Fall					
		Head Deformity					
		Head Injury					

Date:07/20/05ISR Number: 4719092-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03988
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Sudden Cardiac Death		Vioxx	SS	Merck & Co., Inc	ORAL	15	MON

Date:07/20/05ISR Number: 4719093-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01368
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719094-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00581
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719095-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04342
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719096-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00165
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	161 DAY	

Date:07/20/05ISR Number: 4719097-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00645
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	17 MON	
	Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL	57 DAY	
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL	17 MON	
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL	57 DAY	
	Rheumatoid Arthritis		Paxil	C			UNKNOWN	
			Mobic	C			UNKNOWN	

Neurontin	C	UNKNOWN
Prilosec	C	UNKNOWN
Oxycontin	C	UNKNOWN
Nortriptyline	C	UNKNOWN
Glucotrol	C	UNKNOWN

Date:07/20/05ISR Number: 4719098-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00795
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719099-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00551
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:07/20/05ISR Number: 4719100-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00098
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accident
	Barrett'S Oesophagus
	Bifascicular Block
	Bradycardia
	Colon Adenoma

		Congestive Cardiomyopathy					
		Contusion					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrointestinal		Vioxx	SS	Merck & Co., Inc	ORAL
		Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Headache		Vioxx	SS	Merck & Co., Inc	ORAL
		Helicobacter Gastritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Influenza Like Illness		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Sprain		Vioxx	SS	Merck & Co., Inc	ORAL
		Left Ventricular Failure					
		Mitral Valve Incompetence					
		Pain In Extremity					
		Prescribed Overdose					
		Renal Colic					
		Renal Failure Chronic					
		Ventricular Extrasystoles					

Date:07/20/05ISR Number: 4719101-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01778
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Ibuprofen	C		
UNKNOWN		6 YR					

Date:07/20/05ISR Number: 4719102-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Body Tinea
Other	Carpal Tunnel Syndrome
	Coronary Artery
	Atherosclerosis
	Diabetes Mellitus
	Non-Insulin-Dependent

Emotional Distress
Eructation
Fatigue
Hypersensitivity
Lyme Disease
Muscle Spasms
Nerve Compression
Overdose
Pain In Extremity
Pilonidal Cyst
Polytraumatism
Procedural Complication
Sciatica
Sinus Bradycardia
Tendonitis
Tenosynovitis
Trigger Finger
Upper Motor Neurone
Lesion

Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc		UNKNOWN	1 DAY
	Monopril	C			UNKNOWN	
	Pravachol	C			UNKNOWN	
	Flexeril	C			UNKNOWN	

Date:07/20/05ISR Number: 4719104-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00059
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea							
	Prescribed Overdose							

Date:07/20/05ISR Number: 4719105-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03535
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Infarction		Duragesic	C				
UNKNOWN								
Initial or Prolonged	Coronary Artery							
	Atherosclerosis							
	Intervertebral Disc							
	Protrusion							
	Lumbar Spinal Stenosis							
	Myofascial Pain Syndrome							
	Obesity							
	Polyarthritis							

Polycythaemia
Road Traffic Accident
Sleep Apnoea Syndrome
Spondylolisthesis

Date:07/20/05ISR Number: 4719116-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02626
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719117-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02530
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719118-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02625
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719119-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01467
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Pain							
	Polytraumatism							

Date:07/20/05ISR Number: 4719129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02922
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	35 MON	
	Atherosclerosis		Folic Acid	C			UNKNOWN	
	Blood Cholesterol		Clindamycin	C			UNKNOWN	
	Increased		Claritin	C			UNKNOWN	
	Bradycardia							
	Dizziness							
	Dyspnoea							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	Gout							
	Hyperlipidaemia							
	Hypertension							
	Leukoencephalopathy							
	Migraine							
	Myocardial Infarction							

Obesity
Orthostatic Hypotension
Spinal Osteoarthritis
Thyroid Disorder
Transient Ischaemic
Attack

Date:07/20/05ISR Number: 4719130-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON

Date:07/20/05ISR Number: 4719131-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1052	DAY
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719133-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719134-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1512 DAY	

Date:07/20/05ISR Number: 4719135-9Report Type:Expedited (15-DaCompany Report #DK-MERCK-0507DNK00006
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	993 DAY	

Date:07/20/05ISR Number: 4719136-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04403
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Cerebrovascular Accident							
Disability	Confusional State							
	Convulsion							
	Dizziness							
	Hypoaesthesia							
	Loss Of Consciousness							
	Migraine							
	Tremor							

Date:07/20/05ISR Number: 4719137-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00545
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Disorder		Hydrodiuril	C				
UNKNOWN								
	Fall		Potassium					
	Hypergammaglobulinaemia		(Unspecified)	C				
UNKNOWN								
	Myalgia							
	Osteoarthritis							
	Rib Fracture							
	Road Traffic Accident							
	Sciatica							
	Stomach Discomfort							

Date:07/20/05ISR Number: 4719144-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02651
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719148-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02634
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719149-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719152-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719153-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02655
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719154-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02082
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Prerenal Failure
	Acute Respiratory Failure
Disability	Adjustment Disorder With

Other	Depressed Mood
	Anaemia
	Anxiety
	Arthralgia
	Asthenia
	Blood Urea Increased
	Bundle Branch Block
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Cellulitis
	Chest Wall Pain
	Constipation
	Coronary Artery Disease
	Dehydration
	Dizziness
	Epicondylitis
	Feeling Abnormal
	Gastrooesophageal Reflux
	Disease
	Hyperlipidaemia
	Hypersensitivity
	Hypotension

		Hypoxic Encephalopathy					
		Injury					
		Joint Contracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Laceration		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Infiltration		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Oedema Peripheral					
		Peripheral Vascular Disorder					
		Post-Traumatic Stress Disorder					
		Pulmonary Oedema					
		Quadriplegia					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sinus Bradycardia					
		Skin Laceration					
		Spinal Cord Injury					
		Transfusion Reaction					
		Ulcer					
		Urinary Incontinence					
		Urinary Tract Infection					
		Wound Infection					

Date:07/20/05ISR Number: 4719155-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02627
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/20/05ISR Number: 4719157-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02358
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic Attack					

Date:07/20/05ISR Number: 4719158-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02632
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719159-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02361
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/05ISR Number: 4719166-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02327
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/20/05ISR Number: 4719173-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04290
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	54 DAY	
Initial or Prolonged	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL	88 DAY	
Other	Cardiac Failure		Glucovance	C			UNKNOWN	
	Congestive		Lipitor	C			UNKNOWN	670 DAY
	Cholelithiasis		Actos	C			UNKNOWN	
	Coronary Artery Disease		Norvasc	C			UNKNOWN	97 DAY
	Dyspnoea		Amitriptyline Hydrochloride	C			UNKNOWN	
	Dyspnoea Paroxysmal							
	Nocturnal		Neurontin	C			UNKNOWN	
	Hepatic Steatosis		Zyrtec	C			UNKNOWN	
	Insomnia		Flaxseed	C			UNKNOWN	
	Myocardial Infarction							
	Nausea							
	Orthopnoea							
	Pleural Effusion							
	Tricuspid Valve Incompetence							
	Vomiting							

Date:07/20/05ISR Number: 4722532-9Report Type:Expedited (15-DaCompany Report #2005061213
Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)	PS		ORAL	100 MG (100 MG, 1 IN 1 D)	
	Arthritis							
	Arthropathy							
	Back Pain		Bextra (Valdecoxib)	SS		ORAL	10 MG (10 MG, 1 IN 1 D)	
	Diarrhoea							
	Difficulty In Walking							
	Headache		Vioxx (Rofecoxib)	SS				
	Vomiting		Prilosec (Omeprazole)	C				
			Nexium (Esomeprazole)	C				

Date:07/20/05ISR Number: 4731086-2Report Type:Expedited (15-DaCompany Report #WAES 0301GBR00172
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation	Foreign	Tab Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
	Mitral Valve Incompetence	Study						
	Myocardial Ischaemia	Other						
	Tricuspid Valve Incompetence		Nifedipine	C				
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4719681-8Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0514631A
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Creatinine		Avandia	PS	Glaxosmithkline	ORAL	8MG Per day	
	Increased		Metformin	SS			500MG Twice per day	
	Blood Potassium Increased							
	Blood Urea Increased		Vioxx	SS			UNKNOWN	25MG Per day
			Ace Inhibitor	C			UNKNOWN	

Date:07/21/05ISR Number: 4720285-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00717
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
Other	Abdominal Pain Upper
	Acrochordon
	Adhesion
	Angina Pectoris
	Arthralgia
	Autonomic Neuropathy
	Back Pain
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Carotid Artery Stenosis
	Carpal Tunnel Decompression
	Chest Pain
	Chest Wall Pain
	Chronic Sinusitis
	Convulsion
	Cough
	Cubital Tunnel Syndrome
	Decreased Activity
	Diastolic Dysfunction
	Diverticulum
	Dizziness
	Dyspnoea

Dyspnoea Exertional
Essential Tremor
Fall
Fibromyalgia
Flank Pain
Folliculitis
Gastroenteritis
Headache
Hyperglycaemia
Joint Contracture
Kidney Infection
Libido Decreased
Memory Impairment
Muscle Spasms
Myalgia
Nausea
Nephrolithiasis
Neuropathy Peripheral
Non-Cardiac Chest Pain
Oedema Peripheral
Orthostatic Hypotension
Otitis Media Acute

		Pain In Extremity					
		Pruritus					
		Pyrexia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Restless Legs Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Lipitor	C		
UNKNOWN							
		Sciatica		Levothyroxine Sodium	C		
UNKNOWN							
		Skin Lesion		Prevacid	C		
UNKNOWN							
		Syncope		Estratest	C		
UNKNOWN							
		Transient Ischaemic		Vicodin Tablets	C		
UNKNOWN							
		Attack		Fluoxetine			
		Upper Respiratory Tract		Hydrochloride	C		
UNKNOWN							
		Infection					
		Urinary Tract Infection					
		Visual Acuity Reduced					

Date:07/21/05ISR Number: 4720288-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Other		Angina Pectoris		Estradiol	C		ORAL
		Atrioventricular Block		Tylenol	C		
UNKNOWN							
		Complete		Provera	C		ORAL
		Cardiac Arrest		Synthroid	C		ORAL
		Cervical Dysplasia					
		Coronary Artery Disease					
		Fall					
		Haematuria					
		Hyperlipidaemia					
		Injury					
		Intervertebral Disc					
		Degeneration					
		Osteoarthritis					
		Rash					
		Rectal Haemorrhage					

Road Traffic Accident
Scoliosis
Shoulder Pain
Spinal Column Stenosis
Spinal Compression
Fracture
Spinal Osteoarthritis
Toe Deformity
Urinary Tract Infection
Uterine Leiomyoma
Ventricular Fibrillation

Date:07/21/05ISR Number: 4720297-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Atherosclerosis
	Atherosclerosis
	Blood Creatinine Increased
	Blood Pressure Increased
	Cerebral Infarction
	Dermatitis Contact

		Dizziness Hyperlipidaemia Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Non-Cardiac Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
		Peripheral Coldness		Vioxx	SS	Merck & Co., Inc	ORAL
17	MON						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
8	WK						
		Stomach Discomfort		Hydrodiuril	SS		ORAL
		Transient Ischaemic		Methotrexate	C		
UNKNOWN		2219 DAY					
		Attack		Folic Acid	C		ORAL
				Toprol Xl Tablets	C		ORAL
				Aspirin	C		
UNKNOWN							

Date:07/21/05ISR Number: 4720298-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00128
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomegaly		Lipitor	C		
UNKNOWN						
	Cough		Aspirin	C		
UNKNOWN						
	Duodenal Ulcer		Vitamins			
	Gastritis Erosive		(Unspecified)	C		
UNKNOWN						
	Gastrointestinal		[Therapy			
	Angiodysplasia		Unspecified]	C		
UNKNOWN						
	Haemorrhagic		[Therapy			
	Haemorrhoids		Unspecified]	C		
UNKNOWN						
	Hiatus Hernia					
	Intestinal Polyp					
	Leukocytosis					

Date:07/21/05ISR Number: 4720302-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00732
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				
UNKNOWN								

Date:07/21/05ISR Number: 4720303-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00152
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Hospitalization -	Dizziness		Acetaminophen	C				
UNKNOWN								
Initial or Prolonged	Feeling Abnormal							
	General Physical Health							
	Deterioration							
	Hepatic Failure							
	Hepatocellular Damage							
	Malaise							

Date:07/21/05ISR Number: 4720304-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03192
Age:61 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Bundle Branch Block Left
	Cardiac Failure
	Congestive

		Cerebrovascular Accident					
		Chest Pain					
		Congestive Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Diplopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Insomnia		Protonix	C		
UNKNOWN							
		Pain		Zoloft	C		
UNKNOWN							
		Sinus Disorder		Zoloft	C		
UNKNOWN							
		Spinal Osteoarthritis		Xanax	C		
UNKNOWN							
				Indapamide	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Prilosec	C		ORAL
				Vitamin E	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							

Date:07/21/05ISR Number: 4720305-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00022
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
Disability			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Antimicrobial			

(Unspecified) C
UNKNOWN

Date:07/21/05ISR Number: 4720312-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03960
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		489 DAY
	Injury							

Date:07/21/05ISR Number: 4720313-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00414
Age:85 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			[Therapy Unspecified]	C				

UNKNOWN

Date:07/21/05ISR Number: 4720314-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-01096054
Age:42 YR Gender:Female I/FU:F

Outcome
Life-Threatening
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	4	DAY
	Infarction		Thiocolchicoside	C		ORAL		
	Cardio-Respiratory Arrest							
	Coronary Artery							
	Thrombosis							

Date:07/21/05ISR Number: 4720315-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0507GBR00132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720316-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01468
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720318-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01569
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720319-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01507
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720320-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0507GBR00135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720333-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720334-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01613
Age: Gender:Male I/FU:I

Outcome	PT
Disability	Cardiac Arrest
	Cardiac Disorder
	Lung Disorder
	Multi-Organ Disorder
	Pain

Polytraumatism

		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720335-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02365
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720336-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0507GBR00134
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720339-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01410
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720340-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01411
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720341-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL	32 MON	

Date:07/21/05ISR Number: 4720342-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01412
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720343-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01668
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	19 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720344-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01812
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720345-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02119
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720346-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01616
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc			
UNKNOWN								

Date:07/21/05ISR Number: 4720347-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720348-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0507GBR00133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720358-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02451
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720359-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0211DEU00044
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening	Complications Of Transplanted Liver		Vioxx	SS	Merck & Co., Inc	ORAL		
Hospitalization - UNKNOWN			Acetaminophen	C				
Initial or Prolonged	Dizziness Hepatic Failure Hepatitis Fulminant Malaise							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720361-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02450
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720362-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02452
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720363-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02050
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720364-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02459
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720365-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02455
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720373-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01628
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	52	MON

Date:07/21/05ISR Number: 4720374-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01620
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720375-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02119
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anaemia
Other	Anxiety Disorder
	Back Injury
	Chest Discomfort

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain					
		Chromaturia					
		Contusion					
		Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL
		Restenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Decreased Appetite		Vioxx	SS	Merck & Co., Inc	ORAL
		Dehydration		Norvasc	C		
UNKNOWN							
		Depressed Mood		Monopril	C		
UNKNOWN							
		Diarrhoea		Indocin			
		Disturbance In Attention		(Indomethacin)	C		
UNKNOWN							
		Diverticulum Intestinal		Naproxen	C		
UNKNOWN							
		Haemorrhagic		Ecotrin	C		
UNKNOWN							
		Drug Ineffective		Lopressor	C		
UNKNOWN							
		Dyspnoea		Toprol Xl Tablets	C		
UNKNOWN							
		Fatigue		Lipitor	C		
UNKNOWN							
		Fluid Retention		Allopurinol	C		
UNKNOWN							
		Haemorrhoids		Prilosec	C		
UNKNOWN							
		Hypertension		Lasix (Furosemide)	C		
UNKNOWN							
		Hypertensive Crisis		K-Dur	C		
UNKNOWN							
		Hypoaesthesia					
		Injury					
		Insomnia					
		Iron Deficiency					
		Libido Decreased					
		Lung Neoplasm					
		Myocardial Infarction					
		Nausea					
		Non-Cardiac Chest Pain					
		Oedema Peripheral					
		Paraesthesia					
		Pneumonia					
		Prostatic Specific					
		Antigen Increased					

Proteinuria
Renal Cyst
Renal Failure
Rheumatoid Arthritis
Rhinitis Allergic
Stress
Tendon Rupture
Treatment Noncompliance
Umbilical Hernia
Ventricular Extrasystoles

Date:07/21/05ISR Number: 4720377-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02107
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
	Injury							
	Pulmonary Embolism							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720391-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02457
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720392-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02521
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720393-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02522
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720394-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02458
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720395-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720396-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02274
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	55	MON

Date:07/21/05ISR Number: 4720397-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02366
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720398-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	18	MON
Other	Death		Vioxx	SS	Merck & Co., Inc	ORAL	18	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720400-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720401-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720402-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02371
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720404-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02525
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720405-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02523
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720406-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02612
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720407-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02528
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720408-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02456
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720409-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02527
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720411-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02613
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720412-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02614
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720414-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02529
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720415-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02676
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720416-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02674
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720417-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02636
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720419-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02911
Age: Gender:Female I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
	Myocardial Infarction							

Date:07/21/05ISR Number: 4720430-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02532
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	1074	DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	1074	DAY
Disability	Blood Cholesterol		Synthroid	C			UNKNOWN	
	Increased		Zyrtec	C			UNKNOWN	
	Cerebrovascular Accident		Nasonex	C			UNKNOWN	
	Chest Wall Pain		Darvocet-N	C			UNKNOWN	
	Depression		Prozac	C			UNKNOWN	
	Intracranial Aneurysm		Serzone	C			UNKNOWN	62 DAY
	Mental Disability		Motrin	C			UNKNOWN	
	Stress							

Date:07/21/05ISR Number: 4720431-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720433-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02526
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720434-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02585
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720435-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02584
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4720436-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02524
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4720453-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01409
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Polytraumatism							

Date:07/21/05ISR Number: 4720999-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Prevacid	C				
UNKNOWN								
	Arthralgia		Amitriptyline					
	Basal Cell Carcinoma		Hydrochloride	C		ORAL		
	Blood Pressure Increased		Atenolol	C		ORAL		
	Bundle Branch Block Left		Atenolol	C		ORAL		
	Carotid Artery Stenosis		Nitroquick	C				
SUBLINGUAL								
	Carpal Tunnel Syndrome		Aspirin	C				
UNKNOWN								
	Chest Pain		Lipitor	C		ORAL		
	Colon Cancer		Zantac	C		ORAL		
	Convulsion		Plavix	C				
UNKNOWN								
	Coronary Artery Disease		Amaryl	C				
UNKNOWN								
	Diverticulum		Baycol	C				
UNKNOWN								
	Drug Abuser		Pravachol	C				
UNKNOWN								
	Dysphagia		Ambien	C				
UNKNOWN								
	Dyspnoea		Acetaminophen And					
	Hiatus Hernia		Hydrocodone					
	Intestinal Obstruction		Bitartrate	C				
UNKNOWN								
	Limb Discomfort							
	Loss Of Consciousness							
	Oesophagitis							

Osteoarthritis
Polyp
Post Procedural Haematoma
Prostatitis
Renal Cyst
Retrograde Ejaculation
Rotator Cuff Syndrome
Seborrhoeic Keratosis
Tinnitus
Urinary Retention

Date:07/21/05ISR Number: 4721000-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01104
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721001-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02344
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4721002-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00286
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Prednisolone	C				UNKNOWN
Initial or Prolonged	Congestive		Sulfasalazine	C				UNKNOWN
	Coronary Artery		Fosinopril Sodium	C				UNKNOWN
	Atherosclerosis							
	Coronary Artery Disease							
	Myocardial Infarction							

Date:07/21/05ISR Number: 4721003-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01669
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721004-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hyperplasia		Coumadin	C				UNKNOWN
Other	Cardiomyopathy		Celebrex	C				UNKNOWN
	Carotid Artery Stenosis							
	Cerebrovascular Accident							
	Drug Administration Error							
	Drug Hypersensitivity							
	Drug Ineffective							
	Fatigue							
	Haemorrhoids							
	Hemianopia							
	Hypertension							
	Hypoaesthesia							

	International Normalised Ratio Decreased
	International Normalised Ratio Increased
	Intracranial Aneurysm
	Visual Acuity Reduced

Date:07/21/05ISR Number: 4721005-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00230
Age:42 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Accident
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Anxiety
	Arthralgia
	Bronchitis
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diverticulum
	Gastritis
	Gastrooesophageal Reflux Disease
	Groin Pain

	Haemorrhoids						
	Hypertension						
	Pleural Effusion	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Rectal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Skin Irritation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Tension Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Weight Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Tenormin	C			UNKNOWN	
			Tenormin	C			UNKNOWN	
			Monopril	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Clonidine	C			TOPICAL	
			Clonidine	C		ORAL		
			Anaprox	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	

Date:07/21/05ISR Number: 4721006-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721007-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02339
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721008-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721009-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721010-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4721011-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721012-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02537
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cardiac Failure							
Other	Congestive							
	Congestive Cardiomyopathy							
	Depression							
	Generalised Anxiety							
	Disorder							
	Haematochezia							
	Hypertension							
	Injury							
	Myocardial Infarction							
	Nocturia							
	Palpitations							

Date:07/21/05ISR Number: 4721013-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01676
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721014-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01672
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/21/05ISR Number: 4721015-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia
Disability	Back Injury
Other	Breathing-Related Sleep Disorder
	Cellulitis
	Cerebrovascular Accident
	Chest Pain
	Cor Pulmonale
	Coronary Artery Disease
	Diabetes Mellitus Inadequate Control
	Dyspnoea
	Erectile Dysfunction
	Eye Pain
	Hypertension
	Hypoaesthesia
	Joint Effusion

		Myofascial Spasm					
		Nausea					
		Neck Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
		Pigmentary Glaucoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Retinal Vein Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Road Traffic Accident		Xalatan	C		
UNKNOWN							
		Sinus Disorder		Betoptic	C		
UNKNOWN							
		Somnolence		Amaryl	C		
UNKNOWN							
		Whiplash Injury		Accupril	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN		1106 DAY					
				Metoprolol	C		
UNKNOWN							
				Avapro	C		
UNKNOWN		60 DAY					
				Cardura	C		
UNKNOWN		255 DAY					
				Lipitor	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							
				Naproxen	C		
UNKNOWN		82 DAY					
				Tylenol	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:07/21/05ISR Number: 4721016-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03186
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholecystitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis							
	Depression							
	Duodenal Ulcer							
	Gastric Disorder							
	Gastric Ulcer							
	Intervertebral Disc Protrusion							
	Iron Deficiency Anaemia							
	Nervousness							
	Peptic Ulcer							
	Pleural Effusion							
	Weight Gain Poor							

Date:07/21/05ISR Number: 4721017-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	154 DAY	
	Myocardial Infarction							
	Polytraumatism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/21/05ISR Number: 4721018-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/21/05ISR Number: 4724456-XReport Type:Expedited (15-DaCompany Report #104279
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia	Foreign Study Health Professional	Herceptin (Transtuzumab) Pwdr & Solvent, Infusion Soln	PS		INTRAVENOUS	SEE IMAGE	
	Anuria							
	Bacteraemia							
	Blood Urea Increased							
	Cardiac Failure	Other				INTRAVENOUS	1	DAY
	Congestive		Herceptin (Trastuzumab) Pwdr & Solvent, Infusion Soln	SS		INTRAVENOUS	120 MG, Q3W,	
	Dialysis							
	Escherichia Infection							
	Febrile Neutropenia							
	Medical Device Complication		Docetaxel (Docetaxel) Solution For Injection	SS		INTRAVENOUS	635 MG, Q3W,	
	Nausea							
	Neutropenic Sepsis					INTRAVENOUS		
	Oesophagitis		Carboplatn Solution For Injection	SS		INTRAVENOUS		
	Vomiting							
			Rofecoxib (Rofecoxib)	SS				
			Tazocin (Piperacillin Sodium, Tazobactam Sodium)	SS				
			Dexamethasone (Dexamethasone)	C				
			Ondansetron (Ondansetrom)	C				

		Cimetidine (Cimetidine)	C
		Bisoprolol (Bisoprolol)	C
		Otilonium Bromide (Otilonium Bromide)	C
		Rofecoxib (Rofecoxib)	C
		Fluoxetine (Fluoxetine Hydrochloride)	C
		Ranitidine (Ranitidine)	C

Date:07/22/05ISR Number: 4721136-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02586
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721137-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02652
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721138-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02392
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721139-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02553
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721140-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02566
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721141-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02554
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721142-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02397
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721143-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02567
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721144-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02552
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721145-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02378
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721146-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02346
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721147-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02540
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721148-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721149-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02345
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721150-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02404
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721151-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721152-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721153-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02400
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721154-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02394
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721155-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02376
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721156-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02395
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721157-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02393
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721158-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02401
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721159-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02402
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721160-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02558
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721161-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02396
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721162-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02562
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721163-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02559
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721164-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02555
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721165-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02556
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721166-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02561
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721167-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02569
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721168-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02560
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721169-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02571
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721170-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721171-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02654
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721172-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02610
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721173-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02563
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721174-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02817
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721176-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02587
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721178-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02589
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721179-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02375
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721180-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02564
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721182-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02557
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721183-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721184-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02570
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721185-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02611
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721186-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02591
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721187-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02609
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4721188-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02814
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721189-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02565
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721190-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02592
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4721191-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02568
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722594-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0112USA01793
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	DAY

Hospitalization - 10 DAY	Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Vitamins (Unspecified)	C		
Other	Estrogens (Unspecified)	C		
UNKNOWN	Guaifenesin	C		
UNKNOWN				
UNKNOWN				

Date:07/22/05ISR Number: 4722596-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00758
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Affective Disorder
Hospitalization -	Anxiety
Initial or Prolonged	Back Injury
Other	Back Pain
	Cardiomegaly
	Chest Pain
	Colonic Polyp
	Depression
	Drug Dependence
	Drug Detoxification
	Drug Withdrawal Syndrome
	Dyspepsia
	Facet Joint Syndrome
	Gastric Ulcer

		Gastrooesophageal Reflux Disease					
		Haematocrit Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
		Helicobacter Pylori		Vioxx	SS	Merck & Co., Inc	ORAL
		Identification Test		Vioxx	SS	Merck & Co., Inc	ORAL
		Positive		Zoloft	C		
UNKNOWN							
		High Density Lipoprotein		Zoloft	C		
UNKNOWN							
		Abnormal		Avalide	C		
UNKNOWN							
		Hypertension		Claritin	C		
UNKNOWN							
		Intervertebral Disc		Prozac	C		
UNKNOWN							
		Degeneration Intervertebral Disc Disorder Intervertebral Disc Protrusion Mood Altered Nervousness Osteoarthritis Peptic Ulcer Rectal Haemorrhage Rhinitis Allergic Sleep Apnoea Syndrome Spondylolisthesis Spondylolysis					

Date:07/22/05ISR Number: 4722616-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01502
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/22/05ISR Number: 4722619-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04449
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		1042 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		1042 DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1042 DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		1042 DAY
	Myocardial Infarction		Naprosyn	C				
UNKNOWN							689 DAY	

Date:07/22/05ISR Number: 4722620-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04380
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1252 DAY
Initial or Prolonged	Pain		Aspirin	C		ORAL		
Other								

Date:07/22/05ISR Number: 4722621-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02540
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthropathy
Disability	Basilar Artery Occlusion

		Blood Cholesterol Increased					
		Brain Stem Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cerebellar Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebral Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Coma		Coumadin	SS		ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Dilatation Atrial		Aspirin	C		
UNKNOWN							
		Diplopia					
		Drug Interaction					
		Dysarthria					
		Hypertension					
		Hypoaesthesia					
		Laboratory Test Abnormal					
		Lacunar Infarction					
		Muscle Spasms					
		Pain In Jaw					
		Stomach Discomfort					
		Stress					
		Transient Ischaemic					
		Attack					
		Ventricular Hypertrophy					

Date:07/22/05ISR Number: 4722623-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00154
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Death					
		Injury					
		Myocardial Infarction					

Date:07/22/05ISR Number: 4722624-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02705
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL

Pain
Transient Ischaemic
Attack

Date:07/22/05ISR Number: 4722625-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00373
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		643 DAY
Initial or Prolonged	Chondromalacia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Valsartan	C		ORAL		
	Panic Attack		Furosemide	C		ORAL		
	Respiratory Disorder		Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Allopurinol	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722626-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03027
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
	Fatigue							
	Hypertension							

Date:07/22/05ISR Number: 4722627-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04129
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Zantac	C				UNKNOWN
	Chest Pain		Ranitidine	C				UNKNOWN
	Chronic Fatigue Syndrome		Maxalt (Rizatriptan					
	Depression		Benzoate)	C				UNKNOWN
	Diarrhoea		Allegra	C				UNKNOWN
	Dizziness		Acular	C				UNKNOWN
	Fibromyalgia							
	Gastrointestinal Pain							
	Nausea							
	Palpitations							
	Vomiting							

Date:07/22/05ISR Number: 4722629-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA00857
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Disability	Anxiety

Arrhythmia
Arteriospasm Coronary
Balance Disorder
Bladder Squamous Cell
Carcinoma Stage
Unspecified
Bone Pain
Cardiac Murmur
Dyspepsia
Endometriosis
Headache
Heart Rate Abnormal
Insomnia
Intervertebral Disc
Displacement
Meniscus Lesion
Mitral Valve Incompetence
Neuralgia
Pleuritic Pain
Renal Cyst
Sacroiliitis
Sinusitis
Stress
Tachyarrhythmia
Tension
Tricuspid Valve

Incompetence
Uterine Leiomyoma
Weight Increased

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
487 DAY			Vioxx	PS	Merck & Co., Inc	ORAL
487 DAY			Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN			Inderal La	C		
UNKNOWN			Inderal La	C		
UNKNOWN	1758 DAY		Claritin-D	C		
UNKNOWN			Humibid	C		
UNKNOWN			Prevacid	C		
UNKNOWN	764 DAY		Nasonex	C		
UNKNOWN			Darvocet-N	C		
UNKNOWN			Bactrim	C		
UNKNOWN			Pseudoephedrine	C		
UNKNOWN			Maxzide	C		
UNKNOWN			Naprosyn	C		
UNKNOWN			Entex La	C		
UNKNOWN			Voltaren	C		
UNKNOWN			Voltaren	C		ORAL
			Evening Primrose Oil	C		
UNKNOWN			Glucosamine	C		
UNKNOWN			Chondroitin	C		
UNKNOWN			Zantac	C		
UNKNOWN			Sudafed	C		
UNKNOWN			Aspirin	C		
UNKNOWN						

Norco C
UNKNOWN

Date:07/22/05ISR Number: 4722639-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA03459
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Angina Pectoris
	Angina Unstable
	Aortic Aneurysm
	Barrett'S Oesophagus
	Blood Pressure Increased
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Fatigue Syndrome
	Contusion
	Coronary Artery Disease
	Cyst
	Depression
	Disability
	Duodenitis
	Dyspepsia
	Fatigue
	Gastritis Erosive
	Gastrooesophageal Reflux Disease
	Headache
	Hyperhidrosis
	Hypogonadism
	Ischaemic Cardiomyopathy
	Mood Altered
	Paraesthesia
	Peptic Ulcer

		Reflux Oesophagitis Sleep Apnoea Syndrome Tendonitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Ventricular Extrasystoles		Vioxx	PS	Merck & Co., Inc	ORAL
39	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
39	DAY						
				Zocor	C		ORAL
				Cardura	C		ORAL
				Tylenol Pm	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Tagamet	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							

Date:07/22/05ISR Number: 4722647-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01857
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/22/05ISR Number: 4722648-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01503
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/22/05ISR Number: 4722649-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01517
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/22/05ISR Number: 4722651-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02094
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722652-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01880
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	20 DAY	
Hospitalization -	Congestive		Glucovance	C			UNKNOWN	
Initial or Prolonged			Starlix	C			UNKNOWN	
			Coreg	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Lanoxin	C			UNKNOWN	

Date:07/22/05ISR Number: 4722653-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722654-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01518
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722655-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722656-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02039
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722657-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04664
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chronic Obstructive Pulmonary Disease Hallucination, Auditory		Vioxx	PS	Merck & Co., Inc	ORAL		
			Levothyroxine Sodium	C		ORAL		
			Prozac	C				
UNKNOWN								
			Nasonex	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Advair	C				
UNKNOWN								

Date:07/22/05ISR Number: 4722658-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02322
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722659-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02309
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722660-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722661-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02298
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722662-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722663-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02296
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722664-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02308
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722665-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02315
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/22/05ISR Number: 4722672-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02467
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722673-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02482
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722674-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722675-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722676-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02484
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722678-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02469
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722680-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02342
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722681-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722692-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722693-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02297
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722694-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02462
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722695-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02311
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722696-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722697-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02460
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722698-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02379
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	AURICULAR (OTIC)		

Date:07/22/05ISR Number: 4722699-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02380
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722700-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		

Infarction

Date:07/22/05ISR Number: 4722701-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02372
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722709-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02485
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722710-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722711-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02506
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722712-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722713-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722714-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02488
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722715-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02505
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722716-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722717-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02481
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722719-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722720-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02509
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722721-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722732-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02547
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722733-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02578
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722734-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02548
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722735-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02549
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722736-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02575
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722737-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02583
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722738-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02576
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722739-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02507
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722740-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02546
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722741-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02543
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722742-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02582
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722743-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722744-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02545
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722749-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02541
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722750-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722751-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02510
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722752-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02544
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722753-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02537
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722754-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02536
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722755-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02542
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722756-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722757-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02550
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722759-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02647
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722760-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02646
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722761-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722762-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02630
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722763-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02642
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722764-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02628
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722765-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02608
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722766-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02629
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722767-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02645
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722768-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02607
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722769-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02773
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722770-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02663
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722774-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03097
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722776-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02665
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722777-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02922
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722778-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03096
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722779-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02660
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722782-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02919
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722783-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02915
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722784-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722785-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02762
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	DAY

Date:07/22/05ISR Number: 4722786-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02764
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722787-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02661
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722788-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02761
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722789-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02697
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722790-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02777
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722791-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhagic Stroke Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722801-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02787
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722803-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03098
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722804-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03103
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722805-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03105
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722807-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03108
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722808-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03100
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722810-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02775
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722811-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03107
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722812-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03102
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722814-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03095
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722957-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA01088
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety							
	Disability							
	Economic Problem							
	Injury							
	Loss Of Employment							
	Pain							

Date:07/22/05ISR Number: 4722968-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00102
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Cerebral Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722969-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01876
Age: Gender:Male I/FU:F

Outcome	PT
Other	Abdominal Pain
	Aortic Atherosclerosis

		Arrhythmia					
		Atrial Fibrillation					
		Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrointestinal Mucosal		Vioxx	PS	Merck & Co., Inc	ORAL
		Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
1	WK						
		Haemorrhoids		Vioxx	SS	Merck & Co., Inc	ORAL
		Hepatic Steatosis		Vioxx	SS	Merck & Co., Inc	ORAL
1	WK						
		Hepatomegaly					
		Intestinal Polyp					
		Myocardial Infarction					
		Nephrolithiasis					
		Rectal Haemorrhage					
		Renal Cyst					
		Splenomegaly					
		Ventricular Tachycardia					

Date:07/22/05ISR Number: 4722970-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02936
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
				Aspirin	C		
UNKNOWN							
				Nexium	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Niaspan	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Gastrointestinal Preparations (Unspecified)	C		
UNKNOWN							
				Anemagen	C		
UNKNOWN							

Date:07/22/05ISR Number: 4722971-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01832
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Oxycontin	C			UNKNOWN	
	Congestive		Lidoderm	C			UNKNOWN	
	Gastrooesophageal Reflux		Miacalcin	C			UNKNOWN	
	Disease		Hydrocodone Bitartrate	C			UNKNOWN	
	Orthostatic Hypotension		Elavil	C			UNKNOWN	
	Osteoarthritis							
	Pulmonary Hypertension							
	Sleep Apnoea Syndrome							
	Weight Decreased							

Date:07/22/05ISR Number: 4722972-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Arthropod Sting
Other	Cardiac Failure
	Coronary Artery Disease
	Diabetes Mellitus
	Gastrooesophageal Reflux

		Disease					
		Hypercholesterolaemia					
		Hyperlipidaemia					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
		Intentional Misuse		Percocet	SS		
UNKNOWN							
		Major Depression		Xanax	SS		
UNKNOWN							
		Myocardial Infarction		Ambien	SS		
UNKNOWN							
		Spondylitis		Alcohol	SS		
UNKNOWN							
		Stent Occlusion		Advil	C		
UNKNOWN							
		Suicide Attempt		Imdur	C		
UNKNOWN							
		Swelling Face		Soma	C		
UNKNOWN							
		Tooth Disorder					

Date:07/22/05ISR Number: 4722974-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01690
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -							
Initial or Prolonged							
Disability							

Date:07/22/05ISR Number: 4722979-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0503DEU00010
Age:69 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL
665 DAY							
Initial or Prolonged		Carotid Artery Stenosis					
		Confusional State					
		Epilepsy					
		Extrasystoles					
		Fall					

Hemiparesis
Hemiplegia Transient
Supraventricular
Tachycardia
Transient Ischaemic
Attack

Date:07/22/05ISR Number: 4722985-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01646
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722986-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722987-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02280
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722988-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02278
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722989-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02124
Age:39 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
Initial or Prolonged	Dyspepsia		Prednisolon	C			UNKNOWN	
Disability	Fluid Retention		Prevacid	C			UNKNOWN	
Other	Hepatocellular Damage		Norvasc	C			UNKNOWN	
	Hypertension		Prinivil	C			UNKNOWN	
	Insomnia		Lamictal	C			UNKNOWN	
	Mood Altered		Atenolol	C			UNKNOWN	
	Overdose							
	Renal Disorder							
	Stomach Discomfort							
	Weight Increased							

Date:07/22/05ISR Number: 4722990-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02266
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722991-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01526
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Accelerated Hypertension
Disability	Amaurosis Fugax
Other	Anxiety
	Bradycardia
	Cardiac Failure
	Congestive
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Cerebrovascular Disorder
	Circadian Rhythm Sleep
	Disorder
	Coronary Artery Disease
	Depression
	Dermatitis
	Embolic Cerebral
	Infarction
	Epicondylitis
	Erectile Dysfunction
	Headache
	Hypotension

		Memory Impairment					
		Multiple Sclerosis					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
14	DAY						
		Peripheral Vascular Disorder					
		Shoulder Pain					
		Sinusitis					
		Sleep Apnoea Syndrome					
		Syncope					
		Tenosynovitis					
		Vascular Graft Occlusion					
		Ventricular Hypertrophy					

Date:07/22/05ISR Number: 4722993-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00035
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
			Raloxifene Hydrochloride	C		ORAL
			Esomeprazole Magnesium	C		ORAL
			Finasteride	C		ORAL

Date:07/22/05ISR Number: 4722994-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01644
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death					

Date:07/22/05ISR Number: 4722995-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722996-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01645
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4722997-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01852
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4722998-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0507CHE00019
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Vascular Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723001-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02416
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723005-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723006-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02286
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723007-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723008-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02282
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723009-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02289
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723010-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723011-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02307
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723012-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02288
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723013-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02464
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723014-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723015-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02492
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723016-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02415
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723017-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02491
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723018-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02465
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723019-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02405
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723020-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02418
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723021-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02496
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723022-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02497
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723023-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02595
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723024-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02495
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723025-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02615
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723026-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02598
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723027-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02597
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723028-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02593
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723029-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02534
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723030-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02532
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723031-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02531
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723032-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02463
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723033-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02493
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723034-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02606
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723035-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02786
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723036-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02616
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723037-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02778
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723038-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02670
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723039-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02780
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723040-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723041-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02604
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723042-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723043-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02605
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723044-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02603
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723045-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02596
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723046-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02602
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723047-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02617
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723048-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02600
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723053-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03027
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/22/05ISR Number: 4723054-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03030
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723055-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02927
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723056-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02840
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:07/22/05ISR Number: 4723061-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03026
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723062-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02620
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723063-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02923
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723064-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02924
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723065-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723066-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02917
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723067-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02928
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723068-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03029
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723069-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03028
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723070-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03034
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723071-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03036
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723072-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723073-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03033
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/22/05ISR Number: 4723074-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03032
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723075-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03031
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/22/05ISR Number: 4723076-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03037
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723077-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03035
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723088-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03076
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723093-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03044
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723099-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03091
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723100-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03092
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723101-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03110
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723102-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03115
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723103-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03111
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723104-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03112
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723105-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03099
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723106-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03113
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723107-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03114
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723110-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03045
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723111-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03043
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723112-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02419
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723113-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03040
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/22/05ISR Number: 4723114-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03042
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723115-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03038
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723116-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03079
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723117-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03080
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723118-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03041
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723119-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03077
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723120-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03082
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723121-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03083
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723122-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03088
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723123-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03084
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723124-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03093
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723125-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03089
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723126-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03087
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723133-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03085
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723134-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03081
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723135-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03090
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/22/05ISR Number: 4723136-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02320
Age:30 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Initial or Prolonged	Migraine		Oxycontin	C				UNKNOWN
	Stomach Discomfort		Prozac	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:07/22/05ISR Number: 4723141-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03086
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4723148-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03078
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/22/05ISR Number: 4725038-6Report Type:Expedited (15-DaCompany Report #2005072203
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia	Consumer	Bextra (Valdecoxib)	PS		ORAL	10 MG (10 MG,	
Initial or Prolonged	Blood Test Abnormal	Health					1 IN 1 D),	
Other	Body Temperature	Professional					ORAL	

	Increased	Celebrex (Celecoxib)	SS ORAL (1 IN 1 D),
	Chest Wall Pain		ORAL
	Dehydration	Vioxx (Rofecoxib)	SS
	Diarrhoea	Lopressor (Metoprolol Tartrate)	C
	Drug Ineffective	Isosorbide (Isosorbide)	C
	Fall	Metoprolol (Metoprolol)	C
	Influenza	Pravachol (Pravastatin Sodium)	C
	Malaise	Triamterene (Triamterene)	C
	Pain	Paxil (Paroxetine Hydrochloride)	C
	Pneumonia	Xanax (Alprazolam)	C
	Vomiting	Vitamin E (Vitamin E)	C

Date:07/22/05ISR Number: 4725823-0Report Type:Direct Company Report #CTU 253971
Age: Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to
Prevent Permanent

Impairment/Damage

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Pulmonary Embolism		Vioxx 50 Mg	PS		ORAL	50 MG PO QD	

Date:07/22/05ISR Number: 4725834-5Report Type:Direct Company Report #CTU 253963
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Required	Asthenia		Vioxx Tablets	PS			1 OR 2 DAILY	
Intervention to	Biopsy Bone Marrow						3 YEARS TO 4	
Prevent Permanent	Abnormal						YEARS	
Impairment/Damage	Blood Count Abnormal							
	Blood Iron Decreased							
	Renal Injury							

Date:07/25/05ISR Number: 4723568-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00602
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atrophy		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Ear Discomfort		Estrogens					
Other	Gastrooesophageal Reflux		(Unspecified)	C				
TOPICAL								
	Disease		Nonsteroidal					
	Mitral Valve Prolapse		Anti-Inflammatory					
	Renal Disorder		Drug (Unspecified)	C				
UNKNOWN								
	Renal Failure Chronic							
	Renal Injury							
	Urinary Incontinence							
	Urinary Tract Infection							

Date:07/25/05ISR Number: 4723569-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01872
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Life-Threatening								
Disability								

Date:07/25/05ISR Number: 4723570-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01799B1
Age:0 DY Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc		1	MON
	Drug Exposure During Pregnancy							
	Neonatal Disorder							
	Placental Disorder							
	Renal Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723581-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01799M
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Drug Exposure During Pregnancy Placenta Praevia		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON

Date:07/25/05ISR Number: 4723582-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723583-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02439
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723584-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01950
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C				
UNKNOWN								
			Fosamax	C		ORAL		

Date:07/25/05ISR Number: 4723590-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02399
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Death	Anaemia
Hospitalization - Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Candidiasis
	Cardiac Arrest
	Chest Wall Pain
	Deep Vein Thrombosis
	Endocarditis
	Fall
	Gastric Polyps
	Gastritis
	Gastrointestinal Haemorrhage
	Iliac Vein Thrombosis
	Mitral Valve Incompetence
	Myocardial Infarction
	Peripheral Vascular Disorder
	Pulmonary Hypertension
	Sepsis
	Sepsis Syndrome
	Tricuspid Valve Incompetence

		Venous Occlusion Venous Stenosis Ventricular Hypertrophy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
8	DAY						
				Quinine Sulfate	C		
UNKNOWN							
				Renagel	C		
UNKNOWN							
				Glyburide	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Lamisil	C		
UNKNOWN							

Date:07/25/05ISR Number: 4723591-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00704
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
51	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
51	MON						
				Effexor	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Nasonex	C		
UNKNOWN							
				Protopic	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Lisinopril	C		
UNKNOWN							
				Triamcinolone	C		
UNKNOWN							

	Albuterol	C
UNKNOWN		
	Hydroxychloroquine Sulfate	C
UNKNOWN		
	Fluocinonide	C
UNKNOWN		
	Alprazolam	C
UNKNOWN		

Date:07/25/05ISR Number: 4723594-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00678
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Back Pain
Hospitalization - Initial or Prolonged	Blood Pressure Increased
Disability	Bronchitis
Other	Cardiomegaly
	Chronic Obstructive Pulmonary Disease
	Convulsion
	Dizziness
	Drug Interaction
	Dyspepsia
	Emphysema
	Facial Bones Fracture
	Flank Pain
	Gastrooesophageal Reflux Disease
	Headache
	Hepatitis C
	Hiatus Hernia
	Hypercholesterolaemia
	Hypertension
	Intervertebral Disc Protrusion
	Joint Injury

		Mental Status Changes					
		Muscle Spasms					
		Musculoskeletal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
1463	DAY						
		Neck Pain		Neurontin	C		ORAL
		Overdose		Neurontin	C		ORAL
1	MON						
		Peptic Ulcer		Neurontin	C		ORAL
1	MON						
		Radiculopathy		Bextra	C		
UNKNOWN							
		Road Traffic Accident		Viagra	C		
UNKNOWN							
		Skin Exfoliation		Nexium	C		
UNKNOWN							
		Skin Irritation		Amitriptyline Hydrochloride	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							
				Duragesic	C		
UNKNOWN							

Date:07/25/05ISR Number: 4723598-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02373
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/25/05ISR Number: 4723602-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02442
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/25/05ISR Number: 4723605-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02814
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthma
Other	Atrial Fibrillation
	Back Pain
	Blood Pressure Increased
	Blood Triglycerides Increased
	Bradycardia
	Bronchitis
	Bronchospasm
	Bundle Branch Block Left
	Chest Pain
	Coronary Artery Disease
	Diabetes Mellitus Non-Insulin-Dependent
	Dysfunctional Uterine Bleeding
	Fatigue
	Gastroenteritis
	Headache
	Hyperlipidaemia
	Hyperthyroidism
	Hypothyroidism
	Insomnia
	Intervertebral Disc

	Protrusion						
	Metabolic Syndrome						
	Myocardial Infarction						
	Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Orthopnoea		Tiazac	C			UNKNOWN	
	Peripheral Vascular Disorder							
	Rash Pruritic							
	Rhinitis Allergic							
	Seasonal Allergy							
	Sedation							
	Sinusitis							
	Skin Lesion							
	Vertigo							
	Weight Increased							
	Weight Loss Poor							

Date:07/25/05ISR Number: 4723606-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02443
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723607-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02471
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723608-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/25/05ISR Number: 4723609-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02472
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723611-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02474
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723617-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02444
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723618-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02477
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723619-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723620-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723621-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02479
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723622-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723623-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02622
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723624-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02601
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723625-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02501
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723632-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02671
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723633-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723634-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02599
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723635-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02473
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723636-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723637-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02658
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723638-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723643-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723644-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02913
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723645-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02976
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723646-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02982
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723647-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723648-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02985
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723649-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02955
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723650-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02657
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723651-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723652-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723653-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02621
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723654-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02912
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON

Date:07/25/05ISR Number: 4723657-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02981
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723670-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02989
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723671-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03139
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723672-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02990
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723673-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02991
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723674-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02987
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723675-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03025
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723686-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02988
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723687-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02992
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/25/05ISR Number: 4723688-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02440
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723700-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03137
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723703-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02446
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4723720-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02503
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723754-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4723755-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02623
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724058-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03116
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724059-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03073
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724060-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03071
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724061-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03074
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724062-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03117
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724064-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03072
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/25/05ISR Number: 4724068-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03075
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724074-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724075-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03142
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724076-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03049
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/25/05ISR Number: 4724077-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03053
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724078-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03048
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724079-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03047
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724080-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03151
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724081-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03052
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724082-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03146
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/25/05ISR Number: 4724083-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724084-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03118
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724086-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03119
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724092-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03147
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724093-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724094-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03126
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety Emotional Distress Fear Of Disease Heart Injury Injury Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724095-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724096-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Injury Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724097-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724098-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/25/05ISR Number: 4724099-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03148
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724100-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03051
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724101-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02952
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724106-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03062
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/25/05ISR Number: 4724107-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03057
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724108-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03059
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724109-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724110-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03064
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724111-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03060
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724112-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03061
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724113-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724114-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03066
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724115-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03055
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724116-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03056
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724118-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02219
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Cardizem	C				
							UNKNOWN	
Other	Convulsion		Cardizem	C				
							UNKNOWN	
	Gastrooesophageal Reflux		Motrin	C				
							UNKNOWN	
	Disease		Vicodin Tablets	C				
							UNKNOWN	
	Haematochezia		Morphine	C				
							UNKNOWN	
	Intestinal Obstruction		Carisoprodol	C				
							UNKNOWN	

	Myocardial Infarction	Carisoprodol	C
UNKNOWN			
	Nervous System Disorder	Lithium Acetate	C
UNKNOWN			
	Oedema	Dilantin	C
UNKNOWN			
	Peptic Ulcer		
	Peripheral Vascular Disorder		
	Renal Disorder		
	Sleep Apnoea Syndrome		

Date:07/25/05ISR Number: 4724119-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02321
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/25/05ISR Number: 4724120-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03067
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724121-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03068
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724122-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00768
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Fluoxetine					
	Chest Pain		Hydrochloride	C		ORAL		
	Dizziness		Theophylline	C		ORAL		
	Dyspnoea		Tilidine					
	Hypertension		Hydrochloride	C		ORAL		
	Malaise		Verapamil	C		ORAL		
	Tachycardia		Candesartan					
			Cilexetil	C		ORAL		
			Hydrochlorothiazide	C		ORAL		
			Moxonidine	C		ORAL		

Date:07/25/05ISR Number: 4724123-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00578
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
423 DAY								
Initial or Prolonged	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		
423 DAY								
	Increased		Maxzide	C		ORAL		
	Deep Vein Thrombosis		Synthroid	C		ORAL		
	Gastrooesophageal Reflux		Tylenol	C		ORAL		
	Disease							
	Shoulder Pain							

Date:07/25/05ISR Number: 4724124-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02381
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724125-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amblyopia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebrovascular Accident		Allopurinol	C		ORAL		
Other	Diplopia		Nitrendipine	C		ORAL		
	Headache		Aspirin	C		ORAL		
	Thyroid Disorder		Cetirizine Hydrochloride	C		ORAL		
	Transient Ischaemic Attack		Methotrexate	C		ORAL		
	Visual Disturbance		Prednisolone	C			UNKNOWN	
			Cholecalciferol	C			UNKNOWN	
			Cholecalciferol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724126-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03069
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/25/05ISR Number: 4724127-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03070
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724128-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02294
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724129-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02382
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724130-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01262
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724131-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724132-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02249
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724133-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02293
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724134-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02292
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724140-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02383
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724141-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724143-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02295
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724144-XReport Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00011
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrial Fibrillation Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/25/05ISR Number: 4724145-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02431
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724146-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02432
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724147-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02386
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724148-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02388
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724151-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02512
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724152-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02513
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724153-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02515
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724154-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02516
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724155-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724156-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02437
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724157-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02434
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724158-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724159-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02447
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724160-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02384
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724161-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724162-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02435
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724163-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02389
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724164-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02494
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724165-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02433
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724166-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02449
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724167-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02499
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724168-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02438
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724169-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02436
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724170-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02517
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724171-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02574
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724172-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02579
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724173-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02573
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724174-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02520
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724175-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02514
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724176-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02577
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724177-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02581
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724178-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02580
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724179-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02572
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724180-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02518
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724181-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02801
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724182-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02914
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724183-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02806
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724184-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02920
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724185-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02800
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR

Date:07/25/05ISR Number: 4724186-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02788
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724187-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724188-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02641
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724189-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02640
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724190-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724191-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02948
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724192-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02918
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724193-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02916
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724194-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02911
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Subdural Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724195-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02519
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724196-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02639
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724197-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02649
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/25/05ISR Number: 4724198-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02779
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	719	DAY

Date:07/25/05ISR Number: 4724199-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02949
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724200-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02950
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724204-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02802
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	753	DAY

Date:07/25/05ISR Number: 4724205-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724206-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4724207-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/25/05ISR Number: 4726938-3Report Type:Direct Company Report #CTU 254174
Age:57 YR Gender:Male I/FU:I

Outcome	PT
Disability	Arthralgia
Required	Chest Pain
Intervention to	Chondropathy
Prevent Permanent	Fatigue
Impairment/Damage	Fluid Retention

	Ganglion						
	Heart Rate Increased						
	Injury	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Muscular Weakness		Vioxx 25mg					
	Swelling		Merck & Co.	PS	Merck & Co.	ORAL	1-TAB DAILY	
							2-TAB DAILY	
							ORAL	

Date:07/26/05ISR Number: 4724621-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00458
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Lipitor	C			UNKNOWN	
	Arterial Insufficiency		Levothyroxine Sodium	C			UNKNOWN	
	Arteriopathic Disease		Vitamin E	C			UNKNOWN	
	Bursitis							
	Cardiac Arrest							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Deep Vein Thrombosis							
	Dyspepsia							
	Dysphagia							
	Fibrocystic Breast							
	Disease							
	Gastritis							
	Genital Rash							
	Hiatus Hernia							
	Hypercholesterolaemia							
	Myocardial Infarction							
	Peripheral Vascular							
	Disorder							
	Sinusitis							
	Syncope							

Date:07/26/05ISR Number: 4724622-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00085
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Glaucoma		Aspirin	C			UNKNOWN	
Other	Pain		Acetaminophen And Codeine Phosphate	C			UNKNOWN	
	Retinal Artery Occlusion		Acetaminophen And Oxycodone Hydrochloride	C			UNKNOWN	
			Lorazepam	C			UNKNOWN	
			Perindopril Erbumine	C			UNKNOWN	
			Indapamide	C			UNKNOWN	
			Glyburide	C			UNKNOWN	
			Acetaminophen And Oxycodone Hydrochloride	C			UNKNOWN	
			Paroxetine Hydrochloride	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4724634-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02937
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Bayer Aspirin	C				
UNKNOWN								
	Myocardial Infarction							
	Oral Pain							
	Pain In Extremity							
	Paraesthesia							
	Paraesthesia Oral							

Date:07/26/05ISR Number: 4724635-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02268
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Myocardial Infarction							
	Pain							

Date:07/26/05ISR Number: 4724636-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01524
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Lisinopril	C		ORAL		
			Verapamil	C		ORAL		
			Niaspan	C		ORAL		
			Lipitor	C		ORAL		
			Furosemide	C				
UNKNOWN								

Date:07/26/05ISR Number: 4724637-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02270
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724638-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01013
Age:91 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Dreams
Other	Cardiac Failure
	Congestive
	Cataract
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease
	Depression
	Disorientation
	Incontinence
	Ischaemic Cardiomyopathy
	Lung Infiltration
	Myocardial Infarction

		Orthostatic Hypotension					
		Pulmonary Mass					
		Pulmonary Oedema	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sleep Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Vascular Dementia		Vioxx	SS	Merck & Co., Inc	ORAL
				Lasix (Furosemide)	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Iron (Unspecified)	C		
UNKNOWN							
				Detrol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Flomax (Tamsulosin Hydrochloride)	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							

Date:07/26/05ISR Number: 4724639-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02269
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Pain					

Date:07/26/05ISR Number: 4724648-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02267
Age:63 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
9 MON						
			Vioxx	SS	Merck & Co., Inc	ORAL
25 MON						

Date:07/26/05ISR Number: 4724650-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02273
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
32 MON						
Initial or Prolonged	Colitis Ischaemic					
Other						

Date:07/26/05ISR Number: 4724651-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/26/05ISR Number: 4724652-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02271
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4724653-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02427
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724666-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02929
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724667-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:07/26/05ISR Number: 4724668-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02756
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724669-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02637
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724670-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02425
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724671-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02993
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724672-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02760
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	296	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4724673-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02429
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724674-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02638
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724675-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02423
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724676-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02833
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724677-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02426
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724678-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02422
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724679-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02430
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724680-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4724681-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02921
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724682-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02757
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724692-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724693-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03344
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724694-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02995
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724695-8Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0507ZAF00030
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724696-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02998
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724697-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03185
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/26/05ISR Number: 4724698-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02996
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724712-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03177
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4724787-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00315
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Axillary Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Allopurinol	C				
UNKNOWN								
	Coma		Ec Naprosyn	C				
UNKNOWN								
	Disability		Hydrocodone					
	Emotional Distress		Hydrochloride	C				
UNKNOWN								
	Loss Of Consciousness							
	Respiratory Rate							
	Decreased							
	Visual Disturbance							

Date:07/26/05ISR Number: 4724788-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02421
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/26/05ISR Number: 4726518-XReport Type:Expedited (15-DaCompany Report #2005098040
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Discomfort	Foreign	Relpax (Eletriptan)	PS		ORAL	(40 MG, AS NEEDED), ORAL	
	Asthenia	Health Professional	Progynova (Estradiol Valerate)	SS		ORAL	ORAL	
	Balance Disorder		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
	Brain Stem Ischaemia		Atacand (Candesartan Cilexetil)	C				
	Cerebral Ischaemia		Selo-Zok (Metoprolol Succinate)	C				
	Cerebrovascular Accident		Nexium (Esomeprazole)	C				
	Fatigue							
	Hypertension							
	Malaise							
	Paraesthesia							
	Paraesthesia Oral							

Date:07/26/05ISR Number: 4727230-3Report Type:Expedited (15-DaCompany Report #2005103160
Age:58 YR Gender:Female I/FU:I

Outcome	PT
Death	Atherosclerosis
Other	Chest Discomfort

Chest Pain
Muscle Strain

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Health Professional	Celebrex (Celecoxib)	PS			200 MG (200 MG, 1 IN 1 D)	
	Vioxx (Rofecoxib)	SS				

Date:07/27/05ISR Number: 4725606-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725607-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00508
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chronic Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticular Perforation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Epigastric Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Mental Disorder Due To A General Medical Condition		Phenprocoumon	C				
	Nausea		Buprenorphine Hydrochloride	C				
	Polyarthritis		Pantoprazole Sodium	C			3	DAY
	Polyneuropathy		Metoprolol Succinate	C				
	Reflux Oesophagitis		Letrozole	C				

UNKNOWN
TOPICAL
UNKNOWN
UNKNOWN

	Spinal Column Stenosis	Allopurinol	C
UNKNOWN			
	Spinal Disorder	Celecoxib	C
UNKNOWN			
	Vomiting	Acetaminophen	C
UNKNOWN			
		Acetaminophen	C
UNKNOWN			

Date:07/27/05ISR Number: 4725608-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0308USA01980
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
Disability	Atherosclerosis
Other	Benign Prostatic Hyperplasia
	Cataract
	Cellulitis
	Cerebellar Infarction
	Cerebrovascular Accident
	Chalazion
	Chest Pain
	Coronary Artery Disease
	Dyslipidaemia
	Gastric Disorder
	Gastrooesophageal Reflux Disease
	Hypertension

	Injury						
	Lacunar Infarction						
	Syncope	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL	8 DAY
	Vertigo		Vioxx	SS	Merck & Co., Inc	ORAL	
	Vestibular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	8 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Tylenol	C			UNKNOWN

Date:07/27/05ISR Number: 4725609-7Report Type:Expedited (15-DaCompany Report #GB-MERCK-0502GBR00060
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Disability	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	
	Eye Pain		Vioxx	SS	Merck & Co., Inc	ORAL	
	Neuritis						
	Pain						
	Pain In Extremity						
	Radiculitis						
	Sciatica						

Date:07/27/05ISR Number: 4725610-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02805
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/27/05ISR Number: 4725611-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04216
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1464 DAY

Initial or Prolonged	Hip Arthroplasty		Vioxx	SS	Merck & Co., Inc	ORAL
1464 DAY						
Disability	Insomnia		Ambien	C		
UNKNOWN						
	Myocardial Infarction					

Date:07/27/05ISR Number: 4725612-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03368
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Thrombosis					

Date:07/27/05ISR Number: 4725613-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03347
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4725614-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03369
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725615-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02962
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725616-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02966
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725617-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03178
Age:32 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amenorrhoea		Vioxx	PS	Merck & Co., Inc	ORAL	41	MON
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL	41	MON
Disability	Blindness		Percocet	C		ORAL		
	Cerebral Haemorrhage		Xanax	C		ORAL		
	Constipation		Amoxicillin	C		ORAL		
	Disturbance In Attention							
	Dizziness							
	Ecchymosis							
	Epistaxis							
	Eye Haemorrhage							
	Headache							
	Hypoaesthesia							
	Hypothyroidism							
	Infertility							
	Lice Infestation							
	Muscle Spasms							
	Nerve Injury							
	Oedema							
	Overdose							
	Pneumonia							
	Productive Cough							
	Sinusitis							

Superior Sagittal Sinus
Thrombosis
Tooth Infection
Transient Ischaemic
Attack
Transverse Sinus
Thrombosis
Uterine Disorder

Date:07/27/05ISR Number: 4725620-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01755
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		242 YR
Initial or Prolonged	Atrioventricular Block		Procardia	C				UNKNOWN
	Second Degree		Hytrin	C				UNKNOWN
	Cerebrovascular Accident		Prevacid	C				UNKNOWN
	Coronary Artery Disease		Dipyridamole	C				UNKNOWN
	Emotional Distress		Nifedipine	C				UNKNOWN
	Fall							
	Gait Disturbance							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725621-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02645
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		1769 DAY
Hospitalization -	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		1769 DAY
Initial or Prolonged	Coronary Artery Occlusion		Toprol Xl Tablets	C		ORAL		
	Myocardial Infarction		Toprol Xl Tablets	C		ORAL		
			Norvasc	C				UNKNOWN
			Foltx	C				UNKNOWN
			Pravachol	C		ORAL		
			Meperidine Hydrochloride	C				UNKNOWN
			Altace	C		ORAL		
			Metaglip	C		ORAL		
			Ecotrin	C		ORAL		

Date:07/27/05ISR Number: 4725622-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00233
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Increased Hypertension							
	Myocardial Infarction							

Date:07/27/05ISR Number: 4725624-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02968
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725625-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00236
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Blood Cholesterol		Aspirin	C				UNKNOWN
	Increased		Aleve	C				UNKNOWN
	Diabetes Mellitus		Celebrex	C				UNKNOWN
	Hypertension							
	Myocardial Infarction							

Date:07/27/05ISR Number: 4725626-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03370
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725627-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03371
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725628-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03372
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725629-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725631-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03183
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1733 DAY	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Atherosclerosis							
	Coronary Artery Disease							
	Depression							
	Kidney Infection							
	Myocardial Infarction							
	Pain							

Date:07/27/05ISR Number: 4725632-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02969
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725634-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02074
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aciphex	C				
UNKNOWN								
Other	Cardiac Murmur		Lipitor	C				
UNKNOWN								
	Carotid Artery Stenosis		Norvasc	C				
UNKNOWN								
	Cerebrovascular Accident		Amoxicillin	C		ORAL		
	Dyspnoea		Codeine Phosphate And Promethazine Hydrochloride	C				
	Gastric Disorder							
	Hypertension							
UNKNOWN								
	Myocardial Infarction		Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C				
	Thrombosis							
	Transient Ischaemic Attack							
UNKNOWN								
			Quinine Sulfate	C		ORAL		
			Premarin	C				
UNKNOWN								
			Fluocinonide	C				
UNKNOWN								
			Codeine	C				
UNKNOWN								
			Protopic	C				
UNKNOWN								
			Celexa	C				
UNKNOWN								
			Wellbutrin	C		ORAL		
			Plavix	C				
UNKNOWN								
			Hydrocodone Bitartrate	C				
UNKNOWN								
			Albuterol	C				
RESPIRATORY								

(INHALATION)

	Zithromax	C	
UNKNOWN			
	Pentoxifylline	C	
UNKNOWN			
	Ciloxan	C	
UNKNOWN			
	Prednisone	C	
UNKNOWN			
	Alprazolam	C	
UNKNOWN			
	Lamisil	C	
UNKNOWN			

Date:07/27/05ISR Number: 4725635-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02913
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		16 MON
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		16 MON
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Ambien	C				UNKNOWN
	Depression		Neurontin	C		ORAL		
	Disturbance In Attention		Vicodin Tablets	C		ORAL		
	Haematoma		Soma	C				UNKNOWN
	Injury		Paxil	C				UNKNOWN
	Myocardial Infarction		Percocet	C				UNKNOWN
	Panic Attack							
	Sleep Disorder							
	Suicidal Ideation							
	Thyroid Disorder							

Date:07/27/05ISR Number: 4725636-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0302USA01156
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Hospitalization - UNKNOWN	Cardiac Arrest		Zestril	C				
Initial or Prolonged UNKNOWN	Coronary Artery		Lipitor	C				
Other UNKNOWN	Atherosclerosis		Norvasc	C				
	Depression		Acetaminophen And Hydrocodone Bitartrate	C				
	Limb Injury							
	Pain In Extremity							
	Pulmonary Oedema		Bactroban	C				
UNKNOWN								

Date:07/27/05ISR Number: 4725637-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03138
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	26	DAY

Date:07/27/05ISR Number: 4725638-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02773
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725639-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03152
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:07/27/05ISR Number: 4725640-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01611
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atherosclerosis		Keppra	C				
UNKNOWN								
Initial or Prolonged	Atrial Fibrillation		Effexor	C				
UNKNOWN								
	Bipolar Disorder		Topamax	C				
UNKNOWN								
	Bone Disorder		Hydrocodone/Apap	C				
UNKNOWN								
	Bradycardia							
	Cardiac Failure							
	Congestive							
	Cataract							
	Convulsion							
	Diabetes Mellitus							
	Diabetic Nephropathy							
	Diabetic Neuropathy							
	Gastritis							
	Gastrointestinal							
	Haemorrhage							
	Graft Thrombosis							
	Hypertension							
	Hypoglycaemia							
	Major Depression							
	Myocardial Infarction							
	Renal Failure Chronic							

Date:07/27/05ISR Number: 4725641-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01083
Age:45 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization - Initial or Prolonged	Anxiety
Other	Bipolar I Disorder
	Chest Pain
	Cystitis
	Deep Vein Thrombosis
	Diarrhoea
	Fatigue
	Flank Pain
	Gastritis
	Hydronephrosis
	Incisional Hernia
	Kidney Infection
	Nephrolithiasis
	Pseudomonas Infection
	Renal Failure
	Schizoaffective Disorder
	Sepsis
	Staphylococcal Infection
	Ureteric Stenosis
	Urinary Retention
	Urinary Tract Infection

Urosepsis
Weight Increased

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Avapro	C			UNKNOWN	
	Paxil	C			UNKNOWN	
	Geodon	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Prilosec	C			UNKNOWN	
	Levoxyl	C			UNKNOWN	
	Prevacid	C			UNKNOWN	

Date:07/27/05ISR Number: 4725642-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01265
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	54	MON
	Myocardial Infarction							

Date:07/27/05ISR Number: 4725643-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02777
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725644-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01286
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Disability	Acute Sinusitis
Other	Angina Unstable
	Anhedonia
	Anxiety Disorder
	Cerebrovascular Accident
	Chest Pain
	Chills
	Colonic Polyp
	Convulsion
	Coronary Artery Atherosclerosis
	Depression
	Dysgeusia
	Dyspepsia
	Dyspnoea
	Dyspnoea Exertional
	Erectile Dysfunction
	Global Amnesia
	Hyperhidrosis
	Hypersensitivity
	Hypotension
	Injury
	Migraine
	Muscle Strain
	Nasal Congestion

		Nausea					
		Neck Pain					
		Neuropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Otitis Media		Vioxx	PS	Merck & Co., Inc	ORAL
		Overdose		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pharyngolaryngeal Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Productive Cough		Vioxx	SS	Merck & Co., Inc	ORAL
		Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Apnoea Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Sleep Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL
		Urethral Haemorrhage					
		Viral Infection					

Date:07/27/05ISR Number: 4725645-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02276
Age:62 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebral Infarction					
		Injury					

Date:07/27/05ISR Number: 4725647-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02980
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4725648-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03136
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Silent Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
1334 DAY							

Infarction

Date:07/27/05ISR Number: 4725649-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03127
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death		Vioxx	SS	Merck & Co., Inc	ORAL		
			Bextra	SS				

UNKNOWN

Date:07/27/05ISR Number: 4725651-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00659
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Depression
Disability	Drug Hypersensitivity
Other	Dyspnoea

		Gastrointestinal Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
28	MON						
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
28	MON						
		Joint Dislocation		Lisinopril	C		ORAL
		Migraine		Prozac	C		ORAL
		Myocardial Infarction		Premarin	C		ORAL
				Zocor	C		ORAL
				Elavil	C		ORAL
				Elavil	C		ORAL

Date:07/27/05ISR Number: 4725652-8Report Type:Expedited (15-DaCompany Report #GB-MERCK-0507GBR00166
Age:86 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Gastrointestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
				Ramipril	C		
UNKNOWN							
		Myocardial Infarction		Amitriptyline Hydrochloride	C		
		Shock					
UNKNOWN							
				Nifedipine	C		
UNKNOWN							
				Cimetidine	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							
				Atorvastatin Calcium	C		
UNKNOWN							

Date:07/27/05ISR Number: 4725654-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00215
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
34	MON						

Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
34 MON						
	Increased		Prinivil	C		
UNKNOWN						
	Lower Limb Fracture		Xalatan	C		
UNKNOWN						
	Myocardial Infarction		Cosopt	C		
UNKNOWN						
	Rotator Cuff Syndrome					

Date:07/27/05ISR Number: 4725656-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01344
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Glucose Tolerance		Xalatan	C		
UNKNOWN						
	Impaired		Timoptic	C		
UNKNOWN						
	Hypercholesterolaemia		Toprol Xl Tablets	C		ORAL
	Hyperlipidaemia					

Date:07/27/05ISR Number: 4725657-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04179
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Myocardial
Hospitalization -	Infarction
Initial or Prolonged	Blood Cholesterol
Other	Increased

	Cardiac Failure						
	Cardiogenic Shock						
	Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL	22 MON
	Coronary Artery Disease		Prinivil	C		ORAL	18 MON
	Death		Zocor	C			UNKNOWN 18 MON
	Gastrointestinal Haemorrhage						
	Graft Complication						
	Haematoma						
	Hypotension						
	Pericarditis Adhesive						
	Pulmonary Oedema						
	Renal Failure						
	Respiratory Failure						
	Sepsis						
	Stent Occlusion						

Date:07/27/05ISR Number: 4725881-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02216
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	5 DAY
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	5 DAY
Disability	Diverticulum Intestinal		Synthroid	C			UNKNOWN
	Dizziness		Fosamax	C		ORAL	
	Muscle Strain		Prilosec	C			UNKNOWN
	Myocardial Infarction		Zocor	C		ORAL	

Date:07/27/05ISR Number: 4725893-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03731
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Hospitalization - Initial or Prolonged	Acute Myocardial Infarction	Vioxx	PS	Merck & Co., Inc	ORAL	51 MON
		Glucophage	C			UNKNOWN
	Bacterial Infection	Lipitor	C			UNKNOWN
	Bipolar Disorder	Amaryl	C			UNKNOWN
	Depression	Zestoretic	C			UNKNOWN
	Mania	Effexor	C			UNKNOWN
		Glucovance	C			UNKNOWN
		Zyprexa	C			UNKNOWN
		Pepcid	C			UNKNOWN
		Vaseretic	C			UNKNOWN

Date:07/27/05ISR Number: 4725894-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02752
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725895-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02795
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725896-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02039
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		870 DAY
Disability	Chronic Obstructive		Lipitor	C				UNKNOWN
Other	Pulmonary Disease		Aspirin	C				UNKNOWN
	Hypertension							
	Myocardial Infarction							
	Polytraumatism							
	Swelling							

Date:07/27/05ISR Number: 4725897-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01392
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		4 MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		4 MON
	Coronary Artery Disease		Folic Acid	C		ORAL		
	Essential Hypertension		Methotrexate	C		ORAL		
	Overdose		Norvasc	C		ORAL		
	Ventricular Hypertrophy							
	Wound Secretion							

Date:07/27/05ISR Number: 4725898-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02790
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR

Date:07/27/05ISR Number: 4725904-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02946
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725905-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02947
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725906-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02945
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725907-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02970
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725908-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	30	MON

Date:07/27/05ISR Number: 4725909-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725910-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725911-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02073
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Cardizem	C			UNKNOWN	
Other	Breast Disorder		Lasix (Furosemide)	C			UNKNOWN	
	Cerebrovascular Accident		Tylenol	C			UNKNOWN	
	Convulsion		Tylenol With Codeine #3	C			UNKNOWN	
	Depression							
	Hypertension		Flexeril	C			UNKNOWN	
	Ischaemic Stroke		Insulin	C			UNKNOWN	

Myocardial Infarction
Neuropathy

Date:07/27/05ISR Number: 4725912-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02999
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725922-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03318
Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL		
10 DAY								
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
			Prozac	C				
UNKNOWN								
			Pravachol	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Klonopin	C				
UNKNOWN								
			Allegra	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725923-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03004
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725924-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03140
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725925-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03005
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725926-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03198
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension							
	Myocardial Ischaemia							
	Weight Increased							

Date:07/27/05ISR Number: 4725927-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725928-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02867
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Bence Jones Proteinuria		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Cardiac Arrest							
	Cardiac Failure							
	Congestive							
	Death							
	Hypertension							

Date:07/27/05ISR Number: 4725929-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03191
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
47 DAY								
Initial or Prolonged	Erythema Nodosum		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Glucophage	C				
UNKNOWN								
	Pericardial Effusion							
	Pharyngolaryngeal Pain							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4725930-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03000
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/27/05ISR Number: 4725932-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725985-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02941
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725986-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03003
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4725999-5Report Type:Expedited (15-DaCompany Report #IL-MERCK-0507ISR00011
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Fatigue							
	Hypertension							
	Somnolence							

Date:07/27/05ISR Number: 4726000-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02013
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Disease
	Depression
	Dyspepsia
	Gastric Disorder
	Heart Rate Irregular
	Hypersensitivity
	Hypertension
	Pain
	Panic Disorder
	Peptic Ulcer
	Polytraumatism
	Tension Headache
	Thyroid Disorder

		Transient Ischaemic Attack					
		Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Vascular Dementia		Vioxx	PS	Merck & Co., Inc	ORAL
		Visual Disturbance		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4726002-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02789
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4726003-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03348
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction					

Date:07/27/05ISR Number: 4726004-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03353
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4726007-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03323
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/27/05ISR Number: 4726008-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726009-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03349
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726011-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03720
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726012-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03727
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726014-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03350
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726540-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01977
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	24 MON	
Initial or Prolonged	Angina Unstable		Actos	C			UNKNOWN	
Disability	Arrhythmia		Glucophage	C			UNKNOWN	
	Benign Prostatic		Hytrin	C			UNKNOWN	
	Hyperplasia							
	Cardiac Disorder							
	Chest Pain							
	Coronary Artery Disease							
	Dyspepsia							
	Gallbladder Disorder							
	Gastritis							
	Helicobacter Infection							
	Hyperlipidaemia							
	Joint Injury							
	Myocardial Infarction							
	Pulmonary Granuloma							

Date:07/27/05ISR Number: 4726541-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02664
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		379 DAY
Initial or Prolonged	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		379 DAY
Other	Pulmonary Disease		Claritin	C				UNKNOWN
	Deep Vein Thrombosis		Adalat	C				UNKNOWN
	Diabetic Neuropathy		Oxycontin	C				UNKNOWN
	Renal Failure Chronic		Percodan	C				UNKNOWN
	Shoulder Pain		Nortriptyline	C				UNKNOWN
			Amoxicillin	C				UNKNOWN
			Zestril	C				UNKNOWN
			Indocin (Indomethacin Sodium)	C		ORAL		
			Humalog	C				UNKNOWN
			Lantus	C				UNKNOWN
			Erythromycin	C				UNKNOWN
			Phenergan (Promethazine Hydrochloride)	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726542-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01685
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Pulmonary Oedema		Vioxx	PS	Merck & Co., Inc	ORAL		13 MON
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		13 MON
Other	Arteriovenous Fistula		Phoslo	C				UNKNOWN
	Thrombosis		Prednisone	C		ORAL		
	Cardiac Failure		Allopurinol	C		ORAL		
	Congestive		Docusate Sodium	C				UNKNOWN
	Clostridium Colitis		Lipitor	C				UNKNOWN
							1093 DAY	
	Coronary Artery Disease		Norvasc	C				UNKNOWN
							1333 DAY	
	Drug Hypersensitivity		Avandia	C				UNKNOWN
	Faeces Discoloured		Lopressor	C				UNKNOWN
	Fluid Overload		Zoloft	C				UNKNOWN
	Gastrointestinal		Famvir	C				UNKNOWN
	Haemorrhage		Cozaar	C		ORAL		
	Graft Thrombosis		Diatx	C				UNKNOWN
	Gynaecomastia		Duricef	C				UNKNOWN
	Hernia		Acetaminophen And					
	Hypertensive Crisis		Hydrocodone					
	Hypertensive Emergency		Bitartrate	C				UNKNOWN
	Latex Allergy		Nephro-Vite Rx	C				UNKNOWN
	Medical Device		Temazepam	C				UNKNOWN
	Complication		Amoxicillin And					
	Non-Cardiac Chest Pain		Clavulanate					
	Pneumonia		Potassium	C				UNKNOWN
	Pulmonary Infarction		Minoxidil 2%	C				UNKNOWN

			Metronidazole	C	
UNKNOWN					
			Endocet	C	
UNKNOWN					
			Labetalol Hydrochloride	C	
UNKNOWN					
			Amitriptyline Hydrochloride	C	ORAL
			Acetaminophen And Propoxyphene Napsylate	C	
UNKNOWN					
			Nifedipine	C	ORAL
			Zithromax	C	
UNKNOWN					
			Clindamycin	C	
UNKNOWN					
			Triamcinolone Acetonide	C	
UNKNOWN					
			Levaquin	C	
UNKNOWN					
			Tylenol	C	
UNKNOWN					
			Bextra	C	
UNKNOWN	15	DAY			
			Calcitriol	C	
UNKNOWN					
			Colchicine	C	
UNKNOWN					
			Carbidopa And Levodopa	C	ORAL
			Heparin	C	
UNKNOWN					
			Aspirin	C	ORAL
			Pravachol	C	
UNKNOWN					
			Diphenhydramine Hydrochloride	C	
UNKNOWN					

Date:07/27/05ISR Number: 4726544-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00761
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arrhythmia
	Candidiasis

	Depression						
	Dizziness						
	Duodenitis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Gastritis Erosive		Vioxx	PS	Merck & Co., Inc	ORAL	
	Nausea		Fluticasone				
	Reflux Oesophagitis		Propionate	C			UNKNOWN
	Syncope		Albuterol	C			UNKNOWN
	Vomiting						

Date:07/27/05ISR Number: 4726549-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00841
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY
Initial or Prolonged	Ageusia		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	4 DAY
Other	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL	
	Carpal Tunnel Syndrome		Prevacid	SS			UNKNOWN
	Cerebrovascular Accident		Zocor	SS		ORAL	2099 DAY
	Cervicobrachial Syndrome		Prevacid	SS			UNKNOWN
	Cholecystitis Chronic		Monopril	C			UNKNOWN 1183 DAY
	Cholelithiasis		Monopril	C			UNKNOWN
	Colon Adenoma		Effexor	C			UNKNOWN
	Constipation		Effexor	C			UNKNOWN
	Depression		Zantac	C			UNKNOWN
	Dizziness		Naprosyn	C			UNKNOWN 4268 DAY
	Dry Mouth		Naprosyn	C			UNKNOWN 4268 DAY
	Dysplasia		Levaquin	C			UNKNOWN

	Fatigue	Levaquin	C
UNKNOWN			
	Headache	Ambien	C
UNKNOWN			
	Hypertension		
	Insomnia		
	Joint Injury		
	Laceration		
	Mitral Valve Incompetence		
	Prostate Cancer		
	Psoriasis		
	Rash Erythematous		
	Urge Incontinence		
	Urinary Incontinence		

Date:07/27/05ISR Number: 4726554-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01956
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Bruit
Initial or Prolonged	Abdominal Discomfort
Disability	Accident At Work
Other	Acute Myocardial
	Infarction
	Adhesion
	Alcohol Withdrawal
	Syndrome
	Alcoholism
	Anaemia
	Anxiety
	Arthralgia
	Arthropathy
	Bronchitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Cardiac Failure Congestive Cerebrovascular Accident					
		Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Dependence		Vioxx	SS	Merck & Co., Inc	ORAL
		Drug Ineffective		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysuria		Vioxx	SS	Merck & Co., Inc	ORAL
		Emotional Distress		Celebrex	C		
UNKNOWN	362 DAY						
		Facet Joint Syndrome		Lortab	C		
UNKNOWN							
		Faecal Occult Blood		Neurontin	C		
UNKNOWN							
		Positive		Robaxin	C		
UNKNOWN	957 DAY						
		Fatigue		Amitriptyline Hydrochloride	C		
		Gallbladder Polyp					
UNKNOWN	874 DAY						
		Headache		Hydrocodone Bitartrate	C		
		Hepatitis C					
UNKNOWN							
		Hyperlipidaemia		Lorazepam	C		
UNKNOWN	2 DAY						
		Hypertension		Trazodone Hydrochloride	C		
		Insomnia					
UNKNOWN							
		Intervertebral Disc		Ibuprofen	C		
UNKNOWN							
		Protrusion		Acetaminophen And Hydrocodone Bitartrate	C		
		Loss Of Consciousness					
		Lumbar Spinal Stenosis					
UNKNOWN							
		Micturition Urgency					
		Mouth Ulceration					
		Muscle Spasms					
		Myocardial Infarction					
		Myofascial Pain Syndrome					
		Neuropathy Peripheral					
		Osteoarthritis					
		Panic Attack					
		Peripheral Vascular Disorder					
		Pneumonia					
		Pollakiuria					

Prostatitis
Pyrexia
Rash Erythematous
Rash Pruritic
Spinal Osteoarthritis
Syncope
Urinary Tract Infection
Vision Blurred

Date:07/27/05ISR Number: 4726564-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02077
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Murmur		Aspirin	C				
UNKNOWN								
	Cerebrovascular Accident		Plavix	C		ORAL		
	Hypertension		Cozaar	C		ORAL		
	Myocardial Infarction		Labetalol					
	Oedema Peripheral		Hydrochloride	C		ORAL		
			Hydrodiuril	C		ORAL		
			Zocor	C		ORAL		
			Norvasc	C		ORAL		
			Protonix	C		ORAL		

			Hytrin	C		ORAL
			Flavon Glycoside	C		
UNKNOWN						
			Glyburide	C		ORAL
			Hyzaar	C		ORAL

Date:07/27/05ISR Number: 4726565-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03728
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arthropathy		Percocet	C		
UNKNOWN						
Initial or Prolonged	Cardiac Failure					
	Congestive					
	Dyspnoea					
	Hypoaesthesia					
	Meniscus Lesion					
	Sudden Death					

Date:07/27/05ISR Number: 4726566-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01739
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anxiety		Prednisone	C		
UNKNOWN						
Other	Atherosclerosis		Immunotherapy			
	Blood Cholesterol		(Unspecified)	C		
UNKNOWN						
	Increased		Colazal	C		
UNKNOWN						
	Deafness		Imuran			
	Hypertension		(Azathioprine)	C		
UNKNOWN						
	Movement Disorder		Celexa	C		
UNKNOWN						
	Pulmonary Congestion		Rowasa	C		
UNKNOWN						
	Sleep Apnoea Syndrome					

Date:07/27/05ISR Number: 4726567-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03727
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Hospitalization -	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Pulmonary Disease		Bayer Aspirin	C				UNKNOWN
	Hypertension		Ultram	C				UNKNOWN
	Syncope		Fosamax	C				UNKNOWN

Date:07/27/05ISR Number: 4726568-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02234
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		784 MON
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		784 MON
	Intervertebral Disc Degeneration							
	Post-Traumatic Stress Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726569-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02094
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Cerebrovascular Accident		Lasix (Furosemide Sodium)	C			UNKNOWN	
	Gout							
	Polytraumatism		Hydrochlorothiazide And Triamterene	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Prempro	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Trazodone Hydrochloride	C			UNKNOWN	

Date:07/27/05ISR Number: 4726570-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0504CAN00120
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Vasotec	C		ORAL		
			Acetaminophen	C				

Date:07/27/05ISR Number: 4726577-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04185
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Chronic Obstructive		Spironolactone	C				

	Pulmonary Disease		Pacerone	C		
UNKNOWN						
	Retinal Artery Embolism		Prevacid	C		
UNKNOWN						
	Retinal Artery Occlusion		Coumadin	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Amiodarone	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:07/27/05ISR Number: 4726578-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02208
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 421 DAY	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Aspirin	C		
UNKNOWN						
Other	Pleural Effusion		Fosamax	C		ORAL
			Prempro	C		
UNKNOWN						
			Combivent	C		
RESPIRATORY						
(INHALATION)						
			Furosemide	C		
UNKNOWN						
			Aciphex	C		
UNKNOWN						
			Avapro	C		
UNKNOWN						
			Acetaminophen And Codeine	C		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						
			Endocet	C		
UNKNOWN						
			Hydrocodone Bitartrate	C		
UNKNOWN						
			Oxycontin	C		
UNKNOWN						
			Hydrochlorothiazide	C		ORAL
			Dicyclomine			

	Hydrochloride	C	UNKNOWN
	Zithromax	C	UNKNOWN
	Neurontin	C	UNKNOWN
	Metoclopramide	C	UNKNOWN
	Levaquin	C	UNKNOWN
	Alprazolam	C	UNKNOWN
	Benzonatate	C	UNKNOWN
	Guaifenex La	C	UNKNOWN
	Atuss Ms	C	UNKNOWN

Date:07/27/05ISR Number: 4726579-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02076
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension		Prozac	C				UNKNOWN
	Oedema Peripheral		Prozac	C				UNKNOWN
	Panic Disorder		Paxil	C				UNKNOWN
	Upper Respiratory Tract		Paxil	C				UNKNOWN
	Infection		Synthroid	C				UNKNOWN
	Vomiting							

Date:07/27/05ISR Number: 4726580-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02946
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Aleve	C				
UNKNOWN								
	Coronary Artery Disease							
	Diverticulum Intestinal							
	Dyspnoea							
	Headache							
	Hepatic Steatosis							
	Hernia							
	Hypertension							
	Myocardial Infarction							

Date:07/27/05ISR Number: 4726585-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00220
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Repair		Vioxx	PS	Merck & Co., Inc	ORAL		
763 YR								
Initial or Prolonged	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Drug Hypersensitivity		Tylenol	C				
UNKNOWN								
	Haematochezia							
	Transient Ischaemic							
	Attack							

Date:07/27/05ISR Number: 4726586-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02126
Age:69 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Colon Adenoma
Initial or Prolonged	Contusion

	Haematuria Prostatic Disorder Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Attack		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR
			Hyzaar	C		ORAL	
			Warfarin	C			UNKNOWN
			Methotrexate	C			UNKNOWN
			Aspirin	C		ORAL	

Date:07/27/05ISR Number: 4726587-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02933
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Deep Vein Thrombosis Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/27/05ISR Number: 4726588-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02755
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/27/05ISR Number: 4726589-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02931
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:07/27/05ISR Number: 4726590-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02265
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726591-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02930
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726592-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02427
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726593-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02262
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726594-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02251
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Albuterol	C				
			Singulair	C				

Date:07/27/05ISR Number: 4726595-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00212
Age:78 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	General Physical Health		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deterioration		Isosorbide Mononitrate	C		ORAL		
	Hallucination		Aspirin	C		ORAL		
	Joint Swelling		Olanzapine	C		ORAL		
	Oedema Peripheral		Pneumococcal 23v Polysaccharide Vaccine	C				
	Pulmonary Oedema		Carbidopa And Levodopa	C		ORAL		
	Renal Failure		Carbidopa And Levodopa	C		ORAL		
	White Blood Cell Count Increased		Carbidopa And Levodopa	C		ORAL		
			Carbidopa And Levodopa	C		ORAL		
			Influenza Virus Split Virion 3v Vaccine Inactivated	C				

Date:07/27/05ISR Number: 4726596-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00141
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - UNKNOWN	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc			
Initial or Prolonged	Myocardial Infarction							
	Platelet Count Increased							

Date:07/27/05ISR Number: 4726597-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0507CHE00019
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Retinal Vascular Thrombosis							
	Visual Acuity Reduced							

Date:07/27/05ISR Number: 4726598-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		132 DAY

Date:07/27/05ISR Number: 4726599-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726600-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04217
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
1348 DAY								
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
1348 DAY								
Disability	Coronary Artery Disease		Tylenol	C		ORAL		
	Coronary Artery Occlusion		Diovan	C		ORAL		
	Depression		Tenormin	C		ORAL		
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Myocardial Infarction							

Date:07/27/05ISR Number: 4726601-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01913
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726602-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02753
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
90 DAY								

Date:07/27/05ISR Number: 4726603-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02263
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726604-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02975
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726605-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02957
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726606-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03130
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON

Date:07/27/05ISR Number: 4726607-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726608-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726609-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02972
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726610-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02961
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other								

Date:07/27/05ISR Number: 4726611-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03131
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:07/27/05ISR Number: 4726612-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02956
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726615-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02958
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726616-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02935
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726617-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02938
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726618-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02953
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726619-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02954
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726620-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02934
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726622-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726623-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02959
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726624-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726632-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03662
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726633-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03134
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726634-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03288
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726635-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03309
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726636-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03196
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	62 MON	

Date:07/27/05ISR Number: 4726637-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02973
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726638-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03666
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726639-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03261
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL		754 DAY
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		754 DAY
Other	Cerebrovascular Accident Coronary Artery Disease Depressed Mood							

Date:07/27/05ISR Number: 4726640-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Leg Amputation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726641-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03290
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726642-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726643-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03135
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/27/05ISR Number: 4726644-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03129
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
	Emotional Distress							
	Injury							
	Myocardial Infarction							

Date:07/27/05ISR Number: 4726649-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03754
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726650-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03842
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726651-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03812
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	254	DAY

Date:07/27/05ISR Number: 4726652-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03816
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726653-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03690
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726654-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03828
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726656-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03830
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726657-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03817
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726658-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03841
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/27/05ISR Number: 4726659-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03836
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726667-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726668-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03811
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	463 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726670-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03757
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726672-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03759
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	37	MON

Date:07/27/05ISR Number: 4726673-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03778
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726674-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03673
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726675-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03723
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726676-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03784
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726679-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03871
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726681-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03872
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	283 DAY	

Date:07/27/05ISR Number: 4726682-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03873
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/27/05ISR Number: 4726683-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03866
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiovascular Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726684-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03837
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726685-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03865
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Haemorrhage Intracranial		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Life-Threatening	Renal Disorder							
Hospitalization - Initial or Prolonged	Systemic Lupus Erythematosus							
Other								

Date:07/27/05ISR Number: 4726686-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03899
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4726701-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03869
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/27/05ISR Number: 4728219-0Report Type:Expedited (15-DaCompany Report #WAES 0410GBR00275
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adenocarcinoma	Foreign	Vioxx (Rofecoxib)	PS		ORAL	25 MG/DAILY	
Hospitalization -	Bronchopneumonia	Study						
PO								293 DAY
Initial or Prolonged	Cardio-Respiratory Arrest Left Ventricular Failure Pleural Effusion Post Procedural Complication Recurrent Cancer Therapy Non-Responder	Health Professional Other	Allopurinol	C				

Date:07/27/05ISR Number: 4728296-7Report Type:Expedited (15-DaCompany Report #2005103228
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiogenic Shock	Consumer	Celebrex (Celecoxib)	PS		ORAL	ORAL	
Other			Vioxx (Rofecoxib)	SS		ORAL	ORAL	

Date:07/27/05ISR Number: 4728464-4Report Type:Expedited (15-DaCompany Report #2005077695
Age:88 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain	Consumer	Neurontin (Gabapentin)	PS			100 MG (100 MG 1 IN 1 D)	
Other	Constipation							
	Crying		Bextra (Valdecoxib)	SS			TRANSDERMAL	25 MCG, TRANSDERMAL
	Delayed Recovery From Anaesthesia		Mortin (Ibuprofen)	SS				
			Fentanyl (Fentanyl)	SS				
	Dizziness							
	Drug Ineffective		Vioxx (Rofecixob)	SS				
	Feeling Abnormal		Advil (Ibuprofen)	SS				
	Gastritis		Aleve (Naproxen Sodium)	C				
	Impaired Driving Ability		Levoxyl (Levothyroxine Sodium)	C				
	Insomnia		All Other Therapeutic Products (All Other Therapeutic Products)	C				
	Muscle Spasms							
	Nausea							
	Paralysis							
	Pruritus							
	Psychomotor Hyperactivity							
	Somnolence							
	Stomach Discomfort							
	Unevaluable Event							

Date:07/27/05ISR Number: 4728577-7Report Type:Expedited (15-DaCompany Report #2005103275
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper	Consumer	Celebrex (Celecoxib)	PS		ORAL	200 MG (200 MG, 1 IN 1D), ORAL	
	Arrhythmia							
	Post Procedural Pain							
	Treatment Noncompliance		Vioxx (Rofecoxib)	SS		ORAL	ORAL	
			Toprol Xl (Metoprolol Succinate)	C				

Date:07/28/05ISR Number: 4727342-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01277
Age:56 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Carotid Artery Occlusion
	Cerebrovascular Accident
Disability	Colonic Polyp
	Complex Regional Pain Syndrome
	Cough
	Depression
	Haemorrhoids
	Hyperlipidaemia
	Hypertension
	Pain

Tenosynovitis Stenosans
Wheezing

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	91	DAY
	Albuterol	C			UNKNOWN	
	Lortab	C			UNKNOWN	

Date:07/28/05ISR Number: 4727343-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04988
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Celebrex	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Percocet	C			UNKNOWN	

Date:07/28/05ISR Number: 4727344-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02237
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	1193	DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	1193	DAY
Disability	Bursitis		Methylprednisolone	C			UNKNOWN	
	Cervicobrachial Syndrome		Bextra	C			UNKNOWN	
	Condyloma Acuminatum		Colchicine	C			UNKNOWN	
	Coronary Artery		Norvasc	C			UNKNOWN	

Atherosclerosis	Triamterene	C UNKNOWN
Coronary Artery Occlusion	Allopurinol	C UNKNOWN
Diarrhoea	Methocarbamol	C UNKNOWN
Gout	Indomethacin	C UNKNOWN
Gouty Arthritis	Plavix	C UNKNOWN
Headache	Protonix	C UNKNOWN
Hyperlipidaemia	Hydrocodone Bitartrate	C UNKNOWN
Hypertension		
Hypertriglyceridaemia	Altace	C UNKNOWN
Insomnia	Toprol Xl Tablets	C UNKNOWN
Myocardial Infarction	Nitroquick	C UNKNOWN

Date:07/28/05ISR Number: 4727346-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
Disability	Anorexia
Other	Anxiety
	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp
	Back Pain
	Blister
	Blood Pressure Increased
	Bronchitis
	Bursitis
	Cardiac Disorder
	Caustic Injury
	Chest Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Constipation					
		Depression					
		Diastolic Dysfunction					
		Diverticulum Intestinal		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Drug Eruption		Vioxx	SS	Merck & Co., Inc	ORAL
		Dysphonia		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Dysuria		Prinivil	C		
UNKNOWN							
		Ecchymosis		K-Dur	C		
UNKNOWN							
		Epistaxis		Lortab	C		
UNKNOWN							
		Fall		Coumadin	C		
UNKNOWN							
		Frequent Bowel Movements		[Therapy			
		Gastritis		Unspecified]	C		
UNKNOWN							
		Glucose Tolerance		Lasix (Furosemide			
		Impaired		Sodium)	C		
UNKNOWN							
		Gout					
		Haemorrhoids					
		Headache					
		Helicobacter Infection					
		Hypertension					
		Hypoaesthesia					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Crepitation					
		Kidney Infection					
		Labyrinthitis					
		Middle Ear Disorder					
		Muscle Strain					
		Nasopharyngeal Disorder					
		Nasopharyngitis					
		Nausea					
		Oedema Peripheral					
		Osteoarthritis					
		Otitis Media					
		Pain					

Pharyngitis
Polyarthritis
Rash
Rhinitis
Sinusitis
Sleep Disorder
Stomach Discomfort
Syncope
Tricuspid Valve
Incompetence
Vertigo
Vision Blurred
Vomiting

Date:07/28/05ISR Number: 4727349-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01777
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Other	Anxiety
	Convulsion
	Gastrooesophageal Reflux

Disease	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Haematochezia							
Heart Rate Irregular							
Myocardial Infarction							
Rheumatoid Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	348 DAY	
Sleep Apnoea Syndrome		Celebrex	SS			UNKNOWN	
		Celebrex	SS			UNKNOWN	
		Lopid	C			UNKNOWN	366 DAY
		Bextra	C			UNKNOWN	
		Calan	C			UNKNOWN	
		Bextra	C			UNKNOWN	
		Aspirin	C			UNKNOWN	
		Ventilan (Albuterol)	C			UNKNOWN	

Date:07/28/05ISR Number: 4727350-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthralgia		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
Disability	Asthenia		Plavix	SS			UNKNOWN	
Other	Atherosclerosis		Vioxx	SS	Merck & Co., Inc		UNKNOWN	
	Cerebrovascular Accident		Captopril Msd	C		ORAL		
	Cerebrovascular Disorder		Evista	C			UNKNOWN	
	Chondromalacia		Amitriptyline Hydrochloride	C			UNKNOWN	
	Convulsion							
	Diabetes Mellitus		Glucotrol Xl	C			UNKNOWN	
	Inadequate Control		Synthroid	C			UNKNOWN	

	Diabetic Complication	Prilosec	C	ORAL
	Diabetic Neuropathy	Humulin	C	
UNKNOWN				
	Diverticulum			
	Dizziness			
	Eye Injury			
	Fall			
	Fatigue			
	Gastritis			
	Gastrointestinal			
	Haemorrhage			
	Haemorrhoidal Haemorrhage			
	Hand Fracture			
	Hypertension			
	Hypotension			
	Joint Dislocation			
	Ligament Sprain			
	Meniscus Lesion			
	Muscle Spasms			
	Myelodysplastic Syndrome			
	Orthostatic Hypotension			
	Pain In Extremity			
	Pancytopenia			
	Pharyngitis			
	Subcutaneous Abscess			
	Surgery			
	Syncope			
	Upper Respiratory Tract Infection			
	Urinary Tract Infection			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727354-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02964
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727357-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03008
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727358-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01279
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL	69 MON	
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	69 MON	
Disability	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	69 MON	
	Chronic Myeloid Leukaemia		Vioxx	SS	Merck & Co., Inc	ORAL	69 MON	
	Dyspnoea		Catapres	C			UNKNOWN	
	Gastrooesophageal Reflux		Zyrtec	C			UNKNOWN	
	Disease		Zithromax	C			UNKNOWN	
	Hypertension		Clarinex	C			UNKNOWN	
	Lung Neoplasm Malignant		Ampicillin	C			UNKNOWN	
	Myocardial Infarction		Hydrocortisone Acetate	C			UNKNOWN	
	Neuropathy							
	Oedema Peripheral		Ambien	C			UNKNOWN	

	Prostate Cancer		Soma	C
UNKNOWN				
	Spinal Cord Infarction		Detrol La	C
UNKNOWN				
			Isosorbide	C
UNKNOWN				
			Klor-Con	C
UNKNOWN				
			Metoclopramide	C
UNKNOWN				
			[Therapy Unspecified]	C
UNKNOWN				
			Hydroxyzine Hydrochloride	C
UNKNOWN				

Date:07/28/05ISR Number: 4727359-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03901
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727366-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03007
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727367-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02258
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727368-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03006
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727369-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00242
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	40 MON	
Initial or Prolonged	Benign Prostatic Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Naproxen	C			UNKNOWN	
	Blood Pressure Increased		Voltaren	C			UNKNOWN	
	Cerebrovascular Accident		Celebrex	C			UNKNOWN	
	Dilatation Atrial		Zocor	C			UNKNOWN	
	Ejection Fraction		Aspirin	C			UNKNOWN	
	Decreased		Vitamin E	C			UNKNOWN	
	Extrasystoles		Ascorbic Acid	C			UNKNOWN	
	Glaucoma		Glucosamine	C			UNKNOWN	
	Hemiparesis		Chondroitin	C			UNKNOWN	
	Hernia		Mevacor	C			UNKNOWN	
	Hyperlipidaemia		Clotrimazole	C			UNKNOWN	
	Hypertension		Beconase	C			UNKNOWN	
	Influenza Like Illness		Flunisolide	C			UNKNOWN	
	Lacunar Infarction		Hytrin	C			UNKNOWN	
	Mitral Valve Incompetence		Nabumetone	C			UNKNOWN	

	Neoplasm Malignant		Maxzide	C		
UNKNOWN						
	Skin Laceration					

Date:07/28/05ISR Number: 4727370-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01589
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					

Date:07/28/05ISR Number: 4727389-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03965
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Occlusion					
Other	Cerebrovascular Accident					
	Eye Disorder					
	Transient Ischaemic					
	Attack					

Date:07/28/05ISR Number: 4727390-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03814
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727798-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03964
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON

Date:07/28/05ISR Number: 4727816-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03720
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	57	MON
Initial or Prolonged	Cardiac Murmur		Aspirin	C		ORAL	2100	DAY
Other	Cardiac Valve Disease		Tylenol	C		ORAL		
	Cerebrovascular Accident		Vasotec	C		ORAL		
	Depression		Vasotec	C		ORAL		
	Diabetic Complication							
	Dyspepsia							
	Hypersensitivity							
	Sleep Apnoea Syndrome							

Date:07/28/05ISR Number: 4727817-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03761
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	666	YR
Initial or Prolonged	Arrhythmia							
Other	Cardiac Disorder							
	Drug Hypersensitivity							
	Hypertension							
	Myocardial Infarction							
	Osteoarthritis							

Date:07/28/05ISR Number: 4727818-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00988
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Dizziness Post-Traumatic Stress Disorder Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		1 MON

Date:07/28/05ISR Number: 4727819-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02801
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Abnormal Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Advair	C			UNKNOWN	
			Combivent	C			UNKNOWN	
			Aspirin	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727820-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02301
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Meperidine Hydrochloride	C				UNKNOWN
	Atherosclerosis		Cytotec	C				UNKNOWN
	Constipation		Celebrex	C				UNKNOWN
	Coronary Artery		Acetaminophen	C				UNKNOWN
	Thrombosis		Oxycontin	C				UNKNOWN
	Dysuria		Neurontin	C				UNKNOWN
	Erectile Dysfunction		Doxycycline	C				UNKNOWN
	Intervertebral Disc		Valium	C				UNKNOWN
	Protrusion		Viagra	C				UNKNOWN
	Pain						406	DAY
	Prostatitis							
	Suprapubic Pain							

Date:07/28/05ISR Number: 4727822-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00161
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		1749 DAY
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1749 DAY
	Diarrhoea		Aspirin	C				UNKNOWN
	Hyperlipidaemia		Hydrochlorothiazide	C		ORAL		
	Hypertension		Amlodipine Mesylate	C				UNKNOWN
	Vascular Encephalopathy		Tramadol					

	Wrong Technique In Drug		Hydrochloride	C		ORAL
1729 DAY						
	Usage Process		Enalapril Maleate	C		ORAL

Date:07/28/05ISR Number: 4727823-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04002
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/28/05ISR Number: 4727824-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04003
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:07/28/05ISR Number: 4727825-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04023
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL
			Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727826-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01401
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Pain		Prempro	C				
UNKNOWN								
	Cardiac Disorder		Aciphex	C				
UNKNOWN								
	Carotid Artery Stenosis		Quinine Sulfate	C				
UNKNOWN								
	Coronary Artery Occlusion		Norvasc	C		ORAL		
	Depression		Vasotec	C				
UNKNOWN								
	Hypertension		Calcium					
	Hypoaesthesia		(Unspecified)	C				
UNKNOWN								
	Muscle Spasms							
	Psychomotor Hyperactivity							
	Pulmonary Thrombosis							

Date:07/28/05ISR Number: 4727827-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00629
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Exercise Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Goitre		Vioxx	SS	Merck & Co., Inc	ORAL		
	Metabolic Syndrome		Valdecoxib	C		ORAL		
	Myocardial Infarction		Valdecoxib	C		ORAL		
	Osteoarthritis		Insulin Glargine	C				
UNKNOWN								
			Metformin	C				
UNKNOWN								
			Glyburide	C		ORAL		
			Simvastatin	C		ORAL		
			Acarbose	C		ORAL		
			Acarbose	C		ORAL		
			Aspirin	C		ORAL		

Ramipril C
UNKNOWN

Date:07/28/05ISR Number: 4727828-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02540
Age:40 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Agitation
Disability	Anxiety
	Arthropathy
	Basilar Artery Occlusion
	Blood Cholesterol Increased
	Brain Stem Infarction
	Cellulitis
	Cerebellar Infarction
	Cerebral Artery Stenosis
	Cerebral Infarction
	Chest Pain
	Coma
	Depression
	Dilatation Atrial
	Diplopia
	Drug Interaction
	Dysarthria
	Embolic Cerebral

	Infarction						
	Hyperglycaemia						
	Hypertension						
	Hyperventilation	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypoxia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Laboratory Test Abnormal		Vioxx	SS	Merck & Co., Inc	ORAL		
	Lacunar Infarction							
	Muscle Spasms							
	Overdose							
	Pain In Jaw							
	Paraesthesia Oral							
	Pulmonary Embolism							
	Stomach Discomfort							
	Stress							
	Transient Ischaemic							
	Attack							
	Urosepsis							
	Ventricular Hypertrophy							
	Vertigo							

Date:07/28/05ISR Number: 4727829-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0403USA01341
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Myocardial
Other	Infarction
	Acute Psychosis
	Amnesia
	Anxiety
	Asthma
	Back Disorder
	Back Pain
	Blood Triglycerides
	Increased
	Bronchitis Acute
	Cardiac Failure
	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery Disease
	Coronary Artery

Thrombosis
Diarrhoea
Euthyroid Sick Syndrome
Fibromyalgia
Gastroenteritis
Haemorrhage
Hallucination
Headache
Herpes Simplex
Hyperlipidaemia
Hypertension
Irritable Bowel Syndrome
Ischaemic Cardiomyopathy
Nasal Disorder
Nausea
Neck Pain

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Panic Disorder Pyelonephritis Acute Renal Cyst					
252 DAY		Sleep Apnoea Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
252 DAY		Spondylolisthesis		Vioxx	SS	Merck & Co., Inc	ORAL
UNKNOWN		Urinary Tract Infection		Seroquel	C		
UNKNOWN		Vascular Pseudoaneurysm		Seroquel	C		
UNKNOWN				Soma	C		
UNKNOWN				Premarin	C		
UNKNOWN				Ambien	C		
UNKNOWN				Neurontin	C		
UNKNOWN				Potassium (Unspecified)	C		
UNKNOWN				Aspirin	C		
UNKNOWN				Folic Acid	C		
UNKNOWN				Prevacid	C		
UNKNOWN				Toprol Xl Tablets	C		
UNKNOWN				Toprol Xl Tablets	C		
UNKNOWN	8 DAY			Plavix	C		
UNKNOWN				Zocor	C		
UNKNOWN				Lipitor	C		
UNKNOWN	112 DAY			Foltx	C		
UNKNOWN				Linseed Oil	C		
UNKNOWN				Nitroglycerin	C		
UNKNOWN				Vicodin Tablets	C		
UNKNOWN							

				Altace	C		
UNKNOWN							
				Doxepin Hydrochloride	C		
UNKNOWN							
				Flexeril	C		ORAL
				Prozac	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							

Date:07/28/05ISR Number: 4727831-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01269
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Anhedonia		Oxycontin	C		
UNKNOWN	1058 DAY					
Other	Blood Cholesterol		Neurontin	C		
UNKNOWN						
	Increased		Roxicet	C		
UNKNOWN						
	Blood Pressure Increased		Acetaminophen And Oxycodone Hydrochloride	C		
	Cardiac Disorder					
	Coronary Artery Disease					
UNKNOWN						
	Dyspepsia		Tylox	C		
UNKNOWN						
	Hypertension		Percocet	C		
UNKNOWN						
	Myocardial Infarction		Nortriptyline	C		
UNKNOWN						
	Obesity		Prednisone	C		
UNKNOWN						
	Pain		Tamoxifen Citrate	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			Lotensin	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

UNKNOWN

Wellbutrin	C
Ranitidine	C
Nexium	C
Lotrel	C
Augmentin	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727832-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02689
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		5 YR
Disability	Chest Discomfort		Aspirin	C				UNKNOWN
	Chest Pain		Lipitor	C				UNKNOWN
	Chronic Fatigue Syndrome		Zoloft	C				UNKNOWN
	Erectile Dysfunction		Lorazepam	C				UNKNOWN
	Hypertension		Anafranil	C				UNKNOWN
	Insomnia		Serzone	C				UNKNOWN
	Labyrinthitis		Remeron	C				UNKNOWN
	Vestibulitis		Luvox	C				UNKNOWN
			Transderm Scop	C				UNKNOWN
			Novolin	C				UNKNOWN
			Humulin	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Glucovance	C				UNKNOWN

Date:07/28/05ISR Number: 4727833-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00748
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Accident At Home
Initial or Prolonged	Activated Partial
Disability	Thromboplastin Time
Other	Prolonged

Angina Pectoris
Anxiety
Atrial Septal Defect
Balance Disorder
Bipolar Disorder
Borderline Personality
Disorder
Bradycardia
Breast Pain
Bursitis
Cardiac Aneurysm
Cardiac Failure
Congestive
Cardiomegaly
Cellulitis
Cerebral Infarction
Chest Pain
Coronary Artery Disease
Coronary Artery
Restenosis
Death
Diverticulum
Drug Abuser
Drug Dependence
Dyspnoea
Dysthymic Disorder
Emotional Distress
Fibromyalgia
Haemorrhoids
Headache
Hyperkalaemia
Hypertrophy Breast

		Hyponatraemia					
		Injury					
		Intermittent Claudication	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
		Lacunar Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Leukocytosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Limb Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL
		Lung Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Major Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Mitral Valve Incompetence		Aspirin	C		
UNKNOWN		668 DAY					
		Myocardial Infarction		Coumadin	C		
UNKNOWN							
		Obsessive-Compulsive		Coumadin	C		
UNKNOWN							
		Disorder		Coumadin	C		
UNKNOWN		96 DAY					
		Oedema Peripheral		Neurontin	C		
UNKNOWN							
		Overdose		Vicodin Tablets	C		
UNKNOWN							
		Pain		Seroquel	C		
UNKNOWN							
		Pain In Extremity		Ativan	C		
UNKNOWN							
		Panic Disorder With		Ativan	C		
UNKNOWN							
		Agoraphobia		Monopril	C		ORAL
		Pneumonia		Norvasc	C		
UNKNOWN							
		Pollakiuria		Lithium Carbonate	C		ORAL
		Post-Traumatic Stress		Lithium Carbonate	C		ORAL
		Disorder		Zyprexa	C		ORAL
		Pulmonary Hypertension		Zyprexa	C		ORAL
		Skin Cancer		Zithromax	C		ORAL
4	DAY						
		Spinal Osteoarthritis		Navane	C		ORAL
		Suicidal Ideation		Cogentin	C		ORAL
		Transient Ischaemic		Tegretol-Xr	C		ORAL
		Attack		Claritin-D	C		
UNKNOWN							
		Tricuspid Valve					
		Incompetence					
		Upper Respiratory Tract					
		Infection					
		Varices Oesophageal					

Ventricular Dysfunction
Weight Increased

Date:07/28/05ISR Number: 4727840-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00878
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerumen Impaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Wall Pain		Vioxx	SS	Merck & Co., Inc	ORAL		834 DAY
Disability	Contusion		Vioxx	SS	Merck & Co., Inc	ORAL		12 DAY
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
	Dyspnoea At Rest		Lotensin	C				UNKNOWN
	Fatigue		Lipitor	C				UNKNOWN
	Myocardial Infarction		Prilosec	C				UNKNOWN

Date:07/28/05ISR Number: 4727841-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00234
Age:78 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
	Angina Pectoris
	Arrhythmia
	Asthenia
	Chest Discomfort
	Communication Disorder

		Coronary Artery Atherosclerosis					
		Cough	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
574	DAY						
		Drug Administration Error		Vioxx	SS	Merck & Co., Inc	ORAL
474	DAY						
		Drug Interaction		Vioxx	SS	Merck & Co., Inc	ORAL
574	DAY						
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
474	DAY						
		Gouty Arthritis		Sulindac	SS		ORAL
		Headache		Prinivil	SS		ORAL
		Hypertension		Zocor	C		ORAL
		Loss Of Consciousness		Acetaminophen And			
		Neuropathy Peripheral		Propoxyphene			
		Phlebitis Superficial		Napsylate	C		
UNKNOWN							
		Postnasal Drip		Acetaminophen And			
		Radiculopathy		Propoxyphene			
		Spinal Column Stenosis		Napsylate	C		
UNKNOWN							
		Transient Ischaemic		Allopurinol	C		ORAL
		Attack		Allopurinol	C		ORAL
		Trigger Finger		Indomethacin	C		ORAL
		Urinary Tract Infection		Indomethacin	C		ORAL
				Lidocaine	C		
UNKNOWN							

Date:07/28/05ISR Number: 4727842-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00219
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	ORAL
	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides					
	Increased					
	Cardiac Failure					
	Congestive					
	Cerumen Impaction					
	Dizziness					

Eczema
Electrocardiogram
Repolarisation
Abnormality
Hypoacusis
Myocardial Infarction
Nasopharyngitis
Pulmonary Congestion
Renal Function Test
Abnormal

Date:07/28/05ISR Number: 4727843-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00238
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1906 DAY	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrooesophageal Reflux		Vioxx	SS	Merck & Co., Inc	ORAL		
1906 DAY								
	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glaucoma		Hydrocodone Bitartrate	C				
	Hypertension							
UNKNOWN							9	DAY
	Myocardial Infarction		Hydrocodone Bitartrate	C				
UNKNOWN							9	DAY

		Cyclobenzaprine Hydrochloride	C	UNKNOWN
		Cyclobenzaprine Hydrochloride	C	UNKNOWN
		Arthrotec	C	UNKNOWN

Date:07/28/05ISR Number: 4727844-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00223
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Erectile Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Glucose Tolerance		Vioxx	SS	Merck & Co., Inc	ORAL		
	Impaired		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Syncope		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727845-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04451
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		616 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1034 DAY
	Arthropathy		Norvasc	C		ORAL		1675 DAY
	Bradycardia		Hydrocodone Bitartrate	C				UNKNOWN
	Coronary Artery Disease							
	Coronary Artery Occlusion		Hytrin	C		ORAL		1675 DAY
	Intervertebral Disc		Prevacid	C		ORAL		1968 DAY

	Protrusion		Arava	C		ORAL
891 DAY						
	Myocardial Infarction		Asacol	C		ORAL
1696 DAY						
	Palpitations		Enbrel	C		
PARENTERAL						
			Lexapro	C		ORAL
			Levbid	C		ORAL
1483 DAY						
			Hydrodiuril	C		ORAL

Date:07/28/05ISR Number: 4727846-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02230
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
30 MON						
	Coronary Artery Disease		Glucophage	C		
UNKNOWN						
	Depression		Glucotrol Xl	C		
UNKNOWN						
	Dyspnoea		Actos	C		
UNKNOWN						
	Gastrooesophageal Reflux		Neurontin	C		
UNKNOWN						
	Disease					
	Heart Injury					
	Oedema Peripheral					
	Sleep Apnoea Syndrome					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727847-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01282
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Cardura	C			UNKNOWN	
	Coronary Artery Disease		Celebrex	C			UNKNOWN	
	Deafness Neurosensory		Toprol Xl Tablets	C			UNKNOWN	
	Drug Ineffective		Cardura	C			UNKNOWN	
	Dyspnoea		Diovan	C			UNKNOWN	
	Fibromyalgia		Viagra	C			UNKNOWN	
	Gastritis		Prednisone	C			UNKNOWN	
	Hypercholesterolaemia							
	Hypertension							
	Joint Sprain							
	Myalgia							
	Myocardial Infarction							
	Myositis							
	Osteoarthritis							
	Pain							
	Rash							
	Tinnitus							
	Upper Respiratory Tract Infection							

Date:07/28/05ISR Number: 4727848-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00239
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arrhythmia		Tylenol	C			UNKNOWN	
	Asthma							
	Coronary Artery Disease							
	Depression							

Dyspepsia
Dyspnoea
Headache
Loss Of Consciousness
Myocardial Infarction
Pain
Pain In Extremity

Date:07/28/05ISR Number: 4727849-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04290
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
Other	Atelectasis
	Bronchitis
	Cholelithiasis
	Coronary Artery Disease
	Deafness
	Depression
	Dyspnoea
	Folliculitis
	Hepatic Steatosis
	Hypoaesthesia
	Incision Site Complication

		Insomnia					
		Limb Injury					
		Localised Infection	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
54	DAY						
		Nasal Sinus Drainage		Vioxx	SS	Merck & Co., Inc	ORAL
88	DAY						
		Nausea		Glucovance	C		
UNKNOWN							
		Oedema Peripheral		Lipitor	C		
UNKNOWN		670 DAY					
		Otitis Media		Actos	C		
UNKNOWN							
		Pleural Effusion		Norvasc	C		
UNKNOWN		97 DAY					
		Sinusitis		Amitriptyline			
		Skin Lesion		Hydrochloride	C		
UNKNOWN							
		Sunburn		Neurontin	C		
UNKNOWN							
		Tinnitus		Zyrtec	C		
UNKNOWN							
		Vomiting		Flaxseed	C		
UNKNOWN							

Date:07/28/05ISR Number: 4727850-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02004
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Bladder Neoplasm					
	Blood Cholesterol					
	Increased					
	Dehydration					
	Depression					
	Gallbladder Disorder					
	Gastrooesophageal Reflux					
	Disease					
	Hypertension					
	Myocardial Infarction					
	Upper Limb Fracture					

Date:07/28/05ISR Number: 4727851-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03166
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Aortic Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Polytraumatism							

Date:07/28/05ISR Number: 4727852-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03250
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression							
	Hiatus Hernia							
	Muscle Strain							
	Oesophagitis							
	Pain							
	Pain In Extremity							
	Pruritus							
	Tooth Disorder							
	Vomiting							

Date:07/28/05ISR Number: 4727853-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727854-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03164
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Lower Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL		572 DAY
	Haemorrhage							
	Myocardial Infarction							

Date:07/28/05ISR Number: 4727855-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03156
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727856-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00018
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc		UNKNOWN	1034 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc		UNKNOWN	1034 DAY
			Alendronate Sodium	C			UNKNOWN	
			Aspirin And Magnesium Oxide	C			UNKNOWN	
			Raloxifene Hydrochloride	C			UNKNOWN	

				Estradiol And Norethindrone Acetate	C		
UNKNOWN							

Date:07/28/05ISR Number: 4727857-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03022
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727858-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03159
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727859-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02926
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727860-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507PRI00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
Other	Cardiovascular Disorder							
	Multi-Organ Disorder							
	Vascular Injury							

Date:07/28/05ISR Number: 4727861-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01421
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	218 DAY	
	Angiopathy		Aspirin	C			UNKNOWN	
	Cardiac Arrest		Aspirin	C			UNKNOWN	
	Cardiac Disorder		Aspirin	C			UNKNOWN	
	Cardiovascular Disorder		Aspirin	C			UNKNOWN	
	Carotid Artery Disease		Zocor	C		ORAL		
	Intestinal Functional Disorder							
	Lung Disorder							
	Myocardial Infarction							

Date:07/28/05ISR Number: 4727862-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03017
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727863-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03019
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727864-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03013
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727865-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03014
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727866-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03009
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727867-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03010
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727868-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727869-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03171
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727874-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03365
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727875-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03321
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727876-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03168
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged Other	Cardiac Disorder Cardiac Failure Congestive Cerebrovascular Accident Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727881-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03361
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:07/28/05ISR Number: 4727882-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727883-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03364
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:07/28/05ISR Number: 4727884-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03428
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C			UNKNOWN	
	Diplopia		Ambien	C			UNKNOWN	
	Hypertension		Alprazolam	C			UNKNOWN	
			Evista	C			UNKNOWN	
			Aciphex	C		ORAL		
			Dynacirc	C			UNKNOWN	
			Ranitidine	C			UNKNOWN	
			Hyzaar	C		ORAL		
			Dicyclomine Hydrochloride	C			UNKNOWN	
			Mevacor	C		ORAL		

Date:07/28/05ISR Number: 4727885-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03661
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727889-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03652
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727890-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03700
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727891-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03854
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Prescribed Overdose							

Date:07/28/05ISR Number: 4727892-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03695
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727893-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03326
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727895-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03856
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	59	DAY

Date:07/28/05ISR Number: 4727896-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03698
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727897-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03855
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	294	DAY

Date:07/28/05ISR Number: 4727898-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03363
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:07/28/05ISR Number: 4727899-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03362
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727900-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03858
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	174	DAY

Date:07/28/05ISR Number: 4727901-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03322
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:07/28/05ISR Number: 4727907-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03714
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/28/05ISR Number: 4727911-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00779
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Dyspepsia		Lipitor	C				
UNKNOWN								
	Fatigue		Lopressor	C				
UNKNOWN								
	Hypertensive Heart		Zestril	C				
UNKNOWN								
	Disease		Aspirin	C		ORAL		
	Myocardial Infarction							
	Sudden Cardiac Death							

Date:07/28/05ISR Number: 4727912-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02080
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Glucophage	C				
UNKNOWN								
	Dyspepsia		Enalapril Maleate	C				
UNKNOWN								
	Eye Disorder		Glucotrol	C				
UNKNOWN								
	Gastrointestinal Disorder		Aspirin	C				
UNKNOWN								
	Rheumatoid Arthritis		Tylenol	C				
UNKNOWN								
	Visual Acuity Reduced		Zocor	C		ORAL		

Date:07/28/05ISR Number: 4727925-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03650
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:07/28/05ISR Number: 4728169-XReport Type:Direct Company Report #CTU 254609
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx 25mg Merck &					
Required	Cartilage Injury		Co	PS	Merck & Co	ORAL	1-TAB DAILY	
Intervention to	Chest Pain						2-TAB DAIL	
Prevent Permanent	Cyst						ORAL	
Impairment/Damage	Fatigue							
	Ganglion							
	Generalised Oedema							
	Heart Rate Increased							
	Muscular Weakness							
	Swelling							

Date:07/29/05ISR Number: 4734810-8Report Type:Expedited (15-DaCompany Report #2005094600
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arthralgia
Initial or Prolonged	Chest Pain
Other	Convulsion
	Drug Dose Omission
	Dyskinesia
	Dyspepsia
	Extrapyramidal Disorder
	Fall

	Food Allergy						
	Food Interaction						
	Hormone Level Abnormal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Impaired Driving Ability	Consumer	Dilantin Kapseals				
	Intervertebral Disc Degeneration	Health Professional	(Phenytoin Sodium)	PS		ORAL	330 MG (2 IN 1 D), ORAL
	Muscle Twitching						
	Myocardial Infarction		Celebrex				
	Neck Injury						
	Neck Pain		(Celecoxib)	SS		ORAL	ORAL
	Obstructive Airways Disorder		Phenobarbital				
	Pain In Extremity		(Phenobarbital)	SS		ORAL	30 MG (1 IN 1 D)
	Palpitations						
	Pharmaceutical Product Complaint		Vioxx (Rofecoxib)	SS			
	Pharyngeal Oedema		Prempro	C			
	Pregnancy						
	Rash Generalised						
	Speech Disorder						
	Stress						
	Tachycardia						
	Temperature Intolerance						
	Treatment Noncompliance						
	Trigger Finger						
	Urticaria						

Date:08/01/05ISR Number: 4729479-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04049
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 50 DAY	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged			Aldactone	C			UNKNOWN
			Hydrochlorothiazide	C			UNKNOWN

Date:08/01/05ISR Number: 4729480-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03902
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729481-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	480	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	497	DAY

Date:08/01/05ISR Number: 4729482-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729483-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729484-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729485-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03903
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1254 DAY	

Date:08/01/05ISR Number: 4729486-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:08/01/05ISR Number: 4729487-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729489-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729491-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729493-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:08/01/05ISR Number: 4729494-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04251
Age: Gender:Female I/FU:I

Outcome	PT
Other	Cerebrovascular Accident
	Transient Ischaemic

Attack

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729495-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729496-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04063
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged			Plavix	C		
UNKNOWN						
			Norvasc	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Xanax	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729497-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729498-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729499-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729500-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Polytraumatism Pulmonary Embolism Pulmonary Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729501-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729502-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death Thrombosis							

Date:08/01/05ISR Number: 4729503-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729504-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03417
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balanitis		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
Initial or Prolonged	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	11	MON
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	3	MON
	Dysarthria		Vioxx	SS	Merck & Co., Inc	ORAL	11	MON
	Erectile Dysfunction		Zestril	C			UNKNOWN	
	Gastrooesophageal Reflux		Soma	C			UNKNOWN	

	Disease	Vicodin Tablets	C	UNKNOWN
	Headache	Aleve	C	UNKNOWN
	Hemiparesis	Tylenol	C	UNKNOWN
	Hepatic Steatosis	Valium	C	UNKNOWN
	Hiatus Hernia	Xanax	C	ORAL
	Hypertension			
	Hypoxic Encephalopathy			
	Loss Of Consciousness			
	Nocturia			
	Prostate Cancer			
	Pulmonary Embolism			
	Pulmonary Hypertension			
	Renal Cyst			
	Right Ventricular Failure			
	Syncope			
	Transient Ischaemic			
	Attack			
	Tremor			

Date:08/01/05ISR Number: 4729505-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729507-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Actinic Keratosis		Zestril	SS				UNKNOWN
Other	Alopecia		Isosorbide	C				UNKNOWN
	Anaemia		Cardura	C				UNKNOWN
	Angina Pectoris		Zocor	C		ORAL		
	Asthenia		Aspirin	C				UNKNOWN
	Atrial Fibrillation							
	Atrial Flutter							
	Blood Pressure Increased							
	Bradycardia							
	Chest Pain							
	Coccydynia							
	Colon Adenoma							
	Colonic Polyp							
	Convulsion							
	Coronary Artery Disease							
	Coronary Artery Insufficiency							
	Dizziness							
	Drug Ineffective							
	Duodenal Ulcer							
	Dyspnoea							
	Dyspnoea Exertional							
	Eczema							
	Gastritis							
	Gastrointestinal Arteriovenous Malformation							
	Hyperhidrosis							
	Hypotension							
	International Normalised Ratio Increased							
	Joint Sprain							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nasal Congestion							
	Nasal Polyps							

Neck Pain
Oedema Peripheral
Osteoarthritis
Postnasal Drip
Prothrombin Time
Prolonged
Pulmonary Congestion
Reflux Oesophagitis
Rhinitis
Rhinitis Allergic
Rhinorrhoea
Sinusitis
Skin Exfoliation
Skin Lesion
Sleep Disorder
Weight Decreased

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729508-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA00578
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Prevacid	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								

Date:08/01/05ISR Number: 4729509-8Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00015
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
1094 DAY								
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
9 DAY								

Date:08/01/05ISR Number: 4729510-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00230
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Aortic Valve Incompetence		Oxycodone	SS		ORAL		
39 MON								
	Atrial Fibrillation		Oxycodone	SS		ORAL		
39 MON								
	Blood Potassium Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Candidiasis		Aspirin	C				
UNKNOWN								
	Depression		Coumadin	C				
UNKNOWN								
	Embolic Stroke		Soma	C				
UNKNOWN								
	Hemianopia		Niacin	C				
UNKNOWN								
	Hypertension							
	Hyperthyroidism							
	Intestinal Perforation							

Myocardial Infarction

Date:08/01/05ISR Number: 4729511-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00746
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Depression		Effexor	C				UNKNOWN
	Hepatic Steatosis		Capoten	C		ORAL		
	Irritable Bowel Syndrome		Zocor	C		ORAL		
	Panic Disorder		Vicodin Tablets	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Glyburide	C				UNKNOWN
			Insulin Human, Isophane	C				SUBCUTANEOUS
			Insulin	C				UNKNOWN

Date:08/01/05ISR Number: 4729512-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02580
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Carpal Tunnel Syndrome		Toprol Xl Tablets	C		ORAL		
	Myocardial Infarction		Dyazide	C		ORAL		
	Prostate Cancer		Hydrochlorothiazide	C		ORAL		
			Aspirin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729513-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00785
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Infarction		Tylenol	C			UNKNOWN	
	Akinesia		Vitamins					
	Bronchitis		(Unspecified)	C			UNKNOWN	
	Cholelithiasis							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery Disease							
	Haematoma							
	Hernia							
	Insomnia							
	Myocardial Infarction							
	Pulmonary Congestion							
	Renal Cyst							
	Restlessness							

Date:08/01/05ISR Number: 4729514-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02894
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
	Abnormal		Actos	C			UNKNOWN	
	Cardiac Disorder		Hydrochlorothiazide	C			UNKNOWN	
	Cerebrovascular Accident		Glucovance	C			UNKNOWN	
	Depression		Norvasc	C			UNKNOWN	
	Emotional Distress		Zoloft	C			UNKNOWN	
	Fall		Diovan Hct	C			UNKNOWN	
	Hypertension		Lipitor	C			UNKNOWN	
	Ligament Injury							

Pain
Speech Disorder
Walking Aid User

Date:08/01/05ISR Number: 4729515-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety Disorder		Synthroid	C				
UNKNOWN								
	Cerebrovascular Accident		Fosamax	C		ORAL		
	Chest Pain		Evista	C				
UNKNOWN								
	Depression		Aspirin	C				
UNKNOWN								
	Dyspnoea		Premarin	C				
UNKNOWN								
	Hypercholesterolaemia		Prempro	C				
UNKNOWN								
	Hypoaesthesia		Tylenol	C				
UNKNOWN								
	Myocardial Infarction		Meprednisone	C				
UNKNOWN								
	Polytraumatism		Hydrocodone Bitartrate	C				
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729516-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability								

Date:08/01/05ISR Number: 4729517-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03410
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blister		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cardiac Failure		Lasix (Furosemide)	C				
UNKNOWN								
Initial or Prolonged	Congestive		Lasix (Furosemide)	C				
UNKNOWN								
Other	Cellulitis		Tylenol With Codeine #3	C				
UNKNOWN								
	Cerebral Infarction		Aldactone	C				
UNKNOWN								
	Cerebrovascular Accident		Metolazone	C				
UNKNOWN								
	Deep Vein Thrombosis		Vasotec	C				
UNKNOWN								
	Myocardial Infarction		Toprol Xl Tablets	C				
UNKNOWN								
	Pain In Extremity							
	Renal Failure							
	Sinusitis							
	Urinary Tract Infection							
	Venous Insufficiency							

Date:08/01/05ISR Number: 4729518-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04992
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	64	MON
Initial or Prolonged	Myocardial Infarction							

Date:08/01/05ISR Number: 4729519-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00217
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	53 MON	
	Increased		Nexium	C			UNKNOWN	
	Headache							
	Hypertension							
	Myocardial Infarction							

Date:08/01/05ISR Number: 4729520-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03889
Age:77 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Acute Myocardial Infarction
	Asthenia
	Blood Cholesterol Increased
	Coronary Artery Disease
	Crohn'S Disease
	Dehydration
	Diverticulum
	Gastritis

		Gastrooesophageal Reflux Disease					
		Hormone Level Abnormal	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hyperhidrosis		Vioxx	PS	Merck & Co., Inc	ORAL
39	MON						
		Hypotension		Vioxx	SS	Merck & Co., Inc	ORAL
39	MON						
		Iron Deficiency Anaemia		Lipitor	C		
UNKNOWN							
		Lower Gastrointestinal		Ketoconazole	C		
UNKNOWN							
		Haemorrhage		Viagra	C		
UNKNOWN							
		Small Intestinal		Casodex	C		
UNKNOWN							
		Obstruction		Atenolol	C		
UNKNOWN							
		Weight Decreased		Diovan	C		
UNKNOWN							
		Wrong Technique In Drug		Fosamax	C		ORAL
		Usage Process		Tylenol	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Zoladex	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Cozaar	C		
UNKNOWN		63 DAY					

Date:08/01/05ISR Number: 4729521-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00884
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Death		Celebrex	C		
UNKNOWN	20 DAY					
Other	Essential Tremor		Zocor	C		
UNKNOWN						
	Fall		Xanax	C		
UNKNOWN						

	Fatigue	Aspirin	C
UNKNOWN			
	Flatulence	Prempro	C
UNKNOWN			
	Haemorrhage Intracranial		
	Headache		
	Hypercholesterolaemia		
	Insomnia		
	Irritable Bowel Syndrome		
	Loss Of Consciousness		
	Osteoarthritis		
	Postmenopausal		
	Haemorrhage		
	Subarachnoid Haemorrhage		
	Urinary Incontinence		
	Urinary Tract Infection		
	Weight Increased		

Date:08/01/05ISR Number: 4729522-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03762
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
	Blood Cholesterol Increased
	Breast Abscess
	Cerebral Ischaemia
	Colonic Polyp
	Gastrooesophageal Reflux Disease
	Hiatus Hernia
	Hypertension
	Irritable Bowel Syndrome
	Lacunar Infarction

		Meniere'S Disease					
		Mitral Valve Incompetence					
		Mitral Valve Prolapse	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
23	DAY						
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Raynaud'S Phenomenon		Furosemide	C		ORAL
		Seasonal Allergy		Furosemide	C		ORAL
		Sinus Disorder		Entex Pse	C		ORAL
				Humibid L.A.	C		ORAL
				Daypro	C		ORAL
				Synthroid	C		ORAL

Date:08/01/05ISR Number: 4729523-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03341
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:08/01/05ISR Number: 4729524-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03338
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:08/01/05ISR Number: 4729525-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03340
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729526-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729527-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729528-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02780
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729529-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729530-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00609
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729531-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00566
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	29 MON	
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Hypertension		Diltiazem Hydrochloride	C			UNKNOWN	
	Metastatic Gastric Cancer		Neurontin	C			UNKNOWN	

Date:08/01/05ISR Number: 4729532-3Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00017
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Furosemide	C			UNKNOWN	

Date:08/01/05ISR Number: 4729533-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	203 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	SS		ORAL	227 DAY	

Date:08/01/05ISR Number: 4729535-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729536-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03245
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebral Cyst
	Chest Pain
Other	Deep Vein Thrombosis
	Dyspnoea
	Head Injury
	Headache
	Memory Impairment
	Myocardial Infarction

	Pallor Paraesthesia Paraesthesia Oral	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Celexa	SS			UNKNOWN
			Celebrex	SS			UNKNOWN
			Aspirin	C			UNKNOWN
			Vitamins (Unspecified)	C			UNKNOWN
			Calcium (Unspecified)	C			UNKNOWN

Date:08/01/05ISR Number: 4729537-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03260
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 470 DAY	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Increased Cough Dyspnoea Exertional Gastrointestinal Angiodysplasia Haemorrhagic Gastrooesophageal Reflux Disease Haemorrhoidal Haemorrhage Joint Sprain Mediastinal Disorder Pulmonary Embolism Rectal Haemorrhage Rhinitis Allergic Sinus Tachycardia Weight Increased						

Date:08/01/05ISR Number: 4729538-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729539-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03180
Age:58 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
	Aortic Valve Calcification
	Blood Ph Decreased
	Cardiomyopathy
	Chronic Obstructive Airways Disease Exacerbated
	Chronic Obstructive Pulmonary Disease
	Dilatation Atrial
	Dilatation Ventricular
	Drug Screen Positive
	Emphysema

		Hypertension					
		Hypoxia					
		Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Interstitial Lung Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Lung Neoplasm		Tessalon Perles	C		
UNKNOWN							
		Migraine		Guaifenesin	C		
UNKNOWN							
		Myocardial Infarction		Amoxicillin	C		
UNKNOWN							
		Pneumonia		Magnesium Oxide	C		
UNKNOWN							
		Pulmonary Arterial		Zyrtec	C		
UNKNOWN							
		Pressure Increased		Protonix	C		
UNKNOWN							
		Pulmonary Embolism		Tramadol Msd	C		
UNKNOWN							
		Pulmonary Mass		Normodyne	C		
UNKNOWN							
		Sinus Tachycardia		Advair	C		
UNKNOWN							
		Subendocardial Ischaemia		Albuterol	C		
UNKNOWN							
				Megace	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729540-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03336
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							

Date:08/01/05ISR Number: 4729541-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03335
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729542-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729543-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729544-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729545-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729546-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03357
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1203 DAY

Date:08/01/05ISR Number: 4729547-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1214 DAY
Other	Cerebrovascular Accident							
	Facial Palsy							
	Myocardial Infarction							

Date:08/01/05ISR Number: 4729554-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Pain		Synthroid	C				UNKNOWN
	Depression		Fosamax	C		ORAL		
	Dyspnoea		Evista	C				UNKNOWN
	Hypercholesterolaemia		Aspirin	C				UNKNOWN
	Hypoaesthesia		Premarin	C				UNKNOWN
	Myocardial Infarction		Prempro	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Meprednisone	C				UNKNOWN
			Hydrocodone					

			Bitartrate	C			
UNKNOWN							
			Hydrochlorothiazide	C			
UNKNOWN							

Date:08/01/05ISR Number: 4729555-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00810
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abnormal Clotting Factor Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
			Norvasc	C				
UNKNOWN								
Disability	Cerebrovascular Accident		Omeprazole	C				
UNKNOWN							178	DAY
Other	Chest Pain		Foltx	C				
UNKNOWN								
	Emotional Distress		Trazodone Hydrochloride	C				
	Face Injury							
UNKNOWN								
	Facial Bones Fracture		Nasonex	C				
UNKNOWN								
	Fibromyalgia		Lexapro	C				
UNKNOWN								
	Gallbladder Disorder		Gemfibrozil	C				
UNKNOWN								
	Gastrooesophageal Reflux		Baclofen	C				
UNKNOWN								
	Disease		Warfarin Sodium	C				
UNKNOWN								
	Nasal Operation		Hydroxychloroquine Sulfate	C				
	Pancreatitis							
UNKNOWN								
	Panic Attack		Ranitidine	C				
UNKNOWN								
	Panic Disorder		Lipitor	C				
UNKNOWN								
	Pulmonary Embolism		Cephalexin	C				
UNKNOWN								
	Road Traffic Accident		Depakote	C				
UNKNOWN								
	Skeletal Injury		Allegra	C				
UNKNOWN								
	Thrombosis		Alprazolam	C				
UNKNOWN								
	Transient Ischaemic		Prednisone	C				
UNKNOWN								
	Attack		Zyrtec	C				
UNKNOWN								
			Astelin	C				
UNKNOWN								

			Folbee	C		
UNKNOWN						
			Elocon	C		
UNKNOWN						
			Epi-Pen	C		
UNKNOWN						
			Darvocet-N	C		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729556-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02068
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Convulsion		Toprol Xl Tablets	C		ORAL		
Disability	Deep Vein Thrombosis		Toprol Xl Tablets	C		ORAL		
	Depression		Lisinopril	C		ORAL		
	Loss Of Consciousness		Insulin	C				
UNKNOWN								
	Neoplasm Malignant		Lipitor	C				
UNKNOWN								
	Polytraumatism		Clonidine	C				
UNKNOWN								
	Thyroid Disorder							
	Tuberculosis							

Date:08/01/05ISR Number: 4729557-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		211 DAY
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		211 DAY
Other	Cardiomyopathy		Coumadin	C				
UNKNOWN								
	Carotid Artery Stenosis		Celebrex	C				
UNKNOWN								

Cerebrovascular Accident
Drug Administration Error
Drug Hypersensitivity
Drug Ineffective
Fatigue
Haemorrhoids
Hemianopia
Hypertension
Hypoaesthesia
International Normalised
Ratio Decreased
International Normalised
Ratio Increased
Intracranial Aneurysm
Lumbar Spinal Stenosis
Radicular Pain
Sciatica
Visual Acuity Reduced

Date:08/01/05ISR Number: 4729558-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Angina Pectoris
	Arthralgia
	Back Pain
	Blood Pressure Increased
	Carotid Artery Occlusion

		Carotid Artery Stenosis					
		Carpal Tunnel Syndrome					
		Chronic Obstructive	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pulmonary Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Coronary Artery Disease		Flexeril	SS		ORAL
		Depression		Naproxen	SS		
UNKNOWN							
		Dizziness		Lortab	SS		
UNKNOWN							
		Drug Ineffective		Advil	C		
UNKNOWN							
		Dry Eye		Aleve	C		
UNKNOWN							
		Dry Skin		Mobic	C		
UNKNOWN							
		Dyslipidaemia		Tylenol	C		
UNKNOWN							
		Dyspepsia					
		Dysuria					
		Ear Disorder					
		Electrocardiogram St-T					
		Segment Abnormal					
		Eructation					
		Fatigue					
		Gastrooesophageal Reflux					
		Disease					
		Hypoacusis					
		Increased Tendency To					
		Bruise					
		Insomnia					
		Medication Error					
		Memory Impairment					
		Musculoskeletal Stiffness					
		Myocardial Ischaemia					
		Nausea					
		Neck Pain					
		Nocturia					
		Oedema Peripheral					
		Pain In Extremity					
		Polyuria					
		Sinus Congestion					
		Tension					
		Transient Ischaemic					
		Attack					
		Vertigo					

Vomiting
Xanthelasma

Date:08/01/05ISR Number: 4729559-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia
	Anaemia Macrocytic
	Anxiety
	Asthenia
	Back Injury
	Blood Triglycerides Increased
	Bronchitis
	Carotid Artery Disease
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive

	Pulmonary Disease						
	Compression Fracture						
	Depression						
	Drug Ineffective	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Haematochezia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Haematuria		Vioxx	SS	Merck & Co., Inc	ORAL	78	DAY
	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypercholesterolaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperhidrosis		Vioxx	SS	Merck & Co., Inc	ORAL	78	DAY
	Hypoaesthesia		Paxil	C			UNKNOWN	533 DAY
	Insomnia		Nexium	C			UNKNOWN	
	Migraine		Prednisone	C			UNKNOWN	
	Myofascial Pain Syndrome		Zovirax	C			UNKNOWN	
	Nausea		Zyrtec	C			UNKNOWN	
	Neck Pain		Trimox	C			UNKNOWN	
	Neoplasm Malignant		Celebrex	C			UNKNOWN	
	Pain In Extremity		Plavix	C		ORAL		
	Pharyngolaryngeal Pain							
	Rash							
	Red Blood Cell							
	Sedimentation Rate							
	Increased							
	Rhinitis Allergic							
	Sinusitis							
	Stress							
	Suprapubic Pain							
	Thrombocytopenia							
	Transient Ischaemic							
	Attack							

Date:08/01/05ISR Number: 4729560-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01875
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
4 MON						
Hospitalization - Initial or Prolonged	Congestive Coronary Artery		Vioxx Procardia	SS C	Merck & Co., Inc	ORAL
UNKNOWN						
	Thrombosis		Altace	C		
UNKNOWN						
	Death		Etodolac	C		
UNKNOWN	74 DAY					
	Depression					
	Fatigue					
	Heart Rate Irregular					
	Myocardial Infarction					
	Nausea					
	Oedema Peripheral					
	Sepsis					

Date:08/01/05ISR Number: 4729561-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00623
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
	Angina Pectoris					
	Blood Pressure Increased					
	Convulsion					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729565-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02113
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Ziac	C				
UNKNOWN								
	Increased		Aspirin	C				
UNKNOWN								
	Depression							
	Herpes Zoster							
	Hypertension							
	Myocardial Infarction							
	Pain							
	Pneumonia							

Date:08/01/05ISR Number: 4729566-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Estradiol	C		ORAL		
	Atrioventricular Block		Tylenol	C				
UNKNOWN								
	Complete		Provera	C		ORAL		
	Cervical Dysplasia		Synthroid	C		ORAL		
	Coronary Artery Disease							
	Fall							
	Haematuria							
	Haemorrhoids							
	Hyperlipidaemia							
	Intervertebral Disc							
	Degeneration							
	Osteoarthritis							
	Rash							
	Rectal Haemorrhage							
	Road Traffic Accident							
	Scoliosis							
	Shoulder Pain							
	Spinal Column Stenosis							
	Spinal Compression							
	Fracture							

Spinal Osteoarthritis
Toe Deformity
Urinary Tract Infection
Uterine Leiomyoma
Ventricular Fibrillation

Date:08/01/05ISR Number: 4729570-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01232
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blindness Unilateral
Disability	Blood Cholesterol Increased
	Chest Pain
	Fat Embolism
	Headache
	Hypertension
	Retinal Artery Embolism
	Retinal Artery Occlusion
	Retinal Haemorrhage

	Thrombosis Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1005 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	1005 DAY
			Methotrexate	C			UNKNOWN
			Prednisone	C			UNKNOWN
			Prednisone	C			UNKNOWN
			Prevacid	C			UNKNOWN
			Diflunisal	C			UNKNOWN

Date:08/01/05ISR Number: 4729571-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01335
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3 DAY
Initial or Prolonged	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL	386 DAY
Disability	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery Occlusion		Lipitor	C		ORAL	
	Diabetes Mellitus		Depakote	C		ORAL	
	Non-Insulin-Dependent		Lorazepam	C		ORAL	
	Hyperthyroidism						
	Myocardial Infarction						
	Tachycardia						
	Thyroiditis						
	Urinary Tract Infection						

Date:08/01/05ISR Number: 4729575-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729576-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729577-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729578-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01261
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
	Atherosclerosis
	Blood Cholesterol Increased
	Cardiac Disorder
	Cataract

	Coronary Artery Disease						
	Dyspnoea						
	Fluid Retention	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Heart Rate Irregular		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Oedema		Atenolol	C			UNKNOWN	
	Osteoporosis							
	Swelling							

Date:08/01/05ISR Number: 4729579-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05011
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Atrial Fibrillation		Zithromax	C				
	Blood Sodium Decreased		Gani-Tuss Dm Nr	C				
	Cardiac Failure		Tussafed	C				
	Congestive		Zocor	C				
	Cardiomegaly		Warfarin	C				
	Coronary Artery Disease		Digitek	C				
	Coronary Artery Occlusion		Amiodarone Msd	C				
	Facial Spasm		Altace	C				
	Hyperlipidaemia		Demadex	C				
	Mitral Valve Incompetence		Ssd And Ssd Af Cream	C				
	Myocardial Infarction		Fe-Tinic	C				
	Pleural Effusion		Metoprolol-Bc	C				
	Pulmonary Embolism							
	Respiratory Failure							

Respiratory Tract
Irritation

Date:08/01/05ISR Number: 4729580-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02799
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	65	MON
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vitamins (Unspecified)	C			UNKNOWN	
			Humira	C			UNKNOWN	
			Percocet	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

Date:08/01/05ISR Number: 4729581-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00135
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Allopurinol	C		ORAL		
Other	Hyperlipidaemia		Methocarbamol	C		ORAL		
	Pineal Germinoma							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729582-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01309
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Toprol Xl Tablets	C				UNKNOWN
Other	Diabetes Mellitus		Diovan	C				UNKNOWN
	Dyspepsia		Tylenol	C				UNKNOWN
	Hyperkalaemia		Paxil	C				UNKNOWN
	Hypertension		Buspar	C				UNKNOWN
	Insomnia		Potassium Chloride	C				UNKNOWN
	Myocardial Infarction		Hydrochlorothiazide	C				UNKNOWN
	Osteoporosis		Klonopin	C				UNKNOWN
	Panic Attack		Aspirin	C				UNKNOWN

Date:08/01/05ISR Number: 4729583-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729584-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00232
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL	167 YR	
Other	Hyperplasia		Verapamil	C				UNKNOWN
	Cardiac Valve Disease		Zocor	C		ORAL		

	Death		Flunisolide	C			
UNKNOWN							
	Hyperlipidaemia		Aspirin	C			ORAL
	Hypertension						
	Myocardial Infarction						
	Myocardial Ischaemia						
	Orthopnoea						
	Vulval Disorder						
	Weight Increased						

Date:08/01/05ISR Number: 4729585-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Aspirin	C				
UNKNOWN								
	Blood Triglycerides							
	Increased							
	Cerebral Artery Occlusion							
	Mood Altered							

Date:08/01/05ISR Number: 4729586-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729587-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01273
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		55 MON
Initial or Prolonged	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
Disability	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
Other	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
	Carotid Artery Stenosis		Neurontin	C				UNKNOWN
	Cerebrovascular Accident		Allegra	C				UNKNOWN
	Chest Discomfort		Flonase	C				UNKNOWN
	Coronary Artery Disease		Humibid	C				UNKNOWN
	Depression		Atenolol	C				UNKNOWN
	Fatigue		Tylenol	C				UNKNOWN
	Gastrooesophageal Reflux		Lanoxin	C				UNKNOWN
	Disease		Lanoxin	C				UNKNOWN
	Headache		Altace	C				UNKNOWN
	Hernia Repair		Diovan	C				UNKNOWN
	Hypertension		Restoril	C				UNKNOWN
	Nausea		Tricor	C				UNKNOWN
	Pain							
	Personality Change							
	Polytraumatism							
	Suicide Attempt							

Date:08/01/05ISR Number: 4729588-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729589-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Nervous System Disorder							

Date:08/01/05ISR Number: 4729590-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729591-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nerve Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729592-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03286
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729593-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729594-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03328
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729599-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03902
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729600-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03417
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balanitis		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
Initial or Prolonged	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	11 MON	
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	3 MON	
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	11 MON	
	Dysarthria		Zestril	C			UNKNOWN	
	Erectile Dysfunction		Soma	C			UNKNOWN	
	Gastrooesophageal Reflux		Vicodin Tablets	C			UNKNOWN	

	Disease	Aleve	C	
UNKNOWN				
	Headache	Tylenol	C	
UNKNOWN				
	Hemiparesis	Valium	C	
UNKNOWN				
	Hepatic Steatosis	Xanax	C	ORAL
	Hiatus Hernia			
	Hypertension			
	Hypoxic Encephalopathy			
	Loss Of Consciousness			
	Nocturia			
	Prostate Cancer			
	Pulmonary Embolism			
	Pulmonary Hypertension			
	Renal Cyst			
	Right Ventricular Failure			
	Syncope			
	Transient Ischaemic			
	Attack			
	Tremor			

Date:08/01/05ISR Number: 4729601-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	480 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	497 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729602-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729603-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729604-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03903
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1254 DAY	

Date:08/01/05ISR Number: 4729605-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	203 DAY	
	Pharmaceutical Product		Vioxx	SS	Merck & Co., Inc	ORAL		
	Complaint		Celebrex	SS		ORAL	227 DAY	
	Polytraumatism							

Date:08/01/05ISR Number: 4729606-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729607-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729609-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729611-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729612-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Pulmonary Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729613-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729615-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729616-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04063
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Plavix	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Xanax	C			UNKNOWN	

Date:08/01/05ISR Number: 4729617-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04049
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	50 DAY	
Initial or Prolonged			Aldactone	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

Date:08/01/05ISR Number: 4729618-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729619-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729621-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00099
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Tolerance Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyslipidaemia		Zocor	C		ORAL		
	Fatigue		Procardia	C			UNKNOWN	
	Gastric Ulcer		Norvasc	C			UNKNOWN	
	Haemorrhoids		Lotensin	C			UNKNOWN	
	Hypokalaemia		Atenolol	C			UNKNOWN	
	Injury		Bumetanide	C			UNKNOWN	
	Joint Injury		K-Tab	C			UNKNOWN	
	Labile Hypertension		Prempro	C			UNKNOWN	
	Mass		Celebrex	C			UNKNOWN	
	Mitral Valve Incompetence		Coumadin	C			UNKNOWN	
	Oedema		Coumadin	C			UNKNOWN	
	Palpitations		Coumadin	C			UNKNOWN	
	Phlebitis		Coumadin	C			UNKNOWN	
	Thrombosis		Aspirin	C			UNKNOWN	
	Tricuspid Valve		Tylenol	C			UNKNOWN	
	Incompetence		Hydralazine	C			UNKNOWN	
	Umbilical Hernia							
	Weight Increased							

Date:08/01/05ISR Number: 4729625-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	480 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	497 DAY	

Date:08/01/05ISR Number: 4729626-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01974
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Disability	Asthma
Other	Blood Glucose Increased
	Cardiac Disorder
	Cardiac Failure Congestive
	Cardiac Murmur
	Cardiomegaly
	Chest Pain
	Convulsion
	Depression
	Diabetes Mellitus
	Drug Hypersensitivity
	Dyspnoea
	Heart Rate Irregular
	Hypertension
	Myocardial Infarction
	Obesity
	Obsessive-Compulsive Disorder
	Oedema Peripheral
	Rheumatoid Arthritis

	Stomach Discomfort						
	Stress						
	Thrombosis	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729627-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01433
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Coronary Artery Disease		Zocor	C		ORAL	UNKNOWN	
			Plavix	C			UNKNOWN	
			Viagra	C			UNKNOWN	
			Cephalexin	C			UNKNOWN	
			Dextrose	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Zestoretic	C		ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	20 YR

Date:08/01/05ISR Number: 4729628-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00230
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Aortic Valve Incompetence		Oxycodone	SS		ORAL
39 MON						
	Atrial Fibrillation		Oxycodone	SS		ORAL
39 MON						
	Blood Potassium Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
	Candidiasis		Aspirin	C		
UNKNOWN						
	Depression		Coumadin	C		
UNKNOWN						
	Embolic Stroke		Soma	C		
UNKNOWN						
	Hemianopia		Niacin	C		
UNKNOWN						
	Hypertension					
	Hyperthyroidism					
	Intestinal Perforation					
	Myocardial Infarction					

Date:08/01/05ISR Number: 4729629-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					
Disability						

Date:08/01/05ISR Number: 4729630-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00884
Age:73 YR Gender:Female I/FU:F

Outcome
Death
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Death		Celebrex	C			UNKNOWN	20 DAY
Essential Tremor		Zocor	C			UNKNOWN	
Fall		Xanax	C			UNKNOWN	
Fatigue		Aspirin	C			UNKNOWN	
Haemorrhage Intracranial		Prempro	C			UNKNOWN	
Headache							
Hypercholesterolaemia							
Insomnia							
Irritable Bowel Syndrome							
Loss Of Consciousness							
Osteoarthritis							
Pneumonitis							
Postmenopausal							
Haemorrhage							
Urinary Incontinence							
Urinary Tract Infection							
Urine Analysis Abnormal							
Weight Increased							

Date:08/01/05ISR Number: 4729631-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00217
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	53 MON	
	Increased		Nexium	C			UNKNOWN	
	Headache							
	Hypertension							
	Myocardial Infarction							

Date:08/01/05ISR Number: 4729632-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03762
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		23 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Furosemide	C		ORAL		
	Breast Abscess		Furosemide	C		ORAL		
	Cerebral Ischaemia		Entex Pse	C		ORAL		
	Colonic Polyp		Humibid L.A.	C		ORAL		
	Gastrooesophageal Reflux		Daypro	C		ORAL		
	Disease		Synthroid	C		ORAL		
	Hiatus Hernia							
	Hypertension							
	Irritable Bowel Syndrome							
	Lacunar Infarction							
	Meniere'S Disease							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Oedema Peripheral							
	Osteoarthritis							
	Raynaud'S Phenomenon							
	Seasonal Allergy							
	Sinus Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729633-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03889
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		39 MON
Initial or Prolonged	Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL		39 MON
	Infarction		Lipitor	C				UNKNOWN
	Asthenia		Ketoconazole	C				UNKNOWN
	Blood Cholesterol		Viagra	C				UNKNOWN
	Increased		Casodex	C				UNKNOWN
	Coronary Artery Disease		Atenolol	C				UNKNOWN
	Crohn'S Disease		Diovan	C				UNKNOWN
	Dehydration		Fosamax	C		ORAL		
	Diverticulum		Tylenol	C				UNKNOWN
	Gastritis		Hydrochlorothiazide	C				UNKNOWN
	Gastrooesophageal Reflux		Zoladex	C				UNKNOWN
	Disease		Celebrex	C				UNKNOWN
	Hormone Level Abnormal		Cozaar	C				UNKNOWN
	Hyperhidrosis						63 DAY	
	Hypotension							
	Iron Deficiency Anaemia							
	Lower Gastrointestinal Haemorrhage							
	Small Intestinal Obstruction							
	Weight Decreased							
	Wrong Technique In Drug Usage Process							

Date:08/01/05ISR Number: 4729634-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729635-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729636-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729637-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729638-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729639-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02780
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729640-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00017
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Furosemide	C				
UNKNOWN								

Date:08/01/05ISR Number: 4729641-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729642-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00566
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	29 MON	
Hospitalization -	Cardiac Pacemaker		Diltiazem					

Initial or Prolonged	Insertion		Hydrochloride	C		
UNKNOWN						
	Cerebrovascular Accident		Neurontin	C		
UNKNOWN						
	Hypertension					
	Metastatic Gastric Cancer					

Date:08/01/05ISR Number: 4729643-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03410
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Blister		Lasix (Furosemide)	C		
UNKNOWN						
Initial or Prolonged	Cardiac Failure		Lasix (Furosemide)	C		
UNKNOWN						
Other	Congestive		Tylenol With Codeine			
	Cellulitis		#3	C		
UNKNOWN						
	Cerebral Infarction		Aldactone	C		
UNKNOWN						
	Cerebrovascular Accident		Metolazone	C		
UNKNOWN						
	Deep Vein Thrombosis		Vasotec	C		
UNKNOWN						
	Myocardial Infarction		Toprol Xl Tablets	C		
UNKNOWN						
	Pain In Extremity					
	Renal Failure					
	Sinusitis					
	Urinary Tract Infection					
	Venous Insufficiency					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729644-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00609
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Fall Gallbladder Disorder Gallbladder Operation Loss Of Consciousness		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729645-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:08/01/05ISR Number: 4729646-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729647-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729648-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Other	Death Thrombosis						

Date:08/01/05ISR Number: 4729649-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729651-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729654-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02580
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Increased		Toprol Xl Tablets	C		ORAL		
	Carpal Tunnel Syndrome		Dyazide	C		ORAL		
	Myocardial Infarction		Hydrochlorothiazide	C		ORAL		
	Prostate Cancer		Aspirin	C		ORAL		

Date:08/01/05ISR Number: 4729655-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00810
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Norvasc	C				UNKNOWN
Disability	Chest Pain		Omeprazole	C				UNKNOWN
							178 DAY	
Other	Emotional Distress		Foltx	C				UNKNOWN
	Face Injury		Trazodone Hydrochloride	C				UNKNOWN
	Facial Bones Fracture		Nasonex	C				UNKNOWN
	Fibromyalgia		Lexapro	C				UNKNOWN
	Gallbladder Disorder		Gemfibrozil	C				UNKNOWN
	Gastrooesophageal Reflux		Baclofen	C				UNKNOWN
	Disease		Warfarin Sodium	C				UNKNOWN
	Pancreatitis		Hydroxychloroquine Sulfate	C				UNKNOWN
	Panic Disorder		Ranitidine	C				UNKNOWN
	Pulmonary Embolism							
	Road Traffic Accident							

	Skeletal Injury	Lipitor	C
UNKNOWN			
	Thrombosis	Cephalexin	C
UNKNOWN			
	Transient Ischaemic	Depakote	C
UNKNOWN			
	Attack	Allegra	C
UNKNOWN			
		Alprazolam	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Zyrtec	C
UNKNOWN			
		Astelin	C
UNKNOWN			
		Folbee	C
UNKNOWN			
		Elocon	C
UNKNOWN			
		Epi-Pen	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			

Date:08/01/05ISR Number: 4729657-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
Other	Angina Pectoris
	Arthralgia
	Back Pain
	Blood Pressure Increased
	Carotid Artery Occlusion
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Chronic Obstructive Pulmonary Disease
	Constipation
	Coronary Artery Disease

		Depression					
		Dizziness					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dry Eye		Vioxx	PS	Merck & Co., Inc	ORAL
		Dry Skin		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyslipidaemia		Flexeril	SS		ORAL
		Dyspepsia		Naproxen	SS		
UNKNOWN							
		Dysuria		Lortab	SS		
UNKNOWN							
		Ear Disorder		Advil	C		
UNKNOWN							
		Electrocardiogram St-T		Aleve	C		
UNKNOWN							
		Segment Abnormal		Mobic	C		
UNKNOWN							
		Eructation		Tylenol	C		
UNKNOWN							
		Fatigue					
		Gastrooesophageal Reflux					
		Disease					
		Hypoacusis					
		Increased Tendency To					
		Bruise					
		Insomnia					
		Medication Error					
		Memory Impairment					
		Musculoskeletal Stiffness					
		Myocardial Ischaemia					
		Nausea					
		Neck Pain					
		Nocturia					
		Oedema Peripheral					
		Pain In Extremity					
		Polyuria					
		Sinus Congestion					
		Tension					
		Transient Ischaemic					
		Attack					
		Vertigo					
		Vomiting					
		Xanthelasma					

Date:08/01/05ISR Number: 4729658-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02894
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
			Actos	C			UNKNOWN	
	Cardiac Disorder		Hydrochlorothiazide	C			UNKNOWN	
	Cerebrovascular Accident		Glucovance	C			UNKNOWN	
	Depression		Norvasc	C			UNKNOWN	
	Emotional Distress		Zoloft	C			UNKNOWN	
	Fall		Diovan Hct	C			UNKNOWN	
	Hypertension		Lipitor	C			UNKNOWN	
	Ligament Injury							
	Pain							
	Speech Disorder							
	Walking Aid User							

Date:08/01/05ISR Number: 4729659-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL		211 DAY
Initial or Prolonged	Hyperplasia		Vioxx	SS	Merck & Co., Inc	ORAL		211 DAY
Other	Cardiomyopathy		Coumadin	C				UNKNOWN
	Carotid Artery Stenosis		Celebrex	C				UNKNOWN
	Cerebrovascular Accident							
	Drug Administration Error							
	Drug Hypersensitivity							
	Drug Ineffective							
	Fatigue							
	Haemorrhoids							
	Hemianopia							
	Hypertension							
	Hypoaesthesia							
	International Normalised							
	Ratio Decreased							
	International Normalised							
	Ratio Increased							
	Intracranial Aneurysm							
	Lumbar Spinal Stenosis							
	Radicular Pain							
	Sciatica							
	Visual Acuity Reduced							

Date:08/01/05ISR Number: 4729660-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02068
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Convulsion		Toprol Xl Tablets	C		ORAL		
Disability	Deep Vein Thrombosis		Toprol Xl Tablets	C		ORAL		
	Depression		Lisinopril	C		ORAL		
	Neoplasm Malignant		Insulin	C				UNKNOWN

	Thyroid Disorder	Lipitor	C
UNKNOWN			
	Tuberculosis	Clonidine	C
UNKNOWN			

Date:08/01/05ISR Number: 4729661-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Actinic Keratosis
Other	Alopecia
	Anaemia
	Angina Pectoris
	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Blood Pressure Increased
	Bradycardia
	Chest Pain
	Coccydynia
	Colon Adenoma
	Colonic Polyp
	Convulsion
	Coronary Artery Disease
	Coronary Artery

		Insufficiency					
		Dizziness					
		Drug Ineffective					
		Duodenal Ulcer	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Dyspnoea Exertional		Zestril	SS		
UNKNOWN							
		Eczema		Isosorbide	C		
UNKNOWN							
		Gastritis		Cardura	C		
UNKNOWN							
		Gastrointestinal		Zocor	C		ORAL
		Arteriovenous		Aspirin	C		
UNKNOWN							
		Malformation					
		Hyperhidrosis					
		Hypotension					
		International Normalised					
		Ratio Increased					
		Joint Sprain					
		Myocardial Infarction					
		Myocardial Ischaemia					
		Nasal Congestion					
		Nasal Polyps					
		Neck Pain					
		Oedema Peripheral					
		Osteoarthritis					
		Postnasal Drip					
		Prothrombin Time					
		Prolonged					
		Pulmonary Congestion					
		Reflux Oesophagitis					
		Rhinitis					
		Rhinitis Allergic					
		Rhinorrhoea					
		Sinusitis					
		Skin Exfoliation					
		Skin Lesion					
		Sleep Disorder					
		Weight Decreased					

Date:08/01/05ISR Number: 4729662-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety Disorder		Synthroid	C				
UNKNOWN								
	Cerebrovascular Accident		Fosamax	C		ORAL		
	Chest Pain		Evista	C				
UNKNOWN								
	Depression		Aspirin	C				
UNKNOWN								
	Dyspnoea		Premarin	C				
UNKNOWN								
	Hypercholesterolaemia		Prempro	C				
UNKNOWN								
	Hypoaesthesia		Tylenol	C				
UNKNOWN								
	Myocardial Infarction		Meprednisone	C				
UNKNOWN								
	Pain		Hydrocodone Bitartrate	C				
	Polytraumatism							
UNKNOWN								
			Hydrochlorothiazide	C				
UNKNOWN								

Date:08/01/05ISR Number: 4729663-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01875
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization - Initial or Prolonged	Congestive Coronary Artery		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Procardia	C				
	Thrombosis		Altace	C			UNKNOWN	
	Death		Etodolac	C				
	Depression						UNKNOWN	74 DAY
	Fatigue							
	Heart Rate Irregular							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Sepsis							
	Swelling							

Date:08/01/05ISR Number: 4729664-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04992
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	64	MON
	Myocardial Infarction							

Date:08/01/05ISR Number: 4729666-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia
	Anaemia Macrocytic
	Anxiety
	Asthenia
	Back Injury
	Blood Triglycerides

Increased
Bronchitis
Carotid Artery Disease
Cerebrovascular Accident
Chest Pain
Chronic Obstructive
Pulmonary Disease
Compression Fracture
Depression
Drug Ineffective
Dyspnoea
Haematochezia
Haematuria
Headache
Hypercholesterolaemia
Hyperhidrosis
Hypoaesthesia
Insomnia
Migraine
Myofascial Pain Syndrome
Nausea
Neck Pain
Neoplasm Malignant
Pain In Extremity

		Pharyngolaryngeal Pain					
		Rash					
		Red Blood Cell	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sedimentation Rate		Vioxx	PS	Merck & Co., Inc	ORAL
		Increased		Vioxx	SS	Merck & Co., Inc	ORAL
		Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
		Suprapubic Pain		Vioxx	SS	Merck & Co., Inc	ORAL
78	DAY						
		Thrombocytopenia		Paxil	C		
UNKNOWN		533 DAY					
		Transient Ischaemic		Nexium	C		
UNKNOWN							
		Attack		Prednisone	C		
UNKNOWN							
				Zovirax	C		
UNKNOWN							
				Zyrtec	C		
UNKNOWN							
				Trimox	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Plavix	C		ORAL

Date:08/01/05ISR Number: 4729668-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00623
Age: Gender: I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Angina Pectoris					
		Blood Pressure Increased					
		Convulsion					

Date:08/01/05ISR Number: 4729669-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00746
Age:59 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
33 MON						
Initial or Prolonged	Depression		Effexor	C		
UNKNOWN						
	Hepatic Steatosis		Capoten	C		ORAL
	Irritable Bowel Syndrome		Zocor	C		ORAL
	Panic Disorder		Vicodin Tablets	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Glucophage	C		
UNKNOWN						
			Glyburide	C		
UNKNOWN						
			Insulin Human, Isophane	C		
SUBCUTANEOUS						
			Insulin	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729670-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00015
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1094 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	9	DAY

Date:08/01/05ISR Number: 4729671-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00785
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Akinesia
Initial or Prolonged	Bronchitis
	Cholelithiasis

		Chronic Obstructive Pulmonary Disease					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL
8	MON						
		Hernia		Tylenol	C		
UNKNOWN							
		Myocardial Infarction		Vitamins			
		Pulmonary Congestion		(Unspecified)	C		
UNKNOWN							
		Renal Cyst					

Date:08/01/05ISR Number: 4729674-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03180
Age:58 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Cardiomyopathy		Tessalon Perles	C		
UNKNOWN							
		Chronic Obstructive		Guaifenesin	C		
UNKNOWN							
		Pulmonary Disease		Amoxicillin	C		
UNKNOWN							
		Hypertension		Magnesium Oxide	C		
UNKNOWN							
		Migraine		Zyrtec	C		
UNKNOWN							
		Myocardial Infarction		Protonix	C		
UNKNOWN							
		Pneumonia		Tramadol Msd	C		
UNKNOWN							
				Normodyne	C		
UNKNOWN							
				Advair	C		
UNKNOWN							
				Albuterol	C		
UNKNOWN							
				Megace	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729675-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03260
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cough		Vioxx	PS	Merck & Co., Inc	ORAL		470 DAY
Initial or Prolonged	Dyspnoea Exertional							
	Gastrooesophageal Reflux Disease							
	Joint Sprain							
	Pulmonary Embolism							
	Rectal Haemorrhage							
	Rhinitis Allergic							
	Weight Increased							

Date:08/01/05ISR Number: 4729676-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03245
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Celexa	SS				UNKNOWN
Other	Deep Vein Thrombosis		Celebrex	SS				UNKNOWN
	Dyspnoea		Aspirin	C				UNKNOWN
	Head Injury		Vitamins (Unspecified)	C				UNKNOWN
	Headache							
	Memory Impairment		Calcium (Unspecified)	C				UNKNOWN
	Myocardial Infarction							
	Pallor							
	Paraesthesia							
	Paraesthesia Oral							
	Scar							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729677-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nerve Injury Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729678-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729679-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03328
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729680-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729681-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729682-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729683-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729684-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729685-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03357
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1203 DAY

Date:08/01/05ISR Number: 4729686-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729687-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Limb Discomfort							

Date:08/01/05ISR Number: 4729688-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1214 DAY
Other	Cerebrovascular Accident							
	Facial Palsy							
	Myocardial Infarction							
	Polytraumatism							

Date:08/01/05ISR Number: 4729689-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729690-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729691-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	

Date:08/01/05ISR Number: 4729693-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA00578
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Other			Prevacid	C			UNKNOWN	
			Prednisone	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729701-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01974
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Glucose Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure							
	Congestive							
	Cardiac Murmur							
	Cardiomegaly							
	Chest Pain							
	Convulsion							
	Depression							
	Diabetes Mellitus							
	Drug Hypersensitivity							
	Dyspnoea							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							
	Obesity							
	Obsessive-Compulsive							
	Disorder							
	Oedema Peripheral							
	Polytraumatism							
	Rheumatoid Arthritis							
	Stomach Discomfort							
	Stress							
	Thrombosis							

Date:08/01/05ISR Number: 4729703-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729704-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729705-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729706-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729707-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/01/05ISR Number: 4729708-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00135
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Allopurinol	C		ORAL		
Other	Hyperlipidaemia		Methocarbamol	C		ORAL		
	Pineal Germinoma							
	Transient Ischaemic Attack							

Date:08/01/05ISR Number: 4729709-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01261
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		45 MON
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		45 MON
	Atherosclerosis		Atenolol	C				UNKNOWN
	Blood Cholesterol Increased							
	Cardiac Disorder							
	Cataract							
	Cataract Operation							
	Chest Pain							
	Coronary Artery Disease							
	Dyspnoea							
	Fluid Retention							
	Heart Rate Irregular							
	Hypertension							
	Oedema							

Osteoporosis

Date:08/01/05ISR Number: 4729710-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729711-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02113
Age:47 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthropathy
	Blood Cholesterol Increased
	Depression
	Herpes Zoster
	Hypertension
	Myocardial Infarction
	Pain
	Pneumonia

Polytraumatism

		Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
			Vioxx	PS	Merck & Co., Inc	ORAL
			Ziac	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729712-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01433
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
45 MON						
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
45 MON						
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
45 MON						
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
45 MON						
	Coronary Artery Disease		Zocor	C		ORAL
			Plavix	C		
UNKNOWN						
			Viagra	C		
UNKNOWN						
			Cephalexin	C		
UNKNOWN						
			Dextrose	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Zestoretic	C		ORAL
			Aspirin	C		
UNKNOWN	20 YR					

Date:08/01/05ISR Number: 4729713-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01335
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Hospitalization - 3 DAY	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 386 DAY	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Occlusion		Lipitor	C		ORAL
	Diabetes Mellitus		Depakote	C		ORAL
	Non-Insulin-Dependent		Lorazepam	C		ORAL
	Fatigue					
	Hyperthyroidism					
	Mood Altered					
	Myocardial Infarction					
	Respiratory Distress					
	Tachycardia					
	Thyroiditis					
	Urinary Tract Infection					

Date:08/01/05ISR Number: 4729714-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02799
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other 65 MON	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vitamins (Unspecified)	C		
UNKNOWN						
			Humira	C		
UNKNOWN						
			Percocet	C		
UNKNOWN						
			Vicodin Tablets	C		
UNKNOWN						
			Naproxen	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729715-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Estradiol	C		ORAL		
	Atrioventricular Block		Tylenol	C				
UNKNOWN								
	Complete		Provera	C		ORAL		
	Cervical Dysplasia		Synthroid	C		ORAL		
	Coronary Artery Disease							
	Fall							
	Haematuria							
	Haemorrhoids							
	Hyperlipidaemia							
	Intervertebral Disc Degeneration							
	Osteoarthritis							
	Rash							
	Rectal Haemorrhage							
	Road Traffic Accident							
	Scoliosis							
	Shoulder Pain							
	Spinal Column Stenosis							
	Spinal Compression Fracture							
	Spinal Osteoarthritis							
	Toe Deformity							
	Urinary Tract Infection							
	Uterine Leiomyoma							
	Ventricular Fibrillation							

Date:08/01/05ISR Number: 4729716-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01232
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL		1005 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		1005 DAY
Disability	Increased		Methotrexate	C				
UNKNOWN								

	Chest Pain	Prednisone	C
UNKNOWN			
	Fat Embolism	Prednisone	C
UNKNOWN			
	Headache	Prevacid	C
UNKNOWN			
	Hypertension	Diflunisal	C
UNKNOWN			
	Retinal Artery Embolism		
	Retinal Artery Occlusion		
	Retinal Haemorrhage		
	Thrombosis		
	Transient Ischaemic		
	Attack		

Date:08/01/05ISR Number: 4729717-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05011
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Atrial Fibrillation
	Blood Sodium Decreased
	Cardiac Failure
	Congestive
	Coronary Artery Disease

		Facial Spasm					
		Hyperlipidaemia					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Effusion		Vioxx	PS	Merck & Co., Inc	ORAL
		Pulmonary Embolism		Zithromax	C		
UNKNOWN							
		Respiratory Failure		Gani-Tuss Dm Nr	C		
UNKNOWN							
		Respiratory Tract		Tussafed	C		
UNKNOWN							
		Irritation		Zocor	C		
UNKNOWN							
				Warfarin	C		
UNKNOWN							
				Digitek	C		
UNKNOWN							
				Amiodarone Msd	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Demadex	C		
UNKNOWN							
				Ssd And Ssd Af Cream	C		
UNKNOWN							
				Fe-Tinic	C		
UNKNOWN							
				Metoprolol-Bc	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729718-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03286
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729719-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00232
Age:74 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Death	Benign Prostatic	Vioxx	PS	Merck & Co., Inc	ORAL
167 YR					
Other	Hyperplasia	Verapamil	C		
UNKNOWN					
	Cardiac Valve Disease	Zocor	C		ORAL
	Death	Flunisolide	C		
UNKNOWN					
	Dyspnoea	Aspirin	C		ORAL
	Hyperlipidaemia				
	Hypertension				
	Myocardial Infarction				
	Myocardial Ischaemia				
	Orthopnoea				
	Vulval Disorder				
	Weight Increased				

Date:08/01/05ISR Number: 4729720-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01273
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anhedonia
Disability	Cardiac Disorder
Other	Carotid Artery Stenosis
	Cerebrovascular Accident
	Chest Discomfort
	Condition Aggravated
	Coronary Artery Disease
	Depression
	Facial Palsy
	Gastrooesophageal Reflux
	Disease
	Headache

		Hernia Repair					
		Hypertension					
		Hypoaesthesia Oral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Malaise		Vioxx	PS	Merck & Co., Inc	ORAL
55	MON						
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
55	MON						
		Personality Change Due To		Vioxx	SS	Merck & Co., Inc	ORAL
55	MON						
		A General Medical		Vioxx	SS	Merck & Co., Inc	ORAL
55	MON						
		Condition		Neurontin	C		
UNKNOWN							
		Suicide Attempt		Allegra	C		
UNKNOWN							
				Flonase	C		
UNKNOWN							
				Humibid	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Diovan	C		
UNKNOWN							
				Restoril	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729721-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL

	Aortic Atherosclerosis		Aspirin	C		
UNKNOWN						
	Aphasia					
	Blood Pressure Increased					
	Blood Triglycerides					
	Increased					
	Cerebral Artery Occlusion					
	Hemiparesis					
	Ischaemic Stroke					
	Mood Altered					

Date:08/01/05ISR Number: 4729722-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01309
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Depression		Toprol Xl Tablets	C		
UNKNOWN						
Other	Diabetes Mellitus		Diovan	C		
UNKNOWN						
	Dyspepsia		Tylenol	C		
UNKNOWN						
	Hyperkalaemia		Paxil	C		
UNKNOWN						
	Hypertension		Buspar	C		
UNKNOWN						
	Insomnia		Potassium Chloride	C		
UNKNOWN						
	Myocardial Infarction		Hydrochlorothiazide	C		
UNKNOWN						
	Osteoporosis		Klonopin	C		
UNKNOWN						
	Panic Attack		Aspirin	C		
UNKNOWN						
	Polytraumatism					

Date:08/01/05ISR Number: 4729726-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04049
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
50 DAY						
Initial or Prolonged			Aldactone	C		
UNKNOWN						

Hydrochlorothiazide C
UNKNOWN

Date:08/01/05ISR Number: 4729727-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729728-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03998
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729729-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03913
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	203 DAY	
	Pharmaceutical Product		Vioxx	SS	Merck & Co., Inc	ORAL		
	Complaint		Celebrex	SS		ORAL	227 DAY	
	Polytraumatism							

Date:08/01/05ISR Number: 4729730-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04240
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729731-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04237
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729733-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729734-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04250
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:08/01/05ISR Number: 4729735-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03997
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729736-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03999
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Polytraumatism Pulmonary Embolism Pulmonary Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729738-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04063
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Plavix	C			UNKNOWN	
			Norvasc	C			UNKNOWN	
			Zoloft	C			UNKNOWN	
			Xanax	C			UNKNOWN	

Date:08/01/05ISR Number: 4729740-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00623
Age: Gender: I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Angina Pectoris Blood Pressure Increased Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729748-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00099
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Chest Discomfort	Vioxx	SS	Merck & Co., Inc	ORAL
	Coronary Artery Disease	Vioxx	SS	Merck & Co., Inc	ORAL
	Drug Tolerance Decreased	Vioxx	SS	Merck & Co., Inc	ORAL
	Dyslipidaemia	Zocor	C		ORAL
	Fatigue	Procardia	C		
UNKNOWN					
	Gastric Ulcer	Norvasc	C		
UNKNOWN					
	Haemorrhoids	Lotensin	C		
UNKNOWN					
	Hypokalaemia	Atenolol	C		
UNKNOWN					
	Joint Injury	Bumetanide	C		
UNKNOWN					
	Labile Hypertension	K-Tab	C		
UNKNOWN					
	Mass	Prempro	C		
UNKNOWN					
	Mitral Valve Incompetence	Celebrex	C		
UNKNOWN					
	Oedema	Coumadin	C		
UNKNOWN					
	Palpitations	Coumadin	C		
UNKNOWN					
	Phlebitis	Coumadin	C		
UNKNOWN					
	Thrombosis	Coumadin	C		
UNKNOWN					
	Tricuspid Valve	Aspirin	C		
UNKNOWN					
	Incompetence	Tylenol	C		
UNKNOWN					
	Umbilical Hernia	Hydralazine	C		
UNKNOWN					
	Weight Increased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729753-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03908
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729754-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/01/05ISR Number: 4729755-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03417
Age:66 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balanitis		Vioxx	PS	Merck & Co., Inc	ORAL	3 MON	
Initial or Prolonged	Chronic Fatigue Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL	11 MON	
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL	3 MON	
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL	11 MON	
	Dysarthria		Zestril	C			UNKNOWN	
	Erectile Dysfunction		Soma	C			UNKNOWN	
	Gastrooesophageal Reflux		Vicodin Tablets	C			UNKNOWN	
	Disease		Aleve	C			UNKNOWN	
	Headache		Tylenol	C			UNKNOWN	
	Hemiparesis		Valium	C			UNKNOWN	
	Hepatic Steatosis		Xanax	C		ORAL		
	Hiatus Hernia							
	Hypertension							

Hypoxic Encephalopathy
Loss Of Consciousness
Nocturia
Prostate Cancer
Pulmonary Embolism
Pulmonary Hypertension
Renal Cyst
Right Ventricular Failure
Syncope
Transient Ischaemic
Attack
Tremor

Date:08/01/05ISR Number: 4729756-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00017
Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL		
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Furosemide	C				
UNKNOWN								

Date:08/01/05ISR Number: 4729757-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03340
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729758-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03341
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729759-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03153
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729760-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00609
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729761-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03337
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729762-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00217
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx Nexium	PS C	Merck & Co., Inc	ORAL	53 MON UNKNOWN	

Headache
Hypertension
Myocardial Infarction

Date:08/01/05ISR Number: 4729763-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00566
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		29 MON
Hospitalization - Initial or Prolonged	Cardiac Pacemaker Insertion		Diltiazem Hydrochloride	C				UNKNOWN
	Cerebrovascular Accident		Neurontin	C				UNKNOWN
	Hypertension							
	Metastatic Gastric Cancer							

Date:08/01/05ISR Number: 4729764-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729765-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03155
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729766-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02780
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729767-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03903
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1254 DAY	

Date:08/01/05ISR Number: 4729768-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04251
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729769-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03904
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729770-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03902
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729771-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03910
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729772-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03905
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729773-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03911
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729774-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04000
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729775-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03996
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:08/01/05ISR Number: 4729778-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01302
Age:39 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Alopecia
	Anaemia Macrocytic
	Anxiety
	Asthenia
	Back Injury
	Blood Triglycerides Increased
	Bronchitis
	Carotid Artery Disease
	Cerebrovascular Accident
	Chest Pain
	Chronic Obstructive Pulmonary Disease
	Compression Fracture

Depression
Drug Ineffective
Dyspnoea
Haematochezia
Haematuria
Headache
Hypercholesterolaemia
Hyperhidrosis
Hypoaesthesia
Insomnia
Migraine
Myofascial Pain Syndrome
Nausea
Neck Pain
Neoplasm Malignant
Pain In Extremity
Pharyngolaryngeal Pain
Rash
Red Blood Cell
Sedimentation Rate
Increased
Rhinitis Allergic

	Sinusitis						
	Stress						
	Suprapubic Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Thrombocytopenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL	78	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	78	DAY
			Paxil	C			UNKNOWN	533 DAY
			Nexium	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Zovirax	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Trimox	C			UNKNOWN	
			Celebrex	C			UNKNOWN	
			Plavix	C		ORAL		

Date:08/01/05ISR Number: 4729779-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety Disorder		Synthroid	C			UNKNOWN	
	Cerebrovascular Accident		Fosamax	C		ORAL		
	Chest Pain		Evista	C			UNKNOWN	
	Depression		Aspirin	C			UNKNOWN	
	Dyspnoea		Premarin	C			UNKNOWN	

	Hypercholesterolaemia	Prempro	C
UNKNOWN			
	Hypoaesthesia	Tylenol	C
UNKNOWN			
	Myocardial Infarction	Meprednisone	C
UNKNOWN			
	Pain	Hydrocodone	
	Polytraumatism	Bitartrate	C
UNKNOWN			
		Hydrochlorothiazide	C
UNKNOWN			

Date:08/01/05ISR Number: 4729780-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02580
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		6 MON
Disability	Carpal Tunnel Syndrome		Toprol Xl Tablets	C		ORAL		
	Myocardial Infarction		Dyazide	C		ORAL		
	Prostate Cancer		Hydrochlorothiazide	C		ORAL		
			Aspirin	C		ORAL		

Date:08/01/05ISR Number: 4729781-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00644
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Benign Prostatic
Initial or Prolonged	Hyperplasia
Other	Cardiomyopathy
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Drug Administration Error
	Drug Hypersensitivity

	Drug Ineffective						
	Fatigue						
	Haemorrhoids	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hemianopia		Vioxx	PS	Merck & Co., Inc	ORAL	211	DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	211	DAY
	Hypoaesthesia		Coumadin	C			UNKNOWN	
	International Normalised		Celebrex	C			UNKNOWN	
	Ratio Decreased							
	International Normalised							
	Ratio Increased							
	Intracranial Aneurysm							
	Lumbar Spinal Stenosis							
	Radicular Pain							
	Sciatica							
	Visual Acuity Reduced							

Date:08/01/05ISR Number: 4729783-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA01875
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Hospitalization -	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery		Procardia	C			UNKNOWN	
	Thrombosis		Altace	C			UNKNOWN	
	Death		Etodolac	C			UNKNOWN	74 DAY
	Depression							
	Fatigue							
	Heart Rate Irregular							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Sepsis							

Date:08/01/05ISR Number: 4729784-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02068
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Convulsion		Toprol Xl Tablets	C		ORAL		
Disability	Deep Vein Thrombosis		Toprol Xl Tablets	C		ORAL		
	Depression		Lisinopril	C		ORAL		
	Loss Of Consciousness		Insulin	C				UNKNOWN
	Neoplasm Malignant		Lipitor	C				UNKNOWN
	Polytraumatism		Clonidine	C				UNKNOWN
	Thyroid Disorder							
	Tuberculosis							

Date:08/01/05ISR Number: 4729786-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00195
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729787-5Report Type:Expedited (15-DaCompany Report #NO-MERCK-0507NOR00015
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1094 DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		9 DAY

Date:08/01/05ISR Number: 4729788-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03410
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cellulitis		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Cerebrovascular Accident		Lasix (Furosemide)	C				UNKNOWN
Initial or Prolonged	Deep Vein Thrombosis		Lasix (Furosemide)	C				UNKNOWN
Other	Myocardial Infarction		Tylenol With Codeine #3	C				UNKNOWN
	Renal Failure							
	Sinusitis		Aldactone	C				UNKNOWN
	Urinary Tract Infection		Metolazone	C				UNKNOWN
			Vasotec	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN

Date:08/01/05ISR Number: 4729789-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00884
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Brain Herniation		Celebrex	C				UNKNOWN
							20	DAY
Other	Cerebrovascular Accident		Zocor	C				UNKNOWN

	Death	Xanax	C
UNKNOWN			
	Drug Effect Decreased	Aspirin	C
UNKNOWN			
	Electrocardiogram T Wave	Prempro	C
UNKNOWN			
	Inversion		
	Essential Tremor		
	Fall		
	Fatigue		
	Haemorrhage Intracranial		
	Headache		
	Insomnia		
	Irritable Bowel Syndrome		
	Loss Of Consciousness		
	Osteoarthritis		
	Pneumonitis		
	Postmenopausal		
	Haemorrhage		
	Subarachnoid Haemorrhage		
	Urinary Incontinence		
	Urinary Tract Infection		
	Uterine Polyp		
	Weight Increased		

Date:08/01/05ISR Number: 4729790-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00230
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aortic Dissection
	Aortic Valve Incompetence
	Atrial Fibrillation
	Blood Potassium Decreased

		Candidiasis					
		Depression					
		Embolic Stroke	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hemianopia		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertension		Oxycodone	SS		ORAL
39	MON						
		Hyperthyroidism		Oxycodone	SS		ORAL
39	MON						
		Intestinal Perforation		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Aspirin	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Soma	C		
UNKNOWN							
				Niacin	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729791-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03889
Age:77 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
39	MON						
Initial or Prolonged		Acute Myocardial		Vioxx	SS	Merck & Co., Inc	ORAL
39	MON						
		Infarction		Lipitor	C		
UNKNOWN							
		Adhesion		Ketoconazole	C		
UNKNOWN							
		Asthenia		Viagra	C		
UNKNOWN							
		Blood Cholesterol		Casodex	C		
UNKNOWN							
		Increased		Atenolol	C		
UNKNOWN							
		Coronary Artery Disease		Diovan	C		
UNKNOWN							
		Crohn'S Disease		Fosamax	C		ORAL
		Dehydration		Tylenol	C		
UNKNOWN							
		Diverticulum		Hydrochlorothiazide	C		
UNKNOWN							

	Gastritis		Zoladex	C		
UNKNOWN						
	Gastrooesophageal Reflux		Celebrex	C		
UNKNOWN						
	Disease		Cozaar	C		
UNKNOWN	63 DAY					
	Hormone Level Abnormal					
	Hypercholesterolaemia					
	Hyperhidrosis					
	Hypotension					
	Iron Deficiency Anaemia					
	Lower Gastrointestinal					
	Haemorrhage					
	Oral Intake Reduced					
	Sinus Bradycardia					
	Small Intestinal					
	Obstruction					
	Weight Decreased					
	Wrong Technique In Drug					
	Usage Process					

Date:08/01/05ISR Number: 4729792-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00217
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	53 MON	
	Increased		Nexium	C				
UNKNOWN								
	Headache							
	Hypertension							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729793-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03762
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 23 DAY	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		Furosemide	C		ORAL
	Breast Abscess		Furosemide	C		ORAL
	Cerebral Ischaemia		Entex Pse	C		ORAL
	Colonic Polyp		Humibid L.A.	C		ORAL
	Gastrooesophageal Reflux		Daypro	C		ORAL
	Disease		Synthroid	C		ORAL
	Hiatus Hernia					
	Hypertension					
	Irritable Bowel Syndrome					
	Lacunar Infarction					
	Meniere'S Disease					
	Mitral Valve Incompetence					
	Mitral Valve Prolapse					
	Oedema Peripheral					
	Osteoarthritis					
	Raynaud'S Phenomenon					
	Seasonal Allergy					
	Sinus Disorder					

Date:08/01/05ISR Number: 4729794-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00810
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Norvasc	C		
UNKNOWN						
Disability	Chest Pain		Omeprazole	C		
UNKNOWN	178 DAY					
Other	Emotional Distress		Foltx	C		
UNKNOWN						
	Face Injury		Trazodone			
	Fibromyalgia		Hydrochloride	C		
UNKNOWN						
	Gallbladder Disorder		Nasonex	C		
UNKNOWN						

	Gastrooesophageal Reflux	Lexapro	C
UNKNOWN			
	Disease	Gemfibrozil	C
UNKNOWN			
	Pancreatitis	Baclofen	C
UNKNOWN			
	Panic Disorder	Warfarin Sodium	C
UNKNOWN			
	Pulmonary Embolism	Hydroxychloroquine	
	Road Traffic Accident	Sulfate	C
UNKNOWN			
	Skeletal Injury	Ranitidine	C
UNKNOWN			
	Thrombosis	Lipitor	C
UNKNOWN			
		Cephalexin	C
UNKNOWN			
		Depakote	C
UNKNOWN			
		Allegra	C
UNKNOWN			
		Alprazolam	C
UNKNOWN			
		Prednisone	C
UNKNOWN			
		Zyrtec	C
UNKNOWN			
		Astelin	C
UNKNOWN			
		Folbee	C
UNKNOWN			
		Elocon	C
UNKNOWN			
		Epi-Pen	C
UNKNOWN			
		Darvocet-N	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729795-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00785
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Initial or Prolonged	Infarction		Tylenol	C				UNKNOWN
	Akinesia		Vitamins					
	Bronchitis		(Unspecified)	C				UNKNOWN
	Cholelithiasis							
	Chronic Obstructive							
	Pulmonary Disease							
	Coronary Artery Disease							
	Haematoma							
	Hernia							
	Insomnia							
	Myocardial Infarction							
	Pulmonary Congestion							
	Renal Cyst							
	Restlessness							

Date:08/01/05ISR Number: 4729796-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00746
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		33 MON
Initial or Prolonged	Depression		Effexor	C				UNKNOWN
	Hepatic Steatosis		Capoten	C		ORAL		
	Irritable Bowel Syndrome		Zocor	C		ORAL		
	Panic Disorder		Vicodin Tablets	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Glucophage	C				UNKNOWN
			Glyburide	C				UNKNOWN
			Insulin Human,					

Isophane C
SUBCUTANEOUS
Insulin C
UNKNOWN

Date:08/01/05ISR Number: 4729797-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03860
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		480 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		497 DAY

Date:08/01/05ISR Number: 4729798-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03907
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729799-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03024
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729800-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03330
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nerve Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729801-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03647
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729802-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03260
Age:49 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Systolic		Vioxx	PS	Merck & Co., Inc	ORAL		
470 DAY								
Initial or Prolonged	Increased							
	Cough							
	Dyspnoea Exertional							
	Gastrointestinal							
	Angiodysplasia							
	Haemorrhagic							
	Gastrooesophageal Reflux							
	Disease							
	Haemorrhoidal Haemorrhage							
	Joint Sprain							
	Mediastinal Disorder							
	Pulmonary Embolism							
	Rectal Haemorrhage							
	Rhinitis Allergic							
	Weight Increased							

Date:08/01/05ISR Number: 4729803-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03335
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729804-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729805-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03358
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Aortic Dissection		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729806-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03357
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1203 DAY

Date:08/01/05ISR Number: 4729807-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03336
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			UNKNOWN

Date:08/01/05ISR Number: 4729808-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03648
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729809-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03360
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729810-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03359
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardio-Respiratory Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		1214 DAY
Other	Cerebrovascular Accident Facial Palsy							

Myocardial Infarction

Date:08/01/05ISR Number: 4729811-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00622
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Other	Actinic Keratosis
	Alopecia
	Anaemia
	Angina Pectoris
	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Blood Pressure Increased
	Bradycardia
	Chest Pain
	Coccydynia
	Colon Adenoma
	Colonic Polyp
	Convulsion
	Coronary Artery Disease
	Coronary Artery Insufficiency
	Dizziness
	Drug Ineffective

	Duodenal Ulcer						
	Dyspnoea						
	Dyspnoea Exertional	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Eczema		Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Gastritis		Zestril	SS			UNKNOWN	
	Gastrointestinal		Isosorbide	C			UNKNOWN	
	Arteriovenous		Cardura	C			UNKNOWN	
	Malformation		Zocor	C		ORAL		
	Hyperhidrosis		Aspirin	C			UNKNOWN	
	Hypotension							
	International Normalised							
	Ratio Increased							
	Joint Sprain							
	Myocardial Infarction							
	Myocardial Ischaemia							
	Nasal Congestion							
	Nasal Polyps							
	Neck Pain							
	Oedema Peripheral							
	Osteoarthritis							
	Postnasal Drip							
	Prothrombin Time							
	Prolonged							
	Pulmonary Congestion							
	Reflux Oesophagitis							
	Rhinitis							
	Rhinitis Allergic							
	Rhinorrhoea							
	Sinusitis							
	Skin Exfoliation							
	Skin Lesion							
	Sleep Disorder							
	Weight Decreased							

Date:08/01/05ISR Number: 4729816-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0208USA00578
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Death	Injury		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Myocardial Infarction		Prevacid	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729818-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04992
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
64 MON						
Initial or Prolonged	Myocardial Infarction					

Date:08/01/05ISR Number: 4729819-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04217
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction
Other	Angina Pectoris
	Arthralgia
	Back Pain

		Blood Pressure Increased					
		Carotid Artery Occlusion					
		Carotid Artery Stenosis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
		Pulmonary Disease		Flexeril	SS		ORAL
		Constipation		Naproxen	SS		
UNKNOWN							
		Coronary Artery Disease		Lortab	SS		
UNKNOWN							
		Depression		Advil	C		
UNKNOWN							
		Dizziness		Aleve	C		
UNKNOWN							
		Drug Ineffective		Mobic	C		
UNKNOWN							
		Dry Eye		Tylenol	C		
UNKNOWN							
		Dry Skin					
		Dyslipidaemia					
		Dyspepsia					
		Dysuria					
		Ear Disorder					
		Electrocardiogram St-T					
		Segment Abnormal					
		Eructation					
		Fatigue					
		Gastrooesophageal Reflux					
		Disease					
		Hypoacusis					
		Increased Tendency To					
		Bruise					
		Insomnia					
		Medication Error					
		Memory Impairment					
		Musculoskeletal Stiffness					
		Myocardial Ischaemia					
		Nausea					
		Neck Pain					
		Nocturia					
		Oedema Peripheral					
		Pain In Extremity					
		Polyuria					
		Sinus Congestion					
		Tension					
		Transient Ischaemic					

Attack
Vertigo
Vomiting
Xanthelasma

Date:08/01/05ISR Number: 4729820-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02894
Age:60 YR Gender:Female I/FU:F

Outcome PT
Disability Anhedonia
Anxiety
Blood Cholesterol
Abnormal
Cardiac Disorder
Cerebrovascular Accident
Condition Aggravated
Depression
Emotional Distress
Fall
Hypertension

	Ligament Injury						
	Pain						
	Speech Disorder	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Walking Aid User		Vioxx	PS	Merck & Co., Inc	ORAL		
			Actos	C				UNKNOWN
			Hydrochlorothiazide	C				UNKNOWN
			Glucovance	C				UNKNOWN
			Norvasc	C				UNKNOWN
			Zoloft	C				UNKNOWN
			Diovan Hct	C				UNKNOWN
			Lipitor	C				UNKNOWN

Date:08/01/05ISR Number: 4729824-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02113
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Ziac	C				UNKNOWN
	Increased		Aspirin	C				UNKNOWN
	Cardiac Disorder							
	Depression							
	Herpes Zoster							
	Hypertension							
	Myocardial Infarction							
	Pain							
	Pneumonia							
	Polytraumatism							

Date:08/01/05ISR Number: 4729825-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02799
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Gastrointestinal		Vioxx	PS	Merck & Co., Inc	ORAL	65	MON
	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Myocardial Infarction		Vitamins (Unspecified)	C			UNKNOWN	
			Humira	C			UNKNOWN	
			Percocet	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

Date:08/01/05ISR Number: 4729826-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01261
Age:77 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Angina Pectoris
	Atherosclerosis
	Blood Cholesterol Increased
	Cardiac Disorder
	Cataract
	Chest Pain
	Coronary Artery Disease
	Dyspnoea
	Fluid Retention
	Heart Rate Irregular
	Hypertension

	Oedema						
	Osteoporosis						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	45	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
			Atenolol	C			UNKNOWN	

Date:08/01/05ISR Number: 4729828-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00820
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris		Estradiol	C		ORAL		
	Atrioventricular Block		Tylenol	C				
UNKNOWN								
	Complete		Provera	C		ORAL		
	Cervical Dysplasia		Synthroid	C		ORAL		
	Coronary Artery Disease							
	Fall							
	Haematuria							
	Haemorrhoids							
	Hyperlipidaemia							
	Intervertebral Disc							
	Degeneration							
	Osteoarthritis							
	Rash							
	Rectal Haemorrhage							
	Road Traffic Accident							
	Scoliosis							
	Shoulder Pain							
	Spinal Column Stenosis							
	Spinal Compression							
	Fracture							
	Spinal Osteoarthritis							
	Toe Deformity							
	Urinary Tract Infection							
	Uterine Leiomyoma							
	Ventricular Fibrillation							

Date:08/01/05ISR Number: 4729829-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01273
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		55 MON
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
Disability	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		55 MON
	Coronary Artery Disease		Neurontin	C				UNKNOWN
	Hernia Repair		Allegra	C				UNKNOWN
	Hypertension		Flonase	C				UNKNOWN
	Suicide Attempt		Humibid	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Lanoxin	C				UNKNOWN
			Lanoxin	C				UNKNOWN
			Altace	C				UNKNOWN
			Diovan	C				UNKNOWN
			Restoril	C				UNKNOWN
			Tricor	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729830-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03023
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729831-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03015
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/01/05ISR Number: 4729832-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03018
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729833-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01433
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	45	MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL	45	MON
	Coronary Artery Disease		Zocor	C		ORAL	UNKNOWN	
			Plavix	C			UNKNOWN	
			Viagra	C			UNKNOWN	

				Cephalexin	C		
UNKNOWN							
				Dextrose	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Zestoretic	C		ORAL
				Aspirin	C		
UNKNOWN	20 YR						

Date:08/01/05ISR Number: 4729834-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03118
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Antiphospholipid		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Antibodies Positive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Aspirin	C				
UNKNOWN								
	Blood Triglycerides Increased							
	Cerebral Artery Occlusion							
	Mood Altered							

Date:08/01/05ISR Number: 4729836-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03020
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729837-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03016
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729838-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00232
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Benign Prostatic		Vioxx	PS	Merck & Co., Inc	ORAL	167 YR	
Other	Hyperplasia		Verapamil	C			UNKNOWN	
	Death		Zocor	C		ORAL		
	Hyperlipidaemia		Flunisolide	C			UNKNOWN	
	Hypertension		Aspirin	C		ORAL		
	Myocardial Infarction							
	Myocardial Ischaemia							
	Vulval Disorder							

Date:08/01/05ISR Number: 4729839-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01309
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Toprol Xl Tablets	C			UNKNOWN	
Other	Diabetes Mellitus		Diovan	C			UNKNOWN	
	Dyspepsia		Tylenol	C			UNKNOWN	
	Hyperkalaemia		Paxil	C			UNKNOWN	
	Hypertension		Buspar	C			UNKNOWN	
	Insomnia		Potassium Chloride	C			UNKNOWN	

	Myocardial Infarction		Hydrochlorothiazide	C
UNKNOWN				
	Osteoporosis		Klonopin	C
UNKNOWN				
	Panic Attack		Aspirin	C
UNKNOWN				

Date:08/01/05ISR Number: 4729840-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03180
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Respiratory Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiomyopathy		Tessalon Perles	C		
UNKNOWN						
	Chronic Obstructive		Guaifenesin	C		
UNKNOWN						
	Pulmonary Disease		Amoxicillin	C		
UNKNOWN						
	Hypertension		Magnesium Oxide	C		
UNKNOWN						
	Migraine		Zyrtec	C		
UNKNOWN						
	Myocardial Infarction		Protonix	C		
UNKNOWN						
	Pneumonia		Tramadol Msd	C		
UNKNOWN						
			Normodyne	C		
UNKNOWN						
			Advair	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						
			Megace	C		
UNKNOWN						

Date:08/01/05ISR Number: 4729841-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03245
Age:66 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Cerebral Cyst
Initial or Prolonged	Chest Pain
Other	Deep Vein Thrombosis

		Dyspnoea					
		Head Injury					
		Headache	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Memory Impairment		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Celexa	SS		
UNKNOWN							
		Pallor		Celebrex	SS		
UNKNOWN							
		Paraesthesia		Aspirin	C		
UNKNOWN							
		Paraesthesia Oral		Vitamins			
		Scar		(Unspecified)	C		
UNKNOWN							
				Calcium			
				(Unspecified)	C		
UNKNOWN							

Date:08/01/05ISR Number: 4729842-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03286
Age: Gender: I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729843-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03245
Age:66 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebral Cyst		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Chest Pain		Celexa	SS		
UNKNOWN							
Other		Deep Vein Thrombosis		Celebrex	SS		
UNKNOWN							
		Dyspnoea		Aspirin	C		
UNKNOWN							
		Head Injury		Vitamins			
		Headache		(Unspecified)	C		
UNKNOWN							
		Memory Impairment		Calcium			

	Myocardial Infarction		(Unspecified)	C		
UNKNOWN						
	Pallor					
	Paraesthesia					
	Paraesthesia Oral					

Date:08/01/05ISR Number: 4729844-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03287
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4729845-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03328
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL
	Thrombosis					

Date:08/01/05ISR Number: 4729846-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03331
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
	Injury					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4729847-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03329
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729848-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00135
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Allopurinol	C		ORAL		
Other	Hyperlipidaemia		Methocarbamol	C		ORAL		
	Pineal Germinoma							
	Transient Ischaemic Attack							

Date:08/01/05ISR Number: 4729849-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4729852-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00099
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Discomfort		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Tolerance Decreased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyslipidaemia		Zocor	C		ORAL		
	Fatigue		Procardia	C				
UNKNOWN								
	Gastric Ulcer		Norvasc	C				
UNKNOWN								

	Haemorrhoids	Lotensin	C
UNKNOWN			
	Hypokalaemia	Atenolol	C
UNKNOWN			
	Joint Injury	Bumetanide	C
UNKNOWN			
	Labile Hypertension	K-Tab	C
UNKNOWN			
	Mass	Prempro	C
UNKNOWN			
	Mitral Valve Incompetence	Celebrex	C
UNKNOWN			
	Oedema	Coumadin	C
UNKNOWN			
	Palpitations	Coumadin	C
UNKNOWN			
	Phlebitis	Coumadin	C
UNKNOWN			
	Thrombosis	Coumadin	C
UNKNOWN			
	Tricuspid Valve	Aspirin	C
UNKNOWN			
	Incompetence	Tylenol	C
UNKNOWN			
	Umbilical Hernia	Hydralazine	C
UNKNOWN			
	Weight Increased		

Date:08/01/05ISR Number: 4729862-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01974
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Asthma
Disability	Blood Glucose Increased
Other	Cardiac Disorder

		Cardiac Failure					
		Congestive					
		Cardiac Murmur	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diabetes Mellitus					
		Drug Hypersensitivity					
		Dyspnoea					
		Gastric Disorder					
		Heart Rate Irregular					
		Hypertension					
		Myocardial Infarction					
		Obesity					
		Obsessive-Compulsive					
		Disorder					
		Oedema Peripheral					
		Polytraumatism					
		Rheumatoid Arthritis					
		Stomach Discomfort					
		Stress					
		Thrombosis					

Date:08/01/05ISR Number: 4729864-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05011
Age:77 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Atrial Fibrillation		Zithromax	C		
UNKNOWN							
		Blood Sodium Decreased		Gani-Tuss Dm Nr	C		
UNKNOWN							
		Cardiac Failure		Tussafed	C		
UNKNOWN							
		Congestive		Zocor	C		
UNKNOWN							
		Coronary Artery Disease		Warfarin	C		
UNKNOWN							
		Facial Spasm		Digitek	C		
UNKNOWN							
		Hyperlipidaemia		Amiodarone Msd	C		
UNKNOWN							

	Myocardial Infarction	Altace	C
UNKNOWN			
	Pleural Effusion	Demadex	C
UNKNOWN			
	Pulmonary Embolism	Ssd And Ssd Af Cream	C
UNKNOWN			
	Respiratory Failure	Fe-Tinic	C
UNKNOWN			
	Respiratory Tract	Metoprolol-Bc	C
UNKNOWN			
	Irritation		

Date:08/01/05ISR Number: 4729865-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01335
Age:60 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Cardiac Failure Congestive
	Coronary Artery Disease
	Coronary Artery Occlusion
	Diabetes Mellitus Non-Insulin-Dependent
	Hyperthyroidism
	Mood Altered
	Myocardial Infarction
	Respiratory Distress
	Tachycardia
	Thyroiditis

Urinary Tract Infection

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	386	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Lipitor	C		ORAL		
	Depakote	C		ORAL		
	Lorazepam	C		ORAL		

Date:08/01/05ISR Number: 4729866-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01232
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	1005	DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	1005	DAY
Disability	Increased		Methotrexate	C			UNKNOWN	
	Chest Pain		Prednisone	C			UNKNOWN	
	Fat Embolism		Prednisone	C			UNKNOWN	
	Headache		Prevacid	C			UNKNOWN	
	Hypertension		Diflunisal	C			UNKNOWN	
	Optic Atrophy							
	Retinal Artery Embolism							
	Retinal Artery Occlusion							
	Retinal Disorder							
	Retinal Haemorrhage							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/01/05ISR Number: 4729868-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03909
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							
	Thrombosis							

Date:08/01/05ISR Number: 4729869-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03906
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730346-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Visual Acuity Reduced		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Morphine Sulfate	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Verapamil	C		ORAL		
			Furosemide Sodium	C		ORAL		

				Enalapril Maleate	C		ORAL
				Tamoxifen Citrate	C		ORAL
				Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL

Date:08/01/05ISR Number: 4730347-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02464
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730348-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03428
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hyperglycaemia		Glipizide	C		ORAL		
Initial or Prolonged	Hypoaesthesia		Hydrocodone Bitartrate	C		ORAL		
	Pain		Soma	C		ORAL		
	Respiratory Failure		Darvon	C				
	Spinal Osteoarthritis		Estradiol	C		ORAL		
			Zocor	C		ORAL		
			Celebrex	C		ORAL		
			Celexa	C		ORAL		

UNKNOWN

Date:08/01/05ISR Number: 4730350-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02019
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
809 DAY								
Initial or Prolonged	Myocardial Infarction		Lotensin	C				

UNKNOWN

Disability	Pain	Atenolol Msd	C
UNKNOWN			
		Verapamil Msd Lp	C
UNKNOWN	13 MON		
		Hytrin	C
UNKNOWN			
		Hytrin	C
UNKNOWN			

Date:08/01/05ISR Number: 4730351-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02016
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Affective Disorder
	Anxiety
	Blood Cholesterol Increased
	Cerebrovascular Accident
	Constipation
	Convulsion
	Depression
	Erectile Dysfunction
	Hypertension
	Infection
	Inflammation
	Insomnia

	Muscle Spasms Pain Ulcer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	658 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL	658 DAY
			Ferrous Sulfate	C			UNKNOWN
			Rabeprazole Sodium	C			UNKNOWN
			Paroxetine	C			UNKNOWN

Date:08/01/05ISR Number: 4730352-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01982
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON
Initial or Prolonged Disability	Blood Cholesterol Increased		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN
	Cardiac Valve Disease		Celebrex	C			UNKNOWN
	Cholelithiasis		Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN
	Cough Diabetes Mellitus Gout		Toprol Xl Tablets	C			UNKNOWN
	Haematochezia		Toprol Xl Tablets	C			UNKNOWN
	Heart Valve Insufficiency						
	Hypersensitivity Hypertension Infection Myocardial Infarction Oedema Polytraumatism Prostate Cancer						

Date:08/01/05ISR Number: 4730357-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03730
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Blood Creatinine
Other	Increased
	Blood Urea Increased
	Bundle Branch Block Left
	Cardiac Failure
	Congestive
	Cerebral Atrophy
	Cerebrovascular Accident
	Coronary Artery Disease
	Dehydration
	Diabetes Mellitus
	Excoriation
	Gastritis
	Haemorrhoids
	Hepatic Cyst
	Ileus
	Memory Impairment
	Myocardial Infarction
	Oedema
	Post Procedural
	Complication
	Prostatism
	Renal Cyst

		Rhabdomyolysis Supraventricular Tachycardia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Systolic Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
1157 DAY							
		Ventricular Tachycardia		Lipitor	C		
UNKNOWN							
				Triamterene	C		
UNKNOWN							
				Proscar	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Urecholine	C		
UNKNOWN							
				Maxzide	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Potassium Gluconate	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/01/05ISR Number: 4730362-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02094
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL
5 DAY							
Initial or Prolonged		Anaemia		Celebrex	SS		
UNKNOWN							

Disability	Arthropathy	Synthroid	C
UNKNOWN			
Other	Atrial Fibrillation	Nitro-Dur	C
UNKNOWN			
	Cardiac Murmur	Naprosyn	C
UNKNOWN			
	Cardiomegaly	Xalatan	C
UNKNOWN			
	Cholecystitis Acute	Cosopt	C
UNKNOWN			
	Cholelithiasis	Cozaar	C
UNKNOWN			
	Dizziness	Aspirin	C
UNKNOWN			
	Feeling Cold	Prilosec	C
UNKNOWN			
	Gastric Haemorrhage		
	Gastritis		
	Gastrointestinal		
	Haemorrhage		
	Headache		
	Hepatic Cyst		
	Hot Flush		
	Hypertension		
	Injury		
	Iron Deficiency Anaemia		
	Melaena		
	Myocardial Infarction		
	Nephrolithiasis		
	Renal Cyst		

Date:08/01/05ISR Number: 4730372-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01104
Age:30 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Blood Cholesterol
Hospitalization -	Increased
Initial or Prolonged	Bronchitis
Disability	Cardiovascular Disorder
	Chest Pain
	Coronary Artery

	Atherosclerosis						
	Coronary Artery						
	Restenosis						
	Emotional Distress	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	
	Muscle Spasms		Methotrexate	C		ORAL	
	Myocardial Infarction		Ibuprofen	C			UNKNOWN
	Plantar Fasciitis		Folic Acid	C			UNKNOWN
	Psoriatic Arthropathy		Zocor	C		ORAL	
	Renal Disorder		Nitroquick	C			UNKNOWN
	Renal Failure		Prilosec	C			UNKNOWN
			Leucovorin	C			UNKNOWN
			Darvocet-N	C		ORAL	
			Plavix	C		ORAL	
			Lopressor	C		ORAL	

Date:08/01/05ISR Number: 4730391-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03187
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
	Accelerated Hypertension						
	Anaemia						
	Cardiac Disorder						
	Cardiac Failure						
	Congestive						
	Catheter Related						
	Infection						
	Cholelithiasis						
	Drug Hypersensitivity						
	Dyspnoea						
	Flank Pain						
	Haematuria						
	Hernia Repair						
	Hypertensive						
	Cardiomyopathy						
	Incisional Hernia Repair						
	Jugular Vein Thrombosis						

Renal Failure Chronic
Renal Haemorrhage
Renal Transplant
Sepsis
Steal Syndrome
Subclavian Vein
Thrombosis
Transplant Failure
Transplant Rejection

Date:08/01/05ISR Number: 4730392-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01316
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	36	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4730393-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02082
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Swelling		Tylenol	C			UNKNOWN	
	Uterine Disorder		Aleve	C			UNKNOWN	
	Wolff-Parkinson-White		Nexium	C			UNKNOWN	
	Syndrome		Darvocet-N	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	

Date:08/01/05ISR Number: 4730394-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03263
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		507 DAY
Initial or Prolonged	Cerebrovascular Accident		Atenolol	C		ORAL		
			Nexium	C		ORAL		
			Insulin Human	C			UNKNOWN	
			Ambien	C		ORAL		
			Avandia	C		ORAL		
			Betoptic	C			OPHTHALMIC	
			Premarin	C		ORAL		

Date:08/01/05ISR Number: 4730396-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01290
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Neurontin	C			UNKNOWN	
	Cardiovascular Disorder		Dilantin	C			UNKNOWN	
	Chest Pain		Prilosec	C			UNKNOWN	
	Coronary Artery Disease		Nexium	C			UNKNOWN	
	Depression		Accupril	C			UNKNOWN	
	Heart Injury		Insulin	C			UNKNOWN	
	Heart Rate Irregular		Prednisone	C			UNKNOWN	
	Hypertension							
	Migraine							
	Myocardial Infarction							
	Osteoporosis							
	Pain							

Date:08/01/05ISR Number: 4730397-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00657
Age:43 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Abnormal Dreams
Other	Amenorrhoea
	Angina Pectoris
	Aphthous Stomatitis
	Arthralgia
	Atrial Septal Defect

Blood Pressure Abnormal
Blood Pressure Increased
Breast Pain
Breast Tenderness
Bronchitis Acute
Bursitis
Cardiac Disorder
Cerebrovascular Accident
Chest Pain
Conjunctival Haemorrhage
Contusion
Convulsion
Cyst
Deep Vein Thrombosis
Dizziness
Drug Abuser
Drug Dependence
Eczema
Embolic Stroke
Endometriosis
Epistaxis
Fall
Fatigue
Gastroenteritis Viral
Generalised Oedema
Haemorrhage
Headache
Hip Arthroplasty
Hypercoagulation
Hypoaesthesia
Increased Tendency To
Bruise
Ingrowing Nail
Inguinal Hernia
Injury
Laryngitis
Localised Infection
Loss Of Libido
Mastitis
Menorrhagia
Migraine
Munchausen'S Syndrome
Muscle Atrophy
Muscle Spasms
Musculoskeletal
Discomfort
Nausea

Neck Mass
Nervousness
Oligomenorrhoea
Osteoarthritis
Otitis Externa
Otitis Media
Ovarian Cyst
Ovarian Enlargement
Pain
Pain In Jaw
Panic Attack
Paraesthesia
Patent Ductus Arteriosus
Pelvic Pain

		Pharyngitis					
		Pyrexia					
		Rash	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Rhinitis Allergic		Vioxx	PS	Merck & Co., Inc	ORAL
		Sinus Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Splenic Cyst		Vicodin Tablets	C		
UNKNOWN							
		Systemic Lupus		Aspirin	C		
UNKNOWN							
		Erythematosus		Zantac	C		
UNKNOWN							
		Transient Ischaemic		Restoril	C		
UNKNOWN							
		Attack		Flexeril	C		
UNKNOWN							
		Upper Respiratory Tract		Ascriptin	C		
UNKNOWN							
		Infection					
		Urinary Tract Infection					
		Urine Abnormality					
		Vaginal Mycosis					
		Vaginitis Bacterial					
		Viral Infection					

Date:08/01/05ISR Number: 4730400-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03347
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Life-Threatening		Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL
275 DAY							
Hospitalization -		Back Pain		Lisinopril	SS		
UNKNOWN							
Initial or Prolonged		Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Increased		Zocor	SS		
UNKNOWN							
		Blood Pressure Decreased		Vioxx	SS	Merck & Co., Inc	ORAL
275 DAY							
		Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Cardura	C		
UNKNOWN		250 DAY					
		Congestive		Prevacid	C		
UNKNOWN							

	Chest Discomfort	Allegra	C
UNKNOWN			
	Coronary Artery Atherosclerosis Depression Diabetes Mellitus Diverticulum Dizziness Postural Dysphagia Dyspnoea Fatigue Feeling Abnormal Gastrointestinal Haemorrhage Hepatojugular Reflux Hyperlipidaemia Inflammation Ischaemic Cardiomyopathy Mitral Valve Incompetence Myalgia Myocardial Infarction Oedema Pain In Extremity Pain In Jaw Pulmonary Oedema Rhinitis Allergic Thrombosis Tricuspid Valve Incompetence Ventricular Extrasystoles		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4730402-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01422
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haematoma		Vioxx	PS	Merck & Co., Inc	ORAL		57 MON
Initial or Prolonged	Hysterectomy		Vioxx	SS	Merck & Co., Inc	ORAL		57 MON
	Myocardial Infarction		Diovan	C				
UNKNOWN								1584 DAY
	Salpingo-Oophorectomy		Lasix (Furosemide)	C				
UNKNOWN								1583 DAY
	Bilateral Vascular Pseudoaneurysm		Labetalol Hydrochloride	C				
UNKNOWN								1497 DAY
			Zocor	C		ORAL		1619 DAY
			Premarin	C				
UNKNOWN								476 DAY

Date:08/01/05ISR Number: 4730403-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00562
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		10 MON
Hospitalization -	Infarction		Paxil	C				
UNKNOWN								
Initial or Prolonged	Anoxic Encephalopathy		Glucophage	C				
UNKNOWN								
Other	Depression		Ambien	C				
UNKNOWN								
	Diabetes Mellitus		Aciphex	C				
UNKNOWN								
	Non-Insulin-Dependent		Flexeril	C		ORAL		
	Dysuria		Advair Diskus	C				
UNKNOWN								
	Iron Deficiency Anaemia		Xanax	C				
UNKNOWN								
	Pneumonia							
	Pulmonary Embolism							
	Renal Failure							

Date:08/01/05ISR Number: 4730406-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04234
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730407-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04265
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	15 MON	
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Ranitidine	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	

Date:08/01/05ISR Number: 4730409-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03667
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4730410-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04236
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	2	MON

Date:08/01/05ISR Number: 4730412-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03425
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Hip Fracture		Procardia	C			UNKNOWN	
			Prinivil	C			UNKNOWN	
			Inderal	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Actonel	C			UNKNOWN	
			Metoprolol	C			UNKNOWN	
			Prednisone	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	

Date:08/01/05ISR Number: 4730430-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04208
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/01/05ISR Number: 4730431-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03487
Age:83 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged								

Date:08/01/05ISR Number: 4730432-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03993
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730433-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04223
Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730435-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03416
Age:52 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety Disorder Bacterial Infection

	Blood Cholesterol Increased						
	Breast Cancer	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4 MON
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL	4 MON
	Depression		Zestril	C			UNKNOWN
	Eye Infection		Propoxyphene Hydrochloride	C			UNKNOWN
	Fungal Infection						
	Glaucoma		Hydrocodone Bitartrate	C			UNKNOWN
	Hypersensitivity						
	Insomnia		Prednisolone	C			UNKNOWN
			Albuterol	C			UNKNOWN
			Ranitidine Hydrochloride	C			UNKNOWN
			Glucophage	C			UNKNOWN
			Cimetidine	C			UNKNOWN
			Acetaminophen And Codeine	C			UNKNOWN

Date:08/01/05ISR Number: 4730437-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03035
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/01/05ISR Number: 4730438-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03339
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4730439-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04220
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4730440-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04114
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Celebrex	C		
UNKNOWN						
			Zocor	C		ORAL

Date:08/01/05ISR Number: 4730938-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02077
Age:83 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Other	Aortic Valve Stenosis
	Arthralgia
	Asthenia
	Carotid Artery Disease
	Cerebrovascular Accident

		Closed Head Injury					
		Concussion					
		Coronary Artery Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Decreased Appetite		Vioxx	PS	Merck & Co., Inc	ORAL
		Decubitus Ulcer					
		Dementia Alzheimer'S Type					
		Difficulty In Walking					
		Dizziness					
		Drug Hypersensitivity					
		Dry Mouth					
		Faecaloma					
		Fall					
		Hypokalaemia					
		Injury					
		Insomnia					
		Joint Swelling					
		Laceration					
		Myocardial Ischaemia					
		Pain In Extremity					
		Parkinson'S Disease					
		Renal Cyst					
		Seasonal Allergy					
		Skin Ulcer					
		Urinary Retention					
		Urinary Tract Infection					

Date:08/01/05ISR Number: 4730939-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA01983
Age:87 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Arrhythmia		Vioxx	PS	Merck & Co., Inc	
UNKNOWN							
Other		Benign Prostatic		Aspirin	C		
UNKNOWN							
		Hyperplasia		Lasix (Furosemide)	C		
UNKNOWN							
		Cardiac Valve Disease		[Therapy			
		Coronary Artery Disease		Unspecified]	C		
UNKNOWN							
		Death		Coumadin	C		
UNKNOWN							
		Dyspnoea					
		Glaucoma					

Haemorrhage
Heart Rate Irregular
Myocardial Infarction
Peripheral Vascular
Disorder

Date:08/01/05ISR Number: 4730954-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730955-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00645
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Other	Cerebrovascular Accident
	Convulsion
	Dermatitis

		Dyspnoea					
		Folliculitis					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
17	MON						
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
57	DAY						
		Nephrolithiasis		Vioxx	SS	Merck & Co., Inc	ORAL
17	MON						
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
57	DAY						
		Pain In Extremity		Mobic	C		
UNKNOWN							
		Rheumatoid Arthritis		Neurontin	C		
UNKNOWN							
		Seborrhoea		Prilosec	C		
UNKNOWN							
				Oxycontin	C		
UNKNOWN							
				Nortriptyline	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Paxil	C		
UNKNOWN							

Date:08/01/05ISR Number: 4730956-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00675
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Other	Death					
	Myocardial Infarction					

Date:08/01/05ISR Number: 4730957-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00217
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
660	DAY					

Hospitalization - Hytrin C
UNKNOWN 10 YR
Initial or Prolonged

Date:08/01/05ISR Number: 4730958-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03909
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Lorcet 10/650	C				
UNKNOWN								

Date:08/01/05ISR Number: 4730960-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00292
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Disorder							
Disability	Musculoskeletal							
	Discomfort							
	Myocardial Infarction							

Date:08/01/05ISR Number: 4730961-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00934
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Hernia
Initial or Prolonged	Accident At Work
Disability	Amnesia
Other	Anaemia

Anal Fistula
Anal Inflammation
Anastomotic Complication
Aneurysm Ruptured
Angina Unstable
Anxiety
Appendicitis
Appendicitis Perforated
Arrhythmia
Arthralgia
Asthenia
Atelectasis
Back Pain
Blood Testosterone
Abnormal
Bradycardia
Breast Mass
Bronchitis Acute
Cardiac Failure
Cardiomyopathy
Cerebral Artery Stenosis
Cerebral Ischaemia
Cerebrovascular Accident
Chest Pain
Colitis Ulcerative
Contusion
Convulsion
Coronary Artery Disease
Cough
Crohn'S Disease
Defaecation Urgency
Depression
Dermatitis
Diarrhoea
Disability
Dizziness
Drug Ineffective
Dyspepsia
Dyspnoea Exertional
Electrocardiogram St
Segment Depression
Faecal Incontinence
Fall
Flatulence
Gastrooesophageal Reflux
Disease
Haemangioma

Haemorrhoids
Headache
Hernia
Hyperlipidaemia
Hypertension
Hypotension
Ileitis
Ileus
Impaired Healing
Inadequate Analgesia
Incisional Hernia
Infection
Inflammatory Bowel
Disease

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Insomnia					
		Intestinal Perforation					
		Intestinal Spasm					
		Intracranial Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL
		Irritable Bowel Syndrome					
		Joint Injury					
		Joint Sprain					
		Low Density Lipoprotein Increased					
		Migraine					
		Mitral Valve Incompetence					
		Muscle Spasms					
		Musculoskeletal Chest Pain					
		Myalgia					
		Myocardial Ischaemia					
		Pain					
		Pain In Extremity					
		Palpitations					
		Perianal Abscess					
		Perirectal Abscess					
		Pneumoperitoneum					
		Post Procedural Complication					
		Pouchitis					
		Proctalgia					
		Proctitis Ulcerative					
		Pruritus Ani					
		Pyrexia					
		Rectal Haemorrhage					
		Sepsis					
		Serositis					
		Sexual Dysfunction					
		Sleep Disorder					
		Somnolence					
		Stitch Abscess					
		Subarachnoid Haemorrhage					
		Syncope					
		Tachycardia					
		Tunnel Vision					
		Ventricular Dysfunction					
		White Blood Cell Count Increased					

Date:08/01/05ISR Number: 4730963-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Acrochordon
Initial or Prolonged	Anxiety
Other	Aortic Valve Incompetence
	Bronchitis
	Cardiac Failure
	Congestive
	Carotid Artery Disease
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder

		Deafness					
		Depression					
		Diarrhoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
		Dyspnoea		Aspirin	C		ORAL
		Emotional Distress		Premarin	C		ORAL
		Fall		Prinivil	C		ORAL
		Gout		Bumex	C		ORAL
		Headache		Lamisil	C		ORAL
		Heart Rate Irregular					
		Hyperglycaemia					
		Injury					
		Intervertebral Disc					
		Displacement					
		Nephrolithiasis					
		Oedema					
		Oropharyngeal Spasm					
		Parkinson'S Disease					
		Peripheral Vascular					
		Disorder					
		Pneumothorax					
		Renal Failure					
		Sciatica					
		Seborrhoeic Keratosis					
		Sleep Apnoea Syndrome					
		Somatoform Disorder					
		Stomach Discomfort					
		Swelling Face					
		Transient Ischaemic					
		Attack					
		Tremor					
		Urinary Tract Infection					
		Vascular Stenosis					
		Vertigo					
		Visual Acuity Reduced					

Date:08/01/05ISR Number: 4730977-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03827
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/01/05ISR Number: 4730978-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03825
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730979-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04126
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4730980-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03729
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	51	MON
			Aspirin	C			UNKNOWN	
			Oxycontin	C			UNKNOWN	

Date:08/01/05ISR Number: 4730981-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00703
Age:95 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Angina Pectoris							
	Blood Pressure Increased							
	Cardiac Failure							
	Congestive							
	Convulsion							
	Dehydration							
	Gastric Disorder							
	Haemoglobin Decreased							
	Haemoptysis							
	Pneumonia Aspiration							
	Pulmonary Embolism							
	Staphylococcal Infection							
	Urinary Tract Infection							
	Urinary Tract Infection							
	Staphylococcal							

Date:08/01/05ISR Number: 4730994-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03823
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730995-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04124
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730996-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04004
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4730997-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04007
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4731008-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04186
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731009-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04166
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731010-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04207
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:08/01/05ISR Number: 4731011-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04196
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731012-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04190
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731013-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03820
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731014-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04192
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731015-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04193
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1892 DAY	
	Paralysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/01/05ISR Number: 4731017-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04205
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731018-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04246
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Thrombosis Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731019-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04127
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731021-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04181
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/01/05ISR Number: 4731056-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03826
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	555	DAY

Date:08/01/05ISR Number: 4733390-0Report Type:Expedited (15-DaCompany Report #2005105193
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia	Consumer	Halcion (Triazolam)	PS		ORAL	0.25 (0.25 MG AS NEEDED)	
	Arthritis							
	Drug Effect Decreased							
	Drug Ineffective		Bextra (Valdecoxib)	SS		ORAL	20 MG (20 MG 1 IN 1 D)	
	Myocardial Infarction							
	Osteoarthritis							
	Pain		Vioxx (Rofecoxib)	SS				
	Pharmaceutical Product Complaint		Mobic (Meloxicam)	SS				
			Premarin (Estrogens Conjugated)	C				

Date:08/02/05ISR Number: 4731485-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04342
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Haemorrhage		Vioxx	PS	Merck & Co., Inc	UNKNOWN		15 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/05ISR Number: 4731486-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00073
Age:19 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebral Haemangioma		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Convulsion		Celebrex	C				
UNKNOWN								
Other	Emotional Distress							
	Haemarthrosis							
	Ligament Injury							
	Ligament Sprain							

Date:08/02/05ISR Number: 4731487-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04261
Age:75 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		552 DAY
Initial or Prolonged	Ischaemic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL		262 DAY
Disability								
Other								

Date:08/02/05ISR Number: 4731488-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00211
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Vein Thrombosis							

Date:08/02/05ISR Number: 4731490-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01995
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Lower
Initial or Prolonged	Acute Pulmonary Oedema
Disability	Anxiety

Other	Aortic Valve Incompetence
	Asthenia
	Blood Cholesterol
	Increased
	Bundle Branch Block
	Cardiac Failure
	Congestive
	Cerebrovascular Accident
	Chest Discomfort
	Chronic Obstructive
	Pulmonary Disease
	Cognitive Disorder
	Convulsion
	Coronary Artery Disease
	Cystocele
	Depression
	Diabetes Mellitus
	Inadequate Control
	Diabetic Ketoacidosis
	Emotional Distress
	Emphysema
	Hypertension
	Hypokalaemia
	Intervertebral Disc

		Degeneration					
		Mitral Valve Incompetence					
		Myocardial Infarction					
		Nasopharyngitis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Palpitations		Vioxx	PS	Merck & Co., Inc	ORAL
		Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
		Supraventricular		Lasix (Furosemide)	C		
UNKNOWN							
		Extrasystoles		Aspirin	C		
UNKNOWN							
		Supraventricular		Orphenadrine	C		
UNKNOWN							
		Tachycardia		Ativan	C		
UNKNOWN							
		Transient Ischaemic		Lopressor	C		
UNKNOWN							
		Attack		Glyburide	C		
UNKNOWN							
		Urinary Tract Infection		Glucotrol Xl	C		
UNKNOWN							
		Ventricular Extrasystoles					
		Vision Blurred					

Date:08/02/05ISR Number: 4731492-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03189
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abscess Limb		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Aortic Valve Sclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
53 DAY						
Disability	Basal Cell Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL
Other	Bundle Branch Block Right		Vioxx	SS	Merck & Co., Inc	ORAL
53 DAY						
	Cardiac Murmur		Fosamax	C		ORAL
	Cerebrovascular Accident		Hydrodiuril	C		ORAL
	Colonic Polyp					
	Conjunctivitis					
	Coronary Artery Disease					
	Cough					
	Depression					
	Ingrowing Nail					
	Injury					
	Mitral Valve Sclerosis					
	Pain In Extremity					

Sexual Dysfunction
Sleep Apnoea Syndrome
Thrombosis
Transient Ischaemic
Attack
White Blood Cell Count
Increased

Date:08/02/05ISR Number: 4731515-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00008
Age:79 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	88	DAY
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Hyperthyroidism							

Date:08/02/05ISR Number: 4731516-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/05ISR Number: 4731517-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03318
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Meningitis		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prozac	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Klonopin	C			UNKNOWN	
			Allegra	C			UNKNOWN	

Date:08/02/05ISR Number: 4731519-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507PRI00001
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc		UNKNOWN	
	Cardiovascular Disorder							
	Multi-Organ Disorder							
	Vascular Injury							

Date:08/02/05ISR Number: 4731520-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/02/05ISR Number: 4731521-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0309USA00839
Age:61 YR Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Other	Alopecia
	Benign Neoplasm
	Chest Pain
	Colonic Polyp
	Constipation
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Dermatitis
	Diarrhoea
	Drug Intolerance
	Dyspepsia
	Dysuria
	Early Morning Awakening
	Epicondylitis
	Exostosis
	Food Intolerance
	Gastroenteritis Viral
	Generalised Anxiety Disorder
	Gout
	Haematoma
	Hair Texture Abnormal
	Hearing Impaired
	Hypercholesterolaemia
	Hypertension
	Increased Tendency To

		Bruise					
		Insomnia					
		Intervertebral Disc Degeneration	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lung Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Myositis		Vioxx	SS	Merck & Co., Inc	ORAL
		Nasal Congestion		Vioxx	SS	Merck & Co., Inc	ORAL
		Neck Pain		Librax Capsules	C		
UNKNOWN							
		Nervousness		Zantac	C		
UNKNOWN							
		Osteochondrosis		Cyclobenzaprine			
		Pain In Extremity		Hydrochloride	C		
UNKNOWN							
		Pollakiuria		Acetaminophen And			
		Postnasal Drip		Propoxyphene			
		Productive Cough		Napsylate	C		
UNKNOWN							
		Pruritus		Allegra	C		
UNKNOWN							
		Radiculitis Cervical		Prilosec	C		
UNKNOWN							
		Rectal Haemorrhage		Xanax	C		
UNKNOWN							
		Rhinorrhoea		Aspirin	C		
UNKNOWN							
		Rotator Cuff Syndrome		Tylenol	C		
UNKNOWN							
		Sinus Disorder					
		Sleep Disorder					
		Sneezing					
		Spinal Osteoarthritis					
		Stomach Discomfort					
		Tendonitis					
		Tinnitus					
		Urinary Tract Infection					

Date:08/02/05ISR Number: 4731533-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04410
Age:81 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux					

Disease
Hypertension

Date:08/02/05ISR Number: 4732177-2Report Type:Expedited (15-DaCompany Report #US-MERCK-01104471
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthenia
	Benign Prostatic Hyperplasia
	Choking
	Cognitive Disorder
	Cough
	Depression
	Diverticulum
	Dysgeusia
	Dyspepsia
	Dyspnoea
	Dysuria
	Early Satiety
	Erosive Duodenitis
	Erosive Oesophagitis
	Fatigue
	Gastric Disorder

		Gastritis Erosive					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heat Stroke		Vioxx	PS	Merck & Co., Inc	ORAL
		Hiatus Hernia		Aspirin	C		
UNKNOWN							
		Hypertension		Restoril	C		
UNKNOWN							
		Hypoacusis					
		Intestinal Functional Disorder					
		Lung Disorder					
		Malaise					
		Muscle Atrophy					
		Nasopharyngitis					
		Oesophageal Rupture					
		Pancreatitis					
		Renal Cyst					
		Rhinorrhoea					
		Shoulder Pain					
		Stomach Discomfort					
		Stress					
		Supraventricular Extrasystoles					
		Thromboembolic Stroke					
		Transient Ischaemic Attack					
		Upper Respiratory Tract Infection					
		Urinary Retention					
		Urinary Tract Disorder					
		Urinary Tract Infection					
		Weight Decreased					

Date:08/02/05ISR Number: 4732184-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03186
Age:51 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Atelectasis		Vioxx	SS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholecystitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cholelithiasis					

Depression
Duodenal Ulcer
Gastric Disorder
Gastric Ulcer
Intervertebral Disc
Protrusion
Iron Deficiency Anaemia
Nervousness
Peptic Ulcer
Pleural Effusion
Weight Gain Poor

Date:08/02/05ISR Number: 4732186-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03956
Age:48 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	16	DAY
	Increased		Levoxyl	C			UNKNOWN	
	Cardiac Murmur							
	Cardiac Valve Disease							
	Cerebrovascular Accident							
	Depression							
	Disturbance In Attention							
	Dysstasia							
	Hypertension							
	Upper Limb Fracture							

Date:08/02/05ISR Number: 4732188-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00026
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Mirtazapine	SS				
UNKNOWN								

Date:08/02/05ISR Number: 4732201-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01012
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
	Renal Failure							

Date:08/02/05ISR Number: 4732202-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Ibuprofen	C				
Disability	Convulsion		Feosol	C				
	Dyspepsia		Atenolol	C				
	Gastritis		Prevacid	C				
	Hiatus Hernia		Relafen	C				
	Hypertension		Tylenol	C				
	Inflammation							
	Joint Injury							
	Pain In Extremity							
	Peptic Ulcer Haemorrhage							
	Transient Ischaemic Attack							

Date:08/02/05ISR Number: 4732203-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02012
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety
	Benign Prostatic Hyperplasia
	Blood Cholesterol

	Increased Cardiac Failure Carotid Artery Stenosis Cerebrovascular Accident	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Convulsion		Lipitor	C			UNKNOWN	
	Coronary Artery Occlusion		Zocor	C			UNKNOWN	
	Depression		Zocor	C			UNKNOWN	
	Diabetes Mellitus		Tricor	C			UNKNOWN	
	Dyspnoea		Gemfibrozil	C			UNKNOWN	
	Facial Pain		Niaspan	C			UNKNOWN	
	Heart Rate Irregular		Lisinopril	C			UNKNOWN	
	Hypertension		Plavix	C			UNKNOWN	
	Hypoaesthesia		Klor-Con	C			UNKNOWN	
	Oedema Peripheral		Zestril	C			UNKNOWN	
	Pain In Extremity Thrombosis							

Date:08/02/05ISR Number: 4732204-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00132
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/02/05ISR Number: 4732205-4Report Type:Expedited (15-DaCompany Report #US-MERCK-01104492
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
	Carotid Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Cellulitis					
	Cerebrovascular Accident					
	Extrasystoles					
	Hyperlipidaemia					
	Hypertension					
	Injury					
	Osteoarthritis					
	Osteoporosis					
	Pain In Extremity					
	Peripheral Vascular					
	Disorder					
	Renal Failure					
	Shoulder Pain					
	Tendon Injury					
	Ventricular Hypertrophy					

Date:08/02/05ISR Number: 4732207-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00254
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/05ISR Number: 4732213-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0505CAN00017
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Ascites		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - 3 MON	Chromaturia		Atorvastatin Calcium	SS		ORAL
Initial or Prolonged UNKNOWN	Coagulopathy		Ibuprofen	C		
Disability UNKNOWN	Gastroduodenitis		Acetaminophen	C		
Other	Hepatic Failure					
	Hepatitis Toxic					
	Hepatosplenomegaly					
	Jaundice					
	Malnutrition					
	Mobility Decreased					
	Muscle Atrophy					
	Portal Hypertension					
	Renal Failure Acute					
	Varices Oesophageal					

Date:08/02/05ISR Number: 4732214-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00091
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertensive Heart Disease		Lisinopril	C		ORAL
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		ORAL
			Nebivolol Hydrochloride	C		ORAL
			Tramadol Hydrochloride	C		ORAL
			Doxepin Hydrochloride	C		ORAL
			Clomipramine			

			Hydrochloride	C		ORAL
			Hydrochlorothiazide And Triamterene	C		ORAL

Date:08/02/05ISR Number: 4732215-7Report Type:Expedited (15-DaCompany Report #CA-MERCK-0507CAN00208
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/02/05ISR Number: 4732216-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04001
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/05ISR Number: 4732217-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00211
Age:68 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Feeling Abnormal		Vioxx	PS	Merck & Co., Inc	ORAL		
	Retinal Vein Occlusion							
	Retinal Vein Thrombosis							
	Visual Acuity Reduced							

Date:08/02/05ISR Number: 4732218-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00137
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspepsia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastric Disorder		Celebrex	C			UNKNOWN	
	Haematochezia		Norvasc	C			UNKNOWN	
	Haemoptysis		Panlor Ss	C			UNKNOWN	
	Myocardial Infarction		Tylenol	C			UNKNOWN	
	Thrombosis		Meclizine	C			UNKNOWN	
	Ulcer							

Date:08/02/05ISR Number: 4732220-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04129
Age:52 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	47 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	47 MON	

Date:08/02/05ISR Number: 4732221-2Report Type:Expedited (15-DaCompany Report #SE-MERCK-0507SWE00005
Age:75 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebral Artery		Vioxx	PS	Merck & Co., Inc	ORAL		789 DAY
Initial or Prolonged	Thrombosis		Felodipine	C				UNKNOWN
	Cerebral Infarction							

Date:08/02/05ISR Number: 4732222-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04569
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1 YR
	Depression		Glucovance	C				UNKNOWN
	Hypertension		Lipitor	C				UNKNOWN
	Pain		Lotensin	C				UNKNOWN

Date:08/02/05ISR Number: 4732223-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA02748
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		24 MON
Initial or Prolonged	Myocardial Infarction		Pravachol	C				UNKNOWN
			Combivent	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/02/05ISR Number: 4732233-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00092
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		580 DAY
Initial or Prolonged	Headache		Vioxx	SS	Merck & Co., Inc	ORAL		580 DAY
Disability	Myocardial Infarction Overdose Peptic Ulcer							

Date:08/02/05ISR Number: 4732234-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04346
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		32 MON
Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN
			Enalapril Comp	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Trimetoprim-Sulfa	C				UNKNOWN
			Ascorbic Acid	C				UNKNOWN
			Paxil	C				UNKNOWN
			Vitamin E	C			132 MON	UNKNOWN
			Vasotec	C		ORAL		
			Tylenol	C				UNKNOWN

Date:08/02/05ISR Number: 4732235-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04341
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Sinusitis		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Verapamil	C			UNKNOWN	

Date:08/02/05ISR Number: 4732236-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04318
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	14 MON	
	Myocardial Infarction							

Date:08/02/05ISR Number: 4732237-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04321
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733102-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01850
Age:65 YR Gender:Female I/FU:F

Outcome	PT
Other	Angina Pectoris
	Atherosclerosis
	Dyspepsia

Hypertension
Myocardial Infarction

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
			Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN			Prevacid	C		
UNKNOWN			Allegra	C		
UNKNOWN			Desowen	C		
UNKNOWN			Zyrtec-D	C		
UNKNOWN			Premarin	C		
UNKNOWN	4 YR		Meclizine	C		
UNKNOWN			Trimox	C		
UNKNOWN			Nitrostat	C		
UNKNOWN			Flonase	C		
UNKNOWN			Methylprednisolone	C		
UNKNOWN			Cephalexin	C		
UNKNOWN			Denavir	C		
UNKNOWN						

Date:08/03/05ISR Number: 4733103-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00102
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Alopecia		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Lipitor	SS		ORAL
	Chest Pain					
	Colonic Polyp					
	Flatulence					
	Hypertension					
	Myocardial Infarction					
	Swelling					

Date:08/03/05ISR Number: 4733104-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04807
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Murmur		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypertension		Hydrodiuril	C		ORAL		
	Ligament Injury		Chlordiazepoxide	C				
UNKNOWN								
	Myocardial Infarction							
	Sleep Disorder							

Date:08/03/05ISR Number: 4733105-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02961
Age:71 YR Gender:Male I/FU:F

Outcome	PT
Death	Aneurysm
Hospitalization -	Angina Pectoris
Initial or Prolonged	Aortic Aneurysm
Other	Attention
	Deficit/Hyperactivity
	Disorder
	Bipolar Disorder
	Cardiac Failure
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Dermatomyositis
	Diabetes Mellitus
	Hernia
	Hypertension

		Myocardial Infarction Oesophageal Disorder Peripheral Vascular Disorder Swelling Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/03/05ISR Number: 4733106-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01105
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
657 DAY						
			Premarin	C		
UNKNOWN						
			Hydrochlorothiazide	C		
UNKNOWN						

Date:08/03/05ISR Number: 4733108-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00635
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
726 DAY						
Initial or Prolonged	Aortic Valve Disease		Levoxyl	C		
UNKNOWN						
Other	Atherosclerosis		Hydrochlorothiazide	C		
UNKNOWN						
	Atrial Fibrillation		Cardizem	C		
UNKNOWN						
	Blood Cholesterol		Lovastatin	C		
UNKNOWN						
	Increased		Premarin	C		
UNKNOWN						
	Cardiac Failure Congestive Coronary Artery Atherosclerosis Coronary Artery Disease					

Gallbladder Disorder
Gastrointestinal Disorder
Heart Rate Irregular
Hypertension
Myocardial Infarction
Nausea
Rash
Urinary Tract Infection
Vomiting

Date:08/03/05ISR Number: 4733116-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01944
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		226 DAY
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		527 DAY
Disability			Toprol Xl Tablets	C		ORAL		2187 DAY
			Cardura	C				
UNKNOWN								2104 DAY

Date:08/03/05ISR Number: 4733117-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04132
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733118-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea							
	Ejection Fraction Decreased							
	Fatigue							
	Gastrointestinal Ulcer							
	Hypokinesia							
	Pulmonary Oedema							

Date:08/03/05ISR Number: 4733119-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02101
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		154 DAY
	Myocardial Infarction							
	Polytraumatism							

Date:08/03/05ISR Number: 4733120-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04198
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733124-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04197
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733126-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04328
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Pain		[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Imitrex Tablets	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733127-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00579
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:08/03/05ISR Number: 4733128-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02963
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733129-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00563
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Heparin	C			UNKNOWN	
			Nitroglycerin	C			UNKNOWN	
			Isosorbide	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	

Neurontin C
UNKNOWN

Darvocet-N C
UNKNOWN

Elavil C
UNKNOWN

Integrilin C
UNKNOWN

Date:08/03/05ISR Number: 4733130-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04133
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebral Artery Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733143-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04330
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733144-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04336
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Myocardial Infarction							
Other								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733145-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04343
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		907 DAY
Initial or Prolonged			Glucovance	C				UNKNOWN
			Loprox	C				UNKNOWN
			Plendil	C				UNKNOWN
			Prinivil	C				UNKNOWN
			Lipitor	C				UNKNOWN
			Lisinopril	C				UNKNOWN
			Calcium (Unspecified)	C				UNKNOWN
			Lantus	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN
			Clotrimazole	C				UNKNOWN
			Atenolol	C				UNKNOWN

Date:08/03/05ISR Number: 4733146-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04337
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733168-8Report Type:Expedited (15-DaCompany Report #HN-MERCK-0507USA04334
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733217-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00782
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiomegaly		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Prednisone	C				
UNKNOWN								
	Coronary Artery Thrombosis							
	Myocardial Infarction							

Date:08/03/05ISR Number: 4733237-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04796
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C		ORAL		
	Blood Pressure Increased							
	Cardiac Disorder							
	Chest Discomfort							
	Coronary Artery Occlusion							
	Dyspepsia							
	Dyspnoea							
	Flatulence							
	Palpitations							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733795-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00761
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Fluticasone Propionate	C			UNKNOWN	
	Anxiety		Albuterol	C			UNKNOWN	
	Arrhythmia							
	Atrial Fibrillation							
	Candidiasis							
	Chest Pain							
	Depression							
	Dizziness							
	Duodenitis							
	Dyspnoea							
	Gastritis Erosive							
	Nausea							
	Reflux Oesophagitis							
	Syncope							
	Tachycardia							
	Vomiting							

Date:08/03/05ISR Number: 4733796-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02997
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733797-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA01174
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
	Bronchitis
Disability	Bursitis
Other	Carpal Tunnel Syndrome
	Cervicobrachial Syndrome
	Chronic Obstructive Pulmonary Disease

Contusion
Cough
Depression
Drug Ineffective
Dyspepsia
Dysthymic Disorder
Fall
Fibromyalgia
Gravitational Oedema
Hypertension
Increased Tendency To
Bruise
Lacunar Infarction
Lower Respiratory Tract
Infection
Migraine
Neuralgia
Oedema Peripheral
Osteopenia
Osteoporosis
Pain In Extremity

		Radius Fracture					
		Renal Disorder					
		Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Stress		Vioxx	SS	Merck & Co., Inc	ORAL
		Tendonitis		Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
		Urinary Tract Infection		Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
48	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
				Analgesic Or Anesthetic (Unspecified)	C		
UNKNOWN							
				Premarin	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Actonel	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							
				Calcium Carbonate	C		
UNKNOWN							
				Aspirin	C		ORAL
				Paxil	C		ORAL
				Elavil	C		ORAL
				Oxycontin	C		
UNKNOWN							

				Vicodin Tablets	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							

Date:08/03/05ISR Number: 4733798-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02944
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/03/05ISR Number: 4733799-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA02102
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
573 DAY								
Initial or Prolonged	Coagulopathy		Synthroid	C				
UNKNOWN								
Disability	Cough		Spironolactone	C				
UNKNOWN								
	Dehydration		Hydrocodone Hydrochloride	C				
	Depression							
UNKNOWN								
	Haemorrhagic Stroke		Ibuprofen	C				
UNKNOWN								
	Nasal Congestion		Celebrex	C				
UNKNOWN								
	Thrombocytopenia		Demadex	C				
UNKNOWN	615 DAY							
			Lasix (Furosemide)	C				
UNKNOWN	615 DAY							
			Lozol	C				
UNKNOWN	615 DAY							
			Chondroitin Sulfate Sodium And					

			Glucosamine Hydrochloride	C			
UNKNOWN							

Date:08/03/05ISR Number: 4733800-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00059
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nausea		Insulin	C				
UNKNOWN								
	Oedema Peripheral							
	Pneumonia							
	Prescribed Overdose							

Date:08/03/05ISR Number: 4733801-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0405USA00638
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
5 DAY								
Initial or Prolonged	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
17 MON								
	Blood Creatinine		Vioxx	SS	Merck & Co., Inc	ORAL		
8 WK								
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Hydrodiuril	SS		ORAL		
	Cerebral Infarction		Methotrexate	SS				
UNKNOWN	2219 DAY							
	Dermatitis Contact		Folic Acid	C		ORAL		
	Diarrhoea		Toprol Xl Tablets	C		ORAL		
	Dizziness		Aspirin	C				
UNKNOWN								
	Hyperlipidaemia							
	Hypertension							
	Mouth Ulceration							
	Non-Cardiac Chest Pain							
	Pain In Jaw							
	Peripheral Coldness							

Sinusitis
Stomach Discomfort
Transient Ischaemic
Attack

Date:08/03/05ISR Number: 4733834-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00887
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	62 MON	
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetic Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL	62 MON	
	Swelling		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Attack		Vasotec	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Calan	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Cenestin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Insulin	C			UNKNOWN	
			Pyridoxine	C			UNKNOWN	

		Vitamin E	C	
UNKNOWN				
		Vitamin B (Unspecified)	C	
UNKNOWN				
		Furosemide	C	
UNKNOWN				
		Dyazide	C	
UNKNOWN				

Date:08/03/05ISR Number: 4733836-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00227
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropod Bite		Vioxx	PS	Merck & Co., Inc	ORAL		634 DAY
Initial or Prolonged	Atherosclerosis		Lortab	C		ORAL		
	Cerebrovascular Accident		Lisinopril	C		ORAL		
	Diabetes Mellitus		Aspirin	C		ORAL		
	Overdose							

Date:08/03/05ISR Number: 4733837-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00969
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zocor	C				
UNKNOWN								

Date:08/03/05ISR Number: 4733838-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05019
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Pravachol	C				
UNKNOWN								

Other	Gastrointestinal		Prempro	C	
UNKNOWN					
	Haemorrhage		Paxil	C	
UNKNOWN					
	Hypertension		Imdur	C	
UNKNOWN					
	Myocardial Infarction		Norvasc	C	
UNKNOWN					
	Oedema		Lopressor	C	
UNKNOWN					
	Sleep Apnoea Syndrome				

Date:08/03/05ISR Number: 4733839-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03717
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
	Congestive					
	Heart Rate Irregular					
	Myocardial Infarction					

Date:08/03/05ISR Number: 4733840-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02056
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blood Cholesterol		Cyclobenzaprine			
	Increased		Hydrochloride	C		
UNKNOWN						
	Dyspepsia		Lortab	C		
UNKNOWN						
	Hypertension		Zanaflex	C		
UNKNOWN						
	Myocardial Infarction		Acetaminophen And			

			Hydrocodone Bitartrate	C		UNKNOWN
			Trimox	C		UNKNOWN
			Pseudovent	C		UNKNOWN
			Levaquin	C		UNKNOWN
			Rhinocort	C		UNKNOWN
			[Therapy Unspecified]	C		UNKNOWN

Date:08/03/05ISR Number: 4733842-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02731
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Headache		Aspirin	C			UNKNOWN	
	Heart Rate Irregular		Plavix	C			UNKNOWN	
	Myocardial Infarction		Pravachol	C			UNKNOWN	
	Oedema Peripheral		Benicar	C			UNKNOWN	
	Pain							
	Swelling							

Date:08/03/05ISR Number: 4733844-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01374
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	756 DAY	
	Cerebrovascular Accident							

Date:08/03/05ISR Number: 4733845-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01607
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Coma		Lipitor	C				
Initial or Prolonged	Gastritis		Zocor	C				

Date:08/03/05ISR Number: 4733846-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00764
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	1190 DAY	
	Increased Coagulopathy		Propranolol Hydrochloride	C				
	Gastric Disorder		Aspirin	C		ORAL		
	Hypertension		Premarin	C				
	Pulmonary Embolism		Lotrel	C				

Date:08/03/05ISR Number: 4733847-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01981
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cardiac Failure
Initial or Prolonged	Congestive
Other	Cerebrovascular Accident
	Chest Pain
	Diabetes Mellitus

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Dyspepsia Fibromyalgia Myocardial Infarction					
908	DAY	Neck Pain		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Polytraumatism		Isosorbide	C		
UNKNOWN		Sleep Apnoea Syndrome		Diovan	C		
UNKNOWN				Cephalexin	C		
UNKNOWN				Lasix (Furosemide)	C		
UNKNOWN				Zocor	C		
UNKNOWN				Avapro	C		
UNKNOWN				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN				Methylprednisolone	C		
UNKNOWN				Augmentin	C		
UNKNOWN				Triamterene	C		
UNKNOWN				Ultram	C		
UNKNOWN				Lipitor	C		
UNKNOWN				Metoprolol	C		
UNKNOWN				Nitrostat	C		
UNKNOWN				Plavix	C		
UNKNOWN				Folic Acid	C		
UNKNOWN				Zocor	C		
UNKNOWN				Maxzide	C		
UNKNOWN				Norvasc	C		
UNKNOWN							

			Xenical	C			
UNKNOWN							

Date:08/03/05ISR Number: 4733848-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02024
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		36 MON
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		36 MON
Disability	Myocardial Infarction		Glucotrol	C				UNKNOWN
	Pain		Avapro	C				UNKNOWN
	Polytraumatism		Aspirin	C				UNKNOWN
			Detrol	C				UNKNOWN

Date:08/03/05ISR Number: 4733849-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01370
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Cardiac Failure							
	Congestive							
	Cerebrovascular Accident							
	Diplopia							
	Visual Acuity Reduced							

Date:08/03/05ISR Number: 4733852-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01348
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Flonase	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733853-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01842
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Brain Stem Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL	568 DAY	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Glucophage	C			UNKNOWN	
			Prevacid	C			UNKNOWN	

Date:08/03/05ISR Number: 4733854-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00128
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Eye Haemorrhage		Estrace	C			UNKNOWN	
	Hepatitis		Provera	C			UNKNOWN	
	Hypertension		Diovan	C			UNKNOWN	
	Myocardial Infarction							
	Oedema Peripheral							
	Polypectomy							
	Thyroid Disorder							

Date:08/03/05ISR Number: 4733855-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01994
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	46 MON	
Initial or Prolonged	Myocardial Infarction		Aspirin	C			UNKNOWN	

	Ambien	C	
UNKNOWN			
	Paxil	C	
UNKNOWN			
	Hydrodiuril	C	ORAL
	Prinivil	C	ORAL
	Potassium Chloride	C	
UNKNOWN			
	Celebrex	C	
UNKNOWN			
	Omeprazole	C	
UNKNOWN			
	Omeprazole	C	
UNKNOWN			
	Fluoxetine	C	
UNKNOWN			
	Flurazepam	C	
UNKNOWN			
	Zyrtec	C	
UNKNOWN			
	Acetaminophen And Codeine Phosphate	C	
UNKNOWN			
	Tramadol Hydrochloride	C	
UNKNOWN			
	Ultracet	C	
UNKNOWN			
	Paroxetine	C	
UNKNOWN			
	Protonix	C	
UNKNOWN			
	Bextra	C	
UNKNOWN			
	Mirtazapine	C	
UNKNOWN			
	Niaspan	C	
UNKNOWN			
	Zestril	C	
UNKNOWN			
	Norvasc	C	
UNKNOWN			

Date:08/03/05ISR Number: 4733857-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01976
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		463 DAY
Initial or Prolonged	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		463 DAY
Disability	Increased		Cartia Xt	C				UNKNOWN
	Cerebrovascular Accident		Lotrel	C				UNKNOWN
	Coronary Artery Occlusion		Coumadin	C				UNKNOWN
	Osteoporosis		Fosamax	C				UNKNOWN
			Synthroid	C				UNKNOWN
			Xanax	C				UNKNOWN
			Lortab	C				UNKNOWN
			Lexapro	C				UNKNOWN
			Armour Thyroid Tablets	C				UNKNOWN
			Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
			Lovenox	C				UNKNOWN
			Isosorbide	C				UNKNOWN

Date:08/03/05ISR Number: 4733859-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03203
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Prednisone	C				UNKNOWN

			Methotrexate	C			
UNKNOWN							
			Aspirin	C			ORAL
			Plavix	C			
UNKNOWN							
			Tylenol	C			
UNKNOWN							

Date:08/03/05ISR Number: 4733860-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00386
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Neurontin	C				
UNKNOWN								
	Cerebrovascular Accident		Coumadin	C				
UNKNOWN								
	Chronic Obstructive		Prilosec	C				
UNKNOWN								
	Pulmonary Disease		Premarin	C				
UNKNOWN								
	Coagulopathy		Effexor	C				
UNKNOWN								
	Diabetes Mellitus		Lasix (Furosemide)	C				
UNKNOWN								
	Gout		Singulair	C				
UNKNOWN								
	Haemorrhage		Allegra	C				
UNKNOWN								
	Overdose		Prevacid	C				
UNKNOWN								
			Zestril	C				
UNKNOWN								
			Lopid	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			Hydrocodone Bitartrate	C				
UNKNOWN								
			Diflucan	C				
UNKNOWN								
			Lortab	C				
UNKNOWN								
			Synthroid	C				
UNKNOWN								
			Paxil	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733891-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00338
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
	Organ Failure							

Date:08/03/05ISR Number: 4733894-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04332
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
	Congestive							
	Fatigue							
	Myocardial Infarction							
	Peripheral Vascular							
	Disorder							
	Poor Peripheral							
	Circulation							

Date:08/03/05ISR Number: 4733895-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04311
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	640 DAY	
	Myocardial Infarction		Furosemide	C			UNKNOWN	2043 DAY
			Metformin	C			UNKNOWN	
			Nifedipine Er	C			UNKNOWN	
			Quinine	C			UNKNOWN	
			Allegra	C			UNKNOWN	

Date:08/03/05ISR Number: 4733896-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00571
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		268 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Premarin	C			UNKNOWN	
	Headache		Lortab	C			UNKNOWN	
	Hypertension		Iron (Unspecified)	C			UNKNOWN	
	Nervousness		Advair	C			UNKNOWN	
	Treatment Noncompliance		[Therapy Unspecified]	C			UNKNOWN	

Date:08/03/05ISR Number: 4733897-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04218
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/05ISR Number: 4733899-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04291
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733900-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04203
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Thrombosis							
Disability								

Date:08/03/05ISR Number: 4733901-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04215
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	5	DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/03/05ISR Number: 4733902-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04210
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:08/03/05ISR Number: 4733903-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03966
Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Septal Defect		Vioxx	PS	Merck & Co., Inc	ORAL	16 DAY	
	Cerebrovascular Accident		Sulfatrim	C			UNKNOWN	
	Prescribed Overdose		Zitromax	C			UNKNOWN	
	Transient Ischaemic		Ibuprofen	C			UNKNOWN	
	Attack		Methylprednisolone	C			UNKNOWN	

Date:08/04/05ISR Number: 4734647-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4734648-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04274
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Aspirin	C			UNKNOWN	
	Cerebrovascular Accident		Plendil	C		ORAL		
	Ulcer Haemorrhage		Diovan	C			UNKNOWN	

			Hytrin	C		
UNKNOWN						
			Dyazide	C		
UNKNOWN						
			Elavil	C		ORAL

Date:08/04/05ISR Number: 4734649-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00255
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Ammonia Increased		Vioxx	PS	Merck & Co., Inc	ORAL
37 MON						
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
37 MON						
Other	Prescribed Overdose		Vasotec	C		
UNKNOWN						
	Suicidal Ideation		Zestril	C		
UNKNOWN						

Date:08/04/05ISR Number: 4734650-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00079
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Heart Rate Increased		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Transient Ischaemic Attack					

Date:08/04/05ISR Number: 4734662-6Report Type:Expedited (15-DaCompany Report #FR-MERCK-0411FRA00072
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dermatitis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Hypothyroidism		Doxazosin Mesylate	SS		ORAL
	Rash Papular		Acetaminophen And Tramadol Hydrochloride	SS		ORAL
			Hydroxyzine Hydrochloride	SS		ORAL

Amiodarone	SS		ORAL
Betahistine Hydrochloride	SS		ORAL
Fosinopril Sodium	C		ORAL
Clonidine Hydrochloride	C		ORAL
Amlodipine Besylate	C		ORAL
Pravastatin Sodium	C		ORAL
Loprazolam Mesylate	C		ORAL
Acenocoumarol	C		ORAL
Potassium Chloride	C		ORAL

Date:08/04/05ISR Number: 4734664-XReport Type:Expedited (15-DaCompany Report #FR-MERCK-0412FRA00059
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Life-Threatening	Cardiac Arrest		Pindolol	SS		ORAL		
Hospitalization - Initial or Prolonged	General Physical Health Deterioration		Tamsulosin Hydrochloride	SS		ORAL		
	Loss Of Consciousness		Glimepiride	SS		ORAL		
	Nosocomial Infection		Metformin	SS		ORAL		
	Pseudomonas Infection							
	Sepsis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4734665-1Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503CAN00093
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Sertraline Hydrochloride	C				
UNKNOWN								

Date:08/04/05ISR Number: 4734666-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01384
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4734667-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00659
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Anhedonia		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Disorder		Metoprolol Tartrate	C		ORAL		
Disability	Depressed Mood		Tolperisone Hydrochloride	C		ORAL		
	Gastric Ulcer		Amitriptyline Hydrochloride	C		ORAL		
	Gastritis		Pantoprazole Sodium	C		ORAL		
	Helicobacter Pylori		Nonsteroidal Anti-Inflammatory Drug (Unspecified)	C				
	Identification Test Positive							
	Myocardial Infarction							
	Reflux Oesophagitis							
UNKNOWN								
	Sinus Tachycardia		Citalopram Hydrobromide	C				
	Syncope							
UNKNOWN								
	Therapeutic Response Decreased		Equilin Sodium Sulfate And Estrone Sodium Sulfate	C		ORAL		
			Potassium Iodide	C				
UNKNOWN								

Date:08/04/05ISR Number: 4734668-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01941
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Musculoskeletal Disorder							
	Polytraumatism							

Date:08/04/05ISR Number: 4734675-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03353
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4734687-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01281
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Hydrocodone/Apap	C			UNKNOWN	
	Increased		Vicodin Tablets	C			UNKNOWN	
	Coronary Artery Disease		Darvocet-N	C			UNKNOWN	
	Depression		Celebrex	C			UNKNOWN	
	Fatigue		Vicoprofen	C			UNKNOWN	
	Gastritis		Roxicet	C			UNKNOWN	
	Gastrooesophageal Reflux		Ambien	C			UNKNOWN	
	Disease		Temazepam	C			UNKNOWN	
	Hepatic Cirrhosis							
	Hepatitis C							
	Hiatus Hernia							
	Hyperhidrosis							
	Hypertension							
	Myocardial Infarction							
	Oesophagitis							
	Pain							
	Rotator Cuff Syndrome							
	Vomiting							

Date:08/04/05ISR Number: 4734689-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02119
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Cerebrovascular Accident							

Heart Rate Irregular
Hypertension
Myocardial Infarction
Pneumonia
Polytraumatism
Rheumatoid Arthritis
Silent Myocardial
Infarction
Swelling

Date:08/04/05ISR Number: 4734690-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00237
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL	5 MON	
Disability	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	5 MON	
			Celebrex	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4734691-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00103
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		46 MON
Initial or Prolonged	Chest Pain		Zestril	C		ORAL		
Other	Depression		Tylenol	C		ORAL		
	Gastric Infection		Insulin	C		SUBCUTANEOUS		
	Myocardial Infarction		Synthroid	C		ORAL		
	Nephrolithiasis		Lescol	C		ORAL		

Date:08/04/05ISR Number: 4734692-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02143
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		429 MON
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		429 MON
	Increased		Lopressor	C		UNKNOWN		
	Cataract		Saw Palmetto	C		UNKNOWN		
	Glaucoma		Vitamins (Unspecified)	C		UNKNOWN		
	Lower Limb Fracture							
	Myocardial Infarction		Ecotrin	C		UNKNOWN		
	Pain		Cosopt	C		UNKNOWN		
	Thrombosis		Hydrocodone Bitartrate	C		UNKNOWN		
			Lumigan	C		UNKNOWN		
			Zymar	C		UNKNOWN		
			Acular	C		UNKNOWN		
			Zestril	C		UNKNOWN		

			Quixin	C		
UNKNOWN						

Date:08/04/05ISR Number: 4734693-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02116
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
1753 DAY						
Initial or Prolonged	Arthritis Infective		Vioxx	SS	Merck & Co., Inc	ORAL
1753 DAY						
	Arthropathy		Glucovance	C		
UNKNOWN						
	Blood Cholesterol		Celebrex	C		
UNKNOWN						
	Increased		Neurontin	C		
UNKNOWN						
	Blood Triglycerides		Ambien	C		
UNKNOWN						
	Increased		Tylenol	C		
UNKNOWN						
	Chronic Fatigue Syndrome					
	Dyspepsia					
	Dyspnoea					
	Hypertension					
	Myocardial Infarction					
	Surgery					
	Thrombosis					

Date:08/04/05ISR Number: 4734694-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01284
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Atherosclerosis
Initial or Prolonged	Blood Cholesterol
Disability	Increased
Other	Cardiovascular Disorder
	Cerebrovascular Accident

		Constipation					
		Deafness					
		Dyspepsia	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Haematochezia		Diovan	C		
UNKNOWN							
		Hypertension		Atenolol	C		
UNKNOWN							
		Knee Arthroplasty		Lipitor	C		
UNKNOWN							
		Pain		Plavix	C		
UNKNOWN							
		Thrombosis		Warfarin	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Vitamins (Unspecified)	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Glucosamine	C		
UNKNOWN							
				Lovenox	C		
UNKNOWN							
				Alprazolam	C		
UNKNOWN							
				Ultracet	C		
UNKNOWN							
				Darvocet-N	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:08/04/05ISR Number: 4734696-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00780
Age: Gender:Male I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged Other	Adverse Event
	Anaemia
	Angina Pectoris
	Arthralgia
	Basal Cell Carcinoma
	Blood Pressure Increased
	Bronchitis
	Bundle Branch Block Left
	Carotid Artery Stenosis
	Carpal Tunnel Syndrome
	Chest Pain
	Colon Cancer
	Convulsion
	Coronary Artery Disease
	Diverticulum
	Drug Abuser
	Dysphagia
	Dyspnoea
	Hiatus Hernia
	Intestinal Obstruction
	Limb Discomfort
	Loss Of Consciousness
	Oesophagitis
	Osteoarthritis
	Polyp
	Post Procedural Haematoma
	Prostatitis
	Renal Cyst
	Retrograde Ejaculation
	Rotator Cuff Syndrome
	Seborrhoeic Keratosis
	Tinnitus

		Upper Respiratory Tract Infection					
		Urinary Retention	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Prevacid	C		
UNKNOWN							
				Amitriptyline Hydrochloride	C		ORAL
				Atenolol	C		ORAL
				Atenolol	C		ORAL
				Nitroquick	C		
SUBLINGUAL							
				Aspirin	C		
UNKNOWN							
				Lipitor	C		ORAL
				Zantac	C		ORAL
				Plavix	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							
				Baycol	C		
UNKNOWN							
				Pravachol	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Hydrocodone Bitartrate And Acetaminophen	C		
UNKNOWN							

Date:08/04/05ISR Number: 4734698-5Report Type:Expedited (15-DaCompany Report #FR-MERCK-0501FRA00030
Age:60 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Glomerulonephritis		Vioxx	PS	Merck & Co., Inc	ORAL
				Diclofenac Sodium And Misoprostol	SS		ORAL

Date:08/04/05ISR Number: 4734700-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00241
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Theophylline	C				
UNKNOWN								
	Myocardial Infarction		Albuterol	C				
RESPIRATORY								
	Nervous System Disorder							
(INHALATION)								
			Aciphex	C				
UNKNOWN								
			Singulair	C				
UNKNOWN								
			Pulmicort	C				
UNKNOWN								
			Ultram	C				
UNKNOWN								
			Fosamax	C				
UNKNOWN								

Date:08/04/05ISR Number: 4734702-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01961
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
17 MON								
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
17 MON								
Disability	Knee Arthroplasty		Synthroid	C				
UNKNOWN								
	Myocardial Infarction		Premarin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4734775-9Report Type:Expedited (15-DaCompany Report #0405GBR00191
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Eye Haemorrhage		Augmentin	PS	Glaxosmithkline		UNKNOWN	
			Co-Dydramol	SS	Glaxosmithkline		UNKNOWN	
			Methotrexate	SS			UNKNOWN	
			Vioxx	SS		ORAL		
			Fluoxetine	SS			UNKNOWN	
			Premarin	SS			UNKNOWN	
			Humira	SS				
			Premarin	SS			UNKNOWN	

Date:08/04/05ISR Number: 4734801-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00738
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Lortab	C			UNKNOWN	
	Angina Pectoris		Soma	C			UNKNOWN	
	Blood Pressure Increased		Viagra	C			UNKNOWN	
	Chest Discomfort		Vicodin Tablets	C			UNKNOWN	
	Convulsion		Temazepam	C			UNKNOWN	
	Coronary Artery Disease							
	Coronary Artery							
	Restenosis							
	Epicondylitis							
	Hot Flush							
	Myocardial Infarction							
	Pulmonary Hypertension							
	Radial Tunnel Syndrome							

Rotator Cuff Syndrome
Thrombosis

Date:08/04/05ISR Number: 4734811-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00243
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Meprednisone	C			UNKNOWN	
			Diprolene	C			UNKNOWN	

Date:08/04/05ISR Number: 4734812-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04088
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735038-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA00419
Age:51 YR Gender:Female I/FU:F

Outcome	PT
Disability	Anaemia
	Arthropod Bite

		Arthropod Sting					
		Blister					
		Breast Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Bursitis		Vioxx	PS	Merck & Co., Inc	ORAL
15	DAY						
		Cervicobrachial Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
245	DAY						
		Chest Pain		Fosamax	C		ORAL
		Chest Wall Pain		Evista	C		
UNKNOWN							
		Chronic Sinusitis		Nitrostat	C		
UNKNOWN							
		Conjunctivitis		Valtrex	C		
UNKNOWN							
		Constipation		Glucosamine	C		
UNKNOWN							
		Contusion		Neurontin	C		
UNKNOWN							
		Coronary Artery Disease		Neurontin	C		
UNKNOWN							
		Drug Intolerance		Neurontin	C		
UNKNOWN							
		Dyspepsia		Valium	C		
UNKNOWN							
		Fall					
		Fracture Nonunion					
		Generalised Anxiety					
		Disorder					
		Hypercalcaemia					
		Hypoaesthesia					
		Infection					
		Influenza					
		Insomnia					
		Joint Sprain					
		Libido Decreased					
		Metabolic Disorder					
		Metastatic Neoplasm					
		Micturition Urgency					
		Multiple Fractures					
		Oedema Peripheral					
		Osteopenia					
		Osteoporosis					
		Osteoporotic Fracture					
		Panic Disorder					
		Road Traffic Accident					
		Sacroiliitis					

Sebaceous Hyperplasia
Sinusitis
Spinal Disorder
Thoracic Outlet Syndrome
Urinary Tract Infection
Urine Leukocyte Esterase
Positive
Viral Pharyngitis
Weight Increased

Date:08/04/05ISR Number: 4735042-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01938
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
Disability	Cardiac Disorder
Other	Cardiac Failure
	Congestive
	Chest Pain
	Cholelithiasis
	Convulsion
	Cough
	Diabetes Mellitus

		Gastric Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
		Infection		Vioxx	SS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Foltx	C		
UNKNOWN							
		Pain					
		Polytraumatism					
		Ulcer					

Date:08/04/05ISR Number: 4735043-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01917
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Aleve	C		
UNKNOWN						
	Atherosclerosis		Prilosec	C		
UNKNOWN						
	Carpal Tunnel Syndrome					
	Coronary Artery Disease					
	Emotional Distress					
	Joint Injury					
	Musculoskeletal Stiffness					
	Pelvic Discomfort					
	Renal Disorder					
	Rotator Cuff Syndrome					
	Shoulder Pain					
	Sleep Apnoea Syndrome					

Date:08/04/05ISR Number: 4735044-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00280
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Embolic Stroke		Vioxx [Therapy	PS	Merck & Co., Inc	ORAL

Unspecified] C
UNKNOWN

Date:08/04/05ISR Number: 4735045-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01354
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Cardiopulmonary Failure		Vioxx	SS	Merck & Co., Inc	ORAL		7 MON
	Dyspepsia		Paxil	C				UNKNOWN
	Hypertension		Klonopin	C				UNKNOWN
	Pain							
	Prostatitis							
	Respiratory Disorder							
	Sleep Disorder							

Date:08/04/05ISR Number: 4735046-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01928
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Anxiety

	Blood Cholesterol Increased						
	Bradycardia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL	
	Coronary Artery		Allegra	C			UNKNOWN
	Perforation		Vitamins (Unspecified)	C			UNKNOWN
	Emotional Distress						
	Gastric Disorder		Biaxin	C			UNKNOWN
	Gastrooesophageal Reflux Disease						
	Gout						
	Hyperlipidaemia						
	Mitral Valve Incompetence						
	Myocardial Infarction						
	Nasal Disorder						
	Tricuspid Valve Incompetence						

Date:08/04/05ISR Number: 4735047-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01352
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL	52 MON
Initial or Prolonged	Thrombosis		Prempro	C			UNKNOWN
			Tenormin	C			UNKNOWN
			Zocor	C			UNKNOWN
			Tamoxifen Citrate	C			UNKNOWN

Date:08/04/05ISR Number: 4735048-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01897
Age:52 YR Gender:Male I/FU:F

Outcome	PT
Life-Threatening	Acute Myocardial Infarction
Hospitalization - Initial or Prolonged	Anuria
Other	Anxiety Disorder
	Arrhythmia
	Atrial Fibrillation
	Cardiac Arrest
	Cardiac Failure
	Congestive
	Cardiogenic Shock
	Catheter Related Infection
	Cerebrovascular Accident
	Chest Wall Pain
	Cholelithiasis
	Coronary Artery Disease
	Depressed Level Of Consciousness
	Diabetic Gastroparesis
	Dressler'S Syndrome
	Drug Ineffective
	Drug Intolerance
	Emotional Distress
	Gastritis
	Hypertension
	Ileus Paralytic

		Lung Infiltration					
		Musculoskeletal Chest Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Oral Intake Reduced		Vioxx	SS	Merck & Co., Inc	ORAL
		Pleural Effusion		Glucophage	C		
UNKNOWN							
		Post Procedural Pain		Flovent	C		
UNKNOWN							
		Postoperative Thoracic		Serevent	C		
UNKNOWN							
		Procedure Complication		Amaryl	C		
UNKNOWN							
		Renal Failure Acute					
		Renal Failure Chronic					
		Respiratory Failure					
		Sedation					
		Staphylococcal Infection					
		Ventricular Dysfunction					
		White Blood Cell Count Increased					
		Wound Infection					

Date:08/04/05ISR Number: 4735049-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00419
Age:53 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL
		Fluctuation		Metoprolol Succinate	C		ORAL
		Chest Pain		Zocor	C		ORAL
		Dizziness		Acetylcysteine	C		ORAL
		Epistaxis		Pantoprazole	C		ORAL
		General Physical Health		Levothyroxine Sodium	C		ORAL
		Deterioration		Fenoterol			
		Headache		Hydrobromide And			
		Nausea		Ipratropium Bromide	C		
RESPIRATORY							
		Paraesthesia					
(INHALATION)							
				Budesonide	C		
RESPIRATORY							

(INHALATION)

	Folic Acid	C	
UNKNOWN			

Date:08/04/05ISR Number: 4735054-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00275
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL	1634 DAY	
	Anxiety							
	Arrhythmia							
	Cold Sweat							
	Gastritis							
	Hyperthyroidism							
	Palpitations							
	Reflux Oesophagitis							

Date:08/04/05ISR Number: 4735059-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01964
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Disability	Angina Pectoris
	Carotid Artery Stenosis
	Cerebrovascular Accident

	Coronary Artery Disease Diabetes Mellitus Polytraumatism	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Transient Ischaemic		Vioxx	PS	Merck & Co., Inc	ORAL
1738 DAY						
	Attack		Xanax	C		
UNKNOWN						
			Amaryl	C		
UNKNOWN						
			Prevacid	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Endocet	C		
UNKNOWN						

Date:08/04/05ISR Number: 4735060-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04547
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
6 MON						
Disability	Cardiac Disorder		Lipitor	C		
UNKNOWN	8 YR					
Other	Cardiovascular Disorder		Zocor	C		
UNKNOWN						
	Hypertension		Valium	C		
UNKNOWN						
	Myocardial Infarction		Aspirin	C		
UNKNOWN						
	Pain		Advil	C		
UNKNOWN						
	Post Procedural Pain		Medrol	C		
UNKNOWN						

Date:08/04/05ISR Number: 4735061-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02006
Age:84 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					

Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Hernia		Ultracet	C		
UNKNOWN						
	Polytraumatism		Zoloft	C		
UNKNOWN						
			Fosamax	C		
UNKNOWN						
			Flexeril	C		
UNKNOWN						
			Prednisolone	C		
UNKNOWN						
			Glipizide Xl	C		
UNKNOWN						
			Zocor	C		
UNKNOWN						
			Zantac	C		
UNKNOWN						
			Hytrin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:08/04/05ISR Number: 4735062-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01951
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL
1192 DAY						
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
1192 DAY						
Disability	Coagulopathy		Synthroid	C		
UNKNOWN						
Other	Coronary Artery Disease					
	Depression					
	Generalised Anxiety					
	Disorder					
	Myocardial Infarction					
	Oedema					
	Panic Attack					
	Polytraumatism					
	Pulmonary Embolism					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4735063-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02565
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Prerenal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		22 MON
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Angina Unstable		Prempro	C				UNKNOWN
	Asthenia		Questran	C				UNKNOWN
	Bacteria Urine Identified		Mylanta & Mylanta Ds	C				UNKNOWN
	Blood Pressure Increased		Protonix	C				UNKNOWN
	Cataract							
	Cellulitis							
	Dementia							
	Depression							
	Ear Disorder							
	Epistaxis							
	Hallucination							
	Headache							
	Hypokalaemia							
	Hyponatraemia							
	Myocardial Infarction							
	Platelet Aggregation Increased							
	Pleural Effusion							
	Skin Lesion							
	Tachycardia							
	Urine Output Decreased							

Date:08/04/05ISR Number: 4735064-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02121
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc			UNKNOWN
	Cardiac Disorder							
	Cerebrovascular Accident							
	Dyspnoea							

Goitre
Myocardial Infarction
Transient Ischaemic
Attack

Date:08/04/05ISR Number: 4735065-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00721
Age:36 YR Gender:Male I/FU:F

Outcome PT
Disability Accident At Work
Other Anger
Antisocial Personality
Disorder
Anxiety
Arthralgia
Back Pain
Chest Pain
Chondromalacia
Condyloma Acuminatum
Drug Ineffective
Dysuria
Exostosis
Gastrointestinal Disorder

		Grip Strength Decreased					
		Heart Rate Increased					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Degeneration		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Intervertebral Disc		Vioxx	SS	Merck & Co., Inc	ORAL
		Protrusion		Risperdal	C		ORAL
		Joint Injury		Glucosamine	C		
UNKNOWN							
		Myalgia		Zyprexa	C		
UNKNOWN							
		Myocardial Infarction		Lithium Acetate	C		
UNKNOWN							
		Neck Injury		Motrin	C		
UNKNOWN							
		Nocturia		Vicodin Tablets	C		
UNKNOWN							
		Overdose		Neuroton	C		
UNKNOWN							
		Pain In Extremity					
		Palpitations					
		Post-Traumatic Stress Disorder					
		Road Traffic Accident					
		Rotator Cuff Syndrome					
		Sensory Loss					

Date:08/04/05ISR Number: 4735066-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01957
Age:37 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Polytraumatism		Plaquenil	C		
UNKNOWN							
Disability		Systemic Lupus Erythematosus					

Date:08/04/05ISR Number: 4735067-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01268
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Benign Prostatic Hyperplasia Blood Cholesterol Increased Cerebrovascular Accident Depression Hypertension Pain Road Traffic Accident Spinal Cord Injury Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON

Date:08/04/05ISR Number: 4735072-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02276
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		673 DAY
Other			Vioxx	SS	Merck & Co., Inc	ORAL		673 DAY
			Actos	C				UNKNOWN
			Glucophage	C				UNKNOWN

				Prinivil	C		
UNKNOWN		1159 DAY					
				Lipitor	C		
UNKNOWN							
				Tricor	C		
UNKNOWN							

Date:08/04/05ISR Number: 4735077-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03722
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
			Aspirin	C		
UNKNOWN						
			Ambien	C		
UNKNOWN						
			Cutivate	C		
UNKNOWN						
			Doxazosin Mesylate	C		
UNKNOWN						
			Enalapril Maleate	C		
UNKNOWN						
			Loprox	C		
UNKNOWN						
			Lorazepam	C		
UNKNOWN						
			Nifediac	C		
UNKNOWN						
			Paxil	C		
UNKNOWN						
			Ultram	C		
UNKNOWN						
			Vi-Q-Tuss Expectorant	C		
UNKNOWN						
			Zithromax Tripak	C		
UNKNOWN						
			Zithromax Z-Pak	C		
UNKNOWN						
			Zyrtec	C		
UNKNOWN						
			Claritin	C		
UNKNOWN						

				Meclizine	C		
UNKNOWN							
				Methocarbamol	C		
UNKNOWN							
				Procardia	C		
UNKNOWN							
				Dyazide	C		
UNKNOWN							

Date:08/04/05ISR Number: 4735078-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00885
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Oxybutynin	C				
UNKNOWN								
	Cerebrovascular Accident		Clonazepam	C				
UNKNOWN								
	Dementia Alzheimer'S Type		Aricept	C				
UNKNOWN								
	Depression		Lisinopril	C				
UNKNOWN								
	Hypertension		Omeprazole	C				
UNKNOWN								
	Intestinal Ulcer		Omeprazole	C				
UNKNOWN								
	Renal Impairment		Paxil	C				
UNKNOWN								
	Sleep Disorder		Paxil	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Lipitor	C				
UNKNOWN								
			Nortriptyline	C				
UNKNOWN								

Date:08/04/05ISR Number: 4735079-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00773
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 77 DAY	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Deafness Unilateral	Vioxx	SS	Merck & Co., Inc	ORAL
100 DAY					
Other	Joint Swelling	Accupril	C		
UNKNOWN					
	Knee Arthroplasty	Alexin (Cephalexin)	C		
UNKNOWN					
		Lasix (Furosemide)	C		
UNKNOWN					

			Glucotrol Xl	C		
UNKNOWN						
			Hydrocodone/Apap	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:08/04/05ISR Number: 4735080-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00859
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
22 MON						
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
19 MON						
	Diabetes Mellitus		Aspirin	SS		
UNKNOWN	14 MON					
	Non-Insulin-Dependent		Prednisone	C		
UNKNOWN						
	Dyspepsia		Levitra	C		
UNKNOWN						
	Hypertension		Lortab	C		
UNKNOWN						
	Overdose		Tylenol	C		
UNKNOWN						
	Peptic Ulcer		Celebrex	C		
UNKNOWN						
	Renal Disorder					
	Renal Failure					

Date:08/04/05ISR Number: 4735081-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03738
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
60 MON						
Initial or Prolonged	Blood Cholesterol		[Therapy			
	Increased		Unspecified]	C		
UNKNOWN						

	Blood Pressure Increased		Hydrochlorothiazide	
	Cardiac Murmur		And Triamterene	C
UNKNOWN				
	Cerebrovascular Accident		Lotrel	C
UNKNOWN				
	Chest Pain		Celexa	C
UNKNOWN				
	Convulsion		Altace	C
UNKNOWN				
	Fall			
	Loss Of Consciousness			
	Mitral Valve Prolapse			
	Myocardial Infarction			
	Obesity			
	Sleep Apnoea Syndrome			
	Thrombosis			

Date:08/04/05ISR Number: 4735082-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00257
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL	29 MON	
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	29 MON	
	Increased		Premarin	C				
UNKNOWN								
	Fatigue							
	Gastrooesophageal Reflux Disease							
	Hot Flush							
	Myocardial Infarction							
	Pulmonary Embolism							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4735083-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03717
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		1905 DAY
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		1905 DAY
	Diabetes Mellitus		Norvasc	C		ORAL		
	Hernia		Aspirin	C		ORAL		
	Musculoskeletal		Lipitor	C		ORAL		
	Discomfort		Wellbutrin Sr	C		ORAL		
	Myocardial Infarction		Wellbutrin Sr	C		ORAL		
	Transient Ischaemic Attack							

Date:08/04/05ISR Number: 4735084-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04789
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		8 MON
Other	Increased Blood Pressure Inadequately Controlled							
	Bunion							
	Deep Vein Thrombosis							
	Dyspepsia							
	Dyspnoea							
	Gallbladder Disorder							
	Liver Disorder							
	Muscle Spasms							
	Overdose							
	Renal Failure							

Date:08/04/05ISR Number: 4735085-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01962
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Anxiety	Vioxx	PS	Merck & Co., Inc	ORAL
689 DAY					
Other	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	ORAL
689 DAY					
	Increased	Premarin	C		
UNKNOWN					
	Cerebrovascular Accident	Claritin	C		
UNKNOWN					
	Convulsion	Allegra	C		
UNKNOWN					
	Depression	Provera	C		
UNKNOWN					
	Loss Of Consciousness	Nasacort	C		
UNKNOWN					
	Polytraumatism	Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN					
		Cephalexin	C		
UNKNOWN					
		Lamisil	C		
UNKNOWN					
		Prednisone	C		
UNKNOWN					

Date:08/04/05ISR Number: 4735086-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00267
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Other	Adverse Event
	Angina Pectoris
	Anxiety Disorder
	Cardiac Disorder
	Chest Pain

		Chronic Fatigue Syndrome					
		Condition Aggravated					
		Decreased Interest	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Depression		Vioxx	PS	Merck & Co., Inc	ORAL
		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Vioxx	SS	Merck & Co., Inc	ORAL
		Loss Of Consciousness		Coumadin	C		
UNKNOWN							
		Myocardial Infarction		Coumadin	C		
UNKNOWN							
		Overdose		Aspirin	C		
UNKNOWN							
		Panic Disorder		Ambien	C		
UNKNOWN							
		Suicidal Ideation		Acetaminophen And			
		Tachycardia		Hydrocodone			
				Bitartrate	C		
UNKNOWN							
				Neurontin	C		
UNKNOWN							
				Digitek	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							

Date:08/04/05ISR Number: 4735087-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02026
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Blindness Unilateral		Toprol Xl Tablets	C		
UNKNOWN						
Disability	Cerebrovascular Accident		Catapres	C		
UNKNOWN	412 DAY					
Other	Cholelithiasis		Premarin	C		
UNKNOWN						
	Cough					
	Eye Disorder					
	Eye Haemorrhage					
	Gastroenteritis Viral					
	Polytraumatism					
	Tooth Abscess					

Date:08/04/05ISR Number: 4735088-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00173
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
			Tarka	C			UNKNOWN	
			Prinivil	C			UNKNOWN	
			Albuterol	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Lortab	C			UNKNOWN	
			Xanax	C			UNKNOWN	

Date:08/04/05ISR Number: 4735089-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02973
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Zoloft	C			UNKNOWN	
	Dyspepsia		Trazodone Hydrochloride	C			UNKNOWN	
	Hypertension							
	Myocardial Infarction		Allegra	C			UNKNOWN	
	Oedema		Ibuprofen	C			UNKNOWN	
			Xanax	C			UNKNOWN	

Enalapril Maleate C
UNKNOWN

Date:08/04/05ISR Number: 4735090-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00768
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735091-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00502
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735092-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00679
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735093-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00777
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735094-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00775
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735095-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00356
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								1002 DAY

Date:08/04/05ISR Number: 4735096-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02264
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Aspirin	C		ORAL		
Disability	Cerebrovascular Accident		Prinivil	C				
UNKNOWN								
	Epistaxis		Accupril	C				
UNKNOWN								
	Transient Ischaemic		Toprol Xl Tablets	C				
UNKNOWN								
	Attack		Tiazac	C				
UNKNOWN								
			Nexium	C				
UNKNOWN								
			Hydrodiuril	C				
UNKNOWN								
			Allopurinol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/04/05ISR Number: 4735097-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02272
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1606 DAY	
	Cardiac Failure		Zetia	C		ORAL		
	Congestive		Zocor	C		ORAL	944 DAY	
	Cerebrovascular Accident		Atenolol	C			UNKNOWN	939 DAY
	Diabetes Mellitus		Coumadin	C			UNKNOWN	62 DAY
	Myocardial Infarction		Prilosec	C			UNKNOWN	
			Cosopt	C			UNKNOWN	
			Xalatan	C			UNKNOWN	

Date:08/04/05ISR Number: 4735098-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04323
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:08/04/05ISR Number: 4735099-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04273
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Atenolol	C			UNKNOWN	
	Depression		Aspirin	C			UNKNOWN	

Date:08/04/05ISR Number: 4735100-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04247
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR
Initial or Prolonged	Myocardial Infarction							
Disability	Polytraumatism							

Date:08/04/05ISR Number: 4735101-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00888
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Cardiac Murmur							
	Depression							
	Hypertension							
	Myocardial Infarction							
	Overdose							
	Pain In Extremity							

Date:08/04/05ISR Number: 4735102-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00093
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Distension
Initial or Prolonged	Blood Cholesterol
	Increased
	Diabetes Mellitus

	Dyspepsia						
	Gout						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	50 DAY
			Aspirin	C			UNKNOWN
			Zocor	C		ORAL	
			Colchicine	C			UNKNOWN
			Allopurinol	C			UNKNOWN
			Glyburide	C			UNKNOWN
			Fosinopril Sodium	C			UNKNOWN

Date:08/04/05ISR Number: 4735103-5Report Type:Expedited (15-DaCompany Report #IT-MERCK-0508ITA00001
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	18 MON
	Hyperhidrosis						
	Hypertension						
	Insomnia						
	Myocardial Infarction						
	Vertigo						
	Visual Acuity Reduced						

Date:08/04/05ISR Number: 4735104-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00774
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	806 DAY

Date:08/04/05ISR Number: 4735105-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00353
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735106-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00165
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Valve Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ibuprofen	C				
UNKNOWN								

Date:08/04/05ISR Number: 4735107-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00477
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735108-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00087
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/04/05ISR Number: 4735109-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00358
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735110-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04325
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735111-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04378
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Chest Pain Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735112-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00572
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/04/05ISR Number: 4735113-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00478
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4735547-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0202USA01241
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		4 DAY
Initial or Prolonged	Antisocial Behaviour		Vioxx	SS	Merck & Co., Inc	ORAL		4 DAY
Disability	Anxiety							
	Carpal Tunnel							
	Decompression							
	Chest Discomfort							
	Convulsion							
	Depression							
	Disturbance In Attention							
	Headache							
	Insomnia							
	Pneumonia							
	Rhinalgia							
	Rhinitis							
	Sensation Of Pressure							
	Sinus Headache							
	Suicidal Ideation							
	Tinnitus							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735554-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00475
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Diarrhoea		Acupril	C		
UNKNOWN						
Other	Diplopia		Premarin	C		ORAL
	Diverticulum		Lipitor	C		ORAL
	Dyspepsia		Hydrochlorothiazide	C		ORAL
	Eye Disorder		Aspirin	C		ORAL
	Haemorrhoids		Premarin	C		
VAGINAL						
	Headache		Prilosec	C		ORAL
	Intervertebral Disc		Claritin	C		ORAL
	Degeneration		Vitamin E	C		ORAL
	Myasthenia Gravis		Miacalcin	C		
UNKNOWN						
	Nausea					
	Osteopenia					
	Osteoporosis					
	Pain					
	Pain In Extremity					
	Plantar Fasciitis					
	Rectocele					
	Rhinitis Allergic					
	Spinal Column Stenosis					
	Spinal Compression					
	Fracture					
	Spondylolisthesis					
	Vaginal Prolapse					
	Vertigo					
	Vomiting					

Date:08/05/05ISR Number: 4735560-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01985
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
8 MON						
	Sleep Apnoea Syndrome		Aspirin	C		ORAL

UNKNOWN	Prevacid	C
UNKNOWN	Zocor	C
UNKNOWN	Toprol Xl Tablets	C
UNKNOWN	Prednisone	C
UNKNOWN	Genotropin	C
UNKNOWN	Levoxyl	C
UNKNOWN	Ddavp	C
UNKNOWN	Biaxin	C
UNKNOWN	Nasocort	C
UNKNOWN	Depo-Testosterone	C
UNKNOWN	Nitroglycerin	C
UNKNOWN	Advil	C
UNKNOWN	Tylenol	C
UNKNOWN		

Date:08/05/05ISR Number: 4735562-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02040
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1 YR
	Myocardial Infarction		Insulin	C		PARENTERAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735563-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01983
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Blood Cholesterol		Aleve	C				UNKNOWN
Disability	Increased		Tylenol	C				UNKNOWN
	Cardiac Disorder		Premarin	C				UNKNOWN
	Cardiac Failure Congestive							
	Cardiac Valve Disease							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Depression							
	Dyspepsia							
	Dyspnoea							
	Gastrooesophageal Reflux Disease							
	Hypertension							
	Myocardial Infarction							
	Oesophageal Disorder							
	Silent Myocardial Infarction							
	Swelling							

Date:08/05/05ISR Number: 4735565-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02719
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Albuterol	C				UNKNOWN
	Emotional Distress		[Therapy					
	Hypertension		Unspecified]	C				UNKNOWN

Advil C

UNKNOWN

Date:08/05/05ISR Number: 4735566-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA03708
Age:82 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
Other	Angina Pectoris
	Aortic Valve Disease
	Mixed
	Atrial Fibrillation
	Bladder Disorder
	Cardiac Valve Disease
	Coronary Artery Disease
	Heart Rate Irregular
	Mitral Valve Incompetence
	Myocardial Infarction
	Myocardial Ischaemia
	Oedema Peripheral
	Renal Failure Chronic
	Sinus Bradycardia
	Tricuspid Valve Incompetence
	Ventricular Hypertrophy

Vision Blurred

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Actonel	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Flonase	C			UNKNOWN	
	Lipitor	C		ORAL		
	Synthroid	C		ORAL		
	Icaps	C			UNKNOWN	

Date:08/05/05ISR Number: 4735567-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02117
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
745 DAY								
Initial or Prolonged	Cardiovascular Disorder		Ventolin (Albuterol)	C				
UNKNOWN								
Other	Chest Pain		Atrovent	C				
UNKNOWN								
	Coronary Artery Disease		Augmentin	C				
UNKNOWN								
	Gallbladder Disorder		Ceftin	C				
UNKNOWN								
	Myocardial Infarction		Celebrex	C				
UNKNOWN								
	Polytraumatism		Cipro	C				
UNKNOWN								
	Postoperative Infection		Clindamycin	C				
UNKNOWN								
			Cogentin	C				
UNKNOWN								
			Clonazepam	C				
UNKNOWN								
			Clonazepam	C				
UNKNOWN								

UNKNOWN		Clonidine	C
UNKNOWN		[Therapy Unspecified]	C
UNKNOWN		Cortatrigen	C
UNKNOWN		Depakote	C
UNKNOWN		Doxycycline	C
UNKNOWN		Lasix (Furosemide)	C
UNKNOWN		Lasix (Furosemide)	C
UNKNOWN		Hydrocodone Bitartrate	C
UNKNOWN		[Therapy Unspecified]	C
UNKNOWN		Levaquin	C
UNKNOWN		Lorazepam	C
UNKNOWN		Macrobid	C
UNKNOWN		Medroxyprogesterone Acetate	C
UNKNOWN		Miacalcin	C
UNKNOWN		Mobic	C
UNKNOWN		Nasonex	C
UNKNOWN		Neurontin	C
UNKNOWN		Penicillin (Unspecified)	C
UNKNOWN		Premarin	C
UNKNOWN		Prempro	C
UNKNOWN		Promethazine	C
UNKNOWN		Ranitidine	C
UNKNOWN		Seroquel	C
UNKNOWN		Serzone	C

	Serzone	C
UNKNOWN		
	Zestril	C
UNKNOWN		
	Zoloft	C
UNKNOWN		
	Zoloft	C
UNKNOWN		

Zyprexa	C	UNKNOWN
Ibuprofen	C	UNKNOWN
Ultracet	C	UNKNOWN
Roxicet	C	UNKNOWN
Navane	C	UNKNOWN
Navane	C	UNKNOWN
Lanoxin	C	UNKNOWN
Nitro-Spray	C	UNKNOWN
Prilosec	C	UNKNOWN
Fosamax	C	UNKNOWN
[Therapy Unspecified]	C	UNKNOWN
Prednisone	C	UNKNOWN
Prednisone	C	UNKNOWN
Aspirin	C	UNKNOWN
Albuterol	C	UNKNOWN

Date:08/05/05ISR Number: 4735568-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02681
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Disorder		Lipitor	C			UNKNOWN	
	Cardiac Disorder		Glucophage	C			UNKNOWN	
	Carpal Tunnel Syndrome		Insulin	C			UNKNOWN	
	Cerebrovascular Accident							

Depression
Disorientation
Fall
Hypertension
Knee Operation
Nausea
Osteoarthritis
Transient Ischaemic
Attack

Date:08/05/05ISR Number: 4735570-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01965
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
Initial or Prolonged	Arterial Occlusive		Prinivil	C			UNKNOWN	
Disability	Disease		Zestril	C			UNKNOWN	
	Back Disorder		Norvasc	C			UNKNOWN	
	Myocardial Infarction		Hydrochlorothiazide	C			UNKNOWN	
	Surgery		Aspirin	C			UNKNOWN	

Date:08/05/05ISR Number: 4735571-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02140
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Unstable
Initial or Prolonged	Angiopathy
Disability	Arterial Occlusive
Other	Disease
	Cardiac Disorder
	Cerebrovascular Accident
	Chest Pain

		Drug Hypersensitivity Hypersensitivity Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Plendil	C		
UNKNOWN							
				Lasix (Furosemide Sodium)	C		
UNKNOWN							
				Lotrel	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Bextra	C		
UNKNOWN							

Date:08/05/05ISR Number: 4735577-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00503
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Death		Vioxx	PS	Merck & Co., Inc	ORAL
Other		Myocardial Infarction					

Date:08/05/05ISR Number: 4735578-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00345
Age:73 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/05/05ISR Number: 4735579-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00385
Age:61 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 4 MON	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Cardiac Failure 30 YR		Aspirin	C		
Other	Congestive Cardiovascular Disorder		Zocor	C		ORAL
UNKNOWN	Cerebrovascular Accident		Thiamine Hydrochloride	C		
UNKNOWN	Hypertension		Ferrous Sulfate	C		
UNKNOWN	Myocardial Infarction		Sodium Folate	C		

Date:08/05/05ISR Number: 4735580-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04270
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 533 MON	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability UNKNOWN	Blood Cholesterol Increased		Vitamin B (Unspecified)	C		
	Cardiac Failure					
	Diabetes Mellitus					
	Heart Rate Irregular					
	Hypertension					
	Myocardial Infarction					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735581-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01260
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Unstable		Xanax	C			UNKNOWN	
	Dyspnoea		Climara	C			UNKNOWN	
	Hot Flush		Voltaren	C			UNKNOWN	
	Hypertension		Robaxin	C			UNKNOWN	
	Myocardial Infarction		Vasotec	C			UNKNOWN	
	Nausea		Estraderm	C			UNKNOWN	
	Pain		Lopressor	C			UNKNOWN	
			Imdur	C			UNKNOWN	
			Zestril	C			UNKNOWN	
			Maxzide	C			UNKNOWN	
			Elavil	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Penicillin (Unspecified)	C			UNKNOWN	
			Estinyl	C			UNKNOWN	
			Lotensin	C			UNKNOWN	
			Adalat	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Darvocet-N	C			UNKNOWN	
			Anaprox	C			UNKNOWN	
			Plavix	C			UNKNOWN	

	Advil	C	
UNKNOWN			
	Aleve	C	
UNKNOWN			
	Tylenol	C	
UNKNOWN			

Date:08/05/05ISR Number: 4735583-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00134
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol Increased							
	Blood Triglycerides Increased							
	Cerebrovascular Accident							
	Drug Hypersensitivity							
	Gallbladder Disorder							
	Gastrooesophageal Reflux Disease							
	Hernia							
	Hypertension							
	Myocardial Infarction							
	Rib Fracture							

Date:08/05/05ISR Number: 4735584-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01799B1
Age:0 DY Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Congenital Anomaly	Hydronephrosis		Vioxx	PS	Merck & Co., Inc		1	MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735585-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00497
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4735586-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03753
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bacterial Infection		Furosemide	C				
UNKNOWN								
	Bone Infection		Lipitor	C				
UNKNOWN								
	Carotid Artery Stenosis		Advair	C				
UNKNOWN								
	Cerebrovascular Accident		Lisinopril	C				
UNKNOWN								
	Chest Pain		Taztia Xt	C				
UNKNOWN								
	Coronary Artery Disease							
	Drug Hypersensitivity							
	Gastrointestinal Disorder							
	Hernia							
	Hypersensitivity							
	Myocardial Infarction							
	Osteonecrosis							
	Syncope							
	Wound Infection							

Date:08/05/05ISR Number: 4735587-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03703
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrooesophageal Reflux		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Disease		Diovan	C		ORAL		
	Myocardial Infarction		Atenolol	C		ORAL		
			Aspirin	C		ORAL		
			Zocor	C		ORAL		

			Niacin	C		ORAL
			Celexa	C		
UNKNOWN						
			Amitriptyline Hydrochloride	C		
UNKNOWN						
			Amitriptyline Hydrochloride	C		
UNKNOWN						

Date:08/05/05ISR Number: 4735588-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01799M
Age:34 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Drug Exposure During		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Pregnancy							
	Heart Rate Increased							
	Hyperhidrosis							
	Placenta Praevia							

Date:08/05/05ISR Number: 4735589-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03694
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1309	DAY
Initial or Prolonged	Myocardial Infarction		Ambien	C				
UNKNOWN								

				Combivent	C		
UNKNOWN							
				Flovent	C		
UNKNOWN							

Date:08/05/05ISR Number: 4735598-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00496
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/05/05ISR Number: 4735599-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00505
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/05/05ISR Number: 4735961-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00601
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Psoriatic Arthropathy		Diclofenac Resinate	C		ORAL
	Tenosynovitis		Flecainide Acetate	C		ORAL
	Transient Ischaemic Attack		Verapamil Hydrochloride	C		
UNKNOWN						
			Vitamin E	C		
UNKNOWN						
			Aesculus	C		
UNKNOWN						
			Zolpidem Tartrate	C		ORAL
			Equilin Sodium Sulfate And Estrone Sodium Sulfate [Therapy	C		ORAL

Unspecified] C
UNKNOWN

Date:08/05/05ISR Number: 4735962-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA01303
Age:55 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Anaemia
Hospitalization -	Angina Pectoris
Initial or Prolonged	Anxiety
Disability	Arthralgia
Other	Arthritis
	Bereavement Reaction
	Blood Glucose Increased
	Blood Pressure Abnormal
	Bone Pain
	Cardiac Murmur
	Cardiac Valve Disease
	Cardiomegaly
	Chest Pain
	Chest Wall Pain
	Chronic Obstructive
	Pulmonary Disease
	Coronary Artery
	Atherosclerosis
	Coronary Artery Disease

		Coronary Artery Occlusion					
		Coronary Artery Stenosis					
		Depression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL
		Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL
		Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
120	DAY						
		Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL
		Fall		Vioxx	SS	Merck & Co., Inc	ORAL
		Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL
120	DAY						
		Haematoma		Cardizem Cd	C		
UNKNOWN							
		Head Injury		K-Dur	C		
UNKNOWN							
		Headache		Accupril	C		
UNKNOWN		18 DAY					
		Heart Rate Decreased		Accupril	C		
UNKNOWN		38 DAY					
		Herpes Zoster		Accupril	C		
UNKNOWN		152 DAY					
		Hypercholesterolaemia		Paxil	C		
UNKNOWN							
		Hypertension		Paxil	C		
UNKNOWN		42 DAY					
		Hypotension		Paxil	C		
UNKNOWN							
		Insomnia		Paxil	C		
UNKNOWN		145 DAY					
		Irritable Bowel Syndrome		Lasix (Furosemide)	C		
UNKNOWN							
		Mitral Valve Incompetence		Lasix (Furosemide)	C		
UNKNOWN							
		Myocardial Infarction		Lasix (Furosemide)	C		
UNKNOWN							
		Oedema Peripheral		Soma	C		
UNKNOWN							
		Oesophageal Spasm		Aleve	C		
UNKNOWN							
		Oliguria		Nitroglycerin	C		
UNKNOWN							
		Pain		Aspirin	C		
UNKNOWN							
		Paraesthesia		Percocet	C		
UNKNOWN							

	Pelvic Pain	Ferrous Sulfate	C
UNKNOWN			
	Pericardial Effusion	Tylenol Extra	
	Pneumonia	Strength	C
UNKNOWN			
	Procedural Complication		
	Rash Pruritic		
	Restless Legs Syndrome		
	Rhinitis Allergic		
	Sinusitis		
	Somnolence		
	Stress		
	Syncope		
	Tremor		
	Upper Respiratory Tract		
	Infection		
	Ventricular Hypertrophy		

Date:08/05/05ISR Number: 4735965-1Report Type:Expedited (15-DaCompany Report #US-MERCK-01104500
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Acrochordon
Initial or Prolonged	Alcoholic Seizure
Other	Anaemia
	Anion Gap Increased
	Barrett'S Oesophagus
	Blood Pressure
	Fluctuation
	Cardiovascular Disorder
	Change Of Bowel Habit
	Duodenitis
	Encephalopathy
	Gastritis
	Grand Mal Convulsion
	Haematemesis

Headache
Hiatus Hernia
Hordeolum

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	34	DAY

Hypokalaemia
Influenza
Limb Injury
Oedema
Pruritus
Renal Failure
Tenosynovitis Stenosans
Vision Blurred
Weight Decreased

Date:08/05/05ISR Number: 4735966-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00123
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia
Other	Angina Pectoris
	Anxiety
	Asthenia
	Asthma
	Bronchitis
	Bursitis
	Cardiac Failure
	Congestive
	Cataract
	Chest Pain
	Cholecystitis
	Cystitis
	Diabetes Mellitus
	Inadequate Control
	Drug Hypersensitivity
	Duodenitis
	Dyslipidaemia
	Dyspnoea Exertional
	Dysstasia
	Embolic Cerebral
	Infarction
	Emotional Distress
	Fatigue
	Foot Fracture
	Gastritis

Glaucoma
Gout
Haemorrhage
Hypertensive Crisis
Hypertrophic
Cardiomyopathy
Insomnia
Iron Deficiency Anaemia
Irritable Bowel Syndrome
Lactose Intolerance
Macular Degeneration
Malaise
Myocardial Infarction
Optic Disc Drusen
Pain
Pharyngolaryngeal Pain
Renal Failure Chronic

	Restless Legs Syndrome					
	Rheumatoid Arthritis					
	Salivary Gland Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
	Spinal Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL
2	YR					
	Urinary Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
2	YR					
	Urinary Tract Infection		Diovan	C		
UNKNOWN						
	Ventricular Dysfunction		Methotrexate	C		
UNKNOWN						
	Weight Decreased		Prednisone	C		
UNKNOWN						
			Cozaar	C		ORAL

Date:08/05/05ISR Number: 4735969-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02143
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Abdominal Pain					
Other	Anaemia					
	Asthenia					
	Asthma					
	Bronchitis					
	Cardiac Valve Disease					
	Cardiomegaly					
	Carotid Artery Stenosis					
	Cerebrovascular Accident					
	Constipation					
	Contusion					
	Dehydration					
	Dementia Alzheimer'S Type					
	Dizziness					
	Gastritis					
	Glaucoma					
	Goitre					
	Headache					
	Hepatocellular Damage					
	Hypertension					
	Hypoglycaemia					
	Hyponatraemia					
	Injury					

Insomnia
Myocardial Ischaemia
Osteoporosis
Parkinson'S Disease
Renal Failure
Rheumatoid Arthritis
Thyroid Neoplasm
Transient Ischaemic
Attack
Urinary Incontinence
Urinary Tract Infection
Vertigo
Vomiting

Date:08/05/05ISR Number: 4735982-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02802
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased
	Hernia

Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Vioxx	SS	Merck & Co., Inc	ORAL		
	Hytrin	C			UNKNOWN	
	Viagra	C			UNKNOWN	
	Indomethacin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Ascorbic Acid	C			UNKNOWN	
	Vitamins (Unspecified)	C			UNKNOWN	
	Vitamin E	C			UNKNOWN	
	Calcium (Unspecified)	C			UNKNOWN	
	Saw Palmetto	C			UNKNOWN	

Date:08/05/05ISR Number: 4735983-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02101
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome
	Acute Myocardial Infarction
	Angina Unstable
	Anxiety
	Atelectasis
	Blood Cholesterol Increased
	Cervical Stricture
	Cervicitis
	Cholecystitis
	Cold Sweat

Coronary Artery
Atherosclerosis
Coronary Artery Disease
Coronary Artery Occlusion
Coronary Bypass
Thrombosis
Costochondritis
Depression
Dilatation Ventricular
Drug Ineffective
Dyspnoea Exertional
Emotional Distress
Essential Hypertension
Fatigue
Ganglion
Gastrooesophageal Reflux
Disease
Graft Thrombosis
Hiatus Hernia
Hyperlipidaemia
Hypovolaemia
Ileus
Ingrowing Nail
Intervertebral Disc
Degeneration

	Lumbar Radiculopathy						
	Muscle Spasms						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Neuralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Neuritis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ovarian Cyst		Vioxx	SS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Nexium	C			UNKNOWN	
	Panic Attack		Toprol Xl Tablets	C			UNKNOWN	
	Postmenopausal		Vitamins					
	Haemorrhage		(Unspecified)	C			UNKNOWN	
	Respiratory Failure							
	Spinal Column Stenosis							
	Spondylolisthesis							
	Uterine Leiomyoma							

Date:08/05/05ISR Number: 4735985-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02929
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Aspirin	C			UNKNOWN	
	Blood Cholesterol		Duragesic	C			TOPICAL	
	Increased		Oxycodone	C			UNKNOWN	
	Dental Discomfort		Oxycodone	C			UNKNOWN	
	Hypertension		Neurontin	C			UNKNOWN	
	Myocardial Infarction		Hydrocodone					
	Narcolepsy		Hydrochloride	C			UNKNOWN	
	Nerve Injury		Zestril	C			UNKNOWN	
	Pain		Zestril	C			UNKNOWN	
	Seasonal Allergy		Lipitor	C			UNKNOWN	

			Zoloft	C			
UNKNOWN							
			Oxycodone	C			
UNKNOWN							

Date:08/05/05ISR Number: 4735986-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01958
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Disability	Heart Rate Irregular		Glucophage	C				
UNKNOWN								
	Myocardial Infarction		Diflucan	C				
UNKNOWN								
			Cipro	C				
UNKNOWN								
			Xalatan	C				
UNKNOWN								
			Ambien	C				
UNKNOWN								
			Zithromax	C				
UNKNOWN								
			Covera	C				
UNKNOWN								
			Zocor	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								
			Norvasc	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Hyzaar	C				
UNKNOWN								
			Atuss Dm	C				
UNKNOWN								
			Propoxyphene Hydrochloride	C				
UNKNOWN								
			Actos	C				
UNKNOWN								
			Omnicef	C				
UNKNOWN								

				Trimox	C		
UNKNOWN							
				Amaryl	C		
UNKNOWN							

Date:08/05/05ISR Number: 4735987-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02944
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/05/05ISR Number: 4735988-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02131
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arteriosclerosis		Cardizem	C				
UNKNOWN							60	DAY
	Azotaemia		Lipitor	C				
UNKNOWN								
	Blood Cholesterol Increased		Acetaminophen And Hydrocodone Bitartrate	C				
UNKNOWN								
	Coronary Artery Disease							
	Gingival Bleeding		Ultram	C				
UNKNOWN							902	DAY
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Obstructive Airways Disorder							
	Palpitations							
	Tricuspid Valve Incompetence							
	Venous Insufficiency							
	Ventricular Dysfunction							
	Ventricular Fibrillation							

Date:08/05/05ISR Number: 4735989-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01782
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Triglycerides Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiac Failure Congestive							
	Chronic Fatigue Syndrome							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Atherosclerosis							
	Deep Vein Thrombosis							
	Drug Hypersensitivity							
	Emotional Distress							
	Hypertension							
	Lower Gastrointestinal Haemorrhage							
	Myocardial Infarction							
	Pulmonary Embolism							
	Thrombocytopenia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735990-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03353
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4735992-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00150
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4735993-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00130
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Omeprazole Magnesium	C		ORAL		

Date:08/05/05ISR Number: 4735994-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01978
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	65 MON	
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	65 MON	
Disability	Depression		Prilosec	C			UNKNOWN	
Other	Gallbladder Disorder		Librium	C			UNKNOWN	43 YR
	Gout		Ketoprofen	C			UNKNOWN	
	Hypertension		Prednisone	C			UNKNOWN	

	Myocardial Infarction	Prednisone	C
UNKNOWN			
	Transient Ischaemic Attack	Acetaminophen And Hydrocodone Bitartrate	C
UNKNOWN			
		Acetaminophen And Hydrocodone Bitartrate	C
UNKNOWN			
		Indomethacin	C
UNKNOWN			

Date:08/05/05ISR Number: 4735995-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02888
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Occlusion Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4735996-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02997
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4735997-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03158
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
	Cerebrovascular Accident		Celebrex	SS				
Other	Chest Pain							
	Coronary Artery Disease							
	Dementia Alzheimer'S Type							
	General Symptom							
	Hypertension							
	Myocardial Infarction							
	Neck Pain							
	Pain In Extremity							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/05/05ISR Number: 4735998-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01950
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	578 DAY	UNKNOWN
	Anxiety Disorder		Estratest	C				
Disability	Atonic Urinary Bladder		Claritin	C				UNKNOWN
	Blood Cholesterol		Advair	C				UNKNOWN
	Increased		Detrol	C				UNKNOWN
	Cerebrovascular Accident		Nexium	C				UNKNOWN
	Depression		Hydrochlorothiazide	C				UNKNOWN
	Headache							
	Hernia							
	Hypertension							
	Mitral Valve Prolapse							

Date:08/05/05ISR Number: 4736000-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01890
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		23 MON
Initial or Prolonged Disability	Anxiety		Hydrochlorothiazide And Triamterene	C				UNKNOWN
Other	Cerebrovascular Accident		Lotensin	C				UNKNOWN
	Cholecystectomy		Lotensin	C				UNKNOWN
	Deep Vein Thrombosis		Catapres Tts	C				UNKNOWN
	Depression		Naproxen	C				UNKNOWN
	Diabetes Mellitus		Remeron	C				UNKNOWN
	Dyspepsia		Smz-Tmp	C				UNKNOWN
	Dyspnoea		Premarin Vaginal Cream	C				UNKNOWN
	Gastrooesophageal Reflux Disease		Prempro	C				UNKNOWN
	Nausea		Toprol Xl Tablets	C				UNKNOWN
	Oedema Peripheral		Sarafem	C				UNKNOWN
	Pain		Tiazac	C				UNKNOWN
	Pulmonary Embolism		Detrol	C				UNKNOWN
	Sleep Apnoea Syndrome		Synthroid	C				UNKNOWN
	Speech Disorder		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Transient Ischaemic Attack		Klor-Con	C				UNKNOWN
			Lotrel	C				UNKNOWN

			Bextra	C		UNKNOWN
			Hydroxyzine Hydrochloride	C		UNKNOWN
			Ambien	C		UNKNOWN
			Verelan Pm	C		UNKNOWN
			Tricor	C		UNKNOWN
			Ketoprofen	C		UNKNOWN
			Ibuprofen	C		UNKNOWN
			Tylenol	C		UNKNOWN

Date:08/05/05ISR Number: 4736004-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03219
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		[Therapy Unspecified]	C				UNKNOWN
	Constipation		Cefaclor	C				UNKNOWN
	Hypertension		Codeine Phosphate And Guaifenesin	C				UNKNOWN
	Myocardial Infarction		Prednisone	C				UNKNOWN
			Endocet	C				UNKNOWN
			Ultram	C				UNKNOWN
			Amitriptyline Hydrochloride	C				UNKNOWN
			Proventil	C				UNKNOWN
			Advair	C				UNKNOWN

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN

Albuterol	C
Levaquin	C
Bactroban	C
Nystatin	C
Veetids	C
Atacand	C
Gentamicin	C
Methylprednisolone	C
Zithromax	C
Guaifenex	C
Msir	C
Tramadol Hydrochloride	C
Zoloft	C
Lidoderm	C
Nasonex	C
Promethazine	C
Elocon	C
Crestor	C
Biaxin	C
Humibid	C
Lotrisone	C
Tussionex Pennkinetic	C

Date:08/05/05ISR Number: 4736005-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00992
Age:50 YR Gender:Female I/FU:F

Outcome PT

Hospitalization - Initial or Prolonged	Atherosclerosis Blood Pressure Inadequately Controlled

	Coronary Artery Disease						
	Depression						
	Dyspepsia	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Hypersensitivity		Vioxx	PS	Merck & Co., Inc	ORAL	
	Overdose		Vioxx	SS	Merck & Co., Inc	ORAL	
	Post-Traumatic Stress		Celebrex	C			UNKNOWN 4 YR
	Disorder		Benicar Hct	C			UNKNOWN
	Stomach Discomfort						

Date:08/05/05ISR Number: 4736006-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02318
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
	Transient Ischaemic		Cardura	C			UNKNOWN
	Attack		Proscar	C		ORAL	
			Zantac	C			UNKNOWN

Date:08/05/05ISR Number: 4736010-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03891
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	1 YR
Initial or Prolonged	Blood Cholesterol		Soma	C			UNKNOWN
	Increased		Aspirin	C			UNKNOWN
	Chest Pain		Plavix	C			UNKNOWN
	Dyspepsia		Lipitor	C			UNKNOWN
	Eczema		Toprol Xl Tablets	C			UNKNOWN
	Hypertension		Lopressor	C			UNKNOWN

	Myocardial Infarction	Zocor	C
UNKNOWN			
	Rotator Cuff Syndrome	Nexium	C
UNKNOWN			
		Nitroglycerin	C
UNKNOWN			

Date:08/05/05ISR Number: 4736011-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03741
Age:33 YR Gender:Female I/FU:F

Outcome
Other

PT
Bleeding Time Abnormal
Blood Cholesterol
Increased
Blood Triglycerides
Increased
Breast Mass
Cerebrovascular Accident
Chest Pain
Chronic Fatigue Syndrome
Convulsion
Depression
Disturbance In Attention
Dyspnoea
Electrocardiogram
Abnormal
Gallbladder Disorder
Gastrointestinal Disorder
Gastrooesophageal Reflux
Disease
Generalised Anxiety
Disorder

		Hypertension					
		Hypoaesthesia					
		Liver Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Migraine		Vioxx	PS	Merck & Co., Inc	ORAL
		Muscle Spasms		Vioxx	SS	Merck & Co., Inc	ORAL
		Nausea		Vioxx	SS	Merck & Co., Inc	ORAL
		Osteoporosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Panic Attack					
		Panic Disorder					
		Paralysis					
		Renal Disorder					
		Rheumatoid Arthritis					
		Suicidal Ideation					
		Suicide Attempt					
		Swelling					
		Transient Ischaemic					
		Attack					
		Uterine Disorder					
		Vomiting					

Date:08/05/05ISR Number: 4736012-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01605
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction					

Date:08/05/05ISR Number: 4736013-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03740
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
64 DAY						
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
34 DAY						
Other	Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL
5 DAY						
	Lipoma		Vioxx	SS	Merck & Co., Inc	ORAL
345 DAY						

	Myocardial Infarction		Plavix	C		
UNKNOWN	1778 DAY					
	Pigmented Naevus		Zocor	C		ORAL
2136 DAY						

Date:08/05/05ISR Number: 4736014-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01299
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
4 YR						
Initial or Prolonged	Blood Cholesterol		Diovan	C		
UNKNOWN						
Disability	Increased		Nexium	C		
UNKNOWN						
	Chest Pain		Premarin	C		
UNKNOWN						
	Chronic Obstructive		Skelaxin	C		
UNKNOWN						
	Pulmonary Disease					
	Foot Operation					
	Hand Deformity					
	Hip Surgery					
	Hypertension					
	Insomnia					
	Intervertebral Disc					
	Operation					
	Spinal Fusion Surgery					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736015-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02598
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
Initial or Prolonged	Congestive		Bextra	C			UNKNOWN	
Disability	Coronary Artery Disease							
Other	Dyspepsia							
	Headache							
	Myocardial Infarction							

Date:08/05/05ISR Number: 4736016-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05268
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	5 YR	
	Disease							
	Arthropathy							
	Blood Cholesterol							
	Increased							
	Diabetes Mellitus							
	Hypertension							
	Myocardial Infarction							
	Oesophageal Disorder							
	Sleep Apnoea Syndrome							

Date:08/05/05ISR Number: 4736017-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04199
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	10 MON	
Initial or Prolonged	Increased		Synthroid	C			UNKNOWN	
	Dyspepsia		Tylenol	C			UNKNOWN	
	Haemorrhage							

Myocardial Infarction
Sleep Apnoea Syndrome

Date:08/05/05ISR Number: 4736018-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00768
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Uniretic	C				
UNKNOWN	Depression		Tylenol	C				
UNKNOWN	Dyspepsia		Glipizide Xl	C				
UNKNOWN	Gastric Disorder		Metformin	C				
UNKNOWN	Heart Rate Irregular		Prednisone	C				
UNKNOWN	Joint Injury		Zoloft	C				
UNKNOWN	Joint Swelling							
	Myocardial Infarction							
	Nausea							
	Oedema Peripheral							
	Pneumonia							
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736019-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01320
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event Atrial Fibrillation Cardiac Failure Congestive Coma Coronary Artery Disease Depression Hypertension Memory Impairment Myocardial Infarction Renal Disorder Sight Disability		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736020-7Report Type:Expedited (15-DaCompany Report #PT-MERCK-0508PRT00001
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Celecoxib	SS		ORAL		
	Chest Pain		Flupirtine Maleate	SS			UNKNOWN	
	Palpitations		Diclofenac Sodium	C		ORAL		
	Tachycardia		Nandrolone Decanoate	C			UNKNOWN	
			Nimesulide	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Thiocolchicoside	C			UNKNOWN	
			Diazepam	C		ORAL		
			Diazepam	C		ORAL		
			Pyridoxine Hydrochloride And Vitamin A And Vitamin E	C		ORAL		

Date:08/05/05ISR Number: 4736021-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00084
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diabetes Mellitus		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Periarthritis		Dyazide	C				

UNKNOWN

Date:08/05/05ISR Number: 4736022-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00334
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1827 DAY

Date:08/05/05ISR Number: 4736023-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00333
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736024-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00021
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	2 YR

Date:08/05/05ISR Number: 4736025-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00060
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Simvastatin	C		ORAL		
			Atenolol	C		ORAL		
			Aspirin Calcium	C		ORAL		

Date:08/05/05ISR Number: 4736026-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00891
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Tylenol Extra Strength	C				
	Depression						UNKNOWN	
	Retinal Detachment		Insulin	C			UNKNOWN	
	Vomiting							

Date:08/05/05ISR Number: 4736027-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00130
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Death		Norvasc	C				
UNKNOWN								

Initial or Prolonged	Oesophageal Disorder	Avapro	C
UNKNOWN			
		Lasix (Furosemide)	C
UNKNOWN			
		Lasix (Furosemide)	C
UNKNOWN			
		Roxicet	C
UNKNOWN			
		Sodium Bicarbonate	C
UNKNOWN			
		Aspirin	C
UNKNOWN			

Date:08/05/05ISR Number: 4736028-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00256
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Heart Rate Irregular		Vioxx	SS	Merck & Co., Inc	ORAL	3	YR
	Heart Valve Insufficiency							
	Myocardial Infarction							

Date:08/05/05ISR Number: 4736029-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00216
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Cerebrovascular Accident
Initial or Prolonged	Convulsion
Disability	Migraine
Other	Muscle Spasms

	Overdose						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	38 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL	38 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Toprol Xl Tablets	C		ORAL		
			Plavix	C			UNKNOWN	

Date:08/05/05ISR Number: 4736030-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00133
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Gastrooesophageal Reflux		Lipitor	C				
	Disease		Aspirin	C			UNKNOWN	
	Myocardial Infarction							
	Tension Headache							

Date:08/05/05ISR Number: 4736031-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01875
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Indomethacin	C		ORAL	24 YR	
	Blood Triglycerides Increased							
	Drug Hypersensitivity							
	Dyspnoea							
	Gastric Disorder							
	Hypertension							
	Myocardial Infarction							
	Pain In Jaw							

Thyroid Disorder

Date:08/05/05ISR Number: 4736032-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03317
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		42 MON
Initial or Prolonged	Infarction		Carisoprodol	C				UNKNOWN
Disability	Prostatism		Zanaflex	C				UNKNOWN
			Flomax (Morniflumate)	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
			Endocet	C				UNKNOWN
			Acetaminophen And Oxycodone Hydrochloride	C				UNKNOWN
			Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
			Ultram	C				UNKNOWN
			Oxycontin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736033-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00089
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736034-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01782
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4 DAY	
			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Zocor	C			UNKNOWN	

Date:08/05/05ISR Number: 4736035-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02262
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736036-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04804
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	272 MON	
Other	Cerebrovascular Accident							
	Coronary Artery Disease							
	Death							
	Diabetes Mellitus							
	Malaise							

Date:08/05/05ISR Number: 4736037-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00129
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atrial Fibrillation							
	Coronary Artery Disease							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Myocardial Infarction							

Date:08/05/05ISR Number: 4736038-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02268
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Limb Operation		Vioxx	PS	Merck & Co., Inc	ORAL	277 DAY	
	Myocardial Infarction		Aspirin	C			UNKNOWN	
	Oedema Peripheral		Norvasc	C			UNKNOWN	
	Sleep Apnoea Syndrome		Avandia	C			UNKNOWN	
			Synthroid	C			UNKNOWN	
			Zyrtec	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Ibuprofen	C			UNKNOWN	
			Premarin	C			UNKNOWN	

				Centrum Silver	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Vitamin E	C		
UNKNOWN							

Date:08/05/05ISR Number: 4736043-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02277
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1346 DAY	
	Gastrooesophageal Reflux		Pravachol	C			UNKNOWN	
	Disease		Lotrel	C			UNKNOWN	
	Transient Ischaemic		Synthroid	C			UNKNOWN	
	Attack		Celexa	C			UNKNOWN	

Date:08/05/05ISR Number: 4736044-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02271
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Glyburide	C			UNKNOWN	
	Glaucoma		Benazepril					
	Heart Rate Irregular		Hydrochloride	C			UNKNOWN	
	Hypertension							
	Myocardial Infarction							
	Renal Impairment							

Date:08/05/05ISR Number: 4736045-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00087
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736046-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00088
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736047-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00688
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
			Synthroid	C				
UNKNOWN								

Date:08/05/05ISR Number: 4736048-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01106
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Death	Asthenia
Other	Cataract
	Decreased Activity
	Diarrhoea

		Gastric Disorder					
		Hypoaesthesia					
		Lung Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL
		Renal Disorder		Imdur	C		
UNKNOWN							
		Renal Failure		Probenecid	C		
UNKNOWN							
		Respiratory Failure		Allopurinol	C		
UNKNOWN							
				Combivent	C		
UNKNOWN							
				Avandia	C		
UNKNOWN							
				Lopressor	C		
UNKNOWN							
				Insulin	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN							
				Vasotec	C		
UNKNOWN							

Date:08/05/05ISR Number: 4736050-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00764
Age: Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
1190 DAY							
		Increased		Propranolol			
		Hypertension		Hydrochloride	C		
UNKNOWN							
		Pulmonary Embolism		Aspirin	C		ORAL
				Premarin	C		
UNKNOWN							
				Lotrel	C		
UNKNOWN							
				Allopurinol	C		
UNKNOWN							
				Amoxicillin	C		
UNKNOWN							
				Chlorhexidine			

				Acetate	C		
UNKNOWN							
				Hydrochlorothiazide And Triamterene	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							

Date:08/05/05ISR Number: 4736056-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00471
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736057-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00470
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736058-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00448
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736059-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00007
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Bipolar Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Avalide	C				UNKNOWN
	Blood Disorder		Paxil	C				UNKNOWN
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Chronic Obstructive							
	Pulmonary Disease							
	Deep Vein Thrombosis							
	Depression							
	Diabetes Mellitus							
	Drug Hypersensitivity							
	Dyspnoea							
	Glaucoma							
	Haematochezia							
	Haematoma							
	Hypertension							
	Mental Disorder							
	Myocardial Infarction							
	Obesity							
	Overdose							
	Panic Disorder							
	Pulmonary Embolism							
	Schizophrenia							
	Sleep Apnoea Syndrome							
	Swelling							

Date:08/05/05ISR Number: 4736060-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00536
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736061-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00398
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736062-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00467
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736063-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00441
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736065-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00439
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736070-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00020
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	6 MON

Date:08/05/05ISR Number: 4736071-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00022
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc		UNKNOWN	302 DAY

Date:08/05/05ISR Number: 4736072-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00354
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1067 DAY	

Date:08/05/05ISR Number: 4736073-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00461
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736074-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00535
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736075-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00489
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736076-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00533
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736077-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00494
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736078-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00537
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736079-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00487
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736080-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00534
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736081-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00466
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736082-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00486
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736094-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00878
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736095-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00538
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736096-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00516
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736097-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00799
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiomegaly Injury Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736098-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00882
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736099-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00767
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736100-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00879
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Arrest Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736101-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01905
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Biliary Colic		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Disability	Bronchospasm Constipation Deep Vein Thrombosis	Vioxx Ginkgo Biloba Extract	SS C	Merck & Co., Inc	ORAL
UNKNOWN	Diarrhoea Emotional Distress Epistaxis Gastrooesophageal Reflux Disease Hypothyroidism Mental Status Changes Overdose Peptic Ulcer Peripheral Vascular Disorder Pleural Effusion Pulmonary Embolism Rectal Haemorrhage				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736102-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00807
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736104-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00981
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736105-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00958
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736106-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00980
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736107-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00959
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY	

Date:08/05/05ISR Number: 4736108-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00978
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736109-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00934
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736111-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00539
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON
	Myocardial Infarction							

Date:08/05/05ISR Number: 4736112-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736113-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00937
Age:78 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/05/05ISR Number: 4736114-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00936
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736115-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00810
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736116-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00926
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736121-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00796
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	DAY

Date:08/05/05ISR Number: 4736122-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00884
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/05/05ISR Number: 4736126-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02269
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Cardiac Failure		Quinine Sulfate	C				UNKNOWN
Other	Chest Pain		Labelol	C				UNKNOWN
	Diabetes Mellitus		Tarka	C				UNKNOWN
	Oedema Peripheral		Clonidine	C				UNKNOWN
	Pain In Extremity		Uniretic	C				UNKNOWN
	Pulmonary Embolism		Actos	C				UNKNOWN
	Thrombosis							

Date:08/05/05ISR Number: 4736142-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00928
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/05/05ISR Number: 4736260-7Report Type:Direct Company Report #CTU 255509
Age:36 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Unevaluable Event		Vioxx Have In Storage	PS				FOR PAIN
			Celebrex 200mg	SS				FOR PAIN

Date:08/08/05ISR Number: 4736698-8Report Type:Direct Company Report #CTU 255599
Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Confusional State		Vioxx	PS			2 X QDA	
Initial or Prolonged	Dysarthria							
	Hemiparesis							
	Hypoaesthesia							

Date:08/08/05ISR Number: 4736756-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00065
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastroenteritis Viral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Intervertebral Disc		Glyburide	C			UNKNOWN	
	Degeneration		Flonase	C			UNKNOWN	
	Intervertebral Disc		Zyrtec	C			UNKNOWN	
	Protrusion							
	Lacunar Infarction							
	Libido Decreased							
	Nerve Injury							
	Pain In Extremity							
	Rhinitis Allergic							
	Sebaceous Hyperplasia							
	Somnolence							
	Spinal Column Stenosis							
	Stomach Discomfort							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736757-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0407USA01742
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		89 DAY
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		DAY
	Dysphagia		Prevacid	C		ORAL		
	Dyspnoea Exertional		Humulin R	C				UNKNOWN
	Emotional Distress		Naproxen	C		ORAL		
	Gastrooesophageal Reflux		Livostin	C				OPHTHALMIC
	Disease		Naproxen	C		ORAL		
	Hypoaesthesia		Humulin N	C				UNKNOWN
	Hypotension		Vasotec	C				UNKNOWN
	Insomnia							
	Ischaemic Stroke							
	Muscle Spasms							
	Nasopharyngitis							
	Nephropathy							
	Neuropathy Peripheral							
	Oedema Peripheral							
	Pain In Extremity							
	Pollakiuria							
	Spinal Column Stenosis							
	Upper Respiratory Tract Infection							
	Vitreous Haemorrhage							

Date:08/08/05ISR Number: 4736758-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03015
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736767-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02981
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		608 DAY
Initial or Prolonged	Asthenia		Aspirin	C				UNKNOWN
Disability	Atrial Fibrillation							
Other	Cardiomegaly							
	Chest Pain							
	Coronary Artery Disease							
	Dizziness							
	Drug Hypersensitivity							
	Emotional Distress							
	Flushing							
	Headache							
	Left Ventricular Failure							
	Mitral Valve Incompetence							
	Myocardial Infarction							
	Tricuspid Valve Incompetence							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736768-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01997
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		425 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		425 DAY
	Myocardial Infarction		Clarinex	C				UNKNOWN
	Polytraumatism							

Date:08/08/05ISR Number: 4736769-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02810
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Levothroid	C				UNKNOWN
	Depression		Ditropan	C				UNKNOWN
	Hypertension		Menest	C				UNKNOWN
	Osteoporosis							
	Ulcer							

Date:08/08/05ISR Number: 4736770-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03028
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736771-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02025
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
5 YR						
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
5 YR						
	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspnoea		Vioxx	SS	Merck & Co., Inc	ORAL
	Gastrointestinal Disorder		Zoloft	C		
UNKNOWN						
	Myocardial Infarction		Nexium	C		
UNKNOWN						
	Polytraumatism		Valium	C		
UNKNOWN						
	Prescribed Overdose		Hydrocodone/Apap	C		
UNKNOWN						
	Thyroid Mass		Synthroid	C		
UNKNOWN						
			Advil	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						

Date:08/08/05ISR Number: 4736772-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02064
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Musculoskeletal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
	Polytraumatism		Vioxx	SS	Merck & Co., Inc	ORAL
			Miralax	C		
UNKNOWN						
			Glucotrol	C		
UNKNOWN						
			Augmentin	C		
UNKNOWN						
			Proventil	C		
UNKNOWN						
			Glipizide Xl	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736773-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01952
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Depression Post-Traumatic Stress Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736774-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01146
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736775-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01939
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 30 MON	Embolic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Zyrtec	C			UNKNOWN	
			Acetaminophen And Codeine	C			UNKNOWN	
			Amoxicillin	C			UNKNOWN	
			Clindamycin	C			UNKNOWN	
			Acetaminophen And Hydrocodone Bitartrate	C			UNKNOWN	

Date:08/08/05ISR Number: 4736776-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04593
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Esgic-Plus Tablets	C				
UNKNOWN								
	Increased		Premarin	C				
UNKNOWN								
	Coronary Artery Disease		Proventil	C				
UNKNOWN								
	Depression							
	Fluid Retention							
	Hypoaesthesia							
	Limb Injury							
	Migraine							
	Myocardial Infarction							
	Pain							
	Rheumatoid Arthritis							

Date:08/08/05ISR Number: 4736789-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00692
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736790-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00454
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736791-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01834
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypersensitivity		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypoaesthesia		Tylenol	C				
UNKNOWN								
	Hypokinesia		Excedrin					
	Muscle Spasms		(Acetaminophen (+)					
	Neck Pain		Aspirin (+)					
	Oedema Peripheral		Caffeine)	C				
UNKNOWN								
	Pain In Extremity							
	Polytraumatism							
	Sensation Of Pressure							
	Thrombosis							
	Ventricular Hypertrophy							
	Ventricular Hypokinesia							

Date:08/08/05ISR Number: 4736792-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736793-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00708
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736794-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03746
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Gastrooesophageal Reflux Disease							
	Hyperlipidaemia							
	Hypertension							
	Myocardial Infarction							

Date:08/08/05ISR Number: 4736795-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01833
Age:52 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Angina Pectoris
	Angina Unstable

		Anxiety					
		Arthralgia					
		Arthropathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Atelectasis		Vioxx	PS	Merck & Co., Inc	ORAL
		Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
		Congestive		Vioxx	SS	Merck & Co., Inc	ORAL
		Cardiomegaly		Altace	C		
UNKNOWN							
		Cerebrovascular Accident		Ambien	C		
UNKNOWN							
		Chest Pain		Glyburide	C		
UNKNOWN							
		Coronary Artery Disease		Avandamet	C		
UNKNOWN							
		Coronary Artery Stenosis		Bextra	C		
UNKNOWN							
		Depression		Celebrex	C		
UNKNOWN							
		Diabetes Mellitus		Celebrex	C		
UNKNOWN							
		Dyslipidaemia					
		Headache					
		Hot Flush					
		Hypertension					
		Insomnia					
		Ischaemia					
		Musculoskeletal Pain					
		Myalgia					
		Myocardial Infarction					
		Nausea					
		Pain In Extremity					
		Pulmonary Fibrosis					
		Pulmonary Oedema					
		Urinary Tract Infection					

Date:08/08/05ISR Number: 4736796-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00671
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/08/05ISR Number: 4736797-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01781
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		107 DAY
Initial or Prolonged	Road Traffic Accident		Vioxx	SS	Merck & Co., Inc	ORAL		107 DAY
Disability	Tooth Extraction		Sulindac	C				UNKNOWN
			Ultracet	C				UNKNOWN
			Naloxone Hydrochloride And Pentazocine Hydrochloride	C				UNKNOWN

Date:08/08/05ISR Number: 4736798-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01784
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		2 MON
Initial or Prolonged	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		3 MON
	Cardiovascular Disorder		Acetaminophen	C				UNKNOWN
	Eye Infection		Teveten (Eprosartan)	C				UNKNOWN
	Multi-Organ Disorder		Zyrtec	C				UNKNOWN
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736799-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03747
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fibrocystic Breast Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other			Atenolol	C			UNKNOWN	
	Myocardial Infarction		Chlorazepate	C			UNKNOWN	
			Fosamax	C		ORAL		
			Hydrocodone Bitartrate	C			UNKNOWN	
			Inderal La	C			UNKNOWN	
			Inderal La	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Procardia	C			UNKNOWN	
			Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
			Phenergan (Promethazine Hydrochloride)	C			UNKNOWN	
			Premarin	C			UNKNOWN	
			Propranolol Hydrochloride	C			UNKNOWN	
			Hydrochlorothiazide And Triamterene	C			UNKNOWN	
			Hydrochlorothiazide And Triamterene	C			UNKNOWN	
			Trimox	C			UNKNOWN	
			Ultram	C			UNKNOWN	

				Zithromax	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Nifedipine	C		
UNKNOWN							

Date:08/08/05ISR Number: 4736800-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03718
Age:75 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	231	DAY
	Infarction		Allopurinol	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Lodine	C				
UNKNOWN								
			Aciphex	C				
UNKNOWN								
			Simethicone	C				
UNKNOWN								
			Tylenol	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								
			Bisacodyl	C				
UNKNOWN								

Date:08/08/05ISR Number: 4736801-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01205
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	736	DAY
			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736802-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00927
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		120 DAY
Initial or Prolonged	Emotional Distress		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		147 DAY
	Rectal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
	Rotator Cuff Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		120 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		147 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		396 DAY
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vicodin Tablets	C				UNKNOWN
			Ativan	C				UNKNOWN
			Vitamin E	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN
			Zantac	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Tylenol	C				UNKNOWN
			Advil	C				UNKNOWN
			Zocor	C		ORAL		
			Glucosamine	C				UNKNOWN

Date:08/08/05ISR Number: 4736803-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00387
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		691 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		691 DAY
	Myocardial Infarction		Levaquin	C				UNKNOWN
	Polytraumatism		Mobic	C				UNKNOWN
	Sleep Disorder		Neurontin	C				UNKNOWN
	Tongue Neoplasm Malignant		Benzometan	C				UNKNOWN
	Stage Unspecified		Allegra	C				UNKNOWN
			Amitriptylin	C				UNKNOWN
			Tequin	C				UNKNOWN
			Guaifenesin	C				UNKNOWN
			Tagamet	C				UNKNOWN
			Hydrocodone/Apap	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN
			Elavil	C				UNKNOWN

Date:08/08/05ISR Number: 4736804-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736805-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00472
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736806-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03127
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Congestive		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardio-Respiratory Arrest		Vioxx	SS	Merck & Co., Inc	ORAL		
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sudden Cardiac Death		Bextra	SS				
UNKNOWN								

Date:08/08/05ISR Number: 4736809-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736810-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis							

Date:08/08/05ISR Number: 4736811-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00924
Age:57 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/08/05ISR Number: 4736812-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01101
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1552 DAY

Date:08/08/05ISR Number: 4736813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00922
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis

		Transient Ischaemic Attack					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/08/05ISR Number: 4736814-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00883
Age:52 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Disability		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Polytraumatism					

Date:08/08/05ISR Number: 4736815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00457
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/08/05ISR Number: 4736816-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00972
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL
		Congestive					
		Cerebrovascular Accident					

Date:08/08/05ISR Number: 4736817-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00488
Age: Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/08/05ISR Number: 4736822-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01160
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							

Date:08/08/05ISR Number: 4736823-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01155
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736825-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4736836-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00962
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736837-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01124
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:08/08/05ISR Number: 4736838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Other	Death Multi-Organ Failure							

Date:08/08/05ISR Number: 4736839-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01103
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	31	DAY

Date:08/08/05ISR Number: 4736840-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01157
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	66	DAY

Date:08/08/05ISR Number: 4736841-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01158
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736843-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1645	DAY

Date:08/08/05ISR Number: 4736844-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01113
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4736845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01123
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:08/08/05ISR Number: 4736846-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00811
Age:68 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	93	DAY
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/08/05ISR Number: 4736847-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00960
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737172-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01110
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
	Anxiety
Other	Asthenia
	Back Injury
	Cerebrovascular Accident
	Cervical Spasm
	Chest Pain

Chronic Fatigue Syndrome
Coordination Abnormal
Depression
Dyspnoea
Dysuria
Emotional Disorder
Gastrointestinal
Haemorrhage
Gastrooesophageal Reflux
Disease
Headache
Hernia
Hypertension
Hypertensive Crisis
Insomnia
Intervertebral Disc
Protrusion
Lacunar Infarction
Muscle Contracture
Neck Pain
Oedema Peripheral
Peripheral Vascular
Disorder

		Radiculopathy					
		Road Traffic Accident					
		Spinal Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tinnitus		Vioxx	PS	Merck & Co., Inc	ORAL
		Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL
		Attack		Clonidine	C		
UNKNOWN							
		Vertigo Positional		Clonidine	C		
UNKNOWN							
		Vomiting		Vicodin Tablets	C		
UNKNOWN							
		Weight Decreased		Skelaxin	C		
UNKNOWN							
				Desyrel	C		
UNKNOWN							

Date:08/08/05ISR Number: 4737174-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00609
Age:74 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Life-Threatening		Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
Hospitalization -		Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged		Pulmonary Disease		Insulin	C		
UNKNOWN							
		Confusional State		Prednisone	C		
UNKNOWN							
		Constipation		Acetylcysteine	C		
UNKNOWN							
		Dyspnoea		Enalapril Maleate	C		
UNKNOWN							
		Fall		Morphine Sulfate	C		ORAL
		Hepatic Failure		Dipyrone	C		
UNKNOWN							
		Hyperkalaemia		Oxycodone			
		Hypertension		Hydrochloride	C		
UNKNOWN							
		Nausea		Isosorbide Dinitrate	C		
UNKNOWN							
		Normochromic Normocytic					
		Anaemia					
		Vomiting					

Date:08/08/05ISR Number: 4737176-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA00856
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737179-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03057
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737184-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00169
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	43 MON	
Initial or Prolonged	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL	43 MON	
Disability	Depression		Metformin	C			UNKNOWN	
	Pneumonia		Potassium (Unspecified)	C			UNKNOWN	
	Prescribed Overdose							
	Vertigo		Coumadin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	

				Lipitor	C		
UNKNOWN							
				Diabeta	C		
UNKNOWN							
				Lanoxin	C		
UNKNOWN							
				Altace	C		
UNKNOWN							
				Zaroxolyn	C		
UNKNOWN							

Date:08/08/05ISR Number: 4737186-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00166
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	14 MON	
			[Therapy Unspecified]	C				
UNKNOWN								

Date:08/08/05ISR Number: 4737187-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00167
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Initial or Prolonged			Tylenol	C				
UNKNOWN								
Disability			Hydrodiuril	C				
UNKNOWN								
Other								

Date:08/08/05ISR Number: 4737188-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01830
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
633 DAY						
Initial or Prolonged	Coronary Artery		Monopril	C		
UNKNOWN						
Other	Atherosclerosis		Dilacor Xr	C		
UNKNOWN						
	Cough		Zantac	C		
UNKNOWN						
	Dyspepsia		Hydrochlorothiazide	C		
UNKNOWN						
	Dyspnoea					
	Epidermal Naevus					
	Headache					
	Limb Injury					
	Myalgia					
	Myocardial Infarction					
	Pigmented Naevus					
	Polytraumatism					
	Rectal Haemorrhage					
	Rhinitis Allergic					

Date:08/08/05ISR Number: 4737189-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00085
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
918 DAY						

Date:08/08/05ISR Number: 4737190-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04790
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Cholesterol
Initial or Prolonged	Increased
	Myocardial Infarction

	Neck Injury Tendon Injury	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1244 DAY
			Crestor	C		ORAL	
			Glucovance	C		ORAL	
			Acetaminophen And Hydrocodone Bitartrate	C		ORAL	
			Acetaminophen And Hydrocodone Bitartrate	C		ORAL	
			Lotrel	C		ORAL	
			Paroxetine	C		ORAL	

Date:08/08/05ISR Number: 4737191-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00967
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Proventil	C			
Disability	Arthropathy		Diovan	C			UNKNOWN
	Back Disorder		Prevacid	C			UNKNOWN
	Blood Cholesterol		Zyrtec	C			UNKNOWN
	Increased		Prilosec	C			UNKNOWN
			Prozac	C			UNKNOWN

Date:08/08/05ISR Number: 4737192-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03830
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Adverse Event Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Polytraumatism

Date:08/08/05ISR Number: 4737193-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01505
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1601 DAY	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability	Blood Cholesterol Increased							
	Hypertension							
	Myocardial Infarction							
	Osteoarthritis							

Date:08/08/05ISR Number: 4737195-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02724
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737197-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03715
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Aortic Aneurysm Rupture		Aspirin	C				UNKNOWN
Other	Blood Cholesterol		Bacitracin	C				UNKNOWN
	Increased		Casanthranol	C				UNKNOWN
	Carotid Artery Stenosis		Cephalexin	C				UNKNOWN
	Constipation		Clopidogrel Bisulfate	C				UNKNOWN
	Depressed Mood		Acetaminophen And Codeine	C				UNKNOWN
	Dyspnoea		Electrolytes (Unspecified)	C				UNKNOWN
	Hypertension		Cyclobenzaprine Hydrochloride	C				UNKNOWN
	Myocardial Infarction		Donepezil Hydrochloride	C				UNKNOWN
	Oedema		Etodolac	C				UNKNOWN
	Skin Ulcer		Flunisolide	C				UNKNOWN
	Wheezing		Gabapentin	C				UNKNOWN
			Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
			Isosorbide Dinitrate	C				UNKNOWN
			Prinivil	C		ORAL		
			Oxybutynin Chloride	C				UNKNOWN
			Potassium Chloride	C				UNKNOWN

				Quetiapine Fumarate	C		
UNKNOWN							
				Ranitidine Hydrochloride	C		
UNKNOWN							
				Salsalate	C		
UNKNOWN							
				Sennosides	C		
UNKNOWN							
				Terazosin Hydrochloride	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Plavix	C		
UNKNOWN							
				Trolamine Salicylate	C		
UNKNOWN							
				Salmeterol	C		
UNKNOWN							
				Simvastatin	C		
UNKNOWN							

Date:08/08/05ISR Number: 4737198-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01920
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Ankle Fracture		Vioxx	PS	Merck & Co., Inc	ORAL		720 DAY
Initial or Prolonged	Aortic Valve Sclerosis		Pravachol	C				
UNKNOWN								
Disability	Back Pain		Aspirin	C				
UNKNOWN								
Other	Cerebrovascular Accident		Glyburide And Metformin Hydrochloride	C				
	Emotional Distress							
	Hypersensitivity							
UNKNOWN								
	Ventricular Hypertrophy		Glyburide And Metformin Hydrochloride	C				
UNKNOWN								
			Prilosec	C		ORAL		
			Omeprazole	C		ORAL		

Date:08/08/05ISR Number: 4737200-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02467
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Brain Damage							
	Cerebrovascular Accident							
	Pain							
	Personality Change							

Date:08/08/05ISR Number: 4737201-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA02039
Age:19 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		39 MON
Initial or Prolonged	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		39 MON
Other	Cardiac Failure		Lasix (Furosemide)	C				UNKNOWN
	Congestive							
	Cerebrovascular Accident							
	Chest Pain							
	Emotional Distress							
	Fluid Retention							
	Gallbladder Disorder							
	Malaise							
	Mitral Valve Prolapse							
	Nasopharyngitis							
	Pneumonia							
	Systemic Lupus Erythematosus							

Date:08/08/05ISR Number: 4737206-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		62 DAY

Initial or Prolonged	Angina Unstable	Atenolol	C	
UNKNOWN				
Other	Blood Creatinine	Prinivil	C	ORAL
	Increased	Aspirin	C	
UNKNOWN				
	Bursitis	Motrin	C	
UNKNOWN				
	Cardiomegaly	Zocor	C	ORAL
	Cardiovascular Disorder	Glyburide	C	
UNKNOWN				
	Coronary Artery Disease	Pepcid	C	
UNKNOWN				
	Coronary Artery Restenosis			
	Depression			
	Gastrooesophageal Reflux Disease			
	Injury			
	Migraine			
	Rash Pruritic			
	Scrotal Abscess			
	Single Vessel Bypass Graft			
	Syncope Vasovagal			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737208-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02236
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL	1096 DAY	
Other	Cardiomegaly		Vioxx	SS	Merck & Co., Inc	ORAL	1096 DAY	
	Chest Pain							
	Coronary Artery Atherosclerosis							
	Cough							
	Emotional Distress							
	Gastrooesophageal Reflux Disease							
	Hepatic Steatosis							

Date:08/08/05ISR Number: 4737209-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03717
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Rate Irregular							
	Myocardial Infarction							

Date:08/08/05ISR Number: 4737210-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01995
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Initial or Prolonged	Balance Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
Disability	Basilar Migraine		Celebrex	C			UNKNOWN	
	Cerebrovascular Accident							
	Depression							
	Hypertension							
	Panic Disorder							

Photophobia
Self-Medication
Sleep Disorder
Vertebral Artery
Occlusion
Vertigo
Visual Disturbance

Date:08/08/05ISR Number: 4737211-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02262
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		1370 DAY
Initial or Prolonged	Cerebrovascular Accident		Monopril	C				UNKNOWN
Disability	Chest Pain		Vasotec	C		ORAL		
	Intracranial Aneurysm		Lopressor	C				UNKNOWN
	Renal Disorder		Toprol Xl Tablets	C				UNKNOWN
	Renal Failure		Norvasc	C				UNKNOWN
			Hytrin	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN
			Aldomet (Methyldopate Hydrochloride)	C				UNKNOWN
			Plavix	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737212-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00025
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	422 YR

Date:08/08/05ISR Number: 4737213-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01200
Age:40 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Other	Myocardial Infarction							

Date:08/08/05ISR Number: 4737216-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00176
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL	34	MON
Initial or Prolonged	Fluctuation		Vioxx	SS	Merck & Co., Inc	ORAL	34	MON
	Knee Operation		[Therapy					
	Myocardial Infarction		Unspecified]	C				
UNKNOWN								

Date:08/08/05ISR Number: 4737218-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00024
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	4 YR

Date:08/08/05ISR Number: 4737219-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01661
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL		24 MON
Other	Breast Cancer							
	Cardiac Disorder							
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Depression							
	Drug Hypersensitivity							
	Dysphagia							
	Dyspnoea							
	Eye Haemorrhage							
	Organ Failure							
	Pain							
	Thrombosis							
	Vaginal Haemorrhage							

Date:08/08/05ISR Number: 4737220-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00578
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Death	Adverse Event
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Cerebrovascular Accident
Other	Confusional State
	Death

	Dementia						
	Dementia Alzheimer'S Type						
	Gastrointestinal	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL	
	Hyperlipidaemia		Flomax				
	Ischaemic Cerebral		(Morniflumate)	C			UNKNOWN
	Infarction		Lescol	C			UNKNOWN
	Oral Soft Tissue Disorder		Synthroid	C			UNKNOWN
	Transient Ischaemic		Verapamil Msd Lp	C			UNKNOWN
	Attack		Zoloft	C			UNKNOWN

Date:08/08/05ISR Number: 4737221-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00023
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc		UNKNOWN	138 DAY

Date:08/08/05ISR Number: 4737222-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00451
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737223-8Report Type:Expedited (15-DaCompany Report #PT-MERCK-0508PRT00001
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Celecoxib	SS		ORAL		
	Chest Pain		Flupirtine Maleate	SS			UNKNOWN	

	Palpitations		Diclofenac Sodium	C			ORAL
	Tachycardia		Nandrolone Decanoate	C			
UNKNOWN							
			Nimesulide	C			
UNKNOWN							
			Tramadol Hydrochloride	C			
UNKNOWN							
			Thiocolchicoside	C			
UNKNOWN							
			Diazepam	C			ORAL
			Diazepam	C			ORAL
			Pyridoxine Hydrochloride And Vitamin A And Vitamin E	C			ORAL

Date:08/08/05ISR Number: 4737224-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03814
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737225-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00576
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
Other	Transient Ischaemic Attack		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Glucovance	C			UNKNOWN	
			Avalide	C			UNKNOWN	
			Daypro	C			UNKNOWN	
			K-Dur	C			UNKNOWN	
			Pravachol	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Hydrochlorothiazide	C			UNKNOWN	
			Monopril	C			UNKNOWN	
			Verapamil	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Cyclobenzaprine Hydrochloride	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	

Date:08/08/05ISR Number: 4737227-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00577
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Ms Contin	C			UNKNOWN	
			Loratab	C			UNKNOWN	

Date:08/08/05ISR Number: 4737229-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00480
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737230-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00446
Age:62 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737231-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00668
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737232-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737233-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00425
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737236-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00347
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737237-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00104
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737238-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00424
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737245-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00410
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737246-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00458
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737247-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737248-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00428
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737249-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00484
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737250-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00481
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737251-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737252-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00490
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737255-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00483
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737260-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00821
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	60	MON
	Renal Failure							

Date:08/08/05ISR Number: 4737263-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00831
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	22	MON

Date:08/08/05ISR Number: 4737265-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00895
Age:63 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/08/05ISR Number: 4737266-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00846
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:08/08/05ISR Number: 4737267-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00482
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737268-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00823
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737269-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00819
Age:63 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737270-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00737
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		649 DAY
	Polytraumatism							

Date:08/08/05ISR Number: 4737271-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00816
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Mitral Valve Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/08/05ISR Number: 4737272-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00817
Age:68 YR Gender:Male I/FU:I

Outcome	PT
Other	Atherosclerosis
	Cerebrovascular Accident

Coronary Artery Disease
Myocardial Infarction
Thrombosis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Transient Ischaemic Attack	Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:08/08/05ISR Number: 4737276-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00953
Age:56 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction Sudden Cardiac Death		Vioxx	PS	Merck & Co., Inc	ORAL	235	DAY

Date:08/08/05ISR Number: 4737277-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737278-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00966
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737279-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00940
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737280-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00896
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737281-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00734
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		28 MON

Date:08/08/05ISR Number: 4737285-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00902
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1002 DAY	
	Polytraumatism							

Date:08/08/05ISR Number: 4737286-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00948
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	25 MON	

Date:08/08/05ISR Number: 4737287-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00905
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737288-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01131
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/08/05ISR Number: 4737289-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01133
Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737290-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01252
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737291-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00968
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737293-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00986
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737294-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01260
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737295-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00984
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737296-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737297-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00965
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737304-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00164
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737305-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737306-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01264
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/08/05ISR Number: 4737307-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01263
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	345	DAY

Date:08/08/05ISR Number: 4737308-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01116
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/08/05ISR Number: 4737309-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01261
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1588	DAY

Date:08/08/05ISR Number: 4737311-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00731
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1423	DAY

Date:08/08/05ISR Number: 4737312-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00949
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738133-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00671
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hiatus Hernia		Omeprazole	C		ORAL		
	Mucosal Erosion		Metoprolol Succinate	C				
	Pulmonary Embolism							

Date:08/09/05ISR Number: 4738136-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0409DEU00158
Age:90 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Drug Interaction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Duodenal Ulcer		Escitalopram Oxalate	SS		ORAL		
	Haemorrhage		Enoxaparin Sodium	SS		SUBCUTANEOUS		
			Clopidogrel Bisulfate	SS		ORAL		
			Moxifloxacin Hydrochloride	C		ORAL	11 DAY	
			Hydrochlorothiazide	C		ORAL		
			Pantoprazole Sodium	C		ORAL		
			Simvastatin	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738137-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02360
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion							
	Depression							
	Hypertension							

Date:08/09/05ISR Number: 4738138-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01866
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		
							1	WK
Disability			Aspirin	C				
UNKNOWN								
Other								

Date:08/09/05ISR Number: 4738152-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04049
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
							50	DAY
Hospitalization -	Pain In Extremity		Aldactone	C				
UNKNOWN								
Initial or Prolonged	Pulmonary Embolism		Hydrochlorothiazide	C				
UNKNOWN								

Date:08/09/05ISR Number: 4738153-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA03221
Age:76 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amnesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Heart Rate Irregular		Hydrochlorothiazide	C				
UNKNOWN								
	Hypertension		Atenolol	C				
UNKNOWN								
	Hypokalaemia		Plavix	C				
UNKNOWN								
	Myocardial Infarction		Fosamax	C				
UNKNOWN								
	Nasal Congestion							
	Orthostatic Hypotension							
	Pollakiuria							
	Transient Ischaemic Attack							
	Urinary Incontinence							

Date:08/09/05ISR Number: 4738174-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738176-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01290
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738179-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738182-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01289
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738184-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01182
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Norvasc	C			UNKNOWN	
			Lotensin	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	

Date:08/09/05ISR Number: 4738185-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03723
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		366 DAY
Initial or Prolonged	Chest Pain		Aspirin	C				UNKNOWN
Other	Coronary Artery Disease		Covera-Hs	C				UNKNOWN
	Myocardial Infarction		Enalapril Maleate	C				UNKNOWN
	Thrombosis		Lipitor	C				UNKNOWN
			Niaspan	C				UNKNOWN
			Plavix	C				UNKNOWN
			Toprol Xl Tablets	C				UNKNOWN
			Viagra	C				UNKNOWN
			Hydrocodone Bitartrate	C				UNKNOWN

Date:08/09/05ISR Number: 4738186-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00339
Age:39 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Celebrex	SS				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738189-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02609
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738190-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03751
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Triamterene	C				
UNKNOWN								
	Coronary Artery		Premarin	C				
UNKNOWN								
	Atherosclerosis		Lorcet 10/650	C				
UNKNOWN								
	Gastrooesophageal Reflux Disease							
	Myocardial Infarction							
	Overdose							

Date:08/09/05ISR Number: 4738192-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00495
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738193-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00343
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738283-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738810-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01096
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738820-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01256
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	35	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738822-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01121
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738823-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01122
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1792 DAY

Date:08/09/05ISR Number: 4738824-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01146
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS				UNKNOWN
			Celebrex	SS				UNKNOWN

Date:08/09/05ISR Number: 4738826-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01119
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		1386 DAY
Other	Myocardial Infarction Respiratory Failure							

Date:08/09/05ISR Number: 4738829-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01118
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive Pulmonary Disease Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738830-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01120
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	21	MON

Date:08/09/05ISR Number: 4738839-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01269
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738849-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0209USA01001
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Intestinal Acute Myocardial Infarction

		Atherosclerosis					
		Cardiac Murmur					
		Cardiomyopathy	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Cervicobrachial Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
2	DAY						
		Chronic Obstructive					
		Pulmonary Disease					
		Conduction Disorder					
		Diverticular Perforation					
		Diverticulitis					
		Drooling					
		Drug Hypersensitivity					
		Dysarthria					
		Glossodynia					
		Hyperlipidaemia					
		Leukocytosis					
		Muscle Rupture					
		Muscle Spasms					
		Polycythaemia					
		Prostatic Specific					
		Antigen Increased					
		Skin Lesion					
		Viral Infection					

Date:08/09/05ISR Number: 4738851-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01287
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Intestinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:08/09/05ISR Number: 4738852-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01320
Age:58 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/09/05ISR Number: 4738853-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01267
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738854-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01268
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738855-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01266
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738856-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01490
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738857-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01285
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738858-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01478
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738859-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01270
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738868-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02814
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anxiety
Disability	Asthma
Other	Atrial Fibrillation
	Back Pain
	Blood Pressure Increased
	Blood Triglycerides Increased

Bradycardia
Bronchitis
Bronchospasm
Bundle Branch Block Left
Chest Pain
Coronary Artery Disease
Diabetes Mellitus
Non-Insulin-Dependent
Dysfunctional Uterine
Bleeding
Fatigue
Gastroenteritis
Headache
Hyperlipidaemia
Hyperthyroidism
Hypothyroidism
Insomnia
Intervertebral Disc
Protrusion
Metabolic Syndrome
Myocardial Infarction
Nausea
Oedema Peripheral

	Orthopnoea						
	Peripheral Vascular Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Rash Pruritic		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON
	Rhinitis Allergic		Tiazac	C			UNKNOWN
	Seasonal Allergy						
	Sedation						
	Sinusitis						
	Skin Lesion						
	Vertigo						
	Weight Increased						
	Weight Loss Poor						

Date:08/09/05ISR Number: 4738869-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01321
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/09/05ISR Number: 4738870-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01048
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	23 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	23 MON
Other	Cardiac Disorder						
	Collapse Of Lung						
	Diabetes Mellitus						
	Fall						
	Hypoxia						
	Myocardial Infarction						
	Pneumonia						
	Rib Fracture						
	Silent Myocardial Infarction						

Date:08/09/05ISR Number: 4738871-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00110
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738872-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00153
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Psychosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Comminuted Fracture		Vioxx	SS	Merck & Co., Inc	ORAL		
	Femoral Neck Fracture		Dipyrone	C				
	Headache		Amitriptyline Hydrochloride	C				
	Herpes Zoster		Promethazine	C				
	Major Depression							
	Malaise							
	Suicidal Ideation							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738873-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00715
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Adverse Event		Serzone	C			UNKNOWN	
	Anaemia		Fiorinal	C			UNKNOWN	
	Angina Pectoris		Prevacid	C			UNKNOWN	
	Cerebrovascular Accident		Lipitor	C			UNKNOWN	
	Chest Discomfort		Zanaflex	C			UNKNOWN	
	Chest Pain		Depoestradiol	C			UNKNOWN	
	Convulsion		Ecotrin	C			UNKNOWN	
	Coronary Artery Disease		Colace	C			UNKNOWN	
	Diarrhoea		Cardizem	C			UNKNOWN	
	Drug Ineffective		Serzone	C			UNKNOWN	
	Dysphagia		Neurontin	C			UNKNOWN	
	Fibromyalgia		Elavil	C			UNKNOWN	
	Gastritis		Ativan	C			UNKNOWN	
	Gastrooesophageal Reflux Disease		Aggrenox	C			UNKNOWN	
	Haemorrhoids		Deptran (Doxepin Hydrochloride)	C			UNKNOWN	
	Hypertension		Estrace	C			UNKNOWN	
	Hypoaesthesia		Vicodin Tablets	C			UNKNOWN	
	Hypoalbuminaemia							
	Infectious Mononucleosis							
	Intervertebral Disc Degeneration							
	Left Ventricular							

End-Diastolic Pressure
Increased
Liver Disorder
Lymphadenopathy
Memory Impairment
Migraine
Mitral Valve Incompetence
Multi-Organ Disorder
Muscle Spasms
Night Sweats
Normochromic Normocytic
Anaemia
Pain
Pancreatitis
Platelet Count Decreased
Pneumonia
Pulmonary Oedema
Pyoderma Gangrenosum
Pyrexia
Renal Failure
Renal Tubular Necrosis
Respiratory Disorder
Respiratory Failure
Vasculitis
Vision Blurred

Date:08/09/05ISR Number: 4738875-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03729
Age:56 YR Gender:Male I/FU:F

Outcome
Death
Hospitalization -

Initial or Prolonged

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON
Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	51	MON
		Aspirin	C			UNKNOWN	
		Oxycontin	C			UNKNOWN	

Date:08/09/05ISR Number: 4738876-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00097
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738877-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00766
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Advil	C				
UNKNOWN								
Disability	Aortic Valve Sclerosis							
	Cardiomegaly							
	Injury							
	Intracardiac Thrombus							
	Rhinitis							
	Toothache							
	Tricuspid Valve Incompetence							

Date:08/09/05ISR Number: 4738886-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00172
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	1271 DAY	
Hospitalization -	Cerebrovascular Accident		Prednisone	C			UNKNOWN	
Initial or Prolonged	Failure To Thrive		Zoloft	C			UNKNOWN	
Other	Myocardial Infarction		Tramadol Hydrochloride	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Naproxen	C			UNKNOWN	

Date:08/09/05ISR Number: 4738887-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00171
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		[Therapy Unspecified]	C			UNKNOWN	
	Overdose							

Date:08/09/05ISR Number: 4738888-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00511
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738889-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00738
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:08/09/05ISR Number: 4738890-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00808
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738891-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00513
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738892-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00508
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/09/05ISR Number: 4738893-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00880
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738894-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00028
Age:80 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738895-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00029
Age:61 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738896-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00506
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738900-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00741
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Paralysis		Vioxx	PS	Merck & Co., Inc	ORAL	26	MON
	Transient Ischaemic Attack							

Date:08/09/05ISR Number: 4738901-7Report Type:Expedited (15-DaCompany Report #NO-MERCK-0508NOR00001
Age:57 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cor Pulmonale Acute		Vioxx	SS	Merck & Co., Inc	ORAL		
	Deep Vein Thrombosis		Desloratadine	C		ORAL		
	Oedema Peripheral		Tolterodine Tartrate	C		ORAL		
	Pulmonary Embolism		Mirtazapine	C				
			Esomeprazole Magnesium	C				
			Pravastatin Sodium	C				
			Clonazepam	C				
			Pentazocine Hydrochloride	C				
			Carisoprodol	C				
			Sumatriptan	C				
			Naproxen	C		ORAL		
			Celecoxib	C				

UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
RESPIRATORY
(INHALATION)
UNKNOWN

Date:08/09/05ISR Number: 4738902-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA03190
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		37 DAY
Initial or Prolonged	Basal Cell Carcinoma		Goserelin	C				PARENTERAL
Disability	Blood Glucose Increased		Goserelin	C				PARENTERAL
Other	Bradycardia		Casodex	C		ORAL		
	Breast Tenderness		Casodex	C		ORAL		
	Constipation		Ecotrin	C		ORAL		
	Cough		Felodipine	C		ORAL		
	Diabetes Mellitus		Fluticasone					
	Dialysis		Propionate	C				RESPIRATORY
	External Ear Lesion							(INHALATION)
	Excision		Metoprolol	C				UNKNOWN
	Hot Flush		Ranitidine					
	Hypertension		Hydrochloride	C				UNKNOWN
	Influenza		Zocor	C				UNKNOWN
	Injury		Warfarin	C		ORAL		
	Limb Traumatic Amputation		Phillips' Milk Of					
	Musculoskeletal		Magnesia	C				UNKNOWN
	Discomfort		Docusate Sodium	C		ORAL		
	Myocardial Infarction		Hydrocodone					
	Nail Tinea		Bitartrate	C		ORAL		
	Neuropathy							
	Oedema Peripheral							
	Renal Failure							
	Renal Failure Acute							
	Sleep Apnoea Syndrome							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738903-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01172
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Cardiac Valve Disease Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738904-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00565
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Atacand	C				
UNKNOWN								
Other			Plavix	C				
UNKNOWN								

Date:08/09/05ISR Number: 4738905-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0508CAN00029
Age:32 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Emotional Distress Musculoskeletal Stiffness		Vioxx	PS	Merck & Co., Inc	ORAL		
			Methotrexate	C				
UNKNOWN								
	Myocardial Infarction		Terbutaline Sulfate	C				
UNKNOWN								

Date:08/09/05ISR Number: 4738906-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01166
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1327 DAY

Date:08/09/05ISR Number: 4738908-XReport Type:Expedited (15-DaCompany Report #GB-MERCK-0508GBR00031
Age:80 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	5	MON
			Norgestrel	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Atorvastatin Calcium	C			UNKNOWN	

Date:08/09/05ISR Number: 4738913-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00515
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/09/05ISR Number: 4738914-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01034
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Ischaemic Stroke		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/09/05ISR Number: 4738915-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00977
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738916-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00889
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:08/09/05ISR Number: 4738917-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00809
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/09/05ISR Number: 4738918-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738920-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01326
Age:72 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738924-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01288
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/09/05ISR Number: 4738933-9Report Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00091
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Arteriospasm Coronary		Vioxx	SS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cervical Spinal Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Fatigue		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Heart Disease		Clomipramine Hydrochloride	C		ORAL		
			Tramadol Hydrochloride	C		ORAL		
			Sodium Bicarbonate And Sodium Chloride And Polyethylene Glycol 3350 And					

		Potassium Chloride	C	ORAL
		Nebivolol Hydrochloride	C	ORAL
		Lisinopril	C	ORAL
		Doxepin Hydrochloride	C	ORAL
		Hydrochlorothiazide And Triamterene	C	ORAL

Date:08/10/05ISR Number: 4740044-3Report Type:Periodic Company Report #US-GLAXOSMITHKLINE-A0500371A
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Blood Pressure Increased		Paxil	PS	Glaxosmithkline	ORAL	20MG Twice per day	1 MON
	Dyspepsia							
	Melaena		Vioxx	SS				
	Nausea		Elavil	C	Glaxosmithkline			
	Somnolence		Inhalers	C				
			Neurontin	C				
			Xanax	C				
			Tenormin	C				
			Synthroid	C	Glaxosmithkline			

Date:08/10/05ISR Number: 4740623-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0210DEU00010
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	
Initial or Prolonged	Visual Acuity Reduced		Vioxx	SS	Merck & Co., Inc	ORAL	9 DAY	
Disability			Vioxx	SS	Merck & Co., Inc	ORAL	6 MON	
			Vioxx	SS	Merck & Co., Inc	ORAL	9 DAY	
			Morphine Sulfate	C		ORAL		
			Magnesium (Unspecified)	C		ORAL		
			Verapamil	C		ORAL		
			Furosemide Sodium	C		ORAL		

Enalapril Maleate	C	ORAL
Tamoxifen Citrate	C	ORAL
Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C	ORAL

Date:08/10/05ISR Number: 4740624-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00134
Age:73 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Wall Mass
Disability	Anorexia
Other	Anxiety
	Arthritis
	Asthenia
	Atherosclerosis
	Aural Polyp
	Back Pain
	Blister
	Blood Pressure Increased
	Bronchitis

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Bursitis					
		Cardiac Disorder					
		Caustic Injury					
		Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Depression		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
DAY							
		Diverticulum Intestinal		Prinivil	C		
UNKNOWN							
		Dizziness		K-Dur	C		
UNKNOWN							
		Drug Eruption		Lortab	C		
UNKNOWN							
		Dysphonia		Coumadin	C		
UNKNOWN							
		Dysuria		[Therapy			
		Ecchymosis		Unspecified]	C		
UNKNOWN							
		Epistaxis		Lasix (Furosemide			
		Fall		Sodium)	C		
UNKNOWN							
		Frequent Bowel Movements					
		Gastritis					
		Glucose Tolerance					
		Impaired					
		Gout					
		Haemorrhoids					
		Headache					
		Helicobacter Infection					
		Hypertension					
		Hypoaesthesia					
		Insomnia					
		Intervertebral Disc					
		Degeneration					
		Intervertebral Disc					
		Protrusion					
		Joint Crepitation					
		Kidney Infection					
		Labyrinthitis					
		Middle Ear Disorder					
		Muscle Strain					
		Nasopharyngeal Disorder					
		Nasopharyngitis					
		Nausea					

Oedema Peripheral
Osteoarthritis
Otitis Media
Pain
Pharyngitis
Polyarthritis
Rash
Rhinitis
Sinusitis
Sleep Disorder
Stomach Discomfort
Syncope
Tricuspid Valve
Incompetence
Vertigo
Vision Blurred
Vomiting

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4740625-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01274
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740626-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01275
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740627-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01354
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740628-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01272
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740629-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02018
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 1415 YR	Apraxia		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Breast Microcalcification	Vioxx	SS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident	Vioxx	SS	Merck & Co., Inc	ORAL
	Colitis	Fluoxetine	C		
UNKNOWN					
	Colitis Ulcerative	Prevacid	C		
UNKNOWN					
	Diarrhoea Haemorrhagic	Plavix	C		
UNKNOWN					
	Emotional Distress	Albuterol	C		
UNKNOWN					
	Fall	Temazepam	C		
UNKNOWN					
	Generalised Anxiety	Temazepam	C		
UNKNOWN					
	Disorder	Allegra	C		
UNKNOWN					
	Headache	Detrol	C		
UNKNOWN					
	Hypertension	Asacol	C		
UNKNOWN					
	Intestinal Haemorrhage	Klor-Con	C		
UNKNOWN					
	Lymphadenopathy	Cozaar	C		
UNKNOWN					
	Oedema Peripheral	Advair	C		
UNKNOWN					
	Sleep Disorder	Lasix (Furosemide)	C		
UNKNOWN					
	Wound	Lasix (Furosemide)	C		
UNKNOWN					
		Wellbutrin	C		
UNKNOWN					
		Cardizem	C		
UNKNOWN					
		Bupropion Hydrochloride	C		
UNKNOWN					
		Relafen	C		
UNKNOWN					
		Prozac	C		
UNKNOWN					
		Prempro	C		
UNKNOWN					
		Claritin	C		
UNKNOWN					
		Armour Thyroid			

			Tablets	C	
UNKNOWN					
			Potassium Chloride	C	
UNKNOWN					
			K-Dur	C	
UNKNOWN					
			Cartia Xt	C	
UNKNOWN					
			Medroxyprogesterone Acetate	C	
UNKNOWN					
			Theophylline	C	
UNKNOWN					
			Levothroid	C	
UNKNOWN					
			Uniphyl	C	
UNKNOWN					
			Prinivil	C	ORAL
			Furosemide	C	
UNKNOWN					

Date:08/10/05ISR Number: 4740659-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02280
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 5 YR	Anaemia Postoperative		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Vicodin Tablets	C		
UNKNOWN						
Other	Chronic Obstructive		Phentermine	C		
UNKNOWN						
	Pulmonary Disease		Zocor	C		
UNKNOWN						
	Coronary Artery		Nexium	C		
UNKNOWN						
	Atherosclerosis		Lamisil	C		
UNKNOWN						
	Coronary Artery Disease		Nystatin	C		
UNKNOWN						
	Diabetes Mellitus		Lotrel	C		
UNKNOWN						
	Emotional Distress		Fioricet Tablets	C		
UNKNOWN						
	Hypersensitivity		Arthrotec	C		
UNKNOWN						

Hypoaesthesia
Lumbar Radiculopathy
Myocardial Infarction
Nausea
Peptic Ulcer
Thrombosis
Venous Thrombosis Limb

Date:08/10/05ISR Number: 4740660-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01848
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Diarrhoea		Vioxx	PS	Merck & Co., Inc	ORAL		
	Flatulence		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Folliculitis							
	Furuncle							
	Gastritis							
	Gastrointestinal Haemorrhage							
	Insomnia							
	International Normalised Ratio Increased							
	Intertrigo							
	Joint Injury							
	Peptic Ulcer							
	Periarthritis							
	Pulmonary Embolism							
	Rotator Cuff Syndrome							
	Skin Laceration							

Date:08/10/05ISR Number: 4740661-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00170
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Migraine		Vioxx	SS	Merck & Co., Inc	ORAL		
			Darvocet-N	C			UNKNOWN	
			Vicodin Tablets	C			UNKNOWN	
			Flexeril	C		ORAL		

Date:08/10/05ISR Number: 4740662-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02273
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	47 MON	
	Increased		Percocet	C			UNKNOWN	
	Cerebrovascular Accident							
	Gastrooesophageal Reflux Disease							
	Heart Rate Irregular							
	Pain							

Date:08/10/05ISR Number: 4740663-4Report Type:Expedited (15-DaCompany Report #CA-MERCK-0503USA02659
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON	

Date:08/10/05ISR Number: 4740664-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00575
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740665-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03704
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaemia Back Disorder Back Pain Benign Neoplasm Of Prostate Blood Cholesterol Increased Blood Creatine Phosphokinase Increased Blood Lactate Dehydrogenase Increased Blood Triglycerides Increased Bronchitis Buttock Pain Coronary Artery Disease Ear Disorder

	Erectile Dysfunction Exostosis High Density Lipoprotein	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Decreased		Vioxx	PS	Merck & Co., Inc	ORAL	910 DAY
	Hyperkeratosis Palmaris		Vioxx	SS	Merck & Co., Inc	ORAL	910 DAY
	And Plantaris		Monopril	C			UNKNOWN
	Hypertension		Norvasc	C			UNKNOWN
	Mixed Connective Tissue		Plendil	C			UNKNOWN
	Disease		Furosemide	C			UNKNOWN
	Myocardial Infarction		Hydrochlorothiazide	C			UNKNOWN
	Oedema Peripheral		Zocor	C			UNKNOWN
	Osteoarthritis Peripheral Vascular Disorder Peyronie'S Disease Renal Failure Skin Ulcer Toe Deformity Viral Infection						

Date:08/10/05ISR Number: 4740666-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00903
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Myocardial Infarction		Protonix	C			UNKNOWN
Other	Small Intestinal Obstruction						

Date:08/10/05ISR Number: 4740668-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01273
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740713-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01253
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1017 DAY	

Date:08/10/05ISR Number: 4740714-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01271
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4740715-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03904
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4740905-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01222
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Lipitor	C		ORAL		
			Ziac	C		ORAL		

Date:08/10/05ISR Number: 4741721-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00121
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		[Therapy Unspecified]	C				
Disability								
UNKNOWN								
			Blood Thinner (Unspecified)	C				
UNKNOWN								

Date:08/10/05ISR Number: 4741722-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00132
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	497 DAY	
	Myocardial Infarction							
Disability								

Date:08/10/05ISR Number: 4741723-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00059
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1225 DAY	
	Myocardial Infarction		[Therapy					

Disability	Unspecified]	C	
UNKNOWN			
	[Therapy Unspecified]	C	
UNKNOWN			
	Aspirin	C	
UNKNOWN			

Date:08/10/05ISR Number: 4741724-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00031
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dyspnoea Exertional							
	Myocardial Infarction							
	Thyroid Disorder							

Date:08/10/05ISR Number: 4741725-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Pain
	Chest Pain
Disability	Convulsion
	Dyspepsia
	Gastritis
	Hiatus Hernia

		Hypertension					
		Inflammation					
		Joint Injury	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
		Peptic Ulcer Haemorrhage		Ibuprofen	C		
UNKNOWN							
		Transient Ischaemic		Feosol	C		
UNKNOWN							
		Attack		Atenolol	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Relafen	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							

Date:08/10/05ISR Number: 4741727-1Report Type:Expedited (15-DaCompany Report #FR-MERCK-0409FRA00001
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
26 DAY						
Initial or Prolonged	Cardioactive Drug Level		Perindopril Erbumine	SS		ORAL
	Increased		Digoxin	SS		ORAL
	Drug Interaction		Digoxin	SS		ORAL
	Renal Failure		Diltiazem Hydrochloride	SS		ORAL
			Diltiazem Hydrochloride	SS		ORAL
			Fluindione	C		ORAL
			Fluindione	C		ORAL
			Levothyroxine Sodium	C		ORAL
			Amlodipine Besylate	C		ORAL
			Furosemide	C		ORAL
			Potassium Chloride	C		ORAL
			Allopurinol	C		ORAL
			Oxerutins	C		ORAL
			Atorvastatin Calcium	C		ORAL
			Pantoprazole	C		ORAL
			Calcium Carbonate And Cholecalciferol	C		ORAL

Date:08/10/05ISR Number: 4741733-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00066
Age:59 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Other	Acute Respiratory Distress Syndrome
	Acute Respiratory Failure
	Anxiety
	Arthropathy
	Atelectasis
	Back Pain
	Blood Pressure Systolic Abnormal
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident
	Cerebrovascular Accident Prophylaxis
	Chest Discomfort
	Chest Pain
	Cholecystitis
	Convulsion

Coordination Abnormal
Depression
Drug Hypersensitivity
Essential Tremor
Fall
Gastrooesophageal Reflux
Disease
Headache
Hiatus Hernia
Hypertension
Hypotension
Hypoxia
Intention Tremor
Intervertebral Disc
Degeneration
Laryngitis
Mitral Valve Incompetence
Non-Cardiac Chest Pain
Pericardial Effusion
Ph Body Fluid Abnormal
Pneumonia
Shock
Sinus Disorder
Spinal Column Stenosis
Spinal Compression
Fracture
Transient Ischaemic
Attack
Urinary Tract Infection
Ventricular Hypokinesia
Vertigo

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	5	DAY
	Aspirin	C				UNKNOWN
	Lipitor	C				UNKNOWN
	Metformin	C				UNKNOWN
	Prozac	C				UNKNOWN
	Prilosec	C				UNKNOWN
	Glucophage	C				UNKNOWN
	Wellbutrin	C				UNKNOWN

Date:08/10/05ISR Number: 4741742-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01698
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Musculoskeletal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricle Rupture		Glucophage	C			UNKNOWN	
			Avandia	C			UNKNOWN	

Date:08/10/05ISR Number: 4741743-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02981
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	147 DAY	
	Infarction		Norvasc	C			UNKNOWN	
	Anhedonia		Allegra	C			UNKNOWN	
	Emotional Distress		Wellbutrin	C			UNKNOWN	
	Pain		Trazodone Hydrochloride	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Avapro	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741745-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00710
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Emotional Distress Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741746-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01892
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 35 MON	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arteriosclerosis		Ziac	C				
UNKNOWN							9	YR
Disability	Cardiac Disorder		Aspirin	C				
UNKNOWN								
	Emotional Distress		Tylenol	C				
UNKNOWN								
	Gastritis		Pamelor	C				
UNKNOWN								
	Myocardial Infarction		Buspar	C				
UNKNOWN								
	Ventricular Hypokinesia		Skelaxin	C				
UNKNOWN								
			Zanaflex	C				
UNKNOWN								
			Bisoprolol Fumarate And Hydrochlorothiazide	C				
UNKNOWN								
			Dexamethasone	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								

Date:08/10/05ISR Number: 4741748-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01919
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Atenolol	C			UNKNOWN	
	Emotional Distress		Skelaxin	C		ORAL		
	Gastroenteritis		Prilosec	C		ORAL		
	Haematoma		Celebrex	C			UNKNOWN	
	Hypercholesterolaemia		Nicotrol	C			UNKNOWN	
	Hyperlipidaemia		Nexium	C			UNKNOWN	
	Myocardial Infarction		Aspirin	C			UNKNOWN	
	Palpitations							
	Stress Fracture							

Date:08/10/05ISR Number: 4741749-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02947
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741750-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01896
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
	Anxiety
Other	Blood Pressure Decreased
	Chest Discomfort

		Depression					
		Dizziness					
		Drug Ineffective	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL
		Gastrooesophageal Reflux		Benicar	C		
UNKNOWN							
		Disease		Coreg	C		
UNKNOWN							
		Haemorrhage		Lofibra	C		
UNKNOWN							
		Haemorrhoids		Plavix	C		
UNKNOWN							
		Headache		Pletal	C		
UNKNOWN							
		Hypercholesterolaemia		Protonix	C		
UNKNOWN							
		Hypertension		Mobic	C		
UNKNOWN							
		Insomnia		Wellbutrin	C		
UNKNOWN							
		Joint Injury		Cardizem	C		ORAL
		Myocardial Infarction		Aspirin	C		ORAL
		Reflux Oesophagitis					
		Rib Fracture					
		Sinusitis					
		Syncope					
		Transient Ischaemic					
		Attack					
		Ventricular Tachycardia					
		Weight Decreased					

Date:08/10/05ISR Number: 4741751-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA01121
Age:44 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Atenolol	C		
UNKNOWN							
		Anxiety		Norvasc	C		
UNKNOWN							
		Back Pain		Zestril	C		
UNKNOWN							
		Blood Glucose Increased					

Coronary Artery
Atherosclerosis
Dyslipidaemia
High Density Lipoprotein
Decreased
Hypertension
Hypoaesthesia
Sinus Bradycardia
Stent Occlusion
Swelling
Wound

Date:08/10/05ISR Number: 4741752-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0301USA01087
Age:49 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
Disability	Anxiety
Other	Back Disorder
	Blood Cholesterol Increased
	Blood Pressure Decreased
	Blood Triglycerides Increased
	Bronchitis
	Cardiomegaly
	Cerebrovascular Accident

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Chest Pain Chronic Fatigue Syndrome Clostridium Colitis					
560	DAY	Convulsion		Vioxx	PS	Merck & Co., Inc	ORAL
UNKNOWN		Depression		Diovan	C		
UNKNOWN		Dizziness		Lasix (Furosemide)	C		
UNKNOWN		Emotional Distress		Lasix (Furosemide)	C		
UNKNOWN		Fibrosis		Nexium	C		
UNKNOWN		Fluid Retention		Zaroxolyn	C		
UNKNOWN		Gastrooesophageal Reflux		Torsemide	C		
UNKNOWN		Disease		Oxycontin	C		
UNKNOWN		Haematochezia		Ultram	C		
UNKNOWN		Headache		Neurontin	C		
UNKNOWN		Hyperhidrosis		Zanaflex	C		
UNKNOWN		Hyperlipidaemia		Celexa	C		
UNKNOWN		Hypoxia		Potassium Chloride	C		
UNKNOWN		Ileus Lumbar Radiculopathy		Amitriptyline Hydrochloride	C		
UNKNOWN		Myocardial Infarction Nephrolithiasis		Amitriptyline Hydrochloride	C		
UNKNOWN		Oedema		Ambien	C		
UNKNOWN		Pneumonia		Aleve	C		
UNKNOWN		Pneumonia Aspiration		Lexapro	C		
UNKNOWN		Pneumonia Pneumococcal		Alprazolam	C		
UNKNOWN		Rash		Nortriptyline	C		
UNKNOWN		Renal Failure Acute					

Rhabdomyolysis
Sinusitis
Spinal Compression
Fracture
Staphylococcal Infection

Date:08/10/05ISR Number: 4741753-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01768
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event Cerebrovascular Accident Nervous System Disorder Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741785-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00102
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741787-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00098
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	369 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741788-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00009
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		952 DAY
Other	Myocardial Infarction		Ranitidine Hydrochloride	C				UNKNOWN
			Allopurinol	C				UNKNOWN
			Oxazepam	C				UNKNOWN

Date:08/10/05ISR Number: 4741789-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01502
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL		528 DAY
Initial or Prolonged	Adverse Event		Xanax	C				UNKNOWN
Disability	Amnesia		Ecotrin	C				UNKNOWN
	Animal Bite		Tenormin	C				UNKNOWN
	Atherosclerosis		Altace	C				UNKNOWN
	Blood Cholesterol		Plavix	C				UNKNOWN
	Increased		Toprol Xl Tablets	C				UNKNOWN
	Bronchitis		Climara	C				UNKNOWN
	Coronary Artery Disease		Oxycontin	C				UNKNOWN
	Depression							
	Haemorrhage							
	Musculoskeletal Disorder							
	Myocardial Infarction							
	Road Traffic Accident							
	Transient Ischaemic Attack							

Vertigo

Date:08/10/05ISR Number: 4741790-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01847
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Breast Cancer		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Synthroid	C				
Disability	Myocardial Infarction		Estrogens (Unspecified)	C				
	Osteoarthritis							
	Renal Disorder							
	Thyroid Disorder							

Date:08/10/05ISR Number: 4741791-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0504DEU00134
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertension							
	Sensation Of Foreign Body							
	Tachyarrhythmia							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741792-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01654
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arthropathy Pulmonary Embolism		Vioxx Percocet	PS C	Merck & Co., Inc	ORAL		
UNKNOWN								

Date:08/10/05ISR Number: 4741793-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00100
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741794-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00099
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741811-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00874
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741812-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00745
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741813-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01108
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741814-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00165
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 161 DAY	Dyspnoea Exertional		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged UNKNOWN	Myocardial Infarction		Flexeril	C				
Disability UNKNOWN			Neurontin	C				

Date:08/10/05ISR Number: 4741815-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02977
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741816-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01120
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Pulmonary Embolism		Wellbutrin	C				
UNKNOWN								

Date:08/10/05ISR Number: 4741817-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00853
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL	25	MON

Date:08/10/05ISR Number: 4741818-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0508AUS00030
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741819-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00851
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Hypertension
Peripheral Vascular
Disorder

Date:08/10/05ISR Number: 4741820-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00569
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Heart Rate Decreased		Tylenol	C			UNKNOWN	
	Herpes Zoster		Norvasc	C			UNKNOWN	
	Myocardial Infarction		Premarin	C			UNKNOWN	
	Ulcer							

Date:08/10/05ISR Number: 4741838-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00963
Age:74 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia
Disability	Cerebral Infarction
	Cerebrovascular Accident
	Depression
	Diabetes Mellitus

		Hernia Nephrolithiasis Rotator Cuff Syndrome	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aciphex	C		
UNKNOWN							
				Aggrenox	C		
UNKNOWN							
				Alprazolam	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Baclofen	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Doxazosin Mesylate	C		
UNKNOWN							
				Doxycycline	C		
UNKNOWN							
				Flomax (Morniflumate)	C		
UNKNOWN							
				Glucotrol	C		
UNKNOWN							
				Guaifenesin	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Zocor	C		ORAL
				Prevacid	C		
UNKNOWN							
				Quinine Sulfate	C		
UNKNOWN							
				Terazosin Hydrochloride	C		
UNKNOWN							
				Zithromax	C		
UNKNOWN							
				Zoloft	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							

Date:08/10/05ISR Number: 4741839-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00849
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56	MON

Date:08/10/05ISR Number: 4741840-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00930
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Coronary Artery Atherosclerosis Death		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741841-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00938
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741842-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00931
Age:60 YR Gender:Male I/FU:I

Outcome	PT
Other	Adverse Event Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction

		Thrombosis Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/10/05ISR Number: 4741843-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00929
Age:54 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event Atherosclerosis Cardiac Failure Congestive Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/10/05ISR Number: 4741844-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00932
Age:43 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Pulmonary Embolism Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/10/05ISR Number: 4741845-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00856
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741846-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00933
Age:73 YR Gender:Female I/FU:I

Outcome	PT
Other	Adverse Event Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis

	Transient Ischaemic Attack						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741847-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02792
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 371 YR	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged 371 YR	Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ischaemia		Zocor	C				
UNKNOWN								
	Myocardial Infarction		Zyprexa	C				
UNKNOWN								
			Prozac	C				
UNKNOWN								
			Diovan	C				
UNKNOWN								

Date:08/10/05ISR Number: 4741848-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00939
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741851-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01153
Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741852-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01243
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:08/10/05ISR Number: 4741853-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01148
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741854-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01150
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	21	DAY

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741855-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02972
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Carotid Artery Stenosis		Aspirin	C			UNKNOWN	
	Chest Pain		Xanax	C			UNKNOWN	
	Coronary Artery Disease		Prempro	C			UNKNOWN	
	Gastric Ulcer		Nitroglycerin	C			UNKNOWN	
	Hypertension		Plavix	C			UNKNOWN	
	Myocardial Infarction		Celebrex	C			UNKNOWN	
	Sleep Apnoea Syndrome		Bextra	C			UNKNOWN	
	Stress							
	Swelling							

Date:08/10/05ISR Number: 4741856-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01258
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	39 MON	

Date:08/10/05ISR Number: 4741857-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01109
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1038 DAY	

Date:08/10/05ISR Number: 4741858-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction Cardio-Respiratory Arrest Renal Failure Chronic		Vioxx	PS	Merck & Co., Inc	ORAL	288 DAY	

Date:08/10/05ISR Number: 4741859-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01242
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741860-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01259
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741861-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01244
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13 MON	

Date:08/10/05ISR Number: 4741862-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01154
Age:78 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741863-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01324
Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	56 MON	

Date:08/10/05ISR Number: 4741865-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01318
Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741866-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01349
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/10/05ISR Number: 4741867-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01056
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adrenal Neoplasm		Vioxx	PS	Merck & Co., Inc	ORAL	26 MON	
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL	26 MON	
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		

	Depression		Prilosec	C		ORAL
	Dyspnoea		Aspirin	C		
UNKNOWN						
	Hypertension		Hydrocodone			
	Myocardial Infarction		Bitartrate	C		
UNKNOWN						
	Osteoporosis					
	Pain					

Date:08/10/05ISR Number: 4741868-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01351
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	15	MON
Other	Myocardial Infarction							

Date:08/10/05ISR Number: 4741869-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01325
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/10/05ISR Number: 4741870-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01316
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742717-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0402USA00067
Age:39 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acarodermatitis
Other	Aggression
	Anaemia
	Atrial Fibrillation
	Bipolar Disorder
	Blood Testosterone Decreased
	Cardiac Failure
	Cholecystitis
	Cholelithiasis
	Clostridium Colitis
	Coma
	Contusion
	Decreased Appetite
	Depression
	Drug Abuser
	Emotional Distress
	Erectile Dysfunction
	Eye Infection
	Fatigue
	Flank Pain
	Gastrooesophageal Reflux Disease
	Headache
	Hepatic Cirrhosis
	Hepatic Failure
	Hiatus Hernia
	Hypertension
	Impaired Gastric Emptying
	Insomnia
	Intentional Misuse
	Intervertebral Disc Disorder
	Lethargy

Myocardial Infarction
Nasal Septum Deviation
Nervousness
Oedema Peripheral
Platelet Count Decreased
Pneumonia
Psychiatric Symptom
Rash
Rash Generalised
Renal Disorder
Renal Failure Acute
Renal Tubular Necrosis
Respiratory Failure
Rhinitis
Sepsis
Testicular Mass
Upper Respiratory Tract

		Infection					
		Weight Decreased					
		Weight Increased					
			Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL
				Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/11/05ISR Number: 4742718-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00137
Age:38 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Arrest					
		Cardiovascular Disorder					
		Cerebrovascular Accident					
		Depression					
		Lethargy					
		Life Expectancy Shortened					
		Mental Disorder					
		Myocardial Infarction					

Date:08/11/05ISR Number: 4742720-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00131
Age:62 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged				Omeprazole	C		
UNKNOWN							

Date:08/11/05ISR Number: 4742721-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0205USA02069
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Arteriosclerosis
Initial or Prolonged	Azotaemia
Other	Cardiac Failure
	Congestive
	Cholelithiasis

Chronic Obstructive
Pulmonary Disease
Cystitis
Dizziness
Dyspnoea
Emotional Distress
Femur Fracture
Gastritis
Gastrooesophageal Reflux
Disease
Hydronephrosis
Hypertension
Injury
Liver Function Test
Abnormal
Lobar Pneumonia
Myocardial Infarction
Nephritis Interstitial
Nephrolithiasis
Oxygen Saturation
Decreased

		Pancreatitis					
		Pneumonia					
		Pyelonephritis Acute	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Renal Failure Acute		Vioxx	PS	Merck & Co., Inc	ORAL
7 MON							
		Urinary Tract Infection		Accupril	SS		
UNKNOWN							
				Accupril	SS		
UNKNOWN							
				Accupril	SS		
UNKNOWN							
				Accupril	SS		
UNKNOWN							
				Accupril	SS		
UNKNOWN							
				Levaquin	SS		
UNKNOWN							
				Vioxx	SS	Merck & Co., Inc	ORAL
7 MON							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							
				Protonix	C		
UNKNOWN							

Date:08/11/05ISR Number: 4742722-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0302USA00066
Age:63 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abscess Limb
Disability	Adverse Event
Other	Angina Pectoris
	Anxiety
	Astigmatism
	Carpal Tunnel Syndrome
	Cataract
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain

Corneal Disorder
Coronary Artery Disease
Cystitis
Depression
Dizziness
Duodenal Ulcer
Dyspepsia
Dysphagia
Dyspnoea
Emotional Distress
Erectile Dysfunction
Exostosis
Gastritis
Gastroenteritis
Helicobacter
Gastrooesophageal Reflux
Disease
Haematemesis
Haemorrhoids
Helicobacter Infection
Hypercalcaemia
Hyperparathyroidism
Hypertension
Injury
Insomnia
Intervertebral Disc
Degeneration
Intestinal Ulcer
Irritability

		Mediastinitis					
		Nausea					
		Oedema Peripheral	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pain In Extremity		Vioxx	PS	Merck & Co., Inc	ORAL
100	DAY						
		Pericardial Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Plantar Fasciitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pleural Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
		Postoperative Infection		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Postpericardiotomy		Vioxx	SS	Merck & Co., Inc	ORAL
		Syndrome		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Pseudophakia		Vioxx	SS	Merck & Co., Inc	ORAL
		Sinus Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL
		Spinal Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Vioxx	SS	Merck & Co., Inc	ORAL
100	DAY						
		Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL
		Ulnar Nerve Injury		Zoloft	C		
UNKNOWN							
		Venous Thrombosis Limb		Tenormin	C		
UNKNOWN							
		Ventricular Hypertrophy		Tenormin	C		
UNKNOWN							
		Vomiting		Temazepam	C		
UNKNOWN							
		Weight Decreased		Tagamet	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Augmentin	C		
UNKNOWN							
				Zocor	C		ORAL
				Motrin	C		ORAL
				Plavix	C		ORAL
				Relafen	C		
UNKNOWN							
				Nitrostat	C		
UNKNOWN							
				Ultram	C		ORAL
				Ultracet	C		
UNKNOWN							
				Ultracet	C		
UNKNOWN							

	Celebrex	C	UNKNOWN
	Celebrex	C	UNKNOWN
	Trazodone Hydrochloride	C	UNKNOWN
	Trazodone Hydrochloride	C	UNKNOWN
	Trazodone Hydrochloride	C	UNKNOWN
	Bextra	C	UNKNOWN
	Bextra	C	UNKNOWN
	Flexeril	C	UNKNOWN
	Flexeril	C	UNKNOWN
	Paxil	C	UNKNOWN

Date:08/11/05ISR Number: 4742738-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00138
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742739-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00090
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742740-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01574
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Blindness Unilateral		Vioxx	PS	Merck & Co., Inc	ORAL	1007 DAY	
Other								

Date:08/11/05ISR Number: 4742741-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00137
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Insulin	C				
UNKNOWN								

Date:08/11/05ISR Number: 4742742-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00091
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/11/05ISR Number: 4742744-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02060
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	4 YR	
Initial or Prolonged	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	4 YR	
Other	Back Pain		Premarin	C				
UNKNOWN								
	Coronary Artery Disease		Synthroid	C				
UNKNOWN								
	Coronary Artery Stenosis		Prozac	C				
UNKNOWN								

	Drug Administration Error	Zyrtec	C
UNKNOWN			
	Dyspnoea	Prevacid	C
UNKNOWN			
	Emotional Distress	Norvasc	C
UNKNOWN			
	Gastric Disorder	Zomax	C
UNKNOWN			
	Hernia	Aciphex	C
UNKNOWN			
	Intervertebral Disc	Tagamet	C
UNKNOWN			
	Protrusion	Paxil	C
UNKNOWN			
	Ischaemia	Zantac	C
UNKNOWN			
	Meniscus Lesion	Belladonna	C
UNKNOWN			
	Myocardial Infarction	Skelaxin	C
UNKNOWN			
	Night Sweats	Hydrocodone/Apap	C
UNKNOWN			
		Hydrocodone/Apap	C
UNKNOWN			
		Promethazine	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			
		Avapro	C
UNKNOWN			
		Xanax	C
UNKNOWN			
		Xanax	C
UNKNOWN			
		Nexium	C
UNKNOWN			

Date:08/11/05ISR Number: 4742745-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02567
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1044 DAY	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fall		Norvasc	C		
UNKNOWN	50 MON					
Disability	Joint Injury		Prempro	C		
UNKNOWN						
	Joint Sprain		Fosamax	C		
UNKNOWN						

Myocardial Infarction Valium C

UNKNOWN

			A.S.A.	C	ORAL

Date:08/11/05ISR Number: 4742751-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01137
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742753-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01135
Age:52 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742754-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00104
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742755-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742756-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00876
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/11/05ISR Number: 4742757-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00567
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
Other	Chest Pain							
	Hypertension							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742758-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01250
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Fracture							
	Myocardial Infarction							
	Thrombosis							

Date:08/11/05ISR Number: 4742759-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00875
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742760-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00092
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							
	Overdose							

Date:08/11/05ISR Number: 4742761-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02060
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		
180 DAY								
Initial or Prolonged	Bacterial Infection		Folic Acid	C				
UNKNOWN								
	Cardiac Valve Disease		Celebrex	C				
UNKNOWN								
	Cerebrovascular Accident		Atenolol	C				
UNKNOWN	2263 DAY							
	Gastric Disorder		Glipizide	C				
UNKNOWN								

	Hypersensitivity	Trazodone		
	Nasopharyngitis	Hydrochloride	C	
UNKNOWN				
	Pain	[Therapy		
	Urinary Tract Infection	Unspecified]	C	
UNKNOWN				
		Lipitor	C	
UNKNOWN				
		Prevacid	C	
UNKNOWN				
		Alprazolam	C	
UNKNOWN				
		Furosemide	C	
UNKNOWN				
		Guaifenesin	C	
UNKNOWN				
		Glucophage	C	
UNKNOWN				
		Haloperidol	C	
UNKNOWN				
		Temazepam	C	
UNKNOWN				

Date:08/11/05ISR Number: 4742762-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00095
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742763-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00096
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742764-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03393
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anhedonia Anxiety Cardiovascular Disorder Injury Nervous System Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742765-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00097
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742766-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00109
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742767-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00094
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx Vioxx	PS SS	Merck & Co., Inc Merck & Co., Inc	ORAL ORAL		

Date:08/11/05ISR Number: 4742768-0Report Type:Expedited (15-DaCompany Report #CA-MERCK-0508CAN00039
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742774-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01141
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742778-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01951
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742780-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01248
Age:41 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
Other	Overdose							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742781-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01680
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/11/05ISR Number: 4742783-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00877
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4742795-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00887
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	62 MON	
Other	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diabetic Neuropathy		Vioxx	SS	Merck & Co., Inc	ORAL	62 MON	
	Oedema Peripheral		Vioxx	SS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL		
	Attack		Vasotec	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Calan	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Cenestin	C			UNKNOWN	
			Glucophage	C			UNKNOWN	

Insulin	C	UNKNOWN
Pyridoxine	C	UNKNOWN
Vitamin E	C	UNKNOWN
Vitamin B (Unspecified)	C	UNKNOWN
Furosemide	C	UNKNOWN
Dyazide	C	UNKNOWN

Date:08/11/05ISR Number: 4742796-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01501
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL		
	Asthenia		Glucophage	C				
	Attention		Prilosec	C				
	Deficit/Hyperactivity Disorder							
	Carpal Tunnel Syndrome							
	Cerebrovascular Accident							
	Depression							
	Drug Exposure During Pregnancy							
	Headache							
	Limb Operation							
	Oedema Peripheral							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4742857-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03317
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		42 MON
Initial or Prolonged	Infarction		Endocet	C				UNKNOWN
Disability	Back Disorder		Carisoprodol	C				UNKNOWN
	Prostatism		Zanaflex	C				UNKNOWN
			Flomax (Morniflumate)	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
			Acetaminophen And Oxycodone Hydrochloride	C				UNKNOWN
			Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
			Ultram	C				UNKNOWN
			Oxycontin	C				UNKNOWN

Date:08/11/05ISR Number: 4742860-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00093
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743004-1Report Type:Expedited (15-DaCompany Report #GB-ABBOTT-05P-167-0307278-00
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Humira 40 Mg/ 0.8 Ml Pre-Filled Syringe	PS		SUBCUTANEOUS		
			Fluxetine	SS				
			Methotrexate	SS				
			Rofecoxib	SS				
			Paramol-118	SS				
			Estrogens Conjugated	SS				
			Clavulin	SS				

Date:08/11/05ISR Number: 4743072-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00762
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Angina Unstable
Other	Blood Creatinine Increased
	Bursitis
	Cardiomegaly
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Restenosis
	Depression
	Gastrooesophageal Reflux Disease

	Injury Migraine Rash Pruritic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Scrotal Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	62 DAY
	Single Vessel Bypass		Atenolol	C			UNKNOWN
	Graft		Prinivil	C		ORAL	
	Syncope		Aspirin	C			UNKNOWN
	Syncope Vasovagal		Motrin	C			UNKNOWN
			Zocor	C		ORAL	
			Glyburide	C			UNKNOWN
			Pepcid	C			UNKNOWN

Date:08/11/05ISR Number: 4743075-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0401USA01969
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	27 DAY
Initial or Prolonged	Abdominal Pain		[Therapy				
Disability	Cerebrovascular Accident		Unspecified]	SS			UNKNOWN
Other	Coordination Abnormal		Yasmin	SS			UNKNOWN
	Depression		Tylenol	C			UNKNOWN
	Diarrhoea		Advil	C			UNKNOWN
	Dizziness		Skelaxin	C			UNKNOWN
	Dysplasia		Fioricet Tablets	C			UNKNOWN
	Headache Ischaemic Cerebral Infarction Migraine Nausea Nystagmus						

		Photophobia					
		Vomiting					

Date:08/11/05ISR Number: 4743077-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00131
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Optic Ischaemic		Prednisone	C		ORAL		
	Neuropathy		Insulin	C		PARENTERAL		
			Leflunomide	C		ORAL		

Date:08/11/05ISR Number: 4743078-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03387
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL	95	DAY
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL	95	DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	International Normalised Ratio Decreased							
	Lobar Pneumonia							
	Post-Traumatic Stress Disorder							

Date:08/11/05ISR Number: 4743079-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02363
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Coronary Artery Occlusion		Glucovance	C				UNKNOWN
	Depression		Avandia	C				UNKNOWN
	Diabetic Gastroparesis		Tricor	C				UNKNOWN
	Diarrhoea		Zoloft	C				UNKNOWN
	Dysphagia		Aspirin	C				UNKNOWN
	Gastritis		Lotrel	C				UNKNOWN
	Haemorrhoids							
	Myocardial Infarction							
	Personality Disorder							
	Post-Traumatic Stress Disorder							
	Reflux Oesophagitis							
	Stomach Discomfort							
	Suicidal Ideation							
	Tension Headache							

Date:08/11/05ISR Number: 4743080-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04612
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		32 MON
Other	Ankle Fracture		Lipitor	C				UNKNOWN
	Chest Pain							
	Coronary Artery Disease							
	Gastrooesophageal Reflux Disease							
	Glaucoma							

		Hypertension					
		Myocardial Infarction					
		Tuberculosis					

Date:08/11/05ISR Number: 4743081-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00139
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743082-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04544
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Atherosclerosis		Vioxx	SS		ORAL		
Disability	Coronary Artery Disease		Colace	C				
UNKNOWN								
	Depression		Lanoxin	C				
UNKNOWN								
	Diabetes Mellitus		Pepcid	C		ORAL		
	Non-Insulin-Dependent		Zocor	C		ORAL		
	Hypertension							
	Myocardial Infarction							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4743083-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02097
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		55 MON
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Nervous System Disorder		Aspirin	C				UNKNOWN
	Polytraumatism		Combivent	C				UNKNOWN
			Albuterol	C				UNKNOWN

Date:08/11/05ISR Number: 4743084-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00032
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:08/11/05ISR Number: 4743088-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00141
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:08/11/05ISR Number: 4743089-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02045
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		1154 MON

Initial or Prolonged	Cardiac Disorder	Lipitor	C
UNKNOWN			
	Emotional Distress	Levoxyl	C
UNKNOWN			
	Hypertension	Synthroid	C
UNKNOWN			
	Myocardial Infarction	Ranitidine	C
UNKNOWN			
	Oedema Peripheral	Ambien	C
UNKNOWN			
	Osteoarthritis	Acetaminophen And Hydrocodone Bitartrate	C
UNKNOWN			

Date:08/11/05ISR Number: 4743090-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00061
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743091-0Report Type:Expedited (15-DaCompany Report #GB-MERCK-0405GBR00191
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Adalimumab	SS				
SUBCUTANEOUS								
			Methotrexate	SS				
UNKNOWN								
			Estrogens, Conjugated	SS				
UNKNOWN								
			Fluoxetine	SS				
UNKNOWN								

			Amoxicillin And Clavulanate Potassium	SS		
UNKNOWN						
			Acetaminophen And Dihydrocodeine Bitartrate	SS		
UNKNOWN						

Date:08/11/05ISR Number: 4743092-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01709
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL	70 MON	
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL	70 MON	
	Asthma		Darvocet-N	C			UNKNOWN	
	Benign Prostatic Hyperplasia		Bumex	C			UNKNOWN	
			Proventil	C			RESPIRATORY (INHALATION)	
	Blood Cholesterol Increased		Flovent	C			RESPIRATORY (INHALATION)	
	Cellulitis							
	Chest Pain		Xanax	C			UNKNOWN	
	Coronary Artery Atherosclerosis		Valium	C			UNKNOWN	
			Valium	C			UNKNOWN	
	Dehydration		Valium	C			UNKNOWN	
	Depression Diabetes Mellitus		Fluticasone Propionate	C			RESPIRATORY (INHALATION)	
	Haematuria							
	Hand Fracture		Flomax					

	Hyperlipidaemia		(Morniflumate)	C		
UNKNOWN						
	Hypertriglyceridaemia		Ventolin (Albuterol			
	Leukocytosis		Sulfate)	C		
UNKNOWN						
	Lung Neoplasm		Beconase	C		
UNKNOWN						
	Myocardial Infarction		Prinivil	C		ORAL
	Non-Cardiac Chest Pain		Verapamil Msd Lp	C		ORAL
	Pulmonary Embolism		Aspirin	C		
UNKNOWN						
	Ventricular Arrhythmia		Aspirin	C		
UNKNOWN						
	Wound		Prednisone	C		
UNKNOWN						
			Tylenol	C		
UNKNOWN						
			Propoxyphene			
			Hydrochloride	C		
UNKNOWN						
			Imdur	C		
UNKNOWN	547 DAY					
			Nitrostat	C		
UNKNOWN						
			Warfarin Sodium	C		
UNKNOWN						

Date:08/11/05ISR Number: 4743093-4Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00020
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Haematemesis		Aspirin	SS		ORAL
	Oesophagitis		Methaqualone			
			Hydrochloride	C		ORAL
			Thioridazine	C		ORAL
			Piretanide And			
			Ramipril	C		ORAL
			Pantoprazole	C		ORAL
			Lorazepam	C		ORAL
			Calcium Carbonate			
			And Cholecalciferol	C		ORAL
			Betahistine			

Hydrochloride	C		ORAL
Hypericin	C		ORAL
Clomethiazole Edisylate	C		ORAL

Date:08/11/05ISR Number: 4743094-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA03557
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Pain		Zocor	C				
UNKNOWN								
Initial or Prolonged	Chronic Granulomatous		Toprol Xl Tablets	C				
UNKNOWN								
Disability	Disease		Promethazine	C				
UNKNOWN								
	Chronic Obstructive		Estratest	C				
UNKNOWN								
	Pulmonary Disease		Nystatin	C				
UNKNOWN								
	Vascular Skin Disorder		Endocet	C				
UNKNOWN								

Date:08/11/05ISR Number: 4743095-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA00358
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Transient Ischaemic		Dilantin	C				
UNKNOWN								
Disability	Attack		Phenobarbital	C				
UNKNOWN								

Date:08/11/05ISR Number: 4743098-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00143
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743100-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00161
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		966 DAY
Initial or Prolonged	Infarction		Singulair	C				UNKNOWN
Disability	Bladder Disorder		Premarin	C				UNKNOWN
	Bundle Branch Block Left		Zebutal	C				UNKNOWN
	Chest Pain		Detrol	C				UNKNOWN
	Limb Injury							
	Muscle Spasms							
	Nephrolithiasis							
	Pain In Extremity							
	Tendonitis							
	Ventricular Tachycardia							
	White Blood Cell Count Increased							

Date:08/11/05ISR Number: 4743108-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01238
Age:72 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		29 MON
Initial or Prolonged			[Therapy Unspecified]	C				UNKNOWN

Date:08/11/05ISR Number: 4743109-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00499
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743110-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01216
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Haemorrhage		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction		Maxzide	C				
UNKNOWN								
	Stomach Discomfort		Vicodin Tablets	C				
UNKNOWN								

Date:08/11/05ISR Number: 4743111-3Report Type:Expedited (15-DaCompany Report #CA-MERCK-0508CAN00058
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
13 DAY								

Date:08/11/05ISR Number: 4743112-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01232
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
7 MON								
Hospitalization -	Death		Digitek	C				
UNKNOWN								
Initial or Prolonged	Dyspnoea		Combivent	C				
UNKNOWN								
Other			Meclizine	C				
UNKNOWN								
			Labetalol					

Hydrochloride C
UNKNOWN

Date:08/11/05ISR Number: 4743113-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01220
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Remeron	C				
UNKNOWN								

Date:08/11/05ISR Number: 4743114-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02935
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/11/05ISR Number: 4743115-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04566
Age: Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Pectoris
	Asthma
Disability	Blood Cholesterol
Other	Increased
	Coronary Artery Occlusion
	Depression

		Gastrooesophageal Reflux Disease					
		Hypertension	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Pneumonia		Niaspan	C		ORAL
		Sleep Disorder		Prolixin	C		ORAL
				Lithium Sulfate	C		ORAL
				Synthroid	C		ORAL
				Actos	C		ORAL
				Metformin	C		ORAL
				Glyburide	C		ORAL
				Glucovance	C		ORAL
				Oxaprozin	C		ORAL
				Doc-Q-Lace	C		ORAL
				Cogentin	C		ORAL
				[Therapy Unspecified]	C		
UNKNOWN							

Date:08/11/05ISR Number: 4743116-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00964
Age:66 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
35	MON						
Initial or Prolonged		Chronic Obstructive		Viagra	C		
UNKNOWN							
		Pulmonary Disease		Glucophage	C		
UNKNOWN							
		Hypertension		Glyburide	C		
UNKNOWN							

Date:08/11/05ISR Number: 4743117-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00298
Age:76 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Cardiac Failure					
Initial or Prolonged		Congestive					

Cerebrovascular Accident
Hypertensive Heart
Disease
Myocardial Infarction

Date:08/11/05ISR Number: 4743118-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01659
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease							
	Overdose							
	Panic Disorder							
	Polytraumatism							
	Sleep Disorder							
	Umbilical Hernia							
	Wound Complication							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4743119-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01787
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	36 MON	
	Myocardial Infarction		Dyazide	C			UNKNOWN	

Date:08/11/05ISR Number: 4743120-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00168
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Fosamax	C				
Other	Convulsion							
	Renal Failure							
	Transient Ischaemic Attack							

Date:08/11/05ISR Number: 4743121-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0506DEU00035
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Stenosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Emotional Distress		Vioxx	SS	Merck & Co., Inc		UNKNOWN	123 DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
	Hypertensive Heart Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc		UNKNOWN	123 DAY
	Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricular Hypertrophy		Raloxifene Hydrochloride	C		ORAL		
			Esomeprazole Magnesium	C		ORAL		
			Finasteride	C		ORAL		

Date:08/11/05ISR Number: 4743123-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00121
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743124-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00755
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1354 DAY	
			Synthroid	C			UNKNOWN	
			Aricept	C			UNKNOWN	
			Femhrt	C			UNKNOWN	
			Quinine Sulfate	C			UNKNOWN	
			Exelon	C			UNKNOWN	
			Tussionex (Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex)	C			UNKNOWN	
			Acetaminophen And					

				Hydrocodone Bitartrate	C		
UNKNOWN							
				Nizoral	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN		540	DAY				
				Lexapro	C		
UNKNOWN							

Date:08/11/05ISR Number: 4743125-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01198
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743126-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01218
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743127-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01171
Age:78 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON
Initial or Prolonged			Lipitor	C				
UNKNOWN								
			Lotrel	C				
UNKNOWN								

Date:08/11/05ISR Number: 4743128-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01794
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON
Other	Cardiovascular Disorder Death Hypertension Myocardial Infarction Organ Failure							

Date:08/11/05ISR Number: 4743134-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01247
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Coronary Syndrome Coronary Artery Disease Myocardial Ischaemia		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743135-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01130
Age:46 YR Gender:Male I/FU:I

Outcome	PT
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease

	Myocardial Infarction Thrombosis Transient Ischaemic	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Attack		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/11/05ISR Number: 4743136-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00500
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/11/05ISR Number: 4743137-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01248
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/11/05ISR Number: 4743138-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00231
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Oxycodone	C			
Other	Cerebrovascular Accident		Lorazepam	C			UNKNOWN
	Myocardial Infarction		Wellbutrin	C			UNKNOWN
	Polytraumatism		Nabumetone	C			UNKNOWN
	Thrombosis		Prednisone	C			UNKNOWN
			Biaxin	C			UNKNOWN
			Cephalexin	C			UNKNOWN
			[Therapy				

Unspecified] C
UNKNOWN

Propoxyphene
Napsylate C
UNKNOWN

Date:08/11/05ISR Number: 4743139-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00893
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON
Other	Myocardial Infarction Pulmonary Embolism							

Date:08/11/05ISR Number: 4743140-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00498
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743146-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01581
Age: Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged

Disability

	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743147-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01578
Age:82 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Failure Congestive		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743148-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01129
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:08/11/05ISR Number: 4743149-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01538
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743150-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01125
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	33	MON

Date:08/11/05ISR Number: 4743151-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01535
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Injury		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR

Date:08/11/05ISR Number: 4743152-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00815
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4743153-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01541
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743154-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01543
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743155-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01540
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743156-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01542
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Organ Failure Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743157-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01539
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/11/05ISR Number: 4743158-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01493
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Emotional Distress		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
	Myocardial Infarction							

Date:08/11/05ISR Number: 4743159-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01491
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction							

Date:08/11/05ISR Number: 4743160-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01545
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/11/05ISR Number: 4743168-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON

Date:08/11/05ISR Number: 4743184-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01245
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	1391	DAY

Date:08/12/05ISR Number: 4743793-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00125
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder							
	Chest Pain							
	Depression							
	Injury							
	Lethargy							
	Life Expectancy Shortened							
	Myocardial Infarction							

Date:08/12/05ISR Number: 4743795-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0408USA00558
Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Respiratory Failure
Disability	Anxiety
Other	Aortic Aneurysm
	Arthralgia
	Arthritis
	Ascites
	Asthma

Back Disorder
Back Pain
Cerebral Infarction
Cerebrovascular Accident
Chest Wall Pain
Cholecystitis
Cholelithiasis
Chronic Obstructive
Pulmonary Disease
Coronary Artery
Atherosclerosis
Coronary Artery Disease
Decreased Appetite
Depression
Diabetes Mellitus
Inadequate Control
Dizziness
Emotional Distress
Enanthema
Epistaxis
Face Injury
Feeling Drunk
Gait Disturbance

		Gallbladder Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hepatomegaly		Vioxx	PS	Merck & Co., Inc	ORAL
		Hypertensive Heart		Vioxx	SS	Merck & Co., Inc	ORAL
		Disease		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypothyroidism		Vioxx	SS	Merck & Co., Inc	ORAL
		Idiosyncratic Drug		Plavix	C		
UNKNOWN							
		Reaction		Flovent	C		
RESPIRATORY							
		Insomnia					
(INHALATION)							
		Lobar Pneumonia		Levoxyl	C		
UNKNOWN							
		Lung Disorder		Levoxyl	C		
UNKNOWN							
		Nausea		Tylenol With Codeine			
		Nervousness		#3	C		
UNKNOWN							
		Pneumonia		Prednisone	C		
UNKNOWN							
		Post Procedural Nausea		Advair	C		
UNKNOWN							
		Pruritus		Monopril	C		
UNKNOWN							
		Renal Cyst		Azmacort	C		
UNKNOWN							
		Renal Failure Chronic		Aspirin	C		
UNKNOWN							
		Swelling Face		Nexium	C		
UNKNOWN							
		Ulcer		Ventolin (Albuterol)	C		
RESPIRATORY							
		Upper Respiratory Tract					
(INHALATION)							
		Infection		Ranitidine	C		
UNKNOWN							
		Urinary Tract Infection		Hydroxychloroquine			
		Uterine Disorder		Sulfate	C		
UNKNOWN							
				Hydrochlorothiazide	C		
UNKNOWN							
				Cozaar	C		
UNKNOWN							

Date:08/12/05ISR Number: 4743813-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02988
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bronchitis Acute		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Prednisone	C				
Other	Chest Pain		Naproxen	C				
	Dandruff		Ultram	C				
	Dehydration		Flexeril	C				
	Depression		Plaquenil	C				
	Drug Effect Decreased		Acetaminophen And Codeine	C				
	Hypoaesthesia							
	Migraine							
	Otitis Externa							
	Pleurisy							
	Pneumonia							
	Post-Traumatic Stress Disorder							
	Seborrhoeic Dermatitis							
	Temporal Arteritis							
	Tinnitus							
	Vasculitis							

Date:08/12/05ISR Number: 4743814-0Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00015
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amblyopia
	Arthropathy
Disability	Cerebrovascular Accident
Other	Headache

	Thyroid Disorder Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Visual Disturbance		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Allopurinol	C		ORAL	
			Nitrendipine	C		ORAL	
			Aspirin	C		ORAL	
			Cetirizine Hydrochloride	C		ORAL	
			Methotrexate	C		ORAL	
			Prednisolone	C			UNKNOWN
			Cholecalciferol	C			UNKNOWN
			Cholecalciferol	C			UNKNOWN

Date:08/12/05ISR Number: 4743815-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00138
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			[Therapy Unspecified]	C		ORAL	

Date:08/12/05ISR Number: 4743828-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01890
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 23 MON Initial or Prolonged Disability	Amnesia Anxiety Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	
			Hydrochlorothiazide And Triamterene	C			UNKNOWN
Other	Cerebrovascular Accident		Lotensin	C			UNKNOWN
	Prophylaxis		Lotensin	C			UNKNOWN

	Cholecystectomy	Catapres Tts	C
UNKNOWN			
	Cognitive Disorder	Naproxen	C
UNKNOWN			
	Deep Vein Thrombosis	Remeron	C
UNKNOWN			
	Depression	Smz-Tmp	C
UNKNOWN			
	Diabetes Mellitus	Premarin Vaginal	
	Dyspnoea	Cream	C
UNKNOWN			
	Hypersomnia	Prempro	C
UNKNOWN			
	Nausea	Toprol Xl Tablets	C
UNKNOWN			
	Oedema Peripheral	Sarafem	C
UNKNOWN			
	Pain	Tiazac	C
UNKNOWN			
	Panic Attack	Detrol	C
UNKNOWN			
	Pulmonary Embolism	Synthroid	C
UNKNOWN			
	Sleep Apnoea Syndrome	Acetaminophen And	
	Sleep Disorder	Hydrocodone	
	Speech Disorder	Bitartrate	C
UNKNOWN			
	Transient Ischaemic	Klor-Con	C
UNKNOWN			
	Attack	Lotrel	C
UNKNOWN			
		Bextra	C
UNKNOWN			
		Hydroxyzine	
		Hydrochloride	C
UNKNOWN			
		Ambien	C
UNKNOWN			
		Verelan Pm	C
UNKNOWN			
		Tricor	C
UNKNOWN			
		Ketoprofen	C
UNKNOWN			
		Ibuprofen	C
UNKNOWN			
		Tylenol	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743830-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00143
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743831-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00142
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:08/12/05ISR Number: 4743838-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00142
Age:79 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx Digoxin Aspirin	PS C C	Merck & Co., Inc	ORAL ORAL ORAL	3	MON

Date:08/12/05ISR Number: 4743843-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01788
Age:81 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON
	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL	6	MON
	Blood Cholesterol		Metoprolol	C			UNKNOWN	
	Increased		Vitamins					

	Carotid Artery Stenosis	(Unspecified)	C
UNKNOWN			
	Gastrointestinal Ulcer Haemorrhage	Hydrochlorothiazide And Triamterene	C
UNKNOWN			
	Gastrooesophageal Reflux	Moduretic	C
UNKNOWN			
	Disease		
	Myocardial Infarction		
	Nervousness		

Date:08/12/05ISR Number: 4743844-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00116
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743845-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00113
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743846-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00105
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743847-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00111
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743848-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00115
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743849-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00107
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743850-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00106
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743851-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03811
Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cholelithiasis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Thrombosis		Hydrocodone Bitartrate	C			UNKNOWN	
	Hepatic Steatosis		Seroquel	C			UNKNOWN	
	Hyperaemia Hypercholesterolaemia		Topamax	C			UNKNOWN	
	Migraine		[Therapy Unspecified]	C			UNKNOWN	
	Myocardial Ischaemia Pulmonary Oedema		Lorazepam	C			UNKNOWN	
			Tizanidine Hydrochloride	C			UNKNOWN	
			Neurontin	C			UNKNOWN	
			Endocet	C			UNKNOWN	
			Serzone	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Methadone Hydrochloride	C			UNKNOWN	
			Lexapro	C			UNKNOWN	
			Lexapro	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743854-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01045
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		666 DAY
Initial or Prolonged	Atherosclerosis		Lipitor	C				UNKNOWN
Other	Cardiac Disorder		Aspirin	C				UNKNOWN
	Cerebrovascular Accident		Plavix	C				UNKNOWN
	Dental Discomfort		Aggrenox	C				UNKNOWN
	Dizziness		Pravachol	C				UNKNOWN
	Dysphagia							
	Eye Disorder							
	Gastric Disorder							
	Musculoskeletal Disorder							
	Oesophageal Disorder							
	Renal Disorder							
	Skin Cancer							
	Thrombosis							
	Toothache							

Date:08/12/05ISR Number: 4743856-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02051
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Breast Microcalcification		Vioxx	PS	Merck & Co., Inc	ORAL		58 MON
Initial or Prolonged	Cerebrovascular Accident		Cardizem	C				UNKNOWN
Other	Cholecystitis		Premarin	C				UNKNOWN
							10 YR	
	Coronary Artery Disease		Ultram	C				UNKNOWN
	Emotional Distress		Darvocet-N	C				UNKNOWN
							58 MON	
	Hyperlipidaemia							
	Lacunar Infarction							
	Myocardial Infarction							

Myocardial Ischaemia
Oedema Peripheral
Polyp
Sleep Disorder
Spinal Column Stenosis
Vulvovaginitis
Trichomonal

Date:08/12/05ISR Number: 4743857-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00103
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743858-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00144
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Omeprazole	C			UNKNOWN	
Disability			Naproxen	C			UNKNOWN	
			Zolpidem Tartrate	C			UNKNOWN	
			Tramadol Hydrochloride	C			UNKNOWN	
			Moclobemide	C			UNKNOWN	
			Insulin Lispro	C			UNKNOWN	

Date:08/12/05ISR Number: 4743859-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01506
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carotid Artery Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		1019 DAY
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		1019 DAY
			Niferex	C				
			Diovan	C				
			Avelox	C				
			Methylprednisolone	C				
			Tequin	C				
			Chromagen Capsules	C				
			Prinivil	C				
			Meclizine	C				
			Fosamax	C				
			Xanax	C				
			Lipitor	C				
			Lescol	C				
			Pravachol	C				
			Pravachol	C				
			Premarin	C				
			Wellbutrin	C				

Date:08/12/05ISR Number: 4743860-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04557
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Triglycerides Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
			Tylenol	C			UNKNOWN	
			Keflex	C			UNKNOWN	
	Cardiovascular Disorder							
	Cerebrovascular Accident							
	Gastrointestinal Disorder							
	Infection							
	Joint Abscess							
	Pain							
	Paralysis							
	Prostatic Disorder							
	Sciatica							
	Spinal Cord Injury							
	Urinary Tract Disorder							

Date:08/12/05ISR Number: 4743861-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00140
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	General Symptom		Fluticasone Propionate And Salmeterol Xinafoate	C			UNKNOWN	
	Myocardial Infarction		Fosinopril Sodium	C			UNKNOWN	
			[Therapy Unspecified]	C			RESPIRATORY (INHALATION)	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743862-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0412AUS00136
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder		Insulin	C				
Disability	Myocardial Infarction		Metformin Hydrochloride	C				

Date:08/12/05ISR Number: 4743863-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04551
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Paxil	C				
Disability	Chronic Obstructive		Paxil	C				
	Pulmonary Disease		Nicoderm Patch	C				
	Coronary Artery Disease		Prevacid	C				
	Depression		Allegra	C				
	Emphysema		Isosorbide	C				
	Hypertension		Lorazepam	C				
	Myocardial Infarction							
	Oedema							
	Panic Attack							

Date:08/12/05ISR Number: 4743865-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0505AUS00062
Age:69 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	770	DAY

Initial or Prolonged	Aspirin	C
UNKNOWN		
Disability	Metoprolol Tartrate	C
UNKNOWN		
	Irbesartan	C
UNKNOWN		
	Aspirin And Dipyridamole	C
UNKNOWN		
	Simvastatin	C
UNKNOWN		

Date:08/12/05ISR Number: 4743866-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02467
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anaemia		Glynase Prestab			
	Diabetes Mellitus		Tablets	C		ORAL
	Non-Insulin-Dependent		Nexium	C		ORAL
	Hypocoagulable State		Procardia	C		
UNKNOWN						
	Metabolic Acidosis		Dyazide	C		
UNKNOWN						
	Mitral Valve Incompetence					
	Pneumonia					
	Pulmonary Embolism					
	Sinus Tachycardia					
	Therapeutic Response Decreased					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743868-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02185
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		5 YR
Initial or Prolonged	Arthropathy		Terazosin Hydrochloride	C				UNKNOWN
	Blood Disorder		Tylenol	C				UNKNOWN
	Cardiac Disorder		Hydrochlorothiazide	C				UNKNOWN
	Gallbladder Disorder							
	Hernia							
	Herpes Zoster							
	Infection							
	Joint Crepitation							
	Prostatic Disorder							
	Sleep Disorder							
	Transient Ischaemic Attack							

Date:08/12/05ISR Number: 4743869-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01503
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		15 MON
Initial or Prolonged	Cyst		Flexeril	C				UNKNOWN
Disability	Hypersensitivity		Femhrt	C				UNKNOWN
	Hypertension		Tylenol	C				UNKNOWN
			Coumadin	C				UNKNOWN

Date:08/12/05ISR Number: 4743886-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00509
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Chest Pain							
	Headache							
	Hypertension							
	Hypoaesthesia							
	Myocardial Infarction							
	Renal Artery Stenosis							
	Syncope							
	Vomiting							

Date:08/12/05ISR Number: 4743887-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00813
Age:67 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4743889-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01513
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1443 DAY
Other	Eye Injury		Zocor	C		ORAL		
	Visual Disturbance		Atenolol	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Vitamins (Unspecified)	C				UNKNOWN

Date:08/12/05ISR Number: 4743891-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00812
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Stent Placement							

Date:08/12/05ISR Number: 4743892-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA04384
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743893-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00294
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthma		Climara	C				UNKNOWN

	Coronary Artery Disease	Albuterol	C
UNKNOWN			
	Dyslipidaemia	Tobramycin Sulfate	
	Dyspnoea	Injection, Usp	C
UNKNOWN			
	Eye Infection	Acetaminophen And	
	Fatigue	Hydrocodone	
	Haemorrhoids	Bitartrate	C
UNKNOWN			
	Hypertension	Smz-Tmp	C
UNKNOWN			
	Myocardial Infarction	Erythromycin	C
UNKNOWN			
	Nephrolithiasis		
	Rhinitis		
	Sick Sinus Syndrome		

Date:08/12/05ISR Number: 4743894-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00108
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743895-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01183
Age:58 YR Gender:Female I/FU:F

Outcome	PT
Other	Bronchitis
	Cerebrovascular Accident
	Diabetes Mellitus
	Non-Insulin-Dependent

	Retinopathy						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	131	DAY

Date:08/12/05ISR Number: 4743896-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00117
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743897-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01177
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL	1	DAY
Initial or Prolonged	Disease		Hydrocortisone	C				
UNKNOWN								
Disability	Depression							
	Myocardial Infarction							

Date:08/12/05ISR Number: 4743904-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00885
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Chest Pain							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/12/05ISR Number: 4743905-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01182
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4743906-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01213
Age:85 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
1338 DAY								
	Cerebrovascular Accident							
	Depression							
	Mental Disorder							
	Nervous System Disorder							
	Pulmonary Oedema							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744272-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01950
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744273-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01475
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744274-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01848
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Arterial Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Brain Damage							
	Cardiac Disorder							
	Cardiovascular Disorder							
	Injury							
	Peripheral Occlusive Disease							
	Thrombosis							

Date:08/12/05ISR Number: 4744284-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01453
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	10	MON

Date:08/12/05ISR Number: 4744286-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01859
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744287-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01683
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Lower
Disability	Arthralgia
Other	Back Pain
	Cerebrovascular Accident
	Coma
	Convulsion
	Depression
	Diarrhoea
	Face Oedema
	Faeces Discoloured
	Fatigue
	Fluid Retention
	Headache
	Hernia
	Hypertension
	Nausea

		Oedema					
		Oedema Peripheral					
		Oral Soft Tissue Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
		Somnolence		Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
		Suicide Attempt		Vioxx	SS	Merck & Co., Inc	ORAL
		Swelling		Vioxx	SS	Merck & Co., Inc	ORAL
		Upper Respiratory Tract		Vioxx	SS	Merck & Co., Inc	ORAL
4	MON						
		Infection		Valium	C		
UNKNOWN							
		Vomiting		Neurontin	C		
UNKNOWN							
		Weight Increased		Meclizine	C		
UNKNOWN							
				Hydrodiuril	C		ORAL
				Prednisone	C		
UNKNOWN							
				Prinivil	C		ORAL
				Keflex	C		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Effexor	C		
UNKNOWN							

Date:08/12/05ISR Number: 4744289-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01489
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/12/05ISR Number: 4744290-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01825
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/12/05ISR Number: 4744291-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01842
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:08/12/05ISR Number: 4744292-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01374
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744293-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01488
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744302-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02231
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		20 DAY
Initial or Prolonged	Infarction		Lovenox	C				UNKNOWN
Other	Adverse Event		Nitrol					
	Aortic Atherosclerosis		(Nitroglycerin)	C				UNKNOWN
	Asthma		Nexium	C				UNKNOWN
	Blood Potassium Decreased		Zoloft	C				UNKNOWN
	Depression		Zelnorm	C				UNKNOWN
	Haematocrit Decreased		Citrucel	C				UNKNOWN
	Haemoglobin Decreased		Carafate	C				UNKNOWN
	Haemoptysis		Advair	C				UNKNOWN
	Myocardial Infarction		Flonase	C				UNKNOWN
	Pharyngeal Haemorrhage							
	Pulmonary Granuloma							
	Sleep Apnoea Syndrome							
	Transient Ischaemic Attack							

Date:08/12/05ISR Number: 4744303-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02054
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Increased		Metoprolol Tartrate	C				UNKNOWN
Other	Coronary Artery Disease		Coumadin	C				UNKNOWN
	Hypertension							
	Myocardial Infarction							
	Osteoarthritis							

Renal Failure

Date:08/12/05ISR Number: 4744304-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04626
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		18 MON
Initial or Prolonged	Blood Cholesterol		Excedrin					
Disability	Increased		(Acetaminophen (+)					
	Condition Aggravated		Caffeine)	C		ORAL		3 YR
	Deep Vein Thrombosis		Acetaminophen And					
	Depression		Propoxyphene					
	Diabetes Mellitus		Napsylate	C		ORAL		
	Drug Hypersensitivity		Hydrochlorothiazide					
	Emotional Distress		And Lisinopril	C		ORAL		
	Gastrooesophageal Reflux		Metoprolol	C		ORAL		
	Disease							
	Hypertension							
	Injury							
	Myocardial Infarction							
	Pulmonary Embolism							

Date:08/12/05ISR Number: 4744305-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA02879
Age:53 YR Gender:Male I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Other

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hyperlipidaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		
Injury							
Ischaemic Cardiomyopathy							
Mitral Valve Incompetence							
Myocardial Infarction							
Pulmonary Valve Incompetence							
Tricuspid Valve Incompetence							
Ventricular Hypertrophy							

Date:08/12/05ISR Number: 4744307-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01850
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Meclizine	C				
UNKNOWN								
	Chest Pain		Trimox	C				
UNKNOWN								
	Dyspepsia		Nitrostat	C				
UNKNOWN								
	Hypertension		Flonase	C				
UNKNOWN								
	Myocardial Infarction		Allegra	C				
UNKNOWN								
			Zyrtec-D	C				
UNKNOWN								
			Premarin	C				
UNKNOWN							4	YR
			Desowen	C				
UNKNOWN								
			Prevacid	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Cephalexin	C				
UNKNOWN								

				Denavir	C		
UNKNOWN							

Date:08/12/05ISR Number: 4744308-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01714
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Myocardial Infarction		Estradiol	C				
UNKNOWN								
			Premarin	C				
UNKNOWN								
			Elavil	C				
UNKNOWN								
			Trazodone Hydrochloride	C				
UNKNOWN								
			Trazodone Hydrochloride	C				
UNKNOWN								

Date:08/12/05ISR Number: 4744309-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0412USA00302
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744310-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02095
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	28	MON
	Increased		Tricor	C			UNKNOWN	
	Gastrooesophageal Reflux		Lipitor	C			UNKNOWN	
	Disease		Celexa	C			UNKNOWN	
	Myocardial Infarction		Pepcid	C		ORAL		
			Carbidopa And Levodopa	C		ORAL		
			Aggrenox	C			UNKNOWN	

Date:08/12/05ISR Number: 4744311-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02336
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Carpal Tunnel Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
Initial or Prolonged	Cerebral Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	2	YR
	Cerebrovascular Accident		Insulin	C			UNKNOWN	
	Emotional Distress		Lipitor	C		ORAL		
	Flatulence		Altace	C		ORAL		
	Thermal Burn		Tricor	C			UNKNOWN	
			Diovan	C		ORAL		

Date:08/12/05ISR Number: 4744312-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01966
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Injury

Date:08/12/05ISR Number: 4744313-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02663
Age:53 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Upper
Disability	Angina Pectoris
	Angina Unstable
	Anxiety
	Blood Pressure Inadequately Controlled
	Bradycardia
	Cellulitis
	Cervical Spinal Stenosis
	Cervicobrachial Syndrome
	Chest Pain
	Coronary Artery Disease
	Coronary Artery Stenosis
	Coronary Artery Thrombosis
	Emotional Distress
	Gastric Disorder
	Gastritis
	Hypertension
	Intervertebral Disc Space Narrowing
	Joint Swelling
	Lipoma

	Musculoskeletal Pain						
	Myelopathy						
	Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Nasopharyngitis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL		
	Sleep Apnoea Syndrome		Isosorbide	C				UNKNOWN
	Spinal Osteoarthritis		Toprol Xl Tablets	C				UNKNOWN
	Tachycardia		Zocor	C				UNKNOWN
	Thrombosis In Device		Wellbutrin Sr	C				UNKNOWN
	Upper Respiratory Tract		Norvasc	C				UNKNOWN
	Infection		Paxil	C				UNKNOWN
	Weight Increased		Atenolol	C				UNKNOWN
			Nitroquick	C				UNKNOWN
			Pravachol	C				UNKNOWN
			Aspirin	C				UNKNOWN

Date:08/12/05ISR Number: 4744314-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02960
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Emotional Distress		Glucophage	C				UNKNOWN
Disability	Myocardial Infarction		Adalat	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Neurontin	C				UNKNOWN
			Nexium	C				UNKNOWN

Date:08/12/05ISR Number: 4744315-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02365
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Alcoholism		Vioxx	PS	Merck & Co., Inc	ORAL		900 DAY
Initial or Prolonged	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		900 DAY
	Depression Suicidal		Lipitor	C				UNKNOWN
	Helicobacter Pylori		Zoloft	C				UNKNOWN
	Identification Test		Propecia	C				UNKNOWN
	Positive		Biaxin	C				UNKNOWN
	Myocardial Infarction		Niaspan	C				UNKNOWN
	Oesophageal Spasm		Aspirin	C		ORAL		
	Ventricular Hypokinesia		Prevacid	C				UNKNOWN
			Allegra	C				UNKNOWN
			Carisoprodol	C				UNKNOWN
			Trazodone Hydrochloride	C				UNKNOWN
			Neomycin	C				UNKNOWN
			Folic Acid	C				UNKNOWN
			Wellbutrin	C				UNKNOWN
			Metronidazole	C				UNKNOWN
			Nexium	C				UNKNOWN
			Zyrtec	C				UNKNOWN

Date:08/12/05ISR Number: 4744317-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02656
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Disability	Blood Cholesterol
Other	Increased
	Coronary Artery Disease

	Dyspepsia Hypertension Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Sleep Apnoea Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN
			Vasopril (Fosinopril Sodium)	C			UNKNOWN
			Mega Men	C			UNKNOWN

Date:08/12/05ISR Number: 4744318-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02310
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Angiopathy		Vioxx	PS	Merck & Co., Inc	ORAL	397 YR
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL	397 YR
Disability	Back Pain Cerebral Infarction Cerebrovascular Accident		Acetaminophen And Propoxyphene Napsylate	C			UNKNOWN
	Chest Pain		Panmist Dm	C			UNKNOWN
	Colitis		Alprazolam	C			UNKNOWN
	Depression		Ambien	C			UNKNOWN
	Duodenitis		Prednisone	C			UNKNOWN
	Dyspnoea		Prevacid	C			UNKNOWN
	Enteritis		Levaquin	C			UNKNOWN
	Gastric Ulcer		Celexa	C			UNKNOWN
	Gastritis Erosive Haemorrhoids		Cyclobenzaprine Hydrochloride	C			UNKNOWN
	Hypertensive Crisis		Avelox	C			UNKNOWN
	Hypoaesthesia		Prozac	C			UNKNOWN

	Nervousness	Furosemide	C
UNKNOWN			
	Oesophagitis	Furosemide	C
UNKNOWN			
	Pain In Extremity	Serzone	C
UNKNOWN			
	Palpitations	Serzone	C
UNKNOWN			
	Sinus Tachycardia	Estrogens	
	Sinusitis	(Unspecified)	C
UNKNOWN	3 MON		
	Swelling	Atenolol	C
UNKNOWN			
	Ulcer	Atenolol	C
UNKNOWN			
	Vision Blurred		

Date:08/12/05ISR Number: 4744323-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02348
Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Dyspepsia		Vioxx	PS	Merck & Co., Inc	ORAL		20 MON
Initial or Prolonged	Myocardial Infarction		Tylenol	C				
UNKNOWN								

Date:08/12/05ISR Number: 4744324-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01789
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Initial or Prolonged	Headache							
Other	Hypertension							
	Myocardial Infarction							

Date:08/12/05ISR Number: 4744325-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02188
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Norvasc	C			UNKNOWN	
	Hypertension		[Therapy Unspecified]	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Toprol Xl Tablets	C			UNKNOWN	
			Ascorbic Acid	C			UNKNOWN	
			Cyanocobalamin	C			UNKNOWN	
			Plavix	C			UNKNOWN	
			Vitamin E	C			UNKNOWN	
			Atacand	C			UNKNOWN	
			Aspirin	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Thyroxin	C			UNKNOWN	

Date:08/12/05ISR Number: 4744326-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01791
Age:36 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Abdominal Abscess		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Amnesia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Chest Pain		Parlodel	C			UNKNOWN	
	Deep Vein Thrombosis							
	Dizziness							
	Gastric Bypass							
	Hypoxia							

Procedural Complication
Pulmonary Embolism
Systemic Lupus
Erythematosus
Thrombosis

Date:08/12/05ISR Number: 4744327-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01660
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury		Prinzide	C				
Disability	Intervertebral Disc		Prilosec	C				
	Degeneration							
	Transient Ischaemic Attack							

Date:08/12/05ISR Number: 4744335-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00870
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Loss Of Consciousness		Cozaar	C				
	Myocardial Infarction		Theo-Dur	C				
			Lopressor	C				
			Insulin	C				
			Coreg	C				
			Lasix (Furosemide)	C				
			Coumadin	C				

				Minipress	C		
UNKNOWN							
				Norvasc	C		
UNKNOWN							

Date:08/12/05ISR Number: 4744337-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00965
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL	39	MON
Initial or Prolonged	Asthma		Acetaminophen And					
	Barrett'S Oesophagus		Codeine	SS		ORAL		
	Benign Prostatic		Daypro	SS		ORAL		
	Hyperplasia		Relafen	SS		ORAL		
	Cardiac Disorder		Cozaar	C		ORAL		
	Coronary Artery Occlusion		Aspirin	C		ORAL		
	Depression		Nitroquick	C				
UNKNOWN								
	Gastric Ulcer		Pravachol	C		ORAL		
	Herpes Simplex		Zocor	C		ORAL		
	Influenza							
	Knee Arthroplasty							
	Muscle Spasms							
	Peptic Ulcer							
	Rash							

Date:08/12/05ISR Number: 4744339-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01785
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	439	DAY
	Blood Cholesterol							
	Increased							
	Cardiac Failure							
	Congestive							
	Chest Pain							
	Depression							
	Dyspepsia							
	Implant Site Reaction							

Myocardial Infarction
Oedema
Open Wound
Panic Disorder

Date:08/12/05ISR Number: 4744346-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01143
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744347-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01278
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744348-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01110
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
	Congestive							
	Cerebrovascular Accident							
	Diastolic Dysfunction							
	Heart Rate Irregular							
	Injury							

Date:08/12/05ISR Number: 4744350-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01277
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
							155	DAY

Date:08/12/05ISR Number: 4744351-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02270
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
							52	MON
Initial or Prolonged	Infection		Vioxx	SS	Merck & Co., Inc	ORAL		
							52	MON
	Neuralgia		Oxycontin	C				
							UNKNOWN	
	Prescribed Overdose		Oxycodone	C				
							UNKNOWN	
	Thrombosis		Morphine	C				
							UNKNOWN	
			Duragesic	C				
							UNKNOWN	

Date:08/12/05ISR Number: 4744352-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01797
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Condition Aggravated		Premarin	C				
	Hypertension							
	Joint Swelling							
	Myocardial Infarction							

Date:08/12/05ISR Number: 4744353-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01187
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:08/12/05ISR Number: 4744354-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01921
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Death							
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744355-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02022
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		433 DAY
Initial or Prolonged	Diabetes Mellitus		Celebrex	SS		ORAL		
	Gastrooesophageal Reflux		Celebrex	SS		ORAL		
	Disease		Pravachol	C		ORAL		
	Infection		Prempro	C		ORAL		10 YR
	Myocardial Infarction		Glucotrol	C		ORAL		
	Renal Disorder							
	Vaginal Mycosis							

Date:08/12/05ISR Number: 4744356-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01839
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Disability		Vioxx	PS	Merck & Co., Inc	ORAL		
	Emotional Distress							
	Myocardial Infarction							
	Pain							

Date:08/12/05ISR Number: 4744357-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01938
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Percocet	C				UNKNOWN
	Increased		Enalapril Maleate	C				UNKNOWN
	Coronary Artery Disease		Toprol Xl Tablets	C				113 DAY
	Depression		Enbrel	C				UNKNOWN
	Hypotension		Prednisone	C				UNKNOWN

	Myocardial Infarction		Darvocet-N	C	
UNKNOWN					
	Pericardial Effusion		Methotrexate	C	
UNKNOWN	1672 DAY				
	Stress		Patanol	C	
UNKNOWN					
			Altace	C	
UNKNOWN	78 DAY				
			Folic Acid	C	
UNKNOWN					

Date:08/12/05ISR Number: 4744358-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02258
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 596 DAY	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Increased		Paxil	C		
Disability UNKNOWN	Blood Triglycerides		Prozac	C		
Other UNKNOWN	Increased		Glucophage	C		
	Cardiac Disorder		Effexor Xr	C		
UNKNOWN						
	Chronic Obstructive Pulmonary Disease					
	Diabetes Mellitus					
	Gastrooesophageal Reflux Disease					
	Hypertension					
	Joint Injury					
	Muscle Injury					
	Myocardial Infarction					
	Oedema Peripheral					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744359-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00891
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Glucose Increased		Tylenol Extra Strength	C			UNKNOWN	
	Cerebrovascular Accident							
	Depression		Insulin	C			UNKNOWN	
	Ocular Vascular Disorder							
	Retinal Detachment							
	Skin Ulcer							
	Vomiting							

Date:08/12/05ISR Number: 4744360-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01186
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	18 MON	
Initial or Prolonged			Vitamins (Unspecified)	C			UNKNOWN	

Date:08/12/05ISR Number: 4744361-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA01005
Age:39 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL	992 DAY	
Initial or Prolonged	Acute Myocardial		Zestril	C		ORAL	43 MON	
Disability	Infarction		Zocor	C		ORAL	3 YR	
	Bone Graft							
	Coronary Artery							
	Thrombosis							
	Dilatation Atrial							

Dysphagia
Haemorrhoids
Lower Gastrointestinal
Haemorrhage
Mitral Valve Incompetence
Post Procedural Discharge
Post Procedural Haematoma
Rectal Polyp
Spinal Operation
Spinal Osteoarthritis
Tricuspid Valve
Incompetence
Ventricular Extrasystoles
Ventricular Hypertrophy

Date:08/12/05ISR Number: 4744362-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01117
Age: Gender:Female I/FU:I

Outcome PT
Death Acute Respiratory Failure
Other Cerebrovascular Accident
Death
Heart Rate Irregular
Paralysis
Pneumonia
Pulmonary Embolism

	Thrombosis						
		Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	1394 DAY

Date:08/12/05ISR Number: 4744363-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02703
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	
Hospitalization - Initial or Prolonged							

Date:08/12/05ISR Number: 4744364-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00861
Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON
	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	31 MON
	Myocardial Infarction		Advil	C			UNKNOWN
	Road Traffic Accident		Motrin	C			UNKNOWN
			Lipitor	C			UNKNOWN
			Hyzaar	C		ORAL	
			Prednisone	C			UNKNOWN
			Zithromax	C			UNKNOWN
			Flexeril	C			UNKNOWN
			Zocor	C			UNKNOWN
			Tylenol	C			UNKNOWN

Date:08/12/05ISR Number: 4744371-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01276
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		1706 DAY

Date:08/12/05ISR Number: 4744372-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01112
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744373-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01922
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged Disability	Abdominal Discomfort
	Abdominal Pain Upper
	Anxiety
	Atrial Fibrillation
	Cardiomegaly
	Carotid Artery Stenosis
	Cerebral Atrophy
	Cerebrovascular Accident
	Constipation
	Dilatation Atrial
	Dyspnoea

		Emotional Distress					
		Mitral Valve Calcification	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Mitral Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL
28	MON						
		Myocardial Ischaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Tricuspid Valve		Equate	C		
UNKNOWN							
		Incompetence		Cardizem	C		
UNKNOWN							
		Ventricular Hypertrophy		Coumadin	C		
UNKNOWN							
		Ventricular Hypokinesia		Tylenol	C		
UNKNOWN							
				Xanax	C		
UNKNOWN							
				Furosemide	C		ORAL
				Coreg	C		
UNKNOWN							

Date:08/12/05ISR Number: 4744374-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01144
Age: Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL
		Heart Injury					
		Multi-Organ Disorder					

Date:08/12/05ISR Number: 4744375-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01142
Age:52 YR Gender:Female I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident		Celebrex	SS		
UNKNOWN							
		Coronary Artery Disease					
		Myocardial Infarction					
		Thrombosis					
		Transient Ischaemic Attack					

Date:08/12/05ISR Number: 4744386-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01329
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744387-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01367
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744388-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01355
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/05ISR Number: 4744389-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01348
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744390-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01279
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744391-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01284
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744392-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02192
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL	133 DAY	
Hospitalization - Initial or Prolonged	Arrhythmia		Vioxx	SS	Merck & Co., Inc	ORAL	133 DAY	
	Cardiac Arrest		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Condition Aggravated		Methotrexate	C			UNKNOWN	
	Coronary Artery		Naproxen	C			UNKNOWN	
	Atherosclerosis		Ultram	C			UNKNOWN	
	Dyspepsia		Nexium	C			UNKNOWN	

	Emotional Distress	Folic Acid	C
UNKNOWN			
	Gastrooesophageal Reflux	Aciphex	C
UNKNOWN			
	Disease	Cardura	C
UNKNOWN			
	Hypotension	Zantac	C
UNKNOWN			
	Loss Of Consciousness	Tagamet	C
UNKNOWN			
	Myocardial Infarction	Axid	C
UNKNOWN			
	Nausea	Pepcid	C
UNKNOWN			
	Syncope		
	Ventricular Fibrillation		
	Vomiting		

Date:08/12/05ISR Number: 4744401-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01347
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/12/05ISR Number: 4744423-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00970
Age:64 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Cardiac Failure
Other	Congestive
	Chest Pain
	Chronic Obstructive
	Pulmonary Disease

		Coronary Artery Disease					
		Depression					
		Drug Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Gallbladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
25	MON						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
		Peptic Ulcer		Vioxx	SS	Merck & Co., Inc	ORAL
25	MON						
				Vioxx	SS	Merck & Co., Inc	ORAL
				Aspirin	C		
UNKNOWN							
				Lotrel	C		
UNKNOWN		41	MON				
				Zocor	C		ORAL
28	MON						
				Percocet	C		
UNKNOWN							
				Enalapril Maleate	C		
UNKNOWN							
				Humulin	C		
UNKNOWN							
				Glucophage	C		
UNKNOWN							
				Skelaxin	C		
UNKNOWN							
				Magnesium Oxide	C		
UNKNOWN							
				Soma	C		
UNKNOWN							

Date:08/12/05ISR Number: 4744424-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01790
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
4	YR					
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
	Knee Arthroplasty		Vioxx	SS	Merck & Co., Inc	ORAL
			Aspirin	C		
UNKNOWN						
			Aleve	C		
UNKNOWN						

	Advil	C
UNKNOWN		
	Celebrex	C
UNKNOWN		
	Triamterene	C
UNKNOWN		
	Zyban	C
UNKNOWN		
	Warfarin Sodium	C
UNKNOWN		
	Ultram	C
UNKNOWN		
	Cephalexin	C
UNKNOWN		
	Atenolol	C
UNKNOWN		
	Hydrocodone/Apap	C
UNKNOWN		
	Acetaminophen	C
UNKNOWN		
	Dyazide	C
UNKNOWN		
	Norgesic Forte	C
UNKNOWN		
	Diclofenac	C
UNKNOWN		
	Cataflam (Diclofenac Potassium)	C
UNKNOWN		

Date:08/13/05ISR Number: 4744596-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00871
Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/13/05ISR Number: 4744597-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00965
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/13/05ISR Number: 4744598-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00867
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/13/05ISR Number: 4744599-4Report Type:Expedited (15-DaCompany Report #NO-MERCK-0508NOR00003
Age:55 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Brain Damage		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Diltiazem Hydrochloride	C			UNKNOWN	
			Diltiazem Hydrochloride	C			UNKNOWN	
			Sulfasalazine	C			UNKNOWN	
			Insulin, Isophane	C			UNKNOWN	
			Insulin, Isophane	C			UNKNOWN	

Doxazosin Mesylate C
UNKNOWN

Clobetasol
Propionate C
UNKNOWN

Date:08/13/05ISR Number: 4744600-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00868
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/13/05ISR Number: 4744601-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00858
Age:62 YR Gender:Male I/FU:I

Outcome	PT
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Heart Injury

	Myocardial Infarction Thrombosis Transient Ischaemic Attack	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/13/05ISR Number: 4744602-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01976
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cardiac Disorder Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/13/05ISR Number: 4744603-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01975
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/13/05ISR Number: 4744604-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00869
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/13/05ISR Number: 4744605-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00863
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/13/05ISR Number: 4744606-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00866
Age:87 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/13/05ISR Number: 4744607-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01028
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744793-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00758
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abasia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Aspiration		Glucophage	C			UNKNOWN	
	Asthma		Evista	C			UNKNOWN	
	Atrial Fibrillation		Vasotec	C			UNKNOWN	
	Back Disorder		Glucotrol Xl	C			UNKNOWN	
	Blood Pressure Increased		Claritin	C			UNKNOWN	
	Bronchitis		Hydrochlorothiazide And Triamterene	C			UNKNOWN	
	Cardiac Failure							
	Congestive		Aspirin	C			UNKNOWN	
	Cholelithiasis		Aspirin	C			UNKNOWN	
	Chronic Obstructive Pulmonary Disease		Flovent	C			UNKNOWN	
	Convulsion		[Therapy Unspecified]	C			UNKNOWN	
	Coronary Artery Disease		Calcium (Unspecified)	C			UNKNOWN	
	Diplopia							
	Dizziness		Tranxene	C			UNKNOWN	
	Drug Ineffective		Zoloft	C			UNKNOWN	
	Dysphonia		Univasc	C			UNKNOWN	
	Dyspnoea		Avandia	C			UNKNOWN	
	Erythema		Propacet	C			UNKNOWN	
	Excoriation		Wellbutrin Xl	C			UNKNOWN	

	Eye Swelling	Allegra	C
UNKNOWN			
	Facial Pain	Toprol Xl Tablets	C
UNKNOWN			
	Fall	Plavix	C
UNKNOWN			
	Headache	Plavix	C
UNKNOWN			
	Hypertension	Lipitor	C
UNKNOWN			
	Hypoaesthesia	Albuterol	C
UNKNOWN			
	Hypokalaemia	Glucovance	C
UNKNOWN			
	Myocardial Infarction	Lasix (Furosemide)	C
UNKNOWN			
	Neck Injury	Naproxen	C
UNKNOWN			
	Oedema Peripheral	Chlorazepate	C
UNKNOWN			
	Pancreatitis Acute	Vanceril	C
UNKNOWN			
	Pneumonia	Advair	C
UNKNOWN			
	Renal Failure Chronic	Darvocet-N	C
UNKNOWN			
	Sinusitis	Kenalog	C
INTRAMUSCULAR			
	Somnolence	Vicodin Tablets	C
UNKNOWN			
	Swelling Face	Avelox	C
UNKNOWN			
	Tremor	Nasonex	C
UNKNOWN			
	Tricuspid Valve	Spironolactone	C
UNKNOWN			
	Incompetence	Prednisone	C
UNKNOWN			

Date:08/15/05ISR Number: 4744799-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA01538
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction Anxiety Pain		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744819-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03386
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Premarin	C				
UNKNOWN								1909 DAY
Disability	Cerebrovascular Accident		Mevacor	C		ORAL		
	Depression							
	Gastrooesophageal Reflux Disease							
	Osteoarthritis							

Date:08/15/05ISR Number: 4744880-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01955
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
22 MON								
	Chest Pain		Xanax	C				
UNKNOWN								
	Myocardial Infarction							

Date:08/15/05ISR Number: 4744881-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01739
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Anxiety		Prednisone	C				
UNKNOWN								
Other	Atherosclerosis		Immunotherapy (Unspecified)	C				
	Back Pain							
UNKNOWN								
	Blood Cholesterol Increased		Colazal	C				
UNKNOWN								
	Deafness		Imuran (Azathioprine)	C				
UNKNOWN								

	Dilatation Atrial	Celexa	C
UNKNOWN			
	Frequent Bowel Movements	Rowasa	C
UNKNOWN			
	Haematochezia	Asacol	C
UNKNOWN			
	Haemorrhoids		
	Hypertension		
	Movement Disorder		
	Proctitis Ulcerative		
	Productive Cough		
	Pulmonary Congestion		
	Sleep Apnoea Syndrome		
	Thrombosis		
	Tricuspid Valve		
	Incompetence		
	Ventricular Dysfunction		
	Ventricular Hypertrophy		

Date:08/15/05ISR Number: 4744882-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02687
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Asthenia
	Chest Pain
	Coronary Artery Disease
	Delirium Tremens
	Depression

		Dyspnoea					
		Face Injury					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
40	MON						
		Hepatitis Alcoholic		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
40	MON						
		Ligament Injury		Vioxx	SS	Merck & Co., Inc	ORAL
		Oesophageal Disorder		Lipitor	C		
UNKNOWN							
		Rectal Haemorrhage		Vitamins (Unspecified)	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN							
				Wellbutrin	C		
UNKNOWN							
				Flexeril	C		
UNKNOWN							
				Prozac	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							
				Prevacid	C		
UNKNOWN							

Date:08/15/05ISR Number: 4744884-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA00920
Age: Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Carotid Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					
		Quadruple Vessel Bypass Graft					
		Renal Disorder					

Date:08/15/05ISR Number: 4744885-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01652
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability Other	Blood Cholesterol Increased Cerebrovascular Accident Depression Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744886-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0310USA00124
Age:70 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening Hospitalization - Initial or Prolonged Other	Acute Respiratory Distress Syndrome Acute Respiratory Failure Anaphylactic Reaction Angioneurotic Oedema Aortic Atherosclerosis Arrhythmia Asthenia Asthma Blood Cholesterol Increased Breast Mass Bronchitis Cardiac Disorder Cardiomegaly Carpal Tunnel Syndrome Cerebrovascular Accident

		Chronic Obstructive Pulmonary Disease					
		Contusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL
		Cytomegalovirus Colitis		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Deep Vein Thrombosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Diastolic Dysfunction		Vioxx	SS	Merck & Co., Inc	ORAL
34	DAY						
		Disseminated		Zyrtec	C		ORAL
		Cytomegaloviral Infection		Aspirin	C		
UNKNOWN							
		Drug Ineffective		Aspirin	C		
UNKNOWN							
		Dyspnoea		Hydro-Chlor	C		
UNKNOWN							
		Dyspnoea Exertional		Benazepril			
		Emotional Distress		Hydrochloride And			
		Epistaxis		Hydrochlorothiazide	C		ORAL
		Fall		Prednisone	C		ORAL
		Gastrointestinal		Flonase	C		
RESPIRATORY							
		Haemorrhage					
(INHALATION)							
		Gastrooesophageal Reflux		Detrol	C		ORAL
		Disease		Lipitor	C		
UNKNOWN							
		Haemoptysis					
		Heart Rate Irregular					
		Hepatic Enzyme Increased					
		Hypoventilation					
		Hypoxia					
		Ileus					
		Injury					
		Intestinal Ischaemia					
		Leukocytosis					
		Malaise					
		Muscle Spasms					
		Myopathy Steroid					
		Osteoarthritis					
		Pneumonia					
		Pneumonia Cytomegaloviral					
		Pulmonary Oedema					
		Rectal Haemorrhage					
		Rectal Ulcer					
		Rhinitis Allergic					

Sepsis
Sinusitis
Staphylococcal Infection
Swelling Face
Swollen Tongue
Syphilis
Systemic Inflammatory
Response Syndrome
Viral Infection

Date:08/15/05ISR Number: 4744887-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01235
Age:61 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arterial Occlusive Disease Asthenia Carotid Artery Stenosis Cerebral Infarction Chronic Obstructive Pulmonary Disease Emphysema

		Haematuria Hypercholesterolaemia Spinal Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
742	DAY						
				Vioxx	SS	Merck & Co., Inc	ORAL
249	DAY						

Date:08/15/05ISR Number: 4744888-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Death		Abnormal Chest Sound		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aggression		Flexeril	SS		ORAL
Initial or Prolonged		Aspiration		Ultracet	SS		
UNKNOWN							
Other		Completed Suicide		Omeprazole	SS		ORAL
		Depressed Level Of		Elavil	SS		ORAL
		Consciousness		Tizanidine			
		Drug Interaction		Hydrochloride	SS		ORAL
		Drug Screen Positive					
		Drug Toxicity					
		Intentional Misuse					
		Lung Crepitation					
		Lung Disorder					
		Sedation					
		Self-Medication					
		Vomiting					

Date:08/15/05ISR Number: 4744900-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00211
Age:68 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/15/05ISR Number: 4744901-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03804
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Goitre		Vioxx	PS	Merck & Co., Inc	ORAL		1356 DAY
Hospitalization -	Haemorrhagic Stroke		Vioxx	SS	Merck & Co., Inc	ORAL		1356 DAY
Initial or Prolonged	Nephrolithiasis		Aspirin	C				UNKNOWN

Date:08/15/05ISR Number: 4744902-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01185
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		208 DAY
	Chest Pain							

Date:08/15/05ISR Number: 4744904-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01240
Age:44 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Atrial Fibrillation
Initial or Prolonged	Chronic Obstructive
Disability	Pulmonary Disease
	Depression
	Embolism

		Emphysema					
		Fatigue					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Pleural Infection		Vioxx	PS	Merck & Co., Inc	ORAL
		Pneumonia		Lexapro	C		
UNKNOWN							
		Pulmonary Embolism		Flexeril	C		
UNKNOWN							
				Proventil	C		
UNKNOWN							
				Flovent	C		
UNKNOWN							
				Coumadin	C		
UNKNOWN							
				Tylenol With Codeine #3	C		
UNKNOWN							
				Toprol Xl Tablets	C		
UNKNOWN							
				Serevent	C		
UNKNOWN							

Date:08/15/05ISR Number: 4744906-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04560
Age:50 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Gallbladder Disorder		Diovan	C		
UNKNOWN							
		Gastric Cancer		Norvasc	C		
UNKNOWN							
		Haematochezia		Viagra	C		
UNKNOWN							
		Hypertension		Tylenol	C		
UNKNOWN							
		Hypoaesthesia		Advil	C		
UNKNOWN							
		Myocardial Infarction		Aleve	C		
UNKNOWN							
		Pain		Motrin	C		
UNKNOWN							
		Paraesthesia		Tylenol With Codeine			

			#4	C		UNKNOWN
			Hydrocodone/Apap	C		UNKNOWN
			Percocet	C		UNKNOWN
			Percocet	C		UNKNOWN
			Acetaminophen And Oxycodone Hydrochloride	C		UNKNOWN
			Acetaminophen And Oxycodone Hydrochloride	C		UNKNOWN
			Glyburide	C		UNKNOWN
			Metformin	C		UNKNOWN
			Avandia	C		UNKNOWN
			Glucotrol	C		UNKNOWN
			Hydrochlorothiazide	C		UNKNOWN
			Prevacid	C		UNKNOWN
			Prinivil	C		UNKNOWN
			K-Dur	C		UNKNOWN
			[Therapy Unspecified]	C		UNKNOWN
			Vicodin Tablets	C		UNKNOWN

Date:08/15/05ISR Number: 4744907-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01656
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		7 MON
Initial or Prolonged	Transient Ischaemic		Vioxx	SS	Merck & Co., Inc	ORAL		9 MON
	Attack		Vioxx	SS	Merck & Co., Inc	ORAL		7 MON
			Vioxx	SS	Merck & Co., Inc	ORAL		9 MON

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744909-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00113
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744911-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA00148
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Prevacid	C				
	Cardiomegaly		Lipitor	C			UNKNOWN	
	Coronary Artery Disease		Amaryl	C			UNKNOWN	
	Drug Ineffective		Analgesic Or Anesthetic (Unspecified)	C			UNKNOWN	
	Duodenitis							
	Exostosis							
	Gastritis							
	Haematemesis							
	Hiatus Hernia							
	Osteoarthritis							

Date:08/15/05ISR Number: 4744912-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01251
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	3	DAY
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
			Tylenol	C				
			Motrin	C			UNKNOWN	

Date:08/15/05ISR Number: 4744926-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01971
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744927-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00894
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/15/05ISR Number: 4744928-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01181
Age:44 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Disorder							
Other	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744929-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01099
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744930-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01483
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR

Date:08/15/05ISR Number: 4744931-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01254
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	9	MON

Date:08/15/05ISR Number: 4744933-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01476
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744934-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01485
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744935-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01455
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	89 DAY	

Date:08/15/05ISR Number: 4744938-4Report Type:Expedited (15-DaCompany Report #GB-MERCK-0508GBR00057
Age:88 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain		Diclofenac	SS			UNKNOWN	
	Gastric Ulcer Haemorrhage		Celecoxib	SS			UNKNOWN	46 DAY
	Gastrointestinal		Aspirin	SS			UNKNOWN	
	Haemorrhage		Amiloride Hydrochloride And Furosemide	C			UNKNOWN	
	Myocardial Ischaemia							
	Oedema Peripheral							
	Oesophagitis		Digoxin	C			UNKNOWN	
	Pericardial Effusion		Etidronate Disodium	C			UNKNOWN	
	Proctitis		Acetaminophen	C			UNKNOWN	
	Pulmonary Embolism		Aluminum Hydroxide And Magnesium Trisilicate	C			UNKNOWN	
	Renal Failure Acute							
			Lactulose	C			UNKNOWN	
			Cozaar	C		ORAL		

				Nifedipine	C		
UNKNOWN							

Date:08/15/05ISR Number: 4744939-6Report Type:Expedited (15-DaCompany Report #CA-MERCK-0508CAN00081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744940-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01514
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Arthritis		Lotrel	C				
UNKNOWN								
	Cerebrovascular Accident		Lescol	C				
UNKNOWN								
	Chest Pain		Zyprexa	C				
UNKNOWN								
	Myocardial Infarction		Meralop	C				
UNKNOWN								
			Flonase	C				
UNKNOWN								

Date:08/15/05ISR Number: 4744941-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00892
Age:70 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/15/05ISR Number: 4744953-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00968
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744954-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02025
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		52 MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		52 MON
Other	Cardiac Disorder		Folic Acid	C		ORAL		
	Cardiac Failure		Glucosamine	C		ORAL		
	Congestive		Procardia	C		ORAL		
	Hypoxia		Synthroid	C		ORAL		
	Myocardial Infarction							
	Oedema Peripheral							
	Peripheral Vascular Disorder							
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744955-4Report Type:Expedited (15-DaCompany Report #DE-MERCK-0508USA00837
Age:47 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Retinal Vein Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	1	WK
			Vioxx	SS	Merck & Co., Inc	ORAL	2	WK

Date:08/15/05ISR Number: 4744956-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01252
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Congestive							
Other	Myocardial Infarction							
	Nephrolithiasis							
	Renal Failure							

Date:08/15/05ISR Number: 4744957-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01811
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	47	MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	47	MON
Disability	Gastrooesophageal Reflux							
	Disease							
	Hypersensitivity							
	Hypertension							
	Myocardial Infarction							

Date:08/15/05ISR Number: 4744958-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01097
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

Date:08/15/05ISR Number: 4744974-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00740
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Back Pain		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain		Ibuprofen	C		
UNKNOWN						
Disability	Convulsion		Feosol	C		
UNKNOWN						
	Dyspepsia		Atenolol	C		
UNKNOWN						
	Gastritis		Prevacid	C		
UNKNOWN						
	Hiatus Hernia		Relafen	C		
UNKNOWN						
	Hypertension		Tylenol	C		
UNKNOWN						
	Inflammation					
	Meniscus Lesion					
	Pain In Extremity					
	Peptic Ulcer Haemorrhage					
	Transient Ischaemic					
	Attack					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744978-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01973
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744980-3Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0508ZAF00009
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Coronary Syndrome		Rofecoxib	PS	Merck & Co., Inc	ORAL	5	DAY
Initial or Prolonged	Arteriospasm Coronary		Valdecoxib	C		ORAL	4	DAY
	Electrocardiogram St Segment Elevation							
	Hyperhomocysteinaemia							

Date:08/15/05ISR Number: 4744981-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01972
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism							

Date:08/15/05ISR Number: 4744982-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02116
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/15/05ISR Number: 4744983-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01974
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744984-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01963
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744986-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02727
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthropathy Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4744987-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01845
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744993-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00889
Age:51 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arterial Occlusive Disease Atherosclerosis Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR

Date:08/15/05ISR Number: 4745043-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00891
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis Cardiac Failure Congestive Cerebrovascular Accident Coronary Artery Disease Myocardial Infarction Thrombosis Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4745479-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02569
Age:63 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable Aortic Valve Sclerosis Arthralgia Carpal Tunnel Syndrome Cervical Cord Compression Cervicobrachial Syndrome Chest Pain Dermatitis Contact

Dilatation Ventricular
Drug Effect Decreased
Drug Intolerance
Electrocardiogram St-T
Change
Exostosis
Headache
Hypertension
Hypoglycaemia
Insomnia
Joint Sprain
Macular Hole
Malaise
Myofascitis
Nausea
Neck Injury
Peptic Ulcer
Pharmaceutical Product
Complaint
Rash

	Refusal Of Treatment By Patient						
	Respiratory Tract	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Infection		Vioxx	PS	Merck & Co., Inc	ORAL	
	Retinal Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL	
	Rhinitis Allergic		Vioxx	SS	Merck & Co., Inc	ORAL	
	Sciatica		Vioxx	SS	Merck & Co., Inc	ORAL	
	Shoulder Pain		Meclizine	C		ORAL	
	Tinea Pedis		Metformin	C		ORAL	
	Tinnitus		Norvasc	C			UNKNOWN
	Transient Ischaemic		Plavix	C		ORAL	
	Attack		Amaryl	C		ORAL	
	Ventricular Hypertrophy		Glucophage	C			UNKNOWN
	Weight Increased		Estradiol	C		ORAL	
			Levoxyl	C		ORAL	
			Detrol	C		ORAL	
			Aspirin	C		ORAL	
			Zocor	C		ORAL	
			Nitroglycerin	C			SUBLINGUAL
			Altace	C			UNKNOWN
			Actos	C		ORAL	
			Allegra	C		ORAL	
			Ultracet	C			UNKNOWN
			Calcium Alginate	C			UNKNOWN

Date:08/15/05ISR Number: 4745491-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01802
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	27 MON
Initial or Prolonged	Fall		Humulin	C			UNKNOWN
	Polytraumatism		Cozaar	C		ORAL	
	Skin Laceration		Gemfibrozil	C			UNKNOWN

	Vomiting		Norvasc	C		
UNKNOWN						
			Premarin	C		
UNKNOWN		22 YR				
			Ditropan	C		
UNKNOWN						
			Lotrisone	C		
UNKNOWN						
			Silver Nitrate	C		
UNKNOWN						
			Minocycline	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Novolin	C		
UNKNOWN						
			Cipro	C		
UNKNOWN						
			Hydrochlorothiazide And Triamterene	C		
UNKNOWN						
			Nifedipine	C		
UNKNOWN						
			Vasotec	C		ORAL
			Ranitidine	C		
UNKNOWN						
			Trimox	C		
UNKNOWN						
			Coumadin	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						

Date:08/15/05ISR Number: 4745492-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01657
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
	Polytraumatism		Zocor	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								
			Naproxen	C				
UNKNOWN								

				Ibuprofen	C		
UNKNOWN							

Date:08/15/05ISR Number: 4745493-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02043
Age:80 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		387 DAY
Other	Cardiac Disorder		Warfarin	C		ORAL		7 MON
	Cardiovascular Disorder		Isosorbide	C		ORAL		16 MON
	Cerebrovascular Accident		Accupril	C		ORAL		16 MON
	Heart Rate Irregular		Prevacid	C				UNKNOWN
	Hypertensive Heart		Digoxin	C		ORAL		1 YR
	Disease		Zocor	C		ORAL		3 YR
	Myocardial Infarction		Furosemide	C		ORAL		11 MON
			Vitamins (Unspecified)	C		ORAL		4 MON
			Captopril	C		ORAL		3 YR
			Senokot (Senna)	C		ORAL		21 MON
			Famotidine	C		ORAL		15 MON
			Acetaminophen	C		ORAL		3 YR
			Aspirin	C		ORAL		7 MON
			Docusate Sodium	C		ORAL		3 YR

Date:08/15/05ISR Number: 4745494-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01965
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Arterial Occlusive		Proventil	C				
Disability	Disease		Prinivil	C				
	Back Disorder		Norvasc	C				
	Blood Pressure		Aspirin	C				
	Inadequately Controlled		Lipitor	C				
	Coronary Artery Disease		Minoxidil	C				
	Diverticulum Intestinal		Glucotrol	C		ORAL		
	Haemorrhoids		Glucotrol	C				
	Hypertension		Bisoprolol	C				
	Myocardial Infarction		Ecotrin	C				
	Renal Artery Stenosis		Hydrochlorothiazide	C				
	Rotator Cuff Syndrome		Zestril	C				
			Dilantin	C				

Date:08/15/05ISR Number: 4745495-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03807
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL	83	DAY
	Myocardial Infarction		Calan	C				
	Sleep Disorder		Acetazolamide	C				
			Timoptic	C				

Date:08/15/05ISR Number: 4745496-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01651
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Hernia
	Obstructive

		Blood Cholesterol Increased					
		Cardiac Disorder	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Fluocinonide	C		
UNKNOWN							
				Viagra	C		
UNKNOWN							
				Periostat	C		
UNKNOWN							
				Cephalexin	C		
UNKNOWN							
				Chlorhexidine Hydrochloride	C		
UNKNOWN							
				Levitra	C		
UNKNOWN							

Date:08/15/05ISR Number: 4745497-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01795
Age:82 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
34 MON							
		Basal Cell Carcinoma		Vioxx	SS		
UNKNOWN							
		Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL
34 MON							
		Congestive		Vioxx	SS		
UNKNOWN							
		Myocardial Infarction		Alphagan	C		
UNKNOWN							
				Potassium (Unspecified)	C		
UNKNOWN							
				Proscar	C		ORAL
				Prednisone	C		
UNKNOWN							
				Lasix (Furosemide)	C		
UNKNOWN		20 YR					
				Lisinopril	C		
UNKNOWN		19 YR					

	Cephalexin	C
UNKNOWN		
	Doxycycline	C
UNKNOWN		
	Drituss Dm	C
UNKNOWN		
	Detrol	C
UNKNOWN		
	Amoxicillin	C
UNKNOWN		
	Meclizine	C
UNKNOWN		
	Metoprolol	C
UNKNOWN		
	Levaquin	C
UNKNOWN		
	Aspirin	C
UNKNOWN		
	Cosopt	C
OPHTHALMIC		

Date:08/15/05ISR Number: 4745498-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0304USA00752
Age:59 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Aggression
	Anaemia Postoperative
Disability	Anxiety
Other	Appendicitis
	Arthralgia
	Bursitis
	Carpal Tunnel Syndrome
	Cellulitis
	Chest Pain
	Constipation
	Depression
	Diarrhoea
	Dizziness
	Fatigue
	Heart Injury
	Heart Rate Irregular
	Inguinal Hernia

		Joint Dislocation					
		Myocardial Infarction					
		Nerve Compression	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Nerve Injury		Vioxx	PS	Merck & Co., Inc	ORAL
29	DAY						
		Onychomycosis		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Osteoarthritis		Vioxx	SS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
29	DAY						
		Paranoia		Vioxx	SS	Merck & Co., Inc	ORAL
62	DAY						
		Penis Carcinoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Pharyngolaryngeal Pain		Lithium Carbonate	C		
UNKNOWN							
		Post-Traumatic Stress Disorder					
		Rash					
		Rotator Cuff Syndrome					
		Sacroiliitis					
		Sputum Abnormal					
		Squamous Cell Carcinoma					
		Stomach Discomfort					
		Suicidal Ideation					

Date:08/15/05ISR Number: 4745503-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00855
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization - Initial or Prolonged	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
	Adverse Event					
	Angina Unstable					
	Bronchitis					
	Cerebral Atrophy					
	Cerebrovascular Accident					
	Chest Pain					
	Chest Wall Pain					
	Coronary Artery Disease					
	Coronary Artery Stenosis					
	Coronary Ostial Stenosis					
	Dehydration					
	Diabetes Mellitus					
	Hypertension					

Insomnia
Lacunar Infarction
Left Ventricular Failure
Leukoencephalopathy
Myocardial Ischaemia
Oedema Peripheral
Sinusitis
Syncope
Urinary Tract Infection

Date:08/15/05ISR Number: 4745504-7Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00070
Age:56 YR Gender:Male I/FU:F

Outcome PT
Other Adverse Event
Asthenia
Cardiac Failure
Cardiovascular Disorder
Cough
Dyspnoea
Glucose Tolerance

		Impaired Hypersensitivity Micturition Disorder Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Oedema Peripheral		Vioxx	PS	Merck & Co., Inc	ORAL
		Pain In Extremity		Vioxx	SS	Merck & Co., Inc	ORAL
		Phlebitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Plasmacytoma		Vioxx	SS	Merck & Co., Inc	ORAL
		Polyneuropathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Seborrhoeic Dermatitis		Vioxx	SS	Merck & Co., Inc	ORAL
		Tinnitus		Thalidomide	SS		
UNKNOWN							
		Urticaria		Dexamethasone	C		
UNKNOWN							
				Zoledronate Disodium	C		
UNKNOWN							
				Morphine Sulfate	C		
UNKNOWN							
				Piretanide	C		
UNKNOWN							
				Magnesium (Unspecified)	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							
				Pamidronate Disodium	C		
UNKNOWN							
				Zoledronic Acid	C		
UNKNOWN							
				Clemastine Fumarate	C		
UNKNOWN							
				Prednisolone Sodium Succinate	C		
UNKNOWN							
				Moxifloxacin Hydrochloride	C		
UNKNOWN							
				Trifluprom azine Hydrochloride	C		
UNKNOWN							
				Biperiden Hydrochloride	C		
UNKNOWN							

Date:08/15/05ISR Number: 4745505-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00666
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Abdominal Distension		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Constipation		Vioxx	SS	Merck & Co., Inc	ORAL		
	Diarrhoea		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dilatation Atrial							
	Disturbance In Attention							
	Dyspepsia							
	Fatigue							
	Gout							
	Headache							
	Hyperhidrosis							
	Insomnia							
	Joint Injury							
	Knee Operation							
	Malaise							
	Memory Impairment							
	Mitral Valve Incompetence							
	Palpitations							
	Sinus Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4745507-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01798
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
			Effexor	C				
UNKNOWN								
Disability	Cardiac Failure		Plendil	C				
UNKNOWN								
Other	Congestive		Diovan	C				
UNKNOWN								
	Coronary Artery Disease							
	Diabetes Mellitus							
	Dyspnoea							
	Gastric Disorder							
	Heart Rate Irregular							
	Myocardial Infarction							
	Pulmonary Embolism							
	Renal Disorder							

Date:08/15/05ISR Number: 4745508-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA03403
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Insulin	C				
UNKNOWN								
	Silent Myocardial Infarction							

Date:08/15/05ISR Number: 4745509-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00934
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Coronary Artery Disease							
	Myocardial Infarction							
	Thrombosis							
	Transient Ischaemic							

Attack

Date:08/15/05ISR Number: 4745510-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01480
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4745511-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03061
Age:68 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Back Disorder
Disability	Bladder Disorder
Other	Cardiac Disorder
	Cerebrovascular Accident
	Coronary Artery Disease
	Coronary Artery Occlusion
	Depression
	Ear Pain
	Emotional Disorder
	Gastrointestinal Disorder

	Mental Disorder Myocardial Infarction Prescribed Overdose	Report Source	Product	Role	Manufacturer	Route	Dose Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	39 MON
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	39 MON
			Vioxx	SS	Merck & Co., Inc	ORAL	

Date:08/15/05ISR Number: 4745512-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01479
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/15/05ISR Number: 4745513-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01484
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/15/05ISR Number: 4745514-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01184
Age:84 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Confusional State Dizziness Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	

Date:08/15/05ISR Number: 4745515-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0507DEU00202
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration

Other	Phlebothrombosis		Vioxx	PS	Merck & Co., Inc	ORAL
	Retinal Vein Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/15/05ISR Number: 4745516-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01793
Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 52 MON	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Back Pain		Aleve	C		
Disability UNKNOWN	Cardiac Murmur 2 YR		Flexeril	C		
	Cerebrovascular Accident		Cyclobenzaprine(West Point Pharma)	C		
	Gout					
UNKNOWN						
	Hypertension		Chlordiazepoxide	C		
UNKNOWN						
	Insomnia		Lorazepam	C		
UNKNOWN						
	Myocardial Infarction		Fluoxetine	C		
UNKNOWN						

Date:08/15/05ISR Number: 4745517-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA02977
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4745518-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01261
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		45 MON
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		45 MON
	Arrhythmia		Atenolol	C				UNKNOWN
	Supraventricular							
	Atherosclerosis							
	Atrial Fibrillation							
	Atrial Flutter							
	Blood Cholesterol							
	Increased							
	Cardiac Disorder							
	Cataract							
	Chest Pain							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Dyspnoea							
	Dyspnoea Exertional							
	Fluid Retention							
	Hypertension							
	Oedema							
	Oral Intake Reduced							
	Osteoporosis							
	Ventricular Arrhythmia							

Date:08/15/05ISR Number: 4745519-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01168
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Infarction		Albuterol	C				UNKNOWN
	Death		Plavix	C				UNKNOWN
	Myocardial Infarction		Pletal	C				UNKNOWN
	Overdose		Niaspan	C				UNKNOWN

Nitroglycerin C
UNKNOWN

Date:08/15/05ISR Number: 4745529-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01619
Age:90 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	7 WK	
Life-Threatening	Congestive							
Hospitalization - Initial or Prolonged	Gastric Ulcer Perforation							

Date:08/15/05ISR Number: 4745541-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01989
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	533 DAY	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4745542-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02102
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	752	DAY
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/15/05ISR Number: 4745543-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02101
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	12	MON

Date:08/15/05ISR Number: 4745545-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02099
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	70	DAY

Date:08/15/05ISR Number: 4745552-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02100
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	332	DAY

Date:08/16/05ISR Number: 4745892-1Report Type:Expedited (15-DaCompany Report #200512465US
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Glucose Increased		Lantus	PS	Aventis			

Initial or Prolonged Cardiac Valve Disease Pharmaceuticals Inc.
SUBCUTANEOUS Dose unit:
Cerebrovascular Accident
units
Infection Opticlik (Insulin
Pyrexia Injection Pen) SS
dose: UNK
Viral Infection Vioxx SS
dose: UNK
Vomiting Some Type Of Insulin
Nos C
dose: UNK
Proventil C
dose: UNK
Zocor C
Synthroid C
Actos C
dose: 10-12.5
Zestril C
dose: UNK
Plavix C
Amaryl C
Levaquin C
dose: UNK
Namenda C
dose: UNK

Date:08/16/05ISR Number: 4745964-1Report Type:Expedited (15-DaCompany Report #HQWYE663002AUG05
Age: Gender:Female I/FU:I

Outcome PT
Other Angioneurotic Oedema
Condition Aggravated
Drug Effect Decreased
Drug Interaction
Polyarthritis
Rash

Urticaria

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Enbrel	PS			not specified	
	Corticosteroid Nos	C			dose tapered off with start of etanercept	
	Rofecoxib	I				
	Celecoxib	I				
	Etoricoxib	I				

Date:08/16/05ISR Number: 4745969-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0307USA02048
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Percocet	SS				
Disability	Arthropod Sting		Xanax	SS			UNKNOWN	
Other	Cardiac Failure		Ambien	SS			UNKNOWN	
	Coronary Artery Disease		Alcohol	SS			UNKNOWN	
	Diabetes Mellitus		Advil	C			UNKNOWN	
	Gastrooesophageal Reflux		Imdur	C			UNKNOWN	
	Disease		Soma	C			UNKNOWN	
	Hypercholesterolaemia							
	Hyperlipidaemia							
	Hypertension							
	Hypoaesthesia							
	Intentional Misuse							
	Major Depression							
	Myocardial Infarction							

Spondylitis
Stent Occlusion
Suicide Attempt
Swelling Face
Tooth Disorder

Date:08/16/05ISR Number: 4745972-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0411USA02237
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		1193 DAY
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		1193 DAY
Disability	Bursitis		Methylprednisolone	C				UNKNOWN
	Cervicobrachial Syndrome		Bextra	C				UNKNOWN
	Condyloma Acuminatum		Colchicine	C				UNKNOWN
	Coronary Artery		Norvasc	C				UNKNOWN
	Atherosclerosis		Triamterene	C				UNKNOWN
	Coronary Artery Occlusion		Allopurinol	C				UNKNOWN
	Diarrhoea		Methocarbamol	C				UNKNOWN
	Gout		Indomethacin	C				UNKNOWN
	Gouty Arthritis		Plavix	C				UNKNOWN
	Headache		Protonix	C				UNKNOWN
	Hyperlipidaemia		Hydrocodone					
	Hypertension		Bitartrate	C				UNKNOWN
	Hypertriglyceridaemia		Altace	C				UNKNOWN
	Insomnia		Toprol Xl Tablets	C				UNKNOWN
	Myocardial Infarction		Nitroquick	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4745978-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00114
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745979-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00165
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Prednisone	C				
Disability			Olsalazine Sodium	C				

Date:08/16/05ISR Number: 4745980-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01895
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
			Celebrex	C				
			Celebrex	C				
			Aspirin	C				

Date:08/16/05ISR Number: 4745981-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01181
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Bayer Aspirin	C				

			Niaspan	C		
UNKNOWN						
			Zocor	C		ORAL
			Quinapril Hydrochloride	C		
UNKNOWN						
			Propoxyphene Hydrochloride	C		
UNKNOWN						

Date:08/16/05ISR Number: 4745982-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00166
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Cerebrovascular Accident Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745983-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00111
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745984-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00118
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745985-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00164
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745986-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00108
Age:57 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745987-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00107
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4745988-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00092
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction Overdose							

Date:08/16/05ISR Number: 4745989-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01799
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	50	MON

Initial or Prolonged	Joint Injury	Vioxx	SS	Merck & Co., Inc	ORAL	50 MON
Other	Myocardial Infarction	Celebrex	SS			UNKNOWN
	Systemic Lupus	Pancof Hc	C			UNKNOWN
	Erythematosus	Premarin	C			UNKNOWN
	Thrombosis	Hydrocodone Bitartrate	C			UNKNOWN
		Augmentin	C			UNKNOWN
		Ultracet	C			UNKNOWN
		[Therapy Unspecified]	C			UNKNOWN
		Visicol	C			UNKNOWN
		Diphen-Atrop	C			UNKNOWN
		Docusate Sodium	C			UNKNOWN
		Iron (Unspecified)	C			UNKNOWN
		Amoxicillin	C			UNKNOWN
		Potassium Chloride	C			UNKNOWN
		Thera M	C			UNKNOWN
		Lamisil	C			UNKNOWN
		Cephalexin	C			UNKNOWN
		Diflucan	C			UNKNOWN
		Ed-Flex	C			UNKNOWN
		Methylprednisolone	C			UNKNOWN
		Nasonex	C			UNKNOWN
		Ery-Tab	C			UNKNOWN
		Zyrtec	C			UNKNOWN
		Nicotrol	C			UNKNOWN

				Acetaminophen And Codeine	C		
UNKNOWN							
				Veetids	C		
UNKNOWN							
				Erythrocin	C		
UNKNOWN							
				Tobradex	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Patanol	C		
UNKNOWN							
				Topamax	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Penicillin (Unspecified)	C		
UNKNOWN							
				Tequin	C		
UNKNOWN							
				Hyoscyamine	C		
UNKNOWN							
				Lovenox	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Bupropion Hydrochloride	C		
UNKNOWN							
				Oxaprozin	C		
UNKNOWN							

Date:08/16/05ISR Number: 4745990-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01941
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Disability	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
	Musculoskeletal Disorder					

Date:08/16/05ISR Number: 4745991-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02006
Age:86 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Chest Injury		Aspirin	SS				
UNKNOWN								
	Contusion		Aspirin	SS				
UNKNOWN								
	Drug Hypersensitivity		Ultracet	C				
UNKNOWN								
	Drug Interaction		Zoloft	C				
UNKNOWN								
	Dyslipidaemia		Fosamax	C				
UNKNOWN								
	Fall		Flexeril	C				
UNKNOWN								
	Gastric Ulcer		Prednisolone	C				
UNKNOWN								
	Gastrointestinal		Glipizide Xl	C				
UNKNOWN								
	Arteriovenous		Zocor	C				
UNKNOWN								
	Malformation		Zantac	C				
UNKNOWN								
	Hypertension		Hytrin	C				
UNKNOWN								
	Hypokalaemia							
	Intertrigo Candida							
	Osteoarthritis							
	Renal Failure Acute							
	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4745993-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02662
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Amaurosis Fugax		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anaphylactic Shock		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Other	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL		
	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dysphagia		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gait Disturbance		Neurontin	C		ORAL		
	Headache		Synthroid	C		ORAL		
	Hypoaesthesia		Hydrodiuril	C		ORAL		
	Hypoxia		Arava	C		ORAL		
	Multiple Sclerosis		Methotrexate	C				UNKNOWN
	Osteoarthritis		Premarin	C				UNKNOWN
	Pain In Extremity							
	Pleural Effusion							
	Pneumonia							
	Renal Disorder							
	Sleep Disorder							
	Syncope							
	Transient Ischaemic Attack							
	Visual Disturbance							

Date:08/16/05ISR Number: 4745994-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00138
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							
Disability								

Date:08/16/05ISR Number: 4745995-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA02161
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		76 DAY
Initial or Prolonged Disability	Blood Cholesterol Increased		Lopressor	C		ORAL		
	Cerebrovascular Accident		Dyazide	C		ORAL		
	Diabetes Mellitus		Tylenol	C		ORAL		
	Hypertension							
	Osteoporosis							
	Pneumonia							

Date:08/16/05ISR Number: 4745996-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01658
Age:73 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Blood Cholesterol
Initial or Prolonged	Increased
Disability	Blood Pressure Increased
	Blood Triglycerides
	Increased
	Coronary Artery Occlusion
	Dyspepsia
	Dyspnoea

		Fluid Overload					
		Heart Rate Irregular					
		Myocardial Infarction	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL
		Thrombosis		Tramadol			
		Thyroid Disorder		Hydrochloride	C		
UNKNOWN							
				Potassium			
				(Unspecified)	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/16/05ISR Number: 4745997-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01800
Age:58 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
				Celebrex	SS		
UNKNOWN							
				Lipitor	C		
UNKNOWN							
				Atenolol Msd	C		
UNKNOWN							
				Atenolol	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:08/16/05ISR Number: 4745998-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00931
Age:56 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL
		Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL
		Cerebrovascular Accident					
		Coronary Artery Disease					
		Myocardial Infarction					

Thrombosis
Transient Ischaemic
Attack

Date:08/16/05ISR Number: 4745999-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00125
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		268 DAY

Date:08/16/05ISR Number: 4746002-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00124
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746003-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00127
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746007-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00126
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746166-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0503AUS00134
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Zocor	C		ORAL		
	Attack		Omeprazole Magnesium	C		ORAL		
			Aspirin	C		ORAL		

Date:08/16/05ISR Number: 4746167-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00128
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746168-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00129
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746169-0Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00163
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746173-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00146
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746177-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0501AUS00162
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Overdose		[Therapy Unspecified]	C			UNKNOWN	
			Hydrochlorothiazide And Irbesartan	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4746178-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00123
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746179-3Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00122
Age:65 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		1735 DAY

Date:08/16/05ISR Number: 4746180-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00152
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746181-1Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00133
Age:36 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746183-5Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00141
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction Overdose		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746184-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00063
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Quinine Sulfate	C				
UNKNOWN								
Disability			Nicorandil	C				
UNKNOWN								
			Fluvastatin Sodium	C				
UNKNOWN								
			Esomeprazole Magnesium	C				
UNKNOWN								
			Isosorbide Mononitrate	C				
UNKNOWN								
			Clopidogrel Bisulfate	C				
UNKNOWN								
			Amlodipine Besylate	C				
UNKNOWN								
			Aspirin	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4746185-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00167
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Venlafaxine Hydrochloride	C		ORAL		
			Prazosin Hydrochloride	C		ORAL		

Date:08/16/05ISR Number: 4746186-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02614
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cataract		Vioxx	PS	Merck & Co., Inc	ORAL	46 MON	
Initial or Prolonged	Dizziness		Prempro	C			UNKNOWN	
	Gastrointestinal Disorder		Prednisone	C			UNKNOWN	
	Myocardial Infarction		Levoxyl	C			UNKNOWN	
			Remicade	C			UNKNOWN	
			Methotrexate	C			UNKNOWN	
			Folic Acid	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Pepcid	C			UNKNOWN	

Date:08/16/05ISR Number: 4746187-2Report Type:Expedited (15-DaCompany Report #NO-MERCK-0503NOR00025
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL	40 DAY	
Initial or Prolonged	Increased		Ibuprofen	SS		ORAL		

	Blood Glucose Increased	Zocor	C
UNKNOWN			
	Cold Sweat	Buprenorphine	
	Dyspnoea	Hydrochloride	C
UNKNOWN			
	Feeling Abnormal		
	Hypertensive Crisis		
	Left Ventricular Failure		
	Pyrexia		
	Renal Cyst		
	Sinus Tachycardia		

Date:08/16/05ISR Number: 4746188-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0312USA00274
Age:50 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Back Injury
Disability	Breathing-Related Sleep
Other	Disorder
	Carotid Artery Stenosis
	Cellulitis
	Cerebellar Haemorrhage
	Cerebrovascular Accident
	Chest Pain
	Cor Pulmonale
	Coronary Artery Disease
	Diabetes Mellitus
	Inadequate Control
	Dyslipidaemia
	Dyspnoea

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Ecg Signs Of Myocardial Ischaemia					
		Erectile Dysfunction					
		Eye Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Hyperlipidaemia		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL
		Hypoaesthesia		Xalatan	C		
UNKNOWN							
		Joint Effusion		Betoptic	C		
UNKNOWN							
		Myocardial Infarction		Amaryl	C		
UNKNOWN							
		Myofascial Spasm		Accupril	C		
UNKNOWN							
		Nausea		Hydrochlorothiazide	C		
UNKNOWN		1106 DAY					
		Neck Injury		Metoprolol	C		
UNKNOWN							
		Pain In Extremity		Avapro	C		
UNKNOWN		60 DAY					
		Pigmentary Glaucoma		Cardura	C		
UNKNOWN		255 DAY					
		Retinal Vein Occlusion		Lipitor	C		
UNKNOWN							
		Road Traffic Accident		Niacin	C		
UNKNOWN							
		Sinus Disorder		Naproxen	C		
UNKNOWN		82 DAY					
		Somnolence		Tylenol	C		
UNKNOWN							
		Whiplash Injury		Augmentin	C		
UNKNOWN							
				Allegra	C		
UNKNOWN							
				Cipro	C		
UNKNOWN							
				Verapamil	C		
UNKNOWN							
				Aspirin	C		
UNKNOWN							
				Ibuprofen	C		
UNKNOWN							

Date:08/16/05ISR Number: 4746189-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00062
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		1 DAY
Disability								

Date:08/16/05ISR Number: 4746190-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02272
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Death	Abdominal Pain Upper
Hospitalization -	Arteriosclerosis
Initial or Prolonged	Arthralgia
Other	Blood Cholesterol Increased
	Blood Triglycerides Increased
	Bronchitis
	Cataract
	Chest Pain
	Dermatitis
	Ear Disorder
	Hypertension
	Hypertensive Heart Disease
	Intracranial Aneurysm
	Loss Of Consciousness
	Pulmonary Congestion
	Rash Generalised
	Skin Papilloma
	Sudden Death
	Thermal Burn

Urticaria Generalised

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	444	DAY
	Altace	C		ORAL	701	DAY
	Methocarbamol	C			UNKNOWN	
	Zocor	C		ORAL		
	Viagra	C			UNKNOWN	
	Betamethasone	C			UNKNOWN	
	Amoxicillin	C			UNKNOWN	
	[Therapy Unspecified]	C			UNKNOWN	
	Allegra	C			UNKNOWN	
	Triamcinolone	C			UNKNOWN	
	Hydrodiuril	C		ORAL		
	Ocuflox	C			UNKNOWN	
	Zymar	C			UNKNOWN	

Date:08/16/05ISR Number: 4746191-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00131
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746192-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00148
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged Myocardial Infarction
Disability

Date:08/16/05ISR Number: 4746193-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01939
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		30 MON
Initial or Prolonged	Cerebral Artery Embolism		Vioxx	SS	Merck & Co., Inc	ORAL		30 MON
	Colonic Polyp		Zyrtec	C		ORAL		
	Constipation		Zyrtec	C		ORAL		
	Coordination Abnormal		Acetaminophen And Codeine	C				
	Fatigue							UNKNOWN
	Hemiparesis		Amoxicillin	C				UNKNOWN
	Mitral Valve Incompetence		Clindamycin	C				UNKNOWN
	Monoplegia		Acetaminophen And Hydrocodone Bitartrate	C				
	Polyp							
	Prostatic Specific Antigen Increased		Lycopene	C		ORAL		UNKNOWN
	Pruritus		Centrum Silver	C		ORAL		
	Pulmonary Valve Incompetence		Vitamin E	C		ORAL		
	Sleep Disorder		Omega-3 Marine Triglycerides	C		ORAL		
	Tricuspid Valve Incompetence							

Date:08/16/05ISR Number: 4746194-XReport Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00150
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:08/16/05ISR Number: 4746196-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03730
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1157	DAY
Initial or Prolonged	Blood Creatinine		Lipitor	C			UNKNOWN	
Other	Increased		Triamterene	C			UNKNOWN	
	Blood Urea Increased		Proscar	C			UNKNOWN	
	Bundle Branch Block Left		Lopressor	C			UNKNOWN	
	Cardiac Failure		Urecholine	C			UNKNOWN	
	Congestive		Maxzide	C			UNKNOWN	
	Cerebral Atrophy		Xanax	C			UNKNOWN	
	Cerebrovascular Accident		Vitamins					
	Coronary Artery Disease		(Unspecified)	C			UNKNOWN	
	Dehydration		Vitamin E	C			UNKNOWN	
	Diabetes Mellitus		Potassium Gluconate	C			UNKNOWN	
	Excoriation		Aspirin	C			UNKNOWN	
	Gastritis		Cyanocobalamin	C			UNKNOWN	
	Haemorrhoids		Tylenol	C			UNKNOWN	
	Hepatic Cyst		Zantac	C			UNKNOWN	
	Ileus							

Intermittent Claudication
Memory Impairment
Myocardial Infarction
Oedema
Postoperative Ileus
Prostatism
Renal Cyst
Rhabdomyolysis
Sciatica
Skin Laceration
Supraventricular
Tachycardia
Systolic Hypertension
Ventricular Tachycardia
Vision Blurred
Weight Increased

Date:08/16/05ISR Number: 4746197-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03615
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL		1614 DAY
Initial or Prolonged Disability	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Congestive		[Therapy					
UNKNOWN	Cardiac Valve Disease		Unspecified]	C				
	Carotid Artery Stenosis							
	Coronary Artery Disease							
	Endocarditis							
	Hypertension							

Date:08/16/05ISR Number: 4746198-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01211
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Aspirin	C				
UNKNOWN								
	Prostate Cancer		Excedrin					
	Wound Dehiscence		(Acetaminophen (+)					
			Caffeine)	C				
UNKNOWN								

Date:08/16/05ISR Number: 4746199-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01236
Age:43 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL		
16 MON								
Initial or Prolonged	Atrial Fibrillation		Vioxx	SS	Merck & Co., Inc	ORAL		
16 MON								
Other	Cardiac Disorder		Diovan	C				
UNKNOWN								
	Cerebrovascular Accident							

Date:08/16/05ISR Number: 4746200-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01490
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Zocor	C				
UNKNOWN								
	Pain In Extremity		Benicar	C				
UNKNOWN								
	Suicidal Ideation		Flexeril	C				
UNKNOWN								
	Transient Ischaemic		Vicodin Tablets	C				
UNKNOWN								
	Attack		Plavix	C				
UNKNOWN								

Ultracet	C		
UNKNOWN			
Hydrochlorothiazide	C		
UNKNOWN			

Date:08/16/05ISR Number: 4746201-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01009
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746202-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01173
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	506	DAY
Disability	Foot Fracture							
	Myocardial Infarction							

Date:08/16/05ISR Number: 4746203-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01954
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Angina Pectoris
Disability	Arthralgia
	Back Injury
	Blood Cholesterol Increased

	Bunion						
	Cardiac Disorder						
	Chest Pain	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Coronary Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cough		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gallbladder Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Gastrointestinal Disorder		Altace	C			UNKNOWN	
	Gastrooesophageal Reflux		Detrol La	C			UNKNOWN	
	Disease		Norvasc	C			UNKNOWN	
	Granuloma		Norvasc	C			UNKNOWN	
	Headache		Paxil	C			UNKNOWN	
	Hernia		Nasonex	C			UNKNOWN	
	Myocardial Infarction		Singulair	C		ORAL		
	Pain		Atenolol	C			UNKNOWN	
	Pancreatitis		Premarin	C			UNKNOWN	
	Pneumonia		Endocet	C			UNKNOWN	
	Pyrexia		Diovan	C			UNKNOWN	
	Road Traffic Accident		Hydrodiuril	C		ORAL		
	Stomach Discomfort		Nitroquick	C			UNKNOWN	
			Advil	C			UNKNOWN	
			Tylenol	C			UNKNOWN	
			Ultram	C			UNKNOWN	

Date:08/16/05ISR Number: 4746205-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02127
Age:42 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
1839 YR						
Initial or Prolonged	Infarction		Lortab	C		
UNKNOWN						
Disability	Anxiety		Xanax	C		
UNKNOWN						
	Blood Cholesterol		Zoloft	C		
UNKNOWN						
	Increased		Norvasc	C		
UNKNOWN						
	Blood Triglycerides		Altace	C		
UNKNOWN						
	Increased					
	Depression					
	Hypertension					
	Sexual Dysfunction					

Date:08/16/05ISR Number: 4746206-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00130
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Cerebral Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL
16 MON						
Hospitalization -	Cerebral Atrophy		Norvasc	C		
UNKNOWN						
Initial or Prolonged	Cerebrovascular Accident		Avapro	C		
UNKNOWN						
	Death		Lasix (Furosemide)	C		
UNKNOWN						
	Essential Tremor		Lasix (Furosemide)	C		
UNKNOWN						
	Facial Palsy		Roxicet	C		
UNKNOWN						
	Lacunar Infarction		Sodium Bicarbonate	C		
UNKNOWN						
	Microangiopathy		Aspirin	C		
UNKNOWN						
	Oesophageal Disorder					
	Skin Laceration					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4746207-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02278
Age:82 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	52	DAY
			Hytrin	C				
UNKNOWN							39	MON

Date:08/16/05ISR Number: 4746208-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	8	DAY
Initial or Prolonged	Alanine Aminotransferase Increased		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Aspartate Aminotransferase Increased		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Back Pain		Tizanidine Hydrochloride	SS		ORAL	1	DAY
	Blood Alkaline Phosphatase Increased		Diclofenac Sodium	SS		ORAL		
	Bradycardia		Herbs (Unspecified)	C		ORAL		
	Chest Discomfort							
	Diarrhoea							
	Drug Interaction							
	Dyspnoea							
	Fibrin D Dimer Increased							
	Gamma-Glutamyltransferase Increased							
	Haemangioma Of Liver							
	Hepatic Cyst							
	Hepatic Lesion							
	Hyperhidrosis							
	Liver Disorder							
	Liver Function Test Abnormal							
	Pleural Effusion							
	Pulmonary Hypertension							

Right Ventricular Failure
Sinus Bradycardia
Vomiting

Date:08/16/05ISR Number: 4746209-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01950
Age:34 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Injury		Vioxx	PS	Merck & Co., Inc	ORAL		5 MON
Initial or Prolonged	Fall		Vioxx	SS	Merck & Co., Inc	ORAL		5 MON
Disability	Hypertension		Synthroid	C				UNKNOWN
	Myocardial Infarction							
	Prescribed Overdose							
	Skeletal Injury							
	Wrist Fracture							

Date:08/16/05ISR Number: 4746210-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01934
Age:48 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Depression

Myocardial Infarction
Road Traffic Accident

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Vioxx	SS	Merck & Co., Inc	ORAL	4	YR
	Neurontin	C			UNKNOWN	
	Ultram	C			UNKNOWN	
	Zanaflex	C			UNKNOWN	
	Paxil	C			UNKNOWN	

Date:08/16/05ISR Number: 4746211-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02134
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Failure		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Congestive		Flexeril	C			UNKNOWN	
	Coronary Artery Disease		Nasacort	C			UNKNOWN	
	Diabetes Mellitus		Afrin	C			UNKNOWN	
	Myocardial Infarction		Glucophage	C			UNKNOWN	
	Sleep Apnoea Syndrome		Metoprolol	C			UNKNOWN	
			Pravastatin Sodium	C			UNKNOWN	
			Ecotrin	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Lasix (Furosemide)	C			UNKNOWN	
			Foltx	C			UNKNOWN	

			Diovan	C		
UNKNOWN						
			Diovan	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Lopress	C		
UNKNOWN						

Date:08/16/05ISR Number: 4746212-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03891
Age:37 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL
1 YR						
Initial or Prolonged	Increased		Soma	C		
UNKNOWN						
	Chest Pain		Ecotrin	C		
UNKNOWN						
	Coronary Artery		Plavix	C		
UNKNOWN						
	Atherosclerosis		Lipitor	C		
UNKNOWN						
	Coronary Artery Stenosis		Toprol Xl Tablets	C		
UNKNOWN						
	Dyspepsia		Lopressor	C		ORAL
	Eczema		Zocor	C		
UNKNOWN						
	Fatigue		Nexium	C		
UNKNOWN						
	Hyperlipidaemia		Nitrol			
	Hypertension		(Nitroglycerin)	C		
TOPICAL						
	Ischaemia		Colace	C		
UNKNOWN						
	Myocardial Infarction					
	Rotator Cuff Syndrome					

Date:08/16/05ISR Number: 4746213-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00266
Age:54 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Asthma
Initial or Prolonged	Blood Cholesterol
	Increased
	Cerebrovascular Accident

		Haematochezia					
		Loss Of Consciousness					
		Polyp	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
				Plavix	C		
UNKNOWN							

Date:08/16/05ISR Number: 4746219-1Report Type:Expedited (15-DaCompany Report #NO-MERCK-0508NOR00003
Age:55 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Alcohol Use		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Brain Damage		Vioxx	SS	Merck & Co., Inc	ORAL
Disability		Dizziness		Vioxx	SS	Merck & Co., Inc	ORAL
		Facial Palsy		Vioxx	SS	Merck & Co., Inc	ORAL
		Gait Disturbance		Diltiazem			
		Gastric Haemorrhage		Hydrochloride	C		
UNKNOWN							
		Hemiparesis		Diltiazem			
		Intracranial Injury		Hydrochloride	C		
UNKNOWN							
		Nausea		Sulfasalazine	C		
UNKNOWN							
		Oesophagitis		Insulin, Isophane	C		
UNKNOWN							
				Insulin, Isophane	C		
UNKNOWN							
				Doxazosin Mesylate	C		
UNKNOWN							
				Clobetasol			
				Propionate	C		
UNKNOWN							

Date:08/16/05ISR Number: 4746220-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00103
Age:55 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
		Myocardial Infarction					

Date:08/16/05ISR Number: 4746221-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01504
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746223-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01217
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Transient Ischaemic		Plavix	C				
	Attack		Ultram	C				
	Urinary Incontinence		Prevacid	C				
			Clonidine	C				

Date:08/16/05ISR Number: 4746224-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01970
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
			Celebrex	SS		ORAL		

Date:08/16/05ISR Number: 4746225-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02098
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Deep Vein Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746226-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02095
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746227-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01936
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death							

Date:08/16/05ISR Number: 4746228-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01965
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746229-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01969
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction Transient Ischaemic Attack		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746230-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01355
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	8	MON

Date:08/16/05ISR Number: 4746231-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01986
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746232-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00130
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc			
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/16/05ISR Number: 4746235-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02096
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746236-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01547
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/16/05ISR Number: 4746238-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00457
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dyspnoea		Vitamins					
	Hypertension		(Unspecified)	C				
UNKNOWN								
	Insomnia		Synthroid	C				
UNKNOWN								
	Lymphadenopathy		Lipitor	C				
UNKNOWN								
	Migraine With Aura		Captopril	C				
UNKNOWN								
	Myocardial Infarction		Protonix	C				
UNKNOWN								
	Myocarditis							
	Rectal Tenesmus							
	Restless Legs Syndrome							
	Retinal Haemorrhage							

Date:08/17/05ISR Number: 4746795-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04367
Age:59 YR Gender:Male I/FU:F

Outcome PT

Death	Anxiety
Life-Threatening	Arthritis
	Back Pain
	Benign Prostatic
	Hyperplasia
	Bronchitis
	Cardio-Respiratory Arrest
	Chest Discomfort
	Chest Pain
	Coronary Artery Disease
	Dyspnoea
	Feeling Abnormal
	Hyperlipidaemia
	Hypoaesthesia
	Infusion Related Reaction
	Ingrowing Nail
	Joint Effusion
	Myalgia
	Myocardial Infarction
	Nail Infection
	Night Cramps
	Onychomycosis
	Otitis Media Chronic
	Pain In Extremity
	Polyarthritis
	Sinus Congestion

	Skin Lesion Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Ventricular Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	
	Vertigo Positional		Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
			Ibuprofen	C			UNKNOWN
			Tussionex (Chlorpheniramine Polistirex (+) Hydrocodone Polistirex)	C			UNKNOWN
			[Therapy Unspecified]	C			UNKNOWN

Date:08/17/05ISR Number: 4746809-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01497
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - 1 YR	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Myocardial Infarction						

Date:08/17/05ISR Number: 4746812-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01493
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	

Infarction
Cerebrovascular Accident
Depression

Date:08/17/05ISR Number: 4746814-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01932
Age:43 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Amnesia
Hospitalization - Initial or Prolonged	Bladder Disorder
	Cerebrovascular Accident
	Depression
	Erectile Dysfunction
	Gallbladder
	Non-Functioning
	Headache
	Myocardial Infarction
	Neuropathy
	Obesity
	Overdose
	Pain
	Stress

	Thrombosis						
	Visual Disturbance						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Ibuprofen	C				UNKNOWN

Date:08/17/05ISR Number: 4746817-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01201
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Death		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/17/05ISR Number: 4746818-7Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00149
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Hypertension		Trandolapril	C				UNKNOWN
Disability	Myocardial Infarction		Omeprazole	C		ORAL		
			Aspirin	C		ORAL		

Date:08/17/05ISR Number: 4746819-9Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00156
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged			Methotrexate	C				UNKNOWN
Disability			Prednisone	C				UNKNOWN
			Sulfasalazine	C				UNKNOWN

				[Therapy Unspecified]	C		
UNKNOWN							
				[Therapy Unspecified]	C		
UNKNOWN							

Date:08/17/05ISR Number: 4746820-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01498
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Heart Rate Decreased		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4746822-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03516
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Ultracet	SS		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4746824-2Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00151
Age:33 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4746825-4Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00134
Age:71 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4746826-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00147
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cardiac Disorder Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4746827-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00154
Age:56 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	1325 DAY	

Date:08/17/05ISR Number: 4746829-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01193
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Condition Aggravated		Vioxx	PS	Merck & Co., Inc	ORAL		14 MON
Initial or Prolonged	Diabetes Mellitus		Aspirin	C				UNKNOWN
	Emotional Distress		Benazepril Hydrochloride	C				UNKNOWN
	Myocardial Infarction		Metoprolol	C				UNKNOWN
			Clonazepam	C				UNKNOWN
			Leustatin	C				UNKNOWN
			Isosorbide	C				UNKNOWN
			Benzonatate	C				UNKNOWN
			Metformin	C				UNKNOWN
			Nitroglycerin	C				SUBLINGUAL

Date:08/17/05ISR Number: 4746839-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01343
Age:57 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Angiopathy
Initial or Prolonged	Arterial Stenosis
Disability	Cardiac Disorder
	Chest Pain
	Depression
	Diarrhoea
	Dyspnoea

		Emotional Distress					
		Femoral Artery Aneurysm					
		Femoral Artery Occlusion	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Headache		Vioxx	PS	Merck & Co., Inc	ORAL
6	MON						
		Hypersensitivity		Aspirin	C		ORAL
		Hypoaesthesia		Aspirin	C		
UNKNOWN							
		Hysterectomy		Tylenol	C		ORAL
		Intermittent Claudication					
		Muscle Spasms					
		Muscle Tightness					
		Pain					
		Paraesthesia					
		Post-Traumatic Stress					
		Disorder					
		Surgery					
		Thrombosis					

Date:08/17/05ISR Number: 4746883-7Report Type:Expedited (15-DaCompany Report #ZA-MERCK-0508ZAF00009
Age:59 YR Gender:Male I/FU:I

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL
5	DAY						
Initial or Prolonged		Arteriospasm Coronary		Valdecoxib	C		ORAL
4	DAY						
		Hyperhomocysteinaemia					

Date:08/17/05ISR Number: 4746884-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01226
Age:52 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Bronchitis		Vioxx	PS	Merck & Co., Inc	ORAL
27	MON						
Initial or Prolonged		Chest Pain		Vioxx	SS	Merck & Co., Inc	ORAL
27	MON						
		Myocardial Infarction		Glucophage	C		
UNKNOWN							

	Pneumonia		Glyburide	C			
UNKNOWN							
			Prilosec	C			ORAL
			Actos	C			
UNKNOWN							

Date:08/17/05ISR Number: 4746885-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01230
Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		56 MON
Initial or Prolonged	Coronary Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL		56 MON
Other	Musculoskeletal Disorder		Lopressor	C				UNKNOWN
	Myocardial Infarction		Lotensin	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Os-Cal	C				UNKNOWN
			[Therapy Unspecified]	C				UNKNOWN

Date:08/17/05ISR Number: 4746901-6Report Type:Expedited (15-DaCompany Report #AU-MERCK-0502AUS00144
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							
Disability								

Date:08/17/05ISR Number: 4746902-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00141
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4746904-1Report Type:Expedited (15-DaCompany Report #IE-MERCK-0508GBR00065
Age:64 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bone Marrow Depression		Methotrexate	SS		ORAL	14	DAY
	Diarrhoea		Amoxicillin And Clavulanate Potassium	SS		PARENTERAL		
	Retinal Haemorrhage		Acetaminophen And Dihydrocodeine Bitartrate	SS		UNKNOWN		
	Urine Output Decreased		Fluoxetine	SS		UNKNOWN		
			Adalimumab	SS		SUBCUTANEOUS		
			Enalapril Maleate	C		UNKNOWN		
			Allopurinol	C		UNKNOWN		
			Diclofenac Sodium	C		UNKNOWN		
			Rebamipide	C		UNKNOWN		
			Cilnidipine	C		UNKNOWN		
			Amoxicillin And Clavulanate Potassium	C		UNKNOWN		
			Acetaminophen And Dihydrocodeine Bitartrate	C		UNKNOWN		

Date:08/17/05ISR Number: 4747276-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01844
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident							
	Heart Injury							
	Multi-Organ Disorder							
	Organ Failure							
	Pain							
	Polytraumatism							
	Vascular Injury							

Date:08/17/05ISR Number: 4747277-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01535
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	5	YR

Date:08/17/05ISR Number: 4747280-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01967
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery		Vioxx	PS	Merck & Co., Inc	ORAL	35	MON
	Thrombosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747283-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01546
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiac Arrest Cardiac Disorder Lung Disorder Multi-Organ Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747287-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01843
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747298-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01988
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	7	MON

Date:08/17/05ISR Number: 4747299-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00976
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	13	MON

Date:08/17/05ISR Number: 4747300-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00854
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 1174 DAY	Cerebrovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Coronary Artery		Zocor	C		ORAL
Other	Atherosclerosis		Imdur	C		ORAL
	Myocardial Infarction		Flomax			
	Peripheral Vascular		(Morniflumate)	C		
UNKNOWN						
	Disorder		Plavix	C		ORAL
			Atenolol	C		ORAL
			Aspirin	C		ORAL
			Vitamins			
			(Unspecified)	C		ORAL

Date:08/17/05ISR Number: 4747302-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02093
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
	Thrombosis					

Date:08/17/05ISR Number: 4747303-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01985
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
10 MON						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747304-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02012
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON

Date:08/17/05ISR Number: 4747305-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02091
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747306-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0306USA00766
Age:67 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amyotrophy
Disability	Angina Pectoris
Other	Antinuclear Antibody Positive
	Arthralgia
	Asthenia
	Atherosclerosis
	Bursitis
	Cerebral Infarction
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chondromalacia
	Convulsion
	Coronary Artery Disease
	Crepitations
	Diabetes Mellitus Inadequate Control
	Diabetic Complication
	Diabetic Neuropathy
	Diverticulum
	Dizziness
	Ecchymosis
	Eye Injury
	Fall

Fatigue
Gastritis
Gastrointestinal
Haemorrhage
Haemorrhoidal Haemorrhage
Hand Fracture
Hyperglycaemia
Hypertension
Hypotension
Joint Dislocation
Joint Swelling
Ligament Sprain
Limb Injury
Lumbar Radiculopathy
Meniscus Lesion
Muscle Spasms
Myelodysplastic Syndrome
Nerve Injury
Orthostatic Hypotension
Pain In Extremity

	Pancytopenia						
	Pharyngitis						
	Shoulder Pain	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Subcutaneous Abscess		Vioxx	PS	Merck & Co., Inc	ORAL	
	Surgery		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Syncope		Plavix	SS			UNKNOWN
	Tendonitis		Vioxx	SS	Merck & Co., Inc		UNKNOWN
	Thrombosis		Captopril Msd	C		ORAL	
	Upper Respiratory Tract		Evista	C			UNKNOWN
	Infection		Amitriptyline				
	Urinary Tract Infection		Hydrochloride	C			UNKNOWN
	Vertigo		Glucotrol Xl	C			UNKNOWN
			Synthroid	C			UNKNOWN
			Prilosec	C		ORAL	
			Humulin	C			UNKNOWN

Date:08/17/05ISR Number: 4747307-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0508NOR00004
Age:77 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Dyspnoea		Vioxx	PS	Merck & Co., Inc	ORAL	
Initial or Prolonged	Pulmonary Embolism		Levothyroxine Sodium	C		ORAL	
Disability			Clomipramine Hydrochloride	C		ORAL	

Date:08/17/05ISR Number: 4747329-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0207USA01010
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL	6 MON

Initial or Prolonged	Arthritis	Vioxx	SS	Merck & Co., Inc	ORAL
6 MON					
Other	Chest Pain	Baycol	C		
UNKNOWN					
	Claustrophobia	Motrin	C		
UNKNOWN					
	Cold Sweat	Vicodin Tablets	C		
UNKNOWN					
	Contusion				
	Drug Hypersensitivity				
	Dyspnoea				
	Emotional Distress				
	Fall				
	Heart Rate Increased				
	Hyperhidrosis				
	Hypertension				
	Intervertebral Disc Degeneration				
	Intervertebral Disc Protrusion				
	Myocardial Infarction				
	Palpitations				
	Respiratory Disorder				
	Respiratory Rate Increased				
	Rib Fracture				
	Rotator Cuff Syndrome				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747331-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00994
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
	Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		
	Foot Fracture		Propoxyphene					
	Gastrooesophageal Reflux		Napsylate	C		ORAL		
	Disease							
	Joint Injury							
	Myocardial Infarction							
	Road Traffic Accident							

Date:08/17/05ISR Number: 4747332-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01655
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	1	YR
Initial or Prolonged	Basal Cell Carcinoma							
Disability	Cardiac Failure							
Other	Congestive							
	Cardiomyopathy							
	Cerebrovascular Accident							
	Congestive Cardiomyopathy							
	Disability							
	Hepatic Congestion							
	Intervertebral Disc							
	Disorder							
	Malignant Melanoma							
	Myocardial Infarction							
	Nephrolithiasis							
	Pneumonitis							
	Pulmonary Oedema							
	Rash							
	Renal Disorder							
	Respiratory Failure							
	Ventricular Tachycardia							

Date:08/17/05ISR Number: 4747333-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02092
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747334-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02045
Age:66 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Arthropathy
Other	Cardiac Disorder
	Chest Discomfort
	Constipation
	Coronary Artery Atherosclerosis
	Dyspepsia

		Dysphagia Dyspnoea Emotional Distress	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Hypertension		Vioxx	PS	Merck & Co., Inc	ORAL
714	MON						
		Musculoskeletal Chest		Vioxx	SS	Merck & Co., Inc	ORAL
31	DAY						
		Pain		Vioxx	SS	Merck & Co., Inc	ORAL
714	MON						
		Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
31	DAY						
		Nocturia		Lipitor	C		
UNKNOWN							
		Odynophagia		Levoxyl	C		
UNKNOWN							
		Oedema Peripheral		Synthroid	C		
UNKNOWN							
		Stress Incontinence		Ranitidine	C		
UNKNOWN							
				Ambien	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							

Date:08/17/05ISR Number: 4747335-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01840
Age:77 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Abnormal Chest Sound		Vioxx	PS	Merck & Co., Inc	ORAL
1124 DAY						
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL
1124 DAY						
Other	Asthma		Zocor	C		ORAL
	Atherosclerosis		Zantac	C		
UNKNOWN						
	Cardiac Failure		Monopril	C		ORAL
	Congestive		Furosemide	C		
UNKNOWN						
	Carotid Artery Stenosis		Azmacort	C		
UNKNOWN						

	Cataract		Zyrtec	C		
UNKNOWN						
	Coronary Artery Disease					
	Cough					
	Dilatation Atrial					
	Dyspnoea					
	Essential Hypertension					
	Gout					
	Groin Pain					
	Haemorrhoids					
	Herpes Simplex					
	Hypercholesterolaemia					
	Mitral Valve Incompetence					
	Myocardial Infarction					
	Myocardial Ischaemia					
	Rash					
	Tricuspid Valve Incompetence					

Date:08/17/05ISR Number: 4747336-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01842
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Agitation		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Glucose Increased		Aspirin	C				
UNKNOWN								
	Brain Stem Ischaemia		Lipitor	C				
UNKNOWN								
	Feeling Abnormal		Glucophage	C				
UNKNOWN								
	Loss Of Libido		Prevacid	C				
UNKNOWN								
	Neuropathic Pain		Glucotrol	C				
UNKNOWN								
	Sensory Loss		Glucotrol	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747338-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02358
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Dizziness		Ultram	C				
UNKNOWN								
	Emotional Distress		Aspirin	C				
UNKNOWN								
	Hyperhidrosis		Tylenol	C				
UNKNOWN								
	Hypertension							
	Loss Of Consciousness							
	Nephrolithiasis							
	Oesophageal Disorder							
	Vomiting							

Date:08/17/05ISR Number: 4747339-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02119
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Blood Triglycerides Increased							
	Heart Rate Irregular							
	Hypertension							
	Hypertensive Crisis							
	Metabolic Syndrome							
	Myocardial Infarction							
	Pneumonia							
	Rheumatoid Arthritis							
	Silent Myocardial Infarction							
	Swelling							

Date:08/17/05ISR Number: 4747340-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02330
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Myocardial Infarction		Zoloft	C				
UNKNOWN								
			Pravacol	C				
UNKNOWN								
			Xenical	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Toprol Xl Tablets	C				
UNKNOWN								
			Altace	C				
UNKNOWN								
			Vitamins (Unspecified)	C				
UNKNOWN								

Date:08/17/05ISR Number: 4747346-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01519
Age:73 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Carpal Tunnel Syndrome		Tylenol	C				
UNKNOWN								
	Cerebrovascular Accident		Coumadin	C				
UNKNOWN								
	Chest Pain		[Therapy					
	Lung Disorder		Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747347-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01197
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
Other	Arterial Occlusive Disease							
	Back Injury							
	Coronary Artery Occlusion							
	Depression							
	Injection Site Haemorrhage							
	Myocardial Infarction							
	Neck Injury							
	Road Traffic Accident							

Date:08/17/05ISR Number: 4747348-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01520
Age:76 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL		
	Heart Injury		Aspirin	C			UNKNOWN	
			Atenolol	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Flomax (Tamsulosin Hydrochloride)	C			UNKNOWN	

Date:08/17/05ISR Number: 4747349-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01670
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		

	Increased		Skelaxin	C			
UNKNOWN							
	Insomnia						
	Myocardial Infarction						

Date:08/17/05ISR Number: 4747351-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03727
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Chronic Obstructive		Vioxx	PS	Merck & Co., Inc	ORAL	8	MON
Hospitalization -	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	8	MON
Initial or Prolonged	Haemorrhagic Cerebral		Bayer Aspirin	C				
UNKNOWN								
	Infarction		Ultram	C				
UNKNOWN								
	Hypertension		Fosamax	C				
UNKNOWN								
	Syncope							

Date:08/17/05ISR Number: 4747356-8Report Type:Expedited (15-DaCompany Report #AU-MERCK-0506AUS00137
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747357-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01758
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adrenal Adenoma		Vioxx	PS	Merck & Co., Inc	ORAL	3 YR	
Initial or Prolonged	Angina Unstable		Vioxx	SS	Merck & Co., Inc	ORAL	3 YR	
	Anhedonia		Premarin	C			UNKNOWN	
	Aortic Atherosclerosis		Dyazide	C			UNKNOWN	
	Blood Cholesterol		Synthroid	C			UNKNOWN	
	Increased		Aspirin	C			UNKNOWN	
	Blood Lactate		Cytomel	C			UNKNOWN	
	Dehydrogenase Increased							
	Chest Pain							
	Coronary Artery Disease							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							
	Pain							
	Pericardial Effusion							
	Rotator Cuff Syndrome							
	Ventricular Dysfunction							
	Ventricular Hypokinesia							

Date:08/17/05ISR Number: 4747358-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01947
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Fall		Vioxx	PS	Merck & Co., Inc	ORAL	10 DAY	
	Loss Of Consciousness		Vioxx	SS	Merck & Co., Inc	ORAL	10 DAY	
	Pulmonary Embolism		Aspirin	C			UNKNOWN	
	Pulse Absent		Tramadol Hydrochloride	C			UNKNOWN	

			Activella	C			
UNKNOWN							
			Clinoril	C			
UNKNOWN							
			Advil	C			
UNKNOWN							

Date:08/17/05ISR Number: 4747359-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0505DEU00125
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acne		Vioxx	PS	Merck & Co., Inc	ORAL		
153 DAY								
Initial or Prolonged	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Deep Vein Thrombosis		Rabeprazole Sodium	C				
UNKNOWN								
	Exanthem		Minocycline	C				
UNKNOWN								
	Headache		Methotrexate Sodium	C				
UNKNOWN								
	Infection		Methotrexate Sodium	C				
UNKNOWN	153 DAY							
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Methylprednisolone	C				
UNKNOWN								
			Methotrexate Sodium	C				
UNKNOWN								
			Calcium Gluconate And Calcium Phosphate Tribasic And Cholecalciferol	C				
UNKNOWN								
			Meloxicam	C				
UNKNOWN								
			Folic Acid	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747360-XReport Type:Expedited (15-DaCompany Report #DE-MERCK-0508DEU00105
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Osteoarthritis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747361-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01078
Age:87 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
	Aphthous Stomatitis		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
Other	Arthralgia		Xanax	C				UNKNOWN
	Asthenia		Acetaminophen And Hydrocodone Bitartrate	C				UNKNOWN
	Bronchitis							
	Bronchitis Acute							
	Bursitis		Ultram	C				UNKNOWN
	Cataract Operation		Carisoprodol	C				UNKNOWN
	Cerebrovascular Disorder		Darvocet-N	C				UNKNOWN
	Coronary Artery		Premarin	C				UNKNOWN
	Atherosclerosis		Cycrin	C				UNKNOWN
	Coronary Artery Disease		Meclizine	C				UNKNOWN
	Dementia		Zithromax	C				UNKNOWN
	Depression							
	Dysgeusia							
	Dyspepsia							
	Dyspnoea							
	Gastrooesophageal Reflux Disease							
	Generalised Anxiety Disorder							

Headache
Hypertonic Bladder
Hypoacusis
Increased Upper Airway
Secretion
Insomnia
Myocardial Infarction
Pneumonitis
Pulmonary Oedema
Respiratory Disorder
Rhinitis Allergic
Sinusitis
Transient Ischaemic
Attack
Urinary Incontinence
Urinary Tract Infection
Vaginal Mycosis
Vertigo Positional

Date:08/17/05ISR Number: 4747364-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01491
Age:75 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	22 DAY	
Other			Hydrochlorothiazide	C			UNKNOWN	
			Allegra	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/17/05ISR Number: 4747365-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01212
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Road Traffic Accident		Dulcolax	C				
UNKNOWN								

Date:08/17/05ISR Number: 4747366-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01521
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/17/05ISR Number: 4747367-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01502
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Drug Reaction		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Chest Pain		Hydrocodone					
	Depression		Hydrochloride	C				
UNKNOWN								
	Myocardial Infarction		Vicoprofen	C				
UNKNOWN								
	Pneumonia		Soma	C				
UNKNOWN								
			Neurontin	C				
UNKNOWN								
			Amitriptyline Hydrochloride	C				
UNKNOWN								
			Prednisone	C				
UNKNOWN								
			Lortab	C				
UNKNOWN								
			Biaxin	C				
UNKNOWN								

			Panmist Dm	C		
UNKNOWN						
			Tussin Expectorant	C		
UNKNOWN						
			Ultram	C		
UNKNOWN						

Date:08/17/05ISR Number: 4747369-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01191
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cardiac Disorder		Prednisone	C		
UNKNOWN						
	Myocardial Infarction		Imuran (Azathioprine)	C		
UNKNOWN						
			K-Dur	C		
UNKNOWN						
			Prempro	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						

Date:08/17/05ISR Number: 4747370-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00755
Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
1354 DAY						
Initial or Prolonged			Synthroid	C		
UNKNOWN						
			Aricept	C		
UNKNOWN						
			Femhrt	C		
UNKNOWN						
			Quinine Sulfate	C		
UNKNOWN						
			Exelon	C		
UNKNOWN						
			Tussionex			

				(Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex)	C		
UNKNOWN							
				Acetaminophen And Hydrocodone Bitartrate	C		
UNKNOWN							
				Nizoral	C		
UNKNOWN							
				Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN							
				Celebrex	C		
UNKNOWN		540 DAY					
				Lexapro	C		
UNKNOWN							

Date:08/17/05ISR Number: 4747371-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00963
Age:74 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Strangulated Hernia		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Cerebral Infarction		Aciphex	C				
UNKNOWN								
	Depression		Aggrenox	C				
UNKNOWN								
	Diabetes Mellitus		Alprazolam	C				
UNKNOWN								
	Hernia		Ambien	C				
UNKNOWN								
	Nephrolithiasis		Baclofen	C				
UNKNOWN								
	Rotator Cuff Syndrome		Flexeril	C				
UNKNOWN								
			Doxazosin Mesylate	C				
UNKNOWN								
			Doxycycline	C				
UNKNOWN								
			Flomax (Morniflumate)	C				
UNKNOWN								

	Glucotrol	C	
UNKNOWN			
	Guaifenesin	C	
UNKNOWN			
	Lipitor	C	
UNKNOWN			
	Zocor	C	ORAL
	Prevacid	C	
UNKNOWN			
	Quinine Sulfate	C	
UNKNOWN			
	Terazosin Hydrochloride	C	
UNKNOWN			
	Zithromax	C	
UNKNOWN			
	Zoloft	C	
UNKNOWN			
	Aspirin	C	
UNKNOWN			
	Norvasc	C	
UNKNOWN			

Date:08/17/05ISR Number: 4747380-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03417
Age:66 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Balanitis
	Bladder Hypertrophy
	Deep Vein Thrombosis
	Diarrhoea
	Diverticulum
	Dysarthria
	Erectile Dysfunction
	Gastrooesophageal Reflux Disease
	Headache
	Hemiparesis
	Hepatic Cyst
	Hepatic Steatosis

		Hiatus Hernia					
		Hypertension					
		Loss Of Consciousness	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Lumbar Spinal Stenosis		Vioxx	PS	Merck & Co., Inc	ORAL
3	MON						
		Nocturia		Vioxx	SS	Merck & Co., Inc	ORAL
11	MON						
		Pleural Effusion		Vioxx	SS	Merck & Co., Inc	ORAL
3	MON						
		Prostate Cancer		Vioxx	SS	Merck & Co., Inc	ORAL
11	MON						
		Pulmonary Embolism		Zestril	C		
UNKNOWN							
		Pulmonary Hypertension		Soma	C		
UNKNOWN							
		Renal Cyst		Vicodin Tablets	C		
UNKNOWN							
		Right Ventricular Failure		Aleve	C		
UNKNOWN							
		Syncope		Tylenol	C		
UNKNOWN							
		Tremor		Valium	C		
UNKNOWN							
				Xanax	C		ORAL

Date:08/17/05ISR Number: 4747389-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00240
Age:67 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
32	MON						
Initial or Prolonged		Chest Pain					
Other		Transient Ischaemic					
		Attack					

Date:08/18/05ISR Number: 4748085-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02315
Age:65 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						

Hospitalization - 3 YR	Anaemia Postoperative	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged UNKNOWN	Blood Cholesterol	Vioxx	SS	Merck & Co., Inc	
Disability	Increased	Hydroxychloroquine			
Other UNKNOWN	Bradyarrhythmia	Sulfate	C		
	Cardiac Disorder	Atenolol	C		
UNKNOWN					
	Coronary Artery Disease	Omeprazole	C		
UNKNOWN					
	Dyspnoea	Fluocinonide	C		
UNKNOWN					
	Headache	Triamcinolone	C		
UNKNOWN					
	Hyperaemia	Sulfamethoxazole	C		
UNKNOWN					
	Hypertension	Methylprednisolone	C		
UNKNOWN					
	Irritable Bowel Syndrome	Metronidazole	C		
UNKNOWN					
	Myocardial Infarction	Rabeprazole Sodium	C		
UNKNOWN					
	Oesophageal Disorder	Zantac	C		
UNKNOWN					
	Pneumothorax	Sildenafil Citrate	C		
UNKNOWN					
	Sick Sinus Syndrome	Albuterol	C		
UNKNOWN					
	Sleep Disorder	Capsaicin	C		
UNKNOWN					
	Ulcer	Ferrous Sulfate	C		
UNKNOWN					
		Ipratropium Bromide	C		
UNKNOWN					
		Nifedipine	C		
UNKNOWN					
		Ramipril	C		
UNKNOWN					

Date:08/18/05ISR Number: 4748086-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02288
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amnesia
	Anaemia
Other	Anxiety
	Atelectasis
	Biliary Dilatation

		Carotid Artery Stenosis					
		Cerebrovascular Accident					
		Chest Wall Pain	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Chronic Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL
		Complex Partial Seizures		Vioxx	SS	Merck & Co., Inc	ORAL
		Constipation		Vioxx	SS	Merck & Co., Inc	ORAL
		Convulsion		Vioxx	SS	Merck & Co., Inc	ORAL
11	DAY						
		Depression		Plavix	C		ORAL
		Dizziness		Antivert	C		ORAL
		Emotional Distress		Aspirin	C		ORAL
		Fall		Klonopin	C		ORAL
		Gallbladder Disorder		Premarin	C		ORAL
		Granuloma		Trileptal	C		ORAL
		Haematoma		Topamax	C		ORAL
		Insomnia		Synthroid	C		ORAL
		Ischaemic Stroke		Verapamil	C		ORAL
		Joint Injury		Fosamax	C		
UNKNOWN							
		Joint Sprain					
		Lacunar Infarction					
		Liver Function Test					
		Abnormal					
		Migraine Without Aura					
		Myelodysplastic Syndrome					
		Myeloproliferative					
		Disorder					
		Oedema					
		Osteoarthritis					
		Partial Seizures With					
		Secondary Generalisation					
		Pulmonary Granuloma					
		Renal Failure Acute					
		Renal Failure Chronic					
		Restless Legs Syndrome					
		Rib Fracture					
		Sinusitis					
		Skin Oedema					
		Tension Headache					
		Vertigo					

Date:08/18/05ISR Number: 4748088-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02026
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Bladder Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
UNKNOWN	Blindness Unilateral		Toprol Xl Tablets	C				
Disability	Cerebrovascular Accident		Catapres	C				
UNKNOWN							412	DAY
Other	Chest Pain		Premarin	C				
UNKNOWN								
	Cholelithiasis							
	Cough							
	Eye Disorder							
	Eye Haemorrhage							
	Gastroenteritis Viral							
	Hypertension							
	Tooth Abscess							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748089-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01954
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		274 DAY
Initial or Prolonged	Cellulitis		Vioxx	SS	Merck & Co., Inc	ORAL		69 DAY
Disability	Coronary Artery Disease		Furosemide	C				UNKNOWN
Other	Emotional Distress		Singulair	C		ORAL		
	Goitre		Premarin	C				UNKNOWN
								1218 DAY
	Hypermagnesaemia		Ditropan	C				UNKNOWN
	Hypotension		Klor-Con	C				UNKNOWN
	Myocardial Infarction		Captopril	C				UNKNOWN
								1455 DAY
	Neutropenia		Albuterol	C				UNKNOWN
	Renal Failure Acute							
	Sleep Apnoea Syndrome							
	Thrombocytopenia							
	Venous Insufficiency							

Date:08/18/05ISR Number: 4748091-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01352
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL		52 MON
Initial or Prolonged	Breast Cancer		Prempro	C				UNKNOWN
	International Normalised		Tenormin	C				UNKNOWN
	Ratio Increased		Zocor	C				UNKNOWN
	Thrombophlebitis		Tamoxifen Citrate	C				UNKNOWN
	Superficial		Procrit	C				UNKNOWN
			Vitamin B					

(Unspecified) C
UNKNOWN

Date:08/18/05ISR Number: 4748093-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0311USA02115
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Benign Prostatic		Vioxx	SS	Merck & Co., Inc	
UNKNOWN	1 DAY					
Other	Hyperplasia		Monopril	C		
UNKNOWN						
	Body Tinea		Pravachol	C		
UNKNOWN						
	Carpal Tunnel Syndrome		Flexeril	C		
UNKNOWN						
	Coronary Artery					
	Atherosclerosis					
	Diabetes Mellitus					
	Non-Insulin-Dependent					
	Emotional Distress					
	Fatigue					
	Hypersensitivity					
	Overdose					
	Pain In Extremity					
	Pilonidal Cyst					
	Tendonitis					
	Tenosynovitis					
	Trigger Finger					
	Weight Increased					

Date:08/18/05ISR Number: 4748094-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01983
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	16	MON

Date:08/18/05ISR Number: 4748095-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01517
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Chlor-Trimeton	C		ORAL		

Date:08/18/05ISR Number: 4748096-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03993
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction Coronary Artery Disease Coronary Artery Occlusion Diabetes Mellitus Non-Insulin-Dependent		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748097-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA04311
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL	640	DAY
	Myocardial Infarction		Furosemide	C			UNKNOWN	2043 DAY
			Metformin	C			UNKNOWN	

	Nifedipine Er	C
UNKNOWN		
	Quinine	C
UNKNOWN		
	Allegra	C
UNKNOWN		
	Amaryl	C
UNKNOWN		
	Amaryl	C
UNKNOWN		
	Atenol	C
UNKNOWN		
	Bextra	C
UNKNOWN		
	Levoxyl	C
UNKNOWN		
	Magnesium Oxide	C
UNKNOWN		
	Tramadol Msd	C
UNKNOWN		

Date:08/18/05ISR Number: 4748098-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01981
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	SS		ORAL		

Date:08/18/05ISR Number: 4748099-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00991
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Acute Myocardial Infarction
	Back Pain

Nerve Compression
Osteoarthritis

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	845	DAY
	Vioxx	SS	Merck & Co., Inc	ORAL	845	DAY
	Aspirin	C			UNKNOWN	
	Aspirin	C			UNKNOWN	
	Aleve	C			UNKNOWN	
	Advil	C			UNKNOWN	
	Mobic	C			UNKNOWN	
	Accupril	C			UNKNOWN	
	Atacand	C			UNKNOWN	
	Toprol Xl Tablets	C			UNKNOWN	
	Lopressor	C			UNKNOWN	
	Tylenol	C			UNKNOWN	
	Lipitor	C			UNKNOWN	
	Hydrochlorothiazide	C			UNKNOWN	
	Motrin	C			UNKNOWN	

Date:08/18/05ISR Number: 4748100-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01950
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748101-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00748
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		4 YR
Initial or Prolonged	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL		4 YR
	Angina Unstable		Vicodin Tablets	C				UNKNOWN
	Anxiety		Folic Acid	C				UNKNOWN
	Arthropathy		Prevacid	C				UNKNOWN
	Bronchitis		Iron (Unspecified)	C				UNKNOWN
	Cardiac Disorder		Zithromax	C				UNKNOWN
	Coronary Artery Disease		Hydrocodone Bitartrate And Ibuprofen	C				UNKNOWN
	Depression		Ultram	C				UNKNOWN
	Gastrooesophageal Reflux		[Therapy Unspecified]	C				UNKNOWN
	Disease		Prednisone	C				UNKNOWN
	Hepatic Enzyme Increased		Methotrexate	C				UNKNOWN
	Hypertension		Doxepin Hydrochloride	C				UNKNOWN
	Myocardial Infarction		Zyrtec	C				UNKNOWN
	Pain In Extremity							
	Pyrexia							
	Tremor							

Date:08/18/05ISR Number: 4748102-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01505
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Back Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		1043 DAY
Initial or Prolonged	Cerebrovascular Accident		Methotrexate	C				UNKNOWN

Folic Acid C

Synthroid C

UNKNOWN

UNKNOWN

				Arava	C		
UNKNOWN							
				Leucovorin Calcium	C		
UNKNOWN							

Date:08/18/05ISR Number: 4748103-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02124
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		51 MON
Initial or Prolonged	Blood Cholesterol		Relafen	C				
UNKNOWN								
	Increased		Pamine Bromide	C				
UNKNOWN								
	Myocardial Infarction		Nexium	C				
UNKNOWN								
			Desoximetasone	C				
UNKNOWN								
			Alprazolam	C				
UNKNOWN								
			Hydroxyzine Hydrochloride	C				
UNKNOWN								
			Dovonex	C				
UNKNOWN								
			Triamcinolone	C				
UNKNOWN								
			Prilosec	C				
UNKNOWN								
			Isosorbide	C				
UNKNOWN								
			Cozaar	C				
UNKNOWN								

Date:08/18/05ISR Number: 4748104-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00237
Age:82 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Potassium Increased		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Bradycardia		Vioxx	SS	Merck & Co., Inc	ORAL	
5 MON							
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL	
	Diverticulitis		Vioxx	SS	Merck & Co., Inc	ORAL	
5 MON							
	Fall		Celebrex	C			
UNKNOWN							
	Hyperhidrosis		Tylenol	C			
UNKNOWN							
	Hypotension						
	Myocardial Infarction						

Date:08/18/05ISR Number: 4748105-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01309
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cough		Toprol Xl Tablets	C				
UNKNOWN								
Other	Depression		Diovan	C				
UNKNOWN								
	Diabetes Mellitus		Tylenol	C				
UNKNOWN								
	Dyspepsia		Paxil	C				
UNKNOWN								
	Dyspnoea		Buspar	C				
UNKNOWN								
	Dysuria		Potassium Chloride	C				
UNKNOWN								
	Hyperkalaemia		Hydrochlorothiazide	C				
UNKNOWN								
	Hypertension		Klonopin	C				
UNKNOWN								
	Insomnia		Aspirin	C				
UNKNOWN								
	Meniere'S Disease							
	Myocardial Infarction							
	Osteoporosis							
	Panic Attack							
	Periarthritis							
	Shoulder Pain							
	Upper Respiratory Tract Infection							
	Ventricular Extrasystoles							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748106-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02345
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748107-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00369
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	62 MON	
Initial or Prolonged	Infarction		Methocarbamol	C			UNKNOWN	
	Blood Cholesterol		Prevacid	C			UNKNOWN	
	Increased		Fosamax	C			UNKNOWN	
	Cardiac Disorder		Alprazolam	C			UNKNOWN	
	Heart Rate Irregular		Acetaminophen	C			UNKNOWN	
	Hypertension		Zithromax	C			UNKNOWN	
			[Therapy Unspecified]	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Prilosec	C			UNKNOWN	
			Propranolol Hydrochloride	C			UNKNOWN	
			Aciphex	C			UNKNOWN	
			Cipro	C			UNKNOWN	
			Atropine Sulfate And Diphenoxylate Hydrochloride	C			UNKNOWN	

			Prednisolone	C	UNKNOWN
			Mobic	C	UNKNOWN
			Zebutal	C	UNKNOWN
			Quinine Sulfate	C	UNKNOWN
			Diphenhydramine Hydrochloride	C	UNKNOWN
			Tequin	C	UNKNOWN
			Aspirin	C	UNKNOWN
			Tylenol	C	UNKNOWN
			Naprosyn	C	UNKNOWN
UNKNOWN	61	MON	Bextra	C	UNKNOWN
UNKNOWN	61	MON	Celebrex	C	UNKNOWN
UNKNOWN	61	MON	Xanax	C	UNKNOWN

Date:08/18/05ISR Number: 4748108-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03806
Age:64 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	20 MON	
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL	20 MON	
	Migraine		Verapamil	C			UNKNOWN	
	Myocardial Infarction		Fosamax	C			UNKNOWN	
	Pain		Hyoscyamine	C			UNKNOWN	
	Pain In Extremity							

Date:08/18/05ISR Number: 4748109-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01175
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Cerebrovascular Accident
	Transient Ischaemic

Attack

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL		
	Fosinopril Sodium	C			UNKNOWN	
	Amoxicillin	C			UNKNOWN	
	Amantadine Hydrochloride	C			UNKNOWN	

Date:08/18/05ISR Number: 4748110-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01170
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748111-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01982
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748112-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02112
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748113-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02387
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Failure		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR
	Cardiomyopathy							
	Coronary Artery Stenosis							

Date:08/18/05ISR Number: 4748114-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02086
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Injury							

Date:08/18/05ISR Number: 4748115-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02077
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON
	Cardiac Disorder							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748116-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01979
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748117-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02104
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	32	MON

Date:08/18/05ISR Number: 4748118-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02388
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Death		Vioxx	PS	Merck & Co., Inc	ORAL	3	YR

Date:08/18/05ISR Number: 4748119-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02113
Age:58 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748129-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01987
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Coronary Artery Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	56	MON

Date:08/18/05ISR Number: 4748130-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02011
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748131-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02386
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Polytraumatism		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON

Date:08/18/05ISR Number: 4748140-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01980
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748315-1Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00075
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Deafness		Vioxx	PS	Merck & Co., Inc	ORAL		312 DAY
Initial or Prolonged	Dizziness							
Disability	Granuloma							
Other	Haemorrhage							
	Inflammation							
	Sudden Hearing Loss							
	Tinnitus							
	Tooth Extraction							
	Tracheobronchitis							

Date:08/18/05ISR Number: 4748317-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01232
Age:59 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blindness		Vioxx	PS	Merck & Co., Inc	ORAL		1005 DAY
Initial or Prolonged	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		1005 DAY
Disability	Blood Cholesterol		Methotrexate	C				UNKNOWN
	Increased		Prednisone	C				UNKNOWN
	Chest Pain		Prednisone	C				UNKNOWN
	Colonic Polyp		Prevacid	C				UNKNOWN
	Dilatation Atrial		Diflunisal	C				UNKNOWN
	Fat Embolism							
	Headache							
	Hypertension							
	Retinal Artery Embolism							
	Retinal Artery Occlusion							
	Retinal Haemorrhage							
	Thrombosis							
	Transient Ischaemic Attack							

Date:08/18/05ISR Number: 4748318-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01932
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		12 MON
Initial or Prolonged	Blood Cholesterol		Diovan	C				UNKNOWN
Other	Increased		Synthroid	C				UNKNOWN
	Cerebrovascular Accident		Amitriptyline Hydrochloride	C				UNKNOWN
	Gastroenteritis		Glucovance	C				UNKNOWN
	Gastrooesophageal Reflux		Nifedipine	C				UNKNOWN
	Disease		Menest	C				UNKNOWN
	Hypertension		Amaryl	C				UNKNOWN
	Neuropathy Peripheral		Actos	C				UNKNOWN
	Paraesthesia		Pravachol	C				UNKNOWN
	Transient Ischaemic		Celexa	C				UNKNOWN
	Attack		Zetia	C		ORAL		
			Diazepam	C				UNKNOWN
			Lonox	C				UNKNOWN
			Metformin	C				UNKNOWN

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748319-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01962
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		689 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		689 DAY
Disability	Increased		Nasacort	C				UNKNOWN
Other	Carotid Artery Disease		Acetaminophen And Propoxyphene Napsylate	C				UNKNOWN
	Cerebrovascular Accident							
	Convulsion							
	Depression		Cephalexin	C				UNKNOWN
	Embolism		Claritin	C				UNKNOWN
			Allegra	C				UNKNOWN
			Premarin	C				UNKNOWN
			Lamisil	C				UNKNOWN
			Prednisone	C				UNKNOWN
			Provera	C				UNKNOWN

Date:08/18/05ISR Number: 4748320-5Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00487
Age:56 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Valve Incompetence		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Back Pain		Vioxx	SS	Merck & Co., Inc	ORAL		
	Blood Pressure Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Dizziness							
	Hyperhidrosis							
	Nausea							

Date:08/18/05ISR Number: 4748323-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA03234
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		978 DAY
	Hypertension							
	Paraplegia							
	Spinal Cord Infarction							
	Spinal Cord Ischaemia							
	Syncope							
	Transient Ischaemic Attack							

Date:08/18/05ISR Number: 4748330-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02136
Age:62 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		UNKNOWN
			Premarin	C				
	Coronary Artery Disease							
	Dyspepsia							
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748331-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02645
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Back Injury		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bone Lesion		Ultracet	C			UNKNOWN	
	Bronchitis		Ultracet	C			UNKNOWN	
	Cataract		Ortho Tri-Cyclen	C			UNKNOWN	
	Cerebrovascular Accident		Lexapro	C			UNKNOWN	
	Cervicobrachial Syndrome		Claritin	C			UNKNOWN	
	Chest Pain							
	Depression							
	Eye Swelling							
	Factor V Leiden Mutation							
	Fatigue							
	Headache							
	Joint Injury							
	Lacunar Infarction							
	Meniscus Lesion							
	Myositis							
	Neck Pain							
	Photopsia							
	Sinusitis							
	Spinal Osteoarthritis							
	Syncope							
	Synovitis							
	Tracheobronchitis							
	Ulnar Nerve Injury							
	Vision Blurred							

Date:08/18/05ISR Number: 4748332-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01945
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	31 MON	
	Increased		Propoxyphene					

	Myocardial Infarction	Hydrochloride	C
UNKNOWN			
		Catapres	C
UNKNOWN			
		Lescol	C
UNKNOWN			
		Wellbutrin	C
UNKNOWN			
		Duradrin	C
UNKNOWN			
		Methylprednisolone	C
UNKNOWN			
		Carisoprodol	C
UNKNOWN			
		Hydroxyzine Hydrochloride	C
UNKNOWN			
		Ultracet	C
UNKNOWN			
		Fiorinal	C
UNKNOWN			
		Librium	C
UNKNOWN			
		Augmentin	C
UNKNOWN			
		Prilosec	C
UNKNOWN			
		Zyrtec	C
UNKNOWN			
		Analgesic Or Anesthetic (Unspecified)	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748333-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02699
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		1764 DAY
Initial or Prolonged	Anxiety		Zoloft	C		ORAL		1670 DAY
Disability	Atherosclerosis		Ultram	C		ORAL		191 DAY
	Cerebrovascular Accident		Tylenol	C		ORAL		
	Gastrooesophageal Reflux Disease		Amitriptylin	C		ORAL		1186 DAY
	Mitral Valve Prolapse							
	Musculoskeletal Disorder							
	Near Drowning							
	Transient Ischaemic Attack							

Date:08/18/05ISR Number: 4748336-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02193
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Atherosclerosis		Tenormin	C		ORAL		1477 DAY
	Blood Cholesterol		Tenormin	C		ORAL		1477 DAY
	Increased		Tenormin	C		ORAL		1477 DAY
	Carpal Tunnel Syndrome		Tenormin	C		ORAL		1477 DAY
	Coronary Artery Disease		Percocet	C		ORAL		
	Gastrooesophageal Reflux Disease							
	Myocardial Infarction							
	Nausea							

Date:08/18/05ISR Number: 4748337-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02981
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	147 DAY	
Hospitalization - Initial or Prolonged	Infarction		Norvasc	C			UNKNOWN	
	Anhedonia		Allegra	C			UNKNOWN	
	Anxiety		Wellbutrin	C			UNKNOWN	
	Emotional Distress		Trazodone Hydrochloride	C			UNKNOWN	
	Pain		Aspirin	C			UNKNOWN	
			Avapro	C			UNKNOWN	

Date:08/18/05ISR Number: 4748338-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02028
Age:46 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Acute Respiratory Failure
Disability	Adjustment Disorder With Mixed Disturbance Of Emotion And Conduct
	Anaemia
	Anoxic Encephalopathy
	Arthritis Infective
	Chest Pain
	Chondromatosis

		Depression					
		Essential Hypertension					
		Gastrooesophageal Reflux	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Disease		Vioxx	PS	Merck & Co., Inc	ORAL
109 DAY							
		Hypoxia		Paxil	C		
UNKNOWN							
		Infection					
		Mental Status Changes					
		Myocardial Infarction					
		Oedema Peripheral					
		Orthostatic Hypotension					
		Pancreatitis Acute					
		Pneumonia					
		Renal Failure Acute					
		Renal Failure Chronic					
		Rhabdomyolysis					
		Seborrhoeic Dermatitis					
		Septic Shock					
		Staphylococcal Infection					
		Thrombophlebitis					
		Superficial					

Date:08/18/05ISR Number: 4748339-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02038
Age:84 YR Gender:Female I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Other		Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Disorder		[Therapy			
		Depression		Unspecified]	C		
UNKNOWN							
		Dizziness					
		Drug Ineffective					
		Dyspepsia					
		Flatulence					
		Loss Of Consciousness					
		Myocardial Infarction					
		Oedema Peripheral					
		Polytraumatism					
		Post-Traumatic Stress					
		Disorder					

Date:08/18/05ISR Number: 4748340-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02117
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		747 DAY
Initial or Prolonged	Angina Pectoris		Ventolin (Albuterol)	C				UNKNOWN
Other	Angina Unstable		Atrovent	C				UNKNOWN
	Aortic Valve Incompetence		Augmentin	C				UNKNOWN
	Asthma		Ceftin	C				UNKNOWN
	Chest Pain		Celebrex	C				UNKNOWN
	Chronic Obstructive		Cipro	C				UNKNOWN
	Pulmonary Disease		Clindamycin	C				UNKNOWN
	Coronary Artery Disease		Cogentin	C				UNKNOWN
	Gallbladder Disorder		Clonazepam	C				UNKNOWN
	Hypokalaemia		Clonazepam	C				UNKNOWN
	Myocardial Infarction		Clonidine	C				UNKNOWN
	Postoperative Infection		[Therapy Unspecified]	C				UNKNOWN
	Refusal Of Treatment By Patient		Cortatrigen	C				UNKNOWN
			Depakote	C				UNKNOWN

	Doxycycline	C
UNKNOWN		
	Lasix (Furosemide)	C
UNKNOWN		
	Lasix (Furosemide)	C
UNKNOWN		
	Hydrocodone Bitartrate	C
UNKNOWN		
	[Therapy Unspecified]	C
UNKNOWN		
	Levaquin	C
UNKNOWN		
	Lorazepam	C
UNKNOWN		
	Macrobid	C
UNKNOWN		
	Medroxyprogesterone Acetate	C
UNKNOWN		
	Miacalcin	C
UNKNOWN		
	Mobic	C
UNKNOWN		
	Nasonex	C
UNKNOWN		
	Neurontin	C
UNKNOWN		
	Penicillin (Unspecified)	C
UNKNOWN		
	Premarin	C
UNKNOWN		
	Prempro	C
UNKNOWN		
	Promethazine	C
UNKNOWN		
	Ranitidine	C
UNKNOWN		
	Seroquel	C
UNKNOWN		
	Serzone	C
UNKNOWN		
	Serzone	C
UNKNOWN		

			Zestril	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Zoloft	C		
UNKNOWN						
			Zyprexa	C		
UNKNOWN						
			Ibuprofen	C		
UNKNOWN						
			Ultracet	C		
UNKNOWN						
			Roxicet	C		
UNKNOWN						
			Navane	C		
UNKNOWN						
			Navane	C		
UNKNOWN						
			Lanoxin	C		
UNKNOWN						
			Nitro-Spray	C		
UNKNOWN						
			Prilosec	C		
UNKNOWN						
			Fosamax	C		
UNKNOWN						
			[Therapy Unspecified]	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						
			Prednisone	C		
UNKNOWN						
			Aspirin	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						

Date:08/18/05ISR Number: 4748341-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01997
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abscess Of Eyelid		Vioxx	PS	Merck & Co., Inc	ORAL		425 DAY
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		425 DAY
	Increased		Clarinex	C				UNKNOWN
	Cyst							
	Myocardial Infarction							

Polytraumatism
Rotator Cuff Syndrome

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748342-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02360
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Convulsion							
	Depression							
	Hypertension							
	Subarachnoid Haemorrhage							

Date:08/18/05ISR Number: 4748343-6Report Type:Expedited (15-DaCompany Report #DE-MERCK-0412DEU00209
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Asthenia		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization -	Chest Discomfort		Oxybutynin Chloride	C		ORAL		
Initial or Prolonged	Coronary Artery Disease		Amantadine Sulfate	C		ORAL		
Disability	Depression		Levocarnitine					
Other	Dyspepsia		Tartrate	C				
UNKNOWN								
	Dysphagia		Sodium Lauryl					
	Dyspnoea		Sulfoacetate	C				
RECTAL								
	Hypertension							
	Intervertebral Disc							
	Protrusion							
	Multiple Sclerosis							
	Myocardial Infarction							

Date:08/18/05ISR Number: 4748344-8Report Type:Expedited (15-DaCompany Report #DE-MERCK-0411DEU00111
Age:67 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
	Balance Disorder		Hydrochlorothiazide					
	Carotid Artery Aneurysm		And Triamterene	C		ORAL		
	Cerebral Haemorrhage		Potassium					

Cerebrovascular Accident	Bicarbonate And Potassium Citrate	C	ORAL
Dizziness	Thyroid	C	ORAL
Eye Disorder	Bisoprolol Fumarate	C	ORAL
General Physical Health Deterioration	Medicinalproduct Not Specified By Sender	C	ORAL
Headache	Medicinalproduct Not Specified By Sender	C	ORAL
Nausea	Medicinalproduct Not Specified By Sender	C	ORAL
Subarachnoid Haemorrhage	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL
	Medicinalproduct Not Specified By Sender	C	ORAL

			Medicinalproduct Not Specified By Sender	C		ORAL

Date:08/18/05ISR Number: 4748346-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02310
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 494 YR	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 494 YR	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Disability	Back Pain		Acetaminophen And Propoxyphene Napsylate	C		
UNKNOWN	Cerebrovascular Accident					
	Chest Pain					
UNKNOWN	Colitis		Panmist Dm	C		
UNKNOWN	Depression		Alprazolam	C		
UNKNOWN	Duodenitis		Ambien	C		
UNKNOWN	Dyspnoea		Prednisone	C		
UNKNOWN	Emotional Distress		Prevacid	C		
UNKNOWN	Enteritis		Levaquin	C		
UNKNOWN	Fibromyalgia		Celexa	C		
UNKNOWN	Gastric Ulcer		Cyclobenzaprine Hydrochloride	C		
	Gastritis Erosive					
UNKNOWN	Gastrooesophageal Reflux		Avelox	C		
UNKNOWN	Disease		Prozac	C		
UNKNOWN	Haemorrhoids		Furosemide	C		
UNKNOWN	Hypertensive Crisis		Furosemide	C		
UNKNOWN	Hypoaesthesia		Serzone	C		
UNKNOWN	Irritable Bowel Syndrome		Serzone	C		
UNKNOWN						

	Migraine With Aura		Estrogens			
	Oesophagitis		(Unspecified)	C		
UNKNOWN		3 MON				
	Optic Ischaemic		Atenolol	C		
UNKNOWN						
	Neuropathy		Atenolol	C		
UNKNOWN						
	Pain In Extremity					
	Scotoma					
	Sinus Tachycardia					
	Sinusitis					
	Swelling					
	Ulcer					
	Vision Blurred					

Date:08/18/05ISR Number: 4748347-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03956
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abnormal Clotting Factor		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Cardiac Murmur		Vioxx	SS	Merck & Co., Inc	ORAL		
16 DAY								
Disability	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
16 DAY								
	Disturbance In Attention		Levoxyl	C				
UNKNOWN								
	Fall							
	Hyperlipidaemia							
	Hypertension							
	Joint Dislocation							
	Lacunar Infarction							
	Mitral Valve Incompetence							
	Mitral Valve Prolapse							
	Transient Ischaemic							
	Attack							
	Upper Limb Fracture							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748348-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03116
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Depression		Vioxx	PS	Merck & Co., Inc	ORAL		66 MON
Initial or Prolonged	Haemorrhage		Vioxx	SS	Merck & Co., Inc	ORAL		
	Post Procedural		Aciphex	C				UNKNOWN
	Haemorrhage		Ambien	C				UNKNOWN
	Transient Ischaemic Attack							

Date:08/18/05ISR Number: 4748349-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02562
Age: Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Accupril	C				UNKNOWN

Date:08/18/05ISR Number: 4748350-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01941
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		6 MON
Initial or Prolonged	Myocardial Infarction		Aspirin	C		ORAL		
Other			Lipitor	C				UNKNOWN
			Zocor	C				UNKNOWN
			Atenolol	C				UNKNOWN
			Cardizem	C				UNKNOWN
			Plavix	C				UNKNOWN

				Naprosyn	C		
UNKNOWN		619 DAY					
				Pravachol	C		
UNKNOWN							
				Zantac	C		
UNKNOWN							

Date:08/18/05ISR Number: 4748351-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01946
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Arthritis		Vioxx	PS	Merck & Co., Inc	ORAL	1137 DAY	
	Bunion		Vioxx	SS	Merck & Co., Inc	ORAL	976 DAY	
	Chronic Obstructive		Vioxx	SS	Merck & Co., Inc	ORAL	1137 DAY	
	Pulmonary Disease		Vioxx	SS	Merck & Co., Inc	ORAL	976 DAY	
	Constipation		Hydroxyzine					
	Dysphagia		Hydrochloride	C			UNKNOWN	
	Gastrooesophageal Reflux		Methocarbamol	C			UNKNOWN	
	Disease		Avelox	C			UNKNOWN	
	Hypertension		Clindamycin	C			UNKNOWN	
	Hypertensive Heart		Claritin-D 12 Hour	C			UNKNOWN	
	Disease		Prozac	C			UNKNOWN	
	Myocardial Infarction		Lotrel	C			UNKNOWN	
	Nervous System Disorder		Zithromax	C			UNKNOWN	
	Pulmonary Fibrosis		Fiortal	C			UNKNOWN	
	Skin Cancer		Beconase Aq	C			UNKNOWN	
			Hydrocodone/Apap	C			UNKNOWN	
			Furosemide	C			UNKNOWN	
			Chlorazepate	C			UNKNOWN	
			Estratest	C			UNKNOWN	
			Promethazine	C			UNKNOWN	

Promethazine C

UNKNOWN

Hydrochlorothiazide

UNKNOWN	Tablets (Usp 23)	C
UNKNOWN	Triaminicin Tablets	C
UNKNOWN	Nystatin Usp (Paddock)	C
UNKNOWN	Diflucan	C
UNKNOWN	Prevacid	C
UNKNOWN	Actonel	C
UNKNOWN	Pepcid	C
UNKNOWN	Syntest Ds	C
UNKNOWN	Methadone Hcl	C
UNKNOWN	Tramadol Msd	C
UNKNOWN	Lexapro	C
UNKNOWN	Biaxin	C
UNKNOWN	Ambien	C
UNKNOWN	Temazepam	C
UNKNOWN	Nulytely	C
UNKNOWN	Levaquin	C
UNKNOWN	Atuss Hc	C
UNKNOWN	Skelaxin	C
UNKNOWN	Fluoxetine	C
UNKNOWN	Prednisone	C
UNKNOWN	Ketoconazole	C
UNKNOWN	Cefzil	C
UNKNOWN	Zithromax	C
UNKNOWN		

			Cytuss Hc	C		
UNKNOWN						
			Macrobid	C		
UNKNOWN						
			Phenazopyridine Hydrochloride	C		
UNKNOWN						
			Cipro	C		
UNKNOWN						
			Bactroban	C		
UNKNOWN						
			Cozaar	C		
UNKNOWN						
			Allegra-D	C		
UNKNOWN						

Date:08/18/05ISR Number: 4748352-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02275
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Carotid Artery Occlusion		Vioxx	SS	Merck & Co., Inc	ORAL
33 MON						
	Cerebrovascular Accident		Lipitor	C		
UNKNOWN						
	Renal Disorder		Aspirin	C		
UNKNOWN						
			Avapro	C		
UNKNOWN						
			Lopressor	C		
UNKNOWN						
			Procardia	C		
UNKNOWN						

Date:08/18/05ISR Number: 4748354-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA05004
Age:48 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Carotid Artery Dissection		Vioxx	PS	Merck & Co., Inc	ORAL
23 MON						
Initial or Prolonged	Cerebrovascular Accident		Vioxx	SS	Merck & Co., Inc	ORAL
23 MON						
Disability	Depression		Fiorinal	C		
UNKNOWN						
	Fall		Darvocet-N	C		
UNKNOWN						

	Haematemesis	Amoxicillin	C
UNKNOWN			
	Headache	Tylenol	C
UNKNOWN			
	Hypertension	Flexeril	C
UNKNOWN			
	Otitis Media		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748359-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02105
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748360-6Report Type:Expedited (15-DaCompany Report #NO-MERCK-0508NOR00005
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Balance Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Deafness Unilateral		Levothyroxine Sodium	C		ORAL		
Disability	Dizziness		Tibolone	C				
UNKNOWN								
	Meniere'S Disease		Simvastatin	C		ORAL		
	Vertigo							

Date:08/18/05ISR Number: 4748361-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02114
Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748362-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01925
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748363-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA02962
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		

Initial or Prolonged	Ankle Fracture	Imdur	C
UNKNOWN			
Disability	Cardiac Murmur	Altace	C
UNKNOWN			
	Cerebrovascular Accident	Lopressor	C
UNKNOWN			
	Diabetes Mellitus	Avandia	C
UNKNOWN			
	Hypertension		

Date:08/18/05ISR Number: 4748364-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00084
Age:66 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Diabetes Mellitus		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Dyazide	C				
UNKNOWN								
	Periarthritis							

Date:08/18/05ISR Number: 4748365-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00861
Age:41 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Adverse Event
Initial or Prolonged	Angina Pectoris
	Angina Unstable
	Cardiac Disorder

	Coronary Artery Disease Myocardial Infarction Road Traffic Accident	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL	31	MON
			Vioxx	SS	Merck & Co., Inc	ORAL	31	MON
			Advil	C			UNKNOWN	
			Motrin	C			UNKNOWN	
			Lipitor	C			UNKNOWN	
			Hyzaar	C		ORAL		
			Prednisone	C			UNKNOWN	
			Zithromax	C			UNKNOWN	
			Flexeril	C			UNKNOWN	
			Zocor	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

Date:08/18/05ISR Number: 4748366-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03032
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Local Swelling		Vioxx	PS	Merck & Co., Inc	ORAL		
	Musculoskeletal Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Fosamax	C		ORAL		
	Sleep Disorder		Calcium (Unspecified)	C			UNKNOWN	

Date:08/18/05ISR Number: 4748367-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01210
Age:42 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Fibromyalgia		Xanax	C		
UNKNOWN						
Disability			Lortab	C		
UNKNOWN						

Date:08/18/05ISR Number: 4748368-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA03031
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Death	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Renal Failure		Synthroid	C		
UNKNOWN						
Initial or Prolonged	Thrombocytopenic Purpura		Accupril	C		
UNKNOWN						
			Toprol Xl Tablets	C		
UNKNOWN						
			Allopurinol	C		ORAL
			Nifedipine	C		
UNKNOWN						
			Bumetanide	C		
UNKNOWN						
			Catapres	C		
UNKNOWN						

Date:08/18/05ISR Number: 4748371-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01512
Age:48 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Chest Pain					
Disability	Hypertension					
	Joint Injury					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748372-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02087
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Atrioventricular Block		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748373-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02106
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748374-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02124
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748375-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02126
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748376-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02084
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	4	MON

Date:08/18/05ISR Number: 4748377-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01630
Age:33 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cough		Vioxx	PS	Merck & Co., Inc	ORAL	3	MON
	Depression		Zoloft	C		ORAL		
	Dyspnoea		Ultracet	C		ORAL		
	Gastrooesophageal Reflux Disease		Celebrex	C		ORAL		
	Post-Traumatic Stress Disorder							
	Pulmonary Embolism							
	Stomach Discomfort							

Date:08/18/05ISR Number: 4748378-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02078
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Carotid Artery Occlusion		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Myocardial Infarction							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748379-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02115
Age:19 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748381-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02081
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/18/05ISR Number: 4748382-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02631
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	60 DAY	

Date:08/18/05ISR Number: 4748384-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02627
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cerebrovascular Accident Injury Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	19 MON	

Date:08/18/05ISR Number: 4748385-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02932
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
673 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL
			Vioxx	SS	Merck & Co., Inc	ORAL
673 DAY						
			Vioxx	SS	Merck & Co., Inc	ORAL

Date:08/18/05ISR Number: 4748386-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02389
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
5 MON						
	Polytraumatism					

Date:08/18/05ISR Number: 4748387-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02390
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL
30 MON						
	Polytraumatism					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/18/05ISR Number: 4748388-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02214
Age:56 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		265 DAY
Initial or Prolonged	Dehydration		Vioxx	SS	Merck & Co., Inc	ORAL		265 DAY
Other	Dizziness		Floxin	C				UNKNOWN
	Ear Infection		Augmentin	C				UNKNOWN
	Fall		Zyrtec	C				UNKNOWN
	Hypovolaemia		Norvasc	C				UNKNOWN
	Loss Of Consciousness		Aspirin	C				UNKNOWN
	Myocardial Infarction		Celexa	C				UNKNOWN
	Neck Mass		Albuterol	C				UNKNOWN
	Orthostatic Hypotension							
	Palpitations							
	Syncope							

Date:08/18/05ISR Number: 4748390-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02345
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4748928-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00578
Age:61 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		423 DAY
Initial or Prolonged	Blood Triglycerides		Vioxx	SS	Merck & Co., Inc	ORAL		423 DAY

	Increased		Maxzide	C		ORAL
	Deep Vein Thrombosis		Synthroid	C		ORAL
	Gastrooesophageal Reflux Disease		Tylenol	C		ORAL
	Shoulder Pain					

Date:08/19/05ISR Number: 4748929-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01925
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		942 DAY
Hospitalization - Initial or Prolonged	Atrial Fibrillation		Elavil	C		ORAL		
	Cardio-Respiratory Arrest		Prilosec	C		ORAL		
	Cerebrovascular Accident		Potassium Chloride	C		ORAL		
	Convulsion		Coumadin	C			UNKNOWN	
	Loss Of Consciousness		Lanoxin	C		ORAL		
	Pyrexia		Lasix (Furosemide)	C		ORAL		
			Coreg	C		ORAL		
			Tegretol	C		ORAL		
			Baclofen	C		ORAL		
			Zoloft	C		ORAL		
			Avapro	C		ORAL		

Date:08/19/05ISR Number: 4748930-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA03487
Age:53 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

Disability

PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Abdominal Pain Lower		Vioxx	PS	Merck & Co., Inc	ORAL		
Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Aspartate		Synthroid	C				
Aminotransferase Increased						UNKNOWN	
Back Disorder							
Colitis Ischaemic							
Deep Vein Thrombosis							
Depression							
Diverticulum							
Dyspnoea							
Gastric Ulcer Haemorrhage							
Gastrointestinal Disorder							
Gastrooesophageal Reflux Disease							
Hiatus Hernia							
High Density Lipoprotein Decreased							
Hypertension							
Influenza							
Insomnia							
Intervertebral Disc Degeneration							
Intervertebral Disc Protrusion							
Leukocytosis							
Migraine							
Osteoarthritis							
Post-Traumatic Stress Disorder							
Pulmonary Embolism							

Date:08/19/05ISR Number: 4748932-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00837
Age:51 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Angina Unstable
Disability	Ankle Fracture
Other	Atherosclerosis
	Blood Cholesterol

Increased
Blood Triglycerides
Increased
Cardiac Failure
Congestive
Cardiac Valve Disease
Chest Discomfort
Chest Pain
Chronic Fatigue Syndrome
Chronic Obstructive
Pulmonary Disease
Coronary Artery Disease
Diabetes Mellitus
Drug Hypersensitivity
Dyspepsia
Dyspnoea
Fatigue

		Gastrointestinal Disorder					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Heart Disease Congenital		Vioxx	PS	Merck & Co., Inc	ORAL
14	MON						
		Heart Rate Irregular		Aspirin	C		ORAL
		Homocystinaemia		Isosorbide			
		Hypertension		Mononitrate	C		ORAL
		Hypokalaemia		Zocor	C		ORAL
		Hypoxia		Sular	C		ORAL
		Left Ventricular Failure		Hydrochlorothiazide	C		ORAL
		Myocardial Infarction		Micro K	C		ORAL
		Nodal Arrhythmia		Pepcid	C		ORAL
		Panic Disorder					
		Peripheral Vascular Disorder					
		Post-Traumatic Stress Disorder					
		Silent Myocardial Infarction					

Date:08/19/05ISR Number: 4748935-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0410USA01023
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Arterial Occlusive		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Disease		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Myocardial Infarction		Combivent	C		
UNKNOWN						
Disability			Paxil	C		
UNKNOWN						
			Guaifenesin	C		
UNKNOWN						
			Darvocet-N	C		
UNKNOWN						
			Allegra	C		
UNKNOWN						

Date:08/19/05ISR Number: 4748943-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03178
Age:32 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Amenorrhoea
Disability	Back Pain
	Blindness
	Blood Triglycerides Increased
	Bronchitis
	Cerebral Haemorrhage
	Cerebrovascular Accident
	Constipation
	Deep Vein Thrombosis
	Disturbance In Attention
	Dizziness
	Drug Abuser
	Ecchymosis
	Epistaxis
	Eye Haemorrhage
	Headache
	Hypoaesthesia
	Hypothyroidism
	Infertility
	Lice Infestation
	Migraine
	Muscle Spasms

		Nerve Injury					
		Oedema					
		Osteoarthritis	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Overdose		Vioxx	PS	Merck & Co., Inc	ORAL
41	MON						
		Pneumonia		Vioxx	SS	Merck & Co., Inc	ORAL
41	MON						
		Productive Cough		Percocet	C		ORAL
		Sinusitis		Xanax	C		ORAL
		Superior Sagittal Sinus		Amoxicillin	C		ORAL
		Thrombosis					
		Thrombosis					
		Tooth Infection					
		Transient Ischaemic					
		Attack					
		Transverse Sinus					
		Thrombosis					
		Uterine Disorder					
		Weight Increased					

Date:08/19/05ISR Number: 4748946-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA00693
Age:63 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization -		Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Infarction		Aspirin	C		
UNKNOWN							
		Chest Pain		Actos	C		
UNKNOWN							
		Coronary Artery Disease		Micronase	C		
UNKNOWN							
		Coronary Artery Occlusion		Klotrix	C		
UNKNOWN							
		Depression		Pravachol	C		
UNKNOWN							
		Hypokalaemia		Axid	C		
UNKNOWN							
		Hypomagnesaemia		Tenoretic	C		
UNKNOWN							
		Sinusitis		Claritin	C		
UNKNOWN							
				Furosemide	C		
UNKNOWN							

			Klonopin	C		
UNKNOWN						
			Lipitor	C		
UNKNOWN						

Date:08/19/05ISR Number: 4748948-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02068
Age:59 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1017 DAY	Arteriosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged Disability	Cerebrovascular Accident		Toprol Xl Tablets	C		ORAL
	Deep Vein Thrombosis		Toprol Xl Tablets	C		ORAL
	Depression		Lisinopril	C		ORAL
	Grand Mal Convulsion		Insulin	C		
UNKNOWN						
	Neoplasm Malignant		Lipitor	C		ORAL
	Neuropathy Peripheral		Clonidine	C		ORAL
	Tuberculosis		Promethazine	C		ORAL
			Synthroid	C		ORAL
			Ultram	C		ORAL
			Ferrous Sulfate	C		ORAL
			Coumadin	C		ORAL

Date:08/19/05ISR Number: 4748950-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02572
Age:57 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Angina Pectoris
Initial or Prolonged	Angina Unstable

	Blood Triglycerides Increased						
	Breast Tenderness	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Coronary Artery Disease		Vioxx	PS	Merck & Co., Inc	ORAL	
	Dermal Cyst		Vioxx	SS	Merck & Co., Inc	ORAL	
	Dyslipidaemia		Aspirin	C			UNKNOWN
	Hepatic Enzyme Increased		Prilosec	C			UNKNOWN
	Hypercholesterolaemia						
	Myocardial Infarction						
	Toe Deformity						

Date:08/19/05ISR Number: 4748951-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04593
Age:31 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged Disability	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	
			Vioxx	SS	Merck & Co., Inc	ORAL	
	Angina Unstable		Esgic-Plus Tablets	C			UNKNOWN
	Anhedonia		Premarin	C			UNKNOWN
	Anxiety		Proventil	C			UNKNOWN
	Blood Cholesterol Increased		Effexor	C			UNKNOWN
	Bundle Branch Block Right		Trazodone Hydrochloride	C			UNKNOWN
	Coronary Artery Disease		Xanax	C			UNKNOWN
	Depression						
	Extrasystoles						
	Fluid Retention						
	Hypertension						
	Hypoaesthesia						
	Limb Injury						
	Migraine						
	Nervous System Disorder						
	Pain						
	Rash Pruritic						
	Rheumatoid Arthritis						

Torsade De Pointes
Urticaria
Ventricular Fibrillation

Date:08/19/05ISR Number: 4748952-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03203
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Prednisone	C				
	Gouty Arthritis		Methotrexate	C				
	Hypertension		Aspirin	C		ORAL		
	Osteoarthritis		Tylenol	C				
	Peptic Ulcer		Prilosec	C				
	Seasonal Allergy		Folic Acid	C				
			Ventolin (Albuterol)	C				
			Paxil	C				
			Vitamin A	C				
			Klonopin	C				
			Monopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4748954-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02066
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anxiety Disorder		Vioxx	SS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Synthroid	C				UNKNOWN
	Chest Pain		Fosamax	C		ORAL		
	Chronic Obstructive		Evista	C				UNKNOWN
	Pulmonary Disease		Aspirin	C				UNKNOWN
	Coronary Artery Disease		Premarin	C				UNKNOWN
	Depression		Prempro	C				UNKNOWN
	Dyspnoea		Tylenol	C				UNKNOWN
	Gastritis Atrophic		Meprednisone	C				UNKNOWN
	Hypercholesterolaemia		Hydrocodone Bitartrate	C				UNKNOWN
	Hypoaesthesia							
	Hypotension		Hydrochlorothiazide	C				UNKNOWN
	Ischaemic Cardiomyopathy							
	Pernicious Anaemia							
	Polytraumatism							

Date:08/19/05ISR Number: 4748958-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA00562
Age:77 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL		616 DAY
	Dehydration		Imuran (Azathioprine Sodium)	SS		ORAL		
	Fall		Hytrin	C		ORAL		
	Gastrooesophageal Reflux Disease		Tylenol	C		ORAL		
	Knee Arthroplasty		Premarin	C		ORAL		
	Pollakiuria							
	Renal Disorder							

Renal Failure
Skin Lesion
Syncope
Urosepsis

Date:08/19/05ISR Number: 4748959-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02012
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Benign Prostatic
Other	Hyperplasia
	Bronchitis
	Cardiac Failure
	Carotid Artery Stenosis
	Cerebrovascular Accident
	Cerebrovascular Disorder
	Chest Pain
	Chills
	Chronic Obstructive
	Pulmonary Disease
	Convulsion
	Coronary Artery
	Atherosclerosis
	Coronary Artery Occlusion
	Depression
	Diabetes Mellitus

		Dyslipidaemia					
		Dyspepsia					
		Dyspnoea	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Erectile Dysfunction		Vioxx	PS	Merck & Co., Inc	ORAL
		Essential Tremor		Lipitor	C		
UNKNOWN							
		Facial Pain		Zocor	C		
UNKNOWN							
		Haematoma		Zocor	C		
UNKNOWN							
		Heart Rate Irregular		Tricor	C		
UNKNOWN							
		Hemiparesis		Gemfibrozil	C		
UNKNOWN							
		Hyperlipidaemia		Niaspan	C		
UNKNOWN							
		Hypersensitivity		Lisinopril	C		
UNKNOWN							
		Hypertension		Plavix	C		
UNKNOWN							
		Hypoaesthesia		Klor-Con	C		
UNKNOWN							
		Infection		Zestril	C		
UNKNOWN							
		Nephrolithiasis					
		Oedema Peripheral					
		Pain In Extremity					
		Palpitations					
		Stitch Abscess					
		Thrombosis					
		Transient Ischaemic					
		Attack					

Date:08/19/05ISR Number: 4748960-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01985
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL
8 MON						
Initial or Prolonged	Infarction		Aspirin	C		ORAL
Disability	Coronary Artery Disease		Prevacid	C		
UNKNOWN						

	Drug Effect Decreased	Zocor	C
UNKNOWN			
	Muir-Torre Syndrome	Toprol Xl Tablets	C
UNKNOWN			
	Polytraumatism	Prednisone	C
UNKNOWN			
	Sebaceous Adenoma	Genotropin	C
UNKNOWN			
	Sleep Apnoea Syndrome	Levoxyl	C
UNKNOWN			
		Ddavp	C
UNKNOWN			
		Biaxin	C
UNKNOWN			
		Nasocort	C
UNKNOWN			
		Depo-Testosterone	C
UNKNOWN			
		Nitroglycerin	C
UNKNOWN			
		Advil	C
UNKNOWN			
		Tylenol	C
UNKNOWN			
		Vitamins (Unspecified)	C
UNKNOWN			
		Allegra	C
UNKNOWN			

Date:08/19/05ISR Number: 4748961-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0309USA02381
Age:44 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain
	Anxiety
	Carpal Tunnel Syndrome
	Chills
	Depression
	Dyspepsia
	Dysphagia
	Emotional Distress
	Feeling Hot And Cold

		Gastrointestinal Haemorrhage					
		Gastrooesophageal Reflux Disease	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
				Vioxx	PS	Merck & Co., Inc	ORAL
		Haematemesis		Vioxx	SS	Merck & Co., Inc	ORAL
		Joint Effusion		Protonix	C		
UNKNOWN							
		Leukocytosis		Oramorph	C		
UNKNOWN							
		Ligament Injury		Cannabis	C		
UNKNOWN							
		Lumbar Radiculopathy		Ambien	C		
UNKNOWN							
		Migraine		Lorazepam	C		
UNKNOWN							
		Nausea					
		Oedema Peripheral					
		Overdose					
		Pyrexia					
		Radiculopathy					
		Rectal Haemorrhage					
		Renal Pain					
		Road Traffic Accident					
		Sleep Disorder					
		Vomiting					
		Weight Increased					

Date:08/19/05ISR Number: 4748966-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00870
Age:59 YR Gender:Male I/FU:F

Outcome		PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
Hospitalization - Initial or Prolonged		Blood Glucose Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
		Cardiac Failure		Insulin	C		
UNKNOWN							
		Cerebrovascular Accident		Lasix (Furosemide)	C		
UNKNOWN							
		Diabetes Mellitus		Coreg	C		
UNKNOWN							
		Inadequate Control		Cozaar	C		
UNKNOWN							
		Hypoglycaemia		Theo-Dur	C		
UNKNOWN							

	Hyponatraemia		Lopressor	C		
UNKNOWN						
	Hypotension		Coumadin	C		
UNKNOWN						
	Lipoma		Minipress	C		
UNKNOWN						
	Myocardial Infarction		Norvasc	C		
UNKNOWN						
	Nephropathy					
	Neuropathy					
	Pneumonia					
	Renal Failure Chronic					
	Retinopathy					
	Sinus Arrhythmia					
	Transaminases Increased					

Date:08/19/05ISR Number: 4748968-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02618
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1884 DAY	Arthropathy		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Darvocet-N	C		
UNKNOWN						
Other	Hypersensitivity		Aspirin	C		
UNKNOWN						
	Transient Ischaemic		Zocor	C		
UNKNOWN						
	Attack		Flonase	C		
UNKNOWN						
			Zyrtec	C		
UNKNOWN						
			Premarin	C		
UNKNOWN						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4748969-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01495
Age:44 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Depression							
	Myocardial Infarction							

Date:08/19/05ISR Number: 4748970-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02127
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Pulmonary Embolism		Vioxx	PS	Merck & Co., Inc	ORAL		
			Bextra	C				
UNKNOWN							21	MON

Date:08/19/05ISR Number: 4748971-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02128
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction		Celebrex	C				
UNKNOWN								

Date:08/19/05ISR Number: 4748972-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01836
Age:47 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chills							
	Constipation							
	Cough							
	Oedema Peripheral							
	Pyrexia							
	Sputum Discoloured							

Date:08/19/05ISR Number: 4748973-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02260
Age:67 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Lung Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	24 MON	
Hospitalization - Initial or Prolonged	Myocardial Infarction							

Date:08/19/05ISR Number: 4748974-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02130
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Heart Injury Myocardial Infarction Renal Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4748976-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01530
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
	Thrombosis		Norvasc	C		ORAL		
			Diovan	C		ORAL		
			Lipitor	C		ORAL		
			Ecotrin	C		ORAL		

Date:08/19/05ISR Number: 4748977-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01960
Age:46 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL		16 MON
Initial or Prolonged	Increased		Motrin	C				UNKNOWN
Disability	Chest Pain		Lisinopril	C				UNKNOWN
	Hypertension							
	Lung Disorder							
	Myocardial Infarction							

Date:08/19/05ISR Number: 4748980-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01000
Age:55 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Basal Cell Carcinoma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Bronchitis Acute		Vioxx	SS	Merck & Co., Inc	ORAL		360 DAY
	Cardiac Arrest		Coreg	C				UNKNOWN
	Cardiac Failure		Coreg	C				UNKNOWN
	Congestive		Tricor	C				UNKNOWN
	Cardiomyopathy		Diazepam	C				UNKNOWN

	Ejection Fraction	Zestril	C
UNKNOWN			
	Decreased	Glucophage	C
UNKNOWN			
	Hyperlipidaemia	Glucotrol	C
UNKNOWN			
	Hypertension	Depo-Medrol	C
UNKNOWN			
	Myocardial Infarction	Norvasc	C
UNKNOWN			
	Rotator Cuff Syndrome		
	Ventricular Hypertrophy		

Date:08/19/05ISR Number: 4748982-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03109
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		755 DAY
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Coronary Artery Disease		Estrace	C		ORAL		
	Dyslipidaemia		Synthroid	C				
UNKNOWN								
	Gastrooesophageal Reflux Disease							
	Osteoarthritis							

Date:08/19/05ISR Number: 4748984-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA04191
Age:62 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Accident At Work
Initial or Prolonged	Adrenal Mass
Disability	Adverse Event

Dose	Duration		Report Source	Product	Role	Manufacturer	Route
		Anxiety					
		Asthenia					
		Blood Pressure Inadequately Controlled		Vioxx	PS	Merck & Co., Inc	ORAL
1269 MON							
		Blood Pressure Increased		Ambien	C		
UNKNOWN							
		Carpal Tunnel Syndrome		Viagra	C		
UNKNOWN							
		Chest Discomfort		Monopril	C		ORAL
		Contusion		Calan Sr	C		
UNKNOWN							
		Coronary Artery Disease		Celexa	C		
UNKNOWN							
		Coronary Artery		Lortab	C		
UNKNOWN							
		Restenosis		Plaquenil	C		
UNKNOWN							
		Depression		Darvocet-N	C		
UNKNOWN							
		Dizziness		Remicade	C		
UNKNOWN							
		Dysarthria		Xanax	C		
UNKNOWN							
		Dysuria		Nexium	C		
UNKNOWN							
		Erythema		Procardia Xl	C		ORAL
		Excoriation		Diuretic			
		Fatigue		(Unspecified)	C		ORAL
		Gastrooesophageal Reflux		Aspirin	C		ORAL
		Disease		Aspirin	C		ORAL
		Haemangioma Of Liver		Methotrexate	C		ORAL
		Haematoma		Prednisone	C		
UNKNOWN							
		Hyperlipidaemia					
		Hyponatraemia					
		Joint Swelling					
		Localised Infection					
		Myocardial Infarction					
		Nasal Congestion					
		Oedema Peripheral					
		Pain					
		Rash					
		Raynaud'S Phenomenon					
		Renal Cyst					
		Renal Failure					

Sinus Bradycardia
Viral Labyrinthitis
Vision Blurred
Vomiting

Date:08/19/05ISR Number: 4748985-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03717
Age:52 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL		1905 DAY
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		1905 DAY
Disability	Arthropathy		Plavix	SS		ORAL		
Other	Chest Pain		Norvasc	C		ORAL		
	Coronary Artery Disease		Aspirin	C		ORAL		
	Diabetes Mellitus		Lipitor	C		ORAL		
	Inadequate Control		Wellbutrin Sr	C		ORAL		
	Diabetes Mellitus		Wellbutrin Sr	C		ORAL		
	Non-Insulin-Dependent							
	Hernia							
	Hypertension							
	Musculoskeletal							
	Discomfort							
	Myocardial Infarction							
	Wound Haemorrhage							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4748986-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01669
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cyst		Vioxx	PS	Merck & Co., Inc	ORAL		
	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		
	Drug Hypersensitivity		Prozac	C		ORAL		
	Hand Fracture		Risperdal	C		ORAL		
	Myocardial Infarction							
	Pneumonia							

Date:08/19/05ISR Number: 4748987-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02076
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	4	YR
	Myocardial Infarction							

Date:08/19/05ISR Number: 4748998-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02962
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							
	Injury							

Date:08/19/05ISR Number: 4749001-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA03046
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749002-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02085
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Angiopathy Heart Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749003-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01951
Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Chronic Obstructive Pulmonary Disease Coronary Artery Disease Emphysema Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749015-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02630
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749016-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02952
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749017-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02937
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Chest Pain							
Other	Thrombosis							

Date:08/19/05ISR Number: 4749018-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01223
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL	42 DAY	
	Infarction		Aspirin	C			UNKNOWN	
	Cardiac Arrest							

Date:08/19/05ISR Number: 4749019-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02958
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		
	Death							

Date:08/19/05ISR Number: 4749035-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02955
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749056-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02628
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident Myocardial Infarction Thrombosis		Vioxx	PS	Merck & Co., Inc	ORAL	51	MON

Date:08/19/05ISR Number: 4749089-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01013
Age:91 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abnormal Dreams
Other	Back Pain Cardiac Failure Congestive Cataract Contusion Coronary Artery

		Atherosclerosis					
		Coronary Artery Disease					
		Depression					
		Disorientation	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Fall		Vioxx	PS	Merck & Co., Inc	ORAL
		Incontinence		Vioxx	SS	Merck & Co., Inc	ORAL
		Ischaemic Cardiomyopathy		Vioxx	SS	Merck & Co., Inc	ORAL
		Lung Infiltration		Lasix (Furosemide)	C		
UNKNOWN							
		Myocardial Infarction		Zoloft	C		
UNKNOWN							
		Orthostatic Hypotension		Iron (Unspecified)	C		
UNKNOWN							
		Pharmaceutical Product		Detrol	C		
UNKNOWN							
		Complaint		Aspirin	C		
UNKNOWN							
		Pulmonary Mass		Aspirin	C		
UNKNOWN							
		Pulmonary Oedema		Flomax (Tamsulosin			
		Sleep Disorder		Hydrochloride)	C		
UNKNOWN							
		Vascular Dementia		Vitamins			
				(Unspecified)	C		
UNKNOWN							
				Cyanocobalamin	C		
UNKNOWN							
				Oxybutynin Chloride	C		
UNKNOWN							
				Tylenol	C		
UNKNOWN							
				Tylenol Extra			
				Strength	C		
UNKNOWN							
				Ascorbic Acid	C		
UNKNOWN							

Date:08/19/05ISR Number: 4749213-XReport Type:Expedited (15-DaCompany Report #NO-BRISTOL-MYERS SQUIBB COMPANY-13073093
Age:85 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hallucination		Aprovel	PS	Bristol-Myers Squibb	
Initial or Prolonged	Hyperkalaemia				Company	ORAL
	Mental Status Changes		Vioxx	SS		

Renal Failure
Throat Tightness

Date:08/19/05ISR Number: 4749360-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02997
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749361-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02994
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Adverse Event Death Injury		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749362-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01929
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
			Aspirin	C				
Disability			Zocor	C			UNKNOWN	
			Tylenol	C			UNKNOWN	

			Synthroid	C		
UNKNOWN						
			Humulin	C		
UNKNOWN						

Date:08/19/05ISR Number: 4749363-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02633
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	2	YR
	Cerebrovascular Accident							
	Polytraumatism							

Date:08/19/05ISR Number: 4749364-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01930
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Chest Pain		Vioxx	PS	Merck & Co., Inc	ORAL	1	MON
Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Obstruction							
	Renal Pain							

Date:08/19/05ISR Number: 4749365-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02385
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL	43	MON
	Cardiac Disorder							
	Myocardial Infarction							
	Pain							
	Polytraumatism							

Date:08/19/05ISR Number: 4749366-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02133
Age:81 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged			[Therapy Unspecified]	C				
UNKNOWN								

Date:08/19/05ISR Number: 4749367-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA03351
Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cardiac Arrest		Vioxx	PS	Merck & Co., Inc	ORAL		
	Headache		Prednisone	C		ORAL	6	YR
	Myalgia		Methotrexate	C		ORAL	23	MON
	Myocardial Infarction		Sulfasalazine	C		ORAL	2	YR

Date:08/19/05ISR Number: 4749368-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01924
Age:70 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL	161	DAY
UNKNOWN			Tylenol	C				
			[Therapy Unspecified]	C				
UNKNOWN								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749369-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0507USA01228
Age:61 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		3 MON

Date:08/19/05ISR Number: 4749371-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01942
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Acute Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749372-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01902
Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Blood Cholesterol Increased		Vioxx	PS	Merck & Co., Inc	ORAL		9 DAY
	Coronary Artery Disease							
	Myocardial Infarction							

Date:08/19/05ISR Number: 4749373-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0506USA00970
Age:54 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma		Vioxx	PS	Merck & Co., Inc	ORAL		
	Atherosclerosis		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Blood Cholesterol		Levoxyl	C				
UNKNOWN								
	Increased		Wellbutrin	C				
UNKNOWN								
	Carotid Artery Stenosis		Detrol	C				
UNKNOWN								

	Cerebral Infarction	Imitrex Tablets	C
UNKNOWN			
	Cerebrovascular Accident	Neurontin	C
UNKNOWN			
	Confusional State	Neurontin	C
UNKNOWN			
	Dizziness	Flexeril	C
UNKNOWN			
	Emotional Distress	Flexeril	C
UNKNOWN			
	Fall	Diclofenac	C
UNKNOWN			
	Gait Disturbance	Xalatan	C
UNKNOWN			
	Gastrooesophageal Reflux	Ventolin (Albuterol)	C
UNKNOWN			
	Disease	Nicotrol	C
UNKNOWN			
	Hemianopia Heteronymous		
	Hypertension		
	Hypothyroidism		
	Nausea		
	Pneumonia		
	Transient Ischaemic		
	Attack		

Date:08/19/05ISR Number: 4749374-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02392
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749375-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA00008
Age:79 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Acute Coronary Syndrome		Vioxx	PS	Merck & Co., Inc	ORAL		
	Cardiac Arrest							
	Chest Pain							
	Diverticulum							
	Dyspnoea							
	Hyperthyroidism							

Date:08/19/05ISR Number: 4749376-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02135
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Myocardial Infarction		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749377-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02384
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
	Myocardial Infarction							

Date:08/19/05ISR Number: 4749378-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0508USA01984
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Disability	Cardiovascular Disorder		Vioxx	PS	Merck & Co., Inc	ORAL		
	Pulmonary Embolism							

Date:08/19/05ISR Number: 4749379-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01698
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Musculoskeletal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ventricle Rupture		Glucophage	C			UNKNOWN	
			Avandia	C			UNKNOWN	

Date:08/19/05ISR Number: 4749380-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0502USA00710
Age:64 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Adverse Event
	Arthralgia
Other	Atrial Fibrillation
	Cardiac Failure
	Congestive
	Cardiomyopathy
	Coronary Artery
	Atherosclerosis
	Diastolic Dysfunction
	Hypoprothrombinaemia
	Myocardial Infarction
	Myocardial Ischaemia
	Oedema Peripheral

	Pain In Extremity						
		Report Source	Product	Role	Manufacturer	Route	Dose	Duration
			Vioxx	PS	Merck & Co., Inc	ORAL		
			Vioxx	SS	Merck & Co., Inc	ORAL		
			Hyzaar	C		ORAL		

Date:08/19/05ISR Number: 4749381-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0502USA01339
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - 659 DAY	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged Disability UNKNOWN	Infarction		Zocor	C		ORAL		
	Chest Pain		Aspirin	C				
	Coronary Artery		Zyrtec	C				
	Atherosclerosis		Viagra	C				
	Dizziness		Zantac	C				
	Myocardial Infarction							
	Palpitations							
	Sciatica							

Date:08/19/05ISR Number: 4749382-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA02993
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		

Date:08/19/05ISR Number: 4749383-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA04295
Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration

Hospitalization - 48 MON	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 48 MON	Depression		Vioxx	SS	Merck & Co., Inc	ORAL
Disability UNKNOWN	Hypertension		Claritin-D	C		
	Sexual Dysfunction		Flovent	C		
UNKNOWN						
	Temperature Intolerance		Advair	C		
UNKNOWN						
			Allegra-D	C		
UNKNOWN						
			Singulair	C		ORAL
			Albuterol	C		
UNKNOWN						
			Albuterol	C		
UNKNOWN						
			Motrin	C		
UNKNOWN						

Date:08/19/05ISR Number: 4749384-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01354
Age:64 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 7 MON	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 7 MON	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL
	Dyspepsia		Paxil	C		ORAL
	Hypertension		Klonopin	C		ORAL
	Lung Disorder		Aspirin	C		ORAL
	Pain		Atenolol	C		ORAL
	Prostatitis		Vitamin E	C		ORAL
	Sleep Disorder		Minerals (Unspecified) And Vitamins (Unspecified)	C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749385-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0501USA02307
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Arthralgia		Vioxx	PS	Merck & Co., Inc	ORAL		219 DAY
Initial or Prolonged	Asthma		Vioxx	SS	Merck & Co., Inc	ORAL		70 DAY
	Breast Mass		Vioxx	SS	Merck & Co., Inc	ORAL		141 DAY
	Bronchitis		Vioxx	SS	Merck & Co., Inc	ORAL		122 DAY
	Bursitis		Vioxx	SS	Merck & Co., Inc	ORAL		167 DAY
	Depression		Plaquenil	SS				UNKNOWN
	Epicondylitis		Methotrexate	SS				UNKNOWN
	Fibromyalgia		Vioxx	SS	Merck & Co., Inc	ORAL		235 DAY
	Hypertension		Vioxx	SS	Merck & Co., Inc	ORAL		27 DAY
	Intervertebral Disc		Celexa	C				UNKNOWN
	Disorder		Premarin	C				UNKNOWN
	Lymphadenopathy		Klonopin	C				UNKNOWN
	Menopausal Symptoms		Folic Acid	C				UNKNOWN
	Mumps		Vicodin Tablets	C				UNKNOWN
	Oedema Peripheral		Lasix (Furosemide)	C				UNKNOWN
	Rash							
	Respiratory Distress							
	Rotator Cuff Syndrome							
	Sinusitis							
	Swelling Face							

Date:08/19/05ISR Number: 4749386-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01961
Age:68 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Sinusitis		Vioxx	PS	Merck & Co., Inc	ORAL		17 MON
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		17 MON
Disability	Increased		Synthroid	C		ORAL		
	Bronchitis Acute		Premarin	C				
UNKNOWN								
	Constipation							
	Dermatophytosis							
	Influenza Like Illness							
	Knee Arthroplasty							
	Muscle Atrophy							
	Muscle Spasms							
	Myocardial Infarction							
	Pancreatitis							
	Plantar Fasciitis							
	Tinnitus							
	Urinary Tract Infection							

Date:08/19/05ISR Number: 4749387-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL		8 DAY
Initial or Prolonged	Hepatic Enzyme Increased		Tizanidine Hydrochloride	SS		ORAL		1 DAY
			Tizanidine Hydrochloride	SS		ORAL		1 DAY
			Tizanidine Hydrochloride	SS		ORAL		1 DAY
			Diclofenac Sodium	SS		ORAL		
			Herbs (Unspecified)	C		ORAL		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749388-2Report Type:Expedited (15-DaCompany Report #DE-MERCK-0410DEU00031
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged Disability	Anorexia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Asthenia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Cardiovascular Disorder		Oxycodone Hydrochloride	C			UNKNOWN	
	Cerebral Artery Occlusion		Tolperisone Hydrochloride	C			UNKNOWN	
	Cerebrovascular Accident		Omeprazole	C			UNKNOWN	
	Dizziness		Flupirtine Maleate	C			UNKNOWN	
	Infection		Amitriptyline Hydrochloride	C		ORAL		
	Malaise		Fentanyl	C		ORAL		
	Nausea		Ranitidine Hydrochloride	C		ORAL		
	Overdose		Dipyrone	C		ORAL		
	Pain		Zocor	C		ORAL		
	Sleep Disorder		Naloxone Hydrochloride And Tilidine Hydrochloride	C			UNKNOWN	
			Naloxone Hydrochloride And Tilidine Hydrochloride	C			UNKNOWN	
			Naloxone Hydrochloride And Tilidine Hydrochloride	C			UNKNOWN	
			Amitriptyline Hydrochloride	C			UNKNOWN	
			Buprenorphine Hydrochloride	C			UNKNOWN	
			Buprenorphine					

			Hydrochloride	C		
UNKNOWN						
			Hydromorphone Hydrochloride	C		
UNKNOWN						
			Procaine Hydrochloride	C		
UNKNOWN						
			Polyethylene Glycol 3350 And Potassium Chloride And Sodium Bicarbonate And Sodium Chloride	C		
UNKNOWN						
			Amitriptyline Hydrochloride	C		
UNKNOWN						

Date:08/19/05ISR Number: 4749389-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0508USA03144
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death	Cerebrovascular Accident		Vioxx	PS	Merck & Co., Inc	ORAL		
Hospitalization - Initial or Prolonged	Urinary Tract Infection							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749390-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01747
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
	Anorexia		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Anxiety		Atenolol	C			UNKNOWN	
	Arrhythmia		Vicodin Tablets	C			UNKNOWN	
	Atherosclerosis		Oxycontin	C			UNKNOWN	
	Blood Cholesterol Increased							
	Cardiac Disorder							
	Cardiac Murmur							
	Cardiac Valve Disease							
	Cerebrovascular Accident							
	Chest Pain							
	Chronic Fatigue Syndrome							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Depression							
	Diarrhoea							
	Gastrooesophageal Reflux Disease							
	Glaucoma							
	Haematochezia							
	Insomnia							
	Intestinal Mass							
	Myocardial Infarction							
	Nausea							
	Oedema							
	Panic Disorder							
	Suicidal Ideation							
	Syncope							
	Weight Decreased							
	Weight Increased							

Date:08/19/05ISR Number: 4749391-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04609
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Arthropathy		Vioxx	SS	Merck & Co., Inc	ORAL	UNKNOWN	
	Asthma		Prempro	C			UNKNOWN	
	Blood Cholesterol		Zithromax	C			UNKNOWN	
	Increased		Guiatuss	C			UNKNOWN	
	Cerebrovascular Accident		Prempro	C			UNKNOWN	
	Depression		Nizoral	C			TOPICAL	
	Diabetes Mellitus		Lotrisone	C			UNKNOWN	
	Gastrooesophageal Reflux		Tylenol	C			UNKNOWN	
	Disease		Motrin	C			UNKNOWN	1981 DAY
	Hypertension		Ultram	C			UNKNOWN	
	Pain		Ultracet	C			UNKNOWN	
			Lisinopril	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749392-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01754
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Cerebrovascular Accident		Verapamil Msd Lp	C		ORAL		
Other	Chest Discomfort		Naproxen	C				
UNKNOWN								
	Chest Pain							
	Cholelithiasis							
	Constipation							
	Depression							
	Diabetes Mellitus							
	Dizziness							
	Gastrooesophageal Reflux							
	Disease							
	Hallucination							
	Lethargy							
	Neuropathy							
	Osteoporosis							
	Parkinson'S Disease							
	Transient Ischaemic							
	Attack							
	Tremor							
	Vascular Dementia							

Date:08/19/05ISR Number: 4749393-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA03200
Age:49 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Adverse Event		Vioxx	PS	Merck & Co., Inc	ORAL		1276 DAY
Initial or Prolonged	Asthenia		Cyclobenzaprine					
	Fatigue		Hydrochloride	SS				
UNKNOWN								
	Myalgia		Oxycontin	C				
UNKNOWN								
	Myocardial Infarction		[Therapy					
	Pain		Unspecified]	C				
UNKNOWN								
			Methotrexate	C				
UNKNOWN								

	Hydrocortisone And Neomycin Sulfate And Polymyxin B Sulfate	C
UNKNOWN		
	Tussionex (Hydrocodone Polistirex (+) Phenyltoloxamine Polistirex)	C
UNKNOWN		
	Guaifenesin And Pseudoephedrine Hydrochloride	C
UNKNOWN		
	Fluocinonide	C
UNKNOWN		
	Flexeril	C
UNKNOWN		
	Zithromax	C
UNKNOWN		
	Clindamycin	C
UNKNOWN		
	Guaifenesin	C
UNKNOWN		
	Zyban	C
UNKNOWN		
	Levaquin	C
UNKNOWN		
	Enbrel	C
UNKNOWN		
	Alocril	C
UNKNOWN		
	Prednisone	C
UNKNOWN		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749394-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02113
Age:47 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Infarction		Ziac	C				
UNKNOWN								
Disability	Anaemia							
	Blood Magnesium Decreased							
	Coronary Artery Disease							
	Cough							
	Depression							
	Gastrooesophageal Reflux							
	Disease							
	Herpes Zoster							
	Hypokalaemia							
	Hypoxia							
	Osteoarthritis							
	Pain							
	Pneumonia							
	Polytraumatism							
	Procedural Hypotension							

Date:08/19/05ISR Number: 4749395-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04993
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Gastrointestinal Ulcer		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Myocardial Infarction							

Date:08/19/05ISR Number: 4749396-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA04602
Age:60 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Anhedonia		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Wellbutrin	C				
UNKNOWN								
Disability	Increased		Lasix (Furosemide)	C				
UNKNOWN								

UNKNOWN	Cerebrovascular Accident	Lasix (Furosemide)	C
UNKNOWN	Hypersensitivity	Normodyne	C
UNKNOWN	Hypertension	Aldactone	C
UNKNOWN	Oesophageal Disorder	Spironolactone	C
UNKNOWN	Pain	Norvasc	C
UNKNOWN		Glucophage	C
UNKNOWN		Glucotrol	C
UNKNOWN		Lantus	C
UNKNOWN		[Therapy Unspecified]	C
UNKNOWN		Actos	C
UNKNOWN		Metformin	C
UNKNOWN		Insulin	C
UNKNOWN		Albuterol	C
UNKNOWN		Brethine	C
UNKNOWN		Combivent	C
UNKNOWN		Tylenol	C
UNKNOWN		K-Dur	C
UNKNOWN		Digoxin	C
UNKNOWN		Coumadin	C
UNKNOWN			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749397-3Report Type:Expedited (15-DaCompany Report #DE-MERCK-0502DEU00031
Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Pressure Increased		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Coronary Artery Disease		Vioxx	SS	Merck & Co., Inc	ORAL		
	Coronary Artery Stenosis							
	Dyspnoea Exertional							
	Myocardial Infarction							
	Thyroid Disorder							

Date:08/19/05ISR Number: 4749398-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00257
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Acute Myocardial		Vioxx	PS	Merck & Co., Inc	ORAL		29 MON
Initial or Prolonged	Infarction		Vioxx	SS	Merck & Co., Inc	ORAL		29 MON
	Amnesia		Premarin	C				UNKNOWN
	Asthma							
	Blood Cholesterol Increased							
	Bronchitis							
	Chronic Obstructive Pulmonary Disease							
	Gastrooesophageal Reflux Disease							
	Hot Flush							
	Hypotension							

Date:08/19/05ISR Number: 4749399-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00891
Age:51 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Pain Upper		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Anxiety		Vioxx	SS	Merck & Co., Inc	ORAL		
Other	Blood Glucose Increased		Tylenol Extra					

	Cataract	Strength	C
UNKNOWN			
	Cerebrovascular Accident	Insulin	C
UNKNOWN			
	Constipation		
	Depression		
	Diabetes Mellitus		
	Headache		
	Hyperglycaemia		
	Insomnia		
	Ocular Vascular Disorder		
	Renal Failure Chronic		
	Retinal Detachment		
	Skin Ulcer		
	Vomiting		

Date:08/19/05ISR Number: 4749400-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA03719
Age:55 YR Gender:Male I/FU:F

Outcome	PT
Other	Anxiety Disorder
	Atrial Fibrillation
	Diabetes Mellitus
	Gout
	Hernia

Hypertension
Myocardial Infarction

Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Vioxx	PS	Merck & Co., Inc	ORAL	6	MON
	Coumadin	C		ORAL		
	Lanoxin	C		ORAL		

Date:08/19/05ISR Number: 4749401-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA02918
Age:54 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Cholesterol		Vioxx	PS	Merck & Co., Inc	ORAL	17	MON
Initial or Prolonged	Increased		Vioxx	SS	Merck & Co., Inc	ORAL	17	MON
Disability	Cerebrovascular Accident							
	Sleep Disorder							

Date:08/19/05ISR Number: 4749402-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0504USA01273
Age:57 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL	55	MON
Initial or Prolonged	Abdominal Pain Upper		Vioxx	SS	Merck & Co., Inc	ORAL	55	MON
Disability	Angina Pectoris		Vioxx	SS	Merck & Co., Inc	ORAL	55	MON
Other	Cardiac Disorder		Vioxx	SS	Merck & Co., Inc	ORAL	55	MON
	Carotid Artery Stenosis		Tricor	C			UNKNOWN	
	Cerebrovascular Accident		Neurontin	C			UNKNOWN	
	Coronary Artery Disease		Allegra	C			UNKNOWN	
	Fatigue		Flonase	C			UNKNOWN	

	Hernia Repair	Humibid	C
UNKNOWN			
	Hypertension	Atenolol	C
UNKNOWN			
	Limb Discomfort	Tylenol	C
UNKNOWN			
	Memory Impairment	Lanoxin	C
UNKNOWN			
	Nausea	Lanoxin	C
UNKNOWN			
	Pain	Altace	C
UNKNOWN			
	Sleep Disorder	Diovan	C
UNKNOWN			
	Sluggishness	Restoril	C
UNKNOWN			
	Stomach Discomfort		
	Suicide Attempt		

Date:08/19/05ISR Number: 4749403-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00241
Age:65 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Asthma
	Chronic Obstructive Pulmonary Disease
	Coronary Artery Atherosclerosis
	Coronary Artery Disease
	Diverticulum
	Electrocardiogram Abnormal
	Haemorrhoids
	Hiatus Hernia
	Inguinal Hernia
	Musculoskeletal Discomfort
	Myocardial Infarction

		Pleuritic Pain					
		Spinal Compression Fracture	Report Source	Product	Role	Manufacturer	Route
Dose	Duration						
		Tachycardia		Vioxx	PS	Merck & Co., Inc	ORAL
		Vascular Graft Occlusion		Theophylline	C		
UNKNOWN							
		Vertigo		Albuterol	C		
RESPIRATORY							
(INHALATION)							
				Aciphex	C		
UNKNOWN							
				Singulair	C		
UNKNOWN							
				Pulmicort	C		
UNKNOWN							
				Ultram	C		
UNKNOWN							
				Fosamax	C		
UNKNOWN							

Date:08/19/05ISR Number: 4749404-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00884
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Anaemia		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -	Arthralgia		Vioxx	SS	Merck & Co., Inc	ORAL
Initial or Prolonged	Cerebrovascular Accident		Celebrex	C		
UNKNOWN	20 DAY					
Other	Death		Zocor	C		
UNKNOWN						
	Ecchymosis		Xanax	C		
UNKNOWN						
	Essential Tremor		Aspirin	C		
UNKNOWN						
	Fall		Prempro	C		
UNKNOWN						
	Fatigue					
	Flatulence					
	Haemorrhage Intracranial					
	Headache					
	Hyperlipidaemia					
	Insomnia					

Irritable Bowel Syndrome
Osteoarthritis
Postmenopausal
Haemorrhage
Temporomandibular Joint
Syndrome
Urinary Incontinence
Urinary Tract Infection
Weight Increased

Date:08/19/05ISR Number: 4749405-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01106
Age:76 YR Gender:Male I/FU:F

Outcome	PT
Death	Acute Pulmonary Oedema
Hospitalization - Initial or Prolonged	Anaemia
Other	Asthenia
	Atrial Fibrillation
	Atrial Flutter
	Atrial Tachycardia
	Cardiac Failure
	Congestive
	Cataract
	Coagulopathy
	Coronary Artery Disease
	Decreased Activity
	Decubitus Ulcer
	Diabetic Ulcer
	Diarrhoea

	Diverticulum						
	Gastric Disorder						
	Gout	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
	Hypoaesthesia		Vioxx	PS	Merck & Co., Inc	ORAL		
	Hypokalaemia		Vioxx	SS	Merck & Co., Inc	ORAL		
	Ileus		Imdur	C				UNKNOWN
	Lung Disorder		Probenecid	C				UNKNOWN
	Myocardial Infarction		Allopurinol	C				UNKNOWN
	Oedema Peripheral		Combivent	C				UNKNOWN
	Pancreatitis		Avandia	C				UNKNOWN
	Pleural Effusion		Lopressor	C				UNKNOWN
	Pulmonary Congestion		Insulin	C				UNKNOWN
	Renal Disorder		Lasix (Furosemide)	C				UNKNOWN
	Renal Failure		Vasotec	C				UNKNOWN
	Respiratory Failure							
	Syncope							

Date:08/19/05ISR Number: 4749406-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0503USA01992
Age:40 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		
Initial or Prolonged	Blood Cholesterol		Vioxx	SS	Merck & Co., Inc	ORAL		
Disability	Increased		Amoxicillin	C				UNKNOWN
Other	Chest Pain		Albuterol	C				UNKNOWN
	Coronary Artery Disease		Allegra	C				UNKNOWN
	Diabetes Mellitus		Singulair	C				UNKNOWN
	Non-Insulin-Dependent		Nexium	C				UNKNOWN

	Ejection Fraction		Doxycycline	C		
UNKNOWN						
	Decreased					
	Hypertension					
	Hypothyroidism					
	Myocardial Infarction					
	Polytraumatism					

Date:08/19/05ISR Number: 4749407-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02937
Age:50 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Arrhythmia		Vioxx	PS	Merck & Co., Inc	ORAL
	Fall					
	Ligament Sprain					
	Myocardial Infarction					
	Syncope					

Date:08/19/05ISR Number: 4749408-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01949
Age:53 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 5 YR	Angina Unstable		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	Anxiety Disorder		Aspirin	C		
UNKNOWN						
Disability	Coronary Artery Disease					
Other	Hypertension					
	Myocardial Infarction					
	Panic Disorder					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749409-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01951
Age:47 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Cerebrovascular Accident		Aspirin	C				
Disability	Myocardial Infarction		Aspirin	C			UNKNOWN	
Other	Transient Ischaemic Attack		Hytrin	C			UNKNOWN	

Date:08/19/05ISR Number: 4749410-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01527
Age:58 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL	UNKNOWN	
	Angina Pectoris		Coumadin	C				
	Cardiac Disorder		Coumadin	C			UNKNOWN	
	Cardiac Failure		Darvocet-N	C			UNKNOWN	
	Congestive		Darvocet-N	C			UNKNOWN	
	Chest Pain		Prinivil	C			UNKNOWN	10 YR
	Nausea		Lasix (Furosemide)	C			UNKNOWN	
	Sleep Apnoea Syndrome		Lasix (Furosemide)	C			UNKNOWN	
	Thrombosis		Tylenol	C			UNKNOWN	
	Uterine Leiomyoma		Zoloft	C			UNKNOWN	
			Zoloft	C			UNKNOWN	

Date:08/19/05ISR Number: 4749411-5Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00103
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Blood Creatinine		Vioxx	PS	Merck & Co., Inc	ORAL		1327 DAY
Initial or Prolonged	Increased		Heparin	SS			SUBCUTANEOUS	
	Cellulitis		Zestril	C		ORAL		
	Chest Pain		Tylenol	C		ORAL		
	Coronary Artery Disease		Insulin	C			SUBCUTANEOUS	
	Depression		Synthroid	C		ORAL		
	Gastric Infection		Lescol	C		ORAL		
	Haematocrit Decreased							
	Hypotension							
	Myocardial Infarction							
	Nephrolithiasis							
	Platelet Count Decreased							
	Pleural Effusion							
	Postoperative Infection							
	Sarcoma Uterus							

Date:08/19/05ISR Number: 4749412-7Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01955
Age:53 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Blood Cholesterol
Disability	Increased
	Coronary Artery Disease
	Coronary Artery
	Restenosis
	Depression
	Gastrooesophageal Reflux
	Disease

	Haematoma						
	Myocardial Infarction						
	Osteoarthritis	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Osteoporosis		Vioxx	PS	Merck & Co., Inc	ORAL	
	Rheumatoid Arthritis		Vioxx	SS	Merck & Co., Inc	ORAL	
			Methotrexate	C		ORAL	
			Valium	C		ORAL	1434 DAY
			Valium	C		ORAL	1434 DAY
			Synthroid	C		ORAL	
			Vivelle	C		ORAL	
			Prednisone	C			UNKNOWN
			Prometrium	C		ORAL	

Date:08/19/05ISR Number: 4749413-9Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00230
Age:71 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Abdominal Adhesions		Vioxx	PS	Merck & Co., Inc	ORAL	
	Anal Dilation Procedure		Oxycodone	SS		ORAL	39 MON
Disability	Aortic Dissection		Oxycodone	SS		ORAL	39 MON
	Aortic Valve Incompetence		Vioxx	SS	Merck & Co., Inc	ORAL	
	Atrial Fibrillation		Aspirin	C			UNKNOWN
	Blood Potassium Decreased		Coumadin	C			UNKNOWN
	Candidiasis		Soma	C			UNKNOWN
	Colectomy Partial		Niacin	C			UNKNOWN
	Connective Tissue Inflammation						
	Depression						
	Embolic Stroke						
	Haematoma						
	Hemianopia						
	Hernia						
	Hypertension						
	Hyperthyroidism						

Intestinal Perforation
Myocardial Infarction
Oral Candidiasis
Seroma
Vascular Pseudoaneurysm

Date:08/19/05ISR Number: 4749414-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02138
Age:81 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Anxiety		Vioxx	PS	Merck & Co., Inc	ORAL		
	Blood Cholesterol Increased		Vioxx	SS	Merck & Co., Inc	ORAL		
	Bronchitis		[Therapy Unspecified]	C			UNKNOWN	
	Depression		Tylenol	C			UNKNOWN	
	Dyspnoea		Glucotrol	C			UNKNOWN	
	Myocardial Infarction		Hydrochlorothiazide And Triamterene	C			UNKNOWN	
			Allopurinol	C			UNKNOWN	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749415-2Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01523
Age:62 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		2 YR
Initial or Prolonged	Depression		Vioxx	SS	Merck & Co., Inc	ORAL		2 YR
Disability	Hypertension		Vasotec	C				UNKNOWN
	Transient Ischaemic Attack		Metformin Hydrochloride	C				UNKNOWN
			Lotrel	C				UNKNOWN
			Aspirin	C				UNKNOWN
			Pravachol	C				UNKNOWN
			Aleve	C				UNKNOWN
			Naproxen	C				UNKNOWN

Date:08/19/05ISR Number: 4749416-4Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02262
Age:45 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Aortic Aneurysm		Vioxx	PS	Merck & Co., Inc	ORAL		1370 DAY
Initial or Prolonged	Cerebrovascular Accident		Monopril	C				UNKNOWN
Disability	Chest Pain		Vasotec	C		ORAL		
Other	Intracranial Aneurysm		Lopressor	C				UNKNOWN
	Renal Artery Stenosis		Toprol Xl Tablets	C				UNKNOWN
	Renal Failure		Norvasc	C				UNKNOWN
			Hytrin	C				UNKNOWN
			Lasix (Furosemide)	C				UNKNOWN

			Aldomet (Methyldopate Hydrochloride)	C		
UNKNOWN						
			Plavix	C		
UNKNOWN						

Date:08/19/05ISR Number: 4749417-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA02272
Age:66 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1606 DAY	Atrial Fibrillation		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 944 DAY	Cardiac Failure		Zetia	C		ORAL
	Congestive		Zocor	C		ORAL
	Cerebrovascular Accident		Atenolol	C		
UNKNOWN	939 DAY					
	Coronary Artery Occlusion		Coumadin	C		
UNKNOWN	62 DAY					
	Dilatation Ventricular		Prilosec	C		
UNKNOWN						
	Mitral Valve Incompetence		Cosopt	C		
UNKNOWN						
	Myocardial Infarction		Xalatan	C		
UNKNOWN						
	Tricuspid Valve Incompetence					

Date:08/19/05ISR Number: 4749419-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01525
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Anxiety
Disability	Depression
	Dizziness
	Dyspepsia
	Glaucoma
	Haemorrhage
	Heart Rate Irregular

	Pain In Extremity Post-Traumatic Stress Disorder	Report Source	Product	Role	Manufacturer	Route	Dose Duration
	Renal Failure		Vioxx	PS	Merck & Co., Inc	ORAL	48 MON
			Vioxx	SS	Merck & Co., Inc	ORAL	48 MON
			Hyzaar	C		ORAL	
			Toprol Xl Tablets	C			UNKNOWN

Date:08/19/05ISR Number: 4749420-6Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01794
Age:74 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Death	Cardiac Disorder		Vioxx	PS	Merck & Co., Inc	ORAL	4 MON
Other	Cardiovascular Disorder Death Hypertension Myocardial Infarction Organ Failure						

Date:08/19/05ISR Number: 4749421-8Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01676
Age:38 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose Duration
Hospitalization - Initial or Prolonged	Animal Bite		Vioxx	PS	Merck & Co., Inc	ORAL	14 DAY
	Myocardial Infarction		Vioxx	SS	Merck & Co., Inc	ORAL	
Disability	Pharyngitis Streptococcal		Prozac	C			UNKNOWN
			Naprosyn	C			UNKNOWN

Date:08/19/05ISR Number: 4749422-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0505USA01504
Age:68 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Angina Pectoris		Vioxx	PS	Merck & Co., Inc	ORAL		3 YR
Initial or Prolonged	Blindness Unilateral		Vioxx	SS	Merck & Co., Inc	ORAL		3 YR
Disability	Cardiac Failure		Altace	C				UNKNOWN
Other	Congestive		Lopressor	C				UNKNOWN
	Cardiac Murmur		Cardura	C				UNKNOWN
	Cardiac Valve Disease		Lasix (Furosemide)	C				UNKNOWN
	Carotid Bruit		Plavix	C				UNKNOWN
	Cerebrovascular Accident							
	Chest Discomfort							
	Chest Pain							
	Chronic Obstructive Pulmonary Disease							
	Coronary Artery Disease							
	Coronary Artery Stenosis							
	Dyspnoea							
	Heart Rate Irregular							
	Hypertension							
	Myocardial Infarction							
	Obesity							
	Oedema Peripheral							
	Optic Ischaemic Neuropathy							
	Pain In Extremity							
	Spinal Column Stenosis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/05ISR Number: 4749423-1Report Type:Expedited (15-DaCompany Report #US-MERCK-0505USA00859
Age:63 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Atherosclerosis		Vioxx	PS	Merck & Co., Inc	ORAL		56 MON
Initial or Prolonged	Atrioventricular Block		Vioxx	SS	Merck & Co., Inc	ORAL		52 MON
Disability	First Degree		Aspirin	SS				UNKNOWN
	Cardiac Murmur		Levitra	C				UNKNOWN
	Carotid Artery Stenosis		Lortab	C				UNKNOWN
	Cerebrovascular Accident		Tylenol	C				UNKNOWN
	Chest Pain		Celebrex	C				UNKNOWN
	Diabetes Mellitus							
	Non-Insulin-Dependent							
	Erectile Dysfunction							
	Gastric Ulcer							
	Gastrointestinal							
	Haemorrhage							
	Gastrooesophageal Reflux							
	Disease							
	Hypertension							
	Iron Deficiency Anaemia							
	Overdose							
	Peptic Ulcer							
	Renal Failure							
	Ventricular Hypertrophy							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Summary report for FOI selections:

Selection by inexact search of active ingredient: ROFECOXIB%

Selection by inexact search of Tradename/Verbatim: VIOXX%

Total number of reports: 59,015

From: 01-NOV-1997 To: Present